id|nct_id|name
1|NCT03057184|Adult Day Care Center, behavioral problems,caregivers
2|NCT03057171|Helicobacter pylori
3|NCT03057171|long non-coding RNA
4|NCT03057171|THRIL
5|NCT03057171|PACER
6|NCT03057171|cagA
7|NCT03057158|OAB
8|NCT03057158|Insulin resistance
9|NCT03057158|diabetes
10|NCT03057158|pre-diabetes
11|NCT03057145|Solid Tumor
12|NCT03057093|NSTEMI, ECG
13|NCT03057067|Embolization, Therapeutic
14|NCT03057067|Pelvis
15|NCT03056976|Overdenture
16|NCT03056976|Dental implant
17|NCT03056976|Complete denture
18|NCT03056976|Cost analysis
19|NCT03056963|Guided Imagery
20|NCT03056950|Blood Flow Restriciton
21|NCT03056950|Occlusion training
22|NCT03056950|Distal radius fracture
23|NCT03056911|ozone therapy
24|NCT03056911|percutaneous treatment
25|NCT03056911|Oswestry Disability Index (ODI)
26|NCT03056911|Visual analog Scale (VAS)
27|NCT03056911|Neuropathic Pain Questionnaire (DN-4)
28|NCT03056911|cervical
29|NCT03056898|eicosapentaenoic acid
30|NCT03056898|EPA
31|NCT03056898|docosahexaenoic acid
32|NCT03056898|DHA
33|NCT03056898|omega-3 index
34|NCT03056885|one-lung ventilation
35|NCT03056885|broncho-alveolar lavage
36|NCT03056885|protective ventilation
37|NCT03056885|cytokines
38|NCT03056885|thoracic surgery
39|NCT03056859|Operator satisfaction with device
40|NCT03056846|probiotic
41|NCT03056846|gastrointestinal
42|NCT03056846|stress
43|NCT03056846|student
44|NCT03056820|tracheal intubation
45|NCT03056807|tolerable apneic time
46|NCT03056807|bariatric surgery
47|NCT03056807|gastric band surgery
48|NCT03056807|intubation
49|NCT03056794|pyruvate
50|NCT03056794|pyruvate dehydrogenase
51|NCT03056794|PDC
52|NCT03056794|PDCD
53|NCT03056755|advanced breast cancer
54|NCT03056755|PIK3CA
55|NCT03056755|CDK 4/6 inhibitor
56|NCT03056755|fulvestrant
57|NCT03056755|letrozole
58|NCT03056755|HR+
59|NCT03056755|HER-negative
60|NCT03056755|post menopausal
61|NCT03056716|thoracic surgery, silastic drains, conventional drains
62|NCT03056690|ASP0819
63|NCT03056690|Fibromyalgia
64|NCT03056677|Whey protein
65|NCT03056677|Dietary supplementation
66|NCT03056677|Glucose
67|NCT03056677|GLP-1
68|NCT03056677|Satiety
69|NCT03056651|heart failure
70|NCT03056651|day care
71|NCT03056651|prognosis
72|NCT03056638|Androgen Deprivation Therapy
73|NCT03056638|Ultra-Hypofractionated SBRT
74|NCT03056638|16-1686
75|NCT03056625|fortified rice
76|NCT03056625|lactating women
77|NCT03056625|13C2-retinol isotope dilution
78|NCT03056625|vitamin A liver store
79|NCT03056599|in vivo drug sensitivity
80|NCT03056599|personalized medicine
81|NCT03056599|precision oncology
82|NCT03056599|in vivo oncology
83|NCT03056599|soft tissue sarcoma
84|NCT03056599|chemotherapy
85|NCT03056599|microinjection
86|NCT03056599|microdosing
87|NCT03056573|TAVI
88|NCT03056573|Valvular heart disease
89|NCT03056573|Transcatheter aortic valve implantation
90|NCT03056534|Primary Total Hip Arthroplasty
91|NCT03056534|Non-Inflammatory Arthritis
92|NCT03056534|Degenerative Joint Disease
93|NCT03056534|R3 Delta Ceramic Acetabular Insert
94|NCT03056508|diet
95|NCT03056508|nutrition
96|NCT03056508|aerobic exercise
97|NCT03056508|cognition
98|NCT03056508|grey matter
99|NCT03056508|cerebral blood flow
100|NCT03056508|neural activity
101|NCT03056508|resting state connectivity
102|NCT03056482|cannabis
103|NCT03056482|haloperidol
104|NCT03056482|ondansetron
105|NCT03056482|hyperemesis
106|NCT03056482|cyclic vomiting syndrome
107|NCT03056469|patient-reported outcomes
108|NCT03056469|supportive care
109|NCT03056469|clinical practice
110|NCT03056469|hematological cancer
111|NCT03056430|MRI, Neuroplasticity, Balance, Spatial orientation, Hippocampus, Slacklining
112|NCT03056417|chronic pain
113|NCT03056417|telomere
114|NCT03056417|telomerase
115|NCT03056417|life style
116|NCT03056391|knowlesi malaria
117|NCT03056391|paracetamol
118|NCT03056391|renal function
119|NCT03056391|haemolysis
120|NCT03056391|oxidative stress
121|NCT03056365|Detoxification
122|NCT03056365|Outpatient
123|NCT03056365|Advanced Nursing
124|NCT03056365|Health Services
125|NCT03056339|B-Lymphoid Malignancies
126|NCT03056339|Relapsed/Refractory
127|NCT03056339|Acute lymphocytic leukemia
128|NCT03056339|ALL
129|NCT03056339|Chronic lymphocytic leukemia
130|NCT03056339|CLL
131|NCT03056339|Non-Hodgkin lymphoma
132|NCT03056339|NHL
133|NCT03056339|(CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer cells
134|NCT03056339|CB-NK cells
135|NCT03056339|Fludarabine
136|NCT03056339|Fludarabine phosphate
137|NCT03056339|Fludara
138|NCT03056339|Cyclophosphamide
139|NCT03056339|Cytoxan
140|NCT03056339|Neosar
141|NCT03056339|AP1903
142|NCT03056339|Mesna
143|NCT03056339|Mesnex
144|NCT03056313|Delivery, Obstetric
145|NCT03056313|Uterine Contraction
146|NCT03056313|Cervix Uteri
147|NCT03056274|Metformin
148|NCT03056274|Ursodeoxycholic acid
149|NCT03056274|Outcomes
150|NCT03056261|Combined general-epidural anesthesia intestinal recovery
151|NCT03056235|Atrophic acne scar
152|NCT03056209|Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
153|NCT03056157|Moral Injury
154|NCT03056157|Post-traumatic Stress Disorder
155|NCT03056157|Traumatic Loss
156|NCT03056157|Adaptive Disclosure
157|NCT03056157|Veterans
158|NCT03056144|spinal muscular atrophy
159|NCT03056144|total body vibration
160|NCT03056144|children
161|NCT03056118|OPTIMA-C
162|NCT03056105|Well-being, affiliation, inflammation
163|NCT03056092|ranibizumab
164|NCT03056092|aqueous cytokine
165|NCT03056092|age related macular degeneration
166|NCT03056092|diabetic macular edema
167|NCT03056092|retinal vein occlusion
168|NCT03056079|neovascular age related macular degeneration
169|NCT03056079|diabetic macular edema
170|NCT03056079|retinal vein occlusion
171|NCT03056079|aflibercept
172|NCT03056079|aqueous humor cytokine
173|NCT03056053|insomnia
174|NCT03055975|Bacteria
175|NCT03055975|Root canal treatment
176|NCT03055975|Endodontics
177|NCT03055962|Healthy Participants
178|NCT03055962|E2609
179|NCT03055962|Pharmacokinetics
180|NCT03055962|Japan
181|NCT03055949|early rehabilitation
182|NCT03055949|early mobilization
183|NCT03055949|surgical intensive care unit
184|NCT03055884|transcranial Direct Current Stimulation (tDCS)
185|NCT03055884|accelerated learning
186|NCT03055884|memory
187|NCT03055871|Behavioural: Family physical activity habit
188|NCT03055819|Brow Lift
189|NCT03055819|Brow Ptosis
190|NCT03055741|Alzheimer's disease
191|NCT03055728|streptococcal infections
192|NCT03055728|rapid strep testing
193|NCT03055728|rapid antigen detection test
194|NCT03055715|NSCLC
195|NCT03055715|Radiotherapy
196|NCT03055715|young DEGRO
197|NCT03055715|tumor volume
198|NCT03055715|lung cancer
199|NCT03055715|radiochemotherapy
200|NCT03055715|prognostic factors
201|NCT03055702|Short Message Service
202|NCT03055702|appointment reminder
203|NCT03055702|Attendance rate
204|NCT03055689|Colonoscopy
205|NCT03055689|Educational intervention
206|NCT03055676|Pancreaticoduodenectomy
207|NCT03055676|Time of drain removal
208|NCT03055624|prostate artery embolization (PAE)
209|NCT03055624|benign prostatic hyperplasia (BPH)
210|NCT03055624|lower urinary tract symptoms (LUTS)
211|NCT03055611|Blood Coagulation Disorder
212|NCT03055611|Hematologic Diseases
213|NCT03055611|Coagulation Protein Disorder
214|NCT03055611|Hemorrhagic Disorder
215|NCT03055611|Genetic Diseases, Inborn
216|NCT03055585|Wolbachia; Aedes aegypti; Indonesia; Dengue; Cluster-randomised trial
217|NCT03055572|Rhinitis
218|NCT03055572|Chronic Rhinosinusitis
219|NCT03055572|Olfactory Training
220|NCT03055559|Iron, Hemoglobin, Feritin, erytrocyty. transferin
221|NCT03055546|oxytocin
222|NCT03055546|emotion regulation
223|NCT03055533|Behavioral
224|NCT03055533|Social
225|NCT03055533|Headsprout reading program
226|NCT03055520|schizophrenia
227|NCT03055520|cognition
228|NCT03055520|arithmetic training
229|NCT03055520|Kumon method
230|NCT03055481|neonatal jaundice
231|NCT03055481|phototherapy
232|NCT03055481|neonate
233|NCT03055429|Prisoners
234|NCT03055429|End-of-life care
235|NCT03055429|Geriatric care
236|NCT03055429|Palliative care
237|NCT03055429|Hospice care
238|NCT03055416|Overweight
239|NCT03055416|Obesity
240|NCT03055416|Physical Activity
241|NCT03055416|African-American Men
242|NCT03055416|mHealth
243|NCT03055416|Mobile Health
244|NCT03055390|hyoscine butylbromide
245|NCT03055390|progress of labor
246|NCT03055390|duration of labor
247|NCT03055377|cannabis
248|NCT03055377|marijuana
249|NCT03055377|youth
250|NCT03055377|adolescent
251|NCT03055377|pharmacotherapy
252|NCT03055377|medication
253|NCT03055377|n-acetylcysteine
254|NCT03055377|trial
255|NCT03055351|Exercise motivation
256|NCT03055351|Psychological well-being
257|NCT03055351|Healthy living
258|NCT03055351|Physical activity
259|NCT03055351|Autonomy support
260|NCT03055351|Self-determination theory
261|NCT03055338|Schizophrenia, acute episode
262|NCT03055338|Schizophrenia Spectrum and Other Psychotic Disorders
263|NCT03055338|Mental Disorders
264|NCT03055247|Chronic granulomatous disease X-linked
265|NCT03055247|Ibuprofen
266|NCT03055247|Mobilization regimen
267|NCT03055247|Gene Therapy
268|NCT03055234|Oral treprostinil
269|NCT03055234|6-Minute Walk Distance
270|NCT03055234|PH
271|NCT03055234|sickle cell
272|NCT03055221|Remodulin
273|NCT03055221|6-Minute Walk Test
274|NCT03055208|Glioblastoma
275|NCT03055208|Radiosurgery
276|NCT03055208|Gamma Knife
277|NCT03055195|subcutaneous
278|NCT03055195|safety
279|NCT03055195|mepolizumab
280|NCT03055195|efficacy
281|NCT03055195|atopic dermatitis
282|NCT03055182|Isokinetic
283|NCT03055182|oxygenation
284|NCT03055182|deoxygenation
285|NCT03055182|aerobic metabolism
286|NCT03055169|hyperglycemia
287|NCT03055169|Multiple Organ Failure
288|NCT03055169|biobank
289|NCT03055169|diabetes
290|NCT03055156|Sleep Apnea
291|NCT03055156|Insomnia
292|NCT03055156|sleep disorders
293|NCT03055156|sleep environment
294|NCT03055156|core body temperature
295|NCT03055117|Shoulder pain
296|NCT03055117|Physiotherapy
297|NCT03055117|Rehabilitation
298|NCT03055117|Exercise
299|NCT03055104|severe malnutrition
300|NCT03055104|Critically Ill
301|NCT03055104|refeeding syndrome
302|NCT03055104|guideline
303|NCT03055065|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
304|NCT03055000|Mosquito-Borne Diseases
305|NCT03055000|Universal Mosquito Vaccine
306|NCT03055000|Mosquito Transmission
307|NCT03055000|Vector Borne Viruses
308|NCT03055000|Vaccine
309|NCT03054974|Stroke
310|NCT03054974|Traditional Chinese Medicine
311|NCT03054974|Rehabilitation
312|NCT03054961|epilepsy
313|NCT03054961|cytochrome oxidase redox state
314|NCT03054961|childhood epilepsy
315|NCT03054961|partial epilepsy
316|NCT03054961|NIRS
317|NCT03054961|near-infrared spectroscopy
318|NCT03054961|regional cerebral oxygen saturation
319|NCT03054935|Energy Expenditure
320|NCT03054935|Body Composition
321|NCT03054935|Food Intake
322|NCT03054896|Richter Syndrome
323|NCT03054883|Mantle Cell Lymphoma
324|NCT03054883|minimal residual disease
325|NCT03054883|cytosine arabinoside
326|NCT03054870|pulmonary ventilation
327|NCT03054870|ventilation scintigraphy
328|NCT03054844|Intranasal
329|NCT03054844|Pain
330|NCT03054844|Lidocaine
331|NCT03054844|Midazolam
332|NCT03054844|Emergency department
333|NCT03054766|Laser Photocoagulation
334|NCT03054766|Ranibizumab
335|NCT03054766|Branch Retinal Vein Occlusion
336|NCT03054766|Vascular Endothecial Growth Factor
337|NCT03054753|Abduction brace
338|NCT03054753|Compliance
339|NCT03054753|Rotator cuff tear
340|NCT03054753|Rotator cuff repair
341|NCT03054740|Vapocoolant applied prior to IV access
342|NCT03054727|Post Thrombotic Syndrome
343|NCT03054727|Venous Thromboembolism
344|NCT03054727|Incidence
345|NCT03054727|Risk factors
346|NCT03054727|Venous ulcer
347|NCT03054701|Patellofemoral pain
348|NCT03054701|PFP
349|NCT03054701|PFPS
350|NCT03054675|lung resection
351|NCT03054675|lung function
352|NCT03054675|VATS
353|NCT03054675|Thoracotomy
354|NCT03054662|Haemophilia
355|NCT03054610|plantar fascitis
356|NCT03054610|Botulinum toxin A
357|NCT03054610|Betamethason Sodium Phosphate
358|NCT03054610|infiltration
359|NCT03054610|plantar fascia
360|NCT03054558|Junctional zone
361|NCT03054558|recurrent pregnancy loss
362|NCT03054558|3D power Doppler
363|NCT03054480|Fractional Micro-Needle Radiofrequency
364|NCT03054480|Intradermal Botulinum Toxin A
365|NCT03054441|Upper limb
366|NCT03054441|Inertial sensors
367|NCT03054415|neuronal-glial-epithelial unit, anorectal function
368|NCT03054376|Immobilization
369|NCT03054376|Angiogenesis
370|NCT03054376|Skeletal muscle
371|NCT03054376|Exercise training
372|NCT03054376|Vascular function
373|NCT03054363|Metastatic Breast Cancer
374|NCT03054363|Tucatinib
375|NCT03054363|Palbociclib
376|NCT03054363|Letrozole
377|NCT03054363|HR-positive
378|NCT03054363|HER2-positive
379|NCT03054363|ER-positive
380|NCT03054363|PR-positive
381|NCT03054363|HER2-targeted therapy
382|NCT03054363|CDK4/6 inhibitor
383|NCT03054363|ONT-380
384|NCT03054363|Ibrance
385|NCT03054350|Anemia
386|NCT03054350|kidney
387|NCT03054350|dialysis-dependent chronic kidney disease
388|NCT03054350|CKD
389|NCT03054350|DD-CKD
390|NCT03054350|renal
391|NCT03054350|vadadustat
392|NCT03054350|AKB-6548
393|NCT03054350|hypoxia-inducible factor
394|NCT03054350|HIF
395|NCT03054350|hypoxia-inducible factor prolyl-hydroxylase inhibitor
396|NCT03054350|HIF-PHI
397|NCT03054350|Japan
398|NCT03054350|Japanese
399|NCT03054337|Anemia
400|NCT03054337|kidney
401|NCT03054337|non-dialysis dependent chronic kidney disease
402|NCT03054337|CKD
403|NCT03054337|NDD-CKD
404|NCT03054337|renal
405|NCT03054337|vadadustat
406|NCT03054337|AKB-6548
407|NCT03054337|hypoxia-inducible factor
408|NCT03054337|HIF
409|NCT03054337|hypoxia-inducible factor prolyl-hydroxylase inhibitor
410|NCT03054337|HIF-PHI
411|NCT03054337|Japan
412|NCT03054337|Japanese
413|NCT03054324|Cardiovascular Diseases
414|NCT03054324|Fractional Flow Reserve
415|NCT03054324|Ischemic Heart Disease
416|NCT03054324|CT Angiogram
417|NCT03054285|Seizures
418|NCT03054285|Traumatic Brain Injury
419|NCT03054285|Prophylaxis
420|NCT03054285|Levetiracetam
421|NCT03054272|High-fidelity simulation
422|NCT03054272|Eye-tracking
423|NCT03054272|Difficult intubation
424|NCT03054233|spinal anesthesia
425|NCT03054233|spinal-bone contact
426|NCT03054233|caesarian section
427|NCT03054233|crossed leg sitting position
428|NCT03054194|Healthy participants
429|NCT03054194|E2730
430|NCT03054194|Pharmacokinetics
431|NCT03054181|Observational
432|NCT03054181|Infection
433|NCT03054181|Utilisation
434|NCT03054181|Safety
435|NCT03054181|Tolerability
436|NCT03054181|Infusion
437|NCT03054181|chronic
438|NCT03054168|Protein Synthesis
439|NCT03054168|Hypertrophy
440|NCT03054168|Testosterone
441|NCT03054155|hidradenitis suppurativa
442|NCT03054155|hidradenitis
443|NCT03054155|laser
444|NCT03054103|ketamine
445|NCT03054103|midazolam
446|NCT03054103|sedation
447|NCT03054090|Cardiovascular Diseases
448|NCT03054090|Primary Care
449|NCT03054077|pre-procedural anxiety
450|NCT03054077|children
451|NCT03054077|pediatric sedation
452|NCT03054051|HIV prevention
453|NCT03054051|Preadolescence
454|NCT03054051|Mobile phone game
455|NCT03054051|Feasibility
456|NCT03054012|CAD-CAM software
457|NCT03054012|accuracy
458|NCT03054012|head and neck region
459|NCT03054012|mandibular reconstruction
460|NCT03053999|Multiple Endocrine Neoplasia
461|NCT03053999|Pancreatic Neuroendocrine Tumors
462|NCT03053999|Hyperparathyroidism
463|NCT03053999|HPTH
464|NCT03053999|PNET
465|NCT03053999|Biomarkers
466|NCT03053999|Parathyroidectomy
467|NCT03053999|Genome sequencing
468|NCT03053999|Data review
469|NCT03053973|COPD
470|NCT03053973|airway inflammation
471|NCT03053973|airway remodeling
472|NCT03053973|health-related auality of life
473|NCT03053973|forced expiratory volume 1 second
474|NCT03053947|Intranasal Ketamine
475|NCT03053947|Pain Management
476|NCT03053934|Online counselling
477|NCT03053921|gingival recession
478|NCT03053921|Zuchellis technique,
479|NCT03053921|placental membrane
480|NCT03053908|Orexin
481|NCT03053908|Cognitive Behavioral Therapy (CBT)
482|NCT03053882|mouth wash , green tea , peppermint , bad breath
483|NCT03053856|stage IIIA non-small cell lung cancer
484|NCT03053856|Adjuvant pembrolizumab
485|NCT03053843|Atrial fibrillation
486|NCT03053843|Mediterranean Diet
487|NCT03053843|Extra Virgin Olive Oil
488|NCT03053843|Ablation
489|NCT03053830|Ketamine
490|NCT03053830|Major Depressive Disorder
491|NCT03053804|MR/PET
492|NCT03053804|Non-small cell lung cancer (NSCLC)
493|NCT03053791|Deep brain stimulation
494|NCT03053791|DBS
495|NCT03053791|Spinal cord injury
496|NCT03053791|SCI
497|NCT03053791|Paraplegia
498|NCT03053791|Mesencephalic locomotor region
499|NCT03053791|MLR
500|NCT03053791|Pedunculopontine nucleus
501|NCT03053791|PPN
502|NCT03053778|Readmission
503|NCT03053778|Early follow-up
504|NCT03053778|Heart valves
505|NCT03053778|Heart valve surgery
506|NCT03053739|Systemic sclerosis, Associated Pulmonary Arterial Hypertension
507|NCT03053726|Variable Frequency Stimulation
508|NCT03053713|Mediterranean diet pattern
509|NCT03053713|nutrition
510|NCT03053713|diet intervention
511|NCT03053713|disease activity
512|NCT03053713|intestinal microbiome
513|NCT03053713|inflammatory bowel disease
514|NCT03053700|Rosacea, Bromonidine, intensed pulse light
515|NCT03053661|Head and Neck Squamous Cell Carcinoma
516|NCT03053661|cancer-specific immunity
517|NCT03053661|cancer immunology
518|NCT03053661|cancer-testis antigens
519|NCT03053661|human papilloma virus
520|NCT03053661|immune modulatory cells
521|NCT03053648|Insomnia
522|NCT03053648|Randomized controlled trial
523|NCT03053648|Acupressure
524|NCT03053648|Self-help
525|NCT03053635|Photodynamic Therapy
526|NCT03053609|gastroesophageal reflux
527|NCT03053609|apnea
528|NCT03053609|bradycardia
529|NCT03053609|desaturation
530|NCT03053609|impedance
531|NCT03053596|HCC
532|NCT03053596|LifePearl
533|NCT03053583|larynx, laryngoscopy
534|NCT03053583|vocal cords, laryngoscopy
535|NCT03053583|airway
536|NCT03053583|pediatric
537|NCT03053570|Cryoballoon
538|NCT03053570|Contact Force
539|NCT03053570|Persistent Atrial Fibrillation
540|NCT03053557|mental health consumers
541|NCT03053544|rectal cancer
542|NCT03053544|adenocarcinoma of the rectum
543|NCT03053544|node positive rectal tumors
544|NCT03053544|metformin
545|NCT03053544|neoadjuvant chemoradiation
546|NCT03053518|Type 2 Diabetes
547|NCT03053518|Hyperglycemia
548|NCT03053518|Personal Nutrition Project
549|NCT03053505|fecal microbiota transplantation (FMT)
550|NCT03053505|Clostridium difficile infection
551|NCT03053505|gut flora
552|NCT03053505|human microbiome
553|NCT03053505|colitis
554|NCT03053492|Video Games
555|NCT03053479|surgery
556|NCT03053479|native tissue prolapse repair
557|NCT03053479|laparoscopic sacrocolpopexy
558|NCT03053479|vaginal mesh
559|NCT03053466|Advanced Solid Tumor
560|NCT03053466|Relapsed Solid Tumor
561|NCT03053466|Recurrent Solid Tumor
562|NCT03053453|Total Knee Replacement Arthroplasty
563|NCT03053427|Restless Legs Syndrome
564|NCT03053427|Gabapentin enacarbil
565|NCT03053401|Quadriceps muscle strength
566|NCT03053401|Anterior cruciate ligament repair
567|NCT03053401|Femoral nerve block
568|NCT03053401|Adductor Canal block
569|NCT03053401|Saphenous nerve block in the Adductor Canal
570|NCT03053401|Pediatrics
571|NCT03053401|Postoperative analgesia
572|NCT03053401|Ultrasound guided nerve block
573|NCT03053323|Preconception
574|NCT03053323|Pregnancy
575|NCT03053323|Lifestyle
576|NCT03053310|surgery
577|NCT03053310|curative intent
578|NCT03053310|geriatric assessment
579|NCT03053310|30-day postoperative morbidity
580|NCT03053297|EGFR
581|NCT03053297|EGFR mutation
582|NCT03053297|EGFRm
583|NCT03053297|EGFR-TKI
584|NCT03053297|Health care resource utilization
585|NCT03053297|Health-Related Quality of Life
586|NCT03053297|Locally advanced or metastatic lung cancer
587|NCT03053297|NSCLC
588|NCT03053297|Non-Small Cell Lung Cancer
589|NCT03053297|Observational study
590|NCT03053297|Osimertinib
591|NCT03053297|Personalized medicine
592|NCT03053297|PRO
593|NCT03053297|Patient Reported Outcome
594|NCT03053297|Resistance
595|NCT03053297|T790M
596|NCT03053297|Carcinoma, Non-Small-Cell Lung
597|NCT03053297|Carcinoma, Bronchogenic
598|NCT03053297|Bronchial Neoplasms
599|NCT03053297|Lung Neoplasms
600|NCT03053297|Respiratory Tract Neoplasms
601|NCT03053297|Thoracic neoplasms, Neoplasms by site
602|NCT03053297|Lung diseases
603|NCT03053297|Respiratory Tract diseases
604|NCT03053297|Cancer Chemotherapy
605|NCT03053297|Combination Chemotherapy
606|NCT03053297|Immunotherapy
607|NCT03053297|Radiation
608|NCT03053271|Endogenous Cushing's Syndrome
609|NCT03053271|ATR-101
610|NCT03053271|CS
611|NCT03053245|Collaborative Care Model
612|NCT03053245|Intensive Care Unit
613|NCT03053193|breast cancer
614|NCT03053193|stage I
615|NCT03053193|stage II
616|NCT03053193|stage III
617|NCT03053180|Ombitasvir
618|NCT03053180|Dasabuvir
619|NCT03053180|Hepatitis
620|NCT03053180|Chronic Hepatitis C genotype 1b (GT1b)
621|NCT03053180|Paritaprevir
622|NCT03053180|Cirrhosis
623|NCT03053180|Compensated liver cirrhosis
624|NCT03053180|Ribavirin free
625|NCT03053180|Ritonavir
626|NCT03053167|Raltitrexed
627|NCT03053167|Irinotecan
628|NCT03053167|Second-line Treatment
629|NCT03053167|Advanced Colorectal Cancer(ACC)
630|NCT03053154|Pelvic Inclination
631|NCT03053154|Sit to Stand
632|NCT03053154|Stroke
633|NCT03053128|cardiac ischemia
634|NCT03053102|PNH
635|NCT03053102|Paroxysmal
636|NCT03053102|Hemoglobinuria
637|NCT03053089|MPS I; Hurler Syndrome
638|NCT03053076|cord blood mononuclear cells
639|NCT03053076|safety
640|NCT03053076|effect
641|NCT03053076|neonates
642|NCT03053037|apical size
643|NCT03053037|root canal treatment success
644|NCT03053037|micro biome analysis
645|NCT03053037|pulp necrosis
646|NCT03052985|medical devices (meshes)
647|NCT03052985|surgery
648|NCT03052946|fecal incontinence, anorectal manometry, bulking agents
649|NCT03052933|copanlisib
650|NCT03052933|gemcitabine
651|NCT03052933|peripheral T-cell lymphoma
652|NCT03052933|extranodal NK/T-cell lymphoma
653|NCT03052920|cochlear implant
654|NCT03052920|asymmetric hearing loss
655|NCT03052894|anesthesiology
656|NCT03052894|neuromuscular blockade
657|NCT03052894|monitoring device
658|NCT03052855|Psychiatry
659|NCT03052855|Suicidal behaviour
660|NCT03052855|Cerebral metabolites
661|NCT03052855|MRI
662|NCT03052855|Inflammatory markers
663|NCT03052751|UCB7665
664|NCT03052751|Myasthenia Gravis
665|NCT03052738|central nervous system (brain or spinal) tumor
666|NCT03052712|Disorders of socio-emotional
667|NCT03052712|Alzheimer
668|NCT03052712|frontal temporal dementia
669|NCT03052712|Parkinson
670|NCT03052712|Huntington
671|NCT03052712|traumatic brain injury
672|NCT03052712|stroke
673|NCT03052712|focal lesions
674|NCT03052699|Complications; Cesarean Section
675|NCT03052686|Uterine rupture
676|NCT03052673|ketamine
677|NCT03052673|fentanyl
678|NCT03052673|postoperative pain
679|NCT03052660|Midazolam
680|NCT03052660|Anxiety
681|NCT03052660|Clinical trial
682|NCT03052660|Patient Satisfaction
683|NCT03052647|dermaclip
684|NCT03052647|subcuticular
685|NCT03052647|cesarean section
686|NCT03052647|staples
687|NCT03052647|adhesive latch
688|NCT03052647|rousseau
689|NCT03052608|ALK; anaplastic lymphoma kinase; Non-Small-Cell Lung cancer; NSCLC
690|NCT03052556|cystic Fibrosis
691|NCT03052556|cervical cancer
692|NCT03052556|screening
693|NCT03052556|human papilloma virus (HPV)
694|NCT03052556|pap smear test
695|NCT03052517|Asthma, QAW039
696|NCT03052465|Motility
697|NCT03052413|thinning hair
698|NCT03052413|female pattern hair loss
699|NCT03052400|type 2 diabetes mellitus
700|NCT03052400|insulin resistance
701|NCT03052400|mifepristone
702|NCT03052400|glucocorticoids
703|NCT03052374|Video-Feedback Interaction Guidance
704|NCT03052374|Depressed Mothers and their Infants
705|NCT03052361|Children
706|NCT03052361|emergency department
707|NCT03052361|ondansetron
708|NCT03052348|Topical Antibiotics
709|NCT03052348|Supiroban
710|NCT03052348|Atopic Dermatitis
711|NCT03052348|Eczema
712|NCT03052335|colorectal cancer
713|NCT03052335|screening
714|NCT03052335|colon capsule
715|NCT03052335|colonoscopy
716|NCT03052283|Cystic fibrosis
717|NCT03052283|Abdomen
718|NCT03052283|Pancreas
719|NCT03052283|Liver
720|NCT03052283|Gut
721|NCT03052283|Symptom Score
722|NCT03052283|Patient reported outcome measure (PROM)
723|NCT03052257|Glaucoma
724|NCT03052257|Disease management
725|NCT03052257|Smart bottle
726|NCT03052244|tDCS (trans cranial direct current stimulation)
727|NCT03052244|Visual illusion
728|NCT03052244|Neuropathic pain
729|NCT03052244|Spinal cord Injury
730|NCT03052231|adherence
731|NCT03052231|cystic fibrosis
732|NCT03052218|children
733|NCT03052218|pain
734|NCT03052218|Cytochrome P450 CYP2D6 genotype
735|NCT03052218|Cytochrome P450 CYP2D6 phenotype
736|NCT03052218|Pupillometry
737|NCT03052127|Uveal melanoma
738|NCT03052127|Eye cancer
739|NCT03052127|Ocular melanoma
740|NCT03052127|Choroidal melanoma
741|NCT03052114|Electrical Impedance Tomography
742|NCT03052114|EIT
743|NCT03052114|Stroke
744|NCT03052114|Craniocerebral Injury
745|NCT03052114|Head Injury
746|NCT03052101|PLCH
747|NCT03052101|Air travel
748|NCT03052101|pneumothorax
749|NCT03052101|pleurodesis
750|NCT03052075|Primary Hyperparathyroidism
751|NCT03052075|Parathyroidectomy
752|NCT03052075|Bone mineral density
753|NCT03052075|BMD
754|NCT03052075|Data Review
755|NCT03052049|Prostate Artery Embolization
756|NCT03052036|Acute Coronory Syndrome
757|NCT03052023|dual approach
758|NCT03052023|laparoscopic hernioplasty
759|NCT03052010|HIV-1 serodiscordant couples
760|NCT03052010|PrEP as Bridge to ART
761|NCT03051919|Laparoscopic sleeve gastrectomy
762|NCT03051919|reinforcement
763|NCT03051919|leak
764|NCT03051906|Carcinoma, squamous cell
765|NCT03051906|Head and Neck Neoplasms
766|NCT03051906|Radiotherapy
767|NCT03051906|Immunotherapy
768|NCT03051880|Epidermal Growth Factor
769|NCT03051854|Violence
770|NCT03051854|Children
771|NCT03051854|Prevalence
772|NCT03051854|Abuse
773|NCT03051854|Prevention
774|NCT03051828|fencing, cancer
775|NCT03051815|obstructive sleep apnea
776|NCT03051802|Endoscopy
777|NCT03051802|HDR Brachytherapy
778|NCT03051802|navigation
779|NCT03051789|Menstrual hygiene management
780|NCT03051789|Sexual and Reproductive Health
781|NCT03051789|Adolescent schoolgirls
782|NCT03051789|School dropoout
783|NCT03051789|sub-Saharan Africa
784|NCT03051789|Kenya
785|NCT03051776|Compression garments
786|NCT03051776|Kinesio Taping
787|NCT03051776|Breast Cancer-Related Lymphedema
788|NCT03051763|pulmonary hypertension
789|NCT03051763|commercial air travel
790|NCT03051750|Breast Cancer-Related Lymphedema
791|NCT03051750|Complex Physical Therapy
792|NCT03051750|Pressotherapy
793|NCT03051750|Kinesio Taping
794|NCT03051750|Physiotherapy
795|NCT03051750|Manual Lymph Drainage
796|NCT03051750|Multilayer Bandage
797|NCT03051750|TTDL questionnaire
798|NCT03051737|Multi-scale
799|NCT03051737|Prediction
800|NCT03051737|Patient Flow
801|NCT03051737|Emergency Department
802|NCT03051737|Hospitalization
803|NCT03051737|Ile-de-France
804|NCT03051724|OSA
805|NCT03051724|CPAP management
806|NCT03051724|Telemedicine
807|NCT03051698|C1-inhibitor
808|NCT03051698|house dust mite
809|NCT03051698|complement system
810|NCT03051672|Breast Cancer
811|NCT03051659|Breast Cancer
812|NCT03051646|Exercise
813|NCT03051646|Time to Exhaustion
814|NCT03051620|Bone turnover markers
815|NCT03051620|Alendronate
816|NCT03051620|Drug Holiday
817|NCT03051607|Motor Fluctuations
818|NCT03051607|Off time
819|NCT03051607|On time
820|NCT03051607|Dyskinesia
821|NCT03051581|Lymphoma, T-Cell, Peripheral
822|NCT03051581|Positron-Emission Tomography
823|NCT03051581|Prognosis
824|NCT03051568|Lymphoma, T-Cell, Peripheral
825|NCT03051568|Positron-Emission Tomography
826|NCT03051568|Prognosis
827|NCT03051555|Lymphoma, Extranodal NK-T-Cell
828|NCT03051555|Positron-Emission Tomography
829|NCT03051555|Prognosis
830|NCT03051542|Lymphoma, Extranodal NK-T-Cell
831|NCT03051542|Positron-Emission Tomography
832|NCT03051542|Prognosis
833|NCT03051451|Hydrochloride of Metformin / Fluoxetine
834|NCT03051451|Placebo
835|NCT03051451|Obesity
836|NCT03051425|Probiotics
837|NCT03051425|Immune function
838|NCT03051425|Natural killer cell activity
839|NCT03051425|Interleukin-12
840|NCT03051425|Interferon-gamma
841|NCT03051425|Immunoglobulin
842|NCT03051399|Constipation
843|NCT03051399|Gastrointestinal symptoms of discomfort
844|NCT03051399|Quality of life
845|NCT03051399|Saccharomyces cerevisiae
846|NCT03051399|Gut microbiome
847|NCT03051360|aortic valve stenosis
848|NCT03051360|PCSK9 inhibitor
849|NCT03051308|Parathyroid cell viability
850|NCT03051308|Ischemia
851|NCT03051308|Parathyroid allotransplantation
852|NCT03051308|Vitamin D Receptor
853|NCT03051308|Calcium Sensing Receptor
854|NCT03051295|Communication Barriers
855|NCT03051295|Persuasive Communication
856|NCT03051295|Risk
857|NCT03051269|Electroporation
858|NCT03051269|Calcium
859|NCT03051269|Head and Neck cancer
860|NCT03051256|REL-1017
861|NCT03051256|d-Methadone
862|NCT03051256|Methadone
863|NCT03051256|Depression
864|NCT03051256|Refractory Depression
865|NCT03051256|Antidepressant
866|NCT03051256|Adjunctive Treatment
867|NCT03051256|NMDA Receptor Antagonist
868|NCT03051256|Excitatory Amino Acid Antagonist
869|NCT03051256|Glutamate Antagonist
870|NCT03051230|Blood Coagulation Disorders
871|NCT03051230|Cell-Derived Microparticles
872|NCT03051230|Superovulation
873|NCT03051230|Fertilization in Vitro
874|NCT03051230|Biomarkers
875|NCT03051217|Psoriasis
876|NCT03051217|PSO
877|NCT03051217|Chronic plaque psoriasis
878|NCT03051217|Certolizumb Pegol
879|NCT03051217|Cimzia
880|NCT03051217|Generalized pustular psoriasis and erythrodermic psoriasis
881|NCT03051191|atherosclerotic cardiovascular diseases
882|NCT03051191|nonischemic heart failure
883|NCT03051191|cancer
884|NCT03051165|Cardiovascular Disease
885|NCT03051165|Pulmonary Medicine
886|NCT03051165|Hypoglossal Nerve Stimulation
887|NCT03051139|Implementation Science
888|NCT03051139|Low Tidal Volume Ventilation (LTVV)
889|NCT03051126|Parathyroid disease
890|NCT03051126|Parathyroid Tissue Bank
891|NCT03051126|Database
892|NCT03051126|Blood samples
893|NCT03051100|hyperlididemia
894|NCT03051100|LDL
895|NCT03051100|cholesterol
896|NCT03051074|Anxiety
897|NCT03051074|Floating
898|NCT03051061|Atrial Fibrillation
899|NCT03051061|Coronary Heart Disease
900|NCT03051061|antithrombotic treatment
901|NCT03051061|clinical prognosis
902|NCT03051048|Acute Myocardial Infarction
903|NCT03051035|non-hematological malignancies
904|NCT03051035|non-squamous
905|NCT03051035|squamous
906|NCT03051035|BRAF
907|NCT03051035|KRAS
908|NCT03051035|NRAS
909|NCT03051022|Bupivacaine
910|NCT03051022|adjuvant
911|NCT03051022|regional anesthesia
912|NCT03051022|dexamethasone
913|NCT03051022|morphine
914|NCT03050983|Respiratory Compromise
915|NCT03050970|minor head trauma
916|NCT03050970|child
917|NCT03050970|age less than 2 years
918|NCT03050970|Clinically-important traumatic brain injury (ciTBI)
919|NCT03050970|Computed tomography scan
920|NCT03050970|Radiation exposure from CT scans
921|NCT03050944|Fertility
922|NCT03050944|Infertility
923|NCT03050944|Dietary Patterns
924|NCT03050944|Mediterranean diet
925|NCT03050944|Adiponectin
926|NCT03050944|Follistatin
927|NCT03050944|Assisted Reproduction
928|NCT03050944|In Vitro Fertilization
929|NCT03050944|Semen quality
930|NCT03050944|Diet
931|NCT03050944|IVF
932|NCT03050931|Electrical Impedance Tomography
933|NCT03050931|EIT
934|NCT03050931|Epilepsy
935|NCT03050879|Stomach Neoplasms
936|NCT03050879|Indocyanine Green Tracer
937|NCT03050879|Laparoscopic Gastrectomy
938|NCT03050879|Lymph Node Dissection
939|NCT03050866|Androgen Receptor
940|NCT03050866|AR-V7
941|NCT03050866|Predictive Factor
942|NCT03050814|Anti-PDL1 Antibody
943|NCT03050814|Therapeutic Cancer Vaccine
944|NCT03050814|Mismatch Repair Deficiency
945|NCT03050814|Progression Free Survival
946|NCT03050814|Adenovirus Based, CEA-Targeting Vaccine
947|NCT03050801|Explicit Memory
948|NCT03050801|Implicit Memory
949|NCT03050801|Memory Disorder
950|NCT03050788|Smartphone confocal microscopy
951|NCT03050788|Kaposi Sarcoma
952|NCT03050788|Point of care diagnosis
953|NCT03050762|Endocrine Disease
954|NCT03050762|Thyroid disease
955|NCT03050762|Parathyroid disease
956|NCT03050762|Adrenal disease
957|NCT03050762|Data Review
958|NCT03050762|Database
959|NCT03050736|Glioma
960|NCT03050736|Glioblastoma
961|NCT03050736|Glioblastoma multiforme
962|NCT03050736|GBM
963|NCT03050736|brain tumor
964|NCT03050736|brain cancer
965|NCT03050632|working memory
966|NCT03050632|adherence
967|NCT03050606|Exercise Therapy
968|NCT03050606|Exercise Movement Techniques
969|NCT03050606|Pilates-Based Exercises
970|NCT03050606|Cost-effectiveness
971|NCT03050593|HFpEF
972|NCT03050593|HFrEF
973|NCT03050580|Abused women
974|NCT03050580|treatment group
975|NCT03050580|family violence
976|NCT03050567|Microemboli
977|NCT03050554|cancer
978|NCT03050554|Non-Small Cell Lung Cancer
979|NCT03050554|SBRT
980|NCT03050554|Avelumab
981|NCT03050554|Stereotactic Body Radiation Therapy
982|NCT03050554|radiation
983|NCT03050554|NSCLC
984|NCT03050554|PD-1
985|NCT03050554|PD-L1
986|NCT03050554|Immunotherapy
987|NCT03050554|Lung
988|NCT03050541|MDMA
989|NCT03050541|adult
990|NCT03050528|Acceptance and Commitment Therapy
991|NCT03050528|Exercise
992|NCT03050528|Psychology
993|NCT03050528|Psychological therapy
994|NCT03050528|Physiotherapy
995|NCT03050528|Physical therapy
996|NCT03050502|Hemothorax
997|NCT03050502|Management
998|NCT03050489|CABG
999|NCT03050489|Off-Pump CABG
1000|NCT03050489|On-Pump CABG
1001|NCT03050489|ischemic-reperfusion injury during CABG
1002|NCT03050489|comparison of On- and Off- Pump CABG
1003|NCT03050489|Ischemic Heart Disease
1004|NCT03050489|Myocardial ischemia-reperfusion and myeloperoxidase
1005|NCT03050489|Myocardial ischemia-reperfusion biomarkers
1006|NCT03050476|side-effects
1007|NCT03050476|heart-lung machine
1008|NCT03050476|alkaline phosphatase
1009|NCT03050437|Failed in First Line EGFR-TKI
1010|NCT03050437|EGFR Activating Mutation
1011|NCT03050437|Pemetrexed
1012|NCT03050424|COPD
1013|NCT03050424|Iron
1014|NCT03050424|Exercise Capacity
1015|NCT03050424|Non-anaemic iron deficiency
1016|NCT03050411|Non Small Cell Lung Cancer
1017|NCT03050411|EGFR-TKI resistance
1018|NCT03050411|Apatinib
1019|NCT03050411|anti-angiogenesis drugs
1020|NCT03050398|HR-positive
1021|NCT03050398|HER2-negative
1022|NCT03050398|Advanced breast cancer
1023|NCT03050398|LEE011
1024|NCT03050398|ribociclib
1025|NCT03050398|letrozole
1026|NCT03050398|femara
1027|NCT03050398|CDK
1028|NCT03050398|CDK4
1029|NCT03050398|CDK6
1030|NCT03050398|CDK4/6
1031|NCT03050398|CDK4/6 inhibitor
1032|NCT03050398|Phase III
1033|NCT03050398|Phase IIIb
1034|NCT03050398|ER-positive
1035|NCT03050398|PR-positive
1036|NCT03050398|Postmenopausal
1037|NCT03050398|Premenopausal
1038|NCT03050398|Men
1039|NCT03050385|cognitive rehabilitation
1040|NCT03050359|Drug therapy
1041|NCT03050359|Gastrointestinal Diseases
1042|NCT03050359|Digestive System Diseases
1043|NCT03050359|Lansoprazole
1044|NCT03050359|Anti-Ulcer Agents
1045|NCT03050359|Gastrointestinal Agents
1046|NCT03050359|Proton Pump Inhibitors
1047|NCT03050359|Enzyme Inhibitors
1048|NCT03050359|Molecular Mechanisms of Pharmacological Action
1049|NCT03050346|Magnetic Resonance Imaging
1050|NCT03050346|Coronary Artery Disease
1051|NCT03050346|Apnea
1052|NCT03050346|Hyperventilation
1053|NCT03050346|BOLD
1054|NCT03050346|Breathing Maneuvers
1055|NCT03050346|Myocardial Oxygenation
1056|NCT03050320|Resilience
1057|NCT03050320|Exercise in the workplace
1058|NCT03050307|Drug therapy
1059|NCT03050268|Familial cancer
1060|NCT03050268|Genetic predisposition
1061|NCT03050268|Heritable disease
1062|NCT03050268|Cancer risk
1063|NCT03050268|Genome analysis
1064|NCT03050268|Genetic modifiers
1065|NCT03050268|Next generation sequencing (NGS)
1066|NCT03050268|Genetic counseling
1067|NCT03050268|DNA
1068|NCT03050255|supplemental oxygen
1069|NCT03050255|walking capacity
1070|NCT03050255|exercise capacity
1071|NCT03050255|endurance shuttle walk test
1072|NCT03050190|4s CAR-T
1073|NCT03050190|CD19
1074|NCT03050190|B cell leukemia
1075|NCT03050190|B-ALL
1076|NCT03050177|Bioequivalence Study
1077|NCT03050138|Postthrombotic Syndrome
1078|NCT03050138|Venous Thrombosis
1079|NCT03050138|Quality of Life
1080|NCT03050138|Hemorrhage
1081|NCT03050138|Recurrence
1082|NCT03050112|MacNew questionnaire
1083|NCT03050112|Quality of life
1084|NCT03050034|Wireless monitoring system
1085|NCT03050034|Acute Medicine
1086|NCT03050034|Poly-pathological patients
1087|NCT03050034|Internal Medicine core competencies
1088|NCT03050034|Acute Complex Care Model
1089|NCT03050021|Delirium
1090|NCT03050021|Intensive care unit
1091|NCT03050008|Cataract Surgery
1092|NCT03049995|effectiveness; imaging; prognosis; stress echocardiography
1093|NCT03049982|Oral appliance therapy
1094|NCT03049969|Working Memory
1095|NCT03049969|Cognitive Training
1096|NCT03049969|Transcranial Magnetic Stimulation
1097|NCT03049956|Ocular Vestibular Evoked Myogenic Potentials
1098|NCT03049943|low level laser therapy
1099|NCT03049943|hyposalivation
1100|NCT03049930|Burns
1101|NCT03049930|Ketamine
1102|NCT03049930|Anesthesia
1103|NCT03049917|financial incentive
1104|NCT03049917|pediatric HIV testing
1105|NCT03049904|Indian, North America
1106|NCT03049904|Male, Two-Spirit
1107|NCT03049904|HIV Prevention
1108|NCT03049904|MSM
1109|NCT03049891|Antiretroviral Therapy
1110|NCT03049891|Retention
1111|NCT03049891|Loss to Follow Up
1112|NCT03049878|postoperative pain
1113|NCT03049878|paracetamol
1114|NCT03049878|codeine
1115|NCT03049878|tooth extractions
1116|NCT03049878|analgesia
1117|NCT03049878|premedication
1118|NCT03049826|nutrient
1119|NCT03049800|Recent onset psychotic illness
1120|NCT03049800|Healthy controls
1121|NCT03049800|Cognitive training
1122|NCT03049800|7T Magnetic Resonance Imaging
1123|NCT03049787|physical therapy
1124|NCT03049787|home exercise
1125|NCT03049787|adhesive capsulitis
1126|NCT03049748|Heart-Assist Devices, Self-care, Quality of Life
1127|NCT03049709|central blood pressure
1128|NCT03049709|measurement
1129|NCT03049709|oscillometric radial pulse wave analysis
1130|NCT03049696|Roux-En-Y Gastric Bypass
1131|NCT03049696|Bariatric Surgery
1132|NCT03049696|Pre-Operative Physical Activity and Education Program
1133|NCT03049696|Obesity
1134|NCT03049696|Exercise
1135|NCT03049696|Behaviour Modification
1136|NCT03049696|Surgical Outcomes
1137|NCT03049696|Quality of Life
1138|NCT03049683|Vestibular evoked myogenic potentials
1139|NCT03049670|Safety Issue
1140|NCT03049644|chronic lower back pain
1141|NCT03049644|Manual Therapy
1142|NCT03049644|Mechanical Diagnosis and Treatment
1143|NCT03049631|Pre-diabetes
1144|NCT03049631|red raspberry
1145|NCT03049631|fructooligosaccharide
1146|NCT03049631|metagenomics
1147|NCT03049631|polyphenol bioavailability
1148|NCT03049631|glycemic response
1149|NCT03049631|insulin response
1150|NCT03049605|Neuropathies laser and magnetic therapy
1151|NCT03049592|Diabetes
1152|NCT03049592|Contraception
1153|NCT03049592|Prenatal Counseling
1154|NCT03049566|Bleeding
1155|NCT03049566|Adverse Cardiac Events
1156|NCT03049566|Adherence, Medication
1157|NCT03049566|Aspirin
1158|NCT03049566|Acetylsalicylic acid
1159|NCT03049553|Cervical screening
1160|NCT03049553|Human papillomavirus (HPV)
1161|NCT03049553|Cytology
1162|NCT03049553|HPV-test
1163|NCT03049553|Cervical intraepithelial neoplasia (CIN)
1164|NCT03049527|Chronic Kidney Disease
1165|NCT03049527|Unknown Origin
1166|NCT03049514|Thrombolysis
1167|NCT03049514|Recanalization
1168|NCT03049514|Dynamic retinal angiography
1169|NCT03049501|Alzheimer's caregivers
1170|NCT03049501|Technology-based intervention
1171|NCT03049501|Culturally-tailored intervention
1172|NCT03049488|Immune Response
1173|NCT03049488|Respiratory Syncytial Virus
1174|NCT03049488|Vaccine-Mediated Protection
1175|NCT03049488|Neutralizing Antibody
1176|NCT03049488|Antibody Response
1177|NCT03049475|Pain
1178|NCT03049475|Cell Free DNA
1179|NCT03049475|Inflammatory Markers
1180|NCT03049475|Microparticles
1181|NCT03049475|NETosis
1182|NCT03049462|Brown Adipose Tissue
1183|NCT03049462|Energy Expenditure
1184|NCT03049462|Energy Metabolism
1185|NCT03049462|Obesity
1186|NCT03049449|Gene Therapy
1187|NCT03049449|Adoptive T Cell Therapy
1188|NCT03049449|T-cell infusion
1189|NCT03049449|Allogeneic Stem Cell Transplantation
1190|NCT03049449|Immunohistochemistry
1191|NCT03049436|Physical activity
1192|NCT03049436|cancer
1193|NCT03049436|chemotherapy
1194|NCT03049436|daily care unit
1195|NCT03049410|Cystectomy
1196|NCT03049332|Quality of Life
1197|NCT03049306|Obstructive sleep apnea
1198|NCT03049306|CPAP
1199|NCT03049306|Propranolol
1200|NCT03049306|Metabolism
1201|NCT03049293|COPD,IVF
1202|NCT03049267|acne inversa
1203|NCT03049241|Children
1204|NCT03049241|Neuromuscular fatigue
1205|NCT03049241|Muscle group
1206|NCT03049241|Magnetic Nerve stimulation
1207|NCT03049241|Muscle length
1208|NCT03049241|Stiffness
1209|NCT03049241|prepubertal children
1210|NCT03049241|adults
1211|NCT03049228|Spectrum Analysis
1212|NCT03049228|Mitochondria
1213|NCT03049228|Peroxisome Proliferator-Activated Receptors
1214|NCT03049228|Respirometry
1215|NCT03049228|Human
1216|NCT03049228|Heart
1217|NCT03049189|non-functional and functional P-NET
1218|NCT03049189|non-functional GE-NET
1219|NCT03049176|HIV-discordant couple
1220|NCT03049176|ART
1221|NCT03049176|PrEP
1222|NCT03049176|semen washing
1223|NCT03049176|artificial vaginal insemination
1224|NCT03049176|safer conception
1225|NCT03049176|pregnancy
1226|NCT03049150|Urine
1227|NCT03049150|Mass Spectometry
1228|NCT03049150|Observational
1229|NCT03049124|Exercise
1230|NCT03049124|Feasibility trial
1231|NCT03049124|Cancer
1232|NCT03049124|Chemoradiation
1233|NCT03049111|Der F (House Dust Mite)
1234|NCT03049098|Eye-tracking
1235|NCT03049098|High Fidelity Simulation Training
1236|NCT03049098|Visual Perception
1237|NCT03049085|OPCAB
1238|NCT03049085|ASA
1239|NCT03049085|Aspirin
1240|NCT03049020|pelvic organ prolapse
1241|NCT03049020|sacrocolpopexy
1242|NCT03049020|pelvic floor ultrasound
1243|NCT03049007|bereavement
1244|NCT03049007|natural grief
1245|NCT03049007|prolonged grief
1246|NCT03049007|complicated grief
1247|NCT03048994|Glutamine
1248|NCT03048994|Severe sepsis
1249|NCT03048981|Thrombocyte aggregation
1250|NCT03048981|Fish oil
1251|NCT03048981|Alternative medicine
1252|NCT03048981|Point of care testing
1253|NCT03048981|Coagulation monitoring
1254|NCT03048968|Exoskeleton Device
1255|NCT03048968|elderly
1256|NCT03048968|stroke
1257|NCT03048942|Breast cancer
1258|NCT03048942|HER2 negative
1259|NCT03048942|Cabazitaxel
1260|NCT03048942|Paclitaxel
1261|NCT03048942|Chemotherapy
1262|NCT03048916|dysphagia
1263|NCT03048916|stroke
1264|NCT03048916|magnetic resonance imaging
1265|NCT03048916|videofluoroscopy
1266|NCT03048903|Gastrointestinal dysfunction
1267|NCT03048903|sepsis
1268|NCT03048903|trauma
1269|NCT03048890|PAD
1270|NCT03048877|Radioactive iodine-refractory
1271|NCT03048877|differentiated thyroid cancer
1272|NCT03048877|Apatinib
1273|NCT03048877|anti-angiogenesis drugs
1274|NCT03048864|Metabolic Screening
1275|NCT03048864|24 hour urine
1276|NCT03048851|Cerebral palsy
1277|NCT03048851|sensory electrical stimulation
1278|NCT03048851|virtual reality constraint-induced therapy
1279|NCT03048812|Dental implant
1280|NCT03048812|Mandibular overdenture
1281|NCT03048812|Cross-over study
1282|NCT03048786|Peer mentoring
1283|NCT03048786|social support
1284|NCT03048786|text messaging
1285|NCT03048786|smoking cessation
1286|NCT03048773|shockwave therapy
1287|NCT03048773|knee osteoarthritis
1288|NCT03048760|MRI scan
1289|NCT03048760|Organs at Risk
1290|NCT03048708|Bariatric surgery
1291|NCT03048708|Leptin
1292|NCT03048708|Thyroid function tests
1293|NCT03048617|Primary Mitochondrial Disease
1294|NCT03048617|Stealth
1295|NCT03048617|Myopathy
1296|NCT03048617|exercise intolerance
1297|NCT03048617|muscle pain
1298|NCT03048617|Mitochondrial Myopathy
1299|NCT03048617|Primary Mitochondrial Myopathy
1300|NCT03048578|Roux-en-Y gastric bypass (RYGB)
1301|NCT03048565|mindfulness
1302|NCT03048565|caregivers
1303|NCT03048552|drug use
1304|NCT03048552|drug addiction
1305|NCT03048552|drug habituation
1306|NCT03048552|drug use disorders
1307|NCT03048552|organic mental disorders
1308|NCT03048552|substance-induced
1309|NCT03048552|substance abuse
1310|NCT03048552|substance addiction
1311|NCT03048552|substance dependence
1312|NCT03048552|substance use disorders
1313|NCT03048539|Endoscopic surgery
1314|NCT03048539|Thyroidectomy
1315|NCT03048539|Quality of life
1316|NCT03048513|Melioidosis
1317|NCT03048513|Head and Neck
1318|NCT03048513|Clinical
1319|NCT03048474|progressive disease after at least 1 course of chemotherapy
1320|NCT03048448|Hepatic impairment,
1321|NCT03048448|Fevipiprant,
1322|NCT03048448|adults,
1323|NCT03048448|pharmacokinetics
1324|NCT03048435|Cervical Cancer
1325|NCT03048435|Patient Reported Outcomes
1326|NCT03048435|Radiation Therapy
1327|NCT03048435|EORTC QLQ-CX24
1328|NCT03048435|Quality of Life
1329|NCT03048383|Facial paralysis
1330|NCT03048383|Facial synkinesis
1331|NCT03048383|Botulinum toxin
1332|NCT03048344|acute promyelocytic leukemia
1333|NCT03048344|APL
1334|NCT03048344|arsenic trioxide
1335|NCT03048331|Functional Electrical Stimulation
1336|NCT03048331|Tetraplegia
1337|NCT03048331|Reconstructive Hand Surgery
1338|NCT03048292|Embolectomy
1339|NCT03048292|Embolus
1340|NCT03048292|Thrombectomy
1341|NCT03048292|Thrombolysis
1342|NCT03048292|Thrombus
1343|NCT03048292|Mobile
1344|NCT03048292|Interventional
1345|NCT03048292|Neurointervention
1346|NCT03048292|Stroke
1347|NCT03048292|Ischemic
1348|NCT03048292|Acute
1349|NCT03048292|Endovascular
1350|NCT03048292|Cerebrovascular
1351|NCT03048292|Clot
1352|NCT03048292|Stent Retriever
1353|NCT03048292|Tissue Plasminogen Activator
1354|NCT03048292|Drip and Ship
1355|NCT03048292|Mothership
1356|NCT03048292|Trip and Treat
1357|NCT03048279|Multiple Endocrine Neoplasia Syndromes
1358|NCT03048279|MEN1
1359|NCT03048279|MEN2
1360|NCT03048279|Relatives
1361|NCT03048279|Database
1362|NCT03048279|Questionnaires
1363|NCT03048279|Surveys
1364|NCT03048266|Multiple endocrine neoplasia
1365|NCT03048266|MEN1
1366|NCT03048266|Aggressive pancreatic neuroendocrine tumors
1367|NCT03048266|PNET
1368|NCT03048266|Non-aggressive pancreatic neuroendocrine tumors
1369|NCT03048266|Metabolomics
1370|NCT03048266|Genetics
1371|NCT03048266|Biomarkers
1372|NCT03048240|Glioblastoma
1373|NCT03048227|TIDM
1374|NCT03048227|Type1diabetes
1375|NCT03048227|Implantable Pump
1376|NCT03048227|CGM
1377|NCT03048214|Nerve block; Infraclavicular; Acute pain
1378|NCT03048201|Physica KR
1379|NCT03048201|Physica CR
1380|NCT03048201|Physica PS
1381|NCT03048201|Kinematic Retaining
1382|NCT03048201|Cruciate Retaining
1383|NCT03048201|Posterior Stabilized
1384|NCT03048201|Physica System
1385|NCT03048175|C-reactive protein
1386|NCT03048175|Systemic inflammation
1387|NCT03048175|Third molar
1388|NCT03048175|Wisdom tooth
1389|NCT03048149|hazelnut allergy
1390|NCT03048123|Hepatic arterial infusion chemotherapy
1391|NCT03048123|Transarterial Chemoembolization
1392|NCT03048123|Large and unresectable HCC
1393|NCT03048071|Contegra
1394|NCT03048071|Homograft
1395|NCT03048045|chronic periodontitis
1396|NCT03048045|aggressive periodontitis
1397|NCT03048045|supportive periodontal treatment
1398|NCT03048032|acute heart failure
1399|NCT03048032|right ventricular failure
1400|NCT03048032|cardiac biomarkers
1401|NCT03048032|echocardiography
1402|NCT03048032|diagnosis
1403|NCT03048032|prognosis
1404|NCT03047993|Myelodysplastic syndrome
1405|NCT03047993|MDS
1406|NCT03047993|Other diseases of blood and blood-forming organs
1407|NCT03047993|CB-839
1408|NCT03047993|Azacitidine
1409|NCT03047993|5-azacytidine
1410|NCT03047993|5-aza
1411|NCT03047993|Vidaza
1412|NCT03047993|5-AZC
1413|NCT03047993|AZA-CR
1414|NCT03047993|Ladakamycin
1415|NCT03047993|NSC-102816
1416|NCT03047993|Azacytidine
1417|NCT03047993|Pharmacokinetic testing
1418|NCT03047993|Pharmacodynamic testing
1419|NCT03047980|SWS
1420|NCT03047980|Cognitive impairment
1421|NCT03047980|sirolimus
1422|NCT03047915|Anxiety
1423|NCT03047915|Music intervention
1424|NCT03047915|Emergency department (ED)
1425|NCT03047902|Adolescent Smoking Cessation Asthma Carbon Monoxide.
1426|NCT03047876|cardiac
1427|NCT03047876|aortic arch surgery
1428|NCT03047876|Brain vascular reactivity
1429|NCT03047876|neonates
1430|NCT03047876|infants
1431|NCT03047863|Epidermal Growth Factor
1432|NCT03047850|Sternotomy
1433|NCT03047837|Colorectal cancer
1434|NCT03047837|aspirin
1435|NCT03047837|metformin
1436|NCT03047837|chemoprevention
1437|NCT03047798|centella asiatica
1438|NCT03047798|bamboo salt
1439|NCT03047798|magnolia bark
1440|NCT03047798|gingivitis
1441|NCT03047798|dental plaque
1442|NCT03047798|mouthrinse
1443|NCT03047785|Myocardial Infarction
1444|NCT03047785|Highly sensitive troponin
1445|NCT03047785|Hospital population
1446|NCT03047785|99th percentile
1447|NCT03047785|Upper limit of normal
1448|NCT03047733|Vitiligo
1449|NCT03047733|308 nm excimer laser
1450|NCT03047720|bedwetting
1451|NCT03047707|ultrasound elastography
1452|NCT03047707|S-Shearwave
1453|NCT03047707|liver
1454|NCT03047707|fibrosis
1455|NCT03047694|Lexico-semantic stimulation
1456|NCT03047694|tactile tablet
1457|NCT03047681|TAVR
1458|NCT03047681|tryptse
1459|NCT03047681|mast
1460|NCT03047642|biomarker
1461|NCT03047642|low and middle income countries
1462|NCT03047642|fever
1463|NCT03047642|antimicrobial resistance
1464|NCT03047642|diagnostic
1465|NCT03047629|non-motor symptoms
1466|NCT03047603|Hepatocellular carcinoma
1467|NCT03047603|Protein induced by vitamin K absence or antagonist-II
1468|NCT03047603|Differential diagnosis
1469|NCT03047603|Des-γ-carboxy prothrombin
1470|NCT03047603|Alpha-fetoprotein
1471|NCT03047603|Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein-fetoprotein
1472|NCT03047590|exercise behavior
1473|NCT03047590|exercise prescription
1474|NCT03047590|affect-based exercise
1475|NCT03047590|affect-guided exercise
1476|NCT03047590|self-paced exercise
1477|NCT03047590|self-selected exercise
1478|NCT03047577|Brief intervention
1479|NCT03047577|Alcohol
1480|NCT03047577|Alcohol use disorder
1481|NCT03047577|Intensive care unit
1482|NCT03047577|Critically ill
1483|NCT03047577|Audit
1484|NCT03047564|Total Knee Arthroplasty
1485|NCT03047564|Total Knee Replacement
1486|NCT03047564|Outcome
1487|NCT03047564|Metal ion concentration
1488|NCT03047564|Results
1489|NCT03047551|Abortion, induced
1490|NCT03047551|Ultrasonography
1491|NCT03047551|Health Services accessibility
1492|NCT03047551|Pragmatic Clinical Trial
1493|NCT03047551|Randomized controlled trial as topic
1494|NCT03047538|Arterial hypertension
1495|NCT03047538|Dyslipidemia
1496|NCT03047538|Blood pressure control
1497|NCT03047538|Fixed combination
1498|NCT03047525|cytokine-induced killer cell
1499|NCT03047525|dendritic and cytokine-induced killer cells
1500|NCT03047512|Depression in adolescents
1501|NCT03047512|Mental Health
1502|NCT03047512|E-mental health
1503|NCT03047512|Prevention and Early intervention
1504|NCT03047486|insulin pump
1505|NCT03047486|continuous glucose monitoring sensor
1506|NCT03047486|predictive low glucose suspend
1507|NCT03047473|newly diagnosed
1508|NCT03047460|motor evoked potential
1509|NCT03047460|somatosensory evoked potentials
1510|NCT03047460|biomarker
1511|NCT03047408|REM Sleep Behavior Disorder
1512|NCT03047408|Parkinson's Disease
1513|NCT03047408|REM sleep without Atonia
1514|NCT03047395|BI 655066
1515|NCT03047395|ABBV-066
1516|NCT03047369|leukodystrophy
1517|NCT03047369|white matter disease
1518|NCT03047369|leukoencephalopathy
1519|NCT03047369|myelin
1520|NCT03047369|demyelinating
1521|NCT03047369|mdbp
1522|NCT03047343|pulmonary artery strapping
1523|NCT03047330|menopause
1524|NCT03047330|sleep fragmentation
1525|NCT03047330|leuprolide
1526|NCT03047330|adipokine
1527|NCT03047330|weight gain
1528|NCT03047330|leptin
1529|NCT03047317|pharmacokinetics
1530|NCT03047291|mucositis, periimplantitis, probiotic
1531|NCT03047226|Lynch Syndrome
1532|NCT03047226|mismatch repair
1533|NCT03047226|microsatellite instability
1534|NCT03047226|next-generation sequencing
1535|NCT03047226|immunohistochemistry
1536|NCT03047200|Diabetes Mellitus
1537|NCT03047200|Hypoglycemia
1538|NCT03047200|Hyperglycemia
1539|NCT03047200|Type 1 Diabetes
1540|NCT03047200|Islet Cell Transplantation
1541|NCT03047174|Head and Neck Neoplasms, Radio(chemo)therapy
1542|NCT03047161|magnetocardiography
1543|NCT03047135|high-risk biochemically-recurrent
1544|NCT03047122|Breast
1545|NCT03047122|ultrasonography
1546|NCT03047109|Ephedrine
1547|NCT03047109|Phenylephrine
1548|NCT03047109|Spinal Hypotension
1549|NCT03047109|Cesarean Section
1550|NCT03047109|Maternal Cardiodynamics
1551|NCT03047083|Retrospective
1552|NCT03047083|Non-interventional Study
1553|NCT03047083|FMS-like tyrosine kinase-3 (FLT3) mutations
1554|NCT03047044|lumbar fusion surgery
1555|NCT03047044|Patient Controlled Analgesia
1556|NCT03047044|Optimizing Basal Infusion Mode
1557|NCT03047018|Nutrition
1558|NCT03046992|EGFR
1559|NCT03046992|Non-Small Cell Lung Cancer
1560|NCT03046992|T790M
1561|NCT03046992|Brain Metastasis
1562|NCT03046979|apatinib
1563|NCT03046979|advanced hepatocellular carcinoma
1564|NCT03046953|Lymphoma
1565|NCT03046927|Type 1 diabetes
1566|NCT03046927|vitamin D
1567|NCT03046927|honeymoon phase
1568|NCT03046901|Vancomycin
1569|NCT03046901|Primary Sclerosing cholangitis
1570|NCT03046901|Post-liver transplantation
1571|NCT03046849|Lynch Syndrome
1572|NCT03046849|next-generation sequencing
1573|NCT03046849|germline mutation
1574|NCT03046836|Couples
1575|NCT03046836|Oxytocin
1576|NCT03046836|Aggression
1577|NCT03046836|Alcohol
1578|NCT03046771|falls
1579|NCT03046771|readmissions
1580|NCT03046771|emergency department visits
1581|NCT03046771|transitions of care
1582|NCT03046745|Gastric cancer, endoscopy, pepsinogen, TFF3, biomarker
1583|NCT03046732|Kidney Transplant Education
1584|NCT03046732|Transplant Readiness
1585|NCT03046732|Living Donor Kidney Transplant
1586|NCT03046732|Chronic Kidney Disease
1587|NCT03046732|End Stage Kidney Disease
1588|NCT03046732|Renal Replacement Therapy
1589|NCT03046719|bupivacaine
1590|NCT03046719|intravitreal
1591|NCT03046719|analgesia
1592|NCT03046719|silicone oil removal
1593|NCT03046719|retinal detachment
1594|NCT03046719|subconjunctival
1595|NCT03046706|voice rest
1596|NCT03046706|laryngeal surgery
1597|NCT03046706|glottic polyp
1598|NCT03046706|glottic cyst
1599|NCT03046693|Non-arteritic anterior ischemic optic neuropathy
1600|NCT03046693|pattern electroretinography
1601|NCT03046693|citicoline
1602|NCT03046693|retinal ganglion cell
1603|NCT03046693|visual field
1604|NCT03046667|Beta glucans
1605|NCT03046667|Barley
1606|NCT03046667|SCFA
1607|NCT03046667|Calprotectin
1608|NCT03046667|Microbiota
1609|NCT03046667|Hydrogene
1610|NCT03046667|Methane
1611|NCT03046667|Metabolomics
1612|NCT03046667|Stool volume
1613|NCT03046667|Stool frequency
1614|NCT03046641|Caloric Restriction
1615|NCT03046641|Dietary Formulations
1616|NCT03046641|Exercise
1617|NCT03046641|Men
1618|NCT03046615|EEG electrodes
1619|NCT03046563|acupressure
1620|NCT03046563|abdominal massage
1621|NCT03046563|constipation
1622|NCT03046563|stroke patients
1623|NCT03046563|Traditional Chinese medicine
1624|NCT03046524|Parathyroid Carcinoma
1625|NCT03046524|Parathyroid Neoplasm
1626|NCT03046524|Chart Review
1627|NCT03046485|AMD
1628|NCT03046485|vision loss
1629|NCT03046485|self-management strategies
1630|NCT03046485|low-vision rehabilitation
1631|NCT03046485|IVI
1632|NCT03046472|thorax curve angle
1633|NCT03046459|cytokines
1634|NCT03046459|interleukin-2
1635|NCT03046459|Safety Issues
1636|NCT03046446|Osteoarthritis
1637|NCT03046446|Knee
1638|NCT03046446|Pain
1639|NCT03046446|Steroid
1640|NCT03046446|Intra-articular
1641|NCT03046446|Injection
1642|NCT03046433|children
1643|NCT03046433|asthma
1644|NCT03046433|China
1645|NCT03046394|prosthetic feet
1646|NCT03046394|gait pattern
1647|NCT03046394|one leg standing
1648|NCT03046394|walking speed
1649|NCT03046342|Gastroenteritis, Polymerase chain reaction
1650|NCT03046329|patient care planning
1651|NCT03046316|Therapeutics
1652|NCT03046303|ERAS,gastric cancer
1653|NCT03046264|central blood pressure
1654|NCT03046264|measurement
1655|NCT03046264|oscillometric radial pulse wave analysis
1656|NCT03046186|Gastric sleeve
1657|NCT03046186|Gastric bypass
1658|NCT03046160|PPT
1659|NCT03046160|Scapula
1660|NCT03046160|Intervention
1661|NCT03046160|Manual therapy
1662|NCT03046160|mobilization
1663|NCT03046121|dementia
1664|NCT03046121|acute care
1665|NCT03046121|post-acute recovery
1666|NCT03046121|family caregivers
1667|NCT03046095|Muscle Hypertrophy
1668|NCT03046095|Muscle Atrophy
1669|NCT03046095|Resistance Training
1670|NCT03046095|Immobilization
1671|NCT03046069|Triple therapy
1672|NCT03046069|COPD
1673|NCT03046069|DCE
1674|NCT03046069|Qualitative
1675|NCT03046069|Trelegy ELLIPTA inhaler
1676|NCT03046004|breast cancer
1677|NCT03046004|screening
1678|NCT03046004|decision aid
1679|NCT03046004|informed choice
1680|NCT03046004|decisional conflict
1681|NCT03045965|Salpingectomy
1682|NCT03045965|Hysterectomy
1683|NCT03045965|Ovarian cancer
1684|NCT03045952|Multicenter study
1685|NCT03045952|microwave
1686|NCT03045939|cervical ripening
1687|NCT03045939|labor induction
1688|NCT03045939|double balloon device
1689|NCT03045939|cervical ripening device
1690|NCT03045939|unfavorable cervix
1691|NCT03045913|Observational registry
1692|NCT03045913|All-comers open label registry
1693|NCT03045913|Genoss DES
1694|NCT03045913|Multicenter
1695|NCT03045913|Stenting
1696|NCT03045913|Coronary Artery Disease
1697|NCT03045913|Coronary revascularization
1698|NCT03045913|Percutaneous Coronary Intervention
1699|NCT03045887|repeat dose
1700|NCT03045887|GSK2292767
1701|NCT03045887|smoke
1702|NCT03045887|tolerability
1703|NCT03045887|safety
1704|NCT03045887|dry powder inhalation
1705|NCT03045887|pharmacokinetics
1706|NCT03045887|single dose
1707|NCT03045848|Observational registry
1708|NCT03045848|All-comers open label registry
1709|NCT03045848|Drug coated stent
1710|NCT03045848|Multicenter
1711|NCT03045848|Stenting
1712|NCT03045848|Coronary Artery Disease
1713|NCT03045848|Coronary revascularization
1714|NCT03045848|Percutaneous Coronary Intervention
1715|NCT03045835|laparoscopic surgery BASKA mask ambulatory care
1716|NCT03045822|Bioimpedance analysis
1717|NCT03045822|implantable cardioverter-defibrillators
1718|NCT03045822|pacemakers
1719|NCT03045809|Syndromic management
1720|NCT03045809|Point of care testing
1721|NCT03045783|gastric varices
1722|NCT03045783|endoscopic injection of tissue adhesive
1723|NCT03045731|kidney transplantation
1724|NCT03045731|ultrasound
1725|NCT03045731|mathematical model
1726|NCT03045718|Horticultural Therapy
1727|NCT03045718|Dementia
1728|NCT03045718|Randomized Controlled Trial
1729|NCT03045718|Elderly
1730|NCT03045718|Prevention
1731|NCT03045692|drug dosing, eGFR, CCr
1732|NCT03045679|Roux-en Y gastric bypass
1733|NCT03045679|One-anastomosis gastric bypass
1734|NCT03045679|Mini-gastric bypass
1735|NCT03045679|metabolic surgery
1736|NCT03045653|Breast Cancer
1737|NCT03045653|high dose Tamoxifen
1738|NCT03045653|endocrine therapy
1739|NCT03045653|Hormone Receptor Positive Malignant Neoplasm of Breast
1740|NCT03045653|Tamoxifen
1741|NCT03045653|Breast Cancer Metastatic
1742|NCT03045640|ECD
1743|NCT03045640|parenting program
1744|NCT03045640|home visiting
1745|NCT03045627|Acute Myeloid Leukemia
1746|NCT03045627|PEG-G-CSF
1747|NCT03045601|Diagnostic Techniques, Cardiovascular
1748|NCT03045601|Coronary Angiography
1749|NCT03045601|Fractional Flow Reserve, Myocardial
1750|NCT03045601|Echocardiography, Stress
1751|NCT03045510|Decitabine Myelodysplastic syndrome
1752|NCT03045484|nasopharyngeal carcinoma
1753|NCT03045484|Oral Mucositis Pain
1754|NCT03045484|Oxycodone
1755|NCT03045458|one stage dental implant
1756|NCT03045458|two stage dental implant
1757|NCT03045458|Interleukin-1β
1758|NCT03045445|CT
1759|NCT03045445|dual energy
1760|NCT03045445|low dose
1761|NCT03045432|Stroke
1762|NCT03045432|Hemiplegia
1763|NCT03045432|Rotator Cuff Injury
1764|NCT03045419|MRI
1765|NCT03045419|gadoxetic acid
1766|NCT03045419|CT
1767|NCT03045393|Neoadjuvant
1768|NCT03045393|Breast Cancer
1769|NCT03045393|Folate Receptor Alpha
1770|NCT03045393|FRa
1771|NCT03045393|TNBC
1772|NCT03045393|Triple Negative Breast Cancer
1773|NCT03045393|Preoperative
1774|NCT03045393|Presurgery
1775|NCT03045393|Mirvetuximab Soravtansine
1776|NCT03045393|IMGN853
1777|NCT03045367|Metamorphopsia
1778|NCT03045367|Epiretinal membrane
1779|NCT03045367|Vitrectomy
1780|NCT03045354|children
1781|NCT03045354|dietary carbohydrates
1782|NCT03045354|satiety
1783|NCT03045354|appetite
1784|NCT03045354|blood glucose
1785|NCT03045354|solanum tuberosum
1786|NCT03045354|obesity
1787|NCT03045354|breakfast
1788|NCT03045263|ASD
1789|NCT03045237|Pregnancy
1790|NCT03045237|Physical activity
1791|NCT03045237|Newborn
1792|NCT03045237|Depressive Symptoms
1793|NCT03045237|Dietary habits
1794|NCT03045237|Healthy lifestyles
1795|NCT03045224|PAD, PTA, mortality, morbidity, amputation rate, quality of life
1796|NCT03045224|Percutaneous transluminal angioplasty (PTA), Stenting, balloon angioplasty
1797|NCT03045198|cystic fibrosis
1798|NCT03045185|Non Vital teeth
1799|NCT03045185|Traumatised teeth
1800|NCT03045185|Immature teeth
1801|NCT03045185|Regenerative Endodontics
1802|NCT03045172|Lichen Sclerosus
1803|NCT03045172|Platelet Rich Plasma
1804|NCT03045172|Vulvar
1805|NCT03045172|Vulva
1806|NCT03045159|deployment cycle
1807|NCT03045159|military family
1808|NCT03045159|prevention
1809|NCT03045159|stress
1810|NCT03045159|military child
1811|NCT03045159|parenting
1812|NCT03045159|coparenting
1813|NCT03045146|Acute Ischemic Stroke, Thrombectomy
1814|NCT03045133|Postoperative pain
1815|NCT03045133|Postoperative nausea and vomiting
1816|NCT03045133|Quality of recovery
1817|NCT03045133|QoR-40
1818|NCT03045133|Total intravenous anesthesia
1819|NCT03045107|right colon
1820|NCT03045107|laparoscopic right colectomy
1821|NCT03045107|intracorporeal anastomosis
1822|NCT03045107|extracorporeal anastomosis
1823|NCT03045107|hospital stay
1824|NCT03045107|quality of life
1825|NCT03045107|costs
1826|NCT03045094|pediatric
1827|NCT03045094|intubation
1828|NCT03045094|neck movement
1829|NCT03045055|Acute ischemic stroke
1830|NCT03045055|Endovascular treatment
1831|NCT03045055|Remote ischemic conditioning
1832|NCT03045042|Pompe
1833|NCT03045042|microRNA
1834|NCT03045042|biomarker
1835|NCT03045042|muscle MRI
1836|NCT03045042|glycogenosis
1837|NCT03045029|PAH
1838|NCT03045029|Oral Treprostiinil
1839|NCT03045029|Orenitram
1840|NCT03045016|Acute stress Disorder
1841|NCT03045016|Post Traumatic Stress Disorder
1842|NCT03045016|Prevention
1843|NCT03045016|trauma
1844|NCT03045016|prazosin
1845|NCT03045003|Resilience, Supportive Care, Psychosocial Care, Nursing
1846|NCT03044990|Acute coronary syndrome
1847|NCT03044990|renal insufficiency
1848|NCT03044990|mortality
1849|NCT03044977|3-Iodobenzylguanidine
1850|NCT03044977|dose-response relationship, radiation
1851|NCT03044977|theranostic
1852|NCT03044977|radionuclide
1853|NCT03044977|MIBG
1854|NCT03044977|DOTA
1855|NCT03044964|Angina, Chest Pain
1856|NCT03044951|atrial fibrillation
1857|NCT03044951|cryoablation
1858|NCT03044951|irrigated radiofrequency ablation
1859|NCT03044951|pulmonary vein isolation
1860|NCT03044938|Asthma
1861|NCT03044938|Salbutamol
1862|NCT03044938|Exercise
1863|NCT03044938|Heart Rate
1864|NCT03044938|Blood pressure
1865|NCT03044925|persistent atrial fibrillation
1866|NCT03044925|remote magnetic navigation
1867|NCT03044925|cryoablation
1868|NCT03044899|Surgery
1869|NCT03044899|Complications
1870|NCT03044899|Mortality
1871|NCT03044886|Vitamin D
1872|NCT03044821|Neural Tube Defect
1873|NCT03044795|homologous recombination deficiency
1874|NCT03044795|veliparib
1875|NCT03044795|PARP inhibitor
1876|NCT03044795|biomarker
1877|NCT03044769|Congenital Lung Anomalies
1878|NCT03044756|GnRH antagonist
1879|NCT03044756|Pituitary downregulation
1880|NCT03044756|IVF
1881|NCT03044756|ICSI
1882|NCT03044743|PD-1
1883|NCT03044743|CRISPR Cas9
1884|NCT03044743|EBV
1885|NCT03044743|advanced stage malignancies
1886|NCT03044717|Nutrition Education
1887|NCT03044717|Cardiology Fellows
1888|NCT03044652|Vulvovaginal Dryness
1889|NCT03044626|Nivolumab
1890|NCT03044626|Radiotherapy
1891|NCT03044600|Parathyroid disease
1892|NCT03044600|Hyperparathyroidism
1893|NCT03044600|Chart review
1894|NCT03044600|MEN1-negative
1895|NCT03044600|HRPT2 mutations
1896|NCT03044587|Biliary Tract Cancer
1897|NCT03044587|NaI-IRI
1898|NCT03044574|venous thromboembolism
1899|NCT03044574|deep vein thrombosis
1900|NCT03044574|pulmonary embolism
1901|NCT03044574|prevention
1902|NCT03044574|intermittent pneumatic compression
1903|NCT03044574|sequential pneumatic compression
1904|NCT03044574|surgery
1905|NCT03044574|elastic compression
1906|NCT03044574|low-molecular weight heparin
1907|NCT03044574|prophylaxis
1908|NCT03044535|quality of life
1909|NCT03044535|mechanical circulatory support
1910|NCT03044509|Immunodiagnostics tests
1911|NCT03044509|TB exposure
1912|NCT03044509|Latent TB
1913|NCT03044509|TB disease
1914|NCT03044509|Biomarkers
1915|NCT03044496|NIR Spectroscopy
1916|NCT03044496|Nerve Blockade
1917|NCT03044496|Surgical Arteriovenous Shunt
1918|NCT03044483|Sepsis
1919|NCT03044483|Microcirculatory function
1920|NCT03044444|performance
1921|NCT03044444|polyphenols
1922|NCT03044444|nutrition
1923|NCT03044444|sports
1924|NCT03044431|Shortness of breath
1925|NCT03044431|Breathlessness
1926|NCT03044431|Stem cells
1927|NCT03044431|Platelet rich plasma
1928|NCT03044431|Quality of life
1929|NCT03044431|Pulmonary Function
1930|NCT03044418|laser
1931|NCT03044418|endotracheal tube
1932|NCT03044418|total intravenous anesthesia
1933|NCT03044418|side effect
1934|NCT03044418|endolaryngeal surgery
1935|NCT03044405|fluid responsiveness
1936|NCT03044405|focused echocardiography
1937|NCT03044405|major surgery
1938|NCT03044353|echocardiography (ECHO)
1939|NCT03044353|skin biopsy
1940|NCT03044353|monoclonal anti-serum amyloid p component antibody (anti-SAP mAb)
1941|NCT03044353|Amyloidosis
1942|NCT03044353|cardiac magnetic resonance imaging (CMR)
1943|NCT03044353|biomarkers
1944|NCT03044353|cardiac functional measures
1945|NCT03044353|left ventricular mass
1946|NCT03044314|pulmonary hypertension
1947|NCT03044314|vasodilator challenge
1948|NCT03044314|echocardiography
1949|NCT03044314|outcomes
1950|NCT03044314|iloprost
1951|NCT03044314|inhaled nitric oxide
1952|NCT03044249|Psychotic Disorders
1953|NCT03044223|pseudomonas aeruginosa
1954|NCT03044223|critically ill patient
1955|NCT03044223|sepsis
1956|NCT03044223|monocyte
1957|NCT03044223|macrophage
1958|NCT03044223|cytokine
1959|NCT03044223|severity of disease
1960|NCT03044210|Rest energetic cost measured by indirect calorimetry
1961|NCT03044210|Hormonal axis
1962|NCT03044210|Mitochondrial oxidative phosphorylation
1963|NCT03044210|Basal metabolism
1964|NCT03044197|prostate cancer
1965|NCT03044197|magnetic resonance imaging
1966|NCT03044197|transperineal biopsy
1967|NCT03044197|target lesion
1968|NCT03044197|fusion biopsy
1969|NCT03044184|Tranexamic Acid
1970|NCT03044184|Antifibrinolytic
1971|NCT03044158|tuberculosis
1972|NCT03044158|implementation science
1973|NCT03044158|point-of-care
1974|NCT03044158|diagnostics
1975|NCT03044158|GeneXpert
1976|NCT03044158|Uganda
1977|NCT03044145|Cultural Competence
1978|NCT03044145|Patient-Clinician communication
1979|NCT03044132|Diabetic Foot Ulcer
1980|NCT03044132|DFU
1981|NCT03044132|Lower Extremity Wound
1982|NCT03044132|Skin Substitute
1983|NCT03044106|hamstrings
1984|NCT03044106|flexibility
1985|NCT03044106|strength
1986|NCT03044106|pain pressure threshold
1987|NCT03044106|lllt
1988|NCT03044106|photobiomodulation
1989|NCT03044106|cranial reflex
1990|NCT03044106|cranial laser reflex technique
1991|NCT03044106|CLRT
1992|NCT03044080|Walking Disorder
1993|NCT03044080|Stroke
1994|NCT03044080|Botulinum Toxin
1995|NCT03044080|Spasticity
1996|NCT03044067|Chronic pain
1997|NCT03044067|Fibromyalgia
1998|NCT03044067|Pain neuroscience education
1999|NCT03044067|Exercise
2000|NCT03044054|HIFU
2001|NCT03044041|Blood loss
2002|NCT03044041|Tranexamic acid
2003|NCT03044041|Total knee arthroplasty
2004|NCT03044041|Topical administration
2005|NCT03043989|docetaxel
2006|NCT03043989|cabazitaxel
2007|NCT03043989|phase 1b
2008|NCT03043989|castration-resistant
2009|NCT03043989|bone metastasis
2010|NCT03043976|Physical activity
2011|NCT03043976|Steps count
2012|NCT03043950|mCRC
2013|NCT03043950|First line
2014|NCT03043950|Panitumumab
2015|NCT03043950|mCCS Prognostic Score
2016|NCT03043950|Prognosis
2017|NCT03043950|Ras wild type
2018|NCT03043924|hypothalamus
2019|NCT03043924|Diffusion Magnetic Resonance Imaging
2020|NCT03043924|Magnetic Resonance Spectroscopy
2021|NCT03043911|early detection
2022|NCT03043911|respiratory events
2023|NCT03043911|sepsis
2024|NCT03043872|Carcinoma, Small Cell Lung
2025|NCT03043872|Oat Cell Carcinoma of Lung
2026|NCT03043872|Oat Cell Lung Cancer
2027|NCT03043872|Small Cell Cancer Of The Lung
2028|NCT03043872|Small Cell Lung Cancer
2029|NCT03043846|Treat to Target approach
2030|NCT03043820|raloxifene
2031|NCT03043820|selective estrogen receptor modulator (SERM)
2032|NCT03043820|schizophrenia
2033|NCT03043820|psychosis
2034|NCT03043820|cognition
2035|NCT03043820|negative symptoms
2036|NCT03043807|prostatectomy
2037|NCT03043807|androgen deprivation
2038|NCT03043807|chemotherapy
2039|NCT03043807|radiation
2040|NCT03043794|early stage
2041|NCT03043794|low risk
2042|NCT03043768|Parkinson's disease
2043|NCT03043768|Autonomic
2044|NCT03043768|Diagnosis
2045|NCT03043768|Pilomotor
2046|NCT03043768|Alpha-synuclein
2047|NCT03043768|Axon-reflex
2048|NCT03043768|Peripheral nerve fibers
2049|NCT03043729|neoadjuvant
2050|NCT03043729|MRI-defined T3
2051|NCT03043729|mFOLFOX6
2052|NCT03043729|Aflibercept
2053|NCT03043690|menopause
2054|NCT03043690|ammonium succinate
2055|NCT03043664|GEP-NET
2056|NCT03043664|Pembrolizumab
2057|NCT03043664|Lanreotide depot
2058|NCT03043664|PD-1
2059|NCT03043651|Pulmonary Hypertension
2060|NCT03043651|HFpEF
2061|NCT03043651|6-Minute Walk Test
2062|NCT03043651|Oral Treprostinil
2063|NCT03043638|multiple adjacent gingival recessions
2064|NCT03043638|platelet rich plasma
2065|NCT03043638|acellular dermal matrix
2066|NCT03043638|coronally advanced flap
2067|NCT03043638|gingival recession
2068|NCT03043638|root coverage
2069|NCT03043638|clinical attachment level
2070|NCT03043625|Neck pain
2071|NCT03043625|visceral manipulation
2072|NCT03043625|functional dyspepsia
2073|NCT03043625|electromyography
2074|NCT03043625|pain
2075|NCT03043612|Ureteroscopy for urolithiasis
2076|NCT03043599|Thoracic
2077|NCT03043599|Radiotherapy
2078|NCT03043599|Platinum Based Chemotherapy
2079|NCT03043599|Immunotherapy
2080|NCT03043599|Ipilimumab
2081|NCT03043599|Nivolumab
2082|NCT03043599|Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
2083|NCT03043586|Acromegaly
2084|NCT03043560|depression
2085|NCT03043560|anhedonia
2086|NCT03043560|reward
2087|NCT03043547|nal-IRI
2088|NCT03043547|5-Fluorouracil
2089|NCT03043508|Genetic mutation
2090|NCT03043508|MEN1
2091|NCT03043508|Pancreatic neuroendocrine tumor
2092|NCT03043508|PNET
2093|NCT03043508|Chart review
2094|NCT03043508|Questionnaire
2095|NCT03043508|Survey
2096|NCT03043495|dexamethasone
2097|NCT03043495|supraclavicular brachial plexus block
2098|NCT03043495|ultrasound
2099|NCT03043482|VS-105
2100|NCT03043482|Renal Insufficiency, Chronic
2101|NCT03043482|Secondary hyperparathyroidism
2102|NCT03043469|dysfunctional breathing
2103|NCT03043443|sleep
2104|NCT03043443|Alcohol dependence
2105|NCT03043443|Melatonin
2106|NCT03043417|Stigma
2107|NCT03043417|Primary Health Care
2108|NCT03043417|Recovery
2109|NCT03043391|Pediatric Malignant Glioma
2110|NCT03043391|PVSRIPO
2111|NCT03043391|Pro00071228
2112|NCT03043391|Eric Thompson
2113|NCT03043391|Darell Bigner
2114|NCT03043391|Oncolytic Poliovirus
2115|NCT03043378|Malignant Neoplasms of Independent (Primary) Multiple Sites
2116|NCT03043378|Non-malignant pain
2117|NCT03043378|Supportive care
2118|NCT03043378|Questionnaires
2119|NCT03043378|Surveys
2120|NCT03043378|Chronic non-malignant pain
2121|NCT03043365|Fish Oils
2122|NCT03043365|Long Chain Monounsaturated Fatty Acids
2123|NCT03043365|Lipoproteins
2124|NCT03043365|Cardiovascular Disease
2125|NCT03043352|SAM
2126|NCT03043352|Malnutrition
2127|NCT03043352|LHW
2128|NCT03043352|CMAM
2129|NCT03043339|Microbiota composition
2130|NCT03043339|Kidney transplant recipient
2131|NCT03043339|Kidney transplant donor
2132|NCT03043326|Pre-exposure Prophylaxis
2133|NCT03043326|MSM and transgender women
2134|NCT03043300|Travelers' diarrhea
2135|NCT03043300|Intestinal microbiota
2136|NCT03043300|Antibiotic resistance
2137|NCT03043300|Antibiotics
2138|NCT03043300|Gastrointestinal disorders
2139|NCT03043300|Infectious diseases
2140|NCT03043300|International Travel
2141|NCT03043300|Travel Medicine
2142|NCT03043300|Resistome
2143|NCT03043300|Microbiome
2144|NCT03043261|CHF
2145|NCT03043248|TRK-700
2146|NCT03043248|PK
2147|NCT03043248|Digoxin
2148|NCT03043248|Midazolam
2149|NCT03043248|Drug-Drug interaction
2150|NCT03043248|P-glycoprotein
2151|NCT03043248|CYP3A4
2152|NCT03043248|MDR1
2153|NCT03043248|pharmacokinetics
2154|NCT03043248|multidrug resistance 1
2155|NCT03043222|prostate artery embolization
2156|NCT03043222|Prostatic Urethral Lift, Urolift
2157|NCT03043222|Minimally invasive
2158|NCT03043222|non-surgical
2159|NCT03043222|maintenance of sexual function
2160|NCT03043222|complications of TURP , surgery
2161|NCT03043183|gastric cancer
2162|NCT03043183|Enhanced recovery after surgery
2163|NCT03043170|Adults
2164|NCT03043170|Emergency Department
2165|NCT03043170|Haemodynamics
2166|NCT03043170|Resuscitation
2167|NCT03043170|Shock
2168|NCT03043170|Uscom
2169|NCT03043131|Cardiopulmonary bypass prime
2170|NCT03043131|Plasma Lyte - A
2171|NCT03043131|Ringer;s lactate
2172|NCT03043131|Acidosis
2173|NCT03043118|Eating Behaviors
2174|NCT03043118|Preschool
2175|NCT03043118|Vegetable Intake
2176|NCT03043105|Multicentric Castleman's Disease
2177|NCT03043105|Thalidomide, cyclophosphamide and prednisone (TCP regimen)
2178|NCT03043105|Efficacy
2179|NCT03043105|Safety
2180|NCT03043092|ultrasound, transcranial Doppler, arterial diseases
2181|NCT03043066|Chronic Periodontitis
2182|NCT03043066|TRAP-5b
2183|NCT03043066|Non-surgical periodontal therapy
2184|NCT03043066|Systemic antibiotics
2185|NCT03043053|weight loss
2186|NCT03043053|body mass index
2187|NCT03043053|oxytocin
2188|NCT03043053|magnetic resonance imaging
2189|NCT03043040|suicide, attempted
2190|NCT03043040|prevention
2191|NCT03043040|telemedicine
2192|NCT03042988|supine hypertension
2193|NCT03042988|autonomic failure
2194|NCT03042988|heat stress
2195|NCT03042988|orthostatic hypotension
2196|NCT03042975|spasmodic dysphonia
2197|NCT03042975|dystonia
2198|NCT03042975|laryngeal dystonia
2199|NCT03042975|imaging
2200|NCT03042975|genetics
2201|NCT03042962|dystonia
2202|NCT03042962|imaging
2203|NCT03042962|genetics
2204|NCT03042962|neuropathology
2205|NCT03042936|Children
2206|NCT03042936|Teens
2207|NCT03042936|Adolescents
2208|NCT03042936|Type 2 diabetes
2209|NCT03042936|Impaired glucose tolerance
2210|NCT03042936|Exercise
2211|NCT03042936|Nutrition
2212|NCT03042936|Education
2213|NCT03042884|Benign Neoplasms
2214|NCT03042884|In Situ Neoplasms
2215|NCT03042884|Malignant Neoplasms of Independent (Primary) Multiple Sites
2216|NCT03042884|Wearable exercise trackers
2217|NCT03042884|Questionnaires
2218|NCT03042884|Surveys
2219|NCT03042871|PM-CNV ,Ranibizumab, Dosing Strategy
2220|NCT03042858|PPV
2221|NCT03042858|patent processus vaginalis
2222|NCT03042858|inguinal hernia
2223|NCT03042832|Leadership
2224|NCT03042832|Organizational Climate
2225|NCT03042832|Implementation
2226|NCT03042832|Implementation Climate
2227|NCT03042832|Motivational Interviewing
2228|NCT03042832|Fidelity
2229|NCT03042806|Physical Activity
2230|NCT03042806|Questionnaire
2231|NCT03042793|myeloma
2232|NCT03042793|vaccination
2233|NCT03042793|PD-L1
2234|NCT03042793|peptide vaccine
2235|NCT03042793|cancer vaccine
2236|NCT03042793|immunotherapy
2237|NCT03042780|Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)
2238|NCT03042780|Metastatic
2239|NCT03042780|High grade
2240|NCT03042780|Pancreas
2241|NCT03042780|Neuroendocrine carcinoma of gastrointestinal tract
2242|NCT03042754|LAM
2243|NCT03042754|XpertMTB/RIF
2244|NCT03042754|treatment outcome
2245|NCT03042754|Microbacterial tuberculosis
2246|NCT03042715|Supportive Care
2247|NCT03042689|AML
2248|NCT03042676|anti-T lymphocytic globulin (ATG)
2249|NCT03042676|allogeneic stem cell transplant
2250|NCT03042676|prophylaxis of GVHD
2251|NCT03042663|stellate ganglion block
2252|NCT03042663|arterial cannula
2253|NCT03042663|ischemia
2254|NCT03042663|septic shock
2255|NCT03042611|Gastric Cancer
2256|NCT03042611|Gastric Adenocarcinoma
2257|NCT03042611|Gastro-esophageal Cancer
2258|NCT03042611|Gastro-esophageal junction Cancer
2259|NCT03042611|Stomach Cancer
2260|NCT03042611|Tumor
2261|NCT03042611|Oncology
2262|NCT03042611|Antiangiogenesis
2263|NCT03042611|Metastatic
2264|NCT03042598|Safe Apneic Period
2265|NCT03042598|Emergency Intubation
2266|NCT03042598|Biphasic Cuirass Ventilation (BCV)
2267|NCT03042598|Non-invasive ventilation
2268|NCT03042598|Peri-intubation Hemodynamic instability
2269|NCT03042598|desaturation
2270|NCT03042598|waveform capnography
2271|NCT03042598|Patient safety
2272|NCT03042585|BMT
2273|NCT03042585|NHL
2274|NCT03042585|Non-Hodgkin Lymphoma
2275|NCT03042585|Relapsed Non-Hodgkin Lymphoma
2276|NCT03042585|Refractory Non-Hodgkin Lymphoma
2277|NCT03042585|autologous stem cell transplantation
2278|NCT03042572|Critical Limb Ischemia (CLI)
2279|NCT03042572|Severe Limb Ischemia (SLI)
2280|NCT03042572|Peripheral Artery Disease (PAD)
2281|NCT03042572|Peripheral Artery Occlusive Disease (PAOD)
2282|NCT03042572|Cardiovascular disease
2283|NCT03042572|Mesenchymal stromal cell (MSC)
2284|NCT03042572|Mesenchymal stem cell (MSC)
2285|NCT03042494|Prebiotic
2286|NCT03042494|Gut microbiota
2287|NCT03042494|Dietary fiber
2288|NCT03042494|Gastrointestinal tolerance
2289|NCT03042481|chronic hepatitis B
2290|NCT03042481|entecavir
2291|NCT03042481|tenofovir
2292|NCT03042481|off-therapy
2293|NCT03042481|relapse
2294|NCT03042442|pancreatic cancer
2295|NCT03042442|cachexia
2296|NCT03042442|perineural invasion
2297|NCT03042442|pain
2298|NCT03042442|diabetes
2299|NCT03042429|neuroblastoma
2300|NCT03042429|chemotherapy
2301|NCT03042429|autologous stem cell transplantation
2302|NCT03042429|radiotherapy
2303|NCT03042429|mIBG
2304|NCT03042429|tumor resection
2305|NCT03042416|18F-DOPA PET/CT
2306|NCT03042403|hemodynamics
2307|NCT03042403|physiotherapy
2308|NCT03042403|breath stacking
2309|NCT03042377|Endodontics
2310|NCT03042377|Retreatment
2311|NCT03042377|Postoperative Pain
2312|NCT03042377|Visual Analogue Pain Scale
2313|NCT03042364|Endometrium, Cytokines, Endometrial secretion, Implantation, Endometrial scratching
2314|NCT03042351|Urinary Incontinence
2315|NCT03042351|Pelvic Floor
2316|NCT03042325|Drug therapy
2317|NCT03042286|statin
2318|NCT03042286|myalgia
2319|NCT03042286|myopathy
2320|NCT03042286|adverse drug reactions (ADRs)
2321|NCT03042286|pharmacokinetics and pharmacogenetics
2322|NCT03042273|recurrent
2323|NCT03042260|trimethoprim, sulfamethoxazole drug combination
2324|NCT03042260|Infection
2325|NCT03042260|Prophylaxis
2326|NCT03042234|Obesity
2327|NCT03042234|Exercise
2328|NCT03042234|Fat oxidation
2329|NCT03042234|Adolescent
2330|NCT03042234|Insulin resistance
2331|NCT03042195|Supplementary Parenteral Nutrition
2332|NCT03042195|Postoperative Nutrition
2333|NCT03042195|Postoperative complications
2334|NCT03042169|Stage IV gastric cancer
2335|NCT03042169|palliative surgery
2336|NCT03042169|chemotherapy
2337|NCT03042169|survival
2338|NCT03042169|quality of life
2339|NCT03042143|Acute respiratory distress syndrome
2340|NCT03042143|Human umbilical cord-derived mesenchymal stem cells
2341|NCT03042104|Stenosis
2342|NCT03042104|Heart Disease
2343|NCT03042104|Valve
2344|NCT03042104|Tricuspid
2345|NCT03042104|Aortic Valve
2346|NCT03042104|Asymptomatic
2347|NCT03042078|Fluoroscopy
2348|NCT03042078|Ablation
2349|NCT03042078|Three dimensional
2350|NCT03042078|Paroxysmal supraventricular tachycardia
2351|NCT03042078|Radiation
2352|NCT03042065|pediatrics
2353|NCT03042065|asthma
2354|NCT03042065|nebulization
2355|NCT03042065|vibrating mesh
2356|NCT03042065|salbutamol
2357|NCT03042065|Efficiency
2358|NCT03042013|ASP8273
2359|NCT03042013|Non-Small-Cell Lung Cancer
2360|NCT03042013|EGFR mutations
2361|NCT03042013|Oncology
2362|NCT03042000|rectal cancer
2363|NCT03042000|neoadjuvant chemoradiation
2364|NCT03042000|circulating tumor DNA
2365|NCT03042000|local recurrence
2366|NCT03042000|long-term survival
2367|NCT03041987|Cohort studies
2368|NCT03041987|Prognosis
2369|NCT03041974|Red Blood Cell Transfusion
2494|NCT03041181|Docetaxel
2370|NCT03041974|Cell-Derived Microparticles
2371|NCT03041961|Vascular function
2372|NCT03041961|Endothelial function
2373|NCT03041961|(Poly)phenols
2374|NCT03041948|Inguinal hernia
2375|NCT03041948|Caudal nerve block
2376|NCT03041948|Ilioinguinal nerve block
2377|NCT03041948|Pain
2378|NCT03041935|Testicle
2379|NCT03041935|Pain
2380|NCT03041935|Orchiopexy
2381|NCT03041935|Caudal nerve block
2382|NCT03041935|Ilioinguinal nerve block
2383|NCT03041922|Elastography
2384|NCT03041922|Buttocks
2385|NCT03041922|Ultrasound
2386|NCT03041922|Soft tissue
2387|NCT03041870|PET-fMRI
2388|NCT03041870|dominance
2389|NCT03041870|5HT transporter
2390|NCT03041857|Videofluoroscopy
2391|NCT03041857|GMK Sphere
2392|NCT03041857|GMK PS Fixed Bearing
2393|NCT03041857|GMK UC Mobile Bearing
2394|NCT03041844|therapeutic ultrasound
2395|NCT03041844|quality of life
2396|NCT03041831|frail elderly
2397|NCT03041831|telemedicine
2398|NCT03041831|obesity
2399|NCT03041831|rural health
2400|NCT03041831|health promotion
2401|NCT03041818|cerebral palsy
2402|NCT03041818|horseback riding
2403|NCT03041805|venous thromboembolism
2404|NCT03041805|deep vein thrombosis
2405|NCT03041805|pulmonary embolism
2406|NCT03041805|varicose veins
2407|NCT03041805|surgery
2408|NCT03041805|endovenous laser treatment
2409|NCT03041805|radiofrequency ablation
2410|NCT03041805|ultrasound-guided foam sclerotherapy
2411|NCT03041805|register
2412|NCT03041805|anticoagulation
2413|NCT03041766|Schistosomiasis
2414|NCT03041766|Recombinant vaccine
2415|NCT03041766|rSm14
2416|NCT03041766|GLA-SE
2417|NCT03041766|Fatty acid-binding protein (FABP)
2418|NCT03041766|Phase II Clinical Trial
2419|NCT03041766|Senegal
2420|NCT03041753|stroke
2421|NCT03041753|thrombolysis
2422|NCT03041753|metalloproteinases
2423|NCT03041753|blood brain barrier
2424|NCT03041740|Bronchopulmonary Dysplasia
2425|NCT03041740|Neonates
2426|NCT03041714|Essential Tremor
2427|NCT03041714|Cervical Dystonia
2428|NCT03041714|Hand Dystonia
2429|NCT03041714|Neurophysiology
2430|NCT03041714|Dystonic Tremor
2431|NCT03041701|ERMS
2432|NCT03041701|ARMS
2433|NCT03041701|Monoclonal Antibody
2434|NCT03041701|YES
2435|NCT03041701|RMS
2436|NCT03041675|Lacer Acupuncture
2437|NCT03041675|Paralytic ileus
2438|NCT03041649|Gastroesophageal Reflux
2439|NCT03041649|Feeding Disorder
2440|NCT03041649|Gastrostomy tube
2441|NCT03041649|Family Satisfaction
2442|NCT03041649|GT button
2443|NCT03041649|Enteral nutrition
2444|NCT03041649|Gastrostomy button
2445|NCT03041636|Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
2446|NCT03041636|Other Diseases of Blood and Blood-Forming Organs
2447|NCT03041636|Chronic Lymphocytic Leukemia
2448|NCT03041636|CLL
2449|NCT03041636|Ruxolitinib
2450|NCT03041636|Jakafi
2451|NCT03041636|INCB018424
2452|NCT03041623|IIPs
2453|NCT03041558|healthy relationships
2454|NCT03041558|interpersonal relations
2455|NCT03041558|domestic violence
2456|NCT03041532|retroflexion proximal
2457|NCT03041532|colorectal cancer screening programme
2458|NCT03041532|adenoma detection rate
2459|NCT03041532|right colon
2460|NCT03041519|Fluoroscopy
2461|NCT03041519|Ablation
2462|NCT03041519|Three dimensional
2463|NCT03041519|Ventricular arrhythmias
2464|NCT03041519|Radiation
2465|NCT03041506|Shoulder dislocation reduction
2466|NCT03041506|Ultrasound guided interscalene block (ISCB)
2467|NCT03041506|Sedation
2468|NCT03041493|Electronic Cigarettes
2469|NCT03041493|17-071
2470|NCT03041480|chronic periodontitis
2471|NCT03041480|lipids
2472|NCT03041480|Lp-PLA2
2473|NCT03041402|non-invasive ventilation
2474|NCT03041402|Pressure Support Ventilation
2475|NCT03041402|Neurally Adjusted Ventilatory Assist
2476|NCT03041402|patient-ventilator interaction
2477|NCT03041402|ventilator performance
2478|NCT03041402|asynchrony
2479|NCT03041389|Computerized Cognitive Behavioral Therapy
2480|NCT03041350|Emergency Medical Services
2481|NCT03041350|Smartphone
2482|NCT03041350|Survival
2483|NCT03041311|Small Cell Lung Cancer
2484|NCT03041311|CDK 4/6 Inhibitor
2485|NCT03041311|Immune Checkpoint Inhibitor
2486|NCT03041246|pelvic floor
2487|NCT03041207|ventilator associated infection
2488|NCT03041207|ventilator associated pneumonia
2489|NCT03041207|ventilator associated tracheitis
2490|NCT03041207|Lower respiratory infection
2491|NCT03041181|Nivolumab
2492|NCT03041181|BMS-936558-01
2493|NCT03041181|Anti-PD-1 Antibody
2495|NCT03041142|Obesity
2496|NCT03041142|Cardiovascular risk factors
2497|NCT03041142|Interdisciplinary intervention
2498|NCT03041129|hepatic de novo lipogenesis
2499|NCT03041116|PKAN
2500|NCT03041090|infiltration
2501|NCT03041090|extravasation
2502|NCT03041090|PET/CT
2503|NCT03041090|PET
2504|NCT03041090|PET-CT
2505|NCT03041025|Systemic Sclerosis
2506|NCT03041025|Repeat-dose
2507|NCT03041025|Phase IIA
2508|NCT03041025|GSK2330811
2509|NCT03041025|Pharmacodynamics
2510|NCT03041025|Pharmacokinetics
2511|NCT03041025|Proof of mechanism study
2512|NCT03041012|HIV-1
2513|NCT03041012|Latency Reversal Agent
2514|NCT03041012|Immunotherapy
2515|NCT03040999|Head and Neck Squamous Cell Carcinoma
2516|NCT03040999|Programmed Cell Death Receptor 1 (PD-1)
2517|NCT03040999|Programmed Cell Death Receptor Ligand 1 (PD-L1)
2518|NCT03040999|Programmed Cell Death Receptor Ligand 2 (PD-L2)
2519|NCT03040999|PD1
2520|NCT03040999|PD-1
2521|NCT03040999|PDL1
2522|NCT03040999|PD-L1
2523|NCT03040999|PDL2
2524|NCT03040973|capmatinib
2525|NCT03040973|cMET
2526|NCT03040973|advanced solid tumor
2527|NCT03040973|cancer
2528|NCT03040960|infection
2529|NCT03040960|wound infection
2530|NCT03040960|surgical wound infection
2531|NCT03040960|Staphylococcal infections
2532|NCT03040960|wound and injuries
2533|NCT03040960|postoperative complications
2534|NCT03040960|Gram-positive bacterial infections
2535|NCT03040960|bacterial infections
2536|NCT03040895|Parenting practices
2537|NCT03040856|Omega 3
2538|NCT03040856|Supplements
2539|NCT03040856|Alpha Linolenic Acid
2540|NCT03040843|documentation
2541|NCT03040843|altered mental status
2542|NCT03040843|definition
2543|NCT03040843|clinically
2544|NCT03040804|hidradenitis suppurativa
2545|NCT03040804|HS
2546|NCT03040804|radiotherapy
2547|NCT03040791|prostate cancer
2548|NCT03040778|MRONJ
2549|NCT03040778|BRONJ
2550|NCT03040765|Osteoporosis
2551|NCT03040765|Beta-Thalassemia Major
2552|NCT03040765|Denosumab
2553|NCT03040765|Zoledronic Acid
2554|NCT03040739|O'ARM
2555|NCT03040726|In situ neoplasm
2556|NCT03040726|Malignant neoplasms of independent (primary) multiple sites
2557|NCT03040726|Symptoms and signs involving the digestive system and abdomen
2558|NCT03040726|Chronic nausea and vomiting
2559|NCT03040726|Netupitant/Palonosetron
2560|NCT03040726|NEPA
2561|NCT03040726|Placebo
2562|NCT03040726|Sugar pill
2563|NCT03040726|Symptom questionnaires
2564|NCT03040726|Surveys
2565|NCT03040726|Pill diary
2566|NCT03040726|Akynzeo
2567|NCT03040700|coronary artery disease
2568|NCT03040700|surgery
2569|NCT03040700|angina
2570|NCT03040700|myocardial ischemia
2571|NCT03040700|non-invasive testing
2572|NCT03040687|ETEC
2573|NCT03040687|Escherichia coli
2574|NCT03040687|enteritis
2575|NCT03040687|challenge
2576|NCT03040687|CS6
2577|NCT03040687|B7A
2578|NCT03040674|Shortness of breath
2579|NCT03040674|Breathlessness
2580|NCT03040674|Stem cells
2581|NCT03040674|Platelet rich plasma
2582|NCT03040674|Quality of life
2583|NCT03040674|Pulmonary function
2584|NCT03040622|WATCHMAN
2585|NCT03040622|Left Atrial Appendage Closure
2586|NCT03040622|Thrombosis
2587|NCT03040622|Platelet Function
2588|NCT03040609|Profound Multiple Intellectual Disabilities
2589|NCT03040609|Visual-Behavioral Scale
2590|NCT03040596|vocal fold nodules
2591|NCT03040596|inhaled steroid
2592|NCT03040596|steroid
2593|NCT03040596|children
2594|NCT03040596|nodules
2595|NCT03040583|Primary Sjögren's syndrome (PSS)
2596|NCT03040583|auto-immune diseases
2597|NCT03040557|plantar fasciitis
2598|NCT03040557|shoes
2599|NCT03040557|insoles
2600|NCT03040557|pain
2601|NCT03040557|foot
2602|NCT03040544|minimally invasive surgery
2603|NCT03040544|video-based trainer
2604|NCT03040531|glucocorticoid
2605|NCT03040531|genistein
2606|NCT03040531|alendronate
2607|NCT03040518|Behaviour change
2608|NCT03040518|Male obesity
2609|NCT03040518|SMS
2610|NCT03040518|Financial Incentive
2611|NCT03040518|Endowment incentive
2612|NCT03040466|ureteroscopy
2613|NCT03040466|flexible ureteroscope
2614|NCT03040466|randomized controlled trial
2615|NCT03040453|Irreversible electroporation
2616|NCT03040453|Microwave ablation
2617|NCT03040427|F-18 florbetapir
2618|NCT03040427|Amyvid
2619|NCT03040427|PET scan
2620|NCT03040427|Early detection
2621|NCT03040414|Hybrid closed loop
2622|NCT03040414|Closed loop
2623|NCT03040414|Artificial pancreas
2624|NCT03040401|CMML
2625|NCT03040401|Ceplene
2626|NCT03040401|Interleukin-2
2627|NCT03040388|Electroconvulsive therapy
2628|NCT03040388|Depressive Disorder
2629|NCT03040388|Magnetic Resonance Imaging
2630|NCT03040388|Hippocampus
2631|NCT03040388|Brain-Derived Neurotrophic Factor
2632|NCT03040388|Vascular Endothelial Growth Factor
2633|NCT03040388|Blood-Brain Barrier
2634|NCT03040349|primary care
2635|NCT03040349|greece
2636|NCT03040349|cyprus
2637|NCT03040349|tobacco use treatment
2638|NCT03040349|evidence-based guidelines
2639|NCT03040336|surgery
2640|NCT03040336|prehabilitation
2641|NCT03040336|exercise therapy
2642|NCT03040336|nutrition support
2643|NCT03040297|Weaning from mechanical ventilation
2644|NCT03040297|tracheostomized patients
2645|NCT03040297|Tracheal gas insufflation
2646|NCT03040284|noninvasive monitoring
2647|NCT03040284|intracranial pressure
2648|NCT03040284|cochlear electrophysiology
2649|NCT03040284|aneurysmal subarachnoid haemorrhage
2650|NCT03040284|cerebrovascular disorders
2651|NCT03040284|brain diseases
2652|NCT03040271|School-based intervention
2653|NCT03040258|School-based intervention
2654|NCT03040245|Emergency physician
2655|NCT03040245|Whiplash Book
2656|NCT03040245|Whiplash trauma
2657|NCT03040245|Fears
2658|NCT03040245|Beliefs
2659|NCT03040193|Lignocaine
2660|NCT03040180|Neoplasms
2661|NCT03040180|Neoplasms, primary
2662|NCT03040180|Cancer
2663|NCT03040180|Colorectal cancer
2664|NCT03040180|rectal cancer
2665|NCT03040180|rectal cancer, locally advanced
2666|NCT03040180|Electrochemotherapy
2667|NCT03040180|Electroporation
2668|NCT03040180|Neoadjuvant therapy
2669|NCT03040180|Antineoplastic, antibodies
2670|NCT03040180|Bleomycin
2671|NCT03040180|Pathologic processes
2672|NCT03040180|Neoplastic processes
2673|NCT03040154|Filipino
2674|NCT03040102|Advanced Cancer
2675|NCT03040063|aneurysm, poplietl artery, acute limb ischemia
2676|NCT03040024|Anesthesiology
2677|NCT03040011|Vaginal Surgery
2678|NCT03040011|Pelvic Organ Prolapse
2679|NCT03040011|Postoperative Pain
2680|NCT03039959|Chronic Kidney Disease
2681|NCT03039946|Fluid therapy
2682|NCT03039946|Hemodynamic flow monitoring
2683|NCT03039946|Closed-loop system
2684|NCT03039946|Goal-directed fluid therapy
2685|NCT03039946|Anesthesiology
2686|NCT03039907|Knee
2687|NCT03039907|Replacement
2688|NCT03039894|school-based, evaluation, interrupted time series
2689|NCT03039881|Minute ventilation, ExSpiron monitor
2690|NCT03039855|Mitral
2691|NCT03039855|Regurgitation
2692|NCT03039855|Heart valve
2693|NCT03039855|Transcatheter
2694|NCT03039855|Transapical
2695|NCT03039855|Functional
2696|NCT03039855|Degenerative
2697|NCT03039855|TMVR
2698|NCT03039842|dextromethorphan; memantine; treatment response
2699|NCT03039790|Immunogenicity, Norovirus vaccination
2700|NCT03039686|muscular dystrophy
2701|NCT03039686|Duchenne's Muscular Dystrophy
2702|NCT03039686|DMD
2703|NCT03039673|interleukin-2
2704|NCT03039673|low-dose interleukin-2
2705|NCT03039608|esophageal stricture
2706|NCT03039608|endoscopic submucosal dissection
2707|NCT03039608|prevention
2708|NCT03039595|Early rectal cancer
2709|NCT03039595|Ploidy
2710|NCT03039595|Tumour:stroma ratio
2711|NCT03039582|perineal tear
2712|NCT03039582|bidigital palpation
2713|NCT03039582|perineal ultrasound
2714|NCT03039582|post partum diagnostics
2715|NCT03039569|Type 2 diabetes patients
2716|NCT03039569|Diabetes self-management
2717|NCT03039569|Cardiovascular diseases awareness
2718|NCT03039569|Home food environment
2719|NCT03039569|Text message
2720|NCT03039530|Postpartum Depression
2721|NCT03039530|Cognitive Behavioral Therapy
2722|NCT03039530|Public Health
2723|NCT03039530|Mother
2724|NCT03039530|Infant
2725|NCT03039530|Emotion
2726|NCT03039517|Adaptive Compression Therapy Delivery System
2727|NCT03039504|Succinates
2728|NCT03039504|Dietary supplement
2729|NCT03039491|pneumococcal vaccination
2730|NCT03039465|Indwelling Trachea-oesophageal Prosthesis
2731|NCT03039465|Voice Rehabilitation
2732|NCT03039465|Total Laryngectomy
2733|NCT03039439|Immunohistochemical profiling of tumors
2734|NCT03039439|Biomarkers
2735|NCT03039374|OASI
2736|NCT03039374|Faecal incontinence
2737|NCT03039374|Obstetric anal sphincter injury
2738|NCT03039374|MRI
2739|NCT03039348|Breast Cancer Female
2740|NCT03039348|Mastectomy
2741|NCT03039348|Breast Reconstruction
2742|NCT03039348|questionnaire
2743|NCT03039309|Endoscopic Submucosal Dissection
2744|NCT03039296|Low back pain
2745|NCT03039296|Facet joints
2746|NCT03039296|Endoscopic rhizotomy
2747|NCT03039283|Moderate to profound sensorineural hearing loss
2748|NCT03039270|Tooth Sensitivity
2749|NCT03039270|Tooth Bleaching
2750|NCT03039270|Desensitizing agent
2751|NCT03039270|Sonic vibration
2752|NCT03039257|hematopoietic stem cell transplant
2753|NCT03039257|vitamin a
2754|NCT03039244|Photochemotherapy
2755|NCT03039244|Photosensitizing agents
2756|NCT03039244|Smokers
2757|NCT03039231|PTSD
2758|NCT03039218|erectile dysfunction
2759|NCT03039218|shockwave
2760|NCT03039218|Dornier
2761|NCT03039205|Platelet aggregation
2762|NCT03039205|Adenosine
2763|NCT03039205|Coronary artery disease
2764|NCT03039205|Kidney dysfunction
2765|NCT03039205|Ticagrelor
2766|NCT03039205|Clopidogrel
2767|NCT03039127|Hyperthermia
2768|NCT03039127|Laser Coagulation
2769|NCT03039127|Laser Therapy
2770|NCT03039127|Induced
2771|NCT03039114|Follicular lymphoma
2772|NCT03039114|relapsed
2773|NCT03039114|refractory
2774|NCT03039114|non-Hodgkin lymphoma
2775|NCT03039114|phosphatidylinositol 3-kinase (PI3K)
2776|NCT03039101|allergen
2777|NCT03039101|neutrophils
2778|NCT03039101|allergy
2779|NCT03039062|Serum miR-122
2780|NCT03039062|drug-induced liver injury by chemotherapy
2781|NCT03039062|malignant tumor patients
2782|NCT03039049|GnRH agonist trigger
2783|NCT03039049|IVF
2784|NCT03039049|Luteal phase support
2785|NCT03039049|Mid-luteal GnRH agonist
2786|NCT03039036|Labor Induction
2787|NCT03039036|Early Amniotomy
2788|NCT03039036|Foley catheter
2789|NCT03039023|TMAO
2790|NCT03039023|choline
2791|NCT03039023|eggs
2792|NCT03039023|gastrointestinal microbiome
2793|NCT03039023|healthy volunteers
2794|NCT03038984|IBD
2795|NCT03038984|Telemedicine
2796|NCT03038984|At-home monitoring
2797|NCT03038984|Disease activity
2798|NCT03038984|fecal calprotectin
2799|NCT03038984|Total inflammation burden
2800|NCT03038984|11 years follow up
2801|NCT03038958|Local Anaesthetic
2802|NCT03038958|spinal anesthesia
2803|NCT03038958|Knee arthroscopy
2804|NCT03038945|Laparoscopy
2805|NCT03038945|Hysterectomy
2806|NCT03038945|Suture Techniques
2807|NCT03038932|whole genome sequencing (WGS)
2808|NCT03038919|prolonged mechanical ventilation
2809|NCT03038919|critically ill patients
2810|NCT03038919|anabolic steroid
2811|NCT03038893|Ultrasonography
2812|NCT03038893|Point-of-care systems
2813|NCT03038893|Deep venous thrombosis
2814|NCT03038893|Hospitalization
2815|NCT03038776|vaccine
2816|NCT03038750|Healthy Volunteers
2817|NCT03038750|Genetic Risk Markers for Cardiovascular Disease
2818|NCT03038750|Non-Alcoholic Fatty Liver Disease
2819|NCT03038750|Coronary Disease
2820|NCT03038750|Hypertension
2821|NCT03038750|Venous Thromboses
2822|NCT03038750|Venous Thromboembolism
2823|NCT03038750|Coronary Heart Disease
2824|NCT03038750|Coronary Artery Disease
2825|NCT03038737|nylon
2826|NCT03038737|polyamide
2827|NCT03038737|PEEK
2828|NCT03038737|partial denture
2829|NCT03038724|HIV testing
2830|NCT03038698|spirometry
2831|NCT03038698|normative values
2832|NCT03038698|health
2833|NCT03038698|south africa
2834|NCT03038698|children
2835|NCT03038685|Secondary prevention
2836|NCT03038685|Web-based intervention
2837|NCT03038685|Strokecoach
2838|NCT03038646|Pharmacokinetics
2839|NCT03038646|Food Effect
2840|NCT03038620|Obesity
2841|NCT03038620|Visceral
2842|NCT03038620|Cardiovascular Disease
2843|NCT03038620|Fat
2844|NCT03038594|Burns
2845|NCT03038594|Growth Hormone
2846|NCT03038594|Lean Body Mass
2847|NCT03038594|Strength
2848|NCT03038594|Exercise Endurance
2849|NCT03038581|Deep wrist injury
2850|NCT03038581|Self inflicted
2851|NCT03038581|Traumatic wrist injury
2852|NCT03038568|colorectal liver metastases
2853|NCT03038568|CT scan
2854|NCT03038568|17-010
2855|NCT03038555|Medical staff
2856|NCT03038555|preeclampsia
2857|NCT03038555|cohort study
2858|NCT03038555|further effect
2859|NCT03038529|low back pain , Ozone
2860|NCT03038503|refractory septic shock
2861|NCT03038503|catecholamine resistance septic shock
2862|NCT03038503|terlipressin
2863|NCT03038503|methylene blue
2864|NCT03038477|Borderline Resectable Pancreatic Ductal Adenocarcinoma
2865|NCT03038477|Durvalumab
2866|NCT03038399|Duchenne muscular dystrophy
2867|NCT03038399|vamorolone
2868|NCT03038347|cross-cultural competencies
2869|NCT03038347|internet-based training
2870|NCT03038347|cognitive-behavioural therapy (CBT)
2871|NCT03038347|psychotherapy training
2872|NCT03038347|competence training
2873|NCT03038321|BCG Cystitis
2874|NCT03038321|Bladder Cancer
2875|NCT03038321|Levofloxacin
2876|NCT03038321|Solifenacin
2877|NCT03038321|Lornoxicam
2878|NCT03038308|ropinirole
2879|NCT03038308|hyperprolactinemia
2880|NCT03038308|prolactin
2881|NCT03038295|Retinopathy of Prematurity
2882|NCT03038295|propranolol
2883|NCT03038295|ROP
2884|NCT03038269|Robotics
2885|NCT03038269|Upper Extremity
2886|NCT03038256|High Risk Rectal Cancer
2887|NCT03038256|Neoadjuvant chemotherapy
2888|NCT03038256|Delayed total mesorectal excision
2889|NCT03038243|Shigella
2890|NCT03038243|vaccine
2891|NCT03038243|shigellosis
2892|NCT03038243|dysentery
2893|NCT03038243|whole cell
2894|NCT03038230|human bispecific full length IgG antibody, CLEC12A, CD3
2895|NCT03038230|MCLA-117
2896|NCT03038230|First in Human
2897|NCT03038230|Antibodies, Bispecific
2898|NCT03038230|Immunologic Factors
2899|NCT03038230|relapsed, refractory patient
2900|NCT03038230|AML, minimal residual disease (MRD)
2901|NCT03038230|Acute Myelogenous Leukemia
2902|NCT03038230|Acute Myeloid Leukemia
2903|NCT03038230|CD34+CD38
2904|NCT03038230|T-cell recruiting
2905|NCT03038217|rectal cancer
2906|NCT03038217|neoajuvant chemoradiation
2907|NCT03038217|circulating tumor DNA
2908|NCT03038204|Papillary muscles approximation
2909|NCT03038178|Mycobacterium Infections, Nontuberculous
2910|NCT03038178|Mycobacteria, Atypical
2911|NCT03038178|Amikacin
2912|NCT03038178|Inhalation
2913|NCT03038165|Hemodialysis
2914|NCT03038165|Intradialytic hypertension
2915|NCT03038165|Hemodynamics changes
2916|NCT03038152|Disorder of breast
2917|NCT03038152|Breast Cancer
2918|NCT03038152|Lymph node metastasis
2919|NCT03038152|Magseed marker
2920|NCT03038152|Lymph node removal
2921|NCT03038139|forward head posture
2922|NCT03038139|postural correction
2923|NCT03038139|spinal muscles
2924|NCT03038126|chronic kidney disease
2925|NCT03038126|patient safety
2926|NCT03038126|home telehealth
2927|NCT03038061|Diaphragm
2928|NCT03038061|Capnoperitoneum
2929|NCT03038061|EIT
2930|NCT03038061|Laparoscopy
2931|NCT03038009|Coronary Artery Bypass Graft
2932|NCT03038009|Dual Antiplatelet Therapy
2933|NCT03038009|Gastrointestinal
2934|NCT03038009|Mucosal Injury
2935|NCT03038009|Proton Pump Inhibitor
2936|NCT03037996|anesthesia
2937|NCT03037996|satisfaction
2938|NCT03037983|Schizophrenia
2939|NCT03037983|Transcranial magnetic stimulation
2940|NCT03037983|Electroencephalography
2941|NCT03037944|Adenomyosis
2942|NCT03037944|Contraceptive pills
2943|NCT03037944|Levonorgestrel-releasing Intrauterine System
2944|NCT03037918|Gut Microbiota
2945|NCT03037918|High Fat Diets
2946|NCT03037918|Probiotics
2947|NCT03037918|Glycaemic Control
2948|NCT03037853|Atlas
2949|NCT03037853|Full human Body
2950|NCT03037853|MRI
2951|NCT03037840|RF EMF
2952|NCT03037840|In Vivo
2953|NCT03037840|tumor specific frequencies
2954|NCT03037827|endovenous laser ablation
2955|NCT03037827|radial fiber
2956|NCT03037827|linear endovenous energy density
2957|NCT03037827|1470 nm
2958|NCT03037827|occlusion rate
2959|NCT03037814|restorative materials
2960|NCT03037814|primary teeth
2961|NCT03037814|children
2962|NCT03037788|Excessive sweating
2963|NCT03037775|tobacco
2964|NCT03037775|cardiovascular system
2965|NCT03037775|sympathetic nervous system
2966|NCT03037684|neuropathic pain
2967|NCT03037684|chronic postoperative pain
2968|NCT03037671|Malglycemia
2969|NCT03037658|physical activity
2970|NCT03037658|walking
2971|NCT03037658|incentive
2972|NCT03037658|step count
2973|NCT03037645|CLL
2974|NCT03037645|Hematological diseases
2975|NCT03037645|Relapsed
2976|NCT03037645|cancer
2977|NCT03037645|malignancy
2978|NCT03037645|SNS-062
2979|NCT03037645|B-lymphoid
2980|NCT03037645|Chronic lymphocytic leukemia
2981|NCT03037645|Small lymphocytic lymphoma
2982|NCT03037645|Lymphoplasmacytoid lymphoma
2983|NCT03037645|Waldenström's macrogloulinemia
2984|NCT03037645|Mantle cell lymphoma
2985|NCT03037645|SLL
2986|NCT03037645|LPL
2987|NCT03037645|WM
2988|NCT03037645|MCL
2989|NCT03037645|Refractory
2990|NCT03037593|Pregnancy
2991|NCT03037593|Gestational Diabetes
2992|NCT03037580|Pulmonary Hypertension
2993|NCT03037580|6-Minute Walk Test
2994|NCT03037580|HFpEF
2995|NCT03037580|Oral Treprostinil
2996|NCT03037554|Skin Temperature
2997|NCT03037554|Hot Flashes
2998|NCT03037554|Sleep Disturbance
2999|NCT03037541|Wake Forest
3000|NCT03037541|Actinic Keratosis
3001|NCT03037541|Cryosurgery
3002|NCT03037541|Cream
3003|NCT03037502|Men's Health
3004|NCT03037502|weight loss
3005|NCT03037502|African American men
3006|NCT03037502|Latino men
3007|NCT03037437|Hepatocellular Cancer
3008|NCT03037437|Sorafenib
3009|NCT03037437|Hydroxychloroquine
3010|NCT03037424|Cyroprecipitate
3011|NCT03037424|Fibrinogen
3012|NCT03037424|Cardiac Surgery
3013|NCT03037411|Atherosclerosis
3014|NCT03037411|Superficial Femoral Artery (SFA)
3015|NCT03037411|Proximal Popliteal Artery (PPA)
3016|NCT03037411|Stenting
3017|NCT03037411|Paclitaxel
3018|NCT03037411|Health Economics
3019|NCT03037385|medullary thyroid cancer
3020|NCT03037385|non-small cell lung cancer
3021|NCT03037385|papillary thyroid cancer
3022|NCT03037372|adults
3023|NCT03037372|antiretroviral therapy
3024|NCT03037359|PID
3025|NCT03037346|Malignant neoplasms of female genital organs
3026|NCT03037346|Invasive gynecologic malignancy
3027|NCT03037346|Medical Power of Attorney Documents
3028|NCT03037346|MPOAD
3029|NCT03037346|Questionnaires
3030|NCT03037346|Surveys
3031|NCT03037333|echocardiogram
3032|NCT03037333|Electrocardiogram: Electrical Alternans
3033|NCT03037333|fluoroscopy
3034|NCT03037229|Myocardial Infarction
3035|NCT03037229|Ischemia
3036|NCT03037229|Myocardial Ischemia
3037|NCT03037229|Heart Diseases
3038|NCT03037229|Cardiovascular Diseases
3039|NCT03037229|Vascular Diseases
3040|NCT03037216|Exercise
3041|NCT03037164|INTERCEPT
3042|NCT03037164|Red Blood Cells
3043|NCT03037164|RBC
3044|NCT03037164|Pathogen Inactivation
3045|NCT03037164|Zika
3046|NCT03037164|Cerus
3047|NCT03037164|Pathogen Reduction
3048|NCT03037151|Safety
3049|NCT03037151|Efficacy
3050|NCT03037151|grazoprevir
3051|NCT03037151|elbasvir
3052|NCT03037151|compensated cirrhosis
3053|NCT03037151|genotype 1 (GT1)
3054|NCT03037151|genotype 6 (GT6)
3055|NCT03037151|hepatitis virus C (HCV)
3056|NCT03037151|human immunodeficiency virus (HIV)
3057|NCT03037138|postdialysis washed-out
3058|NCT03037099|Glycemic index
3059|NCT03037099|dietary intakes
3060|NCT03037086|NSCLC
3061|NCT03037073|Duloxetine
3062|NCT03037073|Succinylcholine
3063|NCT03037073|Postoperative Myalgia
3064|NCT03037073|Microlaryngoscopy
3065|NCT03037060|Alcohol use, problem
3066|NCT03037021|Sickle Cell Disease
3067|NCT03037021|Needs Assessment
3068|NCT03037021|Barriers to care
3069|NCT03037021|Access to care
3070|NCT03037021|Primary care
3071|NCT03037008|perineal sonography
3072|NCT03037008|male sling
3073|NCT03037008|post prostatectomy incontinence
3074|NCT03037008|ultrasonography
3075|NCT03036956|subclinical hypothyroidism in pregnancy
3076|NCT03036904|venetoclax
3077|NCT03036904|dose-adjusted EPOCH-R
3078|NCT03036904|aggressive B-Cell lymphoma
3079|NCT03036904|Lymphoma
3080|NCT03036904|Non-Hodgkin lymphoma
3081|NCT03036904|Diffuse large B-cell lymphoma
3082|NCT03036904|Double hit lymphoma
3083|NCT03036891|Gastroparesis
3084|NCT03036891|Opioid-Induced
3085|NCT03036891|Delayed Gastric Emptying
3086|NCT03036878|Osteochondral
3087|NCT03036878|Marrow Stimulation
3088|NCT03036878|ReNu
3089|NCT03036865|Healthy participants
3090|NCT03036865|BOS161721
3091|NCT03036865|Pharmacokinetics
3092|NCT03036865|Pharmacodynamics
3093|NCT03036826|renal replacement therapy
3094|NCT03036787|Premature Baby
3095|NCT03036787|motor development
3096|NCT03036787|cognitive development
3097|NCT03036774|Gastric contents
3098|NCT03036774|Ultrasound
3099|NCT03036774|Diabetes
3100|NCT03036761|Auriculotherapy
3101|NCT03036696|Retention
3102|NCT03036696|Lactation
3103|NCT03036696|Human milk
3104|NCT03036696|Pregnancy
3105|NCT03036657|Acupuncture
3106|NCT03036657|Electroacupuncture
3107|NCT03036657|Nerve Conduction Studies
3108|NCT03036657|Quantitative Sensory Testing
3109|NCT03036644|electronic cigarette
3110|NCT03036644|e-cigarette
3111|NCT03036644|oxidative stress
3112|NCT03036644|tobacco smoking
3113|NCT03036618|BMI
3114|NCT03036618|Blood Cholesterol
3115|NCT03036618|Glucose
3116|NCT03036618|Insulin
3117|NCT03036618|Gut health
3118|NCT03036605|dexamethasone
3119|NCT03036605|bupivacaine
3120|NCT03036605|nasal surgery
3121|NCT03036605|nasal packing
3122|NCT03036592|Glucose tolerance test, MTNR1B, nutrigenomics, food timing
3123|NCT03036579|CAD/CAM
3124|NCT03036579|Ceramic
3125|NCT03036579|Crown
3126|NCT03036553|Chronic pain
3127|NCT03036553|Psychological factors
3128|NCT03036553|Musculoskeletal pain
3129|NCT03036553|Prognosis
3130|NCT03036540|upper limb thrombosis, midline catheter
3131|NCT03036527|Bladder
3132|NCT03036527|Sexual Function
3133|NCT03036514|numeric rating scale
3134|NCT03036514|opioid side effects
3135|NCT03036488|PD1
3136|NCT03036488|PD-1
3137|NCT03036488|PDL1
3138|NCT03036488|PD-L1
3139|NCT03036462|intravenous iron
3140|NCT03036462|systolic heart failure
3141|NCT03036462|iron deficiency
3142|NCT03036462|morbidity
3143|NCT03036462|mortality
3144|NCT03036449|Medication errors
3145|NCT03036449|Patient safety
3146|NCT03036436|Cancer
3147|NCT03036436|EHealth
3148|NCT03036436|Cancer Survivor
3149|NCT03036436|Rehabilitation
3150|NCT03036410|Hearing Aid Usage (monaural, binaural)
3151|NCT03036410|Cochlear Implant Usage (monaural, binaural)
3152|NCT03036410|Hearing Aid and Cochlear Implant Usage (monaural)
3153|NCT03036397|Anxiety
3154|NCT03036397|Vasopressin
3155|NCT03036397|Fear-Potentiated Startle
3156|NCT03036397|Shock Threat
3157|NCT03036397|Emotion Recognition
3158|NCT03036384|scheduled cesarean delivery
3159|NCT03036384|spinal anesthesia
3160|NCT03036384|local anesthesia
3161|NCT03036371|Neurogenesis
3162|NCT03036371|Memory
3163|NCT03036371|Spatial Processing
3164|NCT03036371|Hippocampus
3165|NCT03036371|Cognition
3166|NCT03036371|Aerobic Exercise
3167|NCT03036332|aerobic interval training
3168|NCT03036332|biomarkers
3169|NCT03036306|scar
3170|NCT03036306|nefopam
3171|NCT03036306|cicatrix
3172|NCT03036280|E2609
3173|NCT03036280|elenbecestat
3174|NCT03036280|Alzheimer's Disease
3175|NCT03036280|Early Alzheimer's Disease
3176|NCT03036280|Prodromal Alzheimer's Disease
3177|NCT03036280|Dementia
3178|NCT03036280|Dementia, Alzheimer's type
3179|NCT03036280|mild cognitive impairment
3180|NCT03036280|MissionAD2
3181|NCT03036267|health disparity
3182|NCT03036267|motivational interviewing
3183|NCT03036267|African American adults
3184|NCT03036267|Federally Qualified Health Centers
3185|NCT03036267|adherence
3186|NCT03036267|health beliefs
3187|NCT03036267|self-management
3188|NCT03036267|asthma control
3189|NCT03036254|Diabetes Mellitus
3190|NCT03036254|Cognition
3191|NCT03036241|drug-eluting balloon,
3192|NCT03036241|target lesion revascularization (TLR)
3193|NCT03036241|restenosis
3194|NCT03036228|Solid tumours
3195|NCT03036202|epinephrine
3196|NCT03036163|Tuberculosis
3197|NCT03036150|Chronic Kidney Disease (CKD)
3198|NCT03036150|Cardiovascular Events (CV)
3199|NCT03036150|Phase III outcome trial
3200|NCT03036137|Tinnitus
3201|NCT03036137|Electroencephalogram
3202|NCT03036137|Transcranial Direct Current Stimulation
3203|NCT03036124|HFrEF
3204|NCT03036124|Heart Failure (HF)
3205|NCT03036124|Cardiovascular Events (CV)
3206|NCT03036124|Phase III outcome trial
3207|NCT03036085|postoperative pain
3208|NCT03036085|video-assisted thoracoscopic surgery (VATS)
3209|NCT03036085|opioids
3210|NCT03036085|bupivacaine
3211|NCT03036085|liposomal bupivacaine
3212|NCT03036085|analgesia
3213|NCT03036085|local anesthetics
3214|NCT03036072|Therapeutic Hypothermia
3215|NCT03036059|Twice a year treatment
3216|NCT03036059|Biannual treatment
3217|NCT03036059|Wuchereria bancrofti
3218|NCT03036007|Spine, Disc, Neck pain, Rehabilitation, Exercise Therapy, Internet
3219|NCT03035968|Vojta therapy
3220|NCT03035968|reflex locomotion
3221|NCT03035968|stroke rehabilitation
3222|NCT03035968|stroke
3223|NCT03035968|physiotherapy
3224|NCT03035955|Rosacea
3225|NCT03035955|Wake Forest
3226|NCT03035955|Demodex
3227|NCT03035955|Finacea Gel
3228|NCT03035942|Intrathecal morphine
3229|NCT03035942|Nausea and vomiting
3230|NCT03035942|Quality of recovery
3231|NCT03035942|Patient satisfaction
3232|NCT03035942|Pruritus
3233|NCT03035942|Postoperative pain
3234|NCT03035916|transversus abdominal plane block
3235|NCT03035916|epidural anesthesia
3236|NCT03035916|stress response
3237|NCT03035916|anesthetic recovery
3238|NCT03035890|NSCLC
3239|NCT03035890|Lung Cancer
3240|NCT03035890|Non Small Cell Lung Cancer
3241|NCT03035877|Antisocial Behavior
3242|NCT03035877|Alcohol Abuse
3243|NCT03035877|Drug Abuse
3244|NCT03035877|Young Adults
3245|NCT03035864|Ocular discomfort after cataract and refractive surgery
3246|NCT03035864|cataract surgery
3247|NCT03035864|refractive surgery
3248|NCT03035851|Alzheimer Disease
3249|NCT03035851|Dementia
3250|NCT03035851|Exercise
3251|NCT03035851|Physical Activity
3252|NCT03035851|Brain blood flow
3253|NCT03035851|Cognition
3254|NCT03035851|Fitness
3255|NCT03035812|Bicarbonate
3256|NCT03035773|Cancer
3257|NCT03035773|Oncology
3258|NCT03035773|Survivorship
3259|NCT03035760|Helminths
3260|NCT03035760|Oxfendazole
3261|NCT03035760|Pharmacokinetics
3262|NCT03035760|Safety
3263|NCT03035747|registry
3264|NCT03035747|varicose veins
3265|NCT03035747|conventional surgery
3266|NCT03035747|thermal ablation
3267|NCT03035747|radiofrequency
3268|NCT03035747|laser
3269|NCT03035747|sclerotherapy
3270|NCT03035721|Full term healthy infants
3271|NCT03035721|Low protein content formula
3272|NCT03035721|Safety
3273|NCT03035721|Growth
3274|NCT03035721|Body composition
3275|NCT03035695|Trauma
3276|NCT03035695|Scalp injuries
3277|NCT03035695|Profused Bleeding
3278|NCT03035695|Accident
3279|NCT03035656|Pain
3280|NCT03035656|analgesic
3281|NCT03035656|spinal fusion
3282|NCT03035630|Avelumab
3283|NCT03035630|Sunitinib
3284|NCT03035630|MSB0010718C
3285|NCT03035630|Sutent
3286|NCT03035630|IgG1 antibody
3287|NCT03035630|Anti-PD-L1
3288|NCT03035630|Tyrosine kinase inhibitor
3289|NCT03035617|Bupivacaine
3290|NCT03035604|Malnutrition
3291|NCT03035604|Nutritional status
3292|NCT03035604|Mini Nutritional Assessment
3293|NCT03035604|MNA
3294|NCT03035604|Weight loss
3295|NCT03035604|Body Mass Index
3296|NCT03035604|BMI
3297|NCT03035604|Lean muscle mas
3298|NCT03035604|American Society for Parenteral and Enteral Nutrition
3299|NCT03035604|ASPEN
3300|NCT03035578|Pharmacokinetics
3301|NCT03035578|Pharmacodynamics
3302|NCT03035578|Morphine
3303|NCT03035578|Neonatal
3304|NCT03035565|Heart Failure
3305|NCT03035565|Cognition in Heart Failure
3306|NCT03035552|Congenital heart disease (CCHD)
3307|NCT03035552|Non-Nutritive Suck
3308|NCT03035539|Rehabilitation
3309|NCT03035513|Continuous spikes
3310|NCT03035513|Epilepsy
3311|NCT03035513|Nervous system disease
3312|NCT03035513|Neuronal plasticity
3313|NCT03035513|Diffusion MRI
3314|NCT03035513|Functional MRI
3315|NCT03035513|waves during slow sleep (CSWS)
3316|NCT03035474|Heart Failure
3317|NCT03035474|Quality Improvement
3318|NCT03035461|diagnosis annoucement
3319|NCT03035461|patient's feelings
3320|NCT03035448|Malignant neoplasms of independent (primary) multiple sites
3321|NCT03035448|Advanced cancer
3322|NCT03035448|Recurrent cancer
3323|NCT03035448|Metastatic disease
3324|NCT03035448|Palliative care
3325|NCT03035448|Videos
3326|NCT03035448|Questionnaires
3327|NCT03035448|Surveys
3328|NCT03035435|fast-track rehabilitation
3329|NCT03035435|fast-track surgery
3330|NCT03035422|Allogenic cell stem transplant, Sequential chemotherapy Haploidentical transplant
3331|NCT03035409|Malignant neoplasms of independent (primary) multiple sites
3332|NCT03035409|Advanced Cancer
3333|NCT03035409|Metastatic or recurrent incurable solid tumors
3334|NCT03035409|Anamorelin
3335|NCT03035409|Physical activity
3336|NCT03035409|Questionnaires
3337|NCT03035409|Surveys
3338|NCT03035409|Dietary Counseling
3339|NCT03035409|Exercise Counseling
3340|NCT03035383|Large thyroid
3341|NCT03035383|purse string suture
3342|NCT03035383|thyroidectomy
3343|NCT03035370|Pertussis
3344|NCT03035370|Epicutaneous ImmunoTherapy (EPIT)
3345|NCT03035370|Vaccine
3346|NCT03035370|Viaskin PT
3347|NCT03035357|Malignant neoplasms of male genital organs
3348|NCT03035357|Prostate cancer
3349|NCT03035357|Adenocarcinoma of the prostate
3350|NCT03035357|Daratumumab
3351|NCT03035357|Biomarker response
3352|NCT03035305|Seasonal malaria chemoprevention
3353|NCT03035305|Lipid-based nutrient supplement
3354|NCT03035305|Children
3355|NCT03035305|Mali
3356|NCT03035279|Advanced colorectal cancer
3357|NCT03035279|Unresectable colorectal cancer
3358|NCT03035279|Maximum tolerated dose
3359|NCT03035279|Metastatic colorectal cancer
3360|NCT03035279|Cancer
3361|NCT03035279|Pharmacokinetics
3362|NCT03035266|blood flow restriction
3363|NCT03035266|strength
3364|NCT03035266|muscle atrophy
3365|NCT03035266|post-operative therapy
3366|NCT03035266|knee
3367|NCT03035201|Memory
3368|NCT03035201|Mild Cognitive Impairment
3369|NCT03035201|Alzheimer's Disease
3370|NCT03035188|resectable
3371|NCT03035175|Residences
3372|NCT03035175|Video Laryngoscopy
3373|NCT03035175|Intubations
3374|NCT03035175|Neonatal
3375|NCT03035175|NICU
3376|NCT03035175|neonates
3377|NCT03035175|Medical Education
3378|NCT03035162|dual tDCS
3379|NCT03035162|physical rehabilitation
3380|NCT03035162|lower limb functions
3381|NCT03035149|Obesity
3382|NCT03035149|Metabolic Syndrome
3383|NCT03035149|Dyspnea
3384|NCT03035149|Pulmonary Function
3385|NCT03035149|Exercise Capacity
3386|NCT03035136|polyps
3387|NCT03035123|Heart Failure
3388|NCT03035123|Therapeutic education
3389|NCT03035123|Quality of life
3390|NCT03035071|Minimal-invasive esophagectomy
3391|NCT03035071|Esophageal resection
3392|NCT03035071|Hybrid esophagectomy
3393|NCT03035058|Drug therapy
3394|NCT03035032|Leuprolide acetate
3395|NCT03035032|Prostate cancer
3396|NCT03035019|anxiety
3397|NCT03035019|behavioral app
3398|NCT03035006|Hepatocellular carcinoma
3399|NCT03035006|Portal vein tumor thrombosis
3400|NCT03035006|TLC388
3401|NCT03035006|Chemoradiotherapy
3402|NCT03035006|Lipotecan
3403|NCT03034967|HCRU exacerbations
3404|NCT03034967|SGRQ
3405|NCT03034967|CXCR2 antagonist
3406|NCT03034967|GSK1325756
3407|NCT03034967|Danirixin
3408|NCT03034967|COPD
3409|NCT03034941|Obesity
3410|NCT03034941|PCOS
3411|NCT03034941|Infertility
3412|NCT03034941|Liraglutide
3413|NCT03034941|Metformin
3414|NCT03034941|IVF
3415|NCT03034915|Vilanterol
3416|NCT03034915|COPD
3417|NCT03034915|HRQoL
3418|NCT03034915|Salmeterol
3419|NCT03034915|Umeclidinium
3420|NCT03034889|Anesthesia
3421|NCT03034889|Children
3422|NCT03034889|General Anesthesia
3423|NCT03034889|Neurocognitive Outcome
3424|NCT03034876|"Acute Kidney Injury, diagnosis, children, shock"
3425|NCT03034863|Family Caregivers
3426|NCT03034863|Spouse Caregivers
3427|NCT03034863|Veterans
3428|NCT03034863|Suicide
3429|NCT03034863|Clinical Trial
3430|NCT03034863|Military Families
3431|NCT03034863|Military Psychology
3432|NCT03034850|cytoreductive surgery
3433|NCT03034850|hyperthermic intraperitoneal peroperative chemotherapy
3434|NCT03034850|platelet function
3435|NCT03034850|thrombin generation
3436|NCT03034850|thromboelastometry
3437|NCT03034824|diode laser
3438|NCT03034824|Er,Cr:YSGG laser
3439|NCT03034824|Aggressive Periodontitis
3440|NCT03034824|Clinical periodontal parameters
3441|NCT03034824|Gingival crevicular fluid cytokines levels
3442|NCT03034811|Noninflammatory degenerative joint disease
3443|NCT03034811|Osteoarthritis
3444|NCT03034811|Avascular necrosis
3445|NCT03034811|Traumatic arthritis
3446|NCT03034811|Partial knee arthroplasty
3447|NCT03034811|Unicompartmental knee arthroplasty
3448|NCT03034772|neovascular
3449|NCT03034772|wet
3450|NCT03034772|age-related
3451|NCT03034772|macular degeneration
3452|NCT03034772|dorzolamide
3453|NCT03034772|timolol
3454|NCT03034759|continuous glucose monitoring
3455|NCT03034746|alzheimer's disease, physical activity, cognitive training
3456|NCT03034733|Arthroplasty
3457|NCT03034733|Knee Replacement
3458|NCT03034733|Pain, Postoperative
3459|NCT03034733|Glucocorticoids
3460|NCT03034733|Dexamethasone
3461|NCT03034720|Concussion
3462|NCT03034720|persistent post-concussive symptoms
3463|NCT03034720|CBT
3464|NCT03034720|collaborative care
3465|NCT03034720|Depression
3466|NCT03034720|Anxiety
3467|NCT03034707|biotin pharmacokinetic
3468|NCT03034707|biotinylated assay
3469|NCT03034707|hormone measurement
3470|NCT03034707|thyroid
3471|NCT03034707|parathyroid
3472|NCT03034707|prolactin
3473|NCT03034668|Botanical Supplement
3474|NCT03034668|Performance-Enhancing Supplement
3475|NCT03034655|Vestibular rehabilitation
3476|NCT03034655|Falls in elderly
3477|NCT03034655|Computerized dynamic posturography
3478|NCT03034655|Mobile posturography
3479|NCT03034642|Apoptosis
3480|NCT03034642|Bronchoscopy
3481|NCT03034642|Human
3482|NCT03034642|Mice, inbred strains
3483|NCT03034642|Macrophages, Alveolar
3484|NCT03034642|MicroRNAs
3485|NCT03034642|Streptococcus pneumoniae
3486|NCT03034642|Fluticasone
3487|NCT03034616|Primary ovarian insufficiency
3488|NCT03034616|In-vivo activation
3489|NCT03034551|Adherence
3490|NCT03034551|Financial Incentives
3491|NCT03034551|Remote Monitoring
3492|NCT03034551|Self-Weighing
3493|NCT03034551|Behavioral Economics
3494|NCT03034551|Telehealth
3495|NCT03034551|mobile health (mHealth)
3496|NCT03034551|Smartphone App
3497|NCT03034551|Wellth App
3498|NCT03034486|Glaucoma
3499|NCT03034473|locally advanced rectal cancer
3500|NCT03034473|translational research
3501|NCT03034473|Biomarker
3502|NCT03034447|Asthma
3503|NCT03034447|Obstructive Sleep Apnea
3504|NCT03034447|Children
3505|NCT03034447|Teenagers
3506|NCT03034408|Impulsivity
3507|NCT03034408|Nalmefene
3508|NCT03034408|Baclofen
3509|NCT03034395|Melanoma
3510|NCT03034395|cT2N0M0
3511|NCT03034382|morphine
3512|NCT03034382|nalbuphine
3513|NCT03034382|arthroscopic rotator cuff repair
3514|NCT03034382|ultrasound guided interscalene block
3515|NCT03034369|Integration
3516|NCT03034369|Primary Care
3517|NCT03034369|Behavioral Health
3518|NCT03034369|Health Care Reform
3519|NCT03034369|Medical Home
3520|NCT03034369|Accountable Care Organization
3521|NCT03034356|Schizophrenia
3522|NCT03034343|Mindfulness
3523|NCT03034343|Internet program
3524|NCT03034343|Depression
3525|NCT03034343|Cost-effectiveness
3526|NCT03034330|informal care
3527|NCT03034330|empowerment
3528|NCT03034330|family-focused intervention
3529|NCT03034330|stroke rehabilitation
3530|NCT03034317|Diaphragm Pacing
3531|NCT03034304|MASCT-I，DC，T cell
3532|NCT03034304|Advanced solid tumors
3533|NCT03034304|Bladder Cancer
3534|NCT03034304|Soft Tissue Sarcoma
3535|NCT03034291|Cocoa
3536|NCT03034291|obesity
3537|NCT03034291|HOMA-IR
3538|NCT03034291|BMI
3539|NCT03034291|Quality of life
3540|NCT03034278|opioid use
3541|NCT03034265|hypertension; exosome; angiotensin; sodium channel; kidney; aldosterone; renin; urine
3542|NCT03034226|Hypoglycemia-Associated Autonomic Failure (HAAF)
3543|NCT03034213|mesh
3544|NCT03034200|Pheochromocytoma-paraganglioma
3545|NCT03034200|ONC201
3546|NCT03034187|Acute toxicity
3547|NCT03034187|Late toxicity
3548|NCT03034187|Quality of Life since 2011(set-up SFP-prostate)
3549|NCT03034174|tigecycline
3550|NCT03034174|pharmacokinetics
3551|NCT03034148|Coronary artery disease
3552|NCT03034148|Atherothrombosis
3553|NCT03034148|Thrombin generation
3554|NCT03034148|Platelet Acetyl Coenzyme A carboxylase phosphorylation
3555|NCT03034109|Transcranial Direct Current Stimulation
3556|NCT03034109|Stroke
3557|NCT03034109|Electric Stimulation Therapy
3558|NCT03034109|Prefrontal Cortex
3559|NCT03034109|Electroencephalography
3560|NCT03034109|Cognition
3561|NCT03034109|Neurological Rehabilitation
3562|NCT03034109|Memory
3563|NCT03034109|Working Memory
3564|NCT03034109|Attention
3565|NCT03034109|Concentration
3566|NCT03034109|Short-Term Memory
3567|NCT03034109|Planning
3568|NCT03034109|Executive Function
3569|NCT03034109|Cerebrovascular disease
3570|NCT03034083|healthy marriage
3571|NCT03034083|healthy relationships
3572|NCT03034083|parenting
3573|NCT03034083|healthy marriage and relationship education
3574|NCT03034070|MRI
3575|NCT03034070|MRI sequences
3576|NCT03034070|prostate cancer
3577|NCT03034070|cancer
3578|NCT03034070|staging
3579|NCT03034070|bone metastasis
3580|NCT03034070|node metastasis
3581|NCT03034031|Traumatic Brain Injury
3582|NCT03034031|Children
3583|NCT03034031|Pediatric
3584|NCT03034031|MRI
3585|NCT03034031|fMRI
3586|NCT03034031|Cognition
3587|NCT03034031|DTI
3588|NCT03034031|Longitudinal
3589|NCT03034031|Connectivity
3590|NCT03034031|DAI
3591|NCT03034031|Neuropsychology
3592|NCT03034031|Rehabilitation
3593|NCT03034018|insomnia
3594|NCT03034018|hot flashes
3595|NCT03034018|menopause
3596|NCT03034018|suvorexant
3597|NCT03034018|belsomra
3598|NCT03034005|Inhaled corticosteroids
3599|NCT03034005|Airway hyper-responsiveness
3600|NCT03034005|Airway smooth muscle
3601|NCT03034005|sodium-potassium pump
3602|NCT03033966|Cerebral Oximetry
3603|NCT03033966|Cerebral Venous Thrombosis
3604|NCT03033966|Decompressive Craniectomy
3605|NCT03033927|Stage IV Pancreatic Cancer
3606|NCT03033927|FOLFIRINOX
3607|NCT03033927|gem/nab-P chemotherapy
3608|NCT03033927|17-042
3609|NCT03033914|Nivolumab
3610|NCT03033914|adriamycin
3611|NCT03033914|bleomycin
3612|NCT03033914|vinblastine
3613|NCT03033914|dacarbazine
3614|NCT03033914|16-1536
3615|NCT03033901|Veterans
3616|NCT03033901|Comparative Effectiveness Research
3617|NCT03033901|Diagnosis
3618|NCT03033836|transgender women
3619|NCT03033823|Alcoholism
3620|NCT03033823|Delirium
3621|NCT03033823|Magnesium Deficiency
3622|NCT03033797|assitive technology
3623|NCT03033797|virtual reality games
3624|NCT03033797|intellectual disability
3625|NCT03033797|augmentative and alternative communication
3626|NCT03033784|Neuroscience
3627|NCT03033758|comorbidities
3628|NCT03033732|opioid agonist treatment
3629|NCT03033732|pragmatic
3630|NCT03033732|prescription opioid use
3631|NCT03033732|patient engagement
3632|NCT03033719|Colorectal Surgery
3633|NCT03033719|Geriatrics
3634|NCT03033719|Digestive Oncology
3635|NCT03033719|Colon cancer
3636|NCT03033719|Elderly patients
3637|NCT03033719|Laparoscopy
3638|NCT03033719|Laparotomy
3639|NCT03033719|Morbidity
3640|NCT03033667|perioperative fasting
3641|NCT03033667|free fatty acids
3642|NCT03033667|coronary bypass grfting
3643|NCT03033589|Pain control
3644|NCT03033589|Anterior Cruciate Ligament (ACL_ Reconstruction)
3645|NCT03033589|Regional Anesthesia
3646|NCT03033511|Extensive-Stage Small Cell Lung Cancer (ED SCLC)
3647|NCT03033511|Rovalpituzumab tesirine
3648|NCT03033511|first-line chemotherapy
3649|NCT03033511|Cancer
3650|NCT03033511|Platinum-Based Chemotherapy
3651|NCT03033485|Picolinamide
3652|NCT03033485|PET/CT
3653|NCT03033485|Diagnosis
3654|NCT03033485|Melanoma
3655|NCT03033459|breast feeding
3656|NCT03033459|motivational interviewing
3657|NCT03033420|Unipolar disorder
3658|NCT03033420|Bipolar disorder
3659|NCT03033420|Randomized controlled trial
3660|NCT03033420|Smartphone
3661|NCT03033420|Re-admission
3662|NCT03033420|CBT
3663|NCT03033381|Children
3664|NCT03033381|Inguinal hernia
3665|NCT03033381|Testis
3666|NCT03033381|Doppler ultrasonography
3667|NCT03033368|immunological outcome
3668|NCT03033368|virologic outcomes
3669|NCT03033368|HIV-1 infected adolescents
3670|NCT03033368|EFV switch to RPV
3671|NCT03033368|Rilpivirine pharmacokinetic
3672|NCT03033368|neuropsychiatric adverse events
3673|NCT03033355|Neurogenic Bladder, Detrusor Overactivity, Botox, fMRI, neurogenic detrusor overactivity
3674|NCT03033342|Phase 1
3675|NCT03033316|Multiple Myeloma
3676|NCT03033316|Liposomal Dexamethasone
3677|NCT03033316|Targeted Drug Delivery
3678|NCT03033303|Hu3F8
3679|NCT03033303|GM-CSF
3680|NCT03033303|Isotretinoin
3681|NCT03033303|16-1643
3682|NCT03033290|Qi-tonifying regimen
3683|NCT03033290|immune-modulation
3684|NCT03033290|gut microbiota
3685|NCT03033251|COPD exacerbation
3686|NCT03033251|Work of breathing
3687|NCT03033251|Non invasive ventilation
3688|NCT03033251|High Flow Oxygen Cannula
3689|NCT03033225|Pancrease
3690|NCT03033225|Cancer
3691|NCT03033225|Photodynamic Therapy
3692|NCT03033225|Pancreatic
3693|NCT03033225|Tumor
3694|NCT03033225|unresectable
3695|NCT03033199|Gut microbiota
3696|NCT03033199|Immune thrombocytopenia
3697|NCT03033186|Everolimus
3698|NCT03033186|Long term site effects
3699|NCT03033186|Dried Blood Spot
3700|NCT03033186|Therapeutic Drug Monitoring
3701|NCT03033160|Estrogen
3702|NCT03033160|Hematuria
3703|NCT03033121|growth hormone
3704|NCT03033121|children
3705|NCT03033121|metabolism
3706|NCT03033095|TNF inhibitor
3707|NCT03033095|Etanercept
3708|NCT03033095|Spondyloarthritis
3709|NCT03033095|Biomarkers analysis
3710|NCT03033095|Personnalized medicine
3711|NCT03033056|fear-conditioning
3712|NCT03033056|behavioral avoidance
3713|NCT03033056|anxiety disorders
3714|NCT03033056|fMRI
3715|NCT03033043|aortic
3716|NCT03033043|dissection
3717|NCT03033043|type B
3718|NCT03033043|thoracic
3719|NCT03033030|Ultrasound
3720|NCT03033030|Digital Breast Tomosynthesis
3721|NCT03033030|Cancer Detection rate
3722|NCT03033030|Sensitivity
3723|NCT03033030|Specificity
3724|NCT03033030|Breast density
3725|NCT03033017|HIV
3726|NCT03032991|Gestational diabetes
3727|NCT03032991|Neurodevelopment
3728|NCT03032991|Placenta
3729|NCT03032991|Gut microbiota
3730|NCT03032991|Protectins
3731|NCT03032991|MFSD2a
3732|NCT03032991|AdipoRon
3733|NCT03032965|atrial fibrillation
3734|NCT03032965|ablation
3735|NCT03032965|adenosine
3736|NCT03032952|RCT
3737|NCT03032952|Computerised interventions
3738|NCT03032952|Mobile applications
3739|NCT03032952|Stress, Psychological
3740|NCT03032952|Depressive symptoms
3741|NCT03032952|Anxious symptoms
3742|NCT03032952|Students
3743|NCT03032952|Mental health
3744|NCT03032926|Anxiety
3745|NCT03032913|Pancreas
3746|NCT03032913|Pancreatic
3747|NCT03032913|Cancer
3748|NCT03032913|Circulating tumor cell (CTC)
3749|NCT03032913|Adenocarcinoma
3750|NCT03032913|Ductal
3751|NCT03032913|Exosome
3752|NCT03032900|Major lung resection
3753|NCT03032900|Right Ventricular Dysfunction
3754|NCT03032900|2D Strain
3755|NCT03032887|hygiene
3756|NCT03032887|prenatal care
3757|NCT03032887|postnatal care
3758|NCT03032874|Colorectal cancer
3759|NCT03032874|Polyps
3760|NCT03032874|Colonoscopy
3761|NCT03032874|Rectal bleeding
3762|NCT03032874|Nigeria
3763|NCT03032861|Orange juice
3764|NCT03032861|Microbiota
3765|NCT03032861|Prebiotic
3766|NCT03032861|Flavanones
3767|NCT03032861|Bioavailability
3768|NCT03032835|Calciphylaxis
3769|NCT03032835|Warfarin
3770|NCT03032835|Dialysis
3771|NCT03032822|Opioid consumption
3772|NCT03032822|postdischarge
3773|NCT03032822|cystectomy
3774|NCT03032744|Pediatric
3775|NCT03032744|School Based Health Center
3776|NCT03032731|Physical activity
3777|NCT03032731|Diet
3778|NCT03032731|Health Behavior
3779|NCT03032705|Restorations
3780|NCT03032705|Composite
3781|NCT03032679|pain, acute, chronic, knee arthroplasty
3782|NCT03032666|Thalassemia
3783|NCT03032666|HCV
3784|NCT03032666|Sofosbuvir
3785|NCT03032666|Ledipasvir
3786|NCT03032653|ankle, fracture, rehabilitation, weightbearing, early, late
3787|NCT03032640|Glucose
3788|NCT03032640|Sweet taste receptors
3789|NCT03032640|Artificial sweeteners
3790|NCT03032601|MS (Multiple Sclerosis)
3791|NCT03032601|Acute Fulminating
3792|NCT03032601|Sclerosis
3793|NCT03032601|FDG
3794|NCT03032601|18F Fluorodeoxyglucose
3795|NCT03032601|18F-FDG
3796|NCT03032601|18FDG
3797|NCT03032601|2-Fluoro-2-deoxy-D-glucose
3798|NCT03032601|2-Fluoro-2-deoxyglucose
3799|NCT03032601|Fludeoxyglucose F 18
3800|NCT03032601|Fluorine-18-fluorodeoxyglucose
3801|NCT03032601|Fluorodeoxyglucose F 18
3802|NCT03032601|PET Scan
3803|NCT03032601|Tomography, Positron-Emission
3804|NCT03032601|Magnetic Resonance Imaging, Functional
3805|NCT03032601|fMRI
3806|NCT03032601|PET-MRI
3807|NCT03032601|Acetylcysteine
3808|NCT03032601|N-acetyl cysteine
3809|NCT03032601|NAC
3810|NCT03032601|Oral supplements
3811|NCT03032575|HIV
3812|NCT03032562|respiratory muscle strength
3813|NCT03032562|sleep-disordered breathing
3814|NCT03032562|neuromuscular disease
3815|NCT03032562|chronic-obstructive pulmonary disease
3816|NCT03032497|Brain Computer Interface
3817|NCT03032497|Electroencephalogram (EEG)
3818|NCT03032497|Chronic Pain
3819|NCT03032471|Subarachnoid Hemorrhage
3820|NCT03032471|Delayed cerebral ischemia
3821|NCT03032471|Cognitive Impairment
3822|NCT03032471|Montreal Cognitive Assessment
3823|NCT03032471|MoCA
3824|NCT03032471|Cognitive Deterioration
3825|NCT03032458|Shock Wave Lithotripsy
3826|NCT03032458|Ketorolac
3827|NCT03032458|Xylocaine Gel
3828|NCT03032458|Pethidine
3829|NCT03032445|Body Water/physiology
3830|NCT03032445|Hyponatremia/etiology
3831|NCT03032445|Physical Exertion/physiology
3832|NCT03032445|Running/physiology
3833|NCT03032445|Sodium/blood
3834|NCT03032445|Ethanol
3835|NCT03032380|Hospital-acquired pneumonia (HAP)
3836|NCT03032380|S-649266
3837|NCT03032380|linezolid
3838|NCT03032380|meropenem
3839|NCT03032380|Healthcare-associated pneumonia (HCAP)
3840|NCT03032380|nosocomial pneumonia
3841|NCT03032380|Ventilator-associated pneumonia (VAP)
3842|NCT03032380|Gram-negative pathogens
3843|NCT03032380|pneumonia
3844|NCT03032380|cefiderocol
3845|NCT03032354|probiotics
3846|NCT03032354|children
3847|NCT03032354|remission
3848|NCT03032341|mobility assessment tool
3849|NCT03032302|TBI
3850|NCT03032289|active transport
3851|NCT03032289|cycling
3852|NCT03032289|walking
3853|NCT03032276|Safe motherhood
3854|NCT03032276|Newborn survival
3855|NCT03032276|Community
3856|NCT03032276|Cluster Randomized Trial
3857|NCT03032237|Protein intake
3858|NCT03032237|Older adults
3859|NCT03032237|Protein-rich
3860|NCT03032237|Acceptance
3861|NCT03032237|Liking
3862|NCT03032237|Readymade meals
3863|NCT03032224|Body composition
3864|NCT03032224|sarcopenia
3865|NCT03032224|Dysphagia
3866|NCT03032224|Surgery
3867|NCT03032224|Quality of Life
3868|NCT03032224|Morbidity
3869|NCT03032185|menopause
3870|NCT03032185|post-menopause
3871|NCT03032185|transcutaneous electrical nerve stimulation
3872|NCT03032185|electrical stimulation therapy
3873|NCT03032185|women's health
3874|NCT03032133|Total Knee Arthroplasty
3875|NCT03032133|Total Knee Replacement
3876|NCT03032133|Outcome
3877|NCT03032133|Results
3878|NCT03032133|Pain
3879|NCT03032107|Breast Cancer
3880|NCT03032094|Gingival Recession
3881|NCT03032055|sickle cell desease
3882|NCT03032055|vaso occlusive crisis
3883|NCT03032055|acute chest syndrome
3884|NCT03032055|Validation of predictif score of acute chest syndrome
3885|NCT03032042|intestinal microbiome
3886|NCT03032042|soil-transmitted helminths
3887|NCT03032042|mass drug administration
3888|NCT03032016|VOD
3889|NCT03032016|Defibrotide
3890|NCT03032016|Defitelio
3891|NCT03032016|Registry
3892|NCT03032016|SOS
3893|NCT03031990|Yoga
3894|NCT03031990|Oocyte cryopreservation
3895|NCT03031990|In-vitro fertilization
3896|NCT03031951|Former athletes
3897|NCT03031951|Body composition
3898|NCT03031951|Adaptive thermogenesis
3899|NCT03031951|Physical activity
3900|NCT03031951|Energy expenditure
3901|NCT03031951|Sedentary behavior
3902|NCT03031951|Fat mass
3903|NCT03031951|Abdominal fat mass
3904|NCT03031951|Nutrition
3905|NCT03031951|Behavior modification
3906|NCT03031938|Exposure in utero in tanezumab program
3907|NCT03031925|Annexin A2
3908|NCT03031925|biomarker
3909|NCT03030846|pregnancy
3910|NCT03030846|pelvic floor muscles
3911|NCT03030846|Lumbo-pelvic pain
3912|NCT03030846|Stabilization exercises
3913|NCT03030846|abdominal muscles thickness
3914|NCT03030846|Multifidus muscles thickness
3915|NCT03030846|Multifidus muscles cross section area
3916|NCT03031821|Prostate Cancer
3917|NCT03031821|ADT
3918|NCT03031821|iADT
3919|NCT03031821|Metabolic Syndrome
3920|NCT03031821|Androgen Deprivation Therapy
3921|NCT03031821|Phase III
3922|NCT03031821|Phase 3
3923|NCT03031821|Randomized
3924|NCT03031821|Intermittent Androgen Deprivation Therapy
3925|NCT03031795|intrauterine device
3926|NCT03031782|JIA, JPsA, ERA, Secukinumab, ILAR
3927|NCT03031756|Air polishing
3928|NCT03031743|rotavirus vaccine
3929|NCT03031743|human microbiome
3930|NCT03031743|fecal microbiome
3931|NCT03031743|vaccine immunogenicity
3932|NCT03031743|Rotarix
3933|NCT03031743|immune response, mucosal
3934|NCT03031665|GABA
3935|NCT03031665|Depression
3936|NCT03031665|Stress
3937|NCT03031665|Androgens
3938|NCT03031652|pain
3939|NCT03031652|axial length
3940|NCT03031652|anterior chamber depth
3941|NCT03031652|intraocular pressure
3942|NCT03031639|endoscopic
3943|NCT03031639|thyroidectomy
3944|NCT03031613|intraocular pressure
3945|NCT03031613|intracerebral pressure
3946|NCT03031587|Thermometric MRI
3947|NCT03031587|Myocardium
3948|NCT03031574|Serotonin 4 (5-HT4) receptor
3949|NCT03031574|Phase 1
3950|NCT03031509|Nonunion Fracture of limb
3951|NCT03031496|Cross-over
3952|NCT03031496|Hydrochlorothiazide
3953|NCT03031496|Amiloride hydrochloride
3954|NCT03031496|Phase I
3955|NCT03031496|GSK3542503
3956|NCT03031496|Bioequivalence
3957|NCT03031496|FTIH
3958|NCT03031470|Liver Transplant
3959|NCT03031470|Ischemia-reperfusion injury
3960|NCT03031470|Early allograft dysfunction
3961|NCT03031444|colorectal liver metastasis
3962|NCT03031444|preoperative
3963|NCT03031444|chemotherapy
3964|NCT03031444|targeted therapy
3965|NCT03031431|Hypothermia
3966|NCT03031431|Infant Warmer
3967|NCT03031340|Spinal fusion
3968|NCT03031340|pregabalin
3969|NCT03031340|Spinal fusion surgeries
3970|NCT03031340|two or more vertebrae
3971|NCT03031327|Ocular Discomfort Following Refractive Surgery
3972|NCT03031327|Refractive Surgery
3973|NCT03031314|Joint Replacement
3974|NCT03031314|Knee Replacement
3975|NCT03031314|Wound Healing
3976|NCT03031314|Hip Replacement
3977|NCT03031288|gastroesophageal reflux
3978|NCT03031288|swallow
3979|NCT03031288|feeding bottle
3980|NCT03031288|cardiorespiratory
3981|NCT03031288|apnoea
3982|NCT03031288|preterm
3983|NCT03031288|impedance-pH-metry
3984|NCT03031275|extracorporeal circulation
3985|NCT03031275|critical care outcomes
3986|NCT03031236|Early Childhood Development (ECD)
3987|NCT03031236|Psychosocial stimulation
3988|NCT03031236|Cognition
3989|NCT03031236|Parenting
3990|NCT03031236|Malnutrition
3991|NCT03031236|Bangladesh
3992|NCT03031236|Childhood Maltreatment
3993|NCT03031223|Spinal cord injuries
3994|NCT03031223|low-level laser therapy
3995|NCT03031210|Non-severe community-acquired pneumonia
3996|NCT03031210|Amoxicillin treatment
3997|NCT03031210|Twice daily antibiotic regimen
3998|NCT03031197|adherence
3999|NCT03031197|adolescent
4000|NCT03031197|HIV/AIDS
4001|NCT03031197|Vietnam
4002|NCT03031184|Agitation
4003|NCT03031184|Agitated behaviours
4004|NCT03031184|Alzheimer's Disease
4005|NCT03031171|community engagement, navigation, cancer screening
4006|NCT03031132|Protein-rich breakfast
4007|NCT03031132|Breakfast Skipping
4008|NCT03031132|Young Adults
4009|NCT03031132|Breakfast
4010|NCT03031132|Food form
4011|NCT03031132|fMRI
4012|NCT03031132|Ghrelin
4013|NCT03031132|PYY
4014|NCT03031132|Sleep
4015|NCT03031119|nonalcoholic steatohepatitis
4016|NCT03031106|Patient-reported outcomes, Health-related QoL, Internet-based tool
4017|NCT03031093|aerosol therapy
4018|NCT03031093|pulmonary scintigraphy
4019|NCT03031093|upper airways anatomy
4020|NCT03031080|Collagenase, Night-splinting, Dupuytrens, Contracture
4021|NCT03031067|Donors and donation
4022|NCT03031067|Extended criteria donor
4023|NCT03031067|Organ perfusion and preservation
4024|NCT03031067|Liver transplantation
4025|NCT03031067|Kidney transplantation
4026|NCT03031067|Preservation injury
4027|NCT03031067|Ischemia reperfusion injury
4028|NCT03031054|Hydrodissection
4029|NCT03031054|hyaluronic acid
4030|NCT03031041|Hydrodissection
4031|NCT03031041|short-axis
4032|NCT03031041|long-axis
4033|NCT03031028|refractory epilepsy,
4034|NCT03031028|ketogenic diet
4035|NCT03031028|classic ketogenic diet
4036|NCT03031028|seizure rate
4037|NCT03031028|efficacy
4038|NCT03031028|epilepsy
4039|NCT03031015|Reduction, Fracture
4040|NCT03031002|exposure
4041|NCT03031002|spider phobia
4042|NCT03031002|generalization
4043|NCT03031002|extinction
4044|NCT03030976|CD19
4045|NCT03030976|CAR-T
4046|NCT03030976|SLE
4047|NCT03030963|Equal ratio ventilation(ERV)
4048|NCT03030963|Peak inspiratory pressure(PIP)
4049|NCT03030963|Blood loss
4050|NCT03030963|Posterior lumbar interbody fusion(PLIF)
4051|NCT03030963|Prone position
4052|NCT03030924|suicide
4053|NCT03030885|Radiopharmaceutical (131I-MIP-1095)
4054|NCT03030885|16-1110
4055|NCT03030820|cirrhosis
4056|NCT03030820|Periodontitis
4057|NCT03030794|Gulf War Illness
4058|NCT03030794|Headache
4059|NCT03030794|Muscle Pain
4060|NCT03030794|Joint Pain
4061|NCT03030794|TMS
4062|NCT03030768|Pre-Exposure Prophylaxis
4063|NCT03030768|Fertility
4064|NCT03030768|mHealth
4065|NCT03030768|Pregnancy
4066|NCT03030716|antinutrients
4067|NCT03030716|tannins
4068|NCT03030716|proanthocyanidins
4069|NCT03030716|salivary proline-rich proteins
4070|NCT03030703|Phytic acid
4071|NCT03030703|Cystatin
4072|NCT03030703|Salivary proline-rich protein
4073|NCT03030703|antinutrient
4074|NCT03030690|Proximal Dental Caries
4075|NCT03030690|Glass Carbomer
4076|NCT03030690|Hydroxyapatite Enhanced Glass Ionomer
4077|NCT03030690|Primary Teeth
4078|NCT03030677|pecs block
4079|NCT03030677|breast surgery
4080|NCT03030677|ultrasound guidence
4081|NCT03030664|constipation
4082|NCT03030664|Lactobacillus reuteri
4083|NCT03030664|probiotics
4084|NCT03030651|Breastfeeding
4085|NCT03030651|Education and support
4086|NCT03030651|Ethiopia
4087|NCT03030651|Timely initiation of breastfeeding
4088|NCT03030625|Prostate Cancer
4089|NCT03030625|VMAT
4090|NCT03030625|Dominant Intraprostatic Lesion
4091|NCT03030625|Intensity modulated radiotherapy
4092|NCT03030586|Blood cell biomarkers, peripheral circulating biomarkers
4093|NCT03030573|Bile duct injury
4094|NCT03030573|Bile duct defect
4095|NCT03030573|Round ligament
4096|NCT03030573|Reconstruction
4097|NCT03030508|biomarks
4098|NCT03030508|colorectal cancer
4099|NCT03030508|capecitabine
4100|NCT03030508|gene polymorphism
4101|NCT03030495|Ischemic Heart Disease
4102|NCT03030495|Stable angina
4103|NCT03030495|Fractional flow reserve
4104|NCT03030495|Index of Microcirculatory Resistance
4105|NCT03030495|Coronary Flow Reserve
4106|NCT03030495|Intravascular Imaging
4107|NCT03030482|Anxiety
4108|NCT03030482|intensive care
4109|NCT03030482|mechanical ventilation
4110|NCT03030482|touch massage
4111|NCT03030456|whole body vibration
4112|NCT03030456|Oxidative Stress
4113|NCT03030456|Aged
4114|NCT03030456|Biochemical profile
4115|NCT03030456|muscle strength
4116|NCT03030456|flexibility
4117|NCT03030443|Pain management
4118|NCT03030443|Nitrous
4119|NCT03030417|Topoisomerase 1 Inhibitor
4120|NCT03030417|Epithelial-Mesenchymal Transition
4121|NCT03030417|Pharmacodynamics
4122|NCT03030417|DNA Damage
4123|NCT03030417|Pharmacokinetics
4124|NCT03030404|Genetics
4125|NCT03030404|Familial Background
4126|NCT03030404|Inherited Cancer Syndrome
4127|NCT03030404|Germline Mutation in the CDH1 Gene
4128|NCT03030404|Genetic Testing
4129|NCT03030391|Camp
4130|NCT03030391|Radiation Absorbed Dose
4131|NCT03030391|Compartmental Analysis
4132|NCT03030365|Orientation, Disorientation.
4133|NCT03030352|Child Mental Health
4134|NCT03030352|Parenting
4135|NCT03030352|Autonomy Support
4136|NCT03030352|How-to Parenting Program
4137|NCT03030352|Randomized Controlled Trial
4138|NCT03030352|Primary Prevention
4139|NCT03030352|Parental Mental Health
4140|NCT03030352|Child Well-Being
4141|NCT03030339|Vitamin A status
4142|NCT03030339|infant
4143|NCT03030339|dietary assessment
4144|NCT03030339|retinol isotope dilution
4145|NCT03030339|breast milk intake
4146|NCT03030300|type 2 diabetes
4147|NCT03030300|remission
4148|NCT03030300|short-term intensive insulin therapy
4149|NCT03030235|diabetes
4150|NCT03030235|heart failure
4151|NCT03030235|dapagliflozin
4152|NCT03030235|SGLT-2 inhibitors
4153|NCT03030222|diabetes
4154|NCT03030222|heart failure
4155|NCT03030222|empagliflozin
4156|NCT03030222|SGLT-2 inhibitors
4157|NCT03030209|pancreatectomy
4158|NCT03030209|diabetes mellitus
4159|NCT03030183|PNH
4160|NCT03030157|urothelial cancer
4161|NCT03030157|bladder cancer
4162|NCT03030157|nephroureterectomy
4163|NCT03030131|IFCT
4164|NCT03030131|neodjuvant
4165|NCT03030131|immune therapy
4166|NCT03030131|Non small cell lung cancer
4167|NCT03030118|hydroxychloroquine
4168|NCT03030105|Cognition
4169|NCT03030105|Dementia
4170|NCT03030105|Phosphodiesterase Type 4D
4171|NCT03030105|PDE4D
4172|NCT03030105|Scopolamine
4173|NCT03030105|Donepezil
4174|NCT03030066|DS-1001b
4175|NCT03030066|IDH1 mutation
4176|NCT03030066|Developmental Phase I
4177|NCT03030066|Glioma
4178|NCT03030053|Flavanols
4179|NCT03030053|Flavonoids
4180|NCT03030053|Polyphenols
4181|NCT03030053|Cognition
4182|NCT03030053|Aging
4183|NCT03030040|mindfulness-based cognitive therapy
4184|NCT03030040|self-help
4185|NCT03030040|healthcare staff
4186|NCT03030027|Intergeneration
4187|NCT03030027|Reappraisal
4188|NCT03030027|Caregiving
4189|NCT03030001|mesothelin
4190|NCT03030001|PD-1
4191|NCT03030001|CAR T
4192|NCT03030001|solid tumor
4193|NCT03029988|adenocarcinoma, Colorectal Carcinoma, liver metastases
4194|NCT03029975|beef
4195|NCT03029975|protein
4196|NCT03029975|resistance training
4197|NCT03029975|strength
4198|NCT03029975|performance
4199|NCT03029962|Teenage Pregnancy Prevention
4200|NCT03029962|LGB Girls
4201|NCT03029962|Text-Messaging
4202|NCT03029962|Information-Motivation-Behavioral Skills(IMB)Model
4203|NCT03029949|chronic dizziness
4204|NCT03029949|persistent postural-perceptual dizziness
4205|NCT03029949|acceptance and commitment therapy
4206|NCT03029949|behavior therapy
4207|NCT03029949|vestibular rehabilitation
4208|NCT03029936|obesity
4209|NCT03029936|asthma
4210|NCT03029936|diaphragm excursion
4211|NCT03029936|pulmonary function test
4212|NCT03029923|smoking
4213|NCT03029923|depression
4214|NCT03029923|Behavioral Activation
4215|NCT03029910|Eccentric exercise
4216|NCT03029910|Whole body vibration
4217|NCT03029910|Cryotherapy
4218|NCT03029871|lung cancer
4219|NCT03029871|adenovirus
4220|NCT03029871|gene therapy
4221|NCT03029871|SBRT
4222|NCT03029793|Esophageal Cancer
4223|NCT03029793|Prediction
4224|NCT03029793|Biomarker
4225|NCT03029793|MRI-DWI
4226|NCT03029793|PET-CT
4227|NCT03029767|Hypertension
4228|NCT03029767|Anthropometry
4229|NCT03029767|Aerobic exercise
4230|NCT03029767|Resistance exercise
4231|NCT03029728|Hereditary and acquired C1-inhibitor deficiency
4232|NCT03029728|C1 esterase inhibitor, hereditary angioedema,
4233|NCT03029715|Sleeve gastrectomy
4234|NCT03029715|TIVA
4235|NCT03029702|Gestational diabetes
4236|NCT03029702|Diabetes in pregnancy
4237|NCT03029702|Insulin resistance
4238|NCT03029702|Insulin secretion deficiency
4239|NCT03029689|HIV infection
4240|NCT03029689|Gut microbiome
4241|NCT03029689|Raltegravir
4242|NCT03029689|Raltegravir intensification
4243|NCT03029689|Bacterial richness
4244|NCT03029676|spinal anesthesia, TURBT, POCD, premedication
4245|NCT03029663|bladder cancer
4246|NCT03029663|postoperative complications
4247|NCT03029650|Peer Review
4248|NCT03029650|Research
4249|NCT03029637|Resin bonded bridges
4250|NCT03029637|Randomized controlled trial
4251|NCT03029559|Inspiratory threshold loading
4252|NCT03029520|Endodontic Postoperative Pain
4253|NCT03029520|iRoot SP Sealer
4254|NCT03029520|Randomized Clinical Trial
4255|NCT03029520|Herofill carrier-based obturation
4256|NCT03029507|Obesity
4257|NCT03029507|Military
4258|NCT03029507|Acceptance and Commitment Therapy
4259|NCT03029507|Overweight
4260|NCT03029507|Weight-management
4261|NCT03029507|Navy Personnel
4262|NCT03029507|Fitness
4263|NCT03029494|oxidative stress
4264|NCT03029494|saliva
4265|NCT03029442|Spinal Cord Injury
4266|NCT03029442|Denosumab
4267|NCT03029442|Osteoporosis
4268|NCT03029442|Dual Energy X-ray Absorptiometry
4269|NCT03029429|pseudohypoparathyroidism
4270|NCT03029429|AHO
4271|NCT03029429|Albright Hereditary Osteodystrophy
4272|NCT03029390|Prediabetes
4273|NCT03029390|hyperglycemia
4274|NCT03029390|Impaired Fasting Glucose
4275|NCT03029390|Metformin
4276|NCT03029390|Berberine
4277|NCT03029390|glucose intolerance
4278|NCT03029377|CFS
4279|NCT03029377|Stress
4280|NCT03029377|Norepinephrine Transporter (NET)
4281|NCT03029377|Norepinephrine (NE)
4282|NCT03029377|Healthy Controls
4283|NCT03029377|Fatigue
4284|NCT03029364|Maximal Fat Oxidation
4285|NCT03029364|Exercise
4286|NCT03029364|Within-subject Variability
4287|NCT03029364|Determinants
4288|NCT03029351|albuminuria
4289|NCT03029351|GLP-1 Receptor Agonist
4290|NCT03029351|Type 2 Diabetes
4291|NCT03029338|lymphoma
4292|NCT03029338|non-hodgkin
4293|NCT03029338|B-cell
4294|NCT03029338|CD19 CAR T cells
4295|NCT03029338|refractory
4296|NCT03029338|relapse
4297|NCT03029312|whole body vibration
4298|NCT03029312|Muscle function
4299|NCT03029312|Physical activity
4300|NCT03029312|bone density
4301|NCT03029286|Breast Cancer
4302|NCT03029286|Breast Density
4303|NCT03029247|Anemia
4304|NCT03029247|Daprodustat
4305|NCT03029247|Blood pressure
4306|NCT03029247|ESA
4307|NCT03029247|CKD
4308|NCT03029208|Daprodustat, recombinant human erythropoietin, darbepoetin, anemia, chronic kidney disease, dialysis, ESRD
4309|NCT03029195|cleft lip and palate
4310|NCT03029195|nasoalveolar molding
4311|NCT03029195|Egyptian infants
4312|NCT03029195|quantitative analysis
4313|NCT03029182|Exercise
4314|NCT03029182|Cancer
4315|NCT03029182|Obesity
4316|NCT03029169|Supraventricular Arrhythmia
4317|NCT03029169|Septic shock
4318|NCT03029169|Propafenone
4319|NCT03029169|Amiodarone
4320|NCT03029169|Intensive Care
4321|NCT03029156|Asthma
4322|NCT03029156|Aeroneb
4323|NCT03029156|Aerogen
4324|NCT03029156|Bronchodilator
4325|NCT03029143|Drug Therapy
4326|NCT03029130|vesicovaginal fistula
4327|NCT03029130|urinary catheter
4328|NCT03029130|catheter extension
4329|NCT03029117|rheumatic pregnancy
4330|NCT03029104|Keratoconus
4331|NCT03029104|Forme fruste keratoconus
4332|NCT03029104|Post-LASIK ectasia
4333|NCT03029104|Pellucid marginal degeneration
4334|NCT03029104|Forme fruste pellucid marginal degeneration
4335|NCT03029104|Diurnal fluctuation post-radial keratotomy
4336|NCT03029104|Terrien's marginal degeneration
4337|NCT03029078|XDR
4338|NCT03029078|fecal microbiota transplant
4339|NCT03029078|eradicate
4340|NCT03029078|colonization
4341|NCT03029078|CRE
4342|NCT03029078|GRE
4343|NCT03029078|bacteria
4344|NCT03029065|lung Adenocarcinoma with brain (meningeal) metastasis
4345|NCT03029039|Platelet
4346|NCT03029039|severe sepsis
4347|NCT03029039|inflammation
4348|NCT03029039|S. aureus
4349|NCT03029039|biomarkers
4350|NCT03029026|Cardiac amyloidosis
4351|NCT03029026|Aortic stenosis
4352|NCT03029026|DPD scintigraphy
4353|NCT03028987|Quadrivalent, inactivated influenza vaccine
4354|NCT03028987|Quadrivalent, live, attenuated influenza vaccine
4355|NCT03028987|Identical twin adults
4356|NCT03028974|Inactivated influenza vaccine
4357|NCT03028974|Live, attenuated influenza vaccine
4358|NCT03028974|Young children
4359|NCT03028974|Adults
4360|NCT03028922|creos xenogain
4361|NCT03028909|Influenza A
4362|NCT03028909|MEDI8852
4363|NCT03028896|LMA Flexible
4364|NCT03028870|Osteoarthritis
4365|NCT03028870|Pain
4366|NCT03028870|Osteoarthritis Knee
4367|NCT03028844|Neonate
4368|NCT03028844|preterm
4369|NCT03028844|pain
4370|NCT03028844|music
4371|NCT03028844|EEG
4372|NCT03028844|venepuncture
4373|NCT03028805|Informatics
4374|NCT03028805|COPD
4375|NCT03028805|quality improvement
4376|NCT03028792|attention training, youth, latino
4377|NCT03028779|Outpatient,fast-track, arthroplasty, Total knee arthroplasty (TKA), Total hip Arthroplasty (THA)
4378|NCT03028714|University
4379|NCT03028714|College
4380|NCT03028714|University students
4381|NCT03028714|Health education
4382|NCT03028714|Educational techonology
4383|NCT03028714|Internet
4384|NCT03028714|Nutrition knowledge
4385|NCT03028714|Eating behaviour
4386|NCT03028714|Diet
4387|NCT03028714|Physical Activity
4388|NCT03028714|Weight gain prevention
4389|NCT03028701|Formoterol
4390|NCT03028701|Budesonide
4391|NCT03028701|Dry powder inhalation
4392|NCT03028701|Discair
4393|NCT03028701|COPD
4394|NCT03028662|Alcohol Dependence
4395|NCT03028662|Brain Connectivity
4396|NCT03028662|Inhibition
4397|NCT03028649|β-hydroxy-β-methylbutyric acid
4398|NCT03028649|Sport supplements
4399|NCT03028649|Training support
4400|NCT03028649|Adaptation
4401|NCT03028636|fecal incontinence
4402|NCT03028636|bowel control
4403|NCT03028636|accidental bowel leakage
4404|NCT03028636|medical device
4405|NCT03028636|women's health
4406|NCT03028636|vaginal insert
4407|NCT03028636|pessary
4408|NCT03028636|incontinence
4409|NCT03028636|bowel continence
4410|NCT03028636|pump
4411|NCT03028597|Hypertension
4412|NCT03028597|Medication Adherence
4413|NCT03028597|Values Affirmation
4414|NCT03028597|African Americans
4415|NCT03028584|BrCa
4416|NCT03028584|PrCa
4417|NCT03028584|CRCa
4418|NCT03028558|Electronic Cigarettes
4419|NCT03028558|Healthy Volunteers
4420|NCT03028558|E-Cigarettes Smokers
4421|NCT03028558|E-Cigarettes
4422|NCT03028545|schizophrenia
4423|NCT03028545|anorexia
4424|NCT03028545|bipolar disorders
4425|NCT03028545|personality disorders
4426|NCT03028532|Healthy Volunteers
4427|NCT03028532|Sports Medicine
4428|NCT03028532|Anti-doping
4429|NCT03028532|Athletes
4430|NCT03028532|Men's Health
4431|NCT03028480|Exacerbation
4432|NCT03028480|Mepolizumab
4433|NCT03028480|NUCALA
4434|NCT03028467|GSK3196165
4435|NCT03028467|Active Rheumatoid Arthritis
4436|NCT03028467|Methotrexate
4437|NCT03028467|Monoclonal Antibody
4438|NCT03028467|Efficacy
4439|NCT03028467|Electrocardiogram
4440|NCT03028467|Tolerability
4441|NCT03028467|Pharmacokinetics
4442|NCT03028467|Japanese Subjects
4443|NCT03028441|Chikungunya
4444|NCT03028441|Immunogenicity
4445|NCT03028441|Measles
4446|NCT03028441|Vaccine
4447|NCT03028428|Osteoarthritis
4448|NCT03028428|Stem Cell
4449|NCT03028428|Knee
4450|NCT03028428|Mesenchymal Stem Cell
4451|NCT03028389|elderly patients
4452|NCT03028389|non-cardiac surgery
4453|NCT03028389|ischemic preconditioning
4454|NCT03028389|delirium
4455|NCT03028376|biomarker
4456|NCT03028376|point-of-care analysis
4457|NCT03028337|Malignant neoplasms of eye brain and other parts of central nervous system
4458|NCT03028337|Solid tumor malignancy
4459|NCT03028337|Radiographic evidence of spine metastasis
4460|NCT03028337|Spine radiosurgery
4461|NCT03028337|Radiation therapy
4462|NCT03028337|Radiotherapy
4463|NCT03028337|Questionnaires
4464|NCT03028337|Surveys
4465|NCT03028337|XRT
4466|NCT03028311|Malignant neoplasms of digestive organs
4467|NCT03028311|Metastatic liver tumors
4468|NCT03028311|SIR-Spheres treatment
4469|NCT03028311|90Y-radioembolization
4470|NCT03028285|succinate
4471|NCT03028285|arginine
4472|NCT03028285|vasodilation
4473|NCT03028285|peripheral vascular disease
4474|NCT03028272|tympanic membrane perforation
4475|NCT03028233|physical activity
4476|NCT03028233|healthy eating
4477|NCT03028233|weight
4478|NCT03028233|families
4479|NCT03028233|Community Health Worker
4480|NCT03028233|childhood obesity
4481|NCT03028233|built environment
4482|NCT03028207|EPI-Scan-II Study
4483|NCT03028207|COPD
4484|NCT03028207|Epidemiology
4485|NCT03028207|Spain
4486|NCT03028207|Chronic Obstructive Pulmonary Disease
4487|NCT03028207|Prevalence
4488|NCT03028207|Cross-sectional
4489|NCT03028194|Pre-eclampsia
4490|NCT03028194|Eclampsia
4491|NCT03028194|Postpartum uterine curettage
4492|NCT03028181|smoke
4493|NCT03028181|acute pancreatitis
4494|NCT03028181|pro/antioxidant status
4495|NCT03028181|pro-inflammatory factors
4496|NCT03028181|lipid profile
4497|NCT03028181|exocrine functions of pancreas
4498|NCT03028168|Yôga
4499|NCT03028168|Breathing Techniques
4500|NCT03028168|Heart Failure and Preserved Ejection Fraction
4501|NCT03028129|Tuberculosis
4502|NCT03028129|Primary prevention
4503|NCT03028129|Prisoners
4504|NCT03028129|Controlled Clinical Trial
4505|NCT03028129|Isoniazid
4506|NCT03028129|Rifapentine
4507|NCT03028116|vaccine
4508|NCT03028116|1 phase
4509|NCT03028116|safety
4510|NCT03028077|ultrafiltered red ginseng
4511|NCT03028077|hydrolyzed ginseng
4512|NCT03028077|acute respiratory illness
4513|NCT03028077|clinical trial
4514|NCT03028038|Platelet-rich plasma
4515|NCT03028038|Rapid maxillary expansion
4516|NCT03028038|Buccal bone thickness
4517|NCT03028038|Alveolar bone loss
4518|NCT03028038|Alveolar bone resorption
4519|NCT03028025|radial artery occlusion
4520|NCT03028025|time to hemostasis
4521|NCT03028025|radial artery
4522|NCT03028025|transradial catheterization
4523|NCT03028025|TR band
4524|NCT03028025|Statseal
4525|NCT03028025|hemostasis band
4526|NCT03028025|potassium ferrate
4527|NCT03028025|percutaneous coronary intervention
4528|NCT03028012|Trigger Point Injections
4529|NCT03028012|steroid
4530|NCT03028012|nsaid
4531|NCT03027999|Rituximab
4532|NCT03027999|tight monitoring
4533|NCT03027960|cardio-renal
4534|NCT03027947|Phantom Limb Pain
4535|NCT03027947|Lower-Limb Amputation
4536|NCT03027947|Electrodes
4537|NCT03027947|Stimulation
4538|NCT03027947|Pain
4539|NCT03027947|Sensation
4540|NCT03027882|Reliability
4541|NCT03027882|Validity
4542|NCT03027882|Functional Testing
4543|NCT03027856|Percutaneous intervention (PCI)
4544|NCT03027856|Optical coherence tomography (OCT)
4545|NCT03027856|Bifurcation lesion
4546|NCT03027856|Bioresorbable stents (BRS)
4547|NCT03027843|low ovarian reserve
4548|NCT03027843|growth hormone
4549|NCT03027843|embryo quality
4550|NCT03027843|live birth
4551|NCT03027843|clinical pregnancy
4552|NCT03027830|Provisional side-branch intervention strategy
4553|NCT03027830|iFR
4554|NCT03027830|Pilot study
4555|NCT03027817|Prone positioning
4556|NCT03027817|Non-invasive Cardiac Output Monitoring
4557|NCT03027791|Biosensors
4558|NCT03027791|Virtual Reality
4559|NCT03027791|Dietary Sodium
4560|NCT03027778|arterial stiffness
4561|NCT03027778|hemodialysis
4562|NCT03027778|intradialytic pedalling exercise
4563|NCT03027778|carotid-femoral pulse wave velocity
4564|NCT03027778|chronic kidney disease
4565|NCT03027778|hemodynamics
4566|NCT03027778|augmentation index
4567|NCT03027752|carotid endaretectomy
4568|NCT03027713|NAVA: neurally adjusted ventilatory assist
4569|NCT03027713|Diaphragm electromyographic activity
4570|NCT03027713|Weaning
4571|NCT03027687|Smoking
4572|NCT03027687|EMA
4573|NCT03027687|ERPs
4574|NCT03027687|tDCS
4575|NCT03027687|Cigarette consumption
4576|NCT03027687|Inhibitory control
4577|NCT03027687|Reward processing
4578|NCT03027674|Raynaud Phenomena
4579|NCT03027674|System; Sclerosis
4580|NCT03027674|Lupus Erythematosus, Systemic
4581|NCT03027674|Ultrasound
4582|NCT03027674|sildenafil
4583|NCT03027674|Nifedipine
4584|NCT03027661|para-cervical block
4585|NCT03027661|laparoscopic hysterectomy
4586|NCT03027648|levonorgestrel-releasing intrauterine system
4587|NCT03027648|adenomyosis
4588|NCT03027635|diuretic resistant ascites
4589|NCT03027635|Paracentesis
4590|NCT03027635|PleurX
4591|NCT03027635|Peritoneal tunnelated catheter
4592|NCT03027622|quality of life
4593|NCT03027622|pericoronitis
4594|NCT03027622|third molar
4595|NCT03027609|Pseudomonas aeruginosa
4596|NCT03027609|pneumonia
4597|NCT03027570|Exergame
4598|NCT03027570|Cellular apps
4599|NCT03027570|Smartphone
4600|NCT03027570|Overweight
4601|NCT03027570|Obesity
4602|NCT03027570|Children
4603|NCT03027570|Physical activity
4604|NCT03027570|Fitness
4605|NCT03027570|Motivation
4606|NCT03027570|BMI
4607|NCT03027557|Primary Hyperparathyroidism
4608|NCT03027557|Parathyroid Adenoma
4609|NCT03027557|Parathyroid Hyperplasia
4610|NCT03027557|Cinacalcet
4611|NCT03027557|Denosumab
4612|NCT03027557|Drug Therapy
4613|NCT03027557|Bone Mineral Density
4614|NCT03027557|Calcium
4615|NCT03027544|multiple brain metastases
4616|NCT03027544|large brain metastases
4617|NCT03027544|meningeal metastases
4618|NCT03027544|tomotherapy
4619|NCT03027531|reproductive health, condoms, sexually transmitted diseases, contraception
4620|NCT03027505|MUAC
4621|NCT03027505|Acute malnutrition
4622|NCT03027505|RUTF
4623|NCT03027505|Children
4624|NCT03027505|Burkina Faso
4625|NCT03027492|Non-celiac Wheat Sensitivity
4626|NCT03027492|gynaecological disorders
4627|NCT03027492|gluten-free diet
4628|NCT03027479|weight loss
4629|NCT03027479|ovarian cancer
4630|NCT03027479|endometrial cancer
4631|NCT03027479|energy metabolism
4632|NCT03027479|Body mass index
4633|NCT03027479|obesity
4634|NCT03027479|muscle energy
4635|NCT03027466|Quitting Smoking
4636|NCT03027466|Phone Application
4637|NCT03027440|Stress Response
4638|NCT03027440|Neurodevelopment
4639|NCT03027440|Biomarkers
4640|NCT03027440|Cohort Study
4641|NCT03027427|Screening
4642|NCT03027427|Heritable Gastric Malignancy
4643|NCT03027427|Molecular Profiling
4644|NCT03027427|Molecular Alterations
4645|NCT03027414|Anxiety
4646|NCT03027414|Startle
4647|NCT03027414|Dorsolateral Prefrontal Cortex
4648|NCT03027414|Transcranial Magnetic Stimulation (TMS)
4649|NCT03027414|Working Memory
4650|NCT03027401|Genetic Testing
4651|NCT03027401|Tumor Profiling
4652|NCT03027401|Biorepository
4653|NCT03027388|Brain Tumor
4654|NCT03027388|Blood Brain Barrier
4655|NCT03027388|Pharmacokinetics
4656|NCT03027388|Pharmacodynamics
4657|NCT03027375|chronic heart failure
4658|NCT03027375|traditional Chinese medicine
4659|NCT03027375|Qishen granules
4660|NCT03027336|dyslipidemia
4661|NCT03027336|dietary supplement
4662|NCT03027323|undifferentiated hypotension
4663|NCT03027323|central venous cannulation
4664|NCT03027310|Dystonic Tremor
4665|NCT03027310|Essential Tremor
4666|NCT03027310|Tremor
4667|NCT03027310|Voice Tremor
4668|NCT03027310|Parkinson's Disease
4669|NCT03027284|Neoplasm
4670|NCT03027258|Mobile health technology
4671|NCT03027245|locally advanced or metastatic breast cancer
4672|NCT03027245|peripheral neuropathy
4673|NCT03027245|chemotherapy-induced peripheral neuropathy
4674|NCT03027245|eribulin
4675|NCT03027232|infection
4676|NCT03027154|diagnostic test
4677|NCT03027154|children
4678|NCT03027154|diagnosis of tuberculosis
4679|NCT03027141|Face Transplant
4680|NCT03027128|Phase 1
4681|NCT03027128|Metastatic
4682|NCT03027128|Locally Advanced
4683|NCT03027128|Cancer
4684|NCT03027128|Cell Therapy
4685|NCT03027102|allogenic double negative T cells
4686|NCT03027102|DNT cells
4687|NCT03027089|Aspergillus-specific IgG
4688|NCT03027076|prostatitis
4689|NCT03027076|chronic prostatitis
4690|NCT03027076|chronic pelvic pain syndrome
4691|NCT03027076|interstitial cystitis
4692|NCT03027076|painful bladder syndrome
4693|NCT03027076|bladder pain syndrome
4694|NCT03027076|biomarkers
4695|NCT03027076|biological markers
4696|NCT03027076|bacteria
4697|NCT03027076|microbiome
4698|NCT03027076|inflammation
4699|NCT03027063|Speckle tracking echocardiography
4700|NCT03027050|periodontitis
4701|NCT03027050|Growth factors
4702|NCT03027050|Periodontal healing
4703|NCT03027024|Intraocular Lens
4704|NCT03027024|trifocal
4705|NCT03027024|cataract
4706|NCT03027024|PhysIOL
4707|NCT03026998|hereditary retinoblastoma,
4708|NCT03026998|External beam radiation therapy (EBRT)
4709|NCT03026985|Extracorporeal Membrane Oxygenation
4710|NCT03026985|Ultrasonography
4711|NCT03026985|Intensive Care Units
4712|NCT03026972|Safety
4713|NCT03026972|Tolerance
4714|NCT03026946|Alitretinoin
4715|NCT03026946|Cyclosporine A
4716|NCT03026946|Hand eczema
4717|NCT03026920|Fracture
4718|NCT03026920|outcome
4719|NCT03026920|pelvic
4720|NCT03026920|acetabular
4721|NCT03026907|Alitretinoin
4722|NCT03026907|Azathioprine
4723|NCT03026907|Hand eczema
4724|NCT03026881|PARP inhibitor
4725|NCT03026881|VEGFR inhibitor
4726|NCT03026881|Combination therapy
4727|NCT03026881|Gastric cancer
4728|NCT03026868|acetabular
4729|NCT03026868|quadrilateral surface plate
4730|NCT03026855|Autologous PRP
4731|NCT03026855|Non-healing ulcer
4732|NCT03026855|Point-of-care
4733|NCT03026829|Sound therapy
4734|NCT03026829|Tinnitus relief
4735|NCT03026816|epidural stimulation
4736|NCT03026816|spinal cord stimulation
4737|NCT03026790|Opioid analgesics
4738|NCT03026790|Opioid partial agonists
4739|NCT03026790|Health care delivery
4740|NCT03026790|Back pain
4741|NCT03026790|Osteoarthritis
4742|NCT03026790|Veterans health
4743|NCT03026764|cost
4744|NCT03026764|total hip replacement
4745|NCT03026764|outpatient Surgery
4746|NCT03026764|satisfaction
4747|NCT03026764|arthroplasty
4748|NCT03026725|tooth sensitivity
4749|NCT03026725|tri calcium phosphate
4750|NCT03026725|at-home whitening
4751|NCT03026712|Robotic therapy
4752|NCT03026712|tDCS
4753|NCT03026712|non invasive electrical stimulation
4754|NCT03026712|ArmeoPower
4755|NCT03026712|interhemispheric balance
4756|NCT03026699|Brain
4757|NCT03026699|Nervous system
4758|NCT03026699|Neuro-oncology
4759|NCT03026699|Caregivers
4760|NCT03026699|Cancer patient
4761|NCT03026699|Family caregivers
4762|NCT03026699|Brain tumors
4763|NCT03026699|Quality of life
4764|NCT03026699|Stress
4765|NCT03026699|Social support
4766|NCT03026699|Feasibility
4767|NCT03026699|Electronic Social Network Assessment Program (eSNAP)
4768|NCT03026660|Moringa Oleifera
4769|NCT03026634|Sleep-Disordered Breathing
4770|NCT03026634|Heart Failure
4771|NCT03026634|Heart Transplantation
4772|NCT03026569|orange juice
4773|NCT03026569|chronic hepatitis C
4774|NCT03026569|biochemical markers
4775|NCT03026569|oxidative stress
4776|NCT03026569|nutritional status
4777|NCT03026569|antioxidants
4778|NCT03026517|Phenformin
4779|NCT03026517|Dabrafenib
4780|NCT03026517|Trametinib
4781|NCT03026517|BRAF
4782|NCT03026517|15-318
4783|NCT03026478|oral lichen planus
4784|NCT03026478|betamethasone
4785|NCT03026478|clobetasol
4786|NCT03026478|orabase
4787|NCT03026439|mild COPD
4788|NCT03026439|early COPD
4789|NCT03026439|six-min walk test
4790|NCT03026439|computed tomography
4791|NCT03026439|emphysema
4792|NCT03026439|airway disease
4793|NCT03026439|peripheral muscle mass
4794|NCT03026439|Saint George's Respiratory Questionnaire
4795|NCT03026426|Depression
4796|NCT03026426|Chronic diseases
4797|NCT03026426|Mobile technology
4798|NCT03026426|Clinical trial
4799|NCT03026413|atrial fibrillation
4800|NCT03026413|pulmonary vein isolation
4801|NCT03026413|Contact Force
4802|NCT03026413|antrum
4803|NCT03026387|Suicidal behavior
4804|NCT03026387|Suicide attempt
4805|NCT03026387|Emergency department
4806|NCT03026387|Psychometrics
4807|NCT03026387|Neuropsychological tests
4808|NCT03026387|Suicidal ideation
4809|NCT03026374|psychosocial support
4810|NCT03026374|resilience
4811|NCT03026374|metastatic breast cancer
4812|NCT03026374|survival
4813|NCT03026374|Quality of Life
4814|NCT03026348|RSV
4815|NCT03026335|Positive Youth Development
4816|NCT03026296|Physical Fitness
4817|NCT03026296|Health Status
4818|NCT03026296|Exercise
4819|NCT03026296|Tobacco Use Cessation
4820|NCT03026296|Quality of Life
4821|NCT03026296|Healthy Diet
4822|NCT03026296|Health Promotion
4823|NCT03026296|Patient Education as Topic
4824|NCT03026296|Counseling
4825|NCT03026270|Physiotherapy
4826|NCT03026270|Paraffin
4827|NCT03026270|Burn
4828|NCT03026270|Contracture
4829|NCT03026244|Immunity
4830|NCT03026244|Elderly
4831|NCT03026244|Inflammation
4832|NCT03026244|Milk protein
4833|NCT03026244|Prebiotics
4834|NCT03026231|Fecal microbiota transplantation
4835|NCT03026166|Nivolumab
4836|NCT03026166|Ipilimumab
4837|NCT03026166|Rovalpituzumab tesirine
4838|NCT03026166|Cancer
4839|NCT03026166|Extensive-Stage Small Cell Lung Cancer
4840|NCT03026140|MSI tumors
4841|NCT03026140|MSS tumors
4842|NCT03026140|short-term immunotherapy
4843|NCT03026140|surgical resection
4844|NCT03026140|nivolumab
4845|NCT03026140|ipilimumab
4846|NCT03026127|Suicide
4847|NCT03026127|Middle-aged and Older Adults
4848|NCT03026127|Cognitive Reappraisal
4849|NCT03026127|Emotion Regulation
4850|NCT03026088|Chronic Heart Failure
4851|NCT03026088|Bisoprolol
4852|NCT03026088|Heart rate control
4853|NCT03026062|Recurrent Platinum-Resistant Epithelial Ovarian Cancer
4854|NCT03026062|Ovarian Cancer
4855|NCT03026062|epithelial ovarian cancer
4856|NCT03026036|Depression
4857|NCT03026036|MRI
4858|NCT03026036|PET
4859|NCT03026036|Reward
4860|NCT03026023|Heart Transplant
4861|NCT03026023|Cardiac Transplant
4862|NCT03026023|Hepatitis C
4863|NCT03026023|Zepatier
4864|NCT03025971|Severe Aortic Stenosis and/or severe aortic regurgitation
4865|NCT03025919|Advanced glycation end-product
4866|NCT03025919|Glycosuria
4867|NCT03025893|Sunitinib
4868|NCT03025893|Lomustine
4869|NCT03025893|High-dose
4870|NCT03025893|Intermittent
4871|NCT03025880|Advanced Breast Cancer
4872|NCT03025880|Pembrolizumab
4873|NCT03025880|HER2-negative
4874|NCT03025828|Membranous nephropathy
4875|NCT03025828|adrenocorticotropic hormone
4876|NCT03025828|ACTH
4877|NCT03025828|proteinuria
4878|NCT03025828|glomerulonephritis
4879|NCT03025815|Infant, Premature
4880|NCT03025802|Molecular diagnosis
4881|NCT03025802|Pathogen identification
4882|NCT03025802|Sepsis
4883|NCT03025802|Bacteremia
4884|NCT03025802|Rapid diagnostics
4885|NCT03025789|T.b gambiense
4886|NCT03025789|HAT
4887|NCT03025789|outpatients
4888|NCT03025763|Craniosynostosis
4889|NCT03025763|Bone
4890|NCT03025763|Birth Defect
4891|NCT03025763|Congenital Anomaly
4892|NCT03025763|Malformation
4893|NCT03025763|Genetics
4894|NCT03025763|Genomics
4895|NCT03025763|Skull
4896|NCT03025763|Human
4897|NCT03025763|Mouse
4898|NCT03025763|Imaging
4899|NCT03025763|Cell Biology
4900|NCT03025763|Induced Pluripotent Stem Cells
4901|NCT03025763|System Biology
4902|NCT03025737|Hypertrophy, Left Ventricular
4903|NCT03025737|Ventricular Remodeling
4904|NCT03025711|Advanced HER2+ breast cancer
4905|NCT03025711|Pertuzumab
4906|NCT03025711|Trastuzumab emtansine
4907|NCT03025711|Compassionate use
4908|NCT03025711|Early access program
4909|NCT03025711|Effectiveness
4910|NCT03025711|Safety
4911|NCT03025698|Eltrombopag
4912|NCT03025698|hATG
4913|NCT03025698|CsA
4914|NCT03025698|previously untreated or relapsed severe aplastic anemia
4915|NCT03025698|recurrent aplastic anemia
4916|NCT03025698|Severe aplastic anemia
4917|NCT03025698|Pharmacokinetics
4918|NCT03025698|Immunosuppressive therapy
4919|NCT03025698|ETB115
4920|NCT03025685|Percutaneous Coronary Intervention
4921|NCT03025685|Coronary Artery Disease
4922|NCT03025685|Wire
4923|NCT03025685|Coronary stenting
4924|NCT03025659|pediatric
4925|NCT03025659|congenital heart disease
4926|NCT03025646|Maternal depression
4927|NCT03025646|ASD
4928|NCT03025646|Home based training program
4929|NCT03025633|PEARL
4930|NCT03025620|Alphalinolenic acid
4931|NCT03025620|Lipid cardiovascular risk factors
4932|NCT03025620|Inflammation
4933|NCT03025607|Prevention
4934|NCT03025607|Mobile health
4935|NCT03025607|Autonomous motivation
4936|NCT03025594|Paralytic sellfish toxins
4937|NCT03025594|Gonyautoxin
4938|NCT03025594|Post surgery pain management
4939|NCT03025594|total knee arthroplasty
4940|NCT03025568|nylon
4941|NCT03025568|polyamide
4942|NCT03025568|denture base
4943|NCT03025555|nylon
4944|NCT03025555|polyamide
4945|NCT03025555|PEEK
4946|NCT03025555|partial denture
4947|NCT03025542|Psoriasis
4948|NCT03025542|Chronic Plaque Psoriasis
4949|NCT03025542|Bimekizumab
4950|NCT03025490|Capnography
4951|NCT03025490|Electrophysiology
4952|NCT03025477|Intraperitoneal
4953|NCT03025477|Intravenous
4954|NCT03025477|Completeness of cytoreduction score
4955|NCT03025477|Carboplatin
4956|NCT03025477|Epirubicin
4957|NCT03025477|Paclitaxel
4958|NCT03025477|Cisplatin
4959|NCT03025451|nutrition
4960|NCT03025451|exercise
4961|NCT03025451|stress
4962|NCT03025451|gender
4963|NCT03025451|age
4964|NCT03025451|community support
4965|NCT03025451|cardiovascular disease
4966|NCT03025451|diabetes
4967|NCT03025451|hypertension
4968|NCT03025451|dyslipidemia
4969|NCT03025451|cholesterol
4970|NCT03025451|overweight
4971|NCT03025451|obesity
4972|NCT03025451|lifestyle
4973|NCT03025438|angiosarcoma
4974|NCT03025438|Cytology
4975|NCT03025438|liver
4976|NCT03025438|cancer
4977|NCT03025412|Achilles Tendon
4978|NCT03025412|Endoscopy
4979|NCT03025412|Minimally Invasive Surgical Procedures
4980|NCT03025412|Exercise therapy
4981|NCT03025399|tang wang prescription
4982|NCT03025321|Cocaine
4983|NCT03025321|tDCS
4984|NCT03025321|EMA
4985|NCT03025321|Inhibitory control
4986|NCT03025321|Reward processing
4987|NCT03025321|Addiction
4988|NCT03025321|dlPFC
4989|NCT03025321|craving
4990|NCT03025321|cognitive control
4991|NCT03025256|Melanoma and other malignant neoplasms of skin
4992|NCT03025256|Leptomeningeal disease
4993|NCT03025256|LMD
4994|NCT03025256|Nivolumab
4995|NCT03025256|BMS-936558
4996|NCT03025256|Opdivo
4997|NCT03025243|computer aided design , dental implants , accuracy
4998|NCT03025204|Regeneration Procedures
4999|NCT03025204|Intrabony Defects
5000|NCT03025204|Cronic Periodontitis
5001|NCT03025191|incarceration
5002|NCT03025191|HIV
5003|NCT03025152|Hou Gu Mi Xi
5004|NCT03025152|Shen Ling Bai Zhu San
5005|NCT03025152|radical gastrectomy
5006|NCT03025152|gastric cancer
5007|NCT03025152|traditional Chinese medicine
5008|NCT03025152|randomized controlled trial
5009|NCT03025139|breast cancer
5010|NCT03025139|younger women
5011|NCT03025139|education
5012|NCT03025139|mindfulness meditation
5013|NCT03025139|depression
5014|NCT03025139|cancer survivor
5015|NCT03025074|Liver Disease
5016|NCT03025074|Obesity
5017|NCT03025074|Hepatitis
5018|NCT03025074|HIV
5019|NCT03025074|Hepatology
5020|NCT03025061|Breath pattern
5021|NCT03025061|Children
5022|NCT03025061|Repeatability
5023|NCT03025035|BRCA-mutation
5024|NCT03025035|Immune checkpoint inhibition
5025|NCT03025035|Immunotherapy
5026|NCT03025035|Advanced BRCA-mutated breast cancer
5027|NCT03024957|morphine
5028|NCT03024957|dexmedetomidine
5029|NCT03024957|immune system
5030|NCT03024944|Diabetes Mellitus
5031|NCT03024944|Alzheimer's Disease
5032|NCT03024944|Dementia
5033|NCT03024944|THK
5034|NCT03024918|monochorionic
5035|NCT03024918|placental sharing
5036|NCT03024892|Fluorenscent image guided surgery
5037|NCT03024892|indocyanide green
5038|NCT03024892|laparoscopic cholecystectomy
5039|NCT03024892|common bile duct injury
5040|NCT03024879|Motilin
5041|NCT03024879|Erythromycin
5042|NCT03024879|Food intake
5043|NCT03024853|Best Possible Self
5044|NCT03024853|Positive Intervention
5045|NCT03024853|Optimism
5046|NCT03024840|Propofol
5047|NCT03024840|Neurocognitive Disorders
5048|NCT03024840|Liver transplantation
5049|NCT03024840|Pediatrics
5050|NCT03024840|Brain Injuries
5051|NCT03024827|Infantile Spasms
5052|NCT03024827|Lennox Gastaut Syndrome
5053|NCT03024827|Doose Syndrome
5054|NCT03024827|Continuous Spike Wave in Sleep
5055|NCT03024827|Landau-Kleffner Syndrome
5056|NCT03024827|Dravet Syndrome
5057|NCT03024827|Malignant Migrating Partial Seizures of Infancy (MMPSI)
5058|NCT03024788|Glycosylated haemoglobin
5059|NCT03024788|advanced glycation end products
5060|NCT03024775|Non-celiac Wheat Sensitivity
5061|NCT03024775|ancient wheats
5062|NCT03024775|modern wheats
5063|NCT03024775|ATIs
5064|NCT03024749|Spinal Arteriovenous Malformation
5065|NCT03024749|Spinal Arteriovenous Fistula
5066|NCT03024723|Obese patient
5067|NCT03024723|nasal CPAP
5068|NCT03024710|Stunting
5069|NCT03024710|complementary feeding Index
5070|NCT03024710|Bangladesh
5071|NCT03024697|Breast surgery
5072|NCT03024697|Pectoral plane block
5073|NCT03024697|PECs
5074|NCT03024697|Local anaesthesia infusion
5075|NCT03024697|Analgesia
5076|NCT03024684|Hepatocellular carcinoma
5077|NCT03024684|statin
5078|NCT03024684|curative ablation
5079|NCT03024658|Pulmonary artery systolic pressure
5080|NCT03024658|Positive end expiratory pressure
5081|NCT03024658|morbidly obese
5082|NCT03024658|laparoscopic bariatric surgery
5083|NCT03024645|Postpartum Depression
5084|NCT03024645|Cognitive-Behavioral Therapy
5085|NCT03024645|Prevention
5086|NCT03024645|Web-Based Psychological Intervention
5087|NCT03024593|Cyberchondria
5088|NCT03024593|health-related internet use
5089|NCT03024593|pathological health anxiety
5090|NCT03024580|Megestrol Acetate
5091|NCT03024580|Steroid, Receptors
5092|NCT03024567|Calorimetry
5093|NCT03024567|Blood pressure
5094|NCT03024567|Immunophenotyping
5095|NCT03024567|Gut microbial composition
5096|NCT03024554|aortic aneurysm involving iliac arteries
5097|NCT03024554|abdominal aortic aneurysm
5098|NCT03024554|MFM
5099|NCT03024554|Multilayer Flow Modulator
5100|NCT03024554|Multilayer Stent
5101|NCT03024528|Pain
5102|NCT03024528|CPOT
5103|NCT03024528|ICU Delirium
5104|NCT03024528|Critical Care Pain Observation Tool
5105|NCT03024528|NRS
5106|NCT03024528|Behaviour
5107|NCT03024528|Critical care
5108|NCT03024528|Intensive Care
5109|NCT03024502|vulvovaginal candidiasis
5110|NCT03024502|EPPAF mucoadhesive gel
5111|NCT03024502|clotrimazol
5112|NCT03024489|Phase I/II
5113|NCT03024476|behavioral intervention
5114|NCT03024476|prespecified medication algorithm
5115|NCT03024476|bluetooth-equipped sphygmomanometer
5116|NCT03024450|Gastric cancer
5117|NCT03024450|HER2
5118|NCT03024450|trastuzumab
5119|NCT03024450|prognosis
5120|NCT03024437|PD-L1 inhibitor
5121|NCT03024359|Obesity
5122|NCT03024359|Brown adipose tissue
5123|NCT03024359|Monounsaturated fatty acids
5124|NCT03024359|Hypothalamic inflammation
5125|NCT03024333|Dysphagia
5126|NCT03024333|Swallowing Sound
5127|NCT03024333|Acoustic Analysis
5128|NCT03024307|Pharmaceutical Care
5129|NCT03024307|Medication Adherence
5130|NCT03024307|Direct Costs
5131|NCT03024281|Aspergillus
5132|NCT03024281|Antifungal susceptibility
5133|NCT03024281|Azole resistance
5134|NCT03024255|sweat gland disease
5135|NCT03024255|sweating
5136|NCT03024255|underarm
5137|NCT03024190|stroke
5138|NCT03024190|spasticity
5139|NCT03024190|Kinesiotaping
5140|NCT03024190|sonography
5141|NCT03024190|exercise
5142|NCT03024177|Human rhinovirus
5143|NCT03024177|HRV
5144|NCT03024177|Hematopoietic Stem Cell Transplant
5145|NCT03024177|HSCT
5146|NCT03024177|Antiviral
5147|NCT03024177|vapendavir
5148|NCT03024177|Allogeneic
5149|NCT03024177|Autologous
5150|NCT03024164|youth ischemic stroke; etiology; prognosis
5151|NCT03024125|lean mass
5152|NCT03024125|postmenopausal
5153|NCT03024125|protein
5154|NCT03024099|hippotherapy Gross Motor Function Functional performance.
5155|NCT03024060|Actinic Keratosis
5156|NCT03024021|therapeutic hypothermia
5157|NCT03024021|targeted temperature management
5158|NCT03024021|neurological outcome
5159|NCT03024021|post-cardiac arrest syndrome
5160|NCT03024008|Critical Gap
5161|NCT03024008|Comminuted Fracture
5162|NCT03024008|Extra-Articular
5163|NCT03023930|Opioid Use Disorder
5164|NCT03023917|jaundice,complication
5165|NCT03023891|glucocorticoids
5166|NCT03023891|efficacy
5167|NCT03023891|metabolic toxicity
5168|NCT03023865|Long gap esophageal atresia
5169|NCT03023839|Delirium
5170|NCT03023839|Trauma
5171|NCT03023839|Injury
5172|NCT03023839|restraints
5173|NCT03023761|Endodontic retreatments
5174|NCT03023761|Low level laser
5175|NCT03023761|Pain
5176|NCT03023748|activated vitamin D treatment
5177|NCT03023709|Quadrivalent inactivated influenza vaccine
5178|NCT03023709|Quadrivalent live, attenuated influenza vaccine
5179|NCT03023709|Adults with obstructive sleep apnea
5180|NCT03023696|C5 Palsy
5181|NCT03023683|Live, attenuated influenza vaccine
5182|NCT03023683|Children and young adults
5183|NCT03023670|Lung
5184|NCT03023670|Cardiopulmonary Bypass
5185|NCT03023670|Pediatric
5186|NCT03023670|Cardiac surgery
5187|NCT03023657|arousal
5188|NCT03023657|Consciousness Disorders
5189|NCT03023657|vegetative state
5190|NCT03023657|minimally conscious state
5191|NCT03023644|Congenital Heart Disease
5192|NCT03023644|Neurodevelopmental Disorders
5193|NCT03023644|Children
5194|NCT03023644|Executive Function
5195|NCT03023644|Working Memory
5196|NCT03023644|Cognitive interventions
5197|NCT03023644|Infant Open Heart Surgery
5198|NCT03023631|GARDASIL 9
5199|NCT03023631|Post allogeneic stem cell transplantation
5200|NCT03023631|HPV infection prevention
5201|NCT03023618|[G09.330.380]
5202|NCT03023605|Pulmonary embolism
5203|NCT03023605|Adherence to practice guidelines
5204|NCT03023605|Age-adjusted D-dimer
5205|NCT03023605|Clinical prediction rules
5206|NCT03023605|Elderly patients
5207|NCT03023592|Sjogren's Syndrome
5208|NCT03023592|Iguratimod
5209|NCT03023566|Dotarem
5210|NCT03023566|MRI
5211|NCT03023566|pediatric
5212|NCT03023566|safety
5213|NCT03023566|efficacy
5214|NCT03023553|Trivalent, inactivated influenza vaccine
5215|NCT03023553|Live, attenuated influenza vaccine
5216|NCT03023553|Nasopharyngeal swabs
5217|NCT03023553|Young adults
5218|NCT03023540|Charcot Marie Tooth Type 1A
5219|NCT03023540|Peripheral neuropathy
5220|NCT03023540|PXT3003
5221|NCT03023527|Refractory
5222|NCT03023527|Relapsed
5223|NCT03023527|Nivolumab
5224|NCT03023514|Oocyte donation
5225|NCT03023514|IVF
5226|NCT03023514|Lipoic acid
5227|NCT03023514|Implantation rate
5228|NCT03023514|Endometrial receptivity
5229|NCT03023488|flexible ureteroscopy
5230|NCT03023488|blood flow
5231|NCT03023436|Stomach Neoplasms
5232|NCT03023436|Cytoreduction Surgical Procedures
5233|NCT03023410|Revision TKA
5234|NCT03023410|Instability
5235|NCT03023410|Stiffness
5236|NCT03023410|Aseptic Loosening
5237|NCT03023410|Polyethylene Wear
5238|NCT03023410|Malrotation
5239|NCT03023410|Soft Tissue Imbalance
5240|NCT03023397|E-cig smokers
5241|NCT03023384|Acute Myeloid Leukemia
5242|NCT03023384|Chemotherapy
5243|NCT03023384|Autologous Stem Cell Transplantation
5244|NCT03023384|Developing country
5245|NCT03023384|Clinical network
5246|NCT03023371|Registry; cohort study; IgG4-related disease
5247|NCT03023358|peripheral T cell lymphoma
5248|NCT03023345|cancer
5249|NCT03023345|prostate
5250|NCT03023345|PSA
5251|NCT03023345|biopsies
5252|NCT03023345|microwave trans rectal focal treatment
5253|NCT03023332|Caregiver
5254|NCT03023332|Biofeedback
5255|NCT03023332|Resourcefulness
5256|NCT03023332|Self-Management
5257|NCT03023293|n-3 polyunsaturated fatty acids
5258|NCT03023293|irisin
5259|NCT03023241|BPS/IC
5260|NCT03023241|OAB
5261|NCT03023228|Diabetes mellitus
5262|NCT03023228|Hyperglycemia
5263|NCT03023228|Inpatient
5264|NCT03023228|self-management education
5265|NCT03023215|Meditation
5266|NCT03023215|Breast Biopsy
5267|NCT03023215|Stereotactic Breast Biopsy
5268|NCT03023215|SBB
5269|NCT03023215|Guided meditation
5270|NCT03023215|Focused breathing
5271|NCT03023215|Electroencephalogram
5272|NCT03023215|EEG
5273|NCT03023215|Heart rate
5274|NCT03023215|HR
5275|NCT03023215|Questionnaires
5276|NCT03023215|Surveys
5277|NCT03023189|Upper digestive bleeding
5278|NCT03023189|Haemorrhage
5279|NCT03023189|Cirrhosis
5280|NCT03023189|Portal hypertension
5281|NCT03023189|Antifibrinolytic
5282|NCT03023189|Tranexamic acid
5283|NCT03023189|Emergency
5284|NCT03023176|Trivalent, inactivated influenza vaccine
5285|NCT03023176|Child identical twins
5286|NCT03023176|Child fraternal twins
5287|NCT03023163|autonomic dysreflexia
5288|NCT03023163|baroreceptor integrity
5289|NCT03023163|sympathetic integrity
5290|NCT03023163|vagal integrity
5291|NCT03023163|autonomic integrity
5292|NCT03023163|arterial stiffness
5293|NCT03023163|cognitive function
5294|NCT03023163|traumatic brain injury
5295|NCT03023163|cerebral blood flow
5296|NCT03023163|white matter hyperintensities
5297|NCT03023163|cerebral vascular resistance index
5298|NCT03023137|prevention
5299|NCT03023137|carbohydrate
5300|NCT03023137|exercise
5301|NCT03023137|neonatal hypoglycemia
5302|NCT03023111|Cutaneous leishmaniasis
5303|NCT03023111|miltefosine
5304|NCT03023111|cytokines
5305|NCT03023111|treatment
5306|NCT03023098|Restenosis
5307|NCT03023098|Drug-eluting balloon
5308|NCT03023098|Vein graft
5309|NCT03023059|L-DOPA
5310|NCT03023059|GPR143
5311|NCT03023059|PEDF
5312|NCT03023059|VEGF
5313|NCT03023033|PMTCT
5314|NCT03023033|MNCH
5315|NCT03023020|Dual Antiplatelet Therapy
5316|NCT03022994|Non-celiac wheat sensitivity
5317|NCT03022994|eosinophils
5318|NCT03022994|lymphocytes
5319|NCT03022994|duodenal biopsies
5320|NCT03022994|rectal biopsies
5321|NCT03022825|BCG
5322|NCT03022825|bladder cancer
5323|NCT03022825|immunotherapy
5324|NCT03022825|interleukin-15
5325|NCT03022825|intravesical
5326|NCT03022825|non-muscle invasive
5327|NCT03022812|Neck pain
5328|NCT03022812|Rehabilitation
5329|NCT03022812|Exercise Therapy
5330|NCT03022812|Internet
5331|NCT03022799|FAF1
5332|NCT03022799|Fas (TNFRSF6)-associated factor 1
5333|NCT03022799|FAF1 inhibitor
5334|NCT03022799|KM-819
5335|NCT03022786|Dermatitis
5336|NCT03022760|Exhaustion Disorder
5337|NCT03022682|ethnicity
5338|NCT03022682|inflammation
5339|NCT03022669|mobile health
5340|NCT03022669|veterans
5341|NCT03022669|cardiovascular disease
5342|NCT03022669|medication adherence
5343|NCT03022656|Orthotic treatment, Ultrasound Imaging
5344|NCT03022630|palliative care
5345|NCT03022630|cirrhosis
5346|NCT03022630|liver disease
5347|NCT03022630|hepatology
5348|NCT03022630|end of life care
5349|NCT03022630|supportive care
5350|NCT03022578|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
5351|NCT03022578|Glioblastoma
5352|NCT03022578|Anaplastic Astrocytoma
5353|NCT03022578|AA
5354|NCT03022578|Laser interstitial thermal therapy
5355|NCT03022578|LITT
5356|NCT03022578|Lomustine
5357|NCT03022578|CeeNU
5358|NCT03022578|CCNU
5359|NCT03022565|Uveal Melanoma
5360|NCT03022552|Myocardial Infarction
5361|NCT03022552|Women
5362|NCT03022552|Platelets
5363|NCT03022552|Blood Collection
5364|NCT03022552|Genomics
5365|NCT03022526|Pregnant
5366|NCT03022526|Analgesia
5367|NCT03022526|Labor analgesia
5368|NCT03022526|Epidural
5369|NCT03022526|Combined spinal epidural
5370|NCT03022513|Non-celiac Wheat Sensitivity
5371|NCT03022513|fibromyalgia
5372|NCT03022513|synovitis
5373|NCT03022487|Sudden Cardiac Death (SCD)
5374|NCT03022487|implantable cardioverter defibrillator
5375|NCT03022487|electrophysiological
5376|NCT03022487|EP
5377|NCT03022487|Ischaemic cardiomyopathy
5378|NCT03022487|Ventricular Arrhythmia
5379|NCT03022487|ICD
5380|NCT03022474|Childhood obesity
5381|NCT03022461|Heart Failure
5382|NCT03022461|Ventricular Dysfunction
5383|NCT03022461|Cardiomyopathies
5384|NCT03022461|Heart Disease
5385|NCT03022461|Cardiovascular Disease
5386|NCT03022461|Heart-assist Devices
5387|NCT03022461|Thoratec Corporation
5388|NCT03022448|soft tissue sarcomas (STS)
5389|NCT03022448|trabectedin
5390|NCT03022448|metastatic STS patients
5391|NCT03022448|overall survival
5392|NCT03022435|Inactivated influenza vaccine
5393|NCT03022435|Live, attenuated influenza vaccine
5394|NCT03022435|Adult and elderly identical twins
5395|NCT03022435|Adult fraternal twins
5396|NCT03022422|Influenza Vaccine
5397|NCT03022422|High-dose influenza vaccine
5398|NCT03022422|Adult and elderly identical twins
5399|NCT03022422|Adult fraternal twins
5400|NCT03022409|Treatment naïve
5401|NCT03022409|Head and Neck Squamous Cell Carcinoma (HNSCC)
5402|NCT03022409|DNA Damage Repair (DDR)
5403|NCT03022396|Influenza vaccine
5404|NCT03022396|Identical twins
5405|NCT03022396|Fraternal twins
5406|NCT03022396|High-dose influenza vaccine
5407|NCT03022396|Elderly twins
5408|NCT03022396|Child twins
5409|NCT03022383|no known ocular pathology
5410|NCT03022370|informal settlements
5411|NCT03022370|poverty
5412|NCT03022344|DD2 plaque study
5413|NCT03022344|Coronary plaque
5414|NCT03022344|Type-2 diabetes mellitus
5415|NCT03022331|Idiopathic aortitis
5416|NCT03022331|Isolated aortitis
5417|NCT03022331|Vasculitis
5418|NCT03022318|GPR143
5419|NCT03022318|PEDF
5420|NCT03022318|VEGF
5421|NCT03022318|LDOPA
5422|NCT03022305|Hip alignment
5423|NCT03022305|Hip misalignment
5424|NCT03022305|Shoulder function
5425|NCT03022305|Shoulder rotation
5426|NCT03022305|Athletic shoulder injuries
5427|NCT03022305|Athletic hip alignment
5428|NCT03022305|Hip and shoulder alignment
5429|NCT03022305|Hip joint
5430|NCT03022305|Hip joint alignment
5431|NCT03022305|Hip joint misalignment
5432|NCT03022279|Pediatric
5433|NCT03022279|post-operative pain prevention
5434|NCT03022279|Anesthesia, Infiltration
5435|NCT03022279|Nerve Blockade
5436|NCT03022266|Adherence
5437|NCT03022266|CleverCap® Lite BLE C035
5438|NCT03022266|Smartphone App
5439|NCT03022266|Telehealth
5440|NCT03022266|Digital Health
5441|NCT03022266|Mobile Phone App
5442|NCT03022266|Behavioral Economics
5443|NCT03022266|Aspirin
5444|NCT03022266|Wellth App
5445|NCT03022253|PDA
5446|NCT03022253|Platelets
5447|NCT03022214|Dietary supplementation
5448|NCT03022214|Exercise
5449|NCT03022214|Increase Resilience
5450|NCT03022214|Oxidative Stress
5451|NCT03022214|Efficacy
5452|NCT03022201|Motilitone
5453|NCT03022188|pancreatic incidentaloma
5454|NCT03022188|pancreatic neuroendocrine tumor
5455|NCT03022188|EUS-guided fine-needle aspiration
5456|NCT03022188|contrast-enhanced endoscopic ultrasound
5457|NCT03022175|Safety
5458|NCT03022175|Tolerability
5459|NCT03022175|Pharmacokinetics
5460|NCT03022162|Neuropathic Pain, Paclitaxel, CIPN
5461|NCT03022136|epidural block
5462|NCT03022136|dermatome
5463|NCT03022136|human
5464|NCT03022136|spinal nerve
5465|NCT03022136|thoracic
5466|NCT03022071|Cognitive behavior therapy
5467|NCT03022071|Psychodynamic therapy
5468|NCT03022071|Mediators
5469|NCT03022071|Moderators
5470|NCT03022045|Erythrodermic Psoriasis
5471|NCT03022045|Japanese
5472|NCT03022045|Generalized Pustular Psoriasis
5473|NCT03022045|risankizumab
5474|NCT03022032|Gynecologic cancer
5475|NCT03022019|autologous cell suspension grafting
5476|NCT03022019|vitiligo
5477|NCT03022019|non-segmental
5478|NCT03022019|ReNovaCell
5479|NCT03021967|incurable pathologies
5480|NCT03021967|palliative care
5481|NCT03021954|platelet rich plasma
5482|NCT03021954|pelvic floor disorders
5483|NCT03021954|primipara
5484|NCT03021941|Gaucher Disease
5485|NCT03021941|Enzyme Replacement Therapy
5486|NCT03021928|Stroke
5487|NCT03021928|Atrial Fibrillation
5488|NCT03021928|Anticoagulation
5489|NCT03021928|NOAC
5490|NCT03021889|HIV / AIDS
5491|NCT03021889|Dyslipidemia
5492|NCT03021889|Adolescents
5493|NCT03021889|Nutritional Therapy
5494|NCT03021863|Dissemination
5495|NCT03021863|Tone
5496|NCT03021863|Survey reminders
5497|NCT03021863|Questionnaires
5498|NCT03021850|Pliability
5499|NCT03021850|Cryotherapy
5500|NCT03021850|Hot temperature
5501|NCT03021850|Hyperthermia, induced
5502|NCT03021850|Randomized Controlled Trial
5503|NCT03021850|Hamstring muscles
5504|NCT03021850|Muscle stretching exercises
5505|NCT03021824|Acute Respiratory Distress Syndrome
5506|NCT03021824|ARDS
5507|NCT03021824|Acute Lung Injury
5508|NCT03021824|ALI
5509|NCT03021824|Mechanical Ventilation
5510|NCT03021824|Extracorporeal Membrane Oxygenation
5511|NCT03021824|Neuromuscular Blockade
5512|NCT03021824|Vasodilator Agents
5513|NCT03021824|Prone Position
5514|NCT03021824|ECMO
5515|NCT03021824|Acute Respiratory Failure
5516|NCT03021798|Sarcopenia
5517|NCT03021798|Sarcopenic Obesity
5518|NCT03021798|observational study
5519|NCT03021798|6-minute walking distance
5520|NCT03021798|400 meters walking test
5521|NCT03021798|Patient Reported Outcomes
5522|NCT03021785|Neovascular Age-Related Macular Degeneration
5523|NCT03021785|Anti-VEGF
5524|NCT03021785|CNV
5525|NCT03021785|TK001
5526|NCT03021772|Neostigmine
5527|NCT03021772|Dexamethasone
5528|NCT03021772|Intravenous Local Anesthesia
5529|NCT03021746|African-American
5530|NCT03021720|Uterine fibroid embolization
5531|NCT03021720|Uterine artery embolization
5532|NCT03021720|Arterial access
5533|NCT03021720|Radial access
5534|NCT03021720|Interventional radiology
5535|NCT03021720|Quality of life
5536|NCT03021720|Patient Satisfaction
5537|NCT03021720|Patient centered care
5538|NCT03021720|Uterine fibroid
5539|NCT03019848|Redox and pro-inflammatory status
5540|NCT03019835|mivacurium
5541|NCT03019835|neostigmine
5542|NCT03019835|antagonism
5543|NCT03019783|Endothelial function
5544|NCT03019770|Pre-Exposure Prophylaxis
5545|NCT03019770|HIV
5546|NCT03019770|Decision Aid
5547|NCT03019770|Shared Decision Making
5548|NCT03019744|Functional Electrical Stimulation
5549|NCT03019744|Cerebrovascular accident
5550|NCT03019744|Stroke
5551|NCT03019744|Electromyography
5552|NCT03019731|Tics
5553|NCT03019731|Behavioral therapy
5554|NCT03019731|Neurologic Examination
5555|NCT03019718|Inpatient rehabilitation
5556|NCT03019718|Internet-based intervention
5557|NCT03019718|Aftercare
5558|NCT03019718|Return to work
5559|NCT03019718|Psychodynamic
5560|NCT03019705|Cyberchondria
5561|NCT03019705|health-related internet use
5562|NCT03019705|pathological health anxiety
5563|NCT03019705|ambulatory assessment
5564|NCT03019666|MM
5565|NCT03019666|NHL
5566|NCT03021655|Youth
5567|NCT03021655|Randomized controlled trial
5568|NCT03021655|Adventure-based training
5569|NCT03021655|WhatsApp
5570|NCT03021642|healthy volunteer
5571|NCT03021642|Tepotinib
5572|NCT03021642|Mesenchymal-epithelial transition factor
5573|NCT03021642|Translocated promoter region
5574|NCT03021616|energy drink
5575|NCT03021616|qtc interval
5576|NCT03021616|clotting time
5577|NCT03021616|thorough qt study
5578|NCT03021603|Hope
5579|NCT03021603|psychotherapy
5580|NCT03021603|palliative
5581|NCT03021603|low-intensity intervention
5582|NCT03021590|Helicobacter pylori
5583|NCT03021590|Helicobacter Infections
5584|NCT03021590|Proton Pump Inhibitors
5585|NCT03021590|sequential therapy
5586|NCT03021590|Clarithromycin
5587|NCT03021590|Tinidazole
5588|NCT03021577|orbital atherectomy system
5589|NCT03021577|rotational atherectomy
5590|NCT03021577|Fractional flow reserve
5591|NCT03021577|coronary flow reserve
5592|NCT03021577|index of microcirculatory resistance (IMR)
5593|NCT03021551|oxygen
5594|NCT03021551|desaturation
5595|NCT03021551|obesity
5596|NCT03021538|Cardiopulmonary Bypass
5597|NCT03021538|Extracorporeal Membrane Oxygenation
5598|NCT03021538|Primary Graft Dysfunction
5599|NCT03021538|Hemorrhage
5600|NCT03021538|Mechanical Ventilator
5601|NCT03021525|Goal-directed therapy
5602|NCT03021525|postoperative morbidity
5603|NCT03021525|haemodynamic optimisation
5604|NCT03021525|individualised medicine
5605|NCT03021525|Pulse pressure variation
5606|NCT03021525|Cardiac output
5607|NCT03021499|lupus nephritis
5608|NCT03021499|calcineurin inhibitors
5609|NCT03021499|voclosporin
5610|NCT03021486|Malignant neoplasms of independent (primary) multiple sites
5611|NCT03021486|Haloperidol
5612|NCT03021486|Chlorpromazine
5613|NCT03021486|Chlorpromazine hydrochloride
5614|NCT03021486|Thorazine
5615|NCT03021486|Symptom questionnaire
5616|NCT03021486|Survey
5617|NCT03021486|Delirium
5618|NCT03021486|Acute palliative care unit
5619|NCT03021486|APCU
5620|NCT03021473|oxygen reserve index
5621|NCT03021473|desaturation
5622|NCT03021473|safety
5623|NCT03021434|Water Supply/standards
5624|NCT03021434|Water microbiology
5625|NCT03021434|India
5626|NCT03021434|Hand disinfection
5755|NCT03020706|neostigmine
5627|NCT03021434|Escherichia coli Infections/prevention & control
5628|NCT03021434|Hygiene
5629|NCT03021434|Health behavior
5630|NCT03021434|Drinking water
5631|NCT03021434|Informational intervention
5632|NCT03021421|Total knee arthroplasty
5633|NCT03021421|unilateral spinal anaesthesia
5634|NCT03021421|psoas compartment block
5635|NCT03021421|sciatic nerve block
5636|NCT03021421|haemodynamic effects
5637|NCT03021343|Atrial fibrillation
5638|NCT03021343|Colchicine
5639|NCT03021343|Cardiac surgery
5640|NCT03021304|SB240563
5641|NCT03021304|self-administration
5642|NCT03021304|Mepolizumab
5643|NCT03021304|safety syringe
5644|NCT03021304|Eosinophilic asthma
5645|NCT03021278|Tactile acuity
5646|NCT03021278|Chronic pain
5647|NCT03021278|Two-point discrimination
5648|NCT03021278|Point-to-point test
5649|NCT03021278|Two-point estimation
5650|NCT03021278|Body image
5651|NCT03021239|Ramp Test
5652|NCT03021239|Continuous Flow -Left Ventricular Assist Device (CF-LVAD)
5653|NCT03021239|LVAD Hemodynamics
5654|NCT03021226|Health Behavior
5655|NCT03021174|CIPN
5656|NCT03021174|Chemotherapy-induced peripheral neuropathy
5657|NCT03021161|probiotic
5658|NCT03021148|Non-celiac wheat sensitivity
5659|NCT03021148|self-reported
5660|NCT03021122|Medication errors
5661|NCT03021122|Resuscitation
5662|NCT03021122|Drugs
5663|NCT03021122|Pediatrics
5664|NCT03021122|Biomedical technology
5665|NCT03021109|ultrasound
5666|NCT03021109|pediatrics
5667|NCT03021109|gastroenteritis
5668|NCT03021083|Lumbar multi-level fusions
5669|NCT03021083|Patient Controlled Analgesia
5670|NCT03021083|Fentanyl
5671|NCT03021083|Opioid Analgesia
5672|NCT03021070|Ante natal visit
5673|NCT03021070|Facility delivery
5674|NCT03021070|Post natal visit
5675|NCT03021070|Continuum of care
5676|NCT03021070|Conditional cash transfer
5677|NCT03021070|Maternal and child health
5678|NCT03021070|Cluster randomized trial
5679|NCT03021031|Parkinson's Disease
5680|NCT03021018|Epilepsy
5681|NCT03021018|Brivaracetam
5682|NCT03021018|Epilepsy Monitoring Unit
5683|NCT03021018|Increased seizure activity
5684|NCT03020992|Axial Spondyloarthritis
5685|NCT03020992|axSpA
5686|NCT03020992|Anterior Uveitis
5687|NCT03020992|Certolizumab Pegol
5688|NCT03020992|Cimzia
5689|NCT03020875|Acetaminophen
5690|NCT03020875|Pain management
5691|NCT03020862|Dietary nitrate
5692|NCT03020862|Physical performance
5693|NCT03020862|Blood pressure
5694|NCT03020862|Nitrite
5695|NCT03020862|Exercise
5696|NCT03020849|hypofibrinogenemia
5697|NCT03020849|prediction score
5698|NCT03020849|severe trauma
5699|NCT03020823|SCB01A
5700|NCT03020823|squamous cell carcinoma of head and neck
5701|NCT03019640|B-Cell Non-Hodgkin Lymphoma
5702|NCT03019640|Relapsed follicular lymphoma
5703|NCT03019640|Indolent B-cell histology
5704|NCT03019640|Natural killer cells
5705|NCT03019640|NK
5706|NCT03019640|Stem cell transplant
5707|NCT03019640|Rituximab
5708|NCT03019640|Rituxan
5709|NCT03019640|Carmustine
5710|NCT03019640|BCNU
5711|NCT03019640|BiCNU
5712|NCT03019640|Etoposide
5713|NCT03019640|VePesid
5714|NCT03019640|Cytarabine
5715|NCT03019640|Ara-C
5716|NCT03019640|Cytosar
5717|NCT03019640|DepoCyt
5718|NCT03019640|Cytosine arabinosine hydrochloride
5719|NCT03019640|Melphalan
5720|NCT03019640|Alkeran
5721|NCT03019640|Lenalidomide
5722|NCT03019640|CC-5013
5723|NCT03019640|Revlimid
5724|NCT03019640|G-CSF
5725|NCT03019640|Filgrastim
5726|NCT03019640|Neupogen
5727|NCT03019601|HIV
5728|NCT03019601|PMTCT
5729|NCT03019588|PD1
5730|NCT03019588|PD-1
5731|NCT03019588|PDL1
5732|NCT03019588|PD-L1
5733|NCT03019562|postoperative pain
5734|NCT03019523|caffeine
5735|NCT03019523|mental performance
5736|NCT03019523|reaction time
5737|NCT03019523|focus
5738|NCT03020784|acute neuroinflammatory
5739|NCT03020771|Crimean-congo hemorrhagic fever
5740|NCT03020771|vaccine
5741|NCT03020771|human
5742|NCT03020771|phase I
5743|NCT03020745|Pharmacokinetics
5744|NCT03020745|Safety
5745|NCT03020745|Pharmacodynamics
5746|NCT03020745|Chronic Hepatitis B
5747|NCT03020745|Efficiacy
5748|NCT03020745|GSK3389404
5749|NCT03020732|growth factor
5750|NCT03020732|mucogingival surgery
5751|NCT03020732|gingival recession
5752|NCT03020719|Growth Parameters
5753|NCT03020719|Cystic Fibrosis
5754|NCT03020706|magnesium sulphate
5756|NCT03020693|electrostimulation
5757|NCT03020693|exercise program
5758|NCT03020667|Conventional cigarette
5759|NCT03020667|iQOS
5760|NCT03020667|Never smoker
5761|NCT03020667|THS
5762|NCT03020641|low pressure pneumoperitoneum
5763|NCT03020641|standard pressure pneumoperitoneum
5764|NCT03020641|laparoscopy cholecystectomy
5765|NCT03020628|Influenza Vaccines
5766|NCT03020628|Vaccines, Inactivated
5767|NCT03020628|Cell Culture-Derived
5768|NCT03020615|Sickle cell
5769|NCT03020615|Hydroxyurea
5770|NCT03020615|Infants
5771|NCT03020589|Renal Transplant
5772|NCT03020589|Tacrolimus
5773|NCT03020589|UNC
5774|NCT03020589|Phase IV
5775|NCT03020550|GERD
5776|NCT03020550|Galvanic Skin Response
5777|NCT03020550|Heart Rate Variability
5778|NCT03020537|Influenza Vaccine
5779|NCT03020511|Modern grains
5780|NCT03020511|ancient grains
5781|NCT03020511|immunologic response
5782|NCT03020511|microbiota
5783|NCT03020498|Influenza Vaccine
5784|NCT03020472|Influenza Vaccine
5785|NCT03020459|macular holes
5786|NCT03020433|Stroke
5787|NCT03020433|rehab
5788|NCT03020433|rehabilitation
5789|NCT03020433|paresis
5790|NCT03020433|paralysis
5791|NCT03020433|stroke therapy
5792|NCT03020433|CVA
5793|NCT03020433|cerebrovascular accident
5794|NCT03020433|brain diseases
5795|NCT03020433|TMS
5796|NCT03020433|transcranial magnetic stimulation
5797|NCT03020433|CIMT
5798|NCT03020433|constraint induced movement therapy
5799|NCT03020433|MRI
5800|NCT03020407|Septic Shock
5801|NCT03020407|Inferior vene cava diameter
5802|NCT03020407|Resuscitation
5803|NCT03020407|Mortality
5804|NCT03020394|COPD Exacerbation
5805|NCT03020394|Noninvasive Positive Ventilation
5806|NCT03020394|Invasive Positive Ventilation
5807|NCT03020394|severe
5808|NCT03020342|HCC
5809|NCT03020342|chimera DNA
5810|NCT03020342|circulating DNA
5811|NCT03020342|biomarker
5812|NCT03020329|Induction Chemotherapy
5813|NCT03020329|Nasopharyngeal carcinoma
5814|NCT03020329|Chemoradiotherapy
5815|NCT03020290|femoropopliteal artery
5816|NCT03020290|interwoven nitinol stent
5817|NCT03020290|self-expanding-endovascular
5818|NCT03020290|TASC C and TASC D
5819|NCT03020290|Peripheral Arterial Disease
5820|NCT03020264|Type 2 Diabetes
5821|NCT03020264|Hypoglycemia
5822|NCT03020264|Elderly
5823|NCT03020264|Insulinotherapy
5824|NCT03020251|preoperative rehabilitation program
5825|NCT03020251|chest physiotherapy
5826|NCT03020251|lung cancer resection
5827|NCT03020212|Chronic obstructive pulmonary disease
5828|NCT03020212|High altitude
5829|NCT03020212|Oxygen
5830|NCT03020212|long-term oxygen therapy
5831|NCT03020212|pulmonary hypertension
5832|NCT03020212|chronic hypoxemia
5833|NCT03020199|Psoriasis
5834|NCT03020134|pharmacokinetics
5835|NCT03020134|Danoprevir/r
5836|NCT03020134|Ravidasvir
5837|NCT03020095|Ravidasvir
5838|NCT03020095|HCV GT1
5839|NCT03020095|SVR12
5840|NCT03020095|Danoprevir/r
5841|NCT03020082|Danoprevir
5842|NCT03020082|non-cirrhotic
5843|NCT03020082|Chinese HCV G1
5844|NCT03020082|SVR12
5845|NCT03020069|Type 1 Diabetes
5846|NCT03020069|Adolescents
5847|NCT03020069|Glucose Monitoring
5848|NCT03020056|cataract surgery
5849|NCT03020056|economy
5850|NCT03020056|quality of life
5851|NCT03020056|rural area
5852|NCT03020030|acute lymphoblastic leukemia
5853|NCT03020004|Danoprevir
5854|NCT03020004|SVR12
5855|NCT03020004|Chinese HCV G1
5856|NCT03020004|non-cirrhotic
5857|NCT03019991|pharmacokinetics,Danoprevir
5858|NCT03019939|Acute Myeloid Leukemia
5859|NCT03019939|AML
5860|NCT03019939|Myelodysplastic Syndrome
5861|NCT03019939|MDS
5862|NCT03019939|Neutropenia
5863|NCT03019939|Invasive fungal infection
5864|NCT03019939|IFI
5865|NCT03019939|Isavuconazole
5866|NCT03019939|BAL8557
5867|NCT03019926|systemic lupus erythematosus
5868|NCT03019926|observance
5869|NCT03019926|hydroxychloroquine dosage
5870|NCT03019926|risk factors of non-observance
5871|NCT03019926|SLICC score
5872|NCT03019926|SLEDAI score
5873|NCT03019913|Skeletal muscle
5874|NCT03019861|Ayurveda
5875|NCT03019861|IBS
5876|NCT03019861|Complementary medicine
5877|NCT03019861|nutritional counseling
5878|NCT03019497|PTSD
5879|NCT03019497|Related Problems
5880|NCT03019497|Therapy
5881|NCT03019497|Traumatic Event
5882|NCT03019497|Quality of Life
5883|NCT03019497|Cognitive Behavioral Therapy (CBT)
5884|NCT03019497|Major depression
5885|NCT03019497|Sleep disorders
5886|NCT03019497|Pain
5887|NCT03019497|Stressors
5888|NCT03019497|Social support
5889|NCT03019497|Substance use disorder
5890|NCT03019497|Anxiety disorder
5891|NCT03019484|Self-efficacy
5892|NCT03019484|Self Efficacy
5893|NCT03019484|Nurses's Role
5894|NCT03019484|Professional Role
5895|NCT03019484|Clinical Trial
5896|NCT03019484|Breast Feeding
5897|NCT03019458|prospective randomized trial
5898|NCT03019419|sporadic ALS
5899|NCT03019419|perampanel
5900|NCT03019393|non-transferrin bound iron (NTBI)
5901|NCT03019393|Red meat
5902|NCT03019393|Non-transferrin bound iron (NTBI) in serum
5903|NCT03019367|Premature infants
5904|NCT03019367|Umbilical cord milking
5905|NCT03019367|Delayed cord clamping
5906|NCT03019367|Intraventricular Hemorrhage
5907|NCT03019367|Death
5908|NCT03019354|high flow oxygen
5909|NCT03019354|pulmonary atelectasis
5910|NCT03019354|intravenous general anesthesia
5911|NCT03019341|Nausea
5912|NCT03019341|Vomiting
5913|NCT03019341|Non-ionic contrast media
5914|NCT03019341|Side effect
5915|NCT03019328|peanut allergy
5916|NCT03019328|food allergens
5917|NCT03019328|atopic dermatitis
5918|NCT03019328|eczema
5919|NCT03019328|infant food allergy testing
5920|NCT03019328|skin prick testing
5921|NCT03019328|peanut IgE
5922|NCT03019328|early peanut introduction
5923|NCT03019328|food allergy prevention
5924|NCT03019315|Ovarian Cancer
5925|NCT03019315|Chemotherapy
5926|NCT03019315|Response Rate
5927|NCT03019315|Survival
5928|NCT03019250|Colostrum
5929|NCT03019250|Critical Care Outcomes
5930|NCT03019250|Intensive Care Unit
5931|NCT03019250|Inflammation
5932|NCT03019250|Infection
5933|NCT03019250|mortality
5934|NCT03019224|Tooth whitening
5935|NCT03019224|Dentifrice
5936|NCT03019224|Sensitivity
5937|NCT03019211|Physical Therapy Modalities
5938|NCT03019211|Accidental Fall
5939|NCT03019211|Elderly
5940|NCT03019211|Hydrotherapy
5941|NCT03019211|Nursing Home
5942|NCT03019198|Tranexamic Acid
5943|NCT03019198|Blood loss
5944|NCT03019198|Tranfusion
5945|NCT03019185|Alport Syndrome
5946|NCT03019185|Bardoxolone methyl
5947|NCT03019185|CDDO-ME
5948|NCT03019185|RTA 402
5949|NCT03019146|Prehabilitation
5950|NCT03019133|Heart rate
5951|NCT03019133|Blood pressure variability
5952|NCT03019094|overactive bladder
5953|NCT03019094|urge urinary incontinence
5954|NCT03019094|urgency frequency
5955|NCT03019068|recruitment potential
5956|NCT03019068|prediction
5957|NCT03019068|databases
5958|NCT03019068|Clinical Trial Recruitment Support Systems (CTRSS)
5959|NCT03019042|Hou Gu Mi Xi
5960|NCT03019042|Shen Ling Bai Zhu San
5961|NCT03019042|mild gastrointestinal disorders
5962|NCT03019042|traditional Chinese medicine
5963|NCT03019042|randomized controlled trial
5964|NCT03019029|Peripheral Nerve Amyloidosis
5965|NCT03019003|Head and Neck Cancer
5966|NCT03018964|Single incision
5967|NCT03018964|Solo surgery
5968|NCT03018951|frailty, assessement
5969|NCT03018938|mid mixture insulin analog
5970|NCT03018938|basal insulin analog
5971|NCT03018912|Subjective Sleep Vital Sign (VS)
5972|NCT03018912|Primary Care
5973|NCT03018912|Sleep Medicine
5974|NCT03018912|Cognitive Behavioral Therapy (CBT)
5975|NCT03018912|Obstructive Sleep Apnea (OSA)
5976|NCT03018912|Insomnia
5977|NCT03018912|Complex Sleep Disorders
5978|NCT03018912|Predictive Analytics
5979|NCT03018912|Screening
5980|NCT03018912|Therapy Outcomes
5981|NCT03018899|paravertebral block
5982|NCT03018899|ultrasound
5983|NCT03018899|percutaneous nephrolithotomy
5984|NCT03018899|postoperative pain
5985|NCT03018873|remote ischemic preconditioning
5986|NCT03018873|acute myocardial infarction
5987|NCT03018860|Active second stage
5988|NCT03018860|Neonatal morbidity
5989|NCT03018860|Operative delivery
5990|NCT03018860|Labor
5991|NCT03018834|Acute Myocarditis
5992|NCT03018834|ANAKINRA
5993|NCT03018808|Eosinophilia
5994|NCT03018808|COPD prevalence
5995|NCT03018808|Primary care subjects
5996|NCT03018795|peri-implantitis
5997|NCT03018795|Surgical regenerative treatment
5998|NCT03018795|ozone therapy
5999|NCT03018704|alcoholism
6000|NCT03018704|treatment
6001|NCT03018652|COPD
6002|NCT03018652|Ig
6003|NCT03018652|IPRAC
6004|NCT03018652|outpatient
6005|NCT03018626|Non-germinal b-cell-like
6006|NCT03018626|R-ACVBP
6007|NCT03018626|DA-EPOCH-R
6008|NCT03018613|Chronic Functional Constipation
6009|NCT03018613|Intestinal Bacteria Flora Disturbance
6010|NCT03018613|Fecal Microbiota Transplantation
6011|NCT03018600|prednisone, autoimmune disease
6012|NCT03018509|JTE-451
6013|NCT03018509|psoriasis
6014|NCT03018470|COPD
6015|NCT03018470|Non invasive ventilation
6016|NCT03018470|NIV
6017|NCT03018470|Acute exacerbation COPD
6018|NCT03018470|AECOPD
6019|NCT03018470|Telemonitoring
6020|NCT03018457|Trabecular microarchitecture
6021|NCT03018457|alveolar bone
6022|NCT03018457|osseointegration
6023|NCT03018457|dental implant
6024|NCT03018431|Lung ultrasonography
6025|NCT03018431|Chest CT scan
6026|NCT03018431|ventilator-associated pneumonia
6027|NCT03018431|ventilator-associated tracheobronchitis
6028|NCT03018431|antibiotic stewardship
6029|NCT03018418|Anal Cancer
6030|NCT03018379|Obesity
6031|NCT03018379|Body composition
6032|NCT03018379|energy expenditure
6033|NCT03018379|sedentarity
6034|NCT03018379|dietary behaviors
6035|NCT03018366|estrogen
6036|NCT03018366|premenopause
6037|NCT03018366|menopause
6038|NCT03018366|amenorrhea
6039|NCT03018353|Hepatitis C, Chronic
6040|NCT03018353|Jail
6041|NCT03018353|Patient Navigation
6042|NCT03018353|Incarcerated Population
6043|NCT03018353|HCV
6044|NCT03018353|Sofosbuvir/Velpatasvir
6045|NCT03018353|Hepatitis C
6046|NCT03018288|Malignant Gliomas
6047|NCT03018288|Immunotherapy
6048|NCT03018275|Lyophilized Biotherapeutic, Microbiome, Probiotic
6049|NCT03018275|Commensal Gram-negative Bacteria
6050|NCT03018275|Staphylococcus Aureus
6051|NCT03018275|Transepidermal Water Loss
6052|NCT03018275|Allergic Diseases
6053|NCT03018262|Surround Inhibition
6054|NCT03018262|Motor Control
6055|NCT03018262|Transcranial Magnetic Stimulation (TMS)
6056|NCT03018262|TMS-Evoked Potential
6057|NCT03018236|cocaine
6058|NCT03018236|alcohol
6059|NCT03018236|substance use disorders
6060|NCT03018236|addiction
6061|NCT03018236|N-acetylcysteine
6062|NCT03018236|randomized controlled trial
6063|NCT03018223|Acute leukemia in CR
6064|NCT03018223|Chronic myeloid leukemia
6065|NCT03018223|Non-Hodgkin lymphoma in high risk
6066|NCT03018223|Graft vs. Host Disease
6067|NCT03018223|GVHD
6068|NCT03018223|Hematopoietic cell transplant (HCT)
6069|NCT03018197|Personal Health Record
6070|NCT03018197|Medication Knowledge
6071|NCT03018197|Anticoagulants
6072|NCT03018197|Patient Engagement
6073|NCT03018184|MRI
6074|NCT03018184|CCSA
6075|NCT03018184|Contractile Cross Sectional Area
6076|NCT03018184|Strength
6077|NCT03018171|clonidine, spinal injections
6078|NCT03018132|perinatal mental health
6079|NCT03018106|Female sexual disorder
6080|NCT03018106|Aging
6081|NCT03018106|Menopause
6082|NCT03018106|Obstetrics/Gynecology
6083|NCT03018106|Female urogenital disorder
6084|NCT03018093|Relapsed or refractory acute lymphoblastic leukemia
6085|NCT03018093|Anti-CD19 chimeric antigen receptor T-cell
6086|NCT03018054|moderate active ulcerative colitis
6087|NCT03018054|Japanese
6088|NCT03018041|Kidney transplantation
6089|NCT03018041|Renal transplantation
6090|NCT03018041|Omega-3 fatty acids
6091|NCT03018041|Marine n-3 fatty acids
6092|NCT03018041|Fatty acids
6093|NCT03018041|Inflammation
6094|NCT03018041|Interstitial fibrosis
6095|NCT03018041|Glomerular filtration rate
6096|NCT03018041|Renal function
6097|NCT03018041|Allograft function
6098|NCT03018041|Proteinuria
6099|NCT03018041|Blood pressure
6100|NCT03018041|Heart rate variability
6101|NCT03018041|Lipids
6102|NCT03018041|Blood glucose
6103|NCT03018041|Body mass index
6104|NCT03018041|Fatty acid composition
6105|NCT03018041|Gas chromatography
6106|NCT03018041|Interventional study
6107|NCT03018041|Allograft biopsy
6108|NCT03018041|Kidney biopsy
6109|NCT03018015|Bioequivalence
6110|NCT03018015|Healthy
6111|NCT03018015|Bioavailability
6112|NCT03018015|Ibuprofen
6113|NCT03018002|HIV, PMTCT
6114|NCT03017989|Near Infrared Fluorescence Imaging
6115|NCT03017989|Indocyanine green (ICG)
6116|NCT03017963|acute coronary syndrome
6117|NCT03017963|sodium thiosulfate
6118|NCT03017963|maximum tolerable dose
6119|NCT03017963|dose-limiting toxicity
6120|NCT03017911|PICC Line
6121|NCT03017911|Complications
6122|NCT03017911|Thrombosis
6123|NCT03017911|Infection
6124|NCT03017898|FiLaC
6125|NCT03017898|Fistula Laser Closure
6126|NCT03017898|Laser Coagulation
6127|NCT03017872|HIV, second-line
6128|NCT03017833|Solid Tumors
6129|NCT03017833|Advanced Cancer
6130|NCT03017833|Metformin
6131|NCT03017833|Metformin ER
6132|NCT03017833|TAK-228
6133|NCT03017833|MLN0128
6134|NCT03017833|TAK228
6135|NCT03017794|Radiotherapy
6136|NCT03017794|Chromogranin A
6137|NCT03017794|Neuroendocrine differentiation
6138|NCT03017781|Bipolar
6139|NCT03017781|High-Risk Off-Spring
6140|NCT03017781|Psychosocial Functioning
6141|NCT03017768|Acute tryptophan depletion, esophageal sensitivity,
6142|NCT03017716|Inflammatory back pain
6143|NCT03017716|gluten-free diet
6144|NCT03017716|celiac disease
6145|NCT03017716|non-celiac wheat sensitivity
6146|NCT03017703|Endothelial dysfunction
6147|NCT03017703|Insulin resistance
6148|NCT03017703|Type 2 diabetes
6149|NCT03017703|Mineralocorticoid blocker
6150|NCT03017625|COPD
6151|NCT03017625|Cardiovascular Disease
6152|NCT03017625|Platelets
6153|NCT03017625|Inflammation
6154|NCT03017612|Presbyopia
6155|NCT03017573|Immunological biomarkers
6156|NCT03017573|molecular profil
6157|NCT03017573|Circulating tumor DNA (ctDNA)
6158|NCT03017560|Breast Cancer
6159|NCT03017560|Chemotherapy
6160|NCT03017560|Verbal Memory
6161|NCT03017560|Processing Speed
6162|NCT03017534|Patient-Therapist Interaction
6163|NCT03017534|Non-Specific Effects
6164|NCT03017534|Manual Therapy
6165|NCT03017534|Neurodynamics
6166|NCT03017534|Sham
6167|NCT03017521|Refractory solid tumors
6168|NCT03017521|AKT inhibitor
6169|NCT03017508|Cross-over study
6170|NCT03017508|Riluzole
6171|NCT03017508|Double-blind study
6172|NCT03017508|Speech task
6173|NCT03017508|Social Anxiety Disorder
6174|NCT03017495|food-drug interaction
6175|NCT03017495|drug-drug interaction
6176|NCT03017495|pharmacokinetics
6177|NCT03017469|Resilience
6178|NCT03017469|Workplace Stress
6179|NCT03017469|Occupational Fatigue
6180|NCT03017469|Compassion Fatigue
6181|NCT03017469|Peer Support
6182|NCT03017469|Self-Care
6183|NCT03017469|Employee Assistance
6184|NCT03017456|Survivorship
6185|NCT03017456|Prostate Cancer
6186|NCT03017456|Survivorship Care Plan
6187|NCT03017443|Weight Loss
6188|NCT03017443|Obesity
6189|NCT03017443|Overweight
6190|NCT03017391|palliative care
6191|NCT03017391|palliative medicine
6192|NCT03017391|palliative
6193|NCT03017378|influenza vector
6194|NCT03017378|tuberculosis
6195|NCT03017378|vaccine
6196|NCT03017365|Motor Control
6197|NCT03017365|Balance
6198|NCT03017352|Diabetes Mellitus, Type 1
6199|NCT03017352|Exenatide
6200|NCT03017352|Incretins
6201|NCT03017352|GLP-1
6202|NCT03017352|Insulin
6203|NCT03017339|Low Lever Laser Therapy
6204|NCT03017339|Exercise Therapy
6205|NCT03017339|Chronic Pain
6206|NCT03017287|Glucose blood measurements, glucometer, BGM, Diabetes App
6207|NCT03017274|Non-celiac wheat sensitivity
6208|NCT03017274|celiac disease
6209|NCT03017274|abdominal ultrasonography;
6210|NCT03017261|Osteoarthritis
6211|NCT03017261|Arthroplasty
6212|NCT03017261|Robotic Surgery
6213|NCT03017261|Knee
6214|NCT03017248|pain
6215|NCT03017248|ketamine
6216|NCT03017248|morphine
6217|NCT03017248|analgesia
6218|NCT03017248|emergency
6219|NCT03017144|non-technical skills (NTS)
6220|NCT03017144|human factors
6221|NCT03017144|team work
6222|NCT03017144|Crew Resource Management / Crisis Resource Management (CRM)
6223|NCT03017144|technical skills (TS)
6224|NCT03017144|Cardiopulmonary resuscitation
6225|NCT03017144|Advanced cardiac life support
6226|NCT03017079|Semi-solidification
6227|NCT03017079|caloric debt
6228|NCT03017079|enteral nutrition
6229|NCT03017079|critical illness
6230|NCT03017066|Ultrasonography
6231|NCT03017066|Child
6232|NCT03017066|Preoperative period
6233|NCT03017053|Neck dissection
6234|NCT03017053|Survival
6235|NCT03017053|Early oral cancer
6236|NCT03017053|Early oral cavity squamous cancer with node negative neck
6237|NCT03017027|human-animal interaction
6238|NCT03017014|Crohn's Disease
6239|NCT03017014|Humira®
6240|NCT03017014|Adalimumab
6241|NCT03016988|Mantle cell lymphoma
6242|NCT03016988|Bortezomib
6243|NCT03016988|Fludarabine
6244|NCT03016988|Cytarabine
6245|NCT03016936|Metabolic equivalents (METs)
6246|NCT03016936|European Society of Anaesthesiology (ESA)
6247|NCT03016936|Noncardiac surgery
6248|NCT03016936|Cardiovascular Mortality
6249|NCT03016923|cerebral palsy
6250|NCT03016923|hemiplegia
6251|NCT03016923|fes
6252|NCT03016923|grasping
6253|NCT03016897|ALS
6254|NCT03016897|neurodegenerative
6255|NCT03016884|Herpes Zoster
6256|NCT03016884|anti TNF alpha
6257|NCT03016884|tofacitinib
6258|NCT03016884|Rheumatoid Arthritis
6259|NCT03016845|ciprofloxacin
6260|NCT03016845|pharmacokinetics
6261|NCT03016845|Intensive Care Unit
6262|NCT03016845|Cystatin C
6263|NCT03016845|CKD-EPI
6264|NCT03016845|renal function
6265|NCT03016780|Ulcerative Colitis
6266|NCT03016780|Intestinal Bacteria Flora Disturbance
6267|NCT03016780|Fecal Microbiota Transplantation
6268|NCT03016780|Intestinal Mucosal Immunity
6269|NCT03016767|oral feeding
6270|NCT03016767|oral stimulation
6271|NCT03016767|physiotherapy intervention
6272|NCT03016754|sudden cardiac death
6273|NCT03016754|SCD
6274|NCT03016754|sudden cardiac arrest
6275|NCT03016754|SCA
6276|NCT03016754|heart failure
6277|NCT03016754|HF
6278|NCT03016741|cognitive function
6279|NCT03016741|hormonal therapy
6280|NCT03016741|cancer survivorship
6281|NCT03016741|dementia
6282|NCT03016741|cognitive dysfunction
6283|NCT03016741|mild cognitive impairment
6284|NCT03016728|exercise
6285|NCT03016728|physical activity
6286|NCT03016728|pilot study
6287|NCT03016728|randomized controlled trial
6288|NCT03016728|cancer
6289|NCT03016728|adolescent and young adult
6290|NCT03016728|AYA
6291|NCT03016715|Epidermolysis bullosa simplex
6292|NCT03016676|Spinal Manipulation
6293|NCT03016676|Postural Instability
6294|NCT03016676|Quality of Life
6295|NCT03016650|Acetaminophen
6296|NCT03016650|Ibuprofen
6297|NCT03016637|endoscopic ultrasonography
6298|NCT03016637|EUS-FNA
6299|NCT03016598|oxytocin
6300|NCT03016598|substance-related disorders
6301|NCT03016598|Motivational Interviewing
6302|NCT03016598|Psychophysiology
6303|NCT03016598|Psychotherapeutic processes
6304|NCT03016572|Suicide
6305|NCT03016572|Adolescent
6306|NCT03016572|Intervention
6307|NCT03016572|Crisis
6308|NCT03016572|Follow-Up
6309|NCT03016559|releasing muscle, quadratus lumborum, hip angle
6310|NCT03016546|Pregnancy
6311|NCT03016533|Dolutegravir
6312|NCT03016533|Continued access study
6313|NCT03016533|HIV-1
6314|NCT03016533|GSK1349572
6315|NCT03016533|Pediatric
6316|NCT03016507|intraocular pressure
6317|NCT03016507|phacoemulsification
6318|NCT03016507|cataract
6319|NCT03016468|Oral Treprostinil
6320|NCT03016468|Remodulin
6321|NCT03016468|Selexipag
6322|NCT03016468|6 Minute Walk Test
6323|NCT03016455|Kidney Transplant
6324|NCT03016455|Immunology
6325|NCT03016442|Double balloon catheter
6326|NCT03016442|Dinoprostone
6327|NCT03016442|Labor induction
6328|NCT03016429|pacemaker
6329|NCT03016429|defibrillator
6330|NCT03016429|magnetic resonance imaging
6331|NCT03016429|cardiac implantable electronic device
6332|NCT03016390|Cardiac Implantable Electronic Device
6333|NCT03016390|Pacemaker
6334|NCT03016390|Automatic Implantable Cardioverter-Defibrillator (AICD)
6335|NCT03016390|Electromagnetic interference (EMI)
6336|NCT03016390|Keyless access system
6337|NCT03016390|Keyless entry system
6338|NCT03016377|CAR T cells
6339|NCT03016377|CD19
6340|NCT03016377|Leukemia
6341|NCT03016377|T Lymphocytes
6342|NCT03016377|AP1903
6343|NCT03016377|Cytokine Release Syndrome
6344|NCT03016351|Hypertension
6345|NCT03016351|Exercise
6346|NCT03016351|African Americans
6347|NCT03016351|Arterial Function
6348|NCT03016351|Arterial Stiffness
6349|NCT03016286|Whole body vibration
6350|NCT03016286|Bone myoregulation reflex
6351|NCT03016286|H-reflex
6352|NCT03016260|Rheumatoid Arthritis
6353|NCT03016260|Anti TNF
6354|NCT03016260|Infliximab
6355|NCT03016260|Adalimumab
6356|NCT03016260|Etanercept
6357|NCT03016260|Golimumab
6358|NCT03016260|Certolizumab Pegol
6359|NCT03016260|Infliximab biosimilar
6360|NCT03016260|Etanercept biosimilar
6361|NCT03016260|Methotrexate
6362|NCT03016247|magnetic resonance imaging, trust, reward
6363|NCT03016234|intraocular pressure
6364|NCT03016234|trendelenburg position
6365|NCT03016234|pneumoperitoneum
6366|NCT03016221|local skin responses
6367|NCT03016221|hyperemia
6368|NCT03016221|thermal sensation
6369|NCT03016221|topical warming ointments
6370|NCT03016221|topical cooling ointments
6371|NCT03016221|skin perfusion
6372|NCT03016221|subjective thermal sensation
6373|NCT03016221|muscle tissue oxygenation
6374|NCT03016221|skin temperature
6375|NCT03016221|skin redness
6376|NCT03016221|erythema
6377|NCT03016143|phase II
6378|NCT03016143|split
6379|NCT03016143|vaccine
6380|NCT03016130|leukemia
6381|NCT03016130|myelodysplastic
6382|NCT03016130|myeloid
6383|NCT03016130|lymphoblastic
6384|NCT03016130|diet
6385|NCT03016130|infection
6386|NCT03016130|hematopoietic
6387|NCT03016130|stem cell
6388|NCT03016130|transplant
6389|NCT03016104|magnetic seizure therapy
6390|NCT03016104|electroconvulsive therapy
6391|NCT03016104|bipolar mania
6392|NCT03016104|cognition
6393|NCT03016104|controlled trial
6394|NCT03016052|ABMT
6395|NCT03016052|social anxiety
6396|NCT03016052|generalized anxiety
6397|NCT03016026|ERAS,Laparoscopy,Distal Gastrectomy,Safety,Effectiveness
6398|NCT03016000|diffuse large B-cell lymphoma
6399|NCT03016000|Thalidomide
6400|NCT03016000|Maintenance
6401|NCT03015987|Diode laser
6402|NCT03015987|asymptomatic pulp
6403|NCT03015987|Laser activated irrigation
6404|NCT03015987|continuous ultrasonic activation
6405|NCT03015987|post obturation pain
6406|NCT03015935|Obesity, Morbid
6407|NCT03015883|Squamous Cell Carcinoma
6408|NCT03015883|Alpha emitting radiation
6409|NCT03015870|vocal dysfunction
6410|NCT03015870|voice
6411|NCT03015870|vocal folds
6412|NCT03015870|vocal aging
6413|NCT03015844|MIBG
6414|NCT03015844|131I-MIBG
6415|NCT03015844|relapsed
6416|NCT03015844|neuroblastoma
6417|NCT03015844|pheochromocytoma
6418|NCT03015831|Atrial fibrillation
6419|NCT03015831|Cardiac surgery
6420|NCT03015831|Colchicine
6421|NCT03015766|insomnia
6422|NCT03015766|hemodialysis
6423|NCT03015766|auricular acupressure
6424|NCT03015766|randomized controlled trial
6425|NCT03015753|Migraine
6426|NCT03015753|Tai Chi
6427|NCT03015753|Prophylaxis
6428|NCT03015753|Randomized controlled trial
6429|NCT03015740|Malignant neoplasms of urinary tract
6430|NCT03015740|Other disorders of kidney and ureter
6431|NCT03015740|Renal cell carcinoma
6432|NCT03015740|RCC
6433|NCT03015740|Metastatic
6434|NCT03015740|MGCD516
6435|NCT03015740|Nivolumab
6436|NCT03015740|BMS-936558
6437|NCT03015740|Opdivo
6438|NCT03015727|nasopharyngeal carcinoma
6439|NCT03015727|Induction chemotherapy
6440|NCT03015727|radiotherapy
6441|NCT03015727|chemoradiotherapy
6442|NCT03015701|Unresectable
6443|NCT03015688|Biomarkers
6444|NCT03015662|Quality of Life
6445|NCT03015662|Fatigue
6446|NCT03015662|Anxiety
6447|NCT03015662|Physical Therapy Modalities
6448|NCT03015662|Pain
6449|NCT03015649|breast cancer, surgical guidance system
6450|NCT03015636|Cognitive Behaviour Therapy
6451|NCT03015636|Psychological Intervention
6452|NCT03015623|Mesenchymal stromal cells
6453|NCT03015623|MSC
6454|NCT03015623|Stem cells
6455|NCT03015623|Mesenchymal stem cells
6456|NCT03015610|Personalized Medicine
6457|NCT03015610|CYP2C19
6458|NCT03015610|Lansoprazole
6459|NCT03015610|Pharmacokinetics
6460|NCT03015597|Smoking
6461|NCT03015597|Tobacco Smoking
6462|NCT03015597|Smoking, Tobacco
6463|NCT03015597|Smoking Cessation
6464|NCT03015597|Opiate Addiction
6465|NCT03015597|Opiate Dependence
6466|NCT03015597|Contingency Management
6467|NCT03015571|heterotopic gastric mucosa
6468|NCT03015571|cervical inlet patch
6469|NCT03015571|narrow band imaging
6470|NCT03015571|endoscopy
6471|NCT03015558|Drug Resistance
6472|NCT03015558|Neuropathic Pain
6473|NCT03015558|opercular-insular cortex
6474|NCT03015558|Transcranial Direct Current Stimulation
6475|NCT03015545|Muscle Stiffness
6476|NCT03015545|Ultrasound elastography
6477|NCT03015545|H-reflex
6478|NCT03015545|Whole body vibration
6479|NCT03015519|GSK716155
6480|NCT03015519|Type 2 diabetes mellitus
6481|NCT03015519|albiglutide
6482|NCT03015519|safety
6483|NCT03015519|pediatric
6484|NCT03015519|efficacy
6485|NCT03015493|Neck pain
6486|NCT03015493|Neurodynamics
6487|NCT03015493|Spinal manipulative therapy
6488|NCT03015480|Mobile Application
6489|NCT03015480|Chronic Kidney Disease
6490|NCT03015480|Diabetes Mellitus
6491|NCT03015480|Albuminuria
6492|NCT03015480|Diet
6493|NCT03015467|acute pancreatitis
6494|NCT03015467|intestinal mucosal barrier
6495|NCT03015467|Fecal Microbiota Transplantation
6496|NCT03015454|InSight
6497|NCT03015454|Dascena
6498|NCT03015441|Healthy subjects
6499|NCT03015441|Probiotics
6500|NCT03015441|Breath test
6501|NCT03015441|Dihydrogen
6502|NCT03015441|Methane
6503|NCT03015441|Intestinal gas production
6504|NCT03015441|Gut microbiota
6505|NCT03015428|Family caregivers
6506|NCT03015428|training programme
6507|NCT03015428|dementia
6508|NCT03015415|elbow
6509|NCT03015415|posttraumatic stiffness
6510|NCT03015415|elbow contractures
6511|NCT03015415|stiff elbow
6512|NCT03015415|dynamic orthoses
6513|NCT03015415|Dynamic splint
6514|NCT03015415|Rehabilitation
6515|NCT03015415|Splint
6516|NCT03015415|Effectiveness of bracing
6517|NCT03015376|epithelial ovarian cancer
6518|NCT03015376|Hereditary Breast and Ovarian Cancer Syndrome
6519|NCT03015376|next-generation sequencing
6520|NCT03015376|High-Throughput Nucleotide Sequencing
6521|NCT03015363|Hypertension
6522|NCT03015363|Telemonitoring
6523|NCT03015363|Vital signs
6524|NCT03015350|blood sevoflurane concentration
6525|NCT03015350|blood desflurane concentration
6526|NCT03015350|one lung ventilation
6527|NCT03015311|Blood pressure control
6528|NCT03015298|gastric cancer
6529|NCT03015298|Simultaneous PET/MRI
6530|NCT03015298|PET/CT
6531|NCT03015272|minimally-verbal
6532|NCT03015272|children
6533|NCT03015272|intervention
6534|NCT03015272|singing
6535|NCT03015272|music
6536|NCT03015233|Lactate
6537|NCT03015233|Acute Abdominal Pain
6538|NCT03015233|Acute Abdomen
6539|NCT03015233|Strong Ion Gap
6540|NCT03015233|Renal Colic
6541|NCT03015233|Emergency Department
6542|NCT03015233|Emergency
6543|NCT03015233|Surgery
6544|NCT03015233|Stewart
6545|NCT03015194|LVOT (left ventricular outflow tract, obstruction)
6546|NCT03015194|Transcatheter Mitral Valve Implantation
6547|NCT03015194|Transcatheter Heart Valve
6548|NCT03015194|Mitral Valve Regurgitation
6549|NCT03015194|Mitral Valve Stenosis
6550|NCT03015181|Broadly Neutralizing
6551|NCT03015181|HIV Prevention
6552|NCT03015181|Anti-Drug Antibody
6553|NCT03015181|HIV-1
6554|NCT03015181|Immune Response
6555|NCT03015129|Durvalumab
6556|NCT03015129|MEDI4736
6557|NCT03015129|Tremelimumab
6558|NCT03015129|anti-PD-L1 Antibody
6559|NCT03015129|anti-CTLA-4 antibody
6560|NCT03015129|16-1491
6561|NCT03015116|photobiomodulation
6562|NCT03015116|plantar fasciitis
6563|NCT03015090|COPD
6564|NCT03015090|CYP1A2
6565|NCT03015090|Theophylline
6566|NCT03015077|Glutamine
6567|NCT03015051|Bronchiolitis
6568|NCT03015051|High flow nasal cannula
6569|NCT03015051|Oxygen therapy
6570|NCT03015025|Acenocoumarol
6571|NCT03015025|Cytochrome P450
6572|NCT03015025|Pharmacogenetics
6573|NCT03015025|Algorithm
6574|NCT03015025|CYP2C9
6575|NCT03015025|VKORC1
6576|NCT03015025|CYP4F2
6577|NCT03015025|P450 oxidoreductase (POR)
6578|NCT03015012|Nutrigenomics
6579|NCT03015012|Genetics
6580|NCT03015012|Overweight
6581|NCT03015012|Obesity
6582|NCT03015012|Prediabetes
6583|NCT03015012|Transplantation
6584|NCT03015012|Nutrition
6585|NCT03015012|Dietetics
6586|NCT03015012|BMI
6587|NCT03015012|Body Composition
6588|NCT03014999|Transcranial Magnetic Stimulation
6589|NCT03014999|Spinal Cord Injury
6590|NCT03014999|Humans
6591|NCT03014986|HCV
6592|NCT03014947|MSB11022
6593|NCT03014947|Humira®
6594|NCT03014934|Aspergillosis
6595|NCT03014934|IA
6596|NCT03014908|Type 1 diabetes
6597|NCT03014908|1H-NMR spectroscopy
6598|NCT03014908|Metabolomics
6599|NCT03014908|Pediatrics
6600|NCT03014895|E3112
6601|NCT03014895|Pharmacokinetics
6602|NCT03014895|Japanese
6603|NCT03014869|COPD Exacerbation
6604|NCT03014869|High Flow Oxygen
6605|NCT03014869|Noninvasive Positive Ventilation
6606|NCT03014869|moderate
6607|NCT03014856|Metabolic syndrome
6608|NCT03014856|Metabolomics
6609|NCT03014856|NMR spectroscopy
6610|NCT03014843|Esophagal sensitivity, GERD, endogenous opiods
6611|NCT03014791|Epidemiology
6612|NCT03014791|Ethnicity
6613|NCT03014791|Age
6614|NCT03014791|Weight
6615|NCT03014791|Hypertensive
6616|NCT03014791|Cardiac Output
6617|NCT03014791|Peripheral Vascular Resistance
6618|NCT03014791|Arterial Stiffness
6619|NCT03014791|Healthy Volunteers
6620|NCT03014791|Endothelial function
6621|NCT03014791|Arterial Structure
6622|NCT03014791|Left ventricular mass/function
6623|NCT03014765|endothelial dysfunction
6624|NCT03014765|perioperative stress
6625|NCT03014765|cardiovascular complications
6626|NCT03014765|inflammatory markers
6627|NCT03014739|Elastography
6628|NCT03014739|Musculoskeletal System
6629|NCT03014726|reduced urine flow rate
6630|NCT03014726|low peak flow rate
6631|NCT03014726|urinary tract infections
6632|NCT03014713|Dexmedetomidine
6633|NCT03014713|Dezocine
6634|NCT03014713|Flubiprofen
6635|NCT03014713|Analgesia
6636|NCT03014713|Colorectal Surgery
6637|NCT03014687|transsphenoidal surgery
6638|NCT03014674|SB-240563
6639|NCT03014674|subcutaneous
6640|NCT03014674|lyophilized drug product
6641|NCT03014674|Mepolizumab
6642|NCT03014674|liquid drug product
6643|NCT03014674|safety syringe
6644|NCT03014674|auto injector
6645|NCT03014661|pollinosis, quality of life, specific immunotherapy
6646|NCT03014635|glabellar lines, frown lines
6647|NCT03014622|glabellar lines, frown lines
6648|NCT03014609|chronic obstructive pulmonary disease
6649|NCT03014609|cardiovascular risk
6650|NCT03014609|inflammation
6651|NCT03014609|oxidative stress
6652|NCT03014609|peripheral muscle function
6653|NCT03014570|behavior,
6654|NCT03014570|apathy
6655|NCT03014570|mood
6656|NCT03014570|function
6657|NCT03014570|cognition
6658|NCT03014557|atrial fibrillation
6659|NCT03014557|left atrial appendage closure
6660|NCT03014557|WATCHMAN
6661|NCT03014518|Adolescent
6662|NCT03014518|Biological Markers
6663|NCT03014518|Biomarkers
6664|NCT03014518|Biomarkers for suicidality
6665|NCT03014518|Blood brain barrier
6666|NCT03014518|Clinical predictors
6667|NCT03014518|Cytokine
6668|NCT03014518|Feeling suicidal
6669|NCT03014518|Inflammation
6670|NCT03014518|Inflammatory marker
6671|NCT03014518|Inpatient discharge
6672|NCT03014518|Interleukin-1 beta
6673|NCT03014518|IL-1ß
6674|NCT03014518|Interleukin-6
6675|NCT03014518|IL-6
6676|NCT03014518|Kynurenic acid
6677|NCT03014518|Kynurenine pathway
6678|NCT03014518|Neuroinflammation
6679|NCT03014518|Novel marker
6680|NCT03014518|Peripheral blood biomarkers
6681|NCT03014518|Picolinic acid
6682|NCT03014518|Plasma biomarker
6683|NCT03014518|Psychiatric inpatient
6684|NCT03014518|S100B
6685|NCT03014518|Serum biomarker
6686|NCT03014518|Stress
6687|NCT03014518|Suicide
6688|NCT03014518|Suicidal behavior
6689|NCT03014518|Suicidal risk
6690|NCT03014518|Tumor necrosis factor alpha
6691|NCT03014518|TNF-α
6692|NCT03014505|Cirrhosis
6693|NCT03014505|Fecal Microbiota Transplantation
6694|NCT03014505|Intestinal flora
6695|NCT03014505|Intestinal mucosal barrier
6696|NCT03014505|Intestinal Bacteria Flora Disturbance
6697|NCT03014401|stem cell
6698|NCT03014401|knee pain
6699|NCT03014401|osteoarthritis
6700|NCT03014401|arthritis
6701|NCT03014401|ADSC
6702|NCT03014401|fat stem cell
6703|NCT03014349|Glaucoma
6704|NCT03014349|Ocular hypertension
6705|NCT03014336|co2 removal, anesthesia
6706|NCT03014323|insulin sensitivity
6707|NCT03014323|African American
6708|NCT03014323|obese
6709|NCT03014310|A/H5N8
6710|NCT03014310|Adjuvants
6711|NCT03014310|AS03
6712|NCT03014310|Inactivated
6713|NCT03014310|Influenza
6714|NCT03014310|MF59
6715|NCT03014310|Monovalent
6716|NCT03014284|Tissue collection
6717|NCT03014284|colonoscopic surgical procedures
6718|NCT03014258|Biology
6719|NCT03014258|falciparum
6720|NCT03014258|Immunity
6721|NCT03014258|Infections
6722|NCT03014258|Malaria
6723|NCT03014258|Pf
6724|NCT03014258|Plasmodium
6725|NCT03014258|Systems
6726|NCT03014232|sustained low-efficiency diafiltration (SLED-f)
6727|NCT03014232|high cut-off dialyzer
6728|NCT03014232|cytokines
6729|NCT03014180|Heart failure, CRT
6730|NCT03014167|transmission interruption
6731|NCT03014167|intestinal nematodes
6732|NCT03014167|soil-transmitted helminths
6733|NCT03014167|mass drug administration
6734|NCT03014167|Benin
6735|NCT03014167|India
6736|NCT03014167|Malawi
6737|NCT03014154|video games
6738|NCT03014154|asthma
6739|NCT03014154|physical exercise
6740|NCT03014128|musculoskeletal disorders
6741|NCT03014128|upper extremity
6742|NCT03014128|work
6743|NCT03014128|surgical instruments
6744|NCT03014115|arachidonic
6745|NCT03014115|docosahexaenoic acid
6746|NCT03014115|infant formula
6747|NCT03014089|mRNA-1325
6748|NCT03014089|Zika vaccine
6749|NCT03014063|sepsis
6750|NCT03014063|septic shock
6751|NCT03014063|vasopressin
6752|NCT03014063|AVP
6753|NCT03014050|physical activity
6754|NCT03014050|fitness
6755|NCT03014050|cognition
6756|NCT03014050|mood
6757|NCT03014050|depression
6758|NCT03014050|anxiety
6759|NCT03014050|sleep quality
6760|NCT03014050|tremor
6761|NCT03014050|gait
6762|NCT03014037|Orthopedics
6763|NCT03014024|Distal Radius Fracture
6764|NCT03014024|Low Level Laser Therapy
6765|NCT03013985|Blood glucose
6766|NCT03013972|ColoRectal Cancer
6767|NCT03013972|Adjuvant Chemotherapy
6768|NCT03013972|Cancer-related Fatigue
6769|NCT03013972|Brief fatigue inventory (BFI)
6770|NCT03013972|Functional Assessment of Cancer Therapy-General 7 (FACT-G7)
6771|NCT03013920|upper urinary tract cancer
6772|NCT03013920|confocal laser endomicroscopy
6773|NCT03013920|urothelial carcinoma
6774|NCT03013907|Hypertension
6775|NCT03013907|Coping
6776|NCT03013907|Relaxing
6777|NCT03013894|bladder neoplasm
6778|NCT03013894|urothelium carcinoma
6779|NCT03013894|confocal laser endomicroscopy
6780|NCT03013881|UB-921
6781|NCT03013881|anti-HER2 monoclonal antibody
6782|NCT03013881|breast neoplasm
6783|NCT03013881|breast cancer
6784|NCT03013881|Herceptin
6785|NCT03013881|Trastuzumab
6786|NCT03013881|HER2
6787|NCT03013842|pregnancy
6788|NCT03013842|fetal monitoring
6789|NCT03013842|fetal oximetry
6790|NCT03013842|fetal heart rate
6791|NCT03013842|pulse oximetry
6792|NCT03013842|near infrared spectroscopy
6793|NCT03013829|Kidney Paired Donation
6794|NCT03013777|Familial dysautonomia
6795|NCT03013699|diet
6796|NCT03013699|nutrition
6797|NCT03013699|survival
6798|NCT03013699|recurrence
6799|NCT03013699|cruciferous
6800|NCT03013699|dark leafy greens
6801|NCT03013673|leishmaniasis, visceral, neglected, HIV, co-infection, asymptomatic, Ethiopia
6802|NCT03013647|actinic keratosis
6803|NCT03013647|field cancerization
6804|NCT03013647|photodynamic therapy
6805|NCT03013647|daylight photodynamic therapy
6806|NCT03013634|dexmedetomidine
6807|NCT03013621|Renal Failure
6808|NCT03013621|Renal Insufficiency
6809|NCT03013621|Acute Renal Failure
6810|NCT03013621|Acute Renal Injury
6811|NCT03013621|Kidney Failure
6812|NCT03013621|Kidney Insufficiency
6813|NCT03013621|Acute Kidney Failure
6814|NCT03013621|Acute Kidney Injury
6815|NCT03013621|Ventricular dysfunction
6816|NCT03013621|Venous congestion
6817|NCT03013621|Renal function
6818|NCT03013621|Kidney function
6819|NCT03013621|Venous heart failure
6820|NCT03013608|Nail bed injury
6821|NCT03013608|Nail bed injuries
6822|NCT03013608|Nail
6823|NCT03013608|Children
6824|NCT03013608|Fingertip injury
6825|NCT03013595|Mental health
6826|NCT03013595|Youth mental health
6827|NCT03013595|Adolescent
6828|NCT03013595|Health services
6829|NCT03013595|Transition
6830|NCT03013595|Longitudinal cohort study
6831|NCT03013595|Cluster randomised controlled trial
6832|NCT03013595|Young adult
6833|NCT03013556|HBeAg positive
6834|NCT03013543|POMC deficiency obesity
6835|NCT03013543|LepR deficiency obesity
6836|NCT03013543|Bardet-Biedl syndrome
6837|NCT03013543|Alström Syndrome
6838|NCT03013530|Intensive care unit
6839|NCT03013530|Triage and Therapy.
6840|NCT03013530|Advance Directives (AD).
6841|NCT03013530|Simulation model of real situations. (hypothetical scenario)
6842|NCT03013530|Intensivist physician.
6843|NCT03013517|Allergy
6844|NCT03013517|food allergy
6845|NCT03013517|viaskin
6846|NCT03013517|peanut
6847|NCT03013517|epicutaneous
6848|NCT03013504|randomized
6849|NCT03013504|double-blind
6850|NCT03013504|parallel group
6851|NCT03013504|equivalence
6852|NCT03013504|multicentre
6853|NCT03013504|phase III
6854|NCT03013504|efficacy
6855|NCT03013504|safety
6856|NCT03013504|pharmacokinetics
6857|NCT03013504|HD201
6858|NCT03013504|docetaxel
6859|NCT03013504|Herceptin
6860|NCT03013504|HER2 positive
6861|NCT03013504|metastatic breast cancer
6862|NCT03013504|breast cancer
6863|NCT03013491|cancer
6864|NCT03013491|checkpoint inhibitor
6865|NCT03013491|monotherapy
6866|NCT03013491|combination
6867|NCT03013491|PD-L1
6868|NCT03013491|CTLA-4
6869|NCT03013491|solid tumor
6870|NCT03013491|lymphoma
6871|NCT03013491|BRAF
6872|NCT03013374|protein accretion
6873|NCT03013374|body composition
6874|NCT03013361|ropivacaine, bupivacaine
6875|NCT03013335|Clear-cell
6876|NCT03013335|Nivolumab
6877|NCT03013335|Renal cell carcinoma
6878|NCT03013335|Immunotherapy
6879|NCT03013309|Hybrid
6880|NCT03013309|Implementation
6881|NCT03013309|Effectiveness
6882|NCT03013309|Parent training
6883|NCT03013309|Fidelity
6884|NCT03013309|Cost-Effectiveness
6885|NCT03013309|Primary Care
6886|NCT03013296|GIP
6887|NCT03013296|GIP receptor antagonist
6888|NCT03013270|Rehabilitation
6889|NCT03013270|Exercise
6890|NCT03013270|Training
6891|NCT03013257|Relapsed Graves' disease
6892|NCT03013257|High Intensity Focused Ultrasound
6893|NCT03013257|RAI
6894|NCT03013244|prevention
6895|NCT03013244|eating disorder
6896|NCT03013244|men
6897|NCT03013244|intervention
6898|NCT03013244|muscle dysmorphia
6899|NCT03013244|peer-led
6900|NCT03013231|ACL Reconstruction
6901|NCT03013231|Return to Sport
6902|NCT03013231|Resilience
6903|NCT03013218|Neoplasms
6904|NCT03013218|CD47
6905|NCT03013218|SIRPα
6906|NCT03013218|ALX148
6907|NCT03013205|adhesive capsulitis
6908|NCT03013153|Rectal Cancer
6909|NCT03013153|Inferior Mesenteric Artery
6910|NCT03013153|Ligation
6911|NCT03013153|Apical Lymph Nodes
6912|NCT03013153|Laparoscopy
6913|NCT03013153|IMA Types
6914|NCT03013140|Anesthesia, Obstetric
6915|NCT03013140|fluid therapy
6916|NCT03013140|cesarean section
6917|NCT03013140|spinal anesthesia
6918|NCT03013127|Osteogenic Sarcoma
6919|NCT03013127|Osteosarcoma
6920|NCT03013127|Sarcoma, Osteogenic
6921|NCT03013127|Pembrolizumab
6922|NCT03013127|Immunotherapy
6923|NCT03013114|Bortezomib Immune thrombocytopenia
6924|NCT03013101|anti-PD-1 monoclonal antibody
6925|NCT03013101|advanced
6926|NCT03013101|metastatic
6927|NCT03013101|melanoma
6928|NCT03013088|Chronic
6929|NCT03013088|Occlusion
6930|NCT03013088|CTO
6931|NCT03013023|Behavioral and Transaction Interventions
6932|NCT03013023|Parents' Biopsychosocial Well-being
6933|NCT03013023|Preterm Infants
6934|NCT03013023|Sleep
6935|NCT03013023|Salivary cortisol
6936|NCT03013010|Randomized
6937|NCT03013010|Open Label
6938|NCT03013010|Multicenter
6939|NCT03012984|elderly
6940|NCT03012984|surgery
6941|NCT03012984|analgesia
6942|NCT03012984|dexmedetomidine
6943|NCT03012984|delirium
6944|NCT03012971|Elderly
6945|NCT03012971|Surgery
6946|NCT03012971|Analgesia
6947|NCT03012971|Dexmedetomidine
6948|NCT03012971|Long-term outcome
6949|NCT03012945|Elderly
6950|NCT03012945|Cancer surgery
6951|NCT03012945|Epidural anesthesia and analgesia
6952|NCT03012945|Long-term survival
6953|NCT03012945|Quality of life
6954|NCT03012919|active decision support system
6955|NCT03012919|goal directed therapy
6956|NCT03012919|Lidco
6957|NCT03012919|vascular surgery
6958|NCT03012919|hemodynamic optimization
6959|NCT03012893|ultrasonography to identify C7 spinous process
6960|NCT03012867|criticall illness
6961|NCT03012867|enteral nutrition
6962|NCT03012854|Esophageal achalasia
6963|NCT03012854|Peroral endoscopic myotomy
6964|NCT03012854|POEM
6965|NCT03012815|gabapentin
6966|NCT03012815|Alcohol Withdrawal Syndrome
6967|NCT03012815|benzodiazepine
6968|NCT03012815|symptom-triggered
6969|NCT03012724|TMS
6970|NCT03012724|Deep Transcranial Magnetic Stimulation
6971|NCT03012724|MDD
6972|NCT03012724|Major Depressive Disorder
6973|NCT03012659|contraceptive counseling
6974|NCT03012659|cluster randomized trial
6975|NCT03012659|provider counseling training
6976|NCT03012646|Treprostinil
6977|NCT03012646|PH
6978|NCT03012646|COPD
6979|NCT03012646|6 Minute Walk Test
6980|NCT03012633|hyperfibrinolysis, Lysis Timer
6981|NCT03012607|PrEP
6982|NCT03012594|Small bowel motility disorder
6983|NCT03012594|Slow intestinal motility
6984|NCT03012594|Small bowel bacterial overgrowth
6985|NCT03012555|Sickle Cell Disease
6986|NCT03012555|Vitamin D
6987|NCT03012529|Rifampin
6988|NCT03012529|Double-blind
6989|NCT03012529|Clinical Trial
6990|NCT03012529|Veterans
6991|NCT03012529|Diabetes
6992|NCT03012516|Physical Therapy Specialty
6993|NCT03012516|Exercise Test
6994|NCT03012516|Prescriptions
6995|NCT03012516|Counseling
6996|NCT03012516|Primary Health Care
6997|NCT03012516|Exercise
6998|NCT03012490|Remote monitoring
6999|NCT03012477|Triple-negative metastatic breast cancer
7000|NCT03012451|Stress
7001|NCT03012451|Insecurity
7002|NCT03012451|Mental Health
7003|NCT03012438|Near infrared fluorescence
7004|NCT03012438|ICG
7005|NCT03012438|Parathyroid gland
7006|NCT03012425|Cognitive Behavioral Therapy
7007|NCT03012425|Acupuncture
7008|NCT03012425|17-001
7009|NCT03012399|Malignant Neoplasm of Breast
7010|NCT03012399|Breast Cancer
7011|NCT03012399|Hypnosedation
7012|NCT03012399|Hypnotherapist
7013|NCT03012399|Questionnaires
7014|NCT03012399|Surveys
7015|NCT03012386|CD36
7016|NCT03012386|Endothelial dysfunction
7017|NCT03012386|African Americans
7018|NCT03012373|methadone
7019|NCT03012373|heroin
7020|NCT03012373|acupuncture
7021|NCT03012360|Infectiology
7022|NCT03012360|Biology of infectious agents
7023|NCT03012360|Hygiene
7024|NCT03012360|Pneumology
7025|NCT03012360|Critical Care
7026|NCT03012295|Genetic Testing
7027|NCT03012295|Chinese Population
7028|NCT03012256|Cardio-Respiratory Disease Management
7029|NCT03012256|Chronic Disease Management
7030|NCT03012256|Cluster-randomized Trial
7031|NCT03012256|Multi-component Intervention
7032|NCT03012256|DIVERT Scale
7033|NCT03012256|Frail Elderly
7034|NCT03012256|Interprofessional Care
7035|NCT03012256|Pragmatic Trial
7036|NCT03012256|Targeted Intervention
7037|NCT03012256|Home Care
7038|NCT03012204|Cerebrovascular Disease
7039|NCT03012204|Repetitive Transcranial Magnetic Stimulation
7040|NCT03012178|Mitral Regurgitation
7041|NCT03012178|Mitral valve Surgery
7042|NCT03012178|MRI
7043|NCT03012165|ADX-102
7044|NCT03012165|Allergic Conjunctivitis
7045|NCT03012152|Oncoplastic surgery
7046|NCT03012152|Standard conservative surgery
7047|NCT03012152|Patient satisfaction
7048|NCT03012152|Margin Status
7049|NCT03012113|Adipose tissue
7050|NCT03012113|Type 2 Diabetes
7051|NCT03012061|Respiratory
7052|NCT03012061|Efficacy
7053|NCT03012061|Umeclidinium bromide
7054|NCT03012061|Parallel
7055|NCT03012061|Asthma
7056|NCT03012061|Dry powder inhaler
7057|NCT03012048|water treatment
7058|NCT03012035|psychotherapy
7059|NCT03012035|exposition
7060|NCT03012035|spider fear
7061|NCT03012035|expectation
7062|NCT03012022|Healthy Volunteers
7063|NCT03012022|Congestive Heart Failure
7064|NCT03012022|Cardiomyopathies
7065|NCT03012022|Heart Failure
7066|NCT03012022|Risk Factors
7067|NCT03012009|Bowen's Disease
7068|NCT03012009|Superficial Basal Cel Carcinoma
7069|NCT03012009|Non melanoma skin cancer
7070|NCT03012009|Photodynamic therapy
7071|NCT03012009|PDT
7072|NCT03012009|CO2 laser
7073|NCT03012009|Laser assisted drug delivery
7074|NCT03012009|Carbon dioxide laser
7075|NCT03012009|Laser assisted photodynamic therapy
7076|NCT03011983|Magnetoencephalography (MEG)
7077|NCT03011983|Magnetic resonance imaging (MRI)
7078|NCT03011892|Atopic dermatitis
7079|NCT03011892|eczema
7080|NCT03011892|pruritus
7081|NCT03011892|Janus kinase (JAK) inhibitors
7082|NCT03011840|Patient education handout
7083|NCT03011840|Patient satisfaction
7084|NCT03011775|Pioglitazone, Insulin Resistance
7085|NCT03011775|Atherosclerosis, Coronary Heart Disease
7086|NCT03011749|Radium-223 therapy
7087|NCT03011710|e-cigarette
7088|NCT03011710|blood flow
7089|NCT03011710|oral effects
7090|NCT03011710|oral pH
7091|NCT03011684|Fertility Preservation
7092|NCT03011684|Breast Cancer
7093|NCT03011671|Malignant Glioma of Brain
7094|NCT03011671|Acetazolamide
7095|NCT03011671|Temozolomide
7096|NCT03011619|Depression
7097|NCT03011619|Cognitive Behavioral Therapy (CBT)
7098|NCT03011606|prostate
7099|NCT03011606|ablation
7100|NCT03011606|focal
7101|NCT03011606|cancer
7102|NCT03011580|Vitamin D
7103|NCT03011567|Postpartum
7104|NCT03011541|Stem Cells
7105|NCT03011541|Bone Marrow Derived Stem Cells
7106|NCT03011541|BMSC
7107|NCT03011541|Mesenchymal Stem Cells
7108|NCT03011541|MSC
7109|NCT03011541|Eye Disease
7110|NCT03011541|Ophthalmology
7111|NCT03011541|Ophthalmic Disease
7112|NCT03011541|Retina
7113|NCT03011541|Retinal Disease
7114|NCT03011541|Macular Degeneration
7115|NCT03011541|Age Related Macular Degeneration
7116|NCT03011541|Myopic Macular Degeneration
7117|NCT03011541|Geographic Atrophy
7118|NCT03011541|Dry Macular Degeneration
7119|NCT03011541|Wet Macular Degeneration
7120|NCT03011541|Retinal Atrophy
7121|NCT03011541|Retinal Dystrophy
7122|NCT03011541|Hereditary Retinal Dystrophy
7123|NCT03011541|Malattia Leventinese
7124|NCT03011541|Retinitis Pigmentosa
7125|NCT03011541|Stargardt Disease
7126|NCT03011541|Cone Dystrophy
7127|NCT03011541|Rod-Cone Dystrophy
7128|NCT03011541|Cone-Rod Dystrophy
7129|NCT03011541|Maculopathy
7130|NCT03011541|Optic Nerve Disease
7131|NCT03011541|Optic Atrophy
7132|NCT03011541|Optic Neuropathy
7133|NCT03011541|Ischemic Optic Neuropathy
7134|NCT03011541|Optic Nerve Damage
7135|NCT03011541|Optic Nerve Compression
7136|NCT03011541|Compressive Optic Neuropathy
7137|NCT03011541|Devics Syndrome
7138|NCT03011541|Ushers Syndrome
7139|NCT03011541|Neuromyelitis Optica
7140|NCT03011541|Dominant Optic Atrophy
7141|NCT03011541|Kjers Optic Atrophy
7142|NCT03011541|Leber Hereditary Optic Neuropathy
7143|NCT03011437|linked color imaging
7144|NCT03011437|Helicobacter Pylori
7145|NCT03011424|Liver resection
7146|NCT03011424|post hepatectomy liver failure
7147|NCT03011424|liver dialysis
7148|NCT03011424|encephalopathy
7149|NCT03011424|mortality
7150|NCT03011411|methods, qualitative research
7151|NCT03011372|Myeloid/lymphoid neoplasm
7152|NCT03011372|fibroblast growth factor receptor inhibitor
7153|NCT03011372|FGFR1 rearrangement
7154|NCT03011359|Colon resection
7155|NCT03011359|Patient Controlled Analgesia
7156|NCT03011359|Optimizing Basal Infusion Mode
7157|NCT03011346|Aortic valve stenosis
7158|NCT03011346|Transcatheter aortic valve implantation
7159|NCT03011346|Transcatheter aortic valve replacement
7160|NCT03011346|Randomized controlled trial
7161|NCT03011320|ovarian cancer
7162|NCT03011320|specimen collection
7163|NCT03011268|Tumor Necrosis Factor-alpha/antagonists & inhibitors
7164|NCT03011268|Infliximab
7165|NCT03011268|Adalimumab
7166|NCT03011268|Golimumab
7167|NCT03011268|Recurrence
7168|NCT03011255|Esophageal cancer
7169|NCT03011255|Peptide specific CTL
7170|NCT03011255|Radiation
7171|NCT03011242|Psoriatic Arthritis
7172|NCT03011242|PDUS
7173|NCT03011203|glycogen storage disease type IIIa
7174|NCT03011203|exercise
7175|NCT03011203|ketone esters
7176|NCT03011203|magnetic resonance spectroscopy
7177|NCT03011190|Terapia Iconica
7178|NCT03011190|BPD
7179|NCT03011190|adolescence
7180|NCT03011190|suicide
7181|NCT03011164|Running
7182|NCT03011164|Gait velocity
7183|NCT03011164|Kinematics
7184|NCT03011151|pediatric
7185|NCT03011151|critical illness
7186|NCT03011151|surgery
7187|NCT03011151|gastrointestinal dysfunction
7188|NCT03011151|gastric emptying
7189|NCT03011151|epithelial barrier
7190|NCT03011151|nutrition
7191|NCT03011138|knee
7192|NCT03011138|gait velocity
7193|NCT03011138|kinematic parameters
7194|NCT03011112|Osteoarthritis, Knee
7195|NCT03011112|WOMAC
7196|NCT03011112|gait
7197|NCT03011112|kinematics
7198|NCT03011086|Autoantibodies, Oral Submucous Fibrosis
7199|NCT03011060|neo-adjuvant chemotherapy
7200|NCT03011060|pathological complete response
7201|NCT03011060|Neoadjuvant Therapy
7202|NCT03011060|Capecitabine
7203|NCT03011060|Chemotherapy, Adjuvant
7204|NCT03011047|endoscopic, trans-antral, subciliary
7205|NCT03011021|Autoimmune Diabetes
7206|NCT03011021|Umbilical Cord Blood Regulatory T Lymphocyte
7207|NCT03011021|Liraglutide
7208|NCT03010995|electronic cigarette
7209|NCT03010995|endothelial function
7210|NCT03010969|Endothelial dysfunction
7211|NCT03010969|Surgery
7212|NCT03010969|Pulmonary function
7213|NCT03010969|Blood glucose level
7214|NCT03010969|Patient-related outcomes
7215|NCT03010956|Arterial stiffness
7216|NCT03010956|Endothelial glycocalyx
7217|NCT03010956|Coronary flow reserve
7218|NCT03010943|virtual reality
7219|NCT03010943|glioma surgery
7220|NCT03010943|awake craniotomy
7221|NCT03010943|brain tumor
7222|NCT03010943|glioma
7223|NCT03010943|neurosurgery
7224|NCT03010917|Alcohol Dependence
7225|NCT03010917|Fish Oil
7226|NCT03010891|Preterm infant
7227|NCT03010891|Stress
7228|NCT03010891|Salivary DHEA
7229|NCT03010891|Salivary cortisol
7230|NCT03010891|Actigraphy
7231|NCT03010878|yoga
7232|NCT03010878|chronic pain
7233|NCT03010878|occupational therapy
7234|NCT03010878|self-management
7235|NCT03010865|HDAC inhibitors
7236|NCT03010865|Inflammation
7237|NCT03010852|Bariatric Surgery
7238|NCT03010852|Spirometry Monitoring
7239|NCT03010761|addiction
7240|NCT03010761|betel-quid
7241|NCT03010761|drug therapy
7242|NCT03010761|clinical trial
7243|NCT03010748|corneal morphology
7244|NCT03010748|Chinese population
7245|NCT03010748|corneal curvature
7246|NCT03010748|corneal thickness
7247|NCT03010748|higher order aberrations
7248|NCT03010735|Kidney Failure, Chronic
7249|NCT03010735|Probiotics
7250|NCT03010735|Uremic toxins
7251|NCT03010735|Gastrointestinal Microbiome
7252|NCT03010709|Aneurysmal Subarachnoid Haemorrhage
7253|NCT03010709|Delayed Ischaemic Neurological Deficit
7254|NCT03010709|Induced Hypertension
7255|NCT03010709|Partial Brain Tissue Oxygen Tension
7256|NCT03010709|Cerebral Microdialysis
7257|NCT03010696|Kidney Failure, Chronic
7258|NCT03010696|Uremic toxins
7259|NCT03010696|Gastrointestinal Microbiome
7260|NCT03010696|Metabolomics
7261|NCT03010683|Arterial stiffness
7262|NCT03010683|Endothelial glycocalyx
7263|NCT03010683|Coronary flow reserve
7264|NCT03010670|Oxytocin
7265|NCT03010670|Gaze processing
7266|NCT03010670|Interpersonal motor resonance
7267|NCT03010618|hall technique
7268|NCT03010618|stainless steel crowns
7269|NCT03010618|temporomandibular joint
7270|NCT03010618|dental caries
7271|NCT03010618|occlusion
7272|NCT03010605|physical therapy post total knee replacement
7273|NCT03010605|range of motion
7274|NCT03010605|goniometry
7275|NCT03010592|Lung volume reduction treatment
7276|NCT03010592|Endobronchial cryotherapy
7277|NCT03010592|Microvesicles
7278|NCT03010579|Anemia
7279|NCT03010579|Lymphoma
7280|NCT03010579|Hematopoietic stem cell transplantation
7281|NCT03010579|Erythropoietin
7282|NCT03010566|Lung volume reduction coil
7283|NCT03010566|Lung Microbiome
7284|NCT03010527|Chronic plaque psoriasis
7285|NCT03010527|Psoriasis
7286|NCT03010527|Bimekizumab
7287|NCT03010488|Chronotherapy
7288|NCT03010488|Light Therapy
7289|NCT03010449|Lung volume reduction treatment
7290|NCT03010449|Autologous blood instillation
7291|NCT03010449|Intra-bronchial valve (IBV)
7292|NCT03010449|Endobronchial valve
7293|NCT03010423|Non-obstructive coronary artery disease
7294|NCT03010423|Nicorandil
7295|NCT03010371|positive psychotherapy, online, breast cancer, survivors
7296|NCT03010332|Cytomegalovirus
7297|NCT03010332|Cytomegalovirus Viremia
7298|NCT03010332|Cytomegalovirus Infection
7299|NCT03010332|CMV Infection
7300|NCT03010332|Hematopoietic Cell Transplant
7301|NCT03010332|Solid Organ Transplant
7302|NCT03010332|Human Immunodeficiency Virus
7303|NCT03010332|Cytomegalovirus Disease
7304|NCT03010332|Hematopoietic Stem Cell Transplant
7305|NCT03010332|CMV
7306|NCT03010332|CMV syndrome
7307|NCT03010332|Cytomegalovirus syndrome
7308|NCT03010332|CMV disease
7309|NCT03010332|CMV viremia
7310|NCT03010332|allogeneic
7311|NCT03010332|third-party
7312|NCT03010293|Antimicrobial therapy
7313|NCT03010293|Debridement
7314|NCT03010293|Osteomyelitis
7315|NCT03010293|Muscular flap
7316|NCT03010293|Pressure ulcer
7317|NCT03010293|Treatment failure
7318|NCT03010293|Vacuum-assisted closure therapy
7319|NCT03010267|DP-R213
7320|NCT03009214|solid epithelial cancer
7321|NCT03009214|CD44v6
7322|NCT03009214|c-Met
7323|NCT03009214|VEGFR-2
7324|NCT03009214|RON
7325|NCT03009214|receptor tyrosine kinase
7326|NCT03009188|Axenfeld-Rieger syndrom, genetic findings
7327|NCT03009136|Perennial Allergic Rhinitis
7328|NCT03009136|Herbal Medicine
7329|NCT03009136|Korean Medicine
7330|NCT03009136|So-Cheong-Ryong-Tang
7331|NCT03009123|cohort study
7332|NCT03009123|prostate cancer
7333|NCT03009123|population-based study
7334|NCT03009123|benign prostatic hypertrophy
7335|NCT03009097|Chronic periodontitis
7336|NCT03009097|atorvastatin
7337|NCT03009097|intrabony defect
7338|NCT03009071|Neck Pain
7339|NCT03009071|Disability Evaluation
7340|NCT03009071|Costs and Cost Analysis
7341|NCT03009071|Doin Exercise Therapy
7342|NCT03009071|Acupuncture
7343|NCT03009058|Unresectable cancer
7344|NCT03009058|pancreatic
7345|NCT03009058|melanoma
7346|NCT03009058|breast
7347|NCT03009058|lung
7348|NCT03009058|colorectal
7349|NCT03009058|cholangio
7350|NCT03009058|sarcoma
7351|NCT03010241|Diabetes Distal Symmetric Polyneuropathy
7352|NCT03010241|Chinese medicine
7353|NCT03010228|VLA15
7354|NCT03010228|Lyme Borreliosis
7355|NCT03010228|Multivalent Recombinant OspA Vaccine
7356|NCT03010215|Minimally Invasive Surgery
7357|NCT03010215|Percutaneous distal osteotomy
7358|NCT03010215|Distal Metatarsal Minimally-invasive Osteotomy (DMMO)
7359|NCT03010215|Percutaneous Tenotomy
7360|NCT03010215|Forefoot
7361|NCT03010215|Metatarsal bones
7362|NCT03010202|immune thrombocytopenia
7363|NCT03010202|rituximab
7364|NCT03010202|thrombocytopenia
7365|NCT03010189|Cluster headache
7366|NCT03010189|Actigraphy
7367|NCT03010189|Pupillometry
7368|NCT03010163|pedometer
7369|NCT03010163|walking
7370|NCT03010163|taxi driver
7371|NCT03010163|16-1659
7372|NCT03010150|Malignant neoplasms of lip oral cavity and pharynx
7373|NCT03010150|Head and Neck Cancer
7374|NCT03010150|Nasopharyngeal cancer
7375|NCT03010150|Oropharyngeal cancer
7376|NCT03010150|Hypopharyngeal cancer
7377|NCT03010150|Laryngeal cancer
7378|NCT03010150|Unknown primary cancer with cervical metastases
7379|NCT03010150|Questionnaire
7380|NCT03010150|Survey
7381|NCT03010150|Blood draw
7382|NCT03010150|Cytokines
7383|NCT03010111|Latent Tuberculosis
7384|NCT03010111|Interferons
7385|NCT03010111|Tuberculosis
7386|NCT03010111|Healthcare
7387|NCT03010098|POCD
7388|NCT03010098|narcotrend
7389|NCT03010098|closed-loop of target controlled infusion
7390|NCT03010033|pulmonary rehabilitation
7391|NCT03010033|lobectomy
7392|NCT03010033|smoker
7393|NCT03010020|HIV Prevention
7394|NCT03010020|MSM
7395|NCT03010020|Rectal Gonorrhea
7396|NCT03010020|Rectal Chlamydia
7397|NCT03010020|Personalized Cognitive Counseling
7398|NCT03010007|Influenza
7399|NCT03010007|High-Throughput Nucleotide Sequencing
7400|NCT03010007|Viral Transmission
7401|NCT03009981|PSA
7402|NCT03009981|Degarelix
7403|NCT03009981|Apalutamide
7404|NCT03009981|Abiraterone Acetate
7405|NCT03009981|Radical Prostatectomy
7406|NCT03009942|nitric oxide
7407|NCT03009942|arginase
7408|NCT03009942|loading
7409|NCT03009890|elderly
7410|NCT03009890|intra articular
7411|NCT03009890|RCT
7412|NCT03009864|Diabetic Kidney Disease
7413|NCT03009864|TCM
7414|NCT03009864|RCT
7415|NCT03009825|Trauma exposure
7416|NCT03009825|Psychological distress
7417|NCT03009825|Emotion regulation
7418|NCT03009825|Mindfulness
7419|NCT03009825|Eating pathology
7420|NCT03009799|adenoviral conjunctivis
7421|NCT03009799|iota-carrageenan
7422|NCT03009773|subacute stroke
7423|NCT03009773|multitasking rehabilitation
7424|NCT03009773|walking
7425|NCT03009747|rectal cancer
7426|NCT03009747|anterior resection syndrome
7427|NCT03009747|sphincter-preserving surgery
7428|NCT03009708|Allograft
7429|NCT03009708|Cytomegalovirus
7430|NCT03009708|Platelets
7431|NCT03009708|Hematopoietic stem cells
7432|NCT03009708|Graft Versus Host Disease (GVH)
7433|NCT03009708|Hemostasis
7434|NCT03009708|Adaptive immunity
7435|NCT03009708|Innate immunity
7436|NCT03009708|Post graft follow up
7437|NCT03009695|Transcranial Magnetic Stimulation
7438|NCT03009695|Obesity
7439|NCT03009695|Food Craving
7440|NCT03009695|Appetite/Satiety Hormones
7441|NCT03009695|fMRI
7442|NCT03009695|Intestinal microbiota
7443|NCT03009695|Physical activity
7444|NCT03009669|pleth variability index
7445|NCT03009669|stroke volume variation
7446|NCT03009669|perfusion Index
7447|NCT03009669|intraoperative
7448|NCT03009669|intestinal tumor
7449|NCT03009656|Stroke
7450|NCT03009656|Emergency
7451|NCT03009656|Focal Neurological Deficits
7452|NCT03009656|Diagnostic
7453|NCT03009643|Nitric Oxide
7454|NCT03009643|hypoxemia
7455|NCT03009643|aortic surgery
7456|NCT03009630|Electromagnetic navigation bronchoscopy(ENB)
7457|NCT03009630|Radiofrequency ablation(RFA)
7458|NCT03009630|Peripheral lung cancer
7459|NCT03009617|adolescents
7460|NCT03009617|web-based health education
7461|NCT03009617|eHealth literacy
7462|NCT03009591|Hemophilia
7463|NCT03009591|Elbow
7464|NCT03009591|Arthropathy
7465|NCT03009591|Joint pain
7466|NCT03009591|Range of motion
7467|NCT03009591|Myofascial techniques
7468|NCT03009591|Safety patients
7469|NCT03009591|Quality of life
7470|NCT03009591|Functionality
7471|NCT03009565|coronary artery disease
7472|NCT03009565|human gut microbiota
7473|NCT03009565|microbiome
7474|NCT03009552|speckle tracking echocardiography
7475|NCT03009552|strain
7476|NCT03009552|strain rate
7477|NCT03009552|torsion
7478|NCT03009539|Prevention with Hispanic youth
7479|NCT03009539|eHealth preventive intervention in primary care
7480|NCT03009539|Hispanic adolescent
7481|NCT03009539|Familias Unidas
7482|NCT03009539|eHealth Familias Unidas
7483|NCT03009539|effectiveness trial
7484|NCT03009539|sexually transmitted disease
7485|NCT03009539|parent-centered
7486|NCT03009539|Hispanic
7487|NCT03009539|sexual risk behavior
7488|NCT03009526|Malaria
7489|NCT03009526|Pregnancy
7490|NCT03009526|Malawi
7491|NCT03009526|Intermittent preventive treatment
7492|NCT03009526|dihydroartemisinin-piperaquine
7493|NCT03009526|sulfadoxine-pyrimethamine
7494|NCT03009461|Hepatocellular carcinoma
7495|NCT03009461|Portal vein tumor thrombosis
7496|NCT03009461|Hepatic arterial infusion chemotherapy
7497|NCT03009461|Sorafenib
7498|NCT03009396|Crohn's Disease,
7499|NCT03009396|moderate to severe
7500|NCT03009396|remission
7501|NCT03009396|Mycobacterium avium paratuberculosis
7502|NCT03009396|antibiotic
7503|NCT03009370|Ovarian reserve, pregnancy loss
7504|NCT03009357|wearable activity tracker
7505|NCT03009357|thyrotoxicosis
7506|NCT03009344|relapsed or refractory B-cell non-Hodgkin's lymphoma
7507|NCT03009344|tazemetostat
7508|NCT03009344|Japan
7509|NCT03009331|Postoperative pulmonary dysfunction
7510|NCT03009331|Postoperative pulmonary complication
7511|NCT03009331|Recruitment manouver
7512|NCT03009331|Prone position
7513|NCT03009318|Glioma
7514|NCT03009318|Magnetic resonance spectroscopy
7515|NCT03009318|Methionine
7516|NCT03009318|PET/CT
7517|NCT03009292|solid tumor
7518|NCT03009292|Lenvatinib
7519|NCT03009292|pharmacokinetics
7520|NCT03009279|blood pressure
7521|NCT03009279|fasting plasma glucose
7522|NCT03009279|thyroid stimulating hormone
7523|NCT03009253|Neoadjuvant therapy
7524|NCT03009253|Pancreatic Cancer
7525|NCT03009227|colon cancer
7526|NCT03009227|lymph node dissection
7527|NCT03009227|D3 lymph node dissection
7528|NCT03009045|bone and joint infection
7529|NCT03009045|osteomyelitis
7530|NCT03009045|tedizolid
7531|NCT03009032|HIV
7532|NCT03009032|immunologic recovery
7533|NCT03009032|microbiota
7534|NCT03009032|prebiotics
7535|NCT03009032|probiotics
7536|NCT03009032|synbiotics
7537|NCT03009006|Calcium hydroxide intracanal medication
7538|NCT03009006|Ca(OH)2 intracanal medication
7539|NCT03009006|Chlorhexidene gel
7540|NCT03009006|CHX gel
7541|NCT03009006|Root canal treatment
7542|NCT03008967|Total Knee Arthroplasty
7543|NCT03008967|Total Hip Arthroplasty
7544|NCT03008967|Rehabilitation
7545|NCT03008941|HIV
7546|NCT03008941|microbiota
7547|NCT03008941|inflammation
7548|NCT03008941|fecal microbiota restoration
7549|NCT03008915|alpha-1 antitrypsin deficiency
7550|NCT03008915|Emphysema
7551|NCT03008915|chronic obstructive pulmonary disease
7552|NCT03008889|Repetitive Self-Injurious Behavior
7553|NCT03008889|N-acetylcysteine (NAC)
7554|NCT03008876|neonate
7555|NCT03008876|acetaminophen
7556|NCT03008850|Shivering
7557|NCT03008850|Intrathecal
7558|NCT03008850|Magnesium Sulfate
7559|NCT03008811|Atrial Fibrillation
7560|NCT03008811|Catheter Ablation
7561|NCT03008798|Intracranial Artery
7562|NCT03008798|in-stent restenosis
7563|NCT03008798|Herbal Medicine
7564|NCT03008785|isoflavone
7565|NCT03008785|blood pressure
7566|NCT03008785|climateric symptoms
7567|NCT03008785|exercise
7568|NCT03008759|Fluoride
7569|NCT03008759|Dental caries
7570|NCT03008759|Dentifrice
7571|NCT03008720|functional electrical simulation
7572|NCT03008707|Laparoscopic peritoneal lavage
7573|NCT03008707|laparoscopic sigmoidectomy
7574|NCT03008707|complicated acute diverticulitis
7575|NCT03008707|D004238
7576|NCT03008694|PET/CT
7577|NCT03008642|Polycythemia
7578|NCT03008642|CO-Rebreathing
7579|NCT03008642|red cell mass determination
7580|NCT03008642|myeloproliferative neoplasms
7581|NCT03008603|CT-guided minimally invasive procedures
7582|NCT03008603|Robot
7583|NCT03008590|Pain management
7584|NCT03008590|Naltrexone
7585|NCT03008590|Controlled clinical trials, randomized
7586|NCT03008512|Liver Neoplasms
7587|NCT03008512|Antineoplastic Agents
7588|NCT03008512|Carcinoma, Hepatocellular
7589|NCT03008512|Genexol-PM
7590|NCT03008512|Neoplasms by Site
7591|NCT03008512|Sorafenib
7592|NCT03008512|Liver Diseases
7593|NCT03008512|Digestive System Neoplasms
7594|NCT03008499|Metastatic colorectal cancer
7595|NCT03008499|High-activity natural killer
7596|NCT03008447|E2006
7597|NCT03008447|postural stability
7598|NCT03008447|auditory awakening threshold
7599|NCT03008447|cognitive performance
7600|NCT03008447|healthy participants
7601|NCT03008434|yoga
7602|NCT03008434|Traumatic Brain Injury
7603|NCT03008408|Malignant neoplasms of female genital organs
7604|NCT03008408|Endometrial carcinoma
7605|NCT03008408|Advanced or Recurrent
7606|NCT03008408|Endometrioid and mixed endometrioid tumors
7607|NCT03008408|Ribociclib
7608|NCT03008408|LEE011
7609|NCT03008408|Everolimus
7610|NCT03008408|Afinitor
7611|NCT03008408|Zortress
7612|NCT03008408|RAD001
7613|NCT03008408|Letrozole
7614|NCT03008408|Femara
7615|NCT03008382|Interstitial Cystitis
7616|NCT03008382|Pelvic Pain
7617|NCT03008343|Irreversible Electroporation
7618|NCT03008343|NK Immunotherapy
7619|NCT03008343|Recurrent Liver Carcinoma
7620|NCT03008330|Metastatic tongue cancer
7621|NCT03008330|High-activity natural killer
7622|NCT03008304|Metastatic pancreatic cancer
7623|NCT03008304|High-activity natural killer Immunotherapy
7624|NCT03008265|Fascial dehiscence
7625|NCT03008265|Mortality
7626|NCT03008252|Non-celiac wheat sensitivity
7627|NCT03008252|lactose intolerance
7628|NCT03008252|cow's milk protein allergy
7629|NCT03008187|AML
7630|NCT03008174|tracheostomy
7631|NCT03008174|quality of life
7632|NCT03008174|speaking valve
7633|NCT03008174|speech
7634|NCT03008174|mechanically ventilated patients
7635|NCT03008161|GAIM
7636|NCT03008161|amyloid
7637|NCT03008161|anti-aBeta
7638|NCT03008161|anti-tau
7639|NCT03008122|Flavivirus
7640|NCT03008122|Inactivated
7641|NCT03008122|Phase I
7642|NCT03008122|Vaccine
7643|NCT03008122|ZIKA
7644|NCT03008122|ZPIV
7645|NCT03008109|EGFR-TKI
7646|NCT03008109|Recombinant human endostatin
7647|NCT03008070|Non-Alcoholic Steatohepatitis
7648|NCT03008070|NASH
7649|NCT03008070|peroxisome proliferator-activated receptor (PPAR)
7650|NCT03008070|Liver Diseases
7651|NCT03008070|Fibrosis
7652|NCT03008070|Fatty Liver
7653|NCT03008070|Non-alcoholic Fatty Liver Disease
7654|NCT03008070|Digestive System Diseases
7655|NCT03008070|IVA337
7656|NCT03008057|vitamin D
7657|NCT03008057|YKL40
7658|NCT03008057|PAI-1
7659|NCT03008057|RAGE
7660|NCT03008057|AGEs
7661|NCT03008057|glyoxalase enzyme
7662|NCT03008057|TNF-alpha
7663|NCT03008057|IL-6
7664|NCT03008057|Diabetes
7665|NCT03007992|Breast cancer
7666|NCT03007992|Vinorelbine
7667|NCT03007992|Metronomic chemotherapy
7668|NCT03007953|Palliative Care
7669|NCT03007953|Supportive Care
7670|NCT03007940|Implementation Strategies
7671|NCT03007940|Sustainability
7672|NCT03007940|Integrated Services
7673|NCT03007927|pain
7674|NCT03007927|hernia repair
7675|NCT03007927|Dexamethasone
7676|NCT03007914|Pulmonary Disease, Chronic Obstructive
7677|NCT03007914|Medicine, Chinese Traditional
7678|NCT03007914|Humans
7679|NCT03007914|Treatment Outcome
7680|NCT03007888|IPX203 (carbidopa-levodopa) Extended-Release capsules
7681|NCT03007875|Metastatic lung cancer
7682|NCT03007875|High-activity natural killer
7683|NCT03007836|Metastatic Nasopharyngeal Cancer
7684|NCT03007836|High-activity natural killer
7685|NCT03007823|Metastatic Melanoma
7686|NCT03007823|High-activity natural killer
7687|NCT03007784|Consciousness
7688|NCT03007784|Disorder of consciousness
7689|NCT03007784|Minimally conscious state
7690|NCT03007784|Vegetative state
7691|NCT03007784|Exit-MCS
7692|NCT03007784|Transcranial direct current stimulation (tDCS)
7693|NCT03007784|CRS-R
7694|NCT03007784|EEG
7695|NCT03007784|Cognitive ERPs
7696|NCT03007758|Hernia repair
7697|NCT03007758|Robotic hernia repair
7698|NCT03007758|Open hernia repair
7699|NCT03007758|Incisional hernia
7700|NCT03007745|Continuous positive airway pressure
7701|NCT03007628|magnetic seizure therapy
7702|NCT03007628|electroconvulsive therapy
7703|NCT03007628|controlled trial
7704|NCT03007602|Hematopoietic stem cell transplantation
7705|NCT03007602|Aerobic exercise
7706|NCT03007602|Quality of Life
7707|NCT03007602|Muscle Strength
7708|NCT03007589|erythema
7709|NCT03007589|persistent pigment darkening
7710|NCT03007589|sunburn
7711|NCT03007589|suntan
7712|NCT03007563|Diagnosis
7713|NCT03007563|Cell Phones
7714|NCT03007563|Infant, Newborn
7715|NCT03007550|Gastric cancer
7716|NCT03007550|Laparoscopic total gastrectomy
7717|NCT03007550|Open total gastrectomy
7718|NCT03007537|Erythropoietin
7719|NCT03007537|Cardiac Surgery Associated-acute Kidney Injury
7720|NCT03007524|rosuvastatin
7721|NCT03007524|optical coherence tomography
7722|NCT03007524|acute coronary syndrome
7723|NCT03007511|Percutaneous Endoscopic Gastrostomy
7724|NCT03007511|Feeding tube
7725|NCT03007511|Enteral nutrition
7726|NCT03007511|Endoscopy
7727|NCT03007511|Gastrointestinal
7728|NCT03007459|Body composition
7729|NCT03007459|Bone mineral density
7730|NCT03007459|Binge Eating
7731|NCT03007459|Eating Disorder
7732|NCT03007459|Exercise Dependency
7733|NCT03007459|Depression
7734|NCT03007459|Perfectionism
7735|NCT03007459|Body building
7736|NCT03007459|Drive for Muscularity
7737|NCT03007459|Drive for leanness
7738|NCT03007446|Apatinib
7739|NCT03007446|SOX
7740|NCT03007446|Conversion Surgery
7741|NCT03007446|unresectable gastric cancer
7742|NCT03007433|gastric emptying
7743|NCT03007433|functional dyspepsia
7744|NCT03007433|non invasive imaging
7745|NCT03007433|MRI
7746|NCT03007433|gamma scintigraphy
7747|NCT03007433|gastroparesis
7748|NCT03007407|microsatellite stable
7749|NCT03007407|MSS
7750|NCT03007407|durvalumab
7751|NCT03007407|tremelimumab
7752|NCT03007407|mCRC
7753|NCT03007407|NSABP
7754|NCT03007394|Cocaine Use Disorder
7755|NCT03007342|Amoxicillin
7756|NCT03007342|clavulanic acid
7757|NCT03007342|Periapical periodontitis
7758|NCT03007342|Post-operative pain
7759|NCT03007329|SGLT2 inhibitor
7760|NCT03007329|GLP1 agonist
7761|NCT03007329|type 2 Diabetes
7762|NCT03007329|steatosis of the liver
7763|NCT03007329|ectopic lipids
7764|NCT03007329|combined therapy
7765|NCT03007264|cold atmospheric plasma
7766|NCT03007264|pain
7767|NCT03007264|bacteria
7768|NCT03007264|skin parameters
7769|NCT03007186|Blood glucose monitoring
7770|NCT03007186|Glucose tolerance
7771|NCT03007186|HbA1C
7772|NCT03007186|Insulin
7773|NCT03007186|Betamethasone
7774|NCT03007173|umbilical pilonidal sinus
7775|NCT03007082|endovascular treatment
7776|NCT03007082|mechanical thrombectomy
7777|NCT03007082|stent retriever
7778|NCT03007082|human
7779|NCT03007056|high flow nasal cannula
7780|NCT03007056|nasal continuous positive airway pressure
7781|NCT03007056|noninvasive ventilatory support
7782|NCT03007056|newborn developmental care
7783|NCT03007056|bronchopulmonary dysplasia
7784|NCT03007056|weaning
7785|NCT03007056|pain
7786|NCT03007056|length of stay
7787|NCT03007030|Lung Diseases Due to External Agents
7788|NCT03007030|Mesothelioma
7789|NCT03007030|Unresectable malignant pleural mesothelioma
7790|NCT03007030|MPM
7791|NCT03007030|CD30+
7792|NCT03007030|Brentuximab vedotin
7793|NCT03007030|SGN-35
7794|NCT03007030|Adcetris
7795|NCT03007004|Systemic aclerosis
7796|NCT03007004|digital ulcer
7797|NCT03007004|botulinum toxin
7798|NCT03006991|methotrexate, Juvenile Idiopathic Arthritis
7799|NCT03006965|hemophilia
7800|NCT03006965|Hemophilia A
7801|NCT03006965|Factor VIII
7802|NCT03006965|Advate
7803|NCT03006965|Antithrombotic factor
7804|NCT03006965|Pharmacokinetic dosing
7805|NCT03006965|hemarthrosis
7806|NCT03006965|myPKFiT
7807|NCT03006926|hepatocellular carcinoma
7808|NCT03006926|E7080
7809|NCT03006926|lenvatinib
7810|NCT03006926|pembrolizumab
7811|NCT03006926|Japan
7812|NCT03006913|Genetic counseling modes
7813|NCT03006887|solid tumors
7814|NCT03006887|non-small cell lung cancer
7815|NCT03006887|predominantly clear cell renal cell carcinoma
7816|NCT03006887|endometrial carcinoma
7817|NCT03006887|urothelial carcinoma
7818|NCT03006887|squamous cell carcinoma of the head and neck
7819|NCT03006887|non-uveal melanoma
7820|NCT03006887|E7080
7821|NCT03006887|lenvatinib
7822|NCT03006887|pembrolizumab
7823|NCT03006887|Japan
7824|NCT03006835|Clopidogrel; Platelet Inhibition Ratio
7825|NCT03006822|Myofascial Trigger Points
7826|NCT03006822|Liberation for Pression
7827|NCT03006822|Therapy Soft Tissue
7828|NCT03006809|Ulcerative colitis
7829|NCT03006809|FMT
7830|NCT03006809|fecal transplant
7831|NCT03006796|Obesity
7832|NCT03006705|ONO-4538,BMS-936558,Nivolumab,gastric,adjuvant,S-1,CapeOX
7833|NCT03006614|Breast Cancer Model
7834|NCT03006614|Effects of Chemotherapy
7835|NCT03006614|breast cancer
7836|NCT03006588|FNA,EUS,retropharyngeal lymph node (RPLN),NPC
7837|NCT03006575|Non-small cell lung cancer
7838|NCT03006575|Split-course Chemoradiotherapy
7839|NCT03006575|Locoregional recurrence
7840|NCT03006575|Postoperative recurrence
7841|NCT03006575|Consolidation chemotherapy
7842|NCT03006549|Emergency Manual
7843|NCT03006549|Crisis Checklist
7844|NCT03006523|donor intrauterine insemination
7845|NCT03006523|insemination volume
7846|NCT03006523|Live Birth Rates
7847|NCT03006523|donor sperm
7848|NCT03006510|inpatient diabetes
7849|NCT03006510|hypoglycemia
7850|NCT03006497|neck
7851|NCT03006497|motor control
7852|NCT03006497|motor learning
7853|NCT03006484|Cardiac arrest
7854|NCT03006484|Inhospital Cardiac Arrest
7855|NCT03006484|Cardiopulmonary Resuscitation
7856|NCT03006471|Prediabetes
7857|NCT03006471|Prehypertension
7858|NCT03006471|Variability of blood pressure
7859|NCT03006471|ABPM
7860|NCT03006471|Dapagliflozin
7861|NCT03006471|SGLT2
7862|NCT03006432|OESOPHAGO-GASTRIC CARCINOMA
7863|NCT03006419|kidney transplantation
7864|NCT03006419|induction
7865|NCT03006419|thymoglobulin
7866|NCT03006419|basiliximab
7867|NCT03006419|acute rejection
7868|NCT03006419|graft loss
7869|NCT03006406|endometriosis
7870|NCT03006406|long term GnRH-a
7871|NCT03006393|Neuroscience
7872|NCT03006393|Behavioral
7873|NCT03006393|Social
7874|NCT03006354|high frequency oscillatory ventilation
7875|NCT03006354|newborn
7876|NCT03006354|noninvasive ventilation
7877|NCT03006354|transient tachypnea of the newborn
7878|NCT03006328|weight gain
7879|NCT03006328|weight loss
7880|NCT03006315|multiple myeloma
7881|NCT03006315|garmin vivofit
7882|NCT03006302|pancreatic cancer
7883|NCT03006302|vaccine
7884|NCT03006302|immunotherapy
7885|NCT03006302|MK-3475
7886|NCT03006302|PD-1
7887|NCT03006302|IDO
7888|NCT03006289|Metabolic Syndrome
7889|NCT03006289|fasting plasma glucose
7890|NCT03006263|Stomach Neoplasms
7891|NCT03006263|Totally Laparoscopic Total Gastrectomy
7892|NCT03006263|Laparoscopy Assisted Total Gastrectomy
7893|NCT03006250|Desflurane
7894|NCT03006250|Sevoflurane
7895|NCT03006250|Respiratory Complications
7896|NCT03006224|secondary smoking
7897|NCT03006224|one lung ventilation
7898|NCT03006224|arterial oxygen tension
7899|NCT03006224|lobectomy
7900|NCT03006211|nitrogen protoxide
7901|NCT03006211|oxygen
7902|NCT03006211|corneal endothelial
7903|NCT03006211|pediatric
7904|NCT03006107|Irreversible pulpitis
7905|NCT03006107|Post endodontic pain
7906|NCT03006107|Symptomatic pulpitis pain
7907|NCT03006107|Single visit RCT pain
7908|NCT03006107|Root canal treatment flare up
7909|NCT03006107|Single dose piroxicam
7910|NCT03006107|Intraligamentary piroxicam
7911|NCT03006107|Intraligamentary mepecaine
7912|NCT03006094|questionnaire
7913|NCT03006094|hip
7914|NCT03006094|pain
7915|NCT03006081|Retinal nonperfusion
7916|NCT03006081|Aflibercept
7917|NCT03006068|ABT-494
7918|NCT03006068|Safety
7919|NCT03006068|Open-Label Extension (OLE)
7920|NCT03006068|Efficacy
7921|NCT03006068|Ulcerative Colitis (UC)
7922|NCT03006042|bupivacaine
7923|NCT03006042|local anaesthetics
7924|NCT03006042|cesarean section
7925|NCT03006042|transversus abdominis plane block
7926|NCT03006042|toxicity
7927|NCT03006042|ultrasound guidance
7928|NCT03006042|QTc interval
7929|NCT03006003|Osteoporosis
7930|NCT03006003|Raloxifene
7931|NCT03006003|Central nervous disorders
7932|NCT03005990|Sleep disturbance
7933|NCT03005990|Body composition
7934|NCT03005990|Energy metabolism
7935|NCT03005990|Exercise training
7936|NCT03005990|Community-dwelling elderly
7937|NCT03005977|Urodynamics
7938|NCT03005977|Pyridium pad test
7939|NCT03005977|Cough stress test
7940|NCT03005977|Pelvic organ prolapse
7941|NCT03005938|Cerebral Palsy
7942|NCT03005938|Spinal Manipulation
7943|NCT03005938|Muscle Spasticity
7944|NCT03005938|Manual Dexterity
7945|NCT03005912|Speech Comprehension
7946|NCT03005912|Telephony
7947|NCT03005912|VoIP
7948|NCT03005886|Periodontitis
7949|NCT03005886|Periodontal-systemic disease
7950|NCT03005886|Cardiovascular diseases
7951|NCT03005886|Gingival crevicular fluid
7952|NCT03005886|Acute myocardial infarction
7953|NCT03005886|Neopterin
7954|NCT03005886|Vascular cell adhesion molecule-1
7955|NCT03005873|osteoarthritis of the knee
7956|NCT03005873|TLC599
7957|NCT03005873|Dexamethasone
7958|NCT03005873|DSP
7959|NCT03005834|Atherosclerotic cardiovascular diseases, cancers
7960|NCT03005821|pediatric massage
7961|NCT03005821|Tuina therapy
7962|NCT03005821|acute diarrhea
7963|NCT03005808|appendectomy, pediatrics, nerve block, abdominal wall
7964|NCT03005795|cervical dysplasia
7965|NCT03005795|colposcopy
7966|NCT03005795|anxiety
7967|NCT03005795|music
7968|NCT03005795|mozart
7969|NCT03005795|randomized controlled trial
7970|NCT03005769|persistence
7971|NCT03005769|long-acting injectable antipsychotic
7972|NCT03005769|adherence
7973|NCT03005743|Cervical cancer
7974|NCT03005743|Brachytherapy
7975|NCT03005743|Conventional planning
7976|NCT03005743|MR based Brachytherapy
7977|NCT03005717|submental
7978|NCT03005717|Salmeterol Xinafoate
7979|NCT03005717|LIPO-202
7980|NCT03005717|bulge
7981|NCT03005704|Ticagrelor
7982|NCT03005704|Acetylsalicylic acid
7983|NCT03005704|Platelet transfusion
7984|NCT03005704|Reversal
7985|NCT03005691|metabolite
7986|NCT03005691|central sensitization
7987|NCT03005691|whiplash
7988|NCT03005678|glucocorticoids, steroids, osteoporosis
7989|NCT03005665|optic nerve sheath diameter
7990|NCT03005665|acetazolamide
7991|NCT03005652|Subjective Cognitive Decline
7992|NCT03005652|Mental Health
7993|NCT03005652|Meditation
7994|NCT03005652|Health Education
7995|NCT03005613|Pelvic organ prolapse
7996|NCT03005613|Sacrospinous ligament fixation
7997|NCT03005613|Ischial spine fascia fixation
7998|NCT03005613|Clinical outcome
7999|NCT03005600|Screening, diagnosis, risk stratification, ethnic
8000|NCT03005574|Severe Mental Illness
8001|NCT03005574|Cognitive Remediation
8002|NCT03005574|Employment
8003|NCT03005548|Transcranial Direct Current Stimulation
8004|NCT03005548|Pain Postoperative
8005|NCT03005548|Thoracotomy
8006|NCT03005509|Quality improvement
8007|NCT03005509|Injury
8008|NCT03005509|Injuries
8009|NCT03005483|GABAPENTIN POSTOPERATIVE PAIN CHILD
8010|NCT03005470|Prehypertension
8011|NCT03005470|Hypertension
8012|NCT03005470|Blood pressure
8013|NCT03005470|Intervention
8014|NCT03005470|Lifestyle
8015|NCT03005470|Blood pressure monitoring
8016|NCT03005470|Ambulatory Blood Pressure Monitoring
8017|NCT03005470|Text Messages
8018|NCT03005444|liver cirrhosis
8019|NCT03005444|Transjugular Intrahepatic Portosystemic Stent Shunt
8020|NCT03005444|Anticoagulation
8021|NCT03005444|Survival
8022|NCT03005444|Additional decompensation
8023|NCT03005431|Parenting
8024|NCT03005431|Training
8025|NCT03005431|Support
8026|NCT03005431|On-line
8027|NCT03005431|Stress
8028|NCT03005405|Dental Caries
8029|NCT03005405|Primary tooth
8030|NCT03005405|Ionomer Sealants
8031|NCT03005405|Glass Ionomer Restoration
8032|NCT03005392|Cancer
8033|NCT03005392|Physical therapy
8034|NCT03005392|Cardiorespiratory fitness
8035|NCT03005379|FMT
8036|NCT03005379|recurrent c. difficile
8037|NCT03005379|infectious disease
8038|NCT03005379|intestine
8039|NCT03005379|clinical trial
8040|NCT03005379|gastrointestinal
8041|NCT03005379|prevention
8042|NCT03005379|randomized
8043|NCT03005379|diarrhea
8044|NCT03005379|fecal microbiota therapy
8045|NCT03005366|Atrial fibrillation
8046|NCT03005366|vernakalant
8047|NCT03005366|flecainide
8048|NCT03005366|cardioversion
8049|NCT03005301|electroacupuncture instrument
8050|NCT03005288|type 2 diabetes
8051|NCT03005288|obesity
8052|NCT03005288|DXA
8053|NCT03005288|MRI
8054|NCT03005236|Kidney transplant
8055|NCT03005236|Tacrolimus
8056|NCT03005236|Envarsus
8057|NCT03005236|Older adult
8058|NCT03005236|Elderly
8059|NCT03005158|High-sensitivity cardiac troponin I
8060|NCT03005158|Myocardial infarction
8061|NCT03005158|Acute coronary syndrome
8062|NCT03005158|Cluster-randomized trial
8063|NCT03005132|GBM; Integrative Analysis; WES
8064|NCT03004989|Qualitative study
8065|NCT03004989|Musculoskeletal Disorders
8066|NCT03004989|Return to Work Programme
8067|NCT03004976|hematopoietic stem cells
8068|NCT03004976|umbilical cord blood
8069|NCT03004976|stroke
8070|NCT03004976|ischemic stroke
8071|NCT03004963|Peritoneal Dialysis
8072|NCT03004963|Volume Status
8073|NCT03004963|Body Composition Monitor
8074|NCT03004911|fibromyalgia
8075|NCT03004911|mobile application
8076|NCT03004911|self-care
8077|NCT03004911|quality of life
8078|NCT03004872|birth experience
8079|NCT03004872|postpartum depression
8080|NCT03004872|PTSD
8081|NCT03004872|pain during labor
8082|NCT03004872|pain during cesarean delivery
8083|NCT03004872|non-elective induction of labor
8084|NCT03004872|unplanned surgery for urgent/emergent cesarean delivery
8085|NCT03004872|postpartum hemorrhage
8086|NCT03004859|atrial fibrillation
8087|NCT03004859|screening
8088|NCT03004859|electrocardiogram
8089|NCT03004859|community pharmacy
8090|NCT03004859|Germany
8091|NCT03004846|Vehicle- controlled
8092|NCT03004846|GSK2981278
8093|NCT03004846|Plaque psoriasis
8094|NCT03004820|Minor Ischemic Stroke
8095|NCT03004820|Transient Ischemic Attack
8096|NCT03004820|Remote Ischemic Conditioning
8097|NCT03004807|Nutrition
8098|NCT03004807|Aging
8099|NCT03004807|Multivitamin
8100|NCT03004781|parenting intervention
8101|NCT03004781|externalizing behavior
8102|NCT03004781|emotion coaching practices
8103|NCT03004781|self-efficacy beliefs
8104|NCT03004742|polyphenols
8105|NCT03004742|metabolomics
8106|NCT03004742|oxidative stress
8107|NCT03004729|Allergy
8108|NCT03004729|Atopic Dermatitis
8109|NCT03004729|Immunoglobulin E (IgE)
8110|NCT03004729|CMPA
8111|NCT03004703|Interleukin 6
8112|NCT03004703|Tocilizumab
8113|NCT03004703|Acute coronary syndrome
8114|NCT03004703|STEMI
8115|NCT03004703|Inflammation
8116|NCT03004690|biosafety
8117|NCT03004690|outbreaks
8118|NCT03004690|clinic
8119|NCT03004690|personal protective equipment
8120|NCT03004690|ergonomics
8121|NCT03004690|error rates
8122|NCT03004664|Latinos
8123|NCT03004664|Low Income
8124|NCT03004664|Self Management
8125|NCT03004664|Education
8126|NCT03004664|Cultural Competence
8127|NCT03004638|Atherosclerosis
8128|NCT03004638|Cardiovascular Disease
8129|NCT03004638|CAD
8130|NCT03004638|Atherosclerotic Cardiovascular Disease
8131|NCT03004612|prediabetes
8132|NCT03004599|Valvular Heart Disease
8133|NCT03004599|Critical Aortic Stenosis
8134|NCT03004599|Severe Aortic Stenosis
8135|NCT03004599|High Risk
8136|NCT03004599|Aortic Valve Replacement
8137|NCT03004599|Cardiovascular Disease
8138|NCT03004599|Aortic Stenosis
8139|NCT03004599|Heart Valve Therapy
8140|NCT03004599|Transcatheter
8141|NCT03004599|Transfemoral
8142|NCT03004599|TAVI
8143|NCT03004599|TAVR
8144|NCT03004599|ACURATE neo™ Aortic Bioprosthesis
8145|NCT03004599|ACURATE TF™ Transfemoral Delivery System
8146|NCT03004586|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
8147|NCT03004586|Lung cancer
8148|NCT03004586|Ultrasound-guided transbronchial needle aspiration
8149|NCT03004586|EBUS-TBNA
8150|NCT03004586|25-gauge needle
8151|NCT03004586|22-gauge needle
8152|NCT03004573|Parkinson Disease
8153|NCT03004573|emotional recognition
8154|NCT03004573|Deep Brain Stimulation
8155|NCT03004560|Bariatric
8156|NCT03004560|standard laparoscopic surgery
8157|NCT03004560|minimally invasive
8158|NCT03004560|scars
8159|NCT03004560|psychology
8160|NCT03004534|Breast Cancer
8161|NCT03004534|Breast Carcinoma
8162|NCT03004534|Breast Tumours
8163|NCT03004534|Early Breast Cancer
8164|NCT03004521|Lithium
8165|NCT03004521|Quetiapine
8166|NCT03004521|Augmentation
8167|NCT03004508|Ginkgo Biloba Extract
8168|NCT03004508|Safety
8169|NCT03004508|Genomic Stability
8170|NCT03004508|DNA cell maintenance
8171|NCT03004482|NICU
8172|NCT03004482|Recorded video images
8173|NCT03004482|physiological disorders
8174|NCT03004456|Phlebotomy
8175|NCT03004456|Pain
8176|NCT03004456|Distress
8177|NCT03004443|Psychiatry
8178|NCT03004430|Mantra
8179|NCT03004430|Meditation
8180|NCT03004391|Shared decision making
8181|NCT03004391|Follow-up
8182|NCT03004378|obesity
8183|NCT03004378|adolescent
8184|NCT03004378|tracking device
8185|NCT03004378|fitbit
8186|NCT03004326|DIV
8187|NCT03004326|CSS
8188|NCT03004326|EGPA
8189|NCT03004326|HSP
8190|NCT03004326|GPA
8191|NCT03004326|MPA
8192|NCT03004326|PAN
8193|NCT03004326|Wegeners
8194|NCT03004313|migraine
8195|NCT03004300|maxillary expansion
8196|NCT03004300|adenotonsillar hypertrophy
8197|NCT03004300|airway volume
8198|NCT03004261|cytomegalovirus infection
8199|NCT03004261|cytotoxic T lymphocyte
8200|NCT03004261|hematopoietic stem cell transplantation
8201|NCT03004248|glabellar lines, frown lines
8202|NCT03004209|Erythropoietin
8203|NCT03004209|Autoimmune encephalitis
8204|NCT03004196|White Spot Lesion
8205|NCT03004196|Probiotics
8206|NCT03004196|Chlorhexidine
8207|NCT03004196|Streptococcus Mutans
8208|NCT03004196|Fixed Orthodontic Treatment
8209|NCT03004170|HIV
8210|NCT03004170|Motivational Interviewing
8211|NCT03004170|Telephone
8212|NCT03004170|Telehealth
8213|NCT03004170|Risky Sex
8214|NCT03004170|Unprotected Sex
8215|NCT03004170|Condoms
8216|NCT03004170|Older Adults
8217|NCT03004157|infant
8218|NCT03004157|cardiopulmonary resuscitation
8219|NCT03004157|hemodynamics
8220|NCT03004157|chest compressions
8221|NCT03004105|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
8222|NCT03004105|Advanced Lung Cancer
8223|NCT03004105|Recurrent Nonsmall Cell Lung Cancer
8224|NCT03004105|Selumetinib
8225|NCT03004105|AZD6244
8226|NCT03004105|Durvalumab
8227|NCT03004105|MEDI4736
8228|NCT03004092|bis(methylthio)gliotoxin
8229|NCT03004092|lateral flow device
8230|NCT03004092|JF5
8231|NCT03004092|Galactomannan
8232|NCT03004092|Invasive aspergillosis
8233|NCT03004053|Reflectance Confocal Microscopy
8234|NCT03004053|Normal Oral Tissue
8235|NCT03004053|16-1652
8236|NCT03004027|health behaviour change
8237|NCT03004027|implementation intention
8238|NCT03004027|if then plan
8239|NCT03004027|skin condition
8240|NCT03004027|visible difference
8241|NCT03004027|self help
8242|NCT03004014|sleep endoscopy
8243|NCT03004014|sedation
8244|NCT03004001|Severe proteinuria
8245|NCT03004001|Dyslipidemia
8246|NCT03003975|Ablation
8247|NCT03003975|Cryoballoon
8248|NCT03003975|Achieve
8249|NCT03003962|NSCLC
8250|NCT03003962|PD-L1
8251|NCT03003962|Durvalumab
8252|NCT03003962|MEDI4736
8253|NCT03003962|PFS
8254|NCT03003962|OS
8255|NCT03003949|perimenopause
8256|NCT03003949|menopause transition
8257|NCT03003949|estrogen
8258|NCT03003949|stress
8259|NCT03003949|mood
8260|NCT03003936|Glucose tolerance
8261|NCT03003936|MTNR1B
8262|NCT03003936|nutrigenomics
8263|NCT03003936|Food timing
8264|NCT03003923|Vegetable intake
8265|NCT03003923|Taste exposures
8266|NCT03003923|Educational intervention
8267|NCT03003923|Preschool children
8268|NCT03003923|Healthy eating intervention
8269|NCT03003910|Best Possible Self
8270|NCT03003897|Dietary Fiber
8271|NCT03003897|Soluble Fiber
8272|NCT03003897|Body Mass Index
8273|NCT03003897|Body Weight
8274|NCT03003897|Blood Glucose
8275|NCT03003897|Insulin
8276|NCT03003871|stroke
8277|NCT03003871|randomized controled clinical trial
8278|NCT03003871|oral health promotion
8279|NCT03003858|gingivitis
8280|NCT03003858|hyaluronic acid
8281|NCT03003858|pediatrics
8282|NCT03003858|medical devices
8283|NCT03003806|Insulin pump treatment
8284|NCT03003806|Type 1 diabetes
8285|NCT03003806|Pump setting advisor
8286|NCT03002727|Colorectal cancer
8287|NCT03002727|Microsatellite
8288|NCT03002727|Colorectal cancer stem cells
8289|NCT03002714|Resistance Training
8290|NCT03002714|Psychological Stress
8291|NCT03002714|Aging
8292|NCT03002714|Hypertension
8293|NCT03002714|Autonomic Nervous System
8294|NCT03002701|Prevention
8295|NCT03002701|Critical care
8296|NCT03002701|Delirium
8297|NCT03002701|Nurse
8298|NCT03002701|RCT
8299|NCT03002675|Adipose tissue
8300|NCT03002675|Type 2 diabetes
8301|NCT03002649|Dermatomyositis
8302|NCT03002649|Tofacitinib
8303|NCT03002649|Refractory dermatomyositis
8304|NCT03003689|Scaling and Root Planing
8305|NCT03003689|Er:YAG
8306|NCT03003663|Fall Prevention
8307|NCT03003663|Interrupted Time-Series Study
8308|NCT03003663|Patient Safety
8309|NCT03003663|Patient-Centered Care
8310|NCT03003663|Patient Monitoring
8311|NCT03003663|Health Care Technology
8312|NCT03003663|Mobile Applications
8313|NCT03003663|Bedside Monitor
8314|NCT03003663|Mechanical Fall
8315|NCT03003650|Severe Symptomatic Aortic Valve Stenosis
8316|NCT03003624|Incisions
8317|NCT03003624|microdissection needle
8318|NCT03003598|Intraocular pressure
8319|NCT03003598|videolaryngoscope
8320|NCT03003598|direct laryngoscope
8321|NCT03003585|intraocular pressure
8322|NCT03003585|direct laryngoscopy
8323|NCT03003585|fiberoptic bronchoscopy
8324|NCT03003572|Sjögren's syndrome
8325|NCT03003572|Immunoglobulin E
8326|NCT03003572|Anti-Ro/SSA
8327|NCT03003572|Autoimmune disease
8328|NCT03003572|Biomarker
8329|NCT03003559|COPD Exacerbation
8330|NCT03003559|High Flow Oxygen
8331|NCT03003559|Nasal Cannula
8332|NCT03003559|mild
8333|NCT03003533|Adeno-Associated Virus (AAV)
8334|NCT03003533|Blood Coagulation Disorders
8335|NCT03003533|Blood Coagulation Disorders, Inherited
8336|NCT03003533|Coagulation Protein Disorders
8337|NCT03003533|Factor VIII (FVIII)
8338|NCT03003533|Factor VIII (FVIII) Deficiency
8339|NCT03003533|Factor VIII (FVIII) Gene
8340|NCT03003533|Factor VIII (FVIII) Protein
8341|NCT03003533|Genetic Diseases, Inborn
8342|NCT03003533|Genetic Diseases, X-Linked
8343|NCT03003533|Gene Therapy
8344|NCT03003533|Gene Transfer
8345|NCT03003533|Hematologic Diseases
8346|NCT03003533|Hemorrhagic Disorders
8347|NCT03003533|Recombinant
8348|NCT03003533|Vector
8349|NCT03003520|Lymphoma
8350|NCT03003520|Diffuse-large B-Cell Lymphoma
8351|NCT03003520|Durvalumab
8352|NCT03003520|Anti-PD-L1 Antibody
8353|NCT03003520|MEDI4736
8354|NCT03003520|Immune Checkpoint
8355|NCT03003520|Rituximab
8356|NCT03003520|Cyclophosphamide
8357|NCT03003520|Doxorubicin
8358|NCT03003520|Vincristine
8359|NCT03003520|Prednisone/Prednisolone
8360|NCT03003520|Lenalidomide
8361|NCT03003507|Hyperglycemia
8362|NCT03003507|Fructose
8363|NCT03003507|Diabetes mellitus
8364|NCT03003507|Enteral Nutrition
8365|NCT03003507|Glycemic Variability
8366|NCT03003468|Anti-PD-1
8367|NCT03003468|Pembrolizumab
8368|NCT03003468|Imprime PGG
8369|NCT03003468|MK-3475
8370|NCT03003455|Nasotracheal Intubation
8371|NCT03003442|Multivitamin/mineral
8372|NCT03003442|Exercise
8373|NCT03003442|Fatigue
8374|NCT03003442|Stress
8375|NCT03003442|Arousal
8376|NCT03003442|Energy expenditure
8377|NCT03003442|Recovery biomarkers
8378|NCT03003442|Cognition
8379|NCT03003429|Heart rate variability
8380|NCT03003429|anxiety
8381|NCT03003429|Autonomic dysfunction
8382|NCT03003403|mHealth
8383|NCT03003403|Digital Health
8384|NCT03003403|Primary Care
8385|NCT03003403|Pragmatic Clinical Trial
8386|NCT03003403|Behavior Change
8387|NCT03003403|Weight Management
8388|NCT03003390|child
8389|NCT03003390|critical illness
8390|NCT03003390|venous thromboembolism
8391|NCT03003390|enoxaparin
8392|NCT03003390|thrombin generation
8393|NCT03003377|Sevoflurane
8394|NCT03003377|Remifentanil
8395|NCT03003377|Laryngeal mask supreme
8396|NCT03003377|laryngeal mask proseal
8397|NCT03003351|Fistula
8398|NCT03003351|Cohort Study
8399|NCT03003338|chronic HCV Genotype 1b infection
8400|NCT03003338|HCV RNA
8401|NCT03003338|OBV/PTV/r in combination with DSV
8402|NCT03003338|neuropsychiatric manifestations
8403|NCT03003325|low risk of thrombosis
8404|NCT03003325|Interferon
8405|NCT03003312|Urolithiasis
8406|NCT03003312|Uyghur
8407|NCT03003312|Prevalence
8408|NCT03003312|Associated factors
8409|NCT03003312|Children
8410|NCT03003299|Sapien 3
8411|NCT03003299|Partner 3
8412|NCT03003299|cardiovascular disease
8413|NCT03003299|heart disease
8414|NCT03003299|aortic stenosis
8415|NCT03003299|SAVR
8416|NCT03003299|TAVR
8417|NCT03003299|failing surgical valve
8418|NCT03003299|failing bioprosthetic valve
8419|NCT03003299|failing valve
8420|NCT03003286|Contingency Behavior Management
8421|NCT03003286|Flexible
8422|NCT03003286|Unstuck
8423|NCT03003286|Low Income
8424|NCT03003286|Behavior
8425|NCT03003286|Coping
8426|NCT03003286|Disparity
8427|NCT03003286|Problem Solving
8428|NCT03003286|Self-Control
8429|NCT03003286|impulsive
8430|NCT03003286|intervention
8431|NCT03003221|Parent training
8432|NCT03003221|Dental care
8433|NCT03003169|surgery
8434|NCT03003169|breast cancer
8435|NCT03003169|quality of life
8436|NCT03003156|magnetic seizure therapy
8437|NCT03003156|schizophrenia
8438|NCT03003156|controlled trial
8439|NCT03003156|cognition
8440|NCT03003130|Hyaluronic acid
8441|NCT03003130|Comparative study
8442|NCT03003130|NLF
8443|NCT03003117|Infant
8444|NCT03003117|Diet
8445|NCT03003117|Growth
8446|NCT03003117|Breastfeeding
8447|NCT03003117|Complementary feeding
8448|NCT03003117|Pregnancy
8449|NCT03003117|Body mass index
8450|NCT03003117|Social disadvantage
8451|NCT03003117|Randomized controlled trial
8452|NCT03003117|Education
8453|NCT03003117|Food vouchers
8454|NCT03003104|Skin diseases
8455|NCT03003104|rosacea
8456|NCT03003078|Pancreatic cancer
8457|NCT03003078|Pancreas
8458|NCT03003078|metastases
8459|NCT03003078|pancreatic tumour
8460|NCT03003078|unresectable
8461|NCT03003078|locally advanced
8462|NCT03003078|implantable
8463|NCT03003078|radiographic
8464|NCT03003078|device
8465|NCT03003078|Phosphorous-32
8466|NCT03003078|OncoSil™
8467|NCT03003078|brachytherapy
8468|NCT03003078|FOLFIRINOX
8469|NCT03003078|gemcitabine
8470|NCT03003078|nab-paclitaxel
8471|NCT03003078|Abraxane
8472|NCT03003065|Inoperable cholangiocarcinoma
8473|NCT03003065|Photodynamic therapy
8474|NCT03003065|Endoscopic retrograde cholangiopancreatography
8475|NCT03003052|dental implants
8476|NCT03003052|edentulous
8477|NCT03003052|dental hygiene
8478|NCT03003052|evidence-based dentistry
8479|NCT03003039|GB241
8480|NCT03003039|Rituximab
8481|NCT03003039|B-cell Lymphoma
8482|NCT03003026|motor learning
8483|NCT03003026|participation
8484|NCT03003013|Odontogenic cysts
8485|NCT03003013|Bone substitutes materials
8486|NCT03003013|SYMBIOS®
8487|NCT03003013|Platelets rich fibrin (PRF)
8488|NCT03003013|Bone regeneration
8489|NCT03002974|Gout
8490|NCT03002974|Interleukin 1 receptor antagonist
8491|NCT03002974|IL-1 receptor antagonist
8492|NCT03002896|Cancer
8493|NCT03002896|Caregivers
8494|NCT03002896|Pep-pal
8495|NCT03002896|Pep-Pal + Treatment as Usual
8496|NCT03002896|Treatment as Usual
8497|NCT03002857|Laryngeal Mask Airway
8498|NCT03002857|Urologic Surgical Procedure
8499|NCT03002831|CIK
8500|NCT03002831|Chemotherapy
8501|NCT03002831|Pancreatic Cancer
8502|NCT03002818|Genotype 1
8503|NCT03002818|Ritonavir
8504|NCT03002818|Chronic Hepatitis C (HCV)
8505|NCT03002818|Dasabuvir
8506|NCT03002818|Paritaprevir
8507|NCT03002818|Sustained Virological Response
8508|NCT03002818|Ombitasivir
8509|NCT03002805|Phase I
8510|NCT03002805|CBT-1®
8511|NCT03002805|Doxorubicin
8512|NCT03002805|Sarcoma
8513|NCT03002792|anesthesia
8514|NCT03002792|neurodevelopment
8515|NCT03002792|dental caries
8516|NCT03002753|OCD
8517|NCT03002753|obsessive-compulsive disorder
8518|NCT03002753|cognitive therapy
8519|NCT03002753|metacognitive therapy
8520|NCT03002753|cognitive restructuring
8521|NCT03002753|detached mindfulness
8522|NCT03002753|comparison
8523|NCT03002753|Germany
8524|NCT03002753|Muenster
8525|NCT03002753|Christoph-Dornier-Stiftung
8526|NCT03002753|metacognition
8527|NCT03002636|Obesity
8528|NCT03002636|Anesthesia Complications
8529|NCT03002636|Body Mass Index (BMI)
8530|NCT03002623|Dual Inhibitor of HDAC and P13K Signaling
8531|NCT03002623|HDSC2
8532|NCT03002623|EGFR/RAS/RAF/MEK/ERK Signaling Pathway Inhibition
8533|NCT03002584|IBS, population
8534|NCT03002558|Hypertension
8535|NCT03002558|Continuous Positive Airway Pressure
8536|NCT03002558|Obstructive Sleep Apnea
8537|NCT03002558|Cardiovascular Diseases
8538|NCT03002545|Magnesium
8539|NCT03002545|Type II diabetes
8540|NCT03002545|magnesium-sensitive genes
8541|NCT03002532|Breast cancer
8542|NCT03002532|Brain metastasis
8543|NCT03002532|Whole brain radiotherapy
8544|NCT03002532|Hippocampal avoidance
8545|NCT03002532|Neurocognitive function
8546|NCT03002532|intracranial failure
8547|NCT03002506|ceftolozane
8548|NCT03002506|tazobactam
8549|NCT03002493|Rifampicin
8550|NCT03002493|Pharmacokinetics
8551|NCT03002493|Eribulin Mesylate
8552|NCT03002493|E7389
8553|NCT03002493|Advanced Solid Tumors
8554|NCT03002493|Tumors
8555|NCT03002454|99mTc Pertechnetate
8556|NCT03002454|Sodium Pertechnetate
8557|NCT03002454|Technetium
8558|NCT03002454|Molybdenum
8559|NCT03002454|MDP
8560|NCT03002454|neutron activation
8561|NCT03002402|asthma
8562|NCT03002402|insomnia
8563|NCT03002402|cognitive-behavioral treatment
8564|NCT03002389|chronic obstructive pulmonary disease
8565|NCT03002389|COPD
8566|NCT03002389|emphysema
8567|NCT03002389|MRI
8568|NCT03002389|hyper polarized gas MRI
8569|NCT03002363|autism
8570|NCT03002363|audiology
8571|NCT03002363|video modeling
8572|NCT03002363|testing compliance
8573|NCT03002350|Circulating tumor cells (CTCs)
8574|NCT03002350|Optically induced dielectrophoresis (ODEP)
8575|NCT03002350|Cell sorting
8576|NCT03002350|Next-generation sequencing (NGS)
8577|NCT03002350|disruptive mutation
8578|NCT03002337|aromatherapy massage, yoga
8579|NCT03002324|Vaccines
8580|NCT03002324|Childhood Vaccination
8581|NCT03002324|Decision Making
8582|NCT03002324|Health Belief Model
8583|NCT03002311|Bioinformatics
8584|NCT03002311|Electronic pharmacology
8585|NCT03002311|Mobile health
8586|NCT03002311|Electronic health
8587|NCT03002311|Adherence
8588|NCT03002311|Digital health
8589|NCT03002311|Health information technology
8590|NCT03002311|mHealth
8591|NCT03002311|eHealth
8592|NCT03002259|cardiac surgery
8593|NCT03002233|TRK-820
8594|NCT03002233|Hemodialysis
8595|NCT03002233|Uremic Pruritus
8596|NCT03002194|rhytides
8597|NCT03002194|wrinkle
8598|NCT03002142|Alzheimer
8599|NCT03002142|Hearing loss
8600|NCT03002142|Cognition
8601|NCT03002142|Quality of life
8602|NCT03002142|Hearing aids
8603|NCT03002090|iron deficiency
8604|NCT03002090|anemia
8605|NCT03002090|exercise training
8606|NCT03002090|aerobic
8607|NCT03002090|performance
8608|NCT03002090|Chinese medicine
8609|NCT03002090|BaZhen KeLi
8610|NCT03002064|Esophagus squamous carcinoma
8611|NCT03002064|First-line chemotherapy
8612|NCT03002064|Docetaxel
8613|NCT03002064|Cisplatin
8614|NCT03002064|5-fluorouracil
8615|NCT03002038|neuromyelitis optica spectrum disorder
8616|NCT03002038|azathioprine
8617|NCT03002038|rituximab
8618|NCT03002038|clinical trial
8619|NCT03002038|annual relapse rate
8620|NCT03002038|expanded disability status scale
8621|NCT03002012|cryptococcal antigen
8622|NCT03002012|preemptive treatment
8623|NCT03002012|CRAG+
8624|NCT03002012|sertraline
8625|NCT03002012|fluconazole
8626|NCT03002012|randomized clinical trial
8627|NCT03002012|HIV
8628|NCT03001999|Diabetes
8629|NCT03001999|Positive Psychology
8630|NCT03001999|Physical Activity
8631|NCT03001986|safety
8632|NCT03001986|efficacy
8633|NCT03001986|hand, foot and mouth disease (HFMD)
8634|NCT03001973|Lupus nephritis
8635|NCT03001973|Patient survival
8636|NCT03001973|Renal survival
8637|NCT03001947|IgA nephropathy
8638|NCT03001947|All-cause mortality
8639|NCT03001947|Cardiovascular mortality
8640|NCT03001947|A composite renal outcome
8641|NCT03001934|Nephrotic syndrome
8642|NCT03001934|Treatment response
8643|NCT03001934|Renal function
8644|NCT03001921|Hemodialysis
8645|NCT03001921|Patient survival
8646|NCT03001921|Quality of life
8647|NCT03001921|Hemodialysis access
8648|NCT03001908|shoulder
8649|NCT03001908|mobilization
8650|NCT03001908|electromyography
8651|NCT03001908|imaging ultrasound
8652|NCT03001804|Multiple Myeloma
8653|NCT03001804|Revlimid
8654|NCT03001804|Lenalidomide
8655|NCT03001804|Non-transplantable
8656|NCT03001791|CO2 laser
8657|NCT03001791|thermal damage zone
8658|NCT03001791|Er:YAG laser
8659|NCT03001778|Physical Activity
8660|NCT03001778|Older Adults
8661|NCT03001778|Independent Living Facilities
8662|NCT03001778|Multimedia technology
8663|NCT03001752|post-extraction dental implant
8664|NCT03001752|immediate dental implant
8665|NCT03001752|open flap
8666|NCT03001752|flapless
8667|NCT03001752|bone grafting
8668|NCT03001752|CT Cone Beam
8669|NCT03001687|hepcidin
8670|NCT03001687|sepsis
8671|NCT03001687|surgery
8672|NCT03001687|vitamin D
8673|NCT03001661|Propess
8674|NCT03001661|Dilapan-S
8675|NCT03001661|Dinoprostone
8676|NCT03001661|Labour
8677|NCT03001661|Induction
8678|NCT03001661|Child birth
8679|NCT03001596|Neoadjuvant Chemoradiotherapy
8680|NCT03001596|Neoadjuvant Chemotherapy
8681|NCT03001596|Minimally Invasive Esophagectomy
8682|NCT03001596|Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0）
8683|NCT03001583|Mediterranean diet
8684|NCT03001583|weight loss
8685|NCT03001583|type 2 diabetes
8686|NCT03001583|education program
8687|NCT03001583|cooking
8688|NCT03001557|Mild to Moderate Alzheimer's Disease Dementia
8689|NCT03001557|sleep
8690|NCT03001557|circadian rhythms
8691|NCT03001531|Complete paraplegia
8692|NCT03001466|Cataract
8693|NCT03001466|Urea-loaded NPs
8694|NCT03001466|TEM examination
8695|NCT03001453|Exparel
8696|NCT03001453|total hip replacement
8697|NCT03001453|bupivacaine
8698|NCT03001440|REMS
8699|NCT03001440|Smoking cessation
8700|NCT03001440|WELLBUTRIN
8701|NCT03001440|ZYBAN
8702|NCT03001440|Neuropsychiatric adverse events
8703|NCT03001388|Cystic Fibrosis Liver Disease
8704|NCT03001388|Pancreatic insufficiency
8705|NCT03001388|Cystic Fibrosis
8706|NCT03001388|Transient Elastography
8707|NCT03001375|Laparoscopic colectomy.
8708|NCT03001375|Splenic flexure mobilization.
8709|NCT03001375|Anastomotic leakage.
8710|NCT03001349|Malignant neoplasms of digestive organs
8711|NCT03001349|Neuroendocrine Tumors
8712|NCT03001349|NET
8713|NCT03001349|Malignant neoplasms of eye brain and other parts of central nervous system
8714|NCT03001349|PET/CT scan
8715|NCT03001349|68Ga-DOTATOC
8716|NCT03001336|Thyroid
8717|NCT03001336|Diabetes Mellitus
8718|NCT03001297|atherosclerosis; acute coronary syndrome; MEDI5884
8719|NCT03001271|Angiotensin-(1-7)
8720|NCT03001271|Renin-angiotensin System
8721|NCT03001271|Autonomic Nervous System
8722|NCT03001245|adolescents
8723|NCT03001245|depression
8724|NCT03001245|psychotherapy
8725|NCT03001245|interpersonal therapy
8726|NCT03001232|Movement-oriented Dementia Care
8727|NCT03001232|QoL
8728|NCT03001232|ADL
8729|NCT03001232|Nursing Home
8730|NCT03001193|Primary slow progress
8731|NCT03001193|Prolonged latent phase
8732|NCT03001193|Labor arrest
8733|NCT03001180|Generalized Lymphatic Anomaly
8734|NCT03001180|Vascular Anomaly
8735|NCT03001180|Kaposiform Hemangioendothelioma
8736|NCT03001180|Kaposiform Lymphangiomatosis
8737|NCT03001180|Vascular Endothelial Growth Factor
8738|NCT03001180|Biomarkers
8739|NCT03001180|GLA
8740|NCT03001180|KLA
8741|NCT03001180|KHE
8742|NCT03001180|GSD
8743|NCT03001167|Microbiome
8744|NCT03001167|Antibiotics
8745|NCT03001167|Growth
8746|NCT03001141|MultiPoint Pacing
8747|NCT03001141|Heart Failure
8748|NCT03001141|Cardiac Resynchronization Therapy
8749|NCT03001141|Quadripolar pacing
8750|NCT03001115|Korean participants
8751|NCT03001115|Adalimumab
8752|NCT03001115|Safety
8753|NCT03001115|Hidradenitis Suppurativa
8754|NCT03001102|Preoperative Care
8755|NCT03001102|Baths
8756|NCT03001102|Chlorhexidine
8757|NCT03001102|Soaps
8758|NCT03001102|Povidone-Iodine
8759|NCT03001102|Arthroplasty, Replacement, Hip
8760|NCT03001102|Surgical Wound Infection
8761|NCT03001089|Neonatology
8762|NCT03001089|Endocrinology
8763|NCT03001076|hyperlididemia
8764|NCT03001076|LDL
8765|NCT03001076|cholesterol
8766|NCT03001076|statin intolerance
8767|NCT03001037|Functional Outcome Measures
8768|NCT03001037|Wearable Sensors
8769|NCT03001037|ViMove
8770|NCT03001037|Low Back Pain
8771|NCT03001037|Range of Movement
8772|NCT03001037|Muscle Activity
8773|NCT03000998|HPV
8774|NCT03000998|Cancer
8775|NCT03000985|schizophrenia
8776|NCT03000985|psychoeducation program
8777|NCT03000985|family caregiver
8778|NCT03000985|relapse
8779|NCT03000985|medication adherence
8780|NCT03000985|burden
8781|NCT03000972|Augmentation
8782|NCT03000972|PET-CT
8783|NCT03000972|Positron Emission Tomography
8784|NCT03000972|Fluorine-18
8785|NCT03000946|Pancreatectomy
8786|NCT03000946|Somatostatin analogue
8787|NCT03000946|Octreotide
8788|NCT03000946|Pancreatic fistula
8789|NCT03000920|short message service (SMS)
8790|NCT03000920|screening
8791|NCT03000920|cost-effectiveness
8792|NCT03000907|prevention
8793|NCT03000907|frailty
8794|NCT03000907|obese
8795|NCT03000907|elderly
8796|NCT03000907|physical exercise
8797|NCT03000894|cognitive-behavioral therapy for insomnia
8798|NCT03000894|insomnia
8799|NCT03000894|mood disorder
8800|NCT03000868|Colonic Polyps
8801|NCT03000868|Endoscopic Mucosal Resection
8802|NCT03000868|Colonoscopy
8803|NCT03000855|Malignant biliary obstruction
8804|NCT03000855|EUS - guided choledocho-duodenostomy
8805|NCT03000855|ERCP with covered metallic stents
8806|NCT03000842|autonomic control
8807|NCT03000842|transcutaneous vagal nerve stimulation
8808|NCT03000842|transauricular vagal nerve stimulation
8809|NCT03000829|Code blue
8810|NCT03000829|Code team
8811|NCT03000829|Crisis team leadership
8812|NCT03000829|Cardiopulmonary resuscitation
8813|NCT03000829|Telemedicine
8814|NCT03000829|Simulation
8815|NCT03000829|Mock code
8816|NCT03000829|In-hospital cardiac arrest
8817|NCT03000790|Anterior disc displacement
8818|NCT03000790|TMD therapy
8819|NCT03000790|internal derangement
8820|NCT03000790|Lingual Ring
8821|NCT03000777|melatonin
8822|NCT03000777|zinc
8823|NCT03000777|Myalgic Encephalomyelitis
8824|NCT03000777|Chronic Fatigue Syndrome
8825|NCT03000777|sleep
8826|NCT03000777|pain
8827|NCT03000764|Skin biopsy
8828|NCT03000764|Radiotherapy
8829|NCT03000764|RNA biomarker
8830|NCT03000764|HSP biomarker
8831|NCT03000764|Exon junction array
8832|NCT03000764|Gene expression
8833|NCT03000764|Radiosensitivity prediction
8834|NCT03000751|CT scan
8835|NCT03000751|CT exam
8836|NCT03000751|ionizing radiation
8837|NCT03000751|medical imaging
8838|NCT03000751|cat scan
8839|NCT03000751|radiation
8840|NCT03000738|CD16- monocyte/CD16+ monocyte ratio
8841|NCT03000738|CytoDiff flow cytometric system
8842|NCT03000738|Diffuse Large B Cell Lymphoma
8843|NCT03000738|Peripheral T-Cell Lymphoma
8844|NCT03000738|prognosis
8845|NCT03000712|adipose tissue derived mesenchymal stem cell
8846|NCT03000712|osteoarthritis
8847|NCT03000712|degenerative arthritis
8848|NCT03000712|kyung hee university hospital
8849|NCT03000712|biostar
8850|NCT03000712|Rbio
8851|NCT03000712|Osteoarthritis, Knee
8852|NCT03000712|High tibial osteotomy
8853|NCT03000712|Joint Diseases
8854|NCT03000699|cognitive bias modification
8855|NCT03000699|interpretation bias
8856|NCT03000699|suicidal ideation
8857|NCT03000699|depression
8858|NCT03000686|GSK2586881, Acute hypoxia, Exercise
8859|NCT03000660|Amyloidosis
8860|NCT03000660|AL Amyloidosis
8861|NCT03000660|Amyloid Light Chain Amylodosis
8862|NCT03000660|ABT-199
8863|NCT03000660|Venetoclax
8864|NCT03000647|Pelvic floor muscle exercise
8865|NCT03000647|Supervision
8866|NCT03000647|Physiotherapy
8867|NCT03000621|MicroRNA
8868|NCT03000621|miR-122
8869|NCT03000621|Diagnosis
8870|NCT03000621|Prognosis
8871|NCT03000595|eczema
8872|NCT03000569|Parkinson
8873|NCT03000543|Infants
8874|NCT03000543|Children
8875|NCT03000543|Adequate or high vitamin A store
8876|NCT03000530|Depression
8877|NCT03000517|levofloxacin
8878|NCT03000517|multi-drug resistant TB
8879|NCT03000517|pharmacokinetics
8880|NCT03000465|pneumoperitoneum pressure
8881|NCT03000465|laparoscopic pressure
8882|NCT03000465|intra-abdominal insufflation
8883|NCT03000465|intra-abdominal pressures
8884|NCT03000465|abdominal compliance
8885|NCT03000452|Multiple Myeloma
8886|NCT03000452|Daratumumab
8887|NCT03000452|Durvalumab
8888|NCT03000452|Relapsed and Refractory Multiple Myeloma
8889|NCT03000439|systemic Juvenile Idiopathic Arthritis
8890|NCT03000439|Xeljanz
8891|NCT03000439|Tofacitinib
8892|NCT03000439|sJIA
8893|NCT03000439|CP-690 550
8894|NCT03000426|Low level laser therapy
8895|NCT03000387|Nicotine Replacement Therapy
8896|NCT03000387|Smoking Cessation
8897|NCT03000387|Randomized Clinical Trial
8898|NCT03000387|Nicotine Patch
8899|NCT03000387|Abstinence
8900|NCT03000387|Placebo
8901|NCT03000387|Double blind
8902|NCT03000361|Colonoscopy
8903|NCT03000361|motorized spiral endoscopy
8904|NCT03000361|adenoma detection rate
8905|NCT03000348|Exacerbation
8906|NCT03000348|CF
8907|NCT03000348|Lung disease
8908|NCT03000348|Lung infection
8909|NCT03000348|Gram negative
8910|NCT03000348|Bacterial Infection
8911|NCT03000348|pneumonia
8912|NCT03000348|bronchitis
8913|NCT03000335|microRNA
8914|NCT03000335|relapse
8915|NCT03000335|blood
8916|NCT03000335|in vitro diagnostics
8917|NCT03000335|prediction
8918|NCT03000335|lab test
8919|NCT03000296|autologous
8920|NCT03000296|lymphoablation
8921|NCT03000296|hematopoetic stem cell transplant
8922|NCT03000296|immune system
8923|NCT03000296|Bone marrow transplant
8924|NCT03000283|Conivaptan
8925|NCT03000270|Infarct Size
8926|NCT03000270|Impella
8927|NCT03000270|Unloading
8928|NCT03000270|Left Ventricle
8929|NCT03000270|PPCI
8930|NCT03000270|STEMI
8931|NCT03000257|Non-small cell lung cancer (NSCLC)
8932|NCT03000257|Gastric cancer
8933|NCT03000257|Merkel cell carcinoma
8934|NCT03000257|Cholangiocarcinoma
8935|NCT03000257|Advanced Solid Tumors
8936|NCT03000257|Ovarian cancer
8937|NCT03000257|Triple negative breast cancer
8938|NCT03000257|Hepatocellular carcinoma
8939|NCT03000257|Small cell lung cancer
8940|NCT03000257|Mesothelioma,
8941|NCT03000257|Cancer
8942|NCT03000244|Natural History
8943|NCT03000244|HCT
8944|NCT03000205|Dextrose prolotherapy
8945|NCT03000205|patients
8946|NCT03000192|Survivorship
8947|NCT03000192|Cancer
8948|NCT03000192|Recovery
8949|NCT03000192|Self-management
8950|NCT03000192|Cohort
8951|NCT03000127|testosterone
8952|NCT03000127|multiple sclerosis
8953|NCT03000127|fatigue
8954|NCT03000114|Collagenase injection
8955|NCT03000114|percutaneous needle aponeurotomy
8956|NCT03000101|Biomarkers
8957|NCT03000101|Colitis
8958|NCT03000101|Colitis, Ulcerative
8959|NCT03000101|Colonic Diseases
8960|NCT03000101|Crohn Disease
8961|NCT03000101|Digestive System Diseases
8962|NCT03000101|Fruit
8963|NCT03000101|Fruit and Vegetable Juices
8964|NCT03000101|Gastroenteritis
8965|NCT03000101|Gastrointestinal Diseases
8966|NCT03000101|Humans
8967|NCT03000101|Hydrolysable Tannins
8968|NCT03000101|Inflammation
8969|NCT03000101|Inflammatory Bowel Diseases
8970|NCT03000101|Intestinal Diseases
8971|NCT03000101|Punicaceae
8972|NCT03000075|risankizumab
8973|NCT03000075|BI 655066
8974|NCT03000075|ABBV-066
8975|NCT03000062|overweight, general practice
8976|NCT03000049|sepsis
8977|NCT03000049|septic shock
8978|NCT03000049|blood cultures
8979|NCT03000049|anti-infective therapy
8980|NCT03000036|Breast cancer
8981|NCT03000036|Doxorubicin
8982|NCT03000036|Cardiovascular Magnetic Resonance
8983|NCT03000036|T1 mapping
8984|NCT03000023|Hepatitis C
8985|NCT03000023|Patient-Reported Outcomes
8986|NCT03000023|DAA Treatment
8987|NCT03000023|Qualitative
8988|NCT03000023|Mixed methods
8989|NCT03000010|Wound Vac
8990|NCT03000010|Neuromuscular Scoliosis
8991|NCT03000010|Posterior Spinal Fusion
8992|NCT02999997|Physical therapy modalities
8993|NCT02999997|Dual-task performance
8994|NCT02999997|Parkinson's disease
8995|NCT02999997|Active music therapy
8996|NCT02999997|Physical activity
8997|NCT02999971|circuit class therapy
8998|NCT02999971|ICF model
8999|NCT02999971|aquatic therapy
9000|NCT02999971|neuro-rehabilitation
9001|NCT02999945|preterm infants
9002|NCT02999945|SGA infants
9003|NCT02999945|IUGR infants
9004|NCT02999945|growth
9005|NCT02999945|body composition
9006|NCT02999945|metabolomics
9007|NCT02999945|microbiome
9008|NCT02999945|adiposity markers
9009|NCT02999945|metabolic programming
9010|NCT02999945|neurodevelopmental outcome
9011|NCT02999906|PAH
9012|NCT02999906|Oral Treprostinil
9013|NCT02999906|dual therapy
9014|NCT02999906|6 Minute Walk Test
9015|NCT02999854|Haploidentical stem cell transplantation
9016|NCT02999854|Graft-versus-host disease
9017|NCT02999854|Immune reconstitution
9018|NCT02999854|Alloreactive T-cells
9019|NCT02999854|Photodynamic treatment
9020|NCT02999854|Hematologic malignancy
9021|NCT02999854|Transplant-related mortality
9022|NCT02999854|Overall survival
9023|NCT02999854|GRFS
9024|NCT02999854|GVHD
9025|NCT02999841|Visceral fat
9026|NCT02999828|safety
9027|NCT02999828|immune persistence
9028|NCT02999815|Tetanus
9029|NCT02999802|Nutrient Sensing
9030|NCT02999802|Exercise
9031|NCT02999802|Elderly
9032|NCT02999776|Plaques Psoriasis
9033|NCT02999776|Topical
9034|NCT02999776|Laser microporation
9035|NCT02999763|lipolysis
9036|NCT02999763|fat reduction
9037|NCT02999763|circumference reduction
9038|NCT02999737|Platelet Rich Plasma
9039|NCT02999737|PRP
9040|NCT02999737|Hair loss
9041|NCT02999737|Alopecia
9042|NCT02999737|Hypotrichosis
9043|NCT02999737|Hair diseases
9044|NCT02999698|Psoriasis
9045|NCT02999698|Hidradenitis
9046|NCT02999698|Psychological impact
9047|NCT02999698|Quality of life
9048|NCT02999659|pupillometry
9049|NCT02999659|autonomous nerve system
9050|NCT02999646|head and neck squamous cell carcinoma
9051|NCT02999646|cancer
9052|NCT02999646|HNSCC
9053|NCT02999646|immunotherapy
9054|NCT02999646|MVX-ONCO-1
9055|NCT02999607|Transcranial direct current stimulation
9056|NCT02999607|Positron emission tomography
9057|NCT02999529|Chemotherapy
9058|NCT02999529|Oncology
9059|NCT02999503|adhd treatment
9060|NCT02999503|nutrition
9061|NCT02999477|Breast Cancer
9062|NCT02999464|stroke
9063|NCT02999464|qigong
9064|NCT02999464|randomized controlled trial
9065|NCT02999464|body-mind exercise
9066|NCT02999464|balance
9067|NCT02999464|quality of life
9068|NCT02999464|wellbeing
9069|NCT02999412|Integrated Healthcare System
9070|NCT02999412|Inappropriate Prescribing
9071|NCT02999412|Pragmatic Clinical Trial
9072|NCT02999412|Crossover Design
9073|NCT02999412|Randomised Controlled Trial
9074|NCT02999399|Smoker
9075|NCT02999399|Former smoker
9076|NCT02999386|stress, hyperglycemia, inflammatory markers, trauma, HbA1c
9077|NCT02999386|interleukin-6
9078|NCT02999373|prevention, infection, preterm, cord blood mononuclear cells
9079|NCT02999360|Aphasia
9080|NCT02999360|Speech Therapy
9081|NCT02999360|Aerobic Exercise (AE)
9082|NCT02999347|Treatment Outcome
9083|NCT02999347|Mid-urethral slings
9084|NCT02999347|Gynecologic Surgery Procedures
9085|NCT02999334|Group healthcare models
9086|NCT02999334|Antenatal care
9087|NCT02999334|Prenatal care
9088|NCT02999334|Perinatal health
9089|NCT02999334|CenteringPregnancy
9090|NCT02999334|sub-Saharan Africa
9091|NCT02999334|Malawi
9092|NCT02999334|Tanzania
9093|NCT02999334|Pregnancy
9094|NCT02999308|haemophilia
9095|NCT02999308|prophylaxis
9096|NCT02999308|children
9097|NCT02999282|TMS
9098|NCT02999282|tDCS
9099|NCT02999282|Rehabilitation
9100|NCT02999269|electroconvulsive therapy
9101|NCT02999269|MRI
9102|NCT02999269|major depressive disorder
9103|NCT02999256|Tart Cherry Juice
9104|NCT02999256|Fat Oxidation
9105|NCT02999256|Lipid Profile
9106|NCT02999256|Anthocyanins
9107|NCT02999256|Exercise
9108|NCT02999256|Calorie Restrictive Mimetic
9109|NCT02999230|Cavities
9110|NCT02999217|iron isomaltoside
9111|NCT02999217|plasma ferritin
9112|NCT02999217|haemoglobin
9113|NCT02999217|colorectal cancer
9114|NCT02999165|Breastfeeding
9115|NCT02999165|CPAP
9116|NCT02999165|Humidified High Flow Nasal Cannula Oxygen
9117|NCT02999165|preterm neonate
9118|NCT02999152|Bio-markers
9119|NCT02999152|Radiation
9120|NCT02999152|Appropriate therapeutic strategy
9121|NCT02999152|Total Body Irradiation
9122|NCT02999152|Partial Body Irradiation
9123|NCT02999139|Injury
9124|NCT02999139|Prevention
9125|NCT02999126|Total Intravenous Anesthesia
9126|NCT02999126|Titration
9127|NCT02999126|Target Controlled Infusion
9128|NCT02999126|Propofol
9129|NCT02999126|Bispectral index
9130|NCT02999113|non-technical skills
9131|NCT02999113|patient safety
9132|NCT02999113|medical education
9133|NCT02999100|oxytocin
9134|NCT02999100|non-pregnant
9135|NCT02999100|pregnant
9136|NCT02999100|Postpartum Hemorrhage
9137|NCT02999087|Head and Neck cancer
9138|NCT02999087|Immunotherapy
9139|NCT02999074|exercise
9140|NCT02999074|resistance training
9141|NCT02999074|aerobic training
9142|NCT02999074|breast cancer
9143|NCT02999074|neoadjuvant chemotherapy
9144|NCT02999074|fatigue
9145|NCT02999074|quality of life
9146|NCT02999074|tumor response
9147|NCT02999061|pre-term children
9148|NCT02999048|panax notoginseng saponins
9149|NCT02999048|hypertensive intracerebral hemorrhage
9150|NCT02999048|hematoma
9151|NCT02999048|neurological function
9152|NCT02999035|ocular surface sensitivity
9153|NCT02999022|bone fractures
9154|NCT02999022|bony callus
9155|NCT02999022|fractures, bone
9156|NCT02999022|lithium
9157|NCT02999022|lithium carbonate
9158|NCT02999022|osteogenesis
9159|NCT02999022|bone development
9160|NCT02999022|fracture healing
9161|NCT02999022|fracture repair
9162|NCT02998970|Cardiovascular Disease
9163|NCT02998970|Type 2 Diabetes
9164|NCT02998970|Cardiac Magnetic Resonance Imaging
9165|NCT02998957|Acupuncture
9166|NCT02998957|TENS
9167|NCT02998957|Physiotherapy
9168|NCT02998931|Glutamin
9169|NCT02998931|Enteral Nutrition
9170|NCT02998931|Intensive Care Unit
9171|NCT02998931|Critical Care Outcomes
9172|NCT02998931|inflammatory
9173|NCT02998931|Immune System
9174|NCT02998918|Inflammation
9175|NCT02998918|HDL
9176|NCT02998918|Anti-inflammatory
9177|NCT02998918|Supplementation
9178|NCT02998918|Curcumin
9179|NCT02998918|polyphenol
9180|NCT02998918|V-cam
9181|NCT02998918|I-cam
9182|NCT02998918|atherosclerosis
9183|NCT02998918|cardiovascular disease
9184|NCT02998918|atherogenesis
9185|NCT02998918|antioxidant
9186|NCT02998918|resveratrol
9187|NCT02998918|quercetin
9188|NCT02998892|Sedentary Behavior
9189|NCT02998866|Cryoballoon Pulmonary Vein Isolation
9190|NCT02998866|Esophageal Effects
9191|NCT02998853|Non culprit
9192|NCT02998853|STEMI PCI
9193|NCT02998853|angio QFR
9194|NCT02998853|FFR
9195|NCT02998853|Staged procedure
9196|NCT02998840|elevated blood pressure
9197|NCT02998814|fissure sealant
9198|NCT02998814|etch and rinse
9199|NCT02998814|self etch
9200|NCT02998788|heart failure
9201|NCT02998788|risk factor
9202|NCT02998788|cardiovascular disease
9203|NCT02998788|lifestyle behavior
9204|NCT02998775|in vitro protein binding
9205|NCT02998775|hepatic impairment
9206|NCT02998775|renal impairment
9207|NCT02998762|major depression
9208|NCT02998762|major depressive disorder
9209|NCT02998762|biomarkers
9210|NCT02998762|MDD
9211|NCT02998762|long term follow up
9212|NCT02998736|Colon
9213|NCT02998723|Basic Life Support
9214|NCT02998723|Education, Medical
9215|NCT02998723|Cardiopulmonary Resuscitation
9216|NCT02998723|Learning
9217|NCT02998697|Systolic Heart Failure
9218|NCT02998697|Anemia
9219|NCT02998697|Iron Deficiency
9220|NCT02998684|Autism
9221|NCT02998684|Adolescent
9222|NCT02998684|Social skills
9223|NCT02998671|Acne, inflammatory acne, efficacy, safety, PK
9224|NCT02998658|Laparoscopy
9225|NCT02998658|Barbed sutures
9226|NCT02998658|Hysterectomy
9227|NCT02998645|severe acquired aplastic anemia
9228|NCT02998645|SAA
9229|NCT02998645|first line
9230|NCT02998645|eltrombopag
9231|NCT02998645|cyclosporine
9232|NCT02998645|h-ATG
9233|NCT02998645|severe aplastic anemia
9234|NCT02998645|aplastic anemia
9235|NCT02998593|Semen parameters sexual Hormone Male infertility oligospermia Iranian Traditional Medicine
9236|NCT02998580|late-life depression
9237|NCT02998580|treatment resistance
9238|NCT02998515|supplemental oxygen
9239|NCT02998515|concentrator
9240|NCT02998515|endurance shuttle walk test
9241|NCT02998502|Obsessive Compulsive Disorder (OCD)
9242|NCT02998502|Anxiety
9243|NCT02998502|Pediatrics
9244|NCT02998489|enteral nutrition
9245|NCT02998489|infant,premature
9246|NCT02998489|feeding method
9247|NCT02998476|Diffuse large B-cell lymphoma
9248|NCT02998476|relapsed
9249|NCT02998476|refractory
9250|NCT02998476|non-Hodgkin lymphoma
9251|NCT02998476|phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor
9252|NCT02998476|Bruton's tyrosine kinase (BTK)
9253|NCT02998463|Skin-to-skin
9254|NCT02998463|Kangaroo Care
9255|NCT02998463|Kangaroo Mother Care
9256|NCT02998450|Sickle Cell Disease
9257|NCT02998450|Sickle Beta 0 Thalassemia
9258|NCT02998424|propofol
9259|NCT02998424|pupillary diameter
9260|NCT02998411|anti-infectives
9261|NCT02998411|adults
9262|NCT02998411|pharmacokinetic
9263|NCT02998411|pharmacodynamic end-points
9264|NCT02998411|clinical cure
9265|NCT02998398|Biosimilar
9266|NCT02998385|salivary glands
9267|NCT02998385|sinus carcinoma
9268|NCT02998385|radiochemotherapy concomitant
9269|NCT02998385|cisplatin
9270|NCT02998346|Nutrition
9271|NCT02998346|CRRT
9272|NCT02998346|CVVH
9273|NCT02998346|citrate
9274|NCT02998346|anticoagulation
9275|NCT02998346|caloric uptake
9276|NCT02998333|Instability
9277|NCT02998333|Ankle
9278|NCT02998333|Surgical stabilization
9279|NCT02998281|cerebral palsy
9280|NCT02998281|inspiratory muscle training
9281|NCT02998255|PEG
9282|NCT02998255|Bowel preparation
9283|NCT02998255|Colonoscopy
9284|NCT02998203|organic diet
9285|NCT02998203|health
9286|NCT02998203|pesticides
9287|NCT02998203|inflammation biomarkers
9288|NCT02998203|oxidative stress biomarkers
9289|NCT02998177|Postoperative pain
9290|NCT02998177|Rebound pain
9291|NCT02998177|Gut microbiome
9292|NCT02998177|Gut microbiota
9293|NCT02998177|Peripheral nerve block
9294|NCT02998177|Axillary brachial plexus block
9295|NCT02998138|Chronic Pain
9296|NCT02998138|Pain, Postoperative
9297|NCT02998112|fecal microbiota transplantation
9298|NCT02998112|Ulcerative colitis
9299|NCT02998099|Healthy Volunteers
9300|NCT02998099|Rivipansel
9301|NCT02998060|Robot
9302|NCT02998060|Spinal Fusion
9303|NCT02998060|Spine
9304|NCT02998060|Navigation
9305|NCT02998060|Freehand
9306|NCT02998008|Exercise Therapy
9307|NCT02998008|Heart Function Tests
9308|NCT02998008|Heart/physiology
9309|NCT02998008|Echocardiography
9310|NCT02997995|T2-T4 Breast cancer
9311|NCT02997995|Estrogen Receptor Positive Tumor
9312|NCT02997995|PD-1
9313|NCT02997995|Neoadjuvant
9314|NCT02997995|Immune-attractants
9315|NCT02997995|lymphocytes activation
9316|NCT02997982|Alzheimer's Disease
9317|NCT02997982|Herpes Simplex Virus
9318|NCT02997982|HSV
9319|NCT02997982|Antiviral Drugs
9320|NCT02997969|HIV
9321|NCT02997943|Obesity
9322|NCT02997943|Weight Loss
9323|NCT02997943|Diet
9324|NCT02997943|Physical Activity
9325|NCT02997943|Mobile Health
9326|NCT02996864|college students
9327|NCT02996864|physical activity
9328|NCT02996864|sleep behaviors
9329|NCT02996864|diet
9330|NCT02996851|Fibrinolytic Agents
9331|NCT02996851|Adverse effects
9332|NCT02996851|Norway
9333|NCT02996851|Registries
9334|NCT02996812|Post-bariatric hypoglycemia
9335|NCT02996812|Non-insulinoma pancreatogenous hypoglycemia syndrome
9336|NCT02996812|Late dumping syndrome
9337|NCT02997891|cognition
9338|NCT02997891|hip replacement
9339|NCT02997891|physical activity
9340|NCT02997891|quality of life
9341|NCT02997891|psychological distress
9342|NCT02997878|autoimmune
9343|NCT02997878|AiH
9344|NCT02997878|PSC
9345|NCT02997878|liver disease
9346|NCT02997878|cholangitis
9347|NCT02997865|heart failure
9348|NCT02997865|depressive disorder, major
9349|NCT02997865|cognitive therapy
9350|NCT02997865|antidepressive agents
9351|NCT02997865|self-care
9352|NCT02997852|human-animal interaction
9353|NCT02997787|adenomyosis
9354|NCT02997787|leiomyoma
9355|NCT02997787|neutrophil to lymphocyte ratio
9356|NCT02997787|platelet to lymphocyte ratio
9357|NCT02997748|acute kidney injury
9358|NCT02997748|cardiac surgery
9359|NCT02997748|Remote ischemic preconditioning
9360|NCT02997748|[TIMP-2]*[IGFBP7]
9361|NCT02997735|Secondhand Smoke
9362|NCT02997735|Nicotine Replacement Therapy
9363|NCT02997735|Clinical Decision Support
9364|NCT02997735|Tobacco quitline
9365|NCT02997722|ketamine
9366|NCT02997722|suicide
9367|NCT02997709|Prostate Cancer
9368|NCT02997709|Circulating Tumor Cells
9369|NCT02997709|CTCs
9370|NCT02997709|Androgen Deprivation Therapy
9371|NCT02997709|ADT
9372|NCT02997670|Cardiac resynchronization pacing therapy
9373|NCT02997644|patient education
9374|NCT02997644|orthopaedic surgery
9375|NCT02997644|post-surgical pain
9376|NCT02997644|chronic opioid use
9377|NCT02997631|Pain Management
9378|NCT02997631|Distraction Therapy
9379|NCT02997631|Robot Based Distraction
9380|NCT02997631|MEDi
9381|NCT02997605|low disease activity
9382|NCT02997605|remission
9383|NCT02997566|Autonomic Nervous System
9384|NCT02997566|Sympathetic Nervous System
9385|NCT02997566|Heart Rate
9386|NCT02997553|Indocyanine green (ICG)
9387|NCT02997553|Sentinel lymph node biopsy
9388|NCT02997553|Technetium99
9389|NCT02997553|Tumors
9390|NCT02997553|Optonuclear probe
9391|NCT02997553|Surgery
9392|NCT02997540|female breast lesion
9393|NCT02997540|ultrasound examination
9394|NCT02997514|Solution focused coaching
9395|NCT02997514|Self determination
9396|NCT02997488|videolaryngoscope
9397|NCT02997475|Bulimia Nervosa
9398|NCT02997475|Bulimia
9399|NCT02997475|fMRI
9400|NCT02997475|Emotion Regulation
9401|NCT02997475|Response Inhibition
9402|NCT02997462|Monocyte
9403|NCT02997462|Oxidative Stress
9404|NCT02997462|Endothelial Function
9405|NCT02997462|Congestive Heart Failure
9406|NCT02997449|Non-Small Cell Lung Cancer (NSCLC)
9407|NCT02997449|Stereotactic ablative radiotherapy (SABR)
9408|NCT02997449|Intrathoracic nodal staging
9409|NCT02997423|Glioblastoma Multiforme
9410|NCT02997423|Biomarker
9411|NCT02997423|Cytochrome C Oxidase
9412|NCT02997423|Newly diagnosed
9413|NCT02997410|Ozone
9414|NCT02997371|Traumatic brain injury
9415|NCT02997371|Microdialysis
9416|NCT02997371|Interleukin-1 receptor antagonist
9417|NCT02997371|Magnetic Resonance Imaging
9418|NCT02997371|Positron Emission Tomography
9419|NCT02997345|PPROM
9420|NCT02997319|Diabetes Mellitus, Type 2
9421|NCT02997319|Insulin Resistance
9422|NCT02997319|Shift Work
9423|NCT02997319|Circadian Rhythms
9424|NCT02997319|MTNR1B
9425|NCT02997306|Moh's Surgery
9426|NCT02997306|Erythema
9427|NCT02997306|Face
9428|NCT02997306|Simple Interrupted Sutures
9429|NCT02997306|Running Sutures
9430|NCT02997306|Image Processing
9431|NCT02997280|acute graft-versus-host disease
9432|NCT02997280|chronic graft-versus-host disease
9433|NCT02997280|Steroid-refractory GVHD
9434|NCT02997280|ruxolitinib
9435|NCT02997280|JAK inhibitors
9436|NCT02997254|atrial fibrillation
9437|NCT02997254|ablation
9438|NCT02997254|abnormal heart rhythm
9439|NCT02997241|Colonic Neoplasms
9440|NCT02997241|recurrence
9441|NCT02997215|intravenous lidocaine
9442|NCT02997215|postoperative pain management
9443|NCT02997202|Gilteritinib
9444|NCT02997202|ASP2215
9445|NCT02997202|Safety and Efficacy
9446|NCT02997202|Acute Myeloid Leukemia
9447|NCT02997150|Idiopathic nephrotic syndrome-child-steroid dependant-IL2
9448|NCT02997150|Safety
9449|NCT02997150|Efficacy
9450|NCT02997137|Chronic psychological distress
9451|NCT02997137|Chronic exhaustion conditions
9452|NCT02997137|Perceived Stress Questionnaire 30 (PSQ30)
9453|NCT02997137|Stress management
9454|NCT02997137|Dietary supplement
9455|NCT02997124|Alveolar bone grafting
9456|NCT02997124|delirium
9457|NCT02997124|early ambulation
9458|NCT02997098|Hepatectomy
9459|NCT02997085|Pain
9460|NCT02997085|Virtual Reality
9461|NCT02997085|Opioid
9462|NCT02997085|Prescription pain reliever
9463|NCT02997085|Treatment
9464|NCT02997072|electrical impedance tomography
9465|NCT02997072|high frequency jet ventilation
9466|NCT02997072|drive pressure
9467|NCT02997059|Crohn disease
9468|NCT02997059|Candida
9469|NCT02997059|ASCA
9470|NCT02997046|Ferumoxytol
9471|NCT02997046|MRI
9472|NCT02997046|fistula
9473|NCT02997046|graft
9474|NCT02997046|kidney transplant
9475|NCT02997046|angiography
9476|NCT02997046|arteriovenous
9477|NCT02997033|Bone
9478|NCT02997033|Sex steroids
9479|NCT02997033|Body composition
9480|NCT02997033|Men
9481|NCT02997007|tDCS
9482|NCT02997007|Mild Cognitive Impairment
9483|NCT02997007|fMRI
9484|NCT02997007|Healthy ageing
9485|NCT02996955|Low Back Pain
9486|NCT02996955|Social Support
9487|NCT02996955|Illness Perceptions
9488|NCT02996955|Activity Advice
9489|NCT02996942|haemophilia, joint disease, quality of life
9490|NCT02996903|Cardiac Computed Tomography (CT) Angiography (CCTA)
9491|NCT02996903|coronary artery disease
9492|NCT02996903|malignancy induction
9493|NCT02996903|radiation dose
9494|NCT02996903|dose saving techniques
9495|NCT02996903|effective dose
9496|NCT02996773|high-risk malignancies
9497|NCT02996773|Lymphoma
9498|NCT02996773|Haploidentical
9499|NCT02996773|Bone Marrow Transplant (BMT)
9500|NCT02996773|Post-transplant
9501|NCT02996773|myeloablative (MAC)
9502|NCT02996773|reduced intensity conditioning (RIC)
9503|NCT02996773|haploidentical hematopoietic cell transplantation (HHCT)
9504|NCT02996773|Leukemia
9505|NCT02996747|bone tumors
9506|NCT02996747|chondroma
9507|NCT02996747|chondrosarcoma
9508|NCT02996734|bone tumors
9509|NCT02996734|giant cell tumor
9510|NCT02996734|treatment
9511|NCT02996708|Telemedicine
9512|NCT02996708|Health economics
9513|NCT02996695|Chemoprophylaxis
9514|NCT02996695|Chloroquine
9515|NCT02996695|Cryopreserved
9516|NCT02996695|Malaria
9517|NCT02996695|Plasmodium
9518|NCT02996695|Sporozoites
9519|NCT02996682|Communicable Diseases
9520|NCT02996682|Hepatitis
9521|NCT02996682|Hepatitis C
9522|NCT02996682|Virus Diseases
9523|NCT02996682|Liver Diseases
9524|NCT02996682|Digestive System Diseases
9525|NCT02996682|Hepatitis, Viral, Human
9526|NCT02996682|Velpatasvir
9527|NCT02996682|Flaviviridae Infections
9528|NCT02996682|RNA Virus Infections
9529|NCT02996682|Ribavirin
9530|NCT02996682|Sofosbuvir
9531|NCT02996682|Antiviral Agents
9532|NCT02996682|Antimetabolites
9533|NCT02996682|Molecular Mechanisms of Pharmacological Action
9534|NCT02996682|Anti-Infective Agents
9535|NCT02996682|Decompensated Cirrhosis
9536|NCT02996643|Adolescent Idiopathic Scoliosis
9537|NCT02996643|Brace Treatment
9538|NCT02996643|Ultrasound Imaging
9539|NCT02996630|LVOTO
9540|NCT02996630|Fallot
9541|NCT02996630|Great Arteries Transposition
9542|NCT02996617|Lymphomas Non-Hodgkin's B-Cell
9543|NCT02996617|Lymphomas Non-Hodgkin's T-Cell
9544|NCT02996617|PEG-rhG-CSF
9545|NCT02996617|Neutropenia
9546|NCT02996604|acupuncture
9547|NCT02996604|functional dyspepsia
9548|NCT02996604|functional magnetic resonance imaging (fMRI)
9549|NCT02996591|Nerve Block
9550|NCT02996591|General Anesthesia
9551|NCT02996591|Spinal Anesthesia
9552|NCT02996591|Pain
9553|NCT02996591|Postoperative Nausea and Vomiting
9554|NCT02996578|Cognition
9555|NCT02996578|Cacao
9556|NCT02996578|Flavan-3-ols
9557|NCT02996578|Blood Pressure
9558|NCT02996578|hemoglobin A1c protein, human
9559|NCT02996578|Memory
9560|NCT02996565|Clinic care
9561|NCT02996565|Team-based care
9562|NCT02996565|Medication Therapy Management (MTM)
9563|NCT02996565|Telehealth
9564|NCT02996565|Cluster-randomized
9565|NCT02996565|Home blood pressure monitoring
9566|NCT02996565|Pharmacist
9567|NCT02996552|Tricuspid annulus dilation
9568|NCT02996552|mitral valve regurgitation
9569|NCT02996526|vocal cord palsy dysfunction thoracic surgery complication
9570|NCT02996513|Vitamin A status
9571|NCT02996513|Retinol Isotope Dilution
9572|NCT02996513|Nigeria
9573|NCT02996513|Preschool children
9574|NCT02996513|Malaria
9575|NCT02996513|Inflammation
9576|NCT02996474|Pembrolizumab
9577|NCT02996474|Decitabine
9578|NCT02996474|AML (Acute Myelogenous Leukemia)
9579|NCT02996461|Zika Infection
9580|NCT02996461|Immune Response
9581|NCT02996461|Flavivirus
9582|NCT02996461|Arthropod-Borne Virus
9583|NCT02996448|AD-HIES
9584|NCT02996448|Anti-rAls3 Antibody
9585|NCT02996448|Staphylococcus Aureus
9586|NCT02996448|Candida Albicans
9587|NCT02996448|RNA Transcriptome
9588|NCT02996396|AAA, Aortoiliac Aneurysm
9589|NCT02996383|arthroplasty
9590|NCT02996370|esthetic
9591|NCT02996370|inter-implant papilla
9592|NCT02996370|soft tissue tickness
9593|NCT02996370|crestal bone loss
9594|NCT02996370|second stage surgery
9595|NCT02996357|Incontinence-associated dermatitis
9596|NCT02996357|Risk factor
9597|NCT02996357|Intensive care unit
9598|NCT02996357|Prevention
9599|NCT02996292|Crowding
9600|NCT02996292|Self ligating
9601|NCT02996292|CBCT
9602|NCT02996292|RCT
9603|NCT02996279|Neonate
9604|NCT02996279|Chorioamnionitis
9605|NCT02996279|S100A12
9606|NCT02996266|Targeted Temperature Management
9607|NCT02996175|Behavior
9608|NCT02996175|Sleep
9609|NCT02996175|Problems
9610|NCT02996175|Intervention
9611|NCT02996162|Bronchopulmonary Dysplasia
9612|NCT02996162|Chronic Lung Disease
9613|NCT02996162|Prematurity
9614|NCT02996084|Imaging research
9615|NCT02995980|breast cancer screening
9616|NCT02995980|dense breasts
9617|NCT02995980|dual-energy contrast-enhanced digital mammography
9618|NCT02995954|Combination therapy
9619|NCT02995954|ACE inhibitor Calcium Antagonist
9620|NCT02995941|reliability
9621|NCT02995941|validity
9622|NCT02995941|classification
9623|NCT02995941|irritability
9624|NCT02995941|symptom
9625|NCT02995941|intensity
9626|NCT02995941|intervention
9627|NCT02995928|Subarachnoid Hemorrhage
9628|NCT02995928|Decompressive Craniectomy
9629|NCT02995928|Cerebral Aneurysm
9630|NCT02995837|Obstructive Sleep Apnea Syndrome
9631|NCT02995837|Cerebral Blood Flow
9632|NCT02995837|Neurocognition
9633|NCT02995824|Liver transplantation
9634|NCT02995824|HIV infection
9635|NCT02995824|Antiretroviral therapy
9636|NCT02995824|Raltegravir
9637|NCT02995785|Simulation
9638|NCT02995707|Thalidomide NTDT
9639|NCT02995681|COPD
9640|NCT02995681|Falls
9641|NCT02995681|Balance training
9642|NCT02995642|Aortic Aneurysm, Abdominal
9643|NCT02995642|Carotid Stenosis
9644|NCT02995642|Atherosclerosis
9645|NCT02995642|Angiogenesis
9646|NCT02995642|Inflammation
9647|NCT02995642|Macrophages
9648|NCT02995642|Positron-Emission Tomography
9649|NCT02995642|Computerized tomography
9650|NCT02995642|Magnetic Resonance Imaging
9651|NCT02995642|(18F)FPP(RGD)2
9652|NCT02995616|Robot-Assisted Gait Training
9653|NCT02995616|Guidance force
9654|NCT02995616|Stroke
9655|NCT02995616|Energy Consumption
9656|NCT02995616|Cardiorespiratory Load
9657|NCT02994771|Lymphedema, Breast cancer
9658|NCT02994758|Prostate
9659|NCT02994758|bladder
9660|NCT02994758|renal
9661|NCT02994758|NGS
9662|NCT02994758|DSRT
9663|NCT02994758|drug screening
9664|NCT02994758|sequencing
9665|NCT02994758|personalised medicine
9666|NCT02995564|Social Skills
9667|NCT02995564|Asperger's
9668|NCT02995564|High-functioning autism
9669|NCT02995564|Young adults
9670|NCT02995551|Menisci, Tibial
9671|NCT02995551|Knee Injuries
9672|NCT02995551|Arthroscopy
9673|NCT02995551|Exercise
9674|NCT02995551|Young adults
9675|NCT02995551|Treatment Outcome
9676|NCT02995551|Humans
9677|NCT02995512|myocardial infarction
9678|NCT02995512|colchicine
9679|NCT02995512|anti-inflammatory
9680|NCT02995499|ASA-PS classification
9681|NCT02995499|inter-rater reliability
9682|NCT02995499|general surgery
9683|NCT02995473|Psoriasis
9684|NCT02995460|Exercise Therapy
9685|NCT02995447|propofol
9686|NCT02995447|electroencephalogram
9687|NCT02995434|Virtual Reality
9688|NCT02995434|Cancer Survivorship
9689|NCT02995434|Pain Management
9690|NCT02995434|Cancer Pain Management
9691|NCT02995434|Chronic Pain Management
9692|NCT02995434|Adjunctive Pain Management
9693|NCT02995408|resiliency training
9694|NCT02995408|parenting
9695|NCT02995408|Autism Spectrum Disorders
9696|NCT02995369|Sealants
9697|NCT02995369|Dryshield
9698|NCT02995369|Cotton roll
9699|NCT02995369|Isolation
9700|NCT02995369|Efficiency
9701|NCT02995369|Preference
9702|NCT02995356|Ectopic pregnancy
9703|NCT02995356|Axonemal Dynein Heavy Chain 5
9704|NCT02995356|Creatine Kinase
9705|NCT02995356|Cervical fluid
9706|NCT02995330|Metastatic Castration-Resistant Prostate Cancer
9707|NCT02995330|Bone Marrow Transplantation
9708|NCT02995317|Aged
9709|NCT02995317|Gait
9710|NCT02995317|Postural Balance
9711|NCT02995317|Accelerometry
9712|NCT02995317|Physical Activity
9713|NCT02995265|Exoskeleton
9714|NCT02995265|Stroke
9715|NCT02995265|Walking
9716|NCT02995265|Rehabilitation
9717|NCT02995187|Apatinib
9718|NCT02995187|Third-line and Later Therapy
9719|NCT02995187|Small Cell Lung Cancer
9720|NCT02995174|amblyopia
9721|NCT02995174|fixation stability
9722|NCT02995174|perceptual learning
9723|NCT02995083|osteoarthritis
9724|NCT02995057|Microneedles
9725|NCT02995057|Biocompatibility
9726|NCT02995057|Allergy
9727|NCT02995057|Metal
9728|NCT02995057|Nickel
9729|NCT02995057|Contact dermatitis
9730|NCT02995005|mother to child transmission
9731|NCT02995005|hepatitis B
9732|NCT02995005|tenofovir
9733|NCT02994953|Avelumab
9734|NCT02994953|M9241
9735|NCT02994953|NHS-IL12
9736|NCT02994953|Advanced Solid Tumors
9737|NCT02994927|ANCA-associated vasculitis
9738|NCT02994927|complement
9739|NCT02994927|vasculitis
9740|NCT02994927|C5aR
9741|NCT02994927|avacopan
9742|NCT02994927|CCX168
9743|NCT02994914|Breast Cancer
9744|NCT02994914|Onco Geriatric Evaluation
9745|NCT02994914|Radiotherapy
9746|NCT02994914|Hypo fractionated radiotherapy
9747|NCT02994914|Normo fractionated radiotherapy
9748|NCT02994914|Large hypo fractionated radiotherapy
9749|NCT02994901|Sarcopenia
9750|NCT02994901|Geriatrics
9751|NCT02994901|Biomarker
9752|NCT02994836|Crohn's Disease
9753|NCT02994836|Inflammatory bowel disease
9754|NCT02994836|Anti-TNF discontinuation
9755|NCT02994836|Ulcerative colitis
9756|NCT02994810|Breastfeeding
9757|NCT02994810|Orientation
9758|NCT02994797|salivary glands
9759|NCT02994797|ultrasonography
9760|NCT02994797|elastometry
9761|NCT02994797|elastography
9762|NCT02994680|Air Pollution
9763|NCT02994680|Liquefied Petroleum Gas
9764|NCT02994680|Cookstove
9765|NCT02994680|Behavioral Intervention
9766|NCT02994680|Propane Stove
9767|NCT02994667|Electrophysiology
9768|NCT02994641|critical care
9769|NCT02994641|patient discharge
9770|NCT02994641|costs and cost analysis
9771|NCT02994641|length of stay
9772|NCT02994641|hospital mortality
9773|NCT02994628|oxidative stress
9774|NCT02994628|immune function
9775|NCT02994628|muscle damage
9776|NCT02994628|carbohydrate
9777|NCT02994628|polyphenols
9778|NCT02994628|cycling
9779|NCT02994615|Index of Microvascular Resistance
9780|NCT02994615|Microvascular dysfunction
9781|NCT02994602|Healthy Men
9782|NCT02994602|Male Contraception
9783|NCT02994602|Healthy Women
9784|NCT02994602|Transfer
9785|NCT02994602|Transference
9786|NCT02994602|Gel
9787|NCT02994602|Nestorone
9788|NCT02994602|Testosterone
9789|NCT02994550|FSH
9790|NCT02994550|LH
9791|NCT02994550|IVF
9792|NCT02994511|Circulating tumour DNA
9793|NCT02994511|ctDNA
9794|NCT02994420|Obesity
9795|NCT02994420|Menstrual Cycle
9796|NCT02994420|Gonadal Steroid Hormones
9797|NCT02994420|Satiety Response
9798|NCT02994420|Glucagon-Like Peptide 1
9799|NCT02994420|Cholecystokinin
9800|NCT02994420|Magnetic Resonance Imaging
9801|NCT02994381|Healthy Male Adults
9802|NCT02994381|14C
9803|NCT02994381|RPC1063
9804|NCT02994368|retinal degeneration
9805|NCT02994368|eye
9806|NCT02994368|REP-1 gene
9807|NCT02994355|Family planning clinics
9808|NCT02994355|Implementation Science
9809|NCT02994355|Systems Analysis and Improvement Approach (SAIA)
9810|NCT02994342|vaginal dryness
9811|NCT02994342|vaginal gel
9812|NCT02994342|colostrum
9813|NCT02994342|vaginal atrophy
9814|NCT02994329|HIV testing
9815|NCT02994329|Linkage to care
9816|NCT02994303|Fabry disease
9817|NCT02994303|Fabry nephropathy
9818|NCT02994303|end-stage renal disease
9819|NCT02994277|"Artificial Pancreas"
9820|NCT02994277|"control System"
9821|NCT02994277|"Closed loop"
9822|NCT02994277|diabetes
9823|NCT02994277|"T1DM"
9824|NCT02994277|"pump"
9825|NCT02994277|algorithm
9826|NCT02994277|CGM
9827|NCT02994199|Active video gaming
9828|NCT02994199|Energy expenditure
9829|NCT02994186|cognitive function
9830|NCT02994186|obesity
9831|NCT02994186|bariatric surgery
9832|NCT02994186|metabolic surgery
9833|NCT02994160|peripheral nerve
9834|NCT02994160|intraneural electrode
9835|NCT02994160|hand amputation
9836|NCT02994108|Human Papillomavirus
9837|NCT02994108|Men Who Have Sex with Men
9838|NCT02994082|Rural health
9839|NCT02994082|Veterans
9840|NCT02994082|Smokeless tobacco cessation
9841|NCT02994069|Cisplatin
9842|NCT02994069|Squamous Cell
9843|NCT02994069|Carcinoma
9844|NCT02994030|neuromuscular disorder
9845|NCT02994017|cystic fibrosis
9846|NCT02994017|Cardiopulmonary exercise testing
9847|NCT02994017|prognostic
9848|NCT02994004|Hospital, medical decision-making, role conflict, f-MRI
9849|NCT02993978|Pediatric radiotherapy
9850|NCT02993926|Drug Therapy
9851|NCT02993887|Caregiver
9852|NCT02993887|Technology Dependent Children
9853|NCT02993887|Resourcefulness
9854|NCT02993887|Mindfulness
9855|NCT02993874|Ergonemic resources
9856|NCT02993874|Walking capacity
9857|NCT02993874|Peripheral artery disease
9858|NCT02993848|Scapula
9859|NCT02993848|Fracture
9860|NCT02993796|Krabbe disease
9861|NCT02993796|globoid cell leukodystrophy
9862|NCT02993796|galactosylceramide lipidosis
9863|NCT02993796|sphingolipidosis
9864|NCT02993783|Drug Therapy
9865|NCT02993757|Dengue Fever
9866|NCT02993757|Dengue Hemorrhagic Fever
9867|NCT02993757|Human Papillomavirus Disease
9868|NCT02993757|CYD Dengue Vaccine
9869|NCT02993757|Dengvaxia®
9870|NCT02993757|Gardasil®
9871|NCT02993744|preterm birth
9872|NCT02993744|corticosteroids
9873|NCT02993744|inflammatory parameters
9874|NCT02993744|betamethasone
9875|NCT02993744|leukocytes
9876|NCT02993731|Neoplasms
9877|NCT02993731|Neoplasms by Site
9878|NCT02993731|Digestive System Neoplasms
9879|NCT02993731|Endocrine Gland Neoplasms
9880|NCT02993731|Pancreatic Neoplasms
9881|NCT02993731|Adenocarcinoma
9882|NCT02993731|Neoplasms, Glandular and Epithelial
9883|NCT02993731|Neoplasms by Histologic Type
9884|NCT02993731|Digestive System Diseases
9885|NCT02993731|Pancreatic Diseases
9886|NCT02993731|Endocrine System Diseases
9887|NCT02993731|Albumin-Bound Paclitaxel
9888|NCT02993731|Gemcitabine
9889|NCT02993692|direct laryngoscopy
9890|NCT02993692|fiberopitc bronchoscopy
9891|NCT02993692|nasotracheal intubation
9892|NCT02993640|vasopressin
9893|NCT02993640|nitroglycerine
9894|NCT02993640|portal pressure
9895|NCT02993640|portal flow
9896|NCT02993627|obesity
9897|NCT02993627|BMI
9898|NCT02993627|body weight
9899|NCT02993601|Heart Failure
9900|NCT02993601|Edema
9901|NCT02993601|Oedema
9902|NCT02993601|Decompensated Heartfailure
9903|NCT02993588|Melatonin
9904|NCT02993588|IVF/ICSI
9905|NCT02993588|Poor ovarian response
9906|NCT02993575|Pharmacokinetics
9907|NCT02993575|Flucloxacillin
9908|NCT02993575|Continuous infusion
9909|NCT02993575|Intensive Care Unit
9910|NCT02993562|Food intake
9911|NCT02993562|Resting Energy Expenditure
9912|NCT02993562|Gall Bladder emptying
9913|NCT02993562|Insulin response
9914|NCT02993562|Body Composition
9915|NCT02993523|Treatment Naïve
9916|NCT02993523|Acute Myeloid Leukemia
9917|NCT02993523|Venetoclax
9918|NCT02993510|microfracture
9919|NCT02993510|enhanced marrow stimulation
9920|NCT02993510|articular cartilage
9921|NCT02993510|Autologous Matrix-Induced Chondrogenesis
9922|NCT02993510|Chondro-Gide®
9923|NCT02993510|knee surgery
9924|NCT02993510|AMIC
9925|NCT02993458|dietary patterns
9926|NCT02993458|blood pressure
9927|NCT02993458|adolescents
9928|NCT02993458|dietary sodium
9929|NCT02993393|Simulation Training [I02.903.847]
9930|NCT02993393|Problem-Based Learning [F02.463.425.720]
9931|NCT02993380|Olive oil
9932|NCT02993380|Erythrocyte membrane fatty acid contents
9933|NCT02993380|Oleic acid
9934|NCT02993367|Butylphthalide Soft Capsules
9935|NCT02993367|VCIND
9936|NCT02993367|fMRI
9937|NCT02993302|vitamin D
9938|NCT02993302|graves' disease
9939|NCT02993302|dendritic cells
9940|NCT02993224|thalassemia
9941|NCT02993211|Bladder cancer
9942|NCT02993211|Transurethral resection
9943|NCT02993211|En bloc resection
9944|NCT02993211|TURBT
9945|NCT02993185|pregnancy
9946|NCT02993185|adolescents
9947|NCT02993185|sexually transmitted diseases
9948|NCT02993185|decision making
9949|NCT02993185|prevention education
9950|NCT02993107|AR101
9951|NCT02993107|Characterized Peanut Allergen
9952|NCT02993107|CPNA (Characterized Peanut Allergen)
9953|NCT02993107|OIT (oral immunotherapy)
9954|NCT02993107|Peanut Allergy
9955|NCT02993107|Allergy
9956|NCT02993107|Peanut-Allergic Children
9957|NCT02993107|Peanut-Allergic Adults
9958|NCT02993107|Desensitization
9959|NCT02993107|PALISADE
9960|NCT02993094|breast cancer
9961|NCT02993094|advanced triple negative
9962|NCT02993094|ixazomib
9963|NCT02993094|carboplatin
9964|NCT02993094|CARIXA
9965|NCT02993094|Study Group of Medical Tumor Therapy (AGMT)
9966|NCT02993081|YAG laser
9967|NCT02993068|Genetic testing
9968|NCT02993068|Genetic educational video
9969|NCT02993068|Genetic counseling
9970|NCT02993068|Online genetic test results
9971|NCT02993068|Telephone genetic counseling
9972|NCT02993068|Saliva test
9973|NCT02993068|Questionnaires
9974|NCT02993068|Surveys
9975|NCT02993042|Rehabilitation
9976|NCT02993042|Robot-assisted gait training
9977|NCT02993029|99Tc-MDP
9978|NCT02993029|osteoarthritis
9979|NCT02993029|celecoxib
9980|NCT02992977|Vaccine, neoantigen
9981|NCT02992951|Infection
9982|NCT02992951|Surgical Site Infection
9983|NCT02992951|Dialkylcarbamoylchloride
9984|NCT02992938|Opioid hyperalgesia
9985|NCT02992938|Acetazolamide
9986|NCT02992938|Remifentanil
9987|NCT02992925|Haemophilus influenza type b
9988|NCT02992925|Adsorbed Diphteria-purified Pertussis-Tetanus-Inactivate poliovirus combined vaccine
9989|NCT02992925|Hib
9990|NCT02992925|DPT-IPV
9991|NCT02992899|stress disorders, post-traumatic
9992|NCT02992899|posttraumatic stress disorder
9993|NCT02992899|PTSD
9994|NCT02992899|vagal nerve
9995|NCT02992886|elderly patients
9996|NCT02992886|rectal cancer
9997|NCT02992886|preoperative chemoradiotherapy
9998|NCT02992886|comprehensive geriatric assessment
9999|NCT02992860|Myelodysplastic Syndrome (MDS)
10000|NCT02992860|Acute Myeloid Leukemia (AML)
10001|NCT02992860|hypomethylating agent (HMA) treatment
10002|NCT02992860|leukemic stem cell
10003|NCT02992860|CD123
10004|NCT02992860|immunotherapy
10005|NCT02992847|Multiple sclerosis
10006|NCT02992847|Gadolinium based contrast agent
10007|NCT02992847|MRI
10008|NCT02992847|Dentate nucleus
10009|NCT02992821|Hand-held
10010|NCT02992821|Ultrasound
10011|NCT02992821|Diagnosis
10012|NCT02992821|Carotid artery stenosis
10013|NCT02992808|IVF
10014|NCT02992808|Ovarian stimulation
10015|NCT02992808|Androgenic profile
10016|NCT02992808|Follicular fluid
10017|NCT02992808|Recombinant gonadotropins
10018|NCT02992808|human menopausal gonadotropin
10019|NCT02992769|Breast Cancer
10020|NCT02992769|Nomogram
10021|NCT02992769|Ultrasound
10022|NCT02992769|Axillary Metastases
10023|NCT02992743|Sarcoma
10024|NCT02992743|Cell Therapy
10025|NCT02992743|T Cell Therapy
10026|NCT02992743|NY-ESO-1
10027|NCT02992743|Immuno-oncology
10028|NCT02992743|Metastatic
10029|NCT02992743|Previously treated
10030|NCT02992743|T Cell Receptor
10031|NCT02992730|Medication Adherence
10032|NCT02992665|Calcium ionophore
10033|NCT02992665|Fertilization
10034|NCT02992665|Sperm
10035|NCT02992665|Oocyte
10036|NCT02992665|ICSI
10037|NCT02992639|High visceral fat
10038|NCT02992639|Liver enzymes
10039|NCT02992639|Aminotransferase
10040|NCT02992639|Mild calorie restriction
10041|NCT02992600|non-cardiac surgery
10042|NCT02992600|Postoperative Cognitive Dysfunction
10043|NCT02992574|Post-Mastectomy Radiation
10044|NCT02992574|Node Negative
10045|NCT02992574|Early breast Cancer
10046|NCT02992561|Aggression
10047|NCT02992561|Violence
10048|NCT02992561|Post-conflict reconstruction
10049|NCT02992561|Demobilization
10050|NCT02992561|Traumatized offenders
10051|NCT02992548|chronic kidney disease
10052|NCT02992548|pravastatin
10053|NCT02992548|erythrocyte membrane fatty acid
10054|NCT02992483|multiple myeloma
10055|NCT02992483|lymphoma
10056|NCT02992483|dlbcl
10057|NCT02992431|patient care planning
10058|NCT02992431|primary health care
10059|NCT02992431|comorbidity
10060|NCT02992418|Dengue Fever
10061|NCT02992418|Dengue Hemorrhagic Fever
10062|NCT02992418|CYD Dengue Vaccine
10063|NCT02992418|Degavaxia®
10064|NCT02992392|Tear film
10065|NCT02992392|Lipid layer
10066|NCT02992392|Liposic
10067|NCT02992392|Tears Naturale Forte
10068|NCT02992379|Anterior disc displacement
10069|NCT02992379|Stabilizing splint
10070|NCT02992366|socket shield
10071|NCT02992366|volumetric tissue alteration
10072|NCT02992366|immediate implant
10073|NCT02992353|VATS
10074|NCT02992353|NSCLC
10075|NCT02992353|recurrence rate
10076|NCT02992288|Chronic Heart Failure
10077|NCT02992288|Heart Failure with Reduced Ejection Fraction
10078|NCT02992275|Hip
10079|NCT02992275|Muscle
10080|NCT02992275|Skeletal/physiopathology
10081|NCT02992223|Aggressive B-cell non-Hodgkin Lymphoma
10082|NCT02992223|Relapsed
10083|NCT02992223|Refractory
10084|NCT02992223|Zevalin
10085|NCT02992223|Y90 Ibritumomab Tiuxetan
10086|NCT02992223|Autologous stem cell transplant
10087|NCT02992223|BEAM
10088|NCT02992223|Recurrent
10089|NCT02992210|CAR
10090|NCT02992210|chimeric antigen receptor
10091|NCT02992210|adoptive T cell transfer
10092|NCT02992197|Rotavirus
10093|NCT02992197|Oral vaccines
10094|NCT02992197|Vaccine underperformance
10095|NCT02992197|Vaccine shedding
10096|NCT02992184|HCV
10097|NCT02992184|Genedrive
10098|NCT02992184|Point of Care
10099|NCT02992119|safety
10100|NCT02992119|immunogenicity
10101|NCT02992106|Maternal Obesity
10102|NCT02992106|Endothelial Dysfunction
10103|NCT02992106|Childhood Obesity
10104|NCT02992093|Polycystic ovary syndrome
10105|NCT02992093|Metabonomics
10106|NCT02992093|Traditional Chinese medicine syndromes
10107|NCT02992080|Patient with Cystic Fibrosis
10108|NCT02992080|Patient without Cystic fibrosis
10109|NCT02992067|lymph node metastasis
10110|NCT02992067|breast cancer
10111|NCT02992067|CK19
10112|NCT02992067|contrast-enhanced ultrasonography
10113|NCT02992028|Rotator cuff repair
10114|NCT02992028|Vitamin C
10115|NCT02992028|postoperative pain
10116|NCT02991989|Home-based exercise
10117|NCT02991989|Exercise snacking
10118|NCT02991989|Protein
10119|NCT02991989|Yogurt
10120|NCT02991976|Normobaric hyperoxia
10121|NCT02991976|Cerebral oxygenation
10122|NCT02991976|Near-infrared spectroscopy
10123|NCT02991976|Carotid endarterectomy
10124|NCT02991976|TIVA
10125|NCT02991924|endobronchial ultrasound
10126|NCT02991924|EBUS-TBNA
10127|NCT02991924|lung cancer
10128|NCT02991924|staging
10129|NCT02991911|metastatic, prostate cancer
10130|NCT02991898|Acute Leukemias
10131|NCT02991898|Burkitt's Lymphoma
10132|NCT02991898|Natural Killer Cell Malignancies
10133|NCT02991898|Chronic Myelogenous Leukemia
10134|NCT02991898|Myelodysplastic Syndrome
10135|NCT02991898|Large-Cell Lymphoma, Hodgkin Lymphoma, and Multiple Myeloma
10136|NCT02991898|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma:
10137|NCT02991898|Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma Prolymphocytic Leukemia
10138|NCT02991872|Persistence
10139|NCT02991872|Purified chicken-embryo cell rabies vaccine
10140|NCT02991872|Rabies Virus Neutralizing Antibody (RVNA)
10141|NCT02991872|Immunogenicity
10142|NCT02991872|Post-Exposure Prophylaxis (PEP)
10143|NCT02991872|Rabipur
10144|NCT02991859|Dose-response
10145|NCT02991859|AMP challenge
10146|NCT02991859|cortisol suppression
10147|NCT02991859|dose escalation
10148|NCT02991859|therapeutic index
10149|NCT02991846|chronic graft-versus-host disease cGVHD
10150|NCT02991846|Hematopoietic stem cell transplantation HSCT
10151|NCT02991846|NIH consensus criteria
10152|NCT02991846|GITMO
10153|NCT02991833|urinary incontinence
10154|NCT02991833|care product
10155|NCT02991833|bowel incontinence
10156|NCT02991807|PTEN
10157|NCT02991807|PTEN Gene Mutation
10158|NCT02991807|PTEN Hamartoma Tumor Syndrome
10159|NCT02991807|Autism
10160|NCT02991807|Intellectual Disability
10161|NCT02991807|Neurocognition
10162|NCT02991807|Afinitor
10163|NCT02991807|Everolimus
10164|NCT02991807|RAD001
10165|NCT02991794|prostatectomy
10166|NCT02991794|laparoscopy
10167|NCT02991794|3D visualization
10168|NCT02991794|learning curve
10169|NCT02991794|anastomosis
10170|NCT02991742|nephropathy
10171|NCT02991742|catheterization
10172|NCT02991742|contrast media
10173|NCT02991742|ioxaglate
10174|NCT02991742|iodixanol
10175|NCT02991742|high risk
10176|NCT02991742|prevention
10177|NCT02991729|Decision aid
10178|NCT02991703|Arterial stiffness
10179|NCT02991703|pulse wave velocity
10180|NCT02991703|Sphygmocor
10181|NCT02991703|applanation tonometry
10182|NCT02991703|pOpmètre
10183|NCT02991703|children
10184|NCT02991703|EPIPAGE cohort
10185|NCT02991690|Hypothermia
10186|NCT02991690|Cervical Spinal Cord Injury
10187|NCT02991690|Trauma
10188|NCT02991677|exercise
10189|NCT02991677|neuropathy
10190|NCT02991664|glass ionomer cement
10191|NCT02991664|composite resin
10192|NCT02991651|RXR agonist IRX4204 erlotinib
10193|NCT02991599|Hepatitis B, Vaccine
10194|NCT02991599|Immunogenicity
10195|NCT02991599|methadone maintenance treatment
10196|NCT02991599|Randomized Controlled Trial
10197|NCT02991586|Emotional Instability
10198|NCT02991586|Family Therapy
10199|NCT02991586|BPD
10200|NCT02991586|DBT
10201|NCT02991560|physiotherapy
10202|NCT02991560|taping
10203|NCT02991560|conservative treatment
10204|NCT02991534|Patient Participation [N05.300.150.600.620]
10205|NCT02991534|Health Behavior [F01.145.488]
10206|NCT02991534|Women [M01.975]
10207|NCT02991534|Patient Satisfaction [N05.715.360.600]
10208|NCT02991534|Physicians, Primary Care [M01.526.485.810.800]
10209|NCT02991534|Physicians, Women [M01.526.485.810.820]
10210|NCT02991534|Health Educators [M01.526.485.410]
10211|NCT02991534|Cardiovascular Diseases [C14]
10212|NCT02991534|Hypertension [C14.907.489]
10213|NCT02991534|Hyperlipidemias [C18.452.584.500.500]
10214|NCT02991534|Dyslipidemias [C18.452.584.500]
10215|NCT02991534|Obesity [C18.654.726.500]
10216|NCT02991534|Diabetes Mellitus [C18.452.394.750]
10217|NCT02991534|Tobacco Use Disorder [C25.775.912]
10218|NCT02991534|Overweight [C23.888.144.699]
10219|NCT02991508|Adrecizumab
10220|NCT02991508|Phase 1 clinical trial
10221|NCT02991508|Adrenomedullin
10222|NCT02991508|Healthy volunteers
10223|NCT02991508|Monoclonal recombinant antibody
10224|NCT02991495|epidemic response
10225|NCT02991482|MPM
10226|NCT02991456|malignant glioma
10227|NCT02991456|temozolomide
10228|NCT02991456|temodar
10229|NCT02991456|radiation
10230|NCT02991456|emesis
10231|NCT02991456|nausea
10232|NCT02991456|vomiting
10233|NCT02991456|chemotherapy
10234|NCT02991456|Affronti
10235|NCT02991456|Peters
10236|NCT02991456|00076418
10237|NCT02991378|preschool children
10238|NCT02991378|emotional disorders/problems
10239|NCT02991378|stress related disorders/problems
10240|NCT02991378|early intervention
10241|NCT02991352|Vascular Malformations
10242|NCT02991352|Image Guidance
10243|NCT02991339|Dexamethasone
10244|NCT02991339|Liver Dysfunction
10245|NCT02991339|Hepatectomy
10246|NCT02991339|Bilirubinaemia
10247|NCT02991339|Jaundice
10248|NCT02991326|Osteopathic Manipulative Treatment
10249|NCT02991326|Temporomandibular Disorder
10250|NCT02991300|focal defect
10251|NCT02991300|focal lesion
10252|NCT02991300|chondral lesion
10253|NCT02991300|osteochondral lesion
10254|NCT02991274|T790M
10255|NCT02991274|EGFR (Epidermal Growth Factor Receptor) mutation
10256|NCT02991274|NSCLC
10257|NCT02991196|Advanced colorectal cancer
10258|NCT02991196|DNA mismatch repair (MMR)
10259|NCT02991196|MMR-proficient Subjects
10260|NCT02991196|TRAIL-R2 (DR5) Antibody
10261|NCT02991183|Caregivers
10262|NCT02991183|Acceptance and Commitment Therapy
10263|NCT02991170|myocardial infarction
10264|NCT02991170|ventricular arrhythmia
10265|NCT02991170|radiofrequency ablation
10266|NCT02991170|Coronary Artery Bypass Grafts
10267|NCT02991157|cerebral vasospasm
10268|NCT02991157|nimodipine
10269|NCT02991144|Gene Transfer
10270|NCT02991144|OTC Deficiency
10271|NCT02991144|Urea Cycle Disorder
10272|NCT02991131|Acute bacterial skin infection
10273|NCT02991131|Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
10274|NCT02991131|Abscess
10275|NCT02991131|Cellulitis
10276|NCT02991131|Erysipelas
10277|NCT02991131|Wound infection
10278|NCT02991131|Methicillin resistant Staphylococcus aureus (MRSA)
10279|NCT02991118|hyperlipidemia
10280|NCT02991118|cholesterol
10281|NCT02991118|familial hypercholesterolemia
10282|NCT02991118|atherosclerotic cardiovascular disease
10283|NCT02991118|ASCVD
10284|NCT02991118|HeFH
10285|NCT02991118|LDL
10286|NCT02991105|Malignancy
10287|NCT02991105|Cancer
10288|NCT02991105|Organ Transplantation
10289|NCT02991092|colon carcinoma
10290|NCT02991092|liquid treatment
10291|NCT02991092|fast-track surgery
10292|NCT02991079|Food Habits
10293|NCT02991079|Health education
10294|NCT02991079|Physical activity
10295|NCT02991079|Information and Communication Technologies
10296|NCT02991066|Acute promyelocytic leukemia
10297|NCT02991066|Coagulopathy
10298|NCT02991066|Microparticles
10299|NCT02991066|Mechanism
10300|NCT02991053|Intra-operative anesthesia
10301|NCT02991053|Pediatric patient
10302|NCT02991053|Transversus Abdominis Plane Block
10303|NCT02991053|ilioinguinal / iliohypogastric nerve block
10304|NCT02991027|no known ocular pathology
10305|NCT02991014|music intervention
10306|NCT02991014|heart rate variability
10307|NCT02991014|frequency modulation
10308|NCT02991014|pain perception
10309|NCT02991014|cold pressor test (CPT)
10310|NCT02991001|Hydrodissection
10311|NCT02990988|Blood donation
10312|NCT02990988|Iron repletion
10313|NCT02990988|Transfusion
10314|NCT02990975|Intra-operative anesthesia
10315|NCT02990975|Pediatric patient
10316|NCT02990975|Transversus Abdominis Plane Block
10317|NCT02990962|perineural injection
10318|NCT02990962|ultrasound-guided
10319|NCT02990962|dextrose
10320|NCT02990962|steroid
10321|NCT02990936|Oropharynx squamous cell carcinoma
10322|NCT02990936|tumor growth
10323|NCT02990936|predictive markers
10324|NCT02990936|tumoral kinetics
10325|NCT02990910|respiratory morbidity
10326|NCT02990910|obstructive sleep apnea syndrome
10327|NCT02990897|Medical informatics
10328|NCT02990897|Quality of care
10329|NCT02990897|Referral
10330|NCT02990884|Intra-operative anesthesia and analgesia
10331|NCT02990884|ilioinguinal / iliohyogogastric nerve block
10332|NCT02990884|Pediatric patient
10333|NCT02990819|Immunodeficiencies
10334|NCT02990819|Immune dysregulation syndromes
10335|NCT02990793|PTSD
10336|NCT02990793|Concussion
10337|NCT02990793|TBI
10338|NCT02990793|TMS
10339|NCT02990741|atrial fibrillation
10340|NCT02990741|automated ECG system
10341|NCT02990728|Endometrial Cancer.Mirena®
10342|NCT02990715|average risk CRC screening
10343|NCT02990715|Non compliant patients for CRC screening
10344|NCT02990715|Counterindicated patients for colonoscopy
10345|NCT02990702|Infraclavicular block
10346|NCT02990702|Retroclavicular block
10347|NCT02990702|Ultrasound
10348|NCT02990676|Cognition
10349|NCT02990676|Computerised cognitive training
10350|NCT02990676|Feasibility study
10351|NCT02990676|Huntington's disease
10352|NCT02990676|Translational
10353|NCT02990663|Pragmatic
10354|NCT02990663|Primary Care
10355|NCT02990663|Chronotherapy
10356|NCT02990663|Administrative Data
10357|NCT02990663|Stroke
10358|NCT02990663|Myocardial Infarction
10359|NCT02990663|Congestive Heart Failure
10360|NCT02990663|Glaucoma
10361|NCT02990663|Dementia
10362|NCT02990663|Hip Fracture
10363|NCT02990637|Olive leaf extract
10364|NCT02990637|Cardiovascular health
10365|NCT02990637|Cholesterol
10366|NCT02990624|psoriasis
10367|NCT02990624|photochemotherapy
10368|NCT02990624|atherosclerosis
10369|NCT02990624|metabolic syndrome
10370|NCT02990624|cardiovascular risk
10371|NCT02990598|Hydroxyurea
10372|NCT02990572|Amish
10373|NCT02990572|Mennonite
10374|NCT02990559|Iron repletion
10375|NCT02990559|Blood donation
10376|NCT02990559|Transfusion
10377|NCT02990507|mobility impairment
10378|NCT02990507|virtual environment
10379|NCT02990507|exercise
10380|NCT02990507|physical activity
10381|NCT02990468|Mucositis
10382|NCT02990468|Xerostomia
10383|NCT02990455|alcohol
10384|NCT02990455|drinking
10385|NCT02990455|smoking
10386|NCT02990455|cigarette
10387|NCT02990455|nicotine
10388|NCT02990442|rTMS
10389|NCT02990442|Repetitive Transcranial Magnetic Stimulation
10390|NCT02990442|Brain Stimulation
10391|NCT02990429|hypothermia
10392|NCT02990429|Shivering
10393|NCT02990429|Gynecologic laparoscopic surgery
10394|NCT02990429|Warming
10395|NCT02990429|General anesthesia
10396|NCT02990377|Opioid Analgesics
10397|NCT02990377|Opioid Safety
10398|NCT02990377|Emergency Department
10399|NCT02990377|Motivational Enhancement
10400|NCT02990377|Interactive Voice Response
10401|NCT02990377|Reinforcement Learning
10402|NCT02990377|mHealth
10403|NCT02990364|Circumcision
10404|NCT02990364|Analgesia
10405|NCT02990364|Controlled Clinical Trial
10406|NCT02990325|ABX464, HIV infection
10407|NCT02990299|Diabetes Mellitus, Type 2
10408|NCT02990299|Medication Adherence
10409|NCT02990299|Telemedicine
10410|NCT02990299|Community Health Workers
10411|NCT02990299|Pharmacists
10412|NCT02990299|Mobile Health
10413|NCT02990286|Non specific intertitial pneumonia
10414|NCT02990286|interstitial pneumonia with autoimmune feature
10415|NCT02990286|connective tissue disease
10416|NCT02990286|rituximab
10417|NCT02990286|Mycophenolate Mofetil
10418|NCT02990286|pulmonary fibrosis
10419|NCT02990247|Asthma
10420|NCT02990247|Exacerbations
10421|NCT02990247|Telemonitoring
10422|NCT02990247|Biomarkers
10423|NCT02990234|Capsular Repair
10424|NCT02990234|FAI
10425|NCT02990234|Hip
10426|NCT02990221|Field Cancerization
10427|NCT02990208|Diaphragmatic Breathing
10428|NCT02990208|Virtual Reality Exposure Therapy
10429|NCT02990182|Yellow Fever Vaccine
10430|NCT02990182|Immunity, Humoral
10431|NCT02990182|Immunity, Cellular
10432|NCT02990182|children
10433|NCT02990156|Coils
10434|NCT02990091|TBI
10435|NCT02990091|DHA
10436|NCT02990091|omega-3 highly unsaturated fatty acids
10437|NCT02990091|synaptamide
10438|NCT02990078|TBI
10439|NCT02990078|CVR
10440|NCT02990078|Hypercapnia
10441|NCT02990078|fNIRS
10442|NCT02990065|PROTEIN SUPPLEMENTATION
10443|NCT02990065|NUTRITIONAL STATUS
10444|NCT02990039|physical activity
10445|NCT02990039|sedentary time
10446|NCT02990039|feasibility study
10447|NCT02990039|accelerometer
10448|NCT02989987|PTSD
10449|NCT02989987|Shame
10450|NCT02989987|Narrative Exposure Therapy
10451|NCT02989987|Sexual and gender based violence (SGBV)
10452|NCT02989987|DR Congo
10453|NCT02989974|Survivorship Care
10454|NCT02989974|Caregiving
10455|NCT02989948|Endovascular
10456|NCT02989935|respiratory muscle
10457|NCT02989935|bronchodilator
10458|NCT02989896|Perfusion index
10459|NCT02989896|Peripheral nerve block success
10460|NCT02989896|older age
10461|NCT02989883|achalasia
10462|NCT02989883|POEM
10463|NCT02989883|outcome
10464|NCT02989870|Liver Disease
10465|NCT02989870|Child-Pugh Class A
10466|NCT02989870|Child-Pugh Class B7
10467|NCT02989857|IDH1
10468|NCT02989831|diabetic neuropathy
10469|NCT02989831|foot ulcers
10470|NCT02989831|random vibration
10471|NCT02989831|vibration perception threshold
10472|NCT02989831|mechanical noise
10473|NCT02989805|Emergency Medicine
10474|NCT02989805|Psychiatry
10475|NCT02989805|Health Promotion
10476|NCT02989805|Public Health
10477|NCT02989792|pain
10478|NCT02989753|Prevention
10479|NCT02989740|Diabetes Mellitus
10480|NCT02989740|Thincap fibroatheroma
10481|NCT02989740|Optical Coherence Tomography
10482|NCT02989740|Fractional Flow Reserve
10483|NCT02989701|Plerixafor
10484|NCT02989675|pediatric
10485|NCT02989675|critical illness
10486|NCT02989675|Malawi
10487|NCT02989649|Drug Therapy
10488|NCT02989584|bladder cancer
10489|NCT02989584|metastatic bladder cancer
10490|NCT02989584|atezolizumab
10491|NCT02989584|urothelial carcinoma
10492|NCT02989519|preterm labor
10493|NCT02989519|progesterone efficacy
10494|NCT02989519|threatened preterm labor
10495|NCT02989493|Alcoholism
10496|NCT02989493|Stress
10497|NCT02989493|Norepinephrine
10498|NCT02989493|Doxazosin
10499|NCT02989493|Anxiety
10500|NCT02989493|Startle Potentiation
10501|NCT02989493|Relapse
10502|NCT02989493|Adrenergic Antagonists
10503|NCT02989493|Surrogate Endpoint
10504|NCT02989480|Cardiomyopathy
10505|NCT02989441|Perfusion Index
10506|NCT02989441|Hemodynamics
10507|NCT02989441|Anesthesia
10508|NCT02989441|Stroke Volume
10509|NCT02989415|Anesthesia
10510|NCT02989415|Mechanical Ventilation
10511|NCT02989415|Robotic Surgery
10512|NCT02989415|Postoperative Pulmonary Complications
10513|NCT02989402|Alzheimer, Rivastigmine
10514|NCT02989363|deep brain surgery and complex back surgery
10515|NCT02989337|Hyperemesis Gravidarum
10516|NCT02989337|Inflammatory adhesion molecules
10517|NCT02989337|Dehydration
10518|NCT02989311|Iron absorption
10519|NCT02989311|Iron deficiency
10520|NCT02989311|Hepcidin
10521|NCT02989311|Stable isotopes
10522|NCT02989311|Anemia
10523|NCT02989311|Infants
10524|NCT02989298|Peritoneal Dialysis (PD)
10525|NCT02989298|Residual renal function
10526|NCT02989298|Peritoneum function
10527|NCT02989298|Peritonitis rate
10528|NCT02989298|Technical survival
10529|NCT02989298|Patient survival
10530|NCT02989285|HIV
10531|NCT02989285|HIV-associated neurocognitive disorder (HAND)
10532|NCT02989285|Neurology
10533|NCT02989285|Latent HIV
10534|NCT02989285|HIV Reservoirs
10535|NCT02989259|apatinib
10536|NCT02989259|advanced head and neck cancer
10537|NCT02989259|non-squamous
10538|NCT02989246|pediatrics
10539|NCT02989246|ventilator weaning
10540|NCT02989220|Miscarriage
10541|NCT02989207|Glaucoma
10542|NCT02989207|Trabeculectomy
10543|NCT02989207|Glaucoma drainage implant
10544|NCT02989207|Africa and Africa-Caribbean
10545|NCT02989168|Idiopathic pulmonary fibrosis
10546|NCT02989168|hypoxemia
10547|NCT02989168|oxygen
10548|NCT02989142|interpregnancy
10549|NCT02989142|pregnancy-induced hypertension
10550|NCT02989142|gestational diabetes mellitus
10551|NCT02989142|caesarean section
10552|NCT02989142|large-for-gestational-age
10553|NCT02989129|Polyneuropathies and Other Disorders of the Peripheral Nervous System
10554|NCT02989129|Chemotherapy Induced Neuropathic Pain
10555|NCT02989129|CINP
10556|NCT02989129|Quercetin
10557|NCT02989129|Questionnaires
10558|NCT02989129|Surveys
10559|NCT02989116|Learning
10560|NCT02989116|Executive functions
10561|NCT02989116|Cognitive control
10562|NCT02989116|Prefrontal Cortex
10563|NCT02989116|Typically developing children
10564|NCT02989116|Genotype
10565|NCT02989116|Functional Magnetic Resonance Imaging
10566|NCT02989116|Structural Magnetic Resonance Imaging
10567|NCT02989116|Inhibition
10568|NCT02989116|Working Memory
10569|NCT02989116|Metacognition
10570|NCT02989116|Mindfulness
10571|NCT02989116|Preterm children
10572|NCT02989116|Developmental Psychology
10573|NCT02989116|Developmental cognitive neuroscience
10574|NCT02989116|Touch screen tablet
10575|NCT02989116|Adaptive training
10576|NCT02989103|Hyperthyroidism
10577|NCT02989103|Radiation
10578|NCT02989103|Mortality
10579|NCT02989090|Patient Engagement
10580|NCT02989090|Defibrillators
10581|NCT02989090|Health Records, Personal
10582|NCT02989090|Patient Portal
10583|NCT02989077|combined coronary and cerebral ischemia
10584|NCT02989064|Cell Therapy
10585|NCT02989064|T Cell Therapy
10586|NCT02989064|SPEAR T Cell
10587|NCT02989064|MAGE-A10
10588|NCT02989064|Immuno-oncology
10589|NCT02989064|Metastatic
10590|NCT02989064|Urothelial Cancer
10591|NCT02989064|Previously Treated
10592|NCT02989064|T Cell Receptor
10593|NCT02989038|smoker
10594|NCT02989038|young adult
10595|NCT02988999|D-allulose or erythritol
10596|NCT02988986|mTOR
10597|NCT02988986|Tamoxifen
10598|NCT02988986|Breast Cancer
10599|NCT02988973|Anemia
10600|NCT02988973|Non-dialysis chronic kidney disease
10601|NCT02988973|ASP1517
10602|NCT02988960|Pancreatic adenocarcinoma
10603|NCT02988960|Non-small cell lung cancer (NSCLC)
10604|NCT02988960|Squamous cell carcinoma of the head and neck (SCCHN)
10605|NCT02988960|Nivolumab
10606|NCT02988960|Cutaneous melanoma
10607|NCT02988960|Advanced solid tumor
10608|NCT02988960|Cancer
10609|NCT02988947|Knee Arthroplasty
10610|NCT02988947|Hypnosis
10611|NCT02988947|Pain Neuroscience Education
10612|NCT02988947|Pain
10613|NCT02988947|Catastrophizing
10614|NCT02988947|Optimism
10615|NCT02988947|Distress
10616|NCT02988947|Hope
10617|NCT02988947|Self-Efficacy
10618|NCT02986386|Dental Occlusion
10619|NCT02986386|Oral Health
10620|NCT02986386|Mastication
10621|NCT02986386|Dementia
10622|NCT02986386|Psychological health
10623|NCT02986373|ABBV-066
10624|NCT02986373|risankizumab
10625|NCT02986373|BI655066
10626|NCT02986334|chronic
10627|NCT02986334|low back
10628|NCT02986334|back
10629|NCT02986334|pain
10630|NCT02986334|brain
10631|NCT02986334|MRI
10632|NCT02986321|anti-inflammatory respiratory drug
10633|NCT02986321|PDE4 inhibitor
10634|NCT02986308|Metabolomics
10635|NCT02986308|Intestinal Polyps
10636|NCT02986308|TCM Syndromes
10637|NCT02986308|TCM Constitution Types
10638|NCT02988869|COPD
10639|NCT02988869|Tiotropium
10640|NCT02988869|Formoterol
10641|NCT02988843|GCT
10642|NCT02988830|Subcutaneous stimulation
10643|NCT02988804|endoscopic endonasal transsphenoidal surgery
10644|NCT02988804|laryngeal mask
10645|NCT02988765|vulvar cancer
10646|NCT02988765|inguinal lymph node
10647|NCT02988765|lymph node status
10648|NCT02988765|cytology
10649|NCT02988765|core biopsy
10650|NCT02988726|Neurofibroma
10651|NCT02988726|Schwannoma
10652|NCT02988713|stimulation
10653|NCT02988713|chronic pain
10654|NCT02988713|back pain
10655|NCT02988713|leg pain
10656|NCT02988687|fatigue
10657|NCT02988687|quality of life
10658|NCT02988687|depression
10659|NCT02988687|cognitive function
10660|NCT02988687|growth hormone
10661|NCT02988687|traumatic brain injury
10662|NCT02988674|Ankylosing spondylitis
10663|NCT02988674|Humira®
10664|NCT02988674|Adalimumab
10665|NCT02988674|Spondylarthritis
10666|NCT02988674|Psoriatic arthritis
10667|NCT02988661|Autoimmunity
10668|NCT02988661|Immune System Disorders
10669|NCT02988648|Metastatic Breast Cancer
10670|NCT02988635|Early Palliative Care
10671|NCT02988635|Simultaneous Care
10672|NCT02988635|Chemotherapy
10673|NCT02988635|Quality of Life
10674|NCT02988596|Concussion
10675|NCT02988596|Rehabilitation
10676|NCT02988583|silicone oil
10677|NCT02988583|emulsification
10678|NCT02988583|retinal detachment surgery
10679|NCT02988557|cerebral palsy
10680|NCT02988557|gait
10681|NCT02988557|slope
10682|NCT02988557|electromyography
10683|NCT02988531|PET
10684|NCT02988531|MRI
10685|NCT02988531|Attenuation
10686|NCT02988531|Correction
10687|NCT02988531|Cardiovascular
10688|NCT02988531|coronary
10689|NCT02988531|disease
10690|NCT02988518|Psychiatry
10691|NCT02988518|Bipolar disorder
10692|NCT02988518|Memory complaints
10693|NCT02988518|Global functioning
10694|NCT02988518|Cognitive remediation
10695|NCT02988518|Working memory
10696|NCT02988466|Acute Leukemias
10697|NCT02988466|Acute myeloid leukemia (AML)
10698|NCT02988466|Acute lymphoblastic leukemia (ALL)/lymphoma
10699|NCT02988466|Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
10700|NCT02988466|Myelodysplastic syndrome
10701|NCT02988466|Chronic myelogenous leukemia
10702|NCT02988466|Minimal Residual Disease (MRD) positive leukemia
10703|NCT02988466|Leukemia or Myelodysplastic Syndromes (MDS) in aplasia
10704|NCT02988466|Myeloproliferative neoplasms/myelofibrosis
10705|NCT02988466|Relapsed large-cell lymphoma, mantle-cell lymphoma and Hodgkin lymphoma
10706|NCT02988466|Burkitt's lymphoma
10707|NCT02988466|Relapsed T-cell lymphoma
10708|NCT02988466|Natural Killer cell malignancies
10709|NCT02988466|Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma
10710|NCT02988466|Lymphoplasmacytic lymphoma
10711|NCT02988466|Relapsed multiple myeloma
10712|NCT02988466|Bone marrow failure syndromes
10713|NCT02988453|mentalization-based treatment
10714|NCT02988453|conduct disorder
10715|NCT02988453|adolescents
10716|NCT02988440|HCC
10717|NCT02988440|Hepatocellular carcinoma
10718|NCT02988440|Hepatocellular carcinoma (HCC)
10719|NCT02988440|PDR001
10720|NCT02988440|liver cancer
10721|NCT02988440|immunotherapy liver
10722|NCT02988440|malignant hepatoma
10723|NCT02988440|Hepatocellular cancer
10724|NCT02988440|advanced hepatocellular carcinoma (HCC)
10725|NCT02988440|advanced liver cancer
10726|NCT02988440|liver cancer progression
10727|NCT02988440|sorafenib
10728|NCT02988440|anti-PD1
10729|NCT02988440|first line
10730|NCT02988414|Sepsis
10731|NCT02988414|Infection
10732|NCT02988414|Culture
10733|NCT02988414|Sequencing
10734|NCT02988414|Non-invasive
10735|NCT02988414|NGS
10736|NCT02988375|insomnia
10737|NCT02988375|depression
10738|NCT02988375|digital CBTI
10739|NCT02988375|online CBTI
10740|NCT02988336|difficult intubation
10741|NCT02988336|thyromental height
10742|NCT02988323|sport concussion
10743|NCT02988323|cervical spine
10744|NCT02988323|vestibular rehabilitation
10745|NCT02988323|exercise
10746|NCT02988323|rehabilitation
10747|NCT02988323|children
10748|NCT02988323|youth
10749|NCT02988310|Limb Loss
10750|NCT02988310|Gait Characteristics
10751|NCT02988284|Gait variability
10752|NCT02988271|Meditation
10753|NCT02988271|Anxiety
10754|NCT02988271|Psychosocial distress
10755|NCT02988271|Depression
10756|NCT02988271|Questionnaires
10757|NCT02988271|Surveys
10758|NCT02988271|Meditation Video
10759|NCT02988271|Meditation app
10760|NCT02988258|Ex vivo gene therapy
10761|NCT02988258|T cell receptor transduction
10762|NCT02988258|Immunotherapy
10763|NCT02988258|Allogeneic Haematopoietic Stem Cell Transplantation
10764|NCT02988258|CMV
10765|NCT02988232|Work Related Chronic Low Back Pain
10766|NCT02988232|Korean Medicine
10767|NCT02988232|Sogyeonghwalhyeol-tang
10768|NCT02988219|cardiac arrhythmia
10769|NCT02988219|epidural anesthesia
10770|NCT02988219|combined anesthesia
10771|NCT02988219|general anesthesia
10772|NCT02988219|NSS
10773|NCT02988219|radical nephrectomy
10774|NCT02988219|extraperitoneal
10775|NCT02988193|clinical reasoning artificial intelligence
10776|NCT02988193|poorly controlled hypertension
10777|NCT02988167|Spontaneous Breathing Trial (SBT)
10778|NCT02988167|Extubation Decision Support Tool
10779|NCT02988167|Extubation
10780|NCT02988167|Extubation Readiness
10781|NCT02988154|Medical education
10782|NCT02988154|simulation
10783|NCT02988154|neurosurgical education
10784|NCT02988154|Simulation laboratory
10785|NCT02988154|Ventricular drain
10786|NCT02988128|Embolization Device
10787|NCT02988128|Flow Diverter
10788|NCT02988128|Intra saccular device
10789|NCT02988128|Vascular Reconstruction Device
10790|NCT02988128|Ruptured Intracranial Aneurysm
10791|NCT02988128|Unruptured Intracranial Aneurysm
10792|NCT02988115|hyperlipidemia
10793|NCT02988115|cholesterol
10794|NCT02988115|familial hypercholesterolemia
10795|NCT02988115|atherosclerotic cardiovascular disease
10796|NCT02988115|ASCVD
10797|NCT02988115|HeFH
10798|NCT02988115|LDL
10799|NCT02988115|statin intolerence
10800|NCT02988102|S100B, NSE
10801|NCT02988102|moderate brain trauma
10802|NCT02988102|mild brain trauma
10803|NCT02988089|Helicobacter Pylori Infection
10804|NCT02988089|Antimicrobial susceptibility testing (AST)
10805|NCT02986295|BioMime, Ultimaster, Ischemic heart disease, DES
10806|NCT02986282|ankle - brachial index
10807|NCT02986269|Respiratory Function
10808|NCT02986269|Patient Positioning
10809|NCT02986269|anesthesia
10810|NCT02986256|telemedicine
10811|NCT02986230|Cancer prevention
10812|NCT02986230|Clinical Decision Support
10813|NCT02986230|Rural Health
10814|NCT02986230|Shared Decision Making
10815|NCT02986204|implant removal
10816|NCT02986204|Nexplanon
10817|NCT02986204|Implanon
10818|NCT02986204|contraception
10819|NCT02986204|ENG
10820|NCT02986191|gingival graft
10821|NCT02986191|free gingival graft
10822|NCT02986191|coronally advanced flap
10823|NCT02986191|reduced keratinized gingiva
10824|NCT02986178|Glioblastoma
10825|NCT02986178|Glioma
10826|NCT02986178|PVSRIPO
10827|NCT02986178|Duke
10828|NCT02986178|Pro00077024
10829|NCT02986178|Vlahovic
10830|NCT02986178|Brain tumor
10831|NCT02986178|Bigner
10832|NCT02986165|Platelet Aggregation
10833|NCT02986152|PTSD
10834|NCT02986152|anxiety
10835|NCT02986152|depression
10836|NCT02986152|distress
10837|NCT02986152|fear
10838|NCT02986152|coping
10839|NCT02986152|support
10840|NCT02986152|caregiver
10841|NCT02986152|oncology
10842|NCT02986152|app
10843|NCT02986152|mobile app
10844|NCT02986126|Depression
10845|NCT02986126|Resilience
10846|NCT02986126|Minority health
10847|NCT02986126|Community-based participatory research
10848|NCT02986126|Lesbian, gay, bisexual, transgender, and intersex (LGBTI) health
10849|NCT02986126|Racial / ethnic health disparities
10850|NCT02986126|Patient-centered outcomes research
10851|NCT02986126|Comparative-effectiveness research
10852|NCT02986100|rucaparib
10853|NCT02986100|CO-338
10854|NCT02986100|Clovis
10855|NCT02986100|Clovis Oncology
10856|NCT02986100|PARP inhibitor
10857|NCT02986100|Absorption
10858|NCT02986100|Metabolism
10859|NCT02986100|Excretion
10860|NCT02988063|Varithena
10861|NCT02988063|Polidocanol Endovenous Microfoam
10862|NCT02988050|Epilepsy Surgery
10863|NCT02988050|Conscious sedation
10864|NCT02988011|type 2 diabetes
10865|NCT02988011|gastric by-pass surgery
10866|NCT02988011|low calorie diet
10867|NCT02988011|glucose metabolism
10868|NCT02987998|Pembrolizumab
10869|NCT02987998|Chemoradiation
10870|NCT02987985|Opioid-sparing
10871|NCT02987985|Opioid-free
10872|NCT02987959|TAK-228
10873|NCT02987959|MLN0128
10874|NCT02987959|mTOR
10875|NCT02987933|Chronic Pain
10876|NCT02987933|fMRI
10877|NCT02987933|DTI
10878|NCT02987894|TAVI
10879|NCT02987894|Transcatheter Aortic Valve Replacement
10880|NCT02987894|Transcatheter Aortic Valve Implant
10881|NCT02987894|Transfemoral access
10882|NCT02987894|Aortic valve regurgitation
10883|NCT02987868|Somatostatin
10884|NCT02987868|Thyroid Hormone
10885|NCT02987868|Growth Hormone
10886|NCT02987842|Mild cognitive impairment
10887|NCT02987842|Alzhiemer's disease
10888|NCT02987842|Neurofeedback
10889|NCT02987842|EEG
10890|NCT02987803|Patient Engagement
10891|NCT02987803|Public Reporting
10892|NCT02987803|Quality Measurement
10893|NCT02987790|Intensive care
10894|NCT02987790|Sepsis
10895|NCT02987790|Biomarkers
10896|NCT02987790|C-reactive Protein
10897|NCT02987790|Antimicrobial
10898|NCT02987764|Premature
10899|NCT02987764|Birth weight
10900|NCT02987725|Adolescence
10901|NCT02987725|Autonomic Nervous System
10902|NCT02987725|Hypnosis
10903|NCT02987725|Pain
10904|NCT02987725|Sickle Cell Disease
10905|NCT02987712|Thromboelastography
10906|NCT02987699|Hepatocellular Carcinoma
10907|NCT02987699|Hepatic arterial infusion chemotherapy
10908|NCT02987699|optimal dose
10909|NCT02987686|Topical Infliximab
10910|NCT02987686|Cornea
10911|NCT02987686|Keratolysis
10912|NCT02987673|Mini/One anastomosis gastric bypass
10913|NCT02987673|Sleeve Gastrectomy
10914|NCT02987673|Gastro-esophageal sphincter function
10915|NCT02987634|gingivitis
10916|NCT02987634|dental implant
10917|NCT02987634|mouthwash
10918|NCT02987595|intervention
10919|NCT02987595|lignans
10920|NCT02987595|whole-grain
10921|NCT02987582|mental health
10922|NCT02987582|mindfulness
10923|NCT02987582|shame
10924|NCT02987569|Home Parenteral Nutrition
10925|NCT02987569|HPN
10926|NCT02987569|Total Parenteral Nutrition
10927|NCT02987569|TPN
10928|NCT02987569|mConnect
10929|NCT02987569|SBS
10930|NCT02987569|short bowel disorder
10931|NCT02987569|telehealth
10932|NCT02987569|telemedicine
10933|NCT02987543|metastatic castration-resistant prostate cancer (mCRPC)
10934|NCT02987543|homologous recombination repair (HRR)
10935|NCT02987530|primary infection
10936|NCT02987517|running
10937|NCT02987517|vertical load rates
10938|NCT02987517|cadence
10939|NCT02987517|footstrike
10940|NCT02987504|Cancer
10941|NCT02987504|Solid tumor
10942|NCT02987504|Phase 1
10943|NCT02987491|exercise
10944|NCT02987478|Vitamin D following intra cytoplasmic sperm injection
10945|NCT02987452|exercise
10946|NCT02987452|resistant hypertension
10947|NCT02987452|blood pressure
10948|NCT02987439|COPD
10949|NCT02987439|Exacerbation
10950|NCT02987439|Rehabilitation
10951|NCT02987413|Amyotrophic Lateral Sclerosis
10952|NCT02987400|DLBCL
10953|NCT02987400|GA-101
10954|NCT02987400|ABT-199
10955|NCT02987400|relapsed DLBCL
10956|NCT02987400|refractory DLBCL
10957|NCT02987400|AGMT
10958|NCT02987400|Diffuse large B-cell lymphoma
10959|NCT02987400|window of opportunity
10960|NCT02987387|Tetralogy of Fallot
10961|NCT02987387|Aortic Valve Defect/Disease Resulting in Ross Procedure
10962|NCT02987387|Transcatheter pulmonary valve implantation
10963|NCT02987387|Transcatheter pulmonary valve replacement
10964|NCT02987387|Pulmonary Atresia
10965|NCT02987387|Pulmonary Stenosis
10966|NCT02987374|Influenza Vaccine
10967|NCT02987348|type 2 diabetes
10968|NCT02987309|indirect calorimetry
10969|NCT02987309|method comparison
10970|NCT02987296|Colorectal Cancer
10971|NCT02987296|Surgery
10972|NCT02987296|Arginine depletion
10973|NCT02987296|Immune system dysfunction
10974|NCT02987296|Arginine Supplementation
10975|NCT02987270|mass screen and treat
10976|NCT02987270|malaria
10977|NCT02987270|asymptomatic infections
10978|NCT02987270|transmission reduction
10979|NCT02987270|infectious reservoir
10980|NCT02987270|kenya
10981|NCT02987257|Therapeutics
10982|NCT02987257|Management
10983|NCT02987257|Cyclosporine
10984|NCT02987257|Etanercept
10985|NCT02987257|Supportive Care
10986|NCT02987257|Immunopathogenesis
10987|NCT02987257|Genetics
10988|NCT02987257|Adverse Drug Reaction
10989|NCT02987244|Chidamide, T Cell Non-Hodgkin's Lymphoma
10990|NCT02987218|POCD
10991|NCT02987218|subarachnoid hemorrhage
10992|NCT02987218|Propofol
10993|NCT02987218|Desflurane
10994|NCT02986048|proton beam
10995|NCT02986048|registry
10996|NCT02986048|radiation
10997|NCT02986048|cancer
10998|NCT02986022|Self-efficacy
10999|NCT02986022|optimism
11000|NCT02986022|altruism
11001|NCT02986022|goal setting
11002|NCT02986009|emotion management
11003|NCT02986009|positive and negative affect
11004|NCT02986009|satisfaction with parent-child relationship
11005|NCT02986009|subjective happiness
11006|NCT02986009|family harmony
11007|NCT02985996|Preventative Medicine
11008|NCT02985996|Infectious Diseases
11009|NCT02985996|Sexually Transmitted Diseases
11010|NCT02985983|Brodalumab
11011|NCT02985983|KHK4827
11012|NCT02985983|Axial Spondyloarthritis
11013|NCT02985970|crush induction, RSI
11014|NCT02985944|colorectal cancer
11015|NCT02985944|Colon polyp
11016|NCT02985944|Colonoscopy
11017|NCT02985944|Adenoma detection rate
11018|NCT02987192|spinal anesthesia
11019|NCT02987192|anticoagulation
11020|NCT02987192|minimally invasive
11021|NCT02987192|Cesarean Section
11022|NCT02987192|Maternal
11023|NCT02987166|immunotherapy
11024|NCT02987166|pembrolizumab
11025|NCT02987166|MK-3475
11026|NCT02987166|High-dose conformal radiation therapy
11027|NCT02987166|HDCRT
11028|NCT02987166|advanced solid tumor
11029|NCT02987153|Kyphoplasty
11030|NCT02987153|Spinal metastases
11031|NCT02987153|IORT
11032|NCT02987153|Intraoperative radiation therapy
11033|NCT02987153|Pain management
11034|NCT02987140|Parkinson's disease
11035|NCT02987140|freezing of gait
11036|NCT02987140|context-dependency
11037|NCT02987140|transcranial magnetic stimulation
11038|NCT02987140|visual cues
11039|NCT02987062|Atrial Fibrillation
11040|NCT02987062|Non-vitamin K Oral Anticoagulants
11041|NCT02987062|Vitamin K Antagonists
11042|NCT02987062|ROCKET-AF
11043|NCT02987062|RE-LY
11044|NCT02987062|ARISTOTLE
11045|NCT02987049|heart disease, cardiac rehabilitation
11046|NCT02987036|nebulizer technologies, lung mechanics, beta-agonistic drug
11047|NCT02987023|infertility, uterus, transplantation
11048|NCT02986997|epidural anesthesia
11049|NCT02986997|prone position
11050|NCT02986997|percutaneous nephrolithotomy
11051|NCT02986984|Diabetes
11052|NCT02986984|Chronic kidney disease
11053|NCT02986984|Progression
11054|NCT02986984|Genomics
11055|NCT02986984|Transcriptomics
11056|NCT02986971|Contraceptive implant
11057|NCT02986945|Depressive symptoms
11058|NCT02986945|resiliency
11059|NCT02986945|Health Promotion
11060|NCT02986945|minority health
11061|NCT02986945|text-messaging app
11062|NCT02986945|participatory technology development
11063|NCT02986932|Blood-Brain Barrier
11064|NCT02986906|ulnar neuropathy at elbow
11065|NCT02986906|Dextrose
11066|NCT02986906|perineural injection
11067|NCT02986893|Multiple Sclerosis
11068|NCT02986893|Diet
11069|NCT02986893|Clinical Trial
11070|NCT02986854|Meningococcal disease
11071|NCT02986854|Booster vaccination
11072|NCT02986854|Meningitis
11073|NCT02986854|Antibody persistence
11074|NCT02986828|platelet rich plasma
11075|NCT02986828|Hydrodissection
11076|NCT02986737|TAVI
11077|NCT02986737|Aortic Stenosis
11078|NCT02986737|Transcatether Aortic Valve Implantation
11079|NCT02986724|Drug therapy
11080|NCT02986698|intrauterine transfusion
11081|NCT02986698|in utero human stem cell transplantation
11082|NCT02986685|Refractory reflux esophagitis
11083|NCT02986685|Rabeprazole
11084|NCT02986685|trimebutine maleate
11085|NCT02986672|ADHD
11086|NCT02986672|omega 3
11087|NCT02986672|children
11088|NCT02986672|nutrition
11089|NCT02986672|MUFA
11090|NCT02986672|ADD
11091|NCT02986672|PUFA
11092|NCT02986672|Calanus
11093|NCT02986672|learning difficulties
11094|NCT02986633|Cardiac Resynchronization Therapy
11095|NCT02986633|Echocardiography
11096|NCT02986633|Biventricular Pacing
11097|NCT02986568|Ontogenetic surgery
11098|NCT02986568|TMMR
11099|NCT02986568|PMMR
11100|NCT02986568|LEER
11101|NCT02986555|Stress
11102|NCT02986555|Virtual Reality
11103|NCT02986555|Motion sickness
11104|NCT02986555|Visual Fatigue
11105|NCT02986555|Biofeedback
11106|NCT02986542|newborns,femoral artery, catheterization
11107|NCT02986490|Mental disorders
11108|NCT02986490|Antipsychotic agents
11109|NCT02986490|Magnesium
11110|NCT02986490|Cardiovascular risk factor
11111|NCT02986490|Metabolic syndrome
11112|NCT02986464|Virtual reality
11113|NCT02986464|Immersive distraction
11114|NCT02986464|Virtual world
11115|NCT02986464|Virtual environment
11116|NCT02986464|Procedural pain
11117|NCT02986464|Acute pain
11118|NCT02986464|Pain Management
11119|NCT02986464|Children, Child
11120|NCT02986464|Kid, Kids
11121|NCT02986464|Pediatric, Pediatrics
11122|NCT02986464|Young children
11123|NCT02986464|Burns
11124|NCT02986464|Burn injuries
11125|NCT02986464|Burn unit
11126|NCT02986464|Hydrotherapy
11127|NCT02986464|Burn dressing
11128|NCT02986464|Non-pharmacological
11129|NCT02986464|Clinical Research
11130|NCT02986464|Nursing Practice
11131|NCT02986438|Cocaine
11132|NCT02986438|Addiction
11133|NCT02986438|rTMS
11134|NCT02986438|fMRI
11135|NCT02986425|Drug Utilization Review
11136|NCT02986425|Older people
11137|NCT02986399|fast track
11138|NCT02985905|Zinc supplementation
11139|NCT02985905|Thiol
11140|NCT02985905|Glutathione peroxidase
11141|NCT02985905|Sulfhydryl oxidase
11142|NCT02985892|Physical therapy
11143|NCT02985892|Muscle Stretching Exercises
11144|NCT02985892|Low Back pain
11145|NCT02985879|tauopathy
11146|NCT02985879|PSP
11147|NCT02985879|Steele-Richardson-Olszewski syndrome
11148|NCT02985866|Artificial Pancreas
11149|NCT02985866|Closed Loop Control
11150|NCT02985866|Continuous Glucose Monitor (CGM)
11151|NCT02985840|ondansetron
11152|NCT02985840|dexamethasone
11153|NCT02985814|COPD Asthma Overlap
11154|NCT02985775|CMV-specific T cell
11155|NCT02985775|haploidentical stem cell transplantation
11156|NCT02985775|immunologic response
11157|NCT02985775|acute GVHD
11158|NCT02985762|bupivacaine
11159|NCT02985762|exparel
11160|NCT02985762|analgesic
11161|NCT02985762|lumbar spine
11162|NCT02985749|Autism Spectrum Disorders
11163|NCT02985749|Pervasive Developmental Disorder
11164|NCT02985749|ASD
11165|NCT02985749|PDD
11166|NCT02985749|Oxytocin
11167|NCT02985749|Syntocinon
11168|NCT02985749|Social Impairment
11169|NCT02985749|Treatment
11170|NCT02985671|Postural Low Back Pain
11171|NCT02985671|Mechanical Low Back Pain
11172|NCT02985671|Low Back Pain
11173|NCT02985671|acetaminophen
11174|NCT02985671|caffeine
11175|NCT02985671|orphenadrine
11176|NCT02985671|diclofenac sodium
11177|NCT02985645|CGF
11178|NCT02985645|sinus augmentation
11179|NCT02985645|DIVA
11180|NCT02985645|Platelet-Rich Plasma
11181|NCT02985554|hematologic malignancies
11182|NCT02985554|allogeneic stem cell transplantation (allo-SCT)
11183|NCT02985541|Birth Control
11184|NCT02985541|Heavy menstrual bleeding
11185|NCT02985515|Anosmia
11186|NCT02985515|Olfactory Neuroplasticity
11187|NCT02985515|Intranasal Steroid Irrigation
11188|NCT02985502|Quality of Life
11189|NCT02985502|Diabetes Mellitus
11190|NCT02985502|Pancreatectomy
11191|NCT02985476|Electronic health records
11192|NCT02985476|Health records personal
11193|NCT02985437|wound healing
11194|NCT02985437|Bovine Lung Surfactant
11195|NCT02985437|SATOSU
11196|NCT02985385|Congenital Lethal Malformations
11197|NCT02985359|Program impact evaluation
11198|NCT02985359|Malawi
11199|NCT02985359|Lipid-based nutrient supplements
11200|NCT02985359|Social behavior change communication
11201|NCT02985359|Childhood stunting
11202|NCT02985346|Idiopathic pulmonary hemosiderosis
11203|NCT02985346|Bone marrow mesenchymal stem cells
11204|NCT02985333|paclitaxe,cyclophosphamide,dexamethasone, Multiple Myeloma
11205|NCT02985320|Sabin strain
11206|NCT02985320|Inactivated poliovirus vaccine
11207|NCT02985320|poliomyelitis
11208|NCT02985320|safety
11209|NCT02985320|immunogenicity
11210|NCT02985320|infant
11211|NCT02985294|Neuropathic pain
11212|NCT02985294|Quantitative Sensory Testing
11213|NCT02985294|Multiple Excitability Measures
11214|NCT02985294|Threshold Tracking
11215|NCT02985281|direct acting antiviral drugs, chronic hepatitis C virus infection
11216|NCT02985268|MitraClip
11217|NCT02985268|Cardiovascular resynchronization therapy
11218|NCT02985268|Six minute walk test
11219|NCT02985268|Mitral regurgitation
11220|NCT02985268|CRT-D
11221|NCT02985255|Neoadjuvant Chemotherapy
11222|NCT02985255|Tongue Malignancy
11223|NCT02985255|Squamous Cell Carcinoma
11224|NCT02985203|lung cancer
11225|NCT02985203|vinorelbine
11226|NCT02985203|metronomic chemotherapy
11227|NCT02985190|Azacitidine
11228|NCT02985190|MDS
11229|NCT02985190|Systemic auto-immune and inflammatory disorders
11230|NCT02985177|Children
11231|NCT02985177|Musculoskeletal injury
11232|NCT02985177|Emergency department
11233|NCT02985177|Analgesia
11234|NCT02985177|Opioids
11235|NCT02985164|Anesthesiology( H02.403.066 )
11236|NCT02985164|Radiation Protection( N06.850.810.425)
11237|NCT02985164|Cholangiopancreatography, Endoscopic Retrograde(D002760 )
11238|NCT02985151|Scar
11239|NCT02985151|Carbon Dioxide Laser
11240|NCT02985151|Laser Ablation
11241|NCT02985125|Pancreas
11242|NCT02985125|5-FU
11243|NCT02985125|Gemcitabine
11244|NCT02985125|LEE011
11245|NCT02985125|Everolimus
11246|NCT02985125|Refractory
11247|NCT02985125|Chemotherapy
11248|NCT02985086|term premature rupture of membranes, antibiotic prophylaxis, chorioamnionitis, endometritis, neonatal infection
11249|NCT02985060|Therapeutic hypothermia
11250|NCT02985047|Brief admission
11251|NCT02985047|admission
11252|NCT02985047|deliberate self-harm
11253|NCT02985047|self-harm
11254|NCT02985034|HCC
11255|NCT02985034|RFA
11256|NCT02985034|Liver tumor
11257|NCT02985008|Shock, IVBP, ECMO, In hospital death
11258|NCT02984995|FLT3-ITD
11259|NCT02984995|Positive refractory or relapsed acute myeloid leukemia
11260|NCT02984995|Hematology malignancy
11261|NCT02984995|Developmental Phase II
11262|NCT02984956|Hypotension
11263|NCT02984956|Pleth variability index
11264|NCT02984956|Hip Fracture
11265|NCT02984956|Spinal anesthesia
11266|NCT02984943|Rheumatoid Arthritis
11267|NCT02984943|Hyperbaric Oxygen
11268|NCT02984904|Fusarium Infection
11269|NCT02984904|Corneal ulcer
11270|NCT02984904|Spain
11271|NCT02984904|Epidemiology
11272|NCT02984891|Intravascular ultrasound
11273|NCT02984891|Optical coherence tomography
11274|NCT02984137|Lewy body disease
11275|NCT02984137|REM Sleep Behavior Disorder
11276|NCT02984137|Parkinson disease
11277|NCT02984137|Imaging
11278|NCT02984137|Bio-markers
11279|NCT02984137|Prospective cohort
11280|NCT02984865|transversus plane block
11281|NCT02984865|opioid
11282|NCT02984865|nalbuphine
11283|NCT02984865|gastrointestinal surgery
11284|NCT02984865|elderly patient
11285|NCT02984839|intra-abdominal surgery
11286|NCT02984839|neuromuscular blocking agent
11287|NCT02984839|post-anesthesia care unit
11288|NCT02984787|Gastric Cancer
11289|NCT02984787|3D
11290|NCT02984787|2D
11291|NCT02984774|Endometriosis
11292|NCT02984774|Infertility
11293|NCT02984774|Telomerase activity
11294|NCT02984761|Carcinoma, Non-Small Cell Lung
11295|NCT02984761|Respiratory Tract Neoplasms
11296|NCT02984761|Thoracic Neoplasms
11297|NCT02984761|Neoplasms by Site
11298|NCT02984761|Neoplasms
11299|NCT02984761|Lung Diseases
11300|NCT02984761|Respiratory Tract Diseases
11301|NCT02984761|Carcinoma, Bronchogenic
11302|NCT02984761|Bronchial Neoplasms
11303|NCT02984761|Radiosurgery
11304|NCT02984761|Radiotherapy
11305|NCT02984761|Radiotherapy, Image-Guided
11306|NCT02984761|Lung Neoplasms
11307|NCT02984748|cochlear implants
11308|NCT02984748|hearing loss
11309|NCT02984735|chewing
11310|NCT02984735|cerebral palsy
11311|NCT02984735|chewing disorders
11312|NCT02984735|gross motor function
11313|NCT02984722|PCOS
11314|NCT02984722|metformin
11315|NCT02984670|Cognitive therapy
11316|NCT02984670|Behavior therapy
11317|NCT02984670|Moderation
11318|NCT02984670|Mediation
11319|NCT02984657|Hypoxemia
11320|NCT02984657|Reverse Trendelenburg
11321|NCT02984592|premature ejaculation
11322|NCT02984592|intravaginal ejaculatory latency time
11323|NCT02984592|premature ejaculation diagnostic tools
11324|NCT02984566|Primary liver cancer
11325|NCT02984566|Secondary liver cancer
11326|NCT02984566|Kilovoltage Intrafraction Monitoring
11327|NCT02984566|Stereotactic Ablative Body Radiation
11328|NCT02984553|accelerometry
11329|NCT02984553|aerobic fitness
11330|NCT02984553|metabolic thresholds
11331|NCT02984553|moderate to vigorous physical activity
11332|NCT02984501|radiochemotherapy
11333|NCT02984501|neoadjuvant therapy
11334|NCT02984488|necrotic teeth
11335|NCT02984488|single visit
11336|NCT02984488|multiple visits
11337|NCT02984488|protaper next
11338|NCT02984475|Beta Thalassemia
11339|NCT02984475|Metformin
11340|NCT02984475|Oxidative stress
11341|NCT02984475|Iron overload
11342|NCT02984475|Liver function
11343|NCT02984462|percutaneous
11344|NCT02984462|non-fixed
11345|NCT02984462|Akin ;
11346|NCT02984462|osteotomy
11347|NCT02984449|cardiac rehabilitation
11348|NCT02984449|surgical complications
11349|NCT02984449|quality of life
11350|NCT02984449|preoperative
11351|NCT02984449|cardiac surgery
11352|NCT02984423|Ovarian Cancer
11353|NCT02984423|BRCA mutations
11354|NCT02984410|T1-T2, N0 oropharyngeal carcinoma
11355|NCT02984397|pain
11356|NCT02984397|ketotifen
11357|NCT02984397|pediatric
11358|NCT02984397|mast cell
11359|NCT02984384|Trauma
11360|NCT02984384|Blood clot
11361|NCT02984384|Venous Thromboembolism
11362|NCT02984384|Pulmonary Embolism
11363|NCT02984384|Deep Vein Thrombosis
11364|NCT02984384|Thromboprophylaxis
11365|NCT02984384|Blood clot prevention
11366|NCT02984384|trauma patients
11367|NCT02984371|atrial fibrillation
11368|NCT02984371|ganglionated plexi
11369|NCT02984371|ischemic heart disease
11370|NCT02984293|Atorvastatin
11371|NCT02984293|LILRB5
11372|NCT02984293|Statin intolerance
11373|NCT02984254|knee
11374|NCT02984254|knee osteoarthritis
11375|NCT02984254|Bracing
11376|NCT02984254|patellofemoral osteoarthritis
11377|NCT02984189|Physical Exercise
11378|NCT02984189|Physical Therapy
11379|NCT02984189|Physical Performance
11380|NCT02984189|Critical Power
11381|NCT02984189|Respiratory Muscle
11382|NCT02984176|Simethicone
11383|NCT02984176|Laparoscopies
11384|NCT02984176|Pain
11385|NCT02984163|cancer
11386|NCT02984163|exercise
11387|NCT02984111|Coronary Artery Bypass Graft Surgery
11388|NCT02984111|Erythropoietin
11389|NCT02984111|Cardioprotective
11390|NCT02984098|procedural pain, 40% Dextrose, heel lance
11391|NCT02984085|RDEB
11392|NCT02984085|Stem cells
11393|NCT02984085|Gene therapy
11394|NCT02984046|Acute bronchiolitis
11395|NCT02984046|RSV
11396|NCT02984046|CC16
11397|NCT02984046|SP-D
11398|NCT02984046|sRAGE
11399|NCT02984046|Severity
11400|NCT02984046|Biomarkers
11401|NCT02983994|asthma, devices
11402|NCT02983968|Oncology
11403|NCT02983968|Hepatology
11404|NCT02983968|Public Health
11405|NCT02983968|Liver
11406|NCT02983942|ketogenic diet
11407|NCT02983942|Primary Central Nervous System Lymphoma
11408|NCT02983942|chemotherapy
11409|NCT02983916|Adhesions
11410|NCT02983916|Adhesiolysis
11411|NCT02983916|chronic pain
11412|NCT02983916|post-operative complications
11413|NCT02983916|anti-adhesion barrier
11414|NCT02983916|cine-MRI
11415|NCT02983916|shared decision making
11416|NCT02983851|Noninvasive mechanical ventilation
11417|NCT02983851|Invasive mechanical ventilation
11418|NCT02983838|Amyloid
11419|NCT02983838|BDNF
11420|NCT02983838|major depressive disorder
11421|NCT02983838|cognitive decline
11422|NCT02983825|CPAP
11423|NCT02983825|Bronchopulmonary Dysplasia
11424|NCT02983825|Ventilator Induced Lung Injury
11425|NCT02983825|V/Q mismatch
11426|NCT02983799|BRCA, ovarian, platinum, chemotherapy
11427|NCT02983760|Pulmonary embolism
11428|NCT02983747|Platelet Rich Plasma
11429|NCT02983747|Intervertebral Disk Injection Therapy
11430|NCT02983747|Low Back Pain
11431|NCT02983747|Ultrasound Guided
11432|NCT02983747|Degenerative Spinal Disease
11433|NCT02983734|Gulf War
11434|NCT02983734|D-cycloserine
11435|NCT02983734|Neuroinflammation
11436|NCT02983734|Cognition
11437|NCT02983734|Memory
11438|NCT02983708|Neuroregeneration
11439|NCT02983708|G-CSF
11440|NCT02983708|Peripheral blood mononuclear cells
11441|NCT02983708|Cerebral palsy
11442|NCT02983682|Anesthetics, Local
11443|NCT02983682|Lidocaine
11444|NCT02983682|Pediatrics
11445|NCT02983682|Children
11446|NCT02983682|Adolescents
11447|NCT02983669|Thymus Plant
11448|NCT02983669|Multiflotriol [Supplementary Concept]
11449|NCT02983669|Zataria multiflora
11450|NCT02983669|Complementary Therapies
11451|NCT02983669|Herbal Medicine
11452|NCT02983669|Medicine, traditional
11453|NCT02983656|Vaccine Safety
11454|NCT02983643|Skeletal Muscle Index
11455|NCT02983643|Visceral Adipose Tissue
11456|NCT02983643|Metabolic Syndrome
11457|NCT02983604|Exemestane
11458|NCT02983604|Aromasin
11459|NCT02983604|Fulvestrant
11460|NCT02983604|Faslodex
11461|NCT02983604|Breast Cancer,
11462|NCT02983604|HER 2-
11463|NCT02983604|Estrogen receptor positive
11464|NCT02983578|Pancreatic cancer
11465|NCT02983578|Mismatch deficient colorectal cancer
11466|NCT02983578|Non-small cell lung cancer
11467|NCT02983578|NSCLC
11468|NCT02983578|AZD9150
11469|NCT02983578|MEDI4736
11470|NCT02983578|Durvalumab
11471|NCT02983565|Long-term oxygen therapy
11472|NCT02983565|Intelligent oxygen therapy system
11473|NCT02983565|Auto-titrating oxygen system
11474|NCT02983552|Amblyopia
11475|NCT02983539|sarcomas
11476|NCT02983539|immunocytochemistry
11477|NCT02983539|circulating tumor cells
11478|NCT02983526|short stem
11479|NCT02983513|Early intervention
11480|NCT02983513|Brain Development
11481|NCT02983513|Neurodevelopment
11482|NCT02983500|Patient Reported Outcome (PRO)
11483|NCT02983487|Bordetella Pertussis
11484|NCT02983487|Whooping Cough
11485|NCT02983487|vaccine
11486|NCT02983461|urinary incontinence
11487|NCT02983461|pelvic floor dysfunction
11488|NCT02983435|Osteopathic Treatment
11489|NCT02983435|Postural control
11490|NCT02983435|Neuromuscular activation
11491|NCT02983435|Physiotherapy
11492|NCT02983409|computerized tomography
11493|NCT02983409|Urinary Calculi
11494|NCT02983409|Patient admission
11495|NCT02983409|Pain
11496|NCT02983396|RELF method
11497|NCT02983396|Medical device
11498|NCT02983396|Admission delay
11499|NCT02983383|Varicocele
11500|NCT02983383|TAP block
11501|NCT02983383|spinal anesthesia
11502|NCT02983357|Shoulder Arthroplasty
11503|NCT02983357|glenohumeral arthritis
11504|NCT02983344|fascia iliaca compartment block
11505|NCT02983344|fentanyl
11506|NCT02983266|Hyperadrenergia
11507|NCT02983266|Inflammatory stress
11508|NCT02983214|Cilostazol
11509|NCT02983214|Clopidogrel
11510|NCT02983214|Peripheral Artery Disease
11511|NCT02983201|Orthopedic Pain Syndromes
11512|NCT02983201|Thumbtack Intra-dermal Needle
11513|NCT02983201|Filiform needle
11514|NCT02983201|Acupuncture
11515|NCT02983188|Schizophrenia
11516|NCT02983188|Berberine
11517|NCT02983188|Metabolic Syndrome
11518|NCT02983188|Chinese medicine
11519|NCT02983188|Herbal medicine
11520|NCT02983175|ultrasonogaphy
11521|NCT02983175|full stomach
11522|NCT02983175|pulmonary aspiration
11523|NCT02983175|anaesthesia
11524|NCT02983136|Hand Hygiene
11525|NCT02983136|Implementation
11526|NCT02983136|Partnership
11527|NCT02983136|Surgery
11528|NCT02983123|Acute MI
11529|NCT02983123|Acute myocardial infarction cardiac troponin
11530|NCT02983123|High-sensitivity cardiac troponin T
11531|NCT02983123|0/1-hour algorithm
11532|NCT02983123|Outpatient clinic
11533|NCT02983123|Cardiac troponin
11534|NCT02983123|Chest pain
11535|NCT02983110|Hormones, Transgender
11536|NCT02983097|lymphoma
11537|NCT02983097|relapse
11538|NCT02983097|recurrence
11539|NCT02983097|progress
11540|NCT02983097|progressive
11541|NCT02983097|b-cell lymphoma
11542|NCT02983097|chemotherapy
11543|NCT02983097|immunotherapy
11544|NCT02983097|IMiD
11545|NCT02983097|Salvage chemotherapy
11546|NCT02983097|peripheral stem cell mobilization
11547|NCT02983097|lenalidomide
11548|NCT02983097|Rituximab
11549|NCT02983097|CD20
11550|NCT02983097|Cytarabine
11551|NCT02983097|Ara-C
11552|NCT02983097|platinum-based chemotherapy
11553|NCT02983097|Cisplatin
11554|NCT02983097|Carboplatin
11555|NCT02983097|Cisplatinum
11556|NCT02983097|Carboplatinum
11557|NCT02983097|Dexamethasone
11558|NCT02983084|Orthodontic wires
11559|NCT02983084|Root resorption
11560|NCT02983071|Breast Cancer
11561|NCT02983071|CDK 4/6 Inhibitor
11562|NCT02983071|HER2-Negative
11563|NCT02983071|HR-Positive
11564|NCT02983071|HR+
11565|NCT02983071|HER2-
11566|NCT02983071|HER2 -ve
11567|NCT02983071|HER2 +ve
11568|NCT02983032|Caregivers
11569|NCT02983032|Insomnia
11570|NCT02983019|influenza
11571|NCT02983019|flu
11572|NCT02983019|acute respiratory viral infection
11573|NCT02983019|ARVI
11574|NCT02983019|acute upper respiratory infection
11575|NCT02983019|AURI
11576|NCT02983006|TRAIL-DR5
11577|NCT02983006|DS-8273a
11578|NCT02983006|Immunoglobulin gamma-1 (IgG1)
11579|NCT02983006|Cell mediated cytotoxicity (ADCC)
11580|NCT02983006|Complement dependent cytotoxicity (CDC)
11581|NCT02983006|DR5
11582|NCT02983006|Immunoglobulin G4 (IgG4)
11583|NCT02983006|Monoclonal antibody
11584|NCT02983006|Programmed Cell Death 1 (PD-1)
11585|NCT02982993|hepatitis C virus
11586|NCT02982993|linkage-to-care
11587|NCT02982993|World Trade Center Health Program cohort
11588|NCT02982993|Baby Boomer
11589|NCT02982993|risk factors for hepatitis C virus infection
11590|NCT02982967|child
11591|NCT02982967|physical activity
11592|NCT02982967|irisin
11593|NCT02982967|EPCs
11594|NCT02982941|Neuroblastoma
11595|NCT02982941|Rhabdomyosarcoma
11596|NCT02982941|Osteosarcoma
11597|NCT02982941|Ewing Sarcoma
11598|NCT02982941|Wilms Tumor
11599|NCT02982941|Desmoplastic Small Round Cell Tumor
11600|NCT02982941|pediatric
11601|NCT02982928|Obesity
11602|NCT02982928|Bariatrics
11603|NCT02982928|Acetaminophen
11604|NCT02982928|robot-assisted or laparoscopic bariatric surgery
11605|NCT02982928|Pharmacokinetics
11606|NCT02982902|Immunotherapy
11607|NCT02982902|T-Cell Therapy
11608|NCT02982902|Lymphoproliferative Disorder
11609|NCT02982889|Analytical, Diagnostic,Therapeutic Technique and Equipment
11610|NCT02982889|Anesthesia and Analgesia
11611|NCT02982876|Silicone Airway stent
11612|NCT02982850|Atrial Fibrillation
11613|NCT02982850|Valvular Insufficiency
11614|NCT02982850|Valvular Stenosis
11615|NCT02982824|Children
11616|NCT02982824|IQ
11617|NCT02982824|Idiopathic epilepsy
11618|NCT02982824|Magnesium supplementation
11619|NCT02982824|Seizure control
11620|NCT02982824|Chalfont score
11621|NCT02982811|Activity-based
11622|NCT02982811|Client-centred
11623|NCT02982811|Rehabilitation
11624|NCT02982811|Quality of life
11625|NCT02982772|Nicotine Replacement
11626|NCT02982772|Smoking
11627|NCT02982772|HIV
11628|NCT02982746|Head and neck cancer
11629|NCT02982746|Person Centred Care
11630|NCT02982746|Health related quality of life
11631|NCT02982746|EORTC QLQ-C30
11632|NCT02982746|EORTC QLQ-C35
11633|NCT02982720|cholangiocarcinoma
11634|NCT02982720|Pembrolizumab
11635|NCT02982720|MK-3475
11636|NCT02982720|Sylatron
11637|NCT02982720|peginterferon alfa-2b
11638|NCT02982694|MSI
11639|NCT02982694|colorectal
11640|NCT02982694|chemotherapy
11641|NCT02982694|Bevacizumab
11642|NCT02982694|Atezolizumab
11643|NCT02982681|Periodontal disease
11644|NCT02982681|Platelet rich fibrin
11645|NCT02982668|severe stroke
11646|NCT02982668|Acute Stroke
11647|NCT02982668|Enteral Feeding
11648|NCT02982668|Mortality
11649|NCT02982668|Disability
11650|NCT02982668|Clinical trial
11651|NCT02982655|Severe Stroke
11652|NCT02982655|Acute Stroke
11653|NCT02982655|Antihypertension
11654|NCT02982655|mortality
11655|NCT02982655|disability
11656|NCT02982655|clinical trial
11657|NCT02982629|Glaucoma
11658|NCT02982629|Eye Care
11659|NCT02982629|Community Outreach
11660|NCT02982577|Xerostomia
11661|NCT02982577|Pilocarpine
11662|NCT02982577|Quality of life
11663|NCT02982564|Exercise
11664|NCT02982564|Physical Functioning
11665|NCT02982564|Hispanic
11666|NCT02982538|posttraumatic stress symptoms
11667|NCT02982538|implementation
11668|NCT02982538|dissemination
11669|NCT02982538|PTSD
11670|NCT02982525|Mussels
11671|NCT02982525|Dietary Intervention
11672|NCT02982525|Long-term intervention
11673|NCT02982525|Vitamin D status
11674|NCT02982525|Selenium
11675|NCT02982525|Iodine
11676|NCT02982525|Vitamin B12
11677|NCT02982525|Omega-3 index
11678|NCT02982512|Potential local fields
11679|NCT02982512|Subthalamic neuronal activity
11680|NCT02982499|glaucoma
11681|NCT02982499|Leber optic neuropathy
11682|NCT02982499|anterior ischemic optic neuropathy
11683|NCT02982486|nivolumab
11684|NCT02982486|ipilimumab
11685|NCT02982486|immunotherapy
11686|NCT02982486|PD-1 inhibitor
11687|NCT02982486|sarcoma
11688|NCT02982460|Rotator cuff tendinopathy
11689|NCT02982460|Eccentric exercise
11690|NCT02982460|Isoinertial training
11691|NCT02982447|blue laser imaging,detection,randomized trial
11692|NCT02982434|atrial fibrillation
11693|NCT02982434|botulinum toxin
11694|NCT02982434|ischemic heart disease
11695|NCT02982395|Nanoxel M
11696|NCT02982395|Docetaxel PM
11697|NCT02982395|Docetaxel
11698|NCT02982395|Mitomycin C
11699|NCT02982395|BCG
11700|NCT02982395|BCG refractory
11701|NCT02982395|Non muscle invasive bladder cancer
11702|NCT02982395|intravesical
11703|NCT02982395|superficial bladder cancer
11704|NCT02982395|Urothelial carcinoma
11705|NCT02982395|Transitional cell carcinoma
11706|NCT02982382|Low Back Pain
11707|NCT02982382|Musculoskeletal Manipulations
11708|NCT02982382|Neurophysiology
11709|NCT02982382|Education
11710|NCT02982317|Neuraxial anesthesia
11711|NCT02982317|Obstetrics
11712|NCT02982317|Ultrasound
11713|NCT02982252|Power mobility
11714|NCT02982252|Wheelchair skills training
11715|NCT02982252|Older adults
11716|NCT02982226|Plantar Fasciitis
11717|NCT02982226|Jogger's Heel
11718|NCT02982226|ReNu
11719|NCT02982213|Newest Vital Sign
11720|NCT02982213|Anxiety
11721|NCT02982213|Health literacy
11722|NCT02982213|Neuraxial Analgesia
11723|NCT02982213|Epidural catheter placement
11724|NCT02982213|Pregnancy
11725|NCT02982213|Parturients
11726|NCT02982213|Pain Catastrophizing Scale
11727|NCT02982213|STAI questionnaire
11728|NCT02982213|Companion
11729|NCT02982200|Embolization Device
11730|NCT02982200|Medina
11731|NCT02982200|Rupture Intracranial Aneurysm
11732|NCT02982200|Unrupture Intracranial Aneurysm
11733|NCT02982187|HANDIHALER
11734|NCT02982187|ELLIPTA
11735|NCT02982187|TURBUHALER
11736|NCT02982187|DISKUS
11737|NCT02982187|COPD
11738|NCT02982187|critical error
11739|NCT02982187|inhaler preference
11740|NCT02982174|no known ocular pathology
11741|NCT02982161|Third Molar Tooth Extraction
11742|NCT02982148|sentinel lymph node biopsy
11743|NCT02982148|methylene blue
11744|NCT02982148|intradermal injection
11745|NCT02982148|subcutaneous injection
11746|NCT02982135|hemorrhagic moyamoya disease
11747|NCT02982135|bypass
11748|NCT02982135|indirect bypass
11749|NCT02982083|Rheumatoid arthritis
11750|NCT02982083|Raloxifene
11751|NCT02982083|Disease activity
11752|NCT02982070|psychological well-being, academic success
11753|NCT02982044|blood flow
11754|NCT02982044|endothelial function
11755|NCT02982044|shear stress
11756|NCT02982031|Ultrasound-guided lumbar plexus blockade
11757|NCT02982031|Shamrock technique
11758|NCT02982031|Paramedian transverse scan
11759|NCT02982031|USG LPB
11760|NCT02982031|USGRA
11761|NCT02982005|KHK4827 (brodalumab)
11762|NCT02981979|Takayasu Arteritis
11763|NCT02981979|Leflunomide
11764|NCT02981953|Valtech Cardio
11765|NCT02981953|Cardioband
11766|NCT02981953|Tricuspid
11767|NCT02981940|Brain Tumor
11768|NCT02981914|Classical Hodgkin Lymphoma
11769|NCT02981914|B-cell Non-Hodgkin Lymphoma
11770|NCT02981914|Acute Myeloid Leukemia
11771|NCT02981914|Myelodysplastic Syndromes
11772|NCT02981914|pembrolizumab
11773|NCT02981875|reading eye movement
11774|NCT02981862|HPV infection
11775|NCT02981862|Blood sample
11776|NCT02981862|Biopsy
11777|NCT02981836|live attenuated varicella vaccine
11778|NCT02981836|protective effect
11779|NCT02981836|safety
11780|NCT02981836|immunogenicity
11781|NCT02981836|child
11782|NCT02981810|TONSILLAR COBLATION
11783|NCT02981797|symptomatic bone metastasis
11784|NCT02981797|metastatic
11785|NCT02981797|castration resistant
11786|NCT02981784|chronic myeloid leukemia (CML)
11787|NCT02981784|Philadelphia-positive (Ph+)
11788|NCT02981784|Acute Lymphoblastic Leukemia (ALL)
11789|NCT02981732|Osteoporosis
11790|NCT02981732|kidney yin deficiency syndrome
11791|NCT02981732|liuwei dihuang pill
11792|NCT02981706|Arteriovenous Fistula (AVF)
11793|NCT02981706|Arteriovenous Graft (AVG)
11794|NCT02981680|remote ischemic preconditioning; transient limb ischemia; acute kidney injury; coronary artery bypass graft surgery
11795|NCT02981641|Pancreatic cancer
11796|NCT02981641|Intraoperative radiotherapy (IORT)
11797|NCT02981641|Concurrent Chemoradiotherapy (CCRT)
11798|NCT02981602|Hepatitis
11799|NCT02981602|Chronic
11800|NCT02981602|HBV
11801|NCT02981576|Spinal Cord Injury
11802|NCT02981576|Mesenchymal Stem Cells
11803|NCT02981563|engagement
11804|NCT02981563|psychiatric in-patient care
11805|NCT02981563|mental health nursing
11806|NCT02981563|quality interactions
11807|NCT02981550|Infection
11808|NCT02981524|Colorectal Neoplasms
11809|NCT02981524|Gastrointestinal Neoplasms
11810|NCT02981524|Digestive System Neoplasms
11811|NCT02981524|Neoplasms by Site
11812|NCT02981524|Neoplasms
11813|NCT02981524|Digestive System Diseases
11814|NCT02981524|Gastrointestinal Diseases
11815|NCT02981524|Intestinal Diseases
11816|NCT02981524|Rectal Diseases
11817|NCT02981524|Colonic Diseases
11818|NCT02981498|Hepatic arterial infusion chemotherapy
11819|NCT02981498|Sorafenib
11820|NCT02981485|Fat Grafting, Breast Cancer Lymphedema
11821|NCT02981459|bladder pain
11822|NCT02981459|urinary frequency
11823|NCT02981459|urinary urgency
11824|NCT02981459|mirabegron
11825|NCT02981407|Red Blood Cell Transfusion
11826|NCT02981407|Anemia
11827|NCT02981407|Heart Disease
11828|NCT02981407|Cardiovascular Disease
11829|NCT02981381|sTMS
11830|NCT02981381|NeoSync
11831|NCT02981381|NEST
11832|NCT02981381|synchronous
11833|NCT02981381|non-invasive neuromodulation
11834|NCT02981381|TMS
11835|NCT02981381|Transcranial Magnetic Stimulation
11836|NCT02981381|PTSD
11837|NCT02981381|EEG
11838|NCT02981381|Depression
11839|NCT02981368|Diagnostic
11840|NCT02981368|Imaging
11841|NCT02981368|2301
11842|NCT02981368|PET/CT
11843|NCT02981368|PyL
11844|NCT02981368|PSMA
11845|NCT02981368|radical prostatectomy
11846|NCT02981368|metastatic prostate cancer
11847|NCT02981368|recurrent prostate cancer
11848|NCT02981355|BST-CarGel
11849|NCT02981355|Microfracture
11850|NCT02981355|Cartilage Lesion, Chondral Lesion
11851|NCT02981355|Femoral condyle
11852|NCT02981355|Bone Marrow Stimulation
11853|NCT02981355|Cartilage Repair
11854|NCT02981355|Tear of Articular Cartilage of Knee, Current
11855|NCT02981342|pancreatic cancer
11856|NCT02981329|Metformin
11857|NCT02981329|Sickle Cell Anemia
11858|NCT02981329|Sickle Cell Disease
11859|NCT02981329|Hemoglobinopathies
11860|NCT02981329|Hemoglobin Disorder
11861|NCT02981329|Blood Disease
11862|NCT02981329|Hemoglobin Disease; Sickle-Cell, Thalassemia
11863|NCT02981329|Hemoglobin Disease
11864|NCT02981277|Bronchoscopy
11865|NCT02981277|Lignocaine
11866|NCT02981264|Bronchoscopy
11867|NCT02981264|Lignocaine
11868|NCT02981264|Endobronchial Ultrasound
11869|NCT02981251|Hypertension
11870|NCT02981251|Uncontrolled blood pressure
11871|NCT02981251|Health education
11872|NCT02981251|Community based
11873|NCT02981199|microtransplantation
11874|NCT02981199|multiple myeloma
11875|NCT02981186|Intraocular Lens
11876|NCT02981186|trifocal
11877|NCT02981186|cataract
11878|NCT02981186|PhysIOL
11879|NCT02981147|cough
11880|NCT02981147|thyme
11881|NCT02981147|Cisti
11882|NCT02981147|Ivy Leaves
11883|NCT02981134|bioabsorbable scaffold
11884|NCT02981134|computed tomography
11885|NCT02981121|Diabetes Prevention
11886|NCT02981082|Systemic Sclerosis, Scleroderma, PAH, Pulmonary Hypertension
11887|NCT02981056|Skincare regimens
11888|NCT02981056|Skin moisturization
11889|NCT02981056|Skin barrier
11890|NCT02981056|Skin development
11891|NCT02981017|Chronic sinusitis
11892|NCT02981017|Frontal sinusitis
11893|NCT02981017|Skull base neoplasm
11894|NCT02981004|Aortic valve disease, patient prosthesis mismatch
11895|NCT02980965|breast cancer
11896|NCT02980965|neoadjuvant chemotherapy
11897|NCT02980965|endocrine therapy
11898|NCT02980965|concurrent
11899|NCT02980887|Pulmonary arterial hypertension
11900|NCT02980874|RVO
11901|NCT02980874|ME
11902|NCT02980874|Central Subfield Thickness
11903|NCT02980874|OCT
11904|NCT02980874|Optical Coherence Tomography
11905|NCT02980874|Cystoid Macular Edema
11906|NCT02980874|Subretinal Fluid
11907|NCT02980874|Eylea
11908|NCT02980874|Aflibercept
11909|NCT02980874|Anti-VEGF
11910|NCT02980874|Suprachoroidal
11911|NCT02980861|Gastric Cancer
11912|NCT02980861|Splenic Hilum Lymph Nodes Dissection
11913|NCT02980861|Gastrectomy
11914|NCT02980848|digital mammography
11915|NCT02980848|digital breast tomosynthesis
11916|NCT02980848|breast magnetic resonance imaging
11917|NCT02980848|screening
11918|NCT02980848|breast density
11919|NCT02980848|breast imaging
11920|NCT02980848|pre-operative magnetic resonance imaging
11921|NCT02980796|Brain
11922|NCT02980796|MRI
11923|NCT02980796|Exercise
11924|NCT02980796|Rehabilitation
11925|NCT02980796|TMS
11926|NCT02980770|Obstructive Sleep Apnea
11927|NCT02980770|Obesity Hypoventilation Syndrome
11928|NCT02980770|Hypercapnia
11929|NCT02980770|Post-Op Complication
11930|NCT02980770|Acid-Base Imbalance
11931|NCT02980744|Stroke
11932|NCT02980744|Sedentary behaviour
11933|NCT02980744|Intervention
11934|NCT02980731|Duration of overall response (Dor)
11935|NCT02980731|Complete remission rate (CR + CRi)
11936|NCT02980731|B-Cell receptor inhibitor (BCRi)
11937|NCT02980731|TP53 gene
11938|NCT02980731|Progression-free survival (PFS)
11939|NCT02980731|European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
11940|NCT02980731|Refractory CLL
11941|NCT02980731|Overall response rate (ORR)
11942|NCT02980731|Overall survival (OS)
11943|NCT02980731|Relapsed CLL
11944|NCT02980731|17p deletion
11945|NCT02980718|Olfaction training
11946|NCT02980718|Smell
11947|NCT02980653|Phase II study
11948|NCT02980653|Critical body weight loss
11949|NCT02980653|Concurrent chemoradiotherapy
11950|NCT02980653|Megestrol acetate
11951|NCT02980653|Head and neck cancer
11952|NCT02980640|Multiple Sclerosis
11953|NCT02980640|Treatment
11954|NCT02980640|Quality of Life
11955|NCT02980640|Symptoms
11956|NCT02980627|Eating Disorders
11957|NCT02980627|Diabulimia
11958|NCT02980627|ED-T1DM
11959|NCT02980627|Type 1 Diabetes
11960|NCT02980627|Mobile Technology
11961|NCT02980627|Acceptance and Commitment Therapy
11962|NCT02980614|phase-contrast MRI
11963|NCT02980614|blood flow
11964|NCT02980614|velocity mapping
11965|NCT02980614|Quantitative MRI
11966|NCT02980614|Cardiac imaging
11967|NCT02980614|Tetralogy of Fallot
11968|NCT02980601|Traumatic Defect
11969|NCT02980601|Chronic Wounds
11970|NCT02980575|COPD
11971|NCT02980575|Music
11972|NCT02980575|Exercise
11973|NCT02980562|Bowel preparation
11974|NCT02980562|Ascorbic acid
11975|NCT02980562|Bisacodyl
11976|NCT02980562|Polyethylene glycol
11977|NCT02980536|NSCLC
11978|NCT02980536|TKI
11979|NCT02980536|Mutation
11980|NCT02980536|Liquid Biopsy
11981|NCT02980497|mouthrinse
11982|NCT02980497|plaque
11983|NCT02980497|gingivitis
11984|NCT02980497|gum bleeding
11985|NCT02980484|rTMS
11986|NCT02980458|Healthy
11987|NCT02980458|Bioequivalence
11988|NCT02980458|Deferiprone
11989|NCT02980445|Myopia
11990|NCT02980445|Outdoor time
11991|NCT02980445|Children
11992|NCT02980445|Intervention
11993|NCT02980445|Prevention
11994|NCT02980432|vestibular
11995|NCT02980432|spatial orientation
11996|NCT02980432|vision
11997|NCT02980432|optokinetic
11998|NCT02980406|FODMAP
11999|NCT02980406|Irritable bowel syndrome
12000|NCT02980406|Gastric accommodation
12001|NCT02980406|Gastric motility
12002|NCT02980406|brain-gut axis
12003|NCT02980393|congenital heart disease
12004|NCT02980393|smart mobile technology
12005|NCT02980393|children
12006|NCT02980393|adolescents
12007|NCT02980393|lifestyle counselling
12008|NCT02980393|nutrition
12009|NCT02980393|physical activity
12010|NCT02980380|non-invasive brain computer interface
12011|NCT02980380|communication
12012|NCT02980380|amyotrophic lateral sclerosis
12013|NCT02980380|complete locked-in state
12014|NCT02980367|Anterior Cruciate Ligament
12015|NCT02980367|ACL
12016|NCT02980367|Anterior Cruciate Ligament deficiency
12017|NCT02980367|ACL deficiency
12018|NCT02980367|ACLD
12019|NCT02980367|Anterior Cruciate Ligament reconstruction
12020|NCT02980367|ACL reconstruction
12021|NCT02980367|Anterior Cruciate Ligament physiotherapy
12022|NCT02980367|Anterior Cruciate Ligament rehabilitation
12023|NCT02980367|ACL physiotherapy
12024|NCT02980367|ACL rehabilitation
12025|NCT02980367|Anterior Cruciate Ligament management
12026|NCT02980367|ACL management
12027|NCT02980354|endothelial progenitor cells, ischaemic stroke, aging
12028|NCT02980341|Oncology
12029|NCT02980341|HER3
12030|NCT02980341|Antibody drug conjugate
12031|NCT02980341|Developmental Phase I/II
12032|NCT02980328|Overactive bladder
12033|NCT02980328|Urinary incontinence
12034|NCT02980328|Low-level light therapy
12035|NCT02980315|nasopharyngeal carcinoma
12036|NCT02980315|EBV related cancers
12037|NCT02980302|Mental retardation MR
12038|NCT02980302|IQ
12039|NCT02980302|Mutation
12040|NCT02980302|Gene MYT1L
12041|NCT02980276|Gestational Diabetes
12042|NCT02980276|Diabetes
12043|NCT02980276|Pregnancy
12044|NCT02980263|Kawasaki disease
12045|NCT02980263|Coronary artery aneurysm
12046|NCT02980263|mucocutaneous lymph node syndrome
12047|NCT02980263|lymph node syndrome
12048|NCT02980263|canakinumab
12049|NCT02980263|intravenous immunoglobulin naïve (IVIG-naïve)
12050|NCT02980263|intravenous immunoglobulin refractory (IVIG-refractory)
12051|NCT02980263|pediatric
12052|NCT02980250|feeding intolerance
12053|NCT02980250|premature infant
12054|NCT02980250|domperidone
12055|NCT02980237|Office workers
12056|NCT02980237|Quality of life
12057|NCT02980237|e-Learning
12058|NCT02980237|Occupational health
12059|NCT02980211|Alveolar Bone
12060|NCT02980211|Alveolar Ridge
12061|NCT02980211|Bone Resorption
12062|NCT02980211|Bone Grafting
12063|NCT02980211|Barrier Membrane
12064|NCT02980172|triage
12065|NCT02980120|Eating Disorders
12066|NCT02980120|Anorexia Nervosa
12067|NCT02980120|Bulimia Nervosa
12068|NCT02980094|aging
12069|NCT02980094|nutrients
12070|NCT02980094|milk
12071|NCT02980094|dietary supplementation
12072|NCT02980055|connective tissue graft
12073|NCT02980055|transplantation
12074|NCT02980055|collagen
12075|NCT02980055|autologous
12076|NCT02980055|gingiva
12077|NCT02980003|contrast media
12078|NCT02980003|contrast-induced acute kidney injury (AKI)
12079|NCT02980003|contrast-induced nephropathy (CIN)
12080|NCT02979990|infertility
12081|NCT02979990|education
12082|NCT02979951|Observational Study
12083|NCT02979951|Non-Interventional Study
12084|NCT02979951|Registries
12085|NCT02979951|Prospective
12086|NCT02979951|Monitored
12087|NCT02979951|Multicentric
12088|NCT02979951|International
12089|NCT02979951|Fosfomycin
12090|NCT02979951|Infectofos
12091|NCT02979951|Fomicyt
12092|NCT02979951|Bacterial Infections
12093|NCT02979951|Gram-Negative Bacterial Infections
12094|NCT02979951|Gram-Positive Bacterial Infections
12095|NCT02979951|Bone Diseases, Infectious
12096|NCT02979951|Osteomyelitis
12097|NCT02979951|Central Nervous System Bacterial Infections
12098|NCT02979951|Meningitis, Bacterial
12099|NCT02979951|Encephalitis
12100|NCT02979951|Brain Abscess
12101|NCT02979951|Urinary Tract Infections
12102|NCT02979951|Respiratory Tract Infections
12103|NCT02979951|Pneumonia, Bacterial
12104|NCT02979951|Skin Diseases, Bacterial
12105|NCT02979951|Soft Tissue Infections
12106|NCT02979951|Intraabdominal Infections
12107|NCT02979951|Sepsis
12108|NCT02979951|Bacteremia
12109|NCT02979951|Endocarditis, Bacterial
12110|NCT02979951|Treatment Outcome
12111|NCT02979951|Clinical Efficacy
12112|NCT02979951|Microbiological Efficacy
12113|NCT02979951|Safety
12114|NCT02979925|neuropathic pain
12115|NCT02979925|TMS
12116|NCT02979925|nerve injury
12117|NCT02979925|transcutaneous magnetic stimulation
12118|NCT02979912|Persistent corneal epithelial defect
12119|NCT02979912|Platelet Lysate
12120|NCT02979899|angiosarcoma
12121|NCT02979886|single nucleotide polymorphism,GnRH receptor, IVF
12122|NCT02979873|Rapamycin
12123|NCT02979873|Relapse Prevention
12124|NCT02979873|Immune Tolerance
12125|NCT02979847|persistent atrial fibrillation
12126|NCT02979847|catheter ablation
12127|NCT02979847|hybrid
12128|NCT02979834|fetal movement
12129|NCT02979834|placenta site
12130|NCT02979834|body mass index
12131|NCT02979834|maternal education
12132|NCT02979821|pan-HER inhibitor
12133|NCT02979782|cardiac surgery
12134|NCT02979782|neurological outcome
12135|NCT02979782|minimal invasive coronary artery bypass graft (Endo-CABG)
12136|NCT02979769|Open-label extension study
12137|NCT02979769|Clinical trial Phase 2
12138|NCT02979769|Efficacy and safety
12139|NCT02979769|Heterotopic ossification
12140|NCT02979769|Flare-up
12141|NCT02979769|Palovarotene
12142|NCT02979769|Retinoic acide receptor agonist
12143|NCT02979769|Retinoic acide receptor gamma agonist
12144|NCT02979769|Clementia
12145|NCT02979769|Myositis Ossificans
12146|NCT02979769|Munchmeyer's Disease
12147|NCT02979769|FOP
12148|NCT02979717|satiety
12149|NCT02979717|protein
12150|NCT02979717|fiber
12151|NCT02979678|Breast cancer, quality of life
12152|NCT02979639|Herpes Zoster
12153|NCT02979639|Reactogenicity
12154|NCT02979639|Quality of life
12155|NCT02979639|Shingles
12156|NCT02979626|hospitalization
12157|NCT02979626|intensive care unit
12158|NCT02979626|school absenteeism
12159|NCT02979626|work absenteeism
12160|NCT02979600|Oral immunotherapy
12161|NCT02979600|Oral tolerance induction
12162|NCT02979574|acupuncture
12163|NCT02979574|pain
12164|NCT02979574|chronic pain
12165|NCT02979574|pain management
12166|NCT02979574|16-1579
12167|NCT02979561|Dabigatran etexilate
12168|NCT02979561|Recurrence of DVT
12169|NCT02979561|Pulmonary Embolism
12170|NCT02979561|Warfarin
12171|NCT02979548|Aprepitant
12172|NCT02979535|Dengue Fever
12173|NCT02979535|Dengue Hemorrhagic Fever
12174|NCT02979535|Human Papillomavirus Disease
12175|NCT02979535|CYD Dengue Vaccine
12176|NCT02979535|Dengvaxia®
12177|NCT02979535|Cervarix®
12178|NCT02979522|Drug therapy, pediatric Hodgkin disease, frontline Hodgkin disease, advanced stage Hodgkin disease, pediatric lymphoma
12179|NCT02979496|immune
12180|NCT02979496|citrus
12181|NCT02979470|advanced colon cancer
12182|NCT02979470|advanced rectum cancer
12183|NCT02979470|circulating tumor cells
12184|NCT02979470|immune response
12185|NCT02979470|mutations
12186|NCT02979457|telephone consultation, patient involvement
12187|NCT02979418|Water insecurity
12188|NCT02979340|Cystic Fibrosis Liver Disease
12189|NCT02979340|Pancreatic Insufficiency
12190|NCT02979275|acute kidney injury
12191|NCT02979275|cardiopulmonary bypass
12192|NCT02979275|neutrophil gelatinase-associated lipocalin
12193|NCT02979275|tissue hypoxia
12194|NCT02979249|Interventional
12195|NCT02979249|open-label
12196|NCT02979249|EPP
12197|NCT02979249|XLP
12198|NCT02979249|porphyria
12199|NCT02979197|High blood pressure
12200|NCT02979197|Systolic blood pressure
12201|NCT02979197|Diastolic blood pressure
12202|NCT02979197|Antihypertensive
12203|NCT02979184|Lymphedema, Obstructive Sleep Apnea , Intensive Decongestive Physiotherapy
12204|NCT02979119|Hemophilia
12205|NCT02979119|Children, ,
12206|NCT02979119|Inhibitors,
12207|NCT02979119|Prophylaxis
12208|NCT02979119|Long-term outcome
12209|NCT02979119|Congenital
12210|NCT02979093|maternal drug addiction
12211|NCT02979093|mother-infant attachment
12212|NCT02979093|intranasal oxytocin
12213|NCT02979093|unresolved trauma
12214|NCT02979093|maternal brain responses
12215|NCT02979093|mother-infant synchrony
12216|NCT02979067|Apnoea time, preoxygenation, difficult airway, emergency
12217|NCT02979041|neck pain
12218|NCT02979041|Virtual reality
12219|NCT02979041|Range of motion
12220|NCT02979041|physiotherapy
12221|NCT02979041|Air force
12222|NCT02979041|kinematics
12223|NCT02979028|TEAS
12224|NCT02979028|complication
12225|NCT02978989|Laparoscopic cholecystectomy
12226|NCT02978989|Solo surgery
12227|NCT02978989|Camera holder
12228|NCT02978989|Cholecystitis
12229|NCT02978976|RDS
12230|NCT02978976|Doppler on fetal pulmonary artery
12231|NCT02978963|Excessive worry
12232|NCT02978963|Worry
12233|NCT02978963|Adolescents
12234|NCT02978963|Intolerance of uncertainty
12235|NCT02978950|duplex ultrasound
12236|NCT02978950|trauma
12237|NCT02978950|venous thromboembolism
12238|NCT02978950|prevention
12239|NCT02978924|spinal cord
12240|NCT02978924|tsDCS
12241|NCT02978924|3D motion capture
12242|NCT02978924|EMG
12243|NCT02978911|RMI
12244|NCT02978898|Follicular Lymphoma
12245|NCT02978898|flow cytometry
12246|NCT02978898|CD180
12247|NCT02978898|Toll-like receptor
12248|NCT02978898|lymphoproliferative disease
12249|NCT02978885|Acute lung injury
12250|NCT02978885|Chronic obstructive pulmonary disease (COPD)
12251|NCT02978885|Whipple procedures
12252|NCT02978885|pancreatico-duodenectomies
12253|NCT02978872|Cardiac surgery
12254|NCT02978872|Quantra
12255|NCT02978872|Viscoelastic testing
12256|NCT02978872|Coagulation
12257|NCT02978859|MGCD516
12258|NCT02978859|Sarcoma
12259|NCT02978859|liposarcoma
12260|NCT02978859|Unresectable Liposarcoma
12261|NCT02978859|Metastatic Liposarcoma
12262|NCT02978820|scientific exercise approach to scoliosis
12263|NCT02978820|core stabilization training
12264|NCT02978820|bracing
12265|NCT02978820|adolescent idiopathic scoliosis
12266|NCT02978794|stroke, clinical pathway, medical care
12267|NCT02978781|Tremor
12268|NCT02978768|dementia
12269|NCT02978768|Tai Chi
12270|NCT02978768|mental training
12271|NCT02978768|cognitive rehabilitation
12272|NCT02978742|Eating Disorders
12273|NCT02978742|Bulimia Nervosa
12274|NCT02978742|Binge Eating Disorder
12275|NCT02978742|App
12276|NCT02978742|Smartphone
12277|NCT02978742|Self-Help
12278|NCT02978742|Coaching
12279|NCT02978742|Recovery Record
12280|NCT02978742|Mobile Phone
12281|NCT02978742|Cognitive Behavioral Therapy
12282|NCT02978729|Telemedicine
12283|NCT02978729|Counseling, Genetic
12284|NCT02978716|Breast Cancer
12285|NCT02978716|CDK 4/6 Inhibitor
12286|NCT02978716|Triple Negative Breast Cancer
12287|NCT02978677|brain tumors
12288|NCT02978677|proton radiotherapy
12289|NCT02978677|photon radiotherapy
12290|NCT02978664|colonoscopy
12291|NCT02978664|water exchange
12292|NCT02978664|adenoma detection rate
12293|NCT02978664|distraction
12294|NCT02978651|EDS
12295|NCT02978651|OSA
12296|NCT02978638|Spinal cord injury
12297|NCT02978638|Bladder capacity
12298|NCT02978638|Electrical stimulation
12299|NCT02978638|Continence
12300|NCT02978638|Urodynamics
12301|NCT02978612|Colorectal Neoplasms
12302|NCT02978586|PSMA
12303|NCT02978586|PET/MRI
12304|NCT02978573|First MTP Joint
12305|NCT02978573|Hallux Rigidus
12306|NCT02978573|Hallux Limitus
12307|NCT02978573|Cartilage Replacement
12308|NCT02978573|Osteoarthritis
12309|NCT02978573|First MTP Joint Osteoarthritis
12310|NCT02978573|Big Toe Pain
12311|NCT02978547|Resectable pancreatic ductal adenocarcinoma
12312|NCT02978547|PDAC
12313|NCT02978547|Metformin
12314|NCT02978534|pregnant
12315|NCT02978534|quetiapine
12316|NCT02978534|bipolar
12317|NCT02978534|women
12318|NCT02978534|female
12319|NCT02978534|postpartum
12320|NCT02978534|seroquel
12321|NCT02978534|perinatal
12322|NCT02978534|manic-depressive
12323|NCT02978469|Habitual Physical Activity (HPA); Sedentary Behavior;
12324|NCT02978456|IVUS guided PCI
12325|NCT02978456|QCA guided PCI
12326|NCT02978443|Melanoma
12327|NCT02978443|Mucosal
12328|NCT02978443|Acral Lentiginous
12329|NCT02978443|Ipilimumab
12330|NCT02978443|Nivolumab
12331|NCT02978443|Anti-tumor
12332|NCT02978443|Potential Predictors
12333|NCT02978443|Opdivo
12334|NCT02978443|Yervoy
12335|NCT02978430|Fluid therapy
12336|NCT02978430|Anesthesiology
12337|NCT02978430|Major surgery
12338|NCT02978430|Goal-directed fluid therapy
12339|NCT02978430|Fluid responsiveness
12340|NCT02978430|Closed-loop system
12341|NCT02978417|Medication-assisted treatment
12342|NCT02978417|Drug Court
12343|NCT02978417|Pilot study
12344|NCT02978417|Opioid dependence
12345|NCT02978417|Criminal justice
12346|NCT02978404|radiosurgery
12347|NCT02978404|PD-1
12348|NCT02978404|Nivolumab
12349|NCT02978326|Postpartum Care
12350|NCT02978287|Calcium sensing receptor
12351|NCT02978287|Parathyroid cell viability
12352|NCT02978287|Parathyroid allotransplantation
12353|NCT02978287|Transporting solution
12354|NCT02978235|Multiple Myeloma
12355|NCT02978235|Relapsed/Refractory
12356|NCT02978235|Lymphoma
12357|NCT02978235|Non-Hodgkin Lymphoma
12358|NCT02978235|Diffuse Large B-Cell Lymphoma
12359|NCT02978235|DLBCL
12360|NCT02978235|Mantle Cell Lymphoma
12361|NCT02978235|MCL
12362|NCT02978235|Peripheral T-Cell Lymphoma
12363|NCT02978235|PTCL
12364|NCT02978235|TAS4464
12365|NCT02978235|NEDD8
12366|NCT02978235|NAE inhibitor
12367|NCT02978235|Neoplasms
12368|NCT02978235|Hematologic Diseases
12369|NCT02978170|Bronchoscopy
12370|NCT02978170|Lung lesions
12371|NCT02978170|Cone Beam Computed Tomography
12372|NCT02978170|CBCT
12373|NCT02978170|Cone Beam CT
12374|NCT02978157|Helicobacter pylori
12375|NCT02978157|Eradication rate
12376|NCT02978157|Rescue treatment
12377|NCT02978144|Chronic Obstructive Pulmonary Disease (COPD)
12378|NCT02978131|TUBERCULOSIS
12379|NCT02978131|Sensitivity and Specificity
12380|NCT02978131|Polymerase Chain Reaction
12381|NCT02978131|Immunohistochemistry
12382|NCT02978131|Histochemistry
12383|NCT02978131|Paraformaldehyde and paraffin embedded tissues
12384|NCT02977351|Periodontopathogenic microorganisms
12385|NCT02977351|Non-surgical periodontal treatment
12386|NCT02978053|Bright light
12387|NCT02978053|Sleepiness
12388|NCT02978053|Sleep
12389|NCT02978053|Psychomotor vigilance
12390|NCT02978040|Antiplatelet therapy
12391|NCT02978040|Cangrelor
12392|NCT02978040|Tirofiban
12393|NCT02978040|Prasugrel
12394|NCT02978040|Acute Myocardial Infarction
12395|NCT02978040|Primary Percutaneous Coronary Intervention
12396|NCT02978040|Pharmacokinetic/Pharmacodynamic
12397|NCT02978027|motivational interviewing
12398|NCT02978027|brief alcohol intervention in primary care
12399|NCT02978014|Prostate
12400|NCT02978014|Radiotherapy
12401|NCT02978014|Obturator
12402|NCT02978014|Toxicity
12403|NCT02978014|Bowel
12404|NCT02978014|Urinary
12405|NCT02978014|Sexual
12406|NCT02978014|PROM
12407|NCT02978014|EPIC
12408|NCT02977988|Mindfulness
12409|NCT02977988|Women
12410|NCT02977988|Relapse prevention
12411|NCT02977988|Clinical trial
12412|NCT02977988|Substance use disorder
12413|NCT02977988|Ethnically diverse
12414|NCT02977988|Underserved
12415|NCT02977988|Health disparities
12416|NCT02977988|Stress
12417|NCT02977988|Addiction
12418|NCT02977988|Latina/Hispanic
12419|NCT02977988|African American
12420|NCT02977988|Treatment retention
12421|NCT02977988|Residential treatment
12422|NCT02977988|Brain Imaging
12423|NCT02977975|Irritable bowel syndrome
12424|NCT02977975|The human microbiome
12425|NCT02977975|Microbiota
12426|NCT02977975|Gut microbiota
12427|NCT02977975|Probiotics
12428|NCT02977975|Sauerkraut
12429|NCT02977949|SERM
12430|NCT02977949|Season
12431|NCT02977949|Variation
12432|NCT02977949|Vitamin D
12433|NCT02977923|Virtual reality
12434|NCT02977923|Immersive distraction
12435|NCT02977923|Oculus rift
12436|NCT02977923|Virtual world
12437|NCT02977923|Virtual environment
12438|NCT02977923|Procedural pain
12439|NCT02977923|Procedural anxiety
12440|NCT02977923|Acute pain
12441|NCT02977923|Pain management
12442|NCT02977923|Anxiety
12443|NCT02977923|Children, Child
12444|NCT02977923|Kid, Kids
12445|NCT02977923|Pediatric, Pediatrics
12446|NCT02977923|Young children
12447|NCT02977923|Burns
12448|NCT02977923|Burn injuries
12449|NCT02977923|Burn unit
12450|NCT02977923|Physiotherapy
12451|NCT02977923|Physical therapy
12452|NCT02977923|Burn dressing
12453|NCT02977923|Dressing change
12454|NCT02977923|Non-pharmacological, nonpharmacological
12455|NCT02977923|Clinical Research
12456|NCT02977923|Nursing Practice
12457|NCT02977897|Diarrhea
12458|NCT02977897|Immunosuppression
12459|NCT02977897|Post-transplantation
12460|NCT02977897|Octreotide
12461|NCT02977897|Mycophenolate Mofetil
12462|NCT02977897|Fecal Calprotectin
12463|NCT02977884|nutrition
12464|NCT02977884|exercise
12465|NCT02977884|stress
12466|NCT02977884|cardiovascular disease
12467|NCT02977884|diabetes
12468|NCT02977884|hypertension
12469|NCT02977884|dyslipidemia
12470|NCT02977884|cholesterol
12471|NCT02977884|overweight
12472|NCT02977884|obesity
12473|NCT02977884|lifestyle
12474|NCT02977871|Cesarean section
12475|NCT02977871|operating time
12476|NCT02977871|bladder
12477|NCT02977871|urinary retention
12478|NCT02977845|dypsnea
12479|NCT02977845|fatigue
12480|NCT02977845|anxiety
12481|NCT02977845|Qigong
12482|NCT02977845|Lung cancer
12483|NCT02977832|LUTS
12484|NCT02977832|Iresine celosia
12485|NCT02977832|Odyliresin
12486|NCT02977832|medical therapy
12487|NCT02977780|Glioblastoma
12488|NCT02977728|MTBI
12489|NCT02977728|olfaction
12490|NCT02977728|acute
12491|NCT02977715|Democratic Republic of the Congo
12492|NCT02977715|IMVAMUNE
12493|NCT02977715|Modified Vaccinia Ankara (MVA)
12494|NCT02977715|Monkeypox
12495|NCT02977715|Orthopoxvirus
12496|NCT02977715|Vaccine
12497|NCT02977715|Vaccinia virus
12498|NCT02977689|Isocitrate dehydrogenase (IDH)
12499|NCT02977689|R-2-Hydroxyglutarate (2-HG)
12500|NCT02977689|Gene encoding UDP-glucuronosyltransferase (UGT1A1)
12501|NCT02977689|Glioblastoma (GBM)
12502|NCT02977689|IDH305
12503|NCT02977689|IDHR132 mutations
12504|NCT02977689|Astrocytoma
12505|NCT02977689|Oligodendroglioma
12506|NCT02977689|Oligoastrocytoma
12507|NCT02977689|IDH1 R132H
12508|NCT02977689|IDH1
12509|NCT02977637|hht
12510|NCT02977637|hereditary
12511|NCT02977637|hemorrhagic
12512|NCT02977637|telangiectasia
12513|NCT02977637|feraheme
12514|NCT02977585|continous positive airway pressure
12515|NCT02977585|helmet
12516|NCT02977585|non invasive
12517|NCT02977585|positive end expiratory pressure
12518|NCT02977585|severe bronchiolitis
12519|NCT02977585|pediatric intensive care unit
12520|NCT02977572|Non-invasive ventilation,
12521|NCT02977572|continuous positive airway pressure
12522|NCT02977572|cardiogenic pulmonary oedema,
12523|NCT02977572|acute respiratory failure
12524|NCT02977559|Laryngeal Tube Suction Ambu AuraGain Leak Pressure
12525|NCT02977546|Hemodynamics
12526|NCT02977546|Noninvasive
12527|NCT02977546|Pulse contour analysis
12528|NCT02977546|Heart failure
12529|NCT02977546|Swan Ganz Catheterization
12530|NCT02977546|Pulmonary artery Catheter
12531|NCT02977468|triple negative breast cancer
12532|NCT02977468|Pembrolizumab
12533|NCT02977442|Mitochondrial Dynamics
12534|NCT02977442|Insulin Resistance
12535|NCT02977442|Exercise and Diabetes
12536|NCT02977429|Tumor
12537|NCT02977429|Abdominal infection
12538|NCT02977429|Hemodynamics
12539|NCT02977429|Pcv-aCO2
12540|NCT02977429|Early Goal-directed Therapy (EGDT)
12541|NCT02977416|Juvenile idiopathic arthritis
12542|NCT02977416|fat oxidation
12543|NCT02977416|exercise
12544|NCT02977403|Binge Eating
12545|NCT02977403|Eating Behavior
12546|NCT02977403|Children
12547|NCT02977403|Magnetoencephalography
12548|NCT02977403|Loss of Control
12549|NCT02977325|Physical activity level
12550|NCT02977325|Personal efficacy
12551|NCT02977325|Knee osteoarthritis
12552|NCT02977325|Self-management
12553|NCT02977325|Self-care
12554|NCT02977325|Education and exercise in knee osteoarthritis
12555|NCT02977273|Meal size
12556|NCT02977260|Meal size
12557|NCT02977247|SoftVue
12558|NCT02977247|Dense Breast Tissue
12559|NCT02977247|Breast Screening
12560|NCT02977247|Abnormal Breast
12561|NCT02977247|Normal Breast
12562|NCT02977247|Breast Imaging
12563|NCT02977247|Breast Biopsy
12564|NCT02977247|Mammography
12565|NCT02977247|Tomosynthesis
12566|NCT02977247|Automated Breast Ultrasound
12567|NCT02977247|Breast Cancer
12568|NCT02977247|Breast Carcinoma
12569|NCT02977247|Breast Tumors
12570|NCT02977247|Mammary Carcinoma
12571|NCT02977247|Malignant Breast Tumor
12572|NCT02977247|Mammary Neoplasm
12573|NCT02977247|Mammary Cancer
12574|NCT02977247|ABUS
12575|NCT02977247|AWBUS
12576|NCT02977247|Breast Tomography
12577|NCT02977247|ATUS
12578|NCT02977247|ABTUS
12579|NCT02977247|Mammogram
12580|NCT02977247|3D Mammogram
12581|NCT02977247|3D ABUS
12582|NCT02977247|3D Breast Ultrasound
12583|NCT02977247|DBT
12584|NCT02977247|FFDM
12585|NCT02977247|Digital Mammography
12586|NCT02977247|Breast Ultrasound
12587|NCT02977247|Dense Breasts
12588|NCT02977247|Breast Density
12589|NCT02977247|Dense Parenchyma
12590|NCT02977247|Asymptomatic
12591|NCT02977247|Delphinus
12592|NCT02977247|Delphinus Medical Technologies
12593|NCT02977247|Diagnostic Breast Imaging
12594|NCT02977221|corticotomy
12595|NCT02977221|piezocision
12596|NCT02977221|piezosurgery
12597|NCT02977221|acceleration of tooth movement
12598|NCT02977221|crowded anterior teeth
12599|NCT02977208|Gabapentin
12600|NCT02977208|OCT2
12601|NCT02977208|OCTN1
12602|NCT02977208|Pharmacogenetics
12603|NCT02977208|Pharmacokinetics
12604|NCT02977208|Polymorphisms
12605|NCT02977195|First in Human
12606|NCT02977195|monoclonal antibody
12607|NCT02977195|Netrin-1
12608|NCT02977156|Injectable lesion
12609|NCT02977156|Intra-tumoral injection
12610|NCT02977143|fluid responsiveness
12611|NCT02977143|central venous pressure
12612|NCT02977143|positive end-expiratory pressure
12613|NCT02977143|robot surgery
12614|NCT02977117|magnesium
12615|NCT02977117|ectopic calcification
12616|NCT02977117|chronic kidney disease - mineral and bone disorder
12617|NCT02977117|serum calcification propensity
12618|NCT02977091|short stature
12619|NCT02977091|fitness
12620|NCT02977091|children
12621|NCT02977078|Inhaler
12622|NCT02977065|Dyslipidemia
12623|NCT02977065|CETP Inhibitors
12624|NCT02977065|Hyperlipidemia
12625|NCT02977052|Melanoma
12626|NCT02977052|Ipilimumab
12627|NCT02977052|Nivolumab
12628|NCT02977052|Neo-adjuvant
12629|NCT02976987|Colvir
12630|NCT02976987|high grade squamous intraepithelial lesions
12631|NCT02976987|cervix
12632|NCT02976974|chronic pain
12633|NCT02976974|central sensitization
12634|NCT02976974|function
12635|NCT02976974|force
12636|NCT02976974|ultrasonography
12637|NCT02976961|Information
12638|NCT02976961|Empowerment
12639|NCT02976922|RAS
12640|NCT02976922|microbiome
12641|NCT02976922|probiotics
12642|NCT02976883|Hypoxia
12643|NCT02976883|HX4
12644|NCT02976883|PET CT
12645|NCT02976883|Radiotherapy
12646|NCT02976870|Hydronephrosis
12647|NCT02976870|Anterior Lumbar Interbody Fusion
12648|NCT02976857|refractory diffuse large B-cell lymphoma
12649|NCT02976857|anti-CD19 chimeric antigen receptor T-cell
12650|NCT02976844|optimal balloon volume
12651|NCT02976844|positive end-expiratory pressure
12652|NCT02976831|Plaque psoriasis vulgaris
12653|NCT02976792|Transcatheter aortic valve implantation
12654|NCT02976792|Acute Kidney Injury
12655|NCT02976792|early acute kidney injury detection
12656|NCT02976792|Nephrocheck™
12657|NCT02976792|Renal Resistive Index
12658|NCT02976766|Neuroprotection
12659|NCT02976766|Clinical trial
12660|NCT02976766|Traditional Chinese medicine
12661|NCT02976766|Axonal loss
12662|NCT02976766|Jiaogulan
12663|NCT02976766|Gynostemma pentaphyllum
12664|NCT02976766|Optical coherence tomography
12665|NCT02976753|Blood Coagulation Disorders
12666|NCT02976753|Hematologic Diseases
12667|NCT02976753|Coagulation Protein Disorders
12668|NCT02976753|Hemorrhagic Disorders
12669|NCT02976753|Genetic Diseases, Inborn
12670|NCT02976740|lung cancer
12671|NCT02976740|SBRT
12672|NCT02976740|rhGM-CSF
12673|NCT02976740|Thymosin Alpha 1
12674|NCT02976727|Vitamin D
12675|NCT02976727|Calcipotriol
12676|NCT02976727|Ablative fractional laser
12677|NCT02976727|Actinic keratosis
12678|NCT02976727|Photodynamic therapy
12679|NCT02976714|Cystic Fibrosis
12680|NCT02976714|Lung disease
12681|NCT02976714|DNA methylation
12682|NCT02976714|Predictive biomarkers
12683|NCT02976701|STEMI
12684|NCT02976701|acute coronary syndrome
12685|NCT02976701|DLBS1033
12686|NCT02976701|microvascular resistance index
12687|NCT02976701|Left ventricular function
12688|NCT02976688|Endstage renal Disease
12689|NCT02976688|Hemodialysis
12690|NCT02976649|Morbid obesity
12691|NCT02976649|Bariatric surgery
12692|NCT02976649|Multi-dimensional score
12693|NCT02976636|Obesity treatment
12694|NCT02976636|Parenting training
12695|NCT02976636|Parenting style
12696|NCT02976636|Family-based behavioral therapy
12697|NCT02976623|metrics
12698|NCT02976623|feedback
12699|NCT02976623|ultrasound-guided
12700|NCT02976623|procedural skills
12701|NCT02976610|hemolysis
12702|NCT02976597|Abdominal surgery, pain, local, transversus abdominus block.
12703|NCT02976584|EEG
12704|NCT02976584|Cardiac Surgery
12705|NCT02976584|Seizure
12706|NCT02976584|Tranexamic acid
12707|NCT02976558|CAM
12708|NCT02976558|allogenic Stem Cell Transplantation
12709|NCT02976558|Graft-Versus-Host Disease
12710|NCT02976558|Depression
12711|NCT02976558|Quality of Life
12712|NCT02976558|Acupuncture
12713|NCT02976558|Traditional chinese Medicine
12714|NCT02976558|Integrative medicine
12715|NCT02976558|Complementary and Alternative Medicine
12716|NCT02976558|Music therapy TaKeTiNa
12717|NCT02976558|Clown theatrical performance
12718|NCT02976558|Humour
12719|NCT02976558|Chemotherapy side effects
12720|NCT02976558|Psycho neuro immune system
12721|NCT02976558|GvHD
12722|NCT02976558|PNEIS
12723|NCT02976558|CMV
12724|NCT02976558|EBV
12725|NCT02976558|holistic medicine
12726|NCT02976532|Electromagnetic tracking
12727|NCT02976532|Internal rotation gait
12728|NCT02976532|Femoral derotation osteotomy
12729|NCT02976480|Irrigation
12730|NCT02976454|Obesity treatment
12731|NCT02976454|Primary care
12732|NCT02976454|Guided Self-Help
12733|NCT02976428|knee soft tissue balancing
12734|NCT02976428|sensor-guided
12735|NCT02976428|range of motion
12736|NCT02976415|Cardiac Surgery
12737|NCT02976415|Physiotherapy
12738|NCT02976415|In-Bed Cycling
12739|NCT02976415|Mechanical Ventilation
12740|NCT02976415|Cycle Ergometry
12741|NCT02976415|Early Mobilization
12742|NCT02976415|Rehabilitation
12743|NCT02976415|Critical Care
12744|NCT02976415|Intensive Care Unit
12745|NCT02976389|Supplemental Nutrition Assistance Program
12746|NCT02976389|Food insecurity
12747|NCT02976389|fruit and vegetable
12748|NCT02976389|healthy diet
12749|NCT02976376|Myocardial infarction
12750|NCT02976376|e-Health
12751|NCT02976376|mHealth
12752|NCT02976376|mobile phones
12753|NCT02976376|smartphone
12754|NCT02976376|follow-up
12755|NCT02976363|Radiotherapy
12756|NCT02976363|Respiratory muscles
12757|NCT02976363|Neoplasms
12758|NCT02976363|Breast
12759|NCT02976350|Heart failure
12760|NCT02976350|Heart failure with preserved ejection fraction
12761|NCT02976350|GH deficiency
12762|NCT02976350|Testosterone deficiency
12763|NCT02976350|Low- T3 syndrome
12764|NCT02976350|Multiple Hormone Deficiencies
12765|NCT02976337|Central sensitization
12766|NCT02976337|Endogenous opioids
12767|NCT02976337|Humans
12768|NCT02976337|Latent sensitization
12769|NCT02976337|Mandibular third molar extraction
12770|NCT02976337|Naloxone
12771|NCT02976337|Pain
12772|NCT02976337|Pressure algometry
12773|NCT02976337|Randomized controlled trial
12774|NCT02976337|Secondary hyperalgesia
12775|NCT02976337|Target controlled infusion
12776|NCT02976311|inflammatory reaction
12777|NCT02976311|IL-6
12778|NCT02976311|TNF
12779|NCT02976311|Misgav Ladach technique
12780|NCT02976311|Pfannenstiel-Kerr technique
12781|NCT02976311|cesarean delivery
12782|NCT02976311|cesarean technique
12783|NCT02976298|cerebellum
12784|NCT02976298|supplementary motor area
12785|NCT02976285|arthroscopic rotator cuff repair
12786|NCT02976285|patch augmentation
12787|NCT02976272|Bortezomib regimen
12788|NCT02976272|patients with multiple myeloma
12789|NCT02976233|Acute Respiratory Failure
12790|NCT02976233|Non Invasive Ventilation
12791|NCT02976233|Ultrasound
12792|NCT02976233|Diaphragm Thickening
12793|NCT02976168|Cognitive functioning
12794|NCT02976168|Brain tissue oxygenation
12795|NCT02976168|cerebral perfusion
12796|NCT02976168|head down tilt
12797|NCT02976155|critically ill, intensive care, enteral nutrition
12798|NCT02976142|gastric cancer, metastatic
12799|NCT02976142|positive wash cytology
12800|NCT02976142|neoadjuvant intraperitoneal immunotherapy
12801|NCT02976116|Fruquintinib
12802|NCT02976116|NSCLC
12803|NCT02976116|1st line
12804|NCT02976103|recovery
12805|NCT02976103|pain
12806|NCT02976103|surgical drains
12807|NCT02976077|social cognition
12808|NCT02976077|cognitive remediation
12809|NCT02976077|emotions
12810|NCT02976077|theory of mind
12811|NCT02976077|attributions
12812|NCT02976077|social perception
12813|NCT02976064|physical activity
12814|NCT02976064|lifestyle
12815|NCT02976064|adaptive case management
12816|NCT02976064|telemedicine
12817|NCT02976064|integrated care
12818|NCT02976064|collaborative self-management
12819|NCT02976038|Primary Mitochondrial Disease
12820|NCT02976038|Stealth
12821|NCT02976038|elamipretide
12822|NCT02976012|Proliferative Diabetic Retinopathy
12823|NCT02976012|Aflibercept
12824|NCT02976012|Vitreous Hemorrhage
12825|NCT02975986|acidic, urine, nephrolithiasis, free fatty acid.
12826|NCT02975973|tDCS
12827|NCT02975973|cognitive control
12828|NCT02975973|EEG
12829|NCT02975973|gamma oscillations
12830|NCT02975960|systemic sclerosis
12831|NCT02975960|adipose derived stem cell
12832|NCT02975960|stromal vascular fraction
12833|NCT02975960|digital ulcer
12834|NCT02975960|gangrene
12835|NCT02975934|CRPC
12836|NCT02975934|PARP inhibitor
12837|NCT02975934|PARPi
12838|NCT02975934|BRCA
12839|NCT02975934|ATM
12840|NCT02975934|HRD
12841|NCT02975934|TRITON
12842|NCT02975934|homologous recombination
12843|NCT02975934|DNA repair
12844|NCT02975934|DNA defect
12845|NCT02975934|DNA anomaly
12846|NCT02975934|germline
12847|NCT02975934|somatic
12848|NCT02975921|Pleural Effusion
12849|NCT02975921|Thoracentesis
12850|NCT02975921|Pleural Cavity
12851|NCT02975921|Pleurodesis
12852|NCT02975908|Acute Respiratory Distress Syndrome
12853|NCT02975908|epidemiology
12854|NCT02975908|clinical features
12855|NCT02975908|management
12856|NCT02975908|prognosis
12857|NCT02975869|Leukemia
12858|NCT02975869|Acute Myeloid Leukemia
12859|NCT02975856|Anthocyanins
12860|NCT02975856|Bioavailability
12861|NCT02975856|Flavonoids
12862|NCT02975856|Port wine
12863|NCT02975856|Red wine
12864|NCT02975817|pediatric, intraoperative, neurosurgery, inadvertent
12865|NCT02975804|cerebral palsy
12866|NCT02975804|video games
12867|NCT02975804|postural control
12868|NCT02975804|balance
12869|NCT02975804|children
12870|NCT02975791|Airway Obstruction
12871|NCT02975778|80 years old
12872|NCT02975765|corticotomy
12873|NCT02975765|minimally invasive
12874|NCT02975765|piezosurgery
12875|NCT02975765|piezocision
12876|NCT02975765|pain
12877|NCT02975765|discomfort
12878|NCT02975739|Intratumoral
12879|NCT02975739|Tongue
12880|NCT02975739|Microspheres
12881|NCT02975726|Liver Cirrhosis
12882|NCT02975726|Refractory ascites
12883|NCT02975726|PD catheter
12884|NCT02975713|P4,ART,IVF,FSH,LH,AMH
12885|NCT02975700|PLX3397
12886|NCT02975700|Kit-mutant Melanoma
12887|NCT02975687|Acute
12888|NCT02975687|Leukemia
12889|NCT02975687|Lymphoid
12890|NCT02975687|CD19
12891|NCT02975687|Refractory
12892|NCT02975635|Patients' Preferences
12893|NCT02975596|educational intervention
12894|NCT02975583|Atherosclerosis
12895|NCT02975557|Brimonidine
12896|NCT02975557|Dry Eye
12897|NCT02975557|oGVHD
12898|NCT02975557|MGD
12899|NCT02975544|social and emotional competence
12900|NCT02975544|healthy lifestyles
12901|NCT02975544|children
12902|NCT02975544|educational programme
12903|NCT02975531|Pompage
12904|NCT02975479|Hay fever
12905|NCT02975479|Pollen allergy
12906|NCT02975479|Allergic rhinitis
12907|NCT02975440|Vilaprisan
12908|NCT02975440|PK
12909|NCT02975440|rifampicin
12910|NCT02975440|midazolam,
12911|NCT02975440|CYP3A4 induction
12912|NCT02975440|drug-drug interaction
12913|NCT02975427|Diet
12914|NCT02975427|Abdominal bioelectrical impedance analysis
12915|NCT02975427|Anthropometry
12916|NCT02975427|Insulin resistance
12917|NCT02975362|Acupuncture Treatment; Motor Dysfunction; Stroke Patients
12918|NCT02975349|M2951
12919|NCT02975349|Relapsing Multiple Sclerosis
12920|NCT02975349|Bruton's Tyrosine Kinase inhibitor
12921|NCT02975336|Systemic Lupus Erythematosus
12922|NCT02975336|M2951
12923|NCT02975336|Placebo
12924|NCT02975336|Dose response
12925|NCT02975336|Oral Corticosteroids
12926|NCT02975336|Safety
12927|NCT02975336|Efficacy
12928|NCT02975336|Autoimmune And Inflammatory Disorders
12929|NCT02975323|hepatic venous pressure gradient
12930|NCT02975323|liver disease
12931|NCT02975323|US Doppler waveform
12932|NCT02975323|Cirrhosis
12933|NCT02975297|smoking
12934|NCT02975297|pre-diabetes
12935|NCT02975297|overweight
12936|NCT02975297|exenatide
12937|NCT02975297|GLP-1 agonists
12938|NCT02975284|bronchial thermoplasty
12939|NCT02975284|long term
12940|NCT02975284|interventional bronchoscopy
12941|NCT02975258|HIV
12942|NCT02975258|Asthma
12943|NCT02975258|Adiposity
12944|NCT02975258|Lung disease
12945|NCT02975258|Weight
12946|NCT02975258|Fat
12947|NCT02975258|Obese
12948|NCT02975245|Male infertility
12949|NCT02975245|Germ cells
12950|NCT02975245|Chemotherapy
12951|NCT02975245|Sperm
12952|NCT02975232|nutrition disparities
12953|NCT02975232|SNAP population
12954|NCT02975232|behavioral economics
12955|NCT02975232|retail setting
12956|NCT02975232|point of purchase education
12957|NCT02975232|pediatric obesity
12958|NCT02975232|rural population
12959|NCT02975232|fruit and vegetable purchases
12960|NCT02975232|fruit and vegetable consumption
12961|NCT02975193|Parkinsons Disease
12962|NCT02975193|Cognition
12963|NCT02975167|Induction of labor
12964|NCT02975167|mechanical cervical ripening
12965|NCT02975167|patient satisfaction
12966|NCT02975167|outpatient
12967|NCT02975167|cost savings
12968|NCT02975154|osteoarthritis
12969|NCT02975154|microcurrent
12970|NCT02975154|knee
12971|NCT02975154|electrotherapy
12972|NCT02975141|Palliative Chemotherapy
12973|NCT02975141|Afatinib
12974|NCT02975141|Gemcitabine
12975|NCT02975141|nab-paclitaxel
12976|NCT02975141|pancreatic cancer
12977|NCT02975128|Minimal invasive
12978|NCT02975128|Biopsy
12979|NCT02975089|Frailty
12980|NCT02975089|nutrition education
12981|NCT02975089|designed dishware
12982|NCT02975089|balanced diet
12983|NCT02975089|multiple dietary components
12984|NCT02975076|Sanchitongshu
12985|NCT02975076|Acute Minor Stroke
12986|NCT02975076|Transient Ischemic Attack
12987|NCT02975063|Exclusive breastfeeding
12988|NCT02975024|mandibular vestibuloplasty
12989|NCT02975024|wound healing
12990|NCT02975024|microcirculation
12991|NCT02975024|Laser Speckle Contrast Imager
12992|NCT02975024|Mucograft
12993|NCT02975024|strip gingival graft
12994|NCT02975011|Magnetic Resonance Imaging
12995|NCT02975011|Patient Satisfaction
12996|NCT02975011|Numeric Rating Scale
12997|NCT02974998|Human Immunodeficiency Virus (HIV)
12998|NCT02974998|HIV Testing and Counseling (HTC)
12999|NCT02974998|Sexually Transmitted Infections (STIs)
13000|NCT02974998|Substance Abuse
13001|NCT02974998|Gender Based Violence
13002|NCT02974998|Gang Violence
13003|NCT02974998|Victimization
13004|NCT02974998|Linkage to Care
13005|NCT02974998|Sexual Risk
13006|NCT02974998|Out-of-school Adolescents
13007|NCT02974998|Young Women
13008|NCT02974985|Facelift
13009|NCT02974985|HA Filler
13010|NCT02974985|Hyaluronic acid
13011|NCT02974985|Facial Rejuvenation
13012|NCT02974985|Aging Face
13013|NCT02974985|WIZDOM
13014|NCT02974985|Midface lift
13015|NCT02974985|Midface augmentation
13016|NCT02974933|apatinib
13017|NCT02974933|pemetrexed
13018|NCT02974933|NSCLC
13019|NCT02974907|Dry Eye Syndrome
13020|NCT02974907|Dry Eye
13021|NCT02974907|DES
13022|NCT02974868|Phase 2
13023|NCT02974868|randomized
13024|NCT02974868|double-blind
13025|NCT02974868|placebo
13026|NCT02974868|alopecia areata
13027|NCT02974868|safety
13028|NCT02974868|efficacy
13029|NCT02974868|JAK
13030|NCT02974868|janus kinase
13031|NCT02974868|moderate
13032|NCT02974868|severe
13033|NCT02974855|hemophilia
13034|NCT02974829|Chronic Hepatitis B
13035|NCT02974816|Glooko, Type 2 Diabetes, remote patient monitoring
13036|NCT02974816|mobile health application, certified diabetes educator
13037|NCT02974816|insulin treated, mHealth, population health
13038|NCT02974790|echocardiography
13039|NCT02974790|training
13040|NCT02974790|emergency department
13041|NCT02974790|circulatory failure
13042|NCT02974725|NSCLC
13043|NCT02974725|KRAS
13044|NCT02974725|BRAF
13045|NCT02974725|LXH254
13046|NCT02974725|LTT462
13047|NCT02974725|Non-small cell lung carcinoma (NSCLC)
13048|NCT02974725|treatment of lung cancer after first metastasis
13049|NCT02974725|lung cancer
13050|NCT02974725|lung adenocarcinoma
13051|NCT02974725|Large-cell lung carcinoma
13052|NCT02974725|Non small cell lung carcinoma
13053|NCT02974725|Non small cell lung cancer
13054|NCT02974725|Large cell lung carcinoma
13055|NCT02974725|Large cell lung cancer
13056|NCT02974725|squamous cell lung carcinoma
13057|NCT02974712|Arterial blood gases
13058|NCT02974712|MAP
13059|NCT02974712|HR
13060|NCT02974673|Spinal Cord Injury
13061|NCT02974673|Genito sexuals disorders
13062|NCT02974673|Ejaculatory test
13063|NCT02974647|Ruxolitinib
13064|NCT02974647|T or NK Cell
13065|NCT02974647|Relapsed
13066|NCT02974647|Refractory
13067|NCT02974634|Ileostomy
13068|NCT02974608|Placental
13069|NCT02974608|Fetal Loss
13070|NCT02974608|Observational
13071|NCT02974608|Antenatal
13072|NCT02974608|Infection
13073|NCT02974608|Malaria
13074|NCT02974595|Autoinflammation
13075|NCT02974595|Pediatric Syndromes
13076|NCT02974595|Immune Dysregulation
13077|NCT02974595|IL-1 Mediated Diseases
13078|NCT02974595|Interferonopathies
13079|NCT02974582|Marketing
13080|NCT02974582|Smoking
13081|NCT02974582|Cigarette
13082|NCT02974582|Young Adult
13083|NCT02974582|Socioeconomic Status
13084|NCT02974569|adolescents
13085|NCT02974569|young adults
13086|NCT02974543|tinnitus
13087|NCT02974517|time-lapes
13088|NCT02974517|IVF/ICSI
13089|NCT02974517|pregnancy outcome
13090|NCT02974491|hemodialysis
13091|NCT02974491|diabetes mellitus
13092|NCT02974491|apple juice
13093|NCT02974491|potassium
13094|NCT02974478|orange juice consumption
13095|NCT02974478|glucose homeostasis
13096|NCT02974478|antioxidative status
13097|NCT02974465|Brain injuries
13098|NCT02974465|upper extremity
13099|NCT02974465|biofeedback
13100|NCT02974465|electromyography
13101|NCT02974465|recovery of function
13102|NCT02974400|internet-based intervention
13103|NCT02974400|e-mental health
13104|NCT02974400|cognitive behavioural intervention
13105|NCT02974322|Crohn's Disease
13106|NCT02974322|GED-0301
13107|NCT02974322|Mongersen
13108|NCT02974322|Adolescent
13109|NCT02974322|Pediatric
13110|NCT02974322|Children
13111|NCT02974309|Youth
13112|NCT02974309|Diabetes Management
13113|NCT02974309|Sleep
13114|NCT02974283|Normobaric hyperoxia
13115|NCT02974283|r-tPA thrombolytic therapy
13116|NCT02974257|cardiac arrest
13117|NCT02974257|thiamine
13118|NCT02974257|oxygen consumption
13119|NCT02974257|lactate
13120|NCT02974257|shock
13121|NCT02974244|Type 2 diabetes
13122|NCT02974192|Ischemic stroke
13123|NCT02974192|Soluble CD40 Ligand
13124|NCT02974192|Neopetrin
13125|NCT02974192|stroke risk factors
13126|NCT02974192|functional outcome
13127|NCT02974166|Temporomandibular Disorder
13128|NCT02974166|Osteopathic Manipulative Treatment
13129|NCT02974166|Rigid Splint
13130|NCT02974166|Speech Therapy
13131|NCT02974127|intracranial benign meningioma
13132|NCT02974127|radiosurgery
13133|NCT02974127|large meningioma
13134|NCT02974127|critical site
13135|NCT02974127|multisession radiosurgery
13136|NCT02974101|Spinal cord stimulation
13137|NCT02974101|AdaptiveStim
13138|NCT02974062|Position sense
13139|NCT02974062|Lumbar stabilization exercise
13140|NCT02974049|Ivermectin
13141|NCT02974049|Albendazole
13142|NCT02974049|Diethylcarbamazine
13143|NCT02974036|Patient education
13144|NCT02974036|Osteoarthritis
13145|NCT02974036|Primary health care
13146|NCT02974010|d-cycloserine
13147|NCT02974010|lurasidone
13148|NCT02974010|ketamine
13149|NCT02974010|randomized controlled trial
13150|NCT02973984|Anticoagulant Treatments
13151|NCT02973984|Multidimensional Prognostic Index (MPI)
13152|NCT02973984|Comprehensive Geriatric Assessment (CGA)
13153|NCT02973984|Frailty
13154|NCT02973984|Elderly
13155|NCT02973984|Atrial Fibrillation
13156|NCT02973971|Blood cell biomarkers, peripheral circulating biomarkers
13157|NCT02973958|Penis
13158|NCT02973958|Pain
13159|NCT02973958|Ketorolac
13160|NCT02973958|Circumcision
13161|NCT02973945|Pulmonary Rehabilitation
13162|NCT02973945|High Flow Nasal Cannula
13163|NCT02973945|The Venturi Mask
13164|NCT02973945|Exercise capacity
13165|NCT02973945|Aerobic capacity
13166|NCT02973945|HFNC
13167|NCT02973932|cognitive-behavioral psychotherapy
13168|NCT02973932|obsessive-compulsive disorder
13169|NCT02973932|internet-based
13170|NCT02973893|Chronic Venous Leg Ulcer
13171|NCT02973880|Steroid/antibiotic associated treatment
13172|NCT02973880|Phaco-emulsification
13173|NCT02973880|Cataract extraction
13174|NCT02973867|Bone mineral density
13175|NCT02973867|Myokines
13176|NCT02973867|Adipokines
13177|NCT02972879|trigger finger
13178|NCT02972879|Therapeutic Modalities
13179|NCT02972879|Corticosteroid Injection
13180|NCT02972840|Bruton tyrosine kinase inhibitor
13181|NCT02972840|Btk
13182|NCT02972840|ACP-196
13183|NCT02972840|Mantle Cell Lymphoma
13184|NCT02972840|acalabrutinib
13185|NCT02972840|ACE-LY-308
13186|NCT02972840|Treatment naive
13187|NCT02972840|Lymphoma
13188|NCT02972840|non-Hodgkins
13189|NCT02973815|family meals
13190|NCT02973815|home food availability
13191|NCT02973802|Graves Disease
13192|NCT02973802|Phase 1
13193|NCT02973789|Non-Small Cell Lung Cancer
13194|NCT02973789|NSCLC
13195|NCT02973789|Treatment
13196|NCT02973789|Minimal Toxicity
13197|NCT02973789|TTFields
13198|NCT02973789|TTF
13199|NCT02973789|Tumor Treating Fields
13200|NCT02973789|Novocure
13201|NCT02973789|Docetaxel
13202|NCT02973789|PD-1 inhibitor
13203|NCT02973750|high-grade serous cancer
13204|NCT02973750|stage III cancer
13205|NCT02973750|stage IV cancer
13206|NCT02973724|Extubation
13207|NCT02973724|Remifentanil
13208|NCT02973724|Laryngomicrosurgery
13209|NCT02973685|Hepatic arterial infusion chemotherapy
13210|NCT02973685|Transarterial Chemoembolization
13211|NCT02973685|BCLC A/B
13212|NCT02973672|Fluorescence
13213|NCT02973672|Surgery
13214|NCT02973672|Cancer
13215|NCT02973672|SGM-101
13216|NCT02973672|Near Infrared
13217|NCT02973672|Immunophotodetection
13218|NCT02973646|chronic hepatitis b
13219|NCT02973646|peginterferon alfa-2b
13220|NCT02973646|interferon gene mutation
13221|NCT02973646|interferon receptor
13222|NCT02973633|Heart Failure
13223|NCT02973633|Remodeling
13224|NCT02973633|Myocardial Infarction
13225|NCT02973633|Left Ventricular Hypertrophy
13226|NCT02973633|Diffusion Tensor MRI
13227|NCT02973594|left ventricular reverse remodeling
13228|NCT02973594|beta-1 adrenergic receptor signaling
13229|NCT02973594|idiopathic dilated cardiomyopathy
13230|NCT02973594|HCN4 inhibition
13231|NCT02973594|beta-1 adrenergic receptor blocker
13232|NCT02973594|gene expression
13233|NCT02973581|Surgical Pleth Index (SPI)
13234|NCT02973581|General Anaesthesia (GA),
13235|NCT02973581|Numerical Rating Scale (NRS)
13236|NCT02973581|Adequacy of Anaesthesia (AoA)
13237|NCT02973581|Peribulbar Block (PBB)
13238|NCT02973581|Topical Analgesia (TA)
13239|NCT02973581|Oculocardiac reflex (OCR)
13240|NCT02973581|Postoperative nausea nad vomitting (PONV)
13241|NCT02973542|IBS
13242|NCT02973542|Ethosuximide
13243|NCT02973542|Pain
13244|NCT02973529|Percutaneous intervention (PCI)
13245|NCT02973529|Optical coherence tomography (OCT)
13246|NCT02973529|Bifurcation lesion
13247|NCT02973529|Bioresorbable stents (BRS)
13248|NCT02973503|Hepatitis C
13249|NCT02973503|Genotype 1B
13250|NCT02973503|Non Severe Fibrosis
13251|NCT02973503|Treatment Naïve
13252|NCT02973503|8 Weeks of Treatment
13253|NCT02973503|Elbasvir/Grazoprevir Combination
13254|NCT02973490|ESD;Transanal Tube Drainage;Colorectal Tumor
13255|NCT02973438|Spinal Cord Injuries
13256|NCT02973438|Obesity
13257|NCT02973438|Insulin Resistance
13258|NCT02973438|Intermittent hypoxia
13259|NCT02973425|mHealth, Smoking cessation,
13260|NCT02973399|CLL
13261|NCT02973399|Leukemia, Chronic Lymphocytic
13262|NCT02973399|Hsp90
13263|NCT02973399|Ibrutinib
13264|NCT02973386|Local advanced
13265|NCT02973386|High Risk
13266|NCT02973386|Nasopharyngeal Carcinoma
13267|NCT02973373|MRI
13268|NCT02973373|Chest
13269|NCT02973373|Apnea
13270|NCT02973347|Enteral Feeding
13271|NCT02973347|Ventilator-Associated Pneumonia
13272|NCT02973347|Mechanical Ventilation
13273|NCT02973347|Pediatric Intensive Care Unit
13274|NCT02973347|Critical Illness
13275|NCT02973334|sweeteners
13276|NCT02973334|sugar
13277|NCT02973334|stress response
13278|NCT02973295|NAFLD;
13279|NCT02973295|Fibroscan
13280|NCT02973295|Silymarin
13281|NCT02973256|Meningioma grade II
13282|NCT02973256|Meningioma grade III
13283|NCT02973243|early warning scoring
13284|NCT02973243|respiration rate
13285|NCT02973243|acute care teams
13286|NCT02973243|NEWS
13287|NCT02973243|CREWS
13288|NCT02973230|Pregnancy, Ectopic
13289|NCT02973230|Vascular Endothelial Growth Factor A
13290|NCT02973230|Pregnancy, Tubal
13291|NCT02973217|Hyperthermia, Induced
13292|NCT02973217|Laser Coagulation
13293|NCT02973217|Laser Therapy
13294|NCT02973204|tumor DNA
13295|NCT02973204|circulating tumor cells
13296|NCT02973204|biopsy
13297|NCT02973191|Leukemia
13298|NCT02973191|B-Cell Acute Lymphoblastic Leukemia
13299|NCT02973191|JCAR015
13300|NCT02973152|Type I Thyroplasty
13301|NCT02973152|Reinnervation
13302|NCT02973113|Nivolumab
13303|NCT02973113|Hodgkin Lymphoma
13304|NCT02973113|Non-Hodgkin Lymphoma
13305|NCT02973113|Lymphoproliferative Disorders
13306|NCT02973113|EBV-specific T Cells
13307|NCT02973074|iron deficiency
13308|NCT02973074|patient blood management
13309|NCT02973074|anemia
13310|NCT02973048|Cesarean delivery
13311|NCT02973048|Spinal anesthesia
13312|NCT02973048|Local anesthetics
13313|NCT02973009|The Sleeve Gastrectomy (SG)
13314|NCT02973009|bariatric surgery
13315|NCT02973009|laparoscopy
13316|NCT02973009|systematic closure of the epigastric
13317|NCT02972983|Staphylococcus aureus
13318|NCT02972983|Bacteremia
13319|NCT02972983|Daptomycin
13320|NCT02972957|intranasal
13321|NCT02972957|flu vaccine
13322|NCT02972957|Gambian children
13323|NCT02972931|HIV infection
13324|NCT02972931|low HIV reservoir
13325|NCT02972931|functional cure
13326|NCT02972905|pharmacokinetics
13327|NCT02972905|GSK2269557
13328|NCT02972905|Dry powder Inhaler (DPI)
13329|NCT02972905|tolerability
13330|NCT02972905|safety
13331|NCT02972905|ELLIPTA
13332|NCT02972814|Troponin
13333|NCT02972814|Point of care test
13334|NCT02972814|myocardial infarction
13335|NCT02972801|Spermatogonial stem cells
13336|NCT02972801|Testis
13337|NCT02972801|Fertility
13338|NCT02972801|Infertility
13339|NCT02972801|Oncofertility
13340|NCT02972762|depth of anesthesia\postoperation delirium
13341|NCT02972736|Radiation dose
13342|NCT02972736|percutaneous coronary intervention
13343|NCT02972736|Coronary
13344|NCT02972736|Interventional radiology
13345|NCT02972736|Electrophysiology
13346|NCT02972723|Metformin Therapy in HCV
13347|NCT02972684|Cardiopulmonary Bypass
13348|NCT02972684|Hemorrhage
13349|NCT02972684|blood transfusion
13350|NCT02972684|Point-of-care test
13351|NCT02972684|health economics
13352|NCT02972671|MiStent
13353|NCT02972658|Alzheimer's Disease
13354|NCT02972658|Dementia
13355|NCT02972658|Brain Diseases
13356|NCT02972658|Neurodegenerative Diseases
13357|NCT02972658|Central Nervous System Diseases
13358|NCT02972658|Nervous System Diseases
13359|NCT02972658|Mental Disorders
13360|NCT02972658|Delirium, Dementia, Amnestic, Cognitive Disorders
13361|NCT02972658|Tauopathies
13362|NCT02972658|Memory
13363|NCT02972658|Amyloid
13364|NCT02972632|Drug Therapy
13365|NCT02972619|Blood Pressure
13366|NCT02972619|Lipids
13367|NCT02972619|Cardiovascular
13368|NCT02972619|Health Services
13369|NCT02972619|Hypertension
13370|NCT02972606|HIV
13371|NCT02972606|Peripheral Neuropathy
13372|NCT02972606|Chronic Pain
13373|NCT02972606|Qualitative Research
13374|NCT02972567|probiotics
13375|NCT02972567|metabolic syndrome
13376|NCT02972567|non-alcoholic fatty liver disease
13377|NCT02972528|DFU
13378|NCT02972528|Diabetic Foot Ulcer
13379|NCT02972528|Diabetes
13380|NCT02972528|Platelet Rich Plasma
13381|NCT02972515|Smoking
13382|NCT02972515|Smoking cessation
13383|NCT02972515|Multiple behaviors
13384|NCT02972515|mHealth
13385|NCT02972515|Mobile Application
13386|NCT02972502|Metoclopramide (Reglan)
13387|NCT02972502|Haloperidol (Haldol)
13388|NCT02972476|Chronic Obstructive Pulmonary Disease
13389|NCT02972463|Gastrointestinal
13390|NCT02972463|Microbiome
13391|NCT02972463|Inflammation
13392|NCT02972437|GAS in oral cavity
13393|NCT02972424|pelvic fracture
13394|NCT02972424|healing
13395|NCT02972424|teriparatide
13396|NCT02972398|treatment resistant depression
13397|NCT02972398|N-Acetyl Cysteine
13398|NCT02972398|inflammation mediators
13399|NCT02972398|oxidative stress
13400|NCT02972398|brain imaging
13401|NCT02972385|warfarin
13402|NCT02972385|blood clotting
13403|NCT02972372|esophageal cancer
13404|NCT02972372|chemoradiation
13405|NCT02972372|esophagectomy
13406|NCT02972359|Neridronic Acid
13407|NCT02972359|Neridronate
13408|NCT02972359|CRPS
13409|NCT02972359|RSD (reflex sympathetic dystrophy)
13410|NCT02972294|iron isomaltoside
13411|NCT02972294|tranexamic acid
13412|NCT02972203|Mindfulness
13413|NCT02972203|primary care
13414|NCT02972203|self-control
13415|NCT02972203|self-regulation
13416|NCT02972203|adherence
13417|NCT02972177|Lung cancer
13418|NCT02972177|Transbronchial ablation
13419|NCT02972177|Radiofrequency ablation
13420|NCT02972177|Microwave ablation
13421|NCT02972164|Childhood obesity
13422|NCT02972164|Lifestyle
13423|NCT02972164|Prevention
13424|NCT02972164|Intervention
13425|NCT02972164|Behavioural psychology
13426|NCT02972138|Sickle-cells Disease
13427|NCT02972138|bisphosphonates
13428|NCT02972138|Vitamine D
13429|NCT02972125|Lacosamide
13430|NCT02972125|Bioequivalence
13431|NCT02972125|Dry Syrup
13432|NCT02972073|Low back pain
13433|NCT02972073|Neuromuscular control
13434|NCT02972060|Hormone Naive Prostate Cancer
13435|NCT02972047|Reflux
13436|NCT02972021|respiratory insufficiency
13437|NCT02972021|High-flow nasal cannula
13438|NCT02972008|Aortic stenosis
13439|NCT02972008|Transaortic valve replacement
13440|NCT02972008|stroke
13441|NCT02972008|Epigenetic
13442|NCT02971969|gene therapy
13443|NCT02971969|Hemophilia B
13444|NCT02971956|Esophageal Cancer
13445|NCT02971917|Chest radiography
13446|NCT02971917|Image improvements
13447|NCT02971917|Image Reconstruction
13448|NCT02971917|Preprocessing
13449|NCT02971917|MTF
13450|NCT02971904|newborn
13451|NCT02971904|prematurity
13452|NCT02971904|preterm
13453|NCT02971904|human milk
13454|NCT02971904|human milk analyzer
13455|NCT02971904|neonatology
13456|NCT02971904|neonatal intensive care unit
13457|NCT02971904|low birth weight
13458|NCT02971865|Cognitive Behavior Therapy
13459|NCT02971865|Chiropractic
13460|NCT02971865|Diabetes Mellitus, Type 2
13461|NCT02971865|Primary care shared visit
13462|NCT02971852|Hypnosis
13463|NCT02971852|Anesthesia
13464|NCT02971852|Suggestion
13465|NCT02971852|Thermography
13466|NCT02971826|Stroke
13467|NCT02971826|thrombectomy
13468|NCT02971826|REVIVETM SE
13469|NCT02971826|MRI
13470|NCT02971826|Computed Tomography
13471|NCT02971813|cardiac rehabilitation
13472|NCT02971813|social media
13473|NCT02971813|adherence
13474|NCT02971813|motivation
13475|NCT02971800|sodium fluorescein
13476|NCT02971800|ureteral efflux
13477|NCT02971800|laparoscopic hysterectomy
13478|NCT02971774|stroke
13479|NCT02971774|botulinum toxin injection
13480|NCT02971774|daily life
13481|NCT02971748|hormone receptor-positive localized inflammatory breast cancer
13482|NCT02971748|Hormonal therapy
13483|NCT02971748|IBC
13484|NCT02971748|standard adjuvant hormonal therapy
13485|NCT02971748|maintenance therapy
13486|NCT02971748|immune related biomarkers
13487|NCT02971748|PD-L1 expression
13488|NCT02971748|HR positive
13489|NCT02971748|HR-positive localized IBC
13490|NCT02971735|cognitive style
13491|NCT02971735|e-learning
13492|NCT02971735|mobile technology
13493|NCT02971735|randomized controlled trial
13494|NCT02971735|otolaryngology-head and neck surgery
13495|NCT02971722|GLP-1 receptor agonist
13496|NCT02971657|Staphylococcus aureus phenotypic characterization
13497|NCT02971657|Antibiotic resistance
13498|NCT02971657|Orthopedic device related infections
13499|NCT02971657|Phenotypic characterization
13500|NCT02971631|Dumping syndrome
13501|NCT02971631|Gastrectomy
13502|NCT02971631|GLP-1
13503|NCT02971631|Insulin
13504|NCT02971618|dapagliflozin,
13505|NCT02971618|Russia,
13506|NCT02971618|retrospective study,
13507|NCT02971618|diabetes mellitus type 2
13508|NCT02971579|ERCP
13509|NCT02971579|biliary diseases
13510|NCT02971579|Pancreatic diseases
13511|NCT02971579|outcome
13512|NCT02971579|Quality
13513|NCT02971579|Training
13514|NCT02971566|feeding intolerance
13515|NCT02971566|preterm infants
13516|NCT02971566|near infrared spectroscopy
13517|NCT02971566|abnormal antenatal Doppler
13518|NCT02971540|Surgical Pleth Index (SPI)
13519|NCT02971540|General Anaesthesia (GA),
13520|NCT02971540|Numerical Rating Scale (NRS)
13521|NCT02971540|Adequacy of Anaesthesia (AoA
13522|NCT02971540|Spectral Entropy (SE)
13523|NCT02971540|Local Anesthetic (LA)
13524|NCT02971488|Hepatitis C
13525|NCT02971488|PWID
13526|NCT02971488|Linkage-to-care
13527|NCT02971475|Extracorporeal Shock Wave lithotripsy(ESWL)
13528|NCT02971475|Endoscopic Retrograde Cholangiopancreatography(ERCP)
13529|NCT02971475|chronic pancreatitis
13530|NCT02971475|pain relief
13531|NCT02971462|stroke
13532|NCT02971462|Vertebrobasilar atherosclerosis
13533|NCT02971462|remote ischemic conditioning
13534|NCT02971449|Village Healthcare Team
13535|NCT02971449|mHealth
13536|NCT02971449|Telemedicine
13537|NCT02971423|infection
13538|NCT02971423|gram-negative bacterium
13539|NCT02971345|Hepatocellular carcinoma
13540|NCT02971345|main portal vein tumor thrombus
13541|NCT02971345|endovascular brachytherapy
13542|NCT02971345|stent
13543|NCT02971345|chemoembolization
13544|NCT02971306|alcoholic hepatitis
13545|NCT02971306|alcoholic liver disease
13546|NCT02971306|jaundice
13547|NCT02971306|ascites
13548|NCT02971306|regeneration
13549|NCT02971293|AZD8871
13550|NCT02971293|long-acting muscarinic antagonist (LAMA)
13551|NCT02971293|long-acting β2-agonist (LABA)
13552|NCT02971293|inhaled long-acting bronchodilator
13553|NCT02971293|pharmacokinetics
13554|NCT02971293|safety
13555|NCT02971293|tolerability
13556|NCT02971293|efficacy
13557|NCT02971293|Phase IIa
13558|NCT02971293|Muscarinic receptor antagonist β2 adrenoceptor agonist (MABA)
13559|NCT02971267|heart failure
13560|NCT02971267|cardiomyopathy
13561|NCT02971267|myocarditis
13562|NCT02971254|cognitive functions
13563|NCT02971254|anaesthesia recovery
13564|NCT02971254|sevoflurane
13565|NCT02971254|desflurane
13566|NCT02971241|Integeneration
13567|NCT02971241|Mobile technology
13568|NCT02971241|Chronic disease management
13569|NCT02971241|Diabetes self-management
13570|NCT02971228|glucagon
13571|NCT02971228|T1DM
13572|NCT02971228|Bionic Pancreas
13573|NCT02971228|diabetes
13574|NCT02971228|iLet
13575|NCT02971228|iPhone
13576|NCT02971228|Beta Bionics
13577|NCT02971228|Anti-hypoglycemia
13578|NCT02971228|Glucagon Analog
13579|NCT02971202|o-glcnacylation
13580|NCT02971202|hexosamine
13581|NCT02971163|Syncope
13582|NCT02971163|Shared Decision-Making
13583|NCT02971163|Emergency Medicine
13584|NCT02971163|Decision Aid
13585|NCT02971137|Smoking
13586|NCT02971137|Cigarette Smoking
13587|NCT02971137|Veterans
13588|NCT02971137|Tobacco Use
13589|NCT02971137|Pain
13590|NCT02971124|Cognitive Performance
13591|NCT02971124|Meaningful Play
13592|NCT02971124|Screening test
13593|NCT02971124|Dementia
13594|NCT02971085|low-risk prostate cancer
13595|NCT02971085|active surveillance
13596|NCT02971085|pathologic reclassification
13597|NCT02971072|address
13598|NCT02971072|atrophic
13599|NCT02971072|base
13600|NCT02971072|clinical
13601|NCT02971072|cost
13602|NCT02971072|data
13603|NCT02971072|disability
13604|NCT02971072|effectiveness
13605|NCT02971072|attention
13606|NCT02971072|biofeedback
13607|NCT02971072|electrical stimulation
13608|NCT02971072|electromyography
13609|NCT02971072|exercise
13610|NCT02971072|exertion
13611|NCT02971072|health care service utilization
13612|NCT02971072|improved
13613|NCT02971072|injection of therapeutic agent
13614|NCT02971072|innovation
13615|NCT02971072|intervention
13616|NCT02971072|knowledge
13617|NCT02971072|local anesthetics
13618|NCT02971072|measures
13619|NCT02971072|modeling
13620|NCT02971072|motor
13621|NCT02971072|motor control
13622|NCT02971072|muscle
13623|NCT02971072|neuroadaptation
13624|NCT02971072|neurophysiology
13625|NCT02971072|novel
13626|NCT02971072|outcome
13627|NCT02971072|outcome measure
13628|NCT02971072|pain inhibition
13629|NCT02971072|patients
13630|NCT02971072|pattern
13631|NCT02971072|programs
13632|NCT02971072|public health relevance
13633|NCT02971072|rehabilitation strategy
13634|NCT02971072|relating to nervous system
13635|NCT02971072|reporting
13636|NCT02971072|research
13637|NCT02971072|rotator cuff
13638|NCT02971072|shoulder
13639|NCT02971072|staging
13640|NCT02971072|strength training
13641|NCT02971072|success
13642|NCT02971072|systematic review
13643|NCT02971072|techniques
13644|NCT02971072|testing
13645|NCT02971072|time
13646|NCT02971072|training
13647|NCT02971072|treatment strategy
13648|NCT02971072|United States
13649|NCT02971072|work
13650|NCT02971059|Elderly
13651|NCT02971059|Phenylalanine
13652|NCT02971059|Healthy
13653|NCT02971046|healthy children
13654|NCT02971046|protein
13655|NCT02971046|glutathione
13656|NCT02971046|protein requirement
13657|NCT02971033|hepatitis C virus
13658|NCT02971033|antiviral treatment
13659|NCT02971033|viral entry inhibitor
13660|NCT02971033|mathematical modeling
13661|NCT02970994|Linear growth and neurodevelopment outcome
13662|NCT02970994|< 34 weeks
13663|NCT02970981|Monoclonal antibody
13664|NCT02970981|Programmed Death-1 (PD-1)
13665|NCT02970981|Programmed Death-Ligand 1 (PD-L1)
13666|NCT02970981|Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
13667|NCT02970981|Antigen
13668|NCT02970929|Schizophrenia
13669|NCT02970916|metastatic colorectal cancer
13670|NCT02970916|FOLFIRI
13671|NCT02970916|aflibercept
13672|NCT02970916|oxaliplatin
13673|NCT02970916|ACE polymorphisms
13674|NCT02970890|Total Hip Arthroplasty (THA)
13675|NCT02970890|Phototherapy
13676|NCT02970890|Low-level laser therapy
13677|NCT02970890|Light-emitting diodes
13678|NCT02970877|Fecal microbiota transplant
13679|NCT02970877|Intestinal microbiome
13680|NCT02970877|Oral microbiome
13681|NCT02970877|Mucosa associated microbiome
13682|NCT02970877|Appetite
13683|NCT02970877|Metabolome
13684|NCT02970877|Depression
13685|NCT02970877|Anxiety
13686|NCT02970864|Nerve regeneration
13687|NCT02970864|Peripheral nerve injury
13688|NCT02970864|Nerve conduits
13689|NCT02970864|Sensory nerve transection
13690|NCT02970851|Endothelin receptor antagonist (ERA)
13691|NCT02970851|pulmonary artery hypertension (PAH),
13692|NCT02970851|18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT)
13693|NCT02970851|Rubidium-82 (82Rb) PET/CT
13694|NCT02970838|Formula diet
13695|NCT02970825|exercise medicine
13696|NCT02970825|youth
13697|NCT02970825|adolescents
13698|NCT02970825|students
13699|NCT02970695|insomnia
13700|NCT02970695|older people
13701|NCT02970695|auriculotherapy
13702|NCT02970669|Heart failure with reduced left ventricular ejection fraction (LVEF)
13703|NCT02970669|Cardiac dysfunction
13704|NCT02970669|Heart muscle dysfunction
13705|NCT02970669|Left ventricular (LV) dilation
13706|NCT02970669|Left ventricular hypertrophy
13707|NCT02970669|HF
13708|NCT02970669|AHF
13709|NCT02970669|CHF
13710|NCT02970669|acute heart failure
13711|NCT02970669|chronic heart failure
13712|NCT02970669|congestive heart failure
13713|NCT02970669|congestive cardiac failure
13714|NCT02970669|Heart failure
13715|NCT02970669|HReEF
13716|NCT02970669|Physical Activity
13717|NCT02970669|Actigraphy
13718|NCT02970669|Home sleep test
13719|NCT02970669|wake
13720|NCT02970643|Olanzapine
13721|NCT02970643|Chemotherapy-Induced Nausea and Vomiting
13722|NCT02970643|Moderate risk
13723|NCT02970630|prophylaxis
13724|NCT02970591|FODMAPS
13725|NCT02970591|carbohydrates
13726|NCT02970591|metabolomics
13727|NCT02970591|microbiota
13728|NCT02970565|Family Nurture Intervention
13729|NCT02970565|Martha G. Welch MD
13730|NCT02970565|Randomized Control Trial
13731|NCT02970565|Pre-school Intervention
13732|NCT02970565|Preschool Intervention
13733|NCT02970565|Multiple Family Group Intervention
13734|NCT02970565|Emotional Connection
13735|NCT02970565|Co-regulation
13736|NCT02970552|PreTerm Birth
13737|NCT02970552|HIV
13738|NCT02970552|Vaginal Progesterone
13739|NCT02970552|ART
13740|NCT02970526|Colorectal cancer survivors
13741|NCT02970513|Escherichia coli
13742|NCT02970513|Microbiota
13743|NCT02970513|Colorectal cancer
13744|NCT02970513|Psychiatric disorders
13745|NCT02970513|Personality traits
13746|NCT02970500|Cognitive impairment
13747|NCT02970500|Methylphenidate
13748|NCT02970500|Cancer-related cognitive impairment
13749|NCT02970500|Mixed method
13750|NCT02970500|Phase II study
13751|NCT02970500|Breast cancer
13752|NCT02970487|cataract
13753|NCT02970461|personal health record
13754|NCT02970461|gamification
13755|NCT02970461|chronic patient care
13756|NCT02970448|LITT
13757|NCT02970448|Brain Tumor
13758|NCT02970448|Temozolomide
13759|NCT02970435|surgery
13760|NCT02970435|video discharge instructions
13761|NCT02970422|Survey
13762|NCT02970422|Priorities
13763|NCT02970422|Activities
13764|NCT02970422|Participation
13765|NCT02970357|Evaluation
13766|NCT02970357|Therapeutic education
13767|NCT02970357|Type 1 Diabetes
13768|NCT02970357|Children
13769|NCT02970344|Coping Skills Training
13770|NCT02970344|Diabetes Education
13771|NCT02970318|CLL
13772|NCT02970318|BTK
13773|NCT02970318|Bruton Tyrosine Kinase
13774|NCT02970318|acalabrutinib
13775|NCT02970318|ACP-196
13776|NCT02970279|Behavioural activation
13777|NCT02970279|Psychotherapy, group
13778|NCT02970279|Depression
13779|NCT02970279|Depressive disorder
13780|NCT02970266|Leber Congenital Amaurosis
13781|NCT02970266|Genetic Decryption
13782|NCT02970266|The genotype-phenotype correlations
13783|NCT02970266|Ethnicity families
13784|NCT02970240|cardiopulmonary exercise testing
13785|NCT02970240|inflammation
13786|NCT02970240|oxidative status
13787|NCT02970227|heart failure
13788|NCT02970227|cardiomyopathies
13789|NCT02970227|myocarditis
13790|NCT02970214|heart failure
13791|NCT02970214|heart disease
13792|NCT02970214|cardiovascular disease
13793|NCT02970214|metabolic risk
13794|NCT02970214|comorbidities
13795|NCT02970201|eHealth
13796|NCT02970201|mHealth
13797|NCT02970201|Hemodialysis
13798|NCT02970201|Adherence
13799|NCT02970201|Electronic intervention
13800|NCT02970201|ESRD
13801|NCT02970201|Nephrology
13802|NCT02970188|time restricted feeding
13803|NCT02970188|endothelial function
13804|NCT02970188|arterial stiffness
13805|NCT02970188|intermittent fasting
13806|NCT02970175|Terlipressin
13807|NCT02970162|LEMS
13808|NCT02970136|Increased Screening Uptake
13809|NCT02970136|Community Health Worker
13810|NCT02970136|Medically Underserved
13811|NCT02970097|infraclavicular brachial plexus block
13812|NCT02970097|wrist arthroscopy
13813|NCT02970097|quality of recovery score
13814|NCT02970097|pain score
13815|NCT02970097|modified sleep quality assessment
13816|NCT02970071|Spatio-Temporal Image Correlation
13817|NCT02970071|Complicated congenital heart disease
13818|NCT02970071|Echocardiography
13819|NCT02970006|spinal cord stimulation
13820|NCT02970006|virtual reality
13821|NCT02970006|full body illusion
13822|NCT02969980|MDS
13823|NCT02969980|AML progressed from MDS
13824|NCT02969980|CMML
13825|NCT02969967|rehabilitation
13826|NCT02969967|upper extremity
13827|NCT02969967|orthosis
13828|NCT02969967|SaeboFlex
13829|NCT02969941|Parkinson Disease
13830|NCT02969941|Functional Magnetic Resonance Imaging
13831|NCT02969941|Transcranial Magnetic Stimulation
13832|NCT02969928|Full-mouth ultrasonic debridement
13833|NCT02969928|Clarithromycin
13834|NCT02969928|Amoxicillin
13835|NCT02969928|Metronidazole
13836|NCT02969915|people who inject drugs
13837|NCT02969915|men who have sex with men
13838|NCT02969915|HIV
13839|NCT02969915|India
13840|NCT02969902|Procedural pain
13841|NCT02969902|Phlebotomy
13842|NCT02969902|Distraction
13843|NCT02969902|Hand-held computer
13844|NCT02969902|Children
13845|NCT02969889|Airtraq
13846|NCT02969889|Intubating laryngeal mask airway
13847|NCT02969889|BMI>35
13848|NCT02969863|bionic pancreas
13849|NCT02969850|vitamin D supplementation
13850|NCT02969850|calcium supplementation
13851|NCT02969837|Multiple Myeloma
13852|NCT02969837|Elotuzumab
13853|NCT02969837|Carfilzomib (Kyprolis)
13854|NCT02969837|Lenalidomide (Revlimid)
13855|NCT02969837|Dexamethasone (E-KRd)
13856|NCT02969824|Sport Injury
13857|NCT02969824|Concussion
13858|NCT02969824|Active Recovery
13859|NCT02969785|Postural control
13860|NCT02969785|Physiotherapy
13861|NCT02969785|Sports injuries
13862|NCT02969785|Low back pain
13863|NCT02969785|training
13864|NCT02969759|Bioenergetics
13865|NCT02969759|Protein Metabolism
13866|NCT02969759|Sporadic Amyotrophic Lateral Sclerosis
13867|NCT02969746|activated charcoal, direct oral anticoagulant
13868|NCT02969733|postoperative analgesia
13869|NCT02969733|PainMatcher
13870|NCT02969707|repetitive Transcranial Magnetic Stimulation
13871|NCT02969707|functional MRI
13872|NCT02969707|Fibromyalgia
13873|NCT02969707|Hypnosis
13874|NCT02969707|Pain Assessment
13875|NCT02969694|addiction
13876|NCT02969694|hypersexuality
13877|NCT02969694|psychostimulants
13878|NCT02969668|opioid substitution treatment
13879|NCT02969668|interferon-free direct acting antivirals
13880|NCT02969668|hepatitis c therapy
13881|NCT02969655|Safety
13882|NCT02969655|Efficacy
13883|NCT02969655|Daprodustat
13884|NCT02969655|Chronic kidney disease
13885|NCT02969616|lumbar, fusion, DDD, Trinity Elite
13886|NCT02969603|PET/MRI
13887|NCT02969603|muscular activity
13888|NCT02969603|11C-acetate
13889|NCT02969590|Contraception
13890|NCT02969590|Mucus
13891|NCT02969590|Cervix
13892|NCT02969590|progestin
13893|NCT02969590|hormones
13894|NCT02969577|Androgen deprivation therapy
13895|NCT02969577|ADT
13896|NCT02969564|prostate cancer
13897|NCT02969564|bone metastases
13898|NCT02969564|PET/MRI
13899|NCT02969525|Psoriatic Arthritis
13900|NCT02969525|PsA
13901|NCT02969525|Bimekizumab
13902|NCT02969512|Patient education
13903|NCT02969512|Advanced hip osteoarthritis
13904|NCT02969512|Online education
13905|NCT02969512|Computer-assisted instruction
13906|NCT02969512|e-learning
13907|NCT02969512|Older adult
13908|NCT02969499|Electroconvulsive Therapy
13909|NCT02969499|Dementia
13910|NCT02969473|esophageal squamous cell carcinoma
13911|NCT02969473|concurrent chemoradiotherapy
13912|NCT02969473|docetaxel
13913|NCT02969473|cisplatin
13914|NCT02969473|5-fluorouracil
13915|NCT02969447|Retained Placenta
13916|NCT02969447|Second trimester medical termination
13917|NCT02969447|Third stage labor
13918|NCT02969447|Oxytocin
13919|NCT02969395|3T
13920|NCT02969395|Magnetic Resonance Imaging (MRI)
13921|NCT02969395|Implantable Cardioverter Defibrillator (ICD)
13922|NCT02969395|Implantable Pulse Generator (IPG)
13923|NCT02969395|Cardiac Resynchronization Therapy (CRT)
13924|NCT02969395|Cardiac Implantable Electronic Device (CIED)
13925|NCT02969382|Schizophrenia
13926|NCT02969369|Parkinson's Disease Psychosis
13927|NCT02969304|Tecfidera
13928|NCT02969304|Off-label
13929|NCT02969304|Utilization
13930|NCT02969278|vulvar cancer
13931|NCT02969278|sentinel node biopsy
13932|NCT02969278|inguino-femoral lymphadenectomy
13933|NCT02969278|18F FDG- PET/TC
13934|NCT02969278|guidelines
13935|NCT02969278|preoperative imaging
13936|NCT02969265|Drug therapy
13937|NCT02969226|mechanical ventilation
13938|NCT02969226|weaning
13939|NCT02969226|critically ill
13940|NCT02969226|spontaneous breathing trial
13941|NCT02969226|screening
13942|NCT02969226|invasive ventilation
13943|NCT02969226|SBT technique
13944|NCT02969213|Electronic management of epilepsy
13945|NCT02969213|biological etiology
13946|NCT02969213|Chinese children
13947|NCT02969200|Fabry Disease
13948|NCT02969200|Nephropathy
13949|NCT02969200|Measured GFR
13950|NCT02969200|Enzyme replacement therapy
13951|NCT02969161|PMTCT (Prevention of Mother-to-Child Transmission)
13952|NCT02969161|HIV (Human Immunodeficiency Virus)
13953|NCT02969161|Loss to follow-up (LTF)
13954|NCT02969161|Option B+ (B+)
13955|NCT02969161|ART (antiretroviral therapy)
13956|NCT02969148|Laparoscopic
13957|NCT02969148|Bursectomy
13958|NCT02969148|D2 lymphadenectomy
13959|NCT02969148|Gastric Cancer
13960|NCT02969122|gastric cancer
13961|NCT02969122|peritoneal cytology
13962|NCT02969083|UTUC
13963|NCT02969083|Upper Tract Urothelial Carcinoma
13964|NCT02969083|Neoadjuvant chemotherapy
13965|NCT02969083|Adjuvant chemotherapy
13966|NCT02969083|Radical nephroureterectomy
13967|NCT02969057|Lipidemic Response
13968|NCT02969031|communication
13969|NCT02969018|plaque psoriasis
13970|NCT02969005|radiopaque localizer grid
13971|NCT02969005|methylene blue
13972|NCT02969005|reduce radiation exposure
13973|NCT02968979|cachexia
13974|NCT02968979|Non-Small Cell Lung cancer
13975|NCT02968979|anorexia
13976|NCT02968979|malnutrition
13977|NCT02968940|Programmed cell death protein 1 (PD-1)
13978|NCT02968940|Programmed death-ligand 1 (PD-L1)
13979|NCT02968940|Immunotherapy
13980|NCT02968940|Hypofractionated Radiotherapy (HFRT)
13981|NCT02968940|Isocitrate dehydrogenase (IDH)
13982|NCT02968940|Glioma
13983|NCT02968914|Asthma
13984|NCT02968914|Chronic Obstructive pulmonary Disease
13985|NCT02968914|Pharmacokinetics
13986|NCT02968914|Healthy volunteers
13987|NCT02968875|endurance training
13988|NCT02968875|BDNF analysis
13989|NCT02968875|cognitive function
13990|NCT02968875|physiological abilities
13991|NCT02968849|HIV
13992|NCT02968823|Postoperative Pain
13993|NCT02968823|Anesthesia
13994|NCT02968823|Oral Surgery
13995|NCT02968784|Prostate Cancer
13996|NCT02968784|MRgFUS
13997|NCT02968784|ExAblate
13998|NCT02968784|Focused Ultrasound
13999|NCT02968771|Coronary artery disease
14000|NCT02968771|Cardiac perfusion SPECT
14001|NCT02968771|Metabolomics
14002|NCT02967692|PDR001
14003|NCT02967692|dabrafenib
14004|NCT02967692|trametinib
14005|NCT02967692|melanoma
14006|NCT02967692|immunotherapy
14007|NCT02967692|PD 1 inhibitor
14008|NCT02967692|anti PD1
14009|NCT02967692|PD-1
14010|NCT02967692|anti-PD-1
14011|NCT02967692|combination treatment
14012|NCT02967692|malignant skin cancer
14013|NCT02967692|skin cancer
14014|NCT02967692|BRAF V600
14015|NCT02967692|unresectable BRAF V600 mutated melanoma
14016|NCT02967692|metastatic BRAF V600 mutated melanoma
14017|NCT02967679|Neuropathy
14018|NCT02967679|Demyelinating polyradiculoneuropathy
14019|NCT02967640|Ketamine
14020|NCT02967640|Analgesics
14021|NCT02967640|Excitatory Amino Acid Antagonists
14022|NCT02967640|Receptors, Glutamate
14023|NCT02967640|Shoulder
14024|NCT02967601|shivering, cesarean section, anxiety, STAI
14025|NCT02967588|Medication adherence
14026|NCT02967588|Behavioural intervention
14027|NCT02967588|Acute coronary syndrome
14028|NCT02967588|Medication beliefs
14029|NCT02967588|Implementation intentions
14030|NCT02967575|cervical total disc replacement (cTDR)
14031|NCT02967536|cognitive function
14032|NCT02967536|microglia
14033|NCT02967536|neuroinflammation
14034|NCT02967523|Hepatocellular carcinoma
14035|NCT02967523|DEB-TACE
14036|NCT02968745|Rheumatoid arthritis
14037|NCT02968745|human activity
14038|NCT02968745|Canadian Occupational Performance Measure
14039|NCT02968706|High Flow Nasal Cannula
14040|NCT02968706|Colonoscopy
14041|NCT02968706|Obesity
14042|NCT02968654|Blood Transfusion
14043|NCT02968654|Brain Injury
14044|NCT02968654|Outcome
14045|NCT02968654|Hemoglobin
14046|NCT02968615|fiber
14047|NCT02968615|lean protein
14048|NCT02968615|loss weight
14049|NCT02968589|Tele-rehabilitation
14050|NCT02968589|Function
14051|NCT02968589|Quality of life
14052|NCT02968589|Exercise
14053|NCT02968589|Occupational Therapy
14054|NCT02968589|Physiotherapy
14055|NCT02968589|Caregiver burden
14056|NCT02968576|healthy volunteers
14057|NCT02968576|pharmacokinetics
14058|NCT02968537|Alcohol use disorders
14059|NCT02968537|inhibition
14060|NCT02968537|EEG
14061|NCT02968537|cortisol
14062|NCT02968537|Training
14063|NCT02968537|clinical outcome measures
14064|NCT02968498|Blood glucose level
14065|NCT02968498|Oral intake
14066|NCT02968498|Lactulose
14067|NCT02968498|Healthy volunteers
14068|NCT02968485|advanced solid tumor
14069|NCT02968485|Protein Kinase MEK inhibitor (MEKi)
14070|NCT02968485|Safety
14071|NCT02968485|Pharmacokinetics
14072|NCT02968472|4s CAR-T19
14073|NCT02968472|B cell leukemia
14074|NCT02968472|B-ALL
14075|NCT02968459|Mesenchyme Stem Cells
14076|NCT02968459|Cesarean Section
14077|NCT02968459|Uterine Scar
14078|NCT02968446|Valchlor
14079|NCT02968446|Vitamin D
14080|NCT02968433|Young Male Plasma
14081|NCT02968381|tobacco
14082|NCT02968381|smoking
14083|NCT02968381|imagery
14084|NCT02968342|Hypoactive sexual desire disorder
14085|NCT02968212|Mycobacterium avium Complex
14086|NCT02968212|Clofazimine
14087|NCT02968186|Mass Screening
14088|NCT02968186|Counseling
14089|NCT02968186|Primary Health Care
14090|NCT02968173|Bronchopulmonary dysplasia (BPD)
14091|NCT02968173|RSV hospitalization
14092|NCT02968173|Palivizumab
14093|NCT02968173|Immunoprophylaxis
14094|NCT02968173|Chronic lung disease (CLD) of prematurity
14095|NCT02968147|atrial fibrillation
14096|NCT02968147|catheter ablation
14097|NCT02968147|general anaesthesia
14098|NCT02968082|MVD
14099|NCT02968082|Scopolamine
14100|NCT02968082|Microvascular Decompression
14101|NCT02968056|atrial fibrillation
14102|NCT02968056|radiofrequency ablation
14103|NCT02968043|physiotherapeutic scoliosis specific exercise
14104|NCT02968030|Aged
14105|NCT02968030|Postural balance
14106|NCT02968030|Muscle strength
14107|NCT02967991|EUS
14108|NCT02967991|Biopsy
14109|NCT02967991|Liver
14110|NCT02967991|FNA
14111|NCT02967991|FNB
14112|NCT02967978|risk factors
14113|NCT02967978|Calcium isotopes
14114|NCT02967978|calcium turnover
14115|NCT02967978|DXA
14116|NCT02967965|clinical confounders
14117|NCT02967965|myocardial infarction size
14118|NCT02967965|determinants of myocardial infarct injury
14119|NCT02967952|out-of-hospital cardiac arrest (OHCA)
14120|NCT02967952|supraglottic airway (SGA)
14121|NCT02967952|endotracheal intubation (ETI)
14122|NCT02967952|emergency medical system (EMS)
14123|NCT02967952|Supraglottic Airway Versus Endotracheal tube (SAVE)
14124|NCT02967926|common bile duct stone
14125|NCT02967926|cholangioscopy
14126|NCT02967926|SpyGlass
14127|NCT02967926|non-fluoroscopic
14128|NCT02967913|Cesarean delivery
14129|NCT02967913|Obstetrical delivery
14130|NCT02967913|PFDI-20
14131|NCT02967913|UDI-6
14132|NCT02967913|Bladder flap
14133|NCT02967874|Adipose -Derived Stromal Vascular Fraction Cells
14134|NCT02967874|Knee Osteoarthritis
14135|NCT02967874|Intra-articular Administration
14136|NCT02967874|Liposuction
14137|NCT02967861|chronic periodontitis
14138|NCT02967861|Nuclear factor-kappa B
14139|NCT02967861|Pranayama
14140|NCT02967861|Peroxisome proliferator - activated receptor gamma
14141|NCT02967861|Red complex microorganisms
14142|NCT02967848|Radiotherapy
14143|NCT02967848|Mebrofenin
14144|NCT02967848|Liver
14145|NCT02967848|Cancer
14146|NCT02967848|SPECT
14147|NCT02967770|Metastatic
14148|NCT02967770|Pancreas
14149|NCT02967770|Cancer
14150|NCT02967497|Chemotherapy
14151|NCT02967497|Herbal medicine
14152|NCT02967497|Lung cancer
14153|NCT02967484|Acupuncture
14154|NCT02967484|Hypertension
14155|NCT02967484|Second prevention of Stroke
14156|NCT02967484|Efficacy
14157|NCT02967484|RCT
14158|NCT02967484|Study protocol
14159|NCT02967471|ARDS
14160|NCT02967458|prostate cancer
14161|NCT02967458|prostate ultrasound
14162|NCT02967458|subharmonic imaging
14163|NCT02967458|prostate biopsy
14164|NCT02967432|Staphylococcus aureus
14165|NCT02967432|Staphylococcal colonization
14166|NCT02967432|Staphylococcal infection
14167|NCT02967432|Mupirocin
14168|NCT02967432|Mupirocin-resistance
14169|NCT02967419|Repeated Implantation Failure; TWEAK;Fn14;JAK/STAT3;Indoleamine 2,3-dioxygenase
14170|NCT02967406|Lifestyle modification
14171|NCT02967406|Primary prevention
14172|NCT02967406|Community-based intervention
14173|NCT02967406|Randomized control trial
14174|NCT02967328|Reticulated Platelets
14175|NCT02967328|Immune Thrombocytopenia
14176|NCT02967302|knee arthritis, morphine, local injection, pain
14177|NCT02967289|colon
14178|NCT02967289|cancer
14179|NCT02967289|stage 3
14180|NCT02967289|high-risk
14181|NCT02967289|mFolfirinox
14182|NCT02967289|mFolfox6
14183|NCT02967289|adjuvant
14184|NCT02967276|Metformin
14185|NCT02967276|Dexamethasone
14186|NCT02967276|Multiple Myeloma
14187|NCT02967263|Acute Kidney Injury
14188|NCT02967263|Proteinosis
14189|NCT02967263|Epidemiology
14190|NCT02967263|Risk factors
14191|NCT02967198|Fusion
14192|NCT02967198|Ablation
14193|NCT02967198|Percutaneous biopsy
14194|NCT02967198|Shear wave elastography
14195|NCT02967159|chronic obstructive pulmonary disease (COPD)
14196|NCT02967159|asthma
14197|NCT02967107|adenoma
14198|NCT02967107|colorectal cancer
14199|NCT02967107|polypectomy
14200|NCT02967107|colonoscopy
14201|NCT02967081|Pulpitis
14202|NCT02967081|Biomarker
14203|NCT02967081|Diagnostic
14204|NCT02967081|Dentinal fluid
14205|NCT02967068|CSS
14206|NCT02967068|EGPA
14207|NCT02967068|GCA
14208|NCT02967068|GPA
14209|NCT02967068|MPA
14210|NCT02967068|PAN
14211|NCT02967068|TAK
14212|NCT02967068|HSP
14213|NCT02966951|osteoarthrosis
14214|NCT02966951|knee
14215|NCT02966951|adipose tissue
14216|NCT02966951|stem cells
14217|NCT02966951|cell therapy
14218|NCT02966925|Vulvovaginal dryness
14219|NCT02966886|Surgical Management
14220|NCT02966873|Post Traumatic Stress Disorder (PTSD)
14221|NCT02966873|Addiction
14222|NCT02966873|Alcohol Use Disorder
14223|NCT02966873|Cognitive Behavioral Therapy
14224|NCT02966873|N-acetylcysteine (NAC)
14225|NCT02966847|Video assisted thoracoscopy
14226|NCT02966847|Cone beam computed tomography
14227|NCT02966834|PBC
14228|NCT02966834|itch
14229|NCT02966834|GSK2330672
14230|NCT02966834|GLIMMER
14231|NCT02966834|primary biliary cholangitis
14232|NCT02966834|pruritus
14233|NCT02966821|Sulfatinib
14234|NCT02966821|Biliary Tract Cancer
14235|NCT02966821|Second-line
14236|NCT02966795|sofosbuvir (SOF)
14237|NCT02966795|ribavirin (RBV)
14238|NCT02966795|pegylated interferon (pegIFN)
14239|NCT02966795|interferon (IFN)
14240|NCT02966795|pegylated-interferon (pegIFN)
14241|NCT02966795|non-cirrhotic
14242|NCT02966795|glecaprevir
14243|NCT02966795|compensated cirrhosis
14244|NCT02966795|pibrentasvir
14245|NCT02966795|Sustained Virologic Response 12 weeks post dosing (SVR12)
14246|NCT02966782|Azacitidine
14247|NCT02966782|Venetoclax
14248|NCT02966782|Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
14249|NCT02966782|International Prognostic Scoring System (IPSS)
14250|NCT02966782|Hypomethylating Agent-Failure (HMA)
14251|NCT02966756|Relapsed chronic lymphocytic leukemia (CLL)
14252|NCT02966756|Leukemia
14253|NCT02966756|17p deletion
14254|NCT02966756|Refractory chronic lymphocytic leukemia (CLL)
14255|NCT02966756|Lymphoproliferative Disorders
14256|NCT02966756|venetoclax
14257|NCT02966730|follicular lymphoma
14258|NCT02966730|Ibrutinib
14259|NCT02966730|FLIPP
14260|NCT02966730|16-396
14261|NCT02966717|Rituximab
14262|NCT02966717|Mesenchymal stem cells
14263|NCT02966717|primary nephrotic syndrome
14264|NCT02966717|chronic kidney disease
14265|NCT02966678|Glaucoma, Dychromatopsia
14266|NCT02966652|Male
14267|NCT02966652|Hypogonadism
14268|NCT02966652|Primary
14269|NCT02966652|Secondary
14270|NCT02966652|Androgen deficiency
14271|NCT02966626|Pragmatic, Sodium-Glucose Transporter 2 inhibitor, Malaysia
14272|NCT02966574|Whole body MRI
14273|NCT02966574|Breastcancer
14274|NCT02966561|Pulmonary Rehabilitation
14275|NCT02966561|Physical Activity
14276|NCT02966561|Behaviour Change
14277|NCT02966561|Pedometer
14278|NCT02966522|Thalidoide
14279|NCT02966483|Rectal cancer
14280|NCT02966483|Laparoscopic surgery
14281|NCT02966483|Total mesorectal excision
14282|NCT02966483|Transanal
14283|NCT02966483|Multicentre randomised clinical trial
14284|NCT02966470|surgical outcomes
14285|NCT02966457|hematological infection, decolonization
14286|NCT02966418|Cerebrovascular Disease
14287|NCT02966418|Mild Hypoxia preconditioning
14288|NCT02966418|Ischemia, Brain
14289|NCT02966418|Brain Injury, Acute
14290|NCT02966392|Cuff pressure
14291|NCT02966392|Ventilator associated pneumonia
14292|NCT02966392|Respiratory tract infections
14293|NCT02966379|Electroacoustic stimulation
14294|NCT02966353|Ruxolitinib
14295|NCT02966353|anemia
14296|NCT02966353|Primary Myelofibrosis (PMF)
14297|NCT02966353|Post-Polycythemia Vera-Myelofibrosis (PPV-MF)
14298|NCT02966353|Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
14299|NCT02966340|Alcoholism
14300|NCT02966340|Prazosin
14301|NCT02966340|Startle Potentiation
14302|NCT02966340|Norepinephrine
14303|NCT02966340|Anxiety
14304|NCT02966340|Fear
14305|NCT02966340|Stress
14306|NCT02966314|Angioedema
14307|NCT02966314|Idiopathic Angioedema
14308|NCT02966314|IAE
14309|NCT02966301|c GvHD
14310|NCT02966301|Arsenic Trioxyde
14311|NCT02966301|Hematology
14312|NCT02966275|glucagon
14313|NCT02966275|continuous glucose monitorering (CGM)
14314|NCT02966275|artificial pancreas
14315|NCT02966275|hypoglycemia
14316|NCT02966275|post-bariatric hypoglycemia
14317|NCT02966275|bionic pancreas
14318|NCT02966275|bariatric surgery
14319|NCT02966249|dexmetomidine, intrathecally, intavenously,anesthesia
14320|NCT02966236|percutaneous nephrolithotomy
14321|NCT02966171|Advanced Solid Malignancies
14322|NCT02966158|Aerobic Interval Training
14323|NCT02966158|Fitness
14324|NCT02966158|Endothelial Function
14325|NCT02966158|Cognition
14326|NCT02966145|CBD
14327|NCT02966145|CBS
14328|NCT02966145|CBGD
14329|NCT02966145|PSP
14330|NCT02966145|nfvPPA
14331|NCT02966145|oPSP
14332|NCT02966145|vPSP
14333|NCT02966145|o/vPSP
14334|NCT02966145|Corticobasal Degeneration
14335|NCT02966145|Corticobasal Syndrome
14336|NCT02966145|Cortocal-basal Ganglionic Degeneration
14337|NCT02966145|Progressive Supranuclear Palsy
14338|NCT02966145|Nonfluent Variant Primary Progressive Aphasia
14339|NCT02966145|Oligosymptomatic Progressive Supranuclear Palsy
14340|NCT02966145|Variant Progressive Supranuclear Palsy
14341|NCT02966145|Biomarker
14342|NCT02966145|Neuroimaging
14343|NCT02966145|MRI
14344|NCT02966145|PET
14345|NCT02966145|Tau
14346|NCT02966145|Oculomotor
14347|NCT02966145|Retinal Imaging
14348|NCT02966132|Asian American
14349|NCT02966132|Immigrant Health
14350|NCT02966132|Digital Health Intervention
14351|NCT02966132|Federally Qualified Health Centers
14352|NCT02966119|stroke
14353|NCT02966119|intracranial hemorrhage
14354|NCT02966119|intracerebral hemorrhage
14355|NCT02966119|antithrombotic drugs
14356|NCT02966119|brain microbleeds
14357|NCT02966093|Differentiated thyroid cancer
14358|NCT02966093|Chinese participants
14359|NCT02966093|Phase 3
14360|NCT02966093|Lenvatinib
14361|NCT02966093|E7080
14362|NCT02966080|extracorporeal membrane oxygenation
14363|NCT02966080|intravenous heparin
14364|NCT02966067|Microneedles
14365|NCT02966067|Dental Anaesthesia
14366|NCT02966041|Postoperative Nausea and Vomiting
14367|NCT02966041|PONV
14368|NCT02966041|CSICU
14369|NCT02966041|post-cardiac surgery
14370|NCT02966041|cardiac intensive care unit
14371|NCT02966028|CAC
14372|NCT02966028|calcium
14373|NCT02966028|ESRD
14374|NCT02966028|calcification
14375|NCT02966028|cardiovascular
14376|NCT02966028|heart
14377|NCT02966028|kidney
14378|NCT02966028|hemodialysis
14379|NCT02966028|Agatston
14380|NCT02965989|nursery care
14381|NCT02965989|nursery infection
14382|NCT02965989|online learning
14383|NCT02965950|breast cancer
14384|NCT02965950|TP53
14385|NCT02965950|cyclophosphamide
14386|NCT02965937|Attentively embracing story
14387|NCT02965937|story-centred care
14388|NCT02965937|heart rate variability
14389|NCT02965937|cognitive function
14390|NCT02965911|UDCA, Fenofibrate
14391|NCT02965898|chronic pancreatitis
14392|NCT02965898|vitamin d
14393|NCT02965898|pancreatitis
14394|NCT02965898|Pancreatic stellate cell
14395|NCT02965898|rct
14396|NCT02965885|Phase I
14397|NCT02965885|Solid Tumors
14398|NCT02965885|Pharmacokinetics
14399|NCT02965885|Pharmacodynamics
14400|NCT02965885|MTD
14401|NCT02965885|TAS116
14402|NCT02965885|HSP90 Inhibitor
14403|NCT02965885|Neoplasms
14404|NCT02965885|HER2 positive MBC
14405|NCT02965885|NSCLC EGFR T790M Positive
14406|NCT02965885|NSCLC EGFR T790M Negative
14407|NCT02965872|Postural Balance
14408|NCT02965859|Chronic Hepatitis B
14409|NCT02965846|EDE
14410|NCT02965846|evaporative dry eye
14411|NCT02965833|Contact lens induced dryness
14412|NCT02965820|Contact lens induced dryness
14413|NCT02965807|Bronchial Thermoplasty
14414|NCT02965807|moderate asthma
14415|NCT02965807|China
14416|NCT02965794|surgery
14417|NCT02965794|bowel
14418|NCT02965794|rectum
14419|NCT02965794|cancer
14420|NCT02965794|nutrition
14421|NCT02965755|Metastatic Breast Cancer
14422|NCT02965755|Breast Cancer
14423|NCT02965755|Molecular profiling
14424|NCT02965755|Personalized medicine
14425|NCT02965742|DXA
14426|NCT02965742|DMS
14427|NCT02965742|STRATOS
14428|NCT02965729|behavior goals
14429|NCT02965729|self-monitoring
14430|NCT02965729|pedometer
14431|NCT02965729|physical activity
14432|NCT02965690|Total Knee Arthroplasty (TKA)
14433|NCT02965690|TKR
14434|NCT02965690|Knee kinematics
14435|NCT02965690|Dynamic RSA
14436|NCT02965690|Fluoroscopy
14437|NCT02965690|Roentgen Fluoroscopic Stereophotogrammetric Analysis
14438|NCT02965677|drug eluting balloon
14439|NCT02965677|Femoral Popliteal Artery
14440|NCT02965651|embodied conversational agent
14441|NCT02965651|virtual patient agent
14442|NCT02965651|meditation
14443|NCT02965651|mindfulness based stress reduction
14444|NCT02965651|nutrition
14445|NCT02965638|LHH
14446|NCT02965612|Grass Allergy
14447|NCT02965612|Allergic Rhinitis
14448|NCT02965612|Allergic Asthma
14449|NCT02965612|Paediatric
14450|NCT02965599|pharmacodynamics
14451|NCT02965599|tolerability
14452|NCT02965599|GSK3117391
14453|NCT02965599|safety
14454|NCT02965599|efficacy
14455|NCT02965599|rheumatoid arthritis
14456|NCT02965599|pharmacokinetics
14457|NCT02965547|Ischemic Preconditioning
14458|NCT02965547|dynamic cerebral autoregulation
14459|NCT02965534|night vision
14460|NCT02965534|mesopic visual acuity
14461|NCT02965534|aberrometry
14462|NCT02965534|mesopic spectacle correction
14463|NCT02965534|night myopia
14464|NCT02965508|Home-bound
14465|NCT02965508|home-based primary care
14466|NCT02965495|Osteoarthritis
14467|NCT02965482|methacholine, airway hyperresponsiveness
14468|NCT02965417|Resistance to anti-EGFR monoclonal antibodies
14469|NCT02965417|Mutation of ECD-EGFR
14470|NCT02965404|live attenuated varicella vaccine
14471|NCT02965404|safety
14472|NCT02965404|adult
14473|NCT02965404|adolescent
14474|NCT02965404|child
14475|NCT02965391|Circulating Tumor DNA
14476|NCT02965391|Half time
14477|NCT02965391|Lung cancer
14478|NCT02965391|Surgery
14479|NCT02965391|Surveillance
14480|NCT02965339|Vasoplegia
14481|NCT02965339|endothelial dysfunction
14482|NCT02965339|extracorporeal circulation
14483|NCT02965339|cardiac surgery
14484|NCT02965300|Pulmonary lesion
14485|NCT02965300|Volatile Organic Compositions(VOCs)
14486|NCT02965248|Locally advanced colorectal cancer
14487|NCT02965248|Hyperthermic intraperitoneal chemotherapy
14488|NCT02965222|blastocyst
14489|NCT02965222|pregnancy rate
14490|NCT02965209|endoscopy
14491|NCT02965209|small bowel endoscopy
14492|NCT02965209|motorized spiral endoscopy
14493|NCT02965209|spiral endoscopy
14494|NCT02965144|long-term survivors, high-grade glioma
14495|NCT02965079|extracorporeal CO2 removal
14496|NCT02965079|registry
14497|NCT02965079|COPD and ARDS
14498|NCT02965079|CEDIT on behalf of APHP
14499|NCT02965040|ASP1517
14500|NCT02965040|Normal renal function
14501|NCT02965040|Dialysis
14502|NCT02965040|Roxadustat
14503|NCT02965040|Pharmacokinetics
14504|NCT02965040|Impaired renal function
14505|NCT02965027|Chronic Headache
14506|NCT02965027|Post-Traumatic Stress Disorder
14507|NCT02965027|Iraq/Afghanistan Veteran
14508|NCT02965014|Human Immunodeficiency Virus (HIV)
14509|NCT02965014|Sexually transmitted infections (STI)
14510|NCT02965014|mHealth
14511|NCT02965014|Substance abuse
14512|NCT02965014|Violence
14513|NCT02965014|Victimization
14514|NCT02965014|Linkage to care
14515|NCT02965014|Sexual Risk
14516|NCT02965001|Molecular Imaging
14517|NCT02965001|uPAR-PET/CT
14518|NCT02965001|Head and neck cancer
14519|NCT02965001|curative intended radiotherapy
14520|NCT02964949|Nonvalvular Atrial Fibrillation
14521|NCT02964949|High Creatinine Clearance
14522|NCT02964949|Developmental Phase III
14523|NCT02964949|Anticoagulant Naïve
14524|NCT02964936|Anemia
14525|NCT02964936|Non-dialysis chronic kidney disease
14526|NCT02964936|ASP1517
14527|NCT02964923|Genetic polymorphism
14528|NCT02964923|Metabolic side effects of drugs
14529|NCT02964923|schizophrenia
14530|NCT02964923|Second-Generation Antipsychotic
14531|NCT02964923|Cannabinoid Receptor Type 1
14532|NCT02964910|Hepatitis E
14533|NCT02964897|justice involvement
14534|NCT02964897|Homeless
14535|NCT02964897|Vulnerable Populations
14536|NCT02964897|Linkage to care
14537|NCT02964897|Veterans
14538|NCT02964871|Long-term care facility
14539|NCT02964871|Elderly
14540|NCT02964858|Radiation Dose
14541|NCT02964858|Optimization
14542|NCT02964858|NHL
14543|NCT02964858|DLBCL
14544|NCT02964858|R-CHOP
14545|NCT02964832|Basic Cardiac Life Support, Education, Feedback
14546|NCT02964793|Fetal Growth Restriction
14547|NCT02964793|Customised Fetal Weight Reference
14548|NCT02964793|Estimated fetal Weight
14549|NCT02964793|Symphysis Fundal Height
14550|NCT02964767|HIV
14551|NCT02964767|HIV-Tb co infection
14552|NCT02964767|CD4 Cell
14553|NCT02964741|Episodic Migraine
14554|NCT02964741|Headache
14555|NCT02964741|Opioid
14556|NCT02964689|Advanced non-small cell lung cancer
14557|NCT02964689|KRAS mutations
14558|NCT02964689|Binimetinib
14559|NCT02964689|Pemetrexed
14560|NCT02964689|Cisplatin
14561|NCT02964689|Phase IB trial
14562|NCT02964624|Osteoarthritis
14563|NCT02964624|biomarkers
14564|NCT02964624|HMGB1
14565|NCT02964624|knee
14566|NCT02964598|Adolescent
14567|NCT02964598|Population-based
14568|NCT02964598|Social jetlag
14569|NCT02964598|Intervention
14570|NCT02964598|Bright light
14571|NCT02964598|Motivation
14572|NCT02964598|Circadian regulation
14573|NCT02964598|Behavioral change
14574|NCT02964585|Type 2 Diabetes Mellitus
14575|NCT02964585|Chronic Kidney Disease
14576|NCT02964585|Endothelial Cells
14577|NCT02964585|Cellular Biomarker
14578|NCT02964585|Endothelial Dysfunction
14579|NCT02964585|CD34+
14580|NCT02964585|Impaired renal function
14581|NCT02964546|direct oral anticoagulants
14582|NCT02964546|atrial fibrillation
14583|NCT02964546|renal function
14584|NCT02964546|ckd-epi
14585|NCT02964546|plasmatic concentration
14586|NCT02964520|trait anxiety
14587|NCT02964520|A/T neurofeedback
14588|NCT02964520|EEG biofeedback
14589|NCT02964520|randomized
14590|NCT02964507|GSK525762
14591|NCT02964507|ER+ breast cancer
14592|NCT02964507|mTPI
14593|NCT02964481|malignant
14594|NCT02964481|genetics
14595|NCT02964481|RYR1
14596|NCT02964481|CAC-NA1S
14597|NCT02964481|hyperthermia
14598|NCT02964468|Rectal Cancer
14599|NCT02964468|IMRT
14600|NCT02964468|Radiation Dose Escalation
14601|NCT02964455|Esophageal squamous cell carcinoma
14602|NCT02964455|Chemoradiotherapy
14603|NCT02964455|Docetaxel
14604|NCT02964455|Nedaplatin
14605|NCT02964455|Twice weekly
14606|NCT02964416|supratentorial craniotomy
14607|NCT02964416|extubation response
14608|NCT02964416|emergence
14609|NCT02964416|tramadol
14610|NCT02964403|COX-2
14611|NCT02964403|ERCP
14612|NCT02964403|Pancreatitis
14613|NCT02964390|CTEPH
14614|NCT02964390|balloon pulmonary angioplasty
14615|NCT02964377|Pediatric
14616|NCT02964377|muscle disease
14617|NCT02964377|Duchenne muscular dystrophy
14618|NCT02964377|cardiomyopathy
14619|NCT02964364|TAKAYASU ARTERITIS
14620|NCT02964351|MicroRNA
14621|NCT02964351|Prostate Carcinoma
14622|NCT02964351|PET-MR
14623|NCT02964325|hypoproliferative thrombocytopenia
14624|NCT02964325|hematologic malignancies
14625|NCT02964325|thrombocytopenia
14626|NCT02964325|platelet therapy
14627|NCT02964325|apheresis
14628|NCT02964325|pathogen reduction therapy
14629|NCT02964299|Gastrointestinal endoscopy
14630|NCT02964299|Moderate sedation
14631|NCT02964299|Airway management
14632|NCT02964286|Cancer
14633|NCT02964286|Acupressure
14634|NCT02964286|Hematopoietic Cell Growth Factors
14635|NCT02964273|Autosomal Dominant Polycystic Kidney Disease
14636|NCT02964273|ADPKD
14637|NCT02964273|Tolvaptan
14638|NCT02964273|Renal cysts
14639|NCT02964273|Chronic Kidney Disease
14640|NCT02964273|Genetic Kidney Disease
14641|NCT02964260|Hepatocellular Carcinoma; Embolization; Ablation; simultaneously; sequentially
14642|NCT02964234|Mammography Screening
14643|NCT02964234|Latinas
14644|NCT02964234|Breast cancer disparities
14645|NCT02964208|Atrial Fibrillation
14646|NCT02964208|Thromboembolism
14647|NCT02964208|Stroke
14648|NCT02964208|ACP
14649|NCT02964208|Left Atrial Appendage
14650|NCT02964208|Cardiac Plug
14651|NCT02964182|Mental and Behavioral Disorders Due to Use of Tobacco
14652|NCT02964182|Carbon monoxide Testing
14653|NCT02964182|CO
14654|NCT02964182|Questionnaires
14655|NCT02964182|Surveys
14656|NCT02964182|Smartphone assessments
14657|NCT02964182|Electronic assessments
14658|NCT02964182|Usual brand cigarettes
14659|NCT02964182|UB
14660|NCT02964182|Very Low Nicotine Content Cigarettes
14661|NCT02964182|VLNCC
14662|NCT02964182|E-cigarettes
14663|NCT02964182|ECIG
14664|NCT02964156|RA
14665|NCT02964156|Insole
14666|NCT02964156|Forefoot
14667|NCT02964156|Walking Ability
14668|NCT02964156|Pain
14669|NCT02964117|Chronic Obstructive Pulmonary Disease
14670|NCT02964091|Hepatitis C Virus
14671|NCT02964091|sofosbuvir/ledipasvir
14672|NCT02964091|Efficacy
14673|NCT02964078|Kidney Disease
14674|NCT02964078|Metastatic
14675|NCT02964078|Antibody
14676|NCT02964065|Influenza Vaccines
14677|NCT02964065|LAIV
14678|NCT02964039|stroke
14679|NCT02964039|rehabilitation
14680|NCT02964039|gait
14681|NCT02964026|pulmonary artery catheter
14682|NCT02964026|Swan-Ganz catheter
14683|NCT02964000|Pain
14684|NCT02964000|Low level laser therapy
14685|NCT02964000|Sham
14686|NCT02964000|Chronic Pain
14687|NCT02964000|Opioid
14688|NCT02964000|Physical activity
14689|NCT02964000|Quality of sleep
14690|NCT02963974|cochlear implant
14691|NCT02963961|Delirium
14692|NCT02963961|Cognition
14693|NCT02963961|Prehabilitation
14694|NCT02963961|Neuroplasticity
14695|NCT02963909|Adjuvant
14696|NCT02963909|Alum
14697|NCT02963909|Inactivated
14698|NCT02963909|Purified
14699|NCT02963909|Vaccine
14700|NCT02963909|Virus
14701|NCT02963909|Zika
14702|NCT02963896|vestibular rehabilitation
14703|NCT02963883|ScVO2
14704|NCT02963883|Post operative red cell transfusion
14705|NCT02963870|Cognitive behavioral
14706|NCT02963870|security plan
14707|NCT02963870|suicidal Recidivism in adolescents
14708|NCT02963857|breast surgery
14709|NCT02963857|acute pain
14710|NCT02963857|regional anesthesia
14711|NCT02963831|Oncos-102
14712|NCT02963831|Durvalumab
14713|NCT02963831|Peritoneal
14714|NCT02963831|Cyclophosphamide
14715|NCT02963818|Brief intervention
14716|NCT02963818|Harm reduction
14717|NCT02963818|Young adult
14718|NCT02963818|College Student
14719|NCT02963805|Children
14720|NCT02963805|Physical activity
14721|NCT02963805|Physical competence
14722|NCT02963805|Obesity
14723|NCT02963805|School
14724|NCT02963805|Health
14725|NCT02963805|Fundamental movement skills
14726|NCT02963792|Professionalism
14727|NCT02963792|Burnout prevention
14728|NCT02963792|Resiliency
14729|NCT02963792|Student education
14730|NCT02963766|Pediatrics
14731|NCT02963753|Hyperemesis gravidarum
14732|NCT02963753|gestational diabetes mellitus
14733|NCT02963753|oral glucose tolerance test
14734|NCT02963740|breast cancer survivor
14735|NCT02963740|weight loss program
14736|NCT02963727|osteoarthrosis
14737|NCT02963727|Knee
14738|NCT02963727|Wharton Jelly
14739|NCT02963714|Hepatitis B, Vaccine
14740|NCT02963714|Randomized Controlled Trial
14741|NCT02963714|Hemodialysis
14742|NCT02963714|Immunogenicity
14743|NCT02963662|obesity
14744|NCT02963662|bariatric surgery
14745|NCT02963662|gut hormones
14746|NCT02963662|inflammatory adipokine
14747|NCT02963649|Drug-eluting angioplasty balloon, Drug coated angioplasty balloon, Experimental, percutaneous transluminal angioplasty (PTA)
14748|NCT02963636|family medicine group
14749|NCT02963636|pharmacists
14750|NCT02963636|primary health care
14751|NCT02963636|pharmaceutical services
14752|NCT02963636|interprofessional relations
14753|NCT02963623|thromboelastometry
14754|NCT02963623|total hip replacement
14755|NCT02963623|total knee replacement
14756|NCT02963584|chronic total occlusion
14757|NCT02963584|decision aid
14758|NCT02963506|AS
14759|NCT02963506|Ankylosing Spondylitis
14760|NCT02963506|Bimekizumab
14761|NCT02963493|relapsed refractory multiple myeloma
14762|NCT02963467|multiple inert gas elimination technique
14763|NCT02963467|smoking
14764|NCT02963467|pulmonary disorder
14765|NCT02963441|Diabetic Retinopathy
14766|NCT02963441|Macular Edema
14767|NCT02963415|Subjective memory complaint
14768|NCT02963363|Breast cancer
14769|NCT02963363|HER2+
14770|NCT02963363|Adapted physical activity
14771|NCT02963363|Neoadjuvant chemotherapy
14772|NCT02963337|remifentanil
14773|NCT02963337|combined spinal-epidural analgesia
14774|NCT02963337|multiparous
14775|NCT02963272|Heart failure
14776|NCT02963272|ST2
14777|NCT02963272|fibrosis
14778|NCT02963246|mindfulness
14779|NCT02963246|quality of life
14780|NCT02963246|Bowel Disease
14781|NCT02963207|colorectal polyp
14782|NCT02963207|colorectal lesion
14783|NCT02963207|Modified Sano's Classification
14784|NCT02963207|NICE classification
14785|NCT02963207|NBI
14786|NCT02963207|PIVI guidelines
14787|NCT02963207|SSA/P
14788|NCT02963207|sessile serrated adenoma
14789|NCT02963207|sessile serrated polyp
14790|NCT02963194|self-processing
14791|NCT02963194|endowment effect
14792|NCT02963194|neuroimage
14793|NCT02963181|Melatonin
14794|NCT02963181|Yohimbine
14795|NCT02963181|Anti-hypertensive agents
14796|NCT02963155|prostate, metastatic
14797|NCT02963142|Intensive care
14798|NCT02963142|Extra-corporeal membrane oxygenation (ECMO)
14799|NCT02963142|Severe Respiratory Infections
14800|NCT02963142|Sequencing
14801|NCT02963142|Metagenome
14802|NCT02963142|Diagnosis
14803|NCT02963129|Hereditary Hemorrhagic Telangiectasia
14804|NCT02963129|Epistaxis
14805|NCT02963116|Pharmacokinetics (PK)
14806|NCT02963116|Bioavailability (BA)
14807|NCT02963116|Safety
14808|NCT02963116|Tolerability
14809|NCT02963116|Healthy Volunteers
14810|NCT02963103|Tacrolimus
14811|NCT02963103|Kidney transplantation
14812|NCT02963090|SCLC
14813|NCT02963090|small cell lung cancer
14814|NCT02963090|lung cancer
14815|NCT02963090|topotecan
14816|NCT02963090|pembrolizumab
14817|NCT02963064|Immunodeficiency
14818|NCT02963064|Pediatric
14819|NCT02963064|SCID
14820|NCT02963064|Bone Marrow Transplantation
14821|NCT02963064|GVHD
14822|NCT02963064|Stem Cells
14823|NCT02963064|Chimerism
14824|NCT02963064|Transplant
14825|NCT02963064|BMT
14826|NCT02963051|metastatic castrate-resistant prostate cancer (mCRPC)
14827|NCT02963051|neuroendocrine prostate cancer (NEPC)
14828|NCT02963051|adenocarcinoma castrate-resistant prostate cancer (CRPC)
14829|NCT02963051|Copper
14830|NCT02963051|Disulfiram
14831|NCT02962999|Ketamine
14832|NCT02962999|One lung ventilation
14833|NCT02962999|Chronic obstructive pulmonary disease
14834|NCT02962986|vasopressor
14835|NCT02962986|blood pressure
14836|NCT02962986|cesarean section
14837|NCT02962986|spinal anesthesia
14838|NCT02962973|Advanced heart failure
14839|NCT02962973|Total artificial heart
14840|NCT02962947|Melanoma
14841|NCT02962947|Propanolol
14842|NCT02962947|Betablockers
14843|NCT02962908|broad
14844|NCT02962908|universal
14845|NCT02962908|vaccine
14846|NCT02962908|influenza
14847|NCT02962908|peptide
14848|NCT02962908|Tcell
14849|NCT02962908|UNISEC
14850|NCT02962843|Behavior Problem
14851|NCT02962843|Social Competence
14852|NCT02962843|Student
14853|NCT02962843|Children
14854|NCT02962830|fetal pain
14855|NCT02962830|fetal analgesia
14856|NCT02962804|kidney
14857|NCT02962804|renal cell
14858|NCT02962804|cancer
14859|NCT02962804|metastatic
14860|NCT02962804|recurrent
14861|NCT02962791|symptomatic heart failure
14862|NCT02962778|treatment-resistant
14863|NCT02962739|healthy volunteers
14864|NCT02962726|Anorexia
14865|NCT02962726|Depression
14866|NCT02962726|Microbiome
14867|NCT02962713|Atraumatic Restorative Treatment
14868|NCT02962713|glass ionomer cement
14869|NCT02962713|primary teeth
14870|NCT02962713|dental caries.
14871|NCT02962700|continuous haemofiltration
14872|NCT02962700|intermittent haemodialysis
14873|NCT02962687|Veterans
14874|NCT02962687|Cognitive impairments
14875|NCT02962687|Nursing care management
14876|NCT02962687|Videoconferencing
14877|NCT02962674|BPH
14878|NCT02962661|Other forms of heart disease
14879|NCT02962661|Left ventricular dysfunction
14880|NCT02962661|LV
14881|NCT02962661|Heart failure secondary to chemotherapy with anthracyclines
14882|NCT02962661|Human mesenchymal stem cells
14883|NCT02962661|hMSCs
14884|NCT02962661|Mesenchymal Stromal Cells
14885|NCT02962661|MSCs
14886|NCT02962661|Intravenous infusion
14887|NCT02962661|Transendocardial injection
14888|NCT02962661|Standard of care drugs for heart failure
14889|NCT02962648|IDA
14890|NCT02962622|Neurocognition
14891|NCT02962622|Exercise
14892|NCT02962622|Metabolism
14893|NCT02962622|Hispanic women
14894|NCT02962609|Feeding
14895|NCT02962609|preterm infant
14896|NCT02962609|physiological characteristics
14897|NCT02962609|position
14898|NCT02962609|ESL
14899|NCT02962609|ESU
14900|NCT02962557|ventilatory depression
14901|NCT02962544|Femtosecond
14902|NCT02962544|Small incision lenticule extraction
14903|NCT02962544|Lenticule extraction
14904|NCT02962544|LASIK
14905|NCT02962544|Myopia
14906|NCT02962518|Pressure Device
14907|NCT02962518|Clip
14908|NCT02962518|Triamcinolone
14909|NCT02962518|Fillet Technique
14910|NCT02962492|Dapagliflozin
14911|NCT02962492|Ketogenesis
14912|NCT02962492|Type 1 Diabetes
14913|NCT02962492|DKA
14914|NCT02962492|ketones
14915|NCT02962492|exenatide/Bydureon
14916|NCT02962414|Everolimus
14917|NCT02962414|Tuberous sclerosis complex
14918|NCT02962414|TSC
14919|NCT02962414|Refractory seizure
14920|NCT02962414|Roll over study
14921|NCT02962414|Long term safety
14922|NCT02962414|PASS
14923|NCT02962388|efficacy
14924|NCT02962388|safety
14925|NCT02962375|orange pomace fiber
14926|NCT02962375|glycemic response
14927|NCT02962297|Vitamin E, Non Diabetic
14928|NCT02962271|Musculoskeletal Ultrasound
14929|NCT02962271|Psoriatic Arthritis
14930|NCT02962271|Enthesopathy
14931|NCT02962245|Ulcerative Colitis
14932|NCT02962245|Berberine
14933|NCT02962232|drug eluting balloon
14934|NCT02962232|inferior genicular artery
14935|NCT02962219|oesophagectomy
14936|NCT02962193|ADL
14937|NCT02962193|Bariatric surgery
14938|NCT02962193|Daily participation
14939|NCT02962180|derma-rolling system, vitiligo
14940|NCT02962167|measles virus
14941|NCT02962167|recurrent medulloblastoma
14942|NCT02962167|recurrent ATRT
14943|NCT02962154|Invasive Coronary Angiography
14944|NCT02962154|Myocardial Infarction
14945|NCT02962154|Major Depressive Disorder
14946|NCT02962154|Bipolar I Disorder
14947|NCT02962154|Bipolar II Disorder
14948|NCT02962154|Mental Stress
14949|NCT02962141|drug eluting balloon, Arteriovenous Fistulae
14950|NCT02962089|Protein-energy wasting
14951|NCT02962089|Hemodialysis patients
14952|NCT02962089|Microbiota
14953|NCT02962089|Branched chain amino acids
14954|NCT02962089|Undernutrition
14955|NCT02962089|Malnutrition
14956|NCT02962089|Renal failure
14957|NCT02962089|Dialysis
14958|NCT02962089|Protein
14959|NCT02962089|Appetite
14960|NCT02962089|Body composition
14961|NCT02962089|Energy expenditure
14962|NCT02962063|Durvalumab
14963|NCT02962063|Anti-PD-L1 Antibody
14964|NCT02962063|16-1405
14965|NCT02962011|Cesarean, incision, suture,
14966|NCT02961998|hepatocellular carcinoma
14967|NCT02961998|sorafenib
14968|NCT02961998|celecoxib
14969|NCT02961972|vegetarianism
14970|NCT02961972|Hyperhomocysteinemia
14971|NCT02961972|vegan vegetarian
14972|NCT02961933|hypoxemia
14973|NCT02961933|intubation
14974|NCT02961933|apneic oxygenation
14975|NCT02961907|periconceptional habits
14976|NCT02961907|Pregnancy
14977|NCT02961907|Infertility
14978|NCT02961868|Renal Artery Obstruction
14979|NCT02961868|Carotid Artery Diseases
14980|NCT02961868|Genetic Association Studies
14981|NCT02961829|Dendritic Cell vaccination using
14982|NCT02961829|antiretroviral intensification
14983|NCT02961829|Auranofin
14984|NCT02961829|Histone Deacetylase Inhibitor
14985|NCT02961829|residual viral replication
14986|NCT02961829|HIV sanctuaries
14987|NCT02961829|HIV latency
14988|NCT02961816|Lymphoma
14989|NCT02961816|Refractory/Relapsed Lymphoma
14990|NCT02961816|Diffuse large B-cell lymphoma
14991|NCT02961816|Hodgkin's lymphoma
14992|NCT02961816|T-cell Lymphoma
14993|NCT02961816|Palifermin
14994|NCT02961816|Kepivance
14995|NCT02961816|Panobinostat
14996|NCT02961816|LBH589B
14997|NCT02961816|Gemcitabine
14998|NCT02961816|Gemcitabine Hydrochloride
14999|NCT02961816|Gemzar
15000|NCT02961816|Busulfan
15001|NCT02961816|Busulfex
15002|NCT02961816|Myleran
15003|NCT02961816|Melphalan
15004|NCT02961816|Alkeran
15005|NCT02961816|Rituximab
15006|NCT02961816|Rituxan
15007|NCT02961816|Dexamethasone
15008|NCT02961816|Decadron
15009|NCT02961816|Caphosol
15010|NCT02961816|Glutamine
15011|NCT02961816|Enterex
15012|NCT02961816|Glutapak-10
15013|NCT02961816|NutreStore
15014|NCT02961816|Resource
15015|NCT02961816|GlutaSolve
15016|NCT02961816|Sympt-X G.I.
15017|NCT02961816|Sympt-X
15018|NCT02961816|Pyridoxine
15019|NCT02961816|G-CSF
15020|NCT02961816|Filgrastim
15021|NCT02961816|Neupogen
15022|NCT02961816|Stem cell transplant
15023|NCT02961803|AMN
15024|NCT02961803|MD1003
15025|NCT02961803|Adrenomyeloneuropathy
15026|NCT02961803|ALD
15027|NCT02961803|Adrenoleukodystrophy
15028|NCT02961803|Biotin
15029|NCT02961803|2MWT
15030|NCT02961803|Two-minute walk test
15031|NCT02961803|TW25
15032|NCT02961803|Timed 25-Foot Walk
15033|NCT02961764|Critical Pathways
15034|NCT02961764|Health Facilities
15035|NCT02961764|Clinical Protocols
15036|NCT02961764|Patient Satisfaction
15037|NCT02961764|Absenteeism
15038|NCT02961764|Anti-Bacterial Agents
15039|NCT02961764|Quality of Life
15040|NCT02961764|Economics, Medical
15041|NCT02961764|Health Resources
15042|NCT02961764|Health resource utilization
15043|NCT02961764|Acute bacterial skin and skin structure infection (ABSSSI)
15044|NCT02961751|Ciprofloxacin-susceptibility
15045|NCT02961751|Gonorrheaoe
15046|NCT02961751|Neisseria
15047|NCT02960659|Metformin
15048|NCT02960659|Glucose
15049|NCT02960646|Leukemia
15050|NCT02960646|Blood And Marrow Transplantation
15051|NCT02960646|Acute lymphocytic leukemia
15052|NCT02960646|ALL
15053|NCT02960646|Acute myeloid leukemia
15054|NCT02960646|AML
15055|NCT02960646|Chronic lymphocytic leukemia
15056|NCT02960646|CLL
15057|NCT02960646|Chronic myeloid leukemia
15058|NCT02960646|CML
15059|NCT02960646|Hodgkin's disease
15060|NCT02960646|Non-Hodgkin's lymphoma
15061|NCT02960646|NHL
15062|NCT02960646|Small lymphocytic lymphoma
15063|NCT02960646|SLL
15064|NCT02960646|Myelodysplastic syndrome (MDS
15065|NCT02960646|MDS
15066|NCT02960646|Aplastic anemia
15067|NCT02960646|Modified (CD45RA depleted) peripheral blood (PB) stem cell infusion
15068|NCT02960646|T cells
15069|NCT02960646|Haploidentical transplantation
15070|NCT02960646|Rituximab
15071|NCT02960646|Rituxan
15072|NCT02960646|Melphalan
15073|NCT02960646|Alkeran
15074|NCT02960646|Fludarabine
15075|NCT02960646|Fludarabine Phosphate
15076|NCT02960646|Fludara
15077|NCT02960646|Cyclophosphamide
15078|NCT02960646|Cytoxan
15079|NCT02960646|Neosar
15080|NCT02960646|G-CSF
15081|NCT02960646|Filgrastim
15082|NCT02960646|Neupogen
15083|NCT02959593|Primary open-angle glaucoma
15084|NCT02959593|retinal capillary blood flow
15085|NCT02959593|visual stimulation
15086|NCT02961647|Hemodynamic stress test
15087|NCT02961647|Surgical intervention
15088|NCT02961634|onychomycosis
15089|NCT02961634|nail
15090|NCT02961595|Oral polio vaccine
15091|NCT02961595|Inactivated polio vaccine
15092|NCT02961595|Enterovirus
15093|NCT02961595|Type 1 diabetes
15094|NCT02961595|Autoantibody
15095|NCT02961582|Sacral neuromodulation
15096|NCT02961582|Constipation
15097|NCT02961582|Slow-transit constipation
15098|NCT02961582|Surgery
15099|NCT02961582|Colorectal surgery
15100|NCT02961582|Cost-effectiveness
15101|NCT02961582|Quality of life
15102|NCT02961556|AJG555
15103|NCT02961556|Constipation
15104|NCT02961556|Phase 3
15105|NCT02961556|Pediatric participants
15106|NCT02961491|MIBG
15107|NCT02961491|Azedra
15108|NCT02961491|Rare neuroendocrine tumors
15109|NCT02961491|Iobenguane I 131
15110|NCT02961491|Progenics
15111|NCT02961465|Sacral neuromodulation
15112|NCT02961465|Constipation
15113|NCT02961465|Slow-transit constipation
15114|NCT02961465|Surgery
15115|NCT02961465|Colorectal surgery
15116|NCT02961465|Cost-effectiveness
15117|NCT02961465|Quality of life
15118|NCT02961387|Tracheal stenosis, Hydrogen generator, Hydrogen-oxygen, Dyspnea.
15119|NCT02961361|dexmedetomidine
15120|NCT02961361|coracoid
15121|NCT02961361|brachial plexus block
15122|NCT02961348|Oral anticoagulants (NOAC)
15123|NCT02961309|THC
15124|NCT02961309|marijuana
15125|NCT02961309|tobacco cigarette
15126|NCT02961309|smoking
15127|NCT02961296|Helicobacter Pylori
15128|NCT02961283|BRAF Kinases
15129|NCT02961283|PIK3CA protein, human
15130|NCT02961244|Surgical Site Infection
15131|NCT02961244|normothermia
15132|NCT02961244|hypothermia
15133|NCT02961244|prewarming
15134|NCT02961231|Pneumococcal conjugate vaccine
15135|NCT02961231|Herd immunity
15136|NCT02961231|Reduced dosing schedule
15137|NCT02961218|Sickle cell disease
15138|NCT02961218|hemoglobinopathy
15139|NCT02961218|pediatric
15140|NCT02961166|IVIG
15141|NCT02961166|ARDS
15142|NCT02961166|ECMO
15143|NCT02961140|Outcome
15144|NCT02961127|tissue factor pathway inhibitor
15145|NCT02961114|Prostatitis, Chronic
15146|NCT02961114|Nocturia
15147|NCT02961114|BPH With Urinary Obstruction
15148|NCT02961101|relapsed or refractory
15149|NCT02961101|malignancies
15150|NCT02961101|decitabine
15151|NCT02961101|anti-PD-1 antibody
15152|NCT02961088|Systematic review and meta-analysis
15153|NCT02961088|Evidence-based medicine (EBM)
15154|NCT02961088|Evidence-based nutrition (EBN)
15155|NCT02961088|Clinical practice guidelines
15156|NCT02961088|Glycemic index
15157|NCT02961088|Pasta
15158|NCT02961088|Glycemic load
15159|NCT02961088|Body weight
15160|NCT02961088|Cardiovascular risk factors
15161|NCT02961088|Cardiovascular disease
15162|NCT02961062|ocular pain
15163|NCT02961062|photorefractive keratectomy (PRK)
15164|NCT02961062|SAF312
15165|NCT02961062|corneal epithelial defect
15166|NCT02961036|Surveys and Questionnaires
15167|NCT02961010|school based prevention, child sexual and domestic abuse
15168|NCT02960997|epidermolysis bullosa simplex
15169|NCT02960958|Rheumatoid arthritis
15170|NCT02960958|Metabolomics
15171|NCT02960958|urine
15172|NCT02960932|Hemiplegic
15173|NCT02960932|Child
15174|NCT02960932|Elastography
15175|NCT02960932|paralysis
15176|NCT02960893|Ataxia
15177|NCT02960893|SCA
15178|NCT02960893|Spinocerebellar Ataxia
15179|NCT02960880|Rivaroxaban, Phenprocoumon, retrospective cohort study, Non-Valvular Atrial fibrillation, NVAF
15180|NCT02960867|paediatric
15181|NCT02960867|kidney
15182|NCT02960815|influenza vaccine
15183|NCT02960815|Transplantation
15184|NCT02960815|imiquimod
15185|NCT02960815|HIV infection
15186|NCT02960815|immunogenicity
15187|NCT02960802|kidney transplant
15188|NCT02960802|renal blood flow
15189|NCT02960789|Dehydration
15190|NCT02960789|Children
15191|NCT02960789|Measurement
15192|NCT02960776|Body Weight
15193|NCT02960776|Habitual sleep
15194|NCT02960763|Comparative Effectiveness Research
15195|NCT02960763|Pragmatic Clinical Trials
15196|NCT02960763|Patient-Centered Outcomes Research
15197|NCT02960750|workplace
15198|NCT02960750|sedentary behavior
15199|NCT02960750|physical activity
15200|NCT02960750|physical risk factors
15201|NCT02960750|mental well-being
15202|NCT02960750|presenteeism
15203|NCT02960750|work productivity
15204|NCT02960750|activity-related energy expenditures
15205|NCT02960737|Dysphagia
15206|NCT02960737|Stroke
15207|NCT02960737|Intervention
15208|NCT02960737|Oral screen
15209|NCT02960737|Incidence
15210|NCT02960724|Uroplasminogen Plasminogen Activator Receptor
15211|NCT02960724|Oropharyngeal cancer
15212|NCT02960724|oral cancer
15213|NCT02960724|Positron Emission Tomography
15214|NCT02960698|cognitive impulsivity
15215|NCT02960698|IRM
15216|NCT02960698|Tourette Syndrome
15217|NCT02960672|KL-6
15218|NCT02960672|disease progression
15219|NCT02960672|predict
15220|NCT02960672|biomarkers
15221|NCT02960672|MMP-7
15222|NCT02960620|Humanitarian Device Exemption
15223|NCT02960620|Liver Disease
15224|NCT02960620|HDE #980006
15225|NCT02960594|Immunotherapy
15226|NCT02960594|Human Telomerase Reverse Transcriptase (hTERT)
15227|NCT02960594|Breast Neoplasms
15228|NCT02960594|Lung Neoplasms
15229|NCT02960594|Pancreatic Neoplasms
15230|NCT02960594|High Risk of Relapse
15231|NCT02960594|Post Definitive Surgery
15232|NCT02960594|Post Adjuvant Therapy
15233|NCT02960594|No Evidence of Disease
15234|NCT02960568|primaquine
15235|NCT02960568|metabolism
15236|NCT02960568|malaria
15237|NCT02960568|hypnozoite
15238|NCT02960568|vivax
15239|NCT02960568|CYP2D6
15240|NCT02960555|Myeloma
15241|NCT02960555|Smoldering Multiple Myeloma
15242|NCT02960555|SMM
15243|NCT02960555|Intermediate or high risk
15244|NCT02960555|SAR650984
15245|NCT02960555|Diphenhydramine
15246|NCT02960555|Benadryl
15247|NCT02960555|Ranitidine
15248|NCT02960555|Ranitidine Hydrochloride
15249|NCT02960555|Zantac
15250|NCT02960555|Methylprednisolone
15251|NCT02960555|Depo-Medrol
15252|NCT02960555|Medrol
15253|NCT02960555|Solu-Medrol
15254|NCT02960542|lifestyle intervention
15255|NCT02960542|weight-loss
15256|NCT02960503|sickle cell disease
15257|NCT02960503|pulmonary complications
15258|NCT02960503|reduced FEV1
15259|NCT02960503|azithromycin
15260|NCT02960503|lung function
15261|NCT02960490|E6011
15262|NCT02960490|rheumatoid arthritis
15263|NCT02960477|Shoulder pain
15264|NCT02960477|Shoulder surgery
15265|NCT02960477|Pain neuroscience education
15266|NCT02960477|Chronic pain
15267|NCT02960464|Parkinson Disease
15268|NCT02960464|Depression
15269|NCT02960464|Transcranial Direct Current Stimulation
15270|NCT02960464|Neuromodulation
15271|NCT02960451|prodrome
15272|NCT02960451|cognitive behavioral therapy
15273|NCT02960451|family focused therapy
15274|NCT02960438|E6011
15275|NCT02960438|rheumatoid arthritis
15276|NCT02960373|Dried fruit
15277|NCT02960373|Glycemic Index
15278|NCT02960373|Catalytic dose
15279|NCT02960373|Glycemic response
15280|NCT02960373|Fructose
15281|NCT02960373|Postprandial
15282|NCT02960373|Randomized clinical trial
15283|NCT02960373|Carbohydrate metabolism
15284|NCT02960334|Screening
15285|NCT02960334|Silent Atrial Fibrillation
15286|NCT02960334|Undertreated Atrial Fibrillation
15287|NCT02960334|Actionable Atrial Fibrillation
15288|NCT02960334|MyDiagnostick
15289|NCT02960334|Opportunistic Screening
15290|NCT02960334|Preoperative Consultation
15291|NCT02960334|OAC
15292|NCT02960334|VKA
15293|NCT02960334|NOAC
15294|NCT02960321|myocardial injury
15295|NCT02960321|high-sensitivity troponin I
15296|NCT02960321|periprocedural myocardial infarction
15297|NCT02960269|rural health
15298|NCT02960269|telehealth
15299|NCT02960269|physiotherapy
15300|NCT02960269|interprofessional
15301|NCT02960243|Deep Brain Stimulation
15302|NCT02960243|Laryngeal Motor Cortex
15303|NCT02960243|Essential Voice Tremor
15304|NCT02960243|Essential Tremor
15305|NCT02960230|peptide vaccine
15306|NCT02960230|immunotherapy
15307|NCT02960230|DIPG
15308|NCT02960230|vaccine
15309|NCT02960204|cirrhosis
15310|NCT02960204|Portal Hypertension
15311|NCT02960204|Non-alcoholic Steatohepatitis
15312|NCT02960204|Liver cirrhosis
15313|NCT02960152|periodontitis
15314|NCT02960113|cesarean section
15315|NCT02960113|acupressure point p6
15316|NCT02960113|scopolamine patch
15317|NCT02960100|Cancer prevention
15318|NCT02960100|HPV
15319|NCT02960100|Human papillomavirus vaccine
15320|NCT02960074|Allergy, Peanut
15321|NCT02960074|Hypersensitivity Peanut
15322|NCT02960074|Peanut Allergy
15323|NCT02960074|Donor Feces Infusion
15324|NCT02960074|Fecal Transplant
15325|NCT02960074|Fecal Transplantation
15326|NCT02960074|Intestinal Microbiota Transfer
15327|NCT02960074|Fecal Microbiota Transplantation
15328|NCT02960074|Food allergy
15329|NCT02960061|Intraperitoneal chemotherapy
15330|NCT02960061|gastric cancer
15331|NCT02960061|Neo-adjuvant chemotherapy
15332|NCT02960048|Anterior disc displacement
15333|NCT02960048|TMD therapy
15334|NCT02960048|internal derangement
15335|NCT02960048|occlusal splint
15336|NCT02960048|anterior repositioning splint
15337|NCT02960035|Mardird sonographic enthesis index
15338|NCT02960035|Spondyloarthropathy
15339|NCT02960035|Ultrasonics
15340|NCT02960035|Etanercept
15341|NCT02960022|prostate cancer
15342|NCT02960022|prednisone
15343|NCT02960022|MDV3100
15344|NCT02960022|enzalutamide
15345|NCT02960022|Expanded Access
15346|NCT02960022|Xtandi
15347|NCT02960022|abiraterone acetate
15348|NCT02959944|chronic graft versus host disease
15349|NCT02959944|PCYC1140
15350|NCT02959944|PCYC1140IM
15351|NCT02959944|1140
15352|NCT02959944|Ibrutinib
15353|NCT02959944|GVHD
15354|NCT02959944|Steroid dependent
15355|NCT02959944|refractory
15356|NCT02959944|chronic
15357|NCT02959944|PCI32765
15358|NCT02959944|IMBRUVICA
15359|NCT02959944|Pharmacyclics
15360|NCT02959944|PCYC
15361|NCT02959944|graft versus host disease
15362|NCT02959944|immunology
15363|NCT02959944|new onset graft versus host disease
15364|NCT02959944|INTEGRATE
15365|NCT02959944|Corticosteroids
15366|NCT02959944|prednisone
15367|NCT02959931|Dietary Potassium
15368|NCT02959892|Drug therapy
15369|NCT02959879|FOLFOX
15370|NCT02959879|FOLFIRINOX
15371|NCT02959853|Hypogonadism
15372|NCT02959853|Severe obesity
15373|NCT02959827|Hypothyroidism,
15374|NCT02959827|children,
15375|NCT02959827|iodinated contrast agents,
15376|NCT02959827|retrospective cohort,
15377|NCT02959827|database
15378|NCT02959814|Fractional Flow Reserve
15379|NCT02959814|Quantitative Coronary Analysis
15380|NCT02959814|Stable coronary artery disease
15381|NCT02959814|Angina pectoris
15382|NCT02959801|Deep Venous Thrombosis
15383|NCT02959801|Percutaneous Mechanical Thrombectomy
15384|NCT02959788|Heart rate variability
15385|NCT02959775|Hepatitis B vaccination
15386|NCT02959775|Immunogenicity
15387|NCT02959775|Randomized controlled trial
15388|NCT02959775|Drug abuse
15389|NCT02959762|G01 [Biological Sciences]
15390|NCT02959762|G02.513 [Nutrition]
15391|NCT02959762|G06.696.259 [Child Nutrition]
15392|NCT02959762|G07.553.481.398.571 [Obesity]
15393|NCT02959762|G06 [Biochemical Phenomena, Metabolism, and Nutrition]
15394|NCT02959762|G12.392.617 [Insulin Resistance]
15395|NCT02959762|G06.696.259.500 [Adolescent Nutrition]
15396|NCT02959762|A06 [Endocrine System]
15397|NCT02959762|A07 [Cardiovascular System]
15398|NCT02959762|C18.452.297.681 [Obesity in Diabetes]
15399|NCT02959762|C18.452.555 [Insulin Resistance]
15400|NCT02959762|C18 [Nutritional and Metabolic Diseases]
15401|NCT02959762|C18.452.494 [Hyperlipidemia]
15402|NCT02959762|C18.452.460 [Hyperglycemia]
15403|NCT02959762|C14 [Cardiovascular Diseases]
15404|NCT02959762|D11.786.875.844 [Vitamin K 2]
15405|NCT02959762|D02.806.550.750 [Vitamin K 2]
15406|NCT02959762|E02.293 [Diet Therapy]
15407|NCT02959762|E02 [Therapeutics]
15408|NCT02959762|F04.096.544.215.508.428 [Primary Prevention]
15409|NCT02959762|N01.224.425.525 [Nutritional Status]
15410|NCT02959749|Osimertinib
15411|NCT02959749|EGFR T790M Resistant Mutation
15412|NCT02959749|Docetaxel
15413|NCT02959749|Bevacizumab
15414|NCT02959749|Non Small Cell Lung
15415|NCT02959736|Vegetative State
15416|NCT02959736|Minimally Conscious State
15417|NCT02959736|Brain Injuries
15418|NCT02959723|Pulmonary Arterial Hypertension
15419|NCT02959723|BMPR2
15420|NCT02959723|Inflammation
15421|NCT02959710|Healthy volunteers
15422|NCT02959710|AC-1202
15423|NCT02959710|AC-1204
15424|NCT02959710|Pharmacokinetic
15425|NCT02959710|ketone body
15426|NCT02959697|Blepharoptosis
15427|NCT02959697|Ptosis
15428|NCT02959697|Surgery
15429|NCT02959697|Pain Reduction
15430|NCT02959697|Anesthetic
15431|NCT02959697|Local Anesthetic
15432|NCT02959697|Subconjunctival
15433|NCT02959580|Granulomatous
15434|NCT02959580|Mastitis
15435|NCT02959580|topical steroids
15436|NCT02959567|cervix
15437|NCT02959567|cervical dilation
15438|NCT02959567|balloon catheter
15439|NCT02959554|Advanced
15440|NCT02959554|Metastatic
15441|NCT02959554|RCC
15442|NCT02959541|Leukovorin
15443|NCT02959476|Postoperative pain
15444|NCT02959476|Postsurgical pain
15445|NCT02959463|Malignant pleural mesothelioma
15446|NCT02959463|MPM
15447|NCT02959463|Non-metastatic
15448|NCT02959463|Pembrolizumab
15449|NCT02959463|Keytruda
15450|NCT02959463|MK-3475
15451|NCT02959463|SCH-900475
15452|NCT02959463|Radiation therapy
15453|NCT02959463|Radiation treatment
15454|NCT02959463|XRT
15455|NCT02959463|Intensity modulated radiation therapy
15456|NCT02959463|IMRT
15457|NCT02959463|Proton beam therapy
15458|NCT02959463|PBT
15459|NCT02959463|3D conformal therapy
15460|NCT02959450|Nutritional Intervention in Oropharyngeal Dysphagia
15461|NCT02959437|Solid tumors
15462|NCT02959437|NSCLC
15463|NCT02959437|CRC
15464|NCT02959359|Chronic hepatitis C
15465|NCT02959359|Hepatocellular Carcinoma
15466|NCT02959359|Direct-acting antiviral (DAA)
15467|NCT02959359|Recurrence
15468|NCT02959346|Minimal invasive thoracoscopic surgery
15469|NCT02959346|Pain control
15470|NCT02959346|Acupuncture
15471|NCT02959346|Randomized controlled trial
15472|NCT02959307|Depression
15473|NCT02959307|Major Depressive Disorder
15474|NCT02959307|Major Depressive Episode
15475|NCT02959294|TBI
15476|NCT02959294|mTBI
15477|NCT02959294|Concussion, Brain
15478|NCT02959294|Loss Consciousness, Traumatic
15479|NCT02959294|Headaches
15480|NCT02959242|glaucoma, follow-up intervals, treatment efficiency
15481|NCT02959229|Late onset sepsis
15482|NCT02959229|Bovine Lactoferrin
15483|NCT02959203|Central Venous Catheter
15484|NCT02959203|Ultrasound
15485|NCT02959203|Chest X-ray
15486|NCT02959203|Pneumothorax
15487|NCT02959190|prevention
15488|NCT02959190|prophylaxis
15489|NCT02959190|headache
15490|NCT02959177|prevention
15491|NCT02959177|prophylaxis
15492|NCT02959177|headache
15493|NCT02959112|pancreatitis after ERCP
15494|NCT02959112|epinephrine
15495|NCT02959112|papilla
15496|NCT02959112|rectal indomethacin
15497|NCT02959099|Acute myocardial infarction
15498|NCT02959099|ST elevation myocardial infarction
15499|NCT02959099|Non ST elevation myocardial infarction
15500|NCT02959099|Unstable angina
15501|NCT02959099|Coronary computed tomography angiography
15502|NCT02959086|Epidemiology
15503|NCT02959086|Shanghai
15504|NCT02959086|Cancer
15505|NCT02959086|Adolescents
15506|NCT02959086|Children
15507|NCT02959073|Symptom recording
15508|NCT02959047|MRI
15509|NCT02959047|PCSK9 inhibition
15510|NCT02959047|LDL cholesterol
15511|NCT02959021|weight loss
15512|NCT02959021|behavioral
15513|NCT02959021|primary care
15514|NCT02959021|lifestyle
15515|NCT02958995|Drug Therapy
15516|NCT02958982|RP3128
15517|NCT02958982|Phase 1
15518|NCT02958982|Healthy volunteers
15519|NCT02958969|venous thromboembolism
15520|NCT02958969|multiple myeloma
15521|NCT02958969|anticoagulation
15522|NCT02958956|Drug Therapy
15523|NCT02958943|atrial fibrillation
15524|NCT02958943|stroke
15525|NCT02958943|computerized decision support
15526|NCT02958904|Sexuality
15527|NCT02958904|Spinal cord injuries
15528|NCT02958904|Erectile dysfunction
15529|NCT02958904|depression
15530|NCT02958865|Mayo score
15531|NCT02958852|Breast Cancer
15532|NCT02958852|Endocrine Treatment
15533|NCT02958852|Atorvastatin
15534|NCT02958852|Mechanisms of Resistance
15535|NCT02958852|Statins
15536|NCT02958852|Fulvestrant
15537|NCT02958852|Circulating Tumor Cells
15538|NCT02958852|Statins and Endocrine Treatment
15539|NCT02958852|Tumor Marker Expression
15540|NCT02958852|ER+ Metastatic Breast Cancer
15541|NCT02958852|Circulating Tumor DNA
15542|NCT02958852|Cholesterol
15543|NCT02958839|Atrial fibrillation
15544|NCT02958839|Fibroblast Growth factor 23
15545|NCT02958800|Deprescribing
15546|NCT02958800|Single patient open label trial
15547|NCT02958800|Long-term care
15548|NCT02958761|knee arthrosis
15549|NCT02958761|platelet-derived growth factors
15550|NCT02958735|exercise
15551|NCT02958735|cognition
15552|NCT02958735|brain-derived neurotrophic factor
15553|NCT02958735|insulin-like growth factor 1
15554|NCT02958735|cortisol
15555|NCT02958683|Optoelectronic plethysmography
15556|NCT02958683|Structure light plethysmography
15557|NCT02958683|Respiratory Function Tests
15558|NCT02958657|Platelet function
15559|NCT02958657|Autonomic Nervous System
15560|NCT02958657|Multiplate® (Multiple Electrode Aggregometry - MEA)
15561|NCT02958657|VerifyNow®
15562|NCT02958644|prebiotic
15563|NCT02958644|obesity
15564|NCT02958644|body mass index
15565|NCT02958644|microbiota
15566|NCT02958605|Children
15567|NCT02958605|resuscitation
15568|NCT02958605|smartphone
15569|NCT02958592|shear-wave elastography
15570|NCT02958592|hepatic fibrosis
15571|NCT02958592|liver tumor
15572|NCT02958566|Pain control
15573|NCT02958566|Post-operative pain
15574|NCT02958566|Narcotic
15575|NCT02958566|Non-narcotic
15576|NCT02958566|Side effect
15577|NCT02958566|Toxicity
15578|NCT02958553|Lower Extremity Limb Loss
15579|NCT02958553|Prosthesis Use
15580|NCT02958540|Prophylaxis
15581|NCT02958527|Effexor
15582|NCT02958527|Depression
15583|NCT02958527|Depressed state
15584|NCT02958514|IPL
15585|NCT02958514|MGD
15586|NCT02958501|Vitamin D
15587|NCT02958501|Inflammatory Bowel Diseases
15588|NCT02958488|34 to 36 Weeks Preterm Neonates
15589|NCT02958488|Respiratory Distress Syndrom
15590|NCT02958488|High Flow Nasal Cannula
15591|NCT02958436|Safety
15592|NCT02958436|Tolerability
15593|NCT02958436|Pharmacokinetics
15594|NCT02958436|REGN3500
15595|NCT02958410|CD30
15596|NCT02958410|CAR-T
15597|NCT02958397|Myeloid Malignancies
15598|NCT02958397|CAR-T
15599|NCT02958397|CD33
15600|NCT02958384|Myeloid Malignancies
15601|NCT02958384|CAR-T
15602|NCT02958384|LeY
15603|NCT02958371|Functional magnetic resonance imaging
15604|NCT02958371|Taste
15605|NCT02958371|Feeding behavior
15606|NCT02958371|Choice behavior
15607|NCT02958358|pulmonary hypertension
15608|NCT02958358|ambrisentan
15609|NCT02958358|PET imaging
15610|NCT02958358|CT/PET
15611|NCT02958332|video games
15612|NCT02958306|cleft lip repair
15613|NCT02958306|cheiloplasty
15614|NCT02958306|PRP
15615|NCT02958306|platelet rich plasma
15616|NCT02958280|Exercise
15617|NCT02958280|Smartphone
15618|NCT02958267|knee osteoarthritis
15619|NCT02958267|regenerative medicine
15620|NCT02958267|orthobiologics
15621|NCT02958267|cellular therapy
15622|NCT02958254|hamstring
15623|NCT02958254|ultrasonography
15624|NCT02958254|validation
15625|NCT02958254|magnetic resonance imaging
15626|NCT02958254|muscle thickness
15627|NCT02958241|spondylolisthesis
15628|NCT02958241|Lumbar spine
15629|NCT02958241|MRI
15630|NCT02958228|Positive Affect
15631|NCT02958228|Mental Imagery
15632|NCT02958228|Cognitive Bias Modification
15633|NCT02958228|Cognitive Control Training
15634|NCT02958215|Orthostatic
15635|NCT02958215|Cesarean section
15636|NCT02958215|Pregnant
15637|NCT02958215|Phenyephrine
15638|NCT02958215|Hypotension
15639|NCT02958202|Duchenne Muscular Dystrophy
15640|NCT02958202|DMD
15641|NCT02958202|Dystrophin
15642|NCT02958202|BMN 044
15643|NCT02958202|PRO044
15644|NCT02958202|BioMarin
15645|NCT02958189|Twitter
15646|NCT02958189|social support
15647|NCT02958189|internet intervention
15648|NCT02958189|sedentary lifestyle
15649|NCT02958189|walking
15650|NCT02958189|behavior change
15651|NCT02958163|Hepatocellular cancer
15652|NCT02958163|Stereotactic Body Radiotherapy
15653|NCT02958163|Chemoembolization, Therapeutic
15654|NCT02958111|Nasopharyngeal Carcinoma
15655|NCT02958111|Adjuvant chemotherapy
15656|NCT02958111|Capecitabine
15657|NCT02958098|myocardial infarction
15658|NCT02958098|stroke
15659|NCT02958098|dilated cardiomyopathy
15660|NCT02958098|systolic heart failure
15661|NCT02958098|atrial fibrillation
15662|NCT02958098|aortic dissection
15663|NCT02958098|wearable devices
15664|NCT02958098|genomic sequencing
15665|NCT02958072|Malleoli ulcers
15666|NCT02958072|Diabetes
15667|NCT02958072|Healing
15668|NCT02958072|Dressing
15669|NCT02958072|LeucoPatch
15670|NCT02958059|ERCP
15671|NCT02958059|prophylaxis
15672|NCT02958059|antibiotics
15673|NCT02958059|infection
15674|NCT02958059|cholangitis
15675|NCT02958020|cohort, osteoporosis, bone mineral density, Chinese
15676|NCT02957981|BRCA1
15677|NCT02957981|BRCA2
15678|NCT02957981|Men
15679|NCT02957981|Hereditary Cancer
15680|NCT02957981|Prostate Cancer
15681|NCT02957981|Male Breast Cancer
15682|NCT02957968|Breast Cancer
15683|NCT02957968|Invasive adenocarcinoma
15684|NCT02957968|HER2-negative
15685|NCT02957955|Heart failure
15686|NCT02957942|Repetitive transcranial magnetic stimulation (rTMS)
15687|NCT02957942|Spasmodic dysphonia
15688|NCT02957942|Dystonia
15689|NCT02957877|Anticoagulation
15690|NCT02957877|Anti-Xa activity
15691|NCT02957877|Low-molecular weight heparin
15692|NCT02957877|Unfractionated heparin
15693|NCT02957838|Transferrin Receptor
15694|NCT02957838|Type 2 Diabetes
15695|NCT02957838|Stearic Acid (C18:0)
15696|NCT02957838|Mitochondrial Morphology
15697|NCT02957838|Crossover Study
15698|NCT02957812|Gait
15699|NCT02957812|Balance Control
15700|NCT02957812|Orthotics
15701|NCT02957799|Pregnancy
15702|NCT02957799|Home Healthcare Visits
15703|NCT02957799|Community Health Workers
15704|NCT02957799|Infants
15705|NCT02957786|cytisine
15706|NCT02957786|varenicline
15707|NCT02957786|smoking cessation
15708|NCT02957786|indigenous
15709|NCT02957747|Women Veterans
15710|NCT02957747|Sexual Trauma
15711|NCT02957734|Vertical dimension of occlusion
15712|NCT02957734|Direct composite restorations
15713|NCT02957734|Indirect composite restorations
15714|NCT02957734|Tooth wear
15715|NCT02957734|Failure
15716|NCT02957734|Quality of Life
15717|NCT02957695|frontal brain lesions
15718|NCT02957695|neurofeedback
15719|NCT02957695|cognitive functions
15720|NCT02957682|Hyperlipidemias
15721|NCT02957682|Dyslipidemias
15722|NCT02957682|Lipid Metabolism Disorders
15723|NCT02957630|Estetrol (E4)
15724|NCT02957630|Drospirenone (DRSP)
15725|NCT02957630|Ethinylestradiol (EE)
15726|NCT02957630|Levonorgestrel (LNG)
15727|NCT02957630|Oral contraceptive
15728|NCT02957630|Prevention of pregnancy
15729|NCT02957630|Hemostasis
15730|NCT02957630|Metabolism
15731|NCT02957617|Neuropathic Pain From Lumbosacral Radiculopathy, PLSR
15732|NCT02957604|Pregnancy; Cardiovascular Diseases; High serum cholesterol
15733|NCT02957591|Depression
15734|NCT02957591|probiotic supplementation
15735|NCT02957591|Adjuvant Therapy
15736|NCT02957591|Gut microbiome
15737|NCT02957591|Psychological functioning
15738|NCT02957591|Brain imaging
15739|NCT02957591|Brain-Gut interactions
15740|NCT02957591|Sleep
15741|NCT02957578|Tympanostomy Tube
15742|NCT02957578|Ventilation Tube
15743|NCT02957578|Grommet
15744|NCT02957578|Otitis Media
15745|NCT02957578|Middle Ear Effusion
15746|NCT02957565|Malignant neoplasms of independent (primary) multiple sites
15747|NCT02957565|Questionnaires
15748|NCT02957565|Surveys
15749|NCT02957565|Videos
15750|NCT02957565|Advanced Cancer
15751|NCT02957539|motivation
15752|NCT02957539|patient incentives
15753|NCT02957513|Diabetes
15754|NCT02957513|Uncontrolled
15755|NCT02957513|Chronic Disease
15756|NCT02957513|Chronic Conditions
15757|NCT02957513|Medically Underserved Areas
15758|NCT02957513|African Americans
15759|NCT02957513|Health Coaching
15760|NCT02957513|Health Education
15761|NCT02957513|Text Messaging
15762|NCT02957513|Text Messages
15763|NCT02957513|Mobile Health
15764|NCT02957474|Healthy Volunteers
15765|NCT02957474|Pharmacokinetics
15766|NCT02957474|Food Effect
15767|NCT02957474|Proton Pump
15768|NCT02957474|GED-0301
15769|NCT02957474|Mongersen
15770|NCT02957422|neurodegeneration
15771|NCT02957422|cognitive decline
15772|NCT02957422|cognition
15773|NCT02957422|age-related disease
15774|NCT02957422|dairy
15775|NCT02957422|dairy intake
15776|NCT02957409|Heart failure
15777|NCT02957409|Heart Failure with Reduced Ejection Fraction
15778|NCT02957409|HFrEF
15779|NCT02957383|Sleep, Melatonin
15780|NCT02957383|Circadian Rhythm
15781|NCT02957383|Temperature
15782|NCT02957383|screen illumination
15783|NCT02957344|health communication
15784|NCT02957344|Zika virus
15785|NCT02957344|legislation
15786|NCT02957344|vaccination
15787|NCT02957344|Child Care
15788|NCT02957305|misoprostol
15789|NCT02957305|miscarriage
15790|NCT02957279|sepsis
15791|NCT02957279|exosomes
15792|NCT02957279|dendritic cell
15793|NCT02957266|cervical cancer
15794|NCT02957266|interstitial brachytherapy
15795|NCT02957266|gemcitabine
15796|NCT02957266|volumetric arc therapy
15797|NCT02957253|Quality of care
15798|NCT02957253|Health related quality of life
15799|NCT02957253|Nurse-led clinic
15800|NCT02957253|Health economics
15801|NCT02957240|Forearm [A01.378.800.585]
15802|NCT02957240|Radius [A02.835.232.087.090.700]
15803|NCT02957240|Motor Skills [F02.808.260]
15804|NCT02957240|Task Performance and Analysis [F02.808.600]
15805|NCT02957240|Casts, Surgical [E07.858.442.660.430.500]
15806|NCT02957240|Splints [E07.858.690.725.430.750]
15807|NCT02957240|motor representation techniques
15808|NCT02957240|mirror therapy
15809|NCT02957240|Women [M01.975]
15810|NCT02957227|Alzheimer's disease
15811|NCT02957227|Frontotemporal Dementia
15812|NCT02957227|Lewy Body Dementia
15813|NCT02957227|Diagnosis
15814|NCT02957188|Eicosapentaenoic acid
15815|NCT02957188|Arachidonic acid
15816|NCT02957188|Metabolism
15817|NCT02957188|Healthy aging
15818|NCT02957175|Immunophenotyping
15819|NCT02957175|Perioperative Care
15820|NCT02957175|Innate Immunity
15821|NCT02957175|Cardiac Surgical Procedures
15822|NCT02957136|Respiratory Tract Infections
15823|NCT02957136|Influenza, Human
15824|NCT02957136|Common Cold
15825|NCT02957136|Viral Infection
15826|NCT02957136|Pathology, Molecular
15827|NCT02957136|Molecular Diagnostics
15828|NCT02957136|Diagnostic Testing
15829|NCT02957136|Clinical Microbiology
15830|NCT02957136|Polymerase Chain Reaction
15831|NCT02957136|Antibiotic Stewardship
15832|NCT02957136|Antimicrobial Use
15833|NCT02957136|Emergency Department
15834|NCT02957136|Emergency Room
15835|NCT02957123|macrophages M2 type
15836|NCT02957123|cytokines
15837|NCT02957123|intranasal administration
15838|NCT02957123|neuroprotection
15839|NCT02957123|neuroregeneration
15840|NCT02957123|organic brain syndrome
15841|NCT02957123|neurocognitive disorders
15842|NCT02957097|Gabapentin
15843|NCT02957097|acute pain
15844|NCT02957084|difficult laryngoscopy
15845|NCT02957084|neck circumference
15846|NCT02957084|sternomental distance
15847|NCT02957084|thyromental distance
15848|NCT02957084|hyomental distance
15849|NCT02957084|thyrosternal distance
15850|NCT02957058|Colonoscopy
15851|NCT02957058|Endoscopic Mucosal Resection
15852|NCT02957058|Adenoma Recurrence
15853|NCT02957058|EMR defect thermal ablation
15854|NCT02956993|peripheral artery disease
15855|NCT02956993|PAD
15856|NCT02956993|vonapanitase
15857|NCT02956993|critical limb ischemia
15858|NCT02956993|CLI
15859|NCT02956993|tibial artery
15860|NCT02956993|stenosis
15861|NCT02956993|distal popliteal artery
15862|NCT02956993|peroneal artery
15863|NCT02956993|below the knee
15864|NCT02956993|BTK
15865|NCT02956993|elastase
15866|NCT02956993|chymotrypsin-like elastase 1
15867|NCT02956993|CELA1
15868|NCT02956993|PRT-201
15869|NCT02956980|type 1 interferons
15870|NCT02956980|children
15871|NCT02956980|gender
15872|NCT02956980|pubertal status
15873|NCT02956980|sex difference
15874|NCT02956967|Non-Interventional Study
15875|NCT02956954|Enzyme replacement therapy
15876|NCT02956941|Academic performance
15877|NCT02956941|Behaviour change communication
15878|NCT02956941|Nutritional status
15879|NCT02956941|School children
15880|NCT02956941|Ethiopia
15881|NCT02956915|Transcatheter aortic valve implantation
15882|NCT02956889|Carcinoma, Basal Cell
15883|NCT02956889|Vismodegib
15884|NCT02956889|Radiotherapy
15885|NCT02956837|Vaccines
15886|NCT02956837|Respiratory Syncytial Viruses
15887|NCT02956837|Safety
15888|NCT02956837|Reactogenicity
15889|NCT02956837|Ranking of Formulations
15890|NCT02956837|Immunogenicity
15891|NCT02956824|Magnetic Resonance Imaging (MRI)
15892|NCT02956824|Sacro-iliac joints
15893|NCT02956824|Pelvis
15894|NCT02956824|Erosion
15895|NCT02956824|Fat deposit
15896|NCT02956824|Subchondral sclerosis
15897|NCT02956824|Bone marrow edema
15898|NCT02956824|Axial spondyloarthritis
15899|NCT02956811|Type 2 Diabetes
15900|NCT02956811|Left Ventricular Hypertrophy
15901|NCT02956811|Dapagliflozin
15902|NCT02956785|Propess
15903|NCT02956759|diabetic retinopathy
15904|NCT02956759|Pan-retinal photocoagulation
15905|NCT02956759|proliferative
15906|NCT02956759|non-proliferative
15907|NCT02956733|inexpensive, fasciotomy
15908|NCT02956707|neonates
15909|NCT02956707|cardiopulmonary bypass
15910|NCT02956707|adrenal insufficiency
15911|NCT02956707|congenital heart disease
15912|NCT02956694|Aged
15913|NCT02956694|Cognitive impairment
15914|NCT02956694|Neurocognitive Disorders
15915|NCT02956694|Shared decision making
15916|NCT02956694|Distance learning
15917|NCT02956694|Primary care
15918|NCT02956694|Decision support tool
15919|NCT02956694|Patient decision aid
15920|NCT02956668|tDCS
15921|NCT02956668|Visual field
15922|NCT02956668|Stroke
15923|NCT02956616|Enhanced Recovery
15924|NCT02956590|dyslipidemia
15925|NCT02956590|obesity
15926|NCT02956590|pitavastatin
15927|NCT02956590|lipids
15928|NCT02956577|Global Longitudinal Strain (GLS)
15929|NCT02956577|Coronary Flow Velocity Reserve (CFVR)
15930|NCT02956577|Cardiac dysfunction
15931|NCT02956577|Microcirculation
15932|NCT02956577|Coronary Computed Tomography Angiography (CCTA)
15933|NCT02956577|Type 1 Diabetes
15934|NCT02956577|Type 2 Diabetes
15935|NCT02956551|advanced non-small cell lung cancer
15936|NCT02956551|cell based therapy
15937|NCT02956551|safety
15938|NCT02956551|clinical efficacy
15939|NCT02956486|elenbecestat
15940|NCT02956486|E2609
15941|NCT02956486|Alzheimer's Disease
15942|NCT02956486|Early Alzheimer's Disease
15943|NCT02956486|Prodromal Alzheimer's Disease
15944|NCT02956486|Dementia
15945|NCT02956486|Dementia, Alzheimer's type
15946|NCT02956486|mild cognitive impairment
15947|NCT02956486|MissionAD1
15948|NCT02956473|Breast Cancer
15949|NCT02956447|Kisspeptin
15950|NCT02956447|Hyperprolactinemia
15951|NCT02956408|Obesity
15952|NCT02956408|Pediatrics
15953|NCT02956408|Vitamin D deficiency
15954|NCT02956395|adaptive case management approach
15955|NCT02956395|Transitional Care
15956|NCT02956395|multimorbidity
15957|NCT02956382|Ibrutinib
15958|NCT02956382|Venetoclax
15959|NCT02956382|Follicular
15960|NCT02956382|Refractory
15961|NCT02956382|Relapsed
15962|NCT02956382|Lymphoma
15963|NCT02956343|Atrial fibrillation
15964|NCT02956343|cardiovascular App
15965|NCT02956343|Rhythm monitoring
15966|NCT02956343|Stroke prevention
15967|NCT02956330|RVO
15968|NCT02956330|ME
15969|NCT02956330|Central Subfield Thickness
15970|NCT02956330|OCT
15971|NCT02956330|Optical Coherence Tomography
15972|NCT02956330|Cystoid Macular Edema
15973|NCT02956330|Subretinal Fluid
15974|NCT02956330|Eylea
15975|NCT02956330|Aflibercept
15976|NCT02956330|Anti-VEGF
15977|NCT02956291|glioma
15978|NCT02956291|brain tumor
15979|NCT02956291|brain metastasis
15980|NCT02956278|allopurinol
15981|NCT02956252|cholecystectomy, laparoscopic
15982|NCT02956252|spinal anesthesia
15983|NCT02956252|general anesthesia
15984|NCT02956252|cholecystectomy
15985|NCT02956239|cervical precancer
15986|NCT02956239|screening
15987|NCT02956239|treatment
15988|NCT02956239|thermo-coagulation
15989|NCT02956239|thermal ablation
15990|NCT02956239|Reducing overtreatment
15991|NCT02956213|COPD
15992|NCT02956213|air filter
15993|NCT02956213|indoor air quality
15994|NCT02956213|respiratory symptoms
15995|NCT02956213|emphysema
15996|NCT02956213|chronic obstructive pulmonary disease
15997|NCT02956213|tobacco use
15998|NCT02956200|Fingolimod Hydrochloride
15999|NCT02956200|Intravenous thrombolysis
16000|NCT02956200|Mechanical thrombectomy
16001|NCT02956200|Acute ischemic stroke
16002|NCT02956161|Sleep
16003|NCT02956161|Auditory stimulations
16004|NCT02956161|Slow oscillations
16005|NCT02956096|tDCS
16006|NCT02956096|Stroke
16007|NCT02956096|Autonomic Modulation
16008|NCT02956070|dental bleaching
16009|NCT02956070|antiinflammatory
16010|NCT02956070|tooth sensitivity
16011|NCT02956031|cancer prevention
16012|NCT02956031|cervical screening
16013|NCT02956031|cervical cancer
16014|NCT02956031|cervical disease
16015|NCT02956031|cervical neoplasm
16016|NCT02956031|HPV testing
16017|NCT02956031|immunocytochemistry
16018|NCT02956031|triage techniques
16019|NCT02956018|children
16020|NCT02955979|acute renal insufficiency
16021|NCT02955979|Iodinated Contrast Agents
16022|NCT02955979|pediatric
16023|NCT02955966|Aspergillosis
16024|NCT02955966|Haematological malignancy
16025|NCT02955966|18F-FDG PET/CT
16026|NCT02955966|Biomarkers
16027|NCT02955940|Solid tumors
16028|NCT02955940|ruxolitinib
16029|NCT02955940|regorafenib
16030|NCT02955940|capecitabine
16031|NCT02955927|Myopia control,ortho-k, atropine eye drops, children
16032|NCT02955914|Optimism
16033|NCT02955914|Pessimism
16034|NCT02955914|Recovery
16035|NCT02955914|Elective Cardiac surgery
16036|NCT02955901|Randomized controlled trial
16037|NCT02955901|Colonoscopy
16038|NCT02955901|Colon Disease
16039|NCT02955901|Low residue diet
16040|NCT02955901|Colon preparation
16041|NCT02955875|Diabetes Mellitus, Type 2
16042|NCT02955875|Pharmaceutical Services
16043|NCT02955862|Cryptococcal antigenemia
16044|NCT02955862|Cryptococcal meningitis
16045|NCT02955862|HIV/AIDS
16046|NCT02955849|glaucoma
16047|NCT02955849|rural
16048|NCT02955849|China
16049|NCT02955849|SLT
16050|NCT02955836|Patient Safety
16051|NCT02955836|Quality indicator
16052|NCT02955836|Information system
16053|NCT02955836|Nursing
16054|NCT02955836|Healthcare Quality
16055|NCT02955836|Quality measurement
16056|NCT02955823|B cell Lymphoma
16057|NCT02955823|non-Hodgkin Lymphoma
16058|NCT02955823|Elderly patients
16059|NCT02955810|Newly Diagnosed
16060|NCT02955810|Treatment Naiive
16061|NCT02955797|Meningitis
16062|NCT02955797|Meningococcal Meningitis
16063|NCT02955797|MenACYW conjugate vaccine
16064|NCT02955797|Nimenrix®
16065|NCT02955797|Menjugate®
16066|NCT02955771|photodynamic therapy(PDT)
16067|NCT02955771|stenting
16068|NCT02955771|Hilar Cholangiocarcinoma
16069|NCT02955771|Deuteporfin
16070|NCT02955719|Collaborative Care
16071|NCT02955719|Depression
16072|NCT02955719|Anxiety
16073|NCT02955719|Mild Cognitive Impairment
16074|NCT02955719|Integrated Care Pathway
16075|NCT02955693|Pharmacokinetics
16076|NCT02955693|Healthy volunteers
16077|NCT02955693|Monomethylfumarate
16078|NCT02955693|Dimethyl fumarate
16079|NCT02955693|Fumaderm®
16080|NCT02955693|Ethyl fumarate
16081|NCT02955680|emergence delirium
16082|NCT02955680|emergence time
16083|NCT02955680|bispectral index
16084|NCT02955667|invivo microscopy
16085|NCT02955667|colposcopy
16086|NCT02955667|cervical precancer and cancer
16087|NCT02955641|Laser peripheral iridotomy
16088|NCT02955641|topical anti-inflammatory drops
16089|NCT02955602|PBC
16090|NCT02955602|Primary Biliary Cholangitis (PBC)
16091|NCT02955576|Psoriasis
16092|NCT02955563|decision making for incapacitated patients
16093|NCT02955563|intensive care
16094|NCT02955563|surrogate decision making
16095|NCT02955563|patient centered care
16096|NCT02955563|Palliative Care
16097|NCT02955563|End of Life
16098|NCT02955563|Quality of Communication
16099|NCT02955550|Multiple Myeloma
16100|NCT02955550|Plasma Cell Myeloma
16101|NCT02955550|Plasma Cell Neoplasm
16102|NCT02955550|Relapsed/refractory Myeloma
16103|NCT02955550|PNK-007
16104|NCT02955550|Recombinant Human IL-2 (RHIL-2)
16105|NCT02955550|Human IL-2
16106|NCT02955550|Bone Marrow Transplant
16107|NCT02955537|Hypertension
16108|NCT02955537|mHealth
16109|NCT02955485|Ankle
16110|NCT02955485|Instability
16111|NCT02955485|Prediction
16112|NCT02955472|Neuralgia, Postherpetic
16113|NCT02955472|Postherpetic Neuralgia
16114|NCT02955472|Diabetic Neuropathies
16115|NCT02955472|Diabetic Neuralgia
16116|NCT02955472|Diabetic Polyneuropathy
16117|NCT02955472|Diabetic Neuropathy, Painful
16118|NCT02955472|Neuralgia
16119|NCT02955472|Neuropathic Pain
16120|NCT02955472|Pregabalin
16121|NCT02955472|Pharmacokinetics
16122|NCT02955472|Bioequivalent
16123|NCT02955459|Healthy volunteers
16124|NCT02955459|Pharmacokinetics
16125|NCT02955446|Refractory Tumors
16126|NCT02955446|Advanced Solid Tumors
16127|NCT02955433|Rideshare
16128|NCT02955433|Digital transportation network
16129|NCT02955433|Missed appointment
16130|NCT02955420|Autoantibodies
16131|NCT02955420|Heart Failure
16132|NCT02955420|Fatigue Syndrome, Chronic
16133|NCT02955420|Idiopathic Pulmonary Hypertension
16134|NCT02955420|Cardiomyopathies
16135|NCT02955394|ER+/Her2 - breast cancer
16136|NCT02955394|Preoperative Fulvestrant
16137|NCT02955394|Enzalutamide
16138|NCT02955368|DP-R212
16139|NCT02955303|Cognitive training
16140|NCT02955303|Tablet computers
16141|NCT02955277|Cognitive training
16142|NCT02955277|Tablet computers
16143|NCT02955264|Glycosylation
16144|NCT02955264|Glucose Metabolic Disorder
16145|NCT02955264|Galactose
16146|NCT02955251|Non-squamous NSCLC
16147|NCT02955251|Advanced solid tumor
16148|NCT02955251|Ovarian cancer
16149|NCT02955251|Non-small cell lung cancer (NSCLC)
16150|NCT02955251|Cancer
16151|NCT02955251|Neoplasm
16152|NCT02955251|Nivolumab
16153|NCT02955238|Intervention
16154|NCT02955238|Cardiovascular Disease
16155|NCT02955238|CVD
16156|NCT02955238|Diabetes
16157|NCT02955238|Latinos
16158|NCT02955238|CIMT
16159|NCT02955238|Medication Adherence
16160|NCT02955238|Risk Factors
16161|NCT02955238|T2D
16162|NCT02955225|Knee loads
16163|NCT02955225|Knee adduction moment
16164|NCT02955225|Biomechanical intervention
16165|NCT02955225|Insole
16166|NCT02955225|Shoe
16167|NCT02955212|Rheumatoid Arthritis
16168|NCT02955212|Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
16169|NCT02955212|ABT-494
16170|NCT02955134|central blinded histological assessment
16171|NCT02955134|traditional Chinese medicine intervention
16172|NCT02955134|long-term follow-up study
16173|NCT02955134|biological specimen banks
16174|NCT02955121|Cytochrome P-450 CYP2C19
16175|NCT02955121|Pharmacogenetics
16176|NCT02955121|Platelet Aggregation Inhibitors
16177|NCT02955121|Percutaneous Coronary Intervention
16178|NCT02955069|Advanced or metastatic
16179|NCT02955069|NET
16180|NCT02955069|pNET
16181|NCT02955069|GI NET
16182|NCT02955069|thoracic NET
16183|NCT02955056|Weber B
16184|NCT02955043|Hematopoietic Stem Cell Transplantation (HSCT)
16185|NCT02955043|Fatigue
16186|NCT02955043|Insomnia
16187|NCT02955043|Depression
16188|NCT02955043|Behavioral Intervention
16189|NCT02955017|obesity
16190|NCT02955017|children
16191|NCT02955017|adolescents
16192|NCT02955017|new technology
16193|NCT02955017|mobile health
16194|NCT02955017|chronic disease
16195|NCT02955004|silent brain embolism
16196|NCT02955004|atrial fibrillation
16197|NCT02955004|cardioversion
16198|NCT02954965|graduate student
16199|NCT02954965|burnout
16200|NCT02954965|stress
16201|NCT02954965|mood
16202|NCT02954939|lupus nephritis
16203|NCT02954939|lymphocyte subsets
16204|NCT02954939|cytokines
16205|NCT02954939|mycophenolate mofetil
16206|NCT02954939|cyclophosphamide
16207|NCT02954900|Breast Cancer Prevention
16208|NCT02954900|Risk Assessment
16209|NCT02954900|Chemoprevention
16210|NCT02954900|Decision Making
16211|NCT02954887|GWP42003-P
16212|NCT02954887|Cannabidiol
16213|NCT02954809|fatigue
16214|NCT02954809|sleep disturbances
16215|NCT02954809|circadian activity rhythms
16216|NCT02954783|Prostate cancer
16217|NCT02954783|Localized
16218|NCT02954783|Exercise
16219|NCT02954783|Physical activity
16220|NCT02954783|Natural killer cells
16221|NCT02954783|Immune cells
16222|NCT02954757|uterine adenomyosis
16223|NCT02954744|uterine fibroid
16224|NCT02954731|Cognitive Behavior Therapy
16225|NCT02954731|Negative Affect
16226|NCT02954731|Unified Protocol
16227|NCT02954731|Session Tracking
16228|NCT02954731|Mechanisms of Change in Psychotherapy
16229|NCT02954718|activity performance
16230|NCT02954718|juvenile idiopathic arthritis
16231|NCT02954718|virtual reality
16232|NCT02954679|Psychoactive Substances Consumption
16233|NCT02954679|Substance-related Disorder
16234|NCT02954679|Off label-use
16235|NCT02954679|Cognitive Enhancement
16236|NCT02954679|Students
16237|NCT02954679|Doping
16238|NCT02954679|Stimulants
16239|NCT02954679|Drug abuse
16240|NCT02954679|Methylphenidate
16241|NCT02954679|Addictovigilance
16242|NCT02954679|CEIP
16243|NCT02954666|cardio-neuromodulation
16244|NCT02954666|cardio-neuroablation
16245|NCT02954666|ablation
16246|NCT02954666|ganglionated plexi
16247|NCT02954666|anterior right ganglionated plexus
16248|NCT02954666|syncope
16249|NCT02954653|relapsed
16250|NCT02954653|refractory
16251|NCT02954653|acute myeloid leukemia
16252|NCT02954653|AML
16253|NCT02954627|Osteoarthritis
16254|NCT02954627|Obesity
16255|NCT02954627|Liraglutide 3 mg
16256|NCT02954627|Liraglutide
16257|NCT02954627|Ultrasound
16258|NCT02954601|Oral Insulin
16259|NCT02954601|DM T2 (Diabetes Mellitus Type 2)
16260|NCT02954562|anxiety
16261|NCT02954562|fMRI
16262|NCT02954562|emotion regulation
16263|NCT02954549|vitamin D deficiency, genomics, vitamin D supplementation
16264|NCT02954536|pembrolizumab
16265|NCT02954536|trastuzumab
16266|NCT02954536|capecitabine
16267|NCT02954536|cisplatin
16268|NCT02954536|Stage IV
16269|NCT02954536|HER2-positive
16270|NCT02954536|esophagogastric cancer
16271|NCT02954536|16-937
16272|NCT02954523|NSCLC
16273|NCT02954523|Non-small cell
16274|NCT02954523|Lung Cancer
16275|NCT02954523|Dasatinib
16276|NCT02954523|Osimertinib
16277|NCT02954523|AZD9291
16278|NCT02954523|EGFR Mutations
16279|NCT02954523|Epidermal growth factor receptor (EGFR)
16280|NCT02954445|BCMA
16281|NCT02954445|CAR-T
16282|NCT02954432|transcranial Direct Current Stimulation
16283|NCT02954432|Transcranial Ultrasound
16284|NCT02954432|non-invasive brain stimulation
16285|NCT02954419|IgA Nephropathy
16286|NCT02954419|Biomarker
16287|NCT02954406|Drug Therapy
16288|NCT02954393|Periodontal disease
16289|NCT02954393|Metronidazole
16290|NCT02954393|Amoxicillin
16291|NCT02954393|Scaling and root planing
16292|NCT02954393|Healing phase
16293|NCT02954354|Flu
16294|NCT02954354|S-033188
16295|NCT02954354|Oseltamivir
16296|NCT02954354|Tamiflu®
16297|NCT02954302|Delayed gastric emptying
16298|NCT02954302|pancreaticoduodenectomy
16299|NCT02954289|modifiable risk factors
16300|NCT02954289|lifestyle
16301|NCT02954289|nutrition
16302|NCT02954289|weight control
16303|NCT02954289|dietary intervention
16304|NCT02954289|health promotion
16305|NCT02954289|patient-partner outcomes
16306|NCT02954289|survivorship
16307|NCT02954289|prostate cancer outcomes
16308|NCT02954276|safety
16309|NCT02954263|Multiple ascending dose (MAD)
16310|NCT02954237|Non-valvular atrial fibrillation (NVAF)
16311|NCT02954237|Anticoagulant
16312|NCT02954237|Warfarin
16313|NCT02954237|Stroke
16314|NCT02954224|sleep apnea, delirium
16315|NCT02954211|rTMS
16316|NCT02954211|noninvasive brain stimulation
16317|NCT02954211|physical therapy
16318|NCT02954185|Shoulder Pain
16319|NCT02954146|Veterans
16320|NCT02954146|Posttraumatic Stress Disorder
16321|NCT02954146|Anger
16322|NCT02954146|Behavioral Health
16323|NCT02954146|Mobile Health Technology
16324|NCT02954133|Alignment phase
16325|NCT02954133|Photobiomodulation
16326|NCT02954133|Orthodontic treatment
16327|NCT02954133|Malocclusion
16328|NCT02954133|OrthoPulse™
16329|NCT02954133|Invisalign
16330|NCT02954120|8- hydroxy -2´- deoxyguanosine
16331|NCT02954120|Malondialdehyde
16332|NCT02954120|Total antioxidant status
16333|NCT02954120|Oxidative stres
16334|NCT02954068|Oxytocin
16335|NCT02954055|locally advanced
16336|NCT02954055|metastatic
16337|NCT02954055|breast cancer
16338|NCT02954055|ER-positive
16339|NCT02954055|HER2-negative
16340|NCT02954055|Stage IV
16341|NCT02954042|Incontinence
16342|NCT02954016|Obesity
16343|NCT02954016|Weight Loss
16344|NCT02954016|Hypertension
16345|NCT02954016|Type 2 Diabetes Mellitus
16346|NCT02954016|Hyperlipidemia
16347|NCT02954003|Obesity
16348|NCT02954003|Weight Loss
16349|NCT02953990|Pregnancy
16350|NCT02953990|Self-Management
16351|NCT02953990|Yoga
16352|NCT02953951|blood transfusion
16353|NCT02953951|free hemoglobin
16354|NCT02953951|nitric oxide
16355|NCT02953951|endothelium-dependent vasodilatation
16356|NCT02953951|peripheral artery tonometry
16357|NCT02953951|cardiac surgery.
16358|NCT02953938|Ranibizumab
16359|NCT02953938|Grid&Direct short pulse laser photocoagulation
16360|NCT02953938|Macular edema,
16361|NCT02953938|Branch retinal vein occlusion (BRVO)
16362|NCT02953938|BCVA
16363|NCT02953938|CSFT
16364|NCT02953938|pro re nata
16365|NCT02953925|primary health care
16366|NCT02953925|village doctor
16367|NCT02953925|township hospital
16368|NCT02953925|community health center
16369|NCT02953912|Rotation
16370|NCT02953912|Reciprocation
16371|NCT02953912|single file
16372|NCT02953912|postoperative pain
16373|NCT02953912|Reciproc
16374|NCT02953912|One Shape
16375|NCT02953912|Symptomatic irreversible pulpitis
16376|NCT02953899|Internet
16377|NCT02953899|Contingency Management
16378|NCT02953899|Gambling Disorder
16379|NCT02953899|Rural
16380|NCT02953886|Caries
16381|NCT02953886|Cavity
16382|NCT02953886|Silver Diamine Fluoride (SDF)
16383|NCT02953886|HOMINGS
16384|NCT02953860|Advanced Breast Cancer
16385|NCT02953860|ER+/Her2 Advanced Breast Cancer
16386|NCT02953834|insulin regulation in pregnancy
16387|NCT02953834|kisspeptin
16388|NCT02953808|GSK2315698
16389|NCT02953808|Dose-ascending
16390|NCT02953808|Systemic amyloidosis
16391|NCT02953782|Colorectal Neoplasms, Hu5F9-G4, CD47, cetuximab
16392|NCT02953756|Brain metastases
16393|NCT02953756|Cognition
16394|NCT02953756|Radiosurgery
16395|NCT02953756|Stereotactic radiosurgery
16396|NCT02953756|Gamma Knife Radiosurgery
16397|NCT02953756|Quality of Life
16398|NCT02953756|Fatigue
16399|NCT02953756|Anxiety
16400|NCT02953756|Depression
16401|NCT02953743|E7080
16402|NCT02953743|Lenvatinib
16403|NCT02953743|Pharmacokinetic study
16404|NCT02953743|Chinese participants
16405|NCT02953743|Unresectable Hepatocellular Carcinoma
16406|NCT02953717|Brain metastases
16407|NCT02953717|Cognition
16408|NCT02953717|Radiosurgery
16409|NCT02953717|Gamma Knife Radiosurgery
16410|NCT02953717|Stereotactic radiosurgery
16411|NCT02953717|Whole Brain Radiation Therapy
16412|NCT02953717|Quality of Life
16413|NCT02953717|Fatigue
16414|NCT02953717|Anxiety
16415|NCT02953717|Depression
16416|NCT02953704|Myelofibrosis
16417|NCT02953704|essential thrombocythemia
16418|NCT02953704|clinical characteristics
16419|NCT02953704|disease burden
16420|NCT02953704|patient-reported outcomes
16421|NCT02953691|perioperative
16422|NCT02953691|surgery
16423|NCT02953691|pain
16424|NCT02953691|anxiety
16425|NCT02953691|post operative cognitive dysfunction
16426|NCT02953691|cognition
16427|NCT02953678|Graft-versus-host disease (GVHD)
16428|NCT02953678|acute GVHD
16429|NCT02953678|steroid-refractory
16430|NCT02953678|ruxolitinib
16431|NCT02953678|Janus kinase inhibitor
16432|NCT02953665|Parkinson's Disease, Liraglutide
16433|NCT02953665|Antidiabetic agents
16434|NCT02953665|GLP-1 agonists
16435|NCT02953665|Insulin resistance
16436|NCT02953626|pilot RCT
16437|NCT02953626|waitlist-controlled RCT
16438|NCT02953626|postpartum depression
16439|NCT02953613|Cardiac Catheterization
16440|NCT02953613|Cardiac intervention
16441|NCT02953613|coronary angiogram
16442|NCT02953613|coronary artery disease
16443|NCT02953613|atherosclerosis
16444|NCT02953587|Obesity
16445|NCT02953587|Bariatric Surgery
16446|NCT02953574|geriatric nursing
16447|NCT02953561|Relapsed Acute Myeloid Leukemia
16448|NCT02953561|Refractory Acute Myeloid Leukemia
16449|NCT02953561|Acute Myeloid Leukemia
16450|NCT02953561|AML
16451|NCT02953561|Avelumab
16452|NCT02953561|antiPDL1
16453|NCT02953561|5-azacytidine
16454|NCT02953561|Azacitidine
16455|NCT02953561|5-aza
16456|NCT02953561|Vidaza
16457|NCT02953561|5-AZC
16458|NCT02953561|AZA-CR
16459|NCT02953561|Ladakamycin
16460|NCT02953561|NSC-102816
16461|NCT02953561|Azacytidine
16462|NCT02953548|GWP42003-P
16463|NCT02953548|Cannabidiol
16464|NCT02953522|Polymorphism
16465|NCT02953522|Folate
16466|NCT02953522|Oxidative stress
16467|NCT02953522|Overweight and Obesity
16468|NCT02953509|non-Hodgkin's lymphoma
16469|NCT02953509|diffuse large B-cell lymphoma
16470|NCT02953509|indolent lymphoma
16471|NCT02953509|Hu5F9-G4
16472|NCT02953509|CD47
16473|NCT02953496|peripheral artery disease
16474|NCT02953496|PAD
16475|NCT02953496|vonapanitase
16476|NCT02953496|claudication
16477|NCT02953496|superficial femoral artery
16478|NCT02953496|SFA
16479|NCT02953496|popliteal artery
16480|NCT02953496|stenosis
16481|NCT02953496|elastase
16482|NCT02953496|chymotrypsin-like elastase 1
16483|NCT02953496|CELA1
16484|NCT02953496|PRT-201
16485|NCT02953483|Ex Vivo lung perfusion
16486|NCT02953470|chronic pain
16487|NCT02953470|community-dwelling
16488|NCT02953470|older adults
16489|NCT02953470|physical activity
16490|NCT02953470|physiotherapy
16491|NCT02953470|behavioural medicine
16492|NCT02953470|biopsychosocial
16493|NCT02953470|exercise
16494|NCT02953470|independency
16495|NCT02953470|everyday activities
16496|NCT02953470|self-efficacy
16497|NCT02953470|quality of life
16498|NCT02953470|pain-related beliefs
16499|NCT02953470|pain-related disability
16500|NCT02953431|Asthma
16501|NCT02953431|Obesity
16502|NCT02953353|Obesity
16503|NCT02953353|Feeding behavior
16504|NCT02953353|Transcranial direct current stimulation
16505|NCT02953353|Weight loss
16506|NCT02953340|Neutropenia
16507|NCT02953340|Breast Cancer
16508|NCT02953340|Long-acting Myeloid Growth Factor
16509|NCT02953340|Early Stage Breast Cancer
16510|NCT02953340|Docetaxel + Cyclophosphamide (TC) chemotherapy
16511|NCT02953327|Non-Specific Effect of Vaccine
16512|NCT02953327|Middle aged
16513|NCT02953327|Immunity, heterologous
16514|NCT02953301|Cutaneous T-Cell Lymphoma (CTLC)
16515|NCT02953301|Maintenance
16516|NCT02953301|resminostat
16517|NCT02953301|4SC
16518|NCT02953301|HDAC
16519|NCT02953301|Mycosis Fungoides
16520|NCT02953301|Sézary Syndrome
16521|NCT02953262|Diabetes Mellitus
16522|NCT02953262|Personal Health Records
16523|NCT02953262|Patient Outcome Assessment
16524|NCT02953262|Mental Health
16525|NCT02953184|neoadjuvant chemotherapy
16526|NCT02953184|Pegylated liposomal doxorubicin
16527|NCT02953184|breast cancer
16528|NCT02953171|Irritable Bowel Syndrome
16529|NCT02953171|The human microbiome
16530|NCT02953171|Microbiota
16531|NCT02953171|Gut microbiota
16532|NCT02953171|Probiotics
16533|NCT02953171|Sauerkraut
16534|NCT02953106|Asthma
16535|NCT02953106|Rhinitis
16536|NCT02953106|Dymista
16537|NCT02953106|allergy
16538|NCT02953093|acarbose
16539|NCT02953093|aging
16540|NCT02953054|Pain
16541|NCT02953054|Bunionectomy
16542|NCT02953054|Dexmedetomidine
16543|NCT02953054|Transdermal
16544|NCT02953054|Patch
16545|NCT02953054|Postoperative
16546|NCT02953054|DMTS
16547|NCT02953028|Continuous Positive Airway Pressure
16548|NCT02953028|Mandibular Advancing Splint
16549|NCT02953028|Efficacy
16550|NCT02953028|Compliance
16551|NCT02953028|Health related quality of life
16552|NCT02953028|Randomized Controlled Trial
16553|NCT02953028|Snoring
16554|NCT02953028|Mandibular Advancing Appliance
16555|NCT02953028|Mandibular Advancing Device
16556|NCT02953028|Humans
16557|NCT02953028|Quality of Life
16558|NCT02953028|Sleep Apnea, Obstructive
16559|NCT02953015|Chronic Migraine
16560|NCT02953015|Manipulative treatments
16561|NCT02953015|Transcutaneous Electrical Nerve Stimulation
16562|NCT02952976|open abdomen
16563|NCT02952976|Damage control
16564|NCT02952976|Abdominal Compartment Syndrome
16565|NCT02952950|Intra Oral Vacuum
16566|NCT02952950|protein content breastmilk
16567|NCT02952937|Neuralgia, Postherpetic
16568|NCT02952937|Postherpetic Neuralgia
16569|NCT02952937|Diabetic Neuropathies
16570|NCT02952937|Diabetic Neuralgia
16571|NCT02952937|Diabetic Polyneuropathy
16572|NCT02952937|Diabetic Neuropathy, Painful
16573|NCT02952937|Neuralgia
16574|NCT02952937|Neuropathic Pain
16575|NCT02952937|Pregabalin
16576|NCT02952937|Pharmacokinetics
16577|NCT02952937|Bioequivalent
16578|NCT02952898|solar keratoses
16579|NCT02952872|Computerized Brief Intervention
16580|NCT02952833|Inactivated
16581|NCT02952833|Phase I
16582|NCT02952833|placebo-controlled
16583|NCT02952833|Vaccine
16584|NCT02952833|ZIKA
16585|NCT02952820|insomnia
16586|NCT02952794|endoscopic submucosal dissection (ESD)
16587|NCT02952794|endoscopic mucosal band ligation (EMBL)
16588|NCT02952781|ECG Monitoring
16589|NCT02952781|Palpitations
16590|NCT02951793|intensive care unit
16591|NCT02951793|delirium
16592|NCT02951793|substance withdrawal
16593|NCT02951767|anti-PD-L1
16594|NCT02951767|PD-L1
16595|NCT02951767|MPDL3280A
16596|NCT02951767|PD-1
16597|NCT02951767|bladder cancer
16598|NCT02951767|atezolizumab
16599|NCT02951767|Tecentriq
16600|NCT02951754|ADHD
16601|NCT02951754|Adults
16602|NCT02951754|treatment
16603|NCT02951754|Methylphenidate
16604|NCT02951650|vagus nerve stimulation
16605|NCT02951637|Adenocarcinoma, EGFR, Gefitinib, Pemetrexed, Carboplatin
16606|NCT02951624|Exercise
16607|NCT02951624|Breaking prolonged sitting
16608|NCT02951624|physical activity
16609|NCT02951572|Noninvasive Ventilation
16610|NCT02951572|Physical activity
16611|NCT02951520|Patients
16612|NCT02952716|carbon monoxide poisoning
16613|NCT02952716|delayed encephalopathy
16614|NCT02952638|Lipids
16615|NCT02952638|lysophosphatidic acid
16616|NCT02952638|Lysophospholipids
16617|NCT02952638|phosphatidylcholine
16618|NCT02952638|lysophosphatidylcholine
16619|NCT02952638|autotaxin
16620|NCT02952638|dietary
16621|NCT02952625|PET/MRI
16622|NCT02952599|Non-interventional Study
16623|NCT02952599|Real World Evidence
16624|NCT02952599|Patients with Acute VTE treated with Edoxaban
16625|NCT02952599|Efficacy/Safety
16626|NCT02952560|Ultrasound
16627|NCT02952560|Computed Tomography
16628|NCT02952560|Oral cavity size
16629|NCT02952560|The Mallampati classification
16630|NCT02952534|CRPC
16631|NCT02952534|PARP inhibitor
16632|NCT02952534|PARPi
16633|NCT02952534|BRCA
16634|NCT02952534|ATM
16635|NCT02952534|HRD
16636|NCT02952534|TRITON
16637|NCT02952534|homologous recombination
16638|NCT02952534|DNA repair
16639|NCT02952534|DNA defect
16640|NCT02952534|DNA anomaly
16641|NCT02952534|BARD1
16642|NCT02952534|BRIP1
16643|NCT02952534|CDK12
16644|NCT02952534|CHEK2
16645|NCT02952534|FANCA
16646|NCT02952534|NBN
16647|NCT02952534|PALB2
16648|NCT02952534|RAD51
16649|NCT02952534|RAD51B
16650|NCT02952534|RAD51C
16651|NCT02952534|RAD51D
16652|NCT02952534|RAD54L
16653|NCT02952534|germline
16654|NCT02952534|somatic
16655|NCT02952495|Alcohol Consumption
16656|NCT02952495|Older Adults
16657|NCT02952482|adrenoleukodystrophy
16658|NCT02952482|C26:0-lyso-PC
16659|NCT02952469|Positron-Emission Tomography
16660|NCT02952469|(68Ga)Glu-urea-Lys(Ahx)-HBED-CC
16661|NCT02952469|(68Ga)PSMA-HBED-CC
16662|NCT02952456|SUDEP
16663|NCT02952456|Epilepsy
16664|NCT02952456|Qualitative research
16665|NCT02952456|Risks associated with epilepsy
16666|NCT02952456|Epilepsy-related deaths
16667|NCT02952391|cognition
16668|NCT02952391|cholinergic system
16669|NCT02952365|LASIK, Ingrowth, Tissue sealant
16670|NCT02952300|irreversible pulpitis
16671|NCT02952300|reciprocation
16672|NCT02952300|rotation
16673|NCT02952300|single file
16674|NCT02952300|wave one
16675|NCT02952300|neolix
16676|NCT02952209|Alveolar Ridge Preservation
16677|NCT02952209|Xenograft bone graft
16678|NCT02952209|Collagen membrane
16679|NCT02952196|Amphetamine
16680|NCT02952196|Stress
16681|NCT02952196|Craving
16682|NCT02952196|CBD
16683|NCT02952183|Autonomic nerve monitoring
16684|NCT02952183|Nerve-sparing surgery
16685|NCT02952131|IBD,Crohn's,Ulcerative Bowel; Diverticulitis;IBS;UC
16686|NCT02952105|cardiac arrest
16687|NCT02952105|identify of electrocardiac rhythm
16688|NCT02952105|ventricuar fibrillation
16689|NCT02952105|defibrillation
16690|NCT02952092|ASP1517
16691|NCT02952092|Renal anemia
16692|NCT02952092|Hemodialysis
16693|NCT02952053|Myofascial Trigger Points
16694|NCT02952053|Dry needling
16695|NCT02952053|Myotonometry
16696|NCT02952040|ASP1517
16697|NCT02952040|Pharmacokinetics
16698|NCT02952040|Drug-drug interaction
16699|NCT02952001|Uveitis
16700|NCT02952001|UME
16701|NCT02952001|Posterior Uveitis
16702|NCT02952001|Anterior Uveitis
16703|NCT02952001|Intermediate Uveitis
16704|NCT02952001|Panuveitis
16705|NCT02952001|Non-infectious Uveitis
16706|NCT02952001|Triamcinolone
16707|NCT02952001|Choroid
16708|NCT02952001|Choroidal Injection
16709|NCT02952001|Suprachoroidal
16710|NCT02952001|Microneedle
16711|NCT02952001|Microinjection
16712|NCT02951949|atherosclerosis, endogenous estrogens, age
16713|NCT02951897|circulating tumor cells
16714|NCT02951897|lung adenocarcinoma
16715|NCT02951897|treatment
16716|NCT02951897|early diagnosis
16717|NCT02951871|Follicular lymphoma; death, rituximab, treatment related toxicity
16718|NCT02951858|Alcohol,Smoking,and Substance Use Involvement Screening Test
16719|NCT02951858|Brief Intervention
16720|NCT02951858|Substance Use
16721|NCT02951858|Primary Medical and Health Care Institution
16722|NCT02951481|Clostridium difficile.
16723|NCT02951481|Antimicrobial Stewardship.
16724|NCT02951481|Enterocolitis, Pseudomembranous
16725|NCT02951442|Arterial stiffness
16726|NCT02951442|Klotho-FGF23
16727|NCT02951403|elbow arthroscopy
16728|NCT02951403|DASH
16729|NCT02951403|elbow locking
16730|NCT02951403|elbow osteoarthritis
16731|NCT02951390|Surveillance
16732|NCT02951390|Colorectal cancer
16733|NCT02951390|Colonoscopy
16734|NCT02951390|Adenoma
16735|NCT02951390|Chromoendoscopy
16736|NCT02951377|mechanical diagnosis therapy (MDT)
16737|NCT02951377|physical therapy
16738|NCT02951377|steroid injection
16739|NCT02951377|exercise
16740|NCT02951364|observational
16741|NCT02951338|Physical activity
16742|NCT02951338|Exercise
16743|NCT02951338|Behaviour change
16744|NCT02951338|Rehabilitation
16745|NCT02951338|Self-management
16746|NCT02951338|Education
16747|NCT02951325|adjuvant RT
16748|NCT02951312|Emphysema
16749|NCT02951312|Chronic bronchitis
16750|NCT02951312|COPD
16751|NCT02951312|Chronic Obstructive Pulmonary Disease
16752|NCT02951286|Skeletal openbite
16753|NCT02951286|Molar intrusion
16754|NCT02951286|high pull headgear
16755|NCT02951273|abdominal surgery
16756|NCT02951273|blood pressure
16757|NCT02951273|cardiac output
16758|NCT02951273|cerebral blood flow
16759|NCT02951273|cerebral oxygenation
16760|NCT02951273|CO2 reactivity
16761|NCT02951273|duplex ultrasound
16762|NCT02951273|general anaesthesia
16763|NCT02951273|mesenteric traction syndrome
16764|NCT02951273|near-infrared spectroscopy
16765|NCT02951273|upper gastrointestinal cancer surgery
16766|NCT02951234|coronary artery lesions
16767|NCT02951234|intravenous immunoglobulin
16768|NCT02951234|Kawasaki disease
16769|NCT02951234|randomized clinical trial
16770|NCT02951234|aspirin
16771|NCT02951130|CDH
16772|NCT02951130|PPHN
16773|NCT02951130|HRF
16774|NCT02951117|lymphoid malignancies
16775|NCT02951117|Next generation sequencing
16776|NCT02951117|Refractory Multiple Myeloma
16777|NCT02951117|Relapsed Multiple Myeloma
16778|NCT02951052|Long-acting cabotegravir
16779|NCT02951052|Virologic failure
16780|NCT02951052|long-acting rilpivirine
16781|NCT02951052|Antiretroviral
16782|NCT02951039|Non valvular Atrial Fibrillation
16783|NCT02951039|Non-interventional Study
16784|NCT02951039|Efficacy/Safety
16785|NCT02951039|Real World Evidence
16786|NCT02951026|knee
16787|NCT02951026|osteoarthritis
16788|NCT02951026|intra-articular injection
16789|NCT02951026|SM04690
16790|NCT02951000|thyroidectomy
16791|NCT02951000|postoperative pain
16792|NCT02951000|wound healing
16793|NCT02950987|Li-Fraumeni Syndrome (LFS)
16794|NCT02950987|Cancer Predisposition Syndromes
16795|NCT02950987|LFS
16796|NCT02950974|sterofundin
16797|NCT02950974|resuscitation
16798|NCT02950974|normal saline
16799|NCT02950974|chloride
16800|NCT02950974|fluid
16801|NCT02950974|SID
16802|NCT02950974|pH
16803|NCT02950974|osmolality
16804|NCT02950974|urine
16805|NCT02950961|Anxiety [F01.470.132]
16806|NCT02950961|Depression [F01.145.126.350]
16807|NCT02950961|Stress Disorders, Post-Traumatic [F03.950.750.500]
16808|NCT02950961|Primary Health Care [N04.590.233.727]
16809|NCT02950961|Mental Health [F02.418]
16810|NCT02950961|Patient Participation [N05.300.150.600.620]
16811|NCT02950961|Patient Satisfaction [N05.300.150.600.630]
16812|NCT02950961|Patient Preference [N05.300.150.600.630.500]
16813|NCT02950961|Physicians, Primary Care [M01.526.485.810.800]
16814|NCT02950961|Physicians, Women [M01.526.485.810.820]
16815|NCT02950961|Health Behavior [F01.145.488]
16816|NCT02950909|Therapeutic exercise
16817|NCT02950909|Chronic pain
16818|NCT02950909|Neck extensors
16819|NCT02950883|Cystic Fibrosis
16820|NCT02950883|Hypertonic Saline
16821|NCT02950883|Inhaled Saline
16822|NCT02950883|Digestive System Diseases
16823|NCT02950883|Genetic Diseases, Inborn
16824|NCT02950883|Lung Diseases
16825|NCT02950883|Pancreatic Diseases
16826|NCT02950883|Pathologic Processes
16827|NCT02950883|Respiratory Tract Diseases
16828|NCT02950883|Computed Tomography (CT)
16829|NCT02950844|Atrial fibrillation
16830|NCT02950844|Electrogram
16831|NCT02950844|Ablation
16832|NCT02950844|Drivers
16833|NCT02950831|Chronic Pain
16834|NCT02950831|BurstDR
16835|NCT02950831|spinal cord stimulation
16836|NCT02950831|Accelerometry
16837|NCT02950818|self-care
16838|NCT02950818|health education
16839|NCT02950818|chronic disease
16840|NCT02950818|heart diseases
16841|NCT02950818|risk factors for heart disease
16842|NCT02950805|AZD5634
16843|NCT02950805|Mucociliary Clearance
16844|NCT02950805|Safety
16845|NCT02950805|Tolerability
16846|NCT02950805|Pharmacokinetic
16847|NCT02950805|Cystic Fibrosis
16848|NCT02950805|Cross-Over Study
16849|NCT02950792|Non-Small Cell Lung Cancer
16850|NCT02950792|NSCLC
16851|NCT02950766|Kidney Cancer
16852|NCT02950753|Elevated Serum Lactate
16853|NCT02950753|Serum lactate
16854|NCT02950753|Ringer's Lactate
16855|NCT02950753|Lactated Ringer's
16856|NCT02950753|Hyperlactatemia
16857|NCT02950740|malnutrition
16858|NCT02950727|orthognathic surgery
16859|NCT02950727|bicortical screws
16860|NCT02950727|monocortical plates
16861|NCT02950675|Burn patient
16862|NCT02950675|Developmental Disabilities
16863|NCT02950675|Body function
16864|NCT02950675|Participation
16865|NCT02950675|Quality of Life
16866|NCT02950675|longitudinal study
16867|NCT02950636|Epilepsy
16868|NCT02950610|Electronic nose
16869|NCT02950610|Non invasive diagnosis of NAFLD
16870|NCT02950610|NAFLD
16871|NCT02950610|exhaled breath analysis
16872|NCT02950610|Volatile organic compounds
16873|NCT02950545|astigmatism, contact lens, driving
16874|NCT02950532|Posterior ligamentous complex
16875|NCT02950532|Thoracolumbar fractures
16876|NCT02950532|Interspinous distance
16877|NCT02950532|Local kyphosis
16878|NCT02950506|Interictal
16879|NCT02950506|Cognitive
16880|NCT02950506|Dysfunction
16881|NCT02950506|tDCS
16882|NCT02950506|transcranial direct current stimulation
16883|NCT02950480|Mastectomy
16884|NCT02950467|HIV/AIDS
16885|NCT02950467|Demoralization
16886|NCT02950467|Psilocybin
16887|NCT02950467|Group therapy
16888|NCT02950454|Progressive Multiple Sclerosis
16889|NCT02950454|Rehabilitation
16890|NCT02950454|Exercise
16891|NCT02950441|Nicotinamide Riboside
16892|NCT02950441|Nicotinamide Adenine Dinucleotide
16893|NCT02950441|Skeletal muscle
16894|NCT02950441|Metabolism
16895|NCT02950428|TAVI
16896|NCT02950428|Aortic Stenosis
16897|NCT02950428|transcatether Aortic Valve Implantation
16898|NCT02950389|PMMA
16899|NCT02950389|on-line HFR
16900|NCT02950389|free light chains
16901|NCT02950389|toxins
16902|NCT02950389|removal
16903|NCT02950389|hemodialysis
16904|NCT02950376|synthetic drugs
16905|NCT02950376|virtual reality
16906|NCT02950376|addiction evaluation
16907|NCT02950376|physiological data
16908|NCT02950376|eye movement index
16909|NCT02950363|Depression
16910|NCT02950363|Suicide
16911|NCT02950363|Anxiety disorder
16912|NCT02950363|Burn out
16913|NCT02950363|Sleep quality
16914|NCT02950363|Stress
16915|NCT02950350|Cervical cancer
16916|NCT02950350|Precision medicine
16917|NCT02950350|Individualized treatment
16918|NCT02950350|Surgical staging
16919|NCT02950337|Unbiopsied Early Stage Non Small Cell Lung Cancer
16920|NCT02950324|Prehabilitation
16921|NCT02950324|Oesophago-gastric
16922|NCT02950324|Cancer
16923|NCT02950324|Neo-adjuvant
16924|NCT02950324|Exercise
16925|NCT02950324|Cardiopulmonary exercise test
16926|NCT02950324|Insulin resistance
16927|NCT02950298|Pompe
16928|NCT02950298|Glycogen Storage Disease II
16929|NCT02950298|Telemedicine
16930|NCT02950298|Duke University Medical Center
16931|NCT02950259|Breast Cancer
16932|NCT02950259|Early Stage Breast Cancer
16933|NCT02950259|Male breast cancer
16934|NCT02950259|IRX-2
16935|NCT02950259|Immunotherapy
16936|NCT02950233|postoperative pain
16937|NCT02950233|VATS
16938|NCT02950233|activities of daily living
16939|NCT02950233|quality of life
16940|NCT02950194|mesh
16941|NCT02950194|rectus diastasis
16942|NCT02950194|panniculectomy
16943|NCT02950194|abdominoplasty
16944|NCT02950168|Diagnostic procedures
16945|NCT02950168|Interventional procedures
16946|NCT02950168|Planned or unplanned
16947|NCT02950168|Edoxaban-treated population
16948|NCT02950142|order sets
16949|NCT02950142|decision support
16950|NCT02950142|laboratory test
16951|NCT02950142|primary care
16952|NCT02950129|pelvic girdle dysfunction
16953|NCT02950103|solid tumor
16954|NCT02950103|phase II
16955|NCT02950103|phosphoethanolamine
16956|NCT02950090|Knee symptoms
16957|NCT02950090|physical activity
16958|NCT02950090|Fitbit
16959|NCT02950090|Accelerometer
16960|NCT02950090|remote coaching
16961|NCT02950064|BRCA
16962|NCT02950064|BRCA1
16963|NCT02950064|BRCA2
16964|NCT02950064|Pancreatic cancer
16965|NCT02950064|Ovarian cancer
16966|NCT02950064|Castrate resistant prostate cancer
16967|NCT02950064|Triple negative breast cancer
16968|NCT02950064|Breast cancer
16969|NCT02950064|DNA repair mutation-positive solid tumors
16970|NCT02950051|CLL
16971|NCT02950038|Lung Cancer, Nonsmall Cell
16972|NCT02950038|Advanced non-small cell lung cancer
16973|NCT02950038|NSCLC
16974|NCT02950038|Stage IV non-small cell lung cancer
16975|NCT02950038|Recurrent non-small cell lung cancer
16976|NCT02950038|Ibrutinib
16977|NCT02950038|PCI-32765
16978|NCT02950038|Imbruvica
16979|NCT02950038|Nivolumab
16980|NCT02950038|BMS-936558
16981|NCT02950038|Opdivo
16982|NCT02950012|Healthy
16983|NCT02950012|Bloating
16984|NCT02950012|Abdominal Discomfort
16985|NCT02950012|Gas
16986|NCT02950012|Probiotic
16987|NCT02950012|Bacillus Subtillis
16988|NCT02949999|Calcineurin inhibitor
16989|NCT02949999|Voclosporin
16990|NCT02949973|lupus nephritis
16991|NCT02949973|calcineurin inhibitors
16992|NCT02949973|voclosporin
16993|NCT02949960|Eczema
16994|NCT02949960|Dermatitis
16995|NCT02949960|Skin Diseases
16996|NCT02949960|Skin Diseases, Genetic
16997|NCT02949960|Dermatitis, Atopic
16998|NCT02949960|Skin Diseases, Eczematous
16999|NCT02949960|Hypersensitivity
17000|NCT02949960|Immune System Diseases
17001|NCT02949947|Malignant Neoplasms of Mesothelial and Soft Tissue
17002|NCT02949947|Gastrointestinal Stromal Tumor
17003|NCT02949947|GIST
17004|NCT02949947|Iron-deficiency anemia
17005|NCT02949947|Ferric Carboxymaltose
17006|NCT02949947|Injectafer
17007|NCT02949947|Iron supplement
17008|NCT02949947|Health Questionnaire
17009|NCT02949947|Survey
17010|NCT02949908|Relapsing Remitting Multiple Sclerosis
17011|NCT02949908|Rebif
17012|NCT02949908|Treatment Satisfaction Questionnaire for Medication Version II
17013|NCT02949908|Multiple Sclerosis International Quality of Life Questionnaire
17014|NCT02949882|Diarrhea
17015|NCT02949882|Constipation
17016|NCT02949882|Elderly
17017|NCT02949882|Nursing Homes
17018|NCT02949882|Probiotics
17019|NCT02949882|Bowel Habits
17020|NCT02949830|RNAi therapeutic
17021|NCT02949830|Porphyria
17022|NCT02949830|AIP
17023|NCT02949830|Heme/Haem Arginate
17024|NCT02949791|cisplatin
17025|NCT02949791|HIPEC
17026|NCT02949791|Intra abdominal pressure
17027|NCT02949791|tissue drug concentration
17028|NCT02949713|HIV
17029|NCT02949713|infant feeding
17030|NCT02949713|mHealth
17031|NCT02949713|behavioural intervention
17032|NCT02949700|metformin
17033|NCT02949700|head and neck cancer
17034|NCT02949687|ileal interposition
17035|NCT02949687|metabolic surgery
17036|NCT02949687|diabetes
17037|NCT02949687|sympathectomy
17038|NCT02949687|denervation
17039|NCT02949648|Electronic cigarette
17040|NCT02949635|Aged
17041|NCT02949635|Patient readmission
17042|NCT02949635|Geriatric Assessment
17043|NCT02949635|Mortality
17044|NCT02949622|Metabolic syndrome
17045|NCT02949622|Mediterranean diet
17046|NCT02949622|Stress
17047|NCT02949622|quality of life
17048|NCT02949622|psychological factors
17049|NCT02949609|stroke
17050|NCT02949609|mirror therapy
17051|NCT02949609|neurorehabilitation
17052|NCT02949596|quality of sexual life
17053|NCT02949596|intensity-modulated radiotherapy
17054|NCT02949596|concurrent chemoradiotherapy
17055|NCT02949583|DENTAL PLAQUE
17056|NCT02949583|MEDICINAL PLANTS
17057|NCT02949583|GINGIVITIS
17058|NCT02949505|Prehabilitation
17059|NCT02949505|liver transplant
17060|NCT02949505|functional capacity
17061|NCT02949505|exercise
17062|NCT02949492|Liver
17063|NCT02949492|Transplant
17064|NCT02949492|Immunosuppression
17065|NCT02949479|sex offenses
17066|NCT02949466|knee osteoarthritis
17067|NCT02949466|triamcinolone
17068|NCT02949466|therapeutic effects
17069|NCT02949453|suicide
17070|NCT02949453|prevention
17071|NCT02949440|Laparoscopic right Hemicolectomy
17072|NCT02949440|Caudal-to-cranial Approach
17073|NCT02949427|Microbiome
17074|NCT02949427|Mycobiome
17075|NCT02949427|Virome
17076|NCT02949427|Pediatric leukemia
17077|NCT02949427|Pediatric bone marrow transplantation
17078|NCT02949414|Malacia
17079|NCT02949414|Stenosis
17080|NCT02949414|Trachea
17081|NCT02949414|Transplant
17082|NCT02949349|Systemic Lupus Erythematosus
17083|NCT02949349|Lupus Nephritis
17084|NCT02949349|Mycophenolate Mofetil
17085|NCT02949349|Azathioprine
17086|NCT02949349|Maintenance Therapy
17087|NCT02949349|Prednisolone
17088|NCT02949349|Serum albumin
17089|NCT02949349|Serum creatinine
17090|NCT02949349|Spot urine protein/creatinine ratio
17091|NCT02949323|children
17092|NCT02949323|renal stone
17093|NCT02949323|metabolic evaluation
17094|NCT02949323|Mutational analysis
17095|NCT02948491|Complementary Therapies
17096|NCT02948491|Neonate Intensive Care Units (NICU)
17097|NCT02948491|Child Development
17098|NCT02948491|Infants Premature
17099|NCT02948478|precariousness
17100|NCT02948478|care pathways
17101|NCT02948465|Neutrophil Extracellular Traps
17102|NCT02948452|anorexia nervosa
17103|NCT02948452|anxiety
17104|NCT02948452|reward
17105|NCT02948452|recurrence
17106|NCT02948452|magnetic resonance imaging
17107|NCT02948439|pregnancy
17108|NCT02948439|cardiovascular
17109|NCT02948439|nervous system
17110|NCT02948439|exercise
17111|NCT02948426|Immunotherapy
17112|NCT02948426|Adoptive Cell Therapy
17113|NCT02948426|Carcinomatosis
17114|NCT02948426|CA125
17115|NCT02948413|Traumatic Stress
17116|NCT02948413|Oncology
17117|NCT02948413|Lymphoma
17118|NCT02949271|epidural analgesia
17119|NCT02949258|gastric cancer
17120|NCT02949258|Borrmann type 4
17121|NCT02949258|Neoadjuvant chemotherapy
17122|NCT02949258|Intra-arterial administration
17123|NCT02949245|Spine
17124|NCT02949245|Surgery
17125|NCT02949245|Prospective Studies
17126|NCT02949245|Deformity
17127|NCT02949245|Neurologic deficit
17128|NCT02949180|Atrial fibrillation
17129|NCT02949180|Rhythm monitoring
17130|NCT02949180|Cardiovascular App
17131|NCT02949180|m-health
17132|NCT02949167|Nurse-led follow-up after breast cancer
17133|NCT02949115|Red beetroot
17134|NCT02949115|Dietary Nitrate
17135|NCT02949115|Polyphenols
17136|NCT02949115|Endothelial Function
17137|NCT02949115|High-Fat Meal
17138|NCT02949115|Overweight
17139|NCT02949115|Obesity
17140|NCT02949115|Aging
17141|NCT02949115|Cardiometabolic
17142|NCT02949089|safety
17143|NCT02949089|tolerability
17144|NCT02949089|rising multiple doses
17145|NCT02949089|ACH04
17146|NCT02949089|adult
17147|NCT02949089|male
17148|NCT02949063|school lunch
17149|NCT02949063|occupational therapy
17150|NCT02949024|Diabetes mellitus
17151|NCT02949024|Diabetic retinopathy
17152|NCT02949024|Microneedle
17153|NCT02949024|Microinjection
17154|NCT02949024|Triamcinolone
17155|NCT02949024|Choroid
17156|NCT02949024|Choroid Injection
17157|NCT02949024|Aflibercept
17158|NCT02949024|Suprachoroidal
17159|NCT02949011|Tamiflu®
17160|NCT02949011|Influenza
17161|NCT02949011|Oseltamivir
17162|NCT02949011|Flu
17163|NCT02949011|S-033188
17164|NCT02948985|Metastatic colorectal cancer
17165|NCT02948985|Cetuximab
17166|NCT02948985|CTCs
17167|NCT02948985|ct DNA
17168|NCT02948972|deep infiltrating endometriosis
17169|NCT02948972|endometriosis surgery
17170|NCT02948972|In vitro fertilization
17171|NCT02948946|lung cancer
17172|NCT02948946|pancreatic cancer
17173|NCT02948933|Dengue Fever
17174|NCT02948933|Dengue Hemorrhagic Fever
17175|NCT02948933|Dengvaxia®
17176|NCT02948920|ephedrine
17177|NCT02948920|core temperature
17178|NCT02948920|tympanic temperature
17179|NCT02948920|heat loss
17180|NCT02948920|spinal anesthesia
17181|NCT02948920|neuraxial
17182|NCT02948920|hypothermia
17183|NCT02948920|shivering
17184|NCT02948881|Osteoporosis
17185|NCT02948881|bisphosphonates
17186|NCT02948881|bone
17187|NCT02948868|Methamphetamine
17188|NCT02948868|MRI
17189|NCT02948868|South Africa
17190|NCT02948868|Contingency Management
17191|NCT02948855|Long non-coding RNA（LncRNA）
17192|NCT02948855|Thymoma
17193|NCT02948855|Autoimmune disease
17194|NCT02948855|Notch2 Signaling pathway
17195|NCT02948855|Regulatory B cell（Breg）
17196|NCT02948829|Drug therapy
17197|NCT02948803|intervention
17198|NCT02948803|mHealth
17199|NCT02948803|physical activity
17200|NCT02948803|active transport
17201|NCT02948803|smartphone
17202|NCT02948803|application
17203|NCT02948764|breast cancer
17204|NCT02948764|vacuum-assisted biopsy
17205|NCT02948764|pathological complete response
17206|NCT02948712|distress
17207|NCT02948712|survivorship
17208|NCT02948712|transition period
17209|NCT02948699|nasopharyngeal carcinoma
17210|NCT02948699|intensity-modulated radiotherapy
17211|NCT02948699|nutrition support
17212|NCT02948699|nutrition assessment
17213|NCT02948686|dentin bonding agents
17214|NCT02948686|tooth sensitivity
17215|NCT02948686|composite resin restoration
17216|NCT02948673|type 2 diabetes
17217|NCT02948673|mitochondrial reactive oxygen species production
17218|NCT02948673|oxidative stress
17219|NCT02948673|antioxidant treatment
17220|NCT02948673|glutathione supplementation
17221|NCT02948621|Endoscopic sleeve gastroplasty
17222|NCT02948621|Excess weight loss
17223|NCT02948621|Quality of life
17224|NCT02948608|spondyloarthropathy
17225|NCT02948608|ankylosing spondylitis
17226|NCT02948608|spinal diseases
17227|NCT02948608|spondylitis
17228|NCT02948608|spondylarthritis
17229|NCT02948608|psoriasis
17230|NCT02948608|uveitis
17231|NCT02948608|joint diseases
17232|NCT02948582|Chronic Obstructive Pulmonary Disease
17233|NCT02948582|COPD
17234|NCT02948582|Emphysema
17235|NCT02948582|Chronic bronchitis
17236|NCT02948569|Obesity
17237|NCT02948569|Hyperlipidemia
17238|NCT02948569|Impaired fasting glucose
17239|NCT02948569|Insulin resistance
17240|NCT02948569|Hypertension
17241|NCT02948504|Unruptured Intracranial Aneurysm
17242|NCT02948504|Small aneurysms
17243|NCT02948504|Risk of rupture
17244|NCT02948504|Natural history
17245|NCT02948504|Endovascular Coiling
17246|NCT02948504|Surgical clipping
17247|NCT02948335|Microbial communities
17248|NCT02948335|Hospital environment
17249|NCT02948335|Disinfection
17250|NCT02948335|Adenosine triphosphate measures
17251|NCT02948335|Bioburden
17252|NCT02948322|Acromegaly,
17253|NCT02948322|water retention
17254|NCT02948322|myocardial fibrosis
17255|NCT02948322|left ventricular hypertrophy
17256|NCT02948322|left ventricular dysfunction
17257|NCT02948309|Primary diagnosis
17258|NCT02948309|Relapse
17259|NCT02948257|Vessel closure
17260|NCT02948257|Antegrade access
17261|NCT02948257|Femoral arteriotomy
17262|NCT02948257|Peripheral endovascular interventions
17263|NCT02948244|fshd
17264|NCT02948244|creatine monohydrate
17265|NCT02948244|children
17266|NCT02948244|pediatrics
17267|NCT02948244|Facio-Scapulo-Humeral Dystrophy
17268|NCT02948205|Infertility, TU-LESS, 3D laparoscopy
17269|NCT02948192|Preterm Delivery
17270|NCT02948192|Preterm Birth
17271|NCT02948192|Vaginal Microbiome
17272|NCT02948192|Microbiome
17273|NCT02948192|Gut Microbiome
17274|NCT02948192|African American
17275|NCT02948192|Metabolomics
17276|NCT02948192|Pregnancy
17277|NCT02948166|remote endarterectomy
17278|NCT02948166|Angioplasty with stenting of the superficial femoral artery
17279|NCT02948140|Subdiaphragmatic infarction
17280|NCT02948101|Malignant Neoplasm of Female Genital Organs
17281|NCT02948101|Epithelial ovarian cancer
17282|NCT02948101|Fallopian tube cancer
17283|NCT02948101|Primary peritoneal cancer
17284|NCT02948101|PD 0360324
17285|NCT02948101|Cyclophosphamide
17286|NCT02948101|Cytoxan
17287|NCT02948101|Neosar
17288|NCT02948101|Pharmacokinetic testing
17289|NCT02948101|PK
17290|NCT02948101|Pharmacodynamic testing
17291|NCT02948101|PD
17292|NCT02948088|Tenosynovial Giant Cell Tumors
17293|NCT02948088|Disease registry
17294|NCT02948088|Routine clinical practice
17295|NCT02948088|Real World Evidence
17296|NCT02948062|ALD
17297|NCT02948062|Newborn Screening
17298|NCT02948049|Accelerometer
17299|NCT02948049|Spinal Cord Stimulator
17300|NCT02948049|Peripheral Nerve Stimulator
17301|NCT02948049|Physical Function
17302|NCT02947997|Healthy Volunteers
17303|NCT02947984|sphenoid region
17304|NCT02947984|parasellar area
17305|NCT02947984|photon radiation therapy
17306|NCT02947984|proton radiation therapy
17307|NCT02947958|teleconsultation
17308|NCT02947958|urology
17309|NCT02947958|primary care
17310|NCT02947958|tertiary care
17311|NCT02947932|acute pancreatitis
17312|NCT02947932|post-ERCP
17313|NCT02947932|endoscopy
17314|NCT02947919|Perioperative Period
17315|NCT02947919|Music
17316|NCT02947906|Gait
17317|NCT02947906|Loading
17318|NCT02947906|Multiple Sclerosis
17319|NCT02947906|Plantar Pressure
17320|NCT02947893|Nilotinib in Alzheimer's disease
17321|NCT02947880|autism, Bumetanide
17322|NCT02947854|Vaccine
17323|NCT02947854|Photochemical Internalisation
17324|NCT02947854|Immune Response
17325|NCT02947854|Peptide vaccine
17326|NCT02947854|Anti cancer vaccine
17327|NCT02947828|Diabetes Mellitus, Type 2
17328|NCT02947828|Polyneuropathies, Diabetic
17329|NCT02947750|Hypertension
17330|NCT02947750|Kidney Disorder
17331|NCT02947750|Nephrology
17332|NCT02947750|Physiology
17333|NCT02947737|Skin graft
17334|NCT02947724|chocolate cyst
17335|NCT02947724|laparoscopy
17336|NCT02947724|surgicel
17337|NCT02947711|E2027
17338|NCT02947711|Healthy participants
17339|NCT02947711|Pharmacokinetics
17340|NCT02947698|acute kidney injury
17341|NCT02947698|weekend admission
17342|NCT02947698|mortality
17343|NCT02947685|breast cancer
17344|NCT02947685|malignant tumor of the breast
17345|NCT02947685|HER2+
17346|NCT02947685|HR+
17347|NCT02947685|metastatic breast cancer
17348|NCT02947659|Body mass index
17349|NCT02947659|Academic stress
17350|NCT02947659|Musculoskeletal disorders
17351|NCT02947607|Human gut microbiome
17352|NCT02947607|Colorectal cancer
17353|NCT02947607|Colorectal adenoma
17354|NCT02947607|Gut bacteria
17355|NCT02947607|Metagenomics
17356|NCT02947607|Metatranscriptomics
17357|NCT02947581|subarachnoid neurocysticercosis
17358|NCT02947581|albendazole
17359|NCT02947581|praziquantel
17360|NCT02947568|Non-alcoholic Fatty Liver Disease
17361|NCT02947568|Chronic Kidney Disease
17362|NCT02947568|Diabetes Mellitus
17363|NCT02947568|Cross-sectional
17364|NCT02947555|diabetes mellitus
17365|NCT02947555|atherosclerosis
17366|NCT02947555|AGE
17367|NCT02947555|lens autofluorescence
17368|NCT02947529|Hemiarthroplasty
17369|NCT02947529|Intramedullary nail
17370|NCT02947529|Tranexamic acid
17371|NCT02947529|Transfusion
17372|NCT02947516|Endoscopic Ultrasound-Guided Fine Needle Aspiration
17373|NCT02947516|liver
17374|NCT02947516|biopsy
17375|NCT02947516|pain
17376|NCT02947503|Gestational Diabetes
17377|NCT02947503|Insulin Resistance
17378|NCT02947503|Metformin
17379|NCT02947503|Hyperinsulinaemia
17380|NCT02947503|Prevention of Complications
17381|NCT02947503|Long Term Study
17382|NCT02947503|Mother and Child
17383|NCT02947503|Health Benefits
17384|NCT02947490|Blood pressure monitoring
17385|NCT02947490|self BP monitoring
17386|NCT02947490|self BP management
17387|NCT02947438|Renal anemia
17388|NCT02947438|Haemodialysis
17389|NCT02947438|Maintenance phase
17390|NCT02947412|sleeve gastrectomy
17391|NCT02947412|long-term follow-up
17392|NCT02947412|gastroesophageal reflux disease after sleeve
17393|NCT02947412|revisional surgery
17394|NCT02947399|Thyroid
17395|NCT02947399|I-124
17396|NCT02947399|Thyroid hormone Withdrawal
17397|NCT02947373|brain tumor
17398|NCT02947373|children
17399|NCT02947321|Radiofrequency ablation
17400|NCT02947308|Anxiety
17401|NCT02947308|Depression
17402|NCT02947243|Virtual reality
17403|NCT02947243|Immersive distraction
17404|NCT02947243|Oculus rift
17405|NCT02947243|Virtual world
17406|NCT02947243|Virtual environment
17407|NCT02947243|Procedural pain
17408|NCT02947243|Procedural anxiety
17409|NCT02947243|Acute pain
17410|NCT02947243|Pain management
17411|NCT02947243|Anxiety
17412|NCT02947243|Children, Child
17413|NCT02947243|Kid, Kids
17414|NCT02947243|Pediatric, Pediatrics
17415|NCT02947243|Young children
17416|NCT02947243|Burns
17417|NCT02947243|Burn injuries
17418|NCT02947243|Burn unit
17419|NCT02947243|Physiotherapy
17420|NCT02947243|Physical therapy
17421|NCT02947243|Burn dressing
17422|NCT02947243|Dressing change
17423|NCT02947243|Non-pharmacological, nonpharmacological
17424|NCT02947243|Clinical Research
17425|NCT02947243|Nursing Practice
17426|NCT02947230|Mobility
17427|NCT02947230|Aging
17428|NCT02947230|Knowledge Translation
17429|NCT02947230|Physical Activity
17430|NCT02947217|Immunology
17431|NCT02947217|Pregnancy
17432|NCT02947217|Implantation Rate
17433|NCT02947217|Fertilization in Vitro
17434|NCT02947204|Bronchiolitis
17435|NCT02947204|Length of Hospital Stay
17436|NCT02947204|Clinical Trial
17437|NCT02947204|Oxygen Saturation Monitoring
17438|NCT02947152|HKT288
17439|NCT02947152|CDH6
17440|NCT02947152|ADC
17441|NCT02947152|maytansine
17442|NCT02947152|epithelial ovarian cancer
17443|NCT02947152|renal cell carcinoma
17444|NCT02947152|RCC
17445|NCT02947126|cystic fibrosis
17446|NCT02947126|mucociliary clearance
17447|NCT02947126|CFTR
17448|NCT02947113|cancer
17449|NCT02947100|Sickle Cell Disease
17450|NCT02947100|omega-3 fatty acids
17451|NCT02947100|Docosahexaenoic Acid (DHA)
17452|NCT02947100|Eicosapentaenoic Acid (EPA)
17453|NCT02947087|Islet autotransplantation
17454|NCT02947087|Alpha1 anti trypsin
17455|NCT02947074|Yoga
17456|NCT02947074|Meditation
17457|NCT02947074|Glutathione
17458|NCT02947074|Catecholamine
17459|NCT02947074|polysomnography
17460|NCT02947061|Advanced Breast Cancer,first treatment, S1, Capecitabine
17461|NCT02947035|thyroid cancer
17462|NCT02947035|thyroid nodule
17463|NCT02947035|thyroidectomy
17464|NCT02947035|personalized medicine
17465|NCT02947022|gadolinium
17466|NCT02947022|deposition
17467|NCT02947022|GBCA
17468|NCT02947022|Extremity Pain
17469|NCT02947022|Skin Pain
17470|NCT02947022|Chest Wall Pain
17471|NCT02946944|Pulmonary Embolism
17472|NCT02946944|sildenafil
17473|NCT02946944|oral anticoagulation therapy
17474|NCT02946918|levothyroxine
17475|NCT02946853|Atrial Fibrillation
17476|NCT02946853|CRT
17477|NCT02946853|AV Junction Ablation
17478|NCT02946853|LVESV
17479|NCT02946827|FODMAPs diet
17480|NCT02946827|micro-macro nutrients intake
17481|NCT02946827|IBS (Irritable Bowel Syndrome)
17482|NCT02946814|essential oils
17483|NCT02946814|microscope, colfocal
17484|NCT02946814|dental plaque
17485|NCT02946801|Biofilms
17486|NCT02946801|essential oils
17487|NCT02946801|alcohol
17488|NCT02946801|microscopy, confocal
17489|NCT02946801|mouthwashes
17490|NCT02946775|septicemia
17491|NCT02946775|bacteremia
17492|NCT02946775|pneumonia
17493|NCT02946775|meningitis
17494|NCT02946762|HIV
17495|NCT02946762|TB
17496|NCT02946762|Antiretroviral Treatment
17497|NCT02946762|Anti-tuberculosis Treatment
17498|NCT02946762|HIV Counselling and Testing
17499|NCT02946762|Treatment as Prevention
17500|NCT02946749|Scar pregnancy
17501|NCT02946749|Placenta planting abnormal disease
17502|NCT02946749|Early diagnosis
17503|NCT02946749|Individualized treatment
17504|NCT02946736|Sleep
17505|NCT02946736|Physical Health
17506|NCT02946736|Psychological Health
17507|NCT02946736|Well-Being
17508|NCT02946736|Employee
17509|NCT02946736|Actigraphy
17510|NCT02946710|Alzheimer disease
17511|NCT02946710|Alzheimer's disease, biomarkers
17512|NCT02946710|p75NTR-ECD
17513|NCT02946697|Chinese
17514|NCT02946697|cancer survivors
17515|NCT02946697|Quality of Life
17516|NCT02946697|Social Support
17517|NCT02946658|COPD, Emphysema
17518|NCT02946619|Chinese breast cancer survivors
17519|NCT02946619|expressive writing
17520|NCT02946554|Acute-On-Chronic Liver Failure
17521|NCT02946554|ACLF
17522|NCT02946541|DA-1229
17523|NCT02946541|evogliptin
17524|NCT02946541|DPP-IV inhibitor
17525|NCT02946541|Suganon
17526|NCT02946541|DPP-4 inhibitor
17527|NCT02946515|Pediatrics
17528|NCT02946489|cannabis
17529|NCT02946489|mindfulness based relapse prevention
17530|NCT02946489|motivational enhancement therapy
17531|NCT02946437|severe SAH
17532|NCT02946437|prevention of vasospasm and/ or brain oedema
17533|NCT02946437|Sevoflurane
17534|NCT02946437|Postconditioning
17535|NCT02946411|Hyperglycemia
17536|NCT02946385|meningococcal disease
17537|NCT02946385|meningitis
17538|NCT02946385|booster
17539|NCT02946385|antibody persistence
17540|NCT02946372|retina surgery
17541|NCT02946372|macula
17542|NCT02946372|macular hole
17543|NCT02946372|internal limiting membrane (ILM)
17544|NCT02946372|vitrectomy
17545|NCT02946372|autologous transplantation
17546|NCT02946346|Human papillomaviruses
17547|NCT02946346|Clearance
17548|NCT02946346|Kinetics
17549|NCT02946346|Ecology
17550|NCT02946346|Bacterial vaginosis
17551|NCT02946346|Immune response
17552|NCT02946346|Microbiota
17553|NCT02946333|Multiple Myeloma
17554|NCT02946333|autologous stem cell transplant (ASCT)
17555|NCT02946333|QoLMMBuS
17556|NCT02946333|healthcare costs
17557|NCT02946320|PCI, bioabsorbable scaffold
17558|NCT02946281|self-management
17559|NCT02946281|health behavior
17560|NCT02946281|cardiac disease
17561|NCT02946281|habits
17562|NCT02946281|lifestyle
17563|NCT02946255|Psychosis
17564|NCT02946255|Psychosis NOS
17565|NCT02946255|Schizophrenia
17566|NCT02946255|Hospital discharge
17567|NCT02946255|Inpatient psychiatry
17568|NCT02945189|Pregnancy
17569|NCT02945176|Boston Keratoprosthesis
17570|NCT02945150|hemodialysis
17571|NCT02945150|peritoneal dialysis
17572|NCT02945150|renal failure
17573|NCT02945150|kidney transplant
17574|NCT02946190|Acellular pertussis vaccines Genetically-detoxified pertussis toxin Adolescents
17575|NCT02946177|Immunology
17576|NCT02946177|Pregnancy
17577|NCT02946177|Implantation Rate
17578|NCT02946177|Fertilization in Vitro
17579|NCT02946177|Oocyte donor egg recipient
17580|NCT02946151|Epilepsy
17581|NCT02946151|Seizure monitoring
17582|NCT02946151|Electroencephalography
17583|NCT02946138|Hepatocellular Carcinoma
17584|NCT02946138|carbon-ion radiotherapy
17585|NCT02946138|GM-CSF
17586|NCT02946138|immunotherapy
17587|NCT02946086|motor skill learning, visuo-spatial attention
17588|NCT02946047|HIV
17589|NCT02946047|ART
17590|NCT02946047|Antiretroviral
17591|NCT02946047|Therapy
17592|NCT02946047|Resevoir
17593|NCT02946047|Cure
17594|NCT02946034|CKD
17595|NCT02946034|HCV
17596|NCT02946021|Lymphedema
17597|NCT02946021|Cancer
17598|NCT02946021|Head Cancer
17599|NCT02946021|Neck Cancer
17600|NCT02945982|Portal Hypertension
17601|NCT02945982|Fuzheng Huayu
17602|NCT02945982|Hepatitis B
17603|NCT02945969|dietary sodium
17604|NCT02945969|albuminuria
17605|NCT02945969|chronic kidney disease
17606|NCT02945956|Portal Hypertension
17607|NCT02945956|Fuzheng Huayu
17608|NCT02945956|Hepatitis B
17609|NCT02945930|Enbucrilate
17610|NCT02945930|Esophageal and Gastric Varices
17611|NCT02945930|Endoscopy
17612|NCT02945930|Safety
17613|NCT02945930|Efficacy
17614|NCT02945891|mass screening
17615|NCT02945891|coverage
17616|NCT02945891|self-sampling
17617|NCT02945891|clinical validity
17618|NCT02945878|radiotherapy, oral mucositis,oral mucosa protection
17619|NCT02945839|Migraine
17620|NCT02945839|emergency department
17621|NCT02945826|urokinase plasminogen activator receptor
17622|NCT02945826|positron emission tomography
17623|NCT02945826|glioblastoma multiforme
17624|NCT02945813|Prostate Cancer
17625|NCT02945813|Prostate Cancer after Prostatectomy
17626|NCT02945813|Phase II Trial
17627|NCT02945813|Salvage Radiotherapy
17628|NCT02945813|Metformin
17629|NCT02945800|relapsed
17630|NCT02945800|refractory
17631|NCT02945800|soft tissue
17632|NCT02945800|bones and joints
17633|NCT02945800|non-rhabdomyosarcoma soft tissue sarcoma
17634|NCT02945800|pediatric
17635|NCT02945787|Spanish speaking
17636|NCT02945787|self-help
17637|NCT02945787|tobacco abstinence
17638|NCT02945787|public health
17639|NCT02945787|Forever Free
17640|NCT02945787|Stop Smoking for Good
17641|NCT02945774|PET
17642|NCT02945774|MRI
17643|NCT02945774|Inflammation
17644|NCT02945774|Microglia
17645|NCT02945774|FEPPA
17646|NCT02945748|pediatric
17647|NCT02945748|cardiac output
17648|NCT02945748|fluid responsiveness
17649|NCT02945748|critically ill
17650|NCT02945748|hemodynamic monitoring
17651|NCT02945735|depression
17652|NCT02945735|cognitive bias modification
17653|NCT02945735|MDD
17654|NCT02945735|major depressive disorder
17655|NCT02945735|attention bias modification treatment
17656|NCT02945722|Hemodialysis
17657|NCT02945722|S. Aureus
17658|NCT02945722|Decolonization
17659|NCT02945722|Persistent carriage
17660|NCT02945709|PTSD
17661|NCT02945709|attention training
17662|NCT02945709|cognitive bias modification
17663|NCT02945696|nerve block
17664|NCT02945696|laparoscopy
17665|NCT02945696|anesthesia
17666|NCT02945683|atopic dermatitis, probiotics, vitamin D3, L. reuteri
17667|NCT02945644|obstructive sleep apnea
17668|NCT02945644|trazodone
17669|NCT02945644|positive airway pressure
17670|NCT02945644|adherence
17671|NCT02945631|HPV
17672|NCT02945631|Induction Chemotherapy
17673|NCT02945631|De-Intensified Chemoradiotherapy
17674|NCT02945631|Oropharynx Cancer
17675|NCT02945618|cryotherapy
17676|NCT02945618|physical therapy
17677|NCT02945592|Hemispatial Neglect
17678|NCT02945592|cueing
17679|NCT02945592|egocentric-allocentric
17680|NCT02945592|early rehabilitation
17681|NCT02945592|parietal tDCS
17682|NCT02945579|Breast Cancer
17683|NCT02945579|Surveillance
17684|NCT02945579|Breast biopsy
17685|NCT02945579|Questionnaires
17686|NCT02945579|Surveys
17687|NCT02945540|Gestational diabetes
17688|NCT02945540|Patient education
17689|NCT02945540|Patient Satisfaction
17690|NCT02945514|Healthy
17691|NCT02945514|Diet
17692|NCT02945514|Microbiome
17693|NCT02945514|Personalized
17694|NCT02945514|Custom
17695|NCT02945475|functional magnetic resonance imaging
17696|NCT02945475|eating behavior
17697|NCT02945475|sugar
17698|NCT02945475|fructose
17699|NCT02945449|Wharton jelly mesenchymal stem cells
17700|NCT02945449|Erectile Dysfunction
17701|NCT02945449|Diabetes
17702|NCT02945397|Return to work
17703|NCT02945397|Work rehabilitation
17704|NCT02945397|Sick-leave
17705|NCT02945384|family well-being
17706|NCT02945332|exercise
17707|NCT02945332|activity
17708|NCT02945332|behavior
17709|NCT02945306|Sleep Disordered Breathing
17710|NCT02945306|Adenotonsillectomy
17711|NCT02945306|Child
17712|NCT02945293|Pain
17713|NCT02945293|Elderly
17714|NCT02945293|Aged
17715|NCT02945293|Opioid
17716|NCT02945293|Cognition
17717|NCT02945293|Side-effects
17718|NCT02945293|Alcohol
17719|NCT02945293|Alcohol Use Disorder (AUD)
17720|NCT02945293|Older
17721|NCT02945280|apixaban
17722|NCT02945280|factor Xa inhibitors
17723|NCT02945280|antithrombotic agent
17724|NCT02945280|deep vein thrombosis
17725|NCT02945280|upper extremity
17726|NCT02945267|Pancreatic Cancer
17727|NCT02945267|Unresectable
17728|NCT02945267|Maintenance Treatment
17729|NCT02945254|sleep onset latency
17730|NCT02945254|sleep quality
17731|NCT02945254|insomnia
17732|NCT02945228|Paritaprevir
17733|NCT02945228|Genotype 2
17734|NCT02945228|Hepatitis C Virus (HCV)
17735|NCT02945228|Ombitasvir
17736|NCT02945228|Ritonavir
17737|NCT02945085|older adults
17738|NCT02945085|family caregivers
17739|NCT02945085|Medicare Advantage beneficiaries
17740|NCT02945072|Child Behavior
17741|NCT02945072|Problem Behavior
17742|NCT02945072|postoperative behaviour problems
17743|NCT02945059|Liver regeneration
17744|NCT02945059|portal vein embolization
17745|NCT02945059|gelatin powder
17746|NCT02945059|liver surgery
17747|NCT02945059|hepatectomy
17748|NCT02945033|Pi3k mutation
17749|NCT02945033|Aspirin
17750|NCT02944968|Interventional
17751|NCT02944968|Radiofrequency Ablation
17752|NCT02944968|Paroxysmal Atrial Fibrillation
17753|NCT02944929|Spastic hemiparesis
17754|NCT02944929|Stroke
17755|NCT02944929|Self-rehabilitation
17756|NCT02944929|Botulinum Toxin Injections
17757|NCT02944903|audit
17758|NCT02944903|Lung cancer
17759|NCT02944903|screening practice
17760|NCT02944903|Egypt
17761|NCT02944851|Blood donors
17762|NCT02944851|blood donation
17763|NCT02944851|traumatic blood loss
17764|NCT02944851|Trauma
17765|NCT02944838|older adults
17766|NCT02944838|physical activity
17767|NCT02944838|built environment
17768|NCT02944825|Urolithiasis
17769|NCT02944825|UTI
17770|NCT02944786|Chronic pain
17771|NCT02944786|Adolescents
17772|NCT02944786|School nurse
17773|NCT02944773|newborn
17774|NCT02944773|facilitated tucking
17775|NCT02944773|position
17776|NCT02944773|weight
17777|NCT02944773|stress
17778|NCT02944747|Gestational age, Preterm birth, LMP, Bangladesh
17779|NCT02944734|Candesartan
17780|NCT02944734|Amlodipine
17781|NCT02944734|Hypertension
17782|NCT02944734|Vascular Diseases
17783|NCT02944734|Cardiovascular Diseases
17784|NCT02944734|Antihypertensive Agents
17785|NCT02944734|Vasodilator Agents
17786|NCT02944734|Angiotensin II Type 1 Receptor Blockers
17787|NCT02944734|Angiotensin Receptor Antagonists
17788|NCT02944734|Calcium Channel Blockers
17789|NCT02944721|Neuropathic Pain
17790|NCT02944708|maintenance chemotherapy
17791|NCT02944695|audit
17792|NCT02944695|infection control
17793|NCT02944695|bronchoscopy unit
17794|NCT02944695|Egypt
17795|NCT02944682|Obstetrics
17796|NCT02944682|Pregnancy Outcomes
17797|NCT02944682|Pediatrics
17798|NCT02944682|Atherosclerosis
17799|NCT02944682|Cancer
17800|NCT02944682|Cardiovascular Disease
17801|NCT02944682|Public Health
17802|NCT02944682|Environmental Air Pollutants
17803|NCT02944656|Perioperative pain
17804|NCT02944656|Outpatient surgery
17805|NCT02944656|Obstetrics/gynecology
17806|NCT02944656|Pain management
17807|NCT02944630|quality of life
17808|NCT02944630|psychotherapy
17809|NCT02944630|psoriasis
17810|NCT02944630|treatments
17811|NCT02944578|Cancer
17812|NCT02944578|HIV
17813|NCT02944578|Oncology
17814|NCT02944578|Infectious Diseases
17815|NCT02944578|HPV
17816|NCT02944578|Preventive Medicine
17817|NCT02944539|Mitochondrial DNA copy number
17818|NCT02944539|Gastric cancer
17819|NCT02944526|suprascapular nerve
17820|NCT02944500|Brain
17821|NCT02944500|Liraglutide
17822|NCT02944500|MRI
17823|NCT02944487|safety
17824|NCT02944487|pharmacokinetics
17825|NCT02944474|Pharmacokinetics
17826|NCT02944474|Safety
17827|NCT02944448|Osteoarthritis
17828|NCT02944448|Hip
17829|NCT02944448|Knee
17830|NCT02944448|CR485
17831|NCT02944448|Analgesic
17832|NCT02944448|Kappa opioid
17833|NCT02944435|Glutaminase Inhibitor
17834|NCT02944435|Glutaminase
17835|NCT02944435|CB-839
17836|NCT02944396|Common Terminology Criteria for Adverse Events (CTCAE)
17837|NCT02944396|Immuno Oncology
17838|NCT02944396|veliparib
17839|NCT02944396|non-small cell lung cancer
17840|NCT02944396|Poly (ADP) ribose polymerase (PARP)
17841|NCT02944396|Platinum Doublet Chemotherapy
17842|NCT02944396|paclitaxel
17843|NCT02944396|nivolumab
17844|NCT02944396|metastatic
17845|NCT02944396|Response Evaluation Criteria In Solid Tumors (RECIST)
17846|NCT02944396|pemetrexed
17847|NCT02944396|Eastern Cooperative Oncology Group (ECOG)
17848|NCT02944396|carboplatin
17849|NCT02944383|Hypertriglycerides
17850|NCT02944344|breast cancer
17851|NCT02944344|stage 4
17852|NCT02944344|metastatic
17853|NCT02944344|hospice
17854|NCT02944344|palliative care
17855|NCT02944344|end of life
17856|NCT02944344|advance directive
17857|NCT02944344|oncology
17858|NCT02944344|caregiver
17859|NCT02944344|provider
17860|NCT02944344|coping
17861|NCT02944344|support
17862|NCT02944344|online
17863|NCT02944331|Steam ablation
17864|NCT02944331|Endothermal ablation
17865|NCT02944331|Varicose vein treatment
17866|NCT02944331|Venous insufficiency
17867|NCT02944331|Saphenous vein reflux
17868|NCT02944331|Recurrent varicosity
17869|NCT02944318|Physical Activity
17870|NCT02944318|Healthy Lifestyle
17871|NCT02944318|Academic performance
17872|NCT02944292|Intra-abdominal pressure
17873|NCT02944292|Intra-abdominal hypertension
17874|NCT02944266|post general anaesthesia induced
17875|NCT02944253|Diet, Reducing
17876|NCT02944253|Hunger
17877|NCT02944253|Appetite Regulation
17878|NCT02944253|Ketogenic Diet
17879|NCT02944253|Caloric Restriction
17880|NCT02944253|Weight Loss
17881|NCT02944253|Ketosis
17882|NCT02944214|Hyperuricemia
17883|NCT02944214|Renal Function
17884|NCT02944214|Chronic kidney disease
17885|NCT02944214|Febuxostat
17886|NCT02944214|Benzbromarone
17887|NCT02944201|carvedilol
17888|NCT02944201|biomarkers
17889|NCT02944201|autonomic nerves
17890|NCT02944188|enhanced recovery after surgery
17891|NCT02944188|right hemicolectomy
17892|NCT02944162|AML
17893|NCT02944162|CD33
17894|NCT02944162|CAR-NK
17895|NCT02944136|cancer
17896|NCT02944136|stepped collaborative care intervention
17897|NCT02944136|depression
17898|NCT02944136|quality of life
17899|NCT02944136|stress
17900|NCT02944136|dyadic function
17901|NCT02944136|spousal or intimate caregiver
17902|NCT02944123|Half dose
17903|NCT02944123|Newer oral P2Y12 inhibitors
17904|NCT02944123|Acute coronary syndrome
17905|NCT02944097|Bioavailability
17906|NCT02944097|Pharmacokinetics
17907|NCT02944097|trans-resveratrol
17908|NCT02944097|trans-epsilon-viniferin
17909|NCT02944097|Vineatrol 30
17910|NCT02944084|Bioavailability
17911|NCT02944084|Pharmacokinetics
17912|NCT02944084|Rice bran extract
17913|NCT02944084|Vitamin E
17914|NCT02944084|Gamma-oryzanol
17915|NCT02944084|Ferulic acid
17916|NCT02944071|femoropopliteal artery lesions
17917|NCT02944071|Percutaneous Transluminal Angioplasty
17918|NCT02944071|Peripheral Artery Disease
17919|NCT02944071|Drug-coated Balloon
17920|NCT02944058|Multiloc
17921|NCT02944058|Philos
17922|NCT02944058|Locking plate
17923|NCT02944058|Straight nail
17924|NCT02944058|Randomized controlled trial
17925|NCT02944058|3 and 4 part fractures
17926|NCT02944019|Nonvalvular Atrial Fibrillation
17927|NCT02944019|Post Authorisation Safety Study
17928|NCT02944019|Safety
17929|NCT02944019|Real World Evidence
17930|NCT02944006|MRI
17931|NCT02943993|Post-Authorisation Safety Study
17932|NCT02943993|Real World Evidence
17933|NCT02943993|Edoxaban
17934|NCT02943993|Efficacy/Safety
17935|NCT02943980|Intraoperative nerve monitoring, airway management
17936|NCT02943967|Refractive Surgical Procedures
17937|NCT02943967|Photorefractive Keratectomy
17938|NCT02943967|Aberrometry
17939|NCT02943954|Fractional Flow Reserve
17940|NCT02943915|Spinal Cord
17941|NCT02943915|Injury
17942|NCT02943915|Exoskeleton
17943|NCT02943915|Ekso
17944|NCT02943915|Rehabilitation
17945|NCT02943902|immunogenicity
17946|NCT02943889|Mesenchymal stem cells
17947|NCT02943889|Liver cirrhosis
17948|NCT02943889|Stem cell therapy
17949|NCT02943876|risk prediction
17950|NCT02943876|risk score
17951|NCT02943876|accuracy of risk perception
17952|NCT02943876|self-help
17953|NCT02943876|psychological distress
17954|NCT02943850|stem cells
17955|NCT02943850|growth factor
17956|NCT02943850|ALS
17957|NCT02943824|brachytherapy
17958|NCT02943824|machine learning
17959|NCT02943824|treatment planning
17960|NCT02943824|Low-Dose-Rate brachytherapy
17961|NCT02943811|endometrial cancer
17962|NCT02943811|survival
17963|NCT02943811|uterine manipulator
17964|NCT02943798|Pulmonary Large Cell Neuroendocrine Carcinoma,chemotherapy
17965|NCT02943785|Transcatheter Aortic Valve Implantation -- TAVI
17966|NCT02943785|Anticoagulation
17967|NCT02943785|Atrial Fibrillation
17968|NCT02943785|ENVISAGE-TAVI-AF
17969|NCT02943746|Standard Protein Diet
17970|NCT02943746|High Protein Diet
17971|NCT02943746|Growth
17972|NCT02943746|Body Composition
17973|NCT02943746|Extremely Low Birth Weight
17974|NCT02943746|Human Milk Derived Fortifier
17975|NCT02943746|Protein
17976|NCT02943746|Targeted Fortification
17977|NCT02943746|Human Milk Diet
17978|NCT02943746|Prematurity
17979|NCT02943733|Pancreatic neuroendocrine tumors (pNETs)
17980|NCT02943733|Pancreatic neuroendocrine tumors
17981|NCT02943733|pNETs
17982|NCT02943733|NETs
17983|NCT02943707|liver diseases
17984|NCT02943707|Bone Marrow Cell Transplantation
17985|NCT02943694|TaTME
17986|NCT02943694|Complications
17987|NCT02943694|Instrument
17988|NCT02943642|MF
17989|NCT02943642|CTCL
17990|NCT02943642|Cutaneous T Cell Lymphoma
17991|NCT02943616|Absorb GT1 BVS
17992|NCT02943616|BVS
17993|NCT02943616|Bioabsorbable
17994|NCT02943616|Myocardial ischemia
17995|NCT02943616|Stent thrombosis
17996|NCT02943616|Stents
17997|NCT02943603|mFOLFOX6
17998|NCT02943603|pembrolizumab
17999|NCT02943590|Cancer Treatment Related to Heart Failure
18000|NCT02943551|Pediatrics
18001|NCT02943551|Respiratory disease
18002|NCT02943551|antibiotic use
18003|NCT02943538|Crohn's Disease
18004|NCT02943538|Colitis, Ulcerative
18005|NCT02943538|Telemedicine
18006|NCT02943525|vaginal packing
18007|NCT02943525|pelvic organ prolapse
18008|NCT02943525|pain and satisfaction
18009|NCT02943486|Mesenchymal stromal cells
18010|NCT02943486|Fitostimoline
18011|NCT02943486|MSC derivatives
18012|NCT02943486|Diabetes
18013|NCT02943473|Smoldering multiple myeloma
18014|NCT02943473|myeloma
18015|NCT02943473|smoldering
18016|NCT02943473|ibrutinib
18017|NCT02943408|Veterans
18018|NCT02943408|mental health
18019|NCT02943408|Patient-Centered Care
18020|NCT02943382|MGD
18021|NCT02943382|Autologous Serum
18022|NCT02943382|Meibomian gland dysfunction
18023|NCT02943382|Dry eye disease
18024|NCT02943382|FAB
18025|NCT02943382|Fingerprick autologous blood
18026|NCT02943369|cangrelor
18027|NCT02943369|ticagrelor
18028|NCT02943369|P2Y12 receptor antagonist
18029|NCT02943369|acute myocardial infarction
18030|NCT02943330|Depression
18031|NCT02943330|Cytokines
18032|NCT02943330|Hemodialysis
18033|NCT02943330|Interferon treatment
18034|NCT02943330|Hepatitis C
18035|NCT02943304|Pregnancy
18036|NCT02943304|Fetal Development
18037|NCT02943304|Child Development
18038|NCT02943304|Developmental Disabilities
18039|NCT02943304|Zika Virus Infection
18040|NCT02943291|Exercise therapy
18041|NCT02943291|Adipose tissue
18042|NCT02943291|Mitochondria
18043|NCT02943291|Oxidative Phosphorylation
18044|NCT02943265|Care Coordination
18045|NCT02943252|apatinib
18046|NCT02943252|S1
18047|NCT02943252|advanced head and neck cancer
18048|NCT02943252|non-squamous
18049|NCT02943213|Chlorpromazine
18050|NCT02943213|Hydrochloride
18051|NCT02943213|Chlorpromazine Hydrochloride
18052|NCT02943213|Bioavailability
18053|NCT02943213|Variability
18054|NCT02943213|Variable
18055|NCT02943213|Absorption
18056|NCT02943213|USL Pharma
18057|NCT02943213|USL
18058|NCT02943213|Healthy
18059|NCT02943213|South Africa
18060|NCT02943213|Cycle
18061|NCT02943213|Anti-Psychotic
18062|NCT02943161|Obesity
18063|NCT02943161|L-citrulline
18064|NCT02943109|patient portal
18065|NCT02943109|HIT
18066|NCT02943109|Electronic Health Records
18067|NCT02943109|Inpatient Care
18068|NCT02943109|Outpatient Care
18069|NCT02943109|Patient Engagement
18070|NCT02943070|Rezum
18071|NCT02943070|Water Vapor Ablation
18072|NCT02943031|bile duct tumor
18073|NCT02943031|individualized precise treatment programs
18074|NCT02943018|ultrasound anovaginal distance, observer variation
18075|NCT02942979|Facilitation
18076|NCT02942979|Implementation
18077|NCT02942979|Homelessness
18078|NCT02942979|Substance Use Disorder
18079|NCT02942979|Mental Illness
18080|NCT02942979|Co-Occurring Disorders
18081|NCT02942979|Veterans
18082|NCT02942979|Primary Care
18083|NCT02942966|Angioplasty
18084|NCT02942966|Below the Knee
18085|NCT02942966|PAD
18086|NCT02942966|Critical Limb Ischemia
18087|NCT02942966|Lesion
18088|NCT02942966|Claudication
18089|NCT02942953|Pacemaker, Artificial
18090|NCT02942953|Diaphragmatic pacing
18091|NCT02942927|Polypharmacy
18092|NCT02942927|Multimorbidity
18093|NCT02942927|Randomized Control Trial
18094|NCT02942927|Drug Discontinuation
18095|NCT02942927|Patient Preference
18096|NCT02942927|eHealth
18097|NCT02942901|PET-CT
18098|NCT02942901|pulmonary metstasectomy
18099|NCT02942888|Mild Cognitive Impairment
18100|NCT02942888|MCI
18101|NCT02942888|NAD
18102|NCT02942888|nicotinamide riboside
18103|NCT02942888|aging
18104|NCT02942875|upper limb
18105|NCT02942875|mirror therapy
18106|NCT02942875|rehabilitation
18107|NCT02942875|subacute
18108|NCT02942849|Bemfola
18109|NCT02942849|r-hFSH
18110|NCT02942849|Oocytes
18111|NCT02942849|Pregnancy
18112|NCT02942849|OHSS
18113|NCT02942836|Respiration Rate Detection
18114|NCT02942823|obesity
18115|NCT02942823|child
18116|NCT02942823|primary prevention
18117|NCT02942823|serious game
18118|NCT02942823|nutrition
18119|NCT02942823|physical activity
18120|NCT02942823|psychosocial
18121|NCT02942823|stress
18122|NCT02942823|knowledge
18123|NCT02942823|diet
18124|NCT02942823|energy density
18125|NCT02942823|beverages
18126|NCT02942823|food pyramide
18127|NCT02942732|Vitamin D
18128|NCT02942732|Glucose
18129|NCT02942732|HbA1C
18130|NCT02942732|Insulin resistance
18131|NCT02942732|Blood lipids
18132|NCT02942693|Apatinib
18133|NCT02942693|Particle therapy
18134|NCT02942680|coronary artery bypass grafting
18135|NCT02942641|Urethral catheter
18136|NCT02942641|clean intermittent catheterization
18137|NCT02942641|UTI
18138|NCT02942641|pain
18139|NCT02942641|quality of life
18140|NCT02942641|hematuria
18141|NCT02942641|cloudy urine
18142|NCT02942589|Portion Size
18143|NCT02942498|behavior, cognitive
18144|NCT02942472|clinical pregnancy rate after embryo transfer
18145|NCT02942459|music therapy
18146|NCT02942459|double-blinded
18147|NCT02942459|Randomized Controlled study (RCT)
18148|NCT02942459|Schizophrenia, negative symptoms
18149|NCT02942407|Renal dialysis
18150|NCT02942329|humanized anti-PD-1 monoclonal antibody
18151|NCT02942329|apatinib
18152|NCT02942329|Gastric Neoplasms
18153|NCT02942329|Gastric Cancer
18154|NCT02942329|Cancer of Stomach
18155|NCT02942329|Hepatocellular Carcinoma
18156|NCT02942329|Liver Cancer, Adult
18157|NCT02942329|Liver Cell Carcinoma
18158|NCT02942316|Heart Rate
18159|NCT02942316|Reflex, Pupillary
18160|NCT02942316|Monitoring, Intraoperative
18161|NCT02942303|Botulinum Toxin, Rejuvenation, Brow lift, Eyebrow.
18162|NCT02942290|Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
18163|NCT02942290|Myelodysplastic Syndromes (MDS)
18164|NCT02942290|Venetoclax
18165|NCT02942290|Acute Myelogenous Leukemia
18166|NCT02942290|Azacitidine
18167|NCT02942290|Pharmacokinetic
18168|NCT02942277|Malaria
18169|NCT02942277|Reactogenicity
18170|NCT02942277|Antibody
18171|NCT02942277|Direct Skin Feed
18172|NCT02942277|Mosquito
18173|NCT02942264|Brain Tumor
18174|NCT02942264|Glioblastoma
18175|NCT02942264|Relapse
18176|NCT02942264|Randomized
18177|NCT02942264|temodar
18178|NCT02942251|MDD
18179|NCT02942251|big data analytics
18180|NCT02942238|CME
18181|NCT02942238|Right hemi Colon cancer
18182|NCT02942238|D3
18183|NCT02942238|laparoscopy
18184|NCT02942225|Attention-deficit/hyperactivity disorder
18185|NCT02942225|metabolomics
18186|NCT02942225|neuropsychological deficits
18187|NCT02942225|pathway analysis
18188|NCT02942212|Smoking Cessation
18189|NCT02942212|Nicotine patch
18190|NCT02942212|Nicoderm Committed Quitters
18191|NCT02942212|CQ
18192|NCT02942212|Nicoderm CQ
18193|NCT02942212|Questionnaires
18194|NCT02942212|Surveys
18195|NCT02942212|Interviews
18196|NCT02942212|Breath tests
18197|NCT02942173|CD45RA-depletion
18198|NCT02942173|TCR-alpha/beta depletion
18199|NCT02942173|Hematopoietic Stem Cell Transplantation
18200|NCT02942121|surgery education
18201|NCT02942121|radical cystectomy
18202|NCT02942121|cystectomy
18203|NCT02942121|muscle-invasive bladder cancer
18204|NCT02942108|piezolectric surgery
18205|NCT02942108|conventional surgery
18206|NCT02942108|lower third molars
18207|NCT02942095|Advanced Solid Tumors
18208|NCT02942095|Metastatic cancer
18209|NCT02942095|Ixazomib
18210|NCT02942095|MLN9708
18211|NCT02942095|Erlotinib
18212|NCT02942095|Erlotinib hydrochloride
18213|NCT02942095|OSI-774
18214|NCT02942095|CP358774
18215|NCT02942095|Tarceva
18216|NCT02942043|Malignant pleural effusion
18217|NCT02942043|Bevacizumab
18218|NCT02941991|Stargardt's Macular Dystrophy
18219|NCT02941991|Retinal Diseases
18220|NCT02941991|Macular Degeneration
18221|NCT02941991|fundus flavimaculatus
18222|NCT02941991|hESC-RPE
18223|NCT02941991|juvenile macular dystrophy
18224|NCT02941991|SMD
18225|NCT02941939|high intensity interval training
18226|NCT02941939|hyperbaric oxygen
18227|NCT02941926|HR-positive HER2-negative
18228|NCT02941926|advanced breast cancer
18229|NCT02941926|LEE011
18230|NCT02941926|ribociclib
18231|NCT02941926|letrozole
18232|NCT02941926|goserelin
18233|NCT02941926|CDK
18234|NCT02941926|CDK4
18235|NCT02941926|CDK6
18236|NCT02941926|CDK4/6
18237|NCT02941926|Phase IIIb
18238|NCT02941926|ER-positive
18239|NCT02941926|PR-positive
18240|NCT02941926|premenopausal
18241|NCT02941926|postmenopausal
18242|NCT02941926|men with advanced breast cancer
18243|NCT02941900|Genetic Testing
18244|NCT02941900|16-1243
18245|NCT02941887|Social behavior
18246|NCT02941887|Gingivitis
18247|NCT02941887|Periodontitis
18248|NCT02941887|Down's Syndrome
18249|NCT02941874|IRAP
18250|NCT02941874|Insulin Regulated Amino Peptidase
18251|NCT02941874|Diagnostic biomarker
18252|NCT02941874|Type 2 diabetes
18253|NCT02941861|Hepatocellular carcinoma
18254|NCT02941861|Cholangiocarcinoma
18255|NCT02941861|Recurrence
18256|NCT02941835|pre-operative radiotherapy
18257|NCT02941783|Kovaltry
18258|NCT02941783|hemophilia A
18259|NCT02941783|Japan
18260|NCT02941783|Post-marketing surveillance
18261|NCT02941770|Adolescents
18262|NCT02941770|Overweight
18263|NCT02941770|Obesity
18264|NCT02941770|Weight Loss
18265|NCT02941770|Physical activity consultation
18266|NCT02941770|Cardiorespiratory fitness
18267|NCT02941770|Endothelial structure
18268|NCT02941770|Endothelial function
18269|NCT02941757|Mediterranean Diet
18270|NCT02941757|Firefighters
18271|NCT02941757|workplace
18272|NCT02941757|Intervention
18273|NCT02941757|obesity
18274|NCT02941757|Randomized Control Trial
18275|NCT02941744|nivolumab
18276|NCT02941744|ipilimumab
18277|NCT02941744|low fixed dose
18278|NCT02941744|adjuvant therapy
18279|NCT02941744|Melanoma
18280|NCT02941705|stem cell research
18281|NCT02941640|Laparoscopic appendectomy
18282|NCT02941640|Endoloop
18283|NCT02941640|Stapler
18284|NCT02941640|Hem-o-lok clip
18285|NCT02941640|DS clip
18286|NCT02941601|Thoracic Neoplasms
18287|NCT02941601|Lung Diseases
18288|NCT02941601|Lung Cancer
18289|NCT02941601|Respiratory Tract Diseases
18290|NCT02941601|Respiratory Tract Neoplasms
18291|NCT02941601|Antineoplastic Agents
18292|NCT02941601|Monoclonal Antibodies
18293|NCT02941562|rectal cancer, radiotherapy
18294|NCT02941536|Circulating Tumor Cells
18295|NCT02941536|Stereotactic Radiosurgery
18296|NCT02941497|Stress, Psychological
18297|NCT02941497|Obesity
18298|NCT02941497|Physical Activity
18299|NCT02941497|Fruit
18300|NCT02941497|Vegetables
18301|NCT02941497|Social Marketing
18302|NCT02941497|Peer Influence
18303|NCT02941497|Community-Based Participatory Research
18304|NCT02941471|Constipation
18305|NCT02941471|Neuromodulation
18306|NCT02941471|Interferential
18307|NCT02941471|Transabdominal
18308|NCT02941445|DPP4-inhibitors
18309|NCT02941419|Platelet lysate
18310|NCT02941419|Critical limb ischemia
18311|NCT02941419|Peripheral arterial disease
18312|NCT02941406|Retina
18313|NCT02941406|Perimetry
18314|NCT02941393|internal tocodynamometry, external tocodynamometry, cesarean section, labor, newborn, vacuum extraction, dystocia
18315|NCT02941380|coronary artery bypass grafting
18316|NCT02941380|cardiopulmonary bypass
18317|NCT02941380|Cerebral oxidative stress
18318|NCT02941380|Cerebral inflammatory stress
18319|NCT02941380|Cerebral hemodynamics
18320|NCT02941380|Postoperative cognitive dysfunction
18321|NCT02941341|Bemfola
18322|NCT02941341|r-hFSH
18323|NCT02941341|ART
18324|NCT02941341|Oocytes
18325|NCT02941341|OHSS
18326|NCT02941341|Pregnancy
18327|NCT02941328|SMA, SMN1, Kugelberg-Welander
18328|NCT02941315|Cardiomyopathy
18329|NCT02941315|Heart Failure
18330|NCT02941315|Cardiac Magnetic Resonance
18331|NCT02941302|gliomas
18332|NCT02941302|biological boundary
18333|NCT02941302|imaging border
18334|NCT02941302|operation
18335|NCT02941263|AMD
18336|NCT02941263|Georgraphic Atrophy
18337|NCT02941263|Macular Degeneration
18338|NCT02941237|Pulse oximetry
18339|NCT02941237|Children
18340|NCT02941211|cervix
18341|NCT02941211|cervical dilation
18342|NCT02941211|balloon catheter
18343|NCT02941172|Brown adipose tissue
18344|NCT02941172|Cannabinoid receptor
18345|NCT02941172|PET imaging
18346|NCT02941172|Metabolism
18347|NCT02941120|Cartilage defect
18348|NCT02941120|Knee
18349|NCT02941120|ACT (Autologous chondrocyte implantation)
18350|NCT02941120|NOVOCART® Inject
18351|NCT02941107|Aboriginal
18352|NCT02941107|Rotavirus
18353|NCT02941107|Vaccine
18354|NCT02941107|Diarrhoea
18355|NCT02941081|iron supplement
18356|NCT02941068|severe sepsis
18357|NCT02941068|intra-abdominal perforation
18358|NCT02941068|surgical intensive care unit
18359|NCT02941068|fungal infection
18360|NCT02941068|prophylactic anti-fungal treatment
18361|NCT02941055|Diet
18362|NCT02941055|Inflammation
18363|NCT02941055|Metabolomics
18364|NCT02941029|Radiation
18365|NCT02941029|Chemotherapy
18366|NCT02941003|Early stage lung adenocarcinoma
18367|NCT02941003|Intraoperative frozen section
18368|NCT02941003|Diagnostic criteria
18369|NCT02940977|Circulating tumor cell
18370|NCT02940977|Epithelial to mesenchymal transition
18371|NCT02940977|Prostate specific antigen (PSA)
18372|NCT02940977|Partin table
18373|NCT02940925|Nasopharyngeal carcinoma
18374|NCT02940925|induction chemotherapy
18375|NCT02940912|Parkinson disease
18376|NCT02940912|Insomnia
18377|NCT02940912|Sleep disorders
18378|NCT02940912|Polysomnography
18379|NCT02940912|Apomorphine
18380|NCT02940912|Multiple sleep latency test
18381|NCT02940912|Parkinson Disease Sleep Scale 2 (PDSS-2)
18382|NCT02940873|severe hypoglycemia
18383|NCT02940873|impaired awareness of hypoglycemia
18384|NCT02940873|type 1 diabetes mellitus
18385|NCT02940873|cognitive behavioral therapy
18386|NCT02940873|structured education
18387|NCT02940847|ultrasound-guided technique
18388|NCT02940847|blind technique
18389|NCT02940847|medial brachial cutaneous nerve block
18390|NCT02940847|intercostobrachial nerve block
18391|NCT02940821|Tooth Whitening
18392|NCT02940808|Caffeine
18393|NCT02940808|EEG
18394|NCT02940808|Theta/beta ratio
18395|NCT02940808|Eye-blink rates
18396|NCT02940808|Cognitive control
18397|NCT02940808|Emotional Stroop
18398|NCT02940808|Global/local congruency
18399|NCT02940808|N-Back
18400|NCT02940808|Prefrontal Cortex
18401|NCT02940795|breast feeding
18402|NCT02940795|fructose
18403|NCT02940769|depression, insomnia. light, cortisol, melatonin
18404|NCT02940756|Malaria, efficacy, safety, ACT, DR Congo
18405|NCT02940743|Hemodialysis
18406|NCT02940704|Reciproc
18407|NCT02940704|One Shape
18408|NCT02940704|reciprocation
18409|NCT02940704|continuous rotation
18410|NCT02940704|irreversible pulpitis
18411|NCT02940704|postoperative pain
18412|NCT02940678|Trauma
18413|NCT02940678|Clinical prediction models
18414|NCT02940678|Transferability studies
18415|NCT02940678|Sweden
18416|NCT02940652|Laryngeal mask,MRI
18417|NCT02940626|Pneumonia
18418|NCT02940626|S. aureus
18419|NCT02940626|Mechanically ventilated
18420|NCT02940613|Rapid response
18421|NCT02940613|Eating Disorders
18422|NCT02940613|Cognitive Behavior Therapy
18423|NCT02940613|Bulimia Nervosa
18424|NCT02940613|Binge Eating Disorder
18425|NCT02940613|Purging Disorder
18426|NCT02940600|normothermic perfusion
18427|NCT02940600|old donors
18428|NCT02940600|extended criteria grafts
18429|NCT02940600|reconditioning
18430|NCT02940587|Non Healing Wound
18431|NCT02940574|Oxytocin
18432|NCT02940574|Autism Spectrum Disorders
18433|NCT02940548|non-dipper hypertension
18434|NCT02940548|young
18435|NCT02940548|middle-aged
18436|NCT02940548|ambulatory blood pressure monitoring
18437|NCT02940548|arterial stiffness
18438|NCT02940548|nifedipine gastrointestinal therapeutic system (GITS)
18439|NCT02940496|Malignant neoplasms of digestive organs
18440|NCT02940496|Advanced liver cancer
18441|NCT02940496|Advanced hepatocellular carcinoma
18442|NCT02940496|Pembrolizumab
18443|NCT02940496|Keytruda
18444|NCT02940496|MK-3475
18445|NCT02940496|SCH-900475
18446|NCT02940496|Biomarkers
18447|NCT02940483|Ependymoma
18448|NCT02940457|tDCS
18449|NCT02940457|MCI
18450|NCT02940457|Working Memory
18451|NCT02940457|fNIRS
18452|NCT02940418|Diabetes Mellitus
18453|NCT02940418|Type 1
18454|NCT02940418|Adipose derived mesenchymal stem cells
18455|NCT02940405|Ketorolac Premedication
18456|NCT02940405|Anesthetic Efficiency
18457|NCT02940405|Post-Endodontic Pain
18458|NCT02940405|Post-operative pain
18459|NCT02940405|Irreversible Pulpitis
18460|NCT02940405|Oral premedication
18461|NCT02940392|Rezum
18462|NCT02940340|infective endocarditis
18463|NCT02940340|systemic microcirculation
18464|NCT02940327|ECMO
18465|NCT02940327|PPHN
18466|NCT02940327|Pulmonary Hypertension of the Newborn
18467|NCT02940327|Markers of inflammation
18468|NCT02940327|Mi-Ecmo
18469|NCT02940249|Polyphenol
18470|NCT02940249|Apple
18471|NCT02940249|Fruit
18472|NCT02940249|Hyperglycaemia
18473|NCT02940249|Metabolic
18474|NCT02940223|Malignant neoplasms of independent (primary) multiple sites
18475|NCT02940223|Advanced Colorectal Cancer
18476|NCT02940223|Metastatic colorectal cancer
18477|NCT02940223|mCRC
18478|NCT02940223|Cancer-related fatigue
18479|NCT02940223|Regorafenib
18480|NCT02940223|Stivarga
18481|NCT02940223|Fish oil
18482|NCT02940223|Icosapent ethyl
18483|NCT02940223|Quality of life questionnaire
18484|NCT02940223|Symptom questionnaire
18485|NCT02940223|Walk test
18486|NCT02940223|Chair/stand test
18487|NCT02940223|Placebo
18488|NCT02940223|Resistance exercises
18489|NCT02940223|Walking program
18490|NCT02940223|Resistance training
18491|NCT02940223|Stretching exercises
18492|NCT02940197|overweight
18493|NCT02940197|Caloric Restriction
18494|NCT02940184|Physiology
18495|NCT02940171|burns
18496|NCT02940171|critically ill
18497|NCT02940171|surgery outcome
18498|NCT02940171|mortality
18499|NCT02940158|lentils
18500|NCT02940158|diabetes
18501|NCT02940158|glycemia
18502|NCT02940158|insulin
18503|NCT02940158|glucose
18504|NCT02940145|inflammatory biomarkers
18505|NCT02940145|Interleukines
18506|NCT02940145|resistance training
18507|NCT02940145|phase angle
18508|NCT02940145|oxidative stress
18509|NCT02940106|oocyte cryopreservation
18510|NCT02940106|closed vitrification
18511|NCT02940106|open vitrification
18512|NCT02940067|prehabilitation
18513|NCT02940067|pancreatectomy
18514|NCT02940067|nutrition
18515|NCT02940067|exercise
18516|NCT02940054|Early diagnosis
18517|NCT02940041|Diagnosis
18518|NCT02940041|Sonography
18519|NCT02940041|Magnetic Ressonance
18520|NCT02940015|Quality Control
18521|NCT02940015|Urine
18522|NCT02940015|Tissue
18523|NCT02940015|Normal
18524|NCT02940002|Plaque form psoriasis vulgaris
18525|NCT02939989|Virologic failure
18526|NCT02939989|Compensated Cirrhosis
18527|NCT02939989|HCV Genotype 3 (HCV GT3)
18528|NCT02939989|HCV Genotype 5 (HCV GT5)
18529|NCT02939989|Chronic Hepatitis C (HCV)
18530|NCT02939989|HCV Genotype 4 (HCV GT4)
18531|NCT02939989|HCV Genotype 2 (HCV GT2)
18532|NCT02939989|HCV Genotype 1 (HCV GT1)
18533|NCT02939989|HCV Genotype 6 (HCV GT6)
18534|NCT02939989|Non-cirrhotics
18535|NCT02939976|ST-Elevation Myocardial Infarction
18536|NCT02939963|weaning
18537|NCT02939963|mechanical ventilation
18538|NCT02939963|work of breathing
18539|NCT02939963|automatic tube compensation
18540|NCT02939963|pressure support ventilation
18541|NCT02939911|Residual neuromuscular blockade
18542|NCT02939872|DAPT
18543|NCT02939872|BVS
18544|NCT02939872|Bioresorbable Vascular Scaffold
18545|NCT02939872|Dual Antiplatelet Therapy
18546|NCT02939859|Multiple Sclerosis
18547|NCT02939859|Demyelinating Diseases
18548|NCT02939859|Nervous System Diseases
18549|NCT02939859|Autoimmune Disorders
18550|NCT02939846|Safety
18551|NCT02939846|Solid tumor
18552|NCT02939846|Trametinib
18553|NCT02939846|Pharmacokinetics
18554|NCT02939820|RNAi therapeutic
18555|NCT02939820|FAP
18556|NCT02939820|Familial Amyloid Polyneuropathies
18557|NCT02939820|TTR
18558|NCT02939820|Transthyretin
18559|NCT02939820|Amyloidosis
18560|NCT02939807|Yeliva™
18561|NCT02939807|hepatocellular carcinoma
18562|NCT02939807|ABC294640
18563|NCT02939807|hepatic neoplasms
18564|NCT02939807|liver neoplasms
18565|NCT02939807|hepatic cancer
18566|NCT02939794|cardiac surgery
18567|NCT02939794|hemoglobin
18568|NCT02939794|iron
18569|NCT02939755|Collaborative care intervention
18570|NCT02939755|Cancer
18571|NCT02939755|Depression
18572|NCT02939755|Palliative care
18573|NCT02939755|Quality of life
18574|NCT02939755|Fatigue
18575|NCT02939755|Pain
18576|NCT02939742|preterm premature rupture of membranes
18577|NCT02939742|complications of prematurity
18578|NCT02939742|neonatal morbidity
18579|NCT02939742|respiratory distress syndrome
18580|NCT02939742|antenatal corticosteroids
18581|NCT02939742|betamethasone
18582|NCT02939729|prehabilitation
18583|NCT02939729|physiotherapy
18584|NCT02939729|cardiac
18585|NCT02939729|thoracic
18586|NCT02939729|preoperative
18587|NCT02939716|small bowel
18588|NCT02939716|bloating
18589|NCT02939716|flow
18590|NCT02939703|Adipose tissue
18591|NCT02939703|calorimetry
18592|NCT02939703|energy expenditure
18593|NCT02939703|microbiome
18594|NCT02939690|Catheter
18595|NCT02939690|Umbilical vein
18596|NCT02939690|Neonate
18597|NCT02939664|banded gastric bypass
18598|NCT02939664|weight loss
18599|NCT02939651|Metastatic
18600|NCT02939651|High grade
18601|NCT02939638|Plant-based diet
18602|NCT02939638|Obesity
18603|NCT02939638|Insulin sensitivity
18604|NCT02939638|Intracellular lipid
18605|NCT02939638|Postprandial metabolism
18606|NCT02939638|Vegan diet
18607|NCT02939612|Stress management
18608|NCT02939612|App
18609|NCT02939599|Pulmonary hypertension (PH),
18610|NCT02939599|Increase blood pressure in the pulmonary artery
18611|NCT02939599|Increased blood pressure in the pulmonary vein
18612|NCT02939599|Increased blood pressure in the lung vasculature
18613|NCT02939599|Shortness of breath
18614|NCT02939599|Dizziness
18615|NCT02939599|Fainting
18616|NCT02939599|Leg swelling
18617|NCT02939599|Cough
18618|NCT02939599|Angina pector
18619|NCT02939586|Sleep, Sleep apnoea, Haemodialysis, Haemodiafiltration, end stage kidney disease
18620|NCT02939560|Autism Spectrum Disorder
18621|NCT02939560|Autism
18622|NCT02939560|Depressive
18623|NCT02939560|Depression
18624|NCT02939534|Parkinson's disease
18625|NCT02939534|autoimmunity
18626|NCT02939521|Pincer Nail
18627|NCT02939521|Surgery
18628|NCT02939508|Acute lower gastrointestinal dysfunction
18629|NCT02939508|Colon-originated lesions
18630|NCT02939508|Critical patient
18631|NCT02939508|Colonoscopic decompression
18632|NCT02939508|Anticholinergic drugs
18633|NCT02939495|Premature Ejaculation
18634|NCT02939495|Erectile Dysfunction
18635|NCT02939495|DAP-SPEED
18636|NCT02939495|Dapoxetine
18637|NCT02939495|Sildenafil
18638|NCT02939469|Sympathetic Nerve Activity
18639|NCT02939469|Skin Sympathetic Nerve Activity
18640|NCT02939456|prostate
18641|NCT02939456|cancer
18642|NCT02939456|MRI
18643|NCT02939417|Laminate veneers
18644|NCT02939417|Grape seed extract
18645|NCT02939417|Emax
18646|NCT02939417|collagen cross-linking agent
18647|NCT02939404|Energy Intake
18648|NCT02939404|Energy Expenditure
18649|NCT02939404|Eating Behavior
18650|NCT02939404|Cold Exposure
18651|NCT02939378|ketogenic diet
18652|NCT02939378|recurrent glioblastoma
18653|NCT02939378|chemotherapy
18654|NCT02939352|Transcranial Magnetic Stimulation
18655|NCT02939352|Magnetic Resonance Imaging
18656|NCT02939352|MRI, Functional
18657|NCT02939339|Transcranial Magnetic Stimulation
18658|NCT02939313|alcohol
18659|NCT02939313|addiction
18660|NCT02939313|cTBS
18661|NCT02939300|Melanoma
18662|NCT02939300|Leptomeningeal Metastases
18663|NCT02939287|autologous
18664|NCT02939287|myeloma
18665|NCT02939287|transplant
18666|NCT02939209|Rotator cuff repair
18667|NCT02939209|Interscalene block
18668|NCT02939209|Hydromorphone
18669|NCT02939209|Pain
18670|NCT02939209|Rebound pain
18671|NCT02939183|Multiple Myeloma
18672|NCT02939157|Diagnostic Ultrasound
18673|NCT02939157|Primary Care
18674|NCT02939131|Cognitive Behavioral Therapy
18675|NCT02939131|Medication Management
18676|NCT02939092|Gingival Bleeding on probing
18677|NCT02939079|Multiple Sclerosis
18678|NCT02939079|Fingolimod
18679|NCT02939079|Fish Oil
18680|NCT02939053|Bioimpedance spectroscopy
18681|NCT02939040|positive activities intervention
18682|NCT02939040|peri-operative
18683|NCT02939014|Drug therapy
18684|NCT02938988|Periodontal Diseases
18685|NCT02938988|Down Syndrome
18686|NCT02938975|malaria
18687|NCT02938975|personal protection
18688|NCT02938975|permethrin treated clothing
18689|NCT02938975|insect repellents
18690|NCT02938975|army personnel
18691|NCT02938949|Myocardial Infarction
18692|NCT02938949|Low Density Lipoprotein Cholesterol
18693|NCT02938949|proprotein convertase subtilisin kexin 9, human
18694|NCT02938949|alirocumab
18695|NCT02938910|Primary hyperaldosteronism
18696|NCT02938910|Secondary hyperaldosteronism
18697|NCT02938910|Cardiac fibrosis
18698|NCT02938910|magnetic resonance imaging
18699|NCT02938897|Telehealth
18700|NCT02938897|Weight loss
18701|NCT02938897|Diet quality
18702|NCT02938897|Behavioral counseling
18703|NCT02938871|synbiotic
18704|NCT02938871|infections
18705|NCT02938871|probiotics
18706|NCT02938871|liver transplantation
18707|NCT02938832|cardiovascular disease, diet, diabetes
18708|NCT02938819|upper limbs
18709|NCT02938819|physiotherapy
18710|NCT02938793|cancer, malignancy
18711|NCT02938780|Behavioral economics
18712|NCT02938780|Breast cancer survivors
18713|NCT02938780|nutrition
18714|NCT02938780|physical activity
18715|NCT02938767|peritoneal dialysis
18716|NCT02938767|carotid intima-media thickness
18717|NCT02938767|coronary flow reserve
18718|NCT02938767|cardiovascular mortality
18719|NCT02938754|Hemiparesis
18720|NCT02938754|Functional independence
18721|NCT02938754|Virtual Rehabilitation
18722|NCT02938741|Acute Lymphoblastic Leukemia
18723|NCT02938741|lymphoblastic lymphoma
18724|NCT02938741|stem-cell transplant
18725|NCT02938741|T-cell lymphoma
18726|NCT02938741|ATG
18727|NCT02938728|AntiPD1
18728|NCT02938702|Active surveillance
18729|NCT02938650|nitrolipid
18730|NCT02938650|microbiome
18731|NCT02938650|inflammation
18732|NCT02938650|cytokine
18733|NCT02938598|maternal depression
18734|NCT02938598|pediatric-based maternal depression screening
18735|NCT02938598|maternal health services
18736|NCT02938546|Non-small-cell lung cancer
18737|NCT02938546|18F-FDG PET/CT
18738|NCT02938546|treatment response assessment
18739|NCT02938520|Antiretroviral agent
18740|NCT02938520|Maintenance
18741|NCT02938520|rilpivirine
18742|NCT02938520|dolutegravir
18743|NCT02938520|TMC278
18744|NCT02938520|Triumeq
18745|NCT02938520|non-nucleoside reverse transcriptase inhibitor
18746|NCT02938520|once monthly, every 4 weeks, once daily
18747|NCT02938520|GSK1265744
18748|NCT02938520|CAB
18749|NCT02938520|Tivicay
18750|NCT02938520|Long-Acting Intramuscular rilpivirine
18751|NCT02938520|lamivudine
18752|NCT02938520|integrase inhibitor
18753|NCT02938520|Long-Acting Intramuscular Cabotegravir
18754|NCT02938520|ART naïve
18755|NCT02938520|cabotegravir
18756|NCT02938520|abacavir
18757|NCT02938507|Overactive bladder, Incontinence
18758|NCT02938481|colon cancer, lymph node, extent of bowel resection
18759|NCT02938455|Hyperalgesia
18760|NCT02938455|Opioids
18761|NCT02938455|Postoperative pain
18762|NCT02938455|DNA methylation
18763|NCT02938429|congenital
18764|NCT02938390|Nipple Sparing Mastectomy
18765|NCT02938390|Ultrasound
18766|NCT02938351|Intervention
18767|NCT02938351|dialysis
18768|NCT02938325|Electroencephalogram
18769|NCT02938325|awareness
18770|NCT02938286|Fractional laser
18771|NCT02938286|Topical anesthesia
18772|NCT02938286|Drug delivery
18773|NCT02938286|CO2 laser
18774|NCT02938286|Er:YAG laser
18775|NCT02938247|Malnutrition
18776|NCT02938247|Geriatric subjects
18777|NCT02938247|Nursing home
18778|NCT02938234|Malnutrition
18779|NCT02938234|Geriatric subjects
18780|NCT02938234|Nursing home
18781|NCT02938221|TeleStroke
18782|NCT02938221|HINTS
18783|NCT02938221|Diagnosis
18784|NCT02938221|Telemedicine
18785|NCT02938221|Acute Vestibular Syndrome
18786|NCT02938169|low back pain
18787|NCT02938169|surface EMG
18788|NCT02938169|exercise
18789|NCT02938156|Hemophilia
18790|NCT02938143|Jumpers knee
18791|NCT02938143|Patellar Tendinopathy
18792|NCT02938143|Jumping Athletes
18793|NCT02938143|UTE MRI
18794|NCT02938143|Exercise Therapy
18795|NCT02938143|NBA
18796|NCT02938117|obesity
18797|NCT02938117|eccentric exercise
18798|NCT02938117|body composition
18799|NCT02938117|training program
18800|NCT02938091|Hispanics
18801|NCT02938091|Single nucleotide polymorphism
18802|NCT02938091|Hepatic lipase
18803|NCT02938052|Heart Failure
18804|NCT02938052|Positive Psychology
18805|NCT02938052|Adherence to Health Behaviors
18806|NCT02938039|laryngeal airways
18807|NCT02938039|infants
18808|NCT02938039|neonates
18809|NCT02938039|children
18810|NCT02938039|anesthetized
18811|NCT02938000|aerobic training
18812|NCT02938000|stroke
18813|NCT02938000|exercise
18814|NCT02938000|stroke recovery
18815|NCT02937974|Pulmonary Disease, Chronic Obstructive
18816|NCT02937974|Xuebijing
18817|NCT02937948|Locally advanced
18818|NCT02937922|Exercise
18819|NCT02937922|Endothelium
18820|NCT02937922|Hypertension
18821|NCT02937922|Endothelial progenitor cell
18822|NCT02937922|Endothelial microparticle
18823|NCT02937909|woundcare community nursing competence
18824|NCT02937883|Daily Activities
18825|NCT02937818|Platinum Refractory Extensive-Stage Carcinoma, Small Cell Lung
18826|NCT02937818|Platinum Refractory Extensive-Stage Oat Cell Carcinoma of Lung
18827|NCT02937818|Platinum Refractory Extensive-Stage Oat Cell Lung Cancer
18828|NCT02937818|Platinum Refractory Extensive-Stage Small Cell Cancer Of The Lung
18829|NCT02937818|Platinum Refractory Extensive-Stage Small Cell Lung Cancer
18830|NCT02937740|Hypogonadism
18831|NCT02937714|Teachers
18832|NCT02937714|mental health literacy
18833|NCT02937714|school mental health promotion
18834|NCT02937688|Parkinson's disease
18835|NCT02937688|Deep Brain Stimulation
18836|NCT02937675|small molecule inhibitor of protein translation
18837|NCT02937675|immunomodulator
18838|NCT02937675|phase 1 dose escalation
18839|NCT02937649|Obesity
18840|NCT02937649|Bariatric surgery
18841|NCT02937649|Sleeve gastrectomy
18842|NCT02937649|Staple-line Leak
18843|NCT02937649|Bougie
18844|NCT02937649|Calibration
18845|NCT02937597|proficiency based progression
18846|NCT02937597|feedback
18847|NCT02937597|computer based assessment
18848|NCT02937597|non technical skills
18849|NCT02937597|deteriorating patient
18850|NCT02937597|ISBAR
18851|NCT02937571|Carfilzomib
18852|NCT02937571|Lenalidomide
18853|NCT02937571|Dexamethasone
18854|NCT02937571|15-326
18855|NCT02937558|hypoglycemia
18856|NCT02937532|Fear of falling
18857|NCT02937532|Fear avoidance behavior
18858|NCT02937532|cognitive behavioral therapy
18859|NCT02937532|Rehabilitation
18860|NCT02937519|Chronomodulated Chemotherapy
18861|NCT02937519|Intensity Modulated Radiation Therapy
18862|NCT02937519|Advanced Nasopharyngeal Cancer
18863|NCT02937506|propofol
18864|NCT02937506|colonoscopy
18865|NCT02937506|patient satisfaction
18866|NCT02937480|stroke
18867|NCT02937480|physical activity
18868|NCT02937480|task performance
18869|NCT02937480|clinical protocol
18870|NCT02937467|SWE
18871|NCT02937467|diagnosis
18872|NCT02937454|Acute Heart Failure
18873|NCT02937454|Iron Deficiency
18874|NCT02937441|C10.228.140.187
18875|NCT02937428|vaccination
18876|NCT02937428|pain
18877|NCT02937428|fear
18878|NCT02937428|psychological intervention
18879|NCT02937415|carbon monoxide
18880|NCT02937415|oxidative stress
18881|NCT02937415|waterpipe smoking
18882|NCT02937415|cigarette smoking
18883|NCT02937415|pulmonary function test
18884|NCT02937350|chronic kidney disease
18885|NCT02937350|vitamin d catabolism
18886|NCT02937311|Taping, stroke
18887|NCT02937311|rehabilitation
18888|NCT02937311|shoulder pain
18889|NCT02937311|electrical stimulation
18890|NCT02937298|Diet Induced Thermogenesis
18891|NCT02937298|Obesity
18892|NCT02937298|Energy balance
18893|NCT02937298|Energy expenditure
18894|NCT02937298|berries
18895|NCT02937298|Sea Buckthorn
18896|NCT02937298|Wild garlic
18897|NCT02937272|TGF Beta
18898|NCT02937233|Zika
18899|NCT02937233|Vaccine
18900|NCT02937233|ZPIV
18901|NCT02937207|Bronchial Asthma
18902|NCT02937207|Traditional Chinese Medicine
18903|NCT02937194|Early childhood caries (ECC)
18904|NCT02937194|Oral health promotion
18905|NCT02937194|Randomized controlled trial
18906|NCT02937142|Behavior Therapy
18907|NCT02937142|Cognitive Therapy
18908|NCT02937142|Adolescents
18909|NCT02937142|Psychotherapy, Group
18910|NCT02937129|Infrared tympanic thermometer
18911|NCT02937129|Axillary thermometer
18912|NCT02937129|Mercury glass thermometer
18913|NCT02937129|Adult emergency department
18914|NCT02937103|Leukemia
18915|NCT02937103|Myeloid
18916|NCT02937103|CD123
18917|NCT02937103|CAR-T
18918|NCT02937090|Polycystic Ovary Syndrome
18919|NCT02937090|Intestinal Microbiota
18920|NCT02937077|etiology
18921|NCT02937038|Urine Biomarkers
18922|NCT02937038|Child Nutrition
18923|NCT02937038|Hydration
18924|NCT02937038|Parent Nutrition Habits
18925|NCT02937025|Nonvalvular atrial fibrillation
18926|NCT02937025|Stroke
18927|NCT02937025|Left Atrial Appendage Closure
18928|NCT02937025|Intervention
18929|NCT02937012|Primary Biliary Cirrhosis
18930|NCT02937012|Primary Biliary Cholangitis
18931|NCT02937012|Bezafibrate
18932|NCT02937012|Ursodeoxycholic acid
18933|NCT02936973|simple obesity
18934|NCT02936973|catgut implantation
18935|NCT02936934|Adverse Drug Reaction
18936|NCT02936934|Morphine
18937|NCT02936934|Oxycodone
18938|NCT02936934|Abdominal hysterectomy
18939|NCT02936921|Toxoplasma gondii
18940|NCT02936921|Toxoplasmosis
18941|NCT02936921|congenital
18942|NCT02936921|prenatal
18943|NCT02936921|screening
18944|NCT02936921|treatment
18945|NCT02936921|diagnosis
18946|NCT02936908|Neuromuscular Diseases
18947|NCT02936908|Muscular dystrophy
18948|NCT02936908|Amyotrophic Lateral Sclerosis
18949|NCT02936908|Acute respiratory failure
18950|NCT02936908|respiratory care
18951|NCT02936908|mechanical ventilation
18952|NCT02936908|weaning
18953|NCT02936908|Intensive Care Unit
18954|NCT02936908|Critical Care
18955|NCT02936908|Survival
18956|NCT02936882|ultrasonography
18957|NCT02936882|aspiration
18958|NCT02936882|emergency
18959|NCT02936882|children
18960|NCT02936882|antrum
18961|NCT02936843|Pain
18962|NCT02936843|Inflammation
18963|NCT02936843|Diabetes Mellitus
18964|NCT02936843|Adult
18965|NCT02936843|Neuropathy
18966|NCT02936817|HRCT
18967|NCT02936817|High Resolution Computed Tomography scans
18968|NCT02936817|Functional Respiratory Imaging
18969|NCT02936817|CT scan
18970|NCT02936817|Computed Tomography
18971|NCT02936817|COPD
18972|NCT02936817|sputum producing COPD patients
18973|NCT02936817|Aerobika® device
18974|NCT02936804|early stage lung cancer
18975|NCT02936804|LDCT screening
18976|NCT02936804|lung resection
18977|NCT02936804|electromagnetic navigation bronchoscopy
18978|NCT02936804|peripheral biomarker
18979|NCT02936791|autosomal dominant polycystic kidney disease
18980|NCT02936791|ADPKD
18981|NCT02936791|PKD biomarkers
18982|NCT02936791|Kidney Institute
18983|NCT02936791|University of Kansas Medical Center
18984|NCT02936778|Short-term medical and psychosocial functioning
18985|NCT02936713|flatulence
18986|NCT02936713|gas
18987|NCT02936713|probiotics
18988|NCT02936713|fermented milk
18989|NCT02936713|diet
18990|NCT02936713|functional gastrointestinal disorders
18991|NCT02936700|Psychiatry
18992|NCT02936700|Suicide
18993|NCT02936700|Randomized controlled trial
18994|NCT02936700|ACT
18995|NCT02936700|fMRI
18996|NCT02936687|blood flow
18997|NCT02936687|magnetic resonance imaging
18998|NCT02936687|insulin
18999|NCT02936687|vasodilation
19000|NCT02936661|postpartum hemorrhage， cesarean section， tranexamic acid
19001|NCT02936648|Hepatitis C
19002|NCT02936635|Amyotrophic Lateral Sclerosis
19003|NCT02936635|ALS
19004|NCT02936635|tirasemtiv
19005|NCT02936609|healthcare access
19006|NCT02936609|healthcare utilization
19007|NCT02936609|preventive services
19008|NCT02936609|cancer survivors
19009|NCT02936531|evoked response potential
19010|NCT02936531|ERP
19011|NCT02936531|Brain Network Activation
19012|NCT02936531|BNA
19013|NCT02936531|Biomarker
19014|NCT02936518|ankyloglossia
19015|NCT02936518|breastfeeding
19016|NCT02936518|lip tie
19017|NCT02936505|chronic lung allograft dysfunction
19018|NCT02936505|cyclosporin
19019|NCT02936505|tacrolimus
19020|NCT02936505|Bronchiolitis Obliterans Syndrome
19021|NCT02936505|Restrictive Allograft Syndrome
19022|NCT02936505|CLAD
19023|NCT02936492|Phase I
19024|NCT02936492|Healthy volunteers
19025|NCT02936466|Psychiatry
19026|NCT02936466|Randomized controlled trial
19027|NCT02936466|Bipolar disorder
19028|NCT02936466|Serious game
19029|NCT02936466|Compliance
19030|NCT02936466|Psychoeducation
19031|NCT02936453|Spinal Cord Injury
19032|NCT02936453|Epidural Electrical Stimulation
19033|NCT02936453|Robot-assisted
19034|NCT02936440|acute kidney injury
19035|NCT02936440|intensive care unit
19036|NCT02936440|bioelectrical impedance analysis
19037|NCT02936414|Berberine
19038|NCT02936414|Cytokine
19039|NCT02936414|CRP
19040|NCT02936414|Metabolism
19041|NCT02936414|Schizophrenia
19042|NCT02936388|uveal melanoma
19043|NCT02936388|liver metastasis
19044|NCT02936388|chemoembolisation
19045|NCT02936388|radioembolisation
19046|NCT02936375|lupus
19047|NCT02936375|nephritis
19048|NCT02936375|iguratimod
19049|NCT02936362|Bread
19050|NCT02936362|Microbiome
19051|NCT02936362|Blood tests
19052|NCT02936362|Sourdough bread
19053|NCT02936362|Dietary intervention
19054|NCT02936349|Hereditary Hemorrhagic Telangiectasia (HHT)
19055|NCT02936349|Pulmonary Arteriovenous Malformation (PAVM)
19056|NCT02936349|Transthoracic Contrast Echocardiogram (TTCE)
19057|NCT02936323|SCLC small cell lung cancer neuroendocrine NET
19058|NCT02936310|stress
19059|NCT02936310|mindfulness
19060|NCT02936310|Mindful Living With Stress Intervention
19061|NCT02936310|nurse
19062|NCT02936310|HIV/AIDS
19063|NCT02936271|Radiofrequency Ablation
19064|NCT02936271|Sclerotherapy
19065|NCT02936271|Vasculera
19066|NCT02936219|complementary feeding
19067|NCT02936219|breast milk
19068|NCT02936219|formula feeding
19069|NCT02936219|combined feeding
19070|NCT02936219|preterm infants
19071|NCT02936219|body composition
19072|NCT02936206|proliferation Index
19073|NCT02936206|Tamoxifen
19074|NCT02936206|Fulvestrant
19075|NCT02936206|cyclinD1
19076|NCT02936206|Breast cancer
19077|NCT02936180|Rheumatoid arthritis
19078|NCT02936180|Flu vaccine
19079|NCT02936180|Influenza
19080|NCT02936167|Ringer Lactate
19081|NCT02936167|Plasmalyte
19082|NCT02936167|Perioperative Period
19083|NCT02936141|homeless, mental disorders, attendance
19084|NCT02936102|Phase I
19085|NCT02936102|FAZ053
19086|NCT02936102|PDR001
19087|NCT02936102|Checkpoint inhibitor
19088|NCT02936102|PD-L1
19089|NCT02936102|PD-1
19090|NCT02936063|Head and neck surgery
19091|NCT02936063|Scar cosmesis
19092|NCT02936063|Surgical staples
19093|NCT02936063|Sutures
19094|NCT02936063|Patient satisfaction
19095|NCT02936050|Echocardiography
19096|NCT02936050|Telemedicine
19097|NCT02936050|Nurses
19098|NCT02936050|Decision support
19099|NCT02936050|eHealth
19100|NCT02936037|progressive multiple sclerosis
19101|NCT02936037|MS
19102|NCT02936037|EDSS
19103|NCT02936037|TW25
19104|NCT02936037|multiple sclerosis
19105|NCT02935998|schizophrenia
19106|NCT02935998|agitation
19107|NCT02935998|ziprasidone
19108|NCT02935985|spontaneous intracerebral hemorrhage
19109|NCT02935985|point-of-care bio-markers
19110|NCT02935985|multicenter
19111|NCT02935985|Emergency Department
19112|NCT02935985|Romania
19113|NCT02935972|prostate biopsy, analgesia, anesthesia, pain, prostate cancer
19114|NCT02935946|pharyngeal swallow, NICU, intervention, thickening
19115|NCT02935920|PRO, follow up
19116|NCT02935894|oxygenated lipids
19117|NCT02935894|metabolic profiling
19118|NCT02935894|sphingoid bases
19119|NCT02935894|ceramides
19120|NCT02935894|endocannabinoids
19121|NCT02935894|non-invasive sampling
19122|NCT02935868|Saliva
19123|NCT02935855|Diabetic patients
19124|NCT02935855|nondiabetic patients
19125|NCT02935842|Parkinson's Disease
19126|NCT02935842|Word Retrieval
19127|NCT02935842|Apraxia Symptoms
19128|NCT02935842|Dysarthria
19129|NCT02935829|energy intake
19130|NCT02935829|blood glucose
19131|NCT02935829|carob flour
19132|NCT02935790|unresectable
19133|NCT02935790|melanoma
19134|NCT02935777|Pomegranate extract
19135|NCT02935777|cognitive function
19136|NCT02935777|cognition
19137|NCT02935777|polyphenols
19138|NCT02935777|memory
19139|NCT02935738|prednisolone
19140|NCT02935738|anti-sperm antibodies
19141|NCT02935738|sperm penetration assay
19142|NCT02935712|Safety
19143|NCT02935712|Tolerability
19144|NCT02935712|AZD8601
19145|NCT02935712|Type II Diabetes
19146|NCT02935582|Topical
19147|NCT02935582|Real-world
19148|NCT02935582|Local standard of care
19149|NCT02935582|Non-interventional
19150|NCT02935582|Calcipotriol
19151|NCT02935569|Alopecia
19152|NCT02935569|Radiotherapy
19153|NCT02935556|Post Partum Pre-eclampsia
19154|NCT02935517|Color vision deficiency
19155|NCT02935517|Color vision defects
19156|NCT02935517|Vision disorders
19157|NCT02935517|Sensation disorders
19158|NCT02935517|Neurologic manifestations
19159|NCT02935517|Nervous system diseases
19160|NCT02935517|Eye diseases
19161|NCT02935517|Signs and symptoms
19162|NCT02935504|Depression
19163|NCT02935504|Pregnancy
19164|NCT02935504|Postpartum
19165|NCT02935491|TAVI
19166|NCT02935491|Aortic stenosis
19167|NCT02935491|aortic stiffness
19168|NCT02935491|calcifications
19169|NCT02935491|CT-scan
19170|NCT02935491|Vascular impedance
19171|NCT02935478|bariatric surgery
19172|NCT02935478|minimally invasive
19173|NCT02935478|Embolization
19174|NCT02935478|ghrelin
19175|NCT02935478|gastric artery embolization
19176|NCT02935452|Self-management
19177|NCT02935452|Supportive self-management
19178|NCT02935452|Normalisation process theory
19179|NCT02935452|Social networks
19180|NCT02935439|Mobile Phone
19181|NCT02935439|Self-efficacy
19182|NCT02935439|Quality of Life
19183|NCT02935439|Knowledge
19184|NCT02935439|Feasibility
19185|NCT02935426|cyanoacrylate
19186|NCT02935426|sutures
19187|NCT02935400|porphyria
19188|NCT02935400|biomarkers
19189|NCT02935387|Very early rheumatoid arthritis
19190|NCT02935374|children
19191|NCT02935374|intestinal microbiome
19192|NCT02935374|microbiota
19193|NCT02935374|antimicrobial course
19194|NCT02935374|amoxicillin
19195|NCT02935374|amoxicillin-clavulanate
19196|NCT02935374|macrolide
19197|NCT02935322|Prevention
19198|NCT02935309|rectum
19199|NCT02935309|transrectal
19200|NCT02935309|carcinoma
19201|NCT02935270|Stroke
19202|NCT02935270|Neglect
19203|NCT02935270|Rehabilitation
19204|NCT02935244|Epidemiology
19205|NCT02935231|minimal cessation advice
19206|NCT02935231|proactive
19207|NCT02935231|nicotine replacement therapy
19208|NCT02935231|smoking hotspots
19209|NCT02935192|seasonal influenza
19210|NCT02935192|vaccine
19211|NCT02935153|CD22
19212|NCT02935153|CAR-T
19213|NCT02935153|Leukemia
19214|NCT02935153|Lymphoma
19215|NCT02935127|absorbable sutures
19216|NCT02935114|Tooth Bleaching
19217|NCT02935114|Tooth Bleaching Agents
19218|NCT02935114|Tooth Whitening
19219|NCT02935114|Hydrogen Peroxide
19220|NCT02935114|Carbamide Peroxide
19221|NCT02935101|glucocorticoids
19222|NCT02935101|craving
19223|NCT02935101|Heroin
19224|NCT02935101|Cocaine
19225|NCT02935101|dependency
19226|NCT02935088|FFR
19227|NCT02935088|Percutaneous coronary intervention
19228|NCT02935062|Speech
19229|NCT02935062|Speech Therapy
19230|NCT02935062|Speech Sound Disorders
19231|NCT02935062|Phonological Disorders
19232|NCT02935062|Auditory Perception
19233|NCT02935010|Helicobacter pylori
19234|NCT02935010|Bismuth quadruple therapy
19235|NCT02935010|Tailored therapy
19236|NCT02935010|Empiric therapy
19237|NCT02935010|clarithromycin susceptibility
19238|NCT02934997|sepsis
19239|NCT02934997|septic shock
19240|NCT02934997|cholesterol
19241|NCT02934997|high density lipoprotein
19242|NCT02934984|Pancreatic Cancer
19243|NCT02934984|recurrence
19244|NCT02934984|DNA
19245|NCT02934958|Colon Cancer Screening
19246|NCT02934945|Budesonide/formoterol
19247|NCT02934945|Typical asthma
19248|NCT02934945|Cough variant asthma
19249|NCT02934919|Nalmefene
19250|NCT02934919|Impulse control disorders
19251|NCT02934919|Parkinson's disease
19252|NCT02934919|Tolerance
19253|NCT02934919|Efficacy
19254|NCT02934906|Neonatal Alloimmune Thrombocytopenia
19255|NCT02934906|pregnancy
19256|NCT02934906|human platelet allogantigen
19257|NCT02934906|asian
19258|NCT02934906|Chinese
19259|NCT02934880|adapted physical activity, cognitive functions
19260|NCT02934854|GAMT deficiency
19261|NCT02934854|GAMT and AGAT deficiencies
19262|NCT02934854|Creatine Transporter Deficiency
19263|NCT02934854|Brain Creatine Transporter Deficiency
19264|NCT02934815|psychological intervention
19265|NCT02934815|breast cancer
19266|NCT02934815|supportive-expressive group therapy
19267|NCT02934815|emotion regulation
19268|NCT02934815|social support
19269|NCT02934815|attachment
19270|NCT02934815|quality of life
19271|NCT02934789|submucosal fibroids
19272|NCT02934789|heavy menstrual bleeding
19273|NCT02934789|quality of life
19274|NCT02934776|DTI
19275|NCT02934776|prostate cancer
19276|NCT02934776|MRI
19277|NCT02934750|pursed lip breathing
19278|NCT02934750|interstitial lund disease
19279|NCT02934750|exercise physiology
19280|NCT02934737|Obesity
19281|NCT02934737|Diabetes Mellitus
19282|NCT02934724|HPV vaccines
19283|NCT02934724|HPV-6
19284|NCT02934724|HPV-11
19285|NCT02934724|HPV-16
19286|NCT02934724|HPV-18
19287|NCT02934724|Gardasil
19288|NCT02934711|Multimorbidity
19289|NCT02934711|Exercise coordinated groups (GECO)
19290|NCT02934711|Caregivers
19291|NCT02934685|Prostatic Neoplasms
19292|NCT02934685|radiotherapy
19293|NCT02934646|Robotics
19294|NCT02934646|Upper Extremity
19295|NCT02934633|injury
19296|NCT02934633|child
19297|NCT02934633|cars
19298|NCT02934633|pedestrians
19299|NCT02934633|child safety
19300|NCT02934633|interactive
19301|NCT02934633|computer
19302|NCT02934633|prevention
19303|NCT02934633|internet
19304|NCT02934633|CD-ROM
19305|NCT02934620|pregnancy
19306|NCT02934620|condom
19307|NCT02934620|HIV
19308|NCT02934620|sexually transmitted infections
19309|NCT02934607|Asthma
19310|NCT02934607|Chronic obstructive pulmonary disease
19311|NCT02934607|Spacer device
19312|NCT02934607|Symbicort
19313|NCT02934607|Pressurized metered-dose inhaler
19314|NCT02934607|Relative bioavailability
19315|NCT02934607|Crossover
19316|NCT02934607|AstraZeneca
19317|NCT02934607|Safety
19318|NCT02934607|Activated charcoal
19319|NCT02934607|AeroChamber Plus Flow-Vu spacer device
19320|NCT02934568|Ribociclib
19321|NCT02934568|LEE011
19322|NCT02934542|Laparoscope holder
19323|NCT02934542|Colon resection
19324|NCT02934542|Right hemicolectomy
19325|NCT02934542|Left hemicolectomy
19326|NCT02934542|Sigmoid resection
19327|NCT02934542|Anti-reflux
19328|NCT02934542|Hiatal hernia
19329|NCT02934516|Obstructed labor
19330|NCT02934516|C section. push method
19331|NCT02934516|reverse breech
19332|NCT02934503|Chemotherapy
19333|NCT02934503|PD-L1
19334|NCT02934503|Thoracic radiotherapy
19335|NCT02934503|PD-1
19336|NCT02934503|MK-3475
19337|NCT02934477|Myelofibrosis
19338|NCT02934477|Hematopoietic Stem Cell Transplant
19339|NCT02934477|Medicare
19340|NCT02934438|nitric oxide
19341|NCT02934438|Neo40 supplement,
19342|NCT02934438|exercise tolerance
19343|NCT02934425|Pork
19344|NCT02934425|Refined carbohydrates
19345|NCT02934425|Satiety
19346|NCT02934425|Glucose
19347|NCT02934425|Insulin
19348|NCT02934425|Breakfast
19349|NCT02934425|Lipoprotein lipids
19350|NCT02934399|dynamic hormone diagnostics
19351|NCT02934399|adrenal insufficiency
19352|NCT02934399|congenital adrenal hyperplasia
19353|NCT02934399|primary hyperaldosteronism
19354|NCT02934399|cushing syndrome
19355|NCT02934399|growth hormone deficiency
19356|NCT02934399|acromegaly
19357|NCT02934360|Lung Cancer
19358|NCT02934360|Breast Cancer
19359|NCT02934360|cell free DNA
19360|NCT02934360|biomarker
19361|NCT02934347|Intubation, Back-up position; Glottis, View
19362|NCT02934334|major depression
19363|NCT02934334|major depressive episode
19364|NCT02934334|biomarkers
19365|NCT02934334|relapse
19366|NCT02934334|near term relapse
19367|NCT02934334|m-health
19368|NCT02934321|Erythritol
19369|NCT02934321|Satiety Response
19370|NCT02934321|Ghrelin
19371|NCT02934295|Rubeola
19372|NCT02934269|Healthy subjects
19373|NCT02934269|Safety
19374|NCT02934269|CC-90006
19375|NCT02934269|Phase 1
19376|NCT02934269|Tolerability
19377|NCT02934256|Neurofibromatosis Type 2
19378|NCT02934256|Vestibular Schwannoma
19379|NCT02934256|Other NF2-related tumors
19380|NCT02934243|Laryngeal Masks
19381|NCT02934243|Ventilation
19382|NCT02934243|Risk factors
19383|NCT02934204|PCNSL
19384|NCT02934204|DLBCL
19385|NCT02934204|methotrexate
19386|NCT02934204|temozolomide
19387|NCT02934191|Tonsillectomy
19388|NCT02934191|Post-operative complications
19389|NCT02934191|Post-operative pain
19390|NCT02934178|shigellosis
19391|NCT02934178|Enterobacteriaceae Infections
19392|NCT02934178|Gram-Negative Bacterial Infections
19393|NCT02934178|Bacterial Infections
19394|NCT02934178|Gastroenteritis
19395|NCT02934178|Gastrointestinal Diseases
19396|NCT02934178|Digestive System Diseases
19397|NCT02934178|Intestinal Diseases
19398|NCT02934165|child safety
19399|NCT02934165|injury
19400|NCT02934165|computer
19401|NCT02934165|prevention
19402|NCT02934165|internet
19403|NCT02934152|Gastroesophageal reflux disease
19404|NCT02934152|Helicobacter pylori
19405|NCT02934139|N91115
19406|NCT02934139|Cavosonstat
19407|NCT02934139|Healthy Volunteer
19408|NCT02934113|weight loss
19409|NCT02934113|text messaging
19410|NCT02934113|workplace
19411|NCT02934113|participatory approach
19412|NCT02934113|health care workers
19413|NCT02934100|Calcaneal spur
19414|NCT02934100|Heel spur
19415|NCT02934100|ESWT
19416|NCT02934100|Extracorporeal shock wave therapy
19417|NCT02934100|ultrasound therapy
19418|NCT02934100|electric field diathermy
19419|NCT02934100|skanlab 25 bodywave
19420|NCT02934100|sham laser therapy
19421|NCT02934087|snare technique
19422|NCT02934087|cannulation of contralateral gate
19423|NCT02934087|endovascular
19424|NCT02934087|aneurysm
19425|NCT02934087|AAA
19551|NCT02933034|ALL CAUSE MORTALITY
19426|NCT02934087|Abdominal Aortic Aneurysm
19427|NCT02934074|Limb Loss
19428|NCT02934074|Gait Variability
19429|NCT02934074|Phantom Sensation
19430|NCT02934074|Phantom Pain
19431|NCT02934074|Peripheral Sensation
19432|NCT02934061|Acute low back pain
19433|NCT02934022|Maraviroc
19434|NCT02934022|HAART regimen
19435|NCT02934022|Immunologic response
19436|NCT02933996|immunosuppression
19437|NCT02933996|cardiac sugery
19438|NCT02933996|Transcutaneous electrical acupoint stimulation
19439|NCT02933996|postoperative
19440|NCT02933957|Vascular Evaluation
19441|NCT02933957|influencing factor
19442|NCT02933957|She Minority population
19443|NCT02933944|locally recurrent
19444|NCT02933918|Probiotics
19445|NCT02933918|Nasal Irrigation
19446|NCT02933918|Healthy Volunteers
19447|NCT02933801|metastatic castration resistant prostate cancer (mCRPC)
19448|NCT02933801|Prostate Cancer
19449|NCT02933801|phase II trial
19450|NCT02933801|ODM-201
19451|NCT02933801|maintenance therapy
19452|NCT02933788|cardiovascular disease
19453|NCT02933788|atherosclerosis
19454|NCT02933723|influenza vaccine
19455|NCT02933723|nursing home
19456|NCT02933723|influenza
19457|NCT02933723|vaccination
19458|NCT02933723|immunity
19459|NCT02933723|cell-mediated immunity
19460|NCT02933723|humoral immunity
19461|NCT02933710|Japanese encephalitis
19462|NCT02933710|IMOJEV®
19463|NCT02933710|Japanese encephalitis chimeric virus vaccine
19464|NCT02933697|Atrial Fibrillation
19465|NCT02933697|Kidney disease
19466|NCT02933697|Anticoagulation
19467|NCT02933671|suprainguinal fascia iliaca (SIFI)
19468|NCT02933671|nerve block
19469|NCT02933645|Insulin
19470|NCT02933645|Intranasal
19471|NCT02933645|Glucose/metabolism
19472|NCT02933645|Glucose homeostasis
19473|NCT02933632|Osteoarthritis
19474|NCT02933632|Physiotherapy
19475|NCT02933632|Rehabilitation
19476|NCT02933632|Clinical Trials
19477|NCT02933632|Accelerated rehabilitation
19478|NCT02933632|Hip Replacement Arthroplasty
19479|NCT02933554|bariatric surgery
19480|NCT02933554|minimally invasive
19481|NCT02933554|Embolization
19482|NCT02933554|NASH
19483|NCT02933554|ghrelin
19484|NCT02933554|gastric artery embolization
19485|NCT02933515|yoga
19486|NCT02933515|occupational therapy
19487|NCT02933515|stroke
19488|NCT02933463|children with high caries risk
19489|NCT02933437|Brugada syndrome
19490|NCT02933437|SCN5A
19491|NCT02933437|SCN10A
19492|NCT02933437|Ajmaline
19493|NCT02933411|Bleeding Disorders
19494|NCT02933411|Heavy Menstrual Bleeding
19495|NCT02933359|cranial vault
19496|NCT02933359|calvarial trauma
19497|NCT02933359|calvarial reconstruction
19498|NCT02933320|Indolent B-cell Lymphoma
19499|NCT02933320|Chronic Lymphocytic Leukaemia
19500|NCT02933320|Waldenström Macroglobulinaemia
19501|NCT02933320|BI-1206
19502|NCT02933320|CD32b
19503|NCT02933294|uniportal
19504|NCT02933294|lung cancer
19505|NCT02933294|VATS
19506|NCT02933268|Autosomal Dominant Polycystic Kidney Disease
19507|NCT02933268|Polycystic Kidney Disease
19508|NCT02933268|ADPKD
19509|NCT02933268|Water
19510|NCT02933268|Vasopressin
19511|NCT02933268|Dietary
19512|NCT02933255|Safety
19513|NCT02933255|Neoadjuvant
19514|NCT02933255|Prostatectomy
19515|NCT02933255|Immunotherapy
19516|NCT02933255|Vaccine
19517|NCT02933242|Cancer
19518|NCT02933216|Cesarean Scar Diverticula
19519|NCT02933177|Dementia
19520|NCT02933177|Alzheimer disease
19521|NCT02933177|Behavioral and Psychological Symptoms of Dementia
19522|NCT02933177|non-drug intervention
19523|NCT02933138|Lipoprotein Lipase
19524|NCT02933138|Hypertriglyceridemia
19525|NCT02933138|Triglycerides
19526|NCT02933138|Lipolysis
19527|NCT02933138|Multifactorial Chylomicronemia
19528|NCT02933125|substance abuse
19529|NCT02933125|group psychotherapy
19530|NCT02933125|family therapy
19531|NCT02933125|longitudinal study
19532|NCT02933125|child and adolescent
19533|NCT02933112|Oral appliance therapy
19534|NCT02933086|Pregnant
19535|NCT02933086|Low Back Pain
19536|NCT02933086|Postural Control
19537|NCT02933060|intravenous fluid
19538|NCT02933060|headache
19539|NCT02933047|Hysterectomy
19540|NCT02933047|Patient satisfaction
19541|NCT02933047|Rehabilitation
19542|NCT02933047|Laparoscopy
19543|NCT02933047|Return to work
19544|NCT02933047|Exercise
19545|NCT02933034|ISCHEMIC OR CORONARY HEART DISEASE
19546|NCT02933034|MYOCARDIAL INFARCTION
19547|NCT02933034|MAGNETIC RESONANCE IMAGING
19548|NCT02933034|DELAYED GADOLINIUM ENHANCEMENT MRI
19549|NCT02933034|MANGANESE-ENHANCED MRI
19550|NCT02933034|INFARCT VOLUME/SIZE
19552|NCT02933034|VENTRICULAR ARRHYTHMIAS
19553|NCT02933021|MGUS
19554|NCT02933008|ACL
19555|NCT02933008|biofeedback
19556|NCT02933008|injury prevention
19557|NCT02933008|virtual reality
19558|NCT02932995|Optical Coherence Tomography
19559|NCT02932995|Drug-Eluting Stent
19560|NCT02932982|primary care
19561|NCT02932982|chest pain
19562|NCT02932982|dyspnea
19563|NCT02932956|GPC3-Positive Solid Tumors
19564|NCT02932956|GPC3-CAR T cells
19565|NCT02932956|GPC3
19566|NCT02932956|Glypican
19567|NCT02932930|QLB
19568|NCT02932930|Abdominoplasty
19569|NCT02932930|Quadratus lumborum block
19570|NCT02932904|Drug therapy
19571|NCT02932865|azoospermia
19572|NCT02932865|male fertility
19573|NCT02932865|MD-TESE
19574|NCT02932865|miRNA
19575|NCT02932865|piRNA
19576|NCT02932865|male infertility
19577|NCT02932852|stem cell
19578|NCT02932852|mesenchymal
19579|NCT02932852|ADASc
19580|NCT02932852|transplantation
19581|NCT02932852|cornea
19582|NCT02932852|corneal defects
19583|NCT02932852|keratoconus
19584|NCT02932852|scaffold
19585|NCT02932852|lamina
19586|NCT02932839|Epilepsy surgery
19587|NCT02932839|Micro-electrode arrays
19588|NCT02932839|Single-neuron recordings
19589|NCT02932839|Electrocorticography
19590|NCT02932826|Autoimmune Diabetes
19591|NCT02932826|Umbilical Cord Blood Cell
19592|NCT02932826|Regulatory T Lymphocyte
19593|NCT02932826|Cell Therapy
19594|NCT02932800|Catheters
19595|NCT02932800|Vascular Access Devices
19596|NCT02932800|Suture Techniques
19597|NCT02932800|microbiota
19598|NCT02932800|Blood Circulation
19599|NCT02932774|SAR
19600|NCT02932774|seasonal allergic rhinitis
19601|NCT02932774|hay fever
19602|NCT02932774|seasonal allergic rhinoconjunctivitis
19603|NCT02932761|cesarean scar diverticula
19604|NCT02932761|vaginal repair
19605|NCT02932761|GnRHa
19606|NCT02932722|Propofol
19607|NCT02932722|Sevoflurane
19608|NCT02932722|Preconditioning
19609|NCT02932709|Emergency
19610|NCT02932709|follow-up
19611|NCT02932709|nurse
19612|NCT02932709|phone
19613|NCT02932709|suicide attempts
19614|NCT02932683|Resuscitation
19615|NCT02932683|Neonatal
19616|NCT02932683|Education
19617|NCT02932644|Rheumatoid Arthritis
19618|NCT02932644|Cardiovascular event
19619|NCT02932644|Cardiovascular mortality
19620|NCT02932644|Vitamin D
19621|NCT02932631|hemiparesis
19622|NCT02932631|STROKE
19623|NCT02932631|neural plasticity
19624|NCT02932631|PHYSICAL THERAPY
19625|NCT02932605|Schizophrenia
19626|NCT02932605|Cannabidiol
19627|NCT02932605|Positron Emission Tomography (PET)
19628|NCT02932605|Microglia
19629|NCT02932566|Heart failure
19630|NCT02932566|Heart failure with preserved ejection fraction (HFpEF)
19631|NCT02932566|Myocardial fibrosis
19632|NCT02932566|Extracellular volume fraction (ECV)
19633|NCT02932566|Interstitial fibrosis
19634|NCT02932553|bioresorbable vascular scaffold
19635|NCT02932553|variant angina
19636|NCT02932553|moderate coronary artery disease
19637|NCT02932553|vasospastic angina
19638|NCT02932527|cannabis
19639|NCT02932501|Bisphosphonate
19640|NCT02932501|Jaw
19641|NCT02932501|Osteonecrosis
19642|NCT02932501|Antiresorptive drugs
19643|NCT02932501|Denosumab
19644|NCT02932488|PET-MR
19645|NCT02932488|5-HT1B receptor
19646|NCT02932488|Sumatriptan
19647|NCT02932488|phMRI
19648|NCT02932488|[11C]AZ10419369
19649|NCT02932436|empagliflozin
19650|NCT02932436|diastolic function
19651|NCT02932436|poorly controlled type 2 diabetes mellitus
19652|NCT02932423|Sugar-sweetened beverage
19653|NCT02932423|Overweight
19654|NCT02932423|Obese
19655|NCT02932423|Sugar
19656|NCT02932423|Water
19657|NCT02932397|Ambulatory surgery
19658|NCT02932397|Perioperative outcomes
19659|NCT02932397|General anesthesia under desflurane
19660|NCT02932397|Prevention of coughing
19661|NCT02932397|Propofol
19662|NCT02932384|HIV
19663|NCT02932384|Black/African American
19664|NCT02932384|Men
19665|NCT02932384|Gay/bisexual
19666|NCT02932384|Los Angeles
19667|NCT02932371|Cardiac output
19668|NCT02932358|Intensive care units
19669|NCT02932358|Delirium
19670|NCT02932358|Cross infection
19671|NCT02932358|Mortality
19672|NCT02932358|Length of stay
19673|NCT02932358|Burnout, Professional
19674|NCT02932358|Depression
19675|NCT02932358|Anxiety
19676|NCT02932345|EGFR mutation; non-small-cell lung cancer;
19677|NCT02932332|shortness of breath
19678|NCT02932332|oxygen
19679|NCT02932332|breathing therapies
19680|NCT02932319|induction of labour
19681|NCT02932319|nulliparous
19682|NCT02932319|prolonged pregnancy
19683|NCT02932319|foley catheter
19684|NCT02932319|vaginal birth
19685|NCT02932280|Recurrent
19686|NCT02932280|Refractory Disease
19687|NCT02932280|Neratinib
19688|NCT02932280|16-878
19689|NCT02932267|Acne
19690|NCT02932267|Dark skin
19691|NCT02932254|Physiological Effects of Drugs
19692|NCT02932254|Rocuronium
19693|NCT02932254|Sugammadex sodium
19694|NCT02932254|Magnesium
19695|NCT02932254|Neuromuscular block, antagonism
19696|NCT02932215|mobile health device
19697|NCT02932215|substance abuse treatment
19698|NCT02932215|quality of life
19699|NCT02932215|lorcaserin
19700|NCT02932189|Mechanical Ventilator Weaning
19701|NCT02932189|Respiratory Muscle Training
19702|NCT02932189|Mortality Rate
19703|NCT02932176|Arteries
19704|NCT02932163|Chronic low back pain
19705|NCT02932163|disability
19706|NCT02932163|endurance
19707|NCT02932150|CHB
19708|NCT02932150|HBV
19709|NCT02932137|SLE,IL-2
19710|NCT02932124|German Resuscitation Registry
19711|NCT02932124|out-of-hospital cardiac arrest
19712|NCT02932124|cardiopulmonary resuscitation
19713|NCT02932124|mechanical chest compression devices
19714|NCT02932111|IBS
19715|NCT02932111|Osteopathic manipulative treatment
19716|NCT02932111|pain
19717|NCT02932085|Transcranial magnetic stimulation
19718|NCT02932085|Magnetic resonance imaging
19719|NCT02932085|Magnetic resonance spectroscopy
19720|NCT02932059|Metamemory
19721|NCT02932059|Schizophrenia
19722|NCT02932059|Aging
19723|NCT02932059|Learning
19724|NCT02932059|Judgement of learning
19725|NCT02932059|Sentence construction strategy
19726|NCT02932046|eating disorders
19727|NCT02932046|anorexia nervosa
19728|NCT02932046|appetite
19729|NCT02932020|disc herniation
19730|NCT02932020|spinal stenosis
19731|NCT02932007|persistent
19732|NCT02932007|longstanding persistent
19733|NCT02931994|dental floss
19734|NCT02931994|gingival embrasure
19735|NCT02931994|oral hygiene
19736|NCT02931981|DKK4
19737|NCT02931981|Gastrointestinal Stromal Tumor
19738|NCT02931981|Biomarker
19739|NCT02931968|Monolithic Zirconia
19740|NCT02931968|Implant supported prosthesis
19741|NCT02931968|Fixed partial denture
19742|NCT02931955|allergy
19743|NCT02931955|insect venom
19744|NCT02931955|pollen
19745|NCT02931955|systems biology
19746|NCT02931942|AA
19747|NCT02931916|smart-phone
19748|NCT02931916|assessment
19749|NCT02931916|chronic ankle instability
19750|NCT02931903|implant supported restorations
19751|NCT02931903|IPS Emax (lithium disilicate glass-ceramic)
19752|NCT02931903|Vita Enamic (hybrid dental ceramic)
19753|NCT02931903|implant survival
19754|NCT02931903|peri-implant tissue response
19755|NCT02931890|gastric cancer
19756|NCT02931890|radiotherapy
19757|NCT02931890|chemoradiotherapy
19758|NCT02931877|Sevoflurane
19759|NCT02931877|Propofol
19760|NCT02931877|Cardiac valvular surgery
19761|NCT02931877|Cardiopulmonary bypass
19762|NCT02931877|Postoperative cognitive dysfunction
19763|NCT02931825|high risk
19764|NCT02931825|surveillance
19765|NCT02931825|screening
19766|NCT02931825|colonoscopy
19767|NCT02931812|cirrhosis
19768|NCT02931812|reward system
19769|NCT02931812|taste sensitivity
19770|NCT02931812|chronic renal failure
19771|NCT02931799|Colitis, Ulcerative
19772|NCT02931799|Crohn Disease
19773|NCT02931799|Inflammatory Bowel Diseases
19774|NCT02931799|Gastroenterology
19775|NCT02931799|Quality Improvement
19776|NCT02931799|Post-Discharge
19777|NCT02931786|core body temperature
19778|NCT02931786|magnetic resonance imaging
19779|NCT02931786|propofol
19780|NCT02931786|ketofol
19781|NCT02931773|Diabetes Autonomic Cardiovascular
19782|NCT02931747|Bacopa Monnieri
19783|NCT02931747|Working memory
19784|NCT02931747|Cognitive processing
19785|NCT02931747|Student
19786|NCT02931721|Azospermia
19787|NCT02931721|Micro Dissection Testicular Sperm Extraction
19788|NCT02931721|Male infertility
19789|NCT02931721|Testis
19790|NCT02931721|MRI
19791|NCT02931708|Heart Failure
19792|NCT02931708|Diaphragm
19793|NCT02931708|Electrical Stimulation
19794|NCT02931695|post partum
19795|NCT02931682|Creatine transporter
19796|NCT02931682|developmental delay
19797|NCT02931682|intellectual disability
19798|NCT02931682|X-linked
19799|NCT02931682|language
19800|NCT02931682|seizure
19801|NCT02931682|observational
19802|NCT02931682|brain spectroscopy
19803|NCT02931656|Gestational Diabetes
19804|NCT02931643|Spices
19805|NCT02931643|Functional food
19806|NCT02931643|Cardiometabolic risk
19807|NCT02931643|Metabolic syndrome
19808|NCT02931643|Inflammation
19809|NCT02931643|Peripheral blood mononuclear cell
19810|NCT02931643|Acute
19811|NCT02931643|miRNA
19812|NCT02931630|Whey protein
19813|NCT02931630|Dietary fibers
19814|NCT02931630|Wheat bran
19815|NCT02931630|Arabinoxylan
19816|NCT02931630|Postprandial lipaemia
19817|NCT02931630|Body composition
19818|NCT02931630|Blood pressure
19819|NCT02931630|Metabolic rate
19820|NCT02931630|Insulin sensitivity
19821|NCT02931630|Metabolic syndrome
19822|NCT02931604|sinus wash
19823|NCT02931604|sinus lavage
19824|NCT02931604|Sinusitis
19825|NCT02931591|Small for gestational age
19826|NCT02931591|insulin sensitivity
19827|NCT02931591|IGF-1 response
19828|NCT02931591|growth hormone treatment
19829|NCT02931578|glycemic index
19830|NCT02931552|Breast cancer
19831|NCT02931552|Latinas
19832|NCT02931552|Peer support counselor
19833|NCT02931552|Spanish speaking
19834|NCT02931552|Community based
19835|NCT02931552|Rural
19836|NCT02931526|Tigecycline
19837|NCT02931526|Continuous Renal Replacement Therapy
19838|NCT02931526|Pharmacokinetics
19839|NCT02931500|machine learning
19840|NCT02931500|cohort study
19841|NCT02931474|Growth Hormone
19842|NCT02931474|Traumatic Brain Injury
19843|NCT02931474|Insomnia
19844|NCT02931474|Polysomnography
19845|NCT02931474|NREM Sleep
19846|NCT02931461|endobronchial transbronchial needle aspiration lung cancer procore
19847|NCT02931448|Device assessment
19848|NCT02931435|Genicular Radiofrequency Ablation
19849|NCT02931435|Knee Arthroplasty, Total
19850|NCT02931422|HIV
19851|NCT02931422|financial incentive
19852|NCT02931422|pediatric HIV testing
19853|NCT02931409|Positive end-expiratory pressure
19854|NCT02931409|Static pulmonary compliance
19855|NCT02931409|Lung Protective Ventilation
19856|NCT02931409|Radical cystectomy and urinary diversion
19857|NCT02931409|Postoperative pulmonary complications
19858|NCT02931409|Procalcitonin
19859|NCT02931383|Liraglutide
19860|NCT02931383|Liraglutide 3 mg
19861|NCT02931383|Osteoarthritis
19862|NCT02931383|Obesity
19863|NCT02931383|Ultrasound
19864|NCT02931370|Osteoarthritis
19865|NCT02931370|Obesity
19866|NCT02931370|Ultrasound
19867|NCT02931370|Liraglutide
19868|NCT02931370|Liraglutide 3mg
19869|NCT02931357|Treatment of teething in infants
19870|NCT02931344|Osteoarthrtis
19871|NCT02931344|Obesity
19872|NCT02931344|Liraglutide 3 mg
19873|NCT02931344|Liraglutide
19874|NCT02931344|Biomarkers
19875|NCT02931318|Organ donation
19876|NCT02931318|brain death
19877|NCT02931318|public opinion
19878|NCT02931305|Epimedium prenylflavonoids
19879|NCT02931305|Osteoporosis
19880|NCT02931305|Cardiovascular diseases
19881|NCT02931305|Phase 1
19882|NCT02931305|safety
19883|NCT02931305|tolerability
19884|NCT02931292|sleeve gastrectomy
19885|NCT02931292|laparoscopy
19886|NCT02931292|bariatric surgery
19887|NCT02931292|obesity surgery
19888|NCT02931292|metabolic surgery
19889|NCT02931214|Healthy Subjects
19890|NCT02931214|Pharmacokinetics
19891|NCT02931214|Pharmacodynamics
19892|NCT02931201|Positron-Emission Tomography
19893|NCT02931201|Prognosis
19894|NCT02931188|Vascular Diseases
19895|NCT02931188|Lipids
19896|NCT02931188|Cholesteryl Ester Transfer Protein (CETP) Inhibition
19897|NCT02931188|Anacetrapib
19898|NCT02931188|Cardiovascular Disease
19899|NCT02931188|Cholesterol
19900|NCT02931175|ACTH gel
19901|NCT02931175|Non-Infectious Uveitis
19902|NCT02931175|ACTHAR
19903|NCT02931175|Posterior Uveitis
19904|NCT02931175|Intermediate Uveitis
19905|NCT02931175|Pan Uveitis
19906|NCT02931175|Uveitis
19907|NCT02931149|platelet-rich plasma
19908|NCT02931149|endoscopic mucosal resection
19909|NCT02931149|endoscopic submucosal dissection
19910|NCT02931110|Diffuse large B-cell lymphoma (DLBCL)
19911|NCT02931110|follicular lymphoma (FL)
19912|NCT02931110|mantle cell lymphoma (MCL)
19913|NCT02931110|Hodgkin lymphoma (HL)
19914|NCT02931097|Parkinson's disease
19915|NCT02931097|Deep brain stimulation
19916|NCT02931097|Mesencephalic locomotor region
19917|NCT02931058|Knee-extension exercise
19918|NCT02931058|Quadriceps exercise
19919|NCT02931058|Knee osteoarthritis
19920|NCT02931058|Exercise adherence
19921|NCT02931058|Dose-response relationship
19922|NCT02931058|Prehabilitation
19923|NCT02931045|extracellular vesicles
19924|NCT02931045|inflammation
19925|NCT02931045|thrombosis
19926|NCT02931045|antiplatelet drugs
19927|NCT02931032|nano receptor
19928|NCT02931032|oral microbiology
19929|NCT02931032|dental caries
19930|NCT02931032|periodontal disease
19931|NCT02931019|fiberoptic
19932|NCT02931019|intubation
19933|NCT02931019|posture
19934|NCT02930954|NSCLC, EGFR, Bim, mutation abundance
19935|NCT02930941|tranexamic acid
19936|NCT02930941|epistaxis
19937|NCT02930941|emergency medicine
19938|NCT02930941|intranasal
19939|NCT02930941|TXA
19940|NCT02930928|Anaesthesia
19941|NCT02930928|Anthropometry
19942|NCT02930928|Body weight and measures
19943|NCT02930928|Development
19944|NCT02930928|Emergency treatment
19945|NCT02930928|Patient safety
19946|NCT02930915|Head and Neck Cancer
19947|NCT02930915|Radiotherapy
19948|NCT02930889|Therapeutic Embolization
19949|NCT02930889|Prostatic Artery Embolization
19950|NCT02930876|sarcopenia
19951|NCT02930876|cancer
19952|NCT02930876|chemotherapy
19953|NCT02930876|palliative care
19954|NCT02930876|resistance training
19955|NCT02930733|Postoperative Analgesia
19956|NCT02930733|Ultrasound guided serratus plane block
19957|NCT02930720|TAUS
19958|NCT02930720|breathing protocols and cough
19959|NCT02930720|pelvic floor displacement
19960|NCT02930720|women
19961|NCT02930720|SUI
19962|NCT02930707|magnesium sulfate
19963|NCT02930707|postoperative pain
19964|NCT02930707|TAP block
19965|NCT02930707|total abdominal hysterectomy
19966|NCT02930655|Fabry disease
19967|NCT02930655|lucerastat
19968|NCT02930642|Mindfulness
19969|NCT02930642|Obesity
19970|NCT02930642|Food insecurity
19971|NCT02930642|Delay discounting
19972|NCT02930629|Recovery Period, Anesthesia
19973|NCT02930629|Neuromuscular Monitoring
19974|NCT02930603|Developmental Disabilities
19975|NCT02930603|Body function and body structure
19976|NCT02930603|Participation
19977|NCT02930603|Life activities
19978|NCT02930603|Quality of Life
19979|NCT02930577|treatment adherence
19980|NCT02930577|outpatient treatment
19981|NCT02930577|drug dependence
19982|NCT02930525|apnea
19983|NCT02930525|children
19984|NCT02930525|hypercarbia
19985|NCT02930525|procedural sedation
19986|NCT02930525|HFNC
19987|NCT02930512|Bone mineral density
19988|NCT02930512|Osteoporosis
19989|NCT02930512|Parkinson's disease
19990|NCT02930512|Bone turnover markers
19991|NCT02930486|Syndesmosis
19992|NCT02930486|Injury
19993|NCT02930486|Ankle
19994|NCT02930486|Fracture
19995|NCT02930486|Weber C
19996|NCT02930473|Psychotherapy
19997|NCT02930473|Nursing
19998|NCT02930473|Nursing Care
19999|NCT02930473|Nursing Model
20000|NCT02930473|Pilot Randomised Controlled Trial
20001|NCT02930434|Vitamin D
20002|NCT02930434|cholecalciferol
20003|NCT02930434|Antarctica
20004|NCT02930434|Chile
20005|NCT02930434|cathelicidin
20006|NCT02930434|bone metabolism
20007|NCT02930434|cardiovascular risk
20008|NCT02930421|mild COPD
20009|NCT02930421|Pulmonary rehabilitation
20010|NCT02930421|Six minute walking distance
20011|NCT02930421|Quality of life
20012|NCT02930421|Saint George Respiratory Questionnaire (SGRQ)
20013|NCT02930395|Concussion
20014|NCT02930395|Professional rugby players
20015|NCT02930395|S100B
20016|NCT02930330|Exercise
20017|NCT02930330|Interval training
20018|NCT02930330|Blood platelets
20019|NCT02930330|Platelet function tests
20020|NCT02930330|Physical fitness
20021|NCT02930330|Rehabilitation
20022|NCT02930304|tennis elbow
20023|NCT02930304|pain
20024|NCT02930304|shock wave
20025|NCT02930304|kinesio taping
20026|NCT02930252|Self-expandable metal stent
20027|NCT02930252|strictures
20028|NCT02930252|biliary
20029|NCT02930239|ACL-reconstruction
20030|NCT02930239|Gait rehabilitation
20031|NCT02930239|Anti Gravity treadmill
20032|NCT02930239|ACL-rehabilitation
20033|NCT02930213|unresponsive wakefulness syndrome
20034|NCT02930213|minimally conscious state
20035|NCT02930213|circadian rhythms
20036|NCT02930213|free-running period
20037|NCT02930200|Smoking Cessation
20038|NCT02930200|Smartphone Based Smoking Cessation
20039|NCT02930187|Rheumatoid arthritis, remission, ultrasound
20040|NCT02930161|Nonalcoholic Fatty Liver Disease
20041|NCT02930161|Nonalcoholic Steatohepatitis
20042|NCT02930161|Methionine
20043|NCT02930161|Succinic acid
20044|NCT02930148|mHealth
20045|NCT02930148|adolescents
20046|NCT02930148|quasi-experimental study
20047|NCT02930148|apps
20048|NCT02930148|lifestyles
20049|NCT02930148|lifestyles knowledge
20050|NCT02930148|dietary behaviour
20051|NCT02930148|physical activity
20052|NCT02930148|sleeping behaviour
20053|NCT02930135|Indirect Pulp Capping, Young Permanent Molars
20054|NCT02930070|sepsis
20055|NCT02930070|qSOFA
20056|NCT02930070|SOFA
20057|NCT02930070|diagnostic accuracy
20058|NCT02930057|lumbar dorsal root ganglion
20059|NCT02930057|transforaminal epidural steroid injection
20060|NCT02930057|chronic lumbosacral radicular pain
20061|NCT02930057|pulsed radiofrequency treatment
20062|NCT02930057|betamethasone
20063|NCT02930057|dorsal root ganglion
20064|NCT02930044|Emergency department
20065|NCT02930044|Insulin
20066|NCT02930044|Adult
20067|NCT02930031|muscle injury
20068|NCT02930031|exercise
20069|NCT02930031|redox status
20070|NCT02930031|immune cells
20071|NCT02930018|Acute Ischemic Stroke
20072|NCT02930018|Endovascular Thrombectomy
20073|NCT02930018|Neuroprotection
20074|NCT02930018|Tat-NR2B9c
20075|NCT02930018|NA-1
20076|NCT02930005|Psychotic
20077|NCT02930005|Schizophrenia
20078|NCT02930005|Schizoaffective
20079|NCT02930005|Bipolar
20080|NCT02929979|PTSD
20081|NCT02929979|Alcohol Use Disorder
20082|NCT02929979|Cognitive Training
20083|NCT02929979|Veterans
20084|NCT02929953|premature birth
20085|NCT02929953|risk factor
20086|NCT02929953|type 1 diabetes mellitus
20087|NCT02929953|seasonality
20088|NCT02929953|prevalence
20089|NCT02929953|enteral feeding
20090|NCT02929953|immunomodulating medications
20091|NCT02929953|early onset
20092|NCT02929927|PDT
20093|NCT02929914|Carious dentin
20094|NCT02929914|Photodynamic Therapy
20095|NCT02929888|ST-segment elevacion myocardial infarction, platelets
20096|NCT02929836|Ablation Linear Lesions
20097|NCT02929797|pancreatic cancer
20098|NCT02929784|Hemiplegic Shoulder Pain
20099|NCT02929784|transcranial Direct Current Stimulation
20100|NCT02929784|Stroke
20101|NCT02929771|Virtual Reality
20102|NCT02929771|Subcutaneous Port Sampling
20103|NCT02929771|Pain
20104|NCT02929771|Children
20105|NCT02929745|immunology, genetics
20106|NCT02929667|Fluoxetine
20107|NCT02929641|Optical Enhancement technology
20108|NCT02929641|coloractal polyp prediction
20109|NCT02929602|prescribing
20110|NCT02929602|effectiveness
20111|NCT02929602|dental
20112|NCT02929602|opioid
20113|NCT02929602|analgesic
20114|NCT02929576|metastatic
20115|NCT02929576|triple negative
20116|NCT02929550|Cardiovascular disease
20117|NCT02929550|Costs
20118|NCT02929550|Guidelines
20119|NCT02929550|Lipids
20120|NCT02929550|Myocardial infarction
20121|NCT02929537|Pulmonary Disease, Chronic Obstructive
20122|NCT02929537|registration research
20123|NCT02929537|Medicine, Chinese Traditional
20124|NCT02929524|Ketamine
20125|NCT02929524|Intranasal administration
20126|NCT02929524|Pediatric nursing
20127|NCT02929498|GSK2879552
20128|NCT02929498|Revised International Prognostic Scoring System (IPSS-R)
20129|NCT02929498|azacitidine
20130|NCT02929498|hypomethylating agents
20131|NCT02929498|myelodysplastic syndrome
20132|NCT02929472|Physical Activity
20133|NCT02929472|Physical Fitness
20134|NCT02929472|Intervention
20135|NCT02929472|Children and Adolescents
20136|NCT02929459|Gut Microbiota
20137|NCT02929459|Riboflavin
20138|NCT02929459|Vitamin B2
20139|NCT02929459|oGTT
20140|NCT02929459|Faecalibacterium prausnitzii
20141|NCT02929446|mobilisation
20142|NCT02929446|physiotherapy
20143|NCT02929433|disability
20144|NCT02929433|pain
20145|NCT02929433|Rotator Cuff Tear
20146|NCT02929433|rehabilitation
20147|NCT02929433|range of motion (ROM)
20148|NCT02929420|Multicenter
20149|NCT02929420|randomized
20150|NCT02929420|open
20151|NCT02929420|parallel controlled
20152|NCT02929394|Histologically proven locally advanced or metastatic high grade STS (excluding histologies insensitive to chemotherapy such as ASPS, PECOMA subtypes)
20153|NCT02929381|Narrow Band Imaging
20154|NCT02929381|Colorectal Cancer Screening
20155|NCT02929381|Colonoscopy
20156|NCT02929381|Responsive Insertion Technology
20157|NCT02929381|Near Focus
20158|NCT02929368|PICC-Line
20159|NCT02929355|Carotid atherosclerosis
20160|NCT02929355|duplex ultrasonography
20161|NCT02929355|diabetes
20162|NCT02929355|vascular events
20163|NCT02929277|farm children
20164|NCT02929277|non-farm children
20165|NCT02929264|Healthy volunteer
20166|NCT02929264|Experimental hyperalgesia
20167|NCT02929264|fMRI
20168|NCT02929225|bacterial translocation;micro-inflammation;hemodialysis
20169|NCT02929212|Gastric Bypass
20170|NCT02929212|Meal Texture
20171|NCT02929212|Meal Number
20172|NCT02929212|GLP-1
20173|NCT02929212|Glucose
20174|NCT02929134|Lymphedema
20175|NCT02929134|Lymphatic Filariasis
20176|NCT02929134|Filariasis
20177|NCT02929134|Doxycycline
20178|NCT02929121|Lymphedema
20179|NCT02929121|Lymphatic Filariasis
20180|NCT02929121|Filariasis
20181|NCT02929121|Doxycycline
20182|NCT02929108|hospice
20183|NCT02929108|caregiver
20184|NCT02929082|magnetic resonance force
20185|NCT02929069|Minority Stress
20186|NCT02929017|Idiopathic Pulmonary Fibrosis
20187|NCT02929017|Fibrosis
20188|NCT02929017|IPF
20189|NCT02929017|Caregivers
20190|NCT02929017|Pulmonary
20191|NCT02929017|Palliative
20192|NCT02929017|end of life
20193|NCT02929017|Idiopathic
20194|NCT02929004|Anterior Cruciate Ligament Reconstruction
20195|NCT02929004|Local vibration training
20196|NCT02929004|Ligamentoplasty
20197|NCT02929004|Anterior cruciate ligament
20198|NCT02929004|Corticospinal excitability
20199|NCT02929004|Elastography
20200|NCT02929004|Knee extensor muscles
20201|NCT02929004|Readaptation
20202|NCT02928991|Acquired aplastic anemia
20203|NCT02928991|Inherited bone marrow failure
20204|NCT02928978|Premalignant Breast Disease
20205|NCT02928978|ALH
20206|NCT02928978|ADH
20207|NCT02928978|DCIS
20208|NCT02928978|LCIS
20209|NCT02928978|Breast Cancer Prevention
20210|NCT02928978|Ruxolitinib
20211|NCT02928965|psychosis
20212|NCT02928965|schizophrenia
20213|NCT02928965|negative symptoms
20214|NCT02928965|minocycline
20215|NCT02928952|Mindfulness
20216|NCT02928939|multimorbidity
20217|NCT02928939|multiple chronic conditions
20218|NCT02928939|drug-drug interactions
20219|NCT02928939|drug-disease interactions
20220|NCT02928939|polypharmacy
20221|NCT02928939|Oral anticoagulants
20222|NCT02928939|Steroids
20223|NCT02928913|sedentary
20224|NCT02928913|non-sedentary
20225|NCT02928913|populations
20226|NCT02928900|Adolescents
20227|NCT02928900|Clinical training
20228|NCT02928900|HIV care and treatment
20229|NCT02928900|Africa
20230|NCT02928861|Positron-Emission Tomography
20231|NCT02928861|Prognosis
20232|NCT02928835|Total knee arthroplasty
20233|NCT02928835|Knee flexion
20234|NCT02928835|Dynamic orthosis
20235|NCT02928822|stroke
20236|NCT02928822|broca's aphasia
20237|NCT02928822|priming
20238|NCT02928822|Intensive language-action therapy
20239|NCT02928822|Rehabilitation gaming system
20240|NCT02928809|temporomandibular joint
20241|NCT02928809|temporomandibular disorder
20242|NCT02928809|muscle fatigue
20243|NCT02928809|low-level laser therapy
20244|NCT02928796|Attentional capacity
20245|NCT02928796|Working memory
20246|NCT02928796|Simulation-based training
20247|NCT02928796|Eye-tracking
20248|NCT02928796|Visual attention
20249|NCT02928796|Psychophysiological measurement
20250|NCT02928796|Surgical simulation
20251|NCT02928796|Computer-based simulation
20252|NCT02928783|Home-based cardiac rehabilitation
20253|NCT02928783|Quality of Medical Care
20254|NCT02928783|Heart Failure
20255|NCT02928757|Care coordination
20256|NCT02928757|Complex care kids Ontario
20257|NCT02928757|Technology-dependent
20258|NCT02928757|Quality of life
20259|NCT02928744|Resistance
20260|NCT02928744|Forced oscillations
20261|NCT02928744|Dyspnea
20262|NCT02928731|Cancer
20263|NCT02928731|Quality of life
20264|NCT02928731|Child
20265|NCT02928718|Post-ERCP pancreatitis
20266|NCT02928718|Genetic variation
20267|NCT02928705|analgesia
20268|NCT02928705|prehospital
20269|NCT02928705|telemedicine
20270|NCT02928705|ambulance
20271|NCT02928705|opioids
20272|NCT02928705|teleconsultation
20273|NCT02928705|tele-emergency medical services
20274|NCT02928705|adverse events
20275|NCT02928705|prehospital emergency medical service physician
20276|NCT02928692|Minocycline
20277|NCT02928692|Postoperative cognitive dysfunction
20278|NCT02928692|Postoperative delirium
20279|NCT02928679|Magnetic resonance imaging
20280|NCT02928679|Dynamic contrast enhanced MRI
20281|NCT02928679|Liraglutide 3 mg
20282|NCT02928679|Liraglutide
20283|NCT02928679|Obesity
20284|NCT02928679|Osteoarthritis
20285|NCT02928666|decision-support
20286|NCT02928666|ontology
20287|NCT02928666|computer-interpretable guidelines
20288|NCT02928666|comorbidities
20289|NCT02928653|energy intake
20290|NCT02928653|energy expenditure
20291|NCT02928653|appetite
20292|NCT02928614|Osteoarthritis
20293|NCT02928614|Obesity
20294|NCT02928614|Liraglutide 3 mg
20295|NCT02928614|Liraglutide
20296|NCT02928614|Biomarkers
20297|NCT02928575|Glioblastoma
20298|NCT02928575|Sunitinib
20299|NCT02928575|Temozolomide
20300|NCT02928575|Radiation Therapy,
20301|NCT02928575|MGMT
20302|NCT02928575|Biomarkers
20303|NCT02928549|interviews
20304|NCT02928549|16-1378
20305|NCT02928523|Autologous Fecal Microbiota Transplantation
20306|NCT02928497|Non-valvular atrial fibrillation
20307|NCT02928497|Left atrial appendage
20308|NCT02928484|Functional dyspepsia
20309|NCT02928484|Abdominal pain
20310|NCT02928484|Flatulence
20311|NCT02928484|Probiotics
20312|NCT02928484|Bifidobacterium
20313|NCT02928484|Lactobacillus
20314|NCT02928471|Liraglutide
20315|NCT02928471|Liraglutide 3 mg
20316|NCT02928471|Osteoarthritis
20317|NCT02928471|Obesity
20318|NCT02928471|Magnetic resonance imaging
20319|NCT02928471|Computed tomography
20320|NCT02928471|Dynamic contrast enhanced MRI
20321|NCT02928445|Dementia with Lewy bodies
20322|NCT02928445|dementia
20323|NCT02928445|RVT-101
20324|NCT02928445|intepirdine
20325|NCT02928445|Lewy bodies
20326|NCT02928432|Castration-Resistant Prostate Cancer
20327|NCT02928432|Abiraterone acetate
20328|NCT02928432|Steroids Switch
20329|NCT02928354|Asthma
20330|NCT02928354|Chronic obstructive pulmonary disease (COPD)
20331|NCT02928354|Healthy volunteers
20332|NCT02928354|Pharmacokinetics (PK)
20333|NCT02928354|Bioavailability
20334|NCT02928354|AZD7594
20335|NCT02928354|Safety
20336|NCT02928354|Tolerability
20337|NCT02928328|craniofacial pain
20338|NCT02928328|masticatory muscle
20339|NCT02928328|burning mouth syndrome
20340|NCT02928328|temporomandibular disorders
20341|NCT02928276|Rheumakit
20342|NCT02928276|Rheumatoid Arthritis
20343|NCT02928276|anti-TNF
20344|NCT02928237|tDCS
20345|NCT02928237|cancer liver
20346|NCT02928237|chronic abdominal pain
20347|NCT02928237|VAS
20348|NCT02928237|VDS
20349|NCT02928237|HAM-D
20350|NCT02928237|BPI
20351|NCT02928237|analgesia
20352|NCT02928224|Colorectal cancer
20353|NCT02928224|BRAF
20354|NCT02928224|BRAFV600E
20355|NCT02928198|Tomography, Optical Coherence
20356|NCT02928198|Percutaneous Coronary Intervention
20357|NCT02928198|Cardiac Catheterization
20358|NCT02928198|Coronary Biovascular Scaffold
20359|NCT02928185|training manuals
20360|NCT02928185|patients and caregivers
20361|NCT02928185|16-1334
20362|NCT02928172|q-CON
20363|NCT02928172|q-NOX
20364|NCT02928172|BIS
20365|NCT02928172|Electroencephalograms (EEG)
20366|NCT02928172|Laryngeal Mask Airway (LMA)
20367|NCT02928172|Sedation
20368|NCT02928172|General Anesthesia
20369|NCT02928159|Low Pulse Amplitude Seizure Therapy
20370|NCT02928159|Electroconvulsive Therapy
20371|NCT02928159|Low Pulse Amplitude Electroconvulsive Therapy
20372|NCT02928159|Low Pulse Amplitude ECT
20373|NCT02928159|LAP
20374|NCT02928159|LAP-ST
20375|NCT02928159|ECT
20376|NCT02928159|Mood disorders
20377|NCT02928159|Psychotic disorders
20378|NCT02928146|TAPP
20379|NCT02928146|TEP
20380|NCT02928146|Lichtenstein
20381|NCT02928146|syntethic mesh
20382|NCT02928146|hernioplasty
20383|NCT02928133|Non-vitamin K antagonist oral anticoagulant (NOAC)
20384|NCT02928133|Congenital heart disease
20385|NCT02928133|Atrial fibrillation
20386|NCT02928133|Atrial tachyarrhythmia
20387|NCT02928133|Thromboembolism
20388|NCT02928094|refractory angina
20389|NCT02928094|myocardial ischemia
20390|NCT02928094|angiogenesis
20391|NCT02928068|telehealth
20392|NCT02928055|Stroke
20393|NCT02928055|Shoulder Pain
20394|NCT02928055|Electrical stimulation
20395|NCT02928055|Neuromuscular stimulation
20396|NCT02928055|Intramuscular stimulation
20397|NCT02928029|Radium-223 dichloride
20398|NCT02928029|bortezomib
20399|NCT02928029|dexamethasone
20400|NCT02928029|early relapsed multiple myeloma
20401|NCT02928029|combination therapy multiple myeloma
20402|NCT02928016|carbohydrate counting method
20403|NCT02928016|protein
20404|NCT02928016|fat
20405|NCT02928016|glucose
20406|NCT02928016|type 1 diabetes
20407|NCT02928003|Lung surgery
20408|NCT02927977|dry needling
20409|NCT02927977|exercise
20410|NCT02927977|manual therapy
20411|NCT02927951|Diabetes Mellitus
20412|NCT02927951|Peripheral Neuropathy
20413|NCT02927951|Diabetic Pain
20414|NCT02927899|Tomato-Soy-Arugula
20415|NCT02927873|Safety
20416|NCT02927873|Respiratory syncytial virus (RSV)
20417|NCT02927873|Immunogenicity
20418|NCT02927873|Reactogenicity
20419|NCT02927873|Infants
20420|NCT02927873|Vaccine
20421|NCT02927860|sleep
20422|NCT02927860|exercise
20423|NCT02927860|activity
20424|NCT02927821|Adult Day Care Centers
20425|NCT02927821|Caregivers
20426|NCT02927808|Motivational Interviewing
20427|NCT02927808|LDL-C
20428|NCT02927808|LDL target
20429|NCT02927808|Medication adherence
20430|NCT02927782|Cerebrospinal Fluid Leak
20431|NCT02927782|Lumbar
20432|NCT02927756|Non-Hodgkin Lymphoma Transformed Recurrent
20433|NCT02927756|Discordant Lymphomas
20434|NCT02927756|Composite Lymphomas
20435|NCT02927756|Follicular Lymphoma
20436|NCT02927756|Aggressive Lymphoma
20437|NCT02927730|Retained placenta, surgical hysteroscopy, residua
20438|NCT02927717|Grade 3b Follicular Lymphoma
20439|NCT02927717|2016 WHO Criteria
20440|NCT02927717|Front-line treatment
20441|NCT02927717|Rituximab
20442|NCT02927704|Aggressive Periodontitis
20443|NCT02927704|monocyte chemoattractant protein-1
20444|NCT02927704|gingival crevicular fluid
20445|NCT02927704|enzyme-linked immunosorbent assay
20446|NCT02927691|Rehabilitation
20447|NCT02927691|Parkinson's disease
20448|NCT02927691|Swallowing
20449|NCT02927691|Cough
20450|NCT02927691|Dysphagia
20451|NCT02927691|Dystussia
20452|NCT02927678|Diabetic foot
20453|NCT02927678|Osteomyelitis
20454|NCT02927678|Antibiotic treatment
20455|NCT02927678|White Blood Cell SPECT/CT
20456|NCT02927665|Weight Loss
20457|NCT02927613|Home mechanical ventilation
20458|NCT02927613|Mortality
20459|NCT02927613|Complications
20460|NCT02927613|Developing country
20461|NCT02927600|Glycemic response
20462|NCT02927600|Glycemic index
20463|NCT02927600|Meal intervention
20464|NCT02927600|Chinese population
20465|NCT02927587|TCI
20466|NCT02927587|fiberoptic bronchoscopy
20467|NCT02927587|sedation
20468|NCT02927574|drug-coated balloon angioplasty
20469|NCT02927574|angioplasty
20470|NCT02927574|plain old balloon angioplasty
20471|NCT02927574|peripheral arterial disease
20472|NCT02927574|intermittent claudication
20473|NCT02927574|systematic review
20474|NCT02927574|meta-analysis
20475|NCT02927574|Paclitaxel
20476|NCT02927522|Postoperative Cognitive Dysfunction
20477|NCT02927522|Donepezil
20478|NCT02927522|Hip replacement
20479|NCT02927522|Knee replacement
20480|NCT02927496|Lymphedema
20481|NCT02927496|Lymphatic Filariasis
20482|NCT02927496|Filariasis
20483|NCT02927496|Doxycycline
20484|NCT02927483|Venous Insufficiency
20485|NCT02927470|Transcranial Magnetic Stimulation
20486|NCT02927457|Cutaneous Lupus Erythematosus-CLE
20487|NCT02927457|Spleen Tyrosine Kinase-SYK
20488|NCT02927457|Photoprovocation-PV
20489|NCT02927457|GSK2646264
20490|NCT02927431|Anti-inflammatory
20491|NCT02927431|Danirixin
20492|NCT02927431|Influenza
20493|NCT02927431|Hospitalized patients
20494|NCT02927405|gabapentin
20495|NCT02927405|TAP block
20496|NCT02927366|Pulmonary hypertension (PH),
20497|NCT02927366|Increase blood pressure in the pulmonary artery
20498|NCT02927366|Increased blood pressure in the pulmonary vein
20499|NCT02927366|Increased blood pressure in the lung vasculature
20500|NCT02927366|Shortness of breath
20501|NCT02927366|Dizziness
20502|NCT02927366|Fainting
20503|NCT02927366|Leg swelling
20504|NCT02927366|Cough
20505|NCT02927366|Angina pector
20506|NCT02927353|Bioequivalence, Biosimilarity, Pharmacokinetics, adalimumab
20507|NCT02927340|Lung Cancer
20508|NCT02927288|PTSD, mTBI
20509|NCT02927262|Acute myeloid leukemia
20510|NCT02927262|First Complete Remission
20511|NCT02927262|FLT3/ITD
20512|NCT02927262|AML
20513|NCT02927262|ASP2215
20514|NCT02927236|Non-Invasive Brain Stimulation
20515|NCT02927236|Functional Magnetic Resonance Imaging (fMRI)
20516|NCT02927210|Healthy Men
20517|NCT02927210|Male Contraception
20518|NCT02927210|Androgen
20519|NCT02927210|Dimethandrolone
20520|NCT02927171|Skilled Nursing Facility
20521|NCT02927171|Post-Acute Care
20522|NCT02927171|Older Adults
20523|NCT02927171|Physical Function
20524|NCT02927171|Rehabilitation
20525|NCT02927132|Drinking, Alcohol
20526|NCT02927119|thyroglobulin
20527|NCT02927119|iodine
20528|NCT02927119|pregnancy
20529|NCT02927106|leukemia
20530|NCT02927106|myeloid
20531|NCT02927106|genomics
20532|NCT02927080|FSHD
20533|NCT02927041|hemodynamic transesophageal echocardiography
20534|NCT02927028|energy availability
20535|NCT02927028|walnuts
20536|NCT02926989|Isotonic
20537|NCT02926989|Hypotonic
20538|NCT02926989|Intravenous fluids
20539|NCT02926976|Schizophrenia
20540|NCT02926963|Chronic Granulomatous Disease, Nox2, p22phox, iPS cells
20541|NCT02926898|seizure
20542|NCT02926898|tonic clonic
20543|NCT02926898|epilepsy
20544|NCT02926898|myoclonic
20545|NCT02926898|encephalopathy
20546|NCT02926885|liver
20547|NCT02926885|laparoscopy
20548|NCT02926885|Bariatric Surgery
20549|NCT02926885|Esophagogastric Junction
20550|NCT02926885|obesity
20551|NCT02926872|Screening
20552|NCT02926872|Hepatic Injury
20553|NCT02926872|Pediatric Patients
20554|NCT02926846|Peritoneal dialysis
20555|NCT02926846|Lavage
20556|NCT02926820|Huntington disease
20557|NCT02926820|cognitive rehabilitation
20558|NCT02926820|cognitive dysfunction
20559|NCT02926807|Atopic Dermatitis
20560|NCT02926807|Vascular Inflammation
20561|NCT02926807|Coronary Atherosclerosis
20562|NCT02926807|Ascending aorta
20563|NCT02926807|Pet scan
20564|NCT02926768|Cancer
20565|NCT02926768|Non Small Cell Lung Cancer
20566|NCT02926768|EGFR sensitivity mutation
20567|NCT02926768|T790M
20568|NCT02926768|NSCLC
20569|NCT02926768|epidermal growth factor receptor
20570|NCT02926768|EGFR
20571|NCT02926768|EGFR inhibitor
20572|NCT02926768|Solid Tumors
20573|NCT02926755|Intra Venous Ultrasound (IVUS)
20574|NCT02926755|Fractional Flow Reserve (FFR)
20575|NCT02926755|Optical Coherence Tomography (OCT)
20576|NCT02926755|Acute Myocardial Infarction
20577|NCT02926755|Coronary Artery Disease (CAD)
20578|NCT02926755|Angiography
20579|NCT02926742|Thrombolysis
20580|NCT02926742|Ultrasound Thrombolysis
20581|NCT02926742|Pulmonary Embolism
20582|NCT02926742|Saddle PE
20583|NCT02926742|Submassive PE
20584|NCT02926742|Massive PE
20585|NCT02926742|Bilateral PE
20586|NCT02926729|Breast Cancer
20587|NCT02926716|Stomach neoplasm
20588|NCT02926716|Endoscopy
20589|NCT02926716|Narrow band imaging
20590|NCT02926703|seizure
20591|NCT02926703|lactate
20592|NCT02926703|creatine kinase
20593|NCT02926677|PTSD
20594|NCT02926677|Child Trauma
20595|NCT02926677|Cue-Centered Treatment
20596|NCT02926677|Trauma-Focused Cognitive-Behavioral Therapy
20597|NCT02926677|fNIRs
20598|NCT02926677|CCT
20599|NCT02926677|TF-CBT
20600|NCT02926677|Posttraumatic stress
20601|NCT02926677|NIRX
20602|NCT02926625|Unspecific fever
20603|NCT02926625|Ethiopia
20604|NCT02926625|iCCM
20605|NCT02926625|CHW
20606|NCT02926625|HEW
20607|NCT02926599|High Fidelity Simulation
20608|NCT02926586|RUNX1-RUNX1T1
20609|NCT02926586|CBFβ-MYH11
20610|NCT02926586|fludarabine
20611|NCT02926586|cytarabine
20612|NCT02926573|oral cavity
20613|NCT02926573|oropharynx
20614|NCT02926573|hypopharynx and larynx
20615|NCT02926560|Chronic inflammatory rheumatism
20616|NCT02926547|proteomics
20617|NCT02926534|chronic obstructive pulmonary disease
20618|NCT02926534|smoking
20619|NCT02926534|prevalence
20620|NCT02926534|cross-sectional study
20621|NCT02926534|Kazakhstan
20622|NCT02926521|nerve block catheter
20623|NCT02926521|catheter fixation
20624|NCT02926521|catheter dressing
20625|NCT02926508|Reading
20626|NCT02926508|Learning
20627|NCT02926508|Cognition
20628|NCT02926482|Evidence-based practice implementation
20629|NCT02926482|Buprenorphine
20630|NCT02926482|Addiction treatment
20631|NCT02926469|Virtual Reality
20632|NCT02926469|Analgesia
20633|NCT02926469|Immersive Virtual Reality
20634|NCT02926469|VR
20635|NCT02926469|Labor
20636|NCT02926469|Pain
20637|NCT02926443|Shoulder
20638|NCT02926443|Motor control
20639|NCT02926443|Proprioception
20640|NCT02926443|Usual physiotherapy care
20641|NCT02926443|Supervised exercise program
20642|NCT02926404|Sagittal alignment
20643|NCT02926404|Surgical planning
20644|NCT02926404|Patient-specific
20645|NCT02926404|Adult Spinal Deformity
20646|NCT02926352|LLLT
20647|NCT02926352|LLLS
20648|NCT02926352|Low-Level Laser Stimulation
20649|NCT02926352|Low-Level Laser Therapy
20650|NCT02926352|Low-Level Light Therapy
20651|NCT02926352|Transcranial infrared light stimulation
20652|NCT02926352|Near-infrared light
20653|NCT02926352|Photobiomodulation
20654|NCT02926352|Fear Extinction
20655|NCT02926352|Exposure Therapy
20656|NCT02926352|Claustrophobia
20657|NCT02926352|Fear of enclosed spaces
20658|NCT02926352|Fear of contamination
20659|NCT02926352|Fear of public speaking
20660|NCT02926352|Anxiety sensitivity
20661|NCT02926352|Cytochrome oxidase
20662|NCT02926352|Memory consolidation
20663|NCT02926352|Cognitive enhancer
20664|NCT02926326|Healthy Male volunteers
20665|NCT02926313|RCT
20666|NCT02926313|Specialized seating
20667|NCT02926313|Pressure ulcers
20668|NCT02926300|crohn's disease
20669|NCT02926300|stem cell therapy
20670|NCT02926300|inflammatory bowel disease
20671|NCT02926300|hUCB-MSC
20672|NCT02926300|UCB-MSC
20673|NCT02926300|Umbilical cord Blood
20674|NCT02926287|prolapse surgery
20675|NCT02926287|ambulatory surgery
20676|NCT02926274|whole blood
20677|NCT02926274|trauma
20678|NCT02926274|transfusion
20679|NCT02926274|coagulopathy
20680|NCT02926248|Arthrofibrosis
20681|NCT02926235|Total Knee Arthroplasty
20682|NCT02926209|colonoscopy
20683|NCT02926209|adenoma
20684|NCT02926209|polyp
20685|NCT02926209|crc screening
20686|NCT02926196|ER-Negative
20687|NCT02926196|PR-Negative
20688|NCT02926196|HER2-Negative
20689|NCT02926144|Intratracheal intubation
20690|NCT02926144|videolaryngoscope
20691|NCT02926144|McGrath MAC
20692|NCT02926131|stick test
20693|NCT02926118|Glucose
20694|NCT02926118|Continuous glucose monitor
20695|NCT02926118|Glycemic load
20696|NCT02926118|Dietary intervention
20697|NCT02926066|Aromatic L-amino acid decarboxylase (AADC)
20698|NCT02926014|Dysphagia
20699|NCT02926014|Lingual Tonsil Hypertrophy
20700|NCT02926014|Lingual Tonsil Enlargement
20701|NCT02926001|Taxes
20702|NCT02926001|Beverages/economics
20703|NCT02926001|Carbonated Beverages/economics
20704|NCT02926001|Diet, Food and Nutrition/economics
20705|NCT02926001|Economics
20706|NCT02926001|Energy Intake
20707|NCT02926001|Risk Factors
20708|NCT02925988|Critically ill
20709|NCT02925988|High risk neonates
20710|NCT02925949|Treatment
20711|NCT02925949|Adherence
20712|NCT02925949|Intervention
20713|NCT02925949|MSM Couples
20714|NCT02925936|Radiography
20715|NCT02925936|Radiation
20716|NCT02925936|Diagnostic imaging
20717|NCT02925871|stroke
20718|NCT02925871|rehabilitation
20719|NCT02925871|interdisciplinary health team
20720|NCT02925871|patient-centered care
20721|NCT02925871|care transition
20722|NCT02925858|Ketamine
20723|NCT02925858|Lidocaine
20724|NCT02925858|Pain
20725|NCT02925858|Cardiac surgery
20726|NCT02925832|Deep topical fornix nerve block Anesthesia
20727|NCT02925832|Ropivacaine
20728|NCT02925832|Bupivacaine
20729|NCT02925832|Anaesthesia
20730|NCT02925832|Eye surgery blocks
20731|NCT02925832|Phacoemulsification
20732|NCT02925819|Mitral regurgitation
20733|NCT02925819|Mitral stenosis
20734|NCT02925819|Mitral valve repair deterioration
20735|NCT02925819|Bioprosthesis degeneration
20736|NCT02925780|Enamel defects
20737|NCT02925780|Fluorosis
20738|NCT02925741|bed linens
20739|NCT02925728|Finger-Food
20740|NCT02925663|executive functioning
20741|NCT02925650|Alzheimer's Disease
20742|NCT02925650|SILK™
20743|NCT02925650|Pharmacodynamics
20744|NCT02925650|Safety
20745|NCT02925650|Pharmacokinetics
20746|NCT02925624|ablation index
20747|NCT02925624|pulmonary vein isolation
20748|NCT02925624|implantable loop recorder
20749|NCT02925611|Postoperative delirium
20750|NCT02925611|spine surgery
20751|NCT02925611|isoflurane
20752|NCT02925611|desflurane
20753|NCT02925598|Laringeal masks
20754|NCT02925598|Cholecystectomy, Laparascopic
20755|NCT02925598|Intubation, intratracheal
20756|NCT02925572|pediatric obesity
20757|NCT02925572|eccentric exercise
20758|NCT02925572|body composition
20759|NCT02925572|training program
20760|NCT02925559|Diabetes Mellitus, Type 2
20761|NCT02925559|Glycemic Variability
20762|NCT02925559|Dapagliflozin
20763|NCT02925559|Gliclazide MR
20764|NCT02925559|Continuous Glucose Monitoring
20765|NCT02925559|Mean Amplitude of Glycemic Excursions
20766|NCT02925559|MAGE
20767|NCT02925546|Healthy
20768|NCT02925546|Pharmacokinetics
20769|NCT02925546|Phase I
20770|NCT02925546|GSK2798745
20771|NCT02925546|Tablet
20772|NCT02925533|Bladder Cancer
20773|NCT02925533|Urothelial Cancer
20774|NCT02925520|Cholestasis
20775|NCT02925494|Elagolix
20776|NCT02925494|Elagolix plus Norethindrone Acetate
20777|NCT02925494|Uterine Fibroids
20778|NCT02925494|Elagolix Sodium
20779|NCT02925494|Heavy Menstrual Bleeding
20780|NCT02925481|Yoga
20781|NCT02925481|PTSD
20782|NCT02925481|mental health
20783|NCT02925481|stillbirth
20784|NCT02925468|orthodontics
20785|NCT02925455|Hemiplegia
20786|NCT02925455|Functional Electrical Stimulation
20787|NCT02925455|Video Games
20788|NCT02925455|Occupational Therapy
20789|NCT02925442|Unilateral Knee Arthroplasty
20790|NCT02925442|Radiofrequency Ablation
20791|NCT02925442|Genicular
20792|NCT02925442|RFA
20793|NCT02925442|C-RFA
20794|NCT02925442|t-RFA
20795|NCT02925442|total knee replacement
20796|NCT02925364|magnetic resonance imaging
20797|NCT02925364|central pain processing
20798|NCT02925364|anatomical MRI
20799|NCT02925364|fMRI
20800|NCT02925325|Major depressive disorder
20801|NCT02925325|Music therapy
20802|NCT02925325|Residual symptoms
20803|NCT02925286|gambling prevention
20804|NCT02925286|workplace policy
20805|NCT02925273|dementia
20806|NCT02925234|Molecular tumor profile
20807|NCT02925234|Multidisciplinary tumor board
20808|NCT02925234|Antitumor drugs
20809|NCT02925234|Molecular Targeted Therapy
20810|NCT02925234|Drug Repositioning
20811|NCT02925234|Off-Label Use
20812|NCT02925234|Sequence Analysis, DNA
20813|NCT02925221|Kidney Disease
20814|NCT02925221|ADPKD-Related Outcome
20815|NCT02925221|Quality of Life
20816|NCT02925195|Vitamin D
20817|NCT02925195|cardiovascular disease
20818|NCT02925195|MESA
20819|NCT02925195|genetics
20820|NCT02925195|pharmacogenetics
20821|NCT02925195|blood pressure
20822|NCT02925195|biomarkers
20823|NCT02925169|Subglottis, cricoid, airway shape, CT imaging
20824|NCT02925156|Activity Energy Expenditure
20825|NCT02925156|Doubly Labeled Water
20826|NCT02925156|Physical Activity
20827|NCT02925156|Obesity
20828|NCT02925156|Diabetes
20829|NCT02925156|Cardiovascular Disease
20830|NCT02925156|Adiponectin
20831|NCT02925156|Leptin
20832|NCT02925156|Ghrelin
20833|NCT02925143|Residual nerve blockade
20834|NCT02925143|Neuromuscular monitoring
20835|NCT02925143|Residual curarization
20836|NCT02925143|Neuromuscular blocking agents
20837|NCT02925143|E-learning
20838|NCT02925143|Web based learning
20839|NCT02925117|ABT-494
20840|NCT02925117|Atopic Dermatitis
20841|NCT02925104|cMET, INC280, food,
20842|NCT02925065|Parkinson's
20843|NCT02925065|Non-traditional guitar instruction
20844|NCT02925065|Guitar therapy
20845|NCT02925065|Upper extremity motor function
20846|NCT02925065|Hand dexterity
20847|NCT02925039|Rehabilitation
20848|NCT02925039|Geriatric
20849|NCT02925013|Omega 3
20850|NCT02925013|Lipids
20851|NCT02925013|Pregnancy
20852|NCT02925000|Advanced Malignancy
20853|NCT02925000|lymphoma
20854|NCT02925000|TLC178
20855|NCT02924948|Endoscopic ultrasonography
20856|NCT02924922|renal cell carcinoma
20857|NCT02924922|laparoscopic partial nephrectomy
20858|NCT02924922|robot-assisted partial nephrectomy
20859|NCT02924922|nephron sparing surgery
20860|NCT02924922|warm ischemia time
20861|NCT02924922|renal function loss
20862|NCT02924870|health education
20863|NCT02924792|Intraosseous access
20864|NCT02924740|stress urinary incontinence
20865|NCT02924740|quality of life
20866|NCT02924740|pelvic floor muscle training
20867|NCT02924740|pelvic floor muscle exercises
20868|NCT02924740|vaginal tampon training
20869|NCT02924727|Spontaneous AMI
20870|NCT02924727|HF hospitalization
20871|NCT02924727|outpatient HF
20872|NCT02924727|LV systolic dysfunction
20873|NCT02924727|pulmonary congestion
20874|NCT02924727|STEMI
20875|NCT02924727|NSTEMI
20876|NCT02924727|randomized clinical trial
20877|NCT02924727|LCZ696
20878|NCT02924727|ramipril
20879|NCT02924714|GIST
20880|NCT02924701|prognosis
20881|NCT02924688|umeclidinium bromide
20882|NCT02924688|fluticasone furoate
20883|NCT02924688|vilanterol
20884|NCT02924688|fixed dose combination
20885|NCT02924688|lung function
20886|NCT02924688|albuterol/salbutamol
20887|NCT02924688|asthma
20888|NCT02924688|closed triple therapy
20889|NCT02924675|neuropathic pain, ent cancer, pregabalin
20890|NCT02924649|Brain injury
20891|NCT02924649|Early mobilisation
20892|NCT02924649|Consciousness
20893|NCT02924649|Cerebral blood flow
20894|NCT02924649|Blood pressure
20895|NCT02924636|C-section
20896|NCT02924636|Instrumental delivery
20897|NCT02924636|Pregnancy complications
20898|NCT02924636|Macrosomia
20899|NCT02924636|Neonatal complications
20900|NCT02924584|hormonal receptor positive, human epidermal growth factor receptor 2 negative, breast cancer, aromatse inhibitor, overall survival, prevalence
20901|NCT02924558|Egg
20902|NCT02924558|Protein
20903|NCT02924558|Unsaturated fatty acids
20904|NCT02924558|Triglycerides
20905|NCT02924558|Insulin sensitivity
20906|NCT02924558|Lipid triad
20907|NCT02924506|cervical arthroplasty
20908|NCT02924493|Endometriosis
20909|NCT02924493|IBS
20910|NCT02924493|Irritable bowel syndrome
20911|NCT02924493|low FODMAP diet
20912|NCT02924493|FODMAPs
20913|NCT02924493|visceral syndrome
20914|NCT02924493|fermentable carbohydrates
20915|NCT02924493|visceral hypersensitivity
20916|NCT02924493|cross organ effect
20917|NCT02924480|invasive bladder cancer
20918|NCT02924480|cystectomy
20919|NCT02924480|high grade bladder cancer
20920|NCT02924467|reminder systems
20921|NCT02924467|Influenza vaccines
20922|NCT02924454|metoprolol
20923|NCT02924454|lipid emulsion
20924|NCT02924454|pharmacodynamics
20925|NCT02924454|pharmacokinetics
20926|NCT02924441|Mammogram
20927|NCT02924441|Pain Management
20928|NCT02924441|Lidocaine
20929|NCT02924428|Acne
20930|NCT02924402|NHL
20931|NCT02924402|B-cell Prolymphocytic Leukemia
20932|NCT02924402|Transformed Lymphoma
20933|NCT02924402|Burkitt's Lymphoma
20934|NCT02924402|Mantle Cell Lymphoma
20935|NCT02924402|Hairy Cell Leukemia
20936|NCT02924402|Splenic Marginal Zone Lymphoma
20937|NCT02924402|Waldenstrom's Macroglobulinemia
20938|NCT02924402|Variant Hairy Cell Leukemia
20939|NCT02924402|Splenic B-cell Lymphoma/Leukemia
20940|NCT02924402|Lymphoplasmacytic Lymphoma
20941|NCT02924402|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT)
20942|NCT02924402|MALT Lymphoma
20943|NCT02924402|Nodal Marginal Zone Lymphoma
20944|NCT02924402|Follicular Lymphoma
20945|NCT02924402|In Situ Follicular Neoplasia
20946|NCT02924402|Duodenal-type Follicular Lymphoma
20947|NCT02924402|Large B-cell Lymphoma with IRF4 rearrangement
20948|NCT02924402|Primary Cutaneous Follicle Center Lymphoma
20949|NCT02924402|Diffuse Large B-cell Lymphoma
20950|NCT02924402|DLBCL
20951|NCT02924402|T-cell/Histiocyte-Rich Large B-cell Lymphoma
20952|NCT02924402|Primary Cutaneous DLBCL, leg type
20953|NCT02924402|EBV-positive DLBCL, NOS
20954|NCT02924402|EBV-positive Mucocutaneous Ulcer
20955|NCT02924402|DLBCL Associated with Chronic Inflammation
20956|NCT02924402|Lymphomatoid Granulomatosis
20957|NCT02924402|Primary Mediastinal (Thymic) Large B-cell Lymphoma
20958|NCT02924402|Intravascular Large B-cell Lymphoma
20959|NCT02924402|ALK+ Large B-cell Lymphoma
20960|NCT02924402|Plasmablastic Lymphoma
20961|NCT02924402|Primary Effusion Lymphoma
20962|NCT02924402|HHV8+ DLBCL
20963|NCT02924402|Burkitt-like Lymphoma with 11q Aberration
20964|NCT02924402|High-grade B-cell Lymphoma
20965|NCT02924402|B-cell Lymphoma, unclassifiable
20966|NCT02924402|Post-transplant Lymphoproliferative Disorder
20967|NCT02924402|PTLD
20968|NCT02924402|CLL
20969|NCT02924402|SLL
20970|NCT02924402|High-grade Lymphoma
20971|NCT02924376|Cholangiocarcinoma
20972|NCT02924376|fibroblast growth factor (FGF)
20973|NCT02924376|fibroblast growth factor receptor (FGFR)
20974|NCT02924376|FGF/FGFR alterations
20975|NCT02924363|Cardiac Magnetic Resonance
20976|NCT02924363|Mitra Clip
20977|NCT02924363|Mitral Valve
20978|NCT02924337|QT/QTC interval
20979|NCT02924337|Hypoglycemic Agents
20980|NCT02924337|Imeglimin
20981|NCT02924337|Healthy Volunteers
20982|NCT02924324|local Injection
20983|NCT02924324|pain Medication
20984|NCT02924324|propofol
20985|NCT02924324|ropivacaine
20986|NCT02924324|16-1417
20987|NCT02924311|Diabetic Macular Edema
20988|NCT02924272|Drug Therapy
20989|NCT02924259|muscle soreness
20990|NCT02924259|pain
20991|NCT02924259|myofascial release
20992|NCT02924246|immunity
20993|NCT02924246|vaccination
20994|NCT02924246|milk
20995|NCT02924233|Squamous
20996|NCT02924233|Non-Small Cell Lung Cancer
20997|NCT02924233|NSCLC
20998|NCT02924207|diabetes mellitus
20999|NCT02924181|pulmonary vein isolation
21000|NCT02924181|contact force sensing catheter
21001|NCT02924142|Kennedy classification for edentulous ridge
21002|NCT02924129|Chronic Pain
21003|NCT02924129|Back Pain
21004|NCT02924129|Leg Pain
21005|NCT02924129|Pain
21006|NCT02924129|Neurologic Manifestations
21007|NCT02924129|Nervous System Diseases
21008|NCT02924129|Signs and Symptoms
21009|NCT02924129|SCS
21010|NCT02924129|Closed Loop
21011|NCT02924116|insomnia
21012|NCT02924116|sleep
21013|NCT02924116|Bioboosti
21014|NCT02924116|Biomobie
21015|NCT02924116|device
21016|NCT02924103|acute rhinosinusitis
21017|NCT02924103|staphylococcus aureus
21018|NCT02924103|nasal vestibule
21019|NCT02924103|contamination
21020|NCT02924090|Major depressive disorder
21021|NCT02924090|Etomidate
21022|NCT02924090|Ketamine
21023|NCT02924090|Hyperventilation
21024|NCT02924090|Electroconvulsive therapy
21025|NCT02924090|Depression
21026|NCT02924090|Anesthesia
21027|NCT02924090|Nervous System Diseases
21028|NCT02924090|Mental Disorders
21029|NCT02924090|Electroencephalography
21030|NCT02924090|Cerebral Metabolism
21031|NCT02924038|low-grade glioma
21032|NCT02924038|glioma
21033|NCT02924038|immunotherapy
21034|NCT02924038|vaccine
21035|NCT02924038|WHO grade II
21036|NCT02924012|post exercise hypotension
21037|NCT02924012|exercise
21038|NCT02924012|video games
21039|NCT02923999|HIV
21040|NCT02923999|MAB
21041|NCT02923999|PLANT
21042|NCT02923986|Liposomal Grb-2 treatment of Ph+ CML
21043|NCT02923986|Liposomal Grb-2 with Das for Ph+ CML
21044|NCT02923947|Pharmacokinetics,
21045|NCT02923947|Renal impairment,
21046|NCT02923947|Safety assessments,
21047|NCT02923947|Solid tumours,
21048|NCT02923947|EGFRm+
21049|NCT02923947|EGFRm+/T790M+ inhibitor
21050|NCT02923908|Palatability
21051|NCT02923908|Pediatrics
21052|NCT02923908|Facial Recognition
21053|NCT02923908|Taste
21054|NCT02923908|Facial Expressions
21055|NCT02923882|Low-birth-weight
21056|NCT02923882|Model kitchen
21057|NCT02923882|Improved cookstove
21058|NCT02923869|Levobupivacaine
21059|NCT02923869|Bupivacaine
21060|NCT02923869|Nerve Block
21061|NCT02923869|Cleft Palate
21062|NCT02923856|Helicobacter pylori
21063|NCT02923856|Antibiotic resistance
21064|NCT02923856|Sequencing
21065|NCT02923843|frailty
21066|NCT02923843|comprehensive geriatric assessment
21067|NCT02923817|spinal cord injury
21068|NCT02923817|autologous transplants
21069|NCT02923817|bone marrow derived mononuclear cells
21070|NCT02923804|steatosis
21071|NCT02923804|NAFL
21072|NCT02923804|NAFLD
21073|NCT02923804|Polyunsaturated fatty acids
21074|NCT02923804|omega-3
21075|NCT02923804|EPA
21076|NCT02923804|DHA
21077|NCT02923804|fish oil
21078|NCT02923739|Malignant neoplasms of female genital organs
21079|NCT02923739|Ovarian Cancer
21080|NCT02923739|Fallopian Tube Cancer
21081|NCT02923739|Primary Peritoneal Cancer
21082|NCT02923739|relapsed/refractory
21083|NCT02923739|Platinum-resistant disease
21084|NCT02923739|Paclitaxel
21085|NCT02923739|Taxol
21086|NCT02923739|Bevacizumab
21087|NCT02923739|Avastin
21088|NCT02923739|rhuMAb-VEGF
21089|NCT02923739|Anti-VEGF monoclonal antibody
21090|NCT02923739|Emactuzumab
21091|NCT02923739|RO5509554
21092|NCT02923726|Antitachycardia Pacing Therapy
21093|NCT02923726|Shock Therapy
21094|NCT02923726|Primary Prevention
21095|NCT02923700|platelet rich plasma
21096|NCT02923700|intra-articular injection
21097|NCT02923700|leukocytes
21098|NCT02923687|Ketorolac
21099|NCT02923687|Root canal treatment
21100|NCT02923687|Pain
21101|NCT02923687|Premedication
21102|NCT02923661|single implant
21103|NCT02923635|Oncoplastic breast surgery
21104|NCT02923635|Standard Wide Local Excision
21105|NCT02923596|Keloid
21106|NCT02923570|proton-beam radiation therapy (PBRT)
21107|NCT02923570|intensity-modulated radiation therapy (IMRT)
21108|NCT02923570|16-1416
21109|NCT02923544|Uterine Manipulator
21110|NCT02923544|Yukio's Uterine Manipulating Instrument (YUMI)
21111|NCT02923544|16-1397
21112|NCT02923518|Heart Screening
21113|NCT02923518|Master Athletes
21114|NCT02923518|Cardiovascular Disease
21115|NCT02923479|Rehabilitation
21116|NCT02923479|Robotics
21117|NCT02923466|refractory solid tumor
21118|NCT02923427|laryngeal mask Supreme
21119|NCT02923427|i-gel
21120|NCT02923427|laparoscopic gynecological surgery
21121|NCT02923414|Cardioversion
21122|NCT02923401|Exercise
21123|NCT02923401|Biomarkers
21124|NCT02923401|Breast cancer high risk
21125|NCT02923401|Treadmill
21126|NCT02923401|Stationary bicycle
21127|NCT02923401|Questionnaires
21128|NCT02923401|Surveys
21129|NCT02923401|Motivational sessions
21130|NCT02923401|Phone calls
21131|NCT02923401|Printed materials
21132|NCT02923362|GERD
21133|NCT02923362|Reflux
21134|NCT02923362|Acid Reflux
21135|NCT02923362|Heartburn
21136|NCT02923362|Regurgitation
21137|NCT02923362|Laryngopharyngeal Reflux
21138|NCT02923362|Hiatal Hernia
21139|NCT02923362|LPR
21140|NCT02923362|LINX
21141|NCT02923362|Magnetic Sphincter Augmentation
21142|NCT02923362|Antireflux Surgery
21143|NCT02923362|Nissen
21144|NCT02923349|Solid tumor
21145|NCT02923349|adenocarcinoma of the endometrium
21146|NCT02923349|ovarian cancer
21147|NCT02923349|renal cell carcinoma
21148|NCT02923349|melanoma
21149|NCT02923349|non-small cell lung cancer
21150|NCT02923349|OX40
21151|NCT02923349|immunoglobulin G monoclonal antibody
21152|NCT02923336|liver cirrhosis
21153|NCT02923336|variceal bleeding
21154|NCT02923336|non selective beta blockers
21155|NCT02923323|Neurocognitive Function
21156|NCT02923323|MRI
21157|NCT02923323|Diffusion Tensor Imaging (DTI)
21158|NCT02923323|Sleep
21159|NCT02923297|parkinson
21160|NCT02923297|alpha-synuclein
21161|NCT02923297|GALIG
21162|NCT02923297|quantitative PCR (polymerase chain reaction)
21163|NCT02923271|Driving
21164|NCT02923271|Teens
21165|NCT02923271|Texting
21166|NCT02923271|Cellphone
21167|NCT02923271|DriveID
21168|NCT02923271|Motor vehicle accident
21169|NCT02923258|head and neck squamous cell carcinoma
21170|NCT02923258|concurrent chemotherapy
21171|NCT02923258|High-Risk
21172|NCT02923232|Contact lens; Accommodation; Visual performance
21173|NCT02923219|Facial Rejuvenation
21174|NCT02923219|Adipose-Derived Stem Cells
21175|NCT02923206|apheresis
21176|NCT02923206|pregnancy
21177|NCT02923206|pre-eclampsia
21178|NCT02923206|PE
21179|NCT02923206|sFlt-1
21180|NCT02923206|Pre-term
21181|NCT02923167|CP
21182|NCT02923167|Cerebral Palsy
21183|NCT02923167|Robotic
21184|NCT02923167|Hand
21185|NCT02923154|NASH
21186|NCT02923141|substance use
21187|NCT02923141|trauma
21188|NCT02923141|HIV
21189|NCT02923141|viral load
21190|NCT02923141|women
21191|NCT02923115|Venous thromboembolism
21192|NCT02923115|VTE
21193|NCT02923115|Pulmonary embolism
21194|NCT02923115|PE
21195|NCT02923115|Acute Submassive Pulmonary Embolism
21196|NCT02923102|Recovery
21197|NCT02923102|Muscle soreness
21198|NCT02923102|Lemon Verbena
21199|NCT02923089|Diabetes
21200|NCT02923089|Lentils
21201|NCT02923089|Pulses
21202|NCT02923089|Postprandial glycemia
21203|NCT02923076|Allogeneic Hematopoietic Cell Transplantation
21204|NCT02923063|Chronic Kidney Disease
21205|NCT02923063|Mitochondrial Metabolism
21206|NCT02923063|Physical Performance
21207|NCT02923063|Exercise Intolerance
21208|NCT02923063|Muscle Fatigue
21209|NCT02922998|CD64 antigens
21210|NCT02922998|Biomarkers
21211|NCT02922998|Granulocyte Colony-Stimulating Factor
21212|NCT02922998|Interleukin-4
21213|NCT02922998|Interferon-gamma
21214|NCT02922998|C-reactive protein
21215|NCT02922998|lipopolysaccharide-binding protein
21216|NCT02922998|procalcitonin
21217|NCT02922998|Cytokines
21218|NCT02922998|Patients
21219|NCT02922998|Human
21220|NCT02922998|Systemic Inflammatory Response Syndrome
21221|NCT02922998|Sepsis
21222|NCT02922998|Infection
21223|NCT02922998|Antibiotics
21224|NCT02922998|Intensive Care Units
21225|NCT02922998|Point-of-Care Systems
21226|NCT02922998|Bedside Testing
21227|NCT02922985|Cesarean delivery
21228|NCT02922985|Multimodal pain management
21229|NCT02922972|Keloid scar
21230|NCT02922972|Wound healing
21231|NCT02922972|Platelet-Rich Plasma
21232|NCT02922972|RegenLab
21233|NCT02922959|Opioid Substitution Treatment
21234|NCT02922959|Telephone intervention
21235|NCT02922959|secondary prevention
21236|NCT02922959|naloxone
21237|NCT02922946|entinostat
21238|NCT02922946|Histone Deacetylase Inhibitor
21239|NCT02922946|HDAC
21240|NCT02922933|entinostat
21241|NCT02922933|Histone Deacetylase Inhibitor
21242|NCT02922933|HDAC
21243|NCT02922868|Cystoscopy
21244|NCT02922868|EndoSheath
21245|NCT02922868|Infection Control
21246|NCT02922868|Bacteriuria
21247|NCT02922842|transcutaneous electrical nerve stimulation
21248|NCT02922829|Food Insecurity
21249|NCT02922829|Nutrition
21250|NCT02922816|Carbapenem-resistant Enterobacteriaceae (CRE)
21251|NCT02922816|Vancomycin-resistant Enterococcus (VRE)
21252|NCT02922816|Multidrug Resistant Organism (MDRO)
21253|NCT02922816|Fecal Microbiota Transplant (FMT)
21254|NCT02922816|Renal Transplant
21255|NCT02922816|Colonization
21256|NCT02922816|Infection
21257|NCT02922816|Antibiotic Resistance
21258|NCT02922816|Resistome
21259|NCT02922790|smoker
21260|NCT02922790|smoking
21261|NCT02922790|cigarette
21262|NCT02922790|cessation
21263|NCT02922790|DNA
21264|NCT02922790|DNA damage
21265|NCT02922790|blood draw
21266|NCT02922790|feedback
21267|NCT02922790|cellular
21268|NCT02922790|tobacco
21269|NCT02922790|tobacco smoke
21270|NCT02922764|Solid malignancy
21271|NCT02922764|Lymphoma
21272|NCT02922764|Solid tumor
21273|NCT02922764|Melanoma
21274|NCT02922764|Non-small cell lung cancer
21275|NCT02922764|Epithelial ovarian carcinoma
21276|NCT02922764|Breast cancer
21277|NCT02922764|NSCLC
21278|NCT02922764|EOC
21279|NCT02922764|BC
21280|NCT02922764|LXR
21281|NCT02922764|ApoE
21282|NCT02922764|mBC
21283|NCT02922751|transient elastography
21284|NCT02922751|pediatric liver disease
21285|NCT02922751|biliary atresia
21286|NCT02922751|Alagille Syndrome
21287|NCT02922751|Alpha1 Anti-Trypsin Deficiency
21288|NCT02922751|liver fibrosis
21289|NCT02922751|cholestasis
21290|NCT02922738|Clinical Knowledge Systems, Decision support, Dermatology
21291|NCT02922738|Technology Assessment
21292|NCT02922673|human endotoxemia
21293|NCT02922673|LPS
21294|NCT02922673|acetylsalicylic acid
21295|NCT02922673|placebo
21296|NCT02922673|endotoxin tolerance
21297|NCT02922660|Ambulatory surgery
21298|NCT02922660|Ophthalmic
21299|NCT02922660|Inhalation anesthesia
21300|NCT02922660|Desflurane
21301|NCT02922660|Total intravenous anesthesia
21302|NCT02922634|postoperative health outcomes
21303|NCT02922634|older surgical patients
21304|NCT02921581|Dose painting
21305|NCT02921581|18F-FDG
21306|NCT02921581|Positron emission tomography
21307|NCT02921581|Radiotherapy
21308|NCT02921555|RCT (randomized controlled trial)
21309|NCT02921529|Postoperative recovery
21310|NCT02921529|colon surgery
21311|NCT02921516|Adolescence
21312|NCT02921516|Adherence
21313|NCT02921438|Cardiovascular Diseases
21314|NCT02921438|Heart Diseases
21315|NCT02921438|Myocardial Ischemia
21316|NCT02921438|NSTE ACS
21317|NCT02921438|NSTEMI
21318|NCT02921438|Unstable Angina Pectoris
21319|NCT02921438|Coronary Artery Disease
21320|NCT02921425|lifestyle
21321|NCT02921425|patient health record
21322|NCT02921425|Veterans
21323|NCT02921425|prediabetes
21324|NCT02921373|perfluorocarbon imaging
21325|NCT02921373|peripheral blood mononuclear cells
21326|NCT02921373|cancer immunotherapy
21327|NCT02921373|prostate cancer
21328|NCT02921373|MRI
21329|NCT02922608|Education, Medical
21330|NCT02922543|Multiple Myeloma
21331|NCT02922543|Teratogenicity
21332|NCT02922543|Thrombocytopenia and haemorrhage
21333|NCT02922543|Neutropenia and infection
21334|NCT02922543|Venous thromboembolism
21335|NCT02922543|Allergic reactions
21336|NCT02922543|Diarrhoea or constipation
21337|NCT02922543|Peripheral neuropathy
21338|NCT02922543|Cardiac failure
21339|NCT02922543|Arrhythmia
21340|NCT02922543|Renal failure
21341|NCT02922543|Myocardial infarction
21342|NCT02922543|Interstitial lung disease
21343|NCT02922543|Tumour lysis syndrome
21344|NCT02922517|biomarkers
21345|NCT02922517|echocardiography
21346|NCT02922517|MRI imaging
21347|NCT02922517|nuclear medicine
21348|NCT02922504|First trimester abortion
21349|NCT02922504|Surgical abortion
21350|NCT02922504|Music intervention
21351|NCT02922504|Local anesthesia
21352|NCT02922504|Pain
21353|NCT02922439|chronic disease
21354|NCT02922439|multimorbidity
21355|NCT02922439|chronic disease self-management
21356|NCT02922439|tailored information
21357|NCT02922439|mobile applications
21358|NCT02922426|ALKS 3831
21359|NCT02922426|Samidorphan
21360|NCT02922426|Olanzapine
21361|NCT02922413|Porphyria
21362|NCT02922413|Heme
21363|NCT02922400|Autism
21364|NCT02922400|Traumatic Brain Injury
21365|NCT02922400|Schizophrenia
21366|NCT02922400|Virtual-Reality Social Cognition Training
21367|NCT02922387|varenicline
21368|NCT02922387|COPD
21369|NCT02922387|asthma
21370|NCT02922387|pneumonia
21371|NCT02922387|smoking cessation
21372|NCT02922374|acute severe colitis
21373|NCT02922374|corticosteroids
21374|NCT02922374|UCEIS
21375|NCT02922374|fecal calprotectin
21376|NCT02922348|premature ovarian failure
21377|NCT02922348|hormone replacement
21378|NCT02922335|Antisocial Behavior
21379|NCT02922335|Mental Illness
21380|NCT02922335|Emerging Adulthood
21381|NCT02922335|Criminal Behavior
21382|NCT02922335|Serious Mental Illness
21383|NCT02922322|Mat Pilates
21384|NCT02922322|Chronic Nonspecific low back pain
21385|NCT02922322|Quality of life
21386|NCT02922322|Disability
21387|NCT02922322|transverse abdominal muscle
21388|NCT02922283|T cell response
21389|NCT02922283|Interleukin 2
21390|NCT02922283|PET scan
21391|NCT02922283|Ipilimumab
21392|NCT02922283|Pembrolizumab
21393|NCT02922283|Nivolumab
21394|NCT02922270|peritoneal dialysis: outcome
21395|NCT02922270|peritoneal dialysis: complications
21396|NCT02922270|peritoneal dialysis: technique
21397|NCT02922270|peritoneal dialysis: peritonitis
21398|NCT02922244|herbal products
21399|NCT02922244|reduction of radiation-induced dermatitis
21400|NCT02922244|breast cancer
21401|NCT02922244|radiotherapy
21402|NCT02922192|Anti-inflammatory
21403|NCT02922192|Biologics
21404|NCT02922192|Biologic and Biosimilars Collective Intelligence Consortium
21405|NCT02922192|BBCIC
21406|NCT02922179|Insulin
21407|NCT02922179|Diabetes
21408|NCT02922179|Biologic and Biosimilars Collective Intelligence Consortium
21409|NCT02922179|BBCIC
21410|NCT02922179|Descriptive analysis
21411|NCT02922153|CryoAnalgesia
21412|NCT02922153|Thoracotomy
21413|NCT02922153|FEV1
21414|NCT02922153|VAS
21415|NCT02922140|pharmaceutical care service, clinical pharmacist
21416|NCT02922140|Cardiac rehabilitation unit
21417|NCT02922140|Acute coronary syndrome
21418|NCT02922140|patient education and counselling
21419|NCT02922127|Ulipristal Acetate (UPA)
21420|NCT02922127|Breast Cancer
21421|NCT02922127|Combined Oral Contraceptive (COC)
21422|NCT02922114|Ultrasonography
21423|NCT02922114|Clinical assesment
21424|NCT02922114|joint abnormalities
21425|NCT02922088|Vein Graft Failure
21426|NCT02922088|Coronary Artery Bypass Graft Surgery
21427|NCT02922088|Vascular Grafts
21428|NCT02922088|Saphenous Vein Grafts
21429|NCT02922088|Vein Graft Disease
21430|NCT02922088|Vein Graft Treatment
21431|NCT02922088|Vein Graft Handling
21432|NCT02922075|gingival recession
21433|NCT02922075|immediate implant and provisional placement
21434|NCT02922075|bone graft
21435|NCT02922075|connective tissue graft
21436|NCT02922075|collagen matrix
21437|NCT02922062|lipids
21438|NCT02922062|saturated fat
21439|NCT02922062|palm oil
21440|NCT02922049|Probe Based Confocal Laser Endomicroscopy (pCLE)
21441|NCT02922049|Barrett's esophagus
21442|NCT02922049|BORN
21443|NCT02922049|Intestinal metaplasia
21444|NCT02921997|A/H5N1
21445|NCT02921997|A/H7N9
21446|NCT02921997|ASO3 Adjuvant
21447|NCT02921997|influenza
21448|NCT02921997|monovalent
21449|NCT02921997|pH1N1
21450|NCT02921997|vaccines
21451|NCT02921984|Salivary Gland Tumors
21452|NCT02921984|Head and Neck Cancer
21453|NCT02921984|concurrent chemotherapy
21454|NCT02921984|genetic testing
21455|NCT02921958|Parents of children with disabilities
21456|NCT02921932|Physiotherapy
21457|NCT02921932|Inspiratory Muscle Training
21458|NCT02921932|Perioperative Medicine
21459|NCT02921932|Postoperative outcomes
21460|NCT02921932|Preoperative nutrition
21461|NCT02921932|Elderly, frail
21462|NCT02921906|Insulin
21463|NCT02921906|Glucose
21464|NCT02921906|Incretin
21465|NCT02921906|GLP-1
21466|NCT02921906|Food
21467|NCT02921867|ultrasound
21468|NCT02921867|radiology
21469|NCT02921867|simulation
21470|NCT02921867|abdominal ultrasound
21471|NCT02921867|medical education
21472|NCT02921841|Adolescents
21473|NCT02921841|HIV prevention
21474|NCT02921841|computerized intervention
21475|NCT02921841|mental health treatment
21476|NCT02921828|Pomalyst
21477|NCT02921828|Teratogenicity
21478|NCT02921828|bone marrow suppression
21479|NCT02921828|thromboembolism
21480|NCT02921828|peripheral neuropathy
21481|NCT02921828|infection
21482|NCT02921828|tumour lysis syndrome
21483|NCT02921828|somnolence
21484|NCT02921828|depressed level of consciousness
21485|NCT02921828|confusion
21486|NCT02921828|fatigue
21487|NCT02921828|dizziness
21488|NCT02921828|acute renal failure
21489|NCT02921828|heart failure
21490|NCT02921828|arrhythmia
21491|NCT02921828|interstitial pneumonia
21492|NCT02921828|hypersensitivity
21493|NCT02921828|hepatic function disorder
21494|NCT02921828|jaundice
21495|NCT02921815|Leukemia
21496|NCT02921815|Acute Myeloid Leukemia
21497|NCT02921815|Revlimid
21498|NCT02921802|Teratogenicity
21499|NCT02921802|Thrombocytopenia and haemorrhage
21500|NCT02921802|Neutropenia and infection
21501|NCT02921802|Venous thromboembolism
21502|NCT02921802|Allergic reactions
21503|NCT02921802|Diarrhoea or constipation
21504|NCT02921802|Peripheral neuropathy
21505|NCT02921802|Cardiac failure
21506|NCT02921802|Arrhythmia
21507|NCT02921802|Renal failure
21508|NCT02921802|Myocardial infarction
21509|NCT02921802|Interstitial lung disease
21510|NCT02921802|Tumour lysis syndrome
21511|NCT02921802|Transformation from myelodysplastic syndrome to acute myeloid leukemia
21512|NCT02921789|Bleselumab
21513|NCT02921789|ASKP1240
21514|NCT02921789|Efficacy and Safety
21515|NCT02921776|Vidatalk
21516|NCT02921776|App
21517|NCT02921776|Augmentative and Alternative Communication
21518|NCT02921776|iPad
21519|NCT02921776|Android
21520|NCT02921776|Mechanical ventilation
21521|NCT02921776|Patient Communication
21522|NCT02921776|Critical Illness
21523|NCT02921750|wound reduction wound healing, venous ulcers
21524|NCT02921737|metastatic
21525|NCT02921737|pancreatic
21526|NCT02921737|adenocarcinoma
21527|NCT02921724|cancer
21528|NCT02921724|oral drug
21529|NCT02921724|sunitinib
21530|NCT02921724|capecitabine
21531|NCT02921724|mobile app
21532|NCT02921659|nicotinamide riboside
21533|NCT02921659|aging
21534|NCT02921659|arterial stiffness
21535|NCT02921659|endothelial dysfunction
21536|NCT02921646|energetic expenditure
21537|NCT02921633|Immunization
21538|NCT02921633|Behavioural insights
21539|NCT02921633|Children
21540|NCT02921620|Gastrointestinal symptoms
21541|NCT02921620|Diarrhea
21542|NCT02921620|Abdominal pain
21543|NCT02921360|thrombolytic therapy
21544|NCT02921360|tissue plasminogen activator
21545|NCT02921360|aspirin
21546|NCT02921321|MRI
21547|NCT02921321|Muscular Dystrophy
21548|NCT02921321|Cardiac
21549|NCT02921321|Late gadolinium enhancement
21550|NCT02921308|Prematurity
21551|NCT02921308|Bronchopulmonary dysplasia
21552|NCT02921308|MRI
21553|NCT02921308|PFT
21554|NCT02921308|Emphysema
21555|NCT02921282|genes
21556|NCT02921282|cues
21557|NCT02921282|reward
21558|NCT02921282|smoking
21559|NCT02921230|atherosclerosis
21560|NCT02921230|Superficial Femoral Artery (SFA)
21561|NCT02921230|Proximal Popliteal Artery (PPA)
21562|NCT02921230|stenting
21563|NCT02921230|paclitaxel
21564|NCT02921217|Cardiovascular diseases
21565|NCT02921217|abdominal visceral fat
21566|NCT02921217|subcutaneous body fat
21567|NCT02921217|body weight
21568|NCT02921217|waist circumference
21569|NCT02921217|lipid profile
21570|NCT02921217|insulin resistance
21571|NCT02921217|glucose metabolism
21572|NCT02921217|blood pressure
21573|NCT02921217|inflammation
21574|NCT02921217|adiponectin
21575|NCT02921217|leptin
21576|NCT02921217|metabolomics
21577|NCT02921217|cardiovascular risk factor
21578|NCT02921204|Vitamin D
21579|NCT02921204|Calcium
21580|NCT02921204|Phytic Acid
21581|NCT02921204|body weight
21582|NCT02921191|recombinant human granulocyte colony-stimulating factors
21583|NCT02921191|G-CSFs
21584|NCT02921191|biosimilar
21585|NCT02921191|biologics
21586|NCT02921191|High Neutropenia Risk Chemotherapy
21587|NCT02921191|Biologic and Biosimilars Collective Intelligence Consortium
21588|NCT02921191|bbcic
21589|NCT02921165|tooth extraction
21590|NCT02921165|tooth socket healing
21591|NCT02921165|hypertension
21592|NCT02921165|rinses
21593|NCT02921139|Hepatocellular Carcinoma
21594|NCT02921139|Transcatheter Arterial Chemoembolization (TACE)
21595|NCT02921139|Stereotactic ablative radiotherapy (SABR)
21596|NCT02921113|suPAR
21597|NCT02921113|Acute Kidney Injury
21598|NCT02921113|On-Pump Cardiac Surgery
21599|NCT02921113|Biomarker
21600|NCT02921048|Eicosapentaenoic Acid
21601|NCT02921048|Docosahexaenoic Acid
21602|NCT02921048|Ambient Air Pollution
21603|NCT02921035|Relapsing Multiple Sclerosis
21604|NCT02921035|Interferon beta-1a
21605|NCT02921035|Rebif®
21606|NCT02921035|Morisky Medication Adherence Scale
21607|NCT02921022|Gemcitabine
21608|NCT02921022|Nab-paclitaxel
21609|NCT02921022|PEGPH20
21610|NCT02921022|Rivaroxaban
21611|NCT02921022|thromboembolic event (TE)
21612|NCT02921022|16-1066
21613|NCT02920996|NSCLC
21614|NCT02920996|MET
21615|NCT02920996|Non-small cell lung cancer
21616|NCT02920996|MET mutation
21617|NCT02920996|NTRK rearrangement
21618|NCT02920996|NTRK
21619|NCT02920996|targeted therapy
21620|NCT02920996|MET exon 14
21621|NCT02920996|NTRK1
21622|NCT02920996|NTRK2
21623|NCT02920996|NTRK3
21624|NCT02920996|merestinib
21625|NCT02920996|LY2801653
21626|NCT02920918|Systolic Heart Failure
21627|NCT02920918|Canagliflozin
21628|NCT02920918|Sitagliptin Phosphate
21629|NCT02920918|Type 2 Diabetes
21630|NCT02920918|SGLT2 inhibitor
21631|NCT02920918|DPPIV inhibitor
21632|NCT02920866|Functional strength integration
21633|NCT02920866|Rehabilitation
21634|NCT02920866|Hip arthroplasty
21635|NCT02920866|Physical function
21636|NCT02920866|Muscle performance
21637|NCT02920866|Movement compensations
21638|NCT02920853|chronic pain
21639|NCT02920827|HIV Infections
21640|NCT02920827|HIV seronegativity
21641|NCT02920801|saxagliptin
21642|NCT02920801|endothelial progenitor cell
21643|NCT02920801|flow-mediated dilation
21644|NCT02920788|Rehabilitation
21645|NCT02920788|Functional Magnetic Resonance Imaging
21646|NCT02920749|anaesthesia
21647|NCT02920749|costs
21648|NCT02920749|recovery profiles
21649|NCT02920723|Sleep Apnea Syndromes
21650|NCT02920723|Sleep Apnea, Obstructives
21651|NCT02920723|Training
21652|NCT02920684|Early rehabilitation
21653|NCT02920684|Mechanical ventilation
21654|NCT02920684|Physiotherapy
21655|NCT02920658|NAVS Naphthalan
21656|NCT02920658|Betamethasone dipropionate
21657|NCT02920658|Topical treatment
21658|NCT02920645|ICH
21659|NCT02920645|AVM
21660|NCT02920645|intracerebral hemorrhage
21661|NCT02920645|arterio-venous malformation
21662|NCT02920645|AVICH
21663|NCT02920632|Parkinson
21664|NCT02920632|Cognitive training
21665|NCT02920632|Cognitive rehabilitation
21666|NCT02920632|Brain networks
21667|NCT02920619|ultrasound
21668|NCT02920619|muscle
21669|NCT02920606|pulpotomy
21670|NCT02920606|pulpitis
21671|NCT02920606|mature tooth
21672|NCT02920606|tricalcium silicate
21673|NCT02920593|Vitamin D; hypertensive disorders of pregnancy
21674|NCT02920580|Subarachnoid hemorrhage
21675|NCT02920580|Spontaneous intracerebral hemorrhage
21676|NCT02920580|Global cerebral anoxia/cardiac arrest
21677|NCT02920580|Meningitis/Encephalitis/Cerebral abscess
21678|NCT02920580|Seizure
21679|NCT02920580|Traumatic Brain Injury (TBI)
21680|NCT02920580|Ischemic Stroke
21681|NCT02920580|Brain tumor
21682|NCT02920554|gallbladder cancer
21683|NCT02920554|bisegmentectomy
21684|NCT02920515|epidemiology
21685|NCT02920515|treatment
21686|NCT02920515|molecular pathological mechanism
21687|NCT02920515|environmental disrupting chemicals
21688|NCT02920489|severity of labor pain
21689|NCT02920489|individualized administration
21690|NCT02920489|neuraxial labor analgesia
21691|NCT02920476|lung
21692|NCT02920476|metastatic
21693|NCT02920476|carcinoma
21694|NCT02920463|Anti-Infective agents
21695|NCT02920463|Antimicrobial stewardship
21696|NCT02920463|Empirical antibiotic therapy
21697|NCT02920463|De-escalation
21698|NCT02920463|Critical care
21699|NCT02920450|lung
21700|NCT02920450|carcinoma
21701|NCT02920437|dietary salt
21702|NCT02920437|24 hour urinary sodium excretion
21703|NCT02920437|blood pressure
21704|NCT02920437|hypertension
21705|NCT02920346|Neonatal Systemic lupus erythematosus
21706|NCT02920346|Sjogren's syndrome
21707|NCT02920346|Fetal Atrioventricular Block
21708|NCT02920346|Fetal Heart Block
21709|NCT02920333|stroke
21710|NCT02920333|transcraniel direct current stimulation
21711|NCT02920333|repetitive transcraniel magnetic stimulation
21712|NCT02920333|rehabilitation
21713|NCT02920333|lower extremeties
21714|NCT02920307|laparoscopic inguinal hernia repair
21715|NCT02920307|total extraperitoneoscopic hernia repair
21716|NCT02920307|transabdominal preperitoneal hernia repair
21717|NCT02920307|inguinal hernia
21718|NCT02920307|laparoscopy
21719|NCT02920307|hernia repair
21720|NCT02920307|herniorraphy
21721|NCT02920307|laparoscopic surgery
21722|NCT02920294|probiotics, microbiota, ileostoma
21723|NCT02920268|dance-intervention
21724|NCT02920268|yoga
21725|NCT02920268|adolescents
21726|NCT02920268|recurrent abdominal pain
21727|NCT02920242|Travelers
21728|NCT02920242|diarrhea
21729|NCT02920242|rifaximin
21730|NCT02920242|equivalence
21731|NCT02920229|68Ga-PSMA
21732|NCT02920229|HBED-PET/CT
21733|NCT02920229|biochemical relapse
21734|NCT02920229|prostate cancer
21735|NCT02920229|radically treated
21736|NCT02920216|Head and Neck Neoplasms
21737|NCT02920216|Recurrence
21738|NCT02920216|Indocyanine Green
21739|NCT02920216|Salvage surgery
21740|NCT02920203|Sudden unexpected death
21741|NCT02920203|young subjects
21742|NCT02920203|molecular genetic autopsy
21743|NCT02920203|sequencing
21744|NCT02920138|Obesity
21745|NCT02920138|intraabdominal pressure
21746|NCT02920138|cerebral oxymeter
21747|NCT02920138|sleeve gastrectomy
21748|NCT02920138|laparoscopy
21749|NCT02920125|Vascular disease
21750|NCT02920112|Obesity
21751|NCT02920112|Bariatric Surgery
21752|NCT02920112|Bariatrics
21753|NCT02920112|Cognitive Therapy
21754|NCT02920112|Binge eating
21755|NCT02920099|Nutrition literacy
21756|NCT02920073|Microbiota
21757|NCT02920073|anorexia nervosa
21758|NCT02920073|under nutrition
21759|NCT02920073|inpatients
21760|NCT02920073|enteral nutrition
21761|NCT02920060|RSE
21762|NCT02920047|Fimasartan
21763|NCT02920008|AML, acute myeloid leukemia, guadecitabine, SGI-110, Phase 3
21764|NCT02919982|Anticoagulant
21765|NCT02919982|Nonvalvular atrial fibrillation
21766|NCT02919982|Registries
21767|NCT02919969|Anal Cancer
21768|NCT02919956|Single Ventricle
21769|NCT02919956|Fontan
21770|NCT02919904|prostate cancer
21771|NCT02919904|sleep
21772|NCT02919904|androgen deprivation therapy
21773|NCT02919891|intra-epidermal nerve fibre density
21774|NCT02919891|IENFD
21775|NCT02919891|Chronic Pain
21776|NCT02919891|Post-mastectomy
21777|NCT02919891|Post-mastectomy pain syndrome
21778|NCT02919891|PMPS
21779|NCT02919891|Chronic Post-Surgical Pain
21780|NCT02919891|CPSP
21781|NCT02919891|Mastectomy
21782|NCT02919813|mindfulness group therapy
21783|NCT02919813|vulvodynia
21784|NCT02919813|vulvar pain
21785|NCT02919787|Neoadjuvant treatment
21786|NCT02919761|persistant disease activity
21787|NCT02919748|dementia
21788|NCT02919748|cognitive decline
21789|NCT02919748|choral singing
21790|NCT02919748|health education program
21791|NCT02919748|randomized controlled trial
21792|NCT02919735|Alopecia
21793|NCT02919735|Hair
21794|NCT02919735|Chemotherapy
21795|NCT02919735|Cancer
21796|NCT02919722|Music therapy
21797|NCT02919722|sensorimotor cortex
21798|NCT02919722|brain injury
21799|NCT02919696|CDK4/6 Inhibitor
21800|NCT02919683|Head and Neck Cancer
21801|NCT02919670|Stem Cell Transplant
21802|NCT02919644|vaccination
21803|NCT02919644|autologous dendritic cells
21804|NCT02919644|autologous tumour homogenate
21805|NCT02919644|curative resection
21806|NCT02919644|stage IV colorectal cancer
21807|NCT02919618|Ventricular Tachycardia
21808|NCT02919618|Ablation
21809|NCT02919618|Noninvasive
21810|NCT02919605|Cutaneous Leishmaniasis
21811|NCT02919605|pentamidine isothionate
21812|NCT02919605|treatment
21813|NCT02919553|endoscopic ultrasound
21814|NCT02919553|wet-suction technique
21815|NCT02919553|capillary technique
21816|NCT02919553|fine needle aspiration
21817|NCT02919553|fine needle biopsy
21818|NCT02919514|fall prevention
21819|NCT02919514|Aging
21820|NCT02919514|surfaces
21821|NCT02919475|JTE-051
21822|NCT02919475|Active Rheumatoid Arthritis
21823|NCT02919475|Efficacy
21824|NCT02919475|Safety
21825|NCT02919475|Tolerability
21826|NCT02919475|Rheumatoid Arthritis
21827|NCT02919462|Carcinoma, Non-Small-Cell Lung
21828|NCT02919462|advanced stage IIIB
21829|NCT02919462|high Thymidylate Synthase expression
21830|NCT02919462|Treatment
21831|NCT02919462|Chemotherapy Naïve Patients
21832|NCT02919462|stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
21833|NCT02919462|Cisplatin and Pemetrexed
21834|NCT02919462|Cisplatin and Oral Vinorelbine
21835|NCT02919449|Lung Cancer Measles Nivolumab Opdivo
21836|NCT02919384|Embryonic development
21837|NCT02919384|blastocyst stage
21838|NCT02919345|Dapagliflozin
21839|NCT02919345|Glibenclamide
21840|NCT02919345|Endothelial Function
21841|NCT02919345|Vascular Endothelial Cells
21842|NCT02919345|Flow Mediated Dilation
21843|NCT02919267|One lung ventilation
21844|NCT02919267|Lung collapse
21845|NCT02919267|Bronchial blocker
21846|NCT02919267|Double lumen tube
21847|NCT02919267|video assisted thoracoscopic surgery
21848|NCT02919267|VATS
21849|NCT02919267|DLT
21850|NCT02919267|Thoracic surgery
21851|NCT02919267|Video-assisted
21852|NCT02919241|dental anxiety
21853|NCT02919241|cognitive therapy
21854|NCT02919228|cerebral oxygen metabolism
21855|NCT02919228|functional near-infrared spectroscopy
21856|NCT02919228|partial pressure of carbon dioxide
21857|NCT02919228|heart rate variability
21858|NCT02919228|blood pressure
21859|NCT02919228|affect
21860|NCT02919228|mood
21861|NCT02919228|respiration
21862|NCT02919228|systematic randomized cross-over study
21863|NCT02919228|systemic physiology
21864|NCT02919228|electro-dermal activity
21865|NCT02919228|pulse-respiratory quotient
21866|NCT02919189|cerebral oxygen metabolism
21867|NCT02919189|functional near-infrared spectroscopy
21868|NCT02919189|partial pressure of carbon dioxide
21869|NCT02919189|heart rate variability
21870|NCT02919189|blood pressure
21871|NCT02919189|affect
21872|NCT02919189|mood
21873|NCT02919189|respiration
21874|NCT02919189|systematic randomized cross-over study
21875|NCT02919189|systemic physiology
21876|NCT02919189|electro-dermal activity
21877|NCT02919189|pulse-respiratory quotient
21878|NCT02919163|cerebral oxygen metabolism
21879|NCT02919163|functional near-infrared spectroscopy
21880|NCT02919163|partial pressure of carbon dioxide
21881|NCT02919163|heart rate variability
21882|NCT02919163|blood pressure
21883|NCT02919163|affect
21884|NCT02919163|mood
21885|NCT02919163|respiration
21886|NCT02919163|systematic randomized cross-over study
21887|NCT02919163|systemic physiology
21888|NCT02919163|electro-dermal activity
21889|NCT02919163|pulse-respiratory quotient
21890|NCT02919150|Myofascial Trigger Points
21891|NCT02919150|Myotonometry
21892|NCT02919150|Isokinetic Dynamometry
21893|NCT02919150|Assessment
21894|NCT02919150|Reliability
21895|NCT02919137|cerebral oxygen metabolism
21896|NCT02919137|functional near-infrared spectroscopy
21897|NCT02919137|partial pressure of carbon dioxide
21898|NCT02919137|heart rate variability
21899|NCT02919137|blood pressure
21900|NCT02919137|affect
21901|NCT02919137|mood
21902|NCT02919137|respiration
21903|NCT02919137|systematic randomized cross-over study
21904|NCT02919137|systemic physiology
21905|NCT02919137|electro-dermal activity
21906|NCT02919137|pulse-respiratory quotient
21907|NCT02919124|Coronary artery bypass grafting
21908|NCT02919124|Anastomosis
21909|NCT02919124|Ultrasonography
21910|NCT02919059|Diabetes Mellitus, Type 2
21911|NCT02919059|DM
21912|NCT02919046|neuroblastoma
21913|NCT02919046|CAR-T
21914|NCT02919033|randomized controlled trial
21915|NCT02919033|telemedicine
21916|NCT02919033|hypertension
21917|NCT02919033|primary care
21918|NCT02919033|medication adherence
21919|NCT02919020|Proprioceptive Neuromuscular Facilitation (PNF )
21920|NCT02919020|resistance exercise
21921|NCT02918968|enzalutamide
21922|NCT02918968|Xtandi
21923|NCT02918968|Prostate Cancer
21924|NCT02918955|head and neck cancer
21925|NCT02918955|radiotherapy
21926|NCT02918955|chemotherapy
21927|NCT02918955|neck dissection
21928|NCT02918955|surgery
21929|NCT02918955|quality of life
21930|NCT02918955|toxicity
21931|NCT02918955|oropharyngeal cancer
21932|NCT02918955|laryngeal cancer
21933|NCT02918955|hypopharyngeal cancer
21934|NCT02918929|First-in-human
21935|NCT02918929|Single Ascending Dose
21936|NCT02918929|Multiple Ascending Dose
21937|NCT02918890|Pediatric
21938|NCT02918890|HABIT
21939|NCT02918890|CIMT
21940|NCT02918890|Cerebral Palsy
21941|NCT02918890|Hemiplegia
21942|NCT02918890|Children
21943|NCT02918890|Therapy
21944|NCT02918877|Volatile Anesthetics
21945|NCT02918877|Intravenous Anesthetics
21946|NCT02918877|Inflammatory Lung Injury
21947|NCT02918877|Postoperative Pulmonary Complications
21948|NCT02918877|Cardiac Surgery
21949|NCT02918877|Cardiopulmonary Bypass
21950|NCT02918864|Autism Spectrum Disorder
21951|NCT02918864|Oxytocin
21952|NCT02918864|Social Skills
21953|NCT02918864|Social cognitive skills
21954|NCT02918864|Cognitive Behavioral Intervention
21955|NCT02918864|Combination treatment
21956|NCT02918864|Syntocinon
21957|NCT02918864|NETT (Nonverbal communication, Emotion recognition, Theory of mind Training)
21958|NCT02918864|emotion recognition
21959|NCT02918864|theory of mind
21960|NCT02918838|HIV
21961|NCT02918838|Antiretroviral (ARV)
21962|NCT02918838|co-trimoxazole
21963|NCT02918838|SMS
21964|NCT02918838|Lottery incentive
21965|NCT02918838|mobile health
21966|NCT02918838|Uganda
21967|NCT02918838|Youth
21968|NCT02918825|schizophrenia
21969|NCT02918825|clinical trial
21970|NCT02918825|olanzapine
21971|NCT02918825|paliperidone
21972|NCT02918812|Hysterosalpingography
21973|NCT02918812|Pain relief
21974|NCT02918812|Infertility
21975|NCT02918812|Intracervical block
21976|NCT02918812|Diclofenac
21977|NCT02918786|oxygen therapy
21978|NCT02918786|continuous positive airway pressure
21979|NCT02918786|extubation
21980|NCT02918773|Pediatrics
21981|NCT02918773|Emergency Medicine
21982|NCT02918773|Ear infection
21983|NCT02918760|Gabapentin, chronic pelvic pain.
21984|NCT02918734|Anterior Cruciate Ligament
21985|NCT02918734|Bone-Patellar Tendon-Bone Grafting
21986|NCT02918721|Hyaluronic Acid, Nasolabial Fold, Lidocaine
21987|NCT02918708|vaccination
21988|NCT02918708|immunisation
21989|NCT02918708|pneumococcal
21990|NCT02918708|conjugate
21991|NCT02918695|Geriatric assessment
21992|NCT02918695|Fit and frail elderly
21993|NCT02918695|Geriatric oncology
21994|NCT02918656|Cochrane
21995|NCT02918656|Abstract
21996|NCT02918656|Infographics
21997|NCT02918656|Understanding
21998|NCT02918643|Elderly
21999|NCT02918643|Potentially Inappropriate Medications
22000|NCT02918630|E-cigarettes
22001|NCT02918630|Schizophrenia
22002|NCT02918617|dentin hypersensitivity
22003|NCT02918617|nanohydroxyapatite
22004|NCT02918617|calcium sodium phosphosilicate
22005|NCT02918617|toothpaste
22006|NCT02918617|tooth cream
22007|NCT02918604|peripheral vein access
22008|NCT02918604|infrared
22009|NCT02918604|pediatric
22010|NCT02918578|Physical Inactivity
22011|NCT02918578|Behavior Change
22012|NCT02918526|Laryngeal masks
22013|NCT02918513|Wellness
22014|NCT02918513|Mental Wellness
22015|NCT02918513|Well-Being
22016|NCT02918500|Coronary Artery Bypass Surgery (CABG)
22017|NCT02918500|Nicotine Replacement Therapy (NRT)
22018|NCT02918474|Contralateral prophylactic breast cancer
22019|NCT02918474|CPM
22020|NCT02918474|Breast cancer surgery
22021|NCT02918474|Breast Cancer
22022|NCT02918474|Questionnaire
22023|NCT02918474|Survey
22024|NCT02918474|Decision tool
22025|NCT02918474|Contralateral Prophylactic Mastectomy
22026|NCT02918422|Diet Intervention
22027|NCT02918422|Metabolic Syndrome
22028|NCT02918422|Feeding Study
22029|NCT02918422|Prediabetes
22030|NCT02918396|Atrial Fibrillation
22031|NCT02918396|Atrial Fibrosis
22032|NCT02918396|Late Gadolinium Enhancement Magnetic Resonance Imaging
22033|NCT02918396|Computational Modeling
22034|NCT02918396|Rotor Anchor Sites
22035|NCT02918370|Alcohol Use Disorder
22036|NCT02918370|Bipolar Disorder
22037|NCT02918370|Mood
22038|NCT02918370|Alcohol Craving
22039|NCT02918370|Aripiprazole
22040|NCT02918344|calcium phosphate paste
22041|NCT02918305|denervation
22042|NCT02918305|resistant hypertension
22043|NCT02918292|Unrelated Cord Blood (UCB)
22044|NCT02918292|Haploidentical Bone Marrow
22045|NCT02918292|Hematopoietic Stem Cell Transplant (HSCT)
22046|NCT02918292|Severe Aplastic Anemia (SAA)
22047|NCT02918292|Antithymocyte Globulin (ATG)
22048|NCT02918266|Drug Therapy
22049|NCT02918253|High dose-rate brachytherapy
22050|NCT02918227|Ejaculation
22051|NCT02918227|Benign Prostatic Hyperplasia
22052|NCT02918227|Prostate
22053|NCT02918214|Septic Shock
22054|NCT02918214|echocardiography
22055|NCT02918214|diastolic dysfunction
22056|NCT02918214|Transthoracic
22057|NCT02918214|Transesophageal
22058|NCT02918214|hyperkinesia
22059|NCT02918214|prognosis
22060|NCT02918201|Administration, topical
22061|NCT02918201|Tranexamic Acid
22062|NCT02918201|Postoperative Care
22063|NCT02918201|Bandages
22064|NCT02918201|Occlusive Dressings
22065|NCT02918175|mHealth
22066|NCT02918162|pembrolizumab
22067|NCT02918162|adenocarcinoma
22068|NCT02918162|gastric cancer
22069|NCT02918162|Locoregional gastric adenocarcinoma
22070|NCT02918162|Locoregional GE junction adenocarcinoma
22071|NCT02918149|Ultrasonography
22072|NCT02918149|Infant
22073|NCT02918149|Newborn
22074|NCT02918149|Lumbar puncture
22075|NCT02918149|Spinal puncture
22076|NCT02918149|Cerebrospinal fluid
22077|NCT02918123|Psoriasis
22078|NCT02918123|Plaque psoriasis
22079|NCT02918123|Stem cell
22080|NCT02918123|Cell therapy
22081|NCT02918123|Furestem
22082|NCT02918123|Mesenchymal stem cell
22083|NCT02918123|MSC
22084|NCT02918123|Umbilical cord blood
22085|NCT02918123|hUCB-MSC
22086|NCT02918123|UCB-MSC
22087|NCT02918097|Cost effectiveness
22088|NCT02918097|Bipolar disorder
22089|NCT02918097|Depressive episodes
22090|NCT02918097|Quality of Life
22091|NCT02918084|sequential administration chemiotherapy
22092|NCT02918084|early breast cancer
22093|NCT02918084|breast cancer
22094|NCT02918084|aromatase inhibitor
22095|NCT02918084|adjuvant
22096|NCT02918084|post menopausal
22097|NCT02918071|Asthma,
22098|NCT02918071|Bronchial Diseases,
22099|NCT02918071|Respiratory Tract Diseases,
22100|NCT02918071|Lung Diseases,
22101|NCT02918071|Obstructive Lung Diseases,
22102|NCT02918071|Benralizumab
22103|NCT02918058|Frailty
22104|NCT02918058|Deprescription
22105|NCT02918045|Tooth Extraction
22106|NCT02918045|Surgical Hemostasis
22107|NCT02918045|Platelet Aggregation Inhibitors
22108|NCT02918045|Chitosan
22109|NCT02918032|Jordans anomaly
22110|NCT02918032|neutral lipid storage disease
22111|NCT02918032|triglyceride deposit cardiovasculopathy
22112|NCT02918032|ATGL gene
22113|NCT02918032|CGI-58 gene
22114|NCT02918032|primary triglyceride deposit cardiomyovasculopathy (TGCV)
22115|NCT02918032|neutral lipid storage disease with myopathy (NLSD-M)
22116|NCT02917993|non-small cell lung cancer
22117|NCT02917993|locally advanced
22118|NCT02917993|metastatic
22119|NCT02917993|epidermal growth factor receptor (EGFR) inhibition
22120|NCT02917993|Janus kinase inhibition
22121|NCT02917980|structural Heart Diseases
22122|NCT02917980|surgical treatment
22123|NCT02917980|interventional treatment
22124|NCT02917980|hybrid treatment
22125|NCT02917954|eHealth/mHealth solutions
22126|NCT02917954|complex care needs
22127|NCT02917954|seniors
22128|NCT02917954|patient-centred care
22129|NCT02917954|goal-oriented care
22130|NCT02917954|primary health care
22131|NCT02917954|implementation
22132|NCT02917954|pragmatic trial
22133|NCT02917954|health outcomes
22134|NCT02917954|cost-effectiveness analysis
22135|NCT02917928|carnosine, type 2 diabetes, cardiovascular factors
22136|NCT02917915|COPD
22137|NCT02917915|Emphysema
22138|NCT02917915|Chronic Bronchitis
22139|NCT02917915|Pulmonary rehabilitation
22140|NCT02917915|Lung Diseases, Obstructive
22141|NCT02917902|student-run free clinic
22142|NCT02917902|food supply
22143|NCT02917902|food insecure
22144|NCT02917902|medically uninsured
22145|NCT02917902|medically underserved
22146|NCT02917889|Caffeine
22147|NCT02917889|Autonomic Nervous System
22148|NCT02917889|Recovery
22149|NCT02917889|Aerobic exercise
22150|NCT02917876|Obstructive Sleep Apnea
22151|NCT02917876|Pregnancy
22152|NCT02917876|Obesity
22153|NCT02917876|Fluid shifts
22154|NCT02917876|Body composition
22155|NCT02917876|Sleep
22156|NCT02917863|Hypothyroidism
22157|NCT02917863|Microbiota
22158|NCT02917863|Thyroid hormone
22159|NCT02917863|L-Thyroxine
22160|NCT02917863|Celiac disease
22161|NCT02917850|stroke
22162|NCT02917850|gait
22163|NCT02917850|hip flexors
22164|NCT02917850|paresis
22165|NCT02917850|hemiplegia
22166|NCT02917798|Genetic Testing
22167|NCT02917798|16-919
22168|NCT02917772|tailored immuno therapy
22169|NCT02917772|Nivolumab
22170|NCT02917772|Ipilimumab
22171|NCT02917772|boost
22172|NCT02917759|liver cancer
22173|NCT02917759|biliary tract cancer
22174|NCT02917759|cholangiocarcinoma
22175|NCT02917759|hepatocellular carcinoma
22176|NCT02917759|liver tumor
22177|NCT02917759|biliary tumor
22178|NCT02917759|hepatoma
22179|NCT02917759|liver mass
22180|NCT02917746|Cervical intraepithelial neoplasia
22181|NCT02917746|Imiquimod
22182|NCT02917746|Treatment
22183|NCT02917746|Predictive biomarkers
22184|NCT02917720|TKI discontinuation
22185|NCT02917707|CRC
22186|NCT02917707|liver metastasis
22187|NCT02917681|ALS
22188|NCT02917681|mesenchymal stem cells
22189|NCT02917681|intrathecal
22190|NCT02917668|Obesity
22191|NCT02917668|Hyperoxia
22192|NCT02917668|Hypercapnia
22193|NCT02917668|Postoperative complications
22194|NCT02917668|Cardiac surgical procedures
22195|NCT02917655|Education
22196|NCT02917655|Quality of Life
22197|NCT02917655|Osteoarthritis
22198|NCT02917655|Metabolic Syndrome
22199|NCT02917642|bacterial infection
22200|NCT02917642|endotoxin
22201|NCT02917642|passive ultrasonic irrigation
22202|NCT02917642|root canal treatment
22203|NCT02917590|Spinal cord injury
22204|NCT02917590|dual-task obstacle crossing
22205|NCT02917564|Choroidal effusions
22206|NCT02917564|Trabeculectomy
22207|NCT02917551|Bacteremia, duration, non-critically ill, non-ICU
22208|NCT02917525|Calcium metabolism
22209|NCT02917525|Matrix Gla Protein
22210|NCT02917525|Vitamin K2
22211|NCT02917486|ExtraCorporeal Membrane Oxygenation
22212|NCT02917486|patient in intensive care
22213|NCT02917486|pharmacokinetic modeling
22214|NCT02917473|Medical skin examination
22215|NCT02917473|Skin Self Examination
22216|NCT02917473|Sun protection
22217|NCT02917460|Rady
22218|NCT02917460|Pediatric
22219|NCT02917460|Genomic
22220|NCT02917460|Precision medicine
22221|NCT02917460|Biorepository
22222|NCT02917447|PTSD
22223|NCT02917447|Women Veterans
22224|NCT02917447|Online intervention
22225|NCT02917434|Obesity
22226|NCT02917434|Psoriatic arthritis
22227|NCT02917434|Psoriasis
22228|NCT02917434|Metabolic syndrome
22229|NCT02917434|Cardiovascular disease
22230|NCT02917395|hypertrophic cardiomyopathy, disopyramide,
22231|NCT02917369|LCLC; Integrative Analysis; Metastasis
22232|NCT02917356|Healing touch
22233|NCT02917356|Faith Healing
22234|NCT02917356|Pain
22235|NCT02917356|Joint stiffness
22236|NCT02917356|Functional status
22237|NCT02917356|Mental health
22238|NCT02917356|Osteoarthritis
22239|NCT02917304|Quadrivalent Influenza Vaccines
22240|NCT02917291|Trauma Spinal Cord
22241|NCT02917291|Thoracic Acute Spinal Cord Injury
22242|NCT02917291|Neurosurgery
22243|NCT02917291|Cell Therapy
22244|NCT02917291|ATMP
22245|NCT02917291|HC016 adipose mesenchymal stem cell
22246|NCT02917291|SPINE
22247|NCT02916641|Fuzhenghuayu
22248|NCT02916628|smoking cessation
22249|NCT02916628|group counseling
22250|NCT02916628|acupressure
22251|NCT02916628|serotonin
22252|NCT02916628|depressive symptoms
22253|NCT02916628|resilience
22254|NCT02915523|Ovarian Cancer
22255|NCT02915523|Histone Deacetylase Inhibitors
22256|NCT02915523|Entinostat
22257|NCT02915523|Solid tumor
22258|NCT02915523|Avelumab
22259|NCT02915523|SNDX-275
22260|NCT02915523|Ovarian Neoplasms
22261|NCT02915523|Ovarian Diseases
22262|NCT02915523|Fallopian Tube Cancer
22263|NCT02915523|Peritoneal Cancer
22264|NCT02915497|Prolonged Exposure Therapy
22265|NCT02915484|Transcranial Direct Current Stimulation
22266|NCT02915484|Apathy
22267|NCT02915484|Stroke
22268|NCT02915484|Empathy
22269|NCT02915484|Electric Stimulation Therapy
22270|NCT02915484|Depression
22271|NCT02915484|Anhedonia
22272|NCT02915484|Prefrontal Cortex
22273|NCT02915484|Electroencephalography
22274|NCT02915484|Cognition
22275|NCT02915484|Emotions
22276|NCT02915484|Neurological Rehabilitation
22277|NCT02915484|Brain Diseases
22278|NCT02915484|Cerebrovascular Disorders
22279|NCT02915471|Adolescent
22280|NCT02915471|Online Peer Support
22281|NCT02915471|Managing Cancer
22282|NCT02915471|Mentor
22283|NCT02915458|Weaning
22284|NCT02915458|Mechanical ventilation
22285|NCT02915458|synchrosqueezing transform
22286|NCT02915445|EpCAM CAR-T, solid tumors, cancer immunotherapy
22287|NCT02915432|Anti PD-1
22288|NCT02915432|JS001
22289|NCT02915432|Gastric Adenocarcinoma
22290|NCT02915432|Esophageal Squamous Cell Carcinoma
22291|NCT02915432|Nasopharyngeal Carcinoma
22292|NCT02915432|Head and Neck Squamous Cell Carcinoma
22293|NCT02915432|Simon's Two Stage
22294|NCT02915432|ORR
22295|NCT02917213|acute myocardial infarction
22296|NCT02917213|cardiac embolism
22297|NCT02917213|intracardiac fluid dynamics
22298|NCT02917213|silent brain infarct
22299|NCT02917213|intracardiac blood stasis
22300|NCT02917174|asthma
22301|NCT02917174|m-health
22302|NCT02917174|asthma control
22303|NCT02917174|self-management
22304|NCT02917161|Prostate
22305|NCT02917161|Prostatic Neoplams
22306|NCT02917161|Therapeutic Embolization
22307|NCT02917161|Prostatectomy
22308|NCT02917122|Parkinson disease
22309|NCT02917122|transcranial direct current stimulation
22310|NCT02917122|depression
22311|NCT02917122|dopamine transporter
22312|NCT02917122|single photon emission computerized tomography
22313|NCT02917083|chimeric antigen receptors
22314|NCT02917083|immunotherapy
22315|NCT02917083|CAR T-cells
22316|NCT02917083|lymphoma
22317|NCT02917083|Cyclophosphamide
22318|NCT02917083|fludarabine
22319|NCT02917070|Consanguinity-associated kidney diseases
22320|NCT02917070|Turkey population
22321|NCT02917031|Type 2 Diabetes Mellitus
22322|NCT02917031|Heart Failure
22323|NCT02917031|Saxagliptin
22324|NCT02917031|Sitagliptin
22325|NCT02917018|Dexmedetomidine
22326|NCT02917018|Stress response
22327|NCT02917018|Emergence agitation
22328|NCT02917005|breast cancer
22329|NCT02917005|hormone receptor positive, HER2 negative
22330|NCT02917005|palbociclib
22331|NCT02917005|premenopausal
22332|NCT02916992|spontaneous pneumothorax
22333|NCT02916992|familial pneumothorax
22334|NCT02916992|Birt-Hogg-Dube syndrome
22335|NCT02916992|prevalence
22336|NCT02916992|FLCN mutation
22337|NCT02916992|Lung cysts
22338|NCT02916992|BHD
22339|NCT02916992|inherited disease
22340|NCT02916992|genetic disease
22341|NCT02916992|primary pneumothorax
22342|NCT02916992|CAT scan
22343|NCT02916992|CT scan
22344|NCT02916940|sprains of the proximal interphalangeal joints of the long fingers
22345|NCT02916940|Diprophos
22346|NCT02916927|ketamine
22347|NCT02916927|emergency department
22348|NCT02916914|preterm
22349|NCT02916914|feeding
22350|NCT02916914|oral transition
22351|NCT02916901|Dyslipidemia
22352|NCT02916901|CKD-519
22353|NCT02916901|CETP inhibitor
22354|NCT02916901|ABPM
22355|NCT02916888|Atopic dermatitis
22356|NCT02916888|Topical corticosteroid
22357|NCT02916888|Pediatric
22358|NCT02916888|Eczema
22359|NCT02916888|Quality of life
22360|NCT02916875|Shared decision Making
22361|NCT02916875|Follow-up
22362|NCT02916862|fiber
22363|NCT02916862|calcium absorption
22364|NCT02916862|bone mass
22365|NCT02916862|adolescents
22366|NCT02916849|Accidental Falls
22367|NCT02916849|Prevention & Control
22368|NCT02916849|Exercise
22369|NCT02916849|Exercise therapy/methods*
22370|NCT02916849|Aged
22371|NCT02916849|Aged 80 and over
22372|NCT02916849|Smartphone
22373|NCT02916849|Computers
22374|NCT02916849|Computers handheld
22375|NCT02916849|Motivation
22376|NCT02916849|Postural balance
22377|NCT02916849|Health behaviour
22378|NCT02916849|mHealth
22379|NCT02916849|eHealth
22380|NCT02916810|transcranial magnetic stimulation
22381|NCT02916810|schizophrenia
22382|NCT02916810|MRI
22383|NCT02916797|Feedback
22384|NCT02916797|Physical Therapy
22385|NCT02916784|Sit-to-stand
22386|NCT02916784|Walking devices
22387|NCT02916771|Smoldering Multiple Myeloma
22388|NCT02916758|older adults
22389|NCT02916758|community mobility
22390|NCT02916758|wellness
22391|NCT02916758|isolation
22392|NCT02916745|Non-small cell lung cancer
22393|NCT02916745|NSCLC
22394|NCT02916745|lung cancer
22395|NCT02916745|lung carcinoma
22396|NCT02916732|asymptomatics
22397|NCT02916732|microcephaly
22398|NCT02916732|abnormalities
22399|NCT02916719|neo-adjuvant radiotherapy
22400|NCT02916719|breast cancer
22401|NCT02916719|MRI
22402|NCT02916693|Mirabegron
22403|NCT02916693|Overactive Bladder
22404|NCT02916693|Erectile Dysfunction
22405|NCT02916693|Beta 3 agonist
22406|NCT02916680|Pancreatic islet transplantation
22407|NCT02916537|prostate cancer
22408|NCT02916537|prostate specific membrane antigen
22409|NCT02916537|prostate neoplasms
22410|NCT02916537|metastatic prostate cancer
22411|NCT02916537|prostatic hyperplasia
22412|NCT02916524|Aphasia
22413|NCT02916524|Bilingualism
22414|NCT02916524|Language therapy
22415|NCT02916524|Rehabilitation of speech and language disorders
22416|NCT02916524|Speech-language pathology
22417|NCT02916498|chronic neuropathic pain in the low back and legs
22418|NCT02916498|subperception spinal cord stimulation
22419|NCT02916485|bioresorbable scaffold
22420|NCT02916485|vascular restoration therapy
22421|NCT02916472|AYA
22422|NCT02916472|exercise
22423|NCT02916472|cancer
22424|NCT02916472|cybercycling
22425|NCT02916407|Anesthesia
22426|NCT02916407|Agitation
22427|NCT02916407|Extubation
22428|NCT02916316|Lymphoma
22429|NCT02916316|Large B-Cell
22430|NCT02916316|Cardiotoxicity
22431|NCT02916303|Schizophrenia
22432|NCT02916303|Psychosis
22433|NCT02916303|Effectiveness
22434|NCT02916290|Fuzhenghuayu
22435|NCT02916264|scalp block, surgical peth index
22436|NCT02916160|Chronic Heart failure
22437|NCT02916160|Sleep Apnea Syndrome
22438|NCT02916160|Continuous Positive Airways Pressure
22439|NCT02916160|SACUBITRIL - VALSARTAN
22440|NCT02916108|Concussion
22441|NCT02916108|Mild traumatic brain injury
22442|NCT02916108|EEG
22443|NCT02916082|Cervical length
22444|NCT02916082|Prolonged pregnancy
22445|NCT02916082|Vaginal birth
22446|NCT02916069|Spectroscopy
22447|NCT02916069|Transcranial Doppler
22448|NCT02916069|Bispectral index
22449|NCT02916069|Cardiac surgery
22450|NCT02916056|Alzheimer's disease
22451|NCT02916056|RAGE
22452|NCT02916056|ADAS-cog
22453|NCT02916056|CDR-sb
22454|NCT02916043|acute kidney injury
22455|NCT02916043|cardiovascular surgery
22456|NCT02916043|mortality
22457|NCT02916030|Vitamin D
22458|NCT02916030|Stroke
22459|NCT02916030|Parathormone
22460|NCT02916017|Non-infectious Intermediate-, Posterior-, or Pan-uveitis
22461|NCT02916017|Adalimumab
22462|NCT02916017|Humira
22463|NCT02916004|Analgesia
22464|NCT02916004|Pain measurement
22465|NCT02916004|Nociception
22466|NCT02916004|Electromyography
22467|NCT02916004|Electrical stimulation
22468|NCT02916004|Pupillometry
22469|NCT02916004|Critical care
22470|NCT02916004|Sedation
22471|NCT02915991|Coronary catheterization
22472|NCT02915991|Instantaneous wave free ratio (iFR)
22473|NCT02915991|Fractional Flow Reserve (FFR)
22474|NCT02915991|automated co-registration
22475|NCT02915939|Family caregiving
22476|NCT02915939|Institutionalization
22477|NCT02915939|Residential long-term care
22478|NCT02915939|Placement
22479|NCT02915939|Psychosocial support
22480|NCT02915939|Dementia
22481|NCT02915939|Caregivers
22482|NCT02915939|Nursing homes
22483|NCT02915939|Assisted Living Facilities
22484|NCT02915939|Long-Term Care
22485|NCT02915939|Intervention Study
22486|NCT02915939|Psychosocial Support Systems
22487|NCT02915939|Social Support
22488|NCT02915939|Coping
22489|NCT02915900|In vitro fertilization
22490|NCT02915887|neck pain
22491|NCT02915887|chronic
22492|NCT02915887|taping
22493|NCT02915887|kinematics
22494|NCT02915887|motion analysis
22495|NCT02915887|physiotherapy
22496|NCT02915861|immune responses
22497|NCT02915861|vaccines
22498|NCT02915848|deep brain stimulation
22499|NCT02915848|local field potential
22500|NCT02915848|kinematic analysis
22501|NCT02915835|Scleroderma
22502|NCT02915835|Digital Ulcer
22503|NCT02915809|Influenza Vaccines
22504|NCT02915796|Endothelial progenitor cell
22505|NCT02915796|Percutaneous transluminal angioplasty
22506|NCT02915783|unresectable advanced
22507|NCT02915783|metastatic
22508|NCT02915770|Moderate dilatation of common bile duct
22509|NCT02915757|Depression
22510|NCT02915757|EDOR test
22511|NCT02915757|Electrodermal hyporeactivity
22512|NCT02915744|Breast Cancer Brain Metastases (BCBM)
22513|NCT02915744|Carcinoma
22514|NCT02915731|Vitamin A stores
22515|NCT02915731|Stable isotope dilution
22516|NCT02915731|Multiple vitamin A interventions
22517|NCT02915718|dilated cardiomyopathy
22518|NCT02915718|immunoadsorption
22519|NCT02915692|Foley
22520|NCT02915692|CAUTI
22521|NCT02915692|ERASE CAUTI
22522|NCT02915679|Suicidal behavior
22523|NCT02915679|psychological and social pain
22524|NCT02915679|physical pain
22525|NCT02915679|pain perception
22526|NCT02915666|Melanoma, skin
22527|NCT02915627|Antishock Garment
22528|NCT02915614|alpha-1 antitrypsin deficiency
22529|NCT02915614|pulmonary rehabilitation
22530|NCT02915614|exercise training
22531|NCT02915614|skeletal muscle biopsy
22532|NCT02915562|rehabilitation
22533|NCT02915562|exercise
22534|NCT02915562|outcome measurement
22535|NCT02915549|premature infant
22536|NCT02915549|early progressive feeding
22537|NCT02915536|iodine excess
22538|NCT02915536|thyroid disease
22539|NCT02915536|children
22540|NCT02915536|tolerable upper intake level
22541|NCT02915393|Chronic Gastritis
22542|NCT02915393|Qi Deficiency Constitution
22663|NCT02914925|CIT
22543|NCT02915393|Next Generation Sequencing
22544|NCT02915393|Proteomics
22545|NCT02915393|Metabonomics
22546|NCT02915367|HIV/AIDS
22547|NCT02915367|adherence
22548|NCT02915367|women
22549|NCT02915367|real time monitoring
22550|NCT02915367|risk
22551|NCT02915367|SMS
22552|NCT02915367|mHealth
22553|NCT02915315|blood pressure
22554|NCT02915315|Hypertrophy
22555|NCT02915315|Left Ventricular
22556|NCT02915315|arterial Stiffness
22557|NCT02915315|Proteinuria
22558|NCT02915315|baPWV
22559|NCT02915315|ambulatory Blood Pressure
22560|NCT02915302|Influenza
22561|NCT02915302|Influenza virus vaccine
22562|NCT02915302|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
22563|NCT02915289|Caesarean section
22564|NCT02915289|Chlorhexidine gluconate
22565|NCT02915276|Blastocyst
22566|NCT02915276|Human
22567|NCT02915276|DNA
22568|NCT02915276|Blastocentesis
22569|NCT02915263|Diabetes Complications
22570|NCT02915263|Diabetes Mellitus, Type 2
22571|NCT02915263|Diabetic Neuropathies
22572|NCT02915263|Immunoglobulins, Intravenous
22573|NCT02915237|Veterans
22574|NCT02915237|Gulf War Illness
22575|NCT02915237|Gulf War Veterans's Illness
22576|NCT02915237|Gulf War Veterans' Medically Unexplained Illnesses
22577|NCT02915211|Epilepsy
22578|NCT02915211|Glut
22579|NCT02915211|Ketogenic
22580|NCT02915211|Glucose
22581|NCT02915198|Metformin
22582|NCT02915198|Atherosclerosis
22583|NCT02915198|Prediabetic State
22584|NCT02915198|Hemoglobin A, Glycosylated
22585|NCT02915198|Coronary Artery Disease
22586|NCT02915198|Peripheral Arterial Disease
22587|NCT02915198|Cerebrovascular Disorders
22588|NCT02915185|exercise
22589|NCT02915185|rehabilitation
22590|NCT02915185|recovery of function
22591|NCT02915185|transcranial magnetic stimulation
22592|NCT02915185|transcranial direct-current stimulation
22593|NCT02915172|Advanced Cancer
22594|NCT02915172|Malignant neoplasm of breast
22595|NCT02915172|Malignant neoplasms of bone and articular cartilage
22596|NCT02915172|Malignant neoplasms of digestive organs
22597|NCT02915172|Malignant neoplasms of eye brain and other parts of central nervous system
22598|NCT02915172|Malignant neoplasms of female genital organs
22599|NCT02915172|Malignant neoplasms of ill-defined secondary and unspecified sites
22600|NCT02915172|Malignant neoplasms of independent (primary) multiple sites
22601|NCT02915172|Malignant neoplasms of lip oral cavity and pharynx
22602|NCT02915172|Malignant neoplasms of male genital organs
22603|NCT02915172|Malignant neoplasms of mesothelial and soft tissue
22604|NCT02915172|Malignant neoplasms of respiratory and intrathoracic organs
22605|NCT02915172|Malignant neoplasms of thyroid and other endocrine glands
22606|NCT02915172|Malignant neoplasms of urinary tract
22607|NCT02915172|Lenvatinib
22608|NCT02915172|E7080
22609|NCT02915172|Lenvima
22610|NCT02915172|Capecitabine
22611|NCT02915172|Xeloda
22612|NCT02915146|eczema
22613|NCT02915146|phototherapy
22614|NCT02915146|uva1
22615|NCT02915146|uvb
22616|NCT02915146|adults
22617|NCT02915146|children
22618|NCT02915133|high myopia
22619|NCT02915133|myopia foveoschisis
22620|NCT02915133|macular buckling
22621|NCT02915120|Knee pain
22622|NCT02915120|osteoarthritis
22623|NCT02915120|genicular nerve
22624|NCT02915120|ultrasonography
22625|NCT02915120|pulsed radiofrequency
22626|NCT02915107|drug eluting stents
22627|NCT02915107|coronary vascular healing
22628|NCT02915068|patient-provider communication
22629|NCT02915068|Electronic Health Records
22630|NCT02915068|Provider education
22631|NCT02915055|Analgesic efficacy
22632|NCT02915055|knee arthroplasty
22633|NCT02915055|Opioid consumption
22634|NCT02915055|Pain Medicine
22635|NCT02915055|Narcotics
22636|NCT02915055|Multimodal Analgesia
22637|NCT02915042|Pain
22638|NCT02915042|dexmedetomidine
22639|NCT02915042|postoperative
22640|NCT02915029|Native American
22641|NCT02915029|Community Health Representative
22642|NCT02915029|Home base
22643|NCT02915029|Diabetes
22644|NCT02915029|Point of care testing
22645|NCT02915029|Patient Activation Measure
22646|NCT02915029|Patient preferences
22647|NCT02915003|health care navigation
22648|NCT02915003|health literacy
22649|NCT02915003|Affordable Care Act
22650|NCT02914977|Relapsed
22651|NCT02914977|Refractory
22652|NCT02914964|Fatigue
22653|NCT02914964|Quality of Life
22654|NCT02914964|Diet
22655|NCT02914951|Autism
22656|NCT02914951|Irritability
22657|NCT02914951|Disruptive Behavior
22658|NCT02914951|Aggression
22659|NCT02914951|Behavior Therapy
22660|NCT02914951|Cognitive Behavioral Therapy
22661|NCT02914951|Intellectual Disability
22662|NCT02914951|Cognitive Impairment
22664|NCT02914925|ArmeoSpring
22665|NCT02914925|TMS
22666|NCT02914899|Chinese Taxi Drivers
22667|NCT02914899|16-949
22668|NCT02914886|Diabetes
22669|NCT02914886|Lipoatrophy
22670|NCT02914886|children
22671|NCT02914886|adolescents
22672|NCT02914886|adults
22673|NCT02914886|insulin therapy
22674|NCT02914873|prostate cancer
22675|NCT02914873|active surveillance
22676|NCT02914873|standardised treatment triggers
22677|NCT02914873|MRI
22678|NCT02914873|randomized
22679|NCT02914821|consumption
22680|NCT02914821|decision making
22681|NCT02914821|policy
22682|NCT02914821|sweetened beverages
22683|NCT02914821|taxes
22684|NCT02914821|Diet, Food, and Nutrition
22685|NCT02914769|Depression
22686|NCT02914769|Ayahuasca
22687|NCT02914769|Psychedelics
22688|NCT02914743|Oral health
22689|NCT02914743|Diabetes
22690|NCT02914743|Interprofessionalism
22691|NCT02914743|Periodontal disease
22692|NCT02914730|diabetes
22693|NCT02914730|insulin
22694|NCT02914730|medication adherence
22695|NCT02914717|golimumab
22696|NCT02914691|Type 2 diabetes
22697|NCT02914691|Diabetic Nephropathy
22698|NCT02914691|Proteomics
22699|NCT02914691|Albuminuria
22700|NCT02914691|SGLT2 inhibitor
22701|NCT02914678|Emergency Medical Services
22702|NCT02914678|Analgesics
22703|NCT02914665|Heart failure
22704|NCT02914665|diuresis
22705|NCT02914665|dropsy
22706|NCT02914665|congestion
22707|NCT02914665|elamipretide
22708|NCT02914665|MTP-131
22709|NCT02914665|Bendavia™
22710|NCT02914652|Congenital Heart Disease
22711|NCT02914652|Ventricular Septal Defect
22712|NCT02914652|Beta-2-agonists
22713|NCT02914652|Surgery
22714|NCT02914652|Follow-up
22715|NCT02914626|Glaucoma, Neovascular
22716|NCT02914626|Ranibizumab
22717|NCT02914626|Intraocular pressure
22718|NCT02914626|anti-VEGF
22719|NCT02914626|intravitreal injection
22720|NCT02914483|Myocardial Infarction
22721|NCT02914483|Women
22722|NCT02914483|Stress Management
22723|NCT02914470|advanced
22724|NCT02914431|Personalized Titanium Plate
22725|NCT02914431|Orthognathic Surgery
22726|NCT02914431|Maxilla Repositioning
22727|NCT02914431|Accuracy
22728|NCT02914431|Computer-aided Design and Manufacturing
22729|NCT02914418|transcranial magnetic stimulation
22730|NCT02914418|Spinal Cord Injuries
22731|NCT02914418|Muscle Spasticity
22732|NCT02914418|Pain
22733|NCT02914418|Spinal Cord
22734|NCT02914418|Spinal Cord Diseases
22735|NCT02914405|131-I-mIBG therapy
22736|NCT02914405|ch14.18/CHO
22737|NCT02914405|Nivolumab
22738|NCT02914392|case control study
22739|NCT02914392|Environmental Factors
22740|NCT02914392|Fetal Congenital Heart Disease
22741|NCT02914366|Ambroxol
22742|NCT02914366|Dementia
22743|NCT02914366|Parkinson's disease
22744|NCT02914366|Disease modifying treatment
22745|NCT02914366|Pharmacological Chaperone
22746|NCT02914366|GBA1
22747|NCT02914353|Factor X!a
22748|NCT02914353|anticoagulant
22749|NCT02914353|thromboembolism
22750|NCT02914353|venous thromboembolism
22751|NCT02914353|embolism and thrombosis
22752|NCT02914353|enzyme inhibitors
22753|NCT02914353|hematologic agent
22754|NCT02914327|CLL
22755|NCT02914327|Leukemia, Chronic Lymphocytic
22756|NCT02914327|Hsp90
22757|NCT02914327|BTK
22758|NCT02914327|Ibrutinib
22759|NCT02914314|epilepsy
22760|NCT02914314|refractory partial seizures
22761|NCT02914249|Orange juice
22762|NCT02914249|Low-calorie diet
22763|NCT02914249|Body composition
22764|NCT02914249|Weight-loss
22765|NCT02914249|Metabolic biomarkers
22766|NCT02914249|Obese
22767|NCT02914236|Nasal valve
22768|NCT02914236|Nasal airway obstruction
22769|NCT02914210|TKR
22770|NCT02914210|TKA
22771|NCT02914210|Knee
22772|NCT02914210|Surgery
22773|NCT02914210|Replacement
22774|NCT02914210|Rehabilitation
22775|NCT02914210|Virtual
22776|NCT02914210|Physical Therapy
22777|NCT02914210|Telerehabilitation
22778|NCT02914197|Decision
22779|NCT02914197|Mammography
22780|NCT02914197|Informed Choice
22781|NCT02914197|Full Information
22782|NCT02914197|Decision Aid
22783|NCT02914197|Self-efficacy
22784|NCT02914197|Shared decision making
22785|NCT02914197|Over-detection
22786|NCT02914197|Over-diagnosis
22787|NCT02914184|Safety
22788|NCT02914184|Healthy infants
22789|NCT02914184|Immunogenicity
22790|NCT02914184|Human Rotavirus (HRV)
22791|NCT02914171|Myopathic right ventricle
22792|NCT02914158|breast cancer
22793|NCT02914158|ovarian function suppression (OFS)
22794|NCT02914158|aromatase inhibitors（AIs）
22795|NCT02914158|tamoxifen（TAM）
22796|NCT02914119|Residual nerve blockade
22797|NCT02914119|Neuromuscular monitoring
22798|NCT02914119|Residual curarization
22799|NCT02914119|Neuromuscular blocking agents
22800|NCT02914106|Neuroactive steroids
22801|NCT02914106|Acute Ischemic Stroke
22802|NCT02914106|Patients
22803|NCT02914093|Hypercapnia
22804|NCT02914093|Physiotherapy
22805|NCT02914093|Inspiratory Muscle Training
22806|NCT02914067|Pediatric brain tumors
22807|NCT02914067|Cognitive deficits
22808|NCT02914067|Resting state functional connectivity
22809|NCT02914067|NIH toolbox
22810|NCT02914054|ITP
22811|NCT02914041|Kyphosis
22812|NCT02914041|Kyphosis wall distance
22813|NCT02914041|elderly
22814|NCT02914028|TAP block
22815|NCT02914028|subacute pain
22816|NCT02914028|inguinal herniography
22817|NCT02913937|ultrasonic irrigation
22818|NCT02913937|pain
22819|NCT02913937|healing
22820|NCT02913937|apical periodontitis
22821|NCT02913924|Marijuana
22822|NCT02913924|Treatment
22823|NCT02913911|feedback
22824|NCT02913898|learning
22825|NCT02913872|Spirometry
22826|NCT02913872|Exhaled Nitric Oxide
22827|NCT02913872|Primary Care
22828|NCT02913859|prostate cancer
22829|NCT02913859|hormone-sensitive
22830|NCT02913859|metastasis
22831|NCT02913846|denutrition
22832|NCT02913846|hospital length of stay
22833|NCT02913846|patient's autonomy
22834|NCT02913833|Pain
22835|NCT02913833|Hospital length of stay
22836|NCT02913833|Revalidation unit
22837|NCT02913781|Polar body removal
22838|NCT02913781|ICSI
22839|NCT02913781|Fertilization failure
22840|NCT02913742|Intraoperative Neurophysiological Monitoring
22841|NCT02913729|breast cancer
22842|NCT02913703|Ghrelin
22843|NCT02913703|age and weight matched controls
22844|NCT02913690|Hemodialysis
22845|NCT02913690|Tocotrienol
22846|NCT02913690|Vitamin E
22847|NCT02913677|feeding intolerance
22848|NCT02913677|minimal enteral nutrition
22849|NCT02913677|very low birth weight
22850|NCT02913677|preterm infant
22851|NCT02913664|Dementia
22852|NCT02913664|Alzheimer's Disease
22853|NCT02913664|Cognitive Function
22854|NCT02913664|Blood Pressure
22855|NCT02913664|Cholesterol
22856|NCT02913664|Physical Activity
22857|NCT02913664|Exercise
22858|NCT02913664|Magnetic Resonance Imaging
22859|NCT02913651|Idiopathic hypersomnia
22860|NCT02913651|heart rate variability
22861|NCT02913651|parasympathetic activity
22862|NCT02913651|autonomic arousal response
22863|NCT02913625|Brachial plexus
22864|NCT02913625|Regional anesthesia
22865|NCT02913625|Infraclavicular
22866|NCT02913625|Retroclavicular
22867|NCT02913625|Parasagittal
22868|NCT02913625|Upper limb surgery
22869|NCT02913625|Ultrasound guided block
22870|NCT02913625|Coracoid
22871|NCT02913612|Hemangioma
22872|NCT02913612|Infantile Hemangioma
22873|NCT02913612|Pharmacokinetics
22874|NCT02913508|Drug therapy
22875|NCT02913495|Progesterone
22876|NCT02913495|Prevention of preterm birth
22877|NCT02913469|Morphine，Ticagrelor，STEMI，PCI
22878|NCT02913417|uveal melanoma
22879|NCT02913417|liver metastases
22880|NCT02913391|noninvasive ventilation
22881|NCT02913391|myocardial revascularization
22882|NCT02913391|pulmonary atelectasis
22883|NCT02913391|anoxia
22884|NCT02913391|hypoxia
22885|NCT02913391|positive end expiratory pressure
22886|NCT02913365|Haemoptysis
22887|NCT02913365|Hemoptysis
22888|NCT02913365|Airway bleeding
22889|NCT02913365|Pulmonary hemorrhage
22890|NCT02913339|screening
22891|NCT02913339|telemedicine
22892|NCT02913339|risk assessment
22893|NCT02913339|prevention
22894|NCT02913300|Lignocaine
22895|NCT02913261|GvHD (Graft versus Host Disease)
22896|NCT02913261|INC424
22897|NCT02913261|ruxolitinib
22898|NCT02913261|best available therapy (BAT)
22899|NCT02913261|corticosteroid-refractory acute graft vs. host disease
22900|NCT02913261|allogeneic stem cell transplantation
22901|NCT02913261|steroid refractory acute graft vs. host disease
22902|NCT02913261|Janus Kinase (JAK) inhibitor
22903|NCT02913248|periodontitis
22904|NCT02913248|saliva
22905|NCT02913248|bacteria
22906|NCT02913235|biofilm
22907|NCT02913235|saliva
22908|NCT02913235|bacteria
22909|NCT02913235|oral hygiene
22910|NCT02913222|femoroacetabular impingement
22911|NCT02913222|labral tear
22912|NCT02913222|rehabilitation
22913|NCT02913183|acute stroke
22914|NCT02913183|young health plasma
22915|NCT02913183|efficacy
22916|NCT02913183|safety
22917|NCT02913105|Non-alcoholic Steatohepatitis
22918|NCT02913105|NASH
22919|NCT02913105|Fatty liver disease
22920|NCT02913014|Antiarrhythmic Agents
22921|NCT02913014|Catheter Ablation, electric
22922|NCT02913014|Cardiac Arrhythmias
22923|NCT02913014|Anti-Arrhythmia Drugs
22924|NCT02913001|Diet
22925|NCT02913001|glycemic index
22926|NCT02913001|glycemic load
22927|NCT02913001|Acne Vulgaris
22928|NCT02912988|Subfertility
22929|NCT02912988|In-vitro fertilization
22930|NCT02912988|Letrozole
22931|NCT02912949|Bispecific Antibody IgG1, HER2, HER3
22932|NCT02912949|First-in-human
22933|NCT02912949|MCLA-128
22934|NCT02912949|Antibodies, Bispecific
22935|NCT02912949|Immunologic Factors
22936|NCT02912949|Cytokines
22937|NCT02912936|medium chain triglyceride
22938|NCT02912936|MCT
22939|NCT02912936|coconut oil
22940|NCT02912936|MRI
22941|NCT02912936|PET
22942|NCT02912936|ketones
22943|NCT02912923|Stroke
22944|NCT02912923|Rehabilitation Robotics
22945|NCT02912923|Bimanual
22946|NCT02912923|Compensatory Movements
22947|NCT02912923|Hemiplegia
22948|NCT02912923|Kinematics
22949|NCT02912923|Reaching
22950|NCT02912923|Trunk
22951|NCT02912897|EBV-CTL
22952|NCT02912897|Multiple sclerosis
22953|NCT02912897|cellular therapy
22954|NCT02912897|clinically isolated syndrome
22955|NCT02912871|subthalamotomy
22956|NCT02912871|motor features
22957|NCT02912871|deep brain stimulation
22958|NCT02912832|Diagnosis
22959|NCT02912806|Knee Arthroplasty
22960|NCT02912806|Total knee replacement
22961|NCT02912806|Knee osteoarthritis
22962|NCT02912806|Patient-Outcomes Measurement Program
22963|NCT02912806|Surgical Registries
22964|NCT02912806|Shared Decision Making
22965|NCT02912806|Patient Reported Outcomes
22966|NCT02912806|Patient Experience
22967|NCT02912806|Cohort Studies
22968|NCT02912767|lower-extremity lymphedema
22969|NCT02912767|16-1001
22970|NCT02912702|Pegaspargase
22971|NCT02912702|hemophagocytic lymphohistiocytosis
22972|NCT02912702|Epstein Barr virus
22973|NCT02912702|initial treatment
22974|NCT02912689|COPD
22975|NCT02912689|Non-invasive ventilation
22976|NCT02912689|NAVA
22977|NCT02912676|Cancer
22978|NCT02912676|Thioguanine
22979|NCT02912676|Acute Lymphoblastic Leukemia
22980|NCT02912676|6 Mercaptopurine
22981|NCT02912676|Maintenance Therapy of Leukemia
22982|NCT02912676|Denmark
22983|NCT02912650|ibuprofen
22984|NCT02912650|acetaminophen
22985|NCT02912650|pain
22986|NCT02912650|molar extraction
22987|NCT02912624|Physical Examination
22988|NCT02912624|Diagnostic Imaging
22989|NCT02912624|Ultrasonography
22990|NCT02912624|Hemodynamics
22991|NCT02912624|Patient Outcome Assessment
22992|NCT02912624|Mortality
22993|NCT02912585|colostrum
22994|NCT02912572|Endometrial Cancer
22995|NCT02912546|Stroke, Acute
22996|NCT02912455|Post-Bariatric Surgery
22997|NCT02912455|hemoglobin A1c protein, human
22998|NCT02912442|thyroid
22999|NCT02912442|infertility
23000|NCT02912442|autoimmunity
23001|NCT02912442|pregnancy loss
23002|NCT02912442|autoantibodies
23003|NCT02912364|Eslicarbazepine
23004|NCT02912364|Carbamazepine
23005|NCT02912364|cognition
23006|NCT02912351|Total Knee Arthroplasty
23007|NCT02912351|Total Knee Replacement
23008|NCT02912351|Revision Knee Arthroplasty
23009|NCT02912338|Sarcopenic obesity
23010|NCT02912338|Body composition
23011|NCT02912338|Physical function
23012|NCT02912338|quality of life
23013|NCT02912338|long term care
23014|NCT02912312|Malignant neoplasm of breast
23015|NCT02912312|Lymphedema
23016|NCT02912312|Standard regional nodal irradiation
23017|NCT02912312|RNI
23018|NCT02912312|Shortened regional nodal irradiation
23019|NCT02912312|Radiation therapy
23020|NCT02912312|XRT
23021|NCT02912312|Arm swelling
23022|NCT02912312|Questionnaires
23023|NCT02912312|Surveys
23024|NCT02912273|Geriatric assessment
23025|NCT02912247|tumor necrosis factor-a blocker
23026|NCT02912247|pharmacokinetics
23027|NCT02912247|safety
23028|NCT02912169|Alzheimer's Disease
23029|NCT02912169|Alzheimer's
23030|NCT02912169|Stem cell
23031|NCT02912169|Adipose-derived stem cells
23032|NCT02912169|ASC
23033|NCT02912169|ADSC
23034|NCT02912156|Pharmacokinetic
23035|NCT02912130|Exercise
23036|NCT02912130|Nutrition
23037|NCT02912130|Sarcopenia
23038|NCT02912130|Healthy Ageing
23039|NCT02912130|Elderly
23040|NCT02912130|Muscular Hypertrophy
23041|NCT02912104|primary ovarian insufficiency
23042|NCT02912104|premature ovarian failure
23043|NCT02912104|Infertility
23044|NCT02912104|human amniotic epithelial cells transplantation
23045|NCT02912052|Perioperative Chemotherapy
23046|NCT02912052|Postoperative Chemotherapy
23047|NCT02912052|Colon Cancer
23048|NCT02912052|Resectable Liver Metastasis
23049|NCT02912000|Dental Health Services
23050|NCT02912000|Sugar-Sweetened Beverages
23051|NCT02912000|Tobacco control
23052|NCT02912000|Pediatrics
23053|NCT02912000|Parents
23054|NCT02911974|fine needle biopsy
23055|NCT02911974|EUS
23056|NCT02911974|solid pancreatic mass
23057|NCT02911896|physical function
23058|NCT02911896|critical care
23059|NCT02911857|Canakinumab
23060|NCT02911857|TRAPS
23061|NCT02911857|extension study
23062|NCT02911857|interleukin-1
23063|NCT02911857|Periodic Fevers Syndrome
23064|NCT02911857|HIDS
23065|NCT02911857|crFMF
23066|NCT02911857|auto-inflammatory diseases
23067|NCT02911805|Exercise
23068|NCT02911805|Retinal Degeneration
23069|NCT02911805|Neuropharmacology
23070|NCT02911805|Brain-Derived Neurotrophic Factor
23071|NCT02911805|Biometry
23072|NCT02911805|Immunochemistry
23073|NCT02911805|Molecular Biology
23074|NCT02911805|Neurosciences
23075|NCT02911805|Ophthalmology
23076|NCT02911792|hyperfiltering
23077|NCT02911792|Type 2 Diabetes Mellitus
23078|NCT02911766|Periodontal Index
23079|NCT02911727|Cesarean section
23080|NCT02911727|Postnatal Care
23081|NCT02911714|Kidney Transplantation
23082|NCT02911714|Delayed Graft Function
23083|NCT02911714|Acute Allograft Rejection
23084|NCT02911714|Acute Kidney Injury
23085|NCT02911597|Ketamine
23086|NCT02911597|Naltrexone
23087|NCT02911597|Treatment-Resistant
23088|NCT02911597|TRD
23089|NCT02911545|Atrial fibrillation
23090|NCT02911545|Anticoagulation
23091|NCT02911545|Cardioversion
23092|NCT02911532|pterygium
23093|NCT02911532|tissue engineering
23094|NCT02911532|atretoblepharia
23095|NCT02911519|Schizophrenia
23096|NCT02911519|Patient Education
23097|NCT02911493|sedentary time
23098|NCT02911493|number of steps/day
23099|NCT02911493|mobility
23100|NCT02911493|disability
23101|NCT02911428|Ebola
23102|NCT02911428|Ebola Virus Vaccines
23103|NCT02911428|Haemorrhagic Fever
23104|NCT02911428|Ebola Infection
23105|NCT02911428|GP protein, Ebola virus
23106|NCT02911415|Ebola
23107|NCT02911415|Ebola Virus Vaccines
23108|NCT02911415|Haemorrhagic Fever
23109|NCT02911415|Ebola Infection
23110|NCT02911415|GP protein, Ebola virus
23111|NCT02911311|conbercept
23112|NCT02911311|anti-VEGF agent
23113|NCT02911311|panretinal photocoagulation
23114|NCT02911285|Alcohol
23115|NCT02911285|PTSD
23116|NCT02911285|Trauma
23117|NCT02911285|Veteran
23118|NCT02911272|Partograph
23119|NCT02911272|Best action line
23120|NCT02911272|Prolonged labour prevention
23121|NCT02911207|chronic ill patients
23122|NCT02911207|Emotion management skill
23123|NCT02911207|Quality of Life
23124|NCT02911181|BIVA measurement
23125|NCT02911181|SNAQ score
23126|NCT02911168|NERVE BLOCK
23127|NCT02911168|ANESTHESIA RECOVERY PERIOD
23128|NCT02911168|PAIN MANAGEMENT
23129|NCT02911155|Cohort Study
23130|NCT02911155|Radiation
23131|NCT02911155|Occupation
23132|NCT02911142|Treatment Naive
23133|NCT02911142|Immune Modulatory
23134|NCT02911142|Chemotherapy
23135|NCT02911142|AIDS-Related Lymphoma
23136|NCT02911142|PEL
23137|NCT02911129|Chronic Stroke
23138|NCT02911129|Neglect
23139|NCT02911129|Transcranial Magnetic Stimulation
23140|NCT02911129|Visual and Motor Integration
23141|NCT02911129|Visual Fields
23142|NCT02911116|Panuveitis
23143|NCT02911116|Intermediate Uveitis
23144|NCT02911116|Uveitis
23145|NCT02911103|Electrophysiology
23146|NCT02911103|Neurosurgery
23147|NCT02911103|Dystonia
23148|NCT02911103|Deep Brain Stimulation
23149|NCT02911090|Endometriosis
23150|NCT02911090|Chronic pelvic pain
23151|NCT02911090|Dyspareunia
23152|NCT02911077|Bacteria
23153|NCT02911064|Questionnaires
23154|NCT02911064|Surveys
23155|NCT02911064|Benign neoplasms
23156|NCT02911064|Malignant neoplasms of independent (primary) multiple sites
23157|NCT02911064|Inpatient rehabilitation therapy
23158|NCT02911038|Complete denture
23159|NCT02911038|PMMA
23160|NCT02911038|Stereolithography
23161|NCT02911025|epilepsy
23162|NCT02911025|sleep
23163|NCT02911025|antiepileptic drugs
23164|NCT02910986|Mammography
23165|NCT02910986|Breast Density
23166|NCT02910986|Hispanic
23167|NCT02910973|Inflammation, Vagus Nerve Stimulation
23168|NCT02910960|fine needle biopsy
23169|NCT02910960|EUS
23170|NCT02910960|solid pancreatic mass
23171|NCT02910934|Indoor Residual Spray
23172|NCT02910934|IRS
23173|NCT02910934|Insecticide Treated Net
23174|NCT02910934|LLIN
23175|NCT02910934|ITN
23176|NCT02910921|Migraine
23177|NCT02910921|Prediction
23178|NCT02910921|Forecast
23179|NCT02910921|App
23180|NCT02910921|Fitbit
23181|NCT02910921|Individual
23182|NCT02910921|Algorithm
23183|NCT02910921|Machine Learning
23184|NCT02910921|Mayo Clinic
23185|NCT02910921|Allergan
23186|NCT02910921|Second Opinion
23187|NCT02910908|Elderly
23188|NCT02910908|ESRD prognosis
23189|NCT02910908|help decision making dialysis therapeutic project
23190|NCT02910882|Pancreas Cancer
23191|NCT02910882|Unresectable
23192|NCT02910882|Chemoradiation
23193|NCT02910882|PEGPH20
23194|NCT02910843|rectal cancer
23195|NCT02910843|Neoadjuvant treatment
23196|NCT02910843|Regorafenib
23197|NCT02910843|Capecitabine
23198|NCT02910843|locally advanced rectal cancer
23199|NCT02910843|Phase Ib trial
23200|NCT02910804|GBM
23201|NCT02910804|GRPR
23202|NCT02910804|IRDye800
23203|NCT02910804|NIRF
23204|NCT02910804|surgery
23205|NCT02910726|indocyanine green fluorescent dye
23206|NCT02910726|Technetium lymphoscintigraphy
23207|NCT02910726|sentinel lymph node biopsy
23208|NCT02910726|16-1003
23209|NCT02910700|Melanoma
23210|NCT02910700|Metastatic Melanoma
23211|NCT02910700|BRAF- mutated metastatic melanoma
23212|NCT02910700|BRAF-wild type metastatic melanoma
23213|NCT02910700|Nivolumab
23214|NCT02910700|BMS-936558
23215|NCT02910700|Opdivo
23216|NCT02910700|Dabrafenib
23217|NCT02910700|Tafinlar
23218|NCT02910700|GSK2118436
23219|NCT02910700|Trametinib
23220|NCT02910700|GSK1120212
23221|NCT02910687|Non ST Elevation Myocardial Infarction (NSTEMI)
23222|NCT02910687|Elderly
23223|NCT02910687|Frailty
23224|NCT02910687|Prognostic value
23225|NCT02909855|children
23226|NCT02909855|psychological predictors
23227|NCT02909855|side-effects
23228|NCT02909855|vaccination
23229|NCT02909842|influenza
23230|NCT02909842|vaccine
23231|NCT02909842|probiotic
23232|NCT02909842|immune response
23233|NCT02909829|Diabetes Mellitus, Type 1
23234|NCT02909829|Artificial Pancreas
23235|NCT02909829|Closed-Loop Delivery
23236|NCT02909829|Insulin
23237|NCT02909829|Adolescent
23238|NCT02909829|Missed Bolus
23239|NCT02910661|Kidney Transplantation
23240|NCT02910648|healthy
23241|NCT02910648|BMI
23242|NCT02910648|computer task
23243|NCT02910648|learning
23244|NCT02910648|healthy sleeper
23245|NCT02910648|overweight
23246|NCT02910648|obese
23247|NCT02910635|Thorough QTc, Therapeutic dose, supra therapeutic dose
23248|NCT02910622|breast
23249|NCT02910622|ovarian
23250|NCT02910622|cancer
23251|NCT02910609|preterm
23252|NCT02910609|patent ductus arterioles
23253|NCT02910609|treatment
23254|NCT02910557|CTCAE - Common Terminology Criteria for Adverse Events
23255|NCT02910557|eCRF - electronic case report form
23256|NCT02910557|ECOG - Eastern Cooperative Oncology Group
23257|NCT02910557|EDC - electronic data capture
23258|NCT02910557|GM-CSF - human granulocyte macrophage colony-stimulating factor
23259|NCT02910557|HCP - health care provider
23260|NCT02910557|HSV-1 - herpes simplex virus type 1
23261|NCT02910557|ICF - informed consent form
23262|NCT02910557|ICP - infected cell protein
23263|NCT02910557|IEC - Independent Ethics Committee
23264|NCT02910557|IRB - Institutional Review Board
23265|NCT02910557|MedDRA - Medical Dictionary for Regulatory Activities
23266|NCT02910557|PFU - plaque-forming unit
23267|NCT02910557|qPCR - quantitative polymerase chain reaction
23268|NCT02910557|SmPC - Summary of Product Characteristics
23269|NCT02910557|USPI - United States Prescribing Information
23270|NCT02910531|Cystinuria
23271|NCT02910531|Kidney stone
23272|NCT02910531|Alpha lipoic acid
23273|NCT02910479|Body Temperature
23274|NCT02910479|Thermometers
23275|NCT02910453|Pulmonary lobectomy
23276|NCT02910453|Video-Assisted Thoracic Surgery
23277|NCT02910453|Opto-electronic plethysmography
23278|NCT02910453|Posterolateral thoracotomy
23279|NCT02910427|stroke
23280|NCT02910427|potassium and magnesium-enriched salt
23281|NCT02910427|neurological performance
23282|NCT02910388|conization
23283|NCT02910388|LLETZ
23284|NCT02910388|loop excision
23285|NCT02910388|randomized controlled trial
23286|NCT02910388|colposcopy
23287|NCT02910388|direct colposcopic vision
23288|NCT02910388|intraoperative colposcopy
23289|NCT02910375|golimumab
23290|NCT02910375|drug monitoring
23291|NCT02910375|home based care
23292|NCT02910349|valvular hear disease
23293|NCT02910349|echocardiography
23294|NCT02910349|magnetic resonance
23295|NCT02910349|global longitudinal strain
23296|NCT02910349|T1 relaxation time
23297|NCT02910310|Uterine Balloon Tamponade
23298|NCT02910297|cannabidiol
23299|NCT02910297|Dravet Syndrome
23300|NCT02910297|Lennox Gastaut Syndrome
23301|NCT02910284|HSV
23302|NCT02910284|Herpes
23303|NCT02910284|Genital Herpes
23304|NCT02910258|myelofibrosis
23305|NCT02910258|pegylated interferon
23306|NCT02910245|Therapeutic Drug Monitoring
23307|NCT02910245|Mercaptopurine (6-MP)
23308|NCT02910245|Thiopurine
23309|NCT02910245|Efficacy
23310|NCT02910232|Rice starch
23311|NCT02910232|Porous composite
23312|NCT02910232|Biomaterial
23313|NCT02910232|Bone regeneration
23314|NCT02910232|Clinical trial
23315|NCT02910232|Hydroxyapatite
23316|NCT02910219|HER2
23317|NCT02910219|pertuzumab
23318|NCT02910219|trastuzumab
23319|NCT02910219|docetaxel
23320|NCT02910219|paclitaxel
23321|NCT02910219|carboplatin
23322|NCT02910219|crofelemer
23323|NCT02910219|chemotherapy induced diarrhea
23324|NCT02910206|etomidate
23325|NCT02910206|propofol
23326|NCT02910193|alcoholism
23327|NCT02910193|genetics
23328|NCT02910193|functional MRI
23329|NCT02910193|structural MRI
23330|NCT02910193|first-degree relatives
23331|NCT02910180|Tissue Repository
23332|NCT02910180|Cerebrovascular Diseases
23333|NCT02910180|Stroke
23334|NCT02910180|Aneurysm
23335|NCT02910180|Arteriovenous malformation
23336|NCT02910180|Fistula
23337|NCT02910180|Intracranial Stenosis
23338|NCT02910180|Treatment
23339|NCT02910180|Registry
23340|NCT02910180|Outcomes
23341|NCT02910141|Type 2 diabetes
23342|NCT02910141|Continuous subcutaneous insulin infusion
23343|NCT02910141|Meta-analysis
23344|NCT02910141|Insulin pump therapy
23345|NCT02910141|Multiple daily insulin injections
23346|NCT02910102|RVT-101
23347|NCT02910102|intepirdine
23348|NCT02910102|Alzheimer's disease
23349|NCT02910102|Dementia with Lewy bodies
23350|NCT02910102|Lewy body dementia
23351|NCT02910102|Parkinson's Disease Dementia
23352|NCT02910089|Diabetes Mellitus Type 2
23353|NCT02910063|Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma
23354|NCT02910063|Blinatumomab
23355|NCT02910063|Leukemia
23356|NCT02910063|Standard of Care
23357|NCT02910063|SOC
23358|NCT02910063|Cancer
23359|NCT02910063|Chemotherapy
23360|NCT02910050|androgen receptor
23361|NCT02910050|bicalutamide
23362|NCT02910050|aromatase inhibitors
23363|NCT02910050|advanced breast cancer
23364|NCT02910050|letrozole
23365|NCT02910050|anastrozole
23366|NCT02910050|exemestane
23367|NCT02909998|Biomarkers
23368|NCT02909998|Genetic
23369|NCT02909998|Chronic arthritis
23370|NCT02909998|Treatment
23371|NCT02909985|Infrared
23372|NCT02909985|Dark Adaptation
23373|NCT02909985|Vision
23374|NCT02909985|Scotopic Threshold Response
23375|NCT02909985|Transient Receptor Potential (TRP) Channels
23376|NCT02909985|Human
23377|NCT02909959|sulforaphane
23378|NCT02909959|glucoraphanin
23379|NCT02909959|physiologic effects of drugs
23380|NCT02909946|multidrug-resistant organisms
23381|NCT02909946|nursing home
23382|NCT02909946|post-acute care
23383|NCT02909946|long-term care
23384|NCT02909946|infection control
23385|NCT02909920|Telerehabilitation
23386|NCT02909920|Physiotherapy
23387|NCT02909920|Surgery
23388|NCT02909920|Telemedicine
23389|NCT02909894|Sedentary behaviour
23390|NCT02909894|Postprandial glycaemic response
23391|NCT02909881|polysaccharide
23392|NCT02909881|oxidation
23393|NCT02909881|endurance exercise
23394|NCT02909803|glucose
23395|NCT02909803|glycemic index
23396|NCT02909803|lentil
23397|NCT02909803|polyphenols
23398|NCT02909803|metabolites
23399|NCT02909803|bioavailability
23400|NCT02909777|Lymphoma
23401|NCT02909777|Neuroblastoma
23402|NCT02909777|Brain Tumor
23403|NCT02909777|Solid Tumor
23404|NCT02909764|Salty taste
23405|NCT02909764|Psychophysics
23406|NCT02909764|Genetics
23407|NCT02909764|Diet
23408|NCT02909764|Age
23409|NCT02909725|Physical activity
23410|NCT02909725|Sedentary time
23411|NCT02909725|Pregnancy
23412|NCT02909725|Pregnant women
23413|NCT02909725|Weight gain
23414|NCT02909712|sub-Saharan
23415|NCT02909712|dihydroartemisinin
23416|NCT02909712|piperaquine
23417|NCT02909712|sulphadoxine-pyrimethamine
23418|NCT02909712|antimalarials
23419|NCT02909686|Gulf War Syndrome
23420|NCT02909686|Chronic Multisymptom Illnesses
23421|NCT02909686|Medically Unexplained Illnesses
23422|NCT02909673|adolescent behavior
23423|NCT02909673|intimate partner violence
23424|NCT02909673|youth risk behavior
23425|NCT02909673|violence prevention
23426|NCT02909673|teen dating violence
23427|NCT02909621|OsteoArthritis; FLEXOFYTOL®; Curcuma; biomarkers
23428|NCT02909556|Transcatheter Aortic Valve Replacement
23429|NCT02909556|TAVI
23430|NCT02909556|Transcatheter Aortic Valve Implant
23431|NCT02909556|Transfemoral access
23432|NCT02909530|Endoscopic ultrasound-guided fine needle biopsy
23433|NCT02909530|Olympus EZ Shot 3Plus
23434|NCT02909530|Olympus EZ Shot 2
23435|NCT02909452|entinostat
23436|NCT02909452|pembrolizumab
23437|NCT02909452|solid tumor
23438|NCT02909452|Histone Deacetylase Inhibitor
23439|NCT02909426|Screening
23440|NCT02909426|Digital mammography
23441|NCT02909426|Ultrasonography
23442|NCT02909426|Sensitivity
23443|NCT02909426|Specificity
23444|NCT02909413|desflurane
23445|NCT02909413|sevoflurane
23446|NCT02909400|mitochondrial
23447|NCT02909400|oxidative phosphorylation (oxphos)
23448|NCT02909400|MELAS
23449|NCT02909400|MIDD
23450|NCT02909400|KH176
23451|NCT02909400|Proof of Concept
23452|NCT02909387|Epilepsy
23453|NCT02909387|Seizure Disorder
23454|NCT02909374|Implementation
23455|NCT02909374|fall prevention
23456|NCT02909374|balance training
23457|NCT02909348|Neoplasms
23458|NCT02909348|Melanoma
23459|NCT02909348|Immunotherapy
23460|NCT02909348|Biomarkers
23461|NCT02909309|Propofol
23462|NCT02909309|Deep Sedation
23463|NCT02909309|Anoxia
23464|NCT02909309|Hypercapnia
23465|NCT02909231|Patient Outcome Assessment
23466|NCT02909218|HIV/AIDS, Swaziland
23467|NCT02909205|child
23468|NCT02909205|gastrostomy
23469|NCT02909205|supportive care
23470|NCT02909205|educational program
23471|NCT02909192|Parkinson's Disease
23472|NCT02909192|Excessive Daytime Sleepiness
23473|NCT02909192|Circadian Rhythms
23474|NCT02909192|Light Therapy
23475|NCT02909179|Community Health Workers, mHealth, mobile phones, ANC, PNC, essential newborn care
23476|NCT02909153|Triferic
23477|NCT02909153|ferric pyrophosphate citrate
23478|NCT02909153|peritoneal dialysis
23479|NCT02909153|anemia
23480|NCT02909153|chronic kidney disease
23481|NCT02909153|FPC
23482|NCT02909127|deglutition
23483|NCT02909127|deglutition disorders
23484|NCT02909127|pediatric dysphagia
23485|NCT02909127|swallowing
23486|NCT02909114|stereotactic boday radiotherapy, oligometastases
23487|NCT02909101|Working memory
23488|NCT02909101|cognitive training
23489|NCT02909101|HIV
23490|NCT02909101|substance abuse
23491|NCT02909088|stuttering
23492|NCT02909088|childhood onset fluency disorder
23493|NCT02909088|ecopipam
23494|NCT02909075|PET/CT
23495|NCT02909075|MRI
23496|NCT02909075|Assess Thymic Function
23497|NCT02909075|16-1244
23498|NCT02909062|Electronic Activity Monitoring (EAM)
23499|NCT02909062|16-493
23500|NCT02909049|Prostate Biopsy
23501|NCT02909049|Local Anesthesia
23502|NCT02909049|Pain
23503|NCT02909049|Biopsy of prostate
23504|NCT02909036|Melphalan
23505|NCT02909036|Autologous Hematopoietic Progenitor Cell Transplant
23506|NCT02909036|High Dose Therapy
23507|NCT02909036|16-875
23508|NCT02909023|Hepatitis B Virus
23509|NCT02909023|Elispot test
23510|NCT02909023|T cellular immune response
23511|NCT02908984|unilateral headache
23512|NCT02908984|cervical pain
23513|NCT02908984|neck pain
23514|NCT02908984|voxel based morphometry
23515|NCT02908984|diffusion tensor imaging
23516|NCT02908984|structural brain changes
23517|NCT02908984|rehabilitation
23518|NCT02908971|soy based formula
23519|NCT02908971|overweight
23520|NCT02908971|adrenarche,
23521|NCT02908971|gonadarache
23522|NCT02908945|Ketamine
23523|NCT02908945|Anesthesia
23524|NCT02908945|EEG
23525|NCT02908945|NeuroSENSE
23526|NCT02908945|Pain
23527|NCT02908919|Colonoscopy
23528|NCT02908919|Picosulfate sodium
23529|NCT02908919|Polyethylene glycol
23530|NCT02908919|Magnesium citrate
23531|NCT02908919|Ascorbic acid
23532|NCT02908919|SPMC (solution picosulfate + magnesium citrate)
23533|NCT02908919|PEGA (Polyethylene glycol + ascorbic acid)
23534|NCT02908880|MANTA, arterial closure device, large bore closure device
23535|NCT02908867|Sexuality
23536|NCT02908867|Spinal cord injuries
23537|NCT02908867|Complementary Therapies
23538|NCT02908867|Medicinal plants
23539|NCT02908854|Spices
23540|NCT02908854|Herbs
23541|NCT02908854|Vegetables
23542|NCT02908854|National School Lunch Program
23543|NCT02908854|High school
23544|NCT02908828|Biological Products/therapeutic use
23545|NCT02908828|Copepoda
23546|NCT02908828|Dietary Supplements
23547|NCT02908828|Fish Oils
23548|NCT02908828|Fatty Acids, Omega-3
23549|NCT02908828|Oxygen Consumption
23550|NCT02908828|Calanus
23551|NCT02908828|Maximal oxygen uptake
23552|NCT02908828|Zooplankton
23553|NCT02908789|Photochemotherapy
23554|NCT02908763|Chronic Hepatitis B
23555|NCT02908763|Peginterferon Alpha
23556|NCT02908750|oncology
23557|NCT02908750|cancer
23558|NCT02908750|non small cell lung cancer
23559|NCT02908750|anticancer drug
23560|NCT02908750|lung neoplasms
23561|NCT02908750|pharmacokinetics
23562|NCT02908750|AZD9291
23563|NCT02908750|osimertinib
23564|NCT02908750|fexofenadine
23565|NCT02908750|TAGRISSO™
23566|NCT02908750|EGFR genes
23567|NCT02908724|Familial cardiomyopathies
23568|NCT02908724|Hypertrophic cardiomyopathy
23569|NCT02908724|Left ventricular hypertrophy
23570|NCT02908659|intensive care unit
23571|NCT02908659|patient's monitoring
23572|NCT02908659|respiratory rate
23573|NCT02908633|open angle glaucoma
23574|NCT02908633|canaloplasty
23575|NCT02908633|migs
23576|NCT02908633|abic
23577|NCT02908594|Nursing
23578|NCT02908594|ESRD
23579|NCT02908594|hemodialysis
23580|NCT02908594|intradialytic exercise
23581|NCT02908594|depression
23582|NCT02908594|fatigue
23583|NCT02908594|Quality Of Life
23584|NCT02908594|self-efficacy
23585|NCT02908594|resilience
23586|NCT02908568|mandibular stretching, trigeminocardiac reflex
23587|NCT02908555|type 1 diabetes
23588|NCT02908555|adolescents
23589|NCT02908555|sleep
23590|NCT02908490|Arthritis, Rheumatoid
23591|NCT02908490|Atherosclerosis
23592|NCT02908464|Cardiac Surgery
23593|NCT02908464|Delirium
23594|NCT02908464|Postoperative Cognitive Dysfunction
23595|NCT02908451|Cancer
23596|NCT02908451|Antibody Drug Conjugate
23597|NCT02908451|AbGn-107
23598|NCT02908451|Adenocarcinoma
23599|NCT02908451|Gastric
23600|NCT02908451|Colorectal
23601|NCT02908451|Pancreatic
23602|NCT02908412|Nerve Block
23603|NCT02908412|Spectrophotometry
23604|NCT02908412|Bupivacaine
23605|NCT02908412|Spinal Surgery
23606|NCT02908412|Blood Loss, Surgical
23607|NCT02908386|Head and neck tumors
23608|NCT02908386|Proton
23609|NCT02908386|Photon
23610|NCT02908386|replanning timing
23611|NCT02908373|risk management
23612|NCT02908373|nursing home
23613|NCT02908373|elderly
23614|NCT02908373|care
23615|NCT02908360|Double positive lymphocyte T F prausnitzii
23616|NCT02908347|Plaque psoriasis
23617|NCT02908347|chronic
23618|NCT02908347|moderate
23619|NCT02908347|severe
23620|NCT02908347|Plaque
23621|NCT02908308|Induced hypothermia
23622|NCT02908308|Mild induced hypothermia
23623|NCT02908308|Therapeutic hypothermia
23624|NCT02908308|Cardiac arrest
23625|NCT02908308|Out-of-hospital cardiac arrest
23626|NCT02908308|Mortality
23627|NCT02908308|Neurological function
23628|NCT02908308|Randomised clinical trial
23629|NCT02908282|tear film
23630|NCT02908282|omega-3 fatty acids
23631|NCT02908282|eye drops
23632|NCT02908269|Influenza
23633|NCT02908269|Fluzone® Quadrivalent, Influenza Vaccine (2016-2017 formulation)
23634|NCT02908269|Fluzone® High Dose, Influenza Vaccine (2016-2017 formulation)
23635|NCT02908256|PVI
23636|NCT02908256|delta PP
23637|NCT02908256|vascular filling
23638|NCT02908243|Hemophilia
23639|NCT02908243|Primary prophylaxis
23640|NCT02908243|Pettersson Score
23641|NCT02908243|Joint function study
23642|NCT02908243|Comorbidity
23643|NCT02908217|Polymyalgia Rheumatica
23644|NCT02908217|Tocilizumab
23645|NCT02908217|Glucocorticoid
23646|NCT02908204|superficial esophageal squamous cell carcinoma
23647|NCT02908204|efficacy
23648|NCT02908204|survival
23649|NCT02908178|ductal carcinoma in situ (DCIS)
23650|NCT02908178|sentinel lymph node biopsy (SLNB)
23651|NCT02908087|Diabetes Type 1
23652|NCT02908087|Diabetes, Insulin-Dependent
23653|NCT02908087|Liraglutide
23654|NCT02908087|GLP-1 Analogue
23655|NCT02908087|Early diagnosis
23656|NCT02908074|Hypogonadotropic
23657|NCT02908074|hypogonadism
23658|NCT02908074|testosterone
23659|NCT02908061|Mesh Placement
23660|NCT02908061|Radical Cystectomy
23661|NCT02908061|16-1285
23662|NCT02908048|liver cancer
23663|NCT02908048|cholangiocarcinoma (CCA)
23664|NCT02908048|cirrhosis
23665|NCT02908048|hepatitis
23666|NCT02908048|bile duct cancer
23667|NCT02908048|hepatocellular carcinoma (HCC)
23668|NCT02908048|hepatobiliary carcinoma
23669|NCT02908048|hepatoma
23670|NCT02908048|liver mass
23671|NCT02907983|Menopause
23672|NCT02907983|Post-menopausal
23673|NCT02907970|Cervical cancer
23674|NCT02907970|Screening
23675|NCT02907970|Barriers
23676|NCT02907931|hemodynamics
23677|NCT02907931|ultrasonography
23678|NCT02907879|Subarachnoid Hemorrhage
23679|NCT02907879|Ultrasound perfusion imaging
23680|NCT02907879|cerebral hypoperfusion
23681|NCT02907879|vasospasm
23682|NCT02907879|DIND
23683|NCT02907879|infarction
23684|NCT02907827|complete remission
23685|NCT02907827|cfDNA
23686|NCT02907827|DW-MRI
23687|NCT02907827|surveillance
23688|NCT02907814|Uveitis
23689|NCT02907814|Optical Coherence Tomography
23690|NCT02907801|congenital muscular torticollis
23691|NCT02907801|infants
23692|NCT02907801|perception-action approach
23693|NCT02907788|Cystic fibrosis
23694|NCT02907788|Neutrophils
23695|NCT02907788|PMN
23696|NCT02907788|Inflammation
23697|NCT02907788|Lung disease
23698|NCT02907788|PRAGMA
23699|NCT02907762|Endovascular
23700|NCT02907762|EVAR
23701|NCT02907762|Neck Angulation
23702|NCT02907710|Nasopharyngeal carcinoma
23703|NCT02907710|endostar
23704|NCT02907710|chemoradiotherapy
23705|NCT02907697|HIV/AIDS
23706|NCT02907697|adherence
23707|NCT02907697|substance use
23708|NCT02907697|HIV care continuum
23709|NCT02907684|Cardiovascular disease
23710|NCT02907684|Non alcoholic fatty liver
23711|NCT02907684|Diabetes
23712|NCT02907684|Almonds
23713|NCT02907684|Endothelium-dependent vasodilation
23714|NCT02907684|Fecal short chain fatty acids (SCFAs)
23715|NCT02907684|Snacking
23716|NCT02907671|carpal tunnel injection
23717|NCT02907671|corticosteroid
23718|NCT02907671|ultrasound-guided
23719|NCT02907671|musculoskeletal ultrasound
23720|NCT02907658|Internet Use Disorder
23721|NCT02907658|Internet Gaming Disorder
23722|NCT02907658|Cognitive-Behavioral Intervention
23723|NCT02907658|Indicated Prevention
23724|NCT02907658|Adolescents
23725|NCT02907658|Internet Addiction
23726|NCT02907632|Metoclopramide
23727|NCT02907632|Pro kinetic
23728|NCT02907632|Gastroesophageal Reflux
23729|NCT02907632|Premature Infant
23730|NCT02907632|Low Birth Weight
23731|NCT02907632|Kangaroo Mother Care Method
23732|NCT02907619|Duchenne muscular dystrophy, myostatin, open-label
23733|NCT02907606|Non-small-cell Lung Cancer
23734|NCT02907606|circulating tumor DNA
23735|NCT02907606|urine
23736|NCT02907593|Bronchopulmonary dysplasia
23737|NCT02907593|Pulmonary
23738|NCT02907593|Surfactant
23739|NCT02907593|Steroids
23740|NCT02907593|Extremely low gestational age
23741|NCT02907580|influenza
23742|NCT02907580|vaccination
23743|NCT02907554|Preconditioning
23744|NCT02907554|Tissue and organ procurement
23745|NCT02907554|Cyclosporine A
23746|NCT02907554|Kidney transplantation
23747|NCT02907554|Delayed graft function
23748|NCT02907541|eLearning
23749|NCT02907541|Quality Improvement Methods
23750|NCT02907541|Knowledge Transfer
23751|NCT02907541|Impact of learning
23752|NCT02907515|single implant retained mandibular overdenture
23753|NCT02907489|post operative pain
23754|NCT02907489|triple antibiotic paste
23755|NCT02907489|intracanal medication
23756|NCT02907463|Aortic Valve Replacement
23757|NCT02907463|Aortic Stenosis
23758|NCT02907463|EDWARDS INTUITY Elite
23759|NCT02907463|Rapid deployment valves
23760|NCT02907437|Minocycline
23761|NCT02907437|Negative symptoms
23762|NCT02907437|Cognitive symptoms
23763|NCT02907437|Inflammation
23764|NCT02907411|Quadrivas
23765|NCT02907411|Veins
23766|NCT02907411|Lipedema
23767|NCT02907411|Lymphedema
23768|NCT02907398|Neurostimulation
23769|NCT02907398|Hypoglossal nerve
23770|NCT02907398|Tongue
23771|NCT02907398|Upper airway stimulation
23772|NCT02907398|Surgery
23773|NCT02907385|Rectal Cancer
23774|NCT02907385|Low Anterior Resection
23775|NCT02907385|LifeSeal
23776|NCT02907385|Surgical Sealant
23777|NCT02907372|cognitive dysfunctions
23778|NCT02907372|cognitive complaints
23779|NCT02907372|metastatic prostate cancer
23780|NCT02907372|new generations of hormone-therapy
23781|NCT02907333|Condom use
23782|NCT02907333|Human Papillomavirus
23783|NCT02907333|Conization
23784|NCT02907307|LactiSal
23785|NCT02907307|Vaginal therapy
23786|NCT02907294|PDE10 inhibitor
23787|NCT02907294|phosphodiesterase 10 inhibitor
23788|NCT02907294|Huntington's disease
23789|NCT02907294|psychiatric disorders
23790|NCT02907281|Multiple sclerosis
23791|NCT02907281|MS
23792|NCT02907281|Optical coherence tomography
23793|NCT02907281|OCT
23794|NCT02907281|RRMS
23795|NCT02907268|botulinum toxin type A, intradermal
23796|NCT02907255|Pulse oximetry
23797|NCT02907255|vital signs monitoring
23798|NCT02907255|wireless notification of clinicians
23799|NCT02907255|respiratory monitoring system
23800|NCT02907242|stillbirth
23801|NCT02907242|cerebroplacental ratio
23802|NCT02907242|fetal growth restriction
23803|NCT02907216|Healthy Japanese infants
23804|NCT02907216|Safety
23805|NCT02907216|Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) vaccine
23806|NCT02907216|Vaccination
23807|NCT02907216|Oral HRV liquid vaccine
23808|NCT02907216|Immunogenicity
23809|NCT02907190|pulses
23810|NCT02907190|beans
23811|NCT02907190|blood glucose
23812|NCT02907190|insulin
23813|NCT02907112|meat intake
23814|NCT02907112|meat analogues
23815|NCT02907112|LDL Cholesterol
23816|NCT02907112|HDL Cholesterol
23817|NCT02907099|Malignant neoplasms of digestive organs
23818|NCT02907099|Metastatic Pancreatic Cancer
23819|NCT02907099|Pancreatic adenocarcinoma
23820|NCT02907099|BL-8040
23821|NCT02907099|Pembrolizumab
23822|NCT02907099|Keytruda
23823|NCT02907099|MK-3475
23824|NCT02907099|SCH-900475
23825|NCT02907099|Phone call
23826|NCT02907060|prolonged pregnancy
23827|NCT02907060|mechanical cervical ripening
23828|NCT02906995|pharmacokinetics
23829|NCT02906995|nicotine absorption
23830|NCT02906982|Periodontal diseases
23831|NCT02906982|Periodontitis
23832|NCT02906982|Gingivitis
23833|NCT02906982|Teeth Whitening
23834|NCT02906982|Dental Plaque Index
23835|NCT02906982|Periodontal Index
23836|NCT02906982|Teeth Whitening Agents
23837|NCT02906982|Tooth Discoloration
23838|NCT02906982|Mean Probing Depth
23839|NCT02906982|Pocket Depth
23840|NCT02906943|Molecular Profiling
23841|NCT02906943|Advanced Cancer
23842|NCT02906943|Advanced Solid Tumors
23843|NCT02906943|Phase I Clinical Trial Candidates
23844|NCT02906943|Next Generation Sequencing
23845|NCT02906878|Intensive Care
23846|NCT02906878|Haematology
23847|NCT02906878|Platelets prophylactic transfusion
23848|NCT02906839|cardiovascular risk
23849|NCT02906839|risk of atrial fibrillation recurrence
23850|NCT02906839|sleep apnea syndrome
23851|NCT02906839|atrial fibrillation
23852|NCT02906826|Airway clearance technique
23853|NCT02906826|Positive expiratory pressure technique
23854|NCT02906826|Adherence
23855|NCT02906813|Drug Therapy
23856|NCT02906800|cisplatin
23857|NCT02906800|head and neck cancer
23858|NCT02906800|digoxin
23859|NCT02906787|Smoking Cessation
23860|NCT02906787|Weight Loss
23861|NCT02906761|asthma, aspirin
23862|NCT02906748|parathyroid autografting
23863|NCT02906748|thyroidectomy
23864|NCT02906748|survival rate
23865|NCT02906748|hypoparathyroidism
23866|NCT02906722|Nebulized colistin
23867|NCT02906722|Intravenous colistin
23868|NCT02906722|ventilator-associated pneumonia
23869|NCT02906722|multidrug resistance
23870|NCT02906722|Gram-negative bacteria
23871|NCT02906696|Chronic myelogenous leukemia
23872|NCT02906696|CML
23873|NCT02906696|Chronic phase post frontline TKI failure
23874|NCT02906696|Tyrosine kinase inhibitor
23875|NCT02906696|TKI
23876|NCT02906696|Bosutinib
23877|NCT02906696|SKI-606
23878|NCT02906696|Phone calls
23879|NCT02906696|Questionnaires
23880|NCT02906696|Surveys
23881|NCT02906683|Urinary Incontinence
23882|NCT02906683|Urinary Incontinence, Stress
23883|NCT02906683|Lower Urinary Tract Symptoms
23884|NCT02906670|Epithelial malignancies
23885|NCT02906657|Medication Reconciliation
23886|NCT02906657|Adverse Drug Event
23887|NCT02906657|Elderly
23888|NCT02906657|patient pharmaceutical record
23889|NCT02906644|Nicotine addiction
23890|NCT02906644|Cigarette smoking
23891|NCT02906644|Smoking cessation
23892|NCT02906644|lorcaserin
23893|NCT02906644|Belviq
23894|NCT02906644|Nicotine patches
23895|NCT02906631|encephalitis,
23896|NCT02906631|neurologic outcomes of all-cause encephalitis in intensive care unit
23897|NCT02906631|outcome, intensive care unit
23898|NCT02906553|Nitric Oxide
23899|NCT02906553|Cognition
23900|NCT02906527|Cardiology
23901|NCT02906527|Oral anticoagulants
23902|NCT02906527|Risk and Benefit analysis
23903|NCT02906527|Health insurance databases
23904|NCT02906527|Safety
23905|NCT02906527|Elderly
23906|NCT02906514|Hydroxyethyl Starch
23907|NCT02906514|Cardiac surgery
23908|NCT02906514|Priming of cardiopulmonary bypass
23909|NCT02906501|Risperidone
23910|NCT02906501|ADHD
23911|NCT02906501|DBD
23912|NCT02906501|IGT
23913|NCT02906501|CNP
23914|NCT02906501|Executive functions
23915|NCT02906488|Quality of life
23916|NCT02906475|Dermatitis, atopic
23917|NCT02906475|prevention and control
23918|NCT02906475|Infant
23919|NCT02906475|Skin care
23920|NCT02906475|randomized controlled trial
23921|NCT02906462|Leonetti French law
23922|NCT02906462|Palliative care
23923|NCT02906449|concussion, mild head injury, mindfulness
23924|NCT02906436|Lung transplantation
23925|NCT02906436|ExVivo reconditionning
23926|NCT02906423|Quality of Life
23927|NCT02906423|Patient-Centered Care
23928|NCT02906423|Patient Outcome Assessment
23929|NCT02906384|hippocampus avoidance
23930|NCT02906384|volumetric modulated arc therapy
23931|NCT02906384|functional MRI
23932|NCT02906384|hopkins Verbal Learning Test
23933|NCT02906384|prophylactic cranial irradiation
23934|NCT02906345|Septic shock
23935|NCT02906345|Fresh frozen plasma
23936|NCT02906306|Older adults
23937|NCT02906306|Occupational Therapy
23938|NCT02906306|Self-Efficacy
23939|NCT02906306|Psychological Well-being
23940|NCT02906280|EBUS-TBNA
23941|NCT02906241|African Americans
23942|NCT02906241|prostate cancer
23943|NCT02906241|Minority
23944|NCT02906241|Racial /Ethnic disparity
23945|NCT02906241|Cancer care
23946|NCT02906241|patient-physician communication
23947|NCT02906241|cancer clinical trial accrual
23948|NCT02906228|non-ionizing radiation
23949|NCT02906215|mHealth
23950|NCT02906215|implementation
23951|NCT02906163|EGFR mutation positive
23952|NCT02906163|Thymosin Alpha 1
23953|NCT02906163|Tyrosine Kinase inhibitor
23954|NCT02906163|Thymalfasin
23955|NCT02906163|Non Small Cell Lung Cancer
23956|NCT02906150|EGFR Wild Type
23957|NCT02906150|Thymosin Alpha 1
23958|NCT02906150|Non-Small Cell Lung Cancer
23959|NCT02906150|Thymalfasin
23960|NCT02906124|hypercholesterolaemia
23961|NCT02906124|Lipid lowering therapies
23962|NCT02906124|Pregnancy
23963|NCT02906111|Estriol
23964|NCT02906111|Prolapse
23965|NCT02906111|Quality of life
23966|NCT02906111|Vaginal health
23967|NCT02906111|Vaginal surgery
23968|NCT02906098|Gingivitis
23969|NCT02906098|Adolescents
23970|NCT02906098|Oral hygiene
23971|NCT02906098|Oral health behavior
23972|NCT02906098|Periodontal infection control
23973|NCT02906085|[C10.228.140.546.399.750.250]
23974|NCT02906072|Obesity
23975|NCT02906072|Body fat
23976|NCT02906072|Plant-based diet
23977|NCT02906072|Plant-based meal replacement
23978|NCT02906059|RAS
23979|NCT02906059|KRAS
23980|NCT02906059|NRAS
23981|NCT02906059|BRAF
23982|NCT02906059|Mutated
23983|NCT02906059|Wee1 inhibitor
23984|NCT02906046|SCA 3
23985|NCT02906046|Ataxic Gait
23986|NCT02906033|Surgical Procedures, Operative
23987|NCT02906033|Operating Rooms
23988|NCT02906033|Quality of Life
23989|NCT02906033|Surgery-related anxiety
23990|NCT02905994|Leukemia
23991|NCT02905981|IRIDA
23992|NCT02905981|Triferic
23993|NCT02905981|soluble ferric pyrophosphate
23994|NCT02905981|Shohl's solution
23995|NCT02905968|Anastomotic leak
23996|NCT02905968|Low rectal cancer
23997|NCT02905929|sedentary behavior
23998|NCT02905929|standing
23999|NCT02905929|sitting
24000|NCT02905929|inclinometer
24001|NCT02905864|Liraglutide
24002|NCT02905864|Liraglutide 3 mg
24003|NCT02905864|Osteoarthritis
24004|NCT02905864|Obesity
24005|NCT02905799|Osteoarthritis
24006|NCT02905799|Knee
24007|NCT02905799|Resveratrol
24008|NCT02905799|Oral Treatment
24009|NCT02905799|Pain
24010|NCT02905799|Trial
24011|NCT02905786|General Practice
24012|NCT02905786|Nurse practitioner
24013|NCT02905786|Natriuretic peptides
24014|NCT02905786|Clinical audit
24015|NCT02905773|Intensity
24016|NCT02905760|Acute Myocardial Infarction
24017|NCT02905760|Right ventricular infarction
24018|NCT02905760|Diuretic
24019|NCT02905760|Fluid Expansion
24020|NCT02905747|Exercise Therapy
24021|NCT02905747|Musculoskeletal Pain
24022|NCT02905747|Knee osteoarthritis
24023|NCT02905747|Physical Therapy Modalities
24024|NCT02905734|Nicotine replacement therapy
24025|NCT02905734|Tobacco
24026|NCT02905708|normothermia
24027|NCT02905708|hypothermia
24028|NCT02905695|Post-partum Perineal pain
24029|NCT02905695|Episiotomy
24030|NCT02905695|First-degree tear
24031|NCT02905669|distensibility
24032|NCT02905669|impedance planimetry
24033|NCT02905669|esophagus
24034|NCT02905669|esophago-gastric junction
24035|NCT02905669|pylorus
24036|NCT02905656|quitline
24037|NCT02905656|nicotine replacement therapy
24038|NCT02905656|tobacco intervention
24039|NCT02905656|smokers not ready to quit
24040|NCT02905643|Pseudoprogression
24041|NCT02905643|Brain Cancer
24042|NCT02905630|coronary flow reserve
24043|NCT02905630|angina
24044|NCT02905630|exercise training
24045|NCT02905617|Breast Augmentation
24046|NCT02905617|Breast Revision-Augmentation
24047|NCT02905604|rTMS
24048|NCT02905604|negative symptoms
24049|NCT02905604|intermittent theta burst
24050|NCT02905604|iTBS
24051|NCT02905604|repetitive transcranial magnetic stimulation
24052|NCT02905604|dorsomedial prefrontal cortex
24053|NCT02905604|dmPFC
24054|NCT02905604|NIRS
24055|NCT02905591|pharmacological ascorbate
24056|NCT02905591|ascorbic acid
24057|NCT02905591|radiation
24058|NCT02905591|chemotherapy
24059|NCT02905591|carboplatin
24060|NCT02905591|paclitaxel
24061|NCT02905565|Multicenter
24062|NCT02905565|Randomized
24063|NCT02905565|Double-Blind
24064|NCT02905565|Placebo-Controlled
24065|NCT02905565|Add-On to Standard-of-Care
24066|NCT02905565|Safety
24067|NCT02905565|Tolerability
24068|NCT02905565|Efficacy
24069|NCT02905552|Myelodysplastic syndrome (myelodysplasia)
24070|NCT02905552|Infection
24071|NCT02905552|Risk Factors
24072|NCT02905539|Iron
24073|NCT02905539|anemia
24074|NCT02905539|phosphorus
24075|NCT02905539|FGF-23
24076|NCT02905526|Reproductive health
24077|NCT02905513|Reproductive health
24078|NCT02905500|Disability-Adjusted Life Years
24079|NCT02905500|Epidemiology
24080|NCT02905500|Public Health
24081|NCT02905487|Gestational Diabetes Mellitus
24082|NCT02905487|Obesity
24083|NCT02905487|Adipocytokin
24084|NCT02905474|chronic kidney disease, mobile applications, mHealth, medication reconciliation, self-management
24085|NCT02905461|Reproductive health
24086|NCT02905448|Obesity
24087|NCT02905448|Body composition
24088|NCT02905448|Atherosclerosis
24089|NCT02905448|Insulin resistance
24090|NCT02905448|Hyperuricemia
24091|NCT02905435|burns
24092|NCT02905435|autografts
24093|NCT02905435|humans
24094|NCT02905435|biodegradable polyurethane
24095|NCT02905435|dermal matrix
24096|NCT02905435|synthetic
24097|NCT02905422|physical activity
24098|NCT02905422|sleep
24099|NCT02905422|nutrition
24100|NCT02905422|Soldier
24101|NCT02905422|prevention
24102|NCT02905422|remote monitoring
24103|NCT02905422|mobile technology
24104|NCT02905396|small fiber neuropathy
24105|NCT02905396|spinal cord stimulation
24106|NCT02905396|treatment
24107|NCT02905396|pain
24108|NCT02905370|Home Health
24109|NCT02905370|Rehabilitation
24110|NCT02905370|High Intensity
24111|NCT02905370|Hospital Associated Deconditioning
24112|NCT02905370|Functional Mobility
24113|NCT02905370|Physical Function
24114|NCT02905357|Myocardial Infarction
24115|NCT02905357|Women
24116|NCT02905357|Imaging
24117|NCT02905305|cochlear implants
24118|NCT02905305|Dexamethasone
24119|NCT02905305|combined device
24120|NCT02905279|spider phobia
24121|NCT02905279|animal phobia
24122|NCT02905279|exposure therapy
24123|NCT02905279|biofeedback
24124|NCT02905279|relaxation training
24125|NCT02905240|Autologous Protein Solution
24126|NCT02905240|APS
24127|NCT02905240|intra-articular injection
24128|NCT02905240|osteoarthritis
24129|NCT02905227|Adult smokers
24130|NCT02905227|Asthma
24131|NCT02905227|Healthy volunteers
24132|NCT02905188|hepatocellular carcinoma
24133|NCT02905188|GPC3-CAR T cells
24134|NCT02905188|GPC3-positive hepatocellular carcinoma
24135|NCT02905175|rheumatoid arthritis
24136|NCT02905175|Porphyromonas gingivalis
24137|NCT02905149|Oncological
24138|NCT02905149|Surgery
24139|NCT02905149|Breast
24140|NCT02905149|Reconstruction
24141|NCT02905136|autoantibodies
24142|NCT02905136|neuronal synaptic receptors
24143|NCT02905136|autoimmune encephalitis
24144|NCT02905110|Malignant Neoplasms, Brain
24145|NCT02905097|Knee arthroplasty, Total
24146|NCT02905097|Knee replacement, Total
24147|NCT02905097|Survival rate
24148|NCT02905097|Osseointegration
24149|NCT02905097|Gait
24150|NCT02905071|mental health
24151|NCT02905071|well-being at work
24152|NCT02905071|screening
24153|NCT02905071|psychosocial risk
24154|NCT02905071|psychometrics
24155|NCT02905071|questionnaire
24156|NCT02905071|job stress
24157|NCT02905032|Afib
24158|NCT02905032|Atrial fib
24159|NCT02905032|Shared
24160|NCT02905032|Decision
24161|NCT02905032|Making
24162|NCT02905032|Aid
24163|NCT02905032|AF
24164|NCT02905006|Psoriasis
24165|NCT02905006|Chronic Plaque Psoriasis
24166|NCT02905006|Bimekizumab
24167|NCT02904980|Quiet eye training
24168|NCT02904980|Visual Attention
24169|NCT02904954|Lung neoplasms
24170|NCT02904954|Bronchial Neoplasms
24171|NCT02904954|Carcinoma, bronchogenic
24172|NCT02904954|Neoplasms
24173|NCT02904954|Neoplasms by site
24174|NCT02904954|Respiratory Tract Diseases
24175|NCT02904954|Respiratory Tract Neoplasms
24176|NCT02904954|Thoracic Neoplasms
24177|NCT02904941|Children
24178|NCT02904941|Skin Transplantation
24179|NCT02904941|Amniotic Membrane
24180|NCT02904902|adalimumab
24181|NCT02904902|japanese participants
24182|NCT02904902|efficacy
24183|NCT02904902|safety
24184|NCT02904850|Non-small cell lung cancer
24185|NCT02904850|locally advanced or metastatic
24186|NCT02904850|erlotinib monotherapy
24187|NCT02904837|Parkinson Disease
24188|NCT02904837|Gait
24189|NCT02904837|Mental Practice
24190|NCT02904837|Training
24191|NCT02904824|adipose tissue
24192|NCT02904824|adult stem cells
24193|NCT02904824|vocal cord paralysis
24194|NCT02904811|Chlamydia trachomatis
24195|NCT02904811|Pelvic inflammatory disease
24196|NCT02904798|sunscreen
24197|NCT02904798|photoprotection
24198|NCT02904798|visible light
24199|NCT02904746|follow-up
24200|NCT02904746|mental health appointment
24201|NCT02904720|Vitamin D; Pregnancy
24202|NCT02904707|Skin Graft
24203|NCT02904668|chronic pain
24204|NCT02904642|SMS reminder
24205|NCT02904642|incentive
24206|NCT02904642|mobile phone
24207|NCT02904642|Immunization
24208|NCT02904590|IBD
24209|NCT02904590|Infection
24210|NCT02904577|Indolent B-Cell Lymphomas
24211|NCT02904577|prospective collection
24212|NCT02904564|drug delivery
24213|NCT02904564|Idiopathic Guttate Hypomelanosis
24214|NCT02904551|prospective study
24215|NCT02904551|free gingival graft
24216|NCT02904551|keratinized gingiva
24217|NCT02904551|dental implant
24218|NCT02904538|Dexamethasone
24219|NCT02904538|Regional anesthesia
24220|NCT02904538|Front foot surgery
24221|NCT02904538|Metacarpal osteotomy
24222|NCT02904525|newly diagnosed
24223|NCT02904525|MRI
24224|NCT02904499|Atrial Fibrillation
24225|NCT02904499|Anticoagulants
24226|NCT02904499|Pharmacoepidemiology
24227|NCT02904447|hemicap
24228|NCT02904447|hallux rigidus
24229|NCT02904434|voriconazole
24230|NCT02904434|absorption
24231|NCT02904434|pharmacokinetic
24232|NCT02904434|grapefruit juice
24233|NCT02904434|bioavailability
24234|NCT02904434|intestinal first-pass metabolism
24235|NCT02904434|pharmacokinetics
24236|NCT02904434|intestinal
24237|NCT02904421|scoliosis
24238|NCT02904421|spinal deformity
24239|NCT02904421|vitamin D
24240|NCT02904421|bone health
24241|NCT02904408|quality of life
24242|NCT02904408|psychotherapy
24243|NCT02904408|hidradenitis
24244|NCT02904408|treatments
24245|NCT02904356|OCD
24246|NCT02904356|TMS
24247|NCT02904356|Neuromodulation
24248|NCT02904356|Obsessive-Compulsive Disorder
24249|NCT02904356|Transcranial Magnetic Stimulation
24250|NCT02904356|Imaging
24251|NCT02904343|hemodialysis machine
24252|NCT02904343|quality
24253|NCT02904343|safety
24254|NCT02904343|domestic
24255|NCT02904304|Flu
24256|NCT02904304|Treatment
24257|NCT02904291|Bariatric surgery
24258|NCT02904291|Gastrointestinal tract
24259|NCT02904291|Biological availability
24260|NCT02904291|Pharmacokinetics
24261|NCT02904278|Pediatric Heart Transplant Recipient
24262|NCT02904278|Medication Adherence
24263|NCT02904265|continuous spike wave in sleep
24264|NCT02904265|Landau-Kleffner syndrome
24265|NCT02904265|acetazolamide
24266|NCT02904265|diazepam
24267|NCT02904252|Transient elastography
24268|NCT02904252|Fibrotest
24269|NCT02904239|Contrast Media
24270|NCT02904239|Multidetector Computed Tomography
24271|NCT02904239|Individualized Medicine
24272|NCT02904239|Radiation Dosage
24273|NCT02904239|Incidental cardiac findings
24274|NCT02904239|Thoracic high-pitch Computed Tomography
24275|NCT02904226|ICOS
24276|NCT02904226|ICOS agonist monoclonal antibody
24277|NCT02904226|JTX-2011
24278|NCT02904226|Anti-PD-1
24279|NCT02904226|Nivolumab
24280|NCT02904226|ICONIC
24281|NCT02904226|Immunotherapy
24282|NCT02904226|Immuno-oncology
24283|NCT02904226|Cancer
24284|NCT02904226|Solid Tumor
24285|NCT02904226|Dose Escalation
24286|NCT02904226|Dose Expansion
24287|NCT02904213|vaccine
24288|NCT02904213|ComBe Five
24289|NCT02904213|Vietnam
24290|NCT02904213|pentavalent
24291|NCT02904135|Circulating Tumor Cells
24292|NCT02904070|Threat of
24293|NCT02904044|School
24294|NCT02904044|Sport
24295|NCT02904044|Injuries
24296|NCT02904005|Suicide
24297|NCT02904005|Prediction
24298|NCT02904005|Prospective study
24299|NCT02904005|Suicide attempt
24300|NCT02904005|Risk management
24301|NCT02903992|Frail Elderly
24302|NCT02903992|sarcopenia
24303|NCT02903966|Tolerability
24304|NCT02903966|GSK2982772
24305|NCT02903966|Safety
24306|NCT02903966|Pharmacokinetics
24307|NCT02903966|RIP1 kinase inhibitor
24308|NCT02903966|Ulcerative colitis
24309|NCT02903966|Pharmacodynamics
24310|NCT02903914|Immuno-Oncology
24311|NCT02903914|Checkpoint Inhibitors
24312|NCT02903914|Tumor Metabolism
24313|NCT02903914|PD-1 inhibitor
24314|NCT02903914|PD-L1 inhibitor
24315|NCT02903914|Solid Tumors
24316|NCT02903914|RCC
24317|NCT02903914|MEL
24318|NCT02903914|NSCLC
24319|NCT02903914|Arginase
24320|NCT02903914|Arginase Inhibitor
24321|NCT02903914|CB-1158
24322|NCT02903914|SCCHN
24323|NCT02903914|GEJ
24324|NCT02903901|Delirium
24325|NCT02903862|Caregivers
24326|NCT02903862|Case Management
24327|NCT02903862|Alzheimer's Disease
24328|NCT02903862|Cognition
24329|NCT02903862|Caregiver Burden
24330|NCT02903862|Depression
24331|NCT02903823|spinal cord injury
24332|NCT02903823|cerebral palsy
24333|NCT02903823|stroke
24334|NCT02903797|Endometrial hyperplasia
24335|NCT02903797|Irisin
24336|NCT02903797|fibronectin type III domain containing 5
24337|NCT02903797|FNDC5 (fibronectin type III domain containing )
24338|NCT02903771|Cantrixil
24339|NCT02903771|Intraperitoneal
24340|NCT02903719|Phrenic
24341|NCT02903719|Nerve block
24342|NCT02903719|Postoperative shoulder pain
24343|NCT02903719|Liver resection
24344|NCT02903706|gold miners
24345|NCT02903706|plasmodium carriers
24346|NCT02903706|artemisinine resistance
24347|NCT02903680|Relapse Prevention
24348|NCT02903680|Children
24349|NCT02903667|bone grafting
24350|NCT02903667|implantology
24351|NCT02903667|oral surgery
24352|NCT02903628|myopia
24353|NCT02903615|glucose
24354|NCT02903615|inflammation
24355|NCT02903602|sharing histories
24356|NCT02903602|autobiographical memory
24357|NCT02903602|health behavior
24358|NCT02903602|narrative communication
24359|NCT02903602|community health workers
24360|NCT02903602|global health
24361|NCT02903602|maternal and child health
24362|NCT02903602|stunting
24363|NCT02903537|Multiple Sclerosis
24364|NCT02903537|Dendritic Cells
24365|NCT02903537|Immune Tolerance
24366|NCT02903537|Myelin Proteins
24367|NCT02903537|Tolerogenic dendritic cells
24368|NCT02903511|Metformin
24369|NCT02903511|total kidney volume
24370|NCT02903511|glomerular filtration rate
24371|NCT02903498|disease control survival
24372|NCT02903472|SCI
24373|NCT02903472|microbiome
24374|NCT02903472|metabolome
24375|NCT02903472|GI
24376|NCT02903472|UTI
24377|NCT02903472|DNA
24378|NCT02903472|genomics
24379|NCT02903472|infections
24380|NCT02903472|tetraplegic
24381|NCT02903472|paraplegic
24382|NCT02903459|Central Fat
24383|NCT02903459|Subcutaneous Fat
24384|NCT02903459|Lumbar Lordosis Degree
24385|NCT02903459|Cellulite
24386|NCT02903433|Avocado
24387|NCT02903433|Cardiovascular disease
24388|NCT02903407|Ventilators, Mechanical
24389|NCT02903407|Intensive Care Units
24390|NCT02903407|Deep Sedation
24391|NCT02903381|Smoldering Multiple Myeloma
24392|NCT02903368|Prostate Cancer
24393|NCT02903342|Fever
24394|NCT02903342|Febrile illness
24395|NCT02903342|Children
24396|NCT02903316|Fluid responsiveness
24397|NCT02903316|Perioperative
24398|NCT02903316|Extra systoles
24399|NCT02903316|Coronary artery bypass
24400|NCT02903316|Systolic arterial pressure
24401|NCT02903264|Gestational Diabetes Mellitus
24402|NCT02903264|Obesity
24403|NCT02903264|Periodontal Disease
24404|NCT02903251|Oxytocin
24405|NCT02903251|Administration, Intranasal
24406|NCT02903251|Ethanol
24407|NCT02903238|placebo
24408|NCT02903238|pain
24409|NCT02903238|osteoarthritis
24410|NCT02903225|Heart rate variability
24411|NCT02903225|Systolic heart failure
24412|NCT02903225|Physical exercise
24413|NCT02903225|Parasympathetic indexes
24414|NCT02903212|Apoptotic cells
24415|NCT02903199|Whey Protein
24416|NCT02903199|Postprandial Glycaemia
24417|NCT02903199|Appetite Response
24418|NCT02903186|infants
24419|NCT02903186|minorities
24420|NCT02903186|overfeeding
24421|NCT02903186|WIC program
24422|NCT02903186|feeding practices
24423|NCT02903186|breastfeeding
24424|NCT02903173|respiratory depression
24425|NCT02903173|postpartum
24426|NCT02903173|neuraxial morphine
24427|NCT02903173|cesarean delivery
24428|NCT02903160|Castration resistant
24429|NCT02903160|Prostate cancer
24430|NCT02903160|Metastatic
24431|NCT02903160|First-line
24432|NCT02903160|Treatment naive
24433|NCT02903160|Rapidly cycling
24434|NCT02903160|Non-cross resistant
24435|NCT02903147|IVDR; driving behavior patterns; Meta-Cognitive Intervention
24436|NCT02903121|Unscheduled bleeding
24437|NCT02903121|Long acting contraception
24438|NCT02903095|Single ascending dose
24439|NCT02903082|Myeloid-Derivated suppressive cell
24440|NCT02903082|Sepsis
24441|NCT02903082|Inflammatory Response Syndrome, Systemic
24442|NCT02903069|newly diagnosed
24443|NCT02903069|malignant glioma
24444|NCT02903069|WHO Grade 4
24445|NCT02903069|WHO Grade IV
24446|NCT02903069|Marizomib
24447|NCT02903069|MRZ
24448|NCT02903069|TMZ
24449|NCT02903069|RT
24450|NCT02903069|brain cancer
24451|NCT02903069|proteasome inhibitor
24452|NCT02903069|radiation
24453|NCT02903069|temozolomide
24454|NCT02903069|temodar
24455|NCT02903069|chemotherapy
24456|NCT02903069|concurrent
24457|NCT02903069|adjuvant
24458|NCT02903056|functional Magnetic Resonance Imaging
24459|NCT02903056|Diffusion Spectrum Imaging
24460|NCT02903056|Susceptibility weighted imaging
24461|NCT02903056|Magnetic Resonance Imaging
24462|NCT02903043|MicroRNAs
24463|NCT02903043|Angiogenesis
24464|NCT02903043|Skeletal muscle
24465|NCT02903043|COPD
24466|NCT02903030|Gastrointestinal Microbiome
24467|NCT02902991|liquid biopsy, breast cancer,circulating tumor biomarker
24468|NCT02902978|E6130
24469|NCT02902978|Japanese healthy adult male participants
24470|NCT02902978|Phase 1
24471|NCT02902978|Pharmacokinetics
24472|NCT02902965|Bruton's Tyrosine Kinase
24473|NCT02902965|Bortezomib
24474|NCT02902965|Dexamethasone
24475|NCT02902965|Ibrutinib
24476|NCT02902939|Immune Suppression, Inflammatory Response, Cardiac Surgery
24477|NCT02902913|platelet reactivity
24478|NCT02902913|phenolic
24479|NCT02902913|extra virgin olive oil
24480|NCT02902913|cyclooxygenase
24481|NCT02902913|oleocanthal
24482|NCT02902913|oxylipin
24483|NCT02902900|Multiple Myeloma
24484|NCT02902900|Pomalidomide
24485|NCT02902900|Efficacy
24486|NCT02902835|Buprenorphine treatment
24487|NCT02902835|Incarceration
24488|NCT02902835|Linkage Intervention
24489|NCT02902835|Opioid use disorder
24490|NCT02902822|melanoma
24491|NCT02902822|non-melanoma skin cancer
24492|NCT02902822|mole
24493|NCT02902822|app
24494|NCT02902822|cliccailneo
24495|NCT02902809|open-label study
24496|NCT02902809|tralokinumab
24497|NCT02902809|subcutaneous
24498|NCT02902809|inadequately controlled asthma
24499|NCT02902809|asthma
24500|NCT02902809|medium to high-dose of inhaled corticosteroid
24501|NCT02902809|long-acting β2-agonist
24502|NCT02902770|Pain
24503|NCT02902770|Lidocaine
24504|NCT02902770|Ketorolac
24505|NCT02902757|FDG
24506|NCT02902757|PET/CT very early response (48 hrs)
24507|NCT02902705|White adipose tissue
24508|NCT02902705|chronic kidney disease
24509|NCT02902705|uremia
24510|NCT02902705|adipocytes
24511|NCT02902692|brief
24512|NCT02902692|mindfulness
24513|NCT02902666|Bioequivalence
24514|NCT02902666|Paracetamol 1000 mg/codeine 30 mg
24515|NCT02902666|Co-efferalgan 500 mg/30 mg
24516|NCT02902653|misoprostol
24517|NCT02902653|dinoprostonal
24518|NCT02902653|induction
24519|NCT02902614|embryo biopsy
24520|NCT02902614|preimplantation genetic testing
24521|NCT02902614|animal pole
24522|NCT02902614|vegetal pole
24523|NCT02902614|day 3 embryo biopsy
24524|NCT02902614|embryo implantation
24525|NCT02902614|Blastomeres
24526|NCT02902588|Blood-Brain Barrier
24527|NCT02902588|Magnetic Resonance Imaging
24528|NCT02902588|Spectroscopy, Near-Infrared
24529|NCT02902588|Indocyanine green
24530|NCT02902575|Stomach Neoplasms
24531|NCT02902575|Laparoscopy
24532|NCT02902575|Advanced Gastric Cancer
24533|NCT02902575|Neoadjuvant Chemotherapy
24534|NCT02902549|Optical Coherence Tomography
24535|NCT02902549|Fluorescence Imaging
24536|NCT02902549|Sidestream Darkfield Microscopy
24537|NCT02902549|Laser Speckle Contrast Imaging
24538|NCT02902536|Myasthenia Gravis
24539|NCT02902510|yoga
24540|NCT02902510|function
24541|NCT02902510|Parkinson's disease
24542|NCT02902510|gait
24543|NCT02902510|balance
24544|NCT02902458|implantable cardioverter defibrillator
24545|NCT02902458|primary prevention
24546|NCT02902458|psychological follow-up
24547|NCT02902458|anxiety
24548|NCT02902458|depression
24549|NCT02902458|quality of life
24550|NCT02902445|Vaccine
24551|NCT02902445|Polymorphism
24552|NCT02902432|endostar
24553|NCT02902432|cisplatin
24554|NCT02902393|Fibrinolysis
24555|NCT02902393|tPA
24556|NCT02902367|mobility
24557|NCT02902367|exercise
24558|NCT02902367|walking capacity
24559|NCT02902367|fat mass
24560|NCT02902367|muscles
24561|NCT02902341|Nutrition Therapy
24562|NCT02902315|Muscle soreness
24563|NCT02902315|Free radicals
24564|NCT02902315|Ascorbic acid
24565|NCT02902315|Alpha-Tocopherol
24566|NCT02902315|Cryotherapy
24567|NCT02902315|Exercise tolerance
24568|NCT02902315|Resistance training
24569|NCT02902302|Bioequivalence
24570|NCT02902302|Ibuprofen 400 mg/5 ml
24571|NCT02902302|Moment 400 mg coated tablet
24572|NCT02902302|Oral Suspension
24573|NCT02902289|Bioequivalence
24574|NCT02902289|Ibuprofen 200 mg/5 ml
24575|NCT02902289|Moment 200 mg coated tablet
24576|NCT02902289|Oral Suspension
24577|NCT02902276|plasma citrulline
24578|NCT02902276|lipopolysaccharide
24579|NCT02902276|critically ill
24580|NCT02902276|Hospitalization in an Intensive Care Unit
24581|NCT02902263|Telemedecine
24582|NCT02902263|Thrombolysis
24583|NCT02902211|ankle foot orthosis
24584|NCT02902211|biomechanics
24585|NCT02902211|mobility
24586|NCT02902185|Chidamide
24587|NCT02902185|Histone Deacetylase Inhibitor
24588|NCT02902185|HIV-1 Reservoir
24589|NCT02902185|Chronic HIV infections
24590|NCT02902185|HIV Eradication
24591|NCT02902185|Antiretroviral Therapy
24592|NCT02902159|Stress
24593|NCT02902159|Low Mood
24594|NCT02902159|Mental Health
24595|NCT02902159|Peer Support
24596|NCT02902159|Online
24597|NCT02902133|cerebrospinal fluid leak
24598|NCT02902107|Low Dose Rate Brachytherapy
24599|NCT02902107|CivaSheet
24600|NCT02902107|16-605
24601|NCT02902042|Unresectable or metastatic BRAF V600 mutant melanoma
24602|NCT02902042|Encorafenib, binimetinib, pembrolizumab
24603|NCT02902029|unresectable stage IIIB, IIIC, IV melanoma
24604|NCT02902016|PPARgamma
24605|NCT02902016|Lactose intolerance
24606|NCT02902016|Lactase
24607|NCT02901990|mumps
24608|NCT02901990|immunity
24609|NCT02901990|cohort study
24610|NCT02901990|children
24611|NCT02901990|vaccine
24612|NCT02901977|Hypertension
24613|NCT02901977|Blood pressure
24614|NCT02901977|Hemostasis
24615|NCT02901977|Endothelial function
24616|NCT02901951|adult subjects
24617|NCT02901951|Hepatitis B antibody
24618|NCT02901951|Hepatitis B
24619|NCT02901951|HBV
24620|NCT02901925|ABY-029
24621|NCT02901925|Affibody
24622|NCT02901925|Molecular Fluorescence-Guided Surgery
24623|NCT02901925|Epidermal Growth Factor Receptor (EGFR)
24624|NCT02901912|physical activity
24625|NCT02901912|sedentarism
24626|NCT02901912|fecal enzymatic activity
24627|NCT02901886|Rheumatoid Arthritis
24628|NCT02901886|Smoking Cessation
24629|NCT02901886|Disease Activity
24630|NCT02901886|Clinical Prevention
24631|NCT02901808|NOMI
24632|NCT02901808|Angiography
24633|NCT02901808|Digital Subtraction Angiography (DSA)
24634|NCT02901782|Knee
24635|NCT02901782|Titanium Plate
24636|NCT02901730|laser peripheral iridoplasty
24637|NCT02901730|treatment
24638|NCT02901678|skelatal open bite, posterior intrusion
24639|NCT02901626|Short cervix
24640|NCT02901626|Preterm delivery
24641|NCT02901626|Singletons
24642|NCT02901626|Pregnancy
24643|NCT02901626|Pessary
24644|NCT02901600|DMBT1 expression
24645|NCT02901600|Colorectal cancer
24646|NCT02901548|BCG refractory CIS
24647|NCT02901548|Urothelial CIS of bladder
24648|NCT02901548|Carcinoma in situ (CIS)
24649|NCT02901548|Bacillus Calmette-Guérin (BCG)
24650|NCT02901548|Medi4736
24651|NCT02901548|Durvalumab
24652|NCT02901548|CIS of the bladder
24653|NCT02901548|Bladder cancer
24654|NCT02901548|BCG Vaccine
24655|NCT02901548|Bladder diseases
24656|NCT02901548|Urothelial diseases
24657|NCT02901535|telemedicine
24658|NCT02901535|chronic obstructive pulmonary disease
24659|NCT02901535|Primary Health care
24660|NCT02901535|spirometry
24661|NCT02901522|telemedicine
24662|NCT02901522|asthma control test
24663|NCT02901522|Primary Health care
24664|NCT02901522|spirometry
24665|NCT02901509|Chikungunya
24666|NCT02901509|Quality of Life
24667|NCT02901483|Head and Neck
24668|NCT02901457|Body Image
24669|NCT02901418|chronic hepatitis B
24670|NCT02901418|mother to child transmission
24671|NCT02901418|interruption
24672|NCT02901418|hepatitis B immunoglobulin
24673|NCT02901418|pregnancy
24674|NCT02901418|HBsAg
24675|NCT02901418|newborns
24676|NCT02901405|sarcoma
24677|NCT02901405|infection
24678|NCT02901405|negative pressure
24679|NCT02901392|Male Urethral Slings
24680|NCT02901392|Artificial Urinary Sphincter
24681|NCT02901392|Prostatectomy
24682|NCT02901392|Radiotherapy
24683|NCT02901379|atorvastatin
24684|NCT02901379|myocardial edema
24685|NCT02901379|Follistatin-like 1
24686|NCT02901379|FSTL1
24687|NCT02901379|atorvastatin 80mg
24688|NCT02901379|coronary artery bypass surgery
24689|NCT02901366|Mass balance
24690|NCT02901340|Borderline idiopathic isolated oligohydramnios
24691|NCT02901340|Fetal renal artery doppler indices
24692|NCT02901340|neonatal outcomes
24693|NCT02901340|Maternal hydration
24694|NCT02901327|Lumbar Stabilisation Exercise
24695|NCT02901327|Treadmill Walk
24696|NCT02901327|Multifidus Muscle Activation
24697|NCT02901327|Pain Intensity
24698|NCT02901327|Functional Disability
24699|NCT02901288|pulmonary tuberculosis
24700|NCT02901288|shortened regimen
24701|NCT02901288|clinical trial
24702|NCT02901275|Clinical Trial, Phase II
24703|NCT02901275|Analgesia
24704|NCT02901262|continuous EEG
24705|NCT02901249|Cost effectiveness
24706|NCT02901249|Unipolar Depression
24707|NCT02901249|Major Depression Disorder
24708|NCT02901249|Quality of life disorder
24709|NCT02901236|trabeculectomy
24710|NCT02901236|glaucoma
24711|NCT02901236|filtration surgery
24712|NCT02901236|wound healing
24713|NCT02901236|angiogenesis
24714|NCT02901236|mitomycin
24715|NCT02901236|vascular endothelial growth factor inhibition
24716|NCT02901223|Oncoplastic breast surgery
24717|NCT02901223|oncological safety
24718|NCT02901223|patient satisfaction
24719|NCT02901210|Recta prolapse
24720|NCT02901210|Intraoperative bleeding
24721|NCT02901210|mucosal cauterization
24722|NCT02901197|capnography
24723|NCT02901171|Smoking cessation
24724|NCT02901171|Acceptance and Commitment Therapy
24725|NCT02901171|Smartphone
24726|NCT02901158|esophageal pressure
24727|NCT02901158|chest wall elastance
24728|NCT02901158|lung elastance
24729|NCT02901158|transpulmonary pressure
24730|NCT02901145|immunotherapy,solid tumor,pediatric
24731|NCT02901106|Multiple Sclerosis, Relapsing-Remitting
24732|NCT02901106|Dimethyl fumarate
24733|NCT02901093|Stapes surgery
24734|NCT02901093|Sensorineural complications
24735|NCT02901093|Inner ear
24736|NCT02901093|Imaging
24737|NCT02901093|Cone Beam CT
24738|NCT02901067|Fibrinolysis
24739|NCT02901015|schizophrenia
24740|NCT02901002|Complex Regional Pain Syndromes
24741|NCT02901002|Pain
24742|NCT02901002|Spontaneous sensations
24743|NCT02901002|interoception
24744|NCT02900989|Psychiatry
24745|NCT02900989|Pediatrics
24746|NCT02900989|Suicide
24747|NCT02900976|Organ Transplantation
24748|NCT02900963|Nutrition
24749|NCT02900963|Head and Neck Cancer
24750|NCT02900950|cancer
24751|NCT02900950|resection margin
24752|NCT02900950|pathology
24753|NCT02900950|pancreas
24754|NCT02900937|Stents
24755|NCT02900937|Angioplasty
24756|NCT02900937|Coronary Vessels
24757|NCT02900937|Coronary Artery Disease
24758|NCT02900937|Angina Pectoris
24759|NCT02900937|Myocardial Ischemia
24760|NCT02900937|Myocardial Infarction
24761|NCT02900937|Myocardial Revascularization
24762|NCT02900924|PAD
24763|NCT02900924|PVD
24764|NCT02900924|SFA stent
24765|NCT02900911|head and neck cancer
24766|NCT02900911|dysphagia
24767|NCT02900911|rehabilitation
24768|NCT02900911|radiation therapy
24769|NCT02900469|RANK
24770|NCT02900469|RANKL
24771|NCT02900456|Intra-aortic Balloon Pumps
24772|NCT02900456|Registry
24773|NCT02900417|type 2 diabetes
24774|NCT02900417|gut microbiota
24775|NCT02900417|sitagliptin
24776|NCT02900378|physical activity
24777|NCT02900378|actigraphy
24778|NCT02900378|sleep
24779|NCT02900378|sacubitril/valsartan
24780|NCT02900378|enalapril
24781|NCT02900378|heart failure
24782|NCT02900378|reduced ejection fraction
24783|NCT02900378|randomized controlled trial
24784|NCT02900378|accelerometry
24785|NCT02900365|trauma
24786|NCT02900365|cataract
24787|NCT02900365|lensectomy
24788|NCT02900365|time
24789|NCT02900365|early
24790|NCT02900365|late
24791|NCT02900352|Alcohol Use Disorder
24792|NCT02900352|Alcoholism
24793|NCT02900352|Alcohol Dependence
24794|NCT02900352|Zonisamide
24795|NCT02900352|Alcohol Intoxication
24796|NCT02900352|Drinking Behaviors
24797|NCT02900352|Anticonvulsants
24798|NCT02900339|MRI
24799|NCT02900339|Sequence optimization
24800|NCT02900339|Healthy volunteers
24801|NCT02900326|Exercise capacity
24802|NCT02900326|Mindfulness
24803|NCT02900326|Quality of life
24804|NCT02900313|acute kidney injury
24805|NCT02900313|cardiac surgery
24806|NCT02900313|cardiac surgery associated acute kidney injury
24807|NCT02900313|renal replacement therapy
24808|NCT02900313|renal recovery
24809|NCT02900313|serum hyperphosphatemia
24810|NCT02900287|Survival
24811|NCT02900287|Cancer
24812|NCT02900248|Biomarkers
24813|NCT02900248|High-Throughput Nucleotide Sequencing
24814|NCT02900248|Neoplasms
24815|NCT02900248|Myelodysplastic Syndromes
24816|NCT02900235|Healthy
24817|NCT02900820|Anti-Bacterial Agents
24818|NCT02900820|Primary Health Care
24819|NCT02900820|Drug Resistance, Microbial
24820|NCT02900820|Respiratory Tract Infections
24821|NCT02900781|Arthroplasty
24822|NCT02900781|Physical Therapy
24823|NCT02900768|Bone Marrow Transplantation
24824|NCT02900768|Exercise
24825|NCT02900768|Rehabilitation
24826|NCT02900768|Cancer
24827|NCT02900755|Electroencephalography
24828|NCT02900755|Perampanel
24829|NCT02900742|lung cancer
24830|NCT02900742|traditional Chinese medicine
24831|NCT02900742|maintenance therapy
24832|NCT02900742|chemotherapy
24833|NCT02900677|Pancreatic Cancer
24834|NCT02900677|Fatigue
24835|NCT02900677|Nutrition
24836|NCT02900677|Quality of Life
24837|NCT02900664|CRC
24838|NCT02900664|TNBC
24839|NCT02900664|NSCLC (adenocarcinoma)
24840|NCT02900664|Immunomodulation
24841|NCT02900664|Biomarkers
24842|NCT02900664|Bayesian logistic regression model
24843|NCT02900664|PDR001
24844|NCT02900664|Immunotherapy
24845|NCT02900651|MAK683, advanced malignancies, DLBCL, EED - Embryonic ectoderm development, EZH2 - Enhancer of zeste homolog 2
24846|NCT02900638|mentoring
24847|NCT02900638|children
24848|NCT02900638|cardiovascular health
24849|NCT02900612|dyslipidemias,
24850|NCT02900612|aging
24851|NCT02900612|water aerobics training
24852|NCT02900612|resistance aquatic training
24853|NCT02900612|lipid profile
24854|NCT02900599|HIV
24855|NCT02900599|Behavior
24856|NCT02900547|Systolic Heart Failure
24857|NCT02900547|medical algorithm decision support system
24858|NCT02900534|grief
24859|NCT02900534|depression
24860|NCT02900534|bereavement
24861|NCT02900534|divorce
24862|NCT02900534|online self-help
24863|NCT02900495|Nocturnal Enuresis
24864|NCT02900495|Bedwetting
24865|NCT02900495|TENS
24866|NCT02900209|Influenza
24867|NCT02900209|Exacerbations
24868|NCT02900196|Probiotics
24869|NCT02900196|Antibiotic Associated Diarrhea
24870|NCT02900196|Gastro-Intestinal disorders
24871|NCT02900196|Helicobacter pylori
24872|NCT02900170|Rivaroxaban, Acute Kidney Injury
24873|NCT02900157|Advanced Solid Tumor
24874|NCT02900157|Immunotherapy
24875|NCT02900157|MEDI9090
24876|NCT02900157|MEDI4736
24877|NCT02900157|Durvalumab
24878|NCT02900118|Bone metastasis
24879|NCT02900118|PET-CT
24880|NCT02900118|whole-body MRI
24881|NCT02900092|postmenopausal
24882|NCT02900092|women
24883|NCT02900092|depression
24884|NCT02900079|malaria
24885|NCT02900079|rapid diagnostic test
24886|NCT02900079|travel
24887|NCT02900079|fever
24888|NCT02900079|self care
24889|NCT02900066|fever
24890|NCT02900066|traveler
24891|NCT02900066|arbovirus
24892|NCT02900066|rickettsia
24893|NCT02900066|malaria
24894|NCT02900066|filter paper
24895|NCT02900066|diagnosis
24896|NCT02900001|myocardial infarction
24897|NCT02900001|invasive strategy
24898|NCT02900001|elderly
24899|NCT02900001|delayed
24900|NCT02899988|IL-23
24901|NCT02899988|dermatology
24902|NCT02899975|Validation
24903|NCT02899975|Information and Fitness Software
24904|NCT02899975|Elderly
24905|NCT02899975|WeTakeCare
24906|NCT02899949|dapagliflozin
24907|NCT02899949|type 2 diabetes
24908|NCT02899949|real-world data
24909|NCT02899936|Mass drug administration
24910|NCT02899936|Safety Data
24911|NCT02899897|echocardiography
24912|NCT02899884|Drug Therapy
24913|NCT02899871|joint pain
24914|NCT02899858|Thoracic spinal cord injury
24915|NCT02899858|Paralysis
24916|NCT02899858|ASIA A
24917|NCT02899858|Device
24918|NCT02899832|children
24919|NCT02899832|spasms
24920|NCT02899819|pesticides
24921|NCT02899819|exposure
24922|NCT02899819|in utero
24923|NCT02899806|Video Information
24924|NCT02899806|Satisfaction
24925|NCT02899806|Anxiety
24926|NCT02899806|Epidural Analgesia
24927|NCT02899806|Comprehension
24928|NCT02899806|delivery
24929|NCT02899767|transfusion dependency
24930|NCT02899767|transfusion intensity
24931|NCT02899767|prognosis
24932|NCT02899767|chemotherapy
24933|NCT02899754|lung cancer
24934|NCT02899754|decision support
24935|NCT02899754|implementation
24936|NCT02899741|Medically intractable epilepsy, Omega-3
24937|NCT02899689|Labor
24938|NCT02899689|Foley
24939|NCT02899689|Dilapan
24940|NCT02899689|Cervical Dilators
24941|NCT02899689|Induction
24942|NCT02899650|Delayed Onset Muscle Soreness
24943|NCT02899650|Eccentric exercise
24944|NCT02899650|Masters athlete
24945|NCT02899637|Incomplete Spinal Cord Injury
24946|NCT02899637|Rehabilitation
24947|NCT02899637|Non-invasive brain stimulation
24948|NCT02899637|Transcranial Magnetic Stimulation
24949|NCT02899611|Epilepsy
24950|NCT02899585|Palliative care
24951|NCT02899546|Peripherally Inserted Central Catheter
24952|NCT02899546|Infections
24953|NCT02899546|Radiology
24954|NCT02899533|PAH
24955|NCT02899533|Pulmonary hypertension
24956|NCT02899507|Out-of-hospital cardiac arrest
24957|NCT02899507|Prophylactic antibiotics
24958|NCT02899468|TBI
24959|NCT02899468|Virtual Reality
24960|NCT02899455|Hypertension
24961|NCT02899455|Hyperlipidemia
24962|NCT02899442|cardiovascular risk
24963|NCT02899442|Occupational Health
24964|NCT02899442|night work
24965|NCT02899442|Public Health
24966|NCT02899442|Preventive Health Services
24967|NCT02899416|cardiovascular risk
24968|NCT02899416|young adulthood
24969|NCT02899403|Cognitive Tasks
24970|NCT02899403|Mild Cognitive Impairment
24971|NCT02899403|Neurophysiological Correlates
24972|NCT02899403|Healthy Volunteers
24973|NCT02899377|PET/CT
24974|NCT02899377|Primary Sjögren's Syndrome
24975|NCT02899377|Magnetic resonance imaging
24976|NCT02899377|11^C-MET
24977|NCT02899377|18^F-FDG
24978|NCT02899364|Sodium thiosulfate
24979|NCT02899364|STEMI
24980|NCT02899364|Infarct size
24981|NCT02899364|Cardiac magnetic resonance imaging
24982|NCT02899364|Hydrogen sulfide
24983|NCT02899286|Acute myeloid leukemia
24984|NCT02899286|AML
24985|NCT02899286|pegylated recombinant human arginase
24986|NCT02899286|PEG-BCT-100
24987|NCT02899273|Early Childhood Caries
24988|NCT02899273|eye-tracking
24989|NCT02899273|children
24990|NCT02899273|dentistry
24991|NCT02899273|face perception
24992|NCT02899247|composite resin
24993|NCT02899247|surface sealant
24994|NCT02899234|Nicotine
24995|NCT02899234|Electronic Cigarette
24996|NCT02899195|Unresectable Mesothelioma
24997|NCT02899195|Durvalumab
24998|NCT02899195|Anti-Programmed Death-Ligand 1 Antibody
24999|NCT02899169|Acute promyelocytic leukemia
25000|NCT02899169|Realgar-Indigo Naturalis Formula
25001|NCT02899169|All-trans Retinoic Acid
25002|NCT02899091|Alzheimer's disease
25003|NCT02899091|Mesenchymal Stem cells
25004|NCT02899052|Refractory myeloma
25005|NCT02899052|Multiple Myeloma
25006|NCT02899052|Relapsed myeloma
25007|NCT02899026|Glucocorticosteroids
25008|NCT02899026|Sirukumab
25009|NCT02899026|Prednisone
25010|NCT02899026|Polymyalgia Rheumatica
25011|NCT02899013|Perianal Lesions
25012|NCT02898987|HIV
25013|NCT02898987|Hepatitis C
25014|NCT02898987|Comorbidities
25015|NCT02898987|AIDS
25016|NCT02898948|procalcitonin
25017|NCT02898948|bacterial infection
25018|NCT02898909|femtosecond laser-assisted cataract surgery
25019|NCT02898909|nuclear lens fragmentation
25020|NCT02898844|dieting
25021|NCT02898844|dyads
25022|NCT02898844|psychological well-being
25023|NCT02898844|weight loss
25024|NCT02898844|cortisol
25025|NCT02898792|sensitivity, opioid
25026|NCT02898753|GSD-II
25027|NCT02898753|Pompe Disease
25028|NCT02898753|Glycogen Storage Diseases
25029|NCT02898753|GAA
25030|NCT02898740|Parkinson's disease
25031|NCT02898740|exercise therapy
25032|NCT02898740|quality of life
25033|NCT02898701|Motor Learning
25034|NCT02898701|Dose of Motor Practice
25035|NCT02898701|Postural Control
25036|NCT02898701|Serial Reaction Time Task
25037|NCT02898701|Retention
25038|NCT02898701|Transfer
25039|NCT02898701|Overpractice
25040|NCT02898701|Overtraining
25041|NCT02898701|Overlearning
25042|NCT02898688|Influenza vaccine
25043|NCT02898688|Pertussis vaccine
25044|NCT02898688|Perinatal vaccination
25045|NCT02898688|Infant vaccination
25046|NCT02898662|inhaled
25047|NCT02898662|TLR9 agonist
25048|NCT02898662|withdrawal design
25049|NCT02898662|loss of control
25050|NCT02898532|Children, ADHD, target shooting sport
25051|NCT02898506|Diabetes Type 1
25052|NCT02898506|Diabetes, Insulin-Dependent
25053|NCT02898506|Liraglutide
25054|NCT02898506|Preclinical Type 1 Diabetes
25055|NCT02898506|GLP-1 Analogue
25056|NCT02898506|Dysglycemia
25057|NCT02898506|Prevention
25058|NCT02898493|Validation of questionnaire
25059|NCT02898493|Quality of life
25060|NCT02898441|lung cancer screening
25061|NCT02898441|low-dose CT
25062|NCT02898441|high-risk population
25063|NCT02898415|HCC
25064|NCT02898415|Liver Transplantation
25065|NCT02898415|AFP
25066|NCT02898415|Mortality
25067|NCT02898415|Competing risk
25068|NCT02898415|Selection criteria
25069|NCT02898415|Recurrence
25070|NCT02898376|spa care
25071|NCT02898376|randomised controlled trial
25072|NCT02898376|pentoxifylline/tocopherol combination
25073|NCT02898376|late sequelae
25074|NCT02898376|radiotherapy
25075|NCT02898363|Care of disabled population
25076|NCT02898363|Mental retardation
25077|NCT02898363|Cancer screening
25078|NCT02898363|Cancer prevention
25079|NCT02898324|Bullying
25080|NCT02898324|KiVa program
25081|NCT02898324|Primary school students
25082|NCT02898311|CAD-CAM
25083|NCT02898311|composite dental resin
25084|NCT02898311|Immediate dental implant loading
25085|NCT02898259|Lenalidomide
25086|NCT02898259|Ixazomib
25087|NCT02898259|Rituximab
25088|NCT02898246|heart failure
25089|NCT02898246|fear of physical activity
25090|NCT02898246|motor activity
25091|NCT02898233|depression
25092|NCT02898233|internet-based
25093|NCT02898233|treatment
25094|NCT02898233|low-level light therapy
25095|NCT02898233|LLLT
25096|NCT02898233|deprexis
25097|NCT02898194|Surrogate Decision-making
25098|NCT02898194|Health Care
25099|NCT02898194|Medical Decisions
25100|NCT02898194|End of Life Care
25101|NCT02898168|stroke
25102|NCT02898168|Rehabilitation
25103|NCT02898168|WalkAide (WA)
25104|NCT02898168|Functional Electrical Stimulation (FES)
25105|NCT02898155|Avoidable hospitalizations
25106|NCT02898155|primary care
25107|NCT02898155|geographicvariation
25108|NCT02898142|Postprandial test
25109|NCT02898142|Metabolic syndrime
25110|NCT02898142|HTG
25111|NCT02898129|chronic respiratory diseases
25112|NCT02898129|housing
25113|NCT02898129|lung function test
25114|NCT02898116|ALK-rearranged
25115|NCT02898116|ALK-positive
25116|NCT02898116|ALK Inhibitor
25117|NCT02898116|Ensartinib
25118|NCT02898116|X-396
25119|NCT02898116|anti-PD-L1
25120|NCT02898116|Durvalumab
25121|NCT02898116|MEDI4736
25122|NCT02898116|ALK
25123|NCT02898090|Quality indicators
25124|NCT02898090|Appropriateness
25125|NCT02898090|Oral anticoagulant prescriptions
25126|NCT02898090|Development and validation
25127|NCT02898090|Hospital information system
25128|NCT02898090|Information Storage and Retrieval
25129|NCT02898090|Natural Language Processing
25130|NCT02898077|Second line
25131|NCT02898077|Angiogenesis
25132|NCT02898077|Vascular endothelial growth factor receptor 2
25133|NCT02898051|heparin low-molecular-weight;pharmacokinetics
25134|NCT02898012|Glioblastoma Multiforme
25135|NCT02898012|temozolomide
25136|NCT02898012|bevacizumab
25137|NCT02897973|Spinal loads
25138|NCT02897973|Trunk muscle force
25139|NCT02897973|Computational modeling
25140|NCT02897973|Unilateral lower limb amputation
25141|NCT02897960|wheezing
25142|NCT02897960|bronchiolitis
25143|NCT02897960|respiratory sound algorithm
25144|NCT02897947|Lumbosacral Region
25145|NCT02897947|Surgery
25146|NCT02897947|Registries
25147|NCT02897895|Lung transplantation in end-stage lung diseases
25148|NCT02897843|Electroconvulsive Therapy
25149|NCT02897843|Transcranial Direct Current Stimulation
25150|NCT02897843|cognition
25151|NCT02897817|Methotrexate
25152|NCT02897817|Treatment adherence
25153|NCT02897804|multiphase optimization strategy
25154|NCT02897804|college students
25155|NCT02897778|entinostat
25156|NCT02897778|solid tumor
25157|NCT02897778|Histone Deacetylase Inhibitors
25158|NCT02897765|Checkpoint Inhibitor
25159|NCT02897765|Immunotherapy
25160|NCT02897765|Personalized Vaccine
25161|NCT02897765|Neoantigen
25162|NCT02897765|Poly-ICLC
25163|NCT02897765|Peptide
25164|NCT02897752|stroke
25165|NCT02897752|Rehabilitation
25166|NCT02897752|WalkAide (WA)
25167|NCT02897752|Functional Electrical Stimulation (FES)
25168|NCT02897713|mechanical ventilation
25169|NCT02897713|enteral nutrition
25170|NCT02897713|feeding intolerance
25171|NCT02897700|Chemotherapy
25172|NCT02897700|Safety
25173|NCT02897700|Tolerability
25174|NCT02897700|Efficacy
25175|NCT02897687|Autism Spectrum Disorder
25176|NCT02897687|Social Skills
25177|NCT02897687|Social Media
25178|NCT02897661|fecal microbiota transplantation
25179|NCT02897661|enteral nutrition
25180|NCT02897622|Eating disorders
25181|NCT02897622|severe and enduring
25182|NCT02897622|quality of life
25183|NCT02897622|case management
25184|NCT02897609|Beta-lactamine
25185|NCT02897609|β-lactamine
25186|NCT02897570|ghrelin
25187|NCT02897570|breakfast meal
25188|NCT02897570|P-300
25189|NCT02897531|Ileocolic, stapled, laparoscopy, right hemicolectomy
25190|NCT02897518|Videolaryngoscopes
25191|NCT02897518|Intubation
25192|NCT02897505|post traumatic stress disorder (PTSD)
25193|NCT02897466|ventilator-associated pneumonia
25194|NCT02897466|Multidrug-resistant bacteria
25195|NCT02897440|Femoral Neck Fracture
25196|NCT02897440|Hip Arthroplasty
25197|NCT02897440|Repairing of soft tissue
25198|NCT02897427|Oropharyngeal cancer
25199|NCT02897427|Anal cancer
25200|NCT02897427|Penile cancer
25201|NCT02897427|Human papillomavirus
25202|NCT02897427|HPV
25203|NCT02897427|HPV 16 E antigens
25204|NCT02897427|Oropharyngeal cancer screening
25205|NCT02897427|Dysplasia
25206|NCT02897427|Ultrasound scans of throat and the lymph nodes in neck
25207|NCT02897427|Anal cancer screening
25208|NCT02897427|Anal pap test
25209|NCT02897427|High-resolution anoscopy
25210|NCT02897427|HRA
25211|NCT02897427|Penile cancer screening
25212|NCT02897401|urinary N'Nitrosonornicotine
25213|NCT02897401|nicotine
25214|NCT02897401|electronic cigarette
25215|NCT02897401|nicotine remplacement treatment
25216|NCT02897362|ADHD
25217|NCT02897362|Sleep
25218|NCT02897362|Adolescents
25219|NCT02897362|Neurocognition
25220|NCT02897362|Polysomnography
25221|NCT02897310|critically ill patients
25222|NCT02897310|acute kidney injury
25223|NCT02897310|renal replacement therapy
25224|NCT02897310|long term outcome
25225|NCT02897284|Mindfulness-based
25226|NCT02897284|Self-care
25227|NCT02897284|Health workers
25228|NCT02897284|Epigenetics
25229|NCT02897271|Eosinophilic Gastrointestinal Disorders
25230|NCT02897258|Dialysis
25231|NCT02897258|Thrombosis
25232|NCT02897258|Haemorrhage
25233|NCT02897245|Myelogenous
25234|NCT02897245|Chronic
25235|NCT02897245|BCR-ABL Positive
25236|NCT02897232|Human Papillomavirus Vaccine
25237|NCT02897232|HPV
25238|NCT02897232|Patient Acceptance
25239|NCT02897232|Physician Comfort
25240|NCT02897232|Male Vaccination
25241|NCT02897232|HPV Associated Cancers
25242|NCT02897219|SGLT2 inhibitor
25243|NCT02897219|ASP1941
25244|NCT02897219|type 1 diabetes mellitus
25245|NCT02897206|Acute pancreatitis
25246|NCT02897206|Antibiotic prophylaxis
25247|NCT02897206|Imipenem-cilastatin
25248|NCT02897206|Infected pancreatic necrosis
25249|NCT02897206|Infection
25250|NCT02897206|Organ failure
25251|NCT02897180|tuberculosis
25252|NCT02897180|latent tuberculosis infection
25253|NCT02897180|Food supplement
25254|NCT02897180|Mycobacterium manresensis
25255|NCT02897180|Nyaditum resae
25256|NCT02897180|Efficacy trial
25257|NCT02897167|Psychosis
25258|NCT02897167|Antipsychotic Agents
25259|NCT02897167|Immunology
25260|NCT02897167|Schizophrenia Spectrum and Other Psychotic Disorders
25261|NCT02897141|HIV
25262|NCT02897141|Health Management App
25263|NCT02897141|HIV symptoms
25264|NCT02897128|Sarcoma
25265|NCT02897128|Radiation
25266|NCT02897128|Wound healing
25267|NCT02897115|Humira
25268|NCT02897115|Axial Spondyloarthritis
25269|NCT02897089|universal adhesive
25270|NCT02897089|fissure sealants
25271|NCT02897089|retention
25272|NCT02897063|midodrine
25273|NCT02897063|droxidopa
25274|NCT02897063|splanchnic circulation
25275|NCT02897037|Bivalirudin
25276|NCT02897037|Acute myocardial infarction
25277|NCT02897037|percutaneous transluminal coronary angioplasty
25278|NCT02897024|Cerebral Palsy
25279|NCT02897024|Motor Impairments
25280|NCT02896985|C-Reactive Protein (CRP)
25281|NCT02896985|Anti-Adalimumab Antibody (AAA)
25282|NCT02896985|Therapeutic Drug Monitoring (TDM)
25283|NCT02896985|Patient Reported Outcome 2 (PRO 2)
25284|NCT02896985|Adalimumab
25285|NCT02896985|Harvey Bradshaw Index (HBI)
25286|NCT02896972|vitrectomy
25287|NCT02896972|macular hole retinal detachment
25288|NCT02896972|high myopia
25289|NCT02896920|Humira®
25290|NCT02896920|Hidradenitis Suppurativa (HS)
25291|NCT02896920|Canada
25292|NCT02896816|Parkinson's
25293|NCT02896803|Pancreatic Cancer
25294|NCT02896803|Chemotherapy
25295|NCT02896790|Cancer
25296|NCT02896790|Oral Therapy
25297|NCT02896790|Compliance
25298|NCT02896790|Anthropology
25299|NCT02896790|Psychology
25300|NCT02896777|pH
25301|NCT02896777|IVF
25302|NCT02896777|live birth rate
25303|NCT02896751|CPAP
25304|NCT02896751|Noninvasive Ventilation Mask
25305|NCT02896725|Venous leg ulcer
25306|NCT02896725|Acellular skin substitutes
25307|NCT02896725|Keratin dressings
25308|NCT02896699|Pre-exposure prophylaxis (PrEP)
25309|NCT02896699|diffusion of innovation
25310|NCT02896699|men who have sex with men
25311|NCT02896699|LGBT
25312|NCT02896699|African American
25313|NCT02896699|Black
25314|NCT02896699|HIV
25315|NCT02896699|network analysis
25316|NCT02896699|network intervention
25317|NCT02896686|Ileostomy closure
25318|NCT02896686|Polypropylene Mesh
25319|NCT02896686|Incisional hernia
25320|NCT02896673|positive expiratory pressure (PEP)
25321|NCT02896673|Acute Respiratory Distress Syndrome (ARDS)
25322|NCT02896673|electrical impedance tomography (EIT)
25323|NCT02896673|tidal volume (TV)
25324|NCT02896673|transpulmonary pressure (TPP)
25325|NCT02896621|Sleep Apnea
25326|NCT02896621|Hypertension
25327|NCT02896621|Chlortalidone
25328|NCT02896621|Diastolic function
25329|NCT02896569|resurfacing
25330|NCT02896569|ablation
25331|NCT02896556|image analysis
25332|NCT02896543|dendritic cells
25333|NCT02896543|P-selectin
25334|NCT02896504|Chemobrain
25335|NCT02896504|Chemotherapy
25336|NCT02896504|Hormonal Therapy
25337|NCT02896504|Neuroimaging
25338|NCT02896465|Children
25339|NCT02896465|Diarrhea
25340|NCT02896465|Human milk oligosaccharides
25341|NCT02896439|Traumatic
25342|NCT02896439|Acetabular
25343|NCT02896426|Parent training
25344|NCT02896426|Preschoolers
25345|NCT02896426|Behavior problems
25346|NCT02896426|Oppositional Defiant Disorder
25347|NCT02896426|ODD
25348|NCT02896426|Conduct Disorder
25349|NCT02896426|CD
25350|NCT02896426|Children
25351|NCT02896426|Parenting
25352|NCT02896426|Collaborative Problem Solving
25353|NCT02896426|CPS
25354|NCT02896426|Disruptive behavior
25355|NCT02896335|Recurrent Brain metastases
25356|NCT02896283|wound healing
25357|NCT02896283|low-level laser therapy
25358|NCT02896283|gingival recession
25359|NCT02896270|idiopathic podocytopathies
25360|NCT02896270|Neprology
25361|NCT02896257|Quality Improvement
25362|NCT02896257|Quality Enhancement Research Initiatives
25363|NCT02896257|QuERI
25364|NCT02896257|Interventional
25365|NCT02896257|Multicenter
25366|NCT02896257|Inhaled corticosteroids
25367|NCT02896257|Pneumonia
25368|NCT02896257|Safety
25369|NCT02896257|De-implementation
25370|NCT02896257|Respiratory Tract Diseases
25371|NCT02896257|Lung Diseases
25372|NCT02896257|Lung Diseases, Obstructive
25373|NCT02896257|Pulmonary Diseases, Chronic Obstructive COPD
25374|NCT02896244|Clostridium difficile
25375|NCT02896244|Clostridium difficile infection
25376|NCT02896244|antibiotics
25377|NCT02896244|antibiotics associated diarrhea
25378|NCT02896244|microbiome
25379|NCT02896244|microbiota
25380|NCT02896218|Vancomycin
25381|NCT02896218|Critically Ill
25382|NCT02896218|Pharmacist
25383|NCT02896218|Population Pharmacokinetic
25384|NCT02896218|Bayesian Methods
25385|NCT02896192|POMC deficiency obesity
25386|NCT02896192|PCSK1 deficiency obesity
25387|NCT02896179|Multiple sclerosis
25388|NCT02896179|Gait rehabilitation
25389|NCT02896179|Quality of life
25390|NCT02896179|Virtual reality
25391|NCT02896179|Cognitive deficit
25392|NCT02896179|Robot assisted gait training
25393|NCT02896166|nsclc and stage I and microwave ablation
25394|NCT02896140|Type 2 diabetes
25395|NCT02896140|Obesity
25396|NCT02896140|Nutrition
25397|NCT02896140|Dairy
25398|NCT02896127|Ankylosing Spondyloarthritis
25399|NCT02896127|Axial spondyloarthritis
25400|NCT02896101|Mild to moderate
25401|NCT02896075|delayed onset muscle soreness
25402|NCT02896075|laughter
25403|NCT02896049|neoplasms
25404|NCT02896049|hyperthermia
25405|NCT02896036|Laparoscopic Entry
25406|NCT02896036|Veress Needle
25407|NCT02896036|Intraperitoneal insufflation
25408|NCT02896036|Time
25409|NCT02896036|Complications
25410|NCT02896023|predictors
25411|NCT02896023|ovarian reserve
25412|NCT02896023|infertile women
25413|NCT02896010|Mobile Health
25414|NCT02895997|mental fatigue
25415|NCT02895997|critical care
25416|NCT02895984|Social network analysis
25417|NCT02895984|Brief Motivational Interviewing
25418|NCT02895984|College Students
25419|NCT02895971|Venous Thromboembolism
25420|NCT02895971|professional Practices
25421|NCT02895906|22q11.2 DS
25422|NCT02895880|Communication Tool
25423|NCT02895880|Cancer Survivors
25424|NCT02895880|Increase Statin
25425|NCT02895854|Low risk prostate cancer
25426|NCT02895854|Intermediate risk prostate cancer
25427|NCT02895854|Low dose-rate brachytherapy
25428|NCT02895854|Hypofractionated
25429|NCT02895854|Robotic external beam radiation
25430|NCT02895854|Quality of life
25431|NCT02895841|oncology
25432|NCT02895841|bone marrow transplant
25433|NCT02895841|sickle cell disease
25434|NCT02895802|down syndrome
25435|NCT02895789|spinal muscular atrophy
25436|NCT02895789|oxidative capacity
25437|NCT02895789|exercise tolerance
25438|NCT02895789|mitochondrial myopathy
25439|NCT02895789|SMA
25440|NCT02895789|six minute walk test
25441|NCT02895789|neuromuscular disease
25442|NCT02895789|ambulation
25443|NCT02895789|exercise
25444|NCT02895789|mitochondria
25445|NCT02895789|cycle ergometry
25446|NCT02895789|near infrared spectroscopy
25447|NCT02895763|QUALITY OF LIFE
25448|NCT02895763|NEUROMUSCULAR DISEASES
25449|NCT02895750|diabetes type 2
25450|NCT02895750|Metformin
25451|NCT02895750|chronic kidney disease
25452|NCT02895750|CKD
25453|NCT02895737|aortic stenosis, transcatheter aortic valve replacement, stroke, ischemic infarction, cerebral embolic protection device
25454|NCT02895724|Hyperbaric oxygen therapy
25455|NCT02895724|secondary lymphedema
25456|NCT02895698|Cupping
25457|NCT02895698|Dry cupping
25458|NCT02895698|Myofascial trigger points
25459|NCT02895685|Simulation
25460|NCT02895685|Self-regulated training
25461|NCT02895685|Education
25462|NCT02895685|Open surgery
25463|NCT02895685|Dyad training
25464|NCT02895659|fluid management
25465|NCT02895659|critical illness
25466|NCT02895659|hemodynamics
25467|NCT02895659|buffered infusates
25468|NCT02895633|MR imaging
25469|NCT02895633|Diffusion weighted imaging
25470|NCT02895633|MR proton spectroscopy
25471|NCT02895633|CT perfusion
25472|NCT02895633|Contrast enhanced ultrasound
25473|NCT02894879|Postoperative pulmonary complications
25474|NCT02894866|hypoxic-ischemic encephalopathy
25475|NCT02894866|hyperbaric oxygen therapy
25476|NCT02894840|GPO Tri Fluvac Vaccine
25477|NCT02894840|Tri Fluvac Vaccine
25478|NCT02894814|Self administration
25479|NCT02894814|Medication
25480|NCT02894814|Inpatient
25481|NCT02894814|Self-care
25482|NCT02894814|Self-management
25483|NCT02894814|Medical patients
25484|NCT02895568|Antimalarial drug
25485|NCT02895568|Resistance
25486|NCT02895568|Republic of Chard
25487|NCT02895555|ODI
25488|NCT02895503|Stage IA Non-Small Cell Lung Carcinoma
25489|NCT02895503|Stage IB Non-Small Cell Lung Carcinoma
25490|NCT02895503|Stage IIA Non-Small Cell Lung Carcinoma
25491|NCT02895503|Stage IIB Non-Small Cell Lung Carcinoma
25492|NCT02895503|Stage IIIA Non-Small Cell Lung Cancer
25493|NCT02895503|Stage IIIB Non-Small Cell Lung Cancer
25494|NCT02895503|Stage IV Non-Small Cell Lung Cancer
25495|NCT02895451|Exercise-based cardiac rehabilitation
25496|NCT02895451|Physical capacity
25497|NCT02895451|Adherence
25498|NCT02895451|Behavioral medicine
25499|NCT02895438|Gluten-Sensitive
25500|NCT02895438|Diet, Gluten-Free
25501|NCT02895438|Irritable Bowel Syndrome
25502|NCT02895438|non Coeliac Gluten sensitivity
25503|NCT02895438|children
25504|NCT02895425|Renal Transplant
25505|NCT02895373|platelet inhibition
25506|NCT02895373|alprostadil
25507|NCT02895373|extracorporeal membrane oxygenation
25508|NCT02895373|bleeding
25509|NCT02895373|thromboembolic
25510|NCT02895334|CHD
25511|NCT02895334|Congenital Heart Disease
25512|NCT02895321|nano-hydroxyapatite
25513|NCT02895321|potassium nitrate
25514|NCT02895308|compliance
25515|NCT02895295|Medicare Part D
25516|NCT02895295|decision support
25517|NCT02895295|prescription drugs
25518|NCT02895295|expert recommendation
25519|NCT02895295|health insurance choice
25520|NCT02895282|Obesity
25521|NCT02895282|Chronobiology
25522|NCT02895282|Circadian
25523|NCT02895269|Complementary Alternative Providers
25524|NCT02895269|Collaborative Shared Care
25525|NCT02895269|Primary Health Care Providers
25526|NCT02895269|Psychosis
25527|NCT02895230|Androgen-deprivation therapy
25528|NCT02895230|Prostate cancer
25529|NCT02895230|Nationwide population-based cohort
25530|NCT02895230|Myocardial infarction
25531|NCT02895230|Ischemic stroke
25532|NCT02895217|Energy expenditure
25533|NCT02895217|Food intake
25534|NCT02895217|Women
25535|NCT02895217|aquacycling
25536|NCT02895204|Fermented Maillard reacted whey protein
25537|NCT02895204|Natural killer cell activity
25538|NCT02895204|Immune function
25539|NCT02895204|Pre-albumin
25540|NCT02895204|Interleukin-12
25541|NCT02895178|Breast cancer
25542|NCT02895178|Survivors
25543|NCT02895178|Exercise
25544|NCT02895165|breast neoplasms
25545|NCT02895165|fertility preservation
25546|NCT02895165|pregnancy
25547|NCT02895152|COPD
25548|NCT02895152|Chronic Obstructive Pulmonary Disease
25549|NCT02895152|Pulmonary Rehabilitation
25550|NCT02895152|Activity Monitors
25551|NCT02895152|Fitbit
25552|NCT02895152|Fitness Tracker
25553|NCT02895139|Additive Manufacture
25554|NCT02895139|Orthotic Insole
25555|NCT02895113|Aspirin
25556|NCT02895113|Diabetes
25557|NCT02895113|Renal function
25558|NCT02895113|Thromboxane
25559|NCT02895100|ulcerative colitis
25560|NCT02895100|inflammatory bowel disease
25561|NCT02895087|diurnal variation
25562|NCT02895087|stress
25563|NCT02895074|femtosecond laser-assisted cataract surgery (FLACS)
25564|NCT02895074|subfoveal choroidal thickness (SFCT)
25565|NCT02895074|conventional phacoemulsification surgery (CPS)
25566|NCT02895009|Coronary Disease
25567|NCT02895009|Radial artery occlusion
25568|NCT02895009|transradial coronary intervention
25569|NCT02894996|pediatric
25570|NCT02894996|anesthesia
25571|NCT02894996|fluid responsiveness
25572|NCT02894996|hemodynamic
25573|NCT02894983|wrist fracture
25574|NCT02894983|colles fracture
25575|NCT02894983|non-operative
25576|NCT02894983|rehabilitation
25577|NCT02894944|Pancreatic cancer
25578|NCT02894944|Adenovirus
25579|NCT02894944|Gene therapy
25580|NCT02894931|macrophage atherogenicity
25581|NCT02894931|dietary interventions
25582|NCT02894931|sugars
25583|NCT02894931|amino acids
25584|NCT02894931|artificial sweeteners
25585|NCT02894931|atherosclerosis
25586|NCT02894892|Electron Microscopy
25587|NCT02894892|Helicobacter pylori
25588|NCT02894892|Bismuth
25589|NCT02894749|hybrid rooms
25590|NCT02894749|cone-beam computed tomography
25591|NCT02894723|Hypertension,
25592|NCT02894723|Nitric Oxide
25593|NCT02894723|L-Arginine
25594|NCT02894723|Arterial Stiffness
25595|NCT02894723|Ambulatory blood pressure measurement
25596|NCT02894710|postoperative pain
25597|NCT02894710|intravenous lidocaine
25598|NCT02894710|chronic post-surgical pain
25599|NCT02894710|remifentanil
25600|NCT02894710|patient controlled analgesia
25601|NCT02894710|morphine consumption
25602|NCT02894710|ENT surgery
25603|NCT02894632|MRI
25604|NCT02894632|Motion
25605|NCT02894632|Respiratory movement
25606|NCT02894632|Artifacts correction
25607|NCT02894619|urinary incontinence
25608|NCT02894619|anal incontinence
25609|NCT02894619|sexuality
25610|NCT02894619|quality of life
25611|NCT02894606|Kidney Transplant
25612|NCT02894606|Immunology
25613|NCT02894593|Antiplaque agents
25614|NCT02894593|chemical plaque control
25615|NCT02894593|oral hygiene
25616|NCT02894593|essential oils
25617|NCT02894593|alcohol
25618|NCT02894593|mouthwash
25619|NCT02894541|Dyslipidemia
25620|NCT02894541|CKD-519
25621|NCT02894541|CETP inhibitor
25622|NCT02894541|Food Drug Interaction
25623|NCT02894528|Alveolar ridge
25624|NCT02894528|guided bone regeneration
25625|NCT02894528|bone grafts
25626|NCT02894502|Self-care
25627|NCT02894502|Motivational interviewing
25628|NCT02894502|Heart failure
25629|NCT02894502|Caregivers
25630|NCT02894476|satisfaction with care
25631|NCT02894476|outpatient care
25632|NCT02894476|self-reported health status
25633|NCT02894476|alcohol dependence
25634|NCT02894476|opioid dependence
25635|NCT02894463|dental care
25636|NCT02894463|emeno
25637|NCT02894463|abuse
25638|NCT02894450|Atrial fibrillation
25639|NCT02894450|oral anticoagulant
25640|NCT02894450|bioassay
25641|NCT02894450|elderly subject
25642|NCT02894437|prevention
25643|NCT02894437|organization
25644|NCT02894437|pressure ulcers
25645|NCT02894424|Inner limiting membrane
25646|NCT02894424|Microperimetry
25647|NCT02894424|surgical's dye
25648|NCT02894411|MRI
25649|NCT02894411|Excyclotorsion
25650|NCT02894398|HR+
25651|NCT02894398|HER2-
25652|NCT02894398|Locally Advanced (inoperable or metastatic) Breast Cancer
25653|NCT02894398|Palbociclib
25654|NCT02894398|Letrozole
25655|NCT02894398|Postmenopausal women
25656|NCT02894372|Oral spray
25657|NCT02894372|Topical sprays
25658|NCT02894372|Faringomoss
25659|NCT02894372|Local phytotherapy
25660|NCT02894359|Cervical spine
25661|NCT02894359|Musculoskeletal imagery
25662|NCT02894359|computer modelling of cervical spine
25663|NCT02894359|ConeBeam.
25664|NCT02894346|Motivation
25665|NCT02894346|Teachers
25666|NCT02894346|Physical activity
25667|NCT02894346|School
25668|NCT02894333|Parkinson's disease
25669|NCT02894333|Action-effect prediction
25670|NCT02894333|Sensory attenuation
25671|NCT02894333|Voluntary action
25672|NCT02894320|Parkinson's disease
25673|NCT02894320|Voluntary action
25674|NCT02894320|Action-effect preactivation
25675|NCT02894320|Action-effect prediction
25676|NCT02894307|MEchanical valves
25677|NCT02894307|Rivaroxaban
25678|NCT02894294|malaria
25679|NCT02894294|chemoprevention
25680|NCT02894294|season
25681|NCT02894294|anemia
25682|NCT02894294|impact
25683|NCT02894294|coverage
25684|NCT02894294|children
25685|NCT02894281|Pupillary light reflex
25686|NCT02894281|Multiple sclerosis
25687|NCT02894190|Non Invasive Ventilation (NIV)
25688|NCT02894190|Adherence
25689|NCT02894190|Beliefs
25690|NCT02894190|Development
25691|NCT02894190|Validation
25692|NCT02894177|E02.880.820.950
25693|NCT02894125|Chronic Low Back Pain
25694|NCT02894125|Old subject
25695|NCT02894125|SPA Therapy
25696|NCT02894125|Pain
25697|NCT02894125|Function
25698|NCT02894125|Expectations
25699|NCT02894125|Fears
25700|NCT02894112|endothelial dependent vasodilation
25701|NCT02894112|blood flow
25702|NCT02894112|blood glucose
25703|NCT02894112|triglycerides
25704|NCT02894112|non-fat milk
25705|NCT02894112|dairy
25706|NCT02894099|Aged
25707|NCT02894099|Sedentary Behaviour
25708|NCT02894099|Blood Glucose
25709|NCT02894099|Insulin
25710|NCT02894099|Inflammatory markers
25711|NCT02894086|acute appendicitis
25712|NCT02894086|ambulatory appendicectomy
25713|NCT02894073|obese patients
25714|NCT02894073|peripheral venous catheter
25715|NCT02894060|Cardiovascular events
25716|NCT02894047|calcium-sensitive receptor
25717|NCT02894034|optic nerve sheath
25718|NCT02894034|meningeal hemorrhage
25719|NCT02894034|early phase
25720|NCT02894034|prognostic
25721|NCT02894021|padding
25722|NCT02894021|lymphoceles
25723|NCT02894021|prevention
25724|NCT02893995|PAH
25725|NCT02893995|Subcutaneous Treprostinil
25726|NCT02893995|Remodulin
25727|NCT02893995|6 Minute Walk Test
25728|NCT02893969|Physical Activity
25729|NCT02893969|Rest
25730|NCT02893956|Echocardiography
25731|NCT02893956|postural support
25732|NCT02893956|preterm neonate
25733|NCT02893904|Propofol
25734|NCT02893904|Sevoflurane
25735|NCT02893904|Bispectral Index
25736|NCT02893904|Children
25737|NCT02893904|Electroencephalographic signs
25738|NCT02893891|Obesity
25739|NCT02893891|Bariatric medicine
25740|NCT02893891|Sleeve gastric resection
25741|NCT02893891|Gastric plication
25742|NCT02893891|Intragastric ballon
25743|NCT02893891|Body composition
25744|NCT02893891|Adipokines
25745|NCT02893891|Ghrelin
25746|NCT02893891|Bone mineral density
25747|NCT02893891|Quality of life
25748|NCT02893878|Seasonal influenza vaccines
25749|NCT02893878|Passive Enhanced Safety surveillance
25750|NCT02893878|England
25751|NCT02893878|Pilot study
25752|NCT02893865|Apnea syndrome
25753|NCT02893865|Coronary artery disease
25754|NCT02893865|Oxidative stress
25755|NCT02893865|Continuous positive airway pressure
25756|NCT02893865|Endothelial dysfunction
25757|NCT02893839|Allergy
25758|NCT02893839|cross-reactivity
25759|NCT02893839|oral allergy syndrome
25760|NCT02893839|potato
25761|NCT02893839|sensitization
25762|NCT02893826|Aneurysm
25763|NCT02893826|Ruptured
25764|NCT02893826|nimodipine
25765|NCT02893826|subarachnoid hemorrhage
25766|NCT02893800|assistive technology
25767|NCT02893800|dementia care
25768|NCT02893800|tracking technology
25769|NCT02893800|locating systems
25770|NCT02893800|user experience
25771|NCT02893787|Speckle Tracking
25772|NCT02893787|Anthracyclines
25773|NCT02893787|Chilhood cancers
25774|NCT02893787|Myocardial function
25775|NCT02893787|Echocardiography
25776|NCT02893761|breast cancer
25777|NCT02893761|survival
25778|NCT02893761|prognosis factors
25779|NCT02893748|colon
25780|NCT02893748|polyps
25781|NCT02893748|cancer
25782|NCT02893748|screening
25783|NCT02893735|Clinical Trial
25784|NCT02893735|Composite resin
25785|NCT02893722|ivf ,atosiban,repeated implantation failure,RCT
25786|NCT02893683|Paris Visual Learning Test
25787|NCT02893683|visual memory
25788|NCT02893683|criterion validity
25789|NCT02893657|MELD score
25790|NCT02893657|hemodynamics
25791|NCT02893657|liver abnormalities
25792|NCT02893566|overweight
25793|NCT02893566|body mass index
25794|NCT02893566|university students
25795|NCT02893566|physical activity
25796|NCT02893566|sedentary behavior
25797|NCT02893566|body composition
25798|NCT02893566|Mi Band
25799|NCT02893514|Drug Use
25800|NCT02893488|dolutegravir
25801|NCT02893488|abacavir
25802|NCT02893488|relative bioavailability
25803|NCT02893488|palatability
25804|NCT02893488|GSK2619619
25805|NCT02893488|palatability questionnaire
25806|NCT02893488|lamivudine
25807|NCT02893488|pediatric
25808|NCT02893488|calcium
25809|NCT02893488|dispersible tablet
25810|NCT02893462|data warehousing
25811|NCT02893462|data aggregation
25812|NCT02893462|data mining
25813|NCT02893449|Parkinson
25814|NCT02893449|SAS-SR
25815|NCT02893449|Social adaptation
25816|NCT02893449|Patients suffering from Parkinson's disease
25817|NCT02893423|Ropivacaine
25818|NCT02893423|C-Section Analgesia
25819|NCT02893423|Tap Block
25820|NCT02893358|Allisartan Isoproxil
25821|NCT02893358|left ventricular hypertrophy
25822|NCT02893358|large arterial stiffness
25823|NCT02893358|microalbuminuria
25824|NCT02893345|Self Care (Rehabilitation)
25825|NCT02893345|Community Participation
25826|NCT02893345|Patient-Centered Outcomes Research
25827|NCT02893345|Informatics, Clinical
25828|NCT02893319|Infant Feeding
25829|NCT02893319|Infant Growth
25830|NCT02893306|Type1 Diabetes Mellitus
25831|NCT02893306|Multipotent stromal cell
25832|NCT02893306|Mesenchymal stem cell
25833|NCT02893306|Insulin
25834|NCT02893306|Pancreatic reserve
25835|NCT02893306|Disease progression
25836|NCT02893267|Stroke
25837|NCT02893267|Shoulder Pain
25838|NCT02893267|Electrical stimulation
25839|NCT02893267|Neuromuscular stimulation
25840|NCT02893267|Intramuscular stimulation
25841|NCT02893267|Physical Therapy
25842|NCT02893254|ankylosing spondylitis, tumor necrosis factor-α inhibitors
25843|NCT02893228|forced expiratory volume in 1 second
25844|NCT02893228|forced vital capacity
25845|NCT02893228|peak expiratory flow rate
25846|NCT02893228|interscalene block
25847|NCT02893228|diaphragmatic paresis
25848|NCT02893202|PTSD
25849|NCT02893202|Equine assisted activities
25850|NCT02893202|quality of life
25851|NCT02893189|CD19+
25852|NCT02893189|allogeneic transplant
25853|NCT02893189|relapse
25854|NCT02893176|Lung Transplant
25855|NCT02893176|Macitentan
25856|NCT02893176|CLAD
25857|NCT02893176|BOS
25858|NCT02893176|bronchiolitis obliterans
25859|NCT02893176|chronic lung allograft dysfunction
25860|NCT02893176|Organ Rejection
25861|NCT02893163|Metabolic Syndrome
25862|NCT02893163|Cancer Risk
25863|NCT02893163|Lifestyle Interventions
25864|NCT02893163|Primary Care
25865|NCT02893163|Behavioural Change
25866|NCT02893150|Mindful Eating
25867|NCT02893150|Overweight
25868|NCT02893150|Primary Care
25869|NCT02893150|Randomized Clinical Trial
25870|NCT02893137|Tumour treating fields
25871|NCT02893137|Optune
25872|NCT02893137|Craniectomy
25873|NCT02893137|TTFields
25874|NCT02893124|chronic hepatitis B
25875|NCT02893111|neuromyelitis optica spectrum disorders
25876|NCT02893111|Bortezomib
25877|NCT02893111|Velcade
25878|NCT02893111|Proteasome inhibitor
25879|NCT02893072|Diabetes, Gestational
25880|NCT02893072|Nutrition Therapy
25881|NCT02893046|care pathway
25882|NCT02893046|hospital- private network
25883|NCT02893046|early consultation
25884|NCT02893033|Dysphagia
25885|NCT02893033|Repetitive Transcranial Magnetic Stimulation
25886|NCT02893033|Stroke
25887|NCT02893020|Emotional experience and burnout in physicians
25888|NCT02892994|therapeutic ultrasound
25889|NCT02892968|Regional Anesthesia Ultrasound guided
25890|NCT02892968|Emergency Department
25891|NCT02892968|Knowledge to Practice Intervention
25892|NCT02892955|Heart Failure
25893|NCT02892955|LVAS
25894|NCT02892955|Ventricular Dysfunction
25895|NCT02892955|Cardiomyopathy
25896|NCT02892955|Heart Disease
25897|NCT02892955|Cardiovascular Disease
25898|NCT02892955|Heart-assist devices
25899|NCT02892955|Thoratec Corporation
25900|NCT02892942|Controlled ovarian hyperstimulation
25901|NCT02892942|Estradiol
25902|NCT02892942|Embryo implantation
25903|NCT02892942|Endometrial receptivity
25904|NCT02892942|Fertility preservation
25905|NCT02892929|Motivational Interviewing
25906|NCT02892929|Hypertension
25907|NCT02892929|Nursing
25908|NCT02892929|Randomized Controlled Trial
25909|NCT02892929|Life Style
25910|NCT02892916|Delirium
25911|NCT02892916|Ketamine
25912|NCT02892916|Elective orthopaedic surgery
25913|NCT02892903|Fractional flow reserve (FFR)
25914|NCT02892903|Pressure wire (PW)
25915|NCT02892903|Coronary angiography
25916|NCT02892877|Complete Hydatidiform mole
25917|NCT02892877|Partial Hydatidiform mole
25918|NCT02892877|Invasive mole
25919|NCT02892877|Choriocarcinoma
25920|NCT02892877|Post-molar neoplasia
25921|NCT02892877|Placental Site Trophoblastic Tumor (PSTT)
25922|NCT02892877|Epithelioid Trophoblastic Tumor (ETT)
25923|NCT02892877|hCG follow-up
25924|NCT02892864|Bell's Palsy
25925|NCT02892864|Peripheral facial palsy
25926|NCT02892851|STN-DBS
25927|NCT02892851|Craving
25928|NCT02892851|Cocaine addiction
25929|NCT02892838|mobile bearing knee prosthesis
25930|NCT02892825|Music
25931|NCT02892825|cataract surgery
25932|NCT02892825|topical anaesthesia
25933|NCT02892825|anxiety
25934|NCT02892825|hypertension
25935|NCT02892786|circulating tumor cell
25936|NCT02892786|CellSearch™ method
25937|NCT02892786|RT-PCR
25938|NCT02892773|electrical impedance tomography
25939|NCT02892773|incentive spirometry
25940|NCT02892773|EzPAP
25941|NCT02892773|lung volume
25942|NCT02892773|atelectasis
25943|NCT02892773|positive airway pressure
25944|NCT02892773|negative inspiratory pressure
25945|NCT02892773|pulmonary complication
25946|NCT02892773|abdominal surgery
25947|NCT02892773|end-expiratory lung volume
25948|NCT02892747|Chronic Heart Failure (CHF)
25949|NCT02892747|Dietetics education
25950|NCT02892747|Malnutrition
25951|NCT02892721|CT Colonography
25952|NCT02892721|Virtual colonoscopy
25953|NCT02892721|Colorectal cancer
25954|NCT02892721|Colon cancer
25955|NCT02892721|Training
25956|NCT02892708|supratentorial gliomas
25957|NCT02892708|surgery
25958|NCT02892708|magnetic resonance spectroscopy
25959|NCT02892708|elderly
25960|NCT02892630|Immune Thrombocytopenia
25961|NCT02892630|Pregnancy
25962|NCT02892617|Modic 1
25963|NCT02892617|low back pain
25964|NCT02892604|Type 1 diabetes
25965|NCT02892604|artificial pancreas
25966|NCT02892604|closed-loop insulin infusion
25967|NCT02892565|systemic lupus erythematosus
25968|NCT02892565|antiphospholipid syndrome
25969|NCT02892565|antiphospholipid antibodies
25970|NCT02892513|Colorectal Surgery
25971|NCT02892513|transcutaneous electric nerve stimulation
25972|NCT02892487|Quality of life
25973|NCT02892487|Radiotherapy
25974|NCT02892487|Dysphagia
25975|NCT02892487|Oral cavity
25976|NCT02892487|Oropharynx
25977|NCT02892487|Hypopharynx
25978|NCT02892487|Larynx
25979|NCT02892487|Swallowing rehabilitation
25980|NCT02892487|Toxicity
25981|NCT02892474|Coronary Arteriosclerosis
25982|NCT02892474|Hybrid Coronary Revascularization
25983|NCT02892474|Coronary Artery Bypass Grafting
25984|NCT02892461|Anemia, Iron-Deficiency
25985|NCT02892461|Cesarean Section
25986|NCT02892461|Umbilical Cord Milking
25987|NCT02892461|Randomized Controlled Trial
25988|NCT02892409|Drug Therapy
25989|NCT02892344|Phase III, blinded, QMF149, Mometasone furoate (MF), mild asthma, Adolescent, adult
25990|NCT02892331|exercise
25991|NCT02892331|insulin resistance
25992|NCT02892331|mitochondrial function
25993|NCT02892331|arterial stiffness
25994|NCT02892331|exercise intensity
25995|NCT02892331|fitness
25996|NCT02892305|Pancreaticoduodenectomy
25997|NCT02892305|Hepatectomy
25998|NCT02892305|Liver ablation
25999|NCT02892279|Microneurography
26000|NCT02892279|Air pollution
26001|NCT02892266|Transplant recipients
26002|NCT02892266|Adolescents
26003|NCT02892266|Post-Traumatic Stress Symptoms (PTSS)
26004|NCT02892266|Transplant Recipient and Family Impact(s)
26005|NCT02892253|postoperative hypocalcemia
26006|NCT02892253|near infrared imaging
26007|NCT02892253|parathyroid autofluorescence
26008|NCT02892227|bedside echography
26009|NCT02892162|atrial fibrillation
26010|NCT02892162|catheter ablation
26011|NCT02892149|AKB-6548
26012|NCT02892149|Chronic kidney disease
26013|NCT02892149|anemia
26014|NCT02892149|CKD
26015|NCT02892149|chronic renal insufficiency
26016|NCT02892149|renal impairment
26017|NCT02892149|erythropoietin
26018|NCT02892149|kidney
26019|NCT02892149|renal
26020|NCT02892149|oral anemia treatment
26021|NCT02892149|hemoglobin
26022|NCT02892149|hypoxia-inducible factor
26023|NCT02892149|HIF
26024|NCT02892149|hypoxia-inducible factor prolyl-hydroxylase inhibitor
26025|NCT02892149|HIF-PHI
26026|NCT02892149|efficacy
26027|NCT02892149|safety
26028|NCT02892149|Phase 3
26029|NCT02892149|cardiovascular
26030|NCT02892149|DD-CKD
26031|NCT02892123|HER2
26032|NCT02892123|bispecific antibody
26033|NCT02892123|biparatopic antibody
26034|NCT02892123|breast cancer
26035|NCT02892123|gastric cancer
26036|NCT02892123|gastroesophageal cancer
26037|NCT02892123|ovarian cancer
26038|NCT02892123|non-small cell lung cancer
26039|NCT02892110|Marijuana use
26040|NCT02892110|Varenicline/Chantix
26041|NCT02892110|Motivational enhancement therapy
26042|NCT02892097|tDCS
26043|NCT02892097|neglect
26044|NCT02892097|paresis
26045|NCT02892097|transcranial direct current stimulation
26046|NCT02892097|rehabilitation
26047|NCT02892084|Chronic Stroke ( > 6 months)
26048|NCT02892084|non-invasive brain stimulation
26049|NCT02892084|rehabilitation
26050|NCT02892084|walking
26051|NCT02892084|kinetics
26052|NCT02892045|neuromuscular block
26053|NCT02892045|monitoring
26054|NCT02892019|indacaterol acetate, asthma, GINA 2015, pediatrics
26055|NCT02891993|Cancer Care
26056|NCT02891980|Ad26
26057|NCT02891980|Ebola
26058|NCT02891980|immunogenicity response
26059|NCT02891980|MVA-Multi Filo
26060|NCT02891980|Omics
26061|NCT02891980|Zaire
26062|NCT02891954|Glucosuria
26063|NCT02891954|SGLT2 inhibitors
26064|NCT02891954|Canagliflozin
26065|NCT02891954|FGF23
26066|NCT02891954|Parathyroid hormone
26067|NCT02891954|1,25-Dihydroxyvitamin D
26068|NCT02891954|Glucagon
26069|NCT02891954|Ketone bodies
26070|NCT02891954|Uric acid
26071|NCT02891954|Pharmacogenomics
26072|NCT02891928|Type 2 diabetes
26073|NCT02891928|Diabetic neuropathy
26074|NCT02891928|Disorders of equilibrium
26075|NCT02891928|"Rocker sole shoes"
26076|NCT02891928|Walking
26077|NCT02891915|Antimicrobial
26078|NCT02891915|Beta-Lactam
26079|NCT02891915|Pneumonia
26080|NCT02891915|Short Course
26081|NCT02891915|Standard Course
26082|NCT02891915|Therapy
26083|NCT02891876|direct pulp capping, biodentine
26084|NCT02891863|Implantable Cardioverter-Defibrillator
26085|NCT02891837|L-citrulline
26086|NCT02891837|pediatric
26087|NCT02891837|Lung Injury
26088|NCT02891837|Bypass
26089|NCT02891837|Heart Defects
26090|NCT02891837|Clinical Sequelae
26091|NCT02891824|PD-L1
26092|NCT02891824|Atezolizumab
26093|NCT02891824|Randomized, double blinded
26094|NCT02891824|first or second late relapse
26095|NCT02891824|progressive non-mucinous epithelial ovarian cancer, primary peritoneal adenocarcinoma and / or fallopian-tube adenocarcinoma
26096|NCT02891824|progression-free survival
26097|NCT02891811|newly diagnosed multiple myeloma
26098|NCT02891811|carfilzomib
26099|NCT02891811|thalidomide
26100|NCT02891811|lenalidomide
26101|NCT02891811|dexamethasone
26102|NCT02891811|transplant ineligible
26103|NCT02891811|induction therapy
26104|NCT02891811|maintenance
26105|NCT02891811|Study Group of Medical Tumour Therapy (AGMT)
26106|NCT02891798|analgesia,
26107|NCT02891798|buprenorphine
26108|NCT02891798|clonidine
26109|NCT02891798|dexamethasone
26110|NCT02891798|bupivacaine
26111|NCT02891798|nerve block
26112|NCT02891733|Expression of the Neurotensin
26113|NCT02891733|Neurotensin
26114|NCT02891668|Basal Metabolic rate
26115|NCT02891668|Quality of life
26116|NCT02891668|Resting energy expenditure
26117|NCT02891668|Insulin resistance
26118|NCT02891668|Cognitive Function
26119|NCT02891668|Body Composition
26120|NCT02891642|malignancy
26121|NCT02891642|Pleural Effusion
26122|NCT02891642|Pleural Neoplasms
26123|NCT02891642|Ascites
26124|NCT02891616|Melanoma
26125|NCT02891616|18F-FLT
26126|NCT02891616|18F-FDG
26127|NCT02891616|PET/CT
26128|NCT02891616|PET/MR
26129|NCT02891577|intra abdominal hypertension
26130|NCT02891577|shock
26131|NCT02891577|critically ill
26132|NCT02891564|therapeutic video games, mobile interventions
26133|NCT02891551|Leukemia
26134|NCT02891551|Chronic
26135|NCT02891551|Acute
26136|NCT02891551|Observational
26137|NCT02891551|Non-interventional
26138|NCT02891551|OCEAN
26139|NCT02891551|Netherlands
26140|NCT02891551|azacitidine
26141|NCT02891538|EGCG
26142|NCT02891538|Green Tea
26143|NCT02891538|Colon Cancer
26144|NCT02891512|Magnetic Fields
26145|NCT02891512|Pain
26146|NCT02891512|Paresthesia
26147|NCT02891512|Visual Analogue Scale
26148|NCT02891499|Miniscrews
26149|NCT02891499|Mini-implants
26150|NCT02891499|Temporal anchorage devices
26151|NCT02891499|Bone screws
26152|NCT02891499|Stability
26153|NCT02891499|Displacement
26154|NCT02891499|Low-level laser therapy
26155|NCT02891499|Cone-beam computed tomography
26156|NCT02891499|Resonance frequency analysis
26157|NCT02891499|Orthodontic
26158|NCT02891499|Orthodontic miniscrew implant
26159|NCT02891486|spinal surgery, surgical site infection
26160|NCT02891473|Posture
26161|NCT02891473|Pain
26162|NCT02891473|Muscle stretching
26163|NCT02891473|Mézières method
26164|NCT02891473|Camptocormia
26165|NCT02891473|Trunk control
26166|NCT02891460|Mitomycin C
26167|NCT02891460|MMC
26168|NCT02891460|NMIBC
26169|NCT02891460|Non Muscle Invasive Bladder Cancer
26170|NCT02891460|Hydrogel Reverse thermal gelation
26171|NCT02891460|Drug retention
26172|NCT02891460|Urinary Bladder Neoplasms
26173|NCT02891460|Urologic Neoplasms
26174|NCT02891460|Urinary Bladder Diseases
26175|NCT02891460|Urologic Diseases
26176|NCT02891434|Duchenne muscular dystrophy
26177|NCT02891434|motor learning
26178|NCT02891434|motor abilities
26302|NCT02890550|Retinitis pigmentosa
26179|NCT02891395|allogeneic stem cell transplantation, imatinib Mesylate, Nilotinib
26180|NCT02891382|Diabetes Mellitus, Type 2
26181|NCT02891382|Weight Loss
26182|NCT02891382|Financial Incentives
26183|NCT02891382|Hemoglobin A, Glycosylated
26184|NCT02891356|Adiponectin
26185|NCT02891356|Bone remodelling markers
26186|NCT02891343|Cognitive Function
26187|NCT02891343|Hypoxia
26188|NCT02891343|Neurophysiological Function
26189|NCT02891343|Effect of Alzheimer Disease symptomatic drugs
26190|NCT02891343|Healthy Subjects
26191|NCT02891330|Roux-en-Y Gastric ByPass
26192|NCT02891304|esophagogastroduodenoscopy
26193|NCT02891291|optical coherence tomography
26194|NCT02891278|leukemia
26195|NCT02891239|laser treatment
26196|NCT02891226|inflammatory bowel disease
26197|NCT02891226|IL-23
26198|NCT02891226|biologic
26199|NCT02891187|Postoperative Care
26200|NCT02891187|Telephone follow-up
26201|NCT02891187|Healthcare Value
26202|NCT02891174|ibuprofen
26203|NCT02891174|acetaminophen
26204|NCT02891174|blood pressure
26205|NCT02891174|post-partum
26206|NCT02891174|pain control
26207|NCT02891174|pre-eclampsia
26208|NCT02891174|gestational hypertension
26209|NCT02891161|durvalumab
26210|NCT02891161|MEDI4736
26211|NCT02891161|anti-PD-L1
26212|NCT02891096|respiratory complications
26213|NCT02891096|respiratory muscle strength
26214|NCT02891096|discriminator
26215|NCT02891083|adjuvant chemotherapy
26216|NCT02891083|adjuvant radiotherapy
26217|NCT02891083|lymph node metastasis
26218|NCT02891083|surgery
26219|NCT02891083|squamous cell carcinoma
26220|NCT02891070|Cranial Surgery
26221|NCT02891070|Cerebrospinal Fluid Leak
26222|NCT02891070|Tisseel
26223|NCT02891031|Rhus
26224|NCT02891031|Medicine, Traditional
26225|NCT02891031|Herbal medicine
26226|NCT02891031|Uric acid
26227|NCT02890966|SHR4640 pharmacokinetics pharmacodynamics
26228|NCT02890927|Geriatric Nursing
26229|NCT02890927|Geriatric co-management
26230|NCT02890927|Geriatric team
26231|NCT02890901|Escherichia coli
26232|NCT02890901|Bloodstream infections
26233|NCT02890901|Severity
26234|NCT02890901|Score
26235|NCT02890901|Host factors
26236|NCT02890901|Microbiology
26237|NCT02890888|small vessel disease of the brain
26238|NCT02890888|hyperbaric oxygen
26239|NCT02890888|functional connectivity MRI
26240|NCT02890875|ethanol lock
26241|NCT02890875|parenteral nutrition
26242|NCT02890862|Kinematics
26243|NCT02890862|Activity of Daily living
26244|NCT02890862|3D motion analysis
26245|NCT02890836|Blood pressure
26246|NCT02890836|Hypertension
26247|NCT02890836|White coat hypertension
26248|NCT02890836|Preeclampsia
26249|NCT02890836|Anti-hypertensiva
26250|NCT02890823|Antiepileptic Drugs
26251|NCT02890823|Vitamin D Deficiency
26252|NCT02890823|Asian
26253|NCT02890810|Acupuncture
26254|NCT02890810|Back Pain
26255|NCT02890810|Chronic Pain
26256|NCT02890797|Child
26257|NCT02890771|Turmeric
26258|NCT02890771|Chronic periodontitis
26259|NCT02890758|Natural Killer Cell
26260|NCT02890758|ALT-803
26261|NCT02890745|Empagliflozin
26262|NCT02890745|Oxidative stress
26263|NCT02890745|Oxidative nucleic acid modifications
26264|NCT02890745|8-oxo-7,8-dihydro-2'-deoxyguanosine
26265|NCT02890745|8-oxo-7,8-dihydroguanosine
26266|NCT02890706|Pulmonary embolism (PE)
26267|NCT02890706|Dual-Energy CT (DECT)
26268|NCT02890706|Subtraction imaging
26269|NCT02890693|gestational diabetes mellitus
26270|NCT02890693|randomized controlled trial
26271|NCT02890693|lifestyle intervention
26272|NCT02890693|cardiovascular
26273|NCT02890693|metabolic
26274|NCT02890693|mental health
26275|NCT02890693|depression
26276|NCT02890693|physical activity
26277|NCT02890693|dietary intervention
26278|NCT02890680|platelet-rich fibrin
26279|NCT02890680|third molar
26280|NCT02890680|bone regeneration
26281|NCT02890667|Cancer
26282|NCT02890667|incidence
26283|NCT02890667|health insurance data
26284|NCT02890667|algorithms
26285|NCT02890654|Teenagers
26286|NCT02890654|Multidisciplinary approach
26287|NCT02890654|Pain
26288|NCT02890654|Surgery
26289|NCT02890628|Thai-Myanmar border
26290|NCT02890615|Survivors
26291|NCT02890615|Self Care
26292|NCT02890589|Acute coronary syndrome
26293|NCT02890589|ST (Software Test) -elevation
26294|NCT02890576|cochlear implant
26295|NCT02890576|telemedicine
26296|NCT02890576|new organization of patient monitoring
26297|NCT02890563|Varicose veins
26298|NCT02890563|Compression stockings
26299|NCT02890563|Sclerotherapy
26300|NCT02890563|Radiofrequency ablation
26301|NCT02890550|Ciliopathy
26303|NCT02890550|ALMS1 gene
26304|NCT02890537|Osteonecrosis
26305|NCT02890537|Femoral Head
26306|NCT02890537|Hip
26307|NCT02890537|Orthopedics
26308|NCT02890537|Bone
26309|NCT02890537|Musculoskeletal Disorders
26310|NCT02890524|aphthous stomatitis
26311|NCT02890524|night guard
26312|NCT02890524|inflammatory cytokine
26313|NCT02890459|HIV
26314|NCT02890459|incentives
26315|NCT02890459|behavioral economics
26316|NCT02890446|attentional focus
26317|NCT02890446|upper extremity
26318|NCT02890446|hemiparesis
26319|NCT02890446|stroke
26320|NCT02890394|Neck Pain
26321|NCT02890394|Suboccipital inhibition
26322|NCT02890394|Physical Therapy
26323|NCT02890368|CD47
26324|NCT02890368|SIRPa
26325|NCT02890368|Immunotherapy
26326|NCT02890368|Checkpoint inhibitor
26327|NCT02890342|Propionic Acidemia
26328|NCT02890342|Inborn Error of Metabolism
26329|NCT02890342|Genetics
26330|NCT02890342|Pccb
26331|NCT02890342|Pcca
26332|NCT02890290|Frail Elderly
26333|NCT02890290|Diet, Food, and Nutrition
26334|NCT02890290|physical function
26335|NCT02890290|marine protein hydrolysates
26336|NCT02890290|protein intake
26337|NCT02890290|seafood intake
26338|NCT02890290|municipal home care service
26339|NCT02890290|ageing
26340|NCT02890290|old
26341|NCT02890290|nutrition
26342|NCT02890290|frail
26343|NCT02890264|End stage renal disease
26344|NCT02890264|Dialysis
26345|NCT02890251|Infant
26346|NCT02890251|Premature
26347|NCT02890251|Diseases
26348|NCT02890238|Sildenafil Citrate
26349|NCT02890238|Induction of Ovulation
26350|NCT02890238|Pregnancy Rate
26351|NCT02890225|renal residual stones
26352|NCT02890225|external physical vibration lithecbole
26353|NCT02890225|stone free rate
26354|NCT02890225|complications
26355|NCT02890212|Major depression, selenium, placebo, sertraline
26356|NCT02890186|narcotrend
26357|NCT02890186|propofol
26358|NCT02890186|remifentanil
26359|NCT02890186|closed-loop of target controlled infusion
26360|NCT02890173|Essential hypertension
26361|NCT02890173|Mineralocorticoid receptor antagonist
26362|NCT02890173|Esaxerenone
26363|NCT02890173|Ambulatory blood pressure monitoring
26364|NCT02890160|Bioresorbable Vascular Scaffold
26365|NCT02890147|SADs
26366|NCT02890147|Healthy Volunteers
26367|NCT02890147|Molecular profiles
26368|NCT02890147|Omics Techniques
26369|NCT02890134|SADs
26370|NCT02890134|Molecular Reclassification
26371|NCT02890121|SADs
26372|NCT02890121|Molecular Reclassification
26373|NCT02890108|High-Intensity Sweeteners
26374|NCT02890108|Non-Nutritive Sweeteners
26375|NCT02890108|Artificial sweeteners
26376|NCT02890108|Glucose intolerance
26377|NCT02890082|Breast cancer
26378|NCT02890082|fertility
26379|NCT02890082|chemotherapy
26380|NCT02890069|PDR001
26381|NCT02890069|CRC
26382|NCT02890069|TNBC
26383|NCT02890069|NSCLC
26384|NCT02890069|Immunomodulation
26385|NCT02890069|Biomarkers
26386|NCT02890069|Bayesian logistic regression model
26387|NCT02890056|sugar-sweetened beverage consumption
26388|NCT02890056|water consumption
26389|NCT02890056|dietary behaviors
26390|NCT02890056|youth
26391|NCT02890043|spine
26392|NCT02890043|robot-assisted surgery
26393|NCT02890043|pedicle screw
26394|NCT02890030|Cisplatin-based therapy
26395|NCT02890030|Ototoxicity
26396|NCT02890030|Neurotoxicity
26397|NCT02890017|outpatient surgery
26398|NCT02890017|urology medico-economic
26399|NCT02890017|hotel
26400|NCT02890004|Subarachnoid Hemorrhage
26401|NCT02890004|Neurointensive care
26402|NCT02890004|Observational registry
26403|NCT02889991|Myofascial pain.
26404|NCT02889991|Myofascial trigger point.
26405|NCT02889991|Infraspinatus muscle.
26406|NCT02889991|Deep dry needling.
26407|NCT02889991|Local twitch response.
26408|NCT02889991|Fascial mechanotransduction.
26409|NCT02889991|Needle grasp.
26410|NCT02889991|Myofascial fibrosis.
26411|NCT02889991|Elastography.
26412|NCT02889978|Cancer Screening
26413|NCT02889978|High-Throughput Nucleotide Sequencing
26414|NCT02889978|Deep Sequencing
26415|NCT02889978|Circulating cell-free tumor DNA
26416|NCT02889965|Multiple sclerosis
26417|NCT02889965|Pharmacoepidemiology
26418|NCT02889965|Disease modifying drugs
26419|NCT02889965|Neuro-myelitis optica
26420|NCT02889952|postoperative hypocalcemia
26421|NCT02889952|near infrared imaging
26422|NCT02889952|parathyroid autofluorescence
26423|NCT02889939|rehabilitation
26424|NCT02889939|recovery of function
26425|NCT02889939|environment
26426|NCT02889900|ovarian cancer
26427|NCT02889887|Preterm
26428|NCT02889887|Sensory Processing
26429|NCT02889887|Motor Development
26430|NCT02889874|Radiation therapy
26431|NCT02889874|omission
26432|NCT02889874|non-inferiority
26433|NCT02889874|breast cancer
26434|NCT02889861|Uveal melanoma
26435|NCT02889861|Cutaneous melanoma
26436|NCT02889835|Class II
26437|NCT02889835|molar and premolar
26438|NCT02889835|resin composite
26439|NCT02889835|adult
26440|NCT02889835|restoration
26441|NCT02889809|Growth Velocity
26442|NCT02889809|Prepubertal
26443|NCT02889809|Asthma
26444|NCT02889809|Paediatric
26445|NCT02889783|urodynamics
26446|NCT02889783|urethral sensation
26447|NCT02889783|urethral pain
26448|NCT02889757|tuberculosis
26449|NCT02889757|acetylcysteine
26450|NCT02889757|hepatotoxicity
26451|NCT02889744|Temperature
26452|NCT02889744|Hypothermia
26453|NCT02889744|Brain
26454|NCT02889744|Oxygen
26455|NCT02889744|Prognosis
26456|NCT02889731|Suicide
26457|NCT02889731|Heights
26458|NCT02889731|Suicide hot spots
26459|NCT02889731|Bridges
26460|NCT02889705|Ultrasonography
26461|NCT02889705|echotexture
26462|NCT02889705|K value
26463|NCT02889705|SCM muscles
26464|NCT02889705|CMT infants
26465|NCT02889692|lung cancer
26466|NCT02889692|traditional Chinese medicine
26467|NCT02889692|maintenance therapy
26468|NCT02889692|targeted therapy
26469|NCT02889679|Colonoscopy
26470|NCT02889679|Polypectomy
26471|NCT02889666|relapsed
26472|NCT02889666|non-small cell lung cancer
26473|NCT02889666|cisplatin
26474|NCT02889666|carboplatin
26475|NCT02889666|oxaliplatin
26476|NCT02889666|docetaxel
26477|NCT02889666|gemcitabine
26478|NCT02889627|Fecal Microbiota Transplantation
26479|NCT02889627|Gut microbiota
26480|NCT02889627|Brain-gut axis
26481|NCT02889627|Epilepsy
26482|NCT02889588|Refractive Surgery
26483|NCT02889588|higher order aberrations
26484|NCT02889562|apixaban
26485|NCT02889562|anticoagulant
26486|NCT02889562|CABG
26487|NCT02889562|thrombosis
26488|NCT02889562|fibrillation
26489|NCT02889536|parastomal hernia
26490|NCT02889536|ostomy
26491|NCT02889536|qualitative
26492|NCT02889536|phenomenological-hermeneutic research
26493|NCT02889536|symptoms
26494|NCT02889536|parastomal bulging
26495|NCT02889523|Front line therapy
26496|NCT02889523|Age-adjusted International Prognostic Index (aa-IPI) >1
26497|NCT02889523|60 to 80 years
26498|NCT02889510|diabetes
26499|NCT02889510|liraglutide
26500|NCT02889510|lung function
26501|NCT02889497|vaccine
26502|NCT02889497|safety
26503|NCT02889497|immunogenicity
26504|NCT02889458|Chinese
26505|NCT02889458|Breast Cancer
26506|NCT02889458|Women
26507|NCT02889419|Multiple Sclerosis
26508|NCT02889419|Disability
26509|NCT02889419|Underwear
26510|NCT02889419|Urinary catheter
26511|NCT02889419|Self-catheterisation
26512|NCT02889380|Infertility
26513|NCT02889380|Cetrotide
26514|NCT02889380|Assisted reproductive technology (ART)
26515|NCT02889341|Docosahexanoic Acid,
26516|NCT02889341|DNA fragmentation
26517|NCT02889341|male fertility
26518|NCT02889341|Sperm parameters improvements
26519|NCT02889315|PAH
26520|NCT02889315|treprostinil
26521|NCT02889315|LenusPro
26522|NCT02889315|implantable device
26523|NCT02889315|quality of life
26524|NCT02889289|traumatic brain injury
26525|NCT02889289|virtual reality
26526|NCT02889289|Xbox kinect
26527|NCT02889289|balance
26528|NCT02889250|geriatric
26529|NCT02889250|depression
26530|NCT02889250|deep brain stimulation
26531|NCT02889250|subcallosal cingulate
26532|NCT02889237|Fracture healing
26533|NCT02889237|Calcium supplementation
26534|NCT02889237|Vitamin D supplementation
26535|NCT02889237|HR-pQCT
26536|NCT02889224|Obesity
26537|NCT02889224|Cortisol
26538|NCT02889224|Hydrocortisone
26539|NCT02889224|Endocannabinoïds
26540|NCT02889198|web-based tool
26541|NCT02889198|child, preschool
26542|NCT02889198|nutrition
26543|NCT02889198|implementation
26544|NCT02889198|child care
26545|NCT02889185|Optical Coherence Tomography
26546|NCT02889185|Retinal camera
26547|NCT02889159|photoaging
26548|NCT02889146|Intensive Care Units
26549|NCT02889146|Physical Therapy Specialty
26550|NCT02889146|Critical illness
26551|NCT02889146|Muscle weakness
26552|NCT02889146|Bed rest
26553|NCT02889133|Iron deficiency
26554|NCT02889133|Transfusion
26555|NCT02889133|Blood donation
26556|NCT02889120|Drug advice by phone
26557|NCT02889120|Teleprescription
26558|NCT02889120|Medical call centre
26559|NCT02889120|Out of hours call
26560|NCT02889081|birth cohort
26561|NCT02889081|prenatal
26562|NCT02889081|skin barrier
26563|NCT02889081|atopic dermatitis
26564|NCT02889081|key nutritional factors
26565|NCT02889016|PANS
26566|NCT02889016|PANDAS
26567|NCT02888951|Diabetes
26568|NCT02888951|Diabetes Mellitus
26569|NCT02888951|Gastric Ultrasound
26570|NCT02888951|Preoperative fasting
26571|NCT02888951|Empty Stomach
26572|NCT02888951|Gastric Diabetes
26573|NCT02888912|glass ionomer cement
26574|NCT02888912|composite resin
26575|NCT02888886|systemic inflammation
26576|NCT02888873|composite resin
26577|NCT02888873|Clinical trial
26578|NCT02888873|FDI (World Dental Federation) criteria
26579|NCT02888860|genetic susceptibility
26580|NCT02888860|candida infection
26581|NCT02888860|colonization
26582|NCT02888847|post bleaching teeth sensitivity
26583|NCT02888834|elderly
26584|NCT02888834|adverse drug reactions
26585|NCT02888834|hospitalized subjects
26586|NCT02888834|community-dwelling
26587|NCT02888808|gastroesophageal reflux disease
26588|NCT02888808|women
26589|NCT02888808|Nigeria
26590|NCT02888808|obesity
26591|NCT02888795|hypertonic dextrose prolotherapy
26592|NCT02888795|osteoarthritis
26593|NCT02888769|Coronary artery disease
26594|NCT02888769|Text messages
26595|NCT02888769|Blood pressure
26596|NCT02888769|Lifestyle
26597|NCT02888769|Risk factors
26598|NCT02888756|Immunotherapy
26599|NCT02888756|mRNA
26600|NCT02888756|Lentivirus infection
26601|NCT02888756|Virus disease
26602|NCT02888756|Sexually transmitted disease
26603|NCT02888756|Immunodeficiency syndrome
26604|NCT02888730|cystic fibrosis
26605|NCT02888730|chronic rhinosinusitis
26606|NCT02888730|Lung Diseases
26607|NCT02888730|tobramycin
26608|NCT02888730|nebulized sonic aerosol therapy
26609|NCT02888704|Atopic dermatitis
26610|NCT02888704|Mesenchymal stem cells
26611|NCT02888678|ASPIRES
26612|NCT02888652|Coronary Heart Disease
26613|NCT02888652|PCI
26614|NCT02888652|Anti-Platelet Agents
26615|NCT02888613|mini-lumbotomy
26616|NCT02888613|mini-laparotomy
26617|NCT02888613|retroperitoneal approach
26618|NCT02888613|transperitoneal approach
26619|NCT02888613|abdominal aortic surgery
26620|NCT02888535|primary immunodeficiency
26621|NCT02888535|secondary immunodeficiency
26622|NCT02888535|intensive care unit
26623|NCT02888535|infection
26624|NCT02888535|adult
26625|NCT02888509|depression
26626|NCT02888509|anxiety disorder
26627|NCT02888509|bipolar disorder
26628|NCT02888509|Magnetic Resonance Imaging
26629|NCT02888483|physical activity
26630|NCT02888483|energy expenditure
26631|NCT02888457|nasopharyngeal carriage
26632|NCT02888457|Streptococcus pneumoniae
26633|NCT02888457|acute otitis media
26634|NCT02888457|day-care centers
26635|NCT02888431|pH
26636|NCT02888431|base deficit
26637|NCT02888431|lactate values
26638|NCT02888431|venous blood samples
26639|NCT02888431|arterial blood samples
26640|NCT02888418|vaccine
26641|NCT02888418|safety
26642|NCT02888418|immunogenicity
26643|NCT02888405|Body Composition
26644|NCT02888366|breast cancer
26645|NCT02888366|breath test
26646|NCT02888366|Menssana
26647|NCT02888366|Ancillary
26648|NCT02888366|Mammography
26649|NCT02888366|Rapid Point-of-care
26650|NCT02888366|Inflatable Bag
26651|NCT02888353|Magnetic Resonance Imaging and Pacemakers and Defibrillators and Devices
26652|NCT02888340|Acupuncture
26653|NCT02888340|Emergency Department
26654|NCT02888340|Pain
26655|NCT02888314|mHealth
26656|NCT02888314|Pokemon Go
26657|NCT02888288|adolescent
26658|NCT02888288|adolescence
26659|NCT02888288|HIV/AIDS
26660|NCT02888288|mental health
26661|NCT02888288|cognitive behavioral therapy
26662|NCT02888262|Bipolar disorder
26663|NCT02888262|Blood
26664|NCT02888262|Smartphone
26665|NCT02888262|Brain imaging
26666|NCT02888262|Cognition
26667|NCT02888262|Neuropsychology
26668|NCT02888249|Tobacco withdrawal
26669|NCT02888249|Autonomic Agents
26670|NCT02888236|Psoriasis
26671|NCT02888080|pulmonary sarcoidosis
26672|NCT02888080|sarcoidosis
26673|NCT02888080|canakinumab
26674|NCT02888080|autoimmune diseases
26675|NCT02888080|granulomas
26676|NCT02888080|inflammation
26677|NCT02888080|lung function testing
26678|NCT02888080|immunosuppressive agents
26679|NCT02888080|interleukin
26680|NCT02888080|interleukin-1Beta
26681|NCT02888080|[F-18]FDG-PET/CT
26682|NCT02888080|respiratory
26683|NCT02888080|pulmonary
26684|NCT02888080|steroids
26685|NCT02888080|corticosteroids
26686|NCT02888080|lung diseases
26687|NCT02888067|Neuromuscular Blockade
26688|NCT02888041|Cervical ripening
26689|NCT02888041|Pregnancy
26690|NCT02888041|Vaginal Administration
26691|NCT02888028|Remote ICD follow-up
26692|NCT02888028|HRQoL
26693|NCT02888028|Health related Quality of Life
26694|NCT02888028|Depression
26695|NCT02888028|anxiety
26696|NCT02888028|device acceptance
26697|NCT02888028|telemedicine
26698|NCT02888028|telemonitoring
26699|NCT02887989|Virtual Reality
26700|NCT02887989|Non-Opioid Pain Management
26701|NCT02887976|Prostate Cancer
26702|NCT02887976|Castrate Resistant Prostate Cancer (CRPC)
26703|NCT02887976|metastatic
26704|NCT02887976|castrate resistant
26705|NCT02887963|Iron Deficiency
26706|NCT02887963|Iron Deficiency Anemia
26707|NCT02887963|Pregnant Women
26708|NCT02887963|Gestation
26709|NCT02887963|China
26710|NCT02887963|Epidemiology
26711|NCT02887872|stroke
26712|NCT02887872|upper extremity function
26713|NCT02887872|rehabilitation
26714|NCT02887820|ECMO
26715|NCT02887820|TEG
26716|NCT02887807|Cardiac arrest
26717|NCT02887807|Shockable
26718|NCT02887807|Cyclosporine
26719|NCT02887794|pitch discrimination
26720|NCT02887794|auditory processing disorders
26721|NCT02887794|auditory perception
26722|NCT02887794|auditory-verbal hallucinations
26723|NCT02887794|theory of mind
26724|NCT02887729|Polycystic disease
26725|NCT02887703|ataxia
26726|NCT02887703|balance training
26727|NCT02887703|vibrotactile biofeedback
26728|NCT02887703|sensory augmentation
26729|NCT02887703|cerebellar ataxia
26730|NCT02887690|MPL
26731|NCT02887690|prosthetic limb
26732|NCT02887690|upper extremity
26733|NCT02887690|prosthesis
26734|NCT02887677|Dapagliflozin
26735|NCT02887677|Arterial Stiffness
26736|NCT02887677|Aortic Pressure
26737|NCT02887651|cerebrale metastases
26738|NCT02887651|radiotherapy
26739|NCT02887651|surgery
26740|NCT02887651|complete surgical resection
26741|NCT02887651|resection
26742|NCT02887651|cavity boost radiation therapy
26743|NCT02887651|observation
26744|NCT02887586|Auricular Needling
26745|NCT02887586|Mechanism Study
26746|NCT02887586|Anorexia
26747|NCT02887586|Cancer
26748|NCT02887573|Bowel preparation
26749|NCT02887573|Colorectal polyps
26750|NCT02887573|Colon capsule endoscopy
26751|NCT02887560|Right ventricle
26752|NCT02887560|Pulmonary transplantation
26753|NCT02887560|Strain
26754|NCT02887560|isovolumic acceleration (IVA)
26755|NCT02887495|scleroderma
26756|NCT02887495|biorepository
26757|NCT02887482|DNA
26758|NCT02887482|Vaccine
26759|NCT02887469|Hyponatremia
26760|NCT02887469|Hypertonic saline
26761|NCT02887469|Treatment
26762|NCT02887469|Osmotic demyelination syndrome
26763|NCT02887430|foot reflexology
26764|NCT02887430|pain intensity
26765|NCT02887430|health-related quality of life
26766|NCT02887417|platelet activation
26767|NCT02887391|hemodialysis
26768|NCT02887391|nutritional status
26769|NCT02887378|bronchial biopsy
26770|NCT02887365|colon cancer
26771|NCT02887365|MSI-L
26772|NCT02887365|MSS
26773|NCT02887365|Tegafur-Uracil
26774|NCT02887365|Low-Level Microsatellite-Instability
26775|NCT02887339|Informed Consent
26776|NCT02887339|Research donation request
26777|NCT02887339|Effective Communication
26778|NCT02887313|Rectal cancer
26779|NCT02887313|Neoadjuvant chemoradiation therapy
26780|NCT02887300|Quality of Health Care
26781|NCT02887300|Psychological Stress
26782|NCT02887300|Burnout
26783|NCT02887300|Health Care Professional
26784|NCT02887300|Mantra Meditation
26785|NCT02887300|Health Care Economics
26786|NCT02887274|Systemic Inflammatory Response Syndrome (SIRS)
26787|NCT02887274|Sepsis
26788|NCT02887274|Severe Sepsis
26789|NCT02887274|Septic shock
26790|NCT02887274|Multiple organ failure
26791|NCT02887261|Power Port
26792|NCT02887248|nab-paclitaxel
26793|NCT02887248|gemcitabine
26794|NCT02887222|Epidural
26795|NCT02887222|Labor analgesia
26796|NCT02887222|Programmed intermittent epidural bolus
26797|NCT02887196|Breast Cancer
26798|NCT02887183|Heart failure
26799|NCT02887183|Reduced left ventricular ejection fraction
26800|NCT02887183|HFrEF
26801|NCT02887183|NT-proBNP
26802|NCT02887183|Cardiac remodeling
26803|NCT02887170|Adolescent
26804|NCT02887170|Lost to contact
26805|NCT02887170|Recurrence
26806|NCT02887170|Long-term outcome
26807|NCT02887131|Subtalar arthritis
26808|NCT02887131|Subtalar instability
26809|NCT02887118|Erythrocytes
26810|NCT02887118|Sickle Cell Disease
26811|NCT02887092|health determinants
26812|NCT02887092|epidemiology
26813|NCT02887092|maintaining autonomy
26814|NCT02887092|psychology
26815|NCT02887092|osteoarthritis
26816|NCT02887092|perceived health
26817|NCT02887053|MRI
26818|NCT02887053|Healthy subjects
26819|NCT02887040|Diffuse, intrinsic brain stem glioma
26820|NCT02887040|Antineoplaston therapy
26821|NCT02887040|Radiation
26822|NCT02887014|bowel preparation
26823|NCT02887014|colonoscopy
26824|NCT02887014|inpatients
26825|NCT02887014|cathartics
26826|NCT02887001|cost study
26827|NCT02887001|clinical pharmacist
26828|NCT02886988|Botulinum toxin type A, scar
26829|NCT02886975|Renal Insufficiency, Chronic
26830|NCT02886975|Diet, Protein-Restricted
26831|NCT02886936|transtibial amputees
26832|NCT02886910|Chorioamnionitis
26833|NCT02886910|Early onset neonatal sepsis
26834|NCT02886910|Antibiotics
26835|NCT02886910|Clinical observation
26836|NCT02886897|Refractory solid tumors
26837|NCT02886897|Dendritic and Cytokine-induced killer cell
26838|NCT02886897|Anti-PD-1 antibody
26839|NCT02886897|Combination immunotherapy
26840|NCT02886884|Diabetes
26841|NCT02886884|Endothelial dysfunction
26842|NCT02886884|Stem cells
26843|NCT02886858|Depression
26844|NCT02886858|Moods disorders
26845|NCT02886858|electroconvulsive therapy
26846|NCT02886845|SNP,Breast Neoplasms
26847|NCT02886832|Prostate Health
26848|NCT02886819|Whole body vibration
26849|NCT02886819|Tonic vibration reflex
26850|NCT02886819|Bone myoregulation reflex
26851|NCT02886806|closed loop
26852|NCT02886806|remifentanil
26853|NCT02886806|propofol
26854|NCT02886767|skin to skin contact
26855|NCT02886754|Clinical Communication
26856|NCT02886754|ISBAR
26857|NCT02886754|Simulation
26858|NCT02886754|Performance
26859|NCT02886754|Non technical skills
26860|NCT02886754|Proficiency
26861|NCT02886741|campaign
26862|NCT02886741|surgical site infection
26863|NCT02886741|orthopedic surgery
26864|NCT02886741|quality improvement
26865|NCT02886741|infection control
26866|NCT02886650|Paediatrics
26867|NCT02886650|epilepsy surgery
26868|NCT02886650|genetic mutation
26869|NCT02886650|focal seizures
26870|NCT02886637|A baumannii infection
26871|NCT02886637|Immunosuppression
26872|NCT02886637|prognosis
26873|NCT02886637|immune function
26874|NCT02886585|Brain Metastases
26875|NCT02886559|demethylating agent
26876|NCT02886559|chidamide
26877|NCT02886533|Major haemorrhage
26878|NCT02886533|Oral anticoagulation
26879|NCT02886533|Antiplatelet drugs
26880|NCT02886533|Gastrointestinal bleeding
26881|NCT02886533|Intracranial haemorrhage
26882|NCT02886520|Urinary incontinence
26883|NCT02886520|Materials
26884|NCT02886520|Surgery
26885|NCT02886520|Transobturator tape
26886|NCT02886520|Polyvinylidene fluoride
26887|NCT02886520|Polypropylene
26888|NCT02886481|thyroidectomy
26889|NCT02886481|Electrophysiologic
26890|NCT02886481|vocal cord movement
26891|NCT02886429|dexmedetomidine
26892|NCT02886429|bupivacaine
26893|NCT02886429|Ultrasound guided paravertebral block
26894|NCT02886429|pain
26895|NCT02886429|post-thoracotomy
26896|NCT02886416|HIV infection
26897|NCT02886390|remote ischemic conditioning
26898|NCT02886390|r-tPA thrombolytic therapy
26899|NCT02886351|Moderate Sedation
26900|NCT02886351|Pediatric Dentistry
26901|NCT02886351|Anxiety
26902|NCT02886325|Receipt of Preventive Cancer Screening
26903|NCT02886299|Fibrates
26904|NCT02886299|Statins
26905|NCT02886299|Hemodialysis
26906|NCT02886299|Dyslipidemia
26907|NCT02886299|Improved Oxidative Stress
26908|NCT02886299|Egypt
26909|NCT02886273|Sudden Cardiac Arrest
26910|NCT02886273|Out-of-hospital
26911|NCT02886273|Ventricular fibrillation
26912|NCT02886273|Classification
26913|NCT02886273|Mechanisms
26914|NCT02886273|Biomarkers
26915|NCT02886234|HIV
26916|NCT02886234|Mindfulness
26917|NCT02886234|Adherence behaviors
26918|NCT02886234|Stress
26919|NCT02886234|Depression
26920|NCT02886221|Hallux Valgus
26921|NCT02886221|Reverdin-Isham Osteotomy
26922|NCT02886221|Minimally Invasive Surgery
26923|NCT02886221|Percutaneous Distal Osteotomy
26924|NCT02886221|First Ray
26925|NCT02886221|Forefoot
26926|NCT02886182|chronic hepatitis B
26927|NCT02886182|pregnancy
26928|NCT02886182|Cellular immune response
26929|NCT02886182|Clinical implications
26930|NCT02886169|Sacha Inchi
26931|NCT02886169|High-fat meal
26932|NCT02886169|Postprandial inflammatory responses
26933|NCT02886156|OSA
26934|NCT02886156|CPAP
26935|NCT02886156|cognitive function
26936|NCT02886156|gut microbiota
26937|NCT02886156|metabolomics
26938|NCT02886130|Alpha-GPC
26939|NCT02886130|Volleyball
26940|NCT02886130|Athletes
26941|NCT02886130|Executive functions
26942|NCT02886130|Vertical jump
26943|NCT02886130|Peak power
26944|NCT02886104|synchronous
26945|NCT02886104|metachronous
26946|NCT02886104|colorectal liver metastasis
26947|NCT02886104|resection
26948|NCT02886104|ablation
26949|NCT02886091|Keloids
26950|NCT02886091|Shaving
26951|NCT02886091|Ears
26952|NCT02886091|Cryosurgery
26953|NCT02886091|Hypertrophic scars
26954|NCT02886065|Myeloma
26955|NCT02886052|Cognitive behavior therapy
26956|NCT02886052|Internet treatment
26957|NCT02886052|Self-help treatment
26958|NCT02886052|Insomnia
26959|NCT02886052|ICBT
26960|NCT02886052|CBT-i
26961|NCT02886052|Bereavement
26962|NCT02886039|Cardiorespiratory arrest
26963|NCT02886039|Neurologic outcome
26964|NCT02886039|Electroencephalogram
26965|NCT02886039|Somatosensory evoked potential
26966|NCT02886039|Synek classification
26967|NCT02886039|Cerebral performance category
26968|NCT02886039|Hypothermia
26969|NCT02886026|Laser
26970|NCT02886026|Bladder cancer
26971|NCT02886026|Treatment
26972|NCT02886026|Outpatient
26973|NCT02886026|TUR-BT
26974|NCT02886013|prevalence
26975|NCT02885974|Celecoxib
26976|NCT02885974|Bladder Cancer
26977|NCT02885909|type 2 diabetes
26978|NCT02885909|inpatient
26979|NCT02885909|glucose control
26980|NCT02885909|continue glucose monitor
26981|NCT02885896|Call center
26982|NCT02885896|nurses
26983|NCT02885896|pediatrics
26984|NCT02885896|standardized messages
26985|NCT02885896|family counseling
26986|NCT02885870|biomarker
26987|NCT02885870|spinal cord disease
26988|NCT02885870|resonance imaging
26989|NCT02885870|electrophysiology
26990|NCT02885831|Abduction splint
26991|NCT02885831|Pubo-femoral distance
26992|NCT02885792|Schizophrenia
26993|NCT02885792|Cardiovascular disease
26994|NCT02885792|Premature mortality
26995|NCT02885792|Arteriosclerosis
26996|NCT02885792|Risk factor
26997|NCT02885792|Intervention
26998|NCT02885792|Treatment
26999|NCT02885792|Somatic morbidity
27000|NCT02885766|CML
27001|NCT02885766|Myeloid leukaemia chronic
27002|NCT02885766|CML progression
27003|NCT02885766|Chronic phase chronic myeloid leukemia
27004|NCT02885766|PF-114
27005|NCT02885766|Cytogenetic response CCyR
27006|NCT02885766|Major molecular response MMR
27007|NCT02885766|Complete molecular response CMR
27008|NCT02885766|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
27009|NCT02885766|2-nd generation Bcr-Abl inhibitors resistant
27010|NCT02885753|colorectal
27011|NCT02885753|cancer
27012|NCT02885753|metastasis
27013|NCT02885753|hepatic
27014|NCT02885701|postoperative dressing
27015|NCT02885701|postoperative splint
27016|NCT02885701|mini-open carpal tunnel release
27017|NCT02885688|Septic Shock
27018|NCT02885688|Sepsis
27019|NCT02885688|Standard of care
27020|NCT02885688|Liquid nutrition
27021|NCT02885688|Metabolic support
27022|NCT02885688|Enteral nutrition
27023|NCT02885688|Insulin Drip
27024|NCT02885688|Glucose Drip
27025|NCT02885662|Primary aldosteronism
27026|NCT02885662|Hypertension
27027|NCT02885662|mineralocorticoid receptor antagonist
27028|NCT02885636|Heart Failure with Preserved Ejection Fraction
27029|NCT02885636|Pulmonary Hypertension
27030|NCT02885597|Juanbi Pill
27031|NCT02885597|Methotrexate
27032|NCT02885597|Active
27033|NCT02885597|Rheumatoid Arthritis
27034|NCT02885584|Mechanical ventilation
27035|NCT02885558|Receptors, Calcium Channel Blocker
27036|NCT02885532|alcohol
27037|NCT02885519|Vocational Rehabilitation
27038|NCT02885519|Common Mental Disorders
27039|NCT02885519|Return to Work
27040|NCT02885519|Mental Health Services
27041|NCT02885519|Psychological Stress
27042|NCT02885519|Adjustment Disorder
27043|NCT02885519|Burnout
27044|NCT02885519|Integration
27045|NCT02885519|Cognitive Behavior Therapy
27046|NCT02885493|Parkinson march
27047|NCT02885467|Total Knee Arthroplasty
27048|NCT02885441|Inflammation
27049|NCT02885389|Infantile spasms
27050|NCT02885389|West syndrome
27051|NCT02885389|variant
27052|NCT02885389|mutation
27053|NCT02885389|CNV
27054|NCT02885389|sequencing
27055|NCT02885376|Mucositis
27056|NCT02885337|Frail Elderly
27057|NCT02885337|Arthroplasty
27058|NCT02885337|Frailty
27059|NCT02885324|High Grade Glioma
27060|NCT02885324|Cabozantinib
27061|NCT02885311|Drinking
27062|NCT02885311|Excessive drinking
27063|NCT02885311|Alcohol use disorders
27064|NCT02885311|Primary Care
27065|NCT02885285|Parkinson's disease
27066|NCT02885285|fatigue
27067|NCT02885285|anxiety
27068|NCT02885285|depression
27069|NCT02885285|exercise
27070|NCT02885272|Malignant neoplasms of eye brain and other parts of central nervous system
27071|NCT02885272|Glioblastoma
27072|NCT02885272|FDG PET
27073|NCT02885272|CT
27074|NCT02885272|MRI
27075|NCT02885246|Panama
27076|NCT02885246|Influenza B
27077|NCT02885246|Influenza A
27078|NCT02885246|Strain circulation
27079|NCT02885246|Database
27080|NCT02885233|Fall Prevention
27081|NCT02885233|Multiple Sclerosis
27082|NCT02885233|Web-based education
27083|NCT02885233|Self-efficacy
27084|NCT02885207|Limbic encephalitis
27085|NCT02885207|anti-neuronal antibodies
27086|NCT02885194|Parkinson Disease
27087|NCT02885194|Pain
27088|NCT02885194|Deep Brain Stimulation
27089|NCT02885194|Laser-Evoked Potentials
27090|NCT02885168|vasoreactivity
27091|NCT02885168|recombinant activated protein C
27092|NCT02885116|NHF
27093|NCT02885116|pulmonary hypertension
27094|NCT02885103|NHF
27095|NCT02885103|nasal highflow
27096|NCT02885038|Platelet Transfusion
27097|NCT02885025|hypersensitivity
27098|NCT02885025|antioxidants
27099|NCT02884999|trauma
27100|NCT02884999|bleeding
27101|NCT02884999|coagulopathy
27102|NCT02884999|guidelines compliance
27103|NCT02884999|recommendation
27104|NCT02884999|transfusion
27105|NCT02884986|Etoricoxib
27106|NCT02884986|Spinal anaesthesia
27107|NCT02884986|Postoperative pain
27108|NCT02884973|congenital heart
27109|NCT02884973|NIRS
27110|NCT02884960|Uterine Fibroids
27111|NCT02884960|Embolization
27112|NCT02884947|Brain Neoplasms
27113|NCT02884947|Magnetic Resonance Imaging
27114|NCT02884947|Neurosurgery
27115|NCT02884934|venous thromboembolism
27116|NCT02884934|recurrent venous thromboembolism
27117|NCT02884934|anticoagulant-related bleeding
27118|NCT02884921|Postoperative pain
27119|NCT02884921|Dental treatment
27120|NCT02884921|Paracetamol
27121|NCT02884895|Intubating Laryngeal Tube Suction
27122|NCT02884895|Blind intubation
27123|NCT02884882|Stroke Basal Ganglia
27124|NCT02884882|Emotional change
27125|NCT02884869|Blind intubation,
27126|NCT02884869|Laryngeal Mask Airway
27127|NCT02884856|color
27128|NCT02884856|dentistry
27129|NCT02884856|gender
27130|NCT02884843|Laryngeal Tube
27131|NCT02884843|blind intubation
27132|NCT02884843|fiberoptic
27133|NCT02884804|Postpartum Hemorrhage
27134|NCT02884804|Immature platelet
27135|NCT02884791|FGF21
27136|NCT02884791|Fibroblast growth factor
27137|NCT02884791|fructose
27138|NCT02884778|pain
27139|NCT02884778|monitoring
27140|NCT02884778|anesthesia
27141|NCT02884765|mandibular condyle
27142|NCT02884765|subcondylar
27143|NCT02884765|mandible
27144|NCT02884765|fracture
27145|NCT02884700|Legionella
27146|NCT02884700|Legionnaires' disease
27147|NCT02884700|Diagnosis
27148|NCT02884700|Prognosis
27149|NCT02884674|Obsessive-Compulsive Disorder
27150|NCT02884674|Transcranial Magnetic Stimulation
27151|NCT02884648|Malignant neoplasms of female genital organs
27152|NCT02884648|Ovarian Cancer
27153|NCT02884648|Fallopian tube cancer
27154|NCT02884648|Primary peritoneal cancer
27155|NCT02884648|Bevacizumab
27156|NCT02884648|Avastin
27157|NCT02884648|Anti-VEGF monoclonal antibody
27158|NCT02884648|rhuMab-VEGF
27159|NCT02884635|Methotrexate
27160|NCT02884635|ASP1707
27161|NCT02884635|Rheumatoid arthritis
27162|NCT02884622|Lung disease
27163|NCT02884622|Epigenetics
27164|NCT02884622|DNA methylation
27165|NCT02884622|Modifier genes
27166|NCT02884596|Inferior alveolar nerve block
27167|NCT02884596|irreversible pulpitis
27168|NCT02884596|selective serotonin reuptake inhibitor antidepressants
27169|NCT02884583|Food allergy
27170|NCT02884583|asthma
27171|NCT02884583|Predictive factor
27172|NCT02884583|Exacerbation
27173|NCT02884583|Prevalence
27174|NCT02884570|Tracheotomy
27175|NCT02884570|Anxiety
27176|NCT02884570|Depression
27177|NCT02884570|Back Home
27178|NCT02884518|dopamine receptor occupancy
27179|NCT02884518|antipsychotics
27180|NCT02884518|positron emission tomography
27181|NCT02884492|inflammation
27182|NCT02884492|aging
27183|NCT02884492|mild cognitive impairment
27184|NCT02884453|gastrooesophageal carcinoma
27185|NCT02884427|Direct current
27186|NCT02884427|Dynamometry
27187|NCT02884427|Hand strength
27188|NCT02884427|Electrotherapy
27189|NCT02884427|Transcutaneous Electric Nerve Stimulation
27190|NCT02884414|Knee Pathology
27191|NCT02884375|Elderly
27192|NCT02884375|Cancer
27193|NCT02884375|Geriatric assessment
27194|NCT02884375|Treatment
27195|NCT02884375|Epidemiology
27196|NCT02884362|melanoma clinical biological database
27197|NCT02884349|Computer aided orthopaedic surgery
27198|NCT02884349|Implant orientation
27199|NCT02884349|Range of motion
27200|NCT02884310|Remifentanil
27201|NCT02884310|Heart Rate Variability
27202|NCT02884310|Pupil dilation
27203|NCT02884310|SPI
27204|NCT02884284|breast cancer
27205|NCT02884284|database
27206|NCT02884271|CPR
27207|NCT02884271|cardiac arrest
27208|NCT02884271|operating room
27209|NCT02884258|Assisted Reproductive Technology
27210|NCT02884258|Obesity
27211|NCT02884258|Bariatric Surgery
27212|NCT02884258|Infertility
27213|NCT02884258|Fertility Preservation
27214|NCT02884245|Fertility
27215|NCT02884245|Reproductive processes
27216|NCT02884245|In vitro fertilization
27217|NCT02884245|Intracytoplasmic sperm injection
27218|NCT02884245|Estrogens
27219|NCT02884245|Follicule Stimulating Hormon
27220|NCT02884219|Early treatment
27221|NCT02884219|Expectative treatment
27222|NCT02884219|Patent ductus arteriosus
27223|NCT02884219|Preterm
27224|NCT02884206|heart failure
27225|NCT02884206|cognition
27226|NCT02884206|positron emission tomography
27227|NCT02884206|magnetic resonance imaging
27228|NCT02884206|LCZ696
27229|NCT02884206|valsartan
27230|NCT02884193|Cooling
27231|NCT02884193|Cryotherapy
27232|NCT02884193|isometric Force
27233|NCT02884193|Palmar Grip
27234|NCT02884193|Dynamometry
27235|NCT02884180|Dexamethasone
27236|NCT02884180|Arthroplasty, Replacement, Knee
27237|NCT02884180|Revision
27238|NCT02884154|Endoscopic ultrasonography
27239|NCT02884154|Biopsy
27240|NCT02884154|Gastrointestinal tract
27241|NCT02884154|Subepithelial tumor
27242|NCT02884141|Renal Artery Obstruction
27243|NCT02884141|Carotid Artery Diseases
27244|NCT02884141|Genetic Association Studies
27245|NCT02884102|genetic sequencing
27246|NCT02884102|relapsed
27247|NCT02884076|Hemorrhoids
27248|NCT02884076|Sodergren score
27249|NCT02884076|Validation
27250|NCT02884063|PGS
27251|NCT02884063|PGD
27252|NCT02884063|free embryo DNA
27253|NCT02884063|NGS
27254|NCT02884037|NAFLD
27255|NCT02884037|Rifaximin
27256|NCT02884037|Endotoxin and Homeostatic Model Assessment
27257|NCT02884024|obesity
27258|NCT02884024|inflammation
27259|NCT02884024|cancer risk
27260|NCT02884011|Chronic antihypertensives
27261|NCT02884011|Septic shock
27262|NCT02884011|Vasopressor
27263|NCT02884011|Vasopressor dosing
27264|NCT02883998|home-based physical therapy
27265|NCT02883998|outpatient physical therapy
27266|NCT02883998|unicompartmental knee arthroplasty
27267|NCT02883998|PT (Physical Therapy)
27268|NCT02883998|osteoarthritis
27269|NCT02883972|Immunization
27270|NCT02883972|Behavioural insights
27271|NCT02883972|Children
27272|NCT02883959|critically ill
27273|NCT02883959|mechanical ventilation
27274|NCT02883959|pain
27275|NCT02883959|nursing
27276|NCT02883959|music
27277|NCT02883842|Coronary artery disease
27278|NCT02883842|Diabetes
27279|NCT02883842|Text messages
27280|NCT02883777|Kidney Transplantation
27281|NCT02883777|Low Glycemic Index
27282|NCT02883777|High Protein
27283|NCT02883764|eicosapentaenoic acid
27284|NCT02883764|EPA
27285|NCT02883764|docosahexaenoic acid
27286|NCT02883764|DHA
27287|NCT02883764|omega-3 index
27288|NCT02883751|diabetes mellitus
27289|NCT02883751|amputation stumps
27290|NCT02883751|diabetic foot
27291|NCT02883751|phototherapy
27292|NCT02883751|clinical trial
27293|NCT02883725|Esophageal atresia
27294|NCT02883712|epilepsy
27295|NCT02883712|pharmacoresistant
27296|NCT02883712|antiepileptic drug
27297|NCT02883712|pharmacokinetic
27298|NCT02883712|pharmacodynamic
27299|NCT02883712|pharmacogenetic
27300|NCT02883699|Breast cancer
27301|NCT02883699|Prostate cancer
27302|NCT02883699|Exercise prescription
27303|NCT02883699|High intensity interval training
27304|NCT02883699|Daily undulating periodization training
27305|NCT02883699|Aerobic training
27306|NCT02883699|Resistance training
27307|NCT02883699|Physical fitness
27308|NCT02883699|Exercise
27309|NCT02883686|depression
27310|NCT02883686|pregnancy
27311|NCT02883686|behavioral activation
27312|NCT02883686|peer delivery
27313|NCT02883686|effectiveness
27314|NCT02883673|Postpartum Hemorrhage
27315|NCT02883660|genetics
27316|NCT02883660|Antidepressants
27442|NCT02882698|physiotherapy
27317|NCT02883647|chronic hepatitis b, nucleos(t)ide analog
27318|NCT02883634|Back pain
27319|NCT02883634|spinal manipulation
27320|NCT02883621|upper endoscopy
27321|NCT02883621|cap assisted endoscopy
27322|NCT02883621|esophagus
27323|NCT02883608|Papilla
27324|NCT02883608|major duodenal papilla
27325|NCT02883608|ampulla of vater
27326|NCT02883595|thymosin alpha 1; sepsis; monocyte; pharmacokinetics
27327|NCT02883582|asthma ,hydrogen
27328|NCT02883569|Low back pain
27329|NCT02883569|Intervertebral Disc Degeneration
27330|NCT02883569|Spinal stenosis
27331|NCT02883569|Comparative Effectiveness Research
27332|NCT02883569|Cost-Benefit Analysis
27333|NCT02883556|Carcinoma
27334|NCT02883556|Squamous Cell
27335|NCT02883556|Skin
27336|NCT02883556|pembrolizumab
27337|NCT02883556|Programmed Cell Death 1 Ligand 1
27338|NCT02883517|cell-free circulating DNA;
27339|NCT02883517|digital PCR
27340|NCT02883517|liquid biopsy
27341|NCT02883504|E/e' ratio
27342|NCT02883504|Doppler echocardiography, filling pressure
27343|NCT02883504|Left Ventricular end-Diastolic Pressure
27344|NCT02883465|diaphragmatic dysfunction
27345|NCT02883465|mechanical ventilation weaning
27346|NCT02883465|failure extubation rate
27347|NCT02883439|MP29-02
27348|NCT02883426|H3N2v Influenza Viruses
27349|NCT02883413|Adolescents
27350|NCT02883413|Cognitive Flexibility
27351|NCT02883413|Behavioral Flexibility
27352|NCT02883387|DIEP flap
27353|NCT02883387|Deep inferior epigastric artery perforator flap
27354|NCT02883374|cephalic and cervical adenocystic Carcinoma
27355|NCT02883374|Chidamide
27356|NCT02883309|Hemodialysis
27357|NCT02883309|Skeletal muscle
27358|NCT02883309|Exercise
27359|NCT02883309|Rehabilitation
27360|NCT02883309|Disability Evaluation
27361|NCT02883257|Major Depression
27362|NCT02883257|Major Depressive Disorder
27363|NCT02883257|Persistent Depressive Disorder
27364|NCT02883257|Cognitive Behavioral Therapy
27365|NCT02883257|Biomarkers
27366|NCT02883218|immunosuppression
27367|NCT02883218|community-acquired sepsis
27368|NCT02883218|mortality
27369|NCT02883192|Cesarean section
27370|NCT02883192|spinal anesthesia
27371|NCT02883192|hypotension
27372|NCT02883192|ondansetron
27373|NCT02883153|Zirconium-89
27374|NCT02883153|PET/CT
27375|NCT02883153|imaging
27376|NCT02883153|girentuximab
27377|NCT02883140|Sialography
27378|NCT02883140|Cone-beam CT
27379|NCT02883140|MRI sialography
27380|NCT02883140|non tumor salivary symptoms
27381|NCT02883127|Motivational Interviewing
27382|NCT02883127|Diet
27383|NCT02883127|Carbohydrates
27384|NCT02883127|Psychosocial factors
27385|NCT02883114|PF-06648671
27386|NCT02883114|GSM
27387|NCT02883114|CYP3A
27388|NCT02883114|drug interaction
27389|NCT02883088|Optical coherence tomograhpy
27390|NCT02883088|registry
27391|NCT02883088|Coronary artery disease
27392|NCT02883036|tigecycline
27393|NCT02883036|treatment
27394|NCT02883036|mitochondrial biogenesis
27395|NCT02883036|metabolic characteristics
27396|NCT02883023|Bleomycin
27397|NCT02883023|Electroporation
27398|NCT02883010|Surgical incision
27399|NCT02883010|surgical complication
27400|NCT02883010|NPWT
27401|NCT02883010|negative pressure
27402|NCT02883010|colorectal surgery
27403|NCT02883010|dehisced
27404|NCT02882971|chronic pain
27405|NCT02882971|rating scale
27406|NCT02882958|Radiology
27407|NCT02882932|peritonitis
27408|NCT02882932|solutions
27409|NCT02882932|normal saline
27410|NCT02882932|infection
27411|NCT02882932|peritoneal lavage
27412|NCT02882906|Stroke
27413|NCT02882906|Pain
27414|NCT02882906|Shoulder
27415|NCT02882867|Prospective
27416|NCT02882867|Epidemiology
27417|NCT02882867|Track and Field
27418|NCT02882841|AIEC (Adherent and Invasive Escherichia Coli)
27419|NCT02882841|Mucosal Healing
27420|NCT02882841|Non-invasive biomarkers
27421|NCT02882815|IrisFIT PFO
27422|NCT02882802|anger
27423|NCT02882802|aggression
27424|NCT02882763|Early intervention
27425|NCT02882763|ECCE
27426|NCT02882763|Intervention study
27427|NCT02882763|Child development
27428|NCT02882763|At-risk families
27429|NCT02882763|Psychosocial stress
27430|NCT02882763|Prevention
27431|NCT02882763|Educational opportunities
27432|NCT02882763|Randomized controlled trial
27433|NCT02882763|Evaluation
27434|NCT02882763|Parenting
27435|NCT02882763|Parent-child interaction
27436|NCT02882750|Lung Cancer
27437|NCT02882750|Quality of Life
27438|NCT02882750|VATS
27439|NCT02882750|SABR
27440|NCT02882698|Down syndrome
27441|NCT02882698|motor skills
27443|NCT02882698|mobile telephone
27444|NCT02882698|exposure to virtual reality therapy
27445|NCT02882685|Roux-en-Y gastric bypass
27446|NCT02882685|Mini-gastric bypass
27447|NCT02882685|Single anastomosis gastric bypass
27448|NCT02882659|Clinical Trial, Phase I
27449|NCT02882646|stroke
27450|NCT02882646|cerebral palsy
27451|NCT02882646|rehabilitation
27452|NCT02882646|robotics
27453|NCT02882646|therapy
27454|NCT02882646|bilateral
27455|NCT02882633|lumbar plexus block
27456|NCT02882633|fascia iliac block
27457|NCT02882633|quality of recovery score
27458|NCT02882633|pain score
27459|NCT02882620|Colorectal neoplasm
27460|NCT02882620|Screening
27461|NCT02882620|Patient navigation
27462|NCT02882620|Randomized controlled trial
27463|NCT02882620|Cost-benefit analysis
27464|NCT02882620|Health behavior
27465|NCT02882620|Health equity
27466|NCT02882620|American Indians
27467|NCT02882620|Community-based participatory research
27468|NCT02882620|Fecal occult blood test
27469|NCT02882607|HIV
27470|NCT02882607|Prevention
27471|NCT02882607|unintended pregnancy
27472|NCT02882607|Malawi
27473|NCT02882607|adolescent women
27474|NCT02882607|community
27475|NCT02882607|rural
27476|NCT02882581|Metformin
27477|NCT02882581|Pharmacokinetics
27478|NCT02882581|Organic cation transporter
27479|NCT02882581|Multidrug and toxin extrusion
27480|NCT02882581|Pharmacogenetics
27481|NCT02882581|positron emission tomography
27482|NCT02882542|cerebral oxygen metabolism
27483|NCT02882542|functional near-infrared spectroscopy
27484|NCT02882542|partial pressure of carbon dioxide
27485|NCT02882542|heart rate variability
27486|NCT02882542|blood pressure
27487|NCT02882542|affect
27488|NCT02882542|mood
27489|NCT02882542|respiration
27490|NCT02882542|systematic randomized cross-over study
27491|NCT02882542|systemic physiology
27492|NCT02882542|electro-dermal activity
27493|NCT02882542|pulse-respiratory quotient
27494|NCT02882529|cerebral oxygen metabolism
27495|NCT02882529|functional near-infrared spectroscopy
27496|NCT02882529|partial pressure of carbon dioxide
27497|NCT02882529|heart rate variability
27498|NCT02882529|blood pressure
27499|NCT02882529|affect
27500|NCT02882529|mood
27501|NCT02882529|respiration
27502|NCT02882529|systematic randomized cross-over study
27503|NCT02882529|systemic physiology
27504|NCT02882529|electro-dermal activity
27505|NCT02882529|pulse-respiratory quotient
27506|NCT02882516|cerebral oxygen metabolism
27507|NCT02882516|functional near-infrared spectroscopy
27508|NCT02882516|partial pressure of carbon dioxide
27509|NCT02882516|heart rate variability
27510|NCT02882516|blood pressure
27511|NCT02882516|affect
27512|NCT02882516|mood
27513|NCT02882516|respiration
27514|NCT02882516|systematic randomized cross-over study
27515|NCT02882516|systemic physiology
27516|NCT02882516|electro-dermal activity
27517|NCT02882516|pulse-respiratory quotient
27518|NCT02882503|Endoscopic ultrasound
27519|NCT02882503|Radiofrequency ablation
27520|NCT02882503|Pancreas
27521|NCT02882490|Tourette syndrome
27522|NCT02882464|gingival recession
27523|NCT02882464|mucogingival surgery
27524|NCT02882451|bile duct
27525|NCT02882451|endoscopic retrograde cholangiopancreatography
27526|NCT02882451|pinaverium bromide
27527|NCT02882425|selexipag
27528|NCT02882425|bioavailability
27529|NCT02882412|effectiveness
27530|NCT02882412|buprenorphine/naloxone
27531|NCT02882412|iatrogenic opioid dependence
27532|NCT02882399|athletes
27533|NCT02882373|Hypertensive diseases
27534|NCT02882373|Renal failure
27535|NCT02882373|High blood pressure
27536|NCT02882373|Proteinuria
27537|NCT02882373|L-Arginine
27538|NCT02882373|Placebo
27539|NCT02882373|Phone call
27540|NCT02882334|Focal Dystonia
27541|NCT02882334|Writer's cramp
27542|NCT02882321|Malignant Tumor of Lymphoid Hemopoietic and Related Tissue
27543|NCT02882321|Acute myeloid leukemia
27544|NCT02882321|AML
27545|NCT02882321|Relapsed/Refractory
27546|NCT02882321|IACS-010759
27547|NCT02882321|Phone Call follow up
27548|NCT02882282|Diseases of oral cavity salivary glands and jaws
27549|NCT02882282|High risk oral intra-epithelial neoplasias
27550|NCT02882282|IEN
27551|NCT02882282|Oral pre-malignant lesion(s)
27552|NCT02882282|History of invasive oral cancer
27553|NCT02882282|Pembrolizumab
27554|NCT02882282|Keytruda
27555|NCT02882282|MK-3475
27556|NCT02882282|SCH-900475
27557|NCT02882282|Observation only
27558|NCT02882269|locally advanced colon cancer
27559|NCT02882269|neoadjuvant chemotherapy
27560|NCT02882256|laceration
27561|NCT02882256|urinary tract infection
27562|NCT02882256|minor head injury
27563|NCT02882256|concussion
27564|NCT02882217|Double-blind
27565|NCT02882217|Randomized
27566|NCT02882217|Dose-escalating
27567|NCT02882217|Placebo-controlled
27568|NCT02882217|Phase I
27569|NCT02882217|Healthy volunteers
27570|NCT02882217|Bronchial asthma
27571|NCT02882217|Histamine glutarimide
27572|NCT02882217|EURRUS
27573|NCT02882191|contraception
27574|NCT02882178|Prostate cancer
27575|NCT02882178|cabazitaxel
27576|NCT02882178|consensus
27577|NCT02882178|conformity
27578|NCT02882178|prescription
27579|NCT02882178|conditions of use
27580|NCT02882165|COPD
27581|NCT02882165|Early Intervention
27582|NCT02882165|Risk
27583|NCT02882165|Stratification
27584|NCT02882152|Analgesia
27585|NCT02882152|Nerve Block
27586|NCT02882152|Pain, Postoperative
27587|NCT02882139|Electrical storm
27588|NCT02882126|PAH
27589|NCT02882126|Subcutaneous Treprostinil
27590|NCT02882126|Remodulin
27591|NCT02882126|6 Minute Walk Test
27592|NCT02882100|influenza
27593|NCT02882100|vaccine
27594|NCT02882100|vaccination
27595|NCT02882100|nursing home
27596|NCT02882100|cluster randomized trial
27597|NCT02882100|respiratory-related hospitalization
27598|NCT02882061|neck pain
27599|NCT02882061|physical examination
27600|NCT02882061|thoracic manipulation
27601|NCT02882048|Opioid addiction
27602|NCT02882048|Opioid weaning
27603|NCT02882035|pain
27604|NCT02882035|patient comfort
27605|NCT02882022|Eustachian tube dysfunction
27606|NCT02882022|Audiometry
27607|NCT02881996|appendicitis
27608|NCT02881996|pain
27609|NCT02881996|perforation
27610|NCT02881983|alcohol use disorder
27611|NCT02881983|emotion processing
27612|NCT02881983|abstinence
27613|NCT02881983|sympathetic system
27614|NCT02881983|parasympathetic system
27615|NCT02881957|critical illness
27616|NCT02881957|craniocerebral trauma
27617|NCT02881957|intracranial aneurysm
27618|NCT02881957|spinal cord injuries
27619|NCT02881957|seizures
27620|NCT02881957|meningitis
27621|NCT02881957|stroke
27622|NCT02881957|vitamin d deficiency
27623|NCT02881957|cholecalciferol
27624|NCT02881957|intracranial hemorrhages
27625|NCT02881944|Gulf War Illness
27626|NCT02881944|Diet
27627|NCT02881944|IBS
27628|NCT02881944|FODMAP
27629|NCT02881931|Huntington's disease
27630|NCT02881931|functional rating scale
27631|NCT02881931|cognitive pre-testing
27632|NCT02881931|patient reported outcome (PRO)
27633|NCT02881931|HDGEC participant at Pre-Manifest stage
27634|NCT02881931|HDGEC participant at Early-Manifest stage
27635|NCT02881931|Corresponding HDGEC participant companion
27636|NCT02881892|CAPD
27637|NCT02881892|Peritoneal solute transport rate
27638|NCT02881892|Dialysis adequacy
27639|NCT02881866|Air hunger
27640|NCT02881866|Work/effort
27641|NCT02881866|Aerosolized
27642|NCT02881866|Hypercapnia
27643|NCT02881866|Resistive load
27644|NCT02881866|Nebulised
27645|NCT02881853|healthy
27646|NCT02881853|atopic
27647|NCT02881827|Saliva
27648|NCT02881827|Low-level laser therapy
27649|NCT02881827|Masseter muscle
27650|NCT02881827|Salivary glands
27651|NCT02881801|accelerometry
27652|NCT02881775|TMS
27653|NCT02881775|rTMS
27654|NCT02881775|corticospinal
27655|NCT02881775|quadriceps
27656|NCT02881762|hepatitis C virus (HCV)
27657|NCT02881762|Maraviroc
27658|NCT02881762|Human immunodeficiency virus (HCV)
27659|NCT02881671|genetic
27660|NCT02881671|congenital atrioventricular block
27661|NCT02881671|progressive Cardiac Conduction Disease
27662|NCT02881658|Plant sterols
27663|NCT02881658|Low-Density Lipoprotein Cholesterol
27664|NCT02881658|Phytosterols
27665|NCT02881658|Soya Beverage
27666|NCT02881645|Intensive care units
27667|NCT02881645|Nursing Care
27668|NCT02881645|Critical incidents
27669|NCT02881645|Best practices
27670|NCT02881619|Tooth bleaching
27671|NCT02881593|Operating in Minimally Invasive
27672|NCT02881567|Multiple Sclerosis
27673|NCT02881567|Daclizumab
27674|NCT02881567|Tysabri-Switch
27675|NCT02881528|Type 1 Diabetes
27676|NCT02881528|Juvenile Diabetes
27677|NCT02881502|granulocyte activation
27678|NCT02881502|HDAC2
27679|NCT02881502|severe asthma
27680|NCT02881437|Primary Immunodeficiency
27681|NCT02881437|SubCutaneous Immunoglobulins
27682|NCT02881424|Familiarity
27683|NCT02881424|Recollection
27684|NCT02881424|Face Recognition
27685|NCT02881424|Alcohol dependence
27686|NCT02881424|Social cognition
27687|NCT02881411|self-soft tissue therapy
27688|NCT02881411|trigger points
27689|NCT02881411|feasibility study
27690|NCT02881398|Mobile Health
27691|NCT02881398|Telemedicine
27692|NCT02881398|Pocket-Echocardiography
27693|NCT02881385|Synchrony
27694|NCT02881385|Pressure Support Ventilation
27695|NCT02881372|oral food desensitization
27696|NCT02881372|food elimination
27697|NCT02881372|food reintroduction
27698|NCT02881346|Psoriasis vulgaris
27699|NCT02881346|Plaque
27700|NCT02881346|Topical
27701|NCT02881346|Calcipotriol
27702|NCT02881346|Foam
27703|NCT02881346|Spray
27704|NCT02881307|Rheumatoid Arthritis (RA)
27705|NCT02881307|Musculoskeletal Ultrasound (MSUS)
27706|NCT02881255|implantable cardioverter defibrillator
27707|NCT02881255|subcutaneous ICD
27708|NCT02881255|transvenous ICD
27709|NCT02881255|inherited arrhythmia syndrome
27710|NCT02881203|breast cancer
27711|NCT02881203|radiation
27712|NCT02881203|DIBH
27713|NCT02881203|cardiac toxicity
27714|NCT02881177|oxytocin
27715|NCT02881177|tolerability
27716|NCT02881177|HIV
27717|NCT02881177|men who have sex with men (MSM)
27718|NCT02881177|addiction
27719|NCT02881164|Glycemia
27720|NCT02881164|Satiety
27721|NCT02881164|Insulin
27722|NCT02881164|Breakfast
27723|NCT02881164|Low glycemic index
27724|NCT02881164|High glycemic index
27725|NCT02881151|Deep brain stimulation
27726|NCT02881151|DBS
27727|NCT02881151|Central thalamus
27728|NCT02881151|TBI
27729|NCT02881151|Traumatic brain injury
27730|NCT02881086|Acute lymphoblastic leukemia
27731|NCT02881086|Lymphoblastic lymphoma
27732|NCT02881086|Nelarabine
27733|NCT02881086|BCR-ABL
27734|NCT02881086|MRD
27735|NCT02881086|PEG-Asparaginase
27736|NCT02881086|Rituximab
27737|NCT02881073|Placental Growth Factor
27738|NCT02881073|Maternal Morbidity
27739|NCT02881073|Neonatal Morbidity
27740|NCT02881073|Pre-eclampsia
27741|NCT02881073|Heath Economics
27742|NCT02881060|Glucagon
27743|NCT02881060|Ethanol
27744|NCT02881034|Anemia
27745|NCT02881034|Antiviral Agents
27746|NCT02881034|Glomerular Filtration Rate
27747|NCT02881034|Hepatitis C
27748|NCT02881034|Ribavirin
27749|NCT02881034|Telaprevir
27750|NCT02881021|elastic tape
27751|NCT02881021|physiotherapy
27752|NCT02881021|rehabilitation
27753|NCT02881021|rotator cuff
27754|NCT02881021|shoulder pain
27755|NCT02881021|tendinopathy
27756|NCT02880995|dopamine receptor occupancy
27757|NCT02880995|antipsychotics
27758|NCT02880995|positron emission tomography
27759|NCT02880956|Tau
27760|NCT02880956|Nervous system diseases
27761|NCT02880956|Memory loss
27762|NCT02880956|Mild Alzheimer's Disease (AD)
27763|NCT02880956|Early Alzheimer's Disease
27764|NCT02880956|Early dementia
27765|NCT02880956|Mild Cognitive Impairment (MCI)
27766|NCT02880956|AD
27767|NCT02880956|Tauopathies
27768|NCT02880956|Neurodegenerative diseases
27769|NCT02880930|vitamin D
27770|NCT02880917|Attention
27771|NCT02880917|Memory (short and long-term)
27772|NCT02880917|Conflict monitoring tasks
27773|NCT02880917|Verbal fluency
27774|NCT02880878|Subcortical Intracerebral Hemorrhage
27775|NCT02880878|Intracerebral Hemorrhage
27776|NCT02880878|Intracranial Hemorrhages
27777|NCT02880878|ICH
27778|NCT02880878|Hemorrhage
27779|NCT02880878|Cerebrovascular Disorders
27780|NCT02880878|Brain Diseases
27781|NCT02880878|Central Nervous System Diseases
27782|NCT02880878|Nervous System Diseases
27783|NCT02880878|Vascular Diseases
27784|NCT02880878|Cardiovascular Diseases
27785|NCT02880878|Pathologic Processes
27786|NCT02880878|MIPS
27787|NCT02880878|Minimally Invasive Parafascicular Surgery
27788|NCT02880878|Neurosurgery
27789|NCT02880878|Medical Economic
27790|NCT02880878|Hospital Economics
27791|NCT02880865|vaccine
27792|NCT02880852|Systemic Lupus Erythematosus
27793|NCT02880852|Belimumab
27794|NCT02880852|Pharmacodynamics
27795|NCT02880852|safety tolerability
27796|NCT02880852|Pharmacokinetics
27797|NCT02880852|Chinese subjects
27798|NCT02880800|Analgesia, Patient-Controlled
27799|NCT02880800|Analgesics, Opioid
27800|NCT02880800|Drug-Related Side Effects and Adverse Reactions
27801|NCT02880774|Temporomandibular Joint Disorders
27802|NCT02880774|Mandibular Movement
27803|NCT02880774|Músculoesqueléticas Manipulations
27804|NCT02880774|Modalities of Physiotherapy.
27805|NCT02880761|hemodialysis
27806|NCT02880761|chronic renal failure
27807|NCT02880761|arteriovenous fistulae
27808|NCT02880748|Water exchange colonoscopy
27809|NCT02880748|Adenoma miss rate
27810|NCT02880748|Polyps
27811|NCT02880735|Myotonic Dystrophy
27812|NCT02880735|Noninvasive Ventilation
27813|NCT02880735|Respiratory Failure
27814|NCT02880722|Irritable Bowel Syndrome (IBS)
27815|NCT02880722|Experience Sampling Method (ESM)
27816|NCT02880722|Ecological Momentary Assessment (EMA)
27817|NCT02880722|Abdominal pain
27818|NCT02880696|Time Perception
27819|NCT02880696|Tactile Perception
27820|NCT02880696|Spectroscopy, Near-Infrared
27821|NCT02880683|Electrical Stimulation Therapy
27822|NCT02880683|Parasympathetic Nervous System
27823|NCT02880683|Sympathetic Fibers
27824|NCT02880683|Post Ganglionic
27825|NCT02880683|Congestive Heart Failure
27826|NCT02880683|Heart Failure
27827|NCT02880670|Rheumatoid
27828|NCT02880657|superoxide dismutase
27829|NCT02880657|melon concentrate
27830|NCT02880657|oxidative stress
27831|NCT02880657|physical training
27832|NCT02880644|Central retinal vein occlusion
27833|NCT02880644|OCT-A
27834|NCT02880644|CRVO
27835|NCT02880618|Heart Failure
27836|NCT02880618|Reduced ejection fraction
27837|NCT02880540|Adolescent
27838|NCT02880540|Bariatric
27839|NCT02880540|Obesity
27840|NCT02880540|Pain
27841|NCT02880540|Opiate-sparing
27842|NCT02880475|Moderate to severe chronic non-malignant pain
27843|NCT02880462|schizophrenia
27844|NCT02880462|sulforaphane
27845|NCT02880423|salpingectomy
27846|NCT02880423|cesarean section
27847|NCT02880423|tubal ligation
27848|NCT02880423|morbidity
27849|NCT02880410|Glioblastoma
27850|NCT02880410|NeuroBlate
27851|NCT02880410|LITT
27852|NCT02880410|Quality of Life
27853|NCT02880397|Anti-inflammatory agents, antimicrobials, Periodontitis
27854|NCT02880371|Advanced Solid Tumors
27855|NCT02880371|Pembrolizumab
27856|NCT02880371|ARRY-382
27857|NCT02880332|Chronic pain
27858|NCT02880332|Endogenous Pain Processing
27859|NCT02880332|Central sensitization
27860|NCT02880332|Pain neuroscience education
27861|NCT02880319|Bone Cancer
27862|NCT02880293|transplant conditioning
27863|NCT02880293|KIR/HLA based haploidentical donor selection
27864|NCT02880293|allogeneic hematopoietic cell transplantation
27865|NCT02879188|degenerative joint disease
27866|NCT02879188|total knee arthroplasty
27867|NCT02879188|physical therapy
27868|NCT02879188|arthroplasty, replacement, knee
27869|NCT02879149|Ankle Fusions
27870|NCT02879149|AUGMENT® Bone Graft
27871|NCT02879149|Autologous Bone Graft
27872|NCT02879149|arthritis
27873|NCT02879149|ankle pain
27874|NCT02879149|foot pain
27875|NCT02879149|hindfoot fracture
27876|NCT02879149|ankle fracture
27877|NCT02879136|Gait
27878|NCT02879136|Balance
27879|NCT02879136|PD
27880|NCT02879110|Sulforaphane
27881|NCT02879110|clinic trial
27882|NCT02879110|Autism Spectrum Disorder
27883|NCT02879110|Efficacy
27884|NCT02879110|Safety
27885|NCT02879110|Mechanism
27886|NCT02880254|body mass index change
27887|NCT02880254|weight loss
27888|NCT02880254|patient compliance
27889|NCT02880202|Massage Therapy
27890|NCT02880202|Hospice
27891|NCT02880202|Integrative Medicine
27892|NCT02880202|Palliative Care
27893|NCT02880202|Caregivers
27894|NCT02880189|Obesity NOS
27895|NCT02880189|NASH
27896|NCT02880189|NASH with Fibrosis
27897|NCT02880189|Intragastric Balloon
27898|NCT02880189|ORBERA
27899|NCT02880189|ORBERA Intragastric Balloon
27900|NCT02880176|Behavioral Economics
27901|NCT02880176|Financial Incentives
27902|NCT02880176|Bladder Cancer
27903|NCT02880176|Ambulation
27904|NCT02880176|Surgical Co-Morbidity
27905|NCT02880176|Fitbit
27906|NCT02880176|Mobile Health
27907|NCT02880176|Radical Cystectomy
27908|NCT02880150|elite climbers
27909|NCT02880150|near infrared spectroscopy
27910|NCT02880124|Isotope Labeling, Stable
27911|NCT02880124|Exercise, Physical
27912|NCT02880124|Calorimetry, Indirect
27913|NCT02880124|Athletic Performance
27914|NCT02880124|Sugar Maple
27915|NCT02880111|Malignant Brain Tumor
27916|NCT02880111|patient sputum
27917|NCT02880098|Neonatology
27918|NCT02880098|Troponin T
27919|NCT02880098|Standards
27920|NCT02880059|Sleep Apnea, Aneurysm, Subarachnoid Hemorrhage, Blood Pressure.
27921|NCT02880046|immune response
27922|NCT02880046|T lymphocyte
27923|NCT02880046|PD-1/PDL-1 pathway
27924|NCT02880033|Parkinson's disease
27925|NCT02880033|Amyotrophic lateral sclerosis
27926|NCT02880033|Peripheral blood mononuclear cells
27927|NCT02880033|ex vivo model for oxidative stress
27928|NCT02880033|iron metabolism and chelation
27929|NCT02880007|Pulsed dose-rate brachytherapy
27930|NCT02880007|3D dosimetry
27931|NCT02880007|Prospective Studies
27932|NCT02880007|Radiotherapy Dosage
27933|NCT02880007|Uterine Cervical Neoplasms/radiotherapy
27934|NCT02880007|Brachytherapy/methods
27935|NCT02879968|serum squamous cell carcinoma antigen
27936|NCT02879968|tumor volume
27937|NCT02879968|Head and Neck Cancer
27938|NCT02879955|Glucagon-Like Peptide 1
27939|NCT02879955|Carbohydrates
27940|NCT02879955|Gastric bypass
27941|NCT02879955|Bariatric Surgery
27942|NCT02879955|Overweight
27943|NCT02879942|Placental volume
27944|NCT02879942|First-trimester screening
27945|NCT02879942|Ultrasound
27946|NCT02879942|Preeclampsia
27947|NCT02879942|Intrauterine growth restriction
27948|NCT02879942|Biochemical markers
27949|NCT02879942|Uterine artery doppler
27950|NCT02879929|chronic nasal dysfunction
27951|NCT02879929|Quality of life
27952|NCT02879929|measurement
27953|NCT02879929|self-reporting questionnaire
27954|NCT02879929|development
27955|NCT02879929|validation
27956|NCT02879903|Porphyromonas gingivalis
27957|NCT02879903|Periodontal treatment
27958|NCT02879903|Smokers
27959|NCT02879877|First in human
27960|NCT02879877|subjects
27961|NCT02879864|fatigue
27962|NCT02879864|tiredness
27963|NCT02879864|luxo therapy
27964|NCT02879864|therapy by light
27965|NCT02879851|ultrasound
27966|NCT02879851|Koelis system
27967|NCT02879851|MRI
27968|NCT02879851|gold grain
27969|NCT02879825|Ventricular Premature Complexes
27970|NCT02879812|Transplantation Surgery
27971|NCT02879812|Nephrology
27972|NCT02879812|Organ and Tissue Transplantation
27973|NCT02879799|Family-centered care
27974|NCT02879799|Family-integrated care
27975|NCT02879799|Neonatal intensive care unit
27976|NCT02879799|Premature
27977|NCT02879799|Infant
27978|NCT02879773|Respiratory Function Tests
27979|NCT02879773|Computed tomography
27980|NCT02879773|Thoracic surgical procedures
27981|NCT02879773|Diagnosis
27982|NCT02879760|Lung
27983|NCT02879760|Cancer
27984|NCT02879760|Chemotherapy
27985|NCT02879760|Oncolytic virus
27986|NCT02879760|Immunotherapy
27987|NCT02879760|Pembrolizumab
27988|NCT02879760|Keytruda
27989|NCT02879747|treatment
27990|NCT02879747|growth hormone
27991|NCT02879747|childhood
27992|NCT02879747|short stature
27993|NCT02879734|peritoneal dialysis
27994|NCT02879734|laparoscopy
27995|NCT02879734|omentum
27996|NCT02879721|Gastrointestinal
27997|NCT02879708|Social Accountability
27998|NCT02879708|Healthcare Quality
27999|NCT02879708|Health System Strengthening
28000|NCT02879708|Child Health
28001|NCT02879708|Childhood pneumonia
28002|NCT02879708|Childhood diarrhea
28003|NCT02879682|glioma
28004|NCT02879682|brain metastases
28005|NCT02879682|nTMS
28006|NCT02879630|pharmacokinetics
28007|NCT02879630|acyclovir
28008|NCT02879552|Upper blepharoplasty
28009|NCT02879552|brassiere sutures
28010|NCT02879552|tarsal platform show
28011|NCT02879552|eyeshadow space
28012|NCT02879552|brow fat span
28013|NCT02879539|cochlear implants, power consumption,
28014|NCT02879526|Relapse/Refratory Peripheral T Cell Lymphoma
28015|NCT02879526|Chidamide
28016|NCT02879526|Cyclophosphamide、Prednisone、Thalidomide(CPT)
28017|NCT02879500|Systematic review and meta-analysis
28018|NCT02879500|Evidence-based medicine (EBM)
28019|NCT02879500|Evidence-based nutrition (EBN)
28020|NCT02879500|Clinical practice guidelines
28021|NCT02879500|Randomized controlled trials
28022|NCT02879500|Prospective cohort studies
28023|NCT02879500|Body weight
28024|NCT02879500|Body mass index
28025|NCT02879500|Adiposity
28026|NCT02879500|Overweight
28027|NCT02879500|Obesity
28028|NCT02879461|SURGERY
28029|NCT02879461|REHABILITATION
28030|NCT02879448|Non-valvular atrial fibrillation
28031|NCT02879448|Left Atrial Appendage
28032|NCT02879409|HbA1c variability
28033|NCT02879409|Diabetes Mellitus Type 2
28034|NCT02879409|Diabetes microvascular complications
28035|NCT02879409|Diabetes macrovascular complications
28036|NCT02879396|Older adults
28037|NCT02879396|Avoidable admissions
28038|NCT02879396|Assisted living home
28039|NCT02879396|Emergency service calls
28040|NCT02879396|Heading Assisted Living Facilities
28041|NCT02879383|Type 2 Diabetes
28042|NCT02879370|Anastomotic Leak
28043|NCT02879370|Rectal cancer
28044|NCT02879370|Double stapling technique
28045|NCT02879357|Care management
28046|NCT02879357|end of life
28047|NCT02879357|advanced care planning
28048|NCT02879357|palliative care
28049|NCT02879331|pulmonary emphysema
28050|NCT02879331|coils
28051|NCT02879331|cycloergometry
28052|NCT02879331|lung volume reduction
28053|NCT02879305|erythropoiesis stimulating agents
28054|NCT02879305|GSK1278863
28055|NCT02879305|daprodustat
28056|NCT02879305|anemia
28057|NCT02879305|chronic kidney disease
28058|NCT02879305|hemoglobin
28059|NCT02879305|recombinant human erythropoietin
28060|NCT02879292|Pyloric stenosis spinal anesthesia postoperative pain
28061|NCT02879279|Stroke
28062|NCT02879279|Upper limb
28063|NCT02879279|Robotic rehabilitation
28064|NCT02879266|Dengue Vaccine
28065|NCT02879032|Treadmill Scores
28066|NCT02879032|Coronary Angiogram
28067|NCT02879032|Coronary Artery Disease
28068|NCT02879006|Chinese herbal therapy
28069|NCT02879006|Oral immunotherapy
28070|NCT02879006|Food allergy
28071|NCT02879006|Omalizumab
28072|NCT02878928|Pharmacogenetic testing
28073|NCT02878928|PGx
28074|NCT02878928|Depression
28075|NCT02878928|Neuropsychiatric diseases
28076|NCT02878928|IDgenetix
28077|NCT02878928|AltheaDx
28078|NCT02878902|emergency
28079|NCT02878902|coordination
28080|NCT02878902|dialysis
28081|NCT02878824|Neurophysiology
28082|NCT02878824|Autonomic
28083|NCT02878824|Sensory
28084|NCT02878824|Child
28085|NCT02878824|Ethnicity
28086|NCT02878824|Environment
28087|NCT02878811|heart failure
28088|NCT02878811|prospective
28089|NCT02878811|cohort
28090|NCT02878785|AML
28091|NCT02878746|Mirror therapy
28092|NCT02878746|Proprioception
28093|NCT02878746|Rehabilitation
28094|NCT02878746|Stroke
28095|NCT02878746|Hemiplegia
28096|NCT02878720|ischemic stroke
28097|NCT02878720|hemorrhagic chronic
28098|NCT02878720|non-invasive vagus nerve stimulation
28099|NCT02878720|robot-assisted rehabilitation
28100|NCT02878681|Diabetic Macular Edema.
28101|NCT02878668|procalcitonin
28102|NCT02878668|post-operative
28103|NCT02878668|complication
28104|NCT02878668|CRP
28105|NCT02878655|N0 clinical and radiological
28106|NCT02878655|dissection IIb sector
28107|NCT02878564|Schistosomiasis mansoni
28108|NCT02878564|HIV susceptibility
28109|NCT02878564|Genital immunology
28110|NCT02878564|Mucosal immunology
28111|NCT02878564|HIV entry assay
28112|NCT02878564|Adult women
28113|NCT02878512|Segmental Epidural
28114|NCT02878512|Regional Anesthesia for PCNL
28115|NCT02878499|autism
28116|NCT02878499|autism spectrum disorder
28117|NCT02878499|ASD
28118|NCT02878499|sleep
28119|NCT02878499|Circadian
28120|NCT02878499|Biological rhythms
28121|NCT02878499|melatonin
28122|NCT02878499|Cognition
28123|NCT02878499|Behavior
28124|NCT02878499|Longitudinal
28125|NCT02878499|Longitudinal accelerated design
28126|NCT02878486|Physical activity
28127|NCT02878486|Alzheimer's disease
28128|NCT02878486|cognitive impairment
28129|NCT02878486|sedentary behavior
28130|NCT02878486|insulin sensitivity
28131|NCT02878447|Haemoptysis
28132|NCT02878447|Radiotherapy
28133|NCT02878447|Tuberculosis
28134|NCT02878447|Aspergilloma
28135|NCT02878447|Bronchiectasis
28136|NCT02878434|Cancer
28137|NCT02878434|Fertility
28138|NCT02878434|Pregnancy
28139|NCT02878434|Chemotherapy
28140|NCT02878434|Radiotherapy
28141|NCT02878434|Long term
28142|NCT02878434|Follow up
28143|NCT02878395|genomics
28144|NCT02878395|epigenomics
28145|NCT02878395|recurrence
28146|NCT02878382|PDT
28147|NCT02878382|skin cancer
28148|NCT02878382|calcipotriol
28149|NCT02878369|fluid replacement
28150|NCT02878356|Motivational Interviewing, Clinical supervision, Education
28151|NCT02878330|Respiratory Syncytial Virus, RSV
28152|NCT02878330|Preterm Infants
28153|NCT02878330|Lower Respiratory Tract Infection
28154|NCT02878317|Glycosylation End Products, Advanced
28155|NCT02878317|Skin autofluorescence
28156|NCT02878317|Renal Dialysis
28157|NCT02878304|Prognosis
28158|NCT02878304|Hand function
28159|NCT02878304|Rehabilitation
28160|NCT02878304|Spasticity
28161|NCT02878304|MRI
28162|NCT02878278|Chidamide
28163|NCT02878278|Administration method
28164|NCT02878265|malaria
28165|NCT02878265|vitamin A
28166|NCT02878265|Zinc
28167|NCT02878265|Multivitamin
28168|NCT02878252|COPD, Asthma, ACOS
28169|NCT02878239|knee osteoarthritis
28170|NCT02878239|gait
28171|NCT02878239|Kellgren-Lawrence Scores
28172|NCT02878161|rheumatoid arthritis
28173|NCT02878161|tumor necrosis factor α inhibitor
28174|NCT02878161|predictive
28175|NCT02878161|iTRAQ
28176|NCT02878161|signal pathway
28177|NCT02878148|Nephrolithiasis
28178|NCT02878148|Ureteral stone
28179|NCT02878148|Acute renal colic
28180|NCT02878148|Ultrasonography
28181|NCT02878148|Computed tomography
28182|NCT02878148|Diagnosis
28183|NCT02878122|ovarian cancer
28184|NCT02878122|chemo resistance
28185|NCT02878122|predictive factors
28186|NCT02878122|cohort study
28187|NCT02878122|bio bank
28188|NCT02878109|Magnetic resonance imaging (MRI)
28317|NCT02877303|Mesna
28189|NCT02878109|Transarterial chemoembolization (TACE)
28190|NCT02878096|nocturnal polyuria
28191|NCT02878083|vedolizumab,
28192|NCT02878083|confocal endomicroscopy
28193|NCT02878083|biomarker
28194|NCT02878083|ULCERATIVE COLITIS
28195|NCT02878070|Spinal Cord Injuries
28196|NCT02878070|Telemedicine
28197|NCT02878070|Health Behaviors
28198|NCT02878057|Apatinib
28199|NCT02878057|HER-2 Negative
28200|NCT02878057|Chest wall Metastasis
28201|NCT02878057|Multicenter Phase II Study
28202|NCT02878057|Breast cancer
28203|NCT02878044|Shared Decision Making, Decision Aid
28204|NCT02878031|Integrated Community Case Management
28205|NCT02878031|Community Health Worker
28206|NCT02878031|Nigeria
28207|NCT02878018|Cohort Study
28208|NCT02878018|Children
28209|NCT02878018|Henoch-Schonlein Purpura Nephritis
28210|NCT02878018|Diagnosis and Treatment of Traditional Chinese Medicine
28211|NCT02878005|Intubating Laryngeal Tube
28212|NCT02878005|blind intubation
28213|NCT02878005|fiberoptic
28214|NCT02877992|Infertility
28215|NCT02877992|Tachykinin
28216|NCT02877992|Kisspeptin
28217|NCT02877940|ProSeal LMA
28218|NCT02877940|LTS-D
28219|NCT02877940|i-gel
28220|NCT02877914|heart failure, retrospective
28221|NCT02877888|cost effectiveness
28222|NCT02877888|fluoride varnish
28223|NCT02877888|dental caries
28224|NCT02877875|anxiety
28225|NCT02877875|depression
28226|NCT02877875|trauma
28227|NCT02877875|behavior problems
28228|NCT02877875|evidence-based treatments
28229|NCT02877875|manualized treatments
28230|NCT02877875|cognitive-behavioral therapy
28231|NCT02877875|youth
28232|NCT02877875|mental health
28233|NCT02877849|fMRI
28234|NCT02877849|brain networks
28235|NCT02877849|biomarker
28236|NCT02877849|relapse
28237|NCT02877849|alcohol
28238|NCT02877836|Dystonia
28239|NCT02877836|fMRI
28240|NCT02877836|DTI
28241|NCT02877836|DBS
28242|NCT02877823|Pediatric Antipsychotic Treatment
28243|NCT02877823|Pediatric healthy lifestyle intervention
28244|NCT02877823|Parent peer support
28245|NCT02877784|screening
28246|NCT02877784|OPMD
28247|NCT02877784|dysphagia
28248|NCT02877784|dysarthria
28249|NCT02877758|cutaneous aging
28250|NCT02877758|skin rejuvenation
28251|NCT02877758|wrinkles
28252|NCT02877732|Concussion
28253|NCT02877732|Athletes
28254|NCT02877732|Eye-tracking
28255|NCT02877732|Vision
28256|NCT02877706|Register
28257|NCT02877693|ICD
28258|NCT02877693|Thoracic MRI Scan
28259|NCT02877693|tachycardia
28260|NCT02877680|Strengths-based
28261|NCT02877680|Mobile Health (mHealth)
28262|NCT02877680|Adolescence
28263|NCT02877680|Resilience
28264|NCT02877680|Family
28265|NCT02877667|tattoo
28266|NCT02877667|laser
28267|NCT02877654|Plasmatic zonulin
28268|NCT02877654|Irritable Bowel Syndrome
28269|NCT02877654|Intestinal permeability
28270|NCT02877641|Current Smoker
28271|NCT02877641|Former Smoker
28272|NCT02877628|pharmacokinetic
28273|NCT02877628|pharmacodynamic
28274|NCT02877628|tacrolimus
28275|NCT02877628|CYP3A5
28276|NCT02877628|liver transplantation
28277|NCT02877563|peripheral artery disease
28278|NCT02877563|contrast enhanced ultrasound
28279|NCT02877550|untreated Follicular lymphoma
28280|NCT02877550|non-Hodgkin lymphoma
28281|NCT02877550|Obinutuzumab
28282|NCT02877550|Gazyva
28283|NCT02877550|Gazyvaro
28284|NCT02877550|Venetoclax
28285|NCT02877550|Venclexta
28286|NCT02877446|Left ventricular assist device (LVAD)
28287|NCT02877446|Terminal heart failure
28288|NCT02877446|Ventricular assist device (VAD)
28289|NCT02877433|Small diameter implant
28290|NCT02877433|Cross-arch prostheses
28291|NCT02877420|Endoscopy
28292|NCT02877420|Simulation Training
28293|NCT02877420|Non-technical Skills
28294|NCT02877381|Tranexamic Acid
28295|NCT02877381|Blood Transfusion
28296|NCT02877342|Injury
28297|NCT02877342|Injuries
28298|NCT02877342|Triage
28299|NCT02877329|psychological effects
28300|NCT02877303|Leukemia
28301|NCT02877303|Acute lymphoblastic leukemia
28302|NCT02877303|ALL
28303|NCT02877303|Newly diagnosed B-Cell Lineage Acute lymphoblastic leukemia
28304|NCT02877303|Blinatumomab
28305|NCT02877303|Blincyto
28306|NCT02877303|G-CSF
28307|NCT02877303|Filgrastim
28308|NCT02877303|Neupogen
28309|NCT02877303|Pegfilgrastim
28310|NCT02877303|Neulasta
28311|NCT02877303|PEG-G-CSF
28312|NCT02877303|Cyclophosphamide
28313|NCT02877303|Cytoxan
28314|NCT02877303|Neosar
28315|NCT02877303|Revimmune
28316|NCT02877303|Clafen
28318|NCT02877303|Mesnex
28319|NCT02877303|Dexamethasone
28320|NCT02877303|Decadron
28321|NCT02877303|Ofatumumab
28322|NCT02877303|Arzerra
28323|NCT02877303|Methotrexate
28324|NCT02877303|MTX
28325|NCT02877303|Doxorubicin
28326|NCT02877303|Doxorubicin Hydrochloride
28327|NCT02877303|Adriamycin PFS
28328|NCT02877303|Adriamycin RDF
28329|NCT02877303|Adriamycin
28330|NCT02877303|Rubex
28331|NCT02877303|Vincristine
28332|NCT02877303|Oncovin
28333|NCT02877303|Vincasar PFS
28334|NCT02877303|Vincristine Sulfate
28335|NCT02877303|LCR
28336|NCT02877303|VCR
28337|NCT02877303|Cytarabine
28338|NCT02877303|ARA-C
28339|NCT02877303|Cytosar
28340|NCT02877303|DepoCyt
28341|NCT02877303|Cytosine Arabinosine Hydrochloride
28342|NCT02877303|Arabino Sylcytosine
28343|NCT02877303|Cytosine Arabinoside
28344|NCT02877303|Rituximab
28345|NCT02877303|Rituxan
28346|NCT02877303|Leucovorin
28347|NCT02877303|Citrovorum
28348|NCT02877303|Wellcovorin
28349|NCT02877303|6-Mercaptopurine
28350|NCT02877303|Mercaptopurine
28351|NCT02877303|Purinethol
28352|NCT02877303|6-MP
28353|NCT02877303|Prednisone
28354|NCT02877303|Deltasone
28355|NCT02877303|Orasone
28356|NCT02877303|Prednicen-M
28357|NCT02877290|COPD
28358|NCT02877290|NIRS
28359|NCT02877290|NIV
28360|NCT02877290|Exercise
28361|NCT02877264|Vapendavir
28362|NCT02877264|Bioavailability
28363|NCT02877264|Biological Availability
28364|NCT02877264|Volunteers
28365|NCT02877251|Venous Thromboembolism
28366|NCT02877251|Venous Thrombosis
28367|NCT02877251|Pulmonary Thromboembolism
28368|NCT02877251|National Registry
28369|NCT02877251|Mexico
28370|NCT02877251|Major Adverse Cardiovascular Events
28371|NCT02877238|remote ischemic preconditioning
28372|NCT02877238|sevoflurane
28373|NCT02877238|total intravenous anesthetic
28374|NCT02877212|ITP
28375|NCT02877212|Eltrombopag
28376|NCT02877212|Steroid refractory
28377|NCT02877212|Fc Receptor
28378|NCT02877199|Hepatitis C
28379|NCT02877199|anti-E1E2 antibodies
28380|NCT02877199|cirrhosis
28381|NCT02877199|triple therapy
28382|NCT02877173|Arteriosclerosis Obliterans
28383|NCT02877173|Atherosclerotic Occlusive Disease of the Lower Extremities
28384|NCT02877173|Intermittent Claudication
28385|NCT02877121|interstitial lung disease
28386|NCT02877121|Respiratory Muscle Function
28387|NCT02877121|Neural Respiratory Drive
28388|NCT02877056|Colorectal adenocarcinoma
28389|NCT02877056|Neoadjuvant therapy
28390|NCT02877056|Endoscopy
28391|NCT02877056|Endoscopic biopsy
28392|NCT02877056|Biomarkers
28393|NCT02877056|Genes
28394|NCT02876991|choline positron emission tomography
28395|NCT02876991|occult recurrence
28396|NCT02876991|prostatic adenocarcinoma
28397|NCT02876991|sodium fluoride positron emission tomography
28398|NCT02876952|Cardio-respiratory fitness
28399|NCT02876952|high intensity exercise training
28400|NCT02876939|Hereditary Sensory Neuropathy
28401|NCT02876939|Autonomic Neuropathy
28402|NCT02876939|Familial Dysautonomia
28403|NCT02876939|proprioception
28404|NCT02876939|motor control
28405|NCT02876939|sensory nervous system.
28406|NCT02876939|HSAN III
28407|NCT02876939|IKBKAP gene mutation
28408|NCT02876926|HIV testing
28409|NCT02876926|Self-testing
28410|NCT02876926|Counseling
28411|NCT02876926|Referral
28412|NCT02876874|Rheumatoid Arthritis
28413|NCT02876874|lymph nodes morphology
28414|NCT02876874|drainage of lymphatic vessels
28415|NCT02876848|Administrative Claims, Healthcare
28416|NCT02876848|Aromatase Inhibitors
28417|NCT02876848|Breast Neoplasms
28418|NCT02876848|Health Services for the Aged
28419|NCT02876848|Medical Informatics Applications
28420|NCT02876848|Medication Adherence
28421|NCT02876848|Outcome and Process Assessment (Health Care)
28422|NCT02876848|Selective Estrogen Receptor Modulators
28423|NCT02876848|Telemedicine
28424|NCT02876835|hemoglobin
28425|NCT02876835|anemia
28426|NCT02876835|non-dialysis
28427|NCT02876835|GSK1278863
28428|NCT02876835|erythropoiesis stimulating agents
28429|NCT02876835|daprodustat
28430|NCT02876835|chronic kidney disease
28431|NCT02876809|centenarians
28432|NCT02876809|geriatric
28433|NCT02876809|telomere length
28434|NCT02876809|progerin
28435|NCT02876809|metagenome
28436|NCT02876809|metabolome
28437|NCT02876796|fractional de novo lipogenesis
28438|NCT02876796|DNL
28439|NCT02876796|pharmacodynamic
28440|NCT02876796|pharmacokinetic
28441|NCT02876705|Patterns
28442|NCT02876705|Pain
28443|NCT02876705|Cycling
28444|NCT02876705|Running
28445|NCT02876705|Exhaustion
28446|NCT02876679|Hematopoietic Stem Cell
28447|NCT02876679|Transplantation
28448|NCT02876679|Graft vs Host Disease
28449|NCT02876679|Cyclophosphamide
28450|NCT02876679|Anti-Thymocyte Globulin
28451|NCT02876679|GVHD prophylaxis
28452|NCT02876666|Spinal Cord Injuries
28453|NCT02876666|Health Behavior
28454|NCT02876653|Obstructive sleep apnea
28455|NCT02876653|Aging
28456|NCT02876653|Telomere length
28457|NCT02876614|radionuclide cisternography
28458|NCT02876614|CSF leak
28459|NCT02876614|imaging
28460|NCT02876601|Coagulation
28461|NCT02876601|Inflammation
28462|NCT02876601|Defibrotide
28463|NCT02876601|Fibrinolysis
28464|NCT02876588|Wrong-Patient Errors
28465|NCT02876588|Retract-and-Reorder Tool
28466|NCT02876562|Gingival Recession Coverage
28467|NCT02876549|G6PD
28468|NCT02876549|Primaquine
28469|NCT02876510|Ovarian Cancer
28470|NCT02876510|Esophageal Cancer
28471|NCT02876510|Head and neck squamous cell carcinoma
28472|NCT02876510|Squamous non-small cell lung cancer
28473|NCT02876458|Coronary angiogram
28474|NCT02876458|Survival rate
28475|NCT02876458|Neurological sequel
28476|NCT02876445|Huntington's disease
28477|NCT02876445|Caregiver
28478|NCT02876445|ZARIT burden scale
28479|NCT02876419|nucleic acid polymer REP 2139 HBsAg hepatitis B hepatitis D
28480|NCT02876367|Epidemiology
28481|NCT02876354|Hemodialysis
28482|NCT02876354|Vitamin k2
28483|NCT02876354|Vascular calcifications
28484|NCT02876341|Chronic antihypertensives
28485|NCT02876341|New onset atrial fibrillation
28486|NCT02876341|Septic shock
28487|NCT02876328|Ebola Vaccine
28488|NCT02876315|innate immunity
28489|NCT02876315|elderly adults
28490|NCT02876315|multivitamin supplement
28491|NCT02876315|vitamin D
28492|NCT02876315|vitamin C
28493|NCT02876315|zinc
28494|NCT02876302|Inflammatory Breast Cancer
28495|NCT02876302|Breast Cancer
28496|NCT02876302|Triple Negative Breast Cancer
28497|NCT02876263|aortic diseases
28498|NCT02876263|aortic aneurysm
28499|NCT02876263|electroencephalography
28500|NCT02876263|Near-Infrared spectroscopy
28501|NCT02876263|Transcranial Doppler ultrasonography
28502|NCT02876263|Cardiopulmonary arrest
28503|NCT02876263|Hypothermia, Induced
28504|NCT02876250|Lung transplantation
28505|NCT02876250|Cyclosporine
28506|NCT02876250|Postconditioning
28507|NCT02876211|Renal disease
28508|NCT02876211|Erythropoiesis
28509|NCT02876211|Erythropoietin stimulating agent
28510|NCT02876211|Iron
28511|NCT02876211|Klotho
28512|NCT02876211|Selective vitamin D receptor activation
28513|NCT02876198|Retinal neovascularization
28514|NCT02876198|Anti-VEGF
28515|NCT02876198|Retinal Nerve Fiber Layer (RNFL)
28516|NCT02876185|Glaucoma surveillance
28517|NCT02876185|Orthoptist
28518|NCT02876172|PTSD
28519|NCT02876172|psychotherapy
28520|NCT02876172|MDMA
28521|NCT02876172|dyad
28522|NCT02876172|cognitive behavioral therapy
28523|NCT02876159|Vaccination
28524|NCT02876146|Albendazole
28525|NCT02876146|Benzimidazole
28526|NCT02876146|Echinococcus multilocularis
28527|NCT02876146|Alveolar echinococcosis
28528|NCT02876146|Liver Diseases
28529|NCT02876107|Malignant neoplasm of breast
28530|NCT02876107|Breast cancer
28531|NCT02876107|Newly diagnosed primary triple-negative inflammatory breast cancer
28532|NCT02876107|Inflammatory breast cancer
28533|NCT02876107|IBC
28534|NCT02876107|TN-IBC
28535|NCT02876107|Breast biopsy
28536|NCT02876107|Mammogram
28537|NCT02876107|Ultrasound
28538|NCT02876107|Paclitaxel
28539|NCT02876107|Taxol
28540|NCT02876107|Carboplatin
28541|NCT02876107|Paraplatin
28542|NCT02876107|Panitumumab
28543|NCT02876107|Vectibix
28544|NCT02876107|Doxorubicin
28545|NCT02876107|Doxorubicin Hydrochloride
28546|NCT02876107|Adriamycin PFS
28547|NCT02876107|Adriamycin RDF
28548|NCT02876107|Adriamycin
28549|NCT02876107|Rubex
28550|NCT02876107|Cyclophosphamide
28551|NCT02876107|Cytoxan
28552|NCT02876107|Neosar
28553|NCT02876055|Nerve Block/methods
28554|NCT02876055|Pain, Postoperative/prevention & control
28555|NCT02876055|Anesthetics, Local/administration & dosage
28556|NCT02876055|Brachial Plexus/ultrasonography
28557|NCT02876055|Shoulder Pain/prevention & control
28558|NCT02876042|Heart Failure
28559|NCT02876042|Preserved Ejection Fraction
28560|NCT02875938|left middle cerebral artery
28561|NCT02875938|cerebrovascular accident (CVA)
28562|NCT02875938|stroke
28563|NCT02875925|blood coagulation
28564|NCT02875912|Family
28565|NCT02875912|Care Rituals
28566|NCT02875912|End of Life
28567|NCT02875912|Discordance of care
28568|NCT02875860|CDH
28569|NCT02875860|Congenital Diaphragmatic Hernia
28570|NCT02875860|Fetal Tracheal Occlusion
28571|NCT02875860|FETO
28572|NCT02875860|plug-unplug
28573|NCT02875860|GoldBal2
28574|NCT02875860|Balloon
28575|NCT02875860|Goldvalve Balloon
28576|NCT02875860|TOTAL
28577|NCT02875795|linguistic
28578|NCT02875795|quality of life
28579|NCT02875782|Smoking Cessation
28580|NCT02875769|cetylpyridinium chloride
28581|NCT02875769|chlorhexidine
28582|NCT02875769|oral aerosol
28583|NCT02875769|oral splatter
28584|NCT02875769|mouthwash
28585|NCT02875769|microbiology
28586|NCT02875704|DR
28587|NCT02875704|AMD
28588|NCT02875691|disease activity
28589|NCT02875652|circulation tumor DNA
28590|NCT02875652|choroidal melanoma
28591|NCT02875639|Ischemic Heart Failure
28592|NCT02875639|coronary artery disease
28593|NCT02875639|qi deficiency and blood stasis
28594|NCT02875613|Nasopharyngeal
28595|NCT02875613|PD-L1
28596|NCT02875613|monoclonal antibody
28597|NCT02875613|Epstein-barr virus
28598|NCT02875600|chronic gastro-intestinal ischemia
28599|NCT02875600|oxygen deficiency of the gastro-intestinal tract
28600|NCT02875587|OHSS
28601|NCT02875587|Infertility
28602|NCT02875587|Cabergoline
28603|NCT02875587|Calcium gluconate
28604|NCT02875587|IVF-ET
28605|NCT02875574|Isoniazid
28606|NCT02875574|Drug Resistance
28607|NCT02875535|Evidence-based
28608|NCT02875535|lesbian, gay, bisexual, transgender, intersex, and queer
28609|NCT02875535|adolescent
28610|NCT02875535|Suicide prevention
28611|NCT02875535|Implementation study
28612|NCT02875522|COPD
28613|NCT02875522|Exercise Training
28614|NCT02875522|Flow-Mediated Dilation
28615|NCT02875522|Arterial Stiffness
28616|NCT02875522|Echocardiography
28617|NCT02875522|Cerebrovascular Physiology
28618|NCT02875470|non-surgical periodontal debridement
28619|NCT02875470|root planing/instrumentation
28620|NCT02875470|cytokine(s)
28621|NCT02875470|dental plaque
28622|NCT02875470|microscopy, electron, scanning
28623|NCT02875457|small cell lung cancer; apatinib; etoposide; cisplatin
28624|NCT02875405|postoperative
28625|NCT02875405|pericardiotomy
28626|NCT02875405|prevention
28627|NCT02875405|cardiac surgery
28628|NCT02875405|left
28629|NCT02875405|posterior
28630|NCT02875379|Noninvasive Ventilation
28631|NCT02875379|Mechanical Ventilation
28632|NCT02875353|Post-Polypectomy
28633|NCT02875353|Colon bleeding
28634|NCT02875353|Stigmata of recent hemorrhage
28635|NCT02875327|SEER
28636|NCT02875327|Medicaid
28637|NCT02875327|Cancer
28638|NCT02875327|Health Services Research
28639|NCT02875327|Epidemiology
28640|NCT02875301|Exercise
28641|NCT02875301|Brain Health
28642|NCT02875301|Dose Response
28643|NCT02875301|Cognition
28644|NCT02875262|intracranial aneurysm
28645|NCT02875262|subarachnoid hemorrhage
28646|NCT02875262|stroke
28647|NCT02875262|chelator
28648|NCT02875249|post-antibiotic diarrhea
28649|NCT02875249|intestinal microbiome
28650|NCT02875223|Safety
28651|NCT02875223|CC-90011
28652|NCT02875223|Relapsed and/or Refractory Solid Tumors
28653|NCT02875223|Non-Hodgkin's Lymphomas
28654|NCT02875210|Anterior Cruciate Ligament
28655|NCT02875210|A02.835.583.512.100
28656|NCT02875197|Kinetics
28657|NCT02875197|Biomechanics
28658|NCT02875197|Amputation
28659|NCT02875197|Prosthesis
28660|NCT02875197|Transtibial
28661|NCT02875184|Psoriatic Arthritis
28662|NCT02875184|Apremilast
28663|NCT02875184|CC-10004
28664|NCT02875171|Anthracyclines; Cardiotoxicity; 2-D Echocardiography
28665|NCT02875145|Corneal Transplantation
28666|NCT02875145|Graft Survival
28667|NCT02875106|Sinus rhythm
28668|NCT02875041|rehabilitation
28669|NCT02875041|balance
28670|NCT02875028|Coagulations
28671|NCT02875028|Platelets
28672|NCT02875028|Inflammation
28673|NCT02875028|endotoxemia
28674|NCT02875028|vorapaxar
28675|NCT02875015|Anesthetics
28676|NCT02875015|Anesthetic Effects
28677|NCT02875015|Mid-urethral sling
28678|NCT02874976|sedentary lifestyle
28679|NCT02874963|Diabetes
28680|NCT02874963|Oral Hygiene
28681|NCT02874963|Periodontal Surgery
28682|NCT02874963|Periodontal Medicine
28683|NCT02874950|Exercise
28684|NCT02874937|Syncope
28685|NCT02874937|Vasovagal
28686|NCT02874937|Atomoxetine
28687|NCT02874924|Geriatrics
28688|NCT02874911|Exergaming
28689|NCT02874911|Neurodegenerative diseases
28690|NCT02874911|Rare disease
28691|NCT02874911|Motor exercises
28692|NCT02874911|Training
28693|NCT02874911|Spinocerebellar ataxia
28694|NCT02874885|Locally-advanced rectal cancer
28695|NCT02874885|LARC
28696|NCT02874885|Colorectal cancer
28697|NCT02874885|CRC
28698|NCT02874885|Rectosigmoid cancer
28699|NCT02874885|No known diagnosis of colorectal cancer
28700|NCT02874885|Blood draws
28701|NCT02874885|Blood samples
28702|NCT02874885|Circulating tumor cells (CTC)
28703|NCT02874885|CTC
28704|NCT02874872|Nursing homes
28705|NCT02874872|Antibiotic Stewardship
28706|NCT02874872|Antibiotic Resistance
28707|NCT02874859|DIABETIC RETINOPATHY
28708|NCT02874859|Intravitreal aflibercept
28709|NCT02874833|Depression
28710|NCT02874833|Unipolar depression
28711|NCT02874833|Bipolar affective disorder
28712|NCT02874833|Exercise
28713|NCT02874833|Internet-based intervention
28714|NCT02874820|Imidazoline Receptor 2
28715|NCT02874820|(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole
28716|NCT02874820|BU99008
28717|NCT02874820|[11C]-BU99008
28718|NCT02874820|Radionuclide Imaging
28719|NCT02874820|Molecular Imaging
28720|NCT02874807|Hyponatremia
28721|NCT02874807|SGLT2 inhibitor
28722|NCT02874794|Heart Failure
28723|NCT02874794|Reduced Ejection Fraction
28724|NCT02874794|Central Aortic Stiffness
28725|NCT02874794|Vascular
28726|NCT02874794|Echocardiogram
28727|NCT02874755|Quality of Care
28728|NCT02874755|Standardized Patients
28729|NCT02874729|Biomarkers, Tumor
28730|NCT02874729|Biological Assay
28731|NCT02874716|Quality of Care
28732|NCT02874716|Standardized Patients
28733|NCT02874677|Multiple sclerosis
28734|NCT02874677|Ventilatory threshold
28735|NCT02874677|Effort Reeducation
28736|NCT02874651|Nasopharyngeal Carcinoma
28737|NCT02874651|EB Virus
28738|NCT02874651|DNA
28739|NCT02874651|vascular endothecial growth factor receptor inhibitor
28740|NCT02874651|Apatinib
28741|NCT02874612|Young Adults
28742|NCT02874612|Psychosocial Functioning
28743|NCT02874573|Inflammation
28744|NCT02874573|Schizophrenia
28745|NCT02874560|CNS
28746|NCT02874560|Antipsychotic
28747|NCT02874560|Functional remission
28748|NCT02874560|Observational study
28749|NCT02874560|FROGS
28750|NCT02874560|PSP
28751|NCT02874560|Functioning
28752|NCT02874560|Schizophrenia
28753|NCT02874508|leukocyte subpopulations
28754|NCT02874508|perioperative myocardial infarction
28755|NCT02874508|non-cardiac surgery
28756|NCT02874508|perioperative cardiovascular risk
28757|NCT02874495|Crohn's disease
28758|NCT02874495|Rectal Distension
28759|NCT02874495|Remission
28760|NCT02874495|Anticipation
28761|NCT02874495|Painful
28762|NCT02874482|Schizophrenia
28763|NCT02874482|Change blindness
28764|NCT02874482|Eye tracking
28765|NCT02874482|Implicit response
28766|NCT02874469|sudden death
28767|NCT02874469|post-traumatic stress disorder
28768|NCT02874469|psychological distress
28769|NCT02874469|diary
28770|NCT02874469|resuscitation
28771|NCT02874456|Zyca virus
28772|NCT02874352|intensive care
28773|NCT02874352|tracheostomy
28774|NCT02874339|Acute cardiogenic pulmonary
28775|NCT02874339|Respiratory failure
28776|NCT02874339|Hypercapnia
28777|NCT02874339|High flow nasal oxygen
28778|NCT02874339|Non invasive ventilation
28779|NCT02874339|Emergency department
28780|NCT02874326|Sandostatin LAR
28781|NCT02874326|Somatostatin
28782|NCT02874326|Octreotide
28783|NCT02874313|CPAP
28784|NCT02874313|Sleep apnea
28785|NCT02874313|Diabetes
28786|NCT02874313|Diabetic retinopathy
28787|NCT02874287|Coronary Artery Disease
28788|NCT02874287|Hydroxychloroquine
28789|NCT02874287|Cross-Over Study
28790|NCT02874274|Corticobasal syndrome
28791|NCT02874274|Dementia with Lewy Bodies
28792|NCT02874274|Home Visit Program (HVP)
28793|NCT02874274|Multidimensional Caregiver Strain Index
28794|NCT02874274|Parkinson's Disease Dementia
28795|NCT02874274|Progressive Supranuclear Palsy
28796|NCT02874222|aromatase inhibitors
28797|NCT02874183|Heart Failure
28798|NCT02874183|HF
28799|NCT02874183|CHF
28800|NCT02874183|RCT
28801|NCT02874183|Self-efficacy
28802|NCT02874183|Pharmacy
28803|NCT02874183|Pharmacist
28804|NCT02874183|Transition of Care
28805|NCT02874183|Readmission
28806|NCT02874131|Posttraumatic Stress Disorder
28807|NCT02874131|Major Depressive Disorder
28808|NCT02874131|Behavioral Activation
28809|NCT02874131|Cognitive Processing Therapy
28810|NCT02874131|Comorbidity
28811|NCT02874131|Military
28812|NCT02874105|Medical treatment
28813|NCT02874105|physiotherapy
28814|NCT02874092|Methotrexate (MTX)
28815|NCT02874092|Ticagrelor
28816|NCT02874066|Hepatits C virus
28817|NCT02874066|Hemodialysis
28818|NCT02874066|Direct acting antiviral agents
28819|NCT02874053|Risk Perceptions
28820|NCT02874053|Medical Tradeoffs
28821|NCT02874053|Regulatory Focus
28822|NCT02874053|Integral Affect
28823|NCT02874027|gut microbiota
28824|NCT02874027|depression
28825|NCT02874027|gut-brain axis
28826|NCT02874027|circadian rhythm
28827|NCT02874027|Traumatic Brain Injury
28828|NCT02874001|psychology
28829|NCT02874001|caregiver support time
28830|NCT02873975|Advanced Cancers
28831|NCT02873975|Solid tumors
28832|NCT02873975|MYC amplification
28833|NCT02873975|CCNE1 amplification
28834|NCT02873975|Rb loss
28835|NCT02873975|FBXW7 mutation
28836|NCT02873975|BRCA1 mutation
28837|NCT02873975|BRCA2 mutation
28838|NCT02873975|PALB2 mutation
28839|NCT02873975|RAD51C mutation
28840|NCT02873975|RAD51D mutation
28841|NCT02873975|ATR mutation
28842|NCT02873975|ATM mutation
28843|NCT02873975|CHK2 mutation
28844|NCT02873975|Fanconi anemia
28845|NCT02873962|Relapsed Ovarian Cancer
28846|NCT02873949|immunology factors
28847|NCT02873949|TREM
28848|NCT02873949|stress
28849|NCT02873923|clinical trial
28850|NCT02873923|surrogate endpoints
28851|NCT02873923|meta analysis
28852|NCT02873897|elderly
28853|NCT02873858|elderly
28854|NCT02873780|Pulmonary rehabilitation
28855|NCT02873780|COPD
28856|NCT02873780|Evaluation
28857|NCT02873780|oxygen desaturation
28858|NCT02873780|exercise capacity
28859|NCT02873767|First in human
28860|NCT02873767|Healthy volunteers
28861|NCT02873741|Sexually Transmitted Diseases (STDs)
28862|NCT02873741|Cancer
28863|NCT02873741|AIDS
28864|NCT02873728|chronic ulcer
28865|NCT02873728|diabetic ulcer
28866|NCT02873728|venous ulcer
28867|NCT02873728|remote ischemic conditioning
28868|NCT02873715|Childhood weight control
28869|NCT02873702|Drug therapy
28870|NCT02873689|Drug therapy
28871|NCT02873676|prevalence; lifestyle modification; clinical outcomes
28872|NCT02873650|Hepatic impairment
28873|NCT02873650|Healthy volunteers
28874|NCT02873650|Clinical pharmacology study
28875|NCT02873650|DRB436
28876|NCT02873650|dabrafenib
28877|NCT02873650|normal hepatic function
28878|NCT02873650|impaired hepatic function
28879|NCT02873637|total knee replacement
28880|NCT02873637|anesthesia
28881|NCT02873637|catheter
28882|NCT02873624|Acute Kidney Injury , Laparoscopic Cholecystectomy
28883|NCT02873598|Induction Chemotherapy
28884|NCT02873598|Stereotactic Body Radiotherapy (SBRT)
28885|NCT02873598|Dose Escalation
28886|NCT02873598|Locally Advanced Pancreatic Cancer (LAPC)
28887|NCT02873598|Maximum Tolerated Dose (MTD)
28888|NCT02873572|Online poker
28889|NCT02873572|Casino
28890|NCT02873572|Massively Multiplayer Online Role-Playing Game (MMORPG)
28891|NCT02873572|Iowa Gambling Task (IGT)
28892|NCT02873572|High Resolution Electroencephalography (HR-EEG)
28893|NCT02873559|older
28894|NCT02873559|frail
28895|NCT02873559|men
28896|NCT02873559|progressive muscle training
28897|NCT02873559|muscle training
28898|NCT02873559|exercise
28899|NCT02873559|testosterone
28900|NCT02873520|Precision Cell Immunotherapy
28901|NCT02873520|Chemotherapy
28902|NCT02873520|Advanced Gastric Cancer
28903|NCT02873507|transplantation, liver
28904|NCT02873494|Hemodynamic monitoring
28905|NCT02873494|cardiac output
28906|NCT02873494|Transthoracic echocardiography
28907|NCT02873494|Impedance cardiography
28908|NCT02873494|Child
28909|NCT02873494|Physioflow
28910|NCT02873494|pediatric intensive care unit
28911|NCT02873442|Precision Cell Immunotherapy
28912|NCT02873442|Transcatheter Arterial Chemoembolization
28913|NCT02873442|Advanced Liver Cancer
28914|NCT02873416|Precision Cell Immunotherapy
28915|NCT02873416|Chemotherapy
28916|NCT02873416|Advanced Lung Cancer
28917|NCT02873390|PD-1 Antibody
28918|NCT02873390|CAR-T Cells
28919|NCT02873390|EGFR family
28920|NCT02873390|Advanced Malignancies
28921|NCT02873377|Hispanics
28922|NCT02873377|Construction workers
28923|NCT02873377|Tobacco Quitline
28924|NCT02873377|Nicotine replacement therapy
28925|NCT02873351|L-DOPA
28926|NCT02873351|GPR143
28927|NCT02873351|PEDF
28928|NCT02873351|VEGF
28929|NCT02873325|ADV
28930|NCT02873325|CMV
28931|NCT02873325|HSCT
28932|NCT02873299|PTSD, Post Traumatic Stress Disorder
28933|NCT02873286|RSV Vaccines
28934|NCT02873286|Respiratory Syncytial Virus Vaccines
28935|NCT02873260|Dengue Vaccine
28936|NCT02873234|Telemedicine
28937|NCT02873234|Chinese Medicine syndrome differentiation
28938|NCT02873234|Long-term study
28939|NCT02873234|Relapse rate
28940|NCT02873234|Suicide rate
28941|NCT02873234|Antidepressants
28942|NCT02873208|Alkermes
28943|NCT02873208|ALKS 3831
28944|NCT02873208|Samidorphan
28945|NCT02873208|Schizophrenia
28946|NCT02873208|Safety
28947|NCT02873182|Intraoperative monitoring
28948|NCT02873182|Intraoperative neuromonitoring
28949|NCT02873182|Autonomic nervous system
28950|NCT02873182|Spine surgery
28951|NCT02873182|Pelvic surgery
28952|NCT02873182|Sexual function
28953|NCT02873182|Bowel function
28954|NCT02873182|Bladder function
28955|NCT02873169|Left ventricular assist device
28956|NCT02873169|Ventricular Arrhythmias
28957|NCT02873169|Implantable Cardioverter-defibrillator
28958|NCT02873156|E2027
28959|NCT02873156|Healthy participants
28960|NCT02873156|Pharmacokinetics
28961|NCT02873156|Pharmacodynamics
28962|NCT02873117|Benign prostate hyperplasia
28963|NCT02873117|5 alpha reductase inhibitor
28964|NCT02873117|prostate cancer
28965|NCT02873117|Symptomatic
28966|NCT02873117|treated
28967|NCT02873013|prostate cancer
28968|NCT02873013|observational study
28969|NCT02873000|incentive spirometry
28970|NCT02873000|outcome
28971|NCT02873000|length of stay,
28972|NCT02873000|hospital complication
28973|NCT02873000|general internal medicine
28974|NCT02873000|hospital medicine
28975|NCT02873000|non-critically-ill
28976|NCT02872974|Cardiovascular diseases
28977|NCT02872974|Gestational diabetes mellitus
28978|NCT02872974|Pediatrics
28979|NCT02872974|Fetal programming
28980|NCT02872974|Cohort study
28981|NCT02872948|Non invasive prenatal testing
28982|NCT02872948|Down Syndrome
28983|NCT02872948|Digital PCR
28984|NCT02872922|Endothelial function
28985|NCT02872922|Ultrasonic Therapy
28986|NCT02872922|Vascular endothelium
28987|NCT02872922|Nitric oxide
28988|NCT02872922|Ultrasound
28989|NCT02872883|Prelabour rupture of membranes
28990|NCT02872883|term pregnancy
28991|NCT02872883|management
28992|NCT02872883|vaginal examination
28993|NCT02872883|induction of labour
28994|NCT02872883|expectant management
28995|NCT02872870|language disorders
28996|NCT02872870|developmental disorders of oral and written language
28997|NCT02870140|CAD
28998|NCT02870140|ACS
28999|NCT02870140|All comers
29000|NCT02870140|PCI
29001|NCT02870114|Haemophilia
29002|NCT02870114|Quality of Life
29003|NCT02870114|Distress
29004|NCT02870114|Hemarthrosis
29005|NCT02870114|Pain
29006|NCT02870101|Nucleic acid amplification tests
29007|NCT02870101|Neisseria gonorrhoeae infection
29008|NCT02870101|Chlamydia trachomatis infection
29009|NCT02870101|Sexually transmitted diseases
29010|NCT02870101|Pharynx
29011|NCT02870101|Rectum
29012|NCT02870101|Gram-Negative Bacterial Infections
29013|NCT02870101|Bacterial Infections
29014|NCT02870101|Genital Diseases, Male
29015|NCT02870101|Genital Diseases, Female
29016|NCT02872831|Fine needle aspiration
29017|NCT02872818|Apoptotic signal pathway
29018|NCT02872818|Survivin
29019|NCT02872818|Bcl-2
29020|NCT02872818|Bax
29021|NCT02872818|c-Myc
29022|NCT02872818|Caspase-9
29023|NCT02872818|endometrial hyperplasia
29024|NCT02872818|endometrium cancer
29025|NCT02872792|cycloergometer
29026|NCT02872753|Platelet Rich Plasma
29027|NCT02872753|meniscectomy
29028|NCT02872753|randomized controlled trial
29029|NCT02872753|intra-op injection
29030|NCT02872714|Urothelial carcinoma
29031|NCT02872714|fibroblast growth factor (FGF)
29032|NCT02872714|fibroblast growth factor receptor (FGFR)
29033|NCT02872714|FGF/FGFR alterations
29034|NCT02872675|Asthma
29035|NCT02872675|Exercise-Induced Asthma
29036|NCT02872675|Gut Bacteria
29037|NCT02872675|Bimuno® Galactooligosaccharide
29038|NCT02872675|Pulmonary Function
29039|NCT02872610|suicidal thoughts
29040|NCT02872610|suicidal ideation
29041|NCT02872610|Internet intervention
29042|NCT02872610|self-help
29043|NCT02872571|islet of Langerhans
29044|NCT02872571|transplantation
29045|NCT02872571|muscle
29046|NCT02872506|Quality of life
29047|NCT02872506|Crohn's disease
29048|NCT02872506|Ileocecal resection
29049|NCT02872506|Anti TNF
29050|NCT02872493|obesity
29051|NCT02872493|bariatric surgery
29052|NCT02872493|bowel length
29053|NCT02872480|Concussion
29054|NCT02872480|Exercise
29055|NCT02872467|Cocaine
29056|NCT02872467|Mothers
29057|NCT02872467|Pregnant women
29058|NCT02872467|Postpartum women
29059|NCT02872467|Oxytocin
29060|NCT02872467|Substance use disorders
29061|NCT02872467|Substance abuse
29062|NCT02872467|Prenatal substance use
29063|NCT02872467|stress
29064|NCT02872454|Major Depression
29065|NCT02872454|Text Messaging
29066|NCT02872454|Guided Self-Help
29067|NCT02872402|gestational diabetes
29068|NCT02872402|dietary modification
29069|NCT02872402|weight loss
29070|NCT02872402|physical activity
29071|NCT02872402|breastfeeding
29072|NCT02872376|Anemia
29073|NCT02872376|Crohn's disease
29074|NCT02872376|Ulcerative colitis
29075|NCT02872363|breast screening
29076|NCT02872363|breast cancer
29077|NCT02872363|mammogram
29078|NCT02872363|uptake
29079|NCT02872363|reminder
29080|NCT02872363|text message
29081|NCT02872363|SMS
29082|NCT02872311|Vaccine
29083|NCT02872311|Influenza
29084|NCT02872311|High Dose
29085|NCT02872311|Adjuvanted
29086|NCT02872298|Severe
29087|NCT02872298|Refractory
29088|NCT02872259|metastatic melanoma
29089|NCT02872259|advanced Non-resectable melanoma
29090|NCT02872181|Maternal Position
29091|NCT02872181|Tilt
29092|NCT02872181|Left Uterine Displacement
29093|NCT02872181|Cesarean Delivery
29094|NCT02872181|Cesarean Section
29095|NCT02872155|contrast-induced nephropathy
29096|NCT02872155|renal insufficiency
29097|NCT02872155|computed tomography
29098|NCT02872129|Fibromyalgia
29099|NCT02872129|chronic widespread pain
29100|NCT02872129|follow-up
29101|NCT02872129|pain
29102|NCT02872129|fatigue
29103|NCT02872129|symptoms
29104|NCT02872129|workability
29105|NCT02872129|physical function
29106|NCT02872090|COPD
29107|NCT02872090|bronchodilatators
29108|NCT02872090|autonomic nervous system
29109|NCT02872090|cardiovascular system
29110|NCT02872077|AA for NAS
29111|NCT02872064|Early breast cancer
29112|NCT02872064|Photodynamic therapy
29113|NCT02872064|PDT
29114|NCT02872064|Visudyne
29115|NCT02872064|Verteporfin
29116|NCT02872051|Vocational Rehabilitation
29117|NCT02872051|Anxiety
29118|NCT02872051|Depression
29119|NCT02872051|Common Mental Disorders
29120|NCT02872051|Cognitive Behavior Therapy
29121|NCT02872051|Return to Work
29122|NCT02872051|Mental Health Services
29123|NCT02872051|Integration
29124|NCT02871999|Acupuncture Therapy
29125|NCT02871999|Pain degree after surgery
29126|NCT02871973|parenting
29127|NCT02871973|child development
29128|NCT02871973|language
29129|NCT02871947|severe asthma
29130|NCT02871934|Pharmacogenetics
29131|NCT02871934|SLCO1B1 protein, human
29132|NCT02871934|OATP1B1 protein, human
29133|NCT02871934|Simvastatin
29134|NCT02871934|Cardiovascular disease
29135|NCT02871934|Cholesterol
29136|NCT02871934|Statin-related myotoxicity
29137|NCT02871934|Veterans
29138|NCT02871934|Point-of-care
29139|NCT02871921|Behavioral prevention
29140|NCT02871921|social interaction
29141|NCT02871921|dementia
29142|NCT02871921|MRI
29143|NCT02871895|sepsis
29144|NCT02871895|severe sepsis
29145|NCT02871895|septic shock
29146|NCT02871895|multiple organ failure
29147|NCT02871869|Cinobufacini Tablets
29148|NCT02871869|CHOP protocol
29149|NCT02871856|Screening
29150|NCT02871856|Computed tomography
29151|NCT02871856|Lung cancer
29152|NCT02871830|Physical activity
29153|NCT02871830|Walking
29154|NCT02871830|Intervention
29155|NCT02871830|Adolescent girls
29156|NCT02871830|Randomised trial
29157|NCT02871817|Near Corrected Visual Acuity
29158|NCT02871817|Early Treatment Diabetes Retinopathy Study
29159|NCT02871817|Amsler Grid
29160|NCT02871817|Home Monitoring
29161|NCT02871791|Her2-negative metastatic breast cancer
29162|NCT02871791|Hormone receptor (HR)-positive breast cancer
29163|NCT02871765|Patient education
29164|NCT02871765|Knowledge
29165|NCT02871765|Life distress
29166|NCT02871765|Quality of life
29167|NCT02871752|prostate cancer
29168|NCT02871752|active surveillance
29169|NCT02871752|MBSR
29170|NCT02871752|couples
29171|NCT02871752|health promotion
29172|NCT02871752|quality of life
29173|NCT02871739|Communication skills training
29174|NCT02871739|Shared Decision Making
29175|NCT02871739|Decision making
29176|NCT02871739|Decision Aids
29177|NCT02871739|lung cancer screening
29178|NCT02871726|Prostate Cancer Detection
29179|NCT02871726|Prostate Biopsy
29180|NCT02871726|Prostate Cancer
29181|NCT02871726|Transrectal Ultrasound
29182|NCT02871713|quadratus lumborum block
29183|NCT02871700|stroke
29184|NCT02871700|translational rehabilitation
29185|NCT02871700|mirror neuron system
29186|NCT02871700|action observation
29187|NCT02871700|mirror therapy
29188|NCT02871700|MEG
29189|NCT02871674|Behavioural interventions
29190|NCT02871674|Sleep difficulties
29191|NCT02871674|Children
29192|NCT02871674|Attention Deficit Hyperactivity Disorder
29193|NCT02871674|Randomised controlled trial
29194|NCT02871674|Saudi Arabia
29195|NCT02871674|Behavioural Insomnia
29196|NCT02871661|vulvodynia
29197|NCT02871661|pelvic floor muscles
29198|NCT02871661|kinesiotherapy
29199|NCT02871661|electrical therapy
29200|NCT02871661|physical therapy
29201|NCT02871661|amitriptyline
29202|NCT02871661|female sexual dysfunction.
29203|NCT02871648|Healthy
29204|NCT02871609|Biofilm
29205|NCT02871609|Morbidity
29206|NCT02871609|Ureteral Catheterization
29207|NCT02871570|Hepatic Impairment
29208|NCT02871570|Rivipansel
29209|NCT02871544|BNP
29210|NCT02871544|NGAL
29211|NCT02871544|Sepsis
29212|NCT02871544|Mortality
29213|NCT02871531|retinal detachment
29214|NCT02871531|pneumatic retinopexy
29215|NCT02871531|vitrectomy
29216|NCT02871479|Atopic Dermatitis
29217|NCT02871479|Eczema
29218|NCT02871453|Ischemic Stroke
29219|NCT02871453|Motor Dysfunction
29220|NCT02871453|Scalp Acupuncture
29221|NCT02871427|Lewy body dementia
29222|NCT02871427|Dementia with Lewy bodies
29223|NCT02871427|Parkinson's disease dementia
29224|NCT02871427|Visual hallucinations
29225|NCT02871427|REM sleep behavior disorder
29226|NCT02871401|IPF
29227|NCT02871401|Herpesvirus
29228|NCT02871401|Valganciclovir
29229|NCT02871388|Physical activity; diet; nutrition; breast cancer prevention; mammography screening
29230|NCT02871375|myopia
29231|NCT02871375|presbyopia
29232|NCT02871349|Autism
29233|NCT02871349|ASD
29234|NCT02871336|Cata collection
29235|NCT02871336|Pancreatic cancer surgery
29236|NCT02871323|Myelofibrosis Transformation in Essential Thrombocythemia
29237|NCT02871297|adolescent
29238|NCT02871297|children
29239|NCT02871284|cancer
29240|NCT02871284|anticancer treatment
29241|NCT02871284|exercise
29242|NCT02871284|physical activity
29243|NCT02871284|sensorimotor training
29244|NCT02871284|chemotherapy-induced polyneuropathy
29245|NCT02871245|Acupuncture Therapy
29246|NCT02871245|Laparoscopic Surgery
29247|NCT02871245|Gastrointestinal Tract Recovery of Function
29248|NCT02871219|Follicular lymphoma
29249|NCT02871219|Obinutuzumab
29250|NCT02871219|GA101
29251|NCT02871219|Gazyva
29252|NCT02871219|Lenalidomide
29253|NCT02871219|CC-5013
29254|NCT02871219|Revlimid
29255|NCT02871193|paravertebral block
29256|NCT02871193|patient controlled analgesia
29257|NCT02871193|ropivacaine
29258|NCT02871193|dexamethasone
29259|NCT02871180|Hypoglycemia
29260|NCT02871180|Type 1 diabetes
29261|NCT02871167|oocyte/embryo cryopreservation
29262|NCT02871128|Hemoglobin
29263|NCT02871128|serum iron
29264|NCT02871128|serum ferritin
29265|NCT02871128|Hematocrit
29266|NCT02871128|antioxidant
29267|NCT02871115|Cancer Care
29268|NCT02871102|mechanical ventilation
29269|NCT02871102|respiratory mechanics
29270|NCT02871102|acute respiratory distress syndrome
29271|NCT02871102|positive end-expiratory pressure
29272|NCT02871102|tidal volume
29273|NCT02871089|Type 1 Diabetes
29274|NCT02871089|Closed-loop glucose control
29275|NCT02871089|Artificial Pancreas
29276|NCT02871089|Continuous subcutaneous insulin infusion
29277|NCT02871089|Multiple daily injection therapy
29278|NCT02871089|New onset type 1 diabetes
29279|NCT02871089|Residual C-Peptide secretion
29280|NCT02871089|Beta-cell function preservation
29281|NCT02871089|Continuous glucose monitoring
29282|NCT02871050|Biobank
29283|NCT02871050|biorepository
29284|NCT02871050|Castlebank
29285|NCT02871050|Castleman Disease
29286|NCT02871050|CD
29287|NCT02871050|MCD
29288|NCT02871050|iMCD
29289|NCT02871050|Castleman
29290|NCT02871050|Castleman's Disease
29291|NCT02871050|multicentric Castleman's disease
29292|NCT02871050|multicentric Castleman disease
29293|NCT02871050|Angiofollicular Lymph Hyperplasia
29294|NCT02871024|Polymyxin B
29295|NCT02871024|Pneumonia
29296|NCT02871024|Sepsis
29297|NCT02871024|Urinary tract infection
29298|NCT02871011|Tinea Bronchodilator Agents
29299|NCT02871011|Tinea Pedis
29300|NCT02871011|Nitric Oxide
29301|NCT02871011|Dermatomycoses
29302|NCT02871011|Endothelium-Dependent Relaxing Factors
29303|NCT02871011|Infectious
29304|NCT02871011|Infection
29305|NCT02871011|Mycoses
29306|NCT02871011|Skin Diseases
29307|NCT02871011|Foot Dermatoses
29308|NCT02871011|Foot Diseases
29309|NCT02871011|Pruritus
29310|NCT02871011|Skin Manifestations Signs and Symptoms
29311|NCT02870946|Extracorporeal Membrane Oxygenation
29312|NCT02870946|Cardiogenic Shock
29313|NCT02870946|Renal Replacement Therapy
29314|NCT02870933|CD 133+
29315|NCT02870933|Transepicardial with Transseptal Implantation
29316|NCT02870933|CABG
29317|NCT02870907|primary enucleation
29318|NCT02870907|retinoblastoma
29319|NCT02870868|slow breathing
29320|NCT02870868|yoga
29321|NCT02870868|mind-body practicers
29322|NCT02870842|ultrasonography
29323|NCT02870842|child
29324|NCT02870842|perioperative period
29325|NCT02870842|general anesthesia
29326|NCT02870842|lung
29327|NCT02870777|MRD
29328|NCT02870777|Acute myeloid leukemia
29329|NCT02870764|Danshenduofensuanyan
29330|NCT02870764|Lp-PLA2
29331|NCT02870764|coronary artery disease
29332|NCT02870764|Salvia miltiorrhiza
29333|NCT02870751|ETEC
29334|NCT02870751|human challenge study
29335|NCT02870751|heat stable toxin
29336|NCT02870751|tourist diarrhea
29337|NCT02870751|diarrhea
29338|NCT02870751|enterotoxigenic
29339|NCT02870725|chronic headaches, migraines, depression
29340|NCT02870712|perineal tear of first degree
29341|NCT02870712|suture
29342|NCT02870699|chemotherapy neoadjuvant
29343|NCT02870686|ERCP
29344|NCT02870686|EUS guided ERCP without fluoroscopy
29345|NCT02870673|acupuncture
29346|NCT02870673|electrical stimulation
29347|NCT02870673|carpal tunnel syndrome
29348|NCT02870608|Elastography
29349|NCT02870556|cervical epidural, laryngectomy, pharyngocutaneous fistula
29350|NCT02870543|Bruxism
29351|NCT02870543|Sleep bruxism
29352|NCT02870543|Sleep related bruxism
29353|NCT02870543|Homeopathy
29354|NCT02870504|laser peripheral iridoplasty
29355|NCT02870504|treatment
29356|NCT02870491|Child Diarrhea
29357|NCT02870491|Cluster Randomized Controlled Trial
29358|NCT02870491|Oral Rehydration
29359|NCT02870491|ORS
29360|NCT02870491|Zinc
29361|NCT02870491|Brac
29362|NCT02870491|Community Health Workers
29363|NCT02870491|Uganda
29364|NCT02870465|outpatient versus operating room
29365|NCT02870465|k wire infection
29366|NCT02870465|closed reduction internal fixation
29367|NCT02870452|Haemophilia
29368|NCT02870452|RCT
29369|NCT02870452|Pain
29370|NCT02870452|Hemarthrosis
29371|NCT02870452|Hypnosis
29372|NCT02870452|Cognitive-Behavioral Therapy
29373|NCT02870452|Quality of Life
29374|NCT02870452|Distress
29375|NCT02870452|Cytokines
29376|NCT02870426|Olfactory ensheathing cells
29377|NCT02870413|telehealth
29378|NCT02870387|chronic illness
29379|NCT02870387|children
29380|NCT02870387|children with medical complexity
29381|NCT02870387|medical home
29382|NCT02870387|inpatient consultation
29383|NCT02870335|low back
29384|NCT02870335|manual therapy
29385|NCT02870335|stretching
29386|NCT02870322|overweight
29387|NCT02870322|obesity
29388|NCT02870322|lifestyle prescription
29389|NCT02870322|prevention
29390|NCT02870322|physical activity
29391|NCT02870322|healthy eating
29392|NCT02870283|Cost effectiveness
29393|NCT02870283|Bipolar disorder
29394|NCT02870283|Mixed episodes
29395|NCT02870283|Quality of life
29396|NCT02870270|saliva
29397|NCT02870270|microflora
29398|NCT02870270|diet
29399|NCT02870270|quality of life
29400|NCT02870270|oral cancer
29401|NCT02870244|Melanoma
29402|NCT02870244|Gene Therapy
29403|NCT02870244|Adoptive T-Cell Transfer
29404|NCT02870244|IL-2
29405|NCT02870192|Rectal Prolapse
29406|NCT02870179|Pulse Oximetry
29407|NCT02870179|Temperature
29408|NCT02870179|Respiratory Rate
29409|NCT02870179|Respiratory Gases
29410|NCT02870179|This study determines the measurement accuracy of the physiological parameters
29411|NCT02870062|Chlorhexidine baths
29412|NCT02870062|Critical patient
29413|NCT02870062|Healthcare associated infections
29414|NCT02870062|Critical care environment
29415|NCT02870062|Patient colonization
29416|NCT02870049|early detection
29417|NCT02869971|Prostatic artery embolization
29418|NCT02869971|Combined Therapy
29419|NCT02869971|IPSS
29420|NCT02869958|Asthma
29421|NCT02869958|Exacerbation
29422|NCT02869958|Treatment
29423|NCT02869958|Internet
29424|NCT02869958|Emergency care
29425|NCT02869945|de novo untreated Parkinson Disease
29426|NCT02869945|genetic
29427|NCT02869945|COMT Polymorphism
29428|NCT02869945|gene
29429|NCT02869945|brain MRI
29430|NCT02869945|brain MPET
29431|NCT02869841|laparotomy
29432|NCT02869841|pain
29433|NCT02869841|rectus sheath block
29434|NCT02869815|Methylene blue
29435|NCT02869815|Indocyanine green
29436|NCT02869815|Neoadjuvant Therapy
29437|NCT02869815|Sentinel Lymph Node Biopsy
29438|NCT02869815|Breast Neoplasms
29439|NCT02869802|Cancer
29440|NCT02869802|Pancreatic Cancer
29441|NCT02869802|Advanced Pancreatic Ductal Adenocarcinoma
29442|NCT02869802|PDAC
29443|NCT02869802|Genomic Analysis
29444|NCT02869802|Molecular subtyping
29445|NCT02869763|Ethanol
29446|NCT02869763|Steroid profile
29447|NCT02869763|Pharmacokinetics
29448|NCT02869737|Point of Care Device; post traumatic coagulopathy
29449|NCT02869724|IMV : voluntary drug intoxications
29450|NCT02869724|Drug
29451|NCT02869724|Divided prescription
29452|NCT02869672|safety
29453|NCT02869672|immunogenicity
29454|NCT02869672|vaccine
29455|NCT02869659|obesity
29456|NCT02869659|pre-diabetes
29457|NCT02869659|overweight
29458|NCT02869659|lifestyle change
29459|NCT02869659|glucose
29460|NCT02869646|PTSD
29461|NCT02869646|acupuncture
29462|NCT02869646|integrative medicine
29463|NCT02869464|Aneurysm
29464|NCT02869464|Intracranial Aneurysm
29465|NCT02869464|Abdominal Aortic Aneurysm
29466|NCT02869438|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
29467|NCT02869399|head and neck cancer, nutritional intervention
29468|NCT02869386|stroke
29469|NCT02869386|prehospital
29470|NCT02869386|telemedicine
29471|NCT02869386|thrombolysis
29472|NCT02869386|thrombectomy
29473|NCT02869386|endovascular treatment
29474|NCT02869386|functional outcome
29475|NCT02869347|recombinant C1 esterase inhibitor
29476|NCT02869347|acute kidney injury
29477|NCT02869347|coronary angiography
29478|NCT02869347|contrast media
29479|NCT02869347|Conestat alfa
29480|NCT02869347|inflammation
29481|NCT02869308|Cardiomyopathy
29482|NCT02869308|Chemotherapy
29483|NCT02869308|Left ventricular ejection fraction
29484|NCT02869295|Metastatic Solid Tumors
29485|NCT02869295|Locally Advanced Solid Tumors
29486|NCT02869256|chronic myeloid leukemia
29487|NCT02869256|practices evaluation
29488|NCT02869243|A malignant growing astrocytoma of central nervous system
29489|NCT02869230|Breast cancer
29490|NCT02869230|Non palpable breast lesions
29491|NCT02869230|radioguided occult lesion localization
29492|NCT02869217|NY-ESO-1 expressing solid tumors in HLA-A2 positive patients
29493|NCT02869165|Postmenopausal
29494|NCT02869152|sentinel lymph node
29495|NCT02869152|lymphatic mapping
29496|NCT02869152|rectal tumor
29497|NCT02869152|rectal cancer
29498|NCT02869152|early stage
29499|NCT02869139|Thirst
29500|NCT02869139|Ice
29501|NCT02869139|Menthol
29502|NCT02869139|Perioperative Nursing.
29503|NCT02869139|Recovery Room
29504|NCT02869126|99mTc-Sestamibi
29505|NCT02869126|thallium-201
29506|NCT02869126|semiconductor camera
29507|NCT02869100|magnetic resonance imaging
29508|NCT02869100|sodium fluoride positron emission tomography
29509|NCT02869074|von Willebrand disease (VWD)
29510|NCT02869074|von Willebrand factor (VWF)
29511|NCT02869074|von Willebrand factor gene
29512|NCT02869074|next generation sequencing
29513|NCT02869074|diagnosis
29514|NCT02869074|VWD Spanish Cohort
29515|NCT02869061|Bladder neck obstruction
29516|NCT02869061|Bladder outlet obstruction
29517|NCT02869061|Benign prostatic hyperplasia
29518|NCT02869061|Urinary bladder neck obstruction
29519|NCT02869061|Bladder neck contracture
29520|NCT02869061|Bladder neck stricture
29521|NCT02869061|Bladder neck stenosis
29522|NCT02869061|Transurethral resection of the prostate
29523|NCT02869061|Prostatectomy
29524|NCT02869061|Stromal vascular fraction (SVF)
29525|NCT02869061|Adipose-derived regenerative cells (ADRC)
29526|NCT02869061|Adipose tissue
29527|NCT02869061|Stem cells
29528|NCT02869048|Biological Specimen Banks
29529|NCT02869048|Innate Immunity
29530|NCT02869048|Clinical Study
29531|NCT02869048|Complement system proteins
29532|NCT02869048|Amyotrophic lateral sclerosis
29533|NCT02869048|Neurodegenerative disease
29534|NCT02869048|Motor neuron disease
29535|NCT02869035|PET
29536|NCT02869035|Serotonin
29537|NCT02869035|5-HT4R
29538|NCT02869035|MRI
29539|NCT02869035|fMRI
29540|NCT02869035|EEG
29541|NCT02869035|Cortisol awakening response
29542|NCT02869035|Oxidative stress
29543|NCT02869035|Mental health
29544|NCT02869035|Prediction of treatment response
29545|NCT02869035|Inflammation
29546|NCT02869035|5-HTTLPR
29547|NCT02869035|Brain imaging
29548|NCT02869035|Early life stress
29549|NCT02869035|Selective Serotonin Reuptake Inhibitor
29550|NCT02869035|Escitalopram
29551|NCT02869035|Psychometrics
29552|NCT02869035|Moderate depression
29553|NCT02869035|Severe depression
29554|NCT02869035|ERP
29555|NCT02869035|rsfMRI
29556|NCT02869035|11C-SB207145
29557|NCT02869035|Sexual function
29558|NCT02869035|MDD
29559|NCT02869035|Affective cognition
29560|NCT02869035|Cold cognition
29561|NCT02869035|Social cognition
29562|NCT02869035|Anxiety
29563|NCT02869009|stroke
29564|NCT02869009|clopidogrel
29565|NCT02869009|antiplatelets
29566|NCT02868957|CAD
29567|NCT02868957|Digital imaging
29568|NCT02868957|Prosthetic Dentistry
29569|NCT02868931|self-management
29570|NCT02868931|empowerment
29571|NCT02868931|treatment and education program
29572|NCT02868931|insulin pump
29573|NCT02868931|diabetes education
29574|NCT02868866|physical activity
29575|NCT02868866|nutrition
29576|NCT02868866|fruits and vegetables
29577|NCT02868866|faith-based
29578|NCT02868866|churches
29579|NCT02868853|diet
29580|NCT02868853|weight loss
29581|NCT02868853|tracking
29582|NCT02868853|mobile
29583|NCT02868853|calories
29584|NCT02868840|stroke
29585|NCT02868840|Tai ji
29586|NCT02868840|postural balance
29587|NCT02868840|cognition
29588|NCT02868827|cholecalciferol and critical illness
29589|NCT02868827|Mortality and cholecalciferol supplementation
29590|NCT02868801|Pregabalin
29591|NCT02868788|inflammation
29592|NCT02868788|insulin resistance
29593|NCT02868788|type 2 diabetes
29594|NCT02868788|obesity
29595|NCT02868762|neck pain, voice disorder
29596|NCT02868749|Hyaluronic Acid
29597|NCT02868749|histology
29598|NCT02868749|ultrasound
29599|NCT02868749|subcutaneous
29600|NCT02868749|adipose tissue
29601|NCT02868723|cerebrovascular disease
29602|NCT02868723|patient management
29603|NCT02868723|stroke management
29604|NCT02868723|prognosis
29605|NCT02868723|3D Carotid Doppler Imaging
29606|NCT02868723|Randomization
29607|NCT02868710|primary prevention
29608|NCT02868671|mild TBI
29609|NCT02868671|Post-traumatic Stress Disorders
29610|NCT02868671|Acupuncture
29611|NCT02868658|Influenza
29612|NCT02868658|health care workers
29613|NCT02868658|nosocomial
29614|NCT02868658|asymptomatic
29615|NCT02868658|France
29616|NCT02868632|Unresectable
29617|NCT02868632|Locally Advanced
29618|NCT02868632|Non-Metastatic
29619|NCT02868619|fMRI
29620|NCT02868619|Deep brain stimulation
29621|NCT02868619|Food
29622|NCT02868619|Eating
29623|NCT02868619|Reward
29624|NCT02868580|ALS
29625|NCT02868580|Antiretroviral Therapy, Triumeq
29626|NCT02868541|microorganisms
29627|NCT02868541|pilgrim
29628|NCT02868541|hajj
29629|NCT02868528|advanced age women
29630|NCT02868528|blastocyst culture
29631|NCT02868528|PGS
29632|NCT02868528|live birth rate
29633|NCT02868502|Glaucoma
29634|NCT02868502|Open Angle Glaucoma
29635|NCT02868502|Intra Ocular Pressure
29636|NCT02868502|Ocular Hypotensive Drops
29637|NCT02868502|Trabeculectomy
29638|NCT02868502|Cyclophotocoagulation
29639|NCT02868502|Glaucoma Drainage Device
29640|NCT02868489|Microbiota
29641|NCT02868463|oxygen tension
29642|NCT02868463|Female Urinary Microbiome
29643|NCT02868463|Urinary Tract Symptoms
29644|NCT02868463|Urine Oxygen Level
29645|NCT02868398|Ulcerative Colitis
29646|NCT02868398|Golimumab
29647|NCT02868398|Deep and prolonged remission
29648|NCT02868385|Schistosomiasis
29649|NCT02868385|Schistosoma mansoni
29650|NCT02868385|Bilharzia
29651|NCT02868372|Cesarean section
29652|NCT02868372|Betadine
29653|NCT02868372|Wound infection
29654|NCT02868320|SMS
29655|NCT02868320|text messaging
29656|NCT02868320|diabetes self management
29657|NCT02868320|glycemic control
29658|NCT02868320|mHealth
29659|NCT02868320|mobile health
29660|NCT02868320|diabetes education
29661|NCT02868281|Cluster Randomization
29662|NCT02868281|Peak Expiratory Flow
29663|NCT02868281|Forced Expiratory Volume
29664|NCT02868281|Standardized Asthma Quality of Life Questionnaire
29665|NCT02868281|Asthma Control Test
29666|NCT02868268|Neuroblastoma
29667|NCT02868255|Biobank analyses
29668|NCT02868255|Effect evaluation of the drug
29669|NCT02868255|patient-derived cells
29670|NCT02868255|SIRPα/CD47 expression
29671|NCT02868242|HCV genotype 1 or 4 (GT-1 or GT-4)
29672|NCT02868242|Direct Acting Antiviral
29673|NCT02868242|Combination Therapy
29674|NCT02868242|Hepatitis C, Chronic
29675|NCT02868242|Liver Diseases
29676|NCT02868242|Virus Diseases
29677|NCT02868177|Prevention
29678|NCT02868151|Oral mucositis, chemo radiotherapy, vitamin c,
29679|NCT02868138|Sickle cell disease
29680|NCT02868138|Hydroxyurea
29681|NCT02868138|Compliance
29682|NCT02868125|pertrochanteric
29683|NCT02868125|radiography
29684|NCT02868112|Cancer Care
29685|NCT02868112|Palliative Care
29686|NCT02868112|Geriatrics
29687|NCT02868112|Quality of Life
29688|NCT02868086|Age-related macular degeneration
29689|NCT02868086|Optical coherence tomography angiography
29690|NCT02868047|chronic pancreatitis
29691|NCT02868047|endoscopic ultrasound
29692|NCT02868034|Low Back Pain
29693|NCT02868034|Spinal Manipulation
29694|NCT02868034|Exercise
29695|NCT02868021|Elderly
29696|NCT02868021|Exercise
29697|NCT02868008|multimodal imaging
29698|NCT02868008|surgical risk
29699|NCT02868008|arteriovenous malformations
29700|NCT02867982|platform switching
29701|NCT02867982|crestal bone remodeling
29702|NCT02867982|soft tissue thickness
29703|NCT02867982|dental implant
29704|NCT02867969|Spinocerebellar ataxia
29705|NCT02867969|Exergaming
29706|NCT02867969|Neurodegenerative diseases
29707|NCT02867969|Rare disease
29708|NCT02867969|Motor exercises
29709|NCT02867969|Premanifest stage
29710|NCT02867969|Training
29711|NCT02867956|Ovarian cancer
29712|NCT02867956|Apatinib
29713|NCT02867956|Etoposide
29714|NCT02867956|Chemotherapy
29715|NCT02867943|sepsis, shock,Lactate,volume controlled ventilation
29716|NCT02867930|Echocardiography
29717|NCT02867930|Transesophageal
29718|NCT02867930|Dexmedetomidine
29719|NCT02867930|Ketamine
29720|NCT02867930|Propofol
29721|NCT02867917|Fibers
29722|NCT02867917|Constipation
29723|NCT02867891|FLT3-ITD
29724|NCT02867891|AML
29725|NCT02867891|allo-HSCT
29726|NCT02867839|Gastric cancer
29727|NCT02867839|Adjuvant chemotherapy
29728|NCT02867839|S1
29729|NCT02867839|Oxaliplatin
29730|NCT02867826|Endoscopy
29731|NCT02867826|Ampulla of Vater
29732|NCT02867826|Duodenoscopy
29733|NCT02867813|High Cholesterol
29734|NCT02867813|Treatment for high cholesterol
29735|NCT02867813|Lowering cholesterol
29736|NCT02867813|Lowering high cholesterol
29737|NCT02867813|Hypercholesterolemia
29738|NCT02867800|Sickle Cell Disease
29739|NCT02867800|Graft Versus Host Disease
29740|NCT02867800|Abatacept
29741|NCT02867800|Hematopoietic Stem Cell Transplantation
29742|NCT02867787|Shoulder Joint
29743|NCT02867787|A02.835.583.748
29744|NCT02867774|chronic pelvic pain
29745|NCT02867774|central pain amplification
29746|NCT02867774|exercise
29747|NCT02867774|physical activity
29748|NCT02867761|COPD
29749|NCT02867761|Chronic Obstructive Pulmonary Disease
29750|NCT02867761|Pulmonary Function Tests
29751|NCT02867761|Current Smoker
29752|NCT02867761|Former Smoker
29753|NCT02867761|Chronic Obstructive Airway Disease
29754|NCT02867761|Respiratory Symptoms
29755|NCT02867748|tvt abbrevo , Serasis
29756|NCT02867735|Macular Edema
29757|NCT02867735|Diabetic Macular Edema (DME)
29758|NCT02867735|Neovascular age-related Macular Degeneration(AMD)
29759|NCT02867735|Retinal Vein Occlusions(RVO)
29760|NCT02867696|Bariatric Surgery
29761|NCT02867696|Physical Activity
29762|NCT02867696|Weight Management
29763|NCT02867696|Weight Loss
29764|NCT02867683|vibrotactile feedback
29765|NCT02867683|vestibular rehabilitation
29766|NCT02867683|balance
29767|NCT02867670|Transcranial Magnetic Stimulation (TMS)
29768|NCT02867644|conversational hypnosis
29769|NCT02867644|imaging
29770|NCT02867644|care
29771|NCT02867644|breast neoplasia
29772|NCT02867644|anxiety
29773|NCT02867644|pain
29774|NCT02867631|Intervention study
29775|NCT02867631|Maternal obesity
29776|NCT02867631|Nutrition
29777|NCT02867631|Maternal child health
29778|NCT02867514|tobacco
29779|NCT02867514|craving
29780|NCT02867514|tDCS
29781|NCT02867514|attentional tasks
29782|NCT02867501|venous distension
29783|NCT02867501|venous reflux
29784|NCT02867488|carotenoids
29785|NCT02867488|phylloquinone
29786|NCT02867488|tocopherols
29787|NCT02867488|vitamin A
29788|NCT02867384|Graft vs. Host Disease
29789|NCT02867358|acute uncomplicated influenza
29790|NCT02867319|safety
29791|NCT02867319|vaccine
29792|NCT02867306|methotrexate (MTX)
29793|NCT02867306|Pharmacokinetics
29794|NCT02867306|ASP1707
29795|NCT02867306|Rheumatoid Arthritis (RA)
29796|NCT02867280|Sorafenib
29797|NCT02867280|Microvascular invasion
29798|NCT02867280|adjuvant therapy
29799|NCT02867280|hepatocellular carcinoma
29800|NCT02867267|thymosin alpha 1; thymalfasin; sepsis; immunodepression
29801|NCT02867254|candida
29802|NCT02867254|endodontic lesion
29803|NCT02867254|diabetes
29804|NCT02867202|intrauterine balloon
29805|NCT02867202|intrauterine contraceptive device
29806|NCT02867202|Asherman Syndrome
29807|NCT02867189|anterior chamber flare
29808|NCT02867189|cataract
29809|NCT02867189|intraocular pressure
29810|NCT02867189|micro-instrument
29811|NCT02867189|photograph-based atlas
29812|NCT02867189|visual
29813|NCT02867189|training nurse
29814|NCT02867111|sperm selection
29815|NCT02867111|ICSI
29816|NCT02867111|Assisted Reproductive Techniques
29817|NCT02867098|healthy
29818|NCT02867098|volunteer
29819|NCT02867085|MDS
29820|NCT02867085|Myelodysplastic Syndromes
29821|NCT02867033|desmoid tumour
29822|NCT02867020|apalutamide
29823|NCT02867020|abiraterone
29824|NCT02867020|prostate cancer
29825|NCT02867007|KW-0761
29826|NCT02867007|KHK2455
29827|NCT02867007|Metastatic Solid Tumors
29828|NCT02867007|Locally Advanced Solid Tumors
29829|NCT02867007|Mogamulizumab
29830|NCT02867007|Oncology
29831|NCT02867007|Anti-Tumor
29832|NCT02866994|Women
29833|NCT02866981|Brain Metastases
29834|NCT02866955|aromatase inhibitors
29835|NCT02866955|Metastases
29836|NCT02866929|orthodontics
29837|NCT02866929|periodontics
29838|NCT02866929|piezosurgery
29839|NCT02866929|accelerated orthodontics
29840|NCT02866929|Surgically Accelerated Orthodontic Treatment
29841|NCT02866903|Peritoneal carcinosis
29842|NCT02866903|intraperitoneal (IP) OXAliplatin
29843|NCT02866903|Phase I/II dose escalation trial
29844|NCT02866903|FOLFIRI Bevacizumab chemotherapy
29845|NCT02866890|Laryngeal Tube Suction
29846|NCT02866890|seal pressure
29847|NCT02866890|mechanical ventilation
29848|NCT02866877|augmented renal clearance
29849|NCT02866864|Allergen
29850|NCT02866864|Veterinary
29851|NCT02866864|Allergy
29852|NCT02866864|Animals
29853|NCT02866838|Tranexamic acid
29854|NCT02866838|NOAC
29855|NCT02866838|Direct Oral Anticoagulant (DOAC)
29856|NCT02866838|Direct oral anticoagulants
29857|NCT02866838|Non-Vitamin K antagonist oral anticoagulants
29858|NCT02866825|Inflammation
29859|NCT02866825|Systemic Inflammatory Response Syndrome
29860|NCT02866825|Pathologic Processes
29861|NCT02866825|Organ Dysfunction
29862|NCT02866799|Multimorbidity
29863|NCT02866799|Primary Health Care
29864|NCT02866799|Polypharmacy
29865|NCT02866799|Comorbidity
29866|NCT02866799|Medication Adherence
29867|NCT02866799|Medication Appropriateness Index
29868|NCT02866799|Patient-Centered Care
29869|NCT02866773|Family
29870|NCT02866773|well-being
29871|NCT02866773|Physical activity
29872|NCT02866773|Diet
29873|NCT02866760|Smoking Cessation
29874|NCT02866734|Diabetic Retinopathy
29875|NCT02866734|Screening
29876|NCT02866734|Fee for screening
29877|NCT02866734|Private practice
29878|NCT02866721|Human Mesenchymal Stem Cells
29879|NCT02866695|Actinic Keratosis
29880|NCT02866695|lung transplant
29881|NCT02866695|kidney transplant
29882|NCT02866643|contraceptive implant
29883|NCT02866643|postpartum contraception
29884|NCT02866643|breastfeeding and contraception
29885|NCT02866630|Sevoflurane
29886|NCT02866630|Desflurane
29887|NCT02866630|Coronary Sinus
29888|NCT02866630|Oxygenator Exhaust
29889|NCT02866630|Lactate
29890|NCT02866630|Cardiopulmonary bypass
29891|NCT02866617|Quality of Life
29892|NCT02866617|Vacuum formed thermoplastic retainer
29893|NCT02866617|Orthodontic study model
29894|NCT02866617|3D reconstructed study model
29895|NCT02866604|Traumatic brain injury
29896|NCT02866604|isotonic balanced fluid
29897|NCT02866591|mammography
29898|NCT02866591|pain
29899|NCT02866591|quality of life
29900|NCT02866591|screening
29901|NCT02866591|image quality
29902|NCT02866591|radiology
29903|NCT02866526|adolescents
29904|NCT02866526|young adults
29905|NCT02866448|Cardiovascular disease
29906|NCT02866448|Flavonoid
29907|NCT02866448|Isoquercetin
29908|NCT02866448|Aspirin
29909|NCT02866448|Platelet function
29910|NCT02866448|Vascular function
29911|NCT02866448|Blood pressure
29912|NCT02866435|MRI
29913|NCT02866422|OCD
29914|NCT02866409|dexmedetomidine
29915|NCT02866409|nerve block
29916|NCT02866409|anesthesia infiltration
29917|NCT02866396|chronic pain
29918|NCT02866396|oxycodone
29919|NCT02866396|pregabalin
29920|NCT02866396|lumbar spine surgery
29921|NCT02866396|multimodal analgesia
29922|NCT02866344|Microwave ablation
29923|NCT02866344|Ablation techniques
29924|NCT02866344|Operative surgical procedures
29925|NCT02866344|Hepatic resection
29926|NCT02866344|Surgery
29927|NCT02866344|Outcomes assessment
29928|NCT02866305|primary spontaneous pneumothorax
29929|NCT02866305|epidemiology
29930|NCT02866305|genetics
29931|NCT02866305|risk factors
29932|NCT02866292|Pelvic Floor
29933|NCT02866292|Pregnancy
29934|NCT02866292|Physical Therapy Specialty
29935|NCT02866253|Dehydroepiandrosterone（DHEA）
29936|NCT02866253|DOR（Diminished Ovarian Reserve)
29937|NCT02866253|IVF(In vitro fertilization)
29938|NCT02866253|BMP-15(Bone Morphogenetic Protein 15)
30064|NCT02865564|Electric Impedance
29939|NCT02866227|TOL-463, Vaginal, Gel, Insert, Vaginitis, Bacterial, Vaginoses, Vulvovaginal, Candidiasis
29940|NCT02866201|Turista
29941|NCT02866175|percutaneous intervention
29942|NCT02866175|vitamin K antagonist
29943|NCT02866149|Cancer
29944|NCT02866149|circulating tumor biomarkers
29945|NCT02866149|circulating tumor DNA
29946|NCT02866149|Circulating tumor Cell (CTC)
29947|NCT02866097|integrated community case management
29948|NCT02866097|Mobile Health (mHealth)
29949|NCT02866097|rapid diagnostic test
29950|NCT02866097|artemether-lumefantrine
29951|NCT02866097|amoxicillin
29952|NCT02866097|zinc
29953|NCT02866097|oral rehydration solution (ORS)
29954|NCT02866097|District Health Information System 2 (DHIS2)
29955|NCT02866097|iCCM-DHIS2
29956|NCT02866097|ZCAHRD
29957|NCT02866084|vestibular migraines
29958|NCT02866084|dizziness
29959|NCT02866084|migraine headache
29960|NCT02866045|Subepithelial lesions
29961|NCT02866045|Endoscopic Ultrasound-Guided Fine Needle Aspiration
29962|NCT02866006|HPV
29963|NCT02866006|Type 16, 18
29964|NCT02866006|E6E7
29965|NCT02866006|Immune therapeutic vaccine
29966|NCT02865993|cesarean section
29967|NCT02865993|cesarean section complications
29968|NCT02865993|betadine irrigation
29969|NCT02865980|inflammation, infection
29970|NCT02865967|Decision Support Techniques
29971|NCT02865967|Delayed Diagnosis
29972|NCT02865967|Natural Language Processing
29973|NCT02865967|Geographic Information Systems
29974|NCT02865941|Target Fortification
29975|NCT02865941|Breast milk analysis
29976|NCT02865941|Nutrition
29977|NCT02865941|Macronutrient intake
29978|NCT02865941|Protein accretion
29979|NCT02865915|Acne
29980|NCT02865915|Hirsutism
29981|NCT02865915|Menstrual Irregularity
29982|NCT02865915|Alopecia
29983|NCT02865902|Low level laser therapy
29984|NCT02865902|wound healing
29985|NCT02865902|periodontology
29986|NCT02865889|laparoscopic surgery
29987|NCT02865889|Uterine Neoplasms
29988|NCT02865876|Infectious keratitis
29989|NCT02865876|Cross-linking
29990|NCT02865863|Multivitamin
29991|NCT02865863|Eurycomalongifoliawater extract
29992|NCT02865863|Quality of Life
29993|NCT02865863|Mood
29994|NCT02865850|vadadustat
29995|NCT02865850|AKB-6548
29996|NCT02865850|anemia
29997|NCT02865850|chronic kidney disease
29998|NCT02865850|CKD
29999|NCT02865850|chronic renal insufficiency
30000|NCT02865850|renal impairment
30001|NCT02865850|erythropoietin
30002|NCT02865850|kidney
30003|NCT02865850|renal
30004|NCT02865850|oral anemia treatment
30005|NCT02865850|hemoglobin
30006|NCT02865850|hypoxia-inducible factor
30007|NCT02865850|HIF
30008|NCT02865850|efficacy
30009|NCT02865850|safety
30010|NCT02865850|phase 3
30011|NCT02865850|cardiovascular
30012|NCT02865837|Brachytherapy
30013|NCT02865837|Organs at Risk
30014|NCT02865837|Bladder volume
30015|NCT02865837|Cervical cancer
30016|NCT02865824|Colonoscopy
30017|NCT02865811|Ovarian Cancer
30018|NCT02865798|Heart Valve Diseases
30019|NCT02865798|Cardiovascular Diseases
30020|NCT02865798|Heart Disease
30021|NCT02865798|Valvular Heart Diseases
30022|NCT02865785|recurrent implantation failure
30023|NCT02865785|intralipid
30024|NCT02865785|uterine natural killer cells
30025|NCT02865746|Steroids
30026|NCT02865746|Pain measurement
30027|NCT02865733|Remodulin®
30028|NCT02865733|pulmonary vascular resistance
30029|NCT02865733|univentricular physiology
30030|NCT02865707|ulcerative colitis
30031|NCT02865707|prebiotics
30032|NCT02865707|b-fructans
30033|NCT02865707|inulin
30034|NCT02865707|oligofructose
30035|NCT02865707|intestinal microbiota
30036|NCT02865681|Infertility
30037|NCT02865681|Gonadotropins
30038|NCT02865681|Menopur
30039|NCT02865681|Ovarian stimulation
30040|NCT02865642|Stroke
30041|NCT02865642|Serotonin
30042|NCT02865642|Hand Paresis
30043|NCT02865616|CDI
30044|NCT02865616|recurrent infection
30045|NCT02865616|MET-1
30046|NCT02865616|C. difficile
30047|NCT02865590|Maxillary Sinus/surgery
30048|NCT02865590|Bone Substitutes
30049|NCT02865590|Radiography, Panoramic
30050|NCT02865564|Probiotics
30051|NCT02865564|Anti-Bacterial Agents
30052|NCT02865564|Infant, Newborn
30053|NCT02865564|Gastrointestinal Microbiome
30054|NCT02865564|Colic
30055|NCT02865564|Gastrointestinal Diseases
30056|NCT02865564|Body Composition
30057|NCT02865564|Bone Density
30058|NCT02865564|Randomized Controlled Trial
30059|NCT02865564|Lactobacillus reuteri
30060|NCT02865564|Pediatrics
30061|NCT02865564|Feces
30062|NCT02865564|ultrasonography
30063|NCT02865564|High-Throughput Nucleotide Sequencing
30065|NCT02865564|Surveys and Questionnaires
30066|NCT02865538|Hot flashes
30067|NCT02865538|Post-menopausal
30068|NCT02865525|Surveys and Questionnaires
30069|NCT02865525|Patient Education as Topic
30070|NCT02865525|Medication Adherence
30071|NCT02865525|Pulmonary Disease, Chronic Obstructive
30072|NCT02865525|Diabetes Mellitus, Type 2
30073|NCT02865525|Heart failure
30074|NCT02865512|thoracic epidural injection
30075|NCT02865512|patient position
30076|NCT02865486|Gastric emptying
30077|NCT02865486|MRI
30078|NCT02865486|lipid emulsions
30079|NCT02865486|breath test
30080|NCT02865486|GI peptide hormones
30081|NCT02865473|Schlemm's canal lumen area
30082|NCT02865473|PEX
30083|NCT02865460|Chronic Pain
30084|NCT02865460|Cognitive Disorders
30085|NCT02865460|Inflammation
30086|NCT02865460|Neurologic manifestations
30087|NCT02865460|Dementia
30088|NCT02865460|Mental Disorders
30089|NCT02865460|Ubiquinol/ubiquinone
30090|NCT02865460|Pathologic Processes
30091|NCT02865460|Nervous System Diseases
30092|NCT02865460|Hormones, Hormone Substitutes, and Hormone Antagon
30093|NCT02865460|Anti-Inflammatory Agents
30094|NCT02865460|Pharmacologic Actions
30095|NCT02865460|Therapeutic Uses
30096|NCT02865460|Physiological Effects of Drugs
30097|NCT02865460|Gulf war illness
30098|NCT02865460|Chronic fatigue
30099|NCT02865447|dual energy x-ray absorptiometry
30100|NCT02865447|DEXA
30101|NCT02865447|DXA
30102|NCT02865447|total hip arthroplasty
30103|NCT02865447|PROFEMUR
30104|NCT02865447|PRESERVE
30105|NCT02865447|bone mineral density
30106|NCT02865447|BMD
30107|NCT02865447|osteoarthritis
30108|NCT02865447|THA
30109|NCT02865447|musculoskeletal disease
30110|NCT02865408|Amino acids
30111|NCT02865408|critically-ill
30112|NCT02865408|catabolic
30113|NCT02865408|nutrition
30114|NCT02865408|anabolic
30115|NCT02865395|Belladonna and Opium Suppositories
30116|NCT02865382|Adenoma detection rate
30117|NCT02865382|Optical Enhancement Technonogy
30118|NCT02865382|Colonoscopy
30119|NCT02865369|chronic hepatitis C
30120|NCT02865369|Daclatasvir
30121|NCT02865369|Asunaprevir
30122|NCT02865369|fibrosis
30123|NCT02865369|transient elastography
30124|NCT02865356|atopic dermatitis
30125|NCT02865356|eczema
30126|NCT02865356|children
30127|NCT02865356|skin
30128|NCT02865356|topical
30129|NCT02865356|cyclosporine
30130|NCT02865343|Functional Electrical Stimulation (FES)-Rowing
30131|NCT02865330|Intermediate Risk Prostate Cancer
30132|NCT02865330|Low Risk Prostate Cancer
30133|NCT02865330|Active Surveillance
30134|NCT02865304|metastatic breast cancer
30135|NCT02865304|HER-2-negative
30136|NCT02865304|endostar
30137|NCT02865252|manual therapy
30138|NCT02865252|mobilization with movement
30139|NCT02865239|Imaging, Three-Dimensional
30140|NCT02865239|Magnetic Resonance Imaging/methods*
30141|NCT02865239|Breast Neoplasms/diagnosis*
30142|NCT02865239|Prone Position
30143|NCT02865239|Prospective Studies
30144|NCT02865226|thoracic surgery
30145|NCT02865226|thoracotomy
30146|NCT02865213|Open bite
30147|NCT02865213|Molar intrusion
30148|NCT02865213|Temporary anchorage devices
30149|NCT02865200|Nutrition
30150|NCT02865200|Public Health
30151|NCT02865187|Vitamin D
30152|NCT02865187|polycystic ovary syndrome
30153|NCT02865187|polycystic ovarian syndrome
30154|NCT02865187|PCOS
30155|NCT02865187|sexual dysfunction
30156|NCT02865187|female sexual dysfunction
30157|NCT02865187|low libido
30158|NCT02865174|Thrombin-gelatin matrix
30159|NCT02865174|Floseal
30160|NCT02865174|Tranexamic Acid
30161|NCT02865174|Total Knee Arthroplasty
30162|NCT02865135|HPV Related Head and Neck
30163|NCT02865135|Cervical
30164|NCT02865135|Anal Cancer
30165|NCT02865109|Spinal Muscular Atrophy
30166|NCT02865109|SMA
30167|NCT02865109|SMN
30168|NCT02865109|SMNRx
30169|NCT02865109|ISIS-SMNRx
30170|NCT02865109|ISIS-SMN Rx
30171|NCT02865109|ISIS 396443
30172|NCT02865109|ISIS-396443
30173|NCT02865109|ENDEAR
30174|NCT02865109|IONIS-SMNRx
30175|NCT02865109|IONIS-SMN Rx
30176|NCT02865109|EMBRACE
30177|NCT02865109|NURTURE
30178|NCT02865109|IONIS
30179|NCT02865109|BIOGEN
30180|NCT02865109|SHINE
30181|NCT02865109|Nusinersen
30182|NCT02865070|premature
30183|NCT02865070|wireless vitals
30184|NCT02865070|vitals monitor
30185|NCT02865044|Fatty Acids
30186|NCT02865044|Fish Oil
30187|NCT02865044|Marine Copepod
30188|NCT02865044|Fatty Acid Absorption
30189|NCT02865018|Neuromyelitis Optica
30190|NCT02865018|Cetirizine
30191|NCT02864992|lung
30192|NCT02864992|neoplasm
30193|NCT02864992|cancer
30194|NCT02864992|tumor
30195|NCT02864992|adenocarcinoma
30196|NCT02864992|MET exon 14
30197|NCT02864992|METex14
30198|NCT02864992|pulmonary
30199|NCT02864992|stage III
30200|NCT02864992|stage IV
30201|NCT02864992|c-Met
30202|NCT02864992|cMET
30203|NCT02864992|NSCLC
30204|NCT02864992|non-small cell lung cancer
30205|NCT02864979|HNPCC Lynch
30206|NCT02864966|Safety study
30207|NCT02864966|new product
30208|NCT02864966|normal healthy skin.
30209|NCT02864940|Memory
30210|NCT02864940|aneurysm
30211|NCT02864940|deficits
30212|NCT02864940|trouble
30213|NCT02864940|forgetful
30214|NCT02864940|ruptured
30215|NCT02864940|subarachnoid
30216|NCT02864940|hemorrhage
30217|NCT02864927|Meningitis
30218|NCT02864927|Meningococcal Meningitis
30219|NCT02864927|Meningococcal Infections
30220|NCT02864927|Menactra®
30221|NCT02864927|Meningococcal Vaccine
30222|NCT02864888|Diffuse, intrinsic brain stem glioma
30223|NCT02864888|QT/QTc interval
30224|NCT02864888|Radiation
30225|NCT02864888|Antineoplaston therapy
30226|NCT02864875|Fibrinogen
30227|NCT02864875|Tromboelastography
30228|NCT02864849|Rectal cancer
30229|NCT02864849|neoadjuvant
30230|NCT02864849|radiotherapy
30231|NCT02864849|chemotherapy
30232|NCT02864849|toxicity
30233|NCT02864836|Copper
30234|NCT02864836|isotopic distribution
30235|NCT02864836|cancer
30236|NCT02864823|Scleromalacia perforans
30237|NCT02864823|Necrotizing Scleritis
30238|NCT02864823|Perichondrium
30239|NCT02864797|Health related quality of life
30240|NCT02864797|patient reported outcomes
30241|NCT02864797|cohort
30242|NCT02864797|e-health
30243|NCT02864771|Ventricular Arrhythmias
30244|NCT02864771|ICD
30245|NCT02864771|Biological markers
30246|NCT02864745|early rehabilitation
30247|NCT02864745|critically ill
30248|NCT02864745|muscle weakness
30249|NCT02864745|neuromuscular stimulation
30250|NCT02864745|functional electrical stimulation-assisted cycle ergometry
30251|NCT02864745|ICUAW
30252|NCT02864732|Low back pain
30253|NCT02864732|stabilization exercises
30254|NCT02864732|neuromuscular electrical stimulation
30255|NCT02864719|Heart arrest
30256|NCT02864719|Cardiac arrest
30257|NCT02864719|Fatigue
30258|NCT02864693|Microprocessor Controlled Ankle
30259|NCT02864693|Transtibial Amputee
30260|NCT02864693|Pacifica LP
30261|NCT02864693|Kinnex
30262|NCT02864680|cannabis
30263|NCT02864680|magnocellular pathway
30264|NCT02864654|Critical lower limb ischemia
30265|NCT02864654|Atherosclerosis obliterans
30266|NCT02864654|Diabetic angiopathies
30267|NCT02864654|Thromboangiitis obliterans
30268|NCT02864654|Ischemic ulcers
30269|NCT02864654|Peripheral arterial disease
30270|NCT02864654|Indirect revascularisation
30271|NCT02864654|Intramuscular injection
30272|NCT02864654|Ankle-brachial index
30273|NCT02864654|Transcutaneous oxygen tension
30274|NCT02864654|Stromal vascular fraction (SVF)
30275|NCT02864654|Adipose-derived regenerative cells (ADRC)
30276|NCT02864654|Adipose tissue
30277|NCT02864654|Stem cells
30278|NCT02864641|chronic kidney disease
30279|NCT02864641|adolescents
30280|NCT02864641|renal disease
30281|NCT02864641|CKD
30282|NCT02864628|RSV Vaccines
30283|NCT02864628|Respiratory Syncytial Virus Vaccines
30284|NCT02864615|renal cell carcinoma
30285|NCT02864615|metastasis
30286|NCT02864615|stereotactic body radiation therapy
30287|NCT02864615|targted therapy
30288|NCT02864615|immune checkpoint inhibitors
30289|NCT02864602|Regional anesthesia
30290|NCT02864602|Adjuvant
30291|NCT02864602|Dexamethasone
30292|NCT02864589|Tourette, Tic, Tics
30293|NCT02864550|Men who have sex with men
30294|NCT02864550|Human immunodeficiency virus
30295|NCT02864550|Doxycycline
30296|NCT02864550|Tetracycline
30297|NCT02864537|warfarin
30298|NCT02864537|self-management
30299|NCT02864537|Conventional management
30300|NCT02864537|Training
30301|NCT02864537|TTR
30302|NCT02864537|Complications
30303|NCT02864537|Quality of life
30304|NCT02864524|Physical Therapy Modalities
30305|NCT02864524|Exercises
30306|NCT02864524|Musculoskeletal Manipulations
30307|NCT02864485|Live donor liver transplantation
30308|NCT02864459|Ultrasonography
30309|NCT02864459|Weaning
30310|NCT02864433|cholera
30311|NCT02864433|oral cholera vaccine
30312|NCT02864433|diarrhea
30313|NCT02864420|home hospital
30314|NCT02864420|acute care home
30315|NCT02864420|care redesign
30316|NCT02864420|delivery innovation
30317|NCT02864420|heart failure
30318|NCT02864420|pneumonia
30319|NCT02864420|cellulitis
30320|NCT02864420|urinary tract infections
30321|NCT02864342|chronic obstructive pulmonary disease
30322|NCT02864342|COPD
30323|NCT02864342|Respiratory
30324|NCT02864342|adherence
30325|NCT02864342|medication reminders
30326|NCT02864329|Male Infertility
30327|NCT02864329|micro RNAs
30328|NCT02864329|small interfering RNAs
30329|NCT02864329|miRNA
30330|NCT02864329|siRNA
30331|NCT02864316|radiation-induced solid tumors
30332|NCT02864316|Nivolumab
30333|NCT02864316|Phase 2 study
30334|NCT02864303|Alzheimer's disease
30335|NCT02864303|Mild Cognitive Impairment
30336|NCT02864303|Saliva
30337|NCT02864303|Amyloid peptides
30338|NCT02864303|Diagnosis
30339|NCT02864290|Pharmacokinetics of AGS62P1
30340|NCT02864290|AGS62P1
30341|NCT02864290|AML
30342|NCT02864290|Acute Myeloid Leukemia
30343|NCT02864277|Gynecology
30344|NCT02864277|Cancer
30345|NCT02864277|General Surgery
30346|NCT02864277|Recovery Quality
30347|NCT02864277|Length of hospital stay
30348|NCT02864238|electronic milestone pathway
30349|NCT02864238|cardiac valve surgery
30350|NCT02864186|Pain
30351|NCT02864186|Quality of life
30352|NCT02864186|wound healing
30353|NCT02864173|Postoperative cognitive dysfunction
30354|NCT02864173|Postoperative cognitive decline
30355|NCT02864173|Postoperative delirium
30356|NCT02864173|Cognitive outcome
30357|NCT02864173|Neuropsychology
30358|NCT02864173|Genetics
30359|NCT02864160|Language Concordance
30360|NCT02864160|Diabetes Self-Management
30361|NCT02864160|Health Coaching
30362|NCT02864160|Latinos
30363|NCT02864134|Optic neuritis
30364|NCT02864134|ganglion cell layer
30365|NCT02864121|High-risk human papillomavirus
30366|NCT02864121|Integration of HR-HPV DNA
30367|NCT02864121|biomarker of severity
30368|NCT02864121|biomarker of evolution
30369|NCT02864095|Arthroplasty, Replacement, Hip
30370|NCT02864095|Epinephrine
30371|NCT02864095|Tranexamic acid
30372|NCT02864082|X-linked, lamellar
30373|NCT02864043|Barrett's Esophagus
30374|NCT02864043|Barrett's
30375|NCT02864043|OCT
30376|NCT02864043|VLE
30377|NCT02864030|Eribulin mesylate
30378|NCT02864030|Halaven
30379|NCT02864030|Polymorphisms
30380|NCT02864030|Tolerability
30381|NCT02864004|Parkinson disease
30382|NCT02864004|Quality of Life
30383|NCT02864004|Apomorphine infusion
30384|NCT02863978|Sepsis
30385|NCT02863978|Neonates
30386|NCT02863978|Cardio-respiratory maturation
30387|NCT02863978|Neurobehavioral maturation
30388|NCT02863926|BKA
30389|NCT02863926|amputation
30390|NCT02863926|MarrowStim
30391|NCT02863926|below knee amputation
30392|NCT02863926|wound complication
30393|NCT02863926|vascular disease
30394|NCT02863926|critical limb ischemia
30395|NCT02863926|peripheral artery disease
30396|NCT02863926|AKA
30397|NCT02863926|stem cells
30398|NCT02863926|bone marrow
30399|NCT02863887|Weight Loss
30400|NCT02863887|African American
30401|NCT02863887|Community Based
30402|NCT02863887|Mobile technology
30403|NCT02863887|Translational science
30404|NCT02863874|Perineal tear
30405|NCT02863874|Labor
30406|NCT02863874|Triclosan
30407|NCT02863861|Sedation
30408|NCT02863861|Pediatric Patients
30409|NCT02863822|Functional Dyspepsia
30410|NCT02863822|Low FODMAP
30411|NCT02863822|Dietary Modification
30412|NCT02863809|Keratolysis
30413|NCT02863809|Corneal Melting
30414|NCT02863809|Boston KPro
30415|NCT02863809|Keratoprosthesis
30416|NCT02863770|endosonography
30417|NCT02863744|mmp-8
30418|NCT02863744|early stages of wound healing
30419|NCT02863744|wound healing marker
30420|NCT02863731|postural changes
30421|NCT02863731|alternating postures
30422|NCT02863731|Cognitive performance
30423|NCT02863731|Height-adjustable desk
30424|NCT02863731|Worksite
30425|NCT02863718|CLL
30426|NCT02863692|CLL
30427|NCT02863692|B-PLL
30428|NCT02863692|T-PLL
30429|NCT02863692|SLL
30430|NCT02863692|T-NK-LGL
30431|NCT02863692|HCL
30432|NCT02863692|Richter´s Transformation
30433|NCT02863679|tetracaine hydrochloride gel
30434|NCT02863679|analgesia
30435|NCT02863679|intrauterine balloon
30436|NCT02863679|hysteroscope operation
30437|NCT02863666|Cariopulmonary, cardiac arrest
30438|NCT02863653|social participation
30439|NCT02863653|International Classification of Functioning
30440|NCT02863640|Senile macular degeneration
30441|NCT02863640|Parkinson's disease
30442|NCT02863627|Emergencies
30443|NCT02863627|newborn
30444|NCT02863627|care
30445|NCT02863601|Buprenorphine
30446|NCT02863601|Opiate Substitution Treatment
30447|NCT02863575|third molar extraction
30448|NCT02863575|ibuprofen
30449|NCT02863575|ibuprofen/caffeine
30450|NCT02863575|post-surgical dental pain
30451|NCT02863536|Recurrence of Bacterial Vaginosis
30452|NCT02863510|Carbon dioxide angiography
30453|NCT02863510|Renal sympathetic denervation
30454|NCT02863510|Uncontrolled hypertension
30455|NCT02863510|Chronic kidney disease
30456|NCT02863471|Pancreas
30457|NCT02863471|Adenocarcinoma
30458|NCT02863471|Hyperthermic intraperitoneal chemotherapy
30459|NCT02863471|HIPEC
30460|NCT02863471|Pancreatic surgery
30461|NCT02863471|Gemcitabine
30462|NCT02863458|MDS
30463|NCT02863458|AML
30464|NCT02863458|hypomethylating agents (HMA)
30465|NCT02863458|Surveillance Epidemiology and End Results (SEER)
30466|NCT02863445|Obesity
30467|NCT02863445|Body weight
30468|NCT02863445|Emergency contraception
30469|NCT02863445|Levonogestrel
30470|NCT02863445|Ulipristal acetate
30471|NCT02863406|Dust rate
30472|NCT02863406|Microscopic analysis
30473|NCT02863380|Individualized Medicine
30474|NCT02863380|Transcranial Magnetic Stimulation, Repetitive
30475|NCT02863380|Transcranial Direct Current Stimulation Monocentric
30476|NCT02863380|Compariative Cross-Over 3 Arms Study Randomized, Single-Blind Method
30477|NCT02863380|Functional Neuroimaging
30478|NCT02863302|Acute Myeloid Leukemia, Reflexology
30479|NCT02863263|foam dressing
30480|NCT02863263|MedifoamⓇ
30481|NCT02863263|BetafoamⓇ
30482|NCT02863263|povidone iodine
30483|NCT02863237|brain injury
30484|NCT02863237|mechanical ventilation
30485|NCT02863237|weaning
30486|NCT02863198|unexplained infertility
30487|NCT02863198|endometrial injury
30488|NCT02863198|pregnancy
30489|NCT02863185|chronic kidney disease
30490|NCT02863185|pitavastatin
30491|NCT02863185|erythrocyte membrane fatty acid
30492|NCT02863172|Hereditary colorectal cancer syndrome
30493|NCT02863172|Questionnaires
30494|NCT02863172|Surveys
30495|NCT02863172|Blood sample
30496|NCT02863172|Saliva sample
30497|NCT02863146|locally advanced breast cancer
30498|NCT02863146|alopecia
30499|NCT02863146|eribulin
30500|NCT02863120|Bupivacaine
30501|NCT02863120|Osteoarthritis
30502|NCT02863120|Arthritis
30503|NCT02863120|Joint Diseases
30504|NCT02863120|Ropivacaine
30505|NCT02863120|Anesthetics, Local
30506|NCT02863120|Anesthetics
30507|NCT02863107|Colon Cancer
30508|NCT02863107|Rectal Cancer
30509|NCT02863107|Questionnaires
30510|NCT02863107|Surveys
30511|NCT02863107|Blood draw
30512|NCT02863094|schizophrenia
30513|NCT02863094|auditory hallucinations
30514|NCT02863094|functional magnetic resonance imaging
30515|NCT02863094|transcranial magnetic stimulation
30516|NCT02863068|Sickle cell disease
30517|NCT02863068|sodium nitrite
30518|NCT02863068|wound healing
30519|NCT02863068|Ulcer
30520|NCT02863055|MPM
30521|NCT02863055|Unresectable
30522|NCT02863055|Phase II
30523|NCT02863055|Randomized
30524|NCT02863055|Maintenance
30525|NCT02863029|Intestinal stem cells
30526|NCT02863016|dialysis
30527|NCT02863016|hemodiafiltration
30528|NCT02862990|Breast cancer
30529|NCT02862990|Fertility
30530|NCT02862964|back pain
30531|NCT02862951|pregnancy
30532|NCT02862925|fetal monitoring
30533|NCT02862925|cesarean delivery
30534|NCT02862925|obstetrics
30535|NCT02862925|midwifery
30536|NCT02862925|developing countries
30537|NCT02862912|Chloroprocaine
30538|NCT02862912|cervical cerclage
30539|NCT02862912|spinal anesthesia
30540|NCT02862912|Bupivacaine
30541|NCT02862873|Spinal anaesthesia
30542|NCT02862821|biomarkers of psychiatric disorder
30543|NCT02862821|gambling addiction
30544|NCT02862821|high resolution-ElectroEncephaloGraphy (HR-EEG)
30545|NCT02862808|Whole exome sequencing
30546|NCT02862808|Molecular diagnostic
30547|NCT02862808|Genetic counselling
30548|NCT02862795|colonoscopy
30549|NCT02862730|diabetes
30550|NCT02862730|closed-loop
30551|NCT02862730|dual hormone
30552|NCT02862730|exercise
30553|NCT02862717|Cost effectiveness
30554|NCT02862717|cost utility
30555|NCT02862717|ESRD
30556|NCT02862717|hemodialysis
30557|NCT02862717|ICER
30558|NCT02862717|Markov model
30559|NCT02862717|peritoneal dialysis
30560|NCT02862691|toothache
30561|NCT02862626|Diabetic children
30562|NCT02862626|Mothers
30563|NCT02862613|Precision Cells
30564|NCT02862613|Transcatheter Arterial Chemoembolization
30565|NCT02862613|Advanced Liver Cancer
30566|NCT02862600|hypertrophic cardiomyopathy
30567|NCT02862600|hypertrophic
30568|NCT02862600|cardiomyopathy
30690|NCT02861885|Colonoscopy
30569|NCT02862600|familial hypertrophic cardiomyopathy
30570|NCT02862600|heart failure
30571|NCT02862600|cardiopulmonary exercise testing
30572|NCT02862600|6 minute walk test
30573|NCT02862600|perhexiline
30574|NCT02862600|carnitine palmitoyltransferase
30575|NCT02862600|carbohydrate utilization
30576|NCT02862600|coronary ischemia
30577|NCT02862600|angina
30578|NCT02862600|mixed ion channel effects
30579|NCT02862600|late sodium current inhibitor
30580|NCT02862600|calcium channel inhibition
30581|NCT02862587|Precision Cells
30582|NCT02862587|Chemotherapy
30583|NCT02862587|Advanced Lung Cancer
30584|NCT02862574|Rheumatoid Arthritis
30585|NCT02862574|Tumor Necrosis Factor Inhibitor
30586|NCT02862574|TNF-IR
30587|NCT02862574|Methotrexate
30588|NCT02862561|Precision Cell Immunotherapy
30589|NCT02862561|Chemotherapy
30590|NCT02862561|Advanced Malignancies
30591|NCT02862522|uric acid
30592|NCT02862522|microvascular dysfunction
30593|NCT02862522|inflammation
30594|NCT02862509|Post-frontal sinus operation chronic rhinosinusitis patients
30595|NCT02862509|Budesonide nasal instillation
30596|NCT02862509|Vertex to floor position
30597|NCT02862496|Hyperemesis Gravidarum
30598|NCT02862496|Bone Health
30599|NCT02862496|Urine N-telopeptide
30600|NCT02862496|Serum calcium
30601|NCT02862496|Serum parathormone
30602|NCT02862496|Serum vit D
30603|NCT02862470|Lovastatin
30604|NCT02862470|Vildagliptin
30605|NCT02862470|Exosome
30606|NCT02862470|Anaplastic thyroid cancer
30607|NCT02862470|Proteomics
30608|NCT02862470|Urine
30609|NCT02862470|Biological marker
30610|NCT02862457|Advanced Solid Tumors
30611|NCT02862418|MRI
30612|NCT02862418|UTE MRI
30613|NCT02862418|Pulmonary
30614|NCT02862405|Vision loss
30615|NCT02862405|Object recognition
30616|NCT02862405|Space recognition
30617|NCT02862392|Scoliosis
30618|NCT02862392|Adolescent
30619|NCT02862392|Idiopathic scoliosis
30620|NCT02862392|Predictive factors
30621|NCT02862366|myeloproliferative neoplasms
30622|NCT02862366|Circulating Procoagulants Microparticles
30623|NCT02862353|Validation new test
30624|NCT02862327|anaesthetic techniques
30625|NCT02862327|regional anesthesia
30626|NCT02862327|brachial plexus block
30627|NCT02862327|Local Anesthetic
30628|NCT02862327|ropivacaine
30629|NCT02862327|analgesia
30630|NCT02862327|steroid
30631|NCT02862327|dexamethasone
30632|NCT02862327|placebo
30633|NCT02862327|adjuvant
30634|NCT02862327|ultrasound guided
30635|NCT02862314|Procalcitonin
30636|NCT02862301|Histone Deacetylases
30637|NCT02862301|Histone Acetyltransferases
30638|NCT02862223|Coagulation
30639|NCT02862223|Circulatory Function
30640|NCT02862223|Blood Pressure
30641|NCT02862223|Inflammatory response
30642|NCT02862223|Blood Glucose
30643|NCT02862223|Healthy vascular function
30644|NCT02862210|Lithium
30645|NCT02862210|Lithium Carbonate
30646|NCT02862145|Biosy accessible melanoma
30647|NCT02862132|VDZ: Vedolizumab
30648|NCT02862132|UC: Ulcerative colitis
30649|NCT02862132|CD: Crohn's disease
30650|NCT02862132|TDM: Therapeutic drug monitoring
30651|NCT02862119|percutaneous coronary intervention
30652|NCT02862119|fractional flow reserve
30653|NCT02862119|all cause mortality
30654|NCT02862119|myocardial infarction
30655|NCT02862119|registry-based randomized clinical trial
30656|NCT02862106|Chronic Hepatitis B
30657|NCT02862106|HBeAg positive
30658|NCT02862106|Therapeutic HBV Vaccine
30659|NCT02862106|HBV-specific Cytotoxic T Lymphocyte
30660|NCT02862067|SGLT2
30661|NCT02862067|type 2 diabetes mellitus
30662|NCT02862067|systolic heart failure
30663|NCT02862067|heart failure with reduced ejection fraction
30664|NCT02862054|haemophagocytic lymphohistiocytosis
30665|NCT02862054|splenectomy
30666|NCT02862054|unknown etiology
30667|NCT02862028|PD-1 antibody
30668|NCT02862028|CAR-T cells
30669|NCT02862028|EGFR family
30670|NCT02862028|advanced solid tumor
30671|NCT02862002|opioid therapy
30672|NCT02862002|medical oncology.
30673|NCT02861989|osteoporosis
30674|NCT02861989|prevention
30675|NCT02861989|care management
30676|NCT02861989|focus groups
30677|NCT02861963|Femoral Allogenic Vein Valve Conduit
30678|NCT02861963|Rehabilitation of native pulmonary arteries
30679|NCT02861950|hypospadias
30680|NCT02861950|caudal
30681|NCT02861950|urethrocutaneous fistula
30682|NCT02861950|penile nerve block
30683|NCT02861911|Muscle function
30684|NCT02861911|Oxidative stress
30685|NCT02861911|Quality of life
30686|NCT02861911|Physical activities
30687|NCT02861898|EGFR
30688|NCT02861898|Epidermal Growth Factor Receptor
30689|NCT02861898|EGFRvIII
30691|NCT02861885|sessile serrated lesions
30692|NCT02861885|chromoendoscopy
30693|NCT02861885|narrow band imaging
30694|NCT02861885|Indigo Carmin®
30695|NCT02861885|Pit pattern
30696|NCT02861885|Kudo classification
30697|NCT02861885|NICE classification
30698|NCT02861885|neoplasms by histologic type
30699|NCT02861872|Ovarian
30700|NCT02861872|Ovarian cancer
30701|NCT02861872|Chemotherapy
30702|NCT02861872|Intraperitoneal chemotherapy
30703|NCT02861872|pharmacokinetics
30704|NCT02861859|Breast cancer
30705|NCT02861859|Breast Carcinoma
30706|NCT02861859|Breast Tumors
30707|NCT02861859|Chemotherapy
30708|NCT02861859|Antiemetic effects
30709|NCT02861859|Antiemetic drugs
30710|NCT02861859|Drug Therapy
30711|NCT02861846|epilepsy
30712|NCT02861846|Alzheimer
30713|NCT02861846|biomarkers
30714|NCT02861846|predictive value
30715|NCT02861820|fMRI
30716|NCT02861820|brain networks
30717|NCT02861820|biomarker
30718|NCT02861820|relapse
30719|NCT02861820|stimulants
30720|NCT02861794|Total Knee Arthroplasty (TKA)
30721|NCT02861794|Total Knee Replacement (TKR)
30722|NCT02861794|Kinematics
30723|NCT02861794|RSA
30724|NCT02861794|Knee arthroplasty
30725|NCT02861794|Implant stability
30726|NCT02861781|Bariatric surgery
30727|NCT02861755|Depression
30728|NCT02861755|Depressive Disorder
30729|NCT02861755|Psychological Stress
30730|NCT02861755|Behavioral Symptoms
30731|NCT02861755|Mental Disorders
30732|NCT02861755|Mood Disorders
30733|NCT02861729|Partial coverage restoration
30734|NCT02861729|Crown
30735|NCT02861729|Posterior teeth
30736|NCT02861729|All ceramic
30737|NCT02861729|Zirconia reinforced lithium silicate
30738|NCT02861729|Lithium disilicate
30739|NCT02861729|CAD/CAM
30740|NCT02861690|Esophageal Cancer
30741|NCT02861690|nedaplatin
30742|NCT02861690|Liposomal Paclitaxel
30743|NCT02861638|Total hip replacement
30744|NCT02861638|Action observation treatment
30745|NCT02861638|Rehabilitation
30746|NCT02861638|Arthroplasty
30747|NCT02861612|peripheral nerves
30748|NCT02861612|quadriplegia
30749|NCT02861612|nerve transfer
30750|NCT02861612|surgical procedures, operative
30751|NCT02861612|hand
30752|NCT02861612|upper extremity
30753|NCT02861612|quality of life
30754|NCT02861586|Chikungunya, infectious disease
30755|NCT02861573|Metastatic Castration-Resistant Prostate Cancer
30756|NCT02861573|mCRPC
30757|NCT02861573|PD1
30758|NCT02861573|PD-1
30759|NCT02861573|PDL1
30760|NCT02861573|PD-L1
30761|NCT02861508|Ultrasonography
30762|NCT02861495|upper extremity fracture
30763|NCT02861482|PPH, Bakri Ballon
30764|NCT02861469|qualitative study, end of life, ethics, palliative care
30765|NCT02861456|Adolescent
30766|NCT02861456|Low Back Pain
30767|NCT02861456|Athlete
30768|NCT02861430|colon cancer
30769|NCT02861430|sentinel node
30770|NCT02861417|Other diseases of blood and blood-forming organs
30771|NCT02861417|Acute myeloid leukemia
30772|NCT02861417|AML
30773|NCT02861417|Acute lymphocytic leukemia
30774|NCT02861417|ALL
30775|NCT02861417|Chronic myeloid leukemia
30776|NCT02861417|CML
30777|NCT02861417|Chronic lymphocytic leukemia
30778|NCT02861417|CLL
30779|NCT02861417|Myelodysplastic syndrome
30780|NCT02861417|MDS
30781|NCT02861417|Myeloproliferative syndrome
30782|NCT02861417|Non-Hodgkins lymphoma
30783|NCT02861417|NHL
30784|NCT02861417|Hodgkins lymphoma
30785|NCT02861417|HL
30786|NCT02861417|Multiple myeloma
30787|NCT02861417|MM
30788|NCT02861417|Stem cell infusion
30789|NCT02861417|Stem cell transplant
30790|NCT02861417|Haploidentical donor
30791|NCT02861417|Matched donor
30792|NCT02861417|Thiotepa
30793|NCT02861417|Mycophenolate Mofetil
30794|NCT02861417|MMF
30795|NCT02861417|CellCept
30796|NCT02861417|Busulfan
30797|NCT02861417|Busulfex
30798|NCT02861417|Myleran
30799|NCT02861417|Fludarabine
30800|NCT02861417|Fludarabine phosphate
30801|NCT02861417|Fludara
30802|NCT02861417|Mesna
30803|NCT02861417|Mesnex
30804|NCT02861417|Cyclophosphamide
30805|NCT02861417|Cytoxan
30806|NCT02861417|Neosar
30807|NCT02861417|Tacrolimus
30808|NCT02861417|Prograf
30809|NCT02861417|G-CSF
30810|NCT02861417|Filgrastim
30811|NCT02861417|Neupogen
30812|NCT02861404|HPV
30813|NCT02861378|anaesthesia, dental
30814|NCT02861378|lidocaine
30815|NCT02861352|Zinc
30816|NCT02861352|DNA Integrity
30817|NCT02861352|Gene Expression
30818|NCT02861352|diet zinc
30819|NCT02861352|nutrition requirements
30820|NCT02861326|chronic periodontitis, dental scaling, periodontal pockets
30821|NCT02861300|CB-839
30822|NCT02861300|PIK3CA
30823|NCT02861300|capecitabine
30824|NCT02861248|Burn Scar
30825|NCT02861248|Micro-plasma Radiofrequency Therapy
30826|NCT02861183|sodium hyaluronate
30827|NCT02861183|OVT
30828|NCT02861183|hyaluronic acid
30829|NCT02861170|Mindfulness
30830|NCT02861170|Chronic Pain
30831|NCT02861170|Chronic Hip Pain
30832|NCT02861170|Total Hip Arthroplasty
30833|NCT02861170|Disability
30834|NCT02861170|Quality of Life
30835|NCT02861157|Type 1 Diabetes
30836|NCT02861157|Adolescents
30837|NCT02861157|T1D
30838|NCT02861131|Sugammadex
30839|NCT02861131|Neuromuscular Blockade
30840|NCT02861118|Drug Therapy
30841|NCT02861092|Serious adverse event
30842|NCT02861092|bone and joint infection
30843|NCT02861092|obesity
30844|NCT02861092|dose adjustment
30845|NCT02861066|Mindfulness-based Intervention
30846|NCT02861066|Wellbeing
30847|NCT02861066|Treatment
30848|NCT02861027|Osteoarthritis
30849|NCT02861027|Total hip arthroplasty
30850|NCT02861027|Physiotherapy
30851|NCT02861027|Functional Electrical Stimulation
30852|NCT02861001|tracheotomy
30853|NCT02861001|bronchoscopy
30854|NCT02861001|critical care
30855|NCT02860975|Prolonged Hypoxia
30856|NCT02860975|Safety
30857|NCT02860975|Mitochondrial function
30858|NCT02860949|Local anesthetic infiltration
30859|NCT02860949|Posterior capsular infiltration
30860|NCT02860949|Multimodal anesthesia
30861|NCT02860949|Knee arthroplasty
30862|NCT02860949|Pain control
30863|NCT02860949|Osteoarthritis, Knee
30864|NCT02860923|glucagon-like peptide-1
30865|NCT02860923|exenatide
30866|NCT02860923|placebo
30867|NCT02860923|multicenter trial
30868|NCT02860910|hot flashes
30869|NCT02860910|postmenopause
30870|NCT02860910|perimenopause
30871|NCT02860832|Cyberbullying
30872|NCT02860832|Traditional bullying
30873|NCT02860832|Depression
30874|NCT02860819|Multiple relapsed/refractory testicular germ cell tumors
30875|NCT02860819|PARP inhibition
30876|NCT02860819|Chemotherapy
30877|NCT02860819|Gemcitabine
30878|NCT02860819|Carboplatin
30879|NCT02860793|PTK7
30880|NCT02860793|Acute Myeloid Leukemia
30881|NCT02860767|Prosthesis-Related Infections
30882|NCT02860767|Antibiotic dosing
30883|NCT02860767|Reimplantation
30884|NCT02860767|Knee-prothesis
30885|NCT02860767|Hip-prothesis
30886|NCT02860741|Sub-Clinical Depression
30887|NCT02860728|COPD
30888|NCT02860728|Resistance Training
30889|NCT02860728|Exercise Training
30890|NCT02860728|Dyspnea
30891|NCT02860715|Safety
30892|NCT02860715|Pharmacodynamics
30893|NCT02860715|Dose-Limiting Toxicity (DLT)
30894|NCT02860715|Immunogenicity
30895|NCT02860715|Pharmacokinetics
30896|NCT02860702|Single Ventricle
30897|NCT02860702|Congenital Heart Defect
30898|NCT02860689|Sexuality
30899|NCT02860689|Spinal cord injuries
30900|NCT02860689|Penile erection
30901|NCT02860689|erectile dysfunction
30902|NCT02860689|Psychological Sexual Dysfunctions
30903|NCT02860676|CLL
30904|NCT02860676|cancer
30905|NCT02860676|UC-961
30906|NCT02860676|cirmtuzumab
30907|NCT02860637|Sexuality
30908|NCT02860637|Spinal cord injuries
30909|NCT02860637|Penile erection
30910|NCT02860637|erectile dysfunction
30911|NCT02860624|GERD
30912|NCT02860611|Type 1 diabetes
30913|NCT02860611|Type 2 diabetes
30914|NCT02860611|T helper 1 cytokines
30915|NCT02860598|ESAs
30916|NCT02860598|erythropoietin
30917|NCT02860598|AML
30918|NCT02860598|HSCT
30919|NCT02860585|Metastatic breast cancer
30920|NCT02860585|high-dose chemotherapy
30921|NCT02860585|autologous haematopoietic progenitor cell transplantation
30922|NCT02860572|fluid therapy
30923|NCT02860572|oliguria
30924|NCT02860572|endothelial injury
30925|NCT02860559|Hematopoietic Stem Cell Transplantation
30926|NCT02860559|Severe Combined Immunodeficiency
30927|NCT02860546|Refractory
30928|NCT02860546|Metastatic
30929|NCT02860546|Colorectal cancer
30930|NCT02860546|TAS-102
30931|NCT02860546|Nivolumab
30932|NCT02860546|Microsatellite Stable
30933|NCT02860546|Programmed cell death protein1 (PD 1)
30934|NCT02860533|Blood pressure
30935|NCT02860533|smartphone App
30936|NCT02860533|Hypertension
30937|NCT02860533|Stress testing
30938|NCT02860533|Prevention
30939|NCT02860533|Cardiovascular risk factors
30940|NCT02860520|Retinitis pigmentosa:
30941|NCT02860494|Tuberous sclerosis complex (TSC)
30942|NCT02860494|topical everolimus
30943|NCT02860494|seamless design
30944|NCT02860494|dose-escalation study
30945|NCT02860494|m-TOR inhibitor
30946|NCT02860455|CO poisoning
30947|NCT02860455|CO-oximetry
30948|NCT02860455|Pulse oximetry
30949|NCT02860455|Carbon monoxide saturation (SpCO)
30950|NCT02860455|Emergency Department
30951|NCT02860455|Sensitivity
30952|NCT02860455|Specificity
30953|NCT02860442|Alcohol misuse
30954|NCT02860442|Smartphone app
30955|NCT02860442|Screening, Brief Intervention, Referral to Treatment (SBIRT)
30956|NCT02860416|Neurology
30957|NCT02860403|Cervical spinal cord injury
30958|NCT02860403|Motor imagery
30959|NCT02860403|Magnetoencephalography
30960|NCT02860377|emergence agitation
30961|NCT02860377|emergence time
30962|NCT02860377|pediatric
30963|NCT02860351|subclavian vein
30964|NCT02860338|Psuedobulbar affect, PBA
30965|NCT02860299|patients
30966|NCT02860273|Pulmonary Rehabilitation
30967|NCT02860273|COPD
30968|NCT02860273|High Flow Nasal Cannula
30969|NCT02860273|HFNC
30970|NCT02860273|Aerobic capacity
30971|NCT02860260|BDNF
30972|NCT02860247|antibiotic
30973|NCT02860247|MALDI-TOF MS
30974|NCT02860247|susceptibility testing
30975|NCT02860234|Rectal cancer
30976|NCT02860234|neoadjuvant
30977|NCT02860234|radiotherapy
30978|NCT02860234|chemotherapy
30979|NCT02860234|organ preservation
30980|NCT02860221|Arthroplasty, Replacement, Knee
30981|NCT02860221|Epinephrine
30982|NCT02860221|Tranexamic acid
30983|NCT02860208|Peri-Implantitis
30984|NCT02860208|Surgical therapy
30985|NCT02860208|Follow-up
30986|NCT02860208|Supportive peri-implant therapy
30987|NCT02860130|Regional Citrate Anticoagulation (RCA)
30988|NCT02860130|Continuous Renal Replacement Therapy (CRRT)
30989|NCT02860130|Acute Kidney Injury (AKI)
30990|NCT02860130|Kidney Failure, Acute
30991|NCT02860117|ketamine
30992|NCT02860117|continuous infusion
30993|NCT02860117|severe burned patients
30994|NCT02860104|microwave ablation
30995|NCT02860104|breast
30996|NCT02860104|multicenter
30997|NCT02860091|ropivacaine infusion
30998|NCT02860091|regional anesthesia
30999|NCT02860091|paravertebral block
31000|NCT02860078|pain
31001|NCT02860078|epidural
31002|NCT02860078|ultrasound
31003|NCT02860013|Telemedicine
31004|NCT02860013|Effectiveness
31005|NCT02860013|Cost-effectiveness
31006|NCT02859987|US
31007|NCT02859987|Nursing Services
31008|NCT02859974|Paradoxical vocal fold motion disorder (PVFMD)
31009|NCT02859974|vocal cord dysfunction (VCD)
31010|NCT02859974|Respiratory retraining
31011|NCT02859974|Respiratory disorders
31012|NCT02859948|AML
31013|NCT02859935|HIV
31014|NCT02859935|drug abuse
31015|NCT02859935|MSM
31016|NCT02859935|Risk behavior
31017|NCT02859935|Sexually transmitted diseases
31018|NCT02859935|Sexually transmitted infections
31019|NCT02859922|Laryngeal Tube Supreme Spontaneous Ventilation
31020|NCT02859857|Glioblastoma Multiforme, Solid Tumors
31021|NCT02859727|APDS; PASLI; PI3Kdelta; p110delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency; Activated PI3Kdelta Syndrome;
31022|NCT02859662|abdominal compartment syndrome
31023|NCT02859662|abdominal aortic aneurysm
31024|NCT02859662|ruptured aneurysm
31025|NCT02859649|working memory
31026|NCT02859649|short term memory
31027|NCT02859649|gesture
31028|NCT02859584|Acute hepatitis
31029|NCT02859584|acute liver failure
31030|NCT02859584|adrenal dysfunction
31031|NCT02859584|salivary cortisol
31032|NCT02859584|serum free cortisol
31033|NCT02859545|chronic pain
31034|NCT02859545|pain
31035|NCT02859545|validation
31036|NCT02859545|couples
31037|NCT02859545|romantic relationships
31038|NCT02859545|emotional validation
31039|NCT02859532|blood coagulation
31040|NCT02859532|Endogenous Thrombin Potential
31041|NCT02859532|rotational thromboelastometry
31042|NCT02859480|Rosuvastatin Calcium
31043|NCT02859480|Percutaneous Coronary Intervention
31044|NCT02859480|Drug-Eluting Stents
31045|NCT02859480|Patient Outcome Assessment
31046|NCT02859480|Biomarkers
31047|NCT02859480|Hyperlipidemias
31048|NCT02859480|Dyslipidemias
31049|NCT02859480|Atherosclerosis
31050|NCT02859480|Hydroxymethylglutaryl-CoA Reductase Inhibitors
31051|NCT02859480|Anticholesteremic Agents
31052|NCT02859480|Hypolipidemic Agents
31053|NCT02859480|Lipid Regulating Agents
31054|NCT02859467|Physical Therapy Modalities
31055|NCT02859467|Exercise
31056|NCT02859467|Electrical Stimulation Therapy
31057|NCT02859467|Bandages
31058|NCT02859454|PD-L1 Expression
31059|NCT02859454|Human Papilloma Virus (HPV)
31060|NCT02859454|Juvenile-onset Disease
31061|NCT02859454|Papillomatous Lesions
31062|NCT02859454|Monoclonal Antibody
31063|NCT02859441|Intravitreal Injection
31064|NCT02859441|Retinal Capillary Hemangioma
31065|NCT02859428|Hereditary Spastic Paraplegia
31066|NCT02859415|Metastatic Colorectal Cancer
31067|NCT02859415|Metastatic Renal Cell Cancer
31068|NCT02859415|Sarcoma
31069|NCT02859415|ABCB4 Liver Toxicity
31070|NCT02859415|ABCB11 Heptatoxicity
31071|NCT02859402|T-cell Non-Hodgkin Lymphoma
31072|NCT02859402|NK/T-cell Non-Hodgkin Lymphoma
31073|NCT02859402|Relapsed, refractory
31074|NCT02859402|Conditioning
31075|NCT02859402|Allogeneic stem cell transplantation
31076|NCT02859389|Leukemia
31077|NCT02859389|Down Syndrome
31078|NCT02859389|Neurocognitive
31079|NCT02859389|Survivorship
31080|NCT02859389|Attention
31081|NCT02859389|Executive function
31082|NCT02859389|Late effects
31083|NCT02859376|Preterm infants
31084|NCT02859376|Pain
31085|NCT02859376|Sucrose
31086|NCT02859350|Plasmodium falciparum
31087|NCT02859350|PfSPZ Vaccine
31088|NCT02859350|PfSPZ Challenge (NF54)
31089|NCT02859350|CHMI
31090|NCT02859350|Chloroquine
31091|NCT02859350|Chemoprophylaxis
31092|NCT02859350|PfSPZ-CVac
31093|NCT02859337|obesity
31094|NCT02859337|body weight
31095|NCT02859337|BMI
31096|NCT02859337|emergency contraception
31097|NCT02859337|levonorgestrel
31098|NCT02859337|ulipristal acetate
31099|NCT02859324|CC-122
31100|NCT02859324|Nivolumab
31101|NCT02859324|Hepatocellular Carcinoma
31102|NCT02859324|Phase 1/2
31103|NCT02859324|Safety
31104|NCT02859311|Recovery
31105|NCT02859298|Premature Delivery
31106|NCT02859298|Polarimetric Imaging
31107|NCT02859298|Polarimetric colposcope
31108|NCT02859298|Diagnostic tool
31109|NCT02859285|Arousal
31110|NCT02859285|Orgasm
31111|NCT02859285|Clitoral
31112|NCT02859285|Estradiol
31113|NCT02859285|Post Menopausal
31114|NCT02859272|Suspension, benign hysterectomy, post operative prolapse
31115|NCT02859233|Spinal Puncture
31116|NCT02859233|Dural puncture
31117|NCT02859233|Nursing
31118|NCT02859220|hemodialysis
31119|NCT02859220|PTH
31120|NCT02859207|Early Alzheimer's disease
31121|NCT02859207|E2609
31122|NCT02859207|Mild and Moderate Hepatic Impairment
31123|NCT02859181|Increased Metabolic Requirement
31124|NCT02859168|Neck
31125|NCT02859168|Shoulder
31126|NCT02859168|Manual Therapies
31127|NCT02859142|Varenicline
31128|NCT02859129|Epanova
31129|NCT02859129|omega-3 carboxylic acids
31130|NCT02859129|Vascepa
31131|NCT02859129|Eicosapentaenoic acid ethyl ester
31132|NCT02859129|Crestor
31133|NCT02859129|rosuvastatin
31134|NCT02859116|Metabolic diseases
31135|NCT02859077|NSCLC
31136|NCT02859077|BIM
31137|NCT02859077|EGFR mutation
31138|NCT02859064|radioembolization
31139|NCT02859064|somatostatin analogs
31140|NCT02859064|carcinoid
31141|NCT02859064|neuroendocrine
31142|NCT02859064|liver-directed therapy
31143|NCT02859051|Cognitive Behavioral Support provided by Robot
31144|NCT02859025|Alveolar cleft
31145|NCT02859025|Osteoplasty
31146|NCT02859025|Tissue engineering
31147|NCT02859025|Stem cells
31148|NCT02859025|Regenerative medicine
31149|NCT02859025|Bone
31150|NCT02859025|Lateral ramus
31151|NCT02858999|primary plasma cell leukaemia
31152|NCT02858999|treatment
31153|NCT02858960|High Flow Nasal Cannula
31154|NCT02858960|COPD
31155|NCT02858960|Pulmonary rehabilitation
31156|NCT02858960|HFNC
31157|NCT02858960|Oxygen
31158|NCT02858947|composite resin
31159|NCT02858947|bulk-fill
31160|NCT02858947|teeth endodontically-treated
31161|NCT02858934|Short preoperative tomotherapy
31162|NCT02858934|Radiotherapy
31163|NCT02858921|Neoadjuvant Therapy
31164|NCT02858921|Pembrolizumab
31165|NCT02858921|Dabrafenib
31166|NCT02858921|Trametinib
31167|NCT02858921|Pathological response
31168|NCT02858921|RECIST
31169|NCT02858921|Immune response
31170|NCT02858921|BRAF
31171|NCT02858921|Randomised
31172|NCT02858921|Stage IIIB/C
31173|NCT02858921|Biomarkers, Tumour
31174|NCT02858921|Biomarkers, Drug response
31175|NCT02858921|Metabolic Response
31176|NCT02858895|High grade glioma
31177|NCT02858895|malignant glioma
31178|NCT02858895|recurrent glioblastoma
31179|NCT02858895|recurrent GBM
31180|NCT02858895|recurrent GB
31181|NCT02858895|glioblastoma (GB)
31182|NCT02858895|glioblastoma multiforme (GBM)
31183|NCT02858895|progressive glioblastoma
31184|NCT02858843|genetics
31185|NCT02858830|FPL
31186|NCT02858830|adipose tissue
31187|NCT02858830|diabetes
31188|NCT02858830|dyslipidemia
31189|NCT02858830|metabolic
31190|NCT02858830|hyperinsulinemia
31191|NCT02858804|mantle cell lymphoma
31192|NCT02858804|EDOCH
31193|NCT02858804|DHAP
31194|NCT02858804|maintenance therapy
31195|NCT02858778|Palliative Care
31196|NCT02858778|Emergency Department
31197|NCT02858752|Attention
31198|NCT02858752|Short-term memory
31199|NCT02858752|Aural Memory
31200|NCT02858752|Visual Memory
31201|NCT02858752|Child
31202|NCT02858752|EEG
31203|NCT02858726|Hemodialysis
31204|NCT02858726|CR845
31205|NCT02858726|Kappa opioid
31206|NCT02858726|Anti-itch
31207|NCT02858713|psoriasis
31208|NCT02858700|neonatal bacterial infection
31209|NCT02858700|procalcitonin
31210|NCT02858635|Suicidal behaviour
31211|NCT02858635|Impulsivity
31212|NCT02858635|Genetics
31213|NCT02858635|Serotonin
31214|NCT02858622|pediatric
31215|NCT02858622|renal transplant
31216|NCT02858622|pain
31217|NCT02858622|dual TAB
31218|NCT02858570|Meningococcal Vaccines
31219|NCT02858570|Immunogenicity, Reactogenicity and Safety of Vaccine
31220|NCT02858544|Mild traumatic brain injury
31221|NCT02858518|anticoagulant
31222|NCT02858492|efficacy
31223|NCT02858492|safety
31224|NCT02858492|pharmacokinetics
31225|NCT02858492|pharmacodynamics
31226|NCT02858492|Rheumatoid Arthritis
31227|NCT02858492|autoimmune
31228|NCT02858453|Interstitial cystitis
31229|NCT02858453|Bladder pain syndrome
31230|NCT02858453|Painful bladder syndrome
31231|NCT02858453|Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
31232|NCT02858453|AQX-1125
31233|NCT02858453|SHIP1
31234|NCT02858453|Chronic interstitial cystitis
31235|NCT02858440|Primary dose
31236|NCT02858440|Reactogenicity
31237|NCT02858440|Immunogenicity
31238|NCT02858440|Booster dose
31239|NCT02858440|Combined vaccine
31240|NCT02858440|Russian Infants
31241|NCT02858440|Infanrix®-IPV/Hib
31242|NCT02858427|cognitive inhibition
31243|NCT02858427|elderly
31244|NCT02858427|suicide attempt
31245|NCT02858427|depression
31246|NCT02858388|Otitis Media with Effusion
31247|NCT02858388|Exudative otitis media
31248|NCT02858375|quality of life
31249|NCT02858375|botulinum toxin
31250|NCT02858375|provoked vulvodynia
31251|NCT02858362|DMD
31252|NCT02858362|Muscular Dystrophy
31253|NCT02858362|Utrophin
31254|NCT02858362|Duchenne
31255|NCT02858362|PhaseOut DMD
31256|NCT02858336|Luteinizing Hormone (LH)
31257|NCT02858336|Functional Hypothalamic Amenorrhea (HA)
31258|NCT02858336|Energy Deficiency
31259|NCT02858336|Gonadotropin-Releasing Hormone
31260|NCT02858336|Leptin
31261|NCT02858323|Alloimmunization
31262|NCT02858323|Refractoriness
31263|NCT02858323|Corrected Count Increment
31264|NCT02858323|HLA-Compatible
31265|NCT02858310|HPV-16
31266|NCT02858310|E7 TCR
31267|NCT02858310|Pembrolizumab
31268|NCT02858310|Immunotherapy
31269|NCT02858310|Reproductive Cancers
31270|NCT02858297|Oral lichen planus
31271|NCT02858297|Glucosamine
31272|NCT02858297|IL-8
31273|NCT02858258|MCL
31274|NCT02858232|MASCT-I
31275|NCT02858232|Solid Tumors
31276|NCT02858219|Botulinum toxin
31277|NCT02858219|Pain improvement
31278|NCT02858206|Locally advanced esophageal cancer
31279|NCT02858206|Radiotherapy and nimotuzumab
31280|NCT02858206|Concurrent chemoradiotherapy
31281|NCT02858154|OSA
31282|NCT02858154|obstructive sleep apnea
31283|NCT02858154|infants
31284|NCT02858154|high flow nasal cannula
31285|NCT02858154|HFNC
31286|NCT02858141|oncogeriatric evaluation
31287|NCT02858141|pancreatic cancer
31288|NCT02858141|Database
31289|NCT02858102|Schizophrenia
31290|NCT02858102|Psychosis
31291|NCT02858102|Obesity
31292|NCT02858102|Neurocognition
31293|NCT02858102|Depression
31294|NCT02858102|Bipolar disorder
31295|NCT02858102|Metabolomics
31296|NCT02858102|Biomarkers
31297|NCT02858102|Hypertension
31298|NCT02858102|Dyslipidemia
31299|NCT02858102|Hyperglycemia
31300|NCT02858102|Hypertriglyceridemia
31301|NCT02858076|Anti-VEGF
31302|NCT02858076|Vitrectomy
31303|NCT02858063|Breast cancer
31304|NCT02858063|Quality Of Life
31305|NCT02858063|Women
31306|NCT02858063|Partner
31307|NCT02858011|behavior change communication
31308|NCT02858011|cash transfer
31309|NCT02858011|household welfare
31310|NCT02858011|child nutrition status
31311|NCT02857985|Myocardial Infarction
31312|NCT02857985|MRI
31313|NCT02857985|rotational angiography
31314|NCT02857972|Menstruation, Female Barrier, Sanitary pads
31315|NCT02857933|cerebral palsy
31316|NCT02857933|motor impairments
31317|NCT02857920|Vascular Endothelial Growth Factor (VEGF) antibody
31318|NCT02857920|solid tumor
31319|NCT02857920|NK Immunotherapy
31320|NCT02857907|Kidney transplantation
31321|NCT02857907|Immunosuppressive treatment
31322|NCT02857894|Polypoidal choroidal vasculopathy
31323|NCT02857881|keratoconus
31324|NCT02857881|photokeratectomy
31325|NCT02857881|de-epithelization
31326|NCT02857868|Hepatic Impairment
31327|NCT02857868|ABL001
31328|NCT02857868|Child-Pugh
31329|NCT02857868|healthy subjects with normal hepatic function
31330|NCT02857855|liver transplantation
31331|NCT02857855|postoperative infection
31332|NCT02857855|biliary complications
31333|NCT02857855|patient survival
31334|NCT02857855|graft survival
31335|NCT02857855|supplemental oxygen
31336|NCT02857829|Cognition
31337|NCT02857829|working memory
31338|NCT02857829|nootropic
31339|NCT02857829|reaction time
31340|NCT02857829|healthy individuals
31341|NCT02857829|cognitive enhancement
31342|NCT02857803|Virtual Reality
31343|NCT02857803|Cognitive Rehabilitation
31344|NCT02857803|Motor Rehabilitation
31345|NCT02857803|Ecological validity
31346|NCT02857803|Personalisation
31347|NCT02857790|Rotablation
31348|NCT02857790|High speed rotational atherectomy
31349|NCT02857790|Type IV myocardial infarction
31350|NCT02857790|Cardiac magnetic resonance imaging
31351|NCT02857790|CMR
31352|NCT02857790|Percutaneous Coronary Intervention
31353|NCT02857751|depression
31354|NCT02857751|PTSD
31355|NCT02857751|anxiety
31356|NCT02857751|surf therapy
31357|NCT02857699|Quality of life
31358|NCT02857699|Phase I trials
31359|NCT02857673|Children with Special Health Care Needs
31360|NCT02857673|Violence Prevention
31361|NCT02857660|Sarcopenia
31362|NCT02857660|Obesity
31363|NCT02857660|Whole-Body Electromyostimulation
31364|NCT02857660|Protein Supplementation
31365|NCT02857660|community dwelling men
31366|NCT02857647|Bariatric surgery
31367|NCT02857647|Anxiety
31368|NCT02857647|Nutrition knowledge
31369|NCT02857647|Weight loss expectations
31370|NCT02857634|Urinary Bladder cancer
31371|NCT02857634|diagnosis
31372|NCT02857634|Cellvizio Dual Band
31373|NCT02857582|Antibiotic-induced diarrhea
31374|NCT02857582|Clostridium-difficile toxin
31375|NCT02857582|Pseudomembranous colitis
31376|NCT02857504|double lumen tube
31377|NCT02857504|hook
31378|NCT02857439|Trauma of the shoulder
31379|NCT02857413|Xerostomia
31380|NCT02857413|Radiotherapy
31381|NCT02857348|decision making
31382|NCT02857348|heuristics
31383|NCT02857283|Air pollution
31384|NCT02857283|Air pollutant exposure
31385|NCT02857283|Ozone
31386|NCT02857270|MAPK
31387|NCT02857270|RAS
31388|NCT02857270|BRAF
31389|NCT02857257|IBS
31390|NCT02857257|Microbiota
31391|NCT02857244|Freezing of Gait
31392|NCT02857231|Bioimpedance spectroscopy
31393|NCT02857205|Hirschsprung Associated EnteroColitis (HAEC)
31394|NCT02857179|bariatric surgery
31395|NCT02857179|follow-up
31396|NCT02857179|weight loss
31397|NCT02857179|complications
31398|NCT02857179|comorbidities evolution
31399|NCT02857166|JS001
31400|NCT02857166|solid tumors
31401|NCT02857153|MAP
31402|NCT02857153|Blood loss
31403|NCT02857153|Postoperative delirium
31404|NCT02857153|Elderly patients
31405|NCT02857153|Noncardiothoracic surgery
31406|NCT02857127|Low income population
31407|NCT02857127|Motor Activity
31408|NCT02857127|Primary Health Care
31409|NCT02857088|depression
31410|NCT02857088|emotional reactivity
31411|NCT02857036|rhythm
31412|NCT02857036|depression
31413|NCT02857036|antidepressant treatment
31414|NCT02857023|Neurocognitive
31415|NCT02857023|Working memory
31416|NCT02857023|Cogmed
31417|NCT02857023|Cognitive training
31418|NCT02856984|Pregnancy
31419|NCT02856984|Infant
31420|NCT02856971|Hinge Knee Prosthesis
31421|NCT02856971|TKA infection
31422|NCT02856971|rotating hinge prosthesis
31423|NCT02856971|hinge knee arthroplasty
31424|NCT02856945|fracture
31425|NCT02856945|children
31426|NCT02856945|knee
31427|NCT02856945|clinical criteria
31428|NCT02856945|decision making
31429|NCT02856906|Orofacial Pain
31430|NCT02856906|Electromyography
31431|NCT02856906|dental occlusion
31432|NCT02856893|AZD9291
31433|NCT02856893|Osimertinib
31434|NCT02856893|Gefitinib
31435|NCT02856893|NSCLC
31436|NCT02856841|epithelial ovarian cancer
31437|NCT02856841|optimum cytoreduction
31438|NCT02856815|Immuncell-LC
31439|NCT02856815|Transarterial Chemoembolization
31440|NCT02856789|Fibrin structure
31441|NCT02856789|Thromboelastography
31442|NCT02856789|Fibrin formation
31443|NCT02856789|Fibrinolysis
31444|NCT02856789|TEG 5000
31445|NCT02856789|TEG 6S
31446|NCT02856789|Coagulo-lytic balance
31447|NCT02856789|Normal range
31448|NCT02856776|Vitamin D
31449|NCT02856776|Metabolomics
31450|NCT02856776|Microbiota
31451|NCT02856776|Gene Expression
31452|NCT02856711|Group Prenatal Visits,CenteringPregnancy
31453|NCT02856698|Acute heart failure
31454|NCT02856698|morphine
31455|NCT02856698|midazolam
31456|NCT02856698|in-hospital mortality
31457|NCT02856672|Laryngeal Tube Supreme Laryngeal Mask Airway Leak Pressure
31458|NCT02856620|cardiac mechanics
31459|NCT02856620|circulating biomarkers
31460|NCT02856620|frailty
31461|NCT02856542|Psoriasis vulgaris, scalp, topical, applicator, device
31462|NCT02856503|DCIS
31463|NCT02856503|IBC
31464|NCT02856503|Breast Cancer
31465|NCT02856503|Invasive Breast Carcinoma
31466|NCT02856503|High Grade Ductal Carcinoma in-situ
31467|NCT02856412|Stress Disorders, Post-Traumatic
31468|NCT02856412|Exercise
31469|NCT02856412|Mindfulness
31470|NCT02856399|methadone
31471|NCT02856399|cancer pain
31472|NCT02856399|long term effect
31473|NCT02856373|Denervation
31474|NCT02856373|Renal Artery
31475|NCT02856360|Football
31476|NCT02856360|Cleats
31477|NCT02856360|Stiffness
31478|NCT02856347|MEDULLAR
31479|NCT02856334|chronic pelvic pain
31480|NCT02856334|vulvodynia
31481|NCT02856334|pelvic pain
31482|NCT02856334|psychosocial factors
31483|NCT02856334|central sensitization
31484|NCT02856295|postpartum venous thromboembolism
31485|NCT02856295|prophylactic dose of low molecular weight heparin
31486|NCT02856295|anti 10a
31487|NCT02856269|Zinc
31488|NCT02856256|Energy drink
31489|NCT02856256|Choroid
31490|NCT02856230|Critical limb ischemia
31491|NCT02856230|bellow-the-knee angioplasty
31492|NCT02856230|drug-eluting balloon
31493|NCT02856165|infant
31494|NCT02856165|oxygen therapy
31495|NCT02856165|High flow nasal canula oxygen therapy
31496|NCT02856165|Bronchiolitis
31497|NCT02856152|Healthy Volunteer
31498|NCT02856139|ultra-widefield fluorescein angiography
31499|NCT02856139|peripheral retina
31500|NCT02856139|normal eyes
31501|NCT02856126|Hepatic arterial infusion chemotherapy
31502|NCT02856126|Transarterial Chemoembolization
31503|NCT02856113|Drug therapy
31504|NCT02856087|acute pain
31505|NCT02856087|postoperative
31506|NCT02856087|surgery
31507|NCT02856048|GnRH agonist
31508|NCT02856048|Ovarian reserve
31509|NCT02856048|Fertility Preservation
31510|NCT02856048|Alkylating Agents
31511|NCT02856035|chronic stroke
31512|NCT02856035|functional MRI
31513|NCT02856035|functional NIRS
31514|NCT02856035|motor learning
31515|NCT02856035|FES
31516|NCT02856035|upper extremity
31517|NCT02856035|neural feedback
31518|NCT02856035|arm/hand functional training
31519|NCT02856022|electrical ilioinguinal nerve stimulation
31520|NCT02856022|bladder pain syndrome
31521|NCT02856022|intravesical irrigation
31522|NCT02855996|fatherhood
31523|NCT02855996|father involvement
31524|NCT02855996|economic stability
31525|NCT02855996|co-parenting
31526|NCT02855996|healthy relationships
31527|NCT02855996|father-child engagement
31528|NCT02855957|Alpha-Hemoglobin Stabilizing Protein
31529|NCT02855957|alpha-Hb pool
31530|NCT02855957|thalassemias
31531|NCT02855957|diagnostic method
31532|NCT02855957|biomarker
31533|NCT02855944|ovarian cancer
31534|NCT02855944|fallopian tube cancer
31535|NCT02855944|primary peritoneal cancer
31536|NCT02855944|peritoneal cancer
31537|NCT02855944|platinum sensitive
31538|NCT02855944|relapsed disease
31539|NCT02855944|PARP Inhibitor
31540|NCT02855944|PARP
31541|NCT02855944|rucaparib
31542|NCT02855944|ruca
31543|NCT02855944|homologous recombination
31544|NCT02855944|homologous recombination deficiency
31545|NCT02855944|genomic scarring
31546|NCT02855944|loss of heterozygosity
31547|NCT02855944|CO-338
31548|NCT02855944|PF-01367338
31549|NCT02855944|PF 01367338
31550|NCT02855944|CO-338-043
31551|NCT02855944|platinum sensitive ovarian cancer
31552|NCT02855944|platinum sensitive fallopian tube cancer
31553|NCT02855944|platinum sensitive primary peritoneal cancer
31554|NCT02855944|platinum sensitive peritoneal cancer
31555|NCT02855944|gynecological cancer
31556|NCT02855944|Clovis
31557|NCT02855944|Clovis oncology
31558|NCT02855944|ARIEL2
31559|NCT02855944|ARIEL 2
31560|NCT02855944|ARIEL-2
31561|NCT02855944|ARIEL-3
31562|NCT02855944|ARIEL 3
31563|NCT02855944|ARIEL3
31564|NCT02855944|ARIEL4
31565|NCT02855944|ARIEL-4
31566|NCT02855944|ARIEL 4
31567|NCT02855944|A4
31568|NCT02855944|advanced OC
31569|NCT02855944|platinum resistant ovarian cancer
31570|NCT02855944|platinum resistant primary ovarian cancer
31571|NCT02855918|Psychiatry
31572|NCT02855918|Depressive disorder
31573|NCT02855918|Suicidal behavior
31574|NCT02855918|Genetics
31575|NCT02855905|Exercise
31576|NCT02855905|Cold Temperature
31577|NCT02855892|GV1001
31578|NCT02855892|BPH
31579|NCT02855892|Benign prostatic hyperplasia
31580|NCT02855788|gastric cancer
31581|NCT02855788|gastroesophageal cancer
31582|NCT02855788|metastatic
31583|NCT02855788|advanced
31584|NCT02855736|Suicidal inpatients
31585|NCT02855736|Positive Psychology
31586|NCT02855736|Gratitude
31587|NCT02855736|Psychological pain
31588|NCT02855723|Squamous carcinoma of oral cavity and oropharynx
31589|NCT02855723|Sentinel lymph node
31590|NCT02855723|Lymph node dissection
31591|NCT02855723|Equivalence
31592|NCT02855671|microcirculation
31593|NCT02855671|thermal
31594|NCT02855671|temperature
31595|NCT02855658|Sjögren's syndrome
31596|NCT02855658|Gan-Lu-Yin
31597|NCT02855658|Sang-Ju-Yin
31598|NCT02855658|Xuefu-Zhuyu-Decoction
31599|NCT02855658|Oxidative stress
31600|NCT02855658|Immune regulation
31601|NCT02855658|Gene modulation
31602|NCT02855658|SS-1
31603|NCT02855645|Trichosanthes root
31604|NCT02855645|Traditional Chinese Medicine
31605|NCT02855645|Clinical trial
31606|NCT02855632|G-CSF
31607|NCT02855632|adhesion reformation
31608|NCT02855632|Asherman syndrome
31609|NCT02855619|inspiratory muscles training programs
31610|NCT02855619|Ventilator-induced diaphragmatic dysfunction
31611|NCT02855619|Weaning
31612|NCT02855619|Intensive care unit
31613|NCT02855606|Oral PrEP
31614|NCT02855606|TGW
31615|NCT02855606|Thai MSM
31616|NCT02855593|acupuncture
31617|NCT02855580|Pharmacogenomic
31618|NCT02855580|child
31619|NCT02855580|psychiatry
31620|NCT02855580|Obsessive Compulsive Disorder
31621|NCT02855580|Depression
31622|NCT02855580|Anxiety
31623|NCT02855580|CYP2D6
31624|NCT02855580|CYP2C19
31625|NCT02855580|Selective serotonin reuptake inhibitor
31626|NCT02855580|SSRI
31627|NCT02855567|surgery
31628|NCT02855567|acupuncture
31629|NCT02855567|gynecology
31630|NCT02855567|pain
31631|NCT02855567|narcotics
31632|NCT02855554|myocardial tissue characterization
31633|NCT02855541|Blood Glucose
31634|NCT02855541|Physical Fitness
31635|NCT02855541|Body Composition
31636|NCT02855541|Lipids
31637|NCT02855528|Tin Filter
31638|NCT02855528|Coronary Artery Calcium Scoring
31639|NCT02855528|Radiation dose reduction
31640|NCT02855515|drug-induced sleep endoscopy
31641|NCT02855515|obstructive sleep apnoea
31642|NCT02855515|VOTE classification
31643|NCT02855515|AHI
31644|NCT02855515|BMI
31645|NCT02855489|Condom Use
31646|NCT02855489|HIV/STD
31647|NCT02855489|Intervention
31648|NCT02855489|Theory of Planned Behavior
31649|NCT02855489|Dismantling Study Design
31650|NCT02855463|Giant virus
31651|NCT02855463|Amoeba
31652|NCT02855424|stroke
31653|NCT02855424|exercise capacity
31654|NCT02855385|Rectal bleeding, , ,
31655|NCT02855385|Attitude
31656|NCT02855385|Health seeking behaviour
31657|NCT02855385|Nigeria
31658|NCT02855385|Screening
31659|NCT02855385|high risk patients
31660|NCT02855359|Antibodies, Monoclonal
31661|NCT02855359|SGN-19A
31662|NCT02855359|Denintuzumab Mafodotin
31663|NCT02855359|DLBCL
31664|NCT02855359|Antibody-Drug Conjugate
31665|NCT02855359|Antigens, CD19
31666|NCT02855359|Hematologic Diseases
31667|NCT02855359|Immune System Diseases
31668|NCT02855359|Immunoproliferative Disorders
31669|NCT02855359|Immunotherapy
31670|NCT02855359|Lymphatic Diseases
31671|NCT02855359|Lymphoma
31672|NCT02855359|Lymphoma, B-Cell
31673|NCT02855359|Lymphoma, Large B-Cell, Diffuse
31674|NCT02855359|Lymphoma, Non-Hodgkin
31675|NCT02855359|Monomethyl auristatin F
31676|NCT02855359|Neoplasms
31677|NCT02855359|Neoplasms by Histologic Type
31678|NCT02855359|Transformed Lymphoma / DLBCL
31679|NCT02855359|Cyclophosphamide
31680|NCT02855359|Doxorubicin
31681|NCT02855359|Liposomal doxorubicin
31682|NCT02855359|Prednisone
31683|NCT02855359|Rituximab
31684|NCT02855359|Vincristine
31685|NCT02855359|Alkylating Agents
31686|NCT02855359|Anti-Inflammatory Agents
31687|NCT02855359|Antibiotic, Antineoplastic
31688|NCT02855359|Antimitotic Agents
31689|NCT02855359|Antineoplastic Agents, Alkylating
31690|NCT02855359|Antineoplastic Agents
31691|NCT02855359|Phytogenic Antirheumatic Agents
31692|NCT02855359|Glucocorticoids
31693|NCT02855359|Drug Therapy
31694|NCT02855359|Follicular Lymphoma Grade 3b
31695|NCT02855359|immunosuppressive agents
31696|NCT02855333|Merendino procedure
31822|NCT02854514|endometrial -cytokines
31697|NCT02855333|Feasibility, Safety and QoL of the Merendino procedure
31698|NCT02855320|Biologics safety
31699|NCT02855320|Rheumatoid arthritis
31700|NCT02855320|Spondyloarthritis
31701|NCT02855320|patient education
31702|NCT02855320|self-management
31703|NCT02855307|Closed-loop system
31704|NCT02855307|Artificial pancreas
31705|NCT02855307|Exercise
31706|NCT02855307|Hypoglycemia
31707|NCT02855307|Insulin
31708|NCT02855307|Glucagon
31709|NCT02855307|Type 1 diabetes
31710|NCT02855294|oral contraceptive pills
31711|NCT02855294|Joint stability
31712|NCT02855268|Kidney disease, nephritis
31713|NCT02855229|Translational
31714|NCT02855229|Electrophysiology
31715|NCT02855216|Physiotherapy
31716|NCT02855216|Range of motion
31717|NCT02855216|Inhibition sub-occipital techniques
31718|NCT02855190|Ga68-citrate
31719|NCT02855190|FDG
31720|NCT02855190|PET/MR and PET/CT
31721|NCT02855190|Periprosthetic joint infection
31722|NCT02855177|Hyperlipidemia
31723|NCT02855164|LJN452
31724|NCT02855164|non-alcoholic steatohepatitis
31725|NCT02855164|NASH
31726|NCT02855164|phase 2
31727|NCT02855164|adaptive design
31728|NCT02855164|randomized
31729|NCT02855151|EUS
31730|NCT02855138|isotretinoin
31731|NCT02855138|PCOS
31732|NCT02855138|acne vulgaris
31733|NCT02855125|NSCLC
31734|NCT02855125|phase 2 study
31735|NCT02855125|TAS-114
31736|NCT02855125|S-1
31737|NCT02855073|adipose-derived mesenchymal progenitor cells
31738|NCT02855073|Artz
31739|NCT02855034|child and infant
31740|NCT02855034|Blood samples
31741|NCT02855021|Dementia
31742|NCT02855021|Cerebral metabolism
31743|NCT02855021|PET scan
31744|NCT02855008|Social Problem-Solving
31745|NCT02855008|Intellectual Disability
31746|NCT02855008|Problem Behaviors
31747|NCT02855008|Community based intervention
31748|NCT02855008|Prevention
31749|NCT02854956|phenotype
31750|NCT02854956|X-linked mental retardation
31751|NCT02854956|neuronal networks
31752|NCT02854956|cognitive processes
31753|NCT02854930|Clinical death
31754|NCT02854930|state of consciousness
31755|NCT02854904|Immunomodulatory
31756|NCT02854904|dexmedetomidine
31757|NCT02854904|anesthesia
31758|NCT02854904|alpha-2 agonist
31759|NCT02854904|arthrodesis
31760|NCT02854904|spinal fusion
31761|NCT02854904|Immune effect
31762|NCT02854904|double randomized clinical trials
31763|NCT02854891|Effects
31764|NCT02854891|Heat
31765|NCT02854891|Light
31766|NCT02854826|Frail Older Adults, Interprofessional Team
31767|NCT02854813|overactive bladder
31768|NCT02854813|coronary artery disease
31769|NCT02854813|gensini score
31770|NCT02854800|varenicline
31771|NCT02854800|buprenorphine
31772|NCT02854787|Spinal anesthesia
31773|NCT02854787|cesarean
31774|NCT02854787|blood pressure
31775|NCT02854787|Norepinephrine
31776|NCT02854787|Phenylephrine
31777|NCT02854735|Head and Neck Neoplasms
31778|NCT02854735|Total body composition
31779|NCT02854735|Dual-Energy X-Ray Absorptiometry
31780|NCT02854735|Malnutrition
31781|NCT02854735|Muscle quantification
31782|NCT02854722|deferasirox
31783|NCT02854722|iron accumulation
31784|NCT02854696|Islet cell Transplantation
31785|NCT02854696|cost-effectiveness analysis
31786|NCT02854696|Cost-utility analysis
31787|NCT02854696|Type 1 Diabetes
31788|NCT02854683|Chronic Fatigue Syndrome (CFS)
31789|NCT02854683|Myalgic Encephalomyelitis (ME)
31790|NCT02854683|Postural Tachycardia Syndrome (POTS)
31791|NCT02854683|Neurally Mediated Syncope (NMS)
31792|NCT02854683|Systemic Exertion Intolerance Disease (SEID)
31793|NCT02854683|Orthostatic Intolerance (OI)
31794|NCT02854683|Oral Rehydration Solution (ORS)
31795|NCT02854683|Lower Body Negative Pressure (LBNP)
31796|NCT02854670|capsaicin
31797|NCT02854670|pain improvement
31798|NCT02854670|provoked vulvodynia
31799|NCT02854657|melanoma
31800|NCT02854657|skin self-examination
31801|NCT02854631|Cirrhosis
31802|NCT02854631|Prednisone
31803|NCT02854631|Jaundice
31804|NCT02854605|Non-alcoholic fatty liver disease (NAFLD)
31805|NCT02854605|Fibrosis
31806|NCT02854605|GS-9674
31807|NCT02854592|rtPA
31808|NCT02854592|urokinase
31809|NCT02854579|Hypoxic-Ischemic Encephalopathy
31810|NCT02854579|progenitor cell
31811|NCT02854579|paracrine factor
31812|NCT02854579|adipose mesenchymal stem cell
31813|NCT02854579|neonate
31814|NCT02854566|periprosthetic fracture of the femur
31815|NCT02854566|hip prosthesis
31816|NCT02854540|hyperhidrosis
31817|NCT02854540|palmar
31818|NCT02854540|sweating
31819|NCT02854540|iontophoresis
31820|NCT02854540|sweat gland diseases
31821|NCT02854540|skin diseases
31823|NCT02854501|Homocysteine
31824|NCT02854501|Preeclampsia
31825|NCT02854501|poor placentation
31826|NCT02854475|skin parameters
31827|NCT02854475|cholesterol
31828|NCT02854475|Raman spectroscopy
31829|NCT02854462|Language Development
31830|NCT02854462|Shared Picture Book reading
31831|NCT02854462|Preschoolers
31832|NCT02854462|Inference making
31833|NCT02854449|Immune Marker
31834|NCT02854449|Immunologic Marker
31835|NCT02854449|Radiotherapy
31836|NCT02854449|Dose Hypofractionation
31837|NCT02854436|Prostate cancer
31838|NCT02854436|CRPC
31839|NCT02854436|Metastatic castrate-resistant prostate cancer
31840|NCT02854436|Prostate neoplasm
31841|NCT02854436|Galahad
31842|NCT02854436|Niraparib
31843|NCT02854436|DNA anomalies
31844|NCT02854436|DNA defect
31845|NCT02854436|PARP inhibitor
31846|NCT02854436|PARPi
31847|NCT02854410|dietary sodium nitrate
31848|NCT02854410|radiotherapy
31849|NCT02854410|nasopharyngeal carcinoma
31850|NCT02854384|Epilepsy
31851|NCT02854384|Mobile phone
31852|NCT02854371|gadoxetic acid
31853|NCT02854371|T1 map
31854|NCT02854371|MRI
31855|NCT02854345|CZT camera
31856|NCT02854345|pinhole
31857|NCT02854332|Pain
31858|NCT02854332|Analgesic
31859|NCT02854332|Stimulation
31860|NCT02854332|Motor Cortex
31861|NCT02854306|Bariatric surgery
31862|NCT02854306|Mindfulness
31863|NCT02854306|Obese
31864|NCT02854293|palliative care
31865|NCT02854293|cancer
31866|NCT02854293|quality of life
31867|NCT02854280|Hypoxia
31868|NCT02854280|Brain
31869|NCT02854280|Effort
31870|NCT02854267|organ procurement
31871|NCT02854267|brain death
31872|NCT02854267|organ donation
31873|NCT02854267|next of kins
31874|NCT02854254|phlebitis
31875|NCT02854254|catheter
31876|NCT02854254|congestive heart failure
31877|NCT02854254|dobutamine
31878|NCT02854241|MRI
31879|NCT02854241|HCC
31880|NCT02854241|surveillance
31881|NCT02854228|Pituitary tumor
31882|NCT02854228|pituitary carcinoma
31883|NCT02854228|acromegaly
31884|NCT02854228|cushing
31885|NCT02854228|prolactinoma
31886|NCT02854163|Secukinumab
31887|NCT02854163|Neutrophils
31888|NCT02854163|Vitamin D
31889|NCT02854124|Melanoma
31890|NCT02854124|Dissemination
31891|NCT02854124|Initiating stem cells
31892|NCT02854098|BHJS, constipation
31893|NCT02854085|Prevention of Cognitive Decline
31894|NCT02854085|Art Therapy
31895|NCT02854085|Music Reminiscence Activity
31896|NCT02854085|Elderly
31897|NCT02854072|GV1001
31898|NCT02854059|Asymptomatic antibody-mediated TTP
31899|NCT02854046|calcific uremic arteriolopathy
31900|NCT02854046|case-control study
31901|NCT02854046|cohort study
31902|NCT02854033|amyloid
31903|NCT02854033|plaques
31904|NCT02854033|neuroimaging
31905|NCT02854033|biomarkers
31906|NCT02854033|cognition disorder
31907|NCT02854033|early detection
31908|NCT02854033|pre-dementia
31909|NCT02854033|dementia
31910|NCT02854033|Alzheimer's disease
31911|NCT02854033|tau
31912|NCT02854020|Aircraft
31913|NCT02854020|Emergency
31914|NCT02854020|First aid
31915|NCT02854020|Cabin crew
31916|NCT02854020|Burn
31917|NCT02854020|Cardiac arrest
31918|NCT02854007|Coronary artery disease
31919|NCT02854007|Angioplasty
31920|NCT02854007|Bioresorbable coronary device
31921|NCT02854007|QALY (Quality-Adjusted Life Years)
31922|NCT02853994|DCB
31923|NCT02853994|DEB
31924|NCT02853994|Sirolimus
31925|NCT02853994|PCI
31926|NCT02853994|ISR
31927|NCT02853994|SVD
31928|NCT02853994|Restenosis
31929|NCT02853994|Bifurcation
31930|NCT02853994|CAD
31931|NCT02853994|Coronary artery
31932|NCT02853968|Unlock the Cell
31933|NCT02853968|Castleman's Disease
31934|NCT02853968|CD
31935|NCT02853968|Castleman Disease
31936|NCT02853968|MCD
31937|NCT02853968|iMCD
31938|NCT02853968|Angiofollicular Lymph Hyperplasia
31939|NCT02853968|multicentric Castleman's disease
31940|NCT02853968|multicentric Castleman disease
31941|NCT02853968|idiopathic multicentric Castleman disease
31942|NCT02853929|Pertussis
31943|NCT02853929|Immunogenicity
31944|NCT02853929|Poliomyelitis
31945|NCT02853929|Tetanus
31946|NCT02853929|Hepatitis B
31947|NCT02853929|Diptheria
31948|NCT02853903|solid tumor
31949|NCT02853903|NK immunotherapy
31950|NCT02853890|Birth
31951|NCT02853890|obstetric analgesia
31952|NCT02853890|obstetric anesthesia
31953|NCT02853864|Gender
31954|NCT02853864|Propofol
31955|NCT02853864|Dexmedetomidine
31956|NCT02853864|Interaction
31957|NCT02853851|Stress factors,
31958|NCT02853851|intensive care units,
31959|NCT02853851|scale,
31960|NCT02853851|quality of care
31961|NCT02853838|acute viral bronchiolitis
31962|NCT02853838|respiratory syncytial virus
31963|NCT02853838|chest physiotherapy
31964|NCT02853812|tinnitus
31965|NCT02853812|residual inhibition
31966|NCT02853786|cochlear implant
31967|NCT02853786|language environment
31968|NCT02853786|speech therapy assessment
31969|NCT02853786|LENA technology
31970|NCT02853773|sweeteners
31971|NCT02853773|sugar
31972|NCT02853773|EEG
31973|NCT02853773|food viewing
31974|NCT02853773|food intake
31975|NCT02853747|arterial stiffness
31976|NCT02853747|retinal vessels
31977|NCT02853747|physical activity
31978|NCT02853747|children
31979|NCT02853708|E. coli
31980|NCT02853708|extended-spectrum beta-lactamase
31981|NCT02853708|molecular epidemiology
31982|NCT02853708|risk factors
31983|NCT02853695|Hysteroscopy
31984|NCT02853695|Diffusion
31985|NCT02853695|Implementation
31986|NCT02853695|Diagnostic hysteroscopy
31987|NCT02853695|Operative hysteroscopy
31988|NCT02853682|glycocalyx
31989|NCT02853682|capillary leak syndrome
31990|NCT02853656|preterm birth
31991|NCT02853656|gestation
31992|NCT02853617|S. pneumoniae
31993|NCT02853617|N. meningitidis
31994|NCT02853617|H. influenza
31995|NCT02853617|B. pertussis
31996|NCT02853617|C. tetani
31997|NCT02853617|MRSA
31998|NCT02853591|laparoscopy
31999|NCT02853591|hysterectomy
32000|NCT02853500|Liver Cancer
32001|NCT02853487|Cluster headache
32002|NCT02853487|actigraphy
32003|NCT02853487|circadian rhythm
32004|NCT02853461|biofilm
32005|NCT02853461|periprosthetic joint infection
32006|NCT02853461|hip
32007|NCT02853461|endoprothesis
32008|NCT02853461|ceramic
32009|NCT02853461|bearing components
32010|NCT02853461|sonication
32011|NCT02853461|low grade infection
32012|NCT02853461|joint aspiration
32013|NCT02853448|Plasma
32014|NCT02853448|Serum
32015|NCT02853448|Effective Blood Draws
32016|NCT02853435|Cross-over
32017|NCT02853435|Gepotidacin
32018|NCT02853435|Pharmacokinetics
32019|NCT02853435|Relative Bioavailability
32020|NCT02853435|non-compartmental PK analysis
32021|NCT02853435|High shear wet granulation
32022|NCT02853396|internalised stigma
32023|NCT02853396|self stigma
32024|NCT02853396|inpatients
32025|NCT02853396|CBT
32026|NCT02853396|Cognitive therapy
32027|NCT02853383|Chronic Obstructive Pulmonary Diseases, COPD
32028|NCT02853357|Thoracic manipulation
32029|NCT02853357|Low back pain
32030|NCT02853357|Core strengthening
32031|NCT02853357|Thoracic spine thrust manipulation
32032|NCT02853344|PD1
32033|NCT02853344|PD-1
32034|NCT02853344|PDL1
32035|NCT02853344|PD-L1
32036|NCT02853331|PD1
32037|NCT02853331|PD-1
32038|NCT02853331|PDL1
32039|NCT02853331|PD-L1
32040|NCT02853331|VEGFR TKI
32041|NCT02853305|PD1
32042|NCT02853305|PD-1
32043|NCT02853305|PDL1
32044|NCT02853305|PD-L1
32045|NCT02853266|Kawasaki disease
32046|NCT02853266|non-cruzi-related antibody (NCRA)
32047|NCT02853253|Preterm neonates
32048|NCT02853240|Cerebral palsy
32049|NCT02853240|children
32050|NCT02853240|muscle spasticity
32051|NCT02853240|botulinum toxin injection
32052|NCT02853227|Telemark score, reliability
32053|NCT02853214|Dysglobulinemia
32054|NCT02853214|Multiple Myeloma
32055|NCT02853214|MGUS
32056|NCT02853214|Waldenström
32057|NCT02853214|genetic factors
32058|NCT02853214|Sequencing
32059|NCT02853201|Extubation
32060|NCT02853201|Intercostal Muscles
32061|NCT02853201|Diaphragm
32062|NCT02853201|Sternocleidomastoid Muscle
32063|NCT02853162|Stereotactic body radiotherapy
32064|NCT02853162|MRI
32065|NCT02853162|Renal cell carcinoma
32066|NCT02853149|Spinal Cord Injury
32067|NCT02853149|disability
32068|NCT02853149|obesity
32069|NCT02853149|cardiometabolic
32070|NCT02853149|Caregiver
32071|NCT02853110|MRI, stereotactic body radiotherapy, hypofractionation
32072|NCT02853084|Auto-inflammatory diseases
32073|NCT02853084|IL-1 inhibitors
32074|NCT02853084|HL2351
32075|NCT02853084|Cryopyrin‑Associated Periodic Syndromes (CAPS)
32076|NCT02853084|Neonatal Onset Multisystem Inflammatory Disease (NOMID)
32077|NCT02853084|Muckle-Wells Syndrome (MWS)
32078|NCT02853084|Familial Cold Autoinflammatory Syndrome (FCAS)
32079|NCT02853058|stillbirth
32080|NCT02853058|hemorrhage
32081|NCT02853019|Emotion
32082|NCT02853019|motivation
32083|NCT02853019|cognition
32084|NCT02853019|schizophrenia
32085|NCT02853006|Cancer lung
32086|NCT02853006|Fluids
32087|NCT02853006|LungCancerTest
32088|NCT02853006|radiological anomalies
32089|NCT02853006|non-cancerous
32090|NCT02853006|carriers
32091|NCT02853006|Patient reference
32092|NCT02852993|Erythrocyte Transfusion
32093|NCT02852993|Survival
32094|NCT02852967|Skin Diseases
32095|NCT02852967|Auto-Immune Diseases
32096|NCT02852967|Plaque
32097|NCT02852967|Dermatology
32098|NCT02852954|Progesterone Induced Blocking Factor
32099|NCT02852954|Endometrial Cancer
32100|NCT02852941|Impedance
32101|NCT02852941|Kidney Transplantation
32102|NCT02852928|ILD; chILD
32103|NCT02852915|Colonic Neoplasms
32104|NCT02852915|Laparoscopic Surgery
32105|NCT02852915|T4
32106|NCT02852902|Bloodstream infections caused by MDR Enterobacteriaceae
32107|NCT02852902|Extended-spectrum β-lactamase-producers
32108|NCT02852902|Carbapenemase-producing organisms
32109|NCT02852902|Solid Organ Transplantation
32110|NCT02852902|Multidrug-resistant Enterobacteriaceae
32111|NCT02852902|Anti-Infective Agents
32112|NCT02852889|internal jugular vein distensibility,haemodynamics
32113|NCT02852876|Safety of ASP2151
32114|NCT02852876|Phase 1
32115|NCT02852876|Pharmacokinetics
32116|NCT02852876|Healthy male subjects
32117|NCT02852876|Tolerability
32118|NCT02852876|Food effect of ASP2151
32119|NCT02852811|Climacteric
32120|NCT02852811|Education
32121|NCT02852811|Mental health
32122|NCT02852811|Menopause
32123|NCT02852772|Cognitive impairment
32124|NCT02852772|HIV
32125|NCT02852772|Microalbuminuria
32126|NCT02852772|Chronic kidney disease
32127|NCT02852720|Pharmacokinetics
32128|NCT02852720|levobupivacaine
32129|NCT02852720|Pregnancy
32130|NCT02852720|Cesarean section
32131|NCT02852720|Electrocardiography
32132|NCT02852668|elderly
32133|NCT02852668|strength training
32134|NCT02852668|power training
32135|NCT02852668|functional capacity
32136|NCT02852668|gait biomechanics
32137|NCT02852655|Brain Tumor
32138|NCT02852642|power training
32139|NCT02852642|plyometric training
32140|NCT02852642|functional capacity
32141|NCT02852629|decision-support sheet
32142|NCT02852616|Course
32143|NCT02852616|Posttraumatic Stress Disorder
32144|NCT02852616|Narrative Exposure Therapy
32145|NCT02852603|dissection
32146|NCT02852603|aneurysm
32147|NCT02852603|thoracic aorta
32148|NCT02852590|Observational
32149|NCT02852590|Pediatric
32150|NCT02852590|Off-Label Use
32151|NCT02852590|Unlicensed drug use
32152|NCT02852590|Adverse Drug Reaction
32153|NCT02852590|Hospitalized Children
32154|NCT02852590|Pediatric inpatients
32155|NCT02852577|panic disorder
32156|NCT02852577|agoraphobia
32157|NCT02852577|clonazepam
32158|NCT02852577|paroxetine
32159|NCT02852564|Non-Muscle
32160|NCT02852564|Invasive
32161|NCT02852564|Bladder
32162|NCT02852564|Cancer
32163|NCT02852564|Muscle
32164|NCT02852564|Surgery
32165|NCT02852564|Transurethral
32166|NCT02852564|Resection
32167|NCT02852564|Tumor
32168|NCT02852564|Ethacrynic
32169|NCT02852564|Acid
32170|NCT02852564|Mitomycin
32171|NCT02852564|Urine
32172|NCT02852564|NMIBC
32173|NCT02852512|Laparoscopic Sacrocolpopexy
32174|NCT02852512|Robotic Assisted Sacrocolpopexy
32175|NCT02852512|Pelvic Organ Prolapse
32176|NCT02852499|environmental epidemiology
32177|NCT02852499|cohort
32178|NCT02852499|atmospheric pollutant
32179|NCT02852499|chemical pollutant
32180|NCT02852499|growth, neuro-development, respiratory health
32181|NCT02852499|big data
32182|NCT02852499|biological samples (RNA, DNA, urines ...)
32183|NCT02852499|e-dohad and exposome
32184|NCT02852486|BCR-ABL Positive
32185|NCT02852486|Leukemia, Chronic Myeloid
32186|NCT02852486|Imatinib
32187|NCT02852486|Pioglitazone
32188|NCT02852473|Continuous Positive Airway Pressure
32189|NCT02852473|Radiotherapy
32190|NCT02852473|Proton Therapy
32191|NCT02852382|scalp block
32192|NCT02852382|local infiltration
32193|NCT02852330|Voltage tomography
32194|NCT02852304|liver
32195|NCT02852304|transplant
32196|NCT02852304|Lysosomal Acid Lipase
32197|NCT02852278|Amyotrophic Lateral Sclerosis
32198|NCT02852278|ALS
32199|NCT02852278|motor neuron diseases
32200|NCT02852278|Progressive Muscular Atrophy
32201|NCT02852278|Primary Lateral Sclerosis
32202|NCT02852278|Hereditary Spastic Paraplegia
32203|NCT02852265|oral contraceptive
32204|NCT02852265|contraceptive implant
32205|NCT02852265|contraception
32206|NCT02852265|adherence
32207|NCT02852265|adverse event
32208|NCT02852239|Renal impairment
32209|NCT02852239|Healthy volunteers
32210|NCT02852239|Clinical pharmacology study
32211|NCT02852239|DRB436
32212|NCT02852239|dabrafenib
32213|NCT02852239|normal renal function
32214|NCT02852239|impaired renal function
32215|NCT02852213|AADC
32216|NCT02852213|gene therapy
32217|NCT02852187|Intervertebral Disc Degeneration
32218|NCT02852187|Lumbar Spinal Disease
32219|NCT02852148|Wound
32220|NCT02852148|Pressure Ulcer
32221|NCT02852148|Diabetic Foot Ulcer
32222|NCT02852148|Venous Leg Ulcer
32223|NCT02852148|Burn
32224|NCT02852148|Quality of Life
32225|NCT02852135|Laryngeal Masks
32226|NCT02852135|endotracheal tube
32227|NCT02852135|lateral positioned laparoscopic surgery
32228|NCT02852135|general anesthesia
32229|NCT02852122|prostate cancer
32230|NCT02852122|C11 Choline PET/MR
32231|NCT02852122|staging
32232|NCT02852122|biochemical failure
32233|NCT02852096|gastric cancer
32234|NCT02852096|Her2/neu
32235|NCT02852096|dual paraffin blocks
32236|NCT02852096|trastuzumab
32237|NCT02852070|bronchoalveolar lavage
32238|NCT02852070|lower respiratory tract infections
32239|NCT02851979|premature newborns
32240|NCT02851979|apneas prevention
32241|NCT02851979|olfactory stimulation
32242|NCT02851979|latin square design
32243|NCT02851966|Non-obstructive Azoospermia
32244|NCT02851966|Sperm Retrieval
32245|NCT02851966|Infertility, Male
32246|NCT02851966|Semen
32247|NCT02851966|Biomarkers
32248|NCT02851966|Proteomics
32249|NCT02851966|Enzyme-Linked Immunosorbent Assay
32250|NCT02851953|cervix, cervical dilation, balloon catheter
32251|NCT02851940|Pain
32252|NCT02851940|Bleeding
32253|NCT02851940|Hemorrhoids
32254|NCT02851940|Band Ligation
32255|NCT02851940|hypertonic saline sclerotherapy
32256|NCT02851836|attachment
32257|NCT02851836|adolescent
32258|NCT02851836|picture
32259|NCT02851823|Er-YAG lasers
32260|NCT02851823|Nd-YAG lasers
32261|NCT02851823|chronic periodontitis
32262|NCT02851823|nonsurgical periodontal debridement
32263|NCT02851810|attachment
32264|NCT02851810|oculomotor marker
32265|NCT02851810|emotion regulation
32266|NCT02851784|hepatocellular carcinoma
32267|NCT02851784|ablation
32268|NCT02851784|immunotherapy
32269|NCT02851784|cytokine induced kill cell
32270|NCT02851732|Quality Improvement
32271|NCT02851732|Cluster Analysis
32272|NCT02851719|Urinary Incontinence, Stress
32273|NCT02851719|Pelvic Floor
32274|NCT02851719|Exercise
32275|NCT02851719|Patient Compliance
32276|NCT02851706|Brain Tumor
32277|NCT02851706|Glioma
32278|NCT02851706|Astrocytoma
32279|NCT02851706|Brain Cancer
32280|NCT02851706|Spine Cander
32281|NCT02851615|Anemia, Sickle Cell
32282|NCT02851615|Self Care
32283|NCT02851615|Adolescent
32284|NCT02851615|Young Adult
32285|NCT02851615|Disease Management
32286|NCT02851615|Behavioral Activation
32287|NCT02851615|Peer Communication
32288|NCT02851576|Adenovirus
32289|NCT02851550|liver
32290|NCT02851550|transplant
32291|NCT02851550|Lysosomal Acid Lipase
32292|NCT02851472|TRAGI (transfusion related acute gut injury)
32293|NCT02851472|inhaled nitric oxide (iNO)
32294|NCT02851472|prematurity
32295|NCT02851472|PRBC transfusion
32296|NCT02851472|NEC (necrotizing enterocolitis)
32297|NCT02851472|NIRS (near infrared spectroscopy)
32298|NCT02851472|ELGAN (extremely low gestational age neonate)
32299|NCT02851459|Vaccines
32300|NCT02851407|stem cell transplant
32301|NCT02851407|hematopoietic stem cell transplant (HSCT)
32302|NCT02851407|veno-occlusive disease (VOD)
32303|NCT02851407|sinosoidial obstruction syndrome (SOS)
32304|NCT02851368|Indocyanine Green
32305|NCT02851368|Fluorescence Imaging
32306|NCT02851342|Cognition
32307|NCT02851342|MEG
32308|NCT02851329|stage IV EGFR-mutant
32309|NCT02851329|EGFR TKIs
32310|NCT02851329|progression-free survival
32311|NCT02851329|prognosis
32312|NCT02851329|computed tomography
32313|NCT02851290|Hypospadias
32314|NCT02851290|Caudal block
32315|NCT02851290|Dorsal penile nerve block
32316|NCT02851290|Anesthesia
32317|NCT02851290|Urethrocutaneous fistula
32318|NCT02851290|Urethral stricture
32319|NCT02851290|Meatal stenosis
32320|NCT02851290|Glanular dehiscence
32321|NCT02851277|Peanut Allergy
32322|NCT02851277|ASP0892
32323|NCT02851264|Early Esophageal Squamous Neoplasia
32324|NCT02851264|optical enhancement technology
32325|NCT02851264|virtual chromoendoscopy
32326|NCT02851251|eye disease
32327|NCT02851251|neonatal eye disease
32328|NCT02851251|newborn
32329|NCT02851251|screening
32330|NCT02851251|multicenter
32331|NCT02851134|genetic
32332|NCT02851121|Neurophysiological
32333|NCT02851121|Perception-action
32334|NCT02851121|Link
32335|NCT02851108|falciparum malaria
32336|NCT02851108|sub saharan
32337|NCT02851108|africa
32338|NCT02851108|elimination disorder
32339|NCT02851082|Training Program
32340|NCT02851082|Endurance
32341|NCT02851082|Von Willebrand factor
32342|NCT02851069|Observational Study
32343|NCT02851069|Chronic Hepatitis C
32344|NCT02851069|Chronic Hepatitis C genotype 1
32345|NCT02851069|Sustained Virological Response
32346|NCT02851069|Paritaprevir/r - Ombitasvir, ± Dasabuvir
32347|NCT02851056|Myeloma
32348|NCT02851056|Vaccine
32349|NCT02851056|Dendritic cell
32350|NCT02851056|autologous hematopoietic cell transplant
32351|NCT02851056|HCT
32352|NCT02851030|Child, Preschool
32353|NCT02851030|Child Care
32354|NCT02850991|Esophageal cancer, radiation, chemotherapy
32355|NCT02850939|Breast cancer
32356|NCT02850939|Endocrine hormonal therapy
32357|NCT02850939|mHealth
32358|NCT02850926|Concussion
32359|NCT02850926|Soccer
32360|NCT02850926|Adolescent
32361|NCT02850874|hyperthermic intraperitoneal chemotherapy
32362|NCT02850874|perioperative systemic chemotherapy
32363|NCT02850874|peritoneal disease
32364|NCT02850848|Pharmacokinetic
32365|NCT02850835|Decision Aid
32366|NCT02850835|Pelvic Organ Prolapse (POP)
32367|NCT02850822|decitabine
32368|NCT02850822|chemotherapy
32369|NCT02850809|radiofrequency ablation
32370|NCT02850809|complications
32371|NCT02850796|Mindfulness
32372|NCT02850796|self-compassion
32373|NCT02850796|Acceptance and Commitment Therapy
32374|NCT02850796|weight self-stigma
32375|NCT02850796|quality-of-life
32376|NCT02850783|colon cancer
32377|NCT02850757|Modified William's airway
32378|NCT02850757|fiberoptic bronchoscope
32379|NCT02850757|U shape Guedls airway
32380|NCT02850757|oral airways
32381|NCT02850757|efficacy and safety
32382|NCT02850705|Neuromyelitis Optica
32383|NCT02850705|Myelitis
32384|NCT02850705|Optic Neuritis
32385|NCT02850705|autoantibody
32386|NCT02850705|demyelination
32387|NCT02850679|Atrial Fibrillation
32388|NCT02850679|Cardioversion
32389|NCT02850666|social skills
32390|NCT02850666|child
32391|NCT02850666|theory of mind
32392|NCT02850666|drama
32393|NCT02850666|occupational therapy
32394|NCT02850666|Speech-language pathology
32395|NCT02850653|Acute Endophthalmitis.
32396|NCT02850653|PCR
32397|NCT02850653|Ocular sampling
32398|NCT02850627|acute coronary syndrome
32399|NCT02850627|Tongguan capsule
32400|NCT02850627|miRNAs
32401|NCT02850601|Oral lichen planus
32402|NCT02850601|Dexamethasone solution
32403|NCT02850562|body composition,
32404|NCT02850562|Dual-Energy X-Ray Absorptiometry
32405|NCT02850562|sarcopenia
32406|NCT02850562|peripheral quantitative computed tomography
32407|NCT02850562|muscle density
32408|NCT02850562|elderly
32409|NCT02850549|neck pain
32410|NCT02850549|cervical
32411|NCT02850549|classification
32412|NCT02850549|outcomes
32413|NCT02850549|physical therapy
32414|NCT02850536|Colorectal Cancer
32415|NCT02850536|Liver Metastases
32416|NCT02850536|Breast Cancer
32417|NCT02850536|Gastric Cancer
32418|NCT02850536|Pancreas Cancer
32419|NCT02850536|Carcinoembryonic antigen
32420|NCT02850536|CAR-T
32421|NCT02850536|Immunotherapy
32422|NCT02850510|Harsh discipline
32423|NCT02850510|parental competence
32424|NCT02850510|positive parenting
32425|NCT02850497|optical coherence tomography
32426|NCT02850497|malapposition
32427|NCT02850497|endothelization
32428|NCT02850471|Postoperative pulmonary complications
32429|NCT02850471|Transcutaneous electric acupoint stimulation
32430|NCT02850471|pulmonary protection
32431|NCT02850432|Magnetic resonance imaging
32432|NCT02850432|Extracelluar volume matrix fraction
32433|NCT02850432|Peripheral artery disease
32434|NCT02850432|Blood-oxygen level dependent
32435|NCT02850432|Cardiac function
32436|NCT02850393|suppression mnemonic
32437|NCT02850393|emotional response
32438|NCT02850393|inhibitory control of failures
32439|NCT02850393|neurological alterations
32440|NCT02850341|Physical Activity
32441|NCT02850341|Mental Health
32442|NCT02850341|Health Behavior
32443|NCT02850341|Walking
32444|NCT02850341|Physical Exercise
32445|NCT02850341|Mental disorder
32446|NCT02850315|optimal coherence tomography
32447|NCT02850315|myocardial reperfusion
32448|NCT02850276|HIV disease
32449|NCT02850276|gastrointestinal problems
32450|NCT02850263|Diabetic Retinopathy
32451|NCT02850263|Diabetic Macular Oedema
32452|NCT02850263|Diabetic Macular Edema
32453|NCT02850263|Aflibercept
32454|NCT02850250|Observational
32455|NCT02850250|pharmacokinetic
32456|NCT02850250|cardiac
32457|NCT02850250|Cefuroxime
32458|NCT02850250|Paediatric
32459|NCT02850237|cerebral saturation
32460|NCT02850237|capnography
32461|NCT02850237|pre-hospital
32462|NCT02850198|ischemic stroke
32463|NCT02850185|COPD
32464|NCT02850185|hydrogen
32465|NCT02850172|nutrition
32466|NCT02850172|exercise
32467|NCT02850172|inspiratory muscle training
32468|NCT02850146|tau
32469|NCT02850146|cognition
32470|NCT02850146|longitudinal
32471|NCT02850146|cognitive decline
32472|NCT02850146|observational
32473|NCT02850146|imaging
32474|NCT02850120|surgical mesh
32475|NCT02850120|observational study
32476|NCT02850120|intraoperative complications
32477|NCT02850120|postoperative complications
32478|NCT02850107|Atherectomy, Drug-Coated Balloon
32479|NCT02850094|Physical activity
32480|NCT02850094|Exercise
32481|NCT02850094|Financial Incentives
32482|NCT02850081|Carotid endarterectomy
32483|NCT02850081|CEA
32484|NCT02850081|stroke
32485|NCT02850081|asymptomatic stenosis
32486|NCT02850055|physiotherapy, Temporomandibular Joint Disorder, tinnitus.
32487|NCT02850042|motor recovery
32488|NCT02850042|human
32489|NCT02850042|occupation-based practice
32490|NCT02850042|motor training
32491|NCT02850042|transcranial magnetic stimulation
32492|NCT02850029|antimicrobial
32493|NCT02850029|intensive care units
32494|NCT02850016|Romidepsin
32495|NCT02850016|3BNC117
32496|NCT02850016|Broadly neutralizing antibody
32497|NCT02849977|POMC
32498|NCT02849977|PCSK1
32499|NCT02849977|Pro-opiomelanocortin
32500|NCT02849964|Incidence
32501|NCT02849964|Renal Replacement Therapy
32502|NCT02849964|Socioeconomic Factors
32503|NCT02849964|Clinical Practice Pattern
32504|NCT02849951|Colitis
32505|NCT02849951|Colitis, Ulcerative
32506|NCT02849951|Ulcer
32507|NCT02849951|Colonic Diseases
32508|NCT02849951|Digestive System Diseases
32509|NCT02849951|Gastroenteritis
32510|NCT02849951|Gastrointestinal Diseases
32511|NCT02849951|Inflammatory Bowel Diseases
32512|NCT02849951|Intestinal Diseases
32513|NCT02849951|Pathologic Processes
32514|NCT02849951|Mesalamine
32515|NCT02849938|children with medical complexity
32516|NCT02849938|Telemedicine
32517|NCT02849938|Tracheostomy
32518|NCT02849925|Pit and Fissure Sealants
32519|NCT02849925|Caries
32520|NCT02849925|Glass ionomer
32521|NCT02849925|Resin
32522|NCT02849886|GvHD
32523|NCT02849886|Suicide gene
32524|NCT02849886|Dimerizer drug AP1903
32525|NCT02849886|Hematological stem cell transplantation
32526|NCT02848781|Sudden Cardiac Death
32527|NCT02848781|ICD Therapy
32528|NCT02848781|VT Ablation
32529|NCT02847702|Osteoarthritis
32530|NCT02847702|Pain
32531|NCT02847702|Osteoarthritis, knee
32532|NCT02847689|Premature Birth
32533|NCT02847689|Obstetric Labor, Premature
32534|NCT02847689|Obstetric Labor Complications
32535|NCT02847689|Pregnancy Complications
32536|NCT02847676|Peritoneal adhesions
32537|NCT02847676|Stem cells
32538|NCT02847676|MSC
32539|NCT02849834|Neuropathic Pain
32540|NCT02849834|Stimulation of the Motor Cortex (SCM)
32541|NCT02849834|Pharmacoresistant
32542|NCT02849834|rTMS
32543|NCT02849808|Corneal Transplantation
32544|NCT02849795|Obesity, Abdominal
32545|NCT02849795|Adipokines
32546|NCT02849795|Risk of cardiovascular diseases
32547|NCT02849782|Gait analysis
32548|NCT02849782|Fampridine
32549|NCT02849782|Fatigue
32550|NCT02849782|Daily activity
32551|NCT02849782|Cognition
32552|NCT02849756|Intensive care
32553|NCT02849756|elderly
32554|NCT02849756|autonomy
32555|NCT02849756|Future
32556|NCT02849756|older patients
32557|NCT02849756|intensive care unit
32558|NCT02849743|oxytocin
32559|NCT02849743|hypothalamic obesity
32560|NCT02849743|craniopharyngioma
32561|NCT02849743|metabolism
32562|NCT02849730|Epi-PCA
32563|NCT02849730|Patient controlled analgesia
32564|NCT02849730|Epidural patient controlled analgesia
32565|NCT02849730|Elderly patient
32566|NCT02849730|Side effect
32567|NCT02849730|Postoperative pain
32568|NCT02849704|Chronic Pancreatitis
32569|NCT02849704|Pancreatic Function
32570|NCT02849704|Reduced Exocrine Pancreatic Function
32571|NCT02849704|Pancreatic Insufficiency
32572|NCT02849678|Postoperative Pain
32573|NCT02849678|Bowel Surgery
32574|NCT02849678|Regional Anesthesia
32575|NCT02849665|Kangaroo-Mother Care Method; child development
32576|NCT02849652|Smoking cessation
32577|NCT02849652|Nicotine dependence
32578|NCT02849652|Organizational change
32579|NCT02849652|Mental Healthcare
32580|NCT02849626|Partial-Onset Seizures
32581|NCT02849626|Primary Generalized Tonic-Clonic Seizures
32582|NCT02849626|Adjunctive Therapy
32583|NCT02849626|Epilepsy
32584|NCT02849613|cell therapy
32585|NCT02849613|stem cell
32586|NCT02849613|transplantation
32587|NCT02849613|graft
32588|NCT02849613|recovery
32589|NCT02849613|repair
32590|NCT02849613|stroke
32591|NCT02849613|mesenchymal stem cell
32592|NCT02849613|regenerative
32593|NCT02849600|Vital pulp therapy,Young permanent tooth,Treatment outcome
32594|NCT02849587|Driving Under the Influence
32595|NCT02849587|Memory Impairment
32596|NCT02849587|Reaction Time
32597|NCT02849587|Time Perception
32598|NCT02849561|Pupillary light reflex
32599|NCT02849561|Cardio respiratory arrest
32600|NCT02849535|Oral chemotherapy
32601|NCT02849535|Relative dose intensity
32602|NCT02849535|Health related program
32603|NCT02849535|Secured drug intake
32604|NCT02849522|Lower Urinary Tract Symptoms caused by Benign Prostatic Enlargement (LUTS BPE)
32605|NCT02849522|Prostate Artery Embolisation (PAE)
32606|NCT02849522|Transurethral Resection of the Prostate (TURP)
32607|NCT02849522|Open prostatectomy
32608|NCT02849522|Laser enucleation or ablation of the prostate (Green Light, KTP, HoLEP)
32609|NCT02849522|IPSS Score
32610|NCT02849522|IIEF Score
32611|NCT02849522|Complications
32612|NCT02849522|Quality of Life
32613|NCT02849483|PONV
32614|NCT02849483|digestive signs and symptoms
32615|NCT02849483|vomiting
32616|NCT02849483|antiemetics
32617|NCT02849483|nausea
32618|NCT02849483|ramosetron
32619|NCT02849470|Adipose Stem/Stromal Cells
32620|NCT02849470|PRP
32621|NCT02849470|SVF
32622|NCT02849470|Cell Therapy
32623|NCT02849470|Alopecia
32624|NCT02849470|GF
32625|NCT02849444|renal function
32626|NCT02849444|Relapsed Multiple myeloma
32627|NCT02849444|anti-MM therapy
32628|NCT02849431|mindfulness
32629|NCT02849418|Botulinum toxin type A
32630|NCT02849418|Urinary Incontinence
32631|NCT02849418|Neurogenic Detrusor Overactivity
32632|NCT02849392|Pistachio
32633|NCT02849392|Body composition
32634|NCT02849392|Erythrocyte membrane incorporation of fatty acids
32635|NCT02849392|Dietary quality/micronutrient quality
32636|NCT02849392|Blood lipids
32637|NCT02849392|Inflammatory markers
32638|NCT02849392|Bone density
32639|NCT02849392|Bone turnover markers
32640|NCT02849392|Satiety
32641|NCT02849379|tongue cancer
32642|NCT02849379|cryosurgery
32643|NCT02849379|NK immunotherapy
32644|NCT02849366|Sarcoma
32645|NCT02849366|Cryosurgery
32646|NCT02849366|NK Immunotherapy
32647|NCT02849353|Ovarian Cancer
32648|NCT02849353|cryosurgery
32649|NCT02849353|NK immunotherapy
32650|NCT02849340|Cervical Cancer
32651|NCT02849340|cryosurgery
32652|NCT02849340|NK immunotherapy
32653|NCT02849327|Pharyngeal cancer
32654|NCT02849327|Cryosurgery
32655|NCT02849327|NK immunotherapy
32656|NCT02849314|laryngeal cancer
32657|NCT02849314|cryosurgery
32658|NCT02849314|NK immunotherapy
32659|NCT02849249|allergy
32660|NCT02849249|Immunotherapy
32661|NCT02849249|SCIT
32662|NCT02849236|PECS block,
32663|NCT02849236|pectoral block,
32664|NCT02849236|breast augmentation
32665|NCT02849223|Mild Traumatic Brain Injury
32666|NCT02849223|Transcranial Direct Current Stimulation
32667|NCT02849223|Working Memory
32668|NCT02849197|pilonidal sinus
32669|NCT02849197|complication
32670|NCT02849197|recurrence
32671|NCT02849171|18F-fluorocholine (18F-FCH) PET
32672|NCT02849171|16-676
32673|NCT02849171|High-grade Gliomas
32674|NCT02849158|Rectoscopy
32675|NCT02849158|Proctectomy
32676|NCT02849158|Fibroblasts
32677|NCT02849145|Circulating tumor DNA
32678|NCT02849119|Robot; Laparoscopic
32679|NCT02849119|Partial nephrectomy
32680|NCT02849119|Transperitoneal
32681|NCT02849119|Retroperitoneal
32682|NCT02849119|Laparoscopic Surgery
32683|NCT02849119|Surgical Procedures, Robotic
32684|NCT02849119|Nephrectomy
32685|NCT02849106|3D culture
32686|NCT02849106|chemogram
32687|NCT02849106|FOLFOX
32688|NCT02849106|FOLFIRI
32689|NCT02849093|Optical coherence tomography
32690|NCT02849093|imaging of ocular structures
32691|NCT02849067|ischaemic heart disease
32692|NCT02849067|comedy session
32693|NCT02849067|laughter therapy
32694|NCT02849041|Circulating Tumor Cells
32695|NCT02849041|Lung
32696|NCT02849028|gut microbiota
32697|NCT02849028|sleep disorder
32698|NCT02849028|gut-brain axis
32699|NCT02849028|circadian rhythm
32700|NCT02849028|Traumatic Brain Injury
32701|NCT02849015|liver tumor
32702|NCT02849015|cryosurgery
32703|NCT02849015|NK immunotherapy
32704|NCT02849002|Concussion
32705|NCT02848989|Breast Cancer Surgery Pain
32706|NCT02848989|Breast Cancer
32707|NCT02848950|Metformin
32708|NCT02848950|fecundability
32709|NCT02848950|uterine doppler
32710|NCT02848937|calcium balance
32711|NCT02848937|dialysis
32712|NCT02848937|concentrate with citrate
32713|NCT02848924|prevalence
32714|NCT02848924|surgery
32715|NCT02848924|Treatments
32716|NCT02848911|acute lymphoblastic leukemia
32717|NCT02848898|Focal Vibrations
32718|NCT02848898|Neurorehabilitation
32719|NCT02848898|Spasticity
32720|NCT02848898|Multiple Sclerosis
32721|NCT02848885|Magnetic resonance imaging
32722|NCT02848885|Anosognosia
32723|NCT02848885|Electrical stimulation of the brain
32724|NCT02848872|Tumor-infiltrating lymphocytes (TILs)
32725|NCT02848859|cognitive behavioral therapy for insomnia
32726|NCT02848859|randomized controlled trial
32727|NCT02848846|Amputees
32728|NCT02848820|Appendicitis
32729|NCT02848820|Appendectomy
32730|NCT02848820|Antibiotics
32731|NCT02848690|Sodium restriction
32732|NCT02848690|Dietary sodium restriction questionnaire (DSRQ)
32733|NCT02848690|Low-sodium diet
32734|NCT02848690|Adherence
32735|NCT02848690|Educational intervention
32736|NCT02848677|advanced glycation end-products
32737|NCT02848677|Cardiovascular disease
32738|NCT02848677|Low Sodium Diet
32739|NCT02848677|vascular inflammation
32740|NCT02848638|PET, Yttrium-90
32741|NCT02848625|Idiopathic Pulmonary Fibrosis
32742|NCT02848625|Yoga
32743|NCT02848625|Quality of life
32744|NCT02848612|anticoagulation
32745|NCT02848612|aneurysmal subarachnoid haemorrhage
32746|NCT02848612|interventional neuroradiology
32747|NCT02848612|coil embolization
32748|NCT02848599|postoperative analgesia
32749|NCT02848599|postoperative cognitive disfunction
32750|NCT02848586|HIV
32751|NCT02848586|ECIGS
32752|NCT02848586|e-cigarettes
32753|NCT02848586|lung inflammation
32754|NCT02848560|Cystic Fibrosis
32755|NCT02848560|orkambi
32756|NCT02848560|129Xe MRI
32757|NCT02848560|hyperpolarized xenon
32758|NCT02848560|LCI
32759|NCT02848560|CFTR modulator therapy
32760|NCT02848534|fever
32761|NCT02848534|hyperthermia
32762|NCT02848534|inflammatory syndrome
32763|NCT02848521|ADPKD
32764|NCT02848521|CKD
32765|NCT02848521|Rapid progressor
32766|NCT02848521|quality of life
32767|NCT02848521|DCE
32768|NCT02848508|Metformin
32769|NCT02848508|moderate renal failure
32770|NCT02848508|severe renal failure
32771|NCT02848508|chronic kidney disease
32772|NCT02848508|hyperlactatemia
32773|NCT02848508|lactic acidosis
32774|NCT02848495|Aneurysm
32775|NCT02848495|Biocollection
32776|NCT02848495|Familial Form
32777|NCT02848482|Photodynamic therapy
32778|NCT02848456|Manipulation, Spinal
32779|NCT02848456|H-Reflex
32780|NCT02848456|Muscle Contraction
32781|NCT02848456|Muscle Strength Dynamometer
32782|NCT02848443|metastatic
32783|NCT02848443|colorectal
32784|NCT02848443|cancer
32785|NCT02848443|oxaliplatin
32786|NCT02848443|dose-escalation
32787|NCT02848430|Humulus lupulus
32788|NCT02848404|Mild cognitive impairment
32789|NCT02848404|Cognitive rehabilitation
32790|NCT02848404|Cognitive therapy
32791|NCT02848404|Alzheimer's disease
32792|NCT02848404|Memory enhancement
32793|NCT02848404|Categorical language fluency
32794|NCT02848378|Advanced Oxidation Protein Products
32795|NCT02848378|Gingival crevicular fluid
32796|NCT02848378|Monocyte chemoattractant protein-1
32797|NCT02848378|Periodontal Disease
32798|NCT02848365|Measurement
32799|NCT02848248|Acute Myeloid Leukemia
32800|NCT02848248|Antibody-Drug Conjugate
32801|NCT02848248|CD123 Antigen
32802|NCT02848248|Drug Therapy
32803|NCT02848248|AML
32804|NCT02848248|Leukemia, Myeloid, Acute
32805|NCT02848235|Prevention of Mother to Child Transmission
32806|NCT02848235|Antenatal Care for HIV positive women
32807|NCT02848235|Kenya
32808|NCT02848222|contact lens discomfort
32809|NCT02848222|dry eye disease
32810|NCT02848222|meibomian gland dysfunction
32811|NCT02848222|Bruder mask
32812|NCT02848209|Peeling
32813|NCT02848209|Histological skin changes
32814|NCT02848209|Trichloroacetic acid peel
32815|NCT02848209|phenol/croton oil peel
32816|NCT02848170|essential hypertension
32817|NCT02848170|mineralocorticoid receptor antagonist
32818|NCT02848157|dexmedetomidine
32819|NCT02848157|pudendal block
32820|NCT02848157|hypospadias
32821|NCT02848144|Immunoparalysis
32822|NCT02848144|immune response
32823|NCT02848144|sepsis
32824|NCT02848144|toxic shock syndrome
32825|NCT02848118|Hypoventilation
32826|NCT02848118|capnography
32827|NCT02848118|bronchoscopy
32828|NCT02848105|aGVHD
32829|NCT02848105|valproic acid
32830|NCT02848092|Visual Attention
32831|NCT02848092|Automobile Driving
32832|NCT02848001|CC-90009
32833|NCT02848001|Hematologic Cancers
32834|NCT02848001|Leukemia
32835|NCT02848001|Acute Myeloid Leukemia
32836|NCT02847988|muscle strength
32837|NCT02847988|muscle function
32838|NCT02847988|functional status
32839|NCT02847975|Becker
32840|NCT02847975|dystrophy
32841|NCT02847975|sympatholysis
32842|NCT02847962|Fortified-blended foods
32843|NCT02847962|Extrusion
32844|NCT02847962|Sorghum
32845|NCT02847962|Cowpea
32846|NCT02847962|Vitamin A
32847|NCT02847962|Iron
32848|NCT02847962|Protein
32849|NCT02847962|Food Aid
32850|NCT02847962|Anemia, Iron-Deficiency
32851|NCT02847962|Deficiency, Vitamin A
32852|NCT02847962|Growth Velocity
32853|NCT02847962|Stunting
32854|NCT02847962|Wasting
32855|NCT02847962|Protein-Energy Malnutrition
32856|NCT02847962|Complementary Feeding
32857|NCT02847962|Corn
32858|NCT02847962|Soy
32859|NCT02847962|Fortified Foods
32860|NCT02847962|Food assistance
32861|NCT02847936|triclosan
32862|NCT02847936|sutures
32863|NCT02847936|infection
32864|NCT02847923|Mobile Devices
32865|NCT02847923|Augmentative and Alternative Communication
32866|NCT02847923|Cerebral Palsy
32867|NCT02847910|tissue suction tube
32868|NCT02847910|disposable instrument
32869|NCT02847910|induced abortion
32870|NCT02847884|IBD
32871|NCT02847884|Crohn's disease
32872|NCT02847884|Remicade
32873|NCT02847884|Infliximab
32874|NCT02847884|Level
32875|NCT02847884|Drug Level
32876|NCT02847884|Children
32877|NCT02847871|mobility
32878|NCT02847871|exercise
32879|NCT02847871|nutrition
32880|NCT02847871|primary care
32881|NCT02847871|prevention
32882|NCT02847871|care pathway
32883|NCT02847871|elderly patient
32884|NCT02847858|unsafe sex
32885|NCT02847858|unprotected sex
32886|NCT02847858|adolescents
32887|NCT02847858|Latinas
32888|NCT02847858|Hispanic
32889|NCT02847858|mobile health applications
32890|NCT02847858|unintended pregnancy
32891|NCT02847858|teen pregnancy prevention
32892|NCT02847858|school-based health centers
32893|NCT02847845|chronic fatigue syndrome
32894|NCT02847845|idiopathic chronic fatigue
32895|NCT02847845|red ginseng
32896|NCT02847845|cortisol
32897|NCT02847845|anti-oxidant
32898|NCT02847832|Adnexal Diseases
32899|NCT02847832|Ovary
32900|NCT02847832|Ovarian Neoplasms
32901|NCT02847832|Ovarian Cysts
32902|NCT02847832|Ovarian Diseases
32903|NCT02847832|Ultrasonography
32904|NCT02847832|Ultrasonography, Doppler
32905|NCT02847832|Diagnosis
32906|NCT02847832|Early Diagnosis
32907|NCT02847832|Early Detection of Cancer
32908|NCT02847832|Genital Neoplasms, Female
32909|NCT02847832|Genital Diseases, Female
32910|NCT02847832|Urogenital Neoplasms
32911|NCT02847832|Cysts
32912|NCT02847832|Endocrine System Diseases
32913|NCT02847832|Gonadal Disorders
32914|NCT02847832|Neoplasms
32915|NCT02847832|Endocrine Gland Neoplasms
32916|NCT02847832|International Ovarian Tumor Analysis
32917|NCT02847832|Simple Rules
32918|NCT02847832|Preoperative evaluation
32919|NCT02847832|Prediction Models
32920|NCT02847832|Logistic Regression Models
32921|NCT02847832|Mathematical Models
32922|NCT02847832|Adnexal Masses
32923|NCT02847832|Ovarian Tumors
32924|NCT02847832|Risk of Malignancy
32925|NCT02847793|Attentional Bias Modification (ABM)
32926|NCT02847793|Cognitive Bias Modification (CBM)
32927|NCT02847793|Depression
32928|NCT02847793|Dysphoria
32929|NCT02847793|Gaze patterns
32930|NCT02847793|Eye-tracking
32931|NCT02847767|Liver Perfusion
32932|NCT02847767|Hepatocellular Carcinoma
32933|NCT02847767|Dynamic Contrast-Enhanced Computed Tomography
32934|NCT02847754|bony metastases
32935|NCT02847754|physical exercise
32936|NCT02847741|Depression
32937|NCT02847741|Cholesterol
32938|NCT02847741|Suicidal behavior
32939|NCT02847741|Predictive factor
32940|NCT02847715|PRO
32941|NCT02847715|PROM
32942|NCT02847715|Adverse event
32943|NCT02847715|QTool
32944|NCT02847715|Aftercare
32945|NCT02847663|Cold
32946|NCT02847663|recovery
32947|NCT02847650|Early Parkinson Disease
32948|NCT02847650|Phase 2
32949|NCT02847637|Hemophilia A
32950|NCT02847637|Emicizumab
32951|NCT02847611|Dynamometer mechanic
32952|NCT02847611|Strength of prehension
32953|NCT02847611|Comparison
32954|NCT02847611|Device
32955|NCT02847611|Diagnosis
32956|NCT02847611|Healthy Volunteers
32957|NCT02847598|CLE, SLE, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Lupus
32958|NCT02847585|water-soluble ubiquinol supplementation
32959|NCT02847585|pediatric cardiomyopathy
32960|NCT02847585|antioxidant
32961|NCT02847585|inflammation
32962|NCT02847585|complementary therapy
32963|NCT02847533|resistant depression
32964|NCT02847533|inflammation
32965|NCT02847520|Disorders related to gaming and gambling; poker
32966|NCT02847507|HIV
32967|NCT02847507|Hepatitis E
32968|NCT02847481|Fecal Microbiota Transplantation
32969|NCT02847455|Ilaprazole
32970|NCT02847455|Proton pump inhibitor
32971|NCT02847455|Duodenal ulcer
32972|NCT02847455|Acid suppression
32973|NCT02847455|Randomized trial
32974|NCT02847442|Ongentys
32975|NCT02847403|dysglycemia
32976|NCT02847403|MCI
32977|NCT02847403|exenatide LAR
32978|NCT02847403|GLP-1
32979|NCT02847390|diabetes mellitus
32980|NCT02847390|physician education
32981|NCT02847390|nursing education
32982|NCT02847390|hyperglycemia
32983|NCT02847390|hypoglycemia
32984|NCT02847390|inpatient
32985|NCT02847390|hospital
32986|NCT02847390|glycemic control
32987|NCT02847364|chewing gum
32988|NCT02847364|prevention
32989|NCT02847351|arabinoxylan, HOMA index, glycemic control, obesity.
32990|NCT02847338|Hypertension
32991|NCT02847312|Oat
32992|NCT02847312|Phenolic acid
32993|NCT02847312|Avenanthramide
32994|NCT02847312|FMD
32995|NCT02847312|LDI
32996|NCT02847312|Gut microbiota
32997|NCT02847312|Blood Pressure
32998|NCT02847312|Renin Angiotensin
32999|NCT02847312|Nitric Oxide
33000|NCT02847299|cough help
33001|NCT02847299|mechanical insufflation
33002|NCT02847299|mechanical ventilation
33003|NCT02847299|neuromuscular diseases
33004|NCT02847299|peak cough flow
33005|NCT02847273|NIRS
33006|NCT02847273|Regional oxygen saturation
33007|NCT02847273|cardiac surgery with bypass
33008|NCT02847247|healthy
33009|NCT02847234|Cervical necrotizing fasciitis
33010|NCT02847234|mediastinitis
33011|NCT02847221|cough peak flow
33012|NCT02847221|scheduled weaning trial
33013|NCT02847221|scheduled extubation
33014|NCT02847221|prognosis
33015|NCT02847208|cystic fibrosis
33016|NCT02847208|contraception
33017|NCT02847208|gynaecological follow-up
33018|NCT02847208|screening
33019|NCT02847208|Pap smear
33020|NCT02847208|counselling
33021|NCT02847195|pediatric intensive care
33022|NCT02847195|pain assessment
33023|NCT02847195|tracheal aspiration
33024|NCT02847195|sedation
33025|NCT02847195|pupillometer
33026|NCT02847156|cystic fibrosis
33027|NCT02847156|viruses
33028|NCT02847156|respiratory viral infection
33029|NCT02847156|children
33030|NCT02847143|Attachement
33031|NCT02847143|Oxytocin
33032|NCT02847143|fMRI
33033|NCT02847117|Natural Mastiha, Bioavailability
33034|NCT02847091|Ipragliflozin
33035|NCT02847091|SGLT2 inhibitor
33036|NCT02847091|Type 2 diabetes mellitus
33037|NCT02847091|ASP1941
33038|NCT02847078|Coronary Disease
33039|NCT02847078|percutaneous coronary intervention
33040|NCT02847078|secondary prevention
33041|NCT02847078|smart phone app
33042|NCT02847026|inactivated poliovirus vaccine
33043|NCT02847026|fractional inactivated poliovirus vaccine
33044|NCT02847026|Rotavirus
33045|NCT02847026|Rotarix
33046|NCT02847026|RotaTeq
33047|NCT02847026|fIPV
33048|NCT02847026|IPV
33049|NCT02847013|Postcesarean Section
33050|NCT02847013|Postoperative
33051|NCT02847000|Decitabine
33052|NCT02847000|Tetrahydrouridine
33053|NCT02847000|Epigenetic Therapy
33054|NCT02846987|Abemaciclib i
33055|NCT02846987|LY2835219
33056|NCT02846987|16-376
33057|NCT02846974|Pulse Oximetry
33058|NCT02846974|Free and Open Source
33059|NCT02846961|inflammatory bowel disease
33060|NCT02846961|biosimilar
33061|NCT02846961|anti-drug antibody
33062|NCT02846961|trough drug concentration
33063|NCT02846948|sepsis
33064|NCT02846948|echocardiography
33065|NCT02846948|urgent
33066|NCT02846948|abdominal surgery
33067|NCT02846935|p16/CDKN2A
33068|NCT02846935|TP53
33069|NCT02846935|THU
33070|NCT02846935|Decitabine
33071|NCT02846935|Tetrahydrouridine
33072|NCT02846935|DEC
33073|NCT02846883|aneurysms
33074|NCT02846857|Closed-loop system
33075|NCT02846857|Artificial pancreas
33076|NCT02846857|Type 1 diabetes
33077|NCT02846857|Hypoglycemia
33078|NCT02846857|Insulin
33079|NCT02846857|Glucagon
33080|NCT02846831|Type 1 diabetes
33081|NCT02846831|Artificial pancreas
33082|NCT02846831|Closed-loop system
33083|NCT02846831|Hypoglycemia
33084|NCT02846831|Glucagon
33085|NCT02846831|Insulin
33086|NCT02846818|Microdialysis
33087|NCT02846818|Cardiac surgery
33088|NCT02846818|Lactate to pyruvate ratio
33089|NCT02846818|Cardiopulmonary bypass
33090|NCT02846818|Neurological complications
33091|NCT02846779|Insulin persistence
33092|NCT02846779|Telepharmacy
33093|NCT02846766|advanced cancer
33094|NCT02846766|FGF
33095|NCT02846766|FGFR
33096|NCT02846766|Fibroblast Growth Factor Receptor
33097|NCT02846740|cranial electric stimulation
33098|NCT02846740|suicide
33099|NCT02846740|psychiatric inpatients
33100|NCT02846727|Hypoperfusion
33101|NCT02846727|Sepsis
33102|NCT02846714|Education
33103|NCT02846714|Prevention and Control
33104|NCT02846714|Behavioral Research
33105|NCT02846701|Neuropathic pain
33106|NCT02846701|Antidepressant
33107|NCT02846701|Duloxetine
33108|NCT02846701|Liquid Chromatography
33109|NCT02846701|Mass Spectrometry
33110|NCT02846675|SVF
33111|NCT02846675|Stromal Vascular Fraction
33112|NCT02846675|osteoarthritis(OA)
33113|NCT02846675|knee
33114|NCT02846675|adipose
33115|NCT02846662|depression
33116|NCT02846662|mobile technology
33117|NCT02846662|community trial
33118|NCT02846623|Chronic Lymphocytic Leukemia
33119|NCT02846623|CLL
33120|NCT02846623|Relapsed, Refractory
33121|NCT02846623|High-risk Untreated
33122|NCT02846623|High-risk molecular features
33123|NCT02846623|Genetic mutation
33124|NCT02846623|17p/TP53 deletion
33125|NCT02846623|Obinutuzumab
33126|NCT02846623|GA101
33127|NCT02846623|Gazyva
33128|NCT02846623|Atezolizumab
33129|NCT02846623|MPDL3280A
33130|NCT02846623|Tencentriq
33131|NCT02846623|Small Lymphocytic Lymphoma
33132|NCT02846623|SLL
33133|NCT02846610|anesthesia
33134|NCT02846610|continuous regional anesthesia
33135|NCT02846610|complications
33136|NCT02846610|epidural analgesia
33137|NCT02846610|antibiotics
33138|NCT02846597|Respiratory distress syndrome
33139|NCT02846597|Sustained lung inflation
33140|NCT02846597|Delivery room
33141|NCT02846584|CAR T
33142|NCT02846584|HSCT
33143|NCT02846571|Islet Transplantation
33144|NCT02846571|Type 1 Diabetes
33145|NCT02846571|Immune Tolerance Induction
33146|NCT02846571|Diabetes Complications
33147|NCT02846571|Intraocular Transplantation
33148|NCT02846571|Eye Anterior Chamber
33149|NCT02846571|Kidney Transplantation
33150|NCT02846571|Immunosuppression
33151|NCT02846571|Type 2 Diabetes
33152|NCT02846558|calorie restriction
33153|NCT02846558|weight loss
33154|NCT02846532|Thromboembolism
33155|NCT02846532|Fontan Procedure
33156|NCT02846532|Children
33157|NCT02846493|Ovarian hyperstimulation syndrome
33158|NCT02846493|Dexamethasone
33159|NCT02846467|Informed consent
33160|NCT02846467|Patient Education
33161|NCT02846467|Mobile applications
33162|NCT02846441|posthepatectomy liver failure
33163|NCT02846441|ALPPS
33164|NCT02846441|hepatobiliary scintigraphy
33165|NCT02846441|SPECT
33166|NCT02846441|mebrofenin
33167|NCT02846415|Dementia
33168|NCT02846415|Play and Playthings
33169|NCT02846415|Cognition
33170|NCT02846415|Memory
33171|NCT02846402|HIV testing
33172|NCT02846402|Female sex workers
33173|NCT02846402|HIV self-testing
33174|NCT02846389|Radiation therapy for Breast Cancer
33175|NCT02846363|stroke
33176|NCT02846363|public awareness campaign
33177|NCT02846363|call to EMS
33178|NCT02846337|cardio-renal syndrome
33179|NCT02846337|hemodialysis
33180|NCT02846337|peritoneal dialysis
33181|NCT02846337|hemofiltration
33182|NCT02846337|composite endpoint
33183|NCT02846311|test
33184|NCT02846311|winter
33185|NCT02846311|season
33186|NCT02846298|Drug Monitoring
33187|NCT02846298|ICU
33188|NCT02846298|Pharmacokinetic
33189|NCT02846298|Pharmacodynamic
33190|NCT02846298|antibiotic
33191|NCT02846298|Glycopeptides
33192|NCT02846298|β-lactam-aminoglycoside
33193|NCT02846285|Bleeding
33194|NCT02846259|intracranial aneurysm
33195|NCT02846259|cerebral ischemia
33196|NCT02846259|aspirin
33197|NCT02846246|aged care
33198|NCT02846246|health
33199|NCT02846246|home care services
33200|NCT02846246|person-centred care
33201|NCT02846220|Medication Adherence
33202|NCT02846220|Middle Aged 45-64
33203|NCT02846220|Aged 65-79
33204|NCT02846220|Aged, 80 and over
33205|NCT02846207|cerebral infarction
33206|NCT02846207|syndrome of qi deficiency and blood stasis
33207|NCT02846207|Buyanghuanwu decoction
33208|NCT02846207|clinical effects and mechanisms
33209|NCT02846194|Fibromyalgia
33210|NCT02846194|Guided Imagery
33211|NCT02846194|chronic pain
33212|NCT02846155|preparation
33213|NCT02846155|capsule endoscopy
33214|NCT02846129|multiple gestation
33215|NCT02846129|complications
33216|NCT02846129|cesarean delivery
33217|NCT02846116|all ceramic crown
33218|NCT02846116|Lithium disilicate
33219|NCT02846116|e-max
33220|NCT02846116|vita suprinity
33221|NCT02846077|sleep
33222|NCT02846077|social networks
33223|NCT02846077|undergraduates
33224|NCT02846077|mood
33225|NCT02846077|circadian rhythms
33226|NCT02846051|varicose vein
33227|NCT02846051|physical activity
33228|NCT02846038|Pediatric cancer
33229|NCT02846038|Childhood cancer
33230|NCT02846038|High-risk disease
33231|NCT02846038|Prognosis
33232|NCT02846038|Communication
33233|NCT02846038|Bad news
33234|NCT02846038|Pediatric oncologist
33235|NCT02846038|Parent
33236|NCT02846038|Relapse
33237|NCT02846038|Progression
33238|NCT02845999|natural killer cells
33239|NCT02845999|adoptive transfer
33240|NCT02845999|allogenic immunotherapy
33241|NCT02845999|gastrointestinal cancer EGFR+
33242|NCT02845986|Stomach Neoplasms
33243|NCT02845986|Laparoscopy
33244|NCT02845986|Spleen-Preserving
33245|NCT02845986|No.10 Lymph Node Dissection
33246|NCT02845973|gut microbiota
33247|NCT02845921|Propofol
33248|NCT02845921|Hypotension
33249|NCT02845921|Induction of anaesthesia
33250|NCT02845921|Leg elevation
33251|NCT02845921|Leg wrapping
33252|NCT02845895|Screening for nutritional disorder
33253|NCT02845895|Comparison of two organizations
33254|NCT02845895|Indicator IPAQSS
33255|NCT02845856|recurrent lung cancer
33256|NCT02845856|EGFR mutation
33257|NCT02845856|Cetuximab
33258|NCT02845856|NK immunotherapy
33259|NCT02845843|Middle East Respiratory Syndrome Coronavirus
33260|NCT02845843|MERS-CoV
33261|NCT02845843|Clinical trial
33262|NCT02845843|Lopinavir
33263|NCT02845843|Ritonavir
33264|NCT02845843|Interferon beta
33265|NCT02845830|dementia
33266|NCT02845830|elderly
33267|NCT02845830|quality of life
33268|NCT02845830|assessment
33269|NCT02845830|factor
33270|NCT02845830|trajectory
33271|NCT02845830|change
33272|NCT02845830|early stage
33273|NCT02845804|coronary artery disease
33274|NCT02845804|percutaneous coronary intervention
33275|NCT02845804|everolimus-eluting stents
33276|NCT02845778|melatonin
33277|NCT02845778|pharmacokinetics
33278|NCT02845765|Erectile Dysfunction
33279|NCT02845765|ED
33280|NCT02845765|Fundus Oculi
33281|NCT02845765|Retinal Vascularization
33282|NCT02845765|International Index of Erectile Function Questionnaire
33283|NCT02845765|IIEF
33284|NCT02845765|Dynamic Vessel Analyzer
33285|NCT02845765|DVA
33286|NCT02845765|Phosphodiesterase type 5 Inhibitor
33287|NCT02845765|PDE5Is
33288|NCT02845739|kidney transplantation
33289|NCT02845739|human papillomavirus
33290|NCT02845687|nicotine addiction
33291|NCT02845687|cigarette smoking
33292|NCT02845661|Narcotrend index
33293|NCT02845661|OAA/S scale
33294|NCT02845661|Dexmedetomidine
33295|NCT02845661|Sedation
33296|NCT02845648|anticholinergics
33297|NCT02845648|awakener
33298|NCT02845622|Hazelnut
33299|NCT02845622|Cocoa
33300|NCT02845622|Flavonoid
33301|NCT02845622|Lipids
33302|NCT02845622|Vascular Reactivity
33303|NCT02845609|Congenital macrothrombocytopenia
33304|NCT02845609|Sialic acid
33305|NCT02845609|Bleeding
33306|NCT02845583|Nursing
33307|NCT02845583|Diagnosis Related Group
33308|NCT02845583|Activity based costing
33309|NCT02845557|Youth
33310|NCT02845557|Type 2 Diabetes
33311|NCT02845557|glucose homeostasis
33312|NCT02845557|incretin effect
33313|NCT02845544|Postural Balance
33314|NCT02845531|Variant angina
33315|NCT02845531|Aborted sudden cardiac death
33316|NCT02845531|Implantable Cardioverter Defibrillator
33317|NCT02845531|Optimal Medical Therapy
33318|NCT02845531|ICD
33319|NCT02845505|intravascular ultrasonography
33320|NCT02845505|Computed Tomography
33321|NCT02845492|Exercise
33322|NCT02845492|Qigong
33323|NCT02845492|Mind-Body
33324|NCT02845492|Fatigue
33325|NCT02845492|Cancer
33326|NCT02845492|EEG
33327|NCT02845492|HRV
33328|NCT02845466|Venous Leg Ulcer
33329|NCT02845466|Diabetic Foot Ulcer
33330|NCT02845466|Wound Healing
33331|NCT02845466|Growth Factor
33332|NCT02845466|Protease Inhibitor
33333|NCT02845453|youth
33334|NCT02845453|adolescent
33335|NCT02845453|young adult
33336|NCT02845453|substance use disorder
33337|NCT02845453|bipolar disorder
33338|NCT02845453|quetiapine
33339|NCT02845440|Pragmatic Trial
33340|NCT02845440|Community Health Workers
33341|NCT02845440|Academic Detailing
33342|NCT02845427|Closed Suction Drain
33343|NCT02845427|Wound Hematoma
33344|NCT02845388|IVF
33345|NCT02845362|Neuromuscular
33346|NCT02845362|dysphagia
33347|NCT02845362|Swallowing disorders
33348|NCT02845362|Questionnaire
33349|NCT02845362|Assessment
33350|NCT02845284|adolescent
33351|NCT02845284|reproductive health
33352|NCT02845245|Comminuted intra-articular distal tibia fractures
33353|NCT02845245|3D printing
33354|NCT02845245|pre-operative planning
33355|NCT02845232|Acute myeloid leukemia
33356|NCT02845232|Therapy
33357|NCT02845232|Blood transfusion
33358|NCT02845232|Cost-effectiveness
33359|NCT02845232|Prognosis
33360|NCT02845206|Total Knee Replacement
33361|NCT02845206|Patient Specific Instrumentation
33362|NCT02845180|lipectomy
33363|NCT02845180|panniculectomy
33364|NCT02845154|Ischemia reperfusion
33365|NCT02845154|post-reperfusion syndrome
33366|NCT02845154|living donor liver transplantation
33367|NCT02845154|patient outcome
33368|NCT02845141|ACL
33369|NCT02845141|Revision surgery
33370|NCT02845141|tunnel enlargement
33371|NCT02845141|bone substitute material
33372|NCT02845141|bone graft
33373|NCT02845115|Middle Ear Implant
33374|NCT02845115|laser velocimetry
33375|NCT02845102|Chronic Illness
33376|NCT02845102|Chronic Pain
33377|NCT02845102|Depression
33378|NCT02845102|Comorbid Depression
33379|NCT02845102|Cognitive Behavioral Therapy
33380|NCT02845102|Relational Agent Technology
33381|NCT02845102|CBT
33382|NCT02845102|Virtual Counselor
33383|NCT02845076|Noninvasive ventilation
33384|NCT02845076|Respiratory insufficiency
33385|NCT02845076|Hypercapnia
33386|NCT02845076|ventilator weaning
33387|NCT02845063|muscle plasticity
33388|NCT02845063|exercise
33389|NCT02845063|rehabilitation
33390|NCT02845063|perfusion
33391|NCT02845063|ACE
33392|NCT02845063|genotype
33393|NCT02845063|hypertension
33394|NCT02845063|molecular biology
33395|NCT02845050|neo-adjuvant
33396|NCT02845050|vinflunine
33397|NCT02845050|cisplatin
33398|NCT02845050|radical cystectomy
33399|NCT02845050|muscle-invasive bladder cancer
33400|NCT02845050|JaNEO
33401|NCT02845011|Cardio first angle
33402|NCT02845011|CPR
33403|NCT02845011|Cardiopulmonary Arrest
33404|NCT02845011|Clinical trial
33405|NCT02844998|intravaginal ejaculatory latency time
33406|NCT02844998|international physical activity questionnaire
33407|NCT02844998|premature ejaculation diagnostic tool
33408|NCT02844985|Sexual Addiction
33409|NCT02844985|Genomics
33410|NCT02844985|Personality
33411|NCT02844985|Polymorphism
33412|NCT02844972|arrest or limitation of active treatment
33413|NCT02844972|emergency treatment
33414|NCT02844959|Atrial Fibrillation
33415|NCT02844959|Biomarkers
33416|NCT02844959|Inflammatory Response
33417|NCT02844959|C-reactive protein
33418|NCT02844959|FGF2
33419|NCT02844959|MMP8
33420|NCT02844959|troponin I
33421|NCT02844959|body temperature
33422|NCT02844946|Acceptance and Commitment Therapy
33423|NCT02844946|mild Traumatic Brain Injury
33424|NCT02844946|Veterans
33425|NCT02844946|Post Traumatic Stress Disorder
33426|NCT02844907|Incretins
33427|NCT02844907|GLP-1
33428|NCT02844894|intubation, ischemia modified albumine, dexmedetomidine, esmolol
33429|NCT02844868|stroke
33430|NCT02844868|hemiplegia
33431|NCT02844868|transcranial direct current stimulation (tDCS)
33432|NCT02844868|rehabilitation
33433|NCT02844868|lower extremity
33434|NCT02844868|gait training
33435|NCT02844855|Alzheimer
33436|NCT02844855|Parkinson
33437|NCT02844855|Action memory
33438|NCT02844842|mild or moderate
33439|NCT02844829|Prostate Cancer
33440|NCT02844829|Magnetic Resonance Imaging
33441|NCT02844777|topical ointment
33442|NCT02844777|skin
33443|NCT02844777|hexokinase
33444|NCT02844777|precancerous conditions
33445|NCT02844777|carcinoma, squamous cell
33446|NCT02844712|Drug hypersensitivity
33447|NCT02844712|Betalactam
33448|NCT02844712|Drug provocation test
33449|NCT02844699|prostate cancer
33450|NCT02844699|adenovirus
33451|NCT02844699|TLR5
33452|NCT02844699|immunotherapy
33453|NCT02844699|Ad5
33454|NCT02844686|Myocardial perfusion imaging
33455|NCT02844686|Single-Photon Emission Computer-Assisted Tomography
33456|NCT02844673|Sickle cell disease
33457|NCT02844673|Hydroxyurea
33458|NCT02844673|Adherence
33459|NCT02844673|randomized trial
33460|NCT02844673|medication possession ratio
33461|NCT02844660|Diabetes Mellitus
33462|NCT02844660|Foot Diseases
33463|NCT02844660|Foot Ulcer
33464|NCT02844634|pre-exposure prophylaxis
33465|NCT02844634|men who have sex with men
33466|NCT02844634|HIV prevention
33467|NCT02844634|sexually transmitted infection
33468|NCT02844634|syphilis
33469|NCT02844608|Health-related quality of life
33470|NCT02844608|Oncology clinical practice
33471|NCT02844608|Electronic collection
33472|NCT02844595|Smoking, psychological treatment, depression
33473|NCT02844569|Dental Implants
33474|NCT02844569|Bone Grafting
33475|NCT02844556|SMILE surgery
33476|NCT02844556|FS-LASIK surgery
33477|NCT02844556|multicenter
33478|NCT02844543|concussion, eye-tracking, athletes, vision
33479|NCT02844530|adults
33480|NCT02844517|Artificial Pancreas
33481|NCT02844517|Closed Loop Control
33482|NCT02844517|Continuous Glucose Monitor (CGM)
33483|NCT02844504|Fatigue
33484|NCT02844504|Breast cancer
33485|NCT02844504|Force
33486|NCT02844504|Motor imagery
33487|NCT02844504|Cancer Treatment
33488|NCT02844478|Caregiving
33489|NCT02844478|Family caregiving
33490|NCT02844478|Stress
33491|NCT02844478|dementia caregiving
33492|NCT02844478|Hispanics
33493|NCT02844478|Spanish
33494|NCT02844478|Telomere
33495|NCT02844465|epilepsy
33496|NCT02844465|laser ablation
33497|NCT02844465|Visualase
33498|NCT02844465|laser interstitial thermal therapy
33499|NCT02844452|Atopic Dermatitis
33500|NCT02844452|acupuncture
33501|NCT02844452|visit frequency
33502|NCT02844452|adult patient with AD
33503|NCT02844426|synbiotic
33504|NCT02844426|soluble dietary fiber
33505|NCT02844426|slow transit constipation
33506|NCT02844426|microbiota
33507|NCT02844387|cancer
33508|NCT02844387|brain
33509|NCT02844387|arginine
33510|NCT02844387|radiation
33511|NCT02844374|Epilepsy
33512|NCT02844374|Surgery candidate
33513|NCT02844374|EEG's Signal
33514|NCT02844361|high-risk
33515|NCT02844361|ASCT
33516|NCT02844348|Pain
33517|NCT02844348|Hypnosis
33518|NCT02844348|Chronic Dialysis
33519|NCT02844348|Arterial Disease
33520|NCT02844335|Breast Cancer
33521|NCT02844335|Cryosurgery
33522|NCT02844335|NK Immunotherapy
33523|NCT02844296|short-bout exercise
33524|NCT02844296|craving
33525|NCT02844296|handgrip
33526|NCT02844296|smoking cessation
33527|NCT02844296|RCT
33528|NCT02844283|HGF,myocardial infarction
33529|NCT02844257|Acute myeloid leukaemia
33530|NCT02844257|Transfusion dependency
33531|NCT02844257|Transfusion intensity
33532|NCT02844257|Prognosis
33533|NCT02844257|Chemotherapy
33534|NCT02844244|family well-being
33535|NCT02844244|positive psychology
33536|NCT02844218|Acute myeloid leukemia
33537|NCT02844218|Chemotherapy
33538|NCT02844218|Low-intensity therapy
33539|NCT02844218|Older patients
33540|NCT02844218|Prognosis
33541|NCT02844218|Supportive care
33542|NCT02844205|nursing care
33543|NCT02844205|observational scale
33544|NCT02844205|neonate
33545|NCT02844205|premature infant
33546|NCT02844205|developmental care
33547|NCT02844192|Vancomycin
33548|NCT02844192|under dosage
33549|NCT02844192|intensive care unit
33550|NCT02844192|pharmacokinetics
33551|NCT02844153|Metformin
33552|NCT02844153|type 2 diabetes
33553|NCT02844153|chronic kidney disease
33554|NCT02844153|antidiabetic medications
33555|NCT02844153|lactic acidosis
33556|NCT02844114|Ganoderma Lucidum Spore
33557|NCT02844114|Carcinoma, Non-Small-Cell Lung
33558|NCT02844114|Chemotherapy
33559|NCT02844114|Gemcitabine
33560|NCT02844114|Cisplatin
33561|NCT02844088|meningococcus C
33562|NCT02844075|Esophageal Squamous Cell Carcinoma
33563|NCT02844075|pembrolizumab
33564|NCT02844075|PD-1
33565|NCT02844075|neoadjuvant
33566|NCT02844075|chemoradiation
33567|NCT02844049|Deep Brain Stimulation
33568|NCT02844049|Quality of Life
33569|NCT02844036|Distal Lesions
33570|NCT02844036|Post-embolic HTP
33571|NCT02844036|Angioplasty
33572|NCT02844023|Arteritis
33573|NCT02844023|Biomarker
33574|NCT02844023|Horton disease
33575|NCT02843997|Bipolar disorder
33576|NCT02843997|Endophenotype
33577|NCT02843997|Family
33578|NCT02843997|Autosomal dominant expression
33579|NCT02843997|Sequencing
33580|NCT02843997|Heritability
33581|NCT02843984|Amniocentesis
33582|NCT02843971|Water Drinking Test
33583|NCT02843971|Intraocular Pressure
33584|NCT02843971|Sensimed Triggerfish
33585|NCT02843958|Medical device
33586|NCT02843958|Hemoptic
33587|NCT02843958|Vitamin K antagonist
33588|NCT02843958|Diagnostic in vitro
33589|NCT02843932|Somatoform
33590|NCT02843932|Psychogenic
33591|NCT02843919|Electrocardiography
33592|NCT02843919|Electroencephalography
33593|NCT02843919|Neural Correlates
33594|NCT02843919|Mental Workload
33595|NCT02843906|alzheimer disease
33596|NCT02843906|bipolar disorders
33597|NCT02843906|mild cognitive impairement
33598|NCT02843893|Pupillary
33599|NCT02843893|Reflexes
33600|NCT02843893|Analgesia
33601|NCT02843893|Sedation
33602|NCT02843880|CMV reactivation
33603|NCT02843880|CMV disease
33604|NCT02843880|Predictive factors
33605|NCT02843880|Critically ill patients
33606|NCT02843880|Septic shock
33607|NCT02843867|Transplantation
33608|NCT02843867|Immunology
33609|NCT02843867|Atherosclerosis
33610|NCT02843828|Exoskeleton Device
33611|NCT02843828|elderly
33612|NCT02843828|stroke
33613|NCT02843828|gait rehabilitation
33614|NCT02843815|Non-small cell lung cancer
33615|NCT02843815|Cryosurgery
33616|NCT02843815|NK Immunotherapy
33617|NCT02843802|Metastatic liver cancer
33618|NCT02843802|Cryosurgery
33619|NCT02843802|NK Immunotherapy
33620|NCT02843789|Adipokines
33621|NCT02843789|Tocilizumab
33622|NCT02843776|Palliative Care
33623|NCT02843776|Euthanasia
33624|NCT02843776|Epidemiologic Studies
33625|NCT02843750|Rehabilitation
33626|NCT02843750|Inspiratory Muscle Training
33627|NCT02843724|Uncontrolled Type 2 Diabetes
33628|NCT02843724|HbA1c >7.0%
33629|NCT02843711|Lungcarta Panel
33630|NCT02843711|lung adenocarcinoma
33631|NCT02843672|metatarsalgia
33632|NCT02843672|surgery
33633|NCT02843672|weil
33634|NCT02843672|MIS
33635|NCT02843672|percutaneous
33636|NCT02843672|DMMO
33637|NCT02843646|gait training
33638|NCT02843646|stepping
33639|NCT02843633|Acute Coronary Syndrome
33640|NCT02843633|Percutaneous Coronary Intervention
33641|NCT02843633|Drug Coated Stent
33642|NCT02843633|Drug Eluting Stent
33643|NCT02843620|Native Collagen
33644|NCT02843620|Joint
33645|NCT02843620|Osteoarthritis
33646|NCT02843607|Kidney Cancer
33647|NCT02843607|Cryosurgery
33648|NCT02843607|NK Immunotherapy
33649|NCT02843581|Esophageal Cancer
33650|NCT02843581|NK immunotherapy
33651|NCT02843581|Safety
33652|NCT02843581|Efficacy
33653|NCT02843555|Leukodystrophy
33654|NCT02843555|Myelin Gene
33655|NCT02843555|Myelin Protein
33656|NCT02843555|Sural Nerve Biopsy
33657|NCT02843555|Undiagnosed Disease
33658|NCT02843555|Schwann Cell
33659|NCT02843555|White Matter Pathology
33660|NCT02843555|Motor Delay
33661|NCT02843555|Cognitive Regression
33662|NCT02843555|Motor Deterioration
33663|NCT02843555|Unknown Disease
33664|NCT02843542|Positron emission tomography-magnetic resonance imaging (PET-MR)
33665|NCT02843542|Hyperthyroidism
33666|NCT02843542|Positron emission tomography-computed tomography (PET-CT)
33667|NCT02843529|biomarkers
33668|NCT02843529|CSF
33669|NCT02843529|EEG
33670|NCT02843529|MRI
33671|NCT02843490|neovascular age-related macular edema
33672|NCT02843490|biomarker
33673|NCT02843490|ranibizumab
33674|NCT02843490|lucentis
33675|NCT02843438|Toxoplasmosis
33676|NCT02843438|Uveitis
33677|NCT02843438|Chorioretinitis
33678|NCT02843438|Infection
33679|NCT02843425|Cancer Prevention
33680|NCT02843425|Precancerous colorectal polyps
33681|NCT02843425|Canned beans
33682|NCT02843425|Questionnaires
33683|NCT02843425|Surveys
33684|NCT02843425|Stool samples
33685|NCT02843412|Gastric cancer
33686|NCT02843412|Her2/neu
33687|NCT02843412|Dual paraffin blocks
33688|NCT02843412|Trastuzumab
33689|NCT02843412|Clinical Prospective Multicenter Cohort Study
33690|NCT02843399|Diabetes Mellitus Type 2
33691|NCT02843386|Uveal melanoma
33692|NCT02843386|High risk of metastasis
33693|NCT02843386|Genomic high risk signature
33694|NCT02843386|Adjuvant chemotherapy
33695|NCT02843360|public health
33696|NCT02843347|Biorepository
33697|NCT02843347|Genetics
33698|NCT02843334|Fabry disease
33699|NCT02843334|End Stage Renal Disease
33700|NCT02843334|chronic dialysis
33701|NCT02843334|alpha galactosidase A
33702|NCT02843334|Lyso-GB3
33703|NCT02843334|GLA mutation
33704|NCT02843334|Prevalence
33705|NCT02843321|infection
33706|NCT02843308|hoarding disorder
33707|NCT02843308|hoarding
33708|NCT02843308|clutter
33709|NCT02843295|renal transplantation
33710|NCT02843295|immunology
33711|NCT02843295|rejection
33712|NCT02843269|RCT
33713|NCT02843269|Multi-component intervention
33714|NCT02843269|Health personnel
33715|NCT02843269|Physical exercise training
33716|NCT02843230|Brain Tumor
33717|NCT02843204|solid tumor
33718|NCT02843204|anti-PD-L1
33719|NCT02843204|NK immunotherapy
33720|NCT02843191|Rectal Cancer
33721|NCT02843191|Consolidation Chemotherapy
33722|NCT02843178|nutrition
33723|NCT02843178|food security
33724|NCT02843178|behavioral economics
33725|NCT02843165|stereotactic body radiation therapy
33726|NCT02843165|checkpoint blockade immunotherapy
33727|NCT02843139|Circulating microRNA
33728|NCT02843139|Childhood obesity
33729|NCT02843139|Adulthood diabetes
33730|NCT02843126|recurrent breast cancer
33731|NCT02843126|Her-2 positive
33732|NCT02843126|Trastuzumab
33733|NCT02843126|NK immunotherapy
33734|NCT02843113|single father
33735|NCT02843113|parenting behavior
33736|NCT02843100|Crohn's Disease
33737|NCT02843100|Pediatric
33738|NCT02843100|Exclusive Enteral Nutrition
33739|NCT02843100|Diet
33740|NCT02843100|Microbiome
33741|NCT02843087|Breastfeeding
33742|NCT02843087|Microbiome
33743|NCT02843087|BEACH
33744|NCT02843074|B-cell tumors
33745|NCT02843074|autologous stem cell transplantation
33746|NCT02843074|blood cancers
33747|NCT02843061|B lymphoma
33748|NCT02843061|Rituximab
33749|NCT02843061|NK immunotherapy
33750|NCT02843048|Osteoporosis
33751|NCT02843048|Bariatric Surgery
33752|NCT02843048|Physical exercise
33753|NCT02843048|Obesity
33754|NCT02843022|postpartum
33755|NCT02843022|nursing
33756|NCT02843022|follow-up
33757|NCT02842983|Esmolol
33758|NCT02842983|Hypotension
33759|NCT02842983|Shock, Septic
33760|NCT02842983|Sepsis
33761|NCT02842983|Systemic Inflammatory Response Syndrome
33762|NCT02842983|Adrenergic beta-1 Receptor Antagonists
33763|NCT02842983|Adrenergic Antagonists
33764|NCT02842983|Pharmacologic Actions
33765|NCT02842983|Physiological Effects of Drugs
33766|NCT02842931|DLBCL, R-DA-EPOCH-21, R-mNHL-BFM-90, auto-SCT
33767|NCT02842918|Thoracic Spine Manipulation
33768|NCT02842918|Neurodynamics
33769|NCT02842918|Sham
33770|NCT02842866|Meningitis
33771|NCT02842866|Meningococcal Meningitis
33772|NCT02842866|Meningococcal Infections
33773|NCT02842866|MenACYW conjugate vaccine
33774|NCT02842866|Menomune® - A/C/Y/W-135
33775|NCT02842853|Meningitis
33776|NCT02842853|Meningococcal Meningitis
33777|NCT02842853|Meningococcal Infections
33778|NCT02842853|MenACYW conjugate vaccine
33779|NCT02842853|Licensed MCV4 vaccine
33780|NCT02842814|Systemic Lupus Erythematosus
33781|NCT02842814|Stable
33782|NCT02842814|Relapse Risk
33783|NCT02842814|Glucocorticoid Withdrawal
33784|NCT02842788|prone position
33785|NCT02842788|acute respiratory distress syndrome (ARDS)
33786|NCT02842788|mechanical ventilation
33787|NCT02842788|ICU
33788|NCT02842788|prevalence
33789|NCT02842775|rehabilitation
33790|NCT02842762|Echocardiography, Three-dimensional
33791|NCT02842762|Cardiac Surgical Procedures
33792|NCT02842762|Cardiac Pacing, Artificial
33793|NCT02842762|Anesthesia
33794|NCT02842736|heavy menstrual bleeding
33795|NCT02842736|endometrial ablation
33796|NCT02842723|craniopharyngioma
33797|NCT02842723|protontherapy
33798|NCT02842697|clinically significant portal hypertension
33799|NCT02842697|hepatic venous pressure gradient
33800|NCT02842697|computed tomographic angiography
33801|NCT02842671|autism
33802|NCT02842671|ambassador
33803|NCT02842658|Chemotherapy
33804|NCT02842658|Exercise
33805|NCT02842645|Foetal Exposure During Pregnancy
33806|NCT02842645|Health
33807|NCT02842645|Growth
33808|NCT02842580|colorectal
33809|NCT02842580|cancer
33810|NCT02842580|metastasis
33811|NCT02842554|PDN
33812|NCT02842554|Painful Diabetic Neuropathy
33813|NCT02842554|Diabetes
33814|NCT02842502|Skin Substitutes
33815|NCT02842489|colonoscopy insertion
33816|NCT02842489|tilt-down position
33817|NCT02842476|pulse oximetry
33818|NCT02842437|dexmedetomidine
33819|NCT02842437|sepsis
33820|NCT02842437|respiration
33821|NCT02842424|Ramipril
33822|NCT02842424|Angiotensin-converting enzyme
33823|NCT02842424|Claudication
33824|NCT02842424|Myopathy
33825|NCT02842424|Peripheral Arterial Disease
33826|NCT02842411|bowel preparation
33827|NCT02842411|chronic constipation
33828|NCT02842411|risk factor
33829|NCT02842398|gait
33830|NCT02842398|balance
33831|NCT02842398|street-crossing
33832|NCT02842385|soft tissue thickness
33833|NCT02842385|dental implant
33834|NCT02842385|crestal bone loss
33835|NCT02842372|Acute Graft Versus Host Disease in Skin
33836|NCT02842372|GvHD
33837|NCT02842372|Ectoin
33838|NCT02842372|Dermatitis
33839|NCT02842372|Inflammation of the skin
33840|NCT02842372|Topical therapy skin GvHD
33841|NCT02842346|Ultrasound; umbilical Doppler; resistance index; fetal growth
33842|NCT02842307|Acupuncture
33843|NCT02842307|Expertise-based randomized controlled trial
33844|NCT02842307|Nausea
33845|NCT02842307|Vomiting
33846|NCT02842307|Cancer
33847|NCT02842294|bevacizumab
33848|NCT02842294|health related quality of life
33849|NCT02842255|Sleep apnea
33850|NCT02842255|Oximeter
33851|NCT02842255|Calibration
33852|NCT02842255|Oxygen partial pressure
33853|NCT02842229|Myelodysplastic Syndromes
33854|NCT02842229|Leukemia Myeloid Acute
33855|NCT02842229|Multiple Myeloma
33856|NCT02842229|Leukemia, Lymphocytic, Chronic
33857|NCT02842229|Elderly Patients
33858|NCT02842229|Haematological malignancy
33859|NCT02842229|Elderly
33860|NCT02842229|Health Status
33861|NCT02842229|Scale validation
33862|NCT02842229|Retrospective
33863|NCT02842216|Pharmaceutical preparations
33864|NCT02842216|Dietary supplements
33865|NCT02842203|colorectal cancer
33866|NCT02842190|Neonatal
33867|NCT02842190|NIPPV
33868|NCT02842190|BIPAP
33869|NCT02842190|Extubation failure
33870|NCT02842151|IOL
33871|NCT02842125|Colorectal
33872|NCT02842125|colon
33873|NCT02842125|rectal
33874|NCT02842125|Ad-P53
33875|NCT02842125|metastatic
33876|NCT02842112|Acute myeloid leukemia
33877|NCT02842112|prognosis
33878|NCT02842112|stem cell harvest
33879|NCT02842112|autologous transplant
33880|NCT02842112|leukemia stem cell
33881|NCT02842060|Prevention & Control
33882|NCT02842060|Young Adult
33883|NCT02842060|Internet
33884|NCT02842047|caregiver
33885|NCT02842047|end of life
33886|NCT02842034|schizophrenia
33887|NCT02842034|rTMS
33888|NCT02842008|Exercise Therapy
33889|NCT02842008|Shoulder pain
33890|NCT02842008|Shoulder injuries
33891|NCT02842008|Shoulder function
33892|NCT02842008|Prevention
33893|NCT02842008|Wheelchair users
33894|NCT02841995|cGVHD
33895|NCT02841995|Allogeneic hematopoietic stem cell transplantation
33896|NCT02841995|Immune System Diseases
33897|NCT02841995|Steroid refractory chronic graft vs host disease (cGVHD)
33898|NCT02841995|Bone Marrow Transplantation
33899|NCT02841995|Anti-Inflammatory Agents
33900|NCT02841995|Glucocorticoids
33901|NCT02841995|Corticosteroids
33902|NCT02841969|Ulcer
33903|NCT02841969|Electrolysed
33904|NCT02841969|Water
33905|NCT02841943|Fluid responsiveness
33906|NCT02841943|Near-infrared spectroscopy
33907|NCT02841943|Thoracic surgery
33908|NCT02841943|Hypovolemia
33909|NCT02841943|veno-arterial carbon dioxide gradient
33910|NCT02841943|arterio-venous oxygen gradient
33911|NCT02841943|hypercarbia
33912|NCT02841943|Carotid artery
33913|NCT02841943|ultrasonography
33914|NCT02841943|Doppler
33915|NCT02841930|Healthcare Access
33916|NCT02841930|Undocumented Immigrants
33917|NCT02841930|Primary Prevention
33918|NCT02841800|radiofrequency ablation
33919|NCT02841800|malignant biliary stenosis
33920|NCT02841787|Depression
33921|NCT02841787|Web-based intervention
33922|NCT02841787|Aging
33923|NCT02841787|Geriatrics
33924|NCT02841787|Social network
33925|NCT02841787|Older adults
33926|NCT02841748|Pembrolizumab
33927|NCT02841748|HNSCC
33928|NCT02841735|brief intervention
33929|NCT02841735|web-based interventions
33930|NCT02841735|harm reduction
33931|NCT02841735|young adult
33932|NCT02841735|college student
33933|NCT02841709|insomnia
33934|NCT02841709|elderly
33935|NCT02841709|Polysomnography
33936|NCT02841696|Heart failure
33937|NCT02841696|Systolic dysfunction
33938|NCT02841696|GLS
33939|NCT02841696|Arterial stiffness
33940|NCT02841696|Left ventricular hypertrophy
33941|NCT02841657|3 Dimensional Laparoscopy
33942|NCT02841657|Visual work load
33943|NCT02841657|Nasa Task Load Index
33944|NCT02841657|Simulator Sickness Questionnaire
33945|NCT02841553|Endoplasmic Reticulum Stress
33946|NCT02841540|Myelodysplastic Syndromes
33947|NCT02841540|Acute Myeloid Leukemia
33948|NCT02841540|Chronic Myelomonocytic Leukemia
33949|NCT02841540|H3B-8800
33950|NCT02841501|Gene Expression Profiling
33951|NCT02841501|Genome-Wide Association Study
33952|NCT02841501|Polymorphism, Single Nucleotide
33953|NCT02841501|Drug Resistance, Fungal
33954|NCT02841475|Atrial Fibrillation , Comorbidities
33955|NCT02841462|thermal ablation
33956|NCT02841462|recurrent Bursitis
33957|NCT02841462|chronic Bursitis
33958|NCT02841462|olecranon
33959|NCT02841462|intra-bursal perfusion
33960|NCT02841449|Hydration
33961|NCT02841449|Glycemic control
33962|NCT02841449|Appetite
33963|NCT02841449|Endocrinology
33964|NCT02841436|irreversible electroporation
33965|NCT02841436|pancreatic cancer
33966|NCT02841423|physical status I-III;
33967|NCT02841423|age > 55 yr)
33968|NCT02841423|undergoing surgery (duration, > 1 h)
33969|NCT02841410|Food
33970|NCT02841410|Emotion
33971|NCT02841410|Health
33972|NCT02841410|Nutrition
33973|NCT02841410|Heuristic
33974|NCT02841410|Reasoning
33975|NCT02841410|Magnetic Resonance Imaging
33976|NCT02841384|patellofemoral pain syndrome
33977|NCT02841384|postural balance
33978|NCT02841384|knee
33979|NCT02841384|physiotherapy
33980|NCT02841371|estimated glomerular filtration rate
33981|NCT02841371|serum creatinine
33982|NCT02841371|serum cystatin C
33983|NCT02841371|chronic kidney disease
33984|NCT02841358|Niemann-Pick Disease, Type C
33985|NCT02841358|Psychiatric
33986|NCT02841358|Psychotic disorders
33987|NCT02841345|emotional processing
33988|NCT02841345|action
33989|NCT02841332|Recurrent Glioblastoma
33990|NCT02841332|Positron emission tomography
33991|NCT02841332|Fluoro misonidazole
33992|NCT02841332|MRI multimodal
33993|NCT02841319|Virtual reality
33994|NCT02841319|Hemiplegic
33995|NCT02841319|Cerebral Palsy
33996|NCT02841319|upper extremity
33997|NCT02841319|hand function
33998|NCT02841293|Anorectal cancer
33999|NCT02841293|perineal morbidity
34000|NCT02841293|cost-utility analysis
34001|NCT02841293|biological meshes
34002|NCT02841241|esmolol
34003|NCT02841241|adrenergic storm
34004|NCT02841241|septic shock
34005|NCT02841228|SIB-IMRT
34006|NCT02841228|NSCLC
34007|NCT02841228|Radiochemothearpy
34008|NCT02841215|Gale
34009|NCT02841215|Severe forms of scabies
34010|NCT02841215|Oral parasitic drug
34011|NCT02841215|Ivermectin
34012|NCT02841202|optical coherence tomography
34013|NCT02841202|oral contraceptive pills
34014|NCT02841163|Magnetic Resonance Imaging
34015|NCT02841163|Patient Satisfaction
34016|NCT02841163|Numeric Rating Scale
34017|NCT02841124|Decision making
34018|NCT02841098|Carotid stenosis,stroke,endarterectomy,medical therapy
34019|NCT02841085|Genetic
34020|NCT02841085|Thrombophilia
34021|NCT02841059|quality of life
34022|NCT02841059|urinary incontinence
34023|NCT02841059|POP
34024|NCT02841046|stroke volume variation
34025|NCT02841046|cardiac index
34026|NCT02841046|non-severe patients
34027|NCT02841046|gastrointestinal surgery
34028|NCT02840955|Atopic dermatitis
34029|NCT02840955|Staphylococcus aureus
34030|NCT02840955|Microbiome
34031|NCT02840955|Staphefekt
34032|NCT02840942|intravenous line
34033|NCT02840942|robot
34034|NCT02840916|Laser acupuncture
34035|NCT02840916|Postpartum weight retention
34036|NCT02840916|Obesity
34037|NCT02840903|CTA
34038|NCT02840903|Computed Tomographic Angiography
34039|NCT02840851|Magnetic Resonance Imaging
34040|NCT02840851|Transcranial Doppler Ultrasound
34041|NCT02840851|Hypercapnia
34042|NCT02840799|Heart Failure
34043|NCT02840799|Exercise Intolerance
34044|NCT02840799|Ejection Fraction
34045|NCT02840786|stents
34046|NCT02840786|atherectomy
34047|NCT02840786|femoral artery
34048|NCT02840786|popliteal artery
34049|NCT02840773|RANKL
34050|NCT02840773|OPG
34051|NCT02840773|Peri-implant crevicular fluid
34052|NCT02840760|tardive dyskinesia.
34053|NCT02840760|rTMS
34054|NCT02840747|Lymphomatoid Papulosis
34055|NCT02840747|Sézary Syndrome
34056|NCT02840747|T-Cell Lymphoma
34057|NCT02840734|Kinesio taping
34058|NCT02840734|Obese adults
34059|NCT02840734|Muscular function
34060|NCT02840734|Fatigue
34061|NCT02840682|resource limited setting
34062|NCT02840682|Thailand-Myanmar border
34063|NCT02840669|Cardiomyopathy
34064|NCT02840643|hemispherectomy
34065|NCT02840643|brain
34066|NCT02840643|hand function
34067|NCT02840630|n3 LC-PUFA
34068|NCT02840630|Type 2 Diabetes Mellitus
34069|NCT02840630|South Asian
34070|NCT02840630|HbA1c
34071|NCT02840630|Omega 3 status
34072|NCT02840617|ICG
34073|NCT02840617|prostate cancer
34074|NCT02840591|Citicoline, Ramelteon, Rozerem
34075|NCT02840539|Mantle cell lymphoma
34076|NCT02840539|Bortezomib
34077|NCT02840539|Cytarabine
34078|NCT02840526|PVB
34079|NCT02840526|PCA
34080|NCT02840526|nephrectomy
34081|NCT02840526|postoperative pain
34082|NCT02840513|Smartphone app
34083|NCT02840513|CO self-monitoring
34084|NCT02840500|Breakthrough Cancer Pain
34085|NCT02840500|Quality of life
34086|NCT02840500|Palliative Care Units
34087|NCT02840487|Zika Infection
34088|NCT02840487|Flavivirus
34089|NCT02840487|Vaccine-Mediated Protection
34090|NCT02840487|Immune Response
34091|NCT02840487|Arthropod-Borne Virus
34092|NCT02840474|HIV Viral Load
34093|NCT02840474|Antiviral
34094|NCT02840474|CD4 Count
34095|NCT02840474|HIV-1 Infection
34096|NCT02840448|Williams Syndrome
34097|NCT02840448|Blood Flow
34098|NCT02840448|Brain
34099|NCT02840448|Arterial Stiffness
34100|NCT02840435|Nicotine addiction
34101|NCT02840435|Cigarette smoking
34102|NCT02840422|Hyaluronic acid
34103|NCT02840422|Knee osteoarthritis
34104|NCT02840422|Quality of life
34105|NCT02840396|language
34106|NCT02840396|DLPFC
34107|NCT02840396|rTMS
34108|NCT02840396|Executive Functions
34109|NCT02840370|transcranial direct current stimulation
34110|NCT02840370|aphasia
34111|NCT02840370|language production
34112|NCT02840370|prefrontal cortex
34113|NCT02840357|Chronic inflammation
34114|NCT02840357|Adults
34115|NCT02840357|overweight
34116|NCT02840357|obese
34117|NCT02840344|Couple Functioning
34118|NCT02840344|Stress Reduction
34119|NCT02840331|Gastric carcinoma
34120|NCT02840331|Peritoneal carcinomatosis
34121|NCT02840331|Photodynamic diagnosis
34122|NCT02840331|Photodynamic therapy
34123|NCT02840331|St. John's Wort
34124|NCT02840331|Peritoneal metastasis
34125|NCT02840318|Terminal care
34126|NCT02840318|Residential facilities
34127|NCT02840318|Integrated health care systems
34128|NCT02840318|Interdisciplinary health team
34129|NCT02840318|Palliative care
34130|NCT02840305|Natural scenes
34131|NCT02840305|Brain bases
34132|NCT02840305|Visual perception
34133|NCT02840305|MRI
34134|NCT02840292|Late Preterms
34135|NCT02840292|Neurobehavioral Assessment of Preterm Infants (NAPI)
34136|NCT02840279|cognition
34137|NCT02840279|dementia
34138|NCT02840279|phosphodiesterase type 4D
34139|NCT02840279|PDE4D
34140|NCT02840227|Cancer
34141|NCT02840227|General anesthesia
34142|NCT02840227|Epidural anesthesia
34143|NCT02840201|biomarkers
34144|NCT02840188|goalkeeper's fracture
34145|NCT02840175|Treatment tapering
34146|NCT02840175|Oligoarticular
34147|NCT02840175|Juvenile Idiopathic Arthritis
34148|NCT02840175|Inactive disease
34149|NCT02840175|Biologic therapy
34150|NCT02840162|prostate cancer
34151|NCT02840162|NSAIDs
34152|NCT02840162|chemoprevention
34153|NCT02840162|celecoxib
34154|NCT02840162|COX-2 inhibitors
34155|NCT02840149|68Ga-DOTA-NOC, PET/CT
34156|NCT02840136|Respiratory infection
34157|NCT02840136|Antibiotic therapy
34158|NCT02840136|LC-MS/MS
34159|NCT02840136|Sputum antibiotic concentrations
34160|NCT02840097|Brain injuries
34161|NCT02840097|Wounds and injuries
34162|NCT02840097|Hemorrhage
34163|NCT02840097|Tranexamic acid
34164|NCT02840097|Child
34165|NCT02840084|breast implant capsular contracture
34166|NCT02840045|electroencephalography (EEG)
34167|NCT02840019|Fetal MRI
34168|NCT02840019|Pregnancy
34169|NCT02840019|Pregnant Women
34170|NCT02840019|MRI Coil
34171|NCT02840019|MRI Sequence Development/Testing
34172|NCT02840019|Abnormal Fetuses
34173|NCT02840019|Typically Developing Fetuses
34174|NCT02840019|Fetal MRI Technology Development
34175|NCT02840006|Vasoconstrictor Agents
34176|NCT02840006|Vasodilator Agents
34177|NCT02839993|tDCS effects
34178|NCT02839993|associative learning
34179|NCT02839980|oropharyngeal colonization
34180|NCT02839915|Language Impairment
34181|NCT02839850|Arthroplasty
34182|NCT02839850|replacement
34183|NCT02839850|Knee
34184|NCT02839850|function
34185|NCT02839850|radiographic
34186|NCT02839850|survivorship
34187|NCT02839837|Depression
34188|NCT02839837|Depressive Disorder
34189|NCT02839837|Exercise
34190|NCT02839837|Neuroplasticity
34191|NCT02839837|Non-invasive brain stimulation
34192|NCT02839837|Healthy Control
34193|NCT02839824|bowel cleansing
34194|NCT02839824|bowel preparation
34195|NCT02839811|Betalactams
34196|NCT02839811|In vitro diagnosis
34197|NCT02839798|sTMS
34198|NCT02839798|NEST
34199|NCT02839798|NeoSync
34200|NCT02839798|synchronous
34201|NCT02839798|non-invasive neuromodulation
34202|NCT02839798|TMS
34203|NCT02839798|transcranial magnetic stimulation
34204|NCT02839798|EEG
34205|NCT02839798|bipolar
34206|NCT02839798|depression
34207|NCT02839785|Cerebral palsy
34208|NCT02839785|Physiotherapy
34209|NCT02839785|Children
34210|NCT02839785|Ibuprofen
34211|NCT02839785|Pain
34212|NCT02839785|Anxiety
34213|NCT02839772|podoconiosis
34214|NCT02839772|glycerine
34215|NCT02839772|RCT
34216|NCT02839772|SBF
34217|NCT02839772|TEWL
34218|NCT02839772|SC hydration
34219|NCT02839759|Hearing loss
34220|NCT02839759|Presbycusis
34221|NCT02839759|Aging
34222|NCT02839759|Teleaudiology
34223|NCT02839733|Brain Imaging
34224|NCT02839733|Adult
34225|NCT02839733|DNA Testing
34226|NCT02839733|Children
34227|NCT02839694|Lung Resection
34228|NCT02839694|Surgery
34229|NCT02839694|Bilateral Lung Metastases
34230|NCT02839681|Lung Adenocarcinoma
34231|NCT02839681|Immunotoxin
34232|NCT02839681|Immunotherapy
34233|NCT02839668|breast cancer
34234|NCT02839668|angiogenesis
34235|NCT02839668|VEGF
34236|NCT02839603|Visceral leishmaniasis
34237|NCT02839603|HIV co-infection
34238|NCT02839603|Asymptomatic
34239|NCT02839590|Glaucoma
34240|NCT02839590|Ocular hypertension
34241|NCT02839590|Aqueous dynamics
34242|NCT02839564|chronic abdominal pain
34243|NCT02839564|laparoscopic adhesiolysis
34244|NCT02839564|placebo
34245|NCT02839551|Betalactams
34246|NCT02839551|Drug hypersensitivity
34247|NCT02839551|Drug provocation test
34248|NCT02839551|Reactive dose
34249|NCT02839538|infiltration
34250|NCT02839538|hemorrhoidectomy
34251|NCT02839538|postoperative pain
34252|NCT02839525|Eccentric exercise
34253|NCT02839525|Dietary supplement
34254|NCT02839525|Muscle damage
34255|NCT02839499|seniors
34256|NCT02839499|mixed food
34257|NCT02839499|normal texture food
34258|NCT02839486|antibiotic prophylaxis
34259|NCT02839486|pharmacokinetics
34260|NCT02839486|cardiopulmonary bypass
34261|NCT02839447|semen
34262|NCT02839447|sperm
34263|NCT02839447|oxidative stress
34264|NCT02839447|reactive oxygen species
34265|NCT02839447|idiopathic male infertility
34266|NCT02839408|periodontitis
34267|NCT02839408|azithromycin
34268|NCT02839408|probiotic
34269|NCT02839395|screen illumination
34270|NCT02839395|melatonin
34271|NCT02839395|body temperature
34272|NCT02839395|cognitive functioning
34273|NCT02839395|light pollution
34274|NCT02839369|walking performance
34275|NCT02839369|Cerebral Palsy, Typically Developed
34276|NCT02839330|Influenza
34277|NCT02839330|Vaccine
34278|NCT02839330|Flu
34279|NCT02839330|Avian
34280|NCT02839330|Pandemic
34281|NCT02839330|H5N1
34282|NCT02839330|MF59
34283|NCT02839317|Dysbiosis
34284|NCT02839317|Crohn's disease
34285|NCT02839317|Age
34286|NCT02839278|Immunomodulation
34287|NCT02839226|ulcers
34288|NCT02839226|wounds
34289|NCT02839226|diabetes
34290|NCT02839226|venous ulcers
34291|NCT02839226|arterial ulcers
34292|NCT02839226|granulation tissue
34293|NCT02839226|protein kinase c
34294|NCT02839200|Insomnia
34295|NCT02839200|Polysomnography
34296|NCT02839174|low carbohydrate diet
34297|NCT02839161|Hookworm
34298|NCT02839161|Vaccine
34299|NCT02839161|Na-GST-1
34300|NCT02839161|Na-APR-1
34301|NCT02839161|Necator americanus
34302|NCT02839148|Appetite, Stunting, Satiety, Children
34303|NCT02839122|Dutasteride
34304|NCT02839122|Tadalafil
34305|NCT02839070|Sleep
34306|NCT02839070|Learning
34307|NCT02839070|Circadian Rhythms
34308|NCT02839057|Axis fractures
34309|NCT02839057|Elderly
34310|NCT02839057|Mortality
34311|NCT02839057|Surgical treatment
34312|NCT02839031|diabetes mellitus
34313|NCT02839031|glycaemia
34314|NCT02839031|cognitive-behavioral treatment
34315|NCT02839031|coping
34316|NCT02839031|parents
34317|NCT02839031|children
34318|NCT02839005|Wound Closure Thechnical
34319|NCT02839005|Wound Healing
34320|NCT02838992|Cyclophosphamide
34321|NCT02838992|Umbilical Cord Blood
34322|NCT02838992|ATG
34323|NCT02838979|Glutamine
34324|NCT02838979|Chronic Kidney Disease
34325|NCT02838966|immunomodulation
34326|NCT02838966|immunonutrition
34327|NCT02838953|Ultrasonography
34328|NCT02838953|Respiratory Function Tests
34329|NCT02838953|Pulmonary Disease, Chronic Obstructive
34330|NCT02838953|Rehabilitation
34331|NCT02838927|Hypoparathyroidism
34332|NCT02838927|Epidemiology
34333|NCT02838927|Medication Therapy Management
34334|NCT02838914|Right atrium
34335|NCT02838914|Echocardiography
34336|NCT02838914|Remodeling
34337|NCT02838888|Adenoma
34338|NCT02838888|computer
34339|NCT02838888|automatic
34340|NCT02838888|polyp
34341|NCT02838888|detection
34342|NCT02838862|Neuroendocrine Tumors
34343|NCT02838862|MALDI-MS
34344|NCT02838862|Proteomics
34345|NCT02838862|Biomarkers, Tumor
34346|NCT02838862|Precision Medicine
34347|NCT02838836|Cancer
34348|NCT02838836|Circulating tumor cells (CTCs)
34349|NCT02838836|Disseminated tumor cells (DTCs)
34350|NCT02838836|Circulating tumor DNA (ctDNA)
34351|NCT02838823|anti-PD-1 monoclonal antibody
34352|NCT02838823|triple negative breast cancer
34353|NCT02838823|safety
34354|NCT02838810|peginterferon alfa
34355|NCT02838810|Chronic Hepatitis B
34356|NCT02838797|Parkinson's disease
34357|NCT02838797|Gastroparesis
34358|NCT02838797|Constipation
34359|NCT02838797|Prokinetic
34360|NCT02838797|5-HT4-receptor partial agonist
34361|NCT02838771|Swallowing Disorder
34362|NCT02838771|Dysphagia
34363|NCT02838758|Morton's neuroma
34364|NCT02838758|Intermetatarsal neuroma
34365|NCT02838758|forefoot pain
34366|NCT02838758|ultrasound guided cryoablation
34367|NCT02838758|ultrasound guided perineural lidocaine injection
34368|NCT02838706|postoperative anemia
34369|NCT02838706|perfusion index
34370|NCT02838680|aortic stenosis
34371|NCT02838680|transcatheter aortic valve replacement (TAVR)
34372|NCT02838654|cervical epidural space
34373|NCT02838654|wave form analysis
34374|NCT02838615|spinal stenosis
34375|NCT02838615|epidural steroid injection
34376|NCT02838602|carbon ions therapy
34377|NCT02838602|radiotherapy
34378|NCT02838602|radioresistant tumors
34379|NCT02838602|cancer
34380|NCT02838602|randomized trial
34381|NCT02838589|Cerebrovascular Stroke
34382|NCT02838589|Ischemic Stroke
34383|NCT02838589|Glucagon like peptide - 1
34384|NCT02838563|Dementia
34385|NCT02838563|Alzheimer
34386|NCT02838563|Well-Being
34387|NCT02838550|Physical Activity
34388|NCT02838550|Motivational Online Intervention
34389|NCT02838550|Pedometers
34390|NCT02838537|Triptan
34391|NCT02838537|Drug utilization
34392|NCT02838537|Elderly
34393|NCT02838537|Drug abuse
34394|NCT02838537|Cardiovascular disease
34395|NCT02838524|Spontaneous Breathing Trial
34396|NCT02838524|Inspiratory Effort
34397|NCT02838524|Mechanical Ventilation
34398|NCT02838524|Respiratory muscle load-capacity balance
34399|NCT02838498|ERCP
34400|NCT02838498|EMS
34401|NCT02838498|Cannulation
34402|NCT02838498|Successful rate
34403|NCT02838498|Trainee
34404|NCT02838407|Chronic lower respiratory tract infection
34405|NCT02838407|Bonchoalveolar lavage
34406|NCT02838407|Nasopharyngeal swabs
34407|NCT02838290|Burnout
34408|NCT02838290|Psychiatric morbidity
34409|NCT02838290|Anxiety
34410|NCT02838290|Grief
34411|NCT02838290|Alcohol and drug use
34412|NCT02838277|lymphatic vessels
34413|NCT02838277|leaky vessels
34414|NCT02838277|hypertrophic adipocyte
34415|NCT02838212|adverse drug reaction
34416|NCT02838212|hospital mortality
34417|NCT02838212|incidence
34418|NCT02838199|Transcatheter aortic valve replacement
34419|NCT02838199|TAVR
34420|NCT02838199|TAVI
34421|NCT02838199|SAVR
34422|NCT02838186|colonoscopy
34423|NCT02838186|right colon retroflexion
34424|NCT02838186|adenoma detection rate
34425|NCT02838186|feasibility
34426|NCT02838186|surveillance interval
34427|NCT02838160|educational strategies
34428|NCT02838160|KAP
34429|NCT02838160|psychological and clinical outcomes
34430|NCT02838160|intensive care unit
34431|NCT02838160|follow-up study
34432|NCT02838160|RCT
34433|NCT02838134|Laparoscopic donor nephrectomy
34434|NCT02838134|Early quality of recovery
34435|NCT02838121|bisphosphonate
34436|NCT02838121|Total hip replacement
34437|NCT02838121|functional outcomes
34438|NCT02838121|bone mineral density
34439|NCT02838095|nap
34440|NCT02838095|sleep restriction
34441|NCT02838095|recovery sleep
34442|NCT02838095|cognitive performance
34443|NCT02838095|subjective sleepiness
34444|NCT02838095|mood
34445|NCT02838095|neurobehavioural functions
34446|NCT02838082|traumatic brain injury
34447|NCT02838082|sleep-wake cycle disturbance
34448|NCT02838082|circadian disruption
34449|NCT02838056|anesthesia, epidural
34450|NCT02838056|skin temperature
34451|NCT02838030|Preeclampsia
34452|NCT02838030|L-arginine
34453|NCT02838004|Refractive lens exchange (RLE) or cataract surgery
34454|NCT02837991|Kidney Cancer
34455|NCT02837991|Celldex
34456|NCT02837991|Dose Escalation
34457|NCT02837978|Arthritis, Rheumatoid
34458|NCT02837978|Tacrolimus
34459|NCT02837978|Treatment outcome
34460|NCT02837978|Safety
34461|NCT02837952|Ibuprofen, acetaminophen, pain, molar extraction
34462|NCT02837913|Perioperative Warming
34463|NCT02837887|Cancer
34464|NCT02837887|Depression
34465|NCT02837874|Gastric cancer
34466|NCT02837874|gastrojejunostomy
34467|NCT02837874|isoperistaltic
34468|NCT02837874|antiperistaltic
34469|NCT02837861|Metabolic Support
34470|NCT02837861|Nutritional Support
34471|NCT02837861|Neuro-endocrine Event
34472|NCT02837861|Enteral feedings
34473|NCT02837861|Parenteral feeding
34474|NCT02837848|Rotator Cuff Tendinopathy
34475|NCT02837848|Exercises
34476|NCT02837848|Coactivation
34477|NCT02837848|Strengthening
34478|NCT02837822|Spinal Cord Stimulation
34479|NCT02837822|Quantitative Sensory Testing
34480|NCT02837809|low-dose computed tomography
34481|NCT02837809|lung
34482|NCT02837809|randomized controlled trial
34483|NCT02837809|neoplasms
34484|NCT02837809|screening
34485|NCT02837809|smoking
34486|NCT02837770|pain
34487|NCT02837770|intravitreal injection
34488|NCT02837770|anti-VEGF
34489|NCT02837770|diclofenac eye drops
34490|NCT02837770|oral diclofenac
34491|NCT02837770|Short Form of McGill Pain Questionnaire
34492|NCT02837653|cardiovascular Risk
34493|NCT02837640|Retinitis Pigmentosa
34494|NCT02837640|Levodopa
34495|NCT02837627|gastroesophageal reflux
34496|NCT02837627|tube enteral feeding
34497|NCT02837627|preterm infants
34498|NCT02837601|Laparoscopic surgical procedures
34499|NCT02837601|Shoulder Pain
34500|NCT02837601|Abdominal Pain
34501|NCT02837601|Pediatrics
34502|NCT02837588|chronic pelvic pain
34503|NCT02837588|trigger points
34504|NCT02837588|hiperthermy
34505|NCT02837575|HSV-2
34506|NCT02837575|Genital Herpes
34507|NCT02837575|Herpes
34508|NCT02837575|Herpes Simplex Virus, Type 2
34509|NCT02837562|Radiation exposure
34510|NCT02837562|Cardiac catheterization
34511|NCT02837523|Lysosomal Storage Diseases
34512|NCT02837497|pediatric
34513|NCT02837497|heart arrest
34514|NCT02837471|Pedometer usability
34515|NCT02837471|Usability and feasibility
34516|NCT02837471|web application
34517|NCT02837458|Whiplash
34518|NCT02837458|Electric current
34519|NCT02837458|Nerve block
34520|NCT02837458|Pain
34521|NCT02837458|High-frequency current
34522|NCT02837432|Depression
34523|NCT02837432|Cortisol
34524|NCT02837432|Sadness
34525|NCT02837432|Genetics
34526|NCT02837432|Stress
34527|NCT02837419|extracorporeal life support
34528|NCT02837419|health related quality of life
34529|NCT02837380|Long-acting muscarinic antagonist
34530|NCT02837380|Long-acting beta2 agonist
34531|NCT02837380|Dry powder inhaler
34532|NCT02837380|Inhaled corticosteroid
34533|NCT02837367|nutrigenetics
34534|NCT02837367|medical foods
34535|NCT02837367|obesity
34536|NCT02837367|children
34537|NCT02837367|adults
34538|NCT02837354|Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
34539|NCT02837341|medical device
34540|NCT02837328|Magnesium Supplementation
34541|NCT02837328|Magnesium
34542|NCT02837328|Dietary Supplement
34543|NCT02837328|Arrhythmia
34544|NCT02837302|Liver cirrhosis
34545|NCT02837302|Branched chain amino acid
34546|NCT02837302|End-Stage Liver Disease score
34547|NCT02837289|patellofemoral pain syndrome
34548|NCT02837289|therapy taping
34549|NCT02837289|knee
34550|NCT02837289|physical therapy
34551|NCT02837289|runners
34552|NCT02837276|Intermittent Hypoxemia
34553|NCT02837276|Acute Kidney Injury
34554|NCT02837276|Preterm infant
34555|NCT02837250|HIV
34556|NCT02837250|Substance Use
34557|NCT02837224|retained surgical sponge
34558|NCT02837224|adverse event
34559|NCT02837185|Cervical dystonia
34560|NCT02837185|Transcranial magnetic stimulation
34561|NCT02837185|Electromyography
34562|NCT02837185|TMS
34563|NCT02837185|EMG
34564|NCT02837159|colorectal cancer
34565|NCT02837159|Health Life Style Habits
34566|NCT02837159|Health
34567|NCT02837146|RA
34568|NCT02837120|retrospective study
34569|NCT02837120|acute myocardial infarction
34570|NCT02837120|acute aortic dissection
34571|NCT02837120|pulmonary embolism
34572|NCT02837120|unstable angina
34573|NCT02837068|Hemiplegia
34574|NCT02837068|shoulder pain
34575|NCT02837068|wheelchair
34576|NCT02837068|stroke
34577|NCT02837068|rehabilitation
34578|NCT02837055|intubation, intratracheal
34579|NCT02837055|critical care
34580|NCT02837042|penile cancer
34581|NCT02837042|Pembrolizumab
34582|NCT02837042|penile squamous cell carcinoma
34583|NCT02837042|squamous cell cancer
34584|NCT02837016|Self-Control
34585|NCT02837016|Biofeedback
34586|NCT02837016|Respiration
34587|NCT02837003|Drug-Eluting Stent
34588|NCT02836977|tegafur-uracil
34589|NCT02836925|hepatitis C
34590|NCT02836925|NHL
34591|NCT02836925|Indolent B-cell lymphoma
34592|NCT02836912|Rehabilitation
34593|NCT02836899|acute kidney injury; nitric oxide; cardiopulmonary bypass; endothelial dysfunction; cardiac surgery
34594|NCT02836834|immunotherapy
34595|NCT02836834|check point inhibitor
34596|NCT02836834|PD-1 antibody
34597|NCT02836834|solid tumor
34598|NCT02836834|lymphoma
34599|NCT02836834|phase 1 trial
34600|NCT02836808|Multidisciplinary interventions
34601|NCT02836808|Long term control
34602|NCT02836808|Empowerment
34603|NCT02836795|anti-PD-1 monoclonal antibody
34604|NCT02836795|advanced solid tumors
34605|NCT02836795|safety
34606|NCT02836782|HIV/HCV
34607|NCT02836782|Antiretroviral therapy
34608|NCT02836782|HIV-DNA
34609|NCT02836782|Direct acting antiviral
34610|NCT02836769|Rehabilitation
34611|NCT02836769|Head and neck cancer
34612|NCT02836769|Quality of life
34613|NCT02836769|self-efficacy
34614|NCT02836743|REM sleep behavior disorder
34615|NCT02836743|Melatonin
34616|NCT02836717|sacral nerve modulation
34617|NCT02836717|quality of life
34618|NCT02836717|stimulator maintenance
34619|NCT02836717|SNM
34620|NCT02836691|Autonomic nervous system
34621|NCT02836691|Uncontrolled severe asthma
34622|NCT02836691|Paucigranulocitic asthma phenotype
34623|NCT02836691|Stress
34624|NCT02836665|Emergency Room
34625|NCT02836665|Manchester Triage System
34626|NCT02836665|Telemedicine
34627|NCT02836665|Patients
34628|NCT02836652|HeartMate II (HMII)
34629|NCT02836652|Left Ventricular Assist Device (LVAD)
34630|NCT02836600|notch inhibitor
34631|NCT02836548|advanced melanoma
34632|NCT02836548|BRAF V600 mutation
34633|NCT02836548|vorinostat
34634|NCT02836548|HDAC inhibitor
34635|NCT02836535|complications
34636|NCT02836535|surgery
34637|NCT02836522|Health-Related Symptom Index
34638|NCT02836522|ANCHOR( ANal Cancer HSIL (high grade squamous intraepithelial lesions) Outcomes Research study)
34639|NCT02836509|Low Back Pain
34640|NCT02836509|Ibuprofen
34641|NCT02836509|Paracetamol
34642|NCT02836509|Emergency Medicine
34643|NCT02836496|Safety
34644|NCT02836496|Mepolizumab
34645|NCT02836496|Hypereosinophilic syndrome
34646|NCT02836496|HES flare
34647|NCT02836496|Efficacy
34648|NCT02836470|Post-operative Ileus
34649|NCT02836470|Post-Operative Abdominal Adhesions
34650|NCT02836470|Return of Gastrointestinal Function
34651|NCT02836470|Anastomosis
34652|NCT02836470|Enterotomy
34653|NCT02836470|Enterostomy
34654|NCT02836470|Colorectal Surgery
34655|NCT02836470|Intestines Surgery
34656|NCT02836431|Pediatric
34657|NCT02836431|Sedation
34658|NCT02836431|Dexmedetomidine
34659|NCT02836418|FSHD
34660|NCT02836418|LGMD
34661|NCT02836405|Autism
34662|NCT02836405|ASD
34663|NCT02836405|Autistic Disorder
34664|NCT02836405|Pervasive Development Disorders
34665|NCT02836405|Pervasive Child Development Disorders
34666|NCT02836405|Asperger's Syndrome
34667|NCT02836405|Transcranial Magnetic Stimulation
34668|NCT02836405|TMS
34669|NCT02836405|Autism Spectrum Disorder
34670|NCT02836379|Breakthrough Cancer Pain
34671|NCT02836379|Quality of life
34672|NCT02836379|Radiotherapy
34673|NCT02836366|Proximal humerus
34674|NCT02836366|Fracture
34675|NCT02836366|Nailing
34676|NCT02836340|neuroprotection
34677|NCT02836327|MRI
34678|NCT02836327|Multiple Sclerosis
34679|NCT02836327|Neuromyelitis Optica Spectrum Disorders
34680|NCT02836327|Multimodel
34681|NCT02836314|Anorganic bovine bone mineral;
34682|NCT02836314|Graft
34683|NCT02836314|Intrabony periodontal defect
34684|NCT02836314|platelet rich fibrin
34685|NCT02836288|Ketamine
34686|NCT02836288|Treatment of Depression
34687|NCT02836275|Adnexal Diseases
34688|NCT02836275|Ovary
34689|NCT02836275|Ovarian Neoplasms
34690|NCT02836275|Ovarian Cysts
34691|NCT02836275|Ovarian Diseases
34692|NCT02836275|Ultrasonography
34693|NCT02836275|Ultrasonography, Doppler
34694|NCT02836275|Magnetic Resonance Imaging
34695|NCT02836275|Diffusion Magnetic Resonance Imaging
34696|NCT02836275|Diagnosis
34697|NCT02836275|Early Diagnosis
34698|NCT02836275|Early Detection of Cancer
34699|NCT02836275|Genital Neoplasms, Female
34700|NCT02836275|Genital Diseases, Female
34701|NCT02836275|Urogenital Neoplasms
34702|NCT02836275|Cysts
34703|NCT02836275|Endocrine System Diseases
34704|NCT02836275|Gonadal Disorders
34705|NCT02836275|Neoplasms
34706|NCT02836275|Endocrine Gland Neoplasms
34707|NCT02836275|International Ovarian Tumor Analysis
34708|NCT02836275|Simple Rules
34709|NCT02836275|Preoperative Evaluation
34710|NCT02836275|Perfusion -and Diffusion-weighted Imaging
34711|NCT02836275|Adnexal Masses
34712|NCT02836275|Ovarian Tumors
34713|NCT02836249|Hepatitis
34714|NCT02836249|Tenofovir
34715|NCT02836249|Viread
34716|NCT02836236|Hepatitis
34717|NCT02836236|Tenofovir
34718|NCT02836236|Viread
34719|NCT02836210|27-gauge Pars plana vitrectomy
34720|NCT02836197|Uncertainty;hope;Communication training;physicians;oncology
35097|NCT02833805|fludarabine
34721|NCT02836184|Hemodialysis,Hyperphosphatemia,Nicotinic Acids
34722|NCT02836119|Gut Microbiota
34723|NCT02836119|Gut Microbiome
34724|NCT02836119|Sleep
34725|NCT02836119|Infancy
34726|NCT02836119|Development
34727|NCT02836106|Healthy Volunteers
34728|NCT02836106|Obese Volunteers
34729|NCT02836093|Exercise
34730|NCT02836093|Radiation Treatment
34731|NCT02836093|16-941
34732|NCT02836080|Mental Health
34733|NCT02836080|Randomized
34734|NCT02836080|Pragmatic
34735|NCT02836080|Integrated Collaborative Care
34736|NCT02836080|Addiction
34737|NCT02836080|Youth
34738|NCT02836054|biomarkers
34739|NCT02836054|CSF
34740|NCT02836054|MRI
34741|NCT02836054|Alzheimer's disease
34742|NCT02836054|bipolar disorder
34743|NCT02836054|cognitive functions
34744|NCT02836041|assess sleep
34745|NCT02836041|Sleep Deprivation
34746|NCT02836041|16-866
34747|NCT02836015|Shared Medical Visits
34748|NCT02836015|Spanish-speaking
34749|NCT02835989|Community Paramedicine
34750|NCT02835989|Paramedic
34751|NCT02835989|Emergency Medical Services
34752|NCT02835989|High Frequency Callers
34753|NCT02835989|Lift Assists
34754|NCT02835963|acute heart failure
34755|NCT02835963|dyspnea
34756|NCT02835963|predictive value
34757|NCT02835924|regorafenib
34758|NCT02835924|metastatic colorectal cancer
34759|NCT02835872|fiber
34760|NCT02835872|cholesterol
34761|NCT02835859|Obesity, sweet taste receptors
34762|NCT02835846|Overactive Bladder Syndrome
34763|NCT02835846|Female Urinary Microbiome
34764|NCT02835846|Urinary Urgency
34765|NCT02835846|Estrogen
34766|NCT02835846|Nocturia
34767|NCT02835846|Incontinence
34768|NCT02835833|advanced solid tumors
34769|NCT02835833|Nintedanib
34770|NCT02835833|Bevacizumab
34771|NCT02835833|dose escalation
34772|NCT02835820|HIV
34773|NCT02835820|Neurocognitive
34774|NCT02835820|Ketogenic Diet
34775|NCT02835807|skin cancer
34776|NCT02835794|Myelodysplastic Syndromes
34777|NCT02835781|Breast Implants
34778|NCT02835781|Acellular Dermal Matrix
34779|NCT02835729|AML
34780|NCT02835716|Phosphodiesterase type 4 inhibitor
34781|NCT02835716|ustekinumab
34782|NCT02835716|secukinumab
34783|NCT02835716|P40 subunit
34784|NCT02835716|Interleukin IL-12
34785|NCT02835716|Interleukin IL-23
34786|NCT02835716|Apoprotein e4
34787|NCT02835716|Interleukin IL-17A
34788|NCT02835703|Congenital heart disease
34789|NCT02835703|Coarctation of aorta
34790|NCT02835703|Aortic arch hypoplasia
34791|NCT02835703|Cerebral selective antegrade perfusion
34792|NCT02835703|Double arterial cannulation
34793|NCT02835690|PD1
34794|NCT02835690|PD-1
34795|NCT02835690|PDL1
34796|NCT02835690|PD-L1
34797|NCT02835677|Caregivers
34798|NCT02835677|Activities of Daily Living
34799|NCT02835664|Nicotinamide Riboside
34800|NCT02835664|Obesity
34801|NCT02835664|Metabolic health
34802|NCT02835664|Insulin resistance
34803|NCT02835664|Mitochondrial function
34804|NCT02835664|Brown adipose tissue
34805|NCT02835664|Energy expenditure
34806|NCT02835664|Ectopic lipid accumulation
34807|NCT02835664|Cardiovascular risk
34808|NCT02835664|Acetylcarnitine
34809|NCT02835651|Palmitic acid
34810|NCT02835651|Stearic acid
34811|NCT02835651|HDL-metabolism
34812|NCT02835651|Human intervention study
34813|NCT02835625|Diagnostic Imaging
34814|NCT02835625|Mammography
34815|NCT02835625|Randomized Controlled Trial
34816|NCT02835625|Tomosynthesis
34817|NCT02835625|Early performance measures
34818|NCT02835625|Recall
34819|NCT02835625|Radiation dose
34820|NCT02835625|Cancer detection
34821|NCT02835625|Sensitivity
34822|NCT02835625|Specificity
34823|NCT02835625|Cost
34824|NCT02835625|Economy
34825|NCT02835586|paclitaxel
34826|NCT02835586|critical ischemia
34827|NCT02835586|restenosis
34828|NCT02835586|femoropopliteal artery lesions TASC C and D
34829|NCT02835547|cardiovascular event
34830|NCT02835547|risk factors
34831|NCT02835547|inflammatory diseases and acquired dysimmune
34832|NCT02835534|acute ST elevation myocardial infarction
34833|NCT02835456|CAUTI
34834|NCT02835456|Biofilm
34835|NCT02835456|Urinary tract infections
34836|NCT02835456|micropattern
34837|NCT02835456|Catheter
34838|NCT02835443|Ischemic Stroke
34839|NCT02835443|Deep Brain Stimulation
34840|NCT02835443|DBS
34841|NCT02835443|Physical Therapy
34842|NCT02835443|Rehab
34843|NCT02835430|Coronally advanced flap
34844|NCT02835430|Gingival recession
34845|NCT02835430|Bone, demineralized
34846|NCT02835430|Bone, freeze-dried
34847|NCT02835430|platelet-rich fibrin
34848|NCT02835430|root coverage procedures
34849|NCT02835417|fetal heart rate variability
34850|NCT02835417|entropy
34851|NCT02835417|multifractal analysis
34852|NCT02835417|scattering transform
34853|NCT02835417|sparse vector machine
34854|NCT02835417|acidosis
34855|NCT02835378|bilateral upper limb amputation
34856|NCT02835378|prosthetic fitting
34857|NCT02835378|epidemiology
34858|NCT02835378|clinical practices
34859|NCT02835378|totally non-functional hand
34860|NCT02835365|baclofen
34861|NCT02835365|alcohol
34862|NCT02835365|withdrawal
34863|NCT02835352|anxiety
34864|NCT02835326|Older Adults
34865|NCT02835326|Weight Loss
34866|NCT02835326|Exercise
34867|NCT02835326|Knee pain
34868|NCT02835300|Asthma
34869|NCT02835300|Adolescents
34870|NCT02835300|e-Health
34871|NCT02835300|Intervention
34872|NCT02835274|parkinson disease
34873|NCT02835274|deep brain stimulation
34874|NCT02835274|directional stimulation
34875|NCT02835261|Obesity
34876|NCT02835261|Metabolic Disorders
34877|NCT02835209|spontaneous breathing test
34878|NCT02835209|premature infant
34879|NCT02835209|work of breathing
34880|NCT02835170|Immunoglobulin G
34881|NCT02835170|Treatment
34882|NCT02835157|Normal saline
34883|NCT02835157|Balanced saline
34884|NCT02835157|Septic shock
34885|NCT02835157|Children
34886|NCT02835157|Hyperchloremia
34887|NCT02835157|Acute kidney injury
34888|NCT02835131|hyperinsulinemia
34889|NCT02835131|hypoglycemia
34890|NCT02835131|somatostatin
34891|NCT02835131|pasireotide
34892|NCT02835131|congenital
34893|NCT02835079|Duchenne Tamoxifen
34894|NCT02835066|Stage I
34895|NCT02835066|Stage II
34896|NCT02835066|Stage IIIA
34897|NCT02835066|Stage IIIB
34898|NCT02835066|Stage IV
34899|NCT02835066|Non-Small Cell
34900|NCT02835040|Corticosteroid
34901|NCT02835040|Antibiotic
34902|NCT02835040|Early mobilization
34903|NCT02835040|Malnutrition
34904|NCT02835027|Acute limb ischaemia(ALI)
34905|NCT02835027|Acute ischaemia of the lower extremity
34906|NCT02835027|Thrombosis
34907|NCT02835027|Emboli
34908|NCT02835027|Endovascular surgery
34909|NCT02835027|Surgery
34910|NCT02835027|Amputation free survival
34911|NCT02835027|Long time survival
34912|NCT02835027|Demographics
34913|NCT02835014|Diabetes Mellitus Type I
34914|NCT02835014|Adolescents
34915|NCT02835014|Mental Health
34916|NCT02835014|Self efficacy
34917|NCT02835014|parenting styles
34918|NCT02834988|Endometrial Cancer
34919|NCT02834988|Sentinel Lymph Node Dissection
34920|NCT02834988|SLND
34921|NCT02834975|Fallopian Tube Carcinoma
34922|NCT02834975|Peritoneal Carcinoma
34923|NCT02834975|Epithelial Ovarian Cancer
34924|NCT02834962|Anterior Cruciate Ligament Reconstruction
34925|NCT02834897|EOS imagery
34926|NCT02834884|rare cancer
34927|NCT02834884|biomarker
34928|NCT02834884|screening
34929|NCT02834858|Umbilical Cord Mesenchymal Stem Cells
34930|NCT02834819|bronchiolitis
34931|NCT02834819|hypoxia
34932|NCT02834819|hypertonic saline
34933|NCT02834793|Lennox-Gastaut Syndrome (LGS)
34934|NCT02834793|Inadequately controlled seizures
34935|NCT02834780|Advanced Hepatocellular Carcinoma
34936|NCT02834780|H3B-6527
34937|NCT02834754|post-operative
34938|NCT02834715|Diabetes
34939|NCT02834715|Stevia
34940|NCT02834715|insulin secretion
34941|NCT02834715|insulin sensitivity
34942|NCT02834715|Sweetener
34943|NCT02834702|sinew acupuncture
34944|NCT02834702|neck pain
34945|NCT02834702|chronic pain
34946|NCT02834676|DiscoGel(R)
34947|NCT02834676|gelified ethanol
34948|NCT02834676|percutaneous treatment
34949|NCT02834676|Oswestry Disability Index (ODI)
34950|NCT02834676|Visual analog Scale (VAS)
34951|NCT02834676|Neuropathic Pain Questionnaire (DN-4)
34952|NCT02834676|cervical
34953|NCT02834637|HPV
34954|NCT02834637|cervical cancer
34955|NCT02834637|vaccines
34956|NCT02834637|HPV vaccine
34957|NCT02834637|dose reduction
34958|NCT02834637|Human papilloma virus vaccine schedules
34959|NCT02834624|surfactant
34960|NCT02834624|respiratory distress syndrome
34961|NCT02834624|inflammation
34962|NCT02834624|c-reactive protein
34963|NCT02834624|lipid peroxidation
34964|NCT02834546|Hepatocellular Carcinoma
34965|NCT02834546|Sorafenib
34966|NCT02834546|Toxicity
34967|NCT02834546|Plasmatic concentration
34968|NCT02834533|Lokomat;
34969|NCT02834533|robotic rehabilitation.
34970|NCT02834533|Multiple Sclerosis;
34971|NCT02834533|Virtual reality
34972|NCT02834494|locally advanced breast cancer
34973|NCT02834494|neoadjuvant chemotherapy
34974|NCT02834481|Pain Care
34975|NCT02834481|Pediatric and Neonatal Intensive Care Units
34976|NCT02834468|Dexamethasone
34977|NCT02834468|Rituximab
34978|NCT02834468|Cyclosporin
34979|NCT02834468|Intravenous Immunoglobulin
34980|NCT02834455|Thoracoscopy
34981|NCT02834403|breast cancer
34982|NCT02834403|nitric oxide synthase
34983|NCT02834403|docetaxel
34984|NCT02834403|L-NMMA
34985|NCT02834390|AML
34986|NCT02834390|phase 1
34987|NCT02834390|hematology
34988|NCT02834390|malignancy
34989|NCT02834390|newly diagnosed
34990|NCT02834377|Cardiac Output
34991|NCT02834377|Hemodynamics
34992|NCT02834377|Perioperative Care
34993|NCT02834338|activity tracking
34994|NCT02834338|postoperative recovery
34995|NCT02834338|ERAS
34996|NCT02834338|fast-track surgery
34997|NCT02834325|high flow nasal cannula
34998|NCT02834325|success
34999|NCT02834325|failure
35000|NCT02834325|ROX index
35001|NCT02834312|Estetrol
35002|NCT02834312|Vasomotor symptoms
35003|NCT02834312|Menopause
35004|NCT02834260|absorbable implant
35005|NCT02834260|subconjunctival
35006|NCT02834260|immune rejection
35007|NCT02834260|safety profile
35008|NCT02834260|dexamethasone
35009|NCT02834234|mesothelioma
35010|NCT02834234|peritoneum
35011|NCT02834234|genomic
35012|NCT02834234|CGH arrays
35013|NCT02834221|Femoral vein puncture
35014|NCT02834195|Cerebral palsy
35015|NCT02834195|reliability
35016|NCT02834195|upper limb and hand patterns
35017|NCT02834195|classification
35018|NCT02834169|Rare peritoneal surface malignancies
35019|NCT02834169|pseudomyxoma peritonei
35020|NCT02834169|peritoneal mesothelioma
35021|NCT02834169|desmoplastic small round cell tumor
35022|NCT02834169|psammocarcinoma
35023|NCT02834169|primary peritoneal serous carcinoma
35024|NCT02834169|diffuse peritoneal leiomyomatosis
35025|NCT02834169|appendiceal mucinous neoplasms
35026|NCT02834169|registry
35027|NCT02834169|population-based database
35028|NCT02834143|vascular
35029|NCT02834143|Limb Ischemia
35030|NCT02834117|Ovulation Induction
35031|NCT02834117|quality of life
35032|NCT02834117|Reproductive Physiological Processes
35033|NCT02834117|fertility
35034|NCT02834078|HbA1c
35035|NCT02834078|Pre Diabetes
35036|NCT02834078|Berberine
35037|NCT02834065|Postoperative Cognitive Decline
35038|NCT02834065|Deep Hypothermic Circulatory Arrest
35039|NCT02834065|Cardiovascular Surgical Procedures
35040|NCT02834065|Functional Magnetic Resonance Imaging
35041|NCT02834065|Small Ubiquitin-Related Modifier Proteins
35042|NCT02834052|Immunotherapy
35043|NCT02834052|Anti-programmed death 1 (PD-1) inhibitor
35044|NCT02834052|Immunostimulant
35045|NCT02834052|monoclonal antibody
35046|NCT02834052|TLR3 agonist
35047|NCT02834052|Immunologic factors
35048|NCT02834039|Tidal volume
35049|NCT02834039|renal transplant
35050|NCT02834039|donor
35051|NCT02834039|nephrectomy
35052|NCT02834039|ventilation
35053|NCT02834039|Living renal transplant donor patient
35054|NCT02834026|Muscle Strength
35055|NCT02834026|Muscle Strength Dynamometer
35056|NCT02834026|Chronic Renal Disease
35057|NCT02834026|Exercise
35058|NCT02834026|Physical therapy modalities
35059|NCT02833987|Direct oral anticoagulants
35060|NCT02833987|Safety
35061|NCT02833987|Major bleed
35062|NCT02833987|Adverse events
35063|NCT02833974|GSK2245035
35064|NCT02833974|TLR7 agonist
35065|NCT02833974|allergic asthma
35066|NCT02833974|FEV1
35067|NCT02833948|Heart Valve Disease
35068|NCT02833948|Randomized Controlled Trial
35069|NCT02833948|Transcatheter Aortic Valve Replacement
35070|NCT02833948|TAVR
35071|NCT02833948|Valve Thrombosis
35072|NCT02833935|spinal cord injury
35073|NCT02833935|physical activity
35074|NCT02833935|self-determination theory
35075|NCT02833935|life satisfaction
35076|NCT02833883|Enzalutamide
35077|NCT02833883|CC-115
35078|NCT02833883|16-074
35079|NCT02833857|Secondary Hyperparathyroidism, chronic kidney disease, hemodialysis
35080|NCT02833844|Hyperlipidemia
35081|NCT02833844|Dyslipidemia
35082|NCT02833844|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
35083|NCT02833844|Inhibition
35084|NCT02833844|HIV infection
35085|NCT02833844|Cluster of differentiation
35086|NCT02833844|Viral load
35087|NCT02833805|immunosuppression
35088|NCT02833805|nonmyeloablative
35089|NCT02833805|non-myeloablative
35090|NCT02833805|allogeneic
35091|NCT02833805|tacrolimus
35092|NCT02833805|bone marrow
35093|NCT02833805|bone marrow transplant
35094|NCT02833805|cyclophosphamide
35095|NCT02833805|thymoglobulin
35096|NCT02833805|ATG
35098|NCT02833766|Breast Cancer
35099|NCT02833766|advanced triple Negative, EGFR positive breast cancer
35100|NCT02833766|doxorubicin
35101|NCT02833766|triple negative breast cancer (TNBC)
35102|NCT02833740|Mid-Upper Arm Circumference (MUAC)
35103|NCT02833740|Mother MUAC
35104|NCT02833740|Community screening for acute malnutrition
35105|NCT02833727|asthma; smoking; Eosinophils; health care costs
35106|NCT02833675|angioedema
35107|NCT02833675|C1Inhibitor
35108|NCT02833675|bradykinin
35109|NCT02833675|Histamin
35110|NCT02833662|Hypoxia
35111|NCT02833662|Perioperative outcomes
35112|NCT02833649|Keratoconus
35113|NCT02833649|Crosslinking
35114|NCT02833649|Toric ICL
35115|NCT02833623|Helicobacter Pylori eradication rate
35116|NCT02833623|Efficacy of Short-message-based Re-education (SMRE)
35117|NCT02833610|Multiple Myeloma
35118|NCT02833597|peripheral artery disease
35119|NCT02833597|transcutaneous oxygen pressure
35120|NCT02833597|claudication
35121|NCT02833597|rowing ergometer
35122|NCT02833584|Paracetamol
35123|NCT02833558|Endoscopy, Gastrointestinal
35124|NCT02833558|Endoscopic Submucosal Dissection
35125|NCT02833558|Bleeding
35126|NCT02833519|pregnant women
35127|NCT02833519|exercise
35128|NCT02833519|depression
35129|NCT02833519|anxiety
35130|NCT02833493|Magnetic Resonance Imaging
35131|NCT02833493|Iron overload
35132|NCT02833493|Iron chelation therapy
35133|NCT02833493|Follow-up
35134|NCT02833467|Circulating Tumor DNA
35135|NCT02833467|Heterogeneous
35136|NCT02833467|Multiple primary lung cancer
35137|NCT02833454|Anterior Cruciate Ligament Reconstruction
35138|NCT02833454|Direct Insertion of Anterior Cruciate Ligament
35139|NCT02833415|Visceral
35140|NCT02833415|Obesity
35141|NCT02833415|Adipose
35142|NCT02833415|Diabetes
35143|NCT02833402|Sacral Neuromodulation
35144|NCT02833402|Urinary leakage
35145|NCT02833402|Urinary incontinence
35146|NCT02833402|Urinary microbiome
35147|NCT02833376|microbiota
35148|NCT02833376|ethanol
35149|NCT02833376|chlorhexidine
35150|NCT02833363|gastric microbiota
35151|NCT02833363|Helicobacter pylori
35152|NCT02833363|Non-atrophic Gasrititis
35153|NCT02833363|Atrophic gastritis
35154|NCT02833363|Intestinal metaplasia
35155|NCT02833363|intraepithelial neoplasia
35156|NCT02833363|Gastric cancer
35157|NCT02833337|Bone
35158|NCT02833337|Maxilla
35159|NCT02833337|Cone-Beam Computed Tomography
35160|NCT02833337|Regeneration
35161|NCT02833324|Postoperative Period
35162|NCT02833324|Colorectal Surgery
35163|NCT02833324|Surgery
35164|NCT02833311|Neuromusculoskeletal condition
35165|NCT02833298|Sustained Virological Response
35166|NCT02833298|SVR
35167|NCT02833298|patient navigation
35168|NCT02833298|screening
35169|NCT02833298|HCC
35170|NCT02833298|HCV
35171|NCT02833272|benzodiazepines
35172|NCT02833272|Z-drugs
35173|NCT02833259|Pneumonia
35174|NCT02833259|Patient readmission
35175|NCT02833259|Community-acquired infections
35176|NCT02833259|Observational study
35177|NCT02833259|Quality of health care
35178|NCT02833259|Models, Statistical
35179|NCT02833246|texting
35180|NCT02833246|Adherence to Oral Anticancer Medications
35181|NCT02833246|16-810
35182|NCT02833233|Early stage
35183|NCT02833233|Resectable
35184|NCT02833233|Ipilimumab
35185|NCT02833233|Nivolumab
35186|NCT02833233|Cryoablation
35187|NCT02833233|16-495
35188|NCT02833220|blood pressure
35189|NCT02833207|blood flow
35190|NCT02833207|vasodilation
35191|NCT02833207|skeletal muscle
35192|NCT02833207|Doppler Ultrasound
35193|NCT02833207|diabetes prevention program
35194|NCT02833207|endothelium dependent dilation
35195|NCT02833168|Neuromuscular disorders
35196|NCT02833168|Sleep disordered breathing
35197|NCT02833168|Dyspnea
35198|NCT02833155|entinostat
35199|NCT02833155|breast cancer
35200|NCT02833142|Healthy Volunteer
35201|NCT02833142|opicinumab
35202|NCT02833116|radiculalgia
35203|NCT02833116|chronic pain
35204|NCT02833116|quality of life
35205|NCT02833103|Pinaverium Bromide
35206|NCT02833103|cholecystectomy
35207|NCT02833103|Sphincter of Oddi Dysfunction
35208|NCT02833012|Healthy volunteers
35209|NCT02833012|Caprylic triglyceride oil
35210|NCT02833012|AC-1202
35211|NCT02833012|AC-1204
35212|NCT02833012|Pharmacokinetic
35213|NCT02833012|ketone body
35214|NCT02833012|Axona
35215|NCT02832999|Diabetes
35216|NCT02832999|GLP-1
35217|NCT02832999|Insulin secretion
35218|NCT02832999|insulin sensitivity
35219|NCT02832999|Africa
35220|NCT02832999|Liraglutide
35221|NCT02832999|Vildaglipin
35222|NCT02832986|Frailty consultation
35223|NCT02832973|Hypertension Resistant to Conventional Therapy
35224|NCT02832973|Natriuretic Agents
35225|NCT02832973|Renin-Angiotensin System
35226|NCT02832973|Bisoprolol
35227|NCT02832960|Thyroid Dysfunction
35228|NCT02832960|Atherosclerosis
35229|NCT02832960|Heart Failure
35230|NCT02832960|Cardiovascular imaging
35231|NCT02832960|Randomized Controlled Trial
35232|NCT02832934|Thyroid Dysfunction
35233|NCT02832934|Atherosclerosis
35234|NCT02832934|Heart Failure
35235|NCT02832934|Cardiovascular Imaging
35236|NCT02832934|Randomized Controlled Trial
35237|NCT02832921|Alzheimer's disease
35238|NCT02832921|virtual reality
35239|NCT02832921|cognitive training
35240|NCT02832895|Adults
35241|NCT02832895|Frontal bone window
35242|NCT02832895|Transcranial doppler
35243|NCT02832882|HCC
35244|NCT02832882|RFA
35245|NCT02832869|Polyp detection rate
35246|NCT02832869|Adenoma detection rate
35247|NCT02832869|Boston Bowel Preparation Scale
35248|NCT02832830|bony metastases
35249|NCT02832830|palliative radiotherapy
35250|NCT02832817|Oxygen therapy
35251|NCT02832817|Pulse oximeter
35252|NCT02832817|Hypoxia
35253|NCT02832817|Hypoxemia
35254|NCT02832817|Arterial blood gas
35255|NCT02832791|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
35256|NCT02832791|QUADRICEPS TENDON
35257|NCT02832791|HAMSTRING TENDON
35258|NCT02832765|Palliative radiotherapy
35259|NCT02832765|Bone metastases
35260|NCT02832739|Technology acceptance
35261|NCT02832739|Usability
35262|NCT02832739|eHealth
35263|NCT02832739|self-management support in chronic illness
35264|NCT02832739|prevention
35265|NCT02832739|Special Orthopaedic Co-Morbidity after hip/knee replacement
35266|NCT02832726|absorption of Vitamin B12
35267|NCT02832713|Knee osteoarthritis
35268|NCT02832713|Intra-articular botulinum toxin
35269|NCT02832713|Hyaluronic acid
35270|NCT02832713|Pain
35271|NCT02832713|Function
35272|NCT02832700|glycopeptides
35273|NCT02832700|dietary proteins
35274|NCT02832700|whey protein
35275|NCT02832700|caseinomacropeptide
35276|NCT02832700|antiinflammatories
35277|NCT02832700|human microbiome
35278|NCT02832661|renal allograft
35279|NCT02832661|graft injuries
35280|NCT02832661|biopsy
35281|NCT02832661|biomarkers
35282|NCT02832661|omics approach
35283|NCT02832635|brain metastasis
35284|NCT02832635|whole-brain radiotherapy
35285|NCT02832635|TMZ
35286|NCT02832635|avoidance of hippocampus
35287|NCT02832622|MultiPoint Pacing
35288|NCT02832622|Heart Failure
35289|NCT02832622|Cardiac Resynchronization Therapy
35290|NCT02832622|SJM Quadripolar Biventricular Pacing
35291|NCT02832609|closing volume
35292|NCT02832609|expiratory flow limitation
35293|NCT02832609|obesity
35294|NCT02832609|orthopnea
35295|NCT02832596|Anesthesia
35296|NCT02832596|Blood pressure
35297|NCT02832596|Plasma Volume
35298|NCT02832596|Vasopressor agents
35299|NCT02832596|Coronary artery bypass
35300|NCT02832596|Glycocalyx
35301|NCT02832596|ANP
35302|NCT02832596|Coagulation
35303|NCT02832583|PRP, hyaluronic acid, mesotherapy, skin wrinkle, skin rejuvenation
35304|NCT02832557|Autism
35305|NCT02832557|Asperger's Syndrome
35306|NCT02832557|microRNA
35307|NCT02832557|epigenetic
35308|NCT02832557|biomarker
35309|NCT02832544|atrial fibrillation
35310|NCT02832544|stroke
35311|NCT02832531|atrial fibrillation
35312|NCT02832531|stroke
35313|NCT02832492|disorders of consciousness
35314|NCT02832492|unresponsive wakefulness syndrome
35315|NCT02832492|pupil near response
35316|NCT02832492|evaluation of consciousness
35317|NCT02832453|High intensity physical exercise
35318|NCT02832453|Primary health care
35319|NCT02832453|Behaviour change interventions
35320|NCT02832427|Coronary artery bypass grafting
35321|NCT02832427|Heart valve surgery
35322|NCT02832427|Postoperative morbidity
35323|NCT02832427|Operative mortality
35324|NCT02832401|event-related potentials
35325|NCT02832401|EEG
35326|NCT02832401|caffeine
35327|NCT02832401|psychosis
35328|NCT02832401|schizophrenia
35329|NCT02832336|Caffeine
35330|NCT02832336|Caffeine citrate
35331|NCT02832336|Neurological disorder
35332|NCT02832336|Excessive daytime sleepiness
35333|NCT02832336|Orexin
35334|NCT02832336|adenosine antagonist
35335|NCT02832323|hemodialysis
35336|NCT02832323|EPO
35337|NCT02832323|MIRCERA
35338|NCT02832310|valsalva
35339|NCT02831218|bioresorbable vascular scaffold
35340|NCT02831218|coronary artery disease
35341|NCT02831205|bioresorbable vascular scaffold
35342|NCT02831205|coronary artery disease
35343|NCT02831166|Vascular closure devices
35344|NCT02831166|Transradial approach
35345|NCT02831166|Transfemoral approach
35346|NCT02831140|Fast track
35347|NCT02831140|rehabilitation
35348|NCT02831140|post operative complications
35349|NCT02831127|short message service; adherence; stent exchange; ERCP
35350|NCT02832258|Enterobacteria
35351|NCT02832258|Children
35352|NCT02832258|Febrile urinary tract infection
35353|NCT02832258|Cystitis
35354|NCT02832258|Extended-spectrum beta-lactamase-producing Enterobacteriaceae
35355|NCT02832232|Physiotherapy
35356|NCT02832232|Manual Therapy
35357|NCT02832232|Neck Pain
35358|NCT02832219|Overweight
35359|NCT02832219|Molecular hydrogen
35360|NCT02832219|Insulin
35361|NCT02832206|Atrial fibrillation
35362|NCT02832206|Hybrid ablation
35363|NCT02832180|Rheumatoid
35364|NCT02832141|Skin blood flow
35365|NCT02832141|Skin redness
35366|NCT02832141|Sympathetic nervous system
35367|NCT02832141|Regional Blood Flow
35368|NCT02832128|Cochlear Implant
35369|NCT02832115|Radial Artery Spasm
35370|NCT02832115|Cardiac Catheterization
35371|NCT02832115|Vascular Access Site Complications
35372|NCT02832115|Vasodilator
35373|NCT02832115|Nitroglycerine
35374|NCT02832115|Lidocaine
35375|NCT02832102|prognostic modelling
35376|NCT02832102|radiomics
35377|NCT02832102|clinical decision support system
35378|NCT02832102|big data analysis
35379|NCT02832102|multiscale prognostic signatures
35380|NCT02832102|patient-clinician co-decision tools
35381|NCT02832089|atrial fibrillation
35382|NCT02832089|rate reduction
35383|NCT02832050|play
35384|NCT02832050|therapy
35385|NCT02832024|stents
35386|NCT02832024|atherectomy
35387|NCT02832024|femoral artery
35388|NCT02832024|popliteal artery
35389|NCT02832024|In-stent Restenosis
35390|NCT02831985|Child
35391|NCT02831985|Middle ear ventilation
35392|NCT02831985|Follow-up studies
35393|NCT02831985|General practitioners
35394|NCT02831972|Healthy Volunteers
35395|NCT02831959|Non-Small Cell Lung Cancer
35396|NCT02831959|NSCLC
35397|NCT02831959|Brain metastases
35398|NCT02831959|Treatment
35399|NCT02831959|Minimal toxicity
35400|NCT02831959|TTFields
35401|NCT02831959|TTF
35402|NCT02831959|Tumor Treating Fields
35403|NCT02831959|Novocure
35404|NCT02831959|SRS
35405|NCT02831959|Stereotactic radiosurgery
35406|NCT02831946|skin closure
35407|NCT02831946|intracuticular suture
35408|NCT02831946|glue (dermabond)
35409|NCT02831933|lung cancer
35410|NCT02831933|metastatic
35411|NCT02831933|gene therapy
35412|NCT02831933|immunotherapy
35413|NCT02831920|Prostate Cancer
35414|NCT02831920|MRI
35415|NCT02831920|CEUS
35416|NCT02831920|Contrast Ultrasound
35417|NCT02831920|Fusion
35418|NCT02831920|targeted biopsy
35419|NCT02831907|Ultrasonography
35420|NCT02831907|Portal vein Doppler
35421|NCT02831907|Renal Doppler
35422|NCT02831907|Cardio-Intestinal syndrome
35423|NCT02831907|Delirium
35424|NCT02831907|Renal congestion
35425|NCT02831907|Intra-renal hemodynamics
35426|NCT02831894|insomnia
35427|NCT02831894|sedative hypnotics
35428|NCT02831894|hypnotic tapering
35429|NCT02831855|Rheumatoid Arthritis
35430|NCT02831855|Tofacitinib
35431|NCT02831855|CP-690,550
35432|NCT02831855|Xeljanz
35433|NCT02831855|methotrexate withdrawal
35434|NCT02831855|withdrawal study
35435|NCT02831829|cardiac rehabilitation
35436|NCT02831829|coronary artery disease
35437|NCT02831777|non-invasive blood pressure
35438|NCT02831764|tolerability
35439|NCT02831764|HIV 1
35440|NCT02831764|efficacy
35441|NCT02831764|treatment naïve
35442|NCT02831764|two-drug regimen
35443|NCT02831764|safety
35444|NCT02831764|non inferiority
35445|NCT02831751|Influenza
35446|NCT02831751|Human
35447|NCT02831751|RNA Virus Infections
35448|NCT02831751|Immulogic
35449|NCT02831751|Immunogenic Factors
35450|NCT02831751|Physiological Effects of Drug
35451|NCT02831751|Virus Diseases
35452|NCT02831751|Orthomyxoviridae Infections
35453|NCT02831751|Infection
35454|NCT02831738|Fiber
35455|NCT02831738|Polydextrose
35456|NCT02831738|Glycemic Index
35457|NCT02831712|NTBI
35458|NCT02831712|Iron status
35459|NCT02831712|Iron supplement
35460|NCT02831699|Zika
35461|NCT02831699|Guillain Barré
35462|NCT02831686|Selinexor (KPT-330)
35463|NCT02831686|Ixazomib
35464|NCT02831686|dexamethasone
35465|NCT02831686|15-310
35466|NCT02831673|safety
35467|NCT02831673|treatment naïve
35468|NCT02831673|HIV 1
35469|NCT02831673|dolutegravir plus lamivudine
35470|NCT02831673|non inferiority
35471|NCT02831673|tolerability
35472|NCT02831673|dolutegravir plus tenofovir/emtricitabine
35473|NCT02831673|efficacy
35474|NCT02831634|Breast cancer
35475|NCT02831634|cutaneous melanoma
35476|NCT02831621|overweight
35477|NCT02831621|ectopic fat
35478|NCT02831621|exercise
35479|NCT02831621|diet
35480|NCT02831582|Breast Cancer
35481|NCT02831582|Postmenopausal
35482|NCT02831582|Stage IA
35483|NCT02831582|Stage IB
35484|NCT02831582|Stage IIA
35485|NCT02831582|Stage IIB
35486|NCT02831582|Stage IIIA
35487|NCT02831582|Stage IIIB
35488|NCT02831582|Stage IIIC
35489|NCT02831556|Ultrasound
35490|NCT02831556|Abdomen
35491|NCT02831556|Pelvis
35492|NCT02831556|3D
35493|NCT02831504|Myotonic Dystrophy type 1
35494|NCT02831504|DM1
35495|NCT02831504|Muscular Dystrophy
35496|NCT02831504|Neuromuscular Diseases
35497|NCT02831491|metastatic
35498|NCT02831465|Dynamic hyperinflation
35499|NCT02831465|Maximal Voluntary Ventilation
35500|NCT02831465|Inspiratory capacity
35501|NCT02831465|healthy subjects
35502|NCT02831452|pelvic floor muscles
35503|NCT02831452|evaluation
35504|NCT02831452|dynamometer
35505|NCT02831452|perineometer
35506|NCT02831439|Choosing Wisely
35507|NCT02831439|Breast cancer
35508|NCT02831439|Controlled trial
35509|NCT02831439|High-value health care
35510|NCT02831439|Health services research
35511|NCT02831348|Asthma
35512|NCT02831348|Allergic rhinitis
35513|NCT02831348|Rhinitis
35514|NCT02831348|Pneumonia
35515|NCT02831348|Cystic fibrosis
35516|NCT02831322|Transradial
35517|NCT02831322|ﬂow-mediated vasodilation
35518|NCT02831309|physical activity
35519|NCT02831296|SMA
35520|NCT02831296|Werdnig-Hoffmann disease
35521|NCT02831296|Kugelberg-Welander disease
35522|NCT02831283|inflammation
35523|NCT02831283|aging
35524|NCT02831283|mild cognitive impairment
35525|NCT02831270|cardiac surgery
35526|NCT02831270|acute normovolemic hemodilution
35527|NCT02831257|Neurofibromatosis 2
35528|NCT02831101|BIS
35529|NCT02831101|Elderly
35530|NCT02831101|Propofol
35531|NCT02831101|Sufentanil
35532|NCT02831101|Loss of consciousness
35533|NCT02831088|Neu2000KWL
35534|NCT02831088|Neuroprotection
35535|NCT02831088|endovascular therapy
35536|NCT02831088|glutamate
35537|NCT02831088|free radical
35538|NCT02831075|Adipose-derived Stem Cells
35539|NCT02831062|nutrition
35540|NCT02831062|progression
35541|NCT02831049|Reconsolidation
35542|NCT02831010|prematurity
35543|NCT02830971|standardized learning curve
35544|NCT02830971|Nurse
35545|NCT02830971|intensive care unit
35546|NCT02830971|Mastery
35547|NCT02830971|Training
35548|NCT02830971|Developing
35549|NCT02830971|Skills
35550|NCT02830919|Osteoarthritis of knee
35551|NCT02830919|Glucosamine sulfate
35552|NCT02830919|Chondroitin sulfate
35553|NCT02830906|Total Knee Arthroplasty
35554|NCT02830906|Intrathecal Morphine
35555|NCT02830906|Ramosetron
35556|NCT02830906|Ondansetron
35557|NCT02830906|postoperative nausea and vomiting
35558|NCT02830867|glutathione
35559|NCT02830867|glutathione synthetase deficiency
35560|NCT02830867|autosomal inheritance
35561|NCT02830867|recessive
35562|NCT02830841|RIPC
35563|NCT02830841|hepatic ischemic and reperfusion injury
35564|NCT02830841|pediatric living donor liver transplantation
35565|NCT02830815|Broadband click stimulus testing
35566|NCT02830815|General Anesthesia
35567|NCT02830815|Sevoflurane
35568|NCT02830815|Propofol
35569|NCT02830815|Amplitude latency
35570|NCT02830815|Wave V
35571|NCT02830776|dermatochalasis
35572|NCT02830776|bimatoprost
35573|NCT02830776|blepharoplasty
35574|NCT02830763|neutral lipid storage disease
35575|NCT02830763|CNT-02
35576|NCT02830763|primary triglyceride deposit cardiomyovasculopathy (TGCV)
35577|NCT02830763|neutral lipid storage disease with myopathy (NLSD-M)
35578|NCT02830737|Small Hepatocellular Carcinoma
35579|NCT02830737|No-touch RFA
35580|NCT02830737|Traditional RFA
35581|NCT02830737|Recurrence rate
35582|NCT02830724|Metastatic Solid Cancers
35583|NCT02830724|Renal Cell Cancer
35584|NCT02830724|Cell Therapy
35585|NCT02830724|CAR T Cells
35586|NCT02830711|happiness
35587|NCT02830711|anger
35588|NCT02830711|sadness
35589|NCT02830711|anticipation
35590|NCT02830698|Nervous System
35591|NCT02830698|Hypnosis
35592|NCT02830698|Electrocardiography, Ambulatory
35593|NCT02830685|pre-pectoral breast reconstruction
35594|NCT02830685|subcutaneous breast reconstruction
35595|NCT02830633|laparoscopy
35596|NCT02830633|rectal cancer
35597|NCT02830633|pelvic autonomic nerve
35598|NCT02830568|Kidney transplantation
35599|NCT02830568|Surgical procedures
35600|NCT02830568|Kidney living donors
35601|NCT02830568|Quality of life
35602|NCT02830542|Clostridium difficile
35603|NCT02830542|C Diff
35604|NCT02830542|CDI
35605|NCT02830529|Mindfulness
35606|NCT02830529|African American
35607|NCT02830529|fMRI
35608|NCT02830477|Previously treated patients
35609|NCT02830451|Registry
35610|NCT02830451|Spine
35611|NCT02830451|Surgery
35612|NCT02830451|Medical Oncology
35613|NCT02830451|Radiation Oncology
35614|NCT02830451|Neoplasms
35615|NCT02830451|Metastasis
35616|NCT02830451|Chemotherapy
35617|NCT02830451|Radiation Therapy
35618|NCT02830451|Tumor Markers
35619|NCT02830438|kidney disease
35620|NCT02830438|fibrosis
35621|NCT02830438|ultrasound
35622|NCT02830438|elastography
35623|NCT02830425|Multimorbidity
35624|NCT02830425|Polypharmacy
35625|NCT02830425|Appropriateness
35626|NCT02830425|STOPP
35627|NCT02830425|START
35628|NCT02830399|treatment-resistant-depression
35629|NCT02830399|rTMS
35630|NCT02830399|ECT
35631|NCT02830399|Augmentation strategy
35632|NCT02830373|LVIS stents
35633|NCT02830373|Intracranial aneurysm
35634|NCT02830373|Unruptured aneurysm
35635|NCT02830373|Wide-necked aneurysm
35636|NCT02830360|Antiarrhythmic drug therapy
35637|NCT02830360|VT Catheter ablation
35638|NCT02830360|ICD Therapy
35639|NCT02830360|Ischemic Heart Disease
35640|NCT02830347|antibiotic resistance
35641|NCT02830347|oral microbiome
35642|NCT02830334|Suicide
35643|NCT02830334|Youth Suicide
35644|NCT02830308|Hormones
35645|NCT02830308|Endocrine
35646|NCT02830308|Hypercortisolism
35647|NCT02830308|Bone
35648|NCT02830308|Hypothalamic-Pituitary Dysfunction
35649|NCT02830295|body awareness therapy
35650|NCT02830295|physical therapy
35651|NCT02830295|movement therapy
35652|NCT02830269|Neuro-ICU
35653|NCT02830269|Third ventricle
35654|NCT02830269|Computer Tomography
35655|NCT02830269|Transcranial Doppler ultasonography
35656|NCT02830256|Intensive care unit
35657|NCT02830256|Neuro-ICU
35658|NCT02830256|Pain
35659|NCT02830256|Intubation
35660|NCT02830256|critical care
35661|NCT02830256|patients
35662|NCT02830217|STEMI
35663|NCT02830217|primary PCI
35664|NCT02830217|sST2
35665|NCT02830217|prognosis
35666|NCT02830204|mitral valve regurgitation
35667|NCT02830204|mitral valve stenosis
35668|NCT02830191|Cyclosporine, Dried blood spot
35669|NCT02830152|Stroke
35670|NCT02830152|intracerebral hemorrhage
35671|NCT02830152|left atrial appendage occlusion
35672|NCT02830152|atrial fibrillation
35673|NCT02830152|oral anticoagulation
35674|NCT02830152|preventive therapy
35675|NCT02830126|Outcomes
35676|NCT02830126|Information technology
35677|NCT02830113|periodontitis
35678|NCT02830113|diabetes
35679|NCT02830113|prevention
35680|NCT02830113|impaired glucose tolerance
35681|NCT02830113|insulin resistance
35682|NCT02830100|Intern speech
35683|NCT02830100|Speech and visual imaging
35684|NCT02830100|Mind and oral drift
35685|NCT02830100|Cognitive performance
35686|NCT02830100|Magnetic Resonance Imaging
35687|NCT02830087|randomized controlled trial
35688|NCT02830087|tourniquet
35689|NCT02830087|tourniquet cuff pressure
35690|NCT02830087|total knee arthroplasty
35691|NCT02830087|total knee replacement
35692|NCT02830087|pain, postoperative
35693|NCT02830087|range of motion, articular
35694|NCT02830087|blood loss, surgical
35695|NCT02830087|muscle strength, quadriceps
35696|NCT02830087|walking
35697|NCT02830087|manipulation, orthopedic/therapeutic use
35698|NCT02830087|wound healing/surgery
35699|NCT02830074|Sleep Apnea Syndromes
35700|NCT02830074|Spinal Cord Injuries
35701|NCT02830074|Sleep
35702|NCT02830074|Quality of life
35703|NCT02830061|Cancer
35704|NCT02830061|Teenage
35705|NCT02830061|Young Adult
35706|NCT02830061|Fertility
35707|NCT02830061|Cryopreservation
35708|NCT02830061|Experience
35709|NCT02830048|diabetes
35710|NCT02830048|glibenclamide
35711|NCT02830048|glucagon
35712|NCT02830035|ultrasound guided
35713|NCT02830035|spinal anesthesia
35714|NCT02830035|neuraxial block
35715|NCT02830035|paramedian
35716|NCT02830022|autism spectrum disorder
35717|NCT02829996|glaucoma
35718|NCT02829996|primary open-angle glaucoma
35719|NCT02829996|ocular hypertension
35720|NCT02829996|adenosine agonist
35721|NCT02829996|eye drop
35722|NCT02829996|trabodenoson
35723|NCT02829996|trabecular meshwork
35724|NCT02829983|clarithromycin
35725|NCT02829983|periodontal debridement
35726|NCT02829983|aggressive periodontitis
35727|NCT02829970|Attention Deficit Hyperactivity Disorder
35728|NCT02829970|Alcohol-Related Disorders
35729|NCT02829970|Substance-Related Disorders
35730|NCT02829970|Motivational Interviewing
35731|NCT02829970|Behavior Therapy
35732|NCT02829944|Cesarean section
35733|NCT02829931|recurrent glioma
35734|NCT02829931|high grade glioma
35735|NCT02829931|head and neck disease
35736|NCT02829931|grade III glioma
35737|NCT02829931|grade IV glioma
35738|NCT02829931|radiation therapy
35739|NCT02829918|advanced biliary tract cancer
35740|NCT02829918|refractory biliary tract cancer
35741|NCT02829918|digestive diseases
35742|NCT02829918|immunotherapy
35743|NCT02829905|mass screening
35744|NCT02829905|patient satisfaction
35745|NCT02829905|radiography
35746|NCT02829905|mammography
35747|NCT02829879|Dentin Sensitivity
35748|NCT02829879|Arginin
35749|NCT02829879|Potassium Nitrate
35750|NCT02829879|Dentifrice
35751|NCT02829879|RCT
35752|NCT02829853|SARCOIDOSIS
35753|NCT02829853|GRANULOMA DISEASES
35754|NCT02829853|GENETICS
35755|NCT02829853|PREDISPOSITION
35756|NCT02829853|EXOME (WES-NGS)
35757|NCT02829840|Leukemia
35758|NCT02829840|FLT3-Mutated Acute Myeloid Leukemia
35759|NCT02829840|FLT3-Mutated High-Risk Myelodysplastic Syndrome
35760|NCT02829840|Acute Myeloid Leukemia
35761|NCT02829840|AML
35762|NCT02829840|Myelodysplastic Syndrome
35763|NCT02829840|MDS
35764|NCT02829840|Ponatinib
35765|NCT02829840|Iclusig
35766|NCT02829840|AP24534
35767|NCT02829840|5-azacytidine
35768|NCT02829840|Azacitidine
35769|NCT02829840|5-aza
35770|NCT02829840|Vidaza
35771|NCT02829840|5-AZC
35772|NCT02829840|AZA-CR
35773|NCT02829840|Ladakamycin
35774|NCT02829840|NSC-102816
35775|NCT02829840|Azacytidine
35776|NCT02829827|Radiprodil
35777|NCT02829827|Infantile spasms
35778|NCT02829827|IS
35779|NCT02829827|Infantile
35780|NCT02829827|Spasms
35781|NCT02829827|Epilepsy
35782|NCT02829827|Paediatrics
35783|NCT02829827|Drug-resistant
35784|NCT02829827|West Syndrome
35785|NCT02829827|Hypsarrhythmia
35786|NCT02829814|Pain
35787|NCT02829814|Sleep
35788|NCT02829814|Fibromyalgia
35789|NCT02829814|FM
35790|NCT02829801|animal assisted therapy
35791|NCT02829801|well-being
35792|NCT02829801|Alzheimer's Disease
35793|NCT02829788|Digestive peritoneal carcinomatosis
35794|NCT02829788|laparoscopy
35795|NCT02829788|laparotomy
35796|NCT02829788|peritoneal cancer index (PCI)
35797|NCT02829788|staging
35798|NCT02829762|isolated
35799|NCT02829762|at risk of isolation
35800|NCT02829762|patients
35801|NCT02829749|Heart Valve Diseases
35802|NCT02829749|Heart failure
35803|NCT02829749|Heart diseases
35804|NCT02829749|Mitral valve insufficiency
35805|NCT02829736|lung neoplasm
35806|NCT02829736|lung metastasis
35807|NCT02829736|enhanced recovery after surgery
35808|NCT02829736|fast-track surgery
35809|NCT02829736|intraoperative chest tube removal
35810|NCT02829736|pain
35811|NCT02829736|lung function
35812|NCT02829736|reasons for admission
35813|NCT02829723|Phase I/II
35814|NCT02829723|BLZ945
35815|NCT02829723|PDR001
35816|NCT02829723|CSF-1R
35817|NCT02829723|PD-1
35818|NCT02829710|Analgesia
35819|NCT02829710|intensive care units
35820|NCT02829710|clinical protocol
35821|NCT02829710|deep sedation
35822|NCT02829710|nursing assessment
35823|NCT02829697|Regional anaesthesia
35824|NCT02829671|Loneliness
35825|NCT02829671|Suicidal behavior
35826|NCT02829671|Depression
35827|NCT02829645|eating disoders
35828|NCT02829645|neuropsychology
35829|NCT02829645|pronostic
35830|NCT02829632|mobile technology
35831|NCT02829632|feedback message
35832|NCT02829632|self-monitoring
35833|NCT02829619|Obesity
35834|NCT02829619|Nutrigenetics
35835|NCT02829619|Food Timing
35836|NCT02829619|Weight loss
35837|NCT02829606|Age-related Macular Degeneration
35838|NCT02829606|Central Scotoma
35839|NCT02829606|Head Mounted Display
35840|NCT02829580|endothelial function
35841|NCT02829580|flow-mediated dilation
35842|NCT02829580|vascular elastic properties
35843|NCT02829554|Emotion
35844|NCT02829554|Judgment
35845|NCT02829554|Decision Making
35846|NCT02829541|Single Ascending Dose (SAD), Healthy Volunteers
35847|NCT02829502|Cerebrovascular disease
35848|NCT02829502|Glucagon like peptide 1
35849|NCT02829489|nutrition
35850|NCT02829489|foregut tumors
35851|NCT02829489|patient related outcomes
35852|NCT02829489|audit
35853|NCT02829476|Adolescent idiopathic Scoliosis
35854|NCT02829476|Ghrelin
35855|NCT02829450|peritoneal ultrafiltration
35856|NCT02829450|congestive heart failure
35857|NCT02829450|chronic kidney disease
35858|NCT02829398|cerebral ischemia
35859|NCT02829385|Apatinib
35860|NCT02829385|XELOX Regimen
35861|NCT02829385|metastatic colorectal cancer
35862|NCT02829346|Tranexamic acid
35863|NCT02829346|Peri-articular injection
35864|NCT02829346|Total knee arthroplasty
35865|NCT02829346|Blood loss
35866|NCT02829346|Osteoarthritis, Knee
35867|NCT02829333|analgesia
35868|NCT02829333|anesthesia
35869|NCT02829333|leiomyomas
35870|NCT02829333|tumor
35871|NCT02829333|vascular endothelial growth factor
35872|NCT02829333|anesthesia technique on tumor
35873|NCT02829320|efficacy
35874|NCT02829320|hemodialysis (HD)
35875|NCT02829320|hemoglobin (Hgb)
35876|NCT02829320|erythropoiesis-stimulating agents (ESAs)
35877|NCT02829320|GSK1278863
35878|NCT02829307|89Zirconium
35879|NCT02829307|Open label
35880|NCT02829307|Pharmacokinetics
35881|NCT02829307|Radioactive
35882|NCT02829307|Clearance
35883|NCT02829307|Biodistribution
35884|NCT02829281|knee osteoarthritis
35885|NCT02829281|Intra-articular injection
35886|NCT02829281|Botulinum Toxin Type A
35887|NCT02829281|Corticosteroid
35888|NCT02829268|Wolfram syndrome
35889|NCT02829268|Diabetes Mellitus
35890|NCT02829268|Optic Nerve Atrophy
35891|NCT02829268|Ataxia
35892|NCT02829268|Endoplasmic Reticulum Stress
35893|NCT02829255|High altitude
35894|NCT02829255|Cerebral autoregulation
35895|NCT02829255|Transfer function analysis
35896|NCT02829242|Near Infrared Spectroscopy
35897|NCT02829242|Somatic Saturation
35898|NCT02829242|Well Leg Compartment Syndrome
35899|NCT02829242|Robotic Assisted Laparoscopic Surgery
35900|NCT02829242|Trendelenburg Position
35901|NCT02829216|myelosuppression
35902|NCT02829216|mesenchymal stromal cells
35903|NCT02829203|Frailty
35904|NCT02829203|Surgery
35905|NCT02829190|External carotid artery
35906|NCT02829190|Facial artery
35907|NCT02829190|Lingual artery
35908|NCT02829190|Superior thyroid artery
35909|NCT02829190|Internal maxillary artery
35910|NCT02829190|Phase-contrast MRI
35911|NCT02829190|Rate of flow
35912|NCT02829190|Superficial temporal artery
35913|NCT02829177|Type 1 diabetes
35914|NCT02829177|Diabetic nephropathy
35915|NCT02829177|Albuminuria
35916|NCT02829177|Allopurinol
35917|NCT02829164|Tonsillectomy
35918|NCT02829164|primary IgA nephropathy
35919|NCT02829164|primary nephropathy
35920|NCT02829164|IgA
35921|NCT02829164|Berger's disease
35922|NCT02829164|Purpura rheumatoid
35923|NCT02829164|kidney failure
35924|NCT02829151|Peripheral artery disease
35925|NCT02829151|Critical limb ischemia
35926|NCT02829151|Angioplasty
35927|NCT02829151|Antiplatelet therapy
35928|NCT02829125|Early rehabilitation
35929|NCT02829125|abdominal surgery
35930|NCT02829125|ERAS
35931|NCT02829112|Shulman
35932|NCT02829112|fasciitis
35933|NCT02829112|Shulman fasciitis
35934|NCT02829112|eosinophilic fasciitis
35935|NCT02829112|inflammatory disease
35936|NCT02829112|prevalence
35937|NCT02829073|Tinnitus
35938|NCT02829073|Double-blind
35939|NCT02829073|Neuromonic Tinnitus Treatment Program
35940|NCT02829073|Oasis™
35941|NCT02829060|nephrolithiasis
35942|NCT02829060|percutaneous nephrolithiasis
35943|NCT02829060|urinary tract infection (UTI)
35944|NCT02829060|Sepsis
35945|NCT02829034|pulmonary hypertension
35946|NCT02829034|right ventricular function
35947|NCT02829034|ranolazine
35948|NCT02829021|Sensitivity
35949|NCT02829021|Specificity
35950|NCT02829021|Breast cancer
35951|NCT02829021|Mammography
35952|NCT02829021|Thermography
35953|NCT02829021|Infrared
35954|NCT02829021|Dynamic
35955|NCT02829021|Diagnostic accuracy
35956|NCT02829021|Diagnostic odds ratio
35957|NCT02829008|HER2 negative breast cancer
35958|NCT02829008|low-dose bevacizumab
35959|NCT02829008|pemetrexed
35960|NCT02828995|Diabetes Mellitus
35961|NCT02828995|Stigma
35962|NCT02828995|Social Determinants of Health
35963|NCT02828982|powered ankle prosthesis
35964|NCT02828982|activity monitoring
35965|NCT02828982|muscle fatigue
35966|NCT02828982|below knee amputation
35967|NCT02828969|Trajectory
35968|NCT02828969|Emergency room
35969|NCT02828969|Conduct disorder
35970|NCT02828969|Care management
35971|NCT02828956|eating disorders
35972|NCT02828956|ANSOCQ
35973|NCT02828956|anorexia nervosa
35974|NCT02828878|Apoptosis
35975|NCT02828878|FAS Ligand
35976|NCT02828878|Bone marrow transplantation
35977|NCT02828878|GvHD
35978|NCT02828878|Stem cells
35979|NCT02828865|Hepatocellular Carcinoma
35980|NCT02828865|irreversible electroporation
35981|NCT02828865|liver cancer
35982|NCT02828852|pregnancy
35983|NCT02828852|platelets
35984|NCT02828839|Transperineal
35985|NCT02828839|Transrectal
35986|NCT02828839|Needle Guide
35987|NCT02828839|Biopsy
35988|NCT02828761|chest pain
35989|NCT02828761|calcium score
35990|NCT02828761|coronary calcium score
35991|NCT02828761|coronary calcium scoring
35992|NCT02828761|calcium scoring
35993|NCT02828761|cacs
35994|NCT02828761|ccs
35995|NCT02828748|cannabinoids
35996|NCT02828748|inflammatory bowel disease
35997|NCT02828722|Circadian rhythm
35998|NCT02828722|Critical Illness
35999|NCT02828722|Mechanical ventilation
36000|NCT02828722|Environmental modulation
36001|NCT02828696|CAD-CAM composites
36002|NCT02828696|Worn dentition
36003|NCT02828696|minimally invasive treatment
36004|NCT02828683|DES
36005|NCT02828683|PCI
36006|NCT02828683|STEMI
36007|NCT02828683|Interventional Cardiology
36008|NCT02828657|ORBERA
36009|NCT02828644|ADHD
36010|NCT02828592|SAA
36011|NCT02828579|obesity
36012|NCT02828579|bariatric surgery
36013|NCT02828579|non-alcoholic fatty liver disease
36014|NCT02828553|Wearable device
36015|NCT02828553|Fitbit
36016|NCT02828553|Inpatient
36017|NCT02828540|HT047
36018|NCT02828540|Pueraria lobata
36019|NCT02828540|Scutellaria baicalensis
36020|NCT02828501|Pain Threshold
36021|NCT02828436|Hypertension
36022|NCT02828436|High Blood Pressure
36023|NCT02828423|periodontal regeneration
36024|NCT02828384|fodmap diet
36025|NCT02828332|Autism Spectrum Disorders
36026|NCT02828332|Cohort
36027|NCT02828306|stroke
36028|NCT02828306|head trauma
36029|NCT02828306|Patient Specific Implant
36030|NCT02828306|skull defect
36031|NCT02828267|Tanzania
36032|NCT02828267|Alcohol Use
36033|NCT02828267|Brief Intervention
36034|NCT02828228|obesity
36035|NCT02828228|weight loss
36036|NCT02828228|vitamin D deficiency
36037|NCT02828228|body composition
36038|NCT02828202|Melanoma
36039|NCT02828202|Skin
36040|NCT02828202|Biobank
36041|NCT02828189|Physical Therapy Modalities
36042|NCT02828189|Breast Cancer Treatment
36043|NCT02828189|Exercise Therapy
36044|NCT02828189|Dyspnea
36045|NCT02828176|cardiometry
36046|NCT02828176|uterine displacement
36047|NCT02828111|Gorlin Syndrome
36048|NCT02828111|Basal Cell Nevus Syndrome BCNS
36049|NCT02828111|nevoid basal cell carcinoma syndrome
36050|NCT02828111|Basal cell carcinoma
36051|NCT02828111|Hedgehog inhibitor
36052|NCT02828111|Surgically Eligible Basal Cell Carcinomas
36053|NCT02828098|aggressive solid tumors
36054|NCT02828059|Caesarean section
36055|NCT02828007|EIT
36056|NCT02828007|NIV
36057|NCT02827968|PDL-1
36058|NCT02827942|pylori
36059|NCT02827903|Metformin
36060|NCT02827903|Rosuvastatin
36061|NCT02827903|type 2 diabetes
36062|NCT02827903|dyslipidemia
36063|NCT02827864|Mirror therapy
36064|NCT02827864|transcranial direct current stimulation
36065|NCT02827864|stroke
36066|NCT02827864|neurorehabilitation
36067|NCT02827851|Damage of articular cartilage
36068|NCT02827851|Cartilage degeneration
36069|NCT02827851|Intraarticular injection
36070|NCT02827851|SVF
36071|NCT02827851|Stromal vascular fraction
36072|NCT02827851|Adipose-derived regenerative cells (ADRC)
36073|NCT02827851|Adipose tissue
36074|NCT02827851|Stem cells
36075|NCT02827825|Neurosurgical
36076|NCT02827825|Intensive Care
36077|NCT02827799|heart failure
36078|NCT02827799|insomnia
36079|NCT02827799|sleep disorders
36080|NCT02827799|actigraphy
36081|NCT02827799|cardiomyopathy
36082|NCT02827799|depression
36083|NCT02827799|sleepiness
36084|NCT02827799|anxiety
36085|NCT02827799|fatigue
36086|NCT02827786|hepatic tumours
36087|NCT02827773|Literacy
36088|NCT02827747|Keratoconus progression
36089|NCT02827747|Vitamins and keratoconus
36090|NCT02827747|Vitamin supplementation
36091|NCT02827682|IoC
36092|NCT02827682|monitor
36093|NCT02827682|elderly
36094|NCT02827682|postoperative effectiveness
36095|NCT02827656|Fertilization in vitro
36096|NCT02827656|Luteal Phase
36097|NCT02827656|ovarian hyperstimulation syndrome
36098|NCT02827617|Ibrutinib
36099|NCT02827617|TP53
36100|NCT02827617|Chronic lymphocytic leukemia
36101|NCT02827604|Caesarean section
36102|NCT02827604|lower uterine segment
36103|NCT02827604|sonography
36104|NCT02827591|repeat cesarean section
36105|NCT02827591|lower uterine segment
36106|NCT02827591|quantitative sonography
36107|NCT02827565|colorectal cancer
36108|NCT02827565|Kras mutation
36109|NCT02827565|Nras mutation
36110|NCT02827565|Braf mutation
36111|NCT02827552|pediatric oncology
36112|NCT02827552|radiotherapy
36113|NCT02827552|radiosensitivity
36114|NCT02827513|Centanafadine
36115|NCT02827513|Adult attention-deficit hyperactivity disorder
36116|NCT02827513|Healthy participants
36117|NCT02827448|Left Ventricular Assist Device
36118|NCT02827448|Heart transplantation
36119|NCT02827448|Perioperative
36120|NCT02827448|Acute Kidney Injury
36121|NCT02827448|Renal
36122|NCT02827448|Kidney
36123|NCT02827448|Total Artificial Heart
36124|NCT02827422|therapeutic hypothermia
36125|NCT02827409|Delayed cord clamping
36126|NCT02827396|Disability
36127|NCT02827396|children
36128|NCT02827396|parents
36129|NCT02827396|depression
36130|NCT02827396|knowledge
36131|NCT02827396|psychosocial intervention
36132|NCT02827344|PD-1/PD-L1
36133|NCT02827344|Immune checkpoints
36134|NCT02827344|Immunotherapy
36135|NCT02827344|lung cancer
36136|NCT02827344|circulating tumor cells
36137|NCT02827344|immunocytochemistry
36138|NCT02827344|ISET
36139|NCT02827344|MDSC
36140|NCT02827344|Stage IV non-small cell lung cancer
36141|NCT02827331|Benzodiazepines
36142|NCT02827331|Fracture
36143|NCT02827318|Blood glucose
36144|NCT02827305|antiplaque
36145|NCT02827305|antigingivitis
36146|NCT02827292|music
36147|NCT02827292|inflammation
36148|NCT02827279|Autism Spectrum Disorder
36149|NCT02827279|Emotion
36150|NCT02827253|brain
36151|NCT02827253|haemodialysis
36152|NCT02827253|intradialytic hypotension
36153|NCT02827240|Female sex workers
36154|NCT02827240|HIV testing
36155|NCT02827240|HIV self-test
36156|NCT02827227|HIV-infected patients
36157|NCT02827227|cART
36158|NCT02827227|immune restoration
36159|NCT02827227|markers
36160|NCT02827214|Thoracolumbar spine
36161|NCT02827214|Burst fractures
36162|NCT02827214|Conservative treatment
36163|NCT02827214|Surgical treatment
36164|NCT02827214|Thoracic or lumbar vertebrae
36165|NCT02827201|pancreatic cancer
36166|NCT02827162|Dengue Fever
36167|NCT02827162|Dengue Haemorrhagic Fever
36168|NCT02827162|Tetravalent Dengue Vaccine
36169|NCT02827149|HSCT
36170|NCT02827149|high resolution HLA typing
36171|NCT02827149|unrelated donor
36172|NCT02827084|electromyography
36173|NCT02827084|torque
36174|NCT02827084|quadriceps muscle
36175|NCT02827058|Delivery, obstetric
36176|NCT02827058|Analgesia, Epidural
36177|NCT02827058|Injections, Epidural
36178|NCT02827058|Needles
36179|NCT02827058|Cesarean Section
36180|NCT02827032|Hypertension
36181|NCT02827006|Bone graft
36182|NCT02827006|Calcium phosphate bone cement
36183|NCT02827006|RCT
36184|NCT02827006|Xray
36185|NCT02827006|CT
36186|NCT02826993|PillCAM2
36187|NCT02826967|Hydro-San Plus colonic irrigation system
36188|NCT02826967|Screening colonoscopy
36189|NCT02826954|Paranasal Sinus Diseases
36190|NCT02826954|Nasal Obstruction
36191|NCT02826941|hypothermia treatment
36192|NCT02826915|newborn
36193|NCT02826915|infant
36194|NCT02826915|child
36195|NCT02826915|EEG
36196|NCT02826915|NIRS
36197|NCT02826902|Total intravenous anesthesia
36198|NCT02826902|desflurane
36199|NCT02826902|QoR-40
36200|NCT02826902|cosmetic lower limb lengthening
36201|NCT02826889|Fluid responsiveness
36202|NCT02826889|pulse pressure variation
36203|NCT02826889|pleth variability index
36204|NCT02826889|prone position
36205|NCT02826876|Laparoscopic surgery
36206|NCT02826863|seizure
36207|NCT02826863|tonic-atonic
36208|NCT02826863|epilepsy
36209|NCT02826863|myoclonic
36210|NCT02826863|encephalopathy
36211|NCT02826850|Osteoarthritis, Knee
36212|NCT02826850|Pulsed Radiofrequency Treatment
36213|NCT02826850|Ultrasonography, Interventional
36214|NCT02826837|Advanced Colorectal Cancer
36215|NCT02826824|corpus callosum agenesis
36216|NCT02826824|agenesis
36217|NCT02826824|corpus callosum
36218|NCT02826811|Graft dysfunction
36219|NCT02826811|Graft loss
36220|NCT02826811|kidney
36221|NCT02826811|Transplantation
36222|NCT02826811|BKV
36223|NCT02826811|Anti-BKV
36224|NCT02826811|Nephropathy
36225|NCT02826811|Immunosuppression
36226|NCT02826811|Prognostic markers
36227|NCT02826798|VBI-1501A
36228|NCT02826798|VBI-1501
36229|NCT02826798|prophylactic vaccine
36230|NCT02826798|virus diseases
36231|NCT02826798|cytomegalovirus
36232|NCT02826798|CMV
36233|NCT02826798|cytomegalovirus infections
36234|NCT02826798|cytomegalovirus vaccines
36235|NCT02826798|Herpesviridae Infections
36236|NCT02826798|Phase 1
36237|NCT02826798|Human Herpesvirus 5
36238|NCT02826798|HHV5
36239|NCT02826798|Vaccines, virus-like particle
36240|NCT02826798|VLP
36241|NCT02826798|enveloped virus-like particle
36242|NCT02826798|eVLP
36243|NCT02826759|sphingolipid
36244|NCT02826759|diabetes mellitus
36245|NCT02826759|biomarker
36246|NCT02826759|obesity
36247|NCT02826759|insulin resistance
36248|NCT02826733|preterm infants
36249|NCT02826733|term infants
36250|NCT02826733|hemispheric dominance
36251|NCT02826720|HDL cholesterol
36252|NCT02826720|Hyperlipidemia
36253|NCT02826720|LDL cholesterol
36254|NCT02826720|Periodontal disease
36255|NCT02826720|Triglyceride
36256|NCT02826655|WF-OCT
36257|NCT02826655|OCT
36258|NCT02826655|diabetic retinopathy
36259|NCT02826655|diabetic macular edema
36260|NCT02826642|newly diagnosed acute myeloid leukemia
36261|NCT02826642|AML
36262|NCT02826642|myeloid dysplastic syndrome
36263|NCT02826642|MDS
36264|NCT02826642|IDH305
36265|NCT02826642|standard of care in IDH1 mutant acute myeloid leukemia
36266|NCT02826629|Sensorimotor Integration
36267|NCT02826629|Schizophrenia
36268|NCT02826629|TMS
36269|NCT02826629|Oculomotor
36270|NCT02826629|Motor Control
36271|NCT02826616|Trimetazidine
36272|NCT02826616|ST-segment elevation myocardial
36273|NCT02826616|Reperfusion injury
36274|NCT02826616|Percutaneous coronary intervention
36275|NCT02826603|Plaque psoriasis,
36276|NCT02826603|secukinumab,
36277|NCT02826603|ustekinumab
36278|NCT02826564|radiotherapy
36279|NCT02826564|immunotherapy
36280|NCT02826512|BRCA1-like
36281|NCT02826512|HER2 negative
36282|NCT02826499|Pediguard
36283|NCT02826499|Pedicular screws
36284|NCT02826499|Fluoroscopy
36285|NCT02826473|Dementia
36286|NCT02826473|Dementia screening
36287|NCT02826473|General Hospital
36288|NCT02826473|Inpatients
36289|NCT02826460|Transplant
36290|NCT02826460|Adherence
36291|NCT02826434|Breast Cancer
36292|NCT02826434|vaccine
36293|NCT02826434|immunotherapy
36294|NCT02826434|PD-L1 Inhibitor
36295|NCT02826434|triple negative breast cancer
36296|NCT02826421|Intraocular lens
36297|NCT02826395|Prostate cancer
36298|NCT02826395|diagnostic
36299|NCT02826395|imaging
36300|NCT02826395|PET/CT
36301|NCT02826395|Acetate carbon-11
36302|NCT02826369|Algorithms
36303|NCT02826369|Image Processing, Computer-Assisted/methods*
36304|NCT02826369|Magnetic Resonance Imaging/methods*
36305|NCT02826369|Data Compression
36306|NCT02826369|Breast Neoplasms
36307|NCT02826356|Angioedema
36308|NCT02826356|Emergency treatment
36309|NCT02826356|Treatment availability
36310|NCT02826356|Health Equity
36311|NCT02826343|COPD
36312|NCT02826330|Crohn's Disease
36313|NCT02826330|Healthy relatives
36314|NCT02826330|Dysbiosis
36315|NCT02826330|Biomarkers
36316|NCT02826304|Vaginal Hysterectomy
36317|NCT02826304|Laparoscopic assisted vaginal hysterectomy
36318|NCT02826304|Large uteri
36319|NCT02826291|OSNA
36320|NCT02826291|sentinel
36321|NCT02826291|lymph
36322|NCT02826291|node
36323|NCT02826291|endometrial
36324|NCT02826291|cancer
36325|NCT02826278|Newborn genitalia
36326|NCT02826278|reference charts
36327|NCT02826252|Pulmonary Arterial Hypertension (PAH)
36328|NCT02826213|Renal infusion
36329|NCT02826213|Renal infusion device
36330|NCT02826200|Transcatheter aortic valve implantation
36331|NCT02826200|Transcatheter aortic valve replacement
36332|NCT02826200|Prosthetic Cardiac Valve Thrombosis
36333|NCT02826200|Cerebrovascular Accident
36334|NCT02826200|Prosthetic Valve Malfunction
36335|NCT02826200|Four-dimensional volume rendered cardiac CT
36336|NCT02826200|Transesophageal echocardiography
36337|NCT02826200|Transthoracic echocardiography
36338|NCT02826200|Brain MRI
36339|NCT02826187|Acetabular implant
36340|NCT02826161|Neoplasms
36341|NCT02826161|Neoplasms by Site
36342|NCT02826161|Lung Neoplasms
36343|NCT02826161|Thoracic Neoplasms
36344|NCT02826161|Respiratory Tract Neoplasms
36345|NCT02826161|Bronchial Neoplasms
36346|NCT02826096|Psychiatry
36347|NCT02826096|psychological
36348|NCT02826096|psychotherapy
36349|NCT02826096|randomize
36350|NCT02826096|Biofeedback
36351|NCT02826070|Chronic Hepatitis B
36352|NCT02826031|Sodium Hyaluronate
36353|NCT02826031|mild to moderate knee osteoarthritis
36354|NCT02826018|RNAi therapeutic
36355|NCT02826018|Hepatitis B
36356|NCT02826018|Chronic Hepatitis B
36357|NCT02826018|Hepatitis B, Chronic
36358|NCT02826018|Hepatitis B Infection
36359|NCT02826018|HBV
36360|NCT02825927|Dysphagia
36361|NCT02825927|Oral screen
36362|NCT02825927|Intervention
36363|NCT02825927|Oral Health
36364|NCT02825927|Food Intake
36365|NCT02825927|Quality of life
36366|NCT02825927|Elderly
36367|NCT02825927|Short-term care facilities
36368|NCT02825914|glycopeptides
36369|NCT02825914|human microbiome
36370|NCT02825914|caseinomacropeptide
36371|NCT02825914|whey protein
36372|NCT02825914|dietary proteins
36373|NCT02825849|endometrium
36374|NCT02825849|thin uterine lining
36375|NCT02825849|uterine scarring
36376|NCT02825836|M7583
36377|NCT02825836|Bruton's Tyrosine Kinase Inhibitor
36378|NCT02825836|Lymphoma
36379|NCT02825836|Open
36380|NCT02825836|Phase I
36381|NCT02825810|breast cancer
36382|NCT02825810|long-term survival
36383|NCT02825810|motor control
36384|NCT02825810|cervical pain
36385|NCT02825797|Broadly neutralizing antibody
36386|NCT02825797|3BNC117
36387|NCT02825797|10-1074
36388|NCT02825784|potassium chronic kidney disease CKD children
36389|NCT02825758|Micronutrients
36390|NCT02825758|restricted
36391|NCT02825758|ketogenic
36392|NCT02825758|diet
36393|NCT02825758|acceptability
36394|NCT02825732|Alzheimer's disease or related disorder
36395|NCT02825732|Comorbidity
36396|NCT02825732|Charlson comorbidity index
36397|NCT02825732|Caregiver burden
36398|NCT02825732|Cohort
36399|NCT02825732|Dementia
36400|NCT02825732|Behavioral disorders
36401|NCT02825732|Functional dependency
36402|NCT02825719|Fibroid
36403|NCT02825719|Ulipristal
36404|NCT02825719|Selective progesterone receptor modulator
36405|NCT02825719|Chinese
36406|NCT02825706|Hemophilia
36407|NCT02825706|Educational Physiotherapy
36408|NCT02825706|Pain
36409|NCT02825706|Quality of life
36410|NCT02825706|Illness Behaviour
36411|NCT02825706|Elbow
36412|NCT02825680|Weight Loss
36413|NCT02825680|Body Weight Maintenance
36414|NCT02825680|Quality Improvement
36415|NCT02825667|Haemophilia
36416|NCT02825667|Ankle
36417|NCT02825667|Arthropathy
36418|NCT02825667|Pain
36419|NCT02825667|Range of motion
36420|NCT02825667|Myofascial techniques
36421|NCT02825654|Pulmonary
36422|NCT02825654|Lung
36423|NCT02825654|Military and environmental exposures
36424|NCT02825654|Epidemiologic
36425|NCT02825654|Observational
36426|NCT02825654|Interview or questionnaire
36427|NCT02825654|Deployment related
36428|NCT02825654|Enduring Freedom
36429|NCT02825654|Iraqi Freedom
36430|NCT02825615|radial artery cannulation
36431|NCT02825615|ultrasound guided
36432|NCT02825615|first success rate
36433|NCT02825615|systolic blood pressure
36434|NCT02825615|shock
36435|NCT02825602|Vietnam veteran
36436|NCT02825602|aging
36437|NCT02825602|health
36438|NCT02825602|War Injury
36439|NCT02825602|Conventional Warfare
36440|NCT02825602|Toxic Effect
36441|NCT02825602|Chemical
36442|NCT02825589|BIA
36443|NCT02825589|chronic hemodialysis
36444|NCT02825589|sleep quality
36445|NCT02825550|Hepatoma
36446|NCT02825550|Transcatheter Arterial chemo-embolization
36447|NCT02825550|microsphere
36448|NCT02825511|basal cell carcinoma, histological diagnosis, prognostic impact
36449|NCT02825472|Congenital Heart Disease
36450|NCT02825472|Sport
36451|NCT02825472|Exercise training
36452|NCT02825459|abstinence
36453|NCT02825459|abuse liability
36454|NCT02825459|electronic cigarette
36455|NCT02825459|e-cigarette
36456|NCT02825459|electronic nicotine delivery device
36457|NCT02825459|harm reduction
36458|NCT02825459|nicotine
36459|NCT02825459|nicotine dependence
36460|NCT02825459|smoking
36461|NCT02825459|smoking cessation
36462|NCT02825459|tobacco
36463|NCT02825459|vape
36464|NCT02825459|vaping
36465|NCT02825459|withdrawal
36466|NCT02825446|radio frequency denervation
36467|NCT02825446|tibial arteries
36468|NCT02825446|atherosclerosis of the peripheral arteries
36469|NCT02825381|Arthroplasty
36470|NCT02825381|Hip
36471|NCT02825355|robotic surgery procedure
36472|NCT02825355|indocyanine green
36473|NCT02825355|sentinel lymph node mapping
36474|NCT02825342|Gastroesophageal Reflux Disease (GERD)
36475|NCT02825342|Proton Pump Inhibitor (PPI)
36476|NCT02825316|Crohn's disease
36477|NCT02825316|inflammatory bowel diseases
36478|NCT02825316|Mediterranean diet
36479|NCT02825316|microbiome
36480|NCT02825303|postural changes
36481|NCT02825303|Height adjustable desk
36482|NCT02825303|Prolonged sitting
36483|NCT02825303|Cognitive performance
36484|NCT02825290|Frozen-thawed embryo transfer (FET)
36485|NCT02825290|Luteal support
36486|NCT02825290|Progesterone
36487|NCT02825290|Natural cycle
36488|NCT02825290|Cryopreservation
36489|NCT02825290|IVF
36490|NCT02825290|hCG
36491|NCT02825290|GnRH-Agonist
36492|NCT02825290|Pregnancy rate
36493|NCT02825277|3D Power Doppler
36494|NCT02825277|uteroplacental vascularization
36495|NCT02825277|preeclampsia
36496|NCT02825277|intra-uterine growth restriction
36497|NCT02825277|placental morphology
36498|NCT02825264|Glaucoma Drainage Device
36499|NCT02825264|STARflo
36500|NCT02825238|exercise
36501|NCT02825238|osteoarthritis
36502|NCT02825238|knee
36503|NCT02825238|patellofemoral pain
36504|NCT02825225|Prostatic Neoplasms
36505|NCT02825225|Biopsy
36506|NCT02825225|Anesthesia
36507|NCT02825225|Detection
36508|NCT02825212|Hepatitis C
36509|NCT02825212|Cryoglobulinemia
36510|NCT02825160|Iloprost
36511|NCT02825160|Ventavis
36512|NCT02825160|Prostacycline analogue
36513|NCT02825160|Pulmonary arterial hypertension
36514|NCT02825160|Japan
36515|NCT02825160|Post-marketing surveillance
36516|NCT02825147|pegaspargase,methotrexate
36517|NCT02825134|heart valve disease
36518|NCT02825134|valvular bioprosthesis
36519|NCT02825134|aortic valve replacement
36520|NCT02825134|Randomized clinical trial
36521|NCT02825108|human chorionic gonadotropin (hCG), implantation rate intrauterine hCG clinical pregnancy rate frozen embryo transfer cycles
36522|NCT02825095|malignant pleural effusion,talc pleurodesis,quality of life
36523|NCT02825082|Emergency general surgery
36524|NCT02825082|Geriatric
36525|NCT02825082|Outcomes
36526|NCT02825082|Frailty
36527|NCT02825043|COPD
36528|NCT02825004|Burnout
36529|NCT02825004|Health Care Workers
36530|NCT02825004|Coping Skills
36531|NCT02825004|Clinical Trial
36532|NCT02824952|Tagrisso
36533|NCT02824952|AZD9291
36534|NCT02824952|EGFRm
36535|NCT02824952|NSCLC
36536|NCT02824900|Vibration Stimuli
36537|NCT02824900|Contraversive Pusher Syndrome
36538|NCT02824887|Electroacupuncture
36539|NCT02824887|Deep needling
36540|NCT02824887|Lumbar disc herniation five points
36541|NCT02824887|Long term effect
36542|NCT02824887|Prospective cohort study
36543|NCT02824848|congenital muscular torticollis
36544|NCT02824848|infants
36545|NCT02824848|passive stretching
36546|NCT02824848|perception-action approach
36547|NCT02824822|Sudden Unexpected Death in Epilepsy
36548|NCT02824822|SUDEP
36549|NCT02824822|Sudden Cardiac Arrest
36550|NCT02824822|Sudden Cardiac Death
36551|NCT02824822|Sleep
36552|NCT02824822|Ion channel disease
36553|NCT02824822|Long QT syndrome
36554|NCT02824822|Brugada
36555|NCT02824822|Catecholaminergic Polymorphic Ventricular Tachycardia
36556|NCT02824809|hypogonadism
36557|NCT02824809|Chronic Obstructive Pulmonary Disease
36558|NCT02824809|Severity of Illness Index
36559|NCT02824809|Testosterone
36560|NCT02824796|ADHD
36561|NCT02824783|colorectal surgery
36562|NCT02824783|enhanced recovery
36563|NCT02824757|interstitial lung disease
36564|NCT02824757|glucocorticcoid
36565|NCT02824757|glucose
36566|NCT02824757|continuous glucose monitor
36567|NCT02824744|Bronchiolitis
36568|NCT02824744|High flow nasal canula
36569|NCT02824731|brain tumors
36570|NCT02824731|proton radiotherapy
36571|NCT02824731|photon radiotherapy
36572|NCT02824718|Hypoparathyroidism
36573|NCT02824718|PTH(1-34)
36574|NCT02824718|Thiazides
36575|NCT02824718|Hypercalciuria
36576|NCT02824718|Calcium sensing receptor
36577|NCT02824705|Heart
36578|NCT02824705|Abnormality
36579|NCT02824705|Thoracic Aorta
36580|NCT02824705|Pericardium
36581|NCT02824679|Normal labour
36582|NCT02824679|Augmentation of labour
36583|NCT02824679|Hyoscine butylbromide
36584|NCT02824653|acute GVHD
36585|NCT02824653|chronic GVHD
36586|NCT02824653|steroid-refractory
36587|NCT02824653|Mesenchymal Stem Cells
36588|NCT02824640|Addiction
36589|NCT02824640|Adherence
36590|NCT02824640|Adverse Effects
36591|NCT02824640|Direct Acting Antiviral Agent
36592|NCT02824640|Chronic Hepatitis C
36593|NCT02824640|Resistance Development
36594|NCT02824640|Methadone Clinic
36595|NCT02824640|Primary Care
36596|NCT02824640|Directly Observed Therapy
36597|NCT02824640|Randomized Controlled Trial
36598|NCT02824640|Resistance
36599|NCT02824640|Reinfection
36600|NCT02824640|Treatment Outcome
36601|NCT02824640|Patient Navigation
36602|NCT02824640|Multi-Site
36603|NCT02824640|Liver Disease
36604|NCT02824640|Intervention
36605|NCT02824640|Sustained Viral Response
36606|NCT02824588|Pain
36607|NCT02824588|Working memory
36608|NCT02824575|breast cancer
36609|NCT02824575|chemotherapy
36610|NCT02824575|metastasis
36611|NCT02824575|tumor micro-environment
36612|NCT02824549|Flash glucose monitoring
36613|NCT02824549|skin reactions
36614|NCT02824549|usability
36615|NCT02824549|accuracy
36616|NCT02824536|3BNC117
36617|NCT02824536|10-1074
36618|NCT02824536|Broadly neutralizing antibody
36619|NCT02824536|HIV Prevention
36620|NCT02824523|asthma
36621|NCT02824523|nasal polyps
36622|NCT02824523|aspirin sensitivity
36623|NCT02824523|AERD
36624|NCT02824484|Guided written disclosure protocol
36625|NCT02824484|Emotional disclosure
36626|NCT02824484|Meaning
36627|NCT02824484|Post-Traumatic Growth
36628|NCT02824484|Cancer
36629|NCT02824471|Sickle Cell Disease
36630|NCT02824471|Biofluidic Chip Technology
36631|NCT02824458|EGFR tyrosine kinase inhibitors
36632|NCT02824458|VEGFR inhibitor
36633|NCT02824458|NSCLC
36634|NCT02824406|Sickle Cell Anemia
36635|NCT02824406|Cerebrovascular Reserve
36636|NCT02824406|Perfusion
36637|NCT02824406|Vasculopathy
36638|NCT02824406|Magnetic Resonance Imaging
36639|NCT02824393|Mesenchymal stem cell
36640|NCT02824393|Chronic autoimmune urticaria
36641|NCT02824367|Parkinson
36642|NCT02824367|Perfectionism
36643|NCT02824341|Parkinson 's disease
36644|NCT02824341|REM sleep behavior disorder
36645|NCT02824341|Reward system
36646|NCT02824341|Functional MRI
36647|NCT02824289|skin cancer
36648|NCT02824289|prevention
36649|NCT02824289|worksite
36650|NCT02824289|policy
36651|NCT02824263|obstructive sleep apnea
36652|NCT02824263|CPAP
36653|NCT02824263|metabolism
36654|NCT02824250|Migraine
36655|NCT02824250|Mindfulness
36656|NCT02824250|MBSR
36657|NCT02824224|levonorgestrel
36658|NCT02824224|breakthrough bleeding
36659|NCT02824198|Dengue Hemorrhagic Fever
36660|NCT02824198|Dengue Virus
36661|NCT02824198|CYD Dengue Vaccine
36662|NCT02824185|FCH-PET/MRI
36663|NCT02824185|primary HCC
36664|NCT02824185|curative treatment
36665|NCT02824185|resection
36666|NCT02824185|thermo-ablation
36667|NCT02824185|transplantation
36668|NCT02824172|Cast immobilization
36669|NCT02824172|Complete rest
36670|NCT02824172|Osgood Schlatter
36671|NCT02824159|ibrutinib
36672|NCT02824159|idelalisib
36673|NCT02824159|side effect
36674|NCT02824159|pharmacokinetic
36675|NCT02824159|plasma balance mean concentration
36676|NCT02824146|atelectasis
36677|NCT02824146|children
36678|NCT02824146|lung ultrasound
36679|NCT02824146|lung recruitment
36680|NCT02824133|Glioma grade III
36681|NCT02824133|Glioma grade IV
36682|NCT02824133|Glioma recurrent
36683|NCT02824133|IDHwt
36684|NCT02824133|FGFR-TACC fusion
36685|NCT02824120|ischemic heart disease
36686|NCT02824120|laugh therapy
36687|NCT02824094|Expanded Access Protocol
36688|NCT02824094|crizotinib
36689|NCT02824094|Xalkori
36690|NCT02824094|ROS1
36691|NCT02824094|Japanese
36692|NCT02824094|A8081064
36693|NCT02824081|Psychiatry
36694|NCT02824081|Depressive disorder
36695|NCT02824081|Suicide
36696|NCT02824081|Inflammation
36697|NCT02824042|Phase 1
36698|NCT02824042|Solid tumors
36699|NCT02824042|Mesothelin
36700|NCT02824042|Itraconazole
36701|NCT02824042|PK DDI
36702|NCT02824042|ECG thorough QTC
36703|NCT02823977|ketamine
36704|NCT02823977|dexmedetomidine
36705|NCT02823977|alcohol
36706|NCT02823964|exocrine pancreatic insufficiency
36707|NCT02823964|cystic fibrosis
36708|NCT02823964|pancreatic enzyme replacement therapy
36709|NCT02823912|Capsaicin
36710|NCT02823912|Dyslipidemia
36711|NCT02823912|Inflammatory cytokines
36712|NCT02823899|cholera vaccine
36713|NCT02823899|hikojima serotype
36714|NCT02823899|randomized trial
36715|NCT02823899|immunogenicity
36716|NCT02823886|myocardial infarction
36717|NCT02823886|MRI
36718|NCT02823886|inflammatory biomarkers
36719|NCT02823873|Hypertension
36720|NCT02823873|Pregnant
36721|NCT02823873|Preeclampsia
36722|NCT02823873|Gestational Hypertension
36723|NCT02823873|Blood Pressure
36724|NCT02823873|Pregnant Women
36725|NCT02823873|Postpartum Women
36726|NCT02823860|Peritoneal carcinomatosis
36727|NCT02823860|Biobanking
36728|NCT02823860|Biospecimen research
36729|NCT02823860|Prospective clinical database
36730|NCT02823860|Tissue banking
36731|NCT02823860|Quality of Life
36732|NCT02823860|various histological subtypes
36733|NCT02823847|Malignant neoplasms of mesothelial and soft tissue
36734|NCT02823847|Human immunodeficiency virus
36735|NCT02823847|HIV
36736|NCT02823847|Carbon monoxide test
36737|NCT02823847|Self-help materials
36738|NCT02823847|Visual Oral Screening Examination
36739|NCT02823847|Direct Fluorescent Oral Visualization Examination
36740|NCT02823847|Oral Biopsy
36741|NCT02823834|osteoarthritis
36742|NCT02823834|avascular necrosis
36743|NCT02823834|ankylosis
36744|NCT02823834|protrusio acetabuli
36745|NCT02823834|painful hip dysplasia
36746|NCT02823834|rheumatoid arthritis
36747|NCT02823834|correction of functional deformity
36748|NCT02823821|End-Stage Kidney Disease
36749|NCT02823821|Hemodialysis
36750|NCT02823821|Dialysate
36751|NCT02823821|Sodium
36752|NCT02823821|Cluster-randomisation
36753|NCT02823795|Patient participation
36754|NCT02823795|Empowerment
36755|NCT02823795|Medication management
36756|NCT02823795|Symptom management
36757|NCT02823795|Self determination theory
36758|NCT02823795|Motivational Interviewing
36759|NCT02823782|Laminar HP
36760|NCT02823782|Complex HP
36761|NCT02823769|clinical study
36762|NCT02823769|dental fillings
36763|NCT02823743|recurrent pregnancy loss, Habitual abortion
36764|NCT02823704|Sepsis
36765|NCT02823704|Chest pain
36766|NCT02823704|Abdominal pain
36767|NCT02823704|Electrolyte disturbances
36768|NCT02823704|Stroke
36769|NCT02823704|Triage
36770|NCT02823704|Risk for death
36771|NCT02823691|NETs
36772|NCT02823665|gastric bypass surgery
36773|NCT02823665|Hypoglycemia
36774|NCT02823665|sleeve gastrectomy
36775|NCT02823665|glucose tolerance
36776|NCT02823613|ENaC
36777|NCT02823613|Exosomes
36778|NCT02823613|Urinary biomarker
36779|NCT02823613|Salt regulation
36780|NCT02823600|retinal screening
36781|NCT02823600|outpatient dialysis
36782|NCT02823587|Bronchiectasis
36783|NCT02823587|Mucociliary clearance
36784|NCT02823587|Exercise
36785|NCT02823587|Inflammation
36786|NCT02823535|military
36787|NCT02823444|Magnetic Resonance Imaging
36788|NCT02823444|Magnetic Resonance Angiography
36789|NCT02823431|voiding efficiency
36790|NCT02823431|detrusor underactivity
36791|NCT02823431|urodynamics
36792|NCT02823418|primipara
36793|NCT02823418|childbirth
36794|NCT02823418|neuraxial labor analgesia
36795|NCT02823418|postpartum depression
36796|NCT02823405|Advance malignancy
36797|NCT02823392|unexpected difficult bag mask ventilation
36798|NCT02823392|difficult intubation
36799|NCT02823392|predictors
36800|NCT02823392|pediatric anesthesia
36801|NCT02823379|physical activity
36802|NCT02823379|overweight
36803|NCT02823379|obese
36804|NCT02823379|exercise
36805|NCT02823379|women
36806|NCT02823379|African American
36807|NCT02823379|Smartphone
36808|NCT02823379|cardiovascular disease risk
36809|NCT02823366|PBC
36810|NCT02823366|UDCA
36811|NCT02823366|Fenofibrate
36812|NCT02823353|PBC
36813|NCT02823353|UDCA
36814|NCT02823353|Fenofibrate
36815|NCT02823288|intimate partner violence
36816|NCT02823288|masculinity
36817|NCT02823288|community mobilization
36818|NCT02823288|social intervention
36819|NCT02823288|rape
36820|NCT02823262|Breast Cancer
36821|NCT02823262|Estrogen Receptor Positive Breast Cancer
36822|NCT02823262|Node-negative Breast Cancer
36823|NCT02823262|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
36824|NCT02823236|Keloid
36825|NCT02823236|Scar
36826|NCT02823223|Endobronchial Valve
36827|NCT02823197|determinants
36828|NCT02823197|active transport
36829|NCT02823197|intervention
36830|NCT02823197|adolescents
36831|NCT02823184|Myeloproliferative neoplasms
36832|NCT02823184|Endoplasmic reticulum stress
36833|NCT02823171|Bioequivalence Study
36834|NCT02823171|Healthy subjects
36835|NCT02823158|Parkinson Disease
36836|NCT02823158|Morbus Parkinson
36837|NCT02823158|Basal Ganglia
36838|NCT02823158|Pallidal Stimulation
36839|NCT02823145|seizure
36840|NCT02823145|tonic clonic
36841|NCT02823145|epilepsy
36842|NCT02823145|myoclonic
36843|NCT02823145|encephalopathy
36844|NCT02823119|Mini-hysteroscopy
36845|NCT02823119|Office hysteroscopy
36846|NCT02823119|Pain
36847|NCT02823093|vascular calcification
36848|NCT02823093|aortic calcification
36849|NCT02823093|vitamin K antagonist
36850|NCT02823093|fluindione
36851|NCT02823093|warfarin
36852|NCT02823093|matrix gla protein
36853|NCT02823067|Pemphigoid
36854|NCT02823067|Bullous pemphigoid
36855|NCT02823067|Pruritus
36856|NCT02823067|Senile pruritus
36857|NCT02823067|Neuropsychiatric symptoms
36858|NCT02823054|elective surgery
36859|NCT02823054|CABG
36860|NCT02823054|One-lung ventilation
36861|NCT02823054|EZ Blockers
36862|NCT02823054|pleural effusion
36863|NCT02823041|cognitive training
36864|NCT02823041|aerobic exercise
36865|NCT02823041|neurotrophic factors
36866|NCT02823041|randomized controlled trial
36867|NCT02823041|functional outcome
36868|NCT02823028|Smoking
36869|NCT02823028|Social Media
36870|NCT02823028|Twitter
36871|NCT02823028|Behavior Change
36872|NCT02823028|Social Support
36873|NCT02822989|Lupus Erythematosus, Systemic
36874|NCT02822989|Musculoskeletal Pain
36875|NCT02822989|Inflammation
36876|NCT02822963|Transurethral resection of the prostate
36877|NCT02822963|Anticoagulants
36878|NCT02822963|Platelet aggregation inhibitors
36879|NCT02822911|elderly
36880|NCT02822911|chronic alcoholism
36881|NCT02822911|Carbohydrate Deficient Transferrin
36882|NCT02822911|Biological Detection / Diagnosis
36883|NCT02822898|Maintenance
36884|NCT02822898|Intravenous solutions
36885|NCT02822898|Intravenous fluids
36886|NCT02822898|Tonicity
36887|NCT02822898|Potassium
36888|NCT02822898|Sodium
36889|NCT02822898|Fluid retention
36890|NCT02822872|infertility
36891|NCT02822872|stress
36892|NCT02822872|scalp hair
36893|NCT02822872|cortisol
36894|NCT02822846|Lung ultrasound
36895|NCT02822846|Sliding lung
36896|NCT02822846|Probe position
36897|NCT02822755|Exercise
36898|NCT02822755|Adherence
36899|NCT02822755|Physical Therapy
36900|NCT02822703|smoking cessation
36901|NCT02822703|tobacco use disorder
36902|NCT02822703|delay discounting
36903|NCT02822703|repetitive transcranial magnetic stimulation
36904|NCT02822703|relapse prevention
36905|NCT02822690|palliative care
36906|NCT02822690|Quality of dying
36907|NCT02822664|Brain, pedophilia, neuroimaging
36908|NCT02822638|Myocardial infarction
36909|NCT02822638|biomarkers
36910|NCT02822638|STEMI
36911|NCT02822625|Capsaicin
36912|NCT02822625|QUTENZA®
36913|NCT02822625|Hypnosis
36914|NCT02822625|Peripheral Neuropathic
36915|NCT02822612|optical coherence tomography
36916|NCT02822612|optical imaging
36917|NCT02822612|retinal imaging
36918|NCT02822599|CBP, congenital heart defects, cardiopulmonary bypass
36919|NCT02822586|CD30-positive
36920|NCT02822586|Stage IB to Stage IVA
36921|NCT02822560|Endovascular Aortic Repair (EVAR)
36922|NCT02822560|percutaneous EVAR (pEVAR)
36923|NCT02822560|cost analysis
36924|NCT02822560|procedure time
36925|NCT02822521|Rheumatoid Arthritis
36926|NCT02822521|Mobile Health
36927|NCT02822521|Pain
36928|NCT02822521|Arthritis
36929|NCT02822495|Lymphoproliferative Disorders
36930|NCT02822495|Epstein-Barr Virus
36931|NCT02822495|Epstein-Barr Viremia
36932|NCT02822495|Post Transplant Lymphoproliferative Disorder
36933|NCT02822495|EBV-PTLD
36934|NCT02822495|Solid Organ Transplant
36935|NCT02822495|Hematopoietic Cell Transplant
36936|NCT02822495|primary immunodeficiency
36937|NCT02822495|acquired immunodeficiency
36938|NCT02822495|Epstein-Barr Virus Lymphoma
36939|NCT02822469|TMD Infrared Thermography Physical Therapy Modalities
36940|NCT02822456|dysphagia
36941|NCT02822456|intermittent tube
36942|NCT02822456|individual 3D printed guiding tube
36943|NCT02822430|Pain
36944|NCT02822430|Psychiatric disorders
36945|NCT02822417|Recover time
36946|NCT02822404|kidney toxicity
36947|NCT02822378|Postmenopausal Osteoporosis
36948|NCT02822378|Human
36949|NCT02822378|Female
36950|NCT02822378|Non-pharmacologic therapy
36951|NCT02822326|Leukemia
36952|NCT02822326|CART CD19
36953|NCT02822326|Chemotherapy Resistant
36954|NCT02822326|Chemotherapy Refractory
36955|NCT02822326|CD19 +
36956|NCT02822326|Lymphoma
36957|NCT02822235|Drug Therapy
36958|NCT02822222|essential hypertension
36959|NCT02822222|hypertension
36960|NCT02822222|high blood pressure
36961|NCT02822222|cardiovascular diseases
36962|NCT02822222|RMJH-111b
36963|NCT02822222|magnesium
36964|NCT02822222|magnesium citrate
36965|NCT02822222|calcium channel blockers
36966|NCT02822222|vasodilators
36967|NCT02822222|antihypertensive agents
36968|NCT02822209|coordinating nurse of thoracic oncology
36969|NCT02822209|quality of care in thoracic oncology
36970|NCT02822209|lung cancer quality of life
36971|NCT02822144|ischemic stroke
36972|NCT02822144|thrombectomy
36973|NCT02822144|anesthesia
36974|NCT02822144|sedation
36975|NCT02822118|IBS-D; Chang'an I Recipe; Placebo
36976|NCT02822066|Effectivity
36977|NCT02822066|safety
36978|NCT02822066|irreversible electroporation
36979|NCT02822066|liver
36980|NCT02822066|pancreas
36981|NCT02822053|Ultrasonography-guided Laser Ablation
36982|NCT02822040|Root Resorption
36983|NCT02822040|Panoramic Radiograph
36984|NCT02822001|Sugammadex
36985|NCT02821975|Depression
36986|NCT02821975|Cognitive function
36987|NCT02821975|Work
36988|NCT02821962|Sedentary behaviour
36989|NCT02821949|Non Small Cells Lung Cancer
36990|NCT02821949|Procalcitonin
36991|NCT02821936|positron emission tomography
36992|NCT02821936|parametric imaging
36993|NCT02821936|lung cancer
36994|NCT02821884|Stroke
36995|NCT02821884|Transcranial direct current stimulation
36996|NCT02821884|Neuromuscular electrical stimulation
36997|NCT02821884|upper extremity motor recovery
36998|NCT02821832|Tuberculosis
36999|NCT02821832|PET/CT Scanning
37000|NCT02821832|Immunological Markers
37001|NCT02821832|4-Month Treatment Completion
37002|NCT02821819|ovarian stimulation
37003|NCT02821819|random
37004|NCT02821819|egg donation
37005|NCT02821819|antagonist
37006|NCT02821819|gnrh agonist trigger
37007|NCT02821806|Normal Volunteer
37008|NCT02821806|Donation
37009|NCT02821806|Adoptive T Cell Therapy
37010|NCT02821806|Peripheral Blood Mononuclear Cells
37011|NCT02821780|Biospecimen Procurement
37012|NCT02821780|Laboratory Research Specimens
37013|NCT02821767|Pathogenesis
37014|NCT02821767|Ocular Disorders
37015|NCT02821767|Eye
37016|NCT02821767|Eye Diseases
37017|NCT02821754|Liver Cancer
37018|NCT02821754|Monoclonal Antibody
37019|NCT02821754|CTLA-4
37020|NCT02821754|Ablative Therapy
37021|NCT02821741|Sensory Stimulation
37022|NCT02821728|Prostate
37023|NCT02821728|Sulphate
37024|NCT02821728|ATP
37025|NCT02821728|PTEN
37026|NCT02821702|placenta accreta
37027|NCT02821702|cesarean section
37028|NCT02821702|artery embolization
37029|NCT02821689|Dermatopolymyositis
37030|NCT02821689|Interstitial lung disease
37031|NCT02821689|Pirfenidone
37032|NCT02821637|teens
37033|NCT02821637|effort rehabilitation
37034|NCT02821637|quality of life
37035|NCT02821637|wellbeing
37036|NCT02821637|physical skills assessment
37037|NCT02821611|Student Stress
37038|NCT02821611|Meditation
37039|NCT02821611|Sleep Quality
37040|NCT02821611|Blood Pressure
37041|NCT02821559|Colorectal cancer
37042|NCT02821559|raltitrexed
37043|NCT02821559|oxaliplatin
37044|NCT02821559|bevacizumab
37045|NCT02821559|biweekly
37046|NCT02821559|triweekly
37047|NCT02821520|Polypoidal Choroidal Vasculopathy
37048|NCT02821520|Photodynamic Therapy
37049|NCT02821520|Conbercept
37050|NCT02821520|Efficacy
37051|NCT02821520|Safety
37052|NCT02821520|vascular endothelial growth factor
37053|NCT02821494|HPV
37054|NCT02821494|Vaccination
37055|NCT02821494|Immunotherapy
37056|NCT02821481|Neuromuscular
37057|NCT02821481|Supplementation
37058|NCT02821481|Elderly
37059|NCT02821455|Isoflurane
37060|NCT02821455|Sevoflurane
37061|NCT02821455|Bispectral Index
37062|NCT02821455|Pulmonary Surgical Procedures
37063|NCT02821442|Electroacupuncture
37064|NCT02821442|Neuropathic Pain
37065|NCT02821442|Chemotherapy Induced Peripheral Neuropathy
37066|NCT02821429|Respiratory weaning
37067|NCT02821429|Pulmonary ventilation
37068|NCT02821416|asthma
37069|NCT02821390|intravitreal injection
37070|NCT02821390|pain
37071|NCT02821390|non-steroidal anti-inflammatory drugs
37072|NCT02821390|anti-VEGF
37073|NCT02821390|nepafenac
37074|NCT02821377|cirrhosis
37075|NCT02821377|ascites
37076|NCT02821377|immunology
37077|NCT02821377|inflammation
37078|NCT02821377|nutrition
37079|NCT02821351|Afib
37080|NCT02821338|Bioequivalence
37081|NCT02821338|Lamotrigine Extended Release
37082|NCT02821338|Generic
37083|NCT02821338|Pharmacokinetic
37084|NCT02821299|Laryngeal transplantation
37085|NCT02821299|Laryngeal function
37086|NCT02821299|Swallowing
37087|NCT02821299|Voice production
37088|NCT02821299|Respiration
37089|NCT02821299|Quality of life
37090|NCT02821247|Treatment Naïve Patients
37091|NCT02821234|Insomnia
37092|NCT02821234|Hyperarousal
37093|NCT02821208|Psychogenic nonepileptic seizure, quality of life
37094|NCT02821169|sinus surgery
37095|NCT02821169|sphenopalatin ganglion
37096|NCT02821169|ropivacaine
37097|NCT02821169|local anesthesia
37098|NCT02821143|Telemedicine
37099|NCT02821143|Nursing Home
37100|NCT02821143|Hospitalization
37101|NCT02821130|Dyspnea
37102|NCT02821130|Exercise
37103|NCT02821130|Cystic Fibrosis
37104|NCT02821117|Diabetes Mellitus, Paediatric
37105|NCT02821117|Sensing Technology
37106|NCT02821104|Complement
37107|NCT02821104|endothelial function
37108|NCT02821104|insulin sensitivity
37109|NCT02821104|adolescents
37110|NCT02821104|inflammation
37111|NCT02821078|phase-contrast MRI
37112|NCT02821078|blood flow
37113|NCT02821078|velocity mapping
37114|NCT02821078|abdominal imaging
37115|NCT02821078|Quantitative MRI
37116|NCT02821039|Idiopathic Pulmonary Fibrosis, Usual Interstitial Pneumonia
37117|NCT02821000|PD1
37118|NCT02821000|PD-1
37119|NCT02821000|PDL1
37120|NCT02821000|PD-L1
37121|NCT02820987|Septic shock, Beta Lactams, Extended infusion, PK/PD
37122|NCT02820961|Breast Neoplasms
37123|NCT02820961|Breast Diseases
37124|NCT02820961|Exemestane
37125|NCT02820961|Protein Kinase Inhibitors
37126|NCT02820961|Aromatase Inhibitors
37127|NCT02820961|entinostat
37128|NCT02820961|Cancer of the Breast
37129|NCT02820961|Metastatic Breast Cancer
37130|NCT02820961|Hormone Receptor Positive Breast Cancer
37131|NCT02820961|Estrogen Receptor
37132|NCT02820961|ER+ Breast Cancer
37133|NCT02820961|Breast Tumor
37134|NCT02820935|Cytochrome P450
37135|NCT02820935|Pharmacokinetics
37136|NCT02820935|CC-220
37137|NCT02820935|Healthy Subjects
37138|NCT02820922|Emergency orthopedic surgery
37139|NCT02820922|anesthesia
37140|NCT02820922|general anesthesia
37141|NCT02820922|regional anesthesia
37142|NCT02820909|ultrasound guidance
37143|NCT02820909|emergency wards
37144|NCT02820909|arterial and venous catheters
37145|NCT02820909|femoral
37146|NCT02820909|complications
37147|NCT02820870|Cardiovascular Disease
37148|NCT02820870|Quality Improvement
37149|NCT02820870|Decision Support Tool
37150|NCT02820870|Performance Measurement
37151|NCT02820870|Primary Prevention
37152|NCT02820857|Gastroentero-pancreatic neuroendocrine carcinomas
37153|NCT02820857|Second-line treatment
37154|NCT02820857|Bevacizumab
37155|NCT02820857|Folfiri
37156|NCT02820844|Overactive bladder
37157|NCT02820844|Botulinum toxin type A
37158|NCT02820844|Urinary incontinence
37159|NCT02820831|Frail Elderly
37160|NCT02820831|Peripheral Vascular Surgery
37161|NCT02820831|Risk Assessment
37162|NCT02820831|Functional status
37163|NCT02820818|thoracic magnetic resonance imaging
37164|NCT02820818|pulmonary function test
37165|NCT02820805|children
37166|NCT02820805|dietary carbohydrates
37167|NCT02820805|solanum tuberosum
37168|NCT02820805|cognition
37169|NCT02820805|memory
37170|NCT02820805|emotions
37171|NCT02820805|blood glucose
37172|NCT02820779|Willis
37173|NCT02820779|Intracranial aneurysms
37174|NCT02820766|Posterior Stabilized Knee
37175|NCT02820766|Total Knee Arthroscopy
37176|NCT02820766|Journey II BCS
37177|NCT02820753|Universal Medication Schedule
37178|NCT02820753|Health Literacy
37179|NCT02820753|Medication adherence
37180|NCT02820740|Epilepsy
37181|NCT02820740|Medial Temporal Lobe Epilepsy
37182|NCT02820740|Seizure
37183|NCT02820740|NeuroBlate
37184|NCT02820740|LITT
37185|NCT02820740|Quality of Life
37186|NCT02820701|Osteopathic Manipulation
37187|NCT02820701|Somatic Dysfunction
37188|NCT02820701|Musculoskeletal Ultrasound
37189|NCT02820688|Local Anesthtetics
37190|NCT02820688|Nerve Block
37191|NCT02820688|Bupivacaine
37192|NCT02820688|Prilocaine
37193|NCT02820675|quality improvement
37194|NCT02820675|routine data
37195|NCT02820675|risk adjustment
37196|NCT02820675|sepsis, severe sepsis, septic shock
37197|NCT02820675|quality of coding
37198|NCT02820649|Exercise training
37199|NCT02820649|Endothelial function
37200|NCT02820623|implementation
37201|NCT02820623|fidelity
37202|NCT02820623|cognitive behavioral therapy
37203|NCT02820558|Neuropeptide
37204|NCT02820558|Therapy
37205|NCT02820558|Onset
37206|NCT02820545|patient safety culture
37207|NCT02820545|hospital
37208|NCT02820545|patient perception
37209|NCT02820545|healthcare professional perception
37210|NCT02820545|sociological
37211|NCT02820545|qualitative
37212|NCT02820545|questionnaire construct
37213|NCT02820545|psychometrics
37214|NCT02820519|Neuropathic pain
37215|NCT02820519|Loxapine
37216|NCT02820519|Antipsychotics
37217|NCT02820519|Co-Analgesics
37218|NCT02820519|Tolerability
37219|NCT02820519|Analgesic efficacy
37220|NCT02820506|robotic surgery procedures
37221|NCT02820506|indocyanine green
37222|NCT02820506|sentinel lymph node mapping
37223|NCT02820480|stroke
37224|NCT02820480|rehabilitation
37225|NCT02820480|robotics
37226|NCT02820480|cerebral palsy
37227|NCT02820480|therapy
37228|NCT02820467|Indocyanine
37229|NCT02820467|Angiography
37230|NCT02820467|Ischemia
37231|NCT02820454|AGuIX
37232|NCT02820454|polysiloxane gadolinium-chelates based nanoparticles
37233|NCT02820415|aneuploidy
37234|NCT02820415|next generation sequencing
37235|NCT02820415|oocyte vitrification
37236|NCT02820415|preimplantation genetic diagnosis
37237|NCT02820415|preimplantation genetic screening
37238|NCT02820402|Pregnancy
37239|NCT02820402|Obesity
37240|NCT02820402|Diet
37241|NCT02820402|Maternal/child health
37242|NCT02820402|Asthma/allergy
37243|NCT02820402|Air pollution
37244|NCT02820402|Epigenetics
37245|NCT02820402|Cognition/behavior
37246|NCT02820376|4D computed tomography
37247|NCT02820376|Kidney function tests
37248|NCT02820376|Living Donors
37249|NCT02820363|wound
37250|NCT02820363|open fracture
37251|NCT02820363|fracture
37252|NCT02820363|tibial
37253|NCT02820350|Acute Renal Failure
37254|NCT02820350|Acute kidney injury
37255|NCT02820350|Continuous Renal Replacement Therapy
37256|NCT02820350|Selective cytopheretic device
37257|NCT02820350|Pediatric
37258|NCT02820311|Thorough QT (TQT)
37259|NCT02820311|cardiac safety
37260|NCT02820272|Cold water
37261|NCT02820272|Negative pressure wound therapy
37262|NCT02820272|pain
37263|NCT02820246|nutrition assessment
37264|NCT02820246|nutrition therapy
37265|NCT02820246|nutrition surveys
37266|NCT02820246|patient outcome assessment
37267|NCT02820246|outcome and process assessment
37268|NCT02820246|benchmarking
37269|NCT02820246|risk assessment
37270|NCT02820246|scoring system
37271|NCT02820220|Knowledge
37272|NCT02820220|Programs
37273|NCT02820220|Patients
37274|NCT02820220|Students
37275|NCT02820220|Nurses
37276|NCT02820207|Carotid Artery Plaque
37277|NCT02820207|Contrast Enhanced Ultrasound
37278|NCT02820207|Plague Histopathology
37279|NCT02820181|tracheostomy ties
37280|NCT02820168|Designing
37281|NCT02820168|Patient-Oriented
37282|NCT02820168|Prescriptions
37283|NCT02820155|Alzheimer's disease,cognitive function
37284|NCT02820142|biomarker
37285|NCT02820142|Renal Function
37286|NCT02820129|polypharmacy
37287|NCT02820129|wallet card
37288|NCT02820129|medication
37289|NCT02820129|self-efficacy
37290|NCT02820129|patient enablement
37291|NCT02820103|Patient delay
37292|NCT02820103|Behaviour change
37293|NCT02820103|Intervention Modelling Experiment
37294|NCT02820090|Inflammatory Factor
37295|NCT02820090|Mechanical Ventilation
37296|NCT02820077|Endoscopy, Gastrointestinal
37297|NCT02820051|bronchoscopy
37298|NCT02820051|conscious sedation
37299|NCT02820051|midazolam
37300|NCT02820051|patient comfort
37301|NCT02820051|propofol
37302|NCT02820012|Scoliosis
37303|NCT02820012|ST2R
37304|NCT02819986|occupational functioning
37305|NCT02819986|Worries
37306|NCT02819986|Pain
37307|NCT02819986|Disability
37308|NCT02819973|Patient Education
37309|NCT02819973|ICD
37310|NCT02819973|Implantable Cardioverter Defibrillator
37311|NCT02819973|Video
37312|NCT02819973|Decision
37313|NCT02819973|Decision making
37314|NCT02819960|probiotics
37315|NCT02819960|irinotecan
37316|NCT02819960|diarrhea
37317|NCT02819960|Lactobacillus rhamnosus
37318|NCT02819960|Bifidobacterium animalis
37319|NCT02819960|prevention
37320|NCT02819960|chemotherapy
37321|NCT02819947|systemic sclerosis
37322|NCT02819947|cohort
37323|NCT02819947|Korean
37324|NCT02819921|Hot Flashes
37325|NCT02819921|Breast Neoplasms
37326|NCT02819921|Tamoxifen
37327|NCT02819921|Desvenlafaxine Succinate
37328|NCT02819895|Phone Appointment Reminder
37329|NCT02819895|Immunization Rates
37330|NCT02819895|mHealth
37331|NCT02819882|Unresectable
37332|NCT02819882|locally
37333|NCT02819882|advanced
37334|NCT02819882|metastatic disease
37335|NCT02819843|T-VEC (Talimogene Laherparepvec)
37336|NCT02819843|Radiotherapy
37337|NCT02819843|16-224
37338|NCT02819830|Aerobic exercise
37339|NCT02819830|Strength training
37340|NCT02819830|Inflammation
37341|NCT02819830|cardiovascular disease
37342|NCT02819817|Aloe Vera, wound, healing
37343|NCT02819791|Cardiovascular
37344|NCT02819791|therapeutic education
37345|NCT02819778|Diagnosis
37346|NCT02819778|Craniocerebral Trauma
37347|NCT02819778|Pediatrics
37348|NCT02819778|S100B
37349|NCT02819778|mild traumatic brain injury
37350|NCT02819752|squamous cell carcinoma
37351|NCT02819752|squamous cell carcinoma of the head and neck
37352|NCT02819713|Prostate Biopsy
37353|NCT02819713|NRS-score
37354|NCT02819713|instillagel
37355|NCT02819713|ultrasound conductive gel
37356|NCT02819700|behavioural disorders
37357|NCT02819687|Phase I
37358|NCT02819687|Healthy
37359|NCT02819687|Pharmacokinetics
37360|NCT02819687|Pharmacodynamics
37361|NCT02819674|hypertension
37362|NCT02819674|early onset
37363|NCT02819674|target organ damage
37364|NCT02819661|Elective Caesarean Section
37365|NCT02819661|obese women
37366|NCT02819661|BMI≥30
37367|NCT02819661|spinal anesthesia combined with intrathecal morphine
37368|NCT02819648|symptomatic
37369|NCT02819648|irreversible
37370|NCT02819635|ABT-494
37371|NCT02819635|Moderately to Severely Active UC
37372|NCT02819570|early-onset neonatal sepsis
37373|NCT02819570|Prophylactic antibiotics
37374|NCT02819570|Pregnancy
37375|NCT02819570|PPROM
37376|NCT02819570|EOS
37377|NCT02819544|Digestive System
37378|NCT02819531|Coronary Atherectomy
37379|NCT02819531|percutaneous coronary intervention
37380|NCT02819518|PD1
37381|NCT02819518|PD-1
37382|NCT02819518|PDL1
37383|NCT02819518|PD-L1
37384|NCT02819505|beta-alanine
37385|NCT02819505|carnosine
37386|NCT02819505|neuromuscular
37387|NCT02819505|stimulation
37388|NCT02819505|skeletal muscle
37389|NCT02819492|Adenoma
37390|NCT02819492|Colonoscopy
37391|NCT02819492|Withdrawal
37392|NCT02819492|Proximal
37393|NCT02819492|Observation Time
37394|NCT02819479|Radiation necrosis
37395|NCT02819479|Radiation adverse event
37396|NCT02819479|Intra-arterial chemotherapy
37397|NCT02819479|Bevacizumab
37398|NCT02819479|Blood brain barrier disruption
37399|NCT02819479|Blood brain barrier breakdown
37400|NCT02819466|intragastric volume
37401|NCT02819466|stomach
37402|NCT02819466|fasting
37403|NCT02819453|Corticosteroid
37404|NCT02819427|Spectroscopy, Near-Infrared
37405|NCT02819427|Electroencephalography
37406|NCT02819427|children
37407|NCT02819388|randomized control trial; contraception; inequalities
37408|NCT02819375|propofol
37409|NCT02819375|ketamine
37410|NCT02819375|remifentanil
37411|NCT02819349|Relapse Prevention
37412|NCT02819349|People with Schizophrenia
37413|NCT02819349|Text-Messaging
37414|NCT02819349|Assertive Community Treatment (ACT)
37415|NCT02819336|urinary incontinence
37416|NCT02819336|electroacupuncture
37417|NCT02819336|stroke
37418|NCT02819336|complications
37419|NCT02819336|randomized controlled trial
37420|NCT02819336|pilot projects
37421|NCT02819284|Ocular Discomfort
37422|NCT02819284|Pain
37423|NCT02819284|Corticosteroid
37424|NCT02819284|Hyperemia
37425|NCT02819284|Dry Eye
37426|NCT02819219|Dietary Supplements
37427|NCT02819219|Exercise
37428|NCT02819193|Breastfeeding
37429|NCT02819193|mother's milk
37430|NCT02819193|breast milk
37431|NCT02819193|raw milk
37432|NCT02819193|neonate
37433|NCT02819193|Neonatal intensive care unit (NICU)
37434|NCT02819180|Influenza
37435|NCT02819167|ischemic stroke
37436|NCT02819167|brain reserve
37437|NCT02819167|cognitive reserve
37438|NCT02819167|cognitive prognosis
37439|NCT02819115|Influenza
37440|NCT02819089|anterior cervical spine surgery
37441|NCT02819089|ACDF
37442|NCT02819089|Dexmedetomidine
37443|NCT02819089|Anesthesia
37444|NCT02819089|Agitation
37445|NCT02819089|Riker sedation agitation scores
37446|NCT02819050|CPAP
37447|NCT02819050|Extremely Low Birth Weight Infant (ELBW)
37448|NCT02819050|Non-invasive respiratory support
37449|NCT02819050|Premature infants
37450|NCT02819050|Non invasive ventilation weaning
37451|NCT02819037|Gastric bypass
37452|NCT02819037|Intestinal Bacterial Overgrowth Syndrome
37453|NCT02819037|Gas chromatography
37454|NCT02819011|Ankle Foot Orthoses
37455|NCT02819011|falls
37456|NCT02819011|Fall Prevention
37457|NCT02819011|Frailty
37458|NCT02819011|Concern for falls
37459|NCT02819011|Footwear
37460|NCT02819011|Mobility
37461|NCT02818998|Diabetic macular edema
37462|NCT02818998|DME
37463|NCT02818959|Aortic Valve Disease
37464|NCT02818959|Aortic Valve Replacement
37465|NCT02818959|Transcatheter
37466|NCT02818959|Transfemoral
37467|NCT02818959|Aortic Stenosis
37468|NCT02818946|MRI
37469|NCT02818946|Spontaneous Nipple Discharge
37470|NCT02818946|Breast Cancer
37471|NCT02818933|24-hour diet recall
37472|NCT02818933|Adolescents
37473|NCT02818933|Web-based diet recall
37474|NCT02818920|Pembrolizumab
37475|NCT02818920|Neoadjuvant
37476|NCT02818920|Tumor Infiltrating Lymphocytes (TILs)
37477|NCT02818894|THA, Hip Replacement, Spinal Anesthesia
37478|NCT02818894|Total hip arthroplasty
37479|NCT02818894|anterior total hip replacement
37480|NCT02818881|aerobic
37481|NCT02818881|muscle activity
37482|NCT02818881|energy expenditure
37483|NCT02818855|Root coverage
37484|NCT02818855|Gingival recession
37485|NCT02818855|Plastic surgery
37486|NCT02818855|Connective tissue graft
37487|NCT02818855|Mucograft
37488|NCT02818842|Database
37489|NCT02818842|Birth defects
37490|NCT02818842|Neonatal pathologies
37491|NCT02818829|Adenocarcinoma
37492|NCT02818829|Endoscopic ultrasonography
37493|NCT02818829|Fine-needle aspiration
37494|NCT02818829|Biomarkers
37495|NCT02818829|Epidemiology
37496|NCT02818829|DNA tumors
37497|NCT02818816|Brimonidine tartrate
37498|NCT02818816|Intraocular pressure
37499|NCT02818816|Prostate Cancer
37500|NCT02818816|Prostatectomy
37501|NCT02818803|propolis
37502|NCT02818803|therapeutic
37503|NCT02818803|miconazole
37504|NCT02818803|denture stomatitis
37505|NCT02818790|mHealth
37506|NCT02818790|Motivational Interviewing
37507|NCT02818790|Obesity
37508|NCT02818790|Prevention
37509|NCT02818790|Diet
37510|NCT02818790|Physical Activity
37511|NCT02818790|Health Preventive System
37512|NCT02818777|Parkinson's Disease
37513|NCT02818777|Tremor
37514|NCT02818777|tolerability
37515|NCT02818777|safety
37516|NCT02818777|cognition
37517|NCT02818777|anxiety
37518|NCT02818777|psychosis
37519|NCT02818777|mood
37520|NCT02818777|dyskinesia
37521|NCT02818777|cannabidiol
37522|NCT02818777|cannabis
37523|NCT02818777|efficacy
37524|NCT02818777|sleep
37525|NCT02818777|motor symptoms
37526|NCT02818777|non-motor symptoms
37527|NCT02818777|quality of life
37528|NCT02818777|marijuana
37529|NCT02818764|serum biomarkers
37530|NCT02818764|cerebral blood flow
37531|NCT02818764|modified Blessed Dementia Rating scale
37532|NCT02818764|Confusion Assessment Method
37533|NCT02818764|Delirium Rating Scale-98
37534|NCT02818751|Anxiety
37535|NCT02818751|Adolescents with Anxiety
37536|NCT02818738|Idiopathic nephrotic syndrome
37537|NCT02818738|Steroid sensitive nephrotic syndrome
37538|NCT02818738|Levamisole
37539|NCT02818738|Prednisone
37540|NCT02818738|Children
37541|NCT02818686|Ulcerative Colitis, Active Moderate and Severe
37542|NCT02818673|diagnostic performances
37543|NCT02818673|ascites
37544|NCT02818647|tonsillectomy
37545|NCT02818647|electrocautery
37546|NCT02818647|postoperative pain
37547|NCT02818647|visual analogue scale
37548|NCT02818608|Cerebrovascular Accident
37549|NCT02818608|Cerebrovascular Stroke
37550|NCT02818608|Cerebral Stroke
37551|NCT02818595|voice recognition
37552|NCT02818582|Liberia
37553|NCT02818582|EBV
37554|NCT02818582|Semen
37555|NCT02818504|obesity
37556|NCT02818504|dysglycemia
37557|NCT02818504|hypercholesterolemia
37558|NCT02818504|lifestyle
37559|NCT02818504|smoking
37560|NCT02818504|physical activity
37561|NCT02818439|Old person
37562|NCT02818426|cancer immunotherapy
37563|NCT02818426|CD4 T lymphocyte helper
37564|NCT02818426|telomerase
37565|NCT02818413|Stool microbiome
37566|NCT02818413|Stool metabolome
37567|NCT02818413|Single nucleotide polymorphisms
37568|NCT02818400|maxillofacial surgery
37569|NCT02818400|face graft
37570|NCT02818400|composite tissue
37571|NCT02818400|stem cell infusion
37572|NCT02818400|allotransplantation
37573|NCT02818400|microsurgery
37574|NCT02818387|propofol
37575|NCT02818387|midazolam
37576|NCT02818387|remifentanil
37577|NCT02818387|combination
37578|NCT02818387|synergic
37579|NCT02818387|pharmacodynamics
37580|NCT02818387|Loss of consciousness
37581|NCT02818361|Rheumatoid Arthritis
37582|NCT02818361|Tripterygium wilfordii Hook F
37583|NCT02818361|double-blinded
37584|NCT02818361|randomized controlled trial
37585|NCT02818361|Tripterygium
37586|NCT02818361|Administration
37587|NCT02818361|Topical
37588|NCT02818348|HIV infection
37589|NCT02818348|Darunavir/cobicistat
37590|NCT02818348|Etravirine, drug-drug interactions
37591|NCT02818348|Population PK analysis
37592|NCT02818296|Intolerance of uncertainty
37593|NCT02818296|Anxiety
37594|NCT02818283|Human Immunodeficiency Virus
37595|NCT02818283|hypercholesterolemia
37596|NCT02818283|pretzels
37597|NCT02818283|nutritional study
37598|NCT02818283|dietary soy
37599|NCT02818283|antiretroviral therapy
37600|NCT02818244|commercial heart monitors
37601|NCT02818244|accuracy
37602|NCT02818244|EKG
37603|NCT02818244|varying degrees of exertion
37604|NCT02818166|magnetic resonance
37605|NCT02818166|right mini-thoracotomy
37606|NCT02818153|Allergic rhinitis
37607|NCT02818140|Postoperative pain
37608|NCT02818140|Transmuscular quadratus lumborum block
37609|NCT02818140|Block
37610|NCT02818140|Ropivacaine
37611|NCT02818140|TQL
37612|NCT02818140|percutaneous nephrolithotomy
37613|NCT02818140|PNL
37614|NCT02818140|Ultrasound-guided
37615|NCT02818114|PTSD
37616|NCT02818114|Prolonged Exposure
37617|NCT02818114|Peer Support
37618|NCT02818075|Peer support
37619|NCT02818075|Postpartum Depression
37620|NCT02818075|Adolescent Pregnancy
37621|NCT02818062|Endophthalmitis
37622|NCT02818062|Cytokines
37623|NCT02818062|Chemokines
37624|NCT02818062|Inflammation
37625|NCT02818062|Regulation
37626|NCT02818049|Bronchioalveolar Lavage
37627|NCT02818010|physical activity
37628|NCT02818010|chronic kidney disease
37629|NCT02818010|nephrology
37630|NCT02818010|stage 3
37631|NCT02818010|stage 4
37632|NCT02818010|stage 5
37633|NCT02817997|patient registry
37634|NCT02817997|ACCELERATE study
37635|NCT02817997|CD
37636|NCT02817997|MCD
37637|NCT02817997|iMCD
37638|NCT02817997|Castleman
37639|NCT02817997|Castleman's Disease
37640|NCT02817997|Angiofollicular Lymph Hyperplasia
37641|NCT02817997|multicentric Castleman's disease
37642|NCT02817997|multicentric Castleman disease
37643|NCT02817984|Abdominoplasty
37644|NCT02817971|feedback
37645|NCT02817971|pneumonia
37646|NCT02817971|quality of care
37647|NCT02817958|inguinal lymph nodes
37648|NCT02817958|penile cancer
37649|NCT02817958|squamous
37650|NCT02817958|TIP chemotherapy
37651|NCT02817945|TATE-RGD
37652|NCT02817945|SSTR2
37653|NCT02817945|integrin αvβ3
37654|NCT02817919|Pharmacovigilance
37655|NCT02817919|Africa
37656|NCT02817893|∆POP: variation of the plethysmographic waveform of pulse oximetry
37657|NCT02817893|∆PP: pulse pressure variation
37658|NCT02817893|pulse oximetry plethysmographic
37659|NCT02817893|abdominal surgery
37660|NCT02817880|rTMS, tDCS, tsDCS, pain, algoneurodystrophy , neurostimulation
37661|NCT02817841|Estetrol
37662|NCT02817841|Drospirenone
37663|NCT02817841|Prevention of pregnancy
37664|NCT02817841|Oral contraception
37665|NCT02817828|Estetrol
37666|NCT02817815|Atrial fibrillation, blood platelet
37667|NCT02817802|Registry
37668|NCT02817802|Magmaris
37669|NCT02817802|Coronary Artery Disease
37670|NCT02817802|PCI
37671|NCT02817789|TAVI
37672|NCT02817789|Antiplatelet agent
37673|NCT02817789|Ticagrelor
37674|NCT02817789|Cerebrovascular events
37675|NCT02817776|Interventional
37676|NCT02817776|Radiofrequency Ablation
37677|NCT02817776|Persistent Atrial Fibrillation
37678|NCT02817750|volunteers
37679|NCT02817750|Pharmacokinetics
37680|NCT02817724|Breast Neoplasms
37681|NCT02817724|survivor
37682|NCT02817724|occupational therapy
37683|NCT02817724|mobile applications
37684|NCT02817724|Quality of Life
37685|NCT02817711|infection
37686|NCT02817711|bone and joint infection
37687|NCT02817711|relapse
37688|NCT02817711|adverse event
37689|NCT02817698|smoking
37690|NCT02817698|cannabis
37691|NCT02817698|cocaine
37692|NCT02817685|surveillance
37693|NCT02817685|hepatocellular carcinoma
37694|NCT02817685|ultrasound
37695|NCT02817685|cirrhosis
37696|NCT02817685|chronic hepatitis B
37697|NCT02817672|Human
37698|NCT02817672|Mental Disorders
37699|NCT02817672|intervention
37700|NCT02817672|digital health
37701|NCT02817659|Glucagon
37702|NCT02817646|Intensive Care Unit
37703|NCT02817646|Critical Illness
37704|NCT02817646|Body composition
37705|NCT02817646|Protein nutrition
37706|NCT02817633|Anitibodies
37707|NCT02817633|TSR-022
37708|NCT02817633|Advanced solid tumors
37709|NCT02817633|Metastatic solid tumors
37710|NCT02817633|Immunotherapy
37711|NCT02817633|PD-1
37712|NCT02817633|Anti-PD-1
37713|NCT02817633|colorectal cancer
37714|NCT02817633|non-small cell lung cancer
37715|NCT02817633|Melanoma
37716|NCT02817633|Nivolumab
37717|NCT02817607|Sensation
37718|NCT02817594|Sustained Virological Response
37719|NCT02817594|Chronic Hepatitis C genotype 4
37720|NCT02817594|Chronic Hepatitis C genotype 1
37721|NCT02817594|Observational Study
37722|NCT02817594|Paritaprevir/r - Ombitasvir, ± Dasabuvir
37723|NCT02817594|Chronic Hepatitis C
37724|NCT02817581|National Early Warning Score (NEWS)
37725|NCT02817581|Lactate
37726|NCT02817581|Emergency Department
37727|NCT02817568|Aggressive Periodontitis
37728|NCT02817568|C-C chemokine receptor 2
37729|NCT02817568|Gene expression
37730|NCT02817568|monocyte chemoattractant protein-1,
37731|NCT02817568|restriction fragment length polymorphism
37732|NCT02817555|Anemia
37733|NCT02817555|Hemodialysis
37734|NCT02817555|Erythropoiesis Stimulating Agent
37735|NCT02817555|Cost
37736|NCT02817516|Drug Therapy
37737|NCT02817503|hypertension
37738|NCT02817503|BP titration
37739|NCT02817503|intensive blood pressure control
37740|NCT02817503|primary prevention
37741|NCT02817503|China
37742|NCT02817503|H-type Hypertension
37743|NCT02817490|hypermobility
37744|NCT02817490|Ehlers-Danlos Syndrome
37745|NCT02817490|patient education program
37746|NCT02817477|Intranasal Ketamine, Analgesia, Trauma, Morphine, Mass Casualty
37747|NCT02817451|Diphtheria
37748|NCT02817451|Tetanus
37749|NCT02817451|Pertussis
37750|NCT02817451|Hepatitis B
37751|NCT02817451|DTaP IPV HB PRP-T Combined Vaccine
37752|NCT02817451|Human Immunodeficiency Virus
37753|NCT02817425|S-1
37754|NCT02817425|Adjuvant Chemotherapy
37755|NCT02817425|TEGAFOX
37756|NCT02817412|binge eating
37757|NCT02817412|obesity
37758|NCT02817412|overeating
37759|NCT02817399|anterior cruciate ligament reconstruction
37760|NCT02817399|Functional Electrical stimulation
37761|NCT02817399|Gait analysis
37762|NCT02817399|Physical therapy
37763|NCT02817386|postoperative delirium
37764|NCT02817386|microRNA
37765|NCT02817386|HMGB1
37766|NCT02817373|IVF
37767|NCT02817373|embryo transfer
37768|NCT02817373|ultrasound
37769|NCT02817373|implantation
37770|NCT02817334|Near-infrared fluorescence
37771|NCT02817334|Indocyanine green, ICG
37772|NCT02817334|breast cancer
37773|NCT02817308|Antigen, CA-19-9
37774|NCT02817308|Salivas
37775|NCT02817308|body fluids
37776|NCT02817269|Shoulder pain
37777|NCT02817269|Trigger points
37778|NCT02817269|Referred pain
37779|NCT02817269|Visual analogue scale
37780|NCT02817191|age-related cataract
37781|NCT02817191|Holy-Comod
37782|NCT02817191|Tears Naturale Forte
37783|NCT02817191|phacoemulsification
37784|NCT02817191|inflammatory mediators
37785|NCT02817165|Probiotics, diarrhea, antibiotic, children, hospital
37786|NCT02817152|periodontal treatment
37787|NCT02817152|low-level light therapy
37788|NCT02817126|Minimally Invasive Surgical Procedures
37789|NCT02817126|Robotic Surgical Procedures
37790|NCT02817126|Laparoscopic Surgical Procedures
37791|NCT02817126|Rectal Cancer
37792|NCT02817126|Intraoperative Complications
37793|NCT02817126|Postoperative Complications
37794|NCT02817126|Recovery of Function
37795|NCT02817126|Recurrence
37796|NCT02817126|Disease Progression
37797|NCT02817126|Survival
37798|NCT02817087|Stroke
37799|NCT02817061|no keywords for disease type and/or category
37800|NCT02817035|interstitial lung disease
37801|NCT02817035|chronic obstructive pulmonary disease
37802|NCT02817035|mechanical ventilation
37803|NCT02817035|expiratory delay
37804|NCT02817035|neural inspiratory time
37805|NCT02817022|Developmentally Supportive Care
37806|NCT02817009|Behavioral Health Intervention
37807|NCT02817009|Randomized Control Trial
37808|NCT02817009|Family Intervention
37809|NCT02817009|Nutrition
37810|NCT02817009|Weight Management
37811|NCT02817009|Multidisciplinary Program
37812|NCT02816944|Endoscopic ultrasonography
37813|NCT02816944|Laser ablation
37814|NCT02816931|Treatment
37815|NCT02816931|Drug Monitoring
37816|NCT02816931|Minimum Inhibitory Concentration
37817|NCT02816931|Dried Blood Spot Method
37818|NCT02816931|Pharmacokinetics
37819|NCT02816931|Pharmacodynamics
37820|NCT02816905|intraocular pressure
37821|NCT02816905|topical steroids
37822|NCT02816905|strabismus
37823|NCT02816892|aortic dissection
37824|NCT02816892|biomarkers
37825|NCT02816892|diagnosis
37826|NCT02816866|childhood cancer
37827|NCT02816866|survivorship care
37828|NCT02816866|health services
37829|NCT02816866|barriers
37830|NCT02816840|prostate cancer
37831|NCT02816840|radiotherapy
37832|NCT02816840|PET-CT/MRI
37833|NCT02816814|Menopause
37834|NCT02816814|Diet
37835|NCT02816814|Lipidomic profile
37836|NCT02816814|Vasomotor symptoms
37837|NCT02816814|Omega-3 fatty acids
37838|NCT02816788|PTSD
37839|NCT02816788|Equine Assisted Therapy
37840|NCT02816775|hemodynamics
37841|NCT02816775|QT interval
37842|NCT02816762|CPAP
37843|NCT02816762|Sleep apnea
37844|NCT02816762|Diabetes
37845|NCT02816762|Nephropathy
37846|NCT02816762|Albuminuria
37847|NCT02816749|Diabetic Foot
37848|NCT02816749|Wound Healing
37849|NCT02816749|Larva
37850|NCT02816749|Occlusive Dressings
37851|NCT02816736|Heart Failure
37852|NCT02816736|Heart Diseases
37853|NCT02816736|Cardiovascular Diseases
37854|NCT02816736|Valsartan
37855|NCT02816736|Entresto
37856|NCT02816723|mindfulness
37857|NCT02816723|aging
37858|NCT02816723|Veterans
37859|NCT02816697|Smoking Habits
37860|NCT02816684|phobic disorders
37861|NCT02816684|anxiety disorders
37862|NCT02816645|Parkinson's Disease
37863|NCT02816645|Biomarker
37864|NCT02816645|Iron
37865|NCT02816645|R2*
37866|NCT02816645|MRI
37867|NCT02816645|Patients
37868|NCT02816645|UK Parkinson's Disease Society Brain Bank
37869|NCT02816632|functional Magnetic Resonance Imaging
37870|NCT02816632|Galvanic Vestibular Stimulation
37871|NCT02816632|Feedback Processing
37872|NCT02816632|Reward, Social, Vestibular System
37873|NCT02816632|Cingulate Cortex
37874|NCT02816632|Decision-making
37875|NCT02816619|Parkinson's disease
37876|NCT02816619|Physical activity
37877|NCT02816619|Physical exercise
37878|NCT02816606|ACL reconstruction
37879|NCT02816593|carbamide peroxide
37880|NCT02816593|Hydrogen peroxide
37881|NCT02816593|Quality of life
37882|NCT02816554|Japanese Encephalitis
37883|NCT02816554|JECEVAX
37884|NCT02816554|Vietnam
37885|NCT02816528|Antibiotics
37886|NCT02816528|Primary care
37887|NCT02816528|Stewardship
37888|NCT02816528|General practitioners
37889|NCT02816515|Non interventional study
37890|NCT02816515|Ectoin
37891|NCT02816515|Mouth wash
37892|NCT02816515|Mucositis
37893|NCT02816515|Chemotherapy
37894|NCT02816515|Radiotherapy
37895|NCT02816502|childhood
37896|NCT02816502|adversity
37897|NCT02816450|Water
37898|NCT02816450|Children
37899|NCT02816450|Cognition
37900|NCT02816450|Hydration
37901|NCT02816424|Screening and Brief Intervention
37902|NCT02816424|Motivational Interviewing
37903|NCT02816424|Teen Pregnancy Prevention
37904|NCT02816385|PV-loops (pressure-volume loops)
37905|NCT02816385|Myocardial contractility
37906|NCT02816385|Cardioplegia
37907|NCT02816385|Induced
37908|NCT02816359|Position patient
37909|NCT02816359|Esophageal pressure
37910|NCT02816346|shigella
37911|NCT02816320|hospital mortality
37912|NCT02816320|standardized mortality ratios
37913|NCT02816320|patient safety
37914|NCT02816320|healthcare quality
37915|NCT02816320|hospital performance
37916|NCT02816320|administrative data
37917|NCT02816281|Surgical case cancellation
37918|NCT02816281|Pre-operative assessment clinic
37919|NCT02816242|Concept Map
37920|NCT02816242|critical thinking
37921|NCT02816242|medical student teaching
37922|NCT02816229|Haemoptysis
37923|NCT02816229|Aspergillus
37924|NCT02816229|Endobronchial valve
37925|NCT02816229|Interventional pulmonology
37926|NCT02816229|Tuberculosis
37927|NCT02816138|Geriatrics
37928|NCT02816138|Depression
37929|NCT02816138|Elderly
37930|NCT02816138|Cognition
37931|NCT02816138|Memory
37932|NCT02816125|breast cancer
37933|NCT02816125|fatty acids
37934|NCT02816125|omega-3
37935|NCT02816060|pain measurement
37936|NCT02816047|wearable cardioverter defibrillator
37937|NCT02816047|LifeVest
37938|NCT02816047|sudden death
37939|NCT02816047|defibrillator
37940|NCT02816034|Learning
37941|NCT02816034|Cerebellum
37942|NCT02816021|Melanoma and other malignant neoplasms of skin
37943|NCT02816021|Metastatic melanoma
37944|NCT02816021|Advanced melanoma
37945|NCT02816021|Azacitidine
37946|NCT02816021|5-azacytidine
37947|NCT02816021|5-aza
37948|NCT02816021|Vidaza
37949|NCT02816021|5-AZC
37950|NCT02816021|Ladakamycin
37951|NCT02816021|NSC-102816
37952|NCT02816021|Azacytidine
37953|NCT02816021|Pembrolizumab
37954|NCT02816021|Keytruda
37955|NCT02816021|MK-3475
37956|NCT02816021|SCH-900475
37957|NCT02816008|cognitive rehabilitation
37958|NCT02816008|memory
37959|NCT02816008|attention
37960|NCT02816008|spatial neglect
37961|NCT02816008|executive dysfunctioning
37962|NCT02815995|Malignant neoplasms of bone and articular cartilage
37963|NCT02815995|Multiple sarcoma subtypes
37964|NCT02815995|Advanced and/or metastatic sarcoma
37965|NCT02815995|Adipocytic tumors
37966|NCT02815995|Vascular tumors
37967|NCT02815995|Leiomyosarcoma
37968|NCT02815995|Angiosarcoma
37969|NCT02815995|Epithelioid hemangioendothelioma
37970|NCT02815995|Undifferentiated pleomorphic sarcoma
37971|NCT02815995|Synovial sarcoma
37972|NCT02815995|Osteosarcoma
37973|NCT02815995|Other sarcoma histologies
37974|NCT02815995|Durvalumab
37975|NCT02815995|Tremelimumab
37976|NCT02815969|neuroendocrine tumors
37977|NCT02815969|indol profile
37978|NCT02815969|catecholamines
37979|NCT02815969|LC-MS/MS
37980|NCT02815956|percutaneous tibial nerve stimulation
37981|NCT02815956|randomized
37982|NCT02815956|controlled study
37983|NCT02815930|High cost user (HCU)
37984|NCT02815930|Healthcare utilization
37985|NCT02815930|Healthcare expenditures
37986|NCT02815930|Medication use
37987|NCT02815930|Medication expenditures
37988|NCT02815930|Multimorbidity
37989|NCT02815930|Observational study
37990|NCT02815904|Neonates
37991|NCT02815904|physical therapy
37992|NCT02815904|neonatal intensive care units
37993|NCT02815904|yakson touch
37994|NCT02815904|kinesthetic stimulation
37995|NCT02815865|Primiparous
37996|NCT02815865|Foley catheter
37997|NCT02815865|Dinoprostone
37998|NCT02815865|Induction
37999|NCT02815852|breast cancer in women under 40 years old
38000|NCT02815852|biopsy
38001|NCT02815852|ultrasonography
38002|NCT02815852|Magnetic Resonance Imaging
38003|NCT02815839|urate transporter 1
38004|NCT02815839|SHR4640
38005|NCT02815839|single ascending dose
38006|NCT02815839|pharmacokinetics
38007|NCT02815839|pharmacodynamics
38008|NCT02815813|Serious Mental Illness
38009|NCT02815813|Young Adults
38010|NCT02815813|Obesity
38011|NCT02815813|Cardiometabolic Risk
38012|NCT02815813|Physical Activity
38013|NCT02815813|Weight Loss
38014|NCT02815813|Fitness
38015|NCT02815813|Peer Support
38016|NCT02815813|Smartphone
38017|NCT02815813|Mobile Technology
38018|NCT02815813|mHealth
38019|NCT02815813|Social Media
38020|NCT02815813|Facebook
38021|NCT02815800|Treatment
38022|NCT02815800|Motor signs
38023|NCT02815800|Non motor signs
38024|NCT02815800|Fluctuations
38025|NCT02815800|Open labelled
38026|NCT02815787|SP2086
38027|NCT02815787|Glyburide
38028|NCT02815787|drug-drug interaction
38029|NCT02815774|SP2086
38030|NCT02815774|Renal Insufficiency
38031|NCT02815774|Pharmacokinetic
38032|NCT02815748|SP2086
38033|NCT02815748|Metabolite identification
38034|NCT02815748|Material balance
38035|NCT02815722|SP2086
38036|NCT02815722|Simvastatin
38037|NCT02815722|drug-drug interaction
38038|NCT02815696|MRI T2 weighted
38039|NCT02815696|intervertebral disc
38040|NCT02815696|glycosaminoglycans
38041|NCT02815683|Bronchoscopy
38042|NCT02815683|Emphysema
38043|NCT02815657|SP2086
38044|NCT02815657|Valsartan
38045|NCT02815657|Drug-drug Interaction
38046|NCT02815631|fractional flow reserve
38047|NCT02815631|cardiogoniometry
38048|NCT02815618|Time-resolved spectroscopy
38049|NCT02815618|Diffuse correlation spectroscopy
38050|NCT02815618|Neonatology
38051|NCT02815579|HIV
38052|NCT02815579|Food insecurity
38053|NCT02815579|Microcredit loan
38054|NCT02815579|Agriculture
38055|NCT02815579|Livelihoods
38056|NCT02815566|kidney, antiretroviral agent, tenofovir, osteoporosis, women
38057|NCT02815527|enteral nutrition
38058|NCT02815527|intensive care unit
38059|NCT02815527|whey
38060|NCT02815527|protein
38061|NCT02815527|muscle mass
38062|NCT02815527|leucin
38063|NCT02815527|energy expenditure
38064|NCT02815514|aortic valve stenosis
38065|NCT02815514|aortic valve insufficiency
38066|NCT02815514|transapical aortic valve implantation
38067|NCT02815514|aortic valve replacement
38068|NCT02815514|percutaneous aortic valve replacement
38069|NCT02815514|aortic valve valvuloplasty
38070|NCT02815501|Thyroid dysfunction
38071|NCT02815501|obstetric complications
38072|NCT02815462|Frequent hospital admissions
38073|NCT02815462|Risk stratification
38074|NCT02815462|Readmissions
38075|NCT02815449|Iron fortification
38076|NCT02815449|Bioavailability
38077|NCT02815449|Nigeria
38078|NCT02815449|Women
38079|NCT02815449|Bouillon cubes
38080|NCT02815410|Glioblastoma Multiforme
38081|NCT02815410|Levetiracetam
38082|NCT02815410|Temozolomide
38083|NCT02815410|Survival outcome
38084|NCT02815397|Double Hit DLBCL
38085|NCT02815319|Dexamethasone
38086|NCT02815319|Chemotherapy
38087|NCT02815306|Congenital idiopathic clubfoot
38088|NCT02815306|Pirani score
38089|NCT02815306|infant
38090|NCT02815306|polyaxial brace
38091|NCT02815293|EDE
38092|NCT02815293|evaporative dry eye
38093|NCT02815280|acne
38094|NCT02815267|acne
38095|NCT02815254|Physiotherapy
38096|NCT02815254|hip fracture
38097|NCT02815254|rehabilitation
38098|NCT02815254|high dose exercise
38099|NCT02815254|low dose exercise
38100|NCT02815215|congenital clubfoot
38101|NCT02815189|pain
38102|NCT02815176|Plasminogen activator inhibitor-1
38103|NCT02815176|Wide angle fluorescein angiography
38104|NCT02815176|Choroid
38105|NCT02815137|Digital PCR
38106|NCT02815137|classical
38107|NCT02815137|Hodgkin Lymphoma
38108|NCT02815137|mutation
38109|NCT02815085|heart failure
38110|NCT02815085|mHealth
38111|NCT02815072|Fontan palliation
38112|NCT02815072|Marfan's syndrome
38113|NCT02815046|urgency urinary incontinence
38114|NCT02815046|stress urinary incontinence
38115|NCT02815046|Botulinum toxin A
38116|NCT02815046|Bulkamid
38117|NCT02815033|Hormono-Sensitive prostate cancer
38118|NCT02815033|Enzalutamide
38119|NCT02815033|Imaging
38120|NCT02815033|PET/CT
38121|NCT02815033|Whole body MRI
38122|NCT02815033|Circulating tumour cells
38123|NCT02815033|Cell-free tumour DNA
38124|NCT02815020|Primary care
38125|NCT02815020|Self-management support
38126|NCT02815020|Care coordination
38127|NCT02815020|Practice-based research network
38128|NCT02814994|Mechanical Ventilation
38129|NCT02814994|ARDS
38130|NCT02814994|Ventilator Strategy
38131|NCT02814994|Outcome
38132|NCT02814981|hydroxyzine
38133|NCT02814981|Long QT
38134|NCT02814968|Castration-resistant prostate cancer
38135|NCT02814968|Enzalutamide
38136|NCT02814968|Imaging
38137|NCT02814968|PET/CT
38138|NCT02814968|Whole body MRI
38139|NCT02814968|Circulating tumour cells
38140|NCT02814968|Cell-free tumour DNA
38141|NCT02814955|atrial fibrillation
38142|NCT02814955|pulmonary veins
38143|NCT02814955|oral anticoagulant
38144|NCT02814955|electrophysiology
38145|NCT02814955|anticoagulant drugs
38146|NCT02814929|ROP
38147|NCT02814929|Risk factors
38148|NCT02814929|Incidence
38149|NCT02814929|Turkey
38150|NCT02814916|Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
38151|NCT02814903|aldosterone
38152|NCT02814903|cardiac surgery
38153|NCT02814903|atrial fibrillation
38154|NCT02814903|galectin-3
38155|NCT02814903|mitochondria
38156|NCT02814903|ngal
38157|NCT02814903|acute kidney failure
38158|NCT02814903|epicardial fat
38159|NCT02814903|right atrial sample
38160|NCT02814890|Thoracic paravertebral block
38161|NCT02814890|Dexmedetomidine
38162|NCT02814890|Video-assisted Pneumonectomy
38163|NCT02814890|Ropivacaine
38164|NCT02814890|Pain, Postoperative
38165|NCT02814877|Antibiotic stewardship
38166|NCT02814877|cost-effectiveness evaluation
38167|NCT02814877|Antibiotic use
38168|NCT02814864|Hematology
38169|NCT02814864|Mesenchymal Stromal Cell
38170|NCT02814864|radiotherapy
38171|NCT02814864|gastro-intestinal complications
38172|NCT02814864|lower digestive tract cancers
38173|NCT02814864|colitis
38174|NCT02814864|bleeding
38175|NCT02814864|diarrhea
38176|NCT02814864|pelvic radiation disease
38177|NCT02814851|Left atrium appendage (LAA) occlusion
38178|NCT02814851|Transesophageal echocardiography
38179|NCT02814851|Cardiac output hemodynamic measurement
38180|NCT02814851|Leycom Pressure/Volume Combination Catheter
38181|NCT02814838|Diabetes mellitus Type 1
38182|NCT02814838|Beta cells function
38183|NCT02814825|ViviGen
38184|NCT02814825|ACDF
38185|NCT02814825|Cervical
38186|NCT02814760|acute ischemic stroke
38187|NCT02814760|stepped-wedge
38188|NCT02814760|interactive training
38189|NCT02814760|implementation
38190|NCT02814760|emergency department
38191|NCT02814734|Intra-Abdominal Hypertension
38192|NCT02814734|Abdominal Compartment Syndrome
38193|NCT02814734|Round Belly Sign
38194|NCT02814734|Radiology
38195|NCT02814734|CT findings
38196|NCT02814734|Intensive Care
38197|NCT02814708|Sepsis
38198|NCT02814708|Vaccination
38199|NCT02814695|Male infertility
38200|NCT02814695|oxidative stress
38201|NCT02814695|antioxidants
38202|NCT02814695|probiotics
38203|NCT02814695|Vitamin E
38204|NCT02814695|Baker's Yeast
38205|NCT02814682|palliative care
38206|NCT02814682|quality
38207|NCT02814682|indicator
38208|NCT02814682|multi-dimensional
38209|NCT02814656|muscarinic receptor antagonist and β2 adrenoceptor agonist [MABA]
38210|NCT02814656|chronic obstructive pulmonary disease
38211|NCT02814656|Asthma (in combination with an inhaled corticosteroid [ICS]
38212|NCT02814656|alpha-lactose monohydrate
38213|NCT02814656|dry powder inhaler
38214|NCT02814656|long-acting β2-agonist (LABA)
38215|NCT02814656|long-acting muscarinic antagonist (LAMA)
38216|NCT02814656|fixed-dose combination (FDC)
38217|NCT02814643|Male and female adolescent patients
38218|NCT02814643|severe asthma
38219|NCT02814604|Front-of-Pack Labelling
38220|NCT02814604|Star rating system
38221|NCT02814604|Traffic light rating system
38222|NCT02814604|Consumer Behavior
38223|NCT02814604|Health Literacy
38224|NCT02814604|Mobile Apps
38225|NCT02814604|Nutrition Labeling
38226|NCT02814604|Healthy food choices
38227|NCT02814578|OCT
38228|NCT02814578|IVUS
38229|NCT02814578|BVS
38230|NCT02814565|Drug therapy
38231|NCT02814513|Children
38232|NCT02814513|Adolescents
38233|NCT02814487|DAM
38234|NCT02814487|multiple sclerosis
38235|NCT02814487|MSFC
38236|NCT02814487|application
38237|NCT02814487|smartphone
38238|NCT02814474|PET/CT
38239|NCT02814474|Heart failure
38240|NCT02814474|hydroxybutyrate
38241|NCT02814435|Retina
38242|NCT02814435|Retinal Degeneration
38243|NCT02814435|Quality of Life Measures
38244|NCT02814422|Triglyceride-rich lipoprotein
38245|NCT02814422|dementia
38246|NCT02814422|Alzheimer's disease
38247|NCT02814422|mild cognition impairment
38248|NCT02814422|amyloid-beta
38249|NCT02814396|Ventricular
38250|NCT02814396|CVD
38251|NCT02814396|Ventricular arrhythmias
38252|NCT02814383|Prematurity
38253|NCT02814383|Extremely Low Birth Weight (ELBW)
38254|NCT02814383|Cerebral Perfusion
38255|NCT02814383|Cerebral Autoregulation
38256|NCT02814357|Blood glucose, serum insulin
38257|NCT02814344|labour
38258|NCT02814331|Video-EEG
38259|NCT02814331|near-infrared spectroscopy (NIRS)
38260|NCT02814318|Vancomycin
38261|NCT02814318|Penicillin
38262|NCT02814318|Clindamycin
38263|NCT02814318|Group B streptococcal infection
38264|NCT02814318|Rectovaginal GBS colonization
38265|NCT02814318|Vaginal GBS colonization
38266|NCT02814318|Intrapartum
38267|NCT02814318|Prophylaxis
38268|NCT02814227|obstructive sleep apnea screening device
38269|NCT02814201|Motor slowing
38270|NCT02814201|Computerized mental chronometry paradigm
38271|NCT02814188|Exercise
38272|NCT02814175|Psoriatic Arthritis
38273|NCT02814162|Subarachnoid Hemorrhage, Aneurysmal
38274|NCT02814162|Predictive
38275|NCT02814162|Adiponectin
38276|NCT02814149|early implant
38277|NCT02814149|esthetics
38278|NCT02814149|immediate implant
38279|NCT02814149|bone augmentation
38280|NCT02814123|Diabetes Mellitus, Type 1
38281|NCT02814123|Pramlintide
38282|NCT02814123|Artificial Pancreas
38283|NCT02814123|Closed-Loop System
38284|NCT02814123|Insulin
38285|NCT02814110|Granulocyte colony-stimulating factor
38286|NCT02814110|muscular dystrophy
38287|NCT02814110|muscle strength
38288|NCT02814110|children
38289|NCT02814110|adolescents
38290|NCT02814097|Heart Failure
38291|NCT02814097|HFpEF
38292|NCT02814097|elamipretide
38293|NCT02814097|MTP-131
38294|NCT02814097|Bendavia™
38295|NCT02814071|Early Feeding
38296|NCT02814071|Acute Pancreatitis
38297|NCT02814071|Pediatric
38298|NCT02814058|pharmacokinetics
38299|NCT02814058|Healthy Volunteers
38300|NCT02814045|biomarkers, sleep fragmentation, intermittent hypoxia
38301|NCT02814032|proteomic
38302|NCT02814032|cervical lymph node metastasis
38303|NCT02814019|respiratory function in DMD
38304|NCT02814006|marital relationship
38305|NCT02813993|infertility
38306|NCT02813993|fertility awareness
38307|NCT02813993|preconceptional care
38308|NCT02813993|health interventions
38309|NCT02813993|couples
38310|NCT02813980|SUDEP
38311|NCT02813980|Sudden cardiac death
38312|NCT02813980|Sudden unexpected death in epilepsy
38313|NCT02813980|Sleep
38314|NCT02813980|Polysomnography
38315|NCT02813980|Autonomic
38316|NCT02813980|Cardiovascular
38317|NCT02813941|Randomized controlled trial
38318|NCT02813941|Systematic review
38319|NCT02813941|Summary of finding tables
38320|NCT02813941|GRADE
38321|NCT02813941|AHRQ
38322|NCT02813928|ColoRectal Cancer
38323|NCT02813928|Cancerology
38324|NCT02813928|Translational Research
38325|NCT02813928|ccfDNA
38326|NCT02813915|cardiac monitoring, Cheetah Medical, passive leg raises
38327|NCT02813889|infant
38328|NCT02813889|baby
38329|NCT02813889|developmental delay
38330|NCT02813889|robotics
38331|NCT02813889|cerebral palsy
38332|NCT02813850|sickle cell disease
38333|NCT02813850|oxygen therapy
38334|NCT02813850|pregnancy
38335|NCT02813850|pregnancy in sickle cell disease
38336|NCT02813837|relapsed
38337|NCT02813837|refractory
38338|NCT02813837|CD19+
38339|NCT02813837|leukemia
38340|NCT02813837|lymphoma
38341|NCT02813811|Temperature-controlled Laminar Airflow
38342|NCT02813811|Exacerbation frequency
38343|NCT02813798|Renal Insufficiency
38344|NCT02813772|infants
38345|NCT02813772|colic
38346|NCT02813759|GLYCEMIA
38347|NCT02813759|SATIETY
38348|NCT02813759|C PEPTIDE
38349|NCT02813759|PRELOAD
38350|NCT02813759|INSULIN
38351|NCT02813746|Obesity
38352|NCT02813746|Tobacco
38353|NCT02813746|Epigenetic
38354|NCT02813746|Transcriptomic
38355|NCT02813746|microRNAs
38356|NCT02813746|miRNAs
38357|NCT02813733|thyroid surgery
38358|NCT02813733|surgical outcomes
38359|NCT02813733|patient safety
38360|NCT02813733|healthcare quality
38361|NCT02813733|surgeons performance
38362|NCT02813720|Erosions
38363|NCT02813720|Onycholysis
38364|NCT02813720|HR-pQCT
38365|NCT02813720|Psoriatic arthritis
38366|NCT02813707|Vitamins
38367|NCT02813707|Mineral
38368|NCT02813707|Surgery
38369|NCT02813694|Pneumonia
38370|NCT02813694|CABP
38371|NCT02813694|CAP
38372|NCT02813694|Community acquired bacterial pneumonia
38373|NCT02813681|Acute Pain
38374|NCT02813681|ultrasonography
38375|NCT02813668|Nutrition
38376|NCT02813668|Occupational Health
38377|NCT02813655|tetracosactide
38378|NCT02813655|Synacthène®
38379|NCT02813655|cosyntropin
38380|NCT02813655|post-dural syndrom
38381|NCT02813655|post-dural puncture headache
38382|NCT02813642|chronic kidney disease starting dialysis
38383|NCT02813642|cardiovascular risk
38384|NCT02813642|bone mineral metabolism markers
38385|NCT02813629|transcranial Direct Current Stimulation
38386|NCT02813629|Peripheral Electrical Stimulation
38387|NCT02813629|Sickle Cell Disease
38388|NCT02813629|Transcutaneous Electrical Nerve Stimulation
38389|NCT02813629|quantitative Electroencephalography
38390|NCT02813603|EBUS-TBNA
38391|NCT02813603|staging
38392|NCT02813603|lymph node metastases
38393|NCT02813577|Legs
38394|NCT02813577|Drug Coated Angioplasty Balloon
38395|NCT02813577|Experimental
38396|NCT02813577|Standard Angioplasty Balloon
38397|NCT02813564|Autism
38398|NCT02813564|Cognitive Training
38399|NCT02813564|Brain
38400|NCT02813564|fMRI
38401|NCT02813551|Preeclampsia, puerperium
38402|NCT02813538|Thrombelastography
38403|NCT02813538|Antithrombin proteins
38404|NCT02813538|Liver surgery
38405|NCT02813538|Liver function tests
38406|NCT02813525|Aortic Isthmus
38407|NCT02813525|Isthmic Systolic Index
38408|NCT02813525|feasibility
38409|NCT02813525|reproducibility
38410|NCT02813525|mortality
38411|NCT02813525|delivery
38412|NCT02813499|Acute Coronary Syndrome
38413|NCT02813473|SYNTAX Score II
38414|NCT02813473|Multi Slice Computed Tomography
38415|NCT02813473|MSCT
38416|NCT02813473|Heart Team
38417|NCT02813473|Fractional Flow Reserve Computed Tomography
38418|NCT02813473|FFR
38419|NCT02813473|FFR MSCT
38420|NCT02813473|PCI
38421|NCT02813473|CABG
38422|NCT02813473|Percutaneous Coronary Intervention
38423|NCT02813473|Coronary Artery Bypass Graft
38424|NCT02813434|Cerebral amyloid imaging
38425|NCT02813434|Florbetapir
38426|NCT02813434|18F-AV-45
38427|NCT02813434|poststroke
38428|NCT02813421|CGM
38429|NCT02813382|bupivacaine
38430|NCT02813382|prilocaine
38431|NCT02813382|2-chloroprocaine
38432|NCT02813330|Women
38433|NCT02813330|severe
38434|NCT02813330|low back ache
38435|NCT02813330|labor
38436|NCT02813317|Surgery
38437|NCT02813317|Breast cancer
38438|NCT02813317|Quality of life
38439|NCT02813317|Care pathway
38440|NCT02813317|Economic evaluation
38441|NCT02813304|Acute
38442|NCT02813304|rotator cuff tendinopathy
38443|NCT02813304|exercise
38444|NCT02813304|loading
38445|NCT02813304|ice
38446|NCT02813304|cryotherapy
38447|NCT02813304|randomised control trial
38448|NCT02813291|Motor imagery
38449|NCT02813291|transcranial direct current stimulation
38450|NCT02813291|motor learning
38451|NCT02813291|aging
38452|NCT02813265|Ocular Discomfort
38453|NCT02813265|Pain
38454|NCT02813265|Corticosteroid
38455|NCT02813265|Hyperemia
38456|NCT02813265|Dry Eye
38457|NCT02813252|long-term follow-up
38458|NCT02813252|chimeric antigen receptor (CAR) T cells
38459|NCT02813252|JCAR015
38460|NCT02813239|IVF
38461|NCT02813239|Dual trigger
38462|NCT02813239|GnRH agonist
38463|NCT02813239|hCG
38464|NCT02813239|mature oocytes
38465|NCT02813226|castration-resistant
38466|NCT02813226|molecular imaging
38467|NCT02813226|abiraterone acetate
38468|NCT02813226|enzalutamide
38469|NCT02813226|metabolic response
38470|NCT02813213|skin transplantation
38471|NCT02813213|grafting skin
38472|NCT02813200|COPD, inhaler device, handling
38473|NCT02813187|venous leg ulcer
38474|NCT02813187|venous
38475|NCT02813187|QCDR
38476|NCT02813187|quality measure
38477|NCT02813187|wound
38478|NCT02813187|Outcome
38479|NCT02813161|diabetic foot ulcer
38480|NCT02813161|diabetes
38481|NCT02813161|arterial disease
38482|NCT02813161|neuropathy
38483|NCT02813161|amputation
38484|NCT02813161|QCDR
38485|NCT02813161|quality measure
38486|NCT02813161|wound
38487|NCT02813096|HCC
38488|NCT02813096|PVTT
38489|NCT02813096|Folofox4
38490|NCT02813096|Early Recurrence
38491|NCT02813044|anesthesia
38492|NCT02813044|intravenous
38493|NCT02813044|neurosurgery
38494|NCT02813044|pituitary neoplasm
38495|NCT02813044|postoperative period
38496|NCT02813031|functional meat products
38497|NCT02813031|hypocaloric fats
38498|NCT02813031|diglyceride
38499|NCT02813031|obesity
38500|NCT02813018|child
38501|NCT02813018|analgesia
38502|NCT02813018|epidural
38503|NCT02813018|pain
38504|NCT02813018|postoperative
38505|NCT02813018|orthopedics
38506|NCT02813005|High frequency jet ventilation
38507|NCT02812966|peripheral arterial disease
38508|NCT02812966|drug coated balloon
38509|NCT02812927|Glycemic lability index
38510|NCT02812927|Continuous glucose monitoring system
38511|NCT02812927|intensive care
38512|NCT02812927|Insulin
38513|NCT02812888|Hyperthyroidism
38514|NCT02812888|Betatrophin
38515|NCT02812836|anorectal manometry
38516|NCT02812836|children
38517|NCT02812836|constipation
38518|NCT02812823|manometry
38519|NCT02812823|children
38520|NCT02812823|constipation
38521|NCT02812823|functional disorders
38522|NCT02812797|Adipokines
38523|NCT02812797|Chronic Heart Failure
38524|NCT02812797|Prognosis
38525|NCT02812784|Nephrocheck™
38526|NCT02812784|acute kidney injury
38527|NCT02812758|sedation depth
38528|NCT02812758|indices of preload dependence
38529|NCT02812745|anaesthesia
38530|NCT02812732|HPV vaccination
38531|NCT02812732|provider education
38532|NCT02812667|Metastatic
38533|NCT02812667|NSCLC
38534|NCT02812667|nivolumab
38535|NCT02812667|plinabulin
38536|NCT02812667|BPI-2358
38537|NCT02812667|opdivo
38538|NCT02812667|Non-Small Cell Lung Cancer
38539|NCT02812667|cancer
38540|NCT02812654|Sarcoma
38541|NCT02812654|soft tissue sarcoma
38542|NCT02812654|neoadjuvant chemotherapy
38543|NCT02812654|neoadjuvant radiotherapy
38544|NCT02812654|hypofractionated radiotherapy
38545|NCT02812641|Concurrent chemoradiation
38546|NCT02812641|Esophageal squamous cell carcinoma
38547|NCT02812641|Vascular endothelial growth factor
38548|NCT02812628|laparoscopic surgery
38549|NCT02812628|abdominoperineal resection
38550|NCT02812628|rectal cancer
38551|NCT02812628|individualized surgery
38552|NCT02812628|levator muscle
38553|NCT02812615|Environmental Enteric Dysfunction
38554|NCT02812602|Total Knee Replacement
38555|NCT02812602|Stitch
38556|NCT02812602|Removal
38557|NCT02812602|Pain
38558|NCT02812589|MRI
38559|NCT02812576|Group B streptococcus
38560|NCT02812576|Infants
38561|NCT02812576|China
38562|NCT02812550|full-spectrum endoscopy
38563|NCT02812550|polyp detection rate
38564|NCT02812550|colorectal cancer
38565|NCT02812550|colorectal screening
38566|NCT02812550|adenoma detection rate
38567|NCT02812550|endoscopic innovations
38568|NCT02812537|Trajectories
38569|NCT02812537|emergency room
38570|NCT02812537|conduct disorder
38571|NCT02812537|care management
38572|NCT02812524|Immunotherapy
38573|NCT02812524|Yervoy
38574|NCT02812524|Head and neck cancer
38575|NCT02812524|Pre-operative
38576|NCT02812498|teleconsultation
38577|NCT02812498|insulin therapy
38578|NCT02812498|HbA1c
38579|NCT02812459|Electrical Stimulation Therapy
38580|NCT02812459|Kinesio taping
38581|NCT02812459|Exercise
38582|NCT02812446|biofilm
38583|NCT02812446|staphylokinase
38584|NCT02812446|Staphylococcus aureus
38585|NCT02812446|microarrays
38586|NCT02812446|bone binding sialoprotein
38587|NCT02812446|bone and joint infection
38588|NCT02812446|blood group
38589|NCT02812433|birth asphyxia
38590|NCT02812433|brain
38591|NCT02812433|hypoxic-ischemic encephalopathy
38592|NCT02812433|neonate
38593|NCT02812433|neuroprotection
38594|NCT02812433|neurorestoration
38595|NCT02812433|newborn
38596|NCT02812433|sildenafil
38597|NCT02812420|Malignant neoplasms of urinary tract
38598|NCT02812420|Urothelial Carcinoma
38599|NCT02812420|Muscle-invasive, high-risk bladder cancer
38600|NCT02812420|Ineligible for neoadjuvant cisplatin-containing chemotherapies
38601|NCT02812420|Bladder cancer
38602|NCT02812420|Cystectomy
38603|NCT02812420|Bladder cancer surgery
38604|NCT02812420|Durvalumab
38605|NCT02812420|MEDI4736
38606|NCT02812420|Tremelimumab
38607|NCT02812420|Phone calls
38608|NCT02812394|Parkinson's disease
38609|NCT02812394|Episodic motor fluctuations (OFF periods)
38610|NCT02812381|Trigger Points, movement
38611|NCT02812355|off-pump
38612|NCT02812355|coronary artery bypass
38613|NCT02812355|heparinization
38614|NCT02812342|Alopecia
38615|NCT02812316|Myopia
38616|NCT02812316|Scleral lens
38617|NCT02812316|Astigmatism
38618|NCT02812316|Presbyopia
38619|NCT02812290|anitbody mediated rejection, T cell mediated rejection
38620|NCT02812277|anastrozole
38621|NCT02812277|letrozole
38622|NCT02812277|postmenopausal patients
38623|NCT02812238|Inflammasome
38624|NCT02812238|Sirt3
38625|NCT02812238|Nicotinamide Riboside
38626|NCT02812238|Fasting
38627|NCT02812212|ureteropelvic junction obstruction
38628|NCT02812212|cortical transit time
38629|NCT02811341|Scopolamine butylbromide PCLE
38630|NCT02810288|Airway anatomy
38631|NCT02810288|difficult intubation
38632|NCT02810288|congenital syndromes
38633|NCT02810262|Lung cancer
38634|NCT02810262|Bone metastases
38635|NCT02810262|EGFR
38636|NCT02810262|KRAS
38637|NCT02810262|Bone biomarkers
38638|NCT02810262|Metabolic parameters
38639|NCT02810249|African American YMSM
38640|NCT02810249|PrEP
38641|NCT02810249|HIV Pre-Exposure Prophylaxis
38642|NCT02810249|Common Sense Model
38643|NCT02810249|Healthcare
38644|NCT02810249|HIV Prevention
38645|NCT02810236|Focal breast pain
38646|NCT02810236|Directed Ultrasound
38647|NCT02810236|Reassurance
38648|NCT02810236|Anxiety
38649|NCT02810210|Zika
38650|NCT02810210|microcephaly
38651|NCT02810210|congenital abnormalities
38652|NCT02810210|new-born
38653|NCT02810210|infant
38654|NCT02812186|Neuromuscular blockade
38655|NCT02812173|urinary drainage
38656|NCT02812173|urethral catheter
38657|NCT02812173|suprapubic tube
38658|NCT02812173|pain
38659|NCT02812173|discomfort
38660|NCT02812173|radical prostatectomy
38661|NCT02812173|robotic surgery
38662|NCT02812173|urinary infection
38663|NCT02812147|L-dihydoxyphenylserine
38664|NCT02812147|L-DOPS
38665|NCT02812147|Northera
38666|NCT02812134|phosphorus supplementation
38667|NCT02812134|FGF23
38668|NCT02812134|anorexic
38669|NCT02812134|adolescents
38670|NCT02812134|undernutrition
38671|NCT02812108|intracranial aneurysm
38672|NCT02812108|endovascular treatment
38673|NCT02812108|recanalization
38674|NCT02812108|outcome
38675|NCT02812108|hemodynamics
38676|NCT02812108|computational fluid dynamic
38677|NCT02812108|stent
38678|NCT02812108|flow diversion
38679|NCT02812082|Web-based
38680|NCT02812082|patient education application
38681|NCT02812082|16-769
38682|NCT02812056|Malignant neoplasms of digestive organs
38683|NCT02812056|Malignant neoplasms of female genital organs
38684|NCT02812056|Malignant neoplasms of lip oral cavity and pharynx
38685|NCT02812056|Malignant neoplasms of male genital organs
38686|NCT02812056|Human papilloma virus associated malignancies
38687|NCT02812056|HPV
38688|NCT02812056|Alisertib
38689|NCT02812056|MLN8237
38690|NCT02812056|TAK-228
38691|NCT02812056|MLN0128
38692|NCT02812043|onychomycosis
38693|NCT02812043|amorolfine
38694|NCT02812043|long-pulsed Nd:YAG
38695|NCT02812043|fungal infection
38696|NCT02812030|Observational Study
38697|NCT02812030|aflibercept
38698|NCT02812030|Diabetic Retinopathy
38699|NCT02812030|Visual Acuity
38700|NCT02812017|educational intervention
38701|NCT02812017|language development
38702|NCT02812017|postpartum
38703|NCT02812017|parental attachment
38704|NCT02812017|achievement gap
38705|NCT02812017|language gap
38706|NCT02812017|school readiness
38707|NCT02812004|Vitreous Floaters
38708|NCT02812004|Mouches Voulantes
38709|NCT02811991|paracetamol
38710|NCT02811991|post-operative analgesia
38711|NCT02811965|heel
38712|NCT02811965|pressure ulcer
38713|NCT02811965|pressure mapping
38714|NCT02811952|bladder cancer
38715|NCT02811939|Cannabis
38716|NCT02811939|Marijuana
38717|NCT02811939|THC
38718|NCT02811939|Dronabinol
38719|NCT02811939|Pregnenolone
38720|NCT02811939|PREG
38721|NCT02811939|Psychotic Disorders
38722|NCT02811926|parastomal bulging
38723|NCT02811926|peristomal bulging
38724|NCT02811926|ileostomy
38725|NCT02811926|colostomy
38726|NCT02811926|enterostomy
38727|NCT02811926|incidence
38728|NCT02811926|risk factor
38729|NCT02811913|sensory impairment
38730|NCT02811913|sensory deficit
38731|NCT02811913|upper limb
38732|NCT02811913|transcranial magnetic stimulation
38733|NCT02811913|brain stimulation
38734|NCT02811913|rehabilitation
38735|NCT02811900|obesity surgery
38736|NCT02811900|Roux en Y gastric bypass
38737|NCT02811900|sleeve gastrectomy
38738|NCT02811900|excess weight loss
38739|NCT02811900|quality of life
38740|NCT02811874|diabetes education
38741|NCT02811874|community health workers
38742|NCT02811874|diabetes control
38743|NCT02811861|Renal Cell Carcinoma (RCC)
38744|NCT02811861|Lenvatinib
38745|NCT02811861|First-line RCC
38746|NCT02811861|Treatment-naive RCC
38747|NCT02811861|Everolimus
38748|NCT02811861|Pembrolizumab
38749|NCT02811861|Sunitinib
38750|NCT02811861|Phase 3 RCC
38751|NCT02811861|Phase 3 first-line RCC
38752|NCT02811861|Phase 3 treatment-naive RCC
38753|NCT02811822|GMI-1271
38754|NCT02811822|bortezomib
38755|NCT02811822|carfilzomib
38756|NCT02811822|multiple myeloma
38757|NCT02811809|Prostate cancer
38758|NCT02811809|Apalutamide
38759|NCT02811809|IHT
38760|NCT02811809|BCR
38761|NCT02811809|Biochemical recurrence
38762|NCT02811809|intermittent hormone therapy
38763|NCT02811796|drug eluting stents
38764|NCT02811796|flow fractional reserve
38765|NCT02811796|prognosis
38766|NCT02811796|angio-based FFR
38767|NCT02811783|Pruritus
38768|NCT02811783|Mycosis Fungoides
38769|NCT02811783|CTCL
38770|NCT02811783|naloxone
38771|NCT02811783|opiate antagonist
38772|NCT02811718|Stress Management
38773|NCT02811718|Resiliency
38774|NCT02811718|Skype
38775|NCT02811692|Database
38776|NCT02811692|Diabetic Macular Edema (DME)
38777|NCT02811692|Wet Age-related Macular Degeneration (wAMD)
38778|NCT02811692|Retinal Diseases
38779|NCT02811692|Optic Nerve Diseases
38780|NCT02811692|Corneal Diseases
38781|NCT02811692|Vision Disorders
38782|NCT02811679|Lymphoma
38783|NCT02811653|Motor slowing
38784|NCT02811640|Intra-Abdominal Pressure
38785|NCT02811640|Stryker Pressure Monitor
38786|NCT02811627|Magnetic Resonance Spectroscopy
38787|NCT02811627|Memantine
38788|NCT02811627|Treatment prediction biomarker
38789|NCT02811614|intracerebral hemorrhage,hypertensive
38790|NCT02811614|minimally invasive surgery
38791|NCT02811614|neuroendoscopic surgery
38792|NCT02811614|stereotactic aspiration
38793|NCT02811601|Minimally Invasive Surgical Procedures
38794|NCT02811575|Coloscopy
38795|NCT02811549|Cochlear Implant
38796|NCT02811549|HiRes™ 90K Advantage Implant
38797|NCT02811549|HiFocus™ Mid-Scala electrode
38798|NCT02811549|HiFocus™ 1J electrode
38799|NCT02811549|HiFocus Helix™ electrode
38800|NCT02811549|Cochlear Implantation
38801|NCT02811549|Listening Benefits
38802|NCT02811549|Adults
38803|NCT02811549|Cochlear Implant Benefit
38804|NCT02811549|Electrical Stimulation
38805|NCT02811484|Obesity
38806|NCT02811458|Panic Disorder
38807|NCT02811458|Agoraphobia
38808|NCT02811458|Social Anxiety Disorder
38809|NCT02811458|Generalized Anxiety Disorder
38810|NCT02811458|Cognitive-Behavioral Therapy
38811|NCT02811445|microbiome, metabolome, aging, lean mass, physical function
38812|NCT02811432|Kangaroo mother care
38813|NCT02811432|Neonates
38814|NCT02811432|Low birth weight
38815|NCT02811432|Unstable
38816|NCT02811393|Bariatric surgery, sarcopenia
38817|NCT02811380|CVC
38818|NCT02811380|Healthcare associated infections (HAI)
38819|NCT02811380|CLABSI
38820|NCT02811380|Noble metal alloy coating
38821|NCT02811380|CVC related thrombosis
38822|NCT02811276|High-protein diet
38823|NCT02811276|Energy metabolism
38824|NCT02811276|Substrate oxidation
38825|NCT02811250|Renal cancer
38826|NCT02811250|Stereotactic radiotherapy
38827|NCT02811185|PET
38828|NCT02811185|CT
38829|NCT02811185|PET/CT
38830|NCT02811172|Biological multi-paradigm model
38831|NCT02811172|Biomarkers
38832|NCT02811172|Triglycerides
38833|NCT02811172|Cholesterol
38834|NCT02811172|Prolactin
38835|NCT02811172|Glucose
38836|NCT02811146|Heart Failure
38837|NCT02811146|Noninvasive Ventilation
38838|NCT02811146|Positive- Pressure Respiration
38839|NCT02811133|inositol
38840|NCT02811120|meningococcal
38841|NCT02811120|conjugate
38842|NCT02811120|vaccine
38843|NCT02811120|quadrivalent
38844|NCT02811120|meningococcal quadrivalent conjugate vaccine
38845|NCT02811107|anxiety
38846|NCT02811107|pain
38847|NCT02811107|preoperative area
38848|NCT02811107|premedication
38849|NCT02811068|HPV
38850|NCT02811068|vaccine
38851|NCT02811068|Human Papillomavirus Virus Vaccine
38852|NCT02811029|neurological
38853|NCT02811029|difficulties
38854|NCT02811016|High Altitude
38855|NCT02811016|budesonide
38856|NCT02811016|hypoxia
38857|NCT02811003|Insertional Achilles
38858|NCT02810990|bosutinib
38859|NCT02810990|chronic myeloid leukemia
38860|NCT02810977|gastric volume
38861|NCT02810977|gastric content
38862|NCT02810977|ultrasound
38863|NCT02810977|perioperative fasting
38864|NCT02810964|Schizophrenia
38865|NCT02810964|Schizoaffective Disorder
38866|NCT02810964|Sulforaphane
38867|NCT02810964|Sulforaphane supplement
38868|NCT02810951|RDEB
38869|NCT02810938|Ablation
38870|NCT02810938|Mifi technology
38871|NCT02810938|maximum voltage-guided ablation
38872|NCT02810899|child
38873|NCT02810899|craniotomy
38874|NCT02810899|intelligence tests
38875|NCT02810899|dexmedetomidine
38876|NCT02810899|Disruption
38877|NCT02810899|Dehiscence
38878|NCT02810899|Mild Cognitive Disorder
38879|NCT02810886|Prostate Cancer
38880|NCT02810860|laparoscopic cholecystectomy
38881|NCT02810847|Amblyopia
38882|NCT02810847|strabismus
38883|NCT02810847|virtual reality
38884|NCT02810847|computer games
38885|NCT02810834|Executive Function
38886|NCT02810834|Academic Performance
38887|NCT02810821|Gonadal hormones
38888|NCT02810821|Gonadotropins
38889|NCT02810821|Cardiovascular diseases
38890|NCT02810821|Lipids
38891|NCT02810821|Obesity
38892|NCT02810821|Atherosclerosis
38893|NCT02810821|Glucose metabolism disorders
38894|NCT02810821|Metabolic syndrome
38895|NCT02810821|Non-alcoholic fatty liver disease
38896|NCT02810808|Neovascular Age-related Macular Degeneration
38897|NCT02810808|Ranibizumab
38898|NCT02810808|Pro Re Nata
38899|NCT02810795|Coronary
38900|NCT02810795|Artery
38901|NCT02810795|Computed tomography
38902|NCT02810795|FFR
38903|NCT02810795|CT myocardial perfusion
38904|NCT02810795|Dynamic
38905|NCT02810782|opiate dependence
38906|NCT02810782|withdrawal
38907|NCT02810782|newborn
38908|NCT02810730|pancreas
38909|NCT02810730|adenocarcinoma
38910|NCT02810704|Anticoagulant
38911|NCT02810704|Venous Thromboembolism
38912|NCT02810704|Pulmonary Embolism
38913|NCT02810704|Total Knee Arthroplasty
38914|NCT02810704|Total Hip Arthroplasty
38915|NCT02810691|Diabetes
38916|NCT02810691|Fiber
38917|NCT02810691|Supplementation
38918|NCT02810691|Soluble fiber
38919|NCT02810691|Post-prandial blood glucose
38920|NCT02810691|Nutrition
38921|NCT02810678|Tuberculosis
38922|NCT02810665|Repeatability
38923|NCT02810665|Concordance
38924|NCT02810665|Agreement
38925|NCT02810665|ETDRS visual acuity chart
38926|NCT02810665|numeric
38927|NCT02810665|Landolt C
38928|NCT02810665|Roman alphabet
38929|NCT02810652|Cancer Surgery Care
38930|NCT02810639|pain
38931|NCT02810587|Endophthalmitis
38932|NCT02810587|Intravitreous injection
38933|NCT02810587|anti-vascular endothelial growth factor
38934|NCT02810587|topical antibiotics
38935|NCT02810561|Troponin
38936|NCT02810535|Local IgE
38937|NCT02810535|Non-allergic rhinitis
38938|NCT02810535|Allergic rhinitis to house dust mite
38939|NCT02810509|Wafarin
38940|NCT02810509|Cardioembolic (CE) stroke
38941|NCT02810509|ischemic stroke
38942|NCT02810483|Prader-Willi
38943|NCT02810483|SPW
38944|NCT02810483|impulsivity
38945|NCT02810483|eating disorders
38946|NCT02810483|topiramate
38947|NCT02810457|Cancer
38948|NCT02810457|Bevacizumab
38949|NCT02810457|Carboplatin
38950|NCT02810457|Paclitaxel
38951|NCT02810431|Transfer Protocol
38952|NCT02810431|Long-Term Storage
38953|NCT02810431|Sample Retention
38954|NCT02810418|Immunotoxin
38955|NCT02810418|Mesothelin
38956|NCT02810418|Antibody-based Therapeutics
38957|NCT02810418|Advanced Cancer
38958|NCT02810405|Sample
38959|NCT02810405|Storage
38960|NCT02810405|Molecular Profiling
38961|NCT02810405|Biopsy
38962|NCT02810405|Repository
38963|NCT02810379|informed consent
38964|NCT02810379|ERCP
38965|NCT02810379|video
38966|NCT02810366|Verbal Autopsy
38967|NCT02810366|Physician-coded verbal autopsy
38968|NCT02810366|Computer-coded verbal autopsy
38969|NCT02810366|InterVA
38970|NCT02810366|Naive Bayes Classifier (NBC)
38971|NCT02810366|Tariff
38972|NCT02810366|InSilicoVA
38973|NCT02810366|Randomised Control Trial
38974|NCT02810366|SmartVA
38975|NCT02810366|King-Lu
38976|NCT02810327|Alpha-1 antitrypsin deficiency
38977|NCT02810327|AATD
38978|NCT02810327|Alpha-1
38979|NCT02810327|SERPINA1
38980|NCT02810327|MZ
38981|NCT02810327|Carrier
38982|NCT02810327|Heterozygote
38983|NCT02810327|Smoking
38984|NCT02810327|COPD
38985|NCT02810327|Emphysema
38986|NCT02810327|Sequencing
38987|NCT02810301|gluten
38988|NCT02810301|non-celiac
38989|NCT02810301|gluten sensitivity
38990|NCT02810184|bone augmentation
38991|NCT02810184|long-term bone volume changes
38992|NCT02810184|immediate provisional implant
38993|NCT02810171|anxiety
38994|NCT02810171|social anxiety disorder
38995|NCT02810171|generalized anxiety disorder
38996|NCT02810171|phobias
38997|NCT02810171|fears
38998|NCT02810171|worry
38999|NCT02810145|traumatic brain injury
39000|NCT02810145|cerebral desaturation
39001|NCT02810145|intensive care
39002|NCT02810145|hemodynamics
39003|NCT02810145|Loss
39004|NCT02810145|Consciousness
39005|NCT02810106|Spect
39006|NCT02810106|Stress Test
39007|NCT02810106|Myocardial Perfusion CT
39008|NCT02810106|CT angiography
39009|NCT02810093|Breast cancer
39010|NCT02810093|Text mining
39011|NCT02810093|Big Data
39012|NCT02810093|Machine Learning
39013|NCT02810054|regeneration
39014|NCT02810054|intrabony defects
39015|NCT02810054|enamel matrix derivative
39016|NCT02810054|MIST
39017|NCT02810028|Limb girdle muscular dystrophy
39018|NCT02810028|Becker's muscular dystrophy
39019|NCT02810028|Facioscapulohumeral muscular dystrophy
39020|NCT02810028|Inclusion-body myositis
39021|NCT02810028|Acceptance and Commitment Therapy
39022|NCT02810028|ACT
39023|NCT02809950|postoperative nausea and vomiting, oral carbohydrate beverage
39024|NCT02809937|aged
39025|NCT02809937|surgical procedures, operative
39026|NCT02809937|delirium
39027|NCT02809937|dexmedetomidine
39028|NCT02809937|long-term outcome
39029|NCT02809924|endotracheal intubation
39030|NCT02809924|teaching
39031|NCT02809924|just-in-time
39032|NCT02809898|Biomarkers, Neoplasms
39033|NCT02809885|Hepatitis E
39034|NCT02809885|Pediatric
39035|NCT02809885|Transplantation
39036|NCT02809885|Prevalence
39037|NCT02809820|ACS
39038|NCT02809820|Beta Blockers
39039|NCT02809820|platelet aggregation
39040|NCT02809820|light transmission aggregometry
39041|NCT02809820|Beta-Adrenergic Blockers
39042|NCT02809807|Work of Breathing; Hypoxemia; Respiratory Acidosis; Respiratory effort; COPD
39043|NCT02809781|ankylosing spondylitis
39044|NCT02809781|mesenchymal stem cell
39045|NCT02809781|etanercept
39046|NCT02809768|Healthy participants
39047|NCT02809768|Pharmacokinetic Drug-Drug Interaction
39048|NCT02809768|Avatrombopag
39049|NCT02809755|Obesity
39050|NCT02809755|laparoscopic gastric banding
39051|NCT02809755|band revision
39052|NCT02809755|laparoscopic gastric banding sleeve gastrectomy
39053|NCT02809742|Pregnant
39054|NCT02809742|Labor
39055|NCT02809742|Epidural
39056|NCT02809742|Analgesia
39057|NCT02809742|Intermittent
39058|NCT02809651|Infrascanner
39059|NCT02809651|Intracranial hemorrhage
39060|NCT02809625|Dynamic contrast -enhanced MRI
39061|NCT02809625|brucella spondylitis
39062|NCT02809599|vertigo
39063|NCT02809599|dizziness
39064|NCT02809586|Alcohol
39065|NCT02809586|Teens
39066|NCT02809586|Young Adults
39067|NCT02809586|Social Media
39068|NCT02809573|peripheral T-cell lymphoma
39069|NCT02809573|PTCL
39070|NCT02809573|chidamide
39071|NCT02809573|CHOP
39072|NCT02809573|phase Ib
39073|NCT02809560|Lymphocytes Th2
39074|NCT02809560|Cav1 channels
39075|NCT02809534|Anlotinib
39076|NCT02809534|AL3818
39077|NCT02809508|Omega-3
39078|NCT02809508|Child nutrition
39079|NCT02809508|Dietary recommendations
39080|NCT02809508|Cardiovascular risk markers
39081|NCT02809508|Cognitive function
39082|NCT02809508|Mental health
39083|NCT02809482|Volunteers
39084|NCT02809443|Zika
39085|NCT02809443|Vaccine
39086|NCT02809443|DNA
39087|NCT02809391|Postural Balance
39088|NCT02809391|Gait
39089|NCT02809391|Foot Orthotic
39090|NCT02809391|Proprioception
39091|NCT02809391|Somatosensory
39092|NCT02809365|insulin treated
39093|NCT02809339|Chemotherapy
39094|NCT02809339|ovarian cancer
39095|NCT02809339|Patient reported outcome
39096|NCT02809339|Quality of Care
39097|NCT02809326|efficiency
39098|NCT02809326|exposure therapy
39099|NCT02809326|PTSD
39100|NCT02809326|combat
39101|NCT02809326|veterans
39102|NCT02809313|gingivitis
39103|NCT02809313|probiotic
39104|NCT02809313|non- surgical treatment
39105|NCT02809274|iron deficiency
39106|NCT02809274|polycythemia vera
39107|NCT02809261|Carpal Tunnel Syndrome
39108|NCT02809261|Perineural injection
39109|NCT02809261|Dextrose
39110|NCT02809248|LTX Study
39111|NCT02809235|asthma
39112|NCT02809235|smooth muscle
39113|NCT02809235|lauric acid
39114|NCT02809235|dietary supplement
39115|NCT02809222|Myelodysplastic syndrome
39116|NCT02809222|Ascorbic acid
39117|NCT02809222|Oxidative stress
39118|NCT02809222|Preleukemia
39119|NCT02809196|Food Habits
39120|NCT02809196|Adolescents
39121|NCT02809196|Digital Communication
39122|NCT02809183|metabolic acidosis
39123|NCT02809183|serum bicarbonate
39124|NCT02809183|kidney disease
39125|NCT02809131|CIED infection
39126|NCT02809118|Deafness
39127|NCT02809118|Hearing Loss
39128|NCT02809118|Hearing Loss, Sensorineural
39129|NCT02809118|Ear Diseases
39130|NCT02809118|Hearing Disorders
39131|NCT02809118|Nervous System Diseases
39132|NCT02809118|Neurologic Manifestations
39133|NCT02809118|Otorhinolaryngologic Diseases
39134|NCT02809118|Sensation Disorders
39135|NCT02809118|Signs and Symptoms
39136|NCT02809118|Hearing and Speech Impairment
39137|NCT02809118|Hearing Loss, Unilateral
39138|NCT02809105|Chronic constipation
39139|NCT02809105|Linaclotide
39140|NCT02809105|ASP0456
39141|NCT02809092|Acute Myeloid Leukemia, Natural Killer Cells
39142|NCT02809066|premenstrual syndrome
39143|NCT02809066|calcium
39144|NCT02809066|quality of life
39145|NCT02809053|low tumor burden follicular lymphoma (LTBFL)
39146|NCT02809014|Fluoride
39147|NCT02809014|Dental caries
39148|NCT02809014|Dentifrice
39149|NCT02809001|Fat grafting
39150|NCT02809001|Expansion-related complications
39151|NCT02808988|Bisphosphonate
39152|NCT02808988|osteoporosis
39153|NCT02808988|RANKL
39154|NCT02808988|OPG
39155|NCT02808988|periodontitis
39156|NCT02808975|secondary intention
39157|NCT02808975|Hidradenitis Suppurativa
39158|NCT02808975|Hurley Stage I, II, or III
39159|NCT02808975|adalimumab
39160|NCT02808975|axilla
39161|NCT02808975|abcess and inflammatory nodule (AN) count
39162|NCT02808975|inguinal region
39163|NCT02808949|Prevention
39164|NCT02808949|Lactating Women
39165|NCT02808949|Healthy
39166|NCT02808936|remote ischemic conditioning
39167|NCT02808936|orthopedic surgery
39168|NCT02808936|ischemic heart disease
39169|NCT02808910|behavior
39170|NCT02808910|food intake
39171|NCT02808910|salt
39172|NCT02808910|vegetables
39173|NCT02808910|portion size
39174|NCT02808910|weight loss
39175|NCT02808910|habits
39176|NCT02808897|Chest tubes
39177|NCT02808897|Atrial fibrillation
39178|NCT02808897|Thoracic surgery
39179|NCT02808897|Critical care
39180|NCT02808858|MDS
39181|NCT02808858|Myelodisplastic Syndrome
39182|NCT02808845|coronary angiography
39183|NCT02808845|contrast-induced acute kidney injury
39184|NCT02808845|microalbuminuria
39185|NCT02808832|Human papillomavirus (HPV) vaccine
39186|NCT02808832|Cervical cancer screening
39187|NCT02808832|Provider intervention
39188|NCT02808819|Asthma
39189|NCT02808819|Bronchial Diseases
39190|NCT02808819|Respiratory Tract Diseases
39191|NCT02808819|Lung Diseases
39192|NCT02808819|Obstructive Lung Diseases
39193|NCT02808806|stroke
39194|NCT02808806|cerebral infarction
39195|NCT02808806|brain infarction
39196|NCT02808806|ischemic stroke
39197|NCT02808806|treatment
39198|NCT02808806|intravenous thrombolysis
39199|NCT02808806|intraarterial thrombectomy
39200|NCT02808806|delay
39201|NCT02808806|total system delay
39202|NCT02808806|pre-hospital delay
39203|NCT02808806|in-hospital delay
39204|NCT02808806|feedback
39205|NCT02808806|real-time feedback
39206|NCT02808806|visual feedback
39207|NCT02808793|ISM
39208|NCT02808793|Mastocytosis
39209|NCT02808793|Indolent Mastocytosis
39210|NCT02808780|Ulcerative Colitis
39211|NCT02808780|Simponi (Golimumab)
39212|NCT02808780|Thiopurines
39213|NCT02808780|Lymphoma
39214|NCT02808780|Malignancies
39215|NCT02808767|Acute myocardial infarction
39216|NCT02808767|Primary coronary intervention
39217|NCT02808767|Antiplatelet therapy
39218|NCT02808728|Total Knee Arthroplasty
39219|NCT02808728|Total Knee Replacement
39220|NCT02808728|Exparel
39221|NCT02808728|Liposomal Bupivacaine
39222|NCT02808728|Ropivacaine
39223|NCT02808728|Postoperative Pain Management
39224|NCT02808702|Attention
39225|NCT02808702|Cognitive behavioral therapy
39226|NCT02808702|Neuroimaging
39227|NCT02808689|Moderate
39228|NCT02808689|Severe
39229|NCT02808676|Cognitive training
39230|NCT02808676|Vitamin D
39231|NCT02808676|Exercise
39232|NCT02808637|Pain management
39233|NCT02808637|vaccination
39234|NCT02808637|manual pressure
39235|NCT02808637|needle aspiration
39236|NCT02808624|Oxaliplatin, peripheral neuropathy, L-CARNOSINE
39237|NCT02808598|Clinical Trials
39238|NCT02808598|Education
39239|NCT02808598|Hispanic Americans
39240|NCT02808598|African Americans
39241|NCT02808598|Health Disparities
39242|NCT02808598|Patient Participation
39243|NCT02808598|Refusal to Participate
39244|NCT02808572|chronic kidney disease
39245|NCT02808572|vascular calcifications
39246|NCT02808572|cardiovascular risk
39247|NCT02808546|Gallbladder stone
39248|NCT02808546|Risk factor
39249|NCT02808546|Case-control study
39250|NCT02808546|Obesity
39251|NCT02808546|Hypertension
39252|NCT02808546|Alcohol consumption
39253|NCT02808520|Social participation
39254|NCT02808520|Children and adolescents with cancer
39255|NCT02808520|Quality of life with hodgkin-lymphoma
39256|NCT02808520|Social inequalities and cancer
39257|NCT02808494|Preeclampsia
39258|NCT02808494|Fetal Growth Restriction
39259|NCT02808481|systemic sclerosis
39260|NCT02808481|cardiac disease
39261|NCT02808481|Heart transplantation
39262|NCT02808481|primitive cardiac damage
39263|NCT02808468|Sexual assault
39264|NCT02808468|Posttraumatic Stress Disorder
39265|NCT02808468|Alcohol use
39266|NCT02808468|Cognitive therapy
39267|NCT02808429|Berger's disease
39268|NCT02808429|Inflammation of the kidney
39269|NCT02808416|Solid tumors
39270|NCT02808416|Brain metastases
39271|NCT02808416|DC vaccine
39272|NCT02808416|Personalized vaccine
39273|NCT02808416|Tumor antigens
39274|NCT02808416|PBMCs
39275|NCT02808364|Recurrent glioblastoma
39276|NCT02808364|DC vaccine
39277|NCT02808364|tumor antigen
39278|NCT02808364|personalized vaccine
39279|NCT02808299|statin
39280|NCT02808299|hepatitis B virus
39281|NCT02808273|Bemiparine
39282|NCT02808273|Antithrombotic microsurgery protocol
39283|NCT02808273|Comparative study
39284|NCT02808273|Anticoagulant microsurgery protocol
39285|NCT02808260|sub-clinical atrial fibrillation
39286|NCT02808260|biomarkers
39287|NCT02808260|implanted pacemaker or defibrillator
39288|NCT02808247|advanced metastatic soft tissue sarcoma
39289|NCT02808221|Heart failure
39290|NCT02808221|heart disease
39291|NCT02808195|Cerebral Palsy
39292|NCT02808195|Neurological Rehabilitation
39293|NCT02808195|Upper Extremity
39294|NCT02808156|Cerebral Palsy,
39295|NCT02808156|Upper limb neurorehabilitation
39296|NCT02808156|Upper Extremity
39297|NCT02808156|Neurological Rehabilitation
39298|NCT02808130|hyperlipidemia, periodontal disease, oxidative stress,
39299|NCT02808117|microfinance institution
39300|NCT02808117|MFI
39301|NCT02808078|Instrumented treadmill
39302|NCT02808078|Augmented reality
39303|NCT02808078|Neurorehabilitation
39304|NCT02808078|Gait disorders
39305|NCT02808065|Kidney transplant
39306|NCT02808065|Kidney transplantation
39307|NCT02808065|Renal transplant
39308|NCT02808065|Renal transplantation
39309|NCT02808052|Bacterial infections
39310|NCT02808026|severe hypertension
39311|NCT02808026|grade III hypertension
39312|NCT02808026|mineralocorticoid receptor antagonist
39313|NCT02807987|Mineralocorticoid receptor antagonist
39314|NCT02807987|Moderate renal impairment
39315|NCT02807987|Hypertension
39316|NCT02807974|Hypertension with Type 2 Diabetes and Albuminuria
39317|NCT02807974|Diabetic nephropathy
39318|NCT02807974|Diabetic renal disease
39319|NCT02807974|Albuminuria
39320|NCT02807974|Mineralocorticoid receptor antagonist
39321|NCT02807961|Translational read through
39322|NCT02807948|MRI Scan, pacemakers, ICD, CRT
39323|NCT02807922|Palliative Care
39324|NCT02807922|zopiclone
39325|NCT02807896|biomarker
39326|NCT02807896|pancreatic cancer
39327|NCT02807896|bile duct cancer
39328|NCT02807896|miRNA
39329|NCT02807883|Acute Lymphoblastic Leukemia
39330|NCT02807883|ALL
39331|NCT02807883|B-lineage Acute Lymphoblastic Leukemia
39332|NCT02807883|Malignant neoplasms stated as primary lymphoid haematopoietic
39333|NCT02807883|Blinatumomab
39334|NCT02807883|Blincyto
39335|NCT02807883|Post allogeneic stem cell transplant
39336|NCT02807870|Parental training
39337|NCT02807857|low-interventional observational study,
39338|NCT02807857|CHF,
39339|NCT02807857|heart failure,
39340|NCT02807857|primary care,
39341|NCT02807857|ESC guidelines,
39342|NCT02807857|Europe,
39343|NCT02807857|NT-proBNP,
39344|NCT02807857|reduced ventricular ejection fraction (EF),
39345|NCT02807844|Triple negative breast cancer
39346|NCT02807844|Pancreatic carcinoma
39347|NCT02807844|Melanoma
39348|NCT02807844|Endometrial Carcinoma
39349|NCT02807844|Immuno oncology
39350|NCT02807844|Monoclonal antibody
39351|NCT02807844|PDR001
39352|NCT02807844|MCS110
39353|NCT02807831|Executive Function
39354|NCT02807831|Language
39355|NCT02807831|Preschool child
39356|NCT02807831|Development
39357|NCT02807818|Child development
39358|NCT02807818|Infant
39359|NCT02807818|Mother-Child Relations
39360|NCT02807805|castration resistant prostate cancer
39361|NCT02807792|Perianal surgery
39362|NCT02807779|angioplasty
39363|NCT02807779|peripheral artery disease
39364|NCT02807779|peripheral vascular disease
39365|NCT02807779|atherosclerosis
39366|NCT02807779|balloon angioplasty
39367|NCT02807779|dexamethasone
39368|NCT02807779|drug coated balloon
39369|NCT02807779|paclitaxel
39370|NCT02807779|walking
39371|NCT02807779|claudication
39372|NCT02807766|autism
39373|NCT02807766|Brain Plasticity
39374|NCT02807766|Behavioral Intervention
39375|NCT02807766|Magnetic Resonance Imaging
39376|NCT02807753|Hemophilia
39377|NCT02807753|Arthropathy
39378|NCT02807753|Pediatric
39379|NCT02807740|Virtual Reality
39380|NCT02807740|Rehabilitation
39381|NCT02807740|Cardiocirculatory system
39382|NCT02807740|Parkinson Disease
39383|NCT02807688|health promotion
39384|NCT02807688|lifestyles
39385|NCT02807688|physical comorbidity
39386|NCT02807688|risk factors
39387|NCT02807688|behavioural change
39388|NCT02807662|posttraumatic stress disorder
39389|NCT02807662|prenatal care
39390|NCT02807636|Urothelial carcinoma
39391|NCT02807636|Bladder cancer
39392|NCT02807636|Anti-PD-L1
39393|NCT02807636|Transitional carcinoma
39394|NCT02807636|Tecentriq
39395|NCT02807636|Atezolizumab
39396|NCT02807636|IMvigor130
39397|NCT02807610|Etomidate lipuro
39398|NCT02807610|Induction characteristics
39399|NCT02807584|Wound
39400|NCT02807584|burns
39401|NCT02807584|acute
39402|NCT02807584|chronic
39403|NCT02807584|foam
39404|NCT02807584|adhesive
39405|NCT02807584|dressing
39406|NCT02807571|Hand
39407|NCT02807558|AML
39408|NCT02807558|MDS
39409|NCT02807545|Scoliosis-Specific Exercises
39410|NCT02807545|Schroth
39411|NCT02807519|Oral health
39412|NCT02807519|Saliva
39413|NCT02807519|Biomarker
39414|NCT02807519|Cytokines
39415|NCT02807519|Cancer
39416|NCT02807519|children
39417|NCT02807506|elders
39418|NCT02807506|robotics
39419|NCT02807506|low income population
39420|NCT02807506|activities of daily living
39421|NCT02807506|instrumental activities of daily living
39422|NCT02807506|social robotics
39423|NCT02807506|stroke
39424|NCT02807506|aged
39425|NCT02807506|Retirement
39426|NCT02807506|Housing for elderly
39427|NCT02807506|Homes for the aged
39428|NCT02807493|Pregnancy
39429|NCT02807493|Labor and Delivery
39430|NCT02807493|Occlusal Support Device
39431|NCT02807467|reduction
39432|NCT02807467|delirium
39433|NCT02807467|duration
39434|NCT02807467|severity
39435|NCT02807454|Phase 2
39436|NCT02807454|Open-Label
39437|NCT02807454|Durvalumab
39438|NCT02807454|Daratumumab
39439|NCT02807454|Multiple Myeloma
39440|NCT02807454|Relapsed and Refractory (RRMM)
39441|NCT02807454|FUSION MM-003
39442|NCT02807454|PD-L1
39443|NCT02807441|Bleeding
39444|NCT02807441|Aspirin
39445|NCT02807441|Spine
39446|NCT02807441|Surgery
39447|NCT02807428|post-surgical pain
39448|NCT02807428|total knee arthroplasty
39449|NCT02807428|total knee replacement
39450|NCT02807415|cystic fibrosis
39451|NCT02807415|CFTR
39452|NCT02807415|CFTR modulation
39453|NCT02807415|sweat test
39454|NCT02807415|intestinal current measurement, ICM
39455|NCT02807415|nasal transepithelial potential difference measurement, NPD
39456|NCT02807402|Ombitasvir
39457|NCT02807402|Dasabuvir
39458|NCT02807402|Paritaprevir
39459|NCT02807402|HCV
39460|NCT02807402|Chronic Hepatitis C
39461|NCT02807363|endometriosis
39462|NCT02807363|gonadotropin-releasing hormone agonist
39463|NCT02807363|healthy volunteers
39464|NCT02807363|leuprolide oral tablet
39465|NCT02807350|Intermittent Exotropia
39466|NCT02807350|IXT
39467|NCT02807350|overminus
39468|NCT02807337|Oral mucositis
39469|NCT02807311|Malnutrition
39470|NCT02807311|Undernutrition
39471|NCT02807311|lung transplantation
39472|NCT02807311|artificial nutrition
39473|NCT02807311|nutritional supplements
39474|NCT02807311|enteral nutrition
39475|NCT02807298|Intarligamentary
39476|NCT02807298|Articaine
39477|NCT02807298|Lidocaine
39478|NCT02807246|Probiotic
39479|NCT02807246|Neonatal Hyperbilirubinemia
39480|NCT02807220|Imuneks
39481|NCT02807207|To Study pharmacokinetics and Cardiac safety pacritinib study
39482|NCT02807155|Transitional Care
39483|NCT02807155|Young Adult
39484|NCT02807155|Guided Imagery
39485|NCT02807116|Drug-Interaction Study
39486|NCT02807103|Rituximab
39487|NCT02807103|remission induction
39488|NCT02807103|eosinophilic granulomatosis with polyangiitis
39489|NCT02807090|Low Back Pain
39490|NCT02807090|Exercise
39491|NCT02807090|Dance Therapy
39492|NCT02807090|Physical Therapy
39493|NCT02807077|Healthy subjects
39494|NCT02807038|Respiratory Function Tests
39495|NCT02807038|Air pollution
39496|NCT02807038|Pregnancy
39497|NCT02807038|Spirometry
39498|NCT02807012|Home care services
39499|NCT02807012|Nursing
39500|NCT02807012|Clinical trial
39501|NCT02807012|Geriatric nursing
39502|NCT02807012|Family caregiver
39503|NCT02807012|Aged
39504|NCT02806999|Heart disease
39505|NCT02806999|Postoperative period
39506|NCT02806999|Hyperglycemia
39507|NCT02806999|Berberine
39508|NCT02806999|Insulin
39509|NCT02806999|Clinical trials as topic
39510|NCT02806947|Acute GVHD
39511|NCT02806947|Standard-Risk
39512|NCT02806947|Sirolimus
39513|NCT02806947|Refined Minnesota Risk Criteria
39514|NCT02806947|Ann Arbor
39515|NCT02806947|Biomarker
39516|NCT02806947|Steroid-Free
39517|NCT02806921|Scleral Contact Lens
39518|NCT02806921|Tear Proteases
39519|NCT02806921|Tear Cytokines
39520|NCT02806908|Driving
39521|NCT02806895|Driving
39522|NCT02806856|Middle Cerebral Artery Stroke
39523|NCT02806856|tDCS
39524|NCT02806856|Acute
39525|NCT02806843|stroke
39526|NCT02806843|hemiplegia
39527|NCT02806843|healthy
39528|NCT02806843|robotics
39529|NCT02806843|rehabilitation
39530|NCT02806843|therapy
39531|NCT02806830|Intravitreal injection
39532|NCT02806830|AMD
39533|NCT02806830|Diabetic Retinopathy
39534|NCT02806830|Retinal Artery Occlusion
39535|NCT02806830|Myopia, Degenerative
39536|NCT02806830|eye drops
39537|NCT02806804|vaccine
39538|NCT02806804|safety
39539|NCT02806804|immunogenicity
39540|NCT02806791|Patients
39541|NCT02806778|cardiac arrest
39542|NCT02806778|jugular venous oximetry
39543|NCT02806778|hypoxic brain injury
39544|NCT02806765|Dynamic Stability
39545|NCT02806765|Postural Stability
39546|NCT02806765|Gait Speed
39547|NCT02806765|Hand Grip Strength
39548|NCT02806765|Timed Get-up and Go
39549|NCT02806765|Older Adults
39550|NCT02806752|Polypoidal Choroidal Vasculopathy
39551|NCT02806739|Soy protein
39552|NCT02806739|isoflavones
39553|NCT02806739|gestational diabetes
39554|NCT02806700|Diabetes
39555|NCT02806700|Social Media
39556|NCT02806687|Locally advanced pancreatic adenocarcinoma
39557|NCT02806687|gene therapy
39558|NCT02806687|gemcitabine
39559|NCT02806687|chemosensitization
39560|NCT02806674|Helicobacter pylori
39561|NCT02806674|Antibiotic resistance
39562|NCT02806674|Sequencing
39563|NCT02806661|Robotic surgery
39564|NCT02806661|Vagus nerve preserving
39565|NCT02806635|Relationship Distress
39566|NCT02806635|Relationship Satisfaction
39567|NCT02806635|Marriage
39568|NCT02806635|Web-based
39569|NCT02806635|Internet
39570|NCT02806622|Sports
39571|NCT02806622|University
39572|NCT02806622|Lower Extremity
39573|NCT02806622|Hip Joint
39574|NCT02806609|football
39575|NCT02806609|cryotherapy
39576|NCT02806609|balance
39577|NCT02806609|electromyography
39578|NCT02806557|Neoplasms
39579|NCT02806557|Neutropenia
39580|NCT02806557|drug therapy
39581|NCT02806557|Hematologic tests
39582|NCT02806557|Point-of-care Systems
39583|NCT02806557|Febrile neutropenia
39584|NCT02806544|Breast neoplasms
39585|NCT02806544|Breast cancer
39586|NCT02806544|Locally advanced breast cancer
39587|NCT02806544|Neoadjuvant endocrine therapy
39588|NCT02806544|Tamoxifen
39589|NCT02806544|Low and middle income country
39590|NCT02806531|vaccine
39591|NCT02806531|safety
39592|NCT02806518|DIEP
39593|NCT02806518|Computed Tomography
39594|NCT02806518|Doppler
39595|NCT02806518|Thermography
39596|NCT02806440|Low dose naltrexone
39597|NCT02806440|Pain
39598|NCT02806375|Myelofibrosis
39599|NCT02806375|Ruxolitinib
39600|NCT02806375|Cyclophosphamide
39601|NCT02806375|Immunosuppressive Agents
39602|NCT02806375|Immune System Diseases
39603|NCT02806375|Busulfan
39604|NCT02806375|Fludarabine
39605|NCT02806375|Antineoplastic Agents, Alkylating
39606|NCT02806375|Myeloablative Agonists
39607|NCT02806375|Hematopoietic Stem Cell Transplantation
39608|NCT02806375|Allogeneic
39609|NCT02806362|Non-cirrhotic
39610|NCT02806362|End Stage Renal Disease (ESRD)
39611|NCT02806362|moderate fibrosis
39612|NCT02806362|Chronic Hepatitis C Virus ( HCV)
39613|NCT02806362|Chronic Hepatitis C Genotype 1b
39614|NCT02806349|American ginseng
39615|NCT02806349|Konjac glucomannan fiber
39616|NCT02806336|exercise training
39617|NCT02806336|assistive device
39618|NCT02806336|weight loss
39619|NCT02806336|function
39620|NCT02806336|mobility
39621|NCT02806310|Aortic Valve
39622|NCT02806310|Bicuspid
39623|NCT02806297|cholecystectomy
39624|NCT02806284|vaccination
39625|NCT02806284|Streptococcus pneumoniae
39626|NCT02806271|Worry Postponement
39627|NCT02806271|Stimulus Control
39628|NCT02806245|Congenital Heart Disease (CHD)
39629|NCT02806245|Cardiopulmonary Bypass (CPB)
39630|NCT02806245|Cardiac Index
39631|NCT02806245|Hemodynamics
39632|NCT02806245|Pediatrics
39633|NCT02806232|Praziquantel ODT formulation
39634|NCT02806232|Biltricide
39635|NCT02806219|Bioequivalence
39636|NCT02806219|Certolizumab pegol
39637|NCT02806219|Human Volunteers
39638|NCT02806193|cardiovascular
39639|NCT02806193|cardiac
39640|NCT02806193|MRI
39641|NCT02806193|CMR
39642|NCT02806193|CT
39643|NCT02806193|ECG
39644|NCT02806193|magnetic resonance
39645|NCT02806193|imaging
39646|NCT02806154|Cancer
39647|NCT02806154|Chemotherapy toxicity
39648|NCT02806154|Elderly patients
39649|NCT02806154|DEXA
39650|NCT02806154|muscle mass
39651|NCT02806141|Aerosolized colistin
39652|NCT02806141|Intravenous colistin
39653|NCT02806128|cerebral infarction
39654|NCT02806128|kallikrein
39655|NCT02806128|KLK
39656|NCT02806089|chronic kidney disease
39657|NCT02806089|malnutrition inflammation atherogenesis syndrome
39658|NCT02806089|muscle strength
39659|NCT02806089|muscle mass
39660|NCT02806089|lean body mass
39661|NCT02806089|physical activity
39662|NCT02806076|HCC
39663|NCT02806076|RFA
39664|NCT02806063|Prosthesis
39665|NCT02806063|joint infection
39666|NCT02806063|perioperative samples
39667|NCT02806050|FES PET
39668|NCT02806050|Palbociclib
39669|NCT02805985|Degenerative Disc Disease
39670|NCT02805985|Spondylolisthesis
39671|NCT02805985|Retrolisthesis
39672|NCT02805972|Obesity
39673|NCT02805972|Binge eating
39674|NCT02805868|Severe
39675|NCT02805868|Anemia
39676|NCT02805868|Aplastic
39677|NCT02805868|Post-Polycythemic
39678|NCT02805868|Transformation
39679|NCT02805868|Thrombocythemia
39680|NCT02805868|Essential
39681|NCT02805842|non adherence
39682|NCT02805842|Tacrolimus
39683|NCT02805842|Advagraf
39684|NCT02805829|NK cells
39685|NCT02805829|Trastuzumab
39686|NCT02805816|Celiac disease
39687|NCT02805816|Tissue transglutaminase
39688|NCT02805816|Histology
39689|NCT02805790|Primary Mitochondrial Disease
39690|NCT02805790|Mitochondrial Myopathy
39691|NCT02805790|Elamipretide
39692|NCT02805790|MTP-131
39693|NCT02805790|Bendavia™
39694|NCT02805751|Achilles
39695|NCT02805751|Tendon
39696|NCT02805751|Loading
39697|NCT02805751|Rehabilitation
39698|NCT02805738|Chronic Hepatitis B
39699|NCT02805738|tenofovir
39700|NCT02805738|CKD-390
39701|NCT02805725|Advanced solid tumor
39702|NCT02805725|Advanced pretreated soft tissue sarcomas
39703|NCT02805725|Phase I/II trial
39704|NCT02805725|Dose escalation
39705|NCT02805725|PK study
39706|NCT02805712|Heart Failure
39707|NCT02805712|Palliative Care
39708|NCT02805699|Clinical Efficacy
39709|NCT02805699|Baofeikang Granules
39710|NCT02805699|Combined Pulmonary Fibrosis and Emphysema
39711|NCT02805686|Toxicity, Drug
39712|NCT02805673|Osteopathy
39713|NCT02805673|Support
39714|NCT02805673|Treatment
39715|NCT02805673|Pain
39716|NCT02805673|Quality of Life
39717|NCT02805660|MGCD0103
39718|NCT02805660|MEDI4736
39719|NCT02805660|Mocetinostat
39720|NCT02805660|Durvalumab
39721|NCT02805660|HDAC Inhibitor
39722|NCT02805660|PD-L1 Inhibitor
39723|NCT02805660|Phase 1
39724|NCT02805660|Phase 2
39725|NCT02805660|Metastatic Solid Tumor
39726|NCT02805660|Non-small cell lung cancer
39727|NCT02805660|immunotherapy
39728|NCT02805660|checkpoint inhibitor
39729|NCT02805647|25-Hydroxy-vitamin D, children, bone fractures, vitamin D receptor polymorphism
39730|NCT02805634|nine holes peg
39731|NCT02805634|triple stimulation
39732|NCT02805634|multiple sclerosis
39733|NCT02805582|Peripheral Nerve Block
39734|NCT02805569|videolaryngoscope
39735|NCT02805569|intubation stylet
39736|NCT02805569|articulating stylet
39737|NCT02805569|difficult airway
39738|NCT02805530|oligometastatic disease, radical treatment
39739|NCT02805517|Minimally Invasive Surgical Procedures
39740|NCT02805517|Transplant Donors
39741|NCT02805504|Bupivacaine
39742|NCT02805504|Minimally Invasive Surgical Procedures
39743|NCT02805491|Hypospadias
39744|NCT02805491|newborns
39745|NCT02805491|pesticide
39746|NCT02805491|Picardie
39747|NCT02805465|Heart Failure
39748|NCT02805465|Atrial Fibrillation
39749|NCT02805465|CRT
39750|NCT02805465|BiVP
39751|NCT02805465|HBP
39752|NCT02805387|labor dystocia
39753|NCT02805374|Pharmacokinetics
39754|NCT02805374|ASP1517
39755|NCT02805374|Food effect
39756|NCT02805348|Kiklin
39757|NCT02805348|Bixalomer
39758|NCT02805348|Chronic Kidney Disease
39759|NCT02805335|Central Venous Catheter
39760|NCT02805335|Catheter Bloodstream Related Infection
39761|NCT02805335|Economic evaluation
39762|NCT02805309|Transcatheter Aortic Valve Replacement
39763|NCT02805309|Exercise
39764|NCT02805309|Frailty
39765|NCT02805309|Functional Outcomes
39766|NCT02805283|Diabetes Mellitus, Type 2
39767|NCT02805270|adverse drug events, preventable, potential, counselling, medication reconciliation
39768|NCT02805244|JTZ-951
39769|NCT02805244|Pharmacokinetics
39770|NCT02805244|14C-JTZ-951
39771|NCT02805244|Mass balance
39772|NCT02805244|Time course
39773|NCT02805205|PEG-rhG-CSF neutropenia
39774|NCT02805192|Emergency Department
39775|NCT02805192|Estimation of age and weight
39776|NCT02805192|Size measurement
39777|NCT02805166|PEG-rhG-CSF
39778|NCT02805153|PEG-rhG-CSF
39779|NCT02805140|mother
39780|NCT02805140|social support
39781|NCT02805140|mobile app
39782|NCT02805140|videoconference
39783|NCT02805140|sedentary
39784|NCT02805140|physical activity
39785|NCT02805127|Asthma
39786|NCT02805127|COPD
39787|NCT02805127|Capnography
39788|NCT02805114|Asthma
39789|NCT02805114|Chronic Obstructive Pulmonary Disease (COPD)
39790|NCT02805114|Capnography
39791|NCT02805062|Trapped Lung
39792|NCT02805036|alveolar recruitment
39793|NCT02805036|stroke volume/physiology
39794|NCT02805036|cardiac output/physiology
39795|NCT02804997|non-invasive ventilation
39796|NCT02804997|cardiac surgery
39797|NCT02804984|idiopathic cytopenia of undetermined significance (ICUS)
39798|NCT02804984|molecular defects
39799|NCT02804958|ST-segment elevation myocardial infarction
39800|NCT02804958|Primary percutaneous coronary intervention
39801|NCT02804958|Clinical outcomes
39802|NCT02804945|Blood And Marrow Transplantation
39803|NCT02804945|Adult Respiratory Distress Syndrome
39804|NCT02804945|ARDS
39805|NCT02804945|Allogeneic human mesenchymal stem cells
39806|NCT02804945|hMSCs
39807|NCT02804945|Placebo
39808|NCT02804945|Plasma-Lyte A solution
39809|NCT02804945|Standard of Care
39810|NCT02804945|Recent onset pulmonary toxicity
39811|NCT02804893|Lung cancer, video-assisted thoracoscopic surgery, robotic-assisted thoracoscopic surgery
39812|NCT02804880|Smoking cessation
39813|NCT02804880|Quit to Win
39814|NCT02804880|Brief intervention
39815|NCT02804880|Personalized active referral
39816|NCT02804880|Instant messaging
39817|NCT02804880|SMS
39818|NCT02804880|Smoking Cessation Intervention
39819|NCT02804841|Vitamin D supplementation
39820|NCT02804841|Cognitive function
39821|NCT02804841|Physical function
39822|NCT02804841|Successful ageing
39823|NCT02804841|Prevention
39824|NCT02804841|Cholecalciferol
39825|NCT02804841|Dementia
39826|NCT02804841|Muscle mass
39827|NCT02804815|Aspirin
39828|NCT02804815|prostate
39829|NCT02804815|colorectal
39830|NCT02804815|breast
39831|NCT02804815|gastro-oesophageal
39832|NCT02804815|recurrence
39833|NCT02804789|Prevention
39834|NCT02804763|Systemic Lupus Erythematosus (SLE)
39835|NCT02804763|Dapirolizumab Pegol (DZP)
39836|NCT02804750|Cushing's Syndrome
39837|NCT02804750|Cushing's Disease
39838|NCT02804750|Cushings
39839|NCT02804750|Hypercortisolemia
39840|NCT02804750|Cushingoid
39841|NCT02804750|Type 2 Diabetes
39842|NCT02804750|Impaired Glucose Intolerance
39843|NCT02804750|Hypertension
39844|NCT02804750|Adrenal Corticotrophic Hormone (ACTH)
39845|NCT02804750|Adrenocortical Carcinoma
39846|NCT02804750|Primary Pigmented Nodular Adrenal Disease (PPNAD)
39847|NCT02804750|Moon Facies
39848|NCT02804750|Dorsocervical Fat Pad
39849|NCT02804750|Adrenal Adenoma
39850|NCT02804750|Adrenal Carcinoma
39851|NCT02804750|Adrenal Autonomy
39852|NCT02804750|Cortisol
39853|NCT02804724|HIV
39854|NCT02804724|Human immunodeficiency virus
39855|NCT02804724|Late diagnosis
39856|NCT02804672|Cardiovascular health
39857|NCT02804672|Diet
39858|NCT02804672|Functional limitations
39859|NCT02804672|Frailty
39860|NCT02804672|Older adults
39861|NCT02804659|micro-RNA
39862|NCT02804646|Recombinant human endostatin(Endostar)
39863|NCT02804646|Durative transfusion
39864|NCT02804646|adenocarcinoma of lung
39865|NCT02804633|IV acetaminophen
39866|NCT02804633|Colorectal Surgery
39867|NCT02804633|Enhance Recovery
39868|NCT02804633|Opioid Consumption
39869|NCT02804633|Pain Management
39870|NCT02804607|burn
39871|NCT02804607|child
39872|NCT02804607|graft
39873|NCT02804607|development
39874|NCT02804607|complications
39875|NCT02804607|autonomy
39876|NCT02804568|Schizophrenia
39877|NCT02804568|Alkermes
39878|NCT02804568|ALK 3831
39879|NCT02804568|Samidorphan
39880|NCT02804555|reactive oxygen species
39881|NCT02804555|elective cesarean section
39882|NCT02804555|oxygen therapy
39883|NCT02804555|newborn
39884|NCT02804542|fascia iliaca blocks
39885|NCT02804529|Laparoscopic entry
39886|NCT02804529|Meng's point
39887|NCT02804529|Veress needle
39888|NCT02804477|adherence
39889|NCT02804477|opioid
39890|NCT02804477|MMAS 8, morisky medication adherence scale
39891|NCT02804477|validation
39892|NCT02804425|Medical Education
39893|NCT02804425|Simulation
39894|NCT02804425|Anesthesia crisis management
39895|NCT02804425|Learning outcomes
39896|NCT02804412|communication disorders
39897|NCT02804412|language and speech disorder rehabilitation
39898|NCT02804412|stroke
39899|NCT02804399|rifampin
39900|NCT02804399|pharmacokinetics
39901|NCT02804399|PF-06463922
39902|NCT02804399|drug interaction
39903|NCT02804386|HCV
39904|NCT02804386|safety
39905|NCT02804386|efficacy
39906|NCT02804386|EVR
39907|NCT02804386|SVR
39908|NCT02804373|oxytocin
39909|NCT02804373|adults
39910|NCT02804347|Olfactory Dysfunction
39911|NCT02804347|Electroconvulsive Therapy
39912|NCT02804347|Theta Burst Stimulation
39913|NCT02804321|catheter ablation
39914|NCT02804321|galectin 3
39915|NCT02804321|ngal
39916|NCT02804321|aldosterone
39917|NCT02804321|atrial fibrillation
39918|NCT02804308|Combined Training
39919|NCT02804308|Breast Cancer
39920|NCT02804308|Body Composition
39921|NCT02804308|Postmenopausal Women
39922|NCT02804308|Aromatase Inhibitors
39923|NCT02804308|Quality of life
39924|NCT02804295|Prescription Drug
39925|NCT02804295|Misuse
39926|NCT02804269|Healthy Volunteer
39927|NCT02804269|Dilated cardiomyopathy
39928|NCT02804269|Hypertrophic cardiomyopathy
39929|NCT02804269|ischemic heart disease
39930|NCT02804269|Cardiovascular Magnetic Resonance Imaging
39931|NCT02804243|nasal high flow therapy
39932|NCT02804243|rehabilitation
39933|NCT02804243|exercise endurance
39934|NCT02804178|ATR-101
39935|NCT02804178|classic congenital adrenal hyperplasia
39936|NCT02804178|21-hydroxylase deficiency
39937|NCT02804178|CAH
39938|NCT02804165|Type 1 diabetes
39939|NCT02804165|Enterovirus
39940|NCT02804165|Genetics
39941|NCT02804165|Gene-Virus interaction
39942|NCT02804152|pregnancy
39943|NCT02804152|pain
39944|NCT02804152|prescription opioid
39945|NCT02804139|Cesarean Section
39946|NCT02804139|Postpartum issues
39947|NCT02804126|acute pain
39948|NCT02804126|transversus abdominis plane block
39949|NCT02804126|quadratus lumborum block
39950|NCT02804126|neuropathic pain
39951|NCT02804100|Circulating Tumor DNA
39952|NCT02804100|Lung cancer
39953|NCT02804100|Plasma DNA
39954|NCT02804061|nutrition
39955|NCT02804061|exercise
39956|NCT02804061|behavior change
39957|NCT02804061|adherence
39958|NCT02804048|Dyspareunia
39959|NCT02804048|Pelvic floor muscles
39960|NCT02804048|Women
39961|NCT02804022|Respiratory Depression
39962|NCT02804009|anxiety
39963|NCT02804009|coronary angiography
39964|NCT02803957|Degenerative
39965|NCT02803957|Mitral Regurgitation
39966|NCT02803944|azithromycin
39967|NCT02803944|cystic fibrosis
39968|NCT02803944|pulmonary function
39969|NCT02803931|Cardiogoniometry
39970|NCT02803931|Electrocardiography
39971|NCT02803879|cardiac resynchronisation therapy
39972|NCT02803879|cardiogoniometry
39973|NCT02803866|Parenting Self-efficacy
39974|NCT02803866|Parent training program
39975|NCT02803866|Perceived self-efficacy tool
39976|NCT02803853|Native American
39977|NCT02803853|Obesity
39978|NCT02803853|Multi level
39979|NCT02803853|Policy
39980|NCT02803853|Schools
39981|NCT02803853|Worksite
39982|NCT02803853|Social Media
39983|NCT02803853|Food Store
39984|NCT02803840|Large B-Cell
39985|NCT02803840|Diffuse
39986|NCT02803827|diarrhoea
39987|NCT02803827|gastroenteritis
39988|NCT02803827|rapid diagnostics
39989|NCT02803827|probiotics
39990|NCT02803814|Pancreatoduodenectomy
39991|NCT02803814|Pancreatic tumors
39992|NCT02803814|Periampullary tumors
39993|NCT02803801|Parents' ability to guide their child
39994|NCT02803801|Parent perception of competence
39995|NCT02803801|Parent understanding of their child's unique learning style
39996|NCT02803788|ramosetron, ondansetron, dexamethasone,
39997|NCT02803762|ADME
39998|NCT02803762|Pacritinib
39999|NCT02803671|preterm neonates
40000|NCT02803671|EEG-NIRS
40001|NCT02803658|smoking
40002|NCT02803645|healthy subjects
40003|NCT02803645|cardiovascular risk factors
40004|NCT02803645|markers of arterial inflammation
40005|NCT02803645|markers of oxidative stress
40006|NCT02803632|young
40007|NCT02803632|disruptive mood dysregulation disorder
40008|NCT02803632|actigraphic profile
40009|NCT02803619|Non-small cell lung cancer
40010|NCT02803619|leptomeningeal metastasis
40135|NCT02802748|PAM50
40011|NCT02803619|EGFR sensitive mutations
40012|NCT02803606|hypothermia
40013|NCT02803606|routine care
40014|NCT02803606|preterm neonates
40015|NCT02803593|a technology-based intervention
40016|NCT02803593|Asian American
40017|NCT02803593|survivorship
40018|NCT02803541|chronic kidney disease
40019|NCT02803541|exercise
40020|NCT02803541|pediatrics
40021|NCT02803541|summer camp
40022|NCT02803515|intra peritonal chemo hyperthermia
40023|NCT02803515|peritoneal carcinomatosis
40024|NCT02803515|ovarian cancer
40025|NCT02803502|thrombin generation test
40026|NCT02803502|factor VIII
40027|NCT02803502|hemophilia
40028|NCT02803489|chronic heart failure
40029|NCT02803489|chronic obstructive pulmonary disease
40030|NCT02803489|diabetes
40031|NCT02803476|PCO
40032|NCT02803476|Vitamin D
40033|NCT02803476|Insulin resistance
40034|NCT02803463|peritoneal closure
40035|NCT02803463|appendectomy
40036|NCT02803463|postoperative pain
40037|NCT02803463|life quality
40038|NCT02803450|Effects of; Anesthesia
40039|NCT02803450|spinal and epidural
40040|NCT02803437|Castration-resistant prostate cancer
40041|NCT02803424|robot-assisted laparoscopic radical prostatectomy
40042|NCT02803424|Autoflow
40043|NCT02803424|trendelenburg position
40044|NCT02803424|pneumoperitoneum
40045|NCT02803411|Coronary Heart Disease
40046|NCT02803411|Coronary Computed Tomography Angiography (CCTA)
40047|NCT02803411|Coronary Atherosclerotic Plaque
40048|NCT02803411|coronary atherosclerosis
40049|NCT02803398|Compression bandages
40050|NCT02803385|Patient Controlled Epidural Analgesia
40051|NCT02803385|Continous Epidural Infusion Analgesia
40052|NCT02803372|partial nephrectomy
40053|NCT02803372|acute kidney injury
40054|NCT02803372|LiDCOrapid
40055|NCT02803372|circulatory management
40056|NCT02803359|Laryngeal evoked brainstem response (LEBR)
40057|NCT02803359|laryngopharyngeal sensory discrimination testing (LPSDT)
40058|NCT02803359|brainstem activity
40059|NCT02803346|sepsis
40060|NCT02803346|septic shock
40061|NCT02803346|immunosuppression
40062|NCT02803346|HLA-DR
40063|NCT02803346|lymphopenia
40064|NCT02803333|NSCLC
40065|NCT02803333|Carcinoma, Non-Small-Cell Lung
40066|NCT02803333|Lung Diseases
40067|NCT02803333|Thoracic Neoplasms
40068|NCT02803320|Sunscreen active
40069|NCT02803307|osteoarthritis of the knee
40070|NCT02803307|TLC599
40071|NCT02803307|Dexamethasone
40072|NCT02803307|DSP
40073|NCT02803255|Injuries
40074|NCT02803255|Spinal Cord
40075|NCT02803242|copd
40076|NCT02803242|emphysema
40077|NCT02803242|bronchitis
40078|NCT02803242|bronchiectasis
40079|NCT02803203|Osimertinib
40080|NCT02803203|bevacizumab
40081|NCT02803203|metastatic
40082|NCT02803203|16-033
40083|NCT02803190|Spine curve
40084|NCT02803190|Posture
40085|NCT02803190|Fracture
40086|NCT02803190|sarcopenia
40087|NCT02803190|Exercise
40088|NCT02803177|large bone defect
40089|NCT02803177|bone marrow-derived mononuclear cells
40090|NCT02803151|Stereotactic ablative radiotherapy
40091|NCT02803151|Lymph node metastasis
40092|NCT02803151|T cell immunity
40093|NCT02803151|cell-free DNA
40094|NCT02803138|Sustained Virological Response
40095|NCT02803138|Observational Study
40096|NCT02803138|Chronic Hepatitis C genotype 4
40097|NCT02803138|Paritaprevir/r - Ombitasvir, ± Dasabuvir
40098|NCT02803138|Chronic Hepatitis C genotype 1
40099|NCT02803138|Chronic Hepatitis C
40100|NCT02803125|PTSD
40101|NCT02803125|Aging
40102|NCT02803125|Veteran
40103|NCT02803125|Intervention
40104|NCT02803086|Prostate cancer
40105|NCT02803086|Radiotherapy
40106|NCT02803086|Hematopoietic stem cells
40107|NCT02803086|Radiotoxicity
40108|NCT02802982|Thrombocytopenia
40109|NCT02802982|Neonates
40110|NCT02802956|Life participation
40111|NCT02802943|CLL, Peptid Vaccination
40112|NCT02802917|Eye stinging potential
40113|NCT02802904|Healthy subjects
40114|NCT02802891|Asthma
40115|NCT02802891|Allergy
40116|NCT02802891|Diagnosis
40117|NCT02802891|Endocrine disruptors
40118|NCT02802891|Children
40119|NCT02802839|Virtual Reality
40120|NCT02802839|venipuncture
40121|NCT02802826|Exercise
40122|NCT02802826|Chemotherapy
40123|NCT02802826|Physical Activity
40124|NCT02802826|Breast Cancer
40125|NCT02802813|Double-blinded controlled trial
40126|NCT02802813|Primaquine
40127|NCT02802787|Quality of life
40128|NCT02802787|Occupation
40129|NCT02802787|Pain
40130|NCT02802787|Fatigue
40131|NCT02802774|Post-operative treatment
40132|NCT02802748|Early Breast Cancer
40133|NCT02802748|Hormone Receptor-positive
40134|NCT02802748|Window-of-opportunity
40136|NCT02802748|Luminal A
40137|NCT02802748|Luminal B
40138|NCT02802748|proliferation signature
40139|NCT02802748|metronomic vinorelbine
40140|NCT02802748|letrozole
40141|NCT02802735|Pharmacokinetics
40142|NCT02802735|Apremilast
40143|NCT02802735|Healthy Adult Male
40144|NCT02802735|Korean Subjects
40145|NCT02802722|convalescence
40146|NCT02802722|inflammation
40147|NCT02802722|resolution
40148|NCT02802722|vitamin D
40149|NCT02802709|knee
40150|NCT02802696|Transfusion
40151|NCT02802696|Transfusion Medicine
40152|NCT02802696|Diuretic
40153|NCT02802683|Hypotension
40154|NCT02802683|cesarean section
40155|NCT02802657|Age-related Macular Degeneration
40156|NCT02802657|Conbercept
40157|NCT02802657|Treat-and-Extend Regimen
40158|NCT02802657|Pro Re Nata
40159|NCT02802631|Bacterial infections
40160|NCT02802618|Validity
40161|NCT02802618|Reliability
40162|NCT02802618|Rehabilitation
40163|NCT02802618|Translation
40164|NCT02802618|Education
40165|NCT02802579|obesity
40166|NCT02802579|dual source CT
40167|NCT02802579|coronary CT angiography
40168|NCT02802579|prognosis
40169|NCT02802579|bariatric surgery
40170|NCT02802579|gastric bypass surgery
40171|NCT02802579|coronary arterial disease
40172|NCT02802579|major adverse coronary event
40173|NCT02802566|Maternal Obesity
40174|NCT02802566|Inflammation
40175|NCT02802553|SmartGoggles
40176|NCT02802553|sentinel lymph nodes
40177|NCT02802553|indocyanine green
40178|NCT02802553|Cardio-Green
40179|NCT02802553|Spy Elite
40180|NCT02802540|nabilone
40181|NCT02802540|anorexia
40182|NCT02802540|Non-Small Cell Lung Cancer
40183|NCT02802514|Gastrointestinal
40184|NCT02802514|Glucagon like peptide
40185|NCT02802514|Nausea
40186|NCT02802514|Magnetic resonance imaging
40187|NCT02802501|Safety
40188|NCT02802501|Artemisinin Combination Therapy
40189|NCT02802501|Efficacy
40190|NCT02802501|Tafenoquine
40191|NCT02802501|Superiority
40192|NCT02802501|Primaquine
40193|NCT02802501|Radical cure
40194|NCT02802501|Vivax
40195|NCT02802501|ACT
40196|NCT02802501|Plasmodium vivax malaria
40197|NCT02802501|Dihydroartemisinin-piperaquine
40198|NCT02802488|D-dimers
40199|NCT02802488|Atrial fibrillation
40200|NCT02802475|antibodies
40201|NCT02802475|auto-immune encephalitis
40202|NCT02802475|epilepsy
40203|NCT02802475|limbic encephalitis
40204|NCT02802462|endothelial progenitor cell
40205|NCT02802462|hemodynamic
40206|NCT02802462|Exercise
40207|NCT02802462|HIIT
40208|NCT02802449|Vitamin D
40209|NCT02802449|Hypovitaminosis D
40210|NCT02802449|HTN
40211|NCT02802423|TNBC
40212|NCT02802423|Breast cancer
40213|NCT02802423|Triple negative
40214|NCT02802397|Early ovarian reserve decreased
40215|NCT02802384|Paget's Disease of Bone
40216|NCT02802384|Healthy controls
40217|NCT02802371|caregiver burden
40218|NCT02802371|Alzheimer disease and related disorders
40219|NCT02802371|elderly
40220|NCT02802371|pharmaceutical care
40221|NCT02802371|optimization of drug prescribing
40222|NCT02802371|psychosocial intervention
40223|NCT02802358|Falls
40224|NCT02802358|Functionality
40225|NCT02802332|neonatal
40226|NCT02802332|preterm
40227|NCT02802332|Nepal
40228|NCT02802332|family-initiated identification
40229|NCT02802332|basic newborn care
40230|NCT02802306|Angioplasty
40231|NCT02802306|Peripheral Artery Disease
40232|NCT02802306|PAD
40233|NCT02802306|Lesion
40234|NCT02802306|Claudication
40235|NCT02802293|Repetitive Transcranial Magnetic Stimulation
40236|NCT02802293|Major Depressive Disorder
40237|NCT02802280|endothelial dysfunction
40238|NCT02802254|physical activity
40239|NCT02802254|patient feedback
40240|NCT02802254|risk perception
40241|NCT02802254|pedometer
40242|NCT02802215|Diabetes Mellitus
40243|NCT02802215|Pregnancy
40244|NCT02802202|Palpation
40245|NCT02802202|Chronic Pain
40246|NCT02802202|Muscle
40247|NCT02802189|Chronic Mechanical Neck Pain
40248|NCT02802189|exercise
40249|NCT02802189|Integrated Neuromuscular Inhibition Technique
40250|NCT02802163|untreated multiple myeloma
40251|NCT02802163|newly diagnosed myeloma
40252|NCT02802163|transplant eligible
40253|NCT02802150|Zanthoxylum schinifolium seed Oil
40254|NCT02802150|soy bean oil
40255|NCT02802150|omega-3 fatty acid
40256|NCT02802150|dry eye disease
40257|NCT02802137|tafluprost
40258|NCT02802137|dorzolamide
40259|NCT02802137|timolol
40260|NCT02802137|FC
40261|NCT02802124|hepatocellular carcinoma
40262|NCT02802124|carbon-ion radiotherapy
40263|NCT02802124|toxicity
40264|NCT02802124|efficacy
40265|NCT02802111|Beta Agonists
40266|NCT02802111|Asthma
40267|NCT02802111|Albuterol
40268|NCT02802111|Levalbuterol
40269|NCT02802098|Metastatic breast cancer
40270|NCT02802098|bevacizumab maintenance
40271|NCT02802098|Durvalumab
40272|NCT02802085|Total Knee Arthroplasty
40273|NCT02802085|Total Knee Replacement
40274|NCT02802085|TKA
40275|NCT02802085|TKR
40276|NCT02802085|Stiffness of Knee
40277|NCT02802085|Deformity
40278|NCT02802085|Knee Joint
40279|NCT02802085|Instability
40280|NCT02802085|Post-traumatic
40281|NCT02802085|Arthrosis
40282|NCT02802046|FFRCT
40283|NCT02802046|Angina pectoris grade
40284|NCT02802046|Fractional flow reserve
40285|NCT02802046|CCTA
40286|NCT02802033|Registry
40287|NCT02802033|Spine
40288|NCT02802033|Osteobiologics
40289|NCT02802033|Spinal Fusion
40290|NCT02801994|Patient-ventilator interaction
40291|NCT02801994|Inspiratory muscles
40292|NCT02801994|Electromyogram
40293|NCT02801994|Mechanical ventilation
40294|NCT02801994|Proportional Assist Ventilation
40295|NCT02801981|tolerability
40296|NCT02801981|healthy volunteers
40297|NCT02801981|Cholestasis
40298|NCT02801981|safety
40299|NCT02801955|gastric adenocarcinoma
40300|NCT02801955|tumor markers
40301|NCT02801955|peritoneal cytology
40302|NCT02801942|Biomarker
40303|NCT02801942|Immune Profile
40304|NCT02801942|Biopsy
40305|NCT02801942|Leukocyte subsets
40306|NCT02801942|Inguinal lymph nodes
40307|NCT02801942|Type 1 Diabetes Mellitus
40308|NCT02801916|Humans
40309|NCT02801916|Glycemic response
40310|NCT02801916|Oat beta-glucan
40311|NCT02801877|Depression
40312|NCT02801877|Anxiety
40313|NCT02801877|Behavior Therapy
40314|NCT02801877|Technology Assisted
40315|NCT02801877|Mobile Phone
40316|NCT02801877|Cellular Phone
40317|NCT02801877|Smartphone
40318|NCT02801877|App
40319|NCT02801877|Coach
40320|NCT02801864|tDCS
40321|NCT02801864|transcranial direct current stimulation
40322|NCT02801864|intensive speech therapy
40323|NCT02801864|chronic
40324|NCT02801864|post stroke
40325|NCT02801864|aphasia
40326|NCT02801864|production
40327|NCT02801864|language
40328|NCT02801851|Delirium
40329|NCT02801838|Inspiratory muscles
40330|NCT02801838|Patient-ventilator interaction
40331|NCT02801838|Electromyogram
40332|NCT02801838|Mechanical ventilation
40333|NCT02801825|axillay artery
40334|NCT02801825|cannulation
40335|NCT02801825|femoral artery
40336|NCT02801812|Nailfold Capillaroscopy
40337|NCT02801799|Anaesthesia
40338|NCT02801799|Analgesia
40339|NCT02801799|Nerve blocks
40340|NCT02801799|Peripheral nerve blocks
40341|NCT02801799|Regional anaesthesia
40342|NCT02801799|therapeutic techniques
40343|NCT02801799|ropivacaine
40344|NCT02801799|nerve block duration
40345|NCT02801799|lower limb
40346|NCT02801799|Postoperative pain
40347|NCT02801786|Mammography
40348|NCT02801786|Premedication
40349|NCT02801786|Pain
40350|NCT02801786|Discomfort
40351|NCT02801786|Breast
40352|NCT02801773|gingivitis
40353|NCT02801773|probiotic
40354|NCT02801773|non- surgical treatment
40355|NCT02801760|HIV
40356|NCT02801760|Self-Consent
40357|NCT02801760|PrEP
40358|NCT02801760|Autonomous Research Consent
40359|NCT02801760|Participation-associated Outcomes
40360|NCT02801747|HIV care continuum
40361|NCT02801747|antiretroviral therapy
40362|NCT02801747|engagement in HIV care
40363|NCT02801747|Multiphase Optimization Strategy (MOST)
40364|NCT02801708|Embolic stroke of undetermined source
40365|NCT02801708|Atrial fibrillation
40366|NCT02801695|pre-eclampsia
40367|NCT02801695|citrulline
40368|NCT02801695|pregnancy
40369|NCT02801669|anticoagulants
40370|NCT02801669|DU-176b
40371|NCT02801669|edoxaban
40372|NCT02801669|factor Xa
40373|NCT02801669|oral
40374|NCT02801669|prevention
40375|NCT02801669|atrial fibrillation
40376|NCT02801643|PET
40377|NCT02801643|dopamine
40378|NCT02801643|fMRI
40379|NCT02801643|reward
40380|NCT02801617|Latanoprost
40381|NCT02801617|Glaucoma
40382|NCT02801617|Ocular hypertension
40383|NCT02801617|Crossover study
40384|NCT02801578|Chronic Lymphocytic Leukemia
40385|NCT02801578|CLL
40386|NCT02801578|Malignant neoplasms stated as primary lymphoid haematopoietic
40387|NCT02801578|Ibrutinib
40388|NCT02801578|PCI-32765
40389|NCT02801578|Imbruvica
40390|NCT02801578|Pharmacodynamics
40391|NCT02801552|regenerative endodontic treatment
40392|NCT02801552|platelet-rich fibrin
40393|NCT02801552|Immature permanent tooth
40394|NCT02801552|apical periodontitis
40395|NCT02801513|mindfulness
40396|NCT02801513|EEG
40397|NCT02801513|error-related negativity
40398|NCT02801513|late positive potential
40399|NCT02801513|long-range temporal correlations
40400|NCT02801500|bilioenteric anastomosis
40401|NCT02801487|Carbon Ion Therapy
40402|NCT02801487|Concurrent Chemoradiotherapy
40403|NCT02801435|EGFR inhibitor
40404|NCT02801435|topical agent
40405|NCT02801435|psoriasis
40406|NCT02801435|phase 1
40407|NCT02801422|cannabis
40408|NCT02801422|fMRI
40409|NCT02801422|addiction
40410|NCT02801422|relapse
40411|NCT02801409|Lung Cancer
40412|NCT02801409|Surgical Resection
40413|NCT02801409|Epidural Anesthesia and Analgesia
40414|NCT02801409|Long-Term Outcome
40415|NCT02801357|substance withdrawal syndrome
40416|NCT02801357|opiate addiction
40417|NCT02801357|opiate dependence
40418|NCT02801357|opioid withdrawal syndrome
40419|NCT02801357|buprenorphine
40420|NCT02801344|exercise
40421|NCT02801344|performance
40422|NCT02801344|recovery
40423|NCT02801344|muscle
40424|NCT02801344|protein
40425|NCT02801331|Stochastic Resonance
40426|NCT02801331|Fetus/Newborn Infant
40427|NCT02801331|Drug Withdrawal
40428|NCT02801331|Substance Abuse
40429|NCT02801318|Patient
40430|NCT02801305|Scleroderma
40431|NCT02801305|Diltiazem
40432|NCT02801305|Nitroglycerin
40433|NCT02801305|Topical
40434|NCT02801279|Cerebral Palsy
40435|NCT02801279|Occupational Therapy
40436|NCT02801279|Upper Limb Motor Training
40437|NCT02801266|Contraception
40438|NCT02801266|Reproductive and Sexual Health
40439|NCT02801266|Counseling
40440|NCT02801266|Contraceptive Counseling
40441|NCT02801240|Inflammatory Bowel Disease
40442|NCT02801227|premature rupture of membrane
40443|NCT02801227|primipara
40444|NCT02801227|term
40445|NCT02801227|bishop
40446|NCT02801214|cannabis
40447|NCT02801214|fMRI
40448|NCT02801214|emotion
40449|NCT02801201|sedation
40450|NCT02801201|spinal anesthesia
40451|NCT02801162|arterial blood gas
40452|NCT02801123|Complimentary Cancer Therapies
40453|NCT02801123|Psychosocial Oncology
40454|NCT02801123|Behavioural Medicine
40455|NCT02801123|Mindfulness Based Cancer Recovery
40456|NCT02801123|Tai Chi
40457|NCT02801123|Qigong
40458|NCT02801123|Mindfulness-Based Stress Reduction
40459|NCT02801123|Yoga
40460|NCT02801123|Preference-based trial
40461|NCT02801084|Restricted
40462|NCT02801084|Environmental
40463|NCT02801084|Stimulation
40464|NCT02801071|Post-Polio Syndrome
40465|NCT02801071|PPS
40466|NCT02801058|Osteopathic manipulative treatment
40467|NCT02801058|Abdominal Diaphragm mobility
40468|NCT02801058|Thoracic Ultrasounds
40469|NCT02800980|lymphocele
40470|NCT02800980|sclerotherapy
40471|NCT02800980|drainage
40472|NCT02800980|percutaneous
40473|NCT02800967|platelet activation
40474|NCT02800967|platelet aggregation
40475|NCT02800967|Aronia
40476|NCT02800967|flow cytometry
40477|NCT02800967|polyphenols
40478|NCT02800967|cardiovascular disease risk
40479|NCT02800954|Multiple Myeloma
40480|NCT02800954|bone lesions
40481|NCT02800954|Macrophage-Colony Stimulating Factor
40482|NCT02800941|Pulmonary Arterial hypertension
40483|NCT02800941|Oral anticoagulants
40484|NCT02800941|Major bleedings
40485|NCT02800915|Spinal Cord Injury
40486|NCT02800915|Pressure Ulcer
40487|NCT02800915|Health Related Quality of Life
40488|NCT02800915|Telemedicine
40489|NCT02800915|Service Innovation
40490|NCT02800915|Rehabilitation
40491|NCT02800915|Interdisciplinary collaboration
40492|NCT02800915|User- participation
40493|NCT02800915|Activity and participation
40494|NCT02800915|Health economics
40495|NCT02800889|relapsed
40496|NCT02800889|refractory
40497|NCT02800889|solid tumors
40498|NCT02800850|Dementia
40499|NCT02800850|Depression
40500|NCT02800850|Agitation
40501|NCT02800850|Bright Light
40502|NCT02800837|left main
40503|NCT02800837|stent
40504|NCT02800837|self-expandable
40505|NCT02800837|DES
40506|NCT02800837|Stentys
40507|NCT02800811|FR104
40508|NCT02800811|CD28
40509|NCT02800811|immunomodulation
40510|NCT02800811|T regulatory cell
40511|NCT02800811|Pegylated monovalent anti-CD28 Fab antibody
40512|NCT02800798|Obstructive sleep apnea
40513|NCT02800798|Preeclampsia
40514|NCT02800798|Pregnancy
40515|NCT02800798|Stopbang
40516|NCT02800772|pancreatic duct
40517|NCT02800772|ERCP
40518|NCT02800772|acetic acid
40519|NCT02800746|Prognathic surgery
40520|NCT02800720|Fibromyalgia Syndromey
40521|NCT02800681|Asperger Syndrome
40522|NCT02800681|Autism Spectrum Disorder
40523|NCT02800681|Schizotypal disorder
40524|NCT02800681|Schizophrenia Spectrum Disorder
40525|NCT02800681|Psychopathology
40526|NCT02800681|Examination of Anomalous Self Disorder
40527|NCT02800681|Autism Diagnostic Observation Schedule
40528|NCT02800681|Phenomenology
40529|NCT02800681|Differential diagnosis
40530|NCT02800681|Young Adult
40531|NCT02800668|Duodenal Jejunal Bypass Liner
40532|NCT02800668|obesity
40533|NCT02800668|weight loss therapy
40534|NCT02800655|ARV treatment Naive
40535|NCT02800655|Medication Adherence
40536|NCT02800655|Digital Health Feedback System
40537|NCT02800655|Proteus Digital Health
40538|NCT02800642|Bayer
40539|NCT02800642|Aflibercept
40540|NCT02800642|Eylea
40541|NCT02800642|Intravitreal,
40542|NCT02800616|Academic Achievement
40543|NCT02800616|Accelerometry
40544|NCT02800616|Children
40545|NCT02800616|Primary school Intervention
40546|NCT02800616|Nutrition
40547|NCT02800616|Obesity
40548|NCT02800616|Physical Activity
40549|NCT02800616|Prevention
40550|NCT02800616|School Health
40551|NCT02800603|preschool mental health
40552|NCT02800603|emotional and behaviour problems
40553|NCT02800590|Adult participants
40554|NCT02800590|Sedation
40555|NCT02800590|elective
40556|NCT02800525|Benign pigmented lesions
40557|NCT02800525|Picosecond laser
40558|NCT02800525|Q-switched laser
40559|NCT02800512|pelvic organ prolapse
40560|NCT02800512|cystocele
40561|NCT02800512|rectocele
40562|NCT02800512|enterocele
40563|NCT02800473|Bladder cancer
40564|NCT02800473|Hexvix
40565|NCT02800473|Bimodal Endoscopic Imager
40566|NCT02800473|Cystoscopy
40567|NCT02800460|Subthalamic nucleus
40568|NCT02800460|Basal ganglia
40569|NCT02800460|Parkinson disease
40570|NCT02800460|Magnetic Resonance Imaging
40571|NCT02800460|Susceptibility-Weighted Imaging
40572|NCT02800434|allograft
40573|NCT02800434|hands
40574|NCT02800434|immunosuppression
40575|NCT02800434|fMRI
40576|NCT02800395|Alzheimer
40577|NCT02800395|oxydative stress
40578|NCT02800395|nutrition
40579|NCT02800395|biomarkers
40580|NCT02800382|paraoxonase
40581|NCT02800382|lung diseases
40582|NCT02800369|Human papillomavirus
40583|NCT02800369|cervical intraepithelial neoplasia
40584|NCT02800369|zinc finger nuclease
40585|NCT02800356|Age-Related Macular Degeneration
40586|NCT02800356|Geographic Atrophy
40587|NCT02800356|Reticular pseudodrusen
40588|NCT02800356|Lasers
40589|NCT02800356|PASCAL 577
40590|NCT02800304|malnutrition
40591|NCT02800304|food intake
40592|NCT02800304|frailty
40593|NCT02800291|food intake
40594|NCT02800265|healthy volunteer
40595|NCT02800265|healthy
40596|NCT02800265|cancer prevention
40597|NCT02800265|prevention
40598|NCT02800252|fatty acids
40599|NCT02800252|aspirin
40600|NCT02800252|diabetes mellitus
40601|NCT02800252|chronic periodontitis
40602|NCT02800252|periodontal debridement
40603|NCT02800200|platelet rich plasma
40604|NCT02800200|extracorporeal shock wave
40605|NCT02800122|acute dyspnea
40606|NCT02800122|emergency
40607|NCT02800122|acute heart failure
40608|NCT02800109|Fetal growth
40609|NCT02800109|Newborn growth
40610|NCT02800070|autologous stem cell transplant
40611|NCT02800070|gene therapy
40612|NCT02800070|Fabry disease
40613|NCT02800070|lentivirus
40614|NCT02800070|haematopoietic stem cell transplant
40615|NCT02800018|hypothermia therapy
40616|NCT02800018|perinatal asphyxia
40617|NCT02800005|gastric cancer
40618|NCT02800005|gastrectomy
40619|NCT02800005|laparotomy
40620|NCT02800005|surgical outcome
40621|NCT02800005|survival
40622|NCT02800005|abdominal fat area
40623|NCT02800005|Body Mass Index
40624|NCT02799953|diabetes mellitus and hypertension
40625|NCT02799953|consumer health information technology
40626|NCT02799953|self-monitoring
40627|NCT02799953|randomized controlled trial
40628|NCT02799927|Indirect Pulp Treatment
40629|NCT02799927|Primary Teeth
40630|NCT02799927|Biodentine
40631|NCT02799927|Calcium Hydroxide
40632|NCT02799927|Split-Mouth design
40633|NCT02799901|advanced melanoma
40634|NCT02799901|high dose radiotherapy
40635|NCT02799901|Nivolumab
40636|NCT02799888|Graft-versus-host Disease
40637|NCT02799888|Hematopoietic Stem Cell Transplantation
40638|NCT02799888|Acute Leukemia
40639|NCT02799888|Myelodysplastic syndrome
40640|NCT02799888|Lymphoma
40641|NCT02799875|respiratory distress syndrome
40642|NCT02799875|permissive hypercapnia
40643|NCT02799875|ventilator strategy
40644|NCT02799862|metastatic
40645|NCT02799862|locally advanced
40646|NCT02799862|unresectable
40647|NCT02799862|NSCLC
40648|NCT02799849|narcolepsy
40649|NCT02799849|metabolism
40650|NCT02799823|aortic stenosis
40651|NCT02799823|transcatheter aortic valve replacement
40652|NCT02799810|lung transplantation
40653|NCT02799810|psychosocial functioning
40654|NCT02799810|longitudinal
40655|NCT02799810|TERS
40656|NCT02799810|adherence
40657|NCT02799810|Quality of life
40658|NCT02799797|adductor canal block
40659|NCT02799784|tiotropium
40660|NCT02799784|COPD
40661|NCT02799784|olodaterol
40662|NCT02799784|Umeclidinium bromide
40663|NCT02799784|efficacy
40664|NCT02799784|vilanterol
40665|NCT02799771|Pulmonary arterial hypertension
40666|NCT02799771|Interstitial lung disease at HRCT
40667|NCT02799745|Therapeutic Cancer Progression
40668|NCT02799745|Pathological Cancer Progression
40669|NCT02799745|Enzalutamide
40670|NCT02799745|Prostate Cancer
40671|NCT02799745|Active surveillance
40672|NCT02799732|Feasibility Study
40673|NCT02799732|HPV vaccine
40674|NCT02799732|1Dose Trial
40675|NCT02799719|Fat mass
40676|NCT02799719|hemodialysis patients
40677|NCT02799719|inflammation
40678|NCT02799719|adipocytokines
40679|NCT02799719|bioimpedance spectroscopy
40680|NCT02799706|Prostate cancer
40681|NCT02799706|GnRH antagonist
40682|NCT02799706|GnRH agonist
40683|NCT02799706|radiation therapy
40684|NCT02799706|very high risk localized prostate cancer
40685|NCT02799706|locally advanced prostate cancer
40686|NCT02799693|Catheter Ablation
40687|NCT02799693|Ventricular Tachycardia
40688|NCT02799693|Intramural Needle Catheter
40689|NCT02799680|CART
40690|NCT02799680|AML
40691|NCT02799667|negative pressure wound therapy
40692|NCT02799667|cesarean delivery
40693|NCT02799654|Total Hip Arthroplasty
40694|NCT02799641|Contraception
40695|NCT02799641|IUD
40696|NCT02799641|levonorgestrel releasing intrauterine device
40697|NCT02799641|lidocaine
40698|NCT02799641|valium
40699|NCT02799641|diazepam
40700|NCT02799641|pain
40701|NCT02799641|VAS
40702|NCT02799641|visual analog scale
40703|NCT02799628|Trust
40704|NCT02799628|Low Back Pain
40705|NCT02799628|Treatment Outcome
40706|NCT02799602|Metastatic hormone sensitive prostate cancer
40707|NCT02799576|Ultrasound
40708|NCT02799576|Regional blockade
40709|NCT02799576|Infraclavicular brachial plexus
40710|NCT02799550|CART
40711|NCT02799550|ALL
40712|NCT02799550|elderly
40713|NCT02799550|Relapsed
40714|NCT02799550|Refractory
40715|NCT02799550|CD19+
40716|NCT02799511|biological markers
40717|NCT02799498|etanercept
40718|NCT02799498|healthy subject
40719|NCT02799498|open-label
40720|NCT02799498|randomized
40721|NCT02799498|PK
40722|NCT02799498|auto-injection
40723|NCT02799498|pharmacokinetic
40724|NCT02799472|GSK3196165
40725|NCT02799472|magnetic resonance imaging (MRI)
40726|NCT02799472|disease-modifying antirheumatic drugs (DMARDs)
40727|NCT02799472|granulocyte-macrophage colony stimulating factor (GM-CSF)
40728|NCT02799472|Rheumatoid Arthritis
40729|NCT02799472|Methotrexate
40730|NCT02799459|Hypnoanesthesia
40731|NCT02799459|Hypnosis
40732|NCT02799459|conization
40733|NCT02799446|sinusitis, rhinitis, rhinosinusitis, chronic
40734|NCT02799433|Water
40735|NCT02799433|Physical activity
40736|NCT02799433|Child care
40737|NCT02799433|Weight change
40738|NCT02799420|confocal laser endomicroscopy
40739|NCT02799420|undifferentiated gastric cancer
40740|NCT02799420|target biopsy
40741|NCT02799381|efficacy
40742|NCT02799381|carbidopa
40743|NCT02799381|levodopa
40744|NCT02799381|levodopa-carbidopa intestinal gel
40745|NCT02799303|screening
40746|NCT02799303|biopsy
40747|NCT02799303|magnetic resonance imaging
40748|NCT02799303|prostate specific antigen
40749|NCT02799264|fasted
40750|NCT02799264|healthy volunteers
40751|NCT02799264|cabotegravir
40752|NCT02799264|high fat
40753|NCT02799264|pharmacokinetics
40754|NCT02799264|randomized
40755|NCT02799264|Phase I
40756|NCT02799264|two way crossover
40757|NCT02799251|lymphopenia
40758|NCT02799251|postoperative infection
40759|NCT02799251|thoracic cancer surgery
40760|NCT02799251|digestive cancer surgery
40761|NCT02799238|glioblastoma, GBM, immunotherapy, autologous lymphoid effector cells specific against tumour cells, ALECSAT, Stupp regimen, TMZ, radiotherapy/TMZ
40762|NCT02799225|carbapenems
40763|NCT02799212|Hepatocellular carcinoma
40764|NCT02799212|Hepatectomy
40765|NCT02799212|Ascites
40766|NCT02799212|Somatostatin
40767|NCT02799186|Spontaneous Coronary Artery Dissection
40768|NCT02799186|haematoma
40769|NCT02799186|Fibromuscular Dysplasia
40770|NCT02799186|genetic analysis
40771|NCT02799186|Acute Coronary Syndrome
40772|NCT02799173|cardiovascular calcification
40773|NCT02799173|RANK: Receptor Activator of Nuclear Factor kappa B
40774|NCT02799173|RANKL: Receptor Activator of Nuclear Factor kappa B Ligand
40775|NCT02799173|OPG: Osteoprotegerin
40776|NCT02799173|SLE: Systemic lupus erythematosus
40777|NCT02799147|Allogeneic Transplantation
40778|NCT02799147|Hematopoietic Stem Cell Transplantation
40779|NCT02799147|Leukemia, Acute Lymphoblastic
40780|NCT02799147|Acute Myeloid Leukemia
40781|NCT02799147|Mixed-Lineage Acute Leukemias
40782|NCT02799147|Immune System Diseases
40783|NCT02799147|Immunosuppressive Agents
40784|NCT02799147|Myeloablative Agonists
40785|NCT02799147|Busulfan
40786|NCT02799147|Fludarabine
40787|NCT02799147|Antineoplastic Agents, Alkylating
40788|NCT02799147|Bendamustine Hydrochloride
40789|NCT02799134|Cortisol Awakening Response suppression
40790|NCT02799134|Dexamethasone Suppression Test
40791|NCT02799134|high-order cognition
40792|NCT02799134|social cognition
40793|NCT02799108|children
40794|NCT02799108|language
40795|NCT02799108|NIRS
40796|NCT02799095|Immunotherapy
40797|NCT02799095|IL-2
40798|NCT02799095|Interleukin-2
40799|NCT02799095|Solid tumors
40800|NCT02799056|Airway Extubation
40801|NCT02799056|Ultrasonography
40802|NCT02799056|Ventilator Weaning
40803|NCT02799043|FIRMap, Rotor, FIRM-guided procedure
40804|NCT02799017|Aphasia
40805|NCT02799017|Reading
40806|NCT02799017|Writing
40807|NCT02799017|Naming
40808|NCT02799017|Language
40809|NCT02799017|Chronic post stroke
40810|NCT02799017|Phonology
40811|NCT02799017|Semantic Feature Analysis
40812|NCT02799017|Recovery
40813|NCT02798991|REarranged during Transfection Growth Factor Receptor Tyrosine Kinase Inhibitor
40814|NCT02798978|pharmacokinetics
40815|NCT02798978|TLR4 agonist
40816|NCT02798978|cancer
40817|NCT02798978|tolerability
40818|NCT02798978|GSK1795091
40819|NCT02798978|pharmacodynamics
40820|NCT02798978|safety
40821|NCT02798965|parvovirus genome
40822|NCT02798952|Hepatitis B antibodies
40823|NCT02798952|Safety
40824|NCT02798952|Challenge dose
40825|NCT02798952|Persistence
40826|NCT02798952|Engerix B Kinder
40827|NCT02798952|Infanrix hexa
40828|NCT02798952|Immunogenicity
40829|NCT02798952|Adolescents
40830|NCT02798939|spontaneous bacterial peritonitis
40831|NCT02798939|lactoferrin
40832|NCT02798939|procalcitonin
40833|NCT02798939|Aution® urine dipsticks
40834|NCT02798926|hypothermia
40835|NCT02798926|central venous catheter placement
40836|NCT02798926|Polyethylene bag
40837|NCT02798913|dual antiplatelet therapy
40838|NCT02798913|peripheral transluminal angioplasty
40839|NCT02798900|Task-specific exercise
40840|NCT02798900|Ultrasonic Waves
40841|NCT02798900|Biomechanics
40842|NCT02798900|Gait
40843|NCT02798900|Rehabilitation
40844|NCT02798900|Exercise therapy
40845|NCT02798887|Regeneration
40846|NCT02798887|Bone regeneration
40847|NCT02798887|Grafting, Bone
40848|NCT02798887|Allograft
40849|NCT02798887|Xenograft
40850|NCT02798874|Ticagrelor
40851|NCT02798874|No-reflow
40852|NCT02798874|Acute ST-segment elevation myocardial
40853|NCT02798874|Reperfusion injury
40854|NCT02798874|Percutaneous coronary intervention
40855|NCT02798796|breast cancer
40856|NCT02798796|conservative surgery
40857|NCT02798796|MRI
40858|NCT02798783|Vestibular Aqueduct
40859|NCT02798783|SLC26A4
40860|NCT02798783|FOXI1
40861|NCT02798783|Temporal Bone
40862|NCT02798731|Heart transplant
40863|NCT02798731|Microvascular dysfunction
40864|NCT02798731|Cardiac allograft vasculopathy
40865|NCT02798731|Fractional flow reserve
40866|NCT02798731|Coronary flow reserve
40867|NCT02798731|Index of microvascular resistance
40868|NCT02798705|Cardiac amyloidosis
40869|NCT02798705|Fractional flow reserve
40870|NCT02798705|Microvascular dysfunction
40871|NCT02798705|Coronary flow reserve
40872|NCT02798705|Index of microcirculatory resistance
40873|NCT02798692|Prevention
40874|NCT02798666|Physical fitness
40875|NCT02798666|Respiratory exchange ratio
40876|NCT02798666|Insulin sensitivity
40877|NCT02798666|High intensity interval training
40878|NCT02798666|Continuous exercise training
40879|NCT02798601|Cerebral edema
40880|NCT02798601|Hypernatremia
40881|NCT02798601|Extended Glasgow Outcome Scale
40882|NCT02798601|Intracranial pressure
40883|NCT02798601|Mannitol
40884|NCT02798601|Hypertonic saline
40885|NCT02798601|Mortality
40886|NCT02798588|coma
40887|NCT02798588|prognosis
40888|NCT02798588|comparative study
40889|NCT02798588|functional imaging
40890|NCT02798588|PET-MRI
40891|NCT02798588|electrophysiology
40892|NCT02798575|COPD
40893|NCT02798575|invasive ventilation
40894|NCT02798575|exacerbation
40895|NCT02798575|home care
40896|NCT02798575|mechanical ventilation
40897|NCT02798575|unsuccessful weaning
40898|NCT02798575|ventilatory parameters
40899|NCT02798562|low dose CT
40900|NCT02798562|contrast-enhanced
40901|NCT02798562|breast cancer screening
40902|NCT02798562|computer tomography
40903|NCT02798549|HBV
40904|NCT02798549|liver
40905|NCT02798536|Immunotoxin
40906|NCT02798536|Mesothelin
40907|NCT02798536|Targeted Therapy
40908|NCT02798523|Methylprednisolone
40909|NCT02798523|Immunologic
40910|NCT02798523|Infusion
40911|NCT02798523|Topical
40912|NCT02798523|Intravenous
40913|NCT02798510|Gallbladder Carcinoma
40914|NCT02798510|Extrahepatic Cholangiocarcinoma
40915|NCT02798510|Chemoradiotherapy
40916|NCT02798497|PVL
40917|NCT02798497|Pneumonias
40918|NCT02798497|Staphylococcus aureus
40919|NCT02798484|Diffusion Weighted Magnetic Resonance Imaging
40920|NCT02798484|Breast cancer
40921|NCT02798484|Neo-adjuvant therapy
40922|NCT02798471|Pediatric
40923|NCT02798471|Venous thrombolism
40924|NCT02798471|Pulmonary embolism
40925|NCT02798458|Fabry's Disease
40926|NCT02798458|Fabry
40927|NCT02798445|venous ulcer
40928|NCT02798445|vein
40929|NCT02798445|juxta cures
40930|NCT02798445|foam
40931|NCT02798445|laser
40932|NCT02798432|Total Knee Arthroplasty
40933|NCT02798432|Hybrid
40934|NCT02798432|Cemented
40935|NCT02798432|Fixation
40936|NCT02798406|brain
40937|NCT02798406|Central Nervous System (CNS) diseases
40938|NCT02798406|Central Nervous System (CNS) neoplasms
40939|NCT02798406|CNS
40940|NCT02798406|conditionally replicative adenovirus
40941|NCT02798406|DNX-2401
40942|NCT02798406|pembrolizumab
40943|NCT02798406|KEYTRUDA
40944|NCT02798406|MK-3475
40945|NCT02798406|SCH 900475
40946|NCT02798406|lambrolizumab
40947|NCT02798406|neoplasm, germ cell and embryonal
40948|NCT02798406|neoplasm, granular and epithelial
40949|NCT02798406|Alcyone
40950|NCT02798406|Alcyone Lifesciences
40951|NCT02798406|AMC
40952|NCT02798406|cannula
40953|NCT02798406|MEMS cannula
40954|NCT02798406|DNX-2401 + pembrolizumab
40955|NCT02798406|Delta-24
40956|NCT02798406|Delta-24-RGD
40957|NCT02798406|Checkpoint inhibitor
40958|NCT02798406|anti-PD1/PD-L1
40959|NCT02798406|immunotherapy
40960|NCT02798406|monoclonal antibody
40961|NCT02798406|KEYNOTE-192
40962|NCT02798367|insomnia
40963|NCT02798367|cognitive behavioral therapy for insomnia
40964|NCT02798367|melatonin
40965|NCT02798354|Depression
40966|NCT02798354|Blood Pressure
40967|NCT02798354|Anemias, Iron-Deficiency
40968|NCT02798354|Streptococcal Infections
40969|NCT02798354|Sexually Transmitted Diseases
40970|NCT02798354|Lead Poisoning, Nervous System, Childhood
40971|NCT02798354|Thyrotropin
40972|NCT02798315|Paritaprevir/r - Ombitasvir, ± Dasabuvir
40973|NCT02798315|Sustained Virological Response
40974|NCT02798315|Chronic Hepatitis C genotype 4
40975|NCT02798315|Observational Study
40976|NCT02798315|Chronic Hepatitis C genotype 1
40977|NCT02798315|Chronic Hepatitis C
40978|NCT02798276|Myocardial infarction
40979|NCT02798276|Cardiac regeneration
40980|NCT02798276|Cardiac surgery
40981|NCT02798250|Type 1 diabetes
40982|NCT02798250|Artificial pancreas
40983|NCT02798250|Closed-loop system
40984|NCT02798250|Postprandial glucose control
40985|NCT02798250|Hypoglycemia
40986|NCT02798250|Insulin
40987|NCT02798250|Glucagon
40988|NCT02798237|exercise
40989|NCT02798237|walking
40990|NCT02798237|health
40991|NCT02798224|Colorectal Cancer Screening
40992|NCT02798224|CRC Screening
40993|NCT02798224|Rectum
40994|NCT02798224|Colon
40995|NCT02798224|Screening
40996|NCT02798224|Populations at Risk
40997|NCT02798224|CRC
40998|NCT02798224|colorectal cancer (CRC)
40999|NCT02798211|PsA, ACR, CASPAR
41000|NCT02798159|Sexual Dysfunction
41001|NCT02798159|Physiological Sexual Dysfunctions
41002|NCT02798159|Psychological Sexual and Gender Disorders
41003|NCT02798159|Sildenafil
41004|NCT02798146|in-vitro fertilization
41005|NCT02798146|luteal phase
41006|NCT02798081|augmentative and alternative communication
41007|NCT02798081|social inclusion
41008|NCT02798081|serious games
41009|NCT02798081|Information and communication technologies
41010|NCT02798068|Steroids
41011|NCT02798068|Cardiac surgery
41012|NCT02798068|Endothelial dysfunction
41013|NCT02798068|Glycocalyx
41014|NCT02798068|Flow mediated vasodilation
41015|NCT02798029|Brain Metastases
41016|NCT02798029|Parenchymal Brain Metastases
41017|NCT02798029|Oligometastatic brain metastases
41018|NCT02798029|Frameless Fractionated Stereotactic Radiation Therapy
41019|NCT02798029|FFSRT
41020|NCT02798003|Cachexia
41021|NCT02798003|Food reward
41022|NCT02797990|[G08.686.785.760.769.500]
41023|NCT02797990|[G08.686.785.760.769]
41024|NCT02797990|[N02.360]
41025|NCT02797990|[C25.775.650]
41026|NCT02797990|[C25.775.793]
41027|NCT02797990|[C25.775.635]
41028|NCT02797990|[C25.775.675]
41029|NCT02797990|[C25.775.300]
41030|NCT02797990|[C25.775.467]
41031|NCT02797990|[C25.775.225]
41032|NCT02797990|[C25.775.100]
41033|NCT02797990|[C25.775]
41034|NCT02797977|Solid tumours
41035|NCT02797977|non-small cell lung cancer
41036|NCT02797977|pancreatic cancer
41037|NCT02797977|Phase I
41038|NCT02797977|Dose escalation
41039|NCT02797977|CHK1 inhibitor
41040|NCT02797977|checkpoint kinase 1
41041|NCT02797964|Solid tumours
41042|NCT02797964|Phase I
41043|NCT02797964|Dose escalation
41044|NCT02797964|CHK1 inhibitor
41045|NCT02797964|checkpoint kinase 1
41046|NCT02797951|cluster headache
41047|NCT02797951|headache
41048|NCT02797951|brain diseases
41049|NCT02797951|central nervous system diseases
41050|NCT02797951|headache disorders
41051|NCT02797951|headache disorders, primary
41052|NCT02797951|nervous system diseases
41053|NCT02797951|neurologic manifestations
41054|NCT02797951|pain
41055|NCT02797951|trigeminal autonomic cephalalgias
41056|NCT02797925|Achilles tendon
41057|NCT02797925|Patella tendon
41058|NCT02797925|Inflammation
41059|NCT02797925|Edema
41060|NCT02797925|Clinical
41061|NCT02797925|Structural
41062|NCT02797912|pulmonary function
41063|NCT02797912|respiratory muscle function
41064|NCT02797912|body composition
41065|NCT02797912|exercise tolerance
41066|NCT02797886|Hemiplegia
41067|NCT02797886|Drop foot
41068|NCT02797886|Foot drop
41069|NCT02797860|Transabdominal cervicoisthmic cerclage
41070|NCT02797860|Rocuronium
41071|NCT02797860|Pregnant Women
41072|NCT02797847|TTR-mediated Amyloidosis
41073|NCT02797847|Amyloidosis, Hereditary
41074|NCT02797847|Amyloid Neuropathies, Familial
41075|NCT02797847|Familial Amyloid Polyneuropathies
41076|NCT02797847|Amyloid Neuropathies
41077|NCT02797847|Amyloidosis, Hereditary, Transthyretin-Related
41078|NCT02797847|Familial Amyloidosis
41079|NCT02797847|RNAi therapeutic
41080|NCT02797834|Extracellular vesicles
41081|NCT02797834|Endometrial fluid
41082|NCT02797834|Menstrual cycle
41083|NCT02797834|Exosomes
41084|NCT02797834|Microvesicles
41085|NCT02797834|Apoptotic bodies
41086|NCT02797821|HPP
41087|NCT02797821|asfotase alfa
41088|NCT02797808|OCD
41089|NCT02797743|Healthy Volunteers
41090|NCT02797730|Art Therapy
41091|NCT02797730|Caregiver's
41092|NCT02797691|Cognitive Behavior Therapy
41093|NCT02797691|Depression
41094|NCT02797691|Anxiety
41095|NCT02797691|Pashto
41096|NCT02797691|Pakistani
41097|NCT02797691|Afghan
41098|NCT02796638|Acute Heart Failure
41099|NCT02796638|Positive-Pressure Ventilation
41100|NCT02796638|Adaptive Servo-Ventilation
41101|NCT02796625|EEG
41102|NCT02796625|healthy subjects
41103|NCT02796612|anxiety
41104|NCT02796612|breast cancer, suspected
41105|NCT02796612|breast biopsy
41106|NCT02796612|empathy
41107|NCT02796612|standardized and structured information
41108|NCT02796612|anxiety reduction
41109|NCT02796586|Refugee Health
41110|NCT02796586|Resettled Refugee
41111|NCT02796586|Family Planning
41112|NCT02796586|Contraception
41113|NCT02796586|Group Counseling
41114|NCT02796586|Group contraceptive counseling
41115|NCT02796573|blended care
41116|NCT02796573|CBT
41117|NCT02796573|B-CBT
41118|NCT02796573|depression
41119|NCT02796560|Drugs, Generic
41120|NCT02796560|Generic Equivalency
41121|NCT02796547|Episiotomy
41122|NCT02796547|Levobupivacaine
41123|NCT02796534|Obstructive Sleep Apnea Syndrome
41124|NCT02796521|malnutrition
41125|NCT02796521|aging
41126|NCT02796521|diet therapy
41127|NCT02796508|Healthy aging
41128|NCT02796508|Cognitive training
41129|NCT02796508|Video-games
41130|NCT02796508|Attention
41131|NCT02796508|Working memory
41132|NCT02796508|Wellbeing
41133|NCT02796495|Neuroplasticity
41134|NCT02796495|Sensory Feedback
41135|NCT02796495|Nerve stimulation
41136|NCT02796495|Robotic Hand
41137|NCT02796456|apelin
41138|NCT02796456|colostrum
41139|NCT02796456|plasma
41140|NCT02796456|glycemic markers
41141|NCT02796456|lipidic markers
41142|NCT02796456|pregnancy
41143|NCT02796456|postpartum
41144|NCT02796443|acute cholecystitis
41145|NCT02796443|early versus delayed surgery
41146|NCT02797652|Breast cancer
41147|NCT02797652|ctDNA
41148|NCT02797652|Neoadjuvant chemotherapy
41149|NCT02797652|Adjuvant chemotherapy
41150|NCT02797639|Intellectual Disability
41151|NCT02797639|Collaborative Consultation
41152|NCT02797639|Participation
41153|NCT02797600|Appalachia
41154|NCT02797587|Alcohol Use
41155|NCT02797587|Tobacco Use
41156|NCT02797587|Smoking
41157|NCT02797587|Inflammation
41158|NCT02797587|Coronary Heart Disease
41159|NCT02797587|Russia
41160|NCT02797587|Varenicline
41161|NCT02797587|Cytisine
41162|NCT02797587|Nicotine Replacement Therapy
41163|NCT02797587|Partial Agonist Therapy
41164|NCT02797587|HIV
41165|NCT02797587|Reynolds risk score
41166|NCT02797587|VACS index
41167|NCT02797561|Fractional flow reserve
41168|NCT02797561|Tandem
41169|NCT02797561|Percutaneous Coronary Intervention
41170|NCT02797548|drug-eluting stent
41171|NCT02797548|antiplatelet therapy
41172|NCT02797548|noncardiac surgery
41173|NCT02797509|Intensive Care Unit
41174|NCT02797496|Parkinson's disease
41175|NCT02797496|Mild to moderate stage
41176|NCT02797496|Asymmetric Motor Strengthening
41177|NCT02797496|Rehabilitation
41178|NCT02797457|Bilateral amputation of the forearms
41179|NCT02797457|Bilateral allograft
41180|NCT02797457|Prosthetic forehands
41181|NCT02797457|Medical economic evaluation
41182|NCT02797418|Attentional disorders, intellectual deficiency
41183|NCT02797405|radiation therapy
41184|NCT02797405|radiosensitivity
41185|NCT02797405|in vitro diagnostic medical devices
41186|NCT02797405|Adverse Event post radiotherapy
41187|NCT02797392|Tailored lifestyle intervention
41188|NCT02797392|Selective prevention
41189|NCT02797392|Primary care
41190|NCT02797392|Web based health risk assessment
41191|NCT02797392|Patient-centered health information system
41192|NCT02797392|Lifestyle intervention
41193|NCT02797392|preventive treatment
41194|NCT02797379|Psychoeducation
41195|NCT02797379|Self-help
41196|NCT02797327|Molecular signature
41197|NCT02797327|Thailand-Myanmar border
41198|NCT02797314|Type 2 diabetes
41199|NCT02797314|Bone quality
41200|NCT02797314|Bone biopsies
41201|NCT02797314|Vertebral fractures
41202|NCT02797314|Osteodensitometry
41203|NCT02797314|Trabecular Bone Score
41204|NCT02797301|early reading skills
41205|NCT02797249|preeclampsia
41206|NCT02797249|low dose aspirin
41207|NCT02797249|prevention
41208|NCT02797236|Phase I
41209|NCT02797236|conjugate vaccine
41210|NCT02797236|Shigella flexneri 2a
41211|NCT02797236|safety
41212|NCT02797236|Immunogenicity
41213|NCT02797236|Healthy adults
41214|NCT02797223|alopecia
41215|NCT02797223|chemotherapy
41216|NCT02797223|breast cancer
41217|NCT02797158|TAVI
41218|NCT02797158|Aortic stenosis
41219|NCT02797158|Coronary artery disease
41220|NCT02797158|Coronary angiography
41221|NCT02797158|Percutaneous Coronary Intervention
41222|NCT02797158|Myocardial ischemia
41223|NCT02797158|SPECT
41224|NCT02797158|Coronary revascularization
41225|NCT02797145|Digoxin
41226|NCT02797132|CF
41227|NCT02797119|Tranexamic acid
41228|NCT02797119|Fibrinolysis
41229|NCT02797119|Cesarean section
41230|NCT02797119|Pharmacokinetics
41231|NCT02797119|D dimers
41232|NCT02797119|Fibrinogen
41233|NCT02797119|Plasmin
41234|NCT02797119|Transfusion
41235|NCT02797106|Drooling
41236|NCT02797106|Cerebral palsy
41237|NCT02797106|Botulinium toxin
41238|NCT02797106|Practice survey of health professionals
41239|NCT02797106|Children
41240|NCT02797093|anti-retroviral therapy
41241|NCT02797080|ACTIMMUNE
41242|NCT02797080|interferon y-1b
41243|NCT02797067|Extracorporeal Shock Wave lithotripsy(ESWL)
41244|NCT02797067|Prophylaxis
41245|NCT02797067|Indomethacin
41246|NCT02797067|Chronic pancreatitis
41247|NCT02797054|HPV vaccination
41248|NCT02797054|Vaccination decision-making
41249|NCT02797054|Tailored health messaging
41250|NCT02797054|Barriers to vaccination
41251|NCT02797054|Attitudes
41252|NCT02797041|Multiple myeloma
41253|NCT02797041|Bortezomib
41254|NCT02797041|Relapsed multiple myeloma
41255|NCT02797041|Rechallenge
41256|NCT02797028|Hyperuricemia
41257|NCT02797028|endothelial function
41258|NCT02797028|anthocyanidins
41259|NCT02797015|MS
41260|NCT02797015|RMS
41261|NCT02797015|Multiple Sclerosis
41262|NCT02797015|Relapsing Multiple Sclerosis
41263|NCT02796976|arterial stiffness
41264|NCT02796976|retinal vessels
41265|NCT02796976|physical activity
41266|NCT02796976|ageing
41267|NCT02796963|HIV
41268|NCT02796963|MSM
41269|NCT02796963|test uptake
41270|NCT02796963|crowdsourcing
41271|NCT02796950|Acipimox
41272|NCT02796950|GLP-1
41273|NCT02796950|Insulin secretion
41274|NCT02796937|Pulmonary Emphysema
41275|NCT02796937|Alpha-1 Antitrypsin Deficiency
41276|NCT02796937|AATD
41277|NCT02796937|Alpha-1 PI Deficiency
41278|NCT02796937|Alpha-1 Proteinase Inhibitor
41279|NCT02796924|Psychogenic Non-Epileptic Seizure
41280|NCT02796924|Transcranial Magnetic Stimulation
41281|NCT02796924|Brain Stimulation
41282|NCT02796898|Prostate Cancer
41283|NCT02796898|PSA
41284|NCT02796898|Androgen Deprivation Therapy (ADT)
41285|NCT02796859|Inflammation
41286|NCT02796859|Psychosis
41287|NCT02796859|Schizophrenia
41288|NCT02796846|CPAP (continuous positive airway pressure)
41289|NCT02796846|OSA (Obstructive sleep apnea)
41290|NCT02796833|Home parenteral nutrition
41291|NCT02796833|Liver injury
41292|NCT02796833|Intravenous Lipid Emulsions
41293|NCT02796833|Catheter-related infections
41294|NCT02796833|Safety
41295|NCT02796820|Huaier Granule
41296|NCT02796820|After radical surgery
41297|NCT02796820|Prevention of Recurrence and Metastasis
41298|NCT02796820|Efficacy and safety
41299|NCT02796794|Enteral nutrition
41300|NCT02796794|Genistein
41301|NCT02796794|Cytokine
41302|NCT02796755|Central Nervous System (CNS) Glutamate
41303|NCT02796755|Breast Cancer Treatment
41304|NCT02796755|Fatigue
41305|NCT02796755|Cognitive Dysfunction
41306|NCT02796755|Behavioral
41307|NCT02796755|Psychometrics
41308|NCT02796755|Imaging Technology
41309|NCT02796755|Magnetic Resonance Spectroscopy
41310|NCT02796742|SSTIs
41311|NCT02796742|Methicillin-resistant Staphylococcus aureus (MRSA)
41312|NCT02796742|Methicillin susceptible Staphylococcus aureus (MSSA)
41313|NCT02796742|the toxin Panton-Valentine Leukocidin (PVL)
41314|NCT02796742|Emergency Departments
41315|NCT02796716|Wounded warriors
41316|NCT02796716|Battlefield infection
41317|NCT02796716|ESBL
41318|NCT02796716|MRSA
41319|NCT02796716|KPC
41320|NCT02796690|nasal carriage
41321|NCT02796690|Staphylococcus aureus
41322|NCT02796690|good hygiene practices
41323|NCT02796677|Safety
41324|NCT02796677|Efficacy
41325|NCT02796677|Aclidinium bromide
41326|NCT02796677|Formoterol fumarate
41327|NCT02796677|Tiotropium
41328|NCT02796677|Bronchodilation
41329|NCT02796677|COPD
41330|NCT02796664|Ginseng
41331|NCT02796664|Stroke
41332|NCT02796664|Quantitative MR flow analysis
41333|NCT02796651|Perforomist
41334|NCT02796651|Pressair
41335|NCT02796651|COPD
41336|NCT02796651|Cigarette smoking
41337|NCT02796651|Formoterol fumarate
41338|NCT02796651|long-acting β2-adrenergic agonists (LABA)
41339|NCT02796651|long-acting muscarinic antagonists (LAMA)
41340|NCT02796430|Indirect calorimetry
41341|NCT02796430|critical care
41342|NCT02796430|mechanical ventilation
41343|NCT02796430|energy expenditure
41344|NCT02796430|ICALIC study
41345|NCT02796404|home monitoring
41346|NCT02796404|cardiac monitoring
41347|NCT02796391|nicotine
41348|NCT02796391|cigarettes
41349|NCT02796391|very low nicotine content (VLNC)
41350|NCT02796378|physical activity
41351|NCT02796378|statin therapy
41352|NCT02796378|diabetes mellitus
41353|NCT02796378|cardiovascular disease
41354|NCT02796378|Q10-supplementation
41355|NCT02796365|Exercise
41356|NCT02796365|Cancer
41357|NCT02796365|Cardiotoxicity
41358|NCT02796365|Cardiomyopathy
41359|NCT02796365|Cardiac Rehabilitation
41360|NCT02796339|Inflammatory Bowel Diseases
41361|NCT02796339|natural Mastiha
41362|NCT02796339|supplement
41363|NCT02796326|tracheal stenosis
41364|NCT02796326|tracheal dilatation
41365|NCT02796326|ventilation
41366|NCT02796300|bioflo
41367|NCT02796300|Duramax catheter
41368|NCT02796300|dialysis
41369|NCT02796287|Amnesia
41370|NCT02796287|transient global amnesia
41371|NCT02796261|Anaplastic Astrocytoma
41372|NCT02796261|Grade 3 Glioma
41373|NCT02796261|Glioma
41374|NCT02796261|Eflornithine
41375|NCT02796261|Brain Cancer
41376|NCT02796261|Brain Tumor
41377|NCT02796261|Neuro-oncology
41378|NCT02796261|Progressive Anaplastic Astrocytoma
41379|NCT02796261|Recurrent Anaplastic Astrocytoma
41380|NCT02796261|Progressive Glioma
41381|NCT02796261|Recurrent Glioma
41382|NCT02796261|Malignant Glioma
41383|NCT02796261|Progressive Brain Tumor
41384|NCT02796261|Recurrent Brain Tumor
41385|NCT02796248|type 1 diabetes
41386|NCT02796248|glucose control
41387|NCT02796248|stigma
41388|NCT02796248|youth
41389|NCT02796222|Hemophilia
41390|NCT02796222|Recombinant factor VIII
41391|NCT02796222|Recombinant factor VIII Fc
41392|NCT02796222|Recombinant factor IX
41393|NCT02796222|Patient-reported outcomes
41394|NCT02796222|Recombinant factor IX Fc
41395|NCT02796209|atomoxetine
41396|NCT02796209|autonomic failure
41397|NCT02796196|Hematopoietic
41398|NCT02796196|Recipient
41399|NCT02796170|SGLT-2 inhibitor
41400|NCT02796170|urinary angiotensinogen
41401|NCT02796157|bioresorbable vascular scaffold, drug eluting stent, coronary artery disease
41402|NCT02796144|schizophrenia
41403|NCT02796144|schizoaffective disorder
41404|NCT02796144|overweight
41405|NCT02796144|obesity
41406|NCT02796144|weight loss
41407|NCT02796144|metformin
41408|NCT02796144|lorcaserin
41409|NCT02796131|Phase I
41410|NCT02796131|Healthy
41411|NCT02796131|Pharmacodynamics
41412|NCT02796118|Pharmacokinetics
41413|NCT02796118|Healthy non-elderly and elderly subjects
41414|NCT02796118|ASP2151
41415|NCT02796118|Safety
41416|NCT02796092|Pelvic Congestion Syndrome
41417|NCT02796092|Pelvic Venous Insufficiency
41418|NCT02796092|Chronic pelvic pain
41419|NCT02796066|Acne, topical, SCD-1 inhibitor, moderate, severe
41420|NCT02796040|Parkinson's disease
41421|NCT02796040|Impulse control disorders
41422|NCT02796040|Diffusion tensor imaging
41423|NCT02796040|MRI
41424|NCT02796040|Mesocorticolimbic pathway
41425|NCT02796027|Health Services Research
41426|NCT02795988|Secondary
41427|NCT02795962|Endovascular Procedures
41428|NCT02795962|Emergency Medical Services
41429|NCT02795949|Enterobacteriaceae
41430|NCT02795949|Bacteremia
41431|NCT02795949|Escalation
41432|NCT02795949|Bacterial resistance
41433|NCT02795949|Bloodstream infection
41434|NCT02795949|Recurrence
41435|NCT02795936|rehabilitation
41436|NCT02795936|exercise
41437|NCT02795897|genetics
41438|NCT02795897|genomics
41439|NCT02795897|amyotrophic lateral sclerosis (ALS)
41440|NCT02795897|primary lateral sclerosis (PLS)
41441|NCT02795897|progressive muscular atrophy (PMA)
41442|NCT02795897|motor neuron disease
41443|NCT02795884|Lung cancer
41444|NCT02795884|NSCLC
41445|NCT02795884|adjuvant treatment
41446|NCT02795871|Congenital Adrenal Hyperplasia
41447|NCT02795871|Prenatal treatment
41448|NCT02795871|Dexamethasone
41449|NCT02795871|Neuropsychological assessment
41450|NCT02795871|Cognitive development
41451|NCT02795858|Carcinoid Tumors
41452|NCT02795806|Address
41453|NCT02795793|appendicitis
41454|NCT02795793|non-operative management
41455|NCT02795793|children
41456|NCT02795793|pediatric
41457|NCT02795754|GSK2838232
41458|NCT02795754|HIV
41459|NCT02795754|repeated dose escalation
41460|NCT02795754|immediate release tablet
41461|NCT02795754|single dose escalation
41462|NCT02795715|tDCS
41463|NCT02795702|tDCS
41464|NCT02795676|Glomerular filtration rate
41465|NCT02795676|Proteinuria
41466|NCT02795663|Near-InfraRed Spectroscopy (NIRS)
41467|NCT02795663|Deep brain stimulation of SubThalamic Nucleus (DBS)
41468|NCT02795650|Metastatic
41469|NCT02795650|Pancreas
41470|NCT02795637|Attention deficit hyperactivity disorder (ADHD),
41471|NCT02795637|Binge-Eating Disorder (BED)
41472|NCT02795611|Family-centered
41473|NCT02795611|Autism spectrum disorder
41474|NCT02795611|Occupational therapy
41475|NCT02795611|Participation
41476|NCT02795611|Play
41477|NCT02795585|Fractional Flow Reserve
41478|NCT02795585|Coronary Artery Disease
41479|NCT02795572|Breast Neoplasms
41480|NCT02795572|Peripheral Neuropathies
41481|NCT02795559|Nutrition
41482|NCT02795559|Humans
41483|NCT02795559|Obesity
41484|NCT02795559|Blood glucose
41485|NCT02795559|Dietary fiber
41486|NCT02795559|Appetite
41487|NCT02795559|Short chain fatty acids
41488|NCT02795546|periodontal regeneration
41489|NCT02795533|Cognitive function
41490|NCT02795533|Quality of Life
41491|NCT02795507|cross education
41492|NCT02795507|visual feedback
41493|NCT02795468|Peripheral
41494|NCT02795468|Arterial
41495|NCT02795468|Catheterization
41496|NCT02795455|Eating Disorders
41497|NCT02795455|Food Avoidance
41498|NCT02795455|Reward Learning
41499|NCT02795455|Reward System
41500|NCT02795455|Family-based treatment
41501|NCT02795455|interoceptive exposure
41502|NCT02795455|insula-amygdala-ventral striatum subcircuits
41503|NCT02795429|Phase Ib/II
41504|NCT02795429|INC280
41505|NCT02795429|PDR001
41506|NCT02795429|checkpoint inhibitor
41507|NCT02795429|PD-1
41508|NCT02795416|Moderate to severe plaque psoriasis, PASI, secukinumab, monoclonal antibody, Turkish population
41509|NCT02795403|HCV, liver
41510|NCT02795390|Chinese herbal medicine
41511|NCT02795390|Placebo
41512|NCT02795390|Randomized controlled trial
41513|NCT02795390|Constipation
41514|NCT02795377|arterial hypertension
41515|NCT02795377|microparticle
41516|NCT02795377|endothelial function
41517|NCT02795364|High Grade Glioma
41518|NCT02795364|Magnetic Resonance Spectroscopy
41519|NCT02795364|Surgical resection
41520|NCT02795364|Prognosis
41521|NCT02795325|Primary Hyperoxaluria Type 1
41522|NCT02795325|PH1
41523|NCT02795325|Calcium Oxalate Stones
41524|NCT02795325|Kidney Stones
41525|NCT02795325|Liver Enzyme Deficiency
41526|NCT02795325|Genetic Diseases
41527|NCT02795325|Inborn Kidney Diseases
41528|NCT02795325|Metabolic Diseases
41529|NCT02795325|Inborn Errors
41530|NCT02795325|Urological Diseases
41531|NCT02795325|Carbohydrate Metabolism
41532|NCT02795325|Hyperoxaluria
41533|NCT02795325|AGT
41534|NCT02795325|RNAi
41535|NCT02795325|siRNA
41536|NCT02795325|DCR-PH1
41537|NCT02795312|Cigarette Smoking
41538|NCT02795286|Chronic Kidney Disease (CKD)
41539|NCT02795286|End Stage Renal Disease (ESRD)
41540|NCT02795286|Chronic Hemodialysis
41541|NCT02795286|In-center HD
41542|NCT02795286|Sodium
41543|NCT02795286|Isotonic Dialysis
41544|NCT02795273|Rhinitis
41545|NCT02795273|Conjunctivitis
41546|NCT02795273|Grass
41547|NCT02795273|Allergy
41548|NCT02795260|ESAT6
41549|NCT02795260|CFP10
41550|NCT02795260|skin test
41551|NCT02795260|diagnostic test
41552|NCT02795195|re-irradiation
41553|NCT02795195|carbon ion therapy
41554|NCT02795182|Relapsed
41555|NCT02795182|Refractory
41556|NCT02795156|regorafenib
41557|NCT02795156|afatinib
41558|NCT02795156|targeted therapy
41559|NCT02795143|TEN
41560|NCT02795104|RISE
41561|NCT02795091|clean supplies
41562|NCT02795091|ICU floor
41563|NCT02795091|bacteria colony
41564|NCT02795091|catheter associated with infection
41565|NCT02795078|Atherosclerotic Intracranial Arterial Stenosis
41566|NCT02795078|Intracranial Aneurysms
41567|NCT02795052|Neurologic Disease
41568|NCT02795052|Cerebral Vascular Accident
41569|NCT02795052|Stroke
41570|NCT02795052|Traumatic Brain Injury
41571|NCT02795052|Multiple Sclerosis
41572|NCT02795052|Parkinsons Disease
41573|NCT02795052|Neuropathy
41574|NCT02795052|Neurodegeneration
41575|NCT02795052|Diabetic Neuropathy
41576|NCT02795052|Cerebral Ischemia
41577|NCT02795026|dry needling
41578|NCT02795026|vulvodynia
41579|NCT02795026|pelvic pain chronic
41580|NCT02795013|Genetic studies
41581|NCT02795013|Pediatric
41582|NCT02795000|Primary Ovarian Insufficiency
41583|NCT02795000|nomogram
41584|NCT02794987|Bile duct
41585|NCT02794987|indeterminate stricture
41586|NCT02794987|cholangioscopy
41587|NCT02794987|Spyglass
41588|NCT02794948|primary ovarian insufficiency
41589|NCT02794948|TCM intervention
41590|NCT02794935|inspiratory muscle training
41591|NCT02794935|heart failure
41592|NCT02794935|obstructive sleep apnea
41593|NCT02794922|Vitamin B
41594|NCT02794922|Temporomandibular joint disorder
41595|NCT02794922|trpv1
41596|NCT02794909|Point-of-care ultrasound
41597|NCT02794909|ED
41598|NCT02794909|Low and middle-income country
41599|NCT02794909|Echocardiography
41600|NCT02794909|Lung ultrasound
41601|NCT02794909|Resuscitation
41602|NCT02794857|ALS
41603|NCT02794857|Amyotrophic Lateral Sclerosis
41604|NCT02794857|Motor Neuron Disease
41605|NCT02794857|Central Nervous System Diseases
41606|NCT02794857|Nervous System Diseases
41607|NCT02794857|Neurodegenerative Diseases
41608|NCT02794857|Neuromuscular Diseases
41609|NCT02794857|Inflammation
41610|NCT02794857|C-Reactive Protein
41611|NCT02794831|NSAIDs
41612|NCT02794831|Bacterial Infections
41613|NCT02794831|Severity
41614|NCT02794831|Self Medication
41615|NCT02794818|Prevention
41616|NCT02794818|Nutrition
41617|NCT02794792|Type 2 Diabetes Mellitus
41618|NCT02794792|ASP1941
41619|NCT02794792|Ipragliflozin
41620|NCT02794779|cesarean section
41621|NCT02794779|labor
41622|NCT02794779|oxytocin
41623|NCT02794753|Trichotillomania
41624|NCT02794753|Hair-pulling Disorder
41625|NCT02794753|Cognitive Training
41626|NCT02794753|Neuroplasticity
41627|NCT02794753|Working Memory
41628|NCT02794740|Osteoarthritis
41629|NCT02794714|Laparoscopic Gynecologic Surgeries
41630|NCT02794688|Non-lactating
41631|NCT02794688|idiopathic granulomatous mastitis
41632|NCT02794688|periductal mastitis
41633|NCT02794688|ductal lavage
41634|NCT02794675|resectable
41635|NCT02794675|Cesium 131
41636|NCT02794675|brachytherapy
41637|NCT02794662|Oxygen Delivery System, Nasal Cannula
41638|NCT02794662|Oxygen Delivery System, Incubator
41639|NCT02794623|cochlear implants
41640|NCT02794623|hearing loss
41641|NCT02794610|Tacrolimus
41642|NCT02794610|Ocular penetration
41643|NCT02794610|Topical
41644|NCT02794597|Unplanned Pregnancy, LARC
41645|NCT02794558|Breast Cancer, MRgFus, Focused Ultrasound
41646|NCT02794519|Asthma Control Questionnaire
41647|NCT02794519|interleukin-6
41648|NCT02794519|Sirukumab
41649|NCT02794519|severe, poorly controlled asthma
41650|NCT02794519|asthma
41651|NCT02794519|ACQ
41652|NCT02794506|Diabetes mellitus
41653|NCT02794506|Chronic periodontitis
41654|NCT02794506|Propolis
41655|NCT02794480|ELLIPTA
41656|NCT02794480|metered dose inhaler
41657|NCT02794480|Dry powder inhaler
41658|NCT02794467|Heavy menstrual bleeding
41659|NCT02794467|Adenomyosis
41660|NCT02794467|Safety
41661|NCT02794467|Epelsiban
41662|NCT02794467|Tolerability
41663|NCT02794467|Proof of concept
41664|NCT02794428|Gastric adenocarcinoma
41665|NCT02794428|Gastric intestinal metaplasia
41666|NCT02794428|Atrophic gastritis
41667|NCT02794428|Gastric premalignant lesion
41668|NCT02794415|HIV
41669|NCT02794415|disability
41670|NCT02794415|rehabilitation
41671|NCT02794415|exercise
41672|NCT02794389|Acetylcysteine
41673|NCT02794376|IBS
41674|NCT02794350|RBANS-H
41675|NCT02794350|Cochlear implantation
41676|NCT02794350|Cognition
41677|NCT02794350|Older adults
41678|NCT02794350|RBANS
41679|NCT02794285|Lupus Erythematosus, Systemic Autoimmune Diseases, Connective Tissue Diseases,Immune System Diseases
41680|NCT02794272|GABA concentration
41681|NCT02794272|tDCS
41682|NCT02794259|GABA concentration
41683|NCT02794259|tDCS
41684|NCT02794233|Deep Brain Stimulation
41685|NCT02794233|Electric Impedance
41686|NCT02794233|Parkinson disease
41687|NCT02794220|E-cigarette
41688|NCT02794220|healthy volunteer study
41689|NCT02794220|Pharmacokinetics
41690|NCT02794220|Nicorette
41691|NCT02794207|Pediatric
41692|NCT02794207|Cancer
41693|NCT02794207|AML
41694|NCT02794207|Qualitative Interview
41695|NCT02794194|Chronic Ankle Instability
41696|NCT02794194|Whole Body Vibration
41697|NCT02794194|Proprioception
41698|NCT02794181|Transfusion-Transmitted Infections
41699|NCT02794181|Dengue Virus
41700|NCT02794181|Chikungunya Virus
41701|NCT02794181|Natural History
41702|NCT02794181|Blood Transfusion
41703|NCT02794142|hemodialysis
41704|NCT02794142|muscle dysfunction
41705|NCT02794142|mitochondria
41706|NCT02794142|oxidative stress
41707|NCT02794142|inflammation
41708|NCT02794142|renal transplantation
41709|NCT02794103|Virtual reality
41710|NCT02794103|Immersive distraction
41711|NCT02794103|Virtual world
41712|NCT02794103|Virtual environment
41713|NCT02794103|Procedural pain
41714|NCT02794103|Procedural anxiety
41715|NCT02794103|Acute pain
41716|NCT02794103|Pain management
41717|NCT02794103|Anxiety
41718|NCT02794103|Children, Child
41719|NCT02794103|Kid, Kids
41720|NCT02794103|Pediatric, Pediatrics
41721|NCT02794103|Young children
41722|NCT02794103|Burns
41723|NCT02794103|Burn injuries
41724|NCT02794103|Burn unit
41725|NCT02794103|Hydrotherapy
41726|NCT02794103|Burn dressing
41727|NCT02794103|Non-pharmacological
41728|NCT02794103|Clinical Research
41729|NCT02794103|Nursing Practice
41730|NCT02794090|Behavioral treatment
41731|NCT02794090|Telephone coaching
41732|NCT02794090|Outpatient clinic
41733|NCT02794077|Nasopharyngeal undifferentiated carcinoma
41734|NCT02793947|Peri-incisional injection
41735|NCT02793947|Multimodal analgesia
41736|NCT02793947|Femur fracture
41737|NCT02793934|Rehabilitation
41738|NCT02793934|ICF
41739|NCT02793934|Pilot project
41740|NCT02793934|Stroke
41741|NCT02793934|Acute myocardial infarction
41742|NCT02793934|Total hip replacement
41743|NCT02793921|Alteration
41744|NCT02793921|Cognitive Function
41745|NCT02793921|Exercise
41746|NCT02793908|Endometriosis
41747|NCT02793908|Subcutaneous progesterone
41748|NCT02793908|luteal phase
41749|NCT02793895|Atrial fibrillation/flutter
41750|NCT02793895|Postoperative atrial arrhythmia
41751|NCT02793895|Cardiac surgery
41752|NCT02793895|Stroke prevention
41753|NCT02793895|Oral anticoagulation
41754|NCT02793895|Cardiac rhythm monitoring
41755|NCT02793869|congenital cataract;anterior segment characteristics
41756|NCT02793856|lung cancer
41757|NCT02793856|immune checkpoint
41758|NCT02793856|PD-1
41759|NCT02793856|CRISPER
41760|NCT02793856|autologous cell infusion
41761|NCT02793830|medication adherence
41762|NCT02793830|mHealth
41763|NCT02793830|China
41764|NCT02793830|heart disease
41765|NCT02793817|postsurgical
41766|NCT02793817|postoperative
41767|NCT02793817|ocular
41768|NCT02793817|cataract
41769|NCT02793817|inflammation
41770|NCT02793817|pain
41771|NCT02793817|corticosteroid
41772|NCT02793804|HIV self-testing
41773|NCT02793804|HIV
41774|NCT02793804|Zambia
41775|NCT02793791|high grade dysplastic nodule (HGDN)
41776|NCT02793791|low grade dysplastic nodule (LGDN)
41777|NCT02793778|Crohn's Disease
41778|NCT02793778|Digestive System Diseases
41779|NCT02793778|Gastrointestinal Diseases
41780|NCT02793778|Intestinal Diseases
41781|NCT02793778|mucosal healing
41782|NCT02793778|inflammatory bowel disease
41783|NCT02793778|Medical Food
41784|NCT02793765|Advanced Prostate Cancer
41785|NCT02793765|Castration-Resistant Prostate Cancer
41786|NCT02793765|Adenocarcinoma of the prostate
41787|NCT02793765|Metastatic disease
41788|NCT02793765|CRPC
41789|NCT02793752|IVF
41790|NCT02793752|In vitro fertilization
41791|NCT02793752|Cumulus Cells
41792|NCT02793752|Oocyte
41793|NCT02793752|Embryo
41794|NCT02793752|Fertility
41795|NCT02793739|Safety
41796|NCT02793739|Efficacy
41797|NCT02793739|Longevity
41798|NCT02793726|Hip Prosthesis
41799|NCT02793713|EBUS
41800|NCT02793713|Prediction
41801|NCT02793713|malignancy
41802|NCT02793713|lymph nodes
41803|NCT02793713|lung cancer
41804|NCT02793713|Diagnostic Techniques, Respiratory System
41805|NCT02793700|Betamethasone
41806|NCT02793674|effort of breathing
41807|NCT02793674|high flow nasal cannula
41808|NCT02793674|respiratory distress
41809|NCT02793648|Depression
41810|NCT02793648|Elderly
41811|NCT02793635|Paraplegia
41812|NCT02793635|Gait
41813|NCT02793635|Exoskeleton
41814|NCT02793622|Chemoprevention
41815|NCT02793622|Malaria
41816|NCT02793622|Sulfadoxine-Pyrimethamine
41817|NCT02793622|Dihydroartemisinin-Piperaquine
41818|NCT02793609|induction of labor
41819|NCT02793609|double balloon catheter
41820|NCT02793609|mechanical ripening
41821|NCT02793505|metformin
41822|NCT02793505|pregnancy outcomes
41823|NCT02793505|birth defects
41824|NCT02793505|spontaneous abortion
41825|NCT02793505|pharmacoepidemiology
41826|NCT02793466|Durvalumab
41827|NCT02793466|solid tumors
41828|NCT02793466|Immunotherapy
41829|NCT02793466|Check Point Inhibitor
41830|NCT02793466|pediatrics
41831|NCT02793466|children
41832|NCT02793401|High Intensity Laser
41833|NCT02793401|Ultrasound
41834|NCT02793401|Chronic Shoulder Pain
41835|NCT02793375|Montelukast
41836|NCT02793375|Tonsillectomy
41837|NCT02793349|angioplasty
41838|NCT02793349|stents
41839|NCT02793349|polymers
41840|NCT02793349|absorbable implants
41841|NCT02793271|Depression
41842|NCT02793271|Primary Health Care
41843|NCT02793271|Social Stigma
41844|NCT02793271|Stereotyping
41845|NCT02793271|Health Care Quality
41846|NCT02793271|Access
41847|NCT02793271|Evaluation
41848|NCT02793258|tDCS
41849|NCT02793258|neuromodulation
41850|NCT02793258|depression
41851|NCT02793258|cognition
41852|NCT02793232|Safety
41853|NCT02793232|Tolerability
41854|NCT02793232|Pharmacokinetics
41855|NCT02793232|Alzheimer's disease
41856|NCT02793219|Advanced Prostate Cancer
41857|NCT02793219|Castration-Resistant Prostate Cancer
41858|NCT02793219|CRPC
41859|NCT02793219|Adenocarcinoma of the prostate
41860|NCT02793219|Metastatic disease
41861|NCT02793206|Drusen
41862|NCT02793206|SD-OCT
41863|NCT02793167|acute kidney injury
41864|NCT02793167|medication alert systems
41865|NCT02793154|gastric emptying
41866|NCT02793154|albiglutide
41867|NCT02793154|GMA
41868|NCT02793154|exenatide
41869|NCT02793154|type 2 diabetes mellitus
41870|NCT02793141|Pneumonia
41871|NCT02793141|Intensive Care Unit
41872|NCT02793141|Nosocomial pneumonia
41873|NCT02793141|Hospital-acquired pneumonia
41874|NCT02793141|Ventilator-associated pneumonia
41875|NCT02793141|ICU
41876|NCT02793141|HAP
41877|NCT02793141|VAP
41878|NCT02793141|Critical Care
41879|NCT02793128|TC-3
41880|NCT02793128|Mitogel
41881|NCT02793128|UTUC
41882|NCT02793128|Ureteral
41883|NCT02793128|Upper Tract
41884|NCT02793128|Carcinoma
41885|NCT02793128|Kidney
41886|NCT02793128|Renal
41887|NCT02793128|Gel
41888|NCT02793128|Local
41889|NCT02793128|Mitomycin C
41890|NCT02793128|Prolonged Release
41891|NCT02793128|Slow Release
41892|NCT02793128|Kidney Sparing
41893|NCT02793128|T1
41894|NCT02793128|T0
41895|NCT02793128|Low Grade
41896|NCT02793102|mental anorexia
41897|NCT02793102|sensory workshops
41898|NCT02793102|BMI
41899|NCT02793076|Posture
41900|NCT02793076|Body image
41901|NCT02793076|Dancing
41902|NCT02793076|Group
41903|NCT02793076|Survivors
41904|NCT02793063|Brittle Bone
41905|NCT02793063|Osteogenesis Imperfecta
41906|NCT02793063|BBD
41907|NCT02793063|OI
41908|NCT02793063|Congenital Abnormalities
41909|NCT02793063|Congenital Bone Disorder
41910|NCT02793063|Lobstein Syndrome
41911|NCT02793050|Trabectedin
41912|NCT02793050|Soft Tissue Sarcoma
41913|NCT02793050|Observational
41914|NCT02793037|zirconia
41915|NCT02793037|resin bonded bridge
41916|NCT02793024|food shopping intervention
41917|NCT02792972|Analgesic
41918|NCT02792972|Medicinal plants
41919|NCT02792972|Skin
41920|NCT02792972|Antimicrobial agents
41921|NCT02792972|Pain Measurement
41922|NCT02792907|Foot Surgery
41923|NCT02792907|Compliance
41924|NCT02792907|Compressive Stockings
41925|NCT02792894|cluster randomized trial
41926|NCT02792894|developmental delays
41927|NCT02792894|neurodevelopmental disorders
41928|NCT02792894|autism
41929|NCT02792894|intellectual disability
41930|NCT02792894|low resource settings
41931|NCT02792894|family volunteers
41932|NCT02792881|Stomach Neoplasms
41933|NCT02792881|Laparoscopy
41934|NCT02792881|Remnant gastric cancer
41935|NCT02792855|Snifﬁng Position
41936|NCT02792855|Simple Head Extension
41937|NCT02792829|Bioavailability of Lenvatinib suspension
41938|NCT02792829|Palatability of Lenvatinib suspension
41939|NCT02792829|Lenvatinib
41940|NCT02792829|Lenvima
41941|NCT02792829|E7080
41942|NCT02792829|Capsule formulation
41943|NCT02792829|Healthy volunteers
41944|NCT02792803|POAG
41945|NCT02792803|Primary open angle glaucoma
41946|NCT02792803|Ocular Hypertension
41947|NCT02792803|Xalatan
41948|NCT02792803|Latanoprost
41949|NCT02792803|Ocular Hyperemia
41950|NCT02792803|IOP
41951|NCT02792803|Intraocular Pressure
41952|NCT02792803|Allergan
41953|NCT02792803|prostaglandin
41954|NCT02792790|Amyloidosis
41955|NCT02792790|Carpal tunnel syndrome
41956|NCT02792777|Concept Mapping
41957|NCT02792777|VOICe
41958|NCT02792777|Interviews
41959|NCT02792777|Patient-Centered Research
41960|NCT02792764|port
41961|NCT02792764|peripheral intravenous lines
41962|NCT02792764|oncology
41963|NCT02792751|Depth of anesthesia
41964|NCT02792751|BIS
41965|NCT02792751|ERCP
41966|NCT02792751|Positive Regulation
41967|NCT02792712|Acute myocardial infarction
41968|NCT02792712|Antiplatelet agents
41969|NCT02792712|Magnetic resonance imaging (MRI)
41970|NCT02792686|Healthy Volunteers
41971|NCT02792673|Embryo transfer media
41972|NCT02792673|improvement of embryo transfer technique
41973|NCT02792673|improvement of implantation
41974|NCT02792673|"Hyaluronan-enriched media Embryo Glue®"
41975|NCT02792673|"30% Protein-supplemented Culture Medium Global Total®"
41976|NCT02792673|Autologous Follicular Fluid as embryo transfer medium
41977|NCT02792634|Bariatric surgery
41978|NCT02792634|Nonalcoholic Steatohepatitis
41979|NCT02792634|Obesity
41980|NCT02792608|Mindfulness-based Intervention
41981|NCT02792608|Brain Tumour Survivors
41982|NCT02792608|Depressive Symptoms
41983|NCT02792608|Quality of Life
41984|NCT02792608|Perceived Stress
41985|NCT02792608|Wellbeing
41986|NCT02792608|Treatment
41987|NCT02792582|Brain tumor
41988|NCT02792582|Pediatrics
41989|NCT02792582|Radiation therapy
41990|NCT02792582|Proton therapy
41991|NCT02792582|Surgery
41992|NCT02792569|IVA
41993|NCT02792569|Hippo Pathway
41994|NCT02792569|Follicle activation
41995|NCT02792569|Low Responder
41996|NCT02792569|POI
41997|NCT02792569|Poor Ovarian Reserve
41998|NCT02792569|Poor Ovarian Response
41999|NCT02792569|Salvador/Warts/Hippo pathway
42000|NCT02792556|drug abortion
42001|NCT02792556|urine pregnancy test
42002|NCT02792556|negative predictive value
42003|NCT02792556|check Top test
42004|NCT02792556|transvaginal ultrasound
42005|NCT02792543|nutrition
42006|NCT02792543|double enterostomy
42007|NCT02792543|chyme reinfusion
42008|NCT02792543|randomized controlled trial
42009|NCT02792439|Fitness
42010|NCT02792439|Health kit
42011|NCT02792439|Researchkit
42012|NCT02792439|Walking
42013|NCT02792426|Smoking Cessation
42014|NCT02792426|Nicotine Dependence
42015|NCT02792426|Tobacco Dependence
42016|NCT02792413|osteoporosis
42017|NCT02792413|chronic kidney disease
42018|NCT02792413|anti-RANK ligand antibody
42019|NCT02792413|bone mineral density
42020|NCT02792413|vascular calcifications
42021|NCT02792387|cardio-renal syndrome
42022|NCT02792387|right heart dysfunction
42023|NCT02792387|central venous pressure
42024|NCT02792387|eGFR
42025|NCT02792387|low-flow theory
42026|NCT02792374|Dental patients
42027|NCT02792374|Psychological Profile
42028|NCT02792361|Post-Operative Pterional Craniotomy
42029|NCT02792361|Suction Drain
42030|NCT02792361|Benefits
42031|NCT02792348|congenital urine flow impairment
42032|NCT02792348|urinary metabolomics profile
42033|NCT02792348|Nuclear Magnetic Resonance
42034|NCT02792322|Cancer
42035|NCT02792322|Oropharynx
42036|NCT02792270|Surgery
42037|NCT02792231|Relapsing multiple sclerosis
42038|NCT02792231|Ofatumumab
42039|NCT02792218|Relapsing multiple sclerosis
42040|NCT02792218|Ofatumumab
42041|NCT02792205|Willebrand factor deficiency
42042|NCT02792205|hematology
42043|NCT02792205|Willebrand:Collagen-binding
42044|NCT02792166|Morbid obesity
42045|NCT02792166|Metabolic syndrome
42046|NCT02792166|Metabolic surgery
42047|NCT02792166|Bariatric surgery
42048|NCT02792166|SADI
42049|NCT02792166|BPD-DS
42050|NCT02792153|estrogen
42051|NCT02792153|anxiety
42052|NCT02792153|amenorrhea
42053|NCT02792153|eating disorders
42054|NCT02792140|Psychology
42055|NCT02792140|Dreams
42056|NCT02792127|Social Anxiety
42057|NCT02792127|Cognitive Behaviour Therapy
42058|NCT02792127|Online Program
42059|NCT02792114|T-Cell
42060|NCT02792114|Chimeric antigen receptor (CAR)
42061|NCT02792114|CAR T cells
42062|NCT02792114|Triple-negative breast cancer
42063|NCT02792114|Immunotherapy T-cell therapy
42064|NCT02792114|16-040
42065|NCT02792114|immunotherapy
42066|NCT02792114|CAR
42067|NCT02792088|HBV
42068|NCT02792075|Coronary Stenosis
42069|NCT02792075|Intracoronary Imaging
42070|NCT02792075|VH-IVUS
42071|NCT02792075|OCT
42072|NCT02792075|NIRS
42073|NCT02792075|gray scale IVUS
42074|NCT02792023|Colorectal cancer
42075|NCT02792023|Immunochemical occult blood test
42076|NCT02792010|T1rho MRI
42077|NCT02792010|hip
42078|NCT02792010|cartilage
42079|NCT02792010|Healthy participants
42080|NCT02791997|Audition
42081|NCT02791997|Stroke
42082|NCT02791997|Migraine
42083|NCT02791997|Attention
42084|NCT02791997|Short-term memory,
42085|NCT02791997|Emotions
42086|NCT02791997|EEG
42087|NCT02791997|MEG
42088|NCT02791984|Suprasternal
42089|NCT02791984|echography
42090|NCT02791984|fluid responsiveness
42091|NCT02791971|Contraception
42092|NCT02791971|Birth control
42093|NCT02791971|Social communication
42094|NCT02791971|Adolescent
42095|NCT02791971|Social network
42096|NCT02791971|Health education
42097|NCT02791971|Reproductive health
42098|NCT02791945|TBI
42099|NCT02791945|hazardous and harmful alcohol use
42100|NCT02791945|Veterans
42101|NCT02791945|co-occurring disorders
42102|NCT02791945|pharmacotherapy
42103|NCT02791932|Pregnancy
42104|NCT02791932|Postpartum period
42105|NCT02791932|Depression
42106|NCT02791906|Chronic Kidney Diseases
42107|NCT02791906|Chronic Kidney Insufficiency
42108|NCT02791906|Chronic Renal Diseases
42109|NCT02791906|Chronic Renal Insufficiency
42110|NCT02791906|Kidney Insufficiency, Chronic
42111|NCT02791906|Cardiac Failure
42112|NCT02791906|Congestive Heart Failure
42113|NCT02791906|Heart Decompensation
42114|NCT02791906|Heart Failure, Congestive
42115|NCT02791906|Myocardial Failure
42116|NCT02791880|acute kidney injury
42117|NCT02791880|transcatheter aortic valve replacement
42118|NCT02791880|genomics
42119|NCT02791880|biomarker
42120|NCT02791841|Reading
42121|NCT02791841|Developmental Dyslexia,
42122|NCT02791841|Music
42123|NCT02791841|Rhythm
42124|NCT02791841|Action Video Games
42125|NCT02791841|Hemisphere-Specific Stimulation
42126|NCT02791815|selexipag
42127|NCT02791815|pharmacokinetics
42128|NCT02791815|midazolam
42129|NCT02791802|Lipoprotein(a)
42130|NCT02791802|lipoprotein/lipid apheresis
42131|NCT02791802|CV disease
42132|NCT02791789|Autism Spectrum Disorder
42133|NCT02791789|SEMATIC
42134|NCT02791789|software
42135|NCT02791776|scoliosis
42136|NCT02791763|Renal Anemia
42137|NCT02791763|Japanese
42138|NCT02791763|chronic kidney disease
42139|NCT02791763|Peritoneal dialysis
42140|NCT02791763|GSK1278863
42141|NCT02791763|Non-dialysis
42142|NCT02791750|hormone replacement therapy
42143|NCT02791750|breast cancer
42144|NCT02791750|follow up
42145|NCT02791737|Hematologic Malignancy
42146|NCT02791737|Exercise
42147|NCT02791737|Decreased Physical Activity
42148|NCT02791711|Bronchiolitis
42149|NCT02791711|Continuous Positive Airway Pressure
42150|NCT02791711|HFNC
42151|NCT02791698|cortisol
42152|NCT02791698|hair
42153|NCT02791698|urinary
42154|NCT02791685|Cardiac Rehabilitation
42155|NCT02791672|Perioperative Care
42156|NCT02791672|Breast Reconstruction
42157|NCT02791659|radiation exposure
42158|NCT02791659|ERCP
42159|NCT02791659|prone
42160|NCT02791659|left lateral decubitus
42161|NCT02791607|Circulating tumor cells
42162|NCT02791607|Head and neck cancer
42163|NCT02791607|Survival Prognosis
42164|NCT02791607|P16Ink4A
42165|NCT02791607|HPV
42166|NCT02791555|pradaxa
42167|NCT02791555|warfarin
42168|NCT02791542|Asthma
42169|NCT02791516|Osteoporosis.
42170|NCT02791516|Osteoporosis-Postmenopausal.
42171|NCT02791516|Bone Diseases-Metabolic.
42172|NCT02791516|Bone Diseases.
42173|NCT02791516|Musculoskeletal Diseases.
42174|NCT02791503|Irreversible electroporation (IRE
42175|NCT02791503|Stereotactic ablative radiotherapy (SABR
42176|NCT02791503|Efficacy
42177|NCT02791503|Tumor ablation
42178|NCT02791503|Chemotherapy
42179|NCT02791503|Locally advanced pancreatic cancer (LAPC)
42180|NCT02791477|Attune
42181|NCT02791464|Meditation
42182|NCT02791464|TM
42183|NCT02791464|PTSD
42184|NCT02791464|Trauma
42185|NCT02791464|Female Prisoners
42186|NCT02791451|COPD
42187|NCT02791451|telemonitoring
42188|NCT02791451|exacerbation
42189|NCT02791425|Brain-Computer Interface
42190|NCT02791425|Intratracheal intubation
42191|NCT02791425|Mechanical ventilation
42192|NCT02791425|Nonverbal communication
42193|NCT02791425|Critical illness
42194|NCT02791425|Electroencephalography
42195|NCT02791425|Visual Evoked Potential
42196|NCT02791412|left main
42197|NCT02791412|unprotected
42198|NCT02791412|percutaneous coronary intervention
42199|NCT02791412|coronary-artery bypass graft
42200|NCT02791399|opioid safety
42201|NCT02791399|opioid misuse
42202|NCT02791399|opioid abuse
42203|NCT02791399|patient-centered
42204|NCT02791399|opioid
42205|NCT02791399|opiate
42206|NCT02791399|chronic pain
42207|NCT02791399|primary care
42208|NCT02791399|Veteran
42209|NCT02791399|clinical care
42210|NCT02791360|Brain
42211|NCT02791360|Radiotherapy
42212|NCT02791360|MRI
42213|NCT02791360|Sequelae
42214|NCT02791334|PDL1
42215|NCT02791334|PD-L1
42216|NCT02791295|Type 2 diabetes
42217|NCT02791295|lifestyle intervention
42218|NCT02791295|insulin pump treatment
42219|NCT02791295|body weight
42220|NCT02791295|body composition
42221|NCT02791282|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
42222|NCT02791282|MRI
42223|NCT02791282|SPECT
42224|NCT02791230|amyloidosis
42225|NCT02791230|amyloid
42226|NCT02791230|transthyretin
42227|NCT02791230|TTR
42228|NCT02791191|BACE inhibitor
42229|NCT02791100|height
42230|NCT02791100|weight
42231|NCT02791100|diet
42232|NCT02791100|complementary foods
42233|NCT02791100|protein
42234|NCT02791100|calcium
42235|NCT02791009|HF
42236|NCT02791009|HFrEF
42237|NCT02791009|HFpEF
42238|NCT02791009|MRI
42239|NCT02791009|biomarker
42240|NCT02790996|sepsis
42241|NCT02790996|neonate
42242|NCT02790996|vancomycin
42243|NCT02790983|Registry
42244|NCT02790983|Spine
42245|NCT02790983|Surgery
42246|NCT02790983|Medical Oncology
42247|NCT02790983|Radiation Oncology
42248|NCT02790983|Neoplasms
42249|NCT02790944|Germline
42250|NCT02790944|Pancreatic
42251|NCT02790944|Genetic Testing
42252|NCT02790931|diabetic foot
42253|NCT02790931|therapeutic exercises
42254|NCT02790931|foot
42255|NCT02790931|biomechanics
42256|NCT02790931|preventive care
42257|NCT02790931|rehabilitation
42258|NCT02790931|Diabetic Neuropathy
42259|NCT02790931|software
42260|NCT02790918|Pulmonary Hypertension
42261|NCT02790918|MRI
42262|NCT02790905|pregnant and post-partum women
42263|NCT02790905|Validation questionnaires
42264|NCT02790905|Thai-Myanmar border
42265|NCT02790892|type 1 diabetes
42266|NCT02790892|type 2 diabetes
42267|NCT02790892|children
42268|NCT02790892|adolescents
42269|NCT02790892|young adults
42270|NCT02790892|youth
42271|NCT02790892|transition
42272|NCT02790892|art therapy
42273|NCT02790892|behavioral therapy
42274|NCT02790879|Transitional care
42275|NCT02790879|teenagers
42276|NCT02790879|cystic fibrosis
42277|NCT02790879|pulmonary function
42278|NCT02790879|nutritional function
42279|NCT02790879|Patients who experiment a transition pediatric - adult care
42280|NCT02790866|Decision Aid
42281|NCT02790866|Informed Decision Making
42282|NCT02790866|Shared Decision making
42283|NCT02790866|Screening
42284|NCT02790853|Cancer of Head and Neck
42285|NCT02790853|Oral Potentially Malignant Disorders
42286|NCT02790853|OPMD
42287|NCT02790853|Multimodal Imaging
42288|NCT02790853|Suspicious oral mucosal lesion
42289|NCT02790853|Pathologic diagnosis of dysplasia
42290|NCT02790853|History of resected oral cancer
42291|NCT02790853|White Light Examination
42292|NCT02790853|WL
42293|NCT02790853|Wide-field auto-fluorescence imaging device PS2.1/PS3
42294|NCT02790853|Proflavine Hemisulfate
42295|NCT02790853|High-Resolution Optical System
42296|NCT02790853|HRME
42297|NCT02790853|Brush Biopsy
42298|NCT02790853|Tissue Biopsy
42299|NCT02790840|Volunteers
42300|NCT02790801|chronic heart failure
42301|NCT02790801|atrial fibrillation
42302|NCT02790801|anticoagulant
42303|NCT02790762|stem cells
42304|NCT02790762|Mesenchymal Stem Cells
42305|NCT02790762|Umbilical Cord-Mesenchymal Stem Cells
42306|NCT02790762|Pneumoconiosis
42307|NCT02790749|Developmental hip dysplasia
42308|NCT02790749|Intra-articular pathology
42309|NCT02790749|Adult hip dysplasia
42310|NCT02790749|Labral tear, hip
42311|NCT02790749|Chondromalacia, hip
42312|NCT02790736|propranolol
42313|NCT02790736|public speaking anxiety
42314|NCT02790710|propanolol
42315|NCT02790710|obsessive-compulsive disorder
42316|NCT02790697|Indirect calorimetry
42317|NCT02790697|ICALIC Study
42318|NCT02790697|Energy expenditure
42319|NCT02790697|VO2
42320|NCT02790697|VCO2
42321|NCT02790697|Respiratory quotient
42322|NCT02790658|Grumixama
42323|NCT02790658|Urolithins
42324|NCT02790658|Anthocyanins
42325|NCT02790658|Metabolomic Approach
42326|NCT02790658|Ellagitannins
42327|NCT02790658|Subjects
42328|NCT02790645|Type 1 diabetes
42329|NCT02790645|Health technologies
42330|NCT02790645|Continuous subcutaneous insulin infusion
42331|NCT02790645|Telemedicine
42332|NCT02790645|Glycemic variability
42333|NCT02790645|Inflammatory markers,
42334|NCT02790645|Oxidative stress
42335|NCT02790645|Depression
42336|NCT02790645|Quality of life
42337|NCT02790645|Cost-effectiveness
42338|NCT02790632|Aneurysm, Ruptured
42339|NCT02790632|Nimodipine
42340|NCT02790632|Subarachnoid Hemorrhage
42341|NCT02790567|diagnostic performance
42342|NCT02790567|heparin-induced thrombocytopenia
42343|NCT02790567|rapid immunological diagnostic method
42344|NCT02790567|immunoassay
42345|NCT02790567|pretest scoring systems
42346|NCT02790567|4Ts score
42347|NCT02790567|HEP score
42348|NCT02790541|aging
42349|NCT02790541|HBOT
42350|NCT02790541|reverse
42351|NCT02790541|angiogenesis
42352|NCT02790541|elderly
42353|NCT02790541|mitochohndria
42354|NCT02790528|statin
42355|NCT02790528|vasospastic angina
42356|NCT02790476|Safe
42357|NCT02790476|Prescribing
42358|NCT02790476|Opioids
42359|NCT02790463|Allopurinol
42360|NCT02790398|Transdiagnostic treatment protocol
42361|NCT02790398|Transdiagnostic treatment protocol + PA component
42362|NCT02790372|Nursing homes
42363|NCT02790372|Norway
42364|NCT02790359|Carbon dioxide
42365|NCT02790359|Air
42366|NCT02790359|Colonoscopy
42367|NCT02790346|hemiparesis
42368|NCT02790346|deformity of the foot and ankle
42369|NCT02790320|Eribulin mesylate
42370|NCT02790320|Halaven
42371|NCT02790320|Breast cancer
42372|NCT02790307|multiple sclerosis
42373|NCT02790307|overactive bladder
42374|NCT02790307|urinary incontinence
42375|NCT02790307|tibial nerve stimulation
42376|NCT02790294|magnetic resonance imaging
42377|NCT02790268|Cionni Ring
42378|NCT02790268|Ultrasound Biomicroscopy
42379|NCT02790242|Mechanical Circulatory Support Device (MCSD)
42380|NCT02790242|ventricular Assist Device (VAD)
42381|NCT02790229|rehabilitation, anti-gravity treadmill
42382|NCT02790216|Image guided brachytherapy
42383|NCT02790151|working memory, recollection training, transfer
42384|NCT02790138|Drug Therapy
42385|NCT02790112|Body Mass Index
42386|NCT02790112|Body Composition
42387|NCT02790112|Glucose Metabolism Disorders
42388|NCT02790112|Bone Development
42389|NCT02790112|Gonadal Disorders
42390|NCT02790112|Fertility
42391|NCT02790112|Overweight
42392|NCT02790112|Obesity
42393|NCT02790112|Menarche
42394|NCT02790099|Pain
42395|NCT02790099|Postoperative pain control
42396|NCT02790099|Rectus sheath block
42397|NCT02790099|Intrathecal morphine
42398|NCT02790099|Caesarean section
42399|NCT02790086|hypothermia
42400|NCT02790086|prevalence
42401|NCT02790086|perioperative
42402|NCT02790086|anemia
42403|NCT02790086|myocardial injury
42404|NCT02790086|troponin T
42405|NCT02790086|noncardiac surgery
42406|NCT02790073|Calciphylaxis
42407|NCT02790073|Calcific Uremic Arteriolopathy
42408|NCT02790073|Dialysis
42409|NCT02790073|End Stage Renal Disease
42410|NCT02790073|Rare disease (ORPHA280062)
42411|NCT02790073|Calcification
42412|NCT02790073|Calcium Metabolism Disorders
42413|NCT02790073|Calcinosis
42414|NCT02790073|Metabolic Diseases
42415|NCT02790060|diabetes
42416|NCT02790047|Chronic Obstructive Pulmonary Disease
42417|NCT02790047|Exercise Therapy
42418|NCT02790047|Positive Expiratory Pressure
42419|NCT02790047|Physical Fitness
42420|NCT02790047|Quality of Life
42421|NCT02790008|echocardiography
42422|NCT02790008|magnetic resonance imaging
42423|NCT02790008|cardiopulmonary exercise test
42424|NCT02789995|Intensive Care Unit - Acquired Weakness (ICU-AW)
42425|NCT02789982|PTSD
42426|NCT02789982|Trauma related disorders
42427|NCT02789982|Reconsolidation blockade
42428|NCT02789982|Paris attacks
42429|NCT02789956|Internal connection
42430|NCT02789956|Cobalt/Chrome
42431|NCT02789956|Cad-cam Framework
42432|NCT02789956|marginal bone level
42433|NCT02789943|IHD Normal EF
42434|NCT02789930|Weight estimation
42435|NCT02789930|Patient safety
42436|NCT02789917|ACS
42437|NCT02789917|Triple-Therapy
42438|NCT02789917|AF
42439|NCT02789917|oral anticoagulation (OAC)
42440|NCT02789917|non-vitamin-K oral anticoagulant (NOAC)
42441|NCT02789878|Neoadjuvant therapy
42442|NCT02789878|High-risk Prostate Cancer
42443|NCT02789865|Acute appendicitis
42444|NCT02789865|Endoscopic retrograde appendicitis therapy
42445|NCT02789865|Endoscopic retrograde appendicography
42446|NCT02789865|Endoscopic therapy
42447|NCT02789865|Appendectomy
42448|NCT02789865|Antibiotic Therapy
42449|NCT02789787|Cleft Lip
42450|NCT02789787|Palate
42451|NCT02789787|Class III
42452|NCT02789787|Malocclusion
42453|NCT02789787|Protraction
42454|NCT02789761|Flow-mediated dilatation (FMD)
42455|NCT02789761|Vascular function
42456|NCT02789761|cognitive function
42457|NCT02789735|Pregnancy
42458|NCT02789735|laser therapy
42459|NCT02789735|persistent pain
42460|NCT02789735|pelvic pain
42461|NCT02789722|Mate
42462|NCT02789722|Vascular protection
42463|NCT02789722|Endothelial function
42464|NCT02789722|Ilex paraguariensis
42465|NCT02789657|neoadjuvant breast cancer
42466|NCT02789657|stage I-III breast cancer
42467|NCT02789657|HER 2 positive breast cancer
42468|NCT02789644|Ursodeoxycholic acid
42469|NCT02789644|Metabolomics/biomarker
42470|NCT02789644|Pharmacokinetics
42471|NCT02789605|Aphthous Stomatitis [C07.465.864.750]
42472|NCT02789592|REM Sleep Behavior Disorder
42473|NCT02789592|Parkinson Disease
42474|NCT02789592|Randomized Controlled Trial
42475|NCT02789592|Clinical Trial
42476|NCT02789592|Melatonin
42477|NCT02789592|Clonazepam
42478|NCT02789579|prophylactic
42479|NCT02789579|Urinary Tract Infections
42480|NCT02789579|Minimally invasive upper tract lithotomy
42481|NCT02789566|Primaquine
42482|NCT02789566|Pharmacokinetic
42483|NCT02789553|Glucose digestion
42484|NCT02789553|Bypass surgery
42485|NCT02789553|C13-glucose tracer
42486|NCT02789553|Insulin secretion
42487|NCT02789540|COPD symptoms
42488|NCT02789527|healthy volunteers
42489|NCT02789514|esophagogastroduodenoscopy
42490|NCT02789514|paediatric
42491|NCT02789501|Catheter
42492|NCT02789501|Dysfunctions
42493|NCT02789501|Blood Stream Infections
42494|NCT02789501|Haemodialysis
42495|NCT02789501|Taurolidine
42496|NCT02789501|Tunneled
42497|NCT02789436|halitosis
42498|NCT02789436|chronic periodontitis
42499|NCT02789436|probiotic
42500|NCT02789410|Cesarean delivery
42501|NCT02789410|Analgesia
42502|NCT02789410|Intrathecal opioids
42503|NCT02789397|Granulomatous and lymphocytic interstitial lung disease
42504|NCT02789397|common variable immunodeficiency
42505|NCT02789397|Rituximab
42506|NCT02789397|Azathioprine
42507|NCT02789397|primary immunodeficiency
42508|NCT02789397|GLIILD
42509|NCT02789397|CVID
42510|NCT02789384|soft-tissue sarcomas
42511|NCT02789384|CINSARC
42512|NCT02789384|biomarker
42513|NCT02789384|efficacy
42514|NCT02789384|pronostic
42515|NCT02789371|EUS-FNA
42516|NCT02789371|modified wet suction technique
42517|NCT02789371|dry suction technique
42518|NCT02789358|cryotherapy
42519|NCT02789345|T790M
42643|NCT02788708|lenvatinib
42520|NCT02789345|epidermal growth factor receptor (EGFR)
42521|NCT02789332|carboplatin
42522|NCT02789332|olaparib
42523|NCT02789332|pCR
42524|NCT02789332|neoadjuvant
42525|NCT02789332|triple-negative
42526|NCT02789332|hormonreceptor-positive
42527|NCT02789332|BRCA1/2
42528|NCT02789332|HRD, homologous recominant deficient
42529|NCT02789332|breast cancer
42530|NCT02789332|genetic testing (somatic and germline mutations)
42531|NCT02789319|Blood Glucose Monitoring System
42532|NCT02789319|BGMS
42533|NCT02789319|Diabetes
42534|NCT02789319|Patient Use
42535|NCT02789306|Preventive therapy
42536|NCT02789306|Dental implants
42537|NCT02789293|Glaucoma
42538|NCT02789293|Ultrasound
42539|NCT02789293|Ciliary body
42540|NCT02789267|Cancer - Quality of life - Dietary support
42541|NCT02789254|acute myeloid leukemia
42542|NCT02789254|Fms-like receptor tyrosine kinase (FLT3)
42543|NCT02789254|stem cell transplantation
42544|NCT02789254|complete remission
42545|NCT02789254|CD135
42546|NCT02789254|antibodies
42547|NCT02789254|Leukemia
42548|NCT02789254|AML
42549|NCT02789254|Fc-optimized
42550|NCT02789241|Endotoxin
42551|NCT02789241|healthy
42552|NCT02789241|volunteers
42553|NCT02789241|males
42554|NCT02789241|females
42555|NCT02789215|Child care food costs
42556|NCT02789215|Meal participation rates
42557|NCT02789215|Child and Adult Care Food Program
42558|NCT02789202|dental caries
42559|NCT02789202|deciduous tooth
42560|NCT02789176|Phenobarbital
42561|NCT02789176|EEG
42562|NCT02789176|family impact
42563|NCT02789176|neurodevelopment
42564|NCT02789163|breast
42565|NCT02789163|ultrasound
42566|NCT02789163|diagnostic exam
42567|NCT02789163|automated volume breast scanner
42568|NCT02789137|metastatic renal cell carcinoma
42569|NCT02789124|fluid responsiveness
42570|NCT02789124|carotid artery flow time
42571|NCT02789124|passive leg raise
42572|NCT02789098|ST Elevation Myocardial Infarction
42573|NCT02789098|Ventricular remodeling
42574|NCT02789098|Biomarkers
42575|NCT02789098|Coronary endothelial function
42576|NCT02789098|Positron Emission Tomography
42577|NCT02789085|TENS
42578|NCT02789085|ULF-TENS
42579|NCT02789085|ANS
42580|NCT02789085|Dentistry
42581|NCT02789085|TMD
42582|NCT02789059|Becker muscular dystrophy
42583|NCT02789059|Facioscapulohumeral dystrophy
42584|NCT02789059|congenital myopathy
42585|NCT02789059|motor neurone diseases
42586|NCT02789046|adult
42587|NCT02789046|vascular access
42588|NCT02789046|preoperative period
42589|NCT02789046|peripheral venous catheterization
42590|NCT02789033|diabetic foot ulcers
42591|NCT02789033|chitosan
42592|NCT02789033|isosorbide dinitrate spray
42593|NCT02788981|triple-negative breast cancer
42594|NCT02788981|advanced breast cancer
42595|NCT02788981|nab-paclitaxel
42596|NCT02788981|mifepristone
42597|NCT02788981|glucocorticoid receptor-positive breast cancer
42598|NCT02788968|Psychology and Cognitive Neuroscience of development
42599|NCT02788968|Adolescent and young adult healthy volunteers
42600|NCT02788968|Anatomical and functionally Magnetic Resonance Imaging (MRI)
42601|NCT02788968|Conflict detection
42602|NCT02788968|Reasoning
42603|NCT02788955|Protein
42604|NCT02788955|Diet intervention
42605|NCT02788955|Muscle
42606|NCT02788955|Colorectal cancer
42607|NCT02788942|Port
42608|NCT02788942|Infection
42609|NCT02788942|cholecystectomy
42610|NCT02788929|Percutaneous Transluminal Coronary Intervention
42611|NCT02788929|Cardiac Rehabilitation
42612|NCT02788929|Fitbit Charge HR
42613|NCT02788916|Drug Therapy
42614|NCT02788903|Obesity Counseling
42615|NCT02788864|Forest ranger
42616|NCT02788864|P.falciparum
42617|NCT02788864|P.vivax
42618|NCT02788864|Dihydroartemisinine-piperaquine (DP)
42619|NCT02788864|Primaquine
42620|NCT02788851|Stimulant Medication
42621|NCT02788851|Exercise
42622|NCT02788851|Functional Outcome
42623|NCT02788851|Effectiveness
42624|NCT02788851|Symptoms
42625|NCT02788838|Magnetic Resonance Imaging
42626|NCT02788838|Energy Intake
42627|NCT02788838|Commercials
42628|NCT02788838|Children
42629|NCT02788799|ST Elevation
42630|NCT02788799|LCX Artery
42631|NCT02788786|chlorhexidine
42632|NCT02788786|cetylpyridinium chloride
42633|NCT02788786|gingival crevicular fluid
42634|NCT02788734|carpal tunnel syndrome
42635|NCT02788734|CTS
42636|NCT02788734|inherited peripheral neuropathy
42637|NCT02788734|Charcot-Marie-Tooth disease
42638|NCT02788734|Hereditary Neuropathy
42639|NCT02788734|Pressure Palsies
42640|NCT02788734|CMT
42641|NCT02788734|HNPP
42642|NCT02788708|paclitaxel
42644|NCT02788695|Visual Nonspecific
42645|NCT02788682|VDBP
42646|NCT02788682|single nucleotide polymorphisms (SNPs)
42647|NCT02788682|interferon based therapy
42648|NCT02788682|Egypt
42649|NCT02788656|heart failure
42650|NCT02788656|neprilysin
42651|NCT02788656|implantable hemodynamic monitor
42652|NCT02788656|angiotensin-receptor blocker
42653|NCT02788656|angiotensin-converting enzyme inhibitor
42654|NCT02788604|psychosocial screening, quality of life
42655|NCT02788552|Neurological
42656|NCT02788552|Diet and Nutrition
42657|NCT02788552|Mental Health
42658|NCT02788539|Chronic Pain
42659|NCT02788539|mhealth
42660|NCT02788539|Integrative Medicine
42661|NCT02788539|MBSR
42662|NCT02788539|Mindfulness Based Stress Reduction
42663|NCT02788539|Web based
42664|NCT02788539|Internet Based
42665|NCT02788526|Carcinoma,Hepatocellular
42666|NCT02788526|Chemoembolization
42667|NCT02788526|Adjuvant therapy
42668|NCT02788526|Hepatocellular
42669|NCT02788526|Microvessels invasion
42670|NCT02788500|Epidemiology
42671|NCT02788500|Sports medicine
42672|NCT02788500|Research protocol
42673|NCT02788500|Athletic injuries
42674|NCT02788500|Sports for persons with disabilities
42675|NCT02788448|Percutaneous vascular closure device
42676|NCT02788448|Large hole closure device
42677|NCT02788396|STEMI
42678|NCT02788396|PPCI
42679|NCT02788396|post-dilatation
42680|NCT02788396|coronary microcirculation
42681|NCT02788370|Positive expiratory pressure
42682|NCT02788370|Cardiopulmonary responses
42683|NCT02788370|Exercise
42684|NCT02788370|Older people
42685|NCT02788357|motor training
42686|NCT02788357|motor recovery
42687|NCT02788357|human
42688|NCT02788357|neuroplasticity
42689|NCT02788357|transcranial magnetic stimulation
42690|NCT02788344|Observational study
42691|NCT02788344|Myocardial revascularization
42692|NCT02788344|Thrombolytic therapy
42693|NCT02788344|Hospital mortality
42694|NCT02788344|Hemorrhage
42695|NCT02788344|Quality of health care
42696|NCT02788344|Angioplasty
42697|NCT02788318|Epilepsy
42698|NCT02788318|SUDEP
42699|NCT02788318|Serotonin
42700|NCT02788292|acetylcysteine
42701|NCT02788292|three-dimensional reconstruction
42702|NCT02788292|autologous fat grafting
42703|NCT02788279|Locally advanced or Metastatic colorectal adenocarcinoma
42704|NCT02788266|Cervical lesion
42705|NCT02788266|gingival recession
42706|NCT02788266|restorative materials
42707|NCT02788253|Mallampati
42708|NCT02788253|Intubation difficult
42709|NCT02788253|Mask ventilation difficult
42710|NCT02788227|Ebola Vaccine
42711|NCT02788214|Gastric Cancer
42712|NCT02788214|Bacterial Risk Factors
42713|NCT02788214|DNA Methylation
42714|NCT02788214|DNA Sequencing
42715|NCT02788214|Biobank
42716|NCT02788201|COXEN
42717|NCT02788201|Bladder Cancer
42718|NCT02788201|Molecular Profiles
42719|NCT02788201|Algorithm
42720|NCT02788201|Biomarkers
42721|NCT02788188|First in Human
42722|NCT02788188|Middle East Respiratory Syndrome (MERS)
42723|NCT02788188|Tc Bovine-Derived
42724|NCT02788188|Transchromosomic Cattle
42725|NCT02788175|HIV Immune Therapy
42726|NCT02788175|Monoclonal Antibody
42727|NCT02788175|Integrin
42728|NCT02788149|Ultrasonography
42729|NCT02788149|Submental
42730|NCT02788149|Lateral Parapharyngeal wall
42731|NCT02788149|Tongue base thickness
42732|NCT02788149|Polysomnography
42733|NCT02788123|De-Nol
42734|NCT02788123|NSAID-induced gastropathy
42735|NCT02788123|Pantoprazole
42736|NCT02788123|Bismuth tripotassium dicitrate
42737|NCT02788123|Russia
42738|NCT02788097|blastocysts
42739|NCT02788097|progesterone
42740|NCT02788097|implantation
42741|NCT02788097|artificial frozen embryo transfer
42742|NCT02788084|Next Generation Sequencing
42743|NCT02788084|Cell free DNA
42744|NCT02788071|Irritable Bowel Syndrome
42745|NCT02788071|Fecal Microbiota Transplantation
42746|NCT02788071|Microbiota
42747|NCT02788058|Hypofractionated Radiotherapy
42748|NCT02788058|EGFR Positive
42749|NCT02788058|Lung Adenocarcinoma
42750|NCT02788058|Limited Metastases
42751|NCT02788019|Adductor canal block, nerve block
42752|NCT02787941|acute coronary syndrome
42753|NCT02787941|medication adherence
42754|NCT02787941|pharmacist-led interventions
42755|NCT02787941|Vietnam
42756|NCT02787915|dendritic cells
42757|NCT02787915|cytotoxic T lymphocyte
42758|NCT02787915|DC vaccine
42759|NCT02787863|Pneumococcal vaccine
42760|NCT02787863|Polioxidonium
42761|NCT02787837|Prognostic
42762|NCT02787837|Castration
42763|NCT02787837|Resistant
42764|NCT02787837|Abiraterone
42765|NCT02787824|iron deficiency
42766|NCT02787824|hemodialysis
42767|NCT02787811|IUI
42768|NCT02787811|Pregnancy rate
42769|NCT02787811|predictors
42770|NCT02787798|Nervous System
42771|NCT02787798|Cardiac disease
42772|NCT02787785|Subcutaneous
42773|NCT02787785|Implantable Cardioverter Defibrillator
42774|NCT02787785|MADIT
42775|NCT02787785|Diabetes
42776|NCT02787785|Myocardial Infarction
42777|NCT02787759|stroke
42778|NCT02787759|walking
42779|NCT02787759|balance
42780|NCT02787759|exercise
42781|NCT02787746|AD
42782|NCT02787746|Donepezil
42783|NCT02787746|Safety
42784|NCT02787733|performance
42785|NCT02787733|recovery
42786|NCT02787720|Acute Respiratory Distress Syndrome
42787|NCT02787720|Pulmonary Rehabilitation
42788|NCT02787720|Rehabilitation Plan
42789|NCT02787720|Rehabilitation Techniques
42790|NCT02787720|Survivor
42791|NCT02787720|Randomized Controlled Trial
42792|NCT02787707|Breast cancer
42793|NCT02787707|Traditional medicine
42794|NCT02787707|Chemotherapy Induced Nausea and Vomiting
42795|NCT02787707|Bunium Persicum
42796|NCT02787707|Rhus Coriaria
42797|NCT02787694|stroke
42798|NCT02787694|walking
42799|NCT02787694|balance
42800|NCT02787694|exercise
42801|NCT02787668|childhood obesity
42802|NCT02787668|Non-alcoholic fatty liver disease
42803|NCT02787668|insulin resistance
42804|NCT02787668|carbohydrate-restriction
42805|NCT02787655|Aging
42806|NCT02787642|Advanced soft-tissue sarcoma
42807|NCT02787642|Unresectable Soft-tissue Sarcoma
42808|NCT02787629|D007440
42809|NCT02787590|Neurology
42810|NCT02787577|Sleep Duration
42811|NCT02787577|Sleep Quality
42812|NCT02787577|Body Composition
42813|NCT02787577|Energy Intake
42814|NCT02787577|Energy Expenditure
42815|NCT02787577|Energy Balance
42816|NCT02787577|Cardiovascular Risk
42817|NCT02787564|fruit, vegetables
42818|NCT02787538|Rheumatoid Arthritis
42819|NCT02787538|Decision Aids
42820|NCT02787538|Biologics
42821|NCT02787512|ERCP
42822|NCT02787512|stent
42823|NCT02787512|preoperative biliary drainage
42824|NCT02787499|Drug resistance
42825|NCT02787499|Standard of care
42826|NCT02787499|sub-saharan africa
42827|NCT02787499|antiretroviral therapy
42828|NCT02787499|diagnostics
42829|NCT02787499|implementation
42830|NCT02787486|Down syndrome
42831|NCT02787486|Edwards syndrome
42832|NCT02787486|Patau syndrome
42833|NCT02787486|Klinefelter syndrome
42834|NCT02787486|DiGeorge syndrome
42835|NCT02787486|Chromosome Deletion
42836|NCT02787486|Aneuploidy
42837|NCT02787473|Squamous cell lung cancer
42838|NCT02787473|Pemetrexed
42839|NCT02787473|Radiosensitivity
42840|NCT02787460|Parenting
42841|NCT02787460|Family Relations
42842|NCT02787460|Marriage
42843|NCT02787460|Relationships
42844|NCT02787447|Hypofractionated Radiotherapy
42845|NCT02787447|Thymosin Alpha 1
42846|NCT02787447|Lung Adenocarcinoma
42847|NCT02787447|Tyrosine Kinase Inhibitors
42848|NCT02787434|African american men
42849|NCT02787434|prostate cancer screening
42850|NCT02787434|web-based decision aid
42851|NCT02787434|informed decision making
42852|NCT02787434|shared decision-making
42853|NCT02787421|Reconstructive Surgery
42854|NCT02787421|Rhinoplasty
42855|NCT02787382|cytomegalovirus
42856|NCT02787382|TORCH
42857|NCT02787382|prenatal diagnosis
42858|NCT02787382|congenital infections
42859|NCT02787382|fetal abnormalities
42860|NCT02787382|echocardiography
42861|NCT02787382|myocardial deformation
42862|NCT02787369|Refractory Leukemia
42863|NCT02787369|Leukemia
42864|NCT02787356|Skin Diseases, Erythema
42865|NCT02787330|pediatric cancer
42866|NCT02787330|psychosocial
42867|NCT02787330|siblings
42868|NCT02787317|bivalirudin
42869|NCT02787317|myocardial injure
42870|NCT02787304|NAFLD activity score
42871|NCT02787304|ASBTi
42872|NCT02787304|MRI PDFF
42873|NCT02787304|NAS
42874|NCT02787304|NAFLD
42875|NCT02787304|liver disease
42876|NCT02787304|ASBT
42877|NCT02787304|MRI proton density fat fraction
42878|NCT02787304|nonalcoholic steatohepatitis
42879|NCT02787304|apical sodium dependent bile acid transporter inhibitor
42880|NCT02787304|fatty liver
42881|NCT02787304|NASH
42882|NCT02787278|rtPA
42883|NCT02787278|Intracranial hemorrhage
42884|NCT02787265|High density spinal cord stimulation
42885|NCT02787265|Virtual expert registry
42886|NCT02787226|liposomal bupivacaine
42887|NCT02787226|analgesia for total shoulder arthroplasty
42888|NCT02787226|peripheral nerve blocks for total shoulder arthroplasty
42889|NCT02787213|proteomics
42890|NCT02787213|pregnancy
42891|NCT02787213|biomarkers
42892|NCT02787213|preterm birth
42893|NCT02787200|electroencephalogram (EEG),Human brain,Brain-Computer Interface
42894|NCT02787187|Standard lymphadenectomy
42895|NCT02787187|extended lymphadenectomy
42896|NCT02787187|pancreaticoduodenectomy
42897|NCT02787174|Asthma
42898|NCT02787174|Medication adherence
42899|NCT02787174|Intervention study
42900|NCT02787161|Chronic Kidney Disease
42901|NCT02787161|Hemodialysis
42902|NCT02787161|Hemodiafiltration
42903|NCT02787161|Renal Replacement Therapy
42904|NCT02787161|Physical Activity
42905|NCT02787161|Accelerometer
42906|NCT02787148|cognitive behavioral therapy
42907|NCT02787148|psychotherapy
42908|NCT02787148|cardiovascular health
42909|NCT02787148|psychoneuroimmunology
42910|NCT02787135|Delusions
42911|NCT02787135|Schizophrenia
42912|NCT02787135|Cognitive Behavior Therapy
42913|NCT02787135|Emotion
42914|NCT02787135|Emotion regulation
42915|NCT02787135|self-esteem
42916|NCT02787135|sleep quality
42917|NCT02787135|Efficacy of change
42918|NCT02787122|Schizophrenia
42919|NCT02787122|psychotic disorders
42920|NCT02787122|Cognitive Behavior Therapy
42921|NCT02787122|emotion regulation
42922|NCT02787122|self-esteem
42923|NCT02787122|randomized-controlled trial
42924|NCT02787109|Safety
42925|NCT02787109|Immunogenicity
42926|NCT02787109|Phase I
42927|NCT02787096|dynamic knee laxity measurement
42928|NCT02787096|laxi-MRI
42929|NCT02787096|partial anterior cruciate ligament tear
42930|NCT02787083|Interstitial Cystitis
42931|NCT02787044|influenza vaccine
42932|NCT02787044|cardiopulmonary hospitalization
42933|NCT02787044|heart failure
42934|NCT02787044|myocardial infarction
42935|NCT02787044|clinical trial
42936|NCT02787031|hip fracture
42937|NCT02787031|geriatric
42938|NCT02787031|epidemiology
42939|NCT02787031|practice variation
42940|NCT02787031|anesthesia
42941|NCT02787018|Brachial plexus block
42942|NCT02787018|Ropivacaine
42943|NCT02787018|Dexmedetomidine
42944|NCT02787018|Dexamethasone
42945|NCT02787018|Adjuvants, anesthesia
42946|NCT02787005|PD1
42947|NCT02787005|PD-1
42948|NCT02787005|PDL1
42949|NCT02787005|PD-L1
42950|NCT02786992|Misoprostol
42951|NCT02786992|Oxytocin
42952|NCT02786992|Carbetocin
42953|NCT02786992|Prevention
42954|NCT02786992|Post-partum hemorrhage
42955|NCT02786979|Type 2 Diabetes Mellitus
42956|NCT02786979|Arteriosclerosis
42957|NCT02786979|beraprost
42958|NCT02786979|Aspirin
42959|NCT02786966|Cervical spine injuries
42960|NCT02786966|Canadian C-spine Rule
42961|NCT02786966|Emergency Medical Services
42962|NCT02786966|Paramedic
42963|NCT02786966|Cervical spine fracture
42964|NCT02786953|Sleep
42965|NCT02786953|Adherence
42966|NCT02786953|Diabetes Management
42967|NCT02786953|Adolescent
42968|NCT02786940|remote
42969|NCT02786940|cardiac monitoring
42970|NCT02786940|mortality
42971|NCT02786927|HANDIHALER
42972|NCT02786927|Dry Powder Inhaler
42973|NCT02786927|COPD
42974|NCT02786927|ELLIPTA
42975|NCT02786927|Inhaler preference attributes
42976|NCT02786875|lifestyle
42977|NCT02786875|low glycemic index diet
42978|NCT02786875|exercise
42979|NCT02786875|vitamin D
42980|NCT02786875|breast cancer
42981|NCT02786875|Mediterranean diet
42982|NCT02786862|mechanical ventilation
42983|NCT02786862|independent ventilation
42984|NCT02786862|ventilation/perfusion mismatch
42985|NCT02786862|thoracic anesthesia
42986|NCT02786849|Electric Stimulation
42987|NCT02786849|Electric Stimulation Therapy
42988|NCT02786836|acute liver failure
42989|NCT02786836|methacetin
42990|NCT02786836|breath test
42991|NCT02786836|severe acute liver injury
42992|NCT02786836|hepatic encephalopathy
42993|NCT02786836|ALFSG Registry
42994|NCT02786836|acetaminophen toxicity
42995|NCT02786797|breast cancer
42996|NCT02786797|mindfulness-based stress reduction
42997|NCT02786797|cognitive impairment
42998|NCT02786771|Stress Management
42999|NCT02786771|Mindfulness
43000|NCT02786771|Meditation
43001|NCT02786771|Stress Resilience
43002|NCT02786732|Psoriasis
43003|NCT02786719|Sargramostim
43004|NCT02786719|Cyclophosphamide
43005|NCT02786719|Topotecan
43006|NCT02786719|Cisplatin
43007|NCT02786719|Dexrazoxane
43008|NCT02786719|Doxorubicin
43009|NCT02786719|Etoposide
43010|NCT02786719|Filgrastim
43011|NCT02786719|Vincristine
43012|NCT02786719|Mesna
43013|NCT02786706|Traumatic Brain Injury
43014|NCT02786706|Intracranial Pressure
43015|NCT02786706|Ultrasonography
43016|NCT02786706|Computer-Assisted Image Analysis
43017|NCT02786706|Intracranial Hypertension
43018|NCT02786706|Acute brain injuries
43019|NCT02786693|TEP-scan
43020|NCT02786654|Acute myocardial infarction
43021|NCT02786654|mortality
43022|NCT02786654|evidence-based care
43023|NCT02786654|Myocardial Ischaemia National Audit Project
43024|NCT02786654|β blockers
43025|NCT02786641|nasopharyngeal carcinoma
43026|NCT02786641|induction chemotherapy
43027|NCT02786641|concurrent chemotherapy
43028|NCT02786641|docetaxel
43029|NCT02786641|cisplatin
43030|NCT02786641|xeloda
43031|NCT02786641|nomogram
43032|NCT02786615|men who have sex with men (MSM)
43033|NCT02786589|Lung cancer Immunotherapy
43034|NCT02786589|Plasmodium vivax
43035|NCT02786589|Immunotherapy
43036|NCT02786576|Moderate to Severe Hidradenitis Suppurativa
43037|NCT02786576|Adalimumab
43038|NCT02786563|ultrasonographic (US)
43039|NCT02786563|rheumatoid arthritis (RA)
43040|NCT02786563|C-reactive protein (CRP)
43041|NCT02786563|power doppler (PD)
43042|NCT02786563|disease activity scale (DAS)
43043|NCT02786550|Lower blepharoplasty, Botulinum toxin, Scar
43044|NCT02786537|Hepatitis C
43045|NCT02786524|Palliative Care
43046|NCT02786524|Triage
43047|NCT02786524|Symptom Evaluation
43048|NCT02786524|Chemotherapy
43049|NCT02786524|Patient Distress
43050|NCT02786498|Tibial Shaft
43051|NCT02786498|Tibia
43052|NCT02786498|Femoral Shaft
43053|NCT02786498|Femur
43054|NCT02786498|Vitamin D
43055|NCT02786498|Fracture Healing
43056|NCT02786485|BPX-501
43057|NCT02786485|Rimiducid
43058|NCT02786485|AP1903
43059|NCT02786485|Hematological malignancies
43060|NCT02786485|Hematologic diseases
43061|NCT02786485|Leukemias and Myelodysplastic Syndromes
43062|NCT02786485|Lymphomas
43063|NCT02786485|Multiple myeloma
43064|NCT02786472|Bystander behaviors
43065|NCT02786472|Incoming students
43066|NCT02786472|CampusSave
43067|NCT02786472|Prevention
43068|NCT02786472|Sexual Assault
43069|NCT02786472|Incapacitation
43070|NCT02786459|Prostate
43071|NCT02786459|Local Recurrence
43072|NCT02786459|Radical Prostatectomy
43073|NCT02786446|Lidocaine gel
43074|NCT02786446|Extracorporeal shockwave lithotripsy
43075|NCT02786446|Naproxen sodium
43076|NCT02786446|Pain score
43077|NCT02786420|pregnancy
43078|NCT02786420|magnetic resonance imaging
43079|NCT02786420|environmental air pollutants
43080|NCT02786407|overactive bladder
43081|NCT02786407|Botulinum Toxin Type A for Injection
43082|NCT02786368|Food Production
43083|NCT02786368|Inadequacy
43084|NCT02786368|Dietary zinc
43085|NCT02786368|Iron
43086|NCT02786368|vitamin A
43087|NCT02786342|Hepatocellular Carcinoma
43088|NCT02786342|Sorafenib
43089|NCT02786342|HCC
43090|NCT02786342|Angiogenesis
43091|NCT02786342|Polymorphisms
43092|NCT02786329|colorectal cancer
43093|NCT02786329|TIVA
43094|NCT02786329|sevoflurane
43095|NCT02786329|lidocaine
43096|NCT02786264|transcatheter aortic valve replacement
43097|NCT02786264|anesthesia
43098|NCT02786264|conscious sedation
43099|NCT02786264|managed anesthesia care
43100|NCT02786199|Hepatocellular Carcinoma(HCC)
43101|NCT02786199|Ultrasound
43102|NCT02786199|Backscatter
43103|NCT02786199|Differentiation grade
43104|NCT02786199|Survival
43105|NCT02786186|Psoriasis
43106|NCT02786186|Plaque Psoriasis
43107|NCT02786186|Chronic Plaque Psoriasis
43108|NCT02786186|Cosentyx
43109|NCT02786186|Secukinumab
43110|NCT02786186|Moderate to severe plaque psoriasis
43111|NCT02786186|PURE registry
43112|NCT02786186|Registry
43113|NCT02786173|PRIME
43114|NCT02786173|PAD
43115|NCT02786173|PVD
43116|NCT02786173|Observational
43117|NCT02786173|CLI
43118|NCT02786173|PRIME Registry
43119|NCT02786147|Breast Cancer
43120|NCT02786147|Ovarian Cancer
43121|NCT02786147|B-RST
43122|NCT02786121|hip replacement,
43123|NCT02786121|rehabilitation,
43124|NCT02786121|early ambulation,
43125|NCT02786108|left gastric artery
43126|NCT02786108|embolization
43127|NCT02786108|obesity
43128|NCT02786095|Atrial fibrillation
43129|NCT02786095|anti arrhythmic drug
43130|NCT02786095|NOAC
43131|NCT02786095|warfarin
43132|NCT02786095|coumadin
43133|NCT02786056|Respiratory Function Tests
43134|NCT02786056|Lung
43135|NCT02785965|electroacupuncture
43136|NCT02785965|lifestyle modification
43137|NCT02785965|diet
43138|NCT02785965|exercise
43139|NCT02785965|Dai Meridian
43140|NCT02785926|pesticide exposure
43141|NCT02785926|respiratory control
43142|NCT02785926|sleep
43143|NCT02785900|Antibodies, monoclonal
43144|NCT02785900|Antibody drug conjugate
43145|NCT02785900|Antigens, cluster of differentiation 33 (CD33)
43146|NCT02785900|Drug therapy
43147|NCT02785900|Immunotherapy
43148|NCT02785887|Breast cancer
43149|NCT02785887|lung cancer
43150|NCT02785887|Gastrointestinal Cancer
43151|NCT02785887|Ovarian cancer
43152|NCT02785887|Prostate cancer
43153|NCT02785887|bladder cancer
43154|NCT02785861|hormonal therapy
43155|NCT02785861|walking
43156|NCT02785861|fatigue
43157|NCT02785822|Reproductive Techniques, Assisted
43158|NCT02785809|Oral contraceptives
43159|NCT02785809|long-term use
43160|NCT02785809|AMH
43161|NCT02785809|Ovarian reserve parameters
43162|NCT02785783|EndoRings™
43163|NCT02785757|adenocarcinoma
43164|NCT02785757|venous thromboembolism
43165|NCT02785757|thrombin generation assay
43166|NCT02785731|pelvic mass
43167|NCT02785731|ovarian cancer
43168|NCT02785731|gynecological cancer
43169|NCT02785731|risk prediction
43170|NCT02785718|Contact system
43171|NCT02785718|Factor XI deficiency
43172|NCT02785718|Factor XII deficiency
43173|NCT02785718|Global haemostasis assays
43174|NCT02785705|immunization
43175|NCT02785705|vaccine schedule
43176|NCT02785705|poliomyelitis
43177|NCT02785705|polio
43178|NCT02785705|oral polio vaccine
43179|NCT02785705|inactivated polio vaccine
43180|NCT02785692|soft tissue sarcoma
43181|NCT02785692|IMRT and sarcoma
43182|NCT02785692|preoperative highly conformal radiation therapy
43183|NCT02785692|soft tissue sarcoma and wound healing
43184|NCT02785692|postoperative complications
43185|NCT02785692|treatment tolerance of soft tissue IMRT
43186|NCT02785679|Allergy
43187|NCT02785679|Cow's milk
43188|NCT02785679|breast feeding
43189|NCT02785679|Cow's milk formula
43190|NCT02785679|prevention
43191|NCT02785666|Men who have sex with men
43192|NCT02785666|Elimination
43193|NCT02785653|sevoflurane
43194|NCT02785653|rocuronium
43195|NCT02785653|intubation
43196|NCT02785627|Bone health
43197|NCT02785627|Bone microarchitecture
43198|NCT02785627|Androgen deprivation therapy (ADT)
43199|NCT02785588|MR Scanner
43200|NCT02785588|NICU
43201|NCT02785562|PDL1 expression : Protein Death Ligand 1 expression .
43202|NCT02785549|Acute diverticulitis
43203|NCT02785549|Antibiotic
43204|NCT02785549|Outpatient treatment
43205|NCT02785536|minority health
43206|NCT02785536|social class
43207|NCT02785536|healthcare disparities
43208|NCT02785536|tobacco use disorder
43209|NCT02785497|Electrical stimulation
43210|NCT02785497|wound healing
43211|NCT02785497|Polarity current
43212|NCT02785497|Burn
43213|NCT02785497|Chronic ulcer
43214|NCT02785484|Cigarette smoking
43215|NCT02785484|Smoking
43216|NCT02785484|Tobacco use
43217|NCT02785471|Suicide prevention
43218|NCT02785471|men's mental health
43219|NCT02785471|depression
43220|NCT02785471|suicide ideation and behaviors
43221|NCT02785419|Rehabilitation
43222|NCT02785419|Upper Extremity
43223|NCT02785419|Physical Therapy
43224|NCT02785406|cocaine
43225|NCT02785406|sleep
43226|NCT02785406|anxiety
43227|NCT02785406|craving
43228|NCT02785406|addiction
43229|NCT02785406|orexin
43230|NCT02785406|cue reactivity
43231|NCT02785406|suvorexant
43232|NCT02785406|Belsomra
43233|NCT02785393|Methamphetamine
43234|NCT02785393|Dependence
43235|NCT02785341|adapted physical activity
43236|NCT02785328|Memory
43237|NCT02785328|sleep
43238|NCT02785328|narcolepsy
43239|NCT02785328|apnea
43240|NCT02785328|epilepsy
43241|NCT02785302|Pediatric
43242|NCT02785302|HIV
43243|NCT02785302|Transition
43244|NCT02785302|Adult Care
43245|NCT02785263|Anal cancer
43246|NCT02785263|Shared decision making
43247|NCT02785250|vaccine
43248|NCT02785250|immunotherapy
43249|NCT02785250|IDO1 inhibitor
43250|NCT02785250|ovarian
43251|NCT02785250|fallopian tube
43252|NCT02785250|peritoneal
43253|NCT02785250|cancer
43254|NCT02785250|recurrent
43255|NCT02785250|tumor
43256|NCT02785250|measurable
43257|NCT02785237|Drug-eluting stent
43258|NCT02785237|OCT
43259|NCT02785237|Re-endothelialization
43260|NCT02785146|Huaier Granule
43261|NCT02785146|After radical surgery
43262|NCT02785146|Prevention of recurrence and metastasis
43263|NCT02785146|Efficacy and safety
43264|NCT02785120|Phase 2
43265|NCT02785120|Efficacy
43266|NCT02785120|Safety
43267|NCT02785120|Ischemic Stroke
43268|NCT02785107|Exercise
43269|NCT02785107|Habit
43270|NCT02785107|MVPA
43271|NCT02785107|M-PAC
43272|NCT02785107|Automaticity
43273|NCT02785107|Physical Activity
43274|NCT02785094|Caesarean Section Rate
43275|NCT02785094|Primigravida
43276|NCT02785081|Thoracic epidural
43277|NCT02785081|Magnetic Resonance Imaging
43278|NCT02785081|Children
43279|NCT02785068|Phase I
43280|NCT02785068|Cancer
43281|NCT02785068|EGFR
43282|NCT02785068|Metastatic Colorectal Cancer
43283|NCT02785068|Oncology
43284|NCT02785068|RAS/RAF Wild-Type
43285|NCT02785068|Nal-IRI
43286|NCT02785068|EGFR Inhibitor
43287|NCT02785068|Oligoclonal Antibody
43288|NCT02785068|Nanoliposome
43289|NCT02785068|Nanoliposomal Irinotecan
43290|NCT02785016|Stress Urinary Incontinence
43291|NCT02785016|Suburethral Sling
43292|NCT02785003|Colorectal Surgery
43293|NCT02785003|Acute Pain
43294|NCT02785003|Pain
43295|NCT02785003|post-operative pain
43296|NCT02785003|ketamine
43297|NCT02784938|Employment
43298|NCT02784938|Mental Illness
43299|NCT02784938|Photovoice
43300|NCT02784912|Biomarkers
43301|NCT02784912|Ventricular Dysfunction
43302|NCT02784912|Ventricular Tachycardia
43303|NCT02784912|Electrical Storm
43304|NCT02784912|ST2
43305|NCT02784912|Galectin-3
43306|NCT02784912|NT-proBNP
43307|NCT02784912|Iron Deficiency
43308|NCT02784912|hs-CRP
43309|NCT02784912|hs-TnT
43310|NCT02784886|Placenta accreta
43311|NCT02784886|previous caesarean
43312|NCT02784886|placenta praevia
43313|NCT02784886|Cell-free fetal DNA
43314|NCT02784886|Biological markers
43315|NCT02784873|High intensity interval training
43316|NCT02784873|Coronary heart disease
43317|NCT02784873|Exercise training
43318|NCT02784873|Cardiac rehabilitation
43319|NCT02784873|Interval training
43320|NCT02784860|colonoscopy
43321|NCT02784860|lidocaine
43322|NCT02784860|propofol
43323|NCT02784860|sedation
43324|NCT02784834|CLL
43325|NCT02784834|cancer
43326|NCT02784834|DMF
43327|NCT02784834|SLL
43328|NCT02784834|dimethylfumarate
43329|NCT02784834|relapsed
43330|NCT02784834|refractory
43331|NCT02784795|Notch Inhibitor
43332|NCT02784782|Spinal
43333|NCT02784782|Vertebral
43334|NCT02784782|Burstfracture
43335|NCT02784782|Orthesis
43336|NCT02784782|Brace
43337|NCT02784782|Thoracolumbar
43338|NCT02784756|Quantiferon-CMV
43339|NCT02784756|solid organ transplant
43340|NCT02784756|CMV Disease
43341|NCT02784743|Wuchereria bancrofti
43342|NCT02784743|Anopheles
43343|NCT02784743|Albendazole
43344|NCT02784743|Ivermectin
43345|NCT02784743|MDA
43346|NCT02784730|breast cancer
43347|NCT02784730|chemotherapy
43348|NCT02784730|peripherally inserted central catheter
43349|NCT02784730|implantable device
43350|NCT02784730|randomized controlled trial
43351|NCT02784730|iterative placement
43352|NCT02784730|Catheterization, Central Venous
43353|NCT02784717|rivaroxaban,
43354|NCT02784717|non-interventional,
43355|NCT02784717|atrial fibrillation,
43356|NCT02784717|stroke prevention,
43357|NCT02784665|CSC
43358|NCT02784665|Micropulse Laser
43359|NCT02784665|Traditional Laser
43360|NCT02784639|KRAS/BRAF mutational status
43361|NCT02784626|Dexmedetomidine
43362|NCT02784626|Propofol
43363|NCT02784626|Pain, Postoperative
43364|NCT02784600|Partial-thickness
43365|NCT02784600|Full-thickness
43366|NCT02784587|stellate ganglion block
43367|NCT02784587|cardiac surgery
43368|NCT02784574|Rehabilitation
43369|NCT02784574|Aftercare
43370|NCT02784561|allogeneic peripheral blood stem cell transplantation
43371|NCT02784561|conditioning regimen
43372|NCT02784561|acute leukemia
43373|NCT02784561|relapsed/refractory
43374|NCT02784509|Physical Activity
43375|NCT02784509|Sedentary Behavior
43376|NCT02784509|Cardiometabolic Risk Factors
43377|NCT02784509|Childhood and Adolescence
43378|NCT02784496|Myelofibrosis
43379|NCT02784496|Primary Myelofibrosis
43380|NCT02784496|PMF
43381|NCT02784496|Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
43382|NCT02784496|Post-PV/ET MF
43383|NCT02784496|Ruxolitinib
43384|NCT02784496|Jakafi
43385|NCT02784496|INCB018424
43386|NCT02784496|INC424
43387|NCT02784496|Questionnaires
43388|NCT02784496|Surveys
43389|NCT02784444|NASH
43390|NCT02784405|percutaneous coronary intervention
43391|NCT02784405|stent implantation
43392|NCT02784379|Mastalgia
43393|NCT02784379|electromyography
43394|NCT02784379|Pectoral
43395|NCT02784366|Cancer immunotherapy
43396|NCT02784366|Ipilimumab
43397|NCT02784353|Rehabilitation
43398|NCT02784353|Quality of life
43399|NCT02784353|Surgery
43400|NCT02784353|Hepatic neoplasms
43401|NCT02784353|Biliary tract neoplasms
43402|NCT02784353|Pancreatic neoplasms
43403|NCT02784340|Postoperative pain
43404|NCT02784340|dexamethasone
43405|NCT02784340|cesarean section
43406|NCT02784314|Clinically localized prostate cancer
43407|NCT02784314|Robotic-assisted prostatectomy
43408|NCT02784314|Laparoscopic prostatectomy
43409|NCT02784314|Erectile function ;
43410|NCT02784314|Cost efficacy study
43411|NCT02784288|head and neck neoplasms
43412|NCT02784288|HPV
43413|NCT02784288|human papilloma virus
43414|NCT02784288|de-escalation
43415|NCT02784288|low-risk
43416|NCT02784288|oropharyngeal cancer
43417|NCT02784262|Botulinum Toxin Type A
43418|NCT02784262|Block
43419|NCT02784262|Sphenopalatine Ganglion
43420|NCT02784249|Glaucoma
43421|NCT02784249|glaucoma surgery
43422|NCT02784249|ab interno
43423|NCT02784223|F18-choline
43424|NCT02784223|Surgery
43425|NCT02784223|Indeterminate
43426|NCT02784223|Thyroid node
43427|NCT02784210|Multiple Sclerosis
43428|NCT02784210|Corticosteroids
43429|NCT02784184|Hypothalamic-pituitary-gonadal axis
43430|NCT02784158|Non-small cell lung cancer
43431|NCT02784158|Non-small cell lung carcinoma
43432|NCT02784158|Epithelial lung cancer
43433|NCT02784158|Squamous cell carcinoma
43434|NCT02784158|Large cell carcinoma
43435|NCT02784158|Adenocarcinoma
43436|NCT02784158|Anaplastic lymphoma kinase (ALK)
43437|NCT02784158|Carcinoma
43438|NCT02784158|Advanced Cancers
43439|NCT02784158|Brigatinib
43440|NCT02784158|AP26113
43441|NCT02784119|temporary porto-caval shunt
43442|NCT02784119|liver graft
43443|NCT02784119|extended criteria donor
43444|NCT02784106|Rheumatoid Arthritis
43445|NCT02784106|M2951
43446|NCT02784106|Bruton's Tyrosine Kinase (BTK)
43447|NCT02784093|Chronic Constipation
43448|NCT02784093|Fecal impaction
43449|NCT02784093|Gastrografin
43450|NCT02784093|Randomized Controlled Trial
43451|NCT02784080|Liver Transplantation
43452|NCT02784080|HLA alloantibodies
43453|NCT02784080|donor specific antibodies
43454|NCT02784080|Mortality
43455|NCT02784080|Re-transplantation
43456|NCT02784080|Rejection
43457|NCT02784080|Acute rejection
43458|NCT02784080|Chronic rejection
43459|NCT02784080|Biliary complications
43460|NCT02784080|Biliary stricture
43461|NCT02784080|Arterial thrombosis
43462|NCT02784080|Arterial stenosis
43463|NCT02784080|Portal vein thrombosis
43464|NCT02784080|Fibrosis
43465|NCT02784080|Single antigen bead
43466|NCT02784080|Cross-match
43467|NCT02784041|knee arthroplasty
43468|NCT02784041|adductor canal block
43469|NCT02784041|femoral nerve block
43470|NCT02784028|Peritoneal Carcinomatosis
43471|NCT02784028|SGM-101
43472|NCT02783989|Endothelial function
43473|NCT02783989|Inflammation
43474|NCT02783989|Genes related to vascular risk
43475|NCT02783963|Coronary Artery Disease
43476|NCT02783963|Coronary Thrombosis
43477|NCT02783963|Coronary Stenosis
43478|NCT02783963|Tomography, Optical Coherence
43479|NCT02783963|Magnetic Resonance Imaging
43480|NCT02783950|Genomics
43481|NCT02783950|Adjuvant Treatment
43482|NCT02783937|Premature
43483|NCT02783937|Ovarian
43484|NCT02783937|Failure
43485|NCT02783937|Filgrastim
43486|NCT02783924|vitamin D
43487|NCT02783924|genomics
43488|NCT02783924|proteomics
43489|NCT02783924|metabolomics
43490|NCT02783924|adipose tissue
43491|NCT02783911|Clinical and Radiograph
43492|NCT02783898|pre syncope, palpitations
43493|NCT02783859|Children
43494|NCT02783859|Anti-Bacterial Agents
43495|NCT02783859|Indigenous Population
43496|NCT02783859|Hospitals
43497|NCT02783846|Propofol
43498|NCT02783846|Dexmedetomidine
43499|NCT02783846|Dose
43500|NCT02783846|Bispectral index monitor
43501|NCT02783833|malaria, induced blood stage model challenge
43502|NCT02783820|malaria, single ascending dose,
43503|NCT02783794|BP-C1
43504|NCT02783794|CDBPA
43505|NCT02783794|Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
43506|NCT02783794|Benzene polycarboxylic acids complex with cis-diammineplatinum(II)
43507|NCT02783794|Metastatic Breast Cancer
43508|NCT02783794|Platinum analogue
43509|NCT02783794|Metronomic chemotherapy
43510|NCT02783794|Breast cancer
43511|NCT02783794|Cisplatin
43512|NCT02783781|Cardiac surgery (extracorporeal circulation; beating heart)
43513|NCT02783781|Biological data
43514|NCT02783781|Preoperative biological variables
43515|NCT02783781|EuroSCORE II
43516|NCT02783781|Risk prediction
43517|NCT02783768|E-cigarettes
43518|NCT02783768|COPD
43519|NCT02783755|pain
43520|NCT02783755|coping
43521|NCT02783755|mhealth
43522|NCT02783755|Breast cancer
43523|NCT02783742|provider-patient communication
43524|NCT02783742|coaching
43525|NCT02783742|feedback
43526|NCT02783742|burnout
43527|NCT02783729|E2006
43528|NCT02783729|Lemborexant
43529|NCT02783729|zolpidem tartrate
43530|NCT02783729|Ambien CR
43531|NCT02783729|Insomnia
43532|NCT02783664|Breast Cancer
43533|NCT02783664|BRCA1
43534|NCT02783664|BRCA2
43535|NCT02783664|stress
43536|NCT02783664|gene testing
43537|NCT02783664|genetic screening
43538|NCT02783664|psychological support
43539|NCT02783664|State-Trait Anxiety Inventory
43540|NCT02783664|Cancer Worry Scale
43541|NCT02783664|Health Anxiety Inventory
43542|NCT02783664|gene mutations
43543|NCT02783625|Duvelisib
43544|NCT02783625|Romidepsin
43545|NCT02783625|Bortezomib
43546|NCT02783625|16-042
43547|NCT02783573|dementia
43548|NCT02783573|brain diseases
43549|NCT02783573|neurodegenerative diseases
43550|NCT02783573|central nervous system diseases
43551|NCT02783573|nervous system diseases
43552|NCT02783573|mental disorders
43553|NCT02783573|delirium, dementia, amnestic, cognitive
43554|NCT02783573|tauopathies
43555|NCT02783573|memory
43556|NCT02783573|amyloid
43557|NCT02783560|Sleep
43558|NCT02783560|Electrodermal Activity
43559|NCT02783560|Mealtimes
43560|NCT02783534|Acupuncture
43561|NCT02783534|Primary Dysmenorrhea
43562|NCT02783534|Randomized Controlled Trial
43563|NCT02783534|Placebo Effect
43564|NCT02783521|Hispanic men
43565|NCT02783521|Weight loss
43566|NCT02783521|Diet
43567|NCT02783521|Physical activity
43568|NCT02783521|Intervention
43569|NCT02783508|Labor analgesia
43570|NCT02783508|Nitrous Oxide
43571|NCT02783508|Meperidine
43572|NCT02783508|Multiparous
43573|NCT02783508|Visual analogue scale
43574|NCT02783495|glioma
43575|NCT02783495|neurocognitive
43576|NCT02783495|quality of life
43577|NCT02783456|renal hemodynamic
43578|NCT02783456|central hemodynamic
43579|NCT02783456|pilot study
43580|NCT02783456|flight noise
43581|NCT02783456|healthy participant
43582|NCT02783456|renal plasma flow
43583|NCT02783456|filtration fraction
43584|NCT02783456|renal vascular resistance
43585|NCT02783456|calculated intra glomerular pressure
43586|NCT02783443|Anesthesia, glycocalyx, perfused boundary region
43587|NCT02783430|Ketamine
43588|NCT02783430|Palliative care
43589|NCT02783430|Supportive care
43590|NCT02783430|Early palliative care
43591|NCT02783430|Fast acting antidepressant
43592|NCT02783430|End of life care
43593|NCT02783430|Cancer
43594|NCT02783430|psychological distress
43595|NCT02783430|antidepressant
43596|NCT02783430|serotonin norepinephrine reuptake inhibitors
43597|NCT02783417|Visceral fat
43598|NCT02783404|bacteraemia
43599|NCT02783404|endocarditis
43600|NCT02783404|antibiotic prophylaxis
43601|NCT02783404|dentistry
43602|NCT02783378|impedance metry
43603|NCT02783378|gaviscon
43604|NCT02783339|Next Generation Neuroform Stent System
43605|NCT02783339|Intracranial
43606|NCT02783339|Stent system
43607|NCT02783339|Saccular aneurysm
43608|NCT02783339|Stent assisted coiling
43609|NCT02783326|Chronic Disease Obstructive Pulmonary
43610|NCT02783326|Rehabilitation
43611|NCT02783326|Physical Therapy
43612|NCT02783313|pathogen inactivation
43613|NCT02783313|platelets
43614|NCT02783300|GSK3326595
43615|NCT02783300|glioblastoma multiforme (GBM)
43616|NCT02783300|Solid tumor
43617|NCT02783300|Non-Hodgkin's lymphoma (NHL)
43618|NCT02783300|breast cancer
43619|NCT02783300|bladder cancer
43620|NCT02783300|dose escalation
43621|NCT02783287|Exercise adherence
43622|NCT02783287|Medication adherence
43623|NCT02783287|Mobile health
43624|NCT02783287|Cardiac rehabilitation
43625|NCT02783261|radioembolization
43626|NCT02783261|hypertrophy
43627|NCT02783261|Y90
43628|NCT02783248|Percutaneous mitral commissurotomy
43629|NCT02783248|Mitral Stenosis
43630|NCT02783235|VIA
43631|NCT02783235|Cervical Cancer
43632|NCT02783235|Training
43633|NCT02783222|breast cancer
43634|NCT02783222|elderly patients
43635|NCT02783170|Tdap vaccine
43636|NCT02783170|Flu vaccine
43637|NCT02783170|vaccines in pregnancy
43638|NCT02783170|immunizations in pregnancy
43639|NCT02783170|Whooping Cough
43640|NCT02783170|Pertussis
43641|NCT02783170|Influenza
43642|NCT02783157|Autonomic
43643|NCT02783157|Vagal nerve stimulation
43644|NCT02783157|Postoperative atrial fibrillation
43645|NCT02783144|Analgesia
43646|NCT02783144|Dexamethasone
43647|NCT02783144|Levobupivacaine
43648|NCT02783144|Ultrasound-guided
43649|NCT02783144|Tranversus Abdominis
43650|NCT02783131|inventions
43651|NCT02783131|Simulation Training
43652|NCT02783131|Postpartum Haemorrhage
43653|NCT02783131|Non Technical Skills
43654|NCT02783131|teamwork
43655|NCT02783131|Crew Resource Management, Healthcare
43656|NCT02783118|Depression
43657|NCT02783118|Prevention
43658|NCT02783118|CBT
43659|NCT02783118|Smartphone app
43660|NCT02783105|Music therapy
43661|NCT02783105|Paroxysmal sympathetic hyperactivity
43662|NCT02783105|Traumatic brain injury
43663|NCT02783079|Breast Cancer
43664|NCT02783079|Prostate Cancer
43665|NCT02783079|Colon Cancer
43666|NCT02783079|Lung Cancer
43667|NCT02783079|Gynecologic Cancer
43668|NCT02783014|overactive bladder
43669|NCT02782988|Olfaction
43670|NCT02782988|CMV
43671|NCT02782962|nystagmus
43672|NCT02782962|vertigo
43673|NCT02782962|unsteadiness
43674|NCT02782962|emergency duplex ultrasonography
43675|NCT02782936|Work of Breathing; Hypoxemia; Respiratory Acidosis; Respiratory effort
43676|NCT02782923|Cervical Spine Surgery
43677|NCT02782923|Simulation
43678|NCT02782897|intravenous immunoglobulin
43679|NCT02782897|intracerebral hemorrhage
43680|NCT02782897|perihematomal edema
43681|NCT02782884|post-operative pain
43682|NCT02782871|Transfer
43683|NCT02782871|Intra-hospital
43684|NCT02782871|Ventilator
43685|NCT02782871|Manual ventilation
43686|NCT02782871|Head and neck surgery
43687|NCT02782858|Multiple Sclerosis
43688|NCT02782858|Multiple Sclerosis Relapsing-Remitting
43689|NCT02782858|GNbAC1
43690|NCT02782858|MRI
43691|NCT02782858|Monoclonal antibody
43692|NCT02782858|Multiple Sclerosis associated retrovirus MSRV
43693|NCT02782858|MS
43694|NCT02782858|RRMS
43695|NCT02782858|HERV-W
43696|NCT02782832|Neuromuscular
43697|NCT02782832|Blockade
43698|NCT02782832|Surgery
43699|NCT02782819|Shock resuscitation
43700|NCT02782819|colloid
43701|NCT02782819|crystalloid
43702|NCT02782806|Noninvasive
43703|NCT02782806|Pulse
43704|NCT02782806|CO-Oximeter
43705|NCT02782806|Validation
43706|NCT02782793|Endoscopic
43707|NCT02782793|Mucosal
43708|NCT02782793|Resection
43709|NCT02782780|insomnia
43710|NCT02782780|insomnia disorder
43711|NCT02782780|Gulf War Illness
43712|NCT02782780|Chronic Multisymptom Illness
43713|NCT02782728|intimate partner violence
43714|NCT02782728|reproductive coercion
43715|NCT02782728|women's health
43716|NCT02782728|relationship abuse
43717|NCT02782702|Botulism Toxin
43718|NCT02781857|Exhaled Breath
43719|NCT02781857|Mass Spectrometry
43720|NCT02781857|Fingerprinting
43721|NCT02781818|hidradenitis
43722|NCT02781818|intralesional
43723|NCT02781818|triamcinolone
43724|NCT02781779|Cardiac Implantable Electronic Device
43725|NCT02781779|Implant
43726|NCT02782663|Crohn's Disease
43727|NCT02782663|Tolerability
43728|NCT02782663|ABT-494
43729|NCT02782663|Efficacy
43730|NCT02782663|Safety
43731|NCT02782650|Limits
43732|NCT02782650|Prenatal Counseling
43733|NCT02782650|Decision-making
43734|NCT02782650|Foetal Complications
43735|NCT02782650|Counseling
43736|NCT02782650|Viability
43737|NCT02782637|limits of viability
43738|NCT02782637|Prenatal Counseling
43739|NCT02782637|Decision-making
43740|NCT02782637|Viability
43741|NCT02782637|Counseling
43742|NCT02782611|Happiness
43743|NCT02782611|Subjective Well-Being
43744|NCT02782611|Psychological Flourishing
43745|NCT02782611|Well-Being
43746|NCT02782611|Health
43747|NCT02782611|Behavioral Change
43748|NCT02782611|Life Satisfaction
43749|NCT02782611|Affect
43750|NCT02782611|Emotion
43751|NCT02782611|Goals
43752|NCT02782611|Meaning in Life
43753|NCT02782598|Negative
43754|NCT02782598|Atrioventricular
43755|NCT02782598|Hysteresis
43756|NCT02782598|Cardiac Resynchronization
43757|NCT02782598|MultiPoint
43758|NCT02782585|neck pain
43759|NCT02782585|Manual therapy
43760|NCT02782585|psychological interaction
43761|NCT02782572|Exercise
43762|NCT02782572|Cardiac Rehabilitation
43763|NCT02782572|Non-invasive ventilation
43764|NCT02782520|Cardiopulmonary bypass
43765|NCT02782520|Swan Ganz
43766|NCT02782520|Fluid expansion
43767|NCT02782520|hypertonic saline solution
43768|NCT02782507|pilot study
43769|NCT02782507|CBT trial
43770|NCT02782494|Latent tuberculosis infection, dialysis
43771|NCT02782468|Drug Therapy
43772|NCT02782429|ketamine
43773|NCT02782429|Cardiac Surgery
43774|NCT02782429|Neurocognitive Disorders
43775|NCT02782416|Renal
43776|NCT02782416|Latent
43777|NCT02782416|Tuberculosis
43778|NCT02782403|Leukemia
43779|NCT02782403|Chronic Myeloid Leukemia
43780|NCT02782403|CML
43781|NCT02782403|Chronic Myeloid Leukemia, Chronic Phase
43782|NCT02782403|CML-CP
43783|NCT02782403|Chronic Myeloid Leukemia in Accelerated Phase
43784|NCT02782403|CML-AP
43785|NCT02782403|Chronic Myeloid Leukemia in Blast Phase
43786|NCT02782403|CML-BP
43787|NCT02782403|Axitinib
43788|NCT02782403|AG-013736
43789|NCT02782403|Inlyta
43790|NCT02782403|Bosutinib
43791|NCT02782403|SKI-606
43792|NCT02782390|Stainless dental crown
43793|NCT02782390|Composite Resin
43794|NCT02782390|Primary teeth
43795|NCT02782377|Faecal Incontinence
43796|NCT02782377|Obstructive Defaecation
43797|NCT02782377|Rectal Prolapse
43798|NCT02782364|Faecal Incontinence
43799|NCT02782338|warfarin
43800|NCT02782338|Voltaren eye drops
43801|NCT02782338|INR
43802|NCT02782312|Bronchiectasis
43803|NCT02782312|ICS+LABA
43804|NCT02782299|Decision aid
43805|NCT02782299|Shared decision making
43806|NCT02782299|Older adult patients
43807|NCT02782299|Distal radius fracture
43808|NCT02782286|ketorolac
43809|NCT02782286|pain relieve
43810|NCT02782286|morphine
43811|NCT02782273|ketorolac
43812|NCT02782273|pain relieve
43813|NCT02782273|morphine
43814|NCT02782221|lipolysis
43815|NCT02782221|ATGL
43816|NCT02782182|Pancreatic ductal adenocarcinoma
43817|NCT02782182|FOLFIRINOX
43818|NCT02782182|resectable pancreatic cancer
43819|NCT02782156|Process Evaluation
43820|NCT02782156|alcohol withdrawal syndrome
43821|NCT02782143|delirium detection
43822|NCT02782130|HIV
43823|NCT02782130|YMSM
43824|NCT02782130|Trans women
43825|NCT02782130|ART Adherence
43826|NCT02782130|Intervention
43827|NCT02782104|Depressive Disorder, Treatment-Resistant
43828|NCT02782104|Esketamine
43829|NCT02782104|JNJ-54135419
43830|NCT02782091|MET
43831|NCT02782091|Prognosis
43832|NCT02782091|Cognition
43833|NCT02782091|Ecological
43834|NCT02782091|Executive function
43835|NCT02782078|osteoarticular infection
43836|NCT02782078|rifampicin
43837|NCT02782078|clindamycin
43838|NCT02782078|enzymatic induction
43839|NCT02782078|antibiotherapy resistance
43840|NCT02782065|validation
43841|NCT02782065|pediatrics
43842|NCT02782065|asthma severity
43843|NCT02782052|pulmonary arterial hypertension
43844|NCT02782052|spirometry
43845|NCT02782052|dynamic lung hyperinflation
43846|NCT02782052|bronchodilator
43847|NCT02782052|dyspnoea
43848|NCT02782052|Idiopathic
43849|NCT02782052|heritable
43850|NCT02782052|PAH
43851|NCT02782026|pulmonary hypertension
43852|NCT02782026|early detection
43853|NCT02782013|community acquired pneumonia
43854|NCT02782013|CAP
43855|NCT02782013|disease progression
43856|NCT02782000|dementia,early recognition
43857|NCT02782000|early recognition
43858|NCT02782000|general practitioner
43859|NCT02782000|training
43860|NCT02781935|unresectable colorectal liver metastasis
43861|NCT02781935|diffusion weighted MRI
43862|NCT02781935|disappearing liver metastasis
43863|NCT02781922|cardiac stem/progenitor cells
43864|NCT02781922|autologous cell therapy
43865|NCT02781922|functional single ventricle
43866|NCT02781922|congenital heart disease
43867|NCT02781909|NSAIDS
43868|NCT02781909|tuberculosis treatment
43869|NCT02781909|anti-inflammatories
43870|NCT02781909|Host-directed therapies
43871|NCT02781909|TB
43872|NCT02781896|TAVI
43873|NCT02781896|aortic valve bioprothesis
43874|NCT02781896|TAVI simplification
43875|NCT02781896|aortic stenosis
43876|NCT02781896|rapid left ventricular pacing
43877|NCT02781896|TAVR
43878|NCT02781883|Liposomal Grb-2 treatment of AML
43879|NCT02781883|Liposomal Grb-2 with LDAC for AML
43880|NCT02781766|Haemophilia A
43881|NCT02781766|prophylaxis
43882|NCT02781766|thrombin generation assay
43883|NCT02781766|factor VIII
43884|NCT02781766|prophylactic therapy
43885|NCT02781740|Continous Positive Airway Pressure
43886|NCT02781740|CPAP
43887|NCT02781740|Sham CPAP
43888|NCT02781740|CPAP withdrawal
43889|NCT02781740|suboptimal CPAP
43890|NCT02781727|Human Growth Hormone
43891|NCT02781727|hGH
43892|NCT02781727|GHD
43893|NCT02781727|rHGH
43894|NCT02781727|Pediatric Growth Hormone Deficiency
43895|NCT02781727|Long Acting Growth Hormone
43896|NCT02781727|Somatropin
43897|NCT02781727|Prodrug
43898|NCT02781727|Growth Failure
43899|NCT02781727|Growth Hormone Replacement Therapy
43900|NCT02781727|Sustained Release
43901|NCT02781727|Sustained Release Growth Hormone
43902|NCT02781727|Growth Hormone Deficiency
43903|NCT02781714|contraception
43904|NCT02781714|postpartum period
43905|NCT02781714|mobile health
43906|NCT02781714|mHealth
43907|NCT02781714|Kenya
43908|NCT02781714|couples
43909|NCT02781675|Diet
43910|NCT02781675|Mediterranean
43911|NCT02781675|Cholesterol
43912|NCT02781675|Inflammation
43913|NCT02781662|Safety
43914|NCT02781662|Hospitalization
43915|NCT02781662|Older Persons
43916|NCT02781662|High-Risk
43917|NCT02781649|Renal
43918|NCT02781649|Transplants
43919|NCT02781649|Hepatitis C
43920|NCT02781649|HCV-negative
43921|NCT02781649|Infected
43922|NCT02781649|Donors
43923|NCT02781636|Efficacy
43924|NCT02781636|Implantable
43925|NCT02781636|Wireless
43926|NCT02781636|Neuromodulation
43927|NCT02781636|Device
43928|NCT02781636|Tibial
43929|NCT02781623|Quadriceps
43930|NCT02781623|Tibial Plateau
43931|NCT02781623|Fracture
43932|NCT02781610|Cystic fibrosis
43933|NCT02781610|Pulmonary exacerbation
43934|NCT02781610|Antibiotic
43935|NCT02781610|Treatment duration
43936|NCT02781610|Lung infection
43937|NCT02781610|Cystic Fibrosis Foundation
43938|NCT02781610|Cystic Fibrosis Foundation National Patient Registry
43939|NCT02781597|Hemoptysis
43940|NCT02781597|Tranexamic acid
43941|NCT02781597|VAS score
43942|NCT02781545|Child Development
43943|NCT02781545|Psychomotor Performance
43944|NCT02781545|Newborns
43945|NCT02781545|Surgery
43946|NCT02781493|Prucalopride
43947|NCT02781493|Polyethylene Glycol
43948|NCT02781493|bowel preparation
43949|NCT02781467|Acute Myeloid
43950|NCT02781467|Leukemia
43951|NCT02781467|PNK-007
43952|NCT02781467|Human IL-2
43953|NCT02781467|RHIL-2
43954|NCT02781467|Fludarabine
43955|NCT02781467|Cyclophosphamide
43956|NCT02781454|SALS
43957|NCT02781454|Mexiletine
43958|NCT02781454|TMS
43959|NCT02781454|NCS
43960|NCT02781402|Overweight BMI Individuals
43961|NCT02781402|Normal BMI Individuals
43962|NCT02781389|Basal cell carcinoma (BCC)
43963|NCT02781389|advanced BCC (aBCC)
43964|NCT02781389|metastatic BCC (mBCC)
43965|NCT02781376|Primary Care
43966|NCT02781376|Computer Decision Support System
43967|NCT02781376|Guidelines
43968|NCT02781376|Snoring
43969|NCT02781363|thoracic ultrasound
43970|NCT02781363|children
43971|NCT02781363|efficacy
43972|NCT02781363|emergency service
43973|NCT02781350|high fat diet
43974|NCT02781350|insulinogenesis
43975|NCT02781350|Fiber
43976|NCT02781350|inflammation
43977|NCT02781324|Ultrasonic Bone Scalpel
43978|NCT02781324|Adolescent Idiopathic Scoliosis
43979|NCT02781324|Posterior Spinal Fusion
43980|NCT02781324|Estimated Blood Loss
43981|NCT02781272|pelvic mass
43982|NCT02781272|ovarian cancer
43983|NCT02781272|gynecological cancer
43984|NCT02781272|risk prediction
43985|NCT02781259|Sentinel Lymph Node Biopsy
43986|NCT02781259|Fluorescence
43987|NCT02781259|Breast Neoplasms
43988|NCT02781259|Indocyanine Green
43989|NCT02781220|MCI
43990|NCT02781220|Dementia
43991|NCT02781220|amyloid PET
43992|NCT02781220|physician diagnosis
43993|NCT02781220|Alzheimer's disease
43994|NCT02781220|AD
43995|NCT02781220|PET imaging
43996|NCT02781220|Appropriate Use Criteria
43997|NCT02781220|patient-reported outcomes
43998|NCT02781220|patient adherence
43999|NCT02781207|syncope
44000|NCT02781207|point-of-care ultrasound
44001|NCT02781181|Stenting
44002|NCT02781181|Protection device
44003|NCT02781181|EPD usage
44004|NCT02781168|Premature newborn
44005|NCT02781168|Cortisol
44006|NCT02781168|Stress
44007|NCT02781155|Health related quality of life
44008|NCT02781155|Moxibustion
44009|NCT02781155|Cancer
44010|NCT02781155|Chemotherapy
44011|NCT02781155|Neutropenia
44012|NCT02781155|Anaemia
44013|NCT02781155|Thrombocytopenia
44014|NCT02781155|Self management
44015|NCT02781155|Wellbeing
44016|NCT02781129|Memory
44017|NCT02781129|Responsive Neurostimulator System
44018|NCT02781090|HIV
44019|NCT02781090|Tobacco
44020|NCT02781090|Cigarette
44021|NCT02781090|Smoking
44022|NCT02781090|Social Network
44023|NCT02781090|Internet
44024|NCT02781090|Cessation
44025|NCT02781077|Stroke
44026|NCT02781077|walking competency
44027|NCT02781077|Task-oriented exercise program
44028|NCT02781077|Exercise intensity
44029|NCT02781012|Pancreatic Disease
44030|NCT02781012|Pancreas
44031|NCT02781012|Borderline Resectable
44032|NCT02781012|Pancreatic Cancer
44033|NCT02781012|Pancreatitis
44034|NCT02781012|Family history of pancreatic cancer
44035|NCT02781012|Healthy
44036|NCT02781012|Healthy at risk
44037|NCT02780999|Osteoarthritis
44038|NCT02780999|hand
44039|NCT02780999|orthotic
44040|NCT02780999|rehabilitation
44041|NCT02780986|female entertainment worker
44042|NCT02780986|heterosexual men
44043|NCT02780986|entertainment establishment
44044|NCT02780986|condom use
44045|NCT02780986|sexually transmitted infection
44046|NCT02780986|Singapore
44047|NCT02780947|Ventricular tachycardia
44048|NCT02780947|Ablation
44049|NCT02780947|Myocardial Infarction
44050|NCT02780947|Heart Failure
44051|NCT02780934|Pressure Dressing
44052|NCT02780934|Post-operative Care
44053|NCT02780934|Simple Adhesive Dressing
44054|NCT02780934|Mohs
44055|NCT02780921|Prehabilitation
44056|NCT02780921|Oesophageal cancer
44057|NCT02780921|Gastric cancer
44058|NCT02780921|Fitness
44059|NCT02780921|Preconditionning
44060|NCT02780921|two parallel arms
44061|NCT02780895|Parkinson Disease
44062|NCT02780895|stereotactic surgery
44063|NCT02780895|human allogeneic fetal derived stem cells
44064|NCT02780882|Pasireotide
44065|NCT02780882|Ectopic ACTH
44066|NCT02780882|SOM230
44067|NCT02780882|ectopic ACTH-dependent Cushing's syndrome
44068|NCT02780856|Caries Activity Demineralisation
44069|NCT02780856|Demineralisation
44070|NCT02780843|Stroke
44071|NCT02780843|Tomography, X-Ray Computed
44072|NCT02780843|Magnetic Resonance Imaging
44073|NCT02780843|Thrombolytic Therapy
44074|NCT02780830|Lymphoma
44075|NCT02780830|Diffuse Large B-Cell Lymphoma
44076|NCT02780830|non-GCB Diffuse Large B-Cell Lymphoma
44077|NCT02780830|Relapsed or Refractory non-GCB Diffuse Large B-Cell Lymphoma
44078|NCT02780830|Vistusertib
44079|NCT02780830|AZD2014
44080|NCT02780830|Ibrutinib
44081|NCT02780830|Imbruvica
44082|NCT02780791|Infertility
44083|NCT02780791|Ovarian Failure, Premature
44084|NCT02780791|Ovarian Follicle
44085|NCT02780791|Ovary
44086|NCT02780791|Tissue Transplantation
44087|NCT02780791|Cryopreservation
44088|NCT02780791|Pelvis
44089|NCT02780791|Chemotherapy
44090|NCT02780791|Pregnancy Rate
44091|NCT02780791|Folliculogenesis
44092|NCT02780791|Endometrium
44093|NCT02780791|Estrogens
44094|NCT02780791|Progestins
44095|NCT02780791|Follicle Stimulating Hormone
44096|NCT02780791|Estradiol
44097|NCT02780791|Progesterone
44098|NCT02780791|Hormones
44099|NCT02780791|Maturation of Follicles
44100|NCT02780791|Pregnant Women
44101|NCT02780791|Premature Menopause
44102|NCT02780791|Ovarian Insufficiency
44103|NCT02780791|Ovarian Insufficiency, Premature
44104|NCT02780791|Cytotoxic therapy
44105|NCT02780791|Fertility Protection
44106|NCT02780791|Reproductive Medicine
44107|NCT02780791|Reproductive Techniques
44108|NCT02780791|Reproductive Technology
44109|NCT02780791|Cryotherapy
44110|NCT02780791|Pregnancy
44111|NCT02780739|Psychological Tests
44112|NCT02780739|Neuropsychological Tests
44113|NCT02780739|Transcranial Direct Current Stimulation
44114|NCT02780739|Exercise
44115|NCT02780739|Circuit-Based Exercise
44116|NCT02780739|Video Games
44117|NCT02780739|Magnetic Resonance Imaging
44118|NCT02780739|Magnetic Resonance Spectroscopy
44119|NCT02780739|Cognition
44120|NCT02780739|Executive Function
44121|NCT02780739|Learning
44122|NCT02780739|Problem Solving
44123|NCT02780739|Transfer (Psychology)
44124|NCT02780739|Decision Making
44125|NCT02780739|Brain
44126|NCT02780739|Gray Matter
44127|NCT02780739|White Matter
44128|NCT02780726|Peritoneal dialysis
44129|NCT02780726|Renal anemia
44130|NCT02780726|ASP1517
44131|NCT02780713|Breast cancer
44132|NCT02780713|Healthy volunteers
44133|NCT02780713|Pharmacokinetics
44134|NCT02780713|AZD9496
44135|NCT02780713|Safety
44136|NCT02780713|Tolerability
44137|NCT02780674|Polymyositis, dermatomyositis, Sjogren's syndrome, SLE, SSc
44138|NCT02780648|stereotactic radiotherapy
44139|NCT02780648|pancreatic adenocarcinoma
44140|NCT02780635|family, caregiving, ptsd, couples
44141|NCT02780609|autologous hematopoietic cell transplantation (HCT)
44142|NCT02780609|high-dose melphalan
44143|NCT02780609|selinexor
44144|NCT02780596|Infant
44145|NCT02780596|Toddler
44146|NCT02780596|Primary Care
44147|NCT02780570|SVPE
44148|NCT02780570|intravenous immunoglobulin
44149|NCT02780570|plasmapheresis
44150|NCT02780557|Vocabulary
44151|NCT02780557|Book reading
44152|NCT02780557|Infancy
44153|NCT02780557|Parenting
44154|NCT02780544|Infant, premature
44155|NCT02780544|Pain
44156|NCT02780544|Stress, physiological
44157|NCT02780544|Stress, psychological
44158|NCT02780544|skin-to-skin contact
44159|NCT02780518|oxygen
44160|NCT02780518|carbon dioxide
44161|NCT02780492|Duchenne muscular dystrophy
44162|NCT02780492|Natural history
44163|NCT02780492|Outcome measures
44164|NCT02780492|North Star Ambulatory Assessment (NSAA)
44165|NCT02780492|6 minute walk distance (6MWD)
44166|NCT02780492|Myoset
44167|NCT02780492|Exon skipping
44168|NCT02780479|Prednisone
44169|NCT02780479|Dexamethasone
44170|NCT02780479|Asthma exacerbation
44171|NCT02780479|Hospitalized
44172|NCT02780466|Septic shock
44173|NCT02780466|Endotracheal intubation
44174|NCT02780466|Outcome
44175|NCT02780440|Post Stroke Recovery
44176|NCT02780440|Mirror Therapy
44177|NCT02780440|Unimanual mirror therapy
44178|NCT02780440|Bimanual mirror therapy
44179|NCT02780440|Stroke
44180|NCT02780427|Dose-Response Relationship, Drug
44181|NCT02780414|Hypertension
44182|NCT02780414|Proteinuria
44183|NCT02780414|Thrombocytopenia
44184|NCT02780414|Renal Insufficiency
44185|NCT02780414|Impaired Liver Function
44186|NCT02780414|Pulmonary Edema
44187|NCT02780401|Stage I
44188|NCT02780401|Stage II
44189|NCT02780401|Stage III
44190|NCT02780388|MEDI4920, CD40L, RA, rheumatoid arthritis
44191|NCT02780375|Transcriptional Responses
44192|NCT02780375|Radiation
44193|NCT02780323|Celecoxib
44194|NCT02780323|CELBESTA
44195|NCT02780310|Lenvatinib
44196|NCT02780310|15-327
44197|NCT02780297|primary hyperoxaluria
44198|NCT02780297|Dent Disease
44199|NCT02780297|enteric hyperoxaluria
44200|NCT02780297|cystinuria
44201|NCT02780297|Lowe Syndrome
44202|NCT02780297|Adenine phosphoribosyltransferase deficiency
44203|NCT02780297|PH
44204|NCT02780297|APRTd
44205|NCT02780297|APRT
44206|NCT02780297|hyperoxaluria
44207|NCT02780297|oxalate
44208|NCT02780297|oxalosis
44209|NCT02780297|PH type 1
44210|NCT02780297|PH type 2
44211|NCT02780297|PH type 3
44212|NCT02780297|Dents
44213|NCT02780297|Dent
44214|NCT02780297|Dent 1
44215|NCT02780297|Dent 2
44216|NCT02780297|APRT deficiency
44217|NCT02780284|Gut Microbiota
44218|NCT02780284|Butyrate
44219|NCT02780284|Physical activity
44220|NCT02780271|Breast Cancer
44221|NCT02780271|Cancer survivor
44222|NCT02780271|e-communication
44223|NCT02780271|diet and physical activity
44224|NCT02780271|fruits/vegetables daily servings
44225|NCT02780271|energy density
44226|NCT02780245|Caesarean Section
44227|NCT02780245|Tranexamic Acid
44228|NCT02780245|Postpartum Hemorrhage
44229|NCT02780245|Ecbolics
44230|NCT02780232|Depression
44231|NCT02780232|Adolescence
44232|NCT02780232|Prevention
44233|NCT02780232|Early intervention
44234|NCT02780232|E-Mental Health
44235|NCT02780180|Aminopeptidase A inhibitor
44236|NCT02780180|Heart Failure
44237|NCT02780180|Up-titration
44238|NCT02780180|Dose-Response Relationship, Drug
44239|NCT02780180|Pharmacokinetics
44240|NCT02780180|Patient Safety
44241|NCT02780180|Treatment Efficacy
44242|NCT02780167|Phase 2
44243|NCT02780167|randomized
44244|NCT02780167|double-blind
44245|NCT02780167|placebo
44246|NCT02780167|atopic dermatitis
44247|NCT02780167|safety
44248|NCT02780167|efficacy
44249|NCT02780167|JAK
44250|NCT02780167|janus kinase
44251|NCT02780167|moderate
44252|NCT02780167|severe
44253|NCT02780154|7G8 clone
44254|NCT02780154|NF54 strain
44255|NCT02780154|Non-immune
44256|NCT02780154|PCR
44257|NCT02780154|PfSPZ Challenge
44258|NCT02780154|Plasmodium falciparum
44259|NCT02780154|qPCR
44260|NCT02780154|Sporozoites
44261|NCT02780141|Renal anemia
44262|NCT02780141|ASP1517
44263|NCT02780141|Hemodialysis
44264|NCT02780128|neuroblastoma
44265|NCT02780128|cancer
44266|NCT02780128|genetic profiling
44267|NCT02780128|ceritinib
44268|NCT02780128|ribociclib
44269|NCT02780128|trametinib
44270|NCT02780128|HDM201
44271|NCT02780102|ADHD
44272|NCT02780102|Cognitive-motor rehabilitation
44273|NCT02780102|Active Control Group
44274|NCT02780102|Stimulant Medication
44275|NCT02780089|Metastatic
44276|NCT02780089|Unresectable
44277|NCT02780063|Dilation
44278|NCT02780063|Intraocular
44279|NCT02780063|Ophthalmology
44280|NCT02780050|cardiopulmonary resuscitation
44281|NCT02780050|manikins
44282|NCT02780050|physical fitness
44283|NCT02780024|Neo-Adjuvant Metformin
44284|NCT02780024|Neo-Adjuvant Temozolomide
44285|NCT02780024|Temozolomide and accelerated hypofractionation
44286|NCT02780024|Metformin and accelerated hypofractionation
44287|NCT02780024|Adjuvant Temozolomide
44288|NCT02780024|Adjuvant Metformin
44289|NCT02780011|CD30+
44290|NCT02780011|Relapsed
44291|NCT02780011|Refractory
44292|NCT02780011|ALCL
44293|NCT02779985|Lycium Barbarum
44294|NCT02779985|Energy expenditure
44295|NCT02779985|Postprandial metabolism
44296|NCT02779972|Cardiac Physiology
44297|NCT02779972|Physiology
44298|NCT02779933|Hospital-acquired Pneumonia
44299|NCT02779933|Epidemiology
44300|NCT02779933|Risk Factors
44301|NCT02779920|refractory gastroparesis
44302|NCT02779920|per oral pyloromyotomy
44303|NCT02779907|Paediatric
44304|NCT02779907|Malawi
44305|NCT02779894|Sleep Apnea
44306|NCT02779894|Communication Based Technology
44307|NCT02779894|ICT
44308|NCT02779868|body composition
44309|NCT02779868|functional capacity
44310|NCT02779868|quality of life
44311|NCT02779855|triple negative breast cancer (TNBC)
44312|NCT02779855|estrogen receptor
44313|NCT02779855|progesterone receptor
44314|NCT02779855|invasive ductal carcinoma
44315|NCT02779855|breast cancer tumors
44316|NCT02779790|Systematic Review and Meta-Analysis
44317|NCT02779790|Evidence-Based Medicine
44318|NCT02779790|Evidence-Based Nutrition
44319|NCT02779790|Clinical Practice Guidelines
44320|NCT02779790|Liquid Meal Replacements
44321|NCT02779790|Body Weight
44322|NCT02779790|Systolic Blood Pressure
44323|NCT02779790|Diastolic Blood Pressure
44324|NCT02779790|Fasting Blood Glucose
44325|NCT02779790|Fasting Blood Insulin
44326|NCT02779790|HbA1c
44327|NCT02779790|Total Cholesterol
44328|NCT02779790|Triglycerides
44329|NCT02779790|LDL-C
44330|NCT02779790|HDL-C
44331|NCT02779790|Controlled Feeding Trials
44332|NCT02779764|Hemodialysis
44333|NCT02779764|ASP1517
44334|NCT02779764|Renal anemia
44335|NCT02779725|Symptom Management
44336|NCT02779712|Remote ischaemic conditioning
44337|NCT02779686|Macular Degeneration
44338|NCT02779686|Genetic testing
44339|NCT02779686|Age-Related Macular degeneration
44340|NCT02779686|Age-Related Maculopathies
44341|NCT02779660|Atrial Fibrillation
44342|NCT02779647|Overweight, obesity, play, physical activity, accelerometry.
44343|NCT02779608|malignant ascites
44344|NCT02779582|Progesterone
44345|NCT02779582|Menstrual Flow
44346|NCT02779556|Health Literacy
44347|NCT02779556|Diabetes
44348|NCT02779543|In lab sleep studies
44349|NCT02779517|upper extremity
44350|NCT02779517|stroke
44351|NCT02779517|rehabilitation
44352|NCT02779517|robotics
44353|NCT02779517|telepresence
44354|NCT02779517|elderly
44355|NCT02779517|aged
44356|NCT02779517|Housing for the elderly
44357|NCT02779517|retirement
44358|NCT02779517|homes for the aged
44359|NCT02779491|fruit and vegetables
44360|NCT02779491|food intake
44361|NCT02779491|knowledge
44362|NCT02779478|chronic obstructive pulmonary disease (COPD)
44363|NCT02779478|cavitary
44364|NCT02779478|nodular bronchiectatic disease
44365|NCT02779478|NTM
44366|NCT02779465|vitamin D treatment
44367|NCT02779465|chronic hepatitis B
44368|NCT02779452|neurodevelopment
44369|NCT02779452|electroencephalography
44370|NCT02779452|gestational diabetes mellitus
44371|NCT02779452|omega 3 polyunsaturated fatty acids
44372|NCT02779426|Atopic dermatitis
44373|NCT02779426|Text Messages
44374|NCT02779426|Health literacy
44375|NCT02779400|INR
44376|NCT02779400|coagulation
44377|NCT02779400|vitamin K antagonist
44378|NCT02779387|GnRH-a
44379|NCT02779387|endometriosis
44380|NCT02779387|efficiency
44381|NCT02779374|ovarian insufficiency Bone Marrow
44382|NCT02779361|green tea
44383|NCT02779361|steroid profile
44384|NCT02779348|Nebicapone
44385|NCT02779348|Warfarin
44386|NCT02779335|tube-fed
44387|NCT02779335|Formula Tolerance
44388|NCT02779335|Pediatric Patients
44389|NCT02779322|gastric bypass
44390|NCT02779322|hospital charges
44391|NCT02779322|mini gastric bypass
44392|NCT02779309|Frail Older Adults
44393|NCT02779309|Mortality
44394|NCT02779309|Home Care
44395|NCT02779309|Survival Analysis
44396|NCT02779309|Clinical Prediction Rule
44397|NCT02779296|Cyanoacrylates
44398|NCT02779296|Mammaplasty
44399|NCT02779296|Mastectomy
44400|NCT02779257|hypoglycemia
44401|NCT02779244|Orthopedic
44402|NCT02779244|Post-operative
44403|NCT02779244|Weight bearing
44404|NCT02779244|Range of motion
44405|NCT02779218|Hemiplegia
44406|NCT02779205|Cell therapy
44407|NCT02779205|Stromal Cells
44408|NCT02779205|Stem cells
44409|NCT02779205|Adipose tissue
44410|NCT02779205|Children
44411|NCT02779166|hip arthroscopy
44412|NCT02779153|SLE
44413|NCT02779153|H.P. Acthar Gel
44414|NCT02779140|BoNT
44415|NCT02779140|botulinum
44416|NCT02779140|Botulism
44417|NCT02779140|Clostridium
44418|NCT02779140|Neurotoxin
44419|NCT02779140|NTM-1632
44420|NCT02779127|Smoking
44421|NCT02779127|Endothelium
44422|NCT02779127|Passive smoking
44423|NCT02779114|Rheumatoid Arthritis
44424|NCT02779114|Remission
44425|NCT02779114|Dose reduction
44426|NCT02779101|Central nervous system lymphoma
44427|NCT02779101|Pembrolizumab
44428|NCT02779075|Sleeve Gastrectomy
44429|NCT02779075|Roux-en-Y Gastric Bypass
44430|NCT02779036|Stroke
44431|NCT02779036|task-oriented home exercise
44432|NCT02779036|walking competency
44433|NCT02779036|Usual Physiotherapy care
44434|NCT02778997|Shunt
44435|NCT02778997|CSF
44436|NCT02778997|Dysfunction
44437|NCT02778997|Complication
44438|NCT02778984|Anesthesia
44439|NCT02778984|facial mask
44440|NCT02778971|MCI
44441|NCT02778971|Dementia
44442|NCT02778971|amyloid PET
44443|NCT02778971|physician diagnosis
44444|NCT02778971|Alzheimer's disease
44445|NCT02778971|AD
44446|NCT02778971|PET imaging
44447|NCT02778971|Appropriate Use Criteria
44448|NCT02778971|patient-reported outcomes
44449|NCT02778958|bariatric surgery
44450|NCT02778958|morbid obesity
44451|NCT02778958|nonopioid analgesics
44452|NCT02778945|spinal surgery
44453|NCT02778945|sugammadex
44454|NCT02778945|deep neuromuscular block
44455|NCT02778945|shear wave elastography
44456|NCT02778945|neuromuscular monitoring
44457|NCT02778919|Endometriosis
44458|NCT02778906|Abatacept
44459|NCT02778893|Conmana
44460|NCT02778893|Thalidomide
44461|NCT02778893|NSCLC
44462|NCT02778893|EGFR mutation
44463|NCT02778854|NSCLC
44464|NCT02778854|liquid biopsy
44465|NCT02778854|driver mutation
44466|NCT02778828|linezolide
44467|NCT02778828|tuberculosis
44468|NCT02778828|MDR-TB
44469|NCT02778802|Pulmonary Hypertension
44470|NCT02778802|Emphysema
44471|NCT02778802|COPD
44472|NCT02778776|Metformin
44473|NCT02778776|Agave Inulin
44474|NCT02778776|METS
44475|NCT02778776|Inflammation parameters
44476|NCT02778776|Urodynamic parameters
44477|NCT02778776|Prostate hyperplasia
44478|NCT02778763|Breast cancer
44479|NCT02778763|TLR2
44480|NCT02778763|Neutropenia
44481|NCT02778750|Cystic Fibrosis (CF)
44482|NCT02778737|ACT, CBT, Randomized controlled trial, Chronic Pain
44483|NCT02778711|anti-IL-17
44484|NCT02778711|secukinumab
44485|NCT02778672|bacterial pneumonia
44486|NCT02778672|children
44487|NCT02778672|diagnosing pneumonia
44488|NCT02778672|thermal imaging
44489|NCT02778633|Volume responsiveness mean systemic filling pressure
44490|NCT02778620|Volume responsiveness mean systemic filling pressure
44491|NCT02778607|Atypical Parkinsonism Syndrome (APS)
44492|NCT02778581|Cognitive Impairment, Alzheimer's Disease, Vegetal Oil
44493|NCT02778542|Automated Hovering
44494|NCT02778542|Remote Monitoring
44495|NCT02778542|Bidirectional Text Messaging
44496|NCT02778529|stroke
44497|NCT02778529|amputees
44498|NCT02778529|spinal cord injuries
44499|NCT02778529|cerebral palsy
44500|NCT02778529|robotics
44501|NCT02778529|rehabilitation
44502|NCT02778503|Tooth, Deciduous
44503|NCT02778503|Dentition, Permanent
44504|NCT02778503|Dental Atraumatic Restorative Treatment
44505|NCT02778503|Glass Ionomer Cements
44506|NCT02778503|Dental Caries
44507|NCT02778490|sleeve gastrectomy, bariatric surgery
44508|NCT02778464|Inflammatory Bowel Disease
44509|NCT02778464|Pregnancy
44510|NCT02778464|Stool markers
44511|NCT02778464|Calprotectin
44512|NCT02778464|Faecal S100A12 (f-SA12)
44513|NCT02778464|Faecal calprotectin (f-Cp)
44514|NCT02778425|partial splenic embolization
44515|NCT02778412|Thyroid cancer
44516|NCT02778412|Thyroid nodules
44517|NCT02778412|Thyroid neoplasia
44518|NCT02778412|Thyroiditis
44519|NCT02778399|Pelvic Pain
44520|NCT02778399|Endometriosis
44521|NCT02778399|Dysmenorrhea
44522|NCT02778399|Dyspareunia
44523|NCT02778360|Attention deficit
44524|NCT02778360|Neurofeedback
44525|NCT02778360|ADHD
44526|NCT02778360|Methylphenidate
44527|NCT02778347|Palliative care
44528|NCT02778347|Need assessment
44529|NCT02778347|Tools
44530|NCT02778347|Validity
44531|NCT02778347|Quality of care
44532|NCT02778308|Gallbladder cancer, adjuvant chemotherapy, gemcitabine
44533|NCT02778269|ECG
44534|NCT02778269|CGM
44535|NCT02778269|Hypoglycaemia
44536|NCT02778269|Sudden Cardiac Death
44537|NCT02778256|depression, bipolar disorder
44538|NCT02778230|fiber
44539|NCT02778230|gastrointestinal
44540|NCT02778230|microbiota
44665|NCT02777398|Quadrant Channel
44541|NCT02778191|Head and neck squamous cell carcinoma
44542|NCT02778191|cisplatin
44543|NCT02778191|carboplatin
44544|NCT02778191|5-fluorouracil
44545|NCT02778087|motor recovery
44546|NCT02778087|mirror therapy
44547|NCT02778087|upper extremity
44548|NCT02778074|Internet Cognitive Behavioural Therapy
44549|NCT02778061|Intra Uterine Ball
44550|NCT02778061|IUD
44551|NCT02778061|copper
44552|NCT02778061|contraception
44553|NCT02778022|Child behavior disorders
44554|NCT02778022|Parent child relationship
44555|NCT02778022|Primary care
44556|NCT02778009|Medical student
44557|NCT02778009|Activity Monitor
44558|NCT02778009|Medical school
44559|NCT02778009|Fitness
44560|NCT02777996|screening
44561|NCT02777983|patient education
44562|NCT02777983|low back pain
44563|NCT02777983|technology
44564|NCT02777970|Acute pain
44565|NCT02777970|Acute moderate to severe pain
44566|NCT02777970|Postoperative pain
44567|NCT02777970|Dexketoprofen Tramadol
44568|NCT02777970|Dexketoprofen trometamol
44569|NCT02777970|Tramadol hydrochloride
44570|NCT02777970|Multimodal analgesia
44571|NCT02777970|Third molar extraction
44572|NCT02777970|Fixed drug combination
44573|NCT02777970|Paracetamol
44574|NCT02777970|Analgesics
44575|NCT02777957|Echocardiography
44576|NCT02777957|Lung Transplantation
44577|NCT02777944|motivation
44578|NCT02777944|attendance
44579|NCT02777918|food intake
44580|NCT02777905|late life
44581|NCT02777905|mindfulness meditation
44582|NCT02777879|Chronic Obstructive Pulmonary Disease (COPD)
44583|NCT02777853|tea
44584|NCT02777853|cardiovascular
44585|NCT02777853|vascular
44586|NCT02777853|metabolism
44587|NCT02777853|microcirculation
44588|NCT02777853|physical inactivity
44589|NCT02777853|polyphenols
44590|NCT02777853|conduit artery
44591|NCT02777853|endothelial function
44592|NCT02777853|cerebrovascular
44593|NCT02777853|insulin sensitivity
44594|NCT02777827|Abediterol
44595|NCT02777827|Dry powder inhaler
44596|NCT02777827|Pressured metered-dose inhaler
44597|NCT02777827|Pharmacokinetic
44598|NCT02777827|Pharmacodynamic
44599|NCT02777827|Safety
44600|NCT02777814|colorectal cancer
44601|NCT02777814|Entecavir
44602|NCT02777814|Hepatitis B Carrier
44603|NCT02777801|gastric cancer
44604|NCT02777801|hepatitis B carrier
44605|NCT02777801|entecavir
44606|NCT02777788|Chinese Traditional Medicine
44607|NCT02777775|NF1
44608|NCT02777775|CNF
44609|NCT02777775|PNF
44610|NCT02777775|Skin Tumors
44611|NCT02777736|Lymphoma, B cell
44612|NCT02777736|Central nervous system relapse
44613|NCT02777736|Methotrexate
44614|NCT02777736|Intrathecal chemotherapy
44615|NCT02777723|Dry Eye Syndrome
44616|NCT02777723|Sodium Hyaluronate
44617|NCT02777723|CKD-350
44618|NCT02777697|cancer treatment protocols
44619|NCT02777697|chronic cancer pain
44620|NCT02777697|cognitive function
44621|NCT02777697|quality of life
44622|NCT02777697|anxiety
44623|NCT02777697|depression
44624|NCT02777684|Physical activity
44625|NCT02777684|Knee osteoarthritis
44626|NCT02777684|Non pharmacological treatment
44627|NCT02777684|Qualitative study
44628|NCT02777658|Epidermal Growth Factor Receptor (EGFR), non-small cell lung cancer (NSCLC), EGFR T790M, EGFR Mutation-Positive Locally Advanced or Advanced NSCLC
44629|NCT02777619|Pharmacodynamic
44630|NCT02777619|Dexmedetomidine
44631|NCT02777619|Propofol
44632|NCT02777619|Target-controlled Infusion Intravenous Anesthesia
44633|NCT02777606|Severe Sepsis
44634|NCT02777606|Sini Decoction
44635|NCT02777606|Immune Function
44636|NCT02777606|Mortality
44637|NCT02777580|Thrombolytic Therapy
44638|NCT02777580|Primary PCI
44639|NCT02777554|Healthy Subjects
44640|NCT02777554|Apremilast
44641|NCT02777554|Pharmacokinetic
44642|NCT02777541|early enteral nutrition
44643|NCT02777541|children
44644|NCT02777541|percutaneous endoscopic gastrostomy
44645|NCT02777515|electronic cigarette
44646|NCT02777489|obesity
44647|NCT02777489|perindopril
44648|NCT02777489|carboxypeptidase D
44649|NCT02777489|genotyping
44650|NCT02777489|theranostic
44651|NCT02777450|low back pain
44652|NCT02777450|physical examination
44653|NCT02777450|local anesthesia
44654|NCT02777437|Colonic Neoplasms
44655|NCT02777437|Laparoscopic Surgery
44656|NCT02777437|Neoadjuvant chemotherapy
44657|NCT02777437|T4
44658|NCT02777411|Vaccines
44659|NCT02777411|Hand, Foot and Mouth Disease
44660|NCT02777411|EV71 enteroviruses vaccine
44661|NCT02777398|Intra-spinal Canal
44662|NCT02777398|Tumor
44663|NCT02777398|Minimal Invasive Surgery
44664|NCT02777398|Clinical Trial
44666|NCT02777385|Head and Neck
44667|NCT02777385|Locally Advanced
44668|NCT02777385|Squamous Cell Carcinoma
44669|NCT02777385|SCCHN
44670|NCT02777385|Untreated
44671|NCT02777385|High Risk
44672|NCT02777385|Intermediate Risk
44673|NCT02777385|Radiation Therapy
44674|NCT02777385|Cisplatin
44675|NCT02777372|Zoloft
44676|NCT02777372|PMS
44677|NCT02777372|Menses
44678|NCT02777359|patent foramen ovale
44679|NCT02777359|migraine
44680|NCT02777359|treatment
44681|NCT02777346|WOUNDS, PENETRATING
44682|NCT02777346|CHILD, PRESCHOOL
44683|NCT02777346|CHILD
44684|NCT02777346|INFANT
44685|NCT02777346|ADOLESCENT
44686|NCT02777346|SUTURES
44687|NCT02777346|POLYGLACTIN 910
44688|NCT02777346|POLYPROPYLENES
44689|NCT02777333|Simulation
44690|NCT02777333|Arthroscopy
44691|NCT02777333|Motion analysis
44692|NCT02777320|Sciatica
44693|NCT02777320|Ibuprofen
44694|NCT02777320|Paracetamol
44695|NCT02777320|Emergency Medicine
44696|NCT02777307|Laparoscopic
44697|NCT02777307|Cholecistectomy
44698|NCT02777307|Collection
44699|NCT02777307|Bleeding
44700|NCT02777307|reoperation
44701|NCT02777281|Shoulder Pain
44702|NCT02777281|Wheelchair
44703|NCT02777281|Spinal Cord injury
44704|NCT02777242|Hypogonadism
44705|NCT02777242|Testosterone enanthate
44706|NCT02777216|RDN
44707|NCT02777203|morcellation
44708|NCT02777203|myomectomy
44709|NCT02777203|hysterectomy
44710|NCT02777190|misoprostol
44711|NCT02777190|cytotec
44712|NCT02777190|cervical ripening
44713|NCT02777190|labor, induced
44714|NCT02777190|active labor
44715|NCT02777138|Adipose tissue
44716|NCT02777138|Inflammation
44717|NCT02777138|Age Comparison
44718|NCT02777138|Macrophages
44719|NCT02777138|T-lymphocytes
44720|NCT02777138|Adipose Progenitors
44721|NCT02777125|pediatrics
44722|NCT02777125|metered dose inhalers
44723|NCT02777125|breath actuated nebulizers
44724|NCT02777112|high-risk
44725|NCT02777112|early prevention
44726|NCT02777112|productivity
44727|NCT02777112|return on investment
44728|NCT02777112|workplace
44729|NCT02777112|e-mental health program
44730|NCT02777112|job coach
44731|NCT02777099|remote ischemic postconditioning
44732|NCT02777099|autonomic function
44733|NCT02777099|heart rate variability
44734|NCT02777099|acute ischemic stroke
44735|NCT02777099|prognosis
44736|NCT02777086|HIV
44737|NCT02777086|Risk Behaviors
44738|NCT02777086|Decision-making
44739|NCT02777073|Diabetic ketoacidosis
44740|NCT02777073|Insulin
44741|NCT02777073|Type 1 Diabetes
44742|NCT02777073|glucose (sugar) control
44743|NCT02777073|SGLT-2 inhibitors
44744|NCT02777060|virtual reality
44745|NCT02777060|sensor-based balance training
44746|NCT02777060|gait
44747|NCT02777060|balance
44748|NCT02777047|Thromboembolism
44749|NCT02777047|Medication Safety
44750|NCT02777047|Hospital-community collaboration
44751|NCT02777047|Pilot RCT
44752|NCT02777047|Telehealth
44753|NCT02777034|Laparoscopy
44754|NCT02777034|Enhanced Recovery
44755|NCT02777034|Fast-track
44756|NCT02777021|Pediatric
44757|NCT02777021|Acute Myeloid Leukemia
44758|NCT02777021|Quality of Life
44759|NCT02777021|Neutropenia Management
44760|NCT02777021|Patient Centered Outcomes
44761|NCT02777021|Chemotherapy
44762|NCT02776982|Gastroesophageal reflux disease
44763|NCT02776982|GERD
44764|NCT02776982|Barrett's Esophagus
44765|NCT02776982|Esophageal adenocarcinoma
44766|NCT02776969|Papillary Carcinoma
44767|NCT02776969|Gene Hunting
44768|NCT02776969|Familial
44769|NCT02776956|atrial fibrillation;left atrial function
44770|NCT02776930|Injury Prediction
44771|NCT02776930|Return to Work
44772|NCT02776930|Injury Prevention
44773|NCT02776917|metastatic breast cancer
44774|NCT02776917|locally advanced, unresectable breast cancer
44775|NCT02776917|HER2/NEU negative
44776|NCT02776904|Concussion
44777|NCT02776904|Football player
44778|NCT02776904|Movement assessment
44779|NCT02776891|lymphoma
44780|NCT02776891|gallium citrate
44781|NCT02776891|PET
44782|NCT02776865|suprascapular nerve block
44783|NCT02776813|CD20+
44784|NCT02776813|B-cell
44785|NCT02776813|ACTR087
44786|NCT02776813|Relapsed
44787|NCT02776813|Refractory
44788|NCT02776800|Wound
44789|NCT02776800|Surgical Wound
44790|NCT02776800|Trauma Wound
44791|NCT02776800|Home Health Care
44792|NCT02776800|Home Health Nurse
44793|NCT02776800|Pressure Ulcer
44794|NCT02776800|Diabetic Foot Ulcer
44795|NCT02776800|Venous Leg Ulcer
44796|NCT02776800|Arterial Ulcer
44797|NCT02776800|Wound Dehiscence
44798|NCT02776800|Open Wound
44799|NCT02776774|spine
44800|NCT02776748|Tenofovir disoproxil
44801|NCT02776748|Pre-exposure prophylaxis
44802|NCT02776748|Breastfeeding
44803|NCT02776748|Emtricitabine
44804|NCT02776748|Tenofovir
44805|NCT02776748|Post-partum
44806|NCT02776748|HIV prevention
44807|NCT02776748|Women
44808|NCT02776748|Pharmacokinetics
44809|NCT02776722|Systematic Review and Meta-analysis
44810|NCT02776722|randomized controlled trial
44811|NCT02776722|Evidence-Based Medicine
44812|NCT02776722|carbohydrate metabolism
44813|NCT02776722|postprandial
44814|NCT02776722|glycemic response
44815|NCT02776722|glycemic control
44816|NCT02776722|insulin sensitivity
44817|NCT02776722|beta-cell function
44818|NCT02776722|sugars
44819|NCT02776722|fructose
44820|NCT02776722|allulose
44821|NCT02776722|tagatose
44822|NCT02776722|sorbose
44823|NCT02776696|Closed Loop
44824|NCT02776696|Artificial Pancreas
44825|NCT02776644|renal cell carcinoma
44826|NCT02776644|sunitinib, pazopanib
44827|NCT02776644|temsirolimus
44828|NCT02776644|sorafenib
44829|NCT02776644|everolimus
44830|NCT02776644|interferon alpha
44831|NCT02776644|interleukin 2
44832|NCT02776592|Healthy Children
44833|NCT02776579|Resistance Training; Muscle Strength
44834|NCT02776566|Anticoagulation
44835|NCT02776566|Anticoagulation Management
44836|NCT02776566|Self-Testing
44837|NCT02776566|Self-Management
44838|NCT02776566|Warfarin
44839|NCT02776566|Thromboembolism
44840|NCT02776566|Blood Coagulation Disorders
44841|NCT02776566|Health Disparities
44842|NCT02776566|Minorities
44843|NCT02776566|African American
44844|NCT02776566|Hispanic
44845|NCT02776566|Cardiovascular Disease
44846|NCT02776566|Models of Anticoagulation Care
44847|NCT02776566|Tele-Health
44848|NCT02776566|Home Self-Testing
44849|NCT02776527|Gastric cancer
44850|NCT02776527|D2 Lymphadenectomy
44851|NCT02776527|postoprative adjuvant chemotherapy
44852|NCT02776527|Apatinib
44853|NCT02776527|disease free survival
44854|NCT02776488|brain trauma, metabolic therapy
44855|NCT02776462|Eye Tracking
44856|NCT02776462|Concussion
44857|NCT02776462|Outcome Measures
44858|NCT02776410|sustainable healthy eating
44859|NCT02776410|consumer behaviour
44860|NCT02776410|consumer attitudes
44861|NCT02776384|Heart Failure
44862|NCT02776384|Biomarkers
44863|NCT02776384|Echocardiography
44864|NCT02776384|Cardiopulmonary Function Tests
44865|NCT02776371|Helicobacter pylori
44866|NCT02776371|Sequential therapy
44867|NCT02776371|Modified non-clarithromycin triple therapy
44868|NCT02776345|calcific tendonitis
44869|NCT02776345|rotator cuff calcific tendonitis
44870|NCT02776332|breastfeeding
44871|NCT02776332|premature infants
44872|NCT02776332|manual expression
44873|NCT02776319|Non-invasive brain stimulation
44874|NCT02776319|tobacco use disorder
44875|NCT02776319|craving
44876|NCT02776280|water
44877|NCT02776280|salt
44878|NCT02776280|oral fluids
44879|NCT02776280|plaque
44880|NCT02776280|dental caries
44881|NCT02776254|anti-retroviral therapy
44882|NCT02776254|differentiated care
44883|NCT02776241|ADPKD
44884|NCT02776241|total kidney volume
44885|NCT02776241|kidney disease
44886|NCT02776189|Anaesthesia
44887|NCT02776189|MRI
44888|NCT02776189|Brain
44889|NCT02776176|enhanced recovery after surgery
44890|NCT02776176|hirschsprung disease
44891|NCT02776163|Salivary Gland Tumors
44892|NCT02776163|Head-an-Neck cancer
44893|NCT02776163|Concurrent Chemoradiotherapy
44894|NCT02776163|High-Risk
44895|NCT02776163|Cisplatin
44896|NCT02776163|Docetaxel
44897|NCT02776150|probe melting curve
44898|NCT02776150|Drug resistance
44899|NCT02776150|Tuberculosis, Pulmonary
44900|NCT02776137|Docetaxel
44901|NCT02776137|Concurrent Chemoradiotherapy
44902|NCT02776137|High-Risk
44903|NCT02776137|Squamous Cell Carcinoma
44904|NCT02776137|Head-and-Neck Cancer
44905|NCT02776124|Nutritional status
44906|NCT02776124|nasopharyngeal carcinoma
44907|NCT02776124|Nutritional Counseling
44908|NCT02776124|concurrent chemoradiotherapy
44909|NCT02776124|oral nutritional supplements
44910|NCT02776111|Kidney Transplant
44911|NCT02776098|Cystic Fibrosis
44912|NCT02776098|Glucose Intolerance
44913|NCT02776098|Muscle Accrual
44914|NCT02776098|Cystic Fibrosis-related Diabetes
44915|NCT02776085|optic nerve sheath diameter
44916|NCT02776085|ultrasound
44917|NCT02776085|shunt failure
44918|NCT02776072|Tecfidera, DMF, dimethyl fumarate, Fingolimod, Glatiramer acetate, Teriflunomide, Gilenya, Copaxone, Aubagio
44919|NCT02776059|survival
44920|NCT02776059|pegfilgrastim
44921|NCT02776059|cirrhosis, alcoholic
44922|NCT02776046|Oxygen, surgical site infection, postoperative complication, recruitment maneuvers, open lung strategy
44923|NCT02776033|tolerability
44924|NCT02776033|safety
44925|NCT02776033|GSK2982772
44926|NCT02776033|RIP1 kinase inhibitor
44927|NCT02776033|psoriasis
44928|NCT02776007|Continuous Glucose Monitoring System
44929|NCT02775955|Pharmacokinetics
44930|NCT02775929|Tenofovir disoproxil
44931|NCT02775929|Emtricitabine
44932|NCT02775929|Pre-exposure Prophylaxis
44933|NCT02775929|Antiretroviral Therapy
44934|NCT02775929|HIV Prevention
44935|NCT02775929|FTC TDF
44936|NCT02775929|PrEP
44937|NCT02775929|HIV Infected Partners
44938|NCT02775929|HIV Uninfected Partners
44939|NCT02775903|MEDI4736
44940|NCT02775903|Durvalumab
44941|NCT02775903|Myelodysplastic Syndromes
44942|NCT02775903|Acute Myeloid Leukemia
44943|NCT02775903|Hematopoietic Stem Cell Transplantation
44944|NCT02775903|Azacitidine
44945|NCT02775903|Safety
44946|NCT02775903|Efficacy
44947|NCT02775903|PD-L1
44948|NCT02775877|PCOS
44949|NCT02775877|letrozole
44950|NCT02775877|clomiphene
44951|NCT02775786|Pancreatic Adenocarcinoma
44952|NCT02775786|Pancreatic Cancer
44953|NCT02775773|TXA
44954|NCT02775773|PPH
44955|NCT02775760|brain
44956|NCT02775760|brain mapping
44957|NCT02775760|cognition
44958|NCT02775760|exercise
44959|NCT02775760|physical activity
44960|NCT02775760|hippocampus
44961|NCT02775760|entorhinal cortex
44962|NCT02775760|spatial navigation
44963|NCT02775760|learning
44964|NCT02775760|memory
44965|NCT02775760|magnetic resonance imaging
44966|NCT02775760|functional neuroimaging
44967|NCT02775760|physical endurance
44968|NCT02775760|physical fitness
44969|NCT02775760|resistance training
44970|NCT02775760|walking
44971|NCT02775760|muscle stretching exercises
44972|NCT02775760|exercise test
44973|NCT02775760|neuropsychological tests
44974|NCT02775760|executive function
44975|NCT02775760|attention
44976|NCT02775760|body composition
44977|NCT02775734|Polycystic Ovary Syndrome
44978|NCT02775734|N-acetyl-cysteine
44979|NCT02775734|Clomiphene citrate
44980|NCT02775734|Clomiphene citrate resistant
44981|NCT02775734|Laparoscopic ovarian drilling
44982|NCT02775734|therapy
44983|NCT02775721|Nursing Education
44984|NCT02775721|Weight Loss
44985|NCT02775721|Gastrostomy Tube Care
44986|NCT02775695|pancreatic cancer
44987|NCT02775695|Resectable Pancreatic Cancer
44988|NCT02775695|Doxycycline
44989|NCT02775695|Metakaryote cells
44990|NCT02775695|Eukaryotic cells
44991|NCT02775695|Cancer Stem Cells
44992|NCT02775695|Targeted Cancer Stem Cell Therapy
44993|NCT02775695|Multi-metakaryocide therapy
44994|NCT02775695|Doxycycline Hyclate
44995|NCT02775695|Tetracycline
44996|NCT02775682|epilepsy, dynamic cerebral autoregulation
44997|NCT02775669|noninvasive ICP monitoring
44998|NCT02775656|Cimzia®
44999|NCT02775656|CZP
45000|NCT02775656|Pregnancy Follow up study
45001|NCT02775656|Autoimmune diseases
45002|NCT02775656|Pregnancy outcomes
45003|NCT02775656|major congenital malformations
45004|NCT02775656|birth outcomes
45005|NCT02775656|malformation
45006|NCT02775656|birth defect
45007|NCT02775643|Melanoma
45008|NCT02775643|Spitzoid Melanoma
45009|NCT02775643|Congenital Melanoma
45010|NCT02775643|Melanoma Arising in Giant Nevi
45011|NCT02775643|Melanocytic lesions with indeterminate biological behavior
45012|NCT02775643|Pigment synthesizing melanomas
45013|NCT02775604|fall risks at home
45014|NCT02775604|video technology
45015|NCT02775604|home assessment
45016|NCT02775578|heart failure
45017|NCT02775578|coronary artery disease
45018|NCT02775578|biomarkers
45019|NCT02775578|Percutaneous Coronary Intervention, PCI
45020|NCT02775578|Coronary Artery Bypass Grafting, CABG
45021|NCT02775552|Child Nutrition
45022|NCT02775552|Breastfeeding
45023|NCT02775552|Complementary Feeding
45024|NCT02775552|Infant and Young Child Feeding
45025|NCT02775552|Social and Behavior Change Communication
45026|NCT02775552|Ethiopia
45027|NCT02775539|Pulmonary hypertension
45028|NCT02775539|Mirabegron
45029|NCT02775539|Heart failure
45030|NCT02775539|B3 adrenergic
45031|NCT02775526|Mixed urinary incontinence
45032|NCT02775526|Transobturator tape (TOT)
45033|NCT02775526|Tension-Free Vaginal Tape (TVT)
45034|NCT02775526|Burch colposuspension
45035|NCT02775526|Urinary incontinence
45036|NCT02775500|pregnancy
45037|NCT02775500|apremilast
45038|NCT02775500|Otezla
45039|NCT02775500|autoimmune disease
45040|NCT02775500|psoriatic arthritis
45041|NCT02775500|psoriasis
45042|NCT02775500|TNF
45043|NCT02775500|tumor necrosis factor
45044|NCT02775500|birth outcome
45045|NCT02775500|birth defect
45046|NCT02775487|COPD
45047|NCT02775487|Air quality
45048|NCT02775474|Methadone
45049|NCT02775474|Pain, Postoperative
45050|NCT02775474|Chronic Pain
45051|NCT02775474|Bariatric Surgery
45052|NCT02775461|Pancreas Cancer
45053|NCT02775461|Chronic Pancreatitis
45054|NCT02775461|Pancreatic Cyst
45055|NCT02775461|BRCA1
45056|NCT02775461|BRCA2
45057|NCT02775461|Lynch Syndrome
45058|NCT02775461|Peutz-Jeghers syndrome
45059|NCT02775461|ATM mutation
45060|NCT02775461|FAMMM Syndrome
45061|NCT02775461|Pancreatitis
45062|NCT02775461|Family History of Pancreas Cancer
45063|NCT02775461|Family History of Cancer
45064|NCT02775448|Homeopathy
45065|NCT02775448|Carduus marianus
45066|NCT02775448|Dyslipidemia
45067|NCT02775448|Climacteric
45068|NCT02775448|Obesity
45069|NCT02775448|Triglycerides
45070|NCT02775448|Cholesterol
45071|NCT02775448|Insulin resistance
45072|NCT02775448|LDL-cholesterol
45073|NCT02775448|HDL-cholesterol
45074|NCT02775435|PD1
45075|NCT02775435|PD-1
45076|NCT02775435|PDL1
45077|NCT02775435|PD-L1
45078|NCT02775383|National MDS Study
45079|NCT02775383|MDS
45080|NCT02775383|Idiopathic
45081|NCT02775383|cytopenia
45082|NCT02775383|cytopenias
45083|NCT02775383|ICUS
45084|NCT02775383|MDS/MPN
45085|NCT02775383|Myeloproliferative Neoplasm
45086|NCT02775383|Biorepository
45087|NCT02775344|Laparoscopy
45088|NCT02775344|ovarian cystectomy
45089|NCT02775344|three dimension laparoscopy
45090|NCT02775331|shift scheduling
45091|NCT02775331|work-life interaction
45092|NCT02775331|working time control
45093|NCT02775331|public sector
45094|NCT02775318|Stellate Ganglion
45095|NCT02775318|Digital Subtraction Angiography
45096|NCT02775318|Transcranial Doppler Ultrasonography
45097|NCT02775279|acute coronary syndrome, telomere length, predictive factor
45098|NCT02775253|Brown adipose tissue
45099|NCT02775253|Subcutaneous white adipose tissue
45100|NCT02775253|White adipose tissue
45101|NCT02775240|Maribavir
45102|NCT02775214|Storz C-MAC
45103|NCT02775214|direct laryngoscopy
45104|NCT02775214|pyloromyotomy
45105|NCT02775214|rapid sequence
45106|NCT02775201|plantaris
45107|NCT02775201|Tendinopathy
45108|NCT02775201|Achilles
45109|NCT02775201|Release
45110|NCT02775175|Ramadan
45111|NCT02775175|Fasting
45112|NCT02775175|Nutrition
45113|NCT02775175|Quality of Life
45114|NCT02775136|brain injuries
45115|NCT02775136|neurological monitoring
45116|NCT02775084|n-3
45117|NCT02775084|Polyunsaturated
45118|NCT02775084|Fatty acids
45119|NCT02775084|Antigens
45120|NCT02775084|Cognition
45121|NCT02775084|CD4
45122|NCT02775045|EoE
45123|NCT02775032|advance care planning
45124|NCT02775032|general practice
45125|NCT02775032|family practice
45126|NCT02775032|palliative care
45127|NCT02775032|end-of-life care
45128|NCT02774967|root coverage
45129|NCT02774967|gingival recession
45130|NCT02774967|periodontal surgery
45131|NCT02774954|Change the cycle
45132|NCT02774954|social learning theory
45133|NCT02774954|people who inject drugs
45134|NCT02774954|injection drug use
45135|NCT02774954|Information, Motivation, Behavior Skills Model
45136|NCT02774954|Longitudinal cohort study
45137|NCT02774928|Pulmonary Hypertension
45138|NCT02774928|COPD
45139|NCT02774928|ILD
45140|NCT02774928|OSA
45141|NCT02774902|Drug Therapy
45142|NCT02774889|Falls Prevention
45143|NCT02774889|Stepping On
45144|NCT02774889|Health Promotion
45145|NCT02774889|Implementation
45146|NCT02774889|Health Maintenance
45147|NCT02774876|Closed-loop system
45148|NCT02774876|Artificial pancreas
45149|NCT02774876|Glucose control
45150|NCT02774876|Meal
45151|NCT02774850|Pediatric
45152|NCT02774850|Neutropenia Management
45153|NCT02774850|Acute Myeloid Leukemia
45154|NCT02774850|Chart Abstraction
45155|NCT02774850|Chemotherapy
45156|NCT02774837|nucleoside analogues
45157|NCT02774837|tenofovir
45158|NCT02774837|telbivudine
45159|NCT02774837|quantitative HBsAg
45160|NCT02774837|combination therapy
45161|NCT02774798|Rectal Prolapse
45162|NCT02774798|Rectal Intussuception
45163|NCT02774759|Malignant neoplasms of female genital organs
45164|NCT02774759|Endometrial cancer survivors
45165|NCT02774759|Obese
45166|NCT02774759|Weight loss intervention
45167|NCT02774759|Resistance training
45168|NCT02774759|Aerobic exercise
45169|NCT02774759|Questionnaires
45170|NCT02774759|Surveys
45171|NCT02774759|Accelerometer
45172|NCT02774759|Fitness Test
45173|NCT02774759|Telephone Coaching
45174|NCT02774759|Video Chat Sessions
45175|NCT02774707|Dry eye
45176|NCT02774694|nociceptive flexion reflex
45177|NCT02774694|interventional pain management
45178|NCT02774668|gender
45179|NCT02774668|arterial stiffness
45180|NCT02774668|blood pressure
45181|NCT02774668|weight loss
45182|NCT02774668|uric acid
45183|NCT02774655|healthy volunteers
45184|NCT02774655|patient compliance
45185|NCT02774655|exercise
45186|NCT02774655|motivation
45187|NCT02774642|PTSD
45188|NCT02774642|insomnia
45189|NCT02774642|CBT-I
45190|NCT02774642|Prolonged Exposure
45191|NCT02774642|Veteran
45192|NCT02774629|food allergy
45193|NCT02774629|skin prick test
45194|NCT02774629|atopy patch test
45195|NCT02774590|Acne vulgaris
45196|NCT02774590|Rosacea
45197|NCT02774577|Oxygen Consumption
45198|NCT02774577|Aged
45199|NCT02774577|Whole Body Vibration
45200|NCT02774551|Body composition
45201|NCT02774551|Muscle strength
45202|NCT02774551|Health related quality of life
45203|NCT02774538|Cervical HPV infection
45204|NCT02774538|Oral HPV infection
45205|NCT02774538|Sexually transmitted infection
45206|NCT02774525|child welfare system
45207|NCT02774525|parental substance use problem
45208|NCT02774525|child maltreatment
45209|NCT02774525|parenting
45210|NCT02774473|Metastatic
45211|NCT02774473|Rb+
45212|NCT02774473|Breast Cancer
45213|NCT02774408|backup ventilation
45214|NCT02774408|preterm infants
45215|NCT02774408|functional residual capacity
45216|NCT02774408|chronic lung disease
45217|NCT02774382|Recurrence
45218|NCT02774382|Infection
45219|NCT02774369|cancer
45220|NCT02774369|insomnia
45221|NCT02774369|sleep
45222|NCT02774369|physical exercise
45223|NCT02774369|aerobic
45224|NCT02774369|cognitive-behavioral therapy
45225|NCT02774369|self-help
45226|NCT02774369|RCT
45227|NCT02774356|Brainstem
45228|NCT02774356|Encoding
45229|NCT02774356|Pitch
45230|NCT02774304|elastance
45231|NCT02774304|fluid responsiveness
45232|NCT02774265|Fracture
45233|NCT02774265|Prophylaxis
45234|NCT02774226|Flow-Mediated Dilation
45235|NCT02774226|Kuvan
45236|NCT02774226|Antioxidant
45237|NCT02774226|FEV1
45238|NCT02774187|Hepatocellular Carcinoma
45239|NCT02774187|Hepatic arterial infusion chemotherapy
45240|NCT02774187|Sorafenib
45241|NCT02774174|Proximal Humerus
45242|NCT02774109|low back pain
45243|NCT02774109|fish oil
45244|NCT02774109|omega 3
45245|NCT02774096|Aortic dissection
45246|NCT02774096|Cerebral and Spinal Protection
45247|NCT02774096|Post-conditioning
45248|NCT02774083|older people
45249|NCT02774083|cognitive training
45250|NCT02774070|AAJ RA MRI synovitis
45251|NCT02774057|Captafer®
45252|NCT02774057|Iron Sulfate
45253|NCT02774057|Iron deficiency anemia
45254|NCT02774057|inflammatory bowel disease
45255|NCT02774044|preterm neonates, surfactant
45256|NCT02774031|Anesthesia, Inhalation
45257|NCT02774031|Laparoscopy
45258|NCT02774031|Prostatectomy
45259|NCT02774031|Cystectomy
45260|NCT02774031|Gynecologic Surgical Procedures
45261|NCT02774018|Mindfulness
45262|NCT02774018|Elderly
45263|NCT02774018|Psychopathology
45264|NCT02773992|Solitary Pulmonary Nodule
45265|NCT02773992|Itos
45266|NCT02773992|lung cancer
45267|NCT02773979|malaria, vaccine, P. falciparum, PfSPZ, sporozoites, challenge
45268|NCT02773953|CPAP
45269|NCT02773953|Telemonitoring
45270|NCT02773927|Agave inulin
45271|NCT02773927|Adiponectin
45272|NCT02773927|Metabolic syndrome
45273|NCT02773927|Metformin
45274|NCT02773927|Insulin resistance
45275|NCT02773914|Activity of Daily Living (ADL)
45276|NCT02773914|Comprehensive Geriatric Assessment
45277|NCT02773914|Elderly
45278|NCT02773914|Frailty
45279|NCT02773914|Randomized controlled study
45280|NCT02773901|intracranial pressure
45281|NCT02773901|noninvasive monitoring
45282|NCT02773901|lumbar puncture
45283|NCT02773888|intracranial pressure
45284|NCT02773888|noninvasive monitoring
45285|NCT02773875|artificial pancreas
45286|NCT02773862|brain injuries
45287|NCT02773862|noninvasive monitoring
45288|NCT02773862|intracranial pressure
45289|NCT02773849|IFN
45290|NCT02773849|BCG-unresponsive
45291|NCT02773849|Non-Muscle Invasive Bladder Cancer
45292|NCT02773836|tobacco use
45293|NCT02773836|e-cigarettes
45294|NCT02773836|public policy
45295|NCT02773836|ITC
45296|NCT02773823|obesity
45297|NCT02773823|children
45298|NCT02773823|cardiovascular health
45299|NCT02773823|intervention study
45300|NCT02773797|Sedation
45301|NCT02773797|Dexmedetomidine
45302|NCT02773771|Muscle Atrophy
45303|NCT02773771|Critical Illness
45304|NCT02773771|Ultrasound
45305|NCT02773771|beta-hydroxy-beta-methylbutyrate
45306|NCT02773771|ICU
45307|NCT02773680|respiration
45308|NCT02773680|monitoring, physiologic
45309|NCT02773680|diagnostic techniques, respiratory system
45310|NCT02773654|shoulder
45311|NCT02773654|motion
45312|NCT02773654|measurement
45313|NCT02773654|healthy shoulder
45314|NCT02773654|shoulder motion
45315|NCT02773602|Analgesia
45316|NCT02773602|caudal analgesia
45317|NCT02773602|ropivacaine
45318|NCT02773602|clonidine
45319|NCT02773602|dexamethasone
45320|NCT02773550|Multiple Myeloma
45321|NCT02773524|Metastatic
45322|NCT02773524|Locally recurrent
45323|NCT02773524|Oesophago-gastric junction
45324|NCT02773524|Stomach
45325|NCT02773524|Adenocarcinoma
45326|NCT02773524|Undifferentiated Carcinoma
45327|NCT02773472|colorectal
45328|NCT02773472|electroacupuncture
45329|NCT02773472|laparoscopic surgery
45330|NCT02773446|ETEC
45331|NCT02773446|Escherichia coli
45332|NCT02773446|enteritis
45333|NCT02773446|Challenge
45334|NCT02773446|CS6
45335|NCT02773446|Enterotoxigenic
45336|NCT02773407|Undifferentiated febrile illness
45337|NCT02773407|Azithromycin
45338|NCT02773407|Cotrimoxazole
45339|NCT02773407|Efficacy
45340|NCT02773407|Enteric fever
45341|NCT02773407|Fever clearance time
45342|NCT02773394|Hepatitis C Virus
45343|NCT02773394|Observational
45344|NCT02773394|Brazil
45345|NCT02773342|Invasive Pulmonal Aspergillosis
45346|NCT02773342|Neutropenic Patients
45347|NCT02773342|Haematological Malignancies
45348|NCT02773342|Chest Computed Tomography
45349|NCT02773329|chemotherapy induced peripheral neuropathy
45350|NCT02773329|Cancer
45351|NCT02773329|game-based exercise
45352|NCT02773329|exercise
45353|NCT02773329|wearable sensors
45354|NCT02773329|balance
45355|NCT02773329|falls
45356|NCT02773329|virtual reality
45357|NCT02773303|Neurofeedback
45358|NCT02773303|balance, postural
45359|NCT02773303|postural equilibrium
45360|NCT02773303|EEG
45361|NCT02773290|Aplastic Anemia
45362|NCT02773251|Postoperative adhesion
45363|NCT02773251|Laparoscopy
45364|NCT02773251|Adhesion barrier
45365|NCT02773225|non severe Aplastic Anemia,
45366|NCT02773186|postoperative
45367|NCT02773186|behavioral changes
45368|NCT02773173|Colorectal Laparoscopic Surgery
45369|NCT02773134|Post-operative Bracing
45370|NCT02773134|Rigid Lumbosacral Orthosis
45371|NCT02773134|Posterior Spine Fusion
45372|NCT02773134|Quality of Life
45373|NCT02773134|Lumbar Degenerative Conditions
45374|NCT02773121|Cognition
45375|NCT02773121|Learning
45376|NCT02773121|Memory
45377|NCT02773121|Executive Function
45378|NCT02773121|Attention
45379|NCT02773121|Neuropsychological Tests
45380|NCT02773121|Physical Activity
45381|NCT02773121|Physical Fitness
45382|NCT02773121|Exercise
45383|NCT02773121|Resistance Training
45384|NCT02773121|Walking
45385|NCT02773121|Muscle Stretching Exercises
45386|NCT02773121|Exercise Test
45387|NCT02773121|Balance
45388|NCT02773121|Flexibility
45389|NCT02773121|Body Composition
45390|NCT02773082|Treatment-Resistant
45391|NCT02773082|Anxiety
45392|NCT02773056|transfemoral
45393|NCT02773056|amputation
45394|NCT02773056|perspiration
45395|NCT02773056|socket
45396|NCT02773056|socket comfort
45397|NCT02773030|Multiple Myeloma
45398|NCT02773030|Relapsed
45399|NCT02773030|Refractory
45400|NCT02773030|Pharmacokinetics
45401|NCT02773030|Safety
45402|NCT02773030|Efficacy
45403|NCT02773030|CC-220
45404|NCT02773030|Relapsed and refractory multiple myeloma
45405|NCT02773017|sedation
45406|NCT02773017|age
45407|NCT02773017|dexmedetomidine
45408|NCT02773004|Genomic test
45409|NCT02773004|Chemotherapy decision
45410|NCT02772978|decision making
45411|NCT02772978|impulsivity
45412|NCT02772926|Benfotiamine
45413|NCT02772926|Advanced glycation end products
45414|NCT02772926|Soluble receptor for AGEs
45415|NCT02772926|Endogenous secretory receptor for AGEs
45416|NCT02772900|Aging
45417|NCT02772900|Beetroot
45418|NCT02772900|Dietary Nitrate
45419|NCT02772900|Functional Food
45420|NCT02772900|Vascular Function
45421|NCT02772887|pregnancy
45422|NCT02772887|type 2 diabetes
45423|NCT02772887|asymmetric dimethylarginine
45424|NCT02772887|L-arginine
45425|NCT02772887|L-citrulline
45426|NCT02772887|placental growth factor (PlGF)
45427|NCT02772887|blood pressure
45428|NCT02772874|fecal incontinence
45429|NCT02772874|severity
45430|NCT02772874|ultrasound
45431|NCT02772874|anorectal manometry
45432|NCT02772874|classification
45433|NCT02772835|nCPAP
45434|NCT02772835|nHFOV
45435|NCT02772835|Preterm
45436|NCT02772835|RDS
45437|NCT02772835|CO2 Elimination
45438|NCT02772809|stroke
45439|NCT02772809|hemiplegia
45440|NCT02772809|rehabilitation
45441|NCT02772809|robotics
45442|NCT02772809|neuroplasticity
45443|NCT02772796|Pharmacokinetics
45444|NCT02772796|Healthy Volunteer Study
45445|NCT02772783|brain
45446|NCT02772783|fMRI
45447|NCT02772783|carbohydrate
45448|NCT02772783|insulin clamp
45449|NCT02772783|intake regulation
45450|NCT02772783|overweight
45451|NCT02772783|glycemic index
45452|NCT02772757|hearing loss
45453|NCT02772757|hearing aids
45454|NCT02772757|outcome assessment
45455|NCT02772744|Hepatitis C virus genotype 4
45456|NCT02772744|Antiviral
45457|NCT02772744|Virologic Response
45458|NCT02772731|mastectomy
45459|NCT02772718|Hypoglycemia
45460|NCT02772705|Standardized Uptake Value
45461|NCT02772705|Diagnosis
45462|NCT02772679|Diabetes
45463|NCT02772679|Treg
45464|NCT02772666|Relative afferent pupillary defect (RAPD)
45465|NCT02772666|Multiple sclerosis
45466|NCT02772666|Glaucoma
45467|NCT02772653|Microcirculation
45468|NCT02772653|Videomicroscopy
45469|NCT02772653|Spectroscopy, Near-Infrared
45470|NCT02772653|B-Type Natriuretic Peptide
45471|NCT02772653|Thromboelastometry
45472|NCT02772653|Trauma
45473|NCT02772653|Resuscitation
45474|NCT02772653|Hypovolemic shock
45475|NCT02772640|Hypercholesterolemia
45476|NCT02772640|Rosuvastatin
45477|NCT02772640|Statin
45478|NCT02772640|Ezetimibe
45479|NCT02772640|Compliance
45480|NCT02772640|Cholesterol
45481|NCT02772640|Secondary prevention
45482|NCT02772640|Coronary artery disease
45483|NCT02772640|Cholesterol absorption inhibitor
45484|NCT02772627|Parkinson's disease, Nebicapone
45485|NCT02772614|Nebicapone, Parkinson's disease
45486|NCT02772601|ABBV-066
45487|NCT02772601|BI 655066
45488|NCT02772601|risankizumab
45489|NCT02772588|ARN-509
45490|NCT02772588|Abiraterone
45491|NCT02772588|Leuprolide
45492|NCT02772588|Intensity-Modulated and Image-Guided Radiation Therapy
45493|NCT02772588|15-334
45494|NCT02772588|apalutamide,
45495|NCT02772588|JNJ-56021927
45496|NCT02772575|MOLECULAR PREDICTORS
45497|NCT02772575|Hepatic trans-arterial embolization (TAE)
45498|NCT02772575|16-385
45499|NCT02772562|prostate cancer
45500|NCT02772549|Diagnosis
45501|NCT02772536|Chronic Tinnitus Tinted Light Change in Perception
45502|NCT02772523|Primary Prevention
45503|NCT02772510|Stroke
45504|NCT02772510|Rehabilitation
45505|NCT02772510|Hand
45506|NCT02772510|Game
45507|NCT02772510|Functional electrical stimulation
45508|NCT02772510|Virtual reality
45509|NCT02772497|DME
45510|NCT02772497|Anti VEGF
45511|NCT02772497|VEGF trap
45512|NCT02772497|Diabetes
45513|NCT02772497|Diabetic retinopathy
45514|NCT02772497|ZALTRAP
45515|NCT02772497|Ziv aflibercept
45516|NCT02772484|noninvasive monitoring
45517|NCT02772471|intracranial pressure
45518|NCT02772471|noninvasive monitoring
45519|NCT02772458|Crohn's Disease
45520|NCT02772458|gut brain axis
45521|NCT02772458|reduced appetite
45522|NCT02772445|Empowerment
45523|NCT02772445|Caregiver
45524|NCT02772432|resiliency training
45525|NCT02772432|parenting
45526|NCT02772432|special learning disability
45527|NCT02772406|ulcerative colitis
45528|NCT02772406|colonoscopy
45529|NCT02772406|Dysplasia
45530|NCT02772406|Diagnosis
45531|NCT02772367|cardiotoxicity
45532|NCT02772367|16-025
45533|NCT02772354|Pediatric population, ablation
45534|NCT02772341|Asthma
45535|NCT02772341|Halotherapy
45536|NCT02772341|Airway hyper-reactivity
45537|NCT02772341|Metacholine
45538|NCT02772328|Testing
45539|NCT02772328|Access
45540|NCT02772315|genomics
45541|NCT02772315|proteomics
45542|NCT02772315|metabolomics
45543|NCT02772315|endocrine hypertension
45544|NCT02772315|primary aldosteronism
45545|NCT02772315|Cushing syndrom
45546|NCT02772315|pheochromocytoma
45547|NCT02772289|Mesenchyme Stem Cells
45548|NCT02772289|Cesarean Section
45549|NCT02772289|Scars
45550|NCT02772276|Glomerular Filtration Rate
45551|NCT02772263|Paramedicine
45552|NCT02772263|Community Paramedic
45553|NCT02772263|Elderly
45554|NCT02772250|bowel preparation
45555|NCT02772250|polyethylene glycol
45556|NCT02772250|face-to-face re-education
45557|NCT02772250|telephone re-education
45558|NCT02772250|Boston Bowel Preparation Scale
45559|NCT02772237|concussion
45560|NCT02772237|sports-related concussion
45561|NCT02772237|mTBI
45562|NCT02772237|Riboflavin
45563|NCT02772237|Vitamin B2
45564|NCT02772159|COPD
45565|NCT02772159|ADME
45566|NCT02772159|Healthy Normal Males
45567|NCT02772159|Phase 1
45568|NCT02772120|Infertility
45569|NCT02772120|In vitro fertilization
45570|NCT02772120|Embryo transfer
45571|NCT02772120|Blastocyst
45572|NCT02772120|Progesterone
45573|NCT02772120|Crinone
45574|NCT02772107|Small Cell Lung Carcinoma
45575|NCT02772094|glioblastoma multiforme
45576|NCT02772094|glioblastoma
45577|NCT02772094|newly diagnosed glioblastoma
45578|NCT02772094|immunotherapy
45579|NCT02772094|dendritic cells
45580|NCT02772094|grade IV astrocytoma
45581|NCT02772094|oncology
45582|NCT02772094|neurology
45583|NCT02772094|glioma
45584|NCT02772094|brain tumor
45585|NCT02772094|ADCTA-G
45586|NCT02772055|Moxa smoke
45587|NCT02772055|Moxibustion
45588|NCT02772055|Knee osteoarthritis
45589|NCT02772042|Manual Therapy
45590|NCT02772042|Physiotherapy
45591|NCT02772042|Manipulation
45592|NCT02772003|Chronic HCV
45593|NCT02772003|Immunotherapy
45594|NCT02772003|DNA Vaccine
45595|NCT02772003|Electroporation
45596|NCT02771990|Back Pain
45597|NCT02771964|outcome assessment
45598|NCT02771964|postoperative period
45599|NCT02771951|Childhood
45600|NCT02771951|Obesity
45601|NCT02771938|radiotherapy, breast cancer, DIEP flap
45602|NCT02771925|Gabapentin
45603|NCT02771925|Alcohol Dependence
45604|NCT02771899|Imaging, Three-Dimensional
45605|NCT02771899|Spine
45606|NCT02771899|Scoliosis
45607|NCT02771886|mindfulness
45608|NCT02771886|urges
45609|NCT02771886|adolescents
45610|NCT02771886|risk behaviors
45611|NCT02771886|therapy intervention
45612|NCT02771860|denosumab
45613|NCT02771860|RANKL-blockade
45614|NCT02771834|Postural balance
45615|NCT02771834|Osteoporosis
45616|NCT02771834|Postmenopause
45617|NCT02771834|Vitamin D
45618|NCT02771834|Kyfhosis
45619|NCT02771834|Muscle strength
45620|NCT02771808|CABG
45621|NCT02771795|HER2
45622|NCT02771795|Trastuzumab
45623|NCT02771795|Biosimilar
45624|NCT02771795|Cancer
45625|NCT02771795|Breast
45626|NCT02771795|Positive
45627|NCT02771782|BCG
45628|NCT02771782|TDaP-IPV
45629|NCT02771782|DPT Vaccine
45630|NCT02771769|cell-free DNA
45631|NCT02771769|copy number instability
45632|NCT02771769|liquid biopsy
45633|NCT02771769|cancer
45634|NCT02771756|Breast cancer
45635|NCT02771756|Lung cancer
45636|NCT02771756|Nutritional support
45637|NCT02771756|Safety
45638|NCT02771756|Effectiveness
45639|NCT02771743|Neuroblastoma
45640|NCT02771743|High risk
45641|NCT02771743|Tandem high dose chemotherapy
45642|NCT02771691|Adolescent
45643|NCT02771652|Multiple Sclerosis
45644|NCT02771652|Quality of Life
45645|NCT02771652|exercise
45646|NCT02771652|internet
45647|NCT02771639|Hip arthroplasty
45648|NCT02771639|periprosthetic joint infection
45649|NCT02771639|outcome
45650|NCT02771626|RCC
45651|NCT02771626|MEL
45652|NCT02771626|NSCLC
45653|NCT02771626|Immuno-Oncology
45654|NCT02771626|Tumor Metabolism
45655|NCT02771626|Glutaminase
45656|NCT02771626|Glutaminase Inhibitor
45657|NCT02771613|Morbidity Mortality Review
45658|NCT02771613|medical simulation
45659|NCT02771613|in situ simulation
45660|NCT02771613|multi professional simulation
45661|NCT02771613|hospital adverse event
45662|NCT02771600|Procedural pain
45663|NCT02771600|Procedural anxiety
45664|NCT02771600|Pediatrics
45665|NCT02771600|Needle-related procedures
45666|NCT02771587|alcohol
45667|NCT02771587|energy drink
45668|NCT02771587|coagulability
45669|NCT02771587|caffeine
45670|NCT02771587|taurine
45671|NCT02771587|driving performance
45672|NCT02771574|Bariatric surgery complications
45673|NCT02771574|Glucose Metabolism Disorders
45674|NCT02771574|Exendin (9-39)
45675|NCT02771574|GLP-1
45676|NCT02771561|Patent Foramen Ovale
45677|NCT02771561|Obstructive Sleep Apnea
45678|NCT02771561|Apnea-Hypopnea Index
45679|NCT02771561|Oxygen Desaturation Index
45680|NCT02771561|Epworth Sleepiness Scale
45681|NCT02771561|Quality of life
45682|NCT02771561|Continuous Positive Airway Pressure
45683|NCT02771561|Obstructive Sleep Apnea-Hypopnea Syndrome
45684|NCT02771561|Gore™ septal occluder device
45685|NCT02771548|Knee injuries
45686|NCT02771548|Rehabilitation
45687|NCT02771548|Return to sport
45688|NCT02771548|Biomechanics
45689|NCT02771522|Caries, Acitivity, Demineralsiation
45690|NCT02771509|CPB
45691|NCT02771509|Cardiac Surgery
45692|NCT02771509|Acute Kidney Injury
45693|NCT02771470|Gut microflora
45694|NCT02771470|Lung cancer
45695|NCT02771470|Chemotherapy
45696|NCT02771470|Immunity
45697|NCT02771470|Nutrition
45698|NCT02771457|Influximab
45699|NCT02771457|IFX
45700|NCT02771457|Remicade
45701|NCT02771418|Carotid endarterectomy
45702|NCT02771418|postoperative cognitive dysfunction
45703|NCT02771405|HCV-HCC-DAAs
45704|NCT02771366|neuroinflammation
45705|NCT02771366|cognitive function
45706|NCT02771366|aging adults
45707|NCT02771314|NSCLC
45708|NCT02771314|AZD9291
45709|NCT02771314|>= 2nd line
45710|NCT02771314|liquid biopsy
45711|NCT02771314|EGFR TKIs
45712|NCT02771314|EGFR mutant
45713|NCT02771301|IDH1R132H Dendritic cell glioma
45714|NCT02771288|Kawasaki disease
45715|NCT02771288|optical coherence tomography
45716|NCT02771288|multislice computed tomography
45717|NCT02771249|Latent Tuberculosis Infection (LTBI)
45718|NCT02771249|Antiretrovirals (ARVs)
45719|NCT02771249|HIV
45720|NCT02771249|UGT1A1
45721|NCT02771249|Drug-Drug Interaction (DDI)
45722|NCT02771236|Inherited Eye Disease
45723|NCT02771210|Active psoriatic arthritis
45724|NCT02771210|Axial spondyloarthritides
45725|NCT02771210|Subcutaneous
45726|NCT02771210|Secukinumab in prefilled syringe
45727|NCT02771210|Enthesitis
45728|NCT02771210|Achilles tendon
45729|NCT02771197|AML
45730|NCT02771171|Pediatric Airway, Three-dimensional Imaging, CT Scan
45731|NCT02771158|critical care
45732|NCT02771158|shock, septic
45733|NCT02771158|sepsis
45734|NCT02771158|hypotension
45735|NCT02771158|midodrine
45736|NCT02771093|Type 2, Diabetes, Diabetes Mellitus
45737|NCT02771041|Hip prothesis
45738|NCT02771002|critically ill patients
45739|NCT02771002|septic shock
45740|NCT02771002|peripheral perfusion index
45741|NCT02771002|capillary refill time
45742|NCT02771002|mottling score
45743|NCT02771002|microcirculation
45744|NCT02770989|Cardiac Ablation
45745|NCT02770989|Safety
45746|NCT02770989|Performance
45747|NCT02770989|Laser
45748|NCT02770963|discogenic
45749|NCT02770963|Acupuncture Therapy
45750|NCT02770963|randomized controlled trial
45751|NCT02770950|Knee Osteoarthritis
45752|NCT02770937|laparoscopy, simulator
45753|NCT02770924|cataract
45754|NCT02770924|phacoemulsification
45755|NCT02770924|AT LISA TRI TORIC
45756|NCT02770924|IOL
45757|NCT02770911|Rectal Carcinoma
45758|NCT02770911|Laparoscopy
45759|NCT02770911|Anastomotic Leak
45760|NCT02770911|Double-stapling technique
45761|NCT02770898|probation
45762|NCT02770898|evidence-based
45763|NCT02770898|well-being
45764|NCT02770898|physical exercise
45765|NCT02770898|family well-being
45766|NCT02770872|serum amyloid a
45767|NCT02770872|lipoprotein
45768|NCT02770872|insulin resistance
45769|NCT02770872|dyslipidemia
45770|NCT02770859|Achalasia
45771|NCT02770833|Proteins (seafood and meat)
45772|NCT02770833|GI
45773|NCT02770833|Energy expenditure
45774|NCT02770833|Energy balance
45775|NCT02770833|Thermogenesis (DIT)
45776|NCT02770833|Appetite regulating hormones
45777|NCT02770833|Appetite sensations
45778|NCT02770833|Glucose allostatis
45779|NCT02770833|Amino acid metabolism
45780|NCT02770833|Satiety
45781|NCT02770833|Food preferences
45782|NCT02770807|Ataxia Teleangiectasia
45783|NCT02770807|AT
45784|NCT02770807|EryDex system
45785|NCT02770807|Dexamethasone
45786|NCT02770807|Dexamethasone sodium phosphate
45787|NCT02770781|survivors
45788|NCT02770781|physical fitness
45789|NCT02770768|HSDD (Hypoactive Sexual Desire Disorder)
45790|NCT02770768|EEG (Electroencephalogram)
45791|NCT02770742|patient satisfaction
45792|NCT02770742|unsedated colonoscopy
45793|NCT02770742|intestinal diseases
45794|NCT02770729|intracameral moxifloxacin
45795|NCT02770729|endophthalmitis
45796|NCT02770729|Vigamox
45797|NCT02770729|endothelial cell density
45798|NCT02770677|Yoga
45799|NCT02770677|COPD
45800|NCT02770677|rehabilitation
45801|NCT02770651|optical coherence tomography
45802|NCT02770651|everolimus-eluting stent
45803|NCT02770651|zotarolimus-eluting stent
45804|NCT02770638|Healthy
45805|NCT02770638|Sport
45806|NCT02770638|Athlete
45807|NCT02770638|Male
45808|NCT02770638|University
45809|NCT02770638|Adults
45810|NCT02770638|Rugby Football Union
45811|NCT02770638|Professional
45812|NCT02770638|Competitive sport
45813|NCT02770638|Scoop Stretcher
45814|NCT02770638|Ferno Scoop Stretcher
45815|NCT02770638|Long back spinal board
45816|NCT02770638|Emergency Medical Services
45817|NCT02770638|Long backboard
45818|NCT02770638|Patient Extrication
45819|NCT02770638|Triple Immobilisation
45820|NCT02770638|Pre hospital Medicine
45821|NCT02770638|Rigid Cervical Collar
45822|NCT02770638|Pressure Testing
45823|NCT02770638|Tissue Pressure Testing
45824|NCT02770638|Visual Analogue Scale
45825|NCT02770638|Pressure Sores
45826|NCT02770638|Pressure area damage
45827|NCT02770638|Tissue Viability
45828|NCT02770638|Tissue Interface Pressure
45829|NCT02770638|Comfort
45830|NCT02770638|Pain
45831|NCT02770625|Type I Gaucher
45832|NCT02770625|ISU302
45833|NCT02770625|Imiglucerase
45834|NCT02770599|IBD
45835|NCT02770599|HRQoL
45836|NCT02770599|QoC
45837|NCT02770599|Adherence
45838|NCT02770599|IBD nurse
45839|NCT02770599|MDT
45840|NCT02770573|nano-hydroxyapatite
45841|NCT02770508|antiretroviral naive
45842|NCT02770508|dual therapy
45843|NCT02770482|dementia
45844|NCT02770482|biomarkers
45845|NCT02770482|cerebrospinal fluid
45846|NCT02770469|Breast Cancer
45847|NCT02770469|Korean Americans
45848|NCT02770469|Survivorship
45849|NCT02770469|Quality of Life
45850|NCT02770469|Coping Skills
45851|NCT02770469|Perceived Stress
45852|NCT02770456|fish oil, preterm birth, pregnancy, China, prevention
45853|NCT02770443|Recovered LVEF
45854|NCT02770443|DCM
45855|NCT02770391|HSD3B1 Genotype
45856|NCT02770391|Steroid Metabolism
45857|NCT02770391|High-risk Prostate Cancer
45858|NCT02770391|ARN-509
45859|NCT02770378|Temozolomide
45860|NCT02770378|Recurrent Glioblastoma
45861|NCT02770352|retrospective chart review
45862|NCT02770352|prospective chart review
45863|NCT02770352|fistula formation and repair
45864|NCT02770352|database
45865|NCT02770352|demographics of women with fistulas
45866|NCT02770352|internationally accepted risks factors for fistula formation
45867|NCT02770339|Pharmacogenomics
45868|NCT02770339|Psychiatric crisis
45869|NCT02770339|Drug overdose
45870|NCT02770339|Psychotropic medications
45871|NCT02770326|Safety of Stool Transplant
45872|NCT02770326|Fecal Microbiota Transplantation (FMT)
45873|NCT02770326|15-337
45874|NCT02770300|automatic
45875|NCT02770300|personalized
45876|NCT02770300|robotic therapy
45877|NCT02770261|DP-R208
45878|NCT02770222|Pharmacokinetics
45879|NCT02770196|Community-Supported Agriculture
45880|NCT02770196|Local Food System
45881|NCT02770196|Vegetable
45882|NCT02770196|Fruit
45883|NCT02770196|Childhood Obesity
45884|NCT02770183|Myocardial stunning
45885|NCT02770183|Echocardiography, Transesophageal
45886|NCT02770183|Extracorporeal Circulation
45887|NCT02770144|Child Quality of Life
45888|NCT02770144|Financial Coaching
45889|NCT02770144|Socioeconomic Status
45890|NCT02770144|Social Determinants of Health
45891|NCT02770131|hypercholesterolaemia
45892|NCT02770131|lipid-lowering therapies
45893|NCT02770118|sleep restriction
45894|NCT02770118|obesity
45895|NCT02770118|brown adipose tissue
45896|NCT02770105|L-theanine
45897|NCT02770105|caffeine
45898|NCT02770105|selective attention
45899|NCT02770105|fMRI
45900|NCT02770105|RVRT
45901|NCT02770079|Insulin sensitivity
45902|NCT02770053|Foraminal enlargement
45903|NCT02770053|Root canal treatment
45904|NCT02770040|Acute Severe Ulcerative Colitis
45905|NCT02770040|Steroid Refractory Ulcerative Colitis
45906|NCT02770027|Colon Surgery
45907|NCT02770027|blood viscosity
45908|NCT02770014|Non-Small Cell Lung Cancer
45909|NCT02770014|Epidermal Growth Factor Receptor
45910|NCT02770001|Admixture
45911|NCT02770001|African American
45912|NCT02770001|African American Genetics
45913|NCT02769988|Adolescents
45914|NCT02769988|Health Information Literacy
45915|NCT02769988|Health Education
45916|NCT02769975|Endocrinology
45917|NCT02769975|Obesity
45918|NCT02769975|Pediatric
45919|NCT02769975|Growth Disorder
45920|NCT02769975|Pubertal Development
45921|NCT02769962|PARP Inhibitor
45922|NCT02769962|Topoisomerase I (Top1)
45923|NCT02769962|Camptothecins
45924|NCT02769962|Nanoparticle Drug Conjugate
45925|NCT02769949|Genetics
45926|NCT02769949|Metabolic
45927|NCT02769949|Dysmorphic Syndromes
45928|NCT02769949|Developmental Delay
45929|NCT02769949|Genetic Counseling
45930|NCT02769936|Receptors
45931|NCT02769936|N-Methyl-D-Aspartate
45932|NCT02769923|WestPharma ID-adapter
45933|NCT02769923|Star ID syringe
45934|NCT02769923|BCG needle syringe
45935|NCT02769923|fractional dose IPV
45936|NCT02769923|fIPV
45937|NCT02769923|polio
45938|NCT02769923|Polio Endgame
45939|NCT02769923|IPV
45940|NCT02769884|artificial pancreas
45941|NCT02769832|Abraxane
45942|NCT02769832|Albumin-bound Paclitaxel
45943|NCT02769832|SCLC
45944|NCT02769832|Gemzar
45945|NCT02769819|Flexible fiberscope
45946|NCT02769754|LIVER
45947|NCT02769754|RESECTION
45948|NCT02769754|SURGERY
45949|NCT02769741|Cashew
45950|NCT02769741|Lipoprotein
45951|NCT02769715|Removable partial dentures
45952|NCT02769715|partial edentulism
45953|NCT02769702|Uveitis
45954|NCT02769689|Multiple sclerosis
45955|NCT02769689|Natalizumab
45956|NCT02769689|Fingolimod
45957|NCT02769689|Methylprednisolone
45958|NCT02769650|Coronary stenosis
45959|NCT02769650|Drug-eluting stent
45960|NCT02769650|Coronary angioplasty with stenting
45961|NCT02769650|Ischemic Heart Disease
45962|NCT02769650|Chronic total occlusion
45963|NCT02769650|Right coronary artery
45964|NCT02769650|Stress-MRI
45965|NCT02769637|upper gastrointestinal tract
45966|NCT02769637|lung microbiota and inflammation
45967|NCT02769624|Congenital heart disease
45968|NCT02769598|Pain
45969|NCT02769598|Nociception
45970|NCT02769598|Pediatric intensive care
45971|NCT02769598|Pain assessment scale
45972|NCT02769598|ANI index
45973|NCT02769585|Obesity
45974|NCT02769585|Diabetes Mellitus, Type 2
45975|NCT02769585|weight reduction
45976|NCT02769572|Knee osteoarthritis
45977|NCT02769572|moxibustion
45978|NCT02769572|diclofenac sodium gel
45979|NCT02769520|squamous cell carcinoma head and neck
45980|NCT02769520|pembrolizumab
45981|NCT02769494|Oral ulcer
45982|NCT02769494|Crohn's disease
45983|NCT02769468|Temperature-Probe Placement-preterm infant-case room
45984|NCT02769455|Food Labelling
45985|NCT02769442|Intravenous
45986|NCT02769442|Catheter
45987|NCT02769442|Puncture
45988|NCT02769442|Peripheral Catheterization
45989|NCT02769442|First Stick Success
45990|NCT02769442|Contamination
45991|NCT02769442|Terumo
45992|NCT02769442|SurFlash
45993|NCT02769416|spinal cord injury
45994|NCT02769416|traumatic brain injury
45995|NCT02769403|Job Satisfaction
45996|NCT02769403|Job Performance
45997|NCT02769403|Primary Care
45998|NCT02769390|Analgesia
45999|NCT02769390|Bupivacaine
46000|NCT02769390|Clonidine
46001|NCT02769377|diabetes, glucometer, mobile-phone
46002|NCT02769364|Advanced or Metastatic Breast Cancer
46003|NCT02769364|Eribulin
46004|NCT02769351|volume overload
46005|NCT02769351|heart failure
46006|NCT02769351|cardiac decompensation
46007|NCT02769351|ultrafiltration
46008|NCT02769338|Implementation
46009|NCT02769338|Quality Improvement
46010|NCT02769338|Stroke
46011|NCT02769338|Transient Ischemic Attack
46012|NCT02769338|TIA
46013|NCT02769338|System Redesign
46014|NCT02769338|QI Intervention
46015|NCT02769325|atropine
46016|NCT02769325|pain, postoperative
46017|NCT02769312|Quality of Life
46018|NCT02769312|Post-Traumatic Stress Disorder
46019|NCT02769312|Transcranial Magnetic Stimulation
46020|NCT02769312|Feasibility studies
46021|NCT02769260|pyrosequencing
46022|NCT02769260|16S DNA gene
46023|NCT02769260|Confocal Laser Scanning Microscope
46024|NCT02769260|bacterial viability
46025|NCT02769260|bacterial diversity
46026|NCT02769247|naproxen
46027|NCT02769247|lidocaine
46028|NCT02769247|intrauterine device
46029|NCT02769247|IUD
46030|NCT02769247|pain
46031|NCT02769234|EEG
46032|NCT02769234|ERP
46033|NCT02769234|Event-related Potentials
46034|NCT02769234|Alzheimer's
46035|NCT02769234|P300
46036|NCT02769208|Air Pollution
46037|NCT02769208|Air Filtration
46038|NCT02769208|Exposure Assessment
46039|NCT02769208|HEPA Filter
46040|NCT02769208|Electrostatic Precipitator
46041|NCT02769208|Cardiovascular Disease Biomarkers
46042|NCT02769208|Respiratory Disease Biomarkers
46043|NCT02769182|Older adults
46044|NCT02769182|falls
46045|NCT02769182|cognition
46046|NCT02769182|smart phone
46047|NCT02769169|Ranibizumab, regression of the polyps
46048|NCT02769143|Postmenopausal
46049|NCT02769143|Bone Density
46050|NCT02769143|Exercise
46051|NCT02769104|aromatase inhibitors
46052|NCT02769104|chemotherapy
46053|NCT02769104|neoadjuvant
46054|NCT02769104|postmenopausal
46055|NCT02769104|breast cancer
46056|NCT02769078|Anticoagulation
46057|NCT02769065|Drug Therapy
46058|NCT02769052|endometriosis
46059|NCT02769052|dyspareunia
46060|NCT02769052|physical therapy
46061|NCT02769052|sexuality
46062|NCT02769052|transcutaneous electrical nerve stimulation
46063|NCT02769013|Schistosoma haematobium plasmodium falciparum transmission
46064|NCT02768987|exercise
46065|NCT02768987|physical activity
46066|NCT02768987|behavior modification
46067|NCT02768987|coping skills
46068|NCT02768987|self management
46069|NCT02768987|glycemic control
46070|NCT02768987|overweight
46071|NCT02768987|obesity
46072|NCT02768987|body composition
46073|NCT02768987|adherence
46074|NCT02768961|sofosbuvir
46075|NCT02768961|ledipasvir
46076|NCT02768961|ribavirin
46077|NCT02768961|prisoner
46078|NCT02768961|hepatitis c
46079|NCT02768961|prevalence
46080|NCT02768961|hepatitis b
46081|NCT02768922|Telemedicine
46082|NCT02768922|Telerehabilitation
46083|NCT02768922|Speech and language therapy
46084|NCT02768883|Childhood asthma
46085|NCT02768883|Latino
46086|NCT02768844|Stochastic Resonance
46087|NCT02768844|Fetus/Newborn Infant
46088|NCT02768844|Drug Withdrawal
46089|NCT02768844|Substance Abuse
46090|NCT02768818|Maternal Obesity Complicating Pregnancy
46091|NCT02768805|Influenza
46092|NCT02768805|Human
46093|NCT02768805|RNA Virus Infections
46094|NCT02768805|Immunologic
46095|NCT02768805|Immunogenic Factors
46096|NCT02768805|Physiological Effects of Drug
46097|NCT02768805|Virus Diseases
46098|NCT02768805|Orthomyxoviridae Infections
46099|NCT02768805|Infection
46100|NCT02768779|hair
46101|NCT02768766|MEK inhibitor
46102|NCT02768766|Selumetinib
46103|NCT02768766|hyd-sulfate AZD6244
46104|NCT02768766|Uveal melanoma
46105|NCT02768766|Melanoma
46106|NCT02768753|Robotic thyroidectomy
46107|NCT02768753|Robotic central neck dissection
46108|NCT02768753|Axillary bilateral-breast approach
46109|NCT02768753|Bilateral axillo-breast approach
46110|NCT02768727|neurocognitive function
46111|NCT02768727|neural inertia
46112|NCT02768727|xenon gas
46113|NCT02768714|Breast Cancer High risk Stage II or Stage III / IV
46114|NCT02768701|Pembrolizumab
46115|NCT02768701|cyclophosphamide
46116|NCT02768688|Human Brain
46117|NCT02768688|Magnetic Resonance Imaging (MRI)
46118|NCT02768688|Dexmedetomidine
46119|NCT02768688|Cerebral blood flow
46120|NCT02768675|Kyphotic
46121|NCT02768675|Corrective Surgery
46122|NCT02768675|Spinal fractures
46123|NCT02768636|Omega-3, ANS, HRV, SDNN
46124|NCT02768610|dexmedetomidine
46125|NCT02768584|severe mental illness
46126|NCT02768584|nursing
46127|NCT02768584|therapeutic alliance
46128|NCT02768584|psychiatric diseases
46129|NCT02768571|cerebrolysin, stroke, motor function
46130|NCT02768558|Lung Cancer
46131|NCT02768558|NSCLC
46132|NCT02768558|Nivolumab
46133|NCT02768545|Hepatitis C
46134|NCT02768545|Ezetimibe
46135|NCT02768545|Cholesterol
46136|NCT02768545|Enterohepatic Circulation
46137|NCT02768545|Bile
46138|NCT02768545|Feces
46139|NCT02768532|Crohn's disease
46140|NCT02768532|Vedolizumab
46141|NCT02768532|TNF (Tumor Necrosis Factor)
46142|NCT02768532|Clinical response
46143|NCT02768532|Clinical remission
46144|NCT02768519|Participants
46145|NCT02768506|obesity, malabsorption, gastric bypass, SADI-S
46146|NCT02768480|Diabetes
46147|NCT02768480|phone calls
46148|NCT02768480|glycemic control
46149|NCT02768467|Alloderm graft
46150|NCT02768467|Allograft
46151|NCT02768467|Buccal Mucosa
46152|NCT02768454|broad-spectrum antimicrobial
46153|NCT02768454|antibiotics pharmacist
46154|NCT02768428|Knowledge [K01.468]
46155|NCT02768428|Video-Audio Media [V01.255.500]
46156|NCT02768428|Handbooks [V02.520]
46157|NCT02768402|Mitral Valve Regurgitation
46158|NCT02768402|Primary MR
46159|NCT02768402|Secondary MR
46160|NCT02768402|MR
46161|NCT02768402|Heart Failure
46162|NCT02768402|Structural Heart
46163|NCT02768402|Secondary Mitral Valve Regurgitation
46164|NCT02768402|Primary Mitral Valve Regurgitation
46165|NCT02768389|Modified Atkins Diet
46166|NCT02768389|MAD
46167|NCT02768389|Brain Tumor
46168|NCT02768389|Glioblastoma
46169|NCT02768363|Immunotherapy
46170|NCT02768363|Tumor vaccine
46171|NCT02768363|Immuno-oncology
46172|NCT02768363|Cytotoxicity
46173|NCT02768363|Prostate cancer
46174|NCT02768363|Active Surveillance
46175|NCT02768350|lung collapse
46176|NCT02768350|ventilator hyper inflation
46177|NCT02768350|hemodynamic responses
46178|NCT02768350|ventilatory responses
46179|NCT02768350|trauma patients
46180|NCT02768337|brain metastasis
46181|NCT02768337|operable brain metastasis
46182|NCT02768324|sepsis
46183|NCT02768324|Gastrointestinal Microbiome
46184|NCT02768324|Gut microbiota
46185|NCT02768324|Gut Flora
46186|NCT02768324|Intestinal Flora
46187|NCT02768311|Instrumentation Post-operative pain Root canal preparation
46188|NCT02768298|Heart failure
46189|NCT02768298|systolic heart failure
46190|NCT02768298|heart failure with reduced ejection fraction
46191|NCT02768298|exercise capacity
46192|NCT02768285|apical patency
46193|NCT02768285|root canal treatment
46194|NCT02768233|Medication-overuse Headache
46195|NCT02768233|Educational Programme
46196|NCT02768233|Personality Profiles
46197|NCT02768181|nutrition-specific behaviour change communication
46198|NCT02768181|dietary supplements
46199|NCT02768168|Dezocine
46200|NCT02768168|Dexamethasone 21-phosphate
46201|NCT02768168|Pain
46202|NCT02768168|Pruritus
46203|NCT02768155|OA, Osteoarthritis, Knee
46204|NCT02768116|Active Transfer of Plaque
46205|NCT02768103|upper extremity
46206|NCT02768103|spinal cord injury
46207|NCT02768103|surgical reconstruction
46208|NCT02768103|MRI, functional
46209|NCT02768103|rehabilitation
46210|NCT02768077|melatonin
46211|NCT02768077|sleep disturbances
46212|NCT02768025|smoking cessation
46213|NCT02768025|tobacco control
46214|NCT02768025|acupuncture
46215|NCT02768025|Korean Medicine
46216|NCT02768025|Traditional & Complementary Medicine
46217|NCT02767999|Acute ischemic stroke
46218|NCT02767986|Hispanic
46219|NCT02767986|Health Belief Model
46220|NCT02767986|Cultural Consensus Theory
46221|NCT02767986|Cancer Genetics
46222|NCT02767986|Qualitative
46223|NCT02767960|Tenascin-C
46224|NCT02767908|Tobacco
46225|NCT02767908|Smoking Cessation
46226|NCT02767869|Metabolic syndrome
46227|NCT02767869|central obesity
46228|NCT02767869|Banaba
46229|NCT02767869|insulin secretion
46230|NCT02767869|insulin sensitivity
46231|NCT02767804|ALK-positive NSCLC
46232|NCT02767778|Acute ischemic stroke
46233|NCT02767778|Neuroprotection
46234|NCT02767778|Extremely low frequency magnetic fields
46235|NCT02767752|Resectable pancreatic cancer
46236|NCT02767752|Adjuvant
46237|NCT02767713|Cognition Disorders
46238|NCT02767713|Cardiac Surgical Procedures
46239|NCT02767713|dexamethasone
46240|NCT02767687|Postoperative Care
46241|NCT02767687|Postoperative Period
46242|NCT02767687|Heart Surgery
46243|NCT02767674|R-Gemox
46244|NCT02767674|R-miniCHOP
46245|NCT02767674|elderly patients with diffuse large B cell lymphoma
46246|NCT02767661|metronomic capecitabine
46247|NCT02767661|aromatase inhibitor
46248|NCT02767661|first line treatment
46249|NCT02767661|metastatic breast cancer
46250|NCT02767648|cholestasis
46251|NCT02767648|neonatal
46252|NCT02767648|infant
46253|NCT02767596|Type 2 Diabetes Mellitus
46254|NCT02767596|treatment
46255|NCT02767596|GLP-1
46256|NCT02767583|Neuropathology
46257|NCT02767570|Osteoarthritis, Knee
46258|NCT02767570|Arthritis
46259|NCT02767570|Joint Diseases
46260|NCT02767570|Musculoskeletal Diseases
46261|NCT02767570|Rheumatic Diseases
46262|NCT02767544|laparoscopic hysterectomy
46263|NCT02767544|postoperative pain
46264|NCT02767544|local analgesia
46265|NCT02767544|vaginal wound
46266|NCT02767479|eradication rates
46267|NCT02767479|rabeprazole
46268|NCT02767479|esomeprazole
46269|NCT02767453|Shoulder arthroplasty
46270|NCT02767453|Closed suction drainage
46271|NCT02767453|Glenohumeral
46272|NCT02767453|Drainage tube
46273|NCT02767427|Infection Control
46274|NCT02767427|Preoperative Care
46275|NCT02767427|Chlorhexidine
46276|NCT02767427|Pre-Surgical Wash
46277|NCT02767427|Spine Surgery
46278|NCT02767427|Surgical site infections
46279|NCT02767427|Cutaneous bacterial load on skin
46280|NCT02767401|PET-CT
46281|NCT02767401|Cardiac magnetic resonance (CMR) imaging
46282|NCT02767401|Major adverse cardiac events (MACEs)
46283|NCT02767401|coronary artery disease
46284|NCT02767375|Hepatocellular Carcinoma
46285|NCT02767375|Hepatic arterial infusion chemotherapy
46286|NCT02767362|atorvastatin
46287|NCT02767362|endometrium
46288|NCT02767362|endometrial cancer
46289|NCT02767310|Bioequivalence
46290|NCT02767310|two rosuvastatin-containing products
46291|NCT02767284|Contrast Sensitivity
46292|NCT02767284|Diagnostic Techniques, Ophthalmological
46293|NCT02767258|Dry eye
46294|NCT02767258|Diseases of the eye and adnexa
46295|NCT02767245|Thiamine
46296|NCT02767245|Congestive heart failure
46297|NCT02767245|Atrial fibrillation
46298|NCT02767245|Graves' disease
46299|NCT02767232|PHLO
46300|NCT02767232|deep vein thrombosis
46301|NCT02767232|deep venous thrombosis
46302|NCT02767232|blood clot
46303|NCT02767232|catheter-directed thrombolysis
46304|NCT02767232|thrombolysis
46305|NCT02767232|post-thrombotic syndrome
46306|NCT02767232|PTS
46307|NCT02767232|recombinant tissue plasminogen activator
46308|NCT02767232|rt-PA
46309|NCT02767232|Activase
46310|NCT02767232|Alteplase
46311|NCT02767219|Ophthalmology
46312|NCT02767206|Transnasal endoscopy
46313|NCT02767206|ultrathin endoscopes
46314|NCT02767206|esophageal varices
46315|NCT02767206|gastric varices
46316|NCT02767167|Cow's milk
46317|NCT02767167|Iodine
46318|NCT02767167|Selenium
46319|NCT02767167|Women
46320|NCT02767167|Child-bearing age
46321|NCT02767154|extracorporeal circulation
46322|NCT02767141|Hunger
46323|NCT02767141|food insecurity
46324|NCT02767141|behaviors
46325|NCT02767128|pharmacokinetics
46326|NCT02767128|healthy adult volunteer
46327|NCT02767102|Mediterranean diet
46328|NCT02767102|indoleamine
46329|NCT02767102|nutraceuticals
46330|NCT02767102|nutrition
46331|NCT02767102|oxidative stress
46332|NCT02767089|Glucocorticoids, Biomarkers, Dissociated Agonist of the Glucocorticoid Receptor
46333|NCT02767076|paramedian spinal anesthesia
46334|NCT02767076|real time
46335|NCT02767076|ultrasound
46336|NCT02767076|knee surgeries
46337|NCT02767076|conventional
46338|NCT02767050|DENTAL CARIES
46339|NCT02767050|TOBACCO USERS
46340|NCT02767050|SMOKERS
46341|NCT02767050|SMOKELESS TOBACCO CHEWERS
46342|NCT02767011|surgical site infection
46343|NCT02766985|FSHD
46344|NCT02766985|muscular dystrophy
46345|NCT02766972|Intracranial Aneurysm
46346|NCT02766972|Surgical Clipping
46347|NCT02766972|Rapid Ventricular Pacing
46348|NCT02766959|chronic rhinosinusitis
46349|NCT02766959|airway physiology
46350|NCT02766959|taste receptors
46351|NCT02766959|tas2r
46352|NCT02766959|epithelial biology
46353|NCT02766959|upper respiratory disease
46354|NCT02766946|Mechanical Ventilation
46355|NCT02766933|tenofovir
46356|NCT02766933|hepatocellular carcinoma
46357|NCT02766933|cirrhosis
46358|NCT02766881|Ductal Carcinoma in Situ
46359|NCT02766881|DSC
46360|NCT02766881|Breast Conserving Surgery
46361|NCT02766855|cysteamine
46362|NCT02766855|nephropathic cystinosis
46363|NCT02766855|cystine crystals
46364|NCT02766842|SharkCore
46365|NCT02766842|ProCore
46366|NCT02766829|spinal
46367|NCT02766829|anesthesia
46368|NCT02766829|sitting
46369|NCT02766829|cross leg
46370|NCT02766829|spinal-bone contact
46371|NCT02766738|residential aged care
46372|NCT02766738|mobility
46373|NCT02766738|social participation
46374|NCT02766738|functional capability
46375|NCT02766712|catheter ablation
46376|NCT02766712|atrial fibrillation
46377|NCT02766699|Astrocytoma, Grade IV
46378|NCT02766699|Doxorubicin
46379|NCT02766699|Glioblastoma
46380|NCT02766699|Neoplasms
46381|NCT02766699|Neoplasms by Site
46382|NCT02766699|Antineoplastic Agents
46383|NCT02766699|Drug Delivery Systems
46384|NCT02766699|Molecular Targeted Therapy
46385|NCT02766699|Nanoparticles
46386|NCT02766699|Disease Progression
46387|NCT02766699|Recurrence
46388|NCT02766699|Brain Neoplasms
46389|NCT02766699|Immunotherapy
46390|NCT02766699|Receptor, Epidermal Growth Factor
46391|NCT02766699|Antibodies, Bispecific
46392|NCT02766686|Prostate cancer
46393|NCT02766686|proton radiotherapy
46394|NCT02766686|photon radiotherapy
46395|NCT02766660|Thyroid ophthalmopathy
46396|NCT02766660|optical coherence tomography
46397|NCT02766647|Filgrastim
46398|NCT02766634|filgrastim
46399|NCT02766621|First in human, Phase 1, Healthy volunteers
46400|NCT02766608|COPD
46401|NCT02766582|Ovarian
46402|NCT02766582|platinum
46403|NCT02766582|pembrolizumab
46404|NCT02766569|IRFACODE II, ASD closure, ASD device, erosion, arrhythmia
46405|NCT02766543|prostate cancer
46406|NCT02766543|high intensity transurethral ultrasound ablation
46407|NCT02766543|MRI-guided
46408|NCT02766543|minimally invasive
46409|NCT02766543|real-time temperature feedback control
46410|NCT02766491|Stretching
46411|NCT02766465|Sickle Cell Disease
46412|NCT02766465|Young Adults
46413|NCT02766465|Phase II Trial
46414|NCT02766465|Hematopoietic Cell Transplantation (HCT)
46415|NCT02766465|Human Leukocyte Antigen (HLA)
46416|NCT02766400|Stroke
46417|NCT02766400|Rehabilitation
46418|NCT02766400|Cognition
46419|NCT02766400|Disability
46420|NCT02766400|Intervention
46421|NCT02766374|Asthma
46422|NCT02766374|Biofeedback
46423|NCT02766374|Heart rate variability biofeedback
46424|NCT02766374|Inhaled corticosteroids
46425|NCT02766361|Bipolar disorder
46426|NCT02766361|Psychotherapy
46427|NCT02766361|Cognitive rehabilitation
46428|NCT02766348|DC-CTL, NSCLC
46429|NCT02766322|Alcohol metabolism
46430|NCT02766322|Bariatric surgery
46431|NCT02766322|Effects of alcohol on driving
46432|NCT02766309|Self-assessment of health, Sf12-v2
46433|NCT02766296|PTSD
46434|NCT02766296|trauma
46435|NCT02766296|working memory
46436|NCT02766296|working memory training
46437|NCT02766283|Children
46438|NCT02766283|Iodinated contrast agents
46439|NCT02766270|Grade II/III Glioma
46440|NCT02766270|IDH
46441|NCT02766270|TERT
46442|NCT02766270|Chemoradiotherapy
46443|NCT02766270|Temozolomide
46444|NCT02766218|toddler obesity
46445|NCT02766218|responsive feeding
46446|NCT02766218|behavioral weight control
46447|NCT02766218|pregnancy weight gain
46448|NCT02766218|early life risk factors
46449|NCT02766205|Embolic Stroke of Undetermined Source
46450|NCT02766205|Atrial fibrillation
46451|NCT02766205|prognostic score
46452|NCT02766192|ketamine
46453|NCT02766192|mindfulness based cognitive therapy
46454|NCT02766192|PTSD
46455|NCT02766192|trauma memory
46456|NCT02766192|memory extinction
46457|NCT02766192|memory re-consolidation
46458|NCT02766192|metabolomics
46459|NCT02766192|TIMBER (Trauma Intervention using Mindfulness Based Extinction and Re-consolidation of trauma memories)
46460|NCT02766127|radiotherapy
46461|NCT02766114|CTS
46462|NCT02766114|Carpal tunnel syndrome
46463|NCT02766114|Carpal tunnel release
46464|NCT02766114|Mini incision of carpal tunnel release
46465|NCT02766114|Cosmetic surgery of carpal tunnel syndrome
46466|NCT02766114|endoscopic carpal tunnel surgery
46467|NCT02766114|Carpal Tunnel Release Through Mini Transverse Approach
46468|NCT02766114|Dr. Sayed Issa's Approach
46469|NCT02766114|CTRMTA
46470|NCT02766114|OCTR
46471|NCT02766114|ECTR
46472|NCT02766114|Open Carpal Tunnel Release
46473|NCT02766114|Endoscopic Carpal Tunnel Release
46474|NCT02766114|Syria
46475|NCT02766114|Cosmetic
46476|NCT02766114|Safety
46477|NCT02766114|Rehabilitation,
46478|NCT02766114|Complications
46479|NCT02766114|Surgery
46480|NCT02766114|Satisfaction
46481|NCT02766088|Dengue
46482|NCT02766088|Household
46483|NCT02766088|Southeast Asia
46484|NCT02766088|Latin America
46485|NCT02766088|Surveillance
46486|NCT02766075|Transcatheter Aortic Valve Disease
46487|NCT02766075|Supervised TAVR Exercise Program
46488|NCT02766062|Postoperative cognitive dysfunction
46489|NCT02766062|metabolic syndrome
46490|NCT02766062|propofol
46491|NCT02766062|sevoflurane
46492|NCT02766049|HIV
46493|NCT02766049|immunotherapy
46494|NCT02766049|clinical trial
46495|NCT02766049|dendritic cell
46496|NCT02766036|Proteinuria
46497|NCT02766036|Propolis
46498|NCT02766023|Vaginitis, MetroGel®, Lactobacillus, CTV-05, LACTIN-V
46499|NCT02765997|AML
46500|NCT02765997|ALL
46501|NCT02765997|MDS
46502|NCT02765984|implantation site
46503|NCT02765984|placental site
46504|NCT02765984|Doppler
46505|NCT02765971|chewing gums
46506|NCT02765971|laxatives
46507|NCT02765971|bowel function
46508|NCT02765945|Exercise
46509|NCT02765945|Osteoporosis
46510|NCT02765945|Cytokines
46511|NCT02765932|Hip
46512|NCT02765932|Knee
46513|NCT02765932|replacement
46514|NCT02765932|surgery
46515|NCT02765919|Carcinoma cervix
46516|NCT02765919|RCT(randomised controlled trial)
46517|NCT02765919|9 Gray
46518|NCT02765919|Brachytherapy
46519|NCT02765906|video
46520|NCT02765906|educational tool
46521|NCT02765906|preeclampsia
46522|NCT02765906|hypertension
46523|NCT02765906|pregnancy
46524|NCT02765906|patient education
46525|NCT02765906|graphic card
46526|NCT02765906|eclampsia
46527|NCT02765906|HELLP
46528|NCT02765906|anxiety
46529|NCT02765906|anxiety assessment
46530|NCT02765906|STAI 6
46531|NCT02765841|HoFH
46532|NCT02765815|TKA
46533|NCT02765815|Knee replacement
46534|NCT02765815|Arthritis
46535|NCT02765815|Knee
46536|NCT02765776|Anti-HIV Drugs
46537|NCT02765776|Raltegravir Potassium
46538|NCT02765776|Aged
46539|NCT02765776|Retrospective Study
46540|NCT02765776|Medical Records
46541|NCT02765750|Emergence agitation
46542|NCT02765711|ticagrelor
46543|NCT02765711|acute coronary syndrome
46544|NCT02765698|Magnetic Resonance Imaging
46545|NCT02765672|Combat Veterans
46546|NCT02765672|Automobile Driving
46547|NCT02765672|Fitness to Drive
46548|NCT02765659|HIV
46549|NCT02765659|Prevention
46550|NCT02765659|Implementation
46551|NCT02765659|Community based participatory research
46552|NCT02765620|Positron-Emission Tomography
46553|NCT02765620|Response Criteria
46554|NCT02765620|solid tumor
46555|NCT02765607|Blood circulation
46556|NCT02765607|Cardiac surgical procedures
46557|NCT02765607|Homeostasis
46558|NCT02765594|Glomerulonephritis, IGA
46559|NCT02765594|Kidney Diseases
46560|NCT02765594|Autoimmune Diseases
46561|NCT02765594|Glomerulonephritis
46562|NCT02765594|Nephritis
46563|NCT02765594|Immune System Diseases
46564|NCT02765594|Urologic Diseases
46565|NCT02765594|Hydroxychloroquine
46566|NCT02765594|Anti-Infective Agents
46567|NCT02765594|Antimalarials
46568|NCT02765594|Antiparasitic Agents
46569|NCT02765594|Antiprotozoal Agents
46570|NCT02765594|Antirheumatic Agents
46571|NCT02765594|Enzyme Inhibitors
46572|NCT02765594|Molecular Mechanisms of Pharmacological Action
46573|NCT02765594|Pharmacologic Actions
46574|NCT02765594|Therapeutic Uses
46575|NCT02765594|interleukin-6
46576|NCT02765594|interferon-alpha
46577|NCT02765594|tumor necrosis factor-alpha
46578|NCT02765581|Acupuncture
46579|NCT02765581|Migraine
46580|NCT02765581|Randomized Controlled Trial
46581|NCT02765581|Placebo Effect
46582|NCT02765568|Coronary Artery Disease
46583|NCT02765568|Percutaneous Coronary Intervention (PCI)
46584|NCT02765542|Depression
46585|NCT02765542|mHealth
46586|NCT02765542|Interactive Voice Response
46587|NCT02765542|Bolivia
46588|NCT02765542|Mental health
46589|NCT02765529|Environmental Pollution
46590|NCT02765529|Fine particles
46591|NCT02765529|Biomarkers
46592|NCT02765529|Elderly
46593|NCT02765490|Hepatitis C, Chronic
46594|NCT02765490|AL-335
46595|NCT02765490|Odalasvir
46596|NCT02765490|Simeprevir
46597|NCT02765490|ODV
46598|NCT02765490|SMV
46599|NCT02765490|ACH-3102
46600|NCT02765490|ACH-0143102
46601|NCT02765490|TMC435
46602|NCT02765477|Acute myocardial infarction
46603|NCT02765477|ST Elevation Myocardial Infarction
46604|NCT02765477|Acute Coronary Occlusion
46605|NCT02765477|Electrocardiogram
46606|NCT02765477|Ventricular Paced Rhythm
46607|NCT02765477|Modified Sgarbossa Criteria
46608|NCT02765451|non-academic
46609|NCT02765451|health institution
46610|NCT02765451|development
46611|NCT02765451|clinical research
46612|NCT02765451|cancer
46613|NCT02765451|private hospital
46614|NCT02765451|public hospital
46615|NCT02765451|northwestern france
46616|NCT02765451|france
46617|NCT02765451|hospitals
46618|NCT02765412|decision support
46619|NCT02765412|patient preferences
46620|NCT02765412|risk adjustment
46621|NCT02765386|Cochlear implants
46622|NCT02765386|Hybrid fittings
46623|NCT02765386|Cross-over frequency
46624|NCT02765373|aromatase inhibitors
46625|NCT02765373|lipid levels
46626|NCT02765360|EIT
46627|NCT02765360|NIV
46628|NCT02765308|Uveitis
46629|NCT02765308|Glaucoma
46630|NCT02765308|Aqueous humor dynamics
46631|NCT02765295|Hydrogen
46632|NCT02765295|Inhalation
46633|NCT02765295|bronchiectasis
46634|NCT02765282|Deep brain stimulation (DBS)
46635|NCT02765282|Kinesia
46636|NCT02765269|cancer pain
46637|NCT02765269|mobile applications
46638|NCT02765243|neuroblastoma
46639|NCT02765243|GD2
46640|NCT02765243|Chimeric antigen receptor
46641|NCT02765243|Immunotherapy
46642|NCT02765243|Cyclophosphamide
46643|NCT02765243|Fludarabine
46644|NCT02765217|Antibiotic associated diarrhea
46645|NCT02765217|Children
46646|NCT02765217|Prevention
46647|NCT02765217|Lactobacillus reuteri DSM 17938
46648|NCT02765217|Probiotic
46649|NCT02765191|Magnetic Resonance Imaging
46650|NCT02765191|Norepinephrine
46651|NCT02765191|Fluid Therapy
46652|NCT02765191|Renal Circulation
46653|NCT02765165|Phase 1
46654|NCT02765165|Phase 2
46655|NCT02765165|Glioblastoma Multiforme
46656|NCT02765165|Glioblastoma
46657|NCT02765165|GBM
46658|NCT02765165|Brain Tumor
46659|NCT02765165|Brain Cancer
46660|NCT02765165|Tumor
46661|NCT02765165|Solid Tumor
46662|NCT02765165|Tumour
46663|NCT02765165|Lomustine
46664|NCT02765165|CCNU
46665|NCT02765165|CXCR4
46666|NCT02765165|Phase 1 Clinical Trial
46667|NCT02765165|Phase 2 Clinical Trial
46668|NCT02765152|exercise
46669|NCT02765152|rhythmic movement
46670|NCT02765152|discrete movement
46671|NCT02765100|Bipolar Disorder
46672|NCT02765100|Obesity
46673|NCT02765100|Depression
46674|NCT02765074|subcutaneous tocilizumab
46675|NCT02765074|High Resolution peripheral QCT (HR-pQCT)
46676|NCT02765074|bone erosion
46677|NCT02765074|bone microarchitecture
46678|NCT02765074|rheumatoid arthritis
46679|NCT02765048|Adolescent girls
46680|NCT02765048|Child welfare
46681|NCT02765048|Trauma treatment
46682|NCT02765048|PTSD
46683|NCT02765048|Depression
46684|NCT02765048|Social problem-solving
46685|NCT02765009|Fluid overload
46686|NCT02765009|Multiple organ failure
46687|NCT02765009|Diuretics
46688|NCT02765009|Fluid restriction
46689|NCT02765009|Body weight
46690|NCT02764983|Combat Veterans
46691|NCT02764983|Automobile Driving
46692|NCT02764983|Fitness to Drive
46693|NCT02764905|Diabetes
46694|NCT02764905|Cognitive-physical rehabilitation
46695|NCT02764905|Self care management
46696|NCT02764879|Omega 3 fatty acids
46697|NCT02764879|Root planning
46698|NCT02764879|chronic periodontitis
46699|NCT02764866|Lung cancer
46700|NCT02764866|Sleep apnea
46701|NCT02764866|Sleep disordered breathing
46702|NCT02764853|HIV
46703|NCT02764853|Black
46704|NCT02764853|African American
46705|NCT02764853|Women
46706|NCT02764853|Cognitive Behavioral Therapy
46707|NCT02764853|Racism
46708|NCT02764853|Stigma
46709|NCT02764853|Discrimination
46710|NCT02764853|Gender related stressors
46711|NCT02764853|Resilience
46712|NCT02764853|Behavioral Medicine
46713|NCT02764827|skin prick test
46714|NCT02764827|grass and weed pollens
46715|NCT02764788|Auriculotherapy
46716|NCT02764762|Drug Therapy
46717|NCT02764749|vascular function
46718|NCT02764749|endothelial function
46719|NCT02764749|polyphenols
46720|NCT02764697|Glaucoma associated with uveitis
46721|NCT02764671|recombinant hepatitis B vaccine
46722|NCT02764671|safety
46723|NCT02764671|immunogenicity
46724|NCT02764645|Cardiopulmonary Bypass
46725|NCT02764619|Upstream therapy, spironolactone
46726|NCT02764619|Atrial remodelling
46727|NCT02764619|Modified look-locker inversion recover (MOLLI) sequences
46728|NCT02764619|T1 mapping
46729|NCT02764619|Diffuse myocardial fibrosis
46730|NCT02764606|Lung Cancer
46731|NCT02764606|Biomarkers
46732|NCT02764606|Bone
46733|NCT02764606|Metastases
46734|NCT02764593|Head and Neck Squamous Cell Carcinoma
46735|NCT02764593|HNSCC
46736|NCT02764593|Nivolumab
46737|NCT02764554|Post-Marketing Surveillance
46738|NCT02764554|Lenvima
46739|NCT02764554|Lenvatinib
46740|NCT02764554|E7080
46741|NCT02764554|Differentiated thyroid carcinoma
46742|NCT02764554|Refractory to radioactive iodine
46743|NCT02764554|Progressive
46744|NCT02764554|locally recurrent
46745|NCT02764554|metastatic
46746|NCT02764541|Breast Cancer
46747|NCT02764541|Invasive Lobular Carcinoma
46748|NCT02764515|Kunxian Capsule
46749|NCT02764515|efficacy
46750|NCT02764515|rheumatoid arthritis
46751|NCT02764515|Methotrexate
46752|NCT02764502|Epidural Identification pressure gauge
46753|NCT02764476|psychogenic
46754|NCT02764476|non-epileptic seizures
46755|NCT02764476|functional neurological symptom disorder
46756|NCT02764476|PNES
46757|NCT02764476|PMD
46758|NCT02764476|virtual reality
46759|NCT02764476|3D augmented reality
46760|NCT02764476|mirror therapy
46761|NCT02764463|Fiber Reinforced Composites
46762|NCT02764463|Resin cements
46763|NCT02764463|Survival
46764|NCT02764450|composite
46765|NCT02764450|restoration
46766|NCT02764450|polymerization
46767|NCT02764424|Newborn
46768|NCT02764424|Heart Rate Variability (HRV)
46769|NCT02764424|Analgesic Nociception Index (ANI)
46770|NCT02764424|Autonomous Nervous System (ANS)
46771|NCT02764411|Capillary malformations
46772|NCT02764411|Onrealtea
46773|NCT02764411|port-wine stain
46774|NCT02764411|treatment
46775|NCT02764411|topical
46776|NCT02764372|Arm rehabilitation
46777|NCT02764372|Serious games
46778|NCT02764372|stroke
46779|NCT02764372|Multiple sclerosis
46780|NCT02764346|Arthritis
46781|NCT02764346|Self-management
46782|NCT02764346|Pain
46783|NCT02764333|TPIV200/huFR-1
46784|NCT02764333|Anti-PD-L1
46785|NCT02764333|vaccine
46786|NCT02764333|16-011
46787|NCT02764294|anxiety
46788|NCT02764294|pain
46789|NCT02764294|satisfaction
46790|NCT02764294|cystoscopy
46791|NCT02764294|distraction methods
46792|NCT02764268|Gastric Cancer
46793|NCT02764268|Pharmacokinetics
46794|NCT02764268|Dose titration
46795|NCT02764242|insect sting allergy
46796|NCT02764242|recombinant venom allergen
46797|NCT02764203|Dark Chocolate
46798|NCT02764203|Blood Pressure
46799|NCT02764203|Wearable Devices
46800|NCT02764203|Digital Health
46801|NCT02764164|TDCS
46802|NCT02764151|GBM
46803|NCT02764151|malignant glioma
46804|NCT02764151|glioma
46805|NCT02764151|anaplastic glioma
46806|NCT02764151|astrocytoma
46807|NCT02764151|IDO
46808|NCT02764151|IDO1
46809|NCT02764151|PF-06840003
46810|NCT02764138|poverty
46811|NCT02764138|discrimination
46812|NCT02764125|Parkinson's Disease
46813|NCT02764125|Wearing-off
46814|NCT02764112|warfarin
46815|NCT02764073|Heart failure
46816|NCT02764073|Bioimpedance
46817|NCT02764073|Lung ultrasonography
46818|NCT02764060|Periodontitis
46819|NCT02764060|Tongue coating
46820|NCT02764060|Tongue cleaning
46821|NCT02764060|Bacterial load
46822|NCT02764047|Non-alcoholic Fatty Liver Disease
46823|NCT02764047|Nonalcoholic Steatohepatitis
46824|NCT02764047|NAFLD
46825|NCT02764047|NASH
46826|NCT02764034|Low level Laser
46827|NCT02764034|Tissue culture
46828|NCT02764034|Endometrial receptivity
46829|NCT02764021|HbA1c
46830|NCT02764021|Diabetes-Releated Complications
46831|NCT02764021|Diet, Low Carbohydrate
46832|NCT02764021|Carbohydrate-Restricted Diet
46833|NCT02764021|Diabetes Mellitus
46834|NCT02764021|Metabolic Disorder
46835|NCT02764021|Glucose Metabolism Disorders
46836|NCT02764021|Endocrine System Diseases
46837|NCT02764008|Postoperative Analgesia
46838|NCT02764008|Peritubal infiltration
46839|NCT02764008|Ultrasound guided low thoracic paravertebral block
46840|NCT02764008|Percutaneous Nephrolithotomy pain
46841|NCT02763995|HIV
46842|NCT02763995|pharmaceutical care
46843|NCT02763995|older patients
46844|NCT02763995|cardiovascular risk
46845|NCT02763995|pharmacotherapy follow up
46846|NCT02763982|left ventricular ejection fraction
46847|NCT02763982|peak oxygen uptake
46848|NCT02763982|respiratory muscles
46849|NCT02763982|quality of life
46850|NCT02763956|Gelstix, Hydrogel
46851|NCT02763930|Cardiovascular disease
46852|NCT02763930|Blood pressure
46853|NCT02763930|Hypertension
46854|NCT02763930|Dairy products
46855|NCT02763930|Milk
46856|NCT02763930|Cheese
46857|NCT02763891|Balance
46858|NCT02763891|Mobility
46859|NCT02763891|Trunk control
46860|NCT02763878|Uncut Roux-en-Y
46861|NCT02763878|Billroth II anastomosis
46862|NCT02763878|Distal gastric cancer
46863|NCT02763878|Nutrition status
46864|NCT02763878|Postoperative complications
46865|NCT02763852|Parkinson's Disease
46866|NCT02763852|Nebicapone
46867|NCT02763839|Parkinson's disease
46868|NCT02763839|Nebicapone
46869|NCT02763826|Transcranial Direct Current Stimulation
46870|NCT02763826|tDCS
46871|NCT02763800|Parkinson's disease
46872|NCT02763800|Nebicapone
46873|NCT02763774|coronary artery bypass
46874|NCT02763774|sistemic inflammatory response syndrome
46875|NCT02763774|left ventricular dysfunction
46876|NCT02763774|postoperative complications
46877|NCT02763774|physical fitness
46878|NCT02763735|Pulmonary arterial hypertension
46879|NCT02763735|Right ventricle
46880|NCT02763735|Right ventricular function
46881|NCT02763735|Metabolism
46882|NCT02763735|Non-invasive imaging
46883|NCT02763735|Healthy Subjects
46884|NCT02763722|atopic dermatitis
46885|NCT02763722|allergic contact dermatitis
46886|NCT02763722|cosmetics
46887|NCT02763722|transepidermal water loos
46888|NCT02763696|Metagenomics
46889|NCT02763696|Vaginal microflora
46890|NCT02763696|High-throughput sequencing
46891|NCT02763683|Parkinsons Disease
46892|NCT02763683|PET Imaging
46893|NCT02763683|PIB
46894|NCT02763683|VAT
46895|NCT02763683|Dementia
46896|NCT02763670|Heart failure
46897|NCT02763670|patient education as topic
46898|NCT02763670|patient care management
46899|NCT02763657|fMRI
46900|NCT02763657|reasoning
46901|NCT02763657|development
46902|NCT02763644|transplant associated microangiopathy
46903|NCT02763618|Neurofeedback
46904|NCT02763618|theta/beta ratio
46905|NCT02763618|multiple baseline
46906|NCT02763605|Acanthamoeba Keratitis
46907|NCT02763605|in vivo confocal microscopic
46908|NCT02763592|Localized Neuropathic pain
46909|NCT02763592|5% lidocaine medicated plaster
46910|NCT02763592|Knee surgery
46911|NCT02763566|Hormone Receptor-Positive
46912|NCT02763566|HER2-Negative
46913|NCT02763566|CDK4
46914|NCT02763566|CDK6
46915|NCT02763553|Ketone Bodies
46916|NCT02763553|Enteral Nutrition
46917|NCT02763553|Ketogenic Diet
46918|NCT02763540|ILD
46919|NCT02763540|Pathology
46920|NCT02763540|diagnosis
46921|NCT02763540|lung biopsy
46922|NCT02763527|smoking cessation
46923|NCT02763501|bariatric surgery
46924|NCT02763501|gastric bypass
46925|NCT02763501|intestinal obstruction
46926|NCT02763501|postoperative complication
46927|NCT02763501|methods
46928|NCT02763501|laparoscopy
46929|NCT02763488|blood flow restriction training
46930|NCT02763488|occlusion training
46931|NCT02763488|total knee arthroplasty
46932|NCT02763488|post-operative rehabilitation
46933|NCT02763475|Killer Cells, Natural
46934|NCT02763475|Consolidation treatment
46935|NCT02763475|cytologic remission
46936|NCT02763475|Haploidentical NK Cells
46937|NCT02763475|allogeneic
46938|NCT02763475|IL-2 Expanded NK Cells
46939|NCT02763462|Acute Febrile Illness
46940|NCT02763436|term infant, neonatal transition, cord clamping, NIRS, arterial oxygen saturation, regional cerebral oxygen saturation, cerebral blood volume
46941|NCT02763423|umbilical cord stem cell
46942|NCT02763423|diabetic ketoacidosis
46943|NCT02763371|high GI lunch
46944|NCT02763371|low GI lunch
46945|NCT02763358|obesity
46946|NCT02763358|weight loss
46947|NCT02763332|Fibromyalgia
46948|NCT02763332|Efficacy
46949|NCT02763332|Taping
46950|NCT02763319|Diffuse Large B-cell Lymphoma
46951|NCT02763319|bendamustine
46952|NCT02763319|rituximab
46953|NCT02763319|combination therapy
46954|NCT02763319|CD19 monoclonal antibody
46955|NCT02763319|transplant ineligible
46956|NCT02763293|pain
46957|NCT02763293|effectiveness
46958|NCT02763293|manual therapy
46959|NCT02763267|Insulin sensitivity
46960|NCT02763267|Insulin secretion
46961|NCT02763267|Pregnancy
46962|NCT02763267|Placental proteins
46963|NCT02763254|Epstein-Barr Virus (EBV)
46964|NCT02763241|rhinitis
46965|NCT02763228|Physical Activity
46966|NCT02763228|Breast Cancer
46967|NCT02763228|minority
46968|NCT02763228|African American
46969|NCT02763202|transition of care
46970|NCT02763202|pragmatic clinical trial
46971|NCT02763202|telemedicine
46972|NCT02763202|emergency medical technician
46973|NCT02763189|Mentoring
46974|NCT02763189|Endotracheal Tube Exchange
46975|NCT02763189|Training
46976|NCT02763176|hCG testing, multi-level pregnancy test
46977|NCT02763150|Gestational Diabetes Prevention
46978|NCT02763124|Pseudophakic
46979|NCT02763111|ankylosing spondylitis
46980|NCT02763111|interleukin 17
46981|NCT02763111|monoclonal antibody
46982|NCT02763098|cardiovascular responses
46983|NCT02763098|analgesics opioid
46984|NCT02763098|remifentanil
46985|NCT02763046|Ankylosing Spondylitis
46986|NCT02763046|NSAID
46987|NCT02763046|ASAS
46988|NCT02763046|Secukinumab
46989|NCT02763046|Subcutaneous
46990|NCT02763020|high glycemic index, polyphenols, blood glucose, satiety
46991|NCT02762994|interleukin 17
46992|NCT02762994|monoclonal antibody
46993|NCT02762994|psoriasis
46994|NCT02762981|CORT125134
46995|NCT02762981|nabpaclitaxel
46996|NCT02762981|Triple-Negative Breast Cancer
46997|NCT02762981|Ovarian Epithelial Cancer
46998|NCT02762981|GR Antagonist
46999|NCT02762981|Glucocorticoid Receptor Antagonist
47000|NCT02762955|adalimumab
47001|NCT02762955|biosimilar
47002|NCT02762955|BCD-057
47003|NCT02762955|psoriasis
47004|NCT02762955|tumor necrosis factor
47005|NCT02762955|monoclonal antibody
47006|NCT02762942|cervical ripening
47007|NCT02762942|misoprostol
47008|NCT02762942|supracervical balloon
47009|NCT02762942|Foley catheter
47010|NCT02762929|Analgesia
47011|NCT02762929|Bunionectomy
47012|NCT02762903|Shoulder arthroplasty
47013|NCT02762903|Lesser Tuberosity Osteotomy
47014|NCT02762903|Subscapularis tenotomy
47015|NCT02762864|aspirin
47016|NCT02762864|ticagrelor
47017|NCT02762864|clopidogrel
47018|NCT02762851|Influenza
47019|NCT02762851|Vaccine
47020|NCT02762851|Heart failure
47021|NCT02762851|Vascular
47022|NCT02762799|neutrophil count
47023|NCT02762799|filgrastim
47024|NCT02762799|granulocyte colony-stimulating factor
47025|NCT02762747|Hernia, Inguinal
47026|NCT02762747|Extraperitoneal Hernioplasty
47027|NCT02762747|Drain
47028|NCT02762747|Mesh Repair
47029|NCT02762747|Laparoscopic
47030|NCT02762734|adolescent
47031|NCT02762734|suicide
47032|NCT02762721|FGFR2 fusion
47033|NCT02762721|iCCA
47034|NCT02762721|mixed HCC-CCA
47035|NCT02762721|Intrahepatic Cholangiocarcinoma
47036|NCT02762721|Mixed Hepatocellular Cholangiocarcinoma
47037|NCT02762721|Cholangiocarcinoma
47038|NCT02762721|ArQule
47039|NCT02762708|Bariatric Surgery
47040|NCT02762708|Weight loss
47041|NCT02762695|Hypertension
47042|NCT02762695|Diabetes Mellitus, Type 2
47043|NCT02762695|Case Management
47044|NCT02762669|Uterine contraction
47045|NCT02762669|Oxytocin desensitization
47046|NCT02762643|DP-R213
47047|NCT02762617|Healthy Volunteers
47048|NCT02762617|Women's Health
47049|NCT02762552|Stroke
47050|NCT02762552|Etiology
47051|NCT02762552|Recurrence
47052|NCT02762552|Transcranial holter
47053|NCT02762552|Microembolic signals
47054|NCT02762526|lipectomy
47055|NCT02762526|abdominoplasty
47056|NCT02762526|plethysmography optoelectronics
47057|NCT02762526|diaphragmatic mobility
47058|NCT02762526|lung function
47059|NCT02762526|respiratory muscles
47060|NCT02762474|nab-paclitaxel
47061|NCT02762474|IMRT
47062|NCT02762474|esophageal cancer
47063|NCT02762461|Fertilization in Vitro
47064|NCT02762461|Sperm Injections, Intracytoplasmic
47065|NCT02762461|Endometriosis
47066|NCT02762422|endothelial function
47067|NCT02762422|iron stores
47068|NCT02762422|red blood cell
47069|NCT02762422|blood donation
47070|NCT02762409|critical care
47071|NCT02762409|reduction of depression syndrome
47072|NCT02762409|anxiety
47073|NCT02762409|quality of life
47074|NCT02762409|post traumatic stress
47075|NCT02762409|discomforts
47076|NCT02762396|Young ischemic stroke
47077|NCT02762396|Risk factors
47078|NCT02762396|Causes
47079|NCT02762396|Consequences
47080|NCT02762370|Osteoarthritis
47081|NCT02762370|Knee
47082|NCT02762370|Pain
47083|NCT02762370|Diabetes
47084|NCT02762370|Intra-articular
47085|NCT02762370|Injection
47086|NCT02762357|Novosyn Quick
47087|NCT02762357|Episiotomy
47088|NCT02762331|Vitamin C
47089|NCT02762331|Coronary Artery Bypass Grafting
47090|NCT02762331|Atrial Fibrillation
47091|NCT02762331|Cardiac Valve Repair
47092|NCT02762305|fall risk
47093|NCT02762305|RSVP bone builders
47094|NCT02762305|Group Exercise
47095|NCT02762305|Older adults
47096|NCT02762305|Balance confidence
47097|NCT02762305|life satisfaction
47098|NCT02762305|balance
47099|NCT02762292|Mechanical ventilation
47100|NCT02762292|Children
47101|NCT02762292|Work of breathing
47102|NCT02762279|Mechanical ventilation
47103|NCT02762279|Children
47104|NCT02762279|Esophageal Pressure
47105|NCT02762279|Pleural Pressure
47106|NCT02762240|Accreditation
47107|NCT02762240|Certification
47108|NCT02762240|General Practice
47109|NCT02762240|Family Medicine
47110|NCT02762240|Randomized Controlled Trial
47111|NCT02762227|CEUS
47112|NCT02762227|CT
47113|NCT02762227|gallbladder cholesterol polyps
47114|NCT02762227|adenoma
47115|NCT02762227|gallbladder cancer
47116|NCT02762214|Uterin manipulator
47117|NCT02762214|Endometrial Cancer
47118|NCT02762214|Laparoscopy
47119|NCT02762214|Robotic
47120|NCT02762188|wet ARMD
47121|NCT02762188|VEGF
47122|NCT02762188|intra vitreal injections
47123|NCT02762175|maxillomandibular advancement
47124|NCT02762175|obstructive sleep apnea
47125|NCT02762175|apnea-hypopnea index
47126|NCT02762175|quality of life
47127|NCT02762162|antiplatelet
47128|NCT02762162|stent thrombosis
47129|NCT02762149|Tsui Test
47130|NCT02762149|Labour
47131|NCT02762149|Epidural catheter
47132|NCT02762097|polyps
47133|NCT02762097|saline sonography
47134|NCT02762097|infertility
47135|NCT02762084|Gorlin Syndrome
47136|NCT02762084|Basal Cell
47137|NCT02762084|Nevus Syndrome
47138|NCT02762084|BCNS
47139|NCT02762084|nevoid basal cell carcinoma syndrome
47140|NCT02762084|Basal cell carcinoma
47141|NCT02762084|Hedgehog
47142|NCT02762084|Surgically Eligible Basal Cell Carcinomas
47143|NCT02762058|Acquired Brain Injury
47144|NCT02762058|Stroke Rehabilitation
47145|NCT02762045|Therapeutic Vaccine HIV Adenovirus type 5 vector
47146|NCT02762032|Skin Biopsy
47147|NCT02762032|PrimaVie
47148|NCT02762032|Herbal Supplement
47149|NCT02762019|Stomatitis
47150|NCT02762019|Laser
47151|NCT02762019|Children
47152|NCT02762019|Chemotherapy
47153|NCT02762019|Treatment
47154|NCT02762006|durvalumab
47155|NCT02762006|tremelimumab
47156|NCT02762006|Phase Ib
47157|NCT02762006|Locally Advanced
47158|NCT02761980|ibuprofen; acetaminophen; induced fever; fever
47159|NCT02761967|Physical activity
47160|NCT02761967|Pregnancy
47161|NCT02761967|Childbirth
47162|NCT02761967|Postpartum period
47163|NCT02761967|Exercise
47164|NCT02761954|regional anesthesia
47165|NCT02761954|caudal block
47166|NCT02761928|Facet Joint
47167|NCT02761928|Sacroiliac Joint
47168|NCT02761928|Myofascial Trigger Point Pain
47169|NCT02761928|Injectables
47170|NCT02761915|Neuroblastoma
47171|NCT02761915|Immunotherapy
47172|NCT02761915|1RG-CART
47173|NCT02761915|Cyclophosphamide
47174|NCT02761915|Fludarabine
47175|NCT02761915|CAR T-cells
47176|NCT02761915|Anti-GD2
47177|NCT02761915|GD2
47178|NCT02761915|CAR
47179|NCT02761915|Chimeric Antigen Receptor
47180|NCT02761902|Children
47181|NCT02761902|Polysomnography
47182|NCT02761902|sleep
47183|NCT02761902|obstructive sleep apnea;
47184|NCT02761902|Chinese
47185|NCT02761863|Mesothelioma
47186|NCT02761863|CD 74
47187|NCT02761863|VEGF
47188|NCT02761824|Quality of Life
47189|NCT02761824|Occupation
47190|NCT02761772|Preimplantation Factor
47191|NCT02760693|bipolar disorder, naturalistic cohort study,
47192|NCT02760693|defined catchment area,long term treatment
47193|NCT02760680|Chronic Heart Failure
47194|NCT02760680|Sleep-Disordered Breathing
47195|NCT02760680|Peripheral Arterial Tone
47196|NCT02760667|Oropharyngeal cancer
47197|NCT02760667|Laryngeal cancer
47198|NCT02760641|obesity
47199|NCT02760641|low carbohydrate diet
47200|NCT02760641|metabolism
47201|NCT02760641|body composition
47202|NCT02760641|visceral fat
47203|NCT02760641|older adults
47204|NCT02760641|insulin sensitivity
47205|NCT02760615|Drug therapy
47206|NCT02760602|anti-amyloid
47207|NCT02760602|monoclonal antibody
47208|NCT02760589|ACL tear
47209|NCT02760589|ACL lesion
47210|NCT02760589|ACL reconstruction
47211|NCT02760589|InternalBrace
47212|NCT02760589|functional performance test
47213|NCT02760589|anterior cruciate ligament
47214|NCT02761746|HIV
47215|NCT02761746|Adherence
47216|NCT02761746|Health Outcomes
47217|NCT02761733|Shared Decision Making
47218|NCT02761733|Case Management
47219|NCT02761733|Decision Aid
47220|NCT02761694|AKT1
47221|NCT02761694|AKT2
47222|NCT02761694|AKT3
47223|NCT02761694|PI3K
47224|NCT02761694|PTEN-null
47225|NCT02761694|solid tumors
47226|NCT02761694|cancer
47227|NCT02761694|ARQ 751
47228|NCT02761694|ArQule
47229|NCT02761681|Acceptance and Commitment Therapy
47230|NCT02761681|Mindfulness
47231|NCT02761681|Guided self-help
47232|NCT02761681|College students
47233|NCT02761681|Focused Interviews
47234|NCT02761681|RCT Control Condition
47235|NCT02761681|RCT ACT-CL Condition
47236|NCT02761668|Pathological tooth migration
47237|NCT02761668|periodontal regenerative surgery
47238|NCT02761668|vertical infrabony defects
47239|NCT02761668|xenogeneic bone graft
47240|NCT02761668|orthodontic therapy
47241|NCT02761655|Dementia
47242|NCT02761655|Medication Adherence
47243|NCT02761655|Perspective Memory
47244|NCT02761590|intermuscular fat
47245|NCT02761590|circuit training
47246|NCT02761590|adipokines
47247|NCT02761590|inflammation
47248|NCT02761590|computed tomography scan
47249|NCT02761577|Acetylcysteine
47250|NCT02761577|Sodium Bicarbonate
47251|NCT02761577|Lipocalins
47252|NCT02761577|Creatinine
47253|NCT02761577|Blood Urea Nitrogen
47254|NCT02761564|Cardiac surgery
47255|NCT02761564|Blood transfusion
47256|NCT02761564|ScvO2
47257|NCT02761538|obesity
47258|NCT02761538|Overweight
47259|NCT02761538|ICTs
47260|NCT02761538|Cost-effectiveness
47261|NCT02761525|silver nanoparticles antimicrobial activity
47262|NCT02761486|aspirin
47263|NCT02761486|gut microbiome
47264|NCT02761486|inflammation
47265|NCT02761486|placebo
47266|NCT02761486|circulating biomarker
47267|NCT02761447|Motor control Laterality
47268|NCT02761447|Pain Perception
47269|NCT02761447|Lower Extremity
47270|NCT02761447|Complementary Therapies
47271|NCT02761447|Physical Therapy Modalities
47272|NCT02761434|copeptin
47273|NCT02761434|vasopressin
47274|NCT02761434|dehydration
47275|NCT02761434|insulin resistance
47276|NCT02761434|Diabetes
47277|NCT02761434|Glucose regulation
47278|NCT02761421|IOPD
47279|NCT02761408|Head and neck cancer
47280|NCT02761408|Asian
47281|NCT02761408|ALDH2
47282|NCT02761369|food addiction
47283|NCT02761369|obesity
47284|NCT02761369|deep TMS
47285|NCT02761369|PAS
47286|NCT02761369|Food Stroop
47287|NCT02761369|brain laterality
47288|NCT02761369|EEG
47289|NCT02761369|INP
47290|NCT02761343|cardiac arrhythmia
47291|NCT02761343|cardiac ablation
47292|NCT02761343|congenital cardiac disease
47293|NCT02761343|cardiac ablation lesions under Magnetic Resonance imaging
47294|NCT02761330|Anesthesia
47295|NCT02761330|Electroconvulsive therapy
47296|NCT02761330|Delirium
47297|NCT02761330|Electroencephalography
47298|NCT02761330|Seizures
47299|NCT02761330|Depression
47300|NCT02761330|Ketamine
47301|NCT02761330|Etomidate
47302|NCT02761330|Physiological Effects of Drugs
47303|NCT02761330|Pharmacologic Actions
47304|NCT02761330|Confusion
47305|NCT02761330|Mental Disorders
47306|NCT02761330|Neurobehavioral Manifestations
47307|NCT02761330|Signs and Symptoms
47308|NCT02761330|Neurologic Manifestations
47309|NCT02761330|Cognitive Disorders
47310|NCT02761317|bowel preparation
47311|NCT02761317|bisacodyl
47312|NCT02761317|polyethyleneglycol
47313|NCT02761317|colorectal surgery
47314|NCT02761291|Nasopharyngeal carcinoma
47315|NCT02761291|EB virus
47316|NCT02761291|metastasis
47317|NCT02761291|recurrence
47318|NCT02761291|cytolytic viral activation therapy
47319|NCT02761291|gemcitabine
47320|NCT02761291|valproic acid
47321|NCT02761291|ganciclovir
47322|NCT02761291|valganciclovir
47323|NCT02761265|Degenerative Adult Scoliosis
47324|NCT02761265|Gait Analysis
47325|NCT02761265|Balance Analysis
47326|NCT02761265|Biomechanics
47327|NCT02761265|Neuromuscular Control
47328|NCT02761265|Thoracolumbar Deformity
47329|NCT02761252|Bilastine
47330|NCT02761252|Montelukast
47331|NCT02761252|total symptom score
47332|NCT02761252|AQLQ
47333|NCT02761239|cricopharyngeal muscle
47334|NCT02761239|innervation by EBSLN
47335|NCT02761239|A prospective case-controlled study
47336|NCT02761226|platform switching
47337|NCT02761226|dental implant
47338|NCT02761226|crestal bone level
47339|NCT02761226|implant stability
47340|NCT02761226|postoperative complication
47341|NCT02761187|Drug Therapy
47342|NCT02761174|Vascular lesions
47343|NCT02761174|inflammation
47344|NCT02761174|IPL
47345|NCT02761161|PTSD
47346|NCT02761161|Sleep
47347|NCT02761161|Refugee
47348|NCT02761161|IRT
47349|NCT02761161|Mianserin
47350|NCT02761148|white matter hyperintensity
47351|NCT02761148|brain network
47352|NCT02761148|MRI
47353|NCT02761148|cognition
47354|NCT02761148|emotion
47355|NCT02761135|Biopsy technique
47356|NCT02761135|Transrectal ultrasonography probe
47357|NCT02761135|Side-fire
47358|NCT02761135|Prostate cancer
47359|NCT02761135|End-fire
47360|NCT02761083|Eye surgery
47361|NCT02761083|Suture material
47362|NCT02761083|Novosyn Quick
47363|NCT02761083|Vicryl Rapid
47364|NCT02761070|glioblastoma
47365|NCT02761070|recurrent
47366|NCT02761070|dose-dense temozolomide
47367|NCT02761070|bevacizumab
47368|NCT02761031|Heart rate variability
47369|NCT02761031|Electrocardiography
47370|NCT02761031|Observational study
47371|NCT02761031|Non-interventional study
47372|NCT02761031|Risk assessment
47373|NCT02761031|Perioperative
47374|NCT02761005|Eradication therapy
47375|NCT02761005|Mutation of 23S rRNA of H. pylori
47376|NCT02761005|Personalized therapy
47377|NCT02760979|knee arthroplasty
47378|NCT02760940|Inflammatory bowel diseases
47379|NCT02760940|Anemia
47380|NCT02760940|Crohn's disease
47381|NCT02760940|Ulcerative colitis
47382|NCT02760940|Oral iron
47383|NCT02760940|Quality of life
47384|NCT02760914|adipose tissue
47385|NCT02760914|inflammatory mediators
47386|NCT02760914|gene expression
47387|NCT02760875|Achilles Tendon Rupture
47388|NCT02760875|Conservative treatment
47389|NCT02760875|early weight bearing
47390|NCT02760875|Achilles Tendon Length
47391|NCT02760875|Ultrasound
47392|NCT02760875|Foot Pressure Mapping
47393|NCT02760875|ATRA
47394|NCT02760875|Heel Raise Work
47395|NCT02760849|Hereditary Breast and Ovarian Cancer Syndrome
47396|NCT02760849|HBOC
47397|NCT02760849|Deleterious mutation in ovarian cancer genes
47398|NCT02760849|Changes in female sexual function
47399|NCT02760849|Salpingectomy with delayed oophorectomy
47400|NCT02760849|ISDO
47401|NCT02760849|Risk-reducing salpingo-oophorectomy (RRSO)
47402|NCT02760849|RRSO
47403|NCT02760849|Questionnaires
47404|NCT02760849|Surveys
47405|NCT02760836|Crohn's disease
47406|NCT02760836|disease outcomes
47407|NCT02760784|Achilles Tendon Rupture
47408|NCT02760784|Conservative treatment
47409|NCT02760784|early weight bearing
47410|NCT02760784|Dynamic
47411|NCT02760784|ATRS
47412|NCT02760784|ATRA
47413|NCT02760784|Heel Raise Work
47414|NCT02760771|THV (trans-catheter heart valve)
47415|NCT02760771|severe aortic stenosis
47416|NCT02760771|pre-dilation
47417|NCT02760771|rapid pacing
47418|NCT02760771|BAV (balloon artery valvuloplasty
47419|NCT02760758|non-nucleoside inhibitor
47420|NCT02760758|NNI
47421|NCT02760758|HCV
47422|NCT02760758|DAA
47423|NCT02760745|fever
47424|NCT02760745|shivering
47425|NCT02760745|chills
47426|NCT02760745|rigors
47427|NCT02760745|severe bacterial infection
47428|NCT02760719|3% hypertonic solution
47429|NCT02760719|duration of hospitalisation
47430|NCT02760537|Liver Neoplasms
47431|NCT02760537|Hepatitis B
47432|NCT02760537|Hepatitis B vaccination
47433|NCT02760537|Asian Americans
47434|NCT02760537|Lay health workers
47435|NCT02760537|Community health workers
47436|NCT02760511|Randomized Controlled Trial
47437|NCT02760511|Anthocyanin
47438|NCT02760511|Antioxidants
47439|NCT02760485|Diffuse large B-cell lymphoma
47440|NCT02760485|Relapsed Diffuse large B-cell lymphoma
47441|NCT02760485|Refractory Diffuse large B-cell lymphoma
47442|NCT02760485|activated B cell
47443|NCT02760485|germinal center B-cell
47444|NCT02760485|non-Hodgkin lymphoma
47445|NCT02760485|JAK1 inhibitor
47446|NCT02760485|Bruton's tyrosine kinase (BTK) inhibitor
47447|NCT02760472|Retinopathy of Prematurity
47448|NCT02760472|Preterm
47449|NCT02760472|Fatty acids
47450|NCT02760433|moderate Rheumatoid Arthritis
47451|NCT02760433|severe Rheumatoid Arthritis
47452|NCT02760433|Olokizumab
47453|NCT02760407|moderate Rheumatoid Arthritis
47454|NCT02760407|severe Rheumatoid Arthritis
47455|NCT02760407|subcutaneous
47456|NCT02760407|Olokizumab
47457|NCT02760394|chronic ischemic heart disease
47458|NCT02760394|coronary bypass
47459|NCT02760394|refractory stable angina
47460|NCT02760394|HBOT
47461|NCT02760394|reperfusion
47462|NCT02760394|neoangiogenesis
47463|NCT02760394|microvascular
47464|NCT02760394|myocardial perfusion
47465|NCT02760368|moderate Rheumatoid Arthritis
47466|NCT02760368|severe Rheumatoid Arthritis
47467|NCT02760368|subcutaneous
47468|NCT02760368|Olokizumab
47469|NCT02760342|Pharmacokinetics
47470|NCT02760342|Metformin
47471|NCT02760342|Drug-drug interaction
47472|NCT02760342|ASP015K
47473|NCT02760329|asthma
47474|NCT02760329|COPD
47475|NCT02760329|chronic obstructive pulmonary disease
47476|NCT02760329|lung disease
47477|NCT02760329|chronic airways disease
47478|NCT02760329|obstructive lung disease
47479|NCT02760316|Healthy Volunteers
47480|NCT02760316|Obese
47481|NCT02760316|Insulin Resistant Subjects
47482|NCT02760316|Rheumatoid Arthritis
47483|NCT02760303|insulin dependent diabetes mellitus
47484|NCT02760303|adolescents and young adults
47485|NCT02760303|stress reduction
47486|NCT02760303|metabolic control
47487|NCT02760290|Forced Expiratory Volume in 1 second
47488|NCT02760290|Forced expiratory vital capacity
47489|NCT02760290|Peak expiratory flow
47490|NCT02760277|Duchenne muscular dystrophy
47491|NCT02760277|vamorolone
47492|NCT02760264|Duchenne Muscular Dystrophy
47493|NCT02760264|vamorolone
47494|NCT02760251|immunomodulation
47495|NCT02760238|myeloproliferative neoplasm
47496|NCT02760238|myelodysplastic syndrome
47497|NCT02760238|registry
47498|NCT02760238|leukemia
47499|NCT02760238|Bone Marrow Diseases
47500|NCT02760238|Hematologic Diseases
47501|NCT02760238|Neoplasms
47502|NCT02760225|Pembrolizumab
47503|NCT02760225|PET imaging
47504|NCT02760225|Melanoma
47505|NCT02760225|Non-small cell lung cancer
47506|NCT02760212|Shockwave therapy
47507|NCT02760212|fMRI
47508|NCT02760212|blood biomarkers
47509|NCT02760173|verticality perception
47510|NCT02760147|Pressure Support Ventilation
47511|NCT02760134|Super-Mini Percutaneous Nephrolithotomy(SMP)
47512|NCT02760134|Renal Pelvic Pressure
47513|NCT02760121|Acetazolamide
47514|NCT02760121|Methazolamide
47515|NCT02760121|Control of breathing
47516|NCT02760121|Hypoxic pulmonary vasoconstriction
47517|NCT02760108|Early onset Parkinson's disease
47518|NCT02760108|Familial Parkinson's disease
47519|NCT02760108|Parkinson's disease
47520|NCT02760108|Genetics
47521|NCT02760095|environmental enteric dysfunction
47522|NCT02760095|environmental enteropathy
47523|NCT02760095|zinc
47524|NCT02760095|vitamin A
47525|NCT02760095|Bangladesh
47526|NCT02760082|Multiple Sclerosis
47527|NCT02760082|Qualitative study
47528|NCT02760082|Motivation
47529|NCT02760056|Thyroid hormone
47530|NCT02760056|Remyelination
47531|NCT02760004|Depression
47532|NCT02759991|Hepatitis E virus
47533|NCT02759991|Viral Hepatitis Vaccines
47534|NCT02759978|Imaging
47535|NCT02759978|Computed Tomography
47536|NCT02759978|Magnetic Resonance Imaging
47537|NCT02759978|Positron Emission Tomography
47538|NCT02759978|Leukocyte Scintigraphy
47539|NCT02759978|Microbiological diagnostics
47540|NCT02759978|Sonication
47541|NCT02759978|Drug Monitoring
47542|NCT02759978|Cardiac Surgery
47543|NCT02759952|retinitis pigmentosa
47544|NCT02759952|PDE6A
47545|NCT02759952|gene therapy trial
47546|NCT02759939|Shared Decision-Making
47547|NCT02759939|Patient-Provider Communication
47548|NCT02759926|Healthy volunteers
47549|NCT02759926|Obesity
47550|NCT02759926|Bitter
47551|NCT02759913|neuromuscular diseases
47552|NCT02759848|COPD, tuberculosis, mortality
47553|NCT02759835|EGFR Tyrosine Kinase Inhibitors
47554|NCT02759835|T790M Mutation
47555|NCT02759835|Local Ablative Therapies
47556|NCT02759835|Oligoprogressive Disease
47557|NCT02759835|Acquired Resistance
47558|NCT02759822|Haploidentical Hematopoietic Stem Cell Transplantation
47559|NCT02759822|Partially Matched Hematopoietic Stem Cell Transplantation
47560|NCT02759822|Post-transplant Cyclophosphamide
47561|NCT02759822|Hematopoietic Stem Cell Transplantation
47562|NCT02759783|Radiotherapy
47563|NCT02759783|oligometastases
47564|NCT02759783|SBRT
47565|NCT02759757|Kinesio Taping
47566|NCT02759757|Low back Pain
47567|NCT02759757|Electromyographic
47568|NCT02759757|EMG
47569|NCT02759744|Thermal Ablation
47570|NCT02759744|Localized Prostate Cancer
47571|NCT02759744|Medtronic-Visualase
47572|NCT02759744|Thermal Damage
47573|NCT02759744|PSA Levels
47574|NCT02759731|Murine Models
47575|NCT02759731|Rheumatoid Arthritis
47576|NCT02759731|Corticosteroids
47577|NCT02759731|Systemic Therapy
47578|NCT02759731|Inflammatory Cytokines
47579|NCT02759718|pancreatic neuroendocrine tumor
47580|NCT02759718|chromogranin A
47581|NCT02759705|fertility
47582|NCT02759705|sexuality
47583|NCT02759705|male
47584|NCT02759705|exstrophy-epispadias complex
47585|NCT02759705|bladder exstrophy
47586|NCT02759705|epispadias
47587|NCT02759666|PARP
47588|NCT02759666|advanced solid tumor
47589|NCT02759640|c-Met kinase inhibitor
47590|NCT02759640|Advanced solid tumors
47591|NCT02759627|Rehabilitation
47592|NCT02759627|Gait
47593|NCT02759627|Ambulation
47594|NCT02759627|Exercise Therapy
47595|NCT02759627|Physical Exertion
47596|NCT02759627|Motor Skills
47597|NCT02759601|HDAC Inhibitor
47598|NCT02759601|Tefinostat
47599|NCT02759601|Inflammation
47600|NCT02759601|Hepatocellular Carcinoma
47601|NCT02759601|Cancer associated Inflammation in Hepatocellular Carcinoma
47602|NCT02759588|GL-ONC1
47603|NCT02759588|oncolytic virus
47604|NCT02759588|virotherapy
47605|NCT02759588|Viral therapy
47606|NCT02759588|immunotherapy
47607|NCT02759588|immune therapy
47608|NCT02759588|vaccinia
47609|NCT02759588|vaccinia virus
47610|NCT02759588|Genelux
47611|NCT02759588|ovarian cancer
47612|NCT02759588|platinum resistant
47613|NCT02759588|platinum refractory
47614|NCT02759588|peritoneal carcinomatosis
47615|NCT02759588|fallopian cancer
47616|NCT02759588|cancer
47617|NCT02759588|abdominal cancer
47618|NCT02759588|imaging
47619|NCT02759588|carcinoma
47620|NCT02759588|DNA virus
47621|NCT02759588|neoplasms
47622|NCT02759588|neoplasms by histological type
47623|NCT02759588|neoplasms, Glandular and Epithelial
47624|NCT02759588|Poxviridae infections
47625|NCT02759588|Virus diseases
47626|NCT02759588|recurrent ovarian cancer
47627|NCT02759588|intermediate platinum-sensitive
47628|NCT02759549|Radiation Therapy
47629|NCT02759523|Magnetic Resonance Imaging
47630|NCT02759523|Portion Size
47631|NCT02759523|Energy Intake
47632|NCT02759510|cardiac output
47633|NCT02759510|norepinephrin
47634|NCT02759510|cesarean section
47635|NCT02759484|CHWs
47636|NCT02759484|Health Education
47637|NCT02759484|Disease Self Management
47638|NCT02759445|alcohol induced cardiomyopathy
47639|NCT02759445|myocardial deformation imaging
47640|NCT02759432|high-intensity interval training
47641|NCT02759432|adolescents
47642|NCT02759432|physical fitness
47643|NCT02759432|quality of life
47644|NCT02759432|school-based intervention
47645|NCT02759367|Nutrition
47646|NCT02759367|Potassium
47647|NCT02759354|Immune response
47648|NCT02759328|Stroke
47649|NCT02759328|Rehabilitation
47650|NCT02759328|Serious games
47651|NCT02759328|Virtual reality
47652|NCT02759328|Xbox Kinect™
47653|NCT02759302|MRI
47654|NCT02759302|LGMD
47655|NCT02759302|POMT2
47656|NCT02759289|Arsenic
47657|NCT02759276|Nailfold Videocapillaroscopy
47658|NCT02759276|Venous Occlusion Plethysmography
47659|NCT02759276|Endothelial Function
47660|NCT02759276|Microcirculation
47661|NCT02759276|Inflammatory Biomarkers
47662|NCT02759185|PTSD
47663|NCT02759185|marijuana
47664|NCT02759185|cannabis
47665|NCT02759185|sleep
47666|NCT02759185|THC
47667|NCT02759185|CBD
47668|NCT02759172|Suicide prevention
47669|NCT02759172|Jail
47670|NCT02759120|Idiopathic Pulmonary Fibrosis
47671|NCT02759120|IPF
47672|NCT02759120|pulmonary fibrosis
47673|NCT02759120|antimicrobial therapy
47674|NCT02759120|doxycycline
47675|NCT02759120|co-trimoxazole
47676|NCT02759094|GERD
47677|NCT02759094|Implantable medical device
47678|NCT02759094|RefluxStop
47679|NCT02759094|Reflux
47680|NCT02759094|Gastroesophageal Reflux
47681|NCT02759094|Laparoscopy
47682|NCT02759094|pH-Monitoring
47683|NCT02759094|PPI proton pump inhibitors
47684|NCT02759068|vegetative state
47685|NCT02759068|minimally conscious state
47686|NCT02759068|music
47687|NCT02759068|preference
47688|NCT02758990|Food
47689|NCT02758990|Nutrigenomics
47690|NCT02758990|Precision Medicine
47691|NCT02758990|Pharmacogenetics
47692|NCT02758990|Lifestyle
47693|NCT02758977|Colorectal liver metastases
47694|NCT02758977|Liver Surgery
47695|NCT02758977|ALPPS
47696|NCT02758977|Two Stage Hepatectomy
47697|NCT02758977|Surgical Oncology
47698|NCT02758977|Hepatectomy
47699|NCT02758964|TAVR
47700|NCT02758964|TAVI
47701|NCT02758964|Transcatheter Aortic Valve Replacement
47702|NCT02758964|Intracranial Embolism
47703|NCT02758951|Induction Chemotherapy
47704|NCT02758951|Chemotherapy, Adjuvant
47705|NCT02758951|Molecular Targeted Therapy
47706|NCT02758951|Colorectal Surgery
47707|NCT02758951|Cytoreductive Surgery
47708|NCT02758951|Hyperthermic Intraperitoneal Chemotherapy
47709|NCT02758951|Peritoneum
47710|NCT02758951|Peritoneal Lavage
47711|NCT02758951|Peritoneal Cavity
47712|NCT02758951|Ascitic Fluid
47713|NCT02758951|Chemotherapy, Cancer, Regional Perfusion
47714|NCT02758951|Antineoplastic Combined Chemotherapy Protocols
47715|NCT02758951|Drug Therapy, Combination
47716|NCT02758951|Drug Therapy
47717|NCT02758951|Morbidity
47718|NCT02758951|Mortality
47719|NCT02758951|Hospital Mortality
47720|NCT02758951|Chemically-Induced Disorders
47721|NCT02758951|Drug-Related Side Effects and Adverse Reactions
47722|NCT02758951|Laparotomy
47723|NCT02758899|Anterior cervical discectomy
47724|NCT02758899|Anterior cervical fusion
47725|NCT02758860|Colonoscopy
47726|NCT02758860|Diverticular disease of the colon
47727|NCT02758860|Classification
47728|NCT02758847|critical lower limb ischemia with tissue loss
47729|NCT02758834|Preterm Infants
47730|NCT02758834|Phytosterols
47731|NCT02758834|Parenteral Nutrition
47732|NCT02758821|C-reactive protein
47733|NCT02758821|antibiotic
47734|NCT02758795|protein
47735|NCT02758795|inflammation
47736|NCT02758795|anti-inflammatory agents
47737|NCT02758743|smoking
47738|NCT02758743|tobacco
47739|NCT02758743|smoking cessation
47740|NCT02758730|GBA mutation
47741|NCT02758704|Intubation
47742|NCT02758704|Neonatal
47743|NCT02758704|Teaching
47744|NCT02758704|Stress
47745|NCT02758704|Simulation
47746|NCT02758691|memory
47747|NCT02758691|insulin
47748|NCT02758678|P-selectin
47749|NCT02758678|Lung Cancer
47750|NCT02758678|Raman Spectroscopy
47751|NCT02758665|CLL
47752|NCT02758665|chronic lymphocytic leukemia
47753|NCT02758665|ibrutinib
47754|NCT02758665|venetoclax
47755|NCT02758665|obinutuzumab
47756|NCT02758665|TP53 Deletion
47757|NCT02758652|chemoresistance
47758|NCT02758652|miRNA
47759|NCT02758652|microRNA
47760|NCT02758639|parental cancer
47761|NCT02758639|children psychosocial adjustment
47762|NCT02758639|psychosocial intervention
47763|NCT02758574|acute pulmonary embolism
47764|NCT02758574|submassive pulmonary embolism
47765|NCT02758574|thrombolysis
47766|NCT02758574|catheter directed thrombolysis
47767|NCT02758574|ultrasound assisted thrombolysis
47768|NCT02758561|decisional aid
47769|NCT02758561|workshops
47770|NCT02758561|urinary incontinence
47771|NCT02758561|pelvic organ prolapse
47772|NCT02758561|pelvic floor dysfunction
47773|NCT02758561|decisional conflict
47774|NCT02758548|Total IgE measurement
47775|NCT02758548|Novel Point-of-care test device
47776|NCT02758548|atopic conditions
47777|NCT02758548|in vitro diagnostic test
47778|NCT02758522|Diabetes Mellitus
47779|NCT02758522|Hospital Hyperglycemia
47780|NCT02758496|Autism, chart review, transcranial magnetic stimulation (TMS)
47781|NCT02758470|Muscle Fatigue
47782|NCT02758470|Acetazolamide
47783|NCT02758470|Methazolamide
47784|NCT02758457|cad/cam
47785|NCT02758457|dental porcelain
47786|NCT02758457|zirconia
47787|NCT02758457|press on metal
47788|NCT02758444|environmental enteric dysfunction
47789|NCT02758444|environmental enteropathy
47790|NCT02758444|zinc absorption
47791|NCT02758444|Bangladesh
47792|NCT02758444|toddlers
47793|NCT02758444|zinc isotope
47794|NCT02758431|testosterone
47795|NCT02758418|Adjustment disorders online
47796|NCT02758418|Psychological Treatments
47797|NCT02758418|Information and Communication Technologies
47798|NCT02758418|Internet
47799|NCT02758418|Bibliotherapy
47800|NCT02758405|Epidural
47801|NCT02758405|Labor analgesia
47802|NCT02758405|Programmed intermittent epidural bolus
47803|NCT02758392|Healthy
47804|NCT02758392|JNJ-61178104
47805|NCT02758392|Placebo
47806|NCT02758392|Safety
47807|NCT02758379|coronary artery disease
47808|NCT02758379|calcified lesions
47809|NCT02758379|lithotripsy
47810|NCT02758366|glioblastoma multiforme
47811|NCT02758366|high grade glioma
47812|NCT02758366|diffuse intrinsic pontine glioma
47813|NCT02758366|DIPG
47814|NCT02758366|doxorubicin
47815|NCT02758366|temozolomide
47816|NCT02758366|malignant glioma
47817|NCT02758353|Malaria in Pregnancy
47818|NCT02758353|Nigeria
47819|NCT02758353|Sulfadoxine-Pyrimethamine
47820|NCT02758353|Scale up
47821|NCT02758353|Primary Health Care
47822|NCT02758340|induction of labor
47823|NCT02758340|misoprostol
47824|NCT02758340|foley's balloon catheter
47825|NCT02758327|Tear Osmolarity
47826|NCT02758327|Keratitis Sicca
47827|NCT02758327|Ocular Surface Disease
47828|NCT02758327|TheraTears
47829|NCT02758314|PD-1
47830|NCT02758314|PD-L1
47831|NCT02758314|NSCLC
47832|NCT02758288|Kidney transplant
47833|NCT02758288|BK Viremia
47834|NCT02758288|BK Nephropathy
47835|NCT02758275|Medication adherence
47836|NCT02758275|Patient compliance
47837|NCT02758275|Diabetes mellitus, Type 2
47838|NCT02758275|Hypertension
47839|NCT02758275|Nursing
47840|NCT02758275|Nursing process
47841|NCT02758275|Teaching
47842|NCT02758275|Randomized controlled trial
47843|NCT02758210|Bradycardia
47844|NCT02758210|Atrial Tachyarrhythmia
47845|NCT02758210|Smart Phone
47846|NCT02758210|Tablet
47847|NCT02758197|Mindfulness
47848|NCT02758197|Chronic Pain
47849|NCT02758197|Quality of Life
47850|NCT02758197|Immune Function
47851|NCT02758197|Cancer survivors
47852|NCT02758197|Disability
47853|NCT02758132|Castrate-resistant prostate cancer with bone metastases
47854|NCT02758106|chest wall oscillation
47855|NCT02758106|acute respiratory failure
47856|NCT02758106|airway secretion
47857|NCT02758080|Personalized medicine
47858|NCT02758080|Next generation sequencing
47859|NCT02758041|Acne
47860|NCT02758028|Youth
47861|NCT02758015|betaine
47862|NCT02758015|betaine hydrochloride
47863|NCT02758015|healthy volunteer
47864|NCT02758015|gastric pH
47865|NCT02758002|atrial fibrillation ablation
47866|NCT02758002|ablation
47867|NCT02758002|atrial fibrillation rotors
47868|NCT02757989|Low risk MDS
47869|NCT02757989|Transplantation
47870|NCT02757963|Screening tool
47871|NCT02757963|International Prostate Symptom Score
47872|NCT02757963|Lower urinary tract symptoms
47873|NCT02757963|BPO
47874|NCT02757963|BPE
47875|NCT02757963|Benign prostatic enlargement
47876|NCT02757963|Benign prostatic obstruction
47877|NCT02757963|LUTS
47878|NCT02757963|Benign prostatic hyperplasia
47879|NCT02757963|IPSS
47880|NCT02757963|BPH
47881|NCT02757950|exposed and unexposed cohorts
47882|NCT02757950|post-marketing, maternal immunization
47883|NCT02757950|neonate related Adverse Events
47884|NCT02757950|Congenital anomaly
47885|NCT02757950|RefortrixTM
47886|NCT02757950|Pregnancy related Adverse Events
47887|NCT02757937|Medication Adherence
47888|NCT02757937|Self-efficacy
47889|NCT02757937|Behavior
47890|NCT02757937|Diabetes
47891|NCT02757937|Diabetes Mellitus
47892|NCT02757911|XCGD
47893|NCT02757898|Red Blood Cell (RBC) transfusion
47894|NCT02757898|Biotin labeled red blood cells
47895|NCT02757885|bone marrow transplant
47896|NCT02757872|Hypertension
47897|NCT02757872|Kidney Diseases
47898|NCT02757872|Vitamin D
47899|NCT02757872|Omega 3 fatty acids
47900|NCT02757846|Radiomics
47901|NCT02757846|prognosis
47902|NCT02757846|medical images
47903|NCT02757846|Hepatocellular carcinoma
47904|NCT02757820|anesthesia; airway; laryngeal mask airway; I-gel; Air-Q
47905|NCT02757807|Erectile Dysfunction
47906|NCT02757781|Patient empowerment
47907|NCT02757781|Patient involvement
47908|NCT02757781|Patient participation
47909|NCT02757781|Healthcare professional attitudes
47910|NCT02757781|Chronic diseases
47911|NCT02757768|Myrbetriq
47912|NCT02757768|Lower Urinary Tract Symptoms
47913|NCT02757768|Benign Prostatic Hyperplasia
47914|NCT02757768|Overactive Bladder
47915|NCT02757768|Betmiga
47916|NCT02757768|Mirabegron
47917|NCT02757768|Tamsulosin Hydrochloride
47918|NCT02757742|sudden cardiac death
47919|NCT02757742|ventricular arrhythmias
47920|NCT02757742|cardiopathy
47921|NCT02757742|late gadolinium enhancement
47922|NCT02757716|addiction remission
47923|NCT02757716|addiction transfer
47924|NCT02757703|somatostatin
47925|NCT02757703|variceal bleeding
47926|NCT02757703|terlipressin
47927|NCT02757664|achilles
47928|NCT02757664|tendinopathy
47929|NCT02757664|Physical Therapy Modalities
47930|NCT02757664|High-Energy Shock Waves
47931|NCT02757612|laser diode, pain
47932|NCT02757586|chronic lymphocytic leukemia
47933|NCT02757586|XPO1
47934|NCT02757586|in vitro
47935|NCT02757586|in vivo
47936|NCT02757560|saturated fat
47937|NCT02757560|acute insulin resistance
47938|NCT02757560|insulin suppression test
47939|NCT02757560|dietary fatty acids
47940|NCT02757521|Bipolar Depressive Disorder
47941|NCT02757521|Treatment- Resistant Bipolar Disorder
47942|NCT02757521|Nitrous Oxide
47943|NCT02757495|sevoflurane emergence agitation
47944|NCT02757495|caudal dexmedetomidine
47945|NCT02757482|Patient training
47946|NCT02757482|Warfarin
47947|NCT02757482|International Normalized Ratio
47948|NCT02757482|Nursing
47949|NCT02757456|exercise
47950|NCT02757456|hemodialysis
47951|NCT02757456|pulse wave velocity
47952|NCT02757456|micro RNAs
47953|NCT02757443|Phosphocreatine
47954|NCT02757443|Creatine Phosphate
47955|NCT02757443|Neoton
47956|NCT02757443|Phosphate, Creatine
47957|NCT02757443|Phosphorylcreatine
47958|NCT02757404|botulinum toxin
47959|NCT02757404|spasticity
47960|NCT02757404|injection technique
47961|NCT02757404|neuronox
47962|NCT02757404|meditoxin
47963|NCT02757391|Advanced gastrointestinal malignancies
47964|NCT02757391|Metastatic gastrointestinal tumor
47965|NCT02757391|Adoptive T cell infusion
47966|NCT02757391|Cyclophosphamide
47967|NCT02757391|Cytoxan
47968|NCT02757391|Neosar
47969|NCT02757391|IL-2
47970|NCT02757391|Aldesleukin
47971|NCT02757391|Interleukin-2
47972|NCT02757391|Proleukin
47973|NCT02757391|Pembrolizumab
47974|NCT02757391|Keytruda
47975|NCT02757391|MK-3475
47976|NCT02757391|SCH-900475
47977|NCT02757391|Phone calls
47978|NCT02757378|Pain
47979|NCT02757378|Brain
47980|NCT02757378|Plasticity
47981|NCT02757378|Education
47982|NCT02757378|Manual Therapy
47983|NCT02757378|Straight Leg Raise
47984|NCT02757378|Remapping
47985|NCT02757365|aspirin
47986|NCT02757352|ankylosing
47987|NCT02757352|nonradiographic spondyloarthritis
47988|NCT02757339|neurobiology
47989|NCT02757339|PTSD
47990|NCT02757339|DID
47991|NCT02757326|sphingosine kinase 2 inhibitor
47992|NCT02757326|sphingosine kinase 2
47993|NCT02757326|SK2 inhibitor
47994|NCT02757326|SK2
47995|NCT02757313|marijuana
47996|NCT02757313|driving
47997|NCT02757313|THC
47998|NCT02757313|cannabis
47999|NCT02757313|intoxication
48000|NCT02757313|MRI
48001|NCT02757287|Ovarian stimulation
48002|NCT02757287|LH inhibition
48003|NCT02757274|Urologic Surgical Procedure
48004|NCT02757274|Male
48005|NCT02757261|Bruxism
48006|NCT02757261|Child
48007|NCT02757261|Occlusal splint
48008|NCT02757261|Bite force
48009|NCT02757261|Acunpuncture
48010|NCT02757261|Laser
48011|NCT02757261|Muscle actvity
48012|NCT02757261|Salivary Cortisol
48013|NCT02757235|chronic subdural hematoma
48014|NCT02757235|irrigation
48015|NCT02757235|recurrence
48016|NCT02757235|burr hole evacuation
48017|NCT02757235|temperature
48018|NCT02757209|ASTHMA
48019|NCT02757209|COPD
48020|NCT02757209|budesonide
48021|NCT02757209|formoterol
48022|NCT02757209|Salmeterol
48023|NCT02757209|Fluticasone
48024|NCT02757209|Spiromax
48025|NCT02757209|DPI
48026|NCT02757209|Diskus
48027|NCT02757196|Immune Thrombocytopenia
48028|NCT02757196|Rituximab
48029|NCT02757196|methylprednisolone
48030|NCT02757157|Hydrotherapy
48031|NCT02757157|Walking
48032|NCT02757131|Mobility
48033|NCT02757131|Elderly
48034|NCT02757131|Hospitalized patient
48035|NCT02757118|Cardiac Surgery, blood viscosity
48036|NCT02757092|Pulmonary rehabilitation
48037|NCT02757092|lung cancer
48038|NCT02757092|Thoracoscopy
48039|NCT02757079|Melatonin
48040|NCT02757079|NPC-15
48041|NCT02757079|Sleep disorders
48042|NCT02757079|Neurodevelopmental disorder
48043|NCT02757079|Sleep latency
48044|NCT02757079|DSM-5
48045|NCT02757066|Melatonin
48046|NCT02757066|NPC-15
48047|NCT02757066|Sleep disorders
48048|NCT02757066|Autism spectrum disorders
48049|NCT02757066|DSM-5
48050|NCT02757053|Brain Concussion
48051|NCT02757053|Brain Injuries
48052|NCT02757053|Diffuse Axonal Injury
48053|NCT02757053|Football
48054|NCT02757053|Head Protective Devices
48055|NCT02757053|Magnetic Resonance Imaging
48056|NCT02757053|Helmet
48057|NCT02757053|Third party add-on
48058|NCT02757040|chronic lymphocytic leukemia
48059|NCT02757040|ibrutinib
48060|NCT02757040|arsenic trioxide
48061|NCT02757040|phosphatidylinositol 3-kinase
48062|NCT02757027|CABG surgery
48063|NCT02757027|blood viscosity
48064|NCT02757001|Retrievable Inferior Vena Cava Filters
48065|NCT02757001|Pulmonary Embolism
48066|NCT02756923|Male Infertility
48067|NCT02756923|Spermatogonial stem cell
48068|NCT02756910|open abdominal surgery
48069|NCT02756910|anesthesia, general
48070|NCT02756897|Leukemia
48071|NCT02756897|Chronic Lymphocytic Leukemia
48072|NCT02756897|CLL
48073|NCT02756897|Small Lymphocytic Lymphoma
48074|NCT02756897|SLL
48075|NCT02756897|Refractory and/or relapsed
48076|NCT02756897|Ibrutinib
48077|NCT02756897|PCI-32765
48078|NCT02756897|Imbruvica
48079|NCT02756897|Venetoclax
48080|NCT02756897|ABT-199
48081|NCT02756897|GDC-0199
48082|NCT02756845|Non CNS Tumor
48083|NCT02756832|Drug Therapy
48084|NCT02756819|Drug Therapy
48085|NCT02756806|Tattoo removal, Picosecond Laser, Q-switched Laser
48086|NCT02756780|Remission
48087|NCT02756780|Carer
48088|NCT02756780|Psychological
48089|NCT02756780|Bereaved
48090|NCT02756780|Cancer
48091|NCT02756780|Breast
48092|NCT02756780|Prostate
48093|NCT02756780|Colorectal
48094|NCT02756780|Music
48095|NCT02756741|Cirrhosis
48096|NCT02756741|hepatitis B virus
48097|NCT02756741|Alcohol
48098|NCT02756741|varices
48099|NCT02756702|TKA
48100|NCT02756702|TKR
48101|NCT02756702|All-Poly
48102|NCT02756702|posterior stabilized
48103|NCT02756689|Mechanical cervical ripening
48104|NCT02756689|Transcervical catheter
48105|NCT02756689|Foley catheter for labor induction
48106|NCT02756689|Cervical ripening
48107|NCT02756689|Induction of labor
48108|NCT02756676|Parkinson Disease
48109|NCT02756676|Quality of Life
48110|NCT02756676|Rehabilitation
48111|NCT02756663|multiple myeloma
48112|NCT02756663|MM
48113|NCT02756663|relapsed
48114|NCT02756663|relapsed and refractory
48115|NCT02756663|panobinostat
48116|NCT02756663|LBH589
48117|NCT02756663|histone deacetylase inhibitor
48118|NCT02756663|carfilzomib
48119|NCT02756663|proteasome inhibitor
48120|NCT02756650|Behcet Disease
48121|NCT02756650|Inflammation
48122|NCT02756650|Immune system
48123|NCT02756650|Arthritis
48124|NCT02756611|Oncology
48125|NCT02756611|TP53 Mutation
48126|NCT02756611|Refractory
48127|NCT02756611|Relapsed
48128|NCT02756611|B-Cell receptor inhibitor
48129|NCT02756611|17p Deletion
48130|NCT02756611|Chronic Lymphocytic Leukemia
48131|NCT02756598|sufentanil
48132|NCT02756598|propofol
48133|NCT02756598|personality/stress test
48134|NCT02756598|fast-track
48135|NCT02756585|computed tomography
48136|NCT02756585|perfusion imaging
48137|NCT02756585|brain death
48138|NCT02756585|traumatic brain injury
48139|NCT02756559|sepsis
48140|NCT02756559|microRNAs
48141|NCT02756520|chronic kidney disease, pre-dialytic
48142|NCT02756520|Ketosteril, keto-acids
48143|NCT02756520|diet, protein-restricted
48144|NCT02756520|renal function
48145|NCT02756507|anxiety
48146|NCT02756507|depression
48147|NCT02756507|internalizing symptoms
48148|NCT02756468|pancreatic cancer
48149|NCT02756468|procalcitonin
48150|NCT02756455|gastric cancer
48151|NCT02756455|procalcitonin
48152|NCT02756429|atrial fibrillation
48153|NCT02756429|stroke
48154|NCT02756429|thromboembolism
48155|NCT02756429|inflammation
48156|NCT02756416|Reversible Cerebral Vasoconstriction Syndrome (RCVS)
48157|NCT02756416|Arterial spin labeling (ASL) MRI
48158|NCT02756390|Insomnia cancer Survivor
48159|NCT02756364|Drug Therapy
48160|NCT02756325|Azoospermia, IVF, MRI
48161|NCT02756299|Sleep Apnea
48162|NCT02756299|Positive Airway Pressure
48163|NCT02756299|Patient Education
48164|NCT02756286|Electroencephalography
48165|NCT02756286|Attention
48166|NCT02756273|ileostomy
48167|NCT02756273|morbidity
48168|NCT02756273|colorectal surgery
48169|NCT02756247|Buparlisib
48170|NCT02756247|BKM120
48171|NCT02756247|Ibrutinib
48172|NCT02756247|16-009
48173|NCT02756221|symptoms
48174|NCT02756208|vaccine
48175|NCT02756208|healthy volunteer
48176|NCT02756195|Patient safety
48177|NCT02756195|adverse events
48178|NCT02756195|pediatric surgery
48179|NCT02756195|quality improvement
48180|NCT02756195|health systems
48181|NCT02756195|observational study
48182|NCT02756195|non-routine event
48183|NCT02756195|National Surgical Improvement Program
48184|NCT02756169|Obesity
48185|NCT02756169|Breastfeeding
48186|NCT02756169|Grow up
48187|NCT02756169|Milk composition
48188|NCT02756169|Mexico
48189|NCT02756156|interscalene
48190|NCT02756156|infraclavicular
48191|NCT02756156|humerus surgery
48192|NCT02756143|fetal heart
48193|NCT02756143|cesarean section
48194|NCT02756143|exercise
48195|NCT02756143|pregnancy
48196|NCT02756091|Intracranial Artery Dissection
48197|NCT02756091|IAD
48198|NCT02756091|Stroke
48199|NCT02756091|Observational Study
48200|NCT02756065|Bipolar
48201|NCT02756065|schizophrenia
48202|NCT02756065|schizoaffective
48203|NCT02756026|Breast milk
48204|NCT02756026|mineral
48205|NCT02756026|vitamin
48206|NCT02756013|chemotherapy dosing
48207|NCT02756013|Body surface area
48208|NCT02756013|BSA
48209|NCT02756013|paclitaxel
48210|NCT02756013|carboplatin
48211|NCT02756013|dose dense
48212|NCT02756000|myocardial infarction
48213|NCT02756000|percutaneous coronary intervention
48214|NCT02756000|multivessel coronary artery disease
48215|NCT02756000|dobutamine stress echocardiography
48216|NCT02755961|End-stage renal disease
48217|NCT02755961|Phosphate binders
48218|NCT02755961|Hyperphosphatemia
48219|NCT02755961|Dietary education
48220|NCT02755922|Mesenchymal Stem Cells
48221|NCT02755922|Treatment
48222|NCT02755909|Cardiac surgery, anxiety, education
48223|NCT02755883|Physical activity
48224|NCT02755883|non-small lung cancer
48225|NCT02755883|positive affect
48226|NCT02755857|Prophylaxis
48227|NCT02755857|Bioavailability
48228|NCT02755857|Pharmacokinetics
48229|NCT02755844|endometrial carcinomas
48230|NCT02755844|metronomic cyclophosphamide
48231|NCT02755844|metformin
48232|NCT02755844|olaparib
48233|NCT02755844|dose-escalation study
48234|NCT02755818|high density lipoprotein (HDL)
48235|NCT02755818|lipid
48236|NCT02755818|insulin resistance
48237|NCT02755818|glomerular filtration rate (GFR)
48238|NCT02755818|obesity
48239|NCT02755805|Stroke
48240|NCT02755805|Rehabilitation
48241|NCT02755805|Cognition
48242|NCT02755805|Intervention
48243|NCT02755805|Strategy training
48244|NCT02755792|Mild Cognitive Impairment
48245|NCT02755792|Cognitive training
48246|NCT02755792|Calligraphy
48247|NCT02755792|Emotional calmness
48248|NCT02755792|Working memory
48249|NCT02755753|Rebamipide
48250|NCT02755740|Female
48251|NCT02755688|atrial fibrillation
48252|NCT02755688|catheter ablation
48253|NCT02755688|thoracoscopic surgical ablation
48254|NCT02755688|long standing persistent atrial fibrillation
48255|NCT02755662|Obstructive Sleep Apnea Syndrome
48256|NCT02755662|mandibular repositioning device
48257|NCT02755636|Health Behavior Change
48258|NCT02755636|Primary Health Care
48259|NCT02755636|Patient Participation
48260|NCT02755636|Provider-Patient Communication
48261|NCT02755636|Cluster-Randomized Trial
48262|NCT02755636|Mobile Health
48263|NCT02755610|Peritoneal Dialysis
48264|NCT02755610|Checklist
48265|NCT02755597|relapsed/refractory multiple myeloma
48266|NCT02755597|refractory multiple myeloma
48267|NCT02755597|multiple myeloma
48268|NCT02755597|relapsed multiple myeloma
48269|NCT02755584|Aging
48270|NCT02755584|Senescent Cells
48271|NCT02755532|Pharmacokinetics
48272|NCT02755532|Bupivacaine
48273|NCT02755532|Axillary brachial plexus block
48274|NCT02755519|primary aldosteronism
48275|NCT02755519|confirmatory test
48276|NCT02755519|hypertension
48277|NCT02755506|Ultrasound elastography
48278|NCT02755506|Thoracic lesions
48279|NCT02755506|EBUS-TBNA
48280|NCT02755480|bone marrow transplant
48281|NCT02755480|infection
48282|NCT02755480|computed tomography
48283|NCT02755480|radiation dose
48284|NCT02755441|Diagnosis
48285|NCT02755441|Prognosis
48286|NCT02755441|Biomarker
48287|NCT02755415|Rehabilitation
48288|NCT02755415|Robotic
48289|NCT02755415|Gait
48290|NCT02755415|Quality of Life
48291|NCT02755389|Tracheal intubation
48292|NCT02755389|High flow nasal oxygen
48293|NCT02755389|Airway management
48294|NCT02755389|Apneic oxygenation
48295|NCT02755363|COPD
48296|NCT02755363|residual volume
48297|NCT02755363|osteopathy
48298|NCT02755363|hyperinflation
48299|NCT02755350|PrEP
48300|NCT02755350|HIV Prevention
48301|NCT02755350|combination prevention
48302|NCT02755350|demonstration project
48303|NCT02755337|adenocarcinoma
48304|NCT02755337|non-adenocarcinoma
48305|NCT02755298|Treatment Outcome
48306|NCT02755298|Acetazolamide
48307|NCT02755272|Triple Negative Breast Cancer
48308|NCT02755259|Acetazolamide
48309|NCT02755259|Hemodynamics
48310|NCT02755246|subjective cognitive decline
48311|NCT02755246|dementia
48312|NCT02755246|lifestyle
48313|NCT02755246|polyamine
48314|NCT02755246|memory
48315|NCT02755246|elderly
48316|NCT02755246|prevention
48317|NCT02755246|treatment
48318|NCT02755246|dietary supplement
48319|NCT02755246|Polyamine-enriched diet
48320|NCT02755194|pharmacokinetics
48321|NCT02755194|Drug-in-milk
48322|NCT02755194|breastfeeding
48323|NCT02755194|drug safety
48324|NCT02755194|population pharmacokinetics
48325|NCT02755155|acute circulatory failure requiring norepinephrine
48326|NCT02755155|SIRS
48327|NCT02755155|Albumin, therapeutic
48328|NCT02755116|Nausea
48329|NCT02755116|Vomiting
48330|NCT02755103|Mindfulness
48331|NCT02755103|Comorbid PTSD and SUD
48332|NCT02755103|Meditation
48333|NCT02755090|nitrous
48334|NCT02755090|pain
48335|NCT02755077|Anesthesia induction
48336|NCT02755077|Airway
48337|NCT02755077|Mask ventilation
48338|NCT02755038|postmenopausal women
48339|NCT02755038|scalp hair
48340|NCT02755038|estrogen
48341|NCT02755038|progesterone
48342|NCT02755025|Sepsis
48343|NCT02755025|SOFA score
48344|NCT02755025|Automated calculation
48345|NCT02755012|Maternal Health
48346|NCT02755012|Guatemala
48347|NCT02755012|Indigenous Population
48348|NCT02755012|Stunting
48349|NCT02755012|Food Insecurity
48350|NCT02755012|Poverty
48351|NCT02755012|Social Support
48352|NCT02755012|Maternal Autonomy
48353|NCT02755012|Paternal Support
48354|NCT02755012|Cortisol Rhythm
48355|NCT02754986|heart rate variability
48356|NCT02754960|Gastrointestinal bleeding
48357|NCT02754960|Vascular malformation
48358|NCT02754960|Angiodysplasia
48359|NCT02754960|Thalidomide
48360|NCT02754947|Assessment and Consultation Team (ACT)
48361|NCT02754947|Rapid Response Team (RRT)
48362|NCT02754947|Perioperative complications
48363|NCT02754947|Respiratory insufficiency
48364|NCT02754947|ASA status
48365|NCT02754934|chronic
48366|NCT02754895|acute coronary syndrome
48367|NCT02754895|health behavior
48368|NCT02754895|factorial design
48369|NCT02754895|positive psychology
48370|NCT02754882|NSCLC
48371|NCT02754882|bevacizumab
48372|NCT02754882|avastin
48373|NCT02754856|Colorectal Cancer
48374|NCT02754856|Liver Metastases
48375|NCT02754856|Resectable liver metastases
48376|NCT02754856|Tremelimumab
48377|NCT02754856|Fluorouracil
48378|NCT02754856|5-Fluorouracil
48379|NCT02754856|5-FU
48380|NCT02754856|Adrucil
48381|NCT02754856|Efudex
48382|NCT02754856|Leucovorin
48383|NCT02754856|Citrovorum
48384|NCT02754856|Wellcovorin
48385|NCT02754856|Oxaliplatin
48386|NCT02754856|Eloxatin
48387|NCT02754856|Bevacizumab
48388|NCT02754856|Avastin
48389|NCT02754856|Anti-VEGF monoclonal antibody
48390|NCT02754856|MEDI4736
48391|NCT02754856|Durvalumab
48392|NCT02754778|arterial stiffness
48393|NCT02754778|preeclampsia
48394|NCT02754778|HELLP-syndrome
48395|NCT02754778|pulse wave velocity
48396|NCT02754778|advanced glycation endproducts
48397|NCT02754778|skin autofluorescence
48398|NCT02754778|conditional workout
48399|NCT02754778|postpartum
48400|NCT02754778|cardiovascular risk
48401|NCT02754778|pregnancy
48402|NCT02754778|vicorder
48403|NCT02754778|age reader
48404|NCT02754752|Malignant neoplasm of breast
48405|NCT02754752|Post-Mastectomy Pain Syndrome
48406|NCT02754752|PMPS
48407|NCT02754752|Electro-acupuncture
48408|NCT02754752|Questionnaires
48409|NCT02754752|Surveys
48410|NCT02754752|Standard of care
48411|NCT02754739|Pravastatin
48412|NCT02754739|Insulin Resistance
48413|NCT02754700|Anterior Cruciate Ligament
48414|NCT02754687|male contraception
48415|NCT02754687|healthy men
48416|NCT02754687|androgen
48417|NCT02754687|Nortestosterone
48418|NCT02754687|Dodecylcarbonate
48419|NCT02754687|11-Beta
48420|NCT02754687|11β
48421|NCT02754687|contraception
48422|NCT02754661|Polyps; Capsule endoscopy; CT Colonography; Colonoscopy; Average risk patients for colorectal cancer screening
48423|NCT02754635|Abnormal first or second trimester biochemical markers
48424|NCT02754635|maternal and perinatal morbidity/mortality
48425|NCT02754622|Rehabilitation
48426|NCT02754609|Celiac Disease
48427|NCT02754609|Necator americanus
48428|NCT02754609|Helminths
48429|NCT02754609|Autoimmunity
48430|NCT02754609|Clinical Trials, Phase I
48431|NCT02754609|Randomized Controlled Trial
48432|NCT02754583|trachoma
48433|NCT02754583|soil transmitted helminths
48434|NCT02754583|sanitation
48435|NCT02754583|face washing
48436|NCT02754583|antibiotics
48437|NCT02754570|Open-angle glaucoma
48438|NCT02754570|Ocular hypertension
48439|NCT02754570|Latanoprost
48440|NCT02754570|Pilocarpine
48441|NCT02754544|Brain tumor
48442|NCT02754544|Metastatic brain tumor
48443|NCT02754544|Neurosurgery
48444|NCT02754544|Electrocorticogram
48445|NCT02754544|ECoG
48446|NCT02754544|Transcranial magnetic stimulation
48447|NCT02754544|TMS
48448|NCT02754544|Direct electrical stimulation
48449|NCT02754544|DES
48450|NCT02754544|Functional MRI
48451|NCT02754544|fMRI
48452|NCT02754544|PMT High-Resolution Grids
48453|NCT02754544|CorTec High-Resolution Hybrid Grids
48454|NCT02754544|Digital glove
48455|NCT02754544|Neurological exam
48456|NCT02754544|Ad-Tech Grids
48457|NCT02754544|Grip Sensor
48458|NCT02754531|Cole formula
48459|NCT02754531|Pediatric patients
48460|NCT02754531|intubation
48461|NCT02754531|Ultrasonography
48462|NCT02754531|Endotracheal tube
48463|NCT02754531|uncuffed
48464|NCT02754531|pediatric
48465|NCT02754505|Keywords: intensive care, muscle wasting, discharge, neuromuscular weakness, mobilization
48466|NCT02754453|Weight Regain
48467|NCT02754453|Group Treatment
48468|NCT02754453|Weight Loss
48469|NCT02754427|Surveillance
48470|NCT02754427|Physiotherapy
48471|NCT02754427|Arm morbidity
48472|NCT02754414|Platelets
48473|NCT02754414|transfusion
48474|NCT02754414|cold storage
48475|NCT02754414|apheresis
48476|NCT02754414|Isoplate
48477|NCT02754401|public health
48478|NCT02754401|periodontitis
48479|NCT02754401|self-reported questionnaire
48480|NCT02754388|LDCT, screening, health behavior, psychological factors
48481|NCT02754375|biological markers
48482|NCT02754375|rTMS
48483|NCT02754362|Poly-ICLC and bevacizumab
48484|NCT02754362|humanized monoclonal antibody
48485|NCT02754349|pulse wave velocity
48486|NCT02754349|augmentation index
48487|NCT02754349|central pulse pressure
48488|NCT02754310|Education, medical
48489|NCT02754310|Simulation Training
48490|NCT02754297|Neuroendocrine tumors
48491|NCT02754297|Personalized
48492|NCT02754297|Peptide receptor radionuclide therapy
48493|NCT02754297|PRRT
48494|NCT02754297|177Lu-DOTATATE
48495|NCT02754297|177Lu-octreotate
48496|NCT02754245|multicenter study
48497|NCT02754245|emergency department
48498|NCT02754245|overcrowding status
48499|NCT02754245|estimation tool
48500|NCT02754245|validation
48501|NCT02754232|Physical training
48502|NCT02754232|Telemedicine
48503|NCT02754232|Daily activities
48504|NCT02754232|Cross sectoral
48505|NCT02754219|Diabetes Mellitus, Type II
48506|NCT02754193|Venous-Arterial ExtraCorporeal Membrane Oxygenation
48507|NCT02754180|adjuvant
48508|NCT02754180|pancreatic cancer
48509|NCT02754180|R1 resection
48510|NCT02754180|positive lymph nodes
48511|NCT02754167|Hepcidin
48512|NCT02754167|hemoglobin
48513|NCT02754167|iron
48514|NCT02754167|anemia of chronic disease
48515|NCT02754089|Body weight changes
48516|NCT02754089|Medicine, Traditional
48517|NCT02754089|Herbal medicine
48518|NCT02754089|Rhus
48519|NCT02754089|Waist Circumference
48520|NCT02754089|Waist-Hip Ratio
48521|NCT02754089|Body mass index
48522|NCT02754076|Sanfilippo Syndrome Type B
48523|NCT02754024|Stemless shoulder prosthesis
48524|NCT02754011|HER2 negative
48525|NCT02754011|Locally advanced or metastatic
48526|NCT02753998|Stenosis of arteriovenous fistula
48527|NCT02753998|Angioplasty
48528|NCT02753998|Paclitaxel-Coated Balloon Angioplasty
48529|NCT02753920|voiding trial
48530|NCT02753920|prolapse
48531|NCT02753894|Dose-finding
48532|NCT02753894|Hemodialysis
48533|NCT02753894|ASP1585
48534|NCT02753894|Chronic kidney disease
48535|NCT02753868|Intradialytic exercise
48536|NCT02753868|Cardiac and arterial function
48537|NCT02753842|Sexually Transmitted Infections
48538|NCT02753842|Condoms
48539|NCT02753842|Contraceptive Devices
48540|NCT02753842|HIV
48541|NCT02753816|Tranexamic Acid
48542|NCT02753816|Burn
48543|NCT02753816|Surgery
48544|NCT02753816|Tangential
48545|NCT02753816|Excision
48546|NCT02753790|Brain
48547|NCT02753790|Metastasis
48548|NCT02753790|IMRT
48549|NCT02753790|Radiation
48550|NCT02753790|Cancer
48551|NCT02753790|Hippocampus
48552|NCT02753790|Intensity modulated radiotherapy
48553|NCT02753790|Quality of life
48554|NCT02753790|QOL
48555|NCT02753712|Small airway disease
48556|NCT02753712|asthma
48557|NCT02753699|Chronic hepatitis C
48558|NCT02753686|HR+ HER2
48559|NCT02753686|postmenopausal
48560|NCT02753686|advanced breast cancer
48561|NCT02753686|non steroidal aromatase inhibitor (NSAI) exposure
48562|NCT02753686|metastatic
48563|NCT02753686|endocrine therapy
48564|NCT02753686|targeted therapy
48565|NCT02753686|prospective
48566|NCT02753686|observational
48567|NCT02753686|registry
48568|NCT02753686|real world setting
48569|NCT02753686|non-interventional
48570|NCT02753686|Canadian
48571|NCT02753673|Breast Conserving Therapy
48572|NCT02753673|Reported Outcomes Instrument
48573|NCT02753673|16-325
48574|NCT02753660|spinal, anesthesia, pendant, spinal-bone contact, puncture
48575|NCT02753608|exhaled breath condensate
48576|NCT02753608|volatile organic compounds
48577|NCT02753595|PEGylated Recombinant Human Hyaluronidase
48578|NCT02753595|Eribulin Mesylate
48579|NCT02753595|E7389
48580|NCT02753595|PEGPH20
48581|NCT02753595|Human Epidermal Growth Factor Receptor 2-Negative
48582|NCT02753595|High-Hyaluronan
48583|NCT02753582|Elderly, pre-frail, SOD
48584|NCT02753569|Magnetic Resonance Imaging
48585|NCT02753569|PET/CT
48586|NCT02753569|non-small cell lung cancer
48587|NCT02753556|Chronic Obstructive Pulmonary Disease
48588|NCT02753556|COPD
48589|NCT02753556|ScreenFlow
48590|NCT02753556|Screening
48591|NCT02753556|Lung Disease
48592|NCT02753556|Mobile Health
48593|NCT02753556|Peak Flow Meter
48594|NCT02753556|Usability
48595|NCT02753517|hepatobiliary scintigraphy
48596|NCT02753517|extended hepatectomy
48597|NCT02753517|volumetry
48598|NCT02753504|Dyslipidemia
48599|NCT02753491|short interview, diabetes, lifestyle changes, primary care
48600|NCT02753478|hypothermia
48601|NCT02753465|Rectal Neoplasms
48602|NCT02753465|anastomosis
48603|NCT02753465|OS
48604|NCT02753465|DFS
48605|NCT02753465|LCA
48606|NCT02753465|laparoscopic surgery
48607|NCT02753452|youth
48608|NCT02753452|disability
48609|NCT02753452|transition
48610|NCT02753452|life skills
48611|NCT02753452|adolescence
48612|NCT02753413|Vaccine
48613|NCT02753413|Safety
48614|NCT02753413|Reactogenicity
48615|NCT02753413|Respiratory syncytial virus (RSV)
48616|NCT02753387|mouthwash
48617|NCT02753387|head and neck cancer
48618|NCT02753387|chlorhexidine
48619|NCT02753387|pathogens germs
48620|NCT02753374|cystic fibrosis, Chinese, children
48621|NCT02753361|Ultrasound
48622|NCT02753361|regional blockade
48623|NCT02753361|lipoma
48624|NCT02753335|CRPS, graded motor imagery, desensitization, fMRI, DMN
48625|NCT02753322|Dual task training
48626|NCT02753322|Dual task interference
48627|NCT02753322|Sub-acute stroke
48628|NCT02753322|Physiotherapy training
48629|NCT02753322|Community ambulation
48630|NCT02753322|Balance
48631|NCT02753309|BCG
48632|NCT02753309|Rapamycin
48633|NCT02753296|Cancer
48634|NCT02753296|Fertility Preservation
48635|NCT02753296|Patient Decision Aid
48636|NCT02753283|Bone loss
48637|NCT02753283|Frail Geriatric Patients
48638|NCT02753283|Nursing Home Patients
48639|NCT02753283|Long-term Care Patients
48640|NCT02753283|Osteoporosis
48641|NCT02753283|Osteoporotic Fractures
48642|NCT02753257|stroke
48643|NCT02753257|stroke mimic
48644|NCT02753244|Cognitive VideoGames
48645|NCT02753179|Bilateral vestibular hypofunction
48646|NCT02753179|Video Head Impulse Test
48647|NCT02753179|Covert-saccades
48648|NCT02753179|Quality of life
48649|NCT02753179|Dynamic visual acuity
48650|NCT02753166|PTSD (Post Traumatic Stress Disorder)
48651|NCT02753166|Emergency Department
48652|NCT02753127|Colorectal Neoplasms
48653|NCT02753127|Colonic Diseases
48654|NCT02753127|Digestive System Diseases
48655|NCT02753127|Digestive System Neoplasms
48656|NCT02753127|Gastrointestinal Diseases
48657|NCT02753127|Gastrointestinal Neoplasms
48658|NCT02753127|Intestinal Diseases
48659|NCT02753127|Intestinal Neoplasms
48660|NCT02753127|Neoplasms
48661|NCT02753127|Neoplasms by Histologic Type
48662|NCT02753127|Neoplasms by Site
48663|NCT02753127|Neoplasms, Glandular and Epithelial
48664|NCT02753127|Rectal Diseases
48665|NCT02753114|Ketamine
48666|NCT02753114|Intranasal
48667|NCT02753114|Emergency Medical Services
48668|NCT02753114|Pain
48669|NCT02753114|Analgesia
48670|NCT02753101|Positron Emission Tomography
48671|NCT02753101|Magnetic Resonance Imaging
48672|NCT02753101|PET/MRI
48673|NCT02753101|sigma-1 receptor
48674|NCT02753101|radiopharmaceutical
48675|NCT02753101|complex regional pain syndrome
48676|NCT02753101|sciatica
48677|NCT02753101|chronic pain
48678|NCT02753088|Equivalence
48679|NCT02753088|BCD-063
48680|NCT02753088|Copaxone-Teva
48681|NCT02753049|HIV
48682|NCT02753049|AIDS
48683|NCT02753049|Adolescent
48684|NCT02753049|Adherence
48685|NCT02753049|Retention
48686|NCT02753049|mHealth
48687|NCT02753036|cognition
48688|NCT02753036|chemotherapy
48689|NCT02753036|polyneuropathy
48690|NCT02753036|paclitaxel
48691|NCT02753036|carboplatin
48692|NCT02753036|cancer
48693|NCT02752984|Peripherally inserted central venous catheter
48694|NCT02752932|Head and neck cancer
48695|NCT02752932|Patient derived Xenograft
48696|NCT02752932|Chemotherapy
48697|NCT02752932|Metastases
48698|NCT02752906|Meningitis
48699|NCT02752906|Meningococcal Meningitis
48700|NCT02752906|Meningococcal Infections
48701|NCT02752906|MenACYW conjugate vaccine
48702|NCT02752906|Licensed Meningococcal Conjugate Vaccine (MCV4)
48703|NCT02752893|estrogen
48704|NCT02752893|estrogen receptor
48705|NCT02752893|ER+
48706|NCT02752893|HER2
48707|NCT02752893|HER2-
48708|NCT02752893|HER2-negative
48709|NCT02752893|xenograft
48710|NCT02752893|co-clinical
48711|NCT02752893|mice
48712|NCT02752893|patient-derived xenograft
48713|NCT02752893|patient-derived
48714|NCT02752893|breast cancer
48715|NCT02752893|precision medicine
48716|NCT02752893|personalized medicine
48717|NCT02752867|traditional Chinese medicine granules
48718|NCT02752867|Cognitive Impairment
48719|NCT02752867|Acute cerebral infraction
48720|NCT02752867|treatment
48721|NCT02752854|pain scores
48722|NCT02752854|pressure algometer
48723|NCT02752854|healthy volunteer adults
48724|NCT02752802|Contrast Media
48725|NCT02752802|Angiography
48726|NCT02752789|alloantibodies
48727|NCT02752789|donor specific antibodies (DSA)-preformed, de novo
48728|NCT02752789|self-antigens
48729|NCT02752789|chronic allograft function
48730|NCT02752776|Moderate to severe plaque psoriasis
48731|NCT02752763|Dry eye
48732|NCT02752763|isotretinoin, AS
48733|NCT02752763|Autologous serum
48734|NCT02752724|major depressive disorder
48735|NCT02752724|electroconvulsive therapy
48736|NCT02752724|metabolomics
48737|NCT02752724|treatment resistant depression
48738|NCT02752724|anesthesiology
48739|NCT02752724|ketamine
48740|NCT02752724|prospective randomized clinical trial
48741|NCT02752711|Minor head trauma
48742|NCT02752711|Children
48743|NCT02752711|Clinical decision rule
48744|NCT02752685|Nab-Paclitaxel
48745|NCT02752685|Abraxane
48746|NCT02752685|MK-3475
48747|NCT02752672|dithranol
48748|NCT02752672|therapeutic mechanisms
48749|NCT02752659|Monitoring
48750|NCT02752646|cataract
48751|NCT02752633|Xanthine dehydrogenase inhibitor treatment, pharmacotherapy
48752|NCT02752620|osteopathic manipulative treatment
48753|NCT02752620|Chronic nonspecific low back pain
48754|NCT02752620|low back pain
48755|NCT02752594|probiotic
48756|NCT02752594|mutans streptococci
48757|NCT02752594|bacillus coagulans
48758|NCT02752594|caries
48759|NCT02752581|suction drain
48760|NCT02752581|knee arthroscopy
48761|NCT02752581|knee pain
48762|NCT02752555|Oligoasthenoteratozoospermia
48763|NCT02752555|Male factor managment
48764|NCT02752555|Intacytoplasmic sperm injection
48765|NCT02752529|Liver Transplantation
48766|NCT02752529|Individualized Therapy
48767|NCT02752529|Polymorphism
48768|NCT02752477|Opioid-sparing
48769|NCT02752464|Weight Loss
48770|NCT02752464|Health Status Disparities
48771|NCT02752438|high frequency oscillatory ventilation
48772|NCT02752438|rescue
48773|NCT02752438|newborn
48774|NCT02752425|Speech disorders
48775|NCT02752425|Speech therapy
48776|NCT02752425|Visual feedback
48777|NCT02752425|Buccopharyngeal surgery
48778|NCT02752425|Central nervous system damage
48779|NCT02752373|GTC Seizures
48780|NCT02752360|intestinal reconstruction
48781|NCT02752360|end to end anastomosis
48782|NCT02752321|patient discharge
48783|NCT02752321|patient engagement
48784|NCT02752321|patient satisfaction
48785|NCT02752321|continuity of patient care
48786|NCT02752321|hospital discharge
48787|NCT02752321|health technology
48788|NCT02752321|eDischarge
48789|NCT02752321|multimedia
48790|NCT02752321|mobile applications
48791|NCT02752321|software applications
48792|NCT02752321|portable electronic applications
48793|NCT02752282|Family Planning
48794|NCT02752282|LNG-IUS
48795|NCT02752282|Health Education
48796|NCT02752256|tissue plasminogen activator
48797|NCT02752243|acute leukemia
48798|NCT02752243|myelodysplastic syndrome (MDS)
48799|NCT02752243|Stem Cell Transplantation
48800|NCT02752230|Post operative pain
48801|NCT02752230|Bariatric Surgery
48802|NCT02752204|Relapsed
48803|NCT02752204|Refractory
48804|NCT02752204|Lymphoma
48805|NCT02752191|ferumoxytol
48806|NCT02752178|Depression
48807|NCT02752178|Major depressive disorder
48808|NCT02752178|MDD
48809|NCT02752152|Counseling
48810|NCT02752139|Sleep Disorders
48811|NCT02752139|Cerebral Hemodynamics
48812|NCT02752139|Dynamic Cerebral Auto-Regulation
48813|NCT02752139|Stroke
48814|NCT02752126|Esophageal sparing
48815|NCT02752126|Conventional radiotherapy
48816|NCT02752126|Palliative radiation
48817|NCT02752126|Central lung tumors
48818|NCT02752113|diabetes mellitus type 2
48819|NCT02752113|Metformin
48820|NCT02752113|Micro- and macrocirculation
48821|NCT02752113|HbA1c >= 7%
48822|NCT02752100|Lower Extremity Arterial Occlusive Disease
48823|NCT02752100|Interventional Therapy
48824|NCT02752074|Melanoma
48825|NCT02752074|Metastatic Melanoma
48826|NCT02752035|AML
48827|NCT02752035|ASP2215
48828|NCT02752035|Newly Diagnosed AML
48829|NCT02752035|Acute Myeloid Leukemia (AML)
48830|NCT02752035|FLT3
48831|NCT02752022|e-cigarettes
48832|NCT02752022|nitrosamines
48833|NCT02752022|smoking cessation
48834|NCT02752009|Breast Cancer
48835|NCT02752009|Armpit lymph nodes Cancer
48836|NCT02751996|Chronic Hepatitis
48837|NCT02751996|HBV
48838|NCT02751996|Double blind
48839|NCT02751983|Suicide
48840|NCT02751983|Psychiatric Rehabilitation
48841|NCT02751983|Acceptance and Commitment Therapy
48842|NCT02751983|Brief Psychotherapy
48843|NCT02751983|Inpatients
48844|NCT02751970|Dental adhesive
48845|NCT02751970|adhesive systems
48846|NCT02751970|Dental Restoration Failure
48847|NCT02751944|exercise-induced
48848|NCT02751944|joint pain
48849|NCT02751944|joint stiffness
48850|NCT02751944|post-menopausal
48851|NCT02751944|women
48852|NCT02751944|cartilage turnover
48853|NCT02751944|CTX-II
48854|NCT02751931|Pediatrics
48855|NCT02751931|Urodynamics
48856|NCT02751931|Mirabegron
48857|NCT02751931|Phase 3
48858|NCT02751931|Neurogenic Detrusor Overactivity
48859|NCT02751918|Mesothelin-expressing platinum-resistant cancer
48860|NCT02751814|Childcare Center Regulations
48861|NCT02751814|Physical Activity
48862|NCT02751814|Sedentary Behavior
48863|NCT02751814|Screen-time Behavior
48864|NCT02751788|childcare center regulations
48865|NCT02751788|physical activity
48866|NCT02751788|sedentary behavior
48867|NCT02751788|screen-time behavior
48868|NCT02751775|Childcare center regulations
48869|NCT02751775|Physical Activity
48870|NCT02751775|Sedentary Behavior
48871|NCT02751775|Screen-Time Behavior
48872|NCT02751775|Focus groups
48873|NCT02751723|cancer disease
48874|NCT02751723|palliative care
48875|NCT02751723|palliative therapy
48876|NCT02751723|cancer
48877|NCT02751723|patient´s needs
48878|NCT02751723|patient care
48879|NCT02751723|disease burden
48880|NCT02751684|Rapid Sequence Induction
48881|NCT02751684|European
48882|NCT02751684|Evaluation
48883|NCT02751684|EUROpE RSI
48884|NCT02751684|Standards
48885|NCT02751684|RSI
48886|NCT02751645|Pediatric
48887|NCT02751645|Cardiac
48888|NCT02751645|Surgery
48889|NCT02751632|Ultra High Risk of Psychosis
48890|NCT02751632|Prodrome
48891|NCT02751619|Pre-emptive analgesia
48892|NCT02751619|Post-thoracotomy pain
48893|NCT02751619|Lidocaine patch
48894|NCT02751606|Ferumoxtran
48895|NCT02751606|MRI Scans
48896|NCT02751593|pregnancy
48897|NCT02751593|Immune Thrombocytopenia
48898|NCT02751593|dexamethasone
48899|NCT02751554|124I-PU-AD
48900|NCT02751554|PET Imaging
48901|NCT02751554|16-004
48902|NCT02751528|Breast Cancer
48903|NCT02751528|Breast Cancer male
48904|NCT02751528|Breast Neoplasms
48905|NCT02751528|Breast Neoplasms male
48906|NCT02751528|Vaccine
48907|NCT02751528|HER2
48908|NCT02751528|Metastatic
48909|NCT02751528|Locally Advanced
48910|NCT02751528|Unresectable
48911|NCT02751528|Solid Tumor
48912|NCT02751528|Phase 1
48913|NCT02751528|Cancer Vaccine
48914|NCT02751502|Children
48915|NCT02751502|Pediatrics
48916|NCT02751502|Arm
48917|NCT02751502|Upper limb
48918|NCT02751502|bimanual training
48919|NCT02751502|physical training
48920|NCT02751437|preterm
48921|NCT02751437|arginine
48922|NCT02751437|immune function
48923|NCT02751437|nutrition
48924|NCT02751424|Multidrug-resistant
48925|NCT02751424|Gram negative bacterial infection
48926|NCT02751424|Safety
48927|NCT02751424|Pharmacokinetic
48928|NCT02751333|Esophageal stricture
48929|NCT02751333|Esophageal leak
48930|NCT02751333|Esophageal perforation
48931|NCT02751333|Esophageal fistula
48932|NCT02751333|Endostitch
48933|NCT02751333|Esophageal stent
48934|NCT02751307|metformin
48935|NCT02751307|clozapine
48936|NCT02751307|schizophrenia
48937|NCT02751307|metabolic traits
48938|NCT02751294|Healthy Volunteer
48939|NCT02751294|Malaria
48940|NCT02751294|Pharmacokinetics
48941|NCT02751294|Tafenoquine
48942|NCT02751281|pneumatic
48943|NCT02751281|ultra-sonic
48944|NCT02751281|percutaneous nephrolithotomy
48945|NCT02751268|infraorbital nerve block
48946|NCT02751268|infratrochlear nerve block
48947|NCT02751268|septorhinoplasty
48948|NCT02751268|general anesthesia
48949|NCT02751268|postoperative analgesia
48950|NCT02751242|Diuretic Resistance
48951|NCT02751242|Emergency Medicine
48952|NCT02751229|Mental illness
48953|NCT02751229|adolescents
48954|NCT02751229|intervention
48955|NCT02751229|stigma
48956|NCT02751229|disclosure
48957|NCT02751229|secrecy
48958|NCT02751216|high frequency / high density spinal cord stimulation
48959|NCT02751216|EEG
48960|NCT02751216|conditioned pain modulation
48961|NCT02751177|KRAS gene mutation
48962|NCT02751177|NRAS gene mutation
48963|NCT02751177|BRAF gene mutation
48964|NCT02751138|Immune phenotype
48965|NCT02751138|Cytokines
48966|NCT02751138|Genetic aberration
48967|NCT02751138|Overall survival
48968|NCT02751138|Progression free survival
48969|NCT02751125|Mesenchymal stem cells
48970|NCT02751125|bone augmentation
48971|NCT02751125|bone regeneration
48972|NCT02751086|minimally invasive surgery
48973|NCT02751086|gastrectomy
48974|NCT02751086|robotic surgery
48975|NCT02751086|laparoscopic surgery
48976|NCT02751086|laparoscopy
48977|NCT02751086|robot-assisted
48978|NCT02751086|robotic
48979|NCT02751086|robotic gastrectomy
48980|NCT02751086|laparoscopic gastrectomy
48981|NCT02751086|minimally invasive gastrectomy
48982|NCT02751073|Microbiota
48983|NCT02751073|Proteome
48984|NCT02751034|Wrinkle Severity Rating Scale
48985|NCT02751034|Global Aesthetic Improvement Scale
48986|NCT02751034|Hyaluronic acid filler
48987|NCT02751034|filler
48988|NCT02751034|Nasolabial Fold
48989|NCT02750995|myelodysplastic syndrome
48990|NCT02750995|acute myeloid leukemia
48991|NCT02750995|azacitidine
48992|NCT02750995|peptide vaccine
48993|NCT02750995|cancer testis antigen
48994|NCT02750995|cancer vaccine
48995|NCT02750995|immunotherapy
48996|NCT02750995|combination therapy
48997|NCT02750995|NY-ESO-1
48998|NCT02750995|PRAME
48999|NCT02750995|MAGE-A3
49000|NCT02750995|WT-1
49001|NCT02750995|vaccine
49002|NCT02750969|tinnitus
49003|NCT02750969|lidocain patch
49004|NCT02750956|endocan protein
49005|NCT02750956|VEGF A
49006|NCT02750956|TNF-alpha
49007|NCT02750956|after treatment
49008|NCT02750930|Extension
49009|NCT02750930|Long-term Safety
49010|NCT02750930|Pharmacodynamics
49011|NCT02750930|Albiglutide
49012|NCT02750930|Type 2 Diabetes Mellitus
49013|NCT02750917|postoperative pain
49014|NCT02750917|lornoxicam
49015|NCT02750917|etoricoxib
49016|NCT02750917|total knee arthroplasty
49017|NCT02750904|Smoking Cessation
49018|NCT02750904|Acceptance & Commitment Therapy
49019|NCT02750904|Cognitive Behavioral Therapy
49020|NCT02750904|Bipolar Disorder
49021|NCT02750891|high grade glioma
49022|NCT02750891|HGG
49023|NCT02750891|DIPG
49024|NCT02750878|Urinary Incontinence, Stress [C13.351.968.934.814.500]
49025|NCT02750865|biomedical technology
49026|NCT02750865|palliative care
49027|NCT02750800|Patient related outcomes
49028|NCT02750800|Psoriatic arthritis
49029|NCT02750800|Rheumatoid arthritis
49030|NCT02750800|Patient support program
49031|NCT02750800|Ankylosing spondylitis
49032|NCT02750800|Quality of life
49033|NCT02750800|Psoriasis
49034|NCT02750800|Observational study
49035|NCT02750800|Ulcerative colitis
49036|NCT02750800|Crohn's disease
49037|NCT02750722|Exercise
49038|NCT02750722|Lung diffusion capacity
49039|NCT02750722|Sputum viscoelasticity
49040|NCT02750722|Lung disease
49041|NCT02750709|HT-1
49042|NCT02750709|Tyrosinemia
49043|NCT02750709|Nitisinone
49044|NCT02750709|Bioequivalence
49045|NCT02750709|Healthy Volunteer
49046|NCT02750709|Orfadin
49047|NCT02750696|Acetaminophen
49048|NCT02750696|Analgesia
49049|NCT02750696|Codeine
49050|NCT02750696|Drug Combinations
49051|NCT02750696|Endodontics
49052|NCT02750696|Periapical abscess
49053|NCT02750696|Randomized Controlled Trial
49054|NCT02750696|Tramadol
49055|NCT02750696|Visual analog scale
49056|NCT02750683|inotropic effect, norepinephrine, septic shock,
49057|NCT02750670|Lymphoma
49058|NCT02750670|Non-Hodgkin's
49059|NCT02750670|CD20+
49060|NCT02750670|Obinutuzumab
49061|NCT02750670|GDP Chemotherapy
49062|NCT02750670|Refractory and aggressive non-Hodgkin lymphoma
49063|NCT02750631|depression
49064|NCT02750631|melatonin
49065|NCT02750631|light therapy
49066|NCT02750631|Wake Therapy
49067|NCT02750631|chronobiology
49068|NCT02750592|Ankylosing Spondylitis
49069|NCT02750540|Tenofovir enema
49070|NCT02750423|Cardiology
49071|NCT02750423|Surgery
49072|NCT02750397|HIV
49073|NCT02750397|Kidney Transplant
49074|NCT02750397|Liver Transplant
49075|NCT02750397|Transplant
49076|NCT02750371|Cavernous sinus meningioma
49077|NCT02750371|Pituitary adenoma
49078|NCT02750371|Hippocampus
49079|NCT02750371|Irradiation
49080|NCT02750371|Autobiographical memory
49081|NCT02750358|Enzalutamide
49082|NCT02750358|15-307
49083|NCT02750345|HT-1
49084|NCT02750345|Tyrosinemia
49085|NCT02750345|Nitisinone
49086|NCT02750345|Bioavailability
49087|NCT02750345|Healthy Volunteer
49088|NCT02750345|Food-Effect
49089|NCT02750332|HT-1
49090|NCT02750332|Tyrosinemia
49091|NCT02750332|Nitisinone
49092|NCT02750332|Bioavailability
49093|NCT02750332|Healthy Volunteer
49094|NCT02750332|Food-Effect
49095|NCT02750319|Amiodarone
49096|NCT02750319|N-Acetylcysteine
49097|NCT02750319|16-307
49098|NCT02750293|vitamin D
49099|NCT02750293|blood pressure
49100|NCT02750293|serum lipids
49101|NCT02750293|glucose metabolism
49102|NCT02750293|muscle function
49103|NCT02750293|arterial stiffness
49104|NCT02750293|depression
49105|NCT02750293|psoriasis
49106|NCT02750293|sleep
49107|NCT02750293|bone density
49108|NCT02750267|Type 1 Diabetes Mellitus (T1DM)
49109|NCT02750267|Artificial Pancreas Project (APP)
49110|NCT02750267|Diabetes Assistant (DiAs)
49111|NCT02750267|Closed-Loop Control (CLC)
49112|NCT02750267|Continuous Glucose Monitor
49113|NCT02750267|Pediatric
49114|NCT02750267|Insulin Pump
49115|NCT02750241|active video game
49116|NCT02750241|mHealth
49117|NCT02750241|cancer survivor
49118|NCT02750241|women's health
49119|NCT02750241|breast cancer
49120|NCT02750241|physical activity
49121|NCT02750241|support group
49122|NCT02750241|survivorship
49123|NCT02750215|MET exon 14 skipping
49124|NCT02750215|Stage IV non-small cell lung cancer NSCLC
49125|NCT02750202|Genital warts
49126|NCT02750202|HPV types
49127|NCT02750202|HPV vaccine
49128|NCT02750202|Cervical cytology
49129|NCT02750202|Therapeutic vaccine
49130|NCT02750202|Quadrivalent HPV vaccine
49131|NCT02750176|Rehabilitation
49132|NCT02750176|Closed chain exercises
49133|NCT02750137|Tetracaine
49134|NCT02750124|participation
49135|NCT02750124|self sampling
49136|NCT02750124|Screening
49137|NCT02750098|Diabetes Mellitus, Cataract, Aqueous humor
49138|NCT02750085|Hemophilia A
49139|NCT02750085|pharmacokinetics
49140|NCT02750085|myPKFiT
49141|NCT02750020|Telephone survey
49142|NCT02749955|HIV prevention
49143|NCT02749955|Pre exposure prophylaxis
49144|NCT02749955|Men who have sex with men
49145|NCT02749955|Partner services
49146|NCT02749955|Linkage to care
49147|NCT02749955|Seronegative
49148|NCT02749955|Sexually transmitted diseases
49149|NCT02749942|Diabetes
49150|NCT02749942|Remote Ischemic Conditioning
49151|NCT02749942|Neuropathy
49152|NCT02749942|Angiopathy
49153|NCT02749929|Distal radius fracture, Low Level Laser Therapy
49154|NCT02749916|SWI
49155|NCT02749916|MP-RAGE
49156|NCT02749916|DANTE T1-SPACE
49157|NCT02749877|Pediatric Cancer
49158|NCT02749877|Training
49159|NCT02749877|Working Memory
49160|NCT02749877|Physical Activity
49161|NCT02749877|Brain Tumor
49162|NCT02749877|Physical Exercise
49163|NCT02749864|Hepatitis
49164|NCT02749864|Prevalence
49165|NCT02749864|Epidemiology
49166|NCT02749864|Infectious diseases
49167|NCT02749851|pregnancy
49168|NCT02749851|growth restriction
49169|NCT02749838|Cancer
49170|NCT02749838|Genomic testing
49171|NCT02749838|Genetic testing
49172|NCT02749838|Molecular screening
49173|NCT02749838|Molecular Profiling
49174|NCT02749838|Biomarker
49175|NCT02749838|Biopsy
49176|NCT02749838|Tumor sampling
49177|NCT02749838|Registry
49178|NCT02749825|Prostate
49179|NCT02749825|Cancer
49180|NCT02749825|Trelstar
49181|NCT02749760|Ulnar collateral ligament
49182|NCT02749760|elbow injuries
49183|NCT02749760|dynamic elbow stabilizers
49184|NCT02749760|Tommy John's procedure
49185|NCT02749760|elbow injuries in pitchers
49186|NCT02749747|Menopause
49187|NCT02749747|nonhormonal treatment
49188|NCT02749747|sulpiride
49189|NCT02749734|Human embryo stem cell derived retinal pigment epitheliums
49190|NCT02749734|Subretinal transplantation
49191|NCT02749734|Wet Age related Macular degeneration
49192|NCT02749734|Stargardt's macular dystrophy
49193|NCT02749721|depression
49194|NCT02749721|brain network activation
49195|NCT02749721|vortioxetine
49196|NCT02749708|IRX5183
49197|NCT02749708|relapsed/refractory AML
49198|NCT02749708|high-risk MDS
49199|NCT02749695|menopause, climacteric syndrome, insomnia, placental extract
49200|NCT02749682|Nyhus classification
49201|NCT02749682|constipation severity scale
49202|NCT02749682|groin hernia
49203|NCT02749669|Inappropriate hospitalization
49204|NCT02749669|elderly
49205|NCT02749669|mild or moderate cognitive impairment
49206|NCT02749669|qualitative research
49207|NCT02749669|economic evaluation
49208|NCT02749656|Scalp psoriasis
49209|NCT02749656|0.25% Desoximetasone cream
49210|NCT02749591|stroke rehabilitation
49211|NCT02749591|spasticity
49212|NCT02749591|Botulinum toxin type A injection
49213|NCT02749591|robot-assisted therapy
49214|NCT02749591|mirror therapy
49215|NCT02749591|randomized controlled trial
49216|NCT02749565|asthma
49217|NCT02749565|fibrocyte
49218|NCT02749565|airway remodeling
49219|NCT02749565|OSA
49220|NCT02749565|hypoxia
49221|NCT02749539|Mastectomy
49222|NCT02749539|Shoulder Pain
49223|NCT02749539|ROM
49224|NCT02749539|Kinesio Tape
49225|NCT02749526|Recombinant human endostatin，Endo
49226|NCT02749500|Motor control
49227|NCT02749487|Critical Care
49228|NCT02749487|Neutrophils
49229|NCT02749487|Lymphocytes
49230|NCT02749461|preterm infants
49231|NCT02749461|pain
49232|NCT02749461|assessment
49233|NCT02749461|contextual factors
49234|NCT02749461|diagnostic accuracy
49235|NCT02749435|Digital disease management tool
49236|NCT02749435|Type 2 diabetes mellitus/ T2DM
49237|NCT02749435|HbA1c
49238|NCT02749435|Standard care
49239|NCT02749435|PRO questionnaires
49240|NCT02749435|Smart phone/ personal computer with internet access
49241|NCT02749422|cognitive dysfunction
49242|NCT02749422|memory loss
49243|NCT02749422|non-invasive transcranial magnetic stimulation (TMS)
49244|NCT02749422|rTMS
49245|NCT02749422|Magstim Rapid2
49246|NCT02749357|gait
49247|NCT02749357|robotic orthosis
49248|NCT02749344|Frozen Embryo Transfer, Progesterone, Endometrium
49249|NCT02749318|Behavior Modification
49250|NCT02749318|Genetic Testing
49251|NCT02749318|Risk Management
49252|NCT02749318|Oral Health Care
49253|NCT02749292|rituximab
49254|NCT02749292|maintenance
49255|NCT02749292|remission
49256|NCT02749266|chiropractic, cognition
49257|NCT02749253|Post Traumatic Stress Disorder (PTSD)
49258|NCT02749253|Sudarshan Kriya Yoga (SKY)
49259|NCT02749227|Clinically non-functioning pituitary adenomas (CNFAs)
49260|NCT02749227|silent corticotroph adenomas
49261|NCT02749201|Obesity
49262|NCT02749201|sleeve gastrectomy
49263|NCT02749188|Urine Specimen Collection/methods
49264|NCT02749188|Infant
49265|NCT02749188|Newborn
49266|NCT02749188|Feasibility Studies
49267|NCT02749188|Bladder stimulation
49268|NCT02749175|cricoid pressure
49269|NCT02749149|Cardiac
49270|NCT02749149|Surgery
49271|NCT02749149|Frailty
49272|NCT02749149|Frail
49273|NCT02749149|Patients
49274|NCT02749149|Recovery
49275|NCT02749149|Morbidity
49276|NCT02749149|Outcomes
49277|NCT02749149|Mortality
49278|NCT02749149|Heart
49279|NCT02749149|Perioperative
49280|NCT02749149|Disability
49281|NCT02749149|WHODAS
49282|NCT02749136|Pancreatic adenocarcinoma
49283|NCT02749136|Borderline resectable
49284|NCT02749136|Neoadjuvant chemotherapy
49285|NCT02749136|FOLFIRINOX
49286|NCT02749110|Mass screening
49287|NCT02749110|Family medicine
49288|NCT02749110|Human Papillomavirus DNA tests
49289|NCT02749110|Papanicolaou test
49290|NCT02749110|Early detection of cancer/methods*
49291|NCT02749110|Specimen Handling/methods*
49292|NCT02749110|Patient compliance
49293|NCT02749110|Adult
49294|NCT02749110|Female
49295|NCT02749110|Humans
49296|NCT02749110|Randomized controlled trial
49297|NCT02749084|chronic graft versus host disease
49298|NCT02749084|T regulatory cell
49299|NCT02749058|capsulectomy
49300|NCT02749058|capsulotomy
49301|NCT02749019|BBN-RGD
49302|NCT02749019|GRPR
49303|NCT02749019|integrin αvβ3
49304|NCT02749006|Bipolar-I disorder
49305|NCT02749006|Depression
49306|NCT02749006|intermittent Theta-Burst Stimulation (rTMS)
49307|NCT02749006|neuromodulatory technique
49308|NCT02748967|Healthy
49309|NCT02748967|ExPEC4V
49310|NCT02748967|JNJ-63871860
49311|NCT02748967|Safety
49312|NCT02748941|unstable/stable atherosclerotic plaque
49313|NCT02748941|HITS
49314|NCT02748941|GSM
49315|NCT02748941|CEUS
49316|NCT02748941|HR MRI
49317|NCT02748941|mi-RNA
49318|NCT02748915|Cochlear Implant
49319|NCT02748915|ECAP
49320|NCT02748915|EABR
49321|NCT02748915|perceptual levels
49322|NCT02748915|hearing performances
49323|NCT02748902|Verruca vulgaris
49324|NCT02748902|Common warts
49325|NCT02748902|Verruca
49326|NCT02748902|Warts
49327|NCT02748902|Papilloma virus
49328|NCT02748902|ingenol mebutate 0.05% gel
49329|NCT02748902|hands
49330|NCT02748889|SCLC
49331|NCT02748889|Small Cell
49332|NCT02748889|Lung Cancer
49333|NCT02748889|MPDL3280A
49334|NCT02748889|atezolizumab
49335|NCT02748863|psoriasis
49336|NCT02748863|secukinumab
49337|NCT02748863|pre-filled syringes
49338|NCT02748850|apheresis patients
49339|NCT02748824|Age- Related Macular Degeneration; Diabetic Retinopathy; Glaucoma; Cataract
49340|NCT02748811|elderly
49341|NCT02748811|intervention study
49342|NCT02748811|geriatrics
49343|NCT02748811|chemotherapy
49344|NCT02748772|Anti-angiogenesis Drugs
49345|NCT02748772|Advanced Colorectal Cancer
49346|NCT02748772|Endostar
49347|NCT02748772|Thalidomide
49348|NCT02748772|Vascular Endothelial Growth Factor A
49349|NCT02748759|Continous Passive Motion
49350|NCT02748759|Manual Physical Therapy
49351|NCT02748759|Range of Motion, Articular
49352|NCT02748759|Anterior Cruciate Ligament Reconstruction
49353|NCT02748759|Rehabilitation
49354|NCT02748759|Kaltenborn Manual Therapy
49355|NCT02748746|Lymphedema
49356|NCT02748746|Electric Impedance
49357|NCT02748746|Breast Cancer
49358|NCT02748733|Adapted APD
49359|NCT02748733|Dialytic Sodium Removal
49360|NCT02748733|Ultrafiltration
49361|NCT02748733|Clearance rate
49362|NCT02748733|Intraperitoneal pressure
49363|NCT02748720|Premature
49364|NCT02748720|Respiratory Function Monitor
49365|NCT02748694|Drug Therapy
49366|NCT02748681|obstructive sleep apnea
49367|NCT02748681|CPAP
49368|NCT02748681|stroke
49369|NCT02748681|telemedicine
49370|NCT02748681|neurorehabilitation
49371|NCT02748681|systolic blood pressure
49372|NCT02748629|inguinal hernia
49373|NCT02748629|mesh
49374|NCT02748629|lichtenstein
49375|NCT02748629|hernia repair
49376|NCT02748629|selfgripping mesh
49377|NCT02748616|Colitis
49378|NCT02748616|Bile
49379|NCT02748577|Migraines
49380|NCT02748577|Pain responses
49381|NCT02748551|Gastric cancer
49382|NCT02748551|locally advanced gastric cancer
49383|NCT02748551|laparoscopic surgery
49384|NCT02748551|laparoscopic procedure
49385|NCT02748551|comparison laparoscopic with open procedure
49386|NCT02748551|multicenter trials
49387|NCT02748486|schizophrenia
49388|NCT02748486|randomized controlled trial
49389|NCT02748486|metacognitive training
49390|NCT02748486|single sessions
49391|NCT02748473|Pilates exercises
49392|NCT02748473|pelvic floor muscle contraction
49393|NCT02748434|iPro2 Continuous Blood Glucose Recorder
49394|NCT02748434|Subclinical
49395|NCT02748421|retina surgery
49396|NCT02748421|image guided surgery
49397|NCT02748421|optical coherence tomography assisted
49398|NCT02748369|TCA cycle flux
49399|NCT02748369|in vivo measurements
49400|NCT02748369|Stable isotopes
49401|NCT02748369|Arteriovenous balance
49402|NCT02748369|Metabolome
49403|NCT02748369|Proteome
49404|NCT02748369|Exosomes
49405|NCT02748356|Spina Bifida
49406|NCT02748356|Spinal Cord Injury
49407|NCT02748317|Spina Bifida
49408|NCT02748317|Spinal Cord Injury
49409|NCT02748317|Lower Urinary Tract Symptoms
49410|NCT02748317|Probiotics
49411|NCT02748317|Intermittent Catheterization
49412|NCT02748291|Sedentary
49413|NCT02748291|Knee osteoarthritis
49414|NCT02748291|Knee pain
49415|NCT02748291|Gonarthritis
49416|NCT02748291|Arthritis
49417|NCT02748291|Walking
49418|NCT02748291|Pedometer
49419|NCT02748291|Physical Activity
49420|NCT02748291|Activities of Daily Function
49421|NCT02748291|Department of Health Physical Activity Guidelines
49422|NCT02748291|Improve pain
49423|NCT02748291|Decrease pain
49424|NCT02748291|Improve function
49425|NCT02748291|Increase function
49426|NCT02748291|Activity Monitoring
49427|NCT02748291|Monitoring, Ambulatory/instrumentation
49428|NCT02748278|subfertility
49429|NCT02748278|In-vitro fertilization
49430|NCT02748239|diabetes self-management education
49431|NCT02748239|insulin therapy
49432|NCT02748174|Migraine
49433|NCT02748174|Curelator
49434|NCT02748161|Hepatocellular carcinoma
49435|NCT02748161|DEB-TACE
49436|NCT02748161|QED
49437|NCT02748148|Medication Therapy Management
49438|NCT02748148|Pharmacogenomics
49439|NCT02748122|Adolescents
49440|NCT02748122|Insulin
49441|NCT02748122|T2DM
49442|NCT02748109|Physical Therapy
49443|NCT02748109|Balance Disorder
49444|NCT02748109|Concussion
49445|NCT02748109|Mild Traumatic Brain Injury
49446|NCT02748096|Unicompartmental Knee Replacement
49447|NCT02748096|Patient Specific Instrumentation
49448|NCT02748083|tDCS
49449|NCT02748083|schizophrenia
49450|NCT02748083|cognition
49451|NCT02748083|fMRI
49452|NCT02748031|Congenital cataracts
49453|NCT02748031|Opacity location
49454|NCT02748031|Opacity shape
49455|NCT02748031|Classification
49456|NCT02748031|Clinical applicability
49457|NCT02748005|Fenugreek seed extract
49458|NCT02748005|testosterone
49459|NCT02748005|protodioscin
49460|NCT02748005|hypogonadism
49461|NCT02747979|hemodialysis
49462|NCT02747979|hyperparathyroidism
49463|NCT02747979|refractory pruritus
49464|NCT02747979|ostalgia
49465|NCT02747979|insomnia
49466|NCT02747979|CVD incidence
49467|NCT02747979|life quality
49468|NCT02747966|access flow
49469|NCT02747966|access recirculation
49470|NCT02747966|cardiac output
49471|NCT02747966|cardiac index
49472|NCT02747966|hemodialysis
49473|NCT02747927|Drug therapy
49474|NCT02747901|KINESIOTAPING
49475|NCT02747901|COLD THERAPY
49476|NCT02747901|FUNCTIONAL PERFORMANCE
49477|NCT02747888|Thyroid
49478|NCT02747875|pediatric
49479|NCT02747875|cardiac bypass surgery
49480|NCT02747875|methadone
49481|NCT02747875|fentanyl
49482|NCT02747875|morphine
49483|NCT02747862|Attenuated Familial Adenomatous Polyposis
49484|NCT02747862|AFAP
49485|NCT02747862|Deleterious Familial Adenomatous Polyposis
49486|NCT02747862|FAP
49487|NCT02747862|Chart review
49488|NCT02747797|Advanced Cancer
49489|NCT02747797|Lucitanib (E3810)
49490|NCT02747797|Fibroblast Growth Factor Receptor
49491|NCT02747797|FGFR
49492|NCT02747797|Vascular Endothelial Growth Factor Receptor
49493|NCT02747797|VEGFR
49494|NCT02747797|Platelet Derived Growth Factor Receptor
49495|NCT02747797|PDGFR
49496|NCT02747797|metastatic malignancy
49497|NCT02747784|cognitive dysfunction
49498|NCT02747784|cognitive training
49499|NCT02747771|effectiveness
49500|NCT02747771|trichotillomania
49501|NCT02747771|hair pulling
49502|NCT02747771|habit reversal training
49503|NCT02747771|acceptance and commitment therapy
49504|NCT02747771|cognitive behavioral therapy
49505|NCT02747758|neuropathic pain
49506|NCT02747758|neuralgia
49507|NCT02747758|tDCS
49508|NCT02747758|transcranial direct current stimulation
49509|NCT02747745|Caregivers
49510|NCT02747745|Case Management
49511|NCT02747745|Community Dwelling
49512|NCT02747706|peer mentor
49513|NCT02747706|health coach
49514|NCT02747706|parent support
49515|NCT02747706|parent mentor
49516|NCT02747680|type 1 diabetes
49517|NCT02747680|hypoglycemia unawareness
49518|NCT02747680|healthy control
49519|NCT02747667|iol dislocation
49520|NCT02747667|iol complication
49521|NCT02747667|intraocular lens
49522|NCT02747667|Implant or Graft
49523|NCT02747667|Eye
49524|NCT02747654|NAT2 genotype guided dosing
49525|NCT02747628|Transdermal nicotine
49526|NCT02747628|Transdermal melatonin
49527|NCT02747628|Postoperative pain
49528|NCT02747628|Laparoscopic cholecystectomy
49529|NCT02747615|Preoperative autologous blood donation, allogeneic blood transfusion, parenteral iron, tranexamic acid, revision total hip arthroplasty, hemoglobin, hematocrit
49530|NCT02747602|Healthy volunteers
49531|NCT02747602|Caprylic triglyceride oil
49532|NCT02747602|AC-1204
49533|NCT02747602|Pharmacokinetic
49534|NCT02747602|Ketone body
49535|NCT02747576|Childhood Cancer Survivor
49536|NCT02747576|Social-cognition
49537|NCT02747576|Healthy Volunteers
49538|NCT02747563|prostate cancer
49539|NCT02747563|PSA
49540|NCT02747563|digital rectal examination
49541|NCT02747472|GIP
49542|NCT02747472|GIP receptor antagonist
49543|NCT02747446|fructose, triglyceride, oral glucose tolerance
49544|NCT02747433|robot-assisted therapy
49545|NCT02747433|task-oriented training
49546|NCT02747433|motor learning
49547|NCT02747420|Posterior Tibial Nerve Stimulation, Bladder
49548|NCT02747368|Wet age-related macular degeneration
49549|NCT02747368|Age-related macular degeneration
49550|NCT02747368|Ocusweep
49551|NCT02747368|Driving health
49552|NCT02747368|Visual field
49553|NCT02747368|Contrast sensitivity
49554|NCT02747342|Metastatic castration-resistant prostate cancer
49555|NCT02747342|Monotherapy
49556|NCT02747329|BuMA Supreme
49557|NCT02747329|Xience V/Prime
49558|NCT02747329|OCT
49559|NCT02747329|neointima formation
49560|NCT02747316|Iron bioavailability
49561|NCT02747316|Hepcidin
49562|NCT02747316|Iron absorption
49563|NCT02747303|brain metastases
49564|NCT02747303|Stereotactic Radiosurgery
49565|NCT02747290|BBN-RGD
49566|NCT02747290|PET
49567|NCT02747290|integrin αvβ3
49568|NCT02747290|GRPR
49569|NCT02747264|eRAPID
49570|NCT02747264|PRO
49571|NCT02747264|PROM
49572|NCT02747264|Adverse event
49573|NCT02747264|QTool
49574|NCT02747264|CTCAE
49575|NCT02747251|"Shoulder Impingement Syndrome[Mesh]"
49576|NCT02747251|"Rehabilitation[Mesh]"
49577|NCT02747251|"Exercise[Mesh]"
49578|NCT02747251|"Rotator Cuff[Mesh]"
49579|NCT02747238|Pregnancy
49580|NCT02747238|Epidural
49581|NCT02747238|Labor
49582|NCT02747225|electrical properties
49583|NCT02747225|malignant tissues
49584|NCT02747225|in vivo
49585|NCT02747212|electrical properties
49586|NCT02747212|malignant tissues
49587|NCT02747212|ex vivo
49588|NCT02747199|SYNERGY
49589|NCT02747199|Neointimal formation
49590|NCT02747199|OCT
49591|NCT02747199|coronary angioscopy
49592|NCT02747199|coronary artery disease
49593|NCT02747186|lidocaine, jaw
49594|NCT02747173|metastatic, bone metastases
49595|NCT02747160|Cancer
49596|NCT02747160|Anxiety
49597|NCT02747160|Cognitive behavior therapy
49598|NCT02747160|Elderly
49599|NCT02747160|Caregivers
49600|NCT02747121|External inspections
49601|NCT02747108|Veterans
49602|NCT02747108|Type 2 Diabetes Mellitus
49603|NCT02747108|Prediabetes
49604|NCT02747108|Decision-making
49605|NCT02747108|Motivation
49606|NCT02747108|Health Promotion
49607|NCT02747108|Prevention and Control
49608|NCT02747082|endodontic retreatment
49609|NCT02747082|sodium hypochlorite
49610|NCT02747082|chlorhexidine
49611|NCT02747082|calcium hydroxide
49612|NCT02747082|Retreatment
49613|NCT02747069|Heart rate
49614|NCT02747069|Electronic Stethoscope
49615|NCT02747069|Electrocardiogram
49616|NCT02747069|Resuscitation
49617|NCT02747030|Central retinal vein occlusion
49618|NCT02747030|Retinal endovascular surgery
49619|NCT02747030|Retinal vein cannulation
49620|NCT02747030|Ocriplasmin
49621|NCT02747017|transplant
49622|NCT02746965|magnetic seizure therapy
49623|NCT02746965|randomized controlled trials
49624|NCT02746965|schizophrenia
49625|NCT02746965|cognition
49626|NCT02746939|program evaluation
49627|NCT02746939|health literacy
49628|NCT02746939|fitness
49629|NCT02746939|nutrition
49630|NCT02746939|education
49631|NCT02746913|Pelvic, Urodynamic, Vaginal Wall
49632|NCT02746874|Total Knee Replacement, Replacement of the knee joint,
49633|NCT02746861|peer mentor
49634|NCT02746861|peer supporter
49635|NCT02746861|peer coach
49636|NCT02746861|peer-to-peer mentoring
49637|NCT02746848|cornea epithelium healing Amniotic Membrane Eye Drop
49638|NCT02746835|physical condition
49639|NCT02746835|self-efficacy
49640|NCT02746835|fall risk
49641|NCT02746835|exercise program
49642|NCT02746822|acute myocardial infarction,
49643|NCT02746822|thrombus aspiration
49644|NCT02746679|Asherman syndrome
49645|NCT02746679|Mindfulness
49646|NCT02746679|Anxiety
49647|NCT02746679|Depression
49648|NCT02746679|Quality of Life
49649|NCT02746653|Fascia Closure Device, hernia,
49650|NCT02746614|adaptive behavior
49651|NCT02746614|motor proficiency
49652|NCT02746614|psychomotor therapy
49653|NCT02746614|intellectual disability
49654|NCT02746588|miscarriage
49655|NCT02746588|uterine abnormalities
49656|NCT02746588|Chronic infection
49657|NCT02746562|Assisted reproduction
49658|NCT02746562|In vitro fertilisation
49659|NCT02746562|Frozen embryo transfer (FER)
49660|NCT02746536|COPD
49661|NCT02746536|Inspiratory capacity
49662|NCT02746536|Exercise
49663|NCT02746523|NHL
49664|NCT02746523|Concussion
49665|NCT02746523|Biomarkers
49666|NCT02746497|Menopause
49667|NCT02746497|Hot flushes
49668|NCT02746497|Acupuncture
49669|NCT02746497|Randomized controlled trial
49670|NCT02746458|Blood Flow Restriction
49671|NCT02746458|Muscle Weakness
49672|NCT02746458|Physical therapy techniques
49673|NCT02746458|closed femoral fracture injuries
49674|NCT02746445|Autism
49675|NCT02746445|ASD
49676|NCT02746445|Autism Spectrum Disorder
49677|NCT02746432|CRC-Insulin
49678|NCT02746354|Chronic Pain
49679|NCT02746354|Analgesics, Opioid
49680|NCT02746354|Primary Health Care
49681|NCT02745470|lean/obese diabetes mellitus
49682|NCT02745470|functional MRI
49683|NCT02745470|GLP-1
49684|NCT02745470|appetite
49685|NCT02745470|activation of brain
49686|NCT02745470|connectivity
49687|NCT02745444|Living kidney transplantation
49688|NCT02745444|Chronic kidney disease
49689|NCT02745444|Acute kidney injury
49690|NCT02745431|Likeability
49691|NCT02745431|Being liked
49692|NCT02745431|Prospective taking
49693|NCT02745405|Weight Stigma
49694|NCT02745405|Cortisol Reactivity
49695|NCT02745405|Eating Behavior
49696|NCT02745392|migraine
49697|NCT02745392|migraine headache
49698|NCT02745392|acute migraine
49699|NCT02745392|acute migraine headache
49700|NCT02745353|Cancer
49701|NCT02745353|Constipation
49702|NCT02745353|Opioid
49703|NCT02745327|oral vaccination
49704|NCT02745327|nutrition
49705|NCT02745314|Aortic Stenosis, Frailty, Elderly, moertality
49706|NCT02745275|Peer Education
49707|NCT02745275|Health Coaches
49708|NCT02745275|Community Dwelling Seniors
49709|NCT02745275|Health Literacy
49710|NCT02745275|Health Education
49711|NCT02745275|Healthy Ageing
49712|NCT02746276|malnutrition
49713|NCT02746276|antibiotics
49714|NCT02746276|antimicrobial resistance
49715|NCT02746276|pharmacokinetics
49716|NCT02746263|Elective total knee arthroplasty
49717|NCT02746237|Serotonin
49718|NCT02746237|Pulmonary Arterial Hypertension
49719|NCT02746237|Pharmacokinetics
49720|NCT02746237|Phase 1
49721|NCT02746237|Healthy Volunteers
49722|NCT02746224|Colorectal cancer
49723|NCT02746224|Colorectal surgery
49724|NCT02746211|immunology
49725|NCT02746211|pathogenicity
49726|NCT02746198|Probiotics, Antibiotics, AAD, Helicobacter p.
49727|NCT02746185|cancer
49728|NCT02746185|venous thromboembolism
49729|NCT02746185|low-molecular weight heparin
49730|NCT02746185|rivaroxaban
49731|NCT02746172|cochlear implants
49732|NCT02746172|Mapping
49733|NCT02746172|in-situ audiometry
49734|NCT02746107|shared decision making
49735|NCT02746107|oral anticoagulant
49736|NCT02746107|atrial fibrillation
49737|NCT02746107|stroke
49738|NCT02746107|decision to treat
49739|NCT02746081|BAY1436032
49740|NCT02746081|Solid tumors
49741|NCT02746081|IDH1-R132X Mutation
49742|NCT02746081|Cancer
49743|NCT02746081|Safety
49744|NCT02746081|Tolerability
49745|NCT02746081|Pharmacokinetics
49746|NCT02746081|Pharmacodynamics
49747|NCT02746081|Efficacy
49748|NCT02746068|Bone Marrow Lesions
49749|NCT02746068|AXS02
49750|NCT02746068|Axsome
49751|NCT02746068|Knee OA
49752|NCT02746068|Osteoarthritis
49753|NCT02746042|chronic rhinosinusitis
49754|NCT02746042|Sinupret extract
49755|NCT02746042|herbal medicinal product
49756|NCT02746003|drinking water
49757|NCT02746003|salinity
49758|NCT02745990|erythropoietin
49759|NCT02745990|preterm
49760|NCT02745990|brain injury
49761|NCT02745990|cerebral palsy
49762|NCT02745990|PVL
49763|NCT02745951|cardiopulmonary bypass
49764|NCT02745951|cardioplegia
49765|NCT02745951|cardioprotection
49766|NCT02745951|coronary artery bypass graft surgery
49767|NCT02745951|heliox
49768|NCT02745938|Exercise test
49769|NCT02745938|GDF-15
49770|NCT02745938|Growth and Differentiation Factor 15
49771|NCT02745925|Iron bioavailability
49772|NCT02745925|Inflammation
49773|NCT02745925|Hepcidin
49774|NCT02745925|Iron absorption
49775|NCT02745912|Drug Therapy
49776|NCT02745899|asthma
49777|NCT02745899|cow milk
49778|NCT02745899|pulmonary function testing
49779|NCT02745899|children
49780|NCT02745899|mucus
49781|NCT02745860|selexipag
49782|NCT02745860|pharmacokinetics
49783|NCT02745821|coronary flow reserve
49784|NCT02745821|fractional flow reserve
49785|NCT02745821|diabetes mellitus
49786|NCT02745821|coronary artery disease
49787|NCT02745821|percutaneous coronary intervention
49788|NCT02745821|coronary physiology
49789|NCT02745821|index of microcirculatory resistance
49790|NCT02745795|Motivational interview
49791|NCT02745795|adolescents
49792|NCT02745795|obesity
49793|NCT02745795|overweight
49794|NCT02745795|physical activity
49795|NCT02745795|diet
49796|NCT02745782|Pulpitis
49797|NCT02745782|Syncope
49798|NCT02745782|Trigeminal Cardio-Reflex
49799|NCT02745756|Children
49800|NCT02745756|Cancer
49801|NCT02745756|High-risk neuroblastoma
49802|NCT02745743|Phase 1
49803|NCT02745743|Dose escalation
49804|NCT02745743|Dose expansion
49805|NCT02745743|Positive transcription elongation factor b inhibitor
49806|NCT02745743|Cyclin-dependent kinase 9 inhibitor
49807|NCT02745717|Severe aplastic anemia
49808|NCT02745717|immunosuppressive therapy
49809|NCT02745717|cord blood transfusion
49810|NCT02745704|chronic hepatitis B
49811|NCT02745704|peginterferon alfa
49812|NCT02745678|Enema
49813|NCT02745678|Ulcerative Colitis
49814|NCT02745652|median nerve
49815|NCT02745652|wrist joint
49816|NCT02745652|carpal tunnel
49817|NCT02745639|rectal cancer
49818|NCT02745639|radiotherapy
49819|NCT02745639|chemotherapy
49820|NCT02745639|VMAT
49821|NCT02745639|toxicity
49822|NCT02745600|RFA
49823|NCT02745600|Liver
49824|NCT02745600|Ablation Techniques
49825|NCT02745600|Treatment Simulation
49826|NCT02745600|Computer assisted therapy
49827|NCT02745574|should and upper abdominal pain, post-laparoscopy
49828|NCT02745561|Endostatin
49829|NCT02745561|Oxaliplatin
49830|NCT02745561|Esophageal Cancer
49831|NCT02745561|chemoradiotherapy
49832|NCT02745548|Lung Cancer
49833|NCT02745548|NSCLC (Non Small Cell Lung Cancer)
49834|NCT02745548|SABR (Stereotactic ablative radiotherapy)
49835|NCT02745522|Placebo analgesia
49836|NCT02745522|Working memory
49837|NCT02745509|Extensive Intraoperative Peritoneal Lavage
49838|NCT02745509|EIPL
49839|NCT02745509|Gastric Cancer
49840|NCT02745496|Image-guided biopsy
49841|NCT02745496|Tumour detection
49842|NCT02745496|Diagnostic
49843|NCT02745496|Biomarkers
49844|NCT02745483|RFA
49845|NCT02745236|Atrial Fibrillation
49846|NCT02745236|Health Related Quality of Life
49847|NCT02745236|Nurse Practitioner
49848|NCT02745236|Sustainable Models of Healthcare
49849|NCT02745236|Patient Satisfaction
49850|NCT02745171|Parkinson's disease
49851|NCT02745171|Quality of life
49852|NCT02745171|Functional mobility
49853|NCT02745171|Follow up
49854|NCT02745158|Fibrodysplasia ossificans progressiva
49855|NCT02745158|FOP
49856|NCT02745158|International FOP Association
49857|NCT02745158|Patient Advocacy Group
49858|NCT02745158|Patient Registry
49859|NCT02745158|Natural History
49860|NCT02745158|Patient-Reported Outcomes
49861|NCT02745158|Observational Database
49862|NCT02745158|Bone Morphogenetic Protein
49863|NCT02745158|BMP
49864|NCT02745158|Bone Growth
49865|NCT02745158|Joint
49866|NCT02745158|Mobility
49867|NCT02745158|Flare-Up
49868|NCT02745158|Heterotopic Ossification
49869|NCT02745158|Ectopic Bone
49870|NCT02745158|Osteochondroma
49871|NCT02745158|Hallux Valgus
49872|NCT02745158|ALK2
49873|NCT02745158|ACVR1
49874|NCT02745158|Activin A
49875|NCT02745158|IFOPA
49876|NCT02745158|Activin A Receptor Type I
49877|NCT02745158|Activin Receptor-like Kinase-2
49878|NCT02745145|Double-Blind Method
49879|NCT02745145|Interstitial Lung Diseases
49880|NCT02745145|Systemic Scleroderma
49881|NCT02745145|Abituzumab
49882|NCT02745145|Mycophenolate
49883|NCT02745145|Efficacy, Safety
49884|NCT02745132|Chronic, Cognition Disorders
49885|NCT02745132|Neurocognition Disorders
49886|NCT02745132|Cognitive Impairments
49887|NCT02745132|Diffusion Magnetic Resonance Imaging
49888|NCT02745132|MRI functional
49889|NCT02745132|Verbal fluency
49890|NCT02745106|Chronic thromboembolic pulmonary hypertension, Navigation system, Ablation
49891|NCT02745093|Abortion induced
49892|NCT02745093|Patient Acceptance of Healthcare
49893|NCT02745093|safety
49894|NCT02745093|effectiveness
49895|NCT02745093|misoprostol
49896|NCT02745093|mifepristone
49897|NCT02745080|Psoriatic Arthritis
49898|NCT02745080|secukinumab
49899|NCT02745080|adalimumab
49900|NCT02745080|monoclonal antibody
49901|NCT02745080|CASPAR
49902|NCT02745054|oral anticoagulants
49903|NCT02745054|bleeding
49904|NCT02745054|anticoagulation reversal
49905|NCT02745041|Fibrinogen
49906|NCT02745041|Cryoprecipitate
49907|NCT02745028|delayed gastric emptying
49908|NCT02745028|children
49909|NCT02745028|monosodium glutamate
49910|NCT02745015|periodontitis
49911|NCT02745015|diabetes
49912|NCT02745015|HbA1c
49913|NCT02745015|inflammation
49914|NCT02745002|Bronchoscopy
49915|NCT02745002|Bronchoscopes
49916|NCT02744989|Schizophrenia
49917|NCT02744989|Transcranial direct-current stimulation (tDCS)
49918|NCT02744989|Sham
49919|NCT02744989|Positive and Negative Syndrome Scale (PANSS)
49920|NCT02744989|Functional Magnetic Resonance Imaging (fRMI)
49921|NCT02744989|Brain-Derived-Neurotrophic Factor (BDNF)
49922|NCT02744976|Coronary artery disease
49923|NCT02744976|Atherosclerosis
49924|NCT02744976|Prediabetes
49925|NCT02744976|Intravascular ultrasound
49926|NCT02744976|Insulin resistance
49927|NCT02744976|Percutaneous coronary intervention
49928|NCT02744976|Metformin
49929|NCT02744950|pulley
49930|NCT02744950|scalp defects
49931|NCT02744911|speech problems
49932|NCT02744898|uterus
49933|NCT02744898|gynecological
49934|NCT02744872|lung transplantation
49935|NCT02744872|chronic renal insufficiency
49936|NCT02744859|Decision Making
49937|NCT02744859|Consumption
49938|NCT02744859|Economics
49939|NCT02744846|antibiotics
49940|NCT02744846|children
49941|NCT02744846|pediatric
49942|NCT02744846|body mass index
49943|NCT02744846|Observational Study
49944|NCT02744846|Comparative Effectiveness Research
49945|NCT02744846|Obesity
49946|NCT02744846|Growth Trajectory
49947|NCT02744846|Cohort Study
49948|NCT02744846|Electronic Medical Record
49949|NCT02744846|Qualitative Research
49950|NCT02744833|DVT
49951|NCT02744807|intrauterine adhesions
49952|NCT02744807|Chronic endometritis
49953|NCT02744807|infections
49954|NCT02744807|Hysteroscopy
49955|NCT02744781|Muscular Atrophy
49956|NCT02744781|Asymmetry
49957|NCT02744781|Athletes
49958|NCT02744768|Acute Lymphoblastic Leukemia, adult, dasatinib, blinatumomab
49959|NCT02744716|intrauterine balloon
49960|NCT02744716|uterine endometrial repair
49961|NCT02744716|intrauterine adhesion
49962|NCT02744716|aspirin
49963|NCT02744690|Eye Disease
49964|NCT02744690|Intraocular Pressure
49965|NCT02744690|Visual Acuity
49966|NCT02744690|Trabeculectomy
49967|NCT02744677|Tetralogy of Fallot
49968|NCT02744677|Aortic Valve Defect/Disease Resulting in Ross Procedure
49969|NCT02744677|Pulmonary Atresia
49970|NCT02744677|Pulmonary Stenosis
49971|NCT02744677|Truncus Arteriosus
49972|NCT02744677|Transposition of the Great Arteries
49973|NCT02744677|Transcatheter pulmonary valve implantation
49974|NCT02744677|Transcatheter pulmonary valve replacement
49975|NCT02744677|TPV
49976|NCT02744677|TPVR
49977|NCT02744677|TPVI
49978|NCT02744664|Lung Neoplasms
49979|NCT02744664|EGFR mutation
49980|NCT02744664|Cryotherapy
49981|NCT02744664|Icotinib
49982|NCT02744638|bacterial vaginosis
49983|NCT02744638|probiotics
49984|NCT02744638|Amsel Score
49985|NCT02744638|Nugent Score
49986|NCT02744599|Feasibility trial
49987|NCT02744586|Sexually transmitted infections
49988|NCT02744586|Neglected tropical diseases
49989|NCT02744586|Non-communicable diseases
49990|NCT02744534|Prostate Cancer
49991|NCT02744534|Imaging Technology
49992|NCT02744534|Oncology
49993|NCT02744534|Prostate Biopsy
49994|NCT02744508|palonosetron, dexamethasone, PONV (postoperative nausea and vomiting)
49995|NCT02744495|cardiac surgery
49996|NCT02744495|corticoids
49997|NCT02744495|droperidol
49998|NCT02744495|antiemetics
49999|NCT02744495|Postoperative Vomiting
50000|NCT02744495|Postoperative Nausea
50001|NCT02744495|Postoperative Emesis
50002|NCT02744495|prophylaxis
50003|NCT02744469|Tuberculosis
50004|NCT02744469|population structure
50005|NCT02744469|implications
50006|NCT02744469|lineages
50007|NCT02744469|spoligotyping
50008|NCT02744469|sputum
50009|NCT02744469|resistance
50010|NCT02744469|culture
50011|NCT02744469|diagnostics
50012|NCT02744469|outcome
50013|NCT02744469|new/retreatment patient
50014|NCT02744456|Hydrochlorothiazide tablet
50015|NCT02744456|Norvasc
50016|NCT02744456|Cozaar
50017|NCT02744456|amlodipine besylate tablets
50018|NCT02744456|losartan potassium tablets
50019|NCT02744456|Hypertension
50020|NCT02744456|High Blood Pressure
50021|NCT02744430|Medical expulsive therapy
50022|NCT02744430|ureteral stone
50023|NCT02744430|stent pain
50024|NCT02744417|smoking cessation
50025|NCT02744417|tobacco
50026|NCT02744417|periodontal
50027|NCT02744417|subgingival microorganisms
50028|NCT02744352|infraclavicular brachial plexus block
50029|NCT02744352|quality of recovery score
50030|NCT02744352|pain score
50031|NCT02744352|disability assessment of shoulder and hand questionnaire
50032|NCT02744339|PH-HFpEF
50033|NCT02744300|Gestational diabetes mellitus (GDM) in most recent pregnancy
50034|NCT02744287|Non Resectable Pancreatic Cancer
50035|NCT02744287|BPX-601
50036|NCT02744287|AP1903
50037|NCT02744287|CAR T
50038|NCT02744287|PSCA-CAR
50039|NCT02744274|acupuncture
50040|NCT02744274|chemotherapy
50041|NCT02744274|peripheral neuropathy
50042|NCT02744274|randomized clinical trial
50043|NCT02744274|numbness
50044|NCT02744261|HIV
50045|NCT02744261|STI
50046|NCT02744261|Primary Prevention
50047|NCT02744261|Topical Microbicides
50048|NCT02744261|User Experience
50049|NCT02744261|Drug Delivery Systems
50050|NCT02744248|Magnetic Resonance Imaging (MRI)
50051|NCT02744196|rheumatoid arthritis
50052|NCT02744196|rheumatism
50053|NCT02744196|Acellbia
50054|NCT02744196|methotrexate
50055|NCT02744196|biologic therapy
50056|NCT02744196|monoclonal antibody
50057|NCT02744196|rituximab
50058|NCT02744183|Exercise
50059|NCT02744183|Fasted
50060|NCT02744183|Glucose
50061|NCT02744183|Energy Balance
50062|NCT02744170|COPD
50063|NCT02744170|Incremental Shuttle Walk Test
50064|NCT02744170|Endurance Shuttle Walk Test
50065|NCT02744170|oxygen therapy
50066|NCT02744131|PCOS
50067|NCT02744131|Metformin
50068|NCT02744131|OCP
50069|NCT02744131|metabolic parameters
50070|NCT02744118|Media Use
50071|NCT02744092|Rivaroxaban (Xarelto)
50072|NCT02744092|Apixaban (Eliquis)
50073|NCT02744092|Edoxaban (Savaysa)
50074|NCT02744092|Dabigatran (Pradaxa)
50075|NCT02744092|Warfarin (Coumadin)
50076|NCT02744092|Low molecular weight heparin (LMWH)
50077|NCT02744079|diet
50078|NCT02744079|dietary intervention
50079|NCT02744079|carbohydrate restriction
50080|NCT02744079|low carbohydrate
50081|NCT02744079|fat restriction
50082|NCT02744079|low fat
50083|NCT02744079|cancer
50084|NCT02744079|breast cancer
50085|NCT02744079|pre-surgical window
50086|NCT02744079|biomarker
50087|NCT02744053|Breast Cancer
50088|NCT02744053|Malignant neoplasm of breast
50089|NCT02744053|Triple Negative Breast Cancer
50090|NCT02744053|TNBC
50091|NCT02744053|Tc99m Sestamibi Molecular Breast Imaging
50092|NCT02744053|MBI
50093|NCT02744053|Dynamic Contrast Enhanced Molecular Resonance Imaging
50094|NCT02744053|DCE-MRI
50095|NCT02744040|HIV reservoir
50096|NCT02744040|alcohol
50097|NCT02744040|ART
50098|NCT02744027|Generalized Lymphatic Anomaly
50099|NCT02744027|Kaposiform Lymphangiomatosis
50100|NCT02744027|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram
50101|NCT02744027|Magnetic Resonance Imaging
50102|NCT02743988|cerebral oxygenation
50103|NCT02743988|NIRS
50104|NCT02743988|near-infrared spectroscopy
50105|NCT02743988|bradycardia
50106|NCT02743988|hypoxemia
50107|NCT02743988|cerebral perfusion
50108|NCT02743988|cardiac output
50109|NCT02743988|apnea
50110|NCT02743988|desaturation
50111|NCT02743988|oxygen saturation target range
50112|NCT02743949|Drug therapy
50113|NCT02743910|preoperative
50114|NCT02743910|neoadjuvant
50115|NCT02743910|plasma tumor DNA
50116|NCT02743910|ptDNA
50117|NCT02743897|end-stage renal disease
50118|NCT02743871|FIH, Pharmacokinetics
50119|NCT02743858|Lymphedema
50120|NCT02743858|Surveillance Program
50121|NCT02743858|Axillary Lymph Node Dissection
50122|NCT02743858|16-220
50123|NCT02743845|Rare
50124|NCT02743845|Undiagnosed
50125|NCT02743845|Orphan Disease
50126|NCT02743845|Genomic Sequencing
50127|NCT02743832|Surgery, Oral
50128|NCT02743832|Tumor budding
50129|NCT02743819|Melanoma
50130|NCT02743819|Pembrolizumab
50131|NCT02743819|Ipilimumab
50132|NCT02743806|Drug Therapy
50133|NCT02743793|single organ liver or kidney allograft
50134|NCT02743793|operationally tolerant allograft recipients
50135|NCT02743793|longitudinal follow-up
50136|NCT02743780|Ocular Hypertension
50137|NCT02743780|Open-Angle Glaucoma
50138|NCT02743780|POAG
50139|NCT02743780|Glaucoma
50140|NCT02743767|Airway management
50141|NCT02743767|General anaesthesia
50142|NCT02743767|Critical incidents
50143|NCT02743767|Complications
50144|NCT02743741|Somatostatin Receptor Positive Neuroendocrine Tumors
50145|NCT02743728|perinatal stroke
50146|NCT02743728|transcranial magnetic stimulation
50147|NCT02743728|magnetic resonance imaging
50148|NCT02743728|diffusion tensor imaging
50149|NCT02743728|non-invasive brain stimulation
50150|NCT02743728|infant
50151|NCT02743715|Obsessive-Compulsive Disorder
50152|NCT02743715|Transcranial direct current stimulation
50153|NCT02743715|Neuromodulation
50154|NCT02743702|Effectiveness
50155|NCT02743702|Physical therapy modalities
50156|NCT02743702|neuromuscular diseases
50157|NCT02743689|Postoperative
50158|NCT02743689|Cardiac surgery
50159|NCT02743676|Avian Influenza
50160|NCT02743663|pediatric
50161|NCT02743663|lung ventilation inhomogeneity
50162|NCT02743663|preschool
50163|NCT02743663|asthma
50164|NCT02743663|wheeze
50165|NCT02743650|Low Serum Bicarbonate Level
50166|NCT02743650|Sodium Bicarbonate
50167|NCT02743637|Cancer
50168|NCT02743637|Oncology
50169|NCT02743637|Solid Tumors
50170|NCT02743637|Phase 1
50171|NCT02743637|SDX-7320
50172|NCT02743637|SynDevRx
50173|NCT02743637|MetAP2
50174|NCT02743637|Breast
50175|NCT02743637|Post menopausal
50176|NCT02743637|Colorectal
50177|NCT02743637|Pancreatic
50178|NCT02743637|Ovarian
50179|NCT02743637|Endometrial
50180|NCT02743637|Esophageal
50181|NCT02743637|Lung
50182|NCT02743637|Renal
50183|NCT02743637|Prostate
50184|NCT02743637|Liver
50185|NCT02743611|BPX-701
50186|NCT02743611|AP1903
50187|NCT02743611|Rimiducid
50188|NCT02743611|AML
50189|NCT02743611|MDS
50190|NCT02743611|Primary Refractory AML
50191|NCT02743611|Relapsed AML
50192|NCT02743611|Refractory Myeloid Neoplasms
50193|NCT02743598|HIV infection
50194|NCT02743598|Diabetes Mellitus type 2
50195|NCT02743598|Obesity
50196|NCT02743598|Neurocognitive function
50197|NCT02743572|premature infant
50198|NCT02743572|anemia
50199|NCT02743572|iron-fortification
50200|NCT02743572|parenteral nutrition
50201|NCT02743572|randomized controlled trial
50202|NCT02743546|B-Cell, Malignancy
50203|NCT02743546|Lymphoma, Large B-Cell, Diffuse
50204|NCT02743546|Lymphoma, Mantle-Cell
50205|NCT02743546|Lymphoma, Follicular
50206|NCT02743546|Lymphocytic, Chronic, B-Cell
50207|NCT02743546|JNJ-64052781
50208|NCT02743546|Ibrutinib
50209|NCT02743533|cardiovascular diseases, prognosis
50210|NCT02743520|sleep apnea
50211|NCT02743481|Pesticide
50212|NCT02743481|Agriculture
50213|NCT02743481|Cancer
50214|NCT02743481|Childhood
50215|NCT02743481|Leukemia
50216|NCT02743468|Bronchoscopy
50217|NCT02743468|Pollutants
50218|NCT02743468|Human Pulmonary Cells
50219|NCT02743468|Cytochrome P450
50220|NCT02743468|Soluble Epoxide Hydrolase
50221|NCT02743455|Fever
50222|NCT02743455|Immunogenicity
50223|NCT02743455|MVA-BN
50224|NCT02743455|Reactogenicity
50225|NCT02743455|Vaccine
50226|NCT02743455|Yellow
50227|NCT02743429|ch14.18/CHO
50228|NCT02743429|neuroblastoma
50229|NCT02743429|long term infusion
50230|NCT02743416|Screening
50231|NCT02743416|Stroke prevention
50232|NCT02743416|Cost effectiveness
50233|NCT02743390|blood pressure
50234|NCT02743390|inflammation
50235|NCT02743390|tumor Necrosis Factor-alpha
50236|NCT02743377|GsI+/-
50237|NCT02743377|Camp
50238|NCT02743377|GNAS
50239|NCT02743351|Cell Transplants
50240|NCT02743351|Hematopoietic Cell Transplant
50241|NCT02743351|HCT
50242|NCT02743351|Hematologic Malignancies
50243|NCT02743351|Hematologic Malignancy
50244|NCT02743351|Acute Myeloid Leukemia
50245|NCT02743351|Acute Lymphoblastic Leukemia
50246|NCT02743338|Sleep Restriction
50247|NCT02743338|Sleep Compression
50248|NCT02743338|Cognitive Behavioral Therapy
50249|NCT02743312|Balance-Based Torso-Weighting
50250|NCT02743312|Physical Activity
50251|NCT02743312|Neurorehabilitation
50252|NCT02743286|sedentary behavior
50253|NCT02743286|sitting
50254|NCT02743286|feasibility
50255|NCT02743286|endothelial function
50256|NCT02743286|metabolism
50257|NCT02743260|phenotype
50258|NCT02743260|transporter
50259|NCT02743260|cocktail
50260|NCT02743247|Healthy volunteer
50261|NCT02743221|metastatic
50262|NCT02743221|colorectal
50263|NCT02743221|cancer
50264|NCT02743221|untreated
50265|NCT02743221|first-line
50266|NCT02743221|S95005
50267|NCT02743221|bevacizumab
50268|NCT02743221|capecitabine
50269|NCT02743208|Arthroplasty, Replacement, Hip
50270|NCT02743208|Surgical Procedures, Operative
50271|NCT02743208|Hip Prosthesis
50272|NCT02743169|Geographic Information Systems
50273|NCT02743169|Spatial Analysis
50274|NCT02743169|Emergency Medical Services
50275|NCT02743156|IVUS
50276|NCT02743156|Acute Renal Failure
50277|NCT02743156|Angioplasty
50278|NCT02743156|stent
50279|NCT02743156|contrast
50280|NCT02743156|percutaneous coronary intervention
50281|NCT02743156|intravascular ultrasound
50282|NCT02743143|Exercise therapy
50283|NCT02743143|Cardiovascular disease
50284|NCT02743143|Risk
50285|NCT02743130|Berries
50286|NCT02743130|Blackcurrant (Ribes nigrum)
50287|NCT02743130|Lingonberry (Vaccinium vitis-idaea)
50288|NCT02743130|Sucrose
50289|NCT02743130|Inverted sugar
50290|NCT02743130|Postprandial glucose response
50291|NCT02743130|Postprandial insulin response
50292|NCT02743117|Trivalent
50293|NCT02743117|Influenza
50294|NCT02743117|FluMist Quadrivalent
50295|NCT02743117|Vaccine
50296|NCT02743117|Prevention
50297|NCT02743117|Healthy
50298|NCT02743117|Monovalent
50299|NCT02743091|heart failure
50300|NCT02743091|survival
50301|NCT02743091|end-stage kidney disease
50302|NCT02743078|Glioblastoma
50303|NCT02743078|Glioma
50304|NCT02743078|Gliosarcoma
50305|NCT02743078|Optune
50306|NCT02743078|TTFields
50307|NCT02743065|HepaSphere
50308|NCT02743039|Low income
50309|NCT02743039|Education
50310|NCT02743039|Poverty
50311|NCT02743039|Children
50312|NCT02743039|Parents
50313|NCT02743039|Head Start
50314|NCT02743000|fMRI
50315|NCT02743000|emotion conflict task
50316|NCT02743000|monetary incentive delay
50317|NCT02742974|Trauma
50318|NCT02742974|Minimally Invasive Hemodynamic Monitoring
50319|NCT02742974|Perioperative
50320|NCT02742974|Complications
50321|NCT02742974|Hemodynamics
50322|NCT02742974|Operative procedures
50323|NCT02742961|orthopedics
50324|NCT02742961|anesthesiology
50325|NCT02742961|nerve block
50326|NCT02742961|length of stay
50327|NCT02742961|Patient readmission
50328|NCT02742948|elective caesarean section
50329|NCT02742948|antibiotics
50330|NCT02742948|endometritis
50331|NCT02742922|self harm
50332|NCT02742922|culturally adapted therapy
50333|NCT02742922|problem solving therapy
50334|NCT02742922|low and middle income countries
50335|NCT02742896|Erectile dysfunction
50336|NCT02742896|cognitive function
50337|NCT02742870|Diffusion MRI
50338|NCT02742870|ADC histograms
50339|NCT02742870|Adnexal tumor
50340|NCT02742844|phase I/IIa
50341|NCT02742844|mesenchymal stem cells
50342|NCT02742844|ABCB5+
50343|NCT02742844|APZ2
50344|NCT02742844|chronic venous ulcer
50345|NCT02742844|varicose ulcer
50346|NCT02742844|skin ulcer
50347|NCT02742844|advanced therapy medicinal product
50348|NCT02742844|APZ2-II-01
50349|NCT02742844|autologous use
50350|NCT02742844|somatic cell therapy
50351|NCT02742818|forced-air warming
50352|NCT02742818|hypothermia
50353|NCT02742818|endovascular surgery
50354|NCT02742818|blanket
50355|NCT02742805|hives
50356|NCT02742792|sleep apnea
50357|NCT02742792|elderly
50358|NCT02742792|exercise
50359|NCT02742766|Dose escalation study
50360|NCT02742766|Safety
50361|NCT02742766|Pharmacodynamics
50362|NCT02742766|Pharmacokinetics
50363|NCT02742766|GSK3008356
50364|NCT02742766|Tolerability
50365|NCT02742753|Otitis
50366|NCT02742753|Vaccine
50367|NCT02742753|Sweden
50368|NCT02742753|Database
50369|NCT02742675|prostate cancer
50370|NCT02742675|androgen deprivation therapy
50371|NCT02742675|local treatment
50372|NCT02742662|Obesity
50373|NCT02742662|Overweight
50374|NCT02742662|Prediabetes
50375|NCT02742662|Smartphone application
50376|NCT02742662|Technology
50377|NCT02742662|Weight Loss
50378|NCT02742662|Lifestyle Intervention
50379|NCT02742623|Cancer
50380|NCT02742623|Deep Venous Thrombosis
50381|NCT02742623|Pulmonary Embolism
50382|NCT02742584|cough stress test
50383|NCT02742584|urodynamics
50384|NCT02742584|pad test
50385|NCT02742571|Biological evaluation of denutrition
50386|NCT02742571|Denutrition
50387|NCT02742571|PINI score
50388|NCT02742558|cholera vaccine
50389|NCT02742558|randomized trial
50390|NCT02742558|immunogenicity
50391|NCT02742506|Brain-damaged
50392|NCT02742506|Disorders of consciousness
50393|NCT02742506|Post-coma
50394|NCT02742506|consciousness
50395|NCT02742506|coma
50396|NCT02742506|vegetative state
50397|NCT02742506|minimally conscious state
50398|NCT02742506|music
50399|NCT02742506|P300
50400|NCT02742493|relapse
50401|NCT02742493|irregularity
50402|NCT02742493|recession
50403|NCT02742493|retention
50404|NCT02742480|stroke
50405|NCT02742480|oral anticoagulants
50406|NCT02742480|cardioembolic
50407|NCT02742454|Umbilical Cord Clamping
50408|NCT02742454|Intraventricular Hemorrhage
50409|NCT02742454|Extremely Preterm Infants
50410|NCT02742337|Epigenetic
50411|NCT02742324|efficacy
50412|NCT02742324|safety
50413|NCT02742298|Neuromuscular Ultrasound
50414|NCT02742298|Electrical Impedance Myography
50415|NCT02742285|antimalarials
50416|NCT02742285|blood samples
50417|NCT02742285|drug concentrations
50418|NCT02742285|pharmacokinetics
50419|NCT02742285|lumefantrine
50420|NCT02742285|healthy volunteers
50421|NCT02742233|Diabetes
50422|NCT02742233|Wound Healing
50423|NCT02742233|Dipeptidyl Peptidase 4 Inhibition
50424|NCT02742220|intermittent claudication
50425|NCT02742220|exercise
50426|NCT02742220|blood pressure
50427|NCT02742220|cardiovascular system
50428|NCT02742194|ginger obesity
50429|NCT02742194|ginger inflammation
50430|NCT02742194|treatment of obesity
50431|NCT02742155|Family Research
50432|NCT02742116|Expanded carrier screening
50433|NCT02742090|CLL
50434|NCT02742025|Coronary Angiography
50435|NCT02742012|electroencephalogram
50436|NCT02742012|hemodynamic monitoring
50437|NCT02742012|respiratory monitoring
50438|NCT02741986|risk assessment
50439|NCT02741986|sepsis
50440|NCT02741986|acute kidney injury (AKI)
50441|NCT02741973|Yoga
50442|NCT02741973|Stress
50443|NCT02741973|Adolescents
50444|NCT02741973|School
50445|NCT02741973|Children
50446|NCT02741960|metformin
50447|NCT02741960|systemic lupus erythematosus
50448|NCT02741947|Parkinson
50449|NCT02741947|Therapeutic Equivalence
50450|NCT02741947|Levodopa
50451|NCT02741895|Biosensing Techniques
50452|NCT02741895|Patient Readmission
50453|NCT02741882|Microcephaly
50454|NCT02741882|zika Virus
50455|NCT02741882|Case-control study
50456|NCT02741869|Staphylococcus aureus; nare carriage
50457|NCT02741089|Analgosedation
50458|NCT02741089|Internal Quality Assurance
50459|NCT02741063|oxytocin
50460|NCT02741063|attentional bias
50461|NCT02741063|Autism
50462|NCT02741011|Cone-Beam Computed Tomography
50463|NCT02741011|Mentally Handicapped
50464|NCT02740998|Microbiome
50465|NCT02740998|Progestin
50466|NCT02740998|Long-acting contraception
50467|NCT02740985|AZD4635
50468|NCT02740985|durvalumab
50469|NCT02740985|non-small cell lung cancer
50470|NCT02740985|advanced solid malignancies
50471|NCT02741804|Memory
50472|NCT02741791|AXS-05
50473|NCT02741791|Major Depressive Disorder
50474|NCT02741791|Treatment Resistant Depression
50475|NCT02741791|TRD
50476|NCT02741791|MDD
50477|NCT02741791|Axsome
50478|NCT02741791|NMDA receptor
50479|NCT02741791|Refractory depression
50480|NCT02741791|Resistant depression
50481|NCT02741791|Depression
50482|NCT02741778|Esophagogastric Junction
50483|NCT02741778|Adenocarcinoma
50484|NCT02741778|Cardia
50485|NCT02741765|Transcranial Magnetic Stimulation
50486|NCT02741765|Exercise
50487|NCT02741765|Brain Plasticity
50488|NCT02741752|histomorphometry
50489|NCT02741739|Drug concentration
50490|NCT02741739|REGN1033
50491|NCT02741739|blood
50492|NCT02741700|Adherence
50493|NCT02741700|Disparities
50494|NCT02741700|Patient Outcomes
50495|NCT02741687|stress hyperglycemia
50496|NCT02741687|blood glucose
50497|NCT02741674|Observational Study
50498|NCT02741674|Comparative Effectiveness Research
50499|NCT02741648|Red Blood Cell Transfusion
50500|NCT02741648|Digestive tract problems
50501|NCT02741648|Extremely Low Birth Weight
50502|NCT02741622|Exercise therapy
50503|NCT02741609|Borrelia
50504|NCT02741609|spirochetes
50505|NCT02741609|culture
50506|NCT02741609|immunostaining
50507|NCT02741596|DX-2930
50508|NCT02741596|Dyax
50509|NCT02741596|Hereditary Angioedema
50510|NCT02741557|Fixed-dose Combination (FDC)
50511|NCT02741557|Bioequivalence
50512|NCT02741557|Dolutegravir
50513|NCT02741557|Rilpivirine
50514|NCT02741544|Second primary cancers
50515|NCT02741544|Cataracts
50516|NCT02741544|Newly-diagnosed multiple myeloma
50517|NCT02741544|Revlimid capsules
50518|NCT02741518|obesity
50519|NCT02741518|FMT
50520|NCT02741505|cerebrospinal fluid (CSF)
50521|NCT02741505|sleep
50522|NCT02741505|Obstructive Sleep Apnea (OSA)
50523|NCT02741505|Sleep Disordered Breathing (SDB)
50524|NCT02741505|Period Limb Movement during Sleep (PLMS)
50525|NCT02741479|dancers
50526|NCT02741440|Spinocerebellar Ataxia
50527|NCT02741427|Tooth discoloration
50528|NCT02741427|Toothpaste
50529|NCT02741427|Tooth bleaching
50530|NCT02741427|Clinical trial
50531|NCT02741414|Helicobacter pylori
50532|NCT02741414|Antibiotic resistance
50533|NCT02741414|Sequencing
50534|NCT02741414|Mechanism
50535|NCT02741401|Complementary therapies
50536|NCT02741401|Massage
50537|NCT02741401|Gastrointestinal cancer
50538|NCT02741388|selinexor
50539|NCT02741388|lymphoma
50540|NCT02741388|inhibitor of nuclear export
50541|NCT02741362|Type III hypersensitivity autoimmune disease
50542|NCT02741349|Atrial fibrillation
50543|NCT02741349|Risk score
50544|NCT02741297|Spinal Cord Stimulation
50545|NCT02741297|Chronic Pain
50546|NCT02741232|analgesics, opioids
50547|NCT02741232|pectoral block
50548|NCT02741206|psycho-education
50549|NCT02741206|maternal depression
50550|NCT02741206|Reach Out Stay Strong Essentials
50551|NCT02741193|Transcranial magnet stimulation (nTMS)
50552|NCT02741193|Brainsight Neuronavigation
50553|NCT02741193|Electromyography
50554|NCT02741193|EMG
50555|NCT02741167|peritoneal surface malignancies
50556|NCT02741167|cytoreductive surgery
50557|NCT02741167|hyperthermic intraperitoneal chemotherapy
50558|NCT02741154|aromataze inhibitor, poor responder ,induction
50559|NCT02741128|Dengue Fever
50560|NCT02741128|Dengue Hemorrhagic Fever
50561|NCT02741128|Human Immunodeficiency Virus
50562|NCT02741128|CYD Dengue Vaccine
50563|NCT02741115|Fontan
50564|NCT02741115|Maximal Oxygen Consumption
50565|NCT02741115|Vascular Function
50566|NCT02741115|EndoPAT
50567|NCT02741115|Myocardial Performance
50568|NCT02741102|Infertility
50569|NCT02741102|AUFI
50570|NCT02740933|Brain Tumor Surgery
50571|NCT02740868|Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy
50572|NCT02740855|sclerotherapy
50573|NCT02740855|ethanol
50574|NCT02740855|pulmonal hypertension
50575|NCT02740790|Human papillomavirus
50576|NCT02740790|vaccine
50577|NCT02740790|cervical infection
50578|NCT02740790|cervical cancer
50579|NCT02740764|Functional autonomy level
50580|NCT02740764|Lawton Instrumental Activities of Daily Living
50581|NCT02740764|Cognitive disorders
50582|NCT02740764|Potentially inappropriate medication
50583|NCT02740764|elderly
50584|NCT02740764|Optimization of drug prescribing
50585|NCT02740738|Knee Arthroplasty
50586|NCT02740738|Hip Arthroplasty
50587|NCT02740725|Amblyopia
50588|NCT02740725|Interaction Binocular Treatment (I-BiTTM)
50589|NCT02740725|Patch Therapy
50590|NCT02740712|rucaparib
50591|NCT02740712|CO-338
50592|NCT02740712|Clovis
50593|NCT02740712|Clovis Oncology
50594|NCT02740712|PARP Inhibitor
50595|NCT02740712|Drug-Drug Interaction
50596|NCT02740699|Cholesterol
50597|NCT02740699|Heart Disease
50598|NCT02740699|CT Scan
50599|NCT02740699|Crestor
50600|NCT02740699|Lipitor
50601|NCT02740686|COPD
50602|NCT02740686|Exercise
50603|NCT02740686|Immunity
50604|NCT02740686|Inflammation
50605|NCT02740686|Biomarkers
50606|NCT02740660|Albuterol
50607|NCT02740660|Caffeine
50608|NCT02740660|Lean Body Mass
50609|NCT02740660|Fat Mass
50610|NCT02740634|PCA
50611|NCT02740634|LPA
50612|NCT02740595|nicotine
50613|NCT02740595|endothelial function
50614|NCT02740595|oxidative stress
50615|NCT02740569|scleroderma
50616|NCT02740569|sleep apnea
50617|NCT02740569|pulmonary disease
50618|NCT02740556|Hepatitis C
50619|NCT02740556|Adherence
50620|NCT02740556|Adheretech
50621|NCT02740556|HepCure
50622|NCT02740556|Telehealth
50623|NCT02740556|Health apps
50624|NCT02740543|World Trade Center
50625|NCT02740543|WTC
50626|NCT02740543|Induced Sputum
50627|NCT02740543|Exhaled Breath Condensate
50628|NCT02740504|Respiration rate
50629|NCT02740465|ACE
50630|NCT02740465|Anxiety
50631|NCT02740465|COPD
50632|NCT02740452|Rupture
50633|NCT02740452|Anterior Cruciate Ligament (ACL)
50634|NCT02740452|Laxity knee
50635|NCT02740452|Instability knee
50636|NCT02740400|Endobronchial ultrasonography
50637|NCT02740400|guided sheath
50638|NCT02740400|diagnosis
50639|NCT02740400|accuracy
50640|NCT02740400|complication
50641|NCT02740374|ROTEM
50642|NCT02740374|Thromboelastometry
50643|NCT02740374|spine surgery
50644|NCT02740374|allogenic blood transfusion
50645|NCT02740374|blood loss
50646|NCT02740374|red blood cell transfusion
50647|NCT02740335|anticoagulant reversal
50648|NCT02740335|urgent surgery
50649|NCT02740335|invasive procedures
50650|NCT02740335|vitamin K
50651|NCT02740335|prothrombin complex concentrate
50652|NCT02740335|four-factor prothrombin complex concentrate (4F-PCC)
50653|NCT02740322|Hum Test, Weber test, audiogram
50654|NCT02740309|inflammatory bowel disease
50655|NCT02740309|childhood chronic disease
50656|NCT02740309|adolescent depression
50657|NCT02740309|adolescent anxiety
50658|NCT02740309|integrated brief behavioral therapy
50659|NCT02740309|adolescent psychosocial risks
50660|NCT02740309|adolescent chronic disease
50661|NCT02740309|childhood depression
50662|NCT02740309|childhood anxiety
50663|NCT02740309|childhood psychosocial risks
50664|NCT02740283|Gestational Diabetes Mellitus
50665|NCT02740283|Oral Glucose Tolerance Test
50666|NCT02740270|advanced solid tumors
50667|NCT02740270|lymphomas
50668|NCT02740270|GWN323
50669|NCT02740270|PDR001
50670|NCT02740270|advanced malignancies
50671|NCT02740270|anti-GITR
50672|NCT02740270|anti-PD-1
50673|NCT02740270|adults
50674|NCT02740231|viscosupplement
50675|NCT02740231|osteoarthritis
50676|NCT02740231|knee
50677|NCT02740231|intra-articular injection
50678|NCT02740231|arthritis
50679|NCT02740231|degenerative
50680|NCT02740218|Psoriasis
50681|NCT02740218|Apremilast
50682|NCT02740218|APPRECIATE
50683|NCT02740218|Dermatology
50684|NCT02740218|Retrospective
50685|NCT02740218|Observational
50686|NCT02740205|Patients with Enteral Feeding
50687|NCT02740179|Eplerenone
50688|NCT02740179|Cardiovascular Disease
50689|NCT02740179|Mineralocorticoid Receptor Antagonist
50690|NCT02740179|Coronary Vasculature
50691|NCT02740179|Myocardial Inflammation
50692|NCT02740179|Myocardial Fibrosis
50693|NCT02740179|Atherosclerosis
50694|NCT02740179|Aldosterone
50695|NCT02740166|Esophageal Varices; propranolol; banding ligation
50696|NCT02740140|chronic coinfection
50697|NCT02740127|Malignant neoplasms of male genital organs
50698|NCT02740127|Adult Penile Prosthesis Surgery
50699|NCT02740127|Caudal nerve block
50700|NCT02740127|CNB
50701|NCT02740127|General anesthesia
50702|NCT02740127|GA
50703|NCT02740127|Ropivacaine
50704|NCT02740127|Naropin
50705|NCT02740127|Epinephrine
50706|NCT02740127|Decadron
50707|NCT02740127|Dexamethasone
50708|NCT02740127|Clonidine
50709|NCT02740127|Propofol
50710|NCT02740127|Diprivan
50711|NCT02740114|Malignant neoplasms of female genital organs
50712|NCT02740114|Open gynecologic surgery
50713|NCT02740114|Local wound infiltration
50714|NCT02740114|Gynecologic cancer
50715|NCT02740114|Bupivacaine
50716|NCT02740114|Liposomal Bupivacaine
50717|NCT02740114|Oxycodone
50718|NCT02740114|ETH-Oxydose [DSC]
50719|NCT02740114|OxyContin
50720|NCT02740114|OxyIR
50721|NCT02740114|Roxicodone
50722|NCT02740114|Questionnaires
50723|NCT02740114|Surveys
50724|NCT02740114|MD Anderson Symptom Inventory
50725|NCT02740114|MDASI
50726|NCT02740114|Pill diary
50727|NCT02740114|Medication log
50728|NCT02740101|oxytocin
50729|NCT02740101|social reward
50730|NCT02740101|social punishment
50731|NCT02740075|Mechanical versus hand ventilation
50732|NCT02740075|Transport ventilation
50733|NCT02740049|Epithelial Cells
50734|NCT02740010|MIOL
50735|NCT02740010|extended depth of focus
50736|NCT02740010|cataract
50737|NCT02740010|visual acuity
50738|NCT02740010|halos
50739|NCT02739984|diabetes
50740|NCT02739984|type 2 diabetes
50741|NCT02739984|high blood cholesterol
50742|NCT02739984|hypercholesterolemia
50743|NCT02739984|mixed dyslipidemia
50744|NCT02739984|high cholesterol
50745|NCT02739984|statin intolerant
50746|NCT02739945|Ulnar Nerve Compression, Cubital Tunnel
50747|NCT02739932|Attenuated Psychotic Symptoms
50748|NCT02739919|Kidney stones
50749|NCT02739919|Renal Calculi
50750|NCT02739880|Vaginal discomfort
50751|NCT02739880|Vaginal dryness
50752|NCT02739867|occult cancer
50753|NCT02739867|venous thromboembolism
50754|NCT02739867|tumor-educated platelets
50755|NCT02739867|platelet RNA profiling
50756|NCT02739867|early diagnosis
50757|NCT02739867|screening
50758|NCT02739854|trauma
50759|NCT02739854|atelectasis
50760|NCT02739841|hemodynamic response
50761|NCT02739828|Quality of life
50762|NCT02739815|Caesarean Section
50763|NCT02739815|Tranexamic Acid
50764|NCT02739815|Postpartum Hemorrhage
50765|NCT02739815|Ecbolics
50766|NCT02739789|tDCS rejection affect mood fMRI
50767|NCT02739763|PfSPZ
50768|NCT02739763|Semi-immune adults
50769|NCT02739763|Kenya
50770|NCT02739763|challenge
50771|NCT02739763|CHMI
50772|NCT02739763|malaria
50773|NCT02739737|Bias
50774|NCT02739737|Orthopedics
50775|NCT02739737|Peer Review
50776|NCT02739698|ovarian cancer
50777|NCT02739659|prostate carcinoma
50778|NCT02739659|carbon-ion radiotherapy
50779|NCT02739659|efficacy
50780|NCT02739659|toxicity
50781|NCT02739633|Chemotherapy
50782|NCT02739633|Gemcitabine
50783|NCT02739633|Recurrent and metastatic adenocarcinoma of the pancreas
50784|NCT02739633|Genexol-PM
50785|NCT02739633|Paclitaxel
50786|NCT02739607|emotional disorders
50787|NCT02739607|internet-delivered intervention
50788|NCT02739607|anxiety
50789|NCT02739607|depression
50790|NCT02739607|transdiagnostic
50791|NCT02739568|EDS
50792|NCT02739568|OSA
50793|NCT02739555|Osteoid osteoma
50794|NCT02739555|Bisphophonates
50795|NCT02739542|Radiologically Isolated Syndrome (RIS)
50796|NCT02739490|physiotherapeutic techniques
50797|NCT02739490|pelvis
50798|NCT02739490|Muscle strength
50799|NCT02739477|Favipiravir
50800|NCT02739477|Tolerance
50801|NCT02739477|Survivor
50802|NCT02739477|Ebola Virus
50803|NCT02739477|Genital reservoir
50804|NCT02739477|Guinea
50805|NCT02739464|Burn
50806|NCT02739464|Exercise
50807|NCT02739464|Ergometer
50808|NCT02739464|MP-10
50809|NCT02739451|immunocompromized patients
50810|NCT02739451|critically ill patients
50811|NCT02739438|Pulmonary inflammation
50812|NCT02739438|Endothelial dysfunction
50813|NCT02739438|Electronic Cigarettes
50814|NCT02739425|Sentinel lymph node biopsy (SLNB)
50815|NCT02739425|Superparamagnetic iron oxide (SPIO) tracer
50816|NCT02739399|phenylephrine
50817|NCT02739399|alpha mimetics
50818|NCT02739399|pulse pressure variation
50819|NCT02739399|venous return
50820|NCT02739347|tDCS
50821|NCT02739347|cognitive control
50822|NCT02739347|working memory
50823|NCT02739347|EEG
50824|NCT02739347|gamma oscillations
50825|NCT02739321|Autism
50826|NCT02739321|ASD
50827|NCT02739321|Sleep
50828|NCT02739321|Mattress
50829|NCT02739308|proprioception
50830|NCT02739308|ankle sprain
50831|NCT02739308|fencing
50832|NCT02739269|ovarian response
50833|NCT02739269|anti-Mullerian hormone
50834|NCT02739269|antral follicle count
50835|NCT02739256|voiding trial
50836|NCT02739256|pelvic organ prolapse
50837|NCT02739256|post-operative catheterization
50838|NCT02739204|Celecoxib
50839|NCT02739204|Relapse-free OSCC patient
50840|NCT02739204|Recurrence
50841|NCT02739204|Survival
50842|NCT02739204|Prognosis
50843|NCT02739191|NPWT
50844|NCT02739165|Acute exacerbations
50845|NCT02739165|Idiopathic pulmonary fibrosis
50846|NCT02739165|Recombinant human soluble thrombomodulin
50847|NCT02739165|ART-123
50848|NCT02739152|Sepsis
50849|NCT02739152|Severe sepsis
50850|NCT02739152|Infections
50851|NCT02739152|Worsening
50852|NCT02739126|Diagnosis
50853|NCT02739113|OMECs
50854|NCT02739113|Cornea
50855|NCT02739113|Amniotic membrane
50856|NCT02739113|Collagenase
50857|NCT02739100|pharmacokinetics
50858|NCT02739100|bioequivalence
50859|NCT02739087|radiation free cardiac catheterization
50860|NCT02739061|pathogenesis
50861|NCT02739061|cognitive behavioral group therapy
50862|NCT02738996|Diabetes
50863|NCT02738996|Sedentary Lifestyle
50864|NCT02738983|Non-small cell lung cancer
50865|NCT02738983|epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
50866|NCT02738983|Radiotherapy
50867|NCT02738983|wild type
50868|NCT02738931|dolutegravir
50869|NCT02738931|lamivudine
50870|NCT02738931|Bioavailability
50871|NCT02738931|fixed dose combinations
50872|NCT02738918|Renal Transplant
50873|NCT02738918|Anti HLA antibodies
50874|NCT02738918|Humoral rejection
50875|NCT02738892|Pregnancy
50876|NCT02738892|Stillbirth
50877|NCT02738892|Preterm birth
50878|NCT02738866|breast cancer
50879|NCT02738866|Metastatic Breast Cancer
50880|NCT02738866|palbociclib
50881|NCT02738866|fulvestrant
50882|NCT02738814|emergence agitation
50883|NCT02738814|emergence delirium
50884|NCT02738814|PAED scale
50885|NCT02738814|The Modified Aldrete Scoring System
50886|NCT02738814|treatment
50887|NCT02738814|pediatric
50888|NCT02738814|sevoflurane
50889|NCT02738801|Idiopathic Pulmonary Fibrosis
50890|NCT02738801|GLPG1690
50891|NCT02738801|Autotaxin
50892|NCT02738788|airway
50893|NCT02738788|airway changes
50894|NCT02738788|MMS
50895|NCT02738788|prone position
50896|NCT02738788|Trendelenburg position
50897|NCT02738775|multiple sclerosis
50898|NCT02738762|intensive care
50899|NCT02738762|glutamine
50900|NCT02738762|length of stay
50901|NCT02738749|sudden cardiac death, sodium channel splicing variant
50902|NCT02738723|Limited-stage small cell lung cancer
50903|NCT02738723|Stereotactic body radiation therapy
50904|NCT02738723|Intensity modulated radiation therapy
50905|NCT02738723|Radiation
50906|NCT02738723|Chemotherapy
50907|NCT02738697|Carcinoma,Hepatocellular
50908|NCT02738697|Adjuvant chemotherapy
50909|NCT02738697|Microvessels invasion
50910|NCT02738697|Survival
50911|NCT02738697|Recurrence
50912|NCT02738684|lung cancer
50913|NCT02738684|adenocarcinoma
50914|NCT02738684|EGFR
50915|NCT02738684|plasma free nucleic acids
50916|NCT02738671|functional MRI
50917|NCT02738671|olfactory function
50918|NCT02738671|bariatric surgery
50919|NCT02738658|Coronary microcirculatory dysfunction
50920|NCT02738658|Coronary endothelium dysfunction
50921|NCT02738619|allergic rhinitis
50922|NCT02738619|immunotherapy
50923|NCT02738619|vitamin D
50924|NCT02738606|Colorectal Cancer
50925|NCT02738606|Other diseases of intestines
50926|NCT02738606|Liver and Unresectable Pulmonary Metastases
50927|NCT02738606|Resectable liver metastases
50928|NCT02738606|Liver resection
50929|NCT02738606|Chemotherapy
50930|NCT02738554|HBV
50931|NCT02738554|treatment cessation
50932|NCT02738554|HBsAg
50933|NCT02738554|HBcrAg
50934|NCT02738554|nucleoside analogue
50935|NCT02738554|entecavir
50936|NCT02738554|tenofovir
50937|NCT02738502|HIV
50938|NCT02738502|prevention of mother-to-child transmission
50939|NCT02738502|Ritonavir boosted darunavir monotherapy
50940|NCT02738489|PD-1/PD-L1 advanced Melanoma immunotherapy
50941|NCT02738463|ferritin LBW
50942|NCT02738450|cognitive decline
50943|NCT02738437|osteogenesis
50944|NCT02738437|Positron-Emission Tomography
50945|NCT02738437|Radiostereometric analysis
50946|NCT02738424|Low Back Pain
50947|NCT02738424|MRI
50948|NCT02738372|Chronic Pain
50949|NCT02738372|Biopsychosocial Factors
50950|NCT02738372|Shoulder pain
50951|NCT02738372|Prognosis
50952|NCT02738372|Central Nervous System Sensitization
50953|NCT02738346|Small Cell Lung Cancer
50954|NCT02738346|Topotecan
50955|NCT02738346|Etoposide
50956|NCT02738307|High Altitude
50957|NCT02738307|Attention
50958|NCT02738307|Cognitive Function
50959|NCT02738307|Acclimatization
50960|NCT02738307|Sleep
50961|NCT02738255|Obstructive sleep apnea
50962|NCT02738255|Mouth breathing
50963|NCT02738255|Apnea-Hypopnea Index (AHI)
50964|NCT02738242|Functional Electrical Stimulation
50965|NCT02738242|Upper motor neuron injury or disease
50966|NCT02738242|Drop foot
50967|NCT02738242|Thigh muscle weakness
50968|NCT02738203|Pain Management
50969|NCT02738203|IUD insertion
50970|NCT02738203|Endometrial Biopsy
50971|NCT02738190|albumin
50972|NCT02738190|fresh frozen plasma
50973|NCT02738190|extracorporeal circulation
50974|NCT02738190|cardiovascular surgery
50975|NCT02738190|pediatric population
50976|NCT02738177|misopristol
50977|NCT02738177|effox
50978|NCT02738177|cervical ripening
50979|NCT02738138|HCV Genotype 3
50980|NCT02738138|Non-cirrhotic
50981|NCT02738138|HCV Genotype 1
50982|NCT02738138|HCV Genotype 6
50983|NCT02738138|Human Immunodeficiency Virus (HIV) Infection
50984|NCT02738138|HCV Genotype 5
50985|NCT02738138|HCV Treatment Naive
50986|NCT02738138|HCV Genotype 4
50987|NCT02738138|HCV Treatment Experienced
50988|NCT02738138|HCV Genotype 2
50989|NCT02738138|Hepatitis C Virus (HCV) Infection
50990|NCT02738138|Compensated Cirrhosis
50991|NCT02738125|SOTHIS
50992|NCT02738125|Adalimumab
50993|NCT02738125|Ulcerative Colitis
50994|NCT02738125|Effectiveness
50995|NCT02738086|Amputation
50996|NCT02738086|Physical Activity
50997|NCT02738086|Rehabilitation
50998|NCT02738034|Hypertension
50999|NCT02738034|Cognition
51000|NCT02738034|Computerized Training
51001|NCT02738034|Cogmed
51002|NCT02738021|Psychosocial
51003|NCT02738021|Psychotherapy
51004|NCT02738021|Maternal
51005|NCT02737995|Iron deficiency
51006|NCT02737982|coronary heart disease
51007|NCT02737982|gender
51008|NCT02737982|platelet
51009|NCT02737982|microvascular dysfunction
51010|NCT02737982|sexual hormones
51011|NCT02737982|cardiac magnetic resonance
51012|NCT02737982|percutaneous coronary interventions
51013|NCT02737969|Transesophageal Echocardiography/angiography (TEE/Angio)
51014|NCT02737943|Skin graft
51015|NCT02737943|Burn
51016|NCT02737943|MEBO
51017|NCT02737943|Wound dressing
51018|NCT02737943|Wound care
51019|NCT02737943|Raw Area
51020|NCT02737930|Acute ischemic stroke
51021|NCT02737930|Homonymous hemianopia
51022|NCT02737930|Homonymous quadrantanopia
51023|NCT02737930|Visual field loss
51024|NCT02737930|Post-stroke recovery
51025|NCT02737930|Fluoxetine
51026|NCT02737930|Selective serotonin reuptake inhibitor
51027|NCT02737904|Muscle spasticity
51028|NCT02737865|Focal nodular hyperplasia
51029|NCT02737865|Ultrasonography
51030|NCT02737865|Superb-Microvascular imaging
51031|NCT02737865|Contrast-enhanced ultrasonography
51032|NCT02737813|isobaric marcaine
51033|NCT02737813|hyperbaric marcaine
51034|NCT02737787|Second or Greater Remission
51035|NCT02737787|WT1 Analog Peptide Vaccine
51036|NCT02737787|Montanide
51037|NCT02737787|GM-CSF
51038|NCT02737787|Nivolumab
51039|NCT02737787|15-247
51040|NCT02737774|Icotinib
51041|NCT02737774|chemotherapy
51042|NCT02737774|EGFR
51043|NCT02737761|Heart Failure
51044|NCT02737761|Positive Psychology
51045|NCT02737761|Adherence to Health Behaviors
51046|NCT02737748|Donor Site Wounds
51047|NCT02737696|prescription opioid
51048|NCT02737696|prevention
51049|NCT02737696|computer-based
51050|NCT02737696|adolescent
51051|NCT02737683|Disease
51052|NCT02737683|anxiety
51053|NCT02737683|depression
51054|NCT02737683|combine
51055|NCT02737683|negative emotional states
51056|NCT02737683|functional dyspepsia
51057|NCT02737657|Canagliflozin
51058|NCT02737657|Metformin
51059|NCT02737657|Diabetes Mellitus, Type 2
51060|NCT02737657|INVOKANA
51061|NCT02737657|Sulfonylurea
51062|NCT02737644|Congenital Heart Disease
51063|NCT02737644|Key Nutritional Factors
51064|NCT02737644|conception
51065|NCT02737644|pregnant
51066|NCT02736565|metastatic
51067|NCT02736565|askin tumor
51068|NCT02736565|neuroectodermal tumor
51069|NCT02736565|pNET
51070|NCT02736565|sarcoma
51071|NCT02736565|soft tissue
51072|NCT02737605|Esketamine
51073|NCT02737605|Healthy
51074|NCT02737605|Pharmacokinetics
51075|NCT02737605|Electrocardiogram
51076|NCT02737605|Repolarization
51077|NCT02737579|cardiac catheterization
51078|NCT02737579|cardiac MRI
51079|NCT02737566|Smoking Cessation
51080|NCT02737566|Financial Incentives
51081|NCT02737566|Contingency Management
51082|NCT02737566|Vulnerable Populations
51083|NCT02737566|Medically Uninsured
51084|NCT02737566|Medicaid
51085|NCT02737527|ultrasound
51086|NCT02737527|lumbar sympathetic block
51087|NCT02737514|adenoma detection rate
51088|NCT02737514|colonoscopy
51089|NCT02737514|water exchange
51090|NCT02737501|Non-small cell lung cancer
51091|NCT02737501|Non-small cell lung carcinoma
51092|NCT02737501|Epithelial lung cancer
51093|NCT02737501|Squamous cell carcinoma
51094|NCT02737501|Large cell carcinoma
51095|NCT02737501|Adenocarcinoma
51096|NCT02737501|Carcinoma
51097|NCT02737501|Anaplastic Lymphoma Kinase (ALK)
51098|NCT02737501|Advanced Cancers
51099|NCT02737501|Brigatinib
51100|NCT02737501|AP26113
51101|NCT02737488|Therapy
51102|NCT02737488|Trauma Systems Therapy
51103|NCT02737410|Resilience
51104|NCT02737410|Coping
51105|NCT02737410|Psychosomatic
51106|NCT02737410|Hypnosis
51107|NCT02737410|Construct Validation
51108|NCT02737384|Combined immunodeficiencies
51109|NCT02737384|hematopoietic stem cell transplantation
51110|NCT02737384|CD45RA
51111|NCT02737384|primitive immunodeficiencies
51112|NCT02737384|pediatric transplantation
51113|NCT02737384|CD45RA depletion
51114|NCT02737358|nicotine
51115|NCT02737358|tobacco
51116|NCT02737358|smoking
51117|NCT02737358|cessation
51118|NCT02737358|N-acetylcysteine
51119|NCT02737358|NAC
51120|NCT02737358|pharmacotherapy
51121|NCT02737358|relapse
51122|NCT02737358|tobacco use disorder
51123|NCT02737345|fibrinolysis
51124|NCT02737345|liver transplant
51125|NCT02737345|thromboelastometry
51126|NCT02737319|Contrast,nephropathy, angioplasty, stable coronary
51127|NCT02737306|Allogeneic Stem-Cell Transplantation
51128|NCT02737280|infant
51129|NCT02737280|high flow nasal cannulae
51130|NCT02737280|oxygen therapy
51131|NCT02737280|bronchiolitis
51132|NCT02737267|Genetics
51133|NCT02737267|Polymorphism
51134|NCT02737267|Epigenetics
51135|NCT02737267|Metagenomics
51136|NCT02737267|Metabolomics
51137|NCT02737267|Metabolic syndrome conditions
51138|NCT02737267|Precision nutrition
51139|NCT02737254|Attachment
51140|NCT02737254|Oxytocin
51141|NCT02737254|Cognitive bias modification
51142|NCT02737254|Middle childhood
51143|NCT02737241|Prostate
51144|NCT02737241|Laser
51145|NCT02737241|Enucleation
51146|NCT02737202|LAM
51147|NCT02737189|Basilar Artery Occlusion
51148|NCT02737189|Ischemic Stroke
51149|NCT02737189|Mechanical Embolectomy
51150|NCT02737176|Smoking Cessation
51151|NCT02737176|Mouth Diseases
51152|NCT02737176|Periodontal Diseases
51153|NCT02737176|Leukoplakia
51154|NCT02737176|Keratosis
51155|NCT02737176|Implant
51156|NCT02737176|Lichen Planus
51157|NCT02737163|Programmable shunts
51158|NCT02737163|Strata valve
51159|NCT02737124|Acetaminophen
51160|NCT02737124|Surgery
51161|NCT02737124|Meniscectomy
51162|NCT02737098|PTSD
51163|NCT02737098|virtual care
51164|NCT02737098|implementation
51165|NCT02737098|telepsychiatry
51166|NCT02737098|telepsychology
51167|NCT02737085|CD19-targeted CAR-T Cell
51168|NCT02737085|CD20-targeted CAR-T Cell
51169|NCT02737085|Diffuse Large B Cell Lymphoma
51170|NCT02737072|immuno-oncology
51171|NCT02737046|Adult T-cell Leukemia-Lymphoma
51172|NCT02737046|ATLL
51173|NCT02737033|ADHD
51174|NCT02737033|Adults
51175|NCT02737033|Treatment
51176|NCT02737033|Rhodiola
51177|NCT02737020|ADHD
51178|NCT02737020|Adults
51179|NCT02737020|Treatment
51180|NCT02737020|Rhodiola rosea
51181|NCT02737007|Malaria
51182|NCT02737007|Microdose
51183|NCT02737007|GSK3191607
51184|NCT02736994|edentulous
51185|NCT02736994|patients
51186|NCT02736994|with full
51187|NCT02736981|Obesity
51188|NCT02736981|Weight Loss
51189|NCT02736981|Young Adults
51190|NCT02736968|Amebic
51191|NCT02736968|Auranofin
51192|NCT02736968|GI Protozoa
51193|NCT02736968|Giardiasis
51194|NCT02736968|Reprofiled
51195|NCT02736890|Botulinum Toxin A
51196|NCT02736890|Neuropathic pain
51197|NCT02736890|Spinal cord injury
51198|NCT02736890|Pain management
51199|NCT02736890|Rehabilitation
51200|NCT02736877|keratoconus
51201|NCT02736877|bullous keratopathy
51202|NCT02736877|corneal dystrophy
51203|NCT02736851|disability
51204|NCT02736851|home
51205|NCT02736851|stretching exercises
51206|NCT02736838|Pressure
51207|NCT02736838|Pressure Ulcer
51208|NCT02736838|Skin perfusion
51209|NCT02736838|Skin oxygenation
51210|NCT02736812|Randomized controlled trial
51211|NCT02736812|Lyophilized Plasma
51212|NCT02736812|Advanced Trauma Life Support Care
51213|NCT02736786|proton
51214|NCT02736773|Guided Bone
51215|NCT02736773|Pre-implant referred
51216|NCT02736773|Regeneration
51217|NCT02736747|Stroke
51218|NCT02736747|Muscle Spasticity
51219|NCT02736747|Cryotherapy
51220|NCT02736747|Gait
51221|NCT02736747|Muscle Weakness
51222|NCT02736747|Proprioception
51223|NCT02736708|Primary sclerosing cholangitis
51224|NCT02736695|PPA
51225|NCT02736669|weight loss
51226|NCT02736669|body weight
51227|NCT02736669|behavioral
51228|NCT02736643|LDCT, screening
51229|NCT02736630|general anaesthesia
51230|NCT02736630|elective surgery
51231|NCT02736630|national epidemiology
51232|NCT02736630|turkey
51233|NCT02736552|Gastric cancer
51234|NCT02736552|Adjuvant chemotherapy
51235|NCT02736552|S-1
51236|NCT02736552|D2 resection
51237|NCT02736526|moderate intermittent exotropia
51238|NCT02736526|surgical treatment
51239|NCT02736526|observation
51240|NCT02736513|Tagrisso
51241|NCT02736513|AZD9291
51242|NCT02736513|EGFRm
51243|NCT02736513|brain metastases
51244|NCT02736513|NSCLC
51245|NCT02736500|neuroendocrine tumors
51246|NCT02736500|gastro entero pancreatic neuroendocrine tumors
51247|NCT02736500|Radioisotope therapy
51248|NCT02736500|177Lu-DOTATATE
51249|NCT02736500|METRONOMIC CAPECITABINE
51250|NCT02736487|Air Pollution
51251|NCT02736487|Exposure Assessment
51252|NCT02736487|Filtration
51253|NCT02736487|Cardiovascular Outcomes
51254|NCT02736487|Respiratory Outcomes
51255|NCT02736487|Short-term Intervention
51256|NCT02736461|Orbital fractures
51257|NCT02736461|Strabismus
51258|NCT02736461|Predicting factors
51259|NCT02736461|orbital floor fractures
51260|NCT02736448|GEP-NET tumors
51261|NCT02736448|Lu-PRRT
51262|NCT02736448|177Lutethium - Peptide Receptor Radionuclide Therapy
51263|NCT02736448|gastro-entero-pancreatic neuroendocrine tumors
51264|NCT02736448|18-FDG Positron Emission Tomography (PET) positive
51265|NCT02736448|low dose of capecitabine
51266|NCT02736435|Magnetic Resonance Guided High Intensity Focused Ultrasound
51267|NCT02736435|MR-HIFU
51268|NCT02736435|Fibroids
51269|NCT02736435|Leuprolide Acetate
51270|NCT02736357|Lymphoma
51271|NCT02736357|Cohort
51272|NCT02736357|non-Hodgkin
51273|NCT02736344|coronary luminal diameter
51274|NCT02736344|lesions
51275|NCT02736344|vessels
51276|NCT02736331|Cognitive performance
51277|NCT02736331|Metabolic control
51278|NCT02736331|Pharmacokinetic profile
51279|NCT02736331|Anthocyanins
51280|NCT02736305|ovarian
51281|NCT02736305|regorafenib
51282|NCT02736305|platinum resistant
51283|NCT02736305|clear cell
51284|NCT02736305|endometrioid
51285|NCT02736266|Muscle-invasive
51286|NCT02736266|Urothelial bladder carcinoma
51287|NCT02736266|Neoadjuvant therapy
51288|NCT02736266|Radical cystectomy
51289|NCT02736253|foot amputation
51290|NCT02736253|Osteomyelitis
51291|NCT02736253|Diabetic Foot
51292|NCT02736227|liver transplantation
51293|NCT02736227|immunosuppression
51294|NCT02736227|everolimus
51295|NCT02736227|tacrolimus
51296|NCT02736227|kidney function
51297|NCT02736227|liver function
51298|NCT02736227|biomarkers
51299|NCT02736188|GNE Myopathy
51300|NCT02736188|GNEM
51301|NCT02736188|Nonaka
51302|NCT02736188|Hereditary Inclusion Body Myopathy
51303|NCT02736188|HIBM
51304|NCT02736188|DMRV
51305|NCT02736188|QSM
51306|NCT02736162|Perampanel
51307|NCT02736162|E2007
51308|NCT02736162|Phase 4
51309|NCT02736162|Fycompa
51310|NCT02736136|maternal parenting self-efficacy
51311|NCT02736136|parental stress
51312|NCT02736136|maternal sensitivity
51313|NCT02736136|mother-infant bond
51314|NCT02736110|Osteoarthritis, knee
51315|NCT02736084|optimism
51316|NCT02736084|positive affect
51317|NCT02736084|adherence
51318|NCT02736084|health behavior
51319|NCT02736084|diabetes
51320|NCT02736006|Alveolo-capillar membrane
51321|NCT02736006|decompression illness
51322|NCT02736006|diving
51323|NCT02736006|occupational
51324|NCT02735993|Celution
51325|NCT02735993|ADRC
51326|NCT02735993|Heart Failure
51327|NCT02735993|Device
51328|NCT02735980|SCLC
51329|NCT02735980|LY2606368
51330|NCT02735980|CHK1
51331|NCT02735915|Immunogenicity
51332|NCT02735915|Safety
51333|NCT02735915|Long term follow-up
51334|NCT02735915|Adults
51335|NCT02735915|Herpes zoster
51336|NCT02735902|antivitamins K
51337|NCT02735876|Bruton tyrosine kinase inhibitor
51338|NCT02735876|Btk
51339|NCT02735876|ACP-196
51340|NCT02735876|Mantle Cell Lymphoma
51341|NCT02735876|MCL
51342|NCT02735811|Implantable defibrillator
51343|NCT02735811|Cardiomyopathies
51344|NCT02735720|thoracic endovascular aortic repair
51345|NCT02735720|endograft
51346|NCT02735720|cardiac remodelling
51347|NCT02735720|thoracic aortic aneurysm
51348|NCT02735720|penetrating aortic ulcer
51349|NCT02735720|MRI
51350|NCT02735694|Sleep apnea
51351|NCT02735694|Hypoglossal Nerve
51352|NCT02735694|N-methyl-D-aspartate receptors
51353|NCT02735694|Cycloserine
51354|NCT02735694|Short-term potentiation
51355|NCT02735668|Shoulder Pain
51356|NCT02735668|Pattern Motor
51357|NCT02735668|Physical Therapy Modalities
51358|NCT02735668|Breast Cancer Treatment
51359|NCT02735655|endoscopy
51360|NCT02735655|Education
51361|NCT02735655|capsule endoscopy
51362|NCT02735655|Cholangiopancreatography, Endoscopic Retrograde
51363|NCT02735655|esophagogastroduodenoscopy
51364|NCT02735655|colonoscopy
51365|NCT02735655|Double-Balloon Enteroscopy
51366|NCT02735655|Global status
51367|NCT02735655|unmet need
51368|NCT02735616|heart rate variability
51369|NCT02735616|stroke
51370|NCT02735577|Alcohol
51371|NCT02735577|Craving
51372|NCT02735577|Functional MRI
51373|NCT02735577|Cognitive control
51374|NCT02735577|Risky decision-making
51375|NCT02735577|Disulfiram
51376|NCT02735564|Weight Loss
51377|NCT02735564|Magnetic Resonance Imaging
51378|NCT02735564|gut microbiota
51379|NCT02735551|LARC
51380|NCT02735551|IUD
51381|NCT02735551|Contraceptive Implant
51382|NCT02735551|Contraception
51383|NCT02735551|Community college
51384|NCT02735525|telemedicine
51385|NCT02735525|smartphone
51386|NCT02735499|onabotulinum toxin A
51387|NCT02735499|Urinary bladder
51388|NCT02735499|EMDA
51389|NCT02735499|iontophoresis
51390|NCT02735499|electrophoresis
51391|NCT02735499|Urinary incontinence
51392|NCT02735486|Ginger
51393|NCT02735486|blood pressure
51394|NCT02735486|flow mediated dilatation
51395|NCT02735434|Health anxiety
51396|NCT02735434|illness anxiety disorder
51397|NCT02735434|ACT
51398|NCT02735434|internet
51399|NCT02735421|acne
51400|NCT02735421|scars
51401|NCT02735395|Periodontal Diseases
51402|NCT02735395|Metronidazole
51403|NCT02735395|Amoxicillin
51404|NCT02735395|Chronic periodontitis
51405|NCT02735395|Root Planing
51406|NCT02735382|Translational Medical Research
51407|NCT02735382|Clinical Practice Guidelines
51408|NCT02735382|Electronic Health Records
51409|NCT02735382|Smoking
51410|NCT02735382|Tobacco
51411|NCT02735382|Quitline
51412|NCT02735330|CCP
51413|NCT02735317|Nasopharyngeal carcinoma (NPC)
51414|NCT02735317|radiotherapy
51415|NCT02735317|oral mucositis (OM)
51416|NCT02735291|Leukemia CAR-T
51417|NCT02735265|Rehabilitation
51418|NCT02735265|Virtual reality
51419|NCT02735252|Castration Resistant
51420|NCT02735252|Metastatic
51421|NCT02735239|Oesophageal Cancer
51422|NCT02735239|Oesophageal adenocarcinoma
51423|NCT02735239|Oesophageal squamous cell carcinoma
51424|NCT02735239|Immunotherapy
51425|NCT02735239|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
51426|NCT02735239|Programmed cell death protein 1 (PD-1)
51427|NCT02735239|Programmed death ligand 1 (PD-L1)
51428|NCT02735226|stroke
51429|NCT02735226|Shanghai Healthcare
51430|NCT02735226|Healthcare Quality, Access, and Evaluation
51431|NCT02735213|Central Serous Choroidopathy
51432|NCT02735213|Micropulse Laser Treatment
51433|NCT02735213|Traditional laser Treatment
51434|NCT02735213|optical coherence tomography
51435|NCT02735174|Telehealth
51436|NCT02735174|Sensor cap
51437|NCT02735174|School based care
51438|NCT02735174|Community health
51439|NCT02735174|AsthmaTreatSmart Application
51440|NCT02735161|Sarcoidosis
51441|NCT02735161|Fatigue
51442|NCT02735161|Exercise
51443|NCT02735148|Postural balance
51444|NCT02735148|Accidental falls
51445|NCT02735148|Rehabilitation
51446|NCT02735148|Cerebrovascular Accident
51447|NCT02735148|Walking
51448|NCT02735148|Mobility limitation
51449|NCT02735135|bedridden
51450|NCT02735109|VIN
51451|NCT02735096|Bilateral Vestibular Hypofunction
51452|NCT02735096|Unilateral Vestibular Hypofunction
51453|NCT02735096|Imbalance
51454|NCT02735070|Common cold treatment
51455|NCT02735057|oesophagus cancer
51456|NCT02735031|Glucagon-Like Peptide 1
51457|NCT02735031|Impaired hypoglycemic awareness
51458|NCT02734992|Migraines
51459|NCT02734992|Tension-type Headache
51460|NCT02734992|Acceptance
51461|NCT02734979|lymphedema
51462|NCT02734979|edema
51463|NCT02734966|Drug-Induced
51464|NCT02734966|Acute Liver Injury
51465|NCT02734953|Inhaled nitric oxide
51466|NCT02734953|Exercise
51467|NCT02734953|6 minute walk test
51468|NCT02734953|CardioMems
51469|NCT02734927|schizophrenia
51470|NCT02734927|motivation
51471|NCT02734927|executive control
51472|NCT02734901|polyphenols
51473|NCT02734901|vascular function
51474|NCT02734901|endothelial function
51475|NCT02734901|raspberry
51476|NCT02734888|arterial inflammation
51477|NCT02734888|electronic cigarettes
51478|NCT02734888|PET scan
51479|NCT02734875|anticoagulants
51480|NCT02734875|NOACs
51481|NCT02734875|warfarin
51482|NCT02734875|randomized designed delay
51483|NCT02734875|intervention
51484|NCT02734875|machine learning algorithm
51485|NCT02734875|primary care
51486|NCT02734862|mycoses
51487|NCT02734810|Exocrine Pancreatic Insufficiency
51488|NCT02734810|Cystic Fibrosis
51489|NCT02734810|Liprotamase
51490|NCT02734810|Pancreatic Enzyme Replacement Therapy (PERT)
51491|NCT02734771|DLBCL
51492|NCT02734745|diabetes type 1
51493|NCT02734745|flash glucose monitoring
51494|NCT02734732|Prostate
51495|NCT02734732|Biopsy
51496|NCT02734732|Infection
51497|NCT02734732|Prophylaxis
51498|NCT02734732|Antibiotic
51499|NCT02734693|Attention-Deficit Hyperactivity Disorder (ADHD)
51500|NCT02734680|Pancreatic cancer
51501|NCT02734680|Intraoperative radiotherapy(IORT)
51502|NCT02734680|Postoperative radiochemotherapy
51503|NCT02734654|oxidative stress
51504|NCT02734654|lung lobectomy
51505|NCT02734615|LSZ102
51506|NCT02734615|ER+ breast cancer
51507|NCT02734615|advanced ER+ breast cancer
51508|NCT02734615|metastatic ER+ breast cancer
51509|NCT02734615|SERD
51510|NCT02734615|SERM
51511|NCT02734615|fulvestrant
51512|NCT02734615|tamoxifen
51513|NCT02734615|aromatase inhibitor
51514|NCT02734615|ESR1
51515|NCT02734615|estrogen receptor
51516|NCT02734615|endocrine therapy
51517|NCT02734602|depression
51518|NCT02734602|post-traumatic stress disorder
51519|NCT02734602|sv2a
51520|NCT02734602|ketamine
51521|NCT02734602|PET
51522|NCT02734589|Ulcerative Colitis
51523|NCT02734589|Nutrition
51524|NCT02734589|microbiome
51525|NCT02734576|Venous Sinus Stenting
51526|NCT02734576|Dural Sinus Stenting
51527|NCT02734550|Sepsis
51528|NCT02734550|Invasive Candida Infection
51529|NCT02734550|Biomarker
51530|NCT02734550|(1,3)-β-D-glucan
51531|NCT02734550|Antifungal therapy
51532|NCT02734550|Intensive care medicine
51533|NCT02734550|Critically ill
51534|NCT02734524|Natural killer cells
51535|NCT02734524|NSCLC
51536|NCT02734524|NCT
51537|NCT02734524|Combined therapy
51538|NCT02734485|Progressive supranuclear palsy
51539|NCT02734485|Deep transcranial magnetic stimulation
51540|NCT02734472|blood pressure
51541|NCT02734472|Hypertrophy, Left Ventricular
51542|NCT02734472|Vascular Stiffness
51543|NCT02734472|Proteinuria
51544|NCT02734472|Carotid Artery Diseases
51545|NCT02734446|Bronchial Inflammation
51546|NCT02734446|Asthma
51547|NCT02734446|Childhood Asthma Control Test (C-ACT)
51548|NCT02734446|Asthma Exacerbations
51549|NCT02734433|Advanced solid tumors
51550|NCT02734433|asian subjects
51551|NCT02734420|Dental caries
51552|NCT02734420|PDT
51553|NCT02734420|LLLT
51554|NCT02734420|pediatric dentistry
51555|NCT02734394|exercise
51556|NCT02734394|body composition
51557|NCT02734394|metabolism
51558|NCT02734394|nutrition
51559|NCT02734381|elderly patients
51560|NCT02734381|prevalence
51561|NCT02734381|emergency department use
51562|NCT02734381|main presenting disease
51563|NCT02734355|atrial fibrillation
51564|NCT02734355|catheter ablation
51565|NCT02734355|left atrium
51566|NCT02734355|mechanical function
51567|NCT02734355|contractility
51568|NCT02734329|Nephron sparing surgery
51569|NCT02734329|Zero ischemia
51570|NCT02734329|Warm ischemia
51571|NCT02734329|Laparoscopic
51572|NCT02734329|Radiofrequency ablation
51573|NCT02734329|Microwave ablation
51574|NCT02734303|Dietary Radioactivity
51575|NCT02734303|Dietary Assessment
51576|NCT02734303|Retrospective Recall
51577|NCT02734303|Focus Group
51578|NCT02734290|metastatic
51579|NCT02734290|Human epidermal growth factor receptor 2 (Her2) negative breast cancer
51580|NCT02734290|Estrogen Receptor (ER) negative breast cancer
51581|NCT02734290|Progesterone Receptor (PR) negative breast cancer
51582|NCT02734290|Immunotherapy
51583|NCT02734290|Breast Cancer
51584|NCT02734277|Insulin
51585|NCT02734277|Glucose Intolerance
51586|NCT02734277|Prior ITN027AI Study Participants-NCT00129259
51587|NCT02734277|Prior ITN045AI Study Participants-NCT00965458
51588|NCT02734251|Healthy mood
51589|NCT02734251|Stress management
51590|NCT02734251|Relora
51591|NCT02734251|Healthy subjects
51592|NCT02734225|total knee replacement
51593|NCT02734225|total knee arthroplasty
51594|NCT02734225|rehabilitation
51595|NCT02734225|physical therapy
51596|NCT02734225|balance
51597|NCT02734212|Stigmatization
51598|NCT02734199|Birth Control
51599|NCT02734199|Contraception
51600|NCT02734199|IUD
51601|NCT02734186|Filariasis
51602|NCT02734186|Schistosoma Mansoni
51603|NCT02734186|Coinfection
51604|NCT02734160|immunotherapy
51605|NCT02734160|check point inhibitors
51606|NCT02734160|transforming growth factor (TGF)-beta R1 kinase inhibitor
51607|NCT02734134|Periprosthetic joint infection
51608|NCT02734121|breast cancer
51609|NCT02734121|breast reconstruction
51610|NCT02734121|shared decision making
51611|NCT02734121|decision support intervention
51612|NCT02734108|Sever anorexia nervosa
51613|NCT02734082|stroke
51614|NCT02734082|ischemia
51615|NCT02734082|Berne
51616|NCT02734069|carboplatin
51617|NCT02734043|bundled payment
51618|NCT02734030|Anterior Knee Pain Syndrome
51619|NCT02734030|Quadriceps Femoris
51620|NCT02734030|Muscle Inhibition
51621|NCT02734030|Interpolated Twitch Technique
51622|NCT02734030|Muscle Architecture
51623|NCT02734030|Single Leg Squat
51624|NCT02734030|Women Knee Pain
51625|NCT02734004|MEDIOLA
51626|NCT02734004|Olaparib
51627|NCT02734004|MEDI4736
51628|NCT02734004|Ovarian cancer
51629|NCT02734004|Breast cancer
51630|NCT02734004|Small Cell Lung Cancer
51631|NCT02734004|Gastric Cancer
51632|NCT02734004|Phase I/II, Adults
51633|NCT02734004|PDL-1
51634|NCT02733978|Ozone oxygen
51635|NCT02733978|ulcer healing
51636|NCT02733965|clinical pharmacy consultations
51637|NCT02733965|oral anti-cancer therapy
51638|NCT02733965|serious adverse events
51639|NCT02733965|medication reconciliation
51640|NCT02733939|technology
51641|NCT02733939|informal care
51642|NCT02733939|caregiver burden
51643|NCT02733913|atrial fibrillation
51644|NCT02733913|pulmonary vein isolation
51645|NCT02733913|heart rate turbulence
51646|NCT02733913|baroreflex sensitivity
51647|NCT02733900|aseptic osteonecrosis
51648|NCT02733900|femoral head
51649|NCT02733900|micro scanner
51650|NCT02733900|Raman spectrometry
51651|NCT02733900|MRI
51652|NCT02733861|dental implant
51653|NCT02733861|stability
51654|NCT02733861|implant stability quotient
51655|NCT02733848|Roux-en-Y gastric bypass
51656|NCT02733848|Hypoglycemia
51657|NCT02733848|Creon
51658|NCT02733822|opiate
51659|NCT02733822|heroin
51660|NCT02733822|opioid
51661|NCT02733822|overdose
51662|NCT02733822|naloxone
51663|NCT02733809|Hepatocellular Carcinoma
51664|NCT02733809|Sorafenib
51665|NCT02733796|zika virus
51666|NCT02733796|semen analysis
51667|NCT02733796|sexual transmission
51668|NCT02733757|Clonidine
51669|NCT02733757|Sub-Tenon's and Peribulbar block
51670|NCT02733757|IOP
51671|NCT02733757|OPP
51672|NCT02733757|OPA
51673|NCT02733744|Stem cell transplant
51674|NCT02733744|fecal microbiota transplantation
51675|NCT02733718|Necrotizing enterocolitis
51676|NCT02733718|Transfusion
51677|NCT02733718|Mesenteric Oxygenisation
51678|NCT02733705|Pain
51679|NCT02733705|TRUS biopsy
51680|NCT02733692|HIV
51681|NCT02733692|STDs
51682|NCT02733692|web-based app
51683|NCT02733692|women
51684|NCT02733666|Absorbable screw
51685|NCT02733666|Internal fixation
51686|NCT02733666|Children
51687|NCT02733653|Superficial Femoral Artery
51688|NCT02733653|Proximal Popliteal Artery
51689|NCT02733653|Endovascular therapy
51690|NCT02733653|Atherectomy
51691|NCT02733601|breast cancer epidemiology algeria registry
51692|NCT02733588|hypoglycemia
51693|NCT02733588|glucagon
51694|NCT02733588|glucose metabolism disorders
51695|NCT02733588|hormones
51696|NCT02733588|gastrointestinal agents
51697|NCT02733588|bariatric surgery
51698|NCT02733588|incretins
51699|NCT02733536|endotracheal intubation
51700|NCT02733536|cardiopulmonary resuscitation
51701|NCT02733536|trauma
51702|NCT02733536|paramedic
51703|NCT02733510|kidney transplantation
51704|NCT02733510|subclinical rejection
51705|NCT02733510|steroid pulse therapy
51706|NCT02733497|sympathectomy, sympathicotomy, heart rate variability,
51707|NCT02733484|Obesity,Probiotics,Treatment
51708|NCT02733471|Lidocaine
51709|NCT02733471|Endoscopy
51710|NCT02733471|Tolerance
51711|NCT02733393|Thoracotomy
51712|NCT02733393|Postoperative
51713|NCT02733393|Lidocaine
51714|NCT02733393|Sphenopalatine Ganglion Block
51715|NCT02733380|Diffuse Large B-Cell Lymphoma
51716|NCT02733380|Relapsed and refractory
51717|NCT02733380|Histone deacetylase inhibitor
51718|NCT02733380|Chidamide
51719|NCT02733341|Adenosine Diphosphate
51720|NCT02733341|Cardiovascular Magnetic Resonance (CMR)
51721|NCT02733341|Index of microvascular resistance (IMR)
51722|NCT02733341|Vasodilator stimulated phosphoprotein phosphorylation (VASP)
51723|NCT02733341|Pharmacodynamic
51724|NCT02733341|Antiplatelet
51725|NCT02733341|Myocardial Infarction (MI)
51726|NCT02733341|Cangrelor
51727|NCT02733341|Ticagrelor
51728|NCT02733341|Coronary artery bypass graft (CABG)
51729|NCT02733341|Primary percutaneous coronary intervention (PPCI)
51730|NCT02733328|Cardio-pulmonary bypass (CPB)
51731|NCT02733328|renal replacement therapy (RRT)
51732|NCT02733328|enzyme-linked immunosorbent assay (ELISA)
51733|NCT02733263|gut microbiota
51734|NCT02733263|fiber
51735|NCT02733263|diet quality
51736|NCT02733263|immunity
51737|NCT02733250|NSCLC
51738|NCT02733250|Pembrolizumab
51739|NCT02733250|Nab-paclitaxel
51740|NCT02733237|oxytocin
51741|NCT02733237|infidelity
51742|NCT02733224|lenalidomide adherence MEMS
51743|NCT02733211|Closed Loop
51744|NCT02733185|chelation
51745|NCT02733172|Vulvodynia
51746|NCT02733172|Endophenotypes
51747|NCT02733172|functional MRI
51748|NCT02733159|Performance Status 2
51749|NCT02733159|Pembrolizumab
51750|NCT02733159|MK-3475
51751|NCT02733133|Testosterone
51752|NCT02733133|AndroGel
51753|NCT02733133|Transference
51754|NCT02733133|Women
51755|NCT02733133|Children
51756|NCT02733107|Non-small Cell Lung Cancer
51757|NCT02733107|Apatinib
51758|NCT02733107|Etoposide
51759|NCT02733081|Long Acting Reversible Contraception
51760|NCT02733081|Intrauterine Device (IUD)
51761|NCT02733081|Intrauterine Device (IUD) Insertion
51762|NCT02733081|Family Planning
51763|NCT02733081|International Family Planning
51764|NCT02733055|Postural Equilibrium
51765|NCT02733055|Musculoskeletal Equilibrium
51766|NCT02733055|Eye Movements
51767|NCT02733055|Saccades
51768|NCT02733055|Pursuit, Smooth
51769|NCT02733042|Lymphoma
51770|NCT02733042|Chronic Lymphocytic Leukemia
51771|NCT02733042|Durvalumab
51772|NCT02733042|Anti-PD-L1 Antibody
51773|NCT02733042|MEDI4736
51774|NCT02733042|Immune Checkpoint
51775|NCT02733042|Lymphatic Disease
51776|NCT02733042|B-Cell Malignancies
51777|NCT02733042|Abscopal Effect
51778|NCT02733042|Lenalidomide
51779|NCT02733042|Bendamustine
51780|NCT02733042|Rituximab
51781|NCT02733042|Ibrutinib
51782|NCT02733042|Lymphoma, B-Cell
51783|NCT02733042|Lymphoma, Non Hodgkin,
51784|NCT02733042|Hodgkin Disease
51785|NCT02733042|Leukemia, Lymphocytic, Chronic, B-Cell,
51786|NCT02733042|Lymphoma, Follicular
51787|NCT02733042|Lymphoma, Diffuse Large B-Cell
51788|NCT02733042|Lymphoma, Mantle Cell
51789|NCT02733042|Lymphoma, Small Lymphocytic
51790|NCT02733042|Immune System Diseases
51791|NCT02733042|Immunoproliferative Disorders
51792|NCT02733042|Lymphoproliferative Disorders
51793|NCT02733003|Implementation Science
51794|NCT02733003|HIV
51795|NCT02733003|Sexual Risk
51796|NCT02733003|Sexually Transmitted Diseases
51797|NCT02733003|Substance Abuse
51798|NCT02733003|Violence and Victimization
51799|NCT02732990|Training
51800|NCT02732990|One-legged exercise
51801|NCT02732990|Peripheral blood flow
51802|NCT02732990|Cardiac function
51803|NCT02732990|Muscle metaboreflex
51804|NCT02732964|satisfaction
51805|NCT02732938|CCR2i, nab-paclitaxel, Abraxane, gemcitabine, pancreas
51806|NCT02732925|Vertebral Compression Fracture
51807|NCT02732925|Balloon Kyphoplasty
51808|NCT02732925|Conservative treatment
51809|NCT02732925|Sham procedure
51810|NCT02732925|VCFs
51811|NCT02732925|Multiple Myeloma
51812|NCT02732912|falls
51813|NCT02732912|sleep
51814|NCT02732899|AMD
51815|NCT02732886|foam dressing
51816|NCT02732860|personalized patient-derived xenografts (pPDX)
51817|NCT02732860|molecular profiling
51818|NCT02732860|epigenetic analysis
51819|NCT02732860|drug sensitivity testing
51820|NCT02732860|triple negative
51821|NCT02732860|metastatic
51822|NCT02732847|Respiratory infections
51823|NCT02732847|Primary care
51824|NCT02732847|Antibiotics
51825|NCT02732847|Delayed prescriptions
51826|NCT02732834|Doctor-Patient Communication
51827|NCT02732834|16-001
51828|NCT02732821|Gastroparesis
51829|NCT02732821|G-POEM
51830|NCT02732821|Gastric Per Oral Endoscopic Myotomy
51831|NCT02732808|Double stimulations
51832|NCT02732808|luteal-phase ovarian stimulation
51833|NCT02732808|poor ovarian response
51834|NCT02732782|Achilles tendon
51835|NCT02732782|isometric muscle training
51836|NCT02732782|competitive sports
51837|NCT02732782|strength training
51838|NCT02732782|eccentric exercise
51839|NCT02732782|isometric exercise
51840|NCT02732782|chronic condition
51841|NCT02732782|regeneration
51842|NCT02732782|tendon
51843|NCT02732782|tendon properties
51844|NCT02732782|tendinopathy
51845|NCT02732782|tendinosis
51846|NCT02732782|intervention
51847|NCT02732782|training load
51848|NCT02732782|high performance sports
51849|NCT02732756|ADHD
51850|NCT02732756|Sleep
51851|NCT02732756|Attention
51852|NCT02732756|Adolescence
51853|NCT02732743|childhod constipation
51854|NCT02732730|ART (Antir-retroviral therapy)
51855|NCT02732730|PrEP (Pre-Exposure Prophylaxis)
51856|NCT02732730|DAIDS (Division of AIDS)
51857|NCT02732730|HPTN (HIV Prevention Trials Network)
51858|NCT02732613|Laryngeal Mask Airway
51859|NCT02732613|Body weight
51860|NCT02732613|Complication
51861|NCT02732600|Veterans
51862|NCT02732600|Veterans Health
51863|NCT02732600|Patient Compliance
51864|NCT02732600|Primary Health Care
51865|NCT02732600|Health Care Providers
51866|NCT02732600|Health Promotion
51867|NCT02732522|misoprostol
51868|NCT02732522|induction of labor
51869|NCT02732522|sublingual
51870|NCT02732496|Attention-Deficit/Hyperactivity Disorder
51871|NCT02732496|Tourette Syndrome
51872|NCT02732496|Working Memory Training
51873|NCT02732483|gastric cancer
51874|NCT02732483|bleeding
51875|NCT02732483|gastrointestinal hemorrhage
51876|NCT02732470|Systemic Lupus Erythematous
51877|NCT02732470|Qi Gong
51878|NCT02732470|Quality of life
51879|NCT02732457|HIV
51880|NCT02732457|Persistence
51881|NCT02732457|Reservoirs
51882|NCT02732457|Stem Cell Transplant
51883|NCT02732457|Functional Cure
51884|NCT02732444|Erythrocytes Membranes Stability
51885|NCT02732444|Oxidative Stress
51886|NCT02732444|Chronic Obstructive Pulmonary Disease (COPD)
51887|NCT02732444|Advanced Pulmonary Disease (APD)
51888|NCT02732444|Long-Term Home Oxygen Therapy (LTOT)
51889|NCT02732418|CI-contraceptive injection
51890|NCT02732418|DMPA-Depot medroxyprogesterone acetate
51891|NCT02732418|MPA-Medroxyprogesterone Acetate
51892|NCT02732418|subQ-subcutaneous
51893|NCT02732379|Postoperative Nausea and Vomiting
51894|NCT02732379|Aromatherapy
51895|NCT02732379|Quality of Health Care
51896|NCT02732366|aged [MeSH term]
51897|NCT02732366|exercise [MeSH term]
51898|NCT02732340|triple-branched stent graft
51899|NCT02732340|hemi-arch replace
51900|NCT02732340|the occluded rate of false lumen
51901|NCT02732275|Relapsed non-hodgkin lymphoma.
51902|NCT02732275|phase 1
51903|NCT02732275|oncology
51904|NCT02732262|acute pain
51905|NCT02732262|postoperative
51906|NCT02732262|surgery
51907|NCT02732249|Helicobacter pylori
51908|NCT02732249|Clarithromycin
51909|NCT02732249|Amoxicillin
51910|NCT02732249|Metronidazole
51911|NCT02732249|Eradication
51912|NCT02732236|marginal zone lymphoma
51913|NCT02732236|Cohort
51914|NCT02732236|Rituximab
51915|NCT02732236|HBV
51916|NCT02732223|Atherosclerosis
51917|NCT02732223|omega 3
51918|NCT02732223|plant sterols
51919|NCT02732223|polyphenols
51920|NCT02732184|AML
51921|NCT02732184|MDS
51922|NCT02732158|Novel laboratory methods
51923|NCT02732145|Three-Vulvar-Rings
51924|NCT02732145|Three-Rings-Vulvoscopy
51925|NCT02732145|N-S-P scheme
51926|NCT02732145|Vulvoscopy Index
51927|NCT02732145|Vulvar Dermatosis
51928|NCT02732145|Vulvar Lichen Sclerosus
51929|NCT02732145|Lichen Planus
51930|NCT02732145|Lichen Simplex Chronicus
51931|NCT02732145|Vulvodynia
51932|NCT02732145|Provoked Vestibulodynia
51933|NCT02732145|Vulvar Vestibulitis
51934|NCT02732145|Vulvar Diseases
51935|NCT02732119|HR-positive
51936|NCT02732119|HER2-negative
51937|NCT02732119|Advanced breast cancer
51938|NCT02732119|LEE011
51939|NCT02732119|ribociclib
51940|NCT02732119|everolimus
51941|NCT02732119|Afinitor
51942|NCT02732119|exemestane
51943|NCT02732119|Aromasin
51944|NCT02732119|CDK
51945|NCT02732119|CDK4
51946|NCT02732119|CDK6
51947|NCT02732119|CDK4/6
51948|NCT02732119|CDK4/6 inhibitor
51949|NCT02732119|Phase III
51950|NCT02732119|ER-positive
51951|NCT02732119|PR-positive
51952|NCT02732119|Postmenopausal
51953|NCT02732106|ADRCs, cell characterization
51954|NCT02732080|primary percutaneous coronary intervention
51955|NCT02732080|microvascular obstruction
51956|NCT02732080|myocardial edema
51957|NCT02732080|microvascular resistance
51958|NCT02732080|acute myocardial infarction
51959|NCT02732067|Anesthesia
51960|NCT02732054|HBV vaccination, immunity
51961|NCT02732028|GRADE
51962|NCT02732028|Summary of Findings Table
51963|NCT02732028|Systematic Review
51964|NCT02732028|Clinical trial, randomized
51965|NCT02732015|Sarcoma
51966|NCT02732015|Locally advanced
51967|NCT02732015|High risk for relapse
51968|NCT02732015|Metastatic
51969|NCT02732015|Questionnaires
51970|NCT02732015|Surveys
51971|NCT02732015|Rolapitant
51972|NCT02732015|Fosaprepitant
51973|NCT02732015|Dexamethasone
51974|NCT02732015|Decadron
51975|NCT02732015|Ondansetron
51976|NCT02732015|Zofran
51977|NCT02732015|Doxorubicin
51978|NCT02732015|Adriamycin PFS
51979|NCT02732015|Adriamycin RDF
51980|NCT02732015|Rubex
51981|NCT02732015|Mesna
51982|NCT02732015|Mesnex
51983|NCT02732015|Ifosfamide
51984|NCT02732015|Ifex
51985|NCT02732015|Vincristine
51986|NCT02732015|Nausea
51987|NCT02732015|Vomiting
51988|NCT02732002|shoulder
51989|NCT02732002|rotator cuff- injury
51990|NCT02732002|management
51991|NCT02732002|rehabilitation model
51992|NCT02731976|Gluten-Free diet
51993|NCT02731976|Healthy individuals
51994|NCT02731963|Outcomes
51995|NCT02731963|Bowel preparation
51996|NCT02731924|Appendicitis
51997|NCT02731924|Ultrasound
51998|NCT02731924|Emergency Department
51999|NCT02731872|COPD
52000|NCT02731872|oxygen treatment
52001|NCT02731872|quality of life
52002|NCT02731846|Efficacy
52003|NCT02731846|Triple therapy
52004|NCT02731846|Parallel
52005|NCT02731846|Respiratory
52006|NCT02731820|potassium citrate
52007|NCT02731807|TA-65
52008|NCT02731807|Telemorase
52009|NCT02731807|Dietary Supplement
52010|NCT02731794|cardiopulmonary bypass
52011|NCT02731794|coronary artery bypass grafting
52012|NCT02731794|inflammatory response
52013|NCT02731794|cardiac dysfunction
52014|NCT02731781|OUTCOME
52015|NCT02731781|PROGNOSIS
52016|NCT02731781|PEDIATRIC HEAd injury
52017|NCT02731781|CT SCAN
52018|NCT02731755|Oats
52019|NCT02731755|Phenolic acid
52020|NCT02731755|FMD
52021|NCT02731755|LDI
52022|NCT02731755|Renin angiotensin
52023|NCT02731755|Nitric oxide
52024|NCT02731729|Ipilimumab
52025|NCT02731729|Nivolumab
52026|NCT02731729|Stage III-IV Melanoma
52027|NCT02731729|Progressed or Relapsed on PD-1 Inhibitor Therapy
52028|NCT02731729|16-043
52029|NCT02731703|overdenture
52030|NCT02731703|overlay
52031|NCT02731703|implant supported
52032|NCT02731703|denture
52033|NCT02731703|dental prosthesis
52034|NCT02731703|maxillary
52035|NCT02731690|GNE Myopathy
52036|NCT02731690|Nonaka
52037|NCT02731690|GNEM
52038|NCT02731690|Hereditary Inclusion Body Myopathy
52039|NCT02731690|HIBM
52040|NCT02731690|DMRV
52041|NCT02731690|QSM
52042|NCT02731664|Irritable bowel syndrome
52043|NCT02731664|Functional dyspepsia
52044|NCT02731664|Gastric emptying
52045|NCT02731664|Gastrointestinal peptide hormones
52046|NCT02731638|cornea
52047|NCT02731638|ulcer
52048|NCT02731638|fungal
52049|NCT02731638|keratitis
52050|NCT02731625|Kettlebell training
52051|NCT02731625|High-intensity interval training
52052|NCT02731612|Bipolar Disorder
52053|NCT02731612|Cognition
52054|NCT02731612|Euthymic
52055|NCT02731612|Lurasidone
52056|NCT02731599|Parkinson Disease
52057|NCT02731599|treadmill
52058|NCT02731599|Rehabilitation
52059|NCT02731586|Dental Implants
52060|NCT02731586|Allogenic mesenchymal stem cells
52061|NCT02731586|osseointegration
52062|NCT02731586|primary stability
52063|NCT02731586|resonance frequency analysis
52064|NCT02731586|RFA
52065|NCT02731586|implants and stem cells
52066|NCT02731586|use of stem cells
52067|NCT02731586|stem cells
52068|NCT02731560|Pakistan, Rituximab
52069|NCT02731560|RA
52070|NCT02731521|MRS Biomarkers
52071|NCT02731508|Transcranial Direct Current Stimulation
52072|NCT02731508|Neuroplasticity
52073|NCT02731482|Bronchiectasis
52074|NCT02731482|Rehabilitation
52075|NCT02731482|Quality of Life
52076|NCT02731482|Physiotherapy Specialty
52077|NCT02731456|high altitude
52078|NCT02731456|cognition
52079|NCT02731456|sleep
52080|NCT02731443|dreaming
52081|NCT02731443|epilepsy
52082|NCT02731443|neurosurgery
52083|NCT02731443|temporal lobectomy
52084|NCT02731378|erythropoietin
52085|NCT02731378|iron supplementation
52086|NCT02731378|inadequately responsive
52087|NCT02731378|chemotherapy-induced anaemia
52088|NCT02731365|Parkinson's Disease
52089|NCT02731300|Transcranial direct current stimulation
52090|NCT02731300|Cathodal stimulation
52091|NCT02731300|Childhood Pharmacoresistant epilepsy
52092|NCT02731300|Lennox-Gastaut syndrome
52093|NCT02731235|Stroke
52094|NCT02731235|stroke, acute
52095|NCT02731235|Cerebral small vessel disease
52096|NCT02731222|CEAP clasification, CVI:Chronic venous insufficiency,
52097|NCT02731222|CVD: Chronic venous disease , PTS: Posthrombotic syndrome,
52098|NCT02731222|Deep venous system, VH venous hipertension
52099|NCT02731222|Superficial venous system
52100|NCT02731222|Onychodystrophy
52101|NCT02731196|exercise
52102|NCT02731196|lumbar microdiscectomy
52103|NCT02731183|Fecal Microbiota Transplantation
52104|NCT02731183|Chronic intestinal pseudo obstruction
52105|NCT02731183|Efficacy and safety
52106|NCT02731170|Parkinson Disease
52107|NCT02731170|Advanced Stages
52108|NCT02731170|Rehabilitation
52109|NCT02731144|Loss of Physical Function
52110|NCT02731118|glaucoma
52111|NCT02731118|intraocular pressure lowering treatment
52112|NCT02731118|antisectory factor (AF)
52113|NCT02731118|Salovum
52114|NCT02731105|acne
52115|NCT02731105|vulgaris
52116|NCT02731105|Clindamycin
52117|NCT02731105|Tretinoin
52118|NCT02731105|Adapalen
52119|NCT02731105|Benzoylperoxid
52120|NCT02731105|Epiduo
52121|NCT02731105|Acnatac
52122|NCT02731092|lactoferrin
52123|NCT02731092|very low birth weight infants
52124|NCT02731092|preterm infants
52125|NCT02731079|Sleeve gastrectomy stapler Covidien Ethicon bleeding leak
52126|NCT02731053|Depression
52127|NCT02731053|Prevention
52128|NCT02731053|Adolescents
52129|NCT02731053|School
52130|NCT02731053|Effectiveness
52131|NCT02731014|Dry Needling
52132|NCT02730975|pharmacokinetics
52133|NCT02730975|food-effect
52134|NCT02730975|fat diet
52135|NCT02730975|abiraterone acetate
52136|NCT02730949|D-Chiro-Inositol, type 1 diabetes
52137|NCT02730923|Clinical Trials, Randomized
52138|NCT02730923|Clinical Trial, Phase I
52139|NCT02730923|Clinical Trial, Phase II
52140|NCT02730923|Multicenter Trials
52141|NCT02730923|Aromatase Inhibitors
52142|NCT02730923|mTOR kinase inhibitor
52143|NCT02730910|Bioavailability
52144|NCT02730910|adults
52145|NCT02730897|Surgery
52146|NCT02730897|Thoracotomy
52147|NCT02730897|VATS
52148|NCT02730884|Leukemia
52149|NCT02730884|Myelofibrosis
52150|NCT02730884|MF
52151|NCT02730884|Anemia
52152|NCT02730884|Splenomegaly
52153|NCT02730884|Post-polycythemia vera MF
52154|NCT02730884|post-PV
52155|NCT02730884|post-essential thrombocythemia MF
52156|NCT02730884|post-ET
52157|NCT02730884|Rigosertib
52158|NCT02730884|ON 01910.Na
52159|NCT02730884|Questionnaire
52160|NCT02730884|Survey
52161|NCT02730858|Metastatic Breast Cancer
52162|NCT02730858|Palliative Care
52163|NCT02730858|Breast Cancer
52164|NCT02730858|End of life
52165|NCT02730858|Health service research
52166|NCT02730845|Elective
52167|NCT02730845|local anesthesia
52168|NCT02730845|knee arthroscopy
52169|NCT02730845|Dexmedetomidine
52170|NCT02730793|Cystic Fibrosis
52171|NCT02730793|P. aeruginosa (PA)
52172|NCT02730754|Mood Disorders
52173|NCT02730754|Illness Perception
52174|NCT02730754|Primary Care
52175|NCT02730754|Medication Adherence
52176|NCT02730741|diarrhoea
52177|NCT02730741|metfomin
52178|NCT02730741|type 2 diabetes
52179|NCT02730741|microbiota
52180|NCT02730728|adductor canal block
52181|NCT02730728|tinetti score
52182|NCT02730728|time to up and go test
52183|NCT02730728|Ambulation distance
52184|NCT02730728|pain score
52185|NCT02730728|quality of recovery score
52186|NCT02730689|DP-R207
52187|NCT02730689|Rosuvastatin
52188|NCT02730689|Ezetimibe
52189|NCT02730676|electronic cigarettes
52190|NCT02730676|e-cigarette
52191|NCT02730676|combustible cigarette
52192|NCT02730676|cigarette
52193|NCT02730676|menthol
52194|NCT02730676|cig-alike
52195|NCT02730676|subjective measures
52196|NCT02730676|pharmacokinetics
52197|NCT02730676|craving
52198|NCT02730663|Endoscopic ultrasound guided transluminal drainage
52199|NCT02730650|FACE-Q
52200|NCT02730650|Platelet Rich Therapy
52201|NCT02730650|PRT
52202|NCT02730624|piperacillin/tazobactam
52203|NCT02730624|critically ill
52204|NCT02730624|severe sepsis
52205|NCT02730624|septic shock
52206|NCT02730611|Vertical sleeve gastrectomy
52207|NCT02730611|Metabolic syndrome
52208|NCT02730611|Disorder of Bile Acid and Cholesterol Metabolism
52209|NCT02730611|Cholangiocarcinoma
52210|NCT02730611|Hepatocellular carcinoma
52211|NCT02730585|C-reactive protein
52212|NCT02730572|Attention Deficit Hyperactivity Disorder
52213|NCT02730572|Methylphenidate
52214|NCT02730559|Motivational Interviewing
52215|NCT02730533|endoscopic submucosal dissection
52216|NCT02730533|proton pump inhibitor
52217|NCT02730533|bleeding
52218|NCT02730520|respiratory disease
52219|NCT02730520|allergen sensitization
52220|NCT02730520|aging
52221|NCT02730520|skin tests
52222|NCT02730520|air allergens
52223|NCT02730494|mycosis
52224|NCT02730494|Candidiasis
52225|NCT02730494|Lcr35®
52226|NCT02730494|Lcr Regenerans®
52227|NCT02730455|Stroke
52228|NCT02730351|Fluticasone furoate
52229|NCT02730351|activity monitoring
52230|NCT02730351|Vilanterol
52231|NCT02730351|Cross-over
52232|NCT02730351|exercise-induced bronchoconstriction
52233|NCT02730351|exercise challenge
52234|NCT02730351|double-dummy
52235|NCT02730351|asthma
52236|NCT02730351|spirometry
52237|NCT02730351|fluticasone propionate
52238|NCT02730338|Castrate-Resistant
52239|NCT02730325|CDI
52240|NCT02730325|C. diff
52241|NCT02730325|Ulcerative Colitis
52242|NCT02730325|UC
52243|NCT02730325|IBD
52244|NCT02730325|Inflammatory Bowel Disease
52245|NCT02730312|AML
52246|NCT02730312|B-ALL
52247|NCT02730312|BPDCN
52248|NCT02730312|CML
52249|NCT02730312|Blast Crisis
52250|NCT02730286|human activity
52251|NCT02730286|International Classification of Functioning
52252|NCT02729233|mucosal barrier function
52253|NCT02729220|Aging
52254|NCT02729220|Oxidative stress
52255|NCT02729220|Proteases
52256|NCT02729220|Bronchoscopy
52257|NCT02730260|Directive coaching
52258|NCT02730260|Nondirective coaching
52259|NCT02730260|smoking cessation quitline
52260|NCT02730260|social support
52261|NCT02730247|ramucirumab
52262|NCT02730247|docetaxel
52263|NCT02730221|Administrative workload
52264|NCT02730221|Patient data management system
52265|NCT02730221|Intensive Care Unit
52266|NCT02730221|Work sampling method
52267|NCT02730221|Nursing Activity Score
52268|NCT02730182|postural control
52269|NCT02730182|high altitude
52270|NCT02730169|Hypogonadotropic
52271|NCT02730169|hypogonadism
52272|NCT02730169|testosterone
52273|NCT02730143|Altitude
52274|NCT02730143|Nocturnal breathing pattern
52275|NCT02730130|Pembrolizumab
52276|NCT02730130|Radiotherapy
52277|NCT02730130|16-032
52278|NCT02730117|Acute kidney injury
52279|NCT02730117|Furosemide stress test
52280|NCT02730117|critical care
52281|NCT02730078|Mood Disorders
52282|NCT02730078|Self Care
52283|NCT02730078|Primary Care
52284|NCT02730065|Cerebral small vessel disease
52285|NCT02730065|Lifestyle modification
52286|NCT02730065|Physical activity
52287|NCT02730065|Primary prevention
52288|NCT02730065|Aerobic dance
52289|NCT02730065|Cognition
52290|NCT02730065|Depression
52291|NCT02730065|Activities of daily living
52292|NCT02730065|Cerebral autoregulation
52293|NCT02730052|Blood pressure control
52294|NCT02730052|Hypertension
52295|NCT02730052|Office blood pressure
52296|NCT02730052|Self-measured blood pressure,
52297|NCT02730052|Telemonitoring
52298|NCT02730039|Cancer Care Providers
52299|NCT02730039|Psychotherapy
52300|NCT02730039|15-321
52301|NCT02730026|Ketofrofen
52302|NCT02730026|Omeprazole
52303|NCT02730026|Lower Third Molar
52304|NCT02730026|Oral Surgery
52305|NCT02730013|Older adults
52306|NCT02730013|Square stepping exercise
52307|NCT02730013|Mind-motor exercise
52308|NCT02730013|Long-term care
52309|NCT02730013|Global cognitive functioning
52310|NCT02730000|Dental Atraumatic Restorative Treatment
52311|NCT02730000|Primary Teeth
52312|NCT02730000|Clinical Efficacy
52313|NCT02730000|Cost Analysis
52314|NCT02730000|Glass Ionomer Cement
52315|NCT02729987|online
52316|NCT02729987|internet
52317|NCT02729987|CBT
52318|NCT02729987|Stress
52319|NCT02729987|Work
52320|NCT02729987|Internet based treatment
52321|NCT02729974|thromboelastography
52322|NCT02729935|Parecoxib
52323|NCT02729935|Bladder Discomfort
52324|NCT02729909|Drug therapy
52325|NCT02729870|Ketones
52326|NCT02729870|Gastroenteritis
52327|NCT02729844|Incidence
52328|NCT02729844|Risk factors
52329|NCT02729844|Outcome
52330|NCT02729831|decision making
52331|NCT02729831|decision aids
52332|NCT02729831|decision quality instruments
52333|NCT02729831|osteoarthritis
52334|NCT02729831|shared decision making
52335|NCT02729818|Retina
52336|NCT02729818|Microperimetry
52337|NCT02729818|Visual Fields
52338|NCT02729805|ketamine
52339|NCT02729805|chronic pain
52340|NCT02729805|mastectomy
52341|NCT02729805|acute pain
52342|NCT02729792|depression
52343|NCT02729792|treatment resistance
52344|NCT02729792|biomarkers
52345|NCT02729792|repetitive transcranial magnetic stimulation
52346|NCT02729766|Hyponatremia
52347|NCT02729766|SGLT2 inhibitor
52348|NCT02729740|Penumbra Smart coils
52349|NCT02729740|PC 400
52350|NCT02729740|AV malformations
52351|NCT02729740|AV fistulae
52352|NCT02729688|Venous insufficiency
52353|NCT02729688|Compression
52354|NCT02729688|Bandaging
52355|NCT02729675|fruit & vegetable, market, education, worksite, food access
52356|NCT02729597|neuromuscular disorders
52357|NCT02729597|MRI
52358|NCT02729597|white matter
52359|NCT02729597|brain
52360|NCT02729597|myotonic dystrophy
52361|NCT02729558|brain metastases
52362|NCT02729558|radiotherapy
52363|NCT02729558|resection
52364|NCT02729545|acupuncture, POCS
52365|NCT02729532|Extra-pulmonary tuberculosis
52366|NCT02729532|multiple drug resistant tuberculosis
52367|NCT02729532|mycobacterium tuberculosis
52368|NCT02729532|human immunodeficiency virus
52369|NCT02729506|hepatocellular carcinoma
52370|NCT02729506|transarterial radioembolization
52371|NCT02729506|chemoembolization chemoembolization
52372|NCT02729506|clinical trial
52373|NCT02729493|Liver Cancer CAR-T
52374|NCT02729467|Healthy
52375|NCT02729467|JNJ-53718678
52376|NCT02729467|Itraconazole
52377|NCT02729467|Rifampicin
52378|NCT02729467|Pharmacokinetics
52379|NCT02729428|Aging
52380|NCT02729428|White Matter Hyperintensity Volume
52381|NCT02729428|Default Mode Network Connectivity
52382|NCT02729428|Cognitive Function
52383|NCT02729428|Cardiorespiratory Fitness
52384|NCT02729428|Magnetic Resonance Imaging
52385|NCT02729415|Hair Diseases
52386|NCT02729415|Alopecia
52387|NCT02729402|Adults
52388|NCT02729389|Social Status
52389|NCT02729389|Hispanics
52390|NCT02729389|Energy Balance
52391|NCT02729389|Stress
52392|NCT02729376|Healthy Volunteers
52393|NCT02729337|technology
52394|NCT02729337|adolescent
52395|NCT02729337|developing country
52396|NCT02729337|hiv prevention
52397|NCT02729337|mHealth
52398|NCT02729324|nasopharyngeal carcinoma (NPC)
52399|NCT02729324|radiation dermatitis
52400|NCT02729324|intensity modulated radiation therapy (IMRT)
52401|NCT02729311|exercise
52402|NCT02729311|function
52403|NCT02729311|quality of life
52404|NCT02729311|caregiver
52405|NCT02729298|Tolero
52406|NCT02729298|Phase 1
52407|NCT02729298|First in human
52408|NCT02729298|Solid Tumors
52409|NCT02729298|AXL inhibitor
52410|NCT02729298|Advanced Malignancy
52411|NCT02729298|Cancer
52412|NCT02729259|VRD
52413|NCT02729207|NSAID Patch
52414|NCT02729168|Rabies
52415|NCT02729168|Vaccine
52416|NCT02729168|Safety
52417|NCT02729168|INDIRAB
52418|NCT02729168|Vietnam
52419|NCT02729155|Ischemic Preconditioning
52420|NCT02729155|Postconditioning
52421|NCT02729155|Angioplasty
52422|NCT02729155|Angiography
52423|NCT02729155|Contrast-Induced Nephropathy
52424|NCT02729142|HRpQCT
52425|NCT02729142|transplant
52426|NCT02729142|bone microarchitecture
52427|NCT02729129|Diesel exhaust
52428|NCT02729129|Air pollution
52429|NCT02729129|Intervention
52430|NCT02729129|Plethysmography
52431|NCT02729116|Extended-Spectrum ß-lactamase-producing Escherichia coli
52432|NCT02729116|Extended-Spectrum ß-lactamase-producing Klebsiella pneumoniae
52433|NCT02729116|Kidney Transplantation
52434|NCT02729116|Urinary Tract Infections
52435|NCT02729090|Peripheral Arterial Disease, exercise
52436|NCT02729064|Intranasal Insulin
52437|NCT02729064|Insulin concentration
52438|NCT02729064|Blood glucose
52439|NCT02729064|Cerebro Spinal Fluid insulin
52440|NCT02729064|Intraoperative blood glucose
52441|NCT02729064|Cardiac Surgery
52442|NCT02729064|Thoracic Surgery
52443|NCT02729051|Chronic Obstructive Pulmonary Disease (COPD)
52444|NCT02729051|fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI)
52445|NCT02729051|Umeclidinium bromide (UMEC)
52446|NCT02729051|Closed triple therapy
52447|NCT02729051|Placebo
52448|NCT02729051|Open triple therapy
52449|NCT02729051|fluticasone furoate/vilanterol (FF/VI)
52450|NCT02729038|Normal Renal Function
52451|NCT02729038|end stage renal disease (ESRD)
52452|NCT02729038|Pharmacokinetics
52453|NCT02729038|Gepotidacin
52454|NCT02729038|Renal Impairment
52455|NCT02729025|Hyperlipidemia
52456|NCT02729025|Dyslipidemia
52457|NCT02729025|Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition
52458|NCT02729025|Arterial Wall Inflamation
52459|NCT02729025|Elevated lipoprotein a
52460|NCT02729012|Children
52461|NCT02728999|Trendelenburg position
52462|NCT02728999|Robotic assisted gynecologic procedures
52463|NCT02728999|benign gynecologic conditions
52464|NCT02728986|Costs and Cost Analysis
52465|NCT02728986|Humans
52466|NCT02728986|Health Care Costs
52467|NCT02728986|varicose ulcer
52468|NCT02728986|Compression Bandages
52469|NCT02728973|colorectal resection
52470|NCT02728973|enhanced recovery after surgery
52471|NCT02728973|Postoperative Complications
52472|NCT02728973|length of hospital stay
52473|NCT02728947|Parkinson's Disease
52474|NCT02728934|Rheumatoid Arthritis
52475|NCT02728934|Golimumab
52476|NCT02728934|Infliximab
52477|NCT02728895|Drug Therapy
52478|NCT02728882|Lymphoma CAR-T
52479|NCT02728843|Parkinson's disease
52480|NCT02728843|Deferiprone
52481|NCT02728830|gynecologic cancers
52482|NCT02728830|mullerian cancers
52483|NCT02728830|tumoral immunoprofile
52484|NCT02728817|Vascular access
52485|NCT02728817|Hemodialysis
52486|NCT02728817|Arteriovenous fistula
52487|NCT02728817|Stenosis
52488|NCT02728817|Failure
52489|NCT02728752|DM
52490|NCT02728726|Postoperative respiratory depression
52491|NCT02728726|Neuromuscular Agents
52492|NCT02728713|Cranial manipulation
52493|NCT02728713|Visual function
52494|NCT02728687|peripheral neuropathy
52495|NCT02728687|Diabetes
52496|NCT02728687|Pain
52497|NCT02728674|COPD
52498|NCT02728674|Breathlessness
52499|NCT02728674|Symptom
52500|NCT02728674|Opioids
52501|NCT02728674|Gender bias
52502|NCT02728648|Pain Management
52503|NCT02728648|Pharmacokinetics
52504|NCT02728648|Pharmacodynamics
52505|NCT02728635|Adipose tissue, epigenetic, abdominal gluteal fat
52506|NCT02728622|ovarian cancer
52507|NCT02728622|platinum-resistant
52508|NCT02728622|endocrine treatment
52509|NCT02728622|chemotherapy
52510|NCT02728622|tamoxifen
52511|NCT02728583|Plant sterols
52512|NCT02728583|Fish oil
52513|NCT02728583|Blood lipids
52514|NCT02728570|flavonoids
52515|NCT02728570|insulin resistance
52516|NCT02728570|plasma lipids
52517|NCT02728570|intestinal microbiome
52518|NCT02728570|intestinal inflammation
52519|NCT02728570|subclinical inflammation
52520|NCT02728557|Therapeutic alliance
52521|NCT02728557|Psychotherapy
52522|NCT02728557|Psychodynamic psychotherapy
52523|NCT02728557|supportive-expressive treatment
52524|NCT02728557|Process research
52525|NCT02728557|Attachment theory
52526|NCT02728557|Attachment orientation
52527|NCT02728557|Mechanism of change in psychotherapy
52528|NCT02728466|flavanols
52529|NCT02728466|cocoa procyanidins
52530|NCT02728466|vascular function
52531|NCT02728466|endothelial function
52532|NCT02728427|Suprapubic Catheterization
52533|NCT02728427|Transurethral Catheterization
52534|NCT02728427|Rectal Cancer
52535|NCT02728427|Laparoscopic Surgery
52536|NCT02728414|Diabetes Mellitus, Type 2, Probiotics, Treatment
52537|NCT02728401|inflammation
52538|NCT02728401|sepsis
52539|NCT02728401|pediatric
52540|NCT02728401|transcripts
52541|NCT02728401|serum proteins
52542|NCT02728401|cardiopulmonary bypass
52543|NCT02728388|NF1
52544|NCT02728388|Neurofibroma
52545|NCT02728388|Neurofibromatosis Type 1
52546|NCT02728362|tibial shaft fractures
52547|NCT02728284|Magnetic Resonance Imaging (MRI)
52548|NCT02728219|Recurrent Hepatocellular Carcinoma
52549|NCT02728219|transcatheter arterial chemoembolization
52550|NCT02728219|AFP conversion
52551|NCT02728193|treatments
52552|NCT02728193|hepatocellular carcinoma
52553|NCT02728180|Acute Ischemic Stroke
52554|NCT02728180|Xingnaojing injection
52555|NCT02728180|Randomized Controlled Trial
52556|NCT02728180|Traditional Chinese Medicine
52557|NCT02728167|Hepatectomy
52558|NCT02728167|Liver metastasis
52559|NCT02728167|High-Intensity Focused Ultrasound
52560|NCT02728167|Liver metastases (LM) requiring surgery
52561|NCT02728154|pre-clinical diastolic dysfunction (pre-HFpEF)
52562|NCT02728128|Milrinone
52563|NCT02728115|Huntington's Disease
52564|NCT02728115|Stem Cell
52565|NCT02728115|Dental Pulp Stem Cells
52566|NCT02728102|Multiple Myeloma
52567|NCT02728102|Lenalidomide
52568|NCT02728102|Maintenance Therapy
52569|NCT02728102|Hematologic Disorders
52570|NCT02728102|Vaccine
52571|NCT02728102|GM-CSF
52572|NCT02728102|Transplant
52573|NCT02728102|Anti-Myeloma Agents
52574|NCT02728076|Breast Cancer
52575|NCT02728076|Accelerated Partial Breast Irradiation
52576|NCT02728037|Myofascial Trigger Points
52577|NCT02728037|Myofascial Pain
52578|NCT02728037|Intramuscular Anesthetic Injection
52579|NCT02727998|PTSD
52580|NCT02727972|depression
52581|NCT02727972|bipolar
52582|NCT02727972|post-traumatic stress disorder
52583|NCT02727972|mood disorders
52584|NCT02727972|PET
52585|NCT02727972|mGluRr
52586|NCT02727972|glutamate system
52587|NCT02727972|MRI
52588|NCT02727959|UC
52589|NCT02727959|CD
52590|NCT02727959|IBD
52591|NCT02727894|Screening
52592|NCT02727894|pTNM
52593|NCT02727894|Metastasis
52594|NCT02727894|Chemotherapy
52595|NCT02727894|Resection Margins
52596|NCT02727881|AMD, CNV, choroidal neovascularization, retinal eye disease
52597|NCT02727855|Cholera
52598|NCT02727855|Vaccine
52599|NCT02727855|Strategy
52600|NCT02727803|Acute Myelogenous Leukemia
52601|NCT02727803|AML
52602|NCT02727803|Myelodysplastic syndrome
52603|NCT02727803|MDS
52604|NCT02727803|Multiple myeloma
52605|NCT02727803|MM
52606|NCT02727803|Umbilical cord blood transplant
52607|NCT02727803|UCB
52608|NCT02727803|Natural killer cells
52609|NCT02727803|NK
52610|NCT02727803|Busulfan
52611|NCT02727803|Busulfex
52612|NCT02727803|Myleran
52613|NCT02727803|Fludarabine
52614|NCT02727803|Fludarabine Phosphate
52615|NCT02727803|Fludara
52616|NCT02727803|Clofarabine
52617|NCT02727803|Clofarex
52618|NCT02727803|Clolar
52619|NCT02727803|Rabbit ATB
52620|NCT02727803|ATG (Rabbit)
52621|NCT02727803|Rabbit Antithymocyte Globulin
52622|NCT02727803|Rabbit Antilymphocyte Globulin
52623|NCT02727803|rATG Thymoglobulin
52624|NCT02727803|Total Body Irradiation
52625|NCT02727803|TBI
52626|NCT02727803|Radiation therapy
52627|NCT02727803|XRT
52628|NCT02727803|Rituximab
52629|NCT02727803|Rituxan
52630|NCT02727803|Cyclophosphamide
52631|NCT02727803|Cytoxan
52632|NCT02727803|Neosar
52633|NCT02727803|Melphalan
52634|NCT02727803|Alkeran
52635|NCT02727777|Lymphoma
52636|NCT02727777|Relapsed Lymphoma
52637|NCT02727777|MLN0128
52638|NCT02727777|Blood sugar
52639|NCT02727777|Glucometer
52640|NCT02727777|TK228
52641|NCT02727764|Rheumatoid Arthritis
52642|NCT02727764|Gene therapy
52643|NCT02727764|Phase Ib
52644|NCT02727764|Intra-articular
52645|NCT02727738|Hyperthyroidism
52646|NCT02727738|Methimazole
52647|NCT02727738|Selenium
52648|NCT02727712|coronary artery bypass graft
52649|NCT02727712|thoracic paravertebral block
52650|NCT02727699|Mild Dementia
52651|NCT02727699|Actinogen
52652|NCT02727699|Alzheimer's Disease
52653|NCT02727699|Xanamem
52654|NCT02727699|Cortisol
52655|NCT02727699|UE2343
52656|NCT02727699|XanADu
52657|NCT02727686|transsphenoidal pituitary surgery
52658|NCT02727673|cancer stem cells
52659|NCT02727660|COPD
52660|NCT02727647|Moderate hemophilia A
52661|NCT02727647|Severe hemophilia A
52662|NCT02727647|Intermediate dose prophylaxis
52663|NCT02727647|Low dose prophylaxis
52664|NCT02727634|Hemodynamics
52665|NCT02727634|Echocardiography, Doppler, Pulsed
52666|NCT02727621|Dexmedetomidine
52667|NCT02727621|Cardiac
52668|NCT02727621|Coronary Artery Bypass Grapht
52669|NCT02727621|Sedation
52670|NCT02727621|Propofol
52671|NCT02727621|Intravenous Anesthetics
52672|NCT02727582|MDR
52673|NCT02727556|skin conductance response
52674|NCT02727556|facial muscle activity
52675|NCT02727556|heart rate variability
52676|NCT02727556|eyetracking
52677|NCT02727543|Hypertension
52678|NCT02727543|mHealth
52679|NCT02727543|Medication Non-adherence
52680|NCT02727530|Infant Colic
52681|NCT02727530|Manual Therapy
52682|NCT02727530|Effectiveness
52683|NCT02727517|Resuscitation
52684|NCT02727517|Cord clamping
52685|NCT02727504|Aortic valve stenosis
52686|NCT02727504|low flow
52687|NCT02727504|dobutamine stress echocardiography
52688|NCT02727491|opioid analgesics,
52689|NCT02727491|opioid consumption
52690|NCT02727491|adverse effects
52691|NCT02727491|postoperative pain
52692|NCT02727491|tonsillectomy
52693|NCT02727478|Balance
52694|NCT02727478|Rehabilitation
52695|NCT02727478|Exercise
52696|NCT02727478|basal ganglia
52697|NCT02727478|Gait
52698|NCT02727478|Training
52699|NCT02727478|physical activity
52700|NCT02727439|microvascular function
52701|NCT02727439|laser Doppler flowmetry
52702|NCT02727439|exercise
52703|NCT02727426|microvascular function
52704|NCT02727426|laser Doppler flowmetry
52705|NCT02727426|high salt diet
52706|NCT02727374|Fear to Fall
52707|NCT02727374|Geriatric
52708|NCT02727374|Rehabilitation
52709|NCT02727374|Psychology
52710|NCT02727361|Dystonia
52711|NCT02727361|Binding potential
52712|NCT02727361|FEOBV
52713|NCT02727348|femoral sciatic block spinal diabetic foot haemodynamic pain
52714|NCT02727335|Non-squamous non-small cell lung cancer
52715|NCT02727335|crizotinib
52716|NCT02727309|Apatinib
52717|NCT02727309|Second-line Treatment
52718|NCT02727309|Hepatocellular Cancer
52719|NCT02727309|TACE
52720|NCT02727283|Healthy volunteer
52721|NCT02727283|Safety
52722|NCT02727283|Pharmacokinetics
52723|NCT02727283|Dose escalation
52724|NCT02727283|GSK3179106
52725|NCT02727283|Rearranged during Transfection
52726|NCT02727283|Irritable Bowel Syndrome
52727|NCT02727283|Adults
52728|NCT02727270|Movement disorders
52729|NCT02727270|Metabolic Stress
52730|NCT02727257|Parkinson's disease
52731|NCT02727257|rehabilitation
52732|NCT02727257|attention
52733|NCT02727257|executive functions
52734|NCT02727244|Pain Catastrophizing Scale
52735|NCT02727231|closed loop glucose control
52736|NCT02727231|hypoglycemia
52737|NCT02727231|type 1 diabetes
52738|NCT02727231|HbA1C<7.5%
52739|NCT02727166|intestinal gas
52740|NCT02727166|functional gut symptoms
52741|NCT02727166|intestinal sensitivity
52742|NCT02727166|intestinal motility
52743|NCT02727153|Colonic cancer
52744|NCT02727153|E.R.A.S. programs
52745|NCT02727153|Safety
52746|NCT02727114|skin thickness
52747|NCT02727114|high-frequency ultrasound
52748|NCT02727101|Focal epilepsy, Perampanel
52749|NCT02727088|Dental Pulp Disease
52750|NCT02727088|Endodontics
52751|NCT02727088|Pulp Capping
52752|NCT02727088|Pulpotomy
52753|NCT02727088|Pulpectomy
52754|NCT02727075|Occult Gastrointestinal Bleeding
52755|NCT02727075|Iron Deficiency Anemia
52756|NCT02727075|Aged 75 Years and Older
52757|NCT02727062|pain
52758|NCT02727062|radiation
52759|NCT02727062|head and neck cancer
52760|NCT02727062|smartphone pain app
52761|NCT02727062|OM Pain App
52762|NCT02727023|Healthy
52763|NCT02727010|Motor disability
52764|NCT02727010|Motor impairment
52765|NCT02727010|Pregnancy
52766|NCT02727010|Parenthood
52767|NCT02727010|Child psychology
52768|NCT02726997|Malignant neoplasms of female genital organs
52769|NCT02726997|Ovarian Cancer
52770|NCT02726997|Primary Peritoneal Carcinoma
52771|NCT02726997|Fallopian Tube Cancer
52772|NCT02726997|High-grade epithelial non-mucinous ovarian cancer
52773|NCT02726997|Laparoscopy surgery
52774|NCT02726997|Durvalumab
52775|NCT02726997|MEDI4736
52776|NCT02726997|Carboplatin
52777|NCT02726997|Paraplatin
52778|NCT02726997|Paclitaxel
52779|NCT02726997|Taxol
52780|NCT02726984|stroke
52781|NCT02726984|carotid plaque
52782|NCT02726984|18F-sodium fluoride PET/MR
52783|NCT02726971|Intrauterine Adhesion
52784|NCT02726971|Oestrogen Artificial Periodic Therapy
52785|NCT02726958|aortic valve replacement
52786|NCT02726958|percutaneous valve
52787|NCT02726958|blood glucose variability
52788|NCT02726958|TAVI
52789|NCT02726932|Peritonitis
52790|NCT02726932|Inflammatory Markers
52791|NCT02726932|Patient Outcome Assessment
52792|NCT02726932|Classification
52793|NCT02726932|Multiple Organ Failure
52794|NCT02726932|Intraabdominal Infections
52795|NCT02726919|focal epilepsy
52796|NCT02726919|clobazam
52797|NCT02726906|Alzheimer's disease
52798|NCT02726906|Mild Cognitive Impairment
52799|NCT02726906|Brain Imaging
52800|NCT02726867|refractory status epilepticus
52801|NCT02726867|levetiracetam
52802|NCT02726867|lacosamide
52803|NCT02726867|ketamine
52804|NCT02726841|Thoracic aorta
52805|NCT02726841|Abdominal aorta
52806|NCT02726841|Stents
52807|NCT02726789|nucleic acid polymer REP 2139 HBsAg hepatitis B
52808|NCT02726763|Transcranial Direct Current Stimulation (tDCS)
52809|NCT02726763|Cognitive Training
52810|NCT02726763|16-034
52811|NCT02726750|Monoclonal gammopathy of unknown significance
52812|NCT02726750|MGUS
52813|NCT02726750|Smoldering multiple myeloma
52814|NCT02726750|SMM
52815|NCT02726750|Asymptomatic monoclonal gammopathies
52816|NCT02726750|Biomarker testing
52817|NCT02726750|Blood collection
52818|NCT02726750|Blood draw
52819|NCT02726737|inferior alveolar nerve block
52820|NCT02726737|irreversible pulpitis
52821|NCT02726737|local anesthesia
52822|NCT02726737|sodium bicarbonate
52823|NCT02726724|Stress-Resident performance-Observers
52824|NCT02726685|respiratory training
52825|NCT02726685|functional performance
52826|NCT02726672|inspiratory muscles
52827|NCT02726672|multiple sclerosis
52828|NCT02726672|rehabilitation
52829|NCT02726646|Local Drug Delivery
52830|NCT02726646|Antibiotics
52831|NCT02726646|Doxycycline
52832|NCT02726646|Smokers
52833|NCT02726646|Chronic Periodontitis
52834|NCT02726620|Decision support
52835|NCT02726620|Decision Support Systems, Clinical
52962|NCT02725918|EGFR-TKI failure
52836|NCT02726620|Decision Support Techniques
52837|NCT02726620|Hypotension
52838|NCT02726620|Intraoperative Hypotension
52839|NCT02726620|Acute Kidney Injury
52840|NCT02726620|Postoperative Myocardial Injury
52841|NCT02726620|Postoperative Mortality
52842|NCT02726620|Blood Pressure
52843|NCT02726607|Prevention of mother-to-child transmission (PMTCT)
52844|NCT02726607|Kenya
52845|NCT02726607|HITSystem 2.0
52846|NCT02726607|retention through PMTCT cascade of care
52847|NCT02726607|Early Infant Diagnosis
52848|NCT02726607|eHealth system-level intervention
52849|NCT02726594|Magnetic Resonance Imaging, Patient Satisfaction
52850|NCT02726568|EGFR-TKI
52851|NCT02726568|NSCLC
52852|NCT02726568|Icotinib
52853|NCT02726555|Red yeast rice
52854|NCT02726555|Atorvastatin
52855|NCT02726555|Mild cardiovascular disease
52856|NCT02726542|obesity
52857|NCT02726542|adolescence
52858|NCT02726542|fatty liver
52859|NCT02726542|growth hormone
52860|NCT02726516|Performance
52861|NCT02726503|anaplastic thyroid cancer, lenvatinib
52862|NCT02726490|gestational diabetes, pregnancy, diabetes
52863|NCT02726464|Platelet-rich Plasma
52864|NCT02726464|Cell-Derived Microparticles
52865|NCT02726464|Pain Management
52866|NCT02726464|Blood Platelets
52867|NCT02726464|Therapeutics
52868|NCT02726464|Inflammation
52869|NCT02726464|ThromboLUX
52870|NCT02726464|Dynamic Light Scattering
52871|NCT02726399|Ramucirumab
52872|NCT02726399|Trastuzumab
52873|NCT02726399|Capecitabine
52874|NCT02726399|Cisplatin
52875|NCT02726399|HER2-Positive
52876|NCT02726399|15-301
52877|NCT02726360|Communication
52878|NCT02726360|15-316
52879|NCT02726360|Physician
52880|NCT02726360|Use
52881|NCT02726360|Non-English
52882|NCT02726360|Language Skills
52883|NCT02726334|Metastatic
52884|NCT02726308|Dexamethasone
52885|NCT02726308|Super-hydration
52886|NCT02726308|Laparoscopic Cholecystectomy
52887|NCT02726308|Nausea
52888|NCT02726308|Vomiting
52889|NCT02726308|Postoperative
52890|NCT02726269|Helicobacter Pylory infections
52891|NCT02726269|Levofloxacin
52892|NCT02726269|Antibiotic resistance
52893|NCT02726269|Clarithromycin
52894|NCT02726269|Mutations
52895|NCT02726269|Fluorescence
52896|NCT02726269|Hybridization
52897|NCT02726256|Diabetes
52898|NCT02726256|DM complication
52899|NCT02726243|Inflammatory bowel disease
52900|NCT02726243|Crohn's Disease
52901|NCT02726243|Ulcerative Colitis
52902|NCT02726243|colorectal cancer
52903|NCT02726243|primary sclerosing cholangitis
52904|NCT02726217|CareSmarts
52905|NCT02726217|SMS-based mobile
52906|NCT02726178|Apnea
52907|NCT02726178|bradycardia
52908|NCT02726178|immunization
52909|NCT02726178|inflammation
52910|NCT02726178|preterms
52911|NCT02726152|Diagnostic laparoscopy
52912|NCT02726152|Acute appendicitis
52913|NCT02726152|Appendiceal stump
52914|NCT02726139|Factor VIII
52915|NCT02726139|inhibitor
52916|NCT02726139|assay
52917|NCT02726126|Transdermal fentanyl
52918|NCT02726126|Transdermal melatonin
52919|NCT02726126|Postoperative pain
52920|NCT02726126|lumber laminectomy
52921|NCT02726126|Relief
52922|NCT02726113|prostate cancer
52923|NCT02726113|vitamin D
52924|NCT02726100|Telemedicine
52925|NCT02726100|Diabetes Mellitus, Type 2
52926|NCT02726100|Decision Support Systems, Clinical
52927|NCT02726100|Family Health Promoter
52928|NCT02726100|Primary Health Care
52929|NCT02726087|Ministernotomy
52930|NCT02726087|aortic valve stenosis
52931|NCT02726087|quality of life
52932|NCT02726087|satisfaction
52933|NCT02726087|cardiac surgery
52934|NCT02726074|epilepsy
52935|NCT02726074|partial-onset seizures
52936|NCT02726074|secondarily generalized seizures
52937|NCT02726035|Self-injurious behavior
52938|NCT02726035|Self mutilation
52939|NCT02726035|naltrexone
52940|NCT02725996|Hepatocellular Carcinoma
52941|NCT02725996|Natural Killer cells
52942|NCT02725983|Gingivitis
52943|NCT02725983|Oral Hygiene
52944|NCT02725983|Intra oral camera
52945|NCT02725983|Self regulation
52946|NCT02725983|bleeding
52947|NCT02725970|HEALTH
52948|NCT02725970|barriers
52949|NCT02725970|facilitators
52950|NCT02725970|DGA
52951|NCT02725970|BMI
52952|NCT02725970|Public Schools
52953|NCT02725957|Bioblast
52954|NCT02725944|Cryptogenic stroke
52955|NCT02725944|Occult paroxysmal atrial fibrillation
52956|NCT02725931|Chronic obstructive pulmonary disease
52957|NCT02725931|COPD
52958|NCT02725931|Pulmonary rehabilitation
52959|NCT02725931|Physical activity
52960|NCT02725931|Exercise
52961|NCT02725918|NSCLC
52963|NCT02725918|chemotherapy
52964|NCT02725905|Weight Management Counseling
52965|NCT02725905|Medical School Education
52966|NCT02725892|lung cancer epidemiology algeria registry
52967|NCT02725866|Observational Study
52968|NCT02725866|Sustained Virological Response
52969|NCT02725866|Chronic Hepatitis C genotype 1
52970|NCT02725866|Chronic Hepatitis C
52971|NCT02725866|Paritaprevir/r - Ombitasvir, ± Dasabuvir,
52972|NCT02725866|Chronic Hepatitis C genotype 4
52973|NCT02725853|Transcranial Direct Current Stimulation
52974|NCT02725853|Arm Training
52975|NCT02725853|Virtual Reality Exposure Therapy
52976|NCT02725840|pulmonary vasculature
52977|NCT02725840|radiation late effects
52978|NCT02725840|proton therapy
52979|NCT02725814|Sucrose
52980|NCT02725814|Effectiveness
52981|NCT02725814|Healthcare Delivery
52982|NCT02725814|Neonates
52983|NCT02725814|Nursing
52984|NCT02725775|Orange Juice, Polyphenol, Cognition
52985|NCT02725762|Dry AMD
52986|NCT02725762|Vision Loss
52987|NCT02725762|AMD
52988|NCT02725749|shoulder
52989|NCT02725749|low level laser therapy
52990|NCT02725749|exercises
52991|NCT02725710|uterine aspiration
52992|NCT02725658|Neoadjuvant Therapy
52993|NCT02725658|Diffuse Optical Spectroscopic Imaging
52994|NCT02725658|DOSI
52995|NCT02725658|Neoadjuvant Chemotherapy
52996|NCT02725645|Surface electromyography
52997|NCT02725645|children
52998|NCT02725645|backpack
52999|NCT02725632|Sodium channel
53000|NCT02725632|splicing variant
53001|NCT02725632|sleep apnea syndrome
53002|NCT02725606|Neutropenia
53003|NCT02725606|Breast Cancer
53004|NCT02725606|GW003
53005|NCT02725593|Diabetes Mellitus
53006|NCT02725593|Dapagliflozin
53007|NCT02725593|Placebo
53008|NCT02725593|Insulin resistance
53009|NCT02725593|Metabolic Diseases
53010|NCT02725580|Neuronal ceroid lipofuscinosis
53011|NCT02725580|NCL
53012|NCT02725580|Gene Transfer
53013|NCT02725580|Gray Foundation
53014|NCT02725541|HER2 equivocal
53015|NCT02725541|Trastuzumab emtansine
53016|NCT02725541|Breast cancer
53017|NCT02725502|T1DM
53018|NCT02725502|Linagliptin
53019|NCT02725502|mix meal test
53020|NCT02725489|Vigil™, Durvalumab (MEDI4736), Triple Negative Breast Cancer, PD-L1
53021|NCT02725463|vestibular
53022|NCT02725463|implant
53023|NCT02725463|prosthesis
53024|NCT02725463|labyrinth
53025|NCT02725463|ototoxicity
53026|NCT02725463|gentamicin
53027|NCT02725463|oscillopsia
53028|NCT02725463|disequilibrium
53029|NCT02725463|dizziness
53030|NCT02725463|vestibulopathy
53031|NCT02725463|inner ear
53032|NCT02725450|Motor Imagery
53033|NCT02725450|Fine motor skills
53034|NCT02725450|Disabled
53035|NCT02725411|Chronic low back pain
53036|NCT02725411|Chronic pain
53037|NCT02725398|Buscopan
53038|NCT02725398|probe-based confocal laser endomicroscopy
53039|NCT02725398|Imaging Quality
53040|NCT02725385|No Evidence of Disease
53041|NCT02725372|Pulmonary Arterial Hypertension
53042|NCT02725372|PAH
53043|NCT02725372|Inhaled Nitric Oxide
53044|NCT02725372|iNO
53045|NCT02725372|long term oxygen therapy
53046|NCT02725372|oxygen therapy
53047|NCT02725359|Thyroidectomy pain
53048|NCT02725359|Tizanidine
53049|NCT02725359|Postoperative analgesia
53050|NCT02725359|Ultrasound guided Superficial cervical plexus block
53051|NCT02725346|Surgical Planning Solution
53052|NCT02725346|Acromioplasty
53053|NCT02725346|Shoulder Surgery
53054|NCT02725346|Critical Shoulder Angle
53055|NCT02725333|Glenohumeral stabilization
53056|NCT02725333|Computer tomography
53057|NCT02725333|Subtle or minor instability
53058|NCT02725333|Unstable painful shoulder
53059|NCT02725333|Apprehension
53060|NCT02725333|Dislocation
53061|NCT02725333|Subluxation
53062|NCT02725333|Kinematics modeling
53063|NCT02725333|Biomechanics
53064|NCT02725333|Motion capture
53065|NCT02725333|3D simulation
53066|NCT02725320|rotator cuff
53067|NCT02725320|shoulder reconstruction
53068|NCT02725294|exacerbation
53069|NCT02725294|access to care
53070|NCT02725294|telemedicine
53071|NCT02725268|Drug Therapy
53072|NCT02725229|Postoperative pain
53073|NCT02725229|Parasternal block
53074|NCT02725229|Sternotomy
53075|NCT02725229|TENS
53076|NCT02725203|Cardiovascular risk management
53077|NCT02725203|behaviour change techniques
53078|NCT02725203|self-management
53079|NCT02725203|physical activity
53080|NCT02725203|nurse-led
53081|NCT02725203|behaviour change wheel
53082|NCT02725203|primary care
53083|NCT02725203|clustered RCT
53084|NCT02725177|Ocular Sarcoidosis
53085|NCT02725164|oxygen
53086|NCT02725164|nitrous oxide
53087|NCT02725164|sevoflurane
53088|NCT02725164|carbon dioxide
53089|NCT02725164|endotracheal tube
53090|NCT02725164|respiration
53091|NCT02725151|inferior vena cava ultrasound
53092|NCT02725151|acute
53093|NCT02725151|heart failure
53094|NCT02725151|management
53095|NCT02725151|decompensation
53096|NCT02725138|Helicobacter pylori
53097|NCT02725138|probiotic
53098|NCT02725138|bacterial density
53099|NCT02725125|Stomach Cancer CAR-T
53100|NCT02725099|STEMI
53101|NCT02725060|POTS
53102|NCT02725060|Orthostatic Intolerance
53103|NCT02725060|Orthostatic Tachycardia
53104|NCT02725047|Osteoarthritis, Knee
53105|NCT02725047|Cryotherapy
53106|NCT02725047|Thermotherapy
53107|NCT02725047|Hypothermia
53108|NCT02725047|Knee
53109|NCT02725047|Physiotherapy
53110|NCT02725021|tobacco prevention
53111|NCT02725008|Asthma
53112|NCT02725008|Pediatric
53113|NCT02725008|Emergency Department
53114|NCT02725008|Dexamethasone
53115|NCT02725008|Steroid
53116|NCT02724982|Self esteem
53117|NCT02724982|Body mass index
53118|NCT02724969|text messaging
53119|NCT02724969|short message service
53120|NCT02724943|child obesity
53121|NCT02724943|primary prevention
53122|NCT02724943|primary care
53123|NCT02724943|weight management
53124|NCT02724943|child overweight
53125|NCT02724943|BMI
53126|NCT02724930|low back pain, chronic pain, cognitive behavior therapy
53127|NCT02724904|Allogeneic hematopoietic stem cell transplantation
53128|NCT02724904|CNS Non-Hodgkin lymphoma
53129|NCT02724891|Pelvic Floor Dysfunction
53130|NCT02724878|Kidney Cancer
53131|NCT02724865|Oral Appliance Therapy
53132|NCT02724852|MMR
53133|NCT02724852|vaccination
53134|NCT02724852|HIV
53135|NCT02724852|Serologic response
53136|NCT02724826|Expectations
53137|NCT02724826|Outcomes
53138|NCT02724826|Qigong
53139|NCT02724826|Exercise therapy
53140|NCT02724826|Disability
53141|NCT02724826|Neck movements,
53142|NCT02724800|Insomnia
53143|NCT02724800|Veterans
53144|NCT02724800|Cognitive Behavioral Therapy for Insomnia
53145|NCT02724800|Brief Behavioral Treatment for Insomnia
53146|NCT02724800|Comparative Effectiveness Research
53147|NCT02724787|Post-traumatic stress disorder
53148|NCT02724787|Veterans
53149|NCT02724787|Aggression
53150|NCT02724787|Emotion regulation
53151|NCT02724774|infants
53152|NCT02724774|mental health
53153|NCT02724774|postpartum period
53154|NCT02724748|Aggression
53155|NCT02724748|Mental Health
53156|NCT02724748|Education, Continuing
53157|NCT02724735|Depression
53158|NCT02724735|Major Depressive Disorder (MDD)
53159|NCT02724735|Major Depressive Disorder
53160|NCT02724735|Neurogenesis
53161|NCT02724735|Synaptogenesis
53162|NCT02724735|NSI-189
53163|NCT02724735|Neuralstem
53164|NCT02724722|melamine
53165|NCT02724722|phthalate
53166|NCT02724709|Automatic Data Processing
53167|NCT02724709|Three-Dimensional Echocardiography
53168|NCT02724709|Aortic Valve
53169|NCT02724683|ascites
53170|NCT02724683|drainage
53171|NCT02724683|catheter
53172|NCT02724683|symptoms
53173|NCT02724683|management
53174|NCT02724683|quality of life
53175|NCT02724683|malignant
53176|NCT02724683|cancer
53177|NCT02724657|Child
53178|NCT02724657|Breathing exercises
53179|NCT02724631|Clogged enteral access devices
53180|NCT02724631|Occluded enteral access device
53181|NCT02724631|Enteral nutrition
53182|NCT02724631|Enteral access device
53183|NCT02724631|Tube Feeding
53184|NCT02724631|Gastric Feeding Tubes
53185|NCT02724618|Curcumin
53186|NCT02724618|Protection, Radiation
53187|NCT02724618|Controlled Clinical Trials, Randomized
53188|NCT02724618|Radiation Therapy
53189|NCT02724618|Prostate Cancer
53190|NCT02724605|RBCS,
53191|NCT02724605|Transfusion,
53192|NCT02724605|Pediatric
53193|NCT02724605|Changes
53194|NCT02724566|Type 2 diabetic volunteers
53195|NCT02724527|Cystic Fibrosis
53196|NCT02724527|N91115
53197|NCT02724527|Cavosonstat
53198|NCT02724488|Advanced cancer
53199|NCT02724488|Advanced solid tumors
53200|NCT02724488|Phase I clinical trial candidates
53201|NCT02724488|Phase II clinical trial candidates
53202|NCT02724488|Phase III clinical trial candidates
53203|NCT02724488|Head and Neck
53204|NCT02724488|Melanoma
53205|NCT02724488|Upper Aerodigestive cancer
53206|NCT02724488|Oral Cavity
53207|NCT02724488|Immune Checkpoint Inhibitors
53208|NCT02724488|ICIs
53209|NCT02724488|ctDNA
53210|NCT02724488|Whole Exome Sequencing
53211|NCT02724488|Molecular Profiling
53212|NCT02724475|Laser Ablation
53213|NCT02724475|Portal Vein Tumor
53214|NCT02724475|Thrombus
53215|NCT02724462|smoking cessation
53216|NCT02724462|app for quitting smoking
53217|NCT02724449|IAD
53218|NCT02724449|Fecal incontinence
53219|NCT02724436|Yittrium-90
53220|NCT02724436|Hepatocellular Carcinoma
53221|NCT02724423|epilepsy
53222|NCT02724423|seizure
53223|NCT02724410|appendectomy
53224|NCT02724397|Colon cancer
53225|NCT02724397|Diagnosis
53226|NCT02724397|Adenoma
53227|NCT02724397|Serrated lesions
53228|NCT02724358|Carcinoma
53229|NCT02724358|Hepatocellular
53230|NCT02724358|Notch1
53231|NCT02724345|Cell keratin 18
53232|NCT02724332|Aspartate beta hydroxylase
53233|NCT02724332|transcatheter arterial chemoembolization
53234|NCT02724319|percutaneous coronary intervention
53235|NCT02724319|clopidogrel
53236|NCT02724319|loss-of-function allele
53237|NCT02724267|131I-chTNT-1/B treatment
53238|NCT02724254|Genital warts
53239|NCT02724254|HPV types
53240|NCT02724254|Sexually Transmitted Disease
53241|NCT02724254|Papillomavirus Infections
53242|NCT02724254|Viral Disease
53243|NCT02724254|Anogenital warts
53244|NCT02724254|AGW
53245|NCT02724254|HPV6
53246|NCT02724254|HPV11
53247|NCT02724254|Human papillomavirus infection
53248|NCT02724254|HPV
53249|NCT02724254|Aviragen Therapeutics, Inc.
53250|NCT02724254|Aviragen Therapeutics
53251|NCT02724254|Aviragen
53252|NCT02724241|nicotine
53253|NCT02724241|autonomic tone
53254|NCT02724241|oxidative stress
53255|NCT02724228|Achondroplasia
53256|NCT02724228|Dwarfism
53257|NCT02724228|Bone Diseases, Developmental
53258|NCT02724228|Bone Diseases
53259|NCT02724215|Subarachnoid hemorrhage
53260|NCT02724215|Sleep Apnea
53261|NCT02724202|Curcumin
53262|NCT02724202|5FU
53263|NCT02724202|5-fluorouracil
53264|NCT02724202|Adracil
53265|NCT02724202|5FU Resistant
53266|NCT02724202|Metastatic Colon Cancer
53267|NCT02724202|Colon Cancer
53268|NCT02724189|electronic pre-assessment
53269|NCT02724189|preoperative assessment
53270|NCT02724163|Acute Myeloid Leukaemia
53271|NCT02724163|Children
53272|NCT02724163|Gemtuzumab ozogamicin
53273|NCT02724163|Liposomal daunorubicin
53274|NCT02724163|Mitoxantrone
53275|NCT02724163|Randomised controlled trial
53276|NCT02724163|Risk stratification
53277|NCT02724163|Minimal residual disease
53278|NCT02724163|Stem cell transplant
53279|NCT02724150|Gastroduodenal Ulcer
53280|NCT02724150|Marginal Ulcer
53281|NCT02724150|Peptic Ulcer Hemorrhage
53282|NCT02724150|Peptic Ulcer
53283|NCT02724137|Total Knee Replacement
53284|NCT02724137|Physical Therapy
53285|NCT02724137|Fitbit®
53286|NCT02724124|exercise muscle stretching
53287|NCT02724124|electromyography
53288|NCT02724111|Neuromuscular blockade
53289|NCT02724111|Surgical rating scale
53290|NCT02724111|Rocuronium
53291|NCT02724111|Sugammadex
53292|NCT02724111|Spinal surgery
53293|NCT02724111|General anesthesia
53294|NCT02724098|Palliative Therapy
53295|NCT02724072|Thoracic Surgery
53296|NCT02724072|Aortic Arch
53297|NCT02724072|Frozen Elephant Trunk
53298|NCT02724072|Performance Goal
53299|NCT02724046|Neisseria meningitidis
53300|NCT02724046|Ciprofloxacin
53301|NCT02724046|Chemoprevention
53302|NCT02724033|post operative nausea vomiting
53303|NCT02724033|Inner ear surgery
53304|NCT02724020|Drug Therapy
53305|NCT02724007|Trauma
53306|NCT02724007|India
53307|NCT02724007|ICISS
53308|NCT02723994|B-cell acute lymphoblastic leukemia (ALL)
53309|NCT02723994|pediatric
53310|NCT02723994|multi-agent chemotherapy
53311|NCT02723994|JAK inhibitor
53312|NCT02723981|Stent , COMBO Stent, anticoagulation
53313|NCT02723955|ICOS receptor agonist antibody
53314|NCT02723955|Pembrolizumab
53315|NCT02723955|KEYNOTE-478
53316|NCT02723955|GSK3359609
53317|NCT02723955|Dose expansion
53318|NCT02723955|Dose escalation
53319|NCT02723942|glypican-3(GPC3)
53320|NCT02723942|chimeric antigen receptor-modified T cell(CAR-T)
53321|NCT02723942|hepatocellular carcinoma(HCC)
53322|NCT02723929|transcranial direct current stimulation
53323|NCT02723929|transcranial ultrasound
53324|NCT02723929|non-invasive brain stimulation
53325|NCT02723916|Parents
53326|NCT02723916|Child
53327|NCT02723916|Preschool
53328|NCT02723916|eHealth
53329|NCT02723903|somatization symptom score
53330|NCT02723903|SSS checklist
53331|NCT02723903|coronary angiography
53332|NCT02723903|Patient Health Questionnaire
53333|NCT02723903|Generalized Anxiety Disorder 7-items
53334|NCT02723864|Pharmacodynamic
53335|NCT02723864|DNA Damage Repair
53336|NCT02723864|BRCA Null
53337|NCT02723864|Apoptosis
53338|NCT02723864|Combination Therapy
53339|NCT02723838|Bladder
53340|NCT02723838|Cancer
53341|NCT02723838|REOLYSIN®
53342|NCT02723838|Gemcitabine
53343|NCT02723838|Cisplatin
53344|NCT02723838|Reovirus
53345|NCT02723838|Oncolytic virus
53346|NCT02723825|Distal tibia
53347|NCT02723825|fractures
53348|NCT02723825|epiphyses
53349|NCT02723825|children
53350|NCT02723812|Influenza
53351|NCT02723812|GCFLU
53352|NCT02723812|vaccine
53353|NCT02723812|Vietnam
53354|NCT02723799|Hope
53355|NCT02723786|Delayed Graft Function
53356|NCT02723786|Renal Transplantation
53357|NCT02723786|Prevention
53358|NCT02723786|GSK1070806
53359|NCT02723773|Efficacy
53360|NCT02723773|Immunogenicity
53361|NCT02723773|Safety
53362|NCT02723773|Adults
53363|NCT02723773|Herpes zoster
53364|NCT02723747|myocardial ischemia
53365|NCT02723747|magnetic resonance imaging
53366|NCT02723747|perfusion
53367|NCT02723747|software
53368|NCT02723734|Decipher®
53369|NCT02723734|African-American men
53370|NCT02723734|prostate
53371|NCT02723734|low risk PCa
53372|NCT02723734|intermediate risk PCa
53373|NCT02723734|genomic classifier (GC)
53374|NCT02723721|Lentigo maligna
53375|NCT02723695|Cochlear implant
53376|NCT02723695|Perception
53377|NCT02723695|Posture
53378|NCT02723695|Quality of life
53379|NCT02723669|Relative Bioavailability
53380|NCT02723656|smoking
53381|NCT02723656|cancer
53382|NCT02723656|cancer registry
53383|NCT02723656|smoking cessation
53384|NCT02723643|Hypertension
53385|NCT02723643|Essential hypertension
53386|NCT02723643|Blood pressure
53387|NCT02723643|Cardiovascular diseases
53388|NCT02723630|Bioequivalence
53389|NCT02723630|Lenvatinib
53390|NCT02723630|Healthy Volunteers
53391|NCT02723630|Lenvima
53392|NCT02723630|E7080
53393|NCT02723591|FK506
53394|NCT02723591|Kidney Transplantation
53395|NCT02723591|Tacrolimus
53396|NCT02723591|Astagraf XL
53397|NCT02723552|preeclampsia
53398|NCT02723552|young adult hypertension
53399|NCT02723552|preterm birth
53400|NCT02723526|Metastatic Hormone-Sensitive Prostate Cancer；circulating tumor cells；Prognosis；Liquid biopsy
53401|NCT02723513|Proton MRI
53402|NCT02723513|Noble Gas MRI
53403|NCT02723513|Pulmonary Function
53404|NCT02723500|Magnetic Resonance Imaging
53405|NCT02723500|Pulmonary Function
53406|NCT02723487|TAP block
53407|NCT02723487|pediatric
53408|NCT02723487|Laparoscopic
53409|NCT02723487|postoperative pain
53410|NCT02723474|Magnetic Resonance Imaging
53411|NCT02723474|Pulmonary Function
53412|NCT02723396|Parkinson's disease
53413|NCT02723396|Sleep Benefit
53414|NCT02723383|alcoholism
53415|NCT02723383|intensive care
53416|NCT02723383|Baclofen
53417|NCT02723383|restlessness
53418|NCT02723383|Delirium tremens
53419|NCT02723383|Alcohol withdrawal syndrome
53420|NCT02723370|Quality of Healthcare
53421|NCT02723370|Colorectal neoplasms
53422|NCT02723370|Health Literacy
53423|NCT02723370|Teach-Back Communication
53424|NCT02723370|Evidence Based Practice
53425|NCT02723370|Colonoscopy
53426|NCT02723357|Financial Coaching
53427|NCT02723357|Mental Health
53428|NCT02723357|Social Determinants
53429|NCT02723357|Medical-Financial Partnership
53430|NCT02723357|Toxic Stress
53431|NCT02723344|PTSD
53432|NCT02723344|Mild TBI
53433|NCT02723344|Probiotic
53434|NCT02723344|Inflammation
53435|NCT02723331|Stereotactic Body Radiation Therapy
53436|NCT02723331|Perioperative Therapy
53437|NCT02723331|Resectable Pancreas Ductal Adenocarcinoma
53438|NCT02723331|Borderline Resectable Pancreas Ductal Adenocarcinoma
53439|NCT02723331|Nab-paclitaxel
53440|NCT02723331|Abraxane
53441|NCT02723331|Gemcitabine
53442|NCT02723331|Neoadjuvant Therapy
53443|NCT02723331|Adjuvant Therapy
53444|NCT02723318|Cognition
53445|NCT02723318|Financial Coaching
53446|NCT02723318|Social Determinants of Health
53447|NCT02723318|Socioeconomic Status
53448|NCT02723305|Klinefelter syndrome
53449|NCT02723305|XXY
53450|NCT02723305|Sex chromosome aneuploidy
53451|NCT02723305|sex chromosome variation
53452|NCT02723305|hypogonadism
53453|NCT02723305|cardiometabolic
53454|NCT02723305|body composition
53455|NCT02723305|exercise capacity
53456|NCT02723279|Urgency-frequency Syndrome
53457|NCT02723279|Electrical Pudendal Nerve Stimulation
53458|NCT02723279|Tolterodine Tartrate
53459|NCT02723266|American Indian, Alaska Native Adolescents
53460|NCT02723266|Preconception Counseling
53461|NCT02723266|Reproductive Health
53462|NCT02723266|Gestational Diabetes Mellitus
53463|NCT02723253|rectal cancer
53464|NCT02723253|radiotherapy
53465|NCT02723253|chemotherapy
53466|NCT02723253|Raltitrexed
53467|NCT02723253|Oxaliplatin
53468|NCT02723240|NUC-3373
53469|NCT02723240|Dose escalation
53470|NCT02723240|Nucleotide Analogue
53471|NCT02723227|Parenting Stress
53472|NCT02723227|Stress
53473|NCT02723227|Social Determinants
53474|NCT02723227|Socioeconomic status
53475|NCT02723227|Financial Coaching
53476|NCT02723175|Fibromyalgia
53477|NCT02723175|Pain
53478|NCT02723136|Smartphone
53479|NCT02723136|Internship
53480|NCT02723136|Internal Medicine
53481|NCT02723123|CPAP
53482|NCT02723123|NIPPV
53483|NCT02723123|Extubation failure
53484|NCT02723123|Cardiorespiratory behaviour
53485|NCT02723123|NIV-NAVA
53486|NCT02723110|Type 2 Diabetes Risk
53487|NCT02723084|Hepatitis C Virus
53488|NCT02723084|Non-cirrhotic
53489|NCT02723084|Hepatitis C Genotype 2
53490|NCT02723084|Chronic Hepatitis C Virus
53491|NCT02723058|Depression
53492|NCT02723058|Homelessness
53493|NCT02723058|Primary care
53494|NCT02723006|Drug Therapy
53495|NCT02722954|malignancy
53496|NCT02722954|metastatic
53497|NCT02722954|Demcizumab
53498|NCT02722954|Pembrolizumab
53499|NCT02722954|Phase 1b
53500|NCT02722941|autologous hematopoietic cell transplant (HCT)
53501|NCT02722941|autologous
53502|NCT02722928|Postoperative pneumocephalus
53503|NCT02722928|Fraction of inspired oxygen
53504|NCT02722928|Intracranial surgery
53505|NCT02722915|fMRI
53506|NCT02722915|neurofeedback
53507|NCT02722915|hallucination
53508|NCT02722915|schizophrenia
53509|NCT02722902|Metabolic flexibility
53510|NCT02722902|Insulin sensitivity
53511|NCT02722889|Ascending aorta
53512|NCT02722889|Elongation of the aorta
53513|NCT02722889|Type A dissection
53514|NCT02722889|Aortic rupture
53515|NCT02722889|Aortic length
53516|NCT02722876|Rehabilitation
53517|NCT02722876|Cross-education
53518|NCT02722850|breast cancer
53519|NCT02722850|cancer survivorship
53520|NCT02722850|dietary intake
53521|NCT02722850|physical activity
53522|NCT02722850|quality of life
53523|NCT02722824|motor symptoms
53524|NCT02722811|Etanercept
53525|NCT02722811|Osteoarthritis Of Knee
53526|NCT02722811|TNF-α
53527|NCT02722811|IL-1α
53528|NCT02722811|Subcutaneous Injection
53529|NCT02722785|Exercise training
53530|NCT02722785|Surgical complications
53531|NCT02722785|Cancer prognosis
53532|NCT02722785|Muscle function
53533|NCT02722785|Body composition
53534|NCT02722785|Pulmonary function
53535|NCT02722785|Quality of life
53536|NCT02722772|Intra-Articular Injection
53537|NCT02722772|Etanercept
53538|NCT02722772|TNF-α
53539|NCT02722772|IL-1
53540|NCT02722772|Osteoarthritis of Knee
53541|NCT02722746|Epidural Analgesia
53542|NCT02722733|Hodgkin's lymphoma
53543|NCT02722733|Non-Hodgkin's lymphoma
53544|NCT02722733|mobilization
53545|NCT02722733|G-CSF
53546|NCT02722733|filgrastim
53547|NCT02722733|cytosine arabinoside
53548|NCT02722733|autologous stem cell transplantation
53549|NCT02722720|Carotid atherosclerosis
53550|NCT02722720|Carotid stenosis
53551|NCT02722720|Ischemic attack
53552|NCT02722720|Stroke
53553|NCT02722720|Carotid stenting
53554|NCT02722720|Transradial approach
53555|NCT02722720|Transfemoral approach
53556|NCT02722720|Bleeding
53557|NCT02722720|Thromboembolism
53558|NCT02722720|Embolism
53559|NCT02722720|Neurocognitive disorders
53560|NCT02722668|AML
53561|NCT02722668|ALL
53562|NCT02722668|CML
53563|NCT02722668|CLL
53564|NCT02722668|SLL
53565|NCT02722655|Pediatrics
53566|NCT02722629|COPD
53567|NCT02722629|Respiratory Aspiration
53568|NCT02722629|COPD acute exacerbation
53569|NCT02722616|Ultrasound
53570|NCT02722590|Epilepsy
53571|NCT02722590|Partial-onset seizures
53572|NCT02722590|secondarily generalized seizures
53573|NCT02722551|Mitral
53574|NCT02722551|Regurgitation
53575|NCT02722551|Insufficiency
53576|NCT02722551|Degenerative
53577|NCT02722551|Functional
53578|NCT02722551|Primary
53579|NCT02722551|Secondary
53580|NCT02722551|Organic
53581|NCT02722551|Transcatheter
53582|NCT02722551|TMVR
53583|NCT02722551|TMVI
53584|NCT02722551|Heart valve
53585|NCT02722551|Mitral valve
53586|NCT02722551|Transapical
53587|NCT02722551|Transfemoral
53588|NCT02722551|Trans-septal
53589|NCT02722551|Transeptal
53590|NCT02722551|Severe
53591|NCT02722525|ADT
53592|NCT02722525|Prostate cancer
53593|NCT02722499|Diabetes Mellitus, Type 2
53594|NCT02722499|Diabetes Mellitus, Adult-Onset
53595|NCT02722499|Diabetes Mellitus, Non-Insulin-Dependent
53596|NCT02722499|Diabetes Mellitus, Noninsulin Dependent
53597|NCT02722499|Diabetes Mellitus, Type II
53598|NCT02722499|African American
53599|NCT02722499|Blacks
53600|NCT02722499|non-Hispanic Blacks
53601|NCT02722499|Randomized Control Trial
53602|NCT02722499|Controlled Clinical Trial
53603|NCT02722499|Behavioral Research
53604|NCT02722499|Behavioral Medicine
53605|NCT02722421|efavirenz
53606|NCT02722421|levonorgestrel
53607|NCT02722421|contraceptive implant
53608|NCT02722408|LDL-C
53609|NCT02722408|Lipid Regulator
53610|NCT02722382|Chronic Kidney Disease
53611|NCT02722291|presbyopia
53612|NCT02722265|Essential hypertension
53613|NCT02722265|Long-term treatment
53614|NCT02722265|Mineralocorticoid receptor antagonist
53615|NCT02722252|In Vitro Fertilization with ICSI
53616|NCT02722239|Xigduo;
53617|NCT02722239|bioequivalence;
53618|NCT02722239|crossover;
53619|NCT02722239|Russia
53620|NCT02722226|High fidelity simulation
53621|NCT02722226|Sedation
53622|NCT02722226|Medical education
53623|NCT02722200|fMRI obesity
53624|NCT02722148|Eosinophilic Esophagitis
53625|NCT02722148|Diet Elimination Therapy
53626|NCT02722122|Cystic Fibrosis
53627|NCT02722122|CF
53628|NCT02722122|AIR DNase™
53629|NCT02722122|Digestive System Diseases
53630|NCT02722122|Genetic Diseases, Inborn
53631|NCT02722122|Infant, New born, Diseases
53632|NCT02722122|Lung diseases
53633|NCT02722122|Pancreatic Diseases
53634|NCT02722122|Respiratory Tract Diseases
53635|NCT02722096|arteriovenous fistula
53636|NCT02722096|regional anesthesia
53637|NCT02722096|local anesthesia
53638|NCT02722096|early complication
53639|NCT02722031|intensive care
53640|NCT02722031|prevalence
53641|NCT02722031|hypoxemia
53642|NCT02722031|ARDS
53643|NCT02722005|Health related quality of life
53644|NCT02722005|Financial Coaching
53645|NCT02722005|Medical Financial Partnership
53646|NCT02722005|Social Determinants of Health
53647|NCT02722005|Socioeconomic status
53648|NCT02721966|Assessment of spondyloarthritis international society (ASAS)
53649|NCT02721966|ASAS
53650|NCT02721966|axial
53651|NCT02721966|Psoriatic Arthritis (PsA)
53652|NCT02721966|PsA
53653|NCT02721966|Magnetic resonance imaging (MRI)
53654|NCT02721966|MRI
53655|NCT02721927|refugees
53656|NCT02721927|Syrian
53657|NCT02721927|cost
53658|NCT02721927|visit
53659|NCT02721914|low-back pain
53660|NCT02721914|massage therapy
53661|NCT02721914|Gymnastics
53662|NCT02721914|disability
53663|NCT02721901|Gastrointestinal Disorders
53664|NCT02721901|Nutrition
53665|NCT02721901|Behavioral
53666|NCT02721862|gallstones
53667|NCT02721862|cholelithiasis
53668|NCT02721862|sleeve gastrectomy
53669|NCT02721797|hypermobility
53670|NCT02721797|collagen
53671|NCT02721797|joint
53672|NCT02721797|hyperflexation
53673|NCT02721784|MRI
53674|NCT02721784|Radiotherapy
53675|NCT02721758|Motivational Interviewing
53676|NCT02721758|Health Behavior
53677|NCT02721758|Cardiac Rehabilitation
53678|NCT02721732|Advanced Cancers
53679|NCT02721732|Rare tumors
53680|NCT02721732|Squamous cell carcinoma of the skin
53681|NCT02721732|Anaplastic thyroid cancer
53682|NCT02721732|Adrenocortical carcinoma
53683|NCT02721732|Medullary renal cell carcinoma
53684|NCT02721732|Carcinoma of unknown primary
53685|NCT02721732|Penile carcinoma
53686|NCT02721732|Thymoma
53687|NCT02721732|Testicular carcinoma
53688|NCT02721732|Paraganglioma-pheochromocytoma
53689|NCT02721732|Pembrolizumab
53690|NCT02721732|Keytruda
53691|NCT02721732|MK-3475
53692|NCT02721732|SCH-900475
53693|NCT02721719|Ulcerative Colitis
53694|NCT02721719|UC
53695|NCT02721719|Vedolizumab
53696|NCT02721719|Entyvio
53697|NCT02721719|Inflammatory Bowl Disease
53698|NCT02721719|IBD
53699|NCT02721719|T-Lymphocytes, Regulatory
53700|NCT02721706|Nutrition assessment
53701|NCT02721706|inpatients
53702|NCT02721706|cost-benefit analysis
53703|NCT02721706|quality of life
53704|NCT02721706|body composition
53705|NCT02721706|mass screening
53706|NCT02721693|Troponin
53707|NCT02721693|Exercise
53708|NCT02721667|Blood pressure
53709|NCT02721667|Telemonitoring
53710|NCT02721667|Case management
53711|NCT02721667|Seniors
53712|NCT02721654|Plasma-Lyte
53713|NCT02721654|Sodium chloride
53714|NCT02721654|Saline
53715|NCT02721654|Fluid resuscitation
53716|NCT02721654|Intravenous fluid therapy
53717|NCT02721654|Critically ill
53718|NCT02721654|Critical care
53719|NCT02721628|Keratoconus
53720|NCT02721615|intra spinal pressure
53721|NCT02721615|spinal cord perfusion pressure
53722|NCT02721615|microdialysis
53723|NCT02721615|duroplasty
53724|NCT02721537|Brain Nicotinamide Adenine Dinucleotide (NAD+)
53725|NCT02721537|Adenosine Triphosphate (ATP) Depletion
53726|NCT02721537|Polyadenosine Diphosphate-Ribosepolymerase (PARP) Activation
53727|NCT02721524|Ring Annuloplasty
53728|NCT02721524|Suture Annuloplasty
53729|NCT02721524|Functional Tricuspid Regurgitation
53730|NCT02721498|Respiratory Physiotherapy
53731|NCT02721498|Airway clearance techniques
53732|NCT02721498|Outcome measures
53733|NCT02721485|Ringer's Lactate
53734|NCT02721485|Normal Saline
53735|NCT02721485|resuscitation fluids
53736|NCT02721485|hypovolemia
53737|NCT02721459|unresectable melanoma
53738|NCT02721459|stage III melanoma
53739|NCT02721459|stage IV melanoma
53740|NCT02721459|AJCC melanoma staging
53741|NCT02721459|American Joint Committee on Cancer (AJCC)
53742|NCT02721459|BRAF V600 E mutation
53743|NCT02721459|BRAF V600 K mutation
53744|NCT02721394|Challenging Behaviour
53745|NCT02721394|Functional Communication Training
53746|NCT02721394|Positive Behavioural Support
53747|NCT02721394|Family carer training
53748|NCT02721381|Autism Spectrum Disorder
53749|NCT02721381|Parent training
53750|NCT02721381|Telehealth
53751|NCT02721381|RCT
53752|NCT02721355|Chronic gastritis
53753|NCT02721355|Gastric ulcer
53754|NCT02721355|Helicobacter pylori
53755|NCT02721355|IgY
53756|NCT02721342|Chronic proteinuric nephropathies
53757|NCT02721329|Obstructive Sleep Apnea
53758|NCT02721329|OSA
53759|NCT02721329|Insomnia
53760|NCT02721329|CPAP
53761|NCT02721329|SensAwake
53762|NCT02721290|Knee surgery
53763|NCT02721277|Parenteral nutrition, Total
53764|NCT02721277|Infant, newborn
53765|NCT02721277|Cholestasis
53766|NCT02721277|Enterocolitis, Necrotizing
53767|NCT02721251|exercise
53768|NCT02721251|weight loss
53769|NCT02721251|sleep apnea
53770|NCT02721212|Robotic
53771|NCT02721212|Stroke
53772|NCT02721212|Upper Limb Rehabilitation
53773|NCT02721186|Malaria
53774|NCT02721186|Plasmodium
53775|NCT02721186|Mass drug administration
53776|NCT02721186|Malaria elimination
53777|NCT02721186|Zanzibar
53778|NCT02721186|Dihydroartemisinin-Piperaquine
53779|NCT02721186|Single low dose Primaquine
53780|NCT02721173|Tazarotene
53781|NCT02721173|Adapalene
53782|NCT02721173|Clindamycin
53783|NCT02721160|performance-based financing
53784|NCT02721160|malnutrition
53785|NCT02721160|impact evaluation
53786|NCT02721108|Mindfulness
53787|NCT02721108|Headspace
53788|NCT02721108|Psychological approaches
53789|NCT02721108|Progressive muscle relaxation
53790|NCT02721082|tobacco treatment
53791|NCT02721069|Seizures
53792|NCT02721069|Epilepsy
53793|NCT02721043|Personalized vaccine
53794|NCT02721043|Poly-ICLC
53795|NCT02721043|Immunotherapy
53796|NCT02721043|Cancer
53797|NCT02721030|Heartfailure
53798|NCT02721030|1-year mortality
53799|NCT02721030|heartfailure quality of life
53800|NCT02721030|sub-Saharan Africa
53801|NCT02721017|Nuss
53802|NCT02721017|Nuss Procedure
53803|NCT02721017|pectus excavatum
53804|NCT02721017|cryoanalgesia
53805|NCT02721004|Rheumatoid arthritis
53806|NCT02721004|RoActemra
53807|NCT02721004|Tocilizumab
53808|NCT02720965|Pain Acute
53809|NCT02720965|Orthopedic Surgery
53810|NCT02720965|Satisfaction Nerve Blocks
53811|NCT02720913|Time
53812|NCT02720913|COR-KNOT
53813|NCT02720913|Standard
53814|NCT02720913|Cost
53815|NCT02720887|pregnant women
53816|NCT02720887|nanoparticles
53817|NCT02720887|amniotic fluid
53818|NCT02720861|RNF213 rs112735431 Gene
53819|NCT02720861|Acute Non-embolic ischemic stroke
53820|NCT02720848|double-balloon enteroscopy
53821|NCT02720809|micronutrients
53822|NCT02720809|blood pressure
53823|NCT02720809|allergy
53824|NCT02720809|lung function
53825|NCT02720796|PDX
53826|NCT02720796|TumorGraft
53827|NCT02720796|Patient derived xenograft
53828|NCT02720796|sarcoma
53829|NCT02720783|Pharmacokinetics
53830|NCT02720783|Econazole nitrate 150mg
53831|NCT02720783|Benzydamine HCl 6mg
53832|NCT02720783|Vaginal pessary
53833|NCT02720783|Tolerability
53834|NCT02720770|growth hormone
53835|NCT02720718|Gastric Bypass Status for Obesity Complicating Pregnancy, Childbirth and the Puerperium
53836|NCT02720718|Laparoscopy
53837|NCT02720718|Suture Techniques
53838|NCT02720718|Sutures
53839|NCT02720705|sevoflurane emergence agitation
53840|NCT02720692|Pain
53841|NCT02720692|Analgesia
53842|NCT02720692|N1539
53843|NCT02720692|Phase 3
53844|NCT02720679|Genetics
53845|NCT02720679|Whole genome sequencing
53846|NCT02720679|Pediatrics and hematology
53847|NCT02720627|acne
53848|NCT02720627|cortexolone
53849|NCT02720627|anti-androgen
53850|NCT02720614|accelerated hypofractionated radiotherapy
53851|NCT02720614|three-dimensional conformal radiation therapy
53852|NCT02720614|concurrent radiochemotherapy
53853|NCT02720601|irinotecan
53854|NCT02720601|capecitabine
53855|NCT02720601|gemcitabine
53856|NCT02720601|biliary tract cancer
53857|NCT02720601|gallbladder cancer
53858|NCT02720601|second-line
53859|NCT02720575|Vitamin D
53860|NCT02720575|Bioavailability
53861|NCT02720575|Fortified Bread
53862|NCT02720536|Anemia.
53863|NCT02720536|Myelodysplastic Syndrome
53864|NCT02720536|Thalassemia
53865|NCT02720536|Film coated tablet
53866|NCT02720523|rheumatoid arthritis
53867|NCT02720523|ABT-494
53868|NCT02720523|Antirheumatic agents
53869|NCT02720523|Japanese
53870|NCT02720510|multiple myeloma
53871|NCT02720510|farydak
53872|NCT02720510|panobinostat
53873|NCT02720510|LBH589
53874|NCT02720510|ASCT
53875|NCT02720510|transplant
53876|NCT02720471|local analgesia
53877|NCT02720471|total hip replacement
53878|NCT02720471|local infiltrations
53879|NCT02720458|Hypnotics withdrawal in insomniac patients
53880|NCT02720458|Cognitive-Behavioural Therapy (CBT)
53881|NCT02720458|Internet-delivered self-help program
53882|NCT02720458|Sleep restriction
53883|NCT02720458|Stimulus control
53884|NCT02720458|Half-life benzodiazepine
53885|NCT02720458|Z-drug
53886|NCT02720445|Alzheimer's Disease
53887|NCT02720445|Nicotine
53888|NCT02720445|Transdermal Patch
53889|NCT02720432|early intervention, infant
53890|NCT02720419|drug eluting stent
53891|NCT02720419|percutaneous coronary intervention
53892|NCT02720419|real world
53893|NCT02720380|Asthma
53894|NCT02720380|Physical Therapy Specialty
53895|NCT02720380|Breathing Exercises
53896|NCT02720380|Child
53897|NCT02720380|Clinical Trail
53898|NCT02720302|Overweight
53899|NCT02720302|Children
53900|NCT02720302|Treatment
53901|NCT02720302|Prevention
53902|NCT02720302|Lifestyle intervention
53903|NCT02720289|injury prevention
53904|NCT02720276|stroke
53905|NCT02720276|exercise
53906|NCT02720276|walking
53907|NCT02720276|mobility
53908|NCT02720263|Schizophrenia
53909|NCT02720263|ASP4345
53910|NCT02720250|omega-3 fatty acids, microcirculation, laser Doppler flowmetry, lipid profile
53911|NCT02720237|Alcohol use
53912|NCT02720237|HIV
53913|NCT02720237|Viral Load
53914|NCT02720237|ART
53915|NCT02720211|headache
53916|NCT02720211|photophobia
53917|NCT02720211|migraine
53918|NCT02720211|light sensitivity
53919|NCT02720211|tints
53920|NCT02720211|thin films
53921|NCT02720146|Dry eye
53922|NCT02720133|ramadan fasting
53923|NCT02720133|variation of biochemical parameters
53924|NCT02720133|variation of hematological parameters
53925|NCT02720133|verify now assay
53926|NCT02720107|fingolimod,
53927|NCT02720107|Biomarker,
53928|NCT02720107|Multiple sclerosis,
53929|NCT02720107|Relapsing-remitting multiple sclerosis
53930|NCT02720094|Pre-Exposure Prophylaxis
53931|NCT02720094|PrEP
53932|NCT02720068|PD1
53933|NCT02720068|PD-1
53934|NCT02720068|PDL1
53935|NCT02720068|PD-L1
53936|NCT02720055|Distal Radius Fracture
53937|NCT02720055|Outcomes
53938|NCT02720055|Psychological Intervention
53939|NCT02720029|aspiration
53940|NCT02720029|reflux
53941|NCT02720016|Post Traumatic Stress Disorder
53942|NCT02720016|Marital Therapy
53943|NCT02720016|Veterans
53944|NCT02720016|Telemedicine
53945|NCT02720003|Atherosclerosis
53946|NCT02720003|Superficial Femoral Artery
53947|NCT02720003|Proximal Popliteal Artery
53948|NCT02719990|VRS-317
53949|NCT02719990|Long Acting Growth Hormone
53950|NCT02719990|Versartis
53951|NCT02719990|somavaratan
53952|NCT02719990|Growth Hormone Deficiency
53953|NCT02719990|Adult Growth Hormone Deficiency
53954|NCT02719990|AGHD
53955|NCT02719990|Growth Hormone Replacement
53956|NCT02719990|Growth Hormone Replacement Therapy
53957|NCT02719990|XTEN
53958|NCT02719964|Cognitive Training
53959|NCT02719964|Traumatic Brain Injury
53960|NCT02719964|Video Games
53961|NCT02719951|autism
53962|NCT02719951|fragile X syndrome (FXS)
53963|NCT02719951|PET (Positron Emission Tomography)
53964|NCT02719951|glutamate
53965|NCT02719925|magnesium deficiency
53966|NCT02719925|stress psycological
53967|NCT02719925|sleep duration and quality
53968|NCT02719925|mineral water rich in magnesium
53969|NCT02719899|NLRP3 Inflammasome
53970|NCT02719899|Sirtuin 3
53971|NCT02719899|T-Cell Polarity
53972|NCT02719899|Caloric Restriction
53973|NCT02719873|obesity , pregnancy , maternal and fetal outcome
53974|NCT02719847|Lung cancer
53975|NCT02719847|Non-Small Cell Lung
53976|NCT02719847|NSCLC
53977|NCT02719847|Suspected non small cell lung cancer
53978|NCT02719847|Endobronchial ultrasound-guided transbronchial needle aspiration
53979|NCT02719847|EBUS-TBNA
53980|NCT02719821|Hematopoietic Stem Cell Transplantation
53981|NCT02719821|Fatigue
53982|NCT02719821|Insomnia
53983|NCT02719821|Depression
53984|NCT02719821|Behavioral Intervention
53985|NCT02719808|Vertical infection transmission
53986|NCT02719808|Tenofovir
53987|NCT02719795|Breast Neoplasms
53988|NCT02719795|Nerve block
53989|NCT02719795|Anesthesia
53990|NCT02719769|Positive Blood Culture
53991|NCT02719743|children
53992|NCT02719743|H5N1
53993|NCT02719743|observer-blind
53994|NCT02719743|Influenza
53995|NCT02719743|dose-ranging
53996|NCT02719717|VATS lobectomy
53997|NCT02719717|vascular sealing
53998|NCT02719717|energy
53999|NCT02719717|pulmonary artery
54000|NCT02719691|MLN0128
54001|NCT02719691|Dual TORC1/2 Inhibitor
54002|NCT02719691|MLN8237
54003|NCT02719691|Aurora A inhibitor
54004|NCT02719691|Alisertib
54005|NCT02719691|Triple-Negative Breast Cancer
54006|NCT02719652|intracranial atherosclerotic disease（ICAD）
54007|NCT02719652|vulnerable plaque
54008|NCT02719652|high-resolution magnetic resonance imaging （HR-MRI）
54009|NCT02719626|senior
54010|NCT02719626|nutrition
54011|NCT02719626|home delivered meals
54012|NCT02719626|food safety
54013|NCT02719626|emergency prep
54014|NCT02719600|Virtual Reality
54015|NCT02719587|saliva
54016|NCT02719587|omega-3
54017|NCT02719574|AML
54018|NCT02719574|MDS
54019|NCT02719574|IDH1
54020|NCT02719574|IDH
54021|NCT02719535|corneal reshaping therapy
54022|NCT02719535|corneal biomechanics
54023|NCT02719483|Children
54024|NCT02719483|Spasticity
54025|NCT02719483|Extracorporeal shock wave therapy
54026|NCT02719483|Cerebral palsy
54027|NCT02719483|Gross motor function
54028|NCT02719470|Cognition Impairment
54029|NCT02719470|Rehabilitation
54030|NCT02719470|Parkinson's Disease
54031|NCT02719457|Exercise testing
54032|NCT02719457|COPD
54033|NCT02719457|Upper and Lower limb exercise
54034|NCT02719418|Thromboembolism
54035|NCT02719418|Venous Thrombosis
54036|NCT02719418|Embolism and Thrombosis
54037|NCT02719418|Chronic Renal Diseases
54038|NCT02719418|Kidney Failure, Chronic
54039|NCT02719418|Renal Failure, Chronic
54040|NCT02719418|Venous Thromboembolism
54041|NCT02719418|Tinzaparin
54042|NCT02719418|Innohep
54043|NCT02719418|Heparin, Low-Molecular-Weight
54044|NCT02719405|milk
54045|NCT02719405|allergy
54046|NCT02719405|tolerance
54047|NCT02719327|Alzheimer's disease
54048|NCT02719327|Cerebrospinal fluid
54049|NCT02719327|brain blood flow
54050|NCT02719327|cognition
54051|NCT02719327|icosapent ethyl
54052|NCT02719327|Vascepa
54053|NCT02719327|omega-3 fatty acids
54054|NCT02719327|eicosapentaenoic acid
54055|NCT02719262|Melamine
54056|NCT02719262|Renal damage
54057|NCT02719262|Workplace intervention
54058|NCT02719249|ESRD
54059|NCT02719249|Fabry disease
54060|NCT02719236|Coxarthrosis
54061|NCT02719236|Hip arthroplasty
54062|NCT02719236|Direct Anterior Approach
54063|NCT02719236|Direct Lateral Approach
54064|NCT02719223|Intradialytic hypotension
54065|NCT02719223|hemodynamic parameters
54066|NCT02719223|Hemodiafiltration
54067|NCT02719223|NICAS device (non-invasive cardiac system)
54068|NCT02719158|Acute otitis media with tympanostomy tubes
54069|NCT02719158|OTIPRIO
54070|NCT02719145|micro RNA
54071|NCT02719145|asthma
54072|NCT02719145|COPD
54073|NCT02719132|Diabetes Mellitus type 2, dapagliflozin, quality of life
54074|NCT02719106|real world data
54075|NCT02719106|percutaneous coronary intervention
54076|NCT02719106|drug eluting stent
54077|NCT02719093|Infertility Male
54078|NCT02719093|Receptors FSH
54079|NCT02719093|Varicocele
54080|NCT02719093|FSH therapy
54081|NCT02719080|anaesthetists, surgeons, stress, burnout
54082|NCT02719067|neuropsychological function
54083|NCT02719067|neuroimage
54084|NCT02719067|developmental changes
54085|NCT02719054|Depression
54086|NCT02719054|Child Development
54087|NCT02719054|Stimulation
54088|NCT02719054|CBT
54089|NCT02719054|Bangladesh
54090|NCT02719015|Melanoma
54091|NCT02719015|Refractory Metastatic Melanoma
54092|NCT02719015|rAd.CD40L
54093|NCT02719015|ISF35
54094|NCT02719015|Intratumoral
54095|NCT02719015|IT
54096|NCT02719015|Pembrolizumab
54097|NCT02719015|Keytruda
54098|NCT02719015|MK-3475
54099|NCT02719015|SCH-900475
54100|NCT02719015|MM
54101|NCT02718989|H-reflex
54102|NCT02718989|TENS
54103|NCT02718989|Tone
54104|NCT02718976|Hip surgery anesthesia
54105|NCT02718976|Perioperative analgesia
54106|NCT02718950|Brown Adipose Tissue
54107|NCT02718950|Hypothalamic Activation
54108|NCT02718950|Non-shivering Thermogenesis
54109|NCT02718950|Basal Metabolic Rate
54110|NCT02718950|Liraglutide
54111|NCT02718950|Victoza
54112|NCT02718950|Body Composition
54113|NCT02718950|Body weight
54114|NCT02718950|Adipose Tissue Biopsy
54115|NCT02718937|Viral diseases
54116|NCT02718937|Antiviral
54117|NCT02718937|Paramyxoviridae infections
54118|NCT02718937|RSV
54119|NCT02718937|Aviragen Therapeutics, Inc.
54120|NCT02718937|Aviragen Therapeutics
54121|NCT02718937|Aviragen
54122|NCT02718924|Thromboelastometry
54123|NCT02718924|pregnancy
54124|NCT02718924|obesity
54125|NCT02718898|genital
54126|NCT02718885|inulin-type fructans
54127|NCT02718885|hemodialysis
54128|NCT02718885|gut microbiome
54129|NCT02718885|mineral and bone disorder
54130|NCT02718859|advanced pancreatic cancer
54131|NCT02718859|nature killer cell
54132|NCT02718859|irreversible electroporation
54133|NCT02718833|Multiple Myeloma
54134|NCT02718833|Relapse
54135|NCT02718807|Patient Care
54136|NCT02718807|Education
54137|NCT02718794|Simulation Training [I02.903.847]
54138|NCT02718794|Problem-Based Learning [F02.463.425.720]
54139|NCT02718794|Airway Management [E02.041]
54140|NCT02718755|Hematologic malignancy
54141|NCT02718755|Relapsed and refractory hematologic malignancies
54142|NCT02718755|Acute myeloid leukemia
54143|NCT02718755|AML
54144|NCT02718755|Acute lymphoblastic leukemia
54145|NCT02718755|ALL
54146|NCT02718755|Burkitt's leukemia/lymphoma
54147|NCT02718755|Prolymphocytic leukemia
54148|NCT02718755|Biphenotypic acute leukemia
54149|NCT02718755|Blast-phase of chronic myeloid leukemia
54150|NCT02718755|CML
54151|NCT02718755|B-cell lymphoma
54152|NCT02718755|Richter's transformation of chronic lymphocytic leukemia
54153|NCT02718755|CLL
54154|NCT02718755|Fludarabine
54155|NCT02718755|Fludarabine phosphate
54156|NCT02718755|Fludara
54157|NCT02718755|Cytarabine
54158|NCT02718755|Ara-C
54159|NCT02718755|Cytosar
54160|NCT02718755|DepoCyt
54161|NCT02718755|Cytosine arabinosine hydrochloride
54162|NCT02718729|Anastomotic leakage
54163|NCT02718729|Rectal cancer
54164|NCT02718729|Laparoscopic
54165|NCT02718729|Rectal resection
54166|NCT02718716|ITP
54167|NCT02718690|H-Reflex
54168|NCT02718690|Current Density
54169|NCT02718690|TENS
54170|NCT02718651|ALK rearrangement
54171|NCT02718651|Circulating tumor DNA
54172|NCT02718651|Plasma DNA
54173|NCT02718651|Non-small cell lung cancer
54174|NCT02718651|Tyrosine kinase inhibitors
54175|NCT02718625|Pressure Ulcers
54176|NCT02718625|Bed sores
54177|NCT02718625|Long-term care
54178|NCT02718625|Nursing home
54179|NCT02718612|Uraemic Sarcopenia
54180|NCT02718612|Sarcopenic Obesity
54181|NCT02718586|Myokines
54182|NCT02718586|Protein Energy Wasting
54183|NCT02718586|Hemodialysis
54184|NCT02718573|Hepatitis C
54185|NCT02718573|Interferon-free
54186|NCT02718573|DDA's
54187|NCT02718547|Diabetes mellitus
54188|NCT02718547|Diabetic macular edema
54189|NCT02718547|Intra ocular pressure
54190|NCT02718547|Ocular perfusion pressure
54191|NCT02718547|Retinal perfusion
54192|NCT02718521|contrast-induced nephropathy
54193|NCT02718521|hydration therapy combined with intravenous infusion of isosorbide
54194|NCT02718521|percutaneous coronary intervention
54195|NCT02718469|Ebola
54196|NCT02718469|VSV
54197|NCT02718469|Vesicular Stomatitis Virus
54198|NCT02718469|Vaccine
54199|NCT02718469|Zaire
54200|NCT02718417|untreated epithelial ovarian
54201|NCT02718417|fallopian tube
54202|NCT02718417|primary peritoneal cancer
54203|NCT02718404|MR-HIFU
54204|NCT02718404|bone metastases
54205|NCT02718404|pain treatment
54206|NCT02718391|Intradermal Autologous Dendritic Cell Vaccine
54207|NCT02718391|Malignant Melanoma
54208|NCT02718391|Adjuvant
54209|NCT02718391|vaccin
54210|NCT02718391|therapy
54211|NCT02718391|randomized trial
54212|NCT02718391|observation
54213|NCT02718378|safety
54214|NCT02718378|pharmacokinetics
54215|NCT02718378|pharmacodynamics
54216|NCT02718378|randomized
54217|NCT02718365|Lung Neoplasms
54218|NCT02718365|Surgery
54219|NCT02718365|VATS
54220|NCT02718365|GGO
54221|NCT02718365|GGN
54222|NCT02718365|Segmentectomy
54223|NCT02718365|Wedge Resection
54224|NCT02718365|Prognosis
54225|NCT02718313|intraventricular conduction delay
54226|NCT02718300|Primary myelofibrosis (PMF)
54227|NCT02718300|post-polycythemia vera myelofibrosis (PPV-MF)
54228|NCT02718300|post-essential thrombocythemia myelofibrosis (PET-MF)
54229|NCT02718300|myeloproliferative neoplasms (MPNs)
54230|NCT02718300|phosphoinositide 3-kinase (PI3K) inhibitor
54231|NCT02718300|Janus kinase (JAK) inhibitor
54232|NCT02718287|language development
54233|NCT02718287|socio-emotional development
54234|NCT02718287|cognitive development
54235|NCT02718287|motor skills
54236|NCT02718274|HIV self-testing
54237|NCT02718274|Malawi
54238|NCT02718274|HIV
54239|NCT02718248|self-harm
54240|NCT02718248|problem-solving therapy
54241|NCT02718248|emergency department
54242|NCT02718248|e-therapy
54243|NCT02718248|suicide prevention
54244|NCT02718222|Post-partum intrauterine device (PPIUD)
54245|NCT02718144|dose-escalation
54246|NCT02718144|safety
54247|NCT02718144|dose-limiting toxicity
54248|NCT02718131|Tibial Pseudarthrosis
54249|NCT02718105|KIR HLA-C
54250|NCT02718105|ART
54251|NCT02718066|HBI-8000
54252|NCT02718066|nivolumab
54253|NCT02718066|Melanoma
54254|NCT02718066|Renal Cell Carcinoma
54255|NCT02718066|Non-Small Cell Lung Cancer
54256|NCT02718027|Hereditary Nephritis
54257|NCT02718027|Nephritis, Familial
54258|NCT02718027|Hereditary Familial Congenital Hemorrhagic Nephritis
54259|NCT02718014|Non Surgical Therapy
54260|NCT02718001|Mitral
54261|NCT02718001|Regurgitation
54262|NCT02718001|Insufficiency
54263|NCT02718001|Degenerative
54264|NCT02718001|Functional
54265|NCT02718001|Primary
54266|NCT02718001|Secondary
54267|NCT02718001|Organic
54268|NCT02718001|Transcatheter
54269|NCT02718001|TMVR
54270|NCT02718001|TMVI
54271|NCT02718001|Heart Valve
54272|NCT02718001|Mitral Valve
54273|NCT02718001|Transapical
54274|NCT02718001|Transseptal
54275|NCT02718001|Trans-Septal
54276|NCT02718001|Transeptal
54277|NCT02718001|Severe
54278|NCT02717988|rheumatoid arthritis
54279|NCT02717988|healthy volunteers
54280|NCT02717988|moderately to severely active
54281|NCT02717975|Urinary retention
54282|NCT02717975|trial removal of catheter
54283|NCT02717975|valve
54284|NCT02717962|Glioma
54285|NCT02717962|Glioblastoma
54286|NCT02717962|Glioblastoma multiforme
54287|NCT02717962|GBM
54288|NCT02717962|brain tumor
54289|NCT02717962|brain cancer
54290|NCT02717962|recurrent brain tumor
54291|NCT02717962|recurrent brain cancer
54292|NCT02717962|refractory brain tumor
54293|NCT02717962|refractory brain cancer
54294|NCT02717962|recurrent GBM
54295|NCT02717962|refractory GBM
54296|NCT02717962|recurrent glioma
54297|NCT02717962|refractory glioma
54298|NCT02717962|recurrent glioblastoma
54299|NCT02717962|refractory glioblastoma
54300|NCT02717962|recurrent glioblastoma multiforme
54301|NCT02717962|refractory glioblastoma multiforme
54302|NCT02717962|failed bevacizumab
54303|NCT02717962|temodar failure
54304|NCT02717962|temozolomide failure
54305|NCT02717949|hepatitis C
54306|NCT02717949|low-grade lymphoma
54307|NCT02717936|squamous cell carcinoma
54308|NCT02717936|dermatosurgery
54309|NCT02717936|immunohistochemistry
54310|NCT02717923|metastatic colorectal cancer
54311|NCT02717923|maintenance treatment
54312|NCT02717923|cetuximab
54313|NCT02717910|Games
54314|NCT02717910|Adolescent
54315|NCT02717910|Health education
54316|NCT02717910|Smoking
54317|NCT02717910|Health literacy
54318|NCT02717884|AML
54319|NCT02717884|MDS
54320|NCT02717884|relapsed
54321|NCT02717884|trans-retinoic acid ATRA
54322|NCT02717884|epigenetic treatment
54323|NCT02717884|non-M3 AML blasts
54324|NCT02717884|tranylcypromine TCP
54325|NCT02717884|LSD1
54326|NCT02717884|refractory
54327|NCT02717871|Collagen cross-linking, PACK-CXL, infectious keratitis, CXL.
54328|NCT02717845|varus malignment
54329|NCT02717845|osteoarthritis
54330|NCT02717845|knee
54331|NCT02717819|Sarcopenia
54332|NCT02717819|Muscular atrophy
54333|NCT02717819|Frailty
54334|NCT02717819|Acute illness
54335|NCT02717819|Ageing
54336|NCT02717819|Protein supplementation
54337|NCT02717819|Whey protein
54338|NCT02717819|Resistance training
54339|NCT02717819|Strength training
54340|NCT02717767|pneumonia
54341|NCT02717767|diagnosis
54342|NCT02717767|prognosis
54343|NCT02717767|tracheal aspirate
54344|NCT02717767|bronchoalveolar lavage
54345|NCT02717663|Reinforcement
54346|NCT02717663|Walking
54347|NCT02717663|Exercise
54348|NCT02717663|Built Environment
54349|NCT02717663|Adaptive
54350|NCT02717663|Financial incentive
54351|NCT02717663|Walkability
54352|NCT02717650|Exercise Testing
54353|NCT02717650|Maximal Exercise Testing
54354|NCT02717650|Maximal Exercise Capacity
54355|NCT02717650|Peak Exercise Capacity
54356|NCT02717650|Adults
54357|NCT02717650|Step Tests
54358|NCT02717637|oxycodone, caesarean, spinal anesthesia
54359|NCT02717624|Bruton tyrosine kinase inhibitor
54360|NCT02717624|Btk
54361|NCT02717624|ACP-196
54362|NCT02717624|Mantle Cell Lymphoma
54363|NCT02717624|MCL
54364|NCT02717624|acalabrutinib
54365|NCT02717624|ACE-LY-106
54366|NCT02717611|Chronic Lymphocytic Leukemia
54367|NCT02717611|Ibrutinib Intolerant
54368|NCT02717598|cold snare polypectomy
54369|NCT02717598|hot snare polypectomy
54370|NCT02717585|Continuous Positive Airway Pressure therapy
54371|NCT02717585|Chronic Pain
54372|NCT02717585|Sleep Disturbance
54373|NCT02717559|Anterior cruciate ligament / injuries
54374|NCT02717559|Anterior cruciate ligament / surgery
54375|NCT02717559|knee injuries / surgery
54376|NCT02717559|outcomes research
54377|NCT02717559|prospective studies
54378|NCT02717559|osteoarthritis
54379|NCT02717546|Distal Tibia Fracture Screw
54380|NCT02717520|glass hybrid
54381|NCT02717520|composite
54382|NCT02717494|PPV-23
54383|NCT02717494|PCV-10
54384|NCT02717494|HIV
54385|NCT02717494|Immunization
54386|NCT02717494|Pregnancy
54387|NCT02717455|Diffuse Intrinsic Pontine Glioma
54388|NCT02717442|Meniere's Disease
54389|NCT02717442|Vertigo
54390|NCT02717403|Chronic Disease Management
54391|NCT02717403|Rheumatoid Arthritis
54392|NCT02717403|Facebook
54393|NCT02717403|Social networking
54394|NCT02717403|Internet
54395|NCT02717403|Questionnaires
54396|NCT02717403|Surveys
54397|NCT02717403|Phone interview
54398|NCT02717390|Reading
54399|NCT02717390|Early Childhood development
54400|NCT02717390|Talking
54401|NCT02717390|Playing
54402|NCT02717390|Praising
54403|NCT02717390|Safety
54404|NCT02717390|Injury prevention
54405|NCT02717377|Micro bouts
54406|NCT02717377|Physical Activity
54407|NCT02717351|Sunscreening Agent
54408|NCT02717338|blood donor
54409|NCT02717338|retention
54410|NCT02717338|motivation
54411|NCT02717338|self-determination theory
54412|NCT02717325|Sunscreening Agent
54413|NCT02717247|tRNS
54414|NCT02717247|Food addiction,
54415|NCT02717247|Obesity
54416|NCT02717247|Craving
54417|NCT02717247|functional magnetic resonance imaging (fMRI)
54418|NCT02717182|self management program
54419|NCT02717182|patient education
54420|NCT02717182|self care program
54421|NCT02717169|health promotion
54422|NCT02717169|health action process
54423|NCT02717169|activity tracker
54424|NCT02717169|sleep regulation
54425|NCT02717143|Acute myocarditis
54426|NCT02717143|Dilated cardiomyopathy
54427|NCT02717143|Magnetic resonance imaging
54428|NCT02717117|Motility
54429|NCT02717117|MRI
54430|NCT02717117|Gut peptides
54431|NCT02717117|Feeding
54432|NCT02717104|femoropopliteal
54433|NCT02717078|diet
54434|NCT02717078|carbohydrate
54435|NCT02717065|Neuromodulation
54436|NCT02717065|Noninvasive
54437|NCT02717065|Plasticity
54438|NCT02717065|Hearing
54439|NCT02717065|Hyperacusis
54440|NCT02717013|Muscle
54441|NCT02717013|Bone
54442|NCT02717013|Fat
54443|NCT02716974|Lupron
54444|NCT02716974|Bicalutamide
54445|NCT02716974|Docetaxel
54446|NCT02716896|cystectomy
54447|NCT02716896|radiation
54448|NCT02716896|chemotherapy
54449|NCT02716883|keratitis
54450|NCT02716883|AMT
54451|NCT02716883|bacterial keratitis
54452|NCT02716883|medication
54453|NCT02716870|Systematic review and meta-analysis
54454|NCT02716870|Evidence-based medicine (EBM)
54455|NCT02716870|Evidence-based nutrition (EBN)
54456|NCT02716870|Clinical practice guidelines
54457|NCT02716870|Clinical trials
54458|NCT02716870|Dietary sugars
54459|NCT02716870|Fructose
54460|NCT02716870|High fructose corn syrup
54461|NCT02716870|Fruit
54462|NCT02716870|Isocaloric
54463|NCT02716870|Hypercaloric
54464|NCT02716870|Cardiometabolic risk factors
54465|NCT02716870|Triglycerides
54466|NCT02716870|Cholesterol
54467|NCT02716870|Glycemic control
54468|NCT02716870|Insulin resistance
54469|NCT02716870|Body weight
54470|NCT02716870|Uric acid
54471|NCT02716870|Blood pressure
54472|NCT02716870|Fatty liver
54473|NCT02716870|Fasting
54474|NCT02716870|Postprandial
54475|NCT02716844|Osteoporosis
54476|NCT02716844|Clinic Pilates Exercise
54477|NCT02716844|Kinesiophobia
54478|NCT02716844|Pain
54479|NCT02716831|Bulimia Nervosa
54480|NCT02716831|Eating Disorders
54481|NCT02716818|Glucocorticoid therapy
54482|NCT02716805|autologous stem cell transplant
54483|NCT02716805|HDT/ASCT
54484|NCT02716805|CTLA-4
54485|NCT02716805|PD-L1
54486|NCT02716805|peripheral blood mononuclear cells
54487|NCT02716805|PBMC
54488|NCT02716805|ASCT
54489|NCT02716766|Sorafenib
54490|NCT02716766|Drug Therapy
54491|NCT02716740|Post-obesity surgery
54492|NCT02716740|Leucine-enriched amino acid supplementation
54493|NCT02716740|Anabolic substance
54494|NCT02716740|Physical training
54495|NCT02716740|Muscular mass
54496|NCT02716740|Loss of weight
54497|NCT02716714|Korean
54498|NCT02716701|Exercise
54499|NCT02716688|Esophageal cancer
54500|NCT02716688|Radiotherapy
54501|NCT02716688|elder
54502|NCT02716688|S-1
54503|NCT02716675|HIV-1 Infections
54504|NCT02716649|Trauma
54505|NCT02716649|ICISS
54506|NCT02716649|India
54507|NCT02716649|ICD-10
54508|NCT02716597|albumin, septic shock
54509|NCT02716571|Healthy Subjects
54510|NCT02716571|Healthy Participants
54511|NCT02716545|Gastrointestinal vascular malformation
54512|NCT02716545|Endoscopic Therapy
54513|NCT02716519|Diabetes
54514|NCT02716519|diabetic foot ulcer
54515|NCT02716519|foot sore
54516|NCT02716519|type 2 diabetes
54517|NCT02716519|type 1 diabetes
54518|NCT02716519|DFU
54519|NCT02716519|pressure ulcers
54520|NCT02716519|bed sores
54521|NCT02716506|POP surgery
54522|NCT02716493|Telerehabilitation
54523|NCT02716480|Nutrition
54524|NCT02716480|Physical activity
54525|NCT02716480|Bariatric surgery
54526|NCT02716480|Obesity
54527|NCT02716480|Health technology
54528|NCT02716480|Health-connected devices
54529|NCT02716467|nursing
54530|NCT02716467|intercessory prayer
54531|NCT02716467|spirituality
54532|NCT02716467|clinical trials
54533|NCT02716454|Early surgery
54534|NCT02716454|Crohn's disease
54535|NCT02716454|Step-up therapy
54536|NCT02716415|neonates
54537|NCT02716415|infants
54538|NCT02716402|Cyanotic congenital heart disease
54539|NCT02716402|pulmonary thrombosis
54540|NCT02716402|cerebral thrombosis
54541|NCT02716376|Head and neck neoplasms
54542|NCT02716376|Radiotherapy
54543|NCT02716376|Otitis media
54544|NCT02716337|human milk target fortification
54545|NCT02716324|Attention-Deficit/Hyperactivity Disorder
54546|NCT02716324|Shared-Decision Making
54547|NCT02716324|Care Manager
54548|NCT02716324|Children
54549|NCT02716324|Parents
54550|NCT02716324|Teachers
54551|NCT02716311|EGFR
54552|NCT02716311|Lung Cancer
54553|NCT02716285|Irritable Bowel Syndrome
54554|NCT02716285|Abdominal pain
54555|NCT02716285|Targeted Delivery
54556|NCT02716285|Peppermint oil
54557|NCT02716272|mesothelioma
54558|NCT02716272|immunotherapy
54559|NCT02716272|nivolumab
54560|NCT02716272|ipilimumab
54561|NCT02716259|Periodontitis
54562|NCT02716259|Cardiovascular diseases
54563|NCT02716259|Bacteremia
54564|NCT02716259|Scaling and root planing
54565|NCT02716259|Flow-mediated dilation
54566|NCT02716259|carotid intima-media thickness
54567|NCT02716259|Porphyromonas gingivalis
54568|NCT02716259|Aggregatibacter actinomycetemcomitans
54569|NCT02716246|MPS IIIA
54570|NCT02716220|DREAMS 2G
54571|NCT02716220|Scaffold
54572|NCT02716220|Drug Eluting Absorbable Metal Scaffold
54573|NCT02716220|Coronary Artery Disease
54574|NCT02716207|Stereotactic Body Radiotherapy (SBRT)
54575|NCT02716207|CyberKnife
54576|NCT02716207|Dose Escalation
54577|NCT02716181|Atopic Dermatitis
54578|NCT02716181|Topical therapy
54579|NCT02716168|Cancer
54580|NCT02716168|tele-health
54581|NCT02716168|Shared care
54582|NCT02716168|Continuity
54583|NCT02716116|NSCLC
54584|NCT02716116|EGFR
54585|NCT02716116|HER2
54586|NCT02716116|human epidermal growth factor receptor 2
54587|NCT02716116|exon 20 insertions
54588|NCT02716116|exon 19 deletions
54589|NCT02716116|exon 21 substitution
54590|NCT02716116|T790M
54591|NCT02716116|ErbB-2
54592|NCT02716116|Epidermal Growth Factor Receptor
54593|NCT02716103|AL amyloidosis, systemic primary amyloidosis
54594|NCT02716064|chronic conditions, self-management, PHR
54595|NCT02716038|Non-Small Cell Lung Cancer
54596|NCT02716038|Non-Small-Cell Lung Carcinoma
54597|NCT02716038|Nonsmall Cell Lung Cancer
54598|NCT02716038|NSCLC
54599|NCT02716012|Oligonucleotide
54600|NCT02716012|RNA
54601|NCT02716012|saRNA
54602|NCT02716012|Fibrosis
54603|NCT02716012|Cirrhosis
54604|NCT02715986|ECT
54605|NCT02715986|Diffusion Tensor Imaging (DTI)
54606|NCT02715986|fMRI
54607|NCT02715947|Psoriasis Vulgaris
54608|NCT02715947|Methotrexate
54609|NCT02715934|Diabetes Education
54610|NCT02715934|Chronic Disease Management
54611|NCT02715934|Health Care Delivery
54612|NCT02715934|Patient-Centered Medical Home
54613|NCT02715934|Primary Care
54614|NCT02715895|Infant
54615|NCT02715895|Growth
54616|NCT02715895|Body Weight Changes
54617|NCT02715895|Infant Formula
54618|NCT02715895|Randomized Controlled Trial
54619|NCT02715882|Colorectal cancer
54620|NCT02715882|TLR5
54621|NCT02715882|Immunotherapy
54622|NCT02715869|Myocardial Preconditioning, inotropic score
54623|NCT02715856|Bone metastases
54624|NCT02715856|Intramedullary nailing surgery
54625|NCT02715856|IM
54626|NCT02715856|Physical tasks
54627|NCT02715856|Surveys
54628|NCT02715856|Questionnaires
54629|NCT02715856|Smartphone
54630|NCT02715856|Tablet
54631|NCT02715856|Telemedicine
54632|NCT02715856|Telemonitoring
54633|NCT02715843|CD20
54634|NCT02715843|immunotoxin
54635|NCT02715843|NHL
54636|NCT02715843|non-Hodgkin's lymphoma
54637|NCT02715843|lymphoma
54638|NCT02715843|cancer
54639|NCT02715843|antibodies
54640|NCT02715843|immunotherapy
54641|NCT02715843|safety
54642|NCT02715843|pharmacokinetics
54643|NCT02715843|MT-3724
54644|NCT02715843|relapsed
54645|NCT02715843|refractory
54646|NCT02715817|Stroke
54647|NCT02715817|Hemiparesis
54648|NCT02715817|Physical Therapy
54649|NCT02715817|Virtual Reality Exposure Therapy
54650|NCT02715817|Video Games
54651|NCT02715804|Pancreatic ductal adenocarcinoma (PDA)
54652|NCT02715804|Pancreatic ductal carcinoma
54653|NCT02715804|PEGylated Recombinant Human Hyaluronidase (PEGPH20)
54654|NCT02715804|Nab-paclitaxel
54655|NCT02715804|Gemcitabine
54656|NCT02715791|Self-Management
54657|NCT02715791|Health Connectors
54658|NCT02715791|Volunteers
54659|NCT02715791|Technology
54660|NCT02715791|Interprofessional team
54661|NCT02715791|Chronic disease
54662|NCT02715791|Self-efficacy
54663|NCT02715791|Patient-centredness
54664|NCT02715791|Community Engagement
54665|NCT02715739|Trauma
54666|NCT02715739|India
54667|NCT02715739|ICISS
54668|NCT02715713|Autonomic neuropathy, Testosterone Deficiency
54669|NCT02715661|blood flow
54670|NCT02715661|brain health
54671|NCT02715661|exercise
54672|NCT02715661|endothelial activation
54673|NCT02715596|head and neck
54674|NCT02715596|eicosapentanoic acid
54675|NCT02715596|body composition
54676|NCT02715570|Aspergillus species
54677|NCT02715570|Filamentous fungi
54678|NCT02715570|14-alpha Demethylase Inhibitors
54679|NCT02715570|Anti-Infective Agents
54680|NCT02715570|Antifungal Agents
54681|NCT02715570|Enzyme Inhibitors
54682|NCT02715570|Aspergillosis
54683|NCT02715570|Allergic Bronchopulmonary
54684|NCT02715570|Asthma
54685|NCT02715544|Intervention
54686|NCT02715544|Physical activity
54687|NCT02715544|Eating habit
54688|NCT02715544|Connectedness to nature
54689|NCT02715518|Acute ST-segment elevation myocardial infarction
54690|NCT02715518|Acute myocardial infarction
54691|NCT02715518|Fractional flow reserve
54692|NCT02715518|Percutaneous coronary intervention
54693|NCT02715518|Multivessel disease
54694|NCT02715518|STEMI
54695|NCT02715518|NSTEMI
54696|NCT02715505|Inherited Metabolic Disorders (IMD), Hurler syndrome, MLD, Krabbe, cALD, Hematopoietic Stem Cell Transplantation (HSCT)
54697|NCT02715453|Frailty
54698|NCT02715453|Acute myocardial infarction
54699|NCT02715440|Benzodiazepines
54700|NCT02715440|drugs
54701|NCT02715440|withdrawal
54702|NCT02715440|nursing home
54703|NCT02715440|elderly
54704|NCT02715440|therapy elderly
54705|NCT02715440|Adverse Effect
54706|NCT02715440|pharmacokinetics
54707|NCT02715440|Decreased Drug Tolerance
54708|NCT02715375|asthma environment
54709|NCT02715362|immunotherapy GPC3 CAR-T HCC
54710|NCT02715349|schizophrenia
54711|NCT02715349|psychoeducation
54712|NCT02715349|Vietnam
54713|NCT02715336|In vitro fertilization
54714|NCT02715336|IVF
54715|NCT02715336|Assisted Reproductive Technologies
54716|NCT02715336|ART
54717|NCT02715336|OHSS
54718|NCT02715336|Ovarian hyperstimulation
54719|NCT02715336|dual triggering
54720|NCT02715336|GnRH
54721|NCT02715323|dry eye
54722|NCT02715323|immunological profile
54723|NCT02715323|autoimmune
54724|NCT02715297|glioblastoma
54725|NCT02715297|GBM
54726|NCT02715297|radiotherapy
54727|NCT02715297|Re-irradiation
54728|NCT02715297|progression
54729|NCT02715284|Metastatic solid tumors
54730|NCT02715284|Advanced solid tumors
54731|NCT02715284|anti-PD-1
54732|NCT02715284|TSR-042
54733|NCT02715284|Immunotherapy
54734|NCT02715284|PD-1
54735|NCT02715245|home rehabilitation
54736|NCT02715245|Primary Health Care
54737|NCT02715245|Physiotherapy
54738|NCT02715245|chronic disease
54739|NCT02715206|rural adolescents, substance use, prevention, adaptation
54740|NCT02715154|Epidural Anaesthesia
54741|NCT02715154|Cesarean Section
54742|NCT02715154|Dexmedetomidine
54743|NCT02715141|surveillance, molecular stool testing
54744|NCT02715115|Autism
54745|NCT02715115|Rett's syndrome
54746|NCT02715115|Rett disorder
54747|NCT02715115|Rett's disorder
54748|NCT02715115|Ataxia
54749|NCT02715102|lung cancer
54750|NCT02715102|lung neoplasms
54751|NCT02715102|lung nodules
54752|NCT02715102|screening tests for cancer
54753|NCT02715089|NGS
54754|NCT02715089|Liver Neoplasms
54755|NCT02715089|Biliary Tract Neoplasms
54756|NCT02715089|Hepatobiliary Neoplasms
54757|NCT02715076|Thoracic Surgery
54758|NCT02715076|Thoracic surgery, Video assisted
54759|NCT02715076|Open Abdominal Surgery
54760|NCT02715076|Anesthesia, General
54761|NCT02715050|phototherapy
54762|NCT02715050|photobiostimulation
54763|NCT02715050|muscle training
54764|NCT02715050|muscular adaptation
54765|NCT02715037|fusobacterium necrophorum
54766|NCT02715037|acute tonsillitis
54767|NCT02715037|peritonsillar cellulitis
54768|NCT02715037|infectious mononucleosis
54769|NCT02715037|microbiology
54770|NCT02715037|antibody development
54771|NCT02715024|Tamsulosin
54772|NCT02715024|Solifenacin
54773|NCT02715024|Lower urinary tract symptoms
54774|NCT02715024|Overactive bladder
54775|NCT02715011|Leukemia, Myeloid, Acute
54776|NCT02715011|JNJ-63709178
54777|NCT02714998|ectopic pregnancy
54778|NCT02714998|ovarian reserve
54779|NCT02714998|salpingectomy
54780|NCT02714998|methotrexate
54781|NCT02714985|chikungunya virus
54782|NCT02714985|RT-PCR
54783|NCT02714985|urine
54784|NCT02714985|diagnosis
54785|NCT02714946|Thyroid Nodule
54786|NCT02714946|Percutaneous radiofrequency ablation (RFA)
54787|NCT02714946|Percutaneous laser ablation (LA)
54788|NCT02714933|pulmonary
54789|NCT02714933|parenchyma
54790|NCT02714933|MRI sequence Advanced ZTE
54791|NCT02714933|chest computed tomography
54792|NCT02714920|DNA Repair Enzyme Signature
54793|NCT02714920|instrinsic radio- or chemo-resistance
54794|NCT02714920|treatment-induced radio- or chemo-resistance
54795|NCT02714894|magnetic resonance imaging
54796|NCT02714894|magnetic resonance spectroscopy
54797|NCT02714868|repeated measures
54798|NCT02714868|matched comparison
54799|NCT02714868|manualized intervention
54800|NCT02714868|self-determination
54801|NCT02714868|participation
54802|NCT02714868|advocacy
54803|NCT02714868|problem-solving
54804|NCT02714868|commuinity participation
54805|NCT02714868|occupational therapy
54806|NCT02714868|environment
54807|NCT02714829|Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
54808|NCT02714790|Acute Myeloid Leukemia
54809|NCT02714790|Minimal Residual Disease
54810|NCT02714790|Wilms Tumor
54811|NCT02714777|General anesthesia
54812|NCT02714777|Autonomic nervous system
54813|NCT02714777|Children
54814|NCT02714764|Alexander Disease
54815|NCT02714738|Brachial plexus block
54816|NCT02714738|Regional anesthesia
54817|NCT02714738|Ultrasound
54818|NCT02714725|Dexmedetomidine
54819|NCT02714725|Microcirculation
54820|NCT02714725|On Pump
54821|NCT02714725|CABG
54822|NCT02714686|Fertility
54823|NCT02714686|Total Contraception Prevalence Rate
54824|NCT02714686|Family planning methods
54825|NCT02714686|Birth Control
54826|NCT02714686|Mass Media Campaign
54827|NCT02714686|Demand for contraception
54828|NCT02714686|Modern Contraception Prevalence Rate
54829|NCT02714686|Birth intervals
54830|NCT02714647|motor learning
54831|NCT02714647|attention
54832|NCT02714647|priming
54833|NCT02714647|rehabilitation
54834|NCT02714621|Magnetic Resonance Imaging (MRI)
54835|NCT02714621|High Intensity Focused Ultrasound (HIFU)
54836|NCT02714621|Focused Ultrasound Surgery
54837|NCT02714595|cefiderocol
54838|NCT02714595|Bloodstream infections (BSI)
54839|NCT02714595|Complicated urinary tract infection (cUTI)
54840|NCT02714595|Ventilator associated pneumonia (VAP)
54841|NCT02714595|Hospital acquired pneumonia (HAP)
54842|NCT02714595|Sepsis
54843|NCT02714595|multi-drug resistant pathogens
54844|NCT02714595|S-649266
54845|NCT02714595|Gram-negative pathogens
54846|NCT02714595|Healthcare-associated pneumonia (HCAP)
54847|NCT02714595|carbapenem resistant pathogens
54848|NCT02714582|Shift report
54849|NCT02714582|Bedside
54850|NCT02714582|Nursing
54851|NCT02714582|Matched controlled trial
54852|NCT02714582|Mixed method
54853|NCT02714582|Patient participation
54854|NCT02714556|Lung volume
54855|NCT02714556|Lung Clearance Index
54856|NCT02714556|Functional Residual Capacity
54857|NCT02714556|Respiratory function
54858|NCT02714543|OSMF
54859|NCT02714543|Aloevera
54860|NCT02714543|Hydrocortisone
54861|NCT02714543|Hyaluronidase
54862|NCT02714504|Prophylaxis
54863|NCT02714465|Hyperbaric Oxygen Therapy; Gamma Knife Radiosurgery
54864|NCT02714452|Person-centred care
54865|NCT02714452|Thriving
54866|NCT02714452|Satisfaction with care
54867|NCT02714452|Residential aged care
54868|NCT02714452|Caring environment
54869|NCT02714439|Malignant neoplasms of female genital organs
54870|NCT02714439|Cervical Cancer Prevention
54871|NCT02714439|Abnormal Pap test
54872|NCT02714439|Positive HPV test
54873|NCT02714439|History of cervical dysplasia
54874|NCT02714439|Colposcopy
54875|NCT02714439|Proflavine
54876|NCT02714439|Proflavine hemisulfate
54877|NCT02714439|High-Resolution Microendoscopy
54878|NCT02714439|HRME
54879|NCT02714439|Human papillomavirus
54880|NCT02714426|Cognitive Aging
54881|NCT02714426|Attention
54882|NCT02714426|Mindfulness
54883|NCT02714413|D-allulose
54884|NCT02714413|Caucasian
54885|NCT02714413|African American
54886|NCT02714400|Obstructive Sleep Apnea
54887|NCT02714400|Arousal threshold
54888|NCT02714400|Venlafaxine
54889|NCT02714387|Non traumatic acute brain injury
54890|NCT02714374|GL-ONC1
54891|NCT02714374|Eculizumab
54892|NCT02714374|Solid Organ Cancer
54893|NCT02714374|Cancer
54894|NCT02714374|Surgery
54895|NCT02714374|Oncolytic Virus
54896|NCT02714374|Soliris
54897|NCT02714374|Metastatic melanoma
54898|NCT02714374|Esophageal and gastric adenocarcinoma (Stage III/IV)
54899|NCT02714374|Cholangiocarcinoma
54900|NCT02714374|Pancreatic adenocarcinoma
54901|NCT02714374|Gallbladder cancer
54902|NCT02714374|Colorectal cancer (Stage IV)
54903|NCT02714374|High-grade mucinous appendix cancer
54904|NCT02714374|High-grade gastrointestinal neuroendocrine cancer
54905|NCT02714374|Mesothelioma
54906|NCT02714374|High-grade soft tissue sarcoma
54907|NCT02714374|Stage III or IV
54908|NCT02714361|Iron deficiency
54909|NCT02714361|Vitamin D
54910|NCT02714361|Iron absorption
54911|NCT02714361|Hepcidin
54912|NCT02714348|Helminth infection
54913|NCT02714348|Vaccination
54914|NCT02714322|Adalimumab
54915|NCT02714322|Biologics
54916|NCT02714322|Biosimilar
54917|NCT02714309|Postprandial glycemia
54918|NCT02714309|Metabolic health measures
54919|NCT02714296|colon preparation for endoscopy
54920|NCT02714296|enteral feeding
54921|NCT02714296|sip feeding
54922|NCT02714296|nutridrink
54923|NCT02714296|nutridrink compact protein
54924|NCT02714283|nontuberculous mycobacteria
54925|NCT02714283|corticosteroids
54926|NCT02714283|macrolides
54927|NCT02714283|antibiotics
54928|NCT02714205|Hot flash
54929|NCT02714153|Lead extraction
54930|NCT02714153|Superior Vena Cava Tear
54931|NCT02714153|Pacemaker/Defibrillator lead extraction
54932|NCT02714127|Human Papillomavirus
54933|NCT02714127|Biomarker
54934|NCT02714127|Self-sampling
54935|NCT02714127|First-void urine
54936|NCT02714127|Cervicovaginal fluid
54937|NCT02714127|Colposcopy
54938|NCT02714114|Antibodies
54939|NCT02714114|Vaccination
54940|NCT02714114|Self-sampling
54941|NCT02714114|First-void urine
54942|NCT02714114|Serum
54943|NCT02714088|High-intensity interval training
54944|NCT02714088|Functional fitness
54945|NCT02714088|Quality of life
54946|NCT02714088|Older adults
54947|NCT02714062|Adolescent Obesity
54948|NCT02714062|Childhood Obesity
54949|NCT02714062|Qsymia
54950|NCT02714062|Pharmacokinetics
54951|NCT02714062|VI-0521
54952|NCT02714049|hypoactive sexual desire disorder
54953|NCT02714049|Addyi
54954|NCT02714049|flibanserin
54955|NCT02714049|low sexual desire
54956|NCT02714049|HSDD
54957|NCT02714036|ALS
54958|NCT02714010|EGFR-TKI
54959|NCT02714010|whole brain radiotherapy
54960|NCT02714010|brain metastasis
54961|NCT02714010|non-small cell lung cancer
54962|NCT02713984|HER2 CAR-T
54963|NCT02713984|safety
54964|NCT02713984|efficiency
54965|NCT02713984|refractory and relapsed cancer
54966|NCT02713971|Rehabilitation
54967|NCT02713971|Balance
54968|NCT02713971|Gait
54969|NCT02713971|Biofeedback
54970|NCT02713958|Telerehabilitation
54971|NCT02713958|Elbow fractures
54972|NCT02713958|Arthrolysis
54973|NCT02713958|MediTouch
54974|NCT02713958|Occupational Therapy
54975|NCT02713958|Active exercises
54976|NCT02713945|Simvastatin
54977|NCT02713945|Ras
54978|NCT02713945|MAPK
54979|NCT02713932|Aortic valve stenosis
54980|NCT02713932|Aortic valve regurgitation
54981|NCT02713932|Transcatheter aortic valve implantation
54982|NCT02713919|Cancer
54983|NCT02713919|Outpatients
54984|NCT02713919|Family Caregivers
54985|NCT02713893|Pharmacokinetics
54986|NCT02713893|Econazole nitrate 1%
54987|NCT02713893|Benzydamine HCl 0.12%
54988|NCT02713893|Intravaginal cream
54989|NCT02713893|Antimycotic
54990|NCT02713893|Tolerability
54991|NCT02713880|Peripheral Nervous System Diseases
54992|NCT02713880|Neuromuscular Diseases
54993|NCT02713880|Metabolism, Inborn Errors
54994|NCT02713880|Genetic Diseases, Inborn
54995|NCT02713854|Subfertility
54996|NCT02713854|In-vitro fertilization
54997|NCT02713854|BAP-EB
54998|NCT02713854|Endometrial epithelial cells
54999|NCT02713854|Repeated implantation failure
55000|NCT02713828|gpNMB-Expressing Squamous Cell Carcinoma of the Lung
55001|NCT02713828|Stage IIIb
55002|NCT02713828|Stage IV
55003|NCT02713828|Advanced Squamous Cell Cancer of the Lung
55004|NCT02713828|Metastatic Squamous Cell Cancer of the Lung
55005|NCT02713828|gpNMB-Expressing
55006|NCT02713828|Glembatumumab Vedotin
55007|NCT02713815|Amphetamine-type stimulants
55008|NCT02713815|prefrontal-striatal circuits
55009|NCT02713815|Glutamate/GABA
55010|NCT02713815|motivational and cognitive intervention
55011|NCT02713815|rTMS
55012|NCT02713789|ED
55013|NCT02713776|High-Output Enterostomy
55014|NCT02713776|Pasireotide
55015|NCT02713776|Somatostatin Analogues
55016|NCT02713763|Sunitinib
55017|NCT02713750|Combined Oral Contraceptives
55018|NCT02713750|Highly Active Antiretroviral Therapy
55019|NCT02713750|Hormonal Contraception
55020|NCT02713750|Human Immunodeficiency Virus
55021|NCT02713750|Intrauterine Device
55022|NCT02713750|Pharmacokinetic
55023|NCT02713750|Sexually Transmitted Diseases
55024|NCT02713750|Reproductive Health
55025|NCT02713737|hypoxemia
55026|NCT02713737|high-flow
55027|NCT02713737|atrial fibrillation
55028|NCT02713737|sleep
55029|NCT02713711|Psoriasis
55030|NCT02713711|balneotherapy
55031|NCT02713711|phototherapy
55032|NCT02713711|balneophototherapy
55033|NCT02713698|Anaesthetics
55034|NCT02713698|Intravenous
55035|NCT02713698|Propofol
55036|NCT02713698|Pharmacokinetics
55037|NCT02713698|Pharmacodynamics
55038|NCT02713698|Propofol pharmacokinetic-pharmacodynamic model
55039|NCT02713685|regional anesthesia
55040|NCT02713685|lower limb surgery
55041|NCT02713685|Bupivacaine
55042|NCT02713659|Literacy
55043|NCT02713659|Child Development
55044|NCT02713659|Reading
55045|NCT02713646|MRI
55046|NCT02713646|Virtual Endoscopy
55047|NCT02713646|Pain Measurement
55048|NCT02713620|HBV vaccination, immunity
55049|NCT02713581|Proximal venous thromboembolism
55050|NCT02713568|Macrosomia
55051|NCT02713568|Magnetic Resonance- Estimated Fetal Weight
55052|NCT02713568|Ultrasound-Estimated Fetal Weight
55053|NCT02713568|Large-for-date fetus
55054|NCT02713529|Solid Tumor
55055|NCT02713529|Pancreatic Cancer
55056|NCT02713529|Colorectal Cancer
55057|NCT02713529|Non-Small Cell Lung Cancer
55058|NCT02713516|Anxiety
55059|NCT02713516|OCD
55060|NCT02713516|Obsessive Compulsive Disorder
55061|NCT02713516|Generalized Anxiety
55062|NCT02713516|Social Phobia
55063|NCT02713516|Separation Anxiety
55064|NCT02713516|GAD
55065|NCT02713516|Youth
55066|NCT02713516|Teen
55067|NCT02713516|Therapy
55068|NCT02713451|Oxygen
55069|NCT02713438|Physical activity
55070|NCT02713438|Planning
55071|NCT02713438|Implementation intention
55072|NCT02713438|Quality of life
55073|NCT02713438|Body weight
55074|NCT02713425|Anxiety
55075|NCT02713425|Social Phobia
55076|NCT02713425|Separation Anxiety
55077|NCT02713425|Generalized Anxiety
55078|NCT02713425|GAD
55079|NCT02713425|Phobia
55080|NCT02713425|video game
55081|NCT02713425|teen
55082|NCT02713425|youth
55083|NCT02713425|child
55084|NCT02713425|adolescent
55085|NCT02713347|Quality of Life
55086|NCT02713347|Symptom Assessment
55087|NCT02713347|Palliative Care
55088|NCT02713347|Disease Management
55089|NCT02713347|Delivery of Health Care
55090|NCT02713347|Advance Care Planning
55091|NCT02713334|Decision Making
55092|NCT02713334|Communication
55093|NCT02713334|16-080
55094|NCT02713321|diabetes
55095|NCT02713321|vulnerable populations
55096|NCT02713321|comorbidity
55220|NCT02712463|Oral antipsychotics
55097|NCT02713321|patient-centered outcomes research
55098|NCT02713321|Medicaid reform
55099|NCT02713321|health disparities
55100|NCT02713295|Moderate Plaque Psoriasis
55101|NCT02713295|Plaque Psoriasis
55102|NCT02713295|Severe Plaque Psoriasis
55103|NCT02713282|Schizophrenia
55104|NCT02713282|R092670
55105|NCT02713282|Paliperidone Palmitate
55106|NCT02713269|Secondary Malignant Neoplasm of Vertebral Column
55107|NCT02713269|Spine Metastases
55108|NCT02713269|Epidural spinal cord compression
55109|NCT02713269|Stereotactic spine radiosurgery
55110|NCT02713269|SSRS
55111|NCT02713269|Thermal ablation
55112|NCT02713269|Symptom questionnaire
55113|NCT02713269|Surveys
55114|NCT02713256|Graves' disease
55115|NCT02713256|Hyperthyroidism
55116|NCT02713256|CFZ533
55117|NCT02713256|TSH
55118|NCT02713243|Primary bile acid diarrhea,
55119|NCT02713243|FXR agonist,
55120|NCT02713243|bile acid malabsorption.
55121|NCT02713217|depressive disorder
55122|NCT02713217|alcohol-related disorders
55123|NCT02713217|telemedicine
55124|NCT02713217|rural health
55125|NCT02713217|collaborative care
55126|NCT02713191|Bronchoscopy
55127|NCT02713191|Sedation
55128|NCT02713191|Dexmedetomidine
55129|NCT02713165|Gut Microbiota
55130|NCT02713139|vaginal
55131|NCT02713139|discharge
55132|NCT02713139|women
55133|NCT02713048|Cardiac arrest
55134|NCT02713048|Troponin I
55135|NCT02713048|coronary anatomy
55136|NCT02713022|DEXA Scan
55137|NCT02713022|15-235
55138|NCT02713009|Maternal body weight
55139|NCT02713009|Vitamin D
55140|NCT02713009|Pregnancy
55141|NCT02712996|Traumatic Brain Injury
55142|NCT02712996|Attention Deficit
55143|NCT02712996|TBI
55144|NCT02712996|Vyvanse
55145|NCT02712983|Inhaled tobramycin; tobramycin inhalation powder; bronchiectasis; pulmonary Pseudomonas aeruginosa infection; dose-finding study
55146|NCT02712918|Depression
55147|NCT02712918|Inpatient
55148|NCT02712918|Acute
55149|NCT02712918|Brief Behavioral Activation Treatment for Depression
55150|NCT02712905|Acute myeloid leukemia (AML)
55151|NCT02712905|myelodysplastic syndrome (MDS)
55152|NCT02712905|small cell lung cancer (SCLC)
55153|NCT02712905|myelofibrosis (MF)
55154|NCT02712905|solid tumor, lysine-specific demethylase 1 (LSD1) inhibitor
55155|NCT02712840|Single embryo transfer
55156|NCT02712840|Freeze-all
55157|NCT02712840|Fresh
55158|NCT02712840|Vitrification
55159|NCT02712840|Clinical Pregnancy
55160|NCT02712840|Blastocyst
55161|NCT02712827|self-gripping mesh, fibrin glue, total extraperitoneal
55162|NCT02712801|HIV
55163|NCT02712801|antiretroviral treatment
55164|NCT02712801|child
55165|NCT02712801|testing
55166|NCT02712788|Subarachnoid Hemorrhage
55167|NCT02712788|Cerebral Vasospasm
55168|NCT02712788|Milrinone
55169|NCT02712788|Hyperdynamic Therapy
55170|NCT02712762|immunological profiles
55171|NCT02712749|Binaural Beat
55172|NCT02712749|Elderly
55173|NCT02712749|preoperative medication
55174|NCT02712736|Primary Sclerosing Cholangitis
55175|NCT02712723|ER+, HER2-negative breast cancer
55176|NCT02712723|Stage II or III
55177|NCT02712723|Letrozole
55178|NCT02712723|Femara
55179|NCT02712723|Ribociclib
55180|NCT02712723|LEE011
55181|NCT02712723|Neo-adjuvant
55182|NCT02712710|knee, osteoarthritis, brace
55183|NCT02712697|liver-kidney yin deficiency syndrome
55184|NCT02712697|primary severe IgA nephropathy
55185|NCT02712697|Lee's grade Ⅲ
55186|NCT02712671|Cost-Benefit Analysis
55187|NCT02712671|Quality of Life
55188|NCT02712593|Healthy participants
55189|NCT02712593|Dietary supplement
55190|NCT02712593|Bioavailability
55191|NCT02712593|Niagen™
55192|NCT02712593|Nicotinamide riboside
55193|NCT02712593|N-methylnicotinamide
55194|NCT02712580|pediatric burns
55195|NCT02712580|deep dermal wounds
55196|NCT02712580|wound healing
55197|NCT02712580|ChildPain Measurement
55198|NCT02712580|Treatment Outcome Wound Healing/physiology
55199|NCT02712580|wireless electric stimulation
55200|NCT02712580|wireless current stimulation
55201|NCT02712580|wireless technology
55202|NCT02712580|children
55203|NCT02712580|conservative treatment
55204|NCT02712580|deep dermal scalds
55205|NCT02712580|humans
55206|NCT02712580|deep dermal burns
55207|NCT02712580|burns
55208|NCT02712580|wound healing process
55209|NCT02712554|Pain
55210|NCT02712554|Nausea
55211|NCT02712554|Vomiting
55212|NCT02712541|Caregiver burden Index
55213|NCT02712489|HAART-treated participants
55214|NCT02712489|Tat
55215|NCT02712489|Therapeutic immunization
55216|NCT02712476|Mannitol
55217|NCT02712476|Furosemid
55218|NCT02712476|Brain Relaxation
55219|NCT02712463|Schizophrenia
55221|NCT02712463|Long acting Injectable antipsychotics
55222|NCT02712450|geriatric
55223|NCT02712450|emergency
55224|NCT02712450|clinical pathway
55225|NCT02712450|regulation
55226|NCT02712450|SAMU
55227|NCT02712450|training
55228|NCT02712437|Insomnia
55229|NCT02712437|Quality of Life
55230|NCT02712437|Cognitive behavioral therapy
55231|NCT02712424|Vaccine
55232|NCT02712372|AZD4831 oral suspension
55233|NCT02712372|Healthy male subjects
55234|NCT02712372|Safety
55235|NCT02712372|Tolerability
55236|NCT02712372|Pharmacokinetics
55237|NCT02712372|Pharmacodynamics
55238|NCT02712359|Havrix
55239|NCT02712359|Cross-sectional seroprevalence survey
55240|NCT02712359|Panama
55241|NCT02712359|Long-term persistence
55242|NCT02712359|Hepatitis
55243|NCT02712346|Sickle Cell Anemia
55244|NCT02712346|Sickle Cell Thalassemia
55245|NCT02712346|Sickle Beta Thalassemia
55246|NCT02712346|Proteinuria
55247|NCT02712346|Sickle nephropathy
55248|NCT02712333|PM2.5
55249|NCT02712333|air purification
55250|NCT02712333|randomized controlled trial
55251|NCT02712333|metabolomics
55252|NCT02712333|Metabolites
55253|NCT02712333|exhaled nitric oxide
55254|NCT02712320|Prostate Neoplasm Cancer Carcinoma
55255|NCT02712320|Safety Extension
55256|NCT02712294|pulmonary hypertension
55257|NCT02712294|peripheral muscle electrostimulation
55258|NCT02712294|capacity of the exercises
55259|NCT02712294|quality of life
55260|NCT02712281|Food Selectivity
55261|NCT02712281|Autism MEAL Plan
55262|NCT02712281|Parent Education
55263|NCT02712268|Polypharmacy
55264|NCT02712268|Clinical decision-making
55265|NCT02712255|Physical activity
55266|NCT02712255|Quality of life
55267|NCT02712255|Planning
55268|NCT02712255|Implementation intentions
55269|NCT02712255|Cardiovascular disease
55270|NCT02712255|Diabetes
55271|NCT02712203|Measles vaccine
55272|NCT02712203|Priorix
55273|NCT02712203|Priorix-Tetra
55274|NCT02712203|Age at vaccination
55275|NCT02712177|vaccine safety
55276|NCT02712177|interaction
55277|NCT02712164|Split-thickness skin graft
55278|NCT02712164|STSG
55279|NCT02712164|donor site
55280|NCT02712164|negative-pressure wound therapy
55281|NCT02712164|NPWT
55282|NCT02712164|dressing
55283|NCT02712151|transversus abdominal plane block
55284|NCT02712138|Hyperbilirubinemia
55285|NCT02712138|Unconjugated Benign Bilirubinemia
55286|NCT02712060|Ehlers-Danlos Syndrome
55287|NCT02712060|Obstructive Sleep Apnea
55288|NCT02712060|Prevalence
55289|NCT02712060|Children
55290|NCT02712060|Pediatric
55291|NCT02712060|Adolescents
55292|NCT02712047|Fluticasone furoate/vilanterol
55293|NCT02712047|Asthma
55294|NCT02712047|fraction of exhaled nitric oxide
55295|NCT02712047|cross-over
55296|NCT02712034|Medication-assisted treatment (MAT)
55297|NCT02712034|Buprenorphine
55298|NCT02712034|Methadone
55299|NCT02712034|Naltrexone
55300|NCT02712021|Cerebral Palsy
55301|NCT02712021|Lycra
55302|NCT02712021|Motor Function
55303|NCT02712021|Static Balance
55304|NCT02711995|botulinum toxin
55305|NCT02711995|injection augmentation
55306|NCT02711995|essential voice tremor
55307|NCT02711956|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
55308|NCT02711956|Phase 1b
55309|NCT02711956|Prostate Cancer
55310|NCT02711956|Pharmacokinetics (PK)
55311|NCT02711956|ZEN003694
55312|NCT02711956|ZEN-3694
55313|NCT02711956|Metastatic Castrate-Resistant Prostate Cancer
55314|NCT02711956|BET inhibitor (BETi)
55315|NCT02711956|Bromodomain
55316|NCT02711956|Pharmacodynamics (PD)
55317|NCT02711956|Enzalutamide
55318|NCT02711956|XTANDI
55319|NCT02711956|MDV3100
55320|NCT02711956|Epigenetics
55321|NCT02711930|intra-ocular pressure
55322|NCT02711930|prone ventilation
55323|NCT02711917|Propofol
55324|NCT02711917|Sevoflurane
55325|NCT02711917|Etomidate
55326|NCT02711917|Rocuronium
55327|NCT02711917|BIS
55328|NCT02711917|Closed loop infusion system
55329|NCT02711904|Extubation
55330|NCT02711904|Cough
55331|NCT02711904|Target Controlled Anesthesia (TACAN)
55332|NCT02711891|fingerstick
55333|NCT02711891|opioid
55334|NCT02711891|heelstick
55335|NCT02711891|loperamide
55336|NCT02711891|topical opioid
55337|NCT02711826|graft inflammation
55338|NCT02711826|Treg
55339|NCT02711826|polyclonally expanded Tregs (polyTregs)
55340|NCT02711826|darTregs
55341|NCT02711826|calcineurin inhibitors (CNIs)
55342|NCT02711826|mTOR inhibitors
55343|NCT02711787|Hand
55344|NCT02711787|Paralysis
55345|NCT02711787|Stroke
55346|NCT02711722|Neurally adjusted ventilatory assist
55347|NCT02711709|Intra-abdominal sepsis
55348|NCT02711709|Surgical ICU
55349|NCT02711696|Celiac Disease,
55350|NCT02711696|Gluten Free Diet
55351|NCT02711696|Gluten contamination
55352|NCT02711670|nephrolithiasis
55353|NCT02711670|calcium stones
55354|NCT02711670|kidney stones
55355|NCT02711670|hypercalciuria
55356|NCT02711670|thiazide
55357|NCT02711657|Fibrocytes
55358|NCT02711657|Interstitial Lung Diseases
55359|NCT02711657|Rheumatoid Arthritis
55360|NCT02711657|Asthma
55361|NCT02711644|Pregnancy
55362|NCT02711644|Prenatal
55363|NCT02711644|Nutrition
55364|NCT02711631|coronary angioplasty
55365|NCT02711631|cardiac rehabilitation
55366|NCT02711631|coronary artery bypass graft
55367|NCT02711605|ultrasound
55368|NCT02711605|fat
55369|NCT02711592|Orthopaedic Pain Management
55370|NCT02711566|Rehabilitation
55371|NCT02711566|Robot-assisted therapy
55372|NCT02711501|post-operative pain
55373|NCT02711501|diode laser
55374|NCT02711488|school-based intervention
55375|NCT02711488|sedentary behavior
55376|NCT02711488|physical activity
55377|NCT02711488|sugar sweetened beverages
55378|NCT02711462|Healthy Subjects
55379|NCT02711449|acute surgery
55380|NCT02711449|laparoscopy
55381|NCT02711371|addiction
55382|NCT02711371|cannabis
55383|NCT02711371|fMRI
55384|NCT02711345|LTT462
55385|NCT02711345|ERK
55386|NCT02711345|MAPK
55387|NCT02711345|solid tumor
55388|NCT02711267|Open Flow Microperfusion
55389|NCT02711241|Gastroenteritis
55390|NCT02711241|Analgesia
55391|NCT02711241|Emergency department
55392|NCT02711189|Addiction
55393|NCT02711189|Oxytocin
55394|NCT02711189|Functional Magnetic Resonance Imaging (fMRI)
55395|NCT02711189|Alcohol
55396|NCT02711189|Cue Reactivity
55397|NCT02711137|Solid tumor
55398|NCT02711137|lymphoma
55399|NCT02711137|leukemia
55400|NCT02711137|AML
55401|NCT02711137|myelodysplastic syndrome (MDS)
55402|NCT02711137|multiple myeloma
55403|NCT02711137|myeloproliferative neoplasm (MPN)
55404|NCT02711137|MDS/MPN
55405|NCT02711137|myelofibrosis (MF)
55406|NCT02711137|pancreatic cancer
55407|NCT02711137|colorectal cancer
55408|NCT02711137|non-small cell lung cancer
55409|NCT02711137|prostate cancer
55410|NCT02711137|breast cancer
55411|NCT02711137|ovarian cancer
55412|NCT02711137|glioblastoma multiforme (GBM)
55413|NCT02711137|NUT midline carcinoma
55414|NCT02711137|non-Hodgkin lymphoma
55415|NCT02711137|diffuse large B-cell lymphoma (DLBCL)
55416|NCT02711137|double-hit
55417|NCT02711137|triple-hit
55418|NCT02711137|myc
55419|NCT02711137|bromodomain and extra-terminal (BET) inhibitor
55420|NCT02711124|hemoglobin A1c
55421|NCT02711124|coronary artery bypass grafting
55422|NCT02711124|impedance aggregometry
55423|NCT02711124|platelet reactivity
55424|NCT02711124|clinical outcomes
55425|NCT02711098|cardiac arrest
55426|NCT02711098|hypothermia
55427|NCT02711098|critical care
55428|NCT02711059|hyperparathyroidism
55429|NCT02711059|insulin resistance
55430|NCT02711020|Depressive symptoms
55431|NCT02711020|Fibromyalgia
55432|NCT02711020|Cognitive Behavioral Therapy
55433|NCT02711020|Personal Constructs Therapy
55434|NCT02711020|Differential Efficacy
55435|NCT02711007|osteosarcoma
55436|NCT02711007|metastasis
55437|NCT02711007|advanced
55438|NCT02711007|apatinib
55439|NCT02710994|Immediate release omeprazole
55440|NCT02710994|Integrated gastric acidity
55441|NCT02710981|Sildenafil vaginal gel
55442|NCT02710981|endometrium
55443|NCT02710981|clomiphene
55444|NCT02710981|anovulation
55445|NCT02710968|FETO
55446|NCT02710916|Optical Coherence Tomography
55447|NCT02710916|Intraocular pressure
55448|NCT02710916|Optic Nerve Head
55449|NCT02710916|Nerve fiber layer
55450|NCT02710916|Bruch Membrane Opening -Minimum Rim Width
55451|NCT02710903|Periodontitis
55452|NCT02710903|SNP
55453|NCT02710903|Pathogenesis
55454|NCT02710903|IL29
55455|NCT02710903|IL28B
55456|NCT02710890|Epilepsy
55457|NCT02710890|pediatric
55458|NCT02710890|intravenous
55459|NCT02710890|children
55460|NCT02710890|Lacosamide
55461|NCT02710890|VIMPAT®
55462|NCT02710890|seizure
55463|NCT02710877|epidural analgesia
55464|NCT02710877|patient controlled analgesia
55465|NCT02710877|obstetric outcome
55466|NCT02710864|Cytomegalovirus
55467|NCT02710851|human papillomavirus vaccine
55468|NCT02710851|condylomata acuminata
55469|NCT02710838|Early gastric cancer
55470|NCT02710838|Infrared endoscope
55471|NCT02710799|Endocrinology
55472|NCT02710799|Referral list
55473|NCT02710799|Teleconsultation
55474|NCT02710799|Telemedicine
55475|NCT02710799|Cluster randomized clinical trial
55476|NCT02710773|Gait
55477|NCT02710773|Randomized controlled trial
55478|NCT02710773|Chronic Stroke
55479|NCT02710773|Treadmill training
55480|NCT02710760|Biomarkers
55481|NCT02710760|Child Nutrition Sciences
55482|NCT02710760|Economics, Behavioral
55483|NCT02710747|warfarin
55484|NCT02710747|Chinese patients
55485|NCT02710747|heart valve replacement
55486|NCT02710734|Urothelial
55487|NCT02710721|Fasting
55488|NCT02710721|Prostatic Neoplasms
55489|NCT02710721|Complementary Therapies
55490|NCT02710721|Urology
55491|NCT02710708|birth control,
55492|NCT02710708|contraceptives safety,
55493|NCT02710708|contraceptives efficacy,
55494|NCT02710708|moderate acne vulgaris
55495|NCT02710682|Lateral Epicondylitis of the elbow
55496|NCT02710682|Tendon Fenestration
55497|NCT02710682|Minimally invasive Surgery
55498|NCT02710682|Ultrasound-guided procedure
55499|NCT02710682|Ultrasonography
55500|NCT02710682|Elastography
55501|NCT02710669|ablation
55502|NCT02710656|Atherosclerosis
55503|NCT02710656|SFA
55504|NCT02710656|Poplitea
55505|NCT02710656|Drug coated balloon
55506|NCT02710656|Angioplasty
55507|NCT02710656|Restenosis
55508|NCT02710656|Peripheral artery disease (PAD)
55509|NCT02710643|Follicular
55510|NCT02710643|Lymphoma
55511|NCT02710643|Grade 1
55512|NCT02710643|Grade 2
55513|NCT02710604|chronic hepatitis B(CHB)
55514|NCT02710591|Rimeporide
55515|NCT02710578|Alcohol impaired driving
55516|NCT02710578|Driving simulation
55517|NCT02710578|Residual effects of alcohol
55518|NCT02710578|Acute psychomotor effects of alcohol
55519|NCT02710578|Young drivers
55520|NCT02710565|Endo bronchial ultrasound
55521|NCT02710565|Trans bronchial needle aspiration
55522|NCT02710565|Cell line
55523|NCT02710565|Lung cancer
55524|NCT02710552|arterial hypertension
55525|NCT02710552|antihypertensive drugs
55526|NCT02710539|arterial hypertension
55527|NCT02710539|antihypertensive drugs
55528|NCT02710513|beta-glucans
55529|NCT02710513|gut microbiota
55530|NCT02710513|p-cresyl sulphate (pCS)
55531|NCT02710513|indoxyl sulphate (IS)
55532|NCT02710513|short-chain fatty acid (SCFA)
55533|NCT02710500|LGMD2B
55534|NCT02710500|Limb Girdle Muscular Dystrophy
55535|NCT02710500|Miyoshi
55536|NCT02710500|Gene Transfer
55537|NCT02710500|Dysferlin
55538|NCT02710487|Parkinson's disease, Sleep Benefit
55539|NCT02710474|preterm birth
55540|NCT02710474|NICU
55541|NCT02710474|neonatal
55542|NCT02710474|kangaroo care
55543|NCT02710474|separation stress
55544|NCT02710474|family nurture
55545|NCT02710474|maternal confidence
55546|NCT02710474|maternal competence
55547|NCT02710474|calming cycle
55548|NCT02710474|infant neurodevelopment
55549|NCT02710474|infant psychological development
55550|NCT02710474|mother-infant co-regulation
55551|NCT02710474|post-partum depression
55552|NCT02710461|Polyphenols
55553|NCT02710461|Grape
55554|NCT02710461|Pomegranate
55555|NCT02710461|Metabolic syndrome
55556|NCT02710461|Abdominal obesity
55557|NCT02710461|Postprandial glucose
55558|NCT02710461|Insulin resistance
55559|NCT02710435|Coronary Sinus
55560|NCT02710435|Reducer
55561|NCT02710435|Refractory Angina
55562|NCT02710435|Angina Pectoris
55563|NCT02710435|Angina Pectoris, Stable
55564|NCT02710435|Chronic Stable Angina
55565|NCT02710435|Persistent Angina
55566|NCT02710435|Neovasc Reducer System
55567|NCT02710435|Refractory Angina Pectoris
55568|NCT02710435|Coronary Sinus Narrowing
55569|NCT02710435|Reversible Ischemic Heart Disease
55570|NCT02710435|Chronic Angina
55571|NCT02710435|End Stage Angina
55572|NCT02710435|Coronary Sinus Reduction
55573|NCT02710435|Coronary Sinus Reducer
55574|NCT02710435|Chronic Refractory Angina
55575|NCT02710435|Chronic Refractory Angina Pectoris
55576|NCT02710422|Prostate Cancer
55577|NCT02710422|Amniotic Membrane Placement
55578|NCT02710422|Robotic Assisted Radical Prostatectomy
55579|NCT02710422|RARP
55580|NCT02710422|Human Amniotic Membrane Allograft
55581|NCT02710409|safety, immunogenicity , quadrivalent influenza vaccine
55582|NCT02710396|Carcinoma, Non-Small-Cell Lung
55583|NCT02710396|Non-Small Cell Lung Cancer
55584|NCT02710396|Non-Small-Cell Lung Carcinoma
55585|NCT02710396|Nonsmall Cell Lung Cancer
55586|NCT02710396|NSCLC
55587|NCT02710396|Cancer of Neck
55588|NCT02710396|Neoplasms, Head and Neck
55589|NCT02710396|Cancer of the Head
55590|NCT02710396|Cancer of the Head and Neck
55591|NCT02710396|Head, Neck Neoplasms
55592|NCT02710396|Bladder Cancer
55593|NCT02710396|Bladder Neoplasms
55594|NCT02710396|Malignant Tumor of Urinary Bladder
55595|NCT02710396|Urinary Bladder Cancer
55596|NCT02710396|Esophageal Squamous Cell Carcinoma
55597|NCT02710396|Carcinoma, Transitional Cell
55598|NCT02710370|Bariatric Surgery
55599|NCT02710370|Gastric Bypass
55600|NCT02710370|Obesity/surgery
55601|NCT02710370|Endoscopy, Digestive System
55602|NCT02710370|Blood Glucose/metabolism
55603|NCT02710370|Diabetes Mellitus, Experimental/metabolism
55604|NCT02710370|Energy Metabolism
55605|NCT02710370|Glucose/metabolism
55606|NCT02710370|Jejunum/metabolism
55607|NCT02710370|Metabolomics
55608|NCT02710370|Gene Expression
55609|NCT02710357|Mandibular Prosthesis Implantation
55610|NCT02710357|Prostheses and Implants
55611|NCT02710357|Denture, Complete, Lower
55612|NCT02710279|Psychiatry
55613|NCT02710279|Depressive disorder
55614|NCT02710279|Suicide
55615|NCT02710266|Synthetic Protease Inhibitor
55616|NCT02710266|Hepatectomy
55617|NCT02710266|Postoperative Complications
55618|NCT02710253|Metastatic cancer
55619|NCT02710253|Prior treatment with immunotherapy agent
55620|NCT02710253|Salvage radiation therapy
55621|NCT02710253|Radiation therapy
55622|NCT02710253|XRT
55623|NCT02710253|Progressive disease
55624|NCT02710253|PD
55625|NCT02710253|Stereotactic radiation
55626|NCT02710253|External beam radiation
55627|NCT02710253|Whole brain radiation therapy
55628|NCT02710253|WBRT
55629|NCT02710214|Hot flash
55630|NCT02710214|Estrogen
55631|NCT02710214|Women
55632|NCT02710149|CAR-T
55633|NCT02710149|Leukemia
55634|NCT02710149|Lymphoma
55635|NCT02710136|Asthma
55636|NCT02710136|Glycerinated German cockroach allergenic extract
55637|NCT02710136|Cockroach Nasal Allergen Challenge
55638|NCT02710058|support group
55639|NCT02710058|15-246
55640|NCT02710058|The Arab American Breast Cancer Education and Referral Program (AMBER)
55641|NCT02710045|Immunity, Innate
55642|NCT02710045|Immunity, Non-Specific
55643|NCT02710045|Transcriptome
55644|NCT02710045|Antibodies
55645|NCT02710045|Cytokines
55646|NCT02710045|Immunity, Cellular
55647|NCT02710032|Transgender women
55648|NCT02710032|HIV Pre-Exposure Prophylaxis
55649|NCT02710032|Adherence
55650|NCT02710032|Peru
55651|NCT02710032|Social Networks
55652|NCT02710019|substance use
55653|NCT02710019|psychosis
55654|NCT02710019|youth
55655|NCT02710019|video game
55656|NCT02710006|Uterus
55657|NCT02710006|Ultrasound
55658|NCT02709980|Brain Injury
55659|NCT02709980|Insomnia
55660|NCT02709980|Sleep
55661|NCT02709941|Obstructive Sleep Apnea
55662|NCT02709941|Inspiratory Muscle Strength Training
55663|NCT02709941|Baroreceptor Sensitivity
55664|NCT02709941|Blood Pressure
55665|NCT02709928|Multiple ascending dose
55666|NCT02709850|ANGPTL-3
55667|NCT02709837|bioavailability
55668|NCT02709837|amino acid
55669|NCT02709837|carnosine
55670|NCT02709837|lycopene
55671|NCT02709837|mastication
55672|NCT02709837|meat
55673|NCT02709798|Shenfu Injection
55674|NCT02709798|Reperfusion Injury
55675|NCT02709798|Myocardial Protection
55676|NCT02709798|Percutaneous Coronary Intervention
55677|NCT02709746|paediatric patients
55678|NCT02709733|Virtual Reality
55679|NCT02709733|Negative Symptoms
55680|NCT02709720|Lung Cancer
55681|NCT02709720|Cancer Lung Disease
55682|NCT02709720|NORA
55683|NCT02709720|GECP 15/02
55684|NCT02709720|Metronomic administration
55685|NCT02709707|Diabetes, Blood Sugar
55686|NCT02709681|Sickle Cell Disease
55687|NCT02709681|Hydroxyurea
55688|NCT02709668|MTHFR depression vitamins Homocysteine
55689|NCT02709655|paediatric
55690|NCT02709616|Glioblastoma
55691|NCT02709616|DC vaccine
55692|NCT02709616|tumor antigen
55693|NCT02709616|personalized vaccine
55694|NCT02709551|corporate health management
55695|NCT02709551|hrv
55696|NCT02709551|mindfulness
55697|NCT02709525|hyaluronic acid
55698|NCT02709525|bone repair
55699|NCT02709525|dental socket
55700|NCT02709525|cone beam computed tomography
55701|NCT02709512|Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression
55702|NCT02709486|Osteoarthritis, pain, tanezumab.
55703|NCT02709473|propofol
55704|NCT02709473|remifentanil
55705|NCT02709473|rocuronium
55706|NCT02709460|hematoma
55707|NCT02709460|complication
55708|NCT02709460|hysterectomy
55709|NCT02709447|Intimate Partner Violence
55710|NCT02709447|Juvenile Delinquency
55711|NCT02709447|Sexual Behavior
55712|NCT02709421|post-Endoscopic Retrograde cholangiopancreatography pancreatitis
55713|NCT02709421|Risk factors
55714|NCT02709421|Indomethacin
55715|NCT02709408|Carbapenem resistance
55716|NCT02709408|Enterobacteriaceae
55717|NCT02709408|Acinetobacter baumannii
55718|NCT02709408|Bloodstream infections
55719|NCT02709408|Intrabdominal infections
55720|NCT02709408|Urinary tract infections
55721|NCT02709408|Pneumonia
55722|NCT02709408|Risk factors
55723|NCT02709408|Outcome
55724|NCT02709408|Hospitalised patients
55725|NCT02709408|Mortality
55726|NCT02709408|Clinical response
55727|NCT02709408|Length of hospital stay
55728|NCT02709369|HIRREM
55729|NCT02709369|Neuro-technology
55730|NCT02709369|Closed-loop
55731|NCT02709369|Acoustic stimulation
55732|NCT02709369|Allostatic
55733|NCT02709369|heart rate variability
55734|NCT02709369|baroreflex sensitivity
55735|NCT02709369|traumatic brain injury
55736|NCT02709369|sports concussion
55737|NCT02709369|PTSD
55738|NCT02709369|hot flashes
55739|NCT02709369|headache
55740|NCT02709369|insomnia
55741|NCT02709304|urinary catheter discomfort
55742|NCT02709278|BCG
55743|NCT02709278|Aerosol
55744|NCT02709278|Tuberculosis
55745|NCT02709278|Challenge
55746|NCT02709226|Brain Tumor
55747|NCT02709226|Astrocytoma
55748|NCT02709226|GBM
55749|NCT02709226|Radiation Therapy
55750|NCT02709187|DP-R208
55751|NCT02709174|Pulmonary Embolism
55752|NCT02709174|Pregnancy
55753|NCT02709174|D-Dimer
55754|NCT02709161|neurofeedback
55755|NCT02709161|major depressive disorder
55756|NCT02709161|amygdala
55757|NCT02709148|Parkinson's Disease
55758|NCT02709070|highly-purified CTL
55759|NCT02709044|Acute pancreatitis
55760|NCT02709044|Fluid resuscitation
55761|NCT02709044|Crystalloids
55762|NCT02709031|Cicletanine
55763|NCT02709031|Magnesium
55764|NCT02709031|Metabolic disease
55765|NCT02709018|posttraumatic stress disorder
55766|NCT02709018|losartan
55767|NCT02709018|angiotensin receptor blocker
55768|NCT02709005|Bacterial Vaginosis
55769|NCT02709005|Monolaurin Vaginal Gel
55770|NCT02708992|Azithromycin
55771|NCT02708992|Cefixime
55772|NCT02708992|Duration
55773|NCT02708992|High-Dose
55774|NCT02708992|Neisseria gonorrhoeae
55775|NCT02708992|Pharmacokinetics
55776|NCT02708992|Susceptibility
55777|NCT02708979|Stress
55778|NCT02708979|Eating
55779|NCT02708966|Gymnema Sylvestre
55780|NCT02708966|Glycemic control
55781|NCT02708927|social integration
55782|NCT02708927|cognitive impairment
55783|NCT02708927|emotional processing
55784|NCT02708927|quality of life
55785|NCT02708901|Autism Spectrum Disorder
55786|NCT02708901|Probiotic Vivomixx®
55787|NCT02708901|Gastrointestinal Symptoms
55788|NCT02708901|Gut-Brain Axis
55789|NCT02708901|Endophenotypes
55790|NCT02708888|Trunk
55791|NCT02708888|Biomechanical Phenomena
55792|NCT02708888|Gait
55793|NCT02708888|Electromyography
55794|NCT02708888|Rehabilitation
55795|NCT02708888|Balance
55796|NCT02708875|Microvascular
55797|NCT02708875|Insulin resistance
55798|NCT02708875|Mixed Meal
55799|NCT02708875|Glucose tolerance
55800|NCT02708823|Postoperative delirium
55801|NCT02708823|Risk assessment
55802|NCT02708823|Clinical screening tool
55803|NCT02708823|Tablet computer
55804|NCT02708810|radiosurgery (RS)
55805|NCT02708810|trigeminal neuralgia (TGN)
55806|NCT02708797|Cerebral autoregulation
55807|NCT02708797|MRI
55808|NCT02708797|VBM
55809|NCT02708797|Doppler Transcranial
55810|NCT02708784|Glykogen storage disease type 2)
55811|NCT02708784|Dystrophia Myotonica
55812|NCT02708784|Muscular disorders
55813|NCT02708784|MR-imaging
55814|NCT02708784|Muscle strength
55815|NCT02708784|Myopathies
55816|NCT02708745|communication
55817|NCT02708745|immunization
55818|NCT02708719|COPD
55819|NCT02708719|MID
55820|NCT02708719|1-minute sit-to-stand-test
55821|NCT02708706|adhesive capsulitis
55822|NCT02708706|hyaluronic acid
55823|NCT02708667|non-small cell lung cancer
55824|NCT02708667|crizotinib
55825|NCT02708667|hepatic toxicity
55826|NCT02708654|Remote monitoring
55827|NCT02708654|Incentives
55828|NCT02708628|scar prevention
55829|NCT02708628|sectio
55830|NCT02708628|extract of allium cepae
55831|NCT02708628|allantoin
55832|NCT02708628|heparin
55833|NCT02708602|β2-adrenergic receptor
55834|NCT02708602|genetic polymorphisms
55835|NCT02708602|labor progress
55836|NCT02708563|meconium
55837|NCT02708563|neonatal resuscitation
55838|NCT02708498|Palliative care
55839|NCT02708498|Frail elderly
55840|NCT02708498|Comorbidity
55841|NCT02708498|Staff Development
55842|NCT02708498|Nursing Homes
55843|NCT02708472|Generalized Anxiety Disorder
55844|NCT02708472|synchronized Transcranial Magnetic Stimulation
55845|NCT02708472|Anxiety
55846|NCT02708472|Neurostimulation
55847|NCT02708472|TMS
55848|NCT02708446|Second Trimester
55849|NCT02708446|Abortion
55850|NCT02708446|Misoprostol
55851|NCT02708446|Sublingual
55852|NCT02708446|Buccal
55853|NCT02708433|lidocaine, jaw
55854|NCT02708420|Glidescope
55855|NCT02708420|Coronary Artery Bypass Graft Surgery
55856|NCT02708420|Macintosh Laryngoscope
55857|NCT02708420|Hemodynamic response
55858|NCT02708420|Anesthesia
55859|NCT02708381|Population 70 years and older
55860|NCT02708381|Geriatric
55861|NCT02708381|Oncogeriatric
55862|NCT02708381|Senior adult
55863|NCT02708368|Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
55864|NCT02708329|Coronary stenosis
55865|NCT02708329|Drug-eluting stent
55866|NCT02708329|Coronary angioplasty with stenting
55867|NCT02708329|Ischemic Heart Disease
55868|NCT02708329|Chronic total occlusion
55869|NCT02708329|Bifurcational lesion
55870|NCT02708329|Bifurcational stenting
55871|NCT02708303|Esophageal Reflux
55872|NCT02708303|Gastric Acid Reflux
55873|NCT02708303|Gastric Acid Reflux Disease
55874|NCT02708303|Gastro-Esophageal Reflux
55875|NCT02708303|Gastro-oesophageal Reflux
55876|NCT02708303|Gastroesophageal Reflux Disease
55877|NCT02708303|Reflux, Gastroesophageal
55878|NCT02708303|Esophageal Hernia
55879|NCT02708303|Hernia, Esophageal
55880|NCT02708303|Hernia, Paraesophageal
55881|NCT02708303|Hiatal Hernia
55882|NCT02708303|Sliding Hiatal Hernia
55883|NCT02708303|Sliding Esophageal Hernia
55884|NCT02708303|Hernia, Hiatus
55885|NCT02708303|Paraesophageal Hiatal Hernia
55886|NCT02708303|Questionnaires
55887|NCT02708277|intrauterine contraceptive device
55888|NCT02708277|intrauterine balloon
55889|NCT02708238|Infantile colics
55890|NCT02708199|Drug resistance malaria
55891|NCT02708199|Myanmar Artemisinin Resistance Containment Zone
55892|NCT02708199|Asymptomatic malaria
55893|NCT02708199|Serology
55894|NCT02708186|Dementia with Lewy bodies
55895|NCT02708186|Lewy bodies
55896|NCT02708186|REM sleep behavior disorder
55897|NCT02708173|vaccine
55898|NCT02708173|safety
55899|NCT02708134|Chest compressions
55900|NCT02708134|Cardiopulmonary Resuscitation
55901|NCT02708056|Sugammadex
55902|NCT02708056|Rocuronium
55903|NCT02708056|Infant patients
55904|NCT02708017|Subcostal TAP block
55905|NCT02708017|Posterior TAP block
55906|NCT02708017|Ultrasound
55907|NCT02708017|Laparoscopic cholecystectomy
55908|NCT02707991|Continuity of Patient Care
55909|NCT02707991|Treatment Cascade
55910|NCT02707978|Dementia
55911|NCT02707978|Brain Diseases
55912|NCT02707978|Central Nervous System Diseases
55913|NCT02707978|Mild Cognitive Impairment
55914|NCT02707978|tauopathies
55915|NCT02707978|Neurodegenerative Disease
55916|NCT02707965|Generic brittle
55917|NCT02707965|Anti-epileptic drug
55918|NCT02707965|Bioequivalence
55919|NCT02707952|Compensated cirrhosis
55920|NCT02707952|Hepatitis C Genotype 1
55921|NCT02707952|Hepatitis C Genotype 5
55922|NCT02707952|Non-cirrhotic
55923|NCT02707952|Hepatitis C virus
55924|NCT02707952|Hepatitis C Genotype 6
55925|NCT02707952|Hepatitis C Genotype 3
55926|NCT02707952|Hepatitis C Genotype 4
55927|NCT02707952|Renal impairment
55928|NCT02707952|Hepatitis C Genotype 2
55929|NCT02707952|Chronic Hepatitis C
55930|NCT02707900|Vorinostat
55931|NCT02707900|AGS-004
55932|NCT02707900|HIV virus
55933|NCT02707900|AIDS
55934|NCT02707887|Mental Disorders
55935|NCT02707887|Mood Disorders
55936|NCT02707887|Behavioral Activation
55937|NCT02707861|HIV
55938|NCT02707861|Resistant
55939|NCT02707861|Salvage
55940|NCT02707861|ibalizumab
55941|NCT02707861|antibody
55942|NCT02707861|AIDS
55943|NCT02707835|Edema,taping,ultrasound
55944|NCT02707822|tacrolimus
55945|NCT02707822|pharmacokinetics
55946|NCT02707822|gene polymorphism
55947|NCT02707822|clinical factors
55948|NCT02707796|oxygen reserve index, partial oxygen pressure, hemicolectomy
55949|NCT02707783|stable and unstable angina
55950|NCT02707783|bioresorbable vascular scaffold
55951|NCT02707783|BVS
55952|NCT02707783|PCI
55953|NCT02707770|COPD, pulmonary rehabilitation, ambulatory oxygen therapy
55954|NCT02707757|Haemodialysis
55955|NCT02707757|Anaemia
55956|NCT02707757|Iron
55957|NCT02707757|Erythropoeitin stimulating agents
55958|NCT02707744|Heart Failure
55959|NCT02707744|Atrial Fibrillation
55960|NCT02707744|Ambulatory ECG monitor
55961|NCT02707718|sepsis
55962|NCT02707718|biomarker
55963|NCT02707718|prognostic
55964|NCT02707718|emergency department
55965|NCT02707718|diagnosis
55966|NCT02707692|HIV
55967|NCT02707692|AIDS
55968|NCT02707692|Immune Stimulation
55969|NCT02707692|HIV Reservoir
55970|NCT02707679|Knee
55971|NCT02707679|Mobilization
55972|NCT02707679|Taping
55973|NCT02707679|Function
55974|NCT02707679|Balance
55975|NCT02707666|resectable malignant pleural mesothelioma
55976|NCT02707666|Pembrolizumab
55977|NCT02707627|Pediatric
55978|NCT02707627|Laser
55979|NCT02707627|Burn
55980|NCT02707627|Scar
55981|NCT02707627|Photothermolysis
55982|NCT02707601|HIV
55983|NCT02707601|HCV
55984|NCT02707601|Antiretroviral therapy
55985|NCT02707601|HCV direct acting antiviral(s) (DAA)
55986|NCT02707588|Determine the tolerance and efficacy of Pembrolizumab
55987|NCT02707575|Keratin
55988|NCT02707575|Ranibizumab
55989|NCT02707562|Cystic fibrosis G551D mutation
55990|NCT02707562|GLPG1837
55991|NCT02707549|crystalloid solutions
55992|NCT02707549|acid-base imbalance
55993|NCT02707549|water-electrolyte Imbalance
55994|NCT02707523|RSV
55995|NCT02707523|respiratory support
55996|NCT02707523|RSV induced respiratory failure
55997|NCT02707510|logotherapy
55998|NCT02707510|cognitive behavior therapy
55999|NCT02707510|metastatic breast cancer
56000|NCT02707497|sepsis
56001|NCT02707497|thrombocytopenia
56002|NCT02707497|recombinant human thrombopoietin
56003|NCT02707497|platelet
56004|NCT02707497|28-day mortality
56005|NCT02707484|Gastrointestinal vascular malformation
56006|NCT02707484|thalidomide
56007|NCT02707484|Small intestinal bleeding
56008|NCT02707458|apolipoprotein E
56009|NCT02707458|Alzheimer
56010|NCT02707458|pre-clinical
56011|NCT02707458|pre-symptomatic
56012|NCT02707458|dose-finding
56013|NCT02707458|prevention
56014|NCT02707432|Cardiovascular Diseases
56015|NCT02707432|Community-Based Participatory Research
56016|NCT02707432|African Americans
56017|NCT02707419|Total knee replacement
56018|NCT02707419|Action observation treatment
56019|NCT02707419|Rehabilitation
56020|NCT02707393|stem cell transplantation
56021|NCT02707393|pediatrics
56022|NCT02707354|GVHD
56023|NCT02707354|confocal endomicroscopy
56024|NCT02707341|psoriasis
56025|NCT02707341|disease registry
56026|NCT02707328|Gemcitabine
56027|NCT02707328|Gemzar
56028|NCT02707328|CyberKnife
56029|NCT02707328|Cyber knife
56030|NCT02707328|CK
56031|NCT02707328|abraxane
56032|NCT02707328|nab-paclitaxel
56033|NCT02707315|Cyber Knife
56034|NCT02707315|CyberKnife
56035|NCT02707315|Stereotactic Radiosurgery
56036|NCT02707315|CK
56037|NCT02707276|Bipolar Depression
56038|NCT02707276|Geriatric
56039|NCT02707276|Low Field Magnetic Stimulation
56040|NCT02707263|heparin
56041|NCT02707250|pethidine
56042|NCT02707250|laparoscopic cholecystectomy
56043|NCT02707250|bupivacaine
56044|NCT02707224|DP-R208
56045|NCT02707172|Diethylhexyl Phthalate
56046|NCT02707172|Hand hygiene
56047|NCT02707172|Soaps
56048|NCT02707172|N-of-1 design
56049|NCT02707172|Cross-Over Studies
56050|NCT02707159|Circulating tumor cells
56051|NCT02707159|Nab-paclitaxel
56052|NCT02707159|Metastatic pancreatic cancer
56053|NCT02707159|Gemcitabine
56054|NCT02707120|PRGF, Neurotrophic Keratitis, platelet rich plasma, PRP
56055|NCT02707094|back
56056|NCT02707094|pain
56057|NCT02707094|chronic
56058|NCT02707068|Quality of Life
56059|NCT02707068|Self-help intervention
56060|NCT02707055|Alcohol Consumption
56061|NCT02707055|Alcohol Treatment
56062|NCT02707055|Alcoholism
56063|NCT02707055|Ghrelin
56064|NCT02707055|Ghrelin Antagonism
56065|NCT02707042|Microbiome
56066|NCT02707042|Amoxicillin
56067|NCT02707042|Azithromycin
56068|NCT02707042|Metagenome
56069|NCT02707042|Metabolic
56070|NCT02707029|Screening Protocol
56071|NCT02707029|Pain
56072|NCT02707029|Phenotypes
56073|NCT02707016|Emergence delirium
56074|NCT02707016|Sevoflurane
56075|NCT02707016|Pediatric anesthesia
56076|NCT02707003|Post-operative respiratory distress
56077|NCT02706977|Ophthalmology
56078|NCT02706964|metastasis
56079|NCT02706964|3D imaging
56080|NCT02706964|early detection
56081|NCT02706951|Musculoskeletal Disease
56082|NCT02706951|anti-inflammatory agents
56083|NCT02706951|Arthritis
56084|NCT02706951|Joint Disease
56085|NCT02706951|antirheumatic agents
56086|NCT02706938|Gastroesophageal reflux disease
56087|NCT02706938|Head of bed elevation
56088|NCT02706938|Quality of life
56089|NCT02706938|Nocturnal symptoms
56090|NCT02706938|Lifestyle measures
56091|NCT02706912|Stroke
56092|NCT02706912|Hemiparesis
56093|NCT02706912|Activities of Daily Living
56094|NCT02706912|Virtual World
56095|NCT02706912|Occupational Therapy
56096|NCT02706899|Antibody-Drug Conjugate CD33 Antigen
56097|NCT02706886|PH1
56098|NCT02706886|Primary Hyperoxaluria
56099|NCT02706886|RNAi therapeutic
56100|NCT02706886|siRNA
56101|NCT02706886|AGT
56102|NCT02706873|Musculoskeletal disease
56103|NCT02706873|Anti-inflammatory agents
56104|NCT02706873|Arthritis
56105|NCT02706873|Joint disease
56106|NCT02706873|Antirheumatic agents
56107|NCT02706847|Antirheumatic agents
56108|NCT02706847|Anti-inflammatory agents
56109|NCT02706847|Musculoskeletal Disease
56110|NCT02706847|Joint Disease
56111|NCT02706847|Arthritis
56112|NCT02706834|Drug therapy
56113|NCT02706821|prediabetes
56114|NCT02706821|blood glucose
56115|NCT02706821|clinical trial
56116|NCT02706808|chronic kidney disease
56117|NCT02706808|hemodialysis
56118|NCT02706808|conservative treatment
56119|NCT02706808|resistance starch
56120|NCT02706795|Cervical dystonia
56121|NCT02706795|Spasmodic torticollis
56122|NCT02706704|Intravitreal Adalimumab
56123|NCT02706704|Subcutaneous Adalimumab
56124|NCT02706691|BGJ398
56125|NCT02706691|FGFR1-3
56126|NCT02706691|HNSCC (head and neck squamous cell carcinoma)
56127|NCT02706678|Renal transplant recipients
56128|NCT02706678|FK506
56129|NCT02706678|cyclosporin
56130|NCT02706665|Anesthetics
56131|NCT02706665|Propofol
56132|NCT02706665|Electroencephalography
56133|NCT02706665|SEDline monitor
56134|NCT02706652|Screening
56135|NCT02706652|Genotype
56136|NCT02706652|Drug Dosing
56137|NCT02706652|Trial Selection
56138|NCT02706639|Biospecimen Procurement
56139|NCT02706639|Laboratory Research Specimens
56140|NCT02706639|Sample Collection
56141|NCT02706639|Rare Diseases
56142|NCT02706587|Critical illness polyneuropathy
56143|NCT02706587|Neuromuscular Electrical Stimulation
56144|NCT02706574|Eye Tracking
56145|NCT02706574|Blood-based Biomarkers
56146|NCT02706574|CSF-based Biomarkers
56147|NCT02706574|Magnetic Resonance Imaging
56148|NCT02706574|Computed Tomography Scan
56149|NCT02706574|Outcome Measures
56150|NCT02706561|15-317
56151|NCT02706548|occupational therapy
56152|NCT02706548|medication adherence
56153|NCT02706548|intervention studies
56154|NCT02706535|Itraconazole
56155|NCT02706535|Rifampicin
56156|NCT02706535|Pharmacokinetics
56157|NCT02706535|Cross-over
56158|NCT02706496|aging of elderly
56159|NCT02706496|falling prevention
56160|NCT02706496|electroencephalography
56161|NCT02706496|postural control
56162|NCT02706496|biomechanics
56163|NCT02706470|recurrent miscarriage; immunology
56164|NCT02706457|intensive care
56165|NCT02706457|functionality
56166|NCT02706405|PD-L1
56167|NCT02706405|immunotherapy
56168|NCT02706405|non-Hodgkin lymphoma
56169|NCT02706353|Melanoma
56170|NCT02706353|Metastatic Melanoma
56171|NCT02706353|Intratumoral APX005M
56172|NCT02706353|Pembrolizumab
56173|NCT02706353|Keytruda
56174|NCT02706353|MK-3475
56175|NCT02706353|SCH-900475
56176|NCT02706327|orthotic insoles
56177|NCT02706327|pain
56178|NCT02706327|quality of life
56179|NCT02706327|athletic performance
56180|NCT02706301|colorectal cancer survivor
56181|NCT02706301|cancer pain
56182|NCT02706301|psychological distress
56183|NCT02706301|coping skills training
56184|NCT02706301|symptom management
56185|NCT02706301|cancer survivorship
56186|NCT02706210|Mild Cognitive Impairment
56187|NCT02706210|Diffusion Tensor Imaging
56188|NCT02706197|Electron Paramagnetic Resonance
56189|NCT02706197|Hypoxia
56190|NCT02706197|OxyChip
56191|NCT02706184|gastric cancer
56192|NCT02706184|colorectal cancer
56193|NCT02706184|chemotherapy induced diarrhea
56194|NCT02706184|5-Fluoruracil
56195|NCT02706184|chemotherapeutic remedy
56196|NCT02706145|social norms
56197|NCT02706145|youth violence
56198|NCT02706145|media
56199|NCT02706132|Mesenchymal stromal cells
56200|NCT02706132|Liver Transplantation
56201|NCT02706132|ABO blood group
56202|NCT02706119|total parenteral nutrition
56203|NCT02706119|glargine insulin
56204|NCT02706119|insulin
56205|NCT02706080|Antithrombotic agents
56206|NCT02706080|VKA
56207|NCT02706080|Direct Oral Anticoagulant
56208|NCT02706080|Antiplatelet
56209|NCT02706080|Bleeding
56210|NCT02706080|Emergency
56211|NCT02706041|Exploratory Lap (Ex Lap)
56212|NCT02706041|Damage Control Laparotomy (DCL)
56213|NCT02706041|Definitive
56214|NCT02706028|underwater ultrasound
56215|NCT02706028|rheumatoid arthritis
56216|NCT02706015|Headache
56217|NCT02706015|Aura
56218|NCT02706015|Migraine
56219|NCT02705937|xerostomia, Saliva, iatrogenic oral dryness, dairy product
56220|NCT02705898|alcohol use disorders
56221|NCT02705898|physical activity
56222|NCT02705898|women's health
56223|NCT02705885|IgY
56224|NCT02705885|Periodontitis
56225|NCT02705885|Porphyromonas gingivalis
56226|NCT02705885|gingipains
56227|NCT02705885|Efficacy
56228|NCT02705872|Epidural
56229|NCT02705872|Programmed intermittent boluses
56230|NCT02705872|Cesarian section
56231|NCT02705872|Instrumented delivery
56232|NCT02705846|BRCA1
56233|NCT02705846|BRCA2
56234|NCT02705846|Lynch Syndrome
56235|NCT02705820|Metastatic, Lung Cancer, Switch, Maintenance, Pembrolizumab.
56236|NCT02705807|Pulmonary Arterial Hypertension (PAH)
56237|NCT02705807|safety
56238|NCT02705807|FLOLAN
56239|NCT02705807|New Thermostable Formulation
56240|NCT02705807|dose adjustment
56241|NCT02705807|reformulated diluents
56242|NCT02705807|currently marketed diluent
56243|NCT02705794|intubation, laryngoscopy
56244|NCT02705768|Neuron-specific enolase (NSE)
56245|NCT02705768|Carbamazepine
56246|NCT02705768|Oxcarbazepine
56247|NCT02705742|Mesenchymal stem cells
56248|NCT02705742|Liver cirrhosis
56249|NCT02705742|Hepatitis C
56250|NCT02705729|dental caries
56251|NCT02705729|proximal surfaces
56252|NCT02705729|posterior teeth
56253|NCT02705729|carious lesions
56254|NCT02705729|tooth diseases
56255|NCT02705729|dental restorations
56256|NCT02705729|glass-ionomer
56257|NCT02705664|Onychomycosis
56258|NCT02705612|Cervical cancer
56259|NCT02705612|cisplatin
56260|NCT02705612|nimotuzumab
56261|NCT02705599|Ischemic stroke
56262|NCT02705599|High resolution MRI
56263|NCT02705599|Perfusion
56264|NCT02705599|Mechanism
56265|NCT02705586|Movement disorders
56266|NCT02705586|Metabolic Stress
56267|NCT02705547|Friedreich Ataxia
56268|NCT02705534|Hepatitis C
56269|NCT02705534|Cirrhosis
56270|NCT02705534|Sofosbuvir
56271|NCT02705534|Ledipasvir
56272|NCT02705534|Ribavirin
56273|NCT02705521|shoulder
56274|NCT02705521|impingement
56275|NCT02705521|rehabilitation
56276|NCT02705521|physiotherapy
56277|NCT02705521|gamification
56278|NCT02705521|activation
56279|NCT02705521|engagement
56280|NCT02705508|extranodal natural killer/T-cell lymphoma
56281|NCT02705508|nasal type
56282|NCT02705508|chemotherapy
56283|NCT02705508|radiotherapy
56284|NCT02705482|Advanced solid tumors
56285|NCT02705482|MEDI0562
56286|NCT02705482|durvalumab
56287|NCT02705482|tremelimumab
56288|NCT02705482|OX40
56289|NCT02705482|PD-L1
56290|NCT02705482|CTLA-4
56291|NCT02705482|immuno-oncology
56292|NCT02705469|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
56293|NCT02705469|Phase 1
56294|NCT02705469|Prostate Cancer
56295|NCT02705469|Pharmacokinetics (PK)
56296|NCT02705469|ZEN003694
56297|NCT02705469|ZEN-3694
56298|NCT02705469|Metastatic Castrate-Resistant Prostate Cancer
56299|NCT02705469|BET inhibitor (BETi)
56300|NCT02705469|Bromodomain
56301|NCT02705469|Pharmacodynamics (PD)
56302|NCT02705469|Epigenetics
56303|NCT02705456|Dental Caries
56304|NCT02705456|Tooth Paste
56305|NCT02705456|Orthodontics
56306|NCT02705456|Fluorides
56307|NCT02705417|arteriovenous fistula
56308|NCT02705417|colour Doppler
56309|NCT02705417|physical examination
56310|NCT02705417|renal dialysis
56311|NCT02705417|retrospective studies
56312|NCT02705404|multifocal
56313|NCT02705404|genetic
56314|NCT02705404|bronchoalveolar carcinoma
56315|NCT02705404|adenocarcinoma in situ
56316|NCT02705404|ground glass opacity
56317|NCT02705404|next generation sequencing
56318|NCT02705378|Intensive care unit
56319|NCT02705378|ICU
56320|NCT02705378|Critical Illness
56321|NCT02705378|Constipation
56322|NCT02705365|Lung Screening
56323|NCT02705365|Low-Dose Computer Tomography
56324|NCT02705365|Patient Navigation
56325|NCT02705352|Skin graft
56326|NCT02705352|5-Fluorouracil
56327|NCT02705352|Periocular reconstruction
56328|NCT02705313|neuroendocrine tumor
56329|NCT02705313|177Lu-DOTA0-Tyr3-Octreotate
56330|NCT02705287|vitamin D
56331|NCT02705287|half life
56332|NCT02705287|kinetics
56333|NCT02705261|child
56334|NCT02705261|behavior therapy
56335|NCT02705261|cognitive therapy
56336|NCT02705261|parent
56337|NCT02705261|anxiety
56338|NCT02705222|Abnormal uterine bleeding
56339|NCT02705222|Dilatation and curettage
56340|NCT02705222|Hysteroscopy
56341|NCT02705196|oncolytic
56342|NCT02705196|adenovirus
56343|NCT02705196|pancreatic
56344|NCT02705196|cancer
56345|NCT02705196|LOKON
56346|NCT02705196|LOAd703
56347|NCT02705183|surgical treatment
56348|NCT02705183|post-operative radiotherapy
56349|NCT02705183|quality of life
56350|NCT02705183|complications
56351|NCT02705183|survival
56352|NCT02705183|long bones
56353|NCT02705170|index of microvascular resistance
56354|NCT02705157|long bones
56355|NCT02705157|survival
56356|NCT02705157|prognosis
56357|NCT02705157|treatment
56358|NCT02705157|quality of life
56359|NCT02705131|Cervical radiculopathy
56360|NCT02705131|Balance chiropractic therapy
56361|NCT02705118|radiofrequency ablation
56362|NCT02705118|image fusion
56363|NCT02705105|Metastatic Solid Tumors
56364|NCT02705105|Advanced Solid Tumors
56365|NCT02705105|KW-0761
56366|NCT02705105|ONO-4538/BMS-936558
56367|NCT02705105|Anti-tumor
56368|NCT02705105|Mogamulizumab
56369|NCT02705105|Nivolumab
56370|NCT02705105|Oncology
56371|NCT02705053|Diabetes Mellitus, Type 1
56372|NCT02705053|Artificial Pancreas
56373|NCT02705053|Autoimmune Diseases
56374|NCT02705053|Diabetes Mellitus
56375|NCT02705053|Hyperglycemia
56376|NCT02705053|Hypoglycemia
56377|NCT02705040|male osteoporosis
56378|NCT02705040|miRNA
56379|NCT02705040|biomarker
56380|NCT02705014|pituitary stalk interruption syndrome
56381|NCT02705014|pulsatile GnRH therapy
56382|NCT02705014|hypogonadotropic hypogonadism
56383|NCT02705014|hypopituitarism
56384|NCT02704975|Dry Needling, Shoulder Stabilization
56385|NCT02704962|schizophrenia
56386|NCT02704962|olanzapine
56387|NCT02704962|trifluoperazine
56388|NCT02704962|antipsychotic polypharmacy
56389|NCT02704949|Urolithiasis
56390|NCT02704949|Fluoroscopy
56391|NCT02704949|Radiation
56392|NCT02704949|Ureteroscopy
56393|NCT02704923|Atropine
56394|NCT02704923|Pneumonia
56395|NCT02704923|Ventilator
56396|NCT02704923|Adults
56397|NCT02704923|Intensive care unit.
56398|NCT02704871|SeptiCyte
56399|NCT02704858|recurrent glioblastoma
56400|NCT02704858|recurrent GBM
56401|NCT02704845|Inflammatory back pain
56402|NCT02704845|Ankylosing spondylitis
56403|NCT02704845|Non-specific low back pain
56404|NCT02704845|Pain experience
56405|NCT02704845|Disability
56406|NCT02704845|Behavioural
56407|NCT02704845|Psychological
56408|NCT02704845|Biopsychosocial
56409|NCT02704845|Pain profiles
56410|NCT02704832|Geriatric oncology
56411|NCT02704832|Intervention
56412|NCT02704832|Case management
56413|NCT02704819|Decision Support System
56414|NCT02704819|Dizziness
56415|NCT02704819|Vertigo
56416|NCT02704819|Balance
56417|NCT02704130|Therapeutic Chemoembolization
56418|NCT02704130|Ablation Techniques
56419|NCT02704130|Transarterial Chemoembolization
56420|NCT02704130|TACE
56421|NCT02704130|Microwave Ablation
56422|NCT02704130|MWA
56423|NCT02704780|Retained placenta
56424|NCT02704780|Misoprostol
56425|NCT02704780|double blind
56426|NCT02704780|Randomization
56427|NCT02704780|Haemorrhage
56428|NCT02704715|postoperative pain
56429|NCT02704715|general anesthesia
56430|NCT02704702|Fimasartan
56431|NCT02704676|CA-125
56432|NCT02704676|Pre-Eclampsia
56433|NCT02704663|adnexal mass
56434|NCT02704663|laparoscopy
56435|NCT02704663|removal route
56436|NCT02704663|postoperative pain
56437|NCT02704637|vasospasm
56438|NCT02704624|Crohn Disease
56439|NCT02704624|Fatigue
56440|NCT02704624|Osteopenia
56441|NCT02704624|Exercise Tolerance
56442|NCT02704624|Vitamin d
56443|NCT02704585|Neonatal resuscitation
56444|NCT02704585|Pulse oximetry
56445|NCT02704572|Herpes zoster vaccine
56446|NCT02704572|cell-mediated immunity
56447|NCT02704533|Plasmodium falciparum
56448|NCT02704533|PfSPZ Vaccine
56449|NCT02704533|PfSPZ Challenge (NF54)
56450|NCT02704533|PfSPZ Challenge (7G8)
56451|NCT02704533|CHMI
56452|NCT02704520|Rectal Cancer
56453|NCT02704520|Magnetic Resonance Imaging
56454|NCT02704520|Chemoradiotherapy
56455|NCT02704520|Chemotherapy
56456|NCT02704520|Diagnostic Imaging
56457|NCT02704507|tretinoin
56458|NCT02704507|topical steroid
56459|NCT02704507|irritation
56460|NCT02704507|retinoid induced irritation
56461|NCT02704494|Resveratrol
56462|NCT02704494|Diabetes mellitus
56463|NCT02704494|Diabetes complications
56464|NCT02704494|Diabetic nephropathies
56465|NCT02704494|Proteinuria
56466|NCT02704494|Albuminuria
56467|NCT02704494|renal insufficiency
56468|NCT02704481|mifepristone
56469|NCT02704481|misoprostol
56470|NCT02704481|medical abortion
56471|NCT02704468|CAVI
56472|NCT02704468|FGF-21
56473|NCT02704468|arterial stiffness
56474|NCT02704468|renal transplant
56475|NCT02704455|children
56476|NCT02704442|anesthesiology
56477|NCT02704442|ophthalmology
56478|NCT02704416|Ventricular arrhythmias
56479|NCT02704416|aborted cardiac arrest
56480|NCT02704416|cardiac death
56481|NCT02704403|Elafibranor
56482|NCT02704403|NASH
56483|NCT02704403|Nonalcoholic steatohepatitis
56484|NCT02704403|Fatty liver disease
56485|NCT02704403|Fibrosis
56486|NCT02704390|ORADUR®-Methylphenidate
56487|NCT02704377|Prostate Cancer Survivor
56488|NCT02704338|Autoimmune Diseases, Treg
56489|NCT02704325|DMD
56490|NCT02704325|Duchenne Muscular Dystrophy
56491|NCT02704273|MTM
56492|NCT02704273|XLMTM
56493|NCT02704208|Antiretroviral Therapy
56494|NCT02704208|Medication Adherence
56495|NCT02704208|Technology-based Intervention
56496|NCT02704195|Parkinson disease
56497|NCT02704195|Deep brain stimulation
56498|NCT02704195|Freezing of Gait
56499|NCT02704182|Arthroplasties, Knee Replacement
56500|NCT02704169|head and neck cancer
56501|NCT02704169|H&N cancer
56502|NCT02704156|Stereotactic body radiation therapy
56503|NCT02704156|CyberKnife
56504|NCT02704156|Initial treatment
56505|NCT02704065|amyloidosis
56506|NCT02704065|renal transplantation
56507|NCT02704026|Body composition
56508|NCT02704026|Nutritional status
56509|NCT02704013|Neurotrophins
56510|NCT02704013|Nerve Growth Factor
56511|NCT02704013|Brain-Derived Neurotrophic Factor
56512|NCT02704013|Urinary Biomarkers
56513|NCT02704013|Urodynamics
56514|NCT02704013|Anticholinergics
56515|NCT02704013|Children
56516|NCT02703961|CCRT
56517|NCT02703961|adjuvant chemotherapy
56518|NCT02703961|cisplatin and docetaxel
56519|NCT02703909|morbid obesity
56520|NCT02703909|laparoscopic surgery
56521|NCT02703909|neuromuscular blockade
56522|NCT02703896|g a, bile reflux. PPIs, H2RAs, prokinetic agents
56523|NCT02703831|adult spine deformity
56524|NCT02703831|time-driven activity-based costing
56525|NCT02703831|three-column posterior osteotomy
56526|NCT02703805|Community program
56527|NCT02703805|Wellness
56528|NCT02703805|Exercise
56529|NCT02703805|Physical Activity
56530|NCT02703805|Education
56531|NCT02703805|Stroke
56532|NCT02703805|Self-management
56533|NCT02703779|Multiple Myeloma
56534|NCT02703779|Bortezomib
56535|NCT02703779|Autologous
56536|NCT02703779|Stem Cell
56537|NCT02703779|Purging
56538|NCT02703779|In-vivo purging
56539|NCT02703779|Ex-vivo purging
56540|NCT02703779|Leukapheresis
56541|NCT02703779|Contaminated
56542|NCT02703779|Stem Cell Harvest
56543|NCT02703779|Stem Cell Transplant
56544|NCT02703779|Transplantation
56545|NCT02703727|polypharmacy
56546|NCT02703727|polymedication check
56547|NCT02703727|anticoagulation treatment
56548|NCT02703714|Advanced
56549|NCT02703714|Locally-advanced
56550|NCT02703714|Not eligible for resection
56551|NCT02703714|Prior chemotherapy treatment
56552|NCT02703701|Patient Satisfaction
56553|NCT02703701|Emergency Department efficiency
56554|NCT02703662|Biologic mesh
56555|NCT02703662|abdominal wall reconstruction
56556|NCT02703649|Aromatase inhibitor
56557|NCT02703649|induction of ovulation
56558|NCT02703636|Alzheimer's disease
56559|NCT02703623|Prostate cancer
56560|NCT02703623|Metastatic castration-resistant prostate cancer to the bone
56561|NCT02703623|mCRPC
56562|NCT02703623|Adenocarcinoma of the prostate
56563|NCT02703623|Biomarkers
56564|NCT02703623|Abiraterone Acetate
56565|NCT02703623|Zytiga
56566|NCT02703623|Prednisone
56567|NCT02703623|ARN509
56568|NCT02703623|Ipilimumab
56569|NCT02703623|Yervoy
56570|NCT02703623|BMS-734016
56571|NCT02703623|MDX010
56572|NCT02703623|Cabazitaxel
56573|NCT02703623|Jevtana
56574|NCT02703623|Carboplatin
56575|NCT02703623|Paraplatin
56576|NCT02703610|Pain
56577|NCT02703610|Elderly
56578|NCT02703597|Cigarette Smoking Behavior
56579|NCT02703597|Smoking curiosity
56580|NCT02703597|Smoking Cessation
56581|NCT02703597|Smoking Prevention
56582|NCT02703597|Health improvement
56583|NCT02703597|Smoking prevention interactive experience
56584|NCT02703597|ASPIRE
56585|NCT02703597|Game-based social activities
56586|NCT02703597|GSA's
56587|NCT02703597|Surveys
56588|NCT02703597|Questionnaires
56589|NCT02703597|Interviews
56590|NCT02703584|Double trigger
56591|NCT02703571|Trametinib
56592|NCT02703571|Ribociclib
56593|NCT02703571|LEE011
56594|NCT02703571|TMT212
56595|NCT02703571|advanced solid tumors
56596|NCT02703571|pancreatic cancer
56597|NCT02703571|KRAS-mutant colorectal cancer
56598|NCT02703571|colorectal cancer
56599|NCT02703571|advanced pancreatic cancer
56600|NCT02703571|metastatic pancreatic cancer
56601|NCT02703545|familial pancreas cancer
56602|NCT02703545|pancreatic cyst
56603|NCT02703532|Therapy
56604|NCT02703532|Rehabilitation
56605|NCT02703532|Caregiver
56606|NCT02703519|cesarean section, repeat
56607|NCT02703519|uterine scar tissue
56608|NCT02703519|transvaginal ultrasound
56609|NCT02703519|uterine rupture
56610|NCT02703519|placenta accreta
56611|NCT02703519|placenta percreta
56612|NCT02703519|placenta increta
56613|NCT02703467|Exhaled hydrogen sulphide
56614|NCT02703428|Abdominal
56615|NCT02703428|Aortic
56616|NCT02703428|Aneurysm
56617|NCT02703415|immune
56618|NCT02703415|interleukin
56619|NCT02703415|tramadol
56620|NCT02703415|postoperartive analgesia
56621|NCT02703415|pediatric
56622|NCT02703415|caudal bupivacaine
56623|NCT02703402|low back pain
56624|NCT02703402|physical exercise and quality of life
56625|NCT02703389|knowledge translation
56626|NCT02703389|antimicrobial stewardship
56627|NCT02703311|Valtech Cardio
56628|NCT02703311|Cardioband
56629|NCT02703311|Mitral Valve
56630|NCT02703298|Advanced Solid Malignancy
56631|NCT02703298|Safety and Tolerability
56632|NCT02703298|Tumor Response
56633|NCT02703298|Oncology
56634|NCT02703272|Lymphoma, Non-Hodgkin
56635|NCT02703272|Ibrutinib
56636|NCT02703272|JNJ-54179060
56637|NCT02703246|Hysterectomy, Vaginal
56638|NCT02703246|Hysterectomy, Abdominal
56639|NCT02703220|sleep apnea
56640|NCT02703220|chemoresponsiveness
56641|NCT02703220|cerebrovascular response
56642|NCT02703220|hyperoxia
56643|NCT02703220|acetazolamide
56644|NCT02703220|finasteride
56645|NCT02703220|apneic threshold
56646|NCT02703220|carbon-dioxide reserve
56647|NCT02703207|obstructive sleep apnea
56648|NCT02703207|COPD
56649|NCT02703207|Overlap syndrome
56650|NCT02703207|quality of life
56651|NCT02703207|neurocognitive function
56652|NCT02703207|sleepiness
56653|NCT02703207|elderly
56654|NCT02703194|IgG4-related disease
56655|NCT02703194|IgG4-related sclerosing cholangitis
56656|NCT02703194|Mikulicz disease
56657|NCT02703194|Pancreatitis
56658|NCT02703194|Retroperitoneal fibrosis
56659|NCT02703194|Lymphadenopathy
56660|NCT02703181|Safety
56661|NCT02703181|Dose Escalation
56662|NCT02703181|Repeat Dosing
56663|NCT02703181|Epelsiban
56664|NCT02703181|Pharmacokinetics
56665|NCT02703181|Healthy Women Volunteers
56666|NCT02703181|Tolerability
56667|NCT02703181|Oxytocin
56668|NCT02703168|Dental implants
56669|NCT02703142|esophagogastrostomy
56670|NCT02703142|gastric conduit ischemia
56671|NCT02703142|endoscopy
56672|NCT02703129|Migraine
56673|NCT02703129|Diet quality
56674|NCT02703129|Nutritional intervention
56675|NCT02703129|Severity of disease
56676|NCT02703129|Depressive symptoms
56677|NCT02703116|HIV
56678|NCT02703116|Substance Use
56679|NCT02703103|cardiopulmonary resuscitation
56680|NCT02703103|chest compression
56681|NCT02703103|adult
56682|NCT02703103|simulation
56683|NCT02703064|Furocyst
56684|NCT02703064|PCOS
56685|NCT02703038|cardiogenic shock
56686|NCT02703038|observatory
56687|NCT02703025|Obesity, green coffee bean extract, weight management
56688|NCT02702973|Characteristic analysis
56689|NCT02702960|FL-HCC
56690|NCT02702960|living donor liver transplant
56691|NCT02702960|HLA matched first degree relative
56692|NCT02702960|Milan Criteria
56693|NCT02702960|Ephraim Fuchs
56694|NCT02702960|Fibrolamellar Cancer Foundation
56695|NCT02702960|fibrolamellar
56696|NCT02702960|non-fibrolamellar
56697|NCT02702947|BPH
56698|NCT02702947|Prunus Domestica extract
56699|NCT02702882|Fenugreek seed extract, hypogonadism, protodioscin, testosterone
56700|NCT02702869|cleft lip
56701|NCT02702869|cleft palate
56702|NCT02702869|cleft lip and palate
56703|NCT02702869|cleft alveolus
56704|NCT02702869|multidisciplinary team
56705|NCT02702869|interdisciplinary team
56706|NCT02702856|Prostate Cancer
56707|NCT02702856|Gleason Grade
56708|NCT02702856|Prostatic Neoplasms
56709|NCT02702817|Alzheimer's disease, biomarkers, cognitive decline, pre-clinical
56710|NCT02702791|Physical activity
56711|NCT02702791|Pulmonary rehabilitation
56712|NCT02702791|COPD
56713|NCT02702778|Polymyalgia Rheumatica (PMR)
56714|NCT02702765|sCD163
56715|NCT02702765|liver cirrhosis
56716|NCT02702765|disease severity
56717|NCT02702752|Heart diseases stromal differentiation factor alpha 1
56718|NCT02702713|bioactive
56719|NCT02702713|enriched foods
56720|NCT02702713|anthocyanins (AC)
56721|NCT02702713|beta-glucans (BG)
56722|NCT02702713|docosahexaenoic acid (DHA)
56723|NCT02702687|Asthma
56724|NCT02702687|Childhood Asthma
56725|NCT02702687|Bronchial Diseases
56726|NCT02702687|Immune System Diseases
56727|NCT02702687|Lung Diseases
56728|NCT02702687|Lung Diseases, Obstructive
56729|NCT02702687|Respiratory Tract Diseases
56730|NCT02702687|Peak Flow Meter
56731|NCT02702687|Symptom Perception
56732|NCT02702687|Illness Representation
56733|NCT02702661|Fascia Iliaca Block
56734|NCT02702661|Local Anaesthetic Infiltration
56735|NCT02702661|Hip Arthroscopy
56736|NCT02702648|healthy subjects
56737|NCT02702648|first-in-man
56738|NCT02702648|safety
56739|NCT02702622|bananas
56740|NCT02702622|biofortified
56741|NCT02702622|carotenoids
56742|NCT02702622|vitamin A
56743|NCT02702583|Myelosuppressive Chemotherapy
56744|NCT02702583|Febrile Neutropenia
56745|NCT02702583|Solid Tumors
56746|NCT02702583|Dental Infection
56747|NCT02702583|Oral Infection
56748|NCT02702557|Frail Elderly
56749|NCT02702557|Elastic Band Exercises
56750|NCT02702557|Unsupervised Exercises
56751|NCT02702557|Monitoring Technology
56752|NCT02702557|Bandcizer
56753|NCT02702557|Adherence
56754|NCT02702557|Feasibility
56755|NCT02702531|Laparoscopic Surgery
56756|NCT02702531|FloShield Defogging and Cleaning System
56757|NCT02702531|Clearify Defogging and Cleaning System
56758|NCT02702531|gynecologic
56759|NCT02702518|rhDNase I, Pulmozyme, oGVHD, Dry Eye
56760|NCT02702505|Pulp
56761|NCT02702505|pulpotomies
56762|NCT02702505|mineral trioxide aggregate
56763|NCT02702492|PAK4
56764|NCT02702492|KPT-9274
56765|NCT02702492|Karyopharm
56766|NCT02702492|NHL
56767|NCT02702492|solid tumors
56768|NCT02702479|Systematic review and meta-analysis
56769|NCT02702479|Evidence-based medicine (EBM)
56770|NCT02702479|Evidence-based nutrition (EBN)
56771|NCT02702479|Clinical practice guidelines
56772|NCT02702479|Clinical trials
56773|NCT02702479|Dietary sugars
56774|NCT02702479|Fructose
56775|NCT02702479|High fructose corn syrup
56776|NCT02702479|Isocaloric
56777|NCT02702479|Hypercaloric
56778|NCT02702479|Cardiometabolic Risk Factors
56779|NCT02702479|Triglycerides
56780|NCT02702479|Cholesterol
56781|NCT02702479|Glycemic control
56782|NCT02702479|Body weight
56783|NCT02702479|Uric acid
56784|NCT02702479|Blood pressure
56785|NCT02702479|Fatty liver
56786|NCT02702479|Fasting
56787|NCT02702479|Postprandial
56788|NCT02702466|Upper limb musculoskeletal disorders
56789|NCT02702466|Spa treatment
56790|NCT02702466|Randomized controlled trials
56791|NCT02702466|Education
56792|NCT02702466|Self- management
56793|NCT02702466|Self-care
56794|NCT02702466|Exercise
56795|NCT02702466|Non pharmacological treatment
56796|NCT02702440|Systematic review and meta-analysis
56797|NCT02702440|Sugars
56798|NCT02702440|Liquid calories
56799|NCT02702440|Solid calories
56800|NCT02702440|Clinical trials
56801|NCT02702440|Body weight
56802|NCT02702440|Body Mass Index
56803|NCT02702440|Evidence-base nutrition (EBN)
56804|NCT02702440|Evidence-base medicine (EBM)
56805|NCT02702440|Clinical practice guidelines
56806|NCT02702427|viral infections post HSCT, virus-specific T-cells
56807|NCT02702414|PD1
56808|NCT02702414|PD-1
56809|NCT02702414|PDL1
56810|NCT02702414|PD-L1
56811|NCT02702401|PD1
56812|NCT02702401|PD-1
56813|NCT02702401|PDL1
56814|NCT02702401|PD-L1
56815|NCT02702388|Lenvatinib
56816|NCT02702388|E7080
56817|NCT02702388|Iodine-131 Refractory Differentiated Thyroid Cancer
56818|NCT02702388|Lenvima
56819|NCT02702388|Phase 2
56820|NCT02702388|RR-DTC
56821|NCT02702375|Systematic review and meta-analysis
56822|NCT02702375|Evidence-based medicine (EBM)
56823|NCT02702375|Evidence-based nutrition (EBN)
56824|NCT02702375|Clinical practice guidelines
56825|NCT02702375|Prospective cohort studies
56826|NCT02702375|Dietary sugars
56827|NCT02702375|Fructose
56828|NCT02702375|Sucrose
56829|NCT02702375|High fructose corn syrup
56830|NCT02702375|HFCS
56831|NCT02702375|Cohort studies
56832|NCT02702375|Prospective studies
56833|NCT02702375|Diabetes Mellitus
56834|NCT02702375|Metabolic syndrome
56835|NCT02702375|Coronary heart disease
56836|NCT02702375|Stroke
56837|NCT02702375|Hypertension
56838|NCT02702375|Gout
56839|NCT02702362|disorders of consciousness
56840|NCT02702362|minimally conscious state
56841|NCT02702362|traumatic brain injury
56842|NCT02702362|stroke
56843|NCT02702362|transcranial direct current stimulation
56844|NCT02702323|hepatocellular carcinoma
56845|NCT02702323|pulmonary metastasis
56846|NCT02702323|Apatinib
56847|NCT02702323|efficacy
56848|NCT02702323|safety
56849|NCT02702297|Preterm premature rupture of the membranes
56850|NCT02702297|PPROM
56851|NCT02702297|PROM
56852|NCT02702297|fetal membranes
56853|NCT02702297|premature rupture
56854|NCT02702297|neonatal early onset sepsis
56855|NCT02702297|amniotic fluid
56856|NCT02702297|amniotic infection
56857|NCT02702297|fetal inflammatory response syndrome
56858|NCT02702297|adverse neonatal outcome
56859|NCT02702297|FIRS
56860|NCT02702284|Advance Directives
56861|NCT02702284|Healthcare power of attorney
56862|NCT02702258|mindfulness
56863|NCT02702258|blood pressure
56864|NCT02702258|hypertension
56865|NCT02702258|prehypertension
56866|NCT02702206|Shoulder pain
56867|NCT02702206|subdeltoid bursitis
56868|NCT02702206|subacromial bursitis
56869|NCT02702206|intra-bursa injection
56870|NCT02702167|brain stimulation
56871|NCT02702167|rTMS
56872|NCT02702154|brain stimulation
56873|NCT02702154|rTMS
56874|NCT02702141|Non-hodgkin lymphoma
56875|NCT02702141|Antibody-drug conjugate
56876|NCT02702141|CD19
56877|NCT02702141|Diffuse large B-cell lymphoma
56878|NCT02702141|DLBCL
56879|NCT02702141|Grade 3 follicular lymphoma
56880|NCT02702128|Bleeding perioperative
56881|NCT02702128|EXACYL
56882|NCT02702128|Oorthognathism surgery
56883|NCT02702128|Hematoma
56884|NCT02702115|gene specific targeted insertion
56885|NCT02702076|Apomorphine
56886|NCT02702024|efficacy
56887|NCT02702024|double incision technique
56888|NCT02702024|uterus preserving surgery
56889|NCT02701998|Ischemic Stroke
56890|NCT02701998|Transient Ischemic Attack
56891|NCT02701998|Physical Activity
56892|NCT02701998|Sedentary Behavior
56893|NCT02701998|Lifestyle
56894|NCT02701998|Behavior
56895|NCT02701959|Nitric oxide
56896|NCT02701959|Dietary intervention trail
56897|NCT02701946|Blood loss
56898|NCT02701946|Total knee arthroplasty
56899|NCT02701946|Bandage
56900|NCT02701946|Dressing
56901|NCT02701920|Premature Birth
56902|NCT02701920|Infant
56903|NCT02701920|Heart rate
56904|NCT02701881|Femoropopliteal Artery
56905|NCT02701881|Drug-eluting Stent
56906|NCT02701881|Endovascular Therapy
56907|NCT02701868|Infant Formula
56908|NCT02701829|taxi cab drivers
56909|NCT02701829|high blood pressure
56910|NCT02701829|16-038
56911|NCT02701816|Peripheral Artery Disease
56912|NCT02701816|Femoropopliteal Artery
56913|NCT02701816|Nitinol Stent
56914|NCT02701816|Restenosis
56915|NCT02701777|spike timing dependant plasticity
56916|NCT02701764|laser-assisted in situ keratomileusis
56917|NCT02701764|dry eye symptoms
56918|NCT02701764|LASIK
56919|NCT02701764|prevention
56920|NCT02701712|magnetic resonance
56921|NCT02701712|external beam radiotherapy
56922|NCT02701712|brachytherapy
56923|NCT02701712|radiotherapy
56924|NCT02701699|Lung Cancer
56925|NCT02701699|FAZA PET Imaging
56926|NCT02701699|Lung Radiotherapy
56927|NCT02701686|smoking cessation
56928|NCT02701673|Refractory or Relapsed Lymphoma
56929|NCT02701673|Busulfan
56930|NCT02701673|Busulfex
56931|NCT02701673|Myleran
56932|NCT02701673|Caphosol
56933|NCT02701673|Glutamine
56934|NCT02701673|Enterex
56935|NCT02701673|Glutapak-10
56936|NCT02701673|NutreStore
56937|NCT02701673|Resource
56938|NCT02701673|GlutaSolve
56939|NCT02701673|Sympt-X-G.I.
56940|NCT02701673|Sympt-X
56941|NCT02701673|Pyridoxine
56942|NCT02701673|Belinostat
56943|NCT02701673|Azacitidine
56944|NCT02701673|5-azacytidine
56945|NCT02701673|5-aza
56946|NCT02701673|Azacytidine
56947|NCT02701673|Vidaza
56948|NCT02701673|5-AZC
56949|NCT02701673|AZA-CR
56950|NCT02701673|Ladakamycin
56951|NCT02701673|Gemcitabine
56952|NCT02701673|Gemcitabine Hydrochloride
56953|NCT02701673|Gemzar
56954|NCT02701673|Stem cell transplant
56955|NCT02701673|SCT
56956|NCT02701673|Melphalan
56957|NCT02701673|Alkeran
56958|NCT02701660|Pharmaceutical Care
56959|NCT02701660|Adherence
56960|NCT02701660|Polypharmacy
56961|NCT02701660|e-Health
56962|NCT02701660|opioid substitution therapy
56963|NCT02701647|Transcranial Magnetic Stimulation
56964|NCT02701634|Chronic Graft Versus Host Disease (cGVHD)
56965|NCT02701634|newly diagnosed cGVHD
56966|NCT02701634|immune reconstitution
56967|NCT02701634|Immune System Diseases
56968|NCT02701634|allogeneic stem cell transplantation
56969|NCT02701634|SYK inhibitor
56970|NCT02701621|Parkinson's disease, aquatic therapy, balance, MIRT
56971|NCT02701517|conditioning treatment
56972|NCT02701517|alemtuzumab
56973|NCT02701517|allogeneic hematopoietic stem cell transplantation
56974|NCT02701517|chronic lymphoproliferative disorders
56975|NCT02701504|sleep apnea
56976|NCT02701504|coronary artery bypass grafting
56977|NCT02701504|outcomes
56978|NCT02701465|Shoulder
56979|NCT02701465|Exercise therapy
56980|NCT02701452|GnRH agonist triggering
56981|NCT02701426|Macrosomia
56982|NCT02701426|Weight gain
56983|NCT02701426|Participation
56984|NCT02701426|Adhesion
56985|NCT02701426|Physical activity
56986|NCT02701426|Nutrition
56987|NCT02701413|Apex M
56988|NCT02701413|Postpartum
56989|NCT02701413|Pelvic Floor rehabilitation
56990|NCT02701387|bone implant interaction
56991|NCT02701387|implant stability
56992|NCT02701387|resonance frequency analysis (RFA)
56993|NCT02701387|implant stability quotient (ISQ)
56994|NCT02701374|TRK-700
56995|NCT02701374|Post-Herpetic Neuralgia
56996|NCT02701361|mindfulness
56997|NCT02701361|critical illness
56998|NCT02701361|intensive care unit
56999|NCT02701361|mindfulness-based stress reduction
57000|NCT02701348|neoadjuvant endocrine
57001|NCT02701335|Osteoarthritis
57002|NCT02701335|Hand
57003|NCT02701335|Rehabilitation
57004|NCT02701322|Velopharyngeal Insufficiency
57005|NCT02701322|Fluoroscopy
57006|NCT02701309|Iron deficiency
57007|NCT02701309|Child
57008|NCT02701309|Infancy
57009|NCT02701309|Preschool children
57010|NCT02701309|iron deficiency anemia
57011|NCT02701296|Infiltration between popliteal artery and capsule of knee (iPACK)
57012|NCT02701270|Glycemic Index
57013|NCT02701270|Dietary Fiber
57014|NCT02701257|Bionic Pancreas
57015|NCT02701257|Insulin
57016|NCT02701257|Glucagon
57017|NCT02701257|Continuous Glucose Monitor
57018|NCT02701244|Infiltrating Ductal Carcinoma
57019|NCT02701244|Ductal Carcinoma In Situ
57020|NCT02701244|Brachytherapy
57021|NCT02701244|Breast Neoplasms
57022|NCT02701244|Breast Diseases
57023|NCT02701244|Neoplasms
57024|NCT02701244|Neoplasms by Site
57025|NCT02701231|lung cancer
57026|NCT02701231|Low-frequency rotating magnetic therapy system
57027|NCT02701231|systemic anti-tumor therapy
57028|NCT02701218|Canalith repositioning procedure (CRP)
57029|NCT02701218|BPPV
57030|NCT02701205|Plaque Psoriasis
57031|NCT02701205|Skin Disease
57032|NCT02701192|coccygodynia
57033|NCT02701192|coccygectomy
57034|NCT02701192|coccyx
57035|NCT02701179|Lignocaine
57036|NCT02701166|Pruritus
57037|NCT02701166|itch
57038|NCT02701166|cholestasis
57039|NCT02701075|peripheral neuropathy
57040|NCT02701075|traumatic tissue injury
57041|NCT02701075|radiculopathy
57042|NCT02701036|sporadic ataxia
57043|NCT02701036|MSAc
57044|NCT02701036|SAOA
57045|NCT02701036|multiple system atrophy of cerebellar type
57046|NCT02701036|natural history
57047|NCT02701010|behavioral therapy
57048|NCT02701010|overactive bladder
57049|NCT02701010|urinary incontinence
57050|NCT02700958|Remote ischemic preconditioning
57051|NCT02700958|Contrast-induced Nephropathy
57052|NCT02700958|Stable coronary artery disease
57053|NCT02700958|Lower extremity arterial disease
57054|NCT02700958|Low molecular weight metabolites
57055|NCT02700958|Functional properties of arteries
57056|NCT02700932|non-invasive
57057|NCT02700906|Lateral epicondylitis
57058|NCT02700906|tennis elbow
57059|NCT02700906|Lidocaine
57060|NCT02700906|corticosteroid
57061|NCT02700880|wearable cardioverter defibrillator
57062|NCT02700880|ischemic cardiomyopathy
57063|NCT02700880|new onset heart failure
57064|NCT02700880|sudden cardiac death
57065|NCT02700867|intraosseous access
57066|NCT02700867|cardiopulmonary resuscitation
57067|NCT02700867|paramedic
57068|NCT02700867|simulation
57069|NCT02700867|cadaver
57070|NCT02700854|Hypothermia treatment
57071|NCT02700854|Hypocapnia
57072|NCT02700854|Inhaled CO2
57073|NCT02700854|Neuroprotection
57074|NCT02700828|Hypothermia treatment
57075|NCT02700828|Circulatory failure
57076|NCT02700828|Neonatal hypotension
57077|NCT02700828|Relative adrenal insufficiency
57078|NCT02700828|Hydrocortisone supplementation
57079|NCT02700802|food insecurity
57080|NCT02700802|informal caregiver health
57081|NCT02700802|clinic-to-community linkages
57082|NCT02700802|community resources
57083|NCT02700789|diagnostic accuracy
57084|NCT02700789|double decidual sac sign
57085|NCT02700789|intrauterine pregnancy
57086|NCT02700776|screening mammogram
57087|NCT02700776|GP88
57088|NCT02700776|breast cancer
57089|NCT02700763|Brain metastasis
57090|NCT02700737|cardiovascular modeling
57091|NCT02700737|aortic coarctation
57092|NCT02700737|virtual stenting
57093|NCT02700698|Mitochondria
57094|NCT02700698|women
57095|NCT02700698|muscle
57096|NCT02700698|PBMC
57097|NCT02700672|Ageing
57098|NCT02700672|Cognition
57099|NCT02700672|Executive Function
57100|NCT02700672|Gait
57101|NCT02700620|emotional eating
57102|NCT02700620|restrictive eating
57103|NCT02700620|body dissatisfaction
57104|NCT02700607|cerebral aneurysm, coiling embolization, blood viscosity
57105|NCT02700555|colorectal cancer
57106|NCT02700555|diabetes
57107|NCT02700555|metabolic parameters
57108|NCT02700555|Surveillance
57109|NCT02700542|asthma
57110|NCT02700542|pest management
57111|NCT02700503|Diabetes prevention
57112|NCT02700503|type 2 diabetes
57113|NCT02700503|prediabetes
57114|NCT02700503|family
57115|NCT02700477|Type-2 Diabetic
57116|NCT02700477|HbA1c
57117|NCT02700477|FBS
57118|NCT02700477|PPBS
57119|NCT02700477|C-peptide
57120|NCT02700451|IV acetaminophen
57121|NCT02700451|IV Ketorolac
57122|NCT02700451|Post-operative analgesia
57123|NCT02700451|Opioid use
57124|NCT02700425|Wide QRS
57125|NCT02700425|Ventricular Dyssynchrony
57126|NCT02700399|Rehabilitation
57127|NCT02700386|Breast
57128|NCT02700386|Cancer
57129|NCT02700386|Hypofractionated
57130|NCT02700386|Node-Positive Breast Cancer
57131|NCT02700386|Radiation Therapy
57132|NCT02700386|Comprehensive Radiation Therapy
57133|NCT02700360|EC-18
57134|NCT02700360|Hematology
57135|NCT02700360|Cancer
57136|NCT02700360|Neutropenia
57137|NCT02700334|Prediabetes
57138|NCT02700334|Impaired fasting glucose
57139|NCT02700334|Hyperglycemia
57140|NCT02700334|Impaired glucose tolerance
57141|NCT02700334|Glucose intolerance
57142|NCT02700334|Dapagliflozin
57143|NCT02700334|Sodium glucose cotransporter 2 inhibitor
57144|NCT02700334|SGLT2
57145|NCT02700321|non severely hypoxemic respiratory failure
57146|NCT02700321|preoxygenation
57147|NCT02700321|crash induction
57148|NCT02700308|Solid tumors
57149|NCT02700308|Spine metastasis
57150|NCT02700308|Vertebroplasty
57151|NCT02700308|kyphoplasty
57152|NCT02700308|randomization
57153|NCT02700295|Orthokeratology
57154|NCT02700282|Cystic fibrosis
57155|NCT02700282|Backpack carrying
57156|NCT02700282|Respiratory function
57157|NCT02700282|Children
57158|NCT02700256|surgery
57159|NCT02700256|15-315
57160|NCT02700243|Cystic Fibrosis
57161|NCT02700243|Exercise
57162|NCT02700243|Fitbit
57163|NCT02700217|Donor Nephrectomy
57164|NCT02700139|Myopia control, aspheric lenses, children
57165|NCT02700126|propofol
57166|NCT02700126|total intravenous anesthesia
57167|NCT02700126|cerebral aneurysm
57168|NCT02700126|single nucleotide polymorphism
57169|NCT02700087|Laryngomalacia
57170|NCT02700061|Induced Constraint Therapy
57171|NCT02700061|Robotic Occupational Therapy
57172|NCT02700061|Neuroplasticity
57173|NCT02700048|type 1 diabetes
57174|NCT02700048|hypoglycemia
57175|NCT02700048|hypoglycemia unawareness
57176|NCT02700035|Intervention
57177|NCT02700035|Prevention
57178|NCT02700035|Randomized Controlled Trial
57179|NCT02700035|Bii-Zin-Da-De-Dah
57180|NCT02700022|Lineberger Comprehensive Cancer Center
57181|NCT02700022|Alisertib
57182|NCT02699905|Sepsis
57183|NCT02699905|Septic Shock
57184|NCT02699905|Multiple Organ Dysfunction
57185|NCT02699905|FFA2
57186|NCT02699905|GPR43
57187|NCT02699866|Small diameter implant
57188|NCT02699840|Meningitis
57189|NCT02699840|Meningococcal Meningitis
57190|NCT02699840|Meningococcal Infections
57191|NCT02699840|Menactra®
57192|NCT02699840|Meningococcal Vaccine
57193|NCT02699827|Levobupivacaine
57194|NCT02699827|Magnesium
57195|NCT02699827|Preeclampsia
57196|NCT02699827|Epidural
57197|NCT02699814|Depression
57198|NCT02699814|Children
57199|NCT02699814|Anxiety
57200|NCT02699775|Botulinum toxin injections
57201|NCT02699775|Stroke
57202|NCT02699775|3D motion analysis
57203|NCT02699775|Gait pattern
57204|NCT02699762|self rehabilitation
57205|NCT02699762|stroke
57206|NCT02699762|botulinum toxin injection
57207|NCT02699762|arm functions
57208|NCT02699749|Drug Therapy
57209|NCT02699736|HIV
57210|NCT02699736|HIV-1
57211|NCT02699736|Hepatitis C
57212|NCT02699736|HCV
57213|NCT02699736|prospective
57214|NCT02699736|cohort
57215|NCT02699736|coinfection
57216|NCT02699671|Bioresorbable Vascular Scaffold
57217|NCT02699671|Routine Clinical Practice
57218|NCT02699671|Angioplasty, Transluminal, Percutaneous Coronary
57219|NCT02699671|Coronary Artery Disease
57220|NCT02699671|drug eluting stent
57221|NCT02699671|acute myocardial infarction
57222|NCT02699658|levofloxacin
57223|NCT02699658|population pharmacokinetics
57224|NCT02699658|pharmacodynamics
57225|NCT02699632|Survey
57226|NCT02699619|Undisplaced
57227|NCT02699606|Tumor
57228|NCT02699606|Fibroblast Growth Factor Receptor (FGFR)
57229|NCT02699606|Non-Small Cell Lung Cancer (NSCLC)
57230|NCT02699606|Erdafitinib
57231|NCT02699606|Urothelial Cancer
57232|NCT02699606|Esophageal Cancer
57233|NCT02699606|Cholangiocarcinoma
57234|NCT02699580|Biodegradable collagen implant
57235|NCT02699580|scleral thinning
57236|NCT02699580|strabismus surgery
57237|NCT02699567|taste perception
57238|NCT02699567|individual differences
57239|NCT02699567|fat
57240|NCT02699567|genetics
57241|NCT02699541|Diabetes Self-Management Education
57242|NCT02699541|Behavioural change theory
57243|NCT02699541|IMB model
57244|NCT02699541|Diabetes Type 2
57245|NCT02699515|MSB0011359C
57246|NCT02699476|NFL
57247|NCT02699476|veterans
57248|NCT02699476|cognitive training
57249|NCT02699476|TBI
57250|NCT02699476|concussion
57251|NCT02699437|Preeclampsia
57252|NCT02699437|Antiphospholipid Antibodies
57253|NCT02699411|ligament anterior cruciate , dry needling, physioterapy, propioception, knee arthroplasty, vastus medialis.
57254|NCT02699385|Gastroenteritis
57255|NCT02699385|Domperidone
57256|NCT02699385|Pediatric participants
57257|NCT02699372|Healthy Volunteers
57258|NCT02699359|concussion
57259|NCT02699359|mild traumatic brain injuries
57260|NCT02699346|concussion
57261|NCT02699346|mild traumatic brain injuries
57262|NCT02699320|Short bowel syndrome
57263|NCT02699320|Intestinal microbiota
57264|NCT02699320|immune
57265|NCT02699307|physical activity
57266|NCT02699294|Pain Threshold
57267|NCT02699294|Pectoralis Minor
57268|NCT02699294|Proprioceptive Neuromuscular Facilitation (PNF) Stretching
57269|NCT02699294|Physiotherapy
57270|NCT02699294|Rehabilitation
57271|NCT02699242|Fiberoptic intubation Training Simulation Performance
57272|NCT02699216|Macular Degeneration
57273|NCT02699216|Eye Diseases
57274|NCT02699216|Retinal Degeneration
57275|NCT02699216|Retinal Diseases
57276|NCT02699190|Leukodystrophy
57277|NCT02699190|White Matter Disease
57278|NCT02699190|Whole Genome Sequencing
57279|NCT02699190|WGS
57280|NCT02699177|ciliary beat frequency,
57281|NCT02699164|non surgical spinal decompression therapy
57282|NCT02699164|deep friction massage
57283|NCT02699164|exercise
57284|NCT02699099|Children
57285|NCT02699099|Infants
57286|NCT02699099|SB257049
57287|NCT02699099|Malaria
57288|NCT02699099|Immunogenicity
57289|NCT02699099|Surveillance
57290|NCT02699099|Efficacy
57291|NCT02699099|Safety
57292|NCT02699099|Africa
57293|NCT02699099|Plasmodium falciparum
57294|NCT02699073|colorectal cancer
57295|NCT02699073|metastatic
57296|NCT02699073|regorafenib
57297|NCT02699073|CHOI criteria
57298|NCT02699073|RECIST criteria
57299|NCT02699060|GERD
57300|NCT02699060|Barrett`s esophagus
57301|NCT02699060|macrophage
57302|NCT02699060|FSSG questionnaire
57303|NCT02699047|Gastrointestinal cancer
57304|NCT02699047|Fish oil
57305|NCT02699047|Oxidative stress
57306|NCT02699047|Inflammation
57307|NCT02699047|Quality of life
57308|NCT02699047|Nutritional status
57309|NCT02699047|Colorectal cancer
57310|NCT02699047|Stomach cancer
57311|NCT02699047|Chemotherapy
57312|NCT02699047|polyunsaturated fatty acids n-3
57313|NCT02699034|real-time MRI
57314|NCT02699034|electrophysiology study
57315|NCT02699034|atrial flutter ablation
57316|NCT02699034|active tracking
57317|NCT02699008|clopidogrel；antiplatelet therapy
57318|NCT02698982|elderly
57319|NCT02698982|postoperative cognitive dysfunction
57320|NCT02698982|postoperative delirium
57321|NCT02698982|depth of anesthesia
57322|NCT02698982|intraoperative blood pressure monitoring
57323|NCT02698969|Sugammadex
57324|NCT02698969|Post-operative residual curarization
57325|NCT02698969|Diaphragm Ultrasonography
57326|NCT02698956|SAPIEN 3 THV
57327|NCT02698956|TAVI
57328|NCT02698956|Transfemoral
57329|NCT02698956|Transaortic
57330|NCT02698956|Transapical
57331|NCT02698956|Aortic valve
57332|NCT02698943|cataract; intraocular lens; posterior capsule opacification; glistening; ENVISTA
57333|NCT02698930|Infective endocarditis
57334|NCT02698930|acute kidney injury
57335|NCT02698930|dexmedetomidine
57336|NCT02698917|Out-of-Hospital Cardiac Arrest
57337|NCT02698917|Resuscitation
57338|NCT02698917|Hypoxia-Ischemia, Brain
57339|NCT02698904|Chronic Obstructive Pulmonary Disease (COPD)
57340|NCT02698904|Relaxation Technique
57341|NCT02698904|Anxiety
57342|NCT02698891|Early Stage Breast Cancer
57343|NCT02698878|Lupin Protein
57344|NCT02698878|Glucose Metabolism
57345|NCT02698878|GLUT4
57346|NCT02698878|Muscle Unloading
57347|NCT02698878|Neuromuscular Electrical Stimulation
57348|NCT02698852|Drug eluting stents
57349|NCT02698852|Interventional Cardiology
57350|NCT02698839|Drug eluting stents
57351|NCT02698839|Interventional Cardiology
57352|NCT02698826|Cardiac Arrest, Hyperoxia, Ischemia-reperfusion Injury, Reactive Oxygen Species, Oxidative Stress, Neuropsychological Tests
57353|NCT02698761|Vaso-Occlusive Crises
57354|NCT02698761|Sickle Cell Disease
57355|NCT02698761|Decreasing Length of Stay
57356|NCT02698761|Comprehensive Care Plan
57357|NCT02698748|Chloroquine
57358|NCT02698748|Malaria Elimination
57359|NCT02698748|P.falciparum
57360|NCT02698748|Clinical Trial
57361|NCT02698748|Mozambique
57362|NCT02698748|Adults
57363|NCT02698709|Keratoconus
57364|NCT02698709|Corneal Topography
57365|NCT02698709|Diagnosis
57366|NCT02698709|Keratomileusis, Laser In Situ
57367|NCT02698696|Cognitive Remediation
57368|NCT02698696|Mood disorders
57369|NCT02698696|Neuropsychology
57370|NCT02698683|Nutrition
57371|NCT02698683|Lymphocyte Count
57372|NCT02698683|Immunoparalysis
57373|NCT02698683|nutritional status of septic patients
57374|NCT02698670|Cardiac Arrhythmias
57375|NCT02698670|Cardiovascular Disease
57376|NCT02698670|Radiofrequency Ablation
57377|NCT02698670|Cardiac Mapping
57378|NCT02698657|Rheumatoid arthritis (RA)
57379|NCT02698657|Methotrexate
57380|NCT02698657|ASP5094
57381|NCT02698631|Catheter Ablation
57382|NCT02698631|Radiofrequency
57383|NCT02698631|Fibrosis
57384|NCT02698631|Late-gadolinium enhanced MRI
57385|NCT02698618|Diabetes
57386|NCT02698618|IMR
57387|NCT02698618|Microcirculation
57388|NCT02698618|Ticagrelor
57389|NCT02698618|CFR
57390|NCT02698618|FFR
57391|NCT02698618|Coronary microcirculation
57392|NCT02698592|atrial flutter
57393|NCT02698592|ablation
57394|NCT02698592|Thermocool SF catheter
57395|NCT02698579|Adrenoleukodystrophy
57396|NCT02698579|X-linked Adrenoleukodystrophy
57397|NCT02698579|Hematopoietic Stem Cells
57398|NCT02698553|Major depressive disorder
57399|NCT02698553|Extended release Bupropion
57400|NCT02698527|lidocaine
57401|NCT02698501|Asthma
57402|NCT02698501|Airway hyperresponsiveness
57403|NCT02698501|TSLP
57404|NCT02698501|Mast cell
57405|NCT02698501|Eosinophil
57406|NCT02698475|Psoriasis
57407|NCT02698475|Ustekinumab
57408|NCT02698475|STELARA
57409|NCT02698462|Advanced neoplasia
57410|NCT02698462|Colorectal cancer
57411|NCT02698462|Population screening
57412|NCT02698462|Family history
57413|NCT02696564|COPD
57414|NCT02696564|emphysema
57415|NCT02696564|HRCT
57416|NCT02696564|losartan
57417|NCT02698371|composite resins
57418|NCT02698371|dental restoration
57419|NCT02698371|adhesives
57420|NCT02698371|non-carious cervical lesions
57421|NCT02698371|clinical effectiveness
57422|NCT02698371|Adhese universal
57423|NCT02698371|Futurabond U
57424|NCT02698371|Futurabond DC
57425|NCT02698371|self-etch
57426|NCT02698371|multimode/universal
57427|NCT02698371|clinical trial
57428|NCT02698358|Peripheral artery disease, Iliac artery, nitinol stent, restenosis
57429|NCT02698345|Popliteal artery disease, drug-eluting balloon, angioplasty
57430|NCT02698319|Triage
57431|NCT02698319|Systematic Triage
57432|NCT02698280|Bevacizumab
57433|NCT02698280|Nimustine
57434|NCT02698280|Pathology, Molecular
57435|NCT02698254|Brain cancer
57436|NCT02698254|Recurrent brain tumor
57437|NCT02698254|Prior radiation treatment to brain
57438|NCT02698254|Radiation therapy
57439|NCT02698254|XRT
57440|NCT02698254|Questionnaires
57441|NCT02698254|Surveys
57442|NCT02698241|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
57443|NCT02698241|heart failure
57444|NCT02698241|integrated diagnostics
57445|NCT02698241|chronic medication management
57446|NCT02698228|anesthesia
57447|NCT02698202|Tomosynthesis,sensitivity,specificity,screening,mammography
57448|NCT02698176|OTX015
57449|NCT02698176|MK-8628
57450|NCT02698163|Root Canal Therapy
57451|NCT02698150|Mitral regurgitation
57452|NCT02698150|Mitraclip
57453|NCT02698150|Remote monitoring
57454|NCT02698150|Wearables
57455|NCT02698111|nasopharyngeal carcinoma,donafeinib
57456|NCT02698098|Malaysia
57457|NCT02698098|Asia
57458|NCT02698098|Southeast Asia
57459|NCT02698098|Compulsory Drug Detention Centers
57460|NCT02698098|Compulsory Centers for Drug Users
57461|NCT02698098|Methadone
57462|NCT02698098|Drug Relapse
57463|NCT02698098|Drug and Narcotic Control
57464|NCT02698098|Opiate Substitution Treatment
57465|NCT02698098|Prisons
57466|NCT02698085|carpal tunnel syndrome
57467|NCT02698085|physiotherapy
57468|NCT02698085|manual therapy
57469|NCT02698072|Stiffness
57470|NCT02698072|Pain
57471|NCT02698072|Disfunction
57472|NCT02698046|Heart failure
57473|NCT02698046|Iron
57474|NCT02698046|Anemia
57475|NCT02698046|Chronic disease
57476|NCT02698033|food allergy
57477|NCT02698033|peanut
57478|NCT02698033|food challenge
57479|NCT02698020|Newborn
57480|NCT02698020|Anesthesia
57481|NCT02698020|Oxygen
57482|NCT02698020|Hyperoxia
57483|NCT02697994|Sterile Water Injection
57484|NCT02697994|Midwifery
57485|NCT02697981|sleeve gastrectomy
57486|NCT02697929|Rocuronium
57487|NCT02697916|aspirin
57488|NCT02697916|ACSD
57489|NCT02697916|PCORI
57490|NCT02697903|Creatine kinase supplementation
57491|NCT02697903|C-reactive protein
57492|NCT02697903|resistance training
57493|NCT02697903|Pomegranate supplementation
57494|NCT02697903|pomegranate juice
57495|NCT02697903|muscle damage response
57496|NCT02697786|Aortic valve surgery
57497|NCT02697773|osteoarthritis of the knee
57498|NCT02697773|osteoarthritis of the hip
57499|NCT02697773|nerve growth factor inhibitor
57500|NCT02697773|tanezumab
57501|NCT02697760|cadmium-zinc-telluride，CZT cameras
57502|NCT02697760|myocardial blood flow，MBF
57503|NCT02697760|myocardial flow reserve，MFR
57504|NCT02697747|Ultrasound
57505|NCT02697747|Palpation
57506|NCT02697747|Analgesia
57507|NCT02697747|Epidural
57508|NCT02697734|Cushing's disease
57509|NCT02697734|LCI699
57510|NCT02697734|osilodrostat
57511|NCT02697734|Pituitary Gland
57512|NCT02697734|Adrenocorticotropic
57513|NCT02697734|Hormone
57514|NCT02697734|ACTH
57515|NCT02697734|UFC
57516|NCT02697721|Caregivers
57517|NCT02697721|Behavioral symptoms
57518|NCT02697721|Dementia
57519|NCT02697721|Alzheimer disease
57520|NCT02697721|Physical activity
57521|NCT02697721|Depressive symptoms
57522|NCT02697721|Powerful Tools for Caregivers
57523|NCT02697721|Chronic Disease Self-Management Program
57524|NCT02697695|chronic inflammation
57525|NCT02697695|fatty liver index
57526|NCT02697669|Heart failure
57527|NCT02697669|myocardial perfusion
57528|NCT02697669|single-photon emission tomography
57529|NCT02697643|clinical decision support
57530|NCT02697643|substance use
57531|NCT02697643|opioid
57532|NCT02697630|Uveal melanoma
57533|NCT02697591|Solid tumor
57534|NCT02697591|adenocarcinoma of the endometrium
57535|NCT02697591|melanoma, non-small cell lung cancer (NSCLC)
57536|NCT02697591|renal cell carcinoma (RCC)
57537|NCT02697591|glucocorticoid-induced tumor necrosis factor receptor (GITR)
57538|NCT02697565|childhood obesity
57539|NCT02697565|obesity
57540|NCT02697565|prevention
57541|NCT02697565|nutrition
57542|NCT02697565|health
57543|NCT02697565|preschool
57544|NCT02697565|childcare
57545|NCT02697565|role model
57546|NCT02697565|pediatric obesity
57547|NCT02697565|weight
57548|NCT02697565|overweight
57549|NCT02697565|early childhood
57550|NCT02697565|train the trainer
57551|NCT02697526|radial artery
57552|NCT02697526|occlusion
57553|NCT02697526|functional
57554|NCT02697526|complications
57555|NCT02697526|consequences
57556|NCT02697487|Depression
57557|NCT02697487|Cohort
57558|NCT02697474|Hepatitis B
57559|NCT02697474|DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine
57560|NCT02697474|Euvax-B®
57561|NCT02697474|Hexaxim®
57562|NCT02697474|Infanrix® hexa
57563|NCT02697435|Chronic Low Back Pain
57564|NCT02697435|Aged
57565|NCT02697435|Elderly
57566|NCT02697435|Primary Care
57567|NCT02697435|Assessment
57568|NCT02697435|Lumbar
57569|NCT02697435|Spinal Stenosis
57570|NCT02697435|Hip Osteoarthritis
57571|NCT02697435|Myofascial Pain Syndrome
57572|NCT02697435|Fibromyalgia
57573|NCT02697435|Depression
57574|NCT02697435|Maladaptive Coping
57575|NCT02697435|Lumbar Spinal Stenosis
57576|NCT02697435|Insomnia
57577|NCT02697435|Sacroiliac Joint Pain
57578|NCT02697435|Lateral Hip and Thigh Pain
57579|NCT02697435|Anxiety
57580|NCT02697435|Dementia
57581|NCT02697435|Recent Leg Length Discrepancy
57582|NCT02697422|Smoking (tobacco use)
57583|NCT02697422|Peer health coach
57584|NCT02697422|Systolic blood pressure
57585|NCT02697422|Framingham Cardiovascular risk score
57586|NCT02697422|Lipid
57587|NCT02697422|Health related quality of life
57588|NCT02697422|Health care utilization
57589|NCT02697422|Medication adherence
57590|NCT02697422|Physical activity
57591|NCT02697422|Nutrition
57592|NCT02697422|Alcohol use
57593|NCT02697422|Stress management
57594|NCT02697396|Social Marketing Campaign
57595|NCT02697396|Mexican American Children
57596|NCT02697396|16-069
57597|NCT02697383|Ixazomib (MLN9708)
57598|NCT02697383|Dexamethasone
57599|NCT02697383|15-294
57600|NCT02697370|Haemophilia A prophylaxis pharmacokinetic dosing
57601|NCT02697357|Emotion Regulation Therapy
57602|NCT02697357|Distress Among Caregivers
57603|NCT02697357|15-219
57604|NCT02697331|Short cervix, twins, progesterone
57605|NCT02697305|Insulin response
57606|NCT02697305|Incretin effect
57607|NCT02697305|GLP-1
57608|NCT02697305|GIP
57609|NCT02697305|Valine
57610|NCT02697305|Leucine
57611|NCT02697305|Isoleucine
57612|NCT02697305|Branched chain amino acids
57613|NCT02697292|Intravenous Immunoglobulin
57614|NCT02697292|VGKC
57615|NCT02697292|Autoimmune epilepsy
57616|NCT02697292|Gamumex-C
57617|NCT02697279|Abscess
57618|NCT02697279|Loop
57619|NCT02697279|Drainage
57620|NCT02697253|Roux-en-Y Bariatric Surgery
57621|NCT02697253|Psychosocial Variables
57622|NCT02697253|Behavioral Variables
57623|NCT02697253|Weight Loss
57624|NCT02697253|Food Intake
57625|NCT02697253|GLP-1
57626|NCT02697253|Reinforcing Value of Food
57627|NCT02697253|Exendin 9-39
57628|NCT02697240|sickle cell disease
57629|NCT02697240|citrulline
57630|NCT02697227|Smoking cessation
57631|NCT02697227|Smoking behavior
57632|NCT02697227|Behavioral Activation Treatment
57633|NCT02697227|BATS
57634|NCT02697227|Standard Smoking Cessation Counseling
57635|NCT02697227|SC
57636|NCT02697227|Nicotine Replacement Therapy
57637|NCT02697227|NRT
57638|NCT02697227|Nicotine patch
57639|NCT02697227|Questionnaires
57640|NCT02697227|Surveys
57641|NCT02697227|CO Level
57642|NCT02697227|Cotinine Level
57643|NCT02697227|Saliva test
57644|NCT02697214|commercial heart rate monitors
57645|NCT02697214|accuracy
57646|NCT02697214|EKG
57647|NCT02697214|varying degrees of exertion
57648|NCT02697201|Mitochondrial Dynamics
57649|NCT02697201|Insulin Resistance
57650|NCT02697188|testosterone
57651|NCT02697188|male hypogonadism
57652|NCT02697188|low testosterone
57653|NCT02697175|live video-colposcopy
57654|NCT02697175|cervical dysplasia
57655|NCT02697175|anxiety
57656|NCT02697175|randomized controlled trial
57657|NCT02697175|colposcopy
57658|NCT02697162|Intermittent catheterisation
57659|NCT02697162|Antiseptic
57660|NCT02697162|Octenidine chloride
57661|NCT02697162|Children
57662|NCT02697149|ERCP
57663|NCT02697149|nonradiation-to-endoscopist
57664|NCT02697149|gallstones
57665|NCT02697136|Low HDL
57666|NCT02697136|Low apoA-I
57667|NCT02697136|ABCA-1 mutations
57668|NCT02697136|ApoA-I mutations
57669|NCT02697123|Venous Thrombosis
57670|NCT02697123|Pregnancy
57671|NCT02697123|postpartum
57672|NCT02697123|antepartum
57673|NCT02697110|Cognition
57674|NCT02697110|Brain Stimulation
57675|NCT02697110|Early Child Development
57676|NCT02697097|Hip Muscle Strength
57677|NCT02697097|FAI
57678|NCT02697071|Ketamine
57679|NCT02697071|Migraine
57680|NCT02697071|Headache
57681|NCT02697071|Emergency Department
57682|NCT02697045|Schizophrenia
57683|NCT02697045|Quality of Life
57684|NCT02697045|Functionality
57685|NCT02697045|Long Acting Injectable
57686|NCT02697045|Aripiprazole
57687|NCT02697045|Naturalistic
57688|NCT02697045|Open-label
57689|NCT02697045|Single Arm
57690|NCT02697045|Uncontrolled Study
57691|NCT02697032|FDHT
57692|NCT02697032|PET
57693|NCT02697032|Breast cancer
57694|NCT02697032|Bicalutamide
57695|NCT02697019|Nonsuicidal Self-Injury (NSSI), Deliberate Self-Harm (DSH), Self-harm, Self-injury
57696|NCT02696993|Metastatic Brain Cancer
57697|NCT02696993|Non-small cell lung cancer with brain metastasis
57698|NCT02696993|NSCLC
57699|NCT02696993|Intracranial disease
57700|NCT02696993|Stereotactic radiosurgery
57701|NCT02696993|SRS
57702|NCT02696993|Whole brain radiation therapy
57703|NCT02696993|WBRT
57704|NCT02696993|Neurocognitive exam
57705|NCT02696993|Nivolumab
57706|NCT02696993|BMS-936558
57707|NCT02696993|Opdivo
57708|NCT02696993|Ipilimumab
57709|NCT02696993|Yervoy
57710|NCT02696993|BMS-734016
57711|NCT02696993|MDX010
57712|NCT02696980|obesity
57713|NCT02696980|asthma
57714|NCT02696967|Heart Failure
57715|NCT02696954|Artemether-lumefantrine
57716|NCT02696954|Amodiaquine
57717|NCT02696954|Primaquine
57718|NCT02696902|Pseudomonas aeruginosa, Pneumonia
57719|NCT02696889|Infertility
57720|NCT02696889|Premature Ovarian Failure
57721|NCT02696889|Stem Cells
57722|NCT02696889|Amenorrhea
57723|NCT02696876|Cartilage
57724|NCT02696876|Mesenchymal stromal cell
57725|NCT02696876|Microfracture
57726|NCT02696876|Knee
57727|NCT02696876|Defect
57728|NCT02696876|Injury
57729|NCT02696876|Stem cell
57730|NCT02696876|Autologous
57731|NCT02696876|Minimally manipulated
57732|NCT02696850|sinusitis
57733|NCT02696850|rhinosinusitis
57734|NCT02696850|rhinitis
57735|NCT02696850|nasal lavage
57736|NCT02696811|cancer
57737|NCT02696811|inflammation
57738|NCT02696811|dietary intervention trial
57739|NCT02696798|Ankylosing Spondylitis
57740|NCT02696785|Ankylosing Spondylitis
57741|NCT02696759|Breast
57742|NCT02696759|Cancer
57743|NCT02696733|TURBT
57744|NCT02696733|ultrasound guided
57745|NCT02696733|ONB
57746|NCT02696733|interadductor approach
57747|NCT02696720|lidocaine
57748|NCT02696720|phantom limb pain (PLP)
57749|NCT02696720|Primary/secondary scar hyperalgesia
57750|NCT02696707|cardiac toxicities
57751|NCT02696668|multisensory exercises
57752|NCT02696668|group-based balance exercise programme
57753|NCT02696655|transplantation
57754|NCT02696642|mesothelin-expressing advanced solid cancers
57755|NCT02696629|Ventilatory control
57756|NCT02696629|Obstructive sleep apnea
57757|NCT02696629|Loop gain
57758|NCT02696629|Upper airway
57759|NCT02696629|Surgery
57760|NCT02696603|Health app research
57761|NCT02696603|mHealth research
57762|NCT02696603|Mobile health research
57763|NCT02696603|Mobile application health research
57764|NCT02696551|Medical education
57765|NCT02696551|Spondyloarthritis
57766|NCT02696551|Physician action
57767|NCT02696538|Fall risk
57768|NCT02696538|Rehabiliation
57769|NCT02696538|Physical Therapy
57770|NCT02696538|Functional Gait Assessment
57771|NCT02696538|mini-Balance Evaluation Systems Test
57772|NCT02696538|Berg Balance Scale
57773|NCT02696538|Psychometric properties
57774|NCT02696538|Validity
57775|NCT02696538|Inter-rater reliability
57776|NCT02696538|Montreal Cognitive Assessment
57777|NCT02696525|Circulating Tumor DNA
57778|NCT02696525|Lung cancer
57779|NCT02696525|lead time
57780|NCT02696512|Severe Disorders of Consciousness (SDOC)
57781|NCT02696512|Coma
57782|NCT02696512|Vegetative State
57783|NCT02696512|Minimally Conscious State
57784|NCT02696499|Uremic pruritus
57785|NCT02696499|Pruritus
57786|NCT02696499|Chronic itch
57787|NCT02696499|Itch
57788|NCT02696499|Hemodialysis
57789|NCT02696499|End-stage renal disease
57790|NCT02696473|Bioavailability
57791|NCT02696473|Polyacetylenes
57792|NCT02696473|Falcarinol
57793|NCT02696473|Falcarindiol
57794|NCT02696473|Falcarindiol-3-acetate
57795|NCT02696473|Carrot
57796|NCT02696473|Biological Availability
57797|NCT02696460|debridement
57798|NCT02696460|analgesia
57799|NCT02696447|Radiation therapy
57800|NCT02696447|Thrombosis
57801|NCT02696434|naltrexone
57802|NCT02696434|VIVITROL
57803|NCT02696434|buprenorphine
57804|NCT02696434|opioid
57805|NCT02696434|addiction
57806|NCT02696382|Veterans
57807|NCT02696382|Progressive High Intensity Physical Therapy
57808|NCT02696382|Gait Speed
57809|NCT02696382|Acute Hospitalization
57810|NCT02696382|Hospital Associated Deconditioning
57811|NCT02696356|HLA-A*02
57812|NCT02696343|somatosensory stimulation
57813|NCT02696343|orocutaneous
57814|NCT02696343|gene expression
57815|NCT02696291|Dengue
57816|NCT02696291|Arbovirus Infections
57817|NCT02696291|Flaviviridae Infections
57818|NCT02696291|Flavivirus Infections
57819|NCT02696291|Hemorrhagic Fevers, Viral
57820|NCT02696291|RNA Virus Infections
57821|NCT02696291|Virus Diseases
57822|NCT02696291|Pharmaceutical Solutions
57823|NCT02696291|Pharmacologic Actions
57824|NCT02696291|Therapeutic Uses
57825|NCT02696278|gut microbiota
57826|NCT02696278|obesity
57827|NCT02696278|toddlers
57828|NCT02696278|fiber
57829|NCT02696278|unsaturated fats
57830|NCT02696265|Atrial fibrillation
57831|NCT02696265|Complex fractionated atrial electrocardiograms
57832|NCT02696265|pulmonary vein isolation
57833|NCT02696265|ablation
57834|NCT02696252|Endocrine System Diseases
57835|NCT02696252|Glucose Metabolism Disorders
57836|NCT02696252|Metabolic Diseases
57837|NCT02696239|vaginal cuff closure
57838|NCT02696239|Robotic Hysterectomy
57839|NCT02696200|Concussion
57840|NCT02696187|Pulmonary Disease, Chronic Obstructive
57841|NCT02696187|Feasibility
57842|NCT02696187|Health promotion tool
57843|NCT02696187|Self management
57844|NCT02696187|Evidence based care
57845|NCT02696187|Knowledge transfer
57846|NCT02696187|Implementation
57847|NCT02696161|platelet rich plasma
57848|NCT02696161|Perineural injection therapy
57849|NCT02696135|Hypertrophic cardiomyopathy
57850|NCT02696135|Heart failure
57851|NCT02696135|Stroke
57852|NCT02696122|Pain, postoperative
57853|NCT02696122|Hernia, abdominal
57854|NCT02696122|Anesthesia, spinal
57855|NCT02696122|Anesthesia, local
57856|NCT02696122|Anesthesia, general
57857|NCT02696122|Quality of life
57858|NCT02696122|Anesthesia recovery period
57859|NCT02696122|Personal satisfaction
57860|NCT02696122|Postoperative complications
57861|NCT02696122|Quality of recovery
57862|NCT02696109|Transition age youth
57863|NCT02696109|Mental health
57864|NCT02696109|Mental health services
57865|NCT02696109|Engagement
57866|NCT02696070|Pain
57867|NCT02696070|Diabetic Neuropathy
57868|NCT02696070|Pulsed Electromagnetic Energy Field
57869|NCT02696070|PEMF
57870|NCT02696070|PPDN
57871|NCT02696044|Gastrointestinal Disorders
57872|NCT02696031|non-radiographic spondyloarthritis
57873|NCT02696031|axial spondyloarthritis
57874|NCT02696018|Diaphragm
57875|NCT02696018|Ultrasound
57876|NCT02696018|Critically ill patients
57877|NCT02695992|Rate control in atrial fibrillation
57878|NCT02695992|Beta blockers
57879|NCT02695992|Calcium channel blockers
57880|NCT02695992|Permanent atrial fibrillation
57881|NCT02695992|Management of atrial fibrillation
57882|NCT02695992|Atrial fibrillation and biomarkers
57883|NCT02695992|Arrhythmias, cardiac
57884|NCT02695992|Heart Diseases
57885|NCT02695992|Pathological processes
57886|NCT02695992|Diltiazem
57887|NCT02695992|Metoprolol
57888|NCT02695992|Adrenergic Agents
57889|NCT02695992|Adrenergic Antagonists
57890|NCT02695992|Adrenergic beta-1 Receptor Antagonists
57891|NCT02695992|Adrenergic beta-Antagonists
57892|NCT02695992|Anti-Arrhythmia Agents
57893|NCT02695992|Antihypertensive Agents
57894|NCT02695992|Autonomic Agents
57895|NCT02695992|Cardiovascular Agents
57896|NCT02695992|Membrane Transport Modulators
57897|NCT02695992|Molecular Mechanisms of Pharmacological Action
57898|NCT02695992|Neurotransmitter Agents
57899|NCT02695992|Peripheral Nervous System Agents
57900|NCT02695992|Physiological Effects of Drugs
57901|NCT02695992|Sympatholytics
57902|NCT02695992|Therapeutic Uses
57903|NCT02695992|Vasodilator Agents
57904|NCT02695992|Troponins
57905|NCT02695992|NT-proBNP
57906|NCT02695992|Biomarkers
57907|NCT02695953|PTSD
57908|NCT02695953|biomarker
57909|NCT02695953|Cognitive Processing Therapy
57910|NCT02695914|Inflammatory markers
57911|NCT02695901|Plaque index
57912|NCT02695901|Melaleuca alternifolia oil.
57913|NCT02695901|Nanoparticles
57914|NCT02695875|Fibromyalgia
57915|NCT02695875|Pain
57916|NCT02695875|Postural balance
57917|NCT02695875|Physical therapy
57918|NCT02695875|Aquatic therapy
57919|NCT02695849|Non-small cell lung cancer (NSCLC)
57920|NCT02695836|Audit and Feedback
57921|NCT02695836|Nursing Homes
57922|NCT02695836|Organizational Context
57923|NCT02695836|Quality Improvement
57924|NCT02695836|Care Aides
57925|NCT02695836|Leadership
57926|NCT02695836|Resident Assessment Instrument (RAI)
57927|NCT02695836|Alberta Context Tool (ACT)
57928|NCT02695823|intracranial hypertension
57929|NCT02695823|liver transplantation
57930|NCT02695823|transcranial Doppler
57931|NCT02695823|optic nerve sheath diameter
57932|NCT02695797|Intractable cryptogenic epilepsy with autoimmune antibody
57933|NCT02695797|Immunotherapy
57934|NCT02695771|bladder tumors
57935|NCT02695771|urinary tumors
57936|NCT02695771|non-muscle invasive bladder tumors
57937|NCT02695771|NMIBC
57938|NCT02695732|Esophageal and Gastric Varices
57939|NCT02695732|Primary Prophylaxis
57940|NCT02695732|Carvedilol
57941|NCT02695732|Endoscopy
57942|NCT02695719|Drug therapy
57943|NCT02695706|Diabetes
57944|NCT02695706|Skin acceptability
57945|NCT02695706|Clinical Research
57946|NCT02695680|Lung Cancer
57947|NCT02695680|SBRT
57948|NCT02695680|Motion Management
57949|NCT02695641|Arteriovenous Fistula
57950|NCT02695641|Arteriovenous Graft
57951|NCT02695641|Bevacizumab
57952|NCT02695641|Hemodialysis
57953|NCT02695641|VEGF
57954|NCT02695641|Avastin
57955|NCT02695615|cesarean operation
57956|NCT02695615|Spielberger State Trait Anxiety Inventory
57957|NCT02695615|pain
57958|NCT02695563|Amniocentesis
57959|NCT02695524|Rehabilitation
57960|NCT02695524|Shoulder
57961|NCT02695498|migraine with aura
57962|NCT02695498|migraine without aura
57963|NCT02695498|pain
57964|NCT02695498|controls
57965|NCT02695498|mind-body
57966|NCT02695485|dorsal digital island flap
57967|NCT02695485|sensory reconstruction
57968|NCT02695472|Depression
57969|NCT02695472|Major Depressive Disorder (MDD)
57970|NCT02695472|Major Depressive Disorder
57971|NCT02695472|Neurogenesis
57972|NCT02695472|Synaptogenesis
57973|NCT02695472|NSI-189
57974|NCT02695472|Neuralstem
57975|NCT02695433|Pre-diabetes
57976|NCT02695433|Metabolic syndrome
57977|NCT02695433|Matsuda composite index of insulin sensitivity (MISI)
57978|NCT02695433|Blood glucose
57979|NCT02695433|Insulin response
57980|NCT02695433|HbA1c
57981|NCT02695433|Lipid
57982|NCT02695433|Inflammation
57983|NCT02695420|Heart Failure
57984|NCT02695407|artery cannulation
57985|NCT02695407|haemodynamic monitoring
57986|NCT02695342|Balance
57987|NCT02695342|Falls
57988|NCT02695342|Exercise
57989|NCT02695342|COPD
57990|NCT02695329|navigation system
57991|NCT02695329|palm-sized
57992|NCT02695329|total knee arthroplasty
57993|NCT02695316|Migrants
57994|NCT02695316|Communication Barriers
57995|NCT02695316|Maternal Health Services
57996|NCT02695316|Health Services Needs and Demand
57997|NCT02695316|Access to Health Care
57998|NCT02695316|Professional-Patient Relations
57999|NCT02695316|Eritrea
58000|NCT02695316|Kosovo
58001|NCT02695316|Switzerland
58002|NCT02695277|Atrial Fibrillation
58003|NCT02695277|Persistent and Longstanding Persistent AF
58004|NCT02695277|Hybrid Procedure
58005|NCT02695277|Catheter Ablation
58006|NCT02695264|intracranial pressure
58007|NCT02695264|intracranial hypertension
58008|NCT02695264|severe traumatic brain injury
58009|NCT02695199|Doppler Ultrasound
58010|NCT02695199|Laparoscopic
58011|NCT02695199|Microscopic Subinguinal Varicocelectomy
58012|NCT02695186|Intestinal metaplasia
58013|NCT02695186|Metabolic syndrome
58014|NCT02695186|Oxidative stress
58015|NCT02695108|Scapula
58016|NCT02695108|Neck
58017|NCT02695108|Pain
58018|NCT02695108|Therapy
58019|NCT02695108|Kinematic
58020|NCT02695069|Complete Placenta Previa
58021|NCT02695069|Random Placenta Margin Incision
58022|NCT02695069|Cesarean Section
58023|NCT02695069|Hemorrhage
58024|NCT02694991|surgery
58025|NCT02694991|outcome
58026|NCT02694991|pain
58027|NCT02694991|osteopathic manipulative treatment
58028|NCT02694978|iron deficiency anemia
58029|NCT02694978|IDA
58030|NCT02694978|ferumoxytol
58031|NCT02694978|ferric carboxymaltose
58032|NCT02694978|FCM
58033|NCT02694978|Injectafer
58034|NCT02694926|adrenal crisis
58035|NCT02694926|education programme
58036|NCT02694887|Capillary blood
58037|NCT02694887|Venous blood
58038|NCT02694887|Lactate
58039|NCT02694887|Emergency Department
58040|NCT02694874|Adjunctive treatment
58041|NCT02694874|Severe malaria
58042|NCT02694861|Angina Pectoris
58043|NCT02694861|Angina, Stable
58044|NCT02694861|Chest Pain
58045|NCT02694796|Web and smartphone-based physical activity program
58046|NCT02694796|Connected devices
58047|NCT02694796|Balneotherapy
58048|NCT02694783|JC VIRUS
58049|NCT02694783|Progressive Multifocal Encephalopathy (PML)
58050|NCT02694770|aGvHD
58051|NCT02694770|GvHD
58052|NCT02694770|sr-aGvHD
58053|NCT02694770|biologics
58054|NCT02694770|monoclonal antibody
58055|NCT02694757|Ostom-i
58056|NCT02694757|OIA device
58057|NCT02694744|Treatment of Hyperkalemia
58058|NCT02694744|Hyperkalemia
58059|NCT02694744|Potassium
58060|NCT02694744|Chronic Kidney Disease
58061|NCT02694731|Craving
58062|NCT02694731|Mobile Apps
58063|NCT02694705|Oxygen Inhalation Therapy
58064|NCT02694705|Intubation
58065|NCT02694705|Emergency Medicine
58066|NCT02694679|social networks, maternal and child health, global health
58067|NCT02694653|C/section, Acetaminophen
58068|NCT02694640|Breast cancer
58069|NCT02694640|Exercise
58070|NCT02694640|Physical activity
58071|NCT02694640|Community volunteers
58072|NCT02694640|Peer mentors
58073|NCT02694640|Peer coaches
58074|NCT02694640|Social support
58075|NCT02694640|Exercise maintenance
58076|NCT02694627|gender, caregiving, MNCH, violence, sexual and reproductive health, parenting
58077|NCT02694614|weight loss
58078|NCT02694614|individualised dietary coaching
58079|NCT02694614|smartphone-assisted dietary coaching
58080|NCT02694614|health behavior change
58081|NCT02694588|Vedolizumab
58082|NCT02694588|Infliximab
58083|NCT02694562|Metastatic Colorectal Carcinoma
58084|NCT02694549|Vascular Closure Devices
58085|NCT02694549|Catheterization Closure Devices
58086|NCT02694549|Vascular Access Devices
58087|NCT02694523|Psoriasis
58088|NCT02694523|Skin Diseases
58089|NCT02694523|Skin Diseases, Papulosquamous
58090|NCT02694523|Adalimumab
58091|NCT02694523|Anti-Inflammatory Agents
58092|NCT02694523|ABBV-066
58093|NCT02694523|BI 655066
58094|NCT02694523|Risankizumab
58095|NCT02694510|Preterm infants
58096|NCT02694510|Oxidative stress
58097|NCT02694510|Parenteral nutrition
58098|NCT02694497|transmission
58099|NCT02694497|women
58100|NCT02694497|genital
58101|NCT02694497|anorectal
58102|NCT02694484|Cytomegalovirus
58103|NCT02694484|Stool sample
58104|NCT02694484|Healthy Volunteers
58105|NCT02694484|Fecal microbiota transplant
58106|NCT02694471|Ageing
58107|NCT02694471|Physical inactivity
58108|NCT02694471|Functional decline
58109|NCT02694471|Reconditioning
58110|NCT02694458|Vancomycin
58111|NCT02694458|Children
58112|NCT02694458|Infection
58113|NCT02694458|Antibiotic
58114|NCT02694458|Methicillin-resistant Staphylococcus aureus (MRSA)
58115|NCT02694458|Population-based pharmacokinetic modeling
58116|NCT02694458|Pharmacokinetics
58117|NCT02694458|Pharmacodynamics
58118|NCT02694458|Bayesian approach
58119|NCT02694458|Therapeutic drug monitoring
58120|NCT02694432|high blood pressure, systolic, diastolic
58121|NCT02694432|complementary therapies, meditation
58122|NCT02694419|endometrium
58123|NCT02694406|Diagnosis
58124|NCT02694367|genetic basis
58125|NCT02694341|Management
58126|NCT02694328|Alkermes
58127|NCT02694328|ALKS 3831
58128|NCT02694328|Samidorphan
58129|NCT02694328|Schizophrenia
58130|NCT02694328|Olanzapine
58131|NCT02694328|Weight
58132|NCT02694302|Stroke
58133|NCT02694250|cervical
58134|NCT02694250|fusion
58135|NCT02694250|radiculopathy
58136|NCT02694250|DTRAX
58137|NCT02694224|breast cancer
58138|NCT02694224|triple negative
58139|NCT02694224|neoadjuvant
58140|NCT02694211|work related stress
58141|NCT02694185|Medication Adherence
58142|NCT02694185|Randomized Controlled Trial
58143|NCT02694185|Veterans
58144|NCT02694172|diabetes mellitus type 2
58145|NCT02694172|healthy subjects
58146|NCT02694172|human microbiome
58147|NCT02694172|cereal bar
58148|NCT02694146|platelet-rich plasma (PRP)
58149|NCT02694146|hyaluronic acid (Hylan G-F 20).
58150|NCT02694146|NSAIDs
58151|NCT02694146|WOMAC
58152|NCT02694133|telerehabilitation
58153|NCT02694133|aphasia
58154|NCT02694133|speech therapy
58155|NCT02694133|rehabilitation device
58156|NCT02694133|visual action therapy
58157|NCT02694133|naming drills
58158|NCT02694094|cholesterol
58159|NCT02694094|seizure
58160|NCT02694094|epilepsy
58161|NCT02694094|ketogenic
58162|NCT02694094|diet
58163|NCT02694081|reflux
58164|NCT02694081|residue
58165|NCT02694081|Gastric stasis
58166|NCT02694081|Emptying time
58167|NCT02694068|Peritoneal Dialysis
58168|NCT02694068|Genetic
58169|NCT02694068|Peritoneal Membrane
58170|NCT02694068|Peritoneal Equilibrium Test
58171|NCT02694068|Ultrafiltration Capacity
58172|NCT02694068|End Stage Renal Disease (ESRD)
58173|NCT02694055|Community Health Workers
58174|NCT02694055|Community Case Management
58175|NCT02694055|Proactive Case Detection
58176|NCT02694055|Under-five Child Mortality
58177|NCT02694055|Access to Health Care
58178|NCT02694042|Pediatric inflammatory bowel disease
58179|NCT02694042|Crohn's disease
58180|NCT02694042|Ulcerative colitis
58181|NCT02694042|Web-based teaching and support
58182|NCT02694042|disease self-management
58183|NCT02694042|peer support
58184|NCT02694016|Remote ischemic preconditioning
58185|NCT02694016|Neuroprotection
58186|NCT02694003|Autism Spectrum Disorder (ASD)
58187|NCT02694003|Fetal Alcohol Spectrum Disorder (FASD)
58188|NCT02694003|Cerebral Palsy (CP)
58189|NCT02694003|Attention-Deficit/Hyperactivity Disorder (ADHD)
58190|NCT02694003|Behavioural Insomnia
58191|NCT02694003|Neurodevelopmental Disorders
58192|NCT02693990|Tumor lining the brain
58193|NCT02693990|Meningioma
58194|NCT02693990|Brain Tumor
58195|NCT02693977|OSA
58196|NCT02693977|sleep apnea
58197|NCT02693977|AT
58198|NCT02693977|adenotonsillectomy
58199|NCT02693977|pediatric
58200|NCT02693964|Type 1 Diabetes
58201|NCT02693964|Menopause
58202|NCT02693964|Cardiovascular Risk
58203|NCT02693964|Bone Density
58204|NCT02693951|gastric varices
58205|NCT02693951|endoscopic injection of tissue adhesive
58206|NCT02693938|diabetes
58207|NCT02693938|menstrual cycle
58208|NCT02693938|insulin
58209|NCT02693912|efferocytosis
58210|NCT02693912|macrophage
58211|NCT02693873|Osteoarthritis, Hip
58212|NCT02693873|Osteoarthritis, Knee
58213|NCT02693873|Patient Education
58214|NCT02693873|Exercise, Neuromuscular
58215|NCT02693873|Disease Management
58216|NCT02693873|Evidence-Based Health Care
58217|NCT02693873|Pilot Study
58218|NCT02693847|HCV
58219|NCT02693847|HIV
58220|NCT02693847|Liver cirrhosis
58221|NCT02693847|Hepatocellular carcinoma
58222|NCT02693847|Liver transplant
58223|NCT02693847|Liver stiffness
58224|NCT02693847|Transient elastography
58225|NCT02693834|foot drop
58226|NCT02693834|Subacute stroke
58227|NCT02693834|AFO
58228|NCT02693834|gait symmetry
58229|NCT02693834|Gait endurance
58230|NCT02693821|Gabapentin
58231|NCT02693821|prevention
58232|NCT02693821|incidence
58233|NCT02693808|Temporal hollowing
58234|NCT02693808|Lateral orbital wall decompression
58235|NCT02693808|Thyroid eye disease
58236|NCT02693795|myocardial infarction
58237|NCT02693795|left ventricular remodeling
58238|NCT02693782|Fibre
58239|NCT02693782|Wheat Bran Extract
58240|NCT02693782|Microbiota
58241|NCT02693782|Microbiota metabolites
58242|NCT02693782|Gastrointestinal tolerance
58243|NCT02693743|suicidality
58244|NCT02693743|rTMS
58245|NCT02693743|suicide ideation
58246|NCT02693730|Irritable Bowel Syndrome
58247|NCT02693730|IBS
58248|NCT02693730|Ulcerative Colitis
58249|NCT02693730|UC
58250|NCT02693730|Inflammatory Bowel Disease
58251|NCT02693730|IBD
58252|NCT02693730|Healthy Control
58253|NCT02693730|HC
58254|NCT02693730|Visceral Pain
58255|NCT02693730|Gut
58256|NCT02693730|Neuroimaging
58257|NCT02693730|fMRI
58258|NCT02693730|resting state
58259|NCT02693730|structural MRI
58260|NCT02693730|functional MRI
58261|NCT02693730|diffusion tensor imaging
58262|NCT02693730|MR Spectroscopy
58263|NCT02693717|Cancer of urethra
58264|NCT02693717|Cancer of ureters
58265|NCT02693717|MTAP-deficient bladder cancer
58266|NCT02693717|MTAP wild-type bladder cancer
58267|NCT02693717|Metastatic
58268|NCT02693717|Pemetrexed
58269|NCT02693717|LY231514
58270|NCT02693717|Alimta
58271|NCT02693717|MTA
58272|NCT02693717|Multitargeted Antifolate
58273|NCT02693717|NSC-698037
58274|NCT02693717|Folic Acid
58275|NCT02693717|Folinic Acid
58276|NCT02693717|Vitamin B12
58277|NCT02693717|Dexamethasone
58278|NCT02693717|Decadron
58279|NCT02693678|Proprioception
58280|NCT02693678|Doms
58281|NCT02693678|Pain
58282|NCT02693678|Massage
58283|NCT02693678|Diathermy
58284|NCT02693665|pediatric advance care planning
58285|NCT02693665|adolescent
58286|NCT02693665|family
58287|NCT02693665|palliative care
58288|NCT02693665|end of life
58289|NCT02693665|communication
58290|NCT02693665|decision making
58291|NCT02693665|surrogate decision maker
58292|NCT02693665|health care proxy
58293|NCT02693665|intervention
58294|NCT02693665|randomized clinical trial
58295|NCT02693665|cancer
58296|NCT02693665|quality of life
58297|NCT02693665|spiritual
58298|NCT02693665|religion
58299|NCT02693665|treatment congruence
58300|NCT02693665|treatment preferences
58301|NCT02693665|FAmily CEntered (FACE) Advance Care Planning
58302|NCT02693639|PANX1
58303|NCT02693639|Infection
58304|NCT02693639|Liver transplantation
58305|NCT02693626|mobile phone-based text message interventions
58306|NCT02693626|'Happy Quit'
58307|NCT02693626|smoking cessation
58308|NCT02693613|Drug-drug interaction
58309|NCT02693613|Kremezin
58310|NCT02693613|Pharmacokinetics
58311|NCT02693613|ASP1517
58312|NCT02693600|Total Trapeziectomy
58313|NCT02693600|Partial Trapeziectomy
58314|NCT02693600|Ligamentoplasty
58315|NCT02693574|Helicobacter pylori
58316|NCT02693574|Helicobacter Infections
58317|NCT02693574|Proton Pump Inhibitors
58318|NCT02693561|Self-help book
58319|NCT02693561|Deep breathing
58320|NCT02693548|Familial Hypercholesterolaemia
58321|NCT02693548|Prognosis
58322|NCT02693548|Cardiovascular disease
58323|NCT02693535|cancer
58324|NCT02693535|off-label
58325|NCT02693535|precision medicine
58326|NCT02693535|targeted therapy
58327|NCT02693496|ResearchKit
58328|NCT02693496|CT screening
58329|NCT02693496|Early Diagnosis
58330|NCT02693496|Lung Cancer
58331|NCT02693392|Fenugreek seed extract
58332|NCT02693392|HbA1c
58333|NCT02693392|Blood glucose
58334|NCT02693379|cervical cancer
58335|NCT02693379|HPV
58336|NCT02693379|VIA
58337|NCT02693379|screening
58338|NCT02693379|smartphone
58339|NCT02693379|telemedicine
58340|NCT02693366|bone marrow cells, stem cells, cell therapy
58341|NCT02693366|Glomerulosclerosis, Focal Segmental
58342|NCT02693366|Renal Insufficiency, Chronic
58343|NCT02693327|Gut Microbiome
58344|NCT02693327|Mental Disorder
58345|NCT02693327|Dysbiosis
58346|NCT02693314|Jarro-Dophilus
58347|NCT02693314|probiotic
58348|NCT02693314|microbiota
58349|NCT02693314|gastrointestinal
58350|NCT02693301|Asthma
58351|NCT02693301|Respiratory symptoms
58352|NCT02693301|Exercise program
58353|NCT02693301|Functional capacity
58354|NCT02693301|Body composition
58355|NCT02693288|Wrist fracture
58356|NCT02693288|postoperative pain
58357|NCT02693288|local anesthesia
58358|NCT02693275|Community Sampling
58359|NCT02693262|defibrillator
58360|NCT02693262|heart failure
58361|NCT02693262|ICD
58362|NCT02693262|CRT-D
58363|NCT02693262|cardiac resynchronization therapy
58364|NCT02693262|rate response
58365|NCT02693262|CLS
58366|NCT02693262|closed-loop stimulation
58367|NCT02693262|accelerometer
58368|NCT02693262|chronotropic incompetence
58369|NCT02693249|accidents
58370|NCT02693249|adolescents
58371|NCT02693249|children
58372|NCT02693249|posttraumatic cognitions
58373|NCT02693223|stroke
58374|NCT02693197|Hepatic Impairment
58375|NCT02693145|HIV/AIDS
58376|NCT02693145|re-engagement in care
58377|NCT02693145|data to care
58378|NCT02693132|Obesity
58379|NCT02693132|Exercise
58380|NCT02693119|LHON
58381|NCT02693119|Ocuvia™
58382|NCT02693119|elamipretide
58383|NCT02693119|MTP-131
58384|NCT02693041|Probiotics
58385|NCT02693041|inflammation
58386|NCT02693041|immunological response
58387|NCT02693041|preterm birth
58388|NCT02693041|preeclampsia
58389|NCT02693028|Microbiome
58390|NCT02693028|probiotic
58391|NCT02692976|Castration-resistant prostate cancer
58392|NCT02692976|Dendritic Cells
58393|NCT02692976|Immunotherapy
58394|NCT02692976|Vaccines
58395|NCT02692937|Neurosurgical Procedures
58396|NCT02692937|Nerve Block
58397|NCT02692937|Exercise therapy
58398|NCT02692937|Physical Therapy Specialty
58399|NCT02692924|Pregnancy Complications
58400|NCT02692924|Ultrasound
58401|NCT02692911|Gallbaldder
58402|NCT02692911|Cancer
58403|NCT02692911|Gallstones
58404|NCT02692911|Cholecystectomy
58405|NCT02692911|Inflammation
58406|NCT02692898|Brain Tumor
58407|NCT02692898|Molecular Pathology
58408|NCT02692898|Clinical Data
58409|NCT02692898|Imaging Data
58410|NCT02692885|Phenotype
58411|NCT02692885|Adipose Tissue
58412|NCT02692885|Brown Adipose Tissue
58413|NCT02692872|Alpha Thalassemia
58414|NCT02692872|Double Deletion
58415|NCT02692846|CONNECTIVE TISSUE DISEASES
58416|NCT02692846|Cardiovascular Disease
58417|NCT02692846|Elastin Gene Mutation
58418|NCT02692846|Multisystem Developmental Disorder
58419|NCT02692833|Telomere
58420|NCT02692833|Telomerase
58421|NCT02692833|DNA methylation
58422|NCT02692833|Cell aging
58423|NCT02692833|Thoracic Surgery
58424|NCT02692820|Preterm
58425|NCT02692820|Probiotic
58426|NCT02692807|hip arthroscopy
58427|NCT02692807|femoroacetabular impingement
58428|NCT02692807|exercise therapy after hip arthroscopy
58429|NCT02692807|rehabilitation after hip arthroscopy
58430|NCT02692794|sinusitis
58431|NCT02692794|oximetry
58432|NCT02692794|paranasal sinus diseases
58433|NCT02692781|Obesity
58434|NCT02692768|total shoulder arthroplasty
58435|NCT02692768|total shoulder replacement
58436|NCT02692768|adult
58437|NCT02692768|reverse shoulder arthroplasty
58438|NCT02692755|African American
58439|NCT02692742|Chemotherapy
58440|NCT02692742|Chemotherapy-induced Neutropenia
58441|NCT02692742|Supportive Care
58442|NCT02692742|Myelosuppression
58443|NCT02692742|CIN
58444|NCT02692703|HCV Treatment Experienced
58445|NCT02692703|Hepatitis C
58446|NCT02692703|HCV Genotype 3
58447|NCT02692703|Without cirrhosis
58448|NCT02692703|Non-cirrhotic
58449|NCT02692703|HCV Genotype 2
58450|NCT02692703|Renal Transplant
58451|NCT02692703|HCV Treatment Naive
58452|NCT02692703|Post transplant
58453|NCT02692703|HCV Genotype 6
58454|NCT02692703|Liver Transplant
58455|NCT02692703|HCV Genotype 5
58456|NCT02692703|HCV Genotype 4
58457|NCT02692703|Kidney Transplant
58458|NCT02692703|HCV Genotype 1
58459|NCT02692677|Healthy
58460|NCT02692677|JNJ-42756493
58461|NCT02692664|iliac side branch
58462|NCT02692651|vancomycin
58463|NCT02692651|fidaxomicin
58464|NCT02692651|CDI
58465|NCT02692651|diarrhea
58466|NCT02692599|live attenuated mumps vaccine
58467|NCT02692599|safety
58468|NCT02692599|immunogenicity
58469|NCT02692599|infant
58470|NCT02692586|Thromboembolism
58471|NCT02692586|Thrombectomy
58472|NCT02692586|Right Heart Strain
58473|NCT02692586|Submassive PE
58474|NCT02692586|Right Ventricle Dysfunction
58475|NCT02692586|Massive PE
58476|NCT02692560|Sedentary time
58477|NCT02692560|Sit-to-stand transitions
58478|NCT02692534|Anesthesia
58479|NCT02692534|Cocaine Use
58480|NCT02692508|cardiovascular MRI
58481|NCT02692508|apical hypertrophic cardiomyopathy
58482|NCT02692508|giant negative T-wave
58483|NCT02692508|wall thickness
58484|NCT02692508|Nuclear Magnetic Resonance
58485|NCT02692508|Early Diagnosis
58486|NCT02692508|Prognosis
58487|NCT02692495|body odor
58488|NCT02692495|halitosis
58489|NCT02692495|dysbiosis
58490|NCT02692495|leaky gut
58491|NCT02692495|microbiome
58492|NCT02692469|Bariatric Surgery, Obesity, Laparoscopy
58493|NCT02692443|Congenital Heart Disease
58494|NCT02692443|Magnetic Brain Resonance
58495|NCT02692443|CHD
58496|NCT02692443|MRI
58497|NCT02692443|Neurodevelopmental
58498|NCT02692430|Portosystemic Shunt
58499|NCT02692430|Hepatic encephalopathy
58500|NCT02692430|Portal hypertension
58501|NCT02692430|Liver cirrhosis
58502|NCT02692417|hypoactive desire disorder
58503|NCT02692417|female sexual dysfunction
58504|NCT02692417|genital arousal disorder
58505|NCT02692417|sexual
58506|NCT02692417|dysfunction
58507|NCT02692417|female
58508|NCT02692417|arousal
58509|NCT02692417|electrical stimulation
58510|NCT02692417|transcutaneous electrical stimulation
58511|NCT02692417|women
58512|NCT02692404|Postpartum Depression
58513|NCT02692404|Perinatal Depression
58514|NCT02692404|Pregnancy
58515|NCT02692404|Anesthesia
58516|NCT02692404|Obstetric
58517|NCT02692404|Pain
58518|NCT02692404|Analgesia
58519|NCT02692404|Epidural
58520|NCT02692404|Midwife
58521|NCT02692404|Infant Development
58522|NCT02692404|Pain Management
58523|NCT02692391|Acute pancreatitis
58524|NCT02692391|Indomethacin
58525|NCT02692391|Organ failure
58526|NCT02692391|Prevention
58527|NCT02692378|Haemodialysis
58528|NCT02692378|sodium bicarbonate
58529|NCT02692378|potassium
58530|NCT02692378|arrhythmia
58531|NCT02692378|muscle
58532|NCT02692378|symptoms
58533|NCT02692339|Relapsed Multiple Myeloma
58534|NCT02692339|Refractory Multiple Myeloma
58535|NCT02692339|Lenalidomide
58536|NCT02692339|Dexamethasone
58537|NCT02692339|Observational Study
58538|NCT02692339|Safety of Len/Dex
58539|NCT02692326|intrahepatic cholestasis
58540|NCT02692326|infant newborn
58541|NCT02692326|cyclic parenteral nutrition
58542|NCT02692313|epinephrine
58543|NCT02692313|counterregulation
58544|NCT02692313|dose responses
58545|NCT02692300|anesthesia
58546|NCT02692300|delirium
58547|NCT02692300|surgery
58548|NCT02692300|electroencephalography
58549|NCT02692300|burst suppression
58550|NCT02692300|PTSD
58551|NCT02692300|anxiety
58552|NCT02692300|depression
58553|NCT02692300|falls
58554|NCT02692274|Point-of-care diagnostics
58555|NCT02692274|Rural primary health care
58556|NCT02692274|Access
58557|NCT02692274|Need
58558|NCT02692274|Usage
58559|NCT02692274|Maternal Health
58560|NCT02692235|carnitine
58561|NCT02692235|leucine
58562|NCT02692222|pulse pressure variation monitoring
58563|NCT02692222|Captesia
58564|NCT02692222|cardiac output monitoring
58565|NCT02692209|Mammography
58566|NCT02692196|Neurofeedback
58567|NCT02692196|Emotion processing
58568|NCT02692196|Real-time
58569|NCT02692196|fMRI
58570|NCT02692183|Parkinson's disease
58571|NCT02692183|ET
58572|NCT02692183|EEG
58573|NCT02692183|FUS
58574|NCT02692183|BNA
58575|NCT02692183|Essential tremor
58576|NCT02692131|Left Ventricle strain, speckle strain
58577|NCT02692105|prostate adenocarcinoma
58578|NCT02692105|intermediate risk group
58579|NCT02692105|brachytherapy
58580|NCT02692105|High Dose Rate vs Low Dose Rate
58581|NCT02692105|Quality of Life
58582|NCT02692092|Complications
58583|NCT02692092|Arthroplasty, Hip Replacement
58584|NCT02692092|Arthroplasty, Knee Replacement
58585|NCT02692079|Angiogenesis
58586|NCT02692079|Bilateral infrabony defect
58587|NCT02692079|Flap surgery
58588|NCT02692079|Titanium-prepared, platelet-rich ﬁbrin
58589|NCT02692040|obesity
58590|NCT02692040|diabetes mellitus
58591|NCT02692040|glucagon-like peptide-1
58592|NCT02692027|Community-based initiation of antiretroviral therapy
58593|NCT02692027|Home-based HIV testing and counseling
58594|NCT02692027|Lesotho
58595|NCT02692027|Sub-sahara Africa
58596|NCT02692027|antiretroviral therapy
58597|NCT02692027|AIDS
58598|NCT02692027|Test and treat
58599|NCT02691988|Inhaled corticosteroids
58600|NCT02691988|General practice
58601|NCT02691988|Primary care
58602|NCT02691988|Pharmacotherapy
58603|NCT02691936|Genitourinary symptoms of menopause
58604|NCT02691936|Menopause
58605|NCT02691936|Atrophic vaginitis
58606|NCT02691923|High Grade Glioma
58607|NCT02691923|Low Grade Glioma
58608|NCT02691923|Brain Tumor
58609|NCT02691910|malaria
58610|NCT02691910|Plasmodium vivax
58611|NCT02691910|treatment
58612|NCT02691910|Chloroquine
58613|NCT02691910|Primaquine
58614|NCT02691897|Diabetes mellitus
58615|NCT02691897|Melatonin
58616|NCT02691897|Blood Glucose
58617|NCT02691897|Therapeutics
58618|NCT02691897|Pineal gland
58619|NCT02691884|Heart Rate, Fetal
58620|NCT02691884|Electronic Fetal Monitoring
58621|NCT02691884|Transducers, Pressure
58622|NCT02691858|Intussusception
58623|NCT02691819|jailed-balloon technique
58624|NCT02691754|Paracetamol
58625|NCT02691754|PPI
58626|NCT02691754|Opioids
58627|NCT02691754|NSAID
58628|NCT02691754|Drug Prescription
58629|NCT02691702|Multiple Ascending Dose Study
58630|NCT02691702|Safety and Tolerability
58631|NCT02691702|Pharmacokinetics
58632|NCT02691702|Pharmacodynamics
58633|NCT02691702|Melatonin
58634|NCT02691702|Plasma
58635|NCT02691702|Dim Light Melatonin Onset
58636|NCT02691676|crystalloids, fluid therapy, Plasmalyte, Ringerfundin
58637|NCT02691663|Geriatric
58638|NCT02691663|bicarbonate
58639|NCT02691650|serum cholinesterase
58640|NCT02691650|plasma cholinesterase
58641|NCT02691650|pseudocholinesterase
58642|NCT02691650|systemic inflammation
58643|NCT02691650|SIRS
58644|NCT02691650|polytrauma
58645|NCT02691637|Helicobacter pylori infection
58646|NCT02691637|Eradication treatment
58647|NCT02691637|Reversibility
58648|NCT02691637|atrophic gastritis
58649|NCT02691637|intestinal metaplasia
58650|NCT02691624|Lymphedema of Upper Arm
58651|NCT02691624|Breast cancer
58652|NCT02691624|Breast cancer-related Lymphedema
58653|NCT02691624|Lymphoscintigraphy
58654|NCT02691546|Chronic Kidney Diseases
58655|NCT02691546|Older
58656|NCT02691546|Geriatric assessment
58657|NCT02691546|Biomarkers
58658|NCT02691533|Acute
58659|NCT02691520|Treatment Resistant Depression
58660|NCT02691507|Eczema, Itchy Skin
58661|NCT02691494|Elagolix
58662|NCT02691494|Menorrhagia
58663|NCT02691494|Elagolix + Norethindrone acetate
58664|NCT02691494|Elagolix Sodium
58665|NCT02691494|HMB
58666|NCT02691494|Heavy menstrual bleeding
58667|NCT02691494|Leiomyomata
58668|NCT02691494|Heavy uterine bleeding
58669|NCT02691494|ABT-620
58670|NCT02691494|Elagolix + E2/NETA
58671|NCT02691468|one lung ventilation
58672|NCT02691468|double lumen endobronchial tube
58673|NCT02691468|displacement
58674|NCT02691468|Fiberoptic bronchoscope
58675|NCT02691442|Peripheral nerve block
58676|NCT02691429|Vitreoretinal surgery
58677|NCT02691429|euterpe oleracea
58678|NCT02691429|chromovitrectomy
58679|NCT02691325|ELLIPTA
58680|NCT02691325|GSK2269557
58681|NCT02691325|Tolerability
58682|NCT02691325|Safety
58683|NCT02691325|Dry powder Inhaler (DPI)
58684|NCT02691325|Pharmacokinetics
58685|NCT02691312|type 1 diabetes
58686|NCT02691312|retinopathy
58687|NCT02691299|NSCLC
58688|NCT02691260|obesity
58689|NCT02691260|behavioral intervention
58690|NCT02691260|diet
58691|NCT02691247|T1DM
58692|NCT02691247|Type 1 Diabetes Mellitus
58693|NCT02691247|T regulatory cell
58694|NCT02691247|Immunotherapy
58695|NCT02691247|Cell therapy
58696|NCT02691247|T-Reg
58697|NCT02691221|Suicidal behavior, Mobile Application, Mobile Health Tool
58698|NCT02691208|acupuncture
58699|NCT02691208|breast cancer
58700|NCT02691208|rehabilitation
58701|NCT02691208|pain
58702|NCT02691195|Ultrasound
58703|NCT02691195|Serratus Plane Block
58704|NCT02691195|Quality of recovery
58705|NCT02691156|Hematofluorometer
58706|NCT02691130|influenza
58707|NCT02691130|vaccine
58708|NCT02691130|universal
58709|NCT02691130|peptide
58710|NCT02691130|prime
58711|NCT02691130|boost
58712|NCT02691130|HAI
58713|NCT02691130|CMI
58714|NCT02691130|UNISEC
58715|NCT02691117|Alopecia Areata
58716|NCT02691117|Garlic concentrate
58717|NCT02691052|pancreatic cancer
58718|NCT02691052|metastatic
58719|NCT02691026|MPNST
58720|NCT02691026|Pembrolizumab
58721|NCT02691000|depression
58722|NCT02691000|depressive symptoms
58723|NCT02691000|stage b heart failure
58724|NCT02691000|bright white light
58725|NCT02691000|light therapy
58726|NCT02690987|tobacco
58727|NCT02690987|GLP1
58728|NCT02690987|ghrelin
58729|NCT02690987|alcohol
58730|NCT02690987|appetite
58731|NCT02690987|reward
58732|NCT02690987|addiction
58733|NCT02690987|hormone
58734|NCT02690987|cigarette
58735|NCT02690987|fMRI
58736|NCT02690974|HFrEF,
58737|NCT02690974|ACEi,
58738|NCT02690974|ACE inhibitor,
58739|NCT02690974|ARBs,
58740|NCT02690974|systolic heart failure,
58741|NCT02690974|chronic heart failure,
58742|NCT02690974|CHF,
58743|NCT02690974|reduced EF,
58744|NCT02690974|Ejection Fraction
58745|NCT02690961|Healthy
58746|NCT02690935|grass pollen
58747|NCT02690935|homeopathy
58748|NCT02690935|placebo
58749|NCT02690935|quality of life
58750|NCT02690909|Uncontrolled Hypertension
58751|NCT02690909|Resistant Hypertension
58752|NCT02690909|Renal Denervation
58753|NCT02690896|caregiver burden
58754|NCT02690896|caregiver support groups
58755|NCT02690870|tamoxifen
58756|NCT02690870|clomiphene
58757|NCT02690870|mild stimulation
58758|NCT02690870|poor ovarian response
58759|NCT02690870|clinical pregnancy rate
58760|NCT02690831|Asthma
58761|NCT02690831|Inspiratory Muscle Training
58762|NCT02690831|Manual Therapies
58763|NCT02690818|Tuberculosis
58764|NCT02690818|Latent Tuberculosis
58765|NCT02690818|Texting
58766|NCT02690818|Adherence
58767|NCT02690818|Medication
58768|NCT02690792|Healthy
58769|NCT02690792|NAFLD
58770|NCT02690792|NASH
58771|NCT02690792|Liver Metabolism
58772|NCT02690792|Vitamin E
58773|NCT02690766|Cancer
58774|NCT02690766|Breast Cancer
58775|NCT02690766|Endometrial cancer,
58776|NCT02690766|Type 2 Diabetes
58777|NCT02690753|Repositioning
58778|NCT02690753|Incontinence care
58779|NCT02690753|Prevention
58780|NCT02690740|titrated quantitative conjunctival provocation test
58781|NCT02690727|Fasting
58782|NCT02690727|Fed condition
58783|NCT02690727|Pharmacokinetics
58784|NCT02690701|psoriasis
58785|NCT02690701|plaque psoriasis
58786|NCT02690701|secukinumab
58787|NCT02690701|AIN457
58788|NCT02690701|biologic
58789|NCT02690701|monoclonal antibody
58790|NCT02690688|Pulse Pressure Variation
58791|NCT02690688|NIRS
58792|NCT02690688|Pneumoperitoneum
58793|NCT02690688|Abdominal surgery
58794|NCT02690675|Neurodevelopment
58795|NCT02690675|Bayley Scale
58796|NCT02690675|Growth
58797|NCT02690675|Iron fortification
58798|NCT02690662|Obesity
58799|NCT02690662|Kidney stones
58800|NCT02690662|Diet
58801|NCT02690649|anticoagulants
58802|NCT02690649|Personal Health Records
58803|NCT02690623|hospitalist
58804|NCT02690623|pediatric inpatient care
58805|NCT02690610|EBUS, Mediastinal lesions, Mediastinal lymph node
58806|NCT02690597|Anxiety analogic visual scale
58807|NCT02690597|Pain
58808|NCT02690597|State Trait Inventory anxiety scale
58809|NCT02690597|Anxiety
58810|NCT02690584|Psychotherapy
58811|NCT02690571|Air Pollution
58812|NCT02690571|Biodiesel exhaust
58813|NCT02690571|Bronchoscopy
58814|NCT02690571|Metabolomics
58815|NCT02690558|muscle-invasive
58816|NCT02690545|CAR T cells
58817|NCT02690545|CD30
58818|NCT02690545|Lymphoma
58819|NCT02690545|T Lymphocytes
58820|NCT02690532|Celiac
58821|NCT02690532|Gluten
58822|NCT02690532|Sensitivity
58823|NCT02690532|Permeability
58824|NCT02690532|Non-celiac gluten intolerance
58825|NCT02690532|Gastrointestinal Diseases
58826|NCT02690532|Digestive System Diseases
58827|NCT02690519|Cystic fibrosis S1251N mutation
58828|NCT02690519|GLPG1837
58829|NCT02690506|pregabalin
58830|NCT02690506|spinal anesthesia
58831|NCT02690480|fulvestrant
58832|NCT02690480|palbociclib
58833|NCT02690480|metastases
58834|NCT02690480|postmenopausal
58835|NCT02690480|breast cancer
58836|NCT02690480|hormone receptor positive
58837|NCT02690467|Insulin therapy
58838|NCT02690467|Needle
58839|NCT02690454|ticagrelor
58840|NCT02690454|ticagrelor active metabolite (AR-C124910XX)
58841|NCT02690454|platelet function tests
58842|NCT02690454|the flow cytometric VASP assay
58843|NCT02690454|the VerifyNow® device
58844|NCT02690454|the Multiplate® analyzer
58845|NCT02690454|pharmacokinetics
58846|NCT02690454|pharmacodynamics
58847|NCT02690454|Multiplate® ADPtest
58848|NCT02690454|VerifyNow® PRUTest™
58849|NCT02690454|Platelet VASP/P2Y12 assay
58850|NCT02690441|GAD
58851|NCT02690441|CBT
58852|NCT02690441|Physical exercise
58853|NCT02690441|Older adults
58854|NCT02690428|Hyperthermia, Induced
58855|NCT02690428|Laser Coagulation
58856|NCT02690428|Laser Therapy
58857|NCT02690389|Acupuncture
58858|NCT02690389|Flumazenil
58859|NCT02690389|Narcotrend
58860|NCT02690389|General Anaesthesia
58861|NCT02690389|Sedation
58862|NCT02690337|Advanced solid malignant tumors
58863|NCT02690337|phase 1
58864|NCT02690337|oncology
58865|NCT02690337|refractory
58866|NCT02690337|no standard treatment
58867|NCT02690272|kidney transplant
58868|NCT02690272|psychic process
58869|NCT02690259|Sentinel Lymph Node Biopsy
58870|NCT02690233|endothelial dysfunction
58871|NCT02690233|surgery
58872|NCT02690233|cardiovascular complications
58873|NCT02690233|EndoPat
58874|NCT02690233|myocardial injury
58875|NCT02690233|myocardial infarction
58876|NCT02690220|polypropylene mesh
58877|NCT02690220|prolapse
58878|NCT02690220|cystocele
58879|NCT02690220|surgical mesh
58880|NCT02690207|Herpes Zoster
58881|NCT02690207|Safety
58882|NCT02690207|Adults
58883|NCT02690207|Cross-vaccination
58884|NCT02690194|Buddhify
58885|NCT02690194|Stress
58886|NCT02690194|Anxiety
58887|NCT02690194|Relaxation Technique
58888|NCT02690168|Fasting
58889|NCT02690168|Carbon-13 Magnetic Resonance Spectroscopy
58890|NCT02690168|Neuroimaging
58891|NCT02690155|Non-valvular atrial fibrillation (NVAF)
58892|NCT02690155|Prevention
58893|NCT02690155|Stroke
58894|NCT02690129|progesterone
58895|NCT02690129|threatened abortion
58896|NCT02690116|Meditative movement
58897|NCT02690116|Breast cancer survivors
58898|NCT02690116|Qigong
58899|NCT02690116|Tai Chi Easy
58900|NCT02690116|Fatigue
58901|NCT02690103|Arabinoxylan
58902|NCT02690103|HCV
58903|NCT02690103|Viremia
58904|NCT02690103|Biobran
58905|NCT02690103|PEG interferon
58906|NCT02690090|Deep Vein Thrombosis
58907|NCT02690090|Prophylaxis
58908|NCT02690090|Critically ill adults
58909|NCT02690077|Patient Satisfaction
58910|NCT02690077|Earlier Family Bond Initiation
58911|NCT02690077|Maternal and Neonatal Outcomes
58912|NCT02690064|Endothelial Function
58913|NCT02690064|Maximal Exercise Capacity
58914|NCT02690064|Flow Mediated Dilation
58915|NCT02690064|Antioxidant
58916|NCT02690064|FEV1
58917|NCT02690038|AECOPD
58918|NCT02690038|COPD
58919|NCT02689999|Gastroesophageal Reflux Disease (GERD), GERD, impedence
58920|NCT02689986|Cold agglutinin
58921|NCT02689986|Cold agglutinin disease
58922|NCT02689986|Anemia
58923|NCT02689986|Hemolytic
58924|NCT02689986|Autoimmune
58925|NCT02689986|Bendamustine
58926|NCT02689986|Rituximab
58927|NCT02689973|adolescence
58928|NCT02689973|body fat
58929|NCT02689973|physical activity
58930|NCT02689973|psychosocial intervention
58931|NCT02689973|self-efficacy
58932|NCT02689973|planning
58933|NCT02689960|addison disease
58934|NCT02689960|adrenal crisis
58935|NCT02689960|prednisone
58936|NCT02689934|hypercholesterolemia
58937|NCT02689934|bifidobacterium longum BB536
58938|NCT02689934|red yeast rice
58939|NCT02689934|monacolin K
58940|NCT02689934|lactoflorene colesterolo
58941|NCT02689908|Thorax CT
58942|NCT02689908|Low Dose
58943|NCT02689908|Body Mass Index
58944|NCT02689908|Neck Circumference
58945|NCT02689895|adolescents
58946|NCT02689895|second line treatment failure
58947|NCT02689895|adherence
58948|NCT02689895|drug resistance
58949|NCT02689882|nicotinamide riboside
58950|NCT02689882|nicotinamide ribonucleoside
58951|NCT02689882|Nicotinamide-Adenine Dinucleotide
58952|NCT02689869|indolent lymphoma
58953|NCT02689869|novel agents
58954|NCT02689869|chemotherapy free treatment
58955|NCT02689869|ibrutinib
58956|NCT02689869|obinutuzumab
58957|NCT02689869|GA101
58958|NCT02689843|Inflammation
58959|NCT02689843|Complement system proteins
58960|NCT02689843|Homocysteine
58961|NCT02689843|C-Reactive Protein
58962|NCT02689843|Cyproterone
58963|NCT02689843|Ethinyl Estradiol
58964|NCT02689843|Androgen Antagonists
58965|NCT02689843|Metformin
58966|NCT02689843|Thiazolidinediones
58967|NCT02689843|Pioglitazone
58968|NCT02689817|Pressure ulcer
58969|NCT02689817|Monitoring
58970|NCT02689817|Pressure
58971|NCT02689817|Physiologic feedback
58972|NCT02689804|Emergency contraception
58973|NCT02689791|Appetite
58974|NCT02689791|Food Intake
58975|NCT02689791|Satiety Hormones
58976|NCT02689778|Pirfenidone
58977|NCT02689778|Diabetic nephropathy
58978|NCT02689752|mass balance
58979|NCT02689752|14C
58980|NCT02689713|Burn Pain
58981|NCT02689713|Hyperalgesia
58982|NCT02689713|TRPV1
58983|NCT02689713|OLAMs
58984|NCT02689700|Human Cytomegalovirus
58985|NCT02689700|Varicella Zoster Virus
58986|NCT02689700|Materno-fetal antibody transfer
58987|NCT02689700|Pregnancy
58988|NCT02689700|Gestational age
58989|NCT02689622|Hematology
58990|NCT02689622|Elderly
58991|NCT02689622|High Risk Myelodysplastic Syndrome
58992|NCT02689609|Nasopharyngeal carcinoma
58993|NCT02689609|Intensity-modulated radiation therapy
58994|NCT02689609|Hypothyroidism
58995|NCT02689609|Predictors
58996|NCT02689583|Helicobacter pylori
58997|NCT02689583|Antibiotic resistance
58998|NCT02689583|Sequencing
58999|NCT02689583|Mechanism
59000|NCT02689583|Cause
59001|NCT02689570|type 1 diabetes
59002|NCT02689570|coronary artery calcifications
59003|NCT02689570|diastolic dysfunction
59004|NCT02689570|adipokines
59005|NCT02689570|visceral adipose tissue
59006|NCT02689544|exercise muscle stretching
59007|NCT02689544|range of motion
59008|NCT02689544|dynamometer of muscle strength
59009|NCT02689544|electromyography
59010|NCT02689518|AMD
59011|NCT02689518|Wet AMD
59012|NCT02689518|Macular degeneration
59013|NCT02689518|Wet macular degeneration
59014|NCT02689518|Neovascularization
59015|NCT02689518|Retina
59016|NCT02689518|Retinal degeneration
59017|NCT02689479|Clinical Islet Transplantation
59018|NCT02689479|Positron Emission Tomography (PET) Computed Tomography (CT) imaging
59019|NCT02689466|Adult
59020|NCT02689466|Acetylcholine
59021|NCT02689466|Movement Disorder
59022|NCT02689466|Magnetic Resonance Imaging (MRI)
59023|NCT02689466|PET Imaging
59024|NCT02689453|T-cell Lymphoproliferative Disorder
59025|NCT02689453|CD4/CD25 Expressing T-cells in Blood and Lymphoid Tissues
59026|NCT02689453|Anti-CD52 Monoclonal Antibody
59027|NCT02689453|Antibody Dependent Cellular Cytotoxicity
59028|NCT02689440|Chronic Myelogenous Leukemia
59029|NCT02689440|CML
59030|NCT02689440|Ph-positive chronic myelogenous leukemia
59031|NCT02689440|BCR-ABL positive chronic myelogenous leukemia
59032|NCT02689440|Dasatinib
59033|NCT02689440|BMS-354825
59034|NCT02689440|Sprycel
59035|NCT02689427|Breast cancer
59036|NCT02689427|Invasive carcinoma of the breast
59037|NCT02689427|Triple-negative breast cancer
59038|NCT02689427|TNBC
59039|NCT02689427|Enzalutamide
59040|NCT02689427|MDV3100
59041|NCT02689427|XTANDI
59042|NCT02689427|Paclitaxel
59043|NCT02689427|Taxol
59044|NCT02689414|Atherosclerosis
59045|NCT02689401|Esophageal Cancer
59046|NCT02689401|lymph nodes tumor
59047|NCT02689388|analgesia
59048|NCT02689388|regional analgesia
59049|NCT02689388|femoral nerve block
59050|NCT02689388|older persons
59051|NCT02689388|frail
59052|NCT02689362|Diabetes Mellitus Type 2
59053|NCT02689349|hearing
59054|NCT02689349|implant
59055|NCT02689349|moderate degree
59056|NCT02689349|severe degree
59057|NCT02689310|Wound Care
59058|NCT02689310|Medical Grade Honey
59059|NCT02689310|Pressure Ulcers
59060|NCT02689284|Stomach Cancer
59061|NCT02689284|Gastroesophageal Junction
59062|NCT02689284|Gastric Cancer
59063|NCT02689284|Cancer of the Stomach
59064|NCT02689284|Cancer of Stomach
59065|NCT02689284|Stomach
59066|NCT02689284|Pembrolizumab
59067|NCT02689284|Keytruda
59068|NCT02689284|HER2+
59069|NCT02689284|GEJ
59070|NCT02689284|HER2 positive
59071|NCT02689284|Metastatic
59072|NCT02689284|Margetuximab
59073|NCT02689284|Immunotherapy
59074|NCT02689284|Trastuzumab
59075|NCT02689284|Human epidermal growth factor receptor 2
59076|NCT02689284|Human epidermal growth factor receptor 2-positive
59077|NCT02689284|gastroesophageal junction cancer
59078|NCT02689284|Pembro
59079|NCT02689284|PD-L1
59080|NCT02689284|PD-1
59081|NCT02689284|PD
59082|NCT02689284|Tumor
59083|NCT02689284|Cancer
59084|NCT02689271|MRI
59085|NCT02689271|Magnetic resonance imaging
59086|NCT02689271|Biomarkers
59087|NCT02689271|Fluidics
59088|NCT02689271|Diffusion MRI
59089|NCT02689219|Antigens, CD30, Embryonal Germ Cell Tumors
59090|NCT02689206|Chronic kidney disease
59091|NCT02689206|Efficacy
59092|NCT02689206|Erythropoiesis-stimulating agent
59093|NCT02689206|GSK1278863
59094|NCT02689206|Safety
59095|NCT02689206|Hemodialysis-dependent anemia
59096|NCT02689206|Pharmacokinetics
59097|NCT02689193|Proteomics
59098|NCT02689193|Rapid Diagnostic Test
59099|NCT02689193|Salmonellosis
59100|NCT02689180|heart failure
59101|NCT02689180|diuretics
59102|NCT02689180|furosemide
59103|NCT02689167|renal cell carcinoma
59104|NCT02689167|sunitinib
59105|NCT02689167|metastatic
59106|NCT02689167|schedule
59107|NCT02689167|toxicity
59108|NCT02689167|safety
59109|NCT02689154|Pediatric Obesity
59110|NCT02689154|Food Addiction
59111|NCT02689154|Mobile Health (mHealth)
59112|NCT02689154|Weight Management
59113|NCT02689141|chronic lymphocytic leukemia CLL
59114|NCT02689141|untreated chronic lymphocytic leukemia
59115|NCT02689141|relapsed chronic lymphocytic leukemia
59116|NCT02689141|refractory chronic lymphocytic leukemia
59117|NCT02689128|Anesthesia
59118|NCT02689128|postoperative
59119|NCT02689128|nausea
59120|NCT02689128|vomiting
59121|NCT02689115|Nuclear factor Kappa B
59122|NCT02689115|IKK epsilon
59123|NCT02689102|Optical coherence tomography
59124|NCT02689102|Confocal laser endomicroscopy
59125|NCT02689076|Patient transfer
59126|NCT02689076|Patient care management
59127|NCT02689076|Health information exchange
59128|NCT02689063|Analgesic
59129|NCT02689024|Nerve block
59130|NCT02689024|Analgesia
59131|NCT02689011|Total Knee Arthroplasty
59132|NCT02689011|Femoral Nerve Block
59133|NCT02689011|Epidural Analgesia
59134|NCT02689011|Urinary Retention
59135|NCT02689011|Lumbar Epidural
59136|NCT02688998|HER2 negative
59137|NCT02688959|motor attention training
59138|NCT02688959|exercise
59139|NCT02688959|tai chi
59140|NCT02688959|ADHD
59141|NCT02688855|Bone Growth Stimulator
59142|NCT02688855|Ankle Fracture
59143|NCT02688829|stents,percutaneous coronary intervention
59144|NCT02688816|visual inspection with acetic acid
59145|NCT02688816|Xpert HPV
59146|NCT02688816|OncoE6
59147|NCT02688816|screening
59148|NCT02688803|HER2 Negative
59149|NCT02688790|Dalbavancin
59150|NCT02688790|DALVANCE®
59151|NCT02688790|Suspected or Confirmed Bacterial Infection
59152|NCT02688777|Rehabilitation
59153|NCT02688777|Gait
59154|NCT02688777|Postural Balance
59155|NCT02688777|Exercise
59156|NCT02688777|Accidental Falls
59157|NCT02688777|Kinesiology, Applied
59158|NCT02688764|PA21
59159|NCT02688764|phosphate binder
59160|NCT02688712|IIA
59161|NCT02688712|Xeloda
59162|NCT02688712|radiation therapy
59163|NCT02688712|LY2157299
59164|NCT02688712|tumor resection
59165|NCT02688712|capecitabine
59166|NCT02688712|5FU
59167|NCT02688712|Fluorouracil
59168|NCT02688712|IIB
59169|NCT02688712|IIC
59170|NCT02688712|IV
59171|NCT02688712|neoadjuvant
59172|NCT02688712|Rectal cancer
59173|NCT02688712|Immunotherapy
59174|NCT02688660|Pediatrics
59175|NCT02688660|Neuroimaging
59176|NCT02688647|Pulmonary Fibrosis
59177|NCT02688647|Fibrosis
59178|NCT02688647|Idiopathic Interstitial Pneumonias
59179|NCT02688647|Lung Diseases
59180|NCT02688634|Cleft Palate Surgery
59181|NCT02688634|Antibiotic treatment
59182|NCT02688621|weight loss
59183|NCT02688621|financial incentives
59184|NCT02688621|internet weight loss
59185|NCT02688595|Infant, Newborn
59186|NCT02688595|Ultrasonography
59187|NCT02688582|Target Controlled Infusion
59188|NCT02688582|Pharmacokinetics
59189|NCT02688582|Cefepime
59190|NCT02688582|critically ill patients
59191|NCT02688556|KCS
59192|NCT02688556|dry eye
59193|NCT02688556|cyclosporine
59194|NCT02688543|radio frequency treatment
59195|NCT02688543|genicular nerves
59196|NCT02688543|osteoarthritis of the knee
59197|NCT02688504|labelled medicines
59198|NCT02688504|drivers involved in serious and non-serious road accidents
59199|NCT02688504|relevance and effectiveness of pictograms on medicines packaging
59200|NCT02688478|Phthalate
59201|NCT02688478|Dibutylphthalate (DBP)
59202|NCT02688478|Airway responsiveness
59203|NCT02688478|Allergies
59204|NCT02688452|strenuous exercise
59205|NCT02688452|muscle soreness
59206|NCT02688413|Virtual reality
59207|NCT02688413|Stroke
59208|NCT02688413|Neurorehabilitation
59209|NCT02688413|Upper-limb rehabilitation
59210|NCT02688413|Training games
59211|NCT02688400|Osteoarthritis
59212|NCT02688400|Knee
59213|NCT02688400|Osteoarthritis, Knee
59214|NCT02688400|Diacerein
59215|NCT02688400|Celecoxib
59216|NCT02688400|Phase III
59217|NCT02688400|Phase IV
59218|NCT02688400|Phase III-IV
59219|NCT02688400|Canada
59220|NCT02688400|Spain
59221|NCT02688400|Austria
59222|NCT02688400|Czech Republic
59223|NCT02688400|WOMAC
59224|NCT02688387|Ambrisentan
59225|NCT02688387|Bioavailability
59226|NCT02688387|Tadalafil
59227|NCT02688387|Fixed Dose combination
59228|NCT02688322|sulbactam
59229|NCT02688322|pharmacokinetics
59230|NCT02688322|pharmacodynamics
59231|NCT02688322|Acinetobacter infections
59232|NCT02688257|Magnetic Resonance Imaging
59233|NCT02688257|Ultrasound
59234|NCT02688257|Breast Cancer
59235|NCT02688244|complicated appendicitis
59236|NCT02688244|laparoscopic appendectomy
59237|NCT02688244|irrigation
59238|NCT02688244|suction
59239|NCT02688244|abdominal abscess
59240|NCT02688231|Multiple Sclerosis
59241|NCT02688231|Upper limb rehabilitation
59242|NCT02688218|exercise
59243|NCT02688218|artificial pancreas
59244|NCT02688218|hypoglycemia
59245|NCT02688218|type 1 diabetes
59246|NCT02688205|Cyriax's functional examination
59247|NCT02688205|Ultrasound
59248|NCT02688205|Correlation
59249|NCT02688205|Resisted test
59250|NCT02688153|Aortic Valve Replacement
59251|NCT02688153|Aortic Stenosis
59252|NCT02688153|EDWARDS INTUITY
59253|NCT02688140|APL
59254|NCT02688140|acute promyelocytic leukemia (M3)
59255|NCT02688140|high-risk acute promyelocytic leukemia (APL/AML M3)
59256|NCT02688140|acute myeloid leukemia with t(15;17)(q22;q12)
59257|NCT02688140|newly diagnosed
59258|NCT02688140|high-risk
59259|NCT02688127|obstetric bleeding placenta previa
59260|NCT02688075|Diabetes Mellitus Type 2
59261|NCT02688075|Canagliflozin
59262|NCT02688075|Observational Study
59263|NCT02688036|Limited Disease Small Cell Lung Cancer
59264|NCT02688036|concurrent chemoradiotherapy
59265|NCT02688036|dose fractionation
59266|NCT02688023|5-fluorouracil
59267|NCT02688023|Irinotecan
59268|NCT02688023|Oxaliplatin
59269|NCT02688023|Colorectal cancer
59270|NCT02688023|neoadjuvant
59271|NCT02688023|chemotherapy
59272|NCT02688010|noise
59273|NCT02688010|sound
59274|NCT02688010|cycled light
59275|NCT02688010|preterm infants
59276|NCT02688010|neonatal care
59277|NCT02688010|growth
59278|NCT02688010|visual development
59279|NCT02687984|Schizophrenia
59280|NCT02687984|Long-acting Risperidone
59281|NCT02687984|Atrigel
59282|NCT02687958|GEP/ NEC
59283|NCT02687932|Functional Mitral Regurgitation
59284|NCT02687932|Ischemic Mitral Regurgitation
59285|NCT02687919|diet (gluten-free)
59286|NCT02687919|diet therapy
59287|NCT02687919|quality of life
59288|NCT02687893|Sleep
59289|NCT02687893|Exercise
59290|NCT02687867|Non-valvular atrial fibrillation (NVAF)
59291|NCT02687867|Prevention
59292|NCT02687867|Stroke
59293|NCT02687854|Non-valvular atrial fibrillation (NVAF)
59294|NCT02687854|Prevention
59295|NCT02687854|Stroke
59296|NCT02687841|acute kidney injury
59297|NCT02687841|indoxylsulfate
59298|NCT02687841|p-cresol
59299|NCT02687841|AST-120
59300|NCT02687828|Safety
59301|NCT02687828|Adalimumab
59302|NCT02687828|Effectiveness
59303|NCT02687828|AMORE study
59304|NCT02687828|Intestinal Behcet's disease (BD)
59305|NCT02687815|Vitamin D, severe asthma exacerbations, children
59306|NCT02687802|respiratory mechanics
59307|NCT02687802|Respiratory Insufficiency
59308|NCT02687802|artificial, ventilation
59309|NCT02687789|Bacterial Vaginosis
59310|NCT02687789|BV
59311|NCT02687776|Copeptin, human
59312|NCT02687763|vaccines
59313|NCT02687763|ProQuad
59314|NCT02687763|immunosuppressed
59315|NCT02687763|solid organ transplant
59316|NCT02687763|MMRV
59317|NCT02687737|Tongue
59318|NCT02687737|Genioglossus
59319|NCT02687737|genioglossus recruitment
59320|NCT02687711|Non-interventional (NIS)
59321|NCT02687711|Epilepsy
59322|NCT02687711|Partial Onset Seizures (POS)
59323|NCT02687711|add-on therapy
59324|NCT02687685|Skin to Skin Contact
59325|NCT02687685|Infant, Newborn
59326|NCT02687607|Endovascular
59327|NCT02687607|Brain aneurysm
59328|NCT02687607|Ruptured aneurysm
59329|NCT02687542|Parkinson Disease
59330|NCT02687542|Motor Fluctuation
59331|NCT02687529|Tuberculosis
59332|NCT02687529|TB
59333|NCT02687516|Treatment
59334|NCT02687516|Child
59335|NCT02687516|Obesity
59336|NCT02687516|Behavioral treatment
59337|NCT02687503|Immune system
59338|NCT02687503|Probiotics
59339|NCT02687464|Pediatric Surgery
59340|NCT02687464|Pediatrics
59341|NCT02687464|Randomized controlled trial,
59342|NCT02687464|Antibiotics
59343|NCT02687464|Cost effectiveness
59344|NCT02687451|Surgical Pain
59345|NCT02687451|Acute Post-Surgical Pain
59346|NCT02687438|Steroid-eluting implant Mometasone Furoate
59347|NCT02687425|Pioglitazone
59348|NCT02687425|Chronic Myeloid Leukemia
59349|NCT02687412|Fast-track surgery
59350|NCT02687412|Gynecological oncology
59351|NCT02687412|Hospitalization post-operation
59352|NCT02687412|Complication
59353|NCT02687399|knee arthroplasty
59354|NCT02687386|Recurrent
59355|NCT02687386|Refractory
59356|NCT02687373|Plasmodium falciparum
59357|NCT02687373|PfSPZ Vaccine
59358|NCT02687308|Prostatic cancer
59359|NCT02687308|Radical prostatectomy
59360|NCT02687308|Minimally invasive prostate cancer surgery
59361|NCT02687282|Modified Mallampati score
59362|NCT02687282|Cesarean delivery
59363|NCT02687269|myocardial protection
59364|NCT02687269|coronary artery bypass grafting
59365|NCT02687243|pediatrics
59366|NCT02687243|anxiety
59367|NCT02687243|anesthesia
59368|NCT02687243|preoperative
59369|NCT02687217|PerioperativeHyperoxygenation
59370|NCT02687217|Wound Site Infection
59371|NCT02687217|Appendicitis
59372|NCT02687191|safety, maximum tolerated dose, modified continual reassessment method, intracerebral, hemorrhage, hematoma
59373|NCT02687113|ablation
59374|NCT02687113|fusion
59375|NCT02687100|intubation
59376|NCT02687100|intensive care
59377|NCT02687100|cardiac surgery
59378|NCT02687100|sore throat
59379|NCT02687087|Radiotherapy Induced Xerostomia (RIX)
59380|NCT02687074|HFNC
59381|NCT02687074|Respiratory Failure
59382|NCT02687074|Intubation
59383|NCT02687074|Mortality
59384|NCT02687061|Recall study
59385|NCT02687061|Lost to follow-up
59386|NCT02687048|mindful meditation
59387|NCT02687035|S3iCAP
59388|NCT02687035|SAPIEN 3
59389|NCT02687035|Transfemoral
59390|NCT02687035|Commander
59391|NCT02687035|Certitude
59392|NCT02687035|TAVR
59393|NCT02687035|TAVI
59394|NCT02687035|Aortic stenosis
59395|NCT02687035|THV
59396|NCT02687035|Transcatheter Heart Valve
59397|NCT02687035|TVT
59398|NCT02687035|TVTR
59399|NCT02687009|colon cancer
59400|NCT02687009|Wnt pathway
59401|NCT02687009|Frizzled
59402|NCT02686996|carnosine
59403|NCT02686996|Insulin sensitivity
59404|NCT02686996|low grade inflammation
59405|NCT02686996|Oxidative stress
59406|NCT02686996|Advanced glycation
59407|NCT02686996|Type 2 diabetes
59408|NCT02686996|Cardiovascular disease
59409|NCT02686970|Family
59410|NCT02686970|Quality
59411|NCT02686970|Validate
59412|NCT02686970|ICU
59413|NCT02686944|GIST
59414|NCT02686931|Developmental delayed
59415|NCT02686931|Orthopedic disease
59416|NCT02686931|Longitudinal study
59417|NCT02686892|Inflamatory bowel disease
59418|NCT02686892|Crohns disease
59419|NCT02686892|ulcerative colitis
59420|NCT02686892|incidence
59421|NCT02686892|epidemiology
59422|NCT02686879|hyperopes
59423|NCT02686879|axial length
59424|NCT02686879|peripheral defocus
59425|NCT02686853|Intrathecal administration
59426|NCT02686853|Liposomal amphotericin B
59427|NCT02686853|Without Acquired Immune Deficiency Syndrome
59428|NCT02686814|Valvular heart disease
59429|NCT02686814|Severe aortic stenosis
59430|NCT02686814|Aortic valve replacement
59431|NCT02686801|nutrition
59432|NCT02686801|prematurity
59433|NCT02686801|body composition
59434|NCT02686788|multiple sclerosis
59435|NCT02686788|relapsing remitting
59436|NCT02686788|nonsteroidal anti-inflammatory drug
59437|NCT02686788|contrast enhancing lesions
59438|NCT02686762|NASH
59439|NCT02686736|internet-based educational intervention
59440|NCT02686736|risky sexual behaviors
59441|NCT02686736|prevention
59442|NCT02686723|ACL injury
59443|NCT02686723|Return to sport
59444|NCT02686723|Motion analysis
59445|NCT02686723|Isokinetic evaluation
59446|NCT02686723|Risk factor
59447|NCT02686697|L-Carnosine
59448|NCT02686697|Schizophrenia
59449|NCT02686697|Psychosis
59450|NCT02686697|Cognition
59451|NCT02686671|Bursitis
59452|NCT02686671|Injections
59453|NCT02686671|Shoulder Pain
59454|NCT02686658|Geographic Atrophy
59455|NCT02686658|Dry age-related macular degeneration
59456|NCT02686658|AMD
59457|NCT02686658|Zimura®
59458|NCT02686658|Anti-inflammatory
59459|NCT02686658|Complement C5 inhibition
59460|NCT02686645|Fecal Microbiota Transplantation
59461|NCT02686632|Denture Stomatitis
59462|NCT02686632|Denture Erythematous Stomatitis
59463|NCT02686632|Prosthesis Stomatitis
59464|NCT02686632|Oral Candidiasis
59465|NCT02686632|Palatal inflammation
59466|NCT02686593|Clofarabine
59467|NCT02686593|Acute Myeloid Leukemia
59468|NCT02686567|transanal drainage tube
59469|NCT02686567|anastomotic leakage
59470|NCT02686567|laparoscopic anterior resection
59471|NCT02686567|rectal cancer
59472|NCT02686554|Alzheimer´s Disease
59473|NCT02686528|total hip arthroplasty
59474|NCT02686528|hip precautions
59475|NCT02686528|posterior approach
59476|NCT02686515|balance
59477|NCT02686476|Empagliflozin, Fatty Liver Disease
59478|NCT02686463|malignant ovarian cancer
59479|NCT02686463|laparoscopy
59480|NCT02686463|laparotomy
59481|NCT02686437|shoulder dysfunction
59482|NCT02686437|kinesiology tape
59483|NCT02686437|rehabilitation
59484|NCT02686424|MAGE-A3 protein
59485|NCT02686424|NY-ESO-1 protein
59486|NCT02686424|WT1 Proteins
59487|NCT02686424|PRAME protein
59488|NCT02686411|Benign neoplasms
59489|NCT02686411|In situ neoplasms
59490|NCT02686411|Malignant neoplasms of independent (primary) multiple sites
59491|NCT02686411|Consult with palliative care doctor
59492|NCT02686411|Palliative care unit
59493|NCT02686411|PCU
59494|NCT02686411|Questionnaires
59495|NCT02686411|Surveys
59496|NCT02686398|Influenza Vaccines
59497|NCT02686398|MF59 oil emulsion
59498|NCT02686398|End Stage Renal Failure on Dialysis
59499|NCT02686372|hepatocellular carcinoma
59500|NCT02686359|physiology
59501|NCT02686359|pain
59502|NCT02686359|analgesia
59503|NCT02686359|saliva
59504|NCT02686359|opiorphin
59505|NCT02686346|Relapsed
59506|NCT02686346|Refractory
59507|NCT02686333|Meditation
59508|NCT02686333|Dialysis
59509|NCT02686320|Rheumatoid arthritis
59510|NCT02686320|Elderly
59511|NCT02686320|infections
59512|NCT02686320|cardio-vascular disease
59513|NCT02686320|osteoporosis
59514|NCT02686320|cancer
59515|NCT02686268|Amyotrophic Lateral Sclerosis
59516|NCT02686268|ALS
59517|NCT02686268|C9ORF72 gene mutation
59518|NCT02686268|Chromosome 9 open reading frame 72 protein
59519|NCT02686268|Natural history
59520|NCT02686268|Biomarkers
59521|NCT02686268|Amyotrophic Lateral Sclerosis, Familial
59522|NCT02686268|Amyotrophic Lateral Sclerosis, Sporadic
59523|NCT02686268|Frontotemporal Dementia-Amyotrophic Lateral Sclerosis
59524|NCT02686242|cesarean section
59525|NCT02686242|spinal anesthesia
59526|NCT02686242|general anesthesia
59527|NCT02686229|Low grade glioma, registry, neurosurgery, brain tumor
59528|NCT02686216|F-18 THK-5351 PET
59529|NCT02686190|Alzheimer; luxtherapy, sleep disturbance, behaviour disturbance
59530|NCT02686177|Type 2 diabetes
59531|NCT02686177|Angiogenesis
59532|NCT02686177|Liraglutide
59533|NCT02686177|Glucagon like peptide 1 receptor agonist
59534|NCT02686164|Lenvatinib
59535|NCT02686164|Lenvima
59536|NCT02686164|E7080
59537|NCT02686164|Phase 1
59538|NCT02686164|Solid tumors
59539|NCT02686164|Midazolam
59540|NCT02686164|CYP3A4
59541|NCT02686151|Letrozole
59542|NCT02686151|OHSS
59543|NCT02686099|Rigid Fixation
59544|NCT02686099|Sternal Plating
59545|NCT02686099|Sternal Closure
59546|NCT02686099|Sternalock
59547|NCT02686073|BMI
59548|NCT02686073|progress of labor
59549|NCT02686073|nulliparous women
59550|NCT02686047|Knee osteoarthritis
59551|NCT02686047|Hyaluronic acid
59552|NCT02686047|Viscosupplementation
59553|NCT02686034|Migraine
59554|NCT02686034|Non-invasive vagus nerve stimulation
59555|NCT02686034|Vagus nerve stimulation
59556|NCT02686034|Vagal nerve stimulation
59557|NCT02686034|gammaCore
59558|NCT02686034|episodic migraine
59559|NCT02685982|Unipolar
59560|NCT02685982|Depression
59561|NCT02685982|Depressive Disorder
59562|NCT02685982|Behavioural Symptoms
59563|NCT02685982|Mood Disorder
59564|NCT02685982|Adjunctive Therapy
59565|NCT02685982|Music Therapy
59566|NCT02685982|Brain Stimulation
59567|NCT02685969|Prevention
59568|NCT02685969|Positron Emission Tomography
59569|NCT02685930|invasive mechanical ventilation
59570|NCT02685878|urinary continence
59571|NCT02685878|prevalence of depression
59572|NCT02685878|reproductive outcomes
59573|NCT02685878|quality of life
59574|NCT02685878|HIV status
59575|NCT02685878|obstetric fistula
59576|NCT02685865|pancreatic fluid collection; pancreatic necrosis; stent;
59577|NCT02685839|frailty syndrome, Intelligent POWER Rehabilitation Cluster Machine, Internet of Things, wearable
59578|NCT02685826|Open-label
59579|NCT02685826|Phase 1/2
59580|NCT02685826|Durvalumab
59581|NCT02685826|MEDI4736
59582|NCT02685826|Lenalidomide (Len)
59583|NCT02685826|Dexamethasone (dex)
59584|NCT02685826|Multiple Myeloma
59585|NCT02685826|Newly-Diagnosed (NDMM)
59586|NCT02685826|Transplant Non-eligible (TNE)
59587|NCT02685826|PD-L1
59588|NCT02685813|Ultra sound
59589|NCT02685813|birth defects
59590|NCT02685787|Care-giver burden
59591|NCT02685787|Dementia
59592|NCT02685787|Alzheimer's disease
59593|NCT02685787|Care-giver depression
59594|NCT02685787|Care-giver anxiety
59595|NCT02685709|Octreotide Capsules
59596|NCT02685709|Acromegaly
59597|NCT02685709|Somatostatin
59598|NCT02685709|Mpowered
59599|NCT02685709|OOC-ACM-302
59600|NCT02685683|Crohn's Disease
59601|NCT02685683|GED-0301
59602|NCT02685683|Open-label
59603|NCT02685683|Pharmacodynamic
59604|NCT02685683|Mongersen
59605|NCT02685644|endometrioma
59606|NCT02685644|laparoscopy
59607|NCT02685644|anti-mullerian hormone
59608|NCT02685644|ovarian reserve
59609|NCT02685631|Hepatocellular carcinoma
59610|NCT02685631|Colorectal cancer
59611|NCT02685631|Neuroendocrine tumor
59612|NCT02685631|Cholangiocarcinoma
59613|NCT02685631|Breast cancer
59614|NCT02685631|Tumor of unknown primary
59615|NCT02685631|Pancreatic cancer
59616|NCT02685605|Glioblastoma
59617|NCT02685605|Intraoperative Radiotherapy
59618|NCT02685605|Radiotherapy Dose Escalation
59619|NCT02685592|Lentigo Maligna
59620|NCT02685592|Photodynamic Therapy
59621|NCT02685592|Hyperspectral Imaging
59622|NCT02685566|Mammography
59623|NCT02685540|Anesthesia
59624|NCT02685540|mortality
59625|NCT02685514|HIFU
59626|NCT02685514|Graves' disease
59627|NCT02685514|treatment
59628|NCT02685475|Diabetes mellitus
59629|NCT02685475|Axillary brachial plexus block
59630|NCT02685475|Block duration
59631|NCT02685475|Time-to-first pain
59632|NCT02685475|Postoperative analgesia
59633|NCT02685449|diabetes type 1
59634|NCT02685449|insulin pump
59635|NCT02685449|prandial insulin requirement
59636|NCT02685449|pure protein meal
59637|NCT02685449|high protein meal
59638|NCT02685449|square bolus
59639|NCT02685449|square-wave bolus
59640|NCT02685449|insulin bolus
59641|NCT02685449|dietary protein
59642|NCT02685423|Amblyopia
59643|NCT02685423|Lazy Eye
59644|NCT02685423|Anisometropia
59645|NCT02685384|healthcare access
59646|NCT02685384|healthcare utilization
59647|NCT02685384|health expenditures
59648|NCT02685384|preventive services
59649|NCT02685384|biomarkers
59650|NCT02685358|Stress Disorders, Post-traumatic
59651|NCT02685358|Primary Health Care
59652|NCT02685358|Mobile Applications
59653|NCT02685358|Veterans
59654|NCT02685345|Type 2 Diabetes Mellitus
59655|NCT02685345|sitagliptin
59656|NCT02685345|adult
59657|NCT02685345|Phase 2
59658|NCT02685280|rechargeable neurostimulators
59659|NCT02685254|Group Therapy
59660|NCT02685254|Structured Skills Training
59661|NCT02685254|Dialectic Behavioural Therapy
59662|NCT02685241|Exhaled breath
59663|NCT02685241|Biomarker
59664|NCT02685215|intensive care unit
59665|NCT02685215|muscular dystrophy
59666|NCT02685215|mortality
59667|NCT02685215|prognosis
59668|NCT02685215|tracheostomy
59669|NCT02685202|orofacial pain
59670|NCT02685202|sleep-disordered breathing
59671|NCT02685202|temporomandibular disorder
59672|NCT02685202|oral appliance
59673|NCT02685202|upper airway collapse
59674|NCT02685176|hypothermia
59675|NCT02685176|rewarming
59676|NCT02685176|non-shivering
59677|NCT02685150|Endoscopic Tri-Modal Imaging
59678|NCT02685150|Gastric juice
59679|NCT02685150|Functional dyspepsia
59680|NCT02685150|Acid reflux disease
59681|NCT02685150|Bile reflux
59682|NCT02685137|Kernicterus
59683|NCT02685137|Neonatal Jaundice
59684|NCT02685137|Newborn Jaundice
59685|NCT02685111|Breast cancer
59686|NCT02685111|Adjuvant
59687|NCT02685111|Docetaxel
59688|NCT02685111|Adriamycin
59689|NCT02685111|Cyclophosphamide
59690|NCT02685111|Neutropenia
59691|NCT02685111|Filgrastim
59692|NCT02685111|Pegfilgrastim
59693|NCT02685098|Stem cells
59694|NCT02685098|MSCs
59695|NCT02685098|Mesenchymal
59696|NCT02685098|Amputation
59697|NCT02685098|BKA
59698|NCT02685098|below knee amputation
59699|NCT02685098|CHAMP
59700|NCT02685072|Smoking Cessation
59701|NCT02685072|Nicotine Cessation
59702|NCT02685059|breast cancer
59703|NCT02685059|Medi4736
59704|NCT02685059|Anti PD-L1
59705|NCT02685059|Nab-Paclitaxel
59706|NCT02685059|Placebo
59707|NCT02685059|triple negative
59708|NCT02685033|Osteomyelitis
59709|NCT02685033|dalbavancin
59710|NCT02685033|antibiotic
59711|NCT02685020|Healthy
59712|NCT02685020|Human Immunodeficiency Virus
59713|NCT02685020|adenovirus serotype 26
59714|NCT02685020|Ad26.Mos.HIV
59715|NCT02685020|Vaccine
59716|NCT02685020|Placebo
59717|NCT02685020|Glycoprotein
59718|NCT02685020|IPCAVD010
59719|NCT02685007|minimal invasive surgery
59720|NCT02684994|Trauma
59721|NCT02684994|Sexual assault
59722|NCT02684994|Sexual abuse
59723|NCT02684994|Physical assault
59724|NCT02684994|Physical abuse
59725|NCT02684994|PTSD
59726|NCT02684994|Interpersonal Violence
59727|NCT02684994|Women
59728|NCT02684955|cardiac arrest
59729|NCT02684955|near-infrared spectroscopy
59730|NCT02684955|automated infrared pupillometry
59731|NCT02684955|prognostication
59732|NCT02684942|Meperidine
59733|NCT02684942|Fentanyl
59734|NCT02684942|Pain management
59735|NCT02684942|brachytherapy
59736|NCT02684929|insulin resistance
59737|NCT02684929|bcaa
59738|NCT02684929|mitochondrial biogenesis
59739|NCT02684916|Chiropractic spinal manipulation
59740|NCT02684916|Children
59741|NCT02684916|Pediatric
59742|NCT02684916|Headache
59743|NCT02684903|Child Abuse
59744|NCT02684903|Parent Child Interaction Therapy (PCIT)
59745|NCT02684903|Evidenced Based Intervention
59746|NCT02684903|Self-control
59747|NCT02684877|Fatigue
59748|NCT02684877|Quality of life
59749|NCT02684877|Critically ill patients
59750|NCT02684864|biomarker
59751|NCT02684864|inflammation
59752|NCT02684864|knee
59753|NCT02684864|prognosis
59754|NCT02684838|Gliadel, Carmustine wafer implant
59755|NCT02684825|Stroke
59756|NCT02684825|ischemic stroke
59757|NCT02684825|atrial fibrillation
59758|NCT02684825|continuous cardiac monitoring
59759|NCT02684825|insertable cardiac monitoring
59760|NCT02684825|implantable loop recorder
59761|NCT02684825|antithrombotics
59762|NCT02684825|anticoagulants
59763|NCT02684825|stroke subtype
59764|NCT02684825|atherothrombotic stroke
59765|NCT02684825|lacunar stroke
59766|NCT02684812|antifibrinolytic therapy
59767|NCT02684812|recurrent bleeding
59768|NCT02684812|tranexamic acid
59769|NCT02684773|Hemodialysis
59770|NCT02684773|Left Ventricular Mass
59771|NCT02684773|Cardiac Magnetic resonance Imaging
59772|NCT02684760|Inflammatory Bowel Disease
59773|NCT02684747|Healthy Volunteers
59774|NCT02684747|Sports Medicine
59775|NCT02684747|Athletes
59776|NCT02684747|Anti-doping
59777|NCT02684734|Ulcerative Colitis
59778|NCT02684734|UC
59779|NCT02684734|Cytomegalovirus
59780|NCT02684734|CMV
59781|NCT02684721|rehabilitation
59782|NCT02684721|physical capacity
59783|NCT02684721|quality of life
59784|NCT02684695|Magnetic resonance imaging
59785|NCT02684695|Imaging biomarker
59786|NCT02684695|Diffusion-weighted imaging
59787|NCT02684682|Toothbrushing
59788|NCT02684682|Gingivitis
59789|NCT02684682|Dental Plaque
59790|NCT02684682|Periodontal Diseases
59791|NCT02684682|Clinical Trial
59792|NCT02684669|burn injury
59793|NCT02684669|controlled trial
59794|NCT02684669|latent sensitization
59795|NCT02684669|naloxone
59796|NCT02684669|secondary hyperalgesia
59797|NCT02684669|volunteers
59798|NCT02684656|Oxalate
59799|NCT02684656|Inflammation
59800|NCT02684656|Hemodiafiltration
59801|NCT02684656|Hemodialysis
59802|NCT02684656|Oxalate Blood Sample
59803|NCT02684643|individualised therapy
59804|NCT02684643|hyperphosphatemia
59805|NCT02684643|hemodialysis
59806|NCT02684643|clinical trials
59807|NCT02684643|restricted phosphate diet
59808|NCT02684643|phosphate binders
59809|NCT02684565|pre-diabetes
59810|NCT02684565|blood glucose regulation
59811|NCT02684565|branching chain amino acids
59812|NCT02684565|diabetes
59813|NCT02684565|lower blood sugar
59814|NCT02684513|Well-being
59815|NCT02684513|Quality of Recovery
59816|NCT02684513|Maternal complications
59817|NCT02684500|aSAH
59818|NCT02684487|vitamin D
59819|NCT02684487|vitamin D3
59820|NCT02684487|sepsis
59821|NCT02684487|severe sepsis
59822|NCT02684487|critical illness
59823|NCT02684487|ICU
59824|NCT02684396|Drug therapy
59825|NCT02684383|Dengue Vaccine
59826|NCT02684370|Psoriasis
59827|NCT02684370|Skin Diseases
59828|NCT02684370|Skin Diseases, Papulosquamous
59829|NCT02684370|ustekinumab
59830|NCT02684370|Dermatologic Agents
59831|NCT02684370|ABBV-066
59832|NCT02684370|BI 655066
59833|NCT02684370|risankizumab
59834|NCT02684357|ABBV-066
59835|NCT02684357|BI 655066
59836|NCT02684357|risankizumab
59837|NCT02684344|Post-Operative Urinary Retention
59838|NCT02684292|PD1
59839|NCT02684292|PD-1
59840|NCT02684292|PDL1
59841|NCT02684292|PD-L1
59842|NCT02684266|neoplasm, Cycline-Dependent Kinase
59843|NCT02684253|Nivolumab
59844|NCT02684253|Stereotactic Body Radiotherapy (SBRT)
59845|NCT02684253|15-253
59846|NCT02684227|Endometrial cancer
59847|NCT02684227|Advanced Stage Endometrioid Endometrial Cancer
59848|NCT02684227|Recurrent Endometrioid Endometrial Cancer
59849|NCT02684227|Enzalutamide
59850|NCT02684227|MDV3100
59851|NCT02684227|XTANDI
59852|NCT02684227|Carboplatin
59853|NCT02684227|Paclitaxel
59854|NCT02684227|Taxol
59855|NCT02684214|food security
59856|NCT02684201|Phantom Limb
59857|NCT02684201|Upper Amputee
59858|NCT02684201|Electrodes
59859|NCT02684201|Implant
59860|NCT02684201|Pain
59861|NCT02684175|Audiometry
59862|NCT02684175|Cochlear Implants
59863|NCT02684175|Adult
59864|NCT02684175|Telemedicine
59989|NCT02683499|Tooth preparation
59865|NCT02684175|Health Services Accessibility
59866|NCT02684175|Rural Population
59867|NCT02684175|Technology Assessment, Biomedical
59868|NCT02684162|Leukemia
59869|NCT02684162|Myeloproliferative Diseases
59870|NCT02684162|Acute myelogenous leukemia
59871|NCT02684162|AML
59872|NCT02684162|Myelodysplastic syndrome
59873|NCT02684162|MDS
59874|NCT02684162|Donor lymphocyte infusion
59875|NCT02684162|DLI
59876|NCT02684162|Allogeneic stem cell transplant
59877|NCT02684162|Stem cell transplantation
59878|NCT02684162|AlloSCT
59879|NCT02684149|Intensive care
59880|NCT02684149|Arterial puncture
59881|NCT02684149|Cross-over
59882|NCT02684149|Relational touch
59883|NCT02684149|Pain
59884|NCT02684136|insomnia
59885|NCT02684136|fibromyalgia
59886|NCT02684136|polysomnography
59887|NCT02684136|pain management
59888|NCT02684123|Alopecia areata
59889|NCT02684097|Alopecia, Alopecia Totalis, Alopecia Universalis
59890|NCT02684084|Diabetic Macular Edema
59891|NCT02684084|Ozurdex
59892|NCT02684084|Lucentis
59893|NCT02684071|medulloblastoma, ependymoma, AT/RT, embryonal
59894|NCT02684058|Glioma
59895|NCT02684058|Anaplastic astrocytoma
59896|NCT02684058|Glioblastoma
59897|NCT02684058|Giant cell glioblastoma
59898|NCT02684058|Gliosarcoma
59899|NCT02684058|Anaplastic oligodendroglioma
59900|NCT02684058|Anaplastic oligoastrocytoma
59901|NCT02684058|Anaplastic ependymoma
59902|NCT02684058|Choroid plexus carcinoma
59903|NCT02684058|Anaplastic ganglioglioma
59904|NCT02684058|Pineal parenchymal tumor
59905|NCT02684058|Pineoblastoma
59906|NCT02684058|Medulloblastoma
59907|NCT02684058|PNET
59908|NCT02684058|Rhabdoid tumor
59909|NCT02684058|Perineurioma
59910|NCT02684058|MPNST
59911|NCT02684058|Malignant meningloma
59912|NCT02684058|Anaplastic hemangiopericytoma
59913|NCT02684058|Dabrafenib
59914|NCT02684058|Pediatrics
59915|NCT02684058|Brain neoplasma
59916|NCT02684032|PI3K (phosphoinositide 3-kinase)
59917|NCT02684032|mTOR (mechanistic target of rapamycin)
59918|NCT02684032|PI3K/mTOR
59919|NCT02684032|metastatic breast cancer (MBC)
59920|NCT02684032|ER+ (estrogen receptor positive)
59921|NCT02684032|HER2- (human epidermal growth factor receptor 2 negative)
59922|NCT02684019|Endoscopic retrograde cholangiopancreatography
59923|NCT02684019|sedation
59924|NCT02684019|dexmedetomidine
59925|NCT02684019|propofol
59926|NCT02684019|Magnesium sulphate
59927|NCT02684019|Bispectral index monitoring
59928|NCT02684006|Cancer
59929|NCT02684006|renal cell cancer
59930|NCT02684006|kidney disease
59931|NCT02684006|kidney neoplasms
59932|NCT02684006|axitinib, sunitinib
59933|NCT02683915|Acute kidney injury
59934|NCT02683915|Perinatal asphyxia
59935|NCT02683915|Therapeutic hypothermia
59936|NCT02683915|Serum NGAL
59937|NCT02683915|Serum cystatin-C
59938|NCT02683902|prediabetes
59939|NCT02683902|tDCS
59940|NCT02683902|transcranial direct current stimulation
59941|NCT02683902|obesity
59942|NCT02683902|diabetes
59943|NCT02683876|body odor, malodor, halitosis
59944|NCT02683837|Intraoperative Neurophysiological Monitoring
59945|NCT02683837|Reflex, Pupillary
59946|NCT02683837|remifentanil
59947|NCT02683811|adolescence
59948|NCT02683811|prevention
59949|NCT02683811|wellbeing
59950|NCT02683811|evaluation
59951|NCT02683811|effectiveness
59952|NCT02683811|school-based program
59953|NCT02683798|Weight loss maintenance
59954|NCT02683785|Pain intensity
59955|NCT02683785|Hand Osteoarthritis
59956|NCT02683785|GSK3196165
59957|NCT02683785|AUSCAN
59958|NCT02683785|GM-CSF
59959|NCT02683785|Numerical Rating Scale
59960|NCT02683746|Pharmacodynamics
59961|NCT02683746|Safety
59962|NCT02683746|Albiglutide
59963|NCT02683746|Tolerability
59964|NCT02683746|Type 2 Diabetes Mellitus
59965|NCT02683746|Efficacy
59966|NCT02683707|Percutaneous Coronary Intervention
59967|NCT02683707|Blood Platelets
59968|NCT02683707|Fentanyl
59969|NCT02683694|Epiretinal membrane
59970|NCT02683694|lamellar holes of the macula
59971|NCT02683694|macular holes
59972|NCT02683694|vitreomacular traction syndrome
59973|NCT02683668|Inhalers
59974|NCT02683668|Tiotropium
59975|NCT02683629|Parkinson's Disease
59976|NCT02683629|Xenotransplantation
59977|NCT02683629|choroid plexus
59978|NCT02683603|colistin
59979|NCT02683603|aerosol
59980|NCT02683603|ventilator associated pneumonia
59981|NCT02683603|nephrotoxicity
59982|NCT02683603|intravenous
59983|NCT02683590|Sternectomie
59984|NCT02683590|Ceramic Implant
59985|NCT02683590|Bones Tumors
59986|NCT02683538|RFA
59987|NCT02683525|Allogeneic
59988|NCT02683525|Sitagliptin
59990|NCT02683499|Prosthodontics
59991|NCT02683447|Continuing Medical Education
59992|NCT02683447|Simulation
59993|NCT02683447|Non-technical Skills
59994|NCT02683447|Crisis Resource Management
59995|NCT02683434|soccer
59996|NCT02683421|Rheumatoid arthritis
59997|NCT02683421|tilmanocept
59998|NCT02683421|imaging
59999|NCT02683395|PLX51107
60000|NCT02683395|Acute Myeloid Leukemia
60001|NCT02683395|Myelodysplastic Syndrome
60002|NCT02683395|Neoplasms
60003|NCT02683369|Non-anemic Iron Deficiency, Iron Supplementation
60004|NCT02683356|Percutaneous Coronary Intervention
60005|NCT02683356|Stents
60006|NCT02683330|PD
60007|NCT02683330|Parkinson's
60008|NCT02683317|DHA
60009|NCT02683317|Retinopathy of Prematurity
60010|NCT02683291|Kidney transplantation
60011|NCT02683291|sirolimus
60012|NCT02683291|cytomegalovirus
60013|NCT02683291|aged
60014|NCT02683252|Magnetic resonance imaging
60015|NCT02683252|perfusion
60016|NCT02683252|quantitative
60017|NCT02683213|fluoxetine
60018|NCT02683213|outcome
60019|NCT02683213|depression
60020|NCT02683213|plasticity
60021|NCT02683187|insulin secretion
60022|NCT02683187|GLP-1
60023|NCT02683187|alpha cell
60024|NCT02683187|paracrine effect
60025|NCT02683187|Glucagon-Like Peptide 1
60026|NCT02683174|syncope
60027|NCT02683122|Organ dysfunction scores
60028|NCT02683122|Pneumonia, Ventilator-Associated
60029|NCT02683122|Intensive care units
60030|NCT02683070|Catheter-related bladder discomfort
60031|NCT02683070|Pudendal nerve block
60032|NCT02683070|Tramadol
60033|NCT02683070|Randomized controlled trial
60034|NCT02683070|catheter-related bladder discomfort prevention
60035|NCT02683044|Erectile dysfunction
60036|NCT02683044|Low-Density Shock Waves
60037|NCT02683044|Randomized Clinical Trial
60038|NCT02683031|fertilization arrest
60039|NCT02683031|Cleavage failure
60040|NCT02683031|Embryonic development
60041|NCT02683031|Calcium ionophore
60042|NCT02683005|treatment
60043|NCT02683005|pharmacokinetics
60044|NCT02682979|therapeutic limitation code
60045|NCT02682979|emergency unit admittance
60046|NCT02682966|troponin
60047|NCT02682966|coronary artery disease
60048|NCT02682966|pulmonary embolism
60049|NCT02682966|Computed Tomography Angiography
60050|NCT02682966|postoperative myocardial injury
60051|NCT02682927|seizure
60052|NCT02682927|tonic-atonic
60053|NCT02682927|clonic
60054|NCT02682927|epilepsy
60055|NCT02682927|myoclonic
60056|NCT02682927|encephalopathy
60057|NCT02682914|Psychological distress
60058|NCT02682914|Stroke etiology
60059|NCT02682914|Young patients
60060|NCT02682888|brain functional connectivity changes
60061|NCT02682862|tiotropium
60062|NCT02682862|olodaterol
60063|NCT02682862|smoker
60064|NCT02682862|cigarette
60065|NCT02682862|bronchodilator
60066|NCT02682836|physical activity
60067|NCT02682836|chemotherapy
60068|NCT02682836|fatigue
60069|NCT02682810|HIV
60070|NCT02682810|point-of-care HIV diagnosis
60071|NCT02682810|Alere Q
60072|NCT02682810|diagnostic
60073|NCT02682810|children
60074|NCT02682771|gastroplasty, breathing exercices, positive pressure
60075|NCT02682758|xenon
60076|NCT02682758|transpulmonary pressure
60077|NCT02682758|electrical impedance tomography
60078|NCT02682758|tidal volume
60079|NCT02682758|esophageal pressure measurement
60080|NCT02682732|Acute Myeloid Leukemia
60081|NCT02682732|PET/CT Scan
60082|NCT02682719|Natriuretic peptide, brain
60083|NCT02682719|Diabetes Mellitus, Type 2
60084|NCT02682719|Hypertension
60085|NCT02682719|Cardiovascular prevention
60086|NCT02682719|Left atrial volume index
60087|NCT02682719|Angiotensin receptor neprilysin inhibitor
60088|NCT02682719|LCZ696
60089|NCT02682719|Valsartan
60090|NCT02682719|Sacubitril
60091|NCT02682706|brown adipose tissue
60092|NCT02682706|magnetic resonance imaging
60093|NCT02682706|energy expenditure
60094|NCT02682706|non-shivering thermogenesis
60095|NCT02682680|diabetes
60096|NCT02682680|hyperlipidaemia
60097|NCT02682680|colesevelam
60098|NCT02682680|ezetimibe
60099|NCT02682680|LDL cholesterol
60100|NCT02682680|glycated hemoglobin
60101|NCT02682667|Apheresis Products
60102|NCT02682667|Immunological
60103|NCT02682667|Diverse Malignan
60104|NCT02682667|Premalignant
60105|NCT02682667|Protein
60106|NCT02682654|Pain
60107|NCT02682654|Ankle
60108|NCT02682654|Knee
60109|NCT02682654|Brace
60110|NCT02682615|Cardiac Index
60111|NCT02682615|Noninvasive
60112|NCT02682615|esCCO
60113|NCT02682615|PiCCO
60114|NCT02682615|Thermodilution
60115|NCT02682602|total hip arthroplasty
60116|NCT02682589|Complete Mesocolic Excision
60117|NCT02682589|locally advanced Colon Cancer
60118|NCT02682589|Laparoscopic
60119|NCT02682576|brachial artery ultrasound imaging
60120|NCT02682576|flow-mediated dilation
60121|NCT02682576|endothelium
60122|NCT02682563|SGLT-2 inhibition, Renal, Cardiovascular, Type 2 diabetes, forxiga, dapagliflozin
60123|NCT02682550|polytrauma
60124|NCT02682550|hemorrhagic shock
60125|NCT02682550|sepsis
60126|NCT02682550|MODS
60127|NCT02682537|Resting energy expenditure
60128|NCT02682537|Calorie requirements
60129|NCT02682537|Indirect Calorimetry
60130|NCT02682511|Ifetroban
60131|NCT02682511|Scleroderma
60132|NCT02682511|Systemic Sclerosis
60133|NCT02682498|Knee Arthroplasty, Total
60134|NCT02682498|Liposomal Bupivicaine
60135|NCT02682485|Rectal Cancer
60136|NCT02682485|low anterior resection
60137|NCT02682485|SES
60138|NCT02682485|SES-DTA
60139|NCT02682485|anastomotic leak
60140|NCT02682485|anastomotic healing
60141|NCT02682485|intestinal healing
60142|NCT02682485|anastomosis
60143|NCT02682459|Extracapillary glomerulonephritis
60144|NCT02682459|crescentic glomerulonephritis
60145|NCT02682459|rapidly progressive renal failure
60146|NCT02682459|chronic kidney disease
60147|NCT02682459|ACE-inhibitors
60148|NCT02682459|fibrosis
60149|NCT02682446|Early gastric cancer
60150|NCT02682446|endoscopic submucosal dissection
60151|NCT02682446|serum pepsinogen
60152|NCT02682446|Helicobacter pylori
60153|NCT02682407|IgAN
60154|NCT02682407|MN
60155|NCT02682407|C3 Glomerulopathy
60156|NCT02682407|Lupus Nephritis
60157|NCT02682394|Cancer of pancreas
60158|NCT02682394|steatosis
60159|NCT02682394|MRI
60160|NCT02682381|Teduglutide
60161|NCT02682381|pediatric
60162|NCT02682381|GLP-2
60163|NCT02682381|parenteral support
60164|NCT02682381|Short Bowel Syndrome
60165|NCT02682381|short gut syndrome
60166|NCT02682381|short gut
60167|NCT02682381|SBS
60168|NCT02682381|parenteral nutrition
60169|NCT02682368|surgeon performed ultrasound
60170|NCT02682329|Peroxide
60171|NCT02682316|undergoing laparotomy
60172|NCT02682316|15-309
60173|NCT02682303|Adhesive elastic bandaging
60174|NCT02682303|balance
60175|NCT02682303|posturography
60176|NCT02682290|SPUTUM
60177|NCT02682290|RHEOLOGY
60178|NCT02682277|obesity
60179|NCT02682277|body weight
60180|NCT02682277|overweight
60181|NCT02682277|weight loss
60182|NCT02682277|polyglucosamine
60183|NCT02682277|L112
60184|NCT02682277|caloric restriction
60185|NCT02682277|physical activity
60186|NCT02682264|acne
60187|NCT02682251|Cardiac Resynchronization Therapy Devices
60188|NCT02682251|Cardiac Resynchronization Therapy
60189|NCT02682225|Esketamine
60190|NCT02682225|Placebo
60191|NCT02682225|Racemic ketamine
60192|NCT02682225|Pharmacokinetics
60193|NCT02682212|Pelvic floor
60194|NCT02682212|obstetrics
60195|NCT02682212|perineal tear
60196|NCT02682212|physiotherapy
60197|NCT02682186|Prosthetic breast surgery
60198|NCT02682186|Locoregional anesthesia
60199|NCT02682186|Pectoral nerve block
60200|NCT02682186|Pain
60201|NCT02682186|Postoperative analgesia
60202|NCT02682160|bariatric surgery
60203|NCT02682134|Sore Throat
60204|NCT02682134|Intubation
60205|NCT02682134|Xylocaine
60206|NCT02682134|Dexamethasone
60207|NCT02682108|Hepatitis B
60208|NCT02682108|Hepatitis C
60209|NCT02682108|Fibrosis, Liver
60210|NCT02682108|Magnetic Resonance Imaging
60211|NCT02682095|Hypertension
60212|NCT02682095|Blood Pressure Control
60213|NCT02682095|Adherence
60214|NCT02682095|Mixed Methods
60215|NCT02682082|Pancreatic cancer
60216|NCT02682082|Pain Management
60217|NCT02682082|Celiac plexus neurolysis
60218|NCT02682082|Bupivacaine
60219|NCT02682082|Palliative treatment
60220|NCT02682069|Diabetic foot ulcer
60221|NCT02682069|venous leg ulcer
60222|NCT02682069|fluorescence imaging
60223|NCT02682069|wound imaging
60224|NCT02682056|Pediatrics
60225|NCT02682056|Endocrinology
60226|NCT02682056|Adolescent
60227|NCT02682056|Microneedle
60228|NCT02682030|Airway Clearance Devices
60229|NCT02682030|High Frequency Chest Compression Devices
60230|NCT02682030|Cough Assist
60231|NCT02682017|Seaweed
60232|NCT02682017|Pork
60233|NCT02682017|Fucoidan
60234|NCT02682017|Laminarin
60235|NCT02682017|Functional Food
60236|NCT02682017|Antioxidant activity
60237|NCT02681913|Cardioplegia
60238|NCT02681913|Cardiac Surgery
60239|NCT02681913|Adenosine
60240|NCT02681913|Therapeutic Uses
60241|NCT02681913|Intermittent warm blood cardioplegia
60242|NCT02681913|Minimally Invasive Surgery
60243|NCT02681913|minimally invasive mitral valve plasty (mini-MPL)
60244|NCT02681913|minimally invasive mitral valve replacement (mini-MVR)
60245|NCT02681874|dietary pattern
60246|NCT02681874|stress
60247|NCT02681874|nutrition
60248|NCT02681874|health
60249|NCT02681874|obesity
60250|NCT02681874|children
60251|NCT02681874|minority
60252|NCT02681874|pre-schoolers
60253|NCT02681861|Pharmacodynamics
60254|NCT02681861|Pharmacokinetics
60255|NCT02681861|ASP6294
60256|NCT02681861|Maximum tolerated dose
60257|NCT02681861|Healthy subjects
60258|NCT02681848|Primary care attendance
60259|NCT02681848|All-cause
60260|NCT02681848|cause specific
60261|NCT02681848|hospital attendance
60262|NCT02681822|Genome-wide association studies
60263|NCT02681822|Environmental factors
60264|NCT02681822|Behavioral Assessment
60265|NCT02681822|Pathway analysis
60266|NCT02681783|aflibercept
60267|NCT02681770|kidney transplantation
60268|NCT02681770|adherence
60269|NCT02681770|quality of life
60270|NCT02681770|couples
60271|NCT02681770|fundamental frequency
60272|NCT02681770|communication
60273|NCT02681770|social support
60274|NCT02681757|pediatric hand burn
60275|NCT02681757|pediatric foot burn
60276|NCT02681757|mepitel Ag
60277|NCT02681757|soft cast technique for burn wound heaing
60278|NCT02681718|A1C≥9%
60279|NCT02681718|minorities
60280|NCT02681718|economically disadvantaged
60281|NCT02681692|colonoscopy
60282|NCT02681692|colonoscopy education
60283|NCT02681692|magnetic endoscope imaging
60284|NCT02681692|Colonic Diseases
60285|NCT02681666|FODMAP Diet
60286|NCT02681666|Bowel Habit
60287|NCT02681666|Rome III Criteria
60288|NCT02681666|Mindfulness
60289|NCT02681666|Abdominal pain
60290|NCT02681666|Irritable Bowel Syndrome
60291|NCT02681653|Statins
60292|NCT02681653|Septic Shock
60293|NCT02681614|Imaging
60294|NCT02681614|Prostate
60295|NCT02681614|Multiparametric MRI
60296|NCT02681614|brachytherapy
60297|NCT02681601|Diet, Food, and Nutrition
60298|NCT02681588|diabetes, obesity, skinfold, newborn
60299|NCT02681562|olaparib
60300|NCT02681510|medication tolerability
60301|NCT02681497|canagliflozin
60302|NCT02681497|diabetes
60303|NCT02681497|SGLT2
60304|NCT02681497|real-world data
60305|NCT02681471|Monopolar
60306|NCT02681471|Bipolar
60307|NCT02681471|TURP syndrome
60308|NCT02681471|hyponatremia
60309|NCT02681432|HIPEC
60310|NCT02681432|ovarian cancer
60311|NCT02681432|peritoneal carcinomatosis
60312|NCT02681393|Physical activity, brochures, telephone support, stroke
60313|NCT02681380|simulated patient
60314|NCT02681380|Balint
60315|NCT02681380|empathy
60316|NCT02681380|medical student
60317|NCT02681367|Recurrent implantation failure
60318|NCT02681367|Freeze all policy
60319|NCT02681367|endometrial receptivity
60320|NCT02681367|implantation
60321|NCT02681367|clinical outcome
60322|NCT02681354|elderly
60323|NCT02681289|infant
60324|NCT02681289|risk
60325|NCT02681289|rehabilitation
60326|NCT02681276|Irrigation during root canal treatment
60327|NCT02681276|Sodium Hypochlorite
60328|NCT02681250|Zirconium
60329|NCT02681250|Randomized Controlled Trial
60330|NCT02681250|Dental Implants
60331|NCT02681250|Dental Material
60332|NCT02681250|Titanium
60333|NCT02681211|migraine headache
60334|NCT02681211|acupuncture
60335|NCT02681198|Healthy
60336|NCT02681198|Lofexidine
60337|NCT02681198|Paroxetine
60338|NCT02681198|Volunteer
60339|NCT02681172|CSF
60340|NCT02681172|Alzheimer's Disease (AD) and related dementia
60341|NCT02681172|HAS recommendations
60342|NCT02681159|Anesthesia
60343|NCT02681146|education
60344|NCT02681146|physiotherapy
60345|NCT02681133|Physical activity level
60346|NCT02681133|Knee osteoarthritis
60347|NCT02681133|Non pharmacological treatment
60348|NCT02681133|Survey
60349|NCT02681133|Socio-demographic, clinical variables
60350|NCT02681133|Barriers, facilitators Fears and beliefs
60351|NCT02681133|Function
60352|NCT02681120|Biomarkers
60353|NCT02681120|Breast imaging
60354|NCT02681107|Radiation therapy
60355|NCT02681107|Accelerated partial breast irradiation (APBI)
60356|NCT02681107|Breast conserving surgery
60357|NCT02681107|Stage 1
60358|NCT02681094|Diabetes Mellitus Type 2,
60359|NCT02681094|saxagliptin,
60360|NCT02681094|dapagliflozin,
60361|NCT02681094|metformin
60362|NCT02681081|Neuroplasticity
60363|NCT02681068|Fecal microbiota transplantation (FMT)
60364|NCT02681068|Clostridium difficile associated diarrhea (CDAD)
60365|NCT02681055|NASH
60366|NCT02681055|NAFLD
60367|NCT02681029|Cleavage stage blastocyst transfer cryopreservation
60368|NCT02681016|Calypso
60369|NCT02681016|Xience
60370|NCT02681016|Coronary stenosis
60371|NCT02681016|Drug-eluting stent
60372|NCT02681016|Coronary angioplasty with stenting
60373|NCT02681016|Ischemic Heart Disease
60374|NCT02680977|Mucuna pruriens
60375|NCT02680977|Levodopa
60376|NCT02680951|Pediatric
60377|NCT02680951|Adolescent
60378|NCT02680912|Bi syndrome
60379|NCT02680899|science education
60380|NCT02680899|health promotion
60381|NCT02680899|mental health promotion
60382|NCT02680899|stigmatization
60383|NCT02680899|behavioral intervention
60384|NCT02680886|Rapid Absorbable Suture Material
60385|NCT02680886|Children / Adults
60386|NCT02680886|Novosyn Quick
60387|NCT02680873|type 2 diabetes , obesity , SASI
60388|NCT02680847|Pediatric
60389|NCT02680847|pain indication
60390|NCT02680847|controlled release oxycodone
60391|NCT02680834|venous stasis ulcer
60392|NCT02680834|wound
60393|NCT02680834|chronic venous insufficiency
60394|NCT02680821|Laxity
60395|NCT02680821|Knee
60396|NCT02680821|Rupture
60397|NCT02680821|ALL
60398|NCT02680795|UGT1A1*28
60399|NCT02680795|Belinostat
60400|NCT02680795|beleodaq
60401|NCT02680795|wild type genotypes
60402|NCT02680795|heterozygous genotypes
60403|NCT02680795|homozygous genotypes
60404|NCT02680782|Healthy Volunteers
60405|NCT02680782|Comparison
60406|NCT02680782|Once-Daily
60407|NCT02680782|Twice-Daily
60408|NCT02680782|X4P-001
60409|NCT02680756|Iron Deficiency
60410|NCT02680756|Anaemia
60411|NCT02680756|Crohn's Disease
60412|NCT02680756|Deficiency Diseases
60413|NCT02680756|Inflammatory Bowel Diseases
60414|NCT02680756|Intestinal Diseases
60415|NCT02680730|Autonomic nervous system
60416|NCT02680730|Auditory processing disorder
60417|NCT02680730|Social behavior
60418|NCT02680691|infratentorial stroke
60419|NCT02680691|robot
60420|NCT02680691|postural balance
60421|NCT02680691|Rehabilitation
60422|NCT02680652|CVID
60423|NCT02680652|Common Variable Immune Deficiency
60424|NCT02680639|High-Frequency Ventilation
60425|NCT02680639|Biphasic Continuous Positive Airway Pressure
60426|NCT02680574|vadadustat
60427|NCT02680574|AKB-6548
60428|NCT02680574|Chronic kidney disease
60429|NCT02680574|anemia
60430|NCT02680574|CKD
60431|NCT02680574|chronic renal insufficiency
60432|NCT02680574|renal impairment
60433|NCT02680574|erythropoietin
60434|NCT02680574|kidney
60435|NCT02680574|renal
60436|NCT02680574|oral anemia treatment
60437|NCT02680574|hemoglobin
60438|NCT02680574|hypoxia-inducible factor
60439|NCT02680574|HIF
60440|NCT02680574|hypoxia-inducible factor prolyl-hydroxylase inhibitor
60441|NCT02680574|HIF-PHI
60442|NCT02680574|efficacy
60443|NCT02680574|safety
60444|NCT02680574|Phase 3
60445|NCT02680574|cardiovascular
60446|NCT02680574|NDD-CKD
60447|NCT02680548|ankle pain
60448|NCT02680548|foot pain
60449|NCT02680548|methylprednisolone
60450|NCT02680548|neuropathic pain
60451|NCT02680522|Parkinson's disease
60452|NCT02680522|Heart Rate Variability
60453|NCT02680522|Physiotherapy
60454|NCT02680496|Robot-Assistance
60455|NCT02680496|Gait [MeSH]
60456|NCT02680496|Energy Consumption
60457|NCT02680496|Cardiorespiratory Load
60458|NCT02680496|Stroke [MeSH]
60459|NCT02680483|Atrial fibrillation
60460|NCT02680483|Registry
60461|NCT02680483|Middle East
60462|NCT02680483|Jordan
60463|NCT02680483|risk factors
60464|NCT02680483|in hospital management
60465|NCT02680483|long term management
60466|NCT02680470|Tuberculosis
60467|NCT02680470|Management
60468|NCT02680470|Observed therapy
60469|NCT02680444|Mindfulness
60470|NCT02680444|Primary Promotion
60471|NCT02680444|Mental Health
60472|NCT02680444|Well-being
60473|NCT02680444|Positive Reappraisal
60474|NCT02680392|Pulsed and Continuous Radiofrequency Treatment
60475|NCT02680392|Continuous adductor canal block
60476|NCT02680392|Postoperative pain
60477|NCT02680392|Functional recovery
60478|NCT02680392|Total Knee Joint Replacement
60479|NCT02680379|Fragile X Syndrome
60480|NCT02680379|Autism
60481|NCT02680379|FMR1
60482|NCT02680379|FRAXA
60483|NCT02680340|Total Hip Arthroplasty THA
60484|NCT02680314|unripe cervix
60485|NCT02680301|Wet Wraps
60486|NCT02680301|Topical Steroid
60487|NCT02680288|Psychostimulant, Craving, Cocaine.
60488|NCT02680275|Chronic endometritis
60489|NCT02680275|Miscarriage
60490|NCT02680275|Infertility
60491|NCT02680262|HPV self-sampling, cervical cancer screening
60492|NCT02680249|Safety, Bioavailability and Pharmacokinetics
60493|NCT02680236|Pain
60494|NCT02680236|Cancer
60495|NCT02680236|Chemotherapy
60496|NCT02680236|Anxiety
60497|NCT02680236|Depression
60498|NCT02680236|Isolation
60499|NCT02680197|COPD
60500|NCT02680184|Malignant melanoma
60501|NCT02680171|Cognitive Rehabilitation
60502|NCT02680171|Prism Adaptation
60503|NCT02680171|Stroke
60504|NCT02680171|Spatial Neglect
60505|NCT02680145|Pessary
60506|NCT02680145|Prolapse
60507|NCT02680145|Cystocele
60508|NCT02680106|Nanofibers
60509|NCT02680106|Dressing
60510|NCT02680106|Donor site
60511|NCT02680106|Polycaprolactone
60512|NCT02680067|Healthy Individual
60513|NCT02680067|Lymphatic Transport
60514|NCT02680067|Near InfraRed
60515|NCT02680067|Imaging
60516|NCT02680067|Indocyanine Green
60517|NCT02680067|ICG
60518|NCT02680067|NIR
60519|NCT02680067|NIR-ICG
60520|NCT02680067|MSImager
60521|NCT02680015|PEERS
60522|NCT02680015|friendships
60523|NCT02680015|brain
60524|NCT02679989|Insulin sensitivity
60525|NCT02679989|Weight loss
60526|NCT02679989|Intermittent fasting
60527|NCT02679989|Sympathetic nervous system
60528|NCT02679950|Next generation genome sequencing
60529|NCT02679950|Late relapse
60530|NCT02679950|Genetic profiles
60531|NCT02679937|U.S. Military
60532|NCT02679937|Overweight
60533|NCT02679937|Obesity
60534|NCT02679937|Service Members
60535|NCT02679937|Prevention
60536|NCT02679911|Onychomycosis
60537|NCT02679898|Arterial function
60538|NCT02679898|Whole-body vibration training
60539|NCT02679898|Aortic blood pressures
60540|NCT02679898|Wave reflection
60541|NCT02679898|Muscle strength
60542|NCT02679898|Endothelial function
60543|NCT02679898|Blood flow
60544|NCT02679872|Non-technical skills
60545|NCT02679872|Patient safety
60546|NCT02679872|Video-assisted thoracoscopic surgery
60547|NCT02679872|Operating theatre team
60548|NCT02679872|Operating room
60549|NCT02679859|Natriuretic Peptide, Brain
60550|NCT02679859|Surgery
60551|NCT02679846|withdrawal of antiepileptic drugs
60552|NCT02679846|monitoring VEEG
60553|NCT02679846|safety
60554|NCT02679846|adverse event
60555|NCT02679846|standardized protocol
60556|NCT02679833|Cobalamin biomarkers
60557|NCT02679833|Anemia
60558|NCT02679833|Vegan diet
60559|NCT02679833|Subclinical
60560|NCT02679833|Metabolic functional markers
60561|NCT02679833|Holotranscobalamin
60562|NCT02679833|Methylmalonic acid
60563|NCT02679755|Hormone receptor positive advanced breast cancer
60564|NCT02679742|beta hydroxy beta methylbutyrate
60565|NCT02679742|older people
60566|NCT02679742|muscle mass
60567|NCT02679742|muscle strength
60568|NCT02679742|post-acute
60569|NCT02679729|inhaled dose
60570|NCT02679729|intravenous dose
60571|NCT02679729|healthy subjects
60572|NCT02679729|safety
60573|NCT02679729|tolerability
60574|NCT02679729|pharmacokinetics
60575|NCT02679729|AZD5634
60576|NCT02679729|jet nebulizer
60577|NCT02679677|Chronic obstructive pulmonary disease
60578|NCT02679677|Randomized controlled trial
60579|NCT02679677|Physical activity
60580|NCT02679638|breast cancer
60581|NCT02679638|treatment choice
60582|NCT02679638|factor
60583|NCT02679638|perception
60584|NCT02679573|Pneumonia
60585|NCT02679560|femur fracture, hip fracture, exparel, liposomal bupivacaine
60586|NCT02679547|Appendix
60587|NCT02679547|Breastfeeding
60588|NCT02679547|Adult
60589|NCT02679534|pain
60590|NCT02679534|thoracic surgery
60591|NCT02679534|massage
60592|NCT02679521|Extracorporeal Shock Wave Therapy
60593|NCT02679521|Painful Heel
60594|NCT02679521|Plantar fasciitis
60595|NCT02679508|Esophagitis
60596|NCT02679495|early gastric cancer
60597|NCT02679495|lifestyle
60598|NCT02679482|Primary Open Angle Glaucoma
60599|NCT02679482|Selective Laser Trabeculoplasty
60600|NCT02679482|Pattern Scan Laser Trabeculoplasty
60601|NCT02679443|Lung Adenocarcinoma
60602|NCT02679443|Non-squamous NSCLC
60603|NCT02679443|Chemotherapy
60604|NCT02679443|Pemetrexed
60605|NCT02679443|Vitamin B12
60606|NCT02679443|Folate
60607|NCT02679443|Supplementation
60608|NCT02679443|Cytopenia
60609|NCT02679417|Aminotransferase
60610|NCT02679417|Fibrosis, liver
60611|NCT02679417|Anthropometry
60612|NCT02679417|Exercise
60613|NCT02679404|Biological aortic valves
60614|NCT02679404|Mechanical aortic valves
60615|NCT02679404|Aortic conduits
60616|NCT02679404|Sutureless Aortic Valve
60617|NCT02679391|Abdominoplasty
60618|NCT02679391|Early complications
60619|NCT02679391|Guidelines
60620|NCT02679391|Sequelae
60621|NCT02679391|bariatric patients
60622|NCT02679326|Therapeutic ultrasound, Treatment, Plantar fasciitis
60623|NCT02679300|Chronic Low Back Pain
60624|NCT02679300|Virtual Reality
60625|NCT02679300|Serious Gaming
60626|NCT02679300|Exercise Therapy
60627|NCT02679300|Distraction
60628|NCT02679287|Closed-Loop Control (CLC)
60629|NCT02679287|Sensor-Augmented Therapy (SAP)
60630|NCT02679287|USS Virginia
60631|NCT02679287|Continuous Glucose Monitor (CGM)
60632|NCT02679287|Insulin Pump
60633|NCT02679287|Artificial Pancreas (AP)
60634|NCT02679274|Aging, Frailty, Hypogonadism
60635|NCT02679261|Aortic dilation
60636|NCT02679261|Statins
60637|NCT02679261|Aortic degeneration
60638|NCT02679248|Pre-hypertension
60639|NCT02679248|Mild hypertension
60640|NCT02679248|Dietary supplement
60641|NCT02679248|Efficacy
60642|NCT02679248|Nitric oxide
60643|NCT02679248|Neo40 Daily
60644|NCT02679170|ALK+
60645|NCT02679157|Posttraumatic stress disorder
60646|NCT02679157|Depression
60647|NCT02679157|Anxiety
60648|NCT02679157|ADL
60649|NCT02679157|Health-related quality of life
60650|NCT02679157|ICU survivorship
60651|NCT02679131|relapsed/refractory solid tumors
60652|NCT02679131|beleodaq
60653|NCT02679131|renal impairment
60654|NCT02679131|belinostat
60655|NCT02679131|hematological malignancies
60656|NCT02679118|intestinal perforation
60657|NCT02679118|bariatric surgery
60658|NCT02679118|gastric bypass
60659|NCT02679118|gastric perforation
60660|NCT02679118|colonic perforation
60661|NCT02679092|Induced Abortion
60662|NCT02679092|Mifepristone
60663|NCT02679092|Dilation and Evacuation
60664|NCT02679092|Cervical Preparation
60665|NCT02679092|Osmotic Dilators
60666|NCT02679092|Misoprostol
60667|NCT02678962|Multifocal Intraocular Lenses
60668|NCT02678962|bilateral implantation
60669|NCT02678897|Abortion, Drug-Induced
60670|NCT02678897|Pain Management
60671|NCT02678884|Head and Neck Squamous Cell Carcinoma
60672|NCT02678884|Radiation therapy
60673|NCT02678884|Head and Neck Cancers
60674|NCT02678871|Aortic Valve Stenosis
60675|NCT02678871|Left atrial appendage
60676|NCT02678858|social cognition
60677|NCT02678858|social skills
60678|NCT02678858|cognitive remediation
60679|NCT02678858|functional outcome
60680|NCT02678858|treatment adherence
60681|NCT02678767|HIV
60682|NCT02678767|Dementia
60683|NCT02678767|Neuroimaging
60684|NCT02678702|Sleep
60685|NCT02678702|Depression
60686|NCT02678702|Comorbid Insomnia
60687|NCT02678702|Cognitive Behavioral Therapy
60688|NCT02678702|Sleep Restriction
60689|NCT02678702|Stimulus Control therapy
60690|NCT02678702|Relaxation
60691|NCT02678676|Drug Therapy
60692|NCT02678663|Colon polyp
60693|NCT02678663|Polypectomy
60694|NCT02678663|Cold snare
60695|NCT02678663|Endoscopic mucosal resection
60696|NCT02678650|Volatile Anesthetics
60697|NCT02678650|MicroRNA
60698|NCT02678650|Off-pump Coronary Artery Bypass Surgery
60699|NCT02678650|Internal Mammary Artery
60700|NCT02678650|Ascending Aorta
60701|NCT02678637|MRI
60702|NCT02678637|CCSA
60703|NCT02678637|Contractile Cross Sectional Area
60704|NCT02678637|Strength
60705|NCT02678637|Calf muscle
60706|NCT02678611|Healthy participants
60707|NCT02678611|Dietary supplement
60708|NCT02678611|Safety
60709|NCT02678611|Tolerability
60710|NCT02678611|Older Adults
60711|NCT02678611|Basis
60712|NCT02678611|Nicotinamide riboside
60713|NCT02678611|Pterostilbene
60714|NCT02678598|Micafungin
60715|NCT02678598|Candida
60716|NCT02678598|Aspergillosis
60717|NCT02678598|Antifungal
60718|NCT02678572|uveal liver PHP hepatic perfusion chemosaturation Delcath
60719|NCT02678559|Alveolar recruitment manoeuvre
60720|NCT02678559|Lung recruitment
60721|NCT02678559|Preload dependency
60722|NCT02678559|Cardiac surgery
60723|NCT02678559|Transoesophageal echocardiography
60724|NCT02678546|Traditional Chinese Medicine
60725|NCT02678533|Fanconi Anemia
60726|NCT02678533|CD34+ cells mobilization
60727|NCT02678533|G-CSF
60728|NCT02678533|Plerixafor
60729|NCT02678533|gene therapy
60730|NCT02678520|Prostate Cancer
60731|NCT02678520|Post Operative
60732|NCT02678520|Radiation
60733|NCT02678520|Prostatectomy
60734|NCT02678520|3-D CRT
60735|NCT02678520|IMRT
60736|NCT02678520|RT
60737|NCT02678520|CRT
60738|NCT02678520|Conformal Radiation Therapy
60739|NCT02678520|Intensity Modulated Radiation Therapy
60740|NCT02678520|Hormone
60741|NCT02678520|Surgery
60742|NCT02678520|Hormonal Therapy
60743|NCT02678494|Spinal Cord Injury
60744|NCT02678481|multiparametric magnetic resonance imaging
60745|NCT02678481|MR-targeted prostate biopsy
60746|NCT02678481|saturation TRUS-guided prostate biopsy
60747|NCT02678455|Dengue Virus
60748|NCT02678416|comparison
60749|NCT02678403|peripheral artery disease
60750|NCT02678403|transcutaneous electrical nerve stimulation
60751|NCT02678403|walking ability
60752|NCT02678403|endothelial function
60753|NCT02678364|Vitamin D-biofortified eggs
60754|NCT02678364|Vitamin D status
60755|NCT02678364|RCT
60756|NCT02678312|Pediatric Heart failure,
60757|NCT02678312|systemic left ventricle,
60758|NCT02678312|reduced ejection fraction
60759|NCT02678286|Abdominoplasty
60760|NCT02678286|Pain
60761|NCT02678286|Analgesia
60762|NCT02678286|N1539
60763|NCT02678286|Phase 3
60764|NCT02678273|population
60765|NCT02678273|Singapore
60766|NCT02678260|Advanced malignancies
60767|NCT02678260|PDR001
60768|NCT02678260|Japanese patients
60769|NCT02678260|adults
60770|NCT02678247|prosthesis
60771|NCT02678247|prosthetic socket
60772|NCT02678247|transfemoral amputation
60773|NCT02678247|socket comfort
60774|NCT02678247|gait biomechanics
60775|NCT02678156|Dura mater substitute
60776|NCT02678156|Graft
60777|NCT02678156|Lyoplant
60778|NCT02678156|Lyostypt
60779|NCT02678156|Lyoplant onlay
60780|NCT02678156|Xenograft
60781|NCT02678130|Intervertebral disc degeneration
60782|NCT02678130|Bone Disease
60783|NCT02678130|Musculoskeletal disease
60784|NCT02678130|Spinal disease
60785|NCT02678104|Dry Socket
60786|NCT02678104|Honey
60787|NCT02678104|Tooth Extraction
60788|NCT02678078|cancer
60789|NCT02678078|diagnosis
60790|NCT02678078|biopsy
60791|NCT02678078|chemotherapy drugs
60792|NCT02678078|tumor
60793|NCT02678052|Drug therapy
60794|NCT02677961|sarcoma
60795|NCT02677961|registry
60796|NCT02677922|Acute Myeloid Leukemia
60797|NCT02677922|Leukemia
60798|NCT02677922|Azacitidine
60799|NCT02677922|AG-120
60800|NCT02677922|AG-221
60801|NCT02677909|Parenteral Nutrition
60802|NCT02677909|Critical Care
60803|NCT02677896|Androgen Deprivation Therapy (ADT)
60804|NCT02677896|Metastatic hormone sensitive prostate cancer
60805|NCT02677896|Xtandi
60806|NCT02677896|Enzalutamide
60807|NCT02677870|Saproterin dihydrochloride
60808|NCT02677870|Kuvan
60809|NCT02677870|Amish
60810|NCT02677831|Physical functioning
60811|NCT02677831|Neuropsychiatric Disorders
60812|NCT02677831|Frailty
60813|NCT02677818|Plasma Factor VIII Levels
60814|NCT02677818|Ischemic stroke
60815|NCT02677818|Antithrombotic therapy
60816|NCT02677818|Bleeding
60817|NCT02677766|Occupational Therapy
60818|NCT02677766|Complex patients
60819|NCT02677766|Randomized controlled trial
60820|NCT02677766|Occupational performance problem
60821|NCT02677766|Rehabilitation Complexity Scale
60822|NCT02677740|MRI
60823|NCT02677740|MRS
60824|NCT02677740|rTMS
60825|NCT02677727|Cisplatin-based chemotherapy
60826|NCT02677727|Chemotherapy-induced peripheral neuropathy
60827|NCT02677688|systemic lupus erythematosus
60828|NCT02677688|autologous anti-EBV CTL
60829|NCT02677688|adoptive therapy
60830|NCT02677688|phase 1 -2
60831|NCT02677662|Diesel exhaust
60832|NCT02677662|Oxidative stress
60833|NCT02677662|Systemic inflammation
60834|NCT02677662|Air pollution
60835|NCT02677649|cranberry, microbiome, polyphenols, healthy
60836|NCT02677636|Dermatitis, Atopic
60837|NCT02677636|Eczema
60838|NCT02677636|Dermatitis
60839|NCT02677636|Pruritus
60840|NCT02677636|Genetic Diseases, Inborn
60841|NCT02677636|Hypersensitivity
60842|NCT02677636|Hypersensitivity, Immediate
60843|NCT02677636|Immune System Diseases
60844|NCT02677636|Skin Diseases, Eczematous
60845|NCT02677636|Skin Diseases, Genetic
60846|NCT02677636|Skin Diseases
60847|NCT02677636|Itching
60848|NCT02677636|Rash
60849|NCT02677636|Steroid
60850|NCT02677610|Dermatitis, Atopic
60851|NCT02677610|Eczema
60852|NCT02677610|Dermatitis
60853|NCT02677610|Pruritus
60854|NCT02677610|Genetic Diseases, Inborn
60855|NCT02677610|Hypersensitivity
60856|NCT02677610|Hypersensitivity, Immediate
60857|NCT02677610|Immune System Diseases
60858|NCT02677610|Skin Diseases, Eczematous
60859|NCT02677610|Skin Diseases, Genetic
60860|NCT02677610|Skin Diseases
60861|NCT02677610|Itching
60862|NCT02677610|Rash
60863|NCT02677610|Steroid
60864|NCT02677584|caffeine
60865|NCT02677584|apnea
60866|NCT02677584|preterm infant
60867|NCT02677558|Pregnancy
60868|NCT02677558|Obesity
60869|NCT02677558|Echocardiography
60870|NCT02677519|ADHD
60871|NCT02677519|children
60872|NCT02677519|methylphenidate
60873|NCT02677506|elbow
60874|NCT02677480|Microflora
60875|NCT02677480|Probiotics
60876|NCT02677480|Hyposalivation
60877|NCT02677480|Lactobacilli
60878|NCT02677480|Mutans streptococci
60879|NCT02677480|pH-rising components
60880|NCT02677454|Blood Glucose
60881|NCT02677454|Blood Glucose Self-Monitoring
60882|NCT02677428|Veterans
60883|NCT02677428|world wide web
60884|NCT02677428|Counseling
60885|NCT02677428|Workman's Compensation
60886|NCT02677415|Ischemic Stroke
60887|NCT02677415|Anesthesia
60888|NCT02677415|Endovascular Procedures
60889|NCT02677402|femoral vein
60890|NCT02677402|saphenous vein
60891|NCT02677402|hydrostatic pressure
60892|NCT02677402|temperature
60893|NCT02677402|recovery
60894|NCT02677363|Elderly
60895|NCT02677363|Older
60896|NCT02677363|Adults
60897|NCT02677363|Resistant Exercise
60898|NCT02677363|Strength Training
60899|NCT02677363|Cognitive function
60900|NCT02677324|Waldenstrom Macroglobulinemia
60901|NCT02677324|WM
60902|NCT02677272|Nursing home
60903|NCT02677272|emergency department
60904|NCT02677272|inappropriate transfer
60905|NCT02677272|elderly
60906|NCT02677259|luteal phase
60907|NCT02677259|estradiol
60908|NCT02677259|pregnancy rate
60909|NCT02677246|Bone marrow transplantation
60910|NCT02677246|Children
60911|NCT02677246|Bone complications
60912|NCT02677246|Denosumab.
60913|NCT02677181|ATG
60914|NCT02677181|Matched sibling donor
60915|NCT02677181|peripheral blood stem cell transplantation
60916|NCT02677168|obstructive sleep apnea
60917|NCT02677168|sleep apnea
60918|NCT02677168|OSA
60919|NCT02677168|cNEP
60920|NCT02677168|continuous negative external pressure
60921|NCT02677155|Follicular lymphoma
60922|NCT02677155|Intranodal therapy
60923|NCT02677155|Autologous dendritic cells
60924|NCT02677155|Rituximab
60925|NCT02677155|Immunotherapy
60926|NCT02677155|Cancer vaccine
60927|NCT02677155|Anti-PD1
60928|NCT02677155|Pembrolizumab
60929|NCT02677155|Radiotherapy
60930|NCT02677142|pediatric
60931|NCT02677142|Childhood Brain Tumour Survivors
60932|NCT02677142|Social Skills Rating System
60933|NCT02677142|social skills intervention program (SSIP)
60934|NCT02677103|Radial shock wave therapy,calcific tendinitis, ultrasound guidance
60935|NCT02677090|Fiber tolerability
60936|NCT02677090|Children
60937|NCT02677077|RRMS
60938|NCT02677077|MRI
60939|NCT02677064|Allogeneic Hematopoietic Stem Cell Transplantation
60940|NCT02677064|Identify Barriers
60941|NCT02677064|16-024
60942|NCT02677038|Pancreatic Cancer
60943|NCT02677038|Stage IV pancreatic ductal adenocarcinoma (PDAC) with BRCAness
60944|NCT02677038|PDAC
60945|NCT02677038|Metastatic adenocarcinoma of the pancreas
60946|NCT02677038|Family history of breast cancer
60947|NCT02677038|Family history of ovarian cancer
60948|NCT02677038|Family history of pancreatic cancer
60949|NCT02677038|Family history of gastric cancer
60950|NCT02677038|Family history of prostate cancer
60951|NCT02677038|Olaparib
60952|NCT02677038|Lynparza
60953|NCT02677025|HIV
60954|NCT02677025|Sexual Risk
60955|NCT02677025|Sexually Transmitted Diseases
60956|NCT02677025|Substance Abuse
60957|NCT02677025|Violence and Victimization
60958|NCT02677012|Autologous fat grafting
60959|NCT02677012|AFG
60960|NCT02677012|Reconstructive surgery
60961|NCT02677012|Fatty tissue processing
60962|NCT02676986|Primary Breast Cancer
60963|NCT02676986|ER
60964|NCT02676986|AR
60965|NCT02676986|TNBC
60966|NCT02676973|pelvic organ prolapse
60967|NCT02676973|POP
60968|NCT02676973|vault prolapse
60969|NCT02676973|cystocele
60970|NCT02676973|vaginal prolapse
60971|NCT02676973|post-hysterectomy vaginal prolapse
60972|NCT02676921|sinus membrane
60973|NCT02676921|osteogenic
60974|NCT02676908|endovenous ablation
60975|NCT02676908|laser
60976|NCT02676908|radiofrequency
60977|NCT02676908|stockings
60978|NCT02676882|Depressive Disorder
60979|NCT02676882|Depression
60980|NCT02676882|Antidepressants
60981|NCT02676882|Pregnancy
60982|NCT02676882|Folate
60983|NCT02676882|Dietary Supplements
60984|NCT02676882|Omega-3 Fatty Acids
60985|NCT02676882|Women's Health
60986|NCT02676882|Vitamins
60987|NCT02676856|acute myeloid leukemia
60988|NCT02676856|hematopoietic stem cell microtransplantation
60989|NCT02676817|colitis
60990|NCT02676817|endoscopy
60991|NCT02676804|Exercise
60992|NCT02676778|Peripheral T-cell lymphoma
60993|NCT02676778|Cutaneous T-cell lymphoma
60994|NCT02676778|E7777
60995|NCT02676778|Phase 2
60996|NCT02676765|Allergic rhinitis
60997|NCT02676765|Immunotherapy, Allergen
60998|NCT02676765|Sublingual Immunotherapy
60999|NCT02676752|head and neck cancer
61000|NCT02676752|lymphedema and fibrosis
61001|NCT02676726|extraperitoneal
61002|NCT02676726|transperitoneal
61003|NCT02676726|laparoscopic aortic lymphadenectomy
61004|NCT02676726|endometrial cancer
61005|NCT02676726|ovarian cancer
61006|NCT02676726|surgical staging
61007|NCT02676713|Traditional Chinese Medicine
61008|NCT02676713|Chinese Herbal
61009|NCT02676700|Urinary stress incontinence
61010|NCT02676700|pelvic floor muscle
61011|NCT02676700|Kaatsu training
61012|NCT02676687|surgery, noneloquent area
61013|NCT02676661|peri-implant disease
61014|NCT02676661|risk factors
61015|NCT02676661|prevalence
61016|NCT02676622|Crohn's Disease
61017|NCT02676622|Autologous Hematopoietic Stem cell Transplant
61018|NCT02676622|Cyclophosphamide
61019|NCT02676622|IL-2
61020|NCT02676622|Aldesleukin
61021|NCT02676622|Proleukin
61022|NCT02676622|PCDAI
61023|NCT02676609|Type 1 diabetes
61024|NCT02676609|Smart phone application
61025|NCT02676609|carbohydrate counting
61026|NCT02676609|meal insulin dose
61027|NCT02676583|pain
61028|NCT02676583|tonsillectomy
61029|NCT02676583|tonsillar fossa
61030|NCT02676583|suture
61031|NCT02676583|tonsil fossa closure
61032|NCT02676544|Prostate Artery Embolization (PAE)
61033|NCT02676544|Benign Prostatic Hyperplasia (BPH)
61034|NCT02676544|Lower Urinary Tract Symptoms (LUTS)
61035|NCT02676544|PAE
61036|NCT02676544|BPH
61037|NCT02676544|LUTS
61038|NCT02676544|Prostate Artery Embolization
61039|NCT02676544|Embospheres
61040|NCT02676531|Walking Meditation
61041|NCT02676531|Vascular Function
61042|NCT02676531|Flow-mediated dilatation
61043|NCT02676531|Breast Cancer Patients
61044|NCT02676531|Anthracyclines Chemotherapy
61045|NCT02676518|polycystic ovary syndrome
61046|NCT02676518|Serum anti-Mullerian hormone
61047|NCT02676518|glucose intolerance
61048|NCT02676518|metabolic syndrome
61049|NCT02676466|Mobility
61050|NCT02676440|Oral Health
61051|NCT02676401|Diabetic Nephropathy
61052|NCT02676388|Slow Transit Constipation
61053|NCT02676388|Freeze-dried, Capsulized FMT
61054|NCT02676388|Fresh FMT
61055|NCT02676349|mFolfirinox
61056|NCT02676349|Chemoradiotherapy
61057|NCT02676349|Neoadjuvant treatment
61058|NCT02676349|Borderline
61059|NCT02676336|FBC
61060|NCT02676336|cyclic mastalgia
61061|NCT02676336|breast discomfort
61062|NCT02676323|Maximum tolerated dose
61063|NCT02676323|Childhood leukemia
61064|NCT02676323|Hematological malignancies
61065|NCT02676297|inhalation
61066|NCT02676297|anticholinergic
61067|NCT02676258|silicone hydrogel daily disposable soft contact lens
61068|NCT02676245|Prenatal Education
61069|NCT02676245|Residual Specimens
61070|NCT02676232|Online Intervention
61071|NCT02676232|Recurrent Abdominal Pain
61072|NCT02676232|Children
61073|NCT02676193|Tobacco Smoking
61074|NCT02676193|Cigarettes
61075|NCT02676193|Packaging
61076|NCT02676193|Text messaging
61077|NCT02676193|Graphic Images
61078|NCT02676193|Sensor-Based Assessments
61079|NCT02676167|HIV prevention
61080|NCT02676167|men who have sex with men
61081|NCT02676167|pre-exposure prophylaxis
61082|NCT02676167|PrEP
61083|NCT02676167|Greece
61084|NCT02676167|people who inject drugs
61085|NCT02676154|Episodic Hypertension
61086|NCT02676154|Spinal Cord Injury
61087|NCT02676154|Traumatic Spinal Cord Injury
61088|NCT02676154|Blood Pressure
61089|NCT02676154|Fesoterodine
61090|NCT02676154|Neurogenic Detrusor Overactivity
61091|NCT02676154|Autonomic Dysreflexia
61092|NCT02676154|Urodynamic Studies
61093|NCT02676154|24 Hour Ambulatory Blood Pressure Monitoring
61094|NCT02676128|HIV
61095|NCT02676128|Medication Adherence
61096|NCT02676128|Mobile Health
61097|NCT02676115|Cosmetic Wound Healing
61098|NCT02676115|anterior cruciate ligament (ACL)
61099|NCT02676102|barber shops
61100|NCT02676102|organ transplant
61101|NCT02676102|transplants
61102|NCT02676102|organ donor registration
61103|NCT02676089|Asthma, Anticholinergics, Triple combination
61104|NCT02676076|asthma, anticholinergics, triple combination
61105|NCT02676063|predictive factors
61106|NCT02676063|neurodevelopmental disabilities
61107|NCT02676011|Atropine
61108|NCT02676011|Succinycholine
61109|NCT02676011|Laparoscopy
61110|NCT02676011|Gynecology
61111|NCT02675985|Physical Therapy, early intervention
61112|NCT02675972|stroke, blood pressure, prognosis
61113|NCT02675959|stem cell transplantation
61114|NCT02675959|sickle cell disease
61115|NCT02675959|haploidentical
61116|NCT02675959|defibrotide
61117|NCT02675946|WNT inhibitor
61118|NCT02675920|surveillance
61119|NCT02675920|ultrasonography
61120|NCT02675920|computed tomography
61121|NCT02675907|Bunion
61122|NCT02675907|Bunionectomy
61123|NCT02675907|Pain
61124|NCT02675907|Analgesia
61125|NCT02675907|N1539
61126|NCT02675907|Phase 3
61127|NCT02675894|RFA
61128|NCT02675881|RFA
61129|NCT02675868|noradrenaline
61130|NCT02675868|vasopressin
61131|NCT02675868|phenylephrine
61132|NCT02675868|endotoxemia
61133|NCT02675868|Lipopolysaccharide
61134|NCT02675868|vasopressor
61135|NCT02675855|Grafix
61136|NCT02675829|HER2 mutant
61137|NCT02675829|HER2 amplified
61138|NCT02675829|Ado-Trastuzumab Emtansine
61139|NCT02675829|15-335
61140|NCT02675816|Obstructive Sleep Apnea
61141|NCT02675816|OSA
61142|NCT02675816|neurostimulation
61143|NCT02675816|hypoglossal nerve
61144|NCT02675816|tongue
61145|NCT02675816|upper airway stimulation
61146|NCT02675816|surgery
61147|NCT02675803|Rheumatoid arthritis
61148|NCT02675790|hydroxyurea
61149|NCT02675790|sub-Saharan Africa
61150|NCT02675790|secondary stroke prevention
61151|NCT02675777|Alcohol misuse
61152|NCT02675777|Unhealthy alcohol use
61153|NCT02675777|Alcoholism
61154|NCT02675777|Alcohol dependence
61155|NCT02675777|Alcohol abuse
61156|NCT02675777|Risky drinking
61157|NCT02675764|hand function
61158|NCT02675751|myopia
61159|NCT02675673|Enteral Feeding
61160|NCT02675673|G-Tube
61161|NCT02675673|GJ Tube
61162|NCT02675660|kinetic data
61163|NCT02675660|volunteers
61164|NCT02675608|vaccine efficacy
61165|NCT02675608|inflammation
61166|NCT02675608|aging
61167|NCT02675608|Type 2 Diabetes Mellitus
61168|NCT02675608|flu vaccine
61169|NCT02675569|Vascular access
61170|NCT02675569|Hemodialysis
61171|NCT02675569|Kidney failure
61172|NCT02675569|Catheter
61173|NCT02675569|Fistula
61174|NCT02675556|Depression
61175|NCT02675530|NMDA
61176|NCT02675530|glutamate
61177|NCT02675530|schizophrenia
61178|NCT02675504|scary scale
61179|NCT02675491|Advanced solid tumor
61180|NCT02675491|DS-6051b
61181|NCT02675491|ROS1
61182|NCT02675491|NTRK
61183|NCT02675491|refractory to standard therapy
61184|NCT02675491|no standard therapy
61185|NCT02675478|AML
61186|NCT02675478|phase 1
61187|NCT02675478|oncology
61188|NCT02675465|Pompe, rhGAA
61189|NCT02675426|Anti-inflammatory agents
61190|NCT02675426|Joint Disease
61191|NCT02675426|Musculoskeletal Disease
61192|NCT02675426|Antirheumatic agents
61193|NCT02675426|Arthritis
61194|NCT02675413|Cerebral Spinal Fluid
61195|NCT02675413|Dimethyl Fumarate
61196|NCT02675413|Tecfidera
61197|NCT02675413|Multiple Sclerosis
61198|NCT02675413|Relapsing MS
61199|NCT02675413|RRMS
61200|NCT02675413|Mechanism of Action
61201|NCT02675400|ADHD
61202|NCT02675400|ADD
61203|NCT02675400|Attention Deficit/Hyperactivity Disorder
61204|NCT02675400|Attention
61205|NCT02675400|Hyperactivity
61206|NCT02675374|Cardiac surgery
61207|NCT02675374|cardiopulmonary bypass
61208|NCT02675374|dexchlorpheniramine
61209|NCT02675374|H1 blockers
61210|NCT02675374|norepinephrine
61211|NCT02675374|histamine release
61212|NCT02675361|Transfer to adult care
61213|NCT02675361|Continuity of patient care
61214|NCT02675361|Transition program
61215|NCT02675335|Diabetic foot ulcer, Sitagliptin
61216|NCT02675296|outcome
61217|NCT02675283|Point of care test
61218|NCT02675283|Diagnosis
61219|NCT02675283|Case finding
61220|NCT02675257|Diabetes mellitus
61221|NCT02675257|Affective disorders
61222|NCT02675257|Depressive symptoms
61223|NCT02675257|Diabetes distress
61224|NCT02675257|Hyperglycaemia
61225|NCT02675257|Dysglycaemia
61226|NCT02675257|Glycaemic control
61227|NCT02675257|Self-care behaviour
61228|NCT02675257|Quality of Life
61229|NCT02675257|Diabetes acceptance
61230|NCT02675257|Diabetes complications
61231|NCT02675257|Low-grade inflammation
61232|NCT02675257|Inflammatory markers
61233|NCT02675257|Stress reactivity
61234|NCT02675257|Health-care costs
61235|NCT02675244|Tricuspid Valve Regurgitation
61236|NCT02675192|sarcopenia
61237|NCT02675192|elderly
61238|NCT02675192|muscle biopsy
61239|NCT02675166|Childhood cancer
61240|NCT02675166|Sequels
61241|NCT02675166|Complications
61242|NCT02675166|Surgery
61243|NCT02675166|Radiotherapy
61244|NCT02675166|Chemotherapy
61245|NCT02675166|Cancer
61246|NCT02675153|Inflammatory Bowel Disease
61247|NCT02675153|stenosis
61248|NCT02675153|sirolimus
61249|NCT02675153|rapamycin
61250|NCT02675153|stricture
61251|NCT02675114|Sapien 3
61252|NCT02675114|cardiovascular disease
61253|NCT02675114|heart disease
61254|NCT02675114|aortic stenosis
61255|NCT02675114|SAVR
61256|NCT02675114|TAVR
61257|NCT02675088|Extensive Stage Small Cell Lung Cancer
61258|NCT02675088|thoracic radiotherapy
61259|NCT02675088|radiotherapy regimen
61260|NCT02675075|Amyotrophic Lateral Sclerosis
61261|NCT02675075|Voice
61262|NCT02675075|Voice Quality
61263|NCT02675075|Total Lung Capacity
61264|NCT02675062|Accelerometry
61265|NCT02675062|Osteoarthritis
61266|NCT02675062|Habitual physical activity
61267|NCT02675062|Sedentary behaviour
61268|NCT02675062|Knee arthroplasty
61269|NCT02675049|Intranasal
61270|NCT02675049|Dexmedetomidine
61271|NCT02675049|Anaesthesia
61272|NCT02675049|Breast Lumpectomy
61273|NCT02675036|ectopiccanine teeth, impacted teeth, tooth eruption, orthodontics
61274|NCT02674997|Goal setting
61275|NCT02674997|Feasibility
61276|NCT02674997|Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem)
61277|NCT02674997|Patient reported outcome (PRO)
61278|NCT02674997|Goal attainment scaling (GAS)
61279|NCT02674958|endothelial progenitor cells
61280|NCT02674958|aspirin
61281|NCT02674958|acetylsalicylic acid
61282|NCT02674958|alcohol septal ablation
61283|NCT02674945|fitbit
61284|NCT02674945|activity tracker
61285|NCT02674945|sleep
61286|NCT02674945|quality of life
61287|NCT02674919|Repeated-sprint ability
61288|NCT02674919|Nordic Hamstring exercise
61289|NCT02674919|Eccentric hamstring muscle strength
61290|NCT02674893|BMI>27
61291|NCT02674893|Treatment with Liraglutide
61292|NCT02674841|Adolescent
61293|NCT02674841|Physical therapy modalities
61294|NCT02674841|Exercise intervention
61295|NCT02674841|Auditive feedback
61296|NCT02674841|Visual feedback
61297|NCT02674815|Exercise
61298|NCT02674815|Preoperative
61299|NCT02674815|High Intensity Interval Training
61300|NCT02674815|Colorectal
61301|NCT02674815|Thoracic
61302|NCT02674815|Postoperative
61303|NCT02674802|Reinfection
61304|NCT02674802|Eradication therapy
61305|NCT02674802|C-urea breath test
61306|NCT02674802|Helicobacter Pylori
61307|NCT02674789|Exercise
61308|NCT02674789|Athletes
61309|NCT02674789|Ionized Magnesium
61310|NCT02674789|Variation
61311|NCT02674789|Blood
61312|NCT02674763|Acute Myeloid Leukemia
61313|NCT02674763|AML
61314|NCT02674763|IMGN779
61315|NCT02674763|ImmunoGen
61316|NCT02674763|Phase 1
61317|NCT02674763|Relapsed
61318|NCT02674763|Refractory
61319|NCT02674763|CD33
61320|NCT02674763|Dose Escalation
61321|NCT02674763|Dose Expansion
61322|NCT02674750|BCL2
61323|NCT02674750|BCL6
61324|NCT02674750|MYC-Altered
61325|NCT02674750|Double Hit (DH)
61326|NCT02674750|Double Expressor (DE)
61327|NCT02674724|Resistance Training
61328|NCT02674724|Postural Balance
61329|NCT02674724|Exercise
61330|NCT02674711|patient education
61331|NCT02674711|low back pain
61332|NCT02674711|post-surgical pain
61333|NCT02674711|chronic opioid use
61334|NCT02674711|Neck Pain
61335|NCT02674672|VenaTech® Retrievable Vena Cava Filter
61336|NCT02674672|safety
61337|NCT02674672|efficacy
61338|NCT02674659|resistance training, PCSK9, coronary artery bypass
61339|NCT02674633|ADHD
61340|NCT02674594|Anticoagulation
61341|NCT02674568|SCLC
61342|NCT02674568|Small Cell Lung Cancer
61343|NCT02674568|DLL3
61344|NCT02674568|Relapsed
61345|NCT02674568|Refractory
61346|NCT02674555|Phase 1
61347|NCT02674555|Metabolism
61348|NCT02674555|Excretion
61349|NCT02674555|Absorption
61350|NCT02674555|[14C]-radioactivity
61351|NCT02674555|Pharmacokinetics
61352|NCT02674555|Oncology
61353|NCT02674542|Family planning
61354|NCT02674542|Birth spacing
61355|NCT02674529|Depression
61356|NCT02674529|Neuroimaging biomarkers
61357|NCT02674529|MDD
61358|NCT02674529|Neurofeedback
61359|NCT02674516|antisocial behavior
61360|NCT02674516|aggression
61361|NCT02674516|transcranial direct current stimulation
61362|NCT02674516|dorsolateral prefrontal cortex
61363|NCT02674516|associated risk factors
61364|NCT02674503|Walking
61365|NCT02674503|Hospitalization
61366|NCT02674503|Randomized controlled trial
61367|NCT02674490|aphasia, language
61368|NCT02674373|gastric cancer
61369|NCT02674373|biomarker
61370|NCT02674373|Circulating tumor DNA
61371|NCT02674373|Chemotherapy
61372|NCT02674373|Prognosis
61373|NCT02674373|Predictive
61374|NCT02674334|orthopedic procedures
61375|NCT02674321|Tourette Syndrome
61376|NCT02674321|adolescents
61377|NCT02674308|Drug therapy
61378|NCT02674295|Healthy
61379|NCT02674295|JNJ-54135419
61380|NCT02674295|Esketamine
61381|NCT02674282|anterior cruciate ligament reconstruction
61382|NCT02674282|anterior cruciate ligament
61383|NCT02674282|sports medicine
61384|NCT02674282|soccer
61385|NCT02674282|maximum oxygen uptake
61386|NCT02674282|return to play
61387|NCT02674269|Overactive bladder
61388|NCT02674269|Botox
61389|NCT02674269|TC-3 Gel
61390|NCT02674269|Intravesical
61391|NCT02674269|UroGen Pharma
61392|NCT02674269|Botulinum Toxin
61393|NCT02674269|Urgency
61394|NCT02674269|OAB
61395|NCT02674269|Incontinence
61396|NCT02674269|I-QOL
61397|NCT02674269|KHQ
61398|NCT02674269|TBS
61399|NCT02674269|RTG
61400|NCT02674256|health
61401|NCT02674256|age between 18 to 60 years old
61402|NCT02674256|no history of gastrointestinal symptoms or complaints
61403|NCT02674243|Malignant pleural effusion
61404|NCT02674243|Pleurodesis
61405|NCT02674243|Talc
61406|NCT02674243|Iodopovidone solution
61407|NCT02674243|Povidone-iodine
61408|NCT02674204|Statin therapy
61409|NCT02674204|HER2-Negative
61410|NCT02674191|miniplates ,molar intrusion, hyperdivergent
61411|NCT02674139|post placental-caesarean-IUD
61412|NCT02674126|Cardiac Surgery
61413|NCT02674126|Maternal sound
61414|NCT02674126|Cortisol
61415|NCT02674126|Blood sugar
61416|NCT02674126|Stress
61417|NCT02674061|PD1
61418|NCT02674061|PD-1
61419|NCT02674061|PDL1
61420|NCT02674061|PD-L1
61421|NCT02674035|Abdominoplasty
61422|NCT02674035|Sutures
61423|NCT02674035|Abdominal deformities
61424|NCT02674035|Plication
61425|NCT02674035|Monofilament nylon suture
61426|NCT02674035|Barbed suture
61427|NCT02674022|Maternal Health
61428|NCT02674022|Autistic Disorder
61429|NCT02674022|Metabolism
61430|NCT02674022|Folic Acid
61431|NCT02673996|antibody
61432|NCT02673996|autoimmune
61433|NCT02673996|adrenergic
61434|NCT02673996|autonomic
61435|NCT02673983|Intestinal
61436|NCT02673983|Biopsy
61437|NCT02673983|full thickness
61438|NCT02673983|endoscopic
61439|NCT02673970|Melanoma
61440|NCT02673931|Open Heart Surgery
61441|NCT02673931|Organ protection
61442|NCT02673918|Rehabilitation
61443|NCT02673918|Home-Based Intervention
61444|NCT02673905|nasal chondrocytes
61445|NCT02673905|articular chondral lesions
61446|NCT02673905|tissue engineering
61447|NCT02673905|femoral condyle
61448|NCT02673905|trochlea
61449|NCT02673892|discharge
61450|NCT02673892|transitions
61451|NCT02673892|patient experience
61452|NCT02673866|Diabetic Peripheral Neuropathic Pain (DPNP)
61453|NCT02673866|Diabetes
61454|NCT02673866|Pregabalin
61455|NCT02673866|Spontaneous Pain
61456|NCT02673866|Hyperalgesia
61457|NCT02673866|Allodynia
61458|NCT02673866|Average Daily Pain Score (ADPS)
61459|NCT02673866|Pain Associated Sleep Interference
61460|NCT02673853|Supraglottic airway
61461|NCT02673853|Mini-dose atracurium
61462|NCT02673853|Postoperative residual paralysis
61463|NCT02673840|dengue fever
61464|NCT02673840|dengue hemorrhagic fever
61465|NCT02673840|ketotifen
61466|NCT02673840|vascular leakage
61467|NCT02673840|pleural effusion
61468|NCT02673840|plasma leakage
61469|NCT02673801|Referral and Consultation
61470|NCT02673801|Orthopedics
61471|NCT02673775|Macrophage
61472|NCT02673749|Lactose maldigestion
61473|NCT02673749|Dairy intolerance
61474|NCT02673749|Intolerance to milk
61475|NCT02673749|Intolerance to dairy
61476|NCT02673749|Milk intolerance
61477|NCT02673749|GI disorder
61478|NCT02673749|Lactose metabolism
61479|NCT02673749|GI symptoms after dairy ingestion
61480|NCT02673736|PLX73086
61481|NCT02673736|Synovitis, Pigmented Villonodular
61482|NCT02673736|Tenosynovial Giant Cell Tumor
61483|NCT02673736|Joint Diseases
61484|NCT02673736|Neoplasms
61485|NCT02673736|Synovitis
61486|NCT02673723|docozine
61487|NCT02673697|Sutureless valve
61488|NCT02673658|infant development, early intervention
61489|NCT02673645|Educational Achievement
61490|NCT02673632|Anti-Müllerian hormone
61491|NCT02673632|Ovarian stimulation
61492|NCT02673632|Polycystic ovary syndrome
61493|NCT02673632|Intracytoplasmic sperm injection
61494|NCT02673619|Topical
61495|NCT02673619|Palmar Hyperhidrosis
61496|NCT02673619|Umeclidinium
61497|NCT02673593|Safety
61498|NCT02673593|Pharmacokinetics
61499|NCT02673593|Food Effect
61500|NCT02673554|Glucose-dependent Insulinotropic Polypeptide (GIP)
61501|NCT02673554|Glucagon-Like Peptide 1 (GLP-1)
61502|NCT02673554|Incretin
61503|NCT02673554|Insulin secretion
61504|NCT02673554|Tachyphylaxis
61505|NCT02673528|appendectomy
61506|NCT02673528|laparoscopy
61507|NCT02673528|laparoscopic assisted appendectomy
61508|NCT02673528|cost utility
61509|NCT02673515|Alternate Day Fasting
61510|NCT02673502|Carbohydrate drink
61511|NCT02673502|Post operative complication
61512|NCT02673502|insulin resistance
61513|NCT02673502|Fasting blood glucose
61514|NCT02673437|Acute coronary syndrome
61515|NCT02673411|elastography
61516|NCT02673411|ultrasonography
61517|NCT02673372|Geriatric, Pain, Ketamine, Emergency Medicine
61518|NCT02673359|Preterm labor
61519|NCT02673359|Short cervix
61520|NCT02673359|Progesterone
61521|NCT02673359|Cervical cerclage
61522|NCT02673333|Pembrolizumab
61523|NCT02673333|15-286
61524|NCT02673320|Acute Traumatic Cervical Central Cord Syndrom Injury
61525|NCT02673320|Delay of Surgery
61526|NCT02673320|Decompressive Surgery
61527|NCT02673320|Canal Stenosis
61528|NCT02673320|Schneider Syndrom
61529|NCT02673320|Quality of life
61530|NCT02673320|Functional Outcome
61531|NCT02673281|walnuts
61532|NCT02673281|brain
61533|NCT02673281|appetite
61534|NCT02673281|energy intake
61535|NCT02673281|obesity
61536|NCT02673255|Plasma
61537|NCT02673255|Plasma Donor
61538|NCT02673255|Plasma Donation
61539|NCT02673255|Tetanus
61540|NCT02673255|Td
61541|NCT02673255|Immunoglobulin
61542|NCT02673255|Hyper-immunization
61543|NCT02673229|Santyl
61544|NCT02673229|Burn
61545|NCT02673229|Partial Thickness Burn
61546|NCT02673229|Second Degree Burn
61547|NCT02673229|Minor Burn Bacitracin
61548|NCT02673229|Scar Appearance
61549|NCT02673203|glucose monitoring
61550|NCT02673203|hunger levels
61551|NCT02673203|food intake
61552|NCT02673177|robot-assisted total mesorectal excision(RTME)
61553|NCT02673177|laparoscopic total mesorectal excision(LTME)
61554|NCT02673177|urinary function
61555|NCT02673177|sexual function
61556|NCT02673177|sphincter- preservation
61557|NCT02673177|low rectal cancer
61558|NCT02673164|Heart failure
61559|NCT02673164|stem cell
61560|NCT02673164|adipose derived stem cell
61561|NCT02673164|Stem cell therapy
61562|NCT02673164|ischemic heart disease
61563|NCT02673125|Preimplantation Genetic Screening
61564|NCT02673112|Concussion
61565|NCT02673112|mild traumatic brain injury
61566|NCT02673112|post concussion syndrome
61567|NCT02673112|child
61568|NCT02673099|HDF online
61569|NCT02673099|ESRD
61570|NCT02673099|Hemodialysis
61571|NCT02673099|oxidative stress
61572|NCT02673099|quality of life
61573|NCT02673099|Hemodialysis treatment
61574|NCT02673086|retroclavicular approach
61575|NCT02673086|coracoid approach
61576|NCT02673086|ultrasound
61577|NCT02673086|upper limb surgery
61578|NCT02673086|needle visibility
61579|NCT02673086|infraclavicular brachial plexus block
61580|NCT02673073|Heart failure
61581|NCT02673073|patient's diary
61582|NCT02673073|self awareness
61583|NCT02672995|stereotactic radiosurgery,Bevacizumab
61584|NCT02672969|smoke evacuation system
61585|NCT02672969|surgical smoke
61586|NCT02672943|Parkinson disease
61587|NCT02672943|Autonomic nervous system
61588|NCT02672943|MicroRNA
61589|NCT02672943|Inflammation
61590|NCT02672943|Oxidative stress
61591|NCT02672943|noradrenergic network
61592|NCT02672943|Rehabilitation treatment
61593|NCT02672930|calcium gluconate
61594|NCT02672930|hyperpotassemia treatment
61595|NCT02672917|CA19-9 Positive Malignancies
61596|NCT02672904|vocal cord
61597|NCT02672904|carcinoma
61598|NCT02672904|ktp laser
61599|NCT02672904|co2 laser
61600|NCT02672904|endoscopic surgery
61601|NCT02672891|Postpartum Hemorrhage
61602|NCT02672891|Uterine Tamponade
61603|NCT02672891|Condom Catheter
61604|NCT02672878|In-stent restenosis
61605|NCT02672878|Bioresorbable vascular scaffold
61606|NCT02672878|Stent
61607|NCT02672878|Drug-eluting stent
61608|NCT02672878|Coronary angiography
61609|NCT02672852|ABBV-066
61610|NCT02672852|BI 655066
61611|NCT02672852|risankizumab
61612|NCT02672813|Pectoral nerve I and II blocks
61613|NCT02672813|Breast surgery
61614|NCT02672813|Ropivacaine
61615|NCT02672813|Postoperative opioid consumption
61616|NCT02672787|Antihypertensive adherence
61617|NCT02672787|Emergency medicine
61618|NCT02672787|Antihypertensives
61619|NCT02672748|garden
61620|NCT02672748|Native American
61621|NCT02672748|BMI
61622|NCT02672748|Emotional health
61623|NCT02672748|Physical health
61624|NCT02672735|corrective exercise program
61625|NCT02672735|movement efficiency
61626|NCT02672722|This term was found doing the MeSH search and is the only thing that fits since we will be working with healthy subjects with no conditions.
61627|NCT02672709|Factor Xa Inhibitors
61628|NCT02672709|Renal Dialysis
61629|NCT02672696|Navigation
61630|NCT02672696|Gamma Nail
61631|NCT02672657|Health-Related Quality of life
61632|NCT02672657|Cancer
61633|NCT02672657|Elderly
61634|NCT02672657|Caregivers
61635|NCT02672618|heart failure
61636|NCT02672618|infrared thermal imaging
61637|NCT02672592|Metabolic syndrome X
61638|NCT02672592|Hypogonadism
61639|NCT02672592|Testosterone
61640|NCT02672592|Inflammation
61641|NCT02672592|Obesity
61642|NCT02672553|Aortic Valve Replacement
61643|NCT02672553|Minimal Invasive Sternotomy
61644|NCT02672501|immunotherapy
61645|NCT02672501|CAR-T
61646|NCT02672501|leukemia
61647|NCT02672449|Prostate cancer
61648|NCT02672449|Carbon ions
61649|NCT02672449|Radiobiology
61650|NCT02672449|Radiotherapy
61651|NCT02672436|Diabetic Foot Ulcer
61652|NCT02672436|Diabetes Mellitus
61653|NCT02672436|Wound Healing
61654|NCT02672397|Epidural
61655|NCT02672397|Ethnicity
61656|NCT02672397|Education
61657|NCT02672397|Labor
61658|NCT02672397|obstetrical analgesia
61659|NCT02672384|Intensive care unit
61660|NCT02672384|Invasive mechanical ventilation
61661|NCT02672384|Chronic periodontitis
61662|NCT02672384|Point of Care P. gingivalis test
61663|NCT02672358|Non-Small-Cell Lung Cancer
61664|NCT02672358|NSCLC
61665|NCT02672358|dabrafenib
61666|NCT02672358|trametinib
61667|NCT02672358|Japanese patients
61668|NCT02672358|BRAF V600E mutation positive metastatic
61669|NCT02672358|stage IV
61670|NCT02672345|Sevoflurane
61671|NCT02672345|MicroRNAs
61672|NCT02672345|Inflammatory Response
61673|NCT02672345|Cytokines
61674|NCT02672345|Anesthetics, Inhalation
61675|NCT02672345|Macrophage Inflammatory Proteins
61676|NCT02672267|AMI, hBMMSCs, stem cells,
61677|NCT02672241|Radiation Therapy
61678|NCT02672241|Brainstem Tumor in Children
61679|NCT02672202|Chronic Pain
61680|NCT02672202|Pain Modulation Profile
61681|NCT02672202|CPM
61682|NCT02672202|acute post operative pain
61683|NCT02672189|Climacteric symptoms
61684|NCT02672189|Menopause
61685|NCT02672189|Breast Cancer Survivors
61686|NCT02672189|Internet-based
61687|NCT02672189|Cognitive behavioral therapy
61688|NCT02672189|Psychosocial intervention
61689|NCT02672176|Diabetes mellitus
61690|NCT02672176|Motivational Interviewing
61691|NCT02672176|Mobile Health Technology
61692|NCT02672176|Patient-generated Health Data (PGHD)
61693|NCT02672163|autologous micrografts
61694|NCT02672163|heart failure
61695|NCT02672163|coronary artery bypass surgery
61696|NCT02672163|cell therapy
61697|NCT02672163|atrial appendage
61698|NCT02672163|epicardial cell delivery
61699|NCT02672150|evidence-based practice implementation
61700|NCT02672150|system change
61701|NCT02672150|interagency collaboration
61702|NCT02672150|substance use
61703|NCT02672150|treatment services
61704|NCT02672150|data-driven decision making
61705|NCT02672150|juvenile justice
61706|NCT02672150|adolescents
61707|NCT02672150|justice-involved youth
61708|NCT02672150|cluster randomized trial
61709|NCT02672137|myocardial infarction
61710|NCT02672137|knowledge transfer
61711|NCT02672137|acute coronary syndromes
61712|NCT02672020|pheochromocytoma
61713|NCT02672020|paraganglioma
61714|NCT02672020|adrenocortical carcinoma
61715|NCT02672007|Respiratory rate measurement methods.
61716|NCT02671994|Geriatric Assessment
61717|NCT02671994|G8 screening
61718|NCT02671994|Oncologic treatment
61719|NCT02671968|CGM
61720|NCT02671968|hypoglycemic events
61721|NCT02671955|Advanced Cancer
61722|NCT02671955|JNJ-61610588
61723|NCT02671942|roflumilast
61724|NCT02671916|QoL and Survival one year after ICU stay
61725|NCT02671864|Incretin-based therapy
61726|NCT02671864|GLP1
61727|NCT02671864|Angiogenesis Inflammation
61728|NCT02671864|Hypoglycaemic treatment
61729|NCT02671851|Thoracic Paravertebral Blocks
61730|NCT02671851|Ultrasound Guidance
61731|NCT02671851|Reduction Mammoplasty
61732|NCT02671851|Time to First Pain
61733|NCT02671851|Postoperative Analgesia
61734|NCT02671825|Pharmacokinetics
61735|NCT02671812|dental implant
61736|NCT02671812|patient satisfaction
61737|NCT02671812|treatment outcome
61738|NCT02671812|cytokine profile
61739|NCT02671812|risk factor
61740|NCT02671812|risk predictor
61741|NCT02671786|Severe Acute Malnutrition
61742|NCT02671786|Severe Underweight
61743|NCT02671786|IAP Grade III-IV
61744|NCT02671786|Severe Stunting
61745|NCT02671786|Village Health Workers
61746|NCT02671786|MAHAN RUTF & MAHAN Vit-Mim mix
61747|NCT02671773|Microbiota
61748|NCT02671760|Short-term insomnia
61749|NCT02671760|difficulty sleeping
61750|NCT02671760|sedative
61751|NCT02671760|hypnotic
61752|NCT02671734|endoscopy
61753|NCT02671682|Immunoadsorption
61754|NCT02671682|Plasmapheresis
61755|NCT02671656|Uricemia
61756|NCT02671630|Cognitive function
61757|NCT02671630|Depression
61758|NCT02671630|Quality of life
61759|NCT02671630|Community-based computerized cognitive training program
61760|NCT02671630|Randomized controlled trial
61761|NCT02671617|Abdominal Cavity
61762|NCT02671617|Aged
61763|NCT02671604|acute renal failure
61764|NCT02671604|prostatectomy
61765|NCT02671604|minimal invasive surgery
61766|NCT02671578|nitrous oxide
61767|NCT02671578|conscious sedation
61768|NCT02671578|pain
61769|NCT02671578|anxiety
61770|NCT02671565|Intraarticular hyaluronic acid injections
61771|NCT02671565|Total knee replacement
61772|NCT02671565|Observational study
61773|NCT02671565|Intraarticular corticosteroid injections
61774|NCT02671565|Comparative effectiveness
61775|NCT02671539|gene therapy
61776|NCT02671539|hereditary retinal degeneration
61777|NCT02671539|rAAV2.REP1
61778|NCT02671513|Melanoma
61779|NCT02671513|Cycline-Dependent Kinase
61780|NCT02671487|Problem Behavior
61781|NCT02671487|Aggression
61782|NCT02671487|Posttraumatic Stress Disorder
61783|NCT02671487|Adolescents
61784|NCT02671448|Homebound
61785|NCT02671448|Homecare
61786|NCT02671448|15-022
61787|NCT02671396|Virtual Reality
61788|NCT02671396|Postural Stability
61789|NCT02671396|Balance Training
61790|NCT02671396|Parkinson's Disease
61791|NCT02671383|Antiretroviral Agents
61792|NCT02671383|Treatment
61793|NCT02671383|Viral Load
61794|NCT02671357|pancreatic surgery; neoplasms
61795|NCT02671318|cytomegalovirus
61796|NCT02671318|sirolimus
61797|NCT02671318|cytomegalovirus recurrence
61798|NCT02671318|kidney transplant
61799|NCT02671318|conversion
61800|NCT02671305|delayed cord clamping
61801|NCT02671305|cord milking
61802|NCT02671305|bedside neonatal resuscitation
61803|NCT02671292|Loss of Control Eating
61804|NCT02671292|Binge Eating
61805|NCT02671292|Obesity
61806|NCT02671292|Prevention
61807|NCT02671292|Interpersonal Psychotherapy
61808|NCT02671292|Adolescent
61809|NCT02671266|Oxytocin
61810|NCT02671266|Body dysmorphic disorder
61811|NCT02671266|Obsessive-compulsive disorder
61812|NCT02671240|Parkinson disease
61813|NCT02671240|behavioral addiction
61814|NCT02671240|akinéto-rigid syndrome
61815|NCT02671240|dopamine agonist
61816|NCT02671214|guar gum
61817|NCT02671214|konjac mannan
61818|NCT02671214|blood glucose
61819|NCT02671214|legume flour
61820|NCT02671188|C-C chemokine receptor
61821|NCT02671188|Psoriatic arthritis
61822|NCT02671188|Chemokine (C-C motif) ligand 20
61823|NCT02671188|Monoclonal antibody
61824|NCT02671188|psoriasis
61825|NCT02671188|Humanized Immunoglobulin G
61826|NCT02671162|Pruritus
61827|NCT02671162|End-Stage Renal Disease
61828|NCT02671110|weight loss treatment
61829|NCT02671110|Obesity
61830|NCT02671084|Sevoflurane
61831|NCT02671084|Ck-MB
61832|NCT02671071|Cervix Cancer
61833|NCT02671058|bioavailability
61834|NCT02671045|lung cancer
61835|NCT02671045|genomic profile
61836|NCT02671045|targeted therapy
61837|NCT02671045|FoundationOne
61838|NCT02671032|Cochlear Prosthesis Implantation
61839|NCT02670980|Retina Implant
61840|NCT02670980|Visual Prosthesis
61841|NCT02670941|aromatherapy
61842|NCT02670941|chemotherapy
61843|NCT02670941|ginger
61844|NCT02670941|lavender
61845|NCT02670941|orange
61846|NCT02670941|jojoba
61847|NCT02670941|essential oils
61848|NCT02670941|cancer
61849|NCT02670928|Diabetes
61850|NCT02670928|lifestyle change
61851|NCT02670928|weight management
61852|NCT02670928|control of glycemic in HbA1C and FPG
61853|NCT02670889|Urea Cycle Disorder
61854|NCT02670850|Mild Cognitive Impairment
61855|NCT02670850|Family caregiver
61856|NCT02670850|Intervention program
61857|NCT02670850|Elders
61858|NCT02670811|Hypertension
61859|NCT02670811|Fermented Milk
61860|NCT02670811|Clinical Study
61861|NCT02670811|Randomized
61862|NCT02670811|Double-blind
61863|NCT02670798|neuromuscular
61864|NCT02670798|scoliosis
61865|NCT02670772|Antiretroviral Agents
61866|NCT02670746|Pancreatic Cancer
61867|NCT02670746|Observational
61868|NCT02670746|Nab-Paclitaxel
61869|NCT02670746|Abraxane
61870|NCT02670746|ABI-007
61871|NCT02670746|Gemcitabine
61872|NCT02670746|Non-interventional
61873|NCT02670746|Netherlands
61874|NCT02670746|Quality of Life
61875|NCT02670733|mechanical ventilation
61876|NCT02670733|positive end-expiratory pressure
61877|NCT02670720|BCX4161
61878|NCT02670720|avoralstat
61879|NCT02670720|HAE
61880|NCT02670720|hereditary angioedema
61881|NCT02670720|prophylaxis
61882|NCT02670707|vinblastine
61883|NCT02670707|prednisone
61884|NCT02670707|cytarabine
61885|NCT02670707|Langerhans Cell Histiocytosis (LCH)
61886|NCT02670694|Rett Syndrome
61887|NCT02670694|Prader-Willi Syndrome
61888|NCT02670694|Angelman Syndrome
61889|NCT02670694|Sleep Problems
61890|NCT02670681|Exercise
61891|NCT02670681|Aerobic Exercise
61892|NCT02670668|BRCA1/2;Mutations;Neoadjuvant chemotherapy;TNBC
61893|NCT02670655|Ablative fractional laser
61894|NCT02670655|Iontophoresis
61895|NCT02670655|Actinic keratosis
61896|NCT02670655|Photodynamic therapy
61897|NCT02670629|Pediatric orthopedics
61898|NCT02670577|stage I
61899|NCT02670577|stage II
61900|NCT02670577|HER2 positive
61901|NCT02670577|Triple Negative
61902|NCT02670564|pharmacogenetics
61903|NCT02670564|busulfan
61904|NCT02670564|treosulfan
61905|NCT02670564|hematopoietic stem cell transplantation
61906|NCT02670564|fludarabine
61907|NCT02670564|pediatric patients
61908|NCT02670564|TBI
61909|NCT02670564|leukemia
61910|NCT02670564|leukemia, lymphoid
61911|NCT02670564|precursor cell lymphoblastic Leukemia-Lymphoma
61912|NCT02670564|Immune System disease
61913|NCT02670564|Immunoproliferative Disorders
61914|NCT02670564|stem cell transplantation
61915|NCT02670564|children and adolescent
61916|NCT02670564|high risk acute lymphoblastic leukemia
61917|NCT02670564|NCT01949129 add-on
61918|NCT02670564|ALL SCTped FORUM
61919|NCT02670525|Recurrent, Refractory, or High Risk Leukemias
61920|NCT02670525|Matched targeted therapy
61921|NCT02670512|End-Stage Renal Disease
61922|NCT02670512|Peritoneal Dialysis
61923|NCT02670512|Telehomecare
61924|NCT02670512|Telehome Monitoring
61925|NCT02670486|Overactive bladder
61926|NCT02670486|Urge urinary incontinence
61927|NCT02670486|Urodynamics
61928|NCT02670408|Heart transplant
61929|NCT02670408|global gene expression
61930|NCT02670408|molecular diagnostics
61931|NCT02670395|Healthy
61932|NCT02670395|JNJ-54416076
61933|NCT02670395|Ascending Dose
61934|NCT02670369|Sedentary time
61935|NCT02670369|Sit-to-stand transitions
61936|NCT02670356|fish oil
61937|NCT02670356|EPA
61938|NCT02670356|DHA
61939|NCT02670356|krill oil
61940|NCT02670356|Metabolic Syndrome
61941|NCT02670330|Epidermolysis Bullosa
61942|NCT02670330|Simplex
61943|NCT02670330|Recessive Dystrophic
61944|NCT02670330|Junctional non-Herlitz
61945|NCT02670317|DLBCL
61946|NCT02670317|large B cell lymphoma
61947|NCT02670317|nhl
61948|NCT02670304|letrozole
61949|NCT02670304|ovarian hyperstimulating syndrome
61950|NCT02670291|auditory hallucinations
61951|NCT02670291|schizophrenia
61952|NCT02670291|cTBS
61953|NCT02670291|noninvasive brain stimulation
61954|NCT02670265|malnutrition
61955|NCT02670265|parenteral nutrition
61956|NCT02670265|weight loss
61957|NCT02670265|pancreatic cancer
61958|NCT02670265|biliary tract cancer
61959|NCT02670265|quality of life
61960|NCT02670226|Amyotrophic Lateral Sclerosis
61961|NCT02670226|Muscle metabolism
61962|NCT02670226|Metabolomics
61963|NCT02670226|Transcriptomics
61964|NCT02670200|psychooncology
61965|NCT02670200|mental health support
61966|NCT02670200|ICBT
61967|NCT02670200|supportive treatment for cancer patients
61968|NCT02670200|depression
61969|NCT02670200|online-therapy
61970|NCT02670200|Psycho-oncological support via internet
61971|NCT02670200|internet-delivered cognitive behavior medicine
61972|NCT02670187|MERS CoV, Vaccine, DNA
61973|NCT02670174|Shoulder impingement syndrome
61974|NCT02670174|Overhead athletes
61975|NCT02670174|Kinetic chain
61976|NCT02670174|Exercise treatment
61977|NCT02670148|Chiropractic Manipulative Therapy
61978|NCT02670148|Low back pain
61979|NCT02670148|Trunk muscle strength
61980|NCT02670148|Balance
61981|NCT02670148|Active military personnel
61982|NCT02670122|Hepatocellular Carcinoma
61983|NCT02670122|TACE
61984|NCT02670096|acetazolamide
61985|NCT02670096|Treatment Emergent Sleep Disordered Breathing
61986|NCT02670096|Sleep Apnea
61987|NCT02670031|Hypertensive Heart Disease
61988|NCT02670031|Hypertension
61989|NCT02670031|Left Ventricular Hypertrophy
61990|NCT02670031|Myocardial Fibrosis
61991|NCT02670031|Cardiovascular Magnetic Resonance Imaging
61992|NCT02669992|Ileostomy
61993|NCT02669979|elderly
61994|NCT02669979|oral care
61995|NCT02669966|Kidney Transplantation
61996|NCT02669940|Ombitasvir
61997|NCT02669940|Dasabuvir
61998|NCT02669940|Paritaprevir
61999|NCT02669927|hip surgery
62000|NCT02669927|frail older people
62001|NCT02669901|Opioid-Related Disorders
62002|NCT02669901|Naloxone
62003|NCT02669901|Harm Reduction
62004|NCT02669901|Drug Overdose Deaths
62005|NCT02669901|Opioid Misuse
62006|NCT02669901|Naloxone Coprescribing
62007|NCT02669901|Universal Precautions
62008|NCT02669901|Opioid Substance Use Disorder
62009|NCT02669888|Indigo Naturalis
62010|NCT02669888|Atopic Dermatitis
62011|NCT02669888|TCM
62012|NCT02669823|Diagnosis
62013|NCT02669797|Obesity
62014|NCT02669797|Ecological Momentary Intervention
62015|NCT02669797|Video Feedback
62016|NCT02669771|Xtandi
62017|NCT02669771|ASP9785
62018|NCT02669771|long term use
62019|NCT02669771|enzalutamide
62020|NCT02669758|Alkermes
62021|NCT02669758|ALKS 3831
62022|NCT02669758|Samidorphan
62023|NCT02669758|Schizophrenia
62024|NCT02669758|Safety
62025|NCT02669745|Chinese women
62026|NCT02669745|Breast cancer
62027|NCT02669732|Type 2 Diabetes Mellitus
62028|NCT02669732|Adult
62029|NCT02669732|Developmental Phase II
62030|NCT02669719|Lung Cancer
62031|NCT02669719|Chemotherapy
62032|NCT02669719|Immunotherapy
62033|NCT02669693|Olives, oleuropein
62034|NCT02669667|MEDI9314
62035|NCT02669667|Safety
62036|NCT02669667|Tolerability
62037|NCT02669667|Pharmacokinetics
62038|NCT02669667|Immunogenicity
62039|NCT02669641|Steatosis, Fatty liver, Steatohepatitis
62040|NCT02669615|multiple myeloma
62041|NCT02669615|Melphalan HCl
62042|NCT02669615|Autologous Transplantation
62043|NCT02669602|Nutritional epidemiology
62044|NCT02669602|Prospective
62045|NCT02669589|CRRT
62046|NCT02669589|AKI
62047|NCT02669589|anticoagulation
62048|NCT02669589|KDIGO
62049|NCT02669576|Breast cancer
62050|NCT02669576|meopausal syptoms
62051|NCT02669576|mind body medecine
62052|NCT02669576|yoga
62053|NCT02669576|acupuncture
62054|NCT02669550|Fiberoptic bronchoscope
62055|NCT02669550|Disposcope endoscope
62056|NCT02669550|Awake orotracheal intubation
62057|NCT02669485|ICG
62058|NCT02669485|colectomy
62059|NCT02669485|anastomotic leak
62060|NCT02669485|anastomotic leakage rate
62061|NCT02669485|surgical decision
62062|NCT02669459|Cervical Intraepithelial Neoplasia
62063|NCT02669459|Imiquimod
62064|NCT02669459|Human papillomavirus
62065|NCT02669459|quality of life
62066|NCT02669459|biological markers
62067|NCT02669446|Non interventional study
62068|NCT02669446|Ectoin
62069|NCT02669446|Lozenges
62070|NCT02669446|pharyngitis
62071|NCT02669433|Dementia with Lewy bodies
62072|NCT02669433|Lewy bodies
62073|NCT02669433|intepirdine
62074|NCT02669433|RVT-101
62075|NCT02669433|dementia
62076|NCT02669381|Phenylalanine
62077|NCT02669381|Direct Amino Acid Oxidation
62078|NCT02669381|Stable isotopes
62079|NCT02669355|White coat physician attire
62080|NCT02669342|Infection
62081|NCT02669342|Urinary Catheter
62082|NCT02669342|Sharklet
62083|NCT02669316|diet
62084|NCT02669303|Subacromial injection
62085|NCT02669303|methylprednisolone
62086|NCT02669303|treatment
62087|NCT02669303|Platelet-rich plasma
62088|NCT02669251|Optimal Biologic Dose
62089|NCT02669251|Safety
62090|NCT02669251|Chronic Graft-Versus-Host Disease (cGVHD)
62091|NCT02669251|Inflammatory Lung Disease
62092|NCT02669251|FEV1
62093|NCT02669225|18 F florbetaben
62094|NCT02669225|Sleep Deprivation
62095|NCT02669225|rested wakefulness
62096|NCT02669225|glymphatic system
62097|NCT02669212|Chronic Fatigue Syndrome
62098|NCT02669212|Lyme Disease
62099|NCT02669212|Healthy Volunteers
62100|NCT02669212|Movement Disorder
62101|NCT02669186|analgesia
62102|NCT02669186|cancer
62103|NCT02669186|natural killer cell
62104|NCT02669186|opioid
62105|NCT02669173|Myeloid derived suppressor cells
62106|NCT02669173|brain tumor
62107|NCT02669173|MDSC
62108|NCT02669173|GBM
62109|NCT02669173|recurrent
62110|NCT02669160|Motorized Orthotic Devices
62111|NCT02669160|Minors
62112|NCT02669160|CP (Cerebral Palsy)
62113|NCT02669160|Exoskeleton Device
62114|NCT02669134|cardiac resynchronization therapy
62115|NCT02669134|optimization
62116|NCT02669134|heart failure
62117|NCT02669134|reverse left ventricular remodeling
62118|NCT02669121|Drug therapy
62119|NCT02669108|testis
62120|NCT02669108|spermatogenesis
62121|NCT02669082|Drug Therapy
62122|NCT02669004|Analgesia, Epidural,Pain, Postoperative
62123|NCT02668991|Autism Spectrum Disorder
62124|NCT02668991|Janssen Autism Knowledge Engine
62125|NCT02668991|Autism Behavior Inventory
62126|NCT02668978|lung surgery
62127|NCT02668978|air leak
62128|NCT02668978|prevention
62129|NCT02668965|Clinical pregnancy rate
62130|NCT02668913|gynaecology
62131|NCT02668913|Oncology
62132|NCT02668900|Feasibility trial
62133|NCT02668900|Cardiovascular disease
62134|NCT02668900|Decision Support
62135|NCT02668900|Patient Decision Aid
62136|NCT02668900|implantable cardioverter defibrillator
62137|NCT02668900|implantable cardioverter defibrillator replacement
62138|NCT02668874|Pit and Fissure sealants
62139|NCT02668874|Isolation
62140|NCT02668874|permanent teeth
62141|NCT02668874|children
62142|NCT02668874|Isolite®
62143|NCT02668874|Dental caries
62144|NCT02668848|Stroke
62145|NCT02668848|Dehydration
62146|NCT02668848|Fluid therapy
62147|NCT02668770|Advanced Cancers
62148|NCT02668770|Melanoma
62149|NCT02668770|Advanced solid malignancies
62150|NCT02668770|Metastatic
62151|NCT02668770|MGN1703
62152|NCT02668770|Ipilimumab
62153|NCT02668770|Yervoy
62154|NCT02668770|BMS-734016
62155|NCT02668770|MDX010
62156|NCT02668770|Refractory
62157|NCT02668770|Relapsed
62158|NCT02668718|radiotherapy, adjuvant
62159|NCT02668718|prostatectomy
62160|NCT02668692|LEO 80185 gel, calcipotriol, betamethasone
62161|NCT02668679|Dream Doctors
62162|NCT02668679|Medical Clown
62163|NCT02668679|Pediatrics
62164|NCT02668679|Sedation
62165|NCT02668679|Endoscopy
62166|NCT02668666|Palbociclib
62167|NCT02668666|Tamoxifen
62168|NCT02668666|CDK4/6 Inhibitor
62169|NCT02668653|Newly diagnosed Acute Myeloid Leukemia
62170|NCT02668653|FLT3-ITD positive
62171|NCT02668653|Chemotherapy
62172|NCT02668653|Induction chemotherapy
62173|NCT02668653|Consolidation chemotherapy
62174|NCT02668653|Maintenance chemotherapy
62175|NCT02668653|Quizartinib
62176|NCT02668653|Receptor tyrosine kinase inhibitor
62177|NCT02668653|FMS-like tyrosine kinase 3
62178|NCT02668653|AC220
62179|NCT02668653|FLT3-ITD
62180|NCT02668653|AML
62181|NCT02668640|Work productivity
62182|NCT02668640|Rheumatoid arthritis (RA)
62183|NCT02668640|Adalimumab
62184|NCT02668640|Quality of life (QOL)
62185|NCT02668627|Stroke
62186|NCT02668627|Collateral status
62187|NCT02668627|Endovascular treatment
62188|NCT02668614|Detection
62189|NCT02668601|Gestational Diabetes Mellitus
62190|NCT02668601|Childhood Obesity
62191|NCT02668601|Offspring
62192|NCT02668575|Pulmonary Cystic Fibrosis
62193|NCT02668562|acute coronary syndrome
62194|NCT02668562|coronary artery bypass surgery
62195|NCT02668562|ticagrelor
62196|NCT02668562|antiplatelet therapy
62197|NCT02668562|platelet function testing
62198|NCT02668536|sunscreen
62199|NCT02668536|melanoma
62200|NCT02668536|improved protection from uv rays
62201|NCT02668523|Presbyopia
62202|NCT02668523|Corneal Inlay
62203|NCT02668523|Pseudophakic
62204|NCT02668523|Pseudophakia
62205|NCT02668510|Heel Pain
62206|NCT02668510|extracorporeal shock wave therapy
62207|NCT02668510|ESWT
62208|NCT02668510|shock wave
62209|NCT02668510|Soldiers
62210|NCT02668510|Platelet rich plasma
62211|NCT02668510|PRP
62212|NCT02668510|Autologous conditioned plasma
62213|NCT02668510|Military
62214|NCT02668497|Movement disorders
62215|NCT02668497|Botulinum toxin type A
62216|NCT02668497|Tremor
62217|NCT02668497|Kinematics
62218|NCT02668484|TAVI
62219|NCT02668484|trans-femoral
62220|NCT02668484|Sapien
62221|NCT02668484|Lotus
62222|NCT02668445|Concurrent
62223|NCT02668445|muscle
62224|NCT02668445|glycogen
62225|NCT02668445|molecular
62226|NCT02668406|Blood infection, melioidosis, rapid diagnostic test
62227|NCT02668380|Apatinib
62228|NCT02668380|metastatic gastric cancer
62229|NCT02668380|Non-interventionalStudy
62230|NCT02668367|Viral Diseases
62231|NCT02668367|Antiviral
62232|NCT02668367|Paramyxoviridae Infections
62233|NCT02668367|RSV
62234|NCT02668367|Respiratory Syncytial Virus
62235|NCT02668367|Aviragen Therapeutics, Inc.
62236|NCT02668367|Aviragen Therapeutics
62237|NCT02668367|Aviragen
62238|NCT02668354|Childhood Cancer
62239|NCT02668354|Pediatric Oncology
62240|NCT02668354|Infant tumors
62241|NCT02668302|Steroid-eluting implant
62242|NCT02668302|Mometasone furoate
62243|NCT02668276|Prostatic neoplasms
62244|NCT02668276|Oncotype DX
62245|NCT02668276|Treatment Decisions
62246|NCT02668263|Breast cancer
62247|NCT02668263|mastectomy
62248|NCT02668263|seromas
62249|NCT02668211|osteoarthritis
62250|NCT02668211|radiostereometric analysis
62251|NCT02668211|correction of functional deformity
62252|NCT02668211|procedures
62253|NCT02668211|total hip arthroplasty
62254|NCT02668211|musculoskeletal diseases
62255|NCT02668198|Endoscopic mucosal resection, residual polyp, near focus imaging
62256|NCT02668172|pegvisomant
62257|NCT02668172|pasireotide LAR
62258|NCT02668172|long acting somatostatin analogues
62259|NCT02668146|essential tremor
62260|NCT02668146|Perampanel
62261|NCT02668146|clinical trial
62262|NCT02668133|zinc deficiency
62263|NCT02668133|zinc absorption
62264|NCT02668120|chronic histiocytic intervillositis
62265|NCT02668120|serum alkaline phosphatase
62266|NCT02668120|placenta
62267|NCT02668120|case-control study
62268|NCT02668094|propofol
62269|NCT02668094|lidocaine
62270|NCT02668094|pregabalin
62271|NCT02668081|Endoscopic sphincterotomy
62272|NCT02668081|Endoscopic papillary balloon dilation
62273|NCT02668081|Metagenomics
62274|NCT02668068|Pneumoconiosis
62275|NCT02668068|Mesenchymal Stem Cells
62276|NCT02668068|whole-lung lavage (WLL)
62277|NCT02668055|TB4
62278|NCT02668055|Difficult to heal
62279|NCT02668029|Oxygen therapy
62280|NCT02668003|Prevention trial
62281|NCT02668003|Cognitive Behaviour Therapy
62282|NCT02668003|CWP
62283|NCT02668003|Chronic widespread pain
62284|NCT02668003|RCT
62285|NCT02668003|Fibromyalgia
62286|NCT02668003|Prevention
62287|NCT02667990|metatarsalgia
62288|NCT02667990|pedobar
62289|NCT02667990|foot
62290|NCT02667990|stiletto
62291|NCT02667990|insoles
62292|NCT02667977|fluids, pediatric, gastroenteritis
62293|NCT02667951|Elderly
62294|NCT02667951|Dementia
62295|NCT02667951|Intervention program
62296|NCT02667925|ovarian cancer
62297|NCT02667925|intraperitoneal chemotherapy
62298|NCT02667912|Hypertension, Endovascular Procedures, Catheter Ablation, Renal Artery
62299|NCT02667899|disorders of consciousness
62300|NCT02667899|deep brain stimulation
62301|NCT02667899|transcranial magnetic stimulation
62302|NCT02667860|intracorporeal anastomosis
62303|NCT02667860|laparoscopic colectomy
62304|NCT02667860|outcomes
62305|NCT02667860|length of stay
62306|NCT02667860|analgesia
62307|NCT02667860|aesthetic
62308|NCT02667860|extracorporeal anastomosis
62309|NCT02667860|laparoscopic
62310|NCT02667847|preoperative anxiety assessment
62311|NCT02667847|levels of preoperative anxiety using two different scales
62312|NCT02667834|social cognition
62313|NCT02667834|cognitive remediation
62314|NCT02667782|Mindfulness-based interventions
62315|NCT02667782|Dementia
62316|NCT02667782|Caregiving
62317|NCT02667782|Burden
62318|NCT02667782|Stress
62319|NCT02667782|Anxiety
62320|NCT02667782|Depression
62321|NCT02667782|Community care
62322|NCT02667756|biomarker
62323|NCT02667756|inflammation
62324|NCT02667756|prognosis
62325|NCT02667756|knee
62326|NCT02667743|NSCLC
62327|NCT02667743|Paclitaxel Micelles for Injection
62328|NCT02667691|superoxyde dismutase
62329|NCT02667691|melon concentrate
62330|NCT02667691|oxydative stress
62331|NCT02667691|overweight women
62332|NCT02667665|Alzheimer's Disease Dementia
62333|NCT02667652|T2DM
62334|NCT02667652|RYGB
62335|NCT02667652|RCT
62336|NCT02667639|safety
62337|NCT02667639|tolerability
62338|NCT02667639|RPH-104
62339|NCT02667639|RPH104
62340|NCT02667626|Breast cancer survivor
62341|NCT02667626|Cancer survivorship
62342|NCT02667626|Survivorship care plan
62343|NCT02667626|Vaginal dryness
62344|NCT02667626|Vulvovaginal atrophy
62345|NCT02667626|Vasomotor symptom
62346|NCT02667626|Infertility
62347|NCT02667626|Family planning
62348|NCT02667613|motor skill learning
62349|NCT02667613|functional changes
62350|NCT02667613|neuroplastic changes
62351|NCT02667600|Cesarean
62352|NCT02667600|Blood Loss
62353|NCT02667600|Triton
62354|NCT02667574|basal cell carcinoma
62355|NCT02667574|surgery
62356|NCT02667574|stage
62357|NCT02667574|vismodegib
62358|NCT02667548|percutaneous coronary intervention
62359|NCT02667509|Evolutionary Model
62360|NCT02667483|Duchenne muscular dystrophy
62361|NCT02667483|DMD
62362|NCT02667483|Oligonucleotides, Antisense
62363|NCT02667470|Solifenacin
62364|NCT02667470|Overactive bladder
62365|NCT02667431|SUI
62366|NCT02667418|Clostridium
62367|NCT02667418|Difficile
62368|NCT02667418|Fidaxomicin
62369|NCT02667418|Vancomycin
62370|NCT02667418|Recurrent
62371|NCT02667418|Pulse
62372|NCT02667418|Taper
62373|NCT02667392|Stroke
62374|NCT02667392|Gait
62375|NCT02667392|Walking
62376|NCT02667392|Rehabilitation
62377|NCT02667392|Exercise
62378|NCT02667392|Exercise Therapy
62379|NCT02667392|Physical Therapy Modalities
62380|NCT02667392|Exercise Movement Techniques
62381|NCT02667379|Cat
62382|NCT02667379|allergy
62383|NCT02667379|dander
62384|NCT02667379|Fel d 1
62385|NCT02667379|Felis domesticus
62386|NCT02667366|mild and moderate depression
62387|NCT02667353|electroconvulsive
62388|NCT02667353|hippocampus
62389|NCT02667353|elderly
62390|NCT02667353|working mechanism
62391|NCT02667340|exercise
62392|NCT02667340|carbohydrate
62393|NCT02667340|Superstarch
62394|NCT02667327|diabetic foot ulcer
62395|NCT02667327|diabetic complications
62396|NCT02667327|diabetes
62397|NCT02667327|wound healing
62398|NCT02667327|Granexin gel
62399|NCT02667327|FirstString Research
62400|NCT02667314|Cognition
62401|NCT02667314|Cognitive Aging
62402|NCT02667314|Dementia
62403|NCT02667314|Neurocognitive Disorders
62404|NCT02667314|Cognitive Therapy
62405|NCT02667314|Cognitive Reserve
62406|NCT02667314|Cognitive Enrichment
62407|NCT02667314|Jigsaw Puzzles
62408|NCT02667275|seborrheic keratosis
62409|NCT02667249|cholecystectomy, check list
62410|NCT02667236|seborrheic keratosis
62411|NCT02667223|pharmacokinetics
62412|NCT02667223|pharmacodynamics
62413|NCT02667223|RN316
62414|NCT02667223|recombinant human hyaluronidase
62415|NCT02667145|hand osteoarthritis
62416|NCT02667145|self care program
62417|NCT02667145|assistive tecnology
62418|NCT02667132|Granulomatous, Mastitis
62419|NCT02667132|C17.800.090.968.400
62420|NCT02667132|C13.703.844.603.400
62421|NCT02667093|Acute Leukemia
62422|NCT02667093|Acute Myeloid Leukemia
62423|NCT02667093|AML
62424|NCT02667080|Semen quality
62425|NCT02667080|Sexual Abstinence
62426|NCT02667080|sperm motility
62427|NCT02667080|DNA fragmentation
62428|NCT02667015|Substance Use Disorders
62429|NCT02667015|Anxiety
62430|NCT02667015|Anxiety Sensitivity
62431|NCT02667015|Brief Intervention
62432|NCT02667015|Treatment
62433|NCT02666989|Depression
62434|NCT02666989|Placebo
62435|NCT02666989|Open-label
62436|NCT02666989|Clinical practice
62437|NCT02666976|Gastroesophageal reflux, proton pump inhibitors, ilaprazole
62438|NCT02666963|RTA 901
62439|NCT02666963|RTA 901 capsules
62440|NCT02666898|Residual disease
62441|NCT02666885|Personalized Medicine
62442|NCT02666885|Radiation Oncology
62443|NCT02666885|Functional Imaging
62444|NCT02666885|Biomarker
62445|NCT02666885|Decision Support System
62446|NCT02666885|Radiomics
62447|NCT02666872|Vaccination
62448|NCT02666872|Infant
62449|NCT02666872|Parents
62450|NCT02666872|Intention
62451|NCT02666846|UVB Pain Model
62452|NCT02666846|PK
62453|NCT02666846|Topical
62454|NCT02666846|NSAIDs
62455|NCT02666833|Skin Cancer
62456|NCT02666833|Basal Cell Carcinoma
62457|NCT02666833|Squamous Cell Carcinoma
62458|NCT02666833|Mohs Surgery
62459|NCT02666833|Imaging
62460|NCT02666807|NF-κB
62461|NCT02666807|Ginger
62462|NCT02666794|analgesia
62463|NCT02666794|fetal bradycardia
62464|NCT02666794|hypertonic uterine
62465|NCT02666781|OSA, Surgery, Postoperative, Rostral Fluid Shift
62466|NCT02666755|Lung Neoplasms digital polymerase chain reaction
62467|NCT02666716|pharmacokinetics
62468|NCT02666716|fluconazole
62469|NCT02666716|invasive fungal infection
62470|NCT02666716|candidiasis
62471|NCT02666716|intensive care unit
62472|NCT02666703|cardiac surgery
62473|NCT02666703|systemic inflammatory response
62474|NCT02666703|immunoadsorption
62475|NCT02666677|polytrauma, emergency medicine
62476|NCT02666664|hyperlipidemia
62477|NCT02666664|cholesterol
62478|NCT02666664|heterozygous familial hypercholesterolemia
62479|NCT02666664|atherosclerotic cardiovascular disease
62480|NCT02666664|ASCVD
62481|NCT02666664|HeFH
62482|NCT02666664|LDL
62483|NCT02666638|Magnetic Resonance Imaging (MRI)
62484|NCT02666612|Patients
62485|NCT02666599|F-18-FDG
62486|NCT02666599|neoplasm
62487|NCT02666599|probe
62488|NCT02666599|positron
62489|NCT02666599|diagnosis
62490|NCT02666599|surgery
62491|NCT02666599|radioguided surgery
62492|NCT02666573|drug therapy
62493|NCT02666573|Photosensitizing Agents
62494|NCT02666573|therapeutic use
62495|NCT02666560|Auditory Cueing
62496|NCT02666560|Gait
62497|NCT02666547|68Ga-NODAGA-RGD
62498|NCT02666547|18F-FDG
62499|NCT02666547|18F-FET
62500|NCT02666547|PET/CT
62501|NCT02666547|neoangiogenesis
62502|NCT02666534|Ablative fractional laser
62503|NCT02666534|microinvasive squamous cell carcinoma
62504|NCT02666534|photodynamic therapy
62505|NCT02666521|Primary Health Care
62506|NCT02666508|plaque identifying toothpaste
62507|NCT02666508|plaque score
62508|NCT02666508|C-reactive protein
62509|NCT02666495|Schema Therapy
62510|NCT02666482|smoking
62511|NCT02666482|stop smoking
62512|NCT02666482|tobacco use cessation
62513|NCT02666469|Hyperbaric oxygen treatment, rehabilitation
62514|NCT02666443|brachial plexus
62515|NCT02666443|supraclavicular
62516|NCT02666443|duration
62517|NCT02666443|dexamethasone
62518|NCT02666443|block
62519|NCT02666417|Iron fortification
62520|NCT02666417|Anemia
62521|NCT02666417|Iron Deficiency
62522|NCT02666417|Iron Absorption
62523|NCT02666417|Prebiotics
62524|NCT02666417|Stable isotopes
62525|NCT02666404|Volume Resuscitation
62526|NCT02666404|Shock
62527|NCT02666404|Body Impedance Measurement
62528|NCT02666404|Renal Resistive Index
62529|NCT02666404|Acute Kidney Injury
62530|NCT02666404|Renal Replacement Therapy
62531|NCT02666378|HER-2 Positive Breast Cancer
62532|NCT02666365|anesthesia
62533|NCT02666365|surgical antimicrobial prophylaxis
62534|NCT02666365|surgical site infections
62535|NCT02666339|Hortitherapy
62536|NCT02666339|Care-garden
62537|NCT02666339|Anxiety
62538|NCT02666339|Therapeutic alliance
62539|NCT02666326|Acute Coronary Syndrome
62540|NCT02666326|Prehospital emergency care
62541|NCT02666326|Biological markers
62542|NCT02666326|Copeptin
62543|NCT02666326|Troponin
62544|NCT02666326|Rule-out
62545|NCT02666326|Point-of-Care systems
62546|NCT02666326|Infarction
62547|NCT02666326|Cardiovascular Diseases
62548|NCT02666326|Heart Diseases
62549|NCT02666326|Ischemia
62550|NCT02666326|Myocardial Ischemia
62551|NCT02666326|copeptins
62552|NCT02666326|Troponin T
62553|NCT02666326|Diagnostic Techniques (Cardiovascular)
62554|NCT02666300|Postoperative sore throat,Anesthesia
62555|NCT02666287|Fluticasone furoate
62556|NCT02666287|Chronic obstructive pulmonary disease
62557|NCT02666287|Batefenterol
62558|NCT02666287|Dry Powder Inhaler
62559|NCT02666287|Respiratory
62560|NCT02666287|Pharmacokinetics
62561|NCT02666287|Ellipta
62562|NCT02666287|Healthy Subjects
62563|NCT02666274|carbapenem resistance
62564|NCT02666274|bacterial carriage
62565|NCT02666274|multi-drug resistant gram negative bacteria
62566|NCT02666222|hearing loss
62567|NCT02666222|sensorineural
62568|NCT02666222|hearing implant
62569|NCT02666209|Multiple Myeloma
62570|NCT02666209|Relapsed Multiple Myeloma
62571|NCT02666209|Refractory Multiple Myeloma
62572|NCT02666183|cancer
62573|NCT02666183|caregiver
62574|NCT02666183|videoconferencing
62575|NCT02666157|atrial fibrillation
62576|NCT02666157|stroke
62577|NCT02666157|systemic embolism
62578|NCT02666157|bleeding
62579|NCT02666157|oral anticoagulant
62580|NCT02666131|diabetic foot ulcer
62581|NCT02666131|diabetic complications
62582|NCT02666131|diabetes
62583|NCT02666131|wound healing
62584|NCT02666131|Granexin gel
62585|NCT02666131|FirstString Research
62586|NCT02666118|pain
62587|NCT02666118|pain management
62588|NCT02666118|shoulder repair
62589|NCT02666118|nerve blockade
62590|NCT02666118|regional anesthesia
62591|NCT02666118|pediatrics
62592|NCT02666105|NSCLC
62593|NCT02666092|IgE
62594|NCT02666092|Immunoelectrophoresis
62595|NCT02666092|Western Blot
62596|NCT02666092|ImmunoCAP
62597|NCT02666079|Wide local excision (WLE) for breast cancer
62598|NCT02666027|Fluid monitoring
62599|NCT02666014|PONV
62600|NCT02666014|nausea
62601|NCT02666014|vomiting
62602|NCT02666014|sugammadex
62603|NCT02666014|neostigmine
62604|NCT02665988|Transcranial Direct Current Stimulation
62605|NCT02665975|Tinnitus treatment
62606|NCT02665975|Internet-intervention
62607|NCT02665975|CBT
62608|NCT02665962|newly diagnosed patients
62609|NCT02665936|epidural analgesia
62610|NCT02665871|vaccine
62611|NCT02665871|safety
62612|NCT02665871|intranasal administration
62613|NCT02665806|Ciclesonide
62614|NCT02665806|Fluticasone propionate
62615|NCT02665806|Nasal Polyposis
62616|NCT02665806|Chronic Sinuitis
62617|NCT02665806|Chronic rhinosinusitis
62618|NCT02665793|Peanut allergy
62619|NCT02665793|Food allergy
62620|NCT02665793|Thresholds
62621|NCT02665793|Anaphylaxis
62622|NCT02665780|halitosis, periodontal debridement, chemotherapeutics
62623|NCT02665767|Telesonography, Appendix
62624|NCT02665754|Allergic rhinitis
62625|NCT02665754|Injection, intralymphatic
62626|NCT02665754|Immunotherapy
62627|NCT02665754|Dermatophagoides farinae
62628|NCT02665754|Dermatophagoides pteronyssinus
62629|NCT02665754|Dogs
62630|NCT02665754|Cats
62631|NCT02665741|distal colonoscope attachments, colon cancer screening, screening colonoscopy, adenoma detection
62632|NCT02665715|Reactive hypoglycemia
62633|NCT02665715|Hyperinsulinaemia
62634|NCT02665715|Diet
62635|NCT02665715|Glucagon-like Peptide-1
62636|NCT02665715|Glucagon
62637|NCT02665715|Peptide YY
62638|NCT02665715|Ghrelin
62639|NCT02665689|Diabetic Macular Edema, Ranibizumab, Visual Acuity, Diabetic Control,
62640|NCT02665676|Childhood Cancer
62641|NCT02665676|Pediatric Oncology
62642|NCT02665676|Embryonal Neoplasms
62643|NCT02665676|Embryonic Neoplasms
62644|NCT02665676|Embryonic Tumors
62645|NCT02665676|Embryonal Tumors
62646|NCT02665624|Bowel cleansing
62647|NCT02665624|Colonoscopy
62648|NCT02665624|Stewed apricot juice
62649|NCT02665624|Senna
62650|NCT02665598|Posterior Reversible Encephalopathy Syndrome,Prognosis
62651|NCT02665585|carotid disease
62652|NCT02665585|stroke
62653|NCT02665585|stent
62654|NCT02665585|carotid stenting
62655|NCT02665572|renal transplantation
62656|NCT02665572|defunctionalized bladder
62657|NCT02665572|bladder recycling
62658|NCT02665559|HIV
62659|NCT02665559|Hypogonadism
62660|NCT02665559|Metabolic Syndrom
62661|NCT02665559|Reservoirs
62662|NCT02665559|Osteodensitometry
62663|NCT02665559|Erectil dysfonction
62664|NCT02665559|Depression
62665|NCT02665546|Dyspnea
62666|NCT02665546|pulmonary hypertension
62667|NCT02665546|Histiocytosis Langerhans cells
62668|NCT02665546|exercise test
62669|NCT02665533|pain measurement
62670|NCT02665533|edema
62671|NCT02665533|trismus
62672|NCT02665520|stem cells injections
62673|NCT02665520|erectile dysfunction
62674|NCT02665507|Photobiomodulation
62675|NCT02665507|Aviation
62676|NCT02665481|Exercise
62677|NCT02665481|Mindfulness
62678|NCT02665481|Education
62679|NCT02665481|Elderly
62680|NCT02665468|Supported adoption
62681|NCT02665468|Secure messaging
62682|NCT02665468|Patient aligned care team (PACT)
62683|NCT02665468|My HealtheVet Coordinator
62684|NCT02665455|Diabetes Mellitus
62685|NCT02665455|Sensing Technology
62686|NCT02665442|Esophageal Stylet
62687|NCT02665442|EsoSure
62688|NCT02665442|Atrial Fibrillation
62689|NCT02665442|Catheter Ablation
62690|NCT02665442|Mechanical esophageal displacement
62691|NCT02665429|Emergency Medicine
62692|NCT02665390|lung cancer
62693|NCT02665390|Percutaneous cryoablation
62694|NCT02665390|treatment of medically inoperable
62695|NCT02665338|transcranial magnetic stimulation
62696|NCT02665338|fMRI
62697|NCT02665338|cue craving
62698|NCT02665325|TSH-suppressive therapy
62699|NCT02665325|cognitive function
62700|NCT02665312|cardiotoxicity
62701|NCT02665312|fluoropyrimidine
62702|NCT02665312|colorectal cancer
62703|NCT02665299|colon cancer
62704|NCT02665299|colon polyps
62705|NCT02665299|colon adenomas
62706|NCT02665299|colonoscopy
62707|NCT02665299|circulating tumor DNA
62708|NCT02665234|Dry Eye
62709|NCT02665221|Multiple Sclerosis
62710|NCT02665221|erythema
62711|NCT02665208|cigarettes
62712|NCT02665208|smoking
62713|NCT02665208|opiate-dependence
62714|NCT02665208|alcohol
62715|NCT02665208|detoxification
62716|NCT02665182|orchitis
62717|NCT02665182|testicular diseases
62718|NCT02665169|Postural Balance
62719|NCT02665169|Cost-Benefit Analysis
62720|NCT02665169|Morbidity
62721|NCT02665169|Exercise
62722|NCT02665143|acute myeloid leukemia
62723|NCT02665130|COPD
62724|NCT02665130|Pulmonary rehabilitation
62725|NCT02665117|Hypokalemia
62726|NCT02665117|Isoprostanes
62727|NCT02665117|Insulin resistance
62728|NCT02665117|Aldosterone
62729|NCT02665117|Hepatic fat
62730|NCT02665117|Muscle Magnesium
62731|NCT02665117|Liver fat
62732|NCT02665104|Cerebral oxygen saturation
62733|NCT02665104|TCD
62734|NCT02665104|NIRS
62735|NCT02665104|Carotid endarterectomy
62736|NCT02665078|Lung Cancer
62737|NCT02665065|Acute Myeloid Leukemia
62738|NCT02665065|Leukemia, Acute Myeloid
62739|NCT02665065|Myeloid Leukemia, Acute
62740|NCT02665065|Bone Marrow Cell Transplantation
62741|NCT02665065|Transplantation, Bone Marrow
62742|NCT02665065|HCT
62743|NCT02665065|HSCT
62744|NCT02665065|Refractory AML
62745|NCT02665065|Relapsed AML
62746|NCT02665065|BC8
62747|NCT02665065|I-131
62748|NCT02665065|Iomab
62749|NCT02665065|Iomab-B
62750|NCT02665065|CD45
62751|NCT02665065|Iodine
62752|NCT02665065|Iodine-131
62753|NCT02665065|131-I
62754|NCT02665065|AML
62755|NCT02665065|BMT
62756|NCT02665065|radioimmunotherapy
62757|NCT02665052|Rehabilitation
62758|NCT02665052|Motor Recovery
62759|NCT02665052|upper extremity
62760|NCT02664987|pain management, pain control, cancer
62761|NCT02664961|TRC105
62762|NCT02664961|CD105
62763|NCT02664961|Endoglin
62764|NCT02664961|Angiogenesis inhibitor
62765|NCT02664961|GTN
62766|NCT02664961|Bevacizumab
62767|NCT02664961|Avastin
62768|NCT02664948|early follow-up
62769|NCT02664948|geriatrics
62770|NCT02664935|NSCLC
62771|NCT02664935|Lung Cancer
62772|NCT02664935|Adenocarcinoma
62773|NCT02664935|Matrix
62774|NCT02664935|SMP2
62775|NCT02664935|Umbrella Trial Design
62776|NCT02664935|Multi-arm
62777|NCT02664922|Electrophysiology
62778|NCT02664922|Anesthetics
62779|NCT02664909|Hip Hemiarthroplasty
62780|NCT02664909|Tranexamic Acid
62781|NCT02664909|Topical
62782|NCT02664909|Blood Transfusion
62783|NCT02664896|Knee pain
62784|NCT02664896|Knee Osteoarthritis
62785|NCT02664870|synovial fluid
62786|NCT02664870|biomarkers
62787|NCT02664857|Vitamin D
62788|NCT02664857|Postoperative Pain
62789|NCT02664857|Mental Motor Retardation
62790|NCT02664844|Obesity
62791|NCT02664844|Appetite regulation
62792|NCT02664844|Insulin sensitivity
62793|NCT02664844|Adolescents
62794|NCT02664844|Exercise
62795|NCT02664831|cardiac arrest
62796|NCT02664831|inflammation
62797|NCT02664831|obesity
62798|NCT02664831|neuregulin
62799|NCT02664831|lipids
62800|NCT02664818|Heart failure
62801|NCT02664818|China
62802|NCT02664818|Registry
62803|NCT02664818|Characteristic
62804|NCT02664818|Outcome
62805|NCT02664792|Non-small cell lung carcinoma
62806|NCT02664792|PET/CT
62807|NCT02664792|18F-FDG
62808|NCT02664766|Heavy drinking
62809|NCT02664766|Heavy drinking cessation
62810|NCT02664766|Alcohol abuse
62811|NCT02664766|alcohol use disorder
62812|NCT02664740|Phage Therapy
62813|NCT02664727|alcohol
62814|NCT02664727|alcohol abuse
62815|NCT02664727|alcohol dependence
62816|NCT02664727|alcohol use disorder
62817|NCT02664727|heavy drinking
62818|NCT02664727|alcohol abuse cessation
62819|NCT02664714|physiotherapy, perineometer, adherence
62820|NCT02664688|spondylolisthesis
62821|NCT02664688|low back pain
62822|NCT02664688|stabilization exercise
62823|NCT02664662|randomized controlled trial, breast cancer, health literacy, tailored education
62824|NCT02664649|TAVR
62825|NCT02664649|Apixaban
62826|NCT02664649|Anticoagulant
62827|NCT02664649|VKA
62828|NCT02664649|Antiplatelet therapy
62829|NCT02664649|Aortic stenosis
62830|NCT02664610|hypertension treatment
62831|NCT02664610|stroke prevention
62832|NCT02664597|ADNEXMR SCORING system
62833|NCT02664597|MRI
62834|NCT02664597|adnexal masses
62835|NCT02664519|Chronic Kidney Disease
62836|NCT02664519|Functional sympatholysis
62837|NCT02664519|Exercise training
62838|NCT02664519|Exercise intolerance
62839|NCT02664519|Handgrip exercise
62840|NCT02664519|Near infrared spectroscopy
62841|NCT02664519|Lower body negative pressure
62842|NCT02664493|kidney transplantation
62843|NCT02664493|subclinical borderline rejection
62844|NCT02664493|steroid pulse therapy
62845|NCT02664480|Salivary Alpha-amylase
62846|NCT02664480|ovulation
62847|NCT02664454|Elderly
62848|NCT02664454|Health care organization
62849|NCT02664454|Primary care
62850|NCT02664441|Obesity
62851|NCT02664441|Drug intervention
62852|NCT02664441|Children
62853|NCT02664441|Adolescents
62854|NCT02664441|Young adults
62855|NCT02664441|Hypothalamic lesion
62856|NCT02664441|Change of weight status
62857|NCT02664441|Food intake
62858|NCT02664441|Energy expenditure
62859|NCT02664441|Hormonal changes
62860|NCT02664441|Glucagon-like peptide-1 agonist
62861|NCT02664441|Bydureon
62862|NCT02664441|Weight Loss
62863|NCT02664441|Energy balance
62864|NCT02664415|Human Monoclonal Antibody
62865|NCT02664402|Palliative Care
62866|NCT02664402|Pain
62867|NCT02664402|Community Health
62868|NCT02664376|sarcopenia
62869|NCT02664376|geriatry
62870|NCT02664311|Pulmonary Vein Isolation
62871|NCT02664311|Jet Ventilation
62872|NCT02664311|Atrial Fibrillation
62873|NCT02664298|severely atrophic jaw
62874|NCT02664298|cranial bone-graft
62875|NCT02664298|dental implants
62876|NCT02664298|immediate loading
62877|NCT02664298|augmentation maxilla/mandible
62878|NCT02664298|sinus-floor elevation/sinuslift
62879|NCT02664298|dental prosthesis
62880|NCT02664298|implant supported
62881|NCT02664298|provisional implants
62882|NCT02664298|temporary implants
62883|NCT02664298|one-stage surgery
62884|NCT02664298|alveolar ridge augmentation
62885|NCT02664298|maxilla
62886|NCT02664259|Endobronchial ultrasonography
62887|NCT02664259|Peripheral pulmonary lesions
62888|NCT02664259|Ultrathin bronchoscopy
62889|NCT02664246|contrast-induced nephropathy
62890|NCT02664246|Percutaneous coronary intervention
62891|NCT02664246|risk factors
62892|NCT02664246|incidence
62893|NCT02664233|Diabetes
62894|NCT02664233|Diabetes Mellitus, Type 2
62895|NCT02664233|obesity
62896|NCT02664233|self-monitoring
62897|NCT02664233|goal setting
62898|NCT02664233|mobile health
62899|NCT02664233|connected health
62900|NCT02664220|Povidone-iodine irrigation
62901|NCT02664207|Myelomeningocele repair
62902|NCT02664207|Open Neural Tube Defect
62903|NCT02664207|BMI of 35-40 kg/m2,
62904|NCT02664207|Open Fetal Surgery
62905|NCT02664207|Elevated body mass index
62906|NCT02664194|Hypothermia
62907|NCT02664194|Rewarming
62908|NCT02664194|Myocardial Infarction
62909|NCT02664194|Percutaneous Cornonary Intervention
62910|NCT02664181|Cancer
62911|NCT02664181|Nivolumab
62912|NCT02664181|Decitabine
62913|NCT02664181|Tetrahydrouridine
62914|NCT02664155|Renal insufficiency
62915|NCT02664155|Direct oral anticoagulants (DOA)
62916|NCT02664155|Deep Vein Thrombosis (DVT)
62917|NCT02664155|Pulmonary Embolism (PE)
62918|NCT02664155|Venous Thromboembolism (VTE)
62919|NCT02664155|Heparins
62920|NCT02664142|General Surgery
62921|NCT02664142|Child
62922|NCT02664142|Anaesthesia
62923|NCT02664142|Depth of anaesthesia
62924|NCT02664142|BIS monitoring
62925|NCT02664116|Severe Migraine Headache
62926|NCT02664090|acute respiratory distress syndrome
62927|NCT02664090|prone ventilation
62928|NCT02664090|trans-esophageal doppler
62929|NCT02664077|NSABP
62930|NCT02664077|Colon cancer
62931|NCT02664077|Regorafenib
62932|NCT02664077|Stage III
62933|NCT02664077|Adjuvant therapy
62934|NCT02664064|prediabetes, weight loss, behavior modification
62935|NCT02664038|AUD
62936|NCT02664038|Neuropsychology
62937|NCT02664038|Cognitive Remediation
62938|NCT02664025|teaching vaginal examination
62939|NCT02664012|adoption
62940|NCT02664012|electronic cigarettes
62941|NCT02664012|e-cigarettes
62942|NCT02664012|menthol
62943|NCT02664012|combustible cigarettes
62944|NCT02664012|nicotine polacrilex
62945|NCT02664012|own brand cigarette
62946|NCT02664012|subjective measures
62947|NCT02664012|pharmacokinetics
62948|NCT02664012|pharmacodynamics
62949|NCT02664012|cigarette
62950|NCT02663999|dose proportionality
62951|NCT02663999|diazepam nasal spray
62952|NCT02663986|Organization, Time Management, and Planning (OTMP)
62953|NCT02663973|Breast cancer
62954|NCT02663960|Regional citrate anticoagulation
62955|NCT02663960|Protocol
62956|NCT02663960|Filter lifespan
62957|NCT02663947|ventriculoperitoneal shunt
62958|NCT02663947|optic nerve sheath diameter
62959|NCT02663947|intracranial pressure
62960|NCT02663934|HIV, AIDS, Cognition, Memory, Exercise, Stretching
62961|NCT02663921|Fitzpatrick Skin-Type
62962|NCT02663921|Melanin
62963|NCT02663921|Ultraviolet Light (UV)
62964|NCT02663882|smoking
62965|NCT02663882|self control
62966|NCT02662738|Blood glucose
62967|NCT02662725|melanoma
62968|NCT02662725|brain metastasis
62969|NCT02662725|stereotactic radiosurgery
62970|NCT02662725|Ipilimumab
62971|NCT02662725|survival
62972|NCT02662725|safety
62973|NCT02662725|efficacy
62974|NCT02662712|Healthy
62975|NCT02662712|Hepatitis, Chronic
62976|NCT02662712|JNJ-56136379
62977|NCT02662712|Placebo
62978|NCT02662699|Anemia
62979|NCT02662699|Hematologic Diseases
62980|NCT02662699|Erythrocytes
62981|NCT02662699|Hemoglobin
62982|NCT02662699|Hemolytic
62983|NCT02662686|Embryo Implantation
62984|NCT02662686|Mitochondrial genes
62985|NCT02662686|Mitochondrial DNA
62986|NCT02662686|MitoScore
62987|NCT02662686|Embryo selection
62988|NCT02662686|Embryo viability
62989|NCT02662686|Embryo biomarker
62990|NCT02662686|Diagnosis of embryo viability in euploids embryos
62991|NCT02662673|HIFU
62992|NCT02662673|Prostate Cancer
62993|NCT02662673|Focal
62994|NCT02662673|Quality of life
62995|NCT02662673|Index study
62996|NCT02662647|demethylating agent
62997|NCT02662647|lymphocyte infusion
62998|NCT02662634|NSCLC
62999|NCT02662634|resectable
63000|NCT02662634|non-small cell lung cancer
63001|NCT02662634|immunotherapy
63002|NCT02662634|autologous
63003|NCT02662634|dendritic cell
63004|NCT02663791|Alcohol
63005|NCT02663791|Aortic stiffness
63006|NCT02663791|Arterial stiffness
63007|NCT02663791|Pulse wave velocity
63008|NCT02663791|Longitudinal
63009|NCT02663752|deferasirox
63010|NCT02663752|MDS
63011|NCT02663752|RNA expression
63012|NCT02663752|predictive biomarker
63013|NCT02663739|Stanford type B aortic dissection
63014|NCT02663739|Malperfusion
63015|NCT02663739|Rupture
63016|NCT02663739|Acute disease
63017|NCT02663739|Endovascular procedures
63018|NCT02663726|Physically inactive
63019|NCT02663726|Older adults
63020|NCT02663713|Pharmacodynamics
63021|NCT02663713|Ticagrelor
63022|NCT02663713|Clopidogrel
63023|NCT02663713|MI
63024|NCT02663700|Burkina Faso
63025|NCT02663700|healthy adults
63026|NCT02663700|Irradiated
63027|NCT02663700|malaria
63028|NCT02663700|PfSPZ Vaccine
63029|NCT02663700|Sanaria
63030|NCT02663700|Sporozoite
63031|NCT02663700|Vaccine
63032|NCT02663674|Coccidioidomycosis
63033|NCT02663674|FLEET
63034|NCT02663674|Fluconazole
63035|NCT02663674|Parent Study of 16-0008
63036|NCT02663674|Pneumonia
63037|NCT02663661|Diabetes Mellitus, Type 1 (T1DM)
63038|NCT02663661|TrialNet
63039|NCT02663661|Pathway to Prevention (PTP)
63040|NCT02663661|First and second degree relatives of persons with T1DM
63041|NCT02663661|Insulin-glucagon-glucose (IGG)
63042|NCT02663648|myeloproliferative disorders
63043|NCT02663648|cell cycle regulatory protein
63044|NCT02663609|Cushing's Syndrome
63045|NCT02663609|Mifepristone
63046|NCT02663609|Adrenal
63047|NCT02663609|Retrospective
63048|NCT02663609|Chart Review
63049|NCT02663596|Pediatric
63050|NCT02663596|Continuous Renal Replacement Therapy
63051|NCT02663596|Dialysis
63052|NCT02663596|Therapeutic drug monitoring
63053|NCT02663596|Pharmacokinetics
63054|NCT02663596|Pharmacodynamics
63055|NCT02663583|Oropharynx squamous cell carcinoma
63056|NCT02663583|OPSCC
63057|NCT02663583|Actigraph accelerometer
63058|NCT02663583|MD Anderson Symptom Inventory - Head and Neck module
63059|NCT02663583|MDASI-HN
63060|NCT02663583|Intensity-Modulated Proton Therapy
63061|NCT02663583|IMPT
63062|NCT02663583|TransOral Robotic Surgery
63063|NCT02663583|TORS
63064|NCT02663583|Surveys
63065|NCT02663583|Questionnaires
63066|NCT02663557|stroke, blood pressure, prognosis
63067|NCT02663544|Diabetes
63068|NCT02663544|Metabolic syndrome
63069|NCT02663544|Obesity
63070|NCT02663544|NAFLD
63071|NCT02663492|Acupuncture
63072|NCT02663492|electrical stimulation of acupoints
63073|NCT02663492|chemotherapy
63074|NCT02663492|Diyu Shengbai Pian
63075|NCT02663492|nursing care
63076|NCT02663466|pilonidal sinus
63077|NCT02663466|Limberg flap
63078|NCT02663466|off-midline closure concept
63079|NCT02663466|recurrence
63080|NCT02663453|preterm
63081|NCT02663453|parenteral nutrition
63082|NCT02663453|cholestasis
63083|NCT02663453|fish oil
63084|NCT02663427|pepsinogen Ⅰ
63085|NCT02663427|pepsinogen Ⅱ
63086|NCT02663427|gastric cancer screening
63087|NCT02663427|helicobacter pylori
63088|NCT02663427|gastrin
63089|NCT02663375|TAVI
63090|NCT02663375|Aortic Stenosis
63091|NCT02663375|Transcatheter aortic valve replacement
63092|NCT02663375|Transcatheter aortic valve implantation
63093|NCT02663375|Transapical Access
63094|NCT02663362|magnetic resonance imaging
63095|NCT02663362|magnetic resonance spectroscopy
63096|NCT02663336|masked hypertension, chronic kidney disease
63097|NCT02663323|Coronary Artery Disease
63098|NCT02663323|MeRes-1 Extend
63099|NCT02663323|MeRes100
63100|NCT02663323|Sirolimus Eluting Bioresorbable Vascular Scaffold System
63101|NCT02663310|spinal cord injury
63102|NCT02663310|Kunming Locomotor Scale
63103|NCT02663310|surgical decompression
63104|NCT02663310|untethering
63105|NCT02663310|weight bearing rehabilitation
63106|NCT02663297|CAR T cells
63107|NCT02663297|CD30
63108|NCT02663297|Lymphoma
63109|NCT02663297|T Lymphocytes
63110|NCT02663245|Type 2 diabetes mellitus
63111|NCT02663245|glycemic control
63112|NCT02663232|V600 BRAF mutation
63113|NCT02663232|Metastatic melanoma
63114|NCT02663219|MSM
63115|NCT02663219|ART
63116|NCT02663219|CCM
63117|NCT02663219|DAIDS
63118|NCT02663219|HPTN
63119|NCT02663219|ACA
63120|NCT02663219|PAF
63121|NCT02663219|PEP
63122|NCT02663219|RDS
63123|NCT02663206|spastic esophageal disorders
63124|NCT02663206|achalasia
63125|NCT02663206|diffuse esophageal spasm
63126|NCT02663206|hypercontractile (jackhammer) esophagus
63127|NCT02663206|Botulinum toxin injection
63128|NCT02663206|peroral endoscopic myotomy
63129|NCT02663193|Prostate Cancer
63130|NCT02663193|Observational study
63131|NCT02663193|Enzalutamide
63132|NCT02663193|Abiraterone Acetate
63133|NCT02663193|Prednisone
63134|NCT02663193|Tolerability
63135|NCT02663154|Aromatherapy
63136|NCT02663102|Safety
63137|NCT02663102|Post-marketing
63138|NCT02663102|Korea
63139|NCT02663102|Drug utilization study
63140|NCT02663102|Fluarix Tetra
63141|NCT02663089|total radioactivity
63142|NCT02663089|[14C]-GSK961081
63143|NCT02663089|Pharmacokinetics
63144|NCT02663089|Chronic Obstructive Pulmonary Disease (COPD)
63145|NCT02663089|Microtracer
63146|NCT02663063|Complementary and alternative medicine
63147|NCT02663063|Hospice Palliative Care
63148|NCT02663050|Dysmenorrhea
63149|NCT02663050|kinesio tape
63150|NCT02663037|Segmentation
63151|NCT02663037|Health needs
63152|NCT02662985|Power Doppler Ultrasonography, Psoriatic Arthritis, Enthesitis, Synovitis, Outcome Measures in Rheumatology, Spondyloarthritis Research Consortium of Canada
63153|NCT02662972|Nerve block
63154|NCT02662972|Sphenopalatine Ganglion Block
63155|NCT02662972|Botulinum Toxins, Type A
63156|NCT02662959|Chemotherapy, metastatic gastric cancer, irinotecan
63157|NCT02662907|Head and Neck Cancer
63158|NCT02662907|Post-radiotherapy H&N cancer survivors
63159|NCT02662907|Aspiration
63160|NCT02662907|Expiratory muscle strength training
63161|NCT02662907|EMST
63162|NCT02662907|Dysphagia therapy
63163|NCT02662907|Modified barium swallow
63164|NCT02662907|Neurocognitive exams
63165|NCT02662907|Questionnaires
63166|NCT02662907|Surveys
63167|NCT02662907|Digital Manometer
63168|NCT02662868|Breast cancer
63169|NCT02662868|Metastasis
63170|NCT02662842|infusion set
63171|NCT02662842|continuous subcutaneous insulin infusion
63172|NCT02662829|Lesotho
63173|NCT02662829|tuberculosis
63174|NCT02662829|TB
63175|NCT02662829|HIV
63176|NCT02662829|adherence
63177|NCT02662829|community-based intervention
63178|NCT02662829|retention
63179|NCT02662816|Glutathione
63180|NCT02662816|Liver
63181|NCT02662816|Muscle
63182|NCT02662816|Proton magnetic resonance spectroscopy
63183|NCT02662816|Healthy human
63184|NCT02662803|Generalized Anxiety Disorder
63185|NCT02662803|GAD
63186|NCT02662803|physical exercise
63187|NCT02662803|aerobe exercise
63188|NCT02662803|mental disorder
63189|NCT02662803|high-intensive aerobe exercise
63190|NCT02662777|esophageal anastomosis leakage
63191|NCT02662777|endoscopic vacuum therapy
63192|NCT02662777|esophageal perforation
63193|NCT02662777|upper gastrointestinal tract
63194|NCT02662777|esophageal leak
63195|NCT02662777|endoscopy
63196|NCT02662621|personalized care
63197|NCT02662621|early diagnosis
63198|NCT02662621|ovarian cancer
63199|NCT02662621|breast cancer
63200|NCT02662621|lung cancer
63201|NCT02662621|Early Detection
63202|NCT02662621|Cancer [E01.390.500]
63203|NCT02662608|Brontictuzumab
63204|NCT02662595|mHealth
63205|NCT02662595|mobile phones
63206|NCT02662595|measles vaccination
63207|NCT02662582|Chronic Obstructive Pulmonary Disease
63208|NCT02662582|CK-2127107
63209|NCT02662582|COPD
63210|NCT02662543|rotavirus,
63211|NCT02662543|acute gastroenteritis
63212|NCT02662543|vaccination
63213|NCT02662543|Estonia
63214|NCT02662543|impact
63215|NCT02662543|severity scales
63216|NCT02662517|Neurotrophins
63217|NCT02662517|Stem Cells
63218|NCT02662517|Prematurity
63219|NCT02662504|mesothelioma
63220|NCT02662504|multimodal treatment
63221|NCT02662504|PDT
63222|NCT02662504|pleura
63223|NCT02662478|Laparoscopic gastric resection
63224|NCT02662478|gastrointestinal stromal tumor
63225|NCT02662478|laparoscopic surgery
63226|NCT02662465|Interventional
63227|NCT02662465|Treatment
63228|NCT02662465|Laser
63229|NCT02662439|Heart Failure
63230|NCT02662439|Bioimpedance analysis
63231|NCT02662439|Fluid overload
63232|NCT02662426|Seasonal Influenza
63233|NCT02662426|Lingdancao
63234|NCT02662426|RCT
63235|NCT02662361|peri-implant disease; risk factors; prevalence
63236|NCT02662322|Communication
63237|NCT02662322|Confusion
63238|NCT02662322|Intravenous Catheterization
63239|NCT02662322|Comfort
63240|NCT02662309|Muscle invasive bladder cancer
63241|NCT02662309|Transitional cell carcinoma
63242|NCT02662283|IGA Nephropathy
63243|NCT02662283|proteinurien
63244|NCT02662283|Reh-acteoside
63245|NCT02662283|Prednisolone
63246|NCT02662270|Fibromyalgia
63247|NCT02662270|QEEG
63248|NCT02662270|Brain activity
63249|NCT02662270|fMRI
63250|NCT02662270|Diagnosis
63251|NCT02662257|Sevoflurane
63252|NCT02662257|Propofol
63253|NCT02662257|Aged
63254|NCT02662257|Neoplasm
63255|NCT02662257|Surgical Procedure, Operative
63256|NCT02662257|Delirium
63257|NCT02662257|Postoperative Complications
63258|NCT02662231|Surgical Site Infection
63259|NCT02662231|General Surgery
63260|NCT02662231|Laparotomy
63261|NCT02662231|Outcome and Process Assessment (Health Care)
63262|NCT02662231|Developing Countries
63263|NCT02662231|International Cooperation
63264|NCT02662231|Specialties, Surgical
63265|NCT02662231|Developed Countries
63266|NCT02662231|Quality of Health Care
63267|NCT02662179|Elderly patients
63268|NCT02662179|Onco-geriatrics
63269|NCT02662179|Fried criteria
63270|NCT02662166|bladder cancer
63271|NCT02662166|MRI
63272|NCT02662166|TUR-BT
63273|NCT02662166|cystectomy
63274|NCT02662166|chemotherapy
63275|NCT02662075|alternative tobacco products (ATPs)
63276|NCT02662075|electronic cigarettes
63277|NCT02662062|Non-metastatic muscle invasive bladder cancer
63278|NCT02662023|Healthy Human Volunteers
63279|NCT02662010|AGEs
63280|NCT02662010|glycemic control
63281|NCT02662010|T2DM
63282|NCT02661997|Tai Chi
63283|NCT02661997|Wellness
63284|NCT02661997|Mind-body
63285|NCT02661997|Gulf War Illness
63286|NCT02661997|Gulf War Veteran's Illness
63287|NCT02661997|GWVI
63288|NCT02661984|FeNO, exhaled nitric oxide
63289|NCT02661958|acne vulgaris
63290|NCT02661958|acne
63291|NCT02661945|near focus with narrow band imaging
63292|NCT02661945|tumor margin
63293|NCT02661945|indigocarmine chromoendoscopy
63294|NCT02661932|Fertility preservation
63295|NCT02661932|letrozole
63296|NCT02661932|Ovarian stimulation
63297|NCT02661919|Epilepsy
63298|NCT02661919|Seizure
63299|NCT02661919|Seizures
63300|NCT02661919|Mattress monitor
63301|NCT02661919|Bed monitor
63302|NCT02661919|Bed alarm
63303|NCT02661919|Generalized tonic-clonic seizure
63304|NCT02661919|GTC
63305|NCT02661893|Healthy
63306|NCT02661893|JNJ-42847922
63307|NCT02661893|Rifampin
63308|NCT02661893|Pharmacokinetics
63309|NCT02661867|Childbirth
63310|NCT02661867|Pelvic organ prolapse
63311|NCT02661867|Urinary incontinence
63312|NCT02661867|Fecal incontinence
63313|NCT02661854|Rhinitis / Rhinoconjunctivitis
63314|NCT02661854|Vaccine
63315|NCT02661854|Immunotherapy
63316|NCT02661854|Mite
63317|NCT02661854|Allergy
63318|NCT02661828|Tapering Antidepressant Regimen
63319|NCT02661828|Antidepressant Discontinuation Syndrome
63320|NCT02661789|Mental health
63321|NCT02661789|Brain Imaging
63322|NCT02661789|Steroid hormones
63323|NCT02661789|Serotonin
63324|NCT02661789|PET
63325|NCT02661789|MRI
63326|NCT02661789|fMRI
63327|NCT02661789|human
63328|NCT02661789|gender
63329|NCT02661789|risk model
63330|NCT02661776|natural killer cell
63331|NCT02661776|head and neck cancer
63332|NCT02661776|opioid
63333|NCT02661763|Rheumatic heart disease
63334|NCT02661750|Cleansing the colon
63335|NCT02661711|Macular Oedema Retinitis Pigmentosa
63336|NCT02661685|Cancer immunotherapy
63337|NCT02661685|IFN-γ-producing killer dendritic cell-like cells
63338|NCT02661685|Natural killer cells
63339|NCT02661672|Intracranial hemorrhage
63340|NCT02661672|Neurosurgery
63341|NCT02661659|mesothelioma
63342|NCT02661659|multipeptide vaccine
63343|NCT02661659|S-588210
63344|NCT02661646|Chronic Swelling
63345|NCT02661646|Leg Lymphedema
63346|NCT02661646|Primary Lymphedema
63347|NCT02661646|Secondary Lymphedema
63348|NCT02661620|REDAPT Femoral System modular stem implant
63349|NCT02661620|Total Hip arthroplasty revision
63350|NCT02661594|TQT
63351|NCT02661594|amisulpride
63352|NCT02661594|volunteer
63353|NCT02661594|ECG
63354|NCT02661581|Diabetes
63355|NCT02661581|Peer Leader Support
63356|NCT02661529|Shunt
63357|NCT02661529|Echocardiogram
63358|NCT02661490|Norovirus
63359|NCT02661464|Healthy
63360|NCT02661464|Ebola viruses
63361|NCT02661464|Ebola virus disease (EVD)
63362|NCT02661464|Filoviruses
63363|NCT02661464|Safety
63364|NCT02661464|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
63365|NCT02661464|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
63366|NCT02661464|Hemorrhagic fever
63367|NCT02661451|Valve
63368|NCT02661438|Usability Test
63369|NCT02661425|IBS-D
63370|NCT02661425|IBS
63371|NCT02661412|immediate loading
63372|NCT02661412|biological stability
63373|NCT02661412|mechanical stability
63374|NCT02661412|long-term
63375|NCT02661412|marginal bone level
63376|NCT02661412|maxilla
63377|NCT02661412|immediate placement
63378|NCT02661412|dental implant
63510|NCT02660892|Children
63379|NCT02661412|fibre-reinforced provisional fixed prosthesis
63380|NCT02661399|CIPN
63381|NCT02661373|Antimalarial
63382|NCT02661373|First-in-Human
63383|NCT02661373|Pharmacokinetic
63384|NCT02661360|swaddling
63385|NCT02661347|First Episode
63386|NCT02661347|Schizophreniform
63387|NCT02661347|Schizoaffective Disorder
63388|NCT02661347|Psychosis
63389|NCT02661347|Schizophrenia
63390|NCT02661347|tDCS
63391|NCT02661347|Risperidone
63392|NCT02661347|Anti-psychotic medication
63393|NCT02661334|creatine
63394|NCT02661334|creatine monohydrate
63395|NCT02661334|supplement
63396|NCT02661334|exercise
63397|NCT02661334|fitness
63398|NCT02661282|Glioblastoma
63399|NCT02661282|Gliosarcoma
63400|NCT02661282|Brain tumor
63401|NCT02661282|Cytomegalovirus stimulated adoptive T cells
63402|NCT02661282|CMV
63403|NCT02661282|Temozolomide
63404|NCT02661282|Temodar
63405|NCT02661282|TMZ
63406|NCT02661282|Phone call
63407|NCT02661282|T cell infusion
63408|NCT02661282|Surgery
63409|NCT02661256|pharyngeal swallow
63410|NCT02661256|airway compromise
63411|NCT02661256|NICU
63412|NCT02661243|Sjogren's Syndrome
63413|NCT02661243|Dental Implants
63414|NCT02661230|exergaming
63415|NCT02661230|intensive care unit
63416|NCT02661230|feasibility acceptability
63417|NCT02661230|heart
63418|NCT02661230|brain function
63419|NCT02661217|Acute decompensated heart failure, reduced ejection fraction, pre-discharge treatment, post-discharge treatment, angiotensin receptor neprilysine inhibitor.
63420|NCT02661191|asthma
63421|NCT02661191|vitamin D
63422|NCT02661191|exacerbations
63423|NCT02661191|airway obstruction
63424|NCT02661178|Parasitic Diseases
63425|NCT02661178|Helminthiasis
63426|NCT02661178|Nematode Infections
63427|NCT02661178|Secernentea Infections
63428|NCT02661178|Spirurida Infections
63429|NCT02661178|Filariasis
63430|NCT02661178|Skin Diseases, Parasitic
63431|NCT02661178|Skin and Connective Tissue Diseases
63432|NCT02661178|Skin Diseases
63433|NCT02661178|Skin Diseases, Infectious
63434|NCT02661178|Depsipeptides
63435|NCT02661178|Emodepside
63436|NCT02661178|Neglected disease
63437|NCT02661178|Africa
63438|NCT02661178|New drug
63439|NCT02661178|Oral drug
63440|NCT02661178|Parasite
63441|NCT02661178|Anthelmintic drug
63442|NCT02661178|Cyclooctadepsipeptide
63443|NCT02661178|Single ascending dose
63444|NCT02661178|Volunteers
63445|NCT02661178|Phase 1
63446|NCT02661178|Safety
63447|NCT02661178|Tolerability
63448|NCT02661178|Pharmacokinetics
63449|NCT02661178|Relative bioavailability
63450|NCT02661178|Onchocerciasis
63451|NCT02661139|bisphosphonates and/or targeted therapy by monoclonal antibodies
63452|NCT02661139|jaw reconstruction
63453|NCT02661139|prosthetic rehabilitation
63454|NCT02661139|quality of life
63455|NCT02661113|Brain
63456|NCT02661113|CNS Disease
63457|NCT02661113|CNS
63458|NCT02661113|Intracranial Supratentorial GBM
63459|NCT02661113|Gliosarcoma
63460|NCT02661113|GS
63461|NCT02661113|Glioblastoma
63462|NCT02661113|GBM
63463|NCT02661113|Dasatinib
63464|NCT02661113|Sprycel
63465|NCT02661113|Temozolomide
63466|NCT02661113|TMZ
63467|NCT02661113|Temodar
63468|NCT02661113|Radiation Therapy
63469|NCT02661113|Radiotherapy
63470|NCT02661113|RT
63471|NCT02661100|Vaccine
63472|NCT02661100|NY-ESO-1
63473|NCT02661100|DEC-205
63474|NCT02661100|Poly-ICLC
63475|NCT02661100|Pembrolizumab
63476|NCT02661100|Cancer
63477|NCT02661087|submucosal myoma
63478|NCT02661087|hysteroscopic resection
63479|NCT02661087|bipolar energy
63480|NCT02661087|monopolar energy
63481|NCT02661074|Fisherman
63482|NCT02661074|Fish industry
63483|NCT02661061|ketamine
63484|NCT02661061|glutamate
63485|NCT02661061|relapse prevention
63486|NCT02661035|AML
63487|NCT02661035|ALL
63488|NCT02661035|CML
63489|NCT02661035|MDS
63490|NCT02661035|CLL
63491|NCT02661035|SLL
63492|NCT02661035|NHL
63493|NCT02661009|NSCLC
63494|NCT02661009|EGFR
63495|NCT02661009|EGFR-TKI
63496|NCT02661009|PCR
63497|NCT02660970|Iberogast
63498|NCT02660970|Acupressure
63499|NCT02660970|gut-brain-axis
63500|NCT02660957|Smoking cessation
63501|NCT02660931|Pediatrics
63502|NCT02660905|HIV-HCV co-infected
63503|NCT02660905|HCV
63504|NCT02660905|HIV
63505|NCT02660905|Hep C
63506|NCT02660905|Hepatitis C
63507|NCT02660905|HCV positive
63508|NCT02660892|IAAO
63509|NCT02660892|Threonine
63511|NCT02660879|Education
63512|NCT02660879|Inhaler
63513|NCT02660866|intermittent claudication
63514|NCT02660866|randomized controlled trial
63515|NCT02660853|Exacerbations
63516|NCT02660814|Chemerin
63517|NCT02660814|Interleukin-6
63518|NCT02660814|Gingival crevicular fluid
63519|NCT02660801|spinal manipulation
63520|NCT02660801|spinal mobilization
63521|NCT02660801|spinal stiffness
63522|NCT02660788|6-24 months overdue
63523|NCT02660788|screening mammography
63524|NCT02660775|schizophrenia
63525|NCT02660736|Albiglutide
63526|NCT02660736|Randomized
63527|NCT02660736|Pharmacokinetics
63528|NCT02660736|GSK716155
63529|NCT02660736|Bioequivalence study
63530|NCT02660723|M01.774.500
63531|NCT02660723|Volunteers
63532|NCT02660710|single arm phase 2
63533|NCT02660710|safety and efficacy
63534|NCT02660710|R-CHOP
63535|NCT02660697|socket preservation, implant site development
63536|NCT02660684|Prograf
63537|NCT02660684|Graft versus host disease
63538|NCT02660684|Hematopoietic stem cell transplantation
63539|NCT02660684|Prophylaxis
63540|NCT02660684|Peripheral hematopoietic stem cell transplantation
63541|NCT02660645|Cysview
63542|NCT02660645|Hexaminolevulinate
63543|NCT02660645|Hexvix
63544|NCT02660645|NMIBC
63545|NCT02660645|BLCC
63546|NCT02660645|Blue Light Cystoscopy with Cysview
63547|NCT02660645|Cystoscopy
63548|NCT02660645|TURBT
63549|NCT02660645|TUR
63550|NCT02660645|Fluorescent cystoscopy
63551|NCT02660645|Non-muscle invasive bladder cancer (NMIBC)
63552|NCT02660645|Transurethral resection (TUR)
63553|NCT02660593|Diabetes Mellitus
63554|NCT02660593|Chinese medicine
63555|NCT02660593|exercise
63556|NCT02660593|diet
63557|NCT02660580|Adalimumab
63558|NCT02660580|MSB11022
63559|NCT02660580|Psoriasis
63560|NCT02660580|Phase III
63561|NCT02660567|postpartum hemorrhage
63562|NCT02660567|PPH
63563|NCT02660567|atonic
63564|NCT02660567|new maneuver
63565|NCT02660554|Pneumonia
63566|NCT02660554|Methicillin-Resistant Staphylococcus aureus
63567|NCT02660554|Polymerase Chain Reaction
63568|NCT02660554|Intensive care units
63569|NCT02660554|Drug Resistance
63570|NCT02660541|Dressing for burn wounds
63571|NCT02660515|complete articular distal radius fracture
63572|NCT02660515|wrist arthroscopy
63573|NCT02660489|CRTH2 antagonist
63574|NCT02660489|Prostaglandin D2 receptor
63575|NCT02660489|Anti-Asthmatic Agents
63576|NCT02660489|OC459
63577|NCT02660489|Allergic asthma
63578|NCT02660489|Eosinophilia
63579|NCT02660476|Diet
63580|NCT02660476|Middle East and North Africa country
63581|NCT02660476|Health
63582|NCT02660476|Complication
63583|NCT02660476|Cardiovascular disease
63584|NCT02660476|Obesity
63585|NCT02660476|Stress
63586|NCT02660476|Obstructive Sleep Apnoea (OSA)
63587|NCT02660463|incidence
63588|NCT02660463|risk factors
63589|NCT02660437|COPD
63590|NCT02660437|Carbon dioxide partial pressure (pCO2)
63591|NCT02660437|Cerebral blood flow (CBF)
63592|NCT02660437|Cognitive dysfunction
63593|NCT02660437|Mild/Moderate Cognitive Impairment (MCI)
63594|NCT02660437|Pulmonary Rehabilitation (PR)
63595|NCT02660437|Standardized Mini Mental State Examination (SMMSE)
63596|NCT02660437|Addenbrooke's Cognitive Examination (ACE-R)
63597|NCT02660437|Montreal Cognitive Assessment (MoCA)
63598|NCT02660437|Telephone Interview for Cognitive Status (TICS)
63599|NCT02660437|Stroop test (Reaction Time)
63600|NCT02660411|Sevoflurane
63601|NCT02660411|Propofol
63602|NCT02660411|Aged
63603|NCT02660411|Neoplasm
63604|NCT02660411|Surgical Procedure, Operative
63605|NCT02660411|Long-term survival
63606|NCT02660385|pain
63607|NCT02660385|insomnia
63608|NCT02660385|cardiac failure
63609|NCT02660385|sleep
63610|NCT02660385|fatigue
63611|NCT02660385|heart disease
63612|NCT02660385|anxiety
63613|NCT02660385|actigraphy
63614|NCT02660385|psychomotor vigilance
63615|NCT02660385|six minute walk
63616|NCT02660385|depression
63617|NCT02660385|cognitive behavioral therapy
63618|NCT02660385|self-management
63619|NCT02660385|self-care
63620|NCT02660346|IL-10
63621|NCT02660346|MRSA
63622|NCT02660346|Bacteremia
63623|NCT02660333|Obesity
63624|NCT02660333|Inflammation
63625|NCT02660333|Nutritional status
63626|NCT02660333|Prebiotic
63627|NCT02660333|Synbiotic
63628|NCT02660307|stress
63629|NCT02660307|work
63630|NCT02660307|employees
63631|NCT02660307|mindfulness
63632|NCT02660307|depression
63633|NCT02660307|anxiety
63634|NCT02660268|Clinical pathway
63635|NCT02660268|Infection
63636|NCT02660268|Hip
63637|NCT02660268|Prosthesis
63638|NCT02660255|CBD
63639|NCT02660255|Epidiolex
63640|NCT02660255|Myoclonic
63641|NCT02660255|Brain Disease
63642|NCT02660255|Central Nervous System Disease
63643|NCT02660255|GWP42003
63644|NCT02660242|T1D
63645|NCT02660242|Type 1 Diabetes
63646|NCT02660242|Mini-dose Glucagon
63647|NCT02660242|Adults
63648|NCT02660242|Exercise
63649|NCT02660242|Hypoglycemia
63650|NCT02660229|Intravenous injection in cancer pain
63651|NCT02660216|minimally invasive
63652|NCT02660216|le fort I osteotomy
63653|NCT02660216|3D virtual treatment planning
63654|NCT02660216|accuracy
63655|NCT02660203|chest physiotherapy
63656|NCT02660203|post operative period
63657|NCT02660203|forced expiration
63658|NCT02660203|pleural drainage duration
63659|NCT02660164|Concussion
63660|NCT02660125|ICSI
63661|NCT02660125|endometrial injury
63662|NCT02660125|implantation rate
63663|NCT02660086|Weight
63664|NCT02660086|Prevention
63665|NCT02660086|Food choice
63666|NCT02660086|Nutrition
63667|NCT02660086|Behavior change
63668|NCT02660086|Behavioral economics
63669|NCT02660086|Feedback
63670|NCT02660086|Incentives
63671|NCT02660060|Pramipexole
63672|NCT02660060|Bioequivalence
63673|NCT02660060|Pharmacokinetics
63674|NCT02660047|South Asian descent
63675|NCT02660034|Dose Escalation
63676|NCT02660034|Dose Expansion
63677|NCT02660034|BGB-A317
63678|NCT02660034|BGB-290
63679|NCT02660021|three-dimensional virtual treatment planning
63680|NCT02660021|orthognathic surgery
63681|NCT02659995|glycemic variability
63682|NCT02659995|infection
63683|NCT02659956|Multiple Sclerosis
63684|NCT02659956|Longitudinal Prospective Follow-Up
63685|NCT02659943|Gene Therapy
63686|NCT02659943|Adoptive T Cell Therapy
63687|NCT02659943|Allogeneic Stem Cell Transplantation
63688|NCT02659943|T-cell infusion
63689|NCT02659943|Residual Malignancy
63690|NCT02659930|HIV
63691|NCT02659930|AIDS
63692|NCT02659930|Multicentric Castleman Disease
63693|NCT02659917|glass-ionomer cement
63694|NCT02659917|atraumatic restorative treatment
63695|NCT02659917|pit and fissure sealants
63696|NCT02659904|Free gingival graft
63697|NCT02659904|Palatal donor site healing
63698|NCT02659878|Takotsubo cardiomyopathy;NT-proBNP;urine metanephrine
63699|NCT02659852|Hilar malignant biliary obstruction
63700|NCT02659852|bilateral metal stent
63701|NCT02659852|stent in stent
63702|NCT02659852|side by side
63703|NCT02659839|Cancer
63704|NCT02659839|Intensive care unit
63705|NCT02659839|Mortality
63706|NCT02659826|Transcutaneous spinal direct current stimulation
63707|NCT02659826|Transcranial Magnetic Stimulation
63708|NCT02659826|Gait Training
63709|NCT02659826|Central Nervous System Excitability
63710|NCT02659826|Healthy
63711|NCT02659813|Orthodontic wires
63712|NCT02659774|Smoking cessation interventions
63713|NCT02659761|Human Immunodeficiency Virus
63714|NCT02659761|Injection drug use
63715|NCT02659761|Single-tablet antiretroviral treatment
63716|NCT02659761|Dolutegravir
63717|NCT02659761|Tolerability
63718|NCT02659761|Adherence
63719|NCT02659761|Efficacy
63720|NCT02659748|Bioactive fatty acids
63721|NCT02659748|Insulin sensitivity
63722|NCT02659748|Diet
63723|NCT02659748|Milk fat
63724|NCT02659748|Lipid metabolism
63725|NCT02659748|Inflammation markers
63726|NCT02659748|Fecal microbiota composition
63727|NCT02659735|Influenza A virus
63728|NCT02659735|JNJ-63623872
63729|NCT02659735|Healthy
63730|NCT02659722|INTERVERTEBRAL DISC DEGENERATION
63731|NCT02659722|Bone Disease
63732|NCT02659722|Musculoskeletal disease
63733|NCT02659722|Spinal disease
63734|NCT02659709|Glaucoma
63735|NCT02659709|Smartphone
63736|NCT02659709|Tablet
63737|NCT02659709|Application
63738|NCT02659631|P-cadherin
63739|NCT02659631|PF-06671008
63740|NCT02659631|solid tumors
63741|NCT02659631|lung cancer
63742|NCT02659631|breast cancer
63743|NCT02659631|colorectal cancer
63744|NCT02659631|NSCLC
63745|NCT02659631|TNBC
63746|NCT02659631|CRC
63747|NCT02659631|neoplasms
63748|NCT02659631|Triple negative breast cancer
63749|NCT02659631|Non-small cell lung cancer
63750|NCT02659618|Asthma
63751|NCT02659605|pre-term birth
63752|NCT02659605|delayed cord clamping
63753|NCT02659605|skin to skin
63754|NCT02659592|fertility preservation
63755|NCT02659592|ovarian tissue transplantation
63756|NCT02659592|ovarian endocrine function
63757|NCT02659592|assisted reproductive technology
63758|NCT02659592|pregnancy and live birth
63759|NCT02659579|Shared Book Reading
63760|NCT02659579|Vocabulary
63761|NCT02659579|Language Development
63762|NCT02659579|Young Children
63763|NCT02659579|Randomised Control Trial
63764|NCT02659566|Markers
63765|NCT02659566|Parasitemia
63766|NCT02659566|Coartem
63767|NCT02659566|Plasmodium
63768|NCT02659566|Infection
63769|NCT02659553|Liver Transplantation - Steatosis - Fatty Liver
63770|NCT02659540|Ipilimumab
63771|NCT02659540|Nivolumab
63772|NCT02659540|Radiotherapy
63773|NCT02659514|Poziotinib
63774|NCT02659514|Metastatic Breast Cancer
63775|NCT02659514|HER2-positive
63776|NCT02659514|Pan-HER inhibitor
63777|NCT02659501|Breast reconstruction
63778|NCT02659501|Bupivacaine
63779|NCT02659501|Liposomal bupivacaine
63780|NCT02659501|Postoperative analgesia
63781|NCT02659462|Repaired Congenital Heart Disease
63782|NCT02659462|Cardio Pulmonary Exercise Testing
63783|NCT02659462|Fontan
63784|NCT02659462|Fontan Palliation
63785|NCT02659462|functional capacity
63786|NCT02659449|hands
63787|NCT02659436|Cognitive Behavioural Therapy
63788|NCT02659423|Bystanding behaviors
63789|NCT02659423|Campus
63790|NCT02659423|Prevention
63791|NCT02659423|Sexual Assault
63792|NCT02659423|CampusSave
63793|NCT02659410|Physiologically based pharmacokinetic modeling
63794|NCT02659410|Organic solvents
63795|NCT02659397|LDL-cholesterol
63796|NCT02659397|Hypercholesterolemia
63797|NCT02659397|ETC-1002
63798|NCT02659397|Adenosine triphosphate citrate lyase
63799|NCT02659397|Atorvastatin
63800|NCT02659358|Advanced solid malignancy
63801|NCT02659358|Activity monitor
63802|NCT02659358|Biosensor
63803|NCT02659358|Fitbit
63804|NCT02659358|Patient Reported Outcomes (PRO)
63805|NCT02659358|Stage 3/4 cancer
63806|NCT02659358|Performance Status
63807|NCT02659358|Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
63808|NCT02659345|Art Therapy
63809|NCT02659345|Chemotherapy
63810|NCT02659319|Child overweight
63811|NCT02659319|Child obesity
63812|NCT02659319|Family dynamics
63813|NCT02659319|Peer relationships
63814|NCT02659319|Family intervention
63815|NCT02659319|School intervention
63816|NCT02659319|Parenting
63817|NCT02659293|Multiple myeloma
63818|NCT02659293|stem-cell transplant
63819|NCT02659293|Symptomatic myeloma
63820|NCT02659293|lenalidomide
63821|NCT02659293|carfilzomib
63822|NCT02659293|dexamethasone
63823|NCT02659280|telerehabilitation
63824|NCT02659267|Health Promotion
63825|NCT02659267|Physical Activity
63826|NCT02659267|Eating habits
63827|NCT02659267|Health System
63828|NCT02659267|Users from Health Academy Program
63829|NCT02659254|Drug-Eluting Stents,Absorbable Implants,Stents
63830|NCT02659241|Molecular results
63831|NCT02659241|DNA
63832|NCT02659241|RNA
63833|NCT02659241|Protein expression
63834|NCT02659241|AZD1775
63835|NCT02659215|Hyaluronic Acid
63836|NCT02659215|Cartilage Repair
63837|NCT02659215|Knee
63838|NCT02659202|Exercise
63839|NCT02659202|Heart Failure
63840|NCT02659202|Blood Pressure
63841|NCT02659163|cardiometabolic risk
63842|NCT02659163|obesity
63843|NCT02659163|mHealth
63844|NCT02659163|health behaviors
63845|NCT02659150|tocilizumab
63846|NCT02659150|subcutaneous injection
63847|NCT02659150|rheumatoid arthritis
63848|NCT02659150|plaque inflammation
63849|NCT02659150|atherosclerotic plaque
63850|NCT02659150|joint inflammation
63851|NCT02659150|FDG-PET
63852|NCT02659150|PET-MR
63853|NCT02659150|ACTEMRA
63854|NCT02659137|LBBB
63855|NCT02659137|TAVI
63856|NCT02659124|facial laser
63857|NCT02659124|fraction ablative resurfacing
63858|NCT02659124|total ablative resurfacing
63859|NCT02659124|EpiFix
63860|NCT02659124|rhytides
63861|NCT02659124|wrinkles
63862|NCT02659124|AmnioFix
63863|NCT02659111|Exercise Therapy
63864|NCT02659098|Best Corrected Visual Acuity
63865|NCT02659098|Geographic Atrophy
63866|NCT02659098|Macular Degeneration
63867|NCT02659098|CNTO 2476
63868|NCT02659085|Depressive Disorder, Major
63869|NCT02659085|Antidepressive Agents/adverse effects
63870|NCT02659085|Depressive Disorder, Major/drug therapy
63871|NCT02659085|Infusions, Intravenous
63872|NCT02659085|Ketamine/administration & dosage*
63873|NCT02659085|Ketamine/adverse effects
63874|NCT02659085|Treatment Outcome
63875|NCT02659085|Electroconvulsive therapy
63876|NCT02659046|Traumatic Brain Injury
63877|NCT02659033|microbiota
63878|NCT02659033|resistant bacteria
63879|NCT02659007|yoga
63880|NCT02659007|balance
63881|NCT02658968|Radioimmunotherapy
63882|NCT02658968|Lu-177
63883|NCT02658968|Phase I study
63884|NCT02658968|Betalutin
63885|NCT02658968|ARC
63886|NCT02658968|Antibody Radionuclide Conjugate
63887|NCT02658968|HH1
63888|NCT02658968|Rituximab
63889|NCT02658968|177Lu-DOTA-HH1
63890|NCT02658968|Additional relevant MeSH terms:
63891|NCT02658968|Lymphoma
63892|NCT02658968|Lymphoma, Non-Hodgkin
63893|NCT02658968|Immune System Diseases
63894|NCT02658968|Immunoproliferative Disorders
63895|NCT02658968|Diffuse Large B-Cell Lymphoma
63896|NCT02658968|Lymphatic Diseases
63897|NCT02658968|Lymphoproliferative Disorders
63898|NCT02658968|Neoplasms
63899|NCT02658968|Neoplasms by Histologic Type
63900|NCT02658955|Abdominal wall closure
63901|NCT02658942|renal stones
63902|NCT02658942|lower calyx
63903|NCT02658942|Ureteroscopy
63904|NCT02658942|Shockwave lithotripsy
63905|NCT02658942|Holmium laser
63906|NCT02658942|Adult
63907|NCT02658942|Kidney
63908|NCT02658903|Foley
63909|NCT02658903|Infection
63910|NCT02658903|Hospital acquired
63911|NCT02658903|catheter associated
63912|NCT02658903|urinary
63913|NCT02658877|Xolair
63914|NCT02658877|corticosteroids
63915|NCT02658877|asthma
63916|NCT02658877|long-acting beta-agonists
63917|NCT02658864|lafutidine tablet
63918|NCT02658864|pharmacokinetics
63919|NCT02658864|food
63920|NCT02658864|safety
63921|NCT02658864|healthy subjects
63922|NCT02658851|lymphocele
63923|NCT02658851|pelvic lymph node dissection
63924|NCT02658851|robotic assisted radical prostatectomy
63925|NCT02658851|PLND
63926|NCT02658851|RARP
63927|NCT02658851|prostatectomy
63928|NCT02658851|Patel
63929|NCT02658825|Healthy
63930|NCT02658825|JNJ-63623872
63931|NCT02658825|Moxifloxacin
63932|NCT02658812|Breast Cancer
63933|NCT02658812|Inflammatory breast cancer
63934|NCT02658812|IBC
63935|NCT02658812|Non-inflammatory breast cancer
63936|NCT02658812|Inoperable local recurrence
63937|NCT02658812|Talimogene laherparepvec
63938|NCT02658812|T-VEC
63939|NCT02658812|OncoVEX GM-CSF
63940|NCT02658799|periodontitis
63941|NCT02658799|anti-inflammatory agents
63942|NCT02658760|Femoral Fractures
63943|NCT02658721|Systemic Tramadol
63944|NCT02658721|Adjunct Tramadol
63945|NCT02658721|Lidocain
63946|NCT02658695|ICSI
63947|NCT02658695|embryo transfer
63948|NCT02658695|air bubbles depth
63949|NCT02658669|Insomnia
63950|NCT02658669|Injury, Brain, Traumatic Mild
63951|NCT02658656|Exoskeleton
63952|NCT02658643|biliodigestive anastomosis techniques
63953|NCT02658630|arm rehabilitation
63954|NCT02658630|recovery of function
63955|NCT02658617|Empathy
63956|NCT02658617|Interoceptive Awareness
63957|NCT02658617|fMRI
63958|NCT02658617|MRS
63959|NCT02658591|Food intake
63960|NCT02658591|Satiety
63961|NCT02658591|Appetite
63962|NCT02658591|Glycemia
63963|NCT02658591|Faba bean
63964|NCT02658591|Protein
63965|NCT02658591|Snack
63966|NCT02658565|Intraoperative Consultation
63967|NCT02658552|HIFU
63968|NCT02658552|Benign thyroid nodule
63969|NCT02658552|Low risk
63970|NCT02658552|New treatment
63971|NCT02658539|Body fat distribution
63972|NCT02658539|Bone mineral density
63973|NCT02658539|Dual-energy x-ray absorptiometry
63974|NCT02658526|cognition
63975|NCT02658526|anesthesia
63976|NCT02658526|surgery
63977|NCT02658526|stress
63978|NCT02658526|child
63979|NCT02658500|early infant feeding
63980|NCT02658500|infant intestinal flora
63981|NCT02658500|infant health
63982|NCT02658474|Chronic pain
63983|NCT02658474|Acceptance and Commitment Therapy
63984|NCT02658474|Multidisciplinary treatment
63985|NCT02658474|Group treatment
63986|NCT02658435|Malaria
63987|NCT02658435|Retinal
63988|NCT02658435|Ophthalmic
63989|NCT02658435|Plasmodium. vivax
63990|NCT02658435|Tafenoquine
63991|NCT02658435|Pharmacodynamic
63992|NCT02658409|CCIV
63993|NCT02658409|quadrivalent cell-culture based influenza vaccine
63994|NCT02658409|Influenza vaccine
63995|NCT02658409|Vaccination
63996|NCT02658396|Multiple Myeloma
63997|NCT02658396|Relapsed Multiple Myeloma
63998|NCT02658396|Refractory Multiple Myeloma
63999|NCT02658370|physical exercises
64000|NCT02658370|physical therapy
64001|NCT02658370|Wii game console
64002|NCT02658370|patients perspective
64003|NCT02658344|Stem cell
64004|NCT02658344|adipose tissue derived mesenchymal stem cell
64005|NCT02658344|osteoarthritis
64006|NCT02658344|degenerative arthritis
64007|NCT02658344|biostar
64008|NCT02658344|Rbio
64009|NCT02658331|Ebola Virus Disease
64010|NCT02658331|Rapid Diagnosis
64011|NCT02658331|Point of care
64012|NCT02658331|Molecular platform
64013|NCT02658318|peri- and postoperative complications
64014|NCT02658318|airway obstruction
64015|NCT02658318|adapted Furlow palatoplasty
64016|NCT02658305|transoral approach
64017|NCT02658305|transbuccal approach
64018|NCT02658305|postoperative complications
64019|NCT02658292|fungus
64020|NCT02658292|antifungal
64021|NCT02658292|skin infection
64022|NCT02658292|hair infection
64023|NCT02658292|dermatophyte
64024|NCT02658292|scalp
64025|NCT02658292|skin
64026|NCT02658292|eyebrows
64027|NCT02658292|eyelashes
64028|NCT02658292|hair
64029|NCT02658292|Trichophyton
64030|NCT02658292|Microsporum
64031|NCT02658292|Endothrix
64032|NCT02658292|spores
64033|NCT02658279|Pembrolizumab (MK-3475)
64034|NCT02658279|15-227
64035|NCT02658279|Hypermutator Phenotype
64036|NCT02658266|resistance training
64037|NCT02658266|adult
64038|NCT02658266|muscle strength
64039|NCT02658266|muscle endurance
64040|NCT02658266|muscle metabolism
64041|NCT02658253|Placental malaria vaccine
64042|NCT02658253|Plasmodium
64043|NCT02658253|PRIMALVAC
64044|NCT02658240|Nerve block
64045|NCT02658240|Periarticular infiltration
64046|NCT02658240|Ropivacaine
64047|NCT02658240|Pain
64048|NCT02658214|durvalumab, MEDI4736, tremelimumab, small-cell lung, head and neck, triple negative breast, gastric/GEJ or ovarian cancer, immuno oncology, first-line chemo
64049|NCT02658188|Restless legs syndrome patients
64050|NCT02658188|ASP8825
64051|NCT02658188|XP13512
64052|NCT02658110|Postprandial glycemia
64053|NCT02658110|Metabolic health measures
64054|NCT02658097|Lung Cancer
64055|NCT02658097|pembrolizumab
64056|NCT02658097|focal radiation
64057|NCT02658097|RT
64058|NCT02658084|HER2-Positive
64059|NCT02658084|Metastatic Breast Cancer
64060|NCT02658071|exfoliative glaucoma
64061|NCT02658071|cataract
64062|NCT02658071|ocular pressure
64063|NCT02658058|Ultrasound
64064|NCT02658058|Spinal anesthesia
64065|NCT02658058|Elderly
64066|NCT02658058|Landmark
64067|NCT02658045|oxygen saturation
64068|NCT02658045|monitoring
64069|NCT02658045|oximeter
64070|NCT02658019|Hepatocellular Carcinoma
64071|NCT02658019|Advanced Hepatocellular Carcinoma
64072|NCT02658019|Unresectable Hepatocellular Carcinoma
64073|NCT02658006|Near Infrared Spectroscopy
64074|NCT02658006|Ultrasonography
64075|NCT02658006|Hepatic vein Doppler
64076|NCT02658006|Portal vein Doppler
64077|NCT02658006|Lung ultrasound
64078|NCT02658006|Positive fluid balance
64079|NCT02658006|Mixed venous saturation
64080|NCT02657993|Breast Neoplasms
64081|NCT02657993|Aromatase Inhibitors
64082|NCT02657993|Musculoskeletal Pain
64083|NCT02657993|Hypnosis
64084|NCT02657993|Medication Adherence
64085|NCT02657993|Cost-Benefit Analysis
64086|NCT02657993|Treatment Outcomes
64087|NCT02657980|Major Depressive Disorder
64088|NCT02657980|tDCS
64089|NCT02657980|MDD
64090|NCT02657980|transcranial Direct Current Stimulation
64091|NCT02657954|Homeless persons
64092|NCT02657954|Veterans
64093|NCT02657954|Mental disorders
64094|NCT02657954|Cognition
64095|NCT02657954|Rehabilitation
64096|NCT02657941|Schizophrenia
64097|NCT02657941|Obesity
64098|NCT02657941|Metabolic Syndrome
64099|NCT02657915|FF-VEP
64100|NCT02657915|mfVEP
64101|NCT02657915|Human anti-LINGO-1
64102|NCT02657915|BIIB033
64103|NCT02657915|AON
64104|NCT02657889|PARP inhibitor
64105|NCT02657889|PD-1
64106|NCT02657889|Niraparib
64107|NCT02657889|Pembrolizumab
64108|NCT02657889|Keynote
64109|NCT02657889|TOPACIO
64110|NCT02657837|CF
64111|NCT02657837|Multiple Breath Washout
64112|NCT02657837|Lung Clearance Index
64113|NCT02657837|Pediatrics
64114|NCT02657824|Ejection fraction
64115|NCT02657824|mitral valve
64116|NCT02657824|e-point septal separation
64117|NCT02657811|Time-Lapse Imaging
64118|NCT02657811|Embryo Culture Techniques
64119|NCT02657811|Fertilization in Vitro
64120|NCT02657811|Embryology
64121|NCT02657811|Assisted Reproductive Techniques
64122|NCT02657811|Infertility
64123|NCT02657811|Preimplantation diagnosis
64124|NCT02657772|Target Ultra coils
64125|NCT02657772|small aneurysms
64126|NCT02657746|blood pressure monitoring
64127|NCT02657746|high blood pressure
64128|NCT02657746|cardiovascular disease
64129|NCT02657746|Antihypertensive agents
64130|NCT02657746|Non-pharmacological treatment
64131|NCT02657746|community health care workers
64132|NCT02657746|cost-effectiveness
64133|NCT02657733|Respiratory Conditions for Adults
64134|NCT02657720|Respiratory Conditions for Adults
64135|NCT02657707|stent
64136|NCT02657707|stenosis
64137|NCT02657707|artery
64138|NCT02657707|carotid
64139|NCT02657668|Irritable Bowel Syndrome
64140|NCT02657668|Emotion Focused Therapy
64141|NCT02657668|Stress
64142|NCT02657668|Resilience
64143|NCT02657668|Coping Strategies
64144|NCT02657655|Parkinson's Disease
64145|NCT02657655|Dyskinesia
64146|NCT02657655|Tremor
64147|NCT02657655|Symptom Management
64148|NCT02657655|Technology
64149|NCT02657655|Wearable Sensors
64150|NCT02657655|Continuous Monitoring
64151|NCT02657655|Mobility
64152|NCT02657642|drug related problems, elderly
64153|NCT02657603|Peripheral Nerve Blocks
64154|NCT02657577|Women
64155|NCT02657577|Infants and Children
64156|NCT02657551|Thyroid Cancer
64157|NCT02657538|Interproximal caries
64158|NCT02657538|Enamel caries
64159|NCT02657538|Caries detection
64160|NCT02657538|Caries diagnostics
64161|NCT02657538|Near-infrared light transillumination
64162|NCT02657538|DIAGNOcam
64163|NCT02657512|Rivaroxaban, pharmacokinetics, activated charcoal, poisoning
64164|NCT02657499|healthcare access
64165|NCT02657499|utilization
64166|NCT02657499|expenditures
64167|NCT02657499|preventive services
64168|NCT02657486|BGJ398
64169|NCT02657486|15-090
64170|NCT02657460|chemotherapy
64171|NCT02657460|microparticle
64172|NCT02657460|malignant pleural effusion
64173|NCT02657447|Radioimmunotherapy
64174|NCT02657447|Lu-177
64175|NCT02657447|Phase I study
64176|NCT02657447|Betalutin
64177|NCT02657447|ARC
64178|NCT02657447|Antibody Radionuclide Conjugate
64179|NCT02657447|HH1
64180|NCT02657447|Rituximab
64181|NCT02657447|177Lu-DOTA-HH1
64182|NCT02657447|Lymphoma
64183|NCT02657447|Lymphoma Non-Hodgkin
64184|NCT02657447|Immune System Diseases
64185|NCT02657447|Follicular Lymphoma
64186|NCT02657447|Marginal Zone Lymphoma
64187|NCT02657447|Lymphoplasmacytoid
64188|NCT02657447|Lymphatic Diseases
64189|NCT02657447|Lymphoproliferative Disorders
64190|NCT02657447|Neoplasms
64191|NCT02657447|Neoplasms by Histological Type
64192|NCT02657447|Small Lymphocytic Lymphoma
64193|NCT02657447|Classical Mantle Cell Lymphoma
64194|NCT02657447|Lilotomab
64195|NCT02657382|Biofeedback
64196|NCT02657382|Myocardial Imaging
64197|NCT02657369|Lenvatinib
64198|NCT02657369|Thyroid Cancer, Anaplastic
64199|NCT02657369|Lenvima
64200|NCT02657369|E7080
64201|NCT02657356|Pulmonary Hypertension
64202|NCT02657356|Pulmonary Arterial Hypertension
64203|NCT02657356|Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
64204|NCT02657356|Bardoxolone methyl
64205|NCT02657356|PAH
64206|NCT02657356|RTA 402
64207|NCT02657356|6-minute walk distance
64208|NCT02657343|Breast Cancer With Positive HER2
64209|NCT02657330|Locally Advanced
64210|NCT02657330|Metastatic
64211|NCT02657317|chronic pain
64212|NCT02657317|pain management
64213|NCT02657317|trauma
64214|NCT02657317|ptsd
64215|NCT02657317|tbi
64216|NCT02657317|opioid medication
64217|NCT02657304|Sleep Apnea
64218|NCT02657304|CPAP
64219|NCT02657278|Peripheral arterial disease,
64220|NCT02657278|Cardipulmonary Exercise Test
64221|NCT02657252|telangiectasis
64222|NCT02657252|varicose veins
64223|NCT02657252|veins
64224|NCT02657252|glucose
64225|NCT02657252|sclerotherapy
64226|NCT02657239|Physical Function
64227|NCT02657213|Diabetes, Type 1
64228|NCT02657213|Hypoglycemia
64229|NCT02657213|Insulin Infusion Systems
64230|NCT02657200|miscarriage
64231|NCT02657200|Flanders
64232|NCT02657200|spontaneous abortion
64233|NCT02657200|KAP
64234|NCT02657200|midwives
64235|NCT02657174|third molar
64236|NCT02657174|auriculotherapy
64237|NCT02657174|inflammation
64238|NCT02657174|pain
64239|NCT02657122|Single ascending dose
64240|NCT02657122|SAD
64241|NCT02657122|multiple ascending dose
64242|NCT02657122|MAD
64243|NCT02657122|Phase 1
64244|NCT02657122|first-in-human
64245|NCT02657122|volunteers
64246|NCT02657122|TD-1473
64247|NCT02657109|valve replacement
64248|NCT02657109|physical therapy
64249|NCT02657109|early mobilization
64250|NCT02657096|Chronic Periodontitis
64251|NCT02657096|Hybenx
64252|NCT02657096|Desiccant agent
64253|NCT02657096|Healing
64254|NCT02657096|Microbiology
64255|NCT02657096|Periodontal Diseases
64256|NCT02657096|Periodontitis
64257|NCT02657096|Split-mouth clinical Study
64258|NCT02657070|Stroke
64259|NCT02657070|learned non-use
64260|NCT02657070|Virtual Reality
64261|NCT02657070|Hemiparesis
64262|NCT02657044|EMR
64263|NCT02657044|ESD
64264|NCT02657044|endoscopic mucosal resection
64265|NCT02657044|endoscopic submucosal resection
64266|NCT02657044|colorectal adenomas
64267|NCT02657031|Headache, Migraine
64268|NCT02656992|Bronchiectasis
64269|NCT02656992|High-intensity inspiratory muscle training
64270|NCT02656979|Glaucoma
64271|NCT02656979|Blood flow
64272|NCT02656979|Pseudoexfoliation
64273|NCT02656979|Intraocular pressure
64274|NCT02656979|Brain perfusion
64275|NCT02656979|Magnetic Resonance Imaging
64276|NCT02656953|VDU workers
64277|NCT02656953|VDU lenses
64278|NCT02656953|Neck complaints
64279|NCT02656953|Visual complaints
64280|NCT02656940|obesity
64281|NCT02656940|lipids
64282|NCT02656940|energy expenditure
64283|NCT02656940|gene expression
64284|NCT02656927|Spinal Cord Injury
64285|NCT02656927|Yoga
64286|NCT02656927|Psychological Flexibility
64287|NCT02656927|Mindfulness
64288|NCT02656927|Pain
64289|NCT02656849|Solid Tumor
64290|NCT02656823|ANKYLOS
64291|NCT02656823|Simplant
64292|NCT02656823|maxilla
64293|NCT02656823|edentulous
64294|NCT02656823|short implants
64295|NCT02656797|Leishmania major
64296|NCT02656797|Leishmania tropica
64297|NCT02656797|Amphotericin B
64298|NCT02656771|THA
64299|NCT02656771|Hip
64300|NCT02656771|arthroplasties
64301|NCT02656745|Smoking
64302|NCT02656745|Cigarette Smoking
64303|NCT02656745|Tobacco Smoking
64304|NCT02656745|Nicotine
64305|NCT02656745|Drug
64306|NCT02656745|Addiction
64307|NCT02656745|Tobacco
64308|NCT02656719|tracheostomy
64309|NCT02656719|complications
64310|NCT02656719|ultrasound
64311|NCT02656719|bronchoscopy
64312|NCT02656706|Adjuvant melanoma
64313|NCT02656706|Advanced melanoma
64314|NCT02656693|Weight Reduction Programs
64315|NCT02656693|Weight Loss Programs
64316|NCT02656693|Obesity
64317|NCT02656667|COPD pulmonary rehabilitation
64318|NCT02656667|neuromuscular electrical stimulation
64319|NCT02656667|sit to stand test COPD
64320|NCT02656667|quadriceps strengthening
64321|NCT02656602|Computer Assisted Instruction
64322|NCT02656602|Patient Counselling
64323|NCT02656602|Endoscopy
64324|NCT02656589|breast cancer
64325|NCT02656589|herceptin
64326|NCT02656589|microRNA
64327|NCT02656576|Human Papillomavirus
64328|NCT02656576|oropharynx biopsy
64329|NCT02656576|tonsillar lesion
64330|NCT02656550|Uterine Transplant
64331|NCT02656550|AUI
64332|NCT02656550|Rokitansky Syndrome
64333|NCT02656524|Metastatic colorectal cancer
64334|NCT02656511|immediate antiretroviral therapy
64335|NCT02656511|hyperacute infection
64336|NCT02656498|Tau, neurodegeneration, positron emission computed tomography
64337|NCT02656472|Pediatric Cardiac surgery
64338|NCT02656472|Inflammatory response
64339|NCT02656472|Tranexamic acid
64340|NCT02656472|Epsilon Aminocaproic Acid
64341|NCT02656459|gene expression
64342|NCT02656446|Neuraxial
64343|NCT02656446|Ultrasound
64344|NCT02656433|QEEG
64345|NCT02656433|ERP
64346|NCT02656433|tRNS
64347|NCT02656433|Brain injury
64348|NCT02656433|Motor Impairment
64349|NCT02656433|Transcranial Brain non-invasive stimulation
64350|NCT02656433|electroencephalogram
64351|NCT02656407|Functional Ultrasound
64352|NCT02656407|Intraoperative
64353|NCT02656407|Brain
64354|NCT02656407|Doppler
64355|NCT02656407|Ultrasound
64356|NCT02656394|ocular surface disease
64357|NCT02656394|glaucoma medications
64358|NCT02656381|Sarcoidosis
64359|NCT02656381|Behcet's Disease
64360|NCT02656381|Natural History Study
64361|NCT02656381|Biological Specimens
64362|NCT02656381|Immune System
64363|NCT02656355|Gait Initiation
64364|NCT02656355|Freezing of gait
64365|NCT02656355|Balance training
64366|NCT02656355|Anticipatory postural adjustments
64367|NCT02656342|OCD
64368|NCT02656329|Heart Failure (HF)
64369|NCT02656329|Single photon emission computer tomography scan (SPECT)
64370|NCT02656329|Implantable cardioverter defibrillator (ICD)
64371|NCT02656329|Left Ventricular ejection fraction (LVEF)
64372|NCT02656329|New York Health Association (NYHA)
64373|NCT02656329|Metaiodobenzylguanidine (mIBG)
64374|NCT02656329|123I-iobenguane
64375|NCT02656329|Heart-to-mediastinal ratio (H/M)
64376|NCT02656329|ADMIRE-ICD (AdreView Myocardial Imaging for Risk Evaluation - Implantable Cardioverter Defibrillator
64377|NCT02656329|All-cause mortality
64378|NCT02656329|Cardiac mortality
64379|NCT02656251|biofilms
64380|NCT02656251|cross over trial
64381|NCT02656251|chlorhexidine
64382|NCT02656238|CTEPH
64383|NCT02656238|Balloon pulmonary angioplasty
64384|NCT02656238|Chronic thromboembolic pulmonary hypertension
64385|NCT02656238|Pulmonary endarterectomy
64386|NCT02656238|BPA
64387|NCT02656238|PEA
64388|NCT02656225|postpartum anemia
64389|NCT02656225|hemoglobin
64390|NCT02656225|iron metabolism
64391|NCT02656225|Traditional Chinese Medicine
64392|NCT02656225|Ejiao
64393|NCT02656212|epicatechin
64394|NCT02656212|pre-diabetes
64395|NCT02656199|Diaphragm
64396|NCT02656199|Ventilators, Mechanical
64397|NCT02656173|Tamsulosin
64398|NCT02656173|Overactive bladder
64399|NCT02656173|Benign prostatic hypertrophy
64400|NCT02656173|Mirabegron
64401|NCT02656147|Leukemia
64402|NCT02656147|Lymphoma
64403|NCT02656147|CAR γδT
64404|NCT02656134|Familial Adenomatous Polyposis
64405|NCT02656121|PCOS, vitamin D
64406|NCT02656082|Discoid lupus erythematosus
64407|NCT02656082|Intradermal injection of etanercept
64408|NCT02656017|kidney disease
64409|NCT02656017|polycystic kidney disease
64410|NCT02656017|autosomal dominant kidney disease
64411|NCT02656017|kidney cysts
64412|NCT02656017|PKD
64413|NCT02656004|Eucalyptus
64414|NCT02656004|Autonomic nervous system
64415|NCT02656004|Isometric resistance exercise
64416|NCT02655991|Stress Disorders, Post-Traumatic
64417|NCT02655991|Ambulatory Care
64418|NCT02655991|Telemedicine
64419|NCT02655991|Remote Consultation
64420|NCT02655991|Health Services Accessibility
64421|NCT02655965|Breast cancer
64422|NCT02655965|lumpectomy
64423|NCT02655965|mastectomy
64424|NCT02655965|PECS bloc
64425|NCT02655939|Gonarthrosis
64426|NCT02655926|OCD
64427|NCT02655926|DBS
64428|NCT02655926|Deep Brain Stimulation
64429|NCT02655913|Sodium ascorbate
64430|NCT02655913|Non-Small-Cell Lung cancer
64431|NCT02655913|Oncothermia
64432|NCT02655913|Immune function
64433|NCT02655913|Life quality
64434|NCT02655913|Tumor marker
64435|NCT02655913|Survival time
64436|NCT02655900|Obstetric anal sphincter injury,
64437|NCT02655900|Ultrasound diagnosis
64438|NCT02655874|Seasonal Influenza
64439|NCT02655874|Antibody response
64440|NCT02655874|Influenza Vaccines
64441|NCT02655874|Hemagglutination Inhibition
64442|NCT02655874|Elderly
64443|NCT02655874|immunosenescence
64444|NCT02655874|Tropics
64445|NCT02655848|Popeye
64446|NCT02655848|Long Head Biceps Tendon
64447|NCT02655848|Arthroscopy
64448|NCT02655848|Functional result
64449|NCT02655835|mindfulness
64450|NCT02655835|meditation
64451|NCT02655835|internet
64452|NCT02655822|NSCLC
64453|NCT02655822|MEL
64454|NCT02655822|RCC
64455|NCT02655822|TNBC
64456|NCT02655822|Triple Negative Breast Neoplasms
64457|NCT02655822|Neoplasms
64458|NCT02655822|CRC
64459|NCT02655822|Lung Cancer
64460|NCT02655822|Kidney Cancer
64461|NCT02655822|Colon Cancer
64462|NCT02655822|Rectal Cancer
64463|NCT02655822|Skin Cancer
64464|NCT02655822|Breast Cancer
64465|NCT02655796|Accidental Falls
64466|NCT02655796|Risk Assessment
64467|NCT02655796|Frail Elderly
64468|NCT02655783|induction of labor
64469|NCT02655744|Neurobehavioral Assessment
64470|NCT02655744|Radiotherapy (RT)
64471|NCT02655744|Chemotherapy
64472|NCT02655744|Neurotoxicity
64473|NCT02655718|ACS
64474|NCT02655718|Non obstructive coronary atherosclerosis
64475|NCT02655705|Cyclosporine
64476|NCT02655705|Methotrexate
64477|NCT02655692|PTSD
64478|NCT02655692|Ketamine
64479|NCT02655692|Veteran
64480|NCT02655692|Military
64481|NCT02655692|Clinical Trial
64482|NCT02655679|eczema
64483|NCT02655640|illness perceptions
64484|NCT02655627|Type 2 DM
64485|NCT02655627|internet based exercise training
64486|NCT02655627|group exercise training
64487|NCT02655627|glycemic control
64488|NCT02655575|dizziness
64489|NCT02655575|cognitive therapy
64490|NCT02655575|primary care
64491|NCT02655575|vestibular rehabilitation
64492|NCT02655575|chronic
64493|NCT02655484|COPD
64494|NCT02655484|noninvasive ventilation
64495|NCT02655484|exercise
64496|NCT02655484|CO2 rebreathing
64497|NCT02655458|Multiple Myeloma
64498|NCT02655458|Induction Therapy
64499|NCT02655458|Autologous Stem Cell Transplant
64500|NCT02655458|ASCT
64501|NCT02655458|Auto-SCT
64502|NCT02655419|cIAIs in hospitalized adults
64503|NCT02655406|Foam sclerotherapy
64504|NCT02655406|Compression
64505|NCT02655367|MRI
64506|NCT02655367|oats
64507|NCT02655367|porridge
64508|NCT02655367|satiety
64509|NCT02655367|GI hormones
64510|NCT02655367|processing
64511|NCT02655341|Dehydration
64512|NCT02655341|Primary PCI
64513|NCT02655341|Acute Myocardial Infarction
64514|NCT02655341|Bioimpedance
64515|NCT02655341|Renal Angiography
64516|NCT02655328|asthma
64517|NCT02655328|athlete
64518|NCT02655315|Parkinson
64519|NCT02655315|Deferiprone
64520|NCT02655315|Chelation
64521|NCT02655302|Interleukin-17
64522|NCT02655302|Interleukin-22
64523|NCT02655302|Microbiota
64524|NCT02655302|Exacerbations
64525|NCT02655302|Immunity
64526|NCT02655302|Mucosal
64527|NCT02655276|microencapsulated glycine
64528|NCT02655276|attentional performance
64529|NCT02655276|motoric activity
64530|NCT02655276|hyperactivity
64531|NCT02655198|refractory childhood epilepsy
64532|NCT02655198|Lennox Gastaut syndrome
64533|NCT02655198|fenfluramine
64534|NCT02655198|anti-epileptic treatment
64535|NCT02655185|Lipids
64536|NCT02655185|Atrial Fibrillation
64537|NCT02655185|Heart Failure
64538|NCT02655172|Schizophrenia, affordance,
64539|NCT02655172|perception-action binding,
64540|NCT02655172|stimulus-response-compatibility
64541|NCT02655159|Breast Cancer
64542|NCT02655159|Metastatic breast cancer
64543|NCT02655159|nab-paclitaxel
64544|NCT02655159|Abraxane
64545|NCT02655159|Observational
64546|NCT02655159|Retrospective
64547|NCT02655159|AMBER
64548|NCT02655146|Frozen embryo transfer,luteal support, GnRHa
64549|NCT02655120|Femoral head necrosis
64550|NCT02655120|Autologous Bone Marrow
64551|NCT02655120|BMP7
64552|NCT02655107|blood gas monitoring
64553|NCT02655107|non-invasive
64554|NCT02655107|hemoglobin
64555|NCT02655094|minimal-invasive surgery, mitral valve
64556|NCT02655081|Urinary diversion
64557|NCT02655081|Bladder Neoplasm
64558|NCT02655081|Nutritional Supplement
64559|NCT02655081|Cystectomy
64560|NCT02655068|Head and Neck Cancer
64561|NCT02655068|Definitive Therapy
64562|NCT02655068|Positron Emission Tomography - Computed Tomography (PET/CT)
64563|NCT02655068|Computed Tomography (CT)
64564|NCT02655055|apheresis
64565|NCT02655055|citrate anticoagulation
64566|NCT02655055|blood donor
64567|NCT02655055|bone
64568|NCT02655016|Ovarian Cancer
64569|NCT02655016|PARP Inhibitor
64570|NCT02655016|HRD
64571|NCT02655016|HRD positive
64572|NCT02655016|PRIMA
64573|NCT02655016|PRIMA Clinical Trial
64574|NCT02655016|PRIMA Study
64575|NCT02655003|behavioral symptoms
64576|NCT02655003|psychological symptoms
64577|NCT02655003|dementia
64578|NCT02655003|neuropsychiatric symptoms
64579|NCT02654990|multiple myeloma
64580|NCT02654990|relapsed or relapsed/refractory
64581|NCT02654990|LBH589
64582|NCT02654990|panobinostat
64583|NCT02654990|bortezomib
64584|NCT02654990|dexamethasone
64585|NCT02654951|Stroke
64586|NCT02654951|Rehabilitation Robotics
64587|NCT02654951|Bimanual
64588|NCT02654951|Compensatory movements
64589|NCT02654951|Hemiplegia
64590|NCT02654951|Kinematics
64591|NCT02654951|Reaching
64592|NCT02654951|Trunk
64593|NCT02654938|prostate cancer
64594|NCT02654938|adenovirus
64595|NCT02654938|TLR5
64596|NCT02654938|immunotherapy
64597|NCT02654912|malaria
64598|NCT02654912|elimination
64599|NCT02654912|surveillance and response
64600|NCT02654912|dihydroartemisinin+piperaquine
64601|NCT02654899|Healthy subjects
64602|NCT02654899|Single Ascending Dose
64603|NCT02654899|Hyperlipidemia
64604|NCT02654899|Dyslipidemia
64605|NCT02654886|exercise
64606|NCT02654886|Pompe disease
64607|NCT02654886|Pompe
64608|NCT02654873|histopathology
64609|NCT02654873|gallbladder
64610|NCT02654873|specimen
64611|NCT02654847|vasopressor
64612|NCT02654847|blood pressure
64613|NCT02654847|Cesarean section
64614|NCT02654847|spinal anesthesia
64615|NCT02654821|Melanoma
64616|NCT02654821|TCR
64617|NCT02654808|gynecology
64618|NCT02654808|laparoscopy
64619|NCT02654808|pneumoperitoneum
64620|NCT02654808|CO2 absorption
64621|NCT02654756|Risk Assessment
64622|NCT02654704|Personalized Medicine
64623|NCT02654704|Precision Medicine
64624|NCT02654691|Chemotherapy
64625|NCT02654639|Metastatic Colorectal Cancer
64626|NCT02654639|Advanced Colorectal Cancer
64627|NCT02654600|cardiac surgery
64628|NCT02654600|thoracopulmonary compliance
64629|NCT02654587|Non-Small-Cell Lung Cancer
64630|NCT02654587|NSCLC
64631|NCT02654587|Immunotherapy
64632|NCT02654587|Cancer vaccine
64633|NCT02654587|Metastasis
64634|NCT02654574|Alzheimer's disease or related disorders
64635|NCT02654574|Functional autonomy level
64636|NCT02654574|Lawton Instrumental Activities of Daily Living
64637|NCT02654574|The Functional autonomy level
64638|NCT02654561|Severe sepsis
64639|NCT02654561|Disseminated intravascular coagulation
64640|NCT02654561|Unfractionated heparin
64641|NCT02654535|Systematic review and meta-analysis
64642|NCT02654535|Evidence-based medicine (EBM)
64643|NCT02654535|Evidence-based nutrition (EBN)
64644|NCT02654535|Clinical practice guidelines
64645|NCT02654535|Clinical trials
64646|NCT02654535|Tree Nuts
64647|NCT02654535|Peanuts
64648|NCT02654535|Body weight
64649|NCT02654535|Prospective cohort studies
64650|NCT02654496|Gut Microbiota
64651|NCT02654496|Weight Regain
64652|NCT02654496|Gastric Bypass
64653|NCT02654457|Immunohistochemical
64654|NCT02654457|Ki-67
64655|NCT02654457|Breast cancer
64656|NCT02654457|IHC
64657|NCT02654444|Immunohistochemical (IHC)
64658|NCT02654444|Her2/Neu
64659|NCT02654444|Breast cancer
64660|NCT02654431|Immunohistochemical (IHC)
64661|NCT02654431|ER/PR
64662|NCT02654431|Breast cancer
64663|NCT02654418|colonic polyps ≥20 mm,
64664|NCT02654418|adenomas
64665|NCT02654418|polyps
64666|NCT02654405|HDAC inhibitors
64667|NCT02654405|Inflammation
64668|NCT02654392|Omega-3
64669|NCT02654392|Omega-6
64670|NCT02654392|Exercise Performance
64671|NCT02654366|Syringe exchange
64672|NCT02654366|HIV risk reduction
64673|NCT02654366|Drug-free community support
64674|NCT02654353|Persistent atrial fibrillation, catheter ablation, outcome
64675|NCT02654327|Extracorporeal
64676|NCT02654327|Acute Respiratory Distress Syndrome
64677|NCT02654327|Protective Lung Ventilation
64678|NCT02654327|Ventilator Induced Lung Injury
64679|NCT02654327|Carbon Dioxide Removal
64680|NCT02654327|Lung
64681|NCT02654327|Lung Injury
64682|NCT02654314|prevention; delirium; in-patients; melatonin,
64683|NCT02654301|Xylose
64684|NCT02654301|prediabetes
64685|NCT02654301|postprandial hyperglycemia
64686|NCT02654301|glucose
64687|NCT02654288|pancreatic cancer
64688|NCT02654288|gemcitabine
64689|NCT02654288|chemotherapy
64690|NCT02654288|immunoglobulin G 4
64691|NCT02654249|Hemorrhoids grade III and IV
64692|NCT02654249|transanal hemorrhoidal dearterialization
64693|NCT02654249|hemorroidectomy
64694|NCT02654249|THD
64695|NCT02654249|LigaSure
64696|NCT02654223|Rhinitis / Rhinoconjunctivitis
64697|NCT02654223|Vaccine
64698|NCT02654223|Immunotherapy
64699|NCT02654223|Grass pollen
64700|NCT02654223|Allergy
64701|NCT02654210|birth cohort
64702|NCT02654210|infectious diseases
64703|NCT02654210|microbiome
64704|NCT02654210|immune system
64705|NCT02654210|immune response
64706|NCT02654184|Right lateral
64707|NCT02654184|Induction
64708|NCT02654184|Children
64709|NCT02654184|Anesthesia
64710|NCT02654171|RSV
64711|NCT02654171|AK0529
64712|NCT02654158|acute upper respiratory infection
64713|NCT02654145|mepolizumab
64714|NCT02654145|Omalizumab
64715|NCT02654145|SGRQ
64716|NCT02654145|severe eosinophilic asthma
64717|NCT02654145|ACQ
64718|NCT02654145|exacerbations
64719|NCT02654106|multiple brain metastases
64720|NCT02654106|large brain metastases
64721|NCT02654106|meningeal metastases
64722|NCT02654106|fractionated stereotactic radiotherapy
64723|NCT02654106|temozolomide
64724|NCT02654054|Elagolix + E2/NETA
64725|NCT02654054|Menorrhagia
64726|NCT02654054|HMB
64727|NCT02654054|Elagolix + Norethindrone Acetate
64728|NCT02654054|ABT-620
64729|NCT02654054|Heavy Menstrual Bleeding
64730|NCT02654054|Heavy Uterine Bleeding
64731|NCT02654054|Elagolix Sodium
64732|NCT02654054|Leiomyomata
64733|NCT02654054|Elagolix
64734|NCT02654015|intracranial hemorrhage
64735|NCT02654015|neurosurgery
64736|NCT02653963|Steroid, Triamcinolone, Ahmed Glaucoma valve
64737|NCT02653937|IBS
64738|NCT02653937|MUPS
64739|NCT02653937|FSS
64740|NCT02653937|shigyakusan
64741|NCT02653937|Katsumi's points
64742|NCT02653937|Nakatani's N line
64743|NCT02653924|Suture
64744|NCT02653924|bacteria
64745|NCT02653911|Acupuncture
64746|NCT02653898|Malaria
64747|NCT02653898|Antimalarials
64748|NCT02653898|Malaria Elimination
64749|NCT02653898|Mass Drug Administration
64750|NCT02653898|Malaria Prophylaxis
64751|NCT02653898|Mobile population
64752|NCT02653898|Drug resistance
64753|NCT02653898|Focused screening and treatment
64754|NCT02653898|Monthly Malaria Prophylaxis
64755|NCT02653898|Mass screening and treatment
64756|NCT02653898|Primaquine
64757|NCT02653898|Malaria transmission
64758|NCT02653898|Permethrin insecticide
64759|NCT02653898|Thai-Cambodian border
64760|NCT02653898|Cambodia
64761|NCT02653898|AFRIMS
64762|NCT02653885|cardiac surgery
64763|NCT02653885|open heart surgery
64764|NCT02653885|hemogram
64765|NCT02653872|Non-randomized
64766|NCT02653872|Verapamil
64767|NCT02653872|Itraconazole
64768|NCT02653872|Diltiazem
64769|NCT02653872|Safety
64770|NCT02653872|Tolerability
64771|NCT02653872|Pharmacokinetics
64772|NCT02653859|CTC
64773|NCT02653859|PCR
64774|NCT02653833|Becker
64775|NCT02653833|Muscular Dystrophy
64776|NCT02653833|Skeletal Muscle
64777|NCT02653833|blood flow
64778|NCT02653833|Ranolazine
64779|NCT02653833|Ultrasound
64780|NCT02653807|manual therapy
64781|NCT02653807|osteopathy
64782|NCT02653807|mobilization with movement
64783|NCT02653807|ankle
64784|NCT02653807|stiffness
64785|NCT02653794|Juvenile Subjects'characteristics
64786|NCT02653768|Osteoarthritis, Knee
64787|NCT02653768|Exercise
64788|NCT02653755|Breast Cancer Radiation
64789|NCT02653755|Radiotherapy for Favorable-Risk Breast cancer
64790|NCT02653755|Radiotherapy Omission
64791|NCT02653729|cognitive behaviour therapy
64792|NCT02653729|first episode
64793|NCT02653716|New Orleans Intervention Model
64794|NCT02653716|Case Management
64795|NCT02653716|Maltreatment
64796|NCT02653716|Child
64797|NCT02653651|Ketamine
64798|NCT02653651|Lidocaine
64799|NCT02653651|Nephrectomy
64800|NCT02653651|Chronic pain
64801|NCT02653638|Cerebral Vasodilator Function
64802|NCT02653638|White Matter Hyperintensity Volume
64803|NCT02653638|Default Mode Network Connectivity
64804|NCT02653638|Cognitive Function
64805|NCT02653638|Cardiorespiratory Fitness
64806|NCT02653638|Aging
64807|NCT02653625|Primary Sclerosing Cholangitis
64808|NCT02653612|surgery
64809|NCT02653612|folate receptor
64810|NCT02653586|resilience
64811|NCT02653586|prevention program
64812|NCT02653586|body image
64813|NCT02653586|self esteem
64814|NCT02653573|young adult
64815|NCT02653560|Potassium
64816|NCT02653560|Magnesium
64817|NCT02653560|Citrate
64818|NCT02653560|DASH
64819|NCT02653547|tinnitus
64820|NCT02653547|transcranial random noise stimulation
64821|NCT02653547|rTMS
64822|NCT02653547|multisite stimulation
64823|NCT02653547|non-invasive brain stimulation
64824|NCT02653534|Kangaroo Mother Care in community
64825|NCT02653534|mortality
64826|NCT02653521|Esophageal Cancer
64827|NCT02653521|Adaptive Radiation Therapy
64828|NCT02653508|BMI: Body Mass Index
64829|NCT02653508|obesity
64830|NCT02653508|adolescents
64831|NCT02653508|overweight
64832|NCT02653508|CI:confidence interval
64833|NCT02653508|CDC: Center Disease Control
64834|NCT02653482|diabetes
64835|NCT02653482|heart failure
64836|NCT02653482|dapagliflozin
64837|NCT02653482|SGLT-2 inhibitors
64838|NCT02653443|INTERCEPT
64839|NCT02653443|Platelet
64840|NCT02653443|Pathogen Inactivation
64841|NCT02653443|Platelets Components Stored
64842|NCT02653443|Therapeutic Efficacy
64843|NCT02653430|obesity
64844|NCT02653430|BMI
64845|NCT02653430|efficacy
64846|NCT02653430|bariatric surgery
64847|NCT02653430|gut flora
64848|NCT02653430|fMRI
64849|NCT02653391|Fuchs' Corneal Endothelial Dystrophy
64850|NCT02653391|FCED
64851|NCT02653391|Ocuvia™
64852|NCT02653391|MTP-131
64853|NCT02653352|randomized controlled trials
64854|NCT02653352|soft drinks
64855|NCT02653352|hypercholesterolemia
64856|NCT02653352|serum cholesterol
64857|NCT02653352|blood glucose
64858|NCT02653352|overweight
64859|NCT02653352|carbonated beverages
64860|NCT02653339|traditional Chinese medicine
64861|NCT02653339|Loratadine
64862|NCT02653339|questionnaire survey
64863|NCT02653326|Tertiary Prevention
64864|NCT02653326|Telerehabilitation
64865|NCT02653287|Fatigue, Physical Activity, Lupus
64866|NCT02653274|MRI
64867|NCT02653274|blood glucose
64868|NCT02653274|satiety
64869|NCT02653274|breakfast
64870|NCT02653274|porridge
64871|NCT02653274|grains
64872|NCT02653261|tranexamic acid
64873|NCT02653261|Transurethral Resection of the Prostate (TURP)
64874|NCT02653261|Transurethral Resection of a Bladder Tumor (TURBT)
64875|NCT02653261|Hemorrhage
64876|NCT02653261|Blood Transfusion
64877|NCT02653222|Ethanol Sympathicolysis
64878|NCT02653222|Computer Tomography guidance
64879|NCT02653222|Denervation
64880|NCT02653222|Kidney Transplantation
64881|NCT02653222|Dialysis
64882|NCT02653209|Type 2 diabetes
64883|NCT02653209|Stratification
64884|NCT02653209|Biomarkers
64885|NCT02653209|Pharmacogenetics
64886|NCT02653209|SGLT2 inhibitors
64887|NCT02653209|Thiazolidinediones
64888|NCT02653209|DPP4 inhibitors
64889|NCT02653170|acute stroke
64890|NCT02653170|care transitions
64891|NCT02653170|patient engagement
64892|NCT02653170|patient education
64893|NCT02653170|caregivers
64894|NCT02653170|social workers
64895|NCT02653157|multidrug resistance
64896|NCT02653157|burns
64897|NCT02653157|infections, gram-negative bacilli
64898|NCT02653157|ventilator-associated pneumonia
64899|NCT02653157|ventilator-associated tracheobronchitis
64900|NCT02653157|gram-negative bacilli colonization
64901|NCT02653144|post operative pain, Dexmedetomidine, Regional anesthesia
64902|NCT02653131|Short bowel syndrome
64903|NCT02653105|High risk of cancer, BRCA1 or 2 mutation, Olfactomedine 4
64904|NCT02653066|recruitment
64905|NCT02653040|Lighting
64906|NCT02653040|Inpatients
64907|NCT02653040|Recovery
64908|NCT02653040|Sleep
64909|NCT02653027|Genetics
64910|NCT02652988|tDCS
64911|NCT02652988|chronic pain
64912|NCT02652988|fibromyalgia
64913|NCT02652923|ultrasound contrast agent
64914|NCT02652923|lymphosonography
64915|NCT02652923|breast cancer
64916|NCT02652897|bleeding
64917|NCT02652897|clotting tests
64918|NCT02652897|neurosurgery
64919|NCT02652897|clotting time
64920|NCT02652897|maximum clot firmness
64921|NCT02652897|kinetics
64922|NCT02652897|lysis
64923|NCT02652897|primary hemostasis
64924|NCT02652897|platelet dysfunction
64925|NCT02652897|coagulation
64926|NCT02652884|transient hypoparathyroidism
64927|NCT02652884|steroids
64928|NCT02652884|total thyroidectomy
64929|NCT02652871|Leukemia
64930|NCT02652871|Acute Myeloid Leukemia
64931|NCT02652871|AML
64932|NCT02652871|Relapsed or Refractory
64933|NCT02652871|Acute myelogenous leukemia
64934|NCT02652871|LY2510924
64935|NCT02652871|Idarubicin
64936|NCT02652871|Idamycin
64937|NCT02652871|Cytarabine
64938|NCT02652871|Ara-C
64939|NCT02652871|Cytosar
64940|NCT02652871|DepoCyt
64941|NCT02652871|Cytosine Arabinosine Hydrochloride
64942|NCT02652819|Chronic Kidney Disease
64943|NCT02652806|Chronic Kidney Disease
64944|NCT02652780|Leber Hereditary Optic Neuropathy
64945|NCT02652780|Leber Hereditary Optic Atrophy
64946|NCT02652780|Heredity Optic Atrophy
64947|NCT02652780|Eye Diseases
64948|NCT02652780|Hereditary Eye Diseases
64949|NCT02652780|Inborn Genetic Disease
64950|NCT02652780|Genetic Therapy
64951|NCT02652780|Intravitreal Injections
64952|NCT02652780|Mitochondrial Disease
64953|NCT02652780|AAV2 Vectors
64954|NCT02652780|Nervous System Diseases
64955|NCT02652780|Neurodegenerative Disease
64956|NCT02652780|Heredodegenerative Disorders of the Nervous System
64957|NCT02652767|Leber Hereditary Optic Neuropathy
64958|NCT02652767|Leber Hereditary Optic Atrophy
64959|NCT02652767|Heredity Optic Atrophy
64960|NCT02652767|Eye Diseases
64961|NCT02652767|Hereditary Eye Diseases
64962|NCT02652767|Inborn Genetic Disease
64963|NCT02652767|Genetic Therapy
64964|NCT02652767|Intravitreal Injections
64965|NCT02652767|Mitochondrial Disease
64966|NCT02652767|AAV2 Vectors
64967|NCT02652767|Nervous System Diseases
64968|NCT02652767|Neurodegenerative Disease
64969|NCT02652767|Heredodegenerative Disorders of the Nervous System
64970|NCT02652754|Granexin
64971|NCT02652754|diabetic foot ulcers
64972|NCT02652754|pharmacokinetic study
64973|NCT02652754|FirstString Research
64974|NCT02652702|circular stapler-assisted colostomy
64975|NCT02652689|pulmonary embolism
64976|NCT02652689|pulmonary disease
64977|NCT02652689|Lung Doppler signals
64978|NCT02652676|Infant Cardiac Transplantation
64979|NCT02652676|End-stage Idiopathic Dilated Cardiomyopathy
64980|NCT02652676|Mechanical Circulatory Device
64981|NCT02652676|End Stage Dilated Left Ventriculopathy
64982|NCT02652676|Acute-on-Chronic Left Ventricular Failure
64983|NCT02652663|colorectal cancer
64984|NCT02652663|liver
64985|NCT02652663|MRI
64986|NCT02652663|contrast
64987|NCT02652663|gadoxetic acid
64988|NCT02652650|Healthy
64989|NCT02652650|JNJ-63623872
64990|NCT02652650|Ethinylestradiol
64991|NCT02652650|Norethindrone
64992|NCT02652611|Screw Removal vs. Non-screw removal
64993|NCT02652611|Complications
64994|NCT02652611|SI Screw Stabilization
64995|NCT02652585|Alcoholism
64996|NCT02652585|alcohol self-administration
64997|NCT02652572|Granexin
64998|NCT02652572|venous leg ulcer
64999|NCT02652572|pharmacokinetic study
65000|NCT02652572|FirstString Research
65001|NCT02652559|Chronic Obstructive Pulmonary Disease
65002|NCT02652559|Non-invasive ventilation
65003|NCT02652559|Home initiation
65004|NCT02652546|HIV/AIDS
65005|NCT02652546|Immune Activation
65006|NCT02652546|Anti-Inflammatory
65007|NCT02652546|TNF
65008|NCT02652546|Phosphodieterase Inhibitor
65009|NCT02652520|Kidney transplantation
65010|NCT02652520|Organ preservation
65011|NCT02652507|Sedation
65012|NCT02652507|MRI
65013|NCT02652507|Dexmedetomidine
65014|NCT02652507|Ketamine
65015|NCT02652507|General anesthesia
65016|NCT02652507|MRI of Brain
65017|NCT02652507|MRI of Brain/Spine
65018|NCT02652494|Psoriasis
65019|NCT02652494|Observational
65020|NCT02652494|Apremilast
65021|NCT02652494|APRIL
65022|NCT02652494|Non-Interventional
65023|NCT02652494|The Netherlands
65024|NCT02652455|cutaneous
65025|NCT02652455|unresectable
65026|NCT02652455|mucosal metastatic stage III/IV melanoma
65027|NCT02652455|ocular metastatic stage III/IV melanoma
65028|NCT02652442|dizziness
65029|NCT02652442|postural balance
65030|NCT02652442|rehabilitation
65031|NCT02652429|PAH
65032|NCT02652429|Pulmonary Arterial Hypertension
65033|NCT02652429|Inhaled Nitric Oxide
65034|NCT02652429|iNO
65035|NCT02652403|Denture, Complete
65036|NCT02652403|Mouth, Edentulous
65037|NCT02652351|Stem cell
65038|NCT02652351|Human Umbilical Cord Mesenchymal Stem Cell
65039|NCT02652351|Mesenchymal Stem Cell
65040|NCT02652351|Hepatic Cirrhosis
65041|NCT02652338|heart rhythm disturbances and symptoms
65042|NCT02652338|dietary supplement
65043|NCT02652312|Dexmedetomidine
65044|NCT02652312|Desflurane
65045|NCT02652312|Bispectral Index BIS
65046|NCT02652299|Fibrocytes
65047|NCT02652299|Synovial biopsy
65048|NCT02652286|VATS
65049|NCT02652286|Energy sealing
65050|NCT02652247|trauma
65051|NCT02652247|ventilator
65052|NCT02652247|surgical ICU
65053|NCT02652208|decision making
65054|NCT02652208|decision aids
65055|NCT02652208|shared decision making
65056|NCT02652208|stable angina
65057|NCT02652208|cardiology
65058|NCT02652195|Neural correlates
65059|NCT02652195|oxytocin administration
65060|NCT02652156|transversus abdominis plane
65061|NCT02652156|postoperative
65062|NCT02652156|pain
65063|NCT02652143|in vivo culture
65064|NCT02652130|GVHD, Graft versus Host Disease
65065|NCT02652104|Advanced
65066|NCT02652104|Deep brain stimulation
65067|NCT02652091|Adherence
65068|NCT02652091|Persistence
65069|NCT02652091|Patient satisfaction
65070|NCT02652065|Psoriasis
65071|NCT02652065|Microcirculation
65072|NCT02652065|TRPV1
65073|NCT02652026|dental root planing and scaling
65074|NCT02652026|periodontal disease
65075|NCT02652026|type 2 diabetes mellitus
65076|NCT02652026|glycosylated hemoglobin A
65077|NCT02651974|neoplasm
65078|NCT02651974|colorectal
65079|NCT02651974|cancer
65080|NCT02651974|uninsured
65081|NCT02651974|FIT
65082|NCT02651974|fecal immunochemical test
65083|NCT02651961|Total hip prosthesis
65084|NCT02651961|Total knee prosthesis
65085|NCT02651961|Chronic infection
65086|NCT02651961|One stage exchange
65087|NCT02651961|Two stage exchange
65088|NCT02651961|Cost-effectiveness
65089|NCT02651935|Respiration, Artificial
65090|NCT02651935|weaning
65091|NCT02651935|critical care
65092|NCT02651922|Nervous restlessness
65093|NCT02651922|Pascoflair
65094|NCT02651922|Passiflora incarnata
65095|NCT02651922|Benzodiazepine
65096|NCT02651883|Cervical cancer screening
65097|NCT02651883|HPV testing
65098|NCT02651883|Self-collection
65099|NCT02651870|Hypertension
65100|NCT02651844|Progesterone receptor isoforms
65101|NCT02651844|Antiprogestins
65102|NCT02651844|Mifepristone
65103|NCT02651844|Neoadjuvant
65104|NCT02651844|Breast cancer
65105|NCT02651831|ICMs
65106|NCT02651831|Immune checkpoint modulators
65107|NCT02651818|Goiter
65108|NCT02651818|Thyroid disease
65109|NCT02651818|Struma
65110|NCT02651805|Palliative Care
65111|NCT02651805|Respiratory Secretion
65112|NCT02651792|ketamine
65113|NCT02651792|propofol
65114|NCT02651792|pethidine
65115|NCT02651792|ERCP
65116|NCT02651792|endoscopist
65117|NCT02651740|Rifaximin
65118|NCT02651740|Fecal microbiota transplantation
65119|NCT02651610|PPHM 1401
65120|NCT02651610|bavituximab
65121|NCT02651610|Peregrine
65122|NCT02651610|Breast Cancer
65123|NCT02651610|HER-2 Negative
65124|NCT02651610|HER2 Negative
65125|NCT02651597|Oatmeal
65126|NCT02651597|Beta glucan
65127|NCT02651597|Postprandial Glycemic Response
65128|NCT02651597|Blood Glucose
65129|NCT02651571|Knee
65130|NCT02651571|Replacement
65131|NCT02651571|Prosthesis
65132|NCT02651571|Mobile-bearing
65133|NCT02651532|Confocal Laser Endomicroscopy
65134|NCT02651532|inflammation
65135|NCT02651532|Irritable Bowel Syndrome
65136|NCT02651519|bispectral index
65137|NCT02651519|regional cerebral oxygen saturation
65138|NCT02651519|Stellate-ganglion block
65139|NCT02651506|Lung cancer biopsy
65140|NCT02651506|Electromagnetic Navigation Bronchoscopy
65141|NCT02651506|Transthoracic Needle Biopsy
65142|NCT02651480|Diet, Vegetarian
65143|NCT02651480|Diet, Fat-Restricted
65144|NCT02651480|Quality of Life
65145|NCT02651480|Glycemic Index
65146|NCT02651454|metabolic syndrome
65147|NCT02651454|Daesiho-tang
65148|NCT02651454|Taeeumjowi-tang
65149|NCT02651454|Korean medicine
65150|NCT02651441|D-CIK
65151|NCT02651441|lung cancer
65152|NCT02651428|Kidney Failure, Chronic
65153|NCT02651428|Catheter-Related Infections
65154|NCT02651428|Central Venous Catheter
65155|NCT02651415|Metastatic colorectal cancer
65156|NCT02651415|Metastatic colorectal carcinoma
65157|NCT02651415|mCRC
65158|NCT02651415|Regorafenib
65159|NCT02651415|Stivarga
65160|NCT02651415|Perindopril
65161|NCT02651415|Perindopril erbumine
65162|NCT02651415|Coversyl
65163|NCT02651402|Anxiety Disorders
65164|NCT02651402|Internalizing
65165|NCT02651402|Anxiety
65166|NCT02651389|Digital Orthoptic Platform
65167|NCT02651389|Vision test
65168|NCT02651376|Immunodeficiency
65169|NCT02651376|Allogenic HLA-Mismatched Stem-Cell Transplantation
65170|NCT02651350|Drug-induced Liver Injury
65171|NCT02651350|Recurrence
65172|NCT02651350|Methylprednisolone
65173|NCT02651285|G-CSF
65174|NCT02651285|BLASTOCYST
65175|NCT02651285|IVF
65176|NCT02651272|Pulmonary Hypertension
65177|NCT02651272|Sickle Cell Disease
65178|NCT02651272|Pulmonary Arterial Hypertension
65179|NCT02651272|Macitentan
65180|NCT02651194|Treatment-naïve
65181|NCT02651194|HCV Gentoype 6
65182|NCT02651194|HCV Gentoype 1
65183|NCT02651194|Compensated cirrhotic
65184|NCT02651194|HCV Gentoype 2
65185|NCT02651194|Treatment-experienced
65186|NCT02651194|Non-cirrhotic
65187|NCT02651194|Chronic Hepatitis C
65188|NCT02651194|HCV Gentoype 5
65189|NCT02651194|HCV Gentoype 3
65190|NCT02651194|HCV Gentoype 4
65191|NCT02651168|Diabetic Macular Edema
65192|NCT02651168|Ocular Cytokines
65193|NCT02651168|aflibercept
65194|NCT02651168|ranibizumab
65195|NCT02651155|Drug therapy
65196|NCT02651129|noise
65197|NCT02651129|obstetric
65198|NCT02651129|operating rooms
65199|NCT02651116|cough, acute cough, pediatric, Dextromethorphan Hydrobromide, antitussive, ambulatory cough recording device
65200|NCT02651090|contraindication for CECT
65201|NCT02651090|contraindication for CEMRI
65202|NCT02651090|liver pathology
65203|NCT02651090|renal failure
65204|NCT02651090|contrast enhanced ultrasound
65205|NCT02651090|sonazoid
65206|NCT02651077|Endometriosis, chemical contaminants, BFRs
65207|NCT02651064|Supplemental Nutrition Assistance Program (SNAP)
65208|NCT02651064|fruits and vegetables
65209|NCT02651064|price incentive
65210|NCT02651051|Postprandial glycemia
65211|NCT02651051|Metabolic health measures
65212|NCT02651012|acne
65213|NCT02651012|acne vulgaris
65214|NCT02651012|papule
65215|NCT02651012|pustule
65216|NCT02651012|adolescent acne
65217|NCT02650973|Bioequivalence
65218|NCT02650947|Sucralose
65219|NCT02650947|Insulin Secretion
65220|NCT02650947|Insulin Sensitivity
65221|NCT02650947|Incretin
65222|NCT02650947|Gut Microbiota
65223|NCT02650947|Food and Eating Behaviour
65224|NCT02650947|Healthy Volunteers
65225|NCT02650934|STEMI, Heart Failure, Inflammation, Haptoglobin Polymorphisms, Adverse Remodeling, Genetics, GWAS, MRI
65226|NCT02650908|Lesion
65227|NCT02650908|Meniscus
65228|NCT02650908|Avivement
65229|NCT02650908|Suturing area
65230|NCT02650882|Respiratory muscles
65231|NCT02650882|athletic performance
65232|NCT02650882|handball
65233|NCT02650869|Necrotizing Enterocolitis
65234|NCT02650869|probiotics
65235|NCT02650869|very low birth weight
65236|NCT02650856|Blood loss
65237|NCT02650856|Tranexamic acid
65238|NCT02650856|Platelet rich plasma
65239|NCT02650856|Total knee arthroplasty
65240|NCT02650843|Parkinsonism
65241|NCT02650843|DAT Dopamine transporter
65242|NCT02650843|SPECT
65243|NCT02650830|type 2 diabetes
65244|NCT02650830|prediabetes
65245|NCT02650830|bile acids profile
65246|NCT02650830|GLP-1
65247|NCT02650830|FGF-19
65248|NCT02650804|Cancer
65249|NCT02650804|Advanced Pancreatic Cancer
65250|NCT02650778|Breast Cancer
65251|NCT02650778|Automated whole breast ultrasound
65252|NCT02650778|BI-RADS category 3 lesions
65253|NCT02650765|Brain injury
65254|NCT02650765|Head injury
65255|NCT02650765|Computed tomography
65256|NCT02650765|Emergency department
65257|NCT02650752|Lapatinib
65258|NCT02650752|Capecitabine
65259|NCT02650752|HER2
65260|NCT02650752|15-278
65261|NCT02650687|Postoperative Cognitive Dysfunction
65262|NCT02650687|Elderly, geriatric
65263|NCT02650687|Anesthesia
65264|NCT02650687|Anesthetic depth
65265|NCT02650687|Bispectral index monitor
65266|NCT02650687|Function
65267|NCT02650687|Recovery after surgery
65268|NCT02650687|Surgery
65269|NCT02650674|glycemic & insulin response
65270|NCT02650674|SDS
65271|NCT02650674|cereal product
65272|NCT02650674|Nutrition
65273|NCT02650674|Carbohydrate
65274|NCT02650674|Absorption
65275|NCT02650674|Intestine
65276|NCT02650661|Cancer survivors
65277|NCT02650648|Humanized Anti-GD2 Antibody Hu3F8
65278|NCT02650648|Allogeneic Natural Killer Cells
65279|NCT02650648|rIL-2
65280|NCT02650648|15-272
65281|NCT02650622|Metabolism
65282|NCT02650622|Genetics
65283|NCT02650622|Metabolomics
65284|NCT02650622|Genomics
65285|NCT02650609|chronic subdural hematomas
65286|NCT02650609|surgical treatment
65287|NCT02650609|corticosteroids
65288|NCT02650570|Cancer
65289|NCT02650570|Cachexia
65290|NCT02650557|coronary slow flow
65291|NCT02650557|P-wave dispersion
65292|NCT02650544|Carcinoma, Non-Small-Cell Lung
65293|NCT02650544|Depression
65294|NCT02650544|mirtazapine
65295|NCT02650544|patients health questionnaire (PHQ-9)
65296|NCT02650531|Follow up studies
65297|NCT02650531|Risk factors
65298|NCT02650518|Catheter-Associated Urinary Tract Infections
65299|NCT02650518|Antimicrobial Stewardship
65300|NCT02650518|Short-Course Antimicrobials
65301|NCT02650492|Hyperthermia, Induced
65302|NCT02650492|Laser Coagulation
65303|NCT02650492|Laser Therapy
65304|NCT02650453|Stent
65305|NCT02650453|Angioplasty
65306|NCT02650453|Endophlebectomy
65307|NCT02650440|robotics
65308|NCT02650440|locomotion
65309|NCT02650440|gait
65310|NCT02650440|walking
65311|NCT02650440|rehabilitation
65312|NCT02650414|Biological: CART 22
65313|NCT02650401|TRK
65314|NCT02650401|Tyrosine kinase
65315|NCT02650401|NTRK
65316|NCT02650401|NTRK1
65317|NCT02650401|NTRK2
65318|NCT02650401|NTRK3
65319|NCT02650401|ROS1
65320|NCT02650401|ALK
65321|NCT02650401|Pediatric
65322|NCT02650401|Relapsed
65323|NCT02650401|Refractory
65324|NCT02650401|Solid Tumor
65325|NCT02650401|Metastatic Cancer
65326|NCT02650401|Gene rearrangement
65327|NCT02650401|Neuroblastoma
65328|NCT02650401|Infantile fibrosarcoma
65329|NCT02650401|Secretory breast cancer
65330|NCT02650401|Congenital mesoblastic nephroma
65331|NCT02650401|Pontine glioma
65332|NCT02650401|Brain tumors
65333|NCT02650401|CNS tumors
65334|NCT02650401|Sarcoma
65335|NCT02650401|Ewing sarcoma
65336|NCT02650401|Glial tumors
65337|NCT02650401|Salivary Gland Cancer (MASC)
65338|NCT02650401|Papillary thyroid cancer
65339|NCT02650401|Medulloblastoma
65340|NCT02650401|Wilms tumor (anaplastic)
65341|NCT02650362|spinal cord stimulation
65342|NCT02650362|resting state functional magnetic resonance
65343|NCT02650362|voxel-based magnetic resonance morphometry
65344|NCT02650349|spinal cord stimulation
65345|NCT02650349|resting state functional magnetic resonance
65346|NCT02650349|voxel-based magnetic resonance morphometry
65347|NCT02650297|Lymphedema secondary to breast cancer
65348|NCT02650297|Breast cancer
65349|NCT02650297|Body image
65350|NCT02650271|adjuvant
65351|NCT02650271|entecavir
65352|NCT02650271|hepatocellular carcinoma
65353|NCT02650271|hepatic resection
65354|NCT02650245|breath
65355|NCT02650245|gastroenterology
65356|NCT02650245|ammonia
65357|NCT02650245|blood
65358|NCT02650245|protein
65359|NCT02650245|cirrhosis
65360|NCT02650245|encephalopathy
65361|NCT02650232|Volunteers
65362|NCT02650206|diabetes
65363|NCT02650206|macrophage
65364|NCT02650206|inflammation
65365|NCT02650206|adipose tissue
65366|NCT02650206|weight loss
65367|NCT02650206|liraglutide
65368|NCT02650193|HSP-130 Phase 1-2 Study in patients with Breast cancer
65369|NCT02650180|Rehabilitation
65370|NCT02650154|sedation
65371|NCT02650154|children
65372|NCT02650154|infants
65373|NCT02650154|ketamine
65374|NCT02650154|neurotoxicity
65375|NCT02650128|Coronary Artery Disease
65376|NCT02650128|Calcified Coronary Lesions
65377|NCT02650128|Coronary Arterial Stenosis
65378|NCT02650089|Resistance Exercise
65379|NCT02650089|Postexercise Hypotension
65380|NCT02650089|Sympathovagal balance
65381|NCT02650089|Professor
65382|NCT02650011|Chronic liver disease
65383|NCT02650011|Liver cirrhosis
65384|NCT02649998|Fursemide
65385|NCT02649998|Isosorbide Dinitrate
65386|NCT02649998|Heart Decompensation
65387|NCT02649998|Clinical Trials, Randomized
65388|NCT02649998|Clinical Efficacy
65389|NCT02649972|Cobimetinib
65390|NCT02649972|15-216
65391|NCT02649959|Autism
65392|NCT02649933|pregnancy
65393|NCT02649933|obstructive sleep apnea
65394|NCT02649920|unfavorable cervix
65395|NCT02649920|obese pregnant women
65396|NCT02649894|malignant pleural effusion
65397|NCT02649881|macrophage
65398|NCT02649881|vulnerable coronary plaque
65399|NCT02649868|Radio-Opaque Bland Beads
65400|NCT02649868|Thermal Ablation
65401|NCT02649868|Transarterial Embolization
65402|NCT02649855|PSA
65403|NCT02649855|Vaccine
65404|NCT02649855|Immunotherapy
65405|NCT02649855|Immune Response
65406|NCT02649855|Androgen Deprivation Therapy
65407|NCT02649829|dendritic cell vaccination
65408|NCT02649829|chemo-immunotherapy
65409|NCT02649829|Wilms' tumor 1 (WT1)
65410|NCT02649816|Pit and fissure sealants
65411|NCT02649816|Dental Caries
65412|NCT02649816|Prevention
65413|NCT02649816|Dental undergraduate students
65414|NCT02649816|patient's caries risk
65415|NCT02649803|pediatric
65416|NCT02649803|asthma control
65417|NCT02649803|community
65418|NCT02649790|Multiple Myeloma
65419|NCT02649790|Karyopharm
65420|NCT02649790|KPT-8602
65421|NCT02649790|MM
65422|NCT02649790|Phase 1
65423|NCT02649790|Relapsed/refractory Multiple Myeloma
65424|NCT02649777|oxidative stress
65425|NCT02649764|Acute Myelogenous Leukemia
65426|NCT02649764|AML
65427|NCT02649764|Relapsed/Refractory
65428|NCT02649764|High-Risk Myelodysplastic Syndrome
65429|NCT02649764|HRMDS
65430|NCT02649764|LY2606368
65431|NCT02649764|Fludarabine
65432|NCT02649764|Fludarabine Phosphate
65433|NCT02649764|Fludara
65434|NCT02649764|Cytarabine
65435|NCT02649764|Ara-C
65436|NCT02649764|Cytosar
65437|NCT02649764|DepoCyt
65438|NCT02649764|Cytosine Arabinosine Hydrochloride
65439|NCT02649751|Cystic Fibrosis
65440|NCT02649751|Roscovitine
65441|NCT02649751|Seliciclib
65442|NCT02649751|CYC202
65443|NCT02649738|keratoconus
65444|NCT02649738|corneal tissue inlay
65445|NCT02649699|Primary Brain Cancer
65446|NCT02649673|lung carcinoma
65447|NCT02649673|topotecan
65448|NCT02649673|Hycamtin
65449|NCT02649673|ovarian neoplasms
65450|NCT02649673|LCL161
65451|NCT02649673|IAP inhibitors
65452|NCT02649660|Fabry Disease
65453|NCT02649660|Platelets
65454|NCT02649660|Lipidomics
65455|NCT02649660|Sphingolipids
65456|NCT02649660|α-Galactosidase A
65457|NCT02649660|Globotriaosylceramide
65458|NCT02649660|Gb3
65459|NCT02649660|GL-3
65460|NCT02649660|CD77
65461|NCT02649660|Alpha-galactosidase
65462|NCT02649660|Platelet activation
65463|NCT02649660|Lysosomal storage disease
65464|NCT02649660|LysoGb3
65465|NCT02649660|Spingosine-1-Phosphate
65466|NCT02649660|Platelet function
65467|NCT02649660|CD62P
65468|NCT02649660|P-selectin
65469|NCT02649647|Rectal cancer
65470|NCT02649647|Neoadjuvant therapy
65471|NCT02649647|Chemoradiotherapy
65472|NCT02649647|Resection margin
65473|NCT02649647|Bowel function
65474|NCT02649647|Anastomosis
65475|NCT02649634|Motivational Interviewing
65476|NCT02649634|Obesity
65477|NCT02649634|Weight Loss
65478|NCT02649634|Behavioral Medicine
65479|NCT02649621|Limbal Stem Cell Deficiency Amniotic Membrane Extract Eye Drop in vivo cultivation
65480|NCT02649595|Homeless
65481|NCT02649595|Homelessness
65482|NCT02649595|Respite care
65483|NCT02649595|EQ-5D
65484|NCT02649595|Quality of life questionnaire
65485|NCT02649595|Economic evaluation
65486|NCT02649595|Cost-utility analysis
65487|NCT02649582|Dendritic cells
65488|NCT02649582|Chemoimmunotherapy
65489|NCT02649582|Adjuvant therapy
65490|NCT02649556|Candidate modified risk tobacco product
65491|NCT02649556|Conventional cigarette
65492|NCT02649556|Exposure response
65493|NCT02649556|Smoking
65494|NCT02649556|Tobacco Heating System
65495|NCT02649543|Surgical Wound Infection
65496|NCT02649543|Negative-Pressure Wound Therapy
65497|NCT02649543|Wound Closure Techniques
65498|NCT02649543|Laparotomy.
65499|NCT02649543|Abdominal Wound Closure Techniques
65500|NCT02649517|decompensated heart failure
65501|NCT02649517|ischemic heart disease
65502|NCT02649517|inflammatory cardiomyopathy
65503|NCT02649491|Radiotherapy
65504|NCT02649491|Chemotherapy
65505|NCT02649491|Metabonomics
65506|NCT02649491|Electronic Sensing
65507|NCT02649491|GI Toxicity
65508|NCT02649452|Whole body Vibration
65509|NCT02649439|Vaccine
65510|NCT02649439|PSA
65511|NCT02649439|Surveillance
65512|NCT02649439|Immunotherapy
65513|NCT02649426|denervation
65514|NCT02649426|resistant hypertension
65515|NCT02649426|essential hypertension
65516|NCT02649361|Anlotinib
65517|NCT02649335|Non selective beta blockers
65518|NCT02649335|Ascites
65519|NCT02649309|Ischemic Preconditioning
65520|NCT02649309|Postconditioning
65521|NCT02649309|Angioplasty
65522|NCT02649270|Tolerability
65523|NCT02649270|Safety
65524|NCT02649270|Pharmacokinetic Study
65525|NCT02649270|preliminary pharmacodynamic study
65526|NCT02649270|Humanized Anti-CD6 Monoclonal Antibody(T1h)
65527|NCT02649257|IOL rotation
65528|NCT02649257|capsular tension ring
65529|NCT02649257|IOL rotational stability
65530|NCT02649218|QGE031
65531|NCT02649218|chronic
65532|NCT02649218|spontaneous
65533|NCT02649218|Urticaria
65534|NCT02649218|CSU
65535|NCT02649218|adults
65536|NCT02649218|Safety
65537|NCT02649192|Children
65538|NCT02649192|Vitamin Supplements
65539|NCT02649192|Influenza virus vaccine
65540|NCT02649166|Essential tremor
65541|NCT02649166|Kinetic tremor
65542|NCT02649166|Intention tremor
65543|NCT02649140|24-hour urine
65544|NCT02649140|Calcium oxalate
65545|NCT02649140|Vinegar
65546|NCT02649127|exercise
65547|NCT02649127|biomarker
65548|NCT02649088|microcirculation
65549|NCT02649088|tissue oxygenation
65550|NCT02649088|outcome
65551|NCT02649075|IBD
65552|NCT02649075|Inflammatory Bowel Disease
65553|NCT02649075|Crohn's
65554|NCT02649075|Crohns
65555|NCT02649075|SBI
65556|NCT02649075|Serum-derived bovine immunoglobulin / protein isolate
65557|NCT02649075|EnteraGam
65558|NCT02649010|Type 1 Diabetes
65559|NCT02649010|Type 2 Diabetes
65560|NCT02649010|Enlite 3 Sensor
65561|NCT02649010|Continuous Glucose Monitoring
65562|NCT02648997|Atypical Meningioma
65563|NCT02648997|Anaplastic Meningioma
65564|NCT02648984|Pulmonary vascular disease
65565|NCT02648971|knee
65566|NCT02648971|arthroscopy
65567|NCT02648971|portal
65568|NCT02648971|meniscus
65569|NCT02648971|cartilage injury
65570|NCT02648932|Acute Myeloid Leukemia (AML)
65571|NCT02648932|High-Risk Myelodysplastic Syndrome (MDS)
65572|NCT02648932|hematopoietic cell transplantation
65573|NCT02648932|haplo-cord search
65574|NCT02648932|matched unrelated donor search
65575|NCT02648893|iron
65576|NCT02648893|zinc
65577|NCT02648893|vitamin A
65578|NCT02648893|biofortified
65579|NCT02648893|efficacy
65580|NCT02648893|India
65581|NCT02648893|infant
65582|NCT02648893|trial
65583|NCT02648880|Exercise
65584|NCT02648880|Physical Activity
65585|NCT02648841|gastric cancer
65586|NCT02648841|adjuvant chemo-radiotherapy
65587|NCT02648828|Judgment
65588|NCT02648828|risk assessment
65589|NCT02648828|clinical deterioration
65590|NCT02648828|cardiac arrest
65591|NCT02648828|Rothman Index
65592|NCT02648815|Necrotizing pancreatitis
65593|NCT02648815|Sepsis
65594|NCT02648815|Infection
65595|NCT02648815|Drainage
65596|NCT02648802|breast-conserving surgery(BCS)
65597|NCT02648802|Cavity shave margin
65598|NCT02648802|Proportion of positive margins
65599|NCT02648789|Primary oral cancer
65600|NCT02648789|DNA methylation
65601|NCT02648789|Recurrence oral cancer
65602|NCT02648776|hypnotic agents
65603|NCT02648776|sleep disorders
65604|NCT02648776|elderly
65605|NCT02648750|self-management
65606|NCT02648750|rehabilitation
65607|NCT02648737|Parkinson's disease
65608|NCT02648737|Cognitive Behavioural therapy
65609|NCT02648737|generalized anxiety disorder
65610|NCT02648737|social phobia
65611|NCT02648737|cerebral connectivity
65612|NCT02648724|Advanced Solid Tumor Malignancies
65613|NCT02648711|solid tumors
65614|NCT02648698|chronic endometritis
65615|NCT02648698|CD138
65616|NCT02648685|post prandial glucose (PPG)
65617|NCT02648685|basal blood glucose (BBG)
65618|NCT02648685|overall glycaemia
65619|NCT02648633|Brain Cancer
65620|NCT02648633|Immunotherapy
65621|NCT02648633|Nivolumab
65622|NCT02648633|Radiosurgery
65623|NCT02648633|Gamma Knife
65624|NCT02648620|Paclitaxel
65625|NCT02648620|Percutaneous Transluminal Angioplasty
65626|NCT02648620|PAD
65627|NCT02648620|Peripheral Artery Disease
65628|NCT02648620|Pharmacokinetics
65629|NCT02648607|Pelvic Girdle Pain
65630|NCT02648607|Chronic Pelvic Girdle Pain
65631|NCT02648607|Symphysis Pubis Dysfunction
65632|NCT02648607|Sacroiliac Joint Dysfunction
65633|NCT02648607|Physiotherapy
65634|NCT02648607|Physical Therapy
65635|NCT02648607|Orthoses
65636|NCT02648607|Orthosis
65637|NCT02648607|Orthotic Devices
65638|NCT02648594|lung
65639|NCT02648594|thoracoscopy
65640|NCT02648594|hook wire localization
65641|NCT02648581|Behçet
65642|NCT02648581|ulcers
65643|NCT02648581|uveitis
65644|NCT02648581|ustekinumab
65645|NCT02648581|biologics
65646|NCT02648568|Sleepwalking
65647|NCT02648568|sleep terrors
65648|NCT02648568|arousal disorders
65649|NCT02648568|F513 (CIM-10)
65650|NCT02648568|F514 (CIM-10)
65651|NCT02648529|Benign childhood epilepsy with centro-temporal spikes
65652|NCT02648529|rolandic epilepsy
65653|NCT02648529|brain development
65654|NCT02648529|DTI
65655|NCT02648529|functional MRI
65656|NCT02648529|structural MRI
65657|NCT02648529|idiopathic focal epilepsy
65658|NCT02648529|cryptogenic epilepsy of childhood
65659|NCT02648516|Immune Reconstitution
65660|NCT02648516|Allogenic HLA-Mismatched Stem-Cell Transplantation
65661|NCT02648503|Sugammadex
65662|NCT02648503|Post-operative Quality Recovery Scale (PQRS)
65663|NCT02648490|metastatic or recurrent epithelial cancer
65664|NCT02648464|Hydroxychloroquine
65665|NCT02648464|anti-inflammatory
65666|NCT02648464|Myocardial infarction
65667|NCT02648464|cardiovascular diseases
65668|NCT02648438|AZD7594
65669|NCT02648438|Bioavailability
65670|NCT02648438|Healthy male subjects
65671|NCT02648438|Safety
65672|NCT02648438|Tolerability
65673|NCT02648438|Pharmacokinetics
65674|NCT02648438|Monodose inhaler
65675|NCT02648438|Multiple-dose dry powder inhaler
65676|NCT02648425|ASLAN001
65677|NCT02648399|thyroid carcinoma
65678|NCT02648399|center lymph node dissection
65679|NCT02648360|exercise
65680|NCT02648360|diet
65681|NCT02648360|patients, underserved
65682|NCT02648360|text messaging
65683|NCT02648347|vadadustat
65684|NCT02648347|AKB-6548
65685|NCT02648347|Chronic kidney disease
65686|NCT02648347|anemia
65687|NCT02648347|CKD
65688|NCT02648347|chronic renal insufficiency
65689|NCT02648347|renal impairment
65690|NCT02648347|erythropoietin
65691|NCT02648347|kidney
65692|NCT02648347|renal
65693|NCT02648347|oral anemia treatment
65694|NCT02648347|hemoglobin
65695|NCT02648347|hypoxia-inducible factor
65696|NCT02648347|HIF
65697|NCT02648347|hypoxia-inducible factor prolyl-hydroxylase inhibitor
65698|NCT02648347|HIF-PHI
65699|NCT02648347|efficacy
65700|NCT02648347|safety
65701|NCT02648347|Phase 3
65702|NCT02648347|cardiovascular
65703|NCT02648347|NDD-CKD
65704|NCT02648334|Drug-Coated Balloon
65705|NCT02648334|Superficial Femoral artery
65706|NCT02648334|popliteal peripheral Artery
65707|NCT02648321|Motivational Interviewing
65708|NCT02648321|Exercise
65709|NCT02648308|Education, Medical
65710|NCT02648282|vaccine
65711|NCT02648282|immunotherapy
65712|NCT02648282|antibody
65713|NCT02648282|PD-1
65714|NCT02648282|radiation
65715|NCT02648256|Pneumocystis jirovecii
65716|NCT02648256|Polymerase Chain Reaction
65717|NCT02648256|Oropharyngeal Rinse
65718|NCT02648243|Qatar
65719|NCT02648243|Acute Coronary Syndrome
65720|NCT02648243|Pharmacist
65721|NCT02648243|Medication burden
65722|NCT02648243|Mortality
65723|NCT02648243|Readmission
65724|NCT02648243|Adherence
65725|NCT02648243|Impact
65726|NCT02648230|Ischemia
65727|NCT02648230|Fractional Flow Reserve
65728|NCT02648230|Stent
65729|NCT02648191|Obesity
65730|NCT02648191|Bariatric Surgery
65731|NCT02648191|No invasive intra-auricular vagus nerve stimulation
65732|NCT02648191|Weight loss
65733|NCT02648191|Autonomic nervous system
65734|NCT02648113|Myocardial Infarction
65735|NCT02648113|Anemia
65736|NCT02648113|Blood Transfusion
65737|NCT02648100|Muscle invasive bladder cancer
65738|NCT02648100|Basal subtype
65739|NCT02648100|Anti-EGFR treatment
65740|NCT02648100|Nanostring
65741|NCT02648074|asthma
65742|NCT02648074|eosinophils
65743|NCT02648074|airway smooth muscle
65744|NCT02648074|airway remodelling
65745|NCT02648074|integrins
65746|NCT02648074|cytokines
65747|NCT02648061|Blood circulation
65748|NCT02648061|Follow-up studies
65749|NCT02648061|Biological markers
65750|NCT02648061|Hemodynamics
65751|NCT02648048|Idiopathic Pulmonary Fibrosis
65752|NCT02648048|Vismodegib
65753|NCT02648048|Pirfenidone
65754|NCT02648022|Care Integration
65755|NCT02648022|Hepatitis C
65756|NCT02648022|Substance Use Disorder
65757|NCT02648022|PTSD
65758|NCT02647970|Energy metabolism
65759|NCT02647957|acute ischemic stroke
65760|NCT02647957|quality
65761|NCT02647866|4083-002
65762|NCT02647866|Intestinal Diseases
65763|NCT02647866|Ulcerative Colitis
65764|NCT02647866|UC
65765|NCT02647866|Mayo Clinic Scoring
65766|NCT02647866|Gastrointestinal Tract
65767|NCT02647840|dysphonia
65768|NCT02647840|voice therapy
65769|NCT02647827|Acupuncture
65770|NCT02647827|Metformin
65771|NCT02647827|Glucose metabolism
65772|NCT02647827|Hba1c
65773|NCT02647814|Parent activation
65774|NCT02647814|Text-messages
65775|NCT02647814|LEP
65776|NCT02647814|Latino populations
65777|NCT02647814|pediatrics
65778|NCT02647801|Network approach
65779|NCT02647801|mindfulness
65780|NCT02647801|self-control
65781|NCT02647801|ambulatory assessment
65782|NCT02647788|Pain, Postoperative
65783|NCT02647775|Thoracoscopic surgery
65784|NCT02647723|Omega-3
65785|NCT02647723|Fatty acid
65786|NCT02647723|docosahexaenoic
65787|NCT02647723|Pregnant
65788|NCT02647723|neurodevelopment
65789|NCT02647723|stress
65790|NCT02647723|urban
65791|NCT02647723|african-american
65792|NCT02647723|supplement
65793|NCT02647723|nutrition
65794|NCT02647723|mental health
65795|NCT02647710|HIV Prevention
65796|NCT02647710|Juvenile Justice
65797|NCT02647710|Sexual Health
65798|NCT02647710|Evidence Based Intervention
65799|NCT02647697|UCB3491
65800|NCT02647697|Phase 1
65801|NCT02647697|Pharmacokinetics
65802|NCT02647697|Radiprodil
65803|NCT02647697|Healthy volunteers
65804|NCT02647684|Cancer
65805|NCT02647684|Parenting
65806|NCT02647684|Self-directed Triple P
65807|NCT02647671|Colon polyp
65808|NCT02647671|Colorectal cancer
65809|NCT02647671|Chemoprevention
65810|NCT02647671|Natural product
65811|NCT02647658|acute low back pain
65812|NCT02647658|primary care
65813|NCT02647658|psychologically informed physical therapy
65814|NCT02647658|cluster randomized pragmatic trial
65815|NCT02647658|comparative effectiveness
65816|NCT02647658|secondary prevention
65817|NCT02647632|HCV genotype 1 or 4
65818|NCT02647632|failure to DAA
65819|NCT02647619|Primary Dd disase
65820|NCT02647619|MCP joint
65821|NCT02647580|Growth
65822|NCT02647580|Children
65823|NCT02647580|Appetite-regulating hormones
65824|NCT02647580|Gut Microbiota
65825|NCT02647567|Cognitive
65826|NCT02647567|Aerobic Exercise
65827|NCT02647567|Performance
65828|NCT02647554|sepsis
65829|NCT02647554|septic shock
65830|NCT02647554|Ulinastatin
65831|NCT02647554|adult
65832|NCT02647554|China
65833|NCT02647541|Children
65834|NCT02647541|Congenital heart disease
65835|NCT02647541|Nutritional status
65836|NCT02647541|Bioelectrical impedance
65837|NCT02647476|immunonutrition
65838|NCT02647476|gastric cancer
65839|NCT02647476|enteral nutrition
65840|NCT02647463|Attachment
65841|NCT02647463|Cortisol
65842|NCT02647463|Parent sensitivity
65843|NCT02647411|Prevalence
65844|NCT02647411|Myopia
65845|NCT02647398|Cancer survivors
65846|NCT02647398|training
65847|NCT02647398|exercise
65848|NCT02647398|cancer-related fatigue
65849|NCT02647385|serratus anterior plane block
65850|NCT02647385|pectoral nerve block
65851|NCT02647385|breast surgery
65852|NCT02647385|cancer
65853|NCT02647385|analgesia
65854|NCT02647385|inflammatory cytokines
65855|NCT02647372|parkinson
65856|NCT02647372|deep brain stimulation
65857|NCT02647372|globus pallidus
65858|NCT02647372|subthalamic nucleus
65859|NCT02647320|type 2 diabetes mellitus
65860|NCT02647320|interventional
65861|NCT02647320|double blind
65862|NCT02647320|phase 2
65863|NCT02647281|Single dose
65864|NCT02647281|Multiple ascending doses (MAD)
65865|NCT02647281|Pharmacokinetics
65866|NCT02647281|Safety
65867|NCT02647281|GSK3389404
65868|NCT02647281|Tolerability
65869|NCT02647268|Uterine contraction
65870|NCT02647268|Oxytocin
65871|NCT02647268|Magnesium sulphate
65872|NCT02647255|crescentic IgA nephropathy
65873|NCT02647255|plasma exchange treatment or plasmapheresis
65874|NCT02647255|randomized controlled trial
65875|NCT02647255|intensive immunosuppressive treatment
65876|NCT02647255|methylprednisolone pulse
65877|NCT02647216|Mindfulness Based Cognitive Therapy (MBCT)
65878|NCT02647216|anxiety
65879|NCT02647216|depression
65880|NCT02647203|Fluoride toothpaste
65881|NCT02647203|Root caries
65882|NCT02647203|Randomized clinical trial
65883|NCT02647190|Erwinia Chrysanthemi Asparaginase
65884|NCT02647190|15-107
65885|NCT02647164|Non-small-cell lung carcinoma
65886|NCT02647164|Circulating tumor cells
65887|NCT02647151|Acid Methyl Aminolevulinate (MAL)
65888|NCT02647151|Aminolevulinic Gel (ALA) and Actinic Keratosis
65889|NCT02647112|Bladder cancer
65890|NCT02647112|Urine
65891|NCT02647112|Methylation
65892|NCT02647099|Aspirin
65893|NCT02647099|PI3K signaling pathway
65894|NCT02647086|Eczema
65895|NCT02647073|Mobile Monitoring
65896|NCT02647073|Post-Opioid Consumption
65897|NCT02647073|Vital Signs
65898|NCT02647060|cardiopulmonary exercise testing
65899|NCT02647060|right ventricle function
65900|NCT02647060|cardio output
65901|NCT02647060|pulmonary hypertension
65902|NCT02647060|quality of life
65903|NCT02647047|spinal analgesia
65904|NCT02647047|epidural analgesia
65905|NCT02647047|laparotomic liver resection
65906|NCT02647047|ERAS
65907|NCT02647047|length of stay
65908|NCT02647021|physical therapy
65909|NCT02647021|cancer rehabilitation
65910|NCT02647021|exercise
65911|NCT02647008|outpatient hysteroscopy, TENS
65912|NCT02646982|Alzheimer's disease
65913|NCT02646982|Vascular function
65914|NCT02646982|Neuroinflammation
65915|NCT02646956|Sweet Taste
65916|NCT02646956|Psychophysics
65917|NCT02646956|Genetics
65918|NCT02646956|Diet
65919|NCT02646956|Age
65920|NCT02646956|Nonnutritive Sweetener
65921|NCT02646943|Cohort
65922|NCT02646943|Biomarkers
65923|NCT02646943|Cardiomyopathy
65924|NCT02646930|chronic endometritis
65925|NCT02646930|invitro fertilization
65926|NCT02646930|spontaneous abortion
65927|NCT02646891|Rotavirus Vaccine
65928|NCT02646878|Type 1 Diabetes
65929|NCT02646878|Type 2 Diabetes
65930|NCT02646878|Harmony Sensor
65931|NCT02646878|Continuous Glucose Monitoring
65932|NCT02646878|CGM
65933|NCT02646865|social phobia
65934|NCT02646865|compassion
65935|NCT02646865|shame
65936|NCT02646839|Acute Lymphoblastic Leukemia (ALL)
65937|NCT02646839|Acute Myeloid Leukemia (AML)
65938|NCT02646839|Myelodysplastic Syndrome (MDS)
65939|NCT02646839|KIR-Favorable
65940|NCT02646839|Haploidentical Transplantation
65941|NCT02646839|Allogeneic Hematopoietic Cell Transplantation
65942|NCT02646800|Micafungin
65943|NCT02646800|Candidiasis
65944|NCT02646800|Aspergillosis
65945|NCT02646800|Antifungal
65946|NCT02646774|Micafungin
65947|NCT02646774|Aspergillosis
65948|NCT02646774|Antifungal
65949|NCT02646748|Advanced
65950|NCT02646670|diabetic macular edema
65951|NCT02646670|aflibercept
65952|NCT02646670|ranibizumab
65953|NCT02646605|Depression
65954|NCT02646605|AIDS
65955|NCT02646605|HIV
65956|NCT02646579|Orthopedics
65957|NCT02646527|dignity, end of life, existential, treatment
65958|NCT02646514|Cholangiocarcinoma, radiofrequency ablation, metal stent
65959|NCT02646488|cholesterol
65960|NCT02646488|smoking
65961|NCT02646488|aspirin
65962|NCT02646488|chronic care model
65963|NCT02646475|renin-angiotensin system
65964|NCT02646475|angiotensin
65965|NCT02646475|insulin resistance
65966|NCT02646475|blood pressure
65967|NCT02646462|pancreas adenocarcinoma, lymph node metastases
65968|NCT02646449|Major Depressive Disorder
65969|NCT02646449|Alcohol Use Disorder
65970|NCT02646436|unplanned peritoneal dialysis
65971|NCT02646436|unplanned heamodialysis
65972|NCT02646423|Trial of labor after cesarean
65973|NCT02646423|Elective repeat cesarean delivery
65974|NCT02646423|Decision tool
65975|NCT02646423|Shared decision making
65976|NCT02646410|malaria
65977|NCT02646410|seasonal malaria chemoprevention
65978|NCT02646410|immunity
65979|NCT02646410|resistance
65980|NCT02646410|sulfadoxine-pyrimethamine
65981|NCT02646410|amodiaquine
65982|NCT02646410|delivery method
65983|NCT02646397|glomerular filtration rate
65984|NCT02646397|hypertension
65985|NCT02646345|Checklist
65986|NCT02646345|Mortality
65987|NCT02646345|Latin America
65988|NCT02646345|Surgery
65989|NCT02646345|Morbidity
65990|NCT02646332|Helicobacter pylori
65991|NCT02646332|Eradication rate
65992|NCT02646306|shoulder
65993|NCT02646306|proprioception
65994|NCT02646306|movement
65995|NCT02646306|reaching
65996|NCT02646280|Low back pain
65997|NCT02646280|interoceptive awareness
65998|NCT02646280|motor imagery
65999|NCT02646280|massage
66000|NCT02646267|Atrial fibrillation
66001|NCT02646267|Dabigatran
66002|NCT02646267|Warfarin
66003|NCT02646267|Anticoagulation
66004|NCT02646267|Elderly
66005|NCT02646254|tetralogy of fallot, cardioplegia
66006|NCT02646241|stomach neoplasm
66007|NCT02646241|biopsy
66008|NCT02646150|Magnetic Resonance perfusion imaging
66009|NCT02646150|distal perfusion
66010|NCT02646150|Critical Limb Ischemia
66011|NCT02646150|endovascular revascularization
66012|NCT02646111|"Hepatitis C Virus"
66013|NCT02646111|"Triple Therapy"
66014|NCT02646111|"PI Failure"
66015|NCT02646111|"Genotype 1"
66016|NCT02646098|NHL
66017|NCT02646098|mantle cell lymphoma
66018|NCT02646098|diffuse large B-cell lymphoma
66019|NCT02646072|diabetes mellitus
66020|NCT02646072|aqueous humor
66021|NCT02646072|inflammatory cytokines
66022|NCT02646072|cystoid macular edema, postoperative
66023|NCT02646072|nonsteroidal anti-inflammatory drugs
66024|NCT02646046|Cardiopulmonary Resuscitation
66025|NCT02646046|Emergency Medical Services
66026|NCT02646046|Cell phones
66027|NCT02646046|Simulation Training
66028|NCT02646033|Intraocular Pressure, Trendelenburg position
66029|NCT02646020|pruritus
66030|NCT02646020|Non-small Cell Lung Cancer
66031|NCT02646020|Receptor, Epidermal Growth Factor
66032|NCT02646020|tyrosine kinase inhibitor
66033|NCT02646007|Autologous Cell therapy Kienböck's disease
66034|NCT02646007|bone marrow derived mesenchymal stromal/stem cell
66035|NCT02645994|Closed Loop Anesthesia Delivery System
66036|NCT02645994|Target Controlled Infusion
66037|NCT02645981|Donafeinb
66038|NCT02645981|Sorafenib
66039|NCT02645981|Phase 3
66040|NCT02645981|Overall Survival
66041|NCT02645968|Pneumology
66042|NCT02645968|Registry
66043|NCT02645968|EXCITING
66044|NCT02645968|Interstitial lung disease
66045|NCT02645968|ILD
66046|NCT02645942|Carnitine
66047|NCT02645942|placebo
66048|NCT02645942|risk factors
66049|NCT02645916|Cold Hypersensitivity in the Hands
66050|NCT02645916|Korean medicine
66051|NCT02645916|DSGOST
66052|NCT02645903|transversus abdominis plane block
66053|NCT02645903|living liver transplantation
66054|NCT02645903|postoperative analgesia
66055|NCT02645890|Benign Prostatic Hyperplasia
66056|NCT02645890|Healthy Male Volunteer
66057|NCT02645890|Tamsulosin
66058|NCT02645890|Tadalafil
66059|NCT02645877|Pre-hospital Care
66060|NCT02645877|Diseases Spectrum
66061|NCT02645877|Call Demands
66062|NCT02645877|Emergency Response Time
66063|NCT02645864|Esophageal squamous cell carcinoma
66064|NCT02645864|Apatinib
66065|NCT02645864|Irinotecan
66066|NCT02645851|Fluid Therapy
66067|NCT02645851|Plasma Substitutes
66068|NCT02645851|Fluid Balance
66069|NCT02645838|Motivational Interviewing
66070|NCT02645838|Smoking Cessation
66071|NCT02645825|superficial adenopathy - echography
66072|NCT02645812|Fatigue
66073|NCT02645812|Brief Fatigue Inventory (BFI)
66074|NCT02645812|Primary care
66075|NCT02645812|General Practitioners
66076|NCT02645786|thyroid neoplasms
66077|NCT02645786|heart
66078|NCT02645786|thyroxine
66079|NCT02645786|thyrotoxicosis
66080|NCT02645708|RIRS
66081|NCT02645708|EPVL
66082|NCT02645708|PDI(Percussion,Diuresis,Inversion)
66083|NCT02645708|Randomized Controlled Trial
66084|NCT02645695|Pulmonary Rehabilitation
66085|NCT02645695|Chest Physiotherapy
66086|NCT02645695|High Frequency Chest Wall Oscillation
66087|NCT02645682|central venous catheter (CVC)
66088|NCT02645682|catheter-related bloodstream infection (CRBSI)
66089|NCT02645682|catheter-related thrombosis (CRT)
66090|NCT02645656|Oral Submucous Fibrosis
66091|NCT02645656|Curcumin
66092|NCT02645643|medical students
66093|NCT02645643|professionalism
66094|NCT02645643|medical education
66095|NCT02645643|study emotion
66096|NCT02645630|Cervical spine
66097|NCT02645630|Spinal manipulation
66098|NCT02645604|Artemisinin Combination Therapy (ACT)
66099|NCT02645591|Prostate cancer
66100|NCT02645591|Dehydrated human amnion/chorion membrane
66101|NCT02645591|dHACM
66102|NCT02645591|Robotic assisted laparoscopic radical prostatectomy
66103|NCT02645591|RARP
66104|NCT02645591|AmnioFix®
66105|NCT02645591|Sexual function score
66106|NCT02645591|Neurovascular bundle inflammation
66107|NCT02645591|Questionnaire
66108|NCT02645591|Survey
66109|NCT02645578|Coma
66110|NCT02645578|traumatic brain injury
66111|NCT02645578|median nerve stimulation
66112|NCT02645552|Traumatic brain injury
66113|NCT02645513|mHealth
66114|NCT02645513|text message
66115|NCT02645513|case management
66116|NCT02645500|Physical Activity
66117|NCT02645500|Family well-being
66118|NCT02645448|Resistance Exercise
66119|NCT02645448|Diabetes Mellitus
66120|NCT02645448|Heart Rate Variability
66121|NCT02645409|Fluorescence
66122|NCT02645409|Imaging
66123|NCT02645409|Partial nephrectomy
66124|NCT02645409|Radical nephrectomy
66125|NCT02645396|Cytomegalovirus
66126|NCT02645383|Pattern scan laser
66127|NCT02645383|Proliferative diabetic retinopathy
66128|NCT02645383|Pain
66129|NCT02645370|Migraine
66130|NCT02645370|Danzhen
66131|NCT02645370|Topiramate
66132|NCT02645370|Headache diary APP
66133|NCT02645370|preventive treatment
66134|NCT02645357|Oncology Patients
66135|NCT02645357|evidence-based
66136|NCT02645357|computerized
66137|NCT02645357|decision
66138|NCT02645357|support system
66139|NCT02645357|linked
66140|NCT02645357|electronic health records
66141|NCT02645344|Unilateral neglect
66142|NCT02645344|Right hemiplegia
66143|NCT02645318|Circulating Tumor DNA
66144|NCT02645318|Lung cancer
66145|NCT02645318|Targeted sequencing
66146|NCT02645305|Safety and Efficacy
66147|NCT02645305|Adipose stem cells
66148|NCT02645305|Stem Cell therapy
66149|NCT02645279|newborn
66150|NCT02645279|MRI
66151|NCT02645279|oral 30% glucose
66152|NCT02645253|Safety
66153|NCT02645253|Pharmacokinetics
66154|NCT02645253|Pharmacodynamics
66155|NCT02645253|Glucocorticoid receptor modulator
66156|NCT02645253|Healthy male subjects
66157|NCT02645201|probiotic
66158|NCT02645188|Electromyography
66159|NCT02645188|Exercise
66160|NCT02645175|Paclitaxel
66161|NCT02645175|docetaxel
66162|NCT02645175|vinorelbine
66163|NCT02645175|eribulin
66164|NCT02645162|Pakistan
66165|NCT02645162|Early Child Development, Care and Education
66166|NCT02645162|Youth Leaders
66167|NCT02645149|Metastatic Melanoma
66168|NCT02645149|Molecular Testing
66169|NCT02645149|Targeted Therapy
66170|NCT02645123|spinal mobilization
66171|NCT02645123|manual therapy
66172|NCT02645123|gait analysis
66173|NCT02645123|low back pain
66174|NCT02645123|chronic
66175|NCT02645097|Adult
66176|NCT02645097|nerve blocks in foot and ankle surgery
66177|NCT02645097|saphenous
66178|NCT02645071|physical activity
66179|NCT02645071|family well being,
66180|NCT02645071|health
66181|NCT02645058|Ureterorenoscopy
66182|NCT02645058|extracorporeal shock waves lithotripsy
66183|NCT02645045|Dry eye
66184|NCT02645045|Lipiview
66185|NCT02645045|Tear Lipid Layer
66186|NCT02645045|meibomian gland dysfunction
66187|NCT02645032|Typhoid conjugate vaccine
66188|NCT02645032|Vi-DT
66189|NCT02645032|Safety
66190|NCT02645032|Immunogenicuty
66191|NCT02645006|falls
66192|NCT02645006|elderly
66193|NCT02645006|Exercise,Physical
66194|NCT02645006|vitamin d
66195|NCT02645006|home hazards
66196|NCT02645006|mediterranean diet
66197|NCT02645006|body mass index
66198|NCT02645006|lower extremity exercise movement technics
66199|NCT02645006|vitamin D intake
66200|NCT02645006|Short Physical Performance Battery (SPPB o Test de Guralnik)
66201|NCT02644980|Target Controlled Infusion
66202|NCT02644954|psoriasis
66203|NCT02644954|Metformin
66204|NCT02644928|Chronic kidney disease
66205|NCT02644928|Bariatric Surgery Candidate
66206|NCT02644928|Caloric restriction
66207|NCT02644915|ischemia-reperfusion(I/R) injury
66208|NCT02644915|Edaravone
66209|NCT02644902|Avatar assisted cascade training and supervision
66210|NCT02644902|maternal depression
66211|NCT02644902|postconflict
66212|NCT02644902|THP
66213|NCT02644889|Epidermal growth factor receptor(EGFR)
66214|NCT02644889|NSCLC
66215|NCT02644876|Postoperative pulmonary complications
66216|NCT02644876|Selective anticholinergic bronchodilator
66217|NCT02644876|High risk patients
66218|NCT02644876|Postoperative period
66219|NCT02644876|Postoperative complications
66220|NCT02644824|Congenital Heart Disease (CHD)
66221|NCT02644824|Cardiopulmonary Bypass (CPB)
66222|NCT02644824|Cardiac Index
66223|NCT02644824|Hemodynamics
66224|NCT02644824|Pediatrics
66225|NCT02644811|Miniscrew
66226|NCT02644811|Temporary anchorage device (TAD)
66227|NCT02644811|mini-implants
66228|NCT02644798|ARDS
66229|NCT02644798|Gene polymorphism
66230|NCT02644785|cardiac by-pass
66231|NCT02644785|protamine
66232|NCT02644785|tryptase
66233|NCT02644785|hypotension
66234|NCT02644785|anaphylaxis
66235|NCT02644772|Acute Exacerbation of COPD
66236|NCT02644772|Clinical problems in COPD
66237|NCT02644759|Stem Cells
66238|NCT02644759|Transplantation
66239|NCT02644759|Immunomodulation
66240|NCT02644759|CD34
66241|NCT02644759|CD133
66242|NCT02644759|ClinicMACS
66243|NCT02644746|degenerative lumbar spinal stenosis
66244|NCT02644746|acupuncture
66245|NCT02644746|randomized controlled trial
66246|NCT02644655|Recurrent B-Cell Tumor
66247|NCT02644655|Refractory B-Cell Tumor
66248|NCT02644655|New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T Cells
66249|NCT02644655|safety
66250|NCT02644655|prognosis
66251|NCT02644616|tolvaptan
66252|NCT02644616|safety and efficacy
66253|NCT02644616|left heart valves replacement
66254|NCT02644603|Enhanced Recovery After Surgery
66255|NCT02644603|hepatocellular carcinoma
66256|NCT02644590|Melatonin
66257|NCT02644590|Nocturnal Hypertension
66258|NCT02644590|Type 1 Diabetes Melitus
66259|NCT02644577|Metformin
66260|NCT02644577|antipsychotic-induced metabolic syndrome
66261|NCT02644577|bipolar disorder
66262|NCT02644564|Soft tissue shoulder injury
66263|NCT02644564|Rotator cuff tear
66264|NCT02644564|Ultrasonography
66265|NCT02644538|HBsAg clearance
66266|NCT02644525|Cameroon
66267|NCT02644525|Filaricidal
66268|NCT02644525|Randomized
66269|NCT02644525|Ivermectin
66270|NCT02644525|Worm
66271|NCT02644434|Percutaneous Coronary Intervention
66272|NCT02644434|Coronary Bifurcation Intervention
66273|NCT02644434|Randomized Clinical Trial
66274|NCT02644421|Neuropathic Pain
66275|NCT02644421|Sciatica
66276|NCT02644408|Chemoradiotherapy
66277|NCT02644408|Esophageal Squamous Cancer
66278|NCT02644408|Megestrol
66279|NCT02644382|breast cancer
66280|NCT02644382|decision making
66281|NCT02644382|surgery
66282|NCT02644382|qualitative
66283|NCT02644317|Motor development delay
66284|NCT02644317|balance
66285|NCT02644317|flatfoot
66286|NCT02644317|shoe insert
66287|NCT02644291|medulloblastoma
66288|NCT02644291|Diffuse Intrinsic Pontine Glioma (DIPG)
66289|NCT02644291|high grade glioma
66290|NCT02644291|glioblastoma
66291|NCT02644291|brain stem malignant glioma
66292|NCT02644265|Acute acquired brain injury
66293|NCT02644265|Disorders of consciousness
66294|NCT02644265|Traumatic brain injury
66295|NCT02644265|Non-traumatic brain injury
66296|NCT02644265|Anoxic-ischemic encephalopathy
66297|NCT02644265|Stroke
66298|NCT02644265|Vegetative state
66299|NCT02644265|Minimal conscious state
66300|NCT02644265|Locked-in syndrome
66301|NCT02644265|Functional magnetic resonance imaging
66302|NCT02644265|Electroencephalography
66303|NCT02644174|Obesity
66304|NCT02644174|Lung function test
66305|NCT02644174|Bariatric surgery
66306|NCT02644161|stroke
66307|NCT02644161|depression
66308|NCT02644161|stroke sequelae
66309|NCT02644161|acupuncture
66310|NCT02644161|DCEAS
66311|NCT02644161|CAI
66312|NCT02644161|LAS
66313|NCT02644135|Healthy volunteer
66314|NCT02644122|advanced cancer
66315|NCT02644122|metastatic cancer
66316|NCT02644122|Squamous Cell Carcinoma of the Head and Neck
66317|NCT02644122|SCCHN
66318|NCT02644122|gene mutation
66319|NCT02644122|PIK3R1, PIK3R5 and PIK3AP1
66320|NCT02644122|PIK3CG
66321|NCT02644122|AKT and mTOR
66322|NCT02644122|PIK3CA gene
66323|NCT02644122|PI-3 kinase inhibitor
66324|NCT02644122|PI-3 kinase pathway genes
66325|NCT02644096|Rehabilitation
66326|NCT02644096|RCT
66327|NCT02644096|User Involvement
66328|NCT02644096|Self-Rated Health
66329|NCT02644070|Alveolar bone loss
66330|NCT02644070|Alveoloplasty
66331|NCT02644070|Bone remodeling
66332|NCT02644070|Xenograft
66333|NCT02644070|Tooth socket
66334|NCT02644070|Dental implant
66335|NCT02644044|Progressive multiple sclerosis
66336|NCT02644044|methotrexate
66337|NCT02644031|Instrumentation
66338|NCT02644031|Post-operative pain
66339|NCT02644031|Root canal preparation
66340|NCT02644018|Ingavirin
66341|NCT02644018|Common Cold
66342|NCT02644018|Influenza
66343|NCT02644018|Acute Respiratory Viral Infections
66344|NCT02644018|pediatric clinical trial
66345|NCT02644018|Imidazolyl ethanamide pentandioic acid
66346|NCT02643979|Ketamine
66347|NCT02643979|Propofol
66348|NCT02643979|Ketofol
66349|NCT02643979|Obese
66350|NCT02643979|Upper gastrointestinal endoscopy
66351|NCT02643979|Sedation
66352|NCT02643979|Bariatric
66353|NCT02643966|whole breast ultrasound
66354|NCT02643966|digital breast tomosynthesis
66355|NCT02643966|breast density
66356|NCT02643966|breast cancer screening
66357|NCT02643953|Maternal Health
66358|NCT02643953|Maternal Mortality
66359|NCT02643953|Global Health
66360|NCT02643953|RCT
66361|NCT02643940|Percutaneous Coronary Intervention (PCI)
66362|NCT02643940|Chronic Total Occlusion (CTO)
66363|NCT02643940|Cardiac MRI
66364|NCT02643940|Instantaneous wave-free ratio (iFR)
66365|NCT02643875|myopia control
66366|NCT02643875|orthokeratology
66367|NCT02643823|Human Umbilical Cord Mesenchymal Stem Cell
66368|NCT02643823|Mesenchymal Stem Cell
66369|NCT02643823|Rheumatoid Arthritis
66370|NCT02643810|exercise training
66371|NCT02643797|diabetes
66372|NCT02643797|medical assistant
66373|NCT02643797|health coach
66374|NCT02643797|glycemic control
66375|NCT02643797|pragmatic trial
66376|NCT02643784|acute ischemic stroke
66377|NCT02643771|Dental Scaling
66378|NCT02643771|Blood Glucose
66379|NCT02643771|Hemoglobin A, Glycosylated
66380|NCT02643758|Myopia control, bifocal soft contact lenses, children
66381|NCT02643745|acute kidney injury
66382|NCT02643745|cardiac surgery
66383|NCT02643732|Activity
66384|NCT02643719|migraine
66385|NCT02643719|topiramate
66386|NCT02643706|Aldehyde dehydrogenase 2
66387|NCT02643706|contrast induced nephropathy
66388|NCT02643706|Gene polymorphism
66389|NCT02643693|Conventional cigarette
66390|NCT02643693|Nicotine lactate delivery system
66391|NCT02643693|e-cigarette
66392|NCT02643693|VUSE
66393|NCT02643693|Combustible cigarette
66394|NCT02643680|Biocellulose
66395|NCT02643680|Silk sericin
66396|NCT02643680|Polyhexamethylene biguanide
66397|NCT02643680|Split thickness skin graft donor site
66398|NCT02643667|Radical prostatectomy (RP)
66399|NCT02643654|interleukin-1alpha
66400|NCT02643641|Grass pollen allergy
66401|NCT02643641|subcutaneous immunotherapy
66402|NCT02643641|allergy vaccine
66403|NCT02643641|dose regimen
66404|NCT02643615|Visual Evoked Potentials
66405|NCT02643589|haploidentical hematopoietic Stem Cell Transplantation Antithymocyte globulin
66406|NCT02643589|acute graft-versus-host disease
66407|NCT02643589|antithymocyte globulin
66408|NCT02643563|Brachial Plexus Block
66409|NCT02643563|Anesthetics, Local
66410|NCT02643524|Adult
66411|NCT02643524|CAM boot
66412|NCT02643524|controlled ankle movement
66413|NCT02643498|Stereotactic Body Radiotherapy (SBRT)
66414|NCT02643498|15-109
66415|NCT02643472|neonate
66416|NCT02643472|newborn
66417|NCT02643472|neonatal intensive care unit
66418|NCT02643472|NICU
66419|NCT02643472|NICU discharge
66420|NCT02643472|parent navigator
66421|NCT02643472|peer to peer
66422|NCT02643472|peer coaching
66423|NCT02643459|Triage
66424|NCT02643459|Risk stratification
66425|NCT02643459|Acute care
66426|NCT02643459|suPAR
66427|NCT02643446|Poliovirus Vaccine, Inactivated
66428|NCT02643446|Poliovirus Vaccine, Oral
66429|NCT02643446|Immunity
66430|NCT02643446|Seroconversion
66431|NCT02643433|Immunogenicity
66432|NCT02643433|Coadministration
66433|NCT02643433|Measles
66434|NCT02643433|Rubella
66435|NCT02643433|Japanese encephalitis
66436|NCT02643433|Vaccine
66437|NCT02643420|Neutropenia
66438|NCT02643420|Breast Cancer
66439|NCT02643420|Long-acting Myeloid Growth Factor
66440|NCT02643420|Early Stage Breast Cancer
66441|NCT02643420|Docetaxel + Cyclophosphamide (TC) chemotherapy
66442|NCT02643407|squamous cell carcinoma
66443|NCT02643407|nedaplatin
66444|NCT02643407|cisplatin
66445|NCT02643407|docetaxel
66446|NCT02643394|Acetaminophen
66447|NCT02643394|Postoperative pain
66448|NCT02643394|Sinus Surgery
66449|NCT02643381|etomidate
66450|NCT02643381|ketamine
66451|NCT02643381|endotracheal intubation
66452|NCT02643381|anesthesia induction medications
66453|NCT02643368|Polio
66454|NCT02643368|Inactivated polio vaccine
66455|NCT02643368|oral polio vaccine
66456|NCT02643368|monovalent type 2 oral polio vaccine
66457|NCT02643355|Narcotic Withdrawal
66458|NCT02643355|Opiate Withdrawal
66459|NCT02643355|Emergency Department
66460|NCT02643342|myopia control
66461|NCT02643342|orthokeratology
66462|NCT02643303|Durvalumab
66463|NCT02643303|MEDI4736
66464|NCT02643303|Tremelimumab
66465|NCT02643303|PolyICLC
66466|NCT02643303|Hiltonol
66467|NCT02643303|Locally Recurrent Breast Cancer
66468|NCT02643303|Metastatic Melanoma
66469|NCT02643303|In Situ
66470|NCT02643303|CTLA-4 Antibody
66471|NCT02643303|PD-L1 Antibody
66472|NCT02643303|TLR3 Agonist
66473|NCT02643290|Adult Scoliosis
66474|NCT02643290|Pain Management
66475|NCT02643290|Orthosis
66476|NCT02643264|insula
66477|NCT02643264|alcohol addiction
66478|NCT02643264|transcranial magnetic stimulation
66479|NCT02643251|Diabetes Mellitus
66480|NCT02643251|Pain
66481|NCT02643251|Foot Pain
66482|NCT02643251|Neuropathy
66483|NCT02643160|Trunk Training
66484|NCT02643160|Motor Function
66485|NCT02643147|Heart Failure
66486|NCT02643147|Renal Failure
66487|NCT02643147|Biomarker guided-therapy
66488|NCT02643147|Loop diuretics
66489|NCT02643147|Carbohydrate antigen 125
66490|NCT02643134|ESWL
66491|NCT02643134|EPVL
66492|NCT02643134|PDI(Percussion,Diuresis,Inversion)
66493|NCT02643134|Randomized Controlled Trial(RCT)
66494|NCT02643108|Lateral episiotomy
66495|NCT02643108|Obstetrical anal sphincter injury
66496|NCT02643108|Vacuum extraction
66497|NCT02643108|Anal incontinence
66498|NCT02643069|Frailty
66499|NCT02643069|Frailty tools
66500|NCT02643069|Clinical settings
66501|NCT02643069|Disability
66502|NCT02643069|Quality of life
66503|NCT02643069|Functional Autonomy
66504|NCT02643043|Next Generation Sequencing
66505|NCT02643043|Genomic Analysis
66506|NCT02643017|cognitive function
66507|NCT02643017|desflurane
66508|NCT02643017|dexmedetomidine
66509|NCT02642978|minimally invasive surgery
66510|NCT02642978|colorectal liver metastasis
66511|NCT02642978|robotic surgery
66512|NCT02642978|Patients with resectable colorectal liver metastasis
66513|NCT02642952|arterial stiffness, central hemodynamics
66514|NCT02642926|menorrhagia
66515|NCT02642926|higham PBAC score
66516|NCT02642926|endometrial ablation
66517|NCT02642926|bipolar energy
66518|NCT02642926|monopolar energy
66519|NCT02642913|Enzalutamide
66520|NCT02642913|Sorafenib
66521|NCT02642913|15-279
66522|NCT02642900|Complete denture
66523|NCT02642900|Candida spp
66524|NCT02642900|Photodynamic therapy
66525|NCT02642887|gingival recession
66526|NCT02642887|tunnel technique
66527|NCT02642887|Miller Class I and II
66528|NCT02642835|mesh
66529|NCT02642835|pelvic organ prolapse
66530|NCT02642822|Cytomegalovirus
66531|NCT02642796|Percutaneous Electric Nerve Stimulation
66532|NCT02642796|Lumbosacral plexus
66533|NCT02642796|surgical wound
66534|NCT02642796|postoperative analgesia
66535|NCT02642796|transcutaneous electrical stimulation
66536|NCT02642783|laxatives
66537|NCT02642783|sensory evaluation
66538|NCT02642783|acceptability
66539|NCT02642783|colonoscopy
66540|NCT02642770|Transesophageal echocardiography, Speckle tracking strain
66541|NCT02642757|alcohol drinking
66542|NCT02642757|hazardous alcohol use
66543|NCT02642757|risky alcohol consumption
66544|NCT02642757|heavy alcohol consumption
66545|NCT02642731|total knee arthroplasty
66546|NCT02642731|Kidney function
66547|NCT02642731|Renal markers
66548|NCT02642718|preemptive analgesia
66549|NCT02642718|postoperative pain
66550|NCT02642718|NSAIDs
66551|NCT02642718|ketorolac
66552|NCT02642718|abdominal hysterectomy
66553|NCT02642692|ACL reconstruction
66554|NCT02642692|Single bundle
66555|NCT02642692|Clinical results
66556|NCT02642692|Soccer players
66557|NCT02642679|Split-thickness skin graft, donor site, chitosan, dressing
66558|NCT02642666|Attention
66559|NCT02642666|Hyperactivity
66560|NCT02642666|Impulsivity
66561|NCT02642666|Yoga
66562|NCT02642666|Preschool
66563|NCT02642653|Fra(X) Syndrome
66564|NCT02642653|Trinucleotide Repeat Expansion
66565|NCT02642653|Fragile X Syndrome
66566|NCT02642653|Fragile X Mental Retardation Syndrome
66567|NCT02642653|Intellectual Disability
66568|NCT02642653|Parent Implemented Language Intervention (PILI)
66569|NCT02642653|FXS
66570|NCT02642653|Mental Retardation, X-linked
66571|NCT02642653|Genetic Diseases, X-linked
66572|NCT02642653|Neurobehavioral Manifestations
66573|NCT02642653|Chromosome Disorders
66574|NCT02642601|indomethacin, ICSI, difficult embryo transfer
66575|NCT02642562|Intravenous iron
66576|NCT02642562|PROBE design
66577|NCT02642536|Veteran
66578|NCT02642523|natriuretic peptide
66579|NCT02642523|insulin
66580|NCT02642523|lipolysis
66581|NCT02642523|hormones
66582|NCT02642523|metabolism
66583|NCT02642497|postoperative analgesia
66584|NCT02642497|ketamine
66585|NCT02642497|total thyroidectomy
66586|NCT02642471|sentinel lymph node
66587|NCT02642471|pelvic lymphadenectomy
66588|NCT02642471|cervical carcinoma
66589|NCT02642471|surgery
66590|NCT02642471|radiotherapy
66591|NCT02642445|Renal sympathetic denervation;hypertension
66592|NCT02642432|HCV Genotype 1
66593|NCT02642432|HCV Genotype 4
66594|NCT02642432|HCV Genotype 2
66595|NCT02642432|Cirrhotic
66596|NCT02642432|Interferon-Free
66597|NCT02642432|Compensated Cirrhosis
66598|NCT02642432|HCV Genotype 5
66599|NCT02642432|Hepatitis C
66600|NCT02642432|HCV Genotype 6
66601|NCT02642393|SURE-PD3
66602|NCT02642393|Parkinson's disease
66603|NCT02642393|PD
66604|NCT02642393|Inosine
66605|NCT02642393|Urate
66606|NCT02642393|Parkinson Study Group (PSG)
66607|NCT02642380|ITP
66608|NCT02642380|high-dose dexamethasone
66609|NCT02642328|VO2Max
66610|NCT02642328|Aerobic Exercise
66611|NCT02642328|Physical Conditioning
66612|NCT02642302|VO2Max
66613|NCT02642302|Aerobic Exercise
66614|NCT02642302|Physical Conditioning
66615|NCT02642289|Probiotics
66616|NCT02642276|exercise training
66617|NCT02642250|safety
66618|NCT02642250|efficacy
66619|NCT02642237|Fluenz
66620|NCT02642237|innate immune response
66621|NCT02642237|endotoxin tolerance
66622|NCT02642237|priming
66623|NCT02642224|Violence
66624|NCT02642224|firearm
66625|NCT02642224|guns
66626|NCT02642224|homicide
66627|NCT02642224|trauma
66628|NCT02642224|injury
66629|NCT02642198|NiBP
66630|NCT02642185|microwave
66631|NCT02642185|ablation
66632|NCT02642185|resection
66633|NCT02642185|liver
66634|NCT02642185|colorectal
66635|NCT02642185|survival
66636|NCT02642185|metastasis
66637|NCT02642172|Inulin, OFS (oligofructose)
66638|NCT02642107|nasopharyngeal carcinoma
66639|NCT02642107|elective neck irradiation
66640|NCT02642081|NSAIDs
66641|NCT02642081|Heart failure
66642|NCT02642081|Acute kidney injury
66643|NCT02642068|Drug-naïve Adult ADHD
66644|NCT02642068|Neuropsychology
66645|NCT02642068|Neurophysiology
66646|NCT02642068|Neuroimaging
66647|NCT02642068|Follow-up
66648|NCT02642055|ADHD
66649|NCT02642055|Neurofeedback
66650|NCT02642055|Biofeedback
66651|NCT02642055|Neuro+
66652|NCT02642055|Go/no-go
66653|NCT02642055|Attention training
66654|NCT02642029|time perception
66655|NCT02642029|executive function
66656|NCT02642029|psychosis
66657|NCT02642029|mood symptoms
66658|NCT02642016|KTN0158
66659|NCT02642016|Advanced Cancer
66660|NCT02642016|Phase 1
66661|NCT02642016|Monoclonal Antibody
66662|NCT02642016|Safety and Pharmacokinetics
66663|NCT02641925|Metabolic syndrome
66664|NCT02641925|gastric cancer
66665|NCT02641925|omentectomy
66666|NCT02641899|Adult
66667|NCT02641899|Male
66668|NCT02641899|Female
66669|NCT02641899|Volunteers
66670|NCT02641886|traditional Chinese medicine granules
66671|NCT02641886|Cognitive Impairment
66672|NCT02641886|Acute cerebral infraction
66673|NCT02641886|prevention
66674|NCT02641873|metastatic Colorectal Cancer
66675|NCT02641873|mCRC
66676|NCT02641847|triple negative breast cancer
66677|NCT02641847|mRNA-lncRNA signature
66678|NCT02641847|chemotherapy
66679|NCT02641847|high risk
66680|NCT02641834|diet
66681|NCT02641834|vegetarian
66682|NCT02641834|cardiovascular risk
66683|NCT02641795|cochlear implantation
66684|NCT02641795|robotics
66685|NCT02641795|image guidance
66686|NCT02641782|High Risk Neuroblastoma
66687|NCT02641756|HIV reservoir
66688|NCT02641756|phylogenetic analysis
66689|NCT02641756|sequencing
66690|NCT02641730|Guselkumab
66691|NCT02641730|CNTO 1959
66692|NCT02641730|Placebo
66693|NCT02641730|Palmoplantar Pustulosis
66694|NCT02641717|patient-collected
66695|NCT02641717|self-collected
66696|NCT02641717|vaginitis
66697|NCT02641717|vaginosis, bacterial
66698|NCT02641717|candidiasis
66699|NCT02641717|trichomonas
66700|NCT02641717|vaginal discharge
66701|NCT02641678|Atrial Fibrillation
66702|NCT02641678|stroke
66703|NCT02641678|implantable cardiac monitor
66704|NCT02641678|automated ECG analysis
66705|NCT02641652|paroxysmal hypertension
66706|NCT02641652|pseudopheochromocytoma
66707|NCT02641626|cardiac arrest
66708|NCT02641626|survival
66709|NCT02641626|neurologic prognosis
66710|NCT02641626|coronariography
66711|NCT02641626|hypothermia
66712|NCT02641587|Smoking
66713|NCT02641587|Combustible cigarette
66714|NCT02641587|Reduced exposure
66715|NCT02641587|Confinement
66716|NCT02641587|Ambulatory
66717|NCT02641587|Carbon Heated Tobacco Product
66718|NCT02641561|Pancreatitis
66719|NCT02641561|ERCP
66720|NCT02641561|Indomethacin
66721|NCT02641561|Lactated ringer's
66722|NCT02641522|T1D
66723|NCT02641522|Type 1 diabetes
66724|NCT02641496|Obstructive Sleep Apnea
66725|NCT02641496|PTSD
66726|NCT02641496|Posttraumatic Stress Disorder
66727|NCT02641496|Cognitive Behavioral Therapy
66728|NCT02641496|Continuous Positive Airway Pressure
66729|NCT02641496|CPAP
66730|NCT02641496|Cognition
66731|NCT02641496|Memory
66732|NCT02641496|Quality of Life
66733|NCT02641496|Self Efficacy
66734|NCT02641496|CBT
66735|NCT02641457|rubeosis iridis
66736|NCT02641457|glaucoma
66737|NCT02641457|ranibizumab
66738|NCT02641457|aflibercept
66739|NCT02641431|radiofrequency ablation
66740|NCT02641431|mapping
66741|NCT02641431|sudden death
66742|NCT02641431|syncope
66743|NCT02641418|Exercise
66744|NCT02641405|Gait analysis
66745|NCT02641405|Proprioceptive focal stimulation
66746|NCT02641405|Parkinson
66747|NCT02641392|Crohn's Disease
66748|NCT02641392|GED 0301
66749|NCT02641392|Mongersen
66750|NCT02641392|Safety
66751|NCT02641392|IBD
66752|NCT02641353|Apremilast
66753|NCT02641353|Healthy volunteers
66754|NCT02641353|Bioavailability
66755|NCT02641353|Food effect
66756|NCT02641353|Pharmacokinetic
66757|NCT02641327|Inhospital patients
66758|NCT02641314|high risk neuroblastoma
66759|NCT02641301|obesity
66760|NCT02641301|Roux-en-Y-gastric bypass
66761|NCT02641301|pharmacokinetics
66762|NCT02641301|Pain
66763|NCT02641301|morphine
66764|NCT02641275|Parental stress
66765|NCT02641275|Muscular Dystrophies
66766|NCT02641275|Coping
66767|NCT02641275|Parental support
66768|NCT02641262|Myocardial Infarction
66769|NCT02641262|Angioplasty, Balloon, Coronary
66770|NCT02641262|Drug Therapy
66895|NCT02640560|Walnuts
66771|NCT02641236|Hematopoietic Stem Cell Transplantation (HSCT)
66772|NCT02641236|Acute GVH Disease
66773|NCT02641210|Chronic periodontitis
66774|NCT02641210|Hepcidin
66775|NCT02641210|Hemoglobin
66776|NCT02641210|Inflammation
66777|NCT02641197|flow-mediated dilation
66778|NCT02641197|AngioDefender
66779|NCT02641197|device precision
66780|NCT02641197|repeatability
66781|NCT02641197|reproducibility
66782|NCT02641197|cardiovascular diseases
66783|NCT02641184|Myocardial Infarction
66784|NCT02641184|Cardiovascular Diseases
66785|NCT02641184|Heart Diseases
66786|NCT02641184|Infarction
66787|NCT02641184|Diabetes
66788|NCT02641158|HIV
66789|NCT02641158|Hepatitis C
66790|NCT02641158|Substance users
66791|NCT02641158|Drug users
66792|NCT02641145|amyloidosis
66793|NCT02641145|F-18 florbetapir
66794|NCT02641145|Positron emission tomography
66795|NCT02641145|cardiac magnetic resonance imaging
66796|NCT02641119|Albumin
66797|NCT02641119|Resuscitation
66798|NCT02641106|Telemedicine
66799|NCT02641106|Mobile Phone
66800|NCT02641106|Adherence
66801|NCT02641106|Latent Tuberculosis Infection
66802|NCT02641106|Directly Observed Therapy
66803|NCT02641106|Video DOT
66804|NCT02641041|Japanese
66805|NCT02641041|Single Ascending Dose (SAD)
66806|NCT02641041|Multiple Ascending Dose (MAD)
66807|NCT02641015|UTI
66808|NCT02641002|CC-90002
66809|NCT02641002|Monoclonal
66810|NCT02641002|Antibody
66811|NCT02641002|CD47
66812|NCT02641002|Hematologic Cancers
66813|NCT02641002|Acute Myeloid Leukemia
66814|NCT02641002|AML
66815|NCT02641002|Myelodysplastic syndrome
66816|NCT02641002|MDS
66817|NCT02641002|Blood disorder
66818|NCT02640989|Influenza Vaccine
66819|NCT02640989|Safety
66820|NCT02640989|Immunogenicity
66821|NCT02640976|in vitro fertilization
66822|NCT02640976|controlled ovarian hyperstimulation
66823|NCT02640976|poor ovarian response
66824|NCT02640976|estrogen receptor 2 gene polymorphism
66825|NCT02640976|follicle stimulating hormone receptor gene polymorphism
66826|NCT02640976|anti-mullerian hormone
66827|NCT02640963|exercise
66828|NCT02640963|older adults
66829|NCT02640963|physical performance
66830|NCT02640937|Staphylococcus epidermidis
66831|NCT02640937|biofilm formation
66832|NCT02640937|antibiotic resistance
66833|NCT02640937|Orthopaedic device related infections
66834|NCT02640937|risk factor
66835|NCT02640924|Hepatocellular carcinoma
66836|NCT02640924|Proton therapy
66837|NCT02640924|Radiation therapy
66838|NCT02640924|Switching control radiofrequency ablation
66839|NCT02640872|sarcopenia
66840|NCT02640872|sarcopenic obesity
66841|NCT02640872|osteoporosis
66842|NCT02640872|fracture
66843|NCT02640872|cardiovascular disease
66844|NCT02640872|mortality
66845|NCT02640846|Levosimendan
66846|NCT02640846|Milrinone
66847|NCT02640846|Myocardial strain
66848|NCT02640846|Septic cardiomyopathy
66849|NCT02640833|Refractory Lymphoma
66850|NCT02640833|Relapsed Leukemia
66851|NCT02640820|HPV
66852|NCT02640820|Verruca Vulgaris
66853|NCT02640807|sepsis lymphocytopenia IL-7
66854|NCT02640807|immune reconstitution
66855|NCT02640794|Transcatheter aortic valve implantation
66856|NCT02640794|Antithrombotic treatment
66857|NCT02640794|Clopidogrel
66858|NCT02640794|Aspirin/acetylsalicylic acid
66859|NCT02640794|Myocardial Infarction
66860|NCT02640794|Ischemic stroke
66861|NCT02640794|Major bleeding
66862|NCT02640768|in-hospital diabetes
66863|NCT02640768|clinical and management model
66864|NCT02640755|Radiolabelled
66865|NCT02640729|Lewy body dementia
66866|NCT02640729|Dementia with Lewy bodies
66867|NCT02640729|Parkinson's disease dementia
66868|NCT02640729|Lewy bodies
66869|NCT02640729|Visual hallucinations
66870|NCT02640690|Stress Disorders, Post-traumatic
66871|NCT02640690|Yoga
66872|NCT02640690|Cognitive Therapy
66873|NCT02640690|Chronic Pain
66874|NCT02640690|Veterans
66875|NCT02640690|cytokines
66876|NCT02640690|acoustic startle reflex
66877|NCT02640664|open-label, long-term, extension study
66878|NCT02640664|intravitreal ranibizumab
66879|NCT02640664|laser ablation therapy
66880|NCT02640664|retinopathy of prematurity
66881|NCT02640664|preterm infants
66882|NCT02640664|RAINBOW
66883|NCT02640638|Racial disparities
66884|NCT02640625|HIV
66885|NCT02640625|Probiotics
66886|NCT02640625|Microbiota
66887|NCT02640625|Mucosal immunology
66888|NCT02640625|Gut biopsy
66889|NCT02640599|Vestibular
66890|NCT02640599|Rehabilitation
66891|NCT02640560|Children
66892|NCT02640560|Allergy
66893|NCT02640560|Peanuts
66894|NCT02640560|Hazelnuts
66896|NCT02640560|Mollusks
66897|NCT02640560|Shellfish
66898|NCT02640560|Food
66899|NCT02640547|Fibrosis
66900|NCT02640547|Chronic Hepatitis C
66901|NCT02640547|Cirrhosis
66902|NCT02640547|Work Ability
66903|NCT02640547|Dasabuvir
66904|NCT02640547|Quality of Life
66905|NCT02640547|Observational Study
66906|NCT02640547|Paritaprevir/r/Ombitasvir
66907|NCT02640534|Prostate cancer
66908|NCT02640534|Cancer of the prostate
66909|NCT02640534|Metformin
66910|NCT02640534|Enzalutamide
66911|NCT02640534|Xtandi
66912|NCT02640534|castration resistant prostate cancer
66913|NCT02640534|phase II
66914|NCT02640534|Androgen deprivation therapy
66915|NCT02640495|Treatment Efficacy
66916|NCT02640495|drug resistance
66917|NCT02640495|Artemisinin
66918|NCT02640482|Treatment-Naive
66919|NCT02640482|Hepatitis C Virus Genotype 2
66920|NCT02640482|Sofosbuvir (SOF)-Experienced
66921|NCT02640482|Treatment-Experienced
66922|NCT02640482|Non-cirrhotic
66923|NCT02640469|chlorhexidine
66924|NCT02640469|sterility
66925|NCT02640469|sterile hands
66926|NCT02640456|retropharyngeal abscess
66927|NCT02640456|parapharyngeal abscess
66928|NCT02640456|peritonsillar abscess
66929|NCT02640456|bacteriology
66930|NCT02640456|Fusobacterium necrophorum
66931|NCT02640417|Nucleotides (uridine, cytidine)
66932|NCT02640417|Vitamin B1
66933|NCT02640417|Vitamin B6
66934|NCT02640417|Vitamin B12
66935|NCT02640404|Meningitis
66936|NCT02640404|Meningococcal Meningitis
66937|NCT02640404|Meningococcal Infections
66938|NCT02640404|Menactra®
66939|NCT02640404|Meningococcal Vaccine
66940|NCT02640391|Ulcerative colitis
66941|NCT02640391|fecal calprotectin
66942|NCT02640391|mucosal healing
66943|NCT02638675|financial health incentives
66944|NCT02638675|physical activity
66945|NCT02638675|behavioral economics
66946|NCT02638675|randomized control trial
66947|NCT02638675|workplace health
66948|NCT02638649|lung ultrasound
66949|NCT02638636|Cognitive behavior therapy
66950|NCT02638636|Randomized controlled trial
66951|NCT02638636|Exposure therapy
66952|NCT02638636|Fibromyalgia
66953|NCT02638623|Knee Arthroplasty
66954|NCT02638623|Hip Arthroplasty
66955|NCT02638584|Ilaprazole
66956|NCT02638584|Gastric Adenoma
66957|NCT02638584|Early Gastric Cancer
66958|NCT02638584|Endoscopic Submucosal Dissection
66959|NCT02638532|Fat Pad
66960|NCT02638532|Fat Pad Atrophy
66961|NCT02638532|Foot
66962|NCT02638532|Feet
66963|NCT02638532|Heel
66964|NCT02638532|Forefoot
66965|NCT02640365|cancer
66966|NCT02640365|GERCOR
66967|NCT02640365|unresectable
66968|NCT02640365|MM-398
66969|NCT02640365|CPT-11
66970|NCT02640365|colorectal
66971|NCT02640365|non colorectal
66972|NCT02640326|Urinary Catheterization
66973|NCT02640326|Randomized Controlled Trial
66974|NCT02640326|Thoracic Surgery, Video-Assisted
66975|NCT02640326|Quality Improvement
66976|NCT02640326|Evidence-Based Practice
66977|NCT02640326|Post-operative complications
66978|NCT02640313|18F-fluormethylcholine
66979|NCT02640313|[F18] choline
66980|NCT02640313|[F18] fluormethylcholine
66981|NCT02640300|antipsychotics, clozapine, schizophrenia, switching strategy
66982|NCT02640274|Practise Patterns, Nurses'
66983|NCT02640274|Directive Counseling
66984|NCT02640274|Self Care
66985|NCT02640261|r-hLH
66986|NCT02640261|Cytokines
66987|NCT02640261|Follicular Fluid
66988|NCT02640235|Hemostasis
66989|NCT02640235|Oxidized Cellulose Strip
66990|NCT02640235|Traumacel
66991|NCT02640235|Traumastem
66992|NCT02640235|Cardiothoracic Surgery
66993|NCT02640235|General Surgery
66994|NCT02640235|Vascular Surgery
66995|NCT02640196|Laryngoscope
66996|NCT02640196|Macintosh
66997|NCT02640196|Glidescope
66998|NCT02640196|King Vision
66999|NCT02640196|Airtraq
67000|NCT02640196|Double Lumen Tube
67001|NCT02640157|interferon free
67002|NCT02640157|Hepatitis C
67003|NCT02640157|daclatasvir
67004|NCT02640157|Sovaldi
67005|NCT02640157|HCV
67006|NCT02640157|Hepatitis C Virus
67007|NCT02640157|Hepatitis C Genotype 3
67008|NCT02640157|Hep C
67009|NCT02640157|sofosbuvir
67010|NCT02640157|Chronic Hepatitis C
67011|NCT02640157|Daklinza
67012|NCT02640144|Hyaluronic acid
67013|NCT02640144|Knee arthroscopy
67014|NCT02640144|pain reduction
67015|NCT02640144|swelling
67016|NCT02640144|osteoarthritis
67017|NCT02640144|cartilage lesion
67018|NCT02640144|rehabilitation following knee arthroscopy
67019|NCT02640144|Hyaluronic acid injection
67020|NCT02640131|prostate cancer
67021|NCT02640131|radical prostatectomy
67022|NCT02640131|survivorship
67023|NCT02640131|quality of life
67024|NCT02640131|erectile dysfunction
67025|NCT02640131|sexual dysfunction
67026|NCT02640131|feasibility study
67027|NCT02640079|Cognitive behavioral therapy
67028|NCT02640079|Laboratory pain responsivity
67029|NCT02640014|Food allergy
67030|NCT02640014|Health-related quality of life (HRQL)
67031|NCT02640014|Quality-adjusted life-years (QALYs)
67032|NCT02640014|Oral immunotherapy (OIT)
67033|NCT02640014|Cow´s milk allergy (CMA)
67034|NCT02640014|Milk oral immunotherapy (MOIT)
67035|NCT02639988|type 2 diabetes mellitus
67036|NCT02639988|Rheumatoid arthritis
67037|NCT02639975|Adenosine A3 receptor antagonist
67038|NCT02639962|culprit lesion
67039|NCT02639962|arteriosclerosis
67040|NCT02639962|cardiac CT
67041|NCT02639923|TBI
67042|NCT02639923|microRNA
67043|NCT02639923|S-100B
67044|NCT02639910|CD19
67045|NCT02639910|MOR208
67046|NCT02639910|MOR00208
67047|NCT02639910|CLL
67048|NCT02639910|SLL
67049|NCT02639910|COSMOS
67050|NCT02639871|Huntington disease
67051|NCT02639871|Neuroimaging metabolic biomarker
67052|NCT02639832|Triple Negative Breast Cancer
67053|NCT02639832|Breast Cancer
67054|NCT02639832|Natural Killer Cells
67055|NCT02639832|BRCA Mutation
67056|NCT02639819|Intracerebral Hemorrhage
67057|NCT02639819|Stroke
67058|NCT02639819|Cerebrovascular
67059|NCT02639806|stroke
67060|NCT02639806|endovascular
67061|NCT02639806|thrombectomy
67062|NCT02639806|ischemic stroke
67063|NCT02639806|general anesthetic
67064|NCT02639806|local anesthetic
67065|NCT02639806|recanalization
67066|NCT02639793|arrhythmias, quality of life
67067|NCT02639767|Pemetrexed
67068|NCT02639767|Cisplatin
67069|NCT02639767|Intensity Modulated Radiation Therapy
67070|NCT02639767|15-304
67071|NCT02639741|Melatonin
67072|NCT02639741|Vitamin C
67073|NCT02639741|Morphine consumption
67074|NCT02639728|Bowel surgery
67075|NCT02639728|Postoperative bowel recovery
67076|NCT02639702|Clozapine
67077|NCT02639702|Dosing
67078|NCT02639702|Once daily
67079|NCT02639702|Regimen
67080|NCT02639702|Schizophrenia
67081|NCT02639689|Deficits of foot relievers of central origin
67082|NCT02639689|Walkaide
67083|NCT02639676|Infant
67084|NCT02639676|Bronchopulmonary Dysplasia
67085|NCT02639676|Premature
67086|NCT02639650|gestational trophoblastic tumor
67087|NCT02639650|paclitaxel
67088|NCT02639650|cisplatin
67089|NCT02639650|carboplatin
67090|NCT02639650|chemotherapy
67091|NCT02639637|Type 2 Diabetes Mellitus
67092|NCT02639637|Sitagliptin
67093|NCT02639637|Dipeptidyl Peptidase IV Inhibitors
67094|NCT02639637|Angiotensin Converting Enzyme Inhibitors
67095|NCT02639637|Enalaprilat
67096|NCT02639637|Neuropeptide Y
67097|NCT02639624|hemodialysis
67098|NCT02639624|kidney
67099|NCT02639624|dialysis
67100|NCT02639611|Breast Expanders
67101|NCT02639598|chronic migraine
67102|NCT02639598|prophylaxis
67103|NCT02639598|flunarizine
67104|NCT02639598|topiramate
67105|NCT02639585|daclatasvir
67106|NCT02639585|asunaprevir
67107|NCT02639533|fibromyalgia
67108|NCT02639533|pregabalin
67109|NCT02639533|cortical excitability
67110|NCT02639533|functional near infrared spectroscopy
67111|NCT02639520|Uncomplicated urinary tract infection
67112|NCT02638506|Headaches, Migraines, Fentanyl
67113|NCT02638493|HIV
67114|NCT02638493|tenofovir-emtrictabine
67115|NCT02638493|antiretroviral therapy
67116|NCT02638493|Prevention
67117|NCT02638493|tenofovir alafenamide
67118|NCT02638454|Exercise
67119|NCT02638454|Anabolic Resistance
67120|NCT02638454|Skeletal Muscle
67121|NCT02638454|microRNA
67122|NCT02638441|psychological health
67123|NCT02638441|women
67124|NCT02638441|anxiety
67125|NCT02638441|depression
67126|NCT02639481|traumatic brain injury
67127|NCT02639481|stroke
67128|NCT02639481|disorders of consciousness
67129|NCT02639481|rehabilitation
67130|NCT02639481|robotic rehabilitation device
67131|NCT02639416|severe acute malnutrition
67132|NCT02639416|polymeric therapeutic formula
67133|NCT02639416|elemental therapeutic formula
67134|NCT02639403|Rectal cancer
67135|NCT02639403|Radiotherapy
67136|NCT02639403|Occlusion
67137|NCT02639390|Robotics
67138|NCT02639390|upper extremity
67139|NCT02639390|neurorehabilitation
67140|NCT02639390|movement therapy
67141|NCT02639377|Dental Implantation
67142|NCT02639377|Chlorhexidine gluconate
67143|NCT02639338|Chronic
67144|NCT02639325|Brain Tumor
67145|NCT02639325|Brain Cancer
67146|NCT02639325|Seizure Disorder
67147|NCT02639325|Seizures
67148|NCT02639312|Cranofacial
67149|NCT02639312|Microsomia
67150|NCT02639312|Mandibular
67151|NCT02639312|Facial Defects
67152|NCT02639312|Hasburg Jaw
67153|NCT02639299|Subjects
67154|NCT02639299|Venipuncture
67155|NCT02639299|Research
67156|NCT02639299|Evaluate
67157|NCT02639299|Recruit
67158|NCT02639286|Lipodystrophy
67159|NCT02639286|Hypertriglyceridemia
67160|NCT02639273|Nalmefene
67161|NCT02639273|fMRI
67162|NCT02639273|Incentive Salience
67163|NCT02639273|Reward Processing
67164|NCT02639273|Aversive Event Processing
67165|NCT02639260|Nephrotic Syndrome
67166|NCT02639260|Glomerular Filtration Rate
67167|NCT02639260|Sialic Acid
67168|NCT02639260|Proteinuria
67169|NCT02639247|Chronic
67170|NCT02639208|Breast Cancer I
67171|NCT02639208|Breast Cancer Stage II
67172|NCT02639208|Breast Cancer Stage III
67173|NCT02639182|Axitinib
67174|NCT02639182|Metastatic Renal Cell Carcinoma
67175|NCT02639182|AGS-16C3F
67176|NCT02639169|music therapy
67177|NCT02639169|Distress
67178|NCT02639169|Mood
67179|NCT02639169|HSCT
67180|NCT02639130|Gastric Inhibitory Polypeptide (GIP)
67181|NCT02639130|Glucagon-Like Peptide 1 (GLP-1)
67182|NCT02639130|DPP-4 inhibition; Exendin [9-39]
67183|NCT02639130|Gastric emptying
67184|NCT02639130|Glucagon
67185|NCT02639130|Incretin
67186|NCT02639130|Insulin Secretion
67187|NCT02639130|Normal glucose-tolerant
67188|NCT02639117|basal cell carcinoma, photodynamic therapy, vismodegib
67189|NCT02639104|neck pain
67190|NCT02639104|cervical lordosis
67191|NCT02639104|long thoracic nerve
67192|NCT02639091|Phase 1
67193|NCT02639091|Solid tumors
67194|NCT02639091|Mesothelioma
67195|NCT02639091|Lung cancer
67196|NCT02639091|Pemetrexed
67197|NCT02639091|Cisplatin
67198|NCT02639078|Single ascending dose
67199|NCT02639078|volunteers
67200|NCT02639078|Phase 1
67201|NCT02639078|first-in-human
67202|NCT02639078|TD-0714
67203|NCT02639065|Durvalumab
67204|NCT02639065|MEDI4736
67205|NCT02639065|PD-L1 inhibitor
67206|NCT02639052|Itch
67207|NCT02639052|Botox
67208|NCT02639052|Healthy Volunteers
67209|NCT02638987|Dry needling
67210|NCT02638987|office workers
67211|NCT02638987|myofascial pain
67212|NCT02638987|electromyography
67213|NCT02638961|heart failure with preserved ejection fraction
67214|NCT02638961|physical therapy
67215|NCT02638961|exercise capacity
67216|NCT02638961|quality of life
67217|NCT02638935|Virtual Touch Tissue Imaging
67218|NCT02638935|VTIQ
67219|NCT02638935|Elastography
67220|NCT02638935|Breast Cancer
67221|NCT02638935|BI-RADS
67222|NCT02638935|Differentiation of breast lesions
67223|NCT02638935|Breast Lesion
67224|NCT02638909|Gastrointestinal malignancies
67225|NCT02638896|Ankylosing Spondylitis
67226|NCT02638896|Etanercept
67227|NCT02638896|Sulfasalazine
67228|NCT02638896|Efficacy
67229|NCT02638896|Safety
67230|NCT02638896|dose
67231|NCT02638896|reduction
67232|NCT02638857|Recurrence Hepatocellular Carcinoma
67233|NCT02638857|Advanced Hepatocellular Carcinoma
67234|NCT02638857|Dendritic Cell -Precision Multiple Antigen T Cells
67235|NCT02638857|Transcatheter Arterial Chemoembolization
67236|NCT02638844|echocardiography
67237|NCT02638831|Pain
67238|NCT02638831|Gonarthrosis
67239|NCT02638831|Low Back Pain
67240|NCT02638831|Ketorol Gel
67241|NCT02638831|Fastum Gel
67242|NCT02638831|Ketorolac Tromethamine
67243|NCT02638831|Ketoprofen
67244|NCT02638818|pancreaticoduodenectomy
67245|NCT02638818|Whipple
67246|NCT02638779|Septic shock
67247|NCT02638779|severe trauma
67248|NCT02638779|severe burn
67249|NCT02638779|major surgery
67250|NCT02638779|immunosuppression
67251|NCT02638779|Healthcare-Associated Infections
67252|NCT02638766|metastatic
67253|NCT02638766|unresectable
67254|NCT02638766|KIT/PDGFR wild type GIST
67255|NCT02638753|non specific chronic low back pain
67256|NCT02638753|education on pain neurophysiology
67257|NCT02638753|education on pain biology
67258|NCT02638753|education on pain neuroscience
67259|NCT02638753|hypnosis
67260|NCT02638727|vascular disease
67261|NCT02638727|endothelial function
67262|NCT02638727|L-Citrulline
67263|NCT02638714|Optic Neuropathies
67264|NCT02638714|Stem Cell Therapy
67265|NCT02638415|HVPG
67266|NCT02638402|glycosylation
67267|NCT02638402|mucin
67268|NCT02638402|receptor tyrosin kinases
67269|NCT02638402|ovarian cancer
67270|NCT02638402|endometrial cancer
67271|NCT02638376|Keraroconus
67272|NCT02638376|keratectasia
67273|NCT02638376|treatment
67274|NCT02638350|lung ultrasound
67275|NCT02638350|Pulmonary Edema
67276|NCT02638350|Respiratory Distress Syndrome
67277|NCT02638337|Vulvo-vaginal Atrophy
67278|NCT02638337|menopause
67279|NCT02638259|Biosimilars
67280|NCT02638259|Rheumatoid Arthritis
67281|NCT02638259|Etanercept
67282|NCT02638233|CHC
67283|NCT02638233|IVDA (intravenous drug abuse)
67284|NCT02638233|Hepatitis C
67285|NCT02638233|Sofosbuvir
67286|NCT02638233|Ledipasvir
67287|NCT02638233|Opiate Substitution Therapy
67288|NCT02638220|Cerebrotendinous Xanthomatosis
67289|NCT02638220|CTX Prevalence Study
67290|NCT02638220|CTX
67291|NCT02638220|Idiopathic Bilateral Cataracts
67292|NCT02638220|Cataracts
67293|NCT02638220|Bilateral Cataracts
67294|NCT02638220|Early-Onset Idiopathic Bilateral Cataracts
67295|NCT02638220|Observational Study
67296|NCT02638220|Ophthalmology
67297|NCT02638207|Chronic Inflammatory Demyelinating Poly Neuropathy (CIDP)
67298|NCT02638194|Chronic Obstructive Pulmonary Disease (COPD)
67299|NCT02638194|smoking
67300|NCT02638194|secondhand smoke
67301|NCT02638181|matrix metalloproteinase 13
67302|NCT02638181|tissue inhibitor of metalloproteinases 3
67303|NCT02638181|calcium-sensing receptor
67304|NCT02638181|trabecular meshwork
67305|NCT02638181|open-angle glaucoma
67306|NCT02638142|loop diuretic
67307|NCT02638142|heart failure
67308|NCT02638142|renal dysfunction
67309|NCT02638142|congestion signs
67310|NCT02638142|BNP
67311|NCT02638129|Drug therapy
67312|NCT02638116|Ibrutinib
67313|NCT02638116|Proton pump inhibitors
67314|NCT02638116|Pharmacokinetics
67315|NCT02638116|Drug Interaction
67316|NCT02638090|advanced lung cancer
67317|NCT02638090|immune therapy naive
67318|NCT02638090|immune therapy pre-treated
67319|NCT02638090|NSCLC
67320|NCT02638090|Stage IV lung cancer
67321|NCT02638090|pembrolizumab
67322|NCT02638090|vorinostat
67323|NCT02638090|immunogenicity
67324|NCT02638077|Differentiated Thyroid Cancer
67325|NCT02638077|the initial management
67326|NCT02638051|Peritoneal Carcinomatosis
67327|NCT02638051|Malignant Ascites
67328|NCT02638051|Modulated Electro-Hyperthermia
67329|NCT02638051|Traditional Chinese Medicine
67330|NCT02637960|VA106483, fedovapagon, BPH, nocturia, EQUINOC
67331|NCT02637921|bed rest
67332|NCT02637921|bone metabolism
67333|NCT02637908|Mindfulness
67334|NCT02637908|Parents
67335|NCT02637908|Families
67336|NCT02637895|PTSD,
67337|NCT02637895|trauma
67338|NCT02637895|stress disorder
67339|NCT02637895|post-traumatic stress disorder
67340|NCT02637895|anxiety disorder
67341|NCT02637869|Health Expenditures
67342|NCT02637869|Prospective Payment System
67343|NCT02637869|Health Care Utilization
67344|NCT02637869|Health Care Quality, Access, and Evaluation
67345|NCT02637843|radial
67346|NCT02637843|angiography
67347|NCT02637843|angioplasty
67348|NCT02637843|randomized
67349|NCT02637843|sheath
67350|NCT02637843|slender
67351|NCT02637791|Stroke
67352|NCT02637791|Rehabilitation
67353|NCT02637791|Virtual Reality
67354|NCT02637778|nutrient profiles
67355|NCT02637778|menu plans
67356|NCT02637778|n-3 LC-PUFA
67357|NCT02637778|SFA
67358|NCT02637778|MUFA
67359|NCT02637778|PUFA
67360|NCT02637778|cardiovascular risk
67361|NCT02637765|Breast Cancer
67362|NCT02637765|Physical Activity
67363|NCT02637765|Quality of life
67364|NCT02637752|Pediatric Obesity
67365|NCT02637752|Body Mass Index
67366|NCT02637752|Dentistry
67367|NCT02637739|hysteroscope
67368|NCT02637726|Total intravenous anesthesia
67369|NCT02637726|Target Controlled Infusion
67370|NCT02637726|Propofol
67371|NCT02637726|Bispectral index
67372|NCT02637726|Children
67373|NCT02637713|GERD
67374|NCT02637713|sleeve gastrectomy
67375|NCT02637713|reflux
67376|NCT02637713|morbidly obese
67377|NCT02637700|Small Fiber Neuropathy
67378|NCT02637700|Painful Neuropathy
67379|NCT02637700|Intravenous Immunoglobulin Therapy
67380|NCT02637687|Pediatric
67381|NCT02637687|NTRK1
67382|NCT02637687|NTRK2
67383|NCT02637687|NTRK3
67384|NCT02637687|Fusion
67385|NCT02637687|Tumors
67386|NCT02637687|Solid Tumors
67387|NCT02637687|CNS Tumors
67388|NCT02637687|Central Nervous System Tumors
67389|NCT02637687|NTRK Fusion Positive
67390|NCT02637687|TRKA
67391|NCT02637687|TRKB
67392|NCT02637687|TRKC
67393|NCT02637687|Infantile Fibrosarcoma
67394|NCT02637687|NTRK Gene Rearrangements
67395|NCT02637687|TRK Fusion
67396|NCT02637687|NTRK1 fusion
67397|NCT02637687|NTRK2 fusion
67398|NCT02637687|NTRK3 fusion
67399|NCT02637687|NTRK1 gene rearrangement
67400|NCT02637687|NTRK2 gene rearrangement
67401|NCT02637687|NTRK3 gene rearrangement
67402|NCT02637687|ETV6-NTRK3
67403|NCT02637687|ETV6
67404|NCT02637687|ETV6 fusion
67405|NCT02637687|ETV6 gene rearrangement
67406|NCT02637687|Solid CNS tumor
67407|NCT02637687|Primary CNS tumor
67408|NCT02637687|Advanced CNS tumor
67409|NCT02637687|Metastatic CNS tumor
67410|NCT02637687|Metastatic infantile fibrosarcoma
67411|NCT02637687|Advanced infantile fibrosarcoma
67412|NCT02637687|Fibrosarcoma
67413|NCT02637687|Congenital mesoblastic nephroma
67414|NCT02637687|Congenital nephroma
67415|NCT02637687|Thyroid
67416|NCT02637674|allotransplantation
67417|NCT02637661|earlobe crease
67418|NCT02637661|acute myocardial infarction
67419|NCT02637661|risk factor
67420|NCT02637635|Mammaplasty
67421|NCT02637635|Transplantation, Autologous
67422|NCT02637635|Mastectomy
67423|NCT02637635|Breast Implants
67424|NCT02637635|Radiotherapy, Adjuvant
67425|NCT02637622|conjoint analysis
67426|NCT02637622|stated-preference methods
67427|NCT02637622|patient centered outcome research (PCOR)
67428|NCT02637622|community-based participatory research (CBPR)
67429|NCT02637622|patient preference
67430|NCT02637622|diabetes
67431|NCT02637609|conjoint analysis
67432|NCT02637609|stated-preference methods
67433|NCT02637609|patient centered outcome research (PCOR)
67434|NCT02637609|community-based participatory research (CBPR)
67435|NCT02637609|patient priority
67436|NCT02637609|diabetes
67437|NCT02637583|conjugate vaccine
67438|NCT02637583|polysaccharide vaccine
67439|NCT02637570|healthy male athletes
67440|NCT02637570|18-35 years old
67441|NCT02637531|IPI-549
67442|NCT02637531|Phase 1
67443|NCT02637531|Advanced Solid Tumor
67444|NCT02637531|Non-small cell lung cancer
67445|NCT02637531|Melanoma
67446|NCT02637531|PI3K
67447|NCT02637531|Squamous Cell Cancer of the Head and Neck
67448|NCT02637518|Frailty
67449|NCT02637518|Frailty screening tools
67450|NCT02637518|Clinical settings
67451|NCT02637518|Social settings
67452|NCT02637518|Geriatrics
67453|NCT02637518|Functional autonomy
67454|NCT02637518|Disability
67455|NCT02637505|Articular cartilage
67456|NCT02637505|Focal cartilage injury
67457|NCT02637505|Focal cartilage injury in the knee
67458|NCT02637505|Knee cartilage
67459|NCT02637505|Microfracture
67460|NCT02637505|Debridement
67461|NCT02637492|Critical limb ischaemia
67462|NCT02637492|Peripheral occlusive arterial disease
67463|NCT02637492|Clinical prediction
67464|NCT02637492|Ankle pressure
67465|NCT02637492|Transcutaneous oxygen pressure
67466|NCT02637492|Toe pressure
67467|NCT02637492|Microcirculation
67468|NCT02637453|Paroxysmal Atrial Fibrillation;Additional Linear Ablation
67469|NCT02637427|Fresh frozen plasma
67470|NCT02637427|Bleeding
67471|NCT02637414|Stress
67472|NCT02637414|Well-being
67473|NCT02637414|Positive psychology
67474|NCT02637388|Appetite
67475|NCT02637388|Beta-glucans
67476|NCT02637388|Energy Intake
67477|NCT02637388|Glucagon-Like Peptide 1
67478|NCT02637388|Glucose
67479|NCT02637388|Insulin
67480|NCT02637388|Incretins
67481|NCT02637375|triple-negative breast cancer
67482|NCT02637336|Therapies. Autonomic nervous system. Cardiovascular stress
67483|NCT02637323|Osteoarthritis
67484|NCT02637323|Knee
67485|NCT02637323|Pain
67486|NCT02637323|Steroid
67487|NCT02637323|Intra-articular
67488|NCT02637323|Injection
67489|NCT02637284|Healthy volunteers
67490|NCT02637271|Calorie restriction
67491|NCT02637271|Meal replacement
67492|NCT02637271|fMRI
67493|NCT02637271|Food-cue reactivity
67494|NCT02637271|Obesity
67495|NCT02637258|optic nerve sheath diameter
67496|NCT02637258|neurological outcome
67497|NCT02637258|OHCA
67498|NCT02637245|diabetic macular edema
67499|NCT02637245|diabetic retinopathy
67500|NCT02637206|Healthy Japanese
67501|NCT02637206|GSK2894512
67502|NCT02637206|skin safety
67503|NCT02637180|osteoporosis
67504|NCT02637180|fracture
67505|NCT02637180|liaison service
67506|NCT02637167|Heart failure
67507|NCT02637167|inflammation
67508|NCT02637167|rifaximin
67509|NCT02637167|Saccharomyces boulardii
67510|NCT02637167|gut microbiota
67511|NCT02637154|Adolescent
67512|NCT02637154|Type 1 diabetes
67513|NCT02637154|Metabolic control
67514|NCT02637154|Motivational interviewing
67515|NCT02637141|celiac
67516|NCT02637141|gluten
67517|NCT02637141|IL-15
67518|NCT02637141|AMG 714
67519|NCT02637128|MALARIA, FALCIPARUM
67520|NCT02637128|MALAWI
67521|NCT02637128|ARTEMETHER-LUMEFANTRINE
67522|NCT02637128|ARTESUNATE-AMODIAQUINE
67523|NCT02637115|Gut microbiota
67524|NCT02637115|Akkermansia muciniphila
67525|NCT02637076|Xyrem
67526|NCT02637076|narcolepsy with cataplexy
67527|NCT02637076|positron emission tomography
67528|NCT02637076|dopamine
67529|NCT02637063|Lifestyle behavior change
67530|NCT02637050|Type IV Pulmonary Hypertension
67531|NCT02637050|Chronic Thromboembolic Pulmonary Hypertension
67532|NCT02637050|CTEPH
67533|NCT02637037|dapagliflozin/metformin XR 5/500 mg
67534|NCT02637037|dapagliflozin/metformin XR10/1000 mg
67535|NCT02637037|bioequivalence
67536|NCT02637037|fixed dose combination tablets
67537|NCT02637037|pharmacokinetic
67538|NCT02637037|type 2 Diabetes Mellitus (T2DM)
67539|NCT02637037|safety
67540|NCT02637024|Breast Cancer
67541|NCT02637024|DCIS
67542|NCT02637024|Radiotherapy
67543|NCT02637024|Partial breast irradiation
67544|NCT02637024|Radiation fractions
67545|NCT02637011|acute respiratory distress syndrome
67546|NCT02637011|intensive care medicine
67547|NCT02637011|critical illness
67548|NCT02637011|long-term outcomes
67549|NCT02637011|quality of life
67550|NCT02637011|return to work
67551|NCT02637011|quality of care
67552|NCT02636972|TLR2
67553|NCT02636972|TLR4
67554|NCT02636972|Biomarker
67555|NCT02636972|TLR responsiveness
67556|NCT02636972|Peripheral blood responsiveness
67557|NCT02636972|Inflammatory pain
67558|NCT02636933|Asthma
67559|NCT02636933|Allergic Rhinitis
67560|NCT02636933|Children
67561|NCT02636933|Atopy
67562|NCT02636920|Asthma
67563|NCT02636920|Children
67564|NCT02636855|Solid and Hematological Malignancies
67565|NCT02636855|Screening
67566|NCT02636855|Metastatic
67567|NCT02636855|Previously Treated
67568|NCT02636855|NY-ESO-1
67569|NCT02636855|MAGE A10
67570|NCT02636842|Schizophrenia
67571|NCT02636842|Schizoaffective Disorder
67572|NCT02636842|Aripiprazole Lauroxil
67573|NCT02636842|Aripiprazole
67574|NCT02636842|ALKS 9072
67575|NCT02636842|Alkermes
67576|NCT02636803|trichuris
67577|NCT02636803|hookworms
67578|NCT02636803|Ascaris
67579|NCT02636777|low back pain
67580|NCT02636777|chronic pain
67581|NCT02636777|self-management
67582|NCT02636777|longitudinal study
67583|NCT02636777|predictive modelling
67584|NCT02636751|Prehabilitation
67585|NCT02636751|Telemedicine
67586|NCT02636751|Osteoarthritis
67587|NCT02636751|Arthroplasty
67588|NCT02636751|Hip
67589|NCT02636751|Knee
67590|NCT02636725|Advanced Alveolar Soft Part Sarcoma
67591|NCT02636725|ASPS
67592|NCT02636725|Soft Tissue Sarcomas
67593|NCT02636725|STS
67594|NCT02636725|Alveolar Soft Part Sarcoma
67595|NCT02636686|DMD
67596|NCT02636686|Duchenne Muscular Dystrophy
67597|NCT02636686|Drisapersen
67598|NCT02636686|Kyndrisa
67599|NCT02636686|exon-skipping
67600|NCT02636686|exon-51
67601|NCT02636686|BMN-051-302
67602|NCT02636686|051-302
67603|NCT02636660|Critical care
67604|NCT02636660|Mechanical Ventilation
67605|NCT02636660|Quality of Life
67606|NCT02636660|Stressors
67607|NCT02636660|Nursing Sensitive Outcomes
67608|NCT02636660|Nursing
67609|NCT02636647|hepatic encephalopathy
67610|NCT02636647|fecal transplant
67611|NCT02636647|cirrhosis
67612|NCT02636634|diagnostic strategy
67613|NCT02636634|brain metastases
67614|NCT02636634|radiation necrosis
67615|NCT02636634|relapse
67616|NCT02636634|PET-FET and MSR
67617|NCT02636634|radiosurgery
67618|NCT02636621|Fatigue
67619|NCT02636621|excessive daytime sleepiness
67620|NCT02636621|flow limitation
67621|NCT02636608|Observational Study
67622|NCT02636608|Chronic Hepatitis C
67623|NCT02636608|Cirrhosis
67624|NCT02636608|Paritaprevir/r/Ombitasvir
67625|NCT02636608|Dasabuvir
67626|NCT02636608|Work Ability
67627|NCT02636608|Quality of Life
67628|NCT02636608|Fibrosis
67629|NCT02636595|Hepatitis C Genotype 4
67630|NCT02636595|Hepatitis C
67631|NCT02636595|Chronic Hepatitis C
67632|NCT02636595|Hepatitis C Genotype 6
67633|NCT02636595|Hepatitis C Genotype 5
67634|NCT02636556|thymoma
67635|NCT02636556|thymic carcinoma
67636|NCT02636556|chemoradiotherapy
67637|NCT02636556|inoperable
67638|NCT02636543|genetic diagnosis
67639|NCT02636543|information
67640|NCT02636543|letter model
67641|NCT02636517|Fecal Microbiota transplant
67642|NCT02636504|Pulp vitality
67643|NCT02636504|Pulp testing
67644|NCT02636439|Diastolic heart failure
67645|NCT02636439|Heart Failure
67646|NCT02636439|Elderly
67647|NCT02636439|Obesity
67648|NCT02636426|phase I study
67649|NCT02636426|sorafenib
67650|NCT02636426|high-dose schedule
67651|NCT02636426|pharmacokinetics
67652|NCT02636426|drug monitoring
67653|NCT02636400|Infertility
67654|NCT02636400|endometriosis
67655|NCT02636348|Calcium
67656|NCT02636348|Vitamin D
67657|NCT02636322|Lymphoma
67658|NCT02636322|High Risk Diffuse Large B-Cell Lymphoma
67659|NCT02636322|DLBCL
67660|NCT02636322|Rituximab
67661|NCT02636322|Rituxan
67662|NCT02636322|Ibrutinib
67663|NCT02636322|PCI-32765
67664|NCT02636322|Imbruvica
67665|NCT02636322|Lenalidomide
67666|NCT02636322|CC-5013
67667|NCT02636322|Revlimid
67668|NCT02636322|Etoposide
67669|NCT02636322|VePesid
67670|NCT02636322|Prednisone
67671|NCT02636322|Vincristine
67672|NCT02636322|Oncovin
67673|NCT02636322|Cyclophosphamide
67674|NCT02636322|Cytoxan
67675|NCT02636322|Neosar
67676|NCT02636322|Doxorubicin
67677|NCT02636322|Hydroxydaunorubicin
67678|NCT02636322|Adriamycin PFS
67679|NCT02636322|Adriamycin RDF
67680|NCT02636322|Adriamycin
67681|NCT02636322|Rubex
67682|NCT02636309|ergonomics
67683|NCT02636309|multifaceted intervention
67684|NCT02636309|industry
67685|NCT02636309|physiotherapy
67686|NCT02636309|physical exercises
67687|NCT02636309|workplace
67688|NCT02636309|acupuncture
67689|NCT02636309|work
67690|NCT02636309|quality of life
67691|NCT02636309|absenteeism
67692|NCT02636309|efficiency
67693|NCT02636309|musculoskeletal pain
67694|NCT02636309|WMSD
67695|NCT02636296|Pilates method
67696|NCT02636296|elderly
67697|NCT02636296|postural balance
67698|NCT02636257|Silicone Nasolacrimal Intubation
67699|NCT02636257|Dacryocystorhinostomy
67700|NCT02636231|Endostar
67701|NCT02636231|IMRT
67702|NCT02636231|recurrent
67703|NCT02636231|NPC
67704|NCT02636218|Ketamine
67705|NCT02636192|Sodium-glucose co-transporter 2 inhibitors
67706|NCT02636192|Diabetes Mellitus, Type 2
67707|NCT02636179|In Vitro Fertilization, follow-up of children
67708|NCT02636166|Pregnancy
67709|NCT02636153|phosphorus,dietary
67710|NCT02636153|circadian rhythm
67711|NCT02636153|phosphorus
67712|NCT02636088|Phase II study, clinical trial
67713|NCT02636062|Coronary disease
67714|NCT02636062|Coronary artery disease (CAD)
67715|NCT02636062|Endothelial dysfunction
67716|NCT02636062|Coronary artery calcium (CAC)
67717|NCT02636049|pharmacokinetics
67718|NCT02636049|healthy adult volunteer
67719|NCT02635997|osteoporosis
67720|NCT02635997|ibandronate
67721|NCT02635997|vitamine D
67722|NCT02635997|calcium
67723|NCT02635997|bone mineral density
67724|NCT02635997|health-related quality of life
67725|NCT02635971|transcatheter arterial infusion
67726|NCT02635971|randomized controlled trial
67727|NCT02635971|chemotherapy
67728|NCT02635958|Body Mass Index
67729|NCT02635958|BMI
67730|NCT02635958|InBody
67731|NCT02635958|iDXA
67732|NCT02635958|validation
67733|NCT02635945|adenosine A1 receptor antagonist
67734|NCT02635945|adenosine receptor modulator
67735|NCT02635945|COPD
67736|NCT02635945|asthma
67737|NCT02635919|Nicotine addiction
67738|NCT02635919|Cigarette smoking
67739|NCT02635919|Smoking cessation
67740|NCT02635919|Quit smoking
67741|NCT02635906|BED REST
67742|NCT02635906|CORONARY ANGIOPLASTY
67743|NCT02635893|SCI
67744|NCT02635867|vital pulp
67745|NCT02635867|reversible pulpitis
67746|NCT02635867|pulp capping
67747|NCT02635867|deep cavity
67748|NCT02635867|Management of Deep Dental Caries
67749|NCT02635854|leukocyte and platelet aggregates
67750|NCT02635854|platelet activation
67751|NCT02635841|Pantothenate Kinase-Associated Neurodegeneration
67752|NCT02635841|PKAN
67753|NCT02635841|Neurodegeneration with Brain Iron Accumulation
67754|NCT02635841|NBIA
67755|NCT02635841|Deferiprone
67756|NCT02635841|Ferriprox
67757|NCT02635828|Palonosetron
67758|NCT02635828|Craniotomy
67759|NCT02635828|Nausea
67760|NCT02635828|Vomiting
67761|NCT02635802|remifentanil
67762|NCT02635802|analgesia
67763|NCT02635802|intensive care units
67764|NCT02635789|Sirolimus
67765|NCT02635789|Skin lesions
67766|NCT02635789|TSC
67767|NCT02635789|Tuberous Sclerosis Complex
67768|NCT02635789|NPC-12G
67769|NCT02635789|Angiofibroma
67770|NCT02635789|Hypomelanotic macule
67771|NCT02635789|Plaque
67772|NCT02635776|AR101 (Characterized Peanut Allergen)
67773|NCT02635776|Characterized Peanut Allergen
67774|NCT02635776|CPNA (Characterized Peanut Allergen)
67775|NCT02635776|OIT (oral immunotherapy)
67776|NCT02635776|Oral Immunotherapy
67777|NCT02635776|Peanut Allergy
67778|NCT02635776|Allergy
67779|NCT02635776|Peanut-Allergic Children
67780|NCT02635776|Peanut-Allergic Adults
67781|NCT02635776|Desensitization
67782|NCT02635763|nerve block
67783|NCT02635763|general anesthesia
67784|NCT02635763|hip fracture
67785|NCT02635763|recovery
67786|NCT02635724|Acute uncomplicated
67787|NCT02635724|Elderly
67788|NCT02635685|Atrial fibrillation
67789|NCT02635685|Stroke
67790|NCT02635685|Clinical Decision Support
67791|NCT02635685|Anticoagulants
67792|NCT02635672|Solid tumors
67793|NCT02635672|Aggressive non-hodgkin's lymphoma (NHL)
67794|NCT02635659|food intake, satiety, satiation, nutrients, ileal brake
67795|NCT02635633|partial epilepsy
67796|NCT02635633|unifocal neocortical
67797|NCT02635633|treatment resistant
67798|NCT02635633|transcranial magnetic stimulation
67799|NCT02635633|thetaburst stimulation
67800|NCT02635620|e-cigarette, electronic cigarette, lung function
67801|NCT02635607|GnRH antagonist
67802|NCT02635607|fixed protocol
67803|NCT02635607|flexible protocol
67804|NCT02635542|Postoperative Pulmonary Complications
67805|NCT02635542|Residual Neuromuscular Blockade
67806|NCT02635542|Cardiac Surgical Procedures
67807|NCT02635503|colorectal cancer
67808|NCT02635503|laparoscopic surgery
67809|NCT02635503|natural orifice specimen extraction
67810|NCT02635503|Inflammatory response
67811|NCT02635490|prophylactic antibiotics, urinary tract infection.
67812|NCT02635451|vitamin c
67813|NCT02635451|Preterm Premature Rupture of Membranes
67814|NCT02635438|Oropharyngeal Candidiasis
67815|NCT02635412|Placenta
67816|NCT02635412|Accreta
67817|NCT02635412|Morbidly
67818|NCT02635412|Adherent Placenta
67819|NCT02635399|pancreaticoduodenectomy, delayed gastric emptying, duodenojejunopexy
67820|NCT02635386|PCOS
67821|NCT02635386|GLP1 agonists
67822|NCT02635386|SGLT2 inhibitors
67823|NCT02635373|Calciphylaxis
67824|NCT02635373|Rare disease (ORPHA280062)
67825|NCT02635373|Renal insufficiency
67826|NCT02635373|ESRD
67827|NCT02635373|Calcification
67828|NCT02635373|Chronic kidney disease
67829|NCT02635373|Dialysis
67830|NCT02635373|Vascular disease
67831|NCT02635360|advanced
67832|NCT02635360|cervical cancer
67833|NCT02635360|pembrolizumab
67834|NCT02635360|chemoradiation
67835|NCT02635360|immunotherapy
67836|NCT02635347|Remote ischemic preconditioning
67837|NCT02635347|Remote ischemic perconditioning
67838|NCT02635347|Remote ischemic postconditioning
67839|NCT02635347|Remote ischemic conditioning
67840|NCT02635347|Orthotopic liver transplant
67841|NCT02635347|Brain Death Organ Donor
67842|NCT02635321|MRI
67843|NCT02635321|LGMD
67844|NCT02635321|GMPPB
67845|NCT02635308|hip fracture
67846|NCT02635308|physical function
67847|NCT02635308|muscle function
67848|NCT02635308|symmetry
67849|NCT02635295|Clinical practicum
67850|NCT02635295|Nursing student
67851|NCT02635295|Nurse teacher
67852|NCT02635295|Mobile technology
67853|NCT02635295|Cooperation
67854|NCT02635295|Nurse competence
67855|NCT02635269|Ergometry
67856|NCT02635269|Stable isotope tracers
67857|NCT02635256|hypofractionation
67858|NCT02635256|prostate cancer
67859|NCT02635256|radiotherapy
67860|NCT02635230|Atrial Fibrillations
67861|NCT02635230|Heart Valve Prostheses
67862|NCT02635230|Acute Coronary Syndromes
67863|NCT02635230|Percutaneous Coronary Revascularization
67864|NCT02635230|Coronary Artery Bypass Grafting
67865|NCT02635230|Coronary Artery Diseases
67866|NCT02635230|Myocardial Infarction
67867|NCT02635230|Ischemic stroke
67868|NCT02635230|Bleeding
67869|NCT02635230|Thrombosis
67870|NCT02635230|Myocardial Ischemia
67871|NCT02635230|Heart Diseases
67872|NCT02635230|Cardiovascular Diseases
67873|NCT02635230|Embolism and Thrombosis
67874|NCT02635230|Platelet Aggregation Inhibitors
67875|NCT02635230|Aspirin
67876|NCT02635230|Clopidogrel
67877|NCT02635230|Ticagrelor
67878|NCT02635230|Prasugrel
67879|NCT02635230|Antithrombotic treatment
67880|NCT02635230|Oral anticoagulation
67881|NCT02635230|Warfarin
67882|NCT02635230|Dabigatran etexilate mesylate
67883|NCT02635230|Apixaban
67884|NCT02635230|Rivaroxaban
67885|NCT02635230|Direct Factor Xa Inhibitors
67886|NCT02635230|Direct Thrombin Inhibitors
67887|NCT02635217|Colonoscopy
67888|NCT02635217|Esophagogastroduodenoscopy
67889|NCT02635217|Patient satisfaction
67890|NCT02635217|Bidirectional endoscopies
67891|NCT02635191|Helicobacter pylori
67892|NCT02635191|Therapy
67893|NCT02635191|Children
67894|NCT02635139|meal skipping
67895|NCT02635139|isocaloric diet
67896|NCT02635139|macronutrient oxidation
67897|NCT02635139|glucose homeostasis
67898|NCT02635139|arterial stiffness
67899|NCT02635113|balance
67900|NCT02635113|gait
67901|NCT02635113|falls
67902|NCT02635113|sensory deficits
67903|NCT02635113|vibration
67904|NCT02635113|visual acuity
67905|NCT02635113|dizziness
67906|NCT02635113|postural control
67907|NCT02635113|proprioceptive function
67908|NCT02635113|stereoacuity
67909|NCT02635113|depth perception
67910|NCT02635113|vestibular dysfunction
67911|NCT02635100|Sleep Disordered Breathing
67912|NCT02635100|Sleep Apnea
67913|NCT02635048|Percutaneous nephrolithotomy
67914|NCT02635048|Kidney stones
67915|NCT02635048|Efficacy
67916|NCT02635022|Fracture
67917|NCT02635022|Sarcopenia
67918|NCT02635022|Osteoporosis
67919|NCT02635022|Care management
67920|NCT02635022|Medication adherence
67921|NCT02634983|COPD
67922|NCT02634983|Smokers
67923|NCT02634983|Ex-smokers
67924|NCT02634970|wet AMD, ranibizumab, aflibercept, neovascularization
67925|NCT02634957|phonomicrosurgery
67926|NCT02634957|benign vocal fold lesions
67927|NCT02634957|voice rest
67928|NCT02634957|vhi-10
67929|NCT02634957|CPP
67930|NCT02634944|Concussion
67931|NCT02634944|Vestibular
67932|NCT02634944|Ocular-Motor
67933|NCT02634931|Sirolimus
67934|NCT02634931|Skin lesions
67935|NCT02634931|TSC
67936|NCT02634931|Tuberous Sclerosis Complex
67937|NCT02634931|NPC-12G
67938|NCT02634931|Angiofibroma
67939|NCT02634931|Hypomelanotic Macule
67940|NCT02634931|Plaque
67941|NCT02634918|ultrasound,
67942|NCT02634918|ultrasonography
67943|NCT02634918|hemophilic joint
67944|NCT02634918|Doppler
67945|NCT02634905|atopic dermatitis
67946|NCT02634905|Therapeutic patient education
67947|NCT02634905|pediatric dermatology
67948|NCT02634892|Sacral
67949|NCT02634892|Overlay Mattress
67950|NCT02634892|Cooling
67951|NCT02634866|hypertension
67952|NCT02634866|exercise
67953|NCT02634866|diastolic heart failure
67954|NCT02634853|Dry Eye
67955|NCT02634840|inferior alveolar nerve
67956|NCT02634840|neurosensory disturbance
67957|NCT02634840|bilateral sagittal spilt osteotomy
67958|NCT02634840|mandibular surgery
67959|NCT02634840|neurosensory function
67960|NCT02634801|Fumaderm
67961|NCT02634788|Post-Surgical Pain
67962|NCT02634788|Bunionectomy
67963|NCT02634775|Pediatrics
67964|NCT02634775|Nephrology
67965|NCT02634775|Dialysis
67966|NCT02634749|Nordic countries
67967|NCT02634749|Eating behavior
67968|NCT02634749|Human microbiome
67969|NCT02634749|Child nutrition
67970|NCT02634749|Metabolic profile
67971|NCT02634749|Body composition
67972|NCT02634710|soft tissue sarcoma
67973|NCT02634697|Atrial Fibrillation
67974|NCT02634697|Relaxation Response Resiliency Program Intervention
67975|NCT02634697|AF Symptom Severity and Burden
67976|NCT02634697|Stress, Anxiety, Depression and Hostility
67977|NCT02634697|Quality of Life
67978|NCT02634697|AF
67979|NCT02634697|QOL
67980|NCT02634697|3RP
67981|NCT02634684|Schizophrenia
67982|NCT02634684|Schizoaffective Disorder
67983|NCT02634684|Mental Disorders
67984|NCT02634684|Anti-Dyskinesia Agents
67985|NCT02634684|Antiparkinson Agents
67986|NCT02634684|Central Nervous System Agents
67987|NCT02634684|Dopamine Agents
67988|NCT02634684|Excitatory Amino Acid Agents
67989|NCT02634684|Excitatory Amino Acid Antagonists
67990|NCT02634684|Molecular Mechanisms of Pharmacological Action
67991|NCT02634684|Neurotransmitter Agents
67992|NCT02634684|Pharmacologic Actions
67993|NCT02634684|Physiological Effects of Drugs
67994|NCT02634684|Therapeutic Uses
67995|NCT02634684|Prepulse inhibition
67996|NCT02634684|Neurocognition
67997|NCT02634684|Working memory
67998|NCT02634684|Dextroamphetamine
67999|NCT02634684|MATRICS Consensus Cognitive Battery
68000|NCT02634684|Pharmacologic Augmentation of Cognitive Therapies
68001|NCT02634684|Sensory discrimination learning
68002|NCT02634684|Targeted Cognitive Training
68003|NCT02634684|rs4680 polymorphism of catechol-O-methyltransferase (COMT)
68004|NCT02634671|schizophrenia
68005|NCT02634671|Facial emotions
68006|NCT02634619|urethral stricture
68007|NCT02634606|Cholesterol
68008|NCT02634593|nutrition
68009|NCT02634580|Japanese
68010|NCT02634580|High cholesterol
68011|NCT02634580|Treatment of high cholesterol
68012|NCT02634580|Lowering cholesterol
68013|NCT02634580|Lowering high cholesterol
68014|NCT02634580|Hypercholesterolemia
68015|NCT02634580|Statin intolerant
68016|NCT02634528|intermediate-acting human isophane insulin, biosimilar
68017|NCT02634515|soluble human insulin, biosimilar
68018|NCT02634502|radiofrequency
68019|NCT02634502|chemotherapy
68020|NCT02634502|microRNA
68021|NCT02634489|Bladder outlet obstruction
68022|NCT02634489|Overactive bladder
68023|NCT02634489|Urinary incontinence
68024|NCT02634489|Omnic OCAS®
68025|NCT02634489|Vesicare®
68026|NCT02634489|Tamsulosin hydrochloride
68027|NCT02634489|Solifenacin succinate
68028|NCT02634476|Alcohol
68029|NCT02634476|Substance use disorder
68030|NCT02634476|cognitive bias
68031|NCT02634476|behavioral intervention
68032|NCT02634476|computerised training
68033|NCT02634463|Immunoassay
68034|NCT02634463|Antipsychotic
68035|NCT02634463|Aripiprazole
68036|NCT02634463|Olanzapine
68037|NCT02634463|Paliperidone
68038|NCT02634463|Risperidone
68039|NCT02634450|HIV
68040|NCT02634450|Diagnostic
68041|NCT02634450|children
68042|NCT02634424|Hemophilia A
68043|NCT02634424|Prophylaxy
68044|NCT02634424|Pharmacokinetic
68045|NCT02634424|Bayesian
68046|NCT02634411|Ventilator Associated
68047|NCT02634411|Pneumonia
68048|NCT02634411|Antibiotic treatment
68049|NCT02634411|Pseudomonas aeruginosa
68050|NCT02634372|Bipolar Disorder
68051|NCT02634372|Traumatic event
68052|NCT02634372|Eye Movement Desensitization Reprocessing
68053|NCT02634372|Supportive therapy
68054|NCT02634372|Relapse prevention
68055|NCT02634346|Alkermes
68056|NCT02634346|ALKS 3831
68057|NCT02634346|Samidorphan
68058|NCT02634346|Schizophrenia
68059|NCT02634346|Acute Exacerbation of Schizophrenia
68060|NCT02634333|anti-vascular endothelial growth factor
68061|NCT02634333|nonproliferative diabetic retinopathy
68062|NCT02634320|Alkermes
68063|NCT02634320|ARISTADA
68064|NCT02634320|Aripiprazole Lauroxil
68065|NCT02634320|Schizophrenia
68066|NCT02634307|Multiple Sclerosis
68067|NCT02634307|MS
68068|NCT02634307|Relapsing Remitting Multiple Sclerosis
68069|NCT02634307|RRMS
68070|NCT02634307|dimethyl fumarate
68071|NCT02634307|DMF
68072|NCT02634294|Hematological Neoplasms
68073|NCT02634294|recurrence
68074|NCT02634294|Hematopoietic Stem Cell Transplantation
68075|NCT02634294|peginterferon alfa-2b
68076|NCT02634294|Graft vs Host Disease
68077|NCT02634268|randomized controlled trial
68078|NCT02634268|diet
68079|NCT02634268|exercise
68080|NCT02634268|obesity
68081|NCT02634268|overweight
68082|NCT02634268|chronic obstructive pulmonary disease
68083|NCT02634268|lifestyle
68084|NCT02634255|rocuronium
68085|NCT02634255|onset time
68086|NCT02634255|anxiety
68087|NCT02634242|Si Wu Tang
68088|NCT02634242|antioxidation
68089|NCT02634242|anthropometric measurements
68090|NCT02634242|liver
68091|NCT02634242|skin
68092|NCT02634229|monogenic diabetes
68093|NCT02634229|MODY
68094|NCT02634229|beta-cell
68095|NCT02634229|insulin secretion
68096|NCT02634216|Hyperglycemia
68097|NCT02634216|Capros
68098|NCT02634216|Type 1 Diabetes
68099|NCT02634203|Chronic Thromboembolic Pulmonary Hypertension
68100|NCT02634203|Balloon Pulmonary Angioplasty
68101|NCT02634203|Riociguat
68102|NCT02634190|Cervical cancer screening
68103|NCT02634190|High risk Human Papillomavirus
68104|NCT02634190|Aptima HPV Assay
68105|NCT02634177|Genotyping
68106|NCT02634177|Genecept Assay™
68107|NCT02634164|leucine
68108|NCT02634164|isoleucine
68109|NCT02634151|LDL‐C
68110|NCT02634151|Lipid Regulator
68111|NCT02634138|Peripheral Vascular Disease
68112|NCT02634138|Critical Limb Ischaemia
68113|NCT02634112|anastomotic leakage
68114|NCT02634112|rectal cancer surgery
68115|NCT02634112|anastomotic leakage predictive score
68116|NCT02634099|major pediatric surgery
68117|NCT02634099|hemoglobin measurement
68118|NCT02634086|Coronary artery disease
68119|NCT02634086|Percutaneous coronary intervention
68120|NCT02634086|Coronary artery bypass graft
68121|NCT02634086|Medication therapy
68122|NCT02634073|Lamivudine
68123|NCT02634073|Safety
68124|NCT02634073|Sorbitol
68125|NCT02634073|Pharmacokinetics
68126|NCT02634060|adalimumab
68127|NCT02634060|fecal calprotectin
68128|NCT02634060|home based
68129|NCT02634047|transesophageal echocardiography
68130|NCT02634047|videolaryngoscope
68131|NCT02634047|oropharyngeal injury
68132|NCT02634008|Genotype 1
68133|NCT02633956|Non-alcoholic Fatty Liver Disease
68134|NCT02633956|NAFLD
68135|NCT02633956|Fatty Liver Disease
68136|NCT02633956|NASH
68137|NCT02633930|helicobacter pylori
68138|NCT02633930|berberine-containing quadruple therapy
68139|NCT02633930|clarithromycin-containing quadruple therapy
68140|NCT02633917|Low back pain
68141|NCT02633917|Motor control
68142|NCT02633917|Joint mobilization
68143|NCT02633904|Hip Dislocation
68144|NCT02633904|Congenital
68145|NCT02633904|osteotomy
68146|NCT02633904|Femur Head Necrosis
68147|NCT02633891|neuropathies
68148|NCT02633891|metabolic diseases
68149|NCT02633891|nervous system diseases
68150|NCT02633891|peripheral nervous system diseases
68151|NCT02633865|patient characteristics
68152|NCT02633852|Diabetic Macular Edema (DME)
68153|NCT02633852|Aflibercept (EYLEA)
68154|NCT02633839|Adults
68155|NCT02633826|alloreactive T cell
68156|NCT02633826|donor-specific antibody
68157|NCT02633813|Bioequivalence
68158|NCT02633813|Tinea pedis
68159|NCT02633813|Naftin
68160|NCT02633800|squamous cell cancer of the head and neck
68161|NCT02633787|Meningitis
68162|NCT02633787|Meningococcal Meningitis
68163|NCT02633787|Meningococcal Infections
68164|NCT02633787|Menactra®
68165|NCT02633761|Fetal death
68166|NCT02633761|mifepristone
68167|NCT02633761|misoprostol
68168|NCT02633735|Clinical Decision Support
68169|NCT02633696|Clinical trial
68170|NCT02633696|Phase I
68171|NCT02633696|Healthy volunteers
68172|NCT02633696|Clinical Pharmacology
68173|NCT02633696|Bioavailability
68174|NCT02633696|Silybin
68175|NCT02633696|Liver Trasplantation
68176|NCT02633683|Restless Legs Syndrome
68177|NCT02633683|RLS
68178|NCT02633657|Restless Legs Syndrome
68179|NCT02633657|RLS
68180|NCT02633644|Heart Failure
68181|NCT02633644|Cardiovascular Diseases
68182|NCT02633644|Heart Diseases
68183|NCT02633592|High Resolution Anorectal Manometry
68184|NCT02633592|Magnetic Resonance Imaging
68185|NCT02633592|Balloon Expulsion
68186|NCT02633592|Position
68187|NCT02633579|Healthy volunteers
68188|NCT02633566|Flatfoot
68189|NCT02633566|orthoses
68190|NCT02633566|children
68191|NCT02633553|thymoma
68192|NCT02633553|adjuvant radiotherapy
68193|NCT02633553|complete resection
68194|NCT02633540|T1a Larynx Cancer
68195|NCT02633540|T2a Larynx Cancer
68196|NCT02633514|thymoma
68197|NCT02633514|thymic carcinoma
68198|NCT02633514|adjuvant radiotherapy
68199|NCT02633514|adjuvant radiochemotherapy
68200|NCT02633514|incomplete resection
68201|NCT02633475|interleukin-10
68202|NCT02633475|Polymorphism, Single Nucleotide
68203|NCT02633449|tDCS
68204|NCT02633449|cognitive behavioral therapy
68205|NCT02633436|esophageal cancer
68206|NCT02633436|SLC1A5
68207|NCT02633423|Cardiopulmonary bypass
68208|NCT02633423|Mechanical ventilation
68209|NCT02633423|Expiratory Flow Limitation
68210|NCT02633423|Best PEEP
68211|NCT02633397|SCD
68212|NCT02633397|Sickle Cell Disease
68213|NCT02633397|Riociguat
68214|NCT02633397|Adempas
68215|NCT02633384|Parenteral nutrition associated cholestasis
68216|NCT02633384|Intravenous lipid emulsions
68217|NCT02633384|Surgical neonates
68218|NCT02633384|Congenital gastrointestinal abnormalities
68219|NCT02633358|Acute myocardial infarction, cardiogenic shock
68220|NCT02633319|Parenting
68221|NCT02633319|Child maltreatment
68222|NCT02633319|Economic strengthening
68223|NCT02633319|Early childhood development
68224|NCT02633319|Cluster randomized controlled trial
68225|NCT02633319|Pilot evaluation
68226|NCT02633306|trigeminal region pain
68227|NCT02633293|Treprostinil
68228|NCT02633293|PH
68229|NCT02633293|ILD
68230|NCT02633293|CPFE
68231|NCT02633293|6 Minute Walk Test
68232|NCT02633267|social anxiety
68233|NCT02633267|unemployment
68234|NCT02633267|cognitive behavioral therapy
68235|NCT02633267|group therapy
68236|NCT02633267|work
68237|NCT02633267|vocation
68238|NCT02633241|pediatrics
68239|NCT02633241|sedation
68240|NCT02633241|dexmedetomidine
68241|NCT02633241|propofol
68242|NCT02633241|MRI
68243|NCT02633228|Multifocal Intraocular Lens
68244|NCT02633228|Binocular Trifocality
68245|NCT02633228|Cataract Surgery
68246|NCT02633228|Spectacle Independence
68247|NCT02633228|Intermediate Vision
68248|NCT02633228|Photopic Vision
68249|NCT02633228|Mesopic Vision
68250|NCT02633228|Scotopic Vision
68251|NCT02633228|Binocular Vision
68252|NCT02633215|motor recovery
68253|NCT02633215|neuroplasticity
68254|NCT02633215|chronic
68255|NCT02633215|human
68256|NCT02633215|sensory
68257|NCT02633202|Nasopharyngeal carcinoma
68258|NCT02633202|Concurrent chemoradiotherapy
68259|NCT02633202|intermediate risk
68260|NCT02633202|intensity-modulated radiotherapy
68261|NCT02633189|stage IV
68262|NCT02633189|stage IIIB
68263|NCT02633189|EGFR mutation
68264|NCT02633189|non-squamous
68265|NCT02633189|liquid biopsy
68266|NCT02633189|erlotinib
68267|NCT02633189|bevacizumab
68268|NCT02633163|Systemic Lupus Erythematosus
68269|NCT02633163|Stem Cell
68270|NCT02633163|Lupus
68271|NCT02633150|Obesity
68272|NCT02633150|insulinoresistant
68273|NCT02633150|menopausal women
68274|NCT02633150|polyphenol
68275|NCT02633137|Lenalidomide
68276|NCT02633137|15-196
68277|NCT02633124|Premature infants
68278|NCT02633124|Catheter-related bacteremia
68279|NCT02633124|Infusion device
68280|NCT02633124|Neonatal intensive care
68281|NCT02633124|Central Venous Catheter
68282|NCT02633124|Drug Infusion Systems
68283|NCT02633111|DNA Sequencing
68284|NCT02633111|15-180
68285|NCT02633098|Artesunate
68286|NCT02633098|Artemisinins
68287|NCT02633098|Antimalarial
68288|NCT02633098|Neoadjuvant
68289|NCT02633098|Pre-operative
68290|NCT02633085|Unicompartment Knee Replacement
68291|NCT02633072|Multifocal Intraocular Lens
68292|NCT02633072|Binocular Trifocality
68293|NCT02633072|Cataract Surgery
68294|NCT02633072|Spectacle Independence
68295|NCT02633072|Intermediate Vision
68296|NCT02633072|Photopic Vision
68297|NCT02633072|Mesopic Vision
68298|NCT02633072|Scotopic Vision
68299|NCT02633072|Binocular Vision
68300|NCT02633046|FSGS
68301|NCT02633046|primary FSGS
68302|NCT02633046|idiopathic FSGS
68303|NCT02632006|PIK-PD-1 Cells
68304|NCT02632006|dendritic cell-precision multiple antigen T cells
68305|NCT02632006|advanced hepatocellular carcinoma
68306|NCT02631993|Psoralen
68307|NCT02631993|UVA
68308|NCT02631993|Time-to-treatment
68309|NCT02631993|GVL
68310|NCT02631980|Hepcidin
68311|NCT02631967|Crohn disease
68312|NCT02631967|ileocecal resection
68313|NCT02631967|anastomosis
68314|NCT02631967|Kono
68315|NCT02631928|biphasic human insulin
68316|NCT02631928|biosimilar
68317|NCT02631902|Community-based intervention
68318|NCT02631902|Exercise program
68319|NCT02631902|Dietary intervention program
68320|NCT02631902|Health promotion
68321|NCT02631902|Subjective well-being
68322|NCT02631902|Cardiovascular risk
68323|NCT02631876|Epithelial ovarian cancer
68324|NCT02631876|Fallopian tube cancer
68325|NCT02631876|Primary peritoneal cancer
68326|NCT02631876|IMGN853
68327|NCT02631876|ADC
68328|NCT02631876|Antibody drug conjugate
68329|NCT02631876|ImmunoGen
68330|NCT02631876|Antibody
68331|NCT02631876|Folate receptor alpha
68332|NCT02631876|mirvetuximab soravtansine
68333|NCT02631876|Phase 3
68334|NCT02631876|platinum-resistant
68335|NCT02631850|Constraint-induced movement therapy
68336|NCT02631850|gaming
68337|NCT02631850|virtual reality
68338|NCT02631850|upper extremity
68339|NCT02631850|CI therapy
68340|NCT02631850|rehabilitation
68341|NCT02631850|stroke
68342|NCT02631850|hemiparesis
68343|NCT02631850|therapy
68344|NCT02631837|NOTES
68345|NCT02631837|Laparoscopic surgery
68346|NCT02631824|fragility fractures
68347|NCT02631824|hip fractures
68348|NCT02631824|augmentation
68349|NCT02631824|tip-apex distance
68350|NCT02631811|acute leukaemia
68351|NCT02631811|supportive / palliative care
68352|NCT02631785|ANXIETY
68353|NCT02631785|CBT
68354|NCT02631785|fMRI
68355|NCT02631785|Fear conditioning
68356|NCT02631785|Fear extinction
68357|NCT02631759|Acute intraCerebral Haemorrhage, Epileptic seizures, Lévétiracetam
68358|NCT02632981|Interleukin-32
68359|NCT02632981|periodontitis
68360|NCT02632955|arteriovenous fistula
68361|NCT02632955|hemodialysis
68362|NCT02632955|drug coated balloon
68363|NCT02632942|arteriovenous fistula
68364|NCT02632942|hemodialysis
68365|NCT02632942|maturation
68366|NCT02632929|foot ulcer, diabetic
68367|NCT02632929|wound healing
68368|NCT02632929|diabetic foot ulcer
68369|NCT02632877|pirfenidone
68370|NCT02632877|Modified oxide diallyl disulfide (MODD)
68371|NCT02632877|ketanserin
68372|NCT02632877|diabetic foot ulcer
68373|NCT02632851|inhalation
68374|NCT02632851|isotonic saline
68375|NCT02632851|NaCl solution 0.9 %
68376|NCT02632851|Ectoin
68377|NCT02632851|bronchitis
68378|NCT02632851|respiratory tract infection
68379|NCT02632838|Hypertension
68380|NCT02632838|mHealth
68381|NCT02632838|underserved community
68382|NCT02632825|Nasal High Flow
68383|NCT02632825|gas exchange
68384|NCT02632825|newborn
68385|NCT02632799|Nasal High Flow
68386|NCT02632799|CPAP
68387|NCT02632799|airway pressure
68388|NCT02632799|newborn
68389|NCT02632786|amyloidosis
68390|NCT02632786|ntprobnp
68391|NCT02632786|NEOD001
68392|NCT02632786|Prothena
68393|NCT02632786|PRONTO
68394|NCT02632786|amyloid
68395|NCT02632786|plasma cell dyscrasia
68396|NCT02632786|immunotherapy
68397|NCT02632773|Language Intervention
68398|NCT02632773|Parent-Mediated Intervention
68399|NCT02632734|alveolar bone preservation
68400|NCT02632734|coral grafting device
68401|NCT02632708|Acute Myeloid Leukemia
68402|NCT02632708|AML
68403|NCT02632708|Untreated AML
68404|NCT02632708|De novo AML
68405|NCT02632708|Secondary AML
68406|NCT02632708|Newly diagnosed AML
68407|NCT02632708|IDH1
68408|NCT02632708|IDH2
68409|NCT02632708|Induction therapy
68410|NCT02632708|Consolidation therapy
68411|NCT02632708|IDH
68412|NCT02632682|probe-based confocal laser endomicroscopy
68413|NCT02632669|Focal brachytherapy
68414|NCT02632669|Seed implant
68415|NCT02632669|Quality of life
68416|NCT02632669|Toxicity
68417|NCT02632643|TMD
68418|NCT02632643|HYPERTONIA
68419|NCT02632643|PARAFUNCTIONS
68420|NCT02632643|SENSORIMOTOR APPROACH
68421|NCT02632630|Peripheral Parenteral Nutrition
68422|NCT02632630|Oral nutritional supplementation
68423|NCT02632630|Acute Care hospitals
68424|NCT02632617|Heart Valve Diseases
68425|NCT02632617|Coronary Artery Disease
68426|NCT02632617|Computed Tomographic Angiography
68427|NCT02632617|Preoperative Procedure
68428|NCT02632565|osteoarthritis
68429|NCT02632565|lidocaine
68430|NCT02632565|pain
68431|NCT02632565|ultrasound
68432|NCT02632552|care transition
68433|NCT02632552|technology
68434|NCT02632552|chronic heart failure
68435|NCT02632552|chronic obstructive pulmonary disease
68436|NCT02632552|virtual nurse
68437|NCT02632552|texting
68438|NCT02632552|informatics
68439|NCT02632552|Veterans
68440|NCT02632539|ventilator associated pneumonia
68441|NCT02632539|Subglottic Secretion Drainage
68442|NCT02632539|manual air-impingement operation
68443|NCT02632526|AZD5718 oral suspension crystalline
68444|NCT02632526|AZD5718 oral suspension amorphous
68445|NCT02632526|Single ascending dose/multiple ascending dose (SAD/MAD)
68446|NCT02632526|Placebo-controlled
68447|NCT02632526|Safety
68448|NCT02632526|Tolerability
68449|NCT02632526|Pharmacokinetics
68450|NCT02632526|Pharmacodynamics
68451|NCT02632513|continuous ultrasonic irrigation, syringe irrigation
68452|NCT02632500|Cardio-Pulmonary Resuscitation
68453|NCT02632500|Cardiac Arrest
68454|NCT02632500|Training
68455|NCT02632474|HIV Infections
68456|NCT02632474|Tenofovir
68457|NCT02632474|Efavirenz
68458|NCT02632461|Diet
68459|NCT02632461|Weight Loss
68460|NCT02632461|Tracking
68461|NCT02632461|Calories
68462|NCT02632448|Metastatic cancer
68463|NCT02632448|Advanced cancer
68464|NCT02632448|Recurrent cancer
68465|NCT02632448|Colorectal neoplasms
68466|NCT02632448|Triple negative breast cancer
68467|NCT02632448|Ovarian neoplasms
68468|NCT02632448|Colon neoplasms
68469|NCT02632448|Rectal neoplasms
68470|NCT02632448|Triple negative breast neoplasms
68471|NCT02632435|HER2 positive
68472|NCT02632383|Diabetes type 1
68473|NCT02632383|Transition
68474|NCT02632383|Telemedicine
68475|NCT02632383|mHealth app
68476|NCT02632383|Youth
68477|NCT02632383|Self-management
68478|NCT02632370|Malignant Gliomas
68479|NCT02632370|5-ALA
68480|NCT02632370|tumor resection
68481|NCT02632370|malignant tumor
68482|NCT02632357|Neurodynamics
68483|NCT02632344|Laryngeal papilloma, recurrent
68484|NCT02632344|Respiratory papillomatosis
68485|NCT02632344|Juvenile-onset recurrent respiratory papillomatosis
68486|NCT02632344|Human papillomavirus
68487|NCT02632344|Virally-related diseases
68488|NCT02632331|Food effect
68489|NCT02632331|Pharmacokinetics
68490|NCT02632331|ASP8825
68491|NCT02632331|XP13512
68492|NCT02632305|unresectable biliary tract cancer
68493|NCT02632305|nab-paclitaxel
68494|NCT02632305|cisplatin
68495|NCT02632305|gemcitabine
68496|NCT02632279|Parkinson's disease
68497|NCT02632279|Deep Brain Stimulation
68498|NCT02632279|Subthalamic nucleus
68499|NCT02632279|Tryptophan depletion
68500|NCT02632279|Serotonin
68501|NCT02632266|prematurity
68502|NCT02632266|growth
68503|NCT02632266|nutrition
68504|NCT02632266|human milk fortifier
68505|NCT02632253|exercise therapy
68506|NCT02632253|GUCH
68507|NCT02632253|ventricular ejection fraction
68508|NCT02632253|HIIT
68509|NCT02632253|MICE
68510|NCT02632240|gingival recession
68511|NCT02632240|mucogingival surgery
68512|NCT02632240|collagen matrix
68513|NCT02632240|connective tissue graft
68514|NCT02632240|tunnel technique
68515|NCT02632214|Face processing
68516|NCT02632214|asymmetry
68517|NCT02632214|deaf
68518|NCT02632214|fMRI
68519|NCT02632201|gastric cancer
68520|NCT02632201|liver metastasis
68521|NCT02632201|PIK-HER2 cells
68522|NCT02632201|dendritic cell-precision multiple antigen T cells
68523|NCT02632188|Recurrence
68524|NCT02632188|Metastasis
68525|NCT02632188|liver cancer
68526|NCT02632175|Ulcerative Colitis
68527|NCT02632149|PINS Vagus Nerve Stimulator
68528|NCT02632136|Laparoscopic
68529|NCT02632136|TAP Block
68530|NCT02632136|Total extra peritoneal Inguinal hernia repair
68531|NCT02632123|idiopathic pulmonary fibrosis
68532|NCT02632123|outcome
68533|NCT02632123|prognosis
68534|NCT02632123|survival
68535|NCT02632110|Actinic Keratosis
68536|NCT02632097|inguinal hernia
68537|NCT02632097|mesh fixation
68538|NCT02632097|glue
68539|NCT02632097|cyanoacrylate
68540|NCT02632097|Lichtenstein
68541|NCT02632097|ambulatory surgery
68542|NCT02632071|Breast Cancer
68543|NCT02632071|Breast Carcinoma
68544|NCT02632071|Breast tumors
68545|NCT02632071|Cancer of the Breast
68546|NCT02632071|Malignant tumor of the breast
68547|NCT02632071|Metastatic Breast Cancer
68548|NCT02632071|Unresectable breast cancer
68549|NCT02632045|Breast Neoplasms
68550|NCT02632045|Breast Cancer
68551|NCT02632045|Breast Carcinoma
68552|NCT02632045|Breast tumors
68553|NCT02632045|Cancer of the Breast
68554|NCT02632032|Type 1 diabetes
68555|NCT02632032|children
68556|NCT02632032|diabetes camps
68557|NCT02632032|glycemic control
68558|NCT02632019|advanced biliary tract malignant tumor
68559|NCT02632019|dendritic cell
68560|NCT02632019|precision T cell for neo-antigen
68561|NCT02631668|iron deficiency anemia, vitamin C, ferrous succinate
68562|NCT02631629|Vitamin D
68563|NCT02631629|Fortification
68564|NCT02631616|Prostatic Neoplasma, Castration-Resistant
68565|NCT02631616|neuroendocrine differentiation
68566|NCT02631616|68Ga-DOTATET
68567|NCT02631616|PET/CT
68568|NCT02631590|intra-hepatic biliary system
68569|NCT02631590|extra-hepatic biliary system
68570|NCT02631590|gall bladder
68571|NCT02631590|advanced biliary cancer
68572|NCT02631590|unresectable
68573|NCT02631590|locally advanced
68574|NCT02631590|metastatic disease
68575|NCT02631564|mCRC;TACE;hepatic infusion;raltitrexed
68576|NCT02631551|Seasonal Allergic Rhinitis
68577|NCT02631538|Subcutaneous
68578|NCT02631538|Rituximab
68579|NCT02631538|Intravenous
68580|NCT02631538|Safety
68581|NCT02631538|Efficacy
68582|NCT02631538|Sjogren's syndrome
68583|NCT02631538|Belimumab
68584|NCT02631525|Airway extubation
68585|NCT02631525|Anesthesia Recovery Period
68586|NCT02631525|Desflurane
68587|NCT02631525|Propofol
68588|NCT02631525|Intravenous anesthesia
68589|NCT02631525|Balanced Anesthesia
68590|NCT02631499|Circulating Tumor Cells
68591|NCT02631499|Hepatoectomy
68592|NCT02631499|TACE
68593|NCT02631499|prognosis
68594|NCT02631499|relapse
68595|NCT02631499|Chemoembolization, Therapeutic
68596|NCT02631486|Rotator Cuff Tears
68597|NCT02631447|Metastatic Melanoma
68598|NCT02631447|BRAF mutation
68599|NCT02631408|spinal fusion
68600|NCT02631408|topical antibiotics
68601|NCT02631408|vancomycin
68602|NCT02631408|surgical site infection
68603|NCT02631395|Exercise movement techniques
68604|NCT02631382|wet cupping Saudi Arabia
68605|NCT02631343|Kangaroo mother care in the community
68606|NCT02631330|Geriatric Assessment
68607|NCT02631330|Physical Education and Training
68608|NCT02631317|acute ischemic stroke
68609|NCT02631317|intravenous rt-PA thrombolysis
68610|NCT02631317|process reengineering
68611|NCT02631317|door-to-needle time
68612|NCT02631304|Postoperative delirium
68613|NCT02631304|Cholinesterase activity
68614|NCT02631304|Buturylcholinesterase activity
68615|NCT02631304|Acetylcholinesterase activity
68616|NCT02631304|Elderly patients
68617|NCT02631304|Cardiac surgery
68618|NCT02631265|Type 1 diabetes
68619|NCT02631265|Exercise
68620|NCT02631265|Hypoglycemia
68621|NCT02631265|Insulin pump
68622|NCT02631252|Leukemia
68623|NCT02631252|Acute Myelogenous
68624|NCT02631252|Phase I
68625|NCT02631252|Mitoxantrone
68626|NCT02631252|Etoposide
68627|NCT02631252|Hydroxychloroquine
68628|NCT02631252|Relapsed
68629|NCT02631252|Autophagy inhibitor
68630|NCT02631252|AML
68631|NCT02631252|Relapsed AML
68632|NCT02631200|Advance Care Planning
68633|NCT02631200|Palliative care
68634|NCT02631200|Frail Elderly
68635|NCT02631200|Renal Dialysis
68636|NCT02631187|Grade 2 retraction of the pars tensa of the tympanic membrane
68637|NCT02631187|Grade 3 retraction of the pars tensa of the tympanic membrane
68638|NCT02631135|Dexmedetomidine
68639|NCT02631135|cognitive functions
68640|NCT02631135|MMSE
68641|NCT02631122|Retroclavicular
68642|NCT02631122|Supraclavicular
68643|NCT02631122|Diagphram
68644|NCT02631122|hemiparesis
68645|NCT02631122|nerve block
68646|NCT02631122|regional anesthesia
68647|NCT02631122|anesthesiology
68648|NCT02631109|Pegaspargase
68649|NCT02631109|hemophagocytic lymphohistiocytosis
68650|NCT02631109|Epstein Barr virus
68651|NCT02631070|Luspatercept
68652|NCT02631070|Transfusion dependent
68653|NCT02631070|Lower risk
68654|NCT02631070|Low risk
68655|NCT02631070|Myelodysplastic Syndromes
68656|NCT02631070|ESA refractory
68657|NCT02631070|ESA intolerant
68658|NCT02631070|ESA ineligible
68659|NCT02631070|ACE-536
68660|NCT02631070|Anemia
68661|NCT02631070|Ring Sideroblasts
68662|NCT02631070|Require Red Blood Cell Transfusions
68663|NCT02631070|MEDALIST
68664|NCT02631070|MDS
68665|NCT02631070|IPSS-R very low/IPSS-R low/IPSS-R intermediate
68666|NCT02631044|JCAR017
68667|NCT02631044|chimeric antigen receptor
68668|NCT02631044|non-Hodgkin lymphoma
68669|NCT02631044|CAR
68670|NCT02631044|CAR T cells
68671|NCT02631044|autologous T cell therapy
68672|NCT02631044|cell therapy
68673|NCT02631044|NHL
68674|NCT02631031|Chronokinetics
68675|NCT02631031|chronodynamics
68676|NCT02631031|chronopharmacology
68677|NCT02631031|valsartan
68678|NCT02631005|systemic lupus erythematosus
68679|NCT02631005|exercise
68680|NCT02630992|ear infections
68681|NCT02630992|antibiotics
68682|NCT02630992|antibiotic resistance
68683|NCT02630992|pediatrics
68684|NCT02630992|infants
68685|NCT02630992|children
68686|NCT02630992|amoxicillin-clavulanate
68687|NCT02630966|Drug therapy
68688|NCT02630953|Physical Activity
68689|NCT02630953|Latinas
68690|NCT02630953|Spanish-language
68691|NCT02630953|Text-Message
68692|NCT02630927|Safety and Tolerability
68693|NCT02630927|Pharmacokinetic Study
68694|NCT02630927|Healthy Volunteer
68695|NCT02630927|Pyruvate Kinase
68696|NCT02630927|Rare Genetic
68697|NCT02630914|Epicardial surgical removal
68698|NCT02630914|Closure of the left atrial
68699|NCT02630914|Left atrial appendage (LAA)
68700|NCT02630888|Bipolar Disorder
68701|NCT02630888|Memantine
68702|NCT02630888|Lithium
68703|NCT02630888|Aripiprazole
68704|NCT02630888|Quetiapine
68705|NCT02630888|Central Nervous System Agents
68706|NCT02630888|Therapeutic Uses
68707|NCT02630888|Pharmacologic Actions
68708|NCT02630888|Psychotropic Drugs
68709|NCT02630888|Cognitive effect of drugs
68710|NCT02630862|oxidative stress
68711|NCT02630862|atherosclerosis
68712|NCT02630862|carotid stenosis
68713|NCT02630862|oxysterols
68714|NCT02630862|vitamin E
68715|NCT02630862|lipid peroxidation
68716|NCT02630862|antioxidants
68717|NCT02630862|aspirin
68718|NCT02630862|dipyridamole
68719|NCT02630836|mesenchymal stromal cells
68720|NCT02630836|stem cells
68721|NCT02630836|elderly
68722|NCT02630836|allogeneic
68723|NCT02630836|bone marrow
68724|NCT02630836|bone regeneration
68725|NCT02630836|fracture
68726|NCT02630784|Non-invasive ventilation
68727|NCT02630784|NIV ventilator
68728|NCT02630784|Exhalation by a calibrated leak
68729|NCT02630784|ICU ventilator
68730|NCT02630784|Respiratory acidosis
68731|NCT02630784|ICU
68732|NCT02630758|depression
68733|NCT02630758|yoga
68734|NCT02630758|mindfulness
68735|NCT02630745|endodontic treatment
68736|NCT02630745|open flap debridement
68737|NCT02630732|Back School
68738|NCT02630732|Brain School
68739|NCT02630732|Lumbar surgery
68740|NCT02630732|Education
68741|NCT02630719|headache
68742|NCT02630628|Lupus Nephritis
68743|NCT02630628|mycophenolate mofetil
68744|NCT02630628|tacrolimus
68745|NCT02630615|Circulating tumor cells
68746|NCT02630589|tinnitus
68747|NCT02630589|auditory brainstem implant
68748|NCT02630589|electrical stimulation
68749|NCT02630576|electromyography
68750|NCT02630576|neuromuscular blockade
68751|NCT02630550|Cardiac output
68752|NCT02630550|Intraoperative Monitoring
68753|NCT02630550|Echocardiography, Transesophageal
68754|NCT02630550|Vascular cross-clamping
68755|NCT02630550|Endarterectomy
68756|NCT02630550|Monitoring, Physiologic/instrumentation
68757|NCT02630550|Cardiography, Impedance
68758|NCT02630537|Cytomegalovirus
68759|NCT02630537|Epstein- Barr virus
68760|NCT02630537|Cell-mediated immunity
68761|NCT02630537|T-Track® CMV
68762|NCT02630537|T-Track® EBV
68763|NCT02630537|hemodialysis
68764|NCT02630537|ELISpot
68765|NCT02630498|pain
68766|NCT02630498|surgical
68767|NCT02630498|brachial plexus
68768|NCT02630485|Randomized Controlled Trial
68769|NCT02630459|Migraine Prevention
68770|NCT02630459|Headache
68771|NCT02630459|Prophylaxis
68772|NCT02630446|respite care
68773|NCT02630446|effectiveness
68774|NCT02630446|cost-effectiveness
68775|NCT02630446|support
68776|NCT02630446|caregiver
68777|NCT02630446|dementia
68778|NCT02630446|community-based
68779|NCT02630433|Biliary pancreatitis
68780|NCT02630433|Cholecystectomy
68781|NCT02630394|sickle cell disease
68782|NCT02630394|acute chest syndrome
68783|NCT02630381|high-energy shock waves
68784|NCT02630368|Advanced Soft-tissue Sarcoma
68785|NCT02630368|Advanced Breast Cancer
68786|NCT02630368|Maximum Tolerated Dose
68787|NCT02630368|Efficacy and safety
68788|NCT02630342|Mock Scanner
68789|NCT02630342|Child Life Specialist
68790|NCT02630342|Patient Preparation
68791|NCT02630342|Child, Preschool
68792|NCT02630342|Child
68793|NCT02630342|Anxiety
68794|NCT02630342|Human
68795|NCT02630342|Anesthesia, General
68796|NCT02630329|NOTES
68797|NCT02630329|Benign adnexal disease
68798|NCT02630329|Laparoscopy
68799|NCT02630316|Treprostinil
68800|NCT02630316|PH
68801|NCT02630316|ILD
68802|NCT02630316|CPFE
68803|NCT02630316|6 Minute Walk Test
68804|NCT02630303|light emitting diode-red light
68805|NCT02630303|LED-RL
68806|NCT02630303|high fluence
68807|NCT02630303|skin fibrosis
68808|NCT02630303|wound healing
68809|NCT02630303|scar
68810|NCT02630303|keloid
68811|NCT02630303|RCT
68812|NCT02630290|Brachial plexus block
68813|NCT02630290|Dexmedetomidine
68814|NCT02630290|Ropivacaine
68815|NCT02630290|ultrasound-guided nerve block
68816|NCT02630290|supraclavicular brachial plexus block
68817|NCT02630277|Proliferative Diabetic Retinopathy
68818|NCT02630277|High Risk PDR
68819|NCT02630277|aflibercept
68820|NCT02630277|regression of retinal neovascularization
68821|NCT02630264|clinical trial
68822|NCT02630264|Recombinant Human Endostatin Adenovirus
68823|NCT02630264|randomized
68824|NCT02630251|Cancer
68825|NCT02630251|Safety
68826|NCT02630251|GSK2820151
68827|NCT02630251|Dose escalation
68828|NCT02630251|Tolerability
68829|NCT02630251|Pharmacodynamics
68830|NCT02630251|Pharmacokinetics
68831|NCT02630238|Exercise
68832|NCT02630238|Amino Acids, Branched-Chain
68833|NCT02630225|case management
68834|NCT02630225|motivational interviewing
68835|NCT02630212|Aortic dissection
68836|NCT02630212|Aldehyde dehydrogenase 2 polymorphism
68837|NCT02630212|Risk factor
68838|NCT02630212|aldehyde dehydrogenase 2
68839|NCT02630173|endodontic treatment
68840|NCT02630173|scaling
68841|NCT02630173|root planning
68842|NCT02630147|Late preterm
68843|NCT02630147|Vanilla
68844|NCT02630147|Hypoxic intermittent events
68845|NCT02630108|HCC
68846|NCT02630108|TACE
68847|NCT02630108|Thermal Ablation
68848|NCT02630108|Safety/Efficacy
68849|NCT02630095|anticoagulation
68850|NCT02630082|HIV Preventive Vaccine
68851|NCT02630082|HIV Seronegativity
68852|NCT02630082|Immune Response, Mucosal
68853|NCT02630069|amphetamine type stimulant
68854|NCT02630069|adolescents
68855|NCT02630056|radiotherapy hematologic toxicity pelvic bone marrow
68856|NCT02630004|Mucositis
68857|NCT02630004|Head and Neck cancer
68858|NCT02630004|Chemoradiation
68859|NCT02629991|Prader-Willi Syndrome (PWS)
68860|NCT02629991|Hyperphagia
68861|NCT02629978|pulmonary
68862|NCT02629978|lung
68863|NCT02629978|cancer
68864|NCT02629978|carcinoma
68865|NCT02629978|nodule
68866|NCT02629978|malignant
68867|NCT02629978|radiofrequency ablation
68868|NCT02629978|RFA
68869|NCT02629952|glucose tolerance
68870|NCT02629952|type 2 diabetes
68871|NCT02629952|blueberry tea
68872|NCT02629900|Weight Loss
68873|NCT02629900|Intermittent fasting
68874|NCT02629887|supraglottic airway
68875|NCT02629887|neonatal resuscitation
68876|NCT02629887|ventilation
68877|NCT02629887|term infant
68878|NCT02629874|EA-230
68879|NCT02629874|Inflammatory response
68880|NCT02629874|Kidney Injury
68881|NCT02629874|Endotoxemia
68882|NCT02629848|Drug therapy
68883|NCT02629809|Leukemia
68884|NCT02629809|Chronic lymphocytic leukemia
68885|NCT02629809|CLL
68886|NCT02629809|Mutated immunoglobulin heavy chair variable region
68887|NCT02629809|IGHV
68888|NCT02629809|non-del(17p) fluorescence in-situ hybridization
68889|NCT02629809|FISH
68890|NCT02629809|Obinutuzumab
68891|NCT02629809|GA101
68892|NCT02629809|Gazyva
68893|NCT02629809|Fludarabine
68894|NCT02629809|Fludarabine Phosphate
68895|NCT02629809|Fludara
68896|NCT02629809|Cyclophosphamide
68897|NCT02629809|Cytoxan
68898|NCT02629809|Neosar
68899|NCT02629809|Ibrutinib
68900|NCT02629809|PCI-32765
68901|NCT02629809|Imbruvica
68902|NCT02629809|Allopurinol
68903|NCT02629809|Lopurin
68904|NCT02629809|Zurinol
68905|NCT02629809|Zyloprim
68906|NCT02629809|Valacyclovir
68907|NCT02629809|Valtrex
68908|NCT02629796|Biomarker
68909|NCT02629796|CIDP
68910|NCT02629796|IVIG
68911|NCT02629796|treatment response
68912|NCT02629757|High-grade glioma
68913|NCT02629757|chemotherapy
68914|NCT02629757|β-elemene
68915|NCT02629731|foot
68916|NCT02629731|ankle
68917|NCT02629731|osteoarthritis
68918|NCT02629731|flat foot
68919|NCT02629718|neoadjuvant chemotherapy
68920|NCT02629718|radical surgery
68921|NCT02629718|cervical carcinoma
68922|NCT02629653|carotid endarterectomy
68923|NCT02629653|stroke
68924|NCT02629653|hypothermia
68925|NCT02629653|endovascular cooling
68926|NCT02629640|vCJD
68927|NCT02629640|prion disease
68928|NCT02629640|dementia
68929|NCT02629640|old-age
68930|NCT02629640|surveillance
68931|NCT02629640|brain banking
68932|NCT02629640|public health
68933|NCT02629627|Conjugated Linoleic Acid
68934|NCT02629627|Leucine
68935|NCT02629627|visceral fat area
68936|NCT02629627|Epicardial Fat
68937|NCT02629627|Hemodinamic Parameters
68938|NCT02628574|Metastatic
68939|NCT02628574|Stage III or IV
68940|NCT02628574|recurrent
68941|NCT02628574|refractory
68942|NCT02628574|solid tumors
68943|NCT02628535|B7-H3-expressing neoplasms
68944|NCT02628522|ADRC
68945|NCT02628522|Celution
68946|NCT02628509|Acquired Von Willebrand
68947|NCT02628509|Trans aortic valve replacement
68948|NCT02628509|mechanical circulatory support
68949|NCT02628470|Cervical pain, cervicalgia
68950|NCT02628457|occupation ratio
68951|NCT02628457|pseudoatrophy
68952|NCT02628444|Dengue Fever
68953|NCT02628444|Dengue virus
68954|NCT02628444|Dengue Hemorrhagic Fever
68955|NCT02628444|CYD Dengue Vaccine
68956|NCT02628418|Rehabilitation
68957|NCT02628418|Robotics
68958|NCT02629601|physical activity
68959|NCT02629601|financial incentives
68960|NCT02629601|behavioral economics
68961|NCT02629588|Coma
68962|NCT02629588|Persistent Vegetative State
68963|NCT02629588|Sensory Stimulation
68964|NCT02629497|platelets
68965|NCT02629497|12-lipoxygenase
68966|NCT02629497|fatty acids
68967|NCT02629497|DGLA
68968|NCT02629497|DHA
68969|NCT02629497|EPA
68970|NCT02629497|12-LOX
68971|NCT02629484|echocardiography
68972|NCT02629484|hip fracture
68973|NCT02629484|surgery
68974|NCT02629484|outcomes
68975|NCT02629432|MRI
68976|NCT02629432|COPD
68977|NCT02629419|STAT3 deficient Hyper IgE syndrome
68978|NCT02629419|Gain of function STAT1 defects
68979|NCT02629419|Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
68980|NCT02629419|IL-17/IL-22 autoantibodies from thymoma
68981|NCT02629419|Job's Syndrome (Hyperimmunoglobulin E Syndrome, Buckley Syndrome)
68982|NCT02629406|HIF
68983|NCT02629406|hypoxia
68984|NCT02629406|chemoreflex
68985|NCT02629406|baroreflex
68986|NCT02629406|MIR210
68987|NCT02629393|Molybdenum Cofactor Deficiency (MoCD)
68988|NCT02629393|Molybdenum Cofactor (MoCo) biosynthesis
68989|NCT02629393|sulfite oxidase (SO)
68990|NCT02629393|S sulfocysteine (SSC)
68991|NCT02629393|xanthine oxidoreductase
68992|NCT02629393|aldehyde oxidase
68993|NCT02629380|meniscectomy
68994|NCT02629380|hyaluronic acid
68995|NCT02629380|intra-op injection
68996|NCT02629380|randomized controlled trial
68997|NCT02629380|placebo
68998|NCT02629341|woman osteopenia osteoporosis enriched calcium vit D yogurt
68999|NCT02629328|CardioCel
69000|NCT02629328|FDA cleared
69001|NCT02629328|Tri-leaflet repair
69002|NCT02629328|Aortic valves
69003|NCT02629289|HSP-130
69004|NCT02629289|Pharmacodynamic and Pharmacokinetic equivalence
69005|NCT02629289|Pegfilgrastim
69006|NCT02629276|neck pain
69007|NCT02629276|arm pain
69008|NCT02629276|neurodynamic tests
69009|NCT02629276|quantitative sensory testing
69010|NCT02629276|somatosensory profile
69011|NCT02629250|proximal femoral fracture
69012|NCT02629250|goal-directed therapy
69013|NCT02629250|myocardial injury
69014|NCT02629250|supernormal oxygen delivery
69015|NCT02629250|elders
69016|NCT02629250|stroke volume maximization
69017|NCT02629237|glaucoma surgery
69018|NCT02629237|educational intervention
69019|NCT02629237|satisfaction
69020|NCT02629237|rural
69021|NCT02629224|Impaired renal function
69022|NCT02629224|Haemodialysis
69023|NCT02629224|ASP8825
69024|NCT02629224|XP13512
69025|NCT02629211|Inflammatory Bowel Diseases
69026|NCT02629211|Colitis, Ulcerative
69027|NCT02629211|Crohn Disease
69028|NCT02629211|Single-Balloon Enteroscopy
69029|NCT02629211|NaviAid AB™ Device
69030|NCT02629211|NaviAid AB™ Procedure
69031|NCT02629211|AB Device
69032|NCT02629211|Pediatric IBD
69033|NCT02629211|Pediatric Enteroscopy
69034|NCT02629198|Vitamin D
69035|NCT02629185|Bone
69036|NCT02629185|Vitamin D
69037|NCT02629185|Cardiovascular
69038|NCT02629172|Genotype 1
69039|NCT02629172|Ritonavir
69040|NCT02629172|Hepatitis C Virus (HCV)
69041|NCT02629172|Ombitasvir
69042|NCT02629172|Paritaprevir
69043|NCT02629159|Antirheumatic agents
69044|NCT02629159|Anti-inflammatory agents
69045|NCT02629159|Musculoskeletal disease
69046|NCT02629159|Arthritis
69047|NCT02629159|Joint disease
69048|NCT02629146|Midazolam
69049|NCT02629146|Fentanyl
69050|NCT02629133|Intimate Partner Violence
69051|NCT02629133|Sheltered Battered Women
69052|NCT02629133|Substance Use
69053|NCT02629120|Chronic Granulomatous Disease
69054|NCT02629120|Allogeneic Stem Cell Transplantation
69055|NCT02629120|Graft Versus Host Disease
69056|NCT02629120|Matched Unrelated Donor BMT
69057|NCT02629120|Nonmyeloablative Conditioning Regimen
69058|NCT02629107|Sleep
69059|NCT02629107|Functional Magnetic Resonance Imaging (fMRI)
69060|NCT02629107|Electroencephalogram (EEG)
69061|NCT02629094|Hepatic Steatosis
69062|NCT02629094|Cardiac Steatosis
69063|NCT02629094|Aldosterone
69064|NCT02629094|Eplerenone
69065|NCT02629094|Mineralcorticoid Receptor
69066|NCT02629081|heartburn
69067|NCT02629081|GERD
69068|NCT02629081|NERD
69069|NCT02629081|non-erosive reflux disease
69070|NCT02629068|Adolescent
69071|NCT02629068|Social Support
69072|NCT02629068|Social Media
69073|NCT02629068|Parents
69074|NCT02629068|Shame
69075|NCT02629068|Stigma
69076|NCT02629055|Non-invasive ventilation
69077|NCT02629055|Respiratory electromyography
69078|NCT02629042|Anesthesia
69079|NCT02629042|Corticosteroids
69080|NCT02629042|Dental Emergency
69081|NCT02629042|Irreversible Pulpitis
69082|NCT02629042|Mandibulae
69083|NCT02629042|Pain Management
69084|NCT02629042|Partial Endodontic Treatment
69085|NCT02629003|Positron Emission Tomography
69086|NCT02629003|Serotonin
69087|NCT02629003|5-HT2A
69088|NCT02629003|Radioligand
69089|NCT02629003|Radiation dosimetry
69090|NCT02629003|Radiation dosage
69091|NCT02628964|smoking
69092|NCT02628964|cigarettes
69093|NCT02628938|Halitosis
69094|NCT02628938|Oral Malodor
69095|NCT02628938|Miswak
69096|NCT02628938|Salvadora Persica
69097|NCT02628925|mass screening
69098|NCT02628925|Nursing diagnosis
69099|NCT02628925|Psychiatric Status Rating Scale
69100|NCT02628912|Cardiopulmonary Fitness
69101|NCT02628912|Long-Term Survivors
69102|NCT02628912|15-277
69103|NCT02628912|HPV
69104|NCT02628912|Survivors
69105|NCT02628886|maternal and neonatal pneumococcal conjugate vaccination
69106|NCT02628886|pneumococcal carriage
69107|NCT02628873|HSG
69108|NCT02628873|HyCoSy
69109|NCT02628873|Contraception
69110|NCT02628873|Essure
69111|NCT02628873|Saline Infused sonography
69112|NCT02628873|SIS
69113|NCT02628873|Air bubbles
69114|NCT02628860|ferric carboxymaltose
69115|NCT02628860|Ferinject®
69116|NCT02628860|pancreatoduodenectomy
69117|NCT02628847|stroke
69118|NCT02628847|rehabilitation
69119|NCT02628847|motor skills
69120|NCT02628847|sildenafil citrate
69121|NCT02628847|White matter
69122|NCT02628834|Loading
69123|NCT02628834|Gait
69124|NCT02628834|Multiple Sclerosis
69125|NCT02628834|Manual Therapy
69126|NCT02628808|autism
69127|NCT02628808|asperger
69128|NCT02628808|Pervasive Developmental Disorder No Otherwise Specify
69129|NCT02628808|gene
69130|NCT02628808|polymorphism
69131|NCT02628808|mutation
69132|NCT02628795|total hip arthroplasty
69133|NCT02628795|total knee arthroplasty
69134|NCT02628782|large bore endovascular catheterization procedures
69135|NCT02628782|Vascular Closure Device
69136|NCT02628769|Solithromycin
69137|NCT02628769|Chronic Obstructive Pulmonary Disease
69138|NCT02628769|Inflammation
69139|NCT02628769|Macrolide
69140|NCT02628730|Atrial Fibrillation
69141|NCT02628730|Ablation
69142|NCT02628730|Pulmonary vein isolation
69143|NCT02628730|Ablation Index
69144|NCT02628717|Hepatitis C
69145|NCT02628717|sofosbuvir
69146|NCT02628717|ledipasvir
69147|NCT02628717|daclatasvir
69148|NCT02628717|simeprevir
69149|NCT02628704|Karyopharm
69150|NCT02628704|selinexor
69151|NCT02628704|KPT-330
69152|NCT02628704|multiple myeloma
69153|NCT02628704|SCORE
69154|NCT02628678|Prebiotic
69155|NCT02628678|FOS
69156|NCT02628678|fructooligosaccharide
69157|NCT02628678|polyglycan
69158|NCT02628678|microbiome
69159|NCT02628678|microbiota
69160|NCT02628678|Healthy Volunteers
69161|NCT02628652|Microbiome
69162|NCT02628652|FOS
69163|NCT02628652|polyglycan
69164|NCT02628652|prebiotic
69165|NCT02628652|Healthy Volunteers
69166|NCT02628626|Incontinence
69167|NCT02628626|Diarrhea
69168|NCT02628626|Bile acid
69169|NCT02628626|Microbiome
69170|NCT02628613|Breast cancer
69171|NCT02628613|Neoadjuvant chemotherapy
69172|NCT02628613|TEKT4
69173|NCT02628587|Acute Coronary Syndrome
69174|NCT02628587|Clopidogrel
69175|NCT02628587|Platelet reactivity
69176|NCT02628392|Type 2 Diabetes Mellitus
69177|NCT02628392|Adult
69178|NCT02628392|Developmental Phase II
69179|NCT02628379|Genomic Testing
69180|NCT02628379|Cancer of Unknown Primary
69181|NCT02628379|CUP
69182|NCT02628366|Cluster Randomized Controlled Trial
69183|NCT02628366|Personalized Dialysate Temperature
69184|NCT02628366|Cardiovascular Events
69185|NCT02628366|Mortality
69186|NCT02628353|Cardiovascular diseases
69187|NCT02628353|endothelial function
69188|NCT02628353|systolic blood pressure
69189|NCT02628353|metabolomics
69190|NCT02628353|cardiovascular risk factor
69191|NCT02628353|bioavailability
69192|NCT02628353|phenolic compounds
69193|NCT02628353|hypertension
69194|NCT02628327|glaucoma care
69195|NCT02628327|quality of life
69196|NCT02628327|patient satisfaction
69197|NCT02628301|Obesity
69198|NCT02628301|Type 2 Diabetes Mellitus
69199|NCT02628301|Hypercaloric diet
69200|NCT02628301|Microcirculation
69201|NCT02628301|Microvascular dysfunction
69202|NCT02628301|Insulin Resistance
69203|NCT02628301|Insulin Sensitivity
69204|NCT02628301|Insulin signaling
69205|NCT02628262|Macular hole
69206|NCT02628236|Actinic keratosis
69207|NCT02628223|glaucoma
69208|NCT02628223|Elevated IOP
69209|NCT02628223|Selective Laser Trabeculoplasty
69210|NCT02628223|SLT
69211|NCT02628223|open angle glaucoma
69212|NCT02628223|ocular hypertension
69213|NCT02628223|Glaucoma, Open Angle, Pseudo-exfoliative
69214|NCT02628223|pigment dispersion syndrome
69215|NCT02628223|Pseudoexfoliation
69216|NCT02628223|IOP ≥ 21 mmHg
69217|NCT02628158|Epiretinal membrane
69218|NCT02628145|Sarcopenia
69219|NCT02628145|aging
69220|NCT02628145|resistance training
69221|NCT02628145|physical functioning
69222|NCT02628132|triple negative
69223|NCT02628132|breast cancer
69224|NCT02628132|durvalumab
69225|NCT02628132|paclitaxel
69226|NCT02628132|safety
69227|NCT02628132|efficacy
69228|NCT02628132|PD-L1
69229|NCT02628132|PD-1
69230|NCT02628132|Metastatic
69231|NCT02628132|AstraZeneca
69232|NCT02628132|MEDI4736
69233|NCT02628119|Hemodialysis
69234|NCT02628119|vascular access
69235|NCT02628119|access flow
69236|NCT02628080|Hypoxia
69237|NCT02628067|PD1
69238|NCT02628067|PDL1
69239|NCT02628067|PD-1
69240|NCT02628067|PD-L1
69241|NCT02628067|MSI
69242|NCT02628067|microsatellite instability
69243|NCT02628067|MMR
69244|NCT02628067|mismatch repair
69245|NCT02628067|anal carcinoma
69246|NCT02628067|anal cancer
69247|NCT02628067|biliary adenocarcinoma
69248|NCT02628067|biliary cancer
69249|NCT02628067|cholangiocarcinoma
69250|NCT02628067|bile duct cancer
69251|NCT02628067|neuroendocrine tumor
69252|NCT02628067|carcinoid tumor
69253|NCT02628067|endometrial carcinoma
69254|NCT02628067|endometrial cancer
69255|NCT02628067|cervical carcinoma
69256|NCT02628067|cervical cancer
69257|NCT02628067|vulvar carcinoma
69258|NCT02628067|vulvar cancer
69259|NCT02628067|small cell lung carcinoma
69260|NCT02628067|small cell lung cancer
69261|NCT02628067|SCLC
69262|NCT02628067|mesothelioma
69263|NCT02628067|thyroid carcinoma
69264|NCT02628067|thyroid cancer
69265|NCT02628067|salivary gland carcinoma
69266|NCT02628067|salivary gland cancer
69267|NCT02628067|salivary cancer
69268|NCT02628067|parotid gland cancer
69269|NCT02628067|advanced solid tumors
69270|NCT02628054|PSG
69271|NCT02628054|Typhoid Vaccine
69272|NCT02628054|Depression
69273|NCT02628054|Inflammation
69274|NCT02628041|High-Dose-Rate Brachytherapy
69275|NCT02628041|HDR Monotherapy
69276|NCT02628041|LDR monotherapy
69277|NCT02628015|Theory of Mind
69278|NCT02628015|Very Low Birthweight Infants
69279|NCT02628002|antigravity treadmill
69280|NCT02628002|bruce protocol
69281|NCT02628002|stress myocardial perfusion imaging
69282|NCT02628002|single photon emission computed tomography
69283|NCT02628002|cardiac catheterization
69284|NCT02628002|[E01.370.370.380.500]
69285|NCT02628002|[E01.370.370.380.250]
69286|NCT02628002|[E01.370.370.380.140]
69409|NCT02627456|Immunization
69287|NCT02627937|Pediatric obstructive sleep apnea/hypopnea syndrome
69288|NCT02627937|Polysomnography
69289|NCT02627924|patient-reported QoL(Quality of Life)
69290|NCT02627924|Work productivity
69291|NCT02627924|Rheumatoid Arthritis
69292|NCT02627898|Green tea extract
69293|NCT02627898|Arterial stiffness
69294|NCT02627898|PWVao
69295|NCT02627885|internet treatment
69296|NCT02627885|cognitive behavioral therapy
69297|NCT02627885|level of functioning
69298|NCT02627885|quality of life
69299|NCT02627833|induced Sputum
69300|NCT02627833|lung clearance index
69301|NCT02627833|miRNA
69302|NCT02627833|inflammation
69303|NCT02627833|chronic lung disease
69304|NCT02627820|Senile
69305|NCT02627820|ATTRwt
69306|NCT02627820|wild-type transthyretin amyloidosis
69307|NCT02627807|Nasopharyngeal carcinoma
69308|NCT02627807|Intensity modulated radiotherapy
69309|NCT02627807|Clinical target volume
69310|NCT02627807|Clinical trial
69311|NCT02627794|Middle Meatus
69312|NCT02627794|Synechiae
69313|NCT02627794|Endoscopic Sinus Surgery
69314|NCT02627794|Silastic spacer
69315|NCT02627794|Restora™ steroid eluting MM spacer
69316|NCT02627781|acute appendicitis
69317|NCT02627781|Alvarado Score
69318|NCT02627781|negative appendectomy
69319|NCT02627781|right abdominal pain
69320|NCT02627768|STELARA
69321|NCT02627768|Psoriatic Arthritis
69322|NCT02627768|Ustekinumab
69323|NCT02627755|videolaryngoscopy
69324|NCT02627755|difficult airway management
69325|NCT02627716|Psychiatric advanced directives
69326|NCT02627716|Joint crisis plan
69327|NCT02627716|Schizophrenia
69328|NCT02627716|Primary care
69329|NCT02627677|CML
69330|NCT02627677|CP-CML
69331|NCT02627677|Leukemia
69332|NCT02627677|Leukemia, Myeloid
69333|NCT02627677|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
69334|NCT02627677|Neoplasms by Histologic Type
69335|NCT02627677|Neoplasms
69336|NCT02627677|Myeloproliferative Disorders
69337|NCT02627677|Bone Marrow Diseases
69338|NCT02627677|Hematologic Diseases
69339|NCT02627664|Idiopathic early
69340|NCT02627664|Parkinson's Disease
69341|NCT02627638|osteopathy
69342|NCT02627638|complementary therapy
69343|NCT02627638|symptoms in cancer patients
69344|NCT02627625|inhalation
69345|NCT02627625|anticholinergic
69346|NCT02627612|veteran
69347|NCT02627612|mentorship
69348|NCT02627612|Iraq/Afghanistan
69349|NCT02627612|treatment
69350|NCT02627612|PTSD
69351|NCT02627612|Suicide
69352|NCT02627612|Criminal Activity
69353|NCT02627599|COPD
69354|NCT02627599|LTOT
69355|NCT02627599|Long-Term Oxygen Therapy
69356|NCT02627599|Oxygen Conserving Device
69357|NCT02627599|Quality of Life
69358|NCT02627599|Six Minute Walk Distance
69359|NCT02627599|Portable Oxygen Source
69360|NCT02627599|Oxygen Saturation
69361|NCT02627599|Breath Responsive Variable Bolus Oxygen Conserving Device
69362|NCT02627599|BRVB-OCD
69363|NCT02627599|Pulse Oximetry
69364|NCT02627586|exercise therapy
69365|NCT02627586|left ventricular remodeling
69366|NCT02627586|ventricular ejection fraction
69367|NCT02627586|high-intensity interval training
69368|NCT02627573|Cyclophosphamide
69369|NCT02627573|Thymoglobulin
69370|NCT02627573|Myelodysplastic Syndromes
69371|NCT02627573|Immunosuppressive Agents
69372|NCT02627573|Immune System Diseases
69373|NCT02627573|Busulfan
69374|NCT02627573|Fludarabine
69375|NCT02627573|Tacrolimus
69376|NCT02627573|Mycophenolate mofetil
69377|NCT02627573|Antineoplastic Agents, Alkylating
69378|NCT02627573|Myeloablative Agonists
69379|NCT02627573|Hematopoietic Stem Cell Transplantation
69380|NCT02627573|Allogeneic Transplantation
69381|NCT02627573|Leukemia, Chronic Myeloid
69382|NCT02627573|Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
69383|NCT02627560|Administration, topical
69384|NCT02627560|Tranexamic acid
69385|NCT02627560|Postoperative care
69386|NCT02627560|Mastectomy
69387|NCT02627547|Flavanones
69388|NCT02627547|Endurance-trained athletes
69389|NCT02627547|Biological availability
69390|NCT02627534|Photodynamic therapy
69391|NCT02627534|Ultrasonic debridement
69392|NCT02627534|Chronic periodontitis
69393|NCT02627534|Type 2 diabetes
69394|NCT02627508|Autism Spectrum Disorder
69395|NCT02627508|Autism
69396|NCT02627508|Pregnenolone
69397|NCT02627495|maladaptive plasticity
69398|NCT02627495|Limb amputation
69399|NCT02627495|phantom limb pain
69400|NCT02627495|tDCS
69401|NCT02627495|non-invasive brain stimulation
69402|NCT02627469|Microbiota
69403|NCT02627469|aged
69404|NCT02627469|oral health
69405|NCT02627456|Malaria
69406|NCT02627456|Cryopreserved
69407|NCT02627456|Infection
69408|NCT02627456|Human
69410|NCT02627417|ITP
69411|NCT02627417|Dapsone
69412|NCT02627404|Bipolar disorders
69413|NCT02627404|Genetic
69414|NCT02627404|Biomarkers
69415|NCT02627404|Circadian rhythm
69416|NCT02627391|Aortic valve
69417|NCT02627391|Stenosis
69418|NCT02627391|Surgery
69419|NCT02627365|ART
69420|NCT02627365|mobile messaging
69421|NCT02627365|behaviour
69422|NCT02627365|motivation
69423|NCT02627352|Glaucoma
69424|NCT02627352|Micropulse Transscleral Cyclophotocoagulation
69425|NCT02627352|IOP
69426|NCT02627339|Contrast Sensitivity
69427|NCT02627326|chlorhexidine
69428|NCT02627326|endodontic treatment
69429|NCT02627313|Feasibility Studies
69430|NCT02627300|PID
69431|NCT02627261|residual disease
69432|NCT02627235|Physical Activity
69433|NCT02627235|Cancer Prevention
69434|NCT02627222|Pro-vitamin A
69435|NCT02627222|Cassava
69436|NCT02627222|Vitamin A deficiency
69437|NCT02627222|Retinol Isotope Dilution
69438|NCT02627222|Preschool children
69439|NCT02627222|Nigeria
69440|NCT02627209|Angiotensin converting enzyme
69441|NCT02627209|Lysozyme
69442|NCT02627209|Ankylosing spondylitis
69443|NCT02627209|Behcet's disease
69444|NCT02627209|Sarcoidosis
69445|NCT02627209|Syphilis
69446|NCT02627209|Tuberculosis
69447|NCT02627209|Ocular inflammation
69448|NCT02627183|Atrial Fibrillation
69449|NCT02627170|Adults
69450|NCT02627144|Metastatic renal cell carcinoma
69451|NCT02627144|Avastin
69452|NCT02627144|Bevacizumab
69453|NCT02627131|Autism
69454|NCT02627131|Stem Cells
69455|NCT02627105|weight loss
69456|NCT02627066|Exercise
69457|NCT02627066|Nutrition
69458|NCT02627066|Hemodialysis
69459|NCT02627014|Chronic Migraine
69460|NCT02627014|Temporomandibular Disorders
69461|NCT02627014|Physical Therapy
69462|NCT02627014|Manual Therapy
69463|NCT02627014|Home physical Therapy
69464|NCT02626988|Diet Diversity
69465|NCT02626988|Biodiversity
69466|NCT02626988|Agrobiodiversity
69467|NCT02626988|Nutrition
69468|NCT02626988|Vietnam
69469|NCT02626975|knee
69470|NCT02626975|short hamstring autograft
69471|NCT02626975|ligament
69472|NCT02626975|MRI
69473|NCT02626962|melanoma
69474|NCT02626949|HIV
69475|NCT02626949|AIDS
69476|NCT02626949|Mindfulness
69477|NCT02626949|Mindfulness-based stress reduction
69478|NCT02626949|Stress
69479|NCT02626949|Intervention
69480|NCT02626949|Inflammation
69481|NCT02626936|Type 1 diabetes
69482|NCT02626936|Artificial pancreas
69483|NCT02626936|Closed-loop system
69484|NCT02626936|Postprandial glucose control
69485|NCT02626936|Hypoglycemia
69486|NCT02626936|Insulin
69487|NCT02626936|Glucagon
69488|NCT02626910|Disability
69489|NCT02626910|Activity of Daily Living
69490|NCT02626910|Patient Satisfaction
69491|NCT02626897|Sarcoidosis
69492|NCT02626897|Daily activity
69493|NCT02626897|Exercise
69494|NCT02626897|Accelerometer
69495|NCT02626845|Granulomatosis with Polyangiitis
69496|NCT02626845|Wegener's Granulomatosis
69497|NCT02626845|GPA
69498|NCT02626845|Rituximab
69499|NCT02626845|Rituxan
69500|NCT02626845|ENT GPA
69501|NCT02626832|vasopressin
69502|NCT02626832|AVP
69503|NCT02626832|NMDA
69504|NCT02626832|osmolality
69505|NCT02626819|Obesity
69506|NCT02626819|Weight Management
69507|NCT02626819|Primary Care
69508|NCT02626819|Health Coach
69509|NCT02626819|iPad
69510|NCT02626819|Goal Setting
69511|NCT02626819|5As
69512|NCT02626819|technology
69513|NCT02626806|exercise test
69514|NCT02626806|HS -troponin
69515|NCT02626806|Coronary artery disease
69516|NCT02626793|Plaque psoriasis
69517|NCT02626793|Apremilast
69518|NCT02626793|Otezla®
69519|NCT02626793|LAPIS-Pso
69520|NCT02626793|Observational
69521|NCT02626793|CC-10004
69522|NCT02626793|non-interventional
69523|NCT02626793|Germany
69524|NCT02626767|high-intensity interval training
69525|NCT02626767|adolescents
69526|NCT02626767|school-based exercise
69527|NCT02626767|cardiometabolic health
69528|NCT02626754|Sunitinib, 2/1 schedule, Renal cell carcinoma
69529|NCT02626702|immune modulators
69530|NCT02626702|IVF outcomes
69531|NCT02626702|relationship
69532|NCT02626689|Beta-Thalassemia
69533|NCT02626689|Quality of Life
69534|NCT02626689|Healthcare Utilization
69535|NCT02626689|Transfusion dependent (TD) β-thalassemia
69536|NCT02626689|Non-transfusion dependent β-thalassemia
69537|NCT02626689|Standard of care
69538|NCT02626689|TransQoL
69539|NCT02626689|SF36v2
69540|NCT02626689|Fact-An
69541|NCT02626689|NTD beta-thalassemia PRO
69542|NCT02626676|renal dialysis, hyperphosphatemia, educational programme
69543|NCT02626637|children with cancer
69544|NCT02626637|fatigue
69545|NCT02626637|physical activity
69546|NCT02626598|facial wrinkles
69547|NCT02626598|photoaging
69548|NCT02626585|rhinoplasty
69549|NCT02626585|postrhinoplasty taping
69550|NCT02626585|edema
69551|NCT02626585|draping
69552|NCT02626585|postoperative edema
69553|NCT02626585|nasal skin thickness
69554|NCT02626585|supratip fullness
69555|NCT02626585|postoperative swelling
69556|NCT02626533|Cytokines
69557|NCT02626507|ER+/HER2
69558|NCT02626481|Multiple Myeloma
69559|NCT02626481|Cancer
69560|NCT02626481|refractory
69561|NCT02626481|daratumumab
69562|NCT02626455|Clinical trial, Phase III
69563|NCT02626455|Phosphatidylinositol-3-kinase
69564|NCT02626455|Non-Hodgkin's lymphoma
69565|NCT02626455|Indolent B-cell non-Hodgkin's lymphoma
69566|NCT02626442|Cognition
69567|NCT02626442|Exercise
69568|NCT02626416|Telemedicine
69569|NCT02626403|vegetative state
69570|NCT02626403|minimally conscious state
69571|NCT02626403|disorder of consciousness
69572|NCT02626403|transcranial current direct stimulation
69573|NCT02626403|non invasive brain stimulation
69574|NCT02626403|neuromodulation
69575|NCT02626377|Informal caregivers
69576|NCT02626377|Elderly
69577|NCT02626377|Quality of life
69578|NCT02626377|Cost effectiveness
69579|NCT02626377|Cohort study
69580|NCT02626377|Randomized study
69581|NCT02626351|postnatal
69582|NCT02626312|Liver Cancer
69583|NCT02626312|Impaired Liver Function
69584|NCT02626312|Liver tumors
69585|NCT02626312|Hepatocellular carcinoma
69586|NCT02626312|HCC
69587|NCT02626312|Cholangiocarcinoma
69588|NCT02626312|Liver metastases
69589|NCT02626312|Low functional liver volume
69590|NCT02626312|Radiation therapy
69591|NCT02626312|XRT
69592|NCT02626312|Chemotherapy
69593|NCT02626312|Questionnaire
69594|NCT02626312|Survey
69595|NCT02626312|High dose radiotherapy
69596|NCT02626299|Preterm birth, very low birth weight
69597|NCT02626286|HIV
69598|NCT02626286|Men who have sex with men
69599|NCT02626273|obesity
69600|NCT02626273|adolescents
69601|NCT02626273|physical activity
69602|NCT02626273|adipocytes
69603|NCT02626273|osteocytes
69604|NCT02626273|weight loss
69605|NCT02626273|bone
69606|NCT02626273|fat
69607|NCT02626247|elderly
69608|NCT02626234|cMET, INC280, rosuvastatin, digoxin
69609|NCT02626208|Contraceptive vaginal ring
69610|NCT02626195|malnutrition
69611|NCT02626195|nutrition
69612|NCT02626195|nutritional support
69613|NCT02626195|hepatobiliary pancreatic cancer
69614|NCT02626195|hepatobiliary pancreatic surgery
69615|NCT02626169|15-epi-lipoxin A4
69616|NCT02626169|inflammation
69617|NCT02626169|atherosclerosis
69618|NCT02626156|post healed venous leg ulcer
69619|NCT02626156|posted healed diabetic foot ulcer
69620|NCT02626130|Kidney Cancer
69621|NCT02626130|Metastatic Renal Cell Carcinoma
69622|NCT02626130|RCC
69623|NCT02626130|Metastatic clear cell renal cell carcinoma
69624|NCT02626130|Tremelimumab
69625|NCT02626130|Cryoablation
69626|NCT02626130|Cryoprobe
69627|NCT02626104|lactoferrin
69628|NCT02626104|clostridium difficile
69629|NCT02626104|antibiotic associated diarrhoea
69630|NCT02626104|children
69631|NCT02626104|antibiotic therapy
69632|NCT02626104|diarrhoea
69633|NCT02626091|Anastomotic perfusion
69634|NCT02626091|ICG Fluorescence
69635|NCT02626091|Enhanced reality
69636|NCT02626091|Left-sided colonic resection
69637|NCT02626078|Malnutrition
69638|NCT02626078|Food practices
69639|NCT02626078|Elderly
69640|NCT02626078|Nursing Home
69641|NCT02626078|Aging
69642|NCT02626078|Nutritional status
69643|NCT02626078|Quality of life
69644|NCT02626065|Melanoma
69645|NCT02626065|Anti-PD1 monoclonal antibodies
69646|NCT02626065|Immune modulation
69647|NCT02626065|BRAF
69648|NCT02626052|Skull vibration induced nystagmus test
69649|NCT02626052|mastoid vibration test
69650|NCT02626039|Metastatic Breast Cancer
69651|NCT02626039|CTCs
69652|NCT02626039|cfDNA
69653|NCT02626039|genomics
69654|NCT02626039|somatic mutations
69655|NCT02626000|Recurrent Metastatic Squamous Cell Carcinoma Head and Neck
69656|NCT02625987|Appendicectomy, wound complications, skin closure
69657|NCT02625961|PD1
69658|NCT02625961|PDL1
69659|NCT02625961|PD-L1
69660|NCT02625961|PD-1
69661|NCT02625948|Intracerebral Hemorrhage
69662|NCT02625948|tranexamic acid
69663|NCT02625948|spot sign
69664|NCT02625935|Prosigna
69665|NCT02625935|estrogen receptor positive
69666|NCT02625935|node negative
69667|NCT02625935|HER2 negative
69668|NCT02625922|Serelaxin,
69669|NCT02625922|Chronic heart failure,
69670|NCT02625922|Spiroergometry,
69671|NCT02625922|Troponin,
69672|NCT02625922|New York Heart Association (NYHA) functional Class II/III,
69673|NCT02625922|Left ventricular ejection fraction,
69674|NCT02625896|Aviation
69675|NCT02625896|Parachuting
69676|NCT02625883|Resuscitation, quality of life
69677|NCT02625857|Prostatic Neoplasms, Castration-Resistant
69678|NCT02625857|JNJ-64041809
69679|NCT02625857|Listeria monocytogenes
69680|NCT02625831|ficolin-3
69681|NCT02625831|anti-ficolin-3 antibodies
69682|NCT02625831|lupus nephritis
69683|NCT02625831|Lupus Erythematosus, Systemic
69684|NCT02625831|biomarker
69685|NCT02625831|ficolin-2
69686|NCT02625831|anti-ficolin-2 antibodies
69687|NCT02625818|Emergency Services, Psychiatric
69688|NCT02625818|Prognosis
69689|NCT02625818|Biological markers
69690|NCT02625818|Anxiety
69691|NCT02625818|Panic
69692|NCT02625818|Psychomotor Agitation
69693|NCT02625818|Self-injurious Behavior
69694|NCT02625792|Post ESD ulcer
69695|NCT02625792|Bleeding
69696|NCT02625792|Prophylaxis
69697|NCT02625779|Bipolar depression
69698|NCT02625779|Cytidine
69699|NCT02625779|Creatine
69700|NCT02625779|Magnetic resonance spectroscopy
69701|NCT02625766|Operative vs. Non-operative
69702|NCT02625766|LC pelvic fracture
69703|NCT02625766|Complications
69704|NCT02625753|photorefractive keratectomy
69705|NCT02625753|pain
69706|NCT02625753|analgesia
69707|NCT02625753|opioid
69708|NCT02625727|knee osteoarthritis
69709|NCT02625727|hyaluronic acid
69710|NCT02625727|corticosteroid
69711|NCT02625727|intra-articular injection
69712|NCT02625727|therapeutic effect
69713|NCT02625701|operative mortality
69714|NCT02625701|myocardial infarct, arrhythmia, heart failure, stroke
69715|NCT02625701|pneumonia, atelectasis, acute lung injury
69716|NCT02625701|surgical site infection
69717|NCT02625701|acute kidney injury
69718|NCT02625701|body weight
69719|NCT02625662|muscular dystrophy
69720|NCT02625662|natural history
69721|NCT02625662|genetic profilling
69722|NCT02625649|Roux-en-Y gastric bypass
69723|NCT02625649|obesity
69724|NCT02625649|type 2 diabetes mellitus
69725|NCT02625649|diabetic nephropathy
69726|NCT02625649|diabetic retinopathy
69727|NCT02625623|Avelumab
69728|NCT02625623|Gastric cancer
69729|NCT02625623|Gastroesophageal junction adenocarcinoma
69730|NCT02625610|Avelumab
69731|NCT02625610|Cancer
69732|NCT02625610|Unresectable
69733|NCT02625610|Locally advanced
69734|NCT02625610|Metastatic
69735|NCT02625610|Adenocarcinoma of the stomach
69736|NCT02625610|Gastro-esophageal junction
69737|NCT02625584|Shared Book Reading
69738|NCT02625584|Dialogic Reading
69739|NCT02625584|Language Development
69740|NCT02625584|Syntax
69741|NCT02625584|Vocabulary
69742|NCT02625584|Young Children
69743|NCT02625584|Randomised Control Trial
69744|NCT02625584|Language Intervention
69745|NCT02625558|riociguat
69746|NCT02625558|saph
69747|NCT02625558|sarcoidosis
69748|NCT02625558|sarcoidosis associated pulmonary hypertension
69749|NCT02625532|Controlled Ovarian stimulation
69750|NCT02625532|Follicular phase
69751|NCT02625532|Luteal phase
69752|NCT02625532|Reproductive Techniques, Assisted
69753|NCT02625519|Controlled ovarian stimulation
69754|NCT02625519|Follicle-stimulating hormone
69755|NCT02625519|Receptor N680S follicle-stimulating hormone receptor (FSHR) gene polymorphism
69756|NCT02625519|Oocyte donors
69757|NCT02625493|Percutaneous coronary intervention
69758|NCT02625493|Patient Preference
69759|NCT02625493|Radial access
69760|NCT02625493|Femoral access
69761|NCT02625493|Coronary angiography
69762|NCT02625493|Shared decision making
69763|NCT02625467|Keratoconus
69764|NCT02625454|Acetaminophen
69765|NCT02625454|Labor
69766|NCT02625454|Intrapartum Fever
69767|NCT02625454|Maternal Fever
69768|NCT02625454|Fetal Tachycardia
69769|NCT02625454|Intravenous Acetaminophen
69770|NCT02625441|Breast cancer
69771|NCT02625441|docetaxel
69772|NCT02625441|pertuzumab
69773|NCT02625441|trastuzumab
69774|NCT02625441|HER2
69775|NCT02625402|decision making
69776|NCT02625402|decision aids
69777|NCT02625402|decision quality instruments
69778|NCT02625402|osteoarthritis
69779|NCT02625402|shared decision making
69780|NCT02625389|scheduled for selective transarterial catheterization
69781|NCT02625363|Glycemic Index
69782|NCT02625363|Water Intake
69783|NCT02625363|Glycemic Response
69784|NCT02625350|instant noodle
69785|NCT02625350|water content
69786|NCT02625350|glycemic index
69787|NCT02625350|serving method
69788|NCT02625298|periapical diseases
69789|NCT02625298|dental injuries
69790|NCT02625298|MTA
69791|NCT02625272|hand-assisted laparoscopic surgery
69792|NCT02625272|right colon cancer
69793|NCT02625272|complete mesocolic excision
69794|NCT02625272|no touch isolation
69795|NCT02625272|recurrence
69796|NCT02625272|overall survival
69797|NCT02625246|bronchiectasis
69798|NCT02625246|mesenchymal stem cell
69799|NCT02625246|lung
69800|NCT02625246|pulmonary
69801|NCT02625246|interstitial lung disease
69802|NCT02625207|Maraviroc, CYP3A5, pharmacokinetics, pharmacogenomics
69803|NCT02625181|Decision support
69804|NCT02625181|Prediction models
69805|NCT02625181|PONV
69806|NCT02625181|prophylaxis
69807|NCT02625181|Decision Support Systems, Clinical
69808|NCT02625181|Decision Support Techniques
69809|NCT02625168|Afatinib
69810|NCT02625168|Erlotinib
69811|NCT02625168|Metastatic non-small cell lung cancer
69812|NCT02625168|Efficacy
69813|NCT02625168|Safety
69814|NCT02625155|Pharmacogenomics
69815|NCT02625155|Urine Drug Testing
69816|NCT02625155|antidepressants
69817|NCT02625155|benzodiazepines
69818|NCT02625155|opioids
69819|NCT02625155|muscle relaxants
69820|NCT02625155|non-steroidal anti-inflammatory agents
69821|NCT02625155|TDRAE
69822|NCT02625142|Morning Rounds
69823|NCT02625142|Patient-centered Care
69824|NCT02625142|Hospital Medicine
69825|NCT02625142|Pediatrics
69826|NCT02625142|Hospitals, Pediatric
69827|NCT02625116|Cohort
69828|NCT02625103|Schizophrenia, Clozapine, TDM, Serum Concentration
69829|NCT02625090|Drug-resistance
69830|NCT02625090|focal epilepsy
69831|NCT02625090|partial-onset seizures
69832|NCT02625077|Valvuloplasty
69833|NCT02625077|Fundoplication
69834|NCT02625077|Acid reflux
69835|NCT02625077|GERD
69836|NCT02625077|Reflux disease
69837|NCT02625077|Hiatal hernia
69838|NCT02625064|ARDS
69839|NCT02625064|biomarkers
69840|NCT02625064|proteomic
69841|NCT02625012|Ultraviolet Therapy
69842|NCT02625012|Vitiligo
69843|NCT02625012|Melanocytes
69844|NCT02625012|Pigmentation
69845|NCT02624999|Head and Neck Cancer
69846|NCT02624999|SCCHN
69847|NCT02624999|R/M SCCHN
69848|NCT02624999|Carcinoma
69849|NCT02624973|neoadjuvant treatment
69850|NCT02624973|personalized medicine
69851|NCT02624947|RSV
69852|NCT02624895|"metastatic colorectal cancer gene RAS not mutated WILD TYPE"
69853|NCT02624882|blistering distal dactylitis
69854|NCT02624882|Streptococcus pyogenes
69855|NCT02624882|antibiotics
69856|NCT02624869|Hypercholesterolemia
69857|NCT02624869|Elevated Cholesterol
69858|NCT02624869|High Cholesterol
69859|NCT02624869|PCSK9 mutations
69860|NCT02624869|Severe Familial Hypercholesterolemia
69861|NCT02624869|evolocumab
69862|NCT02624869|Repatha
69863|NCT02624869|Heterozygous Familial Hypercholesterolemia
69864|NCT02624869|Homozygous Familial Hypercholesterolemia
69865|NCT02624869|Pediatric
69866|NCT02624869|Paediatric
69867|NCT02624856|primary total knee arthroplasty
69868|NCT02624856|liposomal bupivacaine
69869|NCT02624804|Diabetes
69870|NCT02624791|astigmatism, contact lens, driving
69871|NCT02624765|RCT A: Fetal Atrial Flutter without Hydrops
69872|NCT02624765|RCT B: Fetal Supraventricular Tachycardia without Hydrops
69873|NCT02624765|RCT C: Fetal Supraventricular Tachycardia with Hydrops
69874|NCT02624752|Oral Nutrition Supplementation
69875|NCT02624726|1st line
69876|NCT02624726|FOLFIRI
69877|NCT02624726|Aflibercept
69878|NCT02624726|mCRC
69879|NCT02624713|eating disorder
69880|NCT02624713|childhood obesity
69881|NCT02624713|family based treatment
69882|NCT02624700|ER-negative
69883|NCT02624700|PgR-negative
69884|NCT02624700|Human epidermal growth factor receptor 2 (HER2-negative)
69885|NCT02624700|Triple Negative Breast Cancer
69886|NCT02624700|HER2-negative
69887|NCT02624661|Trigeminal ganglion
69888|NCT02624661|Glycerol
69889|NCT02624661|Nerve block
69890|NCT02624648|Sexual Dysfunction
69891|NCT02624648|Postmenopausal women
69892|NCT02624648|Sexual desire
69893|NCT02624635|Manual Therapy
69894|NCT02624635|Pain
69895|NCT02624635|Hip
69896|NCT02624635|Muscle Strength
69897|NCT02624622|omphalitis
69898|NCT02624622|neonate
69899|NCT02624622|developing countries
69900|NCT02624596|OCD
69901|NCT02624583|Fasting
69902|NCT02624583|Clopidogrel
69903|NCT02624570|AML
69904|NCT02624570|FLT3
69905|NCT02624570|ITD
69906|NCT02624570|TKD
69907|NCT02624570|acute myeloid leukemia
69908|NCT02624570|induction
69909|NCT02624570|consolidation
69910|NCT02624570|continuation
69911|NCT02624570|EAP
69912|NCT02624570|ETP
69913|NCT02624570|midostaurin
69914|NCT02624570|PKC412
69915|NCT02624557|Hepatic impairment
69916|NCT02624557|Healthy volunteers
69917|NCT02624557|Clinical pharmacology study
69918|NCT02624557|BYL719
69919|NCT02624557|alpelisib
69920|NCT02624531|NACT
69921|NCT02624531|Cervical cancer
69922|NCT02624531|Fertility sparing
69923|NCT02624531|Pregnancy
69924|NCT02624531|Treatment Strategy
69925|NCT02624479|Pharmacokinetics
69926|NCT02624466|Pediatrics
69927|NCT02624466|Nephrology
69928|NCT02624466|Dialysis
69929|NCT02624453|cryptococcus
69930|NCT02624453|IMMY LFA
69931|NCT02624453|meningitis
69932|NCT02624453|antigen
69933|NCT02624440|Multiple Myeloma
69934|NCT02624440|Infection
69935|NCT02624440|Clarithromycin
69936|NCT02624440|Trimethoprim-Sulfamethoxazole Combination
69937|NCT02624427|Glaucoma
69938|NCT02624427|Intraocular Pressure
69939|NCT02624388|Genistein
69940|NCT02624388|Soy
69941|NCT02624388|Chemotherapy side-effects
69942|NCT02624388|Pediatric Cancer
69943|NCT02624388|Isoflavone
69944|NCT02624362|Odor
69945|NCT02624362|trigger
69946|NCT02624362|inflammation
69947|NCT02624362|nocebo
69948|NCT02624336|periodontal disease
69949|NCT02624336|caries
69950|NCT02624323|ultrasonography
69951|NCT02624323|catheterization
69952|NCT02624323|central line
69953|NCT02624323|mechanical ventilation
69954|NCT02624323|intensive care
69955|NCT02624323|axillary vein
69956|NCT02624323|jugular vein
69957|NCT02624323|randomization
69958|NCT02624297|Coronary artery disease
69959|NCT02624297|Chemoreceptors
69960|NCT02624297|Sympathetic nerve activity
69961|NCT02624297|Exercise
69962|NCT02624271|gastric cancer
69963|NCT02624271|gastric precancerous lesions
69964|NCT02624271|blood test
69965|NCT02624232|Anorectal malformation
69966|NCT02624232|Anorectal atresia
69967|NCT02624232|anorectal stenosis
69968|NCT02624232|Follow-Up Studies
69969|NCT02624219|A/H5N8
69970|NCT02624219|AS03
69971|NCT02624219|Controlled
69972|NCT02624219|Double-Blind
69973|NCT02624219|Immunogenicity
69974|NCT02624219|Inactivated
69975|NCT02624219|Influenza
69976|NCT02624219|MF59
69977|NCT02624219|Monovalent
69978|NCT02624219|Randomized
69979|NCT02624219|Reactogenicity
69980|NCT02624219|Safety
69981|NCT02624219|Trial
69982|NCT02624219|Vaccine
69983|NCT02624193|Treatment Adherence
69984|NCT02624193|Mental Health
69985|NCT02624193|Well-being
69986|NCT02624193|Emerging Adults
69987|NCT02624193|Youth
69988|NCT02624128|head and neck cancer
69989|NCT02624128|valproic acid
69990|NCT02624128|recurrent
69991|NCT02624128|metastatic
69992|NCT02624102|Major depressive disorder
69993|NCT02624102|Cognitive behavioral therapy
69994|NCT02624102|Trial based cognitive therapy
69995|NCT02624102|Behavioral activation
69996|NCT02624076|unexplained infertility
69997|NCT02624076|Acupuncture
69998|NCT02624050|ACEI
69999|NCT02624050|ARB
70000|NCT02624050|Hypotension
70001|NCT02624050|General Anesthesia
70002|NCT02624050|Methohexital
70003|NCT02624050|Propofol
70004|NCT02624037|Inflammatory Bowel Disease, Ulcerative Colitis
70005|NCT02624037|Crohn's Disease
70006|NCT02624037|Pharmacokinetics, Individualized Dosage, Dashboard System
70007|NCT02624037|Remicade, Infliximab
70008|NCT02623998|Diabetes
70009|NCT02623998|Insulin
70010|NCT02623998|Glargine
70011|NCT02623998|Metformin
70012|NCT02623998|Sitagliptin
70013|NCT02623998|Diet
70014|NCT02623998|Excercise
70015|NCT02623998|Lifestyle
70016|NCT02623972|inflammatory breast cancer
70017|NCT02623972|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
70018|NCT02623959|Advanced Cancers
70019|NCT02623959|Malignant pleural effusions
70020|NCT02623959|MPE
70021|NCT02623959|Indwelling pleural catheter
70022|NCT02623959|IPC
70023|NCT02623959|Questionnaires
70024|NCT02623959|Surveys
70025|NCT02623959|Fentanyl patch
70026|NCT02623959|Fentanyl by vein
70027|NCT02623959|Sublimaze
70028|NCT02623959|Doxycycline
70029|NCT02623959|Vibramycin
70030|NCT02623959|Periostat
70031|NCT02623959|Doryx
70032|NCT02623959|:Phone calls
70033|NCT02623946|motor evoked potentials
70034|NCT02623933|HDR monotherapy
70035|NCT02623933|MRI guidance
70036|NCT02623933|Intraprostatic lesion
70037|NCT02623933|dose paining
70038|NCT02623894|Vascular aging.
70039|NCT02623894|Arterial stiffness.
70040|NCT02623894|Lifestyles.
70041|NCT02623894|Vascular structure.
70042|NCT02623894|Telomere length,
70043|NCT02623894|Psychological factors.
70044|NCT02623894|Inflammatory factors.
70045|NCT02623894|Oxidative stress
70046|NCT02623881|Cervical pessary
70047|NCT02623881|Vaginal progesterone
70048|NCT02623881|Twins
70049|NCT02623881|Premature birth
70050|NCT02623855|Parks
70051|NCT02623855|Well-being
70052|NCT02623855|Stress
70053|NCT02623855|Physical Activity
70054|NCT02623855|Nature
70055|NCT02623855|Greenspace
70056|NCT02623842|urinary incontinence
70057|NCT02623842|woman
70058|NCT02623842|radiofrequency
70059|NCT02623829|scar prophylaxis
70060|NCT02623829|Botulinum Toxin
70061|NCT02623764|Alzheimer´s disease
70062|NCT02623764|Lewy body dementia
70063|NCT02623764|Parkinson dementia
70064|NCT02623764|EEG
70065|NCT02623764|Cholinergic index
70066|NCT02623725|Dengue Fever
70067|NCT02623725|Dengue virus
70068|NCT02623725|Dengue Hemorrhagic Fever
70069|NCT02623725|CYD Dengue Vaccine
70070|NCT02623699|Isis-SOD1Rx
70071|NCT02623699|SOD1
70072|NCT02623699|ALS
70073|NCT02623686|Sleep
70074|NCT02623686|ICU
70075|NCT02623686|Massage Therapy
70076|NCT02623686|Inhalation Patch
70077|NCT02623660|Inflammation
70078|NCT02623660|Edema
70079|NCT02623660|Arthroplasty
70080|NCT02623660|Rehabilitation
70081|NCT02623660|Replacement
70082|NCT02623660|Knee
70083|NCT02623660|Total Knee Replacement
70084|NCT02623660|Pain, Postoperative
70085|NCT02623660|Exercise Therapy
70086|NCT02623660|Therapeutics
70087|NCT02623660|Early Ambulation
70088|NCT02623660|Myofunctional Therapy
70089|NCT02623660|Electric Stimulation Therapy
70090|NCT02623660|Orthopedic Procedures
70091|NCT02623660|Wound Healing
70092|NCT02623660|Total Knee Arthroplasty
70093|NCT02623634|Cuff leak test, relative factors
70094|NCT02623608|type 2 diabetes risk
70095|NCT02623608|cardiovascular disease risk
70096|NCT02623595|non-small cell lung cancer
70097|NCT02623595|Granulocyte-Macrophage Colony-Stimulating Factor
70098|NCT02623595|Stereotactic body radiotherapy
70099|NCT02623595|abscopal effect
70100|NCT02623595|safety
70101|NCT02623595|immunotherapy
70102|NCT02623556|diagnosis of tuberculosis
70103|NCT02623556|ESAT6-CFP10
70104|NCT02623556|skin test
70105|NCT02623556|diagnostic test
70106|NCT02623530|Nursing
70107|NCT02623530|Nursing education research
70108|NCT02623530|Critical thinking
70109|NCT02623530|Decision Making
70110|NCT02623517|CIED
70111|NCT02623517|AF
70112|NCT02623517|arrhythmia
70113|NCT02623517|atrial fibrillation
70114|NCT02623517|cardiac device
70115|NCT02623517|pacemaker
70116|NCT02623517|defibrillator
70117|NCT02623504|Carbamazepine
70118|NCT02623504|Equetro
70119|NCT02623504|Bipolar I Disorder
70120|NCT02623504|Bipolar I Disorder in Children
70121|NCT02623491|JNJ-55375515
70122|NCT02623491|Healthy
70123|NCT02623491|Placebo
70124|NCT02623439|hematologic malignancies
70125|NCT02623426|uveitic macular edema
70126|NCT02623426|uveitis
70127|NCT02623400|preterm birth
70128|NCT02623400|perinatal stress
70129|NCT02623400|growth and development
70130|NCT02623387|paravertebral block
70131|NCT02623348|dialysis
70132|NCT02623348|end-stage renal disease
70133|NCT02623335|patient decision making
70134|NCT02623335|surgical decision making
70135|NCT02623335|question prompt list
70136|NCT02623335|shared decision making
70137|NCT02623335|decision support techniques
70138|NCT02623257|Non-small Cell Lung Cancer
70139|NCT02623257|circulating tumor DNA
70140|NCT02623257|amplification refractory mutation system
70141|NCT02623244|ovarian endometrioma
70142|NCT02623244|lower urinary tract symptoms
70143|NCT02623244|sexual dysfunction
70144|NCT02623244|gastrointestinal symptoms
70145|NCT02623218|traumatic brain injury
70146|NCT02623218|acupuncture
70147|NCT02623218|transcranial doppler ultrasound
70148|NCT02623166|Pneumonia
70149|NCT02623166|Fever
70150|NCT02623166|Diarrhoea
70151|NCT02623140|Coronary drug eluting stents
70152|NCT02623140|Outcomes
70153|NCT02623127|Thymic carcinoma
70154|NCT02623127|Sunitinib
70155|NCT02623127|Metastatic
70156|NCT02623127|Recurrent
70157|NCT02623101|Reflectance confocal microscopy
70158|NCT02623101|Basal cell carcinoma
70159|NCT02623101|Biopsy
70160|NCT02623101|Diagnostics
70161|NCT02623088|Obstructive Sleep Apnea
70162|NCT02623088|Endothelial dysfunction
70163|NCT02623088|Arterial stiffness
70164|NCT02623088|PAP therapies
70165|NCT02623049|New oral anticoagulants
70166|NCT02623049|Blood levels
70167|NCT02623049|Octogenarians
70168|NCT02623036|chronotherapy
70169|NCT02623036|angiotensin converting enzyme inhibitors
70170|NCT02623036|ambulatory blood pressure monitoring
70171|NCT02623010|Primary CNS lymphoma
70172|NCT02623010|Ibrutinib
70173|NCT02623010|Elderly
70174|NCT02623010|Maintenance
70175|NCT02622997|HPV self-sampling
70176|NCT02622971|phototherapy
70177|NCT02622971|cryotherapy
70178|NCT02622971|exercise
70179|NCT02622971|fatigue
70180|NCT02622971|recovery
70181|NCT02622958|Social Anxiety Disorder
70182|NCT02622958|Social Phobia
70183|NCT02622958|Performance Anxiety
70184|NCT02622958|Social Anxiety
70185|NCT02622958|Anxiety
70186|NCT02621866|hypertension
70187|NCT02621866|ultraviolet
70188|NCT02621853|Steatosis
70189|NCT02621827|vitamin D
70190|NCT02621827|Africa
70191|NCT02621814|Infant
70192|NCT02621814|Growth
70193|NCT02621814|Body Weight Changes
70194|NCT02621814|Infant Formula
70195|NCT02621814|Randomized Controlled Trial
70196|NCT02621788|mind/body medicine
70197|NCT02621788|3RP
70198|NCT02621788|stress management
70199|NCT02621788|resident burnout
70200|NCT02621775|Stress management
70201|NCT02621775|Cognitive behavioural therapy (CBT)
70202|NCT02621775|Self-help
70203|NCT02621775|e-health
70204|NCT02621775|Adjustment disorder with anxiety
70205|NCT02621736|children
70206|NCT02621736|desmopressin
70207|NCT02621736|copeptin
70208|NCT02622906|Gastrointestinal angiodysplasia
70209|NCT02622906|Pasireotide
70210|NCT02622906|Gastrointestinal bleeding
70211|NCT02622867|Lactobacillus plantarum
70212|NCT02622867|Maltodextrin
70213|NCT02622867|Probiotics
70214|NCT02622867|Randomized Controlled Trial
70215|NCT02622854|plasma exchange
70216|NCT02622854|hypertriglyceridemia
70217|NCT02622841|First in man
70218|NCT02622841|Spinal metastases
70219|NCT02622841|Stereotactic bodyradiotherapy
70220|NCT02622841|Palliative care
70221|NCT02622841|Safety
70222|NCT02622841|Surgical stabilisation
70223|NCT02622828|wheelchairs
70224|NCT02622828|social participation
70225|NCT02622815|Hypercoagulation
70226|NCT02622815|Thrombosis
70227|NCT02622815|Cancer Risk Assessment
70228|NCT02622815|Cancer Prognosis
70229|NCT02622802|ex-vivo placenta perfusion
70230|NCT02622802|transplacental transfer
70231|NCT02622802|paracetamol
70232|NCT02622802|erythromycin
70233|NCT02622802|azithromycin
70234|NCT02622789|Spinal alignment
70235|NCT02622789|Kinematics
70236|NCT02622789|Pilates
70237|NCT02622789|Physical Therapy
70238|NCT02622763|Tolerogenic Dendritic Cells
70239|NCT02622750|triple-branched stent graft
70240|NCT02622750|total arch replace
70241|NCT02622750|the occluded rate of false lumen
70242|NCT02622737|Parkinson disease
70243|NCT02622737|Accidental Falls
70244|NCT02622737|Exercise therapy
70245|NCT02622737|Virtual Reality Exposure Therapy
70246|NCT02622724|ARDS, human
70247|NCT02622724|Acute Respiratory Distress Syndrome
70248|NCT02622724|Respiratory Insufficiency
70249|NCT02622711|breast cancer
70250|NCT02622711|obesity
70251|NCT02622711|weight control
70252|NCT02622711|exercise and physical fitness
70253|NCT02622672|Antioxidation
70254|NCT02622672|Anti-inflammation
70255|NCT02622672|Blood glucose
70256|NCT02622672|Blood lipids
70257|NCT02622659|acute upper respiratory infection
70258|NCT02622620|dynamic contrast-enhanced MR imaging
70259|NCT02622620|three-dimensional arterial spin labeling
70260|NCT02622620|diffusion-weighted imaging
70261|NCT02622607|ZOL
70262|NCT02622607|Prevention
70263|NCT02622607|NSCLC
70264|NCT02622529|Awake craniotomy
70265|NCT02622529|Psychological consequences
70266|NCT02622529|Fear and Anxiety
70267|NCT02622516|Rehabilitation
70268|NCT02622516|Physical Therapy Specialty
70269|NCT02622516|Postural Balance
70270|NCT02622516|Vertigo
70271|NCT02622516|Dizziness
70272|NCT02622438|FSHD
70273|NCT02622438|Usual care performed at Montpellier hospital
70274|NCT02622438|Muscle function
70275|NCT02622438|Antioxidants
70276|NCT02622438|Oxidative stress
70277|NCT02622438|Quality of life
70278|NCT02622438|Physical activities, development of food-based dietary guidelines
70279|NCT02622438|Co-morbidity
70280|NCT02622425|Carotenoid
70281|NCT02622425|Bacillus
70282|NCT02622425|Microbiota
70283|NCT02622425|Cardiovascular health
70284|NCT02622412|Quality of Life
70285|NCT02622412|Palliative Therapy
70286|NCT02622412|Outpatient Services
70287|NCT02622386|Psoriasis
70288|NCT02622373|Pea Pod
70289|NCT02622373|Body composition
70290|NCT02622308|Arterial leg ulcers
70291|NCT02622308|Intermittent Negative Pressure
70292|NCT02622308|Peripheral Circulation
70293|NCT02622308|Wound healing
70294|NCT02622308|Peripheral blood flow
70295|NCT02622295|metabolism
70296|NCT02622295|glucose
70297|NCT02622295|osteoporosis
70298|NCT02622295|secondary health conditions
70299|NCT02622295|quality of life
70300|NCT02622295|standing
70301|NCT02622295|electrical stimulation
70302|NCT02622295|diabetes
70303|NCT02622295|insulin
70304|NCT02622295|skeletal muscle
70305|NCT02622282|physical activity
70306|NCT02622282|physical inactivity
70307|NCT02622282|PAD
70308|NCT02622282|Diabetes
70309|NCT02622282|High blood pressure
70310|NCT02622282|High cholesterol
70311|NCT02622282|Smoking
70312|NCT02622269|Urography
70313|NCT02622269|Radiation dosage
70314|NCT02622269|image enhancement
70315|NCT02622256|Social Media
70316|NCT02622256|Twitter
70317|NCT02622256|Hypertension
70318|NCT02622256|Cardiovascular
70319|NCT02622256|CVD
70320|NCT02622256|HTN
70321|NCT02622230|Uygur Medicine
70322|NCT02622217|anesthesiology
70323|NCT02622217|non technical kills
70324|NCT02622191|Glaucoma
70325|NCT02622191|Optical Coherence Tomography
70326|NCT02622191|Primary Open Angle Glaucoma
70327|NCT02622191|Visual Field
70328|NCT02622165|health promotion
70329|NCT02622165|nutrition
70330|NCT02622165|intervention
70331|NCT02622165|adolescents
70332|NCT02622165|serious game
70333|NCT02622152|Right lateral
70334|NCT02622152|Oxygenation
70335|NCT02622152|Cardiac
70336|NCT02622152|Congenital
70337|NCT02622152|Pediatric
70338|NCT02622152|Postoperative
70339|NCT02622139|Photoacoustics
70340|NCT02622139|Optoacoustics
70341|NCT02622139|Ultrasound
70342|NCT02622126|Preloading
70343|NCT02622126|Colloid
70344|NCT02622126|Cesarean section
70345|NCT02622126|D-dimer
70346|NCT02622126|Hypotension
70347|NCT02622113|insulin resistance
70348|NCT02622100|Bioresorbable Vascular Scaffold
70349|NCT02622100|Routine Clinical Practice
70350|NCT02622100|Angioplasty, Transluminal, Percutaneous Coronary
70351|NCT02622100|Coronary Artery Disease
70352|NCT02622100|drug eluting stent
70353|NCT02622074|PD1
70354|NCT02622074|PD-1
70355|NCT02622074|PDL1
70356|NCT02622074|PD-L1
70357|NCT02622074|Triple Negative Breast Cancer
70358|NCT02622048|Mental Health
70359|NCT02622048|Psychosis
70360|NCT02622048|Parent
70361|NCT02622035|Virtual Reality Technology
70362|NCT02622035|Methodology
70363|NCT02622022|randomised
70364|NCT02622022|placebo controlled
70365|NCT02622022|clinical trial
70366|NCT02622009|stable COPD; bronchoalveolar lavage; biopsy; HRV; RSV
70367|NCT02621996|Surface Electromyography
70368|NCT02621996|Hypotonia
70369|NCT02621996|Patient Positioning
70370|NCT02621983|Schizophrenia
70371|NCT02621983|Exercise
70372|NCT02621983|Cognition
70373|NCT02621905|Prophylaxis
70374|NCT02621905|Steady-State
70375|NCT02621905|Bioavailability
70376|NCT02621723|Preventability
70377|NCT02621697|dual task
70378|NCT02621697|aging
70379|NCT02621671|Healthy Volunteers
70380|NCT02621658|Colorectal Cancer
70381|NCT02621658|Colonoscopy
70382|NCT02621658|Adenoma Detection Rate
70383|NCT02621658|Bowel Preparation
70384|NCT02621658|Time to Cecal Intubation
70385|NCT02621645|monochorionic
70386|NCT02621645|TRAP
70387|NCT02621645|acardiac twin
70388|NCT02621632|Compression therapy
70389|NCT02621619|Older adults
70390|NCT02621619|Elderly
70391|NCT02621619|Acute pain
70392|NCT02621619|IV acetaminophen
70393|NCT02621619|IV hydromorphone
70394|NCT02621619|Analgesia
70395|NCT02621619|Adjunctive analgesia
70396|NCT02621593|Meibomian Gland Dysfunction
70397|NCT02621593|Dry eye symptoms
70398|NCT02621593|Intense Pulsed Light
70399|NCT02621580|Panretinal Photocoagulation
70400|NCT02621554|Memory
70401|NCT02621554|Resveratrol
70402|NCT02621554|elderly
70403|NCT02621554|cognition
70404|NCT02621541|neuroendocrine tumor
70405|NCT02621541|pancreas
70406|NCT02621541|diagnosis
70407|NCT02621541|positron emission tomography
70408|NCT02621528|CeraFlex occluder
70409|NCT02621515|Nivolumab
70410|NCT02621515|Brain metastasis
70411|NCT02621515|Melanoma
70412|NCT02621502|Quinoa
70413|NCT02621502|Satiety
70414|NCT02621502|Visual analogue scale
70415|NCT02621502|Cross-over studies
70416|NCT02621489|Glucagon-like peptide-1
70417|NCT02621489|Endothelialization
70418|NCT02621489|Cardiac Function
70419|NCT02621489|Exenatide
70420|NCT02621489|Optical Coherence Tomography
70421|NCT02621450|chronic renal failure
70422|NCT02621450|hypertension
70423|NCT02621450|ampulatory blood pressure
70424|NCT02621437|pain
70425|NCT02621437|quality of life
70426|NCT02621437|osteopathy
70427|NCT02621437|oncology
70428|NCT02621437|surgery
70429|NCT02621437|breast
70430|NCT02621424|dementia
70431|NCT02621424|Mild Cognitive Impairment (MCI)
70432|NCT02621424|RTMS
70433|NCT02621424|CVLT
70434|NCT02621411|Substance abuse
70435|NCT02621411|Emergency operation
70436|NCT02621411|Preoperative screen
70437|NCT02621320|Vitamin D
70438|NCT02621320|Exercise Performance
70439|NCT02621320|Wheelchair Athletes
70440|NCT02621320|Indoor sports
70441|NCT02621320|Wingate
70442|NCT02621320|Isokinetic Dynamometer
70443|NCT02621307|postprandial glycemia
70444|NCT02621307|subjective appetite
70445|NCT02621307|Salba
70446|NCT02621307|Flax
70447|NCT02621294|Protein
70448|NCT02621294|indicator amino acid oxidation method
70449|NCT02621294|athletes
70450|NCT02621281|hypothermic machine perfusion
70451|NCT02621281|Kidney Transplantation
70452|NCT02621281|Delayed graft function
70453|NCT02621281|perfusion pressure
70454|NCT02621229|Optimal rate of refeeding
70455|NCT02621229|inpatients
70456|NCT02621229|hospitalized
70457|NCT02621216|percutaneous coronary intervention
70458|NCT02621190|circulating tumor cells
70459|NCT02621190|predictive factor
70460|NCT02621151|combination therapy
70461|NCT02621151|immunotherapy
70462|NCT02621151|immune checkpoint inhibition
70463|NCT02621099|handheld gamma camera
70464|NCT02621086|Oligosaccharide, Tolerability,
70465|NCT02621073|lower extremity
70466|NCT02621073|status-post ORIF
70467|NCT02621060|Chlorogenic acid
70468|NCT02621060|Control glucose
70469|NCT02621060|Insulin Secretion
70470|NCT02621060|Insulin Sensitivity
70471|NCT02621047|Healthy volunteer
70472|NCT02621047|Alectinib
70473|NCT02621047|Hepatic impairment
70474|NCT02621034|Root canal treatment
70475|NCT02621034|pain
70476|NCT02621034|endodontic instruments
70477|NCT02621021|Melanoma
70478|NCT02621021|Skin Cancer
70479|NCT02621021|Immunotherapy
70480|NCT02621021|Cell Therapy
70481|NCT02621008|diabetes
70482|NCT02621008|hypertension
70483|NCT02621008|obesity
70484|NCT02621008|mobile phone
70485|NCT02621008|stress
70486|NCT02621008|healthy living
70487|NCT02621008|pre-diabetes
70488|NCT02620995|hypertension
70489|NCT02620995|endothelial dysfunction
70490|NCT02620995|erectile dysfunction
70491|NCT02620995|sildenafil
70492|NCT02620982|Shockwave
70493|NCT02620982|vascular ED
70494|NCT02620982|Organic ED
70495|NCT02620969|Paediatrics
70496|NCT02620969|Haemodialysis
70497|NCT02620969|Kinetics
70498|NCT02620943|Anemia
70499|NCT02620943|Pregnancy Outcome
70500|NCT02620943|Pregnancy
70501|NCT02620943|Dietary Diversity
70502|NCT02620943|Birth Weight
70503|NCT02620930|Sleep Disorders
70504|NCT02620930|Sleep Apnea
70505|NCT02620930|Apnea-Hypopnea Index (AHI)
70506|NCT02620930|Respiratory Disturbance Index (RDI)
70507|NCT02620917|type 1 diabetes
70508|NCT02620917|CSII
70509|NCT02620904|mifepristone
70510|NCT02620904|randomized controlled trial
70511|NCT02620904|vaginal delivery
70512|NCT02620904|progesterone receptor modulator
70513|NCT02620904|induction of labor
70514|NCT02620891|helium oxygen mixture
70515|NCT02620891|Meconium aspiration syndrome
70516|NCT02620878|Artificial pancreas
70517|NCT02620878|SAP therapy
70518|NCT02620878|children
70519|NCT02620878|adolescents
70520|NCT02620878|type 1 diabetes
70521|NCT02620852|Breast cancer
70522|NCT02620852|Ductal carcinoma in situ
70523|NCT02620852|DCIS
70524|NCT02620839|HPV+
70525|NCT02620813|acne
70526|NCT02620813|sebaceous gland
70527|NCT02620813|lipid
70528|NCT02620813|sebum
70529|NCT02620800|Metastatic Pancreatic Cancer
70530|NCT02620800|Adenocarcinoma
70531|NCT02620800|Open-label
70532|NCT02620800|Phase 1/2
70533|NCT02620800|Metronomic
70534|NCT02620800|Chemotherapy
70535|NCT02620800|ABI-007
70536|NCT02620800|nab-paclitaxel
70537|NCT02620800|Abraxane
70538|NCT02620800|gemcitabine
70539|NCT02620800|Gemzar
70540|NCT02620800|bevacizumab
70541|NCT02620800|Avastin
70542|NCT02620800|5-Fluorouracil (5-FU)
70543|NCT02620800|leucovorin
70544|NCT02620800|oxaliplatin
70545|NCT02620800|Eloxatin
70546|NCT02620735|Exercise, health coaching, RCT, telehealth,
70547|NCT02620722|tourniquet
70548|NCT02620722|safety
70549|NCT02620722|personalized
70550|NCT02620722|surgery
70551|NCT02620709|Native Hawaiians
70552|NCT02620709|Community-based participatory research
70553|NCT02620709|Health disparities
70554|NCT02620709|Minority populations
70555|NCT02620709|Chronic disease
70556|NCT02620683|lidocaine, jaw
70557|NCT02620670|Physical Activity
70558|NCT02620670|Glycemic Variability
70559|NCT02620644|no retinopathy
70560|NCT02620631|Morphine
70561|NCT02620631|TKA
70562|NCT02620631|Pain
70563|NCT02620631|TKR
70564|NCT02620631|Arthroplasty
70565|NCT02620618|Safety
70566|NCT02620618|Efficacy
70567|NCT02620618|intravitreal infliximab
70568|NCT02620618|ocular behcets
70569|NCT02620618|refractory posterior uveitis
70570|NCT02620605|Cabergoline
70571|NCT02620605|Ovarian Hyper Stimulation Syndrome (OHSS)
70572|NCT02620592|Healthy Subject
70573|NCT02620592|ZYDPLA1
70574|NCT02620592|DPPIV inhibitor
70575|NCT02620592|Pharmacokinetics
70576|NCT02620592|Safety
70577|NCT02620579|Personalized Pharmaceutical
70578|NCT02620579|Personalized Education
70579|NCT02620566|caudal block
70580|NCT02620566|local wound infiltration
70581|NCT02620566|hernia repair
70582|NCT02620553|Type 1 Diabetes
70583|NCT02620553|Diabetes
70584|NCT02620553|Autoimmune Diabetes
70585|NCT02620540|Broselow Tape
70586|NCT02620540|Weight estimation
70587|NCT02620540|Patient safety
70588|NCT02620527|Circulating Tumor DNA
70589|NCT02620527|Cancer
70590|NCT02620527|Neoplasms
70591|NCT02620527|Genomic Testing
70592|NCT02620527|FoundationOne
70593|NCT02620527|Cell Free DNA
70594|NCT02620527|ctDNA
70595|NCT02620527|cfDNA
70596|NCT02620514|Digestive Disease and Disorders
70597|NCT02620514|Inflammation
70598|NCT02620501|EGD
70599|NCT02620501|topical lidocaine
70600|NCT02620501|recovery time
70601|NCT02620501|intravenous sedation
70602|NCT02620488|Pain Perception
70603|NCT02620488|Autonomic Nervous System
70604|NCT02620488|Sickle Cell Disease
70605|NCT02620488|Hypnosis
70606|NCT02620488|Guided Imagery
70607|NCT02620462|Postural Balance
70608|NCT02620462|Pain
70609|NCT02620462|Gait
70610|NCT02620462|Physical Activity Level
70611|NCT02620449|phosphorus
70612|NCT02620449|fibroblast growth factor 23
70613|NCT02620449|diet
70614|NCT02620436|Maternal & Child Health
70615|NCT02620436|Mother Shelters
70616|NCT02620436|Maternity Waiting Homes
70617|NCT02620423|Pancreatic
70618|NCT02620423|Cancer
70619|NCT02620423|REOLYSIN®
70620|NCT02620423|Chemotherapy
70621|NCT02620423|Pembrolizumab
70622|NCT02620423|KEYTRUDA®
70623|NCT02620423|Pelareorep
70624|NCT02620423|Reovirus
70625|NCT02620423|Oncolytic virus
70626|NCT02620410|OAB
70627|NCT02620384|Metolazone
70628|NCT02620384|Heart Failure
70629|NCT02620358|Mechanical Ventilation
70630|NCT02620358|Weaning
70631|NCT02620345|Fibroids
70632|NCT02620319|bronchoscopy
70633|NCT02620319|polydioxanone
70634|NCT02620319|absorbable implants
70635|NCT02620319|stents
70636|NCT02620280|Triple Negative Breast Cancer
70637|NCT02620267|Mismatch Negativity
70638|NCT02620267|Transcranial Direct Current Stimulation
70639|NCT02620267|MMN
70640|NCT02620267|tDCS
70641|NCT02620254|mastocytosis
70642|NCT02620254|cutaneous mastocytosis
70643|NCT02620254|urticaria pigmentosa
70644|NCT02620254|telangiectasia macularis eruptiva perstans (TMEP)
70645|NCT02620254|diffuse cutaneous mastocytosis
70646|NCT02620254|solitary cutaneous mastocytosis
70647|NCT02620254|systemic mastocytosis
70648|NCT02620254|indolent systemic mastocytosis
70649|NCT02620254|smoldering systemic mastocytosis
70650|NCT02620254|aggressive systemic mastocytosis
70651|NCT02620254|systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease
70652|NCT02620254|mast cell leukemia
70653|NCT02620241|gastro-oesophageal reflux
70654|NCT02620241|intrapulmonary percussive ventilation
70655|NCT02620241|positioning
70656|NCT02620228|Bioimpedance
70657|NCT02620228|Biopsy
70658|NCT02620228|Liver tumour
70659|NCT02620228|Biopsy needle guidance
70660|NCT02620202|Troponin
70661|NCT02620202|Myocardial infarction
70662|NCT02620150|HIV
70663|NCT02620150|AIDS
70664|NCT02620150|Depression
70665|NCT02620150|SSRI
70666|NCT02620150|Escitalopram
70667|NCT02620150|Immunity
70668|NCT02620085|Graves' disease
70669|NCT02620085|Hyperthyroidism
70670|NCT02620085|Personality traits
70671|NCT02620072|Type 1 diabetes
70672|NCT02620072|T1D
70673|NCT02620072|diabetes mellitus
70674|NCT02620072|oral insulin
70675|NCT02620072|oral tolerance
70676|NCT02620072|autoantigen
70677|NCT02620072|self tolerance
70678|NCT02620072|prevention
70679|NCT02620072|at risk for developing type 1 diabetes
70680|NCT02620072|juvenile diabetes
70681|NCT02620072|dysglycemia
70682|NCT02620059|Postpartum Period
70683|NCT02620046|Drug therapy
70684|NCT02620033|Prostatectomy
70685|NCT02620033|Yoga therapy
70686|NCT02620033|Health related quality of life
70687|NCT02620007|Adult
70688|NCT02620007|AIEC
70689|NCT02619994|MDR tuberculosis
70690|NCT02619994|linezolid
70691|NCT02619994|delamanid
70692|NCT02619994|Korea
70693|NCT02619968|Chronic renal failure
70694|NCT02619968|Arteriovenous fistula
70695|NCT02619968|Isometric exercises
70696|NCT02619968|Vascular endothelium
70697|NCT02619955|hepcidin deficiency
70698|NCT02619955|genetic
70699|NCT02619955|except C282Y Homozygosity
70700|NCT02619942|Right colon cancer, Survival, Laparoscopic surgery
70701|NCT02619929|Oral Vinorelbine
70702|NCT02619929|Advanced Non-Small-Cell Lung Cancer
70703|NCT02619929|Metastatic Breast Cancer
70704|NCT02619916|Cancer
70705|NCT02619916|Depression
70706|NCT02619916|MBCT
70707|NCT02619916|CBT
70708|NCT02619890|Adult Glioma
70709|NCT02619890|MRI
70710|NCT02619838|Double Arthrodesis
70711|NCT02619838|Triple Arthrodesis
70712|NCT02619838|Subtalar Arthrodesis
70713|NCT02619825|Child
70714|NCT02619799|magnesium sulphate
70715|NCT02619799|intrathecal route
70716|NCT02619799|midazolam
70717|NCT02619773|Colorectal Surgery
70718|NCT02619760|Percutaneous Coronary Intervention
70719|NCT02619760|Platelet Aggregation Inhibitors
70720|NCT02619747|pH monitoring
70721|NCT02619734|Cell Therapy
70722|NCT02619734|Sickle cell disease
70723|NCT02619734|Autologous implantation
70724|NCT02619734|Mesenchymal stromal cell
70725|NCT02619734|Edothelial Progenitor cell
70726|NCT02619721|PINS SNS OAB
70727|NCT02619708|immersive preoperative experience
70728|NCT02619695|ketoprofen
70729|NCT02619695|gel
70730|NCT02619695|low back pain
70731|NCT02619695|emergency department
70732|NCT02619669|Neoadjuvant
70733|NCT02619669|TAK-228 (MLN0128)
70734|NCT02619669|Letrozole
70735|NCT02619669|ER+
70736|NCT02619669|HER2-
70737|NCT02619656|PEG
70738|NCT02619656|CO2 insufflation
70739|NCT02619656|Room Air insufflation
70740|NCT02619656|pneumoperitoneum
70741|NCT02619617|Cluster Headache
70742|NCT02619617|Patient Diary collection of headache pain
70743|NCT02619617|Biomarker - saliva samples
70744|NCT02619578|Transcutaneous electric acupoint stimulation (TEAS)
70745|NCT02619578|gynecological laparoscopic surgery
70746|NCT02619578|QoQ-40
70747|NCT02619578|MMSE
70748|NCT02619578|VAS
70749|NCT02619565|Myelodysplastic syndromes
70750|NCT02619565|mutations
70751|NCT02619565|overall survival
70752|NCT02619565|prognosis
70753|NCT02619513|Paravertebral Blocks
70754|NCT02619513|Dexmedetomidine
70755|NCT02619513|Analgesia
70756|NCT02619513|Inflammatory response
70757|NCT02619513|Thoracotomy
70758|NCT02619474|Parent Satisfaction
70759|NCT02619474|Patient Satisfaction
70760|NCT02619474|Whiteboard
70761|NCT02619474|Communication
70762|NCT02619448|inoperable
70763|NCT02619448|Solitary [T1bN0, T2aN0, T2bN0] lesion measuring 2-7 cm
70764|NCT02619435|RAS-mutant
70765|NCT02619422|Cardiac rehabilitation programs
70766|NCT02619422|Adherence to secondary preventive measures
70767|NCT02619422|Acute coronary syndrome
70768|NCT02619422|More intensive cardiac rehabilitation program in less time
70769|NCT02619396|radiofrequency power
70770|NCT02619396|lesion size index
70771|NCT02619396|esophageal temperature alerts
70772|NCT02619383|HBOT
70773|NCT02619383|hyperbaric oxygen
70774|NCT02619383|DCE
70775|NCT02619383|ED
70776|NCT02619383|erectile dysfunction
70777|NCT02619370|advance care planning
70778|NCT02619370|advance directive
70779|NCT02619370|caregiving
70780|NCT02619357|Asthma
70781|NCT02619357|wearable physical activity monitor
70782|NCT02619357|step counts
70783|NCT02619357|Exercise
70784|NCT02619357|energy expenditure
70785|NCT02619357|COPD
70786|NCT02619357|indirect calorimetry
70787|NCT02619318|Balancing Everyday Life (BEL)
70788|NCT02619318|activity-based lifestyle intervention
70789|NCT02619318|standard occupational therapy
70790|NCT02619292|cancer survivor
70791|NCT02619292|immune function
70792|NCT02619266|Cancer Anorexia Cachexia Syndrome
70793|NCT02619266|Acupuncture
70794|NCT02619266|Megestrol acetate
70795|NCT02619266|Poor Appetite
70796|NCT02619266|Anorexia
70797|NCT02619266|Randomized Controlled Trial
70798|NCT02619253|Immunotherapy
70799|NCT02619253|Safety
70800|NCT02619253|Pharmacodynamics
70801|NCT02619253|Efficacy
70802|NCT02619214|Oxidative Stress
70803|NCT02619214|Oxygen
70804|NCT02619214|General Anesthesia
70805|NCT02619201|vomiting in children
70806|NCT02619201|ondansetron
70807|NCT02619201|metoclopramide
70808|NCT02619201|antiemetics
70809|NCT02619188|Nutrition
70810|NCT02619188|Hyperemesis gravidarum
70811|NCT02619188|Prealbumin
70812|NCT02619188|Questionnaire
70813|NCT02619162|breast cancer non metastatic
70814|NCT02619162|adjuvant letrozole
70815|NCT02619162|Nintedanib BIFF1120
70816|NCT02619136|Blood Transfusion
70817|NCT02619123|breast density
70818|NCT02619123|breast cancer
70819|NCT02619123|risk-based screening
70820|NCT02619123|Tailored breast cancer screening
70821|NCT02619123|premenopausal women
70822|NCT02619110|Chronic Stroke
70823|NCT02619110|cardiopulmonary
70824|NCT02619110|Berg Balance Scale (BBS)
70825|NCT02619084|Tourette Syndrome
70826|NCT02619084|Subthalamic Nucleus
70827|NCT02619084|STN
70828|NCT02619084|Deep Brain Stimulation
70829|NCT02619084|DBS
70830|NCT02619084|Tic
70831|NCT02619084|Obsessive-compulsive disorders
70832|NCT02619071|acute myeloid leukemia- refractory AML- relapsed AML- precision medecine-
70833|NCT02619058|NKT
70834|NCT02619058|metastatic melanoma
70835|NCT02619032|remifentanil
70836|NCT02619032|fentanyl
70837|NCT02619032|dental surgery
70838|NCT02619006|Anemia, Iron-Deficiency
70839|NCT02619006|Myelination
70840|NCT02619006|Ferritin
70841|NCT02619006|Umbilical cord clamping
70842|NCT02619006|Umbilical Cord Milking
70843|NCT02619006|Placental Transfusion
70844|NCT02619006|Brain Development
70845|NCT02618993|mandibular nerve block
70846|NCT02618993|mandibular osteotomy
70847|NCT02618980|acute coronary syndrome
70848|NCT02618980|gastrointestinal bleeding
70849|NCT02618980|endoscopy
70850|NCT02618967|Lupus
70851|NCT02618967|Healthy Volunteer
70852|NCT02618967|Safety Study
70853|NCT02618967|Placebo Control
70854|NCT02618967|Phase 1
70855|NCT02618954|Rheumatoid arthritis
70856|NCT02618954|Articular ultrasound
70857|NCT02618954|Synovitis
70858|NCT02618954|Relapse risk
70859|NCT02618928|Chronic Hepatitis C
70860|NCT02618928|HCV
70861|NCT02618915|gene therapy
70862|NCT02618915|Hemophilia B
70863|NCT02618902|patient safety
70864|NCT02618902|tolerogenic dendritic cells
70865|NCT02618902|tolDC
70866|NCT02618850|metabolic response
70867|NCT02618850|chemotherapy
70868|NCT02618850|PET
70869|NCT02618837|NSTEMI
70870|NCT02618837|NSTEACS
70871|NCT02618837|prasugrel
70872|NCT02618837|ticagrelor
70873|NCT02618837|Downstream versus Upstream strategy
70874|NCT02618811|sarcopenia
70875|NCT02618811|myosteatosis
70876|NCT02618811|enhanced recovery after surgery
70877|NCT02618811|colorectal cancer
70878|NCT02618811|minimally invasive surgery
70879|NCT02618811|complications
70880|NCT02618798|chronic liver disease
70881|NCT02618798|CLD
70882|NCT02618798|platelet function
70883|NCT02618785|Hysterosalpingography
70884|NCT02618785|antispasmodic drug
70885|NCT02618785|infertile women
70886|NCT02618772|Pediatrics
70887|NCT02618772|Laceration
70888|NCT02618772|Anxiety
70889|NCT02618772|Anti-Anxiety Agents
70890|NCT02618746|Telemonitoring
70891|NCT02618746|Home Rehabilitation
70892|NCT02618746|Exacerbations
70893|NCT02618746|Physical Activity
70894|NCT02618746|COPD
70895|NCT02618720|Antimicrobial prophylaxis
70896|NCT02618720|Colorectal surgery
70897|NCT02618720|Surgical Site Infection
70898|NCT02618720|Postoperative morbidity
70899|NCT02618707|Lactate
70900|NCT02618707|Congenital cardiac defect
70901|NCT02618707|CPB
70902|NCT02618707|Pediatric
70903|NCT02618694|adrenal
70904|NCT02618694|supra-renal
70905|NCT02618694|adrenalectomy
70906|NCT02618694|retroperitoneoscopy
70907|NCT02618694|posterior retroperitoneoscopy
70908|NCT02618694|Laparoscopic adrenalectomy
70909|NCT02618681|earlobe crease
70910|NCT02618681|acute myocardial infarction
70911|NCT02618655|TBDs；diagnosis
70912|NCT02618603|Stroke
70913|NCT02618603|Should pain
70914|NCT02618603|Botulinum Toxin
70915|NCT02618590|non-small cell lung cancer
70916|NCT02618590|EGFR mutant type
70917|NCT02618590|first/second line EGFR-TKI
70918|NCT02618577|Anticoagulation
70919|NCT02618577|atrial high rate episodes
70920|NCT02618577|Atrial Fibrillation
70921|NCT02618577|VKA
70922|NCT02618577|NOAC
70923|NCT02618551|Thermoplasty
70924|NCT02618551|Severe asthma
70925|NCT02618551|Dynamic hyperinflation
70926|NCT02618499|birth
70927|NCT02618499|oxytocin
70928|NCT02618499|placental transfusion
70929|NCT02618499|umbilical cord clamping
70930|NCT02618473|Coronary computed tomography angiography
70931|NCT02618473|motion artifacts
70932|NCT02618473|motion correction algorithm
70933|NCT02618473|diagnostic utility
70934|NCT02618460|Non-contrast enhanced MRI
70935|NCT02618460|healthy volunteers
70936|NCT02618460|renal diffusion
70937|NCT02618460|renal perfusion
70938|NCT02618369|High Intensity Focused Ultrasound
70939|NCT02618317|renal dialysis
70940|NCT02618304|Meibomian gland dysfunction
70941|NCT02618304|Lipiview
70942|NCT02618304|Tear Lipid Layer
70943|NCT02618291|primary health care
70944|NCT02618265|stroke
70945|NCT02618265|secondary prevention
70946|NCT02618265|platelet response polymorphism
70947|NCT02618265|mobile terminal
70948|NCT02618252|difficult IV access
70949|NCT02618252|ultrasound
70950|NCT02618252|veinviewer
70951|NCT02618252|near infrared device
70952|NCT02618239|intestinal gas
70953|NCT02618239|Healthy subjects
70954|NCT02618239|microbiota
70955|NCT02618239|prebiotics
70956|NCT02618226|Traumatic Brain Injury
70957|NCT02618226|TBI
70958|NCT02618226|Optic nerve ultrasound
70959|NCT02618226|ONUS
70960|NCT02618226|Intracranial pressure
70961|NCT02618226|ICP
70962|NCT02618226|Intracranial hypertension
70963|NCT02618213|Continuous Positive Airway Pressure
70964|NCT02618213|High Flow Oxygenation therapy
70965|NCT02618213|Bronchiolitis
70966|NCT02618213|Children
70967|NCT02618200|Prostate cancer
70968|NCT02618200|Computer-Aided Diagnosis
70969|NCT02618161|EBRT and HDR Brachytherapy
70970|NCT02618109|B acute lymphoblastic leukemia
70971|NCT02618109|leukemia relapse
70972|NCT02618109|pediatric onco-hematology
70973|NCT02618096|membrane sweeping
70974|NCT02618096|dinoprostone
70975|NCT02618096|multiparas
70976|NCT02618096|labor induction
70977|NCT02618096|cesarean delivery
70978|NCT02618044|Gastroesophageal reflux
70979|NCT02618044|Obesity
70980|NCT02618044|Esophageal manometry
70981|NCT02618044|24 H impedance pH-monitoring
70982|NCT02618044|Laparoscopic Roux-en-Y Gastric Bypass
70983|NCT02618031|capillary index score
70984|NCT02618031|acute ischemic stroke
70985|NCT02618031|collateral circulation
70986|NCT02618031|cerebral ischemia
70987|NCT02618031|diagnostic imaging
70988|NCT02618018|astigmatism
70989|NCT02618018|toric intraocular lens
70990|NCT02618005|Astronauts
70991|NCT02618005|Probiotics
70992|NCT02618005|Immune function
70993|NCT02618005|Intestinal microbiota
70994|NCT02617966|Retina
70995|NCT02617966|Retinal Degeneration
70996|NCT02617966|Retinitis Pigmentosa
70997|NCT02617966|Stargardt's Disease
70998|NCT02617966|Dark Adaptation
70999|NCT02617953|Tinnitus
71000|NCT02617953|EEG
71001|NCT02617953|ERP
71002|NCT02617940|dental caries
71003|NCT02617940|primary tooth
71004|NCT02617940|resin-based sealants
71005|NCT02617914|ARDS
71006|NCT02617914|PEEP
71007|NCT02617914|ECMO
71008|NCT02617901|Bone age
71009|NCT02617901|Greulich & Pyle
71010|NCT02617901|TW3
71011|NCT02617901|Radiography
71012|NCT02617901|Dual energy x-ray absorptiometry
71013|NCT02617888|radiation
71014|NCT02617888|cardiac computed tomography
71015|NCT02617888|CCTA
71016|NCT02617888|breast shielding
71017|NCT02617888|Myocardial perfusion scintigraphy
71018|NCT02617888|MPS
71019|NCT02617888|Invasive coronary angiography
71020|NCT02617888|ICA
71021|NCT02617875|Pre-hospital
71022|NCT02617875|Emergency medical system
71023|NCT02617875|Telemedicine
71024|NCT02617875|Tele consultation
71025|NCT02617875|Remote treatment
71026|NCT02617862|Diagnostic imaging
71027|NCT02617862|Retina
71028|NCT02617862|Pediatrics
71029|NCT02617810|Healthy
71030|NCT02617810|JNJ-42847922
71031|NCT02617810|Midazolam
71032|NCT02617810|Warfarin
71033|NCT02617810|Pharmacokinetics
71034|NCT02617797|Urinary Stress Incontinence
71035|NCT02617797|Radiofrequency
71036|NCT02617797|Women
71037|NCT02617758|Healthy
71038|NCT02617758|Bioequivalence Study
71039|NCT02617758|JNJ-35685-AAA-G021
71040|NCT02617758|DURAGESIC
71041|NCT02617745|Stupp protocol, glioblastoma, thrombocytopenia
71042|NCT02617732|glucose variability
71043|NCT02617732|continuous glucose mornitoring system
71044|NCT02617732|traditional Chinese medicine
71045|NCT02617706|Anorectal surgeries
71046|NCT02617706|infection
71047|NCT02617706|topical oxygen
71048|NCT02617680|Desflurane
71049|NCT02617680|end tidal concentration
71050|NCT02617680|age
71051|NCT02617680|anesthesia
71052|NCT02617641|Secondary Prevention
71053|NCT02617641|Walking
71054|NCT02617641|Health Behavior
71055|NCT02617641|Internet
71056|NCT02617641|eHealth
71057|NCT02617641|Computer-Assisted Instruction
71058|NCT02617641|Multicenter Study
71059|NCT02617641|Randomized Controlled Trial
71060|NCT02617641|Intervention Studies
71061|NCT02617641|Motivation
71062|NCT02617641|Self Efficacy
71063|NCT02617641|Theory, Nursing
71064|NCT02617641|Theory, Psychological
71065|NCT02617641|Nursing Research
71066|NCT02617628|opioid addiction
71067|NCT02617615|MB-110
71068|NCT02617602|Congenital heart defect
71069|NCT02617602|Cardiopulmonary bypass
71070|NCT02617602|Goal directed therapy
71071|NCT02617602|Acute heart failure
71072|NCT02617563|spondylolisthesis
71073|NCT02617563|CD Horizon® Spinal Systems
71074|NCT02617563|minimal invasive
71075|NCT02617563|Spinal Fusion
71076|NCT02617563|MAST procedure
71077|NCT02617563|Lumbar fusion
71078|NCT02617524|dedicated sheath
71079|NCT02617498|living donor liver transplantation
71080|NCT02617459|Safety
71081|NCT02617459|efficacy
71082|NCT02617459|Levobetaxolol eye drops
71083|NCT02617459|Chinese patients
71084|NCT02617446|safety
71085|NCT02617446|efficacy
71086|NCT02617446|istaroxime
71087|NCT02617407|Dental Plaque
71088|NCT02617407|Gingivitis
71089|NCT02617407|Bacterial Infection
71090|NCT02617407|Oral Hygiene
71091|NCT02617407|HSCT
71092|NCT02617407|Oral Microbiome
71093|NCT02617368|Keratoconus, Corneal crosslinking, Fourier Analysis of Topographic Data
71094|NCT02617342|Intervention
71095|NCT02617342|Autism Spectrum Disorder
71096|NCT02617342|Social Skills
71097|NCT02617329|Extracorporeal shock wave therapy (ESWT), Neck Pain
71098|NCT02617316|running speeds, strike patterns
71099|NCT02617303|elderly
71100|NCT02617303|accidental falls
71101|NCT02617303|osteoporosis
71102|NCT02617303|fractures
71103|NCT02617303|Primary Care
71104|NCT02617303|Randomized clinical trial
71105|NCT02617303|Otago exercise programme
71106|NCT02617290|Coronary Artery Disease (CAD)
71107|NCT02617290|Percutaneous Coronary Intervention (PCI)
71108|NCT02617277|AZD1775
71109|NCT02617277|MEDI4736
71110|NCT02617277|AZD1775 + MEDI4736
71111|NCT02617277|Advanced Solid Tumours
71112|NCT02617277|Durvalumab
71113|NCT02617238|arterial stiffness
71114|NCT02617238|cardiovascular risk
71115|NCT02617238|cardiovascular events
71116|NCT02617238|renal events
71117|NCT02617212|dental implant
71118|NCT02617212|bone preservation
71119|NCT02617212|definitive abutment
71120|NCT02617212|one abutment one time
71121|NCT02617199|epidural anesthesia
71122|NCT02617199|pain management
71123|NCT02617199|microcirculation
71124|NCT02617160|Insulin Pump Treatment
71125|NCT02617160|Type 1 Diabetes
71126|NCT02617160|Insulin Pump Setting
71127|NCT02617160|Pump Advisor
71128|NCT02617108|uterine septum
71129|NCT02617108|intrauterine adhesions
71130|NCT02617108|Foley balloon
71131|NCT02617082|breast cancer
71132|NCT02617082|partial breast irradiation
71133|NCT02617082|DCIS
71134|NCT02617069|Atrial fibrillation
71135|NCT02617069|botulinum toxin
71136|NCT02617056|electrodermal response
71137|NCT02617043|breast cancer
71138|NCT02617043|hypofractionated whole breast irradiation
71139|NCT02617017|Parkinson disease
71140|NCT02617017|Levodopa induce dyskinesia
71141|NCT02616952|Stress urinary incontinence
71142|NCT02616952|Chinese Herb
71143|NCT02616952|Traditional Chinese medicine
71144|NCT02616952|Pelvic floor muscle training
71145|NCT02616939|Multidetector computed tomography
71146|NCT02616926|hepatocellular carcinoma
71147|NCT02616926|hepatectomy
71148|NCT02616926|transarterial chemoembolization
71149|NCT02616926|radiofrequency ablation
71150|NCT02616874|HIV infection
71151|NCT02616874|Early treatment
71152|NCT02616874|Romidepsin
71153|NCT02616874|HDACi
71154|NCT02616874|Therapeutic Vaccines
71155|NCT02616874|HIVconsv
71156|NCT02616874|HIV reservoir
71157|NCT02616874|Population PK/PD analysis
71158|NCT02616848|Everolimus
71159|NCT02616848|eribulin
71160|NCT02616822|hypertension
71161|NCT02616822|endothelium
71162|NCT02616822|resveratrol
71163|NCT02616822|clinical trials
71164|NCT02616783|HIV 1 Infection
71165|NCT02616783|HIV
71166|NCT02616783|Virologically-Suppressed
71167|NCT02616744|aromatase inhibitors
71168|NCT02616744|breast cancer
71169|NCT02616744|bone mineral density
71170|NCT02616692|HCC
71171|NCT02616692|Patient preferences
71172|NCT02616666|Type 2 diabetes mellitus
71173|NCT02616666|Randomised
71174|NCT02616666|Pragmatic
71175|NCT02616666|Standard of Care
71176|NCT02616666|Dapagliflozin
71177|NCT02616666|FORXIGA
71178|NCT02616640|Multiple Myeloma
71179|NCT02616640|Relapsed
71180|NCT02616640|Refractory
71181|NCT02616640|MEDI4736
71182|NCT02616640|Durvalumab
71183|NCT02616640|Pomalidomide (POM)
71184|NCT02616640|Dexamethasone (DEX)
71185|NCT02616640|PD-L1
71186|NCT02616627|bone mineral density
71187|NCT02616627|chronic dialysis
71188|NCT02616627|end-stage renal disease
71189|NCT02616627|body composition analysis
71190|NCT02616627|sarcopenia
71191|NCT02616588|advanced stage cancer,
71192|NCT02616588|patient navigator,
71193|NCT02616588|social work
71194|NCT02616575|home care
71195|NCT02616575|monitoring system
71196|NCT02616575|risk assessment
71197|NCT02616575|telehealth
71198|NCT02616536|Flipped classroom
71199|NCT02616536|Teaching methods
71200|NCT02616536|Knowledge gain
71201|NCT02616523|dexmedetomidine
71202|NCT02616523|lidocaine
71203|NCT02616523|neuropathic pain
71204|NCT02616523|laparoscopic intestine resection
71205|NCT02616523|cognitive function
71206|NCT02616497|aspirin
71207|NCT02616497|triflusal
71208|NCT02616497|antiplatelet drugs
71209|NCT02616497|atherothrombosis
71210|NCT02616497|secondary prevention
71211|NCT02616484|Sodium Dichloroacetate
71212|NCT02616484|Treatment of PDCD with Dichloracetate
71213|NCT02616471|Cheese
71214|NCT02616471|Dairy
71215|NCT02616471|Saturated fat
71216|NCT02616471|Blood lipid concentrations
71217|NCT02616471|Lipoprotein particle size
71218|NCT02616471|Metabolic Syndrome
71219|NCT02616471|Insulin sensitivity
71220|NCT02616471|Blood glucose concentrations
71221|NCT02616432|Tomosynthesis
71222|NCT02616432|Digital Breast Tomosynthesis (DBT)
71223|NCT02616432|Breast Imaging
71224|NCT02616432|Full-field digital mammography
71225|NCT02616432|Breast screening
71226|NCT02616419|Emergency Department
71227|NCT02616419|Procedural pain
71228|NCT02616419|Procedural anxiety
71229|NCT02616419|Needle-related procedures
71230|NCT02616419|Clinical Nursing Research
71231|NCT02616419|Nursing practice
71232|NCT02616419|Non-pharmacological method
71233|NCT02616406|recovery of function
71234|NCT02616380|Work productivity
71235|NCT02616380|Quality of life (QOL)
71236|NCT02616380|Rheumatoid arthritis (RA)
71237|NCT02616354|Pharmacokinetics; pharmacodynamic; imipenem; sepsis
71238|NCT02616315|Drug therapy
71239|NCT02616302|Drug therapy
71240|NCT02616276|Glycemic Index
71241|NCT02616276|Postprandial Period
71242|NCT02616276|Vascular Stiffness
71243|NCT02616276|Blood glucose
71244|NCT02616276|Cognition
71245|NCT02616237|Chinese population
71246|NCT02616237|acupressure
71247|NCT02616237|physical activity
71248|NCT02616237|nutrition
71249|NCT02616237|Facebook
71250|NCT02616198|glass ionomers
71251|NCT02616198|surface coating
71252|NCT02616198|clinical trial
71253|NCT02616120|Herbal therapy
71254|NCT02616120|Parkinson's Disease
71255|NCT02616120|Non-motor Symptoms
71256|NCT02616120|Randomized controlled trial
71257|NCT02616107|Caregiver
71258|NCT02616107|Self-management
71259|NCT02616107|Care options
71260|NCT02616107|Goals of care
71261|NCT02616107|Breast cancer
71262|NCT02616107|Palliative care
71263|NCT02616042|Centella asiatica
71264|NCT02616042|bamboo salt
71265|NCT02616042|dentifrice
71266|NCT02616003|Morbid Obesity
71267|NCT02616003|Giant Obese
71268|NCT02616003|Preoperative Procedure
71269|NCT02616003|Liraglutide
71270|NCT02616003|Leucine
71271|NCT02615977|Pavlovian conditioning, Operant conditioning
71272|NCT02615977|Pavlovian-to-instrumental transfer
71273|NCT02615977|Functional imaging
71274|NCT02615977|Relapse risk
71275|NCT02615977|Behavioural Intervention
71276|NCT02615951|Regulatory B cells (Breg)
71277|NCT02615951|Genes
71278|NCT02615951|Cell surface proteins
71279|NCT02615951|Nutrient transporters
71280|NCT02615951|Chemokine receptors
71281|NCT02615899|Older Adults, Falls
71282|NCT02615886|rice bran
71283|NCT02615886|infants
71284|NCT02615886|stool metabolome
71285|NCT02615886|stool microbiome
71286|NCT02615886|dietary intervention
71287|NCT02615873|Parkinson's Disease
71288|NCT02615873|Fluctuating Parkinson's Disease
71289|NCT02615873|Carbidopa
71290|NCT02615873|Levodopa
71291|NCT02615873|Accordion
71292|NCT02615860|HIV-infection
71293|NCT02615860|anal cancer (AC)
71294|NCT02615860|anal cancer prevention
71295|NCT02615860|anal dysplasia
71296|NCT02615860|anal intraepithelial neoplasia (AIN)
71297|NCT02615860|human papillomavirus (HPV)
71298|NCT02615860|HPV-induced anal cancer precursor lesions
71299|NCT02615860|electrocautery (ECA)
71300|NCT02615860|topical trichloroacetic acid (TCA) treatment.
71301|NCT02615704|Brilique treatment adherence via electronic device application (APP)
71302|NCT02615678|neuropathy
71303|NCT02615678|peripheral
71304|NCT02615678|chemotherapy
71305|NCT02615678|breast cancer
71306|NCT02615665|NK-cells
71307|NCT02615665|T-cells
71308|NCT02615639|HPDC-T cells
71309|NCT02615639|CHB
71310|NCT02615639|immuno therapy
71311|NCT02615626|Visfatin
71312|NCT02615626|GCF
71313|NCT02615626|serum
71314|NCT02615626|Non-surgical Periodontal Treatment.
71315|NCT02615613|Hedonics, Ghrelin, Hunger
71316|NCT02615600|tinnitus
71317|NCT02615600|transcranial random noise stimulation
71318|NCT02615600|tRNS
71319|NCT02615600|auditory cortex
71320|NCT02615600|non-invasive brain stimulation
71321|NCT02615587|non-valvular Atrial Fibrillation
71322|NCT02615561|Safety
71323|NCT02615561|Efficacy
71324|NCT02615561|Atopic dermatitis
71325|NCT02615561|Cosmetic products
71326|NCT02615548|exercises
71327|NCT02615535|traumatic brain injury
71328|NCT02615522|primary TKR
71329|NCT02614443|Depression
71330|NCT02614443|Anxiety
71331|NCT02614443|Stress
71332|NCT02614443|Online interventions
71333|NCT02614443|University students
71334|NCT02614443|CBT
71335|NCT02614430|Rehabilitation
71336|NCT02614430|Prediction
71337|NCT02614430|Inflammation
71338|NCT02614404|Plasmodium falciparum
71339|NCT02614404|Uncomplicated malarial
71340|NCT02614404|imatinib mesylate
71341|NCT02614404|antimalarials
71342|NCT02614391|Procedural pain
71343|NCT02614391|Phlebotomy
71344|NCT02614391|Distraction
71345|NCT02614391|Videogame
71346|NCT02614391|Computer tablet
71347|NCT02614391|Child
71348|NCT02614378|abortive effect
71349|NCT02615496|Health Care Surveys
71350|NCT02615496|Vascular Endothelial Growth Factor
71351|NCT02615470|Pneumococcal Vaccines
71352|NCT02615470|Shingles
71353|NCT02615470|Pharmacy
71354|NCT02615470|Vaccine
71355|NCT02615470|Immunization
71356|NCT02615444|Metabolic Syndrome X
71357|NCT02615444|Overweight
71358|NCT02615444|Waist Circumference
71359|NCT02615444|Blood Pressure
71360|NCT02615444|Cholesterol
71361|NCT02615444|Oat beta glucan
71362|NCT02615392|RCT
71363|NCT02615392|Park Prescription
71364|NCT02615392|Park Use
71365|NCT02615392|Physical Activity
71366|NCT02615392|Health Promotion
71367|NCT02615392|Health Behavior
71368|NCT02615392|Mental Well-Being
71369|NCT02615392|Body composition
71370|NCT02615392|Blood levels
71371|NCT02615392|Accelerometry
71372|NCT02615392|Improving general physical and mental health
71373|NCT02615379|instrumented spinal fusion
71374|NCT02615379|infection
71375|NCT02615379|topical oxygen
71376|NCT02615340|delirium
71377|NCT02615340|melatonin
71378|NCT02615340|pharmacokinetics
71379|NCT02615340|feasibility
71380|NCT02615340|prevention
71381|NCT02615327|Fiber
71382|NCT02615327|Polydextrose
71383|NCT02615327|Glycemic Index
71384|NCT02615314|migraine
71385|NCT02615314|benign paroxysmal positional vertigo
71386|NCT02615288|Vitamin D
71387|NCT02615275|Head and Neck Cancer
71388|NCT02615275|Bioelectrical impedance analysis
71389|NCT02615275|BIA
71390|NCT02615275|Eight-electrode BIA device
71391|NCT02615275|SECA mBCA
71392|NCT02615275|Computed tomography
71393|NCT02615275|CT
71394|NCT02615275|Positron emission tomography
71395|NCT02615275|PET
71396|NCT02615275|Symptom questionnaire
71397|NCT02615275|Survey
71398|NCT02615275|Radiation therapy
71399|NCT02615275|RT
71400|NCT02615275|XRT
71401|NCT02615262|Pediatric cardiac surgery
71402|NCT02615262|Dexamethasone
71403|NCT02615262|Steroids
71404|NCT02615262|Cardiopulmonary bypass
71405|NCT02615262|Congenital heart defects
71406|NCT02615262|Infants
71407|NCT02615197|PTSD
71408|NCT02615197|Multi-diagnostic
71409|NCT02615197|Dialectical Behavior Therapy
71410|NCT02615197|Prolonged Exposure Therapy
71411|NCT02615184|Drug therapy
71412|NCT02615158|Feeding practices
71413|NCT02615158|Diet
71414|NCT02615158|Physical activity
71415|NCT02615158|Prevention
71416|NCT02615145|Quality of life
71417|NCT02615145|Chronic Hepatitis C
71418|NCT02615145|Dasabuvir
71419|NCT02615145|Observational Study
71420|NCT02615145|Work-ability
71421|NCT02615145|Cirrhosis
71422|NCT02615145|Ombitasvir+Paritaprevir+Ritonavir
71423|NCT02615145|Fibrosis
71424|NCT02615119|heartbeat
71425|NCT02615119|respiration
71426|NCT02615119|interoception
71427|NCT02615119|anxiety
71428|NCT02615119|eating
71429|NCT02615106|Radiation Therapy
71430|NCT02615106|Neuroblastoma
71431|NCT02615067|Diagnostic
71432|NCT02615067|Active surveillance
71433|NCT02615067|Very low risk
71434|NCT02615067|Imaging
71435|NCT02615067|PSMA
71436|NCT02615067|SPECT/CT
71437|NCT02615067|99mTc
71438|NCT02615067|Newly Diagnosed
71439|NCT02615067|Prostatectomy
71440|NCT02615067|Biopsy
71441|NCT02615054|Cardiovascular Impairment
71442|NCT02615054|15-258
71443|NCT02615041|Meropenem
71444|NCT02615041|Ventilator-Associated Pneumonia
71445|NCT02615041|population pharmacokinetics
71446|NCT02615041|pharmacokinetics
71447|NCT02615041|pharmacodynamics
71448|NCT02615028|Force plate, Balance ability
71449|NCT02615015|Deoxyribonuclease
71450|NCT02615002|Cognition
71451|NCT02615002|mild Alzheimer's disease
71452|NCT02615002|Sleep
71453|NCT02614989|Tremor
71454|NCT02614989|Thalamotomy
71455|NCT02614963|Irritable Bowel Syndrome
71456|NCT02614963|Clostridium Butyricum
71457|NCT02614911|Early Onset Entheropathy
71458|NCT02614833|Hormone receptor positive
71459|NCT02614820|Ischemic preconditioning
71460|NCT02614820|sefety
71461|NCT02614820|efficacy
71462|NCT02614820|DMD
71463|NCT02614807|Dietary Supplement
71464|NCT02614794|Tucatinib
71465|NCT02614794|Capecitabine
71466|NCT02614794|Trastuzumab
71467|NCT02614794|Xeloda
71468|NCT02614794|Herceptin
71469|NCT02614794|Breast Cancer
71470|NCT02614794|ARRY-380
71471|NCT02614794|ONT-380
71472|NCT02614768|Glucose Monitoring System
71473|NCT02614755|Older Adults Volunteers
71474|NCT02614755|Seniors
71475|NCT02614755|Brain Performance Test
71476|NCT02614729|High Protein
71477|NCT02614729|Satiety
71478|NCT02614729|Appetite Control
71479|NCT02614729|Protein Distribution
71480|NCT02614729|Cognitive Function
71481|NCT02614729|Ad libitum Food Intake
71482|NCT02614729|Obesity prevention
71483|NCT02614729|Obesity treatment
71484|NCT02614703|Barrett's Esophagus
71485|NCT02614703|Acetic Acid Chromoendoscopy
71486|NCT02614690|Fracture of the upper limb
71487|NCT02614677|Disability Evaluation System
71488|NCT02614677|SF-12
71489|NCT02614677|ICF model
71490|NCT02614612|Acute Graft Versus Host Disease
71491|NCT02614599|ADD
71492|NCT02614599|ADHD
71493|NCT02614599|Proteins
71494|NCT02614599|Dietary
71495|NCT02614599|Nutrition
71496|NCT02614599|QEEG
71497|NCT02614599|ERP
71498|NCT02614599|ICA
71499|NCT02614586|Drug Therapy
71500|NCT02614573|Dependent
71501|NCT02614573|Aged, 80 and over
71502|NCT02614573|Aged
71503|NCT02614560|acute myeloid leukemia
71504|NCT02614560|AML
71505|NCT02614560|antibody-drug conjugate
71506|NCT02614521|Pulmonary veins ablation
71507|NCT02614521|Paroxysmal atrial fibrillation
71508|NCT02614482|Children
71509|NCT02614482|Antimuscarinics
71510|NCT02614482|Antocholinergics
71511|NCT02614482|Overactive bladder
71512|NCT02614326|Depression
71513|NCT02614326|Cognitive risk factors
71514|NCT02614326|Autobiographical memory
71515|NCT02614326|Cognitive bias
71516|NCT02614326|Relapse prevention
71517|NCT02614313|Fructose
71518|NCT02614313|Irritable Bowel Syndrome
71519|NCT02614313|Breath test
71520|NCT02614313|Placebo
71521|NCT02614300|pulmonary rehabilitation
71522|NCT02614300|chest physiotherapy
71523|NCT02614300|non-cystic fibrosis bronchiectasis
71524|NCT02614300|exercise tolerance
71525|NCT02614300|bronchiectasis
71526|NCT02614300|respiratory therapy
71527|NCT02614287|prevention
71528|NCT02614287|prophylaxis
71529|NCT02614287|headache
71530|NCT02614274|knee
71531|NCT02614274|pain
71532|NCT02614274|osteoarthritis
71533|NCT02614274|nutraceutical
71534|NCT02614274|nutrition
71535|NCT02614274|supplement
71536|NCT02614274|non-surgical
71537|NCT02614274|biomarker
71538|NCT02614274|joint health
71539|NCT02614261|prevention
71540|NCT02614261|prophylaxis
71541|NCT02614261|headache
71542|NCT02614235|Cardiac Arrhythmia
71543|NCT02614235|Syncope
71544|NCT02614235|Ambulatory Electrocardiography Monitoring
71545|NCT02614222|Computer Assisted Instrument Guidance (CAIG)
71546|NCT02614222|Peripheral Nerve Block
71547|NCT02614222|Clear Guide ONE
71548|NCT02614222|Needle path
71549|NCT02614222|Needle Guidance
71550|NCT02614222|Ultrasound
71551|NCT02614209|ED
71552|NCT02614209|BNP
71553|NCT02614196|prevention
71554|NCT02614196|prophylaxis
71555|NCT02614196|headache
71556|NCT02614183|prevention
71557|NCT02614183|prophylaxis
71558|NCT02614183|headache
71559|NCT02614157|rectal cancer
71560|NCT02614157|lateral lymph node dissection
71561|NCT02614157|neoadjuvant chemoradiation
71562|NCT02614157|total mesorectal excision
71563|NCT02614157|surgery
71564|NCT02614157|recurrence
71565|NCT02614157|metastasis
71566|NCT02614157|overall survival
71567|NCT02614144|Hospital Acquired Pneumonia
71568|NCT02614144|Mortality
71569|NCT02614118|Endodontic treatment
71570|NCT02614118|non steroid
71571|NCT02614118|pain
71572|NCT02614118|pre medication
71573|NCT02614092|Mild Cognitive Impairment
71574|NCT02614092|memory impairment
71575|NCT02614092|Physical Activity
71576|NCT02614092|Exercise
71577|NCT02614092|Cognitive Training
71578|NCT02614092|Veterans
71579|NCT02614092|Older Adults
71580|NCT02614079|lumbago
71581|NCT02614079|low back pain
71582|NCT02614079|leg pain
71583|NCT02614040|crystalloid
71584|NCT02614040|acute kidney injury
71585|NCT02614001|breathing training, congestive heart failure, stroke
71586|NCT02613988|Glioblastoma
71587|NCT02613988|MRI
71588|NCT02613988|standard treatment
71589|NCT02613949|fibromyalgia
71590|NCT02613949|pain
71591|NCT02613949|stimulation
71592|NCT02613936|traumatic brain injury
71593|NCT02613936|post concussive symptoms
71594|NCT02613936|depression
71595|NCT02613936|executive dysfunction
71596|NCT02613936|brain stimulation
71597|NCT02613923|Breast Cancer
71598|NCT02613923|GO! to sleep
71599|NCT02613923|sleep
71600|NCT02613910|Ofatumumab
71601|NCT02613910|Pemphigus Vulgaris
71602|NCT02613910|Long-Term Extension Study
71603|NCT02613845|Postoperative delirium
71604|NCT02613845|Cardiac surgery
71605|NCT02613845|Cardiopulmonary bypass
71606|NCT02613845|Risk factor
71607|NCT02613832|Noncooperative patients
71608|NCT02613806|Dexmedetomidine
71609|NCT02613806|Coughing Response
71610|NCT02613806|Postoperative Recovery Quality
71611|NCT02613806|Thyroid Surgery
71612|NCT02613793|Preterm pre-eclampsia
71613|NCT02613793|Neurological dysfunction
71614|NCT02613793|Saccadic reaction time
71615|NCT02613728|Colorectal cancer
71616|NCT02613728|Colorectal cancer surgery
71617|NCT02613728|Polyp(s)
71618|NCT02613728|Accelerated Enhanced Recovery
71619|NCT02613728|RecoverMI
71620|NCT02613728|Fluid diary
71621|NCT02613728|Questionnaires
71622|NCT02613728|Surveys
71623|NCT02613728|RecoverMI device
71624|NCT02613715|Flavonoids
71625|NCT02613715|Anthocyanins
71626|NCT02613715|Blackberry Juice
71627|NCT02613715|Bioavailability
71628|NCT02613715|Obesity
71629|NCT02613702|Free gingival graft
71630|NCT02613702|keratinized gingival tissue
71631|NCT02613689|smokeless tobacco, text message, tobacco cessation, tobacco
71632|NCT02613637|lung cancer
71633|NCT02613637|registry study
71634|NCT02613637|Biological Disease Profile
71635|NCT02613624|KMC in community
71636|NCT02613559|Neovascular Age-Related Macular Degeneration, Subfoveal CNV, TK001
71637|NCT02613546|cognitive-behavioral psychotherapy
71638|NCT02613546|Sexual Dysfunctions
71639|NCT02613546|Women
71640|NCT02613520|PfSPZ Vaccine
71641|NCT02613520|Plasmodium falciparum
71642|NCT02613494|clozapine
71643|NCT02613494|hypersalivation
71644|NCT02613494|refractory schizophrenia
71645|NCT02613468|Pregnancy
71646|NCT02613468|Low birth weight
71647|NCT02613468|Gingivitis
71648|NCT02613468|Inflammation
71649|NCT02613468|Periodontitis
71650|NCT02613390|Epidural metastasis
71651|NCT02613390|Magnetic resonance imaging
71652|NCT02613390|MRI
71653|NCT02613390|Guidance system
71654|NCT02613390|Spinal surgery
71655|NCT02613390|Questionnaires
71656|NCT02613390|Surveys
71657|NCT02613377|Transfusion-related acute lung injury, Red Blood Cell
71658|NCT02613351|Exercise Tolerance
71659|NCT02613351|Lung Diseases, Obstructive
71660|NCT02613325|Melanoma
71661|NCT02613325|Imaging
71662|NCT02613325|Pigmented Lesions
71663|NCT02613325|Melanoma Management
71664|NCT02613247|Viscosupplementation
71665|NCT02613247|Hyaluronic acid
71666|NCT02613247|Synvisc
71667|NCT02613247|Synvisc-One
71668|NCT02613247|Patellofemoral pain syndrome
71669|NCT02613247|PFPS
71670|NCT02613247|Anterior knee pain
71671|NCT02613247|Runner's knee
71672|NCT02613234|Epilepsy
71673|NCT02613234|128-Channel EEG
71674|NCT02613234|Dipole Localization
71675|NCT02613234|Transcranial Direct Current Stimulation
71676|NCT02613221|Metastatic colorectal cancer, Panitumumab, TAS-102
71677|NCT02613208|Bevacizumab
71678|NCT02613208|Paclitaxel
71679|NCT02613208|Metastatic Breast Cancer
71680|NCT02613208|Human Epidermal Growth Factor Receptor-Type 2
71681|NCT02613195|Ischemia-Reperfusion Injury
71682|NCT02613195|oxidative stress
71683|NCT02613195|organ preservation
71684|NCT02613195|Hydrogen
71685|NCT02613195|Kidney Transplantation
71686|NCT02613169|M. tuberculosis infection
71687|NCT02613169|isoniazid
71688|NCT02613169|HIV-exposed infants
71689|NCT02613156|laparoscopic
71690|NCT02613156|hepatocellular carcinoma
71691|NCT02613156|recurrence
71692|NCT02613143|malignant glaucoma
71693|NCT02613143|zonulo-hyaloido-vitrectomy
71694|NCT02613091|volunteers
71695|NCT02613078|Children
71696|NCT02613078|Functional Abdominal Pain Syndrome
71697|NCT02613078|Irritable Bowel Syndrome
71698|NCT02613078|Gut-Directed Hypnotherapy
71699|NCT02613078|Probiotic
71700|NCT02613065|Ad libitum
71701|NCT02613065|Energy balance
71702|NCT02613065|Protein
71703|NCT02613039|oral contraceptives
71704|NCT02613039|female sexuality
71705|NCT02613026|Breast tumor
71706|NCT02613026|Neoadjuvant chemotherapy
71707|NCT02613026|Pathological complete remission
71708|NCT02612987|CBT, internet based
71709|NCT02612974|Qurse mafasil
71710|NCT02612974|leech therapy
71711|NCT02612974|Hirudinaria granulosa
71712|NCT02612961|Mechanically ventilated patients
71713|NCT02612961|Normal Saline
71714|NCT02612961|Tracheostomy Tube Suctioning
71715|NCT02612922|Influenza
71716|NCT02612909|Avian Influenza
71717|NCT02612909|A/H5N1 vaccine
71718|NCT02612909|IVAC
71719|NCT02612896|Taenia solium
71720|NCT02612896|control
71721|NCT02612896|elimination
71722|NCT02612896|One Health
71723|NCT02612883|Flux measurement
71724|NCT02612870|Breast Cancer
71725|NCT02612870|Sentinel Node
71726|NCT02612870|Sentinel Node Biopsy
71727|NCT02612870|Breast Surgery
71728|NCT02612857|dermatomyositis
71729|NCT02612857|IMO-8400
71730|NCT02612857|Pioneer
71731|NCT02612818|coelioscopy
71732|NCT02612766|celiac disease
71733|NCT02612766|oat
71734|NCT02612766|gluten free diet
71735|NCT02612753|Aphasia
71736|NCT02612753|Speaking therapy
71737|NCT02612753|Language therapy
71738|NCT02612753|transcranial Direct current stimulation
71739|NCT02612740|Bio Oss
71740|NCT02612740|critical-size defect
71741|NCT02612740|bone grafting
71742|NCT02612740|cyst
71743|NCT02612740|CT bone analysis
71744|NCT02612740|alveolar bone
71745|NCT02612727|Hyperbilirubinemia, Neonatal
71746|NCT02612714|diabetes
71747|NCT02612714|hypercholesterolemia
71748|NCT02612714|sexual dysfunction
71749|NCT02612714|statin
71750|NCT02612714|testosterone
71751|NCT02612701|Myocardial perfusion
71752|NCT02612701|Electronic cigarettes
71753|NCT02612701|Cigarettes
71754|NCT02612701|Cigarette smoking
71755|NCT02612688|Advance Care Planning
71756|NCT02612688|Advance Directives
71757|NCT02612688|Alzheimer Disease
71758|NCT02612688|Dementia
71759|NCT02612688|Do-Not-Resuscitate Orders
71760|NCT02612688|Enteral Nutrition
71761|NCT02612688|Heart Failure
71762|NCT02612688|Hospices
71763|NCT02612688|Hospitalization
71764|NCT02612688|Instructional Films and Videos
71765|NCT02612688|Intubation
71766|NCT02612688|Nursing Homes
71767|NCT02612688|Parenteral Nutrition
71768|NCT02612688|Pragmatic Clinical Trials
71769|NCT02612688|Pulmonary Disease, Chronic Obstructive
71770|NCT02612688|Randomized Controlled Trials
71771|NCT02612688|Resuscitation Orders
71772|NCT02612688|Skilled Nursing Facilities
71773|NCT02612662|AZD4076
71774|NCT02612662|Healthy male subjects
71775|NCT02612662|Safety
71776|NCT02612662|Subcutaneous
71777|NCT02612662|Tolerability
71778|NCT02612649|Irritable bowel syndrome
71779|NCT02612649|YM060
71780|NCT02612649|Ramosetron
71781|NCT02612649|Survey
71782|NCT02612636|Delirium
71783|NCT02612636|Ear Plug
71784|NCT02612636|Eye Mask
71785|NCT02612636|Mechanical ventilation
71786|NCT02612636|Sleep
71787|NCT02612597|before and after bedrest
71788|NCT02612597|healthy untrained
71789|NCT02612597|before and after exercise training
71790|NCT02612558|Warm antibody autoimmune hemolytic anemia (AIHA)
71791|NCT02612545|Plasmodium Falciparum
71792|NCT02612545|Artemisinin Combination Therapy
71793|NCT02612545|Triple Artemisinin Combination Therapy
71794|NCT02612545|Piperaquine
71795|NCT02612545|Mefloquine
71796|NCT02612493|obesity surgery
71797|NCT02612493|type I diabetes
71798|NCT02612493|weight loss
71799|NCT02612493|insulin dosage
71800|NCT02612493|postsurgery metabolic changes
71801|NCT02612480|endotoxin
71802|NCT02612480|LPS
71803|NCT02612480|ticagrelor
71804|NCT02612480|clopidogrel
71805|NCT02612480|acetylsalicyclic acid
71806|NCT02612480|placebo
71807|NCT02612467|start back tool
71808|NCT02612467|stratified care
71809|NCT02612467|targeted treatment
71810|NCT02612454|Eczema
71811|NCT02612441|stroke
71812|NCT02612389|COPD
71813|NCT02612389|Qigong
71814|NCT02612389|ANS
71815|NCT02612389|Meditative Movement
71816|NCT02612389|Flight Attendants
71817|NCT02612389|Secondhand Smoke
71818|NCT02612389|Nicotine
71819|NCT02612389|Blood Pressure
71820|NCT02612389|6 minute walk test
71821|NCT02612363|septic shock
71822|NCT02612363|sedation
71823|NCT02612363|microcirculation
71824|NCT02612350|ctDNA
71825|NCT02612350|high risk for developing cancer
71826|NCT02612350|Plasma
71827|NCT02612350|Relative Risk
71828|NCT02612350|Early Detection of Cancer
71829|NCT02612350|Cancer Screening Tests
71830|NCT02612350|Cancer Screening
71831|NCT02612337|Meniere's Disease
71832|NCT02612337|Vertigo
71833|NCT02612324|adolescents
71834|NCT02612324|teen pregnancy prevention
71835|NCT02612324|sexually transmitted infections prevention
71836|NCT02612324|place-based programs
71837|NCT02612324|health education
71838|NCT02612298|Essential Hypertension
71839|NCT02612298|Arotinolol
71840|NCT02612298|Morning Blood Pressure
71841|NCT02612233|Pain
71842|NCT02612220|liver resection
71843|NCT02612181|dexmedetomidine
71844|NCT02612181|microcirculation
71845|NCT02612181|septic shock
71846|NCT02612168|Diagnosis
71847|NCT02612168|skin imaging
71848|NCT02612155|Hypoxic-ischemic encephalopathy
71849|NCT02612155|autologous cord blood cells
71850|NCT02612155|newborn infants
71851|NCT02612129|NPC1
71852|NCT02612129|Niemann-Pick Type C
71853|NCT02612129|Niemann-Pick
71854|NCT02612129|arimoclomol
71855|NCT02612129|lysosomal storage disorder
71856|NCT02612129|lysosomal storage disease
71857|NCT02612129|NPC2
71858|NCT02612129|NP-C
71859|NCT02612103|Biochemical markers
71860|NCT02612090|Nutrition
71861|NCT02612090|Polyphenols
71862|NCT02612090|Berries
71863|NCT02612090|Lipid Panels
71864|NCT02612051|patients
71865|NCT02612051|FTIH
71866|NCT02612051|healthy volunteers
71867|NCT02612051|GSK3008348
71868|NCT02612051|[18F]-FBA-A20FMDV2
71869|NCT02612051|Idiopathic Pulmonary Fibrosis
71870|NCT02612051|PET
71871|NCT02612038|Obstructive sleep apnea
71872|NCT02612038|Expiratory flow limitation
71873|NCT02612012|breast cancer
71874|NCT02612012|positive sentinel lymph nodes
71875|NCT02612012|axillary radiotherapy
71876|NCT02611999|Physicians' ordering behavior with price information
71877|NCT02611986|Airway management
71878|NCT02611986|video laryngoscope
71879|NCT02611973|Essential Thrombocythemia
71880|NCT02611973|Aspirin
71881|NCT02611960|PD-1
71882|NCT02611960|PD1
71883|NCT02611960|PD-L1
71884|NCT02611960|PDL1
71885|NCT02611947|emphysema
71886|NCT02611947|airway remodelling
71887|NCT02611947|multidetector computed tomography
71888|NCT02611921|Ketamine
71889|NCT02611921|Social Impairment
71890|NCT02611921|Autism
71891|NCT02611921|Autistic Disorder
71892|NCT02611908|CLL
71893|NCT02611908|cancer
71894|NCT02611908|obinutuzumab
71895|NCT02611908|ibrutinib
71896|NCT02611908|SLL
71897|NCT02611895|Aviremic HIV-1 infected patients
71898|NCT02611895|HAART
71899|NCT02611895|Integrase inhibitor Raltegravir
71900|NCT02611895|Ongoing HIV infection
71901|NCT02611856|twin to twin,
71902|NCT02611856|transfusion syndrome
71903|NCT02611843|peer support
71904|NCT02611843|web-based treatment
71905|NCT02611843|veterans
71906|NCT02611843|PTSD
71907|NCT02611843|Substance Use Disorders
71908|NCT02611830|Drug therapy
71909|NCT02611817|Drug therapy
71910|NCT02611791|Treatment by Pulsed Radio Frequency, Collagen, Female
71911|NCT02611713|effectiveness
71912|NCT02611713|Caregiver Burden
71913|NCT02611713|motor and non-motor symptoms
71914|NCT02611713|Duodopa/Duopa
71915|NCT02611713|fluctuations
71916|NCT02611713|OFF time
71917|NCT02611713|carbidopa levodopa enteral suspension (CLES)
71918|NCT02611713|dyskinesia
71919|NCT02611713|Observational
71920|NCT02611713|tremor
71921|NCT02611713|levodopa-carbidopa intestinal gel (LCIG)
71922|NCT02611713|Quality of Life
71923|NCT02611713|Advanced Parkinson's Disease
71924|NCT02611713|Long-term
71925|NCT02611635|non-valvular Atrial Fibrillation
71926|NCT02611635|Patient treatment preference
71927|NCT02611635|NOAC
71928|NCT02611635|VKA
71929|NCT02611583|TENS
71930|NCT02611570|Lung cancer
71931|NCT02611570|Low dose computed tomography
71932|NCT02611570|Screening
71933|NCT02611570|Non-smoker
71934|NCT02611570|Gender issue
71935|NCT02611557|MRI
71936|NCT02611557|lymphedema
71937|NCT02611557|manual lymphatic drainage
71938|NCT02611544|Fear of Cancer Recurrence
71939|NCT02611544|Fear of Cancer Return
71940|NCT02611544|Breast Cancer Survivor
71941|NCT02611544|Breast Cancer Remission
71942|NCT02611518|Healthy
71943|NCT02611518|JNJ-54861911
71944|NCT02611518|Rosuvastatin
71945|NCT02611518|Metformin
71946|NCT02611505|Healthy
71947|NCT02611505|Esketamine
71948|NCT02611505|Hepatic Impairment
71949|NCT02611505|Pharmacokinetics
71950|NCT02611479|patient reported outcomes
71951|NCT02611466|Osteoarthritis
71952|NCT02611466|ASP7962
71953|NCT02611453|choledocholithiasis
71954|NCT02611453|ERCP
71955|NCT02611453|cholangiography
71956|NCT02611453|biliary stricture
71957|NCT02611453|bile ducts
71958|NCT02611453|carbon dioxide
71959|NCT02611440|ischemic stroke
71960|NCT02611440|medication adherence
71961|NCT02611440|cardiovascular disease prevention
71962|NCT02611427|spine
71963|NCT02611427|lumbar
71964|NCT02611427|postoperative
71965|NCT02611427|physical activity
71966|NCT02611414|functional dyspepsia
71967|NCT02611414|tDCS
71968|NCT02611401|multiple sclerosis
71969|NCT02611401|depression
71970|NCT02611401|mindfulness
71971|NCT02611336|Left Ventricular Hypertrophy
71972|NCT02611336|Diastolic Dysfunction
71973|NCT02611336|Myocardial Fibrosis
71974|NCT02611336|Acromegaly
71975|NCT02611297|Cryoprobes
71976|NCT02611297|Cryobiopsy
71977|NCT02611297|Transbronchial lung biopsy
71978|NCT02611284|Beractant
71979|NCT02611284|Feasibility Studies
71980|NCT02611284|Infant, Premature
71981|NCT02611284|Noninvasive Ventilation
71982|NCT02611258|Left Ventricular Hypertrophy
71983|NCT02611258|Diastolic Dysfunction
71984|NCT02611258|Myocardial Fibrosis
71985|NCT02611258|Cushing's Syndrome
71986|NCT02611245|Thoracic Duct
71987|NCT02611245|Sentinel lymph node biopsy
71988|NCT02611232|Diabetes Type 1
71989|NCT02611232|Diabetes, Insulin-Dependent
71990|NCT02611232|Liraglutide
71991|NCT02611232|Preclinical Type 1 Diabetes
71992|NCT02611232|GLP-1 Analogue
71993|NCT02611206|rTMS
71994|NCT02611167|mesenchymal stem cells
71995|NCT02611154|Healthy Volunteers
71996|NCT02611154|Sports Medicine
71997|NCT02611154|Men's Health
71998|NCT02611154|Athletes
71999|NCT02611154|Anti-Doping
72000|NCT02611141|Retromolar Intubation
72001|NCT02611115|Pulmonary Embolism
72002|NCT02611115|Multidetector Computed Tomography
72003|NCT02611115|Radiation Dosage
72004|NCT02611115|Contrast Media
72005|NCT02611115|Individualized Medicine
72006|NCT02611089|Muscle connective tissue
72007|NCT02611089|Small leucine-rich proteoglycans
72008|NCT02611089|Limb development
72009|NCT02611076|smoking cessation
72010|NCT02611076|self-help
72011|NCT02611076|Spanish language
72012|NCT02611063|allogeneic stem cell transplant
72013|NCT02611050|patient decision aid
72014|NCT02611050|multi-vessel coronary artery disease
72015|NCT02611037|MPM
72016|NCT02611037|Unresectable
72017|NCT02611037|Respiratory
72018|NCT02611037|Intrathoracic
72019|NCT02611037|Transarterial
72020|NCT02611037|Chemoperfusion
72021|NCT02611024|lurbinectedin
72022|NCT02611024|PM01183
72023|NCT02611024|tumors
72024|NCT02611024|cancer
72025|NCT02611024|Pharma Mar
72026|NCT02611011|Congo Red Dot Test
72027|NCT02610985|Imaging, Three-Dimensional
72028|NCT02610985|Hysterectomy
72029|NCT02610985|laparoscopic hysterectomy
72030|NCT02610972|Congo Red Dot Test
72031|NCT02610946|pediatric
72032|NCT02610946|adolescent
72033|NCT02610946|compliance
72034|NCT02610933|vascular calcification
72035|NCT02610933|hemodialysis
72036|NCT02610933|rivaroxaban
72037|NCT02610933|vitamin K2
72038|NCT02610894|postoperative symptom management
72039|NCT02610894|symptom management
72040|NCT02610894|mHealth application
72041|NCT02610868|Cerebral Palsy
72042|NCT02610868|ALS
72043|NCT02610868|Stroke
72044|NCT02610868|Neuropletics
72045|NCT02610803|stroke
72046|NCT02610803|ischemic stroke
72047|NCT02610803|recurrent stroke
72048|NCT02610803|atrial fibrillation
72049|NCT02610803|premature atrial complexes
72050|NCT02610803|heart rhythm monitoring
72051|NCT02610803|cardiac telemetry
72052|NCT02610790|connected bracelets, footsteps
72053|NCT02610777|Drug Therapy
72054|NCT02610764|Circulating Tumor Cells
72055|NCT02610764|Response evaluation
72056|NCT02610751|Maternal Smoking
72057|NCT02610751|Female Fetal Testosterone
72058|NCT02610751|Anogenital Distance
72059|NCT02610751|Maternal Testosterone
72060|NCT02610751|Maternal Cotinine
72061|NCT02610712|ketamine
72062|NCT02610712|treatment-resistant
72063|NCT02610712|depression
72064|NCT02610712|spectroscopy
72065|NCT02610712|neuroinflammation
72066|NCT02610686|Plasmodium vivax
72067|NCT02610686|recurrence
72068|NCT02610686|drug resistance
72069|NCT02610634|Parkinson's disease
72070|NCT02610634|Older adults
72071|NCT02610634|Vision
72072|NCT02610634|Cognition
72073|NCT02610634|Visual cues
72074|NCT02610634|Eye-tracking
72075|NCT02610634|Gait
72076|NCT02610634|Saccades
72077|NCT02610634|Dual task
72078|NCT02610634|Visual sampling
72079|NCT02610621|Clinically node negative
72080|NCT02610621|T1 and T2 invasive breast cancer
72081|NCT02610595|Idiopathic Membranous Nephropathy
72082|NCT02610595|Jianpiyiqi Recipe
72083|NCT02610595|Huoxuejiedu Recipe
72084|NCT02610595|Effectiveness
72085|NCT02610595|Safety
72086|NCT02610582|CNGA3-linked
72087|NCT02610569|Colonic capsule
72088|NCT02610569|ulcerative colitis
72089|NCT02610569|mucosal healing
72090|NCT02610569|endoscopic score
72091|NCT02610556|NPC
72092|NCT02610556|concurrent chemotherapy
72093|NCT02610556|docetaxel
72094|NCT02610556|cisplatin
72095|NCT02610543|Primary Sjogren's Syndrome
72096|NCT02610530|type 2 diabetes
72097|NCT02610530|metabolic surgery
72098|NCT02610530|medical treatment
72099|NCT02610517|Hazardous alcohol use
72100|NCT02610517|Computer based intervention (CBI)
72101|NCT02610517|Pharmacotherapy
72102|NCT02610504|degenerative arthritis
72103|NCT02610478|HAI Testing
72104|NCT02610478|Multi-Center Trial
72105|NCT02610478|Oropharyngeal Swab
72106|NCT02610478|Standard of Care
72107|NCT02610478|Viral Shedding
72108|NCT02610465|Computed Tomography
72109|NCT02610465|Image Reconstruction
72110|NCT02610465|Iterative Reconstruction
72111|NCT02610452|clown therapy
72112|NCT02610387|tDCS
72113|NCT02610387|stroke
72114|NCT02610387|Spasticity
72115|NCT02610374|Gut microbiota composition
72116|NCT02610348|Hepatitis B
72117|NCT02610348|Hexaxim®
72118|NCT02610348|Hexyon®
72119|NCT02610348|Hexacima®
72120|NCT02610348|Prevnar®
72121|NCT02610348|DTaP-IPV-HB-Hib hexavalent vaccine
72122|NCT02610335|lumbar spinal stenosis
72123|NCT02610309|family-based crisis intervention
72124|NCT02610309|adolescent suicide
72125|NCT02610283|AKI
72126|NCT02610270|Sport
72127|NCT02610270|fatty acid
72128|NCT02610270|omega 3
72129|NCT02610257|Parkinson's disease
72130|NCT02610257|Freezing of gait
72131|NCT02610257|Motor blocks
72132|NCT02610257|Somatosensory
72133|NCT02610257|Proprioception
72134|NCT02610257|Muscle vibration
72135|NCT02610257|Handwriting
72136|NCT02610231|Parkinson's disease
72137|NCT02610231|Moderate to Severe Parkinson's Disease
72138|NCT02610218|Cell free DNA
72139|NCT02610218|Circulating tumor cell
72140|NCT02610218|Therapeutic efficacy
72141|NCT02610205|Caring touch
72142|NCT02610205|Tactile massage
72143|NCT02610205|Healing touch
72144|NCT02610192|Autologous Protein Solution
72145|NCT02610192|Patellofemoral Osteoarthritis
72146|NCT02610192|Female
72147|NCT02610114|Assisted reproductive technology (ART)
72148|NCT02610114|zygotes
72149|NCT02610114|Z-score (Zygote Score)
72150|NCT02610114|Infertility
72151|NCT02610088|Diabetes
72152|NCT02610088|Atherosclerosis
72153|NCT02610088|Cardiovascular disease
72154|NCT02610088|Endothelial dysfunction
72155|NCT02610088|Vascular function
72156|NCT02610088|Dapagliflozin
72157|NCT02610088|Gliclazide
72158|NCT02610075|AZD1775
72159|NCT02610075|Metastatic solid tumors
72160|NCT02610075|Ovarian cancer
72161|NCT02610062|AML
72162|NCT02610062|Acute Myeloid Leukemia
72163|NCT02610049|veterans
72164|NCT02610049|PTSD
72165|NCT02610049|art therapy
72166|NCT02610049|african americans
72167|NCT02610036|diabetes
72168|NCT02610036|foot ulcer
72169|NCT02610010|NPC
72170|NCT02610010|concurrent chemotherapy
72171|NCT02610010|IMRT
72172|NCT02610010|stage II
72173|NCT02609997|Intraocular lens
72174|NCT02609984|immunotherapy
72175|NCT02609984|CMB305
72176|NCT02609984|LV305
72177|NCT02609984|GLA-SE
72178|NCT02609984|Atezolizumab
72179|NCT02609984|NY-ESO-1
72180|NCT02609971|Anterior cruciate ligament
72181|NCT02609971|Neuromuscular Performance and balance
72182|NCT02609945|Migraine attacks
72183|NCT02609932|Interferon-gamma
72184|NCT02609932|innate immunity
72185|NCT02609919|study of contrast reaction in children under 2 years of age
72186|NCT02609919|safety
72187|NCT02609906|proximal humerus
72188|NCT02609906|AO 11-A3 fracture
72189|NCT02609906|MultiLoc
72190|NCT02609906|Philos augmented
72191|NCT02609893|HCV
72192|NCT02609880|Psycho-Oncology
72193|NCT02609880|Psychoneuroimmunology
72194|NCT02609880|Cognitive Behavioral Therapy
72195|NCT02609880|Gynecologic Cancer
72196|NCT02609880|Insomnia
72197|NCT02609880|Pain
72198|NCT02609880|Distress
72199|NCT02609880|Cortisol
72200|NCT02609880|Cytokines
72201|NCT02609854|herniated disc
72202|NCT02609854|sustained acoustic medicine
72203|NCT02609854|ultrasound
72204|NCT02609854|CLBP
72205|NCT02609828|Metastatic cancer bone pain
72206|NCT02609828|Lung cancer, renal cell cancer, breast cancer, colon cancer, prostate cancer, multiple myeloma
72207|NCT02609789|Systemic Lupus Erythematosus
72208|NCT02609789|JNJ-55920839
72209|NCT02609789|Healthy Volunteers
72210|NCT02609789|CNTO 6358
72211|NCT02609776|Non-Small-Cell Lung Cancer
72212|NCT02609776|JNJ-61186372
72213|NCT02609776|First-in-Human
72214|NCT02609776|Human Bispecific Epidermal Growth Factor Receptor (EGFR)
72215|NCT02609776|cMet Antibody
72216|NCT02609737|Radiolabeled Somatostatin Antagonists
72217|NCT02609737|68Ga-DOTA-JR11
72218|NCT02609737|177Lu-DOTA-JR11
72219|NCT02609737|Pet scan
72220|NCT02609737|CT scan
72221|NCT02609737|15-161
72222|NCT02609724|breast cancer
72223|NCT02609724|lymphedema
72224|NCT02609724|manual lymph drainage
72225|NCT02609724|near infrared fluorescence imaging
72226|NCT02609698|Stent
72227|NCT02609698|Polymer-free
72228|NCT02609698|Antiplatelet therapy
72229|NCT02609698|Clopidogrel
72230|NCT02609698|DES
72231|NCT02609698|DAPT
72232|NCT02609685|Thyroid cancer
72233|NCT02609685|Active surveillance
72234|NCT02609685|PTMC
72235|NCT02609672|Exercise
72236|NCT02609672|Resilience
72237|NCT02609659|Chronic Hepatitis C Infection
72238|NCT02609646|Anti-Infective Agents
72239|NCT02609646|Pharmacokinetics
72240|NCT02609646|Critically ill patients
72241|NCT02609594|human amniotic membrane
72242|NCT02609594|compression therapy
72243|NCT02609594|venous leg ulcer
72244|NCT02609581|Non Interventional Study
72245|NCT02609581|NIS
72246|NCT02609581|sublingual immunotherapy
72247|NCT02609581|allergen
72248|NCT02609581|Mites
72249|NCT02609568|Children
72250|NCT02609568|Head injury
72251|NCT02609568|Salivary biomarker
72252|NCT02609568|Trauma Brain Injury
72253|NCT02609555|TEM
72254|NCT02609555|Rectopexy
72255|NCT02609555|rectal prolapse
72256|NCT02609542|oral language
72257|NCT02609542|STOL
72258|NCT02609542|memory
72259|NCT02609542|eye tracking
72260|NCT02609529|Irritable Bowel Syndrome
72261|NCT02609529|Pediatrics
72262|NCT02609529|Nutrition
72263|NCT02609516|Multimorbidity
72264|NCT02609516|Health inequalities
72265|NCT02609516|Ageing
72266|NCT02609516|Mortality
72267|NCT02609477|Recreational stimulant users
72268|NCT02609477|Recreational Drug Users
72269|NCT02609451|quality of life
72270|NCT02609451|feasibility
72271|NCT02609451|safety
72272|NCT02609451|protective ileostomy closure
72273|NCT02609438|worksite
72274|NCT02609438|intervention
72275|NCT02609438|sitting
72276|NCT02609399|Influenza
72277|NCT02609399|Antiviral treatment
72278|NCT02609399|Emergency department
72279|NCT02609399|Influenza therapeutics
72280|NCT02609399|Rapid influenza testing
72281|NCT02609386|Head and Neck Neoplasms
72282|NCT02609386|Immunotherapy
72283|NCT02609386|Cancer
72284|NCT02609386|Oral Cavity
72285|NCT02609373|shiftwork
72286|NCT02609373|sleep hygiene
72287|NCT02609373|prevention
72288|NCT02609373|intervention
72289|NCT02609373|occupational
72290|NCT02609373|biological
72291|NCT02609373|breast cancer
72292|NCT02609373|lifestyle
72293|NCT02609360|Acute Respiratory Failure
72294|NCT02609360|ARDS
72295|NCT02609360|ECMO
72296|NCT02609360|Lung transplantation
72297|NCT02609360|Acid-Base Equilibrium
72298|NCT02609347|Manual Therapy
72299|NCT02609347|Ankle Fracture
72300|NCT02609347|Hindfoot Fracture
72301|NCT02609321|Paravertebral
72302|NCT02609321|Single injection
72303|NCT02609321|Breast surgery
72304|NCT02609321|Analgesia
72305|NCT02609308|ankle sprain
72306|NCT02609308|platelet-rich plasma
72307|NCT02609308|ankle injuries
72308|NCT02609295|α-linolenic acid
72309|NCT02609295|perilla oil
72310|NCT02609295|aPTT
72311|NCT02609295|Collagen-epinephrine closure time
72312|NCT02609295|Lp-PLA2
72313|NCT02609282|Sedentary behaviour
72314|NCT02609282|sitting
72315|NCT02609282|workplace
72316|NCT02609282|prompts
72317|NCT02609256|Intracranial hypertension
72318|NCT02609256|cerebral herniation
72319|NCT02609256|Stereotactic infarct tissue aspiration
72320|NCT02609256|fatality
72321|NCT02609256|disability
72322|NCT02609243|prediabetes
72323|NCT02609243|diabetes mellitus type 2
72324|NCT02609243|obesity
72325|NCT02609243|NAFLD
72326|NCT02609243|dyslipoproteinemia
72327|NCT02609217|elective
72328|NCT02609217|cesarean
72329|NCT02609178|artificial crown
72330|NCT02609178|biomorphic
72331|NCT02609178|functional generated path
72332|NCT02609178|muscle-action theory
72333|NCT02609178|anatomic theory
72334|NCT02609126|osteoarthritis
72335|NCT02609126|knee
72336|NCT02609113|Carpal Tunnel Syndrome
72337|NCT02609074|bone substitute
72338|NCT02609074|CPC
72339|NCT02609074|rhBMP-2
72340|NCT02609048|PBC
72341|NCT02609022|Myasthenia Gravis
72342|NCT02609022|CV-MG01 therapeutic vaccine
72343|NCT02609022|Acetylcholine receptor mimetic peptides
72344|NCT02609022|Safety
72345|NCT02609022|Immunogenic response
72346|NCT02609022|First-in-Human
72347|NCT02609022|Proof-of-Concept
72348|NCT02609022|Myasterix
72349|NCT02609009|Back Pain
72350|NCT02609009|Adolescent Idiopathic Scoliosis
72351|NCT02609009|Spinal Manipulation
72352|NCT02608983|Seaweed
72353|NCT02608983|Hydrocolloid
72354|NCT02608983|Functional Food
72355|NCT02608983|Dietary Fibre
72356|NCT02608983|Prebiotic
72357|NCT02608983|Low molecular weight polysaccharides
72358|NCT02608983|Alginate
72359|NCT02608983|Agar
72360|NCT02608983|HYFFI
72361|NCT02608983|Low molecular weight seaweed derived hydrocolloids as functional food ingredients
72362|NCT02608983|subjects
72363|NCT02608931|delta-9-tetrahydrocannabinol (THC)
72364|NCT02608892|Breastfeeding
72365|NCT02608892|Skin to skin care
72366|NCT02608892|Sucrose
72367|NCT02608892|Newborn screening
72368|NCT02608892|Blood test
72369|NCT02608892|Neonate
72370|NCT02608892|Infant
72371|NCT02608892|Knowledge translation
72372|NCT02608879|proinflammatory cytokines
72373|NCT02608879|microbiome
72374|NCT02608879|radiation therapy
72375|NCT02608866|stereotactic ablative radiotherapy
72376|NCT02608866|spine metastasis
72377|NCT02608840|slow-wave sleep
72378|NCT02608840|cognition
72379|NCT02608840|auditory stimulation
72380|NCT02608827|Hypertension; slow breathing; sympathetic nerve activity
72381|NCT02608788|postoperative sore throat
72382|NCT02608788|American Society of Anesthesiologists status
72383|NCT02608788|general anesthesia
72384|NCT02608788|post-anesthesia care unit(PACU)
72385|NCT02608775|ANI
72386|NCT02608775|SPI
72387|NCT02608775|Autonomic balance
72388|NCT02608775|Nociception measurement
72389|NCT02608762|Pediatric brain tumors
72390|NCT02608762|Radiation therapy
72391|NCT02608762|Neurobehavioral functions
72392|NCT02608762|Proton radiotherapy
72393|NCT02608749|Osteoporosis
72394|NCT02608749|Fall
72395|NCT02608749|Fracture
72396|NCT02608749|Sacopenia
72397|NCT02608749|Body Composition
72398|NCT02608736|head and neck squamous cell carcinoma
72399|NCT02608736|histone deacetylases
72400|NCT02608736|valproic acid
72401|NCT02608736|acetylation
72402|NCT02608736|chemoprevention
72403|NCT02608736|DNA methyltransferase
72404|NCT02608736|methylation
72405|NCT02608723|shock wave
72406|NCT02608723|plantar fasciitis
72407|NCT02608723|placebo effect
72408|NCT02608723|nocebo effect
72409|NCT02608684|immunotherapy, platinum-resistant ovarian cancer, immune checkpoint inhibitors
72410|NCT02608671|Episiotomy
72411|NCT02608671|continuous suture
72412|NCT02608671|Skin adhesive tape
72413|NCT02608658|Cirrhosis
72414|NCT02608658|Ascites
72415|NCT02608658|SBP
72416|NCT02608632|Renal denervation
72417|NCT02608632|Ablation
72418|NCT02608619|18F-fluorocholine
72419|NCT02608619|Pet imaging
72420|NCT02608619|Biopsy
72421|NCT02608619|15-268
72422|NCT02608580|pediatric hospital care
72423|NCT02608580|adult hospital care
72424|NCT02608580|sickle cell disease
72425|NCT02608554|Polycystic ovary sybdrome
72426|NCT02608554|Taichi
72427|NCT02608541|Multiple Rib Fractures, Frail Chest
72428|NCT02608476|acne
72429|NCT02608463|neuropathic pain
72430|NCT02608463|pregnancy
72431|NCT02608450|acne
72432|NCT02608437|melanoma
72433|NCT02608437|ipilimumab
72434|NCT02608437|SGI-110
72435|NCT02608424|Foot mechanical stimulation
72436|NCT02608424|Autonomic nervous system
72437|NCT02608424|Inflammation
72438|NCT02608424|Parkinson's disease
72439|NCT02608424|Spectral analysis
72440|NCT02608424|Heart rate variability
72441|NCT02608424|Blood pressure variability
72442|NCT02608398|obesity
72443|NCT02608398|weight-loss
72444|NCT02608398|metabonomics
72445|NCT02608398|gut microbiome
72446|NCT02608372|Seaweed
72447|NCT02608372|Insulin
72448|NCT02608372|Glucose tolerance
72449|NCT02608372|C-peptide
72450|NCT02608372|Appetide
72451|NCT02608372|Metabolomics
72452|NCT02608359|Post-Marketing Surveillance
72453|NCT02608359|Abiraterone Acetate
72454|NCT02608359|Zytiga
72455|NCT02608346|Circulating tumor DNA
72456|NCT02608346|BRCA1 mutation
72457|NCT02608333|Early intervention
72458|NCT02608333|ESDM
72459|NCT02608333|behavioral and developmental intervention
72460|NCT02608320|Healthy
72461|NCT02608320|JNJ-35685-AAA-G016
72462|NCT02608320|JNJ-35685-AAA-G021
72463|NCT02608320|DURAGESIC
72464|NCT02608320|Fentanyl
72465|NCT02608307|Treatment Decision-Making
72466|NCT02608307|Adolescents and Young Adult Oncology
72467|NCT02608294|stroke
72468|NCT02608294|gait
72469|NCT02608294|balance
72470|NCT02608281|Spectral Mammography
72471|NCT02608281|Dual energy
72472|NCT02608281|Contrast enhanced
72473|NCT02608268|Solid tumors
72474|NCT02608268|Melanoma
72475|NCT02608268|Non small cell lung cancer
72476|NCT02608268|NSCLC
72477|NCT02608268|Renal cell carcinoma
72478|NCT02608268|RCC
72479|NCT02608268|Phase I-Ib/II
72480|NCT02608268|MBG453
72481|NCT02608268|PDR001
72482|NCT02608268|Checkpoint inhibitor
72483|NCT02608268|PD-1
72484|NCT02608268|TIM-3
72485|NCT02608164|Healthy adults
72486|NCT02608151|neurodevelopement
72487|NCT02608151|Very preterm infant
72488|NCT02608138|iodine
72489|NCT02608138|urine
72490|NCT02608138|children
72491|NCT02608138|schools
72492|NCT02608138|cognitive performance
72493|NCT02608138|salt fortification
72494|NCT02608125|FGFR
72495|NCT02608099|Atrial fibrillation
72496|NCT02608099|Non-valvular atrial fibrillation
72497|NCT02608099|Catheter ablation
72498|NCT02608099|Apixaban
72499|NCT02608099|Warfarin
72500|NCT02608099|Harvard Clinical Research Institute
72501|NCT02608086|PTSD
72502|NCT02608086|Trauma
72503|NCT02608086|Emergency
72504|NCT02608086|RCT
72505|NCT02608086|Psychological First Aid
72506|NCT02608021|Alzheimer's Disease
72507|NCT02608021|MRI
72508|NCT02608008|3D-Ultrasound
72509|NCT02608008|Live X-rays
72510|NCT02608008|EchoNavigator System
72511|NCT02607982|Esophageal cancer
72512|NCT02607982|Concurrent chemoradiotherapy
72513|NCT02607982|Oxaliplatin
72514|NCT02607982|Paclitaxel
72515|NCT02607982|Survival
72516|NCT02607982|Toxicity
72517|NCT02607969|Deformational Plagiocephaly,Treatment,Compliance
72518|NCT02607956|HIV
72519|NCT02607943|acute stroke
72520|NCT02607943|hyperglycemia
72521|NCT02607943|regular insulin
72522|NCT02607943|long-acting insulin
72523|NCT02607930|HIV
72524|NCT02607917|Cardiovascular Disease
72525|NCT02607904|Cannabidiol
72526|NCT02607904|GWP42003-P
72527|NCT02607904|Epidiolex
72528|NCT02607904|Stiripentol
72529|NCT02607904|Valproate
72530|NCT02607891|Cannabidiol
72531|NCT02607891|GWP42003-P
72532|NCT02607891|Epidiolex
72533|NCT02607891|Stiripentol
72534|NCT02607891|Valproate
72535|NCT02607878|Cardiac arrest
72536|NCT02607878|Coma
72537|NCT02607878|Prognosis
72538|NCT02607878|Automated pupillometry
72539|NCT02607878|EEG
72540|NCT02607878|Evoked potentials
72541|NCT02607878|Targeted Temperature Management (TTM)
72542|NCT02607852|Patient Reported Outcomes Measure
72543|NCT02607852|Burns
72544|NCT02607839|lipid handling by the gut and liver
72545|NCT02607813|LXH254, CRAF, MAPK, solid tumor, PDR001
72546|NCT02607800|Chronic Hepatitis C Infection
72547|NCT02607787|Exercise Rehabilitation
72548|NCT02607774|Plaque psoriasis
72549|NCT02607774|disease-drug-drug-interaction
72550|NCT02607774|midazolam
72551|NCT02607774|secukinumab
72552|NCT02607761|infertility
72553|NCT02607761|fertility awareness
72554|NCT02607761|health interventions
72555|NCT02607761|young adults
72556|NCT02607748|18F-NaF PET
72557|NCT02607748|18F-sodium fluoride PET
72558|NCT02607748|Coronary CTA
72559|NCT02607735|Chronic Hepatitis C Infection
72560|NCT02607644|Intubation
72561|NCT02607644|Ventilation
72562|NCT02607644|Cardiac arrest
72563|NCT02607644|prehospital
72564|NCT02607644|Laryngeal Masks
72565|NCT02607644|Laryngeal Tube
72566|NCT02607644|airway management
72567|NCT02607631|Thymic epithelial tumors
72568|NCT02607631|Pembrolizumab
72569|NCT02607605|lung cancer
72570|NCT02607605|leptomeningeal metastases
72571|NCT02607605|cell-free DNA
72572|NCT02607592|Non-Small-Cell Lung cancer
72573|NCT02607592|overall toxicity value
72574|NCT02607566|Diabetes
72575|NCT02607566|Yoga
72576|NCT02607566|Walking
72577|NCT02607566|Stress
72578|NCT02607540|Chemoradiotherapy
72579|NCT02607540|Esophageal Squamous Cancer
72580|NCT02607540|Cisplatin-5-fluorouracil
72581|NCT02607501|coil embolization
72582|NCT02607501|bifurcation
72583|NCT02607488|Obese patients
72584|NCT02607488|Undergoing bariatric surgery
72585|NCT02607475|telesonography
72586|NCT02607475|ultrasound
72587|NCT02607475|robotic telesonography
72588|NCT02607410|Type 2 diabetes
72589|NCT02607410|sitagliptin
72590|NCT02607410|NPH insulin
72591|NCT02607410|GLP-1
72592|NCT02607371|Patient treatment preference
72593|NCT02607371|Non-valvular Atrial Fibrillation
72594|NCT02607371|NOAC
72595|NCT02607371|VKA
72596|NCT02607358|Clopidogrel
72597|NCT02607358|acetacylic acid
72598|NCT02607358|antiplatelet therapy
72599|NCT02607358|HOTPR
72600|NCT02607358|VerifyNow
72601|NCT02607332|single-center
72602|NCT02607332|prospective
72603|NCT02607332|single-arm
72604|NCT02607332|open-label
72605|NCT02607332|phase II
72606|NCT02607319|Recurrent Implantation Failure
72607|NCT02607319|Implantation
72608|NCT02607319|low molecular weight heparin
72609|NCT02607319|In vitro Fertilization
72610|NCT02607319|Assisted Reproductive Technology
72611|NCT02607319|Pregnancy
72612|NCT02607293|Polycystic Ovary Syndrome
72613|NCT02607293|Gonadotropin releasing hormone agonist (GnRH-a)
72614|NCT02607293|Gonal-f
72615|NCT02607293|Assisted Reproductive Technology
72616|NCT02607280|Diabetic peripheral neuropathic pain
72617|NCT02607280|post-herpetic neuralgia
72618|NCT02607280|renal impairment
72619|NCT02607267|EOSS
72620|NCT02607267|Metabolic Surgery
72621|NCT02607267|postoperative outcome
72622|NCT02607267|30 - day mortality
72623|NCT02607241|drug-coated balloon
72624|NCT02607241|bioresorbable scaffold
72625|NCT02607241|fractional flow reserve
72626|NCT02607241|optical coherence tomography
72627|NCT02607150|Spinal Fusion
72628|NCT02607150|Cerebral Oxygenation
72629|NCT02607150|Blood Transfusion
72630|NCT02607111|Dalteparin
72631|NCT02607111|Dosage
72632|NCT02607111|Home Hemodialysis
72633|NCT02607072|APREMEC, aspirin, colorectal cancer, adjuvant therapy, recurrence, metastasis, survival
72634|NCT02607046|rehabilitation
72635|NCT02607046|exercise training
72636|NCT02607033|Exercise
72637|NCT02607033|Weight Loss
72638|NCT02607033|Mobility Limitation
72639|NCT02607007|Dairy
72640|NCT02607007|Post-prandial Glycemia
72641|NCT02607007|Satiety
72642|NCT02607007|Food Intake
72643|NCT02607007|Insulin
72644|NCT02607007|Milk
72645|NCT02607007|Greek yogurt
72646|NCT02607007|Cheese
72647|NCT02607007|Soy beverage
72648|NCT02606994|oral mucositis
72649|NCT02606994|chemotherapy
72650|NCT02606994|toothpaste
72651|NCT02606981|Water treatment
72652|NCT02606981|Child growth
72653|NCT02606981|Enteric infection
72654|NCT02606955|Bioimpedance
72655|NCT02606955|Dry weight
72656|NCT02606955|Hemodialysis
72657|NCT02606955|Resistance
72658|NCT02606942|chondromalacia patellae (CMP)
72659|NCT02606942|patella
72660|NCT02606916|Once-daily Simultaneous Modulated Accelerated Radiotherapy
72661|NCT02606916|S-1
72662|NCT02606916|DDP
72663|NCT02606916|elderly patients
72664|NCT02606890|Magnetic Resonance Imaging
72665|NCT02606890|Stroke Lesion Pattern
72666|NCT02606890|Atrial Fibrillation
72667|NCT02606890|Stroke
72668|NCT02606851|Proton Pump Inhibitor, GERD, GERD Q
72669|NCT02606799|Esophagectomy Inflammation Hemoperfusion Cytokines
72670|NCT02606786|stabilization exercises
72671|NCT02606773|vitamin C supplementation
72672|NCT02606760|Nail psoriasis
72673|NCT02606747|DPN
72674|NCT02606747|fall
72675|NCT02606747|fMRI
72676|NCT02606747|balance
72677|NCT02606721|Food Hypersensitivity
72678|NCT02606721|Oral Food Challenge
72679|NCT02606721|Skin Prick Test
72680|NCT02606721|Food Biomarkers
72681|NCT02606695|Spine Surgery Patients
72682|NCT02606682|Phase 1
72683|NCT02606682|Safety
72684|NCT02606682|Tolerability
72685|NCT02606682|Pharmacokinetics
72686|NCT02606682|Parkinson's Disease
72687|NCT02606630|Relapsing multiple sclerosis
72688|NCT02606617|Mosapride
72689|NCT02606617|blood glucose
72690|NCT02606617|serum lipid
72813|NCT02605941|Cervical cancer
72691|NCT02606604|Functional Electrical Stimulation
72692|NCT02606604|Cycling
72693|NCT02606591|Electroencephalograph
72694|NCT02606591|EEG
72695|NCT02606591|Hair sample
72696|NCT02606591|Cognitive tests
72697|NCT02606591|Cortisol analysis
72698|NCT02606591|Brain activity
72699|NCT02606591|Stress hormones
72700|NCT02606552|drug eluting stent
72701|NCT02606552|atrial appendage closure
72702|NCT02606539|gestaional trophoblastic neoplasm
72703|NCT02606539|hystrectomy
72704|NCT02606539|chemotherapy
72705|NCT02606539|methotrxate
72706|NCT02606513|Computed Tomography Urography
72707|NCT02606513|Magnetic Resonance Urography
72708|NCT02606487|CF
72709|NCT02606487|Exacerbation
72710|NCT02606487|Hyerpolarized xenon MRI
72711|NCT02606487|Pediatrics
72712|NCT02606487|Lung Clearance Index
72713|NCT02606461|Advanced unresectable dedifferentiated liposarcoma
72714|NCT02606461|selinexor
72715|NCT02606461|KCP-330
72716|NCT02606461|Karyopharm
72717|NCT02606461|Phase 2 / 3
72718|NCT02606461|dedifferentiated liposarcoma
72719|NCT02606461|liposarcoma
72720|NCT02606448|pain control
72721|NCT02606448|patient satisfaction
72722|NCT02606448|liposomal bupivacaine
72723|NCT02606448|Anterior cruciate ligament reconstruction
72724|NCT02606422|transcranial direct current stimulation (tDCS)
72725|NCT02606422|neurodegeneration
72726|NCT02606422|language therapy
72727|NCT02606422|Primary Progressive Aphasia (PPA)
72728|NCT02606370|Unstable Shoes;Trunk muscles;Lumbar lordosis;Low Back Pain
72729|NCT02606318|Occupational Therapy
72730|NCT02606318|Quality of Life
72731|NCT02606305|Epithelial ovarian cancer
72732|NCT02606305|Fallopian tube cancer
72733|NCT02606305|Primary peritoneal cancer
72734|NCT02606305|Endometrial cancer
72735|NCT02606305|IMGN853
72736|NCT02606305|ADC
72737|NCT02606305|Antibody drug conjugate
72738|NCT02606305|ImmunoGen
72739|NCT02606305|Antibody
72740|NCT02606305|Phase 1
72741|NCT02606305|Folate receptor alpha
72742|NCT02606253|loop diuretics
72743|NCT02606253|thiazide diuretics
72744|NCT02606253|vasopressin antagonists
72745|NCT02606253|diuretic resistance
72746|NCT02606253|heart failure
72747|NCT02606227|Pregnant smokers
72748|NCT02606227|smoking cessation
72749|NCT02606227|financial incentives
72750|NCT02606227|control group
72751|NCT02606227|randomized study
72752|NCT02606214|Tuberculosis
72753|NCT02606214|TBA-354
72754|NCT02606214|Pulmonary Tuberculosis
72755|NCT02606214|TB
72756|NCT02606201|stress urinary incontinence
72757|NCT02606201|intrinsic sphincter deficiency
72758|NCT02606201|myofiber
72759|NCT02606201|autologous
72760|NCT02606201|skeletal muscle precursor cells
72761|NCT02606201|autologous serum
72762|NCT02606188|Modified High-flow nasal cannula
72763|NCT02606188|Bronchoscopy
72764|NCT02606188|Oxygen therapy
72765|NCT02606175|health literacy
72766|NCT02606175|patient medication knowledge
72767|NCT02606175|kidney transplantation
72768|NCT02606175|medication adherence
72769|NCT02606175|kidney transplant
72770|NCT02606175|renal transplantation
72771|NCT02606149|Lung cancer
72772|NCT02606149|chemotherapy outcome
72773|NCT02606149|ethics
72774|NCT02606149|information
72775|NCT02606136|Duchenne
72776|NCT02606136|muscular
72777|NCT02606136|dystrophy
72778|NCT02606136|DMD
72779|NCT02606136|non-ambulatory
72780|NCT02606123|Prostate Cancer
72781|NCT02606123|Metastatic castration-resistant prostate cancer
72782|NCT02606110|ReBuilder
72783|NCT02606110|breast cancer
72784|NCT02606110|chemotherapy induced
72785|NCT02606084|Renal Impairment
72786|NCT02606084|Healthy
72787|NCT02606084|Esketamine
72788|NCT02606071|cardiac resynchronization therapy
72789|NCT02606071|multipoint left ventricular pacing
72790|NCT02606045|menorrhagia
72791|NCT02606045|VWD
72792|NCT02606032|Fecal Microbiota Transplant
72793|NCT02606032|Antibiotics
72794|NCT02606019|Pentraxin 3
72795|NCT02606019|Vascular Endothelial Growth Factor
72796|NCT02606019|dengue
72797|NCT02606006|Physical Therapy Modalities
72798|NCT02606006|Motivation
72799|NCT02606006|Patient Participation
72800|NCT02606006|Animal Assisted Therapy
72801|NCT02605993|complement inhibitor
72802|NCT02605967|PDR001,
72803|NCT02605967|nasopharyngeal cancer,
72804|NCT02605967|moderately differentiated/undifferentiated,
72805|NCT02605967|locally advanced,
72806|NCT02605967|recurrent or metastatic NPC,
72807|NCT02605967|after first- line platinum-based therapy
72808|NCT02605954|HIV 1 Infection
72809|NCT02605954|HIV
72810|NCT02605954|Virologically-Suppressed
72811|NCT02605954|Antiretroviral agents
72812|NCT02605941|DNA methylation
72814|NCT02605928|Arthritis
72815|NCT02605928|Bioimpedance
72816|NCT02605928|Glucocorticoid
72817|NCT02605928|Intra-articular injection
72818|NCT02605928|Needle Guidance
72819|NCT02605902|Chronic tic disorders
72820|NCT02605902|Tourette syndrome
72821|NCT02605876|anterior cruciate ligament reconstruction
72822|NCT02605863|Enzalutamide
72823|NCT02605863|Non-Muscle Invasive Bladder Cancer
72824|NCT02605863|Androgen Deprivation Therapy
72825|NCT02605850|heart health
72826|NCT02605811|limited small cell lung cancer
72827|NCT02605811|brain metastases
72828|NCT02605811|prophylactic cranial radiotherapy
72829|NCT02605811|temozolomide
72830|NCT02605785|PSP
72831|NCT02605733|Premature infant
72832|NCT02605733|Amplitude integrated EEG
72833|NCT02605733|Near-infrared spectroscopy
72834|NCT02605707|Endothelial Progenitor Cells
72835|NCT02605707|Transplantation
72836|NCT02605707|Stroke
72837|NCT02605681|midkine
72838|NCT02605681|endothelial injury
72839|NCT02605681|sepsis
72840|NCT02605668|Anxiety Disorders
72841|NCT02605668|Extinction Learning
72842|NCT02605668|Optimized Extinction
72843|NCT02605668|Behavioral Therapy
72844|NCT02605668|Massed Confrontation
72845|NCT02605668|Social Anxiety Disorder
72846|NCT02605668|Specific Phobia
72847|NCT02605668|Panic Disorder
72848|NCT02605668|Agoraphobia
72849|NCT02605655|obesity
72850|NCT02605655|hyperlipidemia
72851|NCT02605655|hyperglycemia
72852|NCT02605642|Inflectra
72853|NCT02605642|Infliximab
72854|NCT02605642|Observational
72855|NCT02605642|Remicade
72856|NCT02605603|Gaucher Type 1, Gaucher Type 2, Gaucher Type 3
72857|NCT02605577|late preterm infants
72858|NCT02605577|nutrition
72859|NCT02605577|systemic management
72860|NCT02605525|IgAN
72861|NCT02605512|Radiotherapy
72862|NCT02605512|Echocardiography
72863|NCT02605512|Strain strain rate
72864|NCT02605512|Coronary computed tomography angiography
72865|NCT02605512|Segments of coronary arteries
72866|NCT02605512|Subclinical functional and anatomical cardiac lesions
72867|NCT02605512|Biomarkers
72868|NCT02605512|Heart dosimetry
72869|NCT02605486|palbociclib
72870|NCT02605486|bicalutamide
72871|NCT02605486|AR(+)
72872|NCT02605486|15-207
72873|NCT02605473|Melanoma
72874|NCT02605473|Malignant melanoma
72875|NCT02605473|Unresectable
72876|NCT02605473|Decitabine
72877|NCT02605473|PEG Interferon Alpha-2b
72878|NCT02605473|PEG Intron
72879|NCT02605473|5-Aza-Deoxycytidine
72880|NCT02605473|Dacogen
72881|NCT02605460|Bone Marrow Transplantation
72882|NCT02605460|Conditioning Regimen
72883|NCT02605434|Parkinson's Disease
72884|NCT02605434|Fluctuating Parkinson's Disease
72885|NCT02605434|Advanced Parkinson's Disease
72886|NCT02605434|Carbidopa
72887|NCT02605434|Levodopa
72888|NCT02605434|Accordion
72889|NCT02605434|Accordance
72890|NCT02605421|High-risk neuroblastoma
72891|NCT02605421|Neuroblastoma
72892|NCT02605421|Myeloablative chemotherapy
72893|NCT02605421|Myeloablative consolidation chemotherapy
72894|NCT02605421|Autologous peripheral blood stem cell rescue
72895|NCT02605421|PBSC
72896|NCT02605421|Autologous stem cell rescue
72897|NCT02605395|Bioequivalence
72898|NCT02605395|Fed condition
72899|NCT02605395|PARIET 20 mg
72900|NCT02605395|IDIAZOLE 20mg
72901|NCT02605395|Rabeprazole
72902|NCT02605382|Dental Implantation
72903|NCT02605382|Chlorhexidine gluconate
72904|NCT02605356|Radium-223 dichloride
72905|NCT02605356|bortezomib
72906|NCT02605356|dexamethasone
72907|NCT02605356|early relapsed multiple myeloma
72908|NCT02605356|combination therapy multiple myeloma
72909|NCT02605343|PGx
72910|NCT02605343|pharmacogenetic testing
72911|NCT02605343|Pain Management
72912|NCT02605343|AltheaDx
72913|NCT02605343|Post-Operative Pain Management
72914|NCT02605317|Emergency Physicians
72915|NCT02605317|Consulting Physicians
72916|NCT02605317|WhatsApp
72917|NCT02605278|Primary Health Care, Patient Education, Care Managament
72918|NCT02605265|Neoadjuvant Chemoradiation
72919|NCT02605265|Irinotecan
72920|NCT02605265|UGT1A1
72921|NCT02605252|Chronic hepatitis B
72922|NCT02605252|Peginterferon alfa-2b
72923|NCT02605252|Nucleotide analogue
72924|NCT02605200|Diabetes
72925|NCT02605200|Endocrinology
72926|NCT02605200|Pediatrics
72927|NCT02605187|cesarean
72928|NCT02605187|postoperative pain
72929|NCT02605187|patient choice
72930|NCT02605161|Blood brain barrier
72931|NCT02605161|movement disorder
72932|NCT02605161|deep brain stimulation
72933|NCT02605161|essential tremor
72934|NCT02605161|cervical dystonia
72935|NCT02605161|magnetic resonance imaging
72936|NCT02605161|neostriatum
72937|NCT02605148|Islet autoimmunity
72938|NCT02605148|gluten free diet
72939|NCT02605148|prediabetes
72940|NCT02605148|prevention
72941|NCT02605148|type 1 diabetes
72942|NCT02605148|glucose tolerance test
72943|NCT02605122|pneumonia
72944|NCT02605122|macrolide
72945|NCT02605122|pediatric
72946|NCT02605109|MERS-CoV
72947|NCT02605109|Infection control
72948|NCT02605109|Case-control studies
72949|NCT02605096|suspected scaphoid fracture
72950|NCT02605083|Cancer
72951|NCT02605083|Neoplasm
72952|NCT02605083|Solid Tumor
72953|NCT02605083|Breast
72954|NCT02605083|Head and Neck
72955|NCT02605083|Lung
72956|NCT02605083|Pancreatic
72957|NCT02605083|Hepatic
72958|NCT02605083|Melanoma
72959|NCT02605083|Colon
72960|NCT02605083|Renal
72961|NCT02605083|Thyroid
72962|NCT02605083|Prostate
72963|NCT02605083|Ovarian
72964|NCT02605083|MNK1
72965|NCT02605083|MNK2
72966|NCT02605083|eIF4E
72967|NCT02605005|interscalene block, general anesthesia, shoulder arthroscopy, cerebral oxygen saturation, beach chair position
72968|NCT02604992|Comparative Bioavailability
72969|NCT02604966|P. falciparum
72970|NCT02604966|resistance to artemisinin
72971|NCT02604966|Central Vietnam
72972|NCT02604953|glaucoma
72973|NCT02604953|VEP
72974|NCT02604953|PERG
72975|NCT02604953|SD-tVEP
72976|NCT02604953|ss-PERG
72977|NCT02604940|Postoperative narcotic requirements
72978|NCT02604940|Dexmedetomidine
72979|NCT02604940|Bariatric Surgery
72980|NCT02604901|medication adherence
72981|NCT02604901|community pharmacies
72982|NCT02604901|screening and brief intervention
72983|NCT02604888|Baldness
72984|NCT02604888|Alopecia Areata
72985|NCT02604888|Alopecia
72986|NCT02604888|Hair loss
72987|NCT02604784|Pressurized Intra Peritoneal Air-flow Chemotherapy (PIPAC)
72988|NCT02604784|Chemotherapy
72989|NCT02604784|Peritoneal Carcinomatosis
72990|NCT02604758|Alcoholics [M01.066]
72991|NCT02604745|degenerative mitral regurgitation
72992|NCT02604667|Biomarkers
72993|NCT02604667|Mechanisms
72994|NCT02604667|Transcranial Doppler
72995|NCT02604641|skin rejuvenation
72996|NCT02604641|anti-ageing effects
72997|NCT02604641|minimal erythema dose
72998|NCT02604641|dermis structure
72999|NCT02604641|physiological skin condition
73000|NCT02604641|wrinkling
73001|NCT02604641|dry skin
73002|NCT02604628|Pneumonia
73003|NCT02604628|Antibiotic Stewardship
73004|NCT02604628|Stepped wedge
73005|NCT02604628|Antibiotic
73006|NCT02604615|Chemoradiotherapy
73007|NCT02604615|Esophageal Squamous Cancer
73008|NCT02604615|Capecitabine and oxaliplatin
73009|NCT02604615|Chinese
73010|NCT02604615|Randomized Controlled Trials
73011|NCT02604602|PPH
73012|NCT02604589|Catheters, Indwelling
73013|NCT02604589|Infusion Pumps
73014|NCT02604589|Anesthesia, Local
73015|NCT02604589|Analgesia, Patient-Controlled
73016|NCT02604589|Bupivacaine
73017|NCT02604576|functional dyspepsia
73018|NCT02604524|Type 1 Diabetes Mellitus (T1DM)
73019|NCT02604524|Artificial Pancreas (AP)
73020|NCT02604524|Sensor-Augmented Pump (SAP) Therapy
73021|NCT02604524|Closed Loop Control
73022|NCT02604524|Insulin Pump
73023|NCT02604524|Continuous Glucose Monitor (CGM)
73024|NCT02604511|Waldenstrom's Macroglobulinemia
73025|NCT02604485|Hypoglycemia
73026|NCT02604485|Congenital Hyperinsulinism
73027|NCT02604472|Nasopharyngeal carcinoma
73028|NCT02604472|induction chemotherapy
73029|NCT02604472|concurrent chemoradiotherapy
73030|NCT02604446|Arthroplasty, Replacement, Knee
73031|NCT02604446|Analgesics
73032|NCT02604446|Administration and dosage
73033|NCT02604446|Knee
73034|NCT02604446|Postoperational care
73035|NCT02604446|Pain management
73036|NCT02604433|ACE-536
73037|NCT02604433|Safety
73038|NCT02604433|Efficacy
73039|NCT02604433|Placebo
73040|NCT02604433|Red Blood Cell Transfusions
73041|NCT02604433|Beta -Thalassemia
73042|NCT02604394|Rheolytic Thrombectomy
73043|NCT02604394|Percutaneous Coronary Intervention
73044|NCT02604394|Angioplasty
73045|NCT02604394|Cardiac Magnetic Resonance Imaging
73046|NCT02604394|Myocardial Salvage Index
73047|NCT02604394|STEMI, ST elevation Myocardial Infarction
73048|NCT02604394|Corrected TIMI Frame Count, cTFC
73049|NCT02604394|Index of microcirculatory resistance, thermodilution, IMR
73050|NCT02604381|Osteoarthritis
73051|NCT02604381|Knee
73052|NCT02604381|Glucosamine Sulfate
73053|NCT02604381|Ginkgo Biloba
73054|NCT02604381|WOMAC
73055|NCT02604381|Joint Health Wellness
73056|NCT02604381|Interleukin-1-beta
73057|NCT02604368|hemoglobin SS
73058|NCT02604368|hemoglobin SC
73059|NCT02604368|hemoglobin S/β°-thalassemia
73060|NCT02604329|low level laser therapy
73061|NCT02604329|oral mucositis
73062|NCT02604329|child
73063|NCT02604316|Overweight and Obesity
73064|NCT02604316|Appetite
73065|NCT02604316|Gut hormones and obesity
73066|NCT02604316|Arabinoxylan, Beta-Glucan
73067|NCT02604316|SmartPill
73068|NCT02604303|Abdominal Aortic Aneurysm
73069|NCT02604303|RhoA
73070|NCT02604303|Biomarker
73071|NCT02604290|Kinesio taping
73072|NCT02604290|Neuromuscular taping
73073|NCT02604290|Targeted treatment
73074|NCT02604290|Chronic low back pain
73075|NCT02604290|Randomised controlled trial
73076|NCT02604277|Psychology
73077|NCT02604238|Pulmonary Embolism at intermediate risk
73078|NCT02604225|Anaethesiology
73079|NCT02604186|Spasticity
73080|NCT02604186|Botulinum Toxin
73081|NCT02604186|Hereditary Spastic Paraplegia
73082|NCT02604134|silver nitrate
73083|NCT02604134|children
73084|NCT02604134|dental caries
73085|NCT02604134|medical management
73086|NCT02604134|quality of life
73087|NCT02604121|oral cavity
73088|NCT02604121|cancerous and precancerous lesions
73089|NCT02604108|physical activity
73090|NCT02604108|healthy diet
73091|NCT02604095|Acanthosis nigricans
73092|NCT02604095|Obesity
73093|NCT02604069|Breast reconstruction
73094|NCT02604069|Breast cancer
73095|NCT02604069|Microsurgery
73096|NCT02604069|Continuous flap monitor
73097|NCT02604043|supraglottic pH
73098|NCT02604017|HCV GT1
73099|NCT02604017|Non-cirrhotic
73100|NCT02604017|RBV Free
73101|NCT02604017|Without cirrhosis
73102|NCT02604017|Chronic Hepatitis C
73103|NCT02604017|Hepatitis C Genotype 1 (GT1)
73104|NCT02604017|IFN free
73105|NCT02604017|Hepatitis C
73106|NCT02604017|Ribavirin Free
73107|NCT02604017|Interferon (IFN) Free
73108|NCT02604017|HCV
73109|NCT02604017|Hepatitis C virus
73110|NCT02604017|DAA
73111|NCT02604004|lamivudine
73112|NCT02604004|bioequivalence test
73113|NCT02604004|pharmacokinetics
73114|NCT02604004|high-performance liquid chromatography
73115|NCT02604004|3TC
73116|NCT02604004|LC-MS/MS
73117|NCT02604004|mass spectrometry
73118|NCT02603991|children and adolescents
73119|NCT02603991|Prospective cohort study
73120|NCT02603991|vagus nerve stimulation
73121|NCT02603991|PINS
73122|NCT02603952|Influenza
73123|NCT02603952|Influenza A
73124|NCT02603952|Flu
73125|NCT02603952|Flu A
73126|NCT02603939|Pain
73127|NCT02603939|Magnetic resonance imaging
73128|NCT02603913|Pre-eclampsia
73129|NCT02603913|Pregnancy induced hypertension
73130|NCT02603913|Preterm birth
73131|NCT02603913|Intra-uterine growth restriction
73132|NCT02603913|Oxidative stress
73133|NCT02603900|Adductor Canal Catheter
73134|NCT02603900|Arthroplasty, Replacement, Knee
73135|NCT02603900|Local infiltration of analgesia
73136|NCT02603887|Smoldering Multiple Myeloma
73137|NCT02603887|SMM
73138|NCT02603887|Intermediate or high-risk
73139|NCT02603887|Pembrolizumab
73140|NCT02603887|Keytruda
73141|NCT02603887|MK-3475
73142|NCT02603887|SCH-900475
73143|NCT02603874|Fluoroscopy
73144|NCT02603874|Spinal Fusion
73145|NCT02603874|Wrong Level Surgery
73146|NCT02603848|Inguinal surgery
73147|NCT02603848|Hernia Repair
73148|NCT02603848|Orchidopexy
73149|NCT02603848|Hydrocele
73150|NCT02603848|Pediatric
73151|NCT02603848|Post-operative pain
73152|NCT02603848|Morphine sulfate
73153|NCT02603848|Ibuprofen
73154|NCT02603835|SSO2 Therapy
73155|NCT02603835|Acute myocardial infarction
73156|NCT02603835|Anterior myocardial infarction
73157|NCT02603835|SuperSaturated oxygen delivery
73158|NCT02603835|Left main coronary artery
73159|NCT02603835|Myocardial infarction
73160|NCT02603835|Heart attack
73161|NCT02603835|Percutaneous coronary intervention
73162|NCT02603835|Cardiac catheterization laboratory
73163|NCT02603835|PCI
73164|NCT02603835|Stent
73165|NCT02603835|Stenting
73166|NCT02603835|Stents
73167|NCT02603835|Angioplasty
73168|NCT02603835|LMCA
73169|NCT02603835|Delivery of supersaturated oxygen (SSO2) therapy for the treatment of anterior acute myocardial infarction
73170|NCT02603796|3-Dimensional
73171|NCT02603796|continuous positive airway pressure
73172|NCT02603796|nasal changes
73173|NCT02603757|Vitamin D
73174|NCT02603744|Premature ovarian failure adipose derived stromal cells intraovarian injection
73175|NCT02603718|Stroke
73176|NCT02603718|On-line EEG
73177|NCT02603718|BEI index
73178|NCT02603718|Attention
73179|NCT02603718|Rehabilitation
73180|NCT02603705|chronic pain
73181|NCT02603705|opioid
73182|NCT02603705|oxycodone
73183|NCT02603705|non cancer pain
73184|NCT02603705|moderate to severe
73185|NCT02603692|Newly diagnosed brain tumor
73186|NCT02603692|Progressive brain tumor
73187|NCT02603692|PROMIS
73188|NCT02603692|Quality of life
73189|NCT02603679|Cyclin-Dependent Kinase Inhibitor p16
73190|NCT02603666|cystic fibrosis
73191|NCT02603666|elastography
73192|NCT02603666|liver biopsy
73193|NCT02603614|Chronic Heart Failure
73194|NCT02603614|Renal Insufficiency
73195|NCT02603614|Natriuretic Peptides
73196|NCT02603614|Cenderitide
73197|NCT02603601|Randomized controlled trial
73198|NCT02603601|Mindfulness
73199|NCT02603601|Obesity
73200|NCT02603588|Acupuncture
73201|NCT02603588|Sphenopalatine ganglion
73202|NCT02603588|Nasal ventilation
73203|NCT02603588|Neuropeptides
73204|NCT02603575|Caspofungin
73205|NCT02603575|corticosteroids
73206|NCT02603575|Pneumocystis Pneumonia
73207|NCT02603575|Immunocompromised
73208|NCT02603575|Non-HIV
73209|NCT02603575|respiratory failure
73210|NCT02603562|FSHD
73211|NCT02603536|Text Messaging
73212|NCT02603536|Harm Reduction
73213|NCT02603523|accidental falls
73214|NCT02603523|older people
73215|NCT02603523|dance
73216|NCT02603523|randomized controlled trial
73217|NCT02603497|ASP015K
73218|NCT02603497|impaired renal function
73219|NCT02603497|Pharmacokinetics
73220|NCT02603471|HIV+
73221|NCT02603471|Alcohol dependence
73222|NCT02603471|Mobile Technology
73223|NCT02603458|Schizophrenia
73224|NCT02603458|Naurex
73225|NCT02603458|Intravenous Treatment
73226|NCT02603458|NRX-1074
73227|NCT02603445|BCL201
73228|NCT02603445|idelalisib
73229|NCT02603445|Follicular lymphoma
73230|NCT02603445|FL
73231|NCT02603445|mantle cell lymphoma
73232|NCT02603445|MCL
73233|NCT02603432|Bladder cancer
73234|NCT02603432|Urologic neoplasms
73235|NCT02603432|urothelial carcinoma
73236|NCT02603432|PD-L1
73237|NCT02603432|programmed cell death protein
73238|NCT02603432|maintenance treatment
73239|NCT02603419|classical Hodgkins Lymphoma (relapsed/refractory)
73240|NCT02603419|anti PD-L1
73241|NCT02603419|Phase 1
73242|NCT02603419|PK
73243|NCT02603419|Receptor occupancy
73244|NCT02603419|Immunophenotypic biomarkers
73245|NCT02603393|COPD, QVA149
73246|NCT02603380|Delirium
73247|NCT02603380|Feasibility study
73248|NCT02603380|software application
73249|NCT02603380|qualitative
73250|NCT02603328|Cerebral cavernous malformation
73251|NCT02603328|Statins
73252|NCT02603328|MRI
73253|NCT02603328|Permeability
73254|NCT02603328|Quantitative susceptibility mapping
73255|NCT02603302|rectal cancer
73256|NCT02603302|radiotherapy
73257|NCT02603302|escalated dose
73258|NCT02603302|interval
73259|NCT02603276|hypercholesterolemia
73260|NCT02603276|dietary supplements
73261|NCT02603276|red yeast rice
73262|NCT02603276|plant sterols
73263|NCT02603263|social norms
73264|NCT02603263|healthy eating
73265|NCT02603263|vegetables
73266|NCT02603263|field study
73267|NCT02603250|Anemia
73268|NCT02603250|Iron deficiency
73269|NCT02603250|noninvasive anemia screening
73270|NCT02603211|breast cancer
73271|NCT02603198|third molar
73272|NCT02603198|tooth extraction
73273|NCT02603198|impacted tooth
73274|NCT02603185|Phase 1, Healthy subjects
73275|NCT02603172|GSK3039294
73276|NCT02603172|GSK2315698
73277|NCT02603172|systemic amyloidosis
73278|NCT02603172|CPHPC
73279|NCT02603172|dose-escalation
73280|NCT02603159|Chemoradiotherapy
73281|NCT02603159|Esophageal Squamous Cancer
73282|NCT02603159|Capecitabine
73283|NCT02603146|RA prevention
73284|NCT02603146|hydroxychloroquine (HCQ)
73285|NCT02603146|anti-CCP
73286|NCT02603133|healthcare
73287|NCT02603133|burnout
73288|NCT02603133|resilience
73289|NCT02603133|fatigue
73290|NCT02603133|NICU
73291|NCT02603133|safety culture
73292|NCT02603133|quality of care
73293|NCT02603081|Meniere's
73294|NCT02603081|hearing loss
73295|NCT02603081|vertigo
73296|NCT02603081|tinnitus
73297|NCT02603081|ebselen
73298|NCT02603055|Safety
73299|NCT02603055|immunogenicity
73300|NCT02603055|Hepatitis E
73301|NCT02603029|skin rejuvenation
73302|NCT02603029|anti-ageing effects
73303|NCT02603029|minimal erythema dose
73304|NCT02603029|dermis structure
73305|NCT02603029|physiological skin condition
73306|NCT02603029|wrinkling
73307|NCT02603016|Clinical Nutrition
73308|NCT02603003|Circulating tumor cells(CTCs)
73309|NCT02603003|Traditional Chinese Medicine(TCM)
73310|NCT02603003|Myeloid-derived suppressor cells(MDSCs)
73311|NCT02602990|Cerebral
73312|NCT02602990|Arteriovenous
73313|NCT02602990|Malformation
73314|NCT02602990|Embolization
73315|NCT02602990|Endovascular
73316|NCT02602977|inflammation
73317|NCT02602977|remote ischemic preconditioning
73318|NCT02602938|aspirin
73319|NCT02602938|circulating tumor cells
73320|NCT02602938|metastatic breast cancer
73321|NCT02602938|metastatic colorectal cancer
73322|NCT02602899|PINS
73323|NCT02602899|Deep Brain Stimulator
73324|NCT02602899|Refractory Epilepsy
73325|NCT02602899|Anterior Thalamic Nucleus
73326|NCT02602860|SV2A
73327|NCT02602860|Levetiracetam
73328|NCT02602860|Brivaracetam
73329|NCT02602860|PET
73330|NCT02602847|Liver transplantation
73331|NCT02602847|HBV
73332|NCT02602847|cccDNA
73333|NCT02602834|exercise test
73334|NCT02602834|biological markers
73335|NCT02602808|acute pancreatitis
73336|NCT02602808|non-coding RNA
73337|NCT02602808|biological markers
73338|NCT02602808|receiver operating characteristic curve
73339|NCT02602795|Opiate Dependence
73340|NCT02602795|Sexually Transmitted Diseases
73341|NCT02602795|HIV
73342|NCT02602795|Extended release naltrexone
73343|NCT02602756|Choroid Melanoma
73344|NCT02602743|sedation
73345|NCT02602743|remifentanyl
73346|NCT02602743|pediatric patient
73347|NCT02602743|colonoscopy
73348|NCT02602730|Cigarette smoking
73349|NCT02602730|Smoking, Tobacco
73350|NCT02602730|postpartum
73351|NCT02602730|internet
73352|NCT02602730|interactive
73353|NCT02602730|coach
73354|NCT02602717|follicular origin
73355|NCT02602691|Heart transplantation
73356|NCT02602691|AlloMap® gene expression profiling test
73357|NCT02602691|Medico-economic study
73358|NCT02602678|Children.
73359|NCT02602678|prone position
73360|NCT02602678|acute viral bronchiolitis
73361|NCT02602678|syncytial virus
73362|NCT02602678|work of breathing
73363|NCT02602678|intrinsic PEEP
73364|NCT02602665|catheter placement
73365|NCT02602652|geometric mean titer
73366|NCT02602652|seroprotection
73367|NCT02602652|live attenuated chimeric JE vaccine
73368|NCT02602652|JE-CV
73369|NCT02602652|SA14-14-2 vaccine
73370|NCT02602626|Human Papillomavirus
73371|NCT02602626|HPV
73372|NCT02602626|Postpartum
73373|NCT02602587|acute myeloid leukemia
73374|NCT02602587|Dendrogenin A
73375|NCT02602587|5,6-cholesterol epoxide
73376|NCT02602587|6-oxo-cholestane-3beta
73377|NCT02602587|5alpha-diol
73378|NCT02602587|cholesterol epoxide hydrolase
73379|NCT02602587|oxysterols
73380|NCT02602574|Cholangiopancreatography, Endoscopic Retrograde
73381|NCT02602574|Pancreatitis
73382|NCT02602574|Heat-Shock Proteins
73383|NCT02602574|Pentraxin 3 protein
73384|NCT02602574|C-Reactive Protein
73385|NCT02602574|procalcitonin
73386|NCT02602574|Interleukin-1 beta
73387|NCT02602574|Leukocytes, Mononuclear
73388|NCT02602574|Killer Cells, Natural
73389|NCT02602574|natural-killer group 2, member D receptor
73390|NCT02602561|HMB
73391|NCT02602561|beta-hydroxy-beta-methylbutyrate
73392|NCT02602561|ACL
73393|NCT02602561|surgery
73394|NCT02602561|muscle mass
73395|NCT02602548|Propionibacterium acnes
73396|NCT02602548|shoulder surgery
73397|NCT02602548|infection
73398|NCT02602496|Diet
73399|NCT02602496|Whole grain
73400|NCT02602496|Fruits
73401|NCT02602496|Vegetables
73402|NCT02602496|Gut health
73403|NCT02602496|Anti-inflammatory
73404|NCT02602483|temporomandibular
73405|NCT02602483|joint
73406|NCT02602483|pain
73407|NCT02602483|ibuprofen
73408|NCT02602483|magnesium
73409|NCT02602483|vitamin C
73410|NCT02602457|Atrial Fibrillation
73411|NCT02602444|ticagrelor
73412|NCT02602444|STEMI
73413|NCT02602444|NSTEMI
73414|NCT02602444|pharmacokinetics
73415|NCT02602444|pharmacodynamics
73416|NCT02602431|laser
73417|NCT02602431|third molar
73418|NCT02602431|low laser
73419|NCT02602431|inflammatory response
73420|NCT02602418|HIV
73421|NCT02602418|working memory training
73422|NCT02602418|brain function
73423|NCT02602418|fMRI
73424|NCT02602405|Outcome Assessment (Health Care)
73425|NCT02602405|Return to work
73426|NCT02602405|Registries
73427|NCT02602405|Norway
73428|NCT02602392|Self management
73429|NCT02602392|Education
73430|NCT02602392|Children
73431|NCT02602392|Caregivers
73432|NCT02602392|Health Care Providers
73433|NCT02602379|Pain
73434|NCT02602379|Monitoring
73435|NCT02602379|Analgesia Nociception Index
73436|NCT02602379|NoL
73437|NCT02602379|Nociception Level
73438|NCT02602379|Remifentanil
73439|NCT02602366|HIV
73440|NCT02602366|DCE
73441|NCT02602366|MPT
73442|NCT02602366|Microbicide
73443|NCT02602327|radioembolization
73444|NCT02602327|Yttrium-90
73445|NCT02602327|90Y
73446|NCT02602327|Resin microspheres
73447|NCT02602327|Tas-102
73448|NCT02602327|Lonsurf
73449|NCT02602327|SIR-Sphere
73450|NCT02602314|Chronic myeloid leukemia
73451|NCT02602314|Nilotinib
73452|NCT02602314|Imatinib
73453|NCT02602301|oxytocin
73454|NCT02602223|Alveolar Ridge Augmentation
73455|NCT02602223|Tooth Socket
73456|NCT02602223|Guided Tissue Regeneration
73457|NCT02602223|Membranes
73458|NCT02602210|cirrhosis
73459|NCT02602210|liver
73460|NCT02602210|corticosteroids
73461|NCT02602210|hypotension
73462|NCT02602210|sepsis
73463|NCT02602210|cortisol
73464|NCT02602197|Paracetamol
73465|NCT02602197|Dexketoprofen
73466|NCT02602197|postoperative pain
73467|NCT02602197|septoplasty
73468|NCT02602184|skin regeneration
73469|NCT02602184|re-epithelialization
73470|NCT02602184|split thickness wounds
73471|NCT02602184|Abdominoplasty
73472|NCT02602158|breath test
73473|NCT02602158|lipid emulsions
73474|NCT02602158|MRI
73475|NCT02602158|gastric emptying
73476|NCT02602145|femoral
73477|NCT02602145|popliteal
73478|NCT02602145|stent
73479|NCT02602145|modeling
73480|NCT02602145|flexion
73481|NCT02602132|INDWELLING URINARY CATHETER
73482|NCT02602132|CLAMPING
73483|NCT02602132|REMOVAL
73484|NCT02602106|Aquatic activities
73485|NCT02602106|Aerobic exercise
73486|NCT02602106|Resistance exercise
73487|NCT02602106|Pregnancy
73488|NCT02602106|Maternal weight gain
73489|NCT02602106|birthweight
73490|NCT02602093|Lumbar Disk Herniation
73491|NCT02602093|Percutaneous Transforaminal Endoscopic Discectomy
73492|NCT02602093|Micro Discectomy
73493|NCT02602093|Minimal Invasive Spine Surgery
73494|NCT02602054|persistent ductus arteriosus
73495|NCT02602054|preterm infants
73496|NCT02602054|surgical treatment
73497|NCT02602054|pharmacological treatment
73498|NCT02602028|Familial Mediterranean Fever
73499|NCT02602028|Colchicine
73500|NCT02602002|Remifentanil, Pharmacodynamic Pain assessments, Intravenous, South Korea
73501|NCT02601976|PegInterferon alpha-2a
73502|NCT02601976|Ribavirin
73503|NCT02601976|Hepatitis C Virus
73504|NCT02601976|Sustained Virological Response
73505|NCT02601976|End of Treatment Response
73506|NCT02601976|Unipeg
73507|NCT02601976|Ribazole
73508|NCT02601924|Anesthesia
73509|NCT02601924|injection
73510|NCT02601924|pain
73511|NCT02601924|pressure massage
73512|NCT02601924|topical gel
73513|NCT02601911|Failure
73514|NCT02601911|Injection
73515|NCT02601911|Ketorolac
73516|NCT02601911|Premedication
73517|NCT02601885|Secondary progressive
73518|NCT02601885|Relapsing-remitting
73519|NCT02601885|Relapsing forms
73520|NCT02601885|Glatiramer acetate
73521|NCT02601833|Caries
73522|NCT02601833|Cavity
73523|NCT02601820|patient-reported outcomes
73524|NCT02601820|observational
73525|NCT02601820|HCV
73526|NCT02601820|Hepatitis
73527|NCT02601820|Hepatitis C
73528|NCT02601820|Chronic Liver Disease
73529|NCT02601820|Liver Disease
73530|NCT02601820|Liver
73531|NCT02601820|Infectious Disease
73532|NCT02601820|Hep C
73533|NCT02601820|HepC
73534|NCT02601820|PROs
73535|NCT02601807|Back
73536|NCT02601807|Pain
73537|NCT02601807|PSWT
73538|NCT02601807|ActiPatch
73539|NCT02601807|Pulsed shortwave therapy
73540|NCT02601794|Breast Cancer
73541|NCT02601794|mHealth
73542|NCT02601794|Mindfulness
73543|NCT02601794|Complementary Therapies
73544|NCT02601781|Bioresorbable Vascular Scaffold (BVS)
73545|NCT02601781|STEMI
73546|NCT02601781|Primary PCI
73547|NCT02601768|ASD II
73548|NCT02601768|transcatheter closure
73549|NCT02601768|percutaneous closure
73550|NCT02601768|3D TEE
73551|NCT02601768|balloon-sizing
73552|NCT02601742|zinc
73553|NCT02601742|Duration
73554|NCT02601729|Type 1 diabetes
73555|NCT02601729|real-time continuous glucose monitoring
73556|NCT02601729|observational study
73557|NCT02601729|insulin pump
73558|NCT02601729|Belgium
73559|NCT02601716|Plasmodium falciparum
73560|NCT02601716|PfSPZ Vaccine
73561|NCT02601716|Sporozoites
73562|NCT02601690|Rye Grass
73563|NCT02601690|Ragweed
73564|NCT02601690|Cat
73565|NCT02601690|House Dust Mite
73566|NCT02601677|Obsessive Compulsive Disorder
73567|NCT02601677|Deep Brain Stimulation
73568|NCT02601677|Nucleus accumbens
73569|NCT02601651|Totally Extraperitoneal Inguinal Hernioplasty
73570|NCT02601651|Lidocaine infusion
73571|NCT02601651|Postoperative opioid consumption
73572|NCT02601625|Tolerability
73573|NCT02601625|Anifrolumab
73574|NCT02601625|Subcutaneous injection
73575|NCT02601625|Intravenous infusion
73576|NCT02601599|Smoking Cessation
73577|NCT02601599|Tobacco Use Cessation
73578|NCT02601599|Motivational Interviewing
73579|NCT02601599|Students, Medical
73580|NCT02601599|Randomized Controlled Trial
73581|NCT02601560|Coronary Artery Disease
73582|NCT02601560|CAD
73583|NCT02601547|Positron-Emission Tomography
73584|NCT02601547|chemotherapy-induced brain damage
73585|NCT02601547|neuro-cognitive function alteration
73586|NCT02601534|sedentary behaviour
73587|NCT02601534|physical activity
73588|NCT02601508|deep NM block
73589|NCT02601508|Surgeon's satisfaction
73590|NCT02601508|bridion
73591|NCT02601482|Glycemic control
73592|NCT02601482|exercise
73593|NCT02601482|Interval Training
73594|NCT02601456|Amputation, Traumatic
73595|NCT02601456|Biomechanics
73596|NCT02601456|Asymmetry
73597|NCT02601456|Amputee Running
73598|NCT02601456|Prolonged Effort
73599|NCT02601417|Cholangitis
73600|NCT02601417|Bile culture
73601|NCT02601391|STEPPS-HI
73602|NCT02601391|personality disorder
73603|NCT02601391|evaluation
73604|NCT02601391|forensic
73605|NCT02601378|Uveal melanoma
73606|NCT02601378|Metastatic uveal melanoma
73607|NCT02601378|Phase I
73608|NCT02601378|LXS196
73609|NCT02601378|PKC inhibitor
73610|NCT02601378|dose escalation
73611|NCT02601339|spectroscopy, Near-Infrared
73612|NCT02601300|Ulcerative Colitis
73613|NCT02601300|GED-0301
73614|NCT02601300|Mongersen
73615|NCT02601300|Efficacy
73616|NCT02601300|Safety
73617|NCT02601261|pregnant
73618|NCT02601261|gestational ages
73619|NCT02601261|hospitalized
73620|NCT02601261|problem of pregnancy
73621|NCT02601248|safety, PK
73622|NCT02601235|rhinitis
73623|NCT02601222|chronic eczema
73624|NCT02601222|efficacy and safety
73625|NCT02601222|Runzao zhiyang capsule
73626|NCT02601196|Leiomyoma
73627|NCT02601196|Infertility
73628|NCT02601196|IVF
73629|NCT02601196|Ulipristal acetate
73630|NCT02601183|brain temperture，thrombolysis，early diagnosis
73631|NCT02601170|Platelet Rich Plasma
73632|NCT02601170|Hemophilia
73633|NCT02601170|Hemophilic arthropathy
73634|NCT02601157|stent
73635|NCT02601157|polymer
73636|NCT02601157|antiplatelet therapy
73637|NCT02601157|clopidogrel
73638|NCT02601144|DBS
73639|NCT02601144|VFS
73640|NCT02601144|FOG
73641|NCT02601131|platelet count
73642|NCT02601131|platelet transfusion
73643|NCT02601131|complement factors
73644|NCT02601131|endothelial markers
73645|NCT02601131|stem cell transplantation
73646|NCT02601105|gotu kola
73647|NCT02601105|centella asiatica
73648|NCT02601092|Mini Gastric Bypass
73649|NCT02601092|Roux-en-Y Gastric Bypass
73650|NCT02601092|RCT
73651|NCT02601079|Biopsy
73652|NCT02601079|Diagnostics
73653|NCT02601079|Genetic analysis
73654|NCT02601066|LMNA
73655|NCT02601066|Sudden Death
73656|NCT02601066|Neuromuscular
73657|NCT02601040|Safety
73658|NCT02601040|Immunogenicity
73659|NCT02601040|Vaccine
73660|NCT02601040|Hepatitis A
73661|NCT02601014|Hormone-Resistant Prostate Cancer
73662|NCT02601014|Prostate Carcinoma Metastatic in the Bone
73663|NCT02600988|Graft-Versus-Host-Disease
73664|NCT02600988|post-allogeneic transplant
73665|NCT02600988|haematopoietic progenitors
73666|NCT02600949|Pancreatic cancer
73667|NCT02600949|Colorectal Cancer
73668|NCT02600949|Pancreatic ductal adenocarcinoma
73669|NCT02600949|PDA
73670|NCT02600949|CRC
73671|NCT02600949|Personalized peptide vaccine
73672|NCT02600949|Phone call
73673|NCT02600949|Advanced/metastatic
73674|NCT02600936|venous outflow obstruction
73675|NCT02600936|peripheral venous disease
73676|NCT02600936|vein stent
73677|NCT02600936|Wallstent
73678|NCT02600936|registry
73679|NCT02600936|May Thurner
73680|NCT02600923|palbociclib, ibrance, breast cancer
73681|NCT02600910|Manual Wheelchair
73682|NCT02600910|Shoulder injury
73683|NCT02600910|Shoulder function
73684|NCT02600910|rotator cuff
73685|NCT02600910|Tendinopathy
73686|NCT02600910|Spinal cord injury
73687|NCT02600910|Shoulder pain
73688|NCT02600910|Shoulder impingement
73689|NCT02600871|Abscess
73690|NCT02600871|Antiseptic
73691|NCT02600871|Provodine
73692|NCT02600871|Povidone-Iodine
73693|NCT02600819|end stage renal disease (ESRD)
73694|NCT02600819|hemodialysis (HD)
73695|NCT02600819|open-label
73696|NCT02600819|HIV-1 Infection
73697|NCT02600806|Community-acquired pneumonia
73698|NCT02600806|Procalcitonin
73699|NCT02600806|Outpatients
73700|NCT02600806|Outcomes
73701|NCT02600806|Azithromycin
73702|NCT02600806|Fluoroquinolones
73703|NCT02600780|Febuxostat
73704|NCT02600780|Efficacy
73705|NCT02600780|Safety
73706|NCT02600780|Allopurinol
73707|NCT02600780|Hyperuricemia
73708|NCT02600780|Zurig
73709|NCT02600780|Getz Pharma
73710|NCT02600754|older adults, depressive symptoms, psychosocial treatment
73711|NCT02600741|Schizophrenia
73712|NCT02600741|Caregiver
73713|NCT02600741|Psycho-education and skills training
73714|NCT02600741|Paliperidone Palmitate
73715|NCT02600741|Oral Antipsychotic
73716|NCT02600728|Parkinson Disease
73717|NCT02600728|Gait
73718|NCT02600728|cues
73719|NCT02600728|memory
73720|NCT02600728|training
73721|NCT02600702|Home base exercise
73722|NCT02600689|Pulmonary rehab
73723|NCT02600689|Exergame
73724|NCT02600689|Home-based
73725|NCT02600637|stroke
73726|NCT02600637|depression
73727|NCT02600637|anxiety
73728|NCT02600637|mindfulness
73729|NCT02600637|meditation
73730|NCT02600572|balance, postural
73731|NCT02600572|postural equilibrium
73732|NCT02600572|mental speed
73733|NCT02600572|isometric exercise
73734|NCT02600572|eccentric exercise
73735|NCT02600559|Otitis media
73736|NCT02600559|Ear infection
73737|NCT02600559|Tympanostomy tubes
73738|NCT02600533|minority group recruitment
73739|NCT02600533|stages of implementation
73740|NCT02600533|clinical trials education
73741|NCT02600481|standard-pressure pneumoperitoneum
73742|NCT02600481|prolonged pneumoperitoneum
73743|NCT02600481|myocardial injuries
73744|NCT02600481|troponin T(TnT)
73745|NCT02600481|Trendelenburg position
73746|NCT02600481|chest CT scan
73747|NCT02600481|low-pressure pneumoperitoneum
73748|NCT02600481|robot-assisted surgery
73749|NCT02600442|Neoadjuvant Therapy
73750|NCT02600442|Chemotherapy
73751|NCT02600442|Positron-Emission Tomography
73752|NCT02600442|PET-CT
73753|NCT02600442|FDG
73754|NCT02600442|Fluorodeoxyglucose
73755|NCT02600442|Diagnosis
73756|NCT02600442|Prognosis
73757|NCT02600442|Pathological complete response
73758|NCT02600442|molecular biology
73759|NCT02600442|proliferation genes
73760|NCT02600429|Neurotrophic Keratopathy
73761|NCT02600429|NK
73762|NCT02600403|Visual Evoked Potentials
73763|NCT02600403|Optical Coherence Tomography
73764|NCT02600403|Visual Fields
73765|NCT02600390|Leg Ulcer
73766|NCT02600390|LU
73767|NCT02600390|SANGUINATE
73768|NCT02600390|QOL
73769|NCT02600390|SCD
73770|NCT02600390|Sickle Cell Disease
73771|NCT02600390|Sickle Cell
73772|NCT02600390|Anemia
73773|NCT02600390|Leg Wound
73774|NCT02600390|Leg
73775|NCT02600390|Skin Lesion
73776|NCT02600364|Aneurysm
73777|NCT02600364|intracerebral
73778|NCT02600364|stroke
73779|NCT02600364|p64
73780|NCT02600351|Hepatitis C Virus (HCV)
73781|NCT02600351|Ledipasvir/Sofosbuvir
73782|NCT02600351|Ribavirin
73783|NCT02600338|Systematic review and meta-analysis
73784|NCT02600338|Evidence-based medicine (EBM)
73785|NCT02600338|Evidence-based nutrition (EBN)
73786|NCT02600338|Clinical practice guidelines
73787|NCT02600338|Clinical trials
73788|NCT02600338|Legumes
73789|NCT02600338|Beans, peas, chickpeas, lentils, soy, peanuts, lupins
73790|NCT02600338|Cardiometabolic risk factors
73791|NCT02600338|Blood pressure
73792|NCT02600325|Acute Hepatitis C
73793|NCT02600325|Human Immunodeficiency virus
73794|NCT02600325|Grazoprevir
73795|NCT02600325|Elbasvir
73796|NCT02600286|Physical medicine and rehabilitation
73797|NCT02600286|Neurology
73798|NCT02600260|thrombophilia
73799|NCT02600260|thrombosis
73800|NCT02600260|Pregnancy, High-Risk
73801|NCT02600260|venous thrombosis
73802|NCT02600260|enoxaparin
73803|NCT02600260|risk assessment
73804|NCT02600260|deep vein thrombosis
73805|NCT02600260|pulmonary embolism
73806|NCT02600260|hospitalization
73807|NCT02600247|Total knee arthroplasty
73808|NCT02600247|Duloxetine
73809|NCT02600221|ACOS
73810|NCT02600195|Intensive Care, Neonatal
73811|NCT02600195|Nosocomial Infections
73812|NCT02600195|Quality Improvement
73813|NCT02600182|Thoracic surgery
73814|NCT02600182|Non-invasive ventilation
73815|NCT02600182|Physiotherapy
73816|NCT02600143|Melanoma
73817|NCT02600143|Colitis
73818|NCT02600143|Ipilimumab
73819|NCT02600143|Nivolumab
73820|NCT02600143|Pembrolizumab
73821|NCT02600091|Anxiety
73822|NCT02600091|Depression
73823|NCT02600091|Type 1 Diabetes
73824|NCT02600091|Mindfulness-based Cognitive Therapy
73825|NCT02600091|Glycaemic control
73826|NCT02600078|hypoxia
73827|NCT02600078|ataxia
73828|NCT02600013|incomplete motor SCI
73829|NCT02600013|robotic gait training
73830|NCT02600013|exoskeleton
73831|NCT02600013|rehabilitation tool
73832|NCT02600013|EKSO-GT
73833|NCT02599961|Glut 1 DS
73834|NCT02599935|Nutritional status
73835|NCT02599935|MNA
73836|NCT02599935|GSA
73837|NCT02599909|Liver Cancer
73838|NCT02599909|Hepatocellular Carcinoma
73839|NCT02599909|Liver Tumors
73840|NCT02599909|Liver Resection
73841|NCT02599896|Dose Escalation
73842|NCT02599896|HIV Prevention
73843|NCT02599896|Broadly HIV-1 Neutralizing Activity
73844|NCT02599896|Open-Label
73845|NCT02599896|Half-Life
73846|NCT02599883|Chronic Obstructive Pulmonary Disease
73847|NCT02599883|Diagnostic Imaging
73848|NCT02599883|Disease Management
73849|NCT02599883|Clinical Decision Support Systems
73850|NCT02599883|Cost-Utility Analysis
73851|NCT02599870|PGx
73852|NCT02599870|pharmacogenetic testing
73853|NCT02599870|IDgenetix
73854|NCT02599870|Pain Management
73855|NCT02599870|AltheaDx
73856|NCT02599870|Post-Operative Pain Management
73857|NCT02599844|acute kidney injury
73858|NCT02599831|Electrical pudendal nerve stimulation
73859|NCT02599831|Pelvic floor muscle training
73860|NCT02599831|Transanal electrical stimulation
73861|NCT02599831|Male Stress urinary incontinence
73862|NCT02599831|Comparative study
73863|NCT02599792|Safety and Pharmacokinetics
73864|NCT02599779|Renal cell cancer
73865|NCT02599779|SBRT
73866|NCT02599779|Pembrolizumab
73867|NCT02599766|animal assisted intervention, brain injury, rehabilitation
73868|NCT02599740|Blood glucose
73869|NCT02599727|balance, postural
73870|NCT02599727|postural equilibrium
73871|NCT02599727|heart rate
73872|NCT02599727|blood pressure
73873|NCT02599727|pulse oxygenation
73874|NCT02599727|mental speed
73875|NCT02599714|AZD2014, Palbociclib, Fulvestrant, Hormonal Therapy, Estrogen, Receptor, Positive, Locally-Advanced, Metastatic, Breast Cancer
73876|NCT02599701|Delta Sleep
73877|NCT02599701|Growth Hormone
73878|NCT02599701|IGF-1
73879|NCT02599675|Muscle
73880|NCT02599675|Vitamin D
73881|NCT02599675|Strength
73882|NCT02599675|Endurance
73883|NCT02599675|Muscle fiber
73884|NCT02599662|Cancer
73885|NCT02599662|Intraoperative Radiation Therapy - IORT
73886|NCT02599649|Myelodysplastic syndrome
73887|NCT02599649|MDS
73888|NCT02599649|Low or intermediate-1 MDS
73889|NCT02599649|High Risk MDS
73890|NCT02599649|Lirilumab
73891|NCT02599649|Nivolumab
73892|NCT02599649|BMS-936558
73893|NCT02599649|Opdivo
73894|NCT02599649|Azacitidine
73895|NCT02599649|5-azacytidine
73896|NCT02599649|5-aza
73897|NCT02599649|Vidaza
73898|NCT02599649|5-AZC
73899|NCT02599649|AZA-CR
73900|NCT02599649|Ladakamycin
73901|NCT02599649|NSC-102816
73902|NCT02599649|Azacytidine
73903|NCT02599623|Incarcerated
73904|NCT02599623|Anesthesia
73905|NCT02599623|Hernia
73906|NCT02599610|labor, vaginal examination, transperineal ultrasound, pain, anxiety
73907|NCT02599584|behaviour
73908|NCT02599558|EOE
73909|NCT02599532|Apixaban
73910|NCT02599532|Pharmacokinetics
73911|NCT02599532|Pharmacodynamics
73912|NCT02599506|breast cancer
73913|NCT02599506|fear of recurrence
73914|NCT02599506|longitudinal study
73915|NCT02599506|radiation therapy
73916|NCT02599506|emotional concerns
73917|NCT02599506|trajectory
73918|NCT02599506|psychological constructs
73919|NCT02599506|diary keeping
73920|NCT02599480|HFpEF
73921|NCT02599480|left ventricular hypertrophy
73922|NCT02599480|cardiac remodeling,
73923|NCT02599467|Nerve Pain
73924|NCT02599467|Electromyography
73925|NCT02599467|Median Nerve
73926|NCT02599467|Breast Neoplasms
73927|NCT02599415|psoriasis patients referred to receive TL01 NB-UVB therapy
73928|NCT02599389|in-stent restenosis; drug-coated balloons; Excimer Laser, cost effectiveness study, quality of life
73929|NCT02599350|Ventilation
73930|NCT02599350|Gas exchange
73931|NCT02599350|V/Q ratio
73932|NCT02599350|Requirement for mechanical ventilation
73933|NCT02599337|bioequivalence
73934|NCT02599311|pelvic organ prolapse
73935|NCT02599298|sleep
73936|NCT02599298|treatment
73937|NCT02599259|Stroke
73938|NCT02599259|Oral anticoagulants
73939|NCT02599259|NOAC
73940|NCT02599259|wireless monitoring
73941|NCT02599259|Warfarin
73942|NCT02599259|Xarelto
73943|NCT02599259|compliance
73944|NCT02599259|adherence
73945|NCT02599259|monitoring
73946|NCT02599259|directly observed therapy
73947|NCT02599259|DOT
73948|NCT02599259|mobile device
73949|NCT02599259|electronic monitoring
73950|NCT02599259|artificial intelligence
73951|NCT02599259|oral anticoagulation therapy
73952|NCT02599259|adherence monitoring methods
73953|NCT02599259|nonadherence
73954|NCT02599259|non-adherence
73955|NCT02599246|Home ventilator
73956|NCT02599246|FiO2
73957|NCT02599246|O2
73958|NCT02599246|NIV
73959|NCT02599246|COPD
73960|NCT02599233|pain trajectory
73961|NCT02599181|Perineural cathether
73962|NCT02599181|Catheter infection
73963|NCT02599168|dexmedetomidine
73964|NCT02599168|propofol
73965|NCT02599168|BIS
73966|NCT02599168|CLADS
73967|NCT02599155|crystalloid
73968|NCT02599155|colloid
73969|NCT02599155|children
73970|NCT02599155|infant
73971|NCT02599155|cardiac surgery
73972|NCT02599142|radiotherapy immobilisation
73973|NCT02599142|open-face shells
73974|NCT02599129|Alopecia areata
73975|NCT02599116|cytoreductive surgery
73976|NCT02599116|hyperthermic intraperitoneal chemotherapy
73977|NCT02599116|microbiome
73978|NCT02599090|Glioblastoma
73979|NCT02599090|Gliosarcoma
73980|NCT02599090|Brain Cancer
73981|NCT02599090|Sorafenib
73982|NCT02599090|Temozolomide
73983|NCT02599090|Radiation
73984|NCT02599090|Radiotherapy
73985|NCT02599090|XRT
73986|NCT02599077|oral contraceptives
73987|NCT02599077|endometrioma
73988|NCT02599077|dienogest
73989|NCT02599064|Age-related macular degeneration
73990|NCT02599064|RXI-109
73991|NCT02599064|NVAMD
73992|NCT02599064|Retinal scarring
73993|NCT02599064|Subretinal scarring
73994|NCT02599064|Retinal fibrosis
73995|NCT02599064|Subretinal fibrosis
73996|NCT02599064|Eye diseases
73997|NCT02599038|NAFLD
73998|NCT02599038|NASH
73999|NCT02599038|Serine
74000|NCT02599038|Glutathione
74001|NCT02599025|Cerebral palsy
74002|NCT02599025|passive cycling
74003|NCT02599025|autonomic control system
74004|NCT02598986|glycemic index, pita bread, phosphorus, potassium, magnesium
74005|NCT02598973|Parkinson Disease
74006|NCT02598973|exercise
74007|NCT02598947|posterior shoulder tightness
74008|NCT02598947|shoulder impingement syndrome
74009|NCT02598947|Glenohumeral joint
74010|NCT02598947|exercise
74011|NCT02598921|Assisted reproductive technology
74012|NCT02598882|Elderly
74013|NCT02598882|Videogame
74014|NCT02598882|energy expenditure
74015|NCT02598882|electromyography
74016|NCT02598882|rehabilitation
74017|NCT02598869|Triamcinolone acetonide
74018|NCT02598856|Emergency Treatment
74019|NCT02598856|Morphine Derivates
74020|NCT02598856|Heroin
74021|NCT02598856|Antidotes
74022|NCT02598856|Administration, Intravenous
74023|NCT02598856|Pharmacology
74024|NCT02598856|Naloxone
74025|NCT02598856|Healthy volunteers
74026|NCT02598856|Administration, intramuscular
74027|NCT02598856|Administration, intranasal
74028|NCT02598830|Cachexia
74029|NCT02598830|Vitamin D
74030|NCT02598830|Muscle
74031|NCT02598830|Strength training
74032|NCT02598804|Physical activity level
74033|NCT02598804|Knee osteoarthritis
74034|NCT02598804|Randomized controlled trials
74035|NCT02598804|Alternate month design study
74036|NCT02598804|Self-management
74037|NCT02598804|Self-care
74038|NCT02598804|Education and exercise in knee osteoarthritis
74039|NCT02598804|Education
74040|NCT02598804|Non pharmacological treatment
74041|NCT02598791|incretin hormones
74042|NCT02598791|GIP
74043|NCT02598791|GLP-1
74044|NCT02598765|Glaucoma
74045|NCT02598765|Trabeculectomy
74046|NCT02598765|Eye Disease
74047|NCT02598765|Intraocular Pressure
74048|NCT02598765|Visual Acuity
74049|NCT02598752|functional performance testing
74050|NCT02598752|exercise fitness testing
74051|NCT02598752|15-274
74052|NCT02598739|Physical exercise
74053|NCT02598739|Psoriatic arthritis
74054|NCT02598739|Quality of life
74055|NCT02598700|total hip arthroplasty
74056|NCT02598700|imaging
74057|NCT02598700|arthritis
74058|NCT02598700|surgical technique
74059|NCT02598674|acute kidney injury
74060|NCT02598661|Myelodysplastic Syndromes
74061|NCT02598661|Imetelstat
74062|NCT02598648|FXR
74063|NCT02598648|RIPK3
74064|NCT02598648|Neonates
74065|NCT02598648|Acute Respiratory Distress Syndrome
74066|NCT02598648|Acute Lung Injury
74067|NCT02598635|Cholecalciferol
74068|NCT02598635|peritoneal dialysis
74069|NCT02598635|FGF23
74070|NCT02598635|Calcium
74071|NCT02598635|Phosphorus
74072|NCT02598609|Adverse event
74194|NCT02597751|Neuroimaging
74073|NCT02598609|Neonatal Intensive Care Unit
74074|NCT02598609|Catheter-related Bloodstream Infection (CRBSI) nos
74075|NCT02598609|Extravasation injury
74076|NCT02598609|Medication error
74077|NCT02598609|Central venous catheter complication
74078|NCT02598609|Unprogrammed extubation
74079|NCT02598596|Refractory gout
74080|NCT02598596|Chronic gout
74081|NCT02598583|Paroxysmal Nocturnal Hemoglobinuria
74082|NCT02598583|PNH
74083|NCT02598583|complement inhibitor
74084|NCT02598570|Relapsed Lymphoma
74085|NCT02598570|Phosphoinositide 3-kinase (PI3K) Inhibitor
74086|NCT02598570|Duvelisib
74087|NCT02598570|Japanese
74088|NCT02598570|Refractory Lymphoma
74089|NCT02598518|Integrating Combined Therapies
74090|NCT02598518|Alcohol Use Disorder
74091|NCT02598518|Mental Health Disorder
74092|NCT02598492|Mechanical Ventilator
74093|NCT02598479|Cancer
74094|NCT02598479|Insulin Potentiation Low Dose Chemotherapy
74095|NCT02598479|IPT
74096|NCT02598479|IPTLD
74097|NCT02598479|Nutrition therapy
74098|NCT02598427|Breast Cancer
74099|NCT02598427|HER2 Positive
74100|NCT02598427|HER2+
74101|NCT02598427|Brain Metastases
74102|NCT02598427|Metastatic Breast Cancer
74103|NCT02598427|Intrathecal Treatment
74104|NCT02598427|Lumbar Puncture
74105|NCT02598427|Pertuzumab
74106|NCT02598427|Trastuzumab
74107|NCT02598427|Advanced Breast Cancer
74108|NCT02598427|Duke University
74109|NCT02598414|Colorectal Disease
74110|NCT02598414|Robotic Surgery
74111|NCT02598414|Indocyanine Green Fluorescence Imaging
74112|NCT02598414|Anastomotic Leak
74113|NCT02598414|Short-term Outcomes
74114|NCT02598388|Healthy
74115|NCT02598388|Vaccine
74116|NCT02598388|Ebola viruses
74117|NCT02598388|Ebola virus disease (EVD)
74118|NCT02598388|Filoviruses
74119|NCT02598388|Hemorrhagic fever
74120|NCT02598388|Monovalent vaccine
74121|NCT02598388|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
74122|NCT02598388|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
74123|NCT02598388|Safety
74124|NCT02598388|Immunogenicity
74125|NCT02598375|Early reached target enteral nutrition in PICU feeding intolerance IFABP
74126|NCT02598362|ciprofloxacin
74127|NCT02598362|pharmacokinetics
74128|NCT02598362|excretion
74129|NCT02598362|clearance
74130|NCT02598362|infant
74131|NCT02598362|children
74132|NCT02598362|adolescent
74133|NCT02598349|Unresectable
74134|NCT02598349|Borderline resectable
74135|NCT02598336|Structured Light Plethysmography
74136|NCT02598336|Spirometry
74137|NCT02598336|Pneumotachograph
74138|NCT02598297|Ruxolitinib
74139|NCT02598297|INC424
74140|NCT02598297|early myelofibrosis
74141|NCT02598297|High molecular risk mutations
74142|NCT02598297|HMR
74143|NCT02598284|Preventive measures
74144|NCT02598284|Quality Improvement
74145|NCT02598271|Acute Kidney Injury
74146|NCT02598271|Cardiac Surgery
74147|NCT02598258|Sauna
74148|NCT02598258|Cold water bath
74149|NCT02598245|urinary incontinence, CESA, VASA, TOT, TVT
74150|NCT02598219|Sentinel node
74151|NCT02598206|food effect
74152|NCT02598206|healthy volunteers
74153|NCT02598206|pharmacokinetics
74154|NCT02598206|CCR2i
74155|NCT02598141|Protheses, nails, screws or plates
74156|NCT02598115|collaborative pharmaceutical care
74157|NCT02598089|Seasonal Influenza
74158|NCT02598089|Trivalent Vaccine
74159|NCT02598089|Inactivated Vaccine
74160|NCT02598050|postoperative health outcomes
74161|NCT02598050|older surgical patients
74162|NCT02598037|Obesity
74163|NCT02598037|Polymorphism
74164|NCT02598037|Hormones
74165|NCT02597985|Frailty
74166|NCT02597959|ergonomic risk factors
74167|NCT02597959|allied health professionals
74168|NCT02597959|surgical care
74169|NCT02597881|natural history
74170|NCT02597868|therapy
74171|NCT02597868|Capecitabine
74172|NCT02597868|breast cancer
74173|NCT02597842|Postoperative nausea and vomiting
74174|NCT02597842|TEAS
74175|NCT02597829|Inflammatory Bowel Disease
74176|NCT02597829|Mucosal Healing
74177|NCT02597829|Certolizumab pegol
74178|NCT02597803|Dry Eye Syndrome
74179|NCT02597803|Dry Eye
74180|NCT02597803|DES
74181|NCT02597790|endothelial function
74182|NCT02597790|cardiovascular risk
74183|NCT02597790|HIV
74184|NCT02597790|Hepatitis C
74185|NCT02597790|metabolic disease
74186|NCT02597790|inflammation
74187|NCT02597764|Diaphragmatic breathing (DB)
74188|NCT02597764|Bladder and bowel disorders (BBD)
74189|NCT02597764|Autonomic nervous system (ANS)
74190|NCT02597764|Heart rate variability (HRV)
74191|NCT02597764|Deep breathing
74192|NCT02597764|Randomized controlled trial (RCT)
74193|NCT02597751|DCD
74195|NCT02597751|Rehabilitation
74196|NCT02597725|Urodynamics
74197|NCT02597725|Late effects
74198|NCT02597725|Urinary Incontinence
74199|NCT02597712|acid reflux
74200|NCT02597712|intragastric pH
74201|NCT02597712|gastrin
74202|NCT02597712|hypergastrinemia
74203|NCT02597699|Termination of pregnancy
74204|NCT02597699|Feticide
74205|NCT02597699|Fetal pain
74206|NCT02597699|Remifentanil Ultiva®
74207|NCT02597699|Fetal asystole
74208|NCT02597699|Fetopathologic analysis
74209|NCT02597660|patellar tendinopathy
74210|NCT02597660|somatropin
74211|NCT02597660|jumper's knee
74212|NCT02597647|immunology
74213|NCT02597647|Microbiota
74214|NCT02597582|LigaSure
74215|NCT02597582|Neck dissection
74216|NCT02597582|Operative duration
74217|NCT02597582|Postoperative drainage
74218|NCT02597582|Postoperative pain
74219|NCT02597569|stroke
74220|NCT02597569|Cognitive Orientation to daily Occupational Performance
74221|NCT02597569|health services accessibility
74222|NCT02597569|cognitive impairment
74223|NCT02597569|rehabilitation
74224|NCT02597569|integrated knowledge translation
74225|NCT02597569|interrupted time series
74226|NCT02597569|The CO-OP Approach
74227|NCT02597556|Albendazole
74228|NCT02597556|Ancylostoma duodenale
74229|NCT02597556|Ascariasis lumbricoides
74230|NCT02597556|Coinfection
74231|NCT02597556|Diarrhea
74232|NCT02597556|Helminths
74233|NCT02597556|Necator americanus
74234|NCT02597556|Microbiota
74235|NCT02597556|Trichuris trichiura
74236|NCT02597543|heart transplantation
74237|NCT02597543|cardiac MRI
74238|NCT02597543|graft rejection
74239|NCT02597543|nonspecific allograft dysfunction
74240|NCT02597543|allograft vasculopathy
74241|NCT02597530|TEAS
74242|NCT02597530|anesthesia
74243|NCT02597517|gastritis
74244|NCT02597517|chromoendoscopy
74245|NCT02597517|magnification
74246|NCT02597517|Helicobacter pylori
74247|NCT02597517|Atrophic gastritis
74248|NCT02597491|Smoking,
74249|NCT02597491|Smoking cessation
74250|NCT02597491|Sequential, multiple assignment, randomized trials (SMART)
74251|NCT02597491|Lung cancer screening
74252|NCT02597478|Advanced Cancers
74253|NCT02597478|Fentanyl Sublingual Spray
74254|NCT02597478|Fentanyl SL Spray
74255|NCT02597478|FSS
74256|NCT02597478|Questionnaires
74257|NCT02597478|Surveys
74258|NCT02597478|Mental Abilities Test
74259|NCT02597478|Phone Call
74260|NCT02597478|Shuttle Walk Test
74261|NCT02597452|breast lump
74262|NCT02597452|breast exam
74263|NCT02597452|breast cancer screening
74264|NCT02597452|breast lump detection
74265|NCT02597439|Ultra-high risk
74266|NCT02597439|UHR
74267|NCT02597439|psychosis
74268|NCT02597426|Nasopharyngeal Carcinoma
74269|NCT02597426|Intensity-Modulated Radiotherapy
74270|NCT02597426|Post treatment
74271|NCT02597374|Electroencephalography
74272|NCT02597374|mu rhythm
74273|NCT02597374|Sensorimotor Cortex
74274|NCT02597374|Unilateral Cerebral Palsy
74275|NCT02597374|Child
74276|NCT02597361|Ehlers-Danlos syndrome, vascular type
74277|NCT02597361|Type 2 Angiotensin Receptor Blockers
74278|NCT02597348|Liver
74279|NCT02597348|Metastasis
74280|NCT02597348|Colorectal cancer
74281|NCT02597348|Liver transplantation
74282|NCT02597335|Glioma
74283|NCT02597335|IDH1/IDH2 mutation
74284|NCT02597335|Spectroscopy MRI
74285|NCT02597335|D-2-hydroxyglutarate
74286|NCT02597335|Free circulating DNA
74287|NCT02597322|Axitinib
74288|NCT02597322|T2a Renal tumor
74289|NCT02597322|organ confined tumors
74290|NCT02597322|nephron sparing surgery
74291|NCT02597322|nephron sparing procedure
74292|NCT02597322|radical nephrectomy
74293|NCT02597283|Bifurcation lesions
74294|NCT02597283|Percutaneous coronary intervention
74295|NCT02597283|Randomized controlled trial
74296|NCT02597270|Hepatitis C virus
74297|NCT02597257|Lidocaine infusion therapy
74298|NCT02597244|Lumbar foraminal stenosis
74299|NCT02597231|Delirium
74300|NCT02597231|Melatonin
74301|NCT02597218|Hepatectomy
74302|NCT02597218|Prophylaxis
74303|NCT02597205|Medical adherence
74304|NCT02597205|Lifestyle modification
74305|NCT02597205|Mobile Health
74306|NCT02597205|Secondary Prevention
74307|NCT02597192|gingivitis
74308|NCT02597192|gingival inflammation
74309|NCT02597192|probiotics
74310|NCT02597192|Bacillus
74311|NCT02597075|Colorectal Cancer
74312|NCT02597075|Metastatic Colorectal Cancer
74313|NCT02597075|Physical Activity
74314|NCT02597075|Quality of life
74315|NCT02597036|Advanced, Angiopoietin
74316|NCT02596997|Adenovirus Brincidofovir
74317|NCT02596984|Intensive Care Unit
74318|NCT02596984|Shock
74319|NCT02596984|Antifungal agent
74320|NCT02596984|Pharmacokinetics
74321|NCT02596984|Sepsis
74322|NCT02596932|Intrapartum
74323|NCT02596893|Crohn's Disease
74324|NCT02596893|GED-0301
74325|NCT02596893|Mongersen
74326|NCT02596893|IBD
74327|NCT02596893|Safety
74328|NCT02596893|Efficacy
74329|NCT02596880|Hepatitis C
74330|NCT02596880|Cirrhosis
74331|NCT02596880|Sofosbuvir
74332|NCT02596880|Daclatasvir
74333|NCT02596880|Ribavirin
74334|NCT02596867|B adrenergic pathway
74335|NCT02596867|B Blocker
74336|NCT02596841|Lung diffusing capacity
74337|NCT02596841|Idiopathic Interstitial Pneumonias
74338|NCT02596828|molecular targeted therapy
74339|NCT02596828|protein kinase inhibitor
74340|NCT02596828|mTOR Inhibitor
74341|NCT02596828|cytostatic topoisomerase-I-inhibitor
74342|NCT02596828|temozolomide
74343|NCT02596828|irinotecan
74344|NCT02596828|dasatinib
74345|NCT02596828|rapamycin
74346|NCT02596802|Fetoscopic Endoluminal Tracheal Occlusion
74347|NCT02596802|Congenital Diaphragmatic Hernia
74348|NCT02596763|Off-label prescription
74349|NCT02596763|Alcoholism
74350|NCT02596763|Pharmacovigilance
74351|NCT02596763|Pharmacoepidemiology
74352|NCT02596763|Baclofen
74353|NCT02596737|health
74354|NCT02596737|work
74355|NCT02596737|lifestyle
74356|NCT02596737|behavior
74357|NCT02596737|management
74358|NCT02596737|stress
74359|NCT02596737|physical activity
74360|NCT02596737|nutrition
74361|NCT02596737|mortality
74362|NCT02596737|morbidity
74363|NCT02596737|public health
74364|NCT02596724|Breast Cancer
74365|NCT02596724|Neoadjuvant therapy for breast cancer
74366|NCT02596711|Cancer Prevention
74367|NCT02596711|Tobacco Use Cessation
74368|NCT02596711|Nicotine Patch
74369|NCT02596711|NRT
74370|NCT02596711|Questionnaires
74371|NCT02596711|Surveys
74372|NCT02596711|Carbon Monoxide Test
74373|NCT02596711|CO
74374|NCT02596711|Health Education
74375|NCT02596711|Handouts
74376|NCT02596711|Pamphlets
74377|NCT02596711|Counseling sessions
74378|NCT02596698|Mood Disorder
74379|NCT02596672|physical activity
74380|NCT02596672|older adults
74381|NCT02596672|retirement homes
74382|NCT02596672|walking
74383|NCT02596672|feasibility study
74384|NCT02596659|lateral epicondylosis
74385|NCT02596659|lateral epicondylitis
74386|NCT02596659|shockwave
74387|NCT02596659|sonoelastography
74388|NCT02596659|tennis elbow
74389|NCT02596659|pain intensity
74390|NCT02596659|grip strength
74391|NCT02596659|upper limb function
74392|NCT02596659|stiffness of common extensor tendon
74393|NCT02596620|Helicobacter pylori
74394|NCT02596620|Proton pump inhibitor
74395|NCT02596620|Eradication
74396|NCT02596607|ischemic stroke, acute phase, thrombolysis, management times
74397|NCT02596594|IUGR
74398|NCT02596594|severe IUGR
74399|NCT02596594|brain sparing
74400|NCT02596594|fetal nutrition
74401|NCT02596594|Prolongation
74402|NCT02596594|pregnancy
74403|NCT02596594|neonatal outcome
74404|NCT02596581|periodontitis
74405|NCT02596581|diabetes mellitus
74406|NCT02596581|chemerin
74407|NCT02596581|interleukin-6
74408|NCT02596503|young adults
74409|NCT02596503|adolescents
74410|NCT02596490|Non-Small Cell Lung Cancer
74411|NCT02596490|NSCLC
74412|NCT02596490|Couples-based meditation program
74413|NCT02596490|Couples-based cancer-related discussion program
74414|NCT02596490|Questionnaires
74415|NCT02596490|Surveys
74416|NCT02596490|Metastatic lung cancer
74417|NCT02596490|Quality of life
74418|NCT02596490|QOL
74419|NCT02596477|Heart failure
74420|NCT02596412|children
74421|NCT02596412|botulinum toxin
74422|NCT02596412|augmented reality
74423|NCT02596412|Pain
74424|NCT02596399|Healthy volunteers
74425|NCT02596399|DSTA4637S
74426|NCT02596360|Antinociception
74427|NCT02596360|Freeze-induced hyperalgesia model
74428|NCT02596360|Dextromethorphan
74429|NCT02596360|NMDA-receptors
74430|NCT02596360|Pharmacogenetic
74431|NCT02596360|CYP3A4 gene
74432|NCT02596360|MDR1 gene
74433|NCT02596334|HIV-1 infected patient
74434|NCT02596334|monotherapy
74435|NCT02596334|dolutegravir
74436|NCT02596321|House Dust Mite
74437|NCT02596308|Plague vaccine
74438|NCT02596308|Immunogenicity
74439|NCT02596308|Safety
74440|NCT02596282|neonatal male circumcision
74441|NCT02596282|Clinical officers vs Nurse midwives
74442|NCT02596282|Rakai, Uganda
74443|NCT02596282|acceptability and safety of neonatal male circumcision
74444|NCT02596243|CIN2, CIN2/3, CIN3
74445|NCT02596243|Cervical Intraepithelial Neoplasia
74446|NCT02596243|High-Risk HPV
74447|NCT02596243|HPV infection
74448|NCT02596243|precancer Diseases
74449|NCT02596243|Double Blind
74450|NCT02596243|Safety/Efficacy
74451|NCT02596217|ABBV-066
74452|NCT02596217|BI 655066
74453|NCT02596217|risankizumab
74454|NCT02596165|validation
74455|NCT02596165|pulse wave analysis
74456|NCT02596165|blood pressure monitoring
74457|NCT02596152|balance
74458|NCT02596152|strength
74459|NCT02596152|barriers towards exercise
74460|NCT02596152|quality of life
74461|NCT02596152|body dissatisfaction
74462|NCT02596152|executive functions
74463|NCT02596152|eating behavior
74464|NCT02596152|fitness
74465|NCT02596126|Polypill
74466|NCT02596126|Prevention of Secondary Cardiovascular Disease
74467|NCT02596126|Cardiovascular Disease
74468|NCT02596126|Myocardial Infarction
74469|NCT02596126|Cardiovascular Combination Polypill AAR
74470|NCT02596126|Cardiovascular Disease in the Elderly
74471|NCT02596126|Adherence
74472|NCT02596126|SECURE
74473|NCT02596126|Elderly
74474|NCT02596126|Secondary Cardiovascular Disease
74475|NCT02596126|Secondary Cardiovascular Prevention
74476|NCT02596126|Randomized Cardiovascular Trial
74477|NCT02596126|Randomized Trial
74478|NCT02596126|Cardiovascular Polypill
74479|NCT02596113|colorectal cancer
74480|NCT02596113|genes involved in carcinogenesis of the colon
74481|NCT02596113|screening colorectal cancer
74482|NCT02596100|Bioequivalence
74483|NCT02596009|COPD
74484|NCT02595983|FAP
74485|NCT02595983|Familial Amyloidotic Polyneuropathy
74486|NCT02595983|ATTR Amyloidosis
74487|NCT02595983|Orthotopic Liver Transplant
74488|NCT02595983|RNAi therapeutic
74489|NCT02595970|Psoriasis
74490|NCT02595970|Secukinumab
74491|NCT02595970|Simplified Psoriasis Index
74492|NCT02595970|CAIN457A
74493|NCT02595970|AIN457AFR01
74494|NCT02595970|AIN457A
74495|NCT02595957|Exome Sequencing
74496|NCT02595957|Incidental or Secondary Findings
74497|NCT02595853|Upper GastroIntestinal bleeding, endoscopy, Hemospray
74498|NCT02595827|Pediatrics
74499|NCT02595827|Epidemiology
74500|NCT02595827|Fever
74501|NCT02595827|Democratic Republic of the Congo
74502|NCT02595827|Randomized Controlled Trial
74503|NCT02595814|Registry
74504|NCT02595814|Heart failure
74505|NCT02595814|Hospitalized
74506|NCT02595814|Global
74507|NCT02595814|Morbidity
74508|NCT02595814|Mortality
74509|NCT02595814|Quality of life
74510|NCT02595814|AHF
74511|NCT02595775|endoscopy measures
74512|NCT02595775|audit and feedback
74513|NCT02595775|quality improvement
74514|NCT02595775|randomized controlled trial
74515|NCT02595775|Colonoscopy
74516|NCT02595710|Cryptogenic Chronic Hepatitis
74517|NCT02595710|Bartonellosis
74518|NCT02595684|Obesity
74519|NCT02595684|Tadalfil
74520|NCT02595684|Insulin secretion
74521|NCT02595684|Insulin sensitivity
74522|NCT02595671|Digital coaching
74523|NCT02595671|Sustainable weight loss
74524|NCT02595671|Self-determination theory
74525|NCT02595671|Obesity
74526|NCT02595671|Overweight
74527|NCT02595671|Diet
74528|NCT02595671|Physical activity
74529|NCT02595645|colorectal adenoma
74530|NCT02595645|colorectal cancer
74531|NCT02595645|next generation sequencing
74532|NCT02595645|liquid biopsy
74533|NCT02595645|screening colonoscopy
74534|NCT02595645|surveillance strategies
74535|NCT02595619|AKI
74536|NCT02595619|Extracorporeal Carbon Dioxide Removal
74537|NCT02595619|Renal Replacement Therapy
74538|NCT02595619|Mechanical Ventilation
74539|NCT02595606|dry eye syndromes
74540|NCT02595606|diabetes mellitus
74541|NCT02595593|Trauma
74542|NCT02595593|Rib Plate
74543|NCT02595593|Rib Fixation
74544|NCT02595580|Blood Glucose Self-Monitoring
74545|NCT02595567|Liver disease
74546|NCT02595567|Pleural effusion
74547|NCT02595554|Cervical cancer, Stage IIB, Neoadjuvant chemotherapy
74548|NCT02595541|pediatric
74549|NCT02595541|cardiac
74550|NCT02595541|sildenfil
74551|NCT02595541|milrinone
74552|NCT02595541|pulmonary hypertension
74553|NCT02595489|Leukodystrophy
74554|NCT02595489|ABCD1
74555|NCT02595489|Demyelination
74556|NCT02595489|Inflammation
74557|NCT02595489|ALD
74558|NCT02595489|Vitamin D
74559|NCT02595489|Oxidative Stress
74560|NCT02595489|X- linked
74561|NCT02595489|Adrenoleukodystrophy
74562|NCT02595476|analgesia
74563|NCT02595476|pupillometry
74564|NCT02595476|general anesthesia
74565|NCT02595450|Non-small cell lung cancer
74566|NCT02595437|dialysis
74567|NCT02595437|pediatric
74568|NCT02595437|chronic kidney disease
74569|NCT02595411|Children
74570|NCT02595411|Rehabilitation
74571|NCT02595411|Upper Limb
74572|NCT02595411|Assessments
74573|NCT02595411|Outcome Measures
74574|NCT02595398|Uveitis
74575|NCT02595398|UME
74576|NCT02595398|Posterior Uveitis
74577|NCT02595398|Anterior Uveitis
74578|NCT02595398|Intermediate Uveitis
74579|NCT02595398|Panuveitis
74580|NCT02595398|Non-infectious Uveitis
74581|NCT02595398|Triamcinolone
74582|NCT02595398|Choroid
74583|NCT02595398|Choroidal Injection
74584|NCT02595398|Suprachoroidal
74585|NCT02595398|Microneedle
74586|NCT02595398|Microinjection
74587|NCT02595359|endophthalmitis
74588|NCT02595359|antibiotic therapy
74589|NCT02595359|cataract surgery
74590|NCT02595359|prevention
74591|NCT02595333|repeat cesarean section
74592|NCT02595333|pain
74593|NCT02595320|breast, gastrointestinal,capecitabine, cancer, metastatic
74594|NCT02595307|Risk Recall
74595|NCT02595307|Pamphlet
74596|NCT02595307|Brochure
74597|NCT02595307|Patient satisfaction
74598|NCT02595307|Informed Consent
74599|NCT02595281|Ovarian Carcinoma
74600|NCT02595281|neoadjuvant
74601|NCT02595281|ROMA
74602|NCT02595281|Ca125
74603|NCT02595281|HE4
74604|NCT02595281|biomarker
74605|NCT02595268|Healthy
74606|NCT02595268|Pitavastatin
74607|NCT02595268|JNJ-63623872
74608|NCT02595255|chemotherapy/GnRH analogues/lymphoma/children/fertility
74609|NCT02595203|Bioavailability
74610|NCT02595190|Sacral perineurial cysts(Tarlov Cysts)
74611|NCT02595190|Resting state functional magnetic resonance imaging (rfMRI)
74612|NCT02595190|VAS
74613|NCT02595190|Medicine conservative treatment
74614|NCT02595190|Surgical treatment
74615|NCT02595177|multifocal IOL
74616|NCT02595177|monovision
74617|NCT02595177|hybrid monovision
74618|NCT02595177|spectacles independence
74619|NCT02595151|Probe-based confocal laser endomicroscopy
74620|NCT02595151|chronic atrophic antral gastritis
74621|NCT02595151|microcirculatory dynamics
74622|NCT02595138|zoledronic acid
74623|NCT02595138|triple-negative breast cancer
74624|NCT02595138|adjuvant treatment
74625|NCT02595125|intrauterine device
74626|NCT02595125|contraceptive method
74627|NCT02595125|direct technique
74628|NCT02595125|torpedo technique
74629|NCT02595125|verbal numeric scale
74630|NCT02595112|staphylococcal infections
74631|NCT02595112|nasal carriage
74632|NCT02595112|nasal cavity
74633|NCT02595112|Staphylococcus aureus
74634|NCT02595060|acute lung injury, molgramostim, GM-CSF, pneumonia, barrier restoration
74635|NCT02595047|Self-regeneration, in vivo tissue prefabrication,
74636|NCT02595021|Total or subtotal colectomy
74637|NCT02595021|Ovarian cancer
74638|NCT02595021|Complications
74639|NCT02595021|One-year disease-free survival
74640|NCT02595021|Stage IIIc
74641|NCT02595021|Stage IV
74642|NCT02594982|Delirium
74643|NCT02594982|intensive care nursing
74644|NCT02594982|Acute acquired brain injury
74645|NCT02594982|neurointensive care
74646|NCT02594982|Intensive care delirium screening checklist
74647|NCT02594982|Confusion Assessment Method for the ICU
74648|NCT02594969|atopic dermatitis
74649|NCT02594956|nasogastric decompression
74650|NCT02594943|Diagnostics
74651|NCT02594943|Biopsy
74652|NCT02594943|Diffuse gastric cancer
74653|NCT02594930|synovial biopsy
74654|NCT02594930|knee arthroplasty
74655|NCT02594930|infection
74656|NCT02594904|G6PD Deficiency
74657|NCT02594904|Neonatal Hyperbilirubinemia
74658|NCT02594904|Yinzhihuang Oral Liquid
74659|NCT02594904|Indirect Bilirubin
74660|NCT02594891|cholangitis
74661|NCT02594891|endoscopic retrograde cholangiopancreatography
74662|NCT02594891|complication
74663|NCT02594878|Chronic non-bacterial osteomyelitis
74664|NCT02594878|Chronic recurrent multifocal osteomyelitis
74665|NCT02594878|Non- bacterial osteomyelitis
74666|NCT02594878|SAPHO syndrome
74667|NCT02594878|Whole body MRI
74668|NCT02594878|Pamidronate
74669|NCT02594878|Inflammatory bone disease
74670|NCT02594878|Autoinflammatory disease
74671|NCT02594865|Enteral Nutrition
74672|NCT02594865|Continuous Glucose Monitoring
74673|NCT02594839|interstitial lung disease
74674|NCT02594839|idiopathic interstitial pneumonia
74675|NCT02594839|idiopathic pulmonary fibrosis
74676|NCT02594839|stem cells
74677|NCT02594800|Atherosclerotic Intracranial Arterial Stenosis
74678|NCT02594800|Intensive Rosuvastatin Therapy
74679|NCT02594800|Computed Tomography Perfusion (CTP)
74680|NCT02594735|Juvenile dermatomyositis
74681|NCT02594735|inflammatory myopathies
74682|NCT02594735|Orencia
74683|NCT02594735|Abatacept
74684|NCT02594722|COPD
74685|NCT02594722|Functional Electrical Stimulation Cycling
74686|NCT02594722|Pulmonary Rehabilitation
74687|NCT02594696|Major depression and Cancer
74688|NCT02594696|Schizophrenia and Cancer
74689|NCT02594696|Bipolar disorder and Cancer
74690|NCT02594696|Lung Cancer
74691|NCT02594696|Breast Cancer
74692|NCT02594696|Head and Neck cancer
74693|NCT02594696|GI cancer
74694|NCT02594696|Schizophrenia
74695|NCT02594696|Bipolar disorder
74696|NCT02594670|acupoints
74697|NCT02594670|insomnia
74698|NCT02594670|acupuncture
74699|NCT02594670|randomized controlled trial
74700|NCT02594657|Eccentric
74701|NCT02594657|Ergometer
74702|NCT02594657|Pedal rate
74703|NCT02594657|Oxygen consumption
74704|NCT02594657|Only health volunteers
74705|NCT02594631|Urethral stones
74706|NCT02594631|Acute Cacular urinary retention
74707|NCT02594631|Extracorporeal Shock Wave Lithotripsy (ESWL)
74708|NCT02594631|Visual lithotripsy
74709|NCT02594631|bladder stone
74710|NCT02594592|Osteoporosis
74711|NCT02594592|Osteoporosis Self-Assessment Tool
74712|NCT02594592|One-Minute Osteoporosis Risk Test
74713|NCT02594592|Asians
74714|NCT02594566|Cytomegalovirus
74715|NCT02594566|Vaccine
74716|NCT02594566|Congenital Infection
74717|NCT02594553|Antibiotics
74718|NCT02594553|Children
74719|NCT02594553|General Practitioner
74720|NCT02594553|GP
74721|NCT02594553|After-hours care
74722|NCT02594553|Out-of-hours care
74723|NCT02594553|Booklet
74724|NCT02594553|Primary Health Care
74725|NCT02594553|Child
74726|NCT02594527|Older people
74727|NCT02594527|Physical activity
74728|NCT02594527|Hospital
74729|NCT02594514|cardiovascular risk
74730|NCT02594514|metabolic profile
74731|NCT02594488|Myocardial infarction
74732|NCT02594488|Autonomic nervous system
74733|NCT02594488|Risk stratification
74734|NCT02594488|Implantable cardiac monitor
74735|NCT02594488|Sudden cardiac death
74736|NCT02594488|ECG
74737|NCT02594475|endoscopic retrograde cholangiopancreatography, position
74738|NCT02594462|contraception
74739|NCT02594462|Anemia, Sickle Cell
74740|NCT02594449|Pharmacodynamic Study of BCS
74741|NCT02594436|Actinic Keratosis
74742|NCT02594436|topical
74743|NCT02594436|ingenol mebutate
74744|NCT02594436|Picato®
74745|NCT02594384|Phase 1
74746|NCT02594384|Safety
74747|NCT02594384|Apilimod dimesylate
74748|NCT02594384|Pharmacokinetics
74749|NCT02594384|Non-Hodgkin's Lymphoma
74750|NCT02594358|Caffeine
74751|NCT02594332|eosinophilic asthma
74752|NCT02594332|mepolizumab
74753|NCT02594332|treatment
74754|NCT02594306|drug addiction
74755|NCT02594306|Heroin
74756|NCT02594306|craving
74757|NCT02594306|event related potential
74758|NCT02594306|crystal methamphetamine
74759|NCT02594267|PTCL
74760|NCT02594267|Peripheral T-Cell Lymphoma
74761|NCT02594267|Folotyn
74762|NCT02594267|Pralatrexate
74763|NCT02594267|CHOP
74764|NCT02594241|Ventral hernia
74765|NCT02594241|Abdominal wall reconstruction
74766|NCT02594241|Enhanced recovery after surgery
74767|NCT02594241|Steroid
74768|NCT02594215|Overgrowth
74769|NCT02594202|Specimen Collection
74770|NCT02594202|Carcinogenesis
74771|NCT02594202|Prognostic Biomarkers
74772|NCT02594202|Molecular Mechanims
74773|NCT02594202|Cell Lines
74774|NCT02594189|Influenza A
74775|NCT02594189|H3N2
74776|NCT02594189|Challenge Model
74777|NCT02594189|Influenza
74778|NCT02594189|Human Challenge
74779|NCT02594176|Osteoarthritis
74780|NCT02594176|Pain
74781|NCT02594176|NSAID
74782|NCT02594176|Sequessome
74783|NCT02594137|Decompressive craniectomy
74784|NCT02594137|Brain Edema
74785|NCT02594124|Spinal Muscular Atrophy
74786|NCT02594124|SMA
74787|NCT02594124|SMN
74788|NCT02594124|SMNRx
74789|NCT02594124|ISIS-SMNRx
74790|NCT02594124|ISIS-SMN Rx
74791|NCT02594124|ISIS 396443
74792|NCT02594124|SHINE
74793|NCT02594124|IONIS-SMNRx
74794|NCT02594124|IONIS-SMN Rx
74795|NCT02594111|inflammation
74796|NCT02594111|percutaneous coronary intervention
74797|NCT02594111|coronary artery disease
74798|NCT02594111|colchicine
74799|NCT02594098|Atopic dermatitis
74800|NCT02594098|extrinsic atopic dermatitis
74801|NCT02594098|intrinsic atopic dermatitis
74802|NCT02594059|endothelial function, idiopathic pulmonary fibrosis
74803|NCT02594020|suspected caries
74804|NCT02594020|initial enamel lesions
74805|NCT02594007|telehealth
74806|NCT02594007|heart failure
74807|NCT02593994|Onyx
74808|NCT02593994|drug eluting stent
74809|NCT02593994|Routine Clinical Practice
74810|NCT02593994|Angioplasty, Transluminal, Percutaneous Coronary
74811|NCT02593994|Coronary Artery Disease
74812|NCT02593981|sleep
74813|NCT02593981|fruit
74814|NCT02593981|honey
74815|NCT02593981|geriatric
74816|NCT02593929|squamous cell carcinoma
74817|NCT02593929|head and neck cancer
74818|NCT02593929|operable
74819|NCT02593903|Antibiotic Prophylaxis
74820|NCT02593890|Breast Cancer
74821|NCT02593890|Breast Surgery
74822|NCT02593890|Mastectomy
74823|NCT02593890|Lumpectomy
74824|NCT02593890|Post-operative
74825|NCT02593890|Bra
74826|NCT02593890|Lingerie
74827|NCT02593890|Body Image
74828|NCT02593890|Psycho-social
74829|NCT02593890|Impact
74830|NCT02593877|Trauma
74831|NCT02593877|Hemostasis
74832|NCT02593877|Resuscitation
74833|NCT02593877|Coagulopathy
74834|NCT02593877|Transfusion
74835|NCT02593851|Respiratory Syncytial Virus Infections
74836|NCT02593851|JNJ-53718678
74837|NCT02593851|Placebo
74838|NCT02593851|Infants
74839|NCT02593812|Learning
74840|NCT02593812|Practice
74841|NCT02593799|Liver cirrhosis
74842|NCT02593799|Esophageal and Gastric Varices
74843|NCT02593799|Endoscopy
74844|NCT02593773|Interferon gamma
74845|NCT02593747|Allergy
74846|NCT02593708|HER2+
74847|NCT02593695|Anorexia Nervosa
74848|NCT02593695|Deep Brain Stimulation
74849|NCT02593695|Nucleus accumbens
74850|NCT02593656|protein ingestion
74851|NCT02593656|resistance exercise
74852|NCT02593656|interval exercise
74853|NCT02593656|stretching exercise
74854|NCT02593656|endurance exercise
74855|NCT02593643|Major Depressive Disorder
74856|NCT02593643|Bipolar Disorder
74857|NCT02593643|Depression
74858|NCT02593643|Suicide
74859|NCT02593643|Suicidal Ideation
74860|NCT02593643|Ketamine
74861|NCT02593643|Midazolam
74862|NCT02593643|Inpatients
74863|NCT02593617|Energy Drinks
74864|NCT02593617|Alcohol Drinking
74865|NCT02593617|Substance Use
74866|NCT02593604|Hidradenitis suppurativa
74867|NCT02593604|Wide excision
74868|NCT02593604|Quality of Life
74869|NCT02593604|Sexual Function
74870|NCT02593539|APDS
74871|NCT02593539|Safety
74872|NCT02593539|Pharmacokinetics
74873|NCT02593539|GSK2269557
74874|NCT02593539|PASLI
74875|NCT02593513|Embryo Transfer
74876|NCT02593513|Embryo Selection Criteria for Implantation
74877|NCT02593513|Assisted Reproductive Technology
74878|NCT02593500|Bioequivalence, budesonide,
74879|NCT02593487|Coronary Artery Disease
74880|NCT02593487|Hyperlipidemia
74881|NCT02593487|Rosuvastatin
74882|NCT02593487|Lipoproteins
74883|NCT02593487|high-density lipoprotein
74884|NCT02593487|HDL2
74885|NCT02593474|Adolescent
74886|NCT02593474|Youth
74887|NCT02593461|Embryo Transfer
74888|NCT02593461|Embryo Selection Criteria for Implantation
74889|NCT02593461|Assisted Reproductive Technology
74890|NCT02593448|Cardiopulmonary Bypass
74891|NCT02593448|Anoxia
74892|NCT02593435|BRCA1/2 gene mutation
74893|NCT02593435|Breast Cancer
74894|NCT02593435|Chinese high risk group
74895|NCT02593422|ovarian cancer
74896|NCT02593422|expressive writing
74897|NCT02593422|writing interventions
74898|NCT02593422|psychosocial support
74899|NCT02593409|HIV-1
74900|NCT02593409|pre-exposure prophylaxis (PrEP)
74901|NCT02593409|immune response
74902|NCT02593396|sexual dysfunctions
74903|NCT02593396|erectile dysfunctions
74904|NCT02593396|hypoactive sexual desire dysfunctions
74905|NCT02593383|safety
74906|NCT02593383|efficacy
74907|NCT02593370|Hip surgery anesthesia
74908|NCT02593370|Perioperative analgesia
74909|NCT02593357|endothelial function
74910|NCT02593357|COPD
74911|NCT02593357|pulmonary function
74912|NCT02593344|asthma, endothelial function
74913|NCT02593318|energy metabolism
74914|NCT02593318|oxaloacetate
74915|NCT02593305|nitrate
74916|NCT02593305|blood flow
74917|NCT02593305|blood pressure
74918|NCT02593305|vascular function
74919|NCT02593305|hypoxia
74920|NCT02593292|Clinical pathway
74921|NCT02593292|Electronic Health Records
74922|NCT02593292|Maternal Health Services & administration
74923|NCT02593292|Patient Access to Records
74924|NCT02593292|Patient Satisfaction
74925|NCT02593292|Prenatal Care/methods
74926|NCT02593279|Asthma
74927|NCT02593279|phenotype
74928|NCT02593279|small
74929|NCT02593279|airway
74930|NCT02593279|proximal
74931|NCT02593279|dysfunction
74932|NCT02593266|Prevention
74933|NCT02593266|Family
74934|NCT02593266|Intervention
74935|NCT02593266|Depression
74936|NCT02593266|Children
74937|NCT02593253|Quality Improvement
74938|NCT02593253|Quality Indicators, Health Care
74939|NCT02593253|Hospital Medicine
74940|NCT02593240|Energy
74941|NCT02593240|Presenteeism
74942|NCT02593240|Absenteeism
74943|NCT02593240|Cardiometabolic health
74944|NCT02593240|Obesity
74945|NCT02593240|Overweight
74946|NCT02593240|Weight Loss
74947|NCT02593240|Quality of Life
74948|NCT02593240|Weight Control
74949|NCT02593240|Eating Behavior
74950|NCT02593240|Food Cravings
74951|NCT02593240|Hunger
74952|NCT02593240|Worksite Wellness
74953|NCT02593227|TNBC
74954|NCT02593214|Condoms, Female
74955|NCT02593214|Contraception, Barrier
74956|NCT02593175|Triple-Negative Breast Cancer
74957|NCT02593175|TNBC
74958|NCT02593175|Panitumumab
74959|NCT02593175|Vectibix
74960|NCT02593175|Paclitaxel
74961|NCT02593175|Taxol
74962|NCT02593175|Carboplatin
74963|NCT02593175|Paraplatin
74964|NCT02593175|Biopsy
74965|NCT02593175|Fine-needle aspiration
74966|NCT02593175|FNA
74967|NCT02593136|Vitamins
74968|NCT02593136|Public Health
74969|NCT02593136|Nutrition
74970|NCT02593084|Resistance Training
74971|NCT02593084|Exercise
74972|NCT02593084|Walking
74973|NCT02593084|Safety
74974|NCT02593084|Feasibility Studies
74975|NCT02593058|Anhedonia
74976|NCT02593058|Apathy
74977|NCT02593058|Negative symptoms
74978|NCT02593058|Anticipatory pleasure
74979|NCT02593058|Savoring
74980|NCT02593032|hemoglobin A1c protein, human > 7.5
74981|NCT02593006|Joint Diseases
74982|NCT02593006|Juvenile Arthritis
74983|NCT02593006|treatment
74984|NCT02593006|biologic therapy
74985|NCT02593006|comparative effectiveness
74986|NCT02592967|Carcinoma, Non-Small-Cell Lung
74987|NCT02592967|JNJ-64041757
74988|NCT02592967|Listeria monocytogenes
74989|NCT02592928|eHealth
74990|NCT02592928|Spirometry
74991|NCT02592928|Lung Function
74992|NCT02592928|Primary Care
74993|NCT02592928|Telehealth
74994|NCT02592928|Integrated Care
74995|NCT02592902|recurrent respiratory papillomatosis
74996|NCT02592902|extra oesophageal reflux
74997|NCT02592902|laryngeal cyst
74998|NCT02592902|phonosurgery
74999|NCT02592902|oesophageal impedance
75000|NCT02592889|MITRAL REGURGITATION
75001|NCT02592876|Antibodies, Monoclonal
75002|NCT02592876|Antibody-Drug Conjugate
75003|NCT02592876|Antigens, CD19
75004|NCT02592876|Autologous Stem Cell Transplant
75005|NCT02592876|Drug Therapy
75006|NCT02592876|Follicular Lymphoma Grade 3b
75007|NCT02592876|Hematologic Diseases
75008|NCT02592876|Immune System Diseases
75009|NCT02592876|Immunoproliferative Disorders
75010|NCT02592876|Immunotherapy
75011|NCT02592876|Lymphatic Diseases
75012|NCT02592876|Lymphoma
75013|NCT02592876|Lymphoma, B-Cell
75014|NCT02592876|Lymphoma, Large B-Cell, Diffuse
75015|NCT02592876|Lymphoma, Non-Hodgkin
75016|NCT02592876|Monomethylauristatin F
75017|NCT02592876|Neoplasms
75018|NCT02592876|Neoplasms by Histologic Type
75019|NCT02592876|Transformed Lymphoma / DLBCL
75020|NCT02592876|Rituximab
75021|NCT02592876|Ifosfamide
75022|NCT02592876|Carboplatin
75023|NCT02592876|Etoposide
75024|NCT02592850|Osteopathic manipulative treatment
75025|NCT02592850|Frequent Episodic Tension-Type Headache
75026|NCT02592850|Randomized Controlled Trial
75027|NCT02592837|Endobronchial ultrasound
75028|NCT02592837|EBUS
75029|NCT02592837|TBNA
75030|NCT02592837|Mediastinal ymphadenopathy
75031|NCT02592837|Hilar lymphadenopathy
75032|NCT02592837|Lung cancer
75033|NCT02592824|glutamate, heart failure, coronary artery bypass surgery
75034|NCT02592811|Cholangiopancreatography
75035|NCT02592811|therapeutic strategy
75036|NCT02592811|Endoscopic Retrograde
75037|NCT02592772|menthol
75038|NCT02592772|nicotine
75039|NCT02592772|reduced nicotine
75040|NCT02592772|smoking
75041|NCT02592772|cigarette
75042|NCT02592772|cigarettes
75043|NCT02592772|men smoking
75044|NCT02592772|smoking research
75045|NCT02592772|nicotine dependence
75046|NCT02592720|Acute Coronary Syndromes
75047|NCT02592720|Fractional Flow Reserve
75048|NCT02592720|Percutaneous Coronary Intervention
75049|NCT02592681|menstrual migraine
75050|NCT02592681|acupuncture
75051|NCT02592681|acupressure
75052|NCT02592655|tourniquet
75053|NCT02592655|arterial
75054|NCT02592655|pre-hospital
75055|NCT02592655|SOFTT-W
75056|NCT02592655|Battle Wrap
75057|NCT02592655|windlass
75058|NCT02592655|exsanguination
75059|NCT02592655|hemorrhage
75060|NCT02592655|amputation
75061|NCT02592642|lumbar spinal stenosis
75062|NCT02592642|neurogenic claudication
75063|NCT02592642|non-operative
75064|NCT02592642|treatment
75065|NCT02592642|outcomes
75066|NCT02592642|clinical trial
75067|NCT02592629|subacromial injection
75068|NCT02592629|rotator cuff disease
75069|NCT02592629|steroid injection
75070|NCT02592616|Exercise
75071|NCT02592616|Appetite
75072|NCT02592616|Energy intake
75073|NCT02592603|Serrated lesions
75074|NCT02592603|Surveillance
75075|NCT02592603|Colorectal cancer
75076|NCT02592603|Endocuff
75077|NCT02592603|Sessile serrated adenoma
75078|NCT02592603|Colonoscopy
75079|NCT02592590|Exercise
75080|NCT02592590|Physical Activity
75081|NCT02592590|Smartphone
75082|NCT02592590|Technology
75083|NCT02592577|Previously Treated
75084|NCT02592577|Cell Therapy
75085|NCT02592577|T Cell Therapy
75086|NCT02592577|MAGE-A10
75087|NCT02592577|Immuno-oncology
75088|NCT02592577|T Cell Receptor
75089|NCT02592577|Metastatic
75090|NCT02592564|Magnetic Resonance Imaging
75091|NCT02592564|Cognitive Behavior Therapy
75092|NCT02592564|Telomerase
75093|NCT02592564|Telomere Length, Mean Leukocyte
75094|NCT02592538|Biliary duct carcinoma;
75095|NCT02592538|radiofrequency ablation
75096|NCT02592538|S-1
75097|NCT02592512|Hypoxia
75098|NCT02592512|hypercapnia
75099|NCT02592499|HM III
75100|NCT02592499|survival
75101|NCT02592499|LVAD
75102|NCT02592486|quadrivalent influenza vaccine
75103|NCT02592486|23-valent pneumococcal vaccine
75104|NCT02592486|immunogenicity
75105|NCT02592473|Prostate Artery Embolization (PAE)
75106|NCT02592473|Benign Prostatic Hyperplasia (BPH)
75107|NCT02592473|Lower Urinary Tract Symptoms (LUTS)
75108|NCT02592473|BPH
75109|NCT02592473|PAE
75110|NCT02592473|LUTS
75111|NCT02592473|Prostatic Artery Embolization
75112|NCT02592447|CML
75113|NCT02592447|chronic phase CML
75114|NCT02592447|leukemia
75115|NCT02592434|Arthritis
75116|NCT02592434|Pediatric
75117|NCT02592434|Tofacitinib
75118|NCT02592434|Long-term
75119|NCT02592434|JIA
75120|NCT02592434|polyarticular
75121|NCT02592434|CP-690,550
75122|NCT02592434|Xeljanz
75123|NCT02592395|pancreatic adenocarcinoma
75124|NCT02592395|electrochemotherapy
75125|NCT02592395|electroporation
75126|NCT02592395|radiogenomics
75127|NCT02592395|imaging
75128|NCT02592395|magnetic resonance spectroscopy
75129|NCT02592356|Full-body dual-energy x-ray absorptiometry
75130|NCT02592356|DXA
75131|NCT02592356|Body measurement
75132|NCT02592356|Weight of participant
75133|NCT02592356|Questionnaires
75134|NCT02592356|Surveys
75135|NCT02592356|Chemotherapy
75136|NCT02592356|Advanced Cancers
75137|NCT02592356|Endocrine Tumor
75138|NCT02592343|fecal microbiota transplantation
75139|NCT02592343|lyophilized
75140|NCT02592330|CALEC
75141|NCT02592330|Limbal Stem Cell Deficiency
75142|NCT02592330|LSCD
75143|NCT02592317|JNJ-56021927
75144|NCT02592317|Prostatic Neoplasms, Castration-Resistant
75145|NCT02592291|Mobile health
75146|NCT02592291|Apps
75147|NCT02592291|Applications
75148|NCT02592291|Smart phone
75149|NCT02592291|mHealth
75150|NCT02592291|Chronic and Complex Conditions
75151|NCT02592291|Self-Management
75152|NCT02592291|Self-Care
75153|NCT02592278|Dental Caries
75154|NCT02592278|Fluoride Varnish
75155|NCT02592278|Preschool child
75156|NCT02592278|Prevention
75157|NCT02592239|Functional brain MRI
75158|NCT02592239|functional dyspepsia
75159|NCT02592239|hedonic response
75160|NCT02592200|Female
75161|NCT02592200|Constipation
75162|NCT02592200|Lactobacillus gasseri DSM 27123
75163|NCT02592200|Probiotics
75164|NCT02592187|Life-logging
75165|NCT02592187|Cognitive Training
75166|NCT02592187|Mild Cognitive Impairment
75167|NCT02592187|Memory
75168|NCT02592187|Information and communications technology (ICT) in healthcare
75169|NCT02592187|Portable camera
75170|NCT02592135|Acute Cardiac Insufficiency
75171|NCT02592135|Acute Heart Failure
75172|NCT02592122|Mechanical ventilation
75173|NCT02592122|Chronic obstructive pulmonary disease
75174|NCT02592122|Airway resistance
75175|NCT02592122|Bronchial dilation test
75176|NCT02592109|Complementary Feeding Recommendation
75177|NCT02592109|Linear Programming
75178|NCT02592109|Nutritional Status
75179|NCT02592109|Omega-3 Fatty Acids
75180|NCT02592109|Malondialdehyde
75181|NCT02592109|alpha-Tocopherol
75182|NCT02592096|safety and bioavailability
75183|NCT02592083|Neoadjuvant Therapy
75184|NCT02592083|Cyclin-Dependent Kinase Inhibitor p16
75185|NCT02592044|pain
75186|NCT02592044|anxiety
75187|NCT02592044|Catheterization, Peripheral
75188|NCT02592005|pollution
75189|NCT02591979|Sleep Apnea Syndrome
75190|NCT02591979|Primary Health Care
75191|NCT02591940|cardiovascular modeling
75192|NCT02591940|aortic coarctation
75193|NCT02591940|aortic valve disease
75194|NCT02591927|myocardial infarction
75195|NCT02591927|glucose-insulin-potassium
75196|NCT02591901|Spinal Cord Injuries
75197|NCT02591901|Multiple Sclerosis
75198|NCT02591901|Transverse Myelitis
75199|NCT02591901|Neurogenic Bladder Dysfunction
75200|NCT02591901|Feasibility Study
75201|NCT02591901|Urinary Tract Infection
75202|NCT02591875|Cardiac Catheter Ablation
75203|NCT02591875|Cardiac Arrhythmias
75204|NCT02591875|Atrial Flutter
75205|NCT02591836|LDL‐C
75206|NCT02591836|Lipid Regulator
75207|NCT02591797|pain
75208|NCT02591797|Infant Behavior
75209|NCT02591797|Heart rate
75210|NCT02591797|Dental Anxiety
75211|NCT02591784|nimotuzumab esophageal radiotherapy
75212|NCT02591771|Adrenaline
75213|NCT02591771|Extra Corporeal Life Support
75214|NCT02591771|Inotropes
75215|NCT02591758|Hexo-Skin
75216|NCT02591758|Hexoskin
75217|NCT02591758|NOVA-SKIN
75218|NCT02591758|angina
75219|NCT02591758|biometric vest
75220|NCT02591706|Single missing tooth
75221|NCT02591706|Implants
75222|NCT02591706|Peri-implant bone remodeling
75223|NCT02591706|Bone thickness
75224|NCT02591706|Thickness of soft tissue
75225|NCT02591693|Family Caregivers
75226|NCT02591693|Occupational Therapy
75227|NCT02591693|Activities of Daily Living
75228|NCT02591667|Colorectal cancer
75229|NCT02591667|Peritoneal metastasis
75230|NCT02591667|Neoadjuvant chemotherapy
75231|NCT02591667|5-Fluorouracil
75232|NCT02591667|Oxaliplatin
75233|NCT02591667|Irinotecan
75234|NCT02591667|Bevacizumab
75235|NCT02591667|Histopathological response
75236|NCT02591654|FLT
75237|NCT02591654|Pembrolizumab
75238|NCT02591654|Metastatic Melanoma
75239|NCT02591654|MK-3475
75240|NCT02591641|pre-hospital transport
75241|NCT02591641|shear force
75242|NCT02591641|tissue interface pressure
75243|NCT02591628|Hypertension
75244|NCT02591628|Thiazide diuretics
75245|NCT02591589|Hyperoxia
75246|NCT02591589|Delirium
75247|NCT02591589|Normoxic
75248|NCT02591589|t-MoCA
75249|NCT02591576|Diabetes
75250|NCT02591576|ST-elevation myocardial infarction (STEMI)
75251|NCT02591576|non-STEMI
75252|NCT02591576|Excess mortality
75253|NCT02591576|Relative survival
75254|NCT02591550|chronic cough
75255|NCT02591550|cough reflex sensitivity
75256|NCT02591550|transient receptor potential vanilloid 1
75257|NCT02591550|transient receptor potential ankyrin 1
75258|NCT02591498|cognitive training
75259|NCT02591485|PTSD prevention
75260|NCT02591485|Acute stress disorder
75261|NCT02591485|Attention training
75262|NCT02591485|Cognitive bias modification
75263|NCT02591459|Autism
75264|NCT02591446|TMS
75265|NCT02591446|Autism Spectrum Disorders
75266|NCT02591446|Plasticity
75267|NCT02591407|Continuous Epidural Analgesia
75268|NCT02591407|Transversus Abdominis Plane block
75269|NCT02591381|urinary stress incontinence
75270|NCT02591355|Platelet Rich Plasma
75271|NCT02591355|Hair Loss
75272|NCT02591342|femoral neck fracture
75273|NCT02591342|hip arthroplasty
75274|NCT02591342|complication
75275|NCT02591342|periprosthetic femoral fracture
75276|NCT02591316|nutrition
75277|NCT02591316|physical activity
75278|NCT02591316|breast cancer survivor
75279|NCT02591316|cognition
75280|NCT02591303|Insomnia
75281|NCT02591303|Stress
75282|NCT02591303|Real-life stressful events
75283|NCT02591290|Meningitis
75284|NCT02591290|Meningococcal Meningitis
75285|NCT02591290|Meningococcal Infections
75286|NCT02591290|Menactra®
75287|NCT02591290|Meningococcal Vaccine
75288|NCT02591277|Hepatitis C virus
75289|NCT02591277|observational
75290|NCT02591277|post-marketing
75291|NCT02591277|ledipasvir/sofosbuvir
75292|NCT02591277|Japan
75293|NCT02591238|smoking
75294|NCT02591238|melatonin
75295|NCT02591238|vascular injury
75296|NCT02591225|left atrial thrombus size
75297|NCT02591225|transesophageale echocardiography
75298|NCT02591225|silent cerebral embolism
75299|NCT02591212|Bystanding behaviors
75300|NCT02591212|Campus
75301|NCT02591212|Prevention
75302|NCT02591212|Sexual Assault
75303|NCT02591212|CampusSave
75304|NCT02591173|Autonomic
75305|NCT02591173|Hypertension
75306|NCT02591173|Renin-Angiotensin System
75307|NCT02591134|weight loss
75308|NCT02591134|NNS
75309|NCT02591134|beverages
75310|NCT02591134|diet
75311|NCT02591134|appetite
75312|NCT02591134|satiety
75313|NCT02591134|weight control
75314|NCT02591108|train of four
75315|NCT02591108|neuromuscular blockade
75316|NCT02591108|surgery
75317|NCT02591069|Vagus nerve stimulation
75318|NCT02591069|vegetative state
75319|NCT02591069|minimally conscious state
75320|NCT02591069|akinetic mutism
75321|NCT02591069|consciousness
75322|NCT02591069|connectivity
75323|NCT02591043|Pelvic
75324|NCT02591043|Treatment Outcome
75325|NCT02591030|Bile Duct Cancer
75326|NCT02591030|phase II/III
75327|NCT02591030|Modified folfirinox
75328|NCT02591030|Gemcis
75329|NCT02591004|Neuroprotection
75330|NCT02591004|calcium channel blockers
75331|NCT02591004|magnesium sulhate
75332|NCT02591004|Middle cerebral artery doppler
75333|NCT02590978|gallstone pancreatitis
75334|NCT02590978|mild acute pancreatitis
75335|NCT02590978|adult
75336|NCT02590952|safety, PK
75337|NCT02590926|Fractional Flow Reserve, Myocardial
75338|NCT02590913|fructose
75339|NCT02590913|metabolism
75340|NCT02590913|acute
75341|NCT02590900|pharmacokinetics
75342|NCT02590900|pregnancy
75343|NCT02590900|oral contraceptives
75344|NCT02590900|oestradiol
75345|NCT02590874|Mild Cognitive Impairment
75346|NCT02590874|Cognition
75347|NCT02590874|Memory
75348|NCT02590874|Depression
75349|NCT02590874|Depressive disorder
75350|NCT02590874|Antidepressive agents
75351|NCT02590874|Duloxetine
75352|NCT02590874|Cymbalta
75353|NCT02590874|Selective serotonin and norepinephrine uptake inhibitors
75354|NCT02590861|Partial Dentures
75355|NCT02590861|Dental Implants
75356|NCT02590861|Quality of Life
75357|NCT02590861|Partial Edentulism
75358|NCT02590848|Walnut intake
75359|NCT02590848|Brain development
75360|NCT02590848|Nutritional intervention
75361|NCT02590848|Healthy adolescents
75362|NCT02590835|Adult patients
75363|NCT02590835|Patient demand for orthodontic treatment
75364|NCT02590822|Diabetes
75365|NCT02590822|T2DM
75366|NCT02590822|young adults
75367|NCT02590822|heart
75368|NCT02590822|weight loss
75369|NCT02590822|MRI
75370|NCT02590822|exercise
75371|NCT02590822|diastolic function
75372|NCT02590809|Left ventricular obstruction
75373|NCT02590796|Delirium
75374|NCT02590796|Inattention
75375|NCT02590796|Medical device
75376|NCT02590796|Software application
75377|NCT02590796|Validation study
75378|NCT02590796|Diagnosis
75379|NCT02590796|Dementia
75380|NCT02590783|treatment
75381|NCT02590757|non-invasive ventilation
75382|NCT02590757|non-invasive neurally adjusted ventilatory assist
75383|NCT02590757|nasal continuous positive airway pressure
75384|NCT02590744|Emergence Agitation
75385|NCT02590744|eye patch
75386|NCT02590744|preschool children
75387|NCT02590653|STEMI
75388|NCT02590653|myocardial strain
75389|NCT02590653|atorvastatin
75390|NCT02590627|Parasite clearance, Treatment failure
75391|NCT02590601|PPCM
75392|NCT02590601|Bromocriptine
75393|NCT02590601|Peripartum cardiomyopathy
75394|NCT02590588|IgM-associated AL amyloidosis
75395|NCT02590575|extracorporeal CO2 removal
75396|NCT02590575|renal replacement therapy
75397|NCT02590575|Prismalung
75398|NCT02590575|ARDS
75399|NCT02590575|hypercapnia
75400|NCT02590575|Changes in the arterial pCO2 value
75401|NCT02590575|ventilated
75402|NCT02590575|Hypercapnic
75403|NCT02590549|Keratoconus
75404|NCT02590549|riboflavin
75405|NCT02590549|corneal collagen crosslinking
75406|NCT02590549|intrasromal ring
75407|NCT02590536|Sildenafil
75408|NCT02590536|Fetal growth Restriction
75409|NCT02590536|Umbilical Artery Doppler
75410|NCT02590510|Intrathecal chemotherapy
75411|NCT02590471|Angioplasty with stenting of the superficial femoral artery
75412|NCT02590471|Fasciotomy in Hunter's channel
75413|NCT02590471|Breakage of stent
75414|NCT02590458|Breast Cancer
75415|NCT02590458|Short Breast MRI Scan
75416|NCT02590458|SBMRI
75417|NCT02590458|Routine MRI
75418|NCT02590458|High risk for breast cancer
75419|NCT02590458|Screening
75420|NCT02590432|Immunogenicity
75421|NCT02590432|Irritable Bowel Syndrome with Constipation
75422|NCT02590432|Chronic Idiopathic Constipation
75423|NCT02590432|Linaclotide
75424|NCT02590432|Linzess
75425|NCT02590406|Morbid Obesity
75426|NCT02590406|Bariatric Surgery
75427|NCT02590406|Pre-Oxygenation
75428|NCT02590406|Anesthesia Induction
75429|NCT02590406|Positive pressure ventilation
75430|NCT02590406|Non hypoxic apnea time
75431|NCT02590406|Positive-Pressure Respiration
75432|NCT02590406|Anesthesia, General
75433|NCT02590393|Nicotine addiction
75434|NCT02590393|Cigarette smoking
75435|NCT02590393|E-cigarettes
75436|NCT02590380|Adolescent
75437|NCT02590380|paediatric
75438|NCT02590380|pediatric
75439|NCT02590380|scoliosis
75440|NCT02590380|spine deformity
75441|NCT02590367|oxaliplatin-induced peripheral neuropathy
75442|NCT02590367|HD6610 granule
75443|NCT02590367|colorectal cancer
75444|NCT02590354|Treatment interruption
75445|NCT02590354|functional cure
75446|NCT02590341|myocarditis
75447|NCT02590341|children
75448|NCT02590341|adolescents
75449|NCT02590341|registry
75450|NCT02590341|multi-center
75451|NCT02590341|pediatric
75452|NCT02590341|heart failure
75453|NCT02590341|inflammatory heart disease
75454|NCT02590341|inflammatory cardiomyopathy
75455|NCT02590328|Neonatal Screening
75456|NCT02590328|Severe Combined Immunodeficiency
75457|NCT02590328|Immunologic Deficiency Syndromes
75458|NCT02590328|DNA Repair-Deficiency Disorders
75459|NCT02590328|T-cell Receptor Excision Circle
75460|NCT02590315|BC
75461|NCT02590302|Clinical pathway
75462|NCT02590302|Mental Health
75463|NCT02590302|Emergency Department
75464|NCT02590302|Paediatric
75465|NCT02590302|Risk assessment
75466|NCT02590302|Service integration
75467|NCT02590302|Transitions in care
75468|NCT02590302|Implementation
75469|NCT02590302|Scoring tools
75470|NCT02590302|Clinical Pathway Evaluation
75471|NCT02590276|frontotemporal Dementia
75472|NCT02590276|Amyotrophic lateral sclerosis
75473|NCT02590276|Biomarkers
75474|NCT02590276|brain Imaging PET
75475|NCT02590263|WHO grade III
75476|NCT02590263|WHO grade IV
75477|NCT02590237|Laryngoscopy
75478|NCT02590237|Video Laryngoscopy
75479|NCT02590211|experimental study
75480|NCT02590211|cognitive mechanisms
75481|NCT02590211|poker
75482|NCT02590211|cognitive remediation therapy
75483|NCT02590133|Refractory Nasopharyngeal Carcinoma, Endostar, 5-Fu
75484|NCT02590081|Normal saline
75485|NCT02590081|Destrose 5%
75486|NCT02590081|Blood pressure
75487|NCT02590081|Interdialytic weight gain
75488|NCT02590081|thirst level
75489|NCT02590081|End Stage Renal Failure
75490|NCT02589990|health
75491|NCT02589990|muscle strength
75492|NCT02589990|exercise genomics
75493|NCT02589977|magnetic resonance imaging
75494|NCT02589977|positron-emission tomography
75495|NCT02589977|echocardiography
75496|NCT02589977|myocardial blood flow
75497|NCT02589977|energy metabolism
75498|NCT02589964|probiotics
75499|NCT02589964|antibiotic associated diarrhea
75500|NCT02589964|clostridium difficile
75501|NCT02589925|deep brain stimulation
75502|NCT02589925|subthalamic nucleus
75503|NCT02589925|Nucleus basalis Meynert
75504|NCT02589886|Self-help
75505|NCT02589886|Education
75506|NCT02589886|e-Health
75507|NCT02589873|Lifestyle Intervention
75508|NCT02589873|Workplace
75509|NCT02589873|Diabetes Prevention
75510|NCT02589860|Stem Cell Transplantation
75511|NCT02589847|Clostridium difficile
75512|NCT02589847|C diff
75513|NCT02589847|CDI
75514|NCT02589847|CDAD
75515|NCT02589847|Fecal transplant
75516|NCT02589847|Fecal Microbiota transplant
75517|NCT02589847|diarrhea
75518|NCT02589847|FMT
75519|NCT02589847|microbiota restoration therapy
75520|NCT02589847|microbiota suspension
75521|NCT02589847|fecal bacteriotherapy
75522|NCT02589847|C diff diarrhea
75523|NCT02589808|pre-operative
75524|NCT02589808|transthoracic echocardiography
75525|NCT02589808|handheld
75526|NCT02589795|safety
75527|NCT02589795|immunogenicity
75528|NCT02589795|HIV vaccine
75529|NCT02589782|bedaquiline
75530|NCT02589782|Nitroimidazoles
75531|NCT02589782|diarylquinolines
75532|NCT02589782|linezolid
75533|NCT02589782|clofazimine
75534|NCT02589782|pretomanid
75535|NCT02589782|moxifloxacin
75536|NCT02589756|obesity
75537|NCT02589756|persistent organic pollutants
75538|NCT02589756|metabolic syndrome
75539|NCT02589743|clinical trial
75540|NCT02589743|pit and fissure sealants
75541|NCT02589743|tooth eruption
75542|NCT02589743|retention
75543|NCT02589743|adhesive system
75544|NCT02589743|intermediary layer
75545|NCT02589730|Smartphone app
75546|NCT02589730|diabetic management
75547|NCT02589730|lifestyle behaviors
75548|NCT02589730|medication management
75549|NCT02589678|AIDS
75550|NCT02589678|Immunology
75551|NCT02589678|Public Health
75552|NCT02589678|Female sex workers
75553|NCT02589678|Single mothers
75554|NCT02589665|IL-23 antibody
75555|NCT02589652|Pegylated interferon
75556|NCT02589652|Entecavir
75557|NCT02589600|Bone loss
75558|NCT02589600|Frail Geriatric Women
75559|NCT02589600|Nursing Home Patients
75560|NCT02589600|Long-term Care Patients
75561|NCT02589600|Osteoporosis
75562|NCT02589600|Osteoporotic Fractures
75563|NCT02589561|hearing loss
75564|NCT02589561|hearing aids
75565|NCT02589548|Hodgkin Lymphoma
75566|NCT02589548|Hodgkin Disease
75935|NCT02587351|Smoking
75567|NCT02589509|Event-related potentials
75568|NCT02589509|Attention
75569|NCT02589509|Cognitive rehabilitation
75570|NCT02589509|Independent activities of daily living
75571|NCT02589470|cognitive rehabilitation
75572|NCT02589470|memory
75573|NCT02589470|epilepsy
75574|NCT02589457|Chronic Hepatitis B virus, HIV-1 infection
75575|NCT02589457|Healthy Male Volunteer
75576|NCT02589457|Tenofovir Disoproxil Fumarate
75577|NCT02589444|Clinical Endocrinology
75578|NCT02589444|Immunology
75579|NCT02589444|Inflammation
75580|NCT02589444|Microbiology
75581|NCT02589444|Respiratory Disorders
75582|NCT02589444|Vitamins
75583|NCT02589431|hypothalamo pituitary adrenal axis
75584|NCT02589418|Manual acupuncture
75585|NCT02589418|Experimental dental pain
75586|NCT02589418|Psychophysics
75587|NCT02589418|Autonomic nervous system
75588|NCT02589418|Subjective pain ratings
75589|NCT02589379|postoperative pancreatic fistula
75590|NCT02589379|soft and hard pancreas
75591|NCT02589366|Lymphoseek
75592|NCT02589366|endometrial cancer
75593|NCT02589366|sentinel lymph node
75594|NCT02589366|lymph node dissection
75595|NCT02589275|TNX-102 SL
75596|NCT02589275|bedtime
75597|NCT02589275|sublingual
75598|NCT02589275|3-month
75599|NCT02589275|long term safety
75600|NCT02589275|long term efficacy
75601|NCT02589275|Fibromyalgia
75602|NCT02589236|Cystic Fibrosis
75603|NCT02589236|N91115
75604|NCT02589236|Cavosonstat
75605|NCT02589223|multisensory stimulation
75606|NCT02589210|Diabetes Mellitus
75607|NCT02589210|Foot Disease
75608|NCT02589210|Foot Ulcer
75609|NCT02589197|osteoarthritis
75610|NCT02589197|correction of functional deformity
75611|NCT02589197|procedures
75612|NCT02589197|traumatic osteoarthritis
75613|NCT02589197|degenerative osteoarthritis
75614|NCT02589197|total knee arthroplasty
75615|NCT02589197|Healthy Volunteers
75616|NCT02589197|electromyography
75617|NCT02589197|Musculoskeletal Diseases
75618|NCT02589184|balance, postural
75619|NCT02589184|postural equilibrium
75620|NCT02589184|pain scale
75621|NCT02589184|range of motion
75622|NCT02589145|Blood And Marrow Transplantation
75623|NCT02589145|Diffuse large B-cell lymphoma
75624|NCT02589145|DLBCL
75625|NCT02589145|Busulfan
75626|NCT02589145|Busulfex
75627|NCT02589145|Myleran
75628|NCT02589145|Lenalidomide
75629|NCT02589145|CC-5013
75630|NCT02589145|Revlimid
75631|NCT02589145|Vorinostat
75632|NCT02589145|SAHA
75633|NCT02589145|Suberoylanilide Hydroxamic Acid
75634|NCT02589145|MSK-390
75635|NCT02589145|Zolinza
75636|NCT02589145|Gemcitabine
75637|NCT02589145|Gemcitabine Hydrochloride
75638|NCT02589145|Gemzar
75639|NCT02589145|Melphalan
75640|NCT02589145|Alkeran
75641|NCT02589145|Rituximab
75642|NCT02589145|Rituxan
75643|NCT02589145|Dexamethasone
75644|NCT02589145|Decadron
75645|NCT02589145|Glutamine
75646|NCT02589145|Enterex
75647|NCT02589145|Glutapack-10
75648|NCT02589145|NutreStore
75649|NCT02589145|Resource
75650|NCT02589145|GlutaSolve
75651|NCT02589145|Sympt-X G.I.
75652|NCT02589145|Symptx-X
75653|NCT02589145|Pyridoxine
75654|NCT02589145|Enoxaparin
75655|NCT02589145|Lovenox Injection
75656|NCT02589145|Palifermin
75657|NCT02589145|Kepivance
75658|NCT02589119|cryptoglandular
75659|NCT02589119|perianal fistula
75660|NCT02589119|cryptoglandular perianal fistulas
75661|NCT02589106|Anisotropic Textile Braces
75662|NCT02589093|Analgesia
75663|NCT02589093|Monitoring
75664|NCT02589093|Analgesia Nociception Index
75665|NCT02589093|ANI
75666|NCT02589093|PhysioDoloris
75667|NCT02589093|Pain
75668|NCT02589041|intraneural sciatic block
75669|NCT02589028|diabetes mellitus
75670|NCT02589028|incretin hormone
75671|NCT02589028|glucose level
75672|NCT02589028|GLP-1
75673|NCT02589028|GIP
75674|NCT02589028|premeal protein
75675|NCT02589015|morbid obesity
75676|NCT02589015|neck circumference
75677|NCT02589015|difficult mask ventilation
75678|NCT02589015|difficult laryngoscopy
75679|NCT02589002|sucralose
75680|NCT02589002|insulin sensitivity
75681|NCT02589002|beta-cell response
75682|NCT02589002|appetite regulating hormone
75683|NCT02588976|Activated clotting time
75684|NCT02588976|Sonoclot
75685|NCT02588963|upper respiratory tract infections
75686|NCT02588963|lower respiratory tract infections
75687|NCT02588963|health promotion
75688|NCT02588963|respiratory physiotherapy
75689|NCT02588963|infant
75690|NCT02588937|Entecavir, EntecaBell ODT., Hepatitis B
75691|NCT02588924|Parkinson Disease
75692|NCT02588924|ENVIRONMENTAL AND OCCUPATIONAL EXPOSURE TO METALS
75693|NCT02588911|Radiofrequency Catheter Ablation
75694|NCT02588911|Operative Surgical Procedure
75695|NCT02588911|Saphenous Vein
75696|NCT02588885|physical therapy
75697|NCT02588885|psychotherapy
75698|NCT02588885|dysfunctional sexual behavior
75699|NCT02588885|pelvic pain
75700|NCT02588885|posttraumatic stress
75701|NCT02588885|PTSD
75702|NCT02588885|chronic pain
75703|NCT02588872|platelet-rich plasma
75704|NCT02588872|hyaluronic acid
75705|NCT02588859|T2DM, Diabetes
75706|NCT02588846|Prostate
75707|NCT02588846|Radiotherapy
75708|NCT02588846|IGRT
75709|NCT02588846|VMAT
75710|NCT02588846|Image-guided radiation therapy
75711|NCT02588846|Volumetric modulated arc therapy
75712|NCT02588846|Adaptive radiotherapy
75713|NCT02588820|HIV
75714|NCT02588794|sepsis, acute kidney injury , CytoSorb
75715|NCT02588768|Low-level laser therapy
75716|NCT02588768|Light emitting diodes
75717|NCT02588768|Rugby
75718|NCT02588768|Field test
75719|NCT02588768|Photobiomodulation
75720|NCT02588755|Chemoembolization
75721|NCT02588755|Therapeutic
75722|NCT02588755|Tegafur
75723|NCT02588742|elderly ICU patients
75724|NCT02588729|Gestational diabetes
75725|NCT02588729|app
75726|NCT02588729|RCT
75727|NCT02588729|diet
75728|NCT02588729|physical activity
75729|NCT02588716|Hepatectomy, Surgical Blood Loss, terlipressin
75730|NCT02588677|Amyotrophic Lateral Sclerosis (ALS) - masitinib
75731|NCT02588664|Early Supported Discharge
75732|NCT02588651|Lymphoma
75733|NCT02588651|Leukemia
75734|NCT02588651|Brentuximab Vedotin
75735|NCT02588638|NGS
75736|NCT02588638|Quality of life
75737|NCT02588638|Diagnosis
75738|NCT02588638|Rare disease
75739|NCT02588638|Next-generation sequencing
75740|NCT02588612|Previously Treated
75741|NCT02588612|Cell Therapy
75742|NCT02588612|T Cell Therapy
75743|NCT02588612|NY-ESO-1
75744|NCT02588612|Immuno-oncology
75745|NCT02588612|T Cell Receptor
75746|NCT02588586|HIV
75747|NCT02588586|3BNC117
75748|NCT02588586|Broadly neutralizing antibody
75749|NCT02588560|lymphoma, hepatitis C virus, chemotherapy
75750|NCT02588547|Shivering
75751|NCT02588547|Granisetron
75752|NCT02588547|Pethidine
75753|NCT02588547|Spinal
75754|NCT02588547|Cesarean section
75755|NCT02588534|etanercept, healthy subject,open-label, randomized, auto-injection, bioequivalence, pharmacokinetic
75756|NCT02588508|perineal tear
75757|NCT02588508|pain
75758|NCT02588508|pelvic floor
75759|NCT02588508|Labour
75760|NCT02588495|Ultrasound
75761|NCT02588495|Gastric area
75762|NCT02588495|Accuracy
75763|NCT02588495|Aspirate
75764|NCT02588482|electroencephalography (EEG)
75765|NCT02588482|mismatch negativity (MMN)
75766|NCT02588469|pediatric obesity
75767|NCT02588469|obstructive sleep apnea
75768|NCT02588469|physical exercise
75769|NCT02588469|compression socks
75770|NCT02588469|rostral fluid shift
75771|NCT02588391|premature birth; executive function; preschool
75772|NCT02588365|Attention Deficit Hyperactivity Disorder; executive function; preschool
75773|NCT02588339|Hematologic disorder
75774|NCT02588339|allogeneic hematopoietic cell transplantation
75775|NCT02588326|Bioequivalence
75776|NCT02588326|Suspension nasal spray
75777|NCT02588326|Mometasone furoate
75778|NCT02588326|Pharmacokinetics
75779|NCT02588326|Particle size distribution
75780|NCT02588274|Chronic prostatitis
75781|NCT02588274|chronic pelvic pain syndrome
75782|NCT02588274|acupuncture
75783|NCT02588274|placebo needle
75784|NCT02588274|randomized controlled trial
75785|NCT02588261|erlotinib
75786|NCT02588261|EGFR mutation
75787|NCT02588261|Non-small cell lung cancer (NSCLC)
75788|NCT02588261|ASP8273
75789|NCT02588261|gefitinib
75790|NCT02588183|atrial fibrillation
75791|NCT02588183|catheter ablation
75792|NCT02588183|pulmonary vein
75793|NCT02588183|cryoenergy
75794|NCT02588183|cryoablation
75795|NCT02588183|ArcticFront
75796|NCT02588157|Rapid sequence induction intubation
75797|NCT02588157|McGrath X-Blade
75798|NCT02588157|Glidescope
75799|NCT02588157|Macintosh
75800|NCT02588144|Parkinson's disease
75801|NCT02588144|freezing of gait
75802|NCT02588144|deep brain stimulation
75803|NCT02588144|substantia nigra pars reticulata
75804|NCT02588144|subthalamic nucleus
75805|NCT02588131|tremelimumab
75806|NCT02588131|anti-PD-L1 MEDI4736 (Durvalumab)
75807|NCT02588131|malignant mesothelioma
75808|NCT02588105|Phase I, open label study; safety and efficacy of AZD0156; ATM inhibitor
75809|NCT02588079|Dental Fear
75810|NCT02588079|Dental Phobia
75811|NCT02588079|Internet based cognitive behavioral therapy
75812|NCT02588079|specific phobia
75813|NCT02588079|children and adolescents anxiety
75814|NCT02588079|Self Efficacy
75815|NCT02588040|Chronic Lateral Epicondylitis
75816|NCT02588040|Leukocyte- and Platelet-Rich Plasma
75817|NCT02588040|Recover-L-PRP
75818|NCT02587988|Erectile dysfunction & Hypertension
75819|NCT02587949|acute cerebrovascular stroke
75820|NCT02587936|CKD
75821|NCT02587936|Risk prediction model
75822|NCT02587936|Quality Improvement (QI)
75823|NCT02587936|Pragmatic trial
75824|NCT02587936|Cluster randomization
75825|NCT02587936|Collaborative care
75826|NCT02587936|clinical informatics
75827|NCT02587936|Chronic kidney disease
75828|NCT02587936|hypertension
75829|NCT02587936|high BP
75830|NCT02587936|diabetes
75831|NCT02587897|Ultrasonography
75832|NCT02587897|Nerve Conduction Velocity
75833|NCT02587897|Ergonomics
75834|NCT02587897|Work Related Injury
75835|NCT02587897|Cumulative Trauma Disorders
75836|NCT02587884|Recurrence
75837|NCT02587884|Microvascular Invasion
75838|NCT02587884|Aspartate beta-hydroxylase
75839|NCT02587858|NBIA
75840|NCT02587858|PKAN
75841|NCT02587858|brain iron
75842|NCT02587858|Neurodegeneration with Brain Iron Accumulation
75843|NCT02587858|Hallervorden Spatz Syndrome
75844|NCT02587858|Pantothenate Kinase Associated Neurodegeneration
75845|NCT02587845|total hip arthroplasty
75846|NCT02587845|transexamic acid
75847|NCT02587832|cpap
75848|NCT02587832|HHHFNC
75849|NCT02587832|RDS
75850|NCT02587832|ELBW
75851|NCT02587806|RRMS
75852|NCT02587793|Hepatocellular Carcinoma
75853|NCT02587793|primary culture
75854|NCT02587793|fine-needle aspiration
75855|NCT02587793|cancer-associated fibroblast
75856|NCT02587741|type 2 diabetes mellitus
75857|NCT02587741|Diabetic Retinopathy
75858|NCT02587741|glucose fluctuation
75859|NCT02587741|oxidative stress
75860|NCT02587741|Insulin
75861|NCT02587741|Oral drugs
75862|NCT02587728|Carpal Tunnel Syndrome
75863|NCT02587728|Amyloidosis
75864|NCT02587715|RRMS
75865|NCT02587702|Term Infants
75866|NCT02587650|Metastatic
75867|NCT02587650|BRAF Wild-Type (WT)
75868|NCT02587650|NRAS Wild-Type (WT)
75869|NCT02587650|KRAS Wild-Type (WT)
75870|NCT02587650|HRAS Wild-Type (WT)
75871|NCT02587650|GNAQ Wild-Type (WT)
75872|NCT02587650|GNA11 Wild-Type (WT)
75873|NCT02587650|KIT Wild-Type (WT)
75874|NCT02587624|atrial fibrillation
75875|NCT02587624|catheter ablation
75876|NCT02587624|remote magnetic navigation
75877|NCT02587598|leukemia
75878|NCT02587598|myelodysplastic syndrome (MDS)
75879|NCT02587598|myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
75880|NCT02587598|myelofibrosis (MF)
75881|NCT02587598|lymphoproliferative disorders
75882|NCT02587598|acute myeloid leukemia (AML)
75883|NCT02587598|lymphomas
75884|NCT02587598|multiple myeloma (MM)
75885|NCT02587598|PIM kinases
75886|NCT02587559|physical therapy
75887|NCT02587546|laryngeal carcinoma
75888|NCT02587546|bilateral vocal cord paralysis
75889|NCT02587546|laryngotracheal stenosis
75890|NCT02587546|laser treatment
75891|NCT02587546|decannulation
75892|NCT02587546|voice
75893|NCT02587546|swallowing
75894|NCT02587533|Baroreflex
75895|NCT02587533|Chemoreflex
75896|NCT02587533|Autonomic nervous system
75897|NCT02587533|Sympathetic activity
75898|NCT02587533|Muscle sympathetic nerve activity (MSNA)
75899|NCT02587533|Microneurography
75900|NCT02587533|Electrical baroreflex stimulation
75901|NCT02587533|Resistant hypertension
75902|NCT02587533|Device-based therapy
75903|NCT02587520|Tetanus
75904|NCT02587520|Diphtheria
75905|NCT02587520|Pertussis
75906|NCT02587520|SP0173
75907|NCT02587520|Tdap vaccine
75908|NCT02587481|Acute coronary syndrom
75909|NCT02587481|Chronic obstructive pulmonary disease
75910|NCT02587481|Myocardial infarction
75911|NCT02587481|Blood based biomarkers
75912|NCT02587468|phenolics
75913|NCT02587468|absorption
75914|NCT02587468|fruit & vegetable concentrate
75915|NCT02587468|Bioavailability of phenolic compounds
75916|NCT02587455|Non-small cell carcinoma
75917|NCT02587442|Acute Radiation Syndrome
75918|NCT02587442|ARS
75919|NCT02587442|Amifostine
75920|NCT02587442|Radio-protectants
75921|NCT02587416|Pharmacokinetics
75922|NCT02587416|Lipid Regulator
75923|NCT02587390|Pharmacokinetics
75924|NCT02587390|Lipid Regulator
75925|NCT02587364|Pharmacokinetics
75926|NCT02587364|Lipid Regulator
75927|NCT02587351|Chronic Obstructive Pulmonary Disease
75928|NCT02587351|COPD
75929|NCT02587351|Exacerbation
75930|NCT02587351|Lung function
75931|NCT02587351|Cardiac
75932|NCT02587351|Cardiovascular
75933|NCT02587351|Beta blockers
75934|NCT02587351|Metoprolol succinate
75936|NCT02587338|Subjective Memory Impairment
75937|NCT02587338|tDCS
75938|NCT02587338|NIRS
75939|NCT02587338|Cognitive Training
75940|NCT02587338|Working Memory
75941|NCT02587286|mHealth
75942|NCT02587286|Telemedicine
75943|NCT02587286|Randomized Controlled Trial
75944|NCT02587286|Glucose control
75945|NCT02587273|Critical care
75946|NCT02587273|Intensive Care
75947|NCT02587273|Fentanyl
75948|NCT02587273|Pharmacokinetics
75949|NCT02587273|Multiple Organ Failure
75950|NCT02587260|P2Y12 inhibitors
75951|NCT02587260|Acute Coronary Syndrome (ACS)
75952|NCT02587260|Endothelial function
75953|NCT02587260|Adenosine measurement in human subject
75954|NCT02587260|Endopath
75955|NCT02587234|motor recovery
75956|NCT02587234|chronic
75957|NCT02587234|human
75958|NCT02587234|sensory
75959|NCT02587234|afferent input
75960|NCT02587234|motor training
75961|NCT02587208|circumcision
75962|NCT02587208|plastibell
75963|NCT02587208|infants
75964|NCT02587208|open sleeve
75965|NCT02587195|Multiple Sclerosis
75966|NCT02587169|liposarcoma
75967|NCT02587169|leiomyosarcoma
75968|NCT02587169|retroperitoneum
75969|NCT02587169|chondrosarcoma
75970|NCT02587130|intractable pain
75971|NCT02587130|pressure ulcer
75972|NCT02587130|bed sore
75973|NCT02587130|palliative medicine
75974|NCT02587130|ketamine
75975|NCT02587130|pain management
75976|NCT02587117|Antioxidant
75977|NCT02587117|Lycopene
75978|NCT02587117|Prednisolone
75979|NCT02587104|Diabetes Mellitus
75980|NCT02587104|Foot Diseases
75981|NCT02587104|Foot Ulcer
75982|NCT02587078|Haemodynamic stabilization
75983|NCT02587052|biopsy-proven acute rejection
75984|NCT02587052|graft loss
75985|NCT02587052|graft survival
75986|NCT02587039|delirium
75987|NCT02587039|heart
75988|NCT02587039|valve
75989|NCT02587039|graft
75990|NCT02587039|surgery
75991|NCT02587039|coronary
75992|NCT02587026|Biorepository
75993|NCT02587026|Precision Genomics
75994|NCT02587000|adenomyosis
75995|NCT02587000|ulipristal acetate
75996|NCT02587000|sonography
75997|NCT02587000|Magnetic resonance imaging [MRI]
75998|NCT02587000|Pictorial Blood-loss Assessment Chart [PBAC]
75999|NCT02586987|selumetinib
76000|NCT02586987|MEDI4736
76001|NCT02586987|safety
76002|NCT02586987|tolerability
76003|NCT02586987|pharmacokinetics
76004|NCT02586987|patients with advanced solid tumours
76005|NCT02586987|disease progression
76006|NCT02586974|CO2 insufflation
76007|NCT02586974|robot assisted radical prostatectomy
76008|NCT02586974|laparoscopy
76009|NCT02586974|hypothermia
76010|NCT02586974|cytokine response
76011|NCT02586961|randomized prospective study
76012|NCT02586961|complication rate
76013|NCT02586961|bronchiolitis
76014|NCT02586961|children
76015|NCT02586948|extracorporeal CO2 removal
76016|NCT02586935|ASD
76017|NCT02586935|Autism
76018|NCT02586909|Alzheimer's disease
76019|NCT02586909|RVT-101
76020|NCT02586909|donepezil
76021|NCT02586883|Dilation of the Bronchi
76022|NCT02586883|Bronchial potential difference
76023|NCT02586883|Dilation of the Bronchi (DDB)
76024|NCT02586857|Glioblastoma Multiforme
76025|NCT02586857|GBM
76026|NCT02586844|NET
76027|NCT02586844|PanNET
76028|NCT02586844|Molecular profiling
76029|NCT02586844|Transcriptome sequencing
76030|NCT02586831|Diabetes Mellitus, Type 1
76031|NCT02586831|Hypoglycemia
76032|NCT02586831|Autoimmune Diseases
76033|NCT02586831|Diabetes Mellitus
76034|NCT02586805|DX-2930
76035|NCT02586805|Hereditary Angioedema
76036|NCT02586805|Dyax
76037|NCT02586792|H7N7
76038|NCT02586792|H7N9
76039|NCT02586792|Influenza
76040|NCT02586792|Intramusclar
76041|NCT02586792|Non-adjuvanted
76042|NCT02586792|Open-Label
76043|NCT02586792|sub-study
76044|NCT02586792|Vaccine
76045|NCT02586779|Referral and consultation
76046|NCT02586779|emergency department
76047|NCT02586779|WhatsApp
76048|NCT02586766|Youth Violence
76049|NCT02586727|Radiation Retinopathy
76050|NCT02586727|aflibercept
76051|NCT02586688|child depression
76052|NCT02586688|depression
76053|NCT02586688|Transcranial Magnetic Stimulation
76054|NCT02586688|Adolescent Major Depressive Disorder
76055|NCT02586688|TMS
76056|NCT02586688|adolescent depression
76057|NCT02586675|ER+ breast cancer
76058|NCT02586675|PR+ breast cancer
76059|NCT02586675|hormone receptor positive
76060|NCT02586675|HER2- breast cancer
76061|NCT02586675|HER2 negative
76062|NCT02586675|locally advanced
76063|NCT02586675|metastatic
76064|NCT02586662|scapular dyskinesis
76065|NCT02586662|kinematics
76066|NCT02586649|tiotropium bromide
76067|NCT02586636|Metformin
76068|NCT02586636|OCT1
76069|NCT02586610|Pembrolizumab
76070|NCT02586610|Chemoradiation
76071|NCT02586610|Anti-PD-1 Antibody
76072|NCT02586610|MK-3475
76073|NCT02586597|Stroke
76074|NCT02586597|PAS
76075|NCT02586597|TMS
76076|NCT02586597|cortical excitability
76077|NCT02586597|plasticity
76078|NCT02586584|Patient-Reported Outcome, Antiretroviral Therapy
76079|NCT02586571|Body Composition
76080|NCT02586571|Breast Feeding
76081|NCT02586571|Growth
76082|NCT02586571|Infant
76083|NCT02586571|Milk, Human
76084|NCT02586571|Nutritional Sciences
76085|NCT02586571|Weaning
76086|NCT02586532|Detection
76087|NCT02586532|Cancer
76088|NCT02586532|Antibody
76089|NCT02586532|Biopsy
76090|NCT02586532|Registry
76091|NCT02586519|wearable technology
76092|NCT02586519|Orpyx
76093|NCT02586519|SurroSense Rx
76094|NCT02586519|smart insole
76095|NCT02586519|TCC
76096|NCT02586519|total contact cast
76097|NCT02586519|insole
76098|NCT02586519|removable cast walker
76099|NCT02586519|RCW
76100|NCT02586506|correct use of inhaler
76101|NCT02586506|dose left
76102|NCT02586506|ease of use
76103|NCT02586506|ELLIPTA
76104|NCT02586506|Asthma
76105|NCT02586493|Placebo
76106|NCT02586493|ELLIPTA inhaler
76107|NCT02586493|Correct use
76108|NCT02586493|COPD
76109|NCT02586493|Ease of use
76110|NCT02586480|bradycardia
76111|NCT02586454|Transmuscular quadratus lumborum block, total abdominal hysterectomy
76112|NCT02586441|Bispectral index (BIS)
76113|NCT02586441|EEG
76114|NCT02586441|Depth of anesthesia
76115|NCT02586415|endovascular
76116|NCT02586415|endovascular procedure
76117|NCT02586415|Mechanical Thrombectomy
76118|NCT02586402|ESAs CKD
76119|NCT02586363|Entecavir
76120|NCT02586363|Food effect
76121|NCT02586363|Cavir Tab 0.5mg
76122|NCT02586363|Baraclude Tab. 0.5mg
76123|NCT02586285|S-Adenosyl Methionine
76124|NCT02586285|Recurrence
76125|NCT02586272|Embryo Transfer
76126|NCT02586272|assisted reproductive technology
76127|NCT02586246|CDP870
76128|NCT02586246|Rheumatoid arthritis
76129|NCT02586246|Long-term
76130|NCT02586233|Acute Ischemic Stroke in the anterior circulation
76131|NCT02586207|Larynx
76132|NCT02586207|Squamous Cell
76133|NCT02586207|Oral cavity
76134|NCT02586207|Oropharynx
76135|NCT02586207|Hypopharynx
76136|NCT02586194|Impaired hepatic function
76137|NCT02586194|Pharmacokinetics
76138|NCT02586194|ASP015K
76139|NCT02586168|Insulin Resistance
76140|NCT02586168|Lipid Regulator
76141|NCT02586142|spasticity
76142|NCT02586142|claw toe
76143|NCT02586142|ultrasounds guidance
76144|NCT02586142|botulinum toxin
76145|NCT02586142|stretching exercise
76146|NCT02586090|Pediatric Obesity
76147|NCT02586090|Lifestyle Intervention
76148|NCT02586090|Family-based Intervention
76149|NCT02586090|Motivational Interviewing
76150|NCT02586064|posttraumatic stress disorder
76151|NCT02586064|Veterans
76152|NCT02586064|Psychotherapy
76153|NCT02586064|Randomized Controlled Trial
76154|NCT02585999|Extended use of contraceptive patch
76155|NCT02585973|AZD1775
76156|NCT02585973|Cisplatin
76157|NCT02585973|Head and Neck Squamous Cell Carcinoma
76158|NCT02585973|HNSCC
76159|NCT02585973|Chemoradiotherapy
76160|NCT02585973|Radiotherapy
76161|NCT02585973|CRT
76162|NCT02585947|Non-Hodgkin's Lymphoma
76163|NCT02585947|Tenofovir
76164|NCT02585934|Alzheimer's disease
76165|NCT02585934|RVT-101
76166|NCT02585934|donepezil
76167|NCT02585934|intepirdine
76168|NCT02585934|dementia
76169|NCT02585921|Urban Health
76170|NCT02585895|LDL-C Apheresis
76171|NCT02585895|Hypercholesterolemia
76172|NCT02585895|Elevated Cholesterol
76173|NCT02585895|High Cholesterol
76174|NCT02585895|PCSK9 mutations
76175|NCT02585895|Severe Familial Hypercholesterolemia
76176|NCT02585895|evolocumab
76177|NCT02585895|Repatha
76178|NCT02585869|Lipid Regulator
76179|NCT02585869|TG
76180|NCT02585856|Biliary duct carcinoma
76181|NCT02585856|Photodynamic therapy
76182|NCT02585843|Heart Failure
76183|NCT02585843|Mineralocorticoid receptor antagonists
76184|NCT02585843|Loop diuretic resistance
76185|NCT02585817|Cardiac Implantable Electronic Devices
76186|NCT02585804|FSGS, SGLT2, chronic kidney disease, GFR, proteinuria
76187|NCT02585791|electronic cigarette
76188|NCT02585791|airway inflammation
76189|NCT02585791|nasal potential difference
76190|NCT02585726|Varicose Veins
76191|NCT02585726|Great Saphenous Vein
76192|NCT02585726|Venous Insufficiency
76193|NCT02585687|Liver Perfusion MRI, Hepatocellular carcinoma
76194|NCT02585622|Diabetic Kidney Disease
76195|NCT02585622|Mesenchymal Stromal Cells (MSC)
76196|NCT02585622|immune response
76197|NCT02585622|allogeneic
76198|NCT02585622|disease progression
76199|NCT02585609|Sleep
76200|NCT02585583|Deep Brain
76201|NCT02585583|Essential tremor
76202|NCT02585583|Parkinson Disease
76203|NCT02585583|Tremor
76204|NCT02585583|Radiosurgery
76205|NCT02585583|Thalamotomy
76206|NCT02585583|deep brain stimulation
76207|NCT02585583|DBS
76208|NCT02585583|intractable, drug resistant, invalidating tremor
76209|NCT02585570|shoulder
76210|NCT02585570|phenylephrine
76211|NCT02585570|hypotension
76212|NCT02585544|genital prolapse
76213|NCT02585544|day-care management
76214|NCT02585544|vaginal route
76215|NCT02585544|prosthetic reinforcement
76216|NCT02585531|Bronchiolitis
76217|NCT02585531|Dexamethasone
76218|NCT02585531|Epinephrine
76219|NCT02585531|Hypertonic saline
76220|NCT02585427|Diabetes
76221|NCT02585427|Obesity
76222|NCT02585427|metabolic disorders
76223|NCT02585388|pretreated metastatic breast cancer
76224|NCT02585362|palliative
76225|NCT02585336|Sugar-Sweetened beverages
76226|NCT02585336|Metabolic health
76227|NCT02585336|Soft drinks
76228|NCT02585323|Physical activity
76229|NCT02585323|Osteoarthritis
76230|NCT02585323|Knee
76231|NCT02585323|Exercise
76232|NCT02585323|Arthritis
76233|NCT02585310|PRBC transfusion
76234|NCT02585310|CABGs
76235|NCT02585245|Hospital Nutrition screens
76236|NCT02585232|Behavioral sciences
76237|NCT02585232|Counseling
76238|NCT02585232|Intervention Studies
76239|NCT02585232|Cognitive Behavioral Therapy
76240|NCT02585232|Telemedicine
76241|NCT02585232|Mindfulness
76242|NCT02585206|Mobile Phone
76243|NCT02585206|Text Messaging
76244|NCT02585206|Internet
76245|NCT02585206|Tobacco Use
76246|NCT02585180|Ventilator-associated pneumonia
76247|NCT02585180|Surveillance
76248|NCT02585180|Subglottic-secretions
76249|NCT02585180|Critically ill patients
76250|NCT02585180|Prevention
76251|NCT02585167|VAAFT
76252|NCT02585167|anal fistula
76253|NCT02585167|sphincter reconstruction
76254|NCT02585154|Deep Brain Stimulation
76255|NCT02585128|Delirium
76256|NCT02585128|Transcatheter Aortic Valve Implantation
76257|NCT02585128|Elderly
76258|NCT02585102|Vegetables
76259|NCT02585089|Hypertension
76260|NCT02585089|active biopeptide
76261|NCT02585089|cardiovascular pathophysiology
76262|NCT02585089|angiotensin converting enzyme inhibition
76263|NCT02585089|cured-pork ham
76264|NCT02585076|Stroke prevention
76265|NCT02585076|Risk assessment
76266|NCT02585063|independent prescribing,
76267|NCT02585063|optometrist
76268|NCT02585063|acute care
76269|NCT02585050|do not attempt resuscitation
76270|NCT02585050|neurological outcome
76271|NCT02585050|live discharged ratio
76272|NCT02585024|smoking
76273|NCT02585024|cytisine
76274|NCT02585024|Pharmacokinetics
76275|NCT02585011|Hemiarthroplasty
76276|NCT02585011|Anesthesia, Local
76277|NCT02585011|Pain, Postoperative
76278|NCT02584972|Postural control
76279|NCT02584972|Gait
76280|NCT02584972|Children
76281|NCT02584972|Autism Spectrum Disorder
76282|NCT02584933|ALK
76283|NCT02584933|Malignancies
76284|NCT02584907|Critically ill
76285|NCT02584907|Diet
76286|NCT02584907|Blood glucose
76287|NCT02584894|Stress Disorders, Post-Traumatic
76288|NCT02584894|trauma exposure
76289|NCT02584894|Repeated transcranial magnetic stimulation
76290|NCT02584855|Spondyloarthritis
76291|NCT02584855|Spondylarthropathy
76292|NCT02584816|BRV-PV
76293|NCT02584816|Rotavirus vaccine
76294|NCT02584816|lot-to-lot consistency
76295|NCT02584816|interference with routine immunization
76296|NCT02584790|Nasopharyngeal carcinoma
76297|NCT02584790|Narrow band imaging
76298|NCT02584777|Post-essential thrombocythemia myelofibrosis
76299|NCT02584777|Post-Polycythemia Vera Myelofibrosis
76300|NCT02584738|Asthma
76301|NCT02584738|Exacerbation
76302|NCT02584738|Nebulization
76303|NCT02584738|Magnesium
76304|NCT02584738|Pediatric
76305|NCT02584725|Tranexamic Acid
76306|NCT02584725|Total Joint Arthroplasty
76307|NCT02584725|Intraoperative Blood Loss
76308|NCT02584660|Rivaroxaban
76309|NCT02584660|JNJ39039039
76310|NCT02584660|Pulmonary embolism
76311|NCT02584647|Unresectable
76312|NCT02584634|Non-Small Cell Lung Cancer
76313|NCT02584634|NSCLC
76314|NCT02584634|ALK
76315|NCT02584634|avelumab
76316|NCT02584634|crizotinib
76317|NCT02584634|PF-06463922
76318|NCT02584595|Tachycardia
76319|NCT02584595|Ventricular Tachycardia
76320|NCT02584595|Cardiac Arrhythmias
76321|NCT02584595|Cardiovascular Diseases
76322|NCT02584595|Heart Diseases
76323|NCT02584582|Glucagon
76324|NCT02584582|Glukagon-like peptide-1 (GLP-1)
76325|NCT02584582|GLP-1 receptor agonist (GLP-1RA)
76326|NCT02584582|Incretins
76327|NCT02584569|Drug therapy
76328|NCT02584530|ultrasound
76329|NCT02584530|PICC line
76330|NCT02584530|neonate
76331|NCT02584517|Vasculitis
76332|NCT02584517|Autoimmune disease
76333|NCT02584517|Connective tissue disease
76334|NCT02584517|Polymyalgia rheumatica
76335|NCT02584517|Musculoskeletal Diseases
76336|NCT02584517|Immune disorder
76337|NCT02584517|Rheumatic disease
76338|NCT02584478|Dual receptor Tyrosine Kinase Inhibitor
76339|NCT02584478|Anti-angiogenic therapy
76340|NCT02584478|Combination Therapy
76341|NCT02584439|ivabradine
76342|NCT02584439|heart rate
76343|NCT02584439|aging
76344|NCT02584439|visco-elasticity
76345|NCT02584426|Cefazolin
76346|NCT02584400|prostatic tumors
76347|NCT02584400|[18F]HX4 Pet imaging
76348|NCT02584400|hypoxia
76349|NCT02584400|phase II trial
76350|NCT02584400|esophageal tumors
76351|NCT02584400|rectal tumors
76352|NCT02584400|brain metastases
76353|NCT02584400|primary brain tumors
76354|NCT02584374|iliac vein compression
76355|NCT02584361|Hearing loss
76356|NCT02584361|Cochlear implant
76357|NCT02584348|ultrasound, antrum, pulmonary aspiration, emergency surgery
76358|NCT02584335|wound treatment
76359|NCT02584335|lidocaine
76360|NCT02584335|pain reduction
76361|NCT02584335|local anesthetic
76362|NCT02584283|Liver Transplantation
76363|NCT02584283|Donation after Circulatory Death
76364|NCT02584283|Machine Perfusion
76365|NCT02584270|palatal drop prosthesis
76366|NCT02584231|Desmopressin
76367|NCT02584231|Paediatrics
76368|NCT02584231|urinary concentration test
76369|NCT02584205|inspiratory muscle training
76370|NCT02584205|obstructive sleep apnea
76371|NCT02584205|functional capacity
76372|NCT02584179|mpMRI, significant cancer
76373|NCT02584166|Morbidity
76374|NCT02584166|Mortality
76375|NCT02584166|conferences
76376|NCT02584166|human science
76377|NCT02584153|Hernia
76378|NCT02584153|Ventral
76379|NCT02584153|Incisional
76380|NCT02584153|Abdominal
76381|NCT02584153|Herniorrhaphy
76382|NCT02584153|Recurrence
76383|NCT02584153|laparotomy
76384|NCT02584153|prevention
76385|NCT02584140|PrEP
76386|NCT02584140|Pre-exposure Prophylaxis
76387|NCT02584140|HIV Prevention
76388|NCT02584127|Smoking
76389|NCT02584127|cessation
76390|NCT02584127|Internet program
76391|NCT02584101|Acceptance and Commitment Therapy
76392|NCT02584088|NovaSure
76393|NCT02584088|Ablation
76394|NCT02584088|Menorrhagia
76395|NCT02584088|Endometrium
76396|NCT02584049|Osteopathic treatment
76397|NCT02584049|Care-induced Pain
76398|NCT02584049|Pain
76399|NCT02584049|Elderly
76400|NCT02584036|influenza
76401|NCT02584036|vaccine
76402|NCT02584036|public health
76403|NCT02584036|preventable disease
76404|NCT02584036|vaccine history
76405|NCT02584036|point-of-care
76406|NCT02584023|ultrasonography
76407|NCT02584023|infant
76408|NCT02584023|perioperative period
76409|NCT02584023|general anesthesia
76410|NCT02584010|Postoperative scars
76411|NCT02584010|Cicatrix
76412|NCT02584010|Cicatrization
76413|NCT02583997|To suture or not to suture....
76414|NCT02583997|Tooth extraction
76415|NCT02583997|Third molar
76416|NCT02583971|Direct current cardioversion
76417|NCT02583971|Medical management
76418|NCT02583971|Atrial fibrillation ablation
76419|NCT02583945|acute kidney injury
76420|NCT02583945|hemodynamic stabilisation
76421|NCT02583945|nephrotoxic medication
76422|NCT02583932|Randomized controlled trial
76423|NCT02583932|Psychological
76424|NCT02583932|Meaning
76425|NCT02583932|Existential
76426|NCT02583932|Quality of life
76427|NCT02583932|Intervention
76428|NCT02583932|Cancer
76429|NCT02583932|Advanced disease
76430|NCT02583932|New diagnosis
76431|NCT02583880|nutritional status
76432|NCT02583880|malnutrition
76433|NCT02583880|energy intake
76434|NCT02583880|caloric deficit
76435|NCT02583880|ICU
76436|NCT02583880|hospital
76437|NCT02583880|enteral nutrition
76438|NCT02583880|parenteral nutrition
76439|NCT02583880|nutrition
76440|NCT02583854|Coronary angiography
76441|NCT02583854|Transradial
76442|NCT02583854|Patient experience
76443|NCT02583854|VAS
76444|NCT02583854|Compression device
76445|NCT02583802|MHD
76446|NCT02583802|ear pills
76447|NCT02583802|Shengmai capsule
76448|NCT02583802|Chinese medicine treatment
76449|NCT02583776|continuous glucose monitoring (cgm)
76450|NCT02583776|neonatal hypoglycemia
76451|NCT02583776|very low birth weight infants (VLBWI)
76452|NCT02583776|preterm infants
76453|NCT02583763|pro-brain natriuretic peptide (1-76)
76454|NCT02583763|Insulin-Like Growth Factor Binding Proteins
76455|NCT02583763|Insulin-Like Growth Factor I
76456|NCT02583763|Echocardiography
76457|NCT02583763|Velocity Vector Imaging
76458|NCT02583763|Heart Function Tests
76459|NCT02583750|glucose metabolism
76460|NCT02583750|sleep deprivation
76461|NCT02583737|bone
76462|NCT02583737|maxillary sinus
76463|NCT02583672|Gaucher Disease
76464|NCT02583659|Gastric cancer
76465|NCT02583659|First-line chemotherapy
76466|NCT02583659|Biomarker
76467|NCT02583646|Obesity
76468|NCT02583646|Puberty
76469|NCT02583646|Ultrasound
76470|NCT02583646|Pediatric
76471|NCT02583620|high myopia
76472|NCT02583568|breast cancer
76473|NCT02583568|image-guided surgery
76474|NCT02583555|Quality of Life
76475|NCT02583555|Health Care Utilization
76476|NCT02583542|breast
76477|NCT02583542|lung
76478|NCT02583542|squamous
76479|NCT02583542|KRAS
76480|NCT02583542|AZD
76481|NCT02583542|selumetinib
76482|NCT02583529|Parkinson Disease
76483|NCT02583529|Neurogenic Overactive Bladder
76484|NCT02583529|Posterior Tibial Nerve Electrostimulation
76485|NCT02583503|Total knee arthroplasty
76486|NCT02583503|Total knee replacement
76487|NCT02583503|TKA
76488|NCT02583503|TKR
76489|NCT02583490|Electroconvulsive Therapy
76490|NCT02583490|Low Pulse Amplitude Focal Electroconvulsive Therapy
76491|NCT02583490|ECT
76492|NCT02583490|Depression
76493|NCT02583490|Suicidal Ideation
76494|NCT02583477|Pancreatic Ductal Adenocarcinoma, PDAC, immunotherapy, PDL1, AZD5069, MEDI4736
76495|NCT02583438|Gut Microbiota
76496|NCT02583438|inflammatory marker
76497|NCT02583438|Glucose and lipid metabolism
76498|NCT02583399|Pediatric (Birth to less than 6 months of age)
76499|NCT02583399|Pain
76500|NCT02583399|Fever
76501|NCT02583386|mobility
76502|NCT02583386|falls
76503|NCT02583386|fall prevention
76504|NCT02583386|gait and balance
76505|NCT02583386|automatic fall detector
76506|NCT02583373|Pneumonia
76507|NCT02583373|Streptococcus pneumoniae
76508|NCT02583373|Pneumolysin
76509|NCT02583360|Infant
76510|NCT02583360|Feeding difficulties
76511|NCT02583360|Dysphagia
76512|NCT02583334|acupuncture
76513|NCT02583334|fibromyalgia
76514|NCT02583334|rheumatism
76515|NCT02583334|clinical trial
76516|NCT02583321|chlorhexidine gluconate
76517|NCT02583321|oral care
76518|NCT02583321|mechanical ventilation
76519|NCT02583321|critically ill patients
76520|NCT02583321|tracheal secretions
76521|NCT02583321|subglottic secretions
76522|NCT02583308|Ventilator-associated pneumonia
76523|NCT02583308|Surveillance
76524|NCT02583308|Subglottic-secretions
76525|NCT02583308|Critically ill patients
76526|NCT02583308|Prevention
76527|NCT02583295|Awareness
76528|NCT02583295|Cardiac Surgery
76529|NCT02583295|Maternal
76530|NCT02583295|Pediatric
76531|NCT02583295|Sound
76532|NCT02583295|Music
76533|NCT02583243|Opioid dependence
76534|NCT02583243|HIV/AIDS
76535|NCT02583243|Hepatitis C
76536|NCT02583243|Severe mental illness
76537|NCT02583243|Injection Drug Use
76538|NCT02583230|Antidepressant Medication
76539|NCT02583230|Adherence
76540|NCT02583230|Mobile Smartphone Intervention
76541|NCT02583230|Telemedicine
76542|NCT02583230|Primary Care
76543|NCT02583217|Laryngeal mask
76544|NCT02583217|Ketamine
76545|NCT02583217|Remifentanyl
76546|NCT02583165|advanced solid tumors
76547|NCT02583165|immunotherapy
76548|NCT02583165|immuno-oncology
76549|NCT02583139|Children, Moderate and/or highly emetogenic chemotherapy
76550|NCT02583126|Teenager
76551|NCT02583126|moderate and/or highly emetogenic chemotherapy
76552|NCT02583113|Total Knee Replacement
76553|NCT02583113|Unicompartment Knee Replacement
76554|NCT02583087|Barrett esophagus
76555|NCT02583087|Esophageal adenocarcinoma
76556|NCT02583087|Endoscopic submucosal dissection
76557|NCT02583074|deep brain stimulation
76558|NCT02583074|Subthalamic Nucleus
76559|NCT02583074|dystonia
76560|NCT02583035|cancer
76561|NCT02583035|geriatric
76562|NCT02582996|Headache
76563|NCT02582996|Aura
76564|NCT02582996|Migraine
76565|NCT02582996|Moderate to Severe
76566|NCT02582957|ARDS
76567|NCT02582957|Shock Lung
76568|NCT02582957|Acute Chest Syndrome
76569|NCT02582957|Respiratory Distress Syndrome, Adult
76570|NCT02582957|Respiratory insufficiency
76571|NCT02582957|Trauma
76572|NCT02582918|Randomized Controlled Trial
76573|NCT02582918|Mass Screening
76574|NCT02582905|Alcohol Use Disorder
76575|NCT02582905|Bipolar Disorder
76576|NCT02582905|Mood
76577|NCT02582905|Alcohol craving
76578|NCT02582905|Pregnenolone
76579|NCT02582905|Citicoline
76580|NCT02582879|Chronic Lymphocytic Leukemia
76581|NCT02582879|CLL
76582|NCT02582879|Small Lymphocytic Leukemia
76583|NCT02582879|SLL
76584|NCT02582866|Lacosamide
76585|NCT02582866|Vimpat
76586|NCT02582866|Epilepsy
76587|NCT02582866|Partial onset seizures
76588|NCT02582866|Tonic-clonic seizures
76589|NCT02582866|Monotherapy
76590|NCT02582866|AED
76591|NCT02582853|GBS
76592|NCT02582853|AIDP
76593|NCT02582853|Spinal fluid
76594|NCT02582853|sCD163
76595|NCT02582840|Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
76596|NCT02582827|Advanced Solid Tumors
76597|NCT02582827|solid tumor
76598|NCT02582827|lymphoma
76599|NCT02582814|Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
76600|NCT02582801|PET/CT
76601|NCT02582801|Alfatide Ⅱ
76602|NCT02582801|breast cancer
76603|NCT02582762|Nail gel
76604|NCT02582762|Nail surface abnormality
76605|NCT02582762|Efficacy
76606|NCT02582749|Androgen Deprivation Therapy
76607|NCT02582749|Androgen Receptor Antagonist
76608|NCT02582749|Radium-223 Dichloride
76609|NCT02582749|Placebo
76610|NCT02582736|Antipsychotics
76611|NCT02582736|Drug side effects
76612|NCT02582736|Psychosis
76613|NCT02582736|Hyperglycemic emergencies
76614|NCT02582736|Diabetes
76615|NCT02582736|Epidemiology
76616|NCT02582736|Database research
76617|NCT02582736|CNODES
76618|NCT02582697|Germ Cell
76619|NCT02582697|Intermediate and poor-risk metastatic germ cell tumours
76620|NCT02582671|Real World Effectiveness
76621|NCT02582658|Paritaprevir
76622|NCT02582658|Dasabuvir
76623|NCT02582658|Ombitasvir
76624|NCT02582658|Chronic Hepatitis C
76625|NCT02582658|HCV
76626|NCT02582645|impaction
76627|NCT02582645|impacted canine
76628|NCT02582645|palatally
76629|NCT02582645|open window
76630|NCT02582645|closed window
76631|NCT02582645|management
76632|NCT02582632|Hepatitis C Virus
76633|NCT02582632|Interferon-Free
76634|NCT02582632|Ribavirin-Free
76635|NCT02582632|Hepatitis C
76636|NCT02582632|Hepatitis C Genotype 1b
76637|NCT02582619|Spinal Cord Injury and Employment
76638|NCT02582606|Insulin Resistance
76639|NCT02582606|Meal pattern
76640|NCT02582606|Obese
76641|NCT02582593|Cognitive Aging
76642|NCT02582593|Neuromodulation
76643|NCT02582593|Low Level Light Therapy
76644|NCT02582593|Near Infrared Light
76645|NCT02582593|Neurostimulation
76646|NCT02582580|pelvic floor
76647|NCT02582580|perineal trauma
76648|NCT02582580|physiotherapy
76649|NCT02582580|perineal integrity
76650|NCT02582567|Pregnant Women
76651|NCT02582567|Quality of Life
76652|NCT02582567|Exercise
76653|NCT02582567|Sleep
76654|NCT02582567|Fetal Research
76655|NCT02582567|Diet, Mediterranean
76656|NCT02582567|Physical Fitness
76657|NCT02582567|Oxidative stress
76658|NCT02582567|Inflammation
76659|NCT02582528|cognitive remediation
76660|NCT02582528|cognition
76661|NCT02582528|youth
76662|NCT02582528|mental health
76663|NCT02582528|functional outcome
76664|NCT02582515|d-cycloserine
76665|NCT02582515|comprehensive behavioral intervention for tics
76666|NCT02582515|habit reversal training
76667|NCT02582502|Hyperbaric Oxygen
76668|NCT02582502|HBOT
76669|NCT02582502|Hyperbaric Chamber
76670|NCT02582502|Pressurized Oxygen
76671|NCT02582489|Mesenchymal stem cells
76672|NCT02582489|Bone marrow aspirate concentrate
76673|NCT02582476|Hypokalemic Periodic Paralysis
76674|NCT02582476|Bumetanide
76675|NCT02582476|Periodic Paralysis
76676|NCT02582463|Risk Assessment
76677|NCT02582463|Hospitals
76678|NCT02582463|Pharmacists
76679|NCT02582463|Medication Systems
76680|NCT02582463|Patient Selection
76681|NCT02582463|Prognosis research
76682|NCT02582450|Haemophilia
76683|NCT02582450|Adherence of Treatment
76684|NCT02582450|Knowledge of Illness
76685|NCT02582450|Medical-patient Relationship
76686|NCT02582450|Illness Behavior
76687|NCT02582450|Treatment Difficulties
76688|NCT02582450|Veritas
76689|NCT02582437|Minimum Alveolar Concentration
76690|NCT02582411|Healthy Subjects
76691|NCT02582385|Amyotrophic lateral sclerosis (ALS)
76692|NCT02582385|Cytokines
76693|NCT02582385|Neuropathology
76694|NCT02582359|Acute Myeloid Leukemia
76695|NCT02582346|MRI
76696|NCT02582346|Neurography
76697|NCT02582346|Tractography
76698|NCT02582346|Pelvic nerves
76699|NCT02582203|Ceftaroline fosamil
76700|NCT02582203|Vancomycin
76701|NCT02582203|Acute bacterial skin and skin structure infections
76702|NCT02582203|Methicillin-resistant S. aureus
76703|NCT02582190|electrical cardioversion
76704|NCT02582190|persistent atrial fibrillation
76705|NCT02582177|Fungal infection
76706|NCT02582177|Skin infection
76707|NCT02582177|Dermatophytoses
76708|NCT02582164|Optical Coherence Tomography (OCT)
76709|NCT02582164|Swept Source OCT
76710|NCT02582138|physical frailty
76711|NCT02582138|sarcopenia
76712|NCT02582138|exercise
76713|NCT02582138|nutrition
76714|NCT02582138|information and communications technology
76715|NCT02582125|ONO-4538
76716|NCT02582125|Advanced non-small cell lung cancer
76717|NCT02582047|influenza vaccine
76718|NCT02582047|pneumococcal vaccine
76719|NCT02582047|simultaneous vaccination
76720|NCT02582034|Optimized Dosimetry versus standard Dosimetry
76721|NCT02582034|Internal Radiation Therapy
76722|NCT02582021|Microvascular Coronary Dysfunction (MCD)
76723|NCT02582021|Magnetic resonance imaging (MRI)
76724|NCT02582021|Coronary angiography
76725|NCT02582021|Coronary Vascular Dysfunction (CVD)
76726|NCT02581995|Diabetic macular edema
76727|NCT02581995|Intravitreal injection
76728|NCT02581969|Hemophilia A, Congenital
76729|NCT02581956|Immunology
76730|NCT02581891|Neovascular age-related macular degeneration
76731|NCT02581891|nAMD)
76732|NCT02581878|Thorium-227
76733|NCT02581878|BAY1862864 Injection
76734|NCT02581878|Safety
76735|NCT02581878|Pharmacokinetics
76736|NCT02581878|CD22
76737|NCT02581878|Radioimmunotherapy
76738|NCT02581839|eribulin
76739|NCT02581839|central nervous system
76740|NCT02581839|CNS
76741|NCT02581839|Eribulin Mesylate
76742|NCT02581839|Halaven
76743|NCT02581813|Bone health
76744|NCT02581813|Body composition
76745|NCT02581813|Dairy foods
76746|NCT02581813|Exercise
76747|NCT02581813|inflammation
76748|NCT02581813|nutrition intervention
76749|NCT02581813|weight management
76750|NCT02581774|induction
76751|NCT02581774|cesarean delivery
76752|NCT02581761|Hemodynamically stable women >18 years old
76753|NCT02581761|with abnormal plateauing serum βHCG
76754|NCT02581735|Haemophilia
76755|NCT02581735|Adherence
76756|NCT02581735|Prophylaxis treatment
76757|NCT02581735|Quality of Life
76758|NCT02581735|Illness Behavior
76759|NCT02581735|Veritas-Pro questionnaire
76760|NCT02581735|uPatient
76761|NCT02581722|PrePex, Male Circumcision, HIV Prevention, Adolescents
76762|NCT02581709|Feasibility study
76763|NCT02581709|Cognition
76764|NCT02581709|Chemotherapy
76765|NCT02581709|Neoplasms
76766|NCT02581670|oligometastatic breast cancer
76767|NCT02581618|ischemic preconditioning
76768|NCT02581618|myocardial injury
76769|NCT02581618|percutaneous coronary intervention
76770|NCT02581592|Hepatic Impairment
76771|NCT02581592|Hepatitis
76772|NCT02581592|Liver Cirrhosis
76773|NCT02581579|Tuberculosis
76774|NCT02581579|Tregs
76775|NCT02581579|Tolerance
76776|NCT02581579|Probiotic
76777|NCT02581579|Mycobacteria
76778|NCT02581540|Troponin
76779|NCT02581540|High Sensitivity Troponin T
76780|NCT02581540|MACE
76781|NCT02581540|risk stratification
76782|NCT02581540|suspected cardiac chest pain
76783|NCT02581540|Acute Coronary Syndrome
76784|NCT02581540|GRACE
76785|NCT02581540|TIMI
76786|NCT02581540|HEART
76787|NCT02581514|decision algorithm
76788|NCT02581501|Xeloda
76789|NCT02581501|Gemcitabine
76790|NCT02581501|Abraxane
76791|NCT02581501|Pancreatic Cancer
76792|NCT02581501|Metastatic Cancer
76793|NCT02581501|Phase I
76794|NCT02581501|5-FU
76795|NCT02581501|Capecitabine
76796|NCT02581501|Gemzar
76797|NCT02581501|NAB-Paclitaxel
76798|NCT02581501|Chemotherapy
76799|NCT02581488|Diabetes
76800|NCT02581488|diabetic foot ulcer
76801|NCT02581488|foot sore
76802|NCT02581488|type 2 diabetes
76803|NCT02581488|type 1 diabetes
76804|NCT02581488|neuropathy
76805|NCT02581488|DFU
76806|NCT02581475|Adenoma detection rate
76807|NCT02581475|Colonoscopy
76808|NCT02581475|Withdrawal time
76809|NCT02581449|omega-3 fatty acids
76810|NCT02581449|hemodialysis
76811|NCT02581449|oxidative stress
76812|NCT02581449|dyslipidemia
76813|NCT02581436|Prediction test
76814|NCT02581436|genetic transcription profile
76815|NCT02581436|Transplant follow-up
76816|NCT02581436|Chronic index
76817|NCT02581436|Graft Function
76818|NCT02581410|Zostavax®
76819|NCT02581410|≥ 65 years of age
76820|NCT02581410|Herpes Zoster
76821|NCT02581410|Shingles
76822|NCT02581410|Immunogenicity
76823|NCT02581410|Safety
76824|NCT02581397|cough
76825|NCT02581397|expectorant
76826|NCT02581397|upper respiratory tract infections
76827|NCT02581397|respiratory tract infections
76828|NCT02581397|antitussive agents
76829|NCT02581384|Ewing Sarcoma
76830|NCT02581384|Rhabdomyosarcoma
76831|NCT02581384|Wilms Tumor
76832|NCT02581371|Cerebrolysin
76833|NCT02581371|neuroplasticity
76834|NCT02581371|upper limb
76835|NCT02581371|middle cerebral artery
76836|NCT02581371|NBS
76837|NCT02581371|navigation brain stimulation
76838|NCT02581371|paretic limb
76839|NCT02581371|stroke
76840|NCT02581371|ischemic stroke
76841|NCT02581371|rehabilitation
76842|NCT02581371|Frenchay Arm Test
76843|NCT02581371|NBS eXimia Nexstim
76844|NCT02581371|Barthel index
76845|NCT02581358|scoliosis
76846|NCT02581358|spinal deformity
76847|NCT02581358|Cobb angle
76848|NCT02581358|assessment
76849|NCT02581358|ultrasound
76850|NCT02581345|Moderate to severe chronic plaque psoriasis
76851|NCT02581345|Psoriasis
76852|NCT02581332|behavioral intervention
76853|NCT02581254|Snare
76854|NCT02581254|Polypectomy
76855|NCT02581241|QT interval prolongation
76856|NCT02581215|mFOLFIRINOX
76857|NCT02581215|Ramucirumab
76858|NCT02581202|antiretroviral therapy
76859|NCT02581189|Chronic Hepatitis C
76860|NCT02581189|Patient reported outcomes
76861|NCT02581189|Effectiveness
76862|NCT02581189|Influence of adherence
76863|NCT02581189|Genotype 1 or 4
76864|NCT02581163|Effectiveness
76865|NCT02581163|Influence of adherence
76866|NCT02581150|Outpatient hospitalization
76867|NCT02581150|Randomized trial
76868|NCT02581150|Peripheral arterial disease
76869|NCT02581150|Endovascular treatment
76870|NCT02581150|Health Economics
76871|NCT02581124|JTZ-951
76872|NCT02581124|Lapatinib
76873|NCT02581124|Pharmacokinetics
76874|NCT02581085|Tocotrienol
76875|NCT02581085|Vitamin E
76876|NCT02581059|Regorafenib
76877|NCT02581059|American Ginseng
76878|NCT02581059|Fatigue
76879|NCT02581020|Observation
76880|NCT02581020|Japanese
76881|NCT02581020|Hepatitis C
76882|NCT02581020|Follow-up
76883|NCT02581007|CML
76884|NCT02581007|AML
76885|NCT02581007|MDS
76886|NCT02581007|ALL
76887|NCT02581007|CLL/CPL
76888|NCT02581007|HD
76889|NCT02581007|NHL
76890|NCT02581007|MPS
76891|NCT02581007|CMML
76892|NCT02581007|MM
76893|NCT02580994|Small Cell Lung Cancer
76894|NCT02580994|phase II
76895|NCT02580994|randomized
76896|NCT02580994|pembrolizumab
76897|NCT02580981|Cancer
76898|NCT02580981|Oncology
76899|NCT02580981|Acute Lymphoblastic Leukemia
76900|NCT02580981|ALL
76901|NCT02580981|Genomics
76902|NCT02580981|Genetics
76903|NCT02580981|Sequencing
76904|NCT02580981|DNA
76905|NCT02580981|RNA
76906|NCT02580981|Ph-like
76907|NCT02580968|Electroacupuncture therapy
76908|NCT02580968|Migraine
76909|NCT02580968|Acupuncture Therapy
76910|NCT02580929|Radiotherapy
76911|NCT02580929|General Surgery
76912|NCT02580916|non-melanoma skin cancer
76913|NCT02580916|outcome assessment
76914|NCT02580916|quality of life
76915|NCT02580877|oral insulin
76916|NCT02580838|Stroke
76917|NCT02580838|Spasticity
76918|NCT02580838|OnabotulinumtoxinA
76919|NCT02580825|Childhood obesity
76920|NCT02580825|Ground reaction force
76921|NCT02580825|Knee pain
76922|NCT02580812|Perinatal listeriosis
76923|NCT02580812|Neurological impairment
76924|NCT02580812|Sepsis
76925|NCT02580812|Prematurity
76926|NCT02580812|Neurotropism
76927|NCT02580812|Listeria monocytogenes
76928|NCT02580812|Intellectual Quotient
76929|NCT02580773|Sickle cell disease
76930|NCT02580773|Anemia
76931|NCT02580773|Rare disease
76932|NCT02580773|Reanimation
76933|NCT02580773|Prophylactic anticoagulation
76934|NCT02580760|Silicone
76935|NCT02580760|Transgender
76936|NCT02580760|Dermatology
76937|NCT02580760|Blood contamination
76938|NCT02580760|Adverse event after injection
76939|NCT02580734|burning mouth syndrome
76940|NCT02580734|treatment
76941|NCT02580734|oral chronic pain
76942|NCT02580721|mucosal tissue thickness
76943|NCT02580721|dental implant
76944|NCT02580721|marginal bone loss
76945|NCT02580721|soft tissue
76946|NCT02580643|Autologous Protein Solution
76947|NCT02580643|Osteoarthritis
76948|NCT02580643|Intra-articular Injection
76949|NCT02580630|Strength training, injection, glucocorticoid
76950|NCT02580565|sickle cell disease
76951|NCT02580552|Cutaneous T-cell Lymphoma
76952|NCT02580552|CTCL
76953|NCT02580552|Mycosis Fungoides
76954|NCT02580539|Allogeneic Transplantation
76955|NCT02580539|T cell
76956|NCT02580539|Epstein-Barr Virus
76957|NCT02580513|Circadian Rhythm
76958|NCT02580513|Circadian Misalignment
76959|NCT02580513|Insulin Sensitivity
76960|NCT02580500|Epidural anesthesia
76961|NCT02580500|Spinal anesthesia
76962|NCT02580500|pilonidal dermoid sinus
76963|NCT02580487|acute appendicitis
76964|NCT02580487|pain management
76965|NCT02580487|analgesics
76966|NCT02580487|pediatric patients
76967|NCT02580487|laparoscopy
76968|NCT02580487|open surgery
76969|NCT02580461|family caregivers
76970|NCT02580461|cancer
76971|NCT02580461|exercise intervention
76972|NCT02580461|center based
76973|NCT02580448|Breast Cancer
76974|NCT02580448|Breast
76975|NCT02580448|Advanced Breast Cancer
76976|NCT02580448|Metastatic Breast Cancer
76977|NCT02580448|CYP17
76978|NCT02580448|Male Breast Cancer
76979|NCT02580448|Triple Negative Cancer
76980|NCT02580448|ER+ Breast Cancer
76981|NCT02580435|multiple sclerosis
76982|NCT02580435|microbiome
76983|NCT02580435|prediction
76984|NCT02580435|outcome
76985|NCT02580422|Echocardiography
76986|NCT02580409|health care utilization
76987|NCT02580409|health care costs
76988|NCT02580383|Radiofrequency ablation
76989|NCT02580383|RF-MB
76990|NCT02580383|Lumbar RF
76991|NCT02580383|Facet joint syndrome
76992|NCT02580383|Multifidus twitching
76993|NCT02580383|Sensory stimulation
76994|NCT02580370|REALISE 1
76995|NCT02580357|Connective tissue graft
76996|NCT02580357|Gingival recession
76997|NCT02580357|Low level laser therapy
76998|NCT02580305|SUVN-502
76999|NCT02580305|5-HT6
77000|NCT02580305|Phase 2
77001|NCT02580305|Cognition
77002|NCT02580305|Donepezil
77003|NCT02580305|Memantine
77004|NCT02580305|Alzheimer's Disease
77005|NCT02580279|Breast Neoplasms
77006|NCT02580279|prevention & control
77007|NCT02580279|Epigallocatechin gallate
77008|NCT02580279|Dermatitis
77009|NCT02580266|Kidney
77010|NCT02580266|Diabetes
77011|NCT02580240|septic shock
77012|NCT02580240|hydrocortisone
77013|NCT02580240|mortality
77014|NCT02580227|Tranexamic Acid
77015|NCT02580227|Blood Transfusions
77016|NCT02580188|Neuromuscular blockade
77017|NCT02580188|Sugammadex
77018|NCT02580188|Laparoscopic surgery
77019|NCT02580188|Intra abdominal pressure alarm
77020|NCT02580136|Esthesioneuroblastoma
77021|NCT02580136|Tumor
77022|NCT02580136|Skull Base Surgery
77023|NCT02580136|Sinonasal Cancer
77024|NCT02580110|no specific condition
77025|NCT02580097|Arterial Spin Labeling
77026|NCT02580097|Ischemic stroke
77027|NCT02580097|Collateral Circulation
77028|NCT02580097|Perfusion imaging
77029|NCT02580084|atherosclerosis of the peripheral arteries
77030|NCT02580084|Aorta-femoral Bypass
77031|NCT02580084|Hybrid Intervention
77032|NCT02580084|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
77033|NCT02580084|plastic arteries with lesions of the common femoral artery and deep femoral artery
77034|NCT02580071|Hematopoietic Stem Cell Transplant
77035|NCT02580071|Chinese Herbal Medicine
77036|NCT02580071|immune reconstitution
77037|NCT02580071|clinical trial
77038|NCT02580071|ALL
77039|NCT02580071|AML
77040|NCT02580058|platinum resistant
77041|NCT02580058|platinum refractory
77042|NCT02580045|metastatic cancer
77043|NCT02580045|lumbar puncture
77044|NCT02580045|advanced cancer
77045|NCT02580045|brain metastases
77046|NCT02580045|chemotherapy
77047|NCT02580045|endocrine therapy
77048|NCT02580045|HER2 targeted therapy
77049|NCT02580045|immune therapy
77050|NCT02580045|anti-cancer therapy
77051|NCT02580045|blood brain barrier
77052|NCT02580045|pharmacokinetics
77053|NCT02580045|Duke University
77054|NCT02580045|brain metastasis
77055|NCT02580019|Cellular therapy
77056|NCT02580019|Stroke
77057|NCT02580019|Neuronal Plasticity
77058|NCT02580019|Recovery
77059|NCT02580019|umbilical cord mesenchymal stem cells
77060|NCT02580019|Transplantation
77061|NCT02580019|Cardiovascular Diseases
77062|NCT02580019|Ischemia
77063|NCT02580019|Brain Infarction
77064|NCT02580019|Brain Ischemia
77065|NCT02580019|Cerebrovascular Disorders
77066|NCT02579993|Cornea
77067|NCT02579993|Limbal stem cell
77068|NCT02579967|Haploidentical
77069|NCT02579967|Autoimmunity
77070|NCT02579967|Immune Dysregulation
77071|NCT02579967|Congenital
77072|NCT02579967|Opportunistic Infection
77073|NCT02579941|Hyperfibrinolysis
77074|NCT02579941|Pregnant women at term
77075|NCT02579941|Tranexamic acid
77076|NCT02579928|Ketamine
77077|NCT02579928|Depression
77078|NCT02579928|Major Depressive Disorder
77079|NCT02579902|Irritable Bowel Syndrome
77080|NCT02579902|inflammation
77081|NCT02579902|oxidative stress
77082|NCT02579902|clinical signs
77083|NCT02579902|vitamin D3
77084|NCT02579889|Closed Loop Stimulation
77085|NCT02579889|Atrial Fibrillation
77086|NCT02579889|Stroke
77087|NCT02579889|Heart Failure
77088|NCT02579889|Pacemaker
77089|NCT02579889|ICD
77090|NCT02579876|Milk Allergy
77091|NCT02579876|Viaskin Milk
77092|NCT02579876|Epicutaneous ImmunoTherapy (EPIT)
77093|NCT02579876|Eosinophilic Esophagitis
77094|NCT02579876|Milk-Induced Eosinophilic Esophagitis
77095|NCT02579863|PD1
77096|NCT02579863|PD-1
77097|NCT02579863|PD-L1
77098|NCT02579863|PDL1
77099|NCT02579850|COPD
77100|NCT02579850|COPD Exacerbation
77101|NCT02579850|EXACT-PRO
77102|NCT02579837|screening
77103|NCT02579824|Myeloma
77104|NCT02579824|Relapsed and/or Refractory
77105|NCT02579824|Multiple Myeloma
77106|NCT02579824|MM
77107|NCT02579824|DS-3032b
77108|NCT02579811|Kidney
77109|NCT02579811|Cancer
77110|NCT02579811|Axitinib
77111|NCT02579811|Pd-1 inhibitor
77112|NCT02579811|Pd-L1 inhibitor
77113|NCT02579798|Bariatric surgery
77114|NCT02579798|Post-surgery hypoxemia
77115|NCT02579798|Obesity
77116|NCT02579785|Family Planning
77117|NCT02579785|Abortion
77118|NCT02579785|mHealth
77119|NCT02579785|Behaviour Change Communication
77120|NCT02579785|Menstrual Regulation
77121|NCT02579785|Postabortion
77122|NCT02579785|Bangladesh
77123|NCT02579759|PXT3003
77124|NCT02579746|hypertension
77125|NCT02579746|immigrant
77126|NCT02579746|dietary intervention
77127|NCT02579746|lifestyle modification
77128|NCT02579720|Recurrent Grass Pollen Allergy
77129|NCT02579720|Pollinex® Quattro
77130|NCT02579707|Healthy Volunteers
77131|NCT02579681|Cognition
77132|NCT02579681|Tecfidera
77133|NCT02579681|RRMS
77134|NCT02579681|BG00012
77135|NCT02579642|Moderate to severe depression
77136|NCT02579642|Monopolar
77137|NCT02579642|Bipolar
77138|NCT02579642|Ketamine
77139|NCT02579642|ECT
77140|NCT02579642|Electroconvulsive therapy
77141|NCT02579642|NMDA
77142|NCT02579629|Analgesia
77143|NCT02579629|Cesarean section
77144|NCT02579629|Opiates
77145|NCT02579616|Lenvatinib
77146|NCT02579616|E7080
77147|NCT02579616|Unresectable biliary tract cancer
77148|NCT02579616|BTC
77149|NCT02579616|Gemcitabine-based combination chemotherapy
77150|NCT02579616|Lenvima
77151|NCT02579538|Total Knee Arthroplasty
77152|NCT02579538|Thoracotomy
77153|NCT02579538|Mastectomy
77154|NCT02579538|Video-Assisted Thoracoscopic Surgery (VATS)
77155|NCT02579538|Persistent Pain
77156|NCT02579538|Cognitive Flexibility
77157|NCT02579525|septic shock
77158|NCT02579525|tissue perfusion
77159|NCT02579525|macrocirculatory
77160|NCT02579525|mean arterial pressure
77161|NCT02579525|vasopressor use
77162|NCT02579525|days alive free of organ support
77163|NCT02579499|Coronary artery disease
77164|NCT02579499|LDL choelsterol
77165|NCT02579499|Statin
77166|NCT02579473|Continuous dopaminergic stimulation
77167|NCT02579460|Barrett's esophagus
77168|NCT02579460|Gastroesophageal Reflux Disease
77169|NCT02579434|CYP3A
77170|NCT02579408|NAFLD
77171|NCT02579408|LDLT
77172|NCT02579408|steatosis
77173|NCT02579408|CAP
77174|NCT02579408|transient elastography
77175|NCT02579382|HBV
77176|NCT02579382|Hepatitis
77177|NCT02579382|Liver Disease
77178|NCT02579369|Epidermolysis Bullosa
77179|NCT02579369|stem cell
77180|NCT02579317|Baroreflex mechanism
77181|NCT02579317|Alcohol Use Disorder
77182|NCT02579317|Substance Use Disorder
77183|NCT02579317|Heart Rate Variability
77184|NCT02579317|Breathing
77185|NCT02579291|Stroke
77186|NCT02579291|Dry needling
77187|NCT02579291|Spasticity
77188|NCT02579291|Motor function
77189|NCT02579291|Stabilometry
77190|NCT02579278|EMVI
77191|NCT02579278|Extramural Venous Invasion
77192|NCT02579278|mrEMVI
77193|NCT02579278|Rectal Cancer
77194|NCT02579278|ctDNA
77195|NCT02579278|Neoplasm DNA
77196|NCT02579278|MRI
77197|NCT02579265|Parenteral nutrition
77198|NCT02579265|Neonates
77199|NCT02579265|Infants
77200|NCT02579265|Lipid emulsions
77201|NCT02579265|Intravenous
77202|NCT02579252|vaccine
77203|NCT02579252|tau protein
77204|NCT02579252|active
77205|NCT02579252|immunization
77206|NCT02579252|KLH
77207|NCT02579252|immunotherapy
77208|NCT02579252|tau
77209|NCT02579239|LGMD2B
77210|NCT02579239|FSHD
77211|NCT02579226|AZD2811
77212|NCT02579226|Irinotecan
77213|NCT02579226|Advanced solid tumours
77214|NCT02579213|electronic nose
77215|NCT02579213|abnormal fetal karyotype
77216|NCT02579161|Percutaneous Nephrolithotomy
77217|NCT02579161|Kidney Stones
77218|NCT02579161|Antibiotics
77219|NCT02579148|erectile dysfunction
77220|NCT02579148|stem cell
77221|NCT02579148|collagen scaffold
77222|NCT02579135|Condoms
77223|NCT02579135|Sexual Abstinence
77224|NCT02579135|Sexual Communication
77225|NCT02579122|Reviparin
77226|NCT02579122|Bridging
77227|NCT02579122|Phenprocoumon
77228|NCT02579096|Gout
77229|NCT02579096|Allopurinol
77230|NCT02579096|Febuxostat
77231|NCT02579096|CKD
77232|NCT02579070|Diabetic Foot
77233|NCT02579070|foot temperature
77234|NCT02579070|diabetic foot ulcer
77235|NCT02579057|Congestive heart failure
77236|NCT02579057|Furosemide
77237|NCT02579031|Percutaneous Coronary Intervention
77238|NCT02579031|Stents
77239|NCT02579031|Drug-Eluting Stents
77240|NCT02579031|Coronary Artery Disease
77241|NCT02579031|Acute Coronary Syndrome
77242|NCT02579018|Anorexia Nervosa
77243|NCT02579018|Exercise
77244|NCT02579018|Healthy Adults
77245|NCT02579018|Physical Activity
77246|NCT02579005|Radiation
77247|NCT02579005|Immune response
77248|NCT02579005|Anti-tumor
77249|NCT02579005|Lung Cancer
77250|NCT02578992|intubating stylet
77251|NCT02578992|head and neck position
77252|NCT02578979|atrial fibrillation
77253|NCT02578979|ischemic stroke
77254|NCT02578979|electrocardiogram
77255|NCT02578979|holter
77256|NCT02578966|Early Childhood Caries
77257|NCT02578966|Randomized clinical trial
77258|NCT02578966|Motivational Interviewing
77259|NCT02578953|Bioequivalence
77260|NCT02578953|Fasted state
77261|NCT02578953|Japanese male healthy subjects
77262|NCT02578953|Dutasteride
77263|NCT02578914|allergic conjunctivitis
77264|NCT02578914|seasonal allergies
77265|NCT02578914|ragweed allergy
77266|NCT02578914|grass allergy
77267|NCT02578914|tree allergy
77268|NCT02578914|NS2
77269|NCT02578914|Aldeyra
77270|NCT02578901|Thrombocytopenia
77271|NCT02578901|Tranexamic Acid
77272|NCT02578901|TXA
77273|NCT02578901|Chemotherapy induced thrombocytopenia
77274|NCT02578875|Sequence Technique
77275|NCT02578875|Infectious Disease
77276|NCT02578875|Pathogen Detection
77277|NCT02578875|Diagnostic
77278|NCT02578836|Weight Loss
77279|NCT02578836|Overweight
77280|NCT02578836|Endoscopic treatment for obesity
77281|NCT02578823|Targeted Temperature Management(TTM)
77282|NCT02578823|in-hospital cardiac arrest(IHCA)
77283|NCT02578823|restoration of spontaneous circulation(ROSC)
77284|NCT02578823|unconsciousness
77285|NCT02578823|brain injury
77286|NCT02578797|Castration-Resistant Prostate Cancer (CRPC)
77287|NCT02578797|Prostatic Neoplasms
77288|NCT02578797|Genital Diseases, Male
77289|NCT02578797|Genital Neoplasms, Male
77290|NCT02578797|Neoplasms
77291|NCT02578797|Neoplasms by Site
77292|NCT02578797|Prostatic Diseases
77293|NCT02578797|Urogenital Neoplasms
77294|NCT02578784|Dialysis
77295|NCT02578758|Transdiagnostic Internet-based Protocol
77296|NCT02578758|Positive affect regulation
77297|NCT02578706|HIV
77298|NCT02578706|Aspirin
77299|NCT02578706|Clopidogrel
77300|NCT02578706|Platelet
77301|NCT02578706|Inflammation
77302|NCT02578706|Cardiovascular disease
77303|NCT02578706|Arachidonic acid
77304|NCT02578706|Cyclooxygenase inhibitor
77305|NCT02578706|ADP inhibitor
77306|NCT02578706|Immune activation
77307|NCT02578706|Monocyte
77308|NCT02578706|Coagulation
77309|NCT02578706|Thrombogenicity
77310|NCT02578680|PD1
77311|NCT02578680|PD-1
77312|NCT02578680|PDL1
77313|NCT02578680|PD-L1
77314|NCT02578680|Non-Small-Cell Lung Cancer
77315|NCT02578641|Nasopharyngeal Carcinoma
77316|NCT02578641|Epstein-Barr Virus
77317|NCT02578641|Cell therapy
77318|NCT02578641|Cytotoxic T Lymphocytes
77319|NCT02578576|Diagnostic Techniques
77320|NCT02578576|Digestive System
77321|NCT02578550|Immunodeficiency Virus Type 1, Human
77322|NCT02578550|Darunavir
77323|NCT02578550|Cobicistat
77324|NCT02578550|Emtricitabine
77325|NCT02578550|Tenofovir alafenamide
77326|NCT02578550|Healthy participants
77327|NCT02578537|Ticagrelor
77328|NCT02578537|Pharmacokinetics
77329|NCT02578537|NSTE-ACS
77330|NCT02578537|CKD
77331|NCT02578524|cataract satisfaction
77332|NCT02578511|Acute Lymphoblastic Leukemia in Complete Remission
77333|NCT02578511|Lymphoblastic Lymphoma in Complete Remission
77334|NCT02578511|Mixed Phenotype Acute Leukemia in Complete Remission
77335|NCT02578498|glucagon
77336|NCT02578498|Carbohydrate diet
77337|NCT02578472|Healthy
77338|NCT02578472|JNJ-42847922
77339|NCT02578472|zolpidem
77340|NCT02578472|Placebo
77341|NCT02578459|Cancer pain
77342|NCT02578459|Intrathecal therapy
77343|NCT02578459|Pain
77344|NCT02578459|Pancreatic cancer
77345|NCT02578433|Mindful Self Compassion short form
77346|NCT02578433|Progressive Muscle Relaxation
77347|NCT02578394|Gout
77348|NCT02578394|Kidney
77349|NCT02578394|Depo-Medrone
77350|NCT02578394|Anakinra
77351|NCT02578381|pressure wire
77352|NCT02578381|coronary angiogram
77353|NCT02578381|validation
77354|NCT02578368|gastric cancer
77355|NCT02578368|perioperative
77356|NCT02578368|FLOT
77357|NCT02578368|limited metastatic
77358|NCT02578368|GEJ cancer
77359|NCT02578355|Atherosclerosis
77360|NCT02578355|Coronary Artery Disease
77361|NCT02578355|Cardiovascular Disease
77362|NCT02578355|Coronary Computed Tomographic Angiography
77363|NCT02578355|CCTA
77364|NCT02578355|Myocardial Infarction
77365|NCT02578355|MI
77366|NCT02578355|OPeRA
77367|NCT02578329|Mediterranean diet
77368|NCT02578329|blood fatty acid
77369|NCT02578329|Coronary Artery Disease
77370|NCT02578316|Advanced Solid Tumors
77371|NCT02578316|Lymphomas
77372|NCT02578303|sleep apnea
77373|NCT02578303|phase-contrast MRI
77374|NCT02578303|cerebral blood flow
77375|NCT02578303|vascular risk factor
77376|NCT02578303|dementia
77377|NCT02578290|decision support systems
77378|NCT02578290|clinical
77379|NCT02578238|Korea
77380|NCT02578238|Humira
77381|NCT02578238|Pediatric Crohn's Disease
77382|NCT02578225|Heart
77383|NCT02578225|Chronic
77384|NCT02578225|Failure
77385|NCT02578225|MI
77386|NCT02578225|real life
77387|NCT02578225|Turkey
77388|NCT02578160|pain
77389|NCT02578160|infant behaviour
77390|NCT02578160|heart rate
77391|NCT02578160|dental anxiety
77392|NCT02578147|risky sexual behavior
77393|NCT02578147|early intervention
77394|NCT02578121|Relapsed
77395|NCT02578121|Response Rate
77396|NCT02578121|Progression free
77397|NCT02578082|Renal Impairment
77398|NCT02578082|Renal Insufficiency
77399|NCT02578069|Ischemic Stroke
77400|NCT02578069|Intracranial Stenting
77401|NCT02578056|pelvic organ prolapse
77402|NCT02578056|urinary incontinence
77403|NCT02578017|Sickle Cell Disease
77404|NCT02578017|Hydroxyurea
77405|NCT02578017|Adherence
77406|NCT02578004|Difficult
77407|NCT02578004|environmental, microbial, immunological and genetic factors
77408|NCT02578004|significantly different
77409|NCT02577965|ST segment Elevation Myocardial Infarction
77410|NCT02577965|Optical Coherence Tomography
77411|NCT02577965|Percutaneous Coronary Intervention
77412|NCT02577965|Thrombus histopathology
77413|NCT02577965|Gender differences
77414|NCT02577952|lipodystrophy
77415|NCT02577952|lipodystrophy, congenital generalized
77416|NCT02577952|Berardinelli-Seip Congenital Lipodystrophy
77417|NCT02577952|Congenital generalized lipodystrophy
77418|NCT02577952|generalized lipodystrophy
77419|NCT02577952|lipodystrophy, familial partial
77420|NCT02577952|partial lipodystrophy
77421|NCT02577952|lipodystrophy, partial, acquired
77422|NCT02577952|acquired lipodystrophy
77423|NCT02577913|contraception
77424|NCT02577913|contraceptive patch
77425|NCT02577913|Levonorgestrel
77426|NCT02577913|gestodene
77427|NCT02577913|safety
77428|NCT02577900|foot ulcer and honey and silver
77429|NCT02577861|limbal stem cells deficinecy, LSCD, ocular burn
77430|NCT02577848|Glucagon-like peptide-1
77431|NCT02577848|Non-ST-segment elevation myocardial infarction
77432|NCT02577848|Left ventricular ejection fraction
77433|NCT02577835|Hypertension
77434|NCT02577835|Arterial Stiffness
77435|NCT02577835|Ambulatory blood pressure
77436|NCT02577796|radial artery spasm
77437|NCT02577796|radial artery occlusion
77438|NCT02577796|radial access
77439|NCT02577783|Doxorubicin Hydrochloride
77440|NCT02577770|Acupuncture
77441|NCT02577770|caffeine
77442|NCT02577770|pain
77443|NCT02577757|Languages network
77444|NCT02577757|Functional MRI
77445|NCT02577744|Electrical Impedance Tomography
77446|NCT02577731|Trauma
77447|NCT02577705|food insecurity
77448|NCT02577705|adverse childhood experiences
77449|NCT02577705|violence exposure
77450|NCT02577705|trauma
77451|NCT02577705|poverty
77452|NCT02577705|TANF
77453|NCT02577705|assets
77454|NCT02577705|depression
77455|NCT02577705|randomized control trial
77456|NCT02577679|Dentistry
77457|NCT02577653|balance, postural
77458|NCT02577653|postural equilibrium
77459|NCT02577614|Cardiopulmonary Bypass
77460|NCT02577614|Aortic Valve Repair
77461|NCT02577614|Coronary Re-Implantation
77462|NCT02577614|Deep Hypothermic Circulatory Arrest
77463|NCT02577614|Factor VIII Inhibitor Bypass Activity
77464|NCT02577614|Transfusion
77465|NCT02577601|Emergency contraception
77466|NCT02577601|Birth Control Pills
77467|NCT02577588|p53 Antigen
77468|NCT02577588|T cell therapy
77469|NCT02577588|autologous
77470|NCT02577588|Adoptive Cellular Immunotherapy
77471|NCT02577575|Oxytocin
77472|NCT02577575|Syntocinon
77473|NCT02577575|Social Cognition
77474|NCT02577575|Schizophrenia
77475|NCT02577549|Knee Pain
77476|NCT02577549|Exercise
77477|NCT02577549|Diet
77478|NCT02577549|Weight Loss
77479|NCT02577536|Pregnancy outcome
77480|NCT02577536|Neonatal outcome
77481|NCT02577536|Birth weight
77482|NCT02577536|Weight gain
77483|NCT02577536|Physical disability
77484|NCT02577510|Lateral Femoral Cutaneous Nerve Block
77485|NCT02577510|Meralgia Parasthetica
77486|NCT02577510|nerve stimulator
77487|NCT02577510|ultrasound
77488|NCT02577484|Fractional Flow Reserve
77489|NCT02577484|Rapid Exchange
77490|NCT02577484|Catheter
77491|NCT02577471|Constipation
77492|NCT02577471|pregnancy
77493|NCT02577471|delivery
77494|NCT02577432|spinal anesthesia
77495|NCT02577419|breast milk
77496|NCT02577419|chylothorax
77497|NCT02577419|infants
77498|NCT02577419|cardiac surgery
77499|NCT02577419|modified fat breast milk
77500|NCT02577406|AG-221
77501|NCT02577406|CC-90007
77502|NCT02577406|Efficacy
77503|NCT02577406|Safety
77504|NCT02577406|Leukemia
77505|NCT02577406|Acute myloid meukemia
77506|NCT02577406|Isocitrate dehydrogenase 2 mutation
77507|NCT02577406|Enasidenib
77508|NCT02577393|Lung Neoplasms
77509|NCT02577393|esophagitis
77510|NCT02577393|Prevention & Control
77511|NCT02577393|Epigallocatechin Gallate
77512|NCT02577367|Hypothyroidism
77513|NCT02577367|Tube Feeding
77514|NCT02577341|Nimotuzumab, Chemoradiotherapy,Squamous Cell Lung Cancer
77515|NCT02577289|simultaneous implantation
77516|NCT02577289|Dental implant
77517|NCT02577289|Open sinus Lifting
77518|NCT02577289|PRF
77519|NCT02577289|platelet rich fibrin (PRF)
77520|NCT02577276|stroke
77521|NCT02577276|remote monitoring
77522|NCT02577276|hemiparesis
77523|NCT02577250|ketamine
77524|NCT02577250|stress disorders, post-traumatic
77525|NCT02577250|stress disorders, traumatic
77526|NCT02577250|anxiety disorders
77527|NCT02577250|mental disorders
77528|NCT02577250|adjuvants, anesthesia
77529|NCT02577250|analgesics
77530|NCT02577250|anesthetics
77531|NCT02577250|anesthetics, dissociative
77532|NCT02577250|anesthetics, general
77533|NCT02577250|anesthetics, intravenous
77534|NCT02577250|excitatory amino acid agents
77535|NCT02577250|excitatory amino acid antagonists
77536|NCT02577250|hypnotics and sedatives
77537|NCT02577250|molecular mechanisms of pharmacological action
77538|NCT02577250|neurotransmitter agents
77539|NCT02577250|peripheral nervous system agents
77540|NCT02577250|pharmacologic actions
77541|NCT02577250|physiological effects of drugs
77542|NCT02577250|psychotropic drugs
77543|NCT02577250|sensory system agents
77544|NCT02577250|central nervous system agents
77545|NCT02577250|central nervous system depressants
77546|NCT02577250|depression
77547|NCT02577250|depressive disorder
77548|NCT02577250|depressive disorder, treatment-resistant
77549|NCT02577250|behavioral symptoms
77550|NCT02577250|mood disorders
77551|NCT02577250|therapeutic uses
77552|NCT02577237|caregiver
77553|NCT02577237|simulation
77554|NCT02577224|Patient-led care
77555|NCT02577224|Botulinum toxin
77556|NCT02577224|Dystonia
77557|NCT02577224|Randomised controlled trial
77558|NCT02577224|Acceptability
77559|NCT02577211|Critically ill
77560|NCT02577211|Enteral nutrition
77561|NCT02577172|Testicular cancer
77562|NCT02577172|Physical Exercise
77563|NCT02577172|Chemotherapy
77564|NCT02577159|sodium-glucose cotransporter 2 inhibitor
77565|NCT02577159|Diabetes Mellitus, Type 2
77566|NCT02577159|dyslipidemia
77567|NCT02577159|remnants
77568|NCT02577159|apolipoprotein B-48
77569|NCT02577146|stone
77570|NCT02577146|ureter
77571|NCT02577146|ultrasound
77572|NCT02577133|colic
77573|NCT02577133|probiotic
77574|NCT02577133|Lactobacillus reuteri
77575|NCT02577133|prevention
77576|NCT02577120|Epiceram
77577|NCT02577120|Ceramiseal
77578|NCT02577107|Age-related macular degeneration,
77579|NCT02577107|ranibizumab,
77580|NCT02577107|conbercept,
77581|NCT02577107|plasma VEGF
77582|NCT02577107|PK
77583|NCT02577094|CD22 positive- lymphoblastic leukemia-RIT-Yttrium
77584|NCT02577055|Multiple leiomyoma
77585|NCT02577055|Uterine Artery Embolization
77586|NCT02577055|Surgery
77587|NCT02577055|childbearing age
77588|NCT02577055|Fertility
77589|NCT02577055|Noninferiority trial
77590|NCT02577042|Raltegravir
77591|NCT02577042|protease inhibitors
77592|NCT02577042|darunavir
77593|NCT02577042|inflammation
77594|NCT02577042|statins
77595|NCT02577042|comorbidities
77596|NCT02576990|PD1
77597|NCT02576990|PD-1
77598|NCT02576990|PDL1
77599|NCT02576990|PD-L1
77600|NCT02576977|PDL1
77601|NCT02576977|PD1
77602|NCT02576977|Multiple Myeloma
77603|NCT02576938|Atopic Eczema
77604|NCT02576912|Cannabis
77605|NCT02576912|Marijuana
77606|NCT02576912|THC
77607|NCT02576912|Pregnenolone
77608|NCT02576912|Psychotic Disorders
77609|NCT02576912|PREG
77610|NCT02576899|smoking cessation
77611|NCT02576899|posttraumatic stress disorder
77612|NCT02576899|tobacco
77613|NCT02576899|treatment
77614|NCT02576899|smoking
77615|NCT02576899|mindfulness
77616|NCT02576899|acceptance
77617|NCT02576899|functioning
77618|NCT02576886|supine
77619|NCT02576886|prone
77620|NCT02576886|myocardial perfusion imaging
77621|NCT02576886|radiation exposure
77622|NCT02576886|pre-screening tool
77623|NCT02576873|Survival
77624|NCT02576873|Hemodiafiltration
77625|NCT02576873|End-stage renal disease
77626|NCT02576873|Hemodialysis
77627|NCT02576821|Amnesia, Alzheimer, hippocampal sclerosis, fronto-temporal lobar degeneration
77628|NCT02576795|Haemophilia A
77629|NCT02576795|Gene Therapy
77630|NCT02576795|Clotting Disorders
77631|NCT02576795|Blood Disorder
77632|NCT02576782|regional anesthesia
77633|NCT02576782|dexamethasone
77634|NCT02576782|bupivacaine
77635|NCT02576782|femoral
77636|NCT02576782|sciatic
77637|NCT02576769|Basal cell carcinoma
77638|NCT02576769|Pigmentation
77639|NCT02576769|Melanocyte
77640|NCT02576769|Melanin
77641|NCT02576769|Skin cancer
77642|NCT02576756|Risk on aspiration
77643|NCT02576756|Postoperative
77644|NCT02576756|Difficult Intubation
77645|NCT02576743|Stroke
77646|NCT02576743|AVM
77647|NCT02576743|Aneurysm
77648|NCT02576717|MS
77649|NCT02576717|RMS
77650|NCT02576717|Multiple Sclerosis
77651|NCT02576717|Relapsing Multiple Sclerosis
77652|NCT02576691|cardiac arrest
77653|NCT02576691|percutaneous coronary intervention
77654|NCT02576691|cardiogenic shock
77655|NCT02576691|outcome
77656|NCT02576678|Psoriasis
77657|NCT02576678|Moderate to Severe Plaque Psoriasis
77658|NCT02576678|Plaque Psoriasis
77659|NCT02576678|CC-10004
77660|NCT02576678|Apremilast
77661|NCT02576678|Pharmacokinetics
77662|NCT02576678|Open-label
77663|NCT02576678|Safety
77664|NCT02576678|Pediatric
77665|NCT02576652|bone biopsy
77666|NCT02576652|tetracycline
77667|NCT02576652|demeclocycline
77668|NCT02576652|total hip replacement
77669|NCT02576639|Alzheimer's Disease,
77670|NCT02576639|Amyloid Beta,
77671|NCT02576639|cerebrospinal fluid,
77672|NCT02576639|beta secretase
77673|NCT02576626|Nebulizer
77674|NCT02576626|DPI
77675|NCT02576626|COPD
77676|NCT02576626|indacaterol
77677|NCT02576626|ipratropium
77678|NCT02576626|glycopyrronium
77679|NCT02576626|salbutamol
77680|NCT02576626|Breezhaler
77681|NCT02576626|Nebuliser
77682|NCT02576626|Hyperinflation
77683|NCT02576626|Dyspnea
77684|NCT02576626|SABA
77685|NCT02576626|short-acting muscarinic antagonists (SAMA)
77686|NCT02576626|long-acting beta2-agonist (LABA)
77687|NCT02576626|LAMA
77688|NCT02576626|FEV1
77689|NCT02576574|Avelumab
77690|NCT02576574|MSB0010718C
77691|NCT02576574|Non-Small Cell Lung Cancer
77692|NCT02576561|human papillomavirus
77693|NCT02576561|Cervical Intraepithelial Neoplasia
77694|NCT02576561|Cold Knife Conization
77695|NCT02576561|hysterectomy
77696|NCT02576561|Loop Electrosurgical Excision Procedure
77697|NCT02576561|LEEP
77698|NCT02576561|HSIL
77699|NCT02576561|High-Grade Squamous Intraepithelial Lesion
77700|NCT02576496|phase 1 clinical trial
77701|NCT02576496|multiple myeloma
77702|NCT02576496|Hodgkin's lymphoma
77703|NCT02576496|peripheral T-cell lymphoma
77704|NCT02576496|non-Hodgkin's lymphoma
77705|NCT02576470|swallowing
77706|NCT02576470|stroke
77707|NCT02576470|dysphagia
77708|NCT02576470|deglutition
77709|NCT02576431|NTRK Fusion Positive
77710|NCT02576431|LOXO-101
77711|NCT02576431|Loxo
77712|NCT02576431|TRK
77713|NCT02576431|TRK Fusion
77714|NCT02576431|NTRK1
77715|NCT02576431|NTRK2
77716|NCT02576431|NTRK3
77717|NCT02576431|TRKA
77718|NCT02576431|TRKB
77719|NCT02576431|TRKC
77720|NCT02576431|ETV6
77721|NCT02576431|NTRK
77722|NCT02576418|Partosure TTD test
77723|NCT02576418|CL
77724|NCT02576418|ART
77725|NCT02576418|SN
77726|NCT02576418|SP
77727|NCT02576418|PPV
77728|NCT02576418|NPV
77729|NCT02576379|Helicopter Emergency Medical System
77730|NCT02576379|Mortality
77731|NCT02576379|Labour market affiliation
77732|NCT02576379|Modified Rankin Scale
77733|NCT02576327|Lymphoma
77734|NCT02576327|Aprepitant
77735|NCT02576327|Chemotherapy-induced nausea and vomiting (CINV)
77736|NCT02576327|Autologous Hematopoietic Stem Cell Transplantation
77737|NCT02576327|Hematological Malignancies
77738|NCT02576301|AML
77739|NCT02576301|MDS
77740|NCT02576288|Sitagliptin
77741|NCT02576288|Brachial artery flow mediated dilation
77742|NCT02576288|Carotid stiffness
77743|NCT02576288|Pro-inflammatory
77744|NCT02576288|Pro-atherogenic
77745|NCT02576288|M1 macrophages
77746|NCT02576275|Phase 3
77747|NCT02576275|iNHL
77748|NCT02576275|Follicular Lymphoma
77749|NCT02576275|FL
77750|NCT02576275|PI3K
77751|NCT02576275|Small Lymphocytic Lymphoma
77752|NCT02576275|SLL
77753|NCT02576275|Marginal Zone Lymphoma
77754|NCT02576275|MZL
77755|NCT02576249|osteoarthritis
77756|NCT02576249|injection
77757|NCT02576249|steroid
77758|NCT02576249|anesthetic
77759|NCT02576236|Naïve patient
77760|NCT02576236|Suspicion of H pylori infection
77761|NCT02576236|Endoscopy
77762|NCT02576236|Antibiotics therapeutic strategies
77763|NCT02576236|Urea breath test
77764|NCT02576223|Peripheral Nerve Blocks
77765|NCT02576197|mild to moderate
77766|NCT02576197|probiotic
77767|NCT02576184|Incisional hernia
77768|NCT02576184|Stoma
77769|NCT02576184|rectal cancer
77770|NCT02576184|synthetic mesh
77771|NCT02576184|biologic mesh
77772|NCT02576171|cognitive behavioral therapy;
77773|NCT02576171|guided self-help
77774|NCT02576171|adolescent
77775|NCT02576067|Atherosclerotic cardiovascular disease
77776|NCT02576067|Inflammation reduction
77777|NCT02576041|driving simulator
77778|NCT02576028|Total Hip Replacement
77779|NCT02576028|Manipulation Therapy
77780|NCT02576002|Pulmonary Arterial Hypertension
77781|NCT02575989|Trauma
77782|NCT02575989|Prehospital
77783|NCT02575989|Hypothermia
77784|NCT02575976|Rehabilitation
77785|NCT02575976|Coronary artery disease
77786|NCT02575976|Patient Education
77787|NCT02575976|Randomized Controlled Trial
77788|NCT02575976|Protocol
77789|NCT02575937|low glycemic diet
77790|NCT02575937|diabetes
77791|NCT02575924|media
77792|NCT02575924|blastocyst
77793|NCT02575924|male infertility
77794|NCT02575924|poor responders
77795|NCT02575924|pgs
77796|NCT02575859|HIPEC
77797|NCT02575859|peritoneal lavage
77798|NCT02575833|Angina
77799|NCT02575833|Stable Angina
77800|NCT02575833|Cardiovascular Disease
77801|NCT02575833|Exercise-induced Angina
77802|NCT02575807|Ovarian cancer
77803|NCT02575807|Fallopian cancer
77804|NCT02575807|Primary peritoneal cancer
77805|NCT02575755|Azithromycin
77806|NCT02575755|Piperaquine
77807|NCT02575755|IPTp
77808|NCT02575755|Pharmacokinetics
77809|NCT02575755|Efficacy
77810|NCT02575729|carpal tunnel syndrome
77811|NCT02575729|local steroid injection
77812|NCT02575729|sonography
77813|NCT02575729|sonography-guided
77814|NCT02575716|McGrath®
77815|NCT02575716|Videolaryngoscope
77816|NCT02575716|intubating condition
77817|NCT02575716|muscle relaxant
77818|NCT02575716|intubation
77819|NCT02575690|spirulina, placebo, obesity,antihypertensive treatment
77820|NCT02575677|labor pain
77821|NCT02575677|oxycodone
77822|NCT02575664|Pain
77823|NCT02575664|Arthroplasty
77824|NCT02575664|Buprenorphine
77825|NCT02575651|PARP
77826|NCT02575651|Advanced Solid Malignancies
77827|NCT02575651|Fluzoparib
77828|NCT02575651|Ovarian Cancer
77829|NCT02575651|BRCA
77830|NCT02575625|Liver steatosis
77831|NCT02575625|Steatohepatitis
77832|NCT02575625|Fibroscan
77833|NCT02575599|Self-management
77834|NCT02575599|web-based
77835|NCT02575599|quantitative approach
77836|NCT02575586|Trigger Points
77837|NCT02575586|Dry needling
77838|NCT02575586|Torque
77839|NCT02575586|H-Reflex
77840|NCT02575573|resuscitation decision
77841|NCT02575560|Progression-Free Survival
77842|NCT02575547|Nutritional Status
77843|NCT02575547|Locoregionally Advanced Nasopharyngeal Carcinoma
77844|NCT02575534|anti-arrhythmic therapy
77845|NCT02575482|SUVN-D4010
77846|NCT02575482|serotonin 4 (5-HT4) receptor
77847|NCT02575482|first in human
77848|NCT02575482|safety
77849|NCT02575482|pharmacokinetics
77850|NCT02575482|tolerability
77851|NCT02575482|single dose
77852|NCT02575482|repeat dose
77853|NCT02575417|advance care planning
77854|NCT02575417|end-of-life care
77855|NCT02575417|health games
77856|NCT02575417|Family caregivers
77857|NCT02575417|Advance directives
77858|NCT02575404|Metastatic
77859|NCT02575404|Keytruda
77860|NCT02575404|pembrolizumab
77861|NCT02575404|GR-MD-02
77862|NCT02575404|Galactoarabino-rhamnogalacturonate
77863|NCT02575404|Immunotherapy
77864|NCT02575391|L-Glutamine
77865|NCT02575391|chemotherapy
77866|NCT02575391|radiotherapy
77867|NCT02575391|therapeutic toxicity
77868|NCT02575378|Metastatic Colorectal Cancer
77869|NCT02575378|Maintenance Treatment
77870|NCT02575378|Chinese Traditional Medicine
77871|NCT02575378|Clinical Trial
77872|NCT02575378|efficacy
77873|NCT02575378|safety
77874|NCT02575365|RRMS,
77875|NCT02575365|Cognition,
77876|NCT02575365|brain,
77877|NCT02575365|Fingolimod,
77878|NCT02575365|Multiple Sclerosis,
77879|NCT02575365|neurodegeneration,
77880|NCT02575365|Brain atrophy,
77881|NCT02575365|gray matter atrophy,
77882|NCT02575365|thalamic atrophy,
77883|NCT02575365|biomarkers,
77884|NCT02575365|BICAMS Battery,
77885|NCT02575352|Bone Substitute
77886|NCT02575352|Calcium Phosphate Cement
77887|NCT02575352|GRAFTYS
77888|NCT02575352|GRAFTYS®HBS
77889|NCT02575352|GRAFTYS®QUICKSET
77890|NCT02575352|Bone void filler
77891|NCT02575352|Bone growth
77892|NCT02575352|Registry
77893|NCT02575352|Bone defect
77894|NCT02575352|Revision arthroplasty
77895|NCT02575352|Arthrodesis
77896|NCT02575339|MLN0128
77897|NCT02575339|Sapanisertib
77898|NCT02575339|TORC1/2 inhibitor
77899|NCT02575339|INK128
77900|NCT02575339|Nexavar
77901|NCT02575339|Sorafenib
77902|NCT02575326|Asthma, Body Mass Idex, BMI, Overweight, Obesity
77903|NCT02575313|L-Glutamine
77904|NCT02575313|chemotherapy
77905|NCT02575313|radiotherapy
77906|NCT02575313|therapeutic toxicity
77907|NCT02575300|neuroendocrine tumors (NETs)
77908|NCT02575300|gastroenteropancreatic NETs
77909|NCT02575300|pancreatic NETs
77910|NCT02575300|gastrointestinal (GI) tract NET
77911|NCT02575300|advanced carcinoid tumors
77912|NCT02575274|Peri-implantitis
77913|NCT02575274|Peri-implant disease
77914|NCT02575274|Dental implants
77915|NCT02575274|Guided bone regeneration
77916|NCT02575261|CAR-T cell immunotherapy
77917|NCT02575261|EphA2
77918|NCT02575261|malignant glioma
77919|NCT02575248|dienogest
77920|NCT02575248|infertility
77921|NCT02575248|endometriosis
77922|NCT02575235|Sarcopenia
77923|NCT02575235|Cetylpyridinium chloride
77924|NCT02575222|Immunotherapy
77925|NCT02575222|PD-1
77926|NCT02575222|anti-PD-1
77927|NCT02575222|antibody
77928|NCT02575222|Kidney Cancer
77929|NCT02575222|RCC
77930|NCT02575222|non-metastatic
77931|NCT02575196|Cardiac arrest
77932|NCT02575196|Cardiopulmonary Resuscitation
77933|NCT02575196|CPR
77934|NCT02575196|cerebral blood flow
77935|NCT02575196|cerebral perfusion
77936|NCT02575183|Waterpipe smoking
77937|NCT02575183|Nicotine dependence
77938|NCT02575183|Smoking cessation
77939|NCT02575183|Varinecline, Chantix therapy
77940|NCT02575183|Behavioral therapy
77941|NCT02575170|amino acid
77942|NCT02575170|cesarean delivery
77943|NCT02575170|hypothermia
77944|NCT02575131|satiety
77945|NCT02575131|overweight
77946|NCT02575131|breakfast
77947|NCT02575131|ecological validity
77948|NCT02575105|Bispectral Index Hydrocephalus
77949|NCT02575092|Hyperhomocysteinemia
77950|NCT02575092|Coronary angiography
77951|NCT02575092|Percutaneous coronary intervention
77952|NCT02575092|Hypertension
77953|NCT02575092|Contrast-induced nephropathy
77954|NCT02575066|pazopanib
77955|NCT02575066|radiotherapy
77956|NCT02575053|latex allergy
77957|NCT02575053|latex hypersensitivity
77958|NCT02575053|powder free latex surgical gloves
77959|NCT02575053|latex safe protocol
77960|NCT02575001|Type 1 diabetes
77961|NCT02575001|Children and adolescents
77962|NCT02575001|Stress
77963|NCT02575001|Genetic factors
77964|NCT02575001|Psychological background
77965|NCT02574988|drug allergy
77966|NCT02574988|drug hypersensitivity
77967|NCT02574988|adverse drug reactions
77968|NCT02574988|severe cutaneous adverse reactions
77969|NCT02574949|radiation
77970|NCT02574949|fluoroscopy
77971|NCT02574949|diagnostic
77972|NCT02574936|karydakis modification
77973|NCT02574936|pilonidal sinus
77974|NCT02574936|complication
77975|NCT02574923|Cerebral Palsy
77976|NCT02574923|Stem Cells
77977|NCT02574871|Stress
77978|NCT02574871|Chronic stress
77979|NCT02574871|Perceived stress
77980|NCT02574871|Psychological distress
77981|NCT02574832|Pain
77982|NCT02574832|Surgery
77983|NCT02574832|Pregnancy
77984|NCT02574832|Anesthesia
77985|NCT02574819|opioid-induced constipation
77986|NCT02574806|BNP
77987|NCT02574806|Reference values
77988|NCT02574806|Newborn
77989|NCT02574806|Ventricular function
77990|NCT02574806|Stress
77991|NCT02574806|Pediatrics
77992|NCT02574806|Biomarkers
77993|NCT02574793|Glucose Fluctuation
77994|NCT02574793|GH-Secreting Adenoma
77995|NCT02574793|Cushing Syndrome
77996|NCT02574780|lymphedema
77997|NCT02574780|complex physical therapy
77998|NCT02574780|muscle strength
77999|NCT02574767|Weight gain, Fatty Acids, Omega-3
78000|NCT02574754|warfarin
78001|NCT02574754|pharmacokinetics
78002|NCT02574754|bioequivalence
78003|NCT02574754|healthy volunteer
78004|NCT02574728|Pediatrics
78005|NCT02574728|Brain Tumors
78006|NCT02574728|Neuroblastoma
78007|NCT02574728|Osteosarcoma
78008|NCT02574728|Ewing's Sarcoma
78009|NCT02574728|Rhabdomyosarcoma
78010|NCT02574728|Wilms Tumors
78011|NCT02574728|Soft Tissue Sarcomas
78012|NCT02574702|superficial surgical site infection
78013|NCT02574702|loop ileostomy
78014|NCT02574702|Ileostomy closure
78015|NCT02574689|Physical Activity
78016|NCT02574689|Cancer Prevention
78017|NCT02574637|MEDI2070
78018|NCT02574637|inflammatory bowel disease
78019|NCT02574637|moderate to severe Crohn's Disease
78020|NCT02574637|IL-23
78021|NCT02574598|PDL1
78022|NCT02574598|monoclonal antibody
78023|NCT02574585|Spinal cord injury
78024|NCT02574585|Paraplegia
78025|NCT02574585|Stem cells
78026|NCT02574585|Mesenchymal cells
78027|NCT02574572|Spinal cord injury
78028|NCT02574572|Mesenchymal cells
78029|NCT02574572|Stem cells
78030|NCT02574559|Caregiver
78031|NCT02574559|Stress
78032|NCT02574559|Depression
78033|NCT02574559|Autism Spectrum Disorder
78034|NCT02574559|Compassion Meditation
78035|NCT02574546|Mastectomy
78036|NCT02574533|Immunotherapy
78037|NCT02574533|PD-1 inhibitor
78038|NCT02574533|Keytruda
78039|NCT02574533|checkpoint inhibitor
78040|NCT02574533|vaccine
78041|NCT02574533|FANG
78042|NCT02574533|Vigil
78043|NCT02574520|Post-operative pain
78044|NCT02574520|opioid
78045|NCT02574520|opioid reduction
78046|NCT02574520|laparoscopic cholecystectomy
78047|NCT02574520|laparoscopic surgery
78048|NCT02574520|bupivacaine
78049|NCT02574520|extended release
78050|NCT02574520|locally acting analgesic
78051|NCT02574507|breast cancer
78052|NCT02574507|weight management
78053|NCT02574507|couples
78054|NCT02574507|symptom management
78055|NCT02574481|atherosclerosis
78056|NCT02574481|Superficial Femoral Artery (SFA)
78057|NCT02574481|Proximal Popliteal Artery (PPA)
78058|NCT02574481|lower extremities
78059|NCT02574481|stenting
78060|NCT02574481|paclitaxel
78061|NCT02574468|Dexamethasone
78062|NCT02574468|Direct pulp capping
78063|NCT02574468|MTA
78064|NCT02574468|pulpotomy
78065|NCT02574442|cervical intraepithelial neoplasia grade 1
78066|NCT02574442|cervical intraepithelial neoplasia grade 2
78067|NCT02574442|cervical intraepithelial neoplasia grade 3
78068|NCT02574442|adenocarcinoma in situ
78069|NCT02574429|Borderline Personality Disorder
78070|NCT02574429|Posttraumatic Stress Disorder
78071|NCT02574429|Cognitive Processing Therapy
78072|NCT02574429|Group Therapy
78073|NCT02574429|Comorbidity
78074|NCT02574429|Dialectical Behavior Therapy
78075|NCT02574416|Health behaviour
78076|NCT02574416|Health outcomes
78077|NCT02574416|Diet quality
78078|NCT02574416|Physical function
78079|NCT02574416|Lifestyle
78080|NCT02574416|Older adults
78081|NCT02574403|atypical hemolytic uremic syndrome (aHUS)
78082|NCT02574403|eculizumab discontinuation
78083|NCT02574390|ALS
78084|NCT02574390|stem cell
78085|NCT02574390|biomarker
78086|NCT02574390|disease progression
78087|NCT02574364|abdomen CT
78088|NCT02574364|open appendicectomy
78089|NCT02574312|Mechanical Axis Alignment
78090|NCT02574312|Knee Arthroplasty, Total
78091|NCT02574299|dyslexia
78092|NCT02574299|training
78093|NCT02574299|auditory rehabilitation
78094|NCT02574299|hearing loss
78095|NCT02574299|evoked potentials
78096|NCT02574299|dichotic
78097|NCT02574299|plasticity
78098|NCT02574299|noise
78099|NCT02574247|Audiology
78100|NCT02574247|Auditory Pathways
78101|NCT02574247|Auditory Perception
78102|NCT02574247|Brain Stem
78103|NCT02574247|Cochlea
78104|NCT02574247|Ear, Inner
78105|NCT02574247|Efferent Pathways
78106|NCT02574247|Hair Cells, Auditory, Outer
78107|NCT02574247|Learning
78108|NCT02574247|Neurons, Efferent
78109|NCT02574247|Speech Perception
78110|NCT02574234|Postoperative cognitive disorders POCD
78111|NCT02574234|inflammation
78112|NCT02574234|Surgery
78113|NCT02574208|Adult outpatients
78114|NCT02574208|Paris, France
78115|NCT02574195|Diabetes Mellitus
78116|NCT02574195|microvascular complications
78117|NCT02574195|macrovascular complications
78118|NCT02574195|epidemiology
78119|NCT02574195|Russia
78120|NCT02574182|Mild Cognitive Impairment
78121|NCT02574182|Magnetic Resonance Imaging
78122|NCT02574169|Alveolar Recruitment Maneuvers (ARM)
78123|NCT02574169|Continuous Positive Airway Pressure (CPAP)
78124|NCT02574169|Extended Sigh (eSigh)
78125|NCT02574143|Prognosis
78126|NCT02574143|Prospective Study
78127|NCT02574143|Quality of Life
78128|NCT02574143|Radiology
78129|NCT02574143|Rehabilitation
78130|NCT02574143|Registry;
78131|NCT02574143|Signs and Symptoms
78132|NCT02574143|Therapy
78133|NCT02574143|Bronchiectiasis
78134|NCT02574143|Diagnosis
78135|NCT02574143|Epidemiology
78136|NCT02574143|Etiology
78137|NCT02574143|Longitudinal Study
78138|NCT02574143|Microbiology
78139|NCT02574104|Intensive Care Units, Neonatal
78140|NCT02574104|Patient simulation
78141|NCT02574104|Interdisciplinary Communication
78142|NCT02574104|Human factors
78143|NCT02574104|Hazard Analysis and Critical Control Points
78144|NCT02574091|EGFR inhibitor
78145|NCT02574091|topical agent
78146|NCT02574091|psoriasis
78147|NCT02574091|phase 1
78148|NCT02574065|crying
78149|NCT02574065|colicky
78150|NCT02574065|infants
78151|NCT02574065|Lactobacillus reuteri DSM 17938
78152|NCT02574052|Menu Labelling;
78153|NCT02574052|Nutrition Education;
78154|NCT02574052|dietary assessment tools;
78155|NCT02574039|volunteers
78156|NCT02574039|oat
78157|NCT02574039|phenolic acid
78158|NCT02574039|bioavailability
78159|NCT02574026|MEG
78160|NCT02574026|EEG
78161|NCT02574026|MRI
78162|NCT02574026|Brain mapping
78163|NCT02574026|functional imaging
78164|NCT02574026|brain computer interface
78165|NCT02573974|undernutrition
78166|NCT02573974|gastrointestinal cancer
78167|NCT02573974|skeletal muscle
78168|NCT02573974|energy metabolism
78169|NCT02573948|People who inject drugs
78170|NCT02573948|Vietnam
78171|NCT02573948|Community support groups
78172|NCT02573935|Multiple Myeloma
78173|NCT02573935|Clarithromycin
78174|NCT02573935|Induction Chemotherapy
78175|NCT02573935|Transplantation, Autologous
78176|NCT02573922|constipation
78177|NCT02573922|opioid
78178|NCT02573922|Oxycodone
78179|NCT02573922|Oxycodone-naloxone
78180|NCT02573922|spine surgery
78181|NCT02573896|relapsed refractory neuroblastoma
78182|NCT02573883|Vulva
78183|NCT02573883|Lichen Sclerosus
78184|NCT02573883|Radiofrequency Carbon Dioxide Laser
78185|NCT02573883|Mona Lisa Laser
78186|NCT02573883|Clobetasol Proprionate
78187|NCT02573883|Vulvodynia
78188|NCT02573870|COPD
78189|NCT02573870|DPI
78190|NCT02573870|Batefenterol
78191|NCT02573870|Fluticasone Furoate
78192|NCT02573857|Induced blood stage malaria
78193|NCT02573857|Transmission
78194|NCT02573857|Gametocytemia
78195|NCT02573844|irritable bowel syndrome
78196|NCT02573844|abdominal pain
78197|NCT02573844|rome III criteria
78198|NCT02573844|abdominal distension
78199|NCT02573844|consistency of stools
78200|NCT02573844|stool frequency
78201|NCT02573844|meteorism
78202|NCT02573844|flatulence
78203|NCT02573844|abdominal discomfort
78204|NCT02573844|proklama
78205|NCT02573844|probiotics
78206|NCT02573844|alga klamath
78207|NCT02573844|aphanizomenon flos-aquae
78208|NCT02573844|prebiotics
78209|NCT02573844|colitis ulcerosa
78210|NCT02573831|labor
78211|NCT02573831|pain
78212|NCT02573831|oxycodone
78213|NCT02573831|placenta
78214|NCT02573818|sedation for EGD and colonoscopy procedures
78215|NCT02573805|nocturnal penile tumescence and rigidity
78216|NCT02573805|erectile dysfunction
78217|NCT02573805|Chinese males
78218|NCT02573792|First onset of optical neuritis
78219|NCT02573779|human milk
78220|NCT02573779|enteral nutrition
78221|NCT02573779|microbiome
78222|NCT02573779|Microbiota
78223|NCT02573766|Neurofeedback training
78224|NCT02573766|EEG
78225|NCT02573766|electroencephalograph
78226|NCT02573766|Questionnaires
78227|NCT02573766|Surveys
78228|NCT02573766|Chemotherapy-Induced Peripheral Neuropathy
78229|NCT02573766|CIPN
78230|NCT02573740|Mild Cognitive Impairment
78231|NCT02573740|Alzheimer's Disease
78232|NCT02573714|Ketamine
78233|NCT02573714|Intranasal
78234|NCT02573714|Pain crisis
78235|NCT02573714|Vasoocclusive Pain
78236|NCT02573714|Sickle cell disease
78237|NCT02573701|Schizophrenia
78238|NCT02573701|Adolescents
78239|NCT02573701|Treatment
78240|NCT02573701|Guidelines
78241|NCT02573688|Obesity
78242|NCT02573688|Metabolic Syndrome X
78243|NCT02573688|Interdisciplinary Studies
78244|NCT02573675|hemodialysis
78245|NCT02573675|peritoneal dialysis
78246|NCT02573662|Metabolic complications
78247|NCT02573662|Type 2 diabetes
78248|NCT02573662|Sedentary lifestyle
78249|NCT02573662|Low grade inflammation
78250|NCT02573662|Lipid metabolism
78251|NCT02573662|Glucose metabolism
78252|NCT02573662|Bone metabolism
78253|NCT02573662|Physical inactivity
78254|NCT02573623|Immunology diagnosis test
78255|NCT02573623|Children
78256|NCT02573623|Zambia
78257|NCT02573571|single nucleotide polymorphisms
78258|NCT02573571|cytokines
78259|NCT02573571|microbiome
78260|NCT02573545|liver
78261|NCT02573532|myocardial ischemia/diagnosis
78262|NCT02573532|myocardial ischemia/epidemiology
78263|NCT02573532|perioperative
78264|NCT02573532|perioperative complications/diagnosis
78265|NCT02573532|prognosis
78266|NCT02573519|11C Donepezil PET/CT scan
78267|NCT02573519|3D-Transit
78268|NCT02573519|Diabetes Mellitus
78269|NCT02573519|Gastrointestinal motility disorder
78270|NCT02573519|Diabetic autonomic neuropathy
78271|NCT02573506|Non-small cell lung cancer
78272|NCT02573506|Split-course Chemoradiotherapy
78273|NCT02573506|Consolidation chemotherapy
78274|NCT02573480|youth violence, intervention, emergency medicine
78275|NCT02573467|sporadic inclusion body myositis,
78276|NCT02573467|muscle wasting,
78277|NCT02573467|extension study,
78278|NCT02573467|BYM338,
78279|NCT02573467|bimagrumab,
78280|NCT02573428|Autism Spectrum Disorder
78281|NCT02573428|Eye Gaze
78282|NCT02573428|Remote Eye Gaze Tracking
78283|NCT02573428|Autism
78284|NCT02573402|electric stimulation
78285|NCT02573402|urodynamic study
78286|NCT02573389|pancreatic fistula, pancreatectomy, endoscopic stenting, pancreatic stenting, distal pancreatectomy
78287|NCT02573376|HIV
78288|NCT02573376|Hepatitis C
78289|NCT02573376|Drug Abuse
78290|NCT02573376|Hepatitis C Virus
78291|NCT02573376|sofosbuvir
78292|NCT02573376|ledipasvir
78293|NCT02573376|pharmacology
78294|NCT02573376|pharmacokinetics
78295|NCT02573324|Newly Diagnosed Glioblastoma
78296|NCT02573324|Temozolomide
78297|NCT02573324|Radiology Therapy Oncology Group
78298|NCT02573324|ABT-414
78299|NCT02573324|EGFRvIII
78300|NCT02573324|Antibody Drug Conjugate
78301|NCT02573324|Epithelial Growth Factor Receptor
78302|NCT02573324|Brain Tumor Group
78303|NCT02573324|Brain Tumor
78304|NCT02573298|cryotherapy
78305|NCT02573298|power Doppler score
78306|NCT02573298|synovial fluid cytokines
78307|NCT02573298|pain VAS
78308|NCT02573259|efficacy
78309|NCT02573259|safety
78310|NCT02573259|pharmacokinetics
78311|NCT02573259|pharmacodynamics
78312|NCT02573259|open label
78313|NCT02573259|dose response
78314|NCT02573259|multiple ascending dose
78315|NCT02573259|immunogenicity
78316|NCT02573246|neurostimulation
78317|NCT02573246|cognitive restructuring
78318|NCT02573246|TMS
78319|NCT02573194|Appetite
78320|NCT02573194|Amino acids
78321|NCT02573194|Protein Source
78322|NCT02573168|Pharmacogenomic
78323|NCT02573168|Pharmacogenomic Testing
78324|NCT02573168|Pharmacogenomics
78325|NCT02573168|Genetic Testing
78326|NCT02573168|Genetics
78327|NCT02573168|GeneSight
78328|NCT02573168|Enhanced GeneSight
78329|NCT02573168|Psychotropic
78330|NCT02573155|Pharmacokinetics
78331|NCT02573155|Pharmacodynamics
78332|NCT02573155|AZD8871
78333|NCT02573155|Safety
78334|NCT02573155|Tolerability
78335|NCT02573155|mild persistent asthma
78336|NCT02573155|moderate to severe COPD
78337|NCT02573142|obesity
78338|NCT02573142|treatment
78339|NCT02573142|community
78340|NCT02573142|integrated
78341|NCT02573129|cardiovascular disease risk
78342|NCT02573129|Mediterranean diet
78343|NCT02573129|red meat
78344|NCT02573116|obstructive sleep apnea
78345|NCT02573116|endothelial dysfunction
78346|NCT02573116|periodontitis
78347|NCT02573090|Occlusal caries
78348|NCT02573090|Resin based fissure sealant
78349|NCT02573090|Composite resin restoration
78350|NCT02573090|Effectiveness
78351|NCT02573090|Longevity
78352|NCT02573077|Hyponatremia due to SIADH
78353|NCT02573077|Cancer
78354|NCT02573038|Aflibercept
78355|NCT02573038|choroidal neovascularization
78356|NCT02573038|angioid streaks
78357|NCT02573038|young patient
78358|NCT02572999|Aged
78359|NCT02572999|Frail
78360|NCT02572999|Functional decline
78361|NCT02572999|Impairment
78362|NCT02572999|valvular heart disease
78363|NCT02572999|Cohort
78364|NCT02572999|risk factors
78365|NCT02572947|Dolutegravir
78366|NCT02572947|HIV infection
78367|NCT02572947|Anti-Retroviral Agents
78368|NCT02572947|HIV Integrase Inhibitors
78369|NCT02572947|Integrase Inhibitors
78370|NCT02572947|Pharmacologic Actions
78371|NCT02572947|Therapeutic Uses
78372|NCT02572934|Testicular cancer
78373|NCT02572934|Survivorship
78374|NCT02572934|late adverse treatment effects
78375|NCT02572921|Positive Psychotherapy
78376|NCT02572921|Depression
78377|NCT02572921|Happiness
78378|NCT02572908|wheat, IBS, gluten, ATI
78379|NCT02572895|Cranberry
78380|NCT02572895|Proanthocyanidins
78381|NCT02572895|Urinary catabolites
78382|NCT02572882|hemodialysis
78383|NCT02572882|p-inulin
78384|NCT02572882|gut microbiome
78385|NCT02572869|Mandible Reconstruction
78386|NCT02572869|Fibula Osteomyocutaneous Free Flaps
78387|NCT02572869|Quality of Life
78388|NCT02572869|15-244
78389|NCT02572856|Feasibility
78390|NCT02572856|continuous glucose monitor
78391|NCT02572856|surgery
78392|NCT02572843|NSCLC
78393|NCT02572843|lung cancer
78394|NCT02572843|MEDI4736
78395|NCT02572843|non-small cell lung cancer
78396|NCT02572843|immunotherapy
78397|NCT02572843|anti-PD-L1
78398|NCT02572830|Reconsolidation
78399|NCT02572830|EMDR
78400|NCT02572830|PTSD
78401|NCT02572817|Anti-Influenza Immune Plasma
78402|NCT02572804|bladder cancer-cystectomy
78403|NCT02572804|rectus sheath catheter
78404|NCT02572804|epidural
78405|NCT02572713|Parkinson's Disease
78406|NCT02572713|alpha-synuclein
78407|NCT02572713|biomarker
78408|NCT02572687|metastatic
78409|NCT02572687|advanced
78410|NCT02572687|immuno-oncology
78411|NCT02572687|vascular endothelial growth factor (VEGF)
78412|NCT02572687|angiogenesis
78413|NCT02572687|PD-1
78414|NCT02572687|PD-L1
78415|NCT02572674|Bipolar disorder
78416|NCT02572674|relapse risk factors
78417|NCT02572674|prospective follow up
78418|NCT02572661|Radiotherapy, Sentinel Node Mapping, Spect
78419|NCT02572648|Cardiomyopathy
78420|NCT02572648|Magnetic Resonance Imaging (MRI)
78421|NCT02572635|Pneumococcal Infection
78422|NCT02572635|Phase I
78423|NCT02572635|Immunogenicity
78424|NCT02572635|Safety
78425|NCT02572635|Vaccination
78426|NCT02572622|exercise
78427|NCT02572622|deep friction massage
78428|NCT02572622|spinal decompression
78429|NCT02572622|non-surgical spinal decompression
78430|NCT02572596|Hematopoietic Stem Cell Mobilization
78431|NCT02572596|Thrombopoietin
78432|NCT02572583|Reconciling Exterior and Interior Therapy
78433|NCT02572583|Influenza
78434|NCT02572570|Adult dental care
78435|NCT02572557|Spray Cryotherapy
78436|NCT02572544|young healthy adults
78437|NCT02572544|single pinhole glasses
78438|NCT02572544|multiple pinhole glasses
78439|NCT02572531|Lactobacillus reuteri
78440|NCT02572531|Wound Healing
78441|NCT02572531|Third Molar
78442|NCT02572531|Postoperative Complications
78443|NCT02572518|immunity yellow fever vaccine
78444|NCT02572505|HIV-Discordant
78445|NCT02572505|Preexposure Prophylaxis
78446|NCT02572492|Multiple Myeloma
78447|NCT02572492|Recurrence
78448|NCT02572492|Carfilzomib
78449|NCT02572492|Salvage Therapy
78450|NCT02572492|Transplantation, Autologous
78451|NCT02572479|fatty acids, amyotrophic lateral sclerosis, nutrient status
78452|NCT02572466|high-sensitive troponin-I
78453|NCT02572466|End-stage renal disease
78454|NCT02572466|hemodialysis
78455|NCT02572440|Aortic arch surgery; Blood conservation; aPRP
78456|NCT02572401|Human immunodeficiency virus
78457|NCT02572401|Sexually transmitted disease
78458|NCT02572401|Behavioral intervention
78459|NCT02572401|Randomized controlled trial
78460|NCT02572401|Text messages
78461|NCT02572401|Social cognitive theory
78462|NCT02572401|Theory of planned behavior
78463|NCT02572401|Sexual behavior
78464|NCT02572401|African Americans
78465|NCT02572401|Men
78466|NCT02572349|Healthy Subjects
78467|NCT02572310|total knee arthroplasty
78468|NCT02572297|epilepsy
78469|NCT02572297|SUDEP
78470|NCT02572297|SpO2
78471|NCT02572284|Stereotactic Body Radiation Therapy (SBRT)
78472|NCT02572284|High Risk Prostate Cancer
78473|NCT02572284|Preoperative SBRT
78474|NCT02572284|Prostate Adenocarcinoma
78475|NCT02572284|Prostatectomy
78476|NCT02572284|Quality of Life
78477|NCT02572271|Autologous augmentation
78478|NCT02572271|Mastopexy
78479|NCT02572271|Massive weight loss
78480|NCT02572245|Healthy Subjects
78481|NCT02572245|Device
78482|NCT02572245|PK
78483|NCT02572245|Phase 1
78484|NCT02572245|Bioequivalence
78485|NCT02572245|Adalimumab
78486|NCT02572245|Single Dose
78487|NCT02572193|achalasia
78488|NCT02572193|surgery
78489|NCT02572167|Monomethyl auristatin E
78490|NCT02572167|Antigens, CD30
78491|NCT02572167|Antibody-Drug Conjugate
78492|NCT02572167|Antibodies, Monoclonal
78493|NCT02572167|Immunotherapy
78494|NCT02572167|Autologous stem cell transplant
78495|NCT02572115|After-Hours Care
78496|NCT02572115|Primary Care
78497|NCT02572115|Emergency Medical Services/utilization
78498|NCT02572115|Denmark
78499|NCT02572115|Questionnaires
78500|NCT02572115|Patient Satisfaction
78501|NCT02572115|Patient feeling of safety
78502|NCT02572115|Triage/standards
78503|NCT02572115|Referral and Consultation/statistics & numerical data
78504|NCT02572115|Humans
78505|NCT02572115|Male
78506|NCT02572115|Female
78507|NCT02572115|Hotlines
78508|NCT02572115|telenursing
78509|NCT02572115|Night Care/utilization
78510|NCT02572115|postal service
78511|NCT02572102|ECG
78512|NCT02572102|Blood Pressure
78513|NCT02572102|Energy Drinks
78514|NCT02572102|Panax Ginseng
78515|NCT02572037|Premature ejaculation
78516|NCT02572037|Dapoxetine
78517|NCT02572037|local anaesthetics
78518|NCT02572037|nerve electrophysiology
78519|NCT02572011|Lower limb amputation
78520|NCT02572011|Transtibial
78521|NCT02572011|Balance
78522|NCT02572011|Postural Control
78523|NCT02572011|Limits of Stability
78524|NCT02572011|Rehabilitation
78525|NCT02572011|Home-based intervention
78526|NCT02572011|Nintendo Wii
78527|NCT02572011|Balance Board
78528|NCT02571985|Zenith aortoiliac aneurysm
78529|NCT02571985|iliac aneurysm
78530|NCT02571985|branch
78531|NCT02571985|connections
78532|NCT02571985|endovascular graft
78533|NCT02571985|graft-iliac bifurcation
78534|NCT02571985|Aneurysm
78535|NCT02571985|Vascular Diseases
78536|NCT02571985|Cardiovascular Diseases
78537|NCT02571972|dorzolamide-timolol
78538|NCT02571972|topical aqueous suppression
78539|NCT02571972|neovascular age-related macular degeneration
78540|NCT02571972|macular edema
78541|NCT02571972|intravitreal injection
78542|NCT02571972|anti-vascular endothelial growth factor
78543|NCT02571959|Obesity
78544|NCT02571959|Pharmacology
78545|NCT02571959|Amoxicillin-Potassium Clavulanate Combination
78546|NCT02571933|Pediatrics
78547|NCT02571933|Pain Scale
78548|NCT02571933|Faces Pain Scale - Revised
78549|NCT02571933|Cameroon
78550|NCT02571920|cardiac surgery
78551|NCT02571920|cardiac output
78552|NCT02571907|Zenith aortoiliac aneurysm
78553|NCT02571907|Iliac aneurysm
78554|NCT02571907|Branch
78555|NCT02571907|Connections
78556|NCT02571907|Endovascular graft
78557|NCT02571907|Graft-iliac bifurcation
78558|NCT02571907|Aneurysm
78559|NCT02571907|Vascular Diseases
78560|NCT02571907|Cardiovascular Diseases
78561|NCT02571881|constipation
78562|NCT02571881|oxycodone
78563|NCT02571881|caesarean section
78564|NCT02571855|insomnia
78565|NCT02571855|Pharmacokinetics
78566|NCT02571855|Safety
78567|NCT02571855|Pharmacodynamics
78568|NCT02571855|Healthy
78569|NCT02571842|Recurrent IgA nephropathy
78570|NCT02571842|Rituximab
78571|NCT02571829|Liposarcoma
78572|NCT02571829|Soft tissue sarcoma
78573|NCT02571829|CDK4
78574|NCT02571829|CDK6
78575|NCT02571829|LEE011
78576|NCT02571829|ribociclib
78577|NCT02571816|ASP2215
78578|NCT02571816|Healthy
78579|NCT02571816|Hepatic Impairment
78580|NCT02571816|Mild Hepatic Impairment
78581|NCT02571816|Moderate Hepatic Impairment
78582|NCT02571803|coronary artery disease
78583|NCT02571803|atherosclerosis
78584|NCT02571803|DASH diet
78585|NCT02571790|Patient with Generalized Anxiety Disorders
78586|NCT02571777|Asthma
78587|NCT02571725|Ovarian cancer
78588|NCT02571725|Fallopian tube cancer
78589|NCT02571725|Peritoneal cancer
78590|NCT02571725|PARP
78591|NCT02571725|BRCA
78592|NCT02571725|Immunotherapy
78593|NCT02571725|Olaparib
78594|NCT02571725|Tremelimumab
78595|NCT02571725|CTLA4
78596|NCT02571673|Survivorship
78597|NCT02571673|Quality of Life
78598|NCT02571673|HN-STAR web-based
78599|NCT02571673|15-245
78600|NCT02571660|vitamin d levels
78601|NCT02571660|exacerbation of asthma
78602|NCT02571660|asthma control
78603|NCT02571634|intranasal fentanyl
78604|NCT02571634|conscious sedation
78605|NCT02571608|Type 2 diabetes mellitus, Metformin, peri-operative
78606|NCT02571595|HIV - Human Immunodeficiency Virus
78607|NCT02571595|digital cognitive behavioural therapy for insomnia (dCBT-I)
78608|NCT02571595|insomnia
78609|NCT02571595|cognitive Impairment
78610|NCT02571595|concentration
78611|NCT02571595|productivity
78612|NCT02571582|Predictors of mortality
78613|NCT02571543|Ibuprofen
78614|NCT02571543|IVF
78615|NCT02571543|minimal stimulation
78616|NCT02571543|modified natural-cycle
78617|NCT02571543|nonsteroidal anti-inflammatory drug (NSAID)
78618|NCT02571543|Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
78619|NCT02571543|Oocyte Retrieval
78620|NCT02571543|Ovarian Follicle/drug effects
78621|NCT02571517|Respiratory viral infection.
78622|NCT02571517|Respiratory syncytial virus bronchiolitis
78623|NCT02571517|METHYLPREDNISOLONE SODIUM SUCCINATE
78624|NCT02571504|HIV - Human Immunodeficiency Virus
78625|NCT02571504|Memory
78626|NCT02571504|Concentration
78627|NCT02571478|Military Couples
78628|NCT02571478|Marriage
78629|NCT02571478|Primary Care
78630|NCT02571478|Marriage Intervention
78631|NCT02571478|Air Force
78632|NCT02571465|functional hemodynamic parameter
78633|NCT02571465|passive leg raising
78634|NCT02571465|stroke volume variation
78635|NCT02571465|pulse pressure variation
78636|NCT02571452|Veteran
78637|NCT02571452|Insomnia
78638|NCT02571452|Primary Healthcare
78639|NCT02571439|TAP block, post-cesarean analgesia
78640|NCT02571413|animated cartoon-aided teaching
78641|NCT02571413|oral presentation
78642|NCT02571413|allergic rhinitis
78643|NCT02571413|intranasal corticosteroid
78644|NCT02571413|how to use intranasal corticosteroid
78645|NCT02571400|Risk
78646|NCT02571400|Opioid analgesics
78647|NCT02571400|Opioid-related disorders
78648|NCT02571400|Surgery
78649|NCT02571400|Post-operative care
78650|NCT02571400|Post-operative period
78651|NCT02571400|Post-operative complications
78652|NCT02571400|Opioid Use disorders
78653|NCT02571400|Pain, post-operative
78654|NCT02571400|Opiate Addiction
78655|NCT02571387|Motivation
78656|NCT02571387|Impulsive eating
78657|NCT02571387|Mindfulness
78658|NCT02571387|Self-help
78659|NCT02571387|Physical activity
78660|NCT02571387|Weight-loss
78661|NCT02571374|symbiotic
78662|NCT02571374|colorectal cancer
78663|NCT02571361|Acetaminophen
78664|NCT02571361|Ibuprofen
78665|NCT02571361|Arthroplasty, Replacement, Hip
78666|NCT02571309|Self-management
78667|NCT02571309|Asthma
78668|NCT02571309|Patient education
78669|NCT02571309|Health literacy
78670|NCT02571309|Health-related quality of life
78671|NCT02571309|Asthma control
78672|NCT02571309|Adherence
78673|NCT02571296|Preterm Birth
78674|NCT02571296|Oral Micronized Progesterone
78675|NCT02571283|Total Knee Arthroplasty
78676|NCT02571283|Total Knee Replacement
78677|NCT02571283|Exparel
78678|NCT02571283|Cocktail Injection
78679|NCT02571283|Pain Management
78680|NCT02571270|Exercise
78681|NCT02571270|quality of life
78682|NCT02571270|healthy
78683|NCT02571270|cardiac remodeling
78684|NCT02571257|LDL-C
78685|NCT02571257|Lipid Regulator
78686|NCT02571244|Tobacco Use Disorder
78687|NCT02571244|Hospitalized patients
78688|NCT02571244|Text message
78689|NCT02571244|Motivational Interview
78690|NCT02571244|Substance-Related Disorders
78691|NCT02571244|Behaviors and Mental Disorders
78692|NCT02571218|atrial fibrillation
78693|NCT02571218|mapping
78694|NCT02571218|substrate
78695|NCT02571218|ablation
78696|NCT02571205|testosterone
78697|NCT02571205|pubertal delay
78698|NCT02571192|ADME
78699|NCT02571179|Labor pain
78700|NCT02571179|Fentanyl
78701|NCT02571179|Transmucosal
78702|NCT02571153|Intravenous anesthesia
78703|NCT02571153|Postoperative nausea vomiting
78704|NCT02571153|Postoperative pain
78705|NCT02571153|Patient satisfaction
78706|NCT02571153|Quality of health care
78707|NCT02571153|Ketamine
78708|NCT02571114|Glycemic Responses
78709|NCT02571114|Metabolic Responses
78710|NCT02571114|Males
78711|NCT02571114|Females
78712|NCT02571101|Clomipramine
78713|NCT02571101|Premature ejaculation
78714|NCT02571101|CDFR0812
78715|NCT02571101|Sildenafil
78716|NCT02571088|Sickle Cell Hemoglobin C Disease
78717|NCT02571088|Sports Training
78718|NCT02571088|Hemoglobin S Disease
78719|NCT02571088|Lactate
78720|NCT02571075|auricular
78721|NCT02571075|acupuncture
78722|NCT02571075|pain
78723|NCT02571062|bioequivalence
78724|NCT02571036|Gastrointestinal stromal tumors (GIST)
78725|NCT02571036|systemic mastocytosis (SM)
78726|NCT02571036|PDGFR-alpha
78727|NCT02571036|KIT
78728|NCT02571036|mast cell leukemia (MCL)
78729|NCT02571036|mast cell disease (MCD)
78730|NCT02571036|DCC-2618
78731|NCT02571036|melanoma
78732|NCT02571036|aggressive systemic mastocytosis (ASM)
78733|NCT02571023|Skull Base Trauma
78734|NCT02571023|microscope surgery
78735|NCT02571023|neuroendoscope surgery
78736|NCT02571010|static mechanical allodynia
78737|NCT02571010|somatosensory rehabilitation
78738|NCT02571010|vibrotactile stimulation
78739|NCT02570997|Alzheimer's Disease
78740|NCT02570997|Mild Cognitive Impairment
78741|NCT02570971|mannitol
78742|NCT02570971|treatment
78743|NCT02570958|robotic surgery
78744|NCT02570958|indocyanine green
78745|NCT02570958|electromagnetic navigational bronchoscopy
78746|NCT02570932|Adult Autologous Bone Marrow Mesenchymal Cells Expanded
78747|NCT02570932|chronic spinal cord injury (SCI)
78748|NCT02570919|Prostate cancer
78749|NCT02570919|IGRT
78750|NCT02570919|Hypofractionation
78751|NCT02570919|Extreme
78752|NCT02570919|Single Fraction
78753|NCT02570919|Urethral Sparing
78754|NCT02570919|MRI
78755|NCT02570893|Esophageal cancer;adjuvant therapy;chemotherapy;radiotherapy
78756|NCT02570867|glaucoma
78757|NCT02570867|brain function
78758|NCT02570867|fMRI
78759|NCT02570854|Anemia
78760|NCT02570841|Heat pain threshold
78761|NCT02570841|Cold pain threshold
78762|NCT02570841|Mechanical pain threshold
78763|NCT02570841|High dose Capsaicin
78764|NCT02570828|healthy neonate, tachypnea, thermal imaging, pneumonia
78765|NCT02570815|lung cancer
78766|NCT02570815|segmentectomy
78767|NCT02570815|robotic surgery
78768|NCT02570815|near-infrared fluorescent
78769|NCT02570815|IC-GREEN
78770|NCT02570815|indocyanine green
78771|NCT02570815|early-stage lung cancer
78772|NCT02570776|Helicobacter pylori
78773|NCT02570776|UBT
78774|NCT02570776|Sensitivity
78775|NCT02570776|specificity
78776|NCT02570776|prevalence
78777|NCT02570763|neurostimulation
78778|NCT02570763|comorbidity
78779|NCT02570763|tDCS
78780|NCT02570763|CBT
78781|NCT02570763|anxiety
78782|NCT02570763|alcohol
78783|NCT02570685|Gratitude Intervention
78784|NCT02570685|positive emotion
78785|NCT02570685|friendships
78786|NCT02570685|positive psychology
78787|NCT02570685|life satisfaction
78788|NCT02570659|WAD
78789|NCT02570659|Whiplash
78790|NCT02570659|Information Video
78791|NCT02570633|Migraine
78792|NCT02570633|Ginger
78793|NCT02570633|Prophylactic treatment
78794|NCT02570594|Cognition
78795|NCT02570594|Autobiographical
78796|NCT02570594|memoryCognitive
78797|NCT02570594|remediation
78798|NCT02570581|volonteeres
78799|NCT02570568|Venepuncture
78800|NCT02570568|Transillumination
78801|NCT02570555|driving
78802|NCT02570542|CD34+ Cell Dose
78803|NCT02570542|Autologous Stem Cell Transplantation
78804|NCT02570542|15-193
78805|NCT02570529|Pancreatic cancer
78806|NCT02570529|Chemoradiotherapy
78807|NCT02570529|Gastrointestinal toxicity
78808|NCT02570529|Albis
78809|NCT02570516|Indigo carmine chromoendoscopy
78810|NCT02570516|Narrow band imaging
78811|NCT02570516|Colonoscopy
78812|NCT02570490|fusidic acid
78813|NCT02570490|skin infection
78814|NCT02570451|cognitive impairment
78815|NCT02570451|post surgical outcomes
78816|NCT02570451|elective joint replacement surgery
78817|NCT02570438|postoperative outcomes
78818|NCT02570438|older surgical patients
78819|NCT02570386|In-vitro fertilization
78820|NCT02570386|frozen thawed embryo transfer
78821|NCT02570386|fresh embryo transfer
78822|NCT02570373|Healthy
78823|NCT02570373|Guselkumab
78824|NCT02570347|Snake Envenomation
78825|NCT02570347|Antibiotic Prophylaxis
78826|NCT02570347|Viperidae
78827|NCT02570334|early ART
78828|NCT02570334|neurocognitive evaluation
78829|NCT02570321|Cornea
78830|NCT02570321|Ulcer
78831|NCT02570321|Infectious keratitis
78832|NCT02570321|Bacterial
78833|NCT02570321|Fungal
78834|NCT02570295|Army
78835|NCT02570295|Sport
78836|NCT02570295|Physical Fitness
78837|NCT02570295|Injuries
78838|NCT02570295|Psychological Tests
78839|NCT02570295|Attrition
78840|NCT02570282|Female
78841|NCT02570256|stroke
78842|NCT02570256|upper extremity
78843|NCT02570256|motor exploration
78844|NCT02570256|error augmentation
78845|NCT02570256|robotic rehabilitation
78846|NCT02570243|heparin
78847|NCT02570243|radial artery
78848|NCT02570230|Thoracotomy
78849|NCT02570230|Postoperative pain
78850|NCT02570230|Ketamine
78851|NCT02570217|NCPAP, High Flow Nasal Cannula, pretem infants, NICU
78852|NCT02570178|clinical trial
78853|NCT02570178|accidental falls
78854|NCT02570178|postural balance
78855|NCT02570178|elderly
78856|NCT02570178|primary Health Care
78857|NCT02570165|efficacy
78858|NCT02570165|dry powder inhaler
78859|NCT02570165|vilanterol
78860|NCT02570165|batefenterol
78861|NCT02570152|Dengue
78862|NCT02570152|Non-laboratory confirmed dengue (non-LCD)
78863|NCT02570152|Acute febrile illness (AFI)
78864|NCT02570152|Laboratory confirmed dengue (LCD)
78865|NCT02570126|Immunogenicity
78866|NCT02570126|Varicella
78867|NCT02570126|Safety
78868|NCT02570126|Human serum albumin
78869|NCT02570126|Healthy children
78870|NCT02570126|12 to 23 months
78871|NCT02570100|Cancer Stem Cells
78872|NCT02570087|Coronary ChronicTotal Occlusion
78873|NCT02570087|Coronary Angioplasty
78874|NCT02570087|Reduced Ejection Fraction
78875|NCT02570061|recruitment
78876|NCT02570061|comprehension
78877|NCT02570061|satisfaction
78878|NCT02570061|informed consent
78879|NCT02570061|telephone
78880|NCT02570035|Mirabegron
78881|NCT02570035|Overactive Bladder
78882|NCT02570035|Cardiovascular Disease
78883|NCT02570022|Pain control
78884|NCT02570022|liposomal bupivacaine
78885|NCT02570022|exparel
78886|NCT02570022|shoulder arthroplasty
78887|NCT02570009|couples
78888|NCT02570009|weight loss treatment
78889|NCT02570009|home environment
78890|NCT02569970|Epilepsy
78891|NCT02569970|SUDEP
78892|NCT02569970|fluoxetine
78893|NCT02569970|placebo
78894|NCT02569970|SpO2
78895|NCT02569918|Neuroplasticity
78896|NCT02569918|Sensory Feedback
78897|NCT02569918|Transcutaneous electrical stimulation
78898|NCT02569918|Robotic hand
78899|NCT02569905|flurbiprofen
78900|NCT02569905|Parecoxib sodium
78901|NCT02569905|Postoperative Shivering
78902|NCT02569879|Boostrix™
78903|NCT02569879|Bagota
78904|NCT02569879|maternal vaccination
78905|NCT02569879|Pertussis
78906|NCT02569879|Mortality
78907|NCT02569879|Morbidity
78908|NCT02569866|plastic surgery
78909|NCT02569866|mammaplasty
78910|NCT02569866|wound infection
78911|NCT02569866|prophylaxis
78912|NCT02569827|Uncomplicated Dengue Fever
78913|NCT02569827|Treatment
78914|NCT02569827|Phase Ib/IIa
78915|NCT02569827|single centre
78916|NCT02569827|double-blind
78917|NCT02569827|placebo-controlled
78918|NCT02569827|parallel-group dose ranging trial
78919|NCT02569827|Modipafant
78920|NCT02569827|Celgosivir
78921|NCT02569788|re-irradiation
78922|NCT02569788|carbon ion radiotherapy
78923|NCT02569775|Cerebral Palsy
78924|NCT02569775|Stem Cells
78925|NCT02569762|Non-Nutritive Sweeteners
78926|NCT02569762|Artificial Sweeteners
78927|NCT02569762|Glucose Metabolism
78928|NCT02569762|Microbiota
78929|NCT02569762|Dysbiosis
78930|NCT02569671|Dental Implants, Single-Tooth
78931|NCT02569645|Rectal cancer
78932|NCT02569645|Rosuvastatin
78933|NCT02569632|Meningococcal Vaccines
78934|NCT02569632|Neisseria Meningitidis
78935|NCT02569632|Factor H-binding Protein
78936|NCT02569619|Physical Activity
78937|NCT02569619|Mental Health
78938|NCT02569619|Physical Exercise
78939|NCT02569619|Mental disorder
78940|NCT02569619|Promotion
78941|NCT02569606|consumption of blood
78942|NCT02569606|consumption of coagulation products
78943|NCT02569606|coagulation algorithm
78944|NCT02569606|trauma related transfusion
78945|NCT02569580|anti-lice treatment
78946|NCT02569567|Smart-Shear Wave(SSW)
78947|NCT02569567|Transient Elastography(TE)
78948|NCT02569567|Liver cirrhosis
78949|NCT02569554|PF-06463922
78950|NCT02569554|rabeprazole
78951|NCT02569554|proton pump inhibitor (PPI)
78952|NCT02569554|pharmacokinetics(PK)
78953|NCT02569554|food effect
78954|NCT02569541|fusidic acid
78955|NCT02569541|prosthetic joint infections
78956|NCT02569541|bone infections
78957|NCT02569541|osteomyelitis
78958|NCT02569528|atrial fibrillation
78959|NCT02569528|anticoagulation
78960|NCT02569476|BGB-3111
78961|NCT02569476|Obinutuzumab
78962|NCT02569476|B-cell
78963|NCT02569476|Lymphoma
78964|NCT02569476|Leukemia
78965|NCT02569476|Therapeutic uses
78966|NCT02569450|Surgery
78967|NCT02569450|Performance
78968|NCT02569450|Outcome
78969|NCT02569450|Control chart
78970|NCT02569437|doxycycline
78971|NCT02569437|oral methylprednisone
78972|NCT02569437|sinusitis with nasal polyps
78973|NCT02569424|PEEP level
78974|NCT02569424|Trendelenburg position
78975|NCT02569424|cross-sectional area of the jugular and subclavian veins
78976|NCT02569424|central venous catheter
78977|NCT02569398|Alzheimer disease
78978|NCT02569398|JNJ-54861911
78979|NCT02569398|Dementia
78980|NCT02569385|Weaning TTE
78981|NCT02569385|patients in prolonged weaning
78982|NCT02569346|Triumeq
78983|NCT02569346|Pharmacokinetics
78984|NCT02569346|Crushing
78985|NCT02569346|Drip feed
78986|NCT02569333|ulcerative colitis
78987|NCT02569333|inflammatory bowel disease
78988|NCT02569333|education
78989|NCT02569333|patient-reported outcomes
78990|NCT02569307|At Risk of Mental State
78991|NCT02569307|Prodromal Phase
78992|NCT02569307|Psychosis
78993|NCT02569294|group interventions
78994|NCT02569294|emotional distress
78995|NCT02569294|breast cancer
78996|NCT02569294|yoga
78997|NCT02569294|hypnosis
78998|NCT02569294|cognitive-behavioral therapy
78999|NCT02569281|Subacromial pain syndrome
79000|NCT02569281|Eccentric exercise
79001|NCT02569281|Pressure pain
79002|NCT02569281|US-guided percutaneous electrolysis
79003|NCT02569268|Arteriosclerosis
79004|NCT02569268|Vascular function
79005|NCT02569268|Vascular disease early detection system
79006|NCT02569229|children
79007|NCT02569229|cystic fibrosis
79008|NCT02569229|glucose intolerance
79009|NCT02569229|continuous glucose measurement
79010|NCT02569216|Electrical Inhibition
79011|NCT02569216|Preterm Birth
79012|NCT02569216|Premature Birth
79013|NCT02569216|Preterm Labor
79014|NCT02569216|Premature Labor
79015|NCT02569216|tocolytic
79016|NCT02569216|uterus
79017|NCT02569177|myocardial infarction
79018|NCT02569177|cardiac surgery
79019|NCT02569177|troponin
79020|NCT02569177|heart-type fatty acid binding protein
79021|NCT02569138|Balance
79022|NCT02569138|Footwear
79023|NCT02569138|Shoes
79024|NCT02569138|Falls
79025|NCT02569125|segmental overgrowth syndrome
79026|NCT02569099|stroke survivors
79027|NCT02569099|caregivers
79028|NCT02569099|burden of care
79029|NCT02569099|quality of life
79030|NCT02569099|function
79031|NCT02569099|community reintegration
79032|NCT02569099|caregiver training
79033|NCT02569073|Functional Chest Pain
79034|NCT02569073|Non-Cardiac Chest Pain
79035|NCT02569073|Esophageal Hypersensitivity
79036|NCT02569060|diabetes mellitus
79037|NCT02569060|community intervention
79038|NCT02569060|intervention
79039|NCT02569060|randomized
79040|NCT02569060|dietary intervention
79041|NCT02569060|self-management support
79042|NCT02569060|food bank
79043|NCT02569047|Atraumatic Restorative Treatment
79044|NCT02569047|Occlusoproximal
79045|NCT02569047|Primary Teeth
79046|NCT02569047|Glass Ionomer Cements
79047|NCT02569047|Hall Technique
79048|NCT02569021|Parkinsons Disease
79049|NCT02569021|Essential Tremor
79050|NCT02569021|DBS
79051|NCT02569021|Depp Brain Stimulation
79052|NCT02569008|Fluid Challenge
79053|NCT02569008|Mean systemic filling pressure
79054|NCT02569008|Fluid therapy
79055|NCT02568995|postoperative pain
79056|NCT02568995|morphine
79057|NCT02568995|total hip arthroplasty
79058|NCT02568995|femoral nerve block
79059|NCT02568982|Cushing's disease
79060|NCT02568982|Quality of life
79061|NCT02568982|Metabolic
79062|NCT02568982|patients with Cushing's disease
79063|NCT02568982|cardiovascular
79064|NCT02568982|thromboembolic
79065|NCT02568982|bone complications
79066|NCT02568969|Cardiosurgery, lactate
79067|NCT02568943|multiple myelome, MM, expanded treatment, panobinostat, bortezomib, dexamethasone, relapsed, refractory, LBH589
79068|NCT02568930|quality of life heart failure mechanical support transplant
79069|NCT02568917|Dental Atraumatic Restorative Treatment
79070|NCT02568917|Composite Resins
79071|NCT02568917|Primary Teeth
79072|NCT02568917|Permanent Teeth
79073|NCT02568917|Clinical Effectiveness
79074|NCT02568917|Cost Analysis
79075|NCT02568878|Depression
79076|NCT02568878|Anxiety
79077|NCT02568878|Methamphetamine dependence
79078|NCT02568852|D-dimer
79079|NCT02568852|Fibrinogen
79080|NCT02568852|Laparoscopic cholecystectomy
79081|NCT02568839|Neoadjuvant therapy
79082|NCT02568826|Low Back Pain
79083|NCT02568826|Muscle relaxant
79084|NCT02568813|epilepsy
79085|NCT02568813|depression
79086|NCT02568813|mood disorder
79087|NCT02568813|anxiety
79088|NCT02568813|cyclothymia
79089|NCT02568813|Behavioral neuropsychiatric features
79090|NCT02568787|NAFLD
79091|NCT02568787|cytokines
79092|NCT02568787|interleukin (IL)
79093|NCT02568787|interferon (IFN)
79094|NCT02568787|liver function test (LFTS)
79095|NCT02568787|nutrition
79096|NCT02568787|bran arabinoxylan compound (RBAC)
79097|NCT02568787|tumor necrosis factor -- type I receptor (TNF-RI)
79098|NCT02568787|TNF-RII (tumor necrosis factor -- type II receptor (TNF-RII)
79099|NCT02568774|Post-stroke
79100|NCT02568761|Snoring
79101|NCT02568761|Sleep apnea
79102|NCT02568761|Obstructive sleep apnea
79103|NCT02568761|Speech therapy
79104|NCT02568761|Injection snoreplasty
79105|NCT02568761|Ethanol
79106|NCT02568761|Oropharyngeal exercises
79107|NCT02568735|Dexketoprofen
79108|NCT02568735|Etoricoxib
79109|NCT02568735|hip arthroplasty
79110|NCT02568735|pain
79111|NCT02568722|Renal replacement therapy
79112|NCT02568722|Acute kidney injury
79113|NCT02568722|Dialysis
79114|NCT02568722|Hemodialysis
79115|NCT02568722|Critical illness
79116|NCT02568709|Oxytocin
79117|NCT02568709|Syntocinon
79118|NCT02568709|Social Cognition
79119|NCT02568709|Schizophrenia
79120|NCT02568709|Magnetoencephalography (MEG)
79121|NCT02568696|kidney transplantation
79122|NCT02568696|renal transplantation
79123|NCT02568696|fibrinolysis
79124|NCT02568696|cell mediated rejection
79125|NCT02568696|coagulation
79126|NCT02568696|delayed graft function
79127|NCT02568696|Halloran criteria
79128|NCT02568696|graft rejection
79129|NCT02568696|thrombin generation
79130|NCT02568696|fibrin generation
79131|NCT02568683|DLBCL
79132|NCT02568683|Relapsed
79133|NCT02568683|Refractory
79134|NCT02568644|Migraine
79135|NCT02568644|Ginger
79136|NCT02568644|Acute treatment
79137|NCT02568631|Autistic Disorder
79138|NCT02568618|Military
79139|NCT02568618|Genomics
79140|NCT02568618|Pain
79141|NCT02568605|Dietary intervention
79142|NCT02568605|Prebiotic fibre
79143|NCT02568605|Weight loss
79144|NCT02568605|Gut microbiota
79145|NCT02568605|Obesity
79146|NCT02568605|Liver fat
79147|NCT02568605|Hepatic fibrosis
79148|NCT02568540|Hepatitis C
79149|NCT02568540|Smartphone
79150|NCT02568540|app
79151|NCT02568540|Tracker
79152|NCT02568540|C Tracker
79153|NCT02568527|LSCD
79154|NCT02568527|SLET
79155|NCT02568527|Donor Human Amniotic Membrane (hAM)
79156|NCT02568527|PLGA
79157|NCT02568514|mhealth
79158|NCT02568514|text messaging
79159|NCT02568514|secure text messaging
79160|NCT02568514|communication
79161|NCT02568501|diabetes
79162|NCT02568501|adolescent
79163|NCT02568501|young adult
79164|NCT02568501|behavioral economics
79165|NCT02568501|financial incentives
79166|NCT02568501|social incentives
79167|NCT02568475|nursing home residents, decision aid, acute care transfers
79168|NCT02568462|Stents
79169|NCT02568462|Angioplasty
79170|NCT02568462|Coronary Vessels
79171|NCT02568462|Coronary Artery Disease
79172|NCT02568462|Angina Pectoris
79173|NCT02568462|Myocardial Ischemia
79174|NCT02568462|Myocardial Infarction
79175|NCT02568462|Myocardial Revascularization
79176|NCT02568410|Mast Cells
79177|NCT02568410|Blood Platelets
79178|NCT02568410|cardiac surgical procedures
79179|NCT02568371|biobank
79180|NCT02568371|DNA
79181|NCT02568371|genetic
79182|NCT02568371|young adults
79183|NCT02568371|cohort study
79184|NCT02568345|Dose-Response Relationship
79185|NCT02568345|Drug
79186|NCT02568345|Obesity
79187|NCT02568345|Cyclodextrins
79188|NCT02568267|Entrectinib
79189|NCT02568267|RXDX-101
79190|NCT02568267|TrkA
79191|NCT02568267|TrkB
79192|NCT02568267|TrkC
79193|NCT02568267|NTRK1
79194|NCT02568267|NTRK2
79195|NCT02568267|NTRK3
79196|NCT02568267|ROS1
79197|NCT02568267|ALK
79198|NCT02568267|Trk Fusions
79199|NCT02568267|NTRK Gene Rearrangements
79200|NCT02568267|ROS1 Fusions
79201|NCT02568267|ROS1 Gene Rearrangements
79202|NCT02568267|ALK Fusions
79203|NCT02568267|ALK Gene Rearrangements
79204|NCT02568267|Basket study
79205|NCT02568267|Non-small cell lung cancer
79206|NCT02568267|Colorectal cancer
79207|NCT02568267|Salivary gland cancers
79208|NCT02568267|Primary brain tumors
79209|NCT02568267|Melanoma
79210|NCT02568267|Sarcomas
79211|NCT02568267|Papillary thyroid cancer
79212|NCT02568267|Renal cell cancer
79213|NCT02568267|Pancreatic cancer
79214|NCT02568267|Breast cancer
79215|NCT02568267|Cholangiocarcinoma
79216|NCT02568267|Head & Neck cancers
79217|NCT02568267|Ovarian cancer
79218|NCT02568267|Neuroendocrine tumors
79219|NCT02568267|Anaplastic Large Cell Lymphoma
79220|NCT02568241|Interferon Alfa-2b
79221|NCT02568241|Relapse
79222|NCT02568241|Donor lymphocyte infusion
79223|NCT02568228|Triacylglycerols
79224|NCT02568228|Omega-3 fatty acids
79225|NCT02568228|Krill oil
79226|NCT02568228|Fish
79227|NCT02568228|Healthy Volunteers
79228|NCT02568215|HIV-1 Infections
79229|NCT02568189|Sepsis
79230|NCT02568189|Gastroenteritis
79231|NCT02568189|Dehydration
79232|NCT02568189|Ultrasound
79233|NCT02568189|Ultrasonography
79234|NCT02568189|Inferior Vena Cava
79235|NCT02568176|Healthy
79236|NCT02568176|Pharmacokinetics
79237|NCT02568176|Esketamine
79238|NCT02568176|JNJ-54135419
79239|NCT02568176|Midazolam
79240|NCT02568176|Bupropion
79241|NCT02568137|mobile health
79242|NCT02568137|Behavior change
79243|NCT02568137|Africa
79244|NCT02568124|Tranexamic acid
79245|NCT02568124|Cyklokapron
79246|NCT02568124|Conservative management
79247|NCT02568124|Medical management
79248|NCT02568111|erythema
79249|NCT02568111|PLEGRIDY
79250|NCT02568111|injection site reaction (ISR)
79251|NCT02568111|MS
79252|NCT02568111|RRMS
79253|NCT02568098|Drug combination
79254|NCT02568098|Ivermectin
79255|NCT02568098|Primaquine
79256|NCT02568098|Dihydroartemisinin-Piperaquine
79257|NCT02568098|Albendazole
79258|NCT02568098|Pharmacokinetics
79259|NCT02568098|Mosquito-Lethal Effect
79260|NCT02568098|Healthy adult subject
79261|NCT02568072|exercise
79262|NCT02568072|cardiac remodelling
79263|NCT02568072|left ventricular non-compaction cardiomyopathy
79264|NCT02568046|Metastatic Colorectal Cancer
79265|NCT02567981|chronic undernutrition
79266|NCT02567981|anemia
79267|NCT02567981|micronutrient supplement
79268|NCT02567955|HPV vaccines, interchangeable use
79269|NCT02567877|hypothyroidism
79270|NCT02567877|deiodinase polymorphism
79271|NCT02567877|cognitive function
79272|NCT02567877|thyroidectomy
79273|NCT02567877|levothyroxine
79274|NCT02567851|Brentuximab Vedotin
79275|NCT02567851|PET scans
79276|NCT02567851|Lymphoma
79277|NCT02567825|ear infection
79278|NCT02567825|antibiotics
79279|NCT02567825|infants
79280|NCT02567825|children
79281|NCT02567825|pediatrics
79282|NCT02567825|tympanostomy tubes
79283|NCT02567799|Lung Neoplasms
79284|NCT02567773|Itraconazole
79285|NCT02567773|GSK2881078
79286|NCT02567773|CYP3A4
79287|NCT02567773|Selective Androgen Receptor Modulator
79288|NCT02567773|Safety
79289|NCT02567773|Pharmacokinetics
79290|NCT02567773|Tolerability
79291|NCT02567760|MP1
79292|NCT02567760|cognitive enhancing effect
79293|NCT02567760|menopausal women
79294|NCT02567747|Colombia
79295|NCT02567747|otitis
79296|NCT02567747|Database
79297|NCT02567747|pneumonia
79298|NCT02567734|irreversible electroporation
79299|NCT02567734|ablation
79300|NCT02567734|neoplasms
79301|NCT02567734|cancer
79302|NCT02567734|carcinoma
79303|NCT02567734|NanoKnife
79304|NCT02567734|Ablation Techniques
79305|NCT02567721|Post-authorisation safety study (PASS)
79306|NCT02567721|Adverse Drug Reaction Reporting Systems
79307|NCT02567721|Post marketing product surveillance
79308|NCT02567721|European Medicines Agency (EMA)
79309|NCT02567721|Influenza Vaccine
79310|NCT02567721|Computerized Medical Record System
79311|NCT02567721|United Kingdom
79312|NCT02567721|Primary Health Care
79313|NCT02567708|GSK2269557
79314|NCT02567708|Asthma
79315|NCT02567708|Pharmacokinetics
79316|NCT02567708|Safety
79317|NCT02567708|Adults
79318|NCT02567708|DISKUS Dry Powder Inhaler
79319|NCT02567708|Efficacy
79320|NCT02567682|anemia, sickle cell
79321|NCT02567669|radiotherapy
79322|NCT02567656|CTCL
79323|NCT02567656|PTCL
79324|NCT02567656|RP6530
79325|NCT02567643|Brain
79326|NCT02567643|CNS
79327|NCT02567643|Metastases
79328|NCT02567630|Cerebral Palsy
79329|NCT02567630|physical
79330|NCT02567630|sensory
79331|NCT02567630|motor impairments
79332|NCT02567630|upper extremity
79333|NCT02567630|Constraint-Induced Movement Therapy
79334|NCT02567617|Polyphenols, Prostaglandin E2, hormonal contraceptives
79335|NCT02567591|pre liver transplantation patients
79336|NCT02567552|endometrial receptivity
79337|NCT02567552|endometrial predecidualization
79338|NCT02567552|endometrial genomics
79339|NCT02567552|endometrial receptivity array
79340|NCT02567526|food and fluid intake
79341|NCT02567526|nursing home residents
79342|NCT02567526|staffing
79343|NCT02567513|food and fluid intake
79344|NCT02567513|nursing homes
79345|NCT02567500|emotional
79346|NCT02567500|auditory hallucinations
79347|NCT02567500|non-psychotic children
79348|NCT02567474|chronic lung disease
79349|NCT02567461|dual antiplatelet therapy
79350|NCT02567461|clopidogrel
79351|NCT02567461|aspirin
79352|NCT02567461|edoxaban
79353|NCT02567448|Obstructive Sleep Apnea
79354|NCT02567448|Chronic Obstructive Pulmonary Disease
79355|NCT02567448|Overlap syndrome
79356|NCT02567448|Pcrit
79357|NCT02567448|Critical closing pressure
79358|NCT02567383|head and neck cancer
79359|NCT02567383|hyperthermia, Thermotron RF-8
79360|NCT02567383|radiotherapy
79361|NCT02567370|Schizophrenia or Schizoaffective Disorder
79362|NCT02567357|change triggered temper outbursts
79363|NCT02567357|parent training
79364|NCT02567357|autism
79365|NCT02567357|intellectual disability
79366|NCT02567357|Prader-Willi syndrome
79367|NCT02567357|Fragile X syndrome
79368|NCT02567357|web-based training
79369|NCT02567357|Down syndrome
79370|NCT02567344|Cannabis
79371|NCT02567344|rTMS
79372|NCT02567344|Craving
79373|NCT02567344|Decision making
79374|NCT02567318|Pain
79375|NCT02567318|Secondary hyperalgesia
79376|NCT02567318|Healthy volunteers
79377|NCT02567318|Magnetic Resonance Imaging
79378|NCT02567292|Digestive Disease and Disorders
79379|NCT02567292|Neonatal
79380|NCT02567292|Pediatric Disorders
79381|NCT02567253|Cytoreductive surgery
79382|NCT02567253|(H)ipec
79383|NCT02567253|Ovarian cancer
79384|NCT02567253|Cisplatin
79385|NCT02567253|Peritoneal carcinomatosis
79386|NCT02567253|Pharmacokinetics
79387|NCT02567253|Pharmacodynamics
79388|NCT02567214|dyspnea
79389|NCT02567214|exercise
79390|NCT02567214|shuttle test
79391|NCT02567214|long-acting β2-agonists
79392|NCT02567214|longacting muscarinic antagonist
79393|NCT02567214|indacaterol
79394|NCT02567214|glycopyrronium
79395|NCT02567214|tiotropium
79396|NCT02567201|Voluntary attention
79397|NCT02567201|Electroencephalogram
79398|NCT02567201|Brain-computer interface
79399|NCT02567201|Disorders of consciousness
79400|NCT02567162|Intracerebral hemorrhage
79401|NCT02567162|Hemorrhagic stroke
79402|NCT02567162|Intraparenchymal hemorrhage
79403|NCT02567162|Cerebrovascular disease
79404|NCT02567162|Stroke
79405|NCT02567149|Wart
79406|NCT02567110|Mid-life Depression
79407|NCT02567110|Bipolar Disorder
79408|NCT02567110|DSM-5 MDE
79409|NCT02567110|Inflammation
79410|NCT02567110|CNS Glutamate
79411|NCT02567084|Bone substitute
79412|NCT02567084|benign bone cyst
79413|NCT02567084|ceramic
79414|NCT02567084|remodelling
79415|NCT02567071|C-section
79416|NCT02567071|Microbiota
79417|NCT02567058|Achilles tendon
79418|NCT02567045|Immunochemical fecal occult blood test
79419|NCT02567045|Colonoscopy
79420|NCT02567045|Screening uptake
79421|NCT02567045|Screening participation
79422|NCT02567045|Familiar risk
79423|NCT02567045|Colorectal Cancer
79424|NCT02567032|Oxytocin
79425|NCT02567032|Syntocinon
79426|NCT02567032|Social Cognition
79427|NCT02567032|Schizophrenia
79428|NCT02567006|vaccines
79429|NCT02567006|reminders
79430|NCT02567006|immunization timeliness
79431|NCT02567006|vaccine coverage
79432|NCT02566980|depression
79433|NCT02566980|mood disorder
79434|NCT02566980|post-partum depression
79435|NCT02566980|suicidality
79436|NCT02566980|post-partum suicidality
79437|NCT02566980|perinatal depression
79438|NCT02566980|perinatal mood disorder
79439|NCT02566980|inflammation
79440|NCT02566980|kynurenine pathway
79441|NCT02566980|glutamate
79442|NCT02566954|radiology
79443|NCT02566954|3D measurement
79444|NCT02566954|lower limb
79445|NCT02566941|critical illness polyneuropathy
79446|NCT02566941|critical illness myopathy
79447|NCT02566941|neuromuscular electrical stimulation
79448|NCT02566941|intensive care unit acquired weakness
79449|NCT02566941|prevention of critical illness polyneuropathy
79450|NCT02566928|Methicillin-Resistant Staphylococcus aureus
79451|NCT02566928|Recurrence
79452|NCT02566928|Practice Based Research Network
79453|NCT02566928|Community Health Workers/Promotoras
79454|NCT02566928|Decolonization and Decontamination
79455|NCT02566928|Staphylococcal Skin Infections
79456|NCT02566928|Household Transmission
79457|NCT02566889|Pediatric Inflammatory Bowel Disease
79458|NCT02566889|Infliximab
79459|NCT02566889|Pediatric Participants
79460|NCT02566889|Pediatric Ulcerative Colitis
79461|NCT02566889|Pediatric Crohn's Disease
79462|NCT02566889|Dose Escalation
79463|NCT02566876|Children
79464|NCT02566876|Abdominal Pain
79465|NCT02566876|Functional Dyspepsia
79466|NCT02566876|Irritable Bowel Syndrome
79467|NCT02566876|Quality of Life
79468|NCT02566863|dexmedetomidine
79469|NCT02566863|heart rate
79470|NCT02566863|heart rate variability
79471|NCT02566837|ultrasound
79472|NCT02566837|Electrical stimulation guidance
79473|NCT02566837|botulinum toxin
79474|NCT02566772|Prostate Cancer
79475|NCT02566759|Drug therapy
79476|NCT02566733|remifentanil
79477|NCT02566720|amantadine
79478|NCT02566720|tractography
79479|NCT02566720|mri
79480|NCT02566720|coma
79481|NCT02566720|abi
79482|NCT02566720|tbi
79483|NCT02566720|traumatic brain injury
79484|NCT02566720|acquired brain injury
79485|NCT02566668|Asthma
79486|NCT02566668|Severe Asthma
79487|NCT02566668|IL-10
79488|NCT02566668|IL-27
79489|NCT02566668|IL-13
79490|NCT02566668|Epithelial Cells
79491|NCT02566668|T lymphocytes
79492|NCT02566668|Interferon-g
79493|NCT02566629|microbiota community
79494|NCT02566629|IBS
79495|NCT02566603|ITP
79496|NCT02566603|Thrombocytopenia
79497|NCT02566577|Chronic anemia
79498|NCT02566577|Cardiopulmonary testing
79499|NCT02566577|Transfusion-dependent anemia
79500|NCT02566551|Prostatic artery embolization
79501|NCT02566551|Transurethral resection of the prostate
79502|NCT02566538|Cohort study
79503|NCT02566538|psychometric tests
79504|NCT02566538|cognitive function
79505|NCT02566538|cardiovascular risk
79506|NCT02566538|prediction algorithm
79507|NCT02566525|CytoSorb device
79508|NCT02566525|Plasma free hemoglobin
79509|NCT02566525|inflammation
79510|NCT02566525|extracorporeal bypass
79511|NCT02566512|Tracheostomy
79512|NCT02566512|weaning
79513|NCT02566512|respiratory failure
79514|NCT02566512|cough strength
79515|NCT02566499|Medical imaging
79516|NCT02566499|Microwaves
79517|NCT02566473|Patient reported outcomes
79518|NCT02566473|Osteoarthritis
79519|NCT02566473|Total joint replacement
79520|NCT02566460|Lactate clearance
79521|NCT02566460|systemic central venous oxygen saturation
79522|NCT02566460|septic shock
79523|NCT02566460|haemodynamic therapy
79524|NCT02566434|Dietary Supplements
79525|NCT02566395|Stem Cell Transplantation
79526|NCT02566395|Haploidentical Donors
79527|NCT02566369|Efficacy
79528|NCT02566369|Safety
79529|NCT02566369|Acne vulgaris
79530|NCT02566356|Oxytocin
79531|NCT02566356|Syntocinon
79532|NCT02566356|Social Cognition
79533|NCT02566356|Schizophrenia
79534|NCT02566356|Functional Magnetic Resonance Imaging (fMRI)
79535|NCT02566343|Spirometry
79536|NCT02566343|Exercise Test
79537|NCT02566343|Blood Gas Analysis
79538|NCT02566343|Respiratory Function Tests
79539|NCT02566343|Diagnostic Techniques, Respiratory System
79540|NCT02566343|Surgical Procedures, Operative
79541|NCT02566330|EndoBarrier
79542|NCT02566330|Duodenojejunal Bypass Liner
79543|NCT02566291|laryngeal mask
79544|NCT02566291|airway leakage
79545|NCT02566291|airway morbidity
79546|NCT02566278|Obstructive Sleep Apnea
79547|NCT02566278|Pcrit
79548|NCT02566278|Upper airway collapsibility
79549|NCT02566265|influenza
79550|NCT02566265|multiple myeloma
79551|NCT02566265|Waldenstrom's macroglobulinemia
79552|NCT02566252|Safety
79553|NCT02566252|tolerability
79554|NCT02566239|aging
79555|NCT02566239|ORCATECH
79556|NCT02566239|Oregon Center for Aging & Technology
79557|NCT02566239|Life Lab
79558|NCT02566239|Living Lab
79559|NCT02566239|in-home assessment
79560|NCT02566239|technology and aging
79561|NCT02566213|volunteers
79562|NCT02566200|Acute coronary syndrome
79563|NCT02566200|Cardiology
79564|NCT02566174|Cancer Caregivers
79565|NCT02566174|Cancer Patients
79566|NCT02566174|Role Adjustment
79567|NCT02566174|Mutuality
79568|NCT02566174|Well-Being
79569|NCT02566161|Genetics
79570|NCT02566161|Genomics
79571|NCT02566148|Life-event survey
79572|NCT02566148|observational survey among migrants in France
79573|NCT02566135|C-LMA
79574|NCT02566135|I-gel
79575|NCT02566135|ventilating bougie
79576|NCT02566135|intubation
79577|NCT02566096|major abdominal cancer
79578|NCT02566070|Enteral feeding
79579|NCT02566070|Continuous gastric feeding
79580|NCT02566070|Bolus gastric feeding
79581|NCT02566044|Cystic Fibrosis
79582|NCT02566031|COPD
79583|NCT02566031|open-label
79584|NCT02566031|QVA149
79585|NCT02566031|symptomatic
79586|NCT02566031|tiotropium
79587|NCT02566018|elderly
79588|NCT02566005|Misoprostol
79589|NCT02566005|Induction
79590|NCT02566005|Foley
79591|NCT02565992|pembrolizumab
79592|NCT02565992|coxsackievirus A21
79593|NCT02565979|Resveratrol
79594|NCT02565979|Diabetes Mellitus, Type 2
79595|NCT02565979|Insulin Resistance
79596|NCT02565979|Metabolic Diseases
79597|NCT02565979|Glucose Metabolism Disorders
79598|NCT02565953|Vascular access devices obstruction
79599|NCT02565927|Trachea
79600|NCT02565927|Stent
79601|NCT02565927|Intraluminal brachytherapy
79602|NCT02565888|Hepatitis C
79603|NCT02565888|HIV
79604|NCT02565888|atazanavir
79605|NCT02565888|ritonavir
79606|NCT02565888|daclatasvir
79607|NCT02565888|cobicistat
79608|NCT02565875|Efficiency, Organizational
79609|NCT02565875|Simulation
79610|NCT02565875|Communication
79611|NCT02565875|Laparoscopy
79612|NCT02565875|Medical Education
79613|NCT02565862|HCV
79614|NCT02565862|Diabetes Mellitus
79615|NCT02565862|Daclatasvir
79616|NCT02565862|Metformin
79617|NCT02565862|drug-drug interaction
79618|NCT02565862|pharmacokinetics
79619|NCT02565836|Vitamin K 1
79620|NCT02565836|prothrombin complex concentrates
79621|NCT02565836|warfarin
79622|NCT02565823|Exercise
79623|NCT02565797|Decubitus Ulcer, Peri-operative, support surface, alternating pressure, neurosurgery
79624|NCT02565771|Childhood cancer
79625|NCT02565771|Cancer
79626|NCT02565771|Sequels
79627|NCT02565771|Surgery
79628|NCT02565771|Complications
79629|NCT02565771|Chemotherapy
79630|NCT02565771|Radiotherapy
79631|NCT02565758|Advanced Solid Tumor
79632|NCT02565758|Cancer
79633|NCT02565758|Neoplasm
79634|NCT02565745|Prevention pressure ulcers
79635|NCT02565745|hospitalization
79636|NCT02565706|Fruit, vegetables, income, WIC program, farmers' market
79637|NCT02565680|acute urticaria
79638|NCT02565680|glucocorticoids
79639|NCT02565680|antihistamines
79640|NCT02565680|prurit
79641|NCT02565680|itch score
79642|NCT02565680|rash
79643|NCT02565667|low rectal carcinoma
79644|NCT02565667|anastomosis
79645|NCT02565667|anterior rectal resection
79646|NCT02565654|Irritable bowel syndrome(IBS)
79647|NCT02565654|Small intestinal bacterial overgrowth (SIBO)
79648|NCT02565654|Rifaximin
79649|NCT02565602|Calcium metabolism
79650|NCT02565602|Osteoporosis
79651|NCT02565602|Postmenopausal women
79652|NCT02565576|CFZ533, Myasthenia Gravis
79653|NCT02565563|EMDR
79654|NCT02565563|Mechanisms
79655|NCT02565563|Eye Movement Desensitisation Reprocessing
79656|NCT02565550|Microbiota Community
79657|NCT02565550|FODMAPs
79658|NCT02565550|IBS
79659|NCT02565524|schizophrenia
79660|NCT02565524|early dissociative disorder
79661|NCT02565524|genetic
79662|NCT02565511|Randomization, Placebo controlled, Parallel-group, APOE4 Homozygotes, Preclinical Alzheimer's Disease (AD), Aβ lowering
79663|NCT02565498|Soft tissue sarcoma
79664|NCT02565498|Extremity
79665|NCT02565498|Preoperative radiotherapy
79666|NCT02565498|Postoperative radiotherapy
79667|NCT02565485|pulse pressure
79668|NCT02565485|fetal heart rate
79669|NCT02565485|epidural analgesia
79670|NCT02565485|hypotension
79671|NCT02565485|preload
79672|NCT02565485|fluid bolus
79673|NCT02565485|central hypovolemia
79674|NCT02565459|Mesenchymal stromal cells
79675|NCT02565459|kidney transplantation
79676|NCT02565459|tolerance
79677|NCT02565433|brain metastases
79678|NCT02565433|Gamma Knife
79679|NCT02565433|Radiosurgery
79680|NCT02565433|Quality of Life
79681|NCT02565355|Pediatric Gastroenterology
79682|NCT02565342|Clavicle
79683|NCT02565303|cesarean section
79684|NCT02565303|ropivacaine
79685|NCT02565303|minimum effective dose
79686|NCT02565303|dose-response
79687|NCT02565303|subarachnoid
79688|NCT02565290|polyunsaturated fatty acid
79689|NCT02565290|fetal ductus arteriosus
79690|NCT02565290|inflammation
79691|NCT02565251|sepsis
79692|NCT02565251|hemodynamic monitoring
79693|NCT02565251|septic shock
79694|NCT02565251|volemic resuscitation
79695|NCT02565251|fluid resuscitation
79696|NCT02565212|Montelukast
79697|NCT02565212|Sniffin' Sticks test
79698|NCT02565212|allergic rhinitis
79699|NCT02565212|mometasone furoate
79700|NCT02565199|Transcranial Magnetic Stimulation
79701|NCT02565173|glaucoma
79702|NCT02565173|primary open-angle glaucoma
79703|NCT02565173|ocular hypertension
79704|NCT02565173|adenosine agonist
79705|NCT02565173|eye drop
79706|NCT02565173|trabodenoson
79707|NCT02565173|trabecular meshwork
79708|NCT02565147|STEMI, infarct size, CMR, bivalirudin
79709|NCT02565121|Olfactory perception
79710|NCT02565121|Adrenal cortex hormones
79711|NCT02565121|Steroids
79712|NCT02565121|Education
79713|NCT02565108|Cannabidiol
79714|NCT02565108|GWP42003-P
79715|NCT02565108|Clobazam
79716|NCT02565108|Epidiolex
79717|NCT02565082|Hemostatic potential
79718|NCT02565082|Sickle cell disease
79719|NCT02565082|Thrombin generation test
79720|NCT02565056|Acceptance and Commitment Therapy
79721|NCT02565030|Chronic thromboembolic Pulmonary Hypertension
79722|NCT02565030|Distal Chronic thromboembolic Pulmonary Hypertension
79723|NCT02565030|Proximal Chronic thromboembolic Pulmonary Hypertension
79724|NCT02565030|Operable disease
79725|NCT02565030|In-operable disease
79726|NCT02565030|Pulmonary Endarterectomy
79727|NCT02565030|PH specific targeted therapy
79728|NCT02565030|Phosphodiesterase type 5 Inhibitors
79729|NCT02565030|Endothelin Receptor Antagonist
79730|NCT02565030|Prostacyclin analogues
79731|NCT02565030|Soluble Guanylate cyclase stimulator
79732|NCT02565030|Sildenafil
79733|NCT02565030|Tadalafil
79734|NCT02565030|Bosentan
79735|NCT02565030|Ambrisentan
79736|NCT02565030|Macitentan
79737|NCT02565030|Iloprost
79738|NCT02565030|Riociguat
79739|NCT02565030|Idiopathic Pulmonary Arterial Hypertension
79740|NCT02565017|IBM Watson
79741|NCT02565017|Clinical Decision Support System
79742|NCT02565017|Patient Preferences
79743|NCT02565017|15-226
79744|NCT02565004|Genetic
79745|NCT02565004|Sample Collection
79746|NCT02564991|Alcoholism
79747|NCT02564991|MRI
79748|NCT02564991|Structural MRI
79749|NCT02564991|Cerebellum
79750|NCT02564978|Age-Related Macular Degeneration
79751|NCT02564978|Age-Related Macular Degeneration (AMD)
79752|NCT02564978|Geographic Atrophy
79753|NCT02564978|Minocycline
79754|NCT02564978|Atrophic Macular Degeneration
79755|NCT02564965|Acute Necrotizing Pancreatitis
79756|NCT02564965|Walled-Off Pancreatic Necrosis
79757|NCT02564952|Cannabidiol
79758|NCT02564952|GWP42003-P
79759|NCT02564952|Clobazam
79760|NCT02564952|Epidiolex
79761|NCT02564939|prevention
79762|NCT02564926|DM
79763|NCT02564913|tongue diagnosis
79764|NCT02564913|heart rate variability
79765|NCT02564913|nailfold videocapillaroscopy
79766|NCT02564900|Advanced solid tumors
79767|NCT02564900|phase 1
79768|NCT02564900|oncology
79769|NCT02564900|HER2
79770|NCT02564900|Antibody drug conjugate (ADC)
79771|NCT02564887|dysphagia
79772|NCT02564887|oral pharyngeal cancer
79773|NCT02564887|Iowa Oral Performance Instrument (IOPI)
79774|NCT02564887|IOPI
79775|NCT02564861|pharmacokinetics
79776|NCT02564848|Clinical T1-2N0 ER+
79777|NCT02564848|Invasive breast cancer
79778|NCT02564822|migraine disorders
79779|NCT02564822|cortical excitability
79780|NCT02564822|transcranial magnetic stimulation
79781|NCT02564822|electroencephalography
79782|NCT02564796|Erythropoetin
79783|NCT02564796|Cyanotic Heart Disease
79784|NCT02564796|Transfusion
79785|NCT02564796|Congenital Heart Disease
79786|NCT02564731|children
79787|NCT02564731|prognosis
79788|NCT02564718|Pediatric
79789|NCT02564679|bariatric surgery
79790|NCT02564679|sleeve gastrectomy
79791|NCT02564666|hepatocellular carcinoma
79792|NCT02564666|sorafenib
79793|NCT02564666|telephone counseling
79794|NCT02564640|videolaryngoscope
79795|NCT02564640|direct laryngoscope
79796|NCT02564640|hemodynamic changes
79797|NCT02564640|elderly patients
79798|NCT02564601|intervention
79799|NCT02564601|cognition
79800|NCT02564601|aging
79801|NCT02564601|piano training
79802|NCT02564601|computer brain training
79803|NCT02564575|Ebolavirus
79804|NCT02564562|PF-06463922
79805|NCT02564562|[14C]PF-06463922
79806|NCT02564562|Human ADME
79807|NCT02564562|Radiolabel
79808|NCT02564562|Mass Balance
79809|NCT02564562|Pharmacokinetics
79810|NCT02564549|low risk prostate cancer
79811|NCT02564523|Healthy
79812|NCT02564523|Vaccine
79813|NCT02564523|Ebola viruses
79814|NCT02564523|Ebola virus disease (EVD)
79815|NCT02564523|Filoviruses
79816|NCT02564523|Hemorrhagic fever
79817|NCT02564523|Monovalent vaccine
79818|NCT02564523|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
79819|NCT02564523|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
79820|NCT02564523|Safety
79821|NCT02564523|Immunogenicity
79822|NCT02564484|Cancer Therapy
79823|NCT02564484|Pharmacogenomics
79824|NCT02564484|Drug Response
79825|NCT02564484|Genetic Variants
79826|NCT02564484|Vincristine-Induced Neuropathy
79827|NCT02564484|Cancer Survivor
79828|NCT02564432|amputee
79829|NCT02564354|Cystic Fibrosis
79830|NCT02564354|CF
79831|NCT02564354|ΔF508
79832|NCT02564354|CFTR
79833|NCT02564354|QR-010
79834|NCT02564354|antisense oligonucleotide
79835|NCT02564354|RNA therapy
79836|NCT02564354|F508del
79837|NCT02564354|NPD
79838|NCT02564354|nasal potential difference
79839|NCT02564341|HIV Infection
79840|NCT02564341|Pain
79841|NCT02564341|Collaborative Care
79842|NCT02564341|Chronic Opioid Therapy
79843|NCT02564341|Addiction
79844|NCT02564341|Analgesics, Opioid
79845|NCT02564328|Stroke
79846|NCT02564328|Bone Marrow Mesenchymal Stem Cell
79847|NCT02564328|Transplantation
79848|NCT02564315|Smoking
79849|NCT02564315|Cessation
79850|NCT02564315|Tobacco
79851|NCT02564315|Relapse
79852|NCT02564302|PVI
79853|NCT02564302|Atrial Fibrillation
79854|NCT02564302|MUSE Headband
79855|NCT02564302|Mindfulness
79856|NCT02564289|microvesicles, microparticles
79857|NCT02564289|Plethysmography
79858|NCT02564289|Snus
79859|NCT02564289|Arterial Stiffness
79860|NCT02564289|EPC
79861|NCT02564276|Indocyanine Green
79862|NCT02564276|Sentinel Lymph Node Biopsy
79863|NCT02564263|PD1
79864|NCT02564263|PD-L1
79865|NCT02564263|PDL1
79866|NCT02564263|Gene expression profiling (GEP)
79867|NCT02564237|Group A streptococcal
79868|NCT02564198|relapsed pediatric solid tumors
79869|NCT02564198|unspecified childhood solid tumor
79870|NCT02564198|brain and central nervous system tumors
79871|NCT02564159|malnutrition
79872|NCT02564159|muscle ultrasound
79873|NCT02564159|intensive care unit
79874|NCT02564159|mechanical ventilation
79875|NCT02564159|albumin
79876|NCT02564159|prealbumin
79877|NCT02564159|nutrition
79878|NCT02564055|Vehicle-Controlled
79879|NCT02564055|GSK2894512
79880|NCT02564055|Double blind
79881|NCT02564055|Dose-finding
79882|NCT02564055|Atopic Dermatitis
79883|NCT02564042|Double blind
79884|NCT02564042|Dose-finding
79885|NCT02564042|Vehicle-Controlled
79886|NCT02564042|GSK2894512
79887|NCT02564042|Plaque Psoriasis
79888|NCT02563977|Breast reconstruction
79889|NCT02563977|Deep inferior epigastric perforator flap
79890|NCT02563977|Abdominal wall morbidity
79891|NCT02563977|Plastic and reconstructive surgery
79892|NCT02563964|Myocardial infarction
79893|NCT02563964|vulnerable plaque
79894|NCT02563964|Positron emission tomography (PET)
79895|NCT02563964|Cardiac magnetic resonance imaging (CMR)
79896|NCT02563964|Biomarkers
79897|NCT02563951|Nausea
79898|NCT02563951|Vomiting
79899|NCT02563951|Chemotherapy
79900|NCT02563951|Radiation therapy
79901|NCT02563925|Brain Irradiation
79902|NCT02563925|Tremelimumab
79903|NCT02563925|15-038
79904|NCT02563912|Children
79905|NCT02563912|resuscitation
79906|NCT02563912|simulation
79907|NCT02563912|medication error
79908|NCT02563899|Primary Axillary Hyperhidrosis
79909|NCT02563899|GSK573719
79910|NCT02563899|Hyperhidrosis Disease Severity Scale (HDSS)
79911|NCT02563899|Topical
79912|NCT02563899|PRO
79913|NCT02563899|Hyperhidrosis Symptom Severity Measure (HSSM)
79914|NCT02563899|Umeclidinium
79915|NCT02563821|Termination of pregancy
79916|NCT02563821|Third trimester
79917|NCT02563821|Programmed intermittent epidural bolus
79918|NCT02563821|Continuous epidural infusion
79919|NCT02563821|Epidural analgesia
79920|NCT02563821|Legally induced abortion
79921|NCT02563795|Spinal anesthesia
79922|NCT02563795|Cesarean
79923|NCT02563795|Maternal hypotension
79924|NCT02563769|Cocaine
79925|NCT02563769|Clavulanic Acid
79926|NCT02563756|Medial gonarthritis, knee osteoarthritis,
79927|NCT02563756|Muscle function, muscle mass, muscle atrophy
79928|NCT02563756|Total knee arthroplasty (TKA)
79929|NCT02563756|Unicondylar knee arthroplasty (UKA)
79930|NCT02563756|Total knee replacement (TKR)
79931|NCT02563756|Unicondylar knee replacement (UKR)
79932|NCT02563756|Health-related quality of life (HRQoL)
79933|NCT02563756|Patient related outcome measurements (PROMs)
79934|NCT02563743|Sick-leave
79935|NCT02563743|Return to work
79936|NCT02563743|Occupational health
79937|NCT02563743|Common mental disorder
79938|NCT02563743|Depression
79939|NCT02563743|Anxiety disorders
79940|NCT02563743|Adjustment disorders
79941|NCT02563743|Problem solving therapy
79942|NCT02563743|Occupational Health Services
79943|NCT02563743|Randomized controlled trial
79944|NCT02563743|Intervention studies
79945|NCT02563743|Occupational stress
79946|NCT02563730|Cryobiopsy
79947|NCT02563730|lung biopsy
79948|NCT02563730|interstitial lung disease
79949|NCT02563717|Resuscitation
79950|NCT02563717|Positive-Pressure Respiration
79951|NCT02563717|Infant, Extremely Premature
79952|NCT02563717|Continuous Positive Airway Pressure
79953|NCT02563717|Intubation
79954|NCT02563704|Artesunate
79955|NCT02563704|Quinine
79956|NCT02563704|Efficacy
79957|NCT02563704|Malaria
79958|NCT02563704|Children
79959|NCT02563704|Cameroon
79960|NCT02563652|Abdomen/surgery
79961|NCT02563652|Biological markers
79962|NCT02563652|Length of stay
79963|NCT02563652|Postoperative care
79964|NCT02563652|Anesthesia recovery period
79965|NCT02563652|Prognosis
79966|NCT02563639|newly diagnosed
79967|NCT02563639|paroxysmal
79968|NCT02563639|persistent
79969|NCT02563626|coronary artery aneurysm
79970|NCT02563626|prognosis
79971|NCT02563626|outcomes
79972|NCT02563626|management
79973|NCT02563626|incidence
79974|NCT02563626|heart failure
79975|NCT02563626|acute coronary syndrome
79976|NCT02563626|death
79977|NCT02563613|community-based intervention
79978|NCT02563613|family holistic health
79979|NCT02563613|positive psychology
79980|NCT02563613|physical exercise
79981|NCT02563613|healthy diet
79982|NCT02563587|Laughter
79983|NCT02563587|children
79984|NCT02563587|postoperative
79985|NCT02563587|pain
79986|NCT02563587|anxiety
79987|NCT02563587|cortisol
79988|NCT02563574|Alcohol and brain function
79989|NCT02563574|HIV and brain function
79990|NCT02563574|Motivational Interviewing
79991|NCT02563561|Bladder Cancer
79992|NCT02563561|Non-muscle invasive bladder cancer
79993|NCT02563561|Apaziquone
79994|NCT02563561|TURBT
79995|NCT02563561|Stage Ta, G1-G2
79996|NCT02563522|non healing ulcers
79997|NCT02563522|VM202
79998|NCT02563522|Diabetic ulcers
79999|NCT02563522|foot ulcers
80000|NCT02563509|HIV
80001|NCT02563509|cellular immunity therapy
80002|NCT02563509|functional cure
80003|NCT02563496|pharmacokinetic
80004|NCT02563496|pediatric
80005|NCT02563496|Tafenoquine
80006|NCT02563496|Plasmodium vivax Malaria
80007|NCT02563496|G6PD deficiency
80008|NCT02563483|caregivers
80009|NCT02563483|anxiety
80010|NCT02563483|depression
80011|NCT02563483|yoga
80012|NCT02563483|meditation
80013|NCT02563483|stress
80014|NCT02563457|diabetic patients
80015|NCT02563457|periodontal treatment
80016|NCT02563457|glycaemic control
80017|NCT02563444|Diagnostic (Biopsy) or Therapeutic Procedure (Infiltration, Ablation)
80018|NCT02563431|shoulder pain
80019|NCT02563431|prevention program
80020|NCT02563418|video oculography
80021|NCT02563405|alpha receptor blocker
80022|NCT02563405|uric acid
80023|NCT02563405|CCB
80024|NCT02563405|blood pressure variability
80025|NCT02563366|kidney transplantation
80026|NCT02563366|mesenchymal stem cell therapy
80027|NCT02563366|poor early graft function
80028|NCT02563366|delayed graft function
80029|NCT02563366|ischemia reperfusion injury
80030|NCT02563366|donation after cardiac death
80031|NCT02563353|whole body vibration
80032|NCT02563353|PTH
80033|NCT02563340|kidney transplantation
80034|NCT02563340|antibody-mediated rejection
80035|NCT02563340|mesenchymal stem cell therapy
80036|NCT02563340|donor specific antibody
80037|NCT02563340|acute rejection
80038|NCT02563314|Noninvasive Ventilation
80039|NCT02563314|Pulmonary Disease
80040|NCT02563314|Chronic Obstructive
80041|NCT02563314|Renal Doppler
80042|NCT02563314|Oxygen
80043|NCT02563314|Hypercapnia
80044|NCT02563288|esmolol
80045|NCT02563288|dexmedetomidine
80046|NCT02563288|opioids
80047|NCT02563197|Device study
80048|NCT02563197|Peak inspiratory flow rate
80049|NCT02563197|Non-cystic fibrosis bronchiectasis
80050|NCT02563197|T-326 Inhaler
80051|NCT02563171|visceral adipose-specific serpin
80052|NCT02563171|intelectin 1 (omentin)
80053|NCT02563171|Tumor Necrosis Factor-alpha
80054|NCT02563158|liver resection
80055|NCT02563158|blood inflow control
80056|NCT02563158|ischemia-reperfusion injury
80057|NCT02563158|inflammatory response
80058|NCT02563158|randomized controlled trial
80059|NCT02563145|Real-time fMRI feedback
80060|NCT02563132|colonoscopy
80061|NCT02563132|carbon dioxide
80062|NCT02563132|inflammatory bowel disease
80063|NCT02563093|Influenza
80064|NCT02563093|Fluzone® Quadrivalent, Influenza Vaccine
80065|NCT02563093|Fluzone® Intradermal Quadrivalent, Influenza Vaccine
80066|NCT02563093|Fluzone® High Dose, Influenza Vaccine
80067|NCT02563080|exocrine insufficiency
80068|NCT02563080|acute pancreatitis
80069|NCT02563080|severe
80070|NCT02563080|moderately severe
80071|NCT02563067|Asthma
80072|NCT02563067|QAW039
80073|NCT02563028|Visual Evoked Potentials
80074|NCT02563028|Microdiscectomy
80075|NCT02563028|SightSaver
80076|NCT02563015|Infant
80077|NCT02563015|Vitamin D
80078|NCT02563015|Deficiency
80079|NCT02563015|Lean Mass
80080|NCT02563002|PD1
80081|NCT02563002|PDL1
80082|NCT02563002|PD-L1
80083|NCT02562924|MEDIHONEY
80084|NCT02562924|Chronic Rhinosinusitis With Nasal Polyposis
80085|NCT02562924|Functional Endoscopic Sinus Surgery
80086|NCT02562911|cystic fibrosis
80087|NCT02562911|menstrual cycle
80088|NCT02562911|puberty
80089|NCT02562885|Benign epilepsy with centro-temporal spikes
80090|NCT02562885|Continuous spike waves in slow wave sleep
80091|NCT02562885|Electroencephalography
80092|NCT02562885|Sleep, slow wave
80093|NCT02562872|Controlled
80094|NCT02562872|Human
80095|NCT02562872|Malaria
80096|NCT02562872|Infection
80097|NCT02562872|Healthy
80098|NCT02562872|Volunteer
80099|NCT02562846|electroconvulsive therapy
80100|NCT02562846|response prediction
80101|NCT02562846|cognitive side effects
80102|NCT02562833|Osteoarthritis
80103|NCT02562833|Self-management
80104|NCT02562833|Multi-Component Exercise
80105|NCT02562807|Urinary Incontinence
80106|NCT02562807|Urinary Incontinence, Stress
80107|NCT02562807|Lower Urinary Tract Symptoms
80108|NCT02562794|refugee
80109|NCT02562781|postoperative complications
80110|NCT02562781|postoperative cognitive dysfunction
80111|NCT02562781|oxygen
80112|NCT02562755|Hepatocellular Carcinoma (HCC)
80113|NCT02562755|Pexastimogene Devacirepvec (Pexa-Vec)
80114|NCT02562755|Sorafenib
80115|NCT02562755|GM-CSF therapy
80116|NCT02562755|Thymidine Kinase-Deactivated Vaccinia Virus
80117|NCT02562755|Oncology
80118|NCT02562755|Recombinant Vaccinia Virus
80119|NCT02562755|Oncolytic Virus Therapy
80120|NCT02562755|Oncolytic virotherapy
80121|NCT02562742|Hepatitis C virus
80122|NCT02562742|observational
80123|NCT02562742|post-marketing
80124|NCT02562742|sofosbuvir
80125|NCT02562742|Infection
80126|NCT02562729|Cervical cancer; Nerve-sparing hysterectomy; simplified
80127|NCT02562690|Coronary Artery Disease
80128|NCT02562690|Myocardial Ischemia
80129|NCT02562690|Arterial Occlusive Diseases
80130|NCT02562690|Coronary Thrombosis
80131|NCT02562651|STEMI, adverse LVR (left ventricular remodeling), MMPs, Doxycycline
80132|NCT02562638|NPO
80133|NCT02562638|NBM
80134|NCT02562638|pre-procedure
80135|NCT02562638|cardiac
80136|NCT02562599|Induction Chemotherapy
80137|NCT02562599|Concurrent Chemoradiotherapy
80138|NCT02562586|Suction
80139|NCT02562586|Arthroplasty
80140|NCT02562586|Replacement
80141|NCT02562586|Hip
80142|NCT02562534|ECG
80143|NCT02562534|MRI
80144|NCT02562534|rythm troubles
80145|NCT02562534|conductive troubles
80146|NCT02562534|ECG artifacts
80147|NCT02562534|Database
80148|NCT02562508|Human Papilloma Virus 16
80149|NCT02562508|Human Papilloma Virus 18
80150|NCT02562508|vaccine
80151|NCT02562508|adolescent girl
80152|NCT02562508|bridging trial
80153|NCT02562508|non-inferiority
80154|NCT02562495|severe cerebral pathology
80155|NCT02562495|Ultrasound
80156|NCT02562495|thickness of the quadriceps
80157|NCT02562482|Antibody Response
80158|NCT02562482|Immune Response
80159|NCT02562482|Healthy Volunteer
80160|NCT02562482|Vaccine-Mediated Protection
80161|NCT02562482|Chikungunya Virus
80162|NCT02562482|Vaccines, Virus-like Particles
80163|NCT02562456|Dental Atraumatic Restorative Treatment
80164|NCT02562456|Composite Resins
80165|NCT02562456|Primary Teeth
80166|NCT02562456|Clinical Efficacy
80167|NCT02562456|Cost Analysis
80168|NCT02562443|Myelodysplastic Syndrome
80169|NCT02562443|MDS
80170|NCT02562430|Placebo response
80171|NCT02562391|atrial fibrillation
80172|NCT02562391|ablation
80173|NCT02562391|thoracoscopy
80174|NCT02562391|left atrial appendage
80175|NCT02562365|adjuvent chemotherapy
80176|NCT02562365|ovarian cancer
80177|NCT02562352|polypharmacy
80178|NCT02562352|multimorbidity
80179|NCT02562352|randomized controlled trial
80180|NCT02562352|drug discontinuation
80181|NCT02562352|patient preference
80182|NCT02562352|eHealth
80183|NCT02562274|Menopause
80184|NCT02562274|Cognitive impairment
80185|NCT02562274|Working memory
80186|NCT02562274|Bone formation markers
80187|NCT02562274|Osteoporosis
80188|NCT02562261|sepsis
80189|NCT02562261|platelet
80190|NCT02562261|platelet reactivity
80191|NCT02562261|P2Y12
80192|NCT02562235|Pulmonary arterial hypertension
80193|NCT02562222|migraine disorders
80194|NCT02562222|transcranial direct current stimulation
80195|NCT02562222|electric stimulation therapy
80196|NCT02562222|pain
80197|NCT02562222|rehabilitation
80198|NCT02562209|Obesity
80199|NCT02562209|Abdominal adiposity
80200|NCT02562209|High protein diet
80201|NCT02562196|migraine disorders
80202|NCT02562196|transcranial direct current stimulation
80203|NCT02562196|electric stimulation therapy
80204|NCT02562196|pain
80205|NCT02562170|breast
80206|NCT02562170|reconstruction
80207|NCT02562170|mesh
80208|NCT02562170|acellular dermal matrix
80209|NCT02562131|PET-MR
80210|NCT02562131|recidive
80211|NCT02562131|PET/MR imaging
80212|NCT02562131|18F-Fluciclovine
80213|NCT02562131|radical treatment
80214|NCT02562131|recurrence
80215|NCT02562105|Intensive care unit
80216|NCT02562105|Hematological malignancy
80217|NCT02562105|Acute respiratory failure
80218|NCT02562105|Prognosis
80219|NCT02562105|Mechanical ventilation
80220|NCT02562092|AIDS
80221|NCT02562092|Health Promotion
80222|NCT02562079|T lymphocyte
80223|NCT02562079|OX40/OX40L
80224|NCT02562040|Pediatrics
80225|NCT02562040|Primary Snoring
80226|NCT02562040|Adenotonsillectomy
80227|NCT02562001|Spinal Cord Injuries
80228|NCT02562001|gait training
80229|NCT02562001|robotic
80230|NCT02562001|Lokomat
80231|NCT02562001|Transcranial Magnetic Stimulation
80232|NCT02562001|transcranial direct-current stimulation
80233|NCT02562001|Electroencephalography
80234|NCT02561975|Double pulmonary diffusing capacity to carbon monoxyd (CO) associated to nitric oxide (NO)
80235|NCT02561975|Evolution of membrane and capillar damages
80236|NCT02561975|Early pronostic value of congenital heart disease
80237|NCT02561962|Multiple Myeloma
80238|NCT02561962|Relapsed Multiple Myeloma
80239|NCT02561962|Refractory Multiple Myeloma
80240|NCT02561949|Depression/therapy
80241|NCT02561949|Developing Countries
80242|NCT02561949|Interpersonal Relations
80243|NCT02561949|Life Change Events
80244|NCT02561949|Psychotherapy, group
80245|NCT02561949|Resilience, Psychological
80246|NCT02561949|Sierra Leone
80247|NCT02561949|Survivors/psychology
80248|NCT02561949|Social Adjustment
80249|NCT02561949|Social Behavior
80250|NCT02561949|War
80251|NCT02561936|Healthy
80252|NCT02561936|EUDRANT
80253|NCT02561936|Rilpivirine
80254|NCT02561923|Healthy
80255|NCT02561923|Rivaroxaban
80256|NCT02561923|XARELTO
80257|NCT02561910|Inguinal hernia repair
80258|NCT02561910|laparoscopic inguinal hernia repair
80259|NCT02561910|TAPP
80260|NCT02561871|Ad26.RSV.FA2 (JNJ-61187165-AAA)
80261|NCT02561871|Ad35.RSV.FA2 (JNJ-61187191-AAA)
80262|NCT02561871|Healthy participants
80263|NCT02561858|Renal Ammonium ;uric acid
80264|NCT02561845|Effectiveness of statins, on lipid goal attainment and lipid parameters in Percutaneous Coronary Intervention patients
80265|NCT02561832|breast cancer
80266|NCT02561819|Short Bowel Syndrome
80267|NCT02561819|Congenital Short Bowel Syndrome
80268|NCT02561819|Body Composition
80269|NCT02561819|Parenteral Nutrition
80270|NCT02561819|Intestinal Failure
80271|NCT02561780|Mental Health Knowledge
80272|NCT02561780|Stigma
80273|NCT02561780|Mental Health Literacy
80274|NCT02561767|kidney transplantation
80275|NCT02561767|mesenchymal stem cell
80276|NCT02561767|donation after citizen's death
80277|NCT02561767|ischemia reperfusion injury
80278|NCT02561767|renal function recovery
80279|NCT02561754|Diet
80280|NCT02561754|Obesity
80281|NCT02561754|Adolescents
80282|NCT02561754|Intellectual and Developmental Disability
80283|NCT02561728|Helmet
80284|NCT02561728|Hangar
80285|NCT02561728|P-Pod
80286|NCT02561728|Plagiocephaly
80287|NCT02561728|Surgery
80288|NCT02561715|Parkinson's
80289|NCT02561715|Anosognosia
80290|NCT02561715|DBS
80291|NCT02561715|Deep Brain Surgery
80292|NCT02561689|Occlusal caries
80293|NCT02561689|Resin fissure sealant
80294|NCT02561689|Longevity
80295|NCT02561689|Effectiveness
80296|NCT02561676|Mindfulness
80297|NCT02561676|Spinal Cord Injury
80298|NCT02561663|microcirculation
80299|NCT02561663|blood pressure
80300|NCT02561663|pulse wave analysis
80301|NCT02561663|pulse wave velocity
80302|NCT02561637|Case management
80303|NCT02561624|mHealth
80304|NCT02561624|Text message
80305|NCT02561611|Pedal Desk
80306|NCT02561611|Workplace Intervention
80307|NCT02561611|Physical Activity
80308|NCT02561611|Energy Expenditure
80309|NCT02561546|concurrent
80310|NCT02561520|platelet rich plasma
80311|NCT02561520|platelet poor plasma
80312|NCT02561520|ocular GVHD
80313|NCT02561455|Advanced solid tumors
80314|NCT02561455|Acute myeloid leukemia
80315|NCT02561455|ASP2215
80316|NCT02561416|Fibromyalgia syndrome
80317|NCT02561416|Mindfulness (MBSR)
80318|NCT02561416|Neuroimaging
80319|NCT02561416|Cytokines
80320|NCT02561416|Randomized Controlled Trial
80321|NCT02561416|Cost-effectiveness
80322|NCT02561416|Psychoeducation (FibroQol)
80323|NCT02561403|traumatic brain injury (TBI)
80324|NCT02561403|aging
80325|NCT02561403|cognitive training
80326|NCT02561403|Cognitive Aging
80327|NCT02561377|resistance training
80328|NCT02561377|Prediabetic state
80329|NCT02561377|Metabolomics
80330|NCT02561364|Fetal Biophysical Profile
80331|NCT02561351|bronchial asthma
80332|NCT02561351|fractional exhaled nitric oxide (FeNO)
80333|NCT02561351|asthma exacerbation
80334|NCT02561338|GKA,T2DM,HMS5552
80335|NCT02561325|Blood pressure
80336|NCT02561325|Sodium Chloride
80337|NCT02561325|Sodium Bicarbonate
80338|NCT02561299|Drug-coated Balloons
80339|NCT02561299|Calcified Lesions
80340|NCT02561299|Orbital Atherectomy
80341|NCT02561299|Below the Knee
80342|NCT02561299|Paclitaxel
80343|NCT02561299|Lutonix 014 Drug-coated Balloon
80344|NCT02561286|Human immunodeficiency virus
80345|NCT02561286|Sexually transmitted disease
80346|NCT02561286|Men who have sex with men
80347|NCT02561286|African Americans
80348|NCT02561286|Behavioral intervention
80349|NCT02561286|Randomized controlled trial
80350|NCT02561286|Sexual behavior
80351|NCT02561286|Mediation analysis
80352|NCT02561286|Social cognitive theory
80353|NCT02561286|Theory of planned behavior
80354|NCT02561247|Acute Kidney Injury
80355|NCT02561247|Continuous Renal Replacement Therapy
80356|NCT02561247|Blood Urea Nitrogen (BUN)
80357|NCT02561247|Prismaflex
80358|NCT02561247|Pediatric
80359|NCT02561221|primary care
80360|NCT02561221|pragmatic trial
80361|NCT02561221|weight loss
80362|NCT02561221|overweight
80363|NCT02561221|diet
80364|NCT02561221|physical activity
80365|NCT02561221|PCORI
80366|NCT02561208|Patient adherence
80367|NCT02561208|Mobile Health
80368|NCT02561208|HPV DNA Tests
80369|NCT02561208|Self-collected
80370|NCT02561195|Clostridium difficile, Vaccine.
80371|NCT02561169|antiviral
80372|NCT02561169|oseltamivir
80373|NCT02561156|Drug therapy
80374|NCT02561143|cachexia
80375|NCT02561143|nutrition supplementation
80376|NCT02561143|IAtta
80377|NCT02561143|palliative care
80378|NCT02561143|quality of life
80379|NCT02561130|Diabetes
80380|NCT02561130|Insulin
80381|NCT02561130|Glargine
80382|NCT02561130|Metformin
80383|NCT02561130|Forxiga
80384|NCT02561130|Diet
80385|NCT02561130|Exercise
80386|NCT02561130|Lifestyle
80387|NCT02561104|cataract
80388|NCT02561104|phacoemulsification
80389|NCT02561104|laser-assisted surgery
80390|NCT02561104|femtosecond laser
80391|NCT02561091|Deafness
80392|NCT02561091|Hearing Loss, Sensorineural
80393|NCT02561091|Ear Diseases
80394|NCT02561091|Hearing Disorders
80395|NCT02561091|Otorhinolaryngologic Diseases
80396|NCT02561091|Sensation Disorders
80397|NCT02561091|Signs and Symptoms
80398|NCT02561091|Hearing and Speech impairment
80399|NCT02561091|Hearing Loss, Unilateral
80400|NCT02561078|insulin pumps
80401|NCT02561078|concentrated insulin
80402|NCT02561078|OmniPod
80403|NCT02561065|Health Lifestyle
80404|NCT02561065|Lifestyle Risk Reduction
80405|NCT02561065|Health Behavior
80406|NCT02561065|Sedentary Lifestyle
80407|NCT02561065|Intervention Studies
80408|NCT02561065|Cardiovascular risk in office workers
80409|NCT02561065|Motivational Interview
80410|NCT02561065|Preventive health services
80411|NCT02561065|Health education
80412|NCT02561065|Physical activity
80413|NCT02561065|Dietary behaviour intervention
80414|NCT02561065|Workplace
80415|NCT02561052|ORI validation
80416|NCT02561052|Subjects undergoing hypoxia and hyperoxia
80417|NCT02561026|Frozen plasma
80418|NCT02561026|INR
80419|NCT02561026|procedures
80420|NCT02561000|Platelets
80421|NCT02561000|Platelet Aggregation Inhibitors
80422|NCT02561000|Protease-Activated Receptor 1
80423|NCT02561000|Hemorrhage
80424|NCT02560961|Kinesio Taping
80425|NCT02560961|Soccer
80426|NCT02560961|Hop Test
80427|NCT02560961|Vertical Jump
80428|NCT02560935|primary stroke prevention
80429|NCT02560935|hydroxyurea
80430|NCT02560935|low income country
80431|NCT02560935|sub-Saharan Africa
80432|NCT02560922|Osteoarthritis
80433|NCT02560922|Knee Osteoarthritis
80434|NCT02560922|Hip Osteoarthritis
80435|NCT02560896|Family
80436|NCT02560896|History
80437|NCT02560896|Pancreas
80438|NCT02560896|Cancer
80439|NCT02560896|Genetic
80440|NCT02560883|Hairy Cell
80441|NCT02560857|Quantiferon-Monitor
80442|NCT02560857|organ rejection
80443|NCT02560857|global immunity
80444|NCT02560831|Osteoarthritis
80445|NCT02560831|Therapeutic exercises
80446|NCT02560831|Pain
80447|NCT02560831|Muscle strength
80448|NCT02560831|Postural balance
80449|NCT02560818|splice profiles of messenger RNA
80450|NCT02560779|TRC105
80451|NCT02560779|CD105
80452|NCT02560779|Endoglin
80453|NCT02560779|Angiogenesis inhibitor
80454|NCT02560779|HCC
80455|NCT02560779|TKI
80456|NCT02560779|Tyrosine Kinase Inhibitor
80457|NCT02560779|Sorafenib
80458|NCT02560779|Nexavar
80459|NCT02560766|Restless Leg Syndrome
80460|NCT02560766|RLS
80461|NCT02560727|Inflammatory Bowel Diseases
80462|NCT02560727|Fecal Microbiota Transplantation
80463|NCT02560727|transendoscopic enteral tubing
80464|NCT02560714|sacroiliac joint fusion
80465|NCT02560714|SIJ Fusion
80466|NCT02560714|SI Joint
80467|NCT02560714|SIJ
80468|NCT02560701|high-deductible health plans
80469|NCT02560701|medication adherence
80470|NCT02560688|drug interaction
80471|NCT02560688|clopidogrel
80472|NCT02560688|healthy subjects
80473|NCT02560675|Whiplash Injury Pain
80474|NCT02560675|Chronic Pain
80475|NCT02560675|TBI
80476|NCT02560662|Breast cancer, physical exercise, recovery
80477|NCT02560636|Muscle Invasive
80478|NCT02560636|Metastatic
80479|NCT02560636|Advanced
80480|NCT02560623|Barrett's
80481|NCT02560623|esophagus
80482|NCT02560623|reflux
80483|NCT02560623|esophageal adenocarcinoma
80484|NCT02560597|epilepsy
80485|NCT02560597|epilepsia partialis continua
80486|NCT02560597|status epilepticus
80487|NCT02560597|treatment resistant
80488|NCT02560597|repetitive transcranial magnetic stimulation
80489|NCT02560584|Non-muscle invasive bladder cancer
80490|NCT02560584|NMIBC
80491|NCT02560584|Cysview
80492|NCT02560558|Immunosuppression
80493|NCT02560558|Transplantation Immunology
80494|NCT02560532|aneurysmal subarachnoid hemorrhage
80495|NCT02560532|cerebral vasospasm
80496|NCT02560532|clazosentan
80497|NCT02560519|human serum albumin solution
80498|NCT02560519|Cardiopulmonary Bypass
80499|NCT02560493|BMIz
80500|NCT02560493|Exergaming
80501|NCT02560493|Cardiovascular Disease
80502|NCT02560480|groin pain, groin injury, magnetic resonance imaging
80503|NCT02560454|Cognitive Remediation
80504|NCT02560454|Working Memory Training
80505|NCT02560454|Cognitive training
80506|NCT02560428|Mixed Methods
80507|NCT02560428|Cardiovascular Health
80508|NCT02560428|Implementation Evaluation
80509|NCT02560428|Cardiovascular Prevention Screening
80510|NCT02560415|Autism Spectrum Disorder
80511|NCT02560415|Serious Game
80512|NCT02560415|Controlled trial
80513|NCT02560415|Denver model
80514|NCT02560402|Glomerular hyperfiltration
80515|NCT02560402|Renal Resistive Index (RRI)
80516|NCT02560389|Posttraumatic Stress Disorder
80517|NCT02560389|functional Magnetic Resonance Imaging
80518|NCT02560389|Levodopa (L-DOPA)
80519|NCT02560389|Exposure Therapy
80520|NCT02560389|Fear Extinction
80521|NCT02560376|PET/CT
80522|NCT02560376|glucagon-like peptide-1 receptor (GLP-1R) imaging
80523|NCT02560363|AZD9977
80524|NCT02560363|Safety
80525|NCT02560363|Tolerability
80526|NCT02560363|Pharmacokinetics
80527|NCT02560363|Food effect
80528|NCT02560363|AZD9977 capsules
80529|NCT02560363|AZD9977 suspension
80530|NCT02560350|adipose-derived stem cells
80531|NCT02560350|small intestinal submucosa
80532|NCT02560350|adipocyte-containing hypodermis
80533|NCT02560337|Ovarian cancer
80534|NCT02560337|Relapse
80535|NCT02560337|Recurrence
80536|NCT02560337|Chemotherapy resistance
80537|NCT02560324|Ramelteon
80538|NCT02560324|Nicotine
80539|NCT02560324|Nicotine dependence
80540|NCT02560324|Insomnia
80541|NCT02560324|Tobacco Dependence
80542|NCT02560285|Risk assessment
80543|NCT02560285|Mortality
80544|NCT02560285|Morbidity
80545|NCT02560285|Risk factor
80546|NCT02560272|vaccine
80547|NCT02560272|haemophilus influenzae type b
80548|NCT02560259|knee pain
80549|NCT02560246|Microbiome
80550|NCT02560233|Neurofeedback
80551|NCT02560233|Stress
80552|NCT02560233|fMRI
80553|NCT02560233|Real-time fMRI Neurofeedback
80554|NCT02560233|Anterior cingulate cortex
80555|NCT02560233|Hypothalamic-pituitary-adrenal axis
80556|NCT02560233|Cortisol
80557|NCT02560233|EEG
80558|NCT02560233|Heart rate variability
80559|NCT02560233|Blood pressure
80560|NCT02560233|Simultaneous EEG/fMRI
80561|NCT02560181|recurrent prostate cancer,HDR whole gland salvage
80562|NCT02560168|Coronary artery disease
80563|NCT02560168|iECG
80564|NCT02560168|MyoVista
80565|NCT02560168|Heart Test Labs
80566|NCT02560168|Wavelet analysis
80567|NCT02560168|Surface electrocardiogram
80568|NCT02560155|Orthopedic surgery
80569|NCT02560155|Surgical site infection
80570|NCT02560155|Decolonization
80571|NCT02560155|Staphylococcus aureus
80572|NCT02560129|recovery
80573|NCT02560129|ICU
80574|NCT02560129|clinic
80575|NCT02560129|survivor
80576|NCT02560129|physical function
80577|NCT02560116|Pulmonary artery systolic pressure
80578|NCT02560116|Optison
80579|NCT02560090|Diabetes
80580|NCT02560077|cognitive
80581|NCT02560077|memory
80582|NCT02560077|physical fitness
80583|NCT02560077|psychological fitness
80584|NCT02560077|elderly
80585|NCT02560077|middle aged
80586|NCT02560051|Prostate Cancer
80587|NCT02560051|Advanced
80588|NCT02560051|Local Failures
80589|NCT02560038|Urothelial Cancer
80590|NCT02560038|Bladder Cancer
80591|NCT02560038|Metastatic
80592|NCT02560025|Acute Myeloid Leukemia
80593|NCT02560012|Renal Cell Carcinoma
80594|NCT02560012|RCC
80595|NCT02560012|Personalized therapy
80596|NCT02560012|targeted inhibitors
80597|NCT02559999|Healthy Volunteers
80598|NCT02559999|Pain
80599|NCT02559999|EEG
80600|NCT02559973|Buprenorphine
80601|NCT02559973|opioid use disorder
80602|NCT02559921|Recombinant Human Rabies Immunoglobin (rhRIG)
80603|NCT02559869|Biofluid
80604|NCT02559869|ALS
80605|NCT02559869|MRI
80606|NCT02559869|PET
80607|NCT02559869|Imaging
80608|NCT02559869|Biomarkers
80609|NCT02559869|Amyotrophic Lateral Sclerosis
80610|NCT02559869|TRACK ALS
80611|NCT02559869|pathology
80612|NCT02559843|pomegranate
80613|NCT02559843|diabetes
80614|NCT02559843|oxidative stress
80615|NCT02559817|Irritable Bowel Syndrome with Constipation in children
80616|NCT02559817|Linzess
80617|NCT02559791|Reslizumab
80618|NCT02559791|Eosinophils
80619|NCT02559791|Asthma
80620|NCT02559791|Airway inflammation
80621|NCT02559791|Prednisone
80622|NCT02559765|physiotherapy
80623|NCT02559765|progressive multiple sclerosis
80624|NCT02559765|rehabilitation
80625|NCT02559765|rehabilitation services
80626|NCT02559739|Stroke
80627|NCT02559739|Ischemic Attack, Transient
80628|NCT02559739|Cardiovascular Diseases
80629|NCT02559739|Sleep Apnea Syndromes
80630|NCT02559739|Sleep Initiation and Maintenance Disorders
80631|NCT02559739|Insomnia
80632|NCT02559739|Restless Legs Syndrome
80633|NCT02559739|Sleep Deprivation
80634|NCT02559726|Hypertrophic cardiomyopathy, hyper-synchronicity, outflow-tract obstruction, dual chamber pacing
80635|NCT02559713|Lactation
80636|NCT02559713|Lactating Women
80637|NCT02559713|Vedolizumab
80638|NCT02559713|Colitis Ulcerative
80639|NCT02559713|Crohn Disease
80640|NCT02559713|Crohn's
80641|NCT02559700|Healthy Ageing
80642|NCT02559687|PD1
80643|NCT02559687|PD-L1
80644|NCT02559687|PDL1
80645|NCT02559674|Pancreas
80646|NCT02559674|Pancreatic
80647|NCT02559674|Cancer
80648|NCT02559674|Advanced Pancreatic Cancer
80649|NCT02559674|Immunotherapy
80650|NCT02559674|Immunotherapeutic
80651|NCT02559674|Interleukin-15
80652|NCT02559674|Gemcitabine
80653|NCT02559674|Nab-paclitaxel
80654|NCT02559674|Solid Tumor
80655|NCT02559674|Metastatic Disease
80656|NCT02559674|Combination Immunotherapy
80657|NCT02559583|Multiple Myeloma
80658|NCT02559583|chronic lymphocytic leukemia
80659|NCT02559583|Non-Hodgkin lymphoma
80660|NCT02559570|Functional constipation in children
80661|NCT02559570|Linzess
80662|NCT02559544|failed prior endocrine therapy
80663|NCT02559518|Cerebellum
80664|NCT02559518|Transcranial Direct Current Stimulation
80665|NCT02559518|Repetitive Transcranial Magnetic Stimulation
80666|NCT02559518|Motor Learning
80667|NCT02559518|Serial Reaction Time Task
80668|NCT02559518|HandwritingTask
80669|NCT02559505|natural influenza infection
80670|NCT02559505|live attenuated influenza vaccination (LAIV)
80671|NCT02559505|inactivated influenza vaccination (IIV)
80672|NCT02559505|infants
80673|NCT02559505|children
80674|NCT02559466|pharmaco-resistant depressed patients
80675|NCT02559427|sleep apnea
80676|NCT02559427|Venous Insufficiency
80677|NCT02559427|SPA treatment
80678|NCT02559401|Eloquent cortex
80679|NCT02559349|Stereotactic Body Radiotherapy
80680|NCT02559349|SBRT
80681|NCT02559336|Palliative Care
80682|NCT02559336|Cancer
80683|NCT02559336|Health Services Research
80684|NCT02559310|Pneumonia
80685|NCT02559310|CABP
80686|NCT02559310|CAP
80687|NCT02559310|Community acquired bacterial pneumonia
80688|NCT02559297|Regulatory T cells
80689|NCT02559297|Sevoflurane
80690|NCT02559297|Desflurane
80691|NCT02559297|Cytokines
80692|NCT02559297|Flow cytometry
80693|NCT02559297|Living Donor Kidney Transplant
80694|NCT02559284|Saline Solution, Isotonic / Administration & dosage
80695|NCT02559284|Therapeutic Irrigation / methods
80696|NCT02559284|Postoperative Care / methods
80697|NCT02559284|Quality of life
80698|NCT02559180|Diabetes
80699|NCT02559180|Macular Edema
80700|NCT02559180|Diabetic Retinopathy
80701|NCT02559141|haemodynamic optimization
80702|NCT02559141|cardiac index
80703|NCT02559141|non-invasive
80704|NCT02559141|pulse pressure variation
80705|NCT02559128|Insulin Resistance
80706|NCT02559128|Chronic Heart Failure
80707|NCT02559128|Type 2 Diabetes
80708|NCT02559128|Endothelial Dysfunction
80709|NCT02559115|68Ga-RM2
80710|NCT02559115|PET/CT scan
80711|NCT02559115|Gastrin Releasing Peptide Receptor (GRPr)
80712|NCT02559115|14-146
80713|NCT02559102|Dexmedetomidine sedation
80714|NCT02559102|General anaesthesia
80715|NCT02559102|Neurodevelopment
80716|NCT02559102|Infants
80717|NCT02559102|Neonates
80718|NCT02559076|Overweight
80719|NCT02559076|Obesity
80720|NCT02559076|Preschool children
80721|NCT02559076|United Arab Emirates
80722|NCT02559076|Dietary patterns
80723|NCT02559076|BMI z-scores
80724|NCT02559063|cognitive training
80725|NCT02559063|speed of processing
80726|NCT02559063|neuroplasticity
80727|NCT02559063|cognitive aging
80728|NCT02559037|acupuncture
80729|NCT02559037|moxibustion
80730|NCT02559037|intestinal microbiota
80731|NCT02559037|Mucosal immunity
80732|NCT02559024|Metastatic colorectal cancer
80733|NCT02559024|liver lesion
80734|NCT02559024|anti-OX40 antibody
80735|NCT02559024|MEDI6469
80736|NCT02559024|Immunotherapy
80737|NCT02559011|Arrhythmias, Cardiac
80738|NCT02559011|Transcatheter Aortic Valve implantation
80739|NCT02559011|Aortic Valve Stenosis
80740|NCT02558985|Pulmonary Compliance
80741|NCT02558985|Casting
80742|NCT02558972|Postural Tachycardia Syndrome (POTS)
80743|NCT02558972|Vasovagal Syncope (VVS)
80744|NCT02558972|Fainting
80745|NCT02558972|Orthostatic Intolerance
80746|NCT02558972|Droxidopa
80747|NCT02558972|Northera
80748|NCT02558933|Fetal Alcohol Syndrome
80749|NCT02558933|Prenatal exposure
80750|NCT02558933|Biomarkers
80751|NCT02558933|Oxidative stress
80752|NCT02558933|Epigallocatechin gallate
80753|NCT02558920|Systematic review and meta-analysis
80754|NCT02558920|Evidence-based medicine (EBM)
80755|NCT02558920|Evidence-based nutrition (EBN)
80756|NCT02558920|Clinical practice guidelines
80757|NCT02558920|Clinical trials
80758|NCT02558920|Dietary sugars
80759|NCT02558920|Fructose
80760|NCT02558920|Sucrose
80761|NCT02558920|High fructose corn syrup
80762|NCT02558920|Isocaloric
80763|NCT02558920|Hypercaloric
80764|NCT02558920|Body weight
80765|NCT02558920|Prospective cohort studies
80766|NCT02558907|geriatrics
80767|NCT02558907|cancer
80768|NCT02558907|MMS test
80769|NCT02558907|MoCA test
80770|NCT02558907|cognitive evaluation
80771|NCT02558894|Pancreatic Ductal Adenocarcinoma, PDAC
80772|NCT02558881|screening
80773|NCT02558881|colorectal cancer
80774|NCT02558881|colon capsule
80775|NCT02558881|virtual colonoscopy
80776|NCT02558855|Thrust Joint Manipulation
80777|NCT02558855|Non-thrust Joint Manipulation
80778|NCT02558855|Transversus Abdominis
80779|NCT02558829|Adult Growth Hormone Deficiency
80780|NCT02558803|HPV Vaccinations
80781|NCT02558803|Quadrivalent Vaccine
80782|NCT02558790|Attention Deficit/Hyperactivity Disorder
80783|NCT02558790|ADHD
80784|NCT02558790|Attention Deficit Disorder
80785|NCT02558790|ADD
80786|NCT02558790|Magnesium
80787|NCT02558777|Delirium
80788|NCT02558777|Pilot Study
80789|NCT02558777|Nurse intervention
80790|NCT02558777|Hospitalization
80791|NCT02558751|pneumococcal conjugate vaccine
80792|NCT02558751|aging HIV
80793|NCT02558738|dermatitis and irritations at the outer ear canal
80794|NCT02558738|prevention of subacute otitis externa
80795|NCT02558712|screening
80796|NCT02558712|tele-ophthalmology
80797|NCT02558686|trigger points
80798|NCT02558686|disability
80799|NCT02558686|post-dry needling soreness
80800|NCT02558686|eccentric exercise
80801|NCT02558673|Trimethylamine-N-oxide
80802|NCT02558673|Biomarkers
80803|NCT02558673|Production
80804|NCT02558673|Metabolism
80805|NCT02558673|Gut microbiome
80806|NCT02558673|Healthy
80807|NCT02558660|Supplemental Nutrition Incentive Program (SNAP)
80808|NCT02558660|economic incentive
80809|NCT02558621|Robotic Spinal Fusion Surgery
80810|NCT02558608|Prime Spontaneous Pneumothorax
80811|NCT02558608|recurrence
80812|NCT02558595|PKD
80813|NCT02558595|Kidney disease
80814|NCT02558595|Vitamin B3
80815|NCT02558582|Pulmonary arterial hypertension
80816|NCT02558582|Chronic thromboembolic pulmonary hypertension
80817|NCT02558582|Rehabilitation
80818|NCT02558582|Oxygen
80819|NCT02558569|fentanyl, scalp block
80820|NCT02558556|Laparoscopic cholecystectomy (LC)
80821|NCT02558556|Indocyanine green (ICG)
80822|NCT02558556|Near-Infrared Fluorescence Imaging (NIRF)
80823|NCT02558556|Critical View of Safety (CVS)
80824|NCT02558517|Systemic Lupus Erythematosus
80825|NCT02558517|Corticosteroids
80826|NCT02558517|Chronic disease
80827|NCT02558491|Type 1 Diabetes Mellitus (T1DM)
80828|NCT02558491|Artificial Pancreas Project (APP)
80829|NCT02558491|Diabetes Assistant (DiAs)
80830|NCT02558491|Insulin Pump
80831|NCT02558491|Continuous Glucose Monitor
80832|NCT02558491|Exercise
80833|NCT02558491|Glucose Variability
80834|NCT02558491|Decision Support System
80835|NCT02558491|Multiple Daily Injections (MDI)
80836|NCT02558478|Whole exome sequencing
80837|NCT02558465|Xarelto, rivaroxaban, VTE, PE, DVT, Japan, PMS, SDUI
80838|NCT02558452|elderly kidney transplant recipient
80839|NCT02558452|registry
80840|NCT02558452|tacrolimus once daily
80841|NCT02558426|Chronic Venous Disease
80842|NCT02558426|Estrogen receptors
80843|NCT02558426|GPER
80844|NCT02558413|Viral Diseases
80845|NCT02558413|Antiviral
80846|NCT02558413|Paramyxoviridae Infections
80847|NCT02558413|RSV
80848|NCT02558413|Respiratory Syncytial Virus
80849|NCT02558413|Aviragen Therapeutics, Inc.
80850|NCT02558413|Aviragen Therapeutics
80851|NCT02558413|Aviragen
80852|NCT02558348|Dual receptor Tyrosine Kinase Inhibitor
80853|NCT02558348|Anti-angiogenic therapy
80854|NCT02558257|Advanced Cancers
80855|NCT02558257|Survey
80856|NCT02558257|Questionnaire
80857|NCT02558244|Childhood Cancer
80858|NCT02558244|Image-defined Risk Factors
80859|NCT02558244|Pediatric Oncology
80860|NCT02558192|LGG
80861|NCT02558192|Probiotics
80862|NCT02558192|nosocomial infection prevention
80863|NCT02558192|pediatrics
80864|NCT02558166|Acute Kidney Injury (AKI)
80865|NCT02558166|Renal Resistive Index (RRI)
80866|NCT02558153|drug eluting balloon
80867|NCT02558153|percutaneous balloon angioplasty
80868|NCT02558127|asthma
80869|NCT02558127|cystic fibrosis
80870|NCT02558101|Screening
80871|NCT02558101|Early detection
80872|NCT02558101|Health inequality
80873|NCT02558101|Uptake
80874|NCT02558088|salmeterol
80875|NCT02558088|pharmacokinetics
80876|NCT02558088|doping
80877|NCT02558088|beta2-agonists
80878|NCT02558088|long-acting beta2-agonists
80879|NCT02558062|Ventilator Associated Pneumonia
80880|NCT02558062|Distal lung
80881|NCT02558049|Patient decision aid
80882|NCT02558036|Head Neck Position Videolaryngoscopy
80883|NCT02558023|PRE-ECLAMPSIA
80884|NCT02558023|URAPIDIL
80885|NCT02558023|NICARDIPINE
80886|NCT02558010|Methadone
80887|NCT02558010|Gabapentin
80888|NCT02558010|Postoperative Pain
80889|NCT02558010|Posterior Spinal Fusion
80890|NCT02558010|Pediatric
80891|NCT02557997|HIV reservoir
80892|NCT02557997|HIV-1 DNA
80893|NCT02557997|Immune activation
80894|NCT02557997|Monocyte function
80895|NCT02557997|Activation biomarkers
80896|NCT02557984|Dopamine
80897|NCT02557984|Opioid
80898|NCT02557984|Reward
80899|NCT02557958|COPD, pulmonary disease
80900|NCT02557932|PPI standard triple therapy
80901|NCT02557932|Bismuth quadruple therapy
80902|NCT02557932|Helicobacter
80903|NCT02557906|Acellular dermal matrix
80904|NCT02557906|ADM
80905|NCT02557906|SurgiMend
80906|NCT02557906|Breast reconstruction
80907|NCT02557906|Immediate breast reconstruction
80908|NCT02557906|Autologous reconstruction
80909|NCT02557906|Biological mesh
80910|NCT02557867|dexmedetomidine
80911|NCT02557867|pharmacokinetic
80912|NCT02557867|obesity
80913|NCT02557841|Cerebellum
80914|NCT02557841|Transcranial Direct Current Stimulation
80915|NCT02557841|Motor Learning
80916|NCT02557841|Serial Reaction Time Task
80917|NCT02557841|Handwriting
80918|NCT02557815|Repetitive Transcranial Magnetic Stimulation
80919|NCT02557815|Emotion Regulation
80920|NCT02557815|Craving
80921|NCT02557789|Absolute bioavailability
80922|NCT02557789|Pharmacokinetics
80923|NCT02557776|BRCA1
80924|NCT02557776|BRCA2
80925|NCT02557776|hereditary breast cancer
80926|NCT02557776|genetic counseling
80927|NCT02557763|Oxford UKA
80928|NCT02557763|anterior knee pain
80929|NCT02557763|lateral facet of patella
80930|NCT02557750|Childhood Cancer
80931|NCT02557750|Pediatric Oncology
80932|NCT02557737|stroke
80933|NCT02557737|upper extremity
80934|NCT02557737|spasticity
80935|NCT02557737|botulinum toxin
80936|NCT02557737|ultrasonography
80937|NCT02557737|electric stimulation
80938|NCT02557711|spasticity
80939|NCT02557711|stroke
80940|NCT02557711|ultrasound elastography
80941|NCT02557711|acoustic radiation force impulse
80942|NCT02557659|Low Profile
80943|NCT02557659|Abdominal Aortic Aneurysms
80944|NCT02557659|Endovascular
80945|NCT02557594|Hepatitis B
80946|NCT02557568|nasal carriage
80947|NCT02557568|Staphylococcus aureus
80948|NCT02557568|hemodialysis patients
80949|NCT02557542|Varicose Veins; One Stop Clinic
80950|NCT02557529|Head and Neck Cancer
80951|NCT02557529|Concomitant chemoradiotherapy
80952|NCT02557529|Exercise Training
80953|NCT02557529|Progressive Resistance Training
80954|NCT02557529|Weight loss
80955|NCT02557529|Lean Body Mass
80956|NCT02557529|Body Composition
80957|NCT02557503|TACE; oxaliplatin; fluorouracil; liver cancer
80958|NCT02557490|TACE; hepatic artery infusion; oxaliplatin; raltitrexed
80959|NCT02557464|semantic memory
80960|NCT02557464|eye movements
80961|NCT02557464|reading
80962|NCT02557438|Bone
80963|NCT02557438|Child Health
80964|NCT02557438|Nutrition
80965|NCT02557425|malaria
80966|NCT02557425|infant
80967|NCT02557425|pregnancy
80968|NCT02557425|prophylaxis
80969|NCT02557425|dihyroartemisinin-piperaquine
80970|NCT02557425|sulfadoxine-pyrimethamine
80971|NCT02557425|behavior
80972|NCT02557425|neurodevelopment
80973|NCT02557425|cognitive
80974|NCT02557399|Clindamycin
80975|NCT02557399|Gel
80976|NCT02557399|Benzoyl Peroxide
80977|NCT02557399|Acne Vulgaris
80978|NCT02557386|Cruciate ligament surgery
80979|NCT02557386|Adductor canal
80980|NCT02557386|Nerve block
80981|NCT02557373|rice bran
80982|NCT02557373|infants
80983|NCT02557373|stool metabolome and microbiome
80984|NCT02557373|dietary intervention
80985|NCT02557360|liver injury
80986|NCT02557360|detoxification
80987|NCT02557360|S-adenosyl-L-methionine
80988|NCT02557360|quality of life
80989|NCT02557334|Strawberry Powder
80990|NCT02557334|Cardiovascular Disease Risk Factors
80991|NCT02557269|Pollenosis
80992|NCT02557269|Congestion
80993|NCT02557269|Mucoadhesive Treatment
80994|NCT02557269|Nasal Decongestant
80995|NCT02557269|Nasal Antihistamine
80996|NCT02557269|Nasal Corticosteroid
80997|NCT02557256|Childhood Cancer
80998|NCT02557256|Abdominal Tumors
80999|NCT02557256|Pelvic Tumors
81000|NCT02557256|Pediatric Oncology
81001|NCT02557243|Childhood Cancer
81002|NCT02557243|Soft Tissue Tumors
81003|NCT02557243|Bone Tumors
81004|NCT02557243|Extremity Tumor
81005|NCT02557243|Pediatric Oncology
81006|NCT02557230|Childhood Cancer
81007|NCT02557230|Genitourinary tumors
81008|NCT02557230|urogenital tumors
81009|NCT02557230|Pediatric Oncology
81010|NCT02557204|nasogastric tube insertion
81011|NCT02557204|Video laryngoscope
81012|NCT02557204|success rate
81013|NCT02557165|Muscle regeneration
81014|NCT02557113|cement leakage
81015|NCT02557113|cement augmentation
81016|NCT02557113|vertebral body fracture
81017|NCT02557113|vertebral cavity
81018|NCT02557113|vertebroplasty
81019|NCT02557048|Childhood Cancer
81020|NCT02557048|Head and Neck Tumors
81021|NCT02557048|Pediatric Oncology
81022|NCT02557022|Systematic review and meta-analysis
81023|NCT02557022|Evidence-based medicine (EBM)
81024|NCT02557022|Evidence-based nutrition (EBN)
81025|NCT02557022|Clinical practice guidelines
81026|NCT02557022|Glycemic index
81027|NCT02557022|Glycemic load
81028|NCT02557022|Body weight
81029|NCT02557022|Cardiovascular risk factors
81030|NCT02557022|Cardiovascular disease
81031|NCT02557009|Hemodynamics
81032|NCT02557009|Central Venous Pressure
81033|NCT02557009|Pulmonary Artery Pressure
81034|NCT02557009|Cardiac Output
81035|NCT02556983|Appendicitis
81036|NCT02556983|Tomography, X-Ray Computed
81037|NCT02556983|Receiver operating characteristic (ROC) Curve
81038|NCT02556983|Computer Simulation
81039|NCT02556944|Depth of focus
81040|NCT02556931|immunosuppression
81041|NCT02556931|nonmyeloablative
81042|NCT02556931|non-myeloablative
81043|NCT02556931|allogeneic
81044|NCT02556931|tacrolimus
81045|NCT02556931|peripheral blood
81046|NCT02556931|cyclophosphamide
81047|NCT02556931|mycophenolate mofetil
81048|NCT02556918|Coronary artery bypass graft surgery (CABG)
81049|NCT02556918|Type 2 Diabetes
81050|NCT02556905|Multiple Myeloma
81051|NCT02556905|Revlimid
81052|NCT02556905|Lenalidomide
81053|NCT02556905|Observational
81054|NCT02556905|Korea
81055|NCT02556905|Post Marketing Surveillance[PMS]
81056|NCT02556892|Lymphocytic Leukemia
81057|NCT02556892|Ibrutinib
81058|NCT02556892|PCI-32765
81059|NCT02556892|JNJ-54179060
81060|NCT02556879|Liver transplantation
81061|NCT02556879|Graft failure
81062|NCT02556879|Donor specific antibodies
81063|NCT02556853|Ultrasound
81064|NCT02556853|Double lumen tube
81065|NCT02556840|Monogenic diabetes
81066|NCT02556840|maturity-onset diabetes of the young
81067|NCT02556840|MODY
81068|NCT02556840|Pregnancy
81069|NCT02556840|Gestational diabetes
81070|NCT02556840|Glucokinase
81448|NCT02554474|Rheumatoid
81071|NCT02556840|Insulin therapy during pregnancy
81072|NCT02556840|Evaluation of fetal growth by ultrasonography measurements
81073|NCT02556827|demodex
81074|NCT02556827|oxidative stress
81075|NCT02556827|reflectance confocal microscopy
81076|NCT02556814|ITP
81077|NCT02556814|Caffeic Acid
81078|NCT02556814|dexamethasone
81079|NCT02556801|Sublingual immunotherapy
81080|NCT02556801|Dose range finding
81081|NCT02556801|Grass pollen
81082|NCT02556801|Allergic rhinitis/rhinoconjunctivitis
81083|NCT02556801|Immunogenicity
81084|NCT02556788|Efficacy
81085|NCT02556788|Safety
81086|NCT02556788|Acne vulgaris
81087|NCT02556762|Esophageal cancer
81088|NCT02556762|Simultaneous modulated accelerated boost
81089|NCT02556762|Standard dose radiotherapy
81090|NCT02556762|Chemotherapy
81091|NCT02556762|Survival
81092|NCT02556749|Cranberries
81093|NCT02556749|blood pressure
81094|NCT02556749|cholesterol
81095|NCT02556749|SphygmoCor
81096|NCT02556736|gene therapy
81097|NCT02556736|optogenetics
81098|NCT02556736|channelrhodopsin
81099|NCT02556736|retina
81100|NCT02556736|retinitis pigmentosa
81101|NCT02556710|Osteoarthritis
81102|NCT02556710|Osteoarthritis of the Knee
81103|NCT02556684|Breast-Specific Gamma Imaging
81104|NCT02556684|Locally Advanced Breast Cancer
81105|NCT02556684|Neoadjuvant Chemotherapy
81106|NCT02556684|BSGI
81107|NCT02556658|Smartpilot View
81108|NCT02556658|Hip fracture surgery
81109|NCT02556658|Depth of anaesthesia
81110|NCT02556658|Intraoperative hypotension
81111|NCT02556658|Quality of anaesthesia
81112|NCT02556645|Combat
81113|NCT02556645|Psychological Treatment
81114|NCT02556645|Military
81115|NCT02556645|Psychotherapy
81116|NCT02556645|Trauma
81117|NCT02556645|Posttraumatic Stress
81118|NCT02556645|Posttraumatic Stress Disorder
81119|NCT02556619|Liver Cancer
81120|NCT02556619|Randomized Control Trial
81121|NCT02556619|Palliative Care
81122|NCT02556619|Liver Cell Carcinoma
81123|NCT02556619|Palliative Therapy
81124|NCT02556606|ketamine
81125|NCT02556606|depression
81126|NCT02556606|treatment resistant
81127|NCT02556606|treatment resistant depression
81128|NCT02556606|late life depression
81129|NCT02556606|depression in the elderly
81130|NCT02556606|geriatric depression
81131|NCT02556593|Non-Small Cell Lung Cancer
81132|NCT02556593|IMRT
81133|NCT02556593|erlotinib
81134|NCT02556593|whole-brain radiotherapy
81135|NCT02556580|albumin
81136|NCT02556580|surgery
81137|NCT02556580|inflammation
81138|NCT02556580|volume kinetics
81139|NCT02556567|Sleep patterns
81140|NCT02556567|Physical activity
81141|NCT02556567|Fitbit
81142|NCT02556515|CMC1
81143|NCT02556515|arthritis
81144|NCT02556515|degenerative arthritis
81145|NCT02556515|thumb
81146|NCT02556515|interpositional arthroplasty
81147|NCT02556515|total joint replacement
81148|NCT02556489|immunological memory
81149|NCT02556476|critical care
81150|NCT02556476|intensive care
81151|NCT02556476|health related quality of life
81152|NCT02556476|cost benefit analysis
81153|NCT02556463|MEDI9197
81154|NCT02556463|TLR 7/8 Agonist
81155|NCT02556437|Subcutaneous immunoglobulin
81156|NCT02556437|MMN
81157|NCT02556424|Ophthalmology
81158|NCT02556424|Uveitic macular edema
81159|NCT02556424|Triamcinolone subconjunctival injection
81160|NCT02556424|Dexamethasone intraocular implant
81161|NCT02556372|AIH
81162|NCT02556372|JKB-122
81163|NCT02556372|autoimmune
81164|NCT02556372|hepatitis
81165|NCT02556346|CD20
81166|NCT02556346|immunotoxin
81167|NCT02556346|CLL
81168|NCT02556346|SLL
81169|NCT02556346|leukemia
81170|NCT02556346|lymphocytic lymphoma
81171|NCT02556346|lymphocytic leukemia
81172|NCT02556346|MT-3724
81173|NCT02556346|relapsed
81174|NCT02556346|refractory
81175|NCT02556346|immunotherapy
81176|NCT02556346|cancer
81177|NCT02556346|antibodies
81178|NCT02556346|safety
81179|NCT02556346|pharmacokinetics
81180|NCT02556333|TAF
81181|NCT02556333|F/TAF
81182|NCT02556333|ART
81183|NCT02556333|TDF
81184|NCT02556333|DOT
81185|NCT02556294|HIV risk behavior
81186|NCT02556268|Single-Dose, Open-Label, Non-Blinded, Non-Placebo-
81187|NCT02556268|Controlled, Stratified Design
81188|NCT02556255|Peripheral Arterial Disease
81189|NCT02556255|Peripheral Artery Disease
81190|NCT02556255|PAD
81191|NCT02556255|Atherosclerosis
81192|NCT02556255|Arterial Occlusive Diseases
81193|NCT02556255|Peripheral Vascular Diseases
81194|NCT02556255|PVD
81195|NCT02556242|vector control
81196|NCT02556242|insecticide
81197|NCT02556229|Aflibercept
81198|NCT02556229|inflammatory choroidal neovascularization
81199|NCT02556229|young patient
81200|NCT02556216|bone biopsy; bone density
81201|NCT02556203|TAVR
81202|NCT02556203|TAVI
81203|NCT02556203|Transfemoral aortic valve implantation
81204|NCT02556177|TBI
81205|NCT02556177|MR
81206|NCT02556177|mTBI
81207|NCT02556177|NFL
81208|NCT02556177|MRI
81209|NCT02556164|Electroacupuncture
81210|NCT02556164|Body Worn Sensor
81211|NCT02556164|Gait
81212|NCT02556164|Balance
81213|NCT02556138|Intragastric Balloon
81214|NCT02556138|ORBERA Intragastric Balloon
81215|NCT02556138|Weight Loss
81216|NCT02556138|BMI >35
81217|NCT02556125|SCI
81218|NCT02556125|Respiratory impairment
81219|NCT02556125|Diaphragm pacing
81220|NCT02556125|Diaphragm stimulation
81221|NCT02556073|asthma control
81222|NCT02556073|adherence
81223|NCT02556073|asthma self management plan
81224|NCT02556073|airway inflammation
81225|NCT02556060|ketamine use disorder
81226|NCT02556060|lamotrigine
81227|NCT02556060|craving
81228|NCT02556008|Children
81229|NCT02556008|Epilepsy
81230|NCT02556008|Cannabidiol
81231|NCT02555995|AMD
81232|NCT02555995|OCT
81233|NCT02555982|Essential Head tremor
81234|NCT02555982|Botulinum toxin injections
81235|NCT02555982|Quality of life
81236|NCT02555982|Embarrassment assessment
81237|NCT02555956|Macular grid
81238|NCT02555956|Subthreshold
81239|NCT02555956|diabetic macular edema
81240|NCT02555956|decrease in visual acuity
81241|NCT02555891|Prescriptions
81242|NCT02555891|Epidemiology
81243|NCT02555891|Health Administration Databases
81244|NCT02555891|Elderly
81245|NCT02555891|STOPP/START criteria
81246|NCT02555878|Cancer
81247|NCT02555878|Rivaroxaban
81248|NCT02555878|Venous thromboembolism
81249|NCT02555865|etiology
81250|NCT02555865|children
81251|NCT02555852|Proton Pump Inhibitors
81252|NCT02555852|Pneumonia
81253|NCT02555852|NSAIDs
81254|NCT02555852|Histamine H2 Antagonists
81255|NCT02555852|Drug safety
81256|NCT02555839|Relapsed Multiple Myeloma
81257|NCT02555839|Refractory Multiple Myeloma
81258|NCT02555839|Pomalidomide
81259|NCT02555839|Imnovid
81260|NCT02555839|Non-interventional
81261|NCT02555813|Metastatic Pancreatic Cancer
81262|NCT02555813|nab-Paclitaxel
81263|NCT02555813|Gemcitabine
81264|NCT02555813|Non-interventional
81265|NCT02555800|Laryngeal papillomatosis
81266|NCT02555800|Cidofovir
81267|NCT02555800|Bevacizumab
81268|NCT02555800|Recurrent respiratory papillomatosis
81269|NCT02555787|FK506E
81270|NCT02555787|Tacrolimus
81271|NCT02555787|Observational
81272|NCT02555787|Kidney transplantation
81273|NCT02555787|Advagraf
81274|NCT02555774|subjective memory impairment
81275|NCT02555774|cognitive training
81276|NCT02555735|pancreatic cancer
81277|NCT02555696|Metastatic Breast Cancer
81278|NCT02555696|nab-paclitaxel
81279|NCT02555696|Abraxane
81280|NCT02555683|Asthma
81281|NCT02555683|QAW039
81282|NCT02555670|Muscles
81283|NCT02555670|Intensive Care
81284|NCT02555670|Tomography, X-Ray Computed
81285|NCT02555670|Electric Impedance
81286|NCT02555657|PD1
81287|NCT02555657|PD-1
81288|NCT02555657|PDL1
81289|NCT02555657|PD-LI
81290|NCT02555644|cancer
81291|NCT02555631|type 2 diabetes
81292|NCT02555631|prevention
81293|NCT02555631|men
81294|NCT02555618|Vaccine
81295|NCT02555605|children
81296|NCT02555605|dexmedetomidine
81297|NCT02555605|magnetic resonance imaging scans
81298|NCT02555605|deep sedation
81299|NCT02555605|adverse respiratory events
81300|NCT02555553|Cognitive behavioral therapy guided self-help
81301|NCT02555553|Mobile Mental Health
81302|NCT02555553|Binge Eating
81303|NCT02555553|Cognitive Behavioral Therapy
81304|NCT02555553|Eating Disorder Treatment
81305|NCT02555553|Self-monitoring
81306|NCT02555553|Eating Disorders
81307|NCT02555553|Ecological Momentary Intervention
81308|NCT02555501|children
81309|NCT02555501|cancer
81310|NCT02555501|stomatitis
81311|NCT02555501|clinical trial
81312|NCT02555501|laser therapy, low-level
81313|NCT02555501|methylene blue
81314|NCT02555501|photochemotherapy
81315|NCT02555475|Hepatitis C
81316|NCT02555475|primary care
81317|NCT02555397|Prostate Cancer
81318|NCT02555397|Locally Recurrent
81319|NCT02555397|Gene Therapy
81320|NCT02555397|IL-12
81321|NCT02555397|Adenovirus
81322|NCT02555371|Severe eosinophilic asthma
81323|NCT02555371|mepolizumab
81324|NCT02555371|asthma exacerbation
81325|NCT02555358|Resectable advanced gastric cancer
81326|NCT02555345|classic asthma, cough variant asthma,eosinophilic bronchitis
81327|NCT02555319|Pulmonary Valve
81328|NCT02555319|Transcatheter Pulmonary Valve
81329|NCT02555319|Congenital Heart Disease
81330|NCT02555306|Macular Degeneration
81331|NCT02555293|Liver resection
81332|NCT02555293|fibrosis
81333|NCT02555293|inflammation
81334|NCT02555293|Rifaximin
81335|NCT02555267|geriatric assessment
81336|NCT02555267|diffuse large B-cell lymphoma
81337|NCT02555267|activity of daily living
81338|NCT02555267|instrumental activity of daily living
81339|NCT02555267|Charlson's comorbidity index
81340|NCT02555254|cardiac arrest
81341|NCT02555254|targeted temperature management
81342|NCT02555254|hypothermia induced
81343|NCT02555254|shockable rhythm
81344|NCT02555241|ASD, Children
81345|NCT02555228|simethicone
81346|NCT02555228|gastroscopy
81347|NCT02555228|McNalley score
81348|NCT02555215|Pediatrics
81349|NCT02555202|dyspnea
81350|NCT02555163|bladder cancer, laser
81351|NCT02555137|chronic thromboembolic pulmonary hypertension
81352|NCT02555137|pulmonary embolism
81353|NCT02555137|pulmonary hypertension
81354|NCT02555137|screening
81355|NCT02555137|echocardiography
81356|NCT02555124|Healthy
81357|NCT02555124|JNJ-42847922
81358|NCT02555111|thrombosis
81359|NCT02555072|Yellow Fever Vaccine, immunity evolution
81360|NCT02555059|Ciprofloxacin
81361|NCT02555059|Japan
81362|NCT02555059|Post-marketing surveillance
81363|NCT02555046|Spectroscopy, Near-Infrared
81364|NCT02555046|Endovascular Procedures
81365|NCT02555046|Local Anesthesia
81366|NCT02555046|General Anesthesia
81367|NCT02555033|Instability resistance training
81368|NCT02555033|unstable surface
81369|NCT02555033|elderly people
81370|NCT02554994|ASPRA cohort
81371|NCT02554994|multifactorial intervention
81372|NCT02554994|Medicaid services
81373|NCT02554994|Geriatric disorder
81374|NCT02554994|Short Physical Performance Battery
81375|NCT02554929|Social Anxiety Disorder
81376|NCT02554929|Selective Mutism
81377|NCT02554929|CBT
81378|NCT02554929|preschool anxiety disorders
81379|NCT02554916|Mobility decline
81380|NCT02554903|LVAD
81381|NCT02554890|Acute
81382|NCT02554890|Heart Failure
81383|NCT02554890|reduced ejection fraction
81384|NCT02554890|NTproBNP
81385|NCT02554890|Heart failure with reduced ejection fraction (HFREF)
81386|NCT02554838|Specific phobia
81387|NCT02554838|Fear of Falling
81388|NCT02554838|Life-space area
81389|NCT02554812|anti PD-L1
81390|NCT02554812|anti 4-1BB
81391|NCT02554812|Non-small cell lung cancer (NSCLC)
81392|NCT02554812|melanoma
81393|NCT02554812|squamous cell carcinoma of head and neck (SCCHN)
81394|NCT02554812|triple negative breast cancer (TNBC)
81395|NCT02554812|colorectal cancer (CRC)
81396|NCT02554786|QMF149, Mometasone furoate (MF), asthma
81397|NCT02554773|Hemophilia
81398|NCT02554773|RNAi therapeutic
81399|NCT02554721|Healthy Volunteers
81400|NCT02554708|Aneurysm
81401|NCT02554708|bifurcation
81402|NCT02554708|wide neck
81403|NCT02554708|pCONus
81404|NCT02554708|intracerebral
81405|NCT02554708|stroke
81406|NCT02554695|adrenergic
81407|NCT02554682|Adolescent Health
81408|NCT02554682|Sexual Health
81409|NCT02554682|Parent-Teen Communication
81410|NCT02554682|Teen Driving
81411|NCT02554682|Alcohol Prevention
81412|NCT02554669|Blood glucose (indicated by interstitial glucose)
81413|NCT02554669|Markers of systemic inflammation
81414|NCT02554643|intermittent exercise
81415|NCT02554643|continuous exercise
81416|NCT02554643|blood glucose
81417|NCT02554643|intramyocellular lipids
81418|NCT02554643|diabetes
81419|NCT02554643|gene expression
81420|NCT02554617|healthy people
81421|NCT02554617|fractional exhaled nitric oxide (FeNo)
81422|NCT02554617|factors
81423|NCT02554604|HDL
81424|NCT02554604|Preeclampsia
81425|NCT02554604|saliva
81426|NCT02554578|mHealth
81427|NCT02554578|multidisciplinary team
81428|NCT02554578|immunosuppressive medication
81429|NCT02554578|pharmaceutical care
81430|NCT02554578|adherence
81431|NCT02554578|heart transplant
81432|NCT02554578|recipients
81433|NCT02554565|Patients with cervical cancer
81434|NCT02554552|Osteoarthritis
81435|NCT02554526|hemophilia A
81436|NCT02554526|inhibitor
81437|NCT02554526|bypassing therapy
81438|NCT02554526|factor VIII
81439|NCT02554513|Apraxia of Speech
81440|NCT02554513|Treatment
81441|NCT02554487|stroke
81442|NCT02554487|sleep disordered breathing
81443|NCT02554487|sleep apnea
81444|NCT02554487|infarct volume
81445|NCT02554487|penumbra
81446|NCT02554474|Physical activity
81447|NCT02554474|Exercise
81449|NCT02554474|Arthritis
81450|NCT02554474|Lupus
81451|NCT02554474|SLE
81452|NCT02554448|Circulating Tumor Cells
81453|NCT02554448|rectal Neoplasms
81454|NCT02554448|neoadjuvant otherapy
81455|NCT02554435|physical activity
81456|NCT02554435|activity monitor
81457|NCT02554435|older adults
81458|NCT02554435|5 A's counseling
81459|NCT02554409|Fluzone Quadrivalent Intradermal Influenza Vaccine
81460|NCT02554409|Pregnancy Registry
81461|NCT02554409|Influenza
81462|NCT02554396|ophthalmology
81463|NCT02554396|vision
81464|NCT02554396|ocular
81465|NCT02554383|pediatrics
81466|NCT02554383|antibiotics
81467|NCT02554383|placebo
81468|NCT02554344|CIN3
81469|NCT02554344|Squamous CIN3
81470|NCT02554331|Gait
81471|NCT02554331|REM sleep behavior disorder
81472|NCT02554331|Parkinson's disease
81473|NCT02554331|Follow-up
81474|NCT02554318|Tempeh
81475|NCT02554318|Body weight
81476|NCT02554318|Handgrip strength
81477|NCT02554318|6MWT
81478|NCT02554318|Supplementation
81479|NCT02554318|Wasting
81480|NCT02554305|efficacy and safety of fusion Oxygenation System
81481|NCT02554305|isolated Coronary Artery Bypass Grafting
81482|NCT02554305|Bypass Grafting
81483|NCT02554227|Spondylodiscitis
81484|NCT02554227|erosive osteochondrosis
81485|NCT02554227|infection
81486|NCT02554227|cytokine profiles
81487|NCT02554227|lumbar spine
81488|NCT02554201|pudendal nerve modulation
81489|NCT02554201|transanal/transvaginal electrical stimulation
81490|NCT02554188|Dietary Intervention
81491|NCT02554188|Fasting-mimicking
81492|NCT02554188|Influenza Vaccines
81493|NCT02554175|Propofol
81494|NCT02554175|Schnider model
81495|NCT02554162|Satiety, appetite, wholegrain rye
81496|NCT02554149|total hip
81497|NCT02554149|stem version
81498|NCT02554149|replacement
81499|NCT02554149|hip
81500|NCT02554097|laparoscopic transcystic common bile duct exploration
81501|NCT02554097|laparoscopic common bile duct exploration
81502|NCT02554097|endoscopic sphincterotomy,
81503|NCT02554097|cost-effective analysis
81504|NCT02554058|Spinal cord injury
81505|NCT02554058|rehabilitation
81506|NCT02554058|cycling
81507|NCT02554032|antegrade cerebral perfusion
81508|NCT02554032|innominate artery cannulation
81509|NCT02554032|axillary artery cannulation
81510|NCT02554032|aortic surgery
81511|NCT02554032|deep hypothermic circulatory arrest
81512|NCT02554019|SLE, Lupus
81513|NCT02554019|IL10, IL-10, BT063, BT-063
81514|NCT02553993|Stroke
81515|NCT02553993|Cognition
81516|NCT02553993|Exergames
81517|NCT02553993|Weight shifting
81518|NCT02553993|Balance
81519|NCT02553993|Rehabilitation
81520|NCT02553980|Physical activity
81521|NCT02553980|Information technology
81522|NCT02553980|Middle-aged
81523|NCT02553980|Health promotion
81524|NCT02553967|functional Magnetic Resonance Imaging (fMRI)
81525|NCT02553967|Breast reconstructive surgery
81526|NCT02553967|Breast Q questionnaire
81527|NCT02553954|Mechanisms of Senescence
81528|NCT02553954|Senescence markers
81529|NCT02553915|Omega-3
81530|NCT02553915|EPA
81531|NCT02553915|Depression
81532|NCT02553915|Overweight
81533|NCT02553915|Inflammation
81534|NCT02553915|Eicosapentaenoic acid
81535|NCT02553876|neurostimulation
81536|NCT02553876|dorsal root ganglion
81537|NCT02553876|hand pain
81538|NCT02553876|upper limb pain
81539|NCT02553863|chemotherapy induced peripheral neuropathy
81540|NCT02553863|acupuncture
81541|NCT02553863|pain
81542|NCT02553863|cost-effectiveness
81543|NCT02553837|Healthy Volunteers
81544|NCT02553824|binge eating
81545|NCT02553824|bulimia nervosa
81546|NCT02553824|binge eating disorder
81547|NCT02553824|eating disorder treatment
81548|NCT02553811|carpal tunnel syndrome
81549|NCT02553811|clinical examination
81550|NCT02553811|diagnosis
81551|NCT02553811|clinical trial
81552|NCT02553811|median nerve compression
81553|NCT02553811|accuracy
81554|NCT02553811|ultrasonography
81555|NCT02553811|electromyography
81556|NCT02553811|electrodiagnostic testing
81557|NCT02553785|BioVentrix
81558|NCT02553785|Revivent
81559|NCT02553785|Revivent TC
81560|NCT02553759|observed action
81561|NCT02553759|range of motion
81562|NCT02553759|mirror neuron
81563|NCT02553746|Ultrasound
81564|NCT02553746|Spinal anesthesia
81565|NCT02553746|Epidural anesthesia
81566|NCT02553733|Dietary nitrate supplementation
81567|NCT02553733|Beetroot juice
81568|NCT02553720|Post thrombotic syndrome
81569|NCT02553720|Chronic venous insufficiency
81570|NCT02553694|OSA, Apnea
81571|NCT02553668|Proteomics
81572|NCT02553668|Oxygen
81573|NCT02553668|Pathways
81574|NCT02553642|Tumor Mutation
81575|NCT02553642|Nivolumab
81576|NCT02553642|Nivolumab plus Ipilimumab
81577|NCT02553642|Predicted Neo-antigen Burden
81578|NCT02553642|15-126
81579|NCT02553590|Non Interventional Study
81580|NCT02553590|NIS
81581|NCT02553590|sublingual immunotherapy
81582|NCT02553590|allergen
81583|NCT02553590|tree
81584|NCT02553590|birch
81585|NCT02553590|alder
81586|NCT02553577|prenatal
81587|NCT02553577|cytokines
81588|NCT02553538|cancer screening
81589|NCT02553538|patient navigation
81590|NCT02553525|Deep Brain Stimulation
81591|NCT02553525|Movement Disorders
81592|NCT02553525|Parkinson Disease
81593|NCT02553525|Essential Tremor
81594|NCT02553525|Subthalamic Nucleus
81595|NCT02553525|Globus Pallidus
81596|NCT02553525|Thalamus
81597|NCT02553525|Tremor
81598|NCT02553525|Bradykinesia
81599|NCT02553525|Temporal Pattern
81600|NCT02553525|Electrical Stimulation
81601|NCT02553525|Neuromodulation
81602|NCT02553525|PD
81603|NCT02553525|ET
81604|NCT02553525|MS
81605|NCT02553525|STN
81606|NCT02553525|GPi
81607|NCT02553525|DBS
81608|NCT02553525|Nervous System Diseases
81609|NCT02553525|Neurodegenerative Diseases
81610|NCT02553499|Solid tumor
81611|NCT02553499|PD1
81612|NCT02553499|PD-L1
81613|NCT02553499|PDL1
81614|NCT02553486|adoption
81615|NCT02553486|children
81616|NCT02553486|quality of life
81617|NCT02553460|Infants
81618|NCT02553434|pigtail catheter
81619|NCT02553434|small-bore catheter
81620|NCT02553434|trauma
81621|NCT02553434|hemothorax
81622|NCT02553421|infiltration
81623|NCT02553421|extravasation
81624|NCT02553421|peripheral intravenous therapy
81625|NCT02553356|Female Subjects
81626|NCT02553343|Influenza
81627|NCT02553343|High-Dose Quadrivalent Influenza Vaccine
81628|NCT02553343|High-Dose Trivalent Influenza Vaccine
81629|NCT02553330|Hair loss
81630|NCT02553330|alopecia areata
81631|NCT02553330|alopecia totalis
81632|NCT02553330|alopecia universalis
81633|NCT02553330|JAK inhibitors
81634|NCT02553330|topical hair growth
81635|NCT02553278|abdominoplasty
81636|NCT02553265|Familial dysautonomia (HSAN III)
81637|NCT02553265|Norepinephrine
81638|NCT02553265|Sympathetic nervous system
81639|NCT02553265|Autonomic nervous system
81640|NCT02553265|Blood pressure variability
81641|NCT02553265|Hypertension
81642|NCT02553265|Carbidopa/Lodosyn
81643|NCT02553265|Afferent baroreflex failure
81644|NCT02553265|Clinical trial
81645|NCT02553252|post traumatic stress disorder (PTSD)
81646|NCT02553252|Sudarshan Kriya Yoga (SKY)
81647|NCT02553239|Atrial Fibrillation
81648|NCT02553239|Paroxysmal
81649|NCT02553239|Cryoablation
81650|NCT02553226|Active phase of labour
81651|NCT02553226|Discontinuation
81652|NCT02553226|Caesarean section
81653|NCT02553200|intubated patients
81654|NCT02553200|secretion clearance
81655|NCT02553200|lung function
81656|NCT02553200|breathing exercise
81657|NCT02553161|Depression
81658|NCT02553148|prevalence
81659|NCT02553148|epidemiology
81660|NCT02553148|palliative care
81661|NCT02553148|pediatric
81662|NCT02553135|choroideremia, gene therapy
81663|NCT02553122|Blood Loss
81664|NCT02553122|Tranexamic Acid
81665|NCT02553122|Evicel
81666|NCT02553109|small paraclinoid
81667|NCT02553096|exacerbations
81668|NCT02553096|self-management support
81669|NCT02553096|software application
81670|NCT02553031|Application of MR-PET
81671|NCT02553005|Acupuncture
81672|NCT02553005|Rheumatoid Arthritis
81673|NCT02553005|Quality of life
81674|NCT02553005|Hand Strength
81675|NCT02552979|atopic dermatitis
81676|NCT02552979|atopic patch test
81677|NCT02552927|PDA
81678|NCT02552927|Jaundice
81679|NCT02552927|Phototherapy
81680|NCT02552914|Colli-Pee
81681|NCT02552914|STI
81682|NCT02552914|first-void urine
81683|NCT02552901|hepatic
81684|NCT02552901|liver
81685|NCT02552901|LFT
81686|NCT02552901|hepatic assessment
81687|NCT02552901|ICG dye
81688|NCT02552901|indocyanine green dye
81689|NCT02552901|Diagnostic Green
81690|NCT02552901|Pulsion
81691|NCT02552901|Akorn
81692|NCT02552901|Cardiox
81693|NCT02552901|anazen
81694|NCT02552901|essence
81695|NCT02552901|dye detection monitor
81696|NCT02552901|Earpads
81697|NCT02552901|flow sensor
81698|NCT02552901|scaphoid fossa
81699|NCT02552901|liver disease
81700|NCT02552901|acute hepatic failure
81701|NCT02552901|AHF
81702|NCT02552901|NASH
81703|NCT02552901|hepatitis C
81704|NCT02552901|cirrhosis
81705|NCT02552901|MELD
81706|NCT02552901|pulse dye densitometry
81707|NCT02552901|liver transplant
81708|NCT02552901|fluorescence
81709|NCT02552901|near infra-red
81710|NCT02552901|serial blood draws
81711|NCT02552901|PDR
81712|NCT02552901|plasma disappearance rate
81713|NCT02552901|R15
81714|NCT02552901|k coefficient
81715|NCT02552901|transcutaneously
81716|NCT02552901|liver donor
81717|NCT02552901|liver dysfunction
81718|NCT02552901|Child-Pugh
81719|NCT02552901|AST
81720|NCT02552901|ALT
81721|NCT02552901|GGT
81722|NCT02552901|alk phos
81723|NCT02552901|prothrombin time
81724|NCT02552901|albumin
81725|NCT02552901|serum ICG
81726|NCT02552901|liver function tests
81727|NCT02552888|Endothelial Dysfunction
81728|NCT02552888|Inflammation
81729|NCT02552875|Acceleromyography
81730|NCT02552875|staircase phenomenon
81731|NCT02552875|tetanic stimulation
81732|NCT02552797|Shared Decision Making
81733|NCT02552797|CAMHS
81734|NCT02552758|violence
81735|NCT02552758|PET
81736|NCT02552758|omega-3 fatty acid
81737|NCT02552758|schizophrenia
81738|NCT02552758|patient
81739|NCT02552719|Injustice Experience
81740|NCT02552719|Questionnaire
81741|NCT02552719|Validation
81742|NCT02552719|German translation
81743|NCT02552706|probiotics
81744|NCT02552706|preterm very low birth weight infants
81745|NCT02552706|necrotizing enterocolitis
81746|NCT02552706|gut microflora
81747|NCT02552706|TLR
81748|NCT02552706|NF-KB
81749|NCT02552706|inflammatory factors
81750|NCT02552693|Enhancing retention
81751|NCT02552680|Work-Related Musculoskeletal Disorders
81752|NCT02552680|Quality of life
81753|NCT02552680|Health Education
81754|NCT02552667|Asthma
81755|NCT02552667|Allergic rhinitis
81756|NCT02552628|Wilson's Disease
81757|NCT02552628|Deep Brain Stimulation
81758|NCT02552628|dystonia
81759|NCT02552615|scoliosis, verticality perception, body symmetry
81760|NCT02552602|HIV
81761|NCT02552602|Multivitamins
81762|NCT02552589|clinical trial, phase III
81763|NCT02552589|plaque index
81764|NCT02552589|gingivitis index
81765|NCT02552589|fluoride
81766|NCT02552589|toothpaste
81767|NCT02552550|squamous cell carcinoma of the oropharynx
81768|NCT02552550|swallowing, speech
81769|NCT02552550|quality of life
81770|NCT02552524|pathological gambling
81771|NCT02552524|rTMS
81772|NCT02552524|cognitive tests
81773|NCT02552524|autonomic nervous system
81774|NCT02552524|craving
81775|NCT02552472|Asthma
81776|NCT02552472|Inhaler Use
81777|NCT02552472|Adherence
81778|NCT02552472|Chronic Obstructive Pulmonary Disease
81779|NCT02552459|dexmedetomidine
81780|NCT02552459|patient controlled analgesia
81781|NCT02552433|nutritional deficiencies
81782|NCT02552433|plastic surgery
81783|NCT02552433|post-bariatric
81784|NCT02552433|protein
81785|NCT02552433|skin surplus
81786|NCT02552420|infrared thermal imaging
81787|NCT02552420|deep venous thrombosis
81788|NCT02552407|thrombectomy
81789|NCT02552407|acute coronary syndromes
81790|NCT02552407|percutaneous coronary intervention
81791|NCT02552407|STEMI
81792|NCT02552381|Cancer
81793|NCT02552381|Thromboembolic event
81794|NCT02552381|Fibrin Structure
81795|NCT02552381|LMWH
81796|NCT02552368|Stroke Rehabilitation
81797|NCT02552368|BCI
81798|NCT02552368|Stroke
81799|NCT02552368|Upper Extremity Rehabilitation
81800|NCT02552368|paresis
81801|NCT02552368|hemiparesis
81802|NCT02552329|mild cognitive impairment
81803|NCT02552329|Tai Chi
81804|NCT02552329|cognitive functions
81805|NCT02552316|microbiome
81806|NCT02552316|bacteria
81807|NCT02552316|NB-UVB Phototherapy
81808|NCT02552316|light therapy
81809|NCT02552277|Diabetic
81810|NCT02552277|PDA-002
81811|NCT02552277|Placenta-Derived Cells
81812|NCT02552277|Peripheral neuropathy
81813|NCT02552277|Neuropathy
81814|NCT02552277|Double-Blind
81815|NCT02552277|Safety
81816|NCT02552277|Efficacy
81817|NCT02552277|Human Placenta-derived Cells
81818|NCT02552238|Lumason
81819|NCT02552238|Dobutamine stress echo
81820|NCT02552238|stress echo
81821|NCT02552238|coronary artery disease
81822|NCT02552225|laryngeal sensory neuropathy, chronic laryngeal neuropathy
81823|NCT02552212|Axial Spondyloarthritis
81824|NCT02552212|axSpA
81825|NCT02552212|Ankylosing Spondylitis
81826|NCT02552212|Anti TNF-alpha
81827|NCT02552212|Certolizumab Pegol
81828|NCT02552212|Nr-axSpA
81829|NCT02552212|Non-radiographic
81830|NCT02552212|Spondylarthropathies
81831|NCT02552212|Arthritis
81832|NCT02552212|Spinal Diseases
81833|NCT02552212|Immunosuppressive Agents
81834|NCT02552160|Chronic Obstructive Pulmonary Disease
81835|NCT02552160|Fixed-dose Combination
81836|NCT02552160|LAMA/LABA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists)
81837|NCT02552160|Inhaler
81838|NCT02552160|Aclidinium/Formoterol
81839|NCT02552160|Glycopyrronium/Indacaterol
81840|NCT02552160|Umeclidinium/Vilanterol
81841|NCT02552147|Autism spectrum disorder
81842|NCT02552147|Aggression
81843|NCT02552147|Irritability
81844|NCT02552147|Nicotine
81845|NCT02552147|Nicotinic acetylcholine receptor
81846|NCT02552147|Nicotinic agonist
81847|NCT02552147|Adult autism
81848|NCT02552134|Access to physical activity resources, community based exercise programme, sports-clubs, health resort,
81849|NCT02552121|ovary cancer
81850|NCT02552121|cervix cancer
81851|NCT02552121|endometrium cancer
81852|NCT02552121|bladder cancer
81853|NCT02552121|prostate cancer (CRPC)
81854|NCT02552121|esophagus cancer
81855|NCT02552121|lung cancer (NSCLC)
81856|NCT02552108|Cognitive-behavioural therapy
81857|NCT02552056|Child Adolescent Mental Integration PHC Traditional Healers
81858|NCT02552043|Cystic fibrosis
81859|NCT02552043|Exercise capacity
81860|NCT02552043|Interactive gaming console
81861|NCT02552043|Pulmonary rehabilitation
81862|NCT02552017|adenoma detection rate
81863|NCT02552017|Endocuff
81864|NCT02552017|Endocuff Vision
81865|NCT02552017|colonoscopy
81866|NCT02552017|bowel cancer screening
81867|NCT02552017|bowel cancer
81868|NCT02552004|pCLE
81869|NCT02552004|Digestive surgery
81870|NCT02552004|Endocrine surgery
81871|NCT02551991|Pancreatic cancer
81872|NCT02551991|MM-398
81873|NCT02551991|Metastatic pancreatic cancer
81874|NCT02551991|First line pancreatic cancer treatment
81875|NCT02551978|obesity
81876|NCT02551978|child
81877|NCT02551978|primary prevention
81878|NCT02551978|serious game
81879|NCT02551978|nutrition
81880|NCT02551978|physical activity
81881|NCT02551978|psychosocial
81882|NCT02551978|stress
81883|NCT02551978|knowledge
81884|NCT02551978|diet
81885|NCT02551965|Cancer
81886|NCT02551965|Patient
81887|NCT02551965|Oncology
81888|NCT02551965|Caregiver
81889|NCT02551952|Games
81890|NCT02551952|Cognitive Tests
81891|NCT02551952|General Anesthesia
81892|NCT02551952|Surgery
81893|NCT02551913|Psychological Theory
81894|NCT02551913|adolescents
81895|NCT02551900|Type 2 Diabetes
81896|NCT02551900|Vascular Function
81897|NCT02551900|Water Exercise
81898|NCT02551900|Warm Water
81899|NCT02551900|Cold Water
81900|NCT02551887|HPV Vaccinations
81901|NCT02551887|Quadrivalent Vaccine
81902|NCT02551848|Movement disorders
81903|NCT02551848|Botulinum toxin type A
81904|NCT02551848|Kinematics
81905|NCT02551835|ODIN
81906|NCT02551835|Meta-analysis
81907|NCT02551835|Cholecalciferol
81908|NCT02551835|25(OH)D
81909|NCT02551835|Subgroup effects
81910|NCT02551822|Urge Urinary Incontinence, sacral neuromodulation
81911|NCT02551796|lenticule extraction
81912|NCT02551796|laser in situ keratomileusis
81913|NCT02551796|femtosecond laser-assisted laser in situ keratomileusis
81914|NCT02551796|tear
81915|NCT02551796|inflammatory mediators
81916|NCT02551783|urethral stricture
81917|NCT02551783|urethroplasty
81918|NCT02551783|buccal mucosa
81919|NCT02551783|graft
81920|NCT02551757|Rehabilitation
81921|NCT02551757|Continuous Positive Airway Pressure
81922|NCT02551744|histamine-2 receptor antagonist
81923|NCT02551744|proton pump inhibitor
81924|NCT02551744|thienopyridine
81925|NCT02551744|clopidogrel
81926|NCT02551744|prevention
81927|NCT02551679|Stem cells
81928|NCT02551679|Endothelial progenitor cells
81929|NCT02551679|Autologous cells
81930|NCT02551679|Vascular disease
81931|NCT02551679|Peripheral arterial disease
81932|NCT02551679|Regenerative medicine
81933|NCT02551653|Idiopathic Pulmonary Arterial Hypertension
81934|NCT02551653|Biodistribution
81935|NCT02551653|Positron Emission Tomography
81936|NCT02551653|[11C]-GSK2256098
81937|NCT02551653|Healthy subjects
81938|NCT02551614|lipopolysaccharide
81939|NCT02551614|COPD
81940|NCT02551614|neutrophil
81941|NCT02551601|subfoveal choroidal thickness
81942|NCT02551601|optical coherence tomography
81943|NCT02551601|enhanced depth imaging
81944|NCT02551588|fibrosis
81945|NCT02551588|Magnetic resonance imaging
81946|NCT02551549|Subjects
81947|NCT02551536|Allergic rhinitis
81948|NCT02551536|montelukast
81949|NCT02551536|fexofenadine
81950|NCT02551536|levocetrizine
81951|NCT02551510|Skin Adhesive
81952|NCT02551510|Suture
81953|NCT02551510|Port Incisions
81954|NCT02551497|volunteer drug interaction study
81955|NCT02551471|Locally advanced rectal cancer
81956|NCT02551471|Fixed primary rectal cancer
81957|NCT02551471|Pelvic recurrence
81958|NCT02551471|Benchmarking France Australia
81959|NCT02551432|pembrolizumab
81960|NCT02551432|paclitaxel
81961|NCT02551419|mild cognitive impairment
81962|NCT02551419|ketones
81963|NCT02551419|medium chain triglycerides
81964|NCT02551419|Positron emission tomography
81965|NCT02551419|magnetic resonance imaging
81966|NCT02551419|cognition
81967|NCT02551419|brain
81968|NCT02551419|neuroimaging
81969|NCT02551406|nocturnal hypoventilation
81970|NCT02551406|capno-oxymetry
81971|NCT02551393|Older adults
81972|NCT02551393|Home Blood Pressure Monitoring
81973|NCT02551367|letrozole
81974|NCT02551354|Labor, Obstetric
81975|NCT02551354|pain
81976|NCT02551354|pupil diameter
81977|NCT02551354|Visual Analogic Scale (VAS)
81978|NCT02551341|prostatectomy
81979|NCT02551341|robotic
81980|NCT02551315|Intra-cortical pore volume
81981|NCT02551315|HR-pQCT
81982|NCT02551315|DXA
81983|NCT02551315|bone mineral density
81984|NCT02551315|bone turnover markers
81985|NCT02551315|urinary pentosidine
81986|NCT02551289|MRI
81987|NCT02551289|Gluten
81988|NCT02551289|Imaging
81989|NCT02551289|Enteropathy-Associated T-Cell Lymphoma
81990|NCT02551263|Breast Cancer
81991|NCT02551263|Eribulin
81992|NCT02551263|HER2-negative
81993|NCT02551263|hormone-resistant
81994|NCT02551263|inoperable
81995|NCT02551263|recurrent metastatic
81996|NCT02551250|hepatocellular carcinoma
81997|NCT02551250|surveillance
81998|NCT02551250|liver cirrhosis
81999|NCT02551250|ultrasonography
82000|NCT02551250|magnetic resonance imaging
82001|NCT02551237|Elderly patient
82002|NCT02551237|Radiotherapy
82003|NCT02551237|Radio chemotherapy
82004|NCT02551237|Neoadjuvant treatment
82005|NCT02551224|COPD
82006|NCT02551198|polyethylene glycol with ascorbic acid
82007|NCT02551198|oral sulfate solution
82008|NCT02551198|bowel preparation
82009|NCT02551159|programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN
82010|NCT02551133|Dexamethasone
82011|NCT02551133|mastectomy
82012|NCT02551133|persistent surgical pain
82013|NCT02551120|Idiopathic hypoparathyroidism
82014|NCT02551120|Autosomal dominant hypocalcaemia
82015|NCT02551120|Pseudohypoparathyroidism
82016|NCT02551120|Quality of Life
82017|NCT02551120|Bone Mineral Density
82018|NCT02551120|Muscle strength
82019|NCT02551120|Cardiovascular indices
82020|NCT02551055|Drug Therapy
82021|NCT02551042|Digital Ulcers
82022|NCT02551042|Raynauds Phenomenon
82023|NCT02551042|Factor XIII
82024|NCT02551029|Magnetic Resonance Imaging
82025|NCT02551029|Brainstem
82026|NCT02551029|Solitary Nucleus
82027|NCT02551029|Visceral Nervous System
82028|NCT02551029|Transient Receptor Potential Channels
82029|NCT02550977|Contraception
82030|NCT02550977|Transdermal contraceptive patch
82031|NCT02550977|Safety
82032|NCT02550977|Efficacy
82033|NCT02550977|Pharmacokinetic
82034|NCT02550964|Autoimmune Disease
82035|NCT02550964|Rheumatoid Arthritis
82036|NCT02550964|Systemic Lupus Erythematosus
82037|NCT02550964|Hydroxychloroquine(HCQ)
82038|NCT02550964|Chloroquine(CQ)
82039|NCT02550964|Toxic Maculopathy
82040|NCT02550925|Cancer survivors
82041|NCT02550886|Work Burden
82042|NCT02550886|Ambulatory Orthopedic Surgery
82043|NCT02550886|Anesthesiology
82044|NCT02550886|Perioperative Care
82045|NCT02550860|intravenous fat emulsions
82046|NCT02550860|parenteral nutrition
82047|NCT02550860|skin barrier function
82048|NCT02550860|essential fatty acids
82049|NCT02550860|transepidermal water loss
82050|NCT02550847|MR/PET
82051|NCT02550847|pancreatic cancer
82052|NCT02550834|Core stability
82053|NCT02550834|Indoors curling exercises
82054|NCT02550834|Motivation
82055|NCT02550821|Physical activity levels
82056|NCT02550821|Bronchiectasis
82057|NCT02550782|perineural dexmedetomidine
82058|NCT02550782|infraclavicular perineural catheter
82059|NCT02550782|postoperative analgesia
82060|NCT02550769|Transanal NOTES
82061|NCT02550769|Transanal TME
82062|NCT02550769|Laparoscopic Low Anterior Resection
82063|NCT02550769|Surgery
82064|NCT02550717|Low-dose Acetylsalicylic Acid,
82065|NCT02550717|Bleeding,
82066|NCT02550717|The Health Improvement Network (THIN),
82067|NCT02550717|Cardiovascular
82068|NCT02550717|Secondary prevention of cardiovascular events
82069|NCT02550704|Irritable Bowel syndrome
82070|NCT02550704|Intestinal permeability
82071|NCT02550704|Visceral hypersensitivity
82072|NCT02550704|Low grade inflammation
82073|NCT02550678|Untreated nBCC
82074|NCT02550678|Low-Risk
82075|NCT02550665|Alzheimer's disease
82076|NCT02550665|donepezil
82077|NCT02550626|delirium
82078|NCT02550626|alpha synucleinopathy
82079|NCT02550626|spine surgery
82080|NCT02550613|MR/PET, hepatocellular carcinoma, HCC
82081|NCT02550600|ARDS
82082|NCT02550600|Acute lung impairment
82083|NCT02550600|Extracorporeal lung assist
82084|NCT02550600|ECMO
82085|NCT02550600|ECLA
82086|NCT02550600|Murray-score
82087|NCT02550600|SOFA-score
82088|NCT02550587|Patient Satisfaction
82089|NCT02550587|anesthesia Care
82090|NCT02550561|Posterior tibial nerve stimulation
82091|NCT02550561|PTNS
82092|NCT02550561|IC
82093|NCT02550548|Incretins
82094|NCT02550548|GLP-1
82095|NCT02550548|GIP
82096|NCT02550548|hyperglycemic clamp
82097|NCT02550535|Gene Therapy
82098|NCT02550535|WT1 TCR
82099|NCT02550535|Gene modified T cels
82100|NCT02550522|without associated head injury
82101|NCT02550509|stroke
82102|NCT02550509|Botulinum toxin
82103|NCT02550509|Muscle alterations
82104|NCT02550483|Healthy volunteers
82105|NCT02550444|Clonidine
82106|NCT02550444|Anesthesia, Obstetrical
82107|NCT02550379|Social Anxiety
82108|NCT02550379|Social Phobia
82109|NCT02550379|Depression
82110|NCT02550379|Emotion Recognition Training
82111|NCT02550366|Cardiac MRI
82112|NCT02550366|Accelerate imaging
82113|NCT02550366|coronary artery disease
82114|NCT02550353|lenticule extraction
82115|NCT02550353|femtosecond laser-assisted laser in situ keratomileusis
82116|NCT02550353|tear
82117|NCT02550353|inflammatory mediators
82118|NCT02550340|Arrhythmia
82119|NCT02550340|Alcohol
82120|NCT02550340|ECG
82121|NCT02550327|resectable
82122|NCT02550327|potentially resectable
82123|NCT02550327|Pancreatic adenocarcinoma
82124|NCT02550327|PDAC
82125|NCT02550301|mean platelet volume
82126|NCT02550262|Epidural
82127|NCT02550262|Labor analgesia
82128|NCT02550262|Programmed intermittent epidural bolus
82129|NCT02550236|Children
82130|NCT02550236|Obesity
82131|NCT02550236|Pregnancy
82132|NCT02550236|Growth
82133|NCT02550236|Lifestyle
82134|NCT02550236|Metabolic and cardiovascular health
82135|NCT02550236|Birth
82136|NCT02550236|Development
82137|NCT02550210|Breast Conserving Surgery
82138|NCT02550210|Breast Imaging
82139|NCT02550210|Breast Diagnostics
82140|NCT02550197|Influenza
82141|NCT02550197|Quadrivalent influenza vaccine
82142|NCT02550197|Trivalent influenza vaccine
82143|NCT02550184|Patients with symptoms of acute respiratory problems
82144|NCT02550171|Biobank
82145|NCT02550171|Genetics
82146|NCT02550171|DNA
82147|NCT02550171|Cohort
82148|NCT02550171|normal control
82149|NCT02550158|Crohn's Disease
82150|NCT02550158|Ulcerative Colitis
82151|NCT02550158|Educational program
82152|NCT02550158|Inflammatory Bowel Disease
82153|NCT02550158|Psycho-pedagogic score
82154|NCT02550158|IBD
82155|NCT02550145|Hyperinsulinemic
82156|NCT02550145|post-bariatric surgery
82157|NCT02550132|electromyography
82158|NCT02550132|biomechanical phenomena
82159|NCT02550132|dose-response relationship
82160|NCT02550132|musculoskeletal manipulations
82161|NCT02550132|spinal manipulation
82162|NCT02550106|CHRONIC SPONTANEOUS URTICARIA, OMALIZUMAB, URTICARIA CONTROL TEST
82163|NCT02550093|Volunteers
82164|NCT02550067|HIV infection
82165|NCT02550067|DepoLevonorgestrel
82166|NCT02550067|Contraception
82167|NCT02550067|DMPA
82168|NCT02550067|Copper IUD
82169|NCT02550067|Levonorgestrel implant
82170|NCT02550067|IUD
82171|NCT02550041|Bronchitis aspergillus
82172|NCT02550041|cystic fibrosis
82173|NCT02550028|Neonates
82174|NCT02550028|Seizure
82175|NCT02550015|Exercise training
82176|NCT02550015|Oxygen consumption
82177|NCT02549989|LY3023414
82178|NCT02549989|15-079
82179|NCT02549989|Persistent Endometrial Cancer
82180|NCT02549976|Crohn's Disease
82181|NCT02549976|Digestive Damage
82182|NCT02549976|Lemann Index
82183|NCT02549950|Accelerated orthodontic tooth movement (AOTM)
82184|NCT02549950|Peizo-corticission
82185|NCT02549924|Resveratrol
82186|NCT02549924|Glycemic Variability
82187|NCT02549924|MAGE
82188|NCT02549911|chemotherapy
82189|NCT02549911|surgery
82190|NCT02549911|Surgically-Created Resection Cavity
82191|NCT02549911|Adverse Reaction to Drug
82192|NCT02549885|Migraine disorders
82193|NCT02549885|Muscle stretching exercises
82194|NCT02549872|Dementia
82195|NCT02549872|Validity
82196|NCT02549872|Mortality
82197|NCT02549872|Electronic health records
82198|NCT02549859|DBS
82199|NCT02549859|Low frequency stimulation
82200|NCT02549859|Dysphagia
82201|NCT02549859|Freezing of gait
82202|NCT02549833|low-grade glioma
82203|NCT02549833|WHO grade II
82204|NCT02549833|vaccine
82205|NCT02549833|immunotherapy
82206|NCT02549833|glioma
82207|NCT02549820|Congenital Diaphragmatic Hernia
82208|NCT02549820|Tracheal Occlusion
82209|NCT02549807|Vascular hemiplegia
82210|NCT02549807|2D ultrasound
82211|NCT02549807|Muscle elasticity
82212|NCT02549807|Pennation angle
82213|NCT02549794|low concentration contrast agent
82214|NCT02549794|Low dose contrast agent
82215|NCT02549794|computed tomography
82216|NCT02549781|pathological gambler
82217|NCT02549781|Go-Nogo test
82218|NCT02549768|Dexmedetomidine
82219|NCT02549768|Pituitary
82220|NCT02549768|Transsphenoidal
82221|NCT02549768|Cortisol
82222|NCT02549742|Electrochemotherapy
82223|NCT02549742|head neck cancer
82224|NCT02549742|bleomycin
82225|NCT02549716|Acetaminophen
82226|NCT02549716|interleukin-6
82227|NCT02549716|interleukin-1
82228|NCT02549716|thromboxane A2
82229|NCT02549703|multiple sclerosis
82230|NCT02549703|progressive multiple sclerosis
82231|NCT02549703|mitochondria
82232|NCT02549703|neurodegeneration
82233|NCT02549690|IVF, Testosterone gel, DHEA, poor responder.
82234|NCT02549664|Hypertrophic Cardiomyopathy (HCM)
82235|NCT02549664|Long QT Syndrome (LQTS)
82236|NCT02549651|DLBCL
82237|NCT02549651|MEDI4736
82238|NCT02549651|tremelimumab
82239|NCT02549651|AZD9150
82240|NCT02549651|anti-PD-L1
82241|NCT02549651|anti-CTLA-4
82242|NCT02549651|immunotherapy
82243|NCT02549651|IMTC
82244|NCT02549651|STAT3
82245|NCT02549625|Single right ventricular failure
82246|NCT02549612|Conductive hearing loss
82247|NCT02549612|middle ear pressure equalization
82248|NCT02549612|middle ear effusion
82249|NCT02549599|Digital and mobile health
82250|NCT02549599|Sexual and reproductive health
82251|NCT02549599|Adolescents and young adults
82252|NCT02549586|solid organ transplant
82253|NCT02549586|immune tolerance
82254|NCT02549586|autologous stem cell transplant
82255|NCT02549586|blood and marrow transplant
82256|NCT02549586|autoimmune disease
82257|NCT02549573|Motor Symptoms
82258|NCT02549573|Parkinson's disease
82259|NCT02549573|Apokyn
82260|NCT02549573|Apomorphine
82261|NCT02549573|PD
82262|NCT02549560|tDCS
82263|NCT02549560|Cardiac Surgery
82264|NCT02549547|anxiety
82265|NCT02549547|depression
82266|NCT02549547|exercise
82267|NCT02549547|group
82268|NCT02549547|group medical visit
82269|NCT02549547|mood disorder
82270|NCT02549547|physical activity
82271|NCT02549547|primary care
82272|NCT02549534|Taxane
82273|NCT02549534|Neuropathy
82274|NCT02549534|Chemotherapy-Induced Peripheral Neuropathy (CIPN)
82275|NCT02549534|Breast Cancer
82276|NCT02549534|Local skin heating
82277|NCT02549534|Axon reflex
82278|NCT02549534|Axon flare
82279|NCT02549534|Total Neuropathy Score (TNS)
82280|NCT02549534|Laser Doppler Flowmetry (LDF)
82281|NCT02549534|Laser Speckle Contrast Imaging (LSCI)
82282|NCT02549534|Full-field laser perfusion imaging (FLPI)
82283|NCT02549534|Paclitaxel
82284|NCT02549534|Taxol
82285|NCT02549521|calcium
82286|NCT02549521|magnesium
82287|NCT02549521|vitamin D
82288|NCT02549521|bone turnover markers
82289|NCT02549482|Central volume deficit
82290|NCT02549482|Head-up tilt
82291|NCT02549482|Systolic pressure variation
82292|NCT02549456|natural orifice surgery
82293|NCT02549456|natural orifice specimen extraction
82294|NCT02549443|Catabolic response
82295|NCT02549443|Amino Acids
82296|NCT02549443|Insulin
82297|NCT02549430|Advanced breast cancer
82298|NCT02549430|Postmenopausal
82299|NCT02549430|ER positive
82300|NCT02549430|Her2 negative
82301|NCT02549378|microcirculation
82302|NCT02549378|confocal microscopy
82303|NCT02549378|hypocapnia
82304|NCT02549326|Vitamin D
82305|NCT02549313|brain lesion
82306|NCT02549313|intracranial pressure
82307|NCT02549313|cerebral perfusion pressure
82308|NCT02549300|connective tissue massage
82309|NCT02549300|adolescent tension-type headache
82310|NCT02549274|Cervicalgia
82311|NCT02549274|self-rehabilitation
82312|NCT02549274|physiotherapy
82313|NCT02549261|nimotuzumab
82314|NCT02549261|non-small cell lung cancer
82315|NCT02549261|radiochemotherapy
82316|NCT02549261|stage IIIA/IIIB non-small cell lung cancer
82317|NCT02549248|Interstitial Lung Diseases
82318|NCT02549248|nanoparticles
82319|NCT02549248|lung
82320|NCT02549248|broncho-alveolar lavage
82321|NCT02549248|bronchial washings
82322|NCT02549235|IVF
82323|NCT02549235|Miscarriage
82324|NCT02549235|Uterine septum
82325|NCT02549222|pathogen reduction
82326|NCT02549222|INTERCEPT
82327|NCT02549222|platelet
82328|NCT02549222|pulmonary
82329|NCT02549222|ARDS
82330|NCT02549222|hematology
82331|NCT02549222|oncology
82332|NCT02549222|assisted ventilation
82333|NCT02549222|transfusion of platelet components
82334|NCT02549222|hematology-oncology patients
82335|NCT02549209|Pembrolizumab
82336|NCT02549209|Keytruda
82337|NCT02549209|Anti-Programmed [Cell] Death Protein 1 (PD-1) Antibody
82338|NCT02549209|Carboplatin
82339|NCT02549209|Paclitaxel
82340|NCT02549183|Spinal Cord Stimulation
82341|NCT02549170|Autoimmune Diseases
82342|NCT02549170|Polyneuropathies
82343|NCT02549170|Nervous System Diseases
82344|NCT02549170|Peripheral Nervous System Diseases
82345|NCT02549170|Polyradiculoneuropathy
82346|NCT02549170|Autoimmune Diseases of the Nervous System
82347|NCT02549170|Immunoglobulins
82348|NCT02549170|Immune System Diseases
82349|NCT02549170|Demyelinating Diseases
82350|NCT02549170|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
82351|NCT02549170|Neuromuscular Diseases
82352|NCT02549144|HDL biochemical composition and function
82353|NCT02549105|EMLA CREAM
82354|NCT02549105|LIDOCAINE INFILTERATION
82355|NCT02549105|PAIN RELIEF
82356|NCT02549092|carbidopa
82357|NCT02549092|efficacy
82358|NCT02549092|Advanced Parkinson's Disease
82359|NCT02549092|Parkinson's Disease Sleep Scale PDSS-2
82360|NCT02549092|levodopa-carbidopa intestinal gel
82361|NCT02549092|Non-Motor Symptom Scale NMSS
82362|NCT02549092|levodopa
82363|NCT02549066|cardiopulmonary bypass
82364|NCT02549066|renal blood flow
82365|NCT02549066|renal function
82366|NCT02549066|renal oxygenation
82367|NCT02549001|Onychomycosis
82368|NCT02549001|Nail fungus
82369|NCT02548975|Cardiac surgery
82370|NCT02548975|Risk factors
82371|NCT02548975|Postoperative delirium
82372|NCT02548962|Multiple Myeloma
82373|NCT02548962|Bruton's Tyrosine Kinase
82374|NCT02548962|PCI-32765
82375|NCT02548962|Pomalidomide
82376|NCT02548962|Dexamethasone
82377|NCT02548962|Relapsed Refractory Multiple Myeloma
82378|NCT02548962|Ibrutinib
82379|NCT02548936|Cholesterol, LDL
82380|NCT02548936|Carotid Intima-Media Thickness
82381|NCT02548936|Atherosclerosis
82382|NCT02548936|Ezetimibe, Simvastatin Drug Combination
82383|NCT02548936|Lupus Erythematosus, Systemic
82384|NCT02548897|Parkinson's Disease with Freezing of Gait Symptoms
82385|NCT02548858|Perineorrhaphy
82386|NCT02548858|Pelvic organ prolapse
82387|NCT02548858|Vaginal or abdominal reconstruction
82388|NCT02548858|Body image
82389|NCT02548845|hyponatremia
82390|NCT02548845|SIADH
82391|NCT02548845|Oncologic patients
82392|NCT02548832|Berberine
82393|NCT02548832|Bezafibrate
82394|NCT02548806|Clonidine
82395|NCT02548793|Cardiac Arrest
82396|NCT02548793|CPR
82397|NCT02548793|Family-centered Care
82398|NCT02548793|Health Literacy
82399|NCT02548793|Health Education
82400|NCT02548793|Education Dissemination
82401|NCT02548780|unresectable
82402|NCT02548767|High fructose corn syrup
82403|NCT02548767|Sugar
82404|NCT02548754|atrial fibrillation
82405|NCT02548754|neuromodulation
82406|NCT02548754|inflammation
82407|NCT02548741|Metformin
82408|NCT02548741|diabetes
82409|NCT02548741|type 2 diabetes
82410|NCT02548741|diabetes complications
82411|NCT02548741|methylglyoxal
82412|NCT02548741|Prediabetes
82413|NCT02548728|Opioid Dependence
82414|NCT02548728|Opioid Withdrawal
82415|NCT02548728|Opioid
82416|NCT02548728|Oxytocin
82417|NCT02548728|OT (oxytocin)
82418|NCT02548728|Intranasal administration
82419|NCT02548715|thyroxine
82420|NCT02548715|Otolaryngology
82421|NCT02548702|Sport
82422|NCT02548702|type 2 diabetes
82423|NCT02548702|community intervention programme
82424|NCT02548702|Fit4life
82425|NCT02548702|Exercise
82426|NCT02548689|alopecia
82427|NCT02548689|hair loss
82428|NCT02548663|amyotrophic lateral sclerosis
82429|NCT02548663|sport therapy
82430|NCT02548663|osteopathic manual treatment
82431|NCT02548663|muscle oxidative metabolism
82432|NCT02548650|myocardial infarction
82433|NCT02548650|diabetes mellitus
82434|NCT02548650|vorapaxar
82435|NCT02548585|MEDI0382, diabetes
82436|NCT02548572|Transcorneal Electrical Stimulation
82437|NCT02548572|TES
82438|NCT02548572|Retinitis Pigmentosa
82439|NCT02548572|RP
82440|NCT02548416|Atelectasis
82441|NCT02548416|Positive End-Expiratory Pressure
82442|NCT02548416|Oxygenation
82443|NCT02548416|Anaesthesia
82444|NCT02548416|Computed tomography
82445|NCT02548403|Bowel preparation
82446|NCT02548403|Simethicone
82447|NCT02548403|Polyethylene glycol with ascorbic acid
82448|NCT02548390|Phase 1/1b
82449|NCT02548390|open-label
82450|NCT02548390|dose-escalation
82451|NCT02548390|pharmacokinetics
82452|NCT02548390|solid tumor
82453|NCT02548390|metastatic cancer
82454|NCT02548390|chemotherapy
82455|NCT02548390|nano formulation
82456|NCT02548390|alkylator
82457|NCT02548377|Head and Neck Neoplasms
82458|NCT02548377|Surgical Flaps
82459|NCT02548377|Ischemic Preconditioning
82460|NCT02548377|Hemostasis
82461|NCT02548377|Thrombosis
82462|NCT02548377|Immune System
82463|NCT02548377|Reperfusion Injury
82464|NCT02548364|Vitamin D
82465|NCT02548364|Myocardial Infarction
82466|NCT02548364|Ventricular remodeling
82467|NCT02548364|Biomarkers
82468|NCT02548351|Non Alcoholic Steatohepatitis, fatty liver disease, NASH
82469|NCT02548312|Readers' perceptions
82470|NCT02548299|Diabetes
82471|NCT02548299|Cooking
82472|NCT02548299|Nutrition
82473|NCT02548299|Lifestyle Medicine
82474|NCT02548286|Hypertension
82475|NCT02548286|Healthy male volunteer
82476|NCT02548286|Candesartan, Amlodipine
82477|NCT02548273|Corneal endothelium
82478|NCT02548273|phacoemulsification
82479|NCT02548247|Stool frequency
82480|NCT02548247|Bowel motor function
82481|NCT02548247|Orafti® Inulin
82482|NCT02548247|Dietary Fiber
82483|NCT02548234|Stroke
82484|NCT02548234|Randomized control trial
82485|NCT02548234|Mirror therapy
82486|NCT02548234|Bilateral arm training
82487|NCT02548234|Comparative efficacy research
82488|NCT02548234|Neurorehabilitation
82489|NCT02548221|Thoracentesis
82490|NCT02548221|Pleural Effusions
82491|NCT02548221|Transthoracic echocardiogram
82492|NCT02548221|Lung volume measurements
82493|NCT02548195|GEMOX
82494|NCT02548195|intrahepatic cholangiocarcinoma
82495|NCT02548195|adjuvant therapy
82496|NCT02548195|oxaliplatin
82497|NCT02548195|gemcitabine
82498|NCT02548195|capecitabine
82499|NCT02548195|curative surgery
82500|NCT02548169|Dendritic Cell Vaccine
82501|NCT02548169|FOLFIRINOX
82502|NCT02548169|nab-paclitaxel
82503|NCT02548169|gemcitabine
82504|NCT02548117|Testosterone therapy
82505|NCT02548117|erythrocytosis
82506|NCT02548117|finasteride
82507|NCT02548091|non invasive ventilation
82508|NCT02548091|reperfusion pulmonary edema
82509|NCT02548091|chronic thrombolic pulmonary hypertension
82510|NCT02548091|pulmonary artery angioplasty
82511|NCT02548078|Protection against Ebola Zaire virus
82512|NCT02548065|Fibromyalgia Syndrome
82513|NCT02548065|Balneotherapy
82514|NCT02548065|Vetriolo Water
82515|NCT02548052|retinoic acid receptor-related orphan receptor (ROR) gamma inverse agonist
82516|NCT02548052|Plaque type psoriasis
82517|NCT02548052|psoriasis plaque test
82518|NCT02548052|Topical
82519|NCT02548052|GSK2981278
82520|NCT02548039|Anovulatory
82521|NCT02548039|Clomiphene
82522|NCT02548026|meal frequency
82523|NCT02548026|eating frequency
82524|NCT02548026|ingestive frequency
82525|NCT02548026|positive energy balance
82526|NCT02548026|satiety
82527|NCT02548026|appetite
82528|NCT02548026|hunger
82529|NCT02547987|breast cancer
82530|NCT02547987|triple negative
82531|NCT02547987|TNBC
82532|NCT02547987|triple negative breast cancer
82533|NCT02547974|Safety
82534|NCT02547974|Immunogenicity
82535|NCT02547974|Reactogenicity
82536|NCT02547961|breast cancer
82537|NCT02547961|HER2
82538|NCT02547961|CAR-T cell
82539|NCT02547948|CD19
82540|NCT02547948|CAR T Cells
82541|NCT02547948|Lymphoma
82542|NCT02547922|lupus, nephritis, randomized, placebo, anifrolumab, safety, efficacy, adult
82543|NCT02547896|codeine
82544|NCT02547896|diclofenac
82545|NCT02547896|impacted third molar tooth
82546|NCT02547883|Statins
82547|NCT02547883|Elderly
82548|NCT02547883|Mortality
82549|NCT02547883|Quality of life
82550|NCT02547883|Randomized trial
82551|NCT02547883|Cost effectiveness study
82552|NCT02547870|Rilpivirine
82553|NCT02547870|Healthy participants
82554|NCT02547857|Pelvic ultrasound
82555|NCT02547857|Transvaginal ultrasound
82556|NCT02547818|Early stage AD
82557|NCT02547818|MCI
82558|NCT02547818|aMCI
82559|NCT02547818|prodromal
82560|NCT02547818|Memory loss
82561|NCT02547818|Memory problems
82562|NCT02547818|Aging
82563|NCT02547818|Early Alzheimer's Disease
82564|NCT02547818|Early AD
82565|NCT02547805|Urine Oxalate
82566|NCT02547805|Nephrolithiasis
82567|NCT02547805|Kidney Stones
82568|NCT02547805|Hyperoxaluria
82569|NCT02547805|Enteric Hyperoxaluria
82570|NCT02547805|Idiopathic Hyperoxaluria
82571|NCT02547805|Urological Diseases
82572|NCT02547805|Kidney Diseases
82573|NCT02547805|Supersaturation
82574|NCT02547805|Dietary Oxalate
82575|NCT02547792|Influenza B
82576|NCT02547779|crystalloid
82577|NCT02547779|acute kidney injury
82578|NCT02547766|Ventricular Assist Device
82579|NCT02547766|Recovery of Function
82580|NCT02547753|Tooth extraction
82581|NCT02547753|Antibiotic prophylaxis
82582|NCT02547753|Postoperative complications
82583|NCT02547740|macula
82584|NCT02547740|visual fields
82585|NCT02547740|optical coherence tomography
82586|NCT02547740|glaucoma progression
82587|NCT02547740|retinal ganglion cells
82588|NCT02547727|rabies vaccination
82589|NCT02547714|cyclosporine A
82590|NCT02547610|MR/PET in the evaluation
82591|NCT02547610|patients
82592|NCT02547597|Beta-blockers
82593|NCT02547597|Anti-anginal effect
82594|NCT02547597|Lipid metabolism
82595|NCT02547597|Glucose metabolism
82596|NCT02547571|Outpatient
82597|NCT02547558|Indacaterol
82598|NCT02547558|Pulmonary gas exchange
82599|NCT02547558|Long-acting bronchodilators
82600|NCT02547532|COPD
82601|NCT02547532|alpha-1 antitrypsin deficiency
82602|NCT02547532|microbioma
82603|NCT02547519|Type 1 diabetes
82604|NCT02547519|T1D
82605|NCT02547519|diabetes mellitus
82606|NCT02547519|oral insulin
82607|NCT02547519|oral tolerance
82608|NCT02547519|autoantigen
82609|NCT02547519|self tolerance
82610|NCT02547519|prevention
82611|NCT02547519|at risk for developing type 1 diabetes
82612|NCT02547519|juvenile diabetes
82613|NCT02547506|cardiorespiratory fitness
82614|NCT02547506|group exercise
82615|NCT02547493|Vaccination against Pneumococcal
82616|NCT02547493|Naïve Abatacept patients
82617|NCT02547480|liver
82618|NCT02547480|metastatic
82619|NCT02547467|mortality
82620|NCT02547415|Pain, Chronic
82621|NCT02547415|children
82622|NCT02547376|Telomeres
82623|NCT02547376|Telomerase
82624|NCT02547376|Alternative lengthening of Telomeres Mechanism
82625|NCT02547285|biomechanics of walking
82626|NCT02547285|footwear
82627|NCT02547272|Intensive care
82628|NCT02547272|S Aureus
82629|NCT02547259|schizophrenia
82630|NCT02547259|memory
82631|NCT02547259|pain
82632|NCT02547246|bulimia
82633|NCT02547246|repetitive transcranial magnetic stimulation (rTMS)
82634|NCT02547194|coronary artery bypass grafting
82635|NCT02547194|saphenous vein
82636|NCT02547194|no-touch technique
82637|NCT02547181|Fracture
82638|NCT02547181|Follow-up
82639|NCT02547181|metacarpal
82640|NCT02547168|Atrial Fibrillation
82641|NCT02547168|Symptomatic Atrial Fibrillation
82642|NCT02547168|Asymptomatic Atrial Fibrillation
82643|NCT02547168|Lung Resection
82644|NCT02547168|Ambulatory Cardiac Monitor
82645|NCT02547142|Randomized Controlled Trial
82646|NCT02547142|Early Palliative care
82647|NCT02547142|FACT-E questionnaire
82648|NCT02547142|HADS questionnaire
82649|NCT02547142|Patient Health Questionnaire-9 (PHQ-9)
82650|NCT02547103|Chlorhexidine gluconate
82651|NCT02547103|Mupirocin ointment
82652|NCT02547103|Normal saline
82653|NCT02547103|Peritonitis
82654|NCT02547103|Peritoneal dialysis
82655|NCT02547064|intubation
82656|NCT02547064|stylet
82657|NCT02547064|videolaryngoscope
82658|NCT02547051|Stuttering
82659|NCT02547051|Stammering
82660|NCT02547051|Speech Disorders
82661|NCT02547051|Fluency Disorders
82662|NCT02547038|Helicobacter pylori
82663|NCT02547038|Eradication rate
82664|NCT02547025|Helicobacter pylori
82665|NCT02547025|third-line therapy
82666|NCT02547025|antibiotic susceptibility
82667|NCT02547025|Eradication
82668|NCT02547012|Helicobacter pylori
82669|NCT02547012|Eradication rate
82670|NCT02547012|Rescue treatment
82671|NCT02546999|Botulinum Toxins, Type A
82672|NCT02546999|Walking
82673|NCT02546986|CC-486
82674|NCT02546986|Azacitidine
82675|NCT02546986|Oral azacitidine
82676|NCT02546986|Methyltransferase inhibitor
82677|NCT02546986|Hypomethylation
82678|NCT02546986|Hypomethylating agent
82679|NCT02546986|Epigenetic
82680|NCT02546986|MK-3475
82681|NCT02546986|Pembrolizumab
82682|NCT02546986|Keytruda
82683|NCT02546986|PD-1
82684|NCT02546986|PD-L1
82685|NCT02546986|ImmunotherapyAdvanced non-small cell lung cancer
82686|NCT02546986|Metastatic non-small cell lung cancer
82687|NCT02546986|Non-small cell lung cancer
82688|NCT02546986|NSCLC
82689|NCT02546986|Merck Pembrolizumab (Keynote-117)
82690|NCT02546960|Healthy
82691|NCT02546960|JNJ-63871860
82692|NCT02546960|ExPEC4V
82693|NCT02546947|Respiratory Distress Syndrome, Adult
82694|NCT02546947|Neuromuscular Blocking Agents
82695|NCT02546947|Atracurium
82696|NCT02546947|Mechanical ventilation
82697|NCT02546947|ARDS
82698|NCT02546947|partial pressure of oxygen(PaO2) /inspired oxygen (FiO2) < 200
82699|NCT02546947|Positive End Expiratory Pressure (PEEP) > 5 since less than 48 hrs
82700|NCT02546934|triple negative breast cancer
82701|NCT02546934|fine line chemotherapy
82702|NCT02546921|IgE antibody
82703|NCT02546921|Folate receptor
82704|NCT02546921|Cancer Immunotherapy
82705|NCT02546921|First in class
82706|NCT02546908|Prostatic Neoplasms
82707|NCT02546908|Non-interventional
82708|NCT02546908|Observational
82709|NCT02546895|head and neck cancer patients
82710|NCT02546895|clinical data
82711|NCT02546895|tissue collection
82712|NCT02546895|prospective registration
82713|NCT02546895|patients
82714|NCT02546882|stromal vascular fraction
82715|NCT02546882|skin graft
82716|NCT02546843|rocuronium
82717|NCT02546843|sugammadex
82718|NCT02546843|pediatric anesthesia
82719|NCT02546843|cisatracurium
82720|NCT02546843|surgical conditions
82721|NCT02546817|Treatment
82722|NCT02546817|Tx
82723|NCT02546817|Prevent
82724|NCT02546778|Radio frequency
82725|NCT02546778|Female
82726|NCT02546778|Humans
82727|NCT02546778|Esthetics
82728|NCT02546765|analgesics
82729|NCT02546765|cardiac surgery
82730|NCT02546765|sedation
82731|NCT02546739|Leukemia
82732|NCT02546739|Lymphoma
82733|NCT02546739|CAR T
82734|NCT02546726|heat therapy
82735|NCT02546726|steam-room
82736|NCT02546726|aerobic exercise
82737|NCT02546726|hypertension
82738|NCT02546726|multiple behavior change
82739|NCT02546726|lifestyle modification
82740|NCT02546713|dental implants
82741|NCT02546687|Anastomotic Leak
82742|NCT02546687|Esophagectomy Gastric Pull-up
82743|NCT02546674|Chronic Myeloid Leukemia
82744|NCT02546674|Nilotinib
82745|NCT02546674|Molecular Response
82746|NCT02546674|MR4.5
82747|NCT02546661|AZD4547
82748|NCT02546661|MEDI4736
82749|NCT02546661|Durvalumab
82750|NCT02546661|Olaparib
82751|NCT02546661|AZD2281
82752|NCT02546661|AZD1775
82753|NCT02546661|Muscle invasive bladder cancer
82754|NCT02546661|MIBC
82755|NCT02546661|BISCAY
82756|NCT02546661|AZD2014
82757|NCT02546661|Vistusertib
82758|NCT02546622|Factor
82759|NCT02546622|Coagulation
82760|NCT02546622|Inhibitor
82761|NCT02546622|HTC
82762|NCT02546622|Bleeding
82763|NCT02546557|CABG
82764|NCT02546557|Coronary Artery Bypass Grafting
82765|NCT02546544|Linsitinib
82766|NCT02546544|anti-IGF-1R/IR
82767|NCT02546544|Ewing Sarcoma
82768|NCT02546544|dual IGF-1R/IR inhibition
82769|NCT02546544|Relapsed Ewing Sarcoma
82770|NCT02546544|Refractory Ewing Sarcoma
82771|NCT02546544|Metastatic Ewing Sarcoma
82772|NCT02546518|Conductive hearing loss
82773|NCT02546518|Middle ear effusion
82774|NCT02546518|Middle ear pressure equalization
82775|NCT02546505|Consumer behavior
82776|NCT02546505|Nutrition Labeling
82777|NCT02546479|Mortality
82778|NCT02546479|Radiation
82779|NCT02546479|Spine deformities
82780|NCT02546466|low back pain
82781|NCT02546466|functional taping
82782|NCT02546466|balance
82783|NCT02546466|posture
82784|NCT02546466|rehabilitation
82785|NCT02546466|psychosocial factors
82786|NCT02546466|minimal intervention strategy
82787|NCT02546453|high risk solid tumor pediatric, genetic alteration, Metastatic solid tumor pediatric
82788|NCT02546414|Platelet count/spleen diameter ratio
82789|NCT02546414|China
82790|NCT02546375|Bosutinib
82791|NCT02546375|chronic myeloid leukaemia
82792|NCT02546375|retrospective
82793|NCT02546375|observational
82794|NCT02546349|chronic obstructive pulmonary disease
82795|NCT02546349|airway inflammation
82796|NCT02546349|eosinophilic airway inflammation
82797|NCT02546349|exhaled nitric oxide
82798|NCT02546336|Ultrasound Guidance
82799|NCT02546336|Cooled Radiofrequency
82800|NCT02546336|Hip Denervation
82801|NCT02546323|Rosuvastatin 20 mg treatment, Carotid Intima-Media Thickness, Chinese subjects, Subclinical atherosclerosis
82802|NCT02546297|LAMA,ICS+LABA
82803|NCT02546284|CMML
82804|NCT02546258|Fungal Nail
82805|NCT02546232|locally advanced breast cancer
82806|NCT02546232|metastatic breast cancer
82807|NCT02546219|eosinophilic esophagitis
82808|NCT02546219|EoE
82809|NCT02546219|integrins
82810|NCT02546206|Bifidobacterium
82811|NCT02546206|Gingivitis
82812|NCT02546206|Gingival crevicular fluid
82813|NCT02546206|Interleukin-1beta
82814|NCT02546206|Probiotics
82815|NCT02546180|Patient education
82816|NCT02546180|Preoperative anxiety
82817|NCT02546154|Iron
82818|NCT02546154|Anaemia
82819|NCT02546154|Anaemia, Iron-Deficiency
82820|NCT02546154|Kidney Diseases
82821|NCT02546154|Inflammatory Bowel Diseases
82822|NCT02546154|Fatigue
82823|NCT02546076|Keloid
82824|NCT02546076|Hypertrophic scars
82825|NCT02546076|Er-YAG Lasers
82826|NCT02546050|Gut microbiota
82827|NCT02546050|metformin
82828|NCT02546050|Metabolism
82829|NCT02546050|Metagenomics
82830|NCT02546050|Metabolomics
82831|NCT02546037|coagulation
82832|NCT02546037|haemodialysis
82833|NCT02546024|Major depressive disorder
82834|NCT02546024|late-onset
82835|NCT02546024|treatment response
82836|NCT02546024|predictors
82837|NCT02546024|moderators
82838|NCT02545998|Telehealthcare
82839|NCT02545985|sirolimus
82840|NCT02545985|coronary stent
82841|NCT02545985|Prolim
82842|NCT02545972|immunosuppression
82843|NCT02545959|Intrathecal Rituximab
82844|NCT02545959|intrathecal chemotherapy
82845|NCT02545959|cerebrospinal fluid
82846|NCT02545959|lumbar puncture
82847|NCT02545959|Physiological Effects of Drugs
82848|NCT02545959|Rituximab
82849|NCT02545946|traditional incision and drainage
82850|NCT02545946|minimally invasive incision and drainage
82851|NCT02545946|vessel loop
82852|NCT02545946|emergency department
82853|NCT02545946|pediatrics
82854|NCT02545933|prasugrel
82855|NCT02545933|ticagrelor
82856|NCT02545933|vorapaxar
82857|NCT02545920|haemodialysis
82858|NCT02545920|hypotension
82859|NCT02545907|Amyloidosis
82860|NCT02545907|AL Amyloidosis
82861|NCT02545855|myAIRVO2
82862|NCT02545855|high-flow nasal cannula therapy
82863|NCT02545855|home oxygen therapy
82864|NCT02545855|HOT
82865|NCT02545790|coarctation of aorta
82866|NCT02545790|aortic stenosis
82867|NCT02545790|biomarkers
82868|NCT02545790|cardiac hypertrophy
82869|NCT02545777|Acute gouty arthritis
82870|NCT02545777|tonifying spleen and descending the turbid
82871|NCT02545777|soaking
82872|NCT02545777|wet wrapping
82873|NCT02545764|Gait Analysis
82874|NCT02545764|Knee Adduction Moment
82875|NCT02545764|Physiotherapy
82876|NCT02545764|Obesity
82877|NCT02545751|Esophageal cancer
82878|NCT02545751|Metastatic esophageal cancer
82879|NCT02545751|Radiotherapy
82880|NCT02545751|Thymalfasin
82881|NCT02545751|ZADAXIN's®
82882|NCT02545751|Stereotactic Body Radiation Therapy
82883|NCT02545725|Colorectal Cancer
82884|NCT02545725|Quality of life
82885|NCT02545725|Questionnaires
82886|NCT02545712|Ethanol
82887|NCT02545712|Propylene glycol
82888|NCT02545712|Benzyl alcohol
82889|NCT02545712|Acesulfam potassium
82890|NCT02545712|Aspartame
82891|NCT02545712|Glycerin
82892|NCT02545712|Sorbitol
82893|NCT02545712|Methyl-p-hydroxybenzoate
82894|NCT02545712|Propanyl-p-hydroxybenzoate
82895|NCT02545712|Patients
82896|NCT02545699|Adenoma
82897|NCT02545699|Polyp
82898|NCT02545699|CRC
82899|NCT02545699|Colonoscopy
82900|NCT02545699|Detection Yield
82901|NCT02545673|Intervention Studies
82902|NCT02545673|Access to Health Care
82903|NCT02545673|Social Stigma
82904|NCT02545673|Social Support
82905|NCT02545634|probiotic
82906|NCT02545634|ADHD
82907|NCT02545634|anxiety
82908|NCT02545634|digestive health
82909|NCT02545634|children
82910|NCT02545634|attention deficit
82911|NCT02545634|gut brain axis
82912|NCT02545634|nutritional supplement
82913|NCT02545634|microbiome
82914|NCT02545621|Receptor for advanced glycation end products (RAGE)
82915|NCT02545621|Acute respiratory distress syndrome (ARDS)
82916|NCT02545621|Monocyte/Macrophage activation
82917|NCT02545621|Fluorescence-Activated Cell Sorting (FACS) analysis
82918|NCT02545621|Thioredoxin interacting protein (TXNIP)
82919|NCT02545621|NOD-like receptor family, pyrin domain containing 3 (NLRP3)
82920|NCT02545621|Inflammasome
82921|NCT02545595|General anaesthesia
82922|NCT02545595|Curarization with rocuronium
82923|NCT02545556|Liver Cancer
82924|NCT02545556|HepaSphere
82925|NCT02545556|cryosurgery
82926|NCT02545530|renal dialysis
82927|NCT02545530|hypertension
82928|NCT02545530|clonidine
82929|NCT02545504|Gastroesophageal junction (GEJ)
82930|NCT02545504|Stomach cancer
82931|NCT02545491|CCD
82932|NCT02545491|Child development
82933|NCT02545491|daycare
82934|NCT02545491|caregiver
82935|NCT02545478|septic shock
82936|NCT02545478|infection
82937|NCT02545478|inflammation
82938|NCT02545478|pathologic process
82939|NCT02545478|biomarkers
82940|NCT02545465|Pulmonary Arterial Hypertension
82941|NCT02545465|Inoperable Chronic Thromboembolic Pulmonary Hypertension
82942|NCT02545465|Persistent Chronic Thromboembolic Pulmonary Hypertension
82943|NCT02545465|Recurrent Chronic Thromboembolic Pulmonary Hypertension
82944|NCT02545465|Switch of therapy
82945|NCT02545465|Titration phase
82946|NCT02545465|Retrospective chart review
82947|NCT02545439|Alkermes
82948|NCT02545439|Samidorphan
82949|NCT02545439|ALKS 5461
82950|NCT02545439|Healthy Volunteer
82951|NCT02545439|Pharmacokinetics
82952|NCT02545426|myocardial stunning
82953|NCT02545426|dialysate calcium concentration
82954|NCT02545426|nutritional status
82955|NCT02545426|hemodinamic
82956|NCT02545426|hemodialysis
82957|NCT02545374|chronic wound
82958|NCT02545374|tablet
82959|NCT02545374|telemedicine
82960|NCT02545374|wounds consultation
82961|NCT02545374|Smartphone
82962|NCT02545296|In-vitro Diagnostics
82963|NCT02545296|paediatrics
82964|NCT02545270|Surgery, Laparoscopic
82965|NCT02545270|surgical rating scale
82966|NCT02545257|Aged people
82967|NCT02545257|Home care
82968|NCT02545257|Drug related problems, DRPs
82969|NCT02545257|Coordinated medication management model
82970|NCT02545244|Gingivitis, Black Tea, Green Tea,Chlorhexidine, Biofilm,
82971|NCT02545218|Perineum. Perineorraphy. Pelvic floor exercise.
82972|NCT02545205|Rehabilitation
82973|NCT02545205|Robotics
82974|NCT02545192|PTSD
82975|NCT02545166|Stroke
82976|NCT02545166|Purines
82977|NCT02545166|SMARTChip
82978|NCT02545166|Ischaemia
82979|NCT02545166|Carotid endarterectomy
82980|NCT02545166|Biosensor
82981|NCT02545140|risk factors
82982|NCT02545140|screening
82983|NCT02545140|adolescents
82984|NCT02545127|inadequate milk production
82985|NCT02545114|Hyponatremia
82986|NCT02545114|SIADH, stroke
82987|NCT02545114|SAH; ICH
82988|NCT02545114|AIS
82989|NCT02545101|Hyponatremia due to SIADH
82990|NCT02545101|tolvaptan
82991|NCT02545088|Rehabilitation
82992|NCT02545088|Robotics
82993|NCT02545049|Type 2 Diabetes
82994|NCT02545049|Kidney diseases
82995|NCT02545036|chronic kidney disease
82996|NCT02545036|Daycare
82997|NCT02545036|Traditional Chinese Medicine(TCM)
82998|NCT02544984|prophylactic macrolides
82999|NCT02544984|RSV
83000|NCT02544984|chronic lung disease
83001|NCT02544984|respiratory infections
83002|NCT02544958|Enlarged pores
83003|NCT02544958|Er:YAG laser
83004|NCT02544945|Radiotherapy
83005|NCT02544932|anticoagulant
83006|NCT02544932|atherosclerosis
83007|NCT02544932|endothelium
83008|NCT02544919|SMOF
83009|NCT02544919|neurological complications
83010|NCT02544919|neurotoxicity
83011|NCT02544919|liver transplantation
83012|NCT02544919|Lipid emulsions
83013|NCT02544906|recipients
83014|NCT02544880|HNSCC
83015|NCT02544880|Head and Neck Squamous Cell Carcinoma
83016|NCT02544880|Tadalafil
83017|NCT02544880|PDE5 Inhibition
83018|NCT02544880|Anti-MUC1 Vaccine
83019|NCT02544880|Recurrent Head and Neck Squamous Cell Carcinoma
83020|NCT02544880|Recurrent HNSCC
83021|NCT02544880|Second primary site disease stage III
83022|NCT02544880|Second primary site disease stage IV
83023|NCT02544880|Anti-Influenza Vaccine
83024|NCT02544854|Pharmacokinetics, pharmacodynamics, propofol, pediatrics
83025|NCT02544828|Osteoarthritis
83026|NCT02544828|knee arthroplasty
83027|NCT02544828|iron
83028|NCT02544815|digoxin, eficacy, safety
83029|NCT02544776|pco
83030|NCT02544776|Amlodipine
83031|NCT02544737|Esophageal cancer
83032|NCT02544737|Metastatic esophageal cancer
83033|NCT02544737|Apatinib
83034|NCT02544724|Relapsed
83035|NCT02544724|Refractory
83036|NCT02544724|DLBCL
83037|NCT02544724|Chemotherapy
83038|NCT02544711|Pelvis
83039|NCT02544711|Surgical resection
83040|NCT02544711|Patient specific instrument
83041|NCT02544698|vaccine
83042|NCT02544698|safety
83043|NCT02544685|Febrile neutropenia
83044|NCT02544685|Synbiotic
83045|NCT02544685|Probiotic
83046|NCT02544685|Prebiotic
83047|NCT02544685|Safety
83048|NCT02544685|Cancer
83049|NCT02544685|Oncology
83050|NCT02544685|Chemotherapy
83051|NCT02544685|Symbiotic
83052|NCT02544659|Treatment
83053|NCT02544659|Bisphosphonates
83054|NCT02544659|Response rate
83055|NCT02544646|trabeculectomy
83056|NCT02544633|Mirati
83057|NCT02544633|MGCD265
83058|NCT02544633|MET
83059|NCT02544633|NSCLC
83060|NCT02544607|Ketamine
83061|NCT02544607|Depression
83062|NCT02544607|Anxious Depression
83063|NCT02544607|MRI
83064|NCT02544568|high fat
83065|NCT02544568|high protein
83066|NCT02544568|high carbohydrate
83067|NCT02544568|insulin
83068|NCT02544568|glucose
83069|NCT02544555|Peripheral arterial disease
83070|NCT02544555|Atherosclerosis
83071|NCT02544555|Intraluminal approach
83072|NCT02544555|Subintimal approach
83073|NCT02544542|Mild Hypothermia
83074|NCT02544542|Hypoxic-Ischemic Encephalopathy
83075|NCT02544516|Schizophrenia
83076|NCT02544516|motor and sensory perceptions
83077|NCT02544490|Sepsis
83078|NCT02544490|MicroRNAs
83079|NCT02544490|Diagnosis
83080|NCT02544490|Prognosis
83081|NCT02544464|osteoarthritis
83082|NCT02544464|knee arthroplasty
83083|NCT02544464|iron
83084|NCT02544412|Mindfulness
83085|NCT02544412|School Teachers
83086|NCT02544412|preservice teachers
83087|NCT02544412|teacher education
83088|NCT02544399|Bone microarchitecture
83089|NCT02544399|Playing golf
83090|NCT02544399|Walkers
83091|NCT02544386|bone microarchitecture
83092|NCT02544386|hemiplegia
83093|NCT02544373|OSA
83094|NCT02544373|Obstructive Sleep Apnea
83095|NCT02544373|Cognition
83096|NCT02544373|Cognitive Dysfunction
83097|NCT02544373|Memory
83098|NCT02544373|Positive Aiway Pressure
83099|NCT02544373|CPAP
83100|NCT02544373|MS
83101|NCT02544360|photoaging mobile apps
83102|NCT02544360|adolescent smoking
83103|NCT02544360|tobacco prevention
83104|NCT02544360|school-based prevention
83105|NCT02544360|adolescent health
83106|NCT02544360|school health
83107|NCT02544360|smoking
83108|NCT02544360|tobacco
83109|NCT02544347|vaspin
83110|NCT02544347|omentin
83111|NCT02544347|diabetes mellitus
83112|NCT02544347|chronic periodontitis
83113|NCT02544347|tumor-necrosis factor alfa
83114|NCT02544347|gingival crevicular fluid
83115|NCT02544334|Rheumatoid arthritis
83116|NCT02544334|Metagenome
83117|NCT02544334|microbiome
83118|NCT02544308|Solitary, Bone
83119|NCT02544282|Analgesics
83120|NCT02544282|Opioid
83121|NCT02544282|Mastectomy
83122|NCT02544282|Segmental Mastectomy
83123|NCT02544282|Pecs II
83124|NCT02544269|Lumbosacral plexus blockade
83125|NCT02544269|Continuous spinal anesthesia
83126|NCT02544269|Hemodynamics
83127|NCT02544256|Microcirculation
83128|NCT02544256|Mild Hypothermia, Induced
83129|NCT02544256|Subarachnoid Hemorrhage, Aneurysmal
83130|NCT02544256|Aneurysmal Clipping
83131|NCT02544256|Vasospasms
83132|NCT02544230|granulocyte transfusions
83133|NCT02544191|azoospermia nonobstructive
83134|NCT02544191|male infertility
83135|NCT02544178|radiotherapy
83136|NCT02544178|neurocognitive defect
83137|NCT02544178|leukoencephalopathy
83138|NCT02544165|smoking
83139|NCT02544165|caffeine intake
83140|NCT02544165|haemodynamic parameters
83141|NCT02544165|Advanced Glycation End Products (AGEs)
83142|NCT02544165|Non-invasive measurements devices
83143|NCT02544087|fire-heat syndrome
83144|NCT02544087|blood stasis syndrome
83145|NCT02544087|method of clearing heat
83146|NCT02544087|method of promoting blood circulation
83147|NCT02544048|Immune
83148|NCT02544048|Parasitemia
83149|NCT02544048|Menactra
83150|NCT02544048|Polymerase Chain Reaction (PCR)
83151|NCT02544048|Coartem
83152|NCT02544035|Childhood Growth and Development
83153|NCT02544035|Development
83154|NCT02544022|Pain Scale
83155|NCT02544022|QOL
83156|NCT02544022|Tool Validation
83157|NCT02544022|Cognitive Interviews
83158|NCT02544009|Energy Expenditure
83159|NCT02544009|Obesity
83160|NCT02544009|Behavioral Weight Loss Treatment
83161|NCT02543996|Sample Collection
83162|NCT02543996|Laboratory Research Specimens
83163|NCT02543996|Biospecimen Procurement
83164|NCT02543996|Rare Diseases
83165|NCT02543983|Neurobiology
83166|NCT02543983|Suicide
83167|NCT02543983|Ketamine
83168|NCT02543983|Major Depression Disorder
83169|NCT02543983|Biomarkers
83170|NCT02543957|ERCP
83171|NCT02543957|Cholangitis
83172|NCT02543957|Bacteremia
83173|NCT02543957|Antibiotics
83174|NCT02543931|turmeric
83175|NCT02543931|curcumin
83176|NCT02543931|curcuminoids
83177|NCT02543931|arthritis
83178|NCT02543931|methotrexate
83179|NCT02543892|Vaccine
83180|NCT02543879|AML
83181|NCT02543879|BET Inhibitor
83182|NCT02543879|FT-1101
83183|NCT02543879|Acute Leukemia
83184|NCT02543879|Myelodysplastic Syndrome
83185|NCT02543840|Quality Improvement
83186|NCT02543840|Organization of Services
83187|NCT02543840|Implementation
83188|NCT02543827|Vaccine
83189|NCT02543827|Recurrent Urinary Tract Infections (RUTI)
83190|NCT02543827|Female Urogenital Diseases and Pregnancy Complications
83191|NCT02543788|optic neuritis
83192|NCT02543788|vision
83193|NCT02543788|quality of life
83194|NCT02543788|pathophysiology
83195|NCT02543775|Cervical Cancer
83196|NCT02543775|Sentinel Lymph Node
83197|NCT02543775|Lymphadenectomy
83198|NCT02543762|Chromoendoscopy
83199|NCT02543762|Ulcerative Colitis
83200|NCT02543762|Crohn disease
83201|NCT02543762|Colorectal Neoplasia
83202|NCT02543749|CML
83203|NCT02543749|DC vaccine
83204|NCT02543723|medication adherence, telehealth strategies, nurse coaching
83205|NCT02543684|glycemic response
83206|NCT02543684|diabetes
83207|NCT02543684|insulinemic response
83208|NCT02543684|mixed meals
83209|NCT02543684|glycemic index
83210|NCT02543671|vitamin D status
83211|NCT02543671|25-hydroxyvitamin D
83212|NCT02543671|cheese
83213|NCT02543671|Randomized controlled trial
83214|NCT02543671|postmenopausal women
83215|NCT02543671|enriched
83216|NCT02543671|vitamin D3
83217|NCT02543658|Acute Pancreatitis
83218|NCT02543658|Intra-abdominal hypertension
83219|NCT02543658|Abdominal compartment syndrome
83220|NCT02543658|Curative Effect
83221|NCT02543658|Security
83222|NCT02543658|Neostigmine
83223|NCT02543632|heart failure
83224|NCT02543632|parachute
83225|NCT02543632|partitioning device
83226|NCT02543593|tDCS
83227|NCT02543567|Ebola viruses
83228|NCT02543567|Ebola virus disease (EVD)
83229|NCT02543567|Filoviruses
83230|NCT02543567|Monovalent vaccine
83231|NCT02543567|Safety
83232|NCT02543567|Immunogenicity
83233|NCT02543567|Ebola vaccine
83234|NCT02543567|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
83235|NCT02543567|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
83236|NCT02543567|Healthy participants
83237|NCT02543541|Palliative Care
83238|NCT02543541|Supportive Care
83239|NCT02543541|Caregiver
83240|NCT02543541|Phase I
83241|NCT02542462|mechanisms for intussusception
83242|NCT02542462|rotavirus vaccine
83243|NCT02542449|Green tea
83244|NCT02542449|weight maintenance
83245|NCT02542449|obesity
83246|NCT02542449|fat mass
83247|NCT02542384|abdominal surgery
83248|NCT02542384|laparoscopy
83249|NCT02542384|Hysterectomy
83250|NCT02542384|Prostatectomy
83251|NCT02542384|Hemi-colectomy
83252|NCT02542384|Ventral Hernia repair
83253|NCT02542384|CR845
83254|NCT02542384|analgesic
83255|NCT02542384|kappa opioid
83256|NCT02542384|partial bowel resection
83257|NCT02542371|HIV
83258|NCT02542371|Atherosclerosis
83259|NCT02542371|Tilmanocept
83260|NCT02542345|Cardiac Multislice CT
83261|NCT02542345|MRI coronarography
83262|NCT02542332|lung cancer screening
83263|NCT02542332|statistical background
83264|NCT02542306|Blood loss
83265|NCT02542306|coagulopathy
83266|NCT02542306|fibrinogen concentrate
83267|NCT02542306|transfusion
83268|NCT02542293|NSCLC
83269|NCT02542293|PDL1
83270|NCT02542293|MEDI4736
83271|NCT02542293|Tremelimumab
83272|NCT02542293|OS
83273|NCT02543515|following hysteroscopy
83274|NCT02543502|Periodontitis
83275|NCT02543502|atherosclerosis
83276|NCT02543502|Heart Disease
83277|NCT02543476|PD-L1 status, biomarkers, prevalence, SCCHN, overall survival
83278|NCT02543450|Chronic stroke
83279|NCT02543450|Participation
83280|NCT02543450|Walking ability
83281|NCT02543385|S Ketamine
83282|NCT02543385|Morphine
83283|NCT02543385|Consumption
83284|NCT02543372|concerned significant other
83285|NCT02543372|problem gambling
83286|NCT02543372|internet-delivered cognitive-behavioral therapy
83287|NCT02543372|behavioral couples therapy
83288|NCT02543359|Training
83289|NCT02543359|Implementation
83290|NCT02543359|Community-Based Mental Health Services
83291|NCT02543359|Parent-Child Interaction Therapy
83292|NCT02543359|Children
83293|NCT02543333|Acute Asthma,
83294|NCT02543320|Head and Neck Cancer
83295|NCT02543320|LORETA
83296|NCT02543320|Low Resolution Electromagnetic Tomography
83297|NCT02543320|Pain
83298|NCT02543320|Radiotherapy
83299|NCT02543320|Electroencephalograph
83300|NCT02543320|EEG
83301|NCT02543320|Questionnaires
83302|NCT02543320|Surveys
83303|NCT02543320|Neurofeedback training
83304|NCT02543307|Hip Replacement
83305|NCT02543307|Spinal Diseases
83306|NCT02543307|Rotator Cuff Reconstruction
83307|NCT02543307|Nursing
83308|NCT02543307|Nurse-led
83309|NCT02543307|Pathways
83310|NCT02543307|Patient Satisfaction
83311|NCT02543307|Quality of Nursing Care
83312|NCT02543294|Heart Failure
83313|NCT02543294|Echocardiogram
83314|NCT02543294|ECHO
83315|NCT02543294|Electrocardiogram
83316|NCT02543294|ECG
83317|NCT02543294|Questionnaire
83318|NCT02543294|Survey
83319|NCT02543294|Telephone Follow-Up
83320|NCT02543294|HF
83321|NCT02543294|Cancer treatment induced left ventricular dysfunction
83322|NCT02543294|CILVD
83323|NCT02543294|Left ventricular ejection fraction
83324|NCT02543294|LVEF
83325|NCT02543268|Ebola viruses
83326|NCT02543268|Ebola virus disease (EVD)
83327|NCT02543268|Filoviruses
83328|NCT02543268|Monovalent vaccine
83329|NCT02543268|Safety
83330|NCT02543268|Immunogenicity
83331|NCT02543268|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
83332|NCT02543268|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
83333|NCT02543268|Healthy participants
83334|NCT02543255|High risk
83335|NCT02543242|Urinary Incontinence
83336|NCT02543242|Stress Urinary Incontinence
83337|NCT02543242|Urge Incontinence
83338|NCT02543242|Mixed Urinary Incontience
83339|NCT02543242|Female Pelvic Health
83340|NCT02543216|fatty acids, FADS gene, genotype, diet
83341|NCT02543203|Relaxation
83342|NCT02543190|Care Transition
83343|NCT02543190|Readmission
83344|NCT02543190|Rehospitalization
83345|NCT02543177|NSTEMI, CKD
83346|NCT02543164|Glycemic Index
83347|NCT02543164|glycemic response
83348|NCT02543151|Biliary stricture
83349|NCT02543151|Cholangioscopy
83350|NCT02543151|Spyglass
83351|NCT02543151|Liver transplant
83352|NCT02543125|very low birth weight
83353|NCT02543125|respiratory distress
83354|NCT02543125|NHFOV
83355|NCT02543125|NIPPV
83356|NCT02543112|mepolizumab
83357|NCT02543112|severe asthma
83358|NCT02543112|LAP
83359|NCT02543112|benefit versus risk
83360|NCT02543099|endothelial function
83361|NCT02543099|policosanol
83362|NCT02543099|efficacy
83363|NCT02543099|safety
83364|NCT02543086|Phase 1, malaria, inoculum, P. falciparum, KAE609, Piperaquine
83365|NCT02543021|Colitis
83366|NCT02543021|Dysplasia
83367|NCT02543021|Chromoendoscopy
83368|NCT02543008|Asymptomatic individuals
83369|NCT02542982|tDCS
83370|NCT02542982|motor recovery
83371|NCT02542956|Tummy tuck (abdominoplasty)
83372|NCT02542956|Breast Surgery
83373|NCT02542930|Non-small cell lung cancer
83374|NCT02542930|Metastatic Non-small cell lung cancer
83375|NCT02542930|Radiotherapy
83376|NCT02542930|Thymalfasin
83377|NCT02542930|ZADAXIN's®
83378|NCT02542891|e-health
83379|NCT02542891|depressive disorder
83380|NCT02542891|cost-effectiveness
83381|NCT02542891|Cognitive behavioral treatment
83382|NCT02542878|myofascial release
83383|NCT02542878|back extensors endurance
83384|NCT02542878|foam roller
83385|NCT02542878|sport
83386|NCT02542852|HIV-1
83387|NCT02542839|Botulinum Toxin
83388|NCT02542839|Transcranial Magnetic Stimulation
83389|NCT02542826|Pulmonary Rehabilitation
83390|NCT02542826|3-minute constant rate shuttle walk test
83391|NCT02542826|3-minute constant rate step test
83392|NCT02542826|Dyspnea
83393|NCT02542813|Pharmacokinetics
83394|NCT02542813|safety
83395|NCT02542813|tolerability
83396|NCT02542813|oxytocin
83397|NCT02542787|MS
83398|NCT02542787|Spasticity
83399|NCT02542787|VSN16R
83400|NCT02542774|Diabetes mellitus
83401|NCT02542774|Stroke
83402|NCT02542774|Myocardial infarction
83403|NCT02542774|Stable angina pectoris
83404|NCT02542774|Heart failure
83405|NCT02542774|Quality of care
83406|NCT02542748|norepinephrine
83407|NCT02542748|ephedrine
83408|NCT02542722|lifestyle modification
83409|NCT02542722|olive oil
83410|NCT02542722|Mediterranean diet
83411|NCT02542683|congenital heart diseases
83412|NCT02542683|cognition
83413|NCT02542683|adaptive behavior
83414|NCT02542683|physical activity
83415|NCT02542683|neurodevelopment
83416|NCT02542644|Fuchs' Endothelial Dystrophy, DMEK
83417|NCT02542618|Depression
83418|NCT02542618|Treatment
83419|NCT02542618|IBSR
83420|NCT02542618|CBT
83421|NCT02542605|Migraine
83422|NCT02542605|Headache
83423|NCT02542605|Migraine Headache
83424|NCT02542605|Headache, Migraine
83425|NCT02542605|Amgen
83426|NCT02542592|Glucocorticoids
83427|NCT02542592|Immune Signaling
83428|NCT02542592|Recovery
83429|NCT02542592|Hip arthroplasty, total
83430|NCT02542540|Osteogenesis Imperfecta
83431|NCT02542540|physical exercise training
83432|NCT02542540|Wii
83433|NCT02542540|muscular strength
83434|NCT02542514|PCNSL
83435|NCT02542514|IOL
83436|NCT02542267|Bare Metal Stent
83437|NCT02542267|In-Stent Restenosis
83438|NCT02542241|Open abdomen
83439|NCT02542241|hypertonic saline solution
83440|NCT02542241|intensive care
83441|NCT02542228|Immune Deficiency, antibody
83442|NCT02542228|Quality of Life survey
83443|NCT02542176|Metabolic Syndrome
83444|NCT02542176|Grape
83445|NCT02542176|HDL
83446|NCT02542176|Lipoproteins
83447|NCT02542137|Small cell lung cancer
83448|NCT02542137|Metastatic small cell lung cancer
83449|NCT02542137|ZADAXIN
83450|NCT02542137|radiotherapy
83451|NCT02542137|Thymalfasin
83452|NCT02542124|CTCL
83453|NCT02542124|Total Skin Electron Beam Therapy (TSEBT)
83454|NCT02542124|Mycosis fungoides
83455|NCT02542124|Sézary syndrome
83456|NCT02542124|recombinant human Interleukin-12 (rHuIL-12)
83457|NCT02542124|T Cell
83458|NCT02542111|diffuse large b-cell lymphoma
83459|NCT02542085|incisional hernia
83460|NCT02542085|laparoscopic repair
83461|NCT02542085|hybrid repair
83462|NCT02542085|seroma
83463|NCT02542085|recurrent hernia
83464|NCT02542033|postprandial glycemia; apple juice; sugar reduction; glucose oxidase
83465|NCT02542007|intracoronary stent
83466|NCT02542007|drug eluting stent
83467|NCT02542007|sirolimus
83468|NCT02542007|endothelial progenitor cells
83469|NCT02541981|Heart transplant
83470|NCT02541981|renal insufficiency
83471|NCT02541955|Rheumatoid arthritis (RA)
83472|NCT02541955|Musculoskeletal ultrasound (MSUS)
83473|NCT02541929|Alzheimer's disease
83474|NCT02541929|Docosahexaenoic acid
83475|NCT02541929|brain health
83476|NCT02541929|memory
83477|NCT02541929|fish oil
83478|NCT02541929|cognition
83479|NCT02541929|DHA
83480|NCT02541929|omega 3 fatty acid
83481|NCT02541929|brain
83482|NCT02541916|Transplantation Tolerance
83483|NCT02541916|Immune Tolerance
83484|NCT02541916|Transplantation
83485|NCT02541916|Liver Transplantation
83486|NCT02541916|Biological Markers
83487|NCT02541916|Gene Expression
83488|NCT02541916|Immunosuppression
83489|NCT02541916|Immunology
83490|NCT02541916|Multiplex Polymerase Chain Reaction
83491|NCT02541916|Real-Time Polymerase Chain Reaction
83492|NCT02541903|Epidermal growth factor receptor (EGFR),
83493|NCT02541903|Human Papillomavirus (HPV)
83494|NCT02541903|Penile squamous cell carcinoma (PSCC)
83495|NCT02541903|Gilotrif
83496|NCT02541890|Rehabilitation
83497|NCT02541890|Return to Work
83498|NCT02541864|Helicobacter pylori
83499|NCT02541864|Hybrid therapy
83500|NCT02541864|Bismuth containing quadruple therapy
83501|NCT02541864|Eradication
83502|NCT02541838|Autonomic Neuropathy
83503|NCT02541838|diabetes
83504|NCT02541838|balance control
83505|NCT02541825|transjugular intrahepatic portosystemic shunt
83506|NCT02541812|Obsessive-Compulsive Disorder
83507|NCT02541812|Transcranial Magnetic Stimulation
83508|NCT02541812|Error processing
83509|NCT02541799|informed consent
83510|NCT02541799|telemedicine
83511|NCT02541799|research methods
83512|NCT02541786|dexlansoprazole MR
83513|NCT02541786|rabeprazole
83514|NCT02541786|Helicobacter pylori
83515|NCT02541786|triple therapy
83516|NCT02541773|Chronic Heart Failure
83517|NCT02541773|Cardiac Resynchronization Therapy
83518|NCT02541773|Vascular Biomarker
83519|NCT02541773|miRNA
83520|NCT02541773|Extracellular Matrix
83521|NCT02541773|Brain Natruetic Peptide
83522|NCT02541773|Growth Degradation Factor-15
83523|NCT02541773|Body Composition
83524|NCT02541734|SPECT
83525|NCT02541734|radiopeptides
83526|NCT02541734|gelofusine
83527|NCT02541734|Beta cell
83528|NCT02541695|Experimental challenge trial
83529|NCT02541669|Drug therapy
83530|NCT02541656|Preload dependence indices
83531|NCT02541656|pulse pressure variation
83532|NCT02541656|plethysmographic waveform of pulse oximetry variation
83533|NCT02541656|stroke volume variation
83534|NCT02541656|laparoscopy
83535|NCT02541656|pneumoperitoneum
83536|NCT02541643|Relapsed/Refractory Multiple Myeloma
83537|NCT02541630|Mindfulness
83538|NCT02541591|post cardiac arrest
83539|NCT02541591|hemodynamics
83540|NCT02541578|stroke, acute; gait, complexity
83541|NCT02541552|Knee arthroscopy
83542|NCT02541552|Quadriceps weakness
83543|NCT02541552|ropivacaine
83544|NCT02541552|saphenous nerve block
83545|NCT02541552|Adductor canal
83546|NCT02541526|amphetamine type stimulant dependence
83547|NCT02541526|mirtazepine
83548|NCT02541513|paliparidone
83549|NCT02541513|amphetamine type stimulant dependence
83550|NCT02541500|minocycline
83551|NCT02541500|amphetamine type stimulant dependence
83552|NCT02541474|Controlled trial
83553|NCT02541474|Matched
83554|NCT02541474|Before-After design
83555|NCT02541474|Prospective
83556|NCT02541474|complex interventions
83557|NCT02541461|Procedure: Laparoscopic gastrectomy with Billroth I
83558|NCT02541461|Procedure: Laparoscopic gastrectomy with Roux-en-Y
83559|NCT02541461|Other: Body composition measurement
83560|NCT02541461|Other: Lipid profile
83561|NCT02541435|Radiotherapy
83562|NCT02541435|Biological markers
83563|NCT02541435|Magnetic resonance imaging
83564|NCT02541435|Echocardiography
83565|NCT02541435|Tomography, X-Ray Computed
83566|NCT02541435|Risk factors
83567|NCT02541435|Heart
83568|NCT02541435|Quality of Life
83569|NCT02541409|directly observed therapy
83570|NCT02541409|sofosbuvir
83571|NCT02541409|ribavirin
83572|NCT02541409|pegylated interferon
83573|NCT02541409|resource-limited setting
83574|NCT02541396|Bunion
83575|NCT02541396|Bunionectomy
83576|NCT02541383|Untreated Multiple Myeloma
83577|NCT02541383|daratumumab
83578|NCT02541357|Colorectal Surgery
83579|NCT02541331|IgE-dependent asthma
83580|NCT02541318|peri-menopausal women
83581|NCT02541318|sleep disturbances
83582|NCT02541318|Dao-in exercise
83583|NCT02541318|body constitution
83584|NCT02541305|falls prevention
83585|NCT02541305|proprioception
83586|NCT02541305|physical condition
83587|NCT02541266|Imaging
83588|NCT02541266|Questionnaire
83589|NCT02541240|resilience
83590|NCT02541240|optimism
83591|NCT02541240|stress
83592|NCT02541240|coping
83593|NCT02541240|curriculum
83594|NCT02539498|Primary Hyperparathyroidism
83595|NCT02539498|Parathyroid Hormone
83596|NCT02539498|High-Resolution peripheral Quantitative Computed Tomography
83597|NCT02539498|Bone densitometry
83598|NCT02539498|Bone microarchitecture
83599|NCT02539446|Aging
83600|NCT02539446|External focus
83601|NCT02539446|Internal focus
83602|NCT02539446|Attention
83603|NCT02539446|Posture balance
83604|NCT02539446|Parkinson's disease
83605|NCT02539407|β-lactam antibiotics
83606|NCT02539407|Children
83607|NCT02539407|Anti-infectives
83608|NCT02539407|Aminoglycosides, glycopeptides
83609|NCT02539407|Fluoroquinolone
83610|NCT02539407|Fungal
83611|NCT02539407|Antiviral
83612|NCT02539394|Anterior Cervical Discectomy and Fusion
83613|NCT02539394|Dysphagia
83614|NCT02539394|ACDF
83615|NCT02539368|Infliximab
83616|NCT02539368|Observational
83617|NCT02539368|Follow-up
83618|NCT02539368|Safety
83619|NCT02539368|Effectiveness
83620|NCT02539355|Insulin resistance
83621|NCT02539355|Diabetes
83622|NCT02539355|Cancer
83623|NCT02539355|Obesity
83624|NCT02539355|Inflammation
83625|NCT02539342|Oral Mucositis
83626|NCT02539342|Cancer
83627|NCT02539342|Chemotherapy
83628|NCT02539329|neuropathy
83629|NCT02539329|antibodies antiFGFR3
83630|NCT02539329|Biological diagnostic criteria
83631|NCT02539316|Parenteral Nutrition
83632|NCT02541201|Plant sterols
83633|NCT02541201|Low-Density Lipoprotein Cholesterol
83634|NCT02541201|Phytosterols
83635|NCT02541188|Breast cancer
83636|NCT02541175|Electrocardiography
83637|NCT02541175|Automation
83638|NCT02541175|Arrhythmias, Cardiac
83639|NCT02541175|Atrial Fibrillation
83640|NCT02541175|Atrial Flutter
83641|NCT02541175|Atrial Premature Complexes
83642|NCT02541175|Esophagus
83643|NCT02541136|exercise
83644|NCT02541136|resilience
83645|NCT02541136|physiotherapy
83646|NCT02541136|fMRI
83647|NCT02541123|Traumatic Brain Injury
83648|NCT02541123|Head Injury
83649|NCT02541084|Age-related macular degeneration
83650|NCT02541084|Caregiver burden
83651|NCT02541084|Anti-vascular endothelial growth factor (VEGF) therapy
83652|NCT02541058|Velocardiofacial Syndrome
83653|NCT02541058|Shprintzen Syndrome
83654|NCT02541058|Conotruncal Defects
83655|NCT02541058|Chromosomal Abnormalities
83656|NCT02541058|22q, 22q.11.2
83657|NCT02541058|deletion
83658|NCT02541058|duplication
83659|NCT02541045|non-alcoholic steatohepatitis
83660|NCT02541045|metadoxine
83661|NCT02541045|efficacy
83662|NCT02541045|therapy
83663|NCT02541019|C23.888.821.712.700
83664|NCT02541006|FEV1
83665|NCT02541006|FVC
83666|NCT02541006|AUC 0-24
83667|NCT02541006|bronchodilator efficacy
83668|NCT02541006|tiotropium
83669|NCT02540993|Type 2 Diabetes
83670|NCT02540993|Kidney diseases
83671|NCT02540967|Contrast enhancement in the following MR imaging
83672|NCT02540967|Brain and spine
83673|NCT02540967|Body and extremities
83674|NCT02540967|Gadobutrol
83675|NCT02540954|Age-related macular degeneration (AMD)
83676|NCT02540954|Eylea treatment
83677|NCT02540954|Treat and Extend
83678|NCT02540954|Intravitreal
83679|NCT02540902|Knee replacement
83680|NCT02540902|Knee arthroplasty
83681|NCT02540902|All-polyethylene tibia
83682|NCT02540902|Bone density
83683|NCT02540863|myofascial pain syndrome
83684|NCT02540863|exercise therapy
83685|NCT02540863|randomized controlled trial
83686|NCT02540850|septin 9
83687|NCT02540850|SEPT9
83688|NCT02540850|colorectal cancer
83689|NCT02540850|CRC
83690|NCT02540850|screening
83691|NCT02540850|methylation
83692|NCT02540850|adenoma
83693|NCT02540850|polyps
83694|NCT02540850|FIT
83695|NCT02540850|FOBT
83696|NCT02540850|colonoscopy
83697|NCT02540824|Apatinib
83698|NCT02540824|RET
83699|NCT02540824|gene fusion
83700|NCT02540824|Non-small Cell Lung Cancer
83701|NCT02540798|Anxiety
83702|NCT02540798|Urodynamics
83703|NCT02540798|Symptom reproducibility
83704|NCT02540798|Lower urinary tract symptoms
83705|NCT02540798|Women
83706|NCT02540785|Refractive Surgical Procedures
83707|NCT02540785|small-incision lenticule extraction
83708|NCT02540785|lenticule extraction
83709|NCT02540785|inflammatory mediators
83710|NCT02540772|Confabulations
83711|NCT02540772|Neuropsychological rehabilitation
83712|NCT02540772|Memory
83713|NCT02540759|Buglossoides arvensis
83714|NCT02540759|vegetable oil
83715|NCT02540759|omega-3 fatty acids
83716|NCT02540759|participants
83717|NCT02540746|Emotional Dysregulation
83718|NCT02540746|Early Intervention
83719|NCT02540746|Youth Mental Health
83720|NCT02540746|Staging
83721|NCT02540746|Motivational Enhancement
83722|NCT02540746|Family Connections
83723|NCT02540746|Family Skills Training
83724|NCT02540733|cerebral infarction
83725|NCT02540733|diabetes
83726|NCT02540733|rehabilitation
83727|NCT02540733|MRI
83728|NCT02540681|Transtibial amputation
83729|NCT02540681|Prosthetic fit
83730|NCT02540681|Prosthetic alignment
83731|NCT02540655|Stem Cells
83732|NCT02540655|Adult Stem Cells
83733|NCT02540655|Spinocerebellar Ataxia
83734|NCT02540655|Steminent
83735|NCT02540629|Cardiopulmonary resuscitation
83736|NCT02540629|Emergency Medicine
83737|NCT02540616|MdDS
83738|NCT02540616|TES
83739|NCT02540616|TMS
83740|NCT02540590|microcirculation
83741|NCT02540590|wound healing
83742|NCT02540590|tunnel technique
83743|NCT02540590|gingival recession
83744|NCT02540590|Mucograft
83745|NCT02540590|laser speckle contrast analyzer
83746|NCT02539290|Unexplained infertility
83747|NCT02539290|Infertility
83748|NCT02539290|Tubal flushing
83749|NCT02539290|Uterine flushing
83750|NCT02539290|Live birth
83751|NCT02539290|Pregnancy
83752|NCT02539290|Randomized controlled trial
83753|NCT02539290|Saline
83754|NCT02539290|Physiological saline
83755|NCT02539264|All patients registered for A PSG
83756|NCT02539264|polysomnography
83757|NCT02539251|Early Child Development
83758|NCT02539251|Ages and Stages Questionnaire _3
83759|NCT02539251|Validation
83760|NCT02539238|Medical Education
83761|NCT02539238|cardiopulmonary resuscitation
83762|NCT02539238|feedback
83763|NCT02539238|cost-effectiveness analysis
83764|NCT02539212|microwave
83765|NCT02539212|radiofrequency
83766|NCT02539212|ablation
83767|NCT02539160|coronary artery disease
83768|NCT02539160|diabetes mellitus
83769|NCT02539160|chronic kidney disease
83770|NCT02539160|ticagrelor
83771|NCT02539147|lipopolysaccharide
83772|NCT02539147|sepsis
83773|NCT02539147|caspase-4 and -5
83774|NCT02539147|monocytes
83775|NCT02539147|IL-1β and IL-1α
83776|NCT02539134|Drug therapy
83777|NCT02539121|Labor
83778|NCT02539121|Acupuncture
83779|NCT02539121|Postpartum hemorrhage
83780|NCT02539121|Placental expulsion time
83781|NCT02539121|Postpartum blood loss
83782|NCT02540538|Adjuvants, immunologic
83783|NCT02540538|Interleukin-2
83784|NCT02540538|Hepatitis B vaccines
83785|NCT02540538|Non-responders
83786|NCT02540525|stress incontinence
83787|NCT02540525|transobturator sling
83788|NCT02540525|single-incision mini-sling
83789|NCT02540499|lung cancer
83790|NCT02540499|breath hold
83791|NCT02540499|radiotherapy
83792|NCT02540486|Type 2 diabetes
83793|NCT02540486|T2DM
83794|NCT02540473|Resilience
83795|NCT02540447|Liver transplantation
83796|NCT02540447|Graft rinse
83797|NCT02540447|Ischemia reperfusion injury
83798|NCT02540434|Hypofibrinogenemia
83799|NCT02540434|ROTEM
83800|NCT02540434|Cardiac Surgery
83801|NCT02540434|Concentrated Fibrinogen
83802|NCT02540421|cervical intraepithelial neoplasia
83803|NCT02540421|human papillomavirus
83804|NCT02540421|conization
83805|NCT02540408|Occupational COPD
83806|NCT02540408|Pathophysiology
83807|NCT02540408|Exercise limitation
83808|NCT02540408|Pulmonary hyperinflation
83809|NCT02540408|Arterial stiffness
83810|NCT02540395|Kidney transplantation
83811|NCT02540395|Immunosuppression
83812|NCT02540395|IFN-γ
83813|NCT02540382|TIPS
83814|NCT02540382|Hepatocellular Carcinoma
83815|NCT02540382|Portasystemic Shunt
83816|NCT02540369|Diabetic macular edema
83817|NCT02540369|Wet Age-related macular degeneration
83818|NCT02540343|Translation
83819|NCT02540343|Validation
83820|NCT02540343|Orebro-G
83821|NCT02540291|E7046
83822|NCT02540291|Advanced malignancies
83823|NCT02540291|malignancies
83824|NCT02540265|Bunion
83825|NCT02540265|Bunionectomy
83826|NCT02540265|Pain
83827|NCT02540265|Analgesia
83828|NCT02540265|N1539
83829|NCT02540252|Lower Limb Amputation
83830|NCT02540252|Nutrition
83831|NCT02540252|Eating
83832|NCT02540252|Inflammation
83833|NCT02540252|Nursing
83834|NCT02540226|Tranexamic Acid
83835|NCT02540226|Total Knee Arthroplasty
83836|NCT02540226|Total Knee Replacement
83837|NCT02540187|haemophilia
83838|NCT02540187|TFPI
83839|NCT02540187|thrombin generation
83840|NCT02540187|hemorrhagic score
83841|NCT02540174|alcohol and tobacco consumption
83842|NCT02540174|addiction treatment
83843|NCT02540135|high grade glioma
83844|NCT02540135|glioblastoma multiforme
83845|NCT02540135|anaplastic astrocytoma
83846|NCT02540135|flourescein
83847|NCT02540135|flourescence-guided surgery
83848|NCT02540135|intraoperative MRI
83849|NCT02540135|iMRI
83850|NCT02540109|Stroke
83851|NCT02540109|Anomia
83852|NCT02540096|mental practice
83853|NCT02540096|motor imagery
83854|NCT02540096|hemiparesis
83855|NCT02540096|stroke
83856|NCT02540096|gait
83857|NCT02540096|mobility
83858|NCT02540070|Adductor canal Block
83859|NCT02540070|ultrasound
83860|NCT02540070|periarticular injections
83861|NCT02540070|Dexmedetomidine
83862|NCT02540018|DEB, drug-eluting balloon, Paclitaxel, peripheral artery disease
83863|NCT02539979|IV Paracetamol
83864|NCT02539979|Radiofrequency Lesion/Ablation of medial branch nerve
83865|NCT02539979|Preventative Pain Management
83866|NCT02539940|Below-the-knee
83867|NCT02539914|Virtual reality
83868|NCT02539914|Motor and cognitive rehabilitation
83869|NCT02539914|Positive emotion stimuli
83870|NCT02539901|cochlear implant
83871|NCT02539901|Developmental Psychology
83872|NCT02539901|cognitive development
83873|NCT02539901|communicative development
83874|NCT02539901|perceptual development
83875|NCT02539901|deaf child
83876|NCT02539875|Effectiveness of quit immediately (QI) and cut down to quit (CDTQ) interventions in achieving smoking abstinence
83877|NCT02539862|Insomnia
83878|NCT02539862|behavioral and cognitive therapies
83879|NCT02539836|children's obesity
83880|NCT02539836|gut microbiome
83881|NCT02539836|body mass index
83882|NCT02539836|fruit and vegetable fermentation extraction
83883|NCT02539836|dietary nutrition intervention
83884|NCT02539784|stimulation
83885|NCT02539771|vaso-occlusive crisis
83886|NCT02539771|obstructive sleep apnea
83887|NCT02539771|priapism
83888|NCT02539758|acute angle closure
83889|NCT02539758|ocular massage
83890|NCT02539745|vitamin D
83891|NCT02539745|primary open- angle glaucoma
83892|NCT02539732|Weaning
83893|NCT02539732|Spontaneous breathing trial
83894|NCT02539732|Neurally-adjusted ventilator assist
83895|NCT02539732|Electrical activity of the diaphragm
83896|NCT02539719|Platinum-Resistant
83897|NCT02539719|Refractory
83898|NCT02539680|Phosphate transporter
83899|NCT02539680|CKD
83900|NCT02539680|duodenal biopsies
83901|NCT02539602|High school
83902|NCT02539602|Longitudnal
83903|NCT02539602|Sexual initiation
83904|NCT02539602|Contraception
83905|NCT02539602|Adolescents
83906|NCT02539602|Pregnancy prevention
83907|NCT02539602|Sexual health
83908|NCT02539576|pharmacokinetics
83909|NCT02539576|Healthy subjects
83910|NCT02539576|Abacavir/dolutegravir/lamivudine
83911|NCT02539576|Japanese
83912|NCT02539576|Fixed-dose combination
83913|NCT02539576|safety
83914|NCT02539563|labor duration
83915|NCT02539550|PF-06266047
83916|NCT02539550|safety
83917|NCT02539550|tolerability
83918|NCT02539550|pharmacokinetics
83919|NCT02539550|first-in-human
83920|NCT02539550|healthy volunteers
83921|NCT02539550|PDE4
83922|NCT02539550|phosphodiesterase-4
83923|NCT02539537|locally advanced pancreatic carcinoma
83924|NCT02539537|FOLFIRINOX
83925|NCT02539524|clinical impact
83926|NCT02539524|anxiety
83927|NCT02539524|quality of life
83928|NCT02539524|Yoga
83929|NCT02539108|Influenza
83930|NCT02539108|Influenza virus vaccine
83931|NCT02539108|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
83932|NCT02539095|intra-articular injection
83933|NCT02539095|intra-articular collagen injection
83934|NCT02539095|collagen
83935|NCT02539095|knee joint pain
83936|NCT02539082|collagen
83937|NCT02539082|collagen injection
83938|NCT02539082|plantar fasciitis
83939|NCT02539069|cartilage defects
83940|NCT02539069|Chondron
83941|NCT02539069|Autologous cultured Chondrocyte
83942|NCT02539069|arthroscopy
83943|NCT02539056|cartilage defects
83944|NCT02539056|Chondron
83945|NCT02539056|Autologous cultured Chondrocyte
83946|NCT02539043|Lipolysis
83947|NCT02539043|Subcutaneous Fat, Abdominal/metabolism
83948|NCT02539043|Subcutaneous Fat, Abdominal/ultrasonography
83949|NCT02539043|High-Intensity Focused Ultrasound Ablation/methods
83950|NCT02539043|Waist Circumference
83951|NCT02539043|Pilot Projects
83952|NCT02539043|Subcutaneous Fat
83953|NCT02539043|High-Intensity Focused Ultrasound Ablation
83954|NCT02539043|Adiposity
83955|NCT02539030|Cartilage defect of knee
83956|NCT02539030|microfracture
83957|NCT02539030|modified microfracture
83958|NCT02539030|collagen
83959|NCT02539017|cellular immune therapy
83960|NCT02539017|triple negative breast cancer
83961|NCT02539017|adjuvant therapy
83962|NCT02539004|kidney stones
83963|NCT02539004|ureteral stones
83964|NCT02538991|Bulkamid
83965|NCT02538991|Tension-Free Vaginal Tape
83966|NCT02538991|Women
83967|NCT02538978|CLI
83968|NCT02538965|Lenalidomide
83969|NCT02538965|Revlimid
83970|NCT02538965|Pediatric
83971|NCT02538965|Relapsed or Refractory
83972|NCT02538965|Acute Myeloid Leukemia
83973|NCT02538965|Leukemia
83974|NCT02538952|GeneXpert
83975|NCT02538952|Tuberculosis
83976|NCT02538952|Human immunodeficiency virus
83977|NCT02538952|Diagnostic accuracy
83978|NCT02538952|Impact
83979|NCT02538939|Calcific tendinitis, Shoulder, Needle lavage, Sodium thiosulfate
83980|NCT02538913|Exercise
83981|NCT02538913|Pelvic floor
83982|NCT02538913|Prehabilitation
83983|NCT02538913|Fecal incontinence
83984|NCT02538913|Urinary incontinence
83985|NCT02538913|Sexual dysfunction, physiological
83986|NCT02538900|peripheral arterial disease, peripheral artery disease, PAD, exercise
83987|NCT02538822|aortic aneurysm
83988|NCT02538822|thoracic ascending aorta
83989|NCT02538822|ATA
83990|NCT02538822|dynamic imaging
83991|NCT02538822|mechanical testing
83992|NCT02538796|Anorexia Nervosa
83993|NCT02538796|Cognition
83994|NCT02538796|Conscious
83995|NCT02538796|Non-Conscious
83996|NCT02538757|Vaccine Administration
83997|NCT02538757|Herpes Zoster
83998|NCT02538705|Diabetic foot syndrome
83999|NCT02538705|Ulcers
84000|NCT02538679|transversus abdominis plane block
84001|NCT02538679|tap block
84002|NCT02538679|regional anesthesia
84003|NCT02538679|colorectal surgery
84004|NCT02538653|glycemic & insulin response, SDS, cereal product, Nutrition
84005|NCT02538640|Nutrition, glycemic response, cereal products
84006|NCT02538627|Heregulin-positive
84007|NCT02538627|EGFR
84008|NCT02538627|ErbB3
84009|NCT02538627|Phase I
84010|NCT02538627|Oncology
84011|NCT02538627|Cancer
84012|NCT02538601|Post Traumatic Stress Disorder
84013|NCT02538601|PTSD
84014|NCT02538601|Cigarette Smoking
84015|NCT02538601|Lower Respiratory Symptoms
84016|NCT02538601|Cognitive Behavioral Therapy
84017|NCT02538601|CBT
84018|NCT02538601|Transdiagnostic Treatments
84019|NCT02538601|World Trade Center
84020|NCT02538588|Healthy Volunteers
84021|NCT02538575|Cystic Fibrosis
84022|NCT02538575|Adults
84023|NCT02538575|6-minute walk test
84024|NCT02538497|NBO
84025|NCT02538497|The Newborn Behavioral Observation
84026|NCT02538497|postpartum depression
84027|NCT02538497|postnatal depression
84028|NCT02538497|attachment
84029|NCT02538458|Saline Solution, Hypertonic (3 %)
84030|NCT02538458|Infant
84031|NCT02538445|Schizophrenia
84032|NCT02538445|Memory
84033|NCT02538445|Cognition
84034|NCT02538432|Disease Progression
84035|NCT02538432|Non-Responsive Disease
84036|NCT02538432|Advanced Disease
84037|NCT02538406|Adenoma
84038|NCT02538406|withdrawal time
84039|NCT02538406|Colonoscopy
84040|NCT02538380|Lung cancer
84041|NCT02538380|Adrenal gland metastasis
84042|NCT02538354|Riboflavin (vitamin B2)
84043|NCT02538354|Faecalibacterium prausnitzii
84044|NCT02538328|laparoscopy
84045|NCT02538328|obesity
84046|NCT02538328|harmonic scalpel
84047|NCT02538328|ligasure
84048|NCT02538315|[18F]FODPA, Parkinson's, PET/CT, Stem Cell transplantation
84049|NCT02538302|Minirin
84050|NCT02538302|Oxybutynin
84051|NCT02538302|Nocturnal enuresis
84052|NCT02538289|Dyspnea
84053|NCT02538289|Palliative Care
84054|NCT02538289|Heart Failure
84055|NCT02538289|Chronic Pulmonary Disease
84056|NCT02538289|Opioids
84057|NCT02538276|carotid endarterectomy, carotid stenosis, carotid stenting
84058|NCT02538250|Oral nutritional supplement
84059|NCT02538250|supplementation
84060|NCT02538250|adult patients
84061|NCT02538224|Periodontitis
84062|NCT02538224|doxycycline/ketoprofen topical gel therapeutic
84063|NCT02538198|lenalidomide (CC-5013)
84064|NCT02538198|maintenance
84065|NCT02538198|15-129
84066|NCT02538172|Cell-mediated immunity
84067|NCT02538172|Antiviral prophylaxis
84068|NCT02538172|Transplantation
84069|NCT02538159|Non-tunneled Central venous catheter
84070|NCT02538159|Bacteraemia
84071|NCT02538159|Peripherally inserted central venous catheter
84072|NCT02538146|pain
84073|NCT02538146|depression
84074|NCT02538146|cytokines
84075|NCT02538146|well-being
84076|NCT02538133|99mTc-Exametazime (HMPAO)-Labeled Leukocytes
84077|NCT02538133|suspected subdiaphragmatic vascular prosthesis infection
84078|NCT02538133|diagnosis
84079|NCT02538094|Cognitive Enhancement
84080|NCT02538094|tDCS
84081|NCT02538094|stimulation
84082|NCT02538094|MS
84083|NCT02538094|Multiple Sclerosis
84084|NCT02538094|Encephalitis
84085|NCT02538081|schizophrenia
84086|NCT02538081|olanzapine
84087|NCT02538081|risperidone
84088|NCT02538081|alpha 7 nicotinic receptors
84089|NCT02538081|cognition
84090|NCT02538068|Purpose in Life
84091|NCT02538068|Self-determination
84092|NCT02538068|Physical activity
84093|NCT02538068|Self-monitoring
84094|NCT02538068|Behavior change
84095|NCT02538055|Community Health Workers
84096|NCT02538055|Diabetes Mellitus
84097|NCT02538055|Chronic Pain
84098|NCT02538029|Dual tasking
84099|NCT02538016|Cystinuria
84100|NCT02538016|Kidney Stones
84101|NCT02537964|chlorhexidine
84102|NCT02537951|autofluorescent flavoprotein imaging, capsaicin
84103|NCT02537925|COX-2 inhibitors
84104|NCT02537925|radiosensitivity
84105|NCT02537925|nasopharyngeal carcinoma
84106|NCT02537912|peanut skin
84107|NCT02537912|body fat
84108|NCT02537912|blood glucose
84109|NCT02537912|waistline
84110|NCT02537912|body weight
84111|NCT02537886|PCOR
84112|NCT02537873|Cocaine Use Disorder
84113|NCT02537847|Sitafloxacin
84114|NCT02537847|Extended-Spectrum ß-lactamase-producing Escherichia coli
84115|NCT02537847|Treatment for Acute Pyelonephritis
84116|NCT02537847|Ertapenem
84117|NCT02537795|Deep Brain Stimulation
84118|NCT02537795|Anterior Capsulotomy
84119|NCT02537782|Cardiac Resynchronisation Therapy
84120|NCT02537782|Heart Failure
84121|NCT02537782|Left ventricular dyssynchrony
84122|NCT02537782|Echocardiography
84123|NCT02537782|Apical rocking
84124|NCT02537782|Septal flash
84125|NCT02537769|LVAD
84126|NCT02537769|Tricuspid regurgitation
84127|NCT02537769|Heart failure
84128|NCT02537769|Transplant
84129|NCT02537769|3D transesophageal echocardiography (TEE)
84130|NCT02537769|2D transesophageal echocardiography (TEE)
84131|NCT02537769|Mild
84132|NCT02537769|Moderate
84133|NCT02537743|Patient Reported Outcomes
84134|NCT02537704|Obesity
84135|NCT02537704|Translational
84136|NCT02537704|Diabetes Prevention Program
84137|NCT02537704|Group Lifestyle Balance Program
84138|NCT02537652|Central blood pressure
84139|NCT02537652|Transient ischaemic attack
84140|NCT02537639|Simulator in transesophageal echocardiography
84141|NCT02537613|Chronic Lymphocytic Leukemia
84142|NCT02537600|BRAF mutation
84143|NCT02537600|Brain metastasis
84144|NCT02537600|Cobimetinib + Vemurafenib combination treatment
84145|NCT02537587|Blood glucose
84146|NCT02537587|Blood insulin
84147|NCT02537587|Humans
84148|NCT02537587|Postprandial
84149|NCT02537587|Carbohydrate
84150|NCT02537587|Protein
84151|NCT02537587|Resistant starch
84152|NCT02537587|Sugar
84153|NCT02537574|Alkermes
84154|NCT02537574|Buprenorphine
84155|NCT02537574|Naltrexone
84156|NCT02537574|Vivitrol
84157|NCT02537574|Opioid Use
84158|NCT02537574|Opiates
84159|NCT02537574|Dependence
84160|NCT02537574|Abuse
84161|NCT02537574|Heroin
84162|NCT02537574|Painkillers
84163|NCT02537574|Substance Abuse
84164|NCT02537496|Alzheimer's Disease
84165|NCT02537496|Brain stimulation
84166|NCT02537496|Transcranial Magnetic Stimulation
84167|NCT02537496|Neuroplasticity
84168|NCT02537496|cognitive enhancement
84169|NCT02537496|TMS-EEG
84170|NCT02537496|rTMS
84171|NCT02537496|PAS
84172|NCT02537431|KRN23
84173|NCT02537431|Fibroblast growth factor 23 (FGF23)
84174|NCT02537431|XLH
84175|NCT02537431|X-linked Hypophosphatemia
84176|NCT02537379|Hepatitis C virus
84177|NCT02537379|observational
84178|NCT02537379|post-marketing
84179|NCT02537379|sofosbuvir
84180|NCT02537353|Upper gastrointestinal bleeding
84181|NCT02537353|Hemospray
84182|NCT02537353|Endoscopic hemostasis
84183|NCT02537340|PET/CT
84184|NCT02537340|MRI
84185|NCT02537340|EMVI
84186|NCT02537340|Liver metastasis
84187|NCT02537340|FDG
84188|NCT02537327|Recurrent caries
84189|NCT02537327|Secondary caries
84190|NCT02537327|Dental composite
84191|NCT02537327|Dental amalgam
84192|NCT02537314|Normal Body Weight
84193|NCT02537301|Endoscopic Retrograde Cholangiopancreatography
84194|NCT02537301|social networking
84195|NCT02537301|group chat
84196|NCT02537288|VA106483
84197|NCT02537288|fedovapagon
84198|NCT02537288|males
84199|NCT02537288|females
84200|NCT02537288|moxifloxacin
84201|NCT02537288|TQT
84202|NCT02537288|QT/QTC
84203|NCT02537288|ECG
84204|NCT02537288|Nocturia
84205|NCT02537262|carbohydrate
84206|NCT02537262|quality of recovery(QOR) 40
84207|NCT02537262|enhanced recovery after surgery(ERAS)
84208|NCT02537249|dexmedetomidine
84209|NCT02537249|quality of recovery
84210|NCT02537236|Omega-3 Fatty Acids
84211|NCT02537236|Therapeutic Lifestyle Changes
84212|NCT02537236|Human Immunodeficiency Virus
84213|NCT02537236|Cardiac Risk
84214|NCT02537236|Dyslipidemia
84215|NCT02537171|Apatinib
84216|NCT02537171|Locally Advanced Gastric Cancer
84217|NCT02537171|Metastatic Gastric Cancer
84218|NCT02537158|sorafenib
84219|NCT02537158|transcatheter arterial chemoembolization
84220|NCT02537158|hepatocellular carcinoma
84221|NCT02537158|microvascular invasion
84222|NCT02537145|compliance
84223|NCT02537145|do-it-yourself methodology
84224|NCT02537145|pilot
84225|NCT02537145|human microbiome
84226|NCT02537132|Non Invasive Ventilation (NIV)
84227|NCT02537132|Amyotrophic Lateral sclerosis (ALS)
84228|NCT02537132|adaptation
84229|NCT02537132|home care
84230|NCT02537106|Brain Tumors
84231|NCT02537106|Microcirculation
84232|NCT02537106|Osmotherapy
84233|NCT02537106|Hypertonic NaCl
84234|NCT02537106|Natremia
84235|NCT02537080|Postoperative cognitive dysfunction
84236|NCT02537080|Nimodipin
84237|NCT02537080|Anesthesia
84238|NCT02537067|a partial cartilage defect of ankle
84239|NCT02537067|Chondron
84240|NCT02537067|Autologus Chondrocyte
84241|NCT02537054|Choroidal neovascularization
84242|NCT02537054|Angioid streaks
84243|NCT02537054|Pseudoxanthoma Elasticum
84244|NCT02537054|vascular endothelial growth factor
84245|NCT02537054|aflibercept
84246|NCT02537028|MSC2364447C
84247|NCT02537028|Phase 1
84248|NCT02537028|BTK inhibitor
84249|NCT02537028|Systemic Lupus Erythematosus
84250|NCT02537028|M2951
84251|NCT02537028|Lupus
84252|NCT02537002|PF-05230907
84253|NCT02537002|Pharmacokinetics
84254|NCT02537002|Pharmacodynamic
84255|NCT02537002|Immunogenicity
84256|NCT02536989|peptic ulcer bleeding
84257|NCT02536989|blood clot
84258|NCT02536989|dose
84259|NCT02536976|mirabegron
84260|NCT02536950|bionic pancreas
84261|NCT02536950|closed-loop control
84262|NCT02536950|artificial pancreas
84263|NCT02536885|Postoperative cognitive dysfunction
84264|NCT02536885|Blood pressure
84265|NCT02536885|Anesthesia
84266|NCT02536872|infection overactive bladder
84267|NCT02536846|Healthy volunteers
84268|NCT02536846|antipsychotic drugs
84269|NCT02536846|brain metabolism
84270|NCT02536833|OA
84271|NCT02536833|Samumed
84272|NCT02536781|Anthocyanin
84273|NCT02536781|Inflammation
84274|NCT02536781|Orthodontic treatment
84275|NCT02536742|Metastatic
84276|NCT02536742|Breast
84277|NCT02536742|HER2 negative
84278|NCT02536742|Palbociclib
84279|NCT02536716|Dental Implant
84280|NCT02536690|propofol
84281|NCT02536690|midazolam
84282|NCT02536690|remifentanil
84283|NCT02536690|combination
84284|NCT02536690|synergic
84285|NCT02536690|pharmacodynamics
84286|NCT02536690|Loss of consciousness
84287|NCT02536677|Acute Chest Pain
84288|NCT02536677|Acute Coronary Syndrome
84289|NCT02536677|Evaluation and Management
84290|NCT02536677|Decision Aid
84291|NCT02536677|Healthcare Utilization
84292|NCT02536651|validation studies, patient-reported outcome measures
84293|NCT02536638|urine protein
84294|NCT02536638|pregnancy
84295|NCT02536638|pyelonephritis
84296|NCT02536638|kidney infection
84297|NCT02536625|everolimus
84298|NCT02536625|NK
84299|NCT02536625|metastatic
84300|NCT02536612|Motivation
84301|NCT02536612|Behavioral Economics
84302|NCT02536612|Conditional Economic Incentives
84303|NCT02536612|Conditional cash transfers
84304|NCT02536612|Contingency management
84305|NCT02536599|Febrile Neutropenia
84306|NCT02536599|Childhood Cancer
84307|NCT02536599|Pediatric Oncology
84308|NCT02536599|Fever
84309|NCT02536599|Neutropenia
84310|NCT02536573|Total hip replacement
84311|NCT02536560|intestinal microbiota
84312|NCT02536560|antibiotics
84313|NCT02536560|infant
84314|NCT02536560|allergy
84315|NCT02536547|Clinical pulmonary infection score
84316|NCT02536547|sepsis
84317|NCT02536547|lung ultrasound
84318|NCT02536547|ventilator-associated pneumonia
84319|NCT02536534|Pulmonary Arterial Hypertension (PAH)
84320|NCT02536534|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
84321|NCT02536456|screening
84322|NCT02536456|counseling
84323|NCT02536456|follow-up
84324|NCT02536456|cardiovascular disease
84325|NCT02536456|population-based project
84326|NCT02536456|China
84327|NCT02536443|heart failure
84328|NCT02536443|prognosis
84329|NCT02536443|clinical characteristics
84330|NCT02536430|Infra alveolar nerve block
84331|NCT02536430|Ketorolac
84332|NCT02536430|Success rate
84333|NCT02536417|Melatonin
84334|NCT02536417|Delirium prevention
84335|NCT02536417|End-of-life
84336|NCT02536352|Fluoride Supplementation
84337|NCT02536352|Prenatal Vitamin
84338|NCT02536352|Pregnancy Nutrition
84339|NCT02536352|Prenatal Nutrition
84340|NCT02536287|secondary hyperparathyroidism
84341|NCT02536287|total parathyroidectomy
84342|NCT02536287|autotransplantation
84343|NCT02536287|morbidity
84344|NCT02536287|recurrence
84345|NCT02536287|postoperative hypocalcemia
84346|NCT02536261|Prolactinoma
84347|NCT02536261|dopamine agonist
84348|NCT02536261|withdrawal
84349|NCT02536261|cavernous sinus
84350|NCT02536248|sitagliptin
84351|NCT02536248|diabetes
84352|NCT02536248|inflammation
84353|NCT02536196|Cerebral protection, aortic stenosis, transcatheter aortic valve implantation, TAVI, TriGuard, Keystone Heart
84354|NCT02536183|Solid tumors
84355|NCT02536183|relapsed pediatric solid tumors
84356|NCT02536183|high intensity focused ultrasound
84357|NCT02536183|Lyso-thermosensitive liposomal doxorubicin
84358|NCT02536183|ThermoDox
84359|NCT02536183|relapsed sarcoma
84360|NCT02536183|Ewing Sarcoma family of tumors
84361|NCT02536183|Osteosarcoma
84362|NCT02536183|Neuroblastoma
84363|NCT02536183|Wilms Tumor
84364|NCT02536183|Hepatic Tumor
84365|NCT02536183|Germ Cell Tumors
84366|NCT02536170|Arginine Therapy
84367|NCT02536157|Volar plate
84368|NCT02536144|colon capsule
84369|NCT02536144|magnetic
84370|NCT02536144|maneuverability
84371|NCT02536144|colonoscopy
84372|NCT02536131|Psychosomatics
84373|NCT02536131|Gastroenterology
84374|NCT02536131|Psychoneuroimmunology
84375|NCT02536105|Attention Deficit Hyperactivity Disorder
84376|NCT02536105|ADHD
84377|NCT02536053|[E04.100.814.603]
84378|NCT02536040|silver diamine fluoride
84379|NCT02536040|diammine silver fluoride
84380|NCT02536040|children
84381|NCT02536027|continuous venovenous hemofiltration
84382|NCT02536027|neutrophil gelatinase-associated lipocalin
84383|NCT02536027|sepsis
84384|NCT02536027|acute kidney injury
84385|NCT02536014|Dexmedetomidine
84386|NCT02536014|pneumoperitoneum
84387|NCT02536014|trendelenburg position
84388|NCT02536014|QTc interval
84389|NCT02536014|Tp-e interval
84390|NCT02536014|robotic prostatectomy
84391|NCT02536001|Vaginal mesh
84392|NCT02536001|Total vaginal length
84393|NCT02536001|Quality of life
84394|NCT02535988|Colorectal Cancer
84395|NCT02535988|Metastatic Colorectal Cancer
84396|NCT02535988|ZADAXIN
84397|NCT02535988|Abscopal Effect
84398|NCT02535988|Radiotherapy
84399|NCT02535962|PFAPA
84400|NCT02535936|Cerebral Palsy
84401|NCT02535923|Schizophrenia and Disorders with Psychotic Feature
84402|NCT02535923|Mental Disorders
84403|NCT02535923|Insomnia Disorder
84404|NCT02535910|vitamin D3
84405|NCT02535910|25(OH)D3
84406|NCT02535910|vitamin D status
84407|NCT02535910|risk factors of cardiovascular diease
84408|NCT02535884|Huntington Disease
84409|NCT02535884|DBS
84410|NCT02535884|Chorea
84411|NCT02535858|Anxiety
84412|NCT02535832|Rheumatoid Arthritis
84413|NCT02535819|Cataract surgery
84414|NCT02535806|Relapsed, Refractory
84415|NCT02535767|Primaquine
84416|NCT02535741|Knee Replacement
84417|NCT02535741|Arthroplasty
84418|NCT02535728|Frail Elderly
84419|NCT02535728|Cardiac Surgical Procedure
84420|NCT02535728|Risk Assessment
84421|NCT02535728|Quality of Life
84422|NCT02535715|Oral Insulin
84423|NCT02535702|fMRI
84424|NCT02535702|EEG
84425|NCT02535689|Anti-DNA Antibody
84426|NCT02535689|Tofacitinib
84427|NCT02535689|Lupus
84428|NCT02535689|Safety
84429|NCT02535676|schizophrenia
84430|NCT02535676|transcranial stimulation
84431|NCT02535663|rhamnogalacturonan
84432|NCT02535663|Natural killer cell activity
84433|NCT02535663|interleukin-12
84434|NCT02535663|interferon-gamma
84435|NCT02535663|immune function
84436|NCT02535663|inflammatory
84437|NCT02535572|Electroconvulsive Therapy
84438|NCT02535546|Chronic obstructive pulmonary disease (COPD)
84439|NCT02535546|Streptococcus pneumoniae
84440|NCT02535546|Pneumonia
84441|NCT02535546|Pneumococcal conjugate vaccine-13 (PCV-13)
84442|NCT02535546|Pneumococcal polysaccharide vaccine-23 (PPV-23)
84443|NCT02535546|Pneumococcal vaccine
84444|NCT02535533|Kidney cancer
84445|NCT02535533|Selenium (Se)
84446|NCT02535507|pyrotinib
84447|NCT02535507|HER2
84448|NCT02535507|Non-small Cell Lung Cancer
84449|NCT02535507|Phase II
84450|NCT02535481|epidermal graft
84451|NCT02535481|suction blister
84452|NCT02535481|blister graft
84453|NCT02535481|suction graft
84454|NCT02535481|Epidermis/su, tr [Surgery, Transplantation]
84455|NCT02535390|cognitive remediation
84456|NCT02535390|vocational outcomes
84457|NCT02535377|Cryodamage
84458|NCT02535377|microarrays
84459|NCT02535377|Insemination
84460|NCT02535377|sperm
84461|NCT02535364|acute lymphoblastic leukemia
84462|NCT02535364|ALL
84463|NCT02535364|chimeric antigen receptor
84464|NCT02535364|CAR
84465|NCT02535364|CAR T cells
84466|NCT02535364|JCAR015
84467|NCT02535364|autologous T cell therapy
84468|NCT02535364|cell therapy
84469|NCT02535351|Clear cell Metastatic renal cell carcinoma
84470|NCT02535351|Cytoreductive nephrectomy
84471|NCT02535351|First line treatment
84472|NCT02535299|telomere-telomerase
84473|NCT02535299|Par-4
84474|NCT02535299|GLP-1
84475|NCT02535299|metformin
84476|NCT02535273|dexmedetomidine
84477|NCT02535273|prone position
84478|NCT02535273|spine surgery
84479|NCT02535273|Minimally invasive
84480|NCT02535273|local anesthesia
84481|NCT02535260|Pregnancy
84482|NCT02535221|Premenopausal Patients
84483|NCT02535221|Estrogen Receptor-Positive HER2 negative
84484|NCT02535169|at risk for type 2 diabetes
84485|NCT02535169|currently has type 2 diabetes
84486|NCT02535065|Low Profile
84487|NCT02535065|Abdominal Aortic Aneurysms
84488|NCT02535065|Endovascular
84489|NCT02535039|Elderly
84490|NCT02535039|cognitive retention disorder
84491|NCT02535039|methylprednisolone
84492|NCT02534974|Critical care
84493|NCT02534974|Trauma patients
84494|NCT02534961|Hepatocellular carcinoma
84495|NCT02534961|Radiofrequency ablation
84496|NCT02534961|Antibiotics
84497|NCT02534948|mindfulness
84498|NCT02534948|MABT
84499|NCT02534948|social anxiety
84500|NCT02534948|mindfulness and acceptance
84501|NCT02534948|group therapy
84502|NCT02534935|Phase 2 Immunogenicity
84503|NCT02534935|Safety
84504|NCT02534935|Tolerability Study
84505|NCT02534935|rLP2086 Vaccine
84506|NCT02534935|Healthy Toddlers
84507|NCT02534935|Neisseria meningitidis
84508|NCT02534935|Duration of Immunogenicity
84509|NCT02534909|PNH
84510|NCT02534870|Volunteer
84511|NCT02534857|randomized double blinded study
84512|NCT02534857|live birth rate
84513|NCT02534857|IVF treatment
84514|NCT02534857|brief incubation of oocytes and sperm
84515|NCT02534844|Niemann-Pick Type C1 (NPC1) Disease
84516|NCT02534844|neurologic disease
84517|NCT02534844|gross motor dysfunction
84518|NCT02534844|fine motor dysfunction
84519|NCT02534844|dysphagia
84520|NCT02534844|swallowing problems
84521|NCT02534844|cognitive dysfunction
84522|NCT02534844|gait abnormalities
84523|NCT02534844|pediatrics
84524|NCT02534727|Tuberculosis
84525|NCT02534727|Non-Tuberculous Mycobacterim
84526|NCT02534727|Xpert/MDR-RIF
84527|NCT02534727|TDM
84528|NCT02534701|stroke
84529|NCT02534701|clot retrieval system
84530|NCT02534701|recanalization
84531|NCT02534649|Molecular profiling
84532|NCT02534649|Genomic alteration
84533|NCT02534649|Advanced cancer
84534|NCT02534610|preemptive
84535|NCT02534610|postoperative pain
84536|NCT02534610|etoricoxib
84537|NCT02534584|acute kidney injury
84538|NCT02534584|outcome
84539|NCT02534584|mortality
84540|NCT02534584|care-bundle
84541|NCT02534558|MicroRNA-29
84542|NCT02534558|shoulder stiffness
84543|NCT02534558|mir-29a
84544|NCT02534545|Intracranial atherosclerotic stenosis
84545|NCT02534545|ischemia
84546|NCT02534545|remote ischemic conditioning
84547|NCT02534545|stroke
84548|NCT02534532|Atrial fibrillation screening
84549|NCT02534506|Advanced malignant tumors
84550|NCT02534506|Metastatic malignant tumors
84551|NCT02534480|Amyloid
84552|NCT02534415|Antiinflammatory
84553|NCT02534415|Gingiva
84554|NCT02534415|Hyaluronic acid
84555|NCT02534415|Palate
84556|NCT02534415|Transplants
84557|NCT02534415|Wound healing
84558|NCT02534402|Biomarkers
84559|NCT02534402|Genomics
84560|NCT02534402|Prednisone
84561|NCT02534389|rectal cancer
84562|NCT02534389|inflammation
84563|NCT02534389|omega-3
84564|NCT02534389|fish oil
84565|NCT02534389|nutritional status
84566|NCT02534376|prostatectomy, cholesterol, statin
84567|NCT02534363|Cognition
84568|NCT02534363|Psychosis
84569|NCT02534363|Antipsychotic Agents
84570|NCT02534363|Treatment
84571|NCT02534363|Effectiveness
84572|NCT02534363|Aripiprazole
84573|NCT02534363|Quetiapine
84574|NCT02534363|Ziprasidone
84575|NCT02534363|Neurocognition
84576|NCT02534350|Respiratory Syncytial Virus (RSV)
84577|NCT02534350|Antiviral
84578|NCT02534350|Lung Transplant
84579|NCT02534324|Hypertension
84580|NCT02534324|Emergency
84581|NCT02534298|single sided deafness.
84582|NCT02534298|Auditory plasticity
84583|NCT02534298|Asymmetrical hearing loss
84584|NCT02534298|Cochlear implants
84585|NCT02534298|Inter hemispheric asymmetry
84586|NCT02534298|Lateralization index
84587|NCT02534298|Dichotic hearing
84588|NCT02534285|Anesthesia, Inhalation
84589|NCT02534285|Hearing
84590|NCT02534285|Noise, Occupational
84591|NCT02534246|Core tissue biopsy
84592|NCT02534246|Core needle biopsy
84593|NCT02534246|EUS
84594|NCT02534246|Fine needle biopsy
84595|NCT02534246|Fine needle aspiration
84596|NCT02534233|barrett's esophagus with dysplasia
84597|NCT02534233|early esophageal cancer
84598|NCT02534220|Toothbrushing
84599|NCT02534220|Oral hygiene
84600|NCT02534220|Dental hygiene
84601|NCT02534194|Gestation
84602|NCT02534194|Premature
84603|NCT02534194|Infants
84604|NCT02534181|Refeeding Syndrome
84605|NCT02534181|Cancer
84606|NCT02534168|genetic polymorphisms
84607|NCT02534155|MitraClip®
84608|NCT02534155|MR
84609|NCT02534155|DMR
84610|NCT02534155|high-risk patients
84611|NCT02534155|mitral regurgitation
84612|NCT02534155|surgery
84613|NCT02534155|intermediate risk patients
84614|NCT02534129|breast cancer
84615|NCT02534129|radiation
84616|NCT02534129|dermatitis
84617|NCT02534116|abdominal reconstruction
84618|NCT02534090|Premature
84619|NCT02534090|Preterm
84620|NCT02534090|Necrotizing
84621|NCT02534090|Enterocolitis
84622|NCT02534090|NIRS
84623|NCT02534077|omegaven
84624|NCT02534077|cholestasis
84625|NCT02534077|parenteral nutrition associated liver disease
84626|NCT02534064|Menopause
84627|NCT02534064|Osteoporosis
84628|NCT02534064|Hip fractures
84629|NCT02534064|vitamin D deficiency
84630|NCT02534051|clinical care path
84631|NCT02534051|care pathway
84632|NCT02534051|obesity
84633|NCT02534051|pregnancy
84634|NCT02534038|Disinhibition
84635|NCT02533986|Berry
84636|NCT02533986|Inflammation
84637|NCT02533986|Cognition
84638|NCT02533986|Polyphenols
84639|NCT02533986|Appetite
84640|NCT02533986|Glucose metabolism
84641|NCT02533960|Registry of Acute Stroke Under Novel Oral Anticoagulants
84642|NCT02533947|Allogeneic Stem Cell Transplantation
84643|NCT02533947|Hematological Malignancies
84644|NCT02533947|Exercise Intervention
84645|NCT02533947|Cognitive Function
84646|NCT02533947|Fatigue
84647|NCT02533947|Randomized Controlled Trial
84648|NCT02533934|HIV
84649|NCT02533934|Hepatitis C
84650|NCT02533934|Liver Disease
84651|NCT02533934|HCV Treatment
84652|NCT02533934|transplant
84653|NCT02533921|Palliative Care
84654|NCT02533921|Parkinson's Disease
84655|NCT02533869|low-dose computed tomography
84656|NCT02533817|Fructose
84657|NCT02533817|Insulin
84658|NCT02533817|Postprandial lipemia
84659|NCT02533817|Ambulatory blood pressure
84660|NCT02533817|Ethnicity
84661|NCT02533804|health
84662|NCT02533804|wellness
84663|NCT02533804|life expectancy
84664|NCT02533804|quality of life
84665|NCT02533804|performance
84666|NCT02533804|religion
84667|NCT02533804|skin
84668|NCT02533804|cardiovascular
84669|NCT02533804|joints
84670|NCT02533804|bone
84671|NCT02533804|respiration
84672|NCT02533804|pain
84673|NCT02533804|nervous system diseases
84674|NCT02533804|oral health
84675|NCT02533804|behavior
84676|NCT02533804|child
84677|NCT02533804|depression
84678|NCT02533804|mood
84679|NCT02533804|panic
84680|NCT02533804|sleep
84681|NCT02533804|stress
84682|NCT02533804|nutrition
84683|NCT02533804|exercise
84684|NCT02533804|life change events
84685|NCT02533804|personality
84686|NCT02533804|employment
84687|NCT02533804|social networking
84688|NCT02533804|time management
84689|NCT02533804|residence characteristics
84690|NCT02533791|Safety
84691|NCT02533791|immunogenicity
84692|NCT02533791|Ebola vaccine
84693|NCT02533791|boosting
84694|NCT02533765|Cisplatin-resistant
84695|NCT02533765|Neoplasms, Germ Cell and Embryonal
84696|NCT02533765|Salvage treatment
84697|NCT02533765|olaparib
84698|NCT02533752|Left Atrial Appendage Closure
84699|NCT02533752|Watchman device
84700|NCT02533752|LAA Closure
84701|NCT02533726|Bed Sores
84702|NCT02533726|Bedsores
84703|NCT02533726|Decubitus Ulcer
84704|NCT02533726|Pressure Sore
84705|NCT02533713|rehabilitation
84706|NCT02533713|bone strength
84707|NCT02533713|quality of life
84708|NCT02533687|prostate
84709|NCT02533687|transurethral resection
84710|NCT02533687|bipolar
84711|NCT02533687|monopolar
84712|NCT02533661|Effectiveness
84713|NCT02533661|Genes
84714|NCT02533661|Intervention
84715|NCT02533661|Neurodevelopment
84716|NCT02533661|Prematurity
84717|NCT02533661|Preschool Age
84718|NCT02533648|Type 2 diabetes mellitus, oxidative stress
84719|NCT02533648|insulin sensitivity
84720|NCT02533648|insulin resistance
84721|NCT02533648|mitochondrial dysfunction
84722|NCT02533648|skeletal muscle
84723|NCT02533648|xanthine oxidase
84724|NCT02533648|allopurinol
84725|NCT02533622|progressive mobility
84726|NCT02533583|pulse oximetry
84727|NCT02533583|clinical assessment
84728|NCT02533583|neonate
84729|NCT02533583|lung disease
84730|NCT02533570|Lupus
84731|NCT02533557|brachial plexus block
84732|NCT02533557|nerve stimulator
84733|NCT02533557|ultrasound
84734|NCT02533544|tenofovir disoproxil fumarate
84735|NCT02533505|Respiratory
84736|NCT02533505|COPD
84737|NCT02533505|O2 Consumption
84738|NCT02533492|total knee replacement
84739|NCT02533492|vicryl plus
84740|NCT02533492|surgical site infection
84741|NCT02533453|Type 2 Diabetes Mellitus, T2DM, GLP-1, GLP-1 Once weekly, Exenatide
84742|NCT02533414|kidney stone
84743|NCT02533414|retrograde intrarenal surgery
84744|NCT02533414|ureteral access sheath
84745|NCT02533414|kidney function
84746|NCT02533388|transcutaneous electrical acupoint stimulation
84747|NCT02533388|stress response
84748|NCT02533375|efficacy
84749|NCT02533375|safety
84750|NCT02533349|laryngopharyngeal reflux disease
84751|NCT02533349|prokinetics
84752|NCT02533349|proton pump inhibitor
84753|NCT02533336|Malaria control
84754|NCT02533336|Insecticide treated durable Wall Liners
84755|NCT02533336|Malaria incidence
84756|NCT02533336|Randomized Trial
84757|NCT02533323|NK/T-cell lymphoma
84758|NCT02533323|induction chemotherapy
84759|NCT02533323|survival
84760|NCT02533310|Specific phobia
84761|NCT02533310|Exposure therapy
84762|NCT02533310|Virtual reality
84763|NCT02533310|Randomized controlled trial
84764|NCT02533297|standardization,
84765|NCT02533297|performance clinical skills
84766|NCT02533297|nursing
84767|NCT02533297|learning curve
84768|NCT02533271|rectal cancer
84769|NCT02533271|short-term radiotherapy
84770|NCT02533271|neoadjuvant chemotherapy
84771|NCT02533271|total mesorectal excision
84772|NCT02533258|advanced renal cell carcinoma, disease progression, sunitinib, interferon alpha
84773|NCT02533245|Exercise Training
84774|NCT02533245|Quality of Life
84775|NCT02533245|Patient Reported Outcomes
84776|NCT02533245|Organ Transplantation
84777|NCT02533232|Schizophrenia
84778|NCT02533232|Anti-inflammatory
84779|NCT02533232|Clozapine
84780|NCT02533232|Minocycline
84781|NCT02533232|Psychosis NOS
84782|NCT02533219|Hyperinsulinemic hypoglycemia
84783|NCT02533219|PET/CT
84784|NCT02533219|PET/MRI
84785|NCT02533219|[18F]-DOPA
84786|NCT02533219|PET/MR
84787|NCT02533219|Congenital Hyperinsulinism
84788|NCT02533193|enhanced recovery after surgery protocal
84789|NCT02533193|laparoscopic hepatectomy
84790|NCT02533180|Liver allograft recipient
84791|NCT02533180|Immunosuppression withdrawal
84792|NCT02533180|Calcineurin inhibitor (CNI) based immunosuppression
84793|NCT02533180|Living Donor (of the Respective Liver Transplant Recipient)
84794|NCT02533141|Investigation of the changes of flicker induced vasodilatation before, during and after withdrawal of therapy with simvastatin
84795|NCT02533128|Intraoperative blood pressure
84796|NCT02533128|Triple low
84797|NCT02533128|Anesthetic overdose
84798|NCT02533128|Major adverse cardiac events (MACE)
84799|NCT02533128|Myocardial injury after noncardiac surgery (MINS)
84800|NCT02533128|Perioperative risk stratification
84801|NCT02533128|Brain-type natriuretic peptide (BNP)
84802|NCT02533128|High-sensitivity cardiac Troponin I (hs-cTnI)
84803|NCT02533115|VYXEOS
84804|NCT02533102|Pharmacokinetics
84805|NCT02533102|E7050
84806|NCT02533102|Healthy Subjects
84807|NCT02533050|obstructive sleep apnea
84808|NCT02533050|acute coronary event
84809|NCT02533050|cognitive functions
84810|NCT02533050|Continuous positive airway pressure night
84811|NCT02533011|Sepsis
84812|NCT02533011|Heparin Binding Protein
84813|NCT02532998|Pharmacodynamics
84814|NCT02532998|AZD9977
84815|NCT02532998|Safety
84816|NCT02532998|Tolerability
84817|NCT02532998|Pharmacokinetics
84818|NCT02532998|Eplerenone
84819|NCT02532998|Fludrocortisone
84820|NCT02532985|Gastrointestinal tolerability
84821|NCT02532985|dietary fiber
84822|NCT02532985|clinical trial
84823|NCT02532985|healthy subjects
84824|NCT02532933|Replacement, Knee
84825|NCT02532920|Natural history
84826|NCT02532920|Atopic dermatitis
84827|NCT02532920|Atopic march
84828|NCT02532907|HCV
84829|NCT02532894|endothelial dysfunction
84830|NCT02532894|microvesicles
84831|NCT02532894|endothelial progenitor cells
84832|NCT02532894|electronic cigarettes
84833|NCT02532842|Schizophrenia
84834|NCT02532842|Paliperidone palmitate
84835|NCT02532816|stunting
84836|NCT02532816|indonesia
84837|NCT02532803|Cancer
84838|NCT02532803|Rectum
84839|NCT02532803|Rectal Cancer
84840|NCT02532803|Polyps
84841|NCT02532790|Mild proteinuria
84842|NCT02532764|cystic fibrosis
84843|NCT02532764|ΔF508
84844|NCT02532764|RNA therapies
84845|NCT02532764|antisense oligonucleotide
84846|NCT02532764|CFTR
84847|NCT02532764|F508del
84848|NCT02532764|CF
84849|NCT02532764|RNA therapy
84850|NCT02532738|efficacy of MSC
84851|NCT02532738|refractory
84852|NCT02532725|heat stress response
84853|NCT02532725|cardiopulmonary exercise test
84854|NCT02532725|men
84855|NCT02532725|middle aged
84856|NCT02532725|heat-shock response
84857|NCT02532712|EC-18
84858|NCT02532712|Hematology
84859|NCT02532712|Cancer
84860|NCT02532712|Neutropenia
84861|NCT02532699|Antrodia cinnamomea mycelia
84862|NCT02532699|blood pressure
84863|NCT02532699|adenosine
84864|NCT02532699|antrosterol
84865|NCT02532699|clinical trial
84866|NCT02532699|gamma-aminobutyric acid
84867|NCT02532686|Treatment resistant
84868|NCT02532686|DAAOI
84869|NCT02532686|NMDA
84870|NCT02532634|ramosetron
84871|NCT02532634|palonosetron
84872|NCT02532634|chemotherapy induced nausea and vomiting
84873|NCT02532582|nerve compression
84874|NCT02532530|Aortic valve replacement with or without CABG
84875|NCT02532504|postnatal depression
84876|NCT02532504|Cognitive behaviour Therapy
84877|NCT02532504|Traditional Birth Attendants
84878|NCT02532504|low income country
84879|NCT02532491|Psychosis
84880|NCT02532491|Antipsychotic Agents
84881|NCT02532491|Treatment
84882|NCT02532491|Effectiveness
84883|NCT02532491|Aripiprazole
84884|NCT02532491|Risperidone
84885|NCT02532452|Epstein-Barr Virus (EBV)
84886|NCT02532452|Adenovirus (ADV)
84887|NCT02532452|Cytomegalovirus (CMV)
84888|NCT02532452|T-Cells
84889|NCT02532452|Donor
84890|NCT02532439|fracture osteoporosis
84891|NCT02532439|bone microarchitecture
84892|NCT02532439|Inflammatory joint diseases
84893|NCT02532439|Bone fragility
84894|NCT02532439|Rheumatoid Arthritis
84895|NCT02532439|Spondyloarthritis
84896|NCT02532439|Primary Hyperparathyroidism
84897|NCT02532439|constitutional thinness
84898|NCT02532439|anorexia nervosa
84899|NCT02532426|Chronic Obstructive Pulmonary Disease
84900|NCT02532426|Muscle biopsy
84901|NCT02532426|Chronic hypoxia
84902|NCT02532426|OXYPHEN
84903|NCT02532426|Oxydative phenotype
84904|NCT02532426|Exercise
84905|NCT02532400|Breast Neoplasms
84906|NCT02532400|Neoadjuvant Endocrine Therapy
84907|NCT02532400|Ovarian Function Suppression
84908|NCT02532400|Neoadjuvant chemotherapy
84909|NCT02532374|nicotine absorption
84910|NCT02532374|nicotine containing product
84911|NCT02532374|conventional cigarette
84912|NCT02532374|Nicorette
84913|NCT02532374|combustible cigarette
84914|NCT02532374|nicotine delivery system
84915|NCT02532361|Sterilization
84916|NCT02532361|Hysteroscopic Device Placement
84917|NCT02532361|Tubal Ligation
84918|NCT02532348|Human Immunodeficiency Virus
84919|NCT02532348|HIV
84920|NCT02532348|antiretroviral therapy
84921|NCT02532348|platelets
84922|NCT02532348|Immune activation
84923|NCT02532348|Inflammatory state
84924|NCT02532335|FXR
84925|NCT02532335|bile acids
84926|NCT02532335|FGF19
84927|NCT02532335|C4
84928|NCT02532335|gut microbiota
84929|NCT02532335|Pharmacodynamics of FXR activation in the small bowel
84930|NCT02532309|Rosuvastatin
84931|NCT02532309|Carotid Atherosclerosis plaque
84932|NCT02532309|Crestor
84933|NCT02532309|Rosuvastatin calcium
84934|NCT02532283|Influenza A virus
84935|NCT02532283|JNJ-63623872
84936|NCT02532283|Oseltamivir
84937|NCT02532270|obstetric
84938|NCT02532270|anesthesia
84939|NCT02532270|hypotension
84940|NCT02532270|arterial pressure
84941|NCT02532270|measurement techniques
84942|NCT02532257|Lymphoma
84943|NCT02532257|Follicular Lymphoma
84944|NCT02532257|FL
84945|NCT02532257|Previously untreated
84946|NCT02532257|Lenalidomide
84947|NCT02532257|CC-5013
84948|NCT02532257|Revlimid
84949|NCT02532257|Rituximab
84950|NCT02532257|Rituxan
84951|NCT02532257|Ibrutinib
84952|NCT02532257|PCI-32765
84953|NCT02532257|Imbruvica
84954|NCT02532244|distal hereditary motor neuronopathy
84955|NCT02532231|Leukemia
84956|NCT02532231|Acute myeloid leukemia
84957|NCT02532231|AML
84958|NCT02532231|High risk for relapse
84959|NCT02532231|Nivolumab
84960|NCT02532231|BMS-936558
84961|NCT02532231|Opdivo
84962|NCT02532192|Lymphoma
84963|NCT02532192|Diffuse large B-cell lymphoma
84964|NCT02532192|DLBCL
84965|NCT02532192|Relapsed
84966|NCT02532192|Refractory
84967|NCT02532192|Belinostat
84968|NCT02532192|Rituximab
84969|NCT02532192|Rituxan
84970|NCT02532192|Cisplatin
84971|NCT02532192|Platinol-AQ
84972|NCT02532192|Platinol
84973|NCT02532192|CDDP
84974|NCT02532192|Cytarabine
84975|NCT02532192|Ara-C
84976|NCT02532192|Cytosar
84977|NCT02532192|DepoCyt
84978|NCT02532192|Cytosine arabinosine hydrochloride
84979|NCT02532192|Dexamethasone
84980|NCT02532192|Decadron
84981|NCT02532192|Ciprofloxacin
84982|NCT02532192|Ciprofloxacin hydrochloride
84983|NCT02532192|Cipro
84984|NCT02532192|Fluconazole
84985|NCT02532192|Diflucan
84986|NCT02532179|subcutaneous immunotherapy (SCIT)
84987|NCT02532179|glycerinated mouse allergenic extract
84988|NCT02532179|mouse specific IgE
84989|NCT02532179|mouse specific IgG and IgG4
84990|NCT02532179|mouse prick skin test wheal
84991|NCT02532166|narrow band imaging
84992|NCT02532166|Chromoendoscopy
84993|NCT02532166|Lugol
84994|NCT02532153|Suicidal Ideation
84995|NCT02532153|Suicide
84996|NCT02532153|Suicidal Thoughts
84997|NCT02532153|Depression
84998|NCT02532153|Ketamine
84999|NCT02532127|Low-dose risk
85000|NCT02532075|COPD
85001|NCT02532075|Respiratory Muscle Warm Up
85002|NCT02532062|lung cancer risk
85003|NCT02532062|cigarette smokers
85004|NCT02532049|Malaria
85005|NCT02532049|Vaccine
85006|NCT02532049|Immune Response
85007|NCT02532036|MVA85A
85008|NCT02532036|Tuberculosis
85009|NCT02532036|Vaccine
85010|NCT02532036|Aerosol
85011|NCT02532023|omega 3 fatty acid
85012|NCT02532023|curcumin
85013|NCT02532023|COX-2
85014|NCT02532023|iNOs
85015|NCT02532023|VCAM-1
85016|NCT02532023|ICAM-1
85017|NCT02532023|IL-1β
85018|NCT02532023|IL-6
85019|NCT02532023|TNF-α
85020|NCT02532023|hsCRP
85021|NCT02532023|migraine
85022|NCT02531997|self-image
85023|NCT02531997|sexual health
85024|NCT02531997|breast cancer
85025|NCT02531997|gynecologic cancer
85026|NCT02531997|ovarian cancer
85027|NCT02531997|cervical cancer
85028|NCT02531997|uterine cancer
85029|NCT02531997|mind body
85030|NCT02531997|hypnotic relaxation therapy
85031|NCT02531997|hypnosis
85032|NCT02531997|progressive muscle relaxation
85033|NCT02531971|Bioequivalence
85034|NCT02531971|Therapeutic Equivalency
85035|NCT02531945|topography
85036|NCT02531945|cobb angle
85037|NCT02531932|advanced triple negative breast cancer
85038|NCT02531919|tumor acidity
85039|NCT02531893|Irritability
85040|NCT02531893|Disruptive Mood
85041|NCT02531893|Tantrums
85042|NCT02531893|Frustration
85043|NCT02531893|Interpretation Bias
85044|NCT02531893|Emotional Judgment
85045|NCT02531893|Cognitive-Behavioral
85046|NCT02531893|Exposure
85047|NCT02531893|Research Psychotherapy
85048|NCT02531880|MRI
85049|NCT02531880|Manganese Enhanced MRI
85050|NCT02531880|Seizure Disorder
85051|NCT02531880|Seizures
85052|NCT02531880|Epileptic Focus
85053|NCT02531867|HPP
85054|NCT02531867|Bone Disease
85055|NCT02531867|Soft Bones
85056|NCT02531867|Low Alkaline Phosphatase
85057|NCT02531867|Genetic Metabolic Disorder
85058|NCT02531867|Alkaline Phosphatase
85059|NCT02531867|Rickets
85060|NCT02531867|Osteomalacia
85061|NCT02531815|safety
85062|NCT02531815|tolerability
85063|NCT02531815|pharmacokinetics
85064|NCT02531815|pharmacodynamics
85065|NCT02531815|Phase 1
85066|NCT02531815|first in human
85067|NCT02531815|monoclonal antibody
85068|NCT02531815|tissue factor pathway inhibitor
85069|NCT02531815|japanese
85070|NCT02531802|ETEC diarrhea
85071|NCT02531802|Escherichia Coli (ETEC)
85072|NCT02531776|Diabetes
85073|NCT02531776|Needle
85074|NCT02531776|Pen needle
85075|NCT02531763|mHealth
85076|NCT02531763|behavioral economics
85077|NCT02531763|social incentives
85078|NCT02531750|Metabolism
85079|NCT02531750|Bone metabolism
85080|NCT02531750|Glucose Metabolism
85081|NCT02531750|Lipid metabolism
85082|NCT02531750|Low grade inflamation
85083|NCT02531724|acute kidney injury
85084|NCT02531724|cardiac surgery
85085|NCT02531724|renal blood flow
85086|NCT02531724|levosimendan
85087|NCT02531711|Lumbosacral
85088|NCT02531711|radicular
85089|NCT02531685|dmLT
85090|NCT02531685|Enteric
85091|NCT02531685|Escherichia coli Infections
85092|NCT02531685|Shigella
85093|NCT02531685|Toxin LTR192G/L211A
85094|NCT02531672|11C-choline
85095|NCT02531672|Positron Emission Tomography
85096|NCT02531672|15-117
85097|NCT02531646|pulmonary nodule
85098|NCT02531633|Giant Cell Arteritis, Sirukumab, Prednisone
85099|NCT02531620|prehabilitation
85100|NCT02531620|colorectal surgery
85101|NCT02531555|chronic periodontitis
85102|NCT02531555|dental scaling
85103|NCT02531555|gingival crevicular fluid
85104|NCT02531555|lasers
85105|NCT02531555|periodontal pocket
85106|NCT02531555|root planing
85107|NCT02531516|Prostatic neoplasms
85108|NCT02531516|Prostate Cancer
85109|NCT02531516|High-Risk prostate cancer
85110|NCT02531516|JNJ-56021927
85111|NCT02531516|ARN-509
85112|NCT02531516|Apalutamide
85113|NCT02531516|ATLAS
85114|NCT02531516|Radiation
85115|NCT02531516|Long-term hormone therapy
85116|NCT02531516|Localized or locally advanced prostate cancer
85117|NCT02531516|Janssen
85118|NCT02531503|Asthma remission
85119|NCT02531503|Predicting factors
85120|NCT02531503|Children
85121|NCT02531464|family caregiver
85122|NCT02531464|quality of life
85123|NCT02531464|supportive care
85124|NCT02531464|distress screening
85125|NCT02531464|needs assessment
85126|NCT02531451|Muscle mass
85127|NCT02531451|strength
85128|NCT02531451|NSAID
85129|NCT02531451|Ibuprofen
85130|NCT02531451|resistance exercise
85131|NCT02531425|TNBC
85132|NCT02531425|Triple Negative Breast Cancer
85133|NCT02531412|Acute kidney injury
85134|NCT02531412|Critically ill cancer patients
85135|NCT02531412|Spironolactone
85136|NCT02531399|flicker induced changes
85137|NCT02531399|total volumetric retinal blood flow
85138|NCT02531308|diffuse large b-cell lymphoma (DLBCL),
85139|NCT02531308|lymphoma
85140|NCT02531282|Patient education as topic
85141|NCT02531282|Health promotion
85142|NCT02531282|Patient participation
85143|NCT02531282|Self efficacy
85144|NCT02531256|Laryngeal Mask Airway
85145|NCT02531243|prodrome
85146|NCT02531243|family therapy
85147|NCT02531243|clinical high risk
85148|NCT02531204|ASP1585
85149|NCT02531204|Bioequivalence
85150|NCT02531204|Pharmacodynamic
85151|NCT02531204|Phosphate binder
85152|NCT02531204|Bixalomer
85153|NCT02531204|urinary phosphorus excretion
85154|NCT02531191|ASP015K
85155|NCT02531191|JAK inhibitor
85156|NCT02531191|bioequivalence study
85157|NCT02531178|Rheumatoid Arthritis
85158|NCT02531139|Cerebrovascular Circulation
85159|NCT02531139|Anesthesia
85160|NCT02531139|Blood pressure
85161|NCT02531139|Peripheral Arterial Diseases
85162|NCT02531074|Mobile Applications
85163|NCT02531061|Rheumatoid Arthritis
85164|NCT02531061|bDMARDs
85165|NCT02531061|biotherapy
85166|NCT02531061|remission
85167|NCT02531061|erosion
85168|NCT02531048|healthy volunteers
85169|NCT02530957|Intubation
85170|NCT02530957|Preoxygenation
85171|NCT02530957|Complications
85172|NCT02530957|Non invasive ventilation
85173|NCT02530957|High flow nasal cannula
85174|NCT02530944|Lupus
85175|NCT02530944|Systemic Lupus Erythematosus (SLE)
85176|NCT02530944|genetic
85177|NCT02530944|online
85178|NCT02530944|genome wide association
85179|NCT02530944|systemic lupus erythematosus
85180|NCT02530944|genome wide association study (GWAS)
85181|NCT02530918|Neovascular Age-Related Macular Degeneration
85182|NCT02530918|DS-7080a Monoclonal Antibody
85183|NCT02530905|Duchenne muscular dystrophy
85184|NCT02530905|Exon Skipping
85185|NCT02530892|embryo
85186|NCT02530892|in vitro fertilization
85187|NCT02530892|IVF
85188|NCT02530840|imbalanced diabetic patients
85189|NCT02530840|HbA1c
85190|NCT02530840|peers
85191|NCT02530827|energy expenditure
85192|NCT02530827|doubly labeled water
85193|NCT02530827|accelerometer
85194|NCT02530827|HIV
85195|NCT02530827|lipodystrophy syndrome.
85196|NCT02530814|organochlorine compounds
85197|NCT02530814|pesticides
85198|NCT02530788|Heart Failure
85199|NCT02530788|Cardiac Surgery
85200|NCT02530788|Ventricular Assist Device
85201|NCT02530788|Selenium
85202|NCT02530762|Gastrointestinal tolerability
85203|NCT02530762|dietary fiber
85204|NCT02530762|clinical trial
85205|NCT02530762|healthy subjects
85206|NCT02530749|Surgery
85207|NCT02530749|Frailty
85208|NCT02530736|Gait speed
85209|NCT02530736|Pulmonary Rehabilitation
85210|NCT02530723|power training
85211|NCT02530723|high-speed training
85212|NCT02530723|high-velocity training
85213|NCT02530723|function
85214|NCT02530723|older adults
85215|NCT02530723|older women
85216|NCT02530697|Leishmaniasis
85217|NCT02530697|Mucocutaneous
85218|NCT02530697|Miltefosine
85219|NCT02530697|Pentoxifylline
85220|NCT02530671|multi-directional power toothbrush
85221|NCT02530671|manual toothbrush
85222|NCT02530658|Genetic Predisposition
85223|NCT02530658|Pediatric
85224|NCT02530658|Genomic Analysis
85225|NCT02530658|Heritable Disease
85226|NCT02530658|Cancer Risk
85227|NCT02530658|Genetic Counseling
85228|NCT02530658|DNA
85229|NCT02530658|Clinical Genomics
85230|NCT02530658|Clinical Decision-Making
85231|NCT02530658|Treatment Planning
85232|NCT02530632|microperfusion
85233|NCT02530632|temperature
85234|NCT02530632|near-infrared spectroscopy
85235|NCT02530632|anesthesia
85236|NCT02530632|total intravenous anaesthesia
85237|NCT02530580|GABA modulator
85238|NCT02530580|AZD7325
85239|NCT02530580|Object manipulation
85240|NCT02530580|Cutaneous sensation
85241|NCT02530580|Manual dexterity
85242|NCT02530567|portal pressure
85243|NCT02530567|portosystemic pressure gradient
85244|NCT02530567|azygos blood flow
85245|NCT02530554|Pilot Projects
85246|NCT02530515|Leukemia
85247|NCT02530515|Chronic Lymphocytic Leukemia
85248|NCT02530515|CLL
85249|NCT02530515|T-cells
85250|NCT02530515|Immune cells
85251|NCT02530515|Rituximab
85252|NCT02530515|Rituxan
85253|NCT02530515|Cyclophosphamide
85254|NCT02530515|Cytoxan
85255|NCT02530515|Neosar
85256|NCT02530515|Fludarabine Phosphate
85257|NCT02530515|Fludarabine
85258|NCT02530515|Fludara
85259|NCT02530515|Bendamustine
85260|NCT02530515|Bendamustine Hydrochloride
85261|NCT02530515|Bendamustine HCL
85262|NCT02530515|CEP-18083
85263|NCT02530515|SDX-105
85264|NCT02530515|Treanda
85265|NCT02530515|Lenalidomide
85266|NCT02530515|CC-5013
85267|NCT02530515|Revlimid
85268|NCT02530489|Breast Cancer
85269|NCT02530489|Triple negative breast cancer
85270|NCT02530489|TNBC
85271|NCT02530489|Invasive adenocarcinoma of the breast
85272|NCT02530489|MPDL3280A
85273|NCT02530489|Nab-paclitaxel
85274|NCT02530489|Paclitaxel
85275|NCT02530489|Abraxane
85276|NCT02530489|ABI-007
85277|NCT02530476|Leukemia
85278|NCT02530476|Acute myeloid leukemia
85279|NCT02530476|AML
85280|NCT02530476|Relapsed/Refractory
85281|NCT02530476|FLT3-ITD mutation
85282|NCT02530476|FLT3-mutated high-risk myelodysplastic syndrome
85283|NCT02530476|MDS
85284|NCT02530476|Chronic Myelomonocytic Leukemia
85285|NCT02530476|CMML
85286|NCT02530476|Selinexor
85287|NCT02530476|KPT-330
85288|NCT02530476|Sorafenib
85289|NCT02530476|Nexavar
85290|NCT02530476|BAY 43-9006
85291|NCT02530476|FLT3-inhibitor therapy
85292|NCT02530463|Leukemia
85293|NCT02530463|Myelodysplastic syndrome
85294|NCT02530463|MDS
85295|NCT02530463|Nivolumab
85296|NCT02530463|BMS-936558
85297|NCT02530463|Opdivo
85298|NCT02530463|Ipilimumab
85299|NCT02530463|Yervoy
85300|NCT02530463|BMS-734016
85301|NCT02530463|MDX010
85302|NCT02530463|5-azacitidine
85303|NCT02530463|Azacitidine
85304|NCT02530463|5-AZA
85305|NCT02530463|Vidaza
85306|NCT02530463|5-AZC
85307|NCT02530463|AZA-CR
85308|NCT02530463|Ladakamycin
85309|NCT02530463|NSC-102816
85310|NCT02530463|Azacytidine
85311|NCT02530450|children
85312|NCT02530450|poor adherence
85313|NCT02530450|continuous glucose monitoring
85314|NCT02530437|Esophageal Cancer
85315|NCT02530437|Adenocarcinoma of the Esophagus
85316|NCT02530437|Adenocarcinoma of the Gastroesophageal Junction
85317|NCT02530437|Chemoradiation
85318|NCT02530437|LY2940680
85319|NCT02530437|Paclitaxel (Protein-Bound)
85320|NCT02530437|Taxol
85321|NCT02530437|Carboplatin
85322|NCT02530437|Paraplatin
85323|NCT02530437|Radiation therapy
85324|NCT02530437|XRT
85325|NCT02530437|External beam
85326|NCT02530437|Endoscopy
85327|NCT02530424|HER2-positive
85328|NCT02530424|ER-positive
85329|NCT02530424|invasive
85330|NCT02530424|CDK4,6
85331|NCT02530424|Palbociclib
85332|NCT02530424|neoadjuvant treatment
85333|NCT02530411|Hormone resistance
85334|NCT02530411|vandetanib
85335|NCT02530411|fulvestrant
85336|NCT02530359|septic acute kidney injury
85337|NCT02530359|pirfenidone
85338|NCT02530320|Palbociclib
85339|NCT02530320|oligodendroglioma
85340|NCT02530320|oligoastrocytoma anaplastic
85341|NCT02530307|Stroke,
85342|NCT02530307|Rehabilitation
85343|NCT02530307|Ischemic
85344|NCT02530307|fMRI
85345|NCT02530268|psoriatic arthritis
85346|NCT02530268|spondyloarthritis
85347|NCT02530268|disease registry
85348|NCT02530255|retinal amyloid
85349|NCT02530255|Retinal amyloid index
85350|NCT02530255|Alzheimer disease
85351|NCT02530255|telomere attrition
85352|NCT02530255|telomere activation
85353|NCT02530242|Sickle Cell Anemia
85354|NCT02530229|periprosthetic joint infection
85355|NCT02530229|septic arthritis
85356|NCT02530203|post-operative atrial fibrillation
85357|NCT02530203|spinal cord stimulation
85358|NCT02530203|CABG
85359|NCT02530177|Alopecia
85360|NCT02530177|Skin Aging
85361|NCT02530177|Nail Changes
85362|NCT02530177|Hair Changes
85363|NCT02530177|15-198
85364|NCT02530164|tDCS
85365|NCT02530164|SSRI
85366|NCT02530151|Hip arthroscopy
85367|NCT02530151|Intra-articular injection
85368|NCT02530151|Morphine
85369|NCT02530151|Clonidine
85370|NCT02530073|congenital diaphragmatic hernia
85371|NCT02530073|FETO
85372|NCT02530073|tracheal occlusion
85373|NCT02530060|Healthy
85374|NCT02530060|Rilpivirine
85375|NCT02530060|Tenofovir
85376|NCT02530060|Emtricitabine
85377|NCT02530060|Tenofovir Disoproxil Fumarate
85378|NCT02530047|Ovarian cancer
85379|NCT02530047|Epithelial ovarian cancer
85380|NCT02530047|Mesenchymal Stem Cells Secreting Interferon Beta
85381|NCT02530047|MSC-INFb
85382|NCT02530047|Questionnaires
85383|NCT02530047|Surveys
85384|NCT02530034|Leukemia
85385|NCT02530034|Advanced Hematologic Malignancies
85386|NCT02530034|Myelodysplastic syndrome
85387|NCT02530034|MDS
85388|NCT02530034|Chronic myelomonocytic leukemia
85389|NCT02530034|CMML
85390|NCT02530034|Acute myeloid leukemia
85391|NCT02530034|AML
85392|NCT02530034|Myelofibrosis
85393|NCT02530034|Hu8F4
85394|NCT02530021|Ischemic heart disease
85395|NCT02530021|Heart rate variability
85396|NCT02530021|Exercise Strss Test
85397|NCT02529956|Psoriasis
85398|NCT02529956|UCB4940
85399|NCT02529943|Spinal Stenosis
85400|NCT02529943|Motor Evoked Potential
85401|NCT02529930|HSIL
85402|NCT02529930|CIN 2/3
85403|NCT02529930|Therapeutic DNA vaccine
85404|NCT02529930|Human Papillomavirus
85405|NCT02529930|Immunotherapy
85406|NCT02529891|Chronic Obstructive Pulmonary Disease
85407|NCT02529891|COPD
85408|NCT02529891|Volatile Organic Compounds
85409|NCT02529891|Exacerbation
85410|NCT02529878|gastric caner
85411|NCT02529878|Apatinib
85412|NCT02529878|S1
85413|NCT02529878|conversion therapy
85414|NCT02529878|metastatic gastric cancer
85415|NCT02529865|Cell Transplantation
85416|NCT02529852|Lymphoma
85417|NCT02529852|Diffuse Large B Cell Lymphoma
85418|NCT02529852|DLBCL
85419|NCT02529852|Lenalidomide
85420|NCT02529852|CC-5013
85421|NCT02529852|Revlimid
85422|NCT02529852|Obinutuzumab
85423|NCT02529852|GA101
85424|NCT02529852|Gazyva
85425|NCT02529852|Cyclophosphamide
85426|NCT02529852|Cytoxan
85427|NCT02529852|Neosar
85428|NCT02529852|Doxorubicin
85429|NCT02529852|Doxorubicin Hydrochloride
85430|NCT02529852|Adriamycin PFS
85431|NCT02529852|Adriamycin RDF
85432|NCT02529852|Adriamycin
85433|NCT02529852|Rubex
85434|NCT02529852|Vincristine
85435|NCT02529852|Prednisone
85436|NCT02529839|MS
85437|NCT02529839|BMT
85438|NCT02529826|Cancer-affected prepubertal boys
85439|NCT02529813|Leukemia
85440|NCT02529813|Lymphoma
85441|NCT02529813|Advanced Lymphoid Malignancies
85442|NCT02529813|CD19+ lymphoid malignancy
85443|NCT02529813|Multiple myeloma
85444|NCT02529813|MM
85445|NCT02529813|CD19-specific T cells
85446|NCT02529813|Chimeric Antigen Receptor T cells
85447|NCT02529813|CAR T cells
85448|NCT02529813|Autologous
85449|NCT02529813|Allogeneic
85450|NCT02529813|Fludarabine
85451|NCT02529813|Fludarabine phosphate
85452|NCT02529813|Cyclophosphamide
85453|NCT02529813|Cytoxan
85454|NCT02529813|Neosar
85455|NCT02529813|nonviral
85456|NCT02529813|non-viral
85457|NCT02529813|DNA plasmids
85458|NCT02529761|HCC
85459|NCT02529761|sorafenib
85460|NCT02529761|TACE
85461|NCT02529761|overall survival
85462|NCT02529696|accelerometer
85463|NCT02529696|RASS
85464|NCT02529683|Nuvaring
85465|NCT02529683|contraceptive vaginal ring
85466|NCT02529683|Kenya
85467|NCT02529683|adherence
85468|NCT02529683|acceptability
85469|NCT02529683|immunological effects
85470|NCT02529670|Low Level Laser Therapy
85471|NCT02529670|Low Back Pain
85472|NCT02529670|Diagnosis
85473|NCT02529670|Genetic
85474|NCT02529670|Clinical trial
85475|NCT02529657|Lower Level Laser Therapy (LLLT)
85476|NCT02529657|inflammation
85477|NCT02529657|cytokines
85478|NCT02529657|wound healing
85479|NCT02529657|laminectomy
85480|NCT02529657|clinical study
85481|NCT02529644|HIV Screening
85482|NCT02529644|African American
85483|NCT02529644|Church
85484|NCT02529631|Polyglucosamine
85485|NCT02529631|L 112
85486|NCT02529631|overweight,
85487|NCT02529631|obesity
85488|NCT02529631|orlistat
85489|NCT02529631|weight reduction
85490|NCT02529605|dietary supplement
85491|NCT02529605|pharmacokinetics
85492|NCT02529605|Healthy Volunteers
85493|NCT02529592|Sickness behavior
85494|NCT02529592|Cytokines
85495|NCT02529592|Psychoneuroimmunology
85496|NCT02529579|adoptive Cellular Immunotherapy
85497|NCT02529579|patient safety
85498|NCT02529579|therapeutic effect
85499|NCT02529566|Lumbar Degenerative Disc Disease
85500|NCT02529566|Degenerative Spinal Conditions
85501|NCT02529566|Adjacent Segment Disease
85502|NCT02529566|Autologous Bone Marrow
85503|NCT02529566|Lower Back Pain
85504|NCT02529566|Chronic Lower Back Pain
85505|NCT02529566|Stem Cells
85506|NCT02529566|Lumbar disk
85507|NCT02529566|Mesenchymal Stem Cells
85508|NCT02529566|Stabilization
85509|NCT02529566|CLBP
85510|NCT02529566|Autograft
85511|NCT02529566|Allograft
85512|NCT02529566|Autograft versus Allograft
85513|NCT02529566|Facet Joint
85514|NCT02529566|Radicular Pain
85515|NCT02529566|Adipose
85516|NCT02529566|Disc Replacement
85517|NCT02529566|Facet Joint Replacement
85518|NCT02529553|bladder cancer
85519|NCT02529540|Myopia
85520|NCT02529540|self-refraction
85521|NCT02529540|glasses
85522|NCT02529540|spectacles
85523|NCT02529514|Baclofen
85524|NCT02529514|Cardiac Surgery
85525|NCT02529514|Polysomnography
85526|NCT02529514|Intensive Care Units
85527|NCT02529514|Sleep
85528|NCT02529449|ASP1941
85529|NCT02529449|type 1 diabetes mellitus
85530|NCT02529449|SGLT2 inhibitor
85531|NCT02529436|overuse antidepressant
85532|NCT02529436|dementia
85533|NCT02529423|food intake
85534|NCT02529423|food-related behaviour
85535|NCT02529423|obesity
85536|NCT02529423|socioeconomic environment
85537|NCT02529423|depression
85538|NCT02529423|nutritional strategies
85539|NCT02529397|Working Memory Training, Weight Loss,
85540|NCT02529384|Breast magnetic resonance imaging
85541|NCT02529384|Diffusion-weighted imaging
85542|NCT02529384|Multiple b-value diffusion weighted imaging
85543|NCT02529358|Maintenance intervention
85544|NCT02529358|Text messages
85545|NCT02529358|Emotion Regulation
85546|NCT02529332|Endoscopic Sellar/Parasellar Tumor Resection
85547|NCT02529319|atrial fibrillation
85548|NCT02529319|ablation
85549|NCT02529306|men
85550|NCT02529280|Latinas
85551|NCT02529280|Breast Cancer
85552|NCT02529280|Clinical Trials
85553|NCT02529280|Participation
85554|NCT02529267|Cohort Studies
85555|NCT02529267|intimate partner violence
85556|NCT02529267|orthopaedic surgery
85557|NCT02529267|epidemiology
85558|NCT02529267|outcomes in fracture care
85559|NCT02529254|post graduate surgical education
85560|NCT02529254|video coaching
85561|NCT02529254|Surgical education
85562|NCT02529254|coaching
85563|NCT02529202|Dexmedetomidine
85564|NCT02529202|Neonate
85565|NCT02529202|Pharmacokinetics
85566|NCT02529202|Therapeutic Hypothermia
85567|NCT02529202|Hypoxic-ischemic Encephalopathy
85568|NCT02529202|Adrenergic Agents
85569|NCT02529202|Adrenergic Agonists
85570|NCT02529202|Analgesics
85571|NCT02529202|Adrenergic alpha-2 Receptor Agonists
85572|NCT02529202|Central Nervous System Agents
85573|NCT02529202|Central Nervous System Depressants
85574|NCT02529189|Stable Angina
85575|NCT02529189|Angioplasty
85576|NCT02529189|Optical Coherence Tomography
85577|NCT02529189|Nitrate
85578|NCT02529176|telemetry
85579|NCT02529176|cardiac monitoring
85580|NCT02529163|Integrated Care Pathway
85581|NCT02529163|Acute Psychotic Episode
85582|NCT02529163|Randomised Control Trial
85583|NCT02529124|Ageing
85584|NCT02529124|Body Composition
85585|NCT02529124|Nutrition
85586|NCT02529124|Physical Activity
85587|NCT02529111|Atrial Septal Defects (ASD)
85588|NCT02529111|Percutaneous closure
85589|NCT02529098|functional magnetic resonance imaging
85590|NCT02529098|Lens implantation
85591|NCT02529098|pseudophakia
85592|NCT02529020|mouthguard
85593|NCT02529020|ventilation
85594|NCT02529020|anaerobic power
85595|NCT02529020|ergogenic effects
85596|NCT02529007|Colonoscopy
85597|NCT02529007|early cancer detection
85598|NCT02529007|cancer screening
85599|NCT02528994|Dietary supplements
85600|NCT02528994|Metabolism
85601|NCT02528981|GBS
85602|NCT02528981|Probiotics
85603|NCT02528981|Group B Streptococcal
85604|NCT02528981|Pregnancy
85605|NCT02528968|Pharmacokinetic dosing
85606|NCT02528968|Haemophilia
85607|NCT02528955|Head and neck cancer
85608|NCT02528955|postoperative
85609|NCT02528955|radiotherapy
85610|NCT02528955|de-intensification
85611|NCT02528942|Lung cancer
85612|NCT02528942|Radiation therapy
85613|NCT02528942|4DCT-ventilation imaging
85614|NCT02528890|group B streptococcus
85615|NCT02528890|GBS
85616|NCT02528864|biomarker
85617|NCT02528864|cancer metabolism
85618|NCT02528864|chemical exchange saturation transfer
85619|NCT02528864|endometrial cancer
85620|NCT02528864|diffusion-weighted imaging
85621|NCT02528864|magnetic resonance spectroscopy
85622|NCT02528864|uterine malignancy
85623|NCT02528851|CPAP
85624|NCT02528851|preterm
85625|NCT02528851|cardiac output
85626|NCT02528838|Myeloma
85627|NCT02528838|Non-interventional
85628|NCT02528838|Observational
85629|NCT02528838|Lenalidomide
85630|NCT02528838|REVIEW
85631|NCT02528838|Post-authorization
85632|NCT02528838|Netherlands
85633|NCT02528786|Drug therapy
85634|NCT02528734|pneumothorax
85635|NCT02528708|fibrinogen concentrate
85636|NCT02528708|coagulation
85637|NCT02528695|18F-FDG PET/CT
85638|NCT02528695|Adipose tissue
85639|NCT02528695|type 2 diabetes
85640|NCT02528682|dendritic cells
85641|NCT02528682|PD-L1/L2 silencing
85642|NCT02528682|vaccination
85643|NCT02528682|stem cell transplantation
85644|NCT02528682|minor histocompatibility antigens
85645|NCT02528669|accelerometer
85646|NCT02528669|patient ambulation
85647|NCT02528656|Pectus Excavatum
85648|NCT02528656|Pectus Carinatum
85649|NCT02528656|Vacuum Bell
85650|NCT02528656|Dynamic compression system
85651|NCT02528656|Hearth variability
85652|NCT02528656|Autonomic Nervous System
85653|NCT02528643|MDV3100
85654|NCT02528643|advanced hepatocellular carcinoma
85655|NCT02528643|enzalutamide
85656|NCT02528643|Xtandi
85657|NCT02528643|ASP9785
85658|NCT02528604|Catheter Ablation
85659|NCT02528604|Permanent pacemaker
85660|NCT02528604|AV node ablation
85661|NCT02528604|Electrical Cardioversion
85662|NCT02528604|Implantable loop recorder
85663|NCT02528591|patient
85664|NCT02528591|renal transplant
85665|NCT02528578|healthy volunteers
85666|NCT02528539|Prevention
85667|NCT02528539|lymphedema
85668|NCT02528539|acupuncture
85669|NCT02528539|self-management
85670|NCT02528526|Hypoxia
85671|NCT02528526|Pancreatic Neoplasms
85672|NCT02528526|Hepatocellular Cancer
85673|NCT02528526|Cholangiocarcinoma
85674|NCT02528526|Colorectal Neoplasms
85675|NCT02528526|Treatment
85676|NCT02528513|sedation
85677|NCT02528513|Midazolam
85678|NCT02528513|Propofol
85679|NCT02528513|Dexmedetomidine
85680|NCT02528487|Pulmonary Rehabilitation
85681|NCT02528487|Chronic Obstructive Pulmonary Disease
85682|NCT02528487|Psychiatric Disorders
85683|NCT02528461|Sofosbuvir
85684|NCT02528461|Direct acting anti-viral treatment
85685|NCT02528461|liver cirrhosis
85686|NCT02528448|Vasoactive hormones
85687|NCT02528448|bio markers
85688|NCT02528448|salt regulation
85689|NCT02528448|Renal variables
85690|NCT02528435|Methotrexate
85691|NCT02528383|Postmenopausal Women on Aromatase Inhibitors
85692|NCT02528383|Vagifem
85693|NCT02528370|COPD exacerbation
85694|NCT02528370|Telemedicine
85695|NCT02528370|Intervention Studies
85696|NCT02528370|Patient Readmission
85697|NCT02528357|mAb
85698|NCT02528357|GSK3174998
85699|NCT02528357|anticancer agent
85700|NCT02528357|checkpoint
85701|NCT02528357|OX40
85702|NCT02528357|Pembrolizumab
85703|NCT02528357|MK-3475-167
85704|NCT02528357|solid tumor
85705|NCT02528357|immunotherapy
85706|NCT02528357|KEYNOTE-167
85707|NCT02528357|monoclonal antibody
85708|NCT02528357|antitumor
85709|NCT02528344|High Intensity Interval Training
85710|NCT02528331|Transcranial magnetic stimulation (TMS)
85711|NCT02528331|Cognitive behavioral therapy (CBT)
85712|NCT02528305|High-intensity Interval Training
85713|NCT02528292|Rheumatoid Arthritis
85714|NCT02528292|Anti-TNF
85715|NCT02528292|Ultrasound
85716|NCT02528292|Synovial histomorphology
85717|NCT02528292|Ectopic Lymphoneogenesis
85718|NCT02528279|Plasmodium ovale
85719|NCT02528279|relapse
85720|NCT02528279|artemether-lumefantrine
85721|NCT02528279|mixed species malaria
85722|NCT02528279|non-falciparum malaria
85723|NCT02528253|Chronic low back pain
85724|NCT02528253|Chronic pain
85725|NCT02528240|platelets
85726|NCT02528201|Ankylosing Spondylitis
85727|NCT02528201|Celecoxib
85728|NCT02528201|Diclofenac
85729|NCT02528162|gestational diabetes
85730|NCT02528162|education
85731|NCT02528149|Fibromuscular Dysplasia
85732|NCT02528149|dysplastic renal artery aneurysm
85733|NCT02528149|renal artery aneurysms
85734|NCT02528149|non atheromatous
85735|NCT02528149|dysplastic
85736|NCT02528149|anatomopathologic
85737|NCT02528149|genetic
85738|NCT02528123|Small incision lenticule extraction (SMILE)
85739|NCT02528123|Femtosecond laser
85740|NCT02528084|rotator cuff, shoulder, rehabilitation, yoga
85741|NCT02528071|Amyotrophic Lateral Sclerosis
85742|NCT02528071|ALS
85743|NCT02528071|Diaphragmatic Endurance Test
85744|NCT02528058|Myopic traction maculopathy
85745|NCT02528045|Myopic traction maculopathy
85746|NCT02528032|Left ventricular dysfunction
85747|NCT02528032|Other cardiac dysrhythmias
85748|NCT02528006|Spasmodic Dysphonia
85749|NCT02528006|Type 2 Thyroplasty
85750|NCT02528006|Titanium Bridges
85751|NCT02528006|Operation
85752|NCT02527980|electronic cigarettes
85753|NCT02527980|nicotine dependence
85754|NCT02527980|smoking
85755|NCT02527980|tobacco use
85756|NCT02527967|colorectal cancer
85757|NCT02527967|enhanced recovery after surgery
85758|NCT02527967|perioperative care
85759|NCT02527967|fast-track surgery
85760|NCT02527967|laparoscopy
85761|NCT02527967|minimally invasive surgery
85762|NCT02527967|complications
85763|NCT02527954|Y-chromosome microdeletions
85764|NCT02527954|aneuploidy
85765|NCT02527954|embryos
85766|NCT02527954|spermatozoa
85767|NCT02527941|Genital immunology
85768|NCT02527941|HIV susceptibility
85769|NCT02527941|Microbiome
85770|NCT02527941|Bacterial vaginosis
85771|NCT02527941|Virus entry assay
85772|NCT02527928|pharmacoeconomics
85773|NCT02527902|IGA Glomerulonephritis
85774|NCT02527902|Autonomic nervous system
85775|NCT02527902|ANS
85776|NCT02527889|Exercise
85777|NCT02527889|blood flow velocity
85778|NCT02527889|tissue oxygenation
85779|NCT02527889|BCRL
85780|NCT02527876|Exercise
85781|NCT02527876|Smoking
85782|NCT02527863|Tolvaptan
85783|NCT02527863|L-NMMA
85784|NCT02527863|ADPKD
85785|NCT02527824|biliary tract neoplasm
85786|NCT02527824|oxaliplatin
85787|NCT02527824|irinotecan
85788|NCT02527824|S-1
85789|NCT02527811|ulinastatin
85790|NCT02527811|CPB
85791|NCT02527811|pediatric
85792|NCT02527785|stomach neoplasm
85793|NCT02527785|oxaliplatin
85794|NCT02527785|irinotecan
85795|NCT02527785|S-1
85796|NCT02527720|Mindfulness
85797|NCT02527720|Therapy
85798|NCT02527720|Problem Drinking
85799|NCT02527720|Breathing-based mindfulness training
85800|NCT02527694|Emergency medical services
85801|NCT02527694|Resuscitation
85802|NCT02527512|Scoliosis
85803|NCT02527512|Spine fusion
85804|NCT02527512|0.35% povidone-iodine
85805|NCT02527486|COPD
85806|NCT02527486|Asthma
85807|NCT02527486|ACOS
85808|NCT02527486|Bronchiectasis
85809|NCT02527460|Inflammation
85810|NCT02527460|Cognitive Function
85811|NCT02527460|HIV
85812|NCT02527447|Measurable Residual Disease
85813|NCT02527447|Relapsed/Refractory AML
85814|NCT02527447|Salvage Chemotherapy
85815|NCT02527434|Urothelial bladder cancer, Triple-negative breast cancer, Pancreatic ductal adenocarcinoma, Advanced Solid Tumors, Tremelimumab, MEDI4736, ORR
85816|NCT02527395|Experimental pain
85817|NCT02527395|Men
85818|NCT02527369|Fat Reduction
85819|NCT02527369|Lipolysis
85820|NCT02527330|Myocardial iron deposition
85821|NCT02527330|T2* imaging
85822|NCT02527330|heart failure
85823|NCT02527317|Early
85824|NCT02527291|Cytomegalovirus
85825|NCT02527291|Interleukin
85826|NCT02527291|Polymerase Chain Reaction
85827|NCT02527291|CMV antibodies
85828|NCT02527252|Massage
85829|NCT02527252|Craniosacral
85830|NCT02527252|Disability Evaluation
85831|NCT02527252|Randomized Controlled Trial
85832|NCT02527187|Immune System Diseases
85833|NCT02527187|Prick Test
85834|NCT02527187|Betula verrucosa
85835|NCT02527135|SMS
85836|NCT02527135|Text messages
85837|NCT02527135|Young women
85838|NCT02527135|HIV
85839|NCT02527122|Immune System Diseases
85840|NCT02527122|Prick Test
85841|NCT02527122|Dermatophagoides pteronyssinus
85842|NCT02527122|Dermatophagoides farinae
85843|NCT02527096|dolutegravir(Tivicay®)
85844|NCT02527096|lamivudine(Epivir®)
85845|NCT02527096|HIV-1
85846|NCT02527096|efficacy
85847|NCT02527096|safety
85848|NCT02527057|Diffusion-weighted magnetic resonance imaging
85849|NCT02527057|Preoperative concurrent chemoradiation
85850|NCT02527057|Response
85851|NCT02527044|Coronary Artery Bypass
85852|NCT02527044|Flow Reserve
85853|NCT02527031|Emergency Medical Services
85854|NCT02527031|Extracorporeal Membrane Oxygenation
85855|NCT02527018|OBGYN
85856|NCT02527018|Nexfin
85857|NCT02527018|Hypertensive
85858|NCT02527018|Hemodynamic
85859|NCT02527005|IPT
85860|NCT02527005|malaria
85861|NCT02527005|pregnant
85862|NCT02527005|HIV positive
85863|NCT02526979|OAB
85864|NCT02526979|overactive bladder
85865|NCT02526979|Myrbetric
85866|NCT02526979|neurogenic detrusor overactivity
85867|NCT02526979|Betanis
85868|NCT02526979|Myrbetriq
85869|NCT02526979|NDO
85870|NCT02526979|YM178
85871|NCT02526979|mirabegron
85872|NCT02526979|Betmiga
85873|NCT02526953|anal cancer
85874|NCT02526953|chemoradiation
85875|NCT02526953|intensity-modulated radiotherapy
85876|NCT02526953|paclitaxel
85877|NCT02526940|Human Immunodeficiency Virus
85878|NCT02526940|HIV
85879|NCT02526940|HAART
85880|NCT02526940|Highly Active antiretroviral therapy
85881|NCT02526940|GALT
85882|NCT02526940|Gut Associated Lymphoid Tissue
85883|NCT02526940|reservoir
85884|NCT02526940|rectum
85885|NCT02526927|Anorexia Nervosa
85886|NCT02526927|microarchitecture
85887|NCT02526927|prepubertal
85888|NCT02526914|social cognition
85889|NCT02526914|oxytocin
85890|NCT02526914|vasopressin
85891|NCT02526914|decision making
85892|NCT02526914|social decision making
85893|NCT02526914|economic games
85894|NCT02526888|pharmacokinetic
85895|NCT02526888|interaction
85896|NCT02526875|hypertension, Telmisartan/S-Amlodipine
85897|NCT02526862|noninvasive mechanical ventilation (NIVM)
85898|NCT02526862|continuous positive airway pressure (CPAP) ventilation
85899|NCT02526862|bilevel positive airway pressure (BIPAP) ventilation
85900|NCT02526862|pressure ulcer (PU)
85901|NCT02526862|nursing assessment
85902|NCT02526849|Fecal Microbiota Transplantation
85903|NCT02526849|Slow Transit Constipation
85904|NCT02526849|Randomized Controlled Trial
85905|NCT02526836|colon cancer mesocolic excision central ligation
85906|NCT02526810|glargine
85907|NCT02526810|continuous subcutaneous insulin injection
85908|NCT02526810|blood glucose control
85909|NCT02526810|blood glucose fluctuation
85910|NCT02526810|Oxidative Stress
85911|NCT02526797|prostate biopsy
85912|NCT02526797|prostate cancer
85913|NCT02526797|Magnetic resonance imaging
85914|NCT02526797|Neoplasm staging
85915|NCT02526771|lymph node dissection
85916|NCT02526758|Pulmonary disease
85917|NCT02526758|chronic obstructive
85918|NCT02526758|small airway
85919|NCT02526745|vaccine
85920|NCT02526745|safety
85921|NCT02526745|immunogenicity
85922|NCT02526732|NASH
85923|NCT02526732|fatty Liver
85924|NCT02526732|VO2 max
85925|NCT02526732|M30 antigen
85926|NCT02526719|bilateral prophylactic mastectomies
85927|NCT02526719|immediate breast reconstruction
85928|NCT02526719|nipple sparing
85929|NCT02526719|BRCA1 Protein
85930|NCT02526706|Bleb filtration
85931|NCT02526706|VisionBlue
85932|NCT02526680|OrCam
85933|NCT02526680|Low-vision device
85934|NCT02526680|End-stage glaucoma
85935|NCT02526641|Direct acting antiviral treatment
85936|NCT02526641|sCD163
85937|NCT02526641|Portal hypertension
85938|NCT02526641|Metabolic liver function
85939|NCT02526641|Cirrhosis
85940|NCT02526628|Testosterone
85941|NCT02526628|Neurocognition
85942|NCT02526615|rosiglitazone
85943|NCT02526615|metformin
85944|NCT02526615|muscle
85945|NCT02526576|Facial Atrophy
85946|NCT02526576|Autologous
85947|NCT02526576|Adult
85948|NCT02526576|Adipose Derived Stem Cells
85949|NCT02526576|Stromal Vascular Fraction
85950|NCT02526576|Collagenase
85951|NCT02526550|Live attenuated Japanese Encephalitis vaccine
85952|NCT02526550|IMOJEV
85953|NCT02526550|CD.JEVAX
85954|NCT02526550|Booster
85955|NCT02526550|Thai children
85956|NCT02526550|Immunogenicity
85957|NCT02526550|Safety
85958|NCT02526550|Interchangeability
85959|NCT02526550|Hepatitis A vaccine
85960|NCT02526550|Vaccination or Other Immunization Procedure
85961|NCT02526537|Gefitinib
85962|NCT02526537|NSCLC
85963|NCT02526537|postoperative
85964|NCT02526537|stage Ib
85965|NCT02526537|Relapse Free Survival in 2 years
85966|NCT02526485|heparin
85967|NCT02526485|thrombocytopenia
85968|NCT02526485|genomics
85969|NCT02526472|embryo transfer, in vitro fertilization
85970|NCT02526446|Chinese
85971|NCT02526446|caregiver stress
85972|NCT02526446|self-administered acupressure
85973|NCT02526433|depression
85974|NCT02526433|mental wellbeing
85975|NCT02526433|motherhood
85976|NCT02526433|music
85977|NCT02526433|alternative therapies
85978|NCT02526420|VRS-317
85979|NCT02526420|Long Acting Growth Hormone
85980|NCT02526420|Versartis
85981|NCT02526420|somavaratan
85982|NCT02526420|Growth Hormone Deficiency
85983|NCT02526420|Adult Growth Hormone Deficiency
85984|NCT02526420|AGHD
85985|NCT02526420|Growth Hormone Replacement
85986|NCT02526420|Growth Hormone Replacement Therapy
85987|NCT02526420|XTEN
85988|NCT02526407|postnatal depression
85989|NCT02526407|mental wellbeing
85990|NCT02526407|baby blues
85991|NCT02526407|mothers
85992|NCT02526407|music
85993|NCT02526407|alternative therapies
85994|NCT02526355|Postnatal depression
85995|NCT02526355|Mobile phone based intervention
85996|NCT02526355|Learning Through Play
85997|NCT02526355|CBT
85998|NCT02526355|Intelligent Real Time Therapy
85999|NCT02526316|cervical cancer
86000|NCT02526316|vulvar cancer
86001|NCT02526316|vaginal cancer
86002|NCT02526316|penile cancer
86003|NCT02526316|anal cancer
86004|NCT02526316|head and neck cancer
86005|NCT02526277|RLS
86006|NCT02526264|stoma
86007|NCT02526264|quality of life
86008|NCT02526251|IBD
86009|NCT02526251|Fecal calprotectin
86010|NCT02526251|Microbiome
86011|NCT02526251|Dysbiosis
86012|NCT02526251|Disease activity
86013|NCT02526251|telemedicine
86014|NCT02526238|transcranial magnetic stimulation
86015|NCT02526238|trunk rotation
86016|NCT02526225|acute ischemic stroke
86017|NCT02526225|safety and effectiveness
86018|NCT02526225|Ginkgo diterpene lactone meglumine injection
86019|NCT02526212|opioid use disorder
86020|NCT02526212|group counseling
86021|NCT02526212|office-based buprenorphine treatment
86022|NCT02526199|Local anesthetics
86023|NCT02526199|Perineural nerve blocks
86024|NCT02526199|Perineurial Dexamethasone
86025|NCT02526160|KRN23
86026|NCT02526160|Fibroblast growth factor 23 (FGF23)
86027|NCT02526160|XLH
86028|NCT02526160|X-linked hypophosphatemia
86029|NCT02526134|Laying of medical devices (radio opaque markers)
86030|NCT02526095|Esophagus
86031|NCT02526095|Surgery
86032|NCT02526082|cardiovascular disease
86033|NCT02526082|frailty
86034|NCT02526082|quality of life
86035|NCT02526082|mortality
86036|NCT02526082|prevention
86037|NCT02526030|psychosis
86038|NCT02526030|antipsychotic agents
86039|NCT02526030|treatment
86040|NCT02526030|effectiveness
86041|NCT02526004|Cystic Fibrosis
86042|NCT02526004|Microbiome
86043|NCT02526004|Stratified Antibacterial therapy
86044|NCT02526004|Resistance
86045|NCT02526004|Pathogen Host Interaction
86046|NCT02525991|schizophrenia
86047|NCT02525991|bipolar disorder
86048|NCT02525978|Heart Rate
86049|NCT02525965|Wide resection margin
86050|NCT02525965|Recurrence
86051|NCT02525965|Early-stage hepatocellular carcinoma
86052|NCT02525952|Carcinoma, Hepatocellular
86053|NCT02525952|Hepatectomy
86054|NCT02525952|Transarterial Chemoembolization
86055|NCT02525952|Scoring System
86056|NCT02525913|Breast
86057|NCT02525913|Mastectomy
86058|NCT02525874|Tecfidera
86059|NCT02525874|DMF
86060|NCT02525874|dimethyl fumarate
86061|NCT02525757|Lung Cancer
86062|NCT02525757|Non-small cell lung cancer
86063|NCT02525757|NSCLC
86064|NCT02525757|Unresectable
86065|NCT02525757|MPDL3280A
86066|NCT02525757|Carboplatin
86067|NCT02525757|Paraplatin
86068|NCT02525757|Paclitaxel
86069|NCT02525757|Taxol
86070|NCT02525757|Radiation therapy
86071|NCT02525757|XRT
86072|NCT02525731|HIV Infection
86073|NCT02525731|Pain
86074|NCT02525731|Chronic Opioid Therapy
86075|NCT02525731|Addiction
86076|NCT02525731|Analgesics, Opioid
86077|NCT02525718|Breast Reconstruction
86078|NCT02525718|Mastectomy
86079|NCT02525705|infants
86080|NCT02525705|oesophageal atresia
86081|NCT02525705|dumping syndrome
86082|NCT02525705|prevalence
86083|NCT02525705|Type III and IV
86084|NCT02525705|Oral glucose tolerance test
86085|NCT02525705|early hyperglycemia
86086|NCT02525705|late hypoglycemia
86087|NCT02525653|Albumin-Bound
86088|NCT02525653|Paclitaxel
86089|NCT02525653|Gemcitabine
86090|NCT02525653|15-054
86091|NCT02525640|Single sided hearing loss
86092|NCT02525640|Single sided deafness
86093|NCT02525640|Hearing loss music appreciation
86094|NCT02525536|Drug Therapy
86095|NCT02525497|Automated PD
86096|NCT02525497|Effectiveness
86097|NCT02525497|Safety
86098|NCT02525497|Manipulability
86099|NCT02525458|antimicrobial
86100|NCT02525458|biofilms
86101|NCT02525458|acrylic resin
86102|NCT02525458|polymethyl methacrylate
86103|NCT02525458|confocal laser scanning microscopy
86104|NCT02525458|split-mouth design
86105|NCT02525458|quaternary ammonium methacryloxy silicate
86106|NCT02525445|placebo effects
86107|NCT02525445|communication
86108|NCT02525445|acupuncture therapy
86109|NCT02525445|relaxation
86110|NCT02525432|Mesenchymal Stromal Cells, Multipotent
86111|NCT02525432|Multipotent Mesenchymal Stromal Cells
86112|NCT02525432|Stem Cells, Mesenchymal
86113|NCT02525393|Rehabilitation
86114|NCT02525393|Non Invasive Brain Stimulation
86115|NCT02525380|Transarterial chemoembolization
86116|NCT02525380|Doxorubicin-Eluting-Bead Embolization
86117|NCT02525380|DC Bead TACE
86118|NCT02525380|Hepatocellular carcinoma
86119|NCT02525367|Parkinson's disease
86120|NCT02525367|Multiple Sclerosis
86121|NCT02525367|Depressed Elderly
86122|NCT02525367|Cognitive Dysfunction
86123|NCT02525367|Online Cognitive Training
86124|NCT02525354|arachidonic aci
86125|NCT02525354|adiposity
86126|NCT02525354|atopy
86127|NCT02525341|Yoga
86128|NCT02525341|exercises
86129|NCT02525341|knee osteoarthritis
86130|NCT02525341|older adults
86131|NCT02525328|Constitutional Thinness
86132|NCT02525328|linkage study
86133|NCT02525328|genome wide scan (GWAS)
86134|NCT02525315|Schizophrenia
86135|NCT02525315|auditory hallucinations
86136|NCT02525315|TMS
86137|NCT02525302|DMD
86138|NCT02525302|neuromuscular
86139|NCT02525302|Duchenne
86140|NCT02525289|mobility
86141|NCT02525289|coronary artery bypass
86142|NCT02525289|positioning
86143|NCT02525289|body
86144|NCT02525263|Neo-Kidney Augment
86145|NCT02525263|Type 2 Diabetes
86146|NCT02525263|Chronic Kidney Disease
86147|NCT02525263|Cell Therapy
86148|NCT02525250|Acute myeloid leukemia or myelodysplasic syndrome
86149|NCT02525198|Mild cognitive impairment
86150|NCT02525198|Subjective memory impairment
86151|NCT02525198|Dementia
86152|NCT02525198|Flavonoids
86153|NCT02525198|Fatty acids
86154|NCT02525198|Cognition
86155|NCT02525198|Gut microflora
86156|NCT02525172|immune modulation therapy
86157|NCT02525172|acid α-glucosidase
86158|NCT02525172|antibody
86159|NCT02525159|3,3'-diindolylmethane
86160|NCT02525159|premenopause
86161|NCT02525159|2-hydroxyestrone
86162|NCT02525146|HIV
86163|NCT02525146|Reengagement in HIV Care
86164|NCT02525146|ARTAS
86165|NCT02525133|post operative pain
86166|NCT02525133|hernioplasty
86167|NCT02525133|bupivacaine
86168|NCT02525120|Disc herniation
86169|NCT02525120|Herniated disc
86170|NCT02525120|Triojection
86171|NCT02525120|Ozone
86172|NCT02525120|Lumbar spine
86173|NCT02525120|Leg pain
86174|NCT02525107|Prevention of Vaso Occlusive Painful Crisis
86175|NCT02525094|Eczema
86176|NCT02525081|Microvascular Angina
86177|NCT02525081|therapy
86178|NCT02525068|enzalutamide
86179|NCT02525068|AZD5363
86180|NCT02525068|Prostate
86181|NCT02525055|Flu
86182|NCT02525055|Influenza
86183|NCT02525055|Human Viral Challenge Model
86184|NCT02525055|Wild-Type
86185|NCT02525055|H3N2
86186|NCT02525055|H1N1
86187|NCT02525055|Universal Influenza Vaccine
86188|NCT02525055|intra-seasonal vaccines
86189|NCT02525055|antiviral
86190|NCT02525042|Ankylosing Spondylitis
86191|NCT02525042|Dendritic cells (DC)
86192|NCT02525042|RNA
86193|NCT02525042|Axial spondyloarthritis
86194|NCT02525042|Lod score
86195|NCT02525042|Human leucocyte antigen (HLA-B27)
86196|NCT02525029|GVHD
86197|NCT02525016|Bariatric surgery, lidocaine, plasmatic concentration, MonoEthylGlycineXylidide (MEGx), safety
86198|NCT02525003|vitamin D
86199|NCT02525003|Serum 25-hydroxyvitamin D
86200|NCT02525003|vitamin D2
86201|NCT02525003|UV-irradiated yeast
86202|NCT02525003|serum 25-hydroxyvitamin D3
86203|NCT02525003|serum 25-hydroxyvitamin D2
86204|NCT02525003|randomized controlled trial
86205|NCT02525003|vitamin D3
86206|NCT02525003|bioavailability
86207|NCT02524990|Medical abortion
86208|NCT02524990|pregnancy tests
86209|NCT02524964|left ventricular remodeling
86210|NCT02524964|cardiac magnetic resonance imaging
86211|NCT02524964|acute myocardial infarction
86212|NCT02524938|Dietary polyphenols
86213|NCT02524938|Protein glycation
86214|NCT02524925|fast track surgery
86215|NCT02524925|eras program
86216|NCT02524925|hepatectomy
86217|NCT02524925|pancreatectomy
86218|NCT02524925|NPY
86219|NCT02524925|ACTH/Cortsiosol
86220|NCT02524925|postoperative stress
86221|NCT02524899|Schizotypal Personality Disorder
86222|NCT02524899|SPD
86223|NCT02524899|cognitive remediation therapy
86224|NCT02524899|CRT
86225|NCT02524899|guanfacine
86226|NCT02524899|cognitive impairment
86227|NCT02524899|working memory
86228|NCT02524899|pharmacological cognitive enhancing agent
86229|NCT02524899|neuropsychological testing
86230|NCT02524899|schizophrenia spectrum disorders
86231|NCT02524899|Personality Disorders
86232|NCT02524886|Deep Brain Simulation
86233|NCT02524886|Psychiatric
86234|NCT02524886|Side-effects
86235|NCT02524860|Prostate Cancer
86236|NCT02524860|Biopsy
86237|NCT02524860|Focal Healthcare
86238|NCT02524860|Fusion Targeted Biopsy
86239|NCT02524860|High Risk Cancer
86240|NCT02524860|Imaging
86241|NCT02524860|Diagnostic
86242|NCT02524860|Ultrasound
86243|NCT02524860|Multiparametric Magnetic Resonance Imaging (MP-MRI)
86244|NCT02524860|MRI-Ultrasound Fusion
86245|NCT02524860|Focal-Fusion Bx
86246|NCT02524834|Thoracoabdominal lesions
86247|NCT02524795|Omega 3, Cytokines, Adipokines, Systemic lupus erythematosus
86248|NCT02524782|MEDI-4166, diabetes
86249|NCT02524769|Urge Urinary Incontinence
86250|NCT02524769|Urinary Incontinence
86251|NCT02524756|nerve sparing radical hysterectomy
86252|NCT02524743|Rocuronium
86253|NCT02524743|lidocaine
86254|NCT02524743|acetaminophen,
86255|NCT02524743|pain
86256|NCT02524743|injection
86257|NCT02524717|Hepatic Impairment
86258|NCT02524717|JNJ-56021927
86259|NCT02524704|Cystic fibrosis
86260|NCT02524704|Electrical Impedance Tomography
86261|NCT02524626|Vagus nerve stimulation
86262|NCT02524626|Postoperative ileus
86263|NCT02524561|mammographic density
86264|NCT02524561|abnormal mammogram
86265|NCT02524561|biopsy
86266|NCT02524548|Aromatase inhibitors
86267|NCT02524548|Reminder Systems
86268|NCT02524522|Integrated Pulmonary Index
86269|NCT02524522|automated protocol-driven weaning
86270|NCT02524522|pulmonary recruitment maneuver
86271|NCT02524509|Chonodron
86272|NCT02524509|Microfracture
86273|NCT02524509|autologous cultured chondrocyte
86274|NCT02524509|cartilage defect of knee
86275|NCT02524444|Intermittent preventive therapy
86276|NCT02524444|malaria
86277|NCT02524444|pregnant
86278|NCT02524444|HIV positive
86279|NCT02524444|Prevention
86280|NCT02524431|Mitochondria
86281|NCT02524431|trabeculectomy
86282|NCT02524431|trabecular meshwork
86283|NCT02524431|Glaucoma surgery
86284|NCT02524418|Main Pancreatic Duct
86285|NCT02524392|independent medical evaluation
86286|NCT02524392|sick leave
86287|NCT02524392|sickness absence
86288|NCT02524392|physician primary care
86289|NCT02524392|general practitioner
86290|NCT02524392|family physician
86291|NCT02524366|Stress Urinary Incontinence
86292|NCT02524366|Artificial Urinary Sphincter
86293|NCT02524353|cardiac surgery
86294|NCT02524340|JIA
86295|NCT02524340|Arthritis
86296|NCT02524340|pJIA
86297|NCT02524340|PCATS
86298|NCT02524301|anorexia nervosa
86299|NCT02524301|opioid receptors
86300|NCT02524301|Positron emission tomography (PET)
86301|NCT02524301|diprenorphine
86302|NCT02524262|atrohpic gastritis
86303|NCT02524262|acetaldehyde
86304|NCT02524262|ethanol
86305|NCT02524262|L-cysteine
86306|NCT02524236|BPH, OAB, Botox, dose response
86307|NCT02524223|medically assisted procreation
86308|NCT02524210|volunteers
86309|NCT02524197|Hip
86310|NCT02524197|Knee
86311|NCT02524197|Arthritis
86312|NCT02524197|pain
86313|NCT02524197|CR845
86314|NCT02524197|kappa opioid
86315|NCT02524171|crime
86316|NCT02524171|mental health
86317|NCT02524171|substance abuse
86318|NCT02524171|homelessness
86319|NCT02524171|Veterans
86320|NCT02524158|Yoga
86321|NCT02524158|Mind-Body Therapies
86322|NCT02524158|Chronic Low Back Pain
86323|NCT02524158|Military Veterans
86324|NCT02524158|VA patients
86325|NCT02524080|Ambulance
86326|NCT02524080|Trust
86327|NCT02524080|Patients
86328|NCT02524080|Healthcare chain
86329|NCT02524054|Dyspnea
86330|NCT02524054|Hospitalized patients
86331|NCT02524054|Ambulatory outpatients
86332|NCT02524054|Shortness of breath
86333|NCT02524054|Chronic obstructive pulmonary disease
86334|NCT02524054|Pulmonary disease
86335|NCT02524041|Hyperparathyroidism
86336|NCT02524041|microarchitecture
86337|NCT02524041|periostin
86338|NCT02524028|Atrial Fibrillation
86339|NCT02524028|fMRI
86340|NCT02524015|stroke
86341|NCT02524015|pusher syndrome
86342|NCT02524015|contraversive pushing
86343|NCT02524015|lateropulsion
86344|NCT02524015|rehabilitation
86345|NCT02524015|physical therapy
86346|NCT02524002|Abnormal Labor
86347|NCT02524002|Prolonged Induction
86348|NCT02524002|Ketosis
86349|NCT02524002|Diet
86350|NCT02523989|arsenic
86351|NCT02523989|heavy metal
86352|NCT02523976|Acute
86353|NCT02523976|Leukemia
86354|NCT02523976|Lymphoid
86355|NCT02523976|Philadelphia chromosome
86356|NCT02523976|dasatinib
86357|NCT02523963|family work shop
86358|NCT02523937|Pulmonary Embolism
86359|NCT02523937|Deep Venous Thrombosis
86360|NCT02523937|Soluble Fibrin
86361|NCT02523937|D-Dimers
86362|NCT02523937|Low and intermediate clinical probability
86363|NCT02523911|Suprep
86364|NCT02523911|Simethicone
86365|NCT02523911|Colorectal cancer screening
86366|NCT02523911|Routine colonoscopy
86367|NCT02523911|sodium sulfate/potassium sulfate/magnesium sulfate
86368|NCT02523911|Bowel cleansing
86369|NCT02523911|Mass screening
86370|NCT02523898|Clomiphene
86371|NCT02523898|infertility
86372|NCT02523898|insuline resistant
86373|NCT02523898|metformine
86374|NCT02523898|PCOS
86375|NCT02523885|Pneumonia, Bacterial [C01.252.620]
86376|NCT02523885|Bronchopneumonia [C08.381.677.127]
86377|NCT02523885|Pleuropneumonia [C08.730.610.473]
86378|NCT02523885|Anti-Inflammatory Agents, Non-Steroidal
86379|NCT02523872|Fluid overload
86380|NCT02523872|Acute respiratory failure
86381|NCT02523872|Acute respiratory distress syndrome
86382|NCT02523872|Medication administration
86383|NCT02523846|IV-Patient Controlled Analgesia (IV-PCA)
86384|NCT02523846|background morphine infusion
86385|NCT02523846|patient re-education
86386|NCT02523781|preeclampsia
86387|NCT02523781|information pamphlet
86388|NCT02523781|patient education
86389|NCT02523755|epidural analgesia for labor
86390|NCT02523755|respiratory function
86391|NCT02523755|electrical impedance tomography
86392|NCT02523729|lactation
86393|NCT02523729|human milk
86394|NCT02523729|maltz
86395|NCT02523729|antioxidant
86396|NCT02523716|Hypoxic conditioning
86397|NCT02523716|Cardio pulmonary exercise testing
86398|NCT02523651|Periodontal Diseases
86399|NCT02523651|Bone Regeneration
86400|NCT02523651|Dental Pulp Stem Cell
86401|NCT02523638|Pegylated-Proline-interferon alpha-2b (AOP2014)
86402|NCT02523638|Polycythemia Vera
86403|NCT02523638|PEN-PV
86404|NCT02523638|PROUD-PV
86405|NCT02523638|CONTINUATION-PV
86406|NCT02523638|AOP Orphan
86407|NCT02523638|Polycythemia
86408|NCT02523638|Hematologic Diseases
86409|NCT02523638|Myeloproliferative Disorders
86410|NCT02523638|Bone Marrow Diseases
86411|NCT02523638|Interferon-alpha
86412|NCT02523638|Peginterferon alfa-2b
86413|NCT02523625|Ultrasound
86414|NCT02523599|post operative pain
86415|NCT02523599|hernioplasty
86416|NCT02523599|bupivacaine
86417|NCT02523586|oxygen concentration
86418|NCT02523586|oxygen therapy
86419|NCT02523586|oxygen delivery
86420|NCT02523586|oxygen masks
86421|NCT02523560|Telerehabilitation
86422|NCT02523560|Home Monitoring
86423|NCT02523560|Heart Failure
86424|NCT02523547|entecavir
86425|NCT02523495|Molecular Targeted Therapy
86426|NCT02523495|metastasis colorectal cancer
86427|NCT02523495|biomarker
86428|NCT02523482|Prescriptions
86429|NCT02523482|Epidemiology
86430|NCT02523482|STOPP/START Criteria
86431|NCT02523482|Beers Criteria
86432|NCT02523456|Early warning score
86433|NCT02523456|Cardiac arrest
86434|NCT02523443|Epidural Analgesia
86435|NCT02523443|Intravenous Patient Controlled
86436|NCT02523443|15-148
86437|NCT02523430|Nasopharyngeal Carcinoma
86438|NCT02523430|HepaSphere
86439|NCT02523417|Breast Cancer
86440|NCT02523417|HepaSphere
86441|NCT02523404|Lung Cancer
86442|NCT02523404|HepaSphere
86443|NCT02523378|Advanced Cancers
86444|NCT02523378|Recurrent
86445|NCT02523378|Locally advanced
86446|NCT02523378|Metastatic
86447|NCT02523378|Edmonton Symptom Assessment Scale
86448|NCT02523378|ESAS
86449|NCT02523378|Survey
86450|NCT02523378|Interview
86451|NCT02523378|Symptom questionnaire
86452|NCT02523365|Cervical Carcinoma
86453|NCT02523365|HepaSphere
86454|NCT02523326|Genomic DNA
86455|NCT02523326|chronic periodontitis
86456|NCT02523326|saliva
86457|NCT02523326|mouthwash
86458|NCT02523326|PCR
86459|NCT02523326|genotyping
86460|NCT02523326|sequencing
86461|NCT02523235|moderate pain
86462|NCT02523235|severe pain
86463|NCT02523235|surgery
86464|NCT02523235|postop analgesia
86465|NCT02523235|TKA
86466|NCT02523235|adductor catheter
86467|NCT02523235|poplital catheter
86468|NCT02523235|foot/ankle surgery
86469|NCT02523222|dextrose gel
86470|NCT02523222|newborn hypoglycemia
86471|NCT02523222|late preterm infant
86472|NCT02523222|large for gestational age
86473|NCT02523222|small for gestational age
86474|NCT02523222|prophylactic
86475|NCT02523222|neonatal hypoglycemia
86476|NCT02523209|Osteoporosis
86477|NCT02523209|chronic kidney disease
86478|NCT02523209|kidney transplantation
86479|NCT02523209|fracture risk
86480|NCT02523196|Hepatic Venous Pressure Gradient (HVPG) testing
86481|NCT02523196|HepQuant-SHUNT
86482|NCT02523196|Liver Function
86483|NCT02523183|Epilepsy
86484|NCT02523183|Marijuana
86485|NCT02523144|Transthoracic echocardiography
86486|NCT02523144|echo
86487|NCT02523144|TTE
86488|NCT02523131|Type 1 diabetes
86489|NCT02523131|Closed-loop glucose control
86490|NCT02523131|Artificial Pancreas
86491|NCT02523131|Continuous subcutaneous insulin infusion
86492|NCT02523131|Continuous glucose monitoring
86493|NCT02523131|threshold suspend
86494|NCT02523131|predictive low glucose suspend
86495|NCT02523092|sarcoidosis
86496|NCT02523092|Acthar
86497|NCT02523092|CXCL9
86498|NCT02523092|chemokine ligand 9
86499|NCT02523053|Hepatocellular Carcinoma
86500|NCT02523053|Recurrence
86501|NCT02523053|Microvascular Invasion
86502|NCT02523053|5-Fluorouracil
86503|NCT02523040|Langerhans cell histiocytosis (LCH)
86504|NCT02523040|Erdheim-Chester disease (ECD)
86505|NCT02523040|Histiocytic Sarcoma (HS)
86506|NCT02522988|cancer-related fatigue
86507|NCT02522975|biosimilar epoetin
86508|NCT02522975|efficacy
86509|NCT02522975|safety
86510|NCT02522975|immunogenicity
86511|NCT02522975|renal anaemia
86512|NCT02522962|physical therapy
86513|NCT02522962|group-based
86514|NCT02522962|core stability
86515|NCT02522962|balance
86516|NCT02522962|movement quality
86517|NCT02522962|somatosensory stimulation
86518|NCT02522962|coordination
86519|NCT02522923|Physical Therapy Modalities
86520|NCT02522923|Primary Care
86521|NCT02522923|Health Services Research
86522|NCT02522884|Angioplasty
86523|NCT02522884|Peripheral Artery Disease
86524|NCT02522884|PAD
86525|NCT02522884|Lesion
86526|NCT02522884|Claudication
86527|NCT02522858|premedication
86528|NCT02522858|dexmedetomidine
86529|NCT02522858|anesthesia, spinal
86530|NCT02522845|Varicose Veins
86531|NCT02522845|Compression Stockings
86532|NCT02522845|Laser Ablation
86533|NCT02522845|Catheter Ablation, Radiofrequency
86534|NCT02522819|Obstructive Sleep Apnea Syndrome
86535|NCT02522819|acute stroke
86536|NCT02522819|apnea-hypopnea index (AHI)
86537|NCT02522806|Endometrial biopsy
86538|NCT02522806|previous ovarian hyperstimulation cycle
86539|NCT02522806|first IVF
86540|NCT02522806|antagonist protocol
86541|NCT02522806|clinical pregnancy rate
86542|NCT02522793|skin lesion
86543|NCT02522728|Knee
86544|NCT02522728|Arthroplasty
86545|NCT02522728|Implant
86546|NCT02522689|kidney stone
86547|NCT02522689|percutaneous nephrolithotripsy
86548|NCT02522689|ultra-mini PCNL
86549|NCT02522689|micro PCNL
86550|NCT02522676|kidney stone
86551|NCT02522676|percutaneous nephrolithotripsy
86552|NCT02522676|retrograde intrarenal surgery
86553|NCT02522676|extracorporeal shock wave lithotripsy
86554|NCT02522676|mini PCNL
86555|NCT02522676|ultra-mini PCNL
86556|NCT02522676|micro PCNL
86557|NCT02522663|telephone support
86558|NCT02522663|discharge management
86559|NCT02522663|readmission
86560|NCT02522663|aortic valve replacement
86561|NCT02522650|amiloride
86562|NCT02522650|proteinuric kidney disease
86563|NCT02522650|urokinase plasminogen activator receptor
86564|NCT02522650|proteinuria
86565|NCT02522637|exercise
86566|NCT02522637|training
86567|NCT02522637|endurance
86568|NCT02522624|Health insurance
86569|NCT02522624|Health services accessibility
86570|NCT02522624|Decision making
86571|NCT02522624|Health literacy
86572|NCT02522611|Palliative Care
86573|NCT02522611|Adults
86574|NCT02522611|Cancer Pain
86575|NCT02522611|Nerve Block
86576|NCT02522611|Quality of Life
86577|NCT02522585|expectant management
86578|NCT02522585|p16
86579|NCT02522585|immunohistochemistry
86580|NCT02522585|regression
86581|NCT02522585|progression
86582|NCT02522585|cervical intraepithelial neoplasia
86583|NCT02522572|Renal Transplantation
86584|NCT02522572|Desensitization
86585|NCT02522572|plerixafor
86586|NCT02522572|bortezomib
86587|NCT02522520|Undergoing chemotherapy
86588|NCT02522520|Exercise intervention
86589|NCT02522520|Health counselling
86590|NCT02522520|Symptom management
86591|NCT02522481|Lumason
86592|NCT02522481|Dobutamine stress echo
86593|NCT02522481|stress echo
86594|NCT02522481|coronary artery disease
86595|NCT02522455|Flow-cycled pressure-support ventilation
86596|NCT02522403|distal radius fracture
86597|NCT02522403|laser acupuncture
86598|NCT02522403|rehabilitation
86599|NCT02522390|data collection
86600|NCT02522390|personal health services
86601|NCT02522390|personal health records
86602|NCT02522390|do-it-yourself
86603|NCT02522390|nutrition researchers
86604|NCT02522390|cohort studies
86605|NCT02522390|databases, factual
86606|NCT02522390|self-quantification methods
86607|NCT02522377|Ketamine
86608|NCT02522377|Electroconvulsive Therapy
86609|NCT02522377|Major Depressive Disorder
86610|NCT02522377|Treatment Resistant Depression
86611|NCT02522377|electroconvulsive treatment
86612|NCT02522377|Severe depression
86613|NCT02522364|Postoperative atrial fibrillation
86614|NCT02522364|Dysfunction Following Cardiac Surgery
86615|NCT02522312|Dry Eye
86616|NCT02522299|double-blind
86617|NCT02522299|PI3Kdelta
86618|NCT02522299|GSK2269557
86619|NCT02522299|exacerbation
86620|NCT02522299|Chronic Obstructive Pulmonary Disease
86621|NCT02522299|randomised
86622|NCT02522299|placebo-controlled
86623|NCT02522286|patient engagement
86624|NCT02522286|physician's role
86625|NCT02522286|patient- centered care
86626|NCT02522286|communication
86627|NCT02522273|Obstetric
86628|NCT02522273|Midwifery
86629|NCT02522273|Fetal blood sample
86630|NCT02522273|Lactate
86631|NCT02522273|Handheld meter
86632|NCT02522260|Breast cancer, chemotherapy, symptoms, optimal training
86633|NCT02522234|Neutropenia
86634|NCT02522234|Chemotherapy
86635|NCT02522221|chronic anticoagulation
86636|NCT02522221|vitamin K antagonist
86637|NCT02522221|mechanical heart valve
86638|NCT02522221|CYP2C9
86639|NCT02522221|warfarin
86640|NCT02522221|tecarfarin
86641|NCT02522195|shift work
86642|NCT02522195|nutritional status
86643|NCT02522195|nursing professionals
86644|NCT02522195|meal distribution
86645|NCT02522195|food intake
86646|NCT02522182|Cardiovascular Secondary Prevention
86647|NCT02522182|Nurse's Role
86648|NCT02522143|self-harm
86649|NCT02522143|self-mutilation
86650|NCT02522143|cutting
86651|NCT02522117|Kidney Transplantation
86652|NCT02522117|Atorvastatin
86653|NCT02522117|Human Leukocyte Antigens
86654|NCT02522117|Interleukin
86655|NCT02522104|Pharmacokinetics of Hydroxyurea
86656|NCT02522078|misoprostol
86657|NCT02522078|abortion
86658|NCT02522065|Hypokinesia
86659|NCT02522065|Patient Outcome Assessment
86660|NCT02522013|post-dural puncture headache
86661|NCT02522013|Aminophylline
86662|NCT02521948|MANTA
86663|NCT02521948|Arterial Closure Device
86664|NCT02521948|Large Bore Closure Device
86665|NCT02521909|Root Canal length
86666|NCT02521909|Electronic apex locator
86667|NCT02521909|Endodontics
86668|NCT02521870|Skin Cancer
86669|NCT02521870|Skin Tumors
86670|NCT02521870|Head and Neck Squamous Cell Carcinoma
86671|NCT02521870|Cancer Immunotherapy
86672|NCT02521857|Alkermes
86673|NCT02521857|Samidorphan
86674|NCT02521857|ALKS 5461
86675|NCT02521857|Healthy Volunteer
86676|NCT02521857|Pharmacokinetics
86677|NCT02521844|solid tumors
86678|NCT02521844|responsive to Wnt signalling regulation
86679|NCT02521831|Circumcision
86680|NCT02521818|cognition
86681|NCT02521818|dementia
86682|NCT02521818|neuropsychological
86683|NCT02521818|elderly
86684|NCT02521818|nutrition
86685|NCT02521818|diet
86686|NCT02521805|Appetite
86687|NCT02521805|Protein
86688|NCT02521805|Protein quality
86689|NCT02521805|Dietary fibre
86690|NCT02521805|Satiety
86691|NCT02521792|Open-label study
86692|NCT02521792|Clinical trial Phase 2
86693|NCT02521792|Efficacy and safety
86694|NCT02521792|Heterotopic ossification
86695|NCT02521792|Fibrodysplasia Ossificans Progressiva
86696|NCT02521792|Flare-up
86697|NCT02521792|Palovarotene
86698|NCT02521792|Retinoic acid receptor agonist
86699|NCT02521792|Retinoic acid receptor gamma agonist
86700|NCT02521792|Clementia
86701|NCT02521792|Myositis Ossificans Progressiva
86702|NCT02521792|Munchmeyer's Disease
86703|NCT02521792|FOP
86704|NCT02521779|Inflammation
86705|NCT02521779|Endotoxemia
86706|NCT02521779|Lipopolysaccharide
86707|NCT02521779|Diet
86708|NCT02521779|Fat
86709|NCT02521779|Postprandial
86710|NCT02521753|Polycystic ovary syndrome
86711|NCT02521753|Obesity
86712|NCT02521753|Metformin
86713|NCT02521753|Magnesium
86714|NCT02521753|Polyunsaturated fatty acids
86715|NCT02521740|biological marker
86716|NCT02521740|frailty
86717|NCT02521740|burden
86718|NCT02521740|nutrition
86719|NCT02521740|elderly
86720|NCT02521714|Revlimid
86721|NCT02521714|lenalidomide
86722|NCT02521714|bioavailability
86723|NCT02521714|healthy volunteers
86724|NCT02521714|food effect
86725|NCT02521714|pharmacokinetics
86726|NCT02521662|Electronic Cigarettes
86727|NCT02521662|Nicotine Patch
86728|NCT02521662|Smoking Cessation
86729|NCT02521649|Gastric Cancer
86730|NCT02521649|G17DT
86731|NCT02521649|PAS
86732|NCT02521649|Insegia
86733|NCT02521649|Gastrimmune
86734|NCT02521623|Acelullar Dermal Matrix
86735|NCT02521623|Immediate Breast Reconstruction
86736|NCT02521623|Breast Implant
86737|NCT02521584|Liver transplant recipient
86738|NCT02521545|Oral Remyelination
86739|NCT02521519|Facet induced pain
86740|NCT02521519|Myofascial pain
86741|NCT02521519|Trigger points
86742|NCT02521519|Low back pain
86743|NCT02521454|policing
86744|NCT02521454|resilience
86745|NCT02521454|implicit bias
86746|NCT02521454|violence
86747|NCT02521441|Neutropenia
86748|NCT02521441|Myelotoxic Chemotherapy
86749|NCT02521441|G-CSF
86750|NCT02521363|Implantable Microdevice
86751|NCT02521363|In Vivo Drug Sensitivity Testing
86752|NCT02521363|HER2-Positive
86753|NCT02521363|Triple Negative
86754|NCT02521363|15-127
86755|NCT02521350|Acute Kidney Injury
86756|NCT02521350|Surgery
86757|NCT02521350|Perioperative care
86758|NCT02521311|multiple sclerosis
86759|NCT02521311|eye pain
86760|NCT02521311|vision loss
86761|NCT02521259|anesthetic depth
86762|NCT02521259|emergence agitation
86763|NCT02521220|L-citrulline
86764|NCT02521220|Endothelial dysfunction
86765|NCT02521194|Advanced Cancers
86766|NCT02521194|Inpatient occupational therapy
86767|NCT02521194|Questionnaire
86768|NCT02521194|Survey
86769|NCT02521168|euthyroid sick syndrome
86770|NCT02521168|cardiopulmonary bypass
86771|NCT02521168|congenital heart disease
86772|NCT02521168|time to extubation
86773|NCT02521155|Oral health literacy intervention
86774|NCT02521155|oral hygiene behavior
86775|NCT02521142|OCT Angiography
86776|NCT02521116|retinal oxygenation
86777|NCT02521116|retinal vessel diameters
86778|NCT02521116|Dynamic vessel analyzer (DVA)
86779|NCT02521116|Oxymap T1
86780|NCT02521077|Ascorbic Acid
86781|NCT02521077|Breast Neoplasms
86782|NCT02521077|Fatigue
86783|NCT02521064|IBD
86784|NCT02521064|enteral nutrition
86785|NCT02521064|corticosteroids
86786|NCT02521051|Non-Small Cell Lung Cancer (NSCLC)
86787|NCT02521051|Anaplatic lymphoma kinase
86788|NCT02521051|ALK
86789|NCT02521051|Brain metastases
86790|NCT02521012|Depression
86791|NCT02521012|Depressive symptoms
86792|NCT02521012|Vitamin D
86793|NCT02521012|Intervention
86794|NCT02520986|Sexually transmitted disease
86795|NCT02520986|Genital Warts
86796|NCT02520986|Venereal Warts
86797|NCT02520960|Catheter Ablation
86798|NCT02520960|Pulmonary Vein Isolation
86799|NCT02520960|Radiofrequency
86800|NCT02520947|desflurane
86801|NCT02520947|BIS
86802|NCT02520947|coronary artery bypass grafting surgery
86803|NCT02520934|Enzyme Replacement Therapy
86804|NCT02520934|Miglustat
86805|NCT02520934|Gaucher Disease
86806|NCT02520921|Diabetes mellitus
86807|NCT02520921|Acute coronary syndrome
86808|NCT02520921|Coronary artery disease
86809|NCT02520921|Aspirin
86810|NCT02520921|Secondary prevention
86811|NCT02520895|Chronic Lymphocytic Leukemia
86812|NCT02520895|Non-Hodgkin lymphoma
86813|NCT02520895|Follicular Lymphoma
86814|NCT02520895|Diffuse Large B Cell Lymphoma
86815|NCT02520895|MALT Lymphoma
86816|NCT02520895|T Cell Lymphoma
86817|NCT02520895|Immune Repertoire
86818|NCT02520895|Infection
86819|NCT02520895|relapse
86820|NCT02520895|survival
86821|NCT02520895|treatment response
86822|NCT02520895|VJ rearrangement
86823|NCT02520882|PET/CT
86824|NCT02520882|Bombesin
86825|NCT02520882|gastrin-releasing peptide receptor
86826|NCT02520882|68Gallium labeling
86827|NCT02520830|blueberry polyphenols
86828|NCT02520830|Polyphenol metabolites
86829|NCT02520830|endothelial function
86830|NCT02520830|Molecular mechanisms of action
86831|NCT02520830|Vascular function
86832|NCT02520830|Healthy men
86833|NCT02520817|Antioxidants
86834|NCT02520817|Zinc
86835|NCT02520817|Truck drivers
86836|NCT02520804|balanced salt solution
86837|NCT02520765|Obesity Index, ICSI
86838|NCT02520752|cMET, INC280, caffeine, midazolam
86839|NCT02520739|olive oil
86840|NCT02520739|phenolic compounds
86841|NCT02520739|triterpenes
86842|NCT02520739|oxidation and inflammation
86843|NCT02520726|Posttraumatic stress disorder
86844|NCT02520726|PTSD
86845|NCT02520726|Sertraline
86846|NCT02520726|Burns
86847|NCT02520713|Pediatric Solid Tumor
86848|NCT02520648|Back pain
86849|NCT02520648|Manual therapy
86850|NCT02520635|prognosis
86851|NCT02520635|supra-early chemotherapy
86852|NCT02520609|Metabolomics
86853|NCT02520609|Non-Alcoholic Steatohepatitis
86854|NCT02520609|Non-Alcoholic Fatty Liver Disease
86855|NCT02520609|Energy Expenditure
86856|NCT02520596|Raspberries
86857|NCT02520596|Anthocyanins
86858|NCT02520596|Ellagitannins
86859|NCT02520596|Metabolites
86860|NCT02520557|Epilepsy
86861|NCT02520557|Genetic associations with severe Cutaneous Adverse Reactions
86862|NCT02520492|intracranial pressure
86863|NCT02520479|extranodal natural killer/T-cell lymphoma
86864|NCT02520479|nasal type
86865|NCT02520479|radiotherapy
86866|NCT02520479|chemotherapy
86867|NCT02520440|Citrulline
86868|NCT02520440|GIF
86869|NCT02520440|MOF
86870|NCT02520440|Calprotectina
86871|NCT02520440|intraabdominal pressure
86872|NCT02520427|Amgen
86873|NCT02520427|Phase 1
86874|NCT02520427|Clinical Trial
86875|NCT02520427|Oncology/Hematology
86876|NCT02520427|Relapsed/Refractory AML
86877|NCT02520427|Immunotherapy
86878|NCT02520310|Mitral Regurgitation
86879|NCT02520310|mitral valve surgery
86880|NCT02520310|AVJ-514 Delivery System
86881|NCT02520310|Symptomatic Heart Failure
86882|NCT02520310|Heart Valve Disease
86883|NCT02520297|Pain
86884|NCT02520297|Long bone
86885|NCT02520297|Fracture
86886|NCT02520271|Mood Disorders
86887|NCT02520271|Motivational Interview
86888|NCT02520271|Behavioral Activation
86889|NCT02520258|artificial sweeteners
86890|NCT02520258|obesity
86891|NCT02520258|diabetes
86892|NCT02520258|metabolic syndrome
86893|NCT02520232|chronic exercise
86894|NCT02520232|genetic polymorphisms
86895|NCT02520232|brain imagery
86896|NCT02520232|executive functions
86897|NCT02520232|alzheimer's disease
86898|NCT02520219|Peripheral T-cell lymphomas,Endostar
86899|NCT02520193|Early mobilisation
86900|NCT02520193|Invasive ventilation
86901|NCT02520193|Ventilator free days
86902|NCT02520193|Intensive Care Unit
86903|NCT02520167|Gestational weight gain
86904|NCT02520154|Ovarian Cancer
86905|NCT02520154|Metastatic Ovarian Cancer
86906|NCT02520154|High-grade epithelial non-mucinous ovarian cancer
86907|NCT02520154|Advanced stage ovarian cancer
86908|NCT02520154|Carboplatin
86909|NCT02520154|Paraplatin
86910|NCT02520154|Paclitaxel
86911|NCT02520154|Taxol
86912|NCT02520154|Pembrolizumab
86913|NCT02520154|Keytruda
86914|NCT02520154|MK-3475
86915|NCT02520154|SCH-900475
86916|NCT02520141|Biliary cancer
86917|NCT02520141|Advanced biliary cancers
86918|NCT02520141|Intrahepatic cholangiocarcinoma
86919|NCT02520141|Extrahepatic cholangiocarcinoma
86920|NCT02520141|Gallbladder cancer
86921|NCT02520141|Received prior chemotherapy
86922|NCT02520141|Ramucirumab
86923|NCT02520141|IMC-1121B
86924|NCT02520128|Intensity Modulated Radiotherapy
86925|NCT02520128|Radiotherapy
86926|NCT02520089|platelet-rich plasma
86927|NCT02520089|bone grafting
86928|NCT02520089|pseudoarthrosis
86929|NCT02520076|Islet Transplantation
86930|NCT02520063|hormone-receptor positive breast cancer
86931|NCT02520063|Her2 negative breast cancer
86932|NCT02520063|neoadjuvant
86933|NCT02520063|everolimus
86934|NCT02520063|TRC105
86935|NCT02520063|letrozole
86936|NCT02520050|Type 2 diabetes
86937|NCT02520050|Obesity
86938|NCT02520050|Nutrition
86939|NCT02520050|Medical Nutrition Therapy
86940|NCT02520037|Fluid responsiveness
86941|NCT02520037|Volume responsiveness
86942|NCT02520037|Hemodynamics
86943|NCT02520024|self-directed care
86944|NCT02520024|serious mental illness
86945|NCT02520011|Refractory AML
86946|NCT02520011|Relapsed AML
86947|NCT02520011|AML
86948|NCT02520011|Newly diagnosed high-risk AML
86949|NCT02519998|Biomarkers
86950|NCT02519998|Electrocardiography
86951|NCT02519998|Balance
86952|NCT02519998|Neuropsychiatric assessment
86953|NCT02519998|Cortisol
86954|NCT02519998|Calcitonin-gene-related peptide
86955|NCT02519998|Electroencephalography
86956|NCT02519998|Optical coherence tomography
86957|NCT02519998|Von Frey Testing
86958|NCT02519985|VHF digital ultrasound
86959|NCT02519985|Corneal thickness
86960|NCT02519985|Epithelial thickness
86961|NCT02519985|Angle diameter
86962|NCT02519985|Sulcus diameter
86963|NCT02519985|Anterior chamber depth
86964|NCT02519985|Repeatability
86965|NCT02519985|Reproducibility
86966|NCT02519972|Low dose CT screening
86967|NCT02519972|Family history of lung cancer
86968|NCT02519959|Hypoxia
86969|NCT02519959|Pimonidazole
86970|NCT02519959|[F-18]-Fluoroazomycin arabinoside
86971|NCT02519959|Co-registration
86972|NCT02519959|Histology
86973|NCT02519959|Positron emission tomography
86974|NCT02519946|Heart Transplantation
86975|NCT02519946|Tonometry
86976|NCT02519946|Exercise Test
86977|NCT02519946|Diet
86978|NCT02519946|Cardiovascular Physiology
86979|NCT02519946|Telemedicine
86980|NCT02519946|Pediatrics
86981|NCT02519946|Health Behavior
86982|NCT02519946|Physical Fitness
86983|NCT02519946|Exercise Movement Techniques
86984|NCT02519946|Adolescent Behavior
86985|NCT02519946|Child Behavior
86986|NCT02519933|hemodialysis
86987|NCT02519933|vascular access
86988|NCT02519907|Nerve Stimulation
86989|NCT02519907|Neuroplasticity
86990|NCT02519907|Sensory Feedback
86991|NCT02519881|cartilage defect in ankle
86992|NCT02519881|microfracture
86993|NCT02519881|modified microfracture using collagen
86994|NCT02519881|collagen
86995|NCT02519868|Neuromodulation
86996|NCT02519868|Local anaesthetics
86997|NCT02519829|Suture
86998|NCT02519829|Skin staples
86999|NCT02519829|Vicryl
87000|NCT02519829|Monocryl
87001|NCT02519816|post stem cell transplantation
87002|NCT02519816|Steroid refractory
87003|NCT02519816|dependent chronic
87004|NCT02519777|HIV-Associated Neurocognitive Disorder
87005|NCT02519764|volunteer runners who are participating in the 2015 Mont Blanc Ultra Trail
87006|NCT02519764|hydration protocol
87007|NCT02519764|natremia
87008|NCT02519764|Volunteers
87009|NCT02519725|Family
87010|NCT02519725|PTSD
87011|NCT02519725|Anxiety disorders
87012|NCT02519725|Depression disorders
87013|NCT02519725|Qualitative research
87014|NCT02519712|Induction Chemotherapy
87015|NCT02519712|G-CSF-Mobilized Stem Cells
87016|NCT02519712|Haploidentical Related Donors
87017|NCT02519712|15-141
87018|NCT02519660|Ralydan
87019|NCT02519660|EMLA cream
87020|NCT02519660|Procedural pain
87021|NCT02519660|Phlebotomy
87022|NCT02519660|Child
87023|NCT02519634|Super-Mini Percutaneous Nephrolithotomy
87024|NCT02519634|SMP
87025|NCT02519634|Retrograde Intrarenal Surgery
87026|NCT02519634|RIRS
87027|NCT02519634|Randomized Controlled Trial
87028|NCT02519634|RCT
87029|NCT02519621|diabetic ulcer
87030|NCT02519621|pressure ulcer
87031|NCT02519621|chronic or traumatic wound
87032|NCT02519621|sub-acute or dehisced wound
87033|NCT02519608|chronic obstructive pulmonary disease
87034|NCT02519608|stable coronary artery disease
87035|NCT02519608|ticagrelor
87036|NCT02519608|clopidogrel
87037|NCT02519608|endothelial function
87038|NCT02519608|inflammation
87039|NCT02519608|platelet reactivity
87040|NCT02519595|Procedural sedation
87041|NCT02519595|ketamine
87042|NCT02519595|children
87043|NCT02519582|Colorectal Cancer
87044|NCT02519582|S100A4
87045|NCT02519556|Probiotics
87046|NCT02519556|Inflammation
87047|NCT02519556|Awareness
87048|NCT02519556|Immune tolerance
87049|NCT02519543|insulin resistance
87050|NCT02519530|Positive Youth Development
87051|NCT02519530|Teen Outreach
87052|NCT02519530|Teen Pregnancy Prevention
87053|NCT02519504|Galactose-1-phosphate uridylyltransferase deficiency
87054|NCT02519504|Cognitive disorders
87055|NCT02519478|football
87056|NCT02519478|Training Techniques
87057|NCT02519478|education
87058|NCT02519478|Athletic Injuries
87059|NCT02519478|Brain Concussion
87060|NCT02519465|nasal cannula
87061|NCT02519465|Inhalation Devices
87062|NCT02519452|Multiple Myeloma
87063|NCT02519452|Daratumumab (JNJ-54767414)
87064|NCT02519452|Recombinant Human Hyaluronidase
87065|NCT02519439|Partial Onset Seizures
87066|NCT02519439|complex partial seizures
87067|NCT02519439|simple partial seizures
87068|NCT02519439|anticonvulsant
87069|NCT02519439|ganaxolone
87070|NCT02519439|neurosteroid
87071|NCT02519439|Marinus
87072|NCT02519439|epilepsy
87073|NCT02519426|Third molar
87074|NCT02519426|Classification
87075|NCT02519426|Inferior alveolar nerve
87076|NCT02519426|Lingual nerve injuries
87077|NCT02519426|Mandibular canal
87078|NCT02519413|lymphocyte
87079|NCT02519413|serious infections
87080|NCT02519413|opportunistic infections
87081|NCT02519413|Relapsing Forms
87082|NCT02519400|amitriptyline
87083|NCT02519400|cyp2d6
87084|NCT02519400|cyp2c19
87085|NCT02519374|Fiber tolerability
87086|NCT02519374|Children
87087|NCT02519361|elderly
87088|NCT02519361|immune response
87089|NCT02519361|acute infection
87090|NCT02519348|Hepatocellular Carcinoma
87091|NCT02519348|Immunotherapy
87092|NCT02519348|Antibodies, Monoclonal
87093|NCT02519348|Tremelimumab
87094|NCT02519348|MEDI4736
87095|NCT02519348|Durvalumab
87096|NCT02519335|cardiopulmonary bypass
87097|NCT02519335|ischemia reperfusion injury
87098|NCT02519322|Melanoma
87099|NCT02519322|Oligometastatic melanoma
87100|NCT02519322|Resectable
87101|NCT02519322|Nivolumab
87102|NCT02519322|BMS-936558
87103|NCT02519322|Opdivo
87104|NCT02519322|Ipilimumab
87105|NCT02519322|Yervoy
87106|NCT02519322|BMS-734016
87107|NCT02519322|MDX010
87108|NCT02519283|AHF
87109|NCT02519283|HF
87110|NCT02519283|ED
87111|NCT02519283|ER
87112|NCT02519283|Emergency Department
87113|NCT02519283|Emergency Room
87114|NCT02519257|CAD
87115|NCT02519257|VHD
87116|NCT02519257|Thy-1
87117|NCT02519244|Multiple Sclerosis
87118|NCT02519244|Ambulation
87119|NCT02519244|Rehabilitation
87120|NCT02519244|Wearable Robotic Devices
87121|NCT02519231|IUD
87122|NCT02519231|naproxen
87123|NCT02519231|bleeding
87124|NCT02519153|Phosphodiesterase 5 Inhibitors
87125|NCT02519153|PDE5i
87126|NCT02519153|Sildinafil
87127|NCT02519140|Gastric cancer
87128|NCT02519140|colon cancer
87129|NCT02519140|EMR
87130|NCT02519140|biopsy
87131|NCT02519140|bariatric surgery
87132|NCT02519114|M Myeloma
87133|NCT02519114|KIR ligand mismatch
87134|NCT02519114|Haploidentical
87135|NCT02519088|Homologous Blood Transfusion
87136|NCT02519088|Total Hip Replacement
87137|NCT02519088|Patient Blood Management
87138|NCT02519075|Hepatocarcinoma
87139|NCT02519075|TARE
87140|NCT02519075|response assessment
87141|NCT02519062|Carcinoma
87142|NCT02519062|Non-Small-Cell Lung
87143|NCT02519062|FDG PET
87144|NCT02519062|hypoxia markers
87145|NCT02519062|immune markers
87146|NCT02519049|Mesothelioma
87147|NCT02519049|11C-methionine PET
87148|NCT02519049|talc pleurodesis
87149|NCT02519036|Huntington's Disease
87150|NCT02519036|HTTRx
87151|NCT02519036|Early Manifest Huntington's Disease
87152|NCT02518997|Preterm Infants
87153|NCT02518997|Bedside Reading aloud
87154|NCT02518997|Parental wellbeing
87155|NCT02518997|Parental Bonding
87156|NCT02518997|cardio-respiratory stability
87157|NCT02518945|Type 1 Diabetes
87158|NCT02518945|Liraglutide
87159|NCT02518945|Dapagliflozin
87160|NCT02518945|Triple Therapy
87161|NCT02518919|Children
87162|NCT02518919|Emergency Department
87163|NCT02518919|Sedation
87164|NCT02518906|Psychotherapy
87165|NCT02518906|psychotherapy process
87166|NCT02518906|therapeutic alliance
87167|NCT02518906|psychotherapeutic change
87168|NCT02518906|psychophysiology
87169|NCT02518893|Military Personnel
87170|NCT02518893|Air Force Personnel
87171|NCT02518893|Army Personnel
87172|NCT02518893|Navy Personnel
87173|NCT02518893|Armed Forces Personnel
87174|NCT02518893|Marines
87175|NCT02518893|Soldiers
87176|NCT02518893|Sailors
87177|NCT02518893|Airmen
87178|NCT02518893|Decision Making
87179|NCT02518893|Research Subjects
87180|NCT02518893|Life Experiences
87181|NCT02518893|Patient Participation
87182|NCT02518893|Refusal to Participate
87183|NCT02518893|Healthcare Research
87184|NCT02518893|Qualitative Research
87185|NCT02518893|Interview
87186|NCT02518893|Interviews, Telephone
87187|NCT02518893|Ethics, Research
87188|NCT02518867|Cerebral palsy
87189|NCT02518867|Transcranial magnetic stimulation
87190|NCT02518841|ThermaWedge TM
87191|NCT02518841|stretches
87192|NCT02518828|Acute Heart Failure
87193|NCT02518802|Gefitinib
87194|NCT02518802|Pemetrexed
87195|NCT02518802|Synchronous therapy
87196|NCT02518802|Adjuvent therapy
87197|NCT02518789|myoclonus
87198|NCT02518789|Etomidate
87199|NCT02518789|Dexmedetomidine
87200|NCT02518750|Hematopoietic Stem Cell Transplantation
87201|NCT02518750|Salvage Regimen
87202|NCT02518750|Re-Induction Therapy
87203|NCT02518750|Multi-agent chemotherapy
87204|NCT02518737|Glucose-dependent Insulinotropic Polypeptide
87205|NCT02518737|Receptor Deficiency
87206|NCT02518711|symptoms of ADHD
87207|NCT02518698|Castrated resistant prostate cancer
87335|NCT02517970|infant feeding
87208|NCT02518698|Patients with bone metastases
87209|NCT02518685|Obesity
87210|NCT02518685|Weight loss
87211|NCT02518685|Device
87212|NCT02518685|Non-surgical
87213|NCT02518685|Endoscopic
87214|NCT02518685|TransPyloric Shuttle
87215|NCT02518685|TPS
87216|NCT02518659|hypomagnesemia
87217|NCT02518659|hypocalcemia
87218|NCT02518659|inulin
87219|NCT02518659|FOS
87220|NCT02518659|PPI
87221|NCT02518659|proton-pump inhibitors
87222|NCT02518646|Delirium
87223|NCT02518646|Intensive care unit
87224|NCT02518646|Adult
87225|NCT02518646|Clinical prediction
87226|NCT02518633|obesity
87227|NCT02518633|hypoxia
87228|NCT02518633|adipose tissue
87229|NCT02518607|Safety and Tolerability
87230|NCT02518607|Male Volunteers
87231|NCT02518594|women
87232|NCT02518594|cervical length of less than 30 millimeters
87233|NCT02518594|carrying twins
87234|NCT02518516|Statins, HMG-CoA
87235|NCT02518516|Acute kidney injury
87236|NCT02518516|Kidney diseases
87237|NCT02518516|Renal failure
87238|NCT02518503|Diabetes Mellitus
87239|NCT02518503|Statins
87240|NCT02518503|HMG-CoA reductase inhibitors
87241|NCT02518477|breast cancer surgery
87242|NCT02518477|axillary lymph node dissection
87243|NCT02518477|resistance training
87244|NCT02518477|breast cancer related lymphedema
87245|NCT02518464|headache
87246|NCT02518464|chronic
87247|NCT02518464|migraine
87248|NCT02518464|right to left shunt
87249|NCT02518451|antihypertensive
87250|NCT02518451|bioequivalence
87251|NCT02518451|formulation
87252|NCT02518451|pharmakokinetic
87253|NCT02518451|valsartan
87254|NCT02518451|subjects
87255|NCT02518451|Fasting conditions
87256|NCT02518438|Tramadol
87257|NCT02518438|Postoperative analgesia
87258|NCT02518438|Infiltration
87259|NCT02518438|Cesarean section
87260|NCT02518412|Alzheimers disease
87261|NCT02518412|Transcranial direct current stimulation (tDCS)
87262|NCT02518412|Neuromodulation
87263|NCT02518412|Neuropsychology
87264|NCT02518399|Blood vessels
87265|NCT02518399|Heat
87266|NCT02518399|Cardiovascular diseases
87267|NCT02518386|emergency department
87268|NCT02518386|epidemiology
87269|NCT02518386|prehospital care
87270|NCT02518386|dispatch
87271|NCT02518386|acute self poisoning
87272|NCT02518360|NON SPECIFIC LOW BACK PAIN
87273|NCT02518360|OSTEOPATHY
87274|NCT02518360|FOOT PRESSURE PLATFORM
87275|NCT02518360|POSTURAL BALANCE
87276|NCT02518334|type two diabetes
87277|NCT02518334|glycemic control
87278|NCT02518321|Toileting
87279|NCT02518321|Technology-Assisted Toilets
87280|NCT02518321|Rehabilitation
87281|NCT02518321|Assistive Devices
87282|NCT02518321|Activities of Daily Living
87283|NCT02518282|high-sensitivity troponin T
87284|NCT02518282|Acute myocardial infarction
87285|NCT02518282|Heart valvular surgery
87286|NCT02518282|Cardiac surgery
87287|NCT02518269|hip
87288|NCT02518269|arthroplasty
87289|NCT02518269|G7
87290|NCT02518269|EchoBimetric
87291|NCT02518269|E1
87292|NCT02518269|ceramic
87293|NCT02518269|Arcom XL
87294|NCT02518256|Neoplasms
87295|NCT02518256|Glandular and Epithelial
87296|NCT02518256|Ovarian Neoplasms
87297|NCT02518256|Ovarian cancer
87298|NCT02518204|cognitive assessment
87299|NCT02518204|neuropsychological assessment
87300|NCT02518204|Brain Performance Test
87301|NCT02518204|computerized assessment
87302|NCT02518191|GnRHa
87303|NCT02518191|ovarian function
87304|NCT02518191|anti-mullerian hormone
87305|NCT02518178|NFC
87306|NCT02518178|randomization
87307|NCT02518178|RCT
87308|NCT02518178|mHealth
87309|NCT02518178|maternal and child health
87310|NCT02518165|Cognitive Domain: Speed
87311|NCT02518165|Cognitive Domain: Reaction Time
87312|NCT02518165|Cognitive Domain: Attention
87313|NCT02518165|Cognitive Domain: Executive Function
87314|NCT02518165|Cognitive Domain Memory
87315|NCT02518165|Sleep Quality
87316|NCT02518165|Sleep Efficiency
87317|NCT02518139|Chronic Obstructive Pulmonary Disease, COPD
87318|NCT02518126|LIF IUGR
87319|NCT02518087|CPB
87320|NCT02518087|OXIRIS®
87321|NCT02518087|AKI
87322|NCT02518087|SIRS
87323|NCT02518087|Cytokines
87324|NCT02518087|LPS
87325|NCT02518074|volunteers
87326|NCT02518061|Glioma; 11C-Methionine PET
87327|NCT02518048|Psoriasis
87328|NCT02518022|Type 1 Diabetes mellitus
87329|NCT02518022|Hypoglycemia
87330|NCT02518022|continuous subcutaneous insulin infusion
87331|NCT02518022|Alcohol
87332|NCT02518022|continuous glucose monitoring system
87333|NCT02518022|Nutrition
87334|NCT02517983|chronic respiratory diseases phenotyping
87336|NCT02517970|breast-feeding
87337|NCT02517970|bottle-feeding
87338|NCT02517970|feeding interactions
87339|NCT02517970|maternal feeding practices
87340|NCT02517957|Xiashi surgical
87341|NCT02517944|Familial hypercholesterolemia
87342|NCT02517918|Advanced solid tumor
87343|NCT02517918|Bone metastasis and advanced pretreated osteosarcoma
87344|NCT02517918|Phase I trial
87345|NCT02517918|Dose escalation and expansion cohort
87346|NCT02517918|Biomarkers study
87347|NCT02517879|ITNs
87348|NCT02517879|malaria prevention
87349|NCT02517866|Drug therapy
87350|NCT02517827|common femoral artery
87351|NCT02517827|drug-coated balloon
87352|NCT02517827|surgical endarterectomy
87353|NCT02517801|anthocyanins
87354|NCT02517801|Post-menopausal women
87355|NCT02517801|endothelial function
87356|NCT02517801|vascular function
87357|NCT02517775|polyphenols
87358|NCT02517775|vascular function
87359|NCT02517775|endothelial function
87360|NCT02517775|cranberry
87361|NCT02517775|healthy
87362|NCT02517723|Borderline Personality Disorder
87363|NCT02517723|comorbid Posttraumatic Stress Disorder
87364|NCT02517723|Narrative Exposure Therapy
87365|NCT02517723|Dialectical-Behavioral Therapy
87366|NCT02517684|Crohn's disease
87367|NCT02517684|pediatric
87368|NCT02517684|infliximab
87369|NCT02517684|top-down
87370|NCT02517684|TISKids
87371|NCT02517671|Fitness
87372|NCT02517671|Run time
87373|NCT02517671|VO2max
87374|NCT02517671|VEGF
87375|NCT02517671|Central blood pressure
87376|NCT02517671|Augmentation Index
87377|NCT02517671|Pulse wave analysis
87378|NCT02517632|Physical activity
87379|NCT02517632|Cardiac rehabilitation
87380|NCT02517619|Iontophoresis
87381|NCT02517619|Ophthalmology
87382|NCT02517619|Non-Infectious Anterior Segment Uveitis
87383|NCT02517593|BCRAT
87384|NCT02517593|IBIS
87385|NCT02517593|PRS
87386|NCT02517593|breast cancer
87387|NCT02517593|Tyrer-Cuzick
87388|NCT02517554|meet National Comprehensive Cancer Network® criteria for cancer genetic testing for breast, ovarian and colorectal cancers
87389|NCT02517528|(HCV) Infection
87390|NCT02517528|Compensated Cirrhosis
87391|NCT02517515|HCV Infection
87392|NCT02517502|DHA
87393|NCT02517502|Omega-3
87394|NCT02517502|neoadjuvant chemotherapy
87395|NCT02517502|chemotherapy
87396|NCT02517502|breast cancer
87397|NCT02517489|Community-Acquired Pneumonia (CAP)
87398|NCT02517489|Hydrocortisone
87399|NCT02517489|Corticosteroids
87400|NCT02517463|Emergency contraception
87401|NCT02517463|ulipristal acetate
87402|NCT02517463|efficacy
87403|NCT02517450|Subjects
87404|NCT02517411|COPD
87405|NCT02517411|physiotherapy
87406|NCT02517411|Stable disease
87407|NCT02517398|Solid tumor
87408|NCT02517398|MSB0011359C (M7824)
87409|NCT02517398|Metastatic or Locally Advanced Solid Tumors
87410|NCT02517346|CPAP compliance
87411|NCT02517346|Telemonitoring
87412|NCT02517346|Standard management
87413|NCT02517346|Cost effectiveness
87414|NCT02517333|Motor skill proficiency
87415|NCT02517333|movement difficulties
87416|NCT02517333|Developmental Coordination Disorder (DCD)
87417|NCT02517333|Low physical fitness
87418|NCT02517320|Diabetic Nephropathy
87419|NCT02517294|Nasotracheal intubation
87420|NCT02517294|adenoid size
87421|NCT02517294|epistaxis
87422|NCT02517294|nasopharyngeal mucosal injury
87423|NCT02517255|ST segment elevation myocardial infarction
87424|NCT02517255|Failed Thrombolysis
87425|NCT02517255|Rescue Percutaneous Coronary Intervention
87426|NCT02517255|Cardiac Magnetic Resonance Imaging
87427|NCT02517229|volunteers
87428|NCT02517216|volunteers
87429|NCT02517190|volunteers
87430|NCT02517177|volunteers
87431|NCT02517151|iron
87432|NCT02517151|fatigue
87433|NCT02517151|crohn's disease
87434|NCT02517151|ulcerative colitis
87435|NCT02517151|IBD
87436|NCT02517138|volunteers
87437|NCT02517112|volunteers
87438|NCT02517099|Preschool
87439|NCT02517099|Wheeze
87440|NCT02517099|Moderate
87441|NCT02517099|Severe
87442|NCT02517086|blood circulation
87443|NCT02517073|mechanical ventilation
87444|NCT02517073|epidemiology
87445|NCT02517073|intensive care unit
87446|NCT02517073|national survey
87447|NCT02517060|Social perceptions
87448|NCT02517008|non-monetary incentive
87449|NCT02517008|institutional delivery
87450|NCT02516982|mHealth
87451|NCT02516982|Telemedicine
87452|NCT02516982|Perinatal depression
87453|NCT02516982|Screening
87454|NCT02516982|Edinburgh Postnatal Depression Scale
87455|NCT02516982|Whooley Questions
87456|NCT02516982|Data collection
87457|NCT02516982|Mood disorders
87458|NCT02516982|Mental health
87459|NCT02516982|Antenatal care
87460|NCT02516982|Prenatal Care
87461|NCT02516956|Breakfast
87462|NCT02516956|Food choices
87463|NCT02516956|Lunch
87464|NCT02516956|Eating habits
87465|NCT02516956|Appetite
87466|NCT02516956|Neural activation
87467|NCT02516956|Attention
87468|NCT02516956|Glucose
87469|NCT02516956|Insulin
87470|NCT02516956|fMRI
87471|NCT02516943|Arterial blood gas analysis
87472|NCT02516930|health promotion
87473|NCT02516930|crowdsourcing
87474|NCT02516904|Subjects
87475|NCT02516891|treatment
87476|NCT02516891|stent
87477|NCT02516891|coronary bifurcations lesions
87478|NCT02516878|acupuncture
87479|NCT02516878|Chinese Medicine
87480|NCT02516878|obesity
87481|NCT02516865|postpartum
87482|NCT02516865|physical activity
87483|NCT02516852|community development; poultry; animal-source food; stunting
87484|NCT02516839|Overweight
87485|NCT02516839|Obesity
87486|NCT02516839|Overeating
87487|NCT02516839|Body Mass Index
87488|NCT02516839|Weight
87489|NCT02516839|Treatment
87490|NCT02516839|Cravings
87491|NCT02516839|Intervention
87492|NCT02516839|Behavioral Treatment
87493|NCT02516813|M3814
87494|NCT02516813|Advanced solid tumors
87495|NCT02516813|DNA-PK Inhibitor
87496|NCT02516813|Radiotherapy
87497|NCT02516787|volunteers
87498|NCT02516761|Fibromyalgia
87499|NCT02516644|Parkinson Disease
87500|NCT02516644|Mobility
87501|NCT02516644|Balance
87502|NCT02516644|Virtual Reality
87503|NCT02516644|treadmill training
87504|NCT02516631|Labour, induced
87505|NCT02516631|Misoprostol
87506|NCT02516631|Pharmacokinetics
87507|NCT02516631|Cardiotocography
87508|NCT02516631|Safety
87509|NCT02516605|Primary Biliary Cirrhosis, PBC
87510|NCT02516566|Positive end-expiratory pressure ventilation
87511|NCT02516566|Optic nerve sheath diameter
87512|NCT02516540|hereditary breast and ovarian cancer (HBOC)
87513|NCT02516540|BRCA1/2 mutation carriers
87514|NCT02516540|Mediterranean diet
87515|NCT02516540|Structured exercise training
87516|NCT02516540|prevention
87517|NCT02516514|Blood culture
87518|NCT02516514|Bacteremia
87519|NCT02516514|Single sampling
87520|NCT02516501|Ketogenic Diet
87521|NCT02516501|Body composition
87522|NCT02516501|Radiation therapy
87523|NCT02516436|Bunavail
87524|NCT02516436|Suboxone
87525|NCT02516436|Heroin
87526|NCT02516436|Zubsolv
87527|NCT02516436|Buprenorphine
87528|NCT02516436|Naloxone
87529|NCT02516436|Opioids
87530|NCT02516436|Addiction
87531|NCT02516436|Induction
87532|NCT02516397|body fat mass reduction
87533|NCT02516384|Fecal Microbiota Transplantation
87534|NCT02516384|Ulcerative Colitis
87535|NCT02516345|Physical activity
87536|NCT02516345|Financial incentives
87537|NCT02516345|Children
87538|NCT02516345|Parents
87539|NCT02516345|RCT
87540|NCT02516345|Wireless pedometer
87541|NCT02516306|Presbyopia, Vision
87542|NCT02516280|Total knee replacement
87543|NCT02516280|Cold
87544|NCT02516280|Neurocryostimulation
87545|NCT02516280|CO2 cryotherapy
87546|NCT02516280|mobility
87547|NCT02516267|platelet aggregability
87548|NCT02516267|acute coronary syndrome
87549|NCT02516267|coronary artery bypass graft
87550|NCT02516254|vitamin D
87551|NCT02516254|fortified bread
87552|NCT02516254|efficacy
87553|NCT02516254|Vitamin D Deficiency
87554|NCT02516241|Urothelial Cancer
87555|NCT02516241|Phase III
87556|NCT02516189|Microcirculation
87557|NCT02516189|Electromyography
87558|NCT02516189|Motor Activity
87559|NCT02516176|stroke
87560|NCT02516176|cerebral vascular accident
87561|NCT02516176|balance
87562|NCT02516176|treadmill
87563|NCT02516176|falls
87564|NCT02516176|hemiparesis
87565|NCT02516150|Type 1 Diabetes
87566|NCT02516150|Bionic Pancreas
87567|NCT02516150|Artificial Pancreas
87568|NCT02516150|Insulin
87569|NCT02516150|Glucagon
87570|NCT02516150|Alcohol
87571|NCT02516150|Alcohol Clamp
87572|NCT02516137|Dry needling
87573|NCT02516124|Autoimmune diseases
87574|NCT02516124|Systemic sclerosis
87575|NCT02516124|Autologous Hematopoietic stem cell transplant
87576|NCT02516072|remote ischemic preconditioning
87577|NCT02516059|thoracic epidural analgesia
87578|NCT02516059|oxycodone
87579|NCT02516059|oral naloxone
87580|NCT02516059|radical cystectomy
87581|NCT02516059|bowel function
87582|NCT02516059|pain
87583|NCT02516033|Atrial Fibrillation
87584|NCT02516033|Hybrid Ablation
87585|NCT02516033|Efficacy
87586|NCT02516033|Risk Profile
87587|NCT02516033|Biomarkers
87588|NCT02516020|IVF
87589|NCT02516020|ICSI
87590|NCT02516020|culture media
87591|NCT02516020|sequential
87592|NCT02515981|tobacco dependence
87593|NCT02515981|smoking cessation
87594|NCT02515981|mental health
87595|NCT02515981|cardiovascular disease
87596|NCT02515981|obesity
87597|NCT02515955|Healthy
87598|NCT02515955|JNJ-54175446
87599|NCT02515929|Oligomeric Proanthocyanidins
87600|NCT02515929|Periodontal Disease
87601|NCT02515903|Endoscopy
87602|NCT02515903|Intracerebral hemorrhage
87603|NCT02515903|surgery
87604|NCT02515903|stereotactic aspiration
87605|NCT02515903|Key-hole approach
87606|NCT02515903|Intracerebral hemorrhage surgical treatment
87607|NCT02515903|Transparent endoscopic sheath
87608|NCT02515903|Agitation-aspiration device
87609|NCT02515890|midazolam
87610|NCT02515890|dexmedetomidine
87611|NCT02515890|memory
87612|NCT02515864|Male and Female Volunteers
87613|NCT02515786|Chronic respiratory failure
87614|NCT02515786|Oxygen therapy
87615|NCT02515786|Nasal catheter
87616|NCT02515786|Mucociliary clearance
87617|NCT02515747|Lipoprotein(a)
87618|NCT02515747|coronary artery bypass grafting (CABG)
87619|NCT02515747|apo(a)
87620|NCT02515747|prognosis
87621|NCT02515747|myocardial infarction
87622|NCT02515747|cardiovascular death
87623|NCT02515747|percutaneous coronary intervention (PCI)
87624|NCT02515734|FOLFOXIRI
87625|NCT02515734|Bmab
87626|NCT02515734|Cmab
87627|NCT02515617|Ventilator-associated pneumonia
87628|NCT02515617|Subglottic-secretions drainage
87629|NCT02515617|Critically ill patients
87630|NCT02515617|Cost-utility analysis
87631|NCT02515617|Prevention
87632|NCT02515591|Healthy volunteer
87633|NCT02515591|Respiratory
87634|NCT02515591|Bronchoalveolar lavage
87635|NCT02515578|Primary Health Care
87636|NCT02515578|Cardiovascular Diseases
87637|NCT02515578|Quality Improvement
87638|NCT02515565|pneumonia
87639|NCT02515565|Exacerbation
87640|NCT02515565|physiotherapy
87641|NCT02515565|hospitalization
87642|NCT02515539|Transcatheter Mitral Valve Replacement
87643|NCT02515539|Mitral Regurgitation
87644|NCT02515539|Mitral Insufficiency
87645|NCT02515539|Transapical
87646|NCT02515539|Transfemoral
87647|NCT02515513|Pancreas
87648|NCT02515513|Pancreas Cancer
87649|NCT02515513|Muscle Biopsy
87650|NCT02515513|Cachexia
87651|NCT02515513|Muscle Cachexia
87652|NCT02515500|cigarette reduction
87653|NCT02515500|digital health
87654|NCT02515500|mobile health
87655|NCT02515500|technology
87656|NCT02515500|Quitbit
87657|NCT02515500|mHealth
87658|NCT02515500|smoking cessation
87659|NCT02515500|quit smoking
87660|NCT02515500|self-regulation
87661|NCT02515487|Post-chemotherapy
87662|NCT02515487|cognitive impairment
87663|NCT02515474|Cholangiopancreatography
87664|NCT02515474|Endoscopic
87665|NCT02515474|Common bile duct
87666|NCT02515474|Complication
87667|NCT02515474|Recurrence
87668|NCT02515474|Laparoscopic
87669|NCT02515461|Diabetes mellitus
87670|NCT02515461|Low energy shockwave therapy
87671|NCT02515461|Chronic Renal Insufficiency
87672|NCT02515448|VAP
87673|NCT02515448|Critical care
87674|NCT02515448|Pharmacokinetics
87675|NCT02515448|Gentamicin
87676|NCT02515435|apatinib
87677|NCT02515435|NSCLC
87678|NCT02515435|safety
87679|NCT02515435|efficacy
87680|NCT02515422|Caesarean Section
87681|NCT02515409|Obstructive Sleep Apnea Syndrome (OSAS)
87682|NCT02515409|Heated Humidified High Flow Nasal Cannula (HHHNC)
87683|NCT02515409|Continues positive airway pressure (CPAP)
87684|NCT02515409|Children
87685|NCT02515409|Non invasive ventilation
87686|NCT02515409|Treatment
87687|NCT02515383|Adolescent Cancer
87688|NCT02515383|MD Anderson Symptom Inventory (modified for adolescent use)
87689|NCT02515383|MDASI
87690|NCT02515383|Surveys
87691|NCT02515383|Questionnaires
87692|NCT02515383|Interviews
87693|NCT02515383|Symptoms
87694|NCT02515370|Option B plus
87695|NCT02515370|HIV infected women
87696|NCT02515357|Sleep Disorders
87697|NCT02515357|Metabolic Syndrome
87698|NCT02515357|Mediterranean Diet
87699|NCT02515357|Mediterranean Lifestyle
87700|NCT02515344|Patients
87701|NCT02515344|early detection of cancer
87702|NCT02515344|patient compliance
87703|NCT02515331|resistant hypertension
87704|NCT02515318|COPD
87705|NCT02515318|Exacerbation
87706|NCT02515318|Hospitalisation
87707|NCT02515318|Physiotherapy
87708|NCT02515292|IUGR (intrauterine growth restriction)
87709|NCT02515292|IGF2 (insulin-like growth factor 2)
87710|NCT02515292|morbidity
87711|NCT02515266|protein
87712|NCT02515266|growth
87713|NCT02515266|head circumference
87714|NCT02515253|Breast Pain
87715|NCT02515253|Mastalgia
87716|NCT02515253|Bras
87717|NCT02515253|Breast Support
87718|NCT02515227|peptide
87719|NCT02515227|vaccine
87720|NCT02515227|Montanide ISA-51
87721|NCT02515227|pembrolizumab
87722|NCT02515227|PD-1
87723|NCT02515227|KEYTRUDA
87724|NCT02515214|bariatric surgery
87725|NCT02515214|reproduction
87726|NCT02515175|HSV
87727|NCT02515175|Herpes
87728|NCT02515175|Genital Herpes
87729|NCT02515175|Vaccine
87730|NCT02515162|conization
87731|NCT02515162|LLETZ
87732|NCT02515162|cervical dysplasia
87733|NCT02515162|cervical intraepithelial neoplasia
87734|NCT02515162|Fischer cone biopsy excisor
87735|NCT02515162|loop electrosurgical excision procedure
87736|NCT02515149|linkage to care
87737|NCT02515149|point of care diagnostics
87738|NCT02515149|point of care CD4
87739|NCT02515149|HIV care cascade
87740|NCT02515149|Kenya
87741|NCT02515123|intensive care unit
87742|NCT02515123|malnutrition
87743|NCT02515123|GI motility
87744|NCT02515123|nutritional intake
87745|NCT02515110|lumpectomy
87746|NCT02515110|mastectomy without reconstruction
87747|NCT02515110|mastectomy with reconstruction
87748|NCT02515110|Estrogen Receptor Negative
87749|NCT02515110|Estrogen Receptor Positive
87750|NCT02515110|HER2/Neu Negative
87751|NCT02515110|HER2/Neu Positive
87752|NCT02515110|Progesterone Receptor Negative
87753|NCT02515110|Progesterone Receptor Positive
87754|NCT02515110|Stage IA Breast Cancer
87755|NCT02515110|Stage IB Breast Cancer
87756|NCT02515110|Stage IIA Breast Cancer
87757|NCT02515110|Stage IIB Breast Cancer
87758|NCT02515110|Stage IIIA Breast Cancer
87759|NCT02515084|recurrence Thyroid cancer
87760|NCT02515084|18F-FDG PET-CT
87761|NCT02515084|diffusion-weighted Magnetic Resonance Imaging
87762|NCT02515045|Cataract
87763|NCT02515045|Surgery
87764|NCT02515045|Prophylaxis
87765|NCT02515019|Anaesthetics inhalation
87766|NCT02515019|Bispectral index
87767|NCT02515019|Cardiopulmonary bypass
87768|NCT02514993|Sternal fracture
87769|NCT02514993|Thoracic spine fracture
87770|NCT02514993|Thoracic cage injury
87771|NCT02514967|SLE
87772|NCT02514967|Lupus
87773|NCT02514967|Lupus Erythematosus, Systemic
87774|NCT02514967|Autoimmune Diseases
87775|NCT02514967|A-623
87776|NCT02514967|Blisibimod
87777|NCT02514967|Nephritis
87778|NCT02514902|Lateral Flow Device (LFD)
87779|NCT02514902|Acute Stroke
87780|NCT02514902|Traumatic Brain Injury (TBI)
87781|NCT02514902|Point of Care (POC)
87782|NCT02514902|Biomarker
87783|NCT02514824|recurrent merkel cell carcinoma
87784|NCT02514824|metastatic merkel cell carcinoma
87785|NCT02514798|COPD
87786|NCT02514798|HFNC
87787|NCT02514798|work of breathing
87788|NCT02514746|Japanese Encephalitis Vaccines
87789|NCT02514746|Flavivirus Infections
87790|NCT02514733|kidney
87791|NCT02514733|transplant
87792|NCT02514655|Tracheal intubation
87793|NCT02514655|Cuff pressure
87794|NCT02514655|Ventilator-acquired pneumonia
87795|NCT02514655|Intensive care unit
87796|NCT02514655|Tracheal injuries
87797|NCT02514629|Hypogonadism
87798|NCT02514629|Obesity
87799|NCT02514629|Erectile Dysfunction
87800|NCT02514629|Testosterone
87801|NCT02514629|Metformin
87802|NCT02514629|Weight Loss
87803|NCT02514629|Insulin Resistance
87804|NCT02514616|Reflux
87805|NCT02514616|Reflux disease
87806|NCT02514616|Gastroesophageal reflux disease
87807|NCT02514616|Lower esophageal sphincter stimulation
87808|NCT02514603|Neoplasm metastasis
87809|NCT02514603|Checkpoint Kinase 1
87810|NCT02514603|CHK1
87811|NCT02514603|CHK1 inhibitor
87812|NCT02514551|stomach cancer
87813|NCT02514512|Lung Cancer
87814|NCT02514512|Stereotactic Ablative Radiotherapy (SABR)
87815|NCT02514512|MLC Tracking
87816|NCT02514512|Radiotherapy
87817|NCT02513784|Microbiome
87818|NCT02513784|Esophagus
87819|NCT02513784|Endoscopy
87820|NCT02513784|Mouthwash
87821|NCT02513758|HIV patients
87822|NCT02513758|Genital HIV penetration
87823|NCT02513745|cataract
87824|NCT02513745|toric
87825|NCT02513745|phacoemulsification
87826|NCT02513732|Drug Eluting Stent
87827|NCT02513732|Coronary Stent
87828|NCT02513732|Everolimus
87829|NCT02513732|Stent Thrombosis
87830|NCT02513719|drug eluting stent
87831|NCT02513719|stent
87832|NCT02513719|real world
87833|NCT02513693|Anesthesia
87834|NCT02513693|Rocuronium
87835|NCT02513693|Sugammadex
87836|NCT02513693|Neostigmine
87837|NCT02513693|TOF
87838|NCT02513693|Radical Prostatectomy
87839|NCT02513693|Robotic Surgery
87840|NCT02513693|Accelerometry
87841|NCT02513680|Skin Aging
87842|NCT02513680|laser phototherapy
87843|NCT02513680|Rejuvenation
87844|NCT02513680|Infrared Rays/therapeutic use
87845|NCT02513680|Female
87846|NCT02513680|Humans
87847|NCT02513680|Esthetics
87848|NCT02513680|Phototherapy
87849|NCT02513680|facial rejuvenation
87850|NCT02513654|tolerability
87851|NCT02513654|repeat dosing
87852|NCT02513654|safety
87853|NCT02513654|healthy Chinese subjects
87854|NCT02513654|Pharmacokinetics
87855|NCT02513654|lamotrigine
87856|NCT02514499|patients
87857|NCT02514460|stents
87858|NCT02514460|atherectomy
87859|NCT02514460|femoral artery
87860|NCT02514460|popliteal artery
87861|NCT02514447|SCLC
87862|NCT02514421|pancreatic adenocarcinoma
87863|NCT02514421|electrochemotherapy
87864|NCT02514421|electroporation
87865|NCT02514421|radiogenomics
87866|NCT02514421|imaging
87867|NCT02514421|magnetic resonance spectroscopy
87868|NCT02514395|linguistic validation
87869|NCT02514395|KOOS
87870|NCT02514395|Marathi translation
87871|NCT02514356|behavioral economics
87872|NCT02514356|antiretroviral adherence
87873|NCT02514356|SMS
87874|NCT02514356|mobile health (mHealth)
87875|NCT02514356|Adolescents
87876|NCT02514356|Uganda
87877|NCT02514356|HIV
87878|NCT02514343|radius fracture
87879|NCT02514343|magnesium sulfate
87880|NCT02514343|rehabilitation
87881|NCT02514343|bupivacaine
87882|NCT02514330|Drop Jump
87883|NCT02514330|High Intensity Interval Training
87884|NCT02514330|Muscle Fatigue
87885|NCT02514330|Aerobic Performance
87886|NCT02514278|Organ preservation
87887|NCT02514278|Local excision
87888|NCT02514278|Radiochemotherapy
87889|NCT02514278|Neoadjuvant chemotherapy
87890|NCT02514278|Folfirinox
87891|NCT02514278|Tumour response
87892|NCT02514265|pelvic pain, bladder pain
87893|NCT02514252|Advanced Cancers
87894|NCT02514252|Metastatic
87895|NCT02514252|Recurrent cancer
87896|NCT02514252|Incurable cancer
87897|NCT02514252|Fentanyl sublingual spray
87898|NCT02514252|FSS
87899|NCT02514252|Questionnaires
87900|NCT02514252|Surveys
87901|NCT02514252|Mental ability tests
87902|NCT02514252|Phone calls
87903|NCT02514252|Study diary
87904|NCT02514252|Pain control
87905|NCT02514226|microbiology
87906|NCT02514226|citokynes
87907|NCT02514226|halitosis
87908|NCT02514213|PSA
87909|NCT02514187|Osteogenesis
87910|NCT02514161|Smokers
87911|NCT02514161|Maximum Inspiratory Pressure
87912|NCT02514148|patient education
87913|NCT02514148|therapeutic exercise
87914|NCT02514148|manual therapy
87915|NCT02514109|neuronopathy
87916|NCT02514109|antibodies
87917|NCT02514109|Clinical and biological diagnostic criteria
87918|NCT02514083|Ibrutinib
87919|NCT02514083|Fludarabine
87920|NCT02514083|BTK Inhibitor
87921|NCT02514083|T-Cell Modulation
87922|NCT02514070|LDL-C
87923|NCT02514070|Omega-3 Fatty Acid
87924|NCT02514070|PCSK9
87925|NCT02514070|HDL-C
87926|NCT02514018|Varicella-Zoster Virus
87927|NCT02514018|Immune Activation
87928|NCT02514018|HIV Vaccine
87929|NCT02514018|Mucosal Immunity
87930|NCT02514005|Trigger points
87931|NCT02514005|Manual therapy
87932|NCT02514005|Patellofemoral syndrome
87933|NCT02514005|Dry needling
87934|NCT02513992|ictal SPECT
87935|NCT02513979|Angiotensin type II receptor (AT2R) antagonists
87936|NCT02513979|Acute postoperative pain
87937|NCT02513979|Chronic postoperative pain
87938|NCT02513979|Abdominal surgery
87939|NCT02513953|Endometriosis
87940|NCT02513953|Mesosalpinx
87941|NCT02513953|Broad Ligament
87942|NCT02513953|Laparoscopy
87943|NCT02513940|Torsades de pointes
87944|NCT02513940|Testosterone
87945|NCT02513940|Progesterone
87946|NCT02513940|Clinical trial
87947|NCT02513940|Risk reduction
87948|NCT02513940|Electrocardiography
87949|NCT02513927|Blood pressure variability
87950|NCT02513927|CCB
87951|NCT02513927|beta-receptor blockers
87952|NCT02513927|heart rate
87953|NCT02513914|endovascular neurosurgery
87954|NCT02513901|Chidamide
87955|NCT02513901|Histone Deacetylase Inhibitor
87956|NCT02513901|HIV-1 Reservoir
87957|NCT02513901|Chronic HIV infections
87958|NCT02513901|Antiretroviral Therapy
87959|NCT02513901|HIV Eradication
87960|NCT02513862|autologous platelet rich plasma
87961|NCT02513862|deep hypothermic circulatory arrest
87962|NCT02513862|transfusion
87963|NCT02513849|esophagus
87964|NCT02513849|gastroscopy
87965|NCT02513849|tamoxifen
87966|NCT02513823|blood pressure
87967|NCT02513823|vitamin D
87968|NCT02513628|Cardiac arrest
87969|NCT02513628|neuroprognostication
87970|NCT02513628|optic nerve sheath diameter
87971|NCT02513628|outcome
87972|NCT02513628|ultrasonography
87973|NCT02513615|Fibrosis
87974|NCT02513615|Peritoneal Dialysis
87975|NCT02513615|Epigenetics
87976|NCT02513615|Peritoneal membrane injury
87977|NCT02513615|Glucose exposure
87978|NCT02513602|implantology
87979|NCT02513602|kidney
87980|NCT02513602|renal disease
87981|NCT02513602|edentulism
87982|NCT02513602|tooth loss
87983|NCT02513589|Positron emission tomography
87984|NCT02513589|Carotid plaque
87985|NCT02513589|Inflammation
87986|NCT02513589|Stroke
87987|NCT02513576|Sternal instability
87988|NCT02513576|physical therapy
87989|NCT02513576|Respiratory muscle strength
87990|NCT02513563|Squamous cell lung cancer
87991|NCT02513524|hypertension
87992|NCT02513524|adherence
87993|NCT02513524|resistant hypertension
87994|NCT02513524|blood pressure
87995|NCT02513524|non-adherence
87996|NCT02513511|difficult airway
87997|NCT02513511|awake intubation
87998|NCT02513485|Inflammation
87999|NCT02513485|Anhedonia
88000|NCT02513485|Psychomotor retardation
88001|NCT02513472|Eribulin Mesylate
88002|NCT02513472|Pembrolizumab
88003|NCT02513472|Metastatic Triple-Negative Breast Cancer
88004|NCT02513472|mTNBC
88005|NCT02513459|ABBV-066
88006|NCT02513459|BI 655066
88007|NCT02513459|risankizumab
88008|NCT02513433|Lumbar epidural anaesthesia
88009|NCT02513420|levator ani avulsion
88010|NCT02513420|perineal muscle training
88011|NCT02513420|pelvic floor ultrasound
88012|NCT02513394|HR+/HER2- breast cancer
88013|NCT02513394|Palbociclib
88014|NCT02513368|aesthetic
88015|NCT02513368|connective tissue graft
88016|NCT02513368|mucosa thickness
88017|NCT02513355|Non-small cell lung cancer,Endostar
88018|NCT02513342|Endostar,Advanced lung squamous carcinoma
88019|NCT02513329|Breast Cancer
88020|NCT02513329|Anti-estrogens
88021|NCT02513329|Hot Flushes
88022|NCT02513329|Tamoxifen
88023|NCT02513329|Aromatase inhibitors
88024|NCT02513329|Hot Flashes
88025|NCT02513316|Microbleeds
88026|NCT02513303|Dialysis
88027|NCT02513303|End Stage Renal Disease
88028|NCT02513303|End Stage Kidney Disease
88029|NCT02513303|ESRD
88030|NCT02513303|Chronic Kidney Failure
88031|NCT02513303|Chronic Renal Failure
88032|NCT02513303|Chronic Kidney Disease
88033|NCT02513303|Hemodialysis
88034|NCT02513303|Vascular Access
88035|NCT02513303|Arteriovenous Fistula
88036|NCT02513303|AV Fistula
88037|NCT02513303|AVF
88038|NCT02513303|Nephrology
88039|NCT02513303|Vascular Surgery
88040|NCT02513303|Dialysis Access
88041|NCT02513290|quality of life
88042|NCT02513290|allergic rhinitis
88043|NCT02513290|bilastine
88044|NCT02513290|loratadine
88045|NCT02513290|clinical trial
88046|NCT02513277|type 2 diabetes
88047|NCT02513277|impaired glucose regulation
88048|NCT02513277|intellectual disability
88049|NCT02513277|learning disability
88050|NCT02513277|screening
88051|NCT02513277|prevention
88052|NCT02513277|lifestyle education
88053|NCT02513264|Registry
88054|NCT02513264|Asthma
88055|NCT02513212|Sensitivity
88056|NCT02513199|Hepatocellular Carcinoma
88057|NCT02513199|Trans-Arterial Chemoembolization
88058|NCT02513199|Stereotactic Body Radiation Therapy
88059|NCT02513199|HCC
88060|NCT02513199|TACE
88061|NCT02513199|SBRT
88062|NCT02513173|low back pain
88063|NCT02513173|verbal instruction
88064|NCT02513173|lumbar multifidus
88065|NCT02513173|ultrasound imaging
88066|NCT02513173|Muscle thickness
88067|NCT02513134|IOL power calculations
88068|NCT02513134|Intraoperative
88069|NCT02513134|OCT
88070|NCT02513134|Refractive outcome
88071|NCT02513134|Biometry
88072|NCT02513121|NAFLD
88073|NCT02513121|Steatohepatitis
88074|NCT02513121|NASH
88075|NCT02513121|Liver
88076|NCT02513121|Diet
88077|NCT02513121|Pediatric
88078|NCT02513121|Adolescent
88079|NCT02513056|non-conditional pacemakers
88080|NCT02513056|implantable cardioverter defibrillator
88081|NCT02513017|partially randomized clinical trial
88082|NCT02513017|cardiovascular disease
88083|NCT02513017|insomnia
88084|NCT02513017|preference
88085|NCT02513017|acceptability
88086|NCT02512978|myocardial infarction
88087|NCT02512978|hypothyroidism
88088|NCT02512978|levothyroxine
88089|NCT02512978|cardiac magnetic resonance imaging
88090|NCT02512978|myocardial perfusion/metabolism radionuclide imaging
88091|NCT02512978|myocardial fibrosis
88092|NCT02512978|myocardial perfusion/metabolism
88093|NCT02512978|cardiac function
88094|NCT02512952|Periodontal regeneration
88095|NCT02512952|Growth factors
88096|NCT02512939|tuberculosis
88097|NCT02512939|diagnostic test
88098|NCT02512926|Solid Tumors
88099|NCT02512926|Leukemia
88100|NCT02512926|Relapsed
88101|NCT02512926|Refractory
88102|NCT02512913|Smoking Cessation
88103|NCT02512913|Intervention
88104|NCT02512913|Pregnancy
88105|NCT02512913|Postnatal
88106|NCT02512900|Asthma
88107|NCT02512887|Hypospadias
88108|NCT02512887|Caudal Block
88109|NCT02512887|Dorsal Penile Block
88110|NCT02512887|Anesthesia
88111|NCT02512887|Complications
88112|NCT02512887|Post-operative
88113|NCT02512887|Urethrocutaneous Fistula
88114|NCT02512887|Glans dehiscence
88115|NCT02512861|Bupivacaine
88116|NCT02512861|Cardiac Surgery
88117|NCT02512861|Pediatrics
88118|NCT02512861|Nerve Block
88119|NCT02512848|postmenopause
88120|NCT02512848|endometrial sampling
88121|NCT02512848|vaginal bleeding
88122|NCT02512835|Primary health care
88123|NCT02512835|Public health
88124|NCT02512835|Medical Informatics
88125|NCT02512835|Social Determinants of Health
88126|NCT02512822|radiofrequency
88127|NCT02512822|submental fat
88128|NCT02512822|fat reduction
88129|NCT02512822|body contouring
88130|NCT02512796|Liver transplantation
88131|NCT02512796|Renal transplantation
88132|NCT02512796|Pancreas transplantation
88133|NCT02512783|Propofol
88134|NCT02512783|Lidocaine
88135|NCT02512783|Intravenous propofol
88136|NCT02512757|Neoplasms, Lung
88137|NCT02512757|Pulmonary Neoplasms
88138|NCT02512757|Pulmonary Cancer
88139|NCT02512744|Tracheostomy
88140|NCT02512744|Decannulation
88141|NCT02512744|Adult airway management
88142|NCT02512718|intravenous fat emulsions
88143|NCT02512718|fish oil lipid emulsion
88144|NCT02512692|intrahepatic cholangiocarcinoma
88145|NCT02512692|cholangiocarcinoma
88146|NCT02512692|90Y TARE
88147|NCT02512692|radioembolization
88148|NCT02512692|gemcitabine and cisplatin
88149|NCT02512679|Hematopoietic Stem Cell Transplantation Pediatrics,
88150|NCT02512679|stem cell transplantation
88151|NCT02512679|bone marrow transplantation
88152|NCT02512679|Peripheral Blood Stem Cell Transplantation
88153|NCT02512679|Allogeneic Transplantation
88154|NCT02512679|pediatrics
88155|NCT02512679|Combined Immune Deficiency
88156|NCT02512679|Chronic Granulomatous disease
88157|NCT02512666|Hematologic malignancy
88158|NCT02512653|Allergy to Cupressus pollen
88159|NCT02512640|Pressure-controlled ventilation
88160|NCT02512640|Volume-controlled ventilation
88161|NCT02512640|Laparoscopy
88162|NCT02512640|Oxidative stress
88163|NCT02512627|mild cognitive impairment
88164|NCT02512627|exercise
88165|NCT02512627|cognitive training
88166|NCT02512575|AZD9567
88167|NCT02512575|Healthy subjects
88168|NCT02512575|Phase 1
88169|NCT02512575|placebo controlled
88170|NCT02512575|single ascending dose
88171|NCT02512575|Pharmacokinetics
88172|NCT02512575|Pharmacodynamics
88173|NCT02512575|Rheumatoid Arthritis
88174|NCT02512549|Chronic Obstructive Pulmonary Disease
88175|NCT02512549|rehabiltation
88176|NCT02512523|Type 2 diabetes mellitus
88177|NCT02512523|CGMS
88178|NCT02512523|Teneligliptin
88179|NCT02512523|Sitagliptin
88180|NCT02512510|Chronic Obstructive Pulmonary Disease, COPD
88181|NCT02512497|Cutaneous T-cell Lymphoma
88182|NCT02512497|CTCL
88183|NCT02512497|T-Prolymphocytic Leukemia
88184|NCT02512497|T-PLL
88185|NCT02512497|T-Large Granulocytic Leukemia
88186|NCT02512497|T-LGL
88187|NCT02512497|T-Lymphoblastic Leukemia/Lymphoma
88188|NCT02512497|T-ALL
88189|NCT02512497|Peripheral T-Cell Lymphoma
88190|NCT02512497|PTCL
88191|NCT02512497|Allogeneic stem cell transplantation
88192|NCT02512497|Romidepsin
88193|NCT02512497|Istodax
88194|NCT02512497|Depsipeptide
88195|NCT02512497|FK228
88196|NCT02512497|Busulfan
88197|NCT02512497|Busulfex
88198|NCT02512497|Myleran
88199|NCT02512497|Fludarabine
88200|NCT02512497|Fludarabine phosphate
88201|NCT02512497|Fludara
88202|NCT02512484|tuberculosis
88203|NCT02512484|accident and emergency
88204|NCT02512471|minimum effective volume
88205|NCT02512471|ropivacaine
88206|NCT02512471|ultrasound-guided supraclavicular block
88207|NCT02512419|Physical Activity
88208|NCT02512419|Latinos
88209|NCT02512419|Mexican American Men
88210|NCT02512419|Spanish-Language
88211|NCT02512419|Text-Message
88212|NCT02512406|Tourette Syndrome
88213|NCT02512406|Tics
88214|NCT02512341|Computer Aided Auscultation (CAA)
88215|NCT02512341|Electronic Stethoscope
88216|NCT02512341|Phonocardiography
88217|NCT02512341|Heart Auscultation
88218|NCT02512328|Colonoscopy
88219|NCT02512328|new media
88220|NCT02512328|APP
88221|NCT02512328|colonoscopy preparation
88222|NCT02512328|SPA
88223|NCT02512328|smartphone application
88224|NCT02512315|Nasopharyngeal carcinoma
88225|NCT02512315|Neoadjuvant chemotherapy
88226|NCT02512315|Concurrent chemoradiation
88227|NCT02512315|Distant metastasis
88228|NCT02512315|Survival
88229|NCT02512302|COPD
88230|NCT02512276|Medication Non-adherence
88231|NCT02512276|Hyperlipidemia
88232|NCT02512276|Diabetes
88233|NCT02512276|Hypertension
88234|NCT02512237|HER2
88235|NCT02512237|breast cancer
88236|NCT02512237|ADC
88237|NCT02512237|antibody drug conjugate
88238|NCT02512237|elevated HER2 expression
88239|NCT02512224|parenteral nutrition
88240|NCT02512224|enteral nutrition
88241|NCT02512211|Hemophilia
88242|NCT02512211|Validation
88243|NCT02512211|Questionnaires
88244|NCT02512211|Activities
88245|NCT02512211|Sport
88246|NCT02512211|Patients
88247|NCT02512198|Professional Practice
88248|NCT02512198|General Practitioners
88249|NCT02512198|Inappropriate Prescribing
88250|NCT02512198|Persuasive Communication
88251|NCT02512198|Information Theory
88252|NCT02512198|Feedback
88253|NCT02512185|Prostate cancer
88254|NCT02512185|Chemotherapy
88255|NCT02512185|mCRPC
88256|NCT02512159|Diabetic foot ulcer
88257|NCT02512159|Foot care
88258|NCT02512159|Wound management
88259|NCT02512146|IBS
88260|NCT02512146|Ionotropic glutamate receptors
88261|NCT02512133|MIGS
88262|NCT02512133|SLT
88263|NCT02512094|Barthel index
88264|NCT02512094|Hip fracture
88265|NCT02512094|Validity
88266|NCT02512094|Reliability
88267|NCT02512081|Sciatica
88268|NCT02512081|Patient Experience
88269|NCT02512081|Investigations
88270|NCT02512081|Qualitative Research
88271|NCT02512016|Pelvic floor
88272|NCT02511990|HIV
88273|NCT02511990|10-1074
88274|NCT02511990|Monoclonal Antibody
88275|NCT02511977|Dental Prosthesis
88276|NCT02511977|Implant-Supported
88277|NCT02511964|Aerobic Exercise
88278|NCT02511964|HIT,
88279|NCT02511964|VO2Max
88280|NCT02511964|Performance
88281|NCT02511951|postoperative pancreatic fistula
88282|NCT02511951|postoperative hospital stay time
88283|NCT02511951|anastomosis time
88284|NCT02511951|reoperation rate
88285|NCT02511951|morbidity
88286|NCT02511951|pancreaticojejunostomy
88287|NCT02511951|pancreaticoduodenectomy
88288|NCT02511938|childhood obesity
88289|NCT02511938|restaurant
88290|NCT02511938|away from home foods
88291|NCT02511925|Critical care
88292|NCT02511925|Feedback
88293|NCT02511899|Microcirculation
88294|NCT02511899|Endothelial function
88295|NCT02511899|Metabolism
88296|NCT02511899|Cardiovascular Disease
88297|NCT02511899|human study
88298|NCT02511899|healthy subjects
88299|NCT02511899|Mangifera indica
88300|NCT02511899|Careless
88301|NCT02511886|Alcoholism
88302|NCT02511886|Alcohol Abuse
88303|NCT02511886|Alcohol Addiction
88304|NCT02511886|Alcohol Dependence
88305|NCT02511886|Alcohol Induced Disorders
88306|NCT02511886|Alcoholic Intoxication
88307|NCT02511873|Fycompa
88308|NCT02511873|Small Fiber Neuropathy
88309|NCT02511873|SFN
88310|NCT02511873|Neuropathy
88311|NCT02511873|Pain
88312|NCT02511847|Breast Cancer
88313|NCT02511847|EGFR
88314|NCT02511847|Afatinib
88315|NCT02511847|Paclitaxel
88316|NCT02511847|Pathologic complete remission
88317|NCT02511808|Drinking
88318|NCT02511808|Alcohol Problems
88319|NCT02511808|Alcoholism
88320|NCT02511808|Reduced Drinking
88321|NCT02511808|Problematic Drinking
88322|NCT02511808|Non-Abstinence-based Drinking
88323|NCT02511808|Controlled Drinking
88324|NCT02511808|Heavy Drinking
88325|NCT02511795|AZD1775
88326|NCT02511795|Olaparib
88327|NCT02511795|AZD1775 plus Olaparib
88328|NCT02511795|Refractory solid tumours
88329|NCT02511782|children
88330|NCT02511782|bone marrow transplant
88331|NCT02511782|GVHD
88332|NCT02511756|Perfusion-computed tomography
88333|NCT02511730|Mammography
88334|NCT02511704|Nicotine
88335|NCT02511704|Electronic cigarette
88336|NCT02511704|Cigarette
88337|NCT02511639|Hormone receptor positive
88338|NCT02511639|HER2 negative
88339|NCT02511626|endometriosis
88340|NCT02511626|quality of life
88341|NCT02511626|professional activity
88342|NCT02511626|pain
88343|NCT02511626|infertility
88344|NCT02511626|sexuality
88345|NCT02511626|partnership
88346|NCT02511626|anxiety
88347|NCT02511626|depression
88348|NCT02511626|stress
88349|NCT02511626|childhood trauma
88350|NCT02511626|medical support
88351|NCT02511626|dyspareunia
88352|NCT02511600|Lung Diseases
88353|NCT02511600|Mesothelioma
88354|NCT02511600|Pleurectomy decortication
88355|NCT02511600|Progel
88356|NCT02511600|Talcum powder
88357|NCT02511600|Pain questionnaires
88358|NCT02511600|Surveys
88359|NCT02511600|Intraoperative air leaks
88360|NCT02511600|IAL
88361|NCT02511574|progesterone
88362|NCT02511574|uterine cervix
88363|NCT02511574|cervical pessary
88364|NCT02511561|Otitis externa
88365|NCT02511561|Swimmer's ear
88366|NCT02511561|Ear infection
88367|NCT02511509|Schizophrenia
88368|NCT02511509|Electroconvulsive Therapy
88369|NCT02511509|Bifrontal ECT
88370|NCT02511509|Bitemporal ECT
88371|NCT02511509|Cognitive functions
88372|NCT02511509|Postictal delirium
88373|NCT02511483|COMT
88374|NCT02511483|Beta-blocker
88375|NCT02511483|Hemicolectomy
88376|NCT02511470|Cardiopulmonary Resuscitation
88377|NCT02511470|Pediatric simulation study
88378|NCT02511470|Metronome
88379|NCT02511444|GBS
88380|NCT02511444|GBS culture
88381|NCT02511444|GBS PCR
88382|NCT02511444|GBS colonization
88383|NCT02511431|Delta Hepatitis
88384|NCT02511431|Hepatitis D
88385|NCT02511431|Liver Disease
88386|NCT02511431|Hepatitis D Virus
88387|NCT02511431|Chronic Hepatitis
88388|NCT02511405|rGBM
88389|NCT02511405|Recurrent Glioblastoma
88390|NCT02511405|Recurrent GBM
88391|NCT02511366|ileal brake
88392|NCT02511353|malaria
88393|NCT02511353|plasmodium
88394|NCT02511353|dihydroartemisinin-piperaquine
88395|NCT02511353|ivermectin
88396|NCT02511327|Pertussis
88397|NCT02511327|Pregnancy
88398|NCT02511327|Vaccination
88399|NCT02511327|Preterm
88400|NCT02511327|Breast milk
88401|NCT02511327|Humoral immune response
88402|NCT02511327|Cellular immune response
88403|NCT02511327|Maternal antibodies
88404|NCT02511314|Nursing homes
88405|NCT02511314|quasi-experimental
88406|NCT02511314|mixed methods
88407|NCT02511314|parallel study
88408|NCT02511314|urinary incontinence
88409|NCT02511288|hematologic test
88410|NCT02511275|parenchymal clamping
88411|NCT02511275|microdialysis technique
88412|NCT02511275|partial nephrectomy
88413|NCT02511249|neonatal arterial ischemic stroke
88414|NCT02511249|language development
88415|NCT02511249|global intellectual functioning
88416|NCT02511249|motor abilities
88417|NCT02511197|PET
88418|NCT02511197|lung injury
88419|NCT02511197|integrin receptor
88420|NCT02511184|crizotinib
88421|NCT02511184|pembrolizumab
88422|NCT02511184|ALK-positive NSCLC
88423|NCT02511184|Lung Cancer
88424|NCT02511184|ALK-translocated NSCLC
88425|NCT02511184|Non Small Cell Lung Cancer
88426|NCT02511158|Anterior Cruciate Ligament, Posterior Cruciate Ligament, Medial Collateral Ligament, Lateral Collateral Ligament
88427|NCT02511145|volunteers
88428|NCT02511132|Ewing's Sarcoma Family of Tumors, ESFT, Sarcoma
88429|NCT02511106|Stage IB-IIA-IIIA Non-Small Cell Lung Cancer; EGFRm+; Ex19Del; L858R; AZD9291; Phase III, adjuvant chemotherapy; complete tumour resection; EGFR-TKI
88430|NCT02511093|Hypertension
88431|NCT02511093|Team-based care
88432|NCT02511093|Collaboration
88433|NCT02511093|Healthcare professionals
88434|NCT02511093|Healthcare services
88435|NCT02511080|Spot-on; perioperative hypothermia.
88436|NCT02511054|Immunogenicity
88437|NCT02511054|Liver Stage
88438|NCT02511054|Parasites
88439|NCT02511054|Blood
88440|NCT02511054|Infection
88441|NCT02511041|CDG
88442|NCT02511041|PGM3
88443|NCT02511041|Immune
88444|NCT02511028|MRI
88445|NCT02511028|Multiple Sclerosis
88446|NCT02511028|Healthy Volunteer
88447|NCT02511015|Early Onset Parkinson's Disease
88448|NCT02511015|Cellular Quality Control Programs
88449|NCT02511015|Mitochondria
88450|NCT02511015|Neuroinflammation
88451|NCT02511015|Immunology
88452|NCT02511002|Influenza
88453|NCT02511002|Hemagglutinin (HA)
88454|NCT02511002|Post Influenza Challenge
88455|NCT02511002|Neuranimidase (NA)
88456|NCT02511002|Influenza Illness
88457|NCT02510989|Syndromic obesity
88458|NCT02510989|Genes
88459|NCT02510989|Exome
88460|NCT02510963|Vertical infection transmission
88461|NCT02510963|Tenofovir
88462|NCT02510937|pulmonary fibrosis
88463|NCT02510937|pharmacokinetic
88464|NCT02510937|pharmacodynamics
88465|NCT02510937|CC-90001
88466|NCT02510937|Safety
88467|NCT02510924|Intubation
88468|NCT02510924|Airtraq
88469|NCT02510924|General anesthesia
88470|NCT02510924|Difficult airway
88471|NCT02510911|colectomy
88472|NCT02510911|laparoscopy
88473|NCT02510911|caffeine
88474|NCT02510885|neovascular age-related macular degeneration
88475|NCT02510885|age-related macular degeneration
88476|NCT02510885|diabetic retinopathy
88477|NCT02510885|SD-OCT
88478|NCT02510885|Angiography
88479|NCT02510885|diabetic macular edema
88480|NCT02510846|Polyhandicap
88481|NCT02510846|Behavior disorders
88482|NCT02510846|Educative program
88483|NCT02510846|Caregivers
88484|NCT02510846|Quality of life.
88485|NCT02510833|Parkinson Disease
88486|NCT02510833|Physical Therapy Modalities
88487|NCT02510833|Quality of Life
88488|NCT02510833|Self Care
88489|NCT02510768|alba
88490|NCT02510664|Adolescence
88491|NCT02510664|Adherence
88492|NCT02510651|: non-segmental vitiligo
88493|NCT02510651|melanocyte-keratinocyte suspension
88494|NCT02510651|cryoblebbing
88495|NCT02510651|CO2 laser
88496|NCT02510612|Dexmedetomidine
88497|NCT02510612|Diabetic
88498|NCT02510612|glycometabolism
88499|NCT02510612|sedation
88500|NCT02510599|NASH
88501|NCT02510599|Liver disease
88502|NCT02510508|addiction
88503|NCT02510508|substance abuse
88504|NCT02510508|alcohol
88505|NCT02510508|drugs
88506|NCT02510508|community reinforcement
88507|NCT02510508|family treatment
88508|NCT02510508|randomized control trial
88509|NCT02510495|Sphincterotomy
88510|NCT02510495|Dilatation
88511|NCT02510495|Common bile duct
88512|NCT02510495|Pancreatitis
88513|NCT02510482|cardiac biomarkers
88514|NCT02510443|Permanent contraception method
88515|NCT02510443|Contraceptive device
88516|NCT02510391|modular
88517|NCT02510391|anxiety
88518|NCT02510391|preschool
88519|NCT02510391|exposure and response prevention
88520|NCT02510391|Cognitive behavioral therapy
88521|NCT02510352|Rotator cuff tear
88522|NCT02510352|MRI
88523|NCT02510287|analgesia, epidural
88524|NCT02510287|labor pain
88525|NCT02510287|patient satisfaction
88526|NCT02510274|ASP3325
88527|NCT02510274|pharmacokinetics
88528|NCT02510274|pharmacodynamics
88529|NCT02510274|Chronic Kidney Disease
88530|NCT02510274|Hyperphosphatemia
88531|NCT02510261|RNAi therapeutic
88532|NCT02510261|FAP
88533|NCT02510261|Familial Amyloid Polyneuropathy
88534|NCT02510261|TTR
88535|NCT02510261|Transthyretin
88536|NCT02510261|Amyloidosis
88537|NCT02510235|Dry Eye
88538|NCT02510222|child
88539|NCT02510209|Teen pregnancy
88540|NCT02510183|Acupressure
88541|NCT02510183|Perioperative Care
88542|NCT02510183|Postoperative Nausea and Vomiting
88543|NCT02510183|Nursing Care Management
88544|NCT02510170|Fetus
88545|NCT02510170|Skull
88546|NCT02510170|ultrasonography
88547|NCT02510157|sugammadex
88548|NCT02510157|dexamethasone
88549|NCT02510157|neuromuscular blockade
88550|NCT02510118|ChangTai Keli
88551|NCT02510118|Colon cancer
88552|NCT02510105|Critical Care
88553|NCT02510105|ARDS
88554|NCT02510105|Intrapulmonary Percussive Ventilation
88555|NCT02510105|VDR4
88556|NCT02510105|Lung aeration
88557|NCT02510105|CT scan
88558|NCT02510066|Pancreatic Cancer
88559|NCT02510066|Pain
88560|NCT02510066|Acupuncture
88561|NCT02510040|Convergence Insufficiency
88562|NCT02510040|Divergence Insufficiency
88563|NCT02510040|Small-angle Hypertropia
88564|NCT02510040|Strabismus
88565|NCT02510027|HPV testing
88566|NCT02510027|Triage
88567|NCT02510027|Mexico
88568|NCT02510027|Cervical cancer screening
88569|NCT02510001|RASMT CRC
88570|NCT02510001|RASWT/c-MET CRC
88571|NCT02510001|Dose Escalation
88572|NCT02510001|Histologically or cytologically confirmed
88573|NCT02510001|Dose Expansion
88574|NCT02509988|Nutrition
88575|NCT02509988|Glucose metabolism
88576|NCT02509988|Body composition
88577|NCT02509975|embolization
88578|NCT02509975|prostate
88579|NCT02509962|Energy metabolism
88580|NCT02509962|Glucose tolerance
88581|NCT02509962|Blood pressure
88582|NCT02509962|Immunoregulation
88583|NCT02509923|Male Subjects
88584|NCT02509910|Major abdominal surgery
88585|NCT02509910|Goal directed therapy
88586|NCT02509897|Hypoxia training
88587|NCT02509897|Activity energy expenditure
88588|NCT02509897|Immunoregulation
88589|NCT02509897|Energy Metabolism
88590|NCT02509897|Exercise
88591|NCT02509884|Alveolar Echinococcosis (AE)
88592|NCT02509884|Echinococcus multilocularis
88593|NCT02509884|antiparasitic treatment
88594|NCT02509884|surgery
88595|NCT02509884|classification
88596|NCT02509884|staging
88597|NCT02509884|prospective cohort study
88598|NCT02509871|Body composition
88599|NCT02509858|Diabetes mellitus, thyroxine
88600|NCT02509832|Therapeutic Hypothermia (TH)
88601|NCT02509832|Acute Myocardial Infarction (AMI)
88602|NCT02509832|Percutaneous Coronary Intervention (PCI)
88603|NCT02509819|rehabilitation
88604|NCT02509819|IDEO
88605|NCT02509780|Vichy
88606|NCT02509780|urine alkalization
88607|NCT02509767|Contraceptive Methods
88608|NCT02509767|Female Contraception
88609|NCT02509767|Contraceptive satisfaction
88610|NCT02509767|Injectable contraception
88611|NCT02509767|Birth control
88612|NCT02509754|atrial fibrillation
88613|NCT02509754|congestive heart failure
88614|NCT02509754|catheter ablation
88615|NCT02509754|rate control
88616|NCT02509754|left ventricular function
88617|NCT02509741|obesity
88618|NCT02509741|nutrition
88619|NCT02509741|intervention
88620|NCT02509741|food replacement
88621|NCT02509741|IOT
88622|NCT02509728|choline
88623|NCT02509728|docosahexaenoic acid
88624|NCT02509715|thyroidectomy
88625|NCT02509715|nerve monitoring
88626|NCT02509702|Mobile health
88627|NCT02509702|Screening
88628|NCT02509702|Early detection of cancer
88629|NCT02509702|Telemedicine
88630|NCT02509689|mTBI
88631|NCT02509689|cognition disorders
88632|NCT02509689|post-concussive syndrome
88633|NCT02509689|neuroplasticity
88634|NCT02509689|EEG
88635|NCT02509689|biofeedback
88636|NCT02509689|stress disorder/post-traumatic
88637|NCT02509689|depression
88638|NCT02509676|dynamic stretching training
88639|NCT02509676|muscle tendon unit
88640|NCT02509676|ultrasound
88641|NCT02509650|Exome sequencing
88642|NCT02509650|Skin disease
88643|NCT02509650|Familial lipomatosis
88644|NCT02509637|Respiratory System
88645|NCT02509637|Physical Therapy Modalities
88646|NCT02509611|Yoga
88647|NCT02509611|Parkinson's disease
88648|NCT02509611|redox status
88649|NCT02509611|motor function
88650|NCT02509559|Receptors, Adrenergic
88651|NCT02509559|Propranolol
88652|NCT02509533|Vacuum Assisted Closure
88653|NCT02509520|Nutritional supplementation
88654|NCT02509520|Neuromuscular Electric Stimulation
88655|NCT02509520|ICU acquired weakness
88656|NCT02509520|Post ICU Syndrome
88657|NCT02509520|sarcopenia
88658|NCT02509507|Liver tumours
88659|NCT02509494|Vaccine
88660|NCT02509494|Ebola
88661|NCT02509494|Ebola virus disease
88662|NCT02509494|EVD
88663|NCT02509494|Hemorrhagic fever
88664|NCT02509494|Sierra Leone
88665|NCT02509494|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
88666|NCT02509494|Safety
88667|NCT02509494|Immunogenicity
88668|NCT02509494|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector
88669|NCT02509494|(MVA‐BN Filo)
88670|NCT02509481|malaria
88671|NCT02509481|lymphatic filariasis
88672|NCT02509481|mosquito
88673|NCT02509481|ivermectin
88674|NCT02509481|mass drug administration
88675|NCT02509455|Balance control
88676|NCT02509455|Body-mounted sensors
88677|NCT02509455|Balance Measures
88678|NCT02509442|mapping brain functions
88679|NCT02509442|Direct electric stimulation (DES)
88680|NCT02509442|potential evoked
88681|NCT02509429|T1DM
88682|NCT02509429|Type 1 Diabetes
88683|NCT02509429|Artificial Pancreas
88684|NCT02509429|DiAs platform
88685|NCT02509416|endoscopic ultrasound
88686|NCT02509416|endoscopic retrograde cholangiopancreatography
88687|NCT02509416|competency
88688|NCT02509403|Perineal hygiene
88689|NCT02509403|Hygiene wipes
88690|NCT02509403|Hygiene Towels
88691|NCT02509403|Safety
88692|NCT02509403|Essential oils
88693|NCT02509403|Natural Health Product
88694|NCT02509390|Fibrinogen level
88695|NCT02509390|Hyperfibrinogenemia
88696|NCT02509390|Trauma
88697|NCT02509390|Thrombosis risk
88698|NCT02509377|Fetal Surgery
88699|NCT02509377|Open Fetal Surgery
88700|NCT02509377|Elevated BMI
88701|NCT02509377|Body Mass Index
88702|NCT02509377|Spina Bifida
88703|NCT02509364|AE-IPF
88704|NCT02509312|Analgesia, Obstetrical
88705|NCT02509312|Blood Loss, Surgical
88706|NCT02509312|Analgesics, Opioid/administration & dosage
88707|NCT02509312|Cyclooxygenase Inhibitors/administration & dosage
88708|NCT02509312|Cesarean Section
88709|NCT02509312|Female
88710|NCT02509312|Humans
88711|NCT02509312|Ketorolac/administration & dosage
88712|NCT02509312|Hydromorphone/administration & dosage
88713|NCT02509312|Pain, Postoperative/drug therapy
88714|NCT02509312|Pregnancy
88715|NCT02509312|Morphine/administration & dosage
88716|NCT02509299|COPD
88717|NCT02509299|Quality of life
88718|NCT02509299|Perceived health status
88719|NCT02509286|Esophageal neoplasms
88720|NCT02509286|gastro-esophageal junction neoplasms
88721|NCT02509286|adenocarcinoma
88722|NCT02509286|esophagectomy
88723|NCT02509286|surgery
88724|NCT02509286|radiotherapy
88725|NCT02509286|chemotherapy
88726|NCT02509260|colorectal surgery
88727|NCT02509247|sleep apnea
88728|NCT02509247|CPAP
88729|NCT02509247|telemonitoring
88730|NCT02509247|telecare
88731|NCT02509234|pediatric sarcomas
88732|NCT02509234|Ewing sarcoma
88733|NCT02509234|rhabdomyosarcoma
88734|NCT02509234|soft tissue sarcoma
88735|NCT02509208|iliac crest bone graft
88736|NCT02509208|ICBG
88737|NCT02509208|pelvic osteotomy
88738|NCT02509208|spinal fusion
88739|NCT02509208|hemostasis
88740|NCT02509208|haemostasis
88741|NCT02509208|hemostatic
88742|NCT02509208|haemostatic
88743|NCT02509208|dextran
88744|NCT02509208|SurgiClot
88745|NCT02509208|cancellous bone bleeding
88746|NCT02509182|Hyperoxia
88747|NCT02509182|One-Lung Ventilation
88748|NCT02509182|Thoracic Surgery
88749|NCT02509182|Anesthesiology
88750|NCT02509156|Cardiomyopathy
88751|NCT02509156|AIC
88752|NCT02509156|Anthracyclines
88753|NCT02509156|Chemotherapy
88754|NCT02509156|Allogeneic
88755|NCT02509156|Mesenchymal stem cells
88756|NCT02509156|MSCs
88757|NCT02509156|Cancer survivors
88758|NCT02509156|Breast Cancer
88759|NCT02509156|Leukemia
88760|NCT02509156|Lymphoma
88761|NCT02509156|Sarcoma
88762|NCT02509143|Postoperative Nausea and Vomiting
88763|NCT02509143|Colorectal Neoplasms
88764|NCT02509130|Severe Asthma
88765|NCT02509130|Asthma
88766|NCT02509130|Specialised Asthma Care
88767|NCT02509130|Asthma Care
88768|NCT02509117|Alzheimer's disease
88769|NCT02509104|Bioavailability
88770|NCT02509104|Dutasteride
88771|NCT02509104|Healthy Male Subjects
88772|NCT02509104|Fixed Dose Combination
88773|NCT02509078|ARDS
88774|NCT02509078|neuromuscular blocker
88775|NCT02509078|cisatracurium
88776|NCT02509065|bionic pancreas
88777|NCT02509065|artificial pancreas
88778|NCT02509065|insulin
88779|NCT02509065|glucagon
88780|NCT02509065|continuous glucose monitor (CGM)
88781|NCT02509065|insulin pump
88782|NCT02509065|outpatient
88783|NCT02509039|CC-122
88784|NCT02509039|Phase1
88785|NCT02509039|solid tumor
88786|NCT02509039|non-Hodgkin's lymphom
88787|NCT02509026|non-radiographic axial spondyloarthritis
88788|NCT02509013|chronic kidney disease
88789|NCT02509013|stable coronary heart disease
88790|NCT02509013|prevalence
88791|NCT02508987|Obesity
88792|NCT02508987|oxidative stress
88793|NCT02508987|antioxidants
88794|NCT02508987|periodontal disease
88795|NCT02508961|Physical Activity
88796|NCT02508961|Exercise
88797|NCT02508961|Physiotherapy
88798|NCT02508948|airway management
88799|NCT02508948|critically ill
88800|NCT02508948|hemodynamic management
88801|NCT02508948|intubation
88802|NCT02508948|prospective study
88803|NCT02508948|risk factors
88804|NCT02508909|Videoassisted surgery
88805|NCT02508883|Cancer
88806|NCT02508883|hemorrhage
88807|NCT02508883|endoscopy
88808|NCT02508883|gastrointestinal hemorrhage
88809|NCT02508857|pain, postoperative
88810|NCT02508857|anesthesia adjuvants
88811|NCT02508857|magnesium sulfate
88812|NCT02508844|Probiotics
88813|NCT02508844|Vivomixx®
88814|NCT02508844|Microbiota
88815|NCT02508831|Bilateral amputation
88816|NCT02508831|upper limb
88817|NCT02508831|allograft
88818|NCT02508779|Diabetes
88819|NCT02508779|Blood Glucose Management
88820|NCT02508779|Preconception
88821|NCT02508779|Hypoglycemia
88822|NCT02508779|Women with diabetes
88823|NCT02508766|Postural Control
88824|NCT02508766|Plantar Stimulation
88825|NCT02508766|Volunteers
88826|NCT02508753|QT/QTc Intervals
88827|NCT02508701|HPV
88828|NCT02508701|Message Design
88829|NCT02508701|Adolescent Males
88830|NCT02508688|hepatic hydrothorax
88831|NCT02508688|thoracoscopic surgery
88832|NCT02508688|diaphragmatic defect
88833|NCT02508675|injury
88834|NCT02508675|risk factors
88835|NCT02508675|outcome
88836|NCT02508675|costs
88837|NCT02508662|Advanced Cancers
88838|NCT02508662|Solid Tumors
88839|NCT02508662|Genomic Mutations
88840|NCT02508662|FDA Approved Off-Label Chemotherapy
88841|NCT02508662|Refractory
88842|NCT02508623|Portal hypertension
88843|NCT02508623|liver cirrhosis
88844|NCT02508623|Rifaximin
88845|NCT02508597|Smoking cessation intervention
88846|NCT02508571|Infant, Premature
88847|NCT02508571|Intervention Studies
88848|NCT02508571|Bottle feeding
88849|NCT02508506|ALKS 5461
88850|NCT02508506|Alkermes
88851|NCT02508506|Samidorphan
88852|NCT02508506|Renal Impairment
88853|NCT02508506|Pharmacokinetics
88854|NCT02508506|Buprenorphine
88855|NCT02508480|Stigma
88856|NCT02508480|Community Integration
88857|NCT02508467|Liver cancer
88858|NCT02508467|FGF19 gene amplification
88859|NCT02508467|FGF19 overexpression
88860|NCT02508467|FGF19 upregulation
88861|NCT02508467|Cyclin D1 (CCND1) gene amplification
88862|NCT02508467|Cyclin D1 (CCND1) copy number gain
88863|NCT02508467|BLU-554
88864|NCT02508467|FGFR4
88865|NCT02508467|Hepatocellular carcinoma
88866|NCT02508467|Liver Disease
88867|NCT02508467|Liver Neoplasms
88868|NCT02508454|Prevention
88869|NCT02508454|Screening
88870|NCT02508454|Biobanking
88871|NCT02508441|Neoplasms
88872|NCT02508441|Solid Tumors
88873|NCT02508441|Advanced Malignancy
88874|NCT02508441|Cancer
88875|NCT02508428|Osteolysis
88876|NCT02508428|Polyethylene
88877|NCT02508428|Crosslinked Polyethylene
88878|NCT02508428|Total Hip Replacement
88879|NCT02508428|Marathon
88880|NCT02508415|obesity
88881|NCT02508415|periodontal disease
88882|NCT02508415|intervention
88883|NCT02508389|squamous cell carcinoma of the head and neck
88884|NCT02508389|oral cavity
88885|NCT02508389|oropharynx
88886|NCT02508389|intensity-modulated radiation therapy
88887|NCT02508389|chemotherapy
88888|NCT02508389|oral mucositis
88889|NCT02508389|superoxide dismutase
88890|NCT02508389|radioprotection
88891|NCT02508376|adjuvants
88892|NCT02508376|AP10-602
88893|NCT02508376|GLA-SE
88894|NCT02508376|ID93
88895|NCT02508376|Tuberculosis
88896|NCT02508376|vaccine
88897|NCT02508363|Taxi drivers
88898|NCT02508363|Health care access
88899|NCT02508363|15-163
88900|NCT02508311|Tetraplegia
88901|NCT02508311|High Paraplegia
88902|NCT02508298|ICG
88903|NCT02508298|ARFI
88904|NCT02508298|portal hypertension
88905|NCT02508298|cirrhosis
88906|NCT02508298|diagnostic study
88907|NCT02508272|Transcriptome profiling
88908|NCT02508259|mitochondria
88909|NCT02508259|purinergic signaling
88910|NCT02508259|cell danger response
88911|NCT02508194|RSV
88912|NCT02508194|Older adults
88913|NCT02508194|MEDI7510
88914|NCT02508194|Vaccine
88915|NCT02508194|Efficacy
88916|NCT02508181|intra ocular pressure
88917|NCT02508181|I-gel
88918|NCT02508181|LMA Supreme
88919|NCT02508181|strabismus surgery
88920|NCT02508168|Drug therapy
88921|NCT02508129|Insomnia
88922|NCT02508129|hypertension
88923|NCT02508129|blood pressure
88924|NCT02508129|sleep
88925|NCT02508129|behavioral treatment
88926|NCT02508129|Cognitive Behavioral Treatment of Insomnia (CBTI)
88927|NCT02508129|Brief Behavioral Treatment of Insomnia (BBTI)
88928|NCT02508129|pragmatic trial
88929|NCT02508129|internet
88930|NCT02508116|pharmacogenetics
88931|NCT02508116|clopidogrel
88932|NCT02508116|genotype
88933|NCT02508103|Premenstrual Dysphoric Disorder
88934|NCT02508103|Premenstrual Syndrome
88935|NCT02508103|PMS
88936|NCT02508103|PMDD
88937|NCT02508038|alpha beta depleted
88938|NCT02508038|alphabeta
88939|NCT02508038|TCR alpha beta depleted
88940|NCT02508038|alpha beta
88941|NCT02508038|haploidentical
88942|NCT02508038|Zoledronate
88943|NCT02508038|Zoledronic acid
88944|NCT02508038|Pediatric cancers
88945|NCT02508038|alfa beta
88946|NCT02508038|αβ T cell depleted HSCT
88947|NCT02508038|alpha beta T cell and B cell depleted HSCT
88948|NCT02508038|haploidentical HSCT
88949|NCT02508025|disability evaluation
88950|NCT02508025|psychosocial factors
88951|NCT02508012|anti-TNF
88952|NCT02508012|Immuno-monitoring
88953|NCT02508012|Anti-drug antibody (ADAb)
88954|NCT02508012|Inflammatory bowel disease (IBD)
88955|NCT02508012|Crohn's disease
88956|NCT02508012|Ulcerative colitis
88957|NCT02507973|Mechanical Ventilation
88958|NCT02507973|Intracranial Pressure
88959|NCT02507973|Airway Pressure Release Ventilation
88960|NCT02507934|Dry Eye
88961|NCT02507908|neuroendocrine tumors
88962|NCT02507908|5-hydroxyindolacetic acid
88963|NCT02507908|serotonin
88964|NCT02507908|isotope-dilution massa-spectrometer
88965|NCT02507895|Stroke
88966|NCT02507895|lower extremeties
88967|NCT02507895|Brain-computer interface
88968|NCT02507895|Motor imagery
88969|NCT02507895|Rehabilitation
88970|NCT02507895|TMS
88971|NCT02507843|Vitamin D
88972|NCT02507817|LIF,Magnesium Sulphate
88973|NCT02507791|Fitbit
88974|NCT02507791|Obesity
88975|NCT02507791|Pediatrics
88976|NCT02507778|Lung
88977|NCT02507778|Cancer
88978|NCT02507778|Biomarkers
88979|NCT02507778|Early detection
88980|NCT02507778|Circulating tumor cell
88981|NCT02507765|SBRT
88982|NCT02507713|Amyotrophic lateral sclerosis
88983|NCT02507713|Ultrasonography
88984|NCT02507713|Motor neurons
88985|NCT02507713|Neuromuscular diseases
88986|NCT02507713|Fasciculation
88987|NCT02507700|nerve block
88988|NCT02507674|appendicitis
88989|NCT02507674|pediatric
88990|NCT02507674|ultrasound
88991|NCT02507635|cytokines
88992|NCT02507635|persistent allergic rhinitis
88993|NCT02507635|H1 antihistamines
88994|NCT02507583|Brain Tumor
88995|NCT02507583|Glioma
88996|NCT02507583|Newly Diagnosed
88997|NCT02507557|Therapy, Fluid
88998|NCT02507557|Digestive System Surgical Procedures
88999|NCT02507557|Postoperative Complications
89000|NCT02507544|Advanced Solid Malignancy
89001|NCT02507544|Safety and Tolerability
89002|NCT02507544|Tumor Response
89003|NCT02507544|Hematology
89004|NCT02507544|Oncology
89005|NCT02506439|Vitamin D
89006|NCT02506439|Cholecalciferol
89007|NCT02506439|Dose-response
89008|NCT02506439|Randomized Controlled Trial
89009|NCT02506439|Pregnancy
89010|NCT02506439|Cord blood
89011|NCT02506439|Serum 25-hydroxyvitamin D
89012|NCT02506439|Vitamin D Deficiency
89013|NCT02506439|Nutrition
89014|NCT02506439|Dietary intervention study
89015|NCT02506426|Chronic Sinusitis
89016|NCT02506426|Chronic Rhinosinusitis
89017|NCT02506426|Endoscopic sinus surgery
89018|NCT02506426|Septoplasty
89019|NCT02506413|Maternal and Newborn Health
89020|NCT02505581|Postoperative Wound Infection
89021|NCT02505581|Surgical Wound Infection
89022|NCT02505581|Colorectal Surgery Infection Prophylaxis
89023|NCT02505568|Behcet Disease
89024|NCT02505568|Infliximab
89025|NCT02505568|Adult participants
89026|NCT02505555|feasibility
89027|NCT02505555|accuracy
89028|NCT02505555|tolerability
89029|NCT02505555|four dimensional hysterosalpingo-contrast sonography
89030|NCT02505542|Axial Spondyloarthritis
89031|NCT02505542|axSpA
89032|NCT02505542|Ankylosing Spondylitis
89033|NCT02505542|Anti TNF-alpha
89034|NCT02505542|Certolizumab Pegol
89035|NCT02505542|Remission
89036|NCT02505542|Spondylarthropathies
89037|NCT02505542|Arthritis
89038|NCT02505542|Spinal Diseases
89039|NCT02505542|Immunosuppressive Agents
89040|NCT02505529|Aging
89041|NCT02505529|Muscle
89042|NCT02505529|Weakness
89043|NCT02505529|Sarcopenia
89044|NCT02505529|Dynapenia
89045|NCT02505516|pathology
89046|NCT02505503|Claudication
89047|NCT02505503|Footwear
89048|NCT02505503|Shoes
89049|NCT02505503|Walking capacity
89050|NCT02505503|Walking distance
89051|NCT02505490|Lunch
89052|NCT02505490|Television
89053|NCT02505490|Macaroni and Cheese
89054|NCT02505490|Salad tossed in dressing
89055|NCT02505477|schiozphrenia
89056|NCT02505477|cognition
89057|NCT02505477|negative symptoms
89058|NCT02505477|glutamate
89059|NCT02505477|glutathione
89060|NCT02505477|N-acetylcysteine
89061|NCT02505451|Metabolic syndrome
89062|NCT02505451|diabetes
89063|NCT02505451|myocardial function
89064|NCT02505451|dobutamine
89065|NCT02507518|lung cancer, PET, progression free survival
89066|NCT02507492|POMC, LEPR, PCSK1
89067|NCT02507466|locomotion
89068|NCT02507453|volunteers
89069|NCT02507427|Prostate cancer, robot, nerve mapping and monitoring
89070|NCT02507414|Mesenteric Traction Syndrome
89071|NCT02507414|Upper gastrointestinal cancer surgery
89072|NCT02507375|Non-Squamous
89073|NCT02507362|keratoconus , corneal collagen cross-linking
89074|NCT02507349|serious mental illness
89075|NCT02507349|mental health services research
89076|NCT02507349|measurement-based care
89077|NCT02507349|shared decision making
89078|NCT02507349|psychiatric medication management
89079|NCT02507349|community psychiatry
89080|NCT02507349|comparative effectiveness research
89081|NCT02507349|mixed methods research
89082|NCT02507336|Mantle Cell Lymphoma (MCL)
89083|NCT02507336|Non-Hodgkin's Lymphoma (NHL)
89084|NCT02507245|GHD
89085|NCT02507232|glioma
89086|NCT02507232|temozolomide
89087|NCT02507232|brain
89088|NCT02507232|NovoTTF-200A
89089|NCT02507232|cancer
89090|NCT02507232|low-grade glioma
89091|NCT02507206|schizotypal personality disorder
89092|NCT02507206|cognitive impairment
89093|NCT02507206|working memory
89094|NCT02507206|Dopamine Agonists
89095|NCT02507206|Cognition Disorders
89096|NCT02507206|Personality Disorders
89097|NCT02507206|Delirium
89098|NCT02507206|Dementia
89099|NCT02507206|Amnestic
89100|NCT02507206|Cognitive Disorders
89101|NCT02507206|Mental Disorders
89102|NCT02507206|Dihydrexidine
89103|NCT02507206|Dopamine A
89104|NCT02507180|clinical decision rule
89105|NCT02507180|Ultrasound
89106|NCT02507180|Suspected Deep Vein Thrombosis
89107|NCT02507180|D-Dimer
89108|NCT02507154|cetuximab
89109|NCT02507154|NK cells
89110|NCT02507154|nasopharyngeal cancer
89111|NCT02507154|head and neck squamous cell cancer
89112|NCT02507141|Reflectance Confocal Microscopy
89113|NCT02507141|15-128
89114|NCT02507050|Ivabradine
89115|NCT02507050|Microvascular dysfunction
89116|NCT02507050|PCI
89117|NCT02507050|Procedural related myocardial injury
89118|NCT02507050|IMR
89119|NCT02507050|Index of Microvascular Resistance
89120|NCT02506998|Allergic rhinoconjunctivitis
89121|NCT02506998|Dialyzable Leukocyte Extracts
89122|NCT02506985|Rivaroxaban
89123|NCT02506985|CDT (Catheter directed thrombolysis)
89124|NCT02506985|PE (pulmonary embolism)
89125|NCT02506985|NETs
89126|NCT02506985|factor Xa
89127|NCT02506972|Blood glucose
89128|NCT02506972|Humans
89129|NCT02506972|Postprandial
89130|NCT02506972|Sugar
89131|NCT02506972|Carbohydrate
89132|NCT02506972|Oat beta-glucan
89133|NCT02506959|Multiple myeloma (MM)
89134|NCT02506959|MM
89135|NCT02506959|Refractory
89136|NCT02506959|Relapsed
89137|NCT02506959|Stem Cell Transplant
89138|NCT02506959|Busulfan
89139|NCT02506959|Busulfex
89140|NCT02506959|Myleran
89141|NCT02506959|Palifermin
89142|NCT02506959|Kepivance
89143|NCT02506959|Panobinostat
89144|NCT02506959|LBH589B
89145|NCT02506959|Gemcitabine
89146|NCT02506959|Gemcitabine Hydrochloride
89147|NCT02506959|Gemzar
89148|NCT02506959|Melphalan
89149|NCT02506959|Alkeran
89150|NCT02506959|Dexamethasone
89151|NCT02506959|Decadron
89152|NCT02506959|Pyridoxine
89153|NCT02506959|Caphosol
89154|NCT02506959|Glutamine
89155|NCT02506959|Enterex
89156|NCT02506959|Glutapak
89157|NCT02506959|NutreStore
89158|NCT02506959|Resource
89159|NCT02506959|GlutaSolve
89160|NCT02506959|Sympt-X
89161|NCT02506946|Polycystic Ovary Syndrome
89162|NCT02506946|Non-Alcoholic Fatty Liver Disease
89163|NCT02506946|Adolescents
89164|NCT02506946|Young Women
89165|NCT02506946|MRI
89166|NCT02506946|MRS
89167|NCT02506946|DXA
89168|NCT02506946|Hirsutism
89169|NCT02506946|Amenorrhea
89170|NCT02506946|Metabolic syndrome
89171|NCT02506946|Dyslipidemia
89172|NCT02506946|Percentage liver fat
89173|NCT02506920|Postprandial lipemia
89174|NCT02506920|glycemic response
89175|NCT02506881|darbepoetin alfa
89176|NCT02506881|pharmacokinetics
89177|NCT02506881|pharmacodynamics
89178|NCT02506881|healthy volunteers
89179|NCT02506868|darbepoetin alfa
89180|NCT02506842|Pancreatic Cancer
89181|NCT02506842|Pancreatic Adenocarcinoma
89182|NCT02506842|AG
89183|NCT02506842|OFF
89184|NCT02506842|Second-Line Adjuvant Therapy
89185|NCT02506829|Inpatients
89186|NCT02506790|Melatonin, metformin, toremifene
89187|NCT02506777|Melatonin, metformin, chemotherapy
89188|NCT02506738|telemonitoring
89189|NCT02506738|mHealth
89190|NCT02506738|functional status
89191|NCT02506738|older people
89192|NCT02506725|prenatal care
89193|NCT02506725|pregnancy
89194|NCT02506725|prematurity
89195|NCT02506673|Audiovisual Aids
89196|NCT02506673|Perioperative Period
89197|NCT02506673|Anxiety
89198|NCT02506634|symptom
89199|NCT02506608|Neuroplasticty, Sensory Feedback
89200|NCT02506556|Pi3K pathway
89201|NCT02506543|Adolescent Health
89202|NCT02506543|Ethiopia
89203|NCT02506543|Sexual Violence
89204|NCT02506530|lymphedema
89205|NCT02506530|breast cancer
89206|NCT02506517|HER pathway aberrations
89207|NCT02506361|TOP2α
89208|NCT02506361|anthracyclines
89209|NCT02506361|taxanes
89210|NCT02506361|non dose-dense chemotherapy
89211|NCT02506335|Liver disease
89212|NCT02506335|cardiomyopathy
89213|NCT02506335|congenital heart disease
89214|NCT02506322|Bipolar I Disorder
89215|NCT02506322|Bipolar II Disorder
89216|NCT02506322|Relapse Prevention
89217|NCT02506296|type 2 diabetes
89218|NCT02506296|endogenous insulin secretion
89219|NCT02506283|cryotherapy
89220|NCT02506283|recovery
89221|NCT02506283|athletic performance
89222|NCT02506283|maximum voluntary contraction
89223|NCT02506283|rated perceived exertion
89224|NCT02506283|delayed onset muscle soreness
89225|NCT02506283|jump performance
89226|NCT02506244|Atrial Fibrillation
89227|NCT02506244|Wearable device
89228|NCT02506244|Wristband
89229|NCT02506244|ECG Patch
89230|NCT02506244|Strokes
89231|NCT02506244|Asymptomatic
89232|NCT02506244|Heart Rhythm
89233|NCT02506244|Home Monitoring
89234|NCT02506231|Allogeneic hematopoietic cell transplantation
89235|NCT02506231|GVHD prophylaxis
89236|NCT02506231|Methotrexate
89237|NCT02506231|Folinic acid
89238|NCT02506231|Leucovorin
89239|NCT02506231|Mucositis
89240|NCT02506192|Gulf War Illness
89241|NCT02506192|Chronic Inflammation
89242|NCT02506192|Delayed-Release Prednisone
89243|NCT02506192|Health-Related Quality of Life
89244|NCT02506179|Moderate to severe ulcerative colitis (UC)
89245|NCT02506179|Real-life effect
89246|NCT02506179|Adalimumab
89247|NCT02506179|Ulcerative colitis (UC)
89248|NCT02506179|Patient reported outcomes (PRO)
89249|NCT02506166|sleep apnea
89250|NCT02506166|sleep disordered breathing
89251|NCT02506166|sudden cardiac death
89252|NCT02506166|heart failure
89253|NCT02506166|ischemic cardiomyopathy
89254|NCT02506166|implantable cardioverter-defibrillator (ICD) therapy
89255|NCT02506166|cardiac resynchronization therapy (CRT)
89256|NCT02506166|risk stratification
89257|NCT02506166|positive airway pressure therapy
89258|NCT02506166|SERVE-HF
89259|NCT02506140|minor stroke
89260|NCT02506140|transient ischemic attack
89261|NCT02506140|ticagrelor
89262|NCT02506140|clopidogrel
89263|NCT02506140|dual anti-platelet therapy
89264|NCT02506140|platelet reactivity
89265|NCT02506114|prostate
89266|NCT02506062|ischemic preconditioning
89267|NCT02506062|Raynaud's Phenomenon
89268|NCT02506062|(RP)
89269|NCT02506036|Treatment
89270|NCT02506036|Social-Cognitive Training
89271|NCT02506036|Web-based
89272|NCT02506036|Right Hemisphere Stroke
89273|NCT02506036|Frontotemporal Dementia
89274|NCT02506036|Right Sided Cerebral Hemisphere Cerebrovascular Accident
89275|NCT02506023|Factor VIII antigen
89276|NCT02506023|von Willebrand factor (vWF) antigen
89277|NCT02506023|Mutation type
89278|NCT02506010|Hypoxia
89279|NCT02505984|oxytocin, bonding
89280|NCT02505971|hemangioma, propranolol, nadolol
89281|NCT02505958|insulin resistance, obesity, caloric intake
89282|NCT02505945|Esophageal Reflux
89283|NCT02505945|Gastric Acid Reflux Disease
89284|NCT02505945|Heartburn
89285|NCT02505932|Shoulder instability
89286|NCT02505919|Lower Urinary Tract Symptoms (LUTS)
89287|NCT02505906|Late toxicity
89288|NCT02505906|Simultaneous integrated boost (SIB)
89289|NCT02505906|Radiotherapy
89290|NCT02505880|Hypnosis
89291|NCT02505880|Pediatric surgery
89292|NCT02505880|Anesthesia
89293|NCT02505854|Obesity
89294|NCT02505854|Probiotic
89295|NCT02505854|Symbiotic
89296|NCT02505854|Weight loss
89297|NCT02505854|Gut microbiota
89298|NCT02505854|Bifidobacterium lactis
89299|NCT02505854|Fructooligosaccharide
89300|NCT02505854|Blood sugar
89301|NCT02505854|Lipemia
89302|NCT02505841|Appendectomy
89303|NCT02505841|Laparoscopy
89304|NCT02505841|pediatric surgery
89305|NCT02505828|Arthritis
89306|NCT02505828|septic
89307|NCT02505828|Juvenile idiopathic arthritis
89308|NCT02505828|diagnosis
89309|NCT02505828|proteomic
89310|NCT02505828|cytokine
89311|NCT02505828|monocytes
89312|NCT02505802|Stroke
89313|NCT02505802|Botulinum Toxins
89314|NCT02505802|Muscle Spasticity
89315|NCT02505802|Gait
89316|NCT02505789|Epstein-Barr Virus
89317|NCT02505789|Post-transplant lymphoproliferative disease (PTLD)
89318|NCT02505789|Infection
89319|NCT02505789|Cell Transplants
89320|NCT02505789|Herpesvirus 4, Human
89321|NCT02505711|Agriculture
89322|NCT02505711|Food
89323|NCT02505711|Micronutrients
89324|NCT02505711|Pregnancy
89325|NCT02505711|Infants
89326|NCT02505711|Women's groups
89327|NCT02505711|Bangladesh
89328|NCT02505698|Breast Imaging
89329|NCT02505698|Mammography
89330|NCT02505698|Anatomical Imaging
89331|NCT02505685|Lung
89332|NCT02505685|Cancer
89333|NCT02505685|Biomarkers
89334|NCT02505685|PET-CT
89335|NCT02505685|Early detection
89336|NCT02505672|Vestibular function
89337|NCT02505672|chemoradiotherapy
89338|NCT02505659|Anterior cruciate ligament rupture
89339|NCT02505659|Preoperative re-education
89340|NCT02505659|Knee functional performance
89341|NCT02505659|Anterior cruciate ligament surgery
89342|NCT02505659|Single-leg hop for distance test performance
89343|NCT02505646|circulatory failure
89344|NCT02505646|fluid responsiveness
89345|NCT02505646|abdominal compression
89346|NCT02505633|brachial plexus block
89347|NCT02505633|nerve stimulator
89348|NCT02505633|ultrasound
89349|NCT02505620|Neurocognitive function
89350|NCT02505620|OSAS
89351|NCT02505594|Obstructive Sleep Apnea
89352|NCT02505594|Vasoreactivity
89353|NCT02505594|Endothelial function
89354|NCT02505594|Exercise
89355|NCT02505399|Rotational Atherectomy
89356|NCT02505399|clopidogrel
89357|NCT02505399|thrombosis
89358|NCT02505399|ticagrelor
89359|NCT02505386|Ertapenem
89360|NCT02505386|Subcutaneously
89361|NCT02505386|Aged
89362|NCT02505386|Elderly
89363|NCT02505386|Pharmacokinetics
89364|NCT02505373|Brief Therapy
89365|NCT02505373|Attempted Suicide
89366|NCT02505373|Therapeutic Alliance
89367|NCT02505373|Suicidal Ideation
89368|NCT02505373|Suicide
89369|NCT02505373|ASSIP
89370|NCT02505321|insulin resistance
89371|NCT02505321|physiology
89372|NCT02505321|genetics
89373|NCT02505321|gene variants
89374|NCT02505321|pathogenesis
89375|NCT02505321|type 2 diabetes
89376|NCT02505321|fat
89377|NCT02505321|polygenic lipodystrophy
89378|NCT02505308|insulin
89379|NCT02505308|proinsulin
89380|NCT02505308|genotype
89381|NCT02505308|beta cells
89382|NCT02505308|physiology
89383|NCT02505308|genetics
89384|NCT02505308|pathogenesis
89385|NCT02505308|rare variants
89386|NCT02505308|type 2 diabetes
89387|NCT02505282|Orthostatic hypotension
89388|NCT02505282|Vitamin K
89389|NCT02505269|limited stage
89390|NCT02505269|Hodgkin's disease
89391|NCT02505269|non-bulky
89392|NCT02505243|ribavirin
89393|NCT02505243|direct-acting antivirals
89394|NCT02505243|pharmacokinetics
89395|NCT02505243|therapeutic drug monitoring
89396|NCT02505217|platelet reactivity, thrombin generation
89397|NCT02505204|clonidine
89398|NCT02505204|paravertebral block
89399|NCT02505204|hemodynamic stability
89400|NCT02505191|Pharmacokinetics
89401|NCT02505178|Depression
89402|NCT02505178|Depressive Disorder
89403|NCT02505178|Depressive Disorder, Major
89404|NCT02505178|Mental Disorders
89405|NCT02505178|Mood Disorders
89406|NCT02505178|Behavioural Symptoms
89407|NCT02505178|Problem Solving Therapy
89408|NCT02505165|Intervention
89409|NCT02505165|Illness Uncertainty
89410|NCT02505165|Childhood Cancer
89411|NCT02505165|Solid Tumor
89412|NCT02505165|Leukemia
89413|NCT02505165|Lymphoma
89414|NCT02505165|Brain Tumor
89415|NCT02505165|Randomized clinical trial
89416|NCT02505165|Parental uncertainty management intervention
89417|NCT02505165|Parent
89418|NCT02505165|Oncology
89419|NCT02505165|Pediatric
89420|NCT02505152|Hypertension, Portal
89421|NCT02505152|Portal Vein, Cavernous Transformation Of
89422|NCT02505152|Portosystemic shunt
89423|NCT02505152|Radiology, Interventional
89424|NCT02505139|nasopharyngeal carcinoma
89425|NCT02505139|distant metastasis
89426|NCT02505139|circulating tumor cells
89427|NCT02505139|outcome prediction
89428|NCT02505113|Portal Vein, Cavernous Transformation Of
89429|NCT02505113|Hypertension, Portal
89430|NCT02505100|threat of premature birth
89431|NCT02505087|Selenoprotein N-related myopathy
89432|NCT02505087|biomarkers
89433|NCT02505087|washout
89434|NCT02505087|N-ACETYLCYSTEINE
89435|NCT02505074|mitral valve
89436|NCT02505074|tricuspid valve
89437|NCT02505074|Melody valve
89438|NCT02505035|Palliative care
89439|NCT02505035|Pragmatic trial
89440|NCT02505022|Cognition
89441|NCT02505022|Early mental illness
89442|NCT02505022|Role functioning
89443|NCT02505009|Therapeutic Uses
89444|NCT02505009|Entecavir
89445|NCT02505009|Tenofovir
89446|NCT02505009|Engerix-B
89447|NCT02505009|DNA Virus Infections
89448|NCT02505009|Antiviral Agents
89449|NCT02505009|Vaccination
89450|NCT02504996|sciatalgia
89451|NCT02504996|emergency department
89452|NCT02504996|paracetamol
89453|NCT02504996|morphine
89454|NCT02504983|SNPs
89455|NCT02504970|Anesthesia
89456|NCT02504970|Quality Improvement
89457|NCT02504957|Photodynamic therapy
89458|NCT02504944|Retinopathy of prematurity
89459|NCT02504944|Propranolol
89460|NCT02504944|Newborn
89461|NCT02504944|Eye Drops
89462|NCT02504944|Retinal angiogenesis
89463|NCT02504944|Retinal neovascularization
89464|NCT02504931|PTSD
89465|NCT02504931|Alcohol
89466|NCT02504931|Dual Diagnosis
89467|NCT02504931|Sertraline
89468|NCT02504931|SSRI
89469|NCT02504918|Plasmodium Falciparum
89470|NCT02504918|Regulatory
89471|NCT02504918|Chemoprevention
89472|NCT02504918|Coartem
89473|NCT02504918|Parasitemia
89474|NCT02504905|Parietal Lobe
89475|NCT02504905|Plasticity
89476|NCT02504905|Cerebellum
89477|NCT02504905|Dystonia
89478|NCT02504905|Transcranial Magnetic Stimulation (TMS)
89479|NCT02504892|Overall Response Rate
89480|NCT02504892|Hereditary Cancer Syndrome
89481|NCT02504892|mTOR Therapy Naive
89482|NCT02504879|Osteosclerosis
89483|NCT02504879|Hyperostosis
89484|NCT02504866|Aerobic Exercise Training
89485|NCT02504866|Balance
89486|NCT02504866|TBI
89487|NCT02504853|Eosinophilic Esophagitis
89488|NCT02504853|Loeys-Dietz Syndrome
89489|NCT02504853|TGFbeta
89490|NCT02504840|Multiple Sclerosis
89491|NCT02504840|Clinically Isolated Syndrome
89492|NCT02504840|CNS Inflammatory Demyellnation
89493|NCT02504840|Radiologically Isolated Syndrome
89494|NCT02504827|pharmacokinetics
89495|NCT02504827|ceftazidime/avibactam
89496|NCT02504814|nasal high flow
89497|NCT02504801|primary lung cancer patients
89498|NCT02504788|Whole Brain Radiotherapy (WBRT)
89499|NCT02504788|Neurocognitive Functions (NCFs)
89500|NCT02504788|Hippocampus
89501|NCT02504788|Hippocampus Sparing during Whole Brain Radiotherapy (HS-WBRT)
89502|NCT02504749|GIT motility
89503|NCT02504749|General anaesthesia
89504|NCT02504749|spinal anaesthesia
89505|NCT02504736|LDL cholesterol
89506|NCT02504736|A1c
89507|NCT02504736|High risk South Asians
89508|NCT02504736|Colesevelam
89509|NCT02504723|Gastric varices
89510|NCT02504723|cyanoacrylate
89511|NCT02504723|carvedilol
89512|NCT02504710|Musculoskeletal Manipulations
89513|NCT02504710|Learning
89514|NCT02504710|Feedback
89515|NCT02504710|Kinematics
89516|NCT02504710|Inertial Sensor
89517|NCT02504684|varicose veins
89518|NCT02504684|endovenous laser treatment
89519|NCT02504684|endovenous thermal ablation
89520|NCT02504684|saphenous vein
89521|NCT02504671|DMARD-IR
89522|NCT02504671|GSK3196165
89523|NCT02504671|Rheumatoid Arthritis
89524|NCT02504658|adolescents text messages eating exercise self-efficacy diabetes
89525|NCT02504632|platelet activation
89526|NCT02504632|transcatheter aortic valve implantation
89527|NCT02504593|Quality Assurance
89528|NCT02504593|Monitoring & Evaluation
89529|NCT02504593|Malaria rapid diagnostic test (RDT)
89530|NCT02504593|Community-based malaria diagnosis
89531|NCT02504593|Community health workers
89532|NCT02504567|Catheter Ablation
89533|NCT02504567|Radiofrequency
89534|NCT02504567|Laser
89535|NCT02504567|Atrial Fibrillation
89536|NCT02504554|children
89537|NCT02504541|Hypogonadism
89538|NCT02504541|Testosterone enanthate
89539|NCT02504528|asthma
89540|NCT02504528|allergy
89541|NCT02504528|bronchial hyperresponsiveness
89542|NCT02504528|provocation
89543|NCT02504502|Whole Genome Sequencing
89544|NCT02504502|Laboratory Report
89545|NCT02504502|Patient Centered
89546|NCT02504502|Communication of Results
89547|NCT02504502|Patient Provider Communication
89548|NCT02504476|Schizophrenia or Schizoaffective Disorder
89549|NCT02504463|Alkermes
89550|NCT02504463|Samidorphan
89551|NCT02504463|ALKS 33
89552|NCT02504463|Healthy Volunteer
89553|NCT02504463|Pharmacokinetics
89554|NCT02504450|Bipolar 1 disorder
89555|NCT02504450|schizophrenia
89556|NCT02504424|Tissue Expansion
89557|NCT02504424|Tissue Expander
89558|NCT02504424|Breast Tissue Expansion
89559|NCT02504424|Breast Tissue Expander
89560|NCT02504424|Breast Reconstruction
89561|NCT02504424|2 Stage Breast Reconstruction
89562|NCT02504372|NSCLC
89563|NCT02504372|PDL1
89564|NCT02504372|PD-L1
89565|NCT02504372|PDL
89566|NCT02504359|BEAM
89567|NCT02504359|allogeneic
89568|NCT02504359|myeloma
89569|NCT02504359|ixazomib
89570|NCT02504359|transplant
89571|NCT02504359|plasma cell leukemia
89572|NCT02504333|metastatic pancreatic adenocarcinoma
89573|NCT02504333|Nab-paclitaxel
89574|NCT02504333|Gemcitabine
89575|NCT02504333|modified FOLFOX
89576|NCT02504320|Drug therapy
89577|NCT02504255|Crohn disease
89578|NCT02504255|inflammatory biomarkers
89579|NCT02504255|immunologic markers
89580|NCT02504255|calprotectin
89581|NCT02504216|Rivaroxaban
89582|NCT02504216|Xarelto
89583|NCT02504216|Aspirin
89584|NCT02504216|Acetylic salicylic acid
89585|NCT02504216|Anticoagulant
89586|NCT02504216|Peripheral artery disease
89587|NCT02504216|Peripheral arterial disease
89588|NCT02504216|Revascularization
89589|NCT02504216|Acute limb ischemia
89590|NCT02504216|Amputation
89591|NCT02504216|Cardiovascular events
89592|NCT02504190|Lymphoma
89593|NCT02504190|TEAM conditioning
89594|NCT02504190|autologous stem cells transplantation
89595|NCT02504164|midazolam
89596|NCT02504164|satisfaction
89597|NCT02504164|endoscopic submucosal dissection
89598|NCT02504099|Chronic Hepatitis C Infection
89599|NCT02504099|Early Stage Hepatocellular Carcinoma
89600|NCT02504073|Clinical Reasoning
89601|NCT02504073|Physiotherapists
89602|NCT02504060|diarrhea
89603|NCT02504060|abdominal pain
89604|NCT02504047|Hematopoietic Stem Cell Transplantation
89605|NCT02504034|Portal Vein, Cavernous Transformation Of
89606|NCT02504034|Hypertension, Portal
89607|NCT02504034|Radiology, Interventional
89608|NCT02504034|Portalsystemic shunt
89609|NCT02504008|bisphosphonate
89610|NCT02504008|CRPS
89611|NCT02504008|RSD
89612|NCT02504008|non-opioid
89613|NCT02504008|CRPS-1
89614|NCT02504008|acute on chronic pain
89615|NCT02504008|chronic pain
89616|NCT02504008|zoledronic acid
89617|NCT02503969|Colorectal Cancer
89618|NCT02503969|Mass Screening
89619|NCT02503969|Uptake
89620|NCT02503969|Morbidity
89621|NCT02503969|Mental Health
89622|NCT02503943|GLP-1
89623|NCT02503943|Masked hypertension
89624|NCT02503943|Lipid metabolism
89625|NCT02503917|Imaging, Ultrasound
89626|NCT02503917|Image-guided radiotherapy
89627|NCT02503917|Cancer
89628|NCT02503904|Pharmacology
89629|NCT02503904|Lidocaine
89630|NCT02503904|Epinephrine
89631|NCT02503904|Cefazolin
89632|NCT02503904|Metronidazole
89633|NCT02503904|Infection
89634|NCT02503904|prevention
89635|NCT02503904|prophylaxis
89636|NCT02503904|SSI
89637|NCT02503904|Surgery
89638|NCT02503904|Complications
89639|NCT02503865|Metabolic syndrome
89640|NCT02503865|Diabetes mellitus,
89641|NCT02503865|Hypertension
89642|NCT02503865|Overweight
89643|NCT02503865|analimentary detoxication
89644|NCT02503852|Female Pattern Baldness
89645|NCT02503852|Male Pattern Baldness
89646|NCT02503852|Genetic Alopecia
89647|NCT02503852|Androgenic Alopecia
89648|NCT02503852|Hair Loss
89649|NCT02503839|Host-modulating therapy
89650|NCT02503839|Vaccine
89651|NCT02503839|Cyclooxygenase inhibitors
89652|NCT02503813|brain death
89653|NCT02503813|apnea challenge test
89654|NCT02503787|chronic pain
89655|NCT02503787|intractable pain
89656|NCT02503787|failed back surgery syndrome
89657|NCT02503774|Solid Tumours, MEDI9447, MEDI4736, durvalumab, CD73, PD-L1
89658|NCT02503761|meropenem
89659|NCT02503761|infusion
89660|NCT02503761|late-onset sepsis
89661|NCT02503761|newborn
89662|NCT02503761|management
89663|NCT02503735|CKD
89664|NCT02503735|HCV
89665|NCT02503696|Inflammatory Bowel Disease
89666|NCT02503696|Cancer
89667|NCT02503696|Colorectal Cancer
89668|NCT02503696|Neoplasm
89669|NCT02503696|Colorectal Neoplasm
89670|NCT02503696|Intestinal Neoplasms
89671|NCT02503696|Gastrointestinal Neoplasms
89672|NCT02503696|Digestive System Neoplasms
89673|NCT02503696|Neoplasms by Site
89674|NCT02503696|Neoplasms
89675|NCT02503696|Digestive System Diseases
89676|NCT02503696|Gastrointestinal Diseases
89677|NCT02503696|Colonic Diseases
89678|NCT02503696|Intestinal Diseases
89679|NCT02503696|Rectal Diseases
89680|NCT02503683|RNAi therapeutic
89681|NCT02503683|AAT
89682|NCT02503683|Alpha-1 Antitrypsin Deficiency
89683|NCT02503657|tipelukast
89684|NCT02503657|IPF
89685|NCT02503657|fibrosis
89686|NCT02503657|Idiopathic Pulmonary Fibrosis
89687|NCT02503644|diffuse cutaneous systemic sclerosis
89688|NCT02503644|scleroderma
89689|NCT02503644|IVA337
89690|NCT02503644|dcSSc
89691|NCT02503631|Cancer
89692|NCT02503631|Colorectal Cancer
89693|NCT02503631|Neoplasm
89694|NCT02503631|Colorectal Neoplasm
89695|NCT02503631|Intestinal Neoplasms
89696|NCT02503631|Gastrointestinal Neoplasms
89697|NCT02503631|Digestive System Neoplasms
89698|NCT02503631|Neoplasms by Site
89699|NCT02503631|Neoplasms
89700|NCT02503631|Digestive System Diseases
89701|NCT02503631|Gastrointestinal Diseases
89702|NCT02503631|Colonic Diseases
89703|NCT02503631|Intestinal Diseases
89704|NCT02503631|Rectal Diseases
89705|NCT02503605|Biosimilar
89706|NCT02503605|ovarian stimulation
89707|NCT02503605|oocyte donor
89708|NCT02503579|Brain-derived neurotropic factor
89709|NCT02503579|Executive function
89710|NCT02503566|CAV
89711|NCT02503566|OCT
89712|NCT02503566|heart rate
89713|NCT02503566|antibodies
89714|NCT02503553|option grid
89715|NCT02503553|neurosurgery
89716|NCT02503553|cerebral aneurysm
89717|NCT02503540|macular edema
89718|NCT02503540|rvo
89719|NCT02503540|diabetic macular edema
89720|NCT02503527|Enteral nutrition
89721|NCT02503527|Tube feeding
89722|NCT02503527|Diet, carbohydrate-restricted
89723|NCT02503527|Diabetes
89724|NCT02503527|Aneurysmal Subarachnoid Hemorrhage
89725|NCT02503527|Blood glucose
89726|NCT02503527|Insulin
89727|NCT02503501|Memory
89728|NCT02503501|Insulin glulisine
89729|NCT02503501|Alzheimer's disease
89730|NCT02503501|Mild Cognitive Impairment
89731|NCT02503501|Intranasal insulin
89732|NCT02503501|Cognition Disorders
89733|NCT02503488|Appetitive Aggression
89734|NCT02503462|HIV
89735|NCT02503462|darunavir
89736|NCT02503462|ritonavir
89737|NCT02503462|cobicistat
89738|NCT02503462|CSF
89739|NCT02503462|pharmacokinetics
89740|NCT02503449|Pulmonary Cryptococcosis
89741|NCT02503436|Ovarian Cancer, Fallopian Tube Cancer, primary peritoneal cancer, BRCA1 Gene, BRCA2 Gene
89742|NCT02503410|back
89743|NCT02503410|pain
89744|NCT02503345|Kidney Stones
89745|NCT02503345|Nephrolithiasis
89746|NCT02503345|Urine Oxalate
89747|NCT02503345|Hyperoxaluria
89748|NCT02503345|Enteric Hyperoxaluria
89749|NCT02503345|Idiopathic Hyperoxaluria
89750|NCT02503345|Urological Diseases
89751|NCT02503345|Kidney Diseases
89752|NCT02503345|Dietary Oxalate
89753|NCT02503280|Cardiovascular
89754|NCT02503280|Secondary
89755|NCT02503267|antithrombin III deficiency
89756|NCT02503267|congenital heart diseases
89757|NCT02503254|Smoking
89758|NCT02503254|Modified risk tobacco product
89759|NCT02503254|Conventional cigarette
89760|NCT02503254|Reduced exposure
89761|NCT02503254|Confinement
89762|NCT02503254|Carbon Heated Tobacco Product
89763|NCT02503215|Hemodialysis
89764|NCT02503215|Obstructive sleep apnea
89765|NCT02503215|Compression stockings
89766|NCT02503189|Dry eye syndromes
89767|NCT02503189|Corneal diseases
89768|NCT02503189|Conjunctival diseases
89769|NCT02502487|Analgesia
89770|NCT02502487|Cystoscopy
89771|NCT02502487|Dorsal nerve of penis
89772|NCT02502487|Nerve block
89773|NCT02502487|Ropivacaine
89774|NCT02502474|staphylococcus aureus
89775|NCT02502474|digestive carriage
89776|NCT02502474|mucosal colonization
89777|NCT02502448|rotational thromboelastometry
89778|NCT02502448|cardiac surgery
89779|NCT02502448|acute normovolemic hemodilution
89780|NCT02502422|Laryngeal mask airway
89781|NCT02502409|Hemophilia B
89782|NCT02502409|Hemophilia B with Inhibitors
89783|NCT02502396|Cancer
89784|NCT02502396|Deep-vein thrombosis of the lower and upper extremities
89785|NCT02502396|Pulmonary embolism
89786|NCT02502396|Non-valvular atrial fibrillation
89787|NCT02502396|Chart review
89788|NCT02502396|VTE
89789|NCT02502396|NVAF
89790|NCT02502396|Rivaroxaban
89791|NCT02502383|Adolescent
89792|NCT02502383|Overweight
89793|NCT02502383|Obesity
89794|NCT02502383|Weight loss
89795|NCT02502383|Nutrition
89796|NCT02502383|Physical Activity
89797|NCT02502383|School-based
89798|NCT02502383|Primary care
89799|NCT02502383|Motivational Interviewing
89800|NCT02502357|pain control
89801|NCT02502357|healing statements
89802|NCT02502357|pelvic prolapse
89803|NCT02502344|insulin resistance
89804|NCT02502344|abnormal glucose tolerance
89805|NCT02502344|DM prevention
89806|NCT02502331|Oral Cholera Vaccine
89807|NCT02502331|immunogenicity
89808|NCT02502331|safety
89809|NCT02502318|Proven or suspected lung cancer treated by lobectomy
89810|NCT02502305|health literacy
89811|NCT02502305|attitude
89812|NCT02502305|motivation
89813|NCT02502292|Health Literacy
89814|NCT02502292|Health Ageing
89815|NCT02502292|Health Literacy Interventions
89816|NCT02502292|IROHLA
89817|NCT02502292|Photo Novel Study
89818|NCT02503176|Dry eye syndromes
89819|NCT02503176|Corneal diseases
89820|NCT02503176|Conjunctival diseases
89821|NCT02503163|Dry eye syndromes
89822|NCT02503163|Corneal diseases
89823|NCT02503163|Conjunctival diseases
89824|NCT02503150|Colorectal Cancer
89825|NCT02503150|Tumor Therapeutic Vaccine
89826|NCT02503150|Dendritic Cell
89827|NCT02503137|male pattern baldness
89828|NCT02503137|SM04554
89829|NCT02503137|AGA
89830|NCT02503111|Men who have sex with men
89831|NCT02503111|Human immunodeficiency virus
89832|NCT02503111|Human papillomavirus
89833|NCT02503111|Anal intraepithelial neoplasia
89834|NCT02503111|Squamous cell carcinoma
89835|NCT02503111|High-resolution anoscopy
89836|NCT02503111|Anal cancer
89837|NCT02503111|High-risk oncogenic
89838|NCT02503111|Intraepithelial lesion
89839|NCT02503111|Low-risk non-oncogenic
89840|NCT02503111|Dysplasia
89841|NCT02503111|High-grade squamous intraepithelial lesion
89842|NCT02503111|Low-grade squamous intraepithelial lesion
89843|NCT02503111|Ablative therapy
89844|NCT02503111|Electrocautery
89845|NCT02503111|Infrared coagulation
89846|NCT02503111|Active surveillance
89847|NCT02503098|Eating Disorders
89848|NCT02503098|Cognitive Behavioral Therapy
89849|NCT02503098|Mobile Phone
89850|NCT02503098|Smartphone
89851|NCT02503098|App
89852|NCT02503098|Binge Eating Disorder
89853|NCT02503098|Bulimia Nervosa
89854|NCT02503098|Signal Detection Analysis
89855|NCT02503072|ARV adherence
89856|NCT02503020|Arachidonic acid
89857|NCT02503020|Omega-6/omega-3 ratio
89858|NCT02503020|Preterm infants nutrition
89859|NCT02502981|CKD
89860|NCT02502981|left ventricle
89861|NCT02502981|aldosterone
89862|NCT02502981|spironolactone
89863|NCT02502955|Quality Control
89864|NCT02502955|Cardiosurgery
89865|NCT02502955|Cardiology
89866|NCT02502955|Vascular Surgery
89867|NCT02502955|ICU
89868|NCT02502942|Obstructive Sleep Apnea
89869|NCT02502942|Exercise
89870|NCT02502942|Upper airway muscle
89871|NCT02502929|Diabetes
89872|NCT02502929|Depression
89873|NCT02502929|Medication therapy management
89874|NCT02502929|Community health workers
89875|NCT02502929|Cambodian
89876|NCT02502929|Refugee
89877|NCT02502929|Prevention
89878|NCT02502890|asthma
89879|NCT02502890|nested case-control study
89880|NCT02502890|difficult-to-control asthma
89881|NCT02502890|asthma exacerbations
89882|NCT02502890|cold symptoms
89883|NCT02502890|gene expression
89884|NCT02502838|overactive bladder
89885|NCT02502838|pelvic organ prolapse
89886|NCT02502838|TVT
89887|NCT02502812|bioequivalence
89888|NCT02502812|SB224326
89889|NCT02502812|clopidogrel
89890|NCT02502812|Relative bioavailability
89891|NCT02502786|Humanized Monoclonal Antibody 3F8 (Hu3F8)
89892|NCT02502786|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
89893|NCT02502786|15-096
89894|NCT02502773|Goal-directed therapy
89895|NCT02502773|Fluid loading
89896|NCT02502773|Abdominal surgery
89897|NCT02502773|Postoperative morbidity
89898|NCT02502773|Postoperative mortality
89899|NCT02502773|Individualized goal-directed fluid therapy
89900|NCT02502773|Elective or emergency abdominal surgery
89901|NCT02502773|General Anesthesia
89902|NCT02502773|Moderate-to-high risk surgical patients
89903|NCT02502760|Postoperative Complications
89904|NCT02502760|Perioperative Care
89905|NCT02502760|Colorectal Surgery
89906|NCT02502760|Frail Elderly
89907|NCT02502734|inhaled corticosteroids
89908|NCT02502734|pediatric subjects
89909|NCT02502734|asthma
89910|NCT02502734|fluticasone furoate
89911|NCT02502721|Male
89912|NCT02502708|glioblastoma multiforme
89913|NCT02502708|glioma
89914|NCT02502708|gliosarcoma
89915|NCT02502708|malignant brain tumor
89916|NCT02502708|ependymoma
89917|NCT02502708|medulloblastoma
89918|NCT02502695|VATS Lobectomy and Segmentectomy for Lung Cancer
89919|NCT02502695|Lung Cancer
89920|NCT02502682|Chlorhexidine bathing
89921|NCT02502669|acne
89922|NCT02502669|nodulocystic
89923|NCT02502669|finasteride
89924|NCT02502669|5 alpha reductase inhibitor
89925|NCT02502656|RAS mutation
89926|NCT02502656|DNA
89927|NCT02502656|Colorectal Cancer
89928|NCT02502643|Safety and Efficacy
89929|NCT02502643|Thoracic Surgery
89930|NCT02502617|Psychopathology
89931|NCT02502617|Cognition
89932|NCT02502617|Depression
89933|NCT02502617|Nutrition
89934|NCT02502617|Cortisol
89935|NCT02502617|Anorexia nervosa
89936|NCT02502604|Cognitive Remediation
89937|NCT02502604|Goal Management Training
89938|NCT02502604|Major Depressive Disorder
89939|NCT02502604|Post-traumatic Stress Disorder
89940|NCT02502604|Neuropsychological Functioning
89941|NCT02502578|Triglyceride Deposit Cardiomyovasculopathy
89942|NCT02502552|Crohn's Disease
89943|NCT02502552|Ulcerative Colitis
89944|NCT02502552|Inflammatory Bowel Disease
89945|NCT02502552|anti-glycan antibodies
89946|NCT02502552|antibodies stability
89947|NCT02502552|mucosal healing
89948|NCT02502552|predictive markers
89949|NCT02502539|Juvenile idiopathic arthritis
89950|NCT02502539|Physical exercise
89951|NCT02502539|Pro-anti-inflammatory balance
89952|NCT02502539|Interleukins
89953|NCT02502539|miRNA
89954|NCT02502539|Calgranulins
89955|NCT02502240|ALK
89956|NCT02502240|Latin American
89957|NCT02502227|mindfulness
89958|NCT02502227|psychological stress
89959|NCT02502227|wellness programs
89960|NCT02502227|cortisol
89961|NCT02502214|Preimplantation Genetic Diagnosis
89962|NCT02502214|PGD
89963|NCT02502214|Next-Generation Sequencing
89964|NCT02502214|NGS
89965|NCT02502214|Single-Gene disorders
89966|NCT02502214|Cystic Fibrosis
89967|NCT02502214|CFTR
89968|NCT02502214|Single-cell analysis
89969|NCT02502214|PCR
89970|NCT02502214|SNP
89971|NCT02502214|Whole Genome Amplification
89972|NCT02502201|six-minute walk
89973|NCT02502188|Healthy Subjects
89974|NCT02502188|Severe Plaque Psoriasis
89975|NCT02502188|Moderate
89976|NCT02502188|Phase 1
89977|NCT02502188|Safety
89978|NCT02502188|Tolerability
89979|NCT02502188|CC-90005
89980|NCT02502175|Opium tincture
89981|NCT02502175|opium
89982|NCT02502175|methadone
89983|NCT02502175|opioid dependence
89984|NCT02502175|opiate dependence
89985|NCT02502175|clinical trial
89986|NCT02502175|Iran
89987|NCT02502149|rFVIIIFc
89988|NCT02502149|Eloctate
89989|NCT02502149|Hemophilia
89990|NCT02502136|CO2 insufflation
89991|NCT02502110|Atrial Fibrillation
89992|NCT02502110|statin
89993|NCT02502110|radiofrequency ablation
89994|NCT02502006|Non-steroidal Anti-inflammatory Drugs
89995|NCT02502006|Healthy volunteers
89996|NCT02502006|Celecoxib
89997|NCT02502006|Naproxen
89998|NCT02502006|Prostaglandin
89999|NCT02502006|Cyclooxygenase
90000|NCT02501980|Screening
90001|NCT02501980|Hepatocellular Cancer
90002|NCT02501980|Biomarker
90003|NCT02501980|Mortality rate
90004|NCT02501967|multiple chronic conditions
90005|NCT02501941|Ketamine
90006|NCT02501941|Cortical Spreading Depolarization
90007|NCT02501941|Cortical Spreading Depression
90008|NCT02501928|neurogenic detrusor overactivity
90009|NCT02501928|fesoterodine
90010|NCT02501928|Japan
90011|NCT02501915|Muscle
90012|NCT02501902|Ibrance, palbociclib, Abraxane, nab-paclitaxel, pancreas,
90013|NCT02501889|obesity
90014|NCT02501889|overweight
90015|NCT02501889|weight loss
90016|NCT02501889|satiety
90017|NCT02501889|walnuts
90018|NCT02501889|gastrointestinal peptides
90019|NCT02501876|The risk of progession
90020|NCT02501876|patients
90021|NCT02501850|Lipoprotein (a)
90022|NCT02501837|Healthy women
90023|NCT02501811|Heart Failure
90024|NCT02501811|Ischemia
90025|NCT02501811|Autologous Stem Cells
90026|NCT02501811|LV dysfunction
90027|NCT02501811|Mesenchymal Stem Cells
90028|NCT02501811|ckit Cardiac Stem Cells
90029|NCT02501811|Combination Cell Therapy
90030|NCT02501811|LV function
90031|NCT02501811|Functional status
90032|NCT02501798|ADHD
90033|NCT02501798|Methylphenidate
90034|NCT02501798|Academic
90035|NCT02501798|Motivation
90036|NCT02501785|Quality of Life
90037|NCT02501785|Patient care givers
90038|NCT02501785|15-145
90039|NCT02501785|Ambulatory Extended Recovery
90040|NCT02501746|Group medical care
90041|NCT02501746|Microfinance
90042|NCT02501746|Hypertension
90043|NCT02501746|Community-based intervention
90044|NCT02501746|Global health
90045|NCT02501733|Total Knee Replacement
90046|NCT02501733|Total Knee Arthroplasty
90047|NCT02501720|burn
90048|NCT02501720|hand
90049|NCT02501720|flexion contracture
90050|NCT02501720|tourniquet
90051|NCT02501720|tumescent technique
90052|NCT02501720|children
90053|NCT02501707|echocardiography
90054|NCT02501707|radiation-induced lung injury
90055|NCT02501707|prognostic
90056|NCT02501707|chemo radiotherapy
90057|NCT02501707|non-small cell lung cancer
90058|NCT02501707|NSCLC
90059|NCT02501681|sublingual microcirculation
90060|NCT02501681|cardiovascular surgery
90061|NCT02501616|SGLT2 inhibitor
90062|NCT02501564|Osteoarthritis
90063|NCT02501564|NAPROXEN SODIUM
90064|NCT02501551|Malignant melanoma
90065|NCT02501551|C-KIT mutation
90066|NCT02501525|renal stone
90067|NCT02501525|retrograde intrarenal surgery
90068|NCT02501525|ureteral access sheath
90069|NCT02501525|pain
90070|NCT02501512|transesophageal signal
90071|NCT02501512|swallowing
90072|NCT02501512|newborn
90073|NCT02501486|adrenal insufficiency
90074|NCT02501486|adverse drug reaction
90075|NCT02501486|corticosteroid
90076|NCT02501473|follicular lymphoma
90077|NCT02501473|fNHL
90078|NCT02501473|low-grade lymphoma
90079|NCT02501473|Non-Hodgkin's Lymphoma
90080|NCT02501473|follicular NHL
90081|NCT02501473|Marginal Zone
90082|NCT02501460|Adult cancer survivors
90083|NCT02501460|Exercise
90084|NCT02501460|Dietary supplementation
90085|NCT02501434|aneurysmal subarachnoid hemorrhage
90086|NCT02501434|unfractionated heparin
90087|NCT02501434|neurobehavioral manifestations
90088|NCT02501434|delayed ischemic neurological deficits
90089|NCT02501434|cerebral aneurysm
90090|NCT02501434|coil embolization
90091|NCT02501434|Montreal Cognitive Assessment
90092|NCT02501421|vaccine
90093|NCT02501421|influenza vector
90094|NCT02501421|tuberculosis
90095|NCT02501382|Fasciitis
90096|NCT02501382|Fasciitis, Necrotizing
90097|NCT02501382|Soft tissue infections
90098|NCT02501382|Fournier's gangrene
90099|NCT02501382|Immunopathogenesis
90100|NCT02501356|prebiotic
90101|NCT02501356|dietary supplement
90102|NCT02501343|Alkaline diet
90103|NCT02501343|Insulin resistance
90104|NCT02501343|Potential renal acid load
90105|NCT02501343|Diet induced metabolic acidosis
90106|NCT02501343|Obesity
90107|NCT02501330|Drug use investigation in Japan
90108|NCT02501317|urinary incontinence
90109|NCT02501317|physical therapy
90110|NCT02501317|rehabilitation
90111|NCT02501317|pelvic floor
90112|NCT02501317|perineum
90113|NCT02501317|conservative treatment
90114|NCT02501265|Nicotine addiction
90115|NCT02501265|Cigarette smoking
90116|NCT02501252|Community
90117|NCT02501252|Skilled birth attendance
90118|NCT02501252|Rural
90119|NCT02501252|Ethiopia
90120|NCT02501226|Psychiatry
90121|NCT02501226|Depression
90122|NCT02501226|Psychoeducation
90123|NCT02501226|Randomized controlled trial
90124|NCT02501226|Treatment adherence
90125|NCT02501226|Remission
90126|NCT02501213|Diuretic
90127|NCT02501213|Malignant ascites
90128|NCT02501200|Dyslipidemia
90129|NCT02501200|CKD-391
90130|NCT02501200|Atorvastatin
90131|NCT02501200|Ezetimibe
90132|NCT02501174|Geriatric oncology
90133|NCT02501135|Femoral nerve blocks
90134|NCT02501135|children
90135|NCT02501135|knee and thigh surgery
90136|NCT02501122|Quality
90137|NCT02501122|hospital care
90138|NCT02501122|adenotonsillectomy
90139|NCT02501109|Aripiprazole
90140|NCT02501109|Oral Soluble Film
90141|NCT02501109|Schizophrenia
90142|NCT02501096|Lenvatinib
90143|NCT02501096|Lenvima
90144|NCT02501096|E7080
90145|NCT02501096|Phase 1b/2
90146|NCT02501096|Pembrolizumab
90147|NCT02501096|Solid tumors
90148|NCT02501083|cardiomyopathy
90149|NCT02501083|echocardiography
90150|NCT02501083|prognosis
90151|NCT02501083|respiratory
90152|NCT02501083|home mechanical ventilation
90153|NCT02501083|vital capacity
90154|NCT02501083|maximal inspiratory pressure
90155|NCT02501083|maximal expiratory pressure
90156|NCT02501070|Percutaneous Coronary Intervention
90157|NCT02501070|Angioplasty
90158|NCT02501070|Stent
90159|NCT02501070|Community Networks
90160|NCT02501057|Human Immunodeficiency Virus
90161|NCT02501057|Unsafe Drinking
90162|NCT02501057|Antiretroviral Therapy (ART)
90163|NCT02501031|Flaxseed
90164|NCT02501031|Postmenopause
90165|NCT02501031|Hormones
90166|NCT02501031|Lignans
90167|NCT02501031|No Evidence of Disease
90168|NCT02501018|CLI
90169|NCT02500979|Type 1 Diabetes Mellitus; Pramlintide
90170|NCT02500966|Cervical Intraepithelial Neoplasia
90171|NCT02500966|stenosis
90172|NCT02500966|cervix
90173|NCT02500966|medical device
90174|NCT02500966|inventories
90175|NCT02500966|Uterine Cervix
90176|NCT02500966|Intrauterine Devices
90177|NCT02500966|intrauterine
90178|NCT02500966|conization
90179|NCT02500966|loop electrosurgical excision
90180|NCT02500953|ASP3325
90181|NCT02500953|pharmacokinetics
90182|NCT02500953|pharmacodynamics
90183|NCT02500927|ASP8273
90184|NCT02500927|Non-Small Cell Lung Cancer
90185|NCT02500927|EGFR Tyrosine Kinase Inhibitor
90186|NCT02500927|EGFR Mutation
90187|NCT02500914|small cell lung cancer
90188|NCT02500914|large cell neuroendocrine carcinoma
90189|NCT02500901|Enzalutamide
90190|NCT02500901|Niraparib
90191|NCT02500901|PARP-1 inhibitor
90192|NCT02500901|PARP-2 inhibitor
90193|NCT02500901|Castrate-Resistant Prostate Cancer
90194|NCT02500888|OCD
90195|NCT02500888|Neurosurgery
90196|NCT02500888|Radiosurgery
90197|NCT02500875|Negative-Pressure Wound Therapy
90198|NCT02500875|Topical Negative Pressure Therapy
90199|NCT02500875|Sodium Hypochlorite
90200|NCT02500862|Eye
90201|NCT02500862|Imaging
90202|NCT02500849|Gene therapy
90203|NCT02500849|Acquired Immunodeficiency Syndrome
90204|NCT02500849|HIV Infections
90205|NCT02500849|Retroviridae Infections
90206|NCT02500849|RNA Virus Infections
90207|NCT02500849|Virus Diseases
90208|NCT02500849|Sexually Transmitted Diseases, Viral
90209|NCT02500849|Sexually Transmitted Diseases
90210|NCT02500849|Immunologic Deficiency Syndromes
90211|NCT02500849|Immune System Diseases
90212|NCT02500849|Busulfan
90213|NCT02500849|Pharmacologic Actions
90214|NCT02500836|Ear
90215|NCT02500836|Nose
90216|NCT02500836|Throat
90217|NCT02500823|Mitochondrial DNA copy number
90218|NCT02500823|Peripheral blood cells
90219|NCT02500810|neurotoxicity
90220|NCT02500810|chemotherapy
90221|NCT02500810|monosialoganglioside
90222|NCT02500810|prevention
90223|NCT02500758|Surgical scrubbing
90224|NCT02500758|Chlorhexidine digluconate
90225|NCT02500758|Parachlorometaxylenol
90226|NCT02500719|Posttraumatic Stress Disorder
90227|NCT02500719|Neurofeedback
90228|NCT02500719|fMRI
90229|NCT02500719|Skin Conductance Response
90230|NCT02500693|Lung Cancer, Screening, COPD
90231|NCT02500680|Influenza
90232|NCT02500680|Adjuvant
90233|NCT02500667|N91115
90234|NCT02500667|Rifampin
90235|NCT02500667|drug interaction
90236|NCT02500667|Cavosonstat
90237|NCT02500654|Peri-implantitis
90238|NCT02500654|Regenerative therapy
90239|NCT02500654|Surgical therapy
90240|NCT02500654|Enamel matrix derivative
90241|NCT02500654|Peri-implant microflora
90242|NCT02500654|Peri-implant fluid
90243|NCT02500641|Biological Markers
90244|NCT02500641|Cardiovascular disease
90245|NCT02500641|Humans
90246|NCT02500641|Pulse Wave Velocity
90247|NCT02500641|Cardiovascular risk factors
90248|NCT02500641|Allopurinol
90249|NCT02500641|Pulse Wave Analysis
90250|NCT02500641|Thiazoles
90251|NCT02500641|Inflammation
90252|NCT02500641|Uric acid
90253|NCT02500641|Febuxostat
90254|NCT02500641|Oxidative stress
90255|NCT02500641|Tumor Necrosis Factor
90256|NCT02500641|Arthritis
90257|NCT02500641|Hyperuricemia
90258|NCT02500628|metformin
90259|NCT02500628|mitochondria
90260|NCT02500628|complex 1
90261|NCT02500628|fibromyalgia
90262|NCT02500628|neurogenic pain
90263|NCT02500628|diabetes
90264|NCT02500628|tardive dyskinesia
90265|NCT02500628|heart rate variability
90266|NCT02500602|PTSD
90267|NCT02500602|alcohol use disorders
90268|NCT02500602|posttraumatic stress disorder
90269|NCT02500602|AUD
90270|NCT02500602|Veteran
90271|NCT02500589|smoking
90272|NCT02500589|tobacco
90273|NCT02500576|Melanoma
90274|NCT02500576|Metastatic
90275|NCT02500576|Cyclophosphamide
90276|NCT02500576|Cytoxan
90277|NCT02500576|Neosar
90278|NCT02500576|Mesna
90279|NCT02500576|Mesnex
90280|NCT02500576|Fludarabine
90281|NCT02500576|Fludarabine phosphate
90282|NCT02500576|MK-3475
90283|NCT02500576|Keytruda
90284|NCT02500576|Pembrolizumab
90285|NCT02500576|SCH-900475
90286|NCT02500576|IL-2
90287|NCT02500576|Aldesleukin
90288|NCT02500576|Interleukin-2
90289|NCT02500576|Proleukin
90290|NCT02500576|TIL
90291|NCT02500576|T-cells
90292|NCT02500576|Questionnaires
90293|NCT02500576|Surveys
90294|NCT02500576|Phone calls
90295|NCT02500550|Haploidentical stem cell transplantation
90296|NCT02500550|Graft versus host disease
90297|NCT02500550|Immune reconstitution
90298|NCT02500550|Alloreactive T-cells
90299|NCT02500550|Photodynamic treatment
90300|NCT02500550|Hematologic malignancy
90301|NCT02500550|Transplant-related mortality
90302|NCT02500485|SHR3824 SP2086 drug-drug interaction
90303|NCT02500472|Tobacco
90304|NCT02500472|Smoking
90305|NCT02500459|Topotecan
90306|NCT02500459|Cleveland Multiport Catheter
90307|NCT02500459|Cancer
90308|NCT02500433|Cerebral palsy
90309|NCT02500433|child
90310|NCT02500433|rehabilitation
90311|NCT02500433|video games
90312|NCT02500433|virtual reality.
90313|NCT02500420|Hypertrophic cardiomyopathy
90314|NCT02500420|Stress MRI
90315|NCT02500420|Cardiac MRI
90316|NCT02500420|Stress echocardiography
90317|NCT02500420|T1 mapping
90318|NCT02500420|2D strain
90319|NCT02500394|renal replacement therapy
90320|NCT02500342|Thyroid Dysfunction
90321|NCT02500342|Fatigue
90322|NCT02500342|Randomized Controlled Trial
90323|NCT02500342|Thyroxine
90324|NCT02500342|Hypothyroidism
90325|NCT02500316|Growth hormone deficiency (GHD)
90326|NCT02500316|r-hGH
90327|NCT02500316|Long-acting
90328|NCT02500303|Amputation
90329|NCT02500290|ACS
90330|NCT02500277|thoracoscopy
90331|NCT02500277|pleuroscopy
90332|NCT02500277|semirigid thoracoscopy
90333|NCT02500277|flexible cryoprobe
90334|NCT02500277|cryobiopsy
90335|NCT02500277|pleural biopsy
90336|NCT02500251|Transplantation
90337|NCT02500251|belimumab
90338|NCT02500251|Velcade
90339|NCT02500225|Etomidate
90340|NCT02500225|Sevoflurane
90341|NCT02500199|HER2 positive
90342|NCT02500173|radiotherapy
90343|NCT02500173|side effects
90344|NCT02500147|Polycystic Ovary Syndrome
90345|NCT02500147|Non-Alcoholic Fatty Liver Disease
90346|NCT02500147|Adolescents
90347|NCT02500147|Young Women
90348|NCT02500147|MRI
90349|NCT02500147|MRS
90350|NCT02500147|DXA
90351|NCT02500147|PNPLA3
90352|NCT02500147|Metformin
90353|NCT02500147|Randomized Clinical Trial
90354|NCT02500147|Placebo
90355|NCT02500147|Hirsutism
90356|NCT02500147|Acne
90357|NCT02500147|Amenorrhea
90358|NCT02500147|Metabolic Syndrome
90359|NCT02500147|Dyslipidemia
90360|NCT02500147|Percentage liver fat
90361|NCT02500121|Pembrolizumab
90362|NCT02500121|PD-1 Inhibitor
90363|NCT02500108|Domperidone
90364|NCT02500108|Ventricular Tachyarrhythmia
90365|NCT02500108|Sudden cardiac death
90366|NCT02500108|Pharmacotherapy
90367|NCT02500108|Adverse events
90368|NCT02500082|citrate transporter deficiency
90369|NCT02500082|SLC13A5 gene
90370|NCT02500082|citric acid cycle
90371|NCT02500082|energy metabolism
90372|NCT02500043|Gastric Cancer
90373|NCT02500043|Metastatic Gastric Cancer
90374|NCT02499965|Topical Anesthetic
90375|NCT02499965|Ethyl Chloride
90376|NCT02499965|Pain Reduction
90377|NCT02499965|IV cannulation
90378|NCT02499952|Pembrolizumab
90379|NCT02499952|MK-3475
90380|NCT02499952|PMNSGCT
90381|NCT02499952|PD-L1
90382|NCT02499952|Non Seminomatous Germ Cell Tumors
90383|NCT02499848|MRI Lesion
90384|NCT02499848|transperineal injection
90385|NCT02499848|prostate biopsies
90386|NCT02499822|Hypertension
90387|NCT02499822|Blood pressure variability
90388|NCT02499822|Home systolic blood pressure
90389|NCT02499822|Organ damage
90390|NCT02499822|Nifedipine GITS
90391|NCT02499822|Ramipril
90392|NCT02499809|Vibration therapy
90393|NCT02499809|Recovery from exercise
90394|NCT02499796|Invasive mechanical ventilation
90395|NCT02499796|Humidifying devices
90396|NCT02499796|Respiratory mechanics
90397|NCT02499783|Biologic
90398|NCT02499783|China
90399|NCT02499783|Tumor necrosis factor (TNF)-alpha
90400|NCT02499770|Small Cell Lung Cancer
90401|NCT02499770|CDK 4/6 Inhibitor
90402|NCT02499757|Perception
90403|NCT02499757|brain response
90404|NCT02499757|nicotine
90405|NCT02499757|taste
90406|NCT02499744|NIPPV
90407|NCT02499744|HHFNC
90408|NCT02499744|RDS
90409|NCT02499744|neonate
90410|NCT02499731|physical activity
90411|NCT02499731|nutrition
90412|NCT02499731|social network
90413|NCT02499718|Chronic Obstructive Pulmonary Disease
90414|NCT02499718|Non-invasive positive pressure ventilation
90415|NCT02499718|quality of life
90416|NCT02499718|long-term oxygen therapy
90417|NCT02499666|Exercise Capacity
90418|NCT02499666|Chronic Total Occlusion
90419|NCT02499653|Chronic Obstructive Pulmonary Disease (COPD)
90420|NCT02499653|Non Invasive Ventilation (NIV)
90421|NCT02499653|Acceptance
90422|NCT02499653|Adherence
90423|NCT02499653|Clinical Psychology
90424|NCT02499640|Recovery of function
90425|NCT02499640|Autonomic nervous system
90426|NCT02499640|Heart rate variability
90427|NCT02499640|Cryotherapy
90428|NCT02499640|Immersion
90429|NCT02499627|Lymphoma
90430|NCT02499627|Hodgkin
90431|NCT02499627|PTCL
90432|NCT02499627|CD30+
90433|NCT02499614|MET amplification
90434|NCT02499614|ROS1 translocation
90435|NCT02499614|Crizotinib
90436|NCT02499601|Heart Failure with Preserved Ejection Fraction (HFpEF)
90437|NCT02499601|Heart Failure (HF)
90438|NCT02499601|New York Heart Association functional Class (NYHA f. Cl)
90439|NCT02499575|Exparel
90440|NCT02499575|bupivacaine
90441|NCT02499575|Hallux valgus deformity
90442|NCT02499575|bunionectomy
90443|NCT02499536|Atelectasis
90444|NCT02499536|Postoperative
90445|NCT02499536|Lung ultrasound
90446|NCT02499510|femoropopliteal disease
90447|NCT02499510|restenosis
90448|NCT02499497|Prostate Cancer
90449|NCT02499432|Evidence Based Psychotherapy
90450|NCT02499432|Implementation
90451|NCT02499432|PTSD
90452|NCT02499393|newborn
90453|NCT02499393|therapeutic hypothermia
90454|NCT02499393|magnesium sulphate
90455|NCT02499380|RePneu
90456|NCT02499380|Coil
90457|NCT02499380|LVRC
90458|NCT02499380|PneumRx
90459|NCT02499367|triple negative
90460|NCT02499367|metastatic
90461|NCT02499341|Tramadol
90462|NCT02499341|Ketamine
90463|NCT02499341|Morphine
90464|NCT02499328|Carcinoma of the Head and Neck
90465|NCT02499276|mechanical ventilation
90466|NCT02499276|pressure support ventilation
90467|NCT02499276|NAVA
90468|NCT02499276|PAV
90469|NCT02499276|variable ventilation
90470|NCT02499276|patient ventilator asynchrony
90471|NCT02499263|Adalimumab trough level
90472|NCT02499263|Fecal Calprotectin
90473|NCT02499263|Fecal microbiota
90474|NCT02499250|refractory angina pectoris
90475|NCT02499250|remote ischemic conditioning
90476|NCT02499250|life quality
90477|NCT02499250|anxiety
90478|NCT02499250|depression
90479|NCT02499250|inflammation
90480|NCT02499237|osteoporosis
90481|NCT02499237|denosumab
90482|NCT02499237|zoledronic acid
90483|NCT02499237|bone mineral density
90484|NCT02499237|bone markers
90485|NCT02499211|obesity
90486|NCT02499211|health disparities
90487|NCT02499211|healthy food marketing
90488|NCT02499211|food environments
90489|NCT02499211|marketing environments
90490|NCT02499211|food access
90491|NCT02499211|food purchase decision making
90492|NCT02499198|Nornicotine
90493|NCT02499198|Tobacco
90494|NCT02499198|N'-nitrosonornicotine
90495|NCT02499198|NNN
90496|NCT02499185|Biomarker
90497|NCT02499185|Intra Abdominal Surgery
90498|NCT02499185|AKI
90499|NCT02499172|Adverse pregnancy outcome
90500|NCT02499159|Exparel
90501|NCT02499159|Thoracoscopy
90502|NCT02499159|Bupivicaine
90503|NCT02499159|Liposomal
90504|NCT02499146|Palbociclib
90505|NCT02499146|PD-0332991
90506|NCT02499146|pharmacokinetics
90507|NCT02499146|breast cancer patients
90508|NCT02499146|Chinese
90509|NCT02499120|palbociclib, cetuximab, human papillomavirus, squamous cell carcinoma, head and neck cancer
90510|NCT02499107|food intake
90511|NCT02499107|satiety
90512|NCT02499107|blood glucose
90513|NCT02499107|potato
90514|NCT02499107|insulin
90515|NCT02499081|Relapsed
90516|NCT02499081|Refractory
90517|NCT02499081|Proteasome Inhibitor
90518|NCT02499055|anxiety
90519|NCT02499055|behaviour therapy
90520|NCT02499055|computer assisted therapy
90521|NCT02499055|psychotherapy
90522|NCT02499042|post-resuscitation
90523|NCT02499042|oxygen therapy
90524|NCT02499042|out-of-hospital cardiac arrest
90525|NCT02499016|Appendicitis
90526|NCT02499016|Appendectomy
90527|NCT02499016|Single-incision
90528|NCT02499003|Diffuse large B-cell lymphoma
90529|NCT02499003|Follicular lymphoma
90530|NCT02499003|Transformed indolent lymphoma
90531|NCT02498977|Liver
90532|NCT02498977|Transplant
90533|NCT02498977|Immunosuppression
90534|NCT02498964|cardiac anesthesia simulation,NASA task load index
90535|NCT02498938|Pulmonary disease,chronic obstructive,
90536|NCT02498938|generalized chronic periodontitis
90537|NCT02498938|SERPINA1 gene polymorphism
90538|NCT02498912|T Cells
90539|NCT02498912|Cyclophosphamide
90540|NCT02498912|MUC16ecto antigen
90541|NCT02498912|Intraperitoneal Infusion
90542|NCT02498912|15-014
90543|NCT02498899|Advanced Cancers
90544|NCT02498899|Video
90545|NCT02498899|Questionnaires
90546|NCT02498899|Surveys
90547|NCT02498873|VO2Max
90548|NCT02498873|Physical Conditioning
90549|NCT02498873|Aerobic Exercise
90550|NCT02498873|Performance
90551|NCT02498860|adenocarcinoma
90552|NCT02498860|lung
90553|NCT02498860|adjuvant chemotherapy
90554|NCT02498860|pemetrexed
90555|NCT02498860|cisplatin
90556|NCT02498860|surgery
90557|NCT02498834|Communication
90558|NCT02498834|provider
90559|NCT02498834|caregiver
90560|NCT02498834|adolescent
90561|NCT02498821|PICC
90562|NCT02498821|central catheter
90563|NCT02498821|vascular access
90564|NCT02498808|Interferon lambda
90565|NCT02498808|Interleukin-29
90566|NCT02498808|Neutrophil
90567|NCT02498795|Intratissue Percutaneous Electrolysis
90568|NCT02498795|Dry needling
90569|NCT02498795|Eccentric exercise
90570|NCT02498795|Patella
90571|NCT02498782|Chagas Disease
90572|NCT02498782|Dosage forms
90573|NCT02498782|Regimens
90574|NCT02498769|Cardiac Surgery
90575|NCT02498769|Postoperative Complications
90576|NCT02498769|Autonomic Nerve Block
90577|NCT02498730|bipolar disorder
90578|NCT02498730|VO2max
90579|NCT02498730|aerobic exercise
90580|NCT02498691|endometriosis
90581|NCT02498691|preterm delivery
90582|NCT02498691|caesarean
90583|NCT02498691|Pregnancy outcomes of women with or without endometriosis
90584|NCT02498665|Wilms' Tumor 1
90585|NCT02498665|Vaccine
90586|NCT02498665|Neoplasms
90587|NCT02498639|balloon aortic valvuloplasty
90588|NCT02498639|rapid ventricular pacing
90589|NCT02498639|outcome
90590|NCT02498626|mixed venous saturation
90591|NCT02498626|open heart surgery
90592|NCT02498626|children
90593|NCT02498600|Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian
90594|NCT02498600|Primary Peritoneal or Fallopian
90595|NCT02498600|Tube Cancer
90596|NCT02498587|Severe Acute Respiratory Infection
90597|NCT02498496|COPD
90598|NCT02498496|AECOPD
90599|NCT02498496|Magnesium Sulfate
90600|NCT02498496|Acute exacerbation of COPD
90601|NCT02498496|Chronic Obstructive Pulmonary Disease
90602|NCT02498496|ED
90603|NCT02498496|ER
90604|NCT02498496|Emergency Department
90605|NCT02498483|Infant
90606|NCT02498457|maintenance hemodialysis patients
90736|NCT02497651|Smoking
90607|NCT02498457|coronary artery calcification
90608|NCT02498457|low calcium dialysate
90609|NCT02498457|effects
90610|NCT02498457|safety
90611|NCT02498444|Fontan
90612|NCT02498444|Treprostinil
90613|NCT02498444|Remodulin
90614|NCT02498444|Single ventricle
90615|NCT02498431|irisin
90616|NCT02498431|myocardial infarction
90617|NCT02498431|coronary
90618|NCT02498392|Major Depressive Disorder
90619|NCT02498392|Depression
90620|NCT02498392|Anxiety symptoms
90621|NCT02498392|JNJ-42165279
90622|NCT02498379|novel radiotracer
90623|NCT02498379|biodistribution
90624|NCT02498379|safety
90625|NCT02498340|G6PD
90626|NCT02498340|genotype
90627|NCT02498340|phenotype
90628|NCT02498340|diet restriction
90629|NCT02498327|Chronic
90630|NCT02498314|Manual therapy
90631|NCT02498314|Hip osteoarthritis
90632|NCT02498314|Mobilization
90633|NCT02498301|travelers' diarrhea
90634|NCT02498301|military
90635|NCT02498301|enteric illness
90636|NCT02498301|gastrointestinal
90637|NCT02498288|capsule
90638|NCT02498288|Isotretinoin
90639|NCT02498288|Bioequivalence
90640|NCT02498262|Severe Mobility and Manipulation Impairments
90641|NCT02498249|Low-Level Laser Therapy
90642|NCT02498249|trapezius muscle
90643|NCT02498249|neck pain
90644|NCT02498236|Psychosis
90645|NCT02498236|Schizophrenia
90646|NCT02498236|Oxytocin
90647|NCT02498210|IVM
90648|NCT02498210|HIPPO signaling
90649|NCT02498171|Labour analgesia
90650|NCT02498171|Intrathecal morphine
90651|NCT02498171|Bupivacaine
90652|NCT02498171|Fentanyl
90653|NCT02498132|Mobile Technologies
90654|NCT02498119|Type 2 DM
90655|NCT02498119|lipid bodies
90656|NCT02498106|nutrition
90657|NCT02498106|aggression
90658|NCT02498106|n-3 fatty acids
90659|NCT02498106|psychiatry
90660|NCT02498106|inpatients admitted >2 years
90661|NCT02498093|Resistance training
90662|NCT02498093|Arthroplasty, Replacement, Hip
90663|NCT02498093|Professional-Patient Relations
90664|NCT02498093|Evidence-based practice
90665|NCT02498080|Drug eluting balloons
90666|NCT02498080|Critical limb ischemia
90667|NCT02498080|Infra-popliteal arteries
90668|NCT02498080|Percutaneous transluminal angioplasty
90669|NCT02498041|Ultrathin Nasal Endoscopy
90670|NCT02498041|Barrett's Esophagus
90671|NCT02498041|Transnasal Endoscopy
90672|NCT02498028|cervical fusion
90673|NCT02498028|cervical arthroplasty
90674|NCT02498028|cervicobrachial pain
90675|NCT02498002|Diet
90676|NCT02498002|Fasting
90677|NCT02498002|Intermittent Fasting
90678|NCT02498002|Alternate-day Fasting
90679|NCT02498002|Physical Activity
90680|NCT02498002|Glucose
90681|NCT02498002|Insulin
90682|NCT02498002|Appetite
90683|NCT02497989|Male circumcision
90684|NCT02497989|Demand creation
90685|NCT02497976|Interstitial
90686|NCT02497976|Cystitis
90687|NCT02497976|Bladder
90688|NCT02497976|Pain
90689|NCT02497950|HeartMate 3
90690|NCT02497950|LVAS
90691|NCT02497950|LVAD
90692|NCT02497950|Heart-assist devices
90693|NCT02497950|Thoratec Corporation
90694|NCT02497937|GSK2798745
90695|NCT02497937|TRPV4 Channel Blocker
90696|NCT02497937|Pharmacodynamics
90697|NCT02497937|Adults
90698|NCT02497937|Congestive Heart Failure
90699|NCT02497911|Adductor Canal Catheter
90700|NCT02497911|Intraarticular Catheter
90701|NCT02497911|Arthroplasty, Replacement, Knee
90702|NCT02497885|MERS
90703|NCT02497885|healthcare personnel
90704|NCT02497859|Weight Reduction
90705|NCT02497859|Weight Loss Diet
90706|NCT02497859|Satiety Response
90707|NCT02497859|Insulin
90708|NCT02497859|Glucagon-Like Peptide 1
90709|NCT02497859|PYY (3-36) peptide
90710|NCT02497859|Ghrelin
90711|NCT02497859|Glucose
90712|NCT02497859|Eggs
90713|NCT02497859|Protein
90714|NCT02497859|Energy Intake
90715|NCT02497859|Breakfast
90716|NCT02497846|Hyaluronic acid
90717|NCT02497846|MiconJet needle
90718|NCT02497807|Tourette syndrome
90719|NCT02497807|Iron deficiency
90720|NCT02497794|chew gum
90721|NCT02497794|bowel movements
90722|NCT02497794|cesarean section
90723|NCT02497781|Complicated urinary tract infections (cUTIs)
90724|NCT02497768|mastication
90725|NCT02497768|pistachios
90726|NCT02497768|brazils
90727|NCT02497768|participants
90728|NCT02497729|Endotracheal Intubation
90729|NCT02497729|Checklist
90730|NCT02497729|Positioning
90731|NCT02497690|Cochlear Implant
90732|NCT02497677|parental sensitivity
90733|NCT02497677|child attachment
90734|NCT02497664|Radiotherapy
90735|NCT02497664|Active Breathing Control Technique
90737|NCT02497651|Diabetes
90738|NCT02497651|Incretin hormones
90739|NCT02497651|Glucose tolerance
90740|NCT02497638|metformin
90741|NCT02497638|atorvastatin
90742|NCT02497638|prostate-specific antigen
90743|NCT02497638|biochemical recurrence
90744|NCT02497625|Low back pain
90745|NCT02497625|Empathy
90746|NCT02497625|Subgroups
90747|NCT02497625|Minimal intervention
90748|NCT02497547|Atrophy
90749|NCT02497547|Pathological Conditions, Anatomical
90750|NCT02497547|Oxytocin
90751|NCT02497547|Oxytocics
90752|NCT02497534|ataxia
90753|NCT02497534|neuromuscular
90754|NCT02497521|polycystic kidney disease
90755|NCT02497521|autosomal dominant polycystic kidney disease
90756|NCT02497521|ADPKD
90757|NCT02497521|Tolvaptan
90758|NCT02497521|Jinarc
90759|NCT02497508|progressive disease after at least 1 course of chemotherapy
90760|NCT02497495|Immersion
90761|NCT02497495|Recovery of Function
90762|NCT02497495|Lactate
90763|NCT02497495|Creatine Kinase
90764|NCT02497495|Musculoskeletal Pain
90765|NCT02497469|Drug Therapy
90766|NCT02497456|HIV
90767|NCT02497456|Counselling
90768|NCT02497456|Care
90769|NCT02497456|antiretroviral therapy
90770|NCT02497456|linkage
90771|NCT02497456|Uganda
90772|NCT02497456|Africa
90773|NCT02497443|drug-resistant symptomatic epilepsy
90774|NCT02497443|seizure
90775|NCT02497443|autologous mesenchymal stem cells
90776|NCT02497443|safety
90777|NCT02497443|remission
90778|NCT02497443|electroencephalography
90779|NCT02497443|refractory symptomatic epilepsy
90780|NCT02497443|autologous MSC
90781|NCT02497443|efficacy
90782|NCT02497417|ARIES Clostridium difficile
90783|NCT02497378|Multiple Myeloma
90784|NCT02497378|Daratumumab
90785|NCT02497378|JNJ-54767414
90786|NCT02497378|Bortezomib
90787|NCT02497378|Dexamethasone
90788|NCT02497365|keratits
90789|NCT02497365|besifloxacin
90790|NCT02497339|Smoking cessation interventions
90791|NCT02497339|mindfulness training
90792|NCT02497326|second degree burns
90793|NCT02497326|heparin
90794|NCT02497326|topical
90795|NCT02497300|Mineralocorticoid Receptor Antagonists
90796|NCT02497300|Mineralocorticoid Effects
90797|NCT02497287|Treatment-resistant Depression
90798|NCT02497287|Esketamine
90799|NCT02497287|Oral Antidepressant
90800|NCT02497274|bariatric surgery
90801|NCT02497274|taste perception
90802|NCT02497274|lipid receptors
90803|NCT02497261|Food Allergy
90804|NCT02497261|Peanut
90805|NCT02497261|Sensitization
90806|NCT02497261|Child
90807|NCT02497261|Double-blind placebo-controlled challenge
90808|NCT02497261|Prospective cohort
90809|NCT02497248|Atrial Fibrillation
90810|NCT02497248|Pulmonary Vein Ablation
90811|NCT02497248|Mitral stenosis
90812|NCT02497248|Body surface mapping
90813|NCT02497235|Drug therapy
90814|NCT02497196|TPCS
90815|NCT02497196|tDCS
90816|NCT02497196|visceral pain
90817|NCT02497196|pancreatitis
90818|NCT02497196|healthy subjects
90819|NCT02497196|pelvic pain
90820|NCT02497196|neuromodulation
90821|NCT02497196|non-invasive brain stimulation
90822|NCT02497157|bevacizumab
90823|NCT02497157|oxaliplatin
90824|NCT02497157|irinotecan
90825|NCT02497157|hydrochloride hydrate
90826|NCT02497157|fluorouracil
90827|NCT02497157|levofolinate calcium
90828|NCT02497144|interstitial lung disease
90829|NCT02497144|neuromuscular electrical stimulation
90830|NCT02497144|exercise capacity
90831|NCT02497144|quality of life
90832|NCT02497131|PTCL
90833|NCT02497131|CD30+
90834|NCT02497118|lung cancer Anti angiogenesis therapy survival
90835|NCT02497105|Epilepsy
90836|NCT02497105|Intractable Seizures
90837|NCT02497105|Ketogenic Diet
90838|NCT02497105|Biochemical Profiles
90839|NCT02497079|Bronchoscopy
90840|NCT02497079|Ultrasonography
90841|NCT02497079|Tuberculous lymphadenitis
90842|NCT02497079|Polymerase chain reaction
90843|NCT02497079|Sensitivity and specificity
90844|NCT02497066|topical
90845|NCT02497066|compound
90846|NCT02497066|pain
90847|NCT02497053|MPM
90848|NCT02497040|craniotomy
90849|NCT02497040|local anesthetics
90850|NCT02497040|scalp block
90851|NCT02497040|head pinning
90852|NCT02497027|pharmacogenetic, pharmacogenomic, depressive, mental health
90853|NCT02496988|Cytokine-Induced Killer Cells
90854|NCT02496988|Milignant Gliomas
90855|NCT02496988|Temozolomide
90856|NCT02496962|sleep deprivation
90857|NCT02496936|Energy Expenditure
90858|NCT02496936|Appetite
90859|NCT02496936|Satiety
90860|NCT02496923|prophylactic NHFO
90861|NCT02496923|risk of developing postoperative pulmonary complications
90989|NCT02496403|opioid addiction
90862|NCT02496923|reduces hospital length of stay
90863|NCT02496884|chronic kidney disease
90864|NCT02496884|. α2δ ligands
90865|NCT02496884|mirogabalin
90866|NCT02496884|pain relief
90867|NCT02496884|kidney metabolism
90868|NCT02496858|Young Patient
90869|NCT02496858|Genetic Characteristics
90870|NCT02496832|Hypoxia
90871|NCT02496832|18F-FAZA
90872|NCT02496832|18F-Fluoroazomycin arabinoside
90873|NCT02496832|Positron emission tomography
90874|NCT02496832|PET
90875|NCT02496832|Participating in study EMR200592-001
90876|NCT02496819|Children
90877|NCT02496806|Polyphenols
90878|NCT02496806|Absorption
90879|NCT02496806|Metabolism
90880|NCT02496806|Phlorotannins
90881|NCT02496806|Seaweeds
90882|NCT02496767|fast skeletal troponin activator
90883|NCT02496767|tirasemtiv
90884|NCT02496767|CK-2017357
90885|NCT02496767|double-blind
90886|NCT02496767|randomized
90887|NCT02496767|placebo-controlled
90888|NCT02496741|isocitrate dehydrogenase 1/2 mutation
90889|NCT02496741|metformin
90890|NCT02496741|chloroquine
90891|NCT02496728|Mobile Health
90892|NCT02496728|Smartphone
90893|NCT02496728|Cardiovascular health
90894|NCT02496728|College students
90895|NCT02496728|Smoking
90896|NCT02496728|Physical activity
90897|NCT02496728|Diet
90898|NCT02496728|BMI
90899|NCT02496728|Blood pressure
90900|NCT02496728|Cholesterol
90901|NCT02496728|Glucose
90902|NCT02496728|Text
90903|NCT02496728|Facebook
90904|NCT02496728|Instagram
90905|NCT02496728|Push Notifications
90906|NCT02496728|Ecological Momentary Assessment
90907|NCT02496702|exergaming
90908|NCT02496702|Senior Fitness Test
90909|NCT02496689|HPP
90910|NCT02496689|Bone Disease
90911|NCT02496689|Soft Bones
90912|NCT02496689|Low Alkaline Phosphatase
90913|NCT02496689|genetic metabolic disorder
90914|NCT02496689|alkaline phosphatase
90915|NCT02496689|rickets
90916|NCT02496689|osteomalacia
90917|NCT02496676|Lymphoma
90918|NCT02496676|Epstein-Barr Virus
90919|NCT02496676|Immunodeficiency
90920|NCT02496676|MAGT1 Gene
90921|NCT02496676|Intracellular Magnesium
90922|NCT02496650|alcohol withdrawal state
90923|NCT02496650|dexmedetomidine
90924|NCT02496650|benzodiasepines
90925|NCT02496650|intensive care
90926|NCT02496637|Obesity
90927|NCT02496637|Eating Disorders
90928|NCT02496637|Appetite regulation
90929|NCT02496637|Eating Regulation
90930|NCT02496611|Obesity
90931|NCT02496611|Pharmacotherapy
90932|NCT02496611|GLP-1
90933|NCT02496611|Children
90934|NCT02496611|Exenatide
90935|NCT02496611|BYDUREON
90936|NCT02496611|Weight Loss
90937|NCT02496611|Maintenance
90938|NCT02496598|Reproductive Techniques, Assisted
90939|NCT02496598|Ovarian Follicle
90940|NCT02496585|Nintedanib (BIBF 1120)
90941|NCT02496585|Prednisone
90942|NCT02496585|Radiation Pneumonitis
90943|NCT02496572|Tuberculosis, multidrug resistant
90944|NCT02496572|Short-course regimen
90945|NCT02496572|Medecins sans Frontieres, MSF
90946|NCT02496572|Uzbekistan, Ministry of Health
90947|NCT02496559|C-reactive Protein
90948|NCT02496559|Primary Health Care
90949|NCT02496559|Child Welfare
90950|NCT02496559|After-Hours Care
90951|NCT02496559|Anti-Bacterial Agents
90952|NCT02496559|Drug Prescriptions
90953|NCT02496520|dendritic cell vaccination
90954|NCT02496520|sarcoma
90955|NCT02496520|central nervous system tumor
90956|NCT02496520|childhood
90957|NCT02496520|adolescent
90958|NCT02496520|immunotherapy
90959|NCT02496507|sitting
90960|NCT02496507|intervention
90961|NCT02496507|desks
90962|NCT02496507|workplace
90963|NCT02496507|cardiovascular
90964|NCT02496507|metabolic
90965|NCT02496507|qualitative
90966|NCT02496507|randomised controlled trial
90967|NCT02496468|childhood asthma
90968|NCT02496468|preschool wheeze
90969|NCT02496468|adult asthma
90970|NCT02496468|transition
90971|NCT02496468|phenotype
90972|NCT02496468|endotype
90973|NCT02496468|trajectory
90974|NCT02496455|NAV1.7 Voltage-Gated Sodium Channel
90975|NCT02496455|pain, postoperative
90976|NCT02496455|cesarean section
90977|NCT02496442|Transurethral Resection of Prostate
90978|NCT02496442|Cystoscopy
90979|NCT02496442|PCNL
90980|NCT02496442|RERAS
90981|NCT02496442|Urethroscopy
90982|NCT02496403|buprenorphine-naloxone combination
90983|NCT02496403|Suboxone
90984|NCT02496403|Buprenorphine
90985|NCT02496403|Substance Use
90986|NCT02496403|Behavioral intervention
90987|NCT02496403|Opioid partial agonist
90988|NCT02496403|medication assisted therapy
90990|NCT02496390|Fecal Microbial Transplantation
90991|NCT02496390|Gut microbiome
90992|NCT02496390|Metabolic disorders
90993|NCT02496390|Obesity
90994|NCT02496377|Anaemia
90995|NCT02496377|Iron deficiency
90996|NCT02496377|Ferric carboxymaltose
90997|NCT02496377|Patient blood management
90998|NCT02496377|Hip arthroplasty
90999|NCT02496377|Knee arthroplasty
91000|NCT02496364|Tranexamic Acid
91001|NCT02496364|Scoliosis
91002|NCT02496364|bleeding control
91003|NCT02496351|transcutaneous electrical nerve stimulation
91004|NCT02496338|Menopause
91005|NCT02496338|Quality of Life
91006|NCT02496338|Marital Satisfaction
91007|NCT02496338|training
91008|NCT02496325|Pudendal nerve block
91009|NCT02496325|Ultrasound guided
91010|NCT02496325|Transperineal puncture
91011|NCT02496325|Perineal surgery
91012|NCT02496325|children
91013|NCT02496312|Apathy
91014|NCT02496312|Goal-directed behavior
91015|NCT02496312|Quantitative evaluation
91016|NCT02496312|Sensor
91017|NCT02496312|Ethogram
91018|NCT02496299|COMPARISSON
91019|NCT02496299|CAUDAL BLOCK
91020|NCT02496299|BUPIVACAINE
91021|NCT02496299|DEXAMETHASONE
91022|NCT02496286|Necessary paracentesis for symptom control
91023|NCT02496273|Dendritic Cells
91024|NCT02496273|Cytotoxic T-Lymphocytes
91025|NCT02496273|Adeno-Associated Virus
91026|NCT02496260|Magnetic resonance imaging
91027|NCT02496260|Cardiac function
91028|NCT02496260|Breast Cancer
91029|NCT02496247|malnutrition
91030|NCT02496247|undernutrition
91031|NCT02496247|Z-score
91032|NCT02496247|Guinea-Bissau
91033|NCT02496247|food aid
91034|NCT02496234|Coronary Artery Bypass Graft Surgery
91035|NCT02496234|Acute kidney injury
91036|NCT02496234|Renal failure
91037|NCT02496234|Biomarker
91038|NCT02496221|Cholecystokinin
91039|NCT02496221|ultrasonography
91040|NCT02496221|Albiglutide
91041|NCT02496221|Gallbladder ejection fraction
91042|NCT02496169|PTCA
91043|NCT02496169|stenosis
91044|NCT02496169|sirolimus
91045|NCT02496169|stent
91046|NCT02496156|type 1 diabetes mellitus
91047|NCT02496156|adolescence
91048|NCT02496156|adherence
91049|NCT02496156|insulin pump
91050|NCT02496156|continuous subcutaneous insulin infusion
91051|NCT02496156|continuous glucose monitor
91052|NCT02496156|shared medical decision making
91053|NCT02496143|Healthy Volunteers
91054|NCT02496143|Phase I
91055|NCT02496143|Placebo controlled
91056|NCT02496143|Single Ascending Dose
91057|NCT02496143|PK
91058|NCT02496143|Oral administration
91059|NCT02496143|Softgel
91060|NCT02496130|minilaparotomy
91061|NCT02496130|morcellation
91062|NCT02496130|laparoscopy
91063|NCT02496104|Preterm
91064|NCT02496104|Infant
91065|NCT02496104|Habituation
91066|NCT02496104|APIB
91067|NCT02496065|breast cancer
91068|NCT02496065|BLZ-100
91069|NCT02496065|Tumor Paint
91070|NCT02496065|breast tumors
91071|NCT02496052|amnion graft
91072|NCT02496052|New biological barrier system
91073|NCT02496039|PBA
91074|NCT02496039|involuntary crying
91075|NCT02496039|involuntary laughing
91076|NCT02496000|Diabetes Mellitus type 2
91077|NCT02496000|Metformin
91078|NCT02496000|oral insulin
91079|NCT02495974|Metastatic castration resistant prostate cancer
91080|NCT02495974|Prostate cancer
91081|NCT02495974|Enzalutamide
91082|NCT02495974|Xtandi
91083|NCT02495961|hyperlipidemias
91084|NCT02495961|hyperglycemia
91085|NCT02495961|hypertension
91086|NCT02495961|leptin
91087|NCT02495961|hyperhomocysteinemia
91088|NCT02495909|paediatric schistosomiasis
91089|NCT02495909|morbidity
91090|NCT02495909|immunology
91091|NCT02495883|Essential Tremor
91092|NCT02495883|Magnetic Resonance Imaging
91093|NCT02495883|Therapy
91094|NCT02495883|Alcohol
91095|NCT02495883|Propranolol
91096|NCT02495844|UCB0942
91097|NCT02495844|Treatment-resistant focal epilepsy
91098|NCT02495844|Partial seizures
91099|NCT02495844|Seizure therapy
91100|NCT02495831|PK study
91101|NCT02495818|Rotator cuff syndrome
91102|NCT02495818|supraspinatus tendonitis
91103|NCT02495818|suprascapular nerve block
91104|NCT02495818|ultrasound guided
91105|NCT02495818|supraspinatus
91106|NCT02495805|a continuous proximal adductor canal block (ACB)
91107|NCT02495805|continuous femoral nerve block (FNB)
91108|NCT02495779|PrEP
91109|NCT02495779|HIV
91110|NCT02495779|MSM
91111|NCT02495779|Men Having Sex With Men
91112|NCT02495779|Episodic PrEP
91113|NCT02495779|Adherence
91114|NCT02495779|Episodic HIV Risk
91115|NCT02495766|Multiple sclerosis
91116|NCT02495766|Bone marrow mesenchymal stromal cells
91117|NCT02495766|Stem cells
91118|NCT02495766|Nervous System Diseases
91119|NCT02495766|Demyelinating Diseases
91120|NCT02495766|Autoimmune Diseases
91121|NCT02495753|cesarean section
91122|NCT02495753|wound infection
91123|NCT02495753|vaginal cleansing
91124|NCT02495753|endometritis
91125|NCT02495727|Step-reduction model
91126|NCT02495727|Reduced activity
91127|NCT02495727|Atrophy
91128|NCT02495727|Skeletal Muscle
91129|NCT02495727|Sarcopenia
91130|NCT02495727|Dynapenia
91131|NCT02495714|Exercise
91132|NCT02495714|Diet
91133|NCT02495714|Learning
91134|NCT02495688|General Anesthesia
91135|NCT02495688|Regional Anesthesia
91136|NCT02495662|Vascular access
91137|NCT02495662|Hemodialysis
91138|NCT02495662|Arteriovenous shunt
91139|NCT02495662|Arteriovenous fistula
91140|NCT02495662|Maturation
91141|NCT02495662|Liposomal prednisolone
91142|NCT02495662|PEG-liposomal prednisolone sodium phosphate
91143|NCT02495662|Radio-cephalic
91144|NCT02495662|Shunt
91145|NCT02495610|NPH
91146|NCT02495610|Gait analysis
91147|NCT02495610|neuropsychology
91148|NCT02495610|micturition diary
91149|NCT02495610|MRI
91150|NCT02495597|bronchial inflammation
91151|NCT02495597|Bronchiolitis obliterans
91152|NCT02495597|Sputum
91153|NCT02495597|Blood
91154|NCT02495597|Inflammation
91155|NCT02495597|adaptive immune system
91156|NCT02495597|innate immune system
91157|NCT02495584|Vitamin D
91158|NCT02495584|Fortified milk
91159|NCT02495584|Supplementation
91160|NCT02495584|UV exposure
91161|NCT02495584|Winter
91162|NCT02495584|Healthy adults
91163|NCT02495584|Body Composition
91164|NCT02495584|Muscle function
91165|NCT02495584|Blood pressure
91166|NCT02495571|ALS and Dysphagia
91167|NCT02495571|ALS and cough
91168|NCT02495571|cough reflex test
91169|NCT02495558|Cough Reflex test
91170|NCT02495558|Decannulation
91171|NCT02495545|spinal cord injury (SCI)
91172|NCT02495532|Neoplasm Metastasis
91173|NCT02495532|Colorectal Neoplasms
91174|NCT02495532|Lymph Nodes
91175|NCT02495532|Lymph Node Revealing Solution
91176|NCT02495506|Cardiac surgery
91177|NCT02495506|bleeding
91178|NCT02495506|platelet transfusion
91179|NCT02495480|disposable sheath
91180|NCT02495480|intubation
91181|NCT02495480|colonoscopy
91182|NCT02495428|Bandage
91183|NCT02495428|Treadmill
91184|NCT02495428|Lactate Acid
91185|NCT02495389|urinary urgency incontinence
91186|NCT02495376|YACS
91187|NCT02495376|cancer
91188|NCT02495376|MBSR
91189|NCT02495311|adenomyosis
91190|NCT02495311|uterine myoma
91191|NCT02495311|lower urinary tract symptoms
91192|NCT02495311|sexual dysfunction
91193|NCT02495311|gastrointestinal symptom
91194|NCT02495298|Fascial manipulation
91195|NCT02495298|Carpal Tunnel Syndrome
91196|NCT02495285|pediatric patients gelatine
91197|NCT02495272|Postpartum hemorrhage
91198|NCT02495272|Third stage of labour
91199|NCT02495272|Oxytocin
91200|NCT02495272|Uterotonics
91201|NCT02495272|Active management of third stage of labour
91202|NCT02495259|Double-lumen endobronchial tube
91203|NCT02495259|Laryngoscopy
91204|NCT02495259|intubating stylet
91205|NCT02495233|Erlotinib
91206|NCT02495233|ASP2215
91207|NCT02495233|NSCLC
91208|NCT02495233|Non-Small-Cell Lung Cancer
91209|NCT02495220|dexmedetomidine
91210|NCT02495220|subtenon anesthesia
91211|NCT02495220|postoperative pain
91212|NCT02495220|pov
91213|NCT02495194|Promotion of psychological well-being
91214|NCT02495194|Horticultural therapy
91215|NCT02495194|Randomized Controlled Trial
91216|NCT02495194|Gardening
91217|NCT02495194|Elderly
91218|NCT02495129|Primary Sjögren's syndrome
91219|NCT02495129|Sicca syndrome
91220|NCT02495129|Salivary glands
91221|NCT02495129|Positron Emission Tomography
91222|NCT02495129|B cell depletion
91223|NCT02494063|cervical cancer
91224|NCT02494063|sentinel lymph node
91225|NCT02494063|lymphadenectomy
91226|NCT02494050|Depression
91227|NCT02494050|Bipolar Disorder
91228|NCT02494050|Anhedonia
91229|NCT02494050|Women
91230|NCT02494024|PSP
91231|NCT02494024|C2N-8E12
91232|NCT02494024|tauopathy
91233|NCT02494024|Progressive Supranuclear Palsy
91234|NCT02494024|Steele Richardson Olszewski Syndrome
91235|NCT02494024|Humanized anti-tau antibody
91236|NCT02494011|Colles' Fracture; CKCE; Russian current
91237|NCT02493998|Sanfilippo Syndrome Type B
91238|NCT02493985|Brain physiology
91239|NCT02493985|Intracranial pressure
91240|NCT02493985|Cognition
91241|NCT02493985|Cerebrovascular
91242|NCT02493985|Head down tilt
91243|NCT02493985|Space flight
91244|NCT02493972|ovarian cancer
91245|NCT02493972|peritoneal carcinosis
91246|NCT02493972|manual exploration
91247|NCT02493972|surgery
91248|NCT02493972|GelPort
91249|NCT02493959|PYY
91250|NCT02493959|Degradation
91251|NCT02493959|kinetics
91252|NCT02493959|men
91253|NCT02493920|Respiratory Distress Syndrome, Newborn
91254|NCT02493920|Delivery Room
91255|NCT02493920|Resuscitation
91256|NCT02493920|Premature birth
91257|NCT02493920|Infant, Newborn
91258|NCT02493920|Respiration Artificial
91259|NCT02493894|Bowel preparation
91260|NCT02493894|perioperative bleeding
91261|NCT02493894|lumbar fusion
91262|NCT02493881|Motor function of the extralaryngeal branches
91263|NCT02493881|intraoperative neuromonitoring
91264|NCT02493881|recurrent laryngeal nerve
91265|NCT02493868|Treatment-resistant Depression
91266|NCT02493868|Esketamine
91267|NCT02493868|Placebo
91268|NCT02493868|Oral Antidepressant
91269|NCT02493868|Relapse prevention
91270|NCT02495103|Dose-Escalation
91271|NCT02495103|Maximum Tolerated Dose
91272|NCT02495103|Safety
91273|NCT02495103|Overall Response
91274|NCT02495090|Hypospadias
91275|NCT02495090|exome sequencing
91276|NCT02495090|genital malformation
91277|NCT02495077|Kidney Transplantation
91278|NCT02495077|infliximab
91279|NCT02495077|Tissue Donors
91280|NCT02495077|Remicade
91281|NCT02495077|Induction Therapy
91282|NCT02495077|Deceased Donor Kidney Transplant Recipients
91283|NCT02495051|gastroesophageal reflux
91284|NCT02495051|barrett esophagus
91285|NCT02495038|combination
91286|NCT02495038|rocuronium
91287|NCT02495038|cisatracurium
91288|NCT02495038|neuromuscular blockade monitoring
91289|NCT02495038|drug synergism
91290|NCT02495012|efficacy
91291|NCT02495012|safety
91292|NCT02495012|STEMI
91293|NCT02494999|pneumococcal conjugate vaccine
91294|NCT02494999|immunogenicity
91295|NCT02494999|safety
91296|NCT02494986|Human immunodeficiency virus type 1
91297|NCT02494986|Rilpivirine
91298|NCT02494986|Roll-over study
91299|NCT02494960|smoking cessation intervention
91300|NCT02494947|Coronary Angiography
91301|NCT02494947|Exercise
91302|NCT02494921|Metastatic
91303|NCT02494921|Castration-Resistant
91304|NCT02494908|Parkinson Disease
91305|NCT02494908|MRI
91306|NCT02494882|Ruxolitinib
91307|NCT02494882|Dasatinib
91308|NCT02494882|Dexamethasone
91309|NCT02494882|14-272
91310|NCT02494869|Aerobic Training
91311|NCT02494869|Exercise
91312|NCT02494869|Gene Expression
91313|NCT02494869|15-093
91314|NCT02494856|Naproxen
91315|NCT02494856|Lower third molar
91316|NCT02494856|Oral Surgery
91317|NCT02494856|Esomeprazole
91318|NCT02494830|Anesthetic Drugs
91319|NCT02494817|HIV prevention
91320|NCT02494817|Toolkit
91321|NCT02494817|Male couples
91322|NCT02494817|Sexual agreements
91323|NCT02494804|Cytokine-Induced Killer Cells
91324|NCT02494804|Milignant Gliomas
91325|NCT02494804|Temozolomide
91326|NCT02494765|I-gelTM
91327|NCT02494765|Ambu® AuraOnceTM
91328|NCT02494765|supraglottic devices
91329|NCT02494765|laryngeal mask effects on airway
91330|NCT02494765|3D magnetic resonance imaging
91331|NCT02494752|Contour deformities of face
91332|NCT02494752|autologous fat grafting
91333|NCT02494752|Post traumatic facial contour defects
91334|NCT02494739|antioxidant
91335|NCT02494739|oxidative stress
91336|NCT02494739|inflammation
91337|NCT02494739|polyphenols
91338|NCT02494739|yogurt
91339|NCT02494726|Ischemic stroke
91340|NCT02494726|ICH stroke
91341|NCT02494726|TEG
91342|NCT02494726|Thromboelastography
91343|NCT02494726|Stroke
91344|NCT02494713|Advanced Prostate Cancer
91345|NCT02494713|Neoadjuvant
91346|NCT02494713|Hormone therapy
91347|NCT02494713|ADT
91348|NCT02494713|Androgen Deprivation Therapy
91349|NCT02494713|Chemotherapy
91350|NCT02494713|Radical Prostatectomy
91351|NCT02494700|Lymphoma
91352|NCT02494700|Low grade B lymphocyte (B cell) lymphoma
91353|NCT02494700|Mantle cell lymphoma involving the ocular adnexa
91354|NCT02494700|Limited and advanced stage
91355|NCT02494700|Ocular adnexa
91356|NCT02494700|Radiation therapy
91357|NCT02494700|XRT
91358|NCT02494661|Public Health
91359|NCT02494661|Community
91360|NCT02494661|Obesity
91361|NCT02494661|Hispanic
91362|NCT02494661|Women
91363|NCT02494661|Nutrition
91364|NCT02494661|Mindfulness and stress
91365|NCT02494661|Food shopping
91366|NCT02494648|Obstructive sleep apnea
91367|NCT02494648|Resistive inspiratory muscle training
91368|NCT02494648|Coronary artery disease
91369|NCT02494648|Cardiac rehabilitation
91370|NCT02494583|Gastric carcinoma
91371|NCT02494583|Gastric cancer
91372|NCT02494583|Gastroesophageal junction cancer
91373|NCT02494583|Gastroesophageal junction carcinoma
91374|NCT02494583|PD1
91375|NCT02494583|PD-1
91376|NCT02494583|PDL1
91377|NCT02494583|PD-L1
91378|NCT02494531|Alzheimer Disease
91379|NCT02494531|PET
91380|NCT02494531|diagnosis
91381|NCT02494531|MCI
91382|NCT02494531|illiterate
91383|NCT02494518|stroke
91384|NCT02494518|aerobic exercise
91385|NCT02494518|forced exercise
91386|NCT02494518|repetitive task practice
91387|NCT02494518|arm function
91388|NCT02494518|upper extremity
91389|NCT02494505|chronic inflammatory demyelinating polyradiculopathy
91390|NCT02494505|intravenous immunoglobulin (IVIG)
91391|NCT02494505|withdrawal
91392|NCT02494505|quality of life
91393|NCT02494505|Clinical trial
91394|NCT02494505|cost
91395|NCT02494492|Uveitis
91396|NCT02494492|Lymphocyte cells
91397|NCT02494492|lymphocyte T regulator
91398|NCT02494492|vitreous haze
91399|NCT02494492|intravitreal injection
91400|NCT02494479|Psoriasis
91401|NCT02494479|Topical Psoriasis
91402|NCT02494479|Mild Psoriasis
91403|NCT02494479|Moderate Psoriasis
91404|NCT02494479|Active Psoriasis
91405|NCT02494479|Plaque Psoriasis
91406|NCT02494479|Skin Diseases
91407|NCT02494466|Airway Resistance
91408|NCT02494466|montelukast sodium
91409|NCT02494466|laryngeal mask airway
91410|NCT02494427|Crowns
91411|NCT02494427|Inlays
91412|NCT02494427|Onlays
91413|NCT02494414|Cardiac arrest
91414|NCT02494414|outcome
91415|NCT02494414|neurological status
91416|NCT02494401|systemic sclerosis
91417|NCT02494401|ssc
91418|NCT02494375|Sleep
91419|NCT02494375|glycemic control
91420|NCT02494375|type 1 diabetes
91421|NCT02494375|amylase
91422|NCT02494375|body composition
91423|NCT02494375|lean
91424|NCT02494375|overweight
91425|NCT02494375|obese
91426|NCT02494362|Hand exercises
91427|NCT02494362|Hand function
91428|NCT02494362|Computer based exercises
91429|NCT02494362|Therapeutic gaming
91430|NCT02494349|α1-blockers
91431|NCT02494349|antimuscarinic agent
91432|NCT02494323|Dual Channel Functional Electrical Stimulation
91433|NCT02494323|dropfoot, balanced dorsiflexion
91434|NCT02494284|Coronary artery disease
91435|NCT02494284|Dual antiplatelet platelet therapy
91436|NCT02494284|Drug eluting stent
91437|NCT02494258|CC-486
91438|NCT02494258|Oral Azacitidine
91439|NCT02494258|Solid tumors
91440|NCT02494258|hematological disorders
91441|NCT02494258|rollover study
91442|NCT02494245|Rehabilitation
91443|NCT02494245|Intervention
91444|NCT02494245|Walking
91445|NCT02494232|minor blunt thoracic trauma
91446|NCT02494232|physical examination
91447|NCT02494219|Group A streptococcal pharyngitis
91448|NCT02494219|Rapid streptococcal test
91449|NCT02494219|Throat swab culture
91450|NCT02494206|QBX258
91451|NCT02494206|human monoclonal antibodies
91452|NCT02494206|VAK694
91453|NCT02494206|QAX576
91454|NCT02494206|15-085
91455|NCT02494180|fentanyl
91456|NCT02494180|midazolam
91457|NCT02494180|pethidine
91458|NCT02494180|diazepam
91459|NCT02494167|Acute Myeloid Leukemia
91460|NCT02494167|Myelodysplastic Syndrome
91461|NCT02494167|MultiTAA Specific T cells
91462|NCT02494128|Child health service
91463|NCT02494128|Family health
91464|NCT02494128|Nurse
91465|NCT02494128|Education
91466|NCT02494128|Parental group
91467|NCT02494128|Group leadership
91468|NCT02494128|Health promotion
91469|NCT02494102|Obstructive Sleep Apnea
91470|NCT02494102|General Anesthesia
91471|NCT02494102|Modafinil
91472|NCT02494089|in situ simulation
91473|NCT02494089|in hospital cardiac arrest
91474|NCT02494089|clinical audit
91475|NCT02494089|education
91476|NCT02494089|patient simulation
91477|NCT02493855|Hepatitis C Genotype 1a
91478|NCT02493855|Interferon free
91479|NCT02493855|Chronic Hepatitis C
91480|NCT02493855|Hepatitis C
91481|NCT02493855|Treatment naive
91482|NCT02493855|HCV
91483|NCT02493842|Nerve Stimulation
91484|NCT02493842|Neuroplasticity
91485|NCT02493842|Sensory Feedback
91486|NCT02493790|cognitive dysfunction
91487|NCT02493790|Activity of Daily Living
91488|NCT02493790|interference
91489|NCT02493790|rehabilitation
91490|NCT02493790|cognitive-motor dual task
91491|NCT02493751|Cancer, renal cell cancer, kidney disease, kidney neoplasms, axitinib
91492|NCT02493673|Continuous Positive Airway Pressure
91493|NCT02493673|Stroke
91494|NCT02493673|Cerebrovascular reactivity
91495|NCT02493673|Brain oxygenation
91496|NCT02493660|Massive Rotator Cuff Tear
91497|NCT02493660|Arthroscopy
91498|NCT02493660|Shoulder Joint
91499|NCT02493660|Rotator cuff partial repair
91500|NCT02493634|Magnetic Resonance spectroscopy
91501|NCT02493634|Aortic Arch
91502|NCT02493621|Pain, Postoperative
91503|NCT02493621|Nerve Block
91504|NCT02493621|Anesthesia, Epidural
91505|NCT02493582|CIK
91506|NCT02493582|Apatinib
91507|NCT02493582|Lung Adenocarcinoma
91508|NCT02493569|Breast cancer, hospital, epidemiology, diagnosis, treatment
91509|NCT02493556|Phototherapy
91510|NCT02493556|Plyometric exercise
91511|NCT02493556|Muscle recovery
91512|NCT02493543|autoantibodies
91513|NCT02493530|MDS/MPN
91514|NCT02493504|Heparin
91515|NCT02493491|dysphonia
91516|NCT02493491|dysphagia
91517|NCT02493491|neurogenic
91518|NCT02493491|vocal fold augmentation
91519|NCT02493491|VFA
91520|NCT02493491|vocal fold insufficiency
91521|NCT02493491|Prolaryn
91522|NCT02493491|Radiesse
91523|NCT02493491|Coaptite
91524|NCT02493491|voice
91525|NCT02493491|Parkinson's Disease
91526|NCT02493491|Multiple Sclerosis
91527|NCT02493491|Amyotrophic Lateral Sclerosis
91528|NCT02493491|ALS
91529|NCT02493491|MS
91530|NCT02493491|calcium hydroxylapatite
91531|NCT02493491|hyaluronic acid
91532|NCT02493478|Intubation
91533|NCT02493478|Advanced airway intervention
91534|NCT02493478|Intensive care unit
91535|NCT02493465|everolimus
91536|NCT02493465|left ventricular hypertrophy
91537|NCT02493439|Best Possible Self
91538|NCT02493439|Positive Psychology
91539|NCT02493439|Romanian Immigrants
91540|NCT02493439|Optimism
91541|NCT02493439|Future Thinking
91542|NCT02493413|psychoneuroimmunology
91543|NCT02493413|stress
91544|NCT02493413|lymphocyte population
91545|NCT02493413|personality type
91546|NCT02493413|obesity
91547|NCT02493413|heart rate variability
91548|NCT02493413|awareness
91549|NCT02493400|Follow up
91550|NCT02493400|Exercise
91551|NCT02493400|Rehabilitation
91552|NCT02493387|Physiotherapist led group-based exercise
91553|NCT02493387|Physical activity
91554|NCT02493387|Atrial fibrillation
91555|NCT02493348|Fibromyalgia
91556|NCT02493348|Rhythmic Sensory Stimulation
91557|NCT02493348|Gamma Stimulation
91558|NCT02493283|dapsone
91559|NCT02493283|blood leucocytes
91560|NCT02493283|pharmacokinetics
91561|NCT02493283|metabolism
91562|NCT02493270|smoking cessation
91563|NCT02493270|tobacco
91564|NCT02493270|dental
91565|NCT02493270|periodontal
91566|NCT02493257|nonallergic irritant rhinitis
91567|NCT02493257|nasal congestion
91568|NCT02493257|rhinorrhea
91569|NCT02493218|mindfulness
91570|NCT02493218|intervention
91571|NCT02493218|african american
91572|NCT02493218|youth
91573|NCT02493218|stress
91574|NCT02493218|poverty
91575|NCT02493205|Implantable Cardiac Monitor
91576|NCT02493205|Stent
91577|NCT02493192|Parturition
91578|NCT02493192|Humanizing Deliver
91579|NCT02493192|Labor Pain
91580|NCT02493192|Natural Childbirth
91581|NCT02493192|Labor Onset
91582|NCT02493192|First Labor Stage
91583|NCT02493192|Birth ball
91584|NCT02493192|meperidine
91585|NCT02493192|pethidine
91586|NCT02493140|Weight management
91587|NCT02493140|cashew apple extract
91588|NCT02493140|overweight
91589|NCT02493101|Periostin staining
91590|NCT02493101|Urine periostin level
91591|NCT02493101|Lupus nephritis
91592|NCT02493101|IgA nephropathy
91593|NCT02493075|atrial fibrillation
91594|NCT02493075|Catheter Ablation
91595|NCT02493075|contact force
91596|NCT02493075|Chinese-specific
91597|NCT02493062|Hysterotomy
91598|NCT02493062|Myelomeningocele
91599|NCT02493062|Open fetal surgery
91600|NCT02493062|Sonohysterogram
91601|NCT02493049|Multiple Sclerosis
91602|NCT02493049|Domperidone
91603|NCT02493049|Relapsing-Remitting MS
91604|NCT02493049|Demyelinating disease
91605|NCT02493049|Remyelination
91606|NCT02493023|Bronchoscopy
91607|NCT02493023|Bronchoscopes
91608|NCT02493010|Virtual Reality Exposure Therapy
91609|NCT02493010|Computerized Cognitive Behavioral Therapy
91610|NCT02493010|Public Speaking
91611|NCT02493010|Social Phobia
91612|NCT02493010|Biofeedback
91613|NCT02492997|body fat
91614|NCT02492984|FVIII inhibitor
91615|NCT02492971|Assistive technology
91616|NCT02492971|functional needs
91617|NCT02492971|system usability
91618|NCT02492945|Tennis elbow
91619|NCT02492945|Polydeoxyribonucleotides
91620|NCT02492945|Prolotherapy
91621|NCT02492945|Randomized controlled trial
91622|NCT02492945|Visual analogue scale
91623|NCT02492945|disability
91624|NCT02492945|ultrasonography
91625|NCT02492919|cardiac surgery
91626|NCT02492919|risk factors
91627|NCT02492919|infection
91628|NCT02492880|stimulation
91629|NCT02492880|implantable
91630|NCT02492880|pulse generator
91631|NCT02492880|back pain
91632|NCT02492880|chronic pain
91633|NCT02492880|leg pain
91634|NCT02492854|Lower Extremity Bypass
91635|NCT02492854|Surgical Site Infection
91636|NCT02492854|Wound Dressing
91637|NCT02492854|Negative Pressure Wound Dressing
91638|NCT02492841|dentin substitute
91639|NCT02492841|vital pulp therapy
91640|NCT02492841|Biodentine
91641|NCT02492841|caries
91642|NCT02492789|immunotherapy
91643|NCT02492789|solid tumor
91644|NCT02492789|PD-1 blockade
91645|NCT02492776|Volunteers
91646|NCT02492737|acute myeloid leukemia
91647|NCT02492737|AML
91648|NCT02492737|myelodysplastic syndrome
91649|NCT02492737|MDS
91650|NCT02492737|dual mutation
91651|NCT02492737|MPN
91652|NCT02492737|AITL
91653|NCT02492737|hematologic malignancies
91654|NCT02492737|IDH1
91655|NCT02492737|IDH2
91656|NCT02492737|AG-881
91657|NCT02492724|cervical spine
91658|NCT02492724|total disc replacement (cTDR)
91659|NCT02492724|degenerative disc disease
91660|NCT02492724|activ® C
91661|NCT02492724|clinical outcome
91662|NCT02492724|long-term results
91663|NCT02492724|NDI
91664|NCT02492724|VAS
91665|NCT02492724|heterotopic ossification (HO)
91666|NCT02492724|range of motion (ROM)
91667|NCT02492724|adjacent segment degeneration
91668|NCT02492698|Probiotic
91669|NCT02492698|Weight loss
91670|NCT02492698|Lp-PLA2
91671|NCT02492685|Quantitative analysis
91672|NCT02492685|contrast enhanced endoscopic ultrasonography
91673|NCT02492659|femtosecond laser
91674|NCT02492633|Smoking cessation
91675|NCT02492633|Smoke-free housing
91676|NCT02492633|Affordable housing
91677|NCT02492633|Second-hand smoke
91678|NCT02492633|Tobacco control
91679|NCT02492620|ferric citrate
91680|NCT02492620|phosphate
91681|NCT02492620|kidney
91682|NCT02492607|Women
91683|NCT02492607|DCIS
91684|NCT02492607|Active surveillance
91685|NCT02492607|Standard treatment
91686|NCT02492581|Selincro
91687|NCT02492581|cohort
91688|NCT02492581|real-life
91689|NCT02492581|total alcohol consumption
91690|NCT02492581|heavy drinking days
91691|NCT02492581|clinical global impression-severity
91692|NCT02492581|EQ5D
91693|NCT02492581|AQoLS
91694|NCT02492581|Sheehan disability scale
91695|NCT02492568|recurrent
91696|NCT02492568|NSCLC
91697|NCT02492568|pembrolizumab
91698|NCT02492568|SBRT
91699|NCT02492555|IBD
91700|NCT02492555|Telemedicine
91701|NCT02492555|At-home monitoring
91702|NCT02492555|Disease activity
91703|NCT02492555|fecal calprotectin
91704|NCT02492542|electrical stimulation
91705|NCT02492542|urinary incontinence
91706|NCT02492529|Alzheimer, Recognition Memory, Mild Cognitive Impairment, fMRI
91707|NCT02492516|adipose tissue mesenchymal stem cell intravenous injection ALS
91708|NCT02492503|recurrent or metastatic carcinoma cervix chemotherapy
91709|NCT02492490|Kidney transplantation
91710|NCT02492490|DCD
91711|NCT02492490|Stromal Vascular Fraction
91712|NCT02492490|MSC
91713|NCT02492451|intrauterine insemination
91714|NCT02492451|pregnancy rate
91715|NCT02492451|endometrial injury
91716|NCT02492438|pneumococcal vaccination
91717|NCT02492438|dialysis
91718|NCT02492438|immune response
91719|NCT02492425|Community Acquired Pneumonia
91720|NCT02492425|Healthcare Associated Pneumonia
91721|NCT02492399|hypertrophic cardiomyopathy
91722|NCT02492399|mitral valve
91723|NCT02492399|SAM syndrome
91724|NCT02492386|bioabsorbable vascular scaffold
91725|NCT02492386|erectile dysfunction
91726|NCT02492373|Post inflammatory hyperpigmentation
91727|NCT02492373|topical high potency steroid
91728|NCT02492373|Qs NdYAG laser
91729|NCT02492360|Peripheral Neuropathies
91730|NCT02492360|Testicular Cancer
91731|NCT02492360|Cisplatin
91732|NCT02492360|Pharmacogenomics
91733|NCT02492308|kidney
91734|NCT02492308|transplantation
91735|NCT02492308|MSC
91736|NCT02492217|Ankylosing Spondylitis
91737|NCT02492217|adalimumab
91738|NCT02492217|TNF-alpha agents
91739|NCT02492217|spondyloarthritis
91740|NCT02492217|biologic therapies
91741|NCT02492217|AS
91742|NCT02492217|biomarkers
91743|NCT02492217|efficacy prediction
91744|NCT02492191|Smart Phones
91745|NCT02492191|Ambulatory Care
91746|NCT02492191|Outcome and Process Assessment
91747|NCT02492165|Japanese Encephalitis
91875|NCT02491476|Fast ripples
91748|NCT02492165|Japanese encephalitis chimeric virus vaccine
91749|NCT02492165|IMOJEV®
91750|NCT02492165|Live attenuated vaccine
91751|NCT02492152|women
91752|NCT02492152|active labor
91753|NCT02492126|Chronic Cough
91754|NCT02492126|Gastroesophageal Reflux
91755|NCT02492126|Esophageal Motility
91756|NCT02492126|Cough Sensitivity
91757|NCT02492113|Mechanical ventilation
91758|NCT02492113|Positive end-expiratory pressure
91759|NCT02492113|Work of breathing
91760|NCT02492113|Morbidly obese
91761|NCT02492100|Sexual Dysfunction Post-Bone Marrow Transplant
91762|NCT02492087|topical
91763|NCT02492087|tranexamic acid
91764|NCT02492087|haemostasis
91765|NCT02492087|caesarean section
91766|NCT02492087|bleeding
91767|NCT02492087|postpartum hemorrhage
91768|NCT02492087|prophylactic
91769|NCT02492074|delta-9-tetrahydrocannabinol
91770|NCT02492074|cannabidiol
91771|NCT02492074|COMT
91772|NCT02492061|couples' HCT married couples
91773|NCT02492061|Rakai
91774|NCT02492061|Uganda
91775|NCT02492035|Hypertension
91776|NCT02492035|lifestyle
91777|NCT02492035|clinical trials
91778|NCT02492035|primary care setting
91779|NCT02491996|desire model
91780|NCT02491983|metastatic breast cancer
91781|NCT02491983|Endocrine receptors positive
91782|NCT02491983|HER-2 negative
91783|NCT02491957|Energy Expenditure
91784|NCT02491957|Physical Endurance
91785|NCT02491957|Muscle Stength
91786|NCT02491957|Metabolism
91787|NCT02491931|Cardiac Surgical Procedures
91788|NCT02491931|Cardiovascular Surgical Procedures
91789|NCT02491931|Dietary Supplements
91790|NCT02491931|Glutamine
91791|NCT02491931|TROPONIN I
91792|NCT02491931|cardiopulmonary bypass
91793|NCT02491879|mechanical low back pain
91794|NCT02491879|emergency department
91795|NCT02491879|ketoprofen
91796|NCT02491879|gel
91797|NCT02491840|gastric cancer
91798|NCT02491840|cardia cancer
91799|NCT02491827|optical biopsy
91800|NCT02491814|Dairy
91801|NCT02491814|Breakfast cereal
91802|NCT02491814|Postprandial Glycemia
91803|NCT02491814|Satiety
91804|NCT02491814|Food Intake
91805|NCT02491814|Milk
91806|NCT02491814|Yogurt
91807|NCT02491814|Soy
91808|NCT02491814|Almond
91809|NCT02491801|Dairy
91810|NCT02491801|Milk
91811|NCT02491801|Yogurt
91812|NCT02491801|Cheese
91813|NCT02491801|Postprandial glycaemia
91814|NCT02491801|Satiety
91815|NCT02491801|Food Intake
91816|NCT02491801|Elderly
91817|NCT02491801|Prevention and Treatment
91818|NCT02491762|Serratus Anterior
91819|NCT02491762|Accessory Respiratory
91820|NCT02491762|Tissue Expander
91821|NCT02491762|Respiratory Function Tests
91822|NCT02491749|Cardiac anesthesia
91823|NCT02491749|ultra fast track
91824|NCT02491749|ICU stay
91825|NCT02491710|Surgical education
91826|NCT02491710|Laparoscopy
91827|NCT02491710|Laparoscopic suturing
91828|NCT02491697|DC-CIK
91829|NCT02491697|Breast cancer
91830|NCT02491697|Capecitabine
91831|NCT02491684|asthma
91832|NCT02491684|Upper Respiratory Tract Infection
91833|NCT02491684|exacerbation
91834|NCT02491684|Interferon
91835|NCT02491684|efficacy
91836|NCT02491684|safety
91837|NCT02491684|prevention
91838|NCT02491671|Prevention PAL Prolonged Air Leak (PAL)
91839|NCT02491671|Lung Resection
91840|NCT02491671|Thoracic Surgery
91841|NCT02491671|Post-operative Thoracic Air Leak
91842|NCT02491645|Autistic spectrum disorder
91843|NCT02491645|Sensory processing abnormalities
91844|NCT02491645|Sensory interventions
91845|NCT02491645|occupational therapy
91846|NCT02491632|Advanced Cancers
91847|NCT02491632|Dexamethasone
91848|NCT02491632|Decadron
91849|NCT02491632|Exercise
91850|NCT02491632|Physical activity
91851|NCT02491632|Questionnaires
91852|NCT02491632|Surveys
91853|NCT02491632|Physical activity tests
91854|NCT02491632|Phone calls
91855|NCT02491619|Angle class III
91856|NCT02491619|tomography
91857|NCT02491619|tooth inclination
91858|NCT02491619|bone thickness
91859|NCT02491593|fecal occult blood
91860|NCT02491554|Deep Brain Stimulation
91861|NCT02491554|Essential tremor
91862|NCT02491554|DISTINCT
91863|NCT02491554|MR-tractography guided DBS implantation
91864|NCT02491554|Conventional AC-PC based DBS implantation
91865|NCT02491515|Osteoporosis
91866|NCT02491515|BMD
91867|NCT02491515|denosumab
91868|NCT02491515|previous therapy
91869|NCT02491489|Manual therapy
91870|NCT02491476|Safety
91871|NCT02491476|Electrodes
91872|NCT02491476|Device
91873|NCT02491476|StereoElectroencephalograph
91874|NCT02491476|Epileptogenic zone
91876|NCT02491463|Reactogenicity
91877|NCT02491463|Safety
91878|NCT02491463|Respiratory syncytial virus (RSV)
91879|NCT02491463|Vaccine
91880|NCT02491463|Immunogenicity
91881|NCT02491424|Osseointegration
91882|NCT02491424|Direct skeletal attachment
91883|NCT02491385|Thoracic epidural analgesia
91884|NCT02491385|bowel function recovery
91885|NCT02491333|polycystic ovary syndrome
91886|NCT02491333|acupuncture
91887|NCT02491333|insulin resistance
91888|NCT02491333|HOMA-IR
91889|NCT02491333|metformin
91890|NCT02491320|polycystic ovary syndrome
91891|NCT02491320|acupuncture
91892|NCT02491320|pre-treatment
91893|NCT02491320|Letrozole
91894|NCT02491320|Live Birth
91895|NCT02491294|School
91896|NCT02491294|Family
91897|NCT02491294|Fruit and Vegetables
91898|NCT02491294|Cooking
91899|NCT02491294|Physical Activity
91900|NCT02491281|Primary Osteoarthritis, Total Knee Replacement, cartilage
91901|NCT02491242|HIV
91902|NCT02491242|dolutegravir
91903|NCT02491242|intolerance
91904|NCT02491242|dual therapies
91905|NCT02491229|non-alcoholic fatty liver disease (NAFLD)
91906|NCT02491229|Obesity
91907|NCT02491229|Hepafast
91908|NCT02491216|Frailty
91909|NCT02491216|Frail elderly
91910|NCT02491216|Acupressure
91911|NCT02491216|Pragmatic Randomised Controlled Trial
91912|NCT02491203|Virtual reality
91913|NCT02491203|telerehabilitation
91914|NCT02491203|Stroke rehabilitation
91915|NCT02491177|HIV Transmission
91916|NCT02491177|Prevention of Mother to Child Transmission
91917|NCT02491177|Linkage to care
91918|NCT02491177|Retention in care
91919|NCT02491177|Community Mentor Mothers
91920|NCT02491177|Mobile phone text messaging
91921|NCT02491177|Antiretroviral therapy adherence
91922|NCT02491177|Infant Health
91923|NCT02491177|Maternal CD4/viral loads
91924|NCT02491177|Early infant diagnosis
91925|NCT02491177|Acceptability of interventions
91926|NCT02491177|Vertical transmission
91927|NCT02491138|participants
91928|NCT02491086|intervention, nicotine replacement sampling, smoking cessation, smoking hotspots
91929|NCT02491034|Depression
91930|NCT02491034|Hispanics
91931|NCT02491034|Stigma
91932|NCT02491034|Barriers to Treatment
91933|NCT02491008|Thyroid Dysfunction
91934|NCT02491008|Bone mineral density
91935|NCT02491008|Osteoporosis
91936|NCT02491008|Fractures, Bone
91937|NCT02491008|Randomized Controlled Trial
91938|NCT02490995|children
91939|NCT02490969|copeptin
91940|NCT02490969|rule out marker, emergency department, cheast pain unit
91941|NCT02490969|emergency department
91942|NCT02490969|chest pain unit
91943|NCT02490956|Diagnostic immunization with rabies vaccine
91944|NCT02490956|Primary immunodeficiency
91945|NCT02490943|peginterferon beta-1a
91946|NCT02490943|MS (Multiple Sclerosis)
91947|NCT02490943|Injection Site Reaction Erythema
91948|NCT02490930|lymphopenia
91949|NCT02490917|Female urinary incontinence
91950|NCT02490917|Sphincter deficiency
91951|NCT02490904|Kidney transplantation
91952|NCT02490904|Eplerenon
91953|NCT02490891|Lymphoma, angiogenesis, PET scan
91954|NCT02490839|Helicobacter pylori
91955|NCT02490839|high dose dual therapy
91956|NCT02490839|bismuth-containing quadruple therapy
91957|NCT02490839|antibiotic resistance
91958|NCT02490826|Speech Sound Disorders
91959|NCT02490826|Tabletop
91960|NCT02490826|Digital
91961|NCT02490813|Fish allergy
91962|NCT02490813|shrimp allergy
91963|NCT02490813|crab allergy
91964|NCT02490813|traditional Chinese medicine
91965|NCT02490761|Geriatrics
91966|NCT02490761|Nutritional Status
91967|NCT02490761|Hospitalisation
91968|NCT02490722|Patient education
91969|NCT02490722|Empowerment
91970|NCT02490709|Rectal neoplasms
91971|NCT02490709|Colorectal neoplasms
91972|NCT02490709|Local excision
91973|NCT02490696|PET scan
91974|NCT02490696|FAZA
91975|NCT02490696|F-Miso
91976|NCT02490696|hypoxia
91977|NCT02490696|lung cancer
91978|NCT02490631|skin flora
91979|NCT02490605|Postural balance
91980|NCT02490605|Temporomandibular disorders
91981|NCT02490605|Splints
91982|NCT02490579|video messaging
91983|NCT02490579|exercise
91984|NCT02490579|diet
91985|NCT02490579|weight gain
91986|NCT02490579|pregnancy
91987|NCT02490566|chronic condition
91988|NCT02490566|telehealth
91989|NCT02490566|nutrition
91990|NCT02490566|exercise
91991|NCT02490553|air pollution
91992|NCT02490553|epidemiological survey
91993|NCT02490553|representative sample
91994|NCT02490540|opioids
91995|NCT02490540|analgesia
91996|NCT02490540|pain
91997|NCT02490540|anesthesia
91998|NCT02490527|myopathy
91999|NCT02490527|muscular weakness
92000|NCT02490527|cramping
92001|NCT02490527|fatigue
92002|NCT02490488|ovarian cancer
92003|NCT02490462|Cerebral Palsy
92004|NCT02490462|Physical Therapy
92005|NCT02490462|Family-centered Care
92006|NCT02490384|Cervical cerclage
92007|NCT02490345|gabapentin
92008|NCT02490319|radiation pneumonitis
92009|NCT02490319|lung cancer
92010|NCT02490319|prediction models
92011|NCT02490319|genetic variants
92012|NCT02490241|pregnant
92013|NCT02490241|female
92014|NCT02490241|women
92015|NCT02490241|lithium
92016|NCT02490241|bipolar
92017|NCT02490228|female
92018|NCT02490228|minimally invasive surgery
92019|NCT02490150|Corifollitropin alfa
92020|NCT02490150|Stimulation protocol
92021|NCT02490124|Diabetes Type 1
92022|NCT02490124|Vascular Function
92023|NCT02490098|Type 1 diabetes
92024|NCT02490098|Closed-loop system
92025|NCT02490098|Artificial pancreas
92026|NCT02490098|Insulin
92027|NCT02490098|Glucagon
92028|NCT02490098|Hypoglycemia
92029|NCT02490098|Postprandial glucose
92030|NCT02490085|Type 2 diabetes
92031|NCT02490085|Closed-loop strategy
92032|NCT02490085|Artificial pancreas
92033|NCT02490085|Insulin
92034|NCT02490085|Elderly
92035|NCT02490085|Multiple daily injections
92036|NCT02490085|Hypoglycemia
92037|NCT02490046|D mannose
92038|NCT02490046|multiple sclerosis
92039|NCT02490046|recurrent urinary infections
92040|NCT02490020|Renal transplantation
92041|NCT02490020|mesenchymal stem cell
92042|NCT02490020|Transplantation Rejection
92043|NCT02490020|donation after cardiac death
92044|NCT02490007|Acellular pertussis vaccine
92045|NCT02490007|whole cell pertussis vaccine
92046|NCT02490007|IgE-mediated food allergy
92047|NCT02489916|Metastatic Colorectal Cancer
92048|NCT02489916|CM4307
92049|NCT02489916|Previously treated metastatic colorectal cancer
92050|NCT02489903|Epigenetics
92051|NCT02489903|resensitization
92052|NCT02489903|Platinum doublets
92053|NCT02489903|lung cancer
92054|NCT02489903|Ovarian epithelial cancer
92055|NCT02489877|multiple sclerosis
92056|NCT02489877|HERV-W virus
92057|NCT02489877|Herpesviridae family
92058|NCT02489864|Terlipressin
92059|NCT02489864|mean arterial pressure
92060|NCT02489864|type 2 HRS
92061|NCT02489838|Liver Neoplasma
92062|NCT02489838|Lung Radiation dose
92063|NCT02489825|randomized controlled trial
92064|NCT02489825|vertebral fracture
92065|NCT02489825|osteoporosis
92066|NCT02489825|vertebroplasty
92067|NCT02489825|augmentation
92068|NCT02489812|children
92069|NCT02489812|behavior
92070|NCT02489812|anxiety
92071|NCT02489812|dentistry
92072|NCT02489799|advance care planning
92073|NCT02489773|Lucica
92074|NCT02489773|glycated albumin
92075|NCT02489773|GA
92076|NCT02489773|fructosamine
92077|NCT02489760|Etanercept
92078|NCT02489760|Adalimumab
92079|NCT02489760|Ankylosing Spondylitis
92080|NCT02489760|Switch Study
92081|NCT02489747|cognitive function
92082|NCT02489747|CNT
92083|NCT02489747|memory function
92084|NCT02489747|Triticum aestivum L
92085|NCT02489747|wheat bran
92086|NCT02489734|sevoflurane
92087|NCT02489734|emergence delirium
92088|NCT02489734|preschool
92089|NCT02489721|peripherally inserted central venous catheter
92090|NCT02489721|depp vein thrombosis
92091|NCT02489721|related blood stream infections
92092|NCT02489721|midline
92093|NCT02489708|Bronchiolitis
92094|NCT02489708|Cough
92095|NCT02489708|Ear Infection
92096|NCT02489708|Respiratory Infection
92097|NCT02489708|Wheezing
92098|NCT02489708|Clinical Decision Support Systems
92099|NCT02489695|locally advanced or metastatic
92100|NCT02489656|Double loop ureteral stent
92101|NCT02489656|USSQ
92102|NCT02489656|Quality of life
92103|NCT02489656|Pain
92104|NCT02489604|neuroendocrine tumors
92105|NCT02489578|Community Acquired Pneumonia
92106|NCT02489578|health care associated pneumonia
92107|NCT02489565|Coronary Artery Disease
92108|NCT02489565|stable
92109|NCT02489565|Telemedicine
92110|NCT02489565|Patient Discharge
92111|NCT02489539|Aortic aneurysm
92112|NCT02489539|Abdominal aorta
92113|NCT02489539|Stent graft
92114|NCT02489539|Aneurysm
92115|NCT02489539|Vascular Diseases
92116|NCT02489539|Cardiovascular Diseases
92117|NCT02489500|AL Amyloidosis
92118|NCT02489500|Stem Cell Transplantation
92119|NCT02489448|Breast Cancer
92120|NCT02489383|Asthma
92121|NCT02489383|Continuous Exercise Training
92122|NCT02489383|interval Exercise Training
92123|NCT02489383|Clinical Control
92124|NCT02489383|Inflammation
92125|NCT02489370|home care
92126|NCT02489370|telecare
92127|NCT02489370|telehealth
92128|NCT02489370|telemonitoring
92129|NCT02489370|chronic heart failure
92130|NCT02489370|randomized controlled trial
92131|NCT02489370|Congestive Heart Failure
92132|NCT02489370|telemedicine
92133|NCT02489331|Dyslipidemias
92134|NCT02489318|Prostate Cancer
92135|NCT02489318|JNJ-56021927
92136|NCT02489318|Androgen Deprivation Therapy
92137|NCT02489318|ARN-509
92138|NCT02489318|Apalutamide
92139|NCT02489318|TITAN
92140|NCT02489318|Metastatic Hormone-sensitive Prostate Cancer
92141|NCT02489305|Depressive Disorder, Major
92142|NCT02489305|Depression
92143|NCT02489305|Anti-Depressant
92144|NCT02489305|Observational
92145|NCT02489292|Urea Cycle Disorder
92146|NCT02489292|UCD
92147|NCT02489292|cell therapy
92148|NCT02489292|stem cell
92149|NCT02489279|Attention deficit hyperactivity disorder.
92150|NCT02489279|Attention training
92151|NCT02489279|Mobile devices
92152|NCT02489279|Brain training
92153|NCT02489266|Melanoma
92154|NCT02489266|Immunotherapy
92155|NCT02489227|PsO
92156|NCT02489214|donafenib
92157|NCT02489201|donafenib
92158|NCT02489188|gait asymmetry
92159|NCT02489188|joint angles
92160|NCT02489175|Parastomal hernia
92161|NCT02489175|prevention
92162|NCT02489175|stomaplasty
92163|NCT02489175|ring
92164|NCT02489149|food insecurity
92165|NCT02489136|spiritist passe
92166|NCT02489136|laying of hands
92167|NCT02489136|newborn
92168|NCT02489136|adult
92169|NCT02489136|conditions
92170|NCT02489110|Alzheimer's Disease
92171|NCT02489110|Dementia
92172|NCT02489110|caregiving
92173|NCT02489110|caregiver
92174|NCT02489110|coping
92175|NCT02489110|coping with caregiving
92176|NCT02489110|stress
92177|NCT02489110|Hispanic caregiver
92178|NCT02489110|Latino caregiver
92179|NCT02489084|Head and Neck neoplasms
92180|NCT02489084|Genome-wide association study
92181|NCT02489084|Polymorphism, single nucleotide
92182|NCT02489084|Toxicity
92183|NCT02489019|Anesthesia
92184|NCT02489019|Fentanyl
92185|NCT02489019|Elderly
92186|NCT02488954|Ulcerative colitis
92187|NCT02488954|Probiotics
92188|NCT02488954|treatments
92189|NCT02488954|Propionibacterium freudenreichii
92190|NCT02488941|Liver Function Tests
92191|NCT02488941|Blood Coagulation
92192|NCT02488928|NSCLC
92193|NCT02488928|EBUS
92194|NCT02488928|elastography
92195|NCT02488928|predictive value
92196|NCT02488928|strain
92197|NCT02488915|Brain
92198|NCT02488915|Brain Clot
92199|NCT02488915|Brain Diseases
92200|NCT02488915|Brain Infarction
92201|NCT02488915|Cerebral Ischemia
92202|NCT02488915|Cerebrovascular Disorders
92203|NCT02488915|EmboTrap® Revascularization Device
92204|NCT02488915|EmboTrap
92205|NCT02488915|Ischemia
92206|NCT02488915|Ischemic
92207|NCT02488915|Ischemic Stroke
92208|NCT02488915|Mechanical Thrombectomy
92209|NCT02488915|Neurovascular Intervention
92210|NCT02488915|Revascularization
92211|NCT02488915|Stent Retriever
92212|NCT02488915|Stroke
92213|NCT02488915|Vascular Diseases
92214|NCT02488915|Neuravi
92215|NCT02488889|Chantix
92216|NCT02488876|Cardiac surgery
92217|NCT02488876|Tissue sample database
92218|NCT02488876|Inflammatory responds
92219|NCT02488850|immune monitoring
92220|NCT02488850|T cell activation
92221|NCT02488850|early stage
92222|NCT02488837|Deep Brain Stimulation
92223|NCT02488824|Quadriplegia
92224|NCT02488824|Paraplegia
92225|NCT02488824|Spinal Cord Injury
92226|NCT02488824|Body Temperature Regulation
92227|NCT02488824|Mild Cognitive Impairment
92228|NCT02488785|Type 2 Diabetes Mellitus
92229|NCT02488785|Telehealth
92230|NCT02488785|Hispanics
92231|NCT02488785|Latinos
92232|NCT02488785|Self-Care
92233|NCT02488785|Mobile Health
92234|NCT02488785|mHealth
92235|NCT02488772|sleep quality
92236|NCT02488772|emergency department
92237|NCT02488733|type 2 diabetes mellitus
92238|NCT02488733|obesity
92239|NCT02488733|laparoscopic sleeve gastrectomy
92240|NCT02488733|bariatric surgery
92241|NCT02488733|metabolic surgery
92242|NCT02488720|amyloid imaging
92243|NCT02488720|biomarkers
92244|NCT02488720|cognition
92245|NCT02488720|longitudinal
92246|NCT02488720|cognitive decline
92247|NCT02488720|observational
92248|NCT02488707|low rectal cancer
92249|NCT02488707|minimally invasive colorectal surgery
92250|NCT02488707|trans-anal endoscopic microsurgery
92251|NCT02488707|TEM
92252|NCT02488707|intersphincteric resection
92253|NCT02488707|ISR
92254|NCT02488707|subtotal intersphincteric resection
92255|NCT02488707|total intersphincteric resection
92256|NCT02488707|trans-anal trans-abdominal resection
92257|NCT02488707|laparoscopic intersphincteric resection
92258|NCT02488707|anal sphincter preservation
92259|NCT02488707|total mesorectal excision
92260|NCT02488707|TME
92261|NCT02488707|TATA
92262|NCT02488707|laparoscopic total mesorectal excision
92263|NCT02488707|external sphincter preservation
92264|NCT02488707|Neoadjuvant chemo-radiotherapy for rectal cancer
92265|NCT02488707|fit patients for minimally invasive surgery
92266|NCT02488668|Transcutaneous Electrical Stimulation
92267|NCT02488668|Neuroplasticity
92268|NCT02488668|Sensory Feedback
92269|NCT02488642|Isosorbide dinitrate gel solution
92270|NCT02488642|late intrauterine death
92271|NCT02488642|nitric oxide donors
92272|NCT02488629|Head and neck squamous cell carcinoma
92273|NCT02488616|Closed-loop system
92274|NCT02488616|Artificial pancreas
92275|NCT02488616|Type 1 diabetes
92276|NCT02488616|Hypoglycemia
92277|NCT02488616|Glucagon
92278|NCT02488616|Insulin
92279|NCT02488603|Breast Neoplasms
92280|NCT02488603|Tamoxifen
92281|NCT02488603|Decision Aids
92282|NCT02488564|HER-2 Positive Breast Cancer
92283|NCT02488564|operable breast cancer
92284|NCT02488564|locally advanced breast cancer
92285|NCT02488564|no prior therapy
92286|NCT02488564|pCR
92287|NCT02488525|Acquired Von Willebrand
92288|NCT02488525|Gastro-intestinal bleeding
92289|NCT02488525|LVAD
92290|NCT02488512|Relapsed/refractory diffuse large b cell
92291|NCT02488512|Relapsed/refractory mantle cell lymphomas
92292|NCT02488512|DLBCL
92293|NCT02488512|MCL
92294|NCT02488512|90Y-DOTATOC
92295|NCT02488512|SSR-positive tumour
92296|NCT02488499|Disruptive Behaviour Disorder
92297|NCT02488499|Psychosocial
92298|NCT02488499|Group Treatment
92299|NCT02488473|Volunteers
92300|NCT02488460|Motor Activity
92301|NCT02488460|Cognition
92302|NCT02488460|Academic Acheivement
92303|NCT02488460|Preadolescent Children
92304|NCT02488447|Allergy
92305|NCT02488447|Allergic rhinoconjunctivitis
92306|NCT02488447|Immunotherapy
92307|NCT02488447|Life Quality
92308|NCT02488447|Adherence
92309|NCT02488434|ICSI
92310|NCT02488434|sperm selection
92311|NCT02488434|fertile chip
92312|NCT02488434|ıcsı outcomes
92313|NCT02488395|Parkinson's disease
92314|NCT02488395|Non-motor symptoms
92315|NCT02488395|Visual deficits
92316|NCT02488395|Superior colliculus
92317|NCT02488395|fMRI
92318|NCT02488382|lymphoma
92319|NCT02488382|multiple myeloma
92320|NCT02488382|stem cell mobilization
92321|NCT02488382|autologous stem cell transplantation
92322|NCT02488369|Children and adolescents
92323|NCT02488343|Multiple Sclerosis
92324|NCT02488343|Adherence
92325|NCT02488343|Therapies
92326|NCT02488343|Psychological Intervention
92327|NCT02488317|Chronic Kidney Disease
92328|NCT02488317|Hemodialysis
92329|NCT02488317|Peritoneal Dialysis
92330|NCT02488304|HRCT
92331|NCT02488304|High Resolution Computed Tomography scans
92332|NCT02488304|Functional Respiratory Imaging
92333|NCT02488304|FRI
92334|NCT02488304|Computed Tomography
92335|NCT02488304|CT
92336|NCT02488304|Bronchiolitis Obliterans Syndrome
92337|NCT02488304|BOS
92338|NCT02488304|Lung Transplant
92339|NCT02488291|Epidural
92340|NCT02488291|Analgesia labor
92341|NCT02488291|Perinatal
92342|NCT02488291|anesthesia
92343|NCT02488278|Glucose blood measurements, glucometers ,audio communication
92344|NCT02488265|Parkinson´s disease
92345|NCT02488265|Physicaltherapy
92346|NCT02488265|Postural Balance
92347|NCT02488265|Gait
92348|NCT02488265|Rehabilitation
92349|NCT02488252|Chinese Medicine
92350|NCT02488252|ACEI
92351|NCT02488252|ARB
92352|NCT02488252|Pragmatic trial
92353|NCT02488213|Nutritional Counseling
92354|NCT02488213|Diet
92355|NCT02488187|Breast Cancer
92356|NCT02488187|MRI
92357|NCT02488187|Mammogram
92358|NCT02488187|Whole Breast Sonogram
92359|NCT02488187|ABUS
92360|NCT02488161|Colorectal cancer
92361|NCT02488161|Risk factors
92362|NCT02488161|Adverse events
92363|NCT02488161|Predictive models
92364|NCT02488122|Bone Mineral Density
92365|NCT02488122|Isometric Exercise
92366|NCT02488122|Bone Growth
92367|NCT02488109|anorexia nervosa
92368|NCT02488109|eating disorders
92369|NCT02488109|refeeding
92370|NCT02488109|adolescent medicine
92371|NCT02488109|nutritional rehabilitation
92372|NCT02488083|non-invasive
92373|NCT02488031|SCA, dysmetria
92374|NCT02488018|Glycemic index
92375|NCT02488018|honey
92376|NCT02488018|reference glucose
92377|NCT02488005|Inflammatory Bowel Disease
92378|NCT02488005|Small Bowel
92379|NCT02488005|Crohn's Disease
92380|NCT02488005|Small Bowel Ultrasound
92381|NCT02487966|tDCS
92382|NCT02487966|Mirror Therapy
92383|NCT02487966|Phantom Limb Pain
92384|NCT02487966|Traumatic amputation
92385|NCT02487953|Nicotine addiction
92386|NCT02487953|Cigarette smoking
92387|NCT02487953|Smoking cessation
92388|NCT02487953|Nicotine patches
92389|NCT02487953|E-cigarettes
92390|NCT02487940|Recurrent implantation failure
92391|NCT02487940|IVF
92392|NCT02487940|ICSI
92393|NCT02487940|Intralipid
92394|NCT02487914|Drug Delivery
92395|NCT02487914|Iontophoresis
92396|NCT02487914|Lidocaine
92397|NCT02487914|Pressure
92398|NCT02487914|Tactile perception
92399|NCT02487901|arthrodesiss
92400|NCT02487901|cervical vertebra
92401|NCT02487901|laminoplasty
92402|NCT02487888|Genetic Variation
92403|NCT02487888|Genetic Polymorphism
92404|NCT02487888|Polymorphism, Single Nucleotide
92405|NCT02487888|Genetic Association Studies
92406|NCT02487888|Healthcare Utilization
92407|NCT02487875|Sit-to-stand test
92408|NCT02487875|Muscle strength
92409|NCT02487875|Pulmonary rehabilitation
92410|NCT02487836|Laying of the biliary stent
92411|NCT02487771|DHA
92412|NCT02487771|childhood development
92413|NCT02487745|Cocaine
92414|NCT02487745|Methadone
92415|NCT02487745|Employment
92416|NCT02487745|Opioids
92417|NCT02487732|Diabetic Patients With Non-ST Elevation
92418|NCT02487719|Iron deficiecy
92419|NCT02487719|pregnancy
92420|NCT02487719|prenatal care
92421|NCT02487706|Hemodialysis
92422|NCT02487706|HIV-infection
92423|NCT02487654|Paroxysmal atrial fibrillation
92424|NCT02487654|Pulmonary vein isolation
92425|NCT02487654|Ganglionic plexi
92426|NCT02487654|Radiofrequency
92427|NCT02487654|late gadolinium enhancement cardiac MR imaging
92428|NCT02487654|High Frequency Stimulation
92429|NCT02487641|Ultrasound
92430|NCT02487641|mid-trimester
92431|NCT02487641|Obesity
92432|NCT02487641|pregnancy
92433|NCT02487615|Glycaemia
92434|NCT02487615|Subclinical Atherosclerosis
92435|NCT02487615|Carotid Doppler Ultrasound
92436|NCT02487615|Carotid Plaque
92437|NCT02487615|Intima Media Thickness
92438|NCT02487615|Ankle Brachial Index
92439|NCT02487615|Exercise Stress Test
92440|NCT02487615|Coronary Calcium Score
92441|NCT02487615|Insulinemia
92442|NCT02487615|Leptin
92443|NCT02487615|Inflammation
92444|NCT02487615|Resistin
92445|NCT02487615|Tumor Necrosis Factor alpha
92446|NCT02487615|Phospholipase A2, Group VII
92447|NCT02487615|Body Mass Index
92448|NCT02487615|Adipose Tissue Function
92449|NCT02487615|Single Gene Polymorphism
92450|NCT02487589|Falls
92451|NCT02487589|Elderly
92452|NCT02487589|e-Health
92453|NCT02487589|Telemedicine
92454|NCT02487563|Isolated thrombocytopenia
92455|NCT02487563|decitabine
92456|NCT02487563|rhTPO
92457|NCT02487550|Renal neoplasma
92458|NCT02487550|CIK cells
92459|NCT02487537|incretin release
92460|NCT02487524|Neuropathic Pain
92461|NCT02487524|Breast Cancer
92462|NCT02487524|Post surgical
92463|NCT02487498|Chronic Obstructive Pulmonary Disease (COPD)
92464|NCT02487472|France
92465|NCT02487472|Post-herpetic neuralgia
92466|NCT02487472|Herpes zoster
92467|NCT02487472|Economic burden of disease
92468|NCT02487459|acute lymphoblastic leukemia
92469|NCT02487459|acute myeloid leukemia
92470|NCT02487459|chronic myeloid leukemia
92471|NCT02487459|myelodysplastic syndrome
92472|NCT02487459|non-hodgkin lymphoma
92473|NCT02487459|hodgkin lymphoma
92474|NCT02487446|Chronic Obstructive Pulmonary Disease (COPD)
92475|NCT02487433|food effect
92476|NCT02487433|pharmacokinetics
92477|NCT02487433|healthy volunteers
92478|NCT02487381|delta-9-tetrahydrocannabinol
92479|NCT02487381|cannabidiol
92480|NCT02487381|COMT
92481|NCT02487381|Volunteers
92482|NCT02487355|dexmedetomidine
92483|NCT02487355|magnesium sulphate
92484|NCT02487342|Dairy
92485|NCT02487342|appetite
92486|NCT02487342|feeding behaviour
92487|NCT02487329|Direct pulp capping
92488|NCT02487329|Er,Cr:YSGG laser
92489|NCT02487329|Tricalcium silicate
92490|NCT02487316|Anaplastic Large Cell Lymphoma
92491|NCT02487316|anaplastic lymphoma kinase rearrangement
92492|NCT02487316|crizotinib
92493|NCT02487316|CHOP chemotherapy
92494|NCT02487303|Acetaminophen
92495|NCT02487303|Pain, Postoperative
92496|NCT02487303|Analgesia, Obstetrical
92497|NCT02487303|Cesarean Section
92498|NCT02487277|Pancreatic
92499|NCT02487251|Obesity
92500|NCT02487251|Family Mealtimes
92501|NCT02487251|Prevention
92502|NCT02487238|Microbiome
92503|NCT02487238|Microbiota
92504|NCT02487238|Fecal Microbial Transplant
92505|NCT02487238|FMT
92506|NCT02487238|Pediatrics
92507|NCT02487238|Gastroenterology
92508|NCT02487238|IBD
92509|NCT02487238|Inflammatory Bowel Disease
92510|NCT02487238|Ulcerative Colitis
92511|NCT02487238|UC
92512|NCT02487238|Inflammatory Bowel Disease Unclassified
92513|NCT02487238|IBD-U
92514|NCT02487238|Rebiotix
92515|NCT02487238|RBX2660
92516|NCT02487212|fractional laser
92517|NCT02487212|hypertrophic scar
92518|NCT02487212|topical corticosteroid
92519|NCT02487212|laser assisted delivery systems
92520|NCT02487199|hepatitis C infection
92521|NCT02487199|interferon
92522|NCT02487199|hepatitis C
92523|NCT02487199|treatment experienced
92524|NCT02487199|severe kidney disease
92525|NCT02487199|Chronic Kidney Disease
92526|NCT02487186|Chronic periodontitis
92527|NCT02487186|Local doxycycline
92528|NCT02487186|Ultrasonic debridement
92529|NCT02487186|PLGA microspheres
92530|NCT02487186|Microbiologic assessment
92531|NCT02487147|Live Attenuated Influenza Vaccine (FluMist)
92532|NCT02487147|Free Air Portable Air Powered Respirator
92533|NCT02487147|N95 Respirator
92534|NCT02487147|Personal Protective Equipment
92535|NCT02487147|Viral Transmission
92536|NCT02487121|weight loss
92537|NCT02487095|RB1 Inactivation
92538|NCT02487095|Kinase Inhibitor
92539|NCT02487095|DNA Damage Response Network
92540|NCT02487095|MYC And CCNE1 Activation
92541|NCT02487095|Defective ATM-p53 Signaling Pathway
92542|NCT02487082|Autism Spectrum Disorder
92543|NCT02487082|Children
92544|NCT02487082|Melatonin
92545|NCT02487082|Donepezil
92546|NCT02487082|Sleep disorder
92547|NCT02487056|Heart Failure
92548|NCT02487056|Diagnosis
92549|NCT02487056|Management
92550|NCT02487043|Caries prevention
92551|NCT02487043|Early Childhood Caries
92552|NCT02487030|HCV genotype 4 (GT-4)
92553|NCT02487030|HCV
92554|NCT02487030|Sustained Virologic Response
92555|NCT02487030|Direct Acting Antiviral
92556|NCT02487030|Combination Therapy
92557|NCT02487030|GS-7977
92558|NCT02487030|GS-5885
92559|NCT02487030|Ribavirin
92560|NCT02487030|Sofosbuvir
92561|NCT02487030|ledipasvir
92562|NCT02487030|Hepatitis C
92563|NCT02487030|Hepatitis C, Chronic
92564|NCT02487030|Liver Diseases
92565|NCT02487030|Virus Diseases
92566|NCT02487030|Antiviral Agents
92567|NCT02486965|VAS
92568|NCT02486965|thermode test
92569|NCT02486965|training program
92570|NCT02486965|6MWT
92571|NCT02486913|Primary prevention
92572|NCT02486913|National Health Service Health Check
92573|NCT02486900|Craving
92574|NCT02486900|Cue Reactivity
92575|NCT02486900|Neurofeedback
92576|NCT02486887|telemonitoring
92577|NCT02486874|Human acellular dermal matrix, burns, wound healing
92578|NCT02486861|Tomography, Optical Coherence
92579|NCT02486848|Hairloss
92580|NCT02486848|Female Pattern Hair Loss
92581|NCT02486848|Androgenetic Alopecia
92582|NCT02486848|Minoxidil
92583|NCT02486822|Labor scale
92584|NCT02486822|Partograph
92585|NCT02486822|Spontaneous labor
92586|NCT02486822|Primigravida
92587|NCT02486744|Acthar
92588|NCT02486744|Dialysis
92589|NCT02486744|Kidney
92590|NCT02486744|Non-Diabetic
92591|NCT02486731|Hormonal sensitivity
92592|NCT02486731|bone growth
92593|NCT02486705|ptsd
92594|NCT02486705|family
92595|NCT02486705|caregiver
92596|NCT02486705|burden
92597|NCT02486692|Mental Health
92598|NCT02486692|PTSD
92599|NCT02486692|Stigma
92600|NCT02486692|Peer Education
92601|NCT02486692|Web Education
92602|NCT02486692|Self Help
92603|NCT02486653|tamsulosin
92604|NCT02486653|randomized controlled trials as topic
92605|NCT02486653|double-blind method
92606|NCT02486653|random allocation
92607|NCT02486653|placebos
92608|NCT02486653|Adrenergic alpha-Antagonists
92609|NCT02486653|urinary retention
92610|NCT02486653|urinary tract infections
92611|NCT02486653|urinary catheters
92612|NCT02486653|catheter-related infections
92613|NCT02486653|postoperative complications
92614|NCT02486640|RRMS, CIS
92615|NCT02486627|cUTI
92616|NCT02486627|AP
92617|NCT02486627|ACHN-490
92618|NCT02486627|anti-infective
92619|NCT02486627|anti-bacterial
92620|NCT02486627|antibiotic
92621|NCT02486627|anti-microbial
92622|NCT02486627|UTI
92623|NCT02486627|bacterial infection
92624|NCT02486627|Gram-negative
92625|NCT02486588|Financial incentives
92626|NCT02486588|Messaging
92627|NCT02486575|Residents
92628|NCT02486575|Training
92629|NCT02486575|simulation
92630|NCT02486575|mentoring
92631|NCT02486575|proctor
92632|NCT02486562|Multiple Sclerosis
92633|NCT02486562|MS
92634|NCT02486549|Pain
92635|NCT02486549|Anesthesia Recovery Period
92636|NCT02486549|Brachial Plexus
92637|NCT02486536|capsule endoscopy
92638|NCT02486536|polyethylene glycol
92639|NCT02486536|bowel preparation solutions
92640|NCT02486523|SAM, severe acute malnutrition
92641|NCT02486510|HIV-1
92642|NCT02486510|CCR5 coreceptors
92643|NCT02486510|Maraviroc
92644|NCT02486497|Pancreatic cancer
92645|NCT02486497|Adjuvant chemotherapy
92646|NCT02486497|hENT1
92647|NCT02486497|Gemcitabine
92648|NCT02486484|macular degeneration
92649|NCT02486484|diabetic retinopathy
92650|NCT02486484|macular edema
92651|NCT02486484|retinal vein occlusion
92652|NCT02486484|choroidal neovascularization
92653|NCT02486471|cervical dysplasia
92654|NCT02486471|colposcopy
92655|NCT02486471|haemostatic procedure
92656|NCT02486471|biopsy of the cervix uteri
92657|NCT02486458|Fluoride
92658|NCT02486458|Biofilm fluid
92659|NCT02486458|Calcium fluoride
92660|NCT02486458|Topical
92661|NCT02486445|Deep venous thrombosis
92662|NCT02486445|Rivaroxaban
92663|NCT02486406|Hepatitis C Genotype 4
92664|NCT02486406|Pediatric
92665|NCT02486406|Hepatitis C Genotype 1
92666|NCT02486406|Hepatitis C Virus
92667|NCT02486341|continuous glucose monitoring system
92668|NCT02486341|basal insulin
92669|NCT02486341|diabetes mellitus
92670|NCT02486341|elderly
92671|NCT02486328|Cognitive dysfunction
92672|NCT02486328|Colonoscopy
92673|NCT02486328|Sedation
92674|NCT02486315|coronary bifurcation
92675|NCT02486315|coronary stent
92676|NCT02486289|Mercury toxicity poisoning
92677|NCT02486263|infant
92678|NCT02486263|esophagitis
92679|NCT02486263|neonate
92680|NCT02486263|GERD
92681|NCT02486237|diabetes mellitus
92682|NCT02486237|complications
92683|NCT02486237|prevalence
92684|NCT02486224|deep sea mineral water
92685|NCT02486224|exercise recovery
92686|NCT02486224|hydration
92687|NCT02486224|salivary osmolar concentration
92688|NCT02486224|urinary osmolar concentration
92689|NCT02486211|heart arrest
92690|NCT02486211|resuscitation
92691|NCT02486211|seizures
92692|NCT02486211|hypothermia, induced
92693|NCT02486211|Amantadine
92694|NCT02486198|Gastrointestinal cancer
92695|NCT02486198|oxaliplatin
92696|NCT02486198|neurotoxicity
92697|NCT02486120|Genetic Counseling
92698|NCT02486120|Clinical Decision-Making
92699|NCT02486107|cervical vertebra
92700|NCT02486107|surgery
92701|NCT02486107|tubular retractor
92702|NCT02486107|endoscope
92703|NCT02486094|Imaging, Magnetic Resonance
92704|NCT02486094|Rectal Cancer
92705|NCT02486094|Apoptosis
92706|NCT02486094|Proliferation
92707|NCT02486094|Cancer
92708|NCT02486094|Tissue Study
92709|NCT02486081|Assistive device
92710|NCT02486081|the disabled
92711|NCT02486081|special education
92712|NCT02486081|movement analysis
92713|NCT02486081|system development
92714|NCT02486055|Study safety of BPM31510 in healthy subjects
92715|NCT02486042|ROP
92716|NCT02486042|Premature infant
92717|NCT02486016|Bioequivalence
92718|NCT02486016|Therapeutic Equivalency
92719|NCT02485990|Fallopian Tube
92720|NCT02485990|Epithelial Ovarian
92721|NCT02485990|EOC
92722|NCT02485977|Pulmonary hypertension
92723|NCT02485977|Magnetic Resonance Imaging
92724|NCT02485964|Vaccine
92725|NCT02485951|deep anterior lamellar keratoplasty
92726|NCT02485951|big-bubble technique
92727|NCT02485951|peripheral air injection
92728|NCT02485951|keratoconus
92729|NCT02485938|Duchenne Muscular Dystrophy
92730|NCT02485938|Cardiomyopathy
92731|NCT02485925|Interventional
92732|NCT02485925|Radiofrequency ablation
92733|NCT02485925|Paroxysmal Atrial Fibrillation
92734|NCT02485925|Catheter ablation
92735|NCT02485912|Ebola
92736|NCT02485912|vaccine
92737|NCT02485912|safety
92738|NCT02485912|immunogenicity
92739|NCT02485899|Late infantile Neuronal Ceroid Lipofuscinosis Type 2
92740|NCT02485899|LINCL
92741|NCT02485899|NCL2
92742|NCT02485899|CLN2
92743|NCT02485899|Jansky-Bielschowsky disease
92744|NCT02485886|PET, interstitial pulmonary fibrosis (IPF), cysteine cathepsins, macrophage
92745|NCT02485873|Non-valvular atrial fibrillation (NVAF)
92746|NCT02485873|Pevention
92747|NCT02485873|Stroke
92748|NCT02485860|pilonidal cysts
92749|NCT02485860|Cavity wound
92750|NCT02485860|long healing
92751|NCT02485860|honey
92752|NCT02485847|Eye Diseases
92753|NCT02485821|Estradiol
92754|NCT02485821|Misoprostol
92755|NCT02485821|Induction of labor
92756|NCT02485821|Cervical ripening
92757|NCT02485821|Bishop score
92758|NCT02485808|Lower Urinary Tract Symptoms
92759|NCT02485808|Bladder Symptoms
92760|NCT02485808|Overactive Bladder
92761|NCT02485808|Urinary Urgency
92762|NCT02485808|Lower Urinary Tract Dysfunction
92763|NCT02485795|Pain Management
92764|NCT02485795|Genetic Variation
92765|NCT02485795|Genetic Polymorphism
92766|NCT02485795|Polymorphism, Single Nucleotide Genetic Association Studies
92767|NCT02485795|Healthcare Utilization
92768|NCT02485756|Drug interactions
92769|NCT02485743|satiation
92770|NCT02485743|satiety
92771|NCT02485743|weight loss
92772|NCT02485743|maintained weight loss
92773|NCT02485730|Prevention
92774|NCT02485730|Cohort Analysis
92775|NCT02485730|Healthy Participants
92776|NCT02485678|ambulatory toxicity management
92777|NCT02485678|adjuvant or neoadjuvant chemotherapy
92778|NCT02485665|Prostate cancer
92779|NCT02485665|Robot-assisted laparoscopic surgery
92780|NCT02485665|Radical prostatectomy
92781|NCT02485665|Post-prostatectomy incontinence
92782|NCT02485665|Pelvic floor muscle exercise
92783|NCT02485665|Extracorporeal biofeedback device
92784|NCT02485652|NSCLC
92785|NCT02485652|EGFR-TKI
92786|NCT02485652|non small cell lung cancer
92787|NCT02485652|HM61713
92788|NCT02485652|T790M-positive
92789|NCT02485652|lung cancer
92790|NCT02485652|Phase II
92791|NCT02485652|Olmutinib
92792|NCT02485639|HA-specific plasmablasts,humoral immunity,influenza,memory B cells
92793|NCT02485626|Anthracyclines
92794|NCT02485600|LCIG
92795|NCT02485600|Duodopa
92796|NCT02485600|Parkinson's disease
92797|NCT02485600|Observational
92798|NCT02485600|Cadence
92799|NCT02485600|Levodopa-carbidopa intestinal gel
92800|NCT02485587|Arousal Biofeedback
92801|NCT02485587|Electrodermal activity
92802|NCT02485574|Bone bridging
92803|NCT02485574|Arthrodesis
92804|NCT02485574|Lumbar
92805|NCT02485574|Cage
92806|NCT02485561|Colon cancer screening
92807|NCT02485561|Colorectal cancer screening
92808|NCT02485561|Colonoscopy
92809|NCT02485561|Sigmoidoscopy
92810|NCT02485561|Stool blood test
92811|NCT02485561|Narrative
92812|NCT02485522|fecal incontinence
92813|NCT02485522|diet
92814|NCT02485522|nutrition
92815|NCT02485522|metabolites
92816|NCT02485522|stool
92817|NCT02485522|FI
92818|NCT02485379|Prostate cancer
92819|NCT02485379|Multiparametric MRI
92820|NCT02485379|Prostate biopsy
92821|NCT02485379|Targeted biopsy
92822|NCT02485379|Comparative study
92823|NCT02485366|Rejuvenated packed red blood cells
92824|NCT02485353|Vosaroxin
92825|NCT02485353|Cytarabine
92826|NCT02485353|Remission Induction
92827|NCT02485353|Safety
92828|NCT02485353|Progression-Free Survival
92829|NCT02485353|Mortality Rate
92830|NCT02485353|Length of Stay
92831|NCT02485314|children
92832|NCT02485314|disability
92833|NCT02485314|family
92834|NCT02485314|participation
92835|NCT02485301|Protection against Ebola Zaire virus
92836|NCT02485275|High Resolution MRI
92837|NCT02485275|Infarction
92838|NCT02485275|Intracranial artery stenosis
92839|NCT02485275|Cerebral small-vessel disease
92840|NCT02485262|Protease inhibitor treatment
92841|NCT02485249|Iontophoresis
92842|NCT02485249|Macular Edema
92843|NCT02485249|Ophthalmology
92844|NCT02485223|Multiple Sclerosis
92845|NCT02485223|MS
92846|NCT02485223|Diagnostic test
92847|NCT02485223|Central veins
92848|NCT02485223|MRI
92849|NCT02485210|photodynamic therapy , Endodontic treatment
92850|NCT02485197|Muscle Metabolic Function
92851|NCT02485197|Vitamin D Status
92852|NCT02485197|25(OH)D
92853|NCT02485197|Older Adults
92854|NCT02485158|Subjective Effects
92855|NCT02485158|Alcohol
92856|NCT02485158|Amphetamine
92857|NCT02485158|THC
92858|NCT02485158|Personality
92859|NCT02485145|Topical
92860|NCT02485145|Hand osteoarthritis
92861|NCT02485132|Type 2 diabetes
92862|NCT02485132|Sulfonylurea
92863|NCT02485132|Hypoglycemia
92864|NCT02485132|Quality of life
92865|NCT02485119|BAY 94-9343
92866|NCT02485119|Anetumab ravtansine
92867|NCT02485119|ADC (Antibody Drug Conjugate)
92868|NCT02485119|Phase I
92869|NCT02485119|Japan
92870|NCT02485119|solid cancers
92871|NCT02485119|Advanced, refractory solid tumors
92872|NCT02485119|mesothelin
92873|NCT02485119|endometrial
92874|NCT02485119|adenocarcinoma of lung
92875|NCT02485119|gastrointestinal, ovarian, pancreatic, cholangio, mesothelioma and triple negative breast cancers
92876|NCT02485080|hepatitis C
92877|NCT02485080|liver transplantation
92878|NCT02485080|genotype 1
92879|NCT02485067|Overactive Bladder
93005|NCT02484378|HDL
92880|NCT02485067|Tolterodine (Detrusitol)
92881|NCT02485067|Pilocarpine
92882|NCT02485041|Dapoxetine
92883|NCT02485041|Mirodenafil
92884|NCT02485041|DDI study
92885|NCT02485028|Dapoxetine
92886|NCT02485028|Mirodenafil
92887|NCT02485028|DDI study
92888|NCT02485015|CIK
92889|NCT02485015|gastric cancer
92890|NCT02485015|Apatinib
92891|NCT02485002|kidney
92892|NCT02485002|kidney stone
92893|NCT02485002|NGAL
92894|NCT02485002|ureterorenoscopy
92895|NCT02485002|intrarenal surgery
92896|NCT02485002|kidney function
92897|NCT02484976|Family Based Behavioral Treatment
92898|NCT02484976|functional magnetic resonance imaging (fMRI)
92899|NCT02484976|Childhood Obesity
92900|NCT02484976|Satiety
92901|NCT02484976|BMI z-score
92902|NCT02484976|Impulsive
92903|NCT02484976|Non-obese controls
92904|NCT02484976|Visual food cues
92905|NCT02484976|Leptin
92906|NCT02484976|Hormones
92907|NCT02484950|Mesenchymal stem cells
92908|NCT02484937|Pain management
92909|NCT02484911|chemotherapy nausea vomiting
92910|NCT02484885|Magnetic Resonance Imaging
92911|NCT02484885|Pulmonary Function
92912|NCT02484872|Inflammation
92913|NCT02484872|Glasgow score
92914|NCT02484872|Intensive Care Unit
92915|NCT02484872|Emergency
92916|NCT02484859|Drug: remifentanil
92917|NCT02484859|Drug: tramadol
92918|NCT02484859|Drug: metoprolol
92919|NCT02484859|Functional endoscopic sinus surgery
92920|NCT02484859|Controlled hypotension
92921|NCT02484833|First line
92922|NCT02484833|metastatic colorectal cancer
92923|NCT02484833|Cetuximab
92924|NCT02484833|strategy study
92925|NCT02484820|Preterm Birth
92926|NCT02484820|pessary
92927|NCT02484820|threatened preterm labor
92928|NCT02484794|Eating Disorders
92929|NCT02484794|Smartphone
92930|NCT02484794|App
92931|NCT02484794|Mobile Health
92932|NCT02484794|Recovery Record
92933|NCT02484794|Cognitive Behavioural Therapy
92934|NCT02484794|Outpatient Program
92935|NCT02484794|Self Monitoring
92936|NCT02484781|Gait disorder
92937|NCT02484781|Resurfacing Hip Arthroplasty
92938|NCT02484781|Total Hip Arthroplasty
92939|NCT02484729|AZD9977
92940|NCT02484729|Safety
92941|NCT02484729|Tolerability
92942|NCT02484729|Pharmacokinetics
92943|NCT02484729|First-in-human
92944|NCT02484729|Single Ascending Dose
92945|NCT02484729|Regional absorption
92946|NCT02484729|Healthy male subjects
92947|NCT02484716|Hemorrhagic Hereditary Telangiectasia (HHT)
92948|NCT02484716|Antiangiogenic therapy
92949|NCT02484716|Timolol
92950|NCT02484651|deep neuromuscular block
92951|NCT02484651|sugammadex
92952|NCT02484651|stability of anesthesia
92953|NCT02484651|suppression of EMG activity
92954|NCT02484651|PQRS
92955|NCT02484651|General Anesthesia
92956|NCT02484651|Quality of Recovery
92957|NCT02484625|snacking
92958|NCT02484625|food intake
92959|NCT02484625|satiety
92960|NCT02484625|obesity
92961|NCT02484625|type-2 diabetes
92962|NCT02484599|Eating Disorders
92963|NCT02484599|Anorexia Nervosa
92964|NCT02484599|Attention bias
92965|NCT02484599|Attention bias modification
92966|NCT02484586|Presbyopia
92967|NCT02484586|Refractive error
92968|NCT02484586|Contact lens
92969|NCT02484573|Cirrhosis
92970|NCT02484573|Variceal Bleeding
92971|NCT02484573|Non-selective beta blocker
92972|NCT02484573|Intestinal Permeability
92973|NCT02484573|Gene expression
92974|NCT02484573|Bacterial translocation
92975|NCT02484560|Duchenne Muscular Dystrophy
92976|NCT02484560|Neuromuscular Diseases
92977|NCT02484560|Muscular Dystrophy
92978|NCT02484560|Genetic Diseases, X-linked
92979|NCT02484560|Musculoskeletal Diseases
92980|NCT02484560|Nervous System Diseases
92981|NCT02484547|Aducanumab
92982|NCT02484547|BIIB037
92983|NCT02484534|Coagulation Factor
92984|NCT02484534|cirrhosis
92985|NCT02484508|Guli capsule
92986|NCT02484508|knee osteoarthritis
92987|NCT02484508|Changing of WOMAC and VAS score
92988|NCT02484495|Complementary feeding recommendation
92989|NCT02484495|Program evaluation
92990|NCT02484495|Process and impact evaluation
92991|NCT02484456|Major Depression
92992|NCT02484456|Glycine Receptor Antagonist
92993|NCT02484456|4-Chlorokyneurenine
92994|NCT02484456|Treatment Resistant
92995|NCT02484456|Glutamatergic System
92996|NCT02484417|Neutralizing Antibody
92997|NCT02484417|Viral Shedding
92998|NCT02484417|Mucosal Immune Reponse
92999|NCT02484417|Upper Respiratory Infection
93000|NCT02484404|Immune Checkpoint Inhibitor
93001|NCT02484404|PARP Inhibitor
93002|NCT02484404|VEGFR Inhibitor
93003|NCT02484378|ACS
93004|NCT02484378|IVUS
93006|NCT02484365|Hemoglobins
93007|NCT02484365|Monitoring, Outpatient
93008|NCT02484365|Preoperative Period
93009|NCT02484365|Pediatrics
93010|NCT02484352|dosage of oxycodone during intubation
93011|NCT02484326|ST-elevation myocardial infarction
93012|NCT02484326|Cardiac rupture
93013|NCT02484326|Risk assessment
93014|NCT02484300|loop gain
93015|NCT02484300|chemoreflex control
93016|NCT02484300|melatonin
93017|NCT02484300|antioxidant
93018|NCT02484300|obstructive sleep apnea
93019|NCT02484300|ventilatory control
93020|NCT02484274|iron-deficiency
93021|NCT02484274|iron-deficiency anemia
93022|NCT02484274|infants and toddlers
93023|NCT02484274|industrialised countries
93024|NCT02484274|population-based study
93025|NCT02484274|prevalence and risk factors
93026|NCT02484274|screening strategies
93027|NCT02484274|diagnosis markers
93028|NCT02484274|primary prevention
93029|NCT02484261|childhood leukemia
93030|NCT02484261|relapsed leukemia
93031|NCT02484261|Hematopoietic Stem Cell Transplantation
93032|NCT02484235|obesity
93033|NCT02484235|exercise
93034|NCT02484235|HIIT
93035|NCT02484235|Vo2
93036|NCT02484235|kinetics
93037|NCT02484222|adenotonsillectomy
93038|NCT02484222|fentanyl
93039|NCT02484209|diabetes
93040|NCT02484209|frailty
93041|NCT02484209|aged
93042|NCT02484209|metformin
93043|NCT02484209|sulphonylurea
93044|NCT02484209|hypoglycaemia
93045|NCT02484183|bubble continuous positive airway pressure (CPAP)
93046|NCT02484183|pneumonia
93047|NCT02484183|Human Immunodeficiency Virus (HIV)
93048|NCT02484183|malnutrition
93049|NCT02484183|Malawi
93050|NCT02484183|Africa
93051|NCT02484183|Noninvasive Ventilation
93052|NCT02484183|child
93053|NCT02484183|pediatric
93054|NCT02484183|hypoxemia
93055|NCT02484170|Mannitol
93056|NCT02484170|cream
93057|NCT02484170|neuropathic pain
93058|NCT02484157|Whole Blood Coagulation Time
93059|NCT02484157|cardiac surgery
93060|NCT02484144|information
93061|NCT02484144|coronarography
93062|NCT02484144|understanding
93063|NCT02484131|Osteoporosis
93064|NCT02484131|DXA Screening
93065|NCT02484131|Women
93066|NCT02484131|Breast Cancer
93067|NCT02484131|Survivors
93068|NCT02484131|Educational materials
93069|NCT02484131|Personal choices on delivery methods
93070|NCT02484092|Hemophilia B
93071|NCT02484092|Blood Coagulation Disorders
93072|NCT02484092|Gene Therapy
93073|NCT02484092|Gene Transfer
93074|NCT02484092|Factor IX Deficiency
93075|NCT02484092|Factor IX Gene
93076|NCT02484092|Factor IX Protein
93077|NCT02484092|Vector
93078|NCT02484092|AAV
93079|NCT02484066|Virtual bronchoscopic navigation
93080|NCT02484066|Endobronchial ultrasound
93081|NCT02484066|Guide Sheath
93082|NCT02484066|Transbronchial biopsy
93083|NCT02484066|Peripheral pulmonary lesions
93084|NCT02484053|adult and pediatric cancers
93085|NCT02484053|blood disorders
93086|NCT02484053|lymphoma
93087|NCT02484053|graft-versus-host-disease
93088|NCT02484053|diseases of the immune system
93089|NCT02484040|tumor response
93090|NCT02484040|toxicity
93091|NCT02484040|recurrence
93092|NCT02484040|chemoradiotherpy
93093|NCT02484040|rectum
93094|NCT02484027|acute ischemic stroke
93095|NCT02484027|mRS
93096|NCT02484027|rosuvastatin
93097|NCT02484001|Eslicarbazepine acetate
93098|NCT02484001|BIA 2-093
93099|NCT02484001|Epilepsy
93100|NCT02483975|Fluticasone Furoate
93101|NCT02483975|Asthma
93102|NCT02483975|HPA axis
93103|NCT02483975|Children
93104|NCT02483975|Inhaled corticosteroid
93105|NCT02483962|Chronic
93106|NCT02483923|serratus anterior block
93107|NCT02483923|ultrasound
93108|NCT02483923|breast cancer
93109|NCT02483923|postoperative pain
93110|NCT02483910|school-age children
93111|NCT02483884|Bombesin
93112|NCT02483884|Gastrin-Releasing Peptide
93113|NCT02483884|Prostatic Neoplasms
93114|NCT02483884|Genital Diseases, Male
93115|NCT02483884|Genital Neoplasms, Male
93116|NCT02483884|Neoplasms
93117|NCT02483884|Neoplasms by Site
93118|NCT02483884|Urogenital Neoplasms
93119|NCT02483884|Gastrointestinal Agents
93120|NCT02483884|Molecular Mechanisms of Pharmacological Action
93121|NCT02483884|Neurotransmitter Agents
93122|NCT02483884|Pharmacologic Actions
93123|NCT02483884|Physiological Effects of Drugs
93124|NCT02483884|Therapeutic Uses
93125|NCT02483871|Estrogen Receptor Positive
93126|NCT02483858|oncology, solid tumors
93127|NCT02483819|Elderly patient
93128|NCT02483819|NICOM
93129|NCT02483819|TURP
93130|NCT02483767|Premenopausal Breast Cancer
93131|NCT02483767|Preservation of Ovarian Function
93132|NCT02483767|Gonadotropin-Releasing Hormone Agonist
93133|NCT02483728|Metal Allergy
93134|NCT02483715|Helicobacter pylori
93135|NCT02483715|high dose dual therapy
93136|NCT02483715|bismuth-containing quadruple therapy
93137|NCT02483715|antibiotic resistance
93138|NCT02483702|Irradiated Blood
93139|NCT02483702|Non-Irradiated Blood
93140|NCT02483702|graft versus host disease
93141|NCT02483702|TA-GVHD
93142|NCT02483702|potassium
93143|NCT02483702|Blood transfusion
93144|NCT02483689|Post Operative Pain
93145|NCT02483689|Appendicitis
93146|NCT02483689|Appendectomy
93147|NCT02483689|Local Anesthetic
93148|NCT02483689|Saline
93149|NCT02483689|Pain Management
93150|NCT02483689|Surgery
93151|NCT02483689|Recovery
93152|NCT02483676|Rehabilitation
93153|NCT02483676|Robotics
93154|NCT02483676|Gait
93155|NCT02483663|Twins
93156|NCT02483663|Obesity
93157|NCT02483663|Appetite
93158|NCT02483637|spray cryotherapy
93159|NCT02483637|cryotherapy
93160|NCT02483637|chronic bronchitis
93161|NCT02483637|airflow restrictions
93162|NCT02483611|Onset
93163|NCT02483611|Recovery
93164|NCT02483611|Lidocaine
93165|NCT02483611|Cisatracurium
93166|NCT02483611|Magnesium sulfate
93167|NCT02483611|Isotonic solution
93168|NCT02483598|buspirone
93169|NCT02483598|pharmacokinetics
93170|NCT02483598|Cytochrome P450 3A4
93171|NCT02483585|Migraine
93172|NCT02483585|Headache
93173|NCT02483585|Episodic
93174|NCT02483585|Prevention
93175|NCT02483585|Prophylaxis
93176|NCT02483559|Sleep
93177|NCT02483559|Photoreceptor Cells, Vertebrate
93178|NCT02483559|Melatonin
93179|NCT02483546|Medical education
93180|NCT02483546|simulation
93181|NCT02483546|ACLS
93182|NCT02483520|Family caregiver
93183|NCT02483507|Ultrasound guidance
93184|NCT02483507|Vascular access
93185|NCT02483507|Pediatric anesthesia
93186|NCT02483494|Telemedicine
93187|NCT02483494|Advanced Practice Nurse
93188|NCT02483481|sinusoidal obstruction syndrome
93189|NCT02483481|ultrasound elastography
93190|NCT02483481|bone marrow transplant
93191|NCT02483429|Vertigo
93192|NCT02483429|Dizziness
93193|NCT02483429|Unsteadiness
93194|NCT02483429|Stroke
93195|NCT02483429|Vestibular neuritis
93196|NCT02483429|Benign paroxysmal positional vertigo
93197|NCT02483429|Vestibulo-ocular reflex
93198|NCT02483429|Video-oculography
93199|NCT02483429|Emergency department
93200|NCT02483403|Magnetic Resonance Imaging
93201|NCT02483403|Pulmonary Function
93202|NCT02483403|Volunteers
93203|NCT02483390|palliative care
93204|NCT02483390|e-health
93205|NCT02483390|e-therapy
93206|NCT02483390|psychosocial services
93207|NCT02483377|Sign or Symptom
93208|NCT02483351|Blood Transfusion
93209|NCT02483338|Psychometric validity
93210|NCT02483338|Pain scale
93211|NCT02483338|Postoperative
93212|NCT02483338|Children
93213|NCT02483312|Recurrent
93214|NCT02483299|response to therapy
93215|NCT02483286|Osteoporosis
93216|NCT02483286|Fall
93217|NCT02483286|Fracture
93218|NCT02483286|sarcopenia
93219|NCT02483286|Exercise
93220|NCT02483273|Conjunctival microcirculation
93221|NCT02483273|Sublingual microcirculation
93222|NCT02483273|Sidestream Dark Field (SDF) microscopy
93223|NCT02483247|Neoplasms
93224|NCT02483195|Hair loss
93225|NCT02483195|Post Menopausal
93226|NCT02483182|Herpes labialis, Cold sores, ZEP-3 ointment
93227|NCT02483169|ischemic stroke
93228|NCT02483169|intracranial hemorrhage
93229|NCT02483169|cilostazol
93230|NCT02483169|probucol
93231|NCT02483169|intima media thickness
93232|NCT02483156|HCV
93233|NCT02483156|Sofosbuvir
93234|NCT02483156|Ribavirin
93235|NCT02483143|contrast media
93236|NCT02483143|pulmonary embolism
93237|NCT02483143|N-acetylcysteine
93238|NCT02483104|ABT-888
93239|NCT02483104|BRCA
93240|NCT02483104|Primary peritoneal cancer
93241|NCT02483104|carboplatin
93242|NCT02483104|Fallopian tube
93243|NCT02483104|Poly (ADP-ribose) polymerase (PARP)
93244|NCT02483104|paclitaxel
93245|NCT02483104|Ovarian cancer
93246|NCT02483104|veliparib
93247|NCT02483091|Knowledge translation
93248|NCT02483091|Clinical practice guidelines
93249|NCT02483091|Multimodal care
93250|NCT02483091|Brief Action Planning
93251|NCT02483091|Feasibility outcomes
93252|NCT02483065|dementia
93253|NCT02483065|hospital admission
93254|NCT02483065|mortality
93255|NCT02483065|health-related quality of life
93256|NCT02483065|activities of daily living
93257|NCT02483052|lobectomy
93258|NCT02483052|spray cryotherapy
93259|NCT02483052|lung cancer
93260|NCT02483039|Acute kidney injury
93261|NCT02483039|Chronic kidney disease
93262|NCT02483039|Quality improvement
93263|NCT02483013|whitening dentifrices
93264|NCT02483013|color alteration
93265|NCT02483013|tooth sensitivity
93266|NCT02482987|dental
93267|NCT02482987|extraction
93268|NCT02482987|socket preservation
93269|NCT02482987|ridge preservation
93270|NCT02482987|implant site preparation
93271|NCT02482974|Liver transplantation
93272|NCT02482974|Everolimus
93273|NCT02482974|Sirolimus
93274|NCT02482974|Treatment outcome
93275|NCT02482974|Safety
93276|NCT02482948|Debridement
93277|NCT02482948|collagenase
93278|NCT02482948|leptospermum honey
93279|NCT02482922|feasibility studies
93280|NCT02482922|intervention
93281|NCT02482922|Pre-Hypertensive
93282|NCT02482922|Pre-Hyperlipidemia
93283|NCT02482844|TAVI
93284|NCT02482844|de novo and persistent LBBB
93285|NCT02482844|electrophysiology
93286|NCT02482844|Holter
93287|NCT02482844|pacemaker
93288|NCT02482831|Sciatic nerve block
93289|NCT02482831|block duration
93290|NCT02482831|Semmes Weinstein monofilaments
93291|NCT02482831|fasting blood glucose
93292|NCT02482831|nerve block
93293|NCT02482831|sensory block duration
93294|NCT02482831|motor block duration
93295|NCT02482818|chronic cough
93296|NCT02482818|cough hypersensitivity
93297|NCT02482818|Lyrica
93298|NCT02482818|Pregabalin
93299|NCT02482818|cough reflex sensitivity
93300|NCT02482792|Musculoskeletal disorders
93301|NCT02482792|Psychosomatic
93302|NCT02482792|Pain
93303|NCT02482753|Chidamide
93304|NCT02482753|breast cancer
93305|NCT02482753|exemestane
93306|NCT02482753|Estrogen Receptor
93307|NCT02482740|Uterine Cervical Neoplasms
93308|NCT02482740|antiestrogens
93309|NCT02482727|Blood Flow Restriction
93310|NCT02482727|Occlusion training
93311|NCT02482727|Distal radius fracture
93312|NCT02482714|Quality of Life
93313|NCT02482714|Physical Activity
93314|NCT02482701|EMR
93315|NCT02482701|EAC
93316|NCT02482701|Barrett's Neoplasia
93317|NCT02482701|Multiband Mucosectomy
93318|NCT02482675|Dairy
93319|NCT02482675|Milk
93320|NCT02482675|Glucose
93321|NCT02482675|Postprandial
93322|NCT02482675|Hyperglycemia
93323|NCT02482675|Prediabetes
93324|NCT02482675|Blood glucose
93325|NCT02482675|Oxidative stress
93326|NCT02482675|Vascular health
93327|NCT02482675|Vascular function
93328|NCT02482662|Diagnosis
93329|NCT02482636|infant immunisations
93330|NCT02482636|vaccines
93331|NCT02482636|paediatric
93332|NCT02482636|pneumococcal
93333|NCT02482636|meningococcal
93334|NCT02482623|Dementia
93335|NCT02482623|neuropsychiatric symptoms
93336|NCT02482623|implementation science
93337|NCT02482623|depression
93338|NCT02482623|pain
93339|NCT02482610|Dairy
93340|NCT02482610|Milk
93341|NCT02482610|Glucose
93342|NCT02482610|Postprandial
93343|NCT02482610|Hyperglycemia
93344|NCT02482610|Prediabetes
93345|NCT02482610|Blood glucose
93346|NCT02482610|Oxidative stress
93347|NCT02482610|Vascular health
93348|NCT02482610|Vascular function
93349|NCT02482571|Functional MRS
93350|NCT02482571|Functional MRI
93351|NCT02482558|Glycaemic Index
93352|NCT02482558|NAFLD
93353|NCT02482558|Glycogen
93354|NCT02482558|Liver
93355|NCT02482558|Diet
93356|NCT02482532|Melanoma
93357|NCT02482532|metastatic
93358|NCT02482532|relapsed
93359|NCT02482532|refractory
93360|NCT02482506|African American
93361|NCT02482506|Overweight
93362|NCT02482506|Adults
93363|NCT02482480|SLEEP
93364|NCT02482480|APNEA
93365|NCT02482480|EXERCISE
93366|NCT02482467|ovarian cyst
93367|NCT02482467|prenatal diagnosis
93368|NCT02482467|puberty
93369|NCT02482454|radiofrequency ablation
93370|NCT02482454|cytokine-induced killer cells
93371|NCT02482454|cholangiocarcinoma
93372|NCT02482441|Advanced Solid Tumors and in Combination
93373|NCT02482441|FOLFIRI for Patients with Previously Treated Metastatic
93374|NCT02482441|Colorectal Cancer
93375|NCT02482428|human papilloma virus (HPV), Genital Warts, Sexually transmitted disease (STD), viral disease
93376|NCT02482415|Palliative Care
93377|NCT02482415|Randomized controlled trial
93378|NCT02482415|Family caregivers
93379|NCT02482415|Intervention
93380|NCT02482415|Family
93381|NCT02482415|Intervention studies
93382|NCT02482415|Home Care
93383|NCT02482311|AZD1775
93384|NCT02482311|Ovarian cancer (BRCA1/2 mutation)
93385|NCT02482311|Ovarian cancer (PARP-failure)
93386|NCT02482311|Triple negative breast cancer (TNBC)
93387|NCT02482311|Small-cell lung cancer (SCLC)
93388|NCT02482311|Solid tumours
93389|NCT02482298|Sickle cell disease
93390|NCT02482298|Young adults
93391|NCT02482298|Hestia2
93392|NCT02482298|Ticagrelor
93393|NCT02482233|electronic cigarette
93394|NCT02482233|nicotine replacement therapy
93395|NCT02482233|smoking cessation
93396|NCT02482233|perioperative
93397|NCT02482194|Spinal cord injury
93398|NCT02482194|mesenchymal stem cells
93399|NCT02482194|transplantation
93400|NCT02482181|diffusion weighted magnetic resonance imaging
93401|NCT02482168|immunotherapy
93402|NCT02482168|CD40
93403|NCT02482155|pharmacokinetics
93404|NCT02482155|MOMENTACT
93405|NCT02482155|ibuprofen 400 mg
93406|NCT02482155|oral
93407|NCT02482155|granules
93408|NCT02482142|phosphorus
93409|NCT02482142|lean
93410|NCT02482142|obese
93411|NCT02482142|energy expenditure
93412|NCT02482129|Acute anterior uveitis
93413|NCT02482129|LME636
93414|NCT02482116|malaria
93415|NCT02482116|pneumonia
93416|NCT02482116|Nigeria
93417|NCT02482116|IMCI
93418|NCT02482116|diagnosis
93419|NCT02482103|Therapy resistant hypertension
93420|NCT02482051|Carbapenem-resistant Enterobacteriaceae
93421|NCT02482051|Accelerate ID/AST
93422|NCT02482025|Medications
93423|NCT02482025|Hospitalization
93424|NCT02482025|Electronic medical records
93425|NCT02482012|research
93426|NCT02482012|vulnerable population
93427|NCT02482012|45 CFR 46.406
93428|NCT02481999|Depth of anesthesia
93429|NCT02481973|PMS
93430|NCT02481973|Homoeopathy
93431|NCT02481973|Grant Bentley Method
93432|NCT02481934|Recurrent multiple myeloma
93433|NCT02481934|NK cells
93434|NCT02481934|cell therapy
93435|NCT02481934|NKAE
93436|NCT02481934|Relapsed multiple myeloma
93437|NCT02481921|heart failure
93438|NCT02481921|self-management
93439|NCT02481921|group intervention
93440|NCT02481908|AECOPD
93441|NCT02481908|left ventricular dysfunction
93442|NCT02481908|valsalva maneuver
93443|NCT02481908|systolic time intervals
93444|NCT02481895|cognition
93445|NCT02481895|psychosocial functioning
93446|NCT02481869|Closed
93447|NCT02481869|unilateral
93448|NCT02481869|pilon
93449|NCT02481843|Hyperoxia
93450|NCT02481843|Microcirculation
93451|NCT02481843|Erythropoietin
93452|NCT02481843|Normobaric Oxygen Paradox
93453|NCT02481804|diet
93454|NCT02481804|vitamin
93455|NCT02481778|Radiotherapy
93456|NCT02481778|Cardiac
93457|NCT02481778|Toxicity
93458|NCT02481752|Tobacco Use
93459|NCT02481752|Nicotine Dependence
93460|NCT02481739|endometriosis
93461|NCT02481739|fertility
93462|NCT02481739|endometriosis surgery
93463|NCT02481726|68Ga
93464|NCT02481726|Alfatide II
93465|NCT02481726|RGD
93466|NCT02481726|αvβ3
93467|NCT02481726|PET/CT
93468|NCT02481713|psychosis
93469|NCT02481713|adherence
93470|NCT02481713|motivation
93471|NCT02481674|Prodromal Stage
93472|NCT02481674|Early Manifest Stage
93473|NCT02481635|Blood Vessels
93474|NCT02481635|Reconstructive Surgery
93475|NCT02481622|HIV infection
93476|NCT02481622|vaginal tissues
93477|NCT02481622|uterine tissues
93478|NCT02481609|Loss of Smell
93479|NCT02481609|Olfaction
93480|NCT02481609|Hyposmia
93481|NCT02481596|family
93482|NCT02481596|support
93483|NCT02481596|diet
93484|NCT02481596|exercise
93485|NCT02481596|social
93486|NCT02481583|levosulpiride
93487|NCT02481583|pharmacokinetics
93488|NCT02481583|adverse effects
93489|NCT02481583|bioavailability
93490|NCT02481570|Adolescent Idiopathic Scoliosis
93491|NCT02481570|Scoliosis surgery
93492|NCT02481570|Pharmacokinetic simulation
93493|NCT02481518|Cisplatin nephrotoxicity
93494|NCT02481518|Acute kidney injury
93495|NCT02481492|Circumcision, Male
93496|NCT02481492|Shang Ring
93497|NCT02481492|Children
93498|NCT02481492|Foreskin
93499|NCT02481466|Arterial plaque
93500|NCT02481466|Magnetic resonance imaging (MRI)
93501|NCT02481466|Portfolio diet
93502|NCT02481466|Dietary modification
93503|NCT02481466|Dietary trials
93504|NCT02481466|hypercholesterolemia
93505|NCT02481466|diabetes
93506|NCT02481466|exercise
93507|NCT02481466|cardiovascular disease risk
93508|NCT02481466|glycemic index (GI)
93509|NCT02481440|umbilical cord mesenchymal stem cells
93510|NCT02481440|spinal cord injury
93511|NCT02481427|Total
93512|NCT02481427|Unicondylar
93513|NCT02481427|Osteoarthritis
93514|NCT02481427|Arthroplasty
93515|NCT02481427|Replacement
93516|NCT02481427|Knee
93517|NCT02481401|cardiovascular health
93518|NCT02481401|behavior change
93519|NCT02481401|community-based
93520|NCT02481401|family-based
93521|NCT02481401|prevention
93522|NCT02481375|iron
93523|NCT02481375|ferritin
93524|NCT02481375|soluble transferrin receptor
93525|NCT02481375|hepcidin
93526|NCT02481375|reticulocyte count
93527|NCT02481375|hemoglobin
93528|NCT02481375|supplementation
93529|NCT02481349|Glioma
93530|NCT02481349|Hatha yoga
93531|NCT02481349|Questionnaires
93532|NCT02481349|Surveys
93533|NCT02481336|Chemotherapy
93534|NCT02481336|Peripheral Neuropathy
93535|NCT02481323|cerebral small vessel disease
93536|NCT02481323|cerebrovascular reactivity
93537|NCT02481323|cilostazol
93538|NCT02481323|isosorbide mononitrate
93539|NCT02481297|Leukemia
93540|NCT02481297|Chronic Lymphocytic Leukemia
93541|NCT02481297|CLL
93542|NCT02481297|Refractory/Relapsed
93543|NCT02481297|Untreated with high-risk molecular features
93544|NCT02481297|Small lymphocytic leukemia
93545|NCT02481297|SLL
93546|NCT02481297|Lirilumab
93547|NCT02481297|Rituximab
93548|NCT02481297|Rituxan
93549|NCT02481284|Breast reconstruction
93550|NCT02481284|Deep inferior epigastric artery perforator flap
93551|NCT02481284|Skin perfusion
93552|NCT02481284|Plastic and reconstructive surgery
93553|NCT02481271|cholecystectomy
93554|NCT02481258|Stenosis
93555|NCT02481258|Aortic Valve
93556|NCT02481258|Aorta
93557|NCT02481258|Calcified
93558|NCT02481258|Calcific
93559|NCT02481258|Calcification
93560|NCT02481245|Bipolar Disorder
93561|NCT02481245|Bezafibrate
93562|NCT02481245|Depressive Episode
93563|NCT02481219|Polyps
93564|NCT02481219|Capsule endoscopy
93565|NCT02481219|Bowel preparation regimen
93566|NCT02481219|Average risk patients for colorectal cancer screening
93567|NCT02481206|Ventricular Tachycardia
93568|NCT02481193|Cisatracurium
93569|NCT02481193|Myalgia
93570|NCT02481193|Fasciculation
93571|NCT02481193|Succinylcholine
93572|NCT02481167|Aged
93573|NCT02481167|Meibomian Glands
93574|NCT02481167|dry eye
93575|NCT02481167|Elderly
93576|NCT02481154|Chondrosarcoma
93577|NCT02481154|Cholangiocarcinoma
93578|NCT02481154|Advanced Solid Tumors
93579|NCT02481154|Glioma
93580|NCT02481154|IDH1
93581|NCT02481154|IDH2
93582|NCT02481154|Dual Mutation
93583|NCT02481154|AG-881
93584|NCT02481128|lymphoscintigraphy
93585|NCT02481128|sentinel lymph node biopsy
93586|NCT02481076|malleolar fractures
93587|NCT02481076|ORIF
93588|NCT02481076|compression
93589|NCT02481076|infection
93590|NCT02481076|wound dehisence
93591|NCT02481063|Eccentric
93592|NCT02481063|Running
93593|NCT02481063|Muscle
93594|NCT02481063|Tendon
93595|NCT02481063|Ultrasound
93596|NCT02481063|Thermography
93597|NCT02481050|Eribulin Mesylate
93598|NCT02481050|Human Epidermal Growth Factor Receptor 2
93599|NCT02481050|Metastatic Breast Cancer
93600|NCT02481050|HER2-Negative
93601|NCT02481024|Qualitative
93602|NCT02481024|Care transition
93603|NCT02481024|Medication
93604|NCT02481011|Fibrinolytic agents
93605|NCT02481011|Adverse effects
93606|NCT02481011|Registries
93607|NCT02481011|Incidence
93608|NCT02481011|Risk assessment
93609|NCT02480985|Pituitary Disorders
93610|NCT02480985|Traumatic Brain Injury
93611|NCT02480985|Critical Care
93612|NCT02480985|Outcome Research
93613|NCT02480985|Risk Factors
93614|NCT02480985|Patient Oriented Research
93615|NCT02480972|fibrosis
93616|NCT02480972|cirrhosis
93617|NCT02480972|MRI
93618|NCT02480946|Rheumatoid Arthritis
93619|NCT02480946|Osteoclastogenesis inhibitor
93620|NCT02480946|Anti-Inflammatory Agent
93621|NCT02480946|Musculoskeletal Diseases
93622|NCT02480946|Joint Diseases
93623|NCT02480920|Atrial fibrillation Drug Adherence
93624|NCT02480920|New Oral Anticoagulants
93625|NCT02480920|Drug Adherence
93626|NCT02480907|eating disorders
93627|NCT02480907|caregivers
93628|NCT02480907|parents
93629|NCT02480907|skills training
93630|NCT02480907|workshops
93631|NCT02480907|support
93632|NCT02480907|internet
93633|NCT02480907|online
93634|NCT02480907|family
93635|NCT02480855|work related stress
93636|NCT02480855|questionnaire
93637|NCT02480855|early identification
93638|NCT02480842|Breast Neoplasms
93639|NCT02480842|Mammaplasty
93640|NCT02480842|Breast Implantation
93641|NCT02480842|Range of Motion, Articular
93642|NCT02480842|Shoulder Joint
93643|NCT02480842|Physical Therapy Modalities
93644|NCT02480803|Parkinson
93645|NCT02480803|Parkinson's Disease
93646|NCT02480803|Deep Brain Stimulation
93647|NCT02480803|levodopa-carbidopa
93648|NCT02480803|Duodopa
93649|NCT02480803|continuous intrajejunal infusion
93650|NCT02480764|Drug therapy
93651|NCT02480751|Chronic Renal Failure
93652|NCT02480751|Prostaglandin
93653|NCT02480751|Prostacyclin
93654|NCT02480751|Glomerular Disease; Nephrosclerosis
93655|NCT02480738|subjective cognitive impairment
93656|NCT02480725|CJD
93657|NCT02480725|CSF
93658|NCT02480725|prion
93659|NCT02480725|thrombin
93660|NCT02480673|Metabolic Syndrome X
93661|NCT02480673|Chia
93662|NCT02480673|Dyslipidemia
93663|NCT02480660|Hospitalized
93664|NCT02480660|adolescents
93665|NCT02480660|knowledge
93666|NCT02480660|transition
93667|NCT02480660|educational intervention
93668|NCT02480634|zoledronic acid
93669|NCT02480634|radiotherapy
93670|NCT02480595|Abdominal Aortic Aneurysm
93671|NCT02480595|AAA
93672|NCT02480595|Endovascular
93673|NCT02480595|EVAR
93674|NCT02480595|Stent
93675|NCT02480595|Stent Graft
93676|NCT02480595|High Angle
93677|NCT02480595|Tortuous
93678|NCT02480556|blood loss; caesarean section ; manual placental separation
93679|NCT02480530|Medication Adherence
93680|NCT02480530|Reciprocal Peer
93681|NCT02480530|Telemonitoring
93682|NCT02480517|Hypertension
93683|NCT02480517|Renal Denervation
93684|NCT02480478|Intrahepatic Cholestasis of Pregnancy
93685|NCT02480439|Drug Therapy
93686|NCT02480413|Broselow Tape
93687|NCT02480413|Weight estimation
93688|NCT02480413|Patient safety
93689|NCT02480400|MDD
93690|NCT02480400|Escitalopram
93691|NCT02480400|Placebo
93692|NCT02480361|Acupuncture
93693|NCT02480361|Gastric cancer
93694|NCT02480322|metabolic alterations
93695|NCT02480257|intervention
93696|NCT02480257|emotion regulation
93697|NCT02480257|fMRI
93698|NCT02480257|mindfulness
93699|NCT02480257|yoga-based movement
93700|NCT02480231|Tension-Free Vaginal Tape
93701|NCT02480231|Suburethral Slings
93702|NCT02480231|Midurethral Slings
93703|NCT02480231|Mid-urethral sling
93704|NCT02480231|urinary retention
93705|NCT02480218|cognition
93706|NCT02480218|tamoxifen
93707|NCT02480218|aromatase inhibitors
93708|NCT02480205|CPAP
93709|NCT02480205|NIV
93710|NCT02480205|NIPPV
93711|NCT02480205|Edi
93712|NCT02480192|Vasomotor
93713|NCT02480192|Symptoms
93714|NCT02480179|functional MRI
93715|NCT02480179|appetite
93716|NCT02480179|neurofeedback
93717|NCT02480166|hepatitis C, genotype 6
93718|NCT02480153|Phase 3
93719|NCT02480153|adalimumab
93720|NCT02480153|rheumatoid arthritis
93721|NCT02480140|Self-regulation
93722|NCT02480140|Constraint-induced movement therapy
93723|NCT02480140|Stroke
93724|NCT02480140|Functional recovery
93725|NCT02480140|Randomized controlled trial
93726|NCT02480101|influenza vaccine pandemic
93727|NCT02480075|Genetic Variation
93728|NCT02480075|Genetic Polymorphism
93729|NCT02480075|Polymorphism, Single Nucleotide
93730|NCT02480075|Genetic Association Studies
93731|NCT02480062|Decision Support System
93732|NCT02480062|mHealth
93733|NCT02480062|Primary Health Care
93734|NCT02480062|Non-communicable diseases
93735|NCT02480036|IORT
93736|NCT02480036|Kyphoplasty
93737|NCT02480036|Spine
93738|NCT02480036|Cancer
93739|NCT02479997|Neoadjuvant chemotherapy
93740|NCT02479997|Indocyanine green (ICG)
93741|NCT02479997|Radioisotope (RI)
93742|NCT02479997|Near infrared fluorescence camera
93743|NCT02479984|staging laparoscopy
93744|NCT02479984|pancreatic cancer
93745|NCT02479984|biliary cancer
93746|NCT02479958|Photochemotherapy
93747|NCT02479958|Bacteria
93748|NCT02479932|Extra-peritoneal cesarean
93749|NCT02479932|Intra-peritoneal cesarean
93750|NCT02479919|theta burst stimulation
93751|NCT02479919|Social Cognition
93752|NCT02479919|Schizophrenia
93753|NCT02479919|transcranial magnetic stimulation
93754|NCT02479906|Post-Traumatic Stress Disorder
93755|NCT02479906|PTSD
93756|NCT02479906|dTMS
93757|NCT02479893|cold snare polypectomy
93758|NCT02479893|APC
93759|NCT02479893|hot snare polypectomy
93760|NCT02479815|Complementary feeding recommendation
93761|NCT02479815|Program evaluation
93762|NCT02479815|Process and impact evaluation
93763|NCT02479815|Micronutrient powder (MNP) safety
93764|NCT02479802|plasma exchange
93765|NCT02479802|albumin
93766|NCT02479789|Intravenous Lidocaine
93767|NCT02479789|Recurrent laryngeal nerve
93768|NCT02479789|Intra operative nerve monitoring
93769|NCT02479789|Thyroidectomy
93770|NCT02479763|Epidural waveform analysis
93771|NCT02479763|Loss of resistance
93772|NCT02479737|Chest tube
93773|NCT02479737|chest drainage
93774|NCT02479737|retained blood complications
93775|NCT02479737|chest tube clogging
93776|NCT02479737|hemothorax
93777|NCT02479737|tamponade
93778|NCT02479737|heart surgery
93779|NCT02479737|pleural effusion
93780|NCT02479737|intensive care
93781|NCT02479724|continuous, non-invasive
93782|NCT02479711|glass ionomer
93783|NCT02479711|bulk fill composite
93784|NCT02479698|Stem cell transplant
93785|NCT02479698|Human Leukocyte Antigen
93786|NCT02479698|HLA
93787|NCT02479698|BK specific CTL lines
93788|NCT02479698|BK-CTLs
93789|NCT02479698|Hematopoietic stem cell transplantation
93790|NCT02479698|HSCT
93791|NCT02479698|BK Infection
93792|NCT02479698|Cytotoxic T lymphocytes
93793|NCT02479698|CTLs
93794|NCT02479698|Myeloablative
93795|NCT02479698|Non-myeloablative
93796|NCT02479698|Graft Versus Host Disease
93797|NCT02479698|GVHD
93798|NCT02479672|breathing tube placement
93799|NCT02479672|VideoTrac® laryngoscope
93800|NCT02479672|direct laryngoscopy
93801|NCT02479659|Immunizations
93802|NCT02479646|Pegfilgrastim
93803|NCT02479646|G-CSF
93804|NCT02479646|Pharmacokinetics
93805|NCT02479646|Pharmacodynamics
93806|NCT02479633|prognostic factors
93807|NCT02479607|Breast Cancer
93808|NCT02479607|Cytostatic Agents
93809|NCT02479607|Nursing
93810|NCT02479607|Health Literacy
93811|NCT02479607|Quality of Life
93812|NCT02479607|Oncology Nursing
93813|NCT02479607|Self Care
93814|NCT02479607|Symptom Management
93815|NCT02479607|Participatory Care
93816|NCT02479607|Person-centered Care
93817|NCT02479607|Information and Communication Technology
93818|NCT02479607|Patient-reported symptoms
93819|NCT02479607|Mobile device
93820|NCT02479594|competence-feedback
93821|NCT02479581|Enhanced Recovery after Surgery
93822|NCT02479568|Cardiovascular disease
93823|NCT02479568|biomarkers
93824|NCT02479568|transcriptomics
93825|NCT02479568|orange juice
93826|NCT02479568|hesperidin
93827|NCT02479568|systolic blood pressure
93828|NCT02479568|metabolomics
93829|NCT02479568|cardiovascular risk factor
93830|NCT02479542|Negative-Pressure Wound Therapy
93831|NCT02479542|Wound Healing
93832|NCT02479542|Global Health
93833|NCT02479542|Cameroon
93834|NCT02479516|Diabetes screening
93835|NCT02479516|Health Promotion
93836|NCT02479516|Low and Middle Income Countries
93837|NCT02479516|CHAP
93838|NCT02479503|antibiotic prophylaxis heart transplantation
93839|NCT02479490|metastatic renal cancer
93840|NCT02479490|failure of VEGFR_TKI
93841|NCT02479490|prednisone
93842|NCT02479490|everolimus
93843|NCT02479477|Public Health
93844|NCT02479477|Nursing Staff, Hospital
93845|NCT02479464|AssureRx
93846|NCT02479464|Algorithm
93847|NCT02479464|Major depressive disorder
93848|NCT02479451|End stage renal disease
93849|NCT02479451|Olfaction
93850|NCT02479451|Dialysis
93851|NCT02479451|Hemodialysis
93852|NCT02479451|Malnutrition
93853|NCT02479425|pressure ulcer
93854|NCT02479425|Positioning
93855|NCT02479412|Mild to moderate asthma
93856|NCT02479412|FEV1
93857|NCT02479412|efficacy
93858|NCT02479412|safety
93859|NCT02479399|Suglat
93860|NCT02479399|SGLT-2 inhibitor
93861|NCT02479399|Ipragliflozin L-Proline
93862|NCT02479399|ASP1941 long-term use
93863|NCT02479347|General surgery
93864|NCT02479347|Postoperative
93865|NCT02479334|Spices
93866|NCT02479334|Functional food
93867|NCT02479334|Cardiometabolic risk
93868|NCT02479334|Metabolic syndrome
93869|NCT02479334|Inflammation
93870|NCT02479334|Peripheral blood mononuclear cell
93871|NCT02479334|Acute
93872|NCT02479321|Perioperative Goal-Directed Hemodynamic Therapy
93873|NCT02479321|Fluid therapy
93874|NCT02479321|Aged
93875|NCT02479321|Perioperative complications
93876|NCT02479321|Survival
93877|NCT02479308|Alkermes
93878|NCT02479308|Samidorphan
93879|NCT02479308|ALKS 5461
93880|NCT02479308|QT/QTc
93881|NCT02479308|Buprenorphine
93882|NCT02479308|Pharmacodynamics
93883|NCT02479269|Brain Natriuretic Peptide
93884|NCT02479269|aerobic execise
93885|NCT02479269|C- Reactive Protein
93886|NCT02479256|PCOS
93887|NCT02479256|Induction of ovulation
93888|NCT02479256|Clomiphene citrate
93889|NCT02479256|Tamoxifen
93890|NCT02479243|Arterial Spin Labeling
93891|NCT02479243|MRI
93892|NCT02479243|Atherosclerotic Stenosis
93893|NCT02479243|Collateral Circulation
93894|NCT02479243|Ischemic stroke
93895|NCT02479230|vaccine
93896|NCT02479230|breast cancer
93897|NCT02479230|metastatic
93898|NCT02479204|safety
93899|NCT02479204|heart rate
93900|NCT02479204|pharmacokinetics
93901|NCT02479191|Abdominal
93902|NCT02479191|Aortic
93903|NCT02479191|Aneurysm
93904|NCT02479152|Mechanical CPR
93905|NCT02479152|Hemodynamics
93906|NCT02479126|Interstitial Lung Disease
93907|NCT02479126|Idiopathic Pulmonary Fibrosis
93908|NCT02479126|Electronic Health Records
93909|NCT02479126|Computed Tomography
93910|NCT02479126|Mortality
93911|NCT02479126|Hospitalization
93912|NCT02479126|Acute care visits
93913|NCT02479126|Anti-inflammatory drug therapies
93914|NCT02479113|GDM
93915|NCT02479113|Maternal Hypertriglyceridaemia
93916|NCT02479100|Contrast Enhanced Spectral Mammography
93917|NCT02479100|Breast
93918|NCT02479100|Cancer
93919|NCT02479100|Diagnosis
93920|NCT02479100|Patient management
93921|NCT02479087|von Willebrand Factor
93922|NCT02479087|Factor VIII
93923|NCT02479087|Hemorrhage
93924|NCT02479087|Immune Tolerance
93925|NCT02479087|Hemophilia A
93926|NCT02479074|Chronic
93927|NCT02479061|Observationnal study
93928|NCT02479061|Prevalence
93929|NCT02479061|Palliative care
93930|NCT02479061|Anti cancer center
93931|NCT02479048|satiety/appetite
93932|NCT02479048|glycemic response
93933|NCT02479048|cardiometabolic risk
93934|NCT02479035|insulin sensitive
93935|NCT02479035|insulin resistant
93936|NCT02479035|red raspberry
93937|NCT02479035|polyphenols
93938|NCT02479035|bioavailability
93939|NCT02478996|perioperative
93940|NCT02478996|internet-based
93941|NCT02478996|exercise program
93942|NCT02478957|mastocytosis
93943|NCT02478957|cromolyn sodium
93944|NCT02478944|Inflammatory bowel disease
93945|NCT02478944|Manometry
93946|NCT02478892|high risk
93947|NCT02478892|specifically those with BRCA1/2 mutations
93948|NCT02478827|Cognitive Training
93949|NCT02478827|Working Memory
93950|NCT02478827|Processing Speed
93951|NCT02478788|ADHD
93952|NCT02478775|obesity
93953|NCT02478775|fertility
93954|NCT02478775|infertility
93955|NCT02478775|reproductive hormones
93956|NCT02478762|Foetal glycated hemoglobin
93957|NCT02478762|Glycemic objectives treatment
93958|NCT02478736|postoperative delirium
93959|NCT02478736|on-pump cardiac surgery
93960|NCT02478736|cerebral oximetry
93961|NCT02478736|cerebral blood flow velosity
93962|NCT02478723|requiring therapy
93963|NCT02478723|Teeth
93964|NCT02478697|tobacco smoking behavior
93965|NCT02478697|employment
93966|NCT02478697|job-seeking
93967|NCT02478697|tobacco cessation
93968|NCT02478697|transtheoretical model
93969|NCT02478697|behavior change
93970|NCT02478684|delayed cord clamping
93971|NCT02478684|premature infants
93972|NCT02478684|randomized study
93973|NCT02478684|hematocrit
93974|NCT02478658|irisin
93975|NCT02478658|resistance training
93976|NCT02478658|physical fitness
93977|NCT02478658|Volunteers
93978|NCT02478632|tenofovir disoproxil fumarate
93979|NCT02478632|dolutegravir plus rilpivirine
93980|NCT02478632|two-drug regimen
93981|NCT02478632|bone mineral density
93982|NCT02478632|dual energy X-ray absorptiometry (DEXA)
93983|NCT02478632|Human Immunodeficiency Virus-1
93984|NCT02478632|nucleoside reverse transcriptase inhibitor -sparing regimen
93985|NCT02478632|integrase inhibitor
93986|NCT02478619|Obesity
93987|NCT02478619|Respiratory Muscle Training
93988|NCT02478619|Bariatric Surgery
93989|NCT02478619|Breathing exercises
93990|NCT02478619|Gastroplasty
93991|NCT02478606|Lower Extremity
93992|NCT02478606|Muscle Stretching Exercises
93993|NCT02478606|Muscle Strength
93994|NCT02478606|Static Stretching
93995|NCT02478606|Proprioceptive Neuromuscular Facilitation (PNF) Stretching
93996|NCT02478606|Muscle Strength Dynamometer
93997|NCT02478593|Education
93998|NCT02478593|Geriatric
93999|NCT02478593|Benzodiazepine
94000|NCT02478593|Prevalence
94001|NCT02478580|Obstructive Sleep Apnea
94002|NCT02478580|Obesity
94003|NCT02478580|Postoperative Recovery
94004|NCT02478554|Fetal growth restriction
94005|NCT02478554|macrosomia
94006|NCT02478541|triglycerides
94007|NCT02478541|glucose
94008|NCT02478541|fructose
94009|NCT02478541|fatty acids
94010|NCT02478515|ranibizumab
94011|NCT02478515|PRN regimen
94012|NCT02478515|macular edema
94013|NCT02478515|branch retinal vein occlusion
94014|NCT02478502|testicular cancer
94015|NCT02478502|cisplatin resistancy
94016|NCT02478489|alcohol
94017|NCT02478489|heavy drinking
94018|NCT02478489|naltrexone
94019|NCT02478489|hospital
94020|NCT02478489|alcohol use disorder
94021|NCT02478489|alcohol dependence
94022|NCT02478489|comparative effectiveness
94023|NCT02478463|Cabotegravir
94024|NCT02478463|Pharmacokinetic
94025|NCT02478463|Healthy Adult Volunteers
94026|NCT02478463|GSK1265744
94027|NCT02478437|Lumbar Facet Syndrome
94028|NCT02478411|muscle weakness
94029|NCT02478411|rehabilitation
94030|NCT02478411|intensive care
94031|NCT02478411|mechanical ventilation
94032|NCT02478411|cyclo ergometer
94033|NCT02478411|physiotherapy
94034|NCT02478385|Birth environment
94035|NCT02478385|oxytocin
94036|NCT02478385|epidural
94037|NCT02478385|analgesia
94038|NCT02478385|home-like
94039|NCT02478372|local infiltration analgesia
94040|NCT02478372|Epidural
94041|NCT02478372|Enhanced Recovery
94042|NCT02478372|Total Knee Arthroplasty
94043|NCT02478333|Healthy
94044|NCT02478333|ALS-008176
94045|NCT02478333|Japanese adult participants
94046|NCT02478320|Advanced Cancers
94047|NCT02478320|CDKN2A-Deficient Advanced Solid Cancers
94048|NCT02478320|Advanced or metastatic cancer.
94049|NCT02478320|Ilorasertib
94050|NCT02478320|ABT-348
94051|NCT02478307|chronic low back pain
94052|NCT02478307|mindfulness meditation
94053|NCT02478307|cognitive therapy
94054|NCT02478307|mindfulness-based cognitive therapy
94055|NCT02478307|efficacy
94056|NCT02478307|mechanisms
94057|NCT02478307|coping
94058|NCT02478294|Atrial Fibrillation
94059|NCT02478294|Stroke
94060|NCT02478294|Systemic embolism
94061|NCT02478294|Left atrial appendage excision
94062|NCT02478294|Warfarin
94063|NCT02478268|idiopathic pulmonary fibrosis
94064|NCT02478268|xenon gas
94065|NCT02478255|Radiation induced lung injury
94066|NCT02478255|Xenon gas
94067|NCT02478255|hyperpolarized
94068|NCT02478229|Liver transplant
94069|NCT02478229|Genotype 1 HCV infection
94070|NCT02478229|Sofosbuvir (SOF)/ Ledipasvir (LDV)
94071|NCT02478229|Sustained virological response (SVR12 )
94072|NCT02478203|Airtraq
94073|NCT02478203|Glidescope
94074|NCT02478203|pediatric
94075|NCT02478203|face-to-face
94076|NCT02478177|Anticoagulant
94077|NCT02478177|Stroke
94078|NCT02478177|Ischemic Stroke
94079|NCT02478177|Intracerebral hemorrhage
94080|NCT02478151|Deceased donor liver transplant
94081|NCT02478151|Normothermic machine perfusion
94082|NCT02478125|metastatic castrate resistant prostate cancer
94083|NCT02478112|Intensity Modulated Radiotherapy
94084|NCT02478112|Balloon implant
94085|NCT02478099|MPDL3280A
94086|NCT02478099|bladder cancer
94087|NCT02478099|non small cell lung cancer
94088|NCT02478099|triple negative breast cancer
94089|NCT02478086|amino acids
94090|NCT02478086|renal function
94091|NCT02478086|extreme premature
94092|NCT02478060|Allergy
94093|NCT02478060|Birch
94094|NCT02478060|Rhinitis
94095|NCT02478060|Rhinoconjuntivitis
94096|NCT02478060|SPIRE
94097|NCT02478060|Toleromune
94098|NCT02478047|to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting
94099|NCT02478021|effects of cortisol on cognition
94100|NCT02478008|Transcatheter Mitral Valve Replacement
94101|NCT02478008|Mitral Regurgitation
94102|NCT02478008|Mitral Insufficiency
94103|NCT02478008|Transapical
94104|NCT02477995|Immunogenicity
94105|NCT02477995|Safety
94106|NCT02477995|DTaP Vaccine
94107|NCT02477982|Propofol
94108|NCT02477982|Cardiopulmonary Bypass
94109|NCT02477982|Pharmacokinetics
94110|NCT02477982|Obesity
94111|NCT02477956|vitamin D
94112|NCT02477956|obesity
94113|NCT02477956|bariatric surgery
94114|NCT02477917|allergy
94115|NCT02477917|SCIT
94116|NCT02477904|Autism
94117|NCT02477904|Autism Spectrum Disorder
94118|NCT02477904|Ketogenic Diet
94119|NCT02477904|Biochemical Profiles
94120|NCT02477891|Multiple myeloma
94121|NCT02477891|Daratumumab
94122|NCT02477891|Early access
94123|NCT02477878|Adult leukemias and myelodysplasia
94124|NCT02477878|Adult lymphomas
94125|NCT02477878|Adult multiple myeloma
94126|NCT02477852|tuberculosis
94127|NCT02477852|spinal
94128|NCT02477852|general
94129|NCT02477852|operation
94130|NCT02477852|drug
94131|NCT02477852|therapy
94132|NCT02477839|epilepsy, children, partial-onset seizures, Lacosamide, LCM, pediatric
94133|NCT02477800|BIIB037
94134|NCT02477800|Aducanumab
94135|NCT02477787|HLA-haploidentical hematopoietic cell transplantation
94136|NCT02477787|natural killer cells
94137|NCT02477774|Anterolateral Thigh
94138|NCT02477670|Negative Symptoms
94139|NCT02477670|Schizophrenia
94140|NCT02477670|AVP-786
94141|NCT02477657|Adult patients with refractory malignant ascites secondary to GU or GI malignancy.
94142|NCT02477644|Advanced FIGO IIIB
94143|NCT02477644|IV high grade serious ovarian cancer
94144|NCT02477644|endometrioid ovarian cancer
94145|NCT02477644|standard first-line treatment
94146|NCT02477644|platinum-taxane chemotherapy
94147|NCT02477644|bevacizumab
94148|NCT02477644|olaparib
94149|NCT02477644|placebo
94150|NCT02477631|Myelodysplastic syndrome
94151|NCT02477631|oxidative stress
94152|NCT02477631|labile plasma iron
94153|NCT02477592|long standing persistent atrial fibrillation
94154|NCT02477592|novel approach
94155|NCT02477592|ablation
94156|NCT02477566|pcos
94157|NCT02477566|Long acting Triptorelin
94158|NCT02477566|Short acting Triptorelin
94159|NCT02477566|In Vitro Fertilization
94160|NCT02477553|decision aid
94161|NCT02477553|cancer screening
94162|NCT02477553|colorectal neoplasm
94163|NCT02477553|decision making
94164|NCT02477553|risk communication
94165|NCT02477553|numeracy
94166|NCT02477553|health literacy
94167|NCT02477527|atripla
94168|NCT02477527|stribild
94169|NCT02477527|dreams
94170|NCT02477501|Spinal anesthesia
94171|NCT02477501|cesarean
94172|NCT02477501|blood pressure
94173|NCT02477501|Norepinephrine
94174|NCT02477501|Ephedrine
94175|NCT02477488|Allopurinol
94176|NCT02477488|Renal Dialysis
94177|NCT02477475|reflux esophagitis
94178|NCT02477475|Nexium
94179|NCT02477449|safety
94180|NCT02477449|istaroxime
94181|NCT02477423|Microbiome
94182|NCT02477423|Antibiotics
94183|NCT02477410|porcine protein
94184|NCT02477410|appetite
94185|NCT02477410|muscle protein synthesis
94186|NCT02477410|gastrointestinal hormones
94187|NCT02477397|Spiromax
94188|NCT02477397|Budesonide/formoterol
94189|NCT02477397|COPD
94190|NCT02477397|exacerbations
94191|NCT02477397|SMART
94192|NCT02477345|Cholestasis
94193|NCT02477345|Parenteral Nutrition
94194|NCT02477345|Liver disease
94195|NCT02477332|QGE031
94196|NCT02477332|omalizumab
94197|NCT02477332|chronic
94198|NCT02477332|spontaneous
94199|NCT02477332|urticaria
94200|NCT02477332|adults
94201|NCT02477332|CSU
94202|NCT02477293|Hyeonggaeyeongyo-tang
94203|NCT02477293|Chronic rhinitis
94204|NCT02477293|Pattern identification
94205|NCT02477293|Korean medicine
94206|NCT02477254|lupus
94207|NCT02477241|overactive bladder syndrome
94208|NCT02477241|urgency urinary incontinence
94209|NCT02477241|fMRI
94210|NCT02477241|urodynamics
94211|NCT02477215|Multiple Myeloma
94212|NCT02477202|Mirena® IUD's
94213|NCT02477202|Women
94214|NCT02477202|risk-reducing salpingo-oophorectomy
94215|NCT02477202|risk-reducing salpingectomy
94216|NCT02477163|Nephropathy induced by drugs medicaments and biological substances
94217|NCT02477163|Other nephritis and nephropathy not specified as acute or chronic
94218|NCT02477150|lupus
94219|NCT02477137|Prostate Cancer
94220|NCT02477137|Nursing
94221|NCT02477137|Health Literacy
94222|NCT02477137|Quality of Life
94223|NCT02477137|Radiotherapy
94224|NCT02477137|Oncology Nursing
94225|NCT02477137|Self Care
94226|NCT02477137|Symptom Management
94227|NCT02477137|Participatory Care
94228|NCT02477137|Person-centered Care
94229|NCT02477137|Information and Communication Technology
94230|NCT02477137|Patient-reported symptoms
94231|NCT02477137|Mobile device
94232|NCT02477111|Endovascular repair
94233|NCT02477098|rectus sheath block
94234|NCT02477098|cytokines
94235|NCT02477098|sleep
94236|NCT02477085|Labor
94237|NCT02477085|induction
94238|NCT02477085|delivery
94239|NCT02477085|prostaglandins
94240|NCT02477085|oxytocin
94241|NCT02477085|amniotomy
94242|NCT02477085|balloon catheter
94243|NCT02477059|Hand OA
94244|NCT02477059|Tocilizumab
94245|NCT02477059|Osteoarthritis
94246|NCT02477059|Interleukin-6
94247|NCT02477020|Drug Therapy
94248|NCT02477007|Paediatric emergency
94249|NCT02477007|pain
94250|NCT02477007|long-bones fractures
94251|NCT02477007|morphine
94252|NCT02477007|ibuprofen
94253|NCT02477007|paracetamol
94254|NCT02477007|children
94255|NCT02476994|Essential Fatty Acids (EFA)
94256|NCT02476994|Parenteral Nutrition
94257|NCT02476994|Clinolipid/Clinoleic
94258|NCT02476994|Parenteral Nutrition Associated Cholestasis (PNAC)
94259|NCT02476994|Parenteral Nutrition Associated Liver Disease (PNALD)
94260|NCT02476994|Intestinal Failure Associated Liver Disease (IFALD)
94261|NCT02476994|Phytosterols
94262|NCT02476994|Intralipid
94263|NCT02476994|Infants/Preterm Infants
94264|NCT02476994|FADS1 and FADS2
94265|NCT02476994|Short Bowel Syndrome
94266|NCT02476994|Cancer Nutrition
94267|NCT02476994|Olive Oil Emulsion
94268|NCT02476994|Soybean Oil Emulsion
94269|NCT02476955|ARQ 092
94270|NCT02476955|Carboplatin
94271|NCT02476955|Paclitaxel
94272|NCT02476955|AKT inhibitor in combination therapy
94273|NCT02476955|Targeted therapy
94274|NCT02476955|Molecular therapy
94275|NCT02476955|Tyrosine kinase inhibitor (TKI)
94276|NCT02476955|Receptor tyrosine kinase (RTK)
94277|NCT02476955|Biomarkers
94278|NCT02476955|Phase 1 - Phase I
94279|NCT02476955|Solid tumors
94280|NCT02476955|Metastatic solid tumors
94281|NCT02476955|Recurrent solid tumors
94282|NCT02476955|Ovarian cancer
94283|NCT02476955|Endometrial cancer
94284|NCT02476955|Cervical cancer
94285|NCT02476955|Triple-negative breast cancer
94286|NCT02476955|AKT kinases
94287|NCT02476955|AKT pathway
94288|NCT02476955|AKT signaling
94289|NCT02476955|AKT inhibitor
94290|NCT02476955|AKT pan inhibitor
94291|NCT02476955|Chemotherapy
94292|NCT02476955|PI3K/AKT/mTOR signaling pathway
94293|NCT02476955|AKT1
94294|NCT02476955|AKT2
94295|NCT02476955|AKT3
94296|NCT02476955|Phase I Clinical Trial
94297|NCT02476955|Clinical oncology
94298|NCT02476955|Tumor
94299|NCT02476955|AKT1 inhibitor
94300|NCT02476955|AKT2 inhibitor
94301|NCT02476955|AKT3 inhibitor
94302|NCT02476955|AKT1 mutation
94303|NCT02476955|AKT2 mutation
94304|NCT02476955|AKT3 mutation
94305|NCT02476955|AKT1 amplification
94306|NCT02476955|AKT2 amplification
94307|NCT02476955|AKT3 amplification
94308|NCT02476955|Anastrozole
94309|NCT02476955|Estrogen receptor positive
94310|NCT02476929|Electronic nose
94311|NCT02476929|Nasal nitrous oxide
94312|NCT02476929|Allergic Rhinitis
94313|NCT02476929|Non-Allergic Rhinitis
94314|NCT02476929|Nasal polyps
94315|NCT02476916|Pyruvate Kinase Deficiency
94316|NCT02476916|Hemolytic anemia
94317|NCT02476916|Protein Kinase R (PKR)
94318|NCT02476916|Drive PK
94319|NCT02476877|comorbidity
94320|NCT02476877|epidemiology
94321|NCT02476877|mental illness
94322|NCT02476877|drug abuse
94323|NCT02476864|macitentan
94324|NCT02476864|biocomparison
94325|NCT02476864|safety
94326|NCT02476851|Blood Donation
94327|NCT02476851|Whole Blood
94328|NCT02476838|hand injury
94329|NCT02476838|hand amputation
94330|NCT02476838|hand amputee
94331|NCT02476838|hand surgery
94332|NCT02476825|volunteers
94333|NCT02476773|Hookworm Vaccine
94334|NCT02476773|Na-APR-1 (M74)/Alhydrogel® Hookworm Vaccine
94335|NCT02476773|Na-GST-1/Alhydrogel® Hookworm Vaccine
94336|NCT02476760|Incretins
94337|NCT02476760|Antidiabetic agents
94338|NCT02476760|Pancreatitis
94339|NCT02476747|Colonic polyp
94340|NCT02476734|REDIRECTED AUTOLOGOUS CART- 19 T-CELL IMMUNOTHERAPY
94341|NCT02476721|pulmonary embolism
94342|NCT02476721|emergency department
94343|NCT02476708|schizophrenia
94344|NCT02476708|schizoaffective disorder
94345|NCT02476708|cognition
94346|NCT02476708|curcumin
94347|NCT02476695|CHB
94348|NCT02476682|Sessile serrated polyps
94349|NCT02476682|Advanced mucosal neoplasia
94350|NCT02476669|plasma EBV DNA
94351|NCT02476669|biomarker
94352|NCT02476669|intensity-modulated radiation therapy
94353|NCT02476617|Treatment naive
94354|NCT02476617|Interferon free
94355|NCT02476617|HCV
94356|NCT02476617|Chronic Hepatitis C
94357|NCT02476617|Hepatitis C Genotype 1a
94358|NCT02476617|Hepatitis C
94359|NCT02476617|pegIFN/RBV experienced
94360|NCT02476604|prevention
94361|NCT02476604|adult
94362|NCT02476604|student
94363|NCT02476591|Resource utilization
94364|NCT02476591|intensive care unit
94365|NCT02476578|Hypocholesterolemia
94366|NCT02476578|Frail Elderly
94367|NCT02476578|Aged
94368|NCT02476578|Aged, 80 and over
94369|NCT02476578|Cholesterol
94370|NCT02476578|Clinical Laboratory Information Systems
94371|NCT02476578|Hemoglobin A, Glycosylated
94372|NCT02476578|diet therapy
94373|NCT02476578|Anticholesteremic Agents
94374|NCT02476578|Health Services for the Aged
94375|NCT02476578|Hypoglycemic Agents
94376|NCT02476578|Hypoglycemia
94377|NCT02476565|Intubation
94378|NCT02476461|percutanepus needle fasciotomy
94379|NCT02476461|xiapex
94380|NCT02476461|clostridium histolyticum
94381|NCT02476448|ureteral jet
94382|NCT02476448|pelvic surgery
94383|NCT02476448|cystoscopy
94384|NCT02476435|Depersonalization
94385|NCT02476435|Derealization
94386|NCT02476435|Embodiment
94387|NCT02476435|Emotional numbing
94388|NCT02476435|Transcranial magnetic stimulation
94389|NCT02476435|Angular gyrus
94390|NCT02476435|Temporo-parietal junction
94391|NCT02476422|Diclofenac potassium
94392|NCT02476422|Post-operative dental pain
94393|NCT02476422|Moderate to severe pain
94394|NCT02476409|congestive heart failure
94395|NCT02476409|tolvaptan
94396|NCT02476409|copeptin
94397|NCT02476331|Cognitive training
94398|NCT02476331|Working memory
94399|NCT02476331|Emotion regulation
94400|NCT02476266|resistance training
94401|NCT02476266|strength training
94402|NCT02476266|balance
94403|NCT02476266|muscle strength
94404|NCT02476253|acidosis
94405|NCT02476253|shock
94406|NCT02476253|sodium bicarbonate
94407|NCT02476253|renal replacement therapy
94408|NCT02476240|Exercise
94409|NCT02476240|Attention
94410|NCT02476227|atrial fibrillation
94411|NCT02476227|pulmonary vein isolation
94412|NCT02476227|RF ablation
94413|NCT02476214|group prenatal care, group guidance
94414|NCT02476201|Heart Failure
94415|NCT02476201|Cardiac Resynchronization Therapy
94416|NCT02476201|Quadripolar Left Ventricular Lead
94417|NCT02476201|Multipoint Pacing
94418|NCT02476201|Hemodynamic Response
94419|NCT02476188|Neutrophil extracellular traps, stroke
94420|NCT02476175|mirabegron
94421|NCT02476175|antimuscarinics
94422|NCT02476175|beta 3 agonist
94423|NCT02476175|overactive bladder
94424|NCT02476175|children
94425|NCT02476162|Childhood Cancer Survivor
94426|NCT02476162|Cancer Prevention and Control
94427|NCT02476162|Blood Pressure Monitoring
94428|NCT02476162|Pre-Hypertension
94429|NCT02476136|individual patient data meta-analysis
94430|NCT02476136|anxiety disorder
94431|NCT02476136|antidepressants
94432|NCT02476136|selective serotonin reuptake inhibitors
94433|NCT02476136|serotonin-norepinephrine reuptake inhibitors
94434|NCT02476110|Oral nutritive supplements
94435|NCT02476110|Nutritional risk screening
94436|NCT02476110|Homecare
94437|NCT02476097|esomeprazole randomized study
94438|NCT02476097|proton pump inhibitor
94439|NCT02476097|gastric acid rebound
94440|NCT02476097|randomized study
94441|NCT02476097|esomeprazole
94442|NCT02476071|HIV prevention
94443|NCT02476071|Demand for voluntary male circumcision
94444|NCT02476058|Major Depressive Disorder
94445|NCT02476058|JNJ-42847922
94446|NCT02476058|Diphenhydramine
94447|NCT02476058|Placebo
94448|NCT02476045|metastatic colorectal cancer
94449|NCT02476045|RAS wild-type
94450|NCT02476045|maintenance therapy
94451|NCT02476045|panitumumab
94452|NCT02476019|Obesity
94453|NCT02476019|Energy Expenditure
94454|NCT02475993|Sickle Cell Disease
94455|NCT02475980|Adolescent
94456|NCT02475980|Contraception
94457|NCT02475980|Counseling
94458|NCT02475967|E-Learning
94459|NCT02475967|coronary artery disease
94460|NCT02475967|telerehabilitation
94461|NCT02475967|e-health
94462|NCT02475954|Depression
94463|NCT02475954|Telehealth
94464|NCT02475954|Parkinson's Disease
94465|NCT02475954|Veterans
94466|NCT02475954|Care-partners
94467|NCT02475954|Cognitive-Behavioral Therapy
94468|NCT02475954|Caregiver
94469|NCT02475941|geriatric fractures
94470|NCT02475915|Treatment interruption
94471|NCT02475915|Controlling HIV
94472|NCT02475902|prevention and control
94473|NCT02475824|ERCP
94474|NCT02475824|Sedation
94475|NCT02475824|safety
94476|NCT02475811|3D ultrasonography
94477|NCT02475811|fetal Lung Volume
94478|NCT02475811|neonatal respiratory function
94479|NCT02475798|Zenith aortoiliac aneurysm
94480|NCT02475798|Iliac aneurysm
94481|NCT02475798|Branch
94482|NCT02475798|Connections
94483|NCT02475798|Endovascular graft
94484|NCT02475798|Graft-iliac bifurcation
94485|NCT02475798|Aneurysm
94486|NCT02475798|Vascular Diseases
94487|NCT02475798|Cardiovascular Diseases
94488|NCT02475785|Forsus Fatigue Resistant Device
94489|NCT02475785|Class II
94490|NCT02475785|anchorage
94491|NCT02475785|FFRD
94492|NCT02475785|mini plates
94493|NCT02475785|fixed functional appliance
94494|NCT02475772|ovarian cancer
94495|NCT02475772|recurrent
94496|NCT02475772|chemotherapy
94497|NCT02475772|intraperitoneal
94498|NCT02475772|cisplatin
94499|NCT02475772|doxorubicin
94500|NCT02475746|drug interaction, PF-06372865, itraconazole
94501|NCT02475733|Complicated intra-abdominal infections (cIAIs)
94502|NCT02475707|leukemia
94503|NCT02475707|lymphoblastic
94504|NCT02475707|ALL
94505|NCT02475707|multiTAA-specific T cells
94506|NCT02475707|HSCT
94507|NCT02475590|Sleeve gastrectomy
94508|NCT02475590|Roux-en-Y gastric bypass
94509|NCT02475590|Excess weight loss
94510|NCT02475590|Quality of life
94511|NCT02475577|telemedicine
94512|NCT02475577|heart failure
94513|NCT02475577|home blood pressure monitoring
94514|NCT02475564|resveratrol
94515|NCT02475512|elderly
94516|NCT02475512|long-term care
94517|NCT02475499|Incretins
94518|NCT02475499|Antidiabetic agents
94519|NCT02475499|Pancreatic Cancer
94520|NCT02475486|Rheumatoid Arthritis
94521|NCT02475486|sympathetic nervous system
94522|NCT02475486|SNA
94523|NCT02475486|fatigue
94524|NCT02475473|Volunteers
94525|NCT02475460|HeartMate 3
94526|NCT02475460|LVAS
94527|NCT02475460|LVAD
94528|NCT02475460|Heart-assist Devices
94529|NCT02475460|Advanced
94530|NCT02475460|Ventricular Dysfunction
94531|NCT02475460|refractory left ventricular
94532|NCT02475460|Thoratec Corporation
94533|NCT02475434|Human Milk
94534|NCT02475434|Prematurity
94535|NCT02475434|Nutrition
94536|NCT02475421|Diabetes
94537|NCT02475421|Glucagon
94538|NCT02475421|Metabolic clearance rate of glucagon
94539|NCT02475408|Circulation, Collateral
94540|NCT02475408|Coronary Artery Disease
94541|NCT02475408|Internal Mammary-Coronary Artery Anastomosis
94542|NCT02475408|Ischemia
94543|NCT02475395|Male Fertility
94544|NCT02475395|Male Infertility
94545|NCT02475395|Fertility
94546|NCT02475395|Sperm
94547|NCT02475395|Sperm Concentration
94548|NCT02475369|pancreatic enzyme supplementation
94549|NCT02475356|Mirena
94550|NCT02475356|Heavy Menstrual Bleeding
94551|NCT02475356|Dysmenorrhea
94552|NCT02475356|Japan
94553|NCT02475356|Post-marketing surveillance
94554|NCT02475317|Volunteer
94555|NCT02475278|Drug therapy
94556|NCT02475265|Anorexia Nervosa
94557|NCT02475265|Osteoporosis
94558|NCT02475265|Eating Disorder
94559|NCT02475265|Disordered Eating
94560|NCT02475265|Estrogen
94561|NCT02475265|Bone
94562|NCT02475239|Benign Paroxysmal Positional Vertigo, Postural Restriction
94563|NCT02475226|Traumatic Brain Injury
94564|NCT02475226|Brain Damage
94565|NCT02475226|Mortality
94566|NCT02475226|C10.228.140.199
94567|NCT02475213|Malanoma, Non small cell lung cancer, SCCHN
94568|NCT02475213|Other B7H3 expressing cancers
94569|NCT02475187|TEG
94570|NCT02475187|MEA
94571|NCT02475187|Thrombotic events
94572|NCT02475187|VTE
94573|NCT02475187|LMWH
94574|NCT02475187|Hip fractures
94575|NCT02475161|Healthy
94576|NCT02475161|Rabeprazole
94577|NCT02475161|JNJ-42847922
94578|NCT02475148|JNJ-54175446
94579|NCT02475148|Healthy
94580|NCT02475135|Immunodeficiency Virus Type 1, Human
94581|NCT02475135|Immunodeficiency Virus Type 2, Human
94582|NCT02475135|Darunavir
94583|NCT02475135|Cobicistat
94584|NCT02475135|Tenofovir Alafenamide
94585|NCT02475135|Emtricitabine
94586|NCT02475135|Elvitegravir
94587|NCT02475122|Measurement of azygos blood flow
94588|NCT02475109|Proliferative Diabetic Retinopathy
94589|NCT02475083|Stroke
94590|NCT02475083|Virtual reality
94591|NCT02475083|Balance
94592|NCT02475083|Falls
94593|NCT02475057|Prostate Cancer
94594|NCT02475057|Cardiovascular disease
94595|NCT02475057|Degarelix
94596|NCT02475044|post-concussion
94597|NCT02475044|Cognitive-Behavioral Theray
94598|NCT02475044|parenting
94599|NCT02475031|transversus abdominis plane block
94600|NCT02475018|Shuhua Milk
94601|NCT02475018|plant sterol esters
94602|NCT02475018|serum cholesterol
94603|NCT02475018|human
94604|NCT02475005|self management app
94605|NCT02475005|headache
94606|NCT02475005|adolescent
94607|NCT02474992|HIV
94608|NCT02474992|Social network
94609|NCT02474992|Social support
94610|NCT02474992|Disclosure
94611|NCT02474992|Stigma
94612|NCT02474992|Kenya
94613|NCT02474979|Pressure ulcer
94614|NCT02474979|Prevention
94615|NCT02474979|Pressure mapping
94616|NCT02474953|Curcumin
94617|NCT02474953|Pharmacokinetic
94618|NCT02474940|Multiple Sclerosis
94619|NCT02474940|Chronic Pain
94620|NCT02474940|Chronic Fatigue
94621|NCT02474940|Autoimmune Diseases
94622|NCT02474940|Autoimmune Diseases of the Nervous System
94623|NCT02474940|Central Nervous System Diseases
94624|NCT02474940|Demyelinating Autoimmune Diseases, CNS
94625|NCT02474940|Demyelinating Diseases
94626|NCT02474927|antibody-mediated rejection
94627|NCT02474927|lung transplant
94628|NCT02474927|Carfilzomib
94629|NCT02474901|Shedding
94630|NCT02474901|Immunogenicity
94631|NCT02474901|Safety
94632|NCT02474901|HIV infected
94633|NCT02474901|Children
94634|NCT02474901|Young adults
94635|NCT02474875|Fibromyalgia
94636|NCT02474875|Patient education
94637|NCT02474875|Central sensitization
94638|NCT02474836|Allergy
94639|NCT02474810|central venous catheters
94640|NCT02474810|hemodialysis
94641|NCT02474810|thrombosis
94642|NCT02474810|tissue plasminogen activator
94643|NCT02474797|Ultrasonography
94644|NCT02474797|Diaphragm
94645|NCT02474797|Lung ultrasound
94646|NCT02474797|Sepsis
94647|NCT02474797|Critical care
94648|NCT02474797|Chest physiotherapy
94649|NCT02473705|Geriatric
94650|NCT02473705|bicarbonate
94651|NCT02473705|omega polyunsaturated fatty acids
94652|NCT02473705|exercise capacity
94653|NCT02473679|First Responder
94654|NCT02473679|BLS
94655|NCT02473679|AED
94656|NCT02473679|Resuscitation
94657|NCT02473666|Patient Blood Management
94658|NCT02473666|Red Blood Cells
94659|NCT02473666|Platelet
94660|NCT02473627|Pharmacokinetics
94661|NCT02473601|mivacurium chloramine
94662|NCT02473601|patients with liver cirrhosis
94663|NCT02473601|muscle relaxation effect
94664|NCT02473575|Caffeine, running, performance
94665|NCT02473562|Parkinson's disease
94666|NCT02473562|Varenicline
94667|NCT02473562|Excessive daytime sleepiness
94668|NCT02473549|motor
94669|NCT02473549|rehabilitation
94670|NCT02473549|transcranial direct current stimulation
94671|NCT02473523|Fatigue
94672|NCT02473523|Pain Alleviation
94673|NCT02473523|Emotional Wellbeing
94674|NCT02473523|Physical Wellbeing
94675|NCT02473523|Yoga
94676|NCT02473510|Trivalent
94677|NCT02473510|Influenza
94678|NCT02473510|FluMist Quadrivalent
94679|NCT02473510|Vaccine
94680|NCT02473510|Prevention
94681|NCT02473510|Healthy
94682|NCT02474745|second stage of labor
94683|NCT02474745|pushing techniques
94684|NCT02474719|nephrology
94685|NCT02474719|extra-renal purification
94686|NCT02474719|peritoneal dialysis
94687|NCT02474706|cefoxitin Patient safety
94688|NCT02474706|Infectious diseases
94689|NCT02474706|Extended-Spectrum β-lactamases E.coli
94690|NCT02474706|Antibiotics
94691|NCT02474680|depression
94692|NCT02474680|Major Depressive Disorder
94693|NCT02474680|MDD
94694|NCT02474680|mental health
94695|NCT02474680|pharmacogenomics
94696|NCT02474680|personalized medicine
94697|NCT02474680|precision medicine
94698|NCT02474680|anti-depressants
94699|NCT02474667|DGF
94700|NCT02474667|Delayed Graft Function
94701|NCT02474667|Renal Transplantation
94702|NCT02474667|Deseased Donor Kidney
94703|NCT02474667|BB3
94704|NCT02474667|Kidney Transplantation
94705|NCT02474667|Acute Kidney Injury
94706|NCT02474641|Breast cancer
94707|NCT02474641|Hypofractionation with SIB
94708|NCT02474641|Non-inferiority
94709|NCT02474641|adjuvant radiotherapy with simultaneous integrated boost
94710|NCT02474628|Physiological Phenomena
94711|NCT02474615|Apicoectomy
94712|NCT02474615|Oral surgery
94713|NCT02474615|Biocompatible materials
94714|NCT02474615|Dental Cements
94715|NCT02474615|Translational Medical Research
94716|NCT02474602|phototherapy
94717|NCT02474602|strength training
94718|NCT02474602|photobiostimulation
94719|NCT02474602|muscle development
94720|NCT02474589|Treatment
94721|NCT02474589|orthopoxvirus
94722|NCT02474589|smallpox
94723|NCT02474563|Multiple Myeloma
94724|NCT02474563|Bortezomib
94725|NCT02474563|Melphalan
94726|NCT02474563|Prednisone
94727|NCT02474550|diffuse large b cell lymphoma
94728|NCT02474550|peg-filgrastim
94729|NCT02474550|febrile neutropenia
94730|NCT02474537|hepatic impairment,
94731|NCT02474537|INC280,
94732|NCT02474537|Oral cMET Inhibitor,
94733|NCT02474537|Non-Cancer
94734|NCT02474524|Psychosis
94735|NCT02474524|Schizophrenia
94736|NCT02474524|Self-management
94737|NCT02474524|Recovery
94738|NCT02474524|Tablet computer
94739|NCT02474524|Digital health
94740|NCT02474524|Internet
94741|NCT02474524|Online
94742|NCT02474524|Peer support
94743|NCT02474498|Regenerative therapy
94744|NCT02474498|Randomized clinical trial (RCT)
94745|NCT02474498|Enamel matrix derivative
94746|NCT02474498|Hydroxyapatite-beta tricalcium phosphate
94747|NCT02474498|Buccal furcation
94748|NCT02474485|bioresorbable vascular scaffold
94749|NCT02474485|Absorb
94750|NCT02474485|drug eluting balloon
94751|NCT02474485|percutaneous coronary intervention
94752|NCT02474472|Midline Laparotomy
94753|NCT02474472|Sternotomy
94754|NCT02474472|Thoracotomy
94755|NCT02474472|Thoracoabdominal Incision
94756|NCT02474459|Deep Brain Stimulation
94757|NCT02474459|DBS
94758|NCT02474459|STN
94759|NCT02474459|GPi
94760|NCT02474459|Globus pallidus
94761|NCT02474459|Subthalamic nucleus
94762|NCT02474459|Neuromodulation
94763|NCT02474407|Seizures
94764|NCT02474407|Epilepsy
94765|NCT02474355|NSCLC
94766|NCT02474355|EGFRm
94767|NCT02474355|T790M
94768|NCT02474329|Parkinson's disease
94769|NCT02474329|Ambulatory monitoring
94770|NCT02474329|Disease progression
94771|NCT02474303|Truvada
94772|NCT02474303|EMTRICITABINE/TENOFOVIR DISPROXIL FUMARATE
94773|NCT02474303|HIV PREEXPOSURE PROPHYLAXIS (PrEP)
94774|NCT02474303|Female Sex Workers
94775|NCT02474290|Acute Myeloid Leukemia
94776|NCT02474290|FLT3-ITD
94777|NCT02474290|Hematopoietic Stem Cell Transplantation
94778|NCT02474238|Iridotomy
94779|NCT02474225|intraocular pressure
94780|NCT02474225|intravitreal
94781|NCT02474212|Venous thromboembolism
94782|NCT02474212|pulmonary embolism
94783|NCT02474212|thromboprophylaxis
94784|NCT02474212|anticoagulant
94785|NCT02474212|anti-FXa
94786|NCT02474212|low-molecular weight heparin
94787|NCT02474212|enoxaparin
94788|NCT02474199|Regulatory T Cells ( Treg)
94789|NCT02474199|Donor Alloantigen Reactive Tregs (darTregs)
94790|NCT02474199|Liver Transplant
94791|NCT02474199|Alloantigen Reactive Tregs
94792|NCT02474199|Calcineurin Inhibitors (CNI)
94793|NCT02474199|immunosuppressants (IS)
94794|NCT02474186|breast
94795|NCT02474186|cancer
94796|NCT02474186|metastatic
94797|NCT02474186|breast cancer
94798|NCT02474186|metastatic breast cancer
94799|NCT02474186|radiation
94800|NCT02474186|radiotherapy
94801|NCT02474186|radiation therapy
94802|NCT02474186|abscopal
94803|NCT02474186|abscopal effect
94804|NCT02474186|T-cell
94805|NCT02474186|GM-CSF
94806|NCT02474186|anti-tumor
94807|NCT02474186|immune
94808|NCT02474186|immune response
94809|NCT02474186|capecitabine
94810|NCT02474186|xeloda
94811|NCT02474186|taxol
94812|NCT02474186|paclitaxel
94813|NCT02474186|other solid metastatic tumor
94814|NCT02474108|atrial fibrillation
94815|NCT02474108|radiofrequency ablation
94816|NCT02474108|prevention of AF
94817|NCT02474108|mitral valve
94818|NCT02474108|left atrium enlargement
94819|NCT02474108|cryoablation
94820|NCT02474056|decreased blood volume vein volume flow ultrasound exam
94821|NCT02474043|Injection drug use
94822|NCT02474017|Inhaler
94823|NCT02474017|Adolescent
94824|NCT02473978|During Labor
94825|NCT02473978|Complicating Anesthesia or Other Sedation
94826|NCT02473978|Cerebral
94827|NCT02473926|Physical Activity
94828|NCT02473926|Physical Function
94829|NCT02473926|Physical Impairment
94830|NCT02473926|Sedentary Lifestyle
94831|NCT02473887|ondansetron
94832|NCT02473887|palatability
94833|NCT02473887|vomiting
94834|NCT02473861|exercise training
94835|NCT02473861|breast cancer
94836|NCT02473861|taxane chemotherapy
94837|NCT02473861|peripheral neuropathy
94838|NCT02473861|fatigue
94839|NCT02473861|autonomic function
94840|NCT02473835|T-lymphocyte
94841|NCT02473835|Adipose tissue
94842|NCT02473835|Inflammation
94843|NCT02473835|Calorie restriction
94844|NCT02473822|anterior cruciate ligament
94845|NCT02473822|Tape Locking Screw
94846|NCT02473822|LCA
94847|NCT02473822|joint trauma
94848|NCT02473796|home based child care
94849|NCT02473770|Registry
94850|NCT02473770|Exposures
94851|NCT02473770|Biological Specimens
94852|NCT02473770|Occupational Health
94853|NCT02473757|Recombinant DNA Product
94854|NCT02473757|Laboratory Evaluation
94855|NCT02473757|NIH Office of Biotechnology Activities
94856|NCT02473757|Gamma-Retroviral Vectors
94857|NCT02473744|lower limb edema
94858|NCT02473744|subcutaneous drainage
94859|NCT02473744|bioelectrical impedance
94860|NCT02473744|quality of life
94861|NCT02473497|chromosomal rearrangement
94862|NCT02473497|activating mutation
94863|NCT02473497|activating genetic alteration
94864|NCT02473497|genetic aberration
94865|NCT02473497|ALK
94866|NCT02473497|ROS1
94867|NCT02473497|cMET
94868|NCT02473497|crizotinib
94869|NCT02473497|oral formulation
94870|NCT02473484|High Grade Glioma
94871|NCT02473484|Proteomics
94872|NCT02473484|MALDI-MSI
94873|NCT02473471|Micro-Osteoperforation (MOPs)
94874|NCT02473471|regional acceleratory phenomenon (RAP)
94875|NCT02473471|Malocculsion
94876|NCT02473458|Licorice
94877|NCT02473458|Glycyrrhizic acid
94878|NCT02473458|Ischemic Stroke
94879|NCT02473458|Acute
94880|NCT02473445|inherited mitochondrial disease
94881|NCT02473445|Leigh Syndrome;
94882|NCT02473445|LHON;
94883|NCT02473445|MERFF;
94884|NCT02473445|MELAS;
94885|NCT02473445|Kearn-Sayre syndrome;
94886|NCT02473445|POLG-related disorders;
94887|NCT02473445|MNGIE
94888|NCT02473432|respiratory muscle training
94889|NCT02473432|neuromuscular electrical stimulation
94890|NCT02473432|oropharyngeal dysphagia
94891|NCT02473432|stroke
94892|NCT02473432|rehabilitation
94893|NCT02473419|Medical food
94894|NCT02473419|ADHD
94895|NCT02473419|Vayarin
94896|NCT02473419|Fish Oil
94897|NCT02473380|glioma
94898|NCT02473380|fluorescence spectroscopy
94899|NCT02473341|Bovine Colostrum
94900|NCT02473341|Corticosteriods
94901|NCT02473341|Endotoxin
94902|NCT02473341|MELD
94903|NCT02473341|mDF
94904|NCT02473328|dose reduction study
94905|NCT02473289|Depressive disorder, major
94906|NCT02473289|Sirukumab
94907|NCT02473263|Severe septic syndrome
94908|NCT02473263|mobile intensive care unit
94909|NCT02473263|strategy
94910|NCT02473263|antibiotics
94911|NCT02473263|hemodynamic optimization
94912|NCT02473237|COPD
94913|NCT02473237|biomass
94914|NCT02473224|Norovirus, Snow Mountain filtrate, GII.2, HID50, challenge
94915|NCT02473198|Total Knee Arthroplasty
94916|NCT02473198|Amide Local Anesthetic
94917|NCT02473172|Weaning from mechanical ventilation
94918|NCT02473159|Near-infrared fluorescence
94919|NCT02473159|Indocyanine green, ICG
94920|NCT02473159|breast cancer
94921|NCT02473146|AML
94922|NCT02473146|untreated
94923|NCT02473146|65-80 years old
94924|NCT02473146|favorable and intermediate karyotype
94925|NCT02473133|radiotherapy
94926|NCT02473133|dose redistribution
94927|NCT02473133|boost
94928|NCT02473120|metastatic
94929|NCT02473120|ESR1
94930|NCT02473120|aromatase inhibitor
94931|NCT02473120|breast cancer
94932|NCT02473107|Dental caries
94933|NCT02473107|Primary tooth
94934|NCT02473107|Caries Detection
94935|NCT02473094|Metformin
94936|NCT02473094|Rectal Cancer
94937|NCT02473094|Rectum
94938|NCT02473094|Radiotherapy
94939|NCT02473094|Capecitabine
94940|NCT02473094|Neoadjuvant
94941|NCT02473094|Adenocarcinoma
94942|NCT02473094|Carcinoma
94943|NCT02473081|Type 2 diabetes
94944|NCT02473081|Minimal psychological intervention
94945|NCT02473081|Glycemic control
94946|NCT02473081|Depressive symptoms
94947|NCT02473081|Problem Area in Diabetes
94948|NCT02473081|Middle-aged and older adults
94949|NCT02473081|HbA1c protein, human
94950|NCT02473068|CPAP
94951|NCT02473055|kangaroo care
94952|NCT02473055|sleep
94953|NCT02473055|heart rate
94954|NCT02473055|respiratory rate
94955|NCT02473055|preterm infant
94956|NCT02473042|Post-operative nausea and vomiting
94957|NCT02473042|PONV
94958|NCT02473042|Breast cancer
94959|NCT02473042|Neuromuscular blockade monitor
94960|NCT02473042|NMBM
94961|NCT02473042|Breast cancer surgery
94962|NCT02473042|Prophylactic anti-emetics
94963|NCT02473042|Electrical stimulation
94964|NCT02473042|Zofran
94965|NCT02473042|Ondansetron
94966|NCT02473042|Dexamethasone
94967|NCT02473042|Decadron
94968|NCT02473042|Phenergan
94969|NCT02473042|Promethazine
94970|NCT02473042|Phenazine
94971|NCT02473042|Phencen
94972|NCT02473042|Prometh
94973|NCT02473042|Prorex
94974|NCT02473042|V-Gan
94975|NCT02473042|Pepcid
94976|NCT02473042|Famotidine
94977|NCT02473042|Questionnaire
94978|NCT02473042|Survey
94979|NCT02473016|Classical Trigeminal Neuralgia
94980|NCT02473003|Breast cancer
94981|NCT02473003|prostate cancer
94982|NCT02473003|colorectal cancer
94983|NCT02473003|fatigue
94984|NCT02473003|physical exercise
94985|NCT02473003|randomised trial
94986|NCT02473003|intervention
94987|NCT02472990|DMD
94988|NCT02472990|morphological predictive factors
94989|NCT02472990|Mechanical
94990|NCT02472938|Relapsing remitting Multiple Sclerosis
94991|NCT02472912|Pharmacokinetics
94992|NCT02472912|Adalimumab
94993|NCT02472912|Biosimilar Pharmaceuticals
94994|NCT02472899|Geriatrics
94995|NCT02472899|Neurocognitive Disorder
94996|NCT02472899|Biomarkers
94997|NCT02472899|Immunology
94998|NCT02472886|HCV genotype 1
94999|NCT02472886|HCV
95000|NCT02472886|Sustained Virologic Response
95001|NCT02472886|Direct Acting Antiviral
95002|NCT02472886|Combination Therapy
95003|NCT02472886|GS-7977
95004|NCT02472886|GS-5885
95005|NCT02472886|Ribavirin
95006|NCT02472886|Sofosbuvir
95007|NCT02472886|ledipasvir
95008|NCT02472886|Hepatitis C
95009|NCT02472886|Hepatitis C, Chronic
95010|NCT02472886|Liver Diseases
95011|NCT02472886|Virus Diseases
95012|NCT02472886|Antiviral Agents
95013|NCT02472873|endometrioma
95014|NCT02472873|endometriosis
95015|NCT02472873|sclerotherapy
95016|NCT02472873|ethanol
95017|NCT02472873|aspiration
95018|NCT02472873|laparoscopy
95019|NCT02472860|Autism Spectrum Disorder
95020|NCT02472860|Neuroplasticity-based Cognitive Training
95021|NCT02472847|Marinol
95022|NCT02472847|Dronabinol
95023|NCT02472847|Fear extinction
95024|NCT02472847|Healthy volunteers
95025|NCT02472834|Carbamylation
95026|NCT02472834|Albumin
95027|NCT02472834|Protein structure
95028|NCT02472834|Kidney disease
95029|NCT02472795|Systemic lupus erythematosus
95030|NCT02472782|osteoporosis
95031|NCT02472782|quality of life
95032|NCT02472782|adherence
95033|NCT02472782|treatment
95034|NCT02472743|Phototherapy
95035|NCT02472730|Colonoscopy
95036|NCT02472730|Training Techniques
95037|NCT02472730|Endoscopy, Gastrointestinal
95038|NCT02472717|liraglutide, GLP-1 receptor agonists
95039|NCT02472704|celiac disease
95040|NCT02472704|lymphocytic enteritis
95041|NCT02472704|non-celiac gluten sensitivity
95042|NCT02472704|double-blind gluten rechallenge
95043|NCT02472691|relapse after allogeneic transplantation
95044|NCT02472691|MDS
95045|NCT02472691|AML
95046|NCT02472691|CMML
95047|NCT02472691|DLI
95048|NCT02472691|Azacitidine
95049|NCT02472691|Lenalidomide
95050|NCT02472691|C04.557.337.539.275
95051|NCT02472691|C15.378.190.625
95052|NCT02472691|C04.557.337.539.522
95053|NCT02472665|pediatric
95054|NCT02472665|plasma-derived FVIII concentrate
95055|NCT02472613|Post－Stroke Depression
95056|NCT02472613|Acupunture
95057|NCT02472613|Fluoxetine
95058|NCT02472613|RCT
95059|NCT02472600|extended spectrum beta-lactamase producing enterobacteriaceae
95060|NCT02472600|carbapenemase producing enterobacteriaceae
95061|NCT02472600|multidrug resistant bacteria
95062|NCT02472574|Intracerebral Hemorrhage
95063|NCT02472574|minimally invasive surgery
95064|NCT02472574|recombinant tissue plasminogen activator
95065|NCT02472574|Dose-effect Relationship
95066|NCT02472561|Cardiology
95067|NCT02472561|Vascular
95068|NCT02472561|Peripheral Artery Disease
95069|NCT02472561|Artery
95070|NCT02472561|Mobile Health
95071|NCT02472561|Exercise
95072|NCT02472561|PAD
95073|NCT02472535|HoFH
95074|NCT02472509|Ursodeoxycholic acid (UDCA)
95075|NCT02472509|White blood cells (WBC)
95076|NCT02472509|Alanine Transaminase (ALT)
95077|NCT02472509|Alkaline Phosphatase (ALP)
95078|NCT02472509|Aspartate Aminotransferase (AST)
95079|NCT02472509|Gamma-Glutamyl Transpeptidase (GGT)
95080|NCT02472509|Lactate dehydrogenase (LDH)
95081|NCT02472509|Low-Density Lipoprotein (LDL)
95082|NCT02472509|High-Density Lipoprotein (HDL)
95083|NCT02472509|Glucose-6-phosphate dehydrogenase (G6PD)
95084|NCT02472509|Ultrasound (US)
95085|NCT02472470|rTMS
95086|NCT02472470|Depression
95087|NCT02472470|Youth
95088|NCT02472470|TBS
95089|NCT02472470|Brain Stimulation
95090|NCT02472470|Electrophysiology
95091|NCT02472470|Imaging
95092|NCT02472431|ADRC
95093|NCT02472431|Adipose-Derived Regenerative Cells
95094|NCT02472431|Fat Tissue
95095|NCT02472431|Stem Cells
95096|NCT02472431|Erectile Dysfunction
95097|NCT02472431|Arteriogenic Impotence
95098|NCT02472431|Venogenic Impotence
95099|NCT02472431|Vasculogenic Impotence
95100|NCT02472431|Male Impotence
95101|NCT02472431|Male Sexual Impotence
95102|NCT02472392|EWINGS, SARCOMA
95103|NCT02472379|Immune System
95104|NCT02472379|Behavioral Sciences
95105|NCT02472379|Women's Health
95106|NCT02472379|Health Psychology
95107|NCT02472379|Writing
95108|NCT02472353|breast
95109|NCT02472353|cancer
95110|NCT02472353|doxorubicin
95111|NCT02472353|metformin
95112|NCT02472353|cardiotoxicity
95113|NCT02472353|ejection fraction
95114|NCT02472353|LVEF
95115|NCT02472288|urinary retention
95116|NCT02472288|poststroke
95117|NCT02472288|electroacupuncture
95118|NCT02472288|randomized controlled trial
95119|NCT02472288|effectiveness
95120|NCT02472288|safety
95121|NCT02472262|Environmental
95122|NCT02472262|Enteric
95123|NCT02472249|TACE
95124|NCT02472249|CT perfusion
95125|NCT02472249|Liver blood flow
95126|NCT02472236|Type 2 Diabetes Mellitus
95127|NCT02472223|"Pink Eye"
95128|NCT02472197|Endometrial polyp
95129|NCT02472197|Hysteroscopic resection
95130|NCT02472197|Morcellation
95131|NCT02472184|Office hysteroscopy
95132|NCT02472184|Endometrial biopsy
95133|NCT02472184|Abnormal uterine bleeding
95134|NCT02472184|Uterine fibroids
95135|NCT02472171|n-3 polyunsaturated fatty acids
95136|NCT02472171|blueberries
95137|NCT02472158|Bandages
95138|NCT02472158|Central Venous Catheters
95139|NCT02472158|Catheter-Related Infections
95140|NCT02472145|Leukemia, myeloid, acute
95141|NCT02472145|DACOGEN
95142|NCT02472145|Decitabine
95143|NCT02472145|JNJ-56022473
95144|NCT02472145|CLS362
95145|NCT02472132|Central Venous Catheter
95146|NCT02472132|Point Of Care Ultra Sound
95147|NCT02472132|Sub Clavian Vein
95148|NCT02472132|Internal Jugular Vein
95149|NCT02472132|Trans Thoracic Echocardiography
95150|NCT02472119|Celiac disease
95151|NCT02472119|Gluten-free diet
95152|NCT02472119|Wheat flour treatment
95153|NCT02472119|Microbial transglutaminase
95154|NCT02472119|Lysine Ethyl Ester
95155|NCT02472119|Celiac Disease Treatment
95156|NCT02472106|Aortic Valve
95157|NCT02472106|TAVI
95158|NCT02472106|Stenosis
95159|NCT02472093|Postural exercise
95160|NCT02472093|Back pain
95161|NCT02472093|Tender points
95162|NCT02472093|Fibromyalgia
95163|NCT02472093|Perceptive rehabilitation
95164|NCT02472067|Musculoskeletal Injury
95165|NCT02472067|physical therapy
95166|NCT02472067|psychological intervention
95167|NCT02472067|risk factors
95168|NCT02472054|hemophagocytic lymphohistiocytosis (HLH)
95169|NCT02472054|Alemtuzumab (CAMPATH®)
95170|NCT02472041|chest drain
95171|NCT02472028|Cerebrovascular Disorders
95172|NCT02472028|Stroke
95173|NCT02472028|Antihypertensive Agents
95174|NCT02472028|Arterial Pressure
95175|NCT02472028|Memory Disorders
95176|NCT02472015|neuropsychiatric symptoms
95177|NCT02472015|dementia
95178|NCT02472015|telemedicine
95179|NCT02472015|long-term care facilities
95180|NCT02472002|Transplant coronary diseases
95181|NCT02472002|Mesenchymal cell therapy
95182|NCT02472002|Administration of CSM by NOGA system
95183|NCT02472002|Coronary disease in heart transplant patients
95184|NCT02471989|FODMAP
95185|NCT02471989|Diet
95186|NCT02471989|pH-impedance monitoring
95187|NCT02471976|Leonetti law
95188|NCT02471976|palliative care
95189|NCT02471963|Empagliflozin
95190|NCT02471963|Diabetes mellitus
95191|NCT02471963|Macro- and Microcirculation
95192|NCT02471963|Vascular Improvement
95193|NCT02471963|Endothelium function
95194|NCT02471937|Streptococcus agalactiae
95195|NCT02471937|Group B Streptococcus
95196|NCT02471937|Neonates
95197|NCT02471937|colonization
95198|NCT02471937|meningitis
95199|NCT02471937|Clonal Complex CC17
95200|NCT02471937|microbiota
95201|NCT02471937|next generation sequencing (NGS)
95202|NCT02471924|Pregnant women
95203|NCT02471911|DLBCL
95204|NCT02471911|Aggressive
95205|NCT02471911|Diffuse
95206|NCT02471911|Large
95207|NCT02471885|remote ischaemic conditioning
95208|NCT02471885|remote ischemic conditioning
95209|NCT02471885|cardio-oncology
95210|NCT02471885|anthracycline
95211|NCT02471885|troponin
95212|NCT02471885|chemotherapy
95213|NCT02471885|myocardial reperfusion injury
95214|NCT02471833|Hypertension
95215|NCT02471833|Prevention
95216|NCT02471833|Family History
95217|NCT02471833|inflammation
95218|NCT02471833|blood brain barrier
95219|NCT02471833|amyloid
95220|NCT02471820|Multiple Myeloma
95221|NCT02471794|Type II Diabetes
95222|NCT02471794|Personalized Health Planning
95223|NCT02471794|Shared Medical Appointments
95224|NCT02471781|Aortic Aneurysm
95225|NCT02471781|Aneurysm
95226|NCT02471781|Vascular Prosthesis
95227|NCT02471781|Vascular Disease
95228|NCT02471781|Blood Vessel Prosthesis Implantation
95229|NCT02471768|central pressure
95230|NCT02471768|Gensini score
95231|NCT02471768|pulsatility
95232|NCT02471768|coronary artery disease
95233|NCT02471755|electro-acupuncture
95234|NCT02471755|menopause
95235|NCT02471755|menopausal transition symptoms
95236|NCT02471755|efficacy
95237|NCT02471755|RCT
95238|NCT02471755|placebo control
95239|NCT02471729|Cardio-Renal Syndrome
95240|NCT02471729|Chronic Heart Failure
95241|NCT02471729|Renal Denervation
95242|NCT02471729|Sympathetic activation
95243|NCT02471729|Heart Failure
95244|NCT02471729|Cardiovascular Diseases
95245|NCT02471729|Heart Diseases
95246|NCT02471716|Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
95247|NCT02471703|Total Hip Arthroplasty
95248|NCT02471703|Total Hip Replacement
95249|NCT02471703|Inflammatory Joint Disease
95250|NCT02471703|Non-Inflammatory Joint Disease
95251|NCT02471690|Volunteers
95252|NCT02471677|Ovarian stimulation
95253|NCT02471677|corifollitropin alfa
95254|NCT02471677|GnRH antagonist protocol
95255|NCT02471677|high responders
95256|NCT02471677|follitropin beta
95257|NCT02471664|Percutaneous mitral valve repair
95258|NCT02471664|Coronary sinus annuloplasty
95259|NCT02471664|Mitral loop cerclage
95260|NCT02471625|Controls
95261|NCT02471599|IgA nephropathy
95262|NCT02471599|tonsillitis
95263|NCT02471599|tonsil provocation test
95264|NCT02471599|Tonsillectomy
95265|NCT02471573|IVF
95266|NCT02471573|Freeze-all
95267|NCT02471573|frozen embryo transfer
95268|NCT02471573|fresh transfer
95269|NCT02471560|Microbiota
95270|NCT02471560|DMF
95271|NCT02471560|Gastro intestinal
95272|NCT02471560|MS
95273|NCT02471547|Recurrence
95274|NCT02471495|NMIBC
95275|NCT02471495|Non-Muscle-Invasive Bladder Cancer
95276|NCT02471495|Nonmuscle Invasive Bladder Cancer
95277|NCT02471495|BCG refractory
95278|NCT02471495|BCG failure
95279|NCT02471495|Carcinoma in situ
95280|NCT02471495|CIS
95281|NCT02471482|Near Infra Red Spectrometry
95282|NCT02471482|Cerebral oxygenation
95283|NCT02471482|Mozart music
95284|NCT02471404|Diabetes Mellitus Type 2,
95285|NCT02471404|metformin,
95286|NCT02471404|saxagliptin,
95287|NCT02471404|dapagliflozin,
95288|NCT02471404|glimepiride,
95289|NCT02471404|inadequate glycaemic control
95290|NCT02471378|Assay
95291|NCT02471378|Women
95292|NCT02471378|Infected
95293|NCT02471378|Antibodies
95294|NCT02471365|Exposure Assessment
95295|NCT02471365|Questionnaire
95296|NCT02471365|Product Use
95297|NCT02471365|Biomonitoring
95298|NCT02471352|Dermatologic Condition
95299|NCT02471352|Skin Disease
95300|NCT02471352|Biospecimen
95301|NCT02471352|Healthy Volunteers
95302|NCT02471352|Merkel Cell Carcinoma
95303|NCT02471339|Psychological Intervention
95304|NCT02471339|Coping
95305|NCT02471339|Mindfulness
95306|NCT02471339|Randomized
95307|NCT02471326|HIV Neutralizing Antibodies
95308|NCT02471326|HIV Therapy
95309|NCT02471313|Cross-Sectional Imaging
95310|NCT02471313|Chemoembolization
95311|NCT02471313|Radiation Therapy
95312|NCT02471313|Tumor Hypoxia
95313|NCT02471313|PET Imaging
95314|NCT02471300|Asthma
95315|NCT02471300|Inflammasome
95316|NCT02471300|Fasting
95317|NCT02471300|Airflow Obstruction
95318|NCT02471287|Ocular Genetic Diseases
95319|NCT02471287|GENETIC DISEASE
95320|NCT02471144|pediatric, chronic severe plaque psoriasis, secukinumab, etanercept
95321|NCT02471131|WATCHMAN
95322|NCT02471131|Atrial Fibrillation
95323|NCT02471131|Hybrid Ablation
95324|NCT02471131|Safety
95325|NCT02471131|Feasibility
95326|NCT02471131|Stroke Prevention
95327|NCT02471118|Inflammatory Type
95328|NCT02471092|satiety
95329|NCT02471092|glycemia
95330|NCT02471092|milk protein
95331|NCT02471079|Radiation-induced health problems
95332|NCT02471079|Cardiovascular events
95333|NCT02471079|Lung toxicity
95334|NCT02471053|Exercise
95335|NCT02471053|Quality of Life
95336|NCT02471053|Complementary Therapies
95337|NCT02471053|Neoadjuvant Therapy
95338|NCT02471053|Feasibility Studies
95339|NCT02471040|brain metabolism
95340|NCT02471040|cognitive function
95341|NCT02471027|Locally advanced cervical cancer
95342|NCT02471027|Neoadjuvant chemotherapy
95343|NCT02471027|Disease-free survival
95344|NCT02471027|Overall survival
95345|NCT02471014|Pneumovax23
95346|NCT02471014|Obesity
95347|NCT02471001|concentration
95348|NCT02471001|Isoflurane
95349|NCT02471001|cardioprotective
95350|NCT02471001|cardioplegia
95351|NCT02471001|heart surgery
95352|NCT02471001|Disorder
95353|NCT02471001|Heart
95354|NCT02471001|Functional
95355|NCT02471001|Postoperative
95356|NCT02470949|body weight
95357|NCT02470949|Hispanics
95358|NCT02470949|Energy Intake
95359|NCT02470949|Social Status
95360|NCT02470923|Smoking cessation
95361|NCT02470923|Nicotine
95362|NCT02470923|Spirometry
95363|NCT02470923|Internal medicine
95364|NCT02470910|Prostate Cancer
95365|NCT02470910|Stage I-III prostate adenocarcinoma
95366|NCT02470806|Venous leg ulcer
95367|NCT02470806|ulcer
95368|NCT02470806|venous stasis
95369|NCT02470806|compression
95370|NCT02470806|diabetic foot ulcers
95371|NCT02470806|dfu
95372|NCT02470806|vlu
95373|NCT02470793|Corneal Endothelial Cell Loss
95374|NCT02470793|Fuchs' Endothelial Dystrophy
95375|NCT02470793|Lamellar Keratoplasty
95376|NCT02470793|Descemet Stripping Endothelial Keratoplasty
95377|NCT02470793|Descemet Membrane Endothelial Keratoplasty
95378|NCT02470793|Minimal Surgical Procedure
95379|NCT02470728|patient readmission
95380|NCT02470728|pain relief units
95381|NCT02470728|pain centers
95382|NCT02470728|multidisciplinary pain clinics
95383|NCT02470728|multidisciplinary pain centers
95384|NCT02470728|pain clinics
95385|NCT02470728|hospital readmission
95386|NCT02470728|emergencies
95387|NCT02470728|emergency medicine
95388|NCT02470728|critical care
95389|NCT02470728|emergency treatment
95390|NCT02470728|opioid
95391|NCT02470728|acute pain service
95392|NCT02470715|genetic sequencing
95393|NCT02470715|genome
95394|NCT02470715|cancer
95395|NCT02470715|DNA
95396|NCT02470715|RNA
95397|NCT02470715|protein
95398|NCT02470715|metabolite
95399|NCT02470702|Volunteers
95527|NCT02469935|Gallstones
95400|NCT02470650|comparative effectiveness
95401|NCT02470598|Automated Peritoneal Dialysis
95402|NCT02470598|Adapted APD (aAPD)
95403|NCT02470598|Hydration status
95404|NCT02470598|Residual Renal Function
95405|NCT02470598|Ultrafiltration
95406|NCT02470585|Overall Survival
95407|NCT02470585|BRCA
95408|NCT02470585|Veliparib
95409|NCT02470585|Ovarian
95410|NCT02470585|Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP)
95411|NCT02470585|ABT-888
95412|NCT02470585|Paclitaxel
95413|NCT02470585|Carboplatin
95414|NCT02470585|Randomized
95415|NCT02470546|Hepatic encephalopathy
95416|NCT02470546|Metformin
95417|NCT02470546|Liver cirrhosis
95418|NCT02470481|Psoriatic arthritis
95419|NCT02470468|Immunotherapy
95420|NCT02470468|Metastatic
95421|NCT02470468|NSCLC
95422|NCT02470468|Biological
95423|NCT02470468|Lung Cancer
95424|NCT02470468|Vaccine
95425|NCT02470455|Atorvastatin
95426|NCT02470455|Prediabetics
95427|NCT02470455|HbA1c
95428|NCT02470416|duodenal
95429|NCT02470416|ampulla
95430|NCT02470403|dysglycemic, normoglycemic, prediabetes, type 2 diabetes mellitus
95431|NCT02470390|Volunteer
95432|NCT02470390|Pharmacokenetics (PK) (plasma and Cerebrospinal Fluid [CSF])
95433|NCT02470377|MdDS
95434|NCT02470377|TMS
95435|NCT02470377|fMRI
95436|NCT02470377|EEG
95437|NCT02470364|Myasthenia gravis
95438|NCT02470364|Quality of life
95439|NCT02470325|Cerebral palsy
95440|NCT02470325|Genetic neurodegenerative diseases
95441|NCT02470312|utility of MediGuide system
95442|NCT02470312|CRT
95443|NCT02470312|EP
95444|NCT02470299|ketorolac
95445|NCT02470299|GTPase
95446|NCT02470299|cancer
95447|NCT02470299|peritoneal
95448|NCT02470299|fallopian
95449|NCT02470299|ovarian
95450|NCT02470273|Melanoma
95451|NCT02470260|Diabetes
95452|NCT02470260|Pre-diabetes
95453|NCT02470260|Cognition
95454|NCT02470260|Depressive symptoms
95455|NCT02470247|Transcatheter Aortic Valve Implantation
95456|NCT02470234|ADHD
95457|NCT02470234|Children
95458|NCT02470234|Pharmacokinetics
95459|NCT02470221|goal-directed fluid therapy
95460|NCT02470221|intraoperative hemodynamics
95461|NCT02470221|postoperative complications
95462|NCT02470208|Cytomegalovirus reactivation in stem cell transplant
95463|NCT02470182|sleep apnea
95464|NCT02470182|snoring
95465|NCT02470156|community based participatory research
95466|NCT02470156|healthy eating
95467|NCT02470156|physical activity
95468|NCT02470156|obesity
95469|NCT02470143|Human-computer interaction
95470|NCT02470143|Fear
95471|NCT02470143|Motivation
95472|NCT02470143|Usability
95473|NCT02470130|simulation
95474|NCT02470130|anxiety
95475|NCT02470130|debriefing
95476|NCT02470130|memorization
95477|NCT02470104|children
95478|NCT02470104|bone marrow transplant
95479|NCT02470104|autologous
95480|NCT02470104|allogeneic
95481|NCT02470104|breastmilk
95482|NCT02470104|hematopoietic stem cell transplantation (HSCT)
95483|NCT02470078|extubation
95484|NCT02470065|NSCLC
95485|NCT02470065|Early stage
95486|NCT02470065|Phase II
95487|NCT02470065|Randomized
95488|NCT02470065|EGFR mutated
95489|NCT02470052|Endobronchial Valves
95490|NCT02470052|Intrabronchial Valves
95491|NCT02470052|Bronchial Valve
95492|NCT02470052|Chronic Obstructive Pulmonary Disease
95493|NCT02470052|Pulmonary Disease, Chronic Obstructive
95494|NCT02470052|Bronchoscopic Lung Volume Reduction
95495|NCT02470052|Emphysema
95496|NCT02470052|Pulmonary Emphysema
95497|NCT02470052|Lung Diseases
95498|NCT02470052|Respiratory Tract Disease
95499|NCT02470013|Malnutrition
95500|NCT02470013|Geriatrics
95501|NCT02470013|Enteral Nutrition
95502|NCT02470000|myofascial pain
95503|NCT02470000|neck
95504|NCT02470000|laser
95505|NCT02470000|elastography
95506|NCT02470000|shear wave velocity
95507|NCT02470000|randomized control trial
95508|NCT02470000|Intravascular Laser Irradiation of Blood
95509|NCT02469987|safety
95510|NCT02469987|tolerability
95511|NCT02469987|immunogenicity
95512|NCT02469987|MYL-1402O
95513|NCT02469987|PK
95514|NCT02469987|Avastin®
95515|NCT02469987|biosimilarity
95516|NCT02469987|male
95517|NCT02469974|Myelofibrosis
95518|NCT02469974|RUXOLITINIB
95519|NCT02469974|Autologous stem cell transplant
95520|NCT02469948|spasticity
95521|NCT02469948|botulinum toxin
95522|NCT02469948|ultrasonography guidance
95523|NCT02469948|electric stimulation guidance
95524|NCT02469948|stroke
95525|NCT02469935|Validation
95526|NCT02469935|Surgeon-performed ultrasound
95528|NCT02469909|Decannulation
95529|NCT02469909|tracheostomy
95530|NCT02469896|ALS
95531|NCT02469896|tocilizumab
95532|NCT02469896|biomarker
95533|NCT02469870|Parents of children who have autism
95534|NCT02469870|video-conferencing
95535|NCT02469870|Applied Behavior Analysis
95536|NCT02469870|Acceptance Commitment Training
95537|NCT02469870|optimism training
95538|NCT02469870|Positive Behavior Support
95539|NCT02469857|AB103
95540|NCT02469857|Necrotizing fasciitis
95541|NCT02469818|pocus
95542|NCT02469818|ultrasonography
95543|NCT02469818|glenohumeral dislocation
95544|NCT02469792|Anterior cruciate ligament
95545|NCT02469792|Ligament rupture
95546|NCT02469792|Intraarticular injection
95547|NCT02469792|ADRC
95548|NCT02469792|Adipose-derived regenerative cells
95549|NCT02469792|Adipose tissue
95550|NCT02469792|Stem cells
95551|NCT02469779|Tobacco Prevention
95552|NCT02469779|ASPIRE Website
95553|NCT02469779|Surveys
95554|NCT02469779|Questionnaires
95555|NCT02469779|Focus Groups
95556|NCT02469779|Health Interactive Website
95557|NCT02469766|ureteral stones
95558|NCT02469766|ureter
95559|NCT02469766|ureteroscopy
95560|NCT02469766|flexible
95561|NCT02469766|SWL
95562|NCT02469753|NSAIDs
95563|NCT02469753|Anti-TNF
95564|NCT02469753|syndesmophytes
95565|NCT02469753|mSASSS
95566|NCT02469740|Ticagrelor
95567|NCT02469740|Clopidogrel
95568|NCT02469740|Coronary Artery Disease
95569|NCT02469740|Percutaneous Coronary Intervention
95570|NCT02469740|Acute Coronary Syndrome
95571|NCT02469714|Patient Navigator
95572|NCT02469714|Integrated Care
95573|NCT02469714|Latino
95574|NCT02469714|Mental health and wellness
95575|NCT02469714|Physical health and wellness
95576|NCT02469688|cedar pollinosis
95577|NCT02469688|immunological response,
95578|NCT02469688|ASP4070
95579|NCT02469688|vaccine
95580|NCT02469675|Spinal Cord Injuries
95581|NCT02469675|Amyotrophic Lateral Sclerosis
95582|NCT02469675|Transcranial magnetic stimulation, single pulse
95583|NCT02469675|non-invasive brain stimulation
95584|NCT02469662|Total Elbow Arthroplasty
95585|NCT02469662|TEA
95586|NCT02469662|Elbow Arthroplasty
95587|NCT02469662|Elbow Replacement
95588|NCT02469662|Advanced Rheumatoid Arthritis
95589|NCT02469662|Post-Traumatic Arthritis
95590|NCT02469662|Degenerative Arthritis
95591|NCT02469662|Elbow Joint Destruction
95592|NCT02469662|Post-Traumatic Lesions or Bone Loss
95593|NCT02469662|Ankylosed Joints
95594|NCT02469662|Acute Comminuted Articular Fracture
95595|NCT02469662|significantly compromises daily living activities
95596|NCT02469662|degree of joint or soft tissue damage precludes reliable osteosynthesis
95597|NCT02469662|precludes less radical procedures, including 13-C3 fractures of the distal humerus
95598|NCT02469610|Post surgical pain
95599|NCT02469584|prolapse
95600|NCT02469584|anterior colporrhaphy
95601|NCT02469545|depression
95602|NCT02469545|microbiota-gut-brain axis
95603|NCT02469545|Lactobacillus Plantarum 299v
95604|NCT02469545|probiotic
95605|NCT02469480|MCRC
95606|NCT02469480|iron substitution
95607|NCT02469480|iron deficiency anemia
95608|NCT02469467|phosphate binder
95609|NCT02469467|dialysis
95610|NCT02469454|etonogestrel-implant
95611|NCT02469454|newborn
95612|NCT02469454|growth
95613|NCT02469454|Child Development
95614|NCT02469441|coffee
95615|NCT02469441|postoperative ileus
95616|NCT02469441|colorectal surgery
95617|NCT02469428|Controlled human exposure study
95618|NCT02469428|Ozone
95619|NCT02469428|Inflammation
95620|NCT02469415|Leukemia
95621|NCT02469415|Myelodysplastic syndromes
95622|NCT02469415|MDS
95623|NCT02469415|Lower-risk
95624|NCT02469415|Pacritinib
95625|NCT02469415|5-azacitidine
95626|NCT02469415|Azacitidine
95627|NCT02469415|5-azacytidine
95628|NCT02469415|Vidaza
95629|NCT02469415|5-AZC
95630|NCT02469415|AZA-CR
95631|NCT02469415|Ladakamycin
95632|NCT02469415|NSC-102816
95633|NCT02469415|Azacytidine
95634|NCT02469415|Decitabine
95635|NCT02469415|Dacogen
95636|NCT02469402|reduced
95637|NCT02469402|protein
95638|NCT02469402|formula
95639|NCT02469402|Alpha-lactalbumin
95640|NCT02469402|infant
95641|NCT02469389|Schizophrenia
95642|NCT02469389|Negative Symptoms
95643|NCT02469363|Macintosh laryngoscope
95644|NCT02469363|McCoy laryngoscope
95645|NCT02469363|C-Mac videolaryngoscope
95646|NCT02469363|McGrath videolaryngoscope
95647|NCT02469363|Hemodynamic parameters
95648|NCT02469350|Gait and balance disorders
95649|NCT02469350|serious game
95650|NCT02469311|infection; arthroplasty; chlorhexidine; hip; knee
95651|NCT02469298|acute, uncomplicated influenza
95652|NCT02469298|Danirixin
95653|NCT02469298|oseltamivir
95654|NCT02469285|Fatty acids
95655|NCT02469285|Lipids
95656|NCT02469285|Nitroso compounds
95657|NCT02469285|Lipid metabolism
95658|NCT02469285|Gut metabolism
95659|NCT02469259|oxytocin
95660|NCT02469259|PTSD
95661|NCT02469259|Alcohol Use Disorder
95662|NCT02469259|social cognition
95663|NCT02469259|craving
95664|NCT02469259|fear-potentiated startle
95665|NCT02469246|HIV
95666|NCT02469246|HIV-1 Positive
95667|NCT02469246|Virologically-Suppressed
95668|NCT02469220|Diet
95669|NCT02469220|FODMAP
95670|NCT02469220|Gut microbiota
95671|NCT02469220|Inflammation
95672|NCT02469207|regenerative medicine
95673|NCT02469207|stem cells
95674|NCT02469207|immunomodulatory
95675|NCT02469207|induced pluripotent stem cells
95676|NCT02469207|gut physiology
95677|NCT02469129|positron emission tomography (PET) imaging
95678|NCT02469129|poly(ADP-ribose) polymerase 1 (PARP1)
95679|NCT02469129|[18F]FluorThanatrace ([18F]FTT)
95680|NCT02469129|PARP1 inhibitors
95681|NCT02469129|cancer treatments
95682|NCT02469103|capsule colonoscopy
95683|NCT02469103|ulcerative colitis
95684|NCT02469077|Chronic Low Back Pain
95685|NCT02469064|mechanical ventilation
95686|NCT02469064|respiratory muscle
95687|NCT02469064|weaning
95688|NCT02469064|training
95689|NCT02469064|Intensive care
95690|NCT02469012|chronic hepatitis C
95691|NCT02469012|antiviral treatment
95692|NCT02469012|interferon-free
95693|NCT02469012|neurocognitive performance
95694|NCT02469012|emotional state
95695|NCT02469012|quality of life
95696|NCT02468999|Intranasal insulin
95697|NCT02468986|Rheumatoid Arthritis
95698|NCT02468973|health behavior
95699|NCT02468973|consultation
95700|NCT02468973|undergraduate
95701|NCT02468960|Coronary Artery Disease
95702|NCT02468960|OPN NC
95703|NCT02468960|Angina
95704|NCT02468960|Stable
95705|NCT02468960|Unstable
95706|NCT02468947|Neonatal sepsis
95707|NCT02468934|electrical stimulation
95708|NCT02468934|neurostimulation
95709|NCT02468934|neuromodulation
95710|NCT02468934|TKA pain
95711|NCT02468934|pain following total knee replacement
95712|NCT02468934|total knee arthroplasty
95713|NCT02468921|Goitre
95714|NCT02468921|thyroid disease
95715|NCT02468921|struma
95716|NCT02468895|Myositis
95717|NCT02468895|Idiopathic inflammatory myopathy
95718|NCT02468895|Antibodies
95719|NCT02468895|Genetics
95720|NCT02468895|Biomarkers
95721|NCT02468882|Breast cancer
95722|NCT02468882|Radiotherapy
95723|NCT02468882|Toxicity
95724|NCT02468882|Outcomes
95725|NCT02468882|Watercress
95726|NCT02468869|recall
95727|NCT02468869|discharge communication
95728|NCT02468843|Deep brain stimulation
95729|NCT02468843|DBS
95730|NCT02468843|Dystonia
95731|NCT02468843|DYT1
95732|NCT02468830|mirabegron
95733|NCT02468830|antimuscarinics
95734|NCT02468830|beta 3 agonist
95735|NCT02468830|overactive bladder
95736|NCT02468830|children
95737|NCT02468817|parathyroid hormone (PTH)
95738|NCT02468817|bone mineral density (BMD)
95739|NCT02468804|Parkinson's
95740|NCT02468804|Non-parkinsons
95741|NCT02468791|Rheumatoid Arthritis
95742|NCT02468791|Autoimmune Diseases
95743|NCT02468791|Rituximab
95744|NCT02468791|Immune System Diseases
95745|NCT02468791|Joint Diseases
95746|NCT02468791|Rheumatic Diseases
95747|NCT02468778|HeartMate PHP
95748|NCT02468778|High Risk PCI
95749|NCT02468778|Left Ventricular Dysfunction
95750|NCT02468778|Thoratec Corporation
95751|NCT02468713|Omega-3
95752|NCT02468713|Blood lipid profiles
95753|NCT02468713|DHA
95754|NCT02468713|EPA
95755|NCT02468713|Triglyceride
95756|NCT02468713|Glucose
95757|NCT02468713|Insulin
95758|NCT02468713|LDL
95759|NCT02468713|TPN
95760|NCT02468687|Relapsed/Refractory
95761|NCT02468674|Sarcopenia, muscle wasting, elderly, strength, physical
95762|NCT02468674|function, muscle, gait speed
95763|NCT02468661|Non-Small Cell Lung Cancer
95764|NCT02468648|Oral Therapy
95765|NCT02468648|Liver Biopsy
95766|NCT02468648|Chronic Hepatitis C
95767|NCT02468635|Pulmonary rehabilitation
95768|NCT02468635|chronic obstructive pulmonary disease
95769|NCT02468635|physical ability
95770|NCT02468635|pulmonary function
95771|NCT02468635|quality of daily life
95772|NCT02468596|Axonal excitability
95773|NCT02468596|Neuropathy
95774|NCT02468596|QTRAC
95775|NCT02468596|anti-MAG
95776|NCT02468596|Electrophysiology
95777|NCT02468583|Osteoarthritis
95778|NCT02468583|Post-traumatic
95779|NCT02468583|Knee
95780|NCT02468583|Pain
95781|NCT02468583|Steroid
95782|NCT02468583|Intra-articular
95783|NCT02468583|Injection
95784|NCT02468570|PKU
95785|NCT02468570|PEG-PAL
95786|NCT02468570|Pegvaliase
95787|NCT02468570|BMN 165
95788|NCT02468570|rAv-PAL PEG
95789|NCT02468570|PRISM 302
95790|NCT02468570|PRISM 303
95791|NCT02468570|BioMarin
95792|NCT02468570|165-302
95793|NCT02468557|Relapsed/refractory pancreatic ductal adenocarcinoma
95794|NCT02468557|Previously untreated pancreatic ductal adenocarcinoma
95795|NCT02468544|Engagement in care
95796|NCT02468544|mHealth
95797|NCT02468531|Xenon
95798|NCT02468531|Standford A acute aortic dissection
95799|NCT02468505|Structured transition support program
95800|NCT02468505|Transition 'as usual'
95801|NCT02468492|Knee Osteoarthritis
95802|NCT02468492|Platelet Rich Plasma
95803|NCT02468492|Mechanism of Action
95804|NCT02468492|Stem Cells
95805|NCT02468492|Synovial Fluid
95806|NCT02468479|Liver cirrhosis
95807|NCT02468466|suicide
95808|NCT02468466|prevention
95809|NCT02468453|velos
95810|NCT02468453|Vascular
95811|NCT02468453|Rejuvenation
95812|NCT02468440|renal insufficiency
95813|NCT02468440|kidney transplant
95814|NCT02468440|educational therapy
95815|NCT02468414|Peritoneal Dialysis
95816|NCT02468414|End Stage Renal Disease
95817|NCT02468414|Anemia
95818|NCT02468388|maltitol
95819|NCT02468388|xylitol
95820|NCT02468388|quantitative light-induced fluorescence
95821|NCT02468388|saliva pH
95822|NCT02468388|re-mineralization
95823|NCT02468388|dental caries
95824|NCT02468362|Intersphincteric resection
95825|NCT02468362|laparoscopic rectal rescetion
95826|NCT02468362|total mesorectal excsison
95827|NCT02468349|Acute Myocardial Infarction
95828|NCT02468349|Telemedicine
95829|NCT02468349|Readmissions
95830|NCT02468336|Physiology
95831|NCT02468323|PONV
95832|NCT02468323|Palonosetron
95833|NCT02468323|Ondansetron
95834|NCT02468323|Cesarean section
95835|NCT02468310|Maternal mortality
95836|NCT02468310|Neonatal mortality
95837|NCT02468310|Neonatal morbidity
95838|NCT02468310|Text messaging
95839|NCT02468310|Clinical decision making
95840|NCT02468310|Maternal Morbidity
95841|NCT02468271|Clinimetrics
95842|NCT02468271|Lung function
95843|NCT02468271|Lung clearance index
95844|NCT02468258|Assisted Reproduction
95845|NCT02468245|Nursing intervention
95846|NCT02468245|compliance
95847|NCT02468232|chronic heart failure
95848|NCT02468232|cardiovascular death
95849|NCT02468232|hospitalization
95850|NCT02468232|outcome study
95851|NCT02468232|worsening heart failure
95852|NCT02468232|NT-proBNP
95853|NCT02468232|NYHA
95854|NCT02468232|KCCQ
95855|NCT02468232|HF-rEF
95856|NCT02468219|aortic stenosis
95857|NCT02468219|aortic valve replacement
95858|NCT02468219|transcatheter aortic valve implantation
95859|NCT02468219|frailty
95860|NCT02468219|cardiac rehabilitation
95861|NCT02468193|Cushing's syndrome
95862|NCT02468193|osilodrostat
95863|NCT02468193|LCI699
95864|NCT02468193|ectopic corticotropin syndrome
95865|NCT02468193|adrenal adenoma
95866|NCT02468193|adrenal carcinoma
95867|NCT02468193|ACTH-Independent Macronodular Adrenal Hyperplasia
95868|NCT02468193|AIMAH
95869|NCT02468193|Primary Pigmented Nodular Adrenal Dysplasia
95870|NCT02468193|PPNAD
95871|NCT02468128|Analgesic
95872|NCT02468128|Opioids
95873|NCT02468128|Pain relief after surgery
95874|NCT02468128|Dinalbuphine
95875|NCT02468128|Sebacoyl Dinalbuphine Ester
95876|NCT02468128|SDE
95877|NCT02468128|SDN
95878|NCT02468128|LT1001
95879|NCT02468102|Rivaroxaban
95880|NCT02468102|Venous Thrombosis/Pulmonary Embolism
95881|NCT02468102|Stroke Prevention in Atrial Fibrillation
95882|NCT02468102|Anticoagulants
95883|NCT02468102|Hematologic Agents
95884|NCT02468102|Therapeutic Uses
95885|NCT02468102|Observational
95886|NCT02468102|Pulmonary Embolism
95887|NCT02468102|Venous Thrombosis
95888|NCT02468102|Venous Thromboembolism
95889|NCT02468102|Intracranial Hemorrhages
95890|NCT02468102|Gastrointestinal Hemorrhage
95891|NCT02468076|ERCP
95892|NCT02468076|radiofrequency ablation
95893|NCT02468076|obstructive jaundice
95894|NCT02468050|Anxiety
95895|NCT02468050|Depression
95896|NCT02468050|Exercise
95897|NCT02468050|Breast Cancer
95898|NCT02468050|Biopsy
95899|NCT02468050|Screening
95900|NCT02468050|Diagnosis
95901|NCT02468037|iron
95902|NCT02468037|diabetes
95903|NCT02468037|phlebotomy
95904|NCT02467998|meaningful use
95905|NCT02467998|electronic health records
95906|NCT02467998|structured language
95907|NCT02467998|NPWT
95908|NCT02467998|PQRS
95909|NCT02467985|gynecological laparoscopic surgery
95910|NCT02467972|Hunger and satiety
95911|NCT02467972|Hormones gastrointestinal
95912|NCT02467972|Bowel movements
95913|NCT02467959|emergency ultrasound
95914|NCT02467959|acute appendicitis
95915|NCT02467959|bedside ultrasound
95916|NCT02467920|exenatide
95917|NCT02467920|glargine
95918|NCT02467920|aspart 30
95919|NCT02467894|Adherence
95920|NCT02467894|Exercise
95921|NCT02467881|Physical Activity
95922|NCT02467881|Sedentary
95923|NCT02467881|Lifestyle Intervention
95924|NCT02467868|Pegfilgrastim
95925|NCT02467868|Granulocyte Colony Stimulating Factor (G-CSF)
95926|NCT02467868|Breast Cancer
95927|NCT02467868|Neutropenia
95928|NCT02467855|Drug therapy
95929|NCT02467842|Influenza vaccine
95930|NCT02467842|Quadrivalent
95931|NCT02467842|Inactivated cell culture-derived
95932|NCT02467829|Cerebral Palsy
95933|NCT02467829|Walking Aids
95934|NCT02467816|Secondary schools
95935|NCT02467816|School lunch
95936|NCT02467816|Plate waste
95937|NCT02467803|humeral fracture
95938|NCT02467803|exercise
95939|NCT02467803|musculoskeletal manipulations
95940|NCT02467777|orthopaedics
95941|NCT02467777|post-operative warming
95942|NCT02467764|Knee
95943|NCT02467764|Knee osteoarthritis
95944|NCT02467764|Knee replacement
95945|NCT02467764|Hip
95946|NCT02467764|Hip osteoarthritis
95947|NCT02467764|Hip replacement
95948|NCT02467725|Preimplantation Embryo Development
95949|NCT02467712|Fongal infection
95950|NCT02467712|joint prosthesis
95951|NCT02467712|prosthetic reconstruction
95952|NCT02467699|Knee
95953|NCT02467699|Knee osteoarthritis
95954|NCT02467699|Knee replacement
95955|NCT02467621|Stress ulcer prophylaxis
95956|NCT02467621|Proton pump inhibitor
95957|NCT02467621|Pneumonia
95958|NCT02467621|Clostridium difficile infection
95959|NCT02467608|HUEXC030
95960|NCT02467608|Pulmonary Tuberculosis
95961|NCT02467595|no muscle relaxant
95962|NCT02467595|rocuronium
95963|NCT02467595|intubation condition
95964|NCT02467595|tracheal intubation
95965|NCT02467595|operating room time
95966|NCT02467595|low-dose rocuronium
95967|NCT02467582|Aspirin
95968|NCT02467582|colon cancer
95969|NCT02467582|stage II
95970|NCT02467582|stage III
95971|NCT02467582|PIK3CA
95972|NCT02467582|double-blind
95973|NCT02467582|placebo
95974|NCT02467582|Adjuvant Treatment
95975|NCT02467556|CRPS
95976|NCT02467556|intervention
95977|NCT02467556|multimodal
95978|NCT02467543|Primary dysmenorrhea
95979|NCT02467543|Viburnum opulus 3X
95980|NCT02467543|Homoeopathic
95981|NCT02467530|end stage renal disease
95982|NCT02467530|peritoneal dialysis (PD)
95983|NCT02467530|advanced glycation end products
95984|NCT02467530|Gut Microbiota Inflammation
95985|NCT02467517|Neuropathic pain
95986|NCT02467517|Ketamine
95987|NCT02467517|Magnesium sulfate
95988|NCT02467517|Quality of life
95989|NCT02467517|Anxiety and depression
95990|NCT02467517|Mood and sleep
95991|NCT02467491|Exercise
95992|NCT02467491|Technology
95993|NCT02467491|Aging
95994|NCT02467478|Diabetes Mellitus, Type 2
95995|NCT02467478|Endothelial cells
95996|NCT02467478|Cellular biomarker
95997|NCT02467478|endothelial dysfunction
95998|NCT02467478|CD34+
95999|NCT02467478|Impaired renal function
96000|NCT02467465|Fasciosis plantar
96001|NCT02467465|physiotherapy
96002|NCT02467465|fascitis plantar
96003|NCT02467465|dry needling
96004|NCT02467439|unaware intervention;
96005|NCT02467439|contract sexual partner referral
96006|NCT02467439|peer referral
96007|NCT02467426|Mesothelioma, malignant
96008|NCT02467426|Chemotherapy
96009|NCT02467413|Alzheimer's Disease
96010|NCT02467413|Vascular Dementia
96011|NCT02467400|bone formation
96012|NCT02467387|Non-ischemic Heart Failure
96013|NCT02467387|Stem Cells
96014|NCT02467374|OCD
96015|NCT02467374|Neuroimaging
96016|NCT02467374|Fear Extinction
96017|NCT02467374|Behavior Therapy
96018|NCT02467361|Neoplasms
96019|NCT02467296|Sodium
96020|NCT02467296|outcomes
96021|NCT02467283|chronic periodontitis
96022|NCT02467283|genetics
96023|NCT02467283|microarray analysis
96024|NCT02467283|gingiva
96025|NCT02467283|genes
96026|NCT02467283|inflammation
96027|NCT02467270|Chronic Phase Chronic Myeloid Leukemia
96028|NCT02467270|CML
96029|NCT02467270|Leukemia
96030|NCT02467270|Leukemia, Myeloid
96031|NCT02467270|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
96032|NCT02467270|Neoplasms by Histologic Type
96033|NCT02467270|Neoplasms
96034|NCT02467270|Myeloproliferative Disorders
96035|NCT02467270|Bone Marrow Diseases
96036|NCT02467270|Hematologic Diseases
96037|NCT02467270|CP-CML
96038|NCT02467244|Hypothyroidism
96039|NCT02467244|Serum adiponectin
96040|NCT02467244|hsCRP
96041|NCT02467244|Homeostatic Model Assessment (HOMA-IR)
96042|NCT02467244|Quantitative Insulin Sensitivity Check Index (QUICKI)
96043|NCT02467244|Cardiovascular risk assessment scoring (Framingham scoring)
96044|NCT02467244|Levothyroxin
96045|NCT02467231|new diagnosis of cancer
96046|NCT02467231|chemotherapy
96047|NCT02467231|oncofertility
96048|NCT02467231|alkylating agent
96049|NCT02467231|fertility preservation
96050|NCT02467231|fertility after cancer
96051|NCT02467231|late effects
96052|NCT02467218|Hyperbaric Oxygen Treatment
96053|NCT02467218|Fibromyalgia
96054|NCT02467218|Global Function
96055|NCT02467218|Sleep
96056|NCT02467218|Chronic Pain
96057|NCT02467218|Depression
96058|NCT02467218|Anxiety
96059|NCT02467205|Physical Activity
96060|NCT02467179|Arrhythmia
96061|NCT02467179|cavo-tricuspid isthmus
96062|NCT02467179|atrial fibrillation
96063|NCT02467179|atrial fibrillation ablation
96064|NCT02467166|esophagoscopy
96065|NCT02467166|atrial fibrillation ablation
96066|NCT02467166|radio frequency catheter ablation
96067|NCT02467166|esophageal lesion
96068|NCT02467166|arrhythmia
96069|NCT02467166|atrial fibrillation
96070|NCT02467166|AF
96071|NCT02467166|esophageal damage
96072|NCT02467153|Sarcopenia
96073|NCT02467153|Older adult
96074|NCT02467153|Vitamin D
96075|NCT02467153|Physical activity
96076|NCT02467153|Muscle atrophy
96077|NCT02467153|Muscle strength
96078|NCT02467153|Physical function
96079|NCT02467153|Frailty
96080|NCT02467153|Osteoporosis
96081|NCT02467140|Inguinal hernia repair
96082|NCT02467140|Hernia
96083|NCT02467140|ProGrib self-fixating mesh
96084|NCT02467140|Biological mesh
96085|NCT02467140|Tack fixation
96086|NCT02467101|cicatricial alopecia
96087|NCT02467101|treatment
96088|NCT02467101|placebo
96089|NCT02467101|double-blind
96090|NCT02467088|PMS
96091|NCT02467088|Individualised homoeopathic treatment
96092|NCT02467088|Indian females
96093|NCT02467075|CT, iodinated contrast, contrast-induced AKI, kidney injury
96094|NCT02467062|4D flow
96095|NCT02467049|ECG
96096|NCT02467049|Ultrasound
96097|NCT02467049|Peripherally Inserted Central Catheters
96098|NCT02467049|PICC
96099|NCT02467036|overweight children
96100|NCT02467036|overweight parents
96101|NCT02467036|eating in the absence of hunger
96102|NCT02467036|families with overweight child
96103|NCT02467036|bmi
96104|NCT02467036|body mass index
96105|NCT02467036|treatment
96106|NCT02467036|behavioral treatment
96107|NCT02467036|family based treatment
96108|NCT02467036|experiments
96109|NCT02467036|intervention
96110|NCT02467036|psychophysiological response to food cues
96111|NCT02467023|chronic critical illness
96112|NCT02467023|strength training
96113|NCT02467023|exercise
96114|NCT02467023|sepsis
96115|NCT02467023|mechanical ventilation
96116|NCT02467010|Bortezomib
96117|NCT02467010|cyclophosphamide
96118|NCT02467010|dexamethason
96119|NCT02467010|multiple myeloma
96120|NCT02466997|Vitiligo
96121|NCT02466997|Tacrolimus
96122|NCT02466997|Face
96123|NCT02466984|metoclopramide
96124|NCT02466984|subcutaneous route
96125|NCT02466984|palliative care
96126|NCT02466984|pharmacology
96127|NCT02466984|bioavailability
96128|NCT02466984|nausea
96129|NCT02466984|vomiting
96130|NCT02466958|depressed
96131|NCT02466958|older adults
96132|NCT02466958|antidepressants
96133|NCT02466958|depression
96134|NCT02466958|MDD
96135|NCT02466919|Helicobacter pylori
96136|NCT02466906|Stage III colon cancer
96137|NCT02466906|rhGM-CSF
96138|NCT02466906|Immunotherapy
96139|NCT02466906|Surgery
96140|NCT02466906|Adjuvant chemotherapy
96141|NCT02466880|Type 2
96142|NCT02466880|NIDDM
96143|NCT02466867|Ringworm
96144|NCT02466854|Bleeding
96145|NCT02466854|Acute Coronary Syndrome
96146|NCT02466854|percutaneous coronary intervention
96147|NCT02466854|1 year follow up
96148|NCT02466815|Healthy
96149|NCT02466815|JNJ-42756493
96150|NCT02466802|Advanced
96151|NCT02466789|Bleeding Disorder, inherited
96152|NCT02466789|Von Willebrands Disease
96153|NCT02466789|Hematologic Test
96154|NCT02466789|VWF
96155|NCT02466789|VWD
96156|NCT02466763|round window
96157|NCT02466763|cochlear implants
96158|NCT02466763|cochleostomy
96159|NCT02466737|axillary surgery
96160|NCT02466737|sentinel lymph node biopsy
96161|NCT02466711|gastric motility
96162|NCT02466698|Colectomy
96163|NCT02466698|Surgical Procedures, Operative
96164|NCT02466685|Bipolar
96165|NCT02466685|Depression
96166|NCT02466685|Cognition
96167|NCT02466685|Cognitive
96168|NCT02466659|IXT
96169|NCT02466646|Periodontal Debridement
96170|NCT02466646|Gingival Crevicular Fluid
96171|NCT02466646|Aggressive Periodontitis
96172|NCT02466646|Interleukin-1beta
96173|NCT02466646|Interleukin-17
96174|NCT02466620|Body Weight
96175|NCT02466620|Resuscitation
96176|NCT02466620|Pediatric weight estimation
96177|NCT02466607|Retinal function
96178|NCT02466568|advanced
96179|NCT02466568|metastatic
96180|NCT02466568|lung disease
96181|NCT02466568|adenocarcinoma
96182|NCT02466568|non-small cell lung cancer (NSCLC)
96183|NCT02466542|Esmolol
96184|NCT02466542|Pain
96185|NCT02466542|Anesthesia
96186|NCT02466542|Analgesia
96187|NCT02466516|GS-4997
96188|NCT02466516|Non-alcoholic fatty liver disease (NAFLD)
96189|NCT02466516|Fibrosis
96190|NCT02466516|Simtuzumab
96191|NCT02466477|Pharmacogenomic
96192|NCT02466477|Pharmacogenomic Testing
96193|NCT02466477|Pharmacogenomics
96194|NCT02466477|Genetic Testing
96195|NCT02466477|Genetics
96196|NCT02466477|Major Depressive Disorder
96197|NCT02466477|GeneSight
96198|NCT02466477|Enhanced GeneSight
96199|NCT02466477|Psychotropic
96200|NCT02466438|Antibiotics
96201|NCT02466438|Piperacillin-tazobactam
96202|NCT02466438|Resistant bacteria
96203|NCT02466412|smoking
96204|NCT02466412|nicotine absorption
96205|NCT02466412|modified risk tobacco product
96206|NCT02466412|conventional cigarette
96207|NCT02466412|Carbon Heated Tobacco Product
96208|NCT02466373|clonidine
96209|NCT02466373|pharmacodynamics
96210|NCT02466373|pharmacokinetics
96211|NCT02466373|intensive care
96212|NCT02466373|delirium
96213|NCT02466360|Non-specific chronic lower back pain
96214|NCT02466360|Physical activity
96215|NCT02466360|Self-exercises
96216|NCT02466360|Brakes
96217|NCT02466360|Levers
96218|NCT02466360|Adhesion
96219|NCT02466360|Self-care
96220|NCT02466321|Inverse Reverse Shoulder
96221|NCT02466308|sustained acoustic medicine
96222|NCT02466308|therapeutic ultrasound
96223|NCT02466308|SAM
96224|NCT02466308|LITUS
96225|NCT02466269|Facial Nerve Injuries
96226|NCT02466256|Intraocular lens implantation
96227|NCT02466230|Magnetic stimulation of the brain
96228|NCT02466230|Antidepressant mechanisms
96229|NCT02466217|Auto-immune disease
96230|NCT02466217|Auto-inflammatory disease
96231|NCT02466217|Omics
96232|NCT02466217|System biology
96233|NCT02466191|nystagmus
96234|NCT02466191|pharmacological trial
96235|NCT02466191|multiple sclerosis
96236|NCT02466191|oscillopsia
96237|NCT02466165|cardiometabolic risk
96238|NCT02466165|physical exercise
96239|NCT02466152|PK
96240|NCT02466152|GSK2894512
96241|NCT02466152|Atopic Dermatitis
96242|NCT02466139|microbiology
96243|NCT02466139|c reactive protein
96244|NCT02466139|urgent cardiac surgery
96245|NCT02466126|Depression
96246|NCT02466126|brief Cognitive Behavioral Therapy (bCBT)
96247|NCT02466126|Randomized Controlled Trial
96248|NCT02466074|Acetazolamide
96249|NCT02466074|Lesions
96250|NCT02466074|T1 black hole
96251|NCT02466061|BMI >= 30 kg/m2
96252|NCT02466048|spinal fusion
96253|NCT02466048|bone graft
96254|NCT02466048|collagen
96255|NCT02466009|Colorectal cancer
96256|NCT02466009|metastatic colorectal cancer
96257|NCT02466009|colorectal adenocarcinoma
96258|NCT02465996|barrier dysfunction
96259|NCT02465996|functional dyspepsia
96260|NCT02465996|Confocal Laser Endomicroscopic
96261|NCT02465996|therapeutic response
96262|NCT02465983|Pancreatic Cancer
96263|NCT02465983|CAR / CART
96264|NCT02465983|T cells
96265|NCT02465983|Immunotherapy
96266|NCT02465983|Gene therapy
96267|NCT02465983|Redirected T cells
96268|NCT02465983|Autologous T cells
96269|NCT02465970|Transcranial Direct Current Stimulation
96270|NCT02465957|Merkel Cell Carcinoma
96271|NCT02465957|Neukoplast
96272|NCT02465957|NK-92
96273|NCT02465957|Natural Killer Cell
96274|NCT02465957|MCC
96275|NCT02465957|aNK
96276|NCT02465944|inflammation
96277|NCT02465931|Informed Consent
96278|NCT02465931|Fragile X Syndrome
96279|NCT02465931|Tablets
96280|NCT02465931|Decisional Capacity
96281|NCT02465892|cancer
96282|NCT02465892|stress
96283|NCT02465892|chronic pain
96284|NCT02465892|anxiety
96285|NCT02465892|coping
96286|NCT02465892|balance
96287|NCT02465892|online course
96288|NCT02465892|psychosocial
96289|NCT02465892|support
96290|NCT02465892|tools
96291|NCT02465879|Psoriatic arthritis
96292|NCT02465879|Ankylosing spondylitis
96293|NCT02465879|Rheumatoid arthritis
96294|NCT02465879|Seronegative
96295|NCT02465866|Plasma concentration
96296|NCT02465866|Time to plasma concentration
96297|NCT02465866|Elimination rate constant
96298|NCT02465866|Elimination half life
96299|NCT02465866|Area under the curve
96300|NCT02465853|hemiplegic shoulder pain
96301|NCT02465853|quality of Life
96302|NCT02465853|stroke
96303|NCT02465840|rehabilitation
96304|NCT02465840|functional MRI
96305|NCT02465814|Uterine fibroids
96306|NCT02465814|Heavy Menstrual Bleeding
96307|NCT02465788|Helos
96308|NCT02465788|Hair Removal
96309|NCT02465788|Hair Reduction
96310|NCT02465775|non-invasive
96311|NCT02465762|non-invasive
96312|NCT02465749|Retinitis Pigmentosa
96313|NCT02465749|oxygen
96314|NCT02465749|blue light
96315|NCT02465723|Intravoxel Incoherent Motion (IVIM)
96316|NCT02465723|Diffusion-weighted Magnetic Resonance
96317|NCT02465723|Acid Sphingomyelinase/Ceramide Pathway Activation
96318|NCT02465723|15-104
96319|NCT02465710|pelvic organ prolapse
96320|NCT02465710|pelvic floor reconstruction surgery
96321|NCT02465710|transvaginal mesh surgery
96322|NCT02465710|Women
96323|NCT02465710|Surgical treatment
96324|NCT02465697|Borderline Personality Disorder
96325|NCT02465697|Avoidant Personality Disorder
96326|NCT02465697|Brain Imaging
96327|NCT02465658|uterine prolapse
96328|NCT02465658|cervical elongation
96329|NCT02465658|pelvic floor reconstruction surgery
96330|NCT02465541|Cancer Survivors
96331|NCT02465541|Yoga
96332|NCT02465541|Endometrial Cancer
96333|NCT02465528|ALK
96334|NCT02465528|NSCLC
96335|NCT02465528|hematological malignancy
96336|NCT02465515|cardiovascular events /outcomes
96337|NCT02465515|Type 2 diabetes mellitus
96338|NCT02465515|albiglutide
96339|NCT02465515|glucagon-like peptide-1 receptor agonist
96340|NCT02465502|Colorectal cancer
96341|NCT02465502|Regorafenib
96342|NCT02465489|deferiprone
96343|NCT02465489|deferiprone extended release formulation
96344|NCT02465489|pharmacokinetics
96345|NCT02465476|skin disease
96346|NCT02465476|telemedicine
96347|NCT02465463|fecal microbiota transplant
96348|NCT02465463|probiotic
96349|NCT02465424|quality of life questionnaires
96350|NCT02465398|Fracture shoulder arthroplasty
96351|NCT02465398|Three or four part fracture
96352|NCT02465398|Hemiarthroplasty
96353|NCT02465398|Multi-center
96354|NCT02465398|Europe
96355|NCT02465398|Non-controlled
96356|NCT02465398|Anatomical reconstruction
96357|NCT02465398|Proximal
96358|NCT02465372|Physical Activity
96359|NCT02465372|Youth
96360|NCT02465372|School Health
96361|NCT02465346|acute stroke
96362|NCT02465346|prehospital
96363|NCT02465346|treatment
96364|NCT02465333|heel
96365|NCT02465333|atrophy
96366|NCT02465333|fat
96367|NCT02465333|adipose tissue
96368|NCT02465333|fat pad
96369|NCT02465307|Consciousness
96370|NCT02465307|Alertness
96371|NCT02465307|Cognition
96372|NCT02465307|Activity level
96373|NCT02465307|Delirium
96374|NCT02465307|Hyperactive delirium
96375|NCT02465307|Hypoactive delirium
96376|NCT02465307|Facial expression
96377|NCT02465307|Posture
96378|NCT02465307|Intensive care unit
96379|NCT02465294|Probiotics
96380|NCT02465294|Weight loss
96381|NCT02465294|Body composition
96382|NCT02465255|Acute Abdominal Pain
96383|NCT02465255|Sublingual Analgesia
96384|NCT02465255|Children
96385|NCT02465255|Ketorolac
96386|NCT02465255|Tramadol
96387|NCT02465255|Paracetamol
96388|NCT02465255|Analgesia
96389|NCT02465216|Tuberculosis
96390|NCT02465216|TB
96391|NCT02465216|Pulmonary
96392|NCT02465216|Vaccine
96393|NCT02465216|Adjuvant
96394|NCT02465203|Hepatitis C, chronic
96395|NCT02465190|Vaccine
96396|NCT02465190|Effectiveness
96397|NCT02465190|Influenza
96398|NCT02465177|Unhealthy alcohol use
96399|NCT02465177|ICU survivors
96400|NCT02465177|Alcohol use disorder
96401|NCT02465177|SBIRT
96402|NCT02465177|Screening, brief intervention, and referral to treatment
96403|NCT02465034|Neural plasticity
96404|NCT02465034|Noninvasive brain stimulation
96405|NCT02465034|Motor cortex
96406|NCT02465021|Satiety
96407|NCT02465021|Food intake
96408|NCT02465021|Breakfast cereals/snacks
96409|NCT02465021|Postprandial glycemia
96410|NCT02465008|postoperative
96411|NCT02465008|Patient-reported
96412|NCT02464995|Asthma,
96413|NCT02464995|Asthma exacerbation
96414|NCT02464995|Bronchial thermoplasty
96415|NCT02464969|VTE, thromboembolism, thrombosis, embolism, apixaban, Eliquis
96416|NCT02464943|Aorta
96417|NCT02464943|Thoracic
96418|NCT02464943|Aortic dissection
96419|NCT02464943|Type B
96420|NCT02464943|DeBakey type III
96421|NCT02464943|Endovascular
96422|NCT02464930|Blood
96423|NCT02464930|Cytology
96424|NCT02464930|Esophagus
96425|NCT02464930|microRNA
96426|NCT02464891|Atypical Hemolytic Uremic Syndrome
96427|NCT02464891|CCX168
96428|NCT02464891|dialysis
96429|NCT02464891|C5aR antagonist
96430|NCT02464865|thiamine deficiency
96431|NCT02464865|obese children
96432|NCT02464865|Thai
96433|NCT02464839|Fungal nails and feet infection
96434|NCT02464839|Onychomycosis
96435|NCT02464839|Hallux valgus
96436|NCT02464826|Onychomycosis
96437|NCT02464826|Chronic paronychia
96438|NCT02464826|Treatment
96439|NCT02464813|pregabalin
96440|NCT02464813|idiopathic scoliosis
96441|NCT02464800|diabetic retinopathy
96442|NCT02464787|antioxidants
96443|NCT02464787|carotenoids
96444|NCT02464787|diet
96445|NCT02464774|Breast Cancer
96446|NCT02464774|Triple-Negative Breast Cancer
96447|NCT02464774|Breast-Conserving Therapy
96448|NCT02464774|Mastectomy
96449|NCT02464774|Recurrence
96450|NCT02464735|Sleep disruption
96451|NCT02464735|Spontaneous breathing trial
96452|NCT02464735|Weaning
96453|NCT02464722|Remifentanil
96454|NCT02464722|Dexmedetomidine
96455|NCT02464722|Endoscopic sinus surgery
96456|NCT02464709|Actinic Keratosis
96457|NCT02464709|Photodynamic Therapy
96458|NCT02464709|Natural Daylight
96459|NCT02464696|Hematological Malignancies
96460|NCT02464696|Hypoxemic Respiratory Failure
96461|NCT02464696|Blood cancer
96462|NCT02464696|Non-invasive positive pressure ventilation
96463|NCT02464696|NIPPV
96464|NCT02464696|High flow nasal cannula oxygen therapy
96465|NCT02464670|Ebola
96466|NCT02464670|Vaccine
96467|NCT02464657|Leukemia
96468|NCT02464657|Acute myeloid leukemia
96469|NCT02464657|AML
96470|NCT02464657|Myelodysplastic Syndrome
96471|NCT02464657|MDS
96472|NCT02464657|High-risk
96473|NCT02464657|Nivolumab
96474|NCT02464657|BMS-936558
96475|NCT02464657|Opdivo
96476|NCT02464657|Idarubicin
96477|NCT02464657|Idamycin
96478|NCT02464657|Cytarabine
96479|NCT02464657|Ara-C
96480|NCT02464657|Cytosar
96481|NCT02464657|DepoCyt
96482|NCT02464657|Cytosine Arabinosine Hydrochloride
96483|NCT02464657|Solu-Medrol
96484|NCT02464657|Methylprednisolone
96485|NCT02464657|Depo-Medrol
96486|NCT02464657|Medrol
96487|NCT02464657|Dexamethasone
96488|NCT02464657|Decadron
96489|NCT02464644|On-line Questionnaire
96490|NCT02464644|No travel
96491|NCT02464644|Health
96492|NCT02464644|Medicines
96493|NCT02464644|Drugs
96494|NCT02464644|Lifestyle
96495|NCT02464644|Family
96496|NCT02464644|Help for others
96497|NCT02464644|Rare condition
96498|NCT02464644|General population
96499|NCT02464618|Colonoscopy
96500|NCT02464618|Upper endoscopy
96501|NCT02464618|Adherence
96502|NCT02464618|Disparities
96503|NCT02464592|Cryoprobes
96504|NCT02464592|Transbronchial lung biopsy
96505|NCT02464592|Cryobiopsy
96506|NCT02464579|breastfeeding rate
96507|NCT02464579|preterm infant
96508|NCT02464579|neonatal intensive care unit
96509|NCT02464553|Low Back Pain Pain
96510|NCT02464553|Periradicular therapy
96511|NCT02464553|Spinal Stenosis with neurologic changes
96512|NCT02464540|laminate veneers
96513|NCT02464540|luting agent
96514|NCT02464527|Stimulus-stimulus pairing
96515|NCT02464514|Obesity
96516|NCT02464514|Orexigen
96517|NCT02464514|Insulin
96518|NCT02464514|Leptin
96519|NCT02464514|Adiponectin
96520|NCT02464514|Growth hormone replacement
96521|NCT02464501|PAD
96522|NCT02464501|COPPER-A
96523|NCT02464501|Peripheral Arterial Disease
96524|NCT02464501|OPC
96525|NCT02464501|Occlusion Perfusion Catheter
96526|NCT02464501|Paclitaxel
96527|NCT02464488|Anticoagulants
96528|NCT02464488|Factor Xa Inhibitors
96529|NCT02464488|Antithrombins
96530|NCT02464488|Pharmacokinetics
96531|NCT02464488|Aged, 80 years and older
96532|NCT02464475|osteopathic manipulative treatment
96533|NCT02464475|interoception
96534|NCT02464462|serum calcidiol
96535|NCT02464462|T2DM
96536|NCT02464462|vitamin D3 supplementation
96537|NCT02464462|post-menopausal women
96538|NCT02464462|ethnic diverse
96539|NCT02464462|calcium supplementation
96540|NCT02464449|Cognitive Behavioral Therapy
96541|NCT02464449|Mobile Health Technology
96542|NCT02464449|Patient Care Management
96543|NCT02464436|RP
96544|NCT02464410|Opioid analgesics
96545|NCT02464410|Primary care
96546|NCT02464410|Veterans
96547|NCT02464410|Motivational interviewing
96548|NCT02464410|Cognitive behavioral therapy
96549|NCT02464410|Self-efficacy
96550|NCT02464410|Behavioral symptoms
96551|NCT02464410|Injuries
96552|NCT02464410|Opioid Safety
96553|NCT02464397|Vascular healing of coronary stents in patients with acute coronary syndrome
96554|NCT02464384|ultrasound and cartilage biodegradation markers
96555|NCT02464371|muscle weakness
96556|NCT02464371|microRNAs
96557|NCT02464371|septic shock
96558|NCT02464358|HPV
96559|NCT02464345|BED
96560|NCT02464345|Binge Eating Disorer
96561|NCT02464345|BN
96562|NCT02464345|Bulimia Nervosa
96563|NCT02464345|Obesity
96564|NCT02464332|soft tissue sarcoma
96565|NCT02464332|BLZ-100
96566|NCT02464332|Tumor Paint
96567|NCT02464306|recipients
96568|NCT02464293|depression
96569|NCT02464293|anxiety
96570|NCT02464293|stress
96571|NCT02464280|Tomosynthesis
96572|NCT02464280|osteosynthetic implant
96573|NCT02464280|CT
96574|NCT02464280|monitoring
96575|NCT02464267|patient reported outcome instrument
96576|NCT02464254|Physical activity, positive affect, older adults, aging
96577|NCT02464228|PTCL
96578|NCT02464228|Lymphoma
96579|NCT02464215|gastric cancer
96580|NCT02464215|D2
96581|NCT02464215|laparoscopic
96582|NCT02464215|open
96583|NCT02464215|surgery
96584|NCT02464202|Tooth autotransplantation
96585|NCT02464202|stereolithography tooth replica
96586|NCT02464202|CBCT
96587|NCT02464202|Outcome
96588|NCT02464176|Arthroplasty, Hip, Replacement
96589|NCT02464176|Anesthesia, Local
96590|NCT02464176|Anesthesia Conduction
96591|NCT02464176|Bupivacaine
96592|NCT02464176|Dexamethasone
96593|NCT02464176|Preanesthetic Medications
96594|NCT02464176|Nerve Block
96595|NCT02464176|Lumbar Plexus Block
96596|NCT02464176|Analgesia
96597|NCT02464176|Glucocorticoids
96598|NCT02464176|Local Anesthetics
96599|NCT02464163|Influenza
96600|NCT02464098|Hematological Malignancies
96601|NCT02464098|Solid Tumors
96602|NCT02464098|Hematopoietic Stem Cell Transplantation (HSCT)
96603|NCT02464098|Childhood Cancer
96604|NCT02464098|Polymerase Chain Reaction (PCR)
96605|NCT02464085|Stroke
96606|NCT02464085|Upper limb
96607|NCT02464085|Neuroplastic change
96608|NCT02464085|Longitudinal
96609|NCT02464085|Function
96610|NCT02464072|Parathyroidectomy
96611|NCT02464072|Renal Insufficiency, Chronic
96612|NCT02464059|cathelicidin
96613|NCT02464059|vitamin D
96614|NCT02464046|Insomnia
96615|NCT02464046|JNJ-42847922
96616|NCT02464046|Placebo
96617|NCT02464033|Diamyd
96618|NCT02464033|Diabetes
96619|NCT02464033|Juvenile Diabetes
96620|NCT02464033|Diabetes Type 1
96621|NCT02464033|Type 1 Diabetes
96622|NCT02464033|Autoimmune Diabetes
96623|NCT02464033|Insulin Dependent Diabetes
96624|NCT02464033|Type 1 Diabetes MellitusType 1 Diabetes Mellitus
96625|NCT02464033|rhGAD65
96626|NCT02464033|GAD65
96627|NCT02464033|GAD-Alum
96628|NCT02464033|Diabetes Mellitus
96629|NCT02464033|Diabetes mellitus Type 1
96630|NCT02464033|Glucose Metabolism Disorders
96631|NCT02464033|Metabolic Diseases
96632|NCT02464033|Vitamin D
96633|NCT02464033|Etanercept
96634|NCT02463955|flexible endoscopy
96635|NCT02463929|Diphenhydramine
96636|NCT02463929|emergence agitation
96637|NCT02463929|pediatric anesthesia
96638|NCT02463929|PAEDS
96639|NCT02463929|Withdrawal
96640|NCT02463903|Adaptation, Psychological
96641|NCT02463903|Heart Failure
96642|NCT02463903|Intervention Studies
96643|NCT02463903|Quality of Life
96644|NCT02463903|Hospital Readmission
96645|NCT02463903|Depression
96646|NCT02463903|Anxiety
96647|NCT02463890|Sleep Apnea Syndromes
96648|NCT02463890|Sleep Apnea, Obstructives
96649|NCT02463890|Training
96650|NCT02463864|frailty
96651|NCT02463864|older adult
96652|NCT02463864|hospital
96653|NCT02463864|exercise
96654|NCT02463864|randomised control trial
96655|NCT02463864|functional decline
96656|NCT02463851|Ablation
96657|NCT02463851|Multi-electrode catheter PVAC
96658|NCT02463851|Single-tip catheter Contact Force
96659|NCT02463851|Holter
96660|NCT02463838|Medi-Cal
96661|NCT02463838|Health Plan
96662|NCT02463838|Frequent Users
96663|NCT02463838|Heavy users
96664|NCT02463838|Care Coordination
96665|NCT02463838|Managed Care
96666|NCT02463838|Case Management
96667|NCT02463838|Mental Health
96668|NCT02463838|Substance Use
96669|NCT02463838|Emergency Department
96670|NCT02463799|prostatic neoplasms
96671|NCT02463799|castration-resistant
96672|NCT02463799|bone metastasis
96673|NCT02463799|radium-223
96674|NCT02463799|sipuleucel-T
96675|NCT02463773|ARDS, PEEP, Critical Care Ultrasound
96676|NCT02463747|Neutropenic fever
96677|NCT02463747|extended infusion
96678|NCT02463747|beta-lactam
96679|NCT02463747|empiric antibiotic treatment
96680|NCT02463721|sbp
96681|NCT02463721|culture
96682|NCT02463708|Care Giver
96683|NCT02463708|Dementia
96684|NCT02463695|partial vestibular deficit
96685|NCT02463695|cortical vestibular evoked potential
96686|NCT02463682|Artificial Pancreas
96687|NCT02463682|Diabetes Mellitus, Type 1
96688|NCT02463682|Autoimmune Diseases
96689|NCT02463682|Diabetes Mellitus
96690|NCT02463682|Endocrine System Diseases
96691|NCT02463682|Glucose Metabolism Disorders
96692|NCT02463682|Immune System Diseases
96693|NCT02463682|Metabolic Diseases
96694|NCT02463669|Point-of-care ultrasound
96695|NCT02463630|basilar invagination
96696|NCT02463630|atlantoaxial dislocation
96697|NCT02463630|surgery
96698|NCT02463630|restoration technique
96699|NCT02463591|Direct Thrombin Inhibitor
96700|NCT02463591|Prothrombin Complex Concentrate
96701|NCT02463591|Dabigatran Etexilate
96702|NCT02463591|Beriplex
96703|NCT02463591|Shed Blood
96704|NCT02463591|Washed Blood
96705|NCT02463591|Fibrinopeptide A
96706|NCT02463578|Pneumococcal infection
96707|NCT02463578|Invasive pneumococcal disease (IPD)
96708|NCT02463578|Pneumococcal vaccine
96709|NCT02463578|Vaccinology
96710|NCT02463578|Immunocompromised
96711|NCT02463578|Auto-immune diseases
96712|NCT02463578|Systemic vasculitis
96713|NCT02463578|ANCA-associated vasculitis
96714|NCT02463565|nutritional assessment
96715|NCT02463565|food survey
96716|NCT02463565|hospitalized patients
96717|NCT02463565|hospital food
96718|NCT02463539|Pneumococcal infection
96719|NCT02463539|Invasive pneumococcal disease (IPD)
96720|NCT02463539|Pneumococcal vaccine
96721|NCT02463539|Systemic vasculitis
96722|NCT02463539|ANCA-associated vasculitis
96723|NCT02463539|Vaccinology
96724|NCT02463539|Immunocompromised
96725|NCT02463539|Auto-immune disease
96726|NCT02463526|Shoulder Impingement Syndrome
96727|NCT02463526|Mulligan's Mobilization with Movement
96728|NCT02463526|Physical Therapy
96729|NCT02463513|Riboflavin
96730|NCT02463513|Blood pressure
96731|NCT02463513|MTHFR
96732|NCT02463513|Methylenetetrahydrofolate reductase
96733|NCT02463448|Underactive Bladder
96734|NCT02463435|nutritional management
96735|NCT02463435|olive oil
96736|NCT02463435|weight loss
96737|NCT02463435|body composition
96738|NCT02463435|nutrigenomics
96739|NCT02463435|polymorphisms
96740|NCT02463435|cardiovascular risk
96741|NCT02463435|sarcopenia
96742|NCT02463435|inflammation
96743|NCT02463435|food intake
96744|NCT02463435|sedentary lifestyle
96745|NCT02463435|patient adherence
96746|NCT02463435|bone density
96747|NCT02463396|MBCT
96748|NCT02463396|Mindfulness
96749|NCT02463396|ADHD
96750|NCT02463383|PPAR-gamma
96751|NCT02463383|estrogens
96752|NCT02463383|NSAIDS
96753|NCT02463383|polymorphism
96754|NCT02463383|metabolomics
96755|NCT02463357|Exercise, Aerobic
96756|NCT02463357|Cognitive Function
96757|NCT02463344|Dry AMD
96758|NCT02463344|Geographic atrophy
96759|NCT02463331|autoimmune hepatitis
96760|NCT02463331|chloroquine
96761|NCT02463331|treatment
96762|NCT02463318|Multiple sclerosis
96763|NCT02463318|SIRT1
96764|NCT02463318|MnSOD
96765|NCT02463318|Catalase
96766|NCT02463318|Oxidative stress
96767|NCT02463318|Antioxidant enzyme
96768|NCT02463305|Colitis, ulcerative
96769|NCT02463305|Inflammatory bowel diseases
96770|NCT02463292|quality of life
96771|NCT02463292|young adults
96772|NCT02463292|congenital heart disease
96773|NCT02463266|Primary Care
96774|NCT02463266|Elderly
96775|NCT02463266|Depression
96776|NCT02463253|Renal Biopsy
96777|NCT02463253|elevated serum creatinine
96778|NCT02463253|proteinuria
96779|NCT02463201|Sleep Apnea, Obstructive
96780|NCT02463201|Pediatric Obesity
96781|NCT02463188|Sleep
96782|NCT02463188|Substance Use
96783|NCT02463188|Adolescents
96784|NCT02463175|Fluid Therapy;
96785|NCT02463175|Transesophageal Doppler
96786|NCT02463149|School health
96787|NCT02463136|Adolescence
96788|NCT02463136|Brain Development
96789|NCT02463136|Neuroimaging
96790|NCT02463136|Neurofeedback
96791|NCT02463136|Anxiety
96792|NCT02463110|Acute Coronary Syndrome
96793|NCT02463110|Depression
96794|NCT02463110|Coronary Artery Disease
96795|NCT02463110|Myocardial Infarction
96796|NCT02463110|Percutaneous Coronary Intervention
96797|NCT02463019|hepatitis B virus
96798|NCT02463019|tenofovir
96799|NCT02462967|Liver Cirrhosis
96800|NCT02462954|Contraception
96801|NCT02462954|Vaginal Gel
96802|NCT02462954|Diaphragm
96803|NCT02462941|Heart transplant
96804|NCT02462941|Adenosine
96805|NCT02462941|Pediatrics
96806|NCT02462863|Diabetes
96807|NCT02462863|fish oil
96808|NCT02462863|arginine
96809|NCT02462863|hyperglycemia
96810|NCT02462850|Pain
96811|NCT02462850|Nausea
96812|NCT02462850|Vomiting
96813|NCT02462837|Ureteral Stents
96814|NCT02462837|Pain and Discomfort
96815|NCT02462837|Bladder Storage Symptoms
96816|NCT02462824|Peripheral Artery Disease
96817|NCT02462824|Peripheral Arterial Disease
96818|NCT02462824|PAD
96819|NCT02462811|Pain
96820|NCT02462811|Nausea
96821|NCT02462811|Vomiting
96822|NCT02462785|Type 1 Diabetes Mellitus
96823|NCT02462785|Adolescents
96824|NCT02462785|Carbohydrate Counting
96825|NCT02462785|Glycemic Control
96826|NCT02462785|Self-Management
96827|NCT02462785|T1DM
96828|NCT02462772|Cabotegravir
96829|NCT02462772|safety
96830|NCT02462772|long-acting injectable
96831|NCT02462772|HIV prevention
96832|NCT02462772|acceptability
96833|NCT02462759|EMBRACE
96834|NCT02462759|Spinal Muscular Atrophy
96835|NCT02462759|SMA
96836|NCT02462746|Postpartum
96837|NCT02462746|Dietary Supplements
96838|NCT02462746|Breastfeeding Women
96839|NCT02462733|Self-control
96840|NCT02462733|Preschoolers
96841|NCT02462733|Tools of the Mind
96842|NCT02462733|Playing to Learn
96843|NCT02462681|ketamine
96844|NCT02462681|adjuvant
96845|NCT02462681|paravertebral block
96846|NCT02462668|Bronchoscopy
96847|NCT02462668|Intubation
96848|NCT02462668|Noninvasive positive pressure ventilation
96849|NCT02462642|Brahmi, Cognition, Anxiety, Pharmacokinetics
96850|NCT02462629|central nervous system tumor
96851|NCT02462629|BLZ-100
96852|NCT02462629|pediatrics
96853|NCT02462629|Tumor Paint
96854|NCT02462629|brain cancer
96855|NCT02462616|risk analysis
96856|NCT02462616|general Chinese population
96857|NCT02462616|cardiovascular autonomic neuropathy
96858|NCT02462603|Parkinson's Disease
96859|NCT02462603|PD
96860|NCT02462603|EPI-589
96861|NCT02462603|EPI589
96862|NCT02462590|Probiotics
96863|NCT02462590|Ventilator Associated Pneumonia
96864|NCT02462590|Infections
96865|NCT02462590|C-Difficile
96866|NCT02462590|Antibiotic-associated Diarrhea
96867|NCT02462590|Diarrhea
96868|NCT02462577|Local morphine
96869|NCT02462577|Postmastectomy pain
96870|NCT02462564|peritoneal surface malignancies
96871|NCT02462564|Post operative cognitive dysfunction
96872|NCT02462551|Depression
96873|NCT02462551|Treatment Resistant Depression
96874|NCT02462525|relapsed multiple myeloma
96875|NCT02462525|antibody drug conjugate
96876|NCT02462525|refractory multiple myeloma
96877|NCT02462512|Elastography
96878|NCT02462512|Thyroid nodule
96879|NCT02462473|Schizophrenia
96880|NCT02462473|Schizoaffective Disorder
96881|NCT02462473|Aripiprazole
96882|NCT02462473|Olanzapine
96883|NCT02462473|Paliperidone
96884|NCT02462473|Quetiapine
96885|NCT02462473|Risperidone
96886|NCT02462473|Liquid Chromatography-Tandem Mass Spectrometry
96887|NCT02462460|Breast MRI
96888|NCT02462460|T1 weighted and diffusion weighted MR
96889|NCT02462460|screening pancreatic
96890|NCT02462460|screening ovarian
96891|NCT02462460|15-120
96892|NCT02462447|prostate
96893|NCT02462447|cancer
96894|NCT02462447|biopsy
96895|NCT02462447|PET
96896|NCT02462434|Pediatric palliative care
96897|NCT02462421|SGLT2
96898|NCT02462421|SLC5A2
96899|NCT02462421|SLC5A4
96900|NCT02462421|SLC5A9
96901|NCT02462421|SLC2A9
96902|NCT02462421|GLUT9
96903|NCT02462421|SGLT3
96904|NCT02462421|SGLT4
96905|NCT02462421|pharmacogenomics
96906|NCT02462356|CVATS
96907|NCT02462356|UVATS
96908|NCT02462356|perioperative effect
96909|NCT02462356|ergonomic influence
96910|NCT02462330|Mesenchymal stem cells
96911|NCT02462330|ischemic cardiomyopathy
96912|NCT02462330|NogaStar XP system catheter
96913|NCT02462317|Spasticity
96914|NCT02462317|Post stroke motor recovery
96915|NCT02462317|Botulinum toxin
96916|NCT02462317|Baclofen
96917|NCT02462317|Pharmacological modulation
96918|NCT02462304|Diabetic Macula Edema
96919|NCT02462304|End-Point-Management
96920|NCT02462304|ranibizumab
96921|NCT02462304|bevacizumab
96922|NCT02462291|Neurological Disorders
96923|NCT02462291|Non Pharmacological Treatment
96924|NCT02462291|Ecological Therapy
96925|NCT02462278|Fertility
96926|NCT02462278|Continuous temperature monitor
96927|NCT02462278|Basal Body Temperature
96928|NCT02462278|Natural family planning
96929|NCT02462239|Muscle-invasive bladder cancer
96930|NCT02462239|Bladder cancer
96931|NCT02462239|PET imaging
96932|NCT02462239|FDG
96933|NCT02462213|Cardiac amyloidosis
96934|NCT02462213|Cardiac MRI
96935|NCT02462213|Infiltrative cardiomyopathies
96936|NCT02462187|genital warts
96937|NCT02462187|perianal warts
96938|NCT02462174|anesthesia
96939|NCT02462174|analgesia
96940|NCT02462174|caudal
96941|NCT02462174|ketamine
96942|NCT02462174|bupivacaine
96943|NCT02462148|Anesthesia
96944|NCT02462148|Anesthesia, Conduction
96945|NCT02462148|Anesthesia, Local
96946|NCT02462148|Bupivacaine
96947|NCT02462148|Dexamethasone
96948|NCT02462148|Saphenous
96949|NCT02462148|Adductor Canal
96950|NCT02462148|Nerve Block
96951|NCT02462148|Analgesia
96952|NCT02462148|Preanesthetic Medication
96953|NCT02462148|Perioperative Period
96954|NCT02462148|Peripheral Nerve Block
96955|NCT02462135|Mild cognitive impairment
96956|NCT02462135|Memory training
96957|NCT02462135|Randomized controlled study
96958|NCT02462044|Computed tomography
96959|NCT02462044|Coronary CTA
96960|NCT02462044|Contrast media
96961|NCT02462018|Cerebral Palsy
96962|NCT02462018|Muscle Spasticity
96963|NCT02462018|Orthoses
96964|NCT02462018|Functional Electrical Stimulation
96965|NCT02462018|Prospective
96966|NCT02461992|FVIII activity
96967|NCT02461953|hemodialysis
96968|NCT02461953|hemoperfusion
96969|NCT02461953|quality of life
96970|NCT02461940|Sexual behavior
96971|NCT02461940|condom use
96972|NCT02461940|secondary abstinence
96973|NCT02461914|Type 2 diabetes mellitus
96974|NCT02461901|clostridium difficile
96975|NCT02461901|environment
96976|NCT02461901|contamination
96977|NCT02461901|fidaxomicin
96978|NCT02461888|Relapsed
96979|NCT02461888|Refractory
96980|NCT02461888|Cyclophosphamide
96981|NCT02461888|Dexamethasone
96982|NCT02461875|OHSS
96983|NCT02461875|Infertility
96984|NCT02461875|Cabergoline
96985|NCT02461875|GnRH antagonist
96986|NCT02461875|IVF-ET
96987|NCT02461862|Contraception
96988|NCT02461862|Contraception Behavior
96989|NCT02461862|Intra uterine device
96990|NCT02461862|Intra uterine System
96991|NCT02461862|IUD
96992|NCT02461862|IUS
96993|NCT02461862|Acute Pain
96994|NCT02461771|AMD
96995|NCT02461771|Wet AMD
96996|NCT02461771|Neovascular AMD
96997|NCT02461745|VIEKIRA PAK
96998|NCT02461732|posttraumatic stress disorder
96999|NCT02461732|PTSD
97000|NCT02461732|substance dependence
97001|NCT02461732|substance use
97002|NCT02461706|Drug resistant epilepsy
97003|NCT02461693|Vigilance
97004|NCT02461693|Mood
97005|NCT02461693|Randomized Controlled Trial
97006|NCT02461693|Probability
97007|NCT02461680|partial section of the flexor tendons
97008|NCT02461667|alendronate, metformin
97009|NCT02461641|amniotic tissue
97010|NCT02461641|diabetic foot ulcer
97011|NCT02461641|Affinity
97012|NCT02461641|NuShield
97013|NCT02461628|Malaria
97014|NCT02461628|Antimalarial subsidy
97015|NCT02461628|Malaria rapid diagnostic test (RDT)
97016|NCT02461628|Public-private partnership
97017|NCT02461628|Community health workers
97018|NCT02461615|Pulmonary Surfactant
97019|NCT02461615|Rare Lung Disease
97020|NCT02461615|Registry
97021|NCT02461602|Warfarin
97022|NCT02461576|HIV-1
97023|NCT02461550|Irreversible Electroporation Ablation
97024|NCT02461550|15-001
97025|NCT02461498|Warfarin
97026|NCT02461485|adults
97027|NCT02461485|moderate constipation
97028|NCT02461472|risk factors
97029|NCT02461472|risk analysis
97030|NCT02461472|diabetic cardiovascular autonomic neuropathy
97031|NCT02461472|general Chinese population
97032|NCT02461459|Tuberous Sclerosis Complex
97033|NCT02461459|TSC
97034|NCT02461459|Autism
97035|NCT02461459|ASD
97036|NCT02461459|Intellectual Disability
97037|NCT02461459|ID
97038|NCT02461459|MRI
97039|NCT02461446|germline heterozygous PTEN mutations
97040|NCT02461446|MRI
97041|NCT02461446|10q23.3
97042|NCT02461446|ASD
97043|NCT02461446|Autism
97044|NCT02461446|Macrocephaly
97045|NCT02461446|PTEN Hamartoma Tumor Syndrome
97046|NCT02461446|PTEN
97047|NCT02461433|Obesity
97048|NCT02461433|Obese
97049|NCT02461433|surgical site infection
97050|NCT02461433|closed incisions
97051|NCT02461433|negative pressure therapy
97052|NCT02461420|Phelan-McDermid Syndrome
97053|NCT02461420|PMS
97054|NCT02461420|Genotype
97055|NCT02461420|Phenotype
97056|NCT02461420|Natural History
97057|NCT02461420|Mapping
97058|NCT02461420|22q13 Deletion Syndrome
97059|NCT02461420|SHANK3
97060|NCT02461420|Autism Spectrum Disorder
97061|NCT02461420|ASD
97062|NCT02461420|Intellectual Disability
97063|NCT02461420|ID
97064|NCT02461381|Bayesian estimation, short-term heart rate variability, diabetic cardiovascular autonomic neuropathy, diagnostic performance
97065|NCT02461381|Diagnostic performance
97066|NCT02461381|short-term heart rate variability
97067|NCT02461381|diabetic cardiovascular autonomic neuropathy
97068|NCT02461381|DCAN
97069|NCT02461342|Genetic
97070|NCT02461342|environment
97071|NCT02461342|interaction analysis
97072|NCT02461342|cardiovascular autonomic neuropathy
97073|NCT02461342|CAN
97074|NCT02461329|Hip Replacement, Total
97075|NCT02461329|Gelatine solution
97076|NCT02461329|Balanced Crystaloid Solution
97077|NCT02461329|Volume therapy
97078|NCT02461329|Platelet aggregation
97079|NCT02461303|Klinefelter
97080|NCT02461303|Spermatogenesis
97081|NCT02461303|Puberty
97082|NCT02461303|Fertility
97083|NCT02461277|postoperative care
97084|NCT02461277|exercise test
97085|NCT02461277|early ambulation
97086|NCT02461277|Fast-track
97087|NCT02461251|Thromboelastometry
97088|NCT02461251|Obstetric Hemorrhage
97089|NCT02461251|Blood Component Transfusion
97090|NCT02461212|HepaFat-Scan
97091|NCT02461212|Liver Disease
97092|NCT02461212|Pediatrics
97093|NCT02461199|Fecal microbiota transplantation
97094|NCT02461199|Gut colonization
97095|NCT02461199|Multidrug-resistant bacteria
97096|NCT02461199|Blood disorders
97097|NCT02461199|Drug Resistance, Multiple
97098|NCT02461199|Disease Eradication
97099|NCT02461186|Arterolane-piperaquine
97100|NCT02461186|Dehydroartemisinin-piperaquine
97101|NCT02461186|therapeutic efficacy
97102|NCT02461186|Uncomplicated falciparum malaria
97103|NCT02461186|Artemisinin-resistant
97104|NCT02461160|Drug therapy
97105|NCT02461134|GVHD
97106|NCT02461134|ponesimod
97107|NCT02461121|Acute Myeloid Leukemia
97108|NCT02461121|microtransplantationHLA-mismatched microtransplantation
97109|NCT02461121|nonmyeloablative stem cell transplantation
97110|NCT02461121|graft-versus-host disease
97111|NCT02461108|Public policy
97112|NCT02461108|Food choice
97113|NCT02461108|Nutrition labeling
97114|NCT02461108|Fat tax
97115|NCT02461108|Vegetable subsidy
97116|NCT02461108|Behavioral economics
97117|NCT02461108|Health behavior
97118|NCT02461069|dimethyl fumarate
97119|NCT02461056|ibuprofen
97120|NCT02461056|hydromorphone
97121|NCT02461056|drug interactions
97122|NCT02461043|esophageal cancer
97123|NCT02461043|adjuvant chemotherapy
97124|NCT02461043|esophageal surgery
97125|NCT02461043|paclitaxel
97126|NCT02461030|Dentin hypersensitivity
97127|NCT02461030|Periodontal disease
97128|NCT02461030|Arginine
97129|NCT02461017|intubation
97130|NCT02461017|ventilation
97131|NCT02461017|airway
97132|NCT02461017|airleak
97133|NCT02461004|Dyslipidemia
97134|NCT02461004|CKD-391
97135|NCT02461004|Atorvastatin
97136|NCT02461004|Ezetimibe
97137|NCT02460978|Dapagliflozin
97138|NCT02460978|Efficacy
97139|NCT02460978|Safety
97140|NCT02460978|Add on to insulin
97141|NCT02460978|Oral Antidiabetic
97142|NCT02460978|Type 1 diabetes
97143|NCT02460952|Pulmonary Embolism;
97144|NCT02460952|perioperative period;
97145|NCT02460952|general anesthesia
97146|NCT02460939|Pulmonary Vessel Disease
97147|NCT02460939|metabolism of small molecules
97148|NCT02460926|Scaling and root planning
97149|NCT02460926|C-reactive protein
97150|NCT02460913|acupuncture
97151|NCT02460913|morphine
97152|NCT02460913|acute pain
97153|NCT02460887|nasopharyngeal carcinoma
97154|NCT02460887|induction chemotherapy
97155|NCT02460874|Brain Metastases
97156|NCT02460874|Stereotactic Radiosurgery
97157|NCT02460874|Glyburide
97158|NCT02460861|Prostate Cancer
97159|NCT02460861|Molecular staging
97160|NCT02460861|GSTP1
97161|NCT02460861|Surgical margins
97162|NCT02460861|prostatovesiculectomy
97163|NCT02460848|Malnutrition
97164|NCT02460848|Severe Acute Malnutrition
97165|NCT02460848|Cash Transfer
97166|NCT02460848|Democratic Republic of Congo
97167|NCT02460848|Cluster randomize trial
97168|NCT02460796|Parkinson's disease
97169|NCT02460796|Quality of life
97170|NCT02460796|Gait velocity
97171|NCT02460796|Capacity
97172|NCT02460783|Biomarkers
97173|NCT02460783|Diabetes
97174|NCT02460783|Obesity
97175|NCT02460783|Dementia of the Alzheimer Type
97176|NCT02460783|Functional Magnetic Resonance Imaging (fMRI)
97177|NCT02460770|Left Ventricular Assist Device
97178|NCT02460770|stem cell therapy
97179|NCT02460770|ischemic heart failure
97180|NCT02460757|glottic movement
97181|NCT02460757|emphysema
97182|NCT02460757|copd
97183|NCT02460757|vocal cord
97184|NCT02460744|Breast cancer
97185|NCT02460744|hypofractionation
97186|NCT02460744|radiotherapy
97187|NCT02460731|PSP
97188|NCT02460731|Young Plasma
97189|NCT02460718|diabetes mellitus
97190|NCT02460718|peer support
97191|NCT02460718|pragmatic clinical trial
97192|NCT02460666|depressed
97193|NCT02460666|older adults
97194|NCT02460666|Major Depressive Disorder
97195|NCT02460666|Tai-Chi
97196|NCT02460666|geriatric
97197|NCT02460653|High flow nasal cannula
97198|NCT02460653|Oxygen therapy
97199|NCT02460653|Ventilation
97200|NCT02460640|Minimally invasive surgery
97201|NCT02460640|Partial nephrectomy
97202|NCT02460627|Arthroscopy
97203|NCT02460627|Meniscus
97204|NCT02460627|Lidocaine
97205|NCT02460614|bronchiolitis
97206|NCT02460614|respiratory physiotherapy
97207|NCT02460614|pediatrics
97208|NCT02460614|rhinopharyngeal clearance
97209|NCT02460575|Safety
97210|NCT02460562|resin denture base
97211|NCT02460549|therapeutic patient education
97212|NCT02460549|insulinoresistance
97213|NCT02460549|empowerment
97214|NCT02460549|prostate cancer
97215|NCT02460549|oral endocrine therapy
97216|NCT02460549|side effects
97217|NCT02460536|attention bias modification treatment
97218|NCT02460536|attention training
97219|NCT02460536|anxiety disorders
97220|NCT02460536|clinical trials
97221|NCT02460471|Radiotherapy
97222|NCT02460471|Palliative Care
97223|NCT02460471|IMRT
97224|NCT02460458|Factor VIII
97225|NCT02460458|Hemorrhage
97226|NCT02460458|von Willebrand Diseases
97227|NCT02460458|von Willebrand Factor
97228|NCT02460445|Functional hyperandrogenism
97229|NCT02460445|Polycystic ovary syndrome
97230|NCT02460445|Idiopathic hyperandrogenism
97231|NCT02460445|Iron tissue depots
97232|NCT02460445|Phlebotomy
97233|NCT02460445|Insulin resistance
97234|NCT02460445|Carbohydrate metabolism
97235|NCT02460445|Blood pressure
97236|NCT02460445|Autonomic dysfunction
97237|NCT02460445|Oxidative stress
97238|NCT02460445|Blood clotting tests
97239|NCT02460445|Efficacy
97240|NCT02460445|Side effects
97241|NCT02460445|Randomized clinical trial
97242|NCT02460432|Drug-eluting Biliary stent
97243|NCT02460432|Covered metalic stent
97244|NCT02460419|Nasopharyngeal carcinoma
97245|NCT02460419|metastasis
97246|NCT02460419|capecitabine
97247|NCT02460406|strength training
97248|NCT02460406|virtual reality
97249|NCT02460406|plyometric exercises
97250|NCT02460406|cerebral palsy
97251|NCT02460406|hemiplegic
97252|NCT02460393|tolerance
97253|NCT02460393|safety and pharmacokinetic characteristics
97254|NCT02460367|Non-small Cell Lung Cancer
97255|NCT02460367|Vaccine Therapy
97256|NCT02460367|Immunotherapy
97257|NCT02460367|Second line therapy
97258|NCT02460367|Progressive
97259|NCT02460367|Relapsed
97260|NCT02460367|IDO
97261|NCT02460367|IDO Inhibitor
97262|NCT02460354|Congenital nephrogenic diabetes insipidus
97263|NCT02460341|fMRI
97264|NCT02460341|Brain function
97265|NCT02460341|Sensory processing
97266|NCT02460315|time of cholecystectomy after ERCP
97267|NCT02460276|Mantle cell lymphoma
97268|NCT02460276|Relapsed mantle cell lymphoma
97269|NCT02460276|Lenalidomide
97270|NCT02460276|Rituximab
97271|NCT02460276|Ibrutinib
97272|NCT02460276|Response duration
97273|NCT02460276|Complete remission rate
97274|NCT02460276|Quality of life
97275|NCT02460276|Overall survival
97276|NCT02460276|Safety
97277|NCT02460250|Tissue and Organ Harvesting
97278|NCT02460250|Liver graft
97279|NCT02460250|Brain Death
97280|NCT02460250|FibroScan®
97281|NCT02460237|HPV
97282|NCT02460224|Non-small cell lung cancer
97283|NCT02460224|Melanoma
97284|NCT02460224|Renal cancer
97285|NCT02460211|Cardiovascular Disease
97286|NCT02460211|Vitamin D
97287|NCT02460211|Open Heart Surgery
97288|NCT02460198|PD1
97289|NCT02460198|PD-1
97290|NCT02460198|PDL1
97291|NCT02460198|PD-L1
97292|NCT02460172|bi lateral
97293|NCT02460172|knee surgery
97294|NCT02460172|arthroplasty
97295|NCT02460172|orthopedics
97296|NCT02460081|PDA-002
97297|NCT02460081|Diabetic Foot Ulcer
97298|NCT02460081|Peripheral arterial disease
97299|NCT02460081|Phase 2
97300|NCT02460081|Randomized
97301|NCT02460068|melanoma brain metastases
97302|NCT02460068|nivolumab
97303|NCT02460068|ipilimumab
97304|NCT02460055|EGD Dysphagia
97305|NCT02460055|ETT Intubation dysphagia
97306|NCT02459990|Hypertension malformation fetal mortality
97307|NCT02459964|Advanced Cancers
97308|NCT02459964|Pain
97309|NCT02459964|Fentanyl nasal spray
97310|NCT02459964|Hydromorphone hydrochloride
97311|NCT02459964|Phone call
97312|NCT02459964|Numeric Rating Scale
97313|NCT02459964|NRS
97314|NCT02459951|Muscle Spasticity
97315|NCT02459951|Botox A
97316|NCT02459951|Upper limb hemiplegia
97317|NCT02459912|Prostate
97318|NCT02459912|Minimally
97319|NCT02459912|Low-Risk
97320|NCT02459912|Invasive
97321|NCT02459912|Cancer
97322|NCT02459886|alpha synuclein
97323|NCT02459886|PD
97324|NCT02459860|depression
97325|NCT02459860|randomized behavioral trial
97326|NCT02459860|aged
97327|NCT02459860|Latinos
97328|NCT02459860|Spanish-speaking
97329|NCT02459860|chronic medical conditions
97330|NCT02459834|Allulose
97331|NCT02459834|Fructose
97332|NCT02459834|Dose Response
97333|NCT02459834|Catalytic Dose
97334|NCT02459834|Carbohydrate metabolism
97335|NCT02459834|Randomized clinical trials
97336|NCT02459821|Multiple sclerosis
97337|NCT02459821|Gait rehabilitation
97338|NCT02459821|Quality of life
97339|NCT02459821|Stair climbing
97340|NCT02459821|Robotic
97341|NCT02459782|Ultrasound guided peribulbar anesthesia
97342|NCT02459756|anthocyanins
97343|NCT02459756|bioavailability
97344|NCT02459743|Hematological malignancies
97345|NCT02459743|Next Generation Sequencing
97346|NCT02459743|Genotype-phenotype correlations
97347|NCT02459743|Prognosis
97348|NCT02459743|Diagnosis
97349|NCT02459730|Dental caries
97350|NCT02459730|glass ionomer cement
97351|NCT02459730|ART
97352|NCT02459704|Gingival Recession
97353|NCT02459704|Semilunar flap
97354|NCT02459704|Enamel matrix derivative
97355|NCT02459704|Periodontal regeneration
97356|NCT02459691|prediabetes
97357|NCT02459691|metabolic syndrome
97358|NCT02459691|lifestyle
97359|NCT02459691|behavior change
97360|NCT02459691|primary care
97361|NCT02459691|latinos
97362|NCT02459691|diet
97363|NCT02459691|physical activity
97364|NCT02459652|Borderline Resectable Pancreatic Cancer
97365|NCT02459639|Chronic Widespread Pain
97366|NCT02459639|Telomere length
97367|NCT02459639|Multimodal rehabilitation
97368|NCT02459639|Integrative care
97369|NCT02459639|Existential aspects
97370|NCT02459613|Radionuclide imaging
97371|NCT02459613|Annexin
97372|NCT02459600|Eye surgery
97373|NCT02459600|Children
97374|NCT02459587|Self-Injurious Behavior
97375|NCT02459587|suicide prevention
97376|NCT02459574|Heart Failure
97377|NCT02459561|Obesity
97378|NCT02459561|Diabetes
97379|NCT02459561|Overweight
97380|NCT02459561|Medical device
97381|NCT02459561|Endobarrier
97382|NCT02459561|Clinical trial
97383|NCT02459561|Diet
97384|NCT02459561|Exercise
97385|NCT02459561|Body weight
97386|NCT02459561|Medical therapy
97387|NCT02459561|Medicine
97388|NCT02459561|Device
97389|NCT02459561|Randomised
97390|NCT02459561|Control
97391|NCT02459561|Intervention
97392|NCT02459561|EndoBarrier Medical device
97393|NCT02459548|OSA
97394|NCT02459548|CPAP treatment
97395|NCT02459548|Primary care
97396|NCT02459548|Efficacy
97397|NCT02459535|incretin release
97398|NCT02459522|Bayesian estimation
97399|NCT02459522|short-term heart rate variability
97400|NCT02459522|cardiovascular autonomic neuropathy
97401|NCT02459522|diagnostic performance
97402|NCT02459509|Sedation
97403|NCT02459509|dexmedetomidine
97404|NCT02459509|pediatric
97405|NCT02459509|preoperative period
97406|NCT02459470|Fluid Responsiveness
97407|NCT02459470|Pulse Pressure Variation
97408|NCT02459470|Stroke Volume Variation
97409|NCT02459457|esophageal squamous cell carcinoma
97410|NCT02459457|concurrent chemoradiotherapy
97411|NCT02459457|paclitaxel
97412|NCT02459457|cisplatin
97413|NCT02459457|carboplatin
97414|NCT02459457|fluorouracil
97415|NCT02459444|Inspiratory muscle training
97416|NCT02459444|Physical Therapy
97417|NCT02459444|Powerbreathe
97418|NCT02459418|Finox
97419|NCT02459418|Afolia
97420|NCT02459418|Follitropin
97421|NCT02459405|Colorectal surgery
97422|NCT02459405|Near infrared
97423|NCT02459405|Indocyanine green
97424|NCT02459405|anastomotic leak
97425|NCT02459405|Prevention of leak
97426|NCT02459392|Epiduroscopy,
97427|NCT02459392|Failed back surgery syndrome
97428|NCT02459392|Spinal Stenosis with neurologic changes
97429|NCT02459366|Thoracolumbar fascia
97430|NCT02459366|Mechanical properties
97431|NCT02459366|Low back pain
97432|NCT02459353|dapagliflozin
97433|NCT02459353|glucose variability
97434|NCT02459327|Infant behavior
97435|NCT02459327|Child behavior
97436|NCT02459327|Parenting
97437|NCT02459327|Child rearing
97438|NCT02459327|Depression
97439|NCT02459327|Personal satisfaction
97440|NCT02459327|Randomized controlled trials
97441|NCT02459327|Intervention studies
97442|NCT02459327|Behavioral symptoms
97443|NCT02459327|Social behavior
97444|NCT02459288|Acute coronary syndrome
97445|NCT02459288|Chronic kidney disease
97446|NCT02459288|End-Stage Renal Disease
97447|NCT02459288|eGFR
97448|NCT02459288|Ticagrelor
97449|NCT02459288|Clopidogrel
97450|NCT02459275|feeding protocol
97451|NCT02459275|enteral nutrition protocol
97452|NCT02459275|critically ill
97453|NCT02459275|surgical ICU
97454|NCT02459275|enteral nutrition
97455|NCT02459275|nutrition therapy
97456|NCT02459223|Nutritional intervention
97457|NCT02459223|iron deficiency anemia
97458|NCT02459210|clinical high risk for psychosis
97459|NCT02459210|psychosis prodrome
97460|NCT02459210|cognitive remediation
97461|NCT02459210|psychosis prevention
97462|NCT02459197|Pain
97463|NCT02459184|preventive medicine
97464|NCT02459184|social determinants of health
97465|NCT02459184|primary health care
97466|NCT02459184|poverty
97467|NCT02459184|income
97468|NCT02459184|health promotion
97469|NCT02459132|High-intensity interval training
97470|NCT02459132|VO2peak
97471|NCT02459132|Brachial flow-mediated dilation
97472|NCT02459132|Carotid-femoral pulse wave velocity
97473|NCT02459132|Carotid intima-media thickness
97474|NCT02459132|Carotid distensibility
97475|NCT02459132|Respiratory sinus arrhythmia
97476|NCT02459119|urothelial cancer
97477|NCT02459119|Regorafenib
97478|NCT02459106|micro-RNA
97479|NCT02459106|insulin resistance
97480|NCT02459093|wound complications
97481|NCT02459080|Chronic Obstructive Pulmonary Disease, COPD
97482|NCT02459054|Artificial Heart
97483|NCT02459054|Biventricular Heart Failure
97484|NCT02459054|SynCardia
97485|NCT02459002|Advanced lung cancer
97486|NCT02459002|NSCLC
97487|NCT02459002|palliative care
97488|NCT02458989|Thyroidectomy
97489|NCT02458989|Thyroid surgery
97490|NCT02458989|Scalpel
97491|NCT02458989|Electrocautery
97492|NCT02458976|Scar
97493|NCT02458976|Pulsed-dye laser
97494|NCT02458976|PDL
97495|NCT02458963|PCOS
97496|NCT02458963|Clomiphene citrate resistant
97497|NCT02458963|Gonadotropin
97498|NCT02458963|IVF
97499|NCT02458950|Anorexia nervosa
97500|NCT02458950|Siriraj Hospital
97501|NCT02458950|Thai
97502|NCT02458937|Leukemia
97503|NCT02458937|Hodgkin Disease
97504|NCT02458937|Non-Hodgkin's Lymphoma
97505|NCT02458937|Sickle Cell Disease
97506|NCT02458937|Hip Core Decompression
97507|NCT02458937|Function Outcomes
97508|NCT02458885|myocardial infarction
97509|NCT02458885|observational registry
97510|NCT02458885|mortality
97511|NCT02458872|Clinical Alarms
97512|NCT02458872|Patient Safety
97513|NCT02458859|Chronic
97514|NCT02458859|Subacute
97515|NCT02458833|Obesity
97516|NCT02458833|Nutrition
97517|NCT02458833|Home Food Preparation
97518|NCT02458833|Home Food Environment
97519|NCT02458833|Peer Mentoring
97520|NCT02458833|Early Head Start
97521|NCT02458833|Cooking
97522|NCT02458833|Diet
97523|NCT02458820|Cardiopulmonary Resuscitation
97524|NCT02458820|Return of Spontaneous Circulation
97525|NCT02458820|ROSC
97526|NCT02458820|Electroencephalogram
97527|NCT02458742|spinal anesthesia
97528|NCT02458742|intrathecal morphine
97529|NCT02458742|transurethral resection of prostate
97530|NCT02458742|postoperative pain
97531|NCT02458729|Tranexamic Acid
97532|NCT02458729|Total Knee Arthroplasty
97533|NCT02458729|Rivaroxaban
97534|NCT02458703|workload
97535|NCT02458703|oxygen level
97536|NCT02458703|oxygen consumption
97537|NCT02458703|breathing reserve
97538|NCT02458703|ventilatory efficiency
97539|NCT02458690|Primary Care
97540|NCT02458690|Older Adults
97541|NCT02458690|Antidepressant Medications
97542|NCT02458690|Cognitive-Behavioral Therapy
97543|NCT02458690|Computer-Based Psychotherapy
97544|NCT02458612|cerebral palsy
97545|NCT02458612|mirror therapy
97546|NCT02458612|strength training
97547|NCT02458560|Transcatheter Aortic Valve Replacement
97548|NCT02458560|Aortic Stenosis
97549|NCT02458534|Simulated manikin
97550|NCT02458508|MC4R
97551|NCT02458508|chemotherapy
97552|NCT02458508|radiotherapy
97553|NCT02458495|Internet
97554|NCT02458495|Mobile Health
97555|NCT02458495|Hemoglobin A, Glycosylated
97556|NCT02458495|Medication Adherence
97557|NCT02458495|Psychological Theory
97558|NCT02458482|Children
97559|NCT02458482|Positive Airway Pressure
97560|NCT02458482|Nebulizer
97561|NCT02458482|Moderate
97562|NCT02458482|Acute
97563|NCT02458482|AccuPAP
97564|NCT02458417|Ablative laser
97565|NCT02458417|Fractional laser
97566|NCT02458417|Vitiligo
97567|NCT02458417|Piebaldism
97568|NCT02458417|Cell suspension grafting
97569|NCT02458391|Breast Cancer
97570|NCT02458391|Lymphedema
97571|NCT02458365|Violence
97572|NCT02458365|Bullying
97573|NCT02458365|Social skills
97574|NCT02458365|Prevention & control
97575|NCT02458365|Adolescent
97576|NCT02458339|Brain tumor
97577|NCT02458339|Malignant Fourth Ventricular Brain Tumors
97578|NCT02458326|Migraine
97579|NCT02458326|Fibromyalgia
97580|NCT02458326|Aerobic exercise
97581|NCT02458300|Bronchiolitis
97582|NCT02458300|Chest
97583|NCT02458300|Physical therapy
97584|NCT02458287|mixed dyslipidemia
97585|NCT02458248|Chronic Kidney Disease
97586|NCT02458248|Sodium Reduction
97587|NCT02458248|eGFR 30-60ml/min/1.73m2
97588|NCT02458235|pediatric leukemia myelodysplastic syndrome azacitidine
97589|NCT02458209|PK, bococizumab, comparability, LDL-C
97590|NCT02458196|IgG4 related disease
97591|NCT02458196|IgG4-RD
97592|NCT02458196|Response rate
97593|NCT02458196|Relapse
97594|NCT02458170|Rheumatoid arthritis
97595|NCT02458170|Synovial tissue
97596|NCT02458170|Joint destruction
97597|NCT02458170|Inflammation
97598|NCT02458157|ICU
97599|NCT02458157|Intensive
97600|NCT02458157|CRRT
97601|NCT02458157|Fluid Removal
97602|NCT02458157|AKI
97603|NCT02458157|Critical Care
97604|NCT02458131|community-based participatory research
97605|NCT02458131|adolescents
97606|NCT02458118|chronic
97607|NCT02458118|pancreatitis
97608|NCT02458118|secretin
97609|NCT02458118|Blood flow
97610|NCT02458105|Acceptance and commitment therapy
97611|NCT02458105|Cognitive behavior therapy
97612|NCT02458053|African American
97613|NCT02458053|male
97614|NCT02458053|couples
97615|NCT02458053|randomized control trial
97616|NCT02458014|Leukemia
97617|NCT02458014|B-cell Lineage Acute Lymphocytic Leukemia
97618|NCT02458014|Positive minimal residual disease
97619|NCT02458014|MRD
97620|NCT02458014|Acute lymphocytic leukemia
97621|NCT02458014|ALL
97622|NCT02458014|Blinatumomab
97623|NCT02458014|Blinacyto
97624|NCT02458014|Phone calls
97625|NCT02457949|Social Assistance
97626|NCT02457949|Drug Use
97627|NCT02457949|Drug-Related harm
97628|NCT02457923|mobile phone counselling
97629|NCT02457923|infant feeding
97630|NCT02457923|nutrition
97631|NCT02457897|Brown Adipose Tissue
97632|NCT02457897|Liothyronine
97633|NCT02457897|Insulin Receptors
97634|NCT02457884|Diabetic macular oedema
97635|NCT02457884|Perceptual learning
97636|NCT02457884|Chinese
97637|NCT02457884|Hong Kong
97638|NCT02457858|Type 1 Diabetes
97639|NCT02457858|Islet Transplant
97640|NCT02457845|Brain Tumor, Recurrent
97641|NCT02457845|Glioma
97642|NCT02457845|Glioblastoma
97643|NCT02457845|Gliosarcoma
97644|NCT02457845|Anaplastic Astrocytoma
97645|NCT02457845|Oligodendroglioma
97646|NCT02457845|Rhabdoid Tumor
97647|NCT02457845|Cerebral Primitive Neuroectodermal Tumor
97648|NCT02457845|PNET
97649|NCT02457845|Ependymoma
97650|NCT02457845|Germ Cell Tumor
97651|NCT02457845|Choroid Plexus Carcinoma
97652|NCT02457845|Oncolytic Virus Therapy
97653|NCT02457845|Virotherapy, Oncolytic
97654|NCT02457845|Immunotherapy
97655|NCT02457845|Central Nervous System Agents
97656|NCT02457845|Antineoplastic Agents
97657|NCT02457845|Neoplasms
97658|NCT02457845|Pediatric
97659|NCT02457845|Pediatrics
97660|NCT02457832|Magnetic Resonance Imaging
97661|NCT02457832|Neurology
97662|NCT02457832|Neurosciences
97663|NCT02457832|Physical Medicine
97664|NCT02457832|Parkinson Disease
97665|NCT02457832|Rehabilitation
97666|NCT02457806|Dental Anesthesia
97667|NCT02457780|PTSD
97668|NCT02457780|Trauma
97669|NCT02457780|World Trade Center
97670|NCT02457780|Respiratory
97671|NCT02457780|Mind-Body
97672|NCT02457741|Mechanical ventilation
97673|NCT02457741|PEEP
97674|NCT02457741|Respiratory mechanics
97675|NCT02457741|End-expiratory lung volume
97676|NCT02457689|Human Immunodeficiency Virus
97677|NCT02457689|Immunodeficiency Virus, Human
97678|NCT02457676|Self-Regulation Training
97679|NCT02457676|Neuroimaging
97680|NCT02457676|Response Inhibition
97681|NCT02457676|Behavioral Regulation
97682|NCT02457676|Emotional Regulation
97683|NCT02457663|Burns
97684|NCT02457637|chronic liver disease
97685|NCT02457637|acute liver injury
97686|NCT02457637|acute decompensation
97687|NCT02457637|multiple organ failures
97688|NCT02457637|acute on chronic liver failure
97689|NCT02457624|gastric cancer
97690|NCT02457624|chronic atrophic gastritis
97691|NCT02457624|intestinal metaplasia
97692|NCT02457546|Fibrin sealant
97693|NCT02457546|CSF leak
97694|NCT02457494|CALVIH
97695|NCT02457494|Renal stone
97696|NCT02457494|HIV1
97697|NCT02457494|Renal colic
97698|NCT02457494|Atazanavir
97699|NCT02457494|Crystalluria
97700|NCT02457494|Chronic Kidney Disease
97701|NCT02457494|Calcium Oxalate
97702|NCT02457481|Embryo Culture Techniques
97703|NCT02457481|Embryonic Development
97704|NCT02457468|coflex
97705|NCT02457468|interlaminar stabilization
97706|NCT02457468|lumbar spinal stenosis
97707|NCT02457468|neurogenic claudication
97708|NCT02457468|decompression
97709|NCT02457455|inflight emergencies
97710|NCT02457442|Anesthetics, Inhalation
97711|NCT02457442|Anesthetics, Intravenous
97712|NCT02457442|Analgesics, Opioid
97713|NCT02457429|Gastro-oesophageal reflux
97714|NCT02457429|Children
97715|NCT02457429|Dx-pH Pharyngeal probe
97716|NCT02457429|GORD
97717|NCT02457429|Trans-nasal catheter
97718|NCT02457416|Peanut allergy
97719|NCT02457416|Oral immunotherapy
97720|NCT02457390|contrast enhanced laparoscopic ultrasound
97721|NCT02457390|CE-LUS
97722|NCT02457390|LUS
97723|NCT02457390|robot assisted CRC resection
97724|NCT02457377|recurrent abortion
97725|NCT02457377|cerclage
97726|NCT02457377|laparoscopy
97727|NCT02457377|cervical imcompetence
97728|NCT02457364|non-operative management
97729|NCT02457351|Phase 1
97730|NCT02457351|Advanced solid tumor
97731|NCT02457351|pan-CDK inhibitor
97732|NCT02457351|Drug-drug Interaction
97733|NCT02457338|C-section
97734|NCT02457338|Infants
97735|NCT02457338|Probiotic
97736|NCT02457338|B. infantis
97737|NCT02457338|Microbiota
97738|NCT02457338|Gut
97739|NCT02457338|Breast milk
97740|NCT02457338|Vaginal
97741|NCT02457325|Articaine
97742|NCT02457325|Lower third molar
97743|NCT02457325|Oral Surgery
97744|NCT02457299|Esophagectomy
97745|NCT02457299|Gastric Conduit
97746|NCT02457299|Esophageal Cancer
97747|NCT02457273|PDNC(Poorly Differentiated Neuroendocrine Carcinomas)
97748|NCT02457273|TLC-388 (Lipotecan®)
97749|NCT02457247|Drug therapy
97750|NCT02457234|fruits and vegetables
97751|NCT02457234|cultural immersion
97752|NCT02457221|Tacrolimus
97753|NCT02457221|Cyclophosphamide
97754|NCT02457221|Prograf
97755|NCT02457221|lupus nephritis
97756|NCT02457208|pharmacokinetics
97757|NCT02457195|PONV
97758|NCT02457195|anesthesia
97759|NCT02457195|granisetron
97760|NCT02457156|Pancreatico-jejunostomy
97761|NCT02457156|Pancreato-duodenectomy
97762|NCT02457156|Cattell-Warren anastomosis
97763|NCT02457156|Blumgart anastomosis
97764|NCT02457143|recall
97765|NCT02457143|income-related disparities
97766|NCT02457143|cancer screening
97767|NCT02457117|CyberKnife
97768|NCT02457117|Partial breast irradiation
97769|NCT02457117|accelerated partial breast irradiation
97770|NCT02457117|breast sbrt
97771|NCT02457091|multiple sclerosis
97772|NCT02457091|exercise
97773|NCT02457091|home-based
97774|NCT02457091|training
97775|NCT02457091|fitness
97776|NCT02457078|nutritional supplements
97777|NCT02457078|lutein
97778|NCT02457078|DHA
97779|NCT02457078|vitamin E
97780|NCT02457078|infant brain development
97781|NCT02457065|survivors
97782|NCT02457065|family
97783|NCT02457052|Medical device
97784|NCT02457039|Chemo-brain
97785|NCT02457039|Drug-Related Side Effects and Adverse Reactions
97786|NCT02457039|Mild Cognitive Impairment
97787|NCT02457039|Breast cancer
97788|NCT02457026|neovascular age-related macular degeneration
97789|NCT02457026|age-related macular degeneration
97790|NCT02457026|verteporfin
97791|NCT02457026|persistent disease activity
97792|NCT02457026|photodynamic therapy
97793|NCT02457026|Aflibercept
97794|NCT02457000|Sleep
97795|NCT02457000|Skin
97796|NCT02457000|Circadian Rhythm
97797|NCT02456961|Collagen crosslinking (CXL)
97798|NCT02456961|Standard corneal crosslinking (CXL)
97799|NCT02456961|Transepithelial CXL
97800|NCT02456961|Iontophoresis
97801|NCT02456961|Riboflavin
97802|NCT02456948|treatment resistant depression
97803|NCT02456948|inflammation
97804|NCT02456948|microglia
97805|NCT02456948|minocycline
97806|NCT02456922|Type 1 Diabetes
97807|NCT02456922|Type 2 Diabetes
97808|NCT02456922|Harmony 1
97809|NCT02456896|Oxcarbazepine
97810|NCT02456896|Brain Derived Neurotrophic Factor
97811|NCT02456896|Bipolar disorder
97812|NCT02456896|Neuroprotection
97813|NCT02456883|ASP2215
97814|NCT02456883|14C-labeled gilteritinib
97815|NCT02456883|Advanced Solid Tumors
97816|NCT02456883|Pharmacokinetics
97817|NCT02456883|gilteritinib
97818|NCT02456870|Adipose tissue
97819|NCT02456870|Overfeeding
97820|NCT02456857|Breast cancer
97821|NCT02456857|Triple-Negative Breast Cancer
97822|NCT02456857|TNBC
97823|NCT02456857|Tumors insensitive to standard neoadjuvant chemotherapy
97824|NCT02456857|Temsirolimus
97825|NCT02456857|CCI-779
97826|NCT02456857|Torisel
97827|NCT02456857|Liposomal Doxorubicin
97828|NCT02456857|Doxil
97829|NCT02456857|Doxorubicin Hydrochloride (Liposomal)
97830|NCT02456857|Bevacizumab
97831|NCT02456857|Avastin
97832|NCT02456857|Anti-VEGF Monoclonal Antibody
97833|NCT02456857|rhuMAb-VEGF
97834|NCT02456818|Colonization
97835|NCT02456818|Multi-resistant gram negative bacteria
97836|NCT02456818|Infection control measures
97837|NCT02456818|Hand hygiene program
97838|NCT02456818|Contact precautions
97839|NCT02456818|Immunocompromised host
97840|NCT02456792|PCOS
97841|NCT02456792|Clomiphene citrate resistant
97842|NCT02456792|LOD
97843|NCT02456792|IVF
97844|NCT02456779|pepsin
97845|NCT02456779|peptest
97846|NCT02456779|GERD
97847|NCT02456779|NERD
97848|NCT02456779|diagnostic
97849|NCT02456766|FibroTouch
97850|NCT02456766|acoustic attenuation parameter
97851|NCT02456766|liver biopsy
97852|NCT02456766|hepatic steatosis
97853|NCT02456753|in labor
97854|NCT02456753|Ultrasonography
97855|NCT02456753|clinical examination
97856|NCT02456753|Prenatal
97857|NCT02456740|Migraine
97858|NCT02456740|Headache
97859|NCT02456740|Prevention
97860|NCT02456740|Prophylaxis
97861|NCT02456727|Acupuncture
97862|NCT02456727|Group/Community Acupuncture
97863|NCT02456727|Individual Acupuncture
97864|NCT02456727|Chronic Pain
97865|NCT02456727|Underserved
97866|NCT02456727|Urban Primary Care
97867|NCT02456727|Osteoarthritis
97868|NCT02456727|Back Pain
97869|NCT02456727|Neck Pain
97870|NCT02456714|Cholangiocarcinoma
97871|NCT02456714|FOLFIRINOX
97872|NCT02456714|Phase II study
97873|NCT02456675|Refractory Hodgkin lymphoma
97874|NCT02456675|Relapsed Hodgkin Lymphoma
97875|NCT02456649|lumpectomy margins
97876|NCT02456636|Weight loss
97877|NCT02456636|Weight management
97878|NCT02456636|Diabetes
97879|NCT02456636|Heart disease
97880|NCT02456597|Peripheral Nerve Blocks
97881|NCT02456584|depot medroxyprogesterone acetate (DMPA)
97882|NCT02456584|confidence interval (CI)
97883|NCT02456584|Subcutaneous (sub-Q)
97884|NCT02456584|Intrauterine device (IUD)
97885|NCT02456584|Levonorgestrel (LNG)
97886|NCT02456584|intrauterine system (IUS)
97887|NCT02456558|HIV infection
97888|NCT02456558|antiretroviral drugs
97889|NCT02456558|deferiprone
97890|NCT02456558|pharmacokinetics
97891|NCT02456519|children
97892|NCT02456519|surgery
97893|NCT02456428|Incretins
97894|NCT02456428|Antidiabetic Agents
97895|NCT02456428|Heart Failure
97896|NCT02456389|Probable cancer
97897|NCT02456389|Proven cancer
97898|NCT02456389|Elective cancer surgery
97899|NCT02456389|Postoperative death
97900|NCT02456389|Postoperative complications
97901|NCT02456389|Healthcare utilization
97902|NCT02456389|Quality of life
97903|NCT02456389|Adjuvant therapy
97904|NCT02456389|Disease-free survival
97905|NCT02456389|Overall survival
97906|NCT02456376|Sensor Fusion
97907|NCT02456376|Stochastic Resonance Stimulation
97908|NCT02456376|Sensory deficits
97909|NCT02456376|Postural Control
97910|NCT02456363|Adalimumab
97911|NCT02456363|NSAIDs
97912|NCT02456363|safety
97913|NCT02456363|efficacy
97914|NCT02456337|Gingival Recession
97915|NCT02456337|Coronally advanced flap
97916|NCT02456337|Periodontal regeneration
97917|NCT02456324|Fistula, Anorectal
97918|NCT02456311|VATS
97919|NCT02456311|Energy sealing
97920|NCT02456298|Telehealth
97921|NCT02456298|Applied behavior analysis
97922|NCT02456272|Otosclerosis
97923|NCT02456272|Surgical treatment
97924|NCT02456272|Hearing aids
97925|NCT02456259|internal jugular vein patency
97926|NCT02456259|MICS
97927|NCT02456259|neck cannula
97928|NCT02456259|Jugular veins
98180|NCT02454504|Curare
97929|NCT02456246|Stereotactive Body Radiation Therapy (SBRT)
97930|NCT02456246|Lung Fibrosis
97931|NCT02456246|FLT-PET
97932|NCT02456246|NSCLC
97933|NCT02456233|rotor
97934|NCT02456233|FIRM
97935|NCT02456233|paroxysmal atrial fibrillation
97936|NCT02456233|persistent atrial fibrillation
97937|NCT02456233|atrial tachyarrhythmia
97938|NCT02456233|ablation
97939|NCT02456233|contact mapping
97940|NCT02456233|clinical trial
97941|NCT02456233|signal processing
97942|NCT02456220|Herbst appliance
97943|NCT02456220|Computed tomography
97944|NCT02456220|3D imaging
97945|NCT02456220|Growth and development
97946|NCT02456220|Orthodontic Appliances, Functional
97947|NCT02456168|Lupus
97948|NCT02456168|SLE
97949|NCT02456155|bedside placement
97950|NCT02456155|nasal jejunal tube
97951|NCT02456155|ultrasound
97952|NCT02456155|severe acute pancreatitis
97953|NCT02456155|endoscope
97954|NCT02456155|efficacy
97955|NCT02456155|safety
97956|NCT02456129|Clinical Trial, Phase I
97957|NCT02456077|MCV4: Meningococcal Conjugate Vaccine
97958|NCT02456077|HPV: Human Papillomavirus
97959|NCT02456051|Pancreatic Carcinoma
97960|NCT02456051|New-Onset Diabetes
97961|NCT02456051|Adrenomedullin
97962|NCT02456051|Early Diagnosis
97963|NCT02456051|Biological Markers
97964|NCT02456012|peptic ulcer hemorrhage
97965|NCT02456012|comorbidity
97966|NCT02456012|clinical trial
97967|NCT02455973|obesity
97968|NCT02455973|overweight
97969|NCT02455947|Burnout
97970|NCT02455947|Teachers
97971|NCT02455947|Meditation
97972|NCT02455947|IBSR
97973|NCT02455947|"The Work"
97974|NCT02455947|Byron Katie
97975|NCT02455895|Blepharitis
97976|NCT02455856|Healthy
97977|NCT02455856|Itraconazole
97978|NCT02455856|JNJ-42847922
97979|NCT02455843|microwave ablation
97980|NCT02455843|chemotherapy
97981|NCT02455830|Neonatal encephalopathy
97982|NCT02455830|Hypoxic-ischemic encephalopathy
97983|NCT02455830|Newborn infants
97984|NCT02455830|Cytokines
97985|NCT02455830|Trophic factors
97986|NCT02455791|Breast Cancer
97987|NCT02455791|Triple negative breast cancer
97988|NCT02455791|HER2 amplified breast cancer
97989|NCT02455791|Ultrasound-guided biopsy
97990|NCT02455791|Fine needle aspirate
97991|NCT02455791|FNA
97992|NCT02455791|Core biopsy
97993|NCT02455752|LE-TME
97994|NCT02455752|Laparoscopic rectal resection
97995|NCT02455752|Retroperitoneal resection
97996|NCT02455739|intestinal function
97997|NCT02455739|chewing gum
97998|NCT02455726|Peripheral Arterial Disease
97999|NCT02455726|Magnesium Oxide
98000|NCT02455726|Pain
98001|NCT02455687|Bronchial asthma
98002|NCT02455687|Magnesium Sulfate
98003|NCT02455687|Inhaled budesonide
98004|NCT02455674|weight estimation
98005|NCT02455674|emergency
98006|NCT02455674|child
98007|NCT02455635|Office Hysteroscopy
98008|NCT02455635|tubal patency
98009|NCT02455635|infertility
98010|NCT02455635|Lower Abdominal Pain
98011|NCT02455609|dexmedetomidine
98012|NCT02455609|ketamine
98013|NCT02455609|postoperative pain
98014|NCT02455596|Novaferon
98015|NCT02455596|Recombinant anti-tumor and anti-virus protein for injection
98016|NCT02455596|Carcinoid Tumor
98017|NCT02455596|Pancreatic Neuroendocrine Tumor
98018|NCT02455583|HIV prevention
98019|NCT02455583|Sexual activity biomarker
98020|NCT02455583|Youth
98021|NCT02455583|Adolescents
98022|NCT02455570|Endoscopic Ultrasound
98023|NCT02455570|Quality Management
98024|NCT02455570|Education and training
98025|NCT02455570|Safety
98026|NCT02455570|Learning curve
98027|NCT02455544|Urine congophilia
98028|NCT02455518|pain
98029|NCT02455505|Cancer Care and Bereavement
98030|NCT02455505|Supportive Care
98031|NCT02455505|15-095
98032|NCT02455492|Mortality
98033|NCT02455492|Perioperative period
98034|NCT02455492|Elective surgical procedures
98035|NCT02455479|cocaine vaccine
98036|NCT02455479|cocaine dependence
98037|NCT02455479|Cocaine
98038|NCT02455440|esmolol
98039|NCT02455440|anesthetics
98040|NCT02455427|transcranial direct current stimulation
98041|NCT02455427|conventional physical therapy
98042|NCT02455401|Postoperative Vomiting
98043|NCT02455388|Nutrition
98044|NCT02455388|Obesity
98045|NCT02455388|Pediatric
98046|NCT02455375|Puumala virus
98047|NCT02455375|diagnostic
98048|NCT02455375|France
98049|NCT02455349|Veterans
98050|NCT02455349|Community Engagement
98051|NCT02455349|Negative Symptoms
98052|NCT02455336|tetraplegia
98053|NCT02455336|paraplegia
98054|NCT02455336|hypertriglyceridemia
98055|NCT02455336|hyperlipidemia
98056|NCT02455336|peroxisome proliferator-activated receptor alpha
98057|NCT02455323|Efficacy
98058|NCT02455323|Tension-type headache
98059|NCT02455323|Manual therapy
98060|NCT02455284|MRI
98061|NCT02455284|Tractography
98062|NCT02455284|white
98063|NCT02455284|physiology
98064|NCT02455284|analysis
98065|NCT02455284|matter
98066|NCT02455284|tracts
98067|NCT02455271|Insomnia
98068|NCT02455258|Inactivity
98069|NCT02455180|Critical Care
98070|NCT02455167|HCV
98071|NCT02455167|Hepatitis C
98072|NCT02455154|Chinese Traditional Medicine
98073|NCT02455154|Osteoporosis
98074|NCT02455154|adjuvant endocrine therapy
98075|NCT02455154|early breast cancer
98076|NCT02455141|chemptherapy
98077|NCT02455141|triple negative
98078|NCT02455141|paclitaxel
98079|NCT02455141|carboplatin
98080|NCT02455128|Anxiety
98081|NCT02455128|Fear
98082|NCT02455128|Colorectal Surgery
98083|NCT02455128|Colorectal Neoplasms
98084|NCT02455115|Acute kidney injury
98085|NCT02455115|Liver transplantation
98086|NCT02455115|Postoperative care
98087|NCT02455115|Glomerular filtration rate
98088|NCT02455115|Renal blood flow
98089|NCT02455115|Vasopressor
98090|NCT02455115|Norepinephrine
98091|NCT02455102|Prevention
98092|NCT02455102|Anticoagulation
98093|NCT02455102|Electronic warning system
98094|NCT02455089|Flare
98095|NCT02455089|Therapeutic adjustments
98096|NCT02455089|Biological Marker
98097|NCT02455089|Immunologic Marker
98098|NCT02455089|Prognosis
98099|NCT02455076|Hypoglycemia
98100|NCT02455037|Concussion
98101|NCT02455037|Contact sport
98102|NCT02455037|Collision sport
98103|NCT02455037|Neck strengthening
98104|NCT02455024|Leukemia
98105|NCT02455024|Leukemia, Myeloid
98106|NCT02455024|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
98107|NCT02455024|ponatinib
98108|NCT02455024|Pharmacologic Actions
98109|NCT02455024|Protein Kinase Inhibitors
98110|NCT02455024|Risk factor
98111|NCT02455024|Leukemia, Myelogenous, Chronic
98112|NCT02455024|CML
98113|NCT02455024|CP-CML
98114|NCT02455024|Iclusig
98115|NCT02455024|AP24534
98116|NCT02454998|Unilateral complete cleft lip
98117|NCT02454998|Alveolar bone graft
98118|NCT02454946|Blood Group Antigens
98119|NCT02454946|erectile dysfunction
98120|NCT02454933|Phase III Open Label Study; AZD9291 plus MEDI4736 versus AZD9291 Monotherapy; NSCLC After Previous EGFR TKI Therapy; T790M Mutation Positive Tumours.
98121|NCT02454920|Strabismus
98122|NCT02454920|Optical Coherence Tomography
98123|NCT02454920|Extraocular muscles
98124|NCT02454868|Remifentanil
98125|NCT02454868|Intubation
98126|NCT02454868|Children
98127|NCT02454855|quality of life
98128|NCT02454855|melatonin
98129|NCT02454855|Elderly patient
98130|NCT02454842|TH-4000
98131|NCT02454842|low-oxygen conditions
98132|NCT02454842|hypoxia
98133|NCT02454842|non-small cell lung cancer
98134|NCT02454842|NSCLC
98135|NCT02454842|squamous cell carcinoma
98136|NCT02454842|Tarloxotinib
98137|NCT02454829|Ovarian cortex cryopreservation
98138|NCT02454829|ovarian function
98139|NCT02454790|Acute toxicity
98140|NCT02454790|Late toxicity
98141|NCT02454790|Prediction models
98142|NCT02454738|pulmonary tuberculosis
98143|NCT02454738|chest
98144|NCT02454738|ultralow dose computed tomography
98145|NCT02454725|HIV Testing
98146|NCT02454725|Latino
98147|NCT02454712|Prodrug
98148|NCT02454712|PF614
98149|NCT02454712|oxycodone extended-release
98150|NCT02454712|oral
98151|NCT02454699|Cytomegalovirus, MBX-400, antiviral, food effect, ascending dose, Herpesviridae
98152|NCT02454686|Complications after hepatectomy
98153|NCT02454673|Radiotherapy
98154|NCT02454673|Neoadjuvant therapy
98155|NCT02454673|Pharmacodynamics
98156|NCT02454673|Pharmacokinetics
98157|NCT02454673|Nonlinear Dynamics
98158|NCT02454660|adherence
98159|NCT02454660|hypertension
98160|NCT02454660|mobile technology
98161|NCT02454660|intervention
98162|NCT02454647|Radiotherapy
98163|NCT02454647|Neoadjuvant therapy
98164|NCT02454647|Induction chemotherapy
98165|NCT02454647|Concurrent chemoradiotherapy
98166|NCT02454647|Preoperative factors
98167|NCT02454647|Dynamic factors
98168|NCT02454647|Prognostic Factor
98169|NCT02454634|IDH1R132H
98170|NCT02454634|peptide vaccine
98171|NCT02454634|immunotherapy
98172|NCT02454634|IDH1R132H-mutated glioma
98173|NCT02454556|Assisted reproduction technologies
98174|NCT02454556|Follicle stimulating hormone (FSH).
98175|NCT02454543|metastatic
98176|NCT02454543|prostatectomy
98177|NCT02454543|androgen deprivation
98178|NCT02454504|Sugammadex
98179|NCT02454504|Delayed Emergence from Anesthesia
98181|NCT02454504|Robotic Surgical Procedures
98182|NCT02454491|percutaneous coronary interventions
98183|NCT02454491|radial artery access
98184|NCT02454491|access site complications
98185|NCT02454491|verapamil
98186|NCT02454491|heparin
98187|NCT02454478|lenvatinib
98188|NCT02454478|Everolimus
98189|NCT02454478|Carcinoma
98190|NCT02454478|Unresectable advanced renal cell carcinoma
98191|NCT02454478|Metastatic renal cell carcinoma
98192|NCT02454452|Varicose Veins
98193|NCT02454439|Heart Failure with reduced ejection fraction (<35%)
98194|NCT02454439|Cardiac Resynchronisation Therapy
98195|NCT02454439|Non specific intraventricular conduction
98196|NCT02454439|Efficacy
98197|NCT02454439|Life expectancy expected to exceed one year with a good functional status
98198|NCT02454439|QRS morphology : NICD according to the AHA/ACCF/HRS Recommendations (non-LBBB and non-RBBB):
98199|NCT02454439|QRS duration > 130 ms
98200|NCT02454426|Depression
98201|NCT02454426|Heart disease
98202|NCT02454413|dentures hygiene
98203|NCT02454413|biofilm formation
98204|NCT02454413|oral health
98205|NCT02454400|physical therapy
98206|NCT02454400|lumbar spine surgery
98207|NCT02454400|pre-surgical intervention
98208|NCT02454400|RCT
98209|NCT02454374|Physiotherapy
98210|NCT02454374|Knee Loading
98211|NCT02454374|Randomised Controlled Trial
98212|NCT02454374|Pain
98213|NCT02454361|Safety
98214|NCT02454361|tolerability
98215|NCT02454361|pharmacokinetics
98216|NCT02454361|KBP-7072
98217|NCT02454348|septic shock
98218|NCT02454348|vasopressin
98219|NCT02454348|norepinephrine
98220|NCT02454296|Laminaria
98221|NCT02454270|First-in-Human
98222|NCT02454270|B-Cell Chronic Lymphocytic Leukemia
98223|NCT02454270|Diffuse Large-Cell Lymphoma
98224|NCT02454270|Follicular Lymphoma
98225|NCT02454270|Mantle-Cell Lymphoma
98226|NCT02454270|Acute Lymphoid Leukemia
98227|NCT02454270|Dose Escalation Study
98228|NCT02454270|Duvortuxizumab
98229|NCT02454231|EPC
98230|NCT02454231|CD34+
98231|NCT02454231|CD14+CD34low
98232|NCT02454218|Fibromyalgia
98233|NCT02454218|Transcranial direct current stimulation
98234|NCT02454192|Evidence-based intervention
98235|NCT02454192|Implementation
98236|NCT02454192|Underserved communities
98237|NCT02454127|nutrition
98238|NCT02454127|popular diets
98239|NCT02454127|weight loss
98240|NCT02454127|lifestyle
98241|NCT02454127|counseling
98242|NCT02454114|Pneumonia
98243|NCT02454114|Community
98244|NCT02454114|Hospital
98245|NCT02454114|Respiratory
98246|NCT02454114|Infection
98247|NCT02454088|Volume
98248|NCT02454088|Hands
98249|NCT02454088|Filler
98250|NCT02454088|Radiesse
98251|NCT02454088|Calcium hydroxylapatite
98252|NCT02454075|YF476
98253|NCT02454075|netazepide
98254|NCT02454075|gastric carcinoids
98255|NCT02454075|Zollinger-Ellison syndrome
98256|NCT02454062|Phase I
98257|NCT02454062|Solid Tumors
98258|NCT02454062|Pharmacokinetics
98259|NCT02454062|Pharmacodynamics
98260|NCT02454062|MTD
98261|NCT02454023|Stroke
98262|NCT02454023|Transient ischemic attack
98263|NCT02454023|Obstructive sleep apnea
98264|NCT02454023|Portable sleep monitor
98265|NCT02454023|Screening
98266|NCT02453997|lupus nephritis
98267|NCT02453997|mycophenolic acid
98268|NCT02453997|pharmacokinetics
98269|NCT02453997|pharmacogenomics
98270|NCT02453984|89Zr-MPLD3280A-PET
98271|NCT02453984|triple-negative breast cancer
98272|NCT02453984|non small cell lung cancer
98273|NCT02453984|bladder cancer
98274|NCT02453971|alcohol consumption
98275|NCT02453971|binge drinking
98276|NCT02453971|web-based personalized feedback program
98277|NCT02453971|students
98278|NCT02453958|Injury
98279|NCT02453958|Brain
98280|NCT02453958|Traumatic Mild
98281|NCT02453958|Mild Traumatic Brain Injury
98282|NCT02453945|pain
98283|NCT02453945|comfort
98284|NCT02453945|healing
98285|NCT02453945|quality of life
98286|NCT02453932|Vascular dementia
98287|NCT02453932|Tianzhi granule
98288|NCT02453932|Herbal medicine
98289|NCT02453932|Randomized controlled trial
98290|NCT02453932|Three arms
98291|NCT02453919|functional cardiac abnormality
98292|NCT02453919|morphologic cardiac abnormality
98293|NCT02453919|blood pressure abnormality
98294|NCT02453893|Iloperidone
98295|NCT02453893|Risperidone
98296|NCT02453893|PANSS
98297|NCT02453880|anxiety
98298|NCT02453880|depression
98299|NCT02453880|chronic illness
98300|NCT02453880|teen
98301|NCT02453880|young adult
98302|NCT02453867|kidney transplantation
98303|NCT02453867|senior kidney transplant recipients
98304|NCT02453867|tacrolimus once daily
98305|NCT02453867|reduced immunosuppression
98306|NCT02453867|recipients >65 years
98307|NCT02453867|Senior
98308|NCT02453802|Tranexamic Acid
98309|NCT02453802|Total Knee Arthroplasty
98310|NCT02453802|Rivaroxaban
98311|NCT02453789|alginate oligosaccharide
98312|NCT02453789|cystic fibrosis
98313|NCT02453789|Burkholderia
98314|NCT02453789|aztreonam
98315|NCT02453776|Crohns Disease
98316|NCT02453776|Ulcerative Colitis
98317|NCT02453776|Infliximab
98318|NCT02453776|Sustained
98319|NCT02453776|Remission
98320|NCT02453776|Inflammatory bowel disease
98321|NCT02453776|IBD
98322|NCT02453763|Transcranial direct current stimulation
98323|NCT02453763|Noninvasive brain stimulation
98324|NCT02453763|Brain
98325|NCT02453763|Central Nervous System Diseases
98326|NCT02453763|Nervous System Diseases
98327|NCT02453763|Parkinson disease
98328|NCT02453763|Stroke
98329|NCT02453763|Epilepsy
98330|NCT02453763|Depression
98331|NCT02453763|Schizophrenia
98332|NCT02453763|Brain imaging
98333|NCT02453763|Electrical impedance tomography
98334|NCT02453763|Magnetic resonance electrical impedance tomography
98335|NCT02453763|Diffusion tensor imaging
98336|NCT02453763|Functional magnetic imaging
98337|NCT02453763|Rehabilitation
98338|NCT02453750|Congenital Diaphragmatic Hernia
98339|NCT02453750|Airway Inflammation
98340|NCT02453750|Asthma
98341|NCT02453750|Hypersaline
98342|NCT02453750|Pediatrics
98343|NCT02453737|Proton
98344|NCT02453737|Brachytherapy
98345|NCT02453737|Partial Breast Irradiation
98346|NCT02453737|3D Conformal Photon
98347|NCT02453724|Ultrasonography
98348|NCT02453724|Lung
98349|NCT02453724|Hemorrhage
98350|NCT02453724|Point of care ultrasound
98351|NCT02453698|Stop task
98352|NCT02453698|modulatory effect of MPH
98353|NCT02453698|bottom-up and top-down
98354|NCT02453698|cognitive processes
98355|NCT02453633|Appointment reminder
98356|NCT02453633|Attendance
98357|NCT02453633|No-show
98358|NCT02453594|PD1
98359|NCT02453594|PD-1
98360|NCT02453594|PDL1
98361|NCT02453594|PD-L1
98362|NCT02453542|hemophilia
98363|NCT02453542|inhibitors
98364|NCT02453542|thrombin
98365|NCT02453529|plasma concentration
98366|NCT02453529|pulmonary concentration
98367|NCT02453516|Serratus Block
98368|NCT02453516|Breast Surgery
98369|NCT02453503|Lichen planus
98370|NCT02453503|Mucoadhesive film
98371|NCT02453503|licorice
98372|NCT02453490|Colorectal Cancer
98373|NCT02453490|liver metastasis
98374|NCT02453490|neoadjuvant chemotherapy
98375|NCT02453477|Beta thalassemia
98376|NCT02453477|Gene therapy
98377|NCT02453477|Lentiviral vector
98378|NCT02453451|MitraClip
98379|NCT02453451|atrial septal defect
98380|NCT02453451|iatrogenic
98381|NCT02453425|renal blood flow
98382|NCT02453425|renal oxygenation
98383|NCT02453425|glomerular filtration rate
98384|NCT02453425|filtration fraction
98385|NCT02453425|blood pressure
98386|NCT02453412|Arteriovenous fistulae (AVFs)
98387|NCT02453412|Non-maturation
98388|NCT02453412|Computational simulation
98389|NCT02453386|Motor fluctuations
98390|NCT02453386|Off time
98391|NCT02453386|On time
98392|NCT02453386|Dyskinesia
98393|NCT02453360|Anesthesia
98394|NCT02453360|Analgesia
98395|NCT02453347|Stable chronic medical conditions
98396|NCT02453347|No current alcohol or substance abuse
98397|NCT02453347|Alpha Stim
98398|NCT02453321|Continuous Femoral Nerve Block
98399|NCT02453321|Continuous Adductor Canal Block
98400|NCT02453308|Artemisinin combination Therapies
98401|NCT02453295|Lymphedema
98402|NCT02453295|Arm Disability
98403|NCT02453295|Cancer Survivorship
98404|NCT02453295|Intervention
98405|NCT02453282|NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS
98406|NCT02453269|Obesity
98407|NCT02453269|Children
98408|NCT02453269|Health Colective
98409|NCT02453243|Suicide screening in the ED
98410|NCT02453243|Safety Planning
98411|NCT02453217|severe mental illness
98412|NCT02453217|physical health screening
98413|NCT02453217|randomised controlled trial
98414|NCT02453217|health behaviour change
98415|NCT02453178|physical activity
98416|NCT02453178|aging
98417|NCT02453178|cognition
98418|NCT02453178|brain
98419|NCT02453178|exercise
98420|NCT02453165|vaginal dehiscence
98421|NCT02453152|myotubular myopathy
98422|NCT02453152|respiratory muscles
98423|NCT02453152|natural history
98424|NCT02453126|Eosinophilic Esophagitis
98425|NCT02453126|Esophageal Stricture
98426|NCT02452099|DMSO
98427|NCT02452099|cryopreservation
98428|NCT02452099|autologous transplantation
98677|NCT02451293|Depression
98429|NCT02452099|hematopoietic stem cells
98430|NCT02452099|hematological malignancies
98431|NCT02452073|low triiodothyronine syndrome
98432|NCT02452073|chronic radiation enteritis
98433|NCT02452073|triiodothyronine
98434|NCT02452073|thyroxine
98435|NCT02452073|thyroid stimulating hormone
98436|NCT02452060|perioperative period
98437|NCT02452060|pain
98438|NCT02452060|gastric bypass
98439|NCT02452008|metastatic castration-resistant prostate cancer
98440|NCT02452008|enzalutamide
98441|NCT02452008|LY2157299
98442|NCT02452008|TGF-β receptor inhibitor
98443|NCT02453048|Pertussis
98444|NCT02453048|Colonization
98445|NCT02453048|Vaccine
98446|NCT02453048|Immune response
98447|NCT02453048|BPZE1
98448|NCT02453048|Infection
98449|NCT02453048|Bordetella pertussis
98450|NCT02453048|B. pertussis
98451|NCT02453048|respiratory Tract Infection
98452|NCT02453035|bioresorbable scaffold
98453|NCT02453035|CAD
98454|NCT02453022|Bioavailability
98455|NCT02453022|Pharmacokinetics
98456|NCT02453022|Food Effect
98457|NCT02453022|Omeprazole
98458|NCT02453022|Danirixin
98459|NCT02452996|GNbAC1
98460|NCT02452996|Multiple Sclerosis
98461|NCT02452996|Multiple Sclerosis Associated Retrovirus (MSRV)
98462|NCT02452996|MSRV-Envelope protein
98463|NCT02452996|Monoclonal antibody
98464|NCT02452983|Anemia
98465|NCT02452983|Leukemia
98466|NCT02452983|Hematologic diseases
98467|NCT02452983|Cytopenias
98468|NCT02452983|Bone marrow diseases
98469|NCT02452983|Preleukemia
98470|NCT02452944|nerve stimulator, obturator nerve, ultrasound
98471|NCT02452918|skin infection
98472|NCT02452892|Depression
98473|NCT02452892|Major depression
98474|NCT02452892|Low-field magnetic stimulation
98475|NCT02452892|LFMS
98476|NCT02452840|neovascular age-related macular degeneration
98477|NCT02452840|anti-vascular endothelial growth factor
98478|NCT02452840|verteporfin
98479|NCT02452840|photodynamic therapy
98480|NCT02452840|persistent disease activity
98481|NCT02452710|Fatigue in Cancer Survivors
98482|NCT02452697|Nonmyeloablative
98483|NCT02452697|Stem Cell
98484|NCT02452697|Transplant
98485|NCT02452684|Insomnia
98486|NCT02452658|Fast food literacy
98487|NCT02452645|Food
98488|NCT02452645|Nutrition
98489|NCT02452645|Physical Activity
98490|NCT02452645|Family
98491|NCT02452645|Child Care
98492|NCT02452645|Home
98493|NCT02452645|Environment
98494|NCT02452632|ASP1941
98495|NCT02452632|Type 2 diabetes mellitus
98496|NCT02452619|Hyperbaric oxygen therapy
98497|NCT02452619|brain trauma
98498|NCT02452619|cognitive impairment
98499|NCT02452606|Stalevo
98500|NCT02452606|sleep disturbance
98501|NCT02452606|central circadian clock
98502|NCT02452606|narcolepsy
98503|NCT02452593|incontinence; pelvic floor exercises; neuromodulation
98504|NCT02452580|Kangaroo Mother Care
98505|NCT02452580|Neonatal Intensive Care Units
98506|NCT02452580|Postnatal growth
98507|NCT02452541|Traumatic Brain Injury
98508|NCT02452541|Critically ill Patients
98509|NCT02452541|Death
98510|NCT02452541|Head Injury
98511|NCT02452541|TBI-Prognosis
98512|NCT02452541|Critical Care Medicine
98513|NCT02452541|Withdrawal of Life Sustaining Therapy
98514|NCT02452541|Prognosis
98515|NCT02452541|Prognostic Evaluation
98516|NCT02452541|Outcome Research
98517|NCT02452541|Mortality
98518|NCT02452541|Decision-making
98519|NCT02452528|Hepatitis B Virus
98520|NCT02452528|Chronic Hepatitis B
98521|NCT02452528|HBV
98522|NCT02452502|stroke
98523|NCT02452502|thrombolytic therapy
98524|NCT02452502|atorvastatin
98525|NCT02452489|Different acupoints compatibility
98526|NCT02452437|oxycodone
98527|NCT02452437|hemodialysis
98528|NCT02452411|Internet
98529|NCT02452411|Adjustment disorders
98530|NCT02452411|Homework assignments
98531|NCT02452411|Cognitive-Behavioral treatment
98532|NCT02452411|Online therapy
98533|NCT02452411|Emotional Regulation
98534|NCT02452411|ICT's
98535|NCT02452398|Hair removal
98536|NCT02452398|depilation
98537|NCT02452398|epilation
98538|NCT02452372|RNAi therapeutic
98539|NCT02452372|Porphyria
98540|NCT02452372|AIP
98541|NCT02452359|stretch marks
98542|NCT02452346|MDS
98543|NCT02452333|Excisional breast biopsy
98544|NCT02452333|Oncoplastic surgery
98545|NCT02452333|Oncoplastic reconstruction
98546|NCT02452333|Breast conserving surgery
98547|NCT02452333|Tezel method of breast volume measurement
98548|NCT02452320|bariatric
98549|NCT02452320|Post-operative nausea and vomiting
98550|NCT02452320|laparoscopic Sleeve gastrectomy
98551|NCT02452320|intravenous acetaminophen
98552|NCT02452294|Brain
98553|NCT02452281|Therapeutically Unresectable
98554|NCT02452281|Stage III or Stage IV
98555|NCT02452281|Malignant Melanoma
98556|NCT02452281|Advanced Melanoma
98557|NCT02452177|parenteral nutrition associated liver disease
98558|NCT02452177|vitamin D
98559|NCT02452177|short bowel syndrome
98560|NCT02452177|farnesoid X receptor
98561|NCT02452177|cholestasis
98562|NCT02452164|otoscopy
98563|NCT02452164|otitis media
98564|NCT02452164|cellphone
98565|NCT02452164|family
98566|NCT02452151|Inflectra
98567|NCT02452151|Infliximab
98568|NCT02452151|Biosimilar
98569|NCT02451943|leiomyosarcoma
98570|NCT02451943|soft tissue sarcoma (STS)
98571|NCT02451943|advanced soft tissue sarcoma
98572|NCT02451943|metastatic soft tissue sarcoma
98573|NCT02451943|liposarcoma
98574|NCT02451943|undifferentiated pleomorphic sarcoma
98575|NCT02451943|doxorubicin
98576|NCT02451917|Glargine insulin
98577|NCT02451917|Chronic Kidney Disease
98578|NCT02451917|CGMS
98579|NCT02451904|Pathogenesis
98580|NCT02451904|Microvascular function
98581|NCT02451904|Metabolic dysregulation
98582|NCT02451904|Metabolomics
98583|NCT02451878|shyness
98584|NCT02451878|internet
98585|NCT02451878|self-help
98586|NCT02451878|psychology
98587|NCT02451878|wellbeing
98588|NCT02451839|Adalimumab
98589|NCT02451839|Quality of Life
98590|NCT02451839|Crohn Disease
98591|NCT02451839|Patient Outcome Assessment
98592|NCT02451839|Psoriasis
98593|NCT02451839|Global Health
98594|NCT02451839|Arthritis, Rheumatoid
98595|NCT02451826|ovulation inhibition
98596|NCT02451826|endometrial changes
98597|NCT02451826|bleeding patterns
98598|NCT02451813|opening injection pressure
98599|NCT02451813|femoral nerve block
98600|NCT02451813|fascia iliaca
98601|NCT02451813|ultrasound guided nerve block
98602|NCT02451774|pediatric
98603|NCT02451774|apoptosis
98604|NCT02451761|chromosomal rearrangement
98605|NCT02451761|next generation sequencing
98606|NCT02451761|intellectual disability
98607|NCT02451761|multiple congenital anomalies
98608|NCT02451761|gene disruption
98609|NCT02451735|female breast cancer
98610|NCT02451735|bilateral breast cancer
98611|NCT02451735|triple negative breast cancer
98612|NCT02451735|breast cancer diagnosis
98613|NCT02451735|BRCA 1
98614|NCT02451735|BRCA 2
98615|NCT02451735|psychoeducational intervention (PEI)
98616|NCT02451735|genetic counseling
98617|NCT02451735|hereditary breast and ovarian cancer (HBOC)
98618|NCT02451735|cancer education materials
98619|NCT02451683|SCI
98620|NCT02451631|Mobile Application
98621|NCT02451631|Diabetes management
98622|NCT02451618|Perinatal Depression
98623|NCT02451605|surgery
98624|NCT02451592|Fungemia
98625|NCT02451592|Hematologic malignancies
98626|NCT02451579|Actinic Keratoses
98627|NCT02451579|Photodynamic Therapy
98628|NCT02451579|PDT
98629|NCT02451579|Blue Light
98630|NCT02451566|Abdominal
98631|NCT02451566|Aortic
98632|NCT02451566|Aneurysm
98633|NCT02451540|Pulmonary Disease, Chronic Obstructive
98634|NCT02451540|dynamics hyperinflation
98635|NCT02451540|Computed Tomography scan
98636|NCT02451540|CT scan
98637|NCT02451540|Functional Respiratory Imaging
98638|NCT02451540|FRI
98639|NCT02451540|Roflumilast
98640|NCT02451540|PRO
98641|NCT02451514|Antibody persistence
98642|NCT02451514|Young Adults
98643|NCT02451514|Healthy Adolescents
98644|NCT02451514|MenABCWY vaccine
98645|NCT02451514|Booster response
98646|NCT02451514|MenABCWY+OMV
98647|NCT02451475|Pregabalin
98648|NCT02451475|Fibromyalgia
98649|NCT02451462|hematopoietic stem cell transplant
98650|NCT02451462|bone marrow transplant
98651|NCT02451449|Celiac disease
98652|NCT02451449|Infertility
98653|NCT02451449|Prevalence study
98654|NCT02451436|Adolescents, sleep, media use, obesity, type 2 diabetes
98655|NCT02451423|Non-metastatic
98656|NCT02451423|Bladder
98657|NCT02451410|Nutrition
98658|NCT02451410|Physical activity
98659|NCT02451410|Overweight
98660|NCT02451410|Obesity
98661|NCT02451410|Malnutrition
98662|NCT02451371|Schizophrenia
98663|NCT02451371|Refractory auditory hallucination
98664|NCT02451371|tDCS
98665|NCT02451358|Influenza
98666|NCT02451358|Quadrivalent Inactivated Influenza Vaccine (QIV)
98667|NCT02451345|Prostate cancer
98668|NCT02451345|Tranformative Impact Award
98669|NCT02451345|Early stage
98670|NCT02451345|Active Surveillance
98671|NCT02451345|Decision aid
98672|NCT02451345|Coaching session
98673|NCT02451345|Personalized
98674|NCT02451345|UCSF
98675|NCT02451345|validation
98676|NCT02451319|RIRS, holmium, 1-2 cm,stones,kidney
98678|NCT02451293|Acute Coronary Syndrome
98679|NCT02451293|Anxiety
98680|NCT02451293|Sleep
98681|NCT02451293|Circadian
98682|NCT02451280|stroke rehabilitation
98683|NCT02451280|robot-assisted therapy
98684|NCT02451280|hybrid therapy
98685|NCT02451267|neck pain
98686|NCT02451267|aerobic exercise
98687|NCT02451267|cervical pain
98688|NCT02451241|Acupuncture
98689|NCT02451228|Pharmacokinetics
98690|NCT02451228|Pharmacodynamics
98691|NCT02451228|Preterm labor
98692|NCT02451228|Preterm birth
98693|NCT02451228|Estradiol
98694|NCT02451228|Indomethacin
98695|NCT02451228|Pregnancy
98696|NCT02451228|Short Cervix
98697|NCT02451228|CYP2C9 Genotype
98698|NCT02451202|"surgical conditions"
98699|NCT02451202|"deep neuromuscular blockade"
98700|NCT02451202|"deep neuromuscular paralysis"
98701|NCT02451189|Obesity
98702|NCT02451189|Weight maintenance
98703|NCT02451189|Appetite
98704|NCT02451189|Energy intake
98705|NCT02451189|Dietary fibre
98706|NCT02451189|Short-chain fatty acids
98707|NCT02451189|Fermentation
98708|NCT02451189|Overweight
98709|NCT02451150|Drug therapy
98710|NCT02451124|Barrett
98711|NCT02451124|Cancer
98712|NCT02451124|Screening
98713|NCT02451111|Rituximab
98714|NCT02451111|Ibrutinib
98715|NCT02451111|Follicular Lymphoma
98716|NCT02451085|hip
98717|NCT02451085|surgery
98718|NCT02451085|Replacement
98719|NCT02451059|community resource
98720|NCT02451059|well-child care visit
98721|NCT02451059|low-income
98722|NCT02451046|Liver transplantation
98723|NCT02451046|Primary dysfunction
98724|NCT02451033|Regenerative medicine
98725|NCT02451020|healthy volunteers
98726|NCT02451020|acclimatization
98727|NCT02451020|sleep
98728|NCT02451020|hypoxia
98729|NCT02450994|airway disease
98730|NCT02450994|bronchitis
98731|NCT02450994|emphysema
98732|NCT02450994|lung
98733|NCT02450994|treatment
98734|NCT02450994|sleep
98735|NCT02450968|airway disease
98736|NCT02450968|bronchitis
98737|NCT02450968|emphysema
98738|NCT02450968|lung
98739|NCT02450968|treatment
98740|NCT02450955|Tension-type headache
98741|NCT02450955|manual therapy
98742|NCT02450955|disability
98743|NCT02450955|spinal manipulation
98744|NCT02450929|post operative
98745|NCT02450929|pneumonia
98746|NCT02450929|vascular
98747|NCT02450929|orthopedic
98748|NCT02450929|urologic
98749|NCT02450929|neurologic
98750|NCT02450916|work-related injury
98751|NCT02450916|occupational disease
98752|NCT02450916|workers' compensation
98753|NCT02450916|psychological
98754|NCT02450916|policy
98755|NCT02450903|Non-Small-Cell Lung Cancer, ALK, LDK378
98756|NCT02450890|ORADUR®-Methylphenidate
98757|NCT02450877|Children
98758|NCT02450877|Young Adults
98759|NCT02450877|Azacitidine
98760|NCT02450877|Acute Myeloid Leukemia
98761|NCT02450877|Molecular Relapse
98762|NCT02450877|Vidaza
98763|NCT02450877|AZA-AML-004
98764|NCT02450864|Stiffness of Shoulder, Not Elsewhere Classified
98765|NCT02450851|Rare Diseases
98766|NCT02450851|Undiagnosed Disease
98767|NCT02450838|Dengue Vaccine
98768|NCT02450812|mCRPC
98769|NCT02450773|postpartum
98770|NCT02450773|preeclampsia
98771|NCT02450773|gestational hypertension
98772|NCT02450747|Visual Acuity
98773|NCT02450734|ultrasound-guided intermediate cervical plexus block
98774|NCT02450721|atherosclerosis
98775|NCT02450721|biomarkers
98776|NCT02450721|carotid artery stenosis
98777|NCT02450721|ischemic stroke.
98778|NCT02450708|Allogeneic Hematopoietic Cell Donors
98779|NCT02450708|KIR and HLA Genotypes
98780|NCT02450708|15-059
98781|NCT02450695|rTMS
98782|NCT02450695|treatment refractory
98783|NCT02450695|treatment resistant
98784|NCT02450695|SSRI
98785|NCT02450695|clomipramine
98786|NCT02450669|Intubation
98787|NCT02450669|Extubation
98788|NCT02450669|Weaning
98789|NCT02450669|Mechanical ventilation
98790|NCT02450617|Complex PTSD
98791|NCT02450604|Prevalence Study
98792|NCT02450604|Fabry's disease
98793|NCT02450604|Chronic pain
98794|NCT02450591|Sensitizing EGFR Mutations
98795|NCT02450591|Erlotinib
98796|NCT02450591|Surgery
98797|NCT02450591|Radiation Therapy
98798|NCT02450591|15-067
98799|NCT02450552|Amyotrophic Lateral Sclerosis
98800|NCT02450552|ALS
98801|NCT02450552|Lou Gehrig
98802|NCT02450539|patient reported outcomes (PRO)
98803|NCT02450539|patient focused outcomes (PFO)
98804|NCT02450539|biomarkers
98805|NCT02450539|CDK 4 and 6
98806|NCT02450513|adalimumab
98807|NCT02450513|anti-TNF
98808|NCT02450513|pharmacokinetics
98809|NCT02450513|trough level
98810|NCT02450513|immunogenicity
98811|NCT02450487|Piroxicam
98812|NCT02450487|Pharmacogenetic
98813|NCT02450487|Lower Third molar
98814|NCT02450448|Renal Neoplasms
98815|NCT02450448|Circulating Tumor Cells
98816|NCT02450435|Prostatic Neoplasms
98817|NCT02450435|Circulating TUmor Cells
98818|NCT02450422|Colorectal Neoplasms
98819|NCT02450422|Circulating Tumor Cells
98820|NCT02450409|Total knee arthroplasty
98821|NCT02450409|Midflexion instability
98822|NCT02450409|Gap technique
98823|NCT02450409|Anatomical alignment
98824|NCT02450396|Rare diseases
98825|NCT02450396|pregnancy
98826|NCT02450396|pregnancy,
98827|NCT02450357|Breast Neoplasms
98828|NCT02450357|Circulating Tumor Cells
98829|NCT02450279|Aerosol delivery
98830|NCT02450279|Invasive mechanical ventilation
98831|NCT02450279|Jet Nebulizer
98832|NCT02450279|Vibrating-Mesh nebulizer
98833|NCT02450266|Primary disease
98834|NCT02450266|multiparametric MRI
98835|NCT02450266|targeted prostate biopsy
98836|NCT02450266|MRI/ultrasound fusion-guided prostate biopsy
98837|NCT02450266|systematic transrectal ultrasound-guided prostate biopsy
98838|NCT02450253|Vascular cognitive impairment
98839|NCT02450240|Depression
98840|NCT02450240|Anxiety
98841|NCT02450240|Eating Disorders
98842|NCT02450240|Substance Use
98843|NCT02450240|Functional Magnetic Resonance Imaging
98844|NCT02450240|Genetics
98845|NCT02450240|Behavior
98846|NCT02450240|Mental Health
98847|NCT02450214|Ketamine
98848|NCT02450214|Magnesium
98849|NCT02450214|Analgesia
98850|NCT02450214|Liposuction
98851|NCT02450214|Lipoabdominoplasty
98852|NCT02450214|Preemptive analgesia
98853|NCT02450188|Erectile Dysfunction
98854|NCT02450188|PDE5 inhibitors
98855|NCT02450188|Cognitive-behavioral Sex Therapy
98856|NCT02450175|Platelet Activation
98857|NCT02450175|metastasis
98858|NCT02450110|spinal cord stimulation
98859|NCT02450110|heart failure
98860|NCT02450110|autonomic regulation
98861|NCT02450110|BNP
98862|NCT02450110|left ventricle systolic dysfunction
98863|NCT02450071|Pre-hospital
98864|NCT02450071|Out-of-hospital
98865|NCT02450071|Prehospital emergency care (MeSH)
98866|NCT02450071|Emergency medical services (MeSH)
98867|NCT02450071|Helicopter emergency medical service
98868|NCT02450071|Critical care (MeSH)
98869|NCT02450071|Airway management (MeSH)
98870|NCT02450071|Endotracheal intubation (MeSH)
98871|NCT02450071|Difficult endotracheal intubation
98872|NCT02450071|Complications (MeSH)
98873|NCT02450071|Patient safety
98874|NCT02450058|early breast cancer
98875|NCT02450058|adjuvant chemotherapy
98876|NCT02450058|FEC
98877|NCT02450058|paclitaxel
98878|NCT02449993|diagnostic study
98879|NCT02449993|analysis of estrogen receptor
98880|NCT02449993|progesterone receptor
98881|NCT02449993|Human epidermal growth factor receptor 2
98882|NCT02449993|Ki-67
98883|NCT02449980|Spontaneous Pneumothorax
98884|NCT02449980|Video Assisted Thoracoscopic Surgery
98885|NCT02449980|Tube Thoracostomy
98886|NCT02449980|Pediatric Surgery
98887|NCT02449967|Pancreatic Cancer
98888|NCT02449967|HepaSphere
98889|NCT02449954|Stress and Immune Responses
98890|NCT02449954|morphine
98891|NCT02449954|tramadol
98892|NCT02449954|ketorolac
98893|NCT02449941|Stomach Neoplasms
98894|NCT02449941|proton pump inhibitor
98895|NCT02449941|endoscopic submucosal dissection
98896|NCT02449941|Helicobacter pylori
98897|NCT02449941|Gastritis, Atrophic
98898|NCT02449928|Severe Sepsis with Septic Shock, Lactate
98899|NCT02449915|sacrocolpopexy
98900|NCT02449915|rectocele repair
98901|NCT02449902|VVA
98902|NCT02449902|Postmenopausal
98903|NCT02449902|Painful Sex
98904|NCT02449863|Lung ultrasound
98905|NCT02449863|Mechanical ventilation
98906|NCT02449863|Respiratory distress syndrome
98907|NCT02449863|Transient tachypnea of the newborn
98908|NCT02449850|In-utero environment
98909|NCT02449850|Asthma
98910|NCT02449850|Allergic diseases
98911|NCT02449850|Food allergy
98912|NCT02449850|Birth cohort study
98913|NCT02449850|Primary prevention
98914|NCT02449850|Intervention study
98915|NCT02449850|Atopic dermatitis
98916|NCT02449850|Rhinitis
98917|NCT02449850|Allergy
98918|NCT02449850|Lung function
98919|NCT02449850|Non-communicable diseases
98920|NCT02449850|Foetal growth
98921|NCT02449824|neoadjuvant chemotherapy
98922|NCT02449824|magnetic resonance imaging
98923|NCT02449798|Difficult IV access
98924|NCT02449798|AccuCath
98925|NCT02449798|IV outcomes
98926|NCT02449798|patient satisfaction
98927|NCT02449785|Cystic fibrosis
98928|NCT02449785|MRI
98929|NCT02449785|UTE
98930|NCT02449785|CT
98931|NCT02449785|Exacerbation
98932|NCT02449785|Quality of life
98933|NCT02449785|Pulmonary function
98934|NCT02449772|N04.452.442.422.336
98935|NCT02449746|Schizophrenia
98936|NCT02449746|Psychosis
98937|NCT02449746|Mental Health
98938|NCT02449746|Autoimmunity
98939|NCT02449746|Psychoneuroimmunology
98940|NCT02449733|voluntary counseling and testing (VCT)
98941|NCT02449733|couples voluntary counseling and testing (CVCT)
98942|NCT02449733|pre-exposure prophylaxis (PrEP)
98943|NCT02449733|homosexuality
98944|NCT02449733|male
98945|NCT02449733|South Africa
98946|NCT02449720|intraperitoneal
98947|NCT02449720|ropivacaine
98948|NCT02449720|bowel resection
98949|NCT02449720|local anaesthetic
98950|NCT02449720|recovery
98951|NCT02449681|squamous cell carcinoma
98952|NCT02449681|the head and neck
98953|NCT02449681|skin
98954|NCT02449681|TH-4000
98955|NCT02449681|Hypoxia
98956|NCT02449681|Tarloxotinib
98957|NCT02449668|Acupuncture
98958|NCT02449668|Shoulder pain
98959|NCT02449668|Impingement syndrome
98960|NCT02449668|Rotator cuff tendinitis
98961|NCT02449668|Traditional Chinese medicine (TCM)
98962|NCT02449642|luteinizing hormone pulsatility
98963|NCT02449642|estradiol level
98964|NCT02449642|progesterone level
98965|NCT02449629|HIV
98966|NCT02449629|Transgender
98967|NCT02449629|HIV Continuum of Care
98968|NCT02449616|Sickle cell
98969|NCT02449616|vaso-occlusive crisis
98970|NCT02449603|Chinese population
98971|NCT02449590|Onion
98972|NCT02449590|Cardiovascular disease
98973|NCT02449590|metabolomics
98974|NCT02449590|Gene expression
98975|NCT02449590|Biomarker
98976|NCT02449577|Metabolomics
98977|NCT02449577|Beer
98978|NCT02449577|Biomarker
98979|NCT02449577|Glucose response
98980|NCT02449577|Insulin response
98981|NCT02449486|Requirement of postoperative pain medication
98982|NCT02449473|Asthma
98983|NCT02449473|Reactive Airways
98984|NCT02449473|Respiratory Tract Disease
98985|NCT02449473|Obstructive Tract Disease
98986|NCT02449473|Lung Diseases
98987|NCT02449460|hypertension
98988|NCT02449460|epidemiology
98989|NCT02449460|glucose
98990|NCT02449460|body mass index
98991|NCT02449460|lipids
98992|NCT02449460|smoking
98993|NCT02449460|coronary artery disease
98994|NCT02449460|arterial stiffness
98995|NCT02449460|carotid ultrasound
98996|NCT02449447|Major Depressive Disorder (MDD)
98997|NCT02449447|Blended treatment
98998|NCT02449447|Cognitive behavior Therapy (CBT)
98999|NCT02449447|Face-to-face
99000|NCT02449447|internet-based treatment
99001|NCT02449421|trauma
99002|NCT02449382|continuous venovenous hemofiltration
99003|NCT02449382|conventional treatment
99004|NCT02449382|mortality
99005|NCT02449382|acute severe hypernatremia
99006|NCT02449356|ventilation in prone position
99007|NCT02449356|the endotracheal tube shifting and falling
99008|NCT02449317|contrast induced acute kidney injury
99009|NCT02449317|bioimpedance
99010|NCT02449304|endometrial ablation, heavy menstrual bleeding, novosure
99011|NCT02449278|advanced-stage DLBCL
99012|NCT02449278|ISRT
99013|NCT02449278|chemotherapy
99014|NCT02449265|limited-stage DLBCL
99015|NCT02449265|consolidation involved-site radiotherapy
99016|NCT02449265|Chemotherapy
99017|NCT02449252|limited stage FL
99018|NCT02449252|Involved-site Radiotherapy
99019|NCT02449252|Chemotherapy
99020|NCT02449239|Urinary Bladder Cancer
99021|NCT02449239|Non-muscle invasive bladder cancer
99022|NCT02449239|Bladder Neoplasm
99023|NCT02449239|Bladder Tumor
99024|NCT02449239|CIS
99025|NCT02449239|Papillary bladder cancer
99026|NCT02449239|High grade bladder cancer
99027|NCT02449200|cervical radiculopathy
99028|NCT02449200|exercise
99029|NCT02449200|manual therapy
99030|NCT02449200|tape
99031|NCT02449174|C. difficile
99032|NCT02449174|Fecal Microbiota transplantation
99033|NCT02449161|endometrial ablation
99034|NCT02449148|energy restriction
99035|NCT02449148|fasting
99036|NCT02449148|intermittent fast
99037|NCT02449148|cancer prevention
99038|NCT02449148|subcutaneous fat tissue gene expression
99039|NCT02449135|Pancreatic Cancer
99040|NCT02449135|Nano drug
99041|NCT02449122|Lung Cancer
99042|NCT02449122|Nano drug
99043|NCT02449109|Liver Cancer
99044|NCT02449109|Nano drug
99045|NCT02449083|MRI
99046|NCT02449083|Shunt
99047|NCT02449083|COPD
99048|NCT02449083|Dynamic T2 Preparation Puls
99049|NCT02449083|new sequences
99050|NCT02449083|magnet resonance imaging
99051|NCT02449083|ventricular septal defect
99052|NCT02449083|Atrial septal defect
99053|NCT02449070|Nicorandil
99054|NCT02449070|Cardiac MRI
99055|NCT02449044|Hyponatremia
99056|NCT02449018|COPD,
99057|NCT02449018|chronic bronchitis,
99058|NCT02449018|inflammation,
99059|NCT02449018|airway,
99060|NCT02449018|LCI,
99061|NCT02449018|pulmonary function test,
99062|NCT02449018|lung function,
99063|NCT02449018|controlled clinical trial,
99064|NCT02449018|randomized,
99065|NCT02449018|airflow,
99066|NCT02449018|smoker
99067|NCT02449005|regeneration
99068|NCT02449005|stem cells
99069|NCT02449005|infrabony periodontal defect
99070|NCT02449005|fibrin glue
99071|NCT02449005|collagen fleece
99072|NCT02448992|Neurobehavioral Assessments
99073|NCT02448992|Neurocognitive Functions (NCF)
99074|NCT02448992|Prophylactic Cranial Irradiation (PCI)
99075|NCT02448992|Hippocampus
99076|NCT02448992|Hippocampal-Sparing PCI
99077|NCT02448953|Without cervical lymph node involvement
99078|NCT02448940|probiotics
99079|NCT02448940|Lactobacillus
99080|NCT02448940|obesity
99081|NCT02448940|body composition
99082|NCT02448927|transcatheter aortic valve implantation
99083|NCT02448927|Balloon aortic valvuloplasty
99084|NCT02448927|Aortic stenosis
99085|NCT02448927|TAVI
99086|NCT02448927|TAVR (transcatheter aortic valve replacement)
99087|NCT02448927|CoreValve
99088|NCT02448927|BAV
99089|NCT02448927|Evolut R
99090|NCT02448862|IV-PCA
99091|NCT02448862|Elderly patients
99092|NCT02448862|Yound adults
99093|NCT02448862|Side effect
99094|NCT02448862|Postoperative pain
99095|NCT02448862|Postoperative nausea and vomiting
99096|NCT02448849|Autologous
99097|NCT02448849|nonunion fracture
99098|NCT02448849|bone marrow
99099|NCT02448849|mesenchymal
99100|NCT02448849|stromal cell
99101|NCT02448849|platelet lysate product
99102|NCT02448823|HIV
99103|NCT02448823|combined prevention
99104|NCT02448823|demand generation
99105|NCT02448784|Donepezil Hydrochloride
99106|NCT02448784|ARICEPT
99107|NCT02448784|Dementia
99108|NCT02448784|Lewy bodies
99109|NCT02448784|Dementia with Lewy bodies
99110|NCT02448784|Post-marketing surveillance
99111|NCT02448771|Unresectable locally advanced invasive breast cancer
99112|NCT02448771|Metastatic invasive breast cancer
99113|NCT02448758|mutation
99114|NCT02448732|ACM-1
99115|NCT02448732|intravitreal injection
99116|NCT02448732|neovascularization
99117|NCT02448706|hearing aid
99118|NCT02448693|endoscopic mucosal resection
99119|NCT02448693|piecemeal polypectomy scar
99120|NCT02448693|colorectal neoplasms
99121|NCT02448693|Narrow Band Imaging
99122|NCT02448693|chromoendoscopy
99123|NCT02448641|ischemic stroke
99124|NCT02448641|chronic stroke
99125|NCT02448641|fixed motor deficits
99126|NCT02448628|Hypertension
99127|NCT02448628|moderate renal impairment
99128|NCT02448628|mineralocorticoid receptor antagonist
99129|NCT02448628|CS-3150
99130|NCT02448628|Japanese
99131|NCT02448615|Kenya
99132|NCT02448615|Cohort
99133|NCT02448602|Different acupoints compatibility
99134|NCT02448589|Advanced Solid Tumors
99135|NCT02448589|Dose Escalation
99136|NCT02448589|Dose Expansion
99137|NCT02448589|MTD
99138|NCT02448589|TAS-119
99139|NCT02448589|Aurora A Kinase Inhibitor
99140|NCT02448576|phase 3 randomized controlled trial
99141|NCT02448576|prophylactic cranial irradiation
99142|NCT02448576|triple negative breast cancer
99143|NCT02448576|brain metastasis
99144|NCT02448576|advanced breast cancer
99145|NCT02448563|Pregnancy
99146|NCT02448563|African American
99147|NCT02448563|Weight Management Program
99148|NCT02448563|Behavioral Modifications
99149|NCT02448537|Metastatic Sarcoma
99150|NCT02448537|Unresectable Sarcoma
99151|NCT02448537|PM01183
99152|NCT02448524|Treatment
99153|NCT02448524|patients
99154|NCT02448524|primary in situ CHD (de novo) lesions
99155|NCT02448511|ozone gas
99156|NCT02448511|ulcer
99157|NCT02448511|infected ulcer
99158|NCT02448433|Phototherapy
99159|NCT02448433|Light
99160|NCT02448433|Depression
99161|NCT02448433|Sleep and circadian disturbances
99162|NCT02448433|Youth
99163|NCT02448407|Knee osteoarthritis
99164|NCT02448407|Platelet-rich plasma
99165|NCT02448407|Pain's treatment
99166|NCT02448394|community support workers
99167|NCT02448394|retention in care
99168|NCT02448381|CTCL
99169|NCT02448381|Mycosis fungoides
99170|NCT02448381|Hypericin
99171|NCT02448381|SGX301
99172|NCT02448381|MF
99173|NCT02448355|OCT
99174|NCT02448342|Heart Failure
99175|NCT02448342|Remote Patient Monitoring
99176|NCT02448342|Non Invasive Lung Fluid Status Monitor
99300|NCT02447263|Liver Cancer
99177|NCT02448290|gastric adenocarcinoma patients with low/high MEK signature,
99178|NCT02448277|Macintosh laryngoscope, Pentax, Glidescope
99179|NCT02448264|kallikrein inhibitor
99180|NCT02448264|oral prophylaxis
99181|NCT02448264|BioCryst
99182|NCT02448264|first-in-human
99183|NCT02448264|hereditary angioedema
99184|NCT02448238|Human Immunodeficiency Virus
99185|NCT02448238|probiotic
99186|NCT02448238|microbial translocation
99187|NCT02448238|immune activation
99188|NCT02448238|inflammation
99189|NCT02448238|VSL#3
99190|NCT02448238|Mali
99191|NCT02448238|Africa
99192|NCT02448212|PET
99193|NCT02448212|Receptor Occupancy
99194|NCT02448199|pain
99195|NCT02448199|Knee
99196|NCT02448147|Heart failure
99197|NCT02448147|Exercise
99198|NCT02448147|Biomarkers
99199|NCT02448147|Sympathetic Nervous System
99200|NCT02448147|MicroRNA
99201|NCT02448121|Cell therapy
99202|NCT02448121|Sickle cell disease
99203|NCT02448121|Hip Osteonecrosis
99204|NCT02448121|Autologous implantation
99205|NCT02448121|Mesenchymal stromal cell
99206|NCT02448095|Chronic myeloid leukemia
99207|NCT02448095|Philadelphia positive
99208|NCT02448095|Compassionate use
99209|NCT02448082|Dandruff
99210|NCT02448082|Pityriasis capitis
99211|NCT02448082|Ichthyol® Pale
99212|NCT02448082|Sodium shale oil sulponate 1%
99213|NCT02448043|brittleness
99214|NCT02448030|Metaboreflex
99215|NCT02448030|Variation of blood flow
99216|NCT02448030|Functional electrical stimulation
99217|NCT02448030|Isometric exercise.
99218|NCT02448004|Healthy
99219|NCT02448004|JNJ-63623872
99220|NCT02448004|14C-JNJ-63623872
99221|NCT02447965|Rectus Sheath Blocks
99222|NCT02447965|Abdominal Surgery
99223|NCT02447952|Amyotrophic Lateral Sclerosis
99224|NCT02447952|Biotelemetry
99225|NCT02447939|pharmacokinetics
99226|NCT02447939|trametinib
99227|NCT02447939|cutaneous melanoma
99228|NCT02447939|dabrafenib
99229|NCT02447939|safety
99230|NCT02447926|leukapheresis
99231|NCT02447926|regulatory T cells
99232|NCT02447926|liver transplantation
99233|NCT02447913|Family planning
99234|NCT02447913|Voucher
99235|NCT02447913|Immunisations
99236|NCT02447835|Metabolic Disorders
99237|NCT02447809|microRNA
99238|NCT02447809|Platelet
99239|NCT02447809|Clopidogrel low response
99240|NCT02447796|(AVF)
99241|NCT02447796|surgery
99242|NCT02447783|Flavanols
99243|NCT02447783|Cocoa flavanols
99244|NCT02447783|Blood pressure
99245|NCT02447783|Platelet Function
99246|NCT02447770|Flavanols
99247|NCT02447770|Cocoa flavanols
99248|NCT02447770|Blood pressure
99249|NCT02447770|Platelet Function
99250|NCT02447757|Remifentanil, delivery, childbirth, analgesia, parturition, confinement
99251|NCT02447744|depression
99252|NCT02447744|anxiety
99253|NCT02447744|early life stress
99254|NCT02447731|respiratory insufficiency
99255|NCT02447692|Proportional Assist Ventilation
99256|NCT02447692|Pressure Support Ventilation
99257|NCT02447692|Weaning
99258|NCT02447666|Azacitidine
99259|NCT02447666|Myelodysplastic syndrome
99260|NCT02447666|Juvenile myelomonocytic leukemia
99261|NCT02447666|Hematopoietic stem cell transplantation
99262|NCT02447666|Vidaza
99263|NCT02447666|Hypomethylating agent
99264|NCT02447640|Volunteers
99265|NCT02447614|follow up
99266|NCT02447614|Primary Snoring
99267|NCT02447614|Obstructive Sleep Apnea Syndrome
99268|NCT02447588|intrauterine insemination
99269|NCT02447588|progesterone
99270|NCT02447549|IMRT
99271|NCT02447549|IGRT
99272|NCT02447549|Muscle invasive
99273|NCT02447549|Adaptive Radiotherapy
99274|NCT02447536|Immunization
99275|NCT02447536|Morbidity
99276|NCT02447536|Mortality
99277|NCT02447536|BCG
99278|NCT02447484|female sex workers
99279|NCT02447484|HIV sexual risk reduction
99280|NCT02447484|behavior maintenance
99281|NCT02447484|text messaging
99282|NCT02447458|Drug therapy
99283|NCT02447432|Invasive disease by Streptococcus pneumoniae (S. pneumoniae) (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media)
99284|NCT02447432|Infants
99285|NCT02447432|Multidose
99286|NCT02447432|Haemophilus influenzae
99287|NCT02447432|Streptococcus pneumoniae
99288|NCT02447432|Preservative
99289|NCT02447432|Safety
99290|NCT02447432|Pneumonia
99291|NCT02447432|Immunogenicity
99292|NCT02447432|Pneumococcal conjugate vaccine
99293|NCT02447432|Acute otitis media caused by non-typeable Haemophilus influenzae (NTHi).
99294|NCT02447432|Respiratory tract infections
99295|NCT02447367|α1-blockers
99296|NCT02447367|antimuscarinic agent
99297|NCT02447315|Pilocarpine
99298|NCT02447289|Dental caries
99299|NCT02447289|Moderate sedation
99301|NCT02447263|HepaSphere
99302|NCT02447250|Bronchopulmonary dysplasia
99303|NCT02447250|very low birth weight
99304|NCT02447250|albuterol
99305|NCT02447250|pulmonary function test
99306|NCT02447237|liquid diet
99307|NCT02447237|solid diet
99308|NCT02447224|appendicitis
99309|NCT02447224|non operative management
99310|NCT02447224|appendectomy
99311|NCT02447185|Lucentis
99312|NCT02447185|Ranibizumab
99313|NCT02447185|Triamcinolone Acetonide
99314|NCT02447185|Vitrectomy
99315|NCT02447185|PDR
99316|NCT02447185|25-Gauge Vitrectomy
99317|NCT02447159|Nigeria
99318|NCT02447159|Developing Countries
99319|NCT02447159|Hospitals, Maternity/Utilization
99320|NCT02447159|Hospitals/Economics
99321|NCT02447159|HIV
99322|NCT02447133|no known ocular pathology
99323|NCT02447120|Volunteers with Healthy Eyes
99324|NCT02447107|Chronic Pain
99325|NCT02447107|Technology
99326|NCT02447107|Mobile Phone Applications
99327|NCT02447094|ischemic
99328|NCT02447094|tPA
99329|NCT02447094|tele-medicine
99330|NCT02447094|robot
99331|NCT02447094|tele-stroke
99332|NCT02447042|sepsis
99333|NCT02447042|Fluids
99334|NCT02447042|Mean systemic filling pressure
99335|NCT02447029|abortion
99336|NCT02447029|pain management
99337|NCT02447003|PD1
99338|NCT02447003|PDL1
99339|NCT02447003|PD-L1
99340|NCT02446977|ischemic
99341|NCT02446977|stroke
99342|NCT02446977|vitamin B2
99343|NCT02446938|mechanical ventilation
99344|NCT02446938|esophageal pressure
99345|NCT02446938|catheter position
99346|NCT02446938|validation
99347|NCT02446912|Active Systemic Lupus Erythematosus
99348|NCT02446899|Active Systemic Lupus Erythematosus
99349|NCT02446886|Multiple Sclerosis
99350|NCT02446886|MS
99351|NCT02446886|RRMS
99352|NCT02446886|SPMS
99353|NCT02446886|ACTH
99354|NCT02446873|children
99355|NCT02446873|Ecuador
99356|NCT02446873|rural
99357|NCT02446873|poor
99358|NCT02446847|HIV
99359|NCT02446847|3BNC117
99360|NCT02446847|Broadly neutralizing antibody
99361|NCT02446834|PCOS
99362|NCT02446834|intensive lifestyle intervention
99363|NCT02446834|IGT
99364|NCT02446834|drugs treatment
99365|NCT02446795|Renal cell carcinoma
99366|NCT02446795|Isoquercetin
99367|NCT02446795|kidney cancer
99368|NCT02446795|sunitinib
99369|NCT02446795|fatigue
99370|NCT02446782|thoracoscopy
99371|NCT02446782|pleuroscopy
99372|NCT02446782|antibiotic prophylaxis
99373|NCT02446782|pleural effusion
99374|NCT02446756|Osteoarthritis
99375|NCT02446756|MRI
99376|NCT02446756|Cartilage
99377|NCT02446756|Acupuncture
99378|NCT02446743|Nervous System Diseases
99379|NCT02446743|Meningitis
99380|NCT02446743|Central Nervous System Diseases
99381|NCT02446717|HCV GT5
99382|NCT02446717|Interferon (IFN) free
99383|NCT02446717|Hepatitis C
99384|NCT02446717|HCV Genotype 4
99385|NCT02446717|HCV Genotype 5
99386|NCT02446717|HCV
99387|NCT02446717|HCV Genotype 6
99388|NCT02446717|Chronic Hepatitis C
99389|NCT02446717|HCV Genotype 1
99390|NCT02446717|Chronic HCV
99391|NCT02446717|Hepatitis C Genotype 1
99392|NCT02446717|HCV GT4
99393|NCT02446717|HCV GT1
99394|NCT02446704|Small Cell Lung Cancer
99395|NCT02446704|SCLC
99396|NCT02446678|Gastrointestinal bleeding
99397|NCT02446678|emergency department
99398|NCT02446678|PillCam ESO2
99399|NCT02446652|Advanced cervical cancer
99400|NCT02446652|Epigenetic therapy
99401|NCT02446652|Randomized phase III
99402|NCT02446626|Lyme Disease
99403|NCT02446626|Ixodes scapularis
99404|NCT02446626|Borrelia Burgdorferi
99405|NCT02446626|Post treatment
99406|NCT02446626|Infection
99407|NCT02446613|Allergic Rhinitis
99408|NCT02446613|Nasal allergen challenge
99409|NCT02446613|Allergic Asthma
99410|NCT02446613|Effect on Allergen Reactivity
99411|NCT02446587|endovascular therapy
99412|NCT02446587|thrombectomy
99413|NCT02446587|selection
99414|NCT02446587|imaging
99415|NCT02446587|perfusion
99416|NCT02446587|collaterals
99417|NCT02446587|ASPECTS
99418|NCT02446574|chemoradiation
99419|NCT02446574|dose escalation
99420|NCT02446561|Healthy Volunteer
99421|NCT02446561|Pharmacokinetics
99422|NCT02446548|direct renin inhibitor
99423|NCT02446548|kidney transplantation
99424|NCT02446548|albuminuria
99425|NCT02446496|Bioequivalence
99426|NCT02446496|film coated tablets
99427|NCT02446496|cefadroxil
99428|NCT02446483|PARIET 20 mg
99429|NCT02446483|Rabeprazole
99430|NCT02446483|Idiazole 20mg
99431|NCT02446483|bioequivalence
99432|NCT02446470|calcaneus
99433|NCT02446470|fracture fixation, internal
99434|NCT02446457|Lymphoma
99435|NCT02446457|Follicular lymphoma
99436|NCT02446457|FL
99437|NCT02446457|Relapsed
99438|NCT02446457|Rituximab
99439|NCT02446457|Rituxan
99440|NCT02446457|Pembrolizumab
99441|NCT02446457|Keytruda
99442|NCT02446457|MK-3475
99443|NCT02446457|SCH-900475
99444|NCT02446444|High risk
99445|NCT02446444|clinically localised prostate cancer
99446|NCT02446431|Metronomic Drug Therapy
99447|NCT02446418|dry powder inahler
99448|NCT02446418|vilanerol
99449|NCT02446418|efficacy
99450|NCT02446418|safety
99451|NCT02446418|fluticasone furoate
99452|NCT02446418|quality of life
99453|NCT02446405|metastatic prostate cancer
99454|NCT02446405|prostate cancer
99455|NCT02446405|prostate cancer treatment
99456|NCT02446405|enzalutamide
99457|NCT02446353|Male Volunteers
99458|NCT02446340|ShK-186
99459|NCT02446340|dalazatide
99460|NCT02446340|Kv1.3
99461|NCT02446340|SHK
99462|NCT02446301|Nalbuphine
99463|NCT02446301|SDE
99464|NCT02446301|dinalbuphine
99465|NCT02446301|SDN
99466|NCT02446301|pain
99467|NCT02446301|LT1001
99468|NCT02446275|efficacy, manual therapy, migraine, quality of life
99469|NCT02446262|Pain
99470|NCT02446262|Visual Analogue Pain Scale
99471|NCT02446262|Placebo
99472|NCT02446262|Affective Neuroscience
99473|NCT02446262|Functional Magnetic Resonance Imaging (fMRI)
99474|NCT02446249|Gene Therapy
99475|NCT02446249|Xerostomia
99476|NCT02446223|Actinic Keratosis AKs Chest Pre-Cancer
99477|NCT02446210|SCI
99478|NCT02446210|Neural Control
99479|NCT02446210|Bilateral Movement
99480|NCT02446210|TMS
99481|NCT02446184|urethral obstruction
99482|NCT02446184|posterior urethral valves
99483|NCT02446184|lower urinary tract obstruction
99484|NCT02446171|naloxegol tablet crushed
99485|NCT02446171|naloxegol oral solution
99486|NCT02446171|naloxegol whole tablet
99487|NCT02446171|relative bioavailability
99488|NCT02446171|Phase I
99489|NCT02446171|healthy subjects
99490|NCT02446106|Monosodium L-Glutamate (MSG)
99491|NCT02446106|Satiety
99492|NCT02446106|Soups
99493|NCT02446106|Energy Intake
99494|NCT02446106|Snack Intake
99495|NCT02446093|pancreas
99496|NCT02446093|pancreatic adenocarcinoma
99497|NCT02446093|GMCI
99498|NCT02446093|AdV-tk
99499|NCT02446093|aglatimagene besadenovec
99500|NCT02446080|Constipation
99501|NCT02446080|Probiotics
99502|NCT02446080|Women
99503|NCT02446067|Transcranial Doppler (TCD) sonography
99504|NCT02446067|rTMS
99505|NCT02446067|Cerebral hemodynamics
99506|NCT02446054|T2DM, type II diabetes Mellitus, HbA1c
99507|NCT02446041|COPD
99508|NCT02446041|Chronic Bronchitis
99509|NCT02446041|Pulmonary Emphysema
99510|NCT02446002|Volunteer
99511|NCT02445989|HIV
99512|NCT02445989|Contraceptive Vaginal Ring
99513|NCT02445989|Bacterial Vaginosis
99514|NCT02445976|mCRPC
99515|NCT02445976|metastatic
99516|NCT02445976|castration-resistant prostate cancer
99517|NCT02445950|Coaching
99518|NCT02445950|Well-being
99519|NCT02445950|Digital Health
99520|NCT02445950|Profiling
99521|NCT02445950|Customer Satisfaction
99522|NCT02445950|User Experience
99523|NCT02445950|Occupational Health
99524|NCT02445950|Lifestyle
99525|NCT02445950|Psychological Stress
99526|NCT02445950|Cost-Effectiveness
99527|NCT02445950|Guideline Adherence
99528|NCT02445937|decision making for incapacitated patients
99529|NCT02445937|intensive care
99530|NCT02445937|surrogate decision making
99531|NCT02445937|patient centered care
99532|NCT02445937|palliative care
99533|NCT02445924|genetic signature
99534|NCT02445924|non-small cell lung cancer
99535|NCT02445924|micro RNA
99536|NCT02445898|Glucocorticoid
99537|NCT02445898|Orthostatic Intolerance
99538|NCT02445898|Heart Rate Variability
99539|NCT02445898|Hip arthroplasty, total
99540|NCT02445885|Myocardial infarction
99541|NCT02445885|Late presenters
99542|NCT02445885|Primary percutaneous coronary intervention
99543|NCT02445885|Reperfusion
99544|NCT02445885|Angioplasty
99545|NCT02445885|Duration of ischemia
99546|NCT02445885|Cardiovascular magnetic resonance imaging
99547|NCT02445872|Nausea
99548|NCT02445872|Vomiting
99549|NCT02445872|Chemotherapy-induced Nausea and Vomiting
99550|NCT02445872|CINV
99551|NCT02445872|Aprepitant
99552|NCT02445872|Lung cancer
99553|NCT02445859|Antibiotic
99554|NCT02445859|prophylaxis
99555|NCT02445859|surgical site infection
99556|NCT02445833|Obesity
99557|NCT02445833|Internet intervention
99558|NCT02445833|Cardiovascular disease
99559|NCT02445833|Hypertension
99560|NCT02445833|Lifestyle intervention
99561|NCT02445833|Weight loss treatment
99562|NCT02445755|Neonates
99563|NCT02445755|Bilicare System
99564|NCT02445742|Chronic Myeloblastic Leukaemia
99565|NCT02445729|Cesarean Section
99566|NCT02445729|Wound Healing
99567|NCT02445677|TENS
99568|NCT02445677|chronic pain
99569|NCT02445677|rehabilitation
99570|NCT02445664|Patient education
99571|NCT02445664|Video intervention
99572|NCT02445651|Integrative Medicine
99573|NCT02445651|Alternative Medicine
99574|NCT02445651|Complementary Medicine
99575|NCT02445651|Parkinson's disease
99576|NCT02445651|Neurodegenerative Diseases
99577|NCT02445651|Idiopathic Parkinson's disease
99578|NCT02445651|Single Photon Emission Computed Tomography (SPECT)
99579|NCT02445651|Central Nervous System Diseases
99580|NCT02445651|Movement Disorders
99581|NCT02445651|Nervous System Diseases
99582|NCT02445651|Brain Diseases
99583|NCT02445651|Oral supplements
99584|NCT02445651|N-acetyl cysteine
99585|NCT02445612|SMD
99586|NCT02445612|long term follow-up
99587|NCT02445612|fundus flavimaculatus
99588|NCT02445612|juvenile macular dystrophy
99589|NCT02445599|thoracotomy
99590|NCT02445599|pain management
99591|NCT02445599|analgesia
99592|NCT02445599|postoperative care
99593|NCT02445599|premedication
99594|NCT02445599|preventive
99595|NCT02445573|stress urinary incontinence
99596|NCT02445573|electroacupuncture
99597|NCT02445573|efficacy
99598|NCT02445560|probiotics
99599|NCT02445560|prebiotics
99600|NCT02445560|high protein diet
99601|NCT02445560|microbiota
99602|NCT02445534|Cell Therapy
99603|NCT02445456|Rectal cancer
99604|NCT02445456|Sentinel Lymph Node Biopsy
99605|NCT02445417|Perinatal depression
99606|NCT02445378|Aromatherapy
99607|NCT02445378|essential oils
99608|NCT02445378|Acute Leukemia
99609|NCT02445365|Ulcerative colitis
99610|NCT02445365|Remote ischemic conditioning
99611|NCT02445339|Alcohol Dependence
99612|NCT02445339|Alcohol Use Disorder
99613|NCT02445339|Care Management
99614|NCT02445339|Case Management
99615|NCT02445339|Emergency Care Services
99616|NCT02445339|Emergency Department
99617|NCT02445339|Emergency Room
99618|NCT02445339|Extended-release naltrexone
99619|NCT02445339|Frequent Users
99620|NCT02445339|Health Care Utilization
99621|NCT02445339|Medical Management
99622|NCT02445339|Naltrexone
99623|NCT02445339|Population Health
99624|NCT02445339|Public Health
99625|NCT02445339|Vivitrol
99626|NCT02445339|XR-NTX
99627|NCT02445339|XR-NTX+CM
99628|NCT02445339|Alcoholism
99629|NCT02445339|Alcohol-Related Disorders
99630|NCT02445339|Central Nervous System Agents
99631|NCT02445339|Chemically-Induced Disorders
99632|NCT02445339|Clinical Trial
99633|NCT02445339|Emergency Medicine
99634|NCT02445339|Mental Disorders
99635|NCT02445339|Narcotic Antagonists
99636|NCT02445339|Peripheral Nervous System Agents
99637|NCT02445339|Pharmacologic Actions
99638|NCT02445339|Physiological Effects of Drugs
99639|NCT02445339|Sensory System Agents
99640|NCT02445339|Substance-Related Disorders
99641|NCT02445300|dressing
99642|NCT02445300|TKA
99643|NCT02445261|MOBILE PHONE ON AND IN AND
99644|NCT02445261|UMBILICAL ARTERY DOPPLER
99645|NCT02445261|FETAL CARDIOTOCOGRAPHY
99646|NCT02445261|GROWTH RESTRICTED FETUS
99647|NCT02445261|NORMAL GROWTH FETUS
99648|NCT02445248|Diffuse large B-cell lymphoma,
99649|NCT02445248|DLBCL,
99650|NCT02445248|Relapsed/refractory,
99651|NCT02445248|CTL019
99652|NCT02445248|CART19
99653|NCT02445248|CART
99654|NCT02445248|CAR T cells
99655|NCT02445248|Chimeric antigen receptor
99656|NCT02445235|pain
99657|NCT02445235|wound care
99658|NCT02445235|fungal infections
99659|NCT02445235|scars
99660|NCT02445235|chronic pain
99661|NCT02445235|outcomes
99662|NCT02445235|PRO
99663|NCT02445209|HER2-negative gastric and GEJ adenocarcinoma
99664|NCT02445209|first-line palliative chemotherapy
99665|NCT02445209|EOX
99666|NCT02445209|mDCF
99667|NCT02445209|efficacy
99668|NCT02445209|safety
99669|NCT02445170|Diabetes
99670|NCT02445170|amputation
99671|NCT02445170|below-knee
99672|NCT02445170|transmetatarsal
99673|NCT02445170|[M01.150.100]
99674|NCT02445170|[C19.246.099]
99675|NCT02445157|Gait speed
99676|NCT02445157|Functional outcome measure
99677|NCT02445144|Inflammation
99678|NCT02445144|Blood Flow
99679|NCT02445144|Cognition
99680|NCT02445131|CLL
99681|NCT02445118|adipose, allograft
99682|NCT02445092|Intrauterine insemination
99683|NCT02445092|Insemination catheter prewashing
99684|NCT02445092|Pregnancy outcome
99685|NCT02445066|Vitamin D
99686|NCT02445053|Cystic Fibrosis
99687|NCT02445040|High Frequency Oscillatory Ventilation
99688|NCT02445040|Infant, Very Low Birth Weight
99689|NCT02445040|Periventricular Leukomalacia
99690|NCT02445040|Intraventricular Hemorrhage
99691|NCT02445040|multi-center study
99692|NCT02445027|Primary Care
99693|NCT02445027|Healthy
99694|NCT02445014|Barrett's
99695|NCT02445014|GERD
99696|NCT02445014|Capsule
99697|NCT02445014|SECM
99698|NCT02444988|crystalloid
99699|NCT02444988|acute kidney injury
99700|NCT02444975|Urinary Tract Infections
99701|NCT02444975|Water intake
99702|NCT02444936|solid tumor
99703|NCT02444936|chemotherapy
99704|NCT02444936|vaccine
99705|NCT02444923|Corneal rigid gas permeable contact lenses
99706|NCT02444923|Scleral rigid gas permeable contact lenses
99707|NCT02444923|Custom Scleral contact lenses
99708|NCT02444923|Irregular cornea
99709|NCT02444923|Keratoconus
99710|NCT02444923|Pellucid marginal degeneration
99711|NCT02444923|Post keratoplasty irregular cornea
99712|NCT02444923|Post refractive surgery irregular cornea
99713|NCT02444923|Traumatic irregular cornea
99714|NCT02444910|KDT501
99715|NCT02444910|Diabetes
99716|NCT02444910|Diabetes Mellitus
99717|NCT02444910|Type 2
99718|NCT02444910|KinDex
99719|NCT02444897|Gastric cancer
99720|NCT02444897|epidural
99721|NCT02444897|PCA
99722|NCT02444897|laparoscopy
99723|NCT02444871|IgM-enriched immunoglobulins
99724|NCT02444871|endotoxin activity assay
99725|NCT02444871|thrombelastometry
99726|NCT02444871|aggregometry
99727|NCT02444858|paraquat poisoning
99728|NCT02444858|lung injury
99729|NCT02444858|stem cell therapy
99730|NCT02444858|human umbilical cord mesenchymal stem cell
99731|NCT02444858|phase 1/2 clinical study
99732|NCT02444858|allogeneic stem cell transplantation
99733|NCT02444819|HM61713
99734|NCT02444819|Epidermal Growth Factor Receptor mutation positive NSCLC
99735|NCT02444819|olmutinib
99736|NCT02444806|Sleep disordered breathing
99737|NCT02444806|Domiciliary NIV
99738|NCT02444741|Lung Cancer
99739|NCT02444741|Non-small cell lung cancer
99740|NCT02444741|NSCLC
99741|NCT02444741|Metastatic
99742|NCT02444741|Pembrolizumab
99743|NCT02444741|Keytruda
99744|NCT02444741|MK-3475
99745|NCT02444741|SCH-900475
99746|NCT02444741|Stereotactic body radiation therapy
99747|NCT02444741|SBRT
99748|NCT02444741|Wide-field radiation therapy
99749|NCT02444741|WFRT
99750|NCT02444741|Radiation therapy
99751|NCT02444741|XRT
99752|NCT02444728|thrombocytopenia
99753|NCT02444728|systemic lupus erythematosus
99754|NCT02444728|hydroxychloroquine
99755|NCT02444728|cyclophosphamide
99756|NCT02444728|remission
99757|NCT02444715|Lifestyle coaching
99758|NCT02444715|Phone-based system
99759|NCT02444715|CVD prevention
99760|NCT02444715|Patient-centered decision support
99761|NCT02444702|spinal stenosis, clinical predictors rules, MRI, fusion, low back pain
99762|NCT02444689|Blood pressure
99763|NCT02444689|Cardiovascular disease
99764|NCT02444689|Children
99765|NCT02444689|Adolescent
99766|NCT02444689|Pediatrics
99767|NCT02444689|End-organ damage
99768|NCT02444650|Correlation
99769|NCT02444650|pulse wave velocity measurement
99770|NCT02444650|tonometry
99771|NCT02444624|necrotizing enterocolitis
99772|NCT02444624|Clostridium
99773|NCT02444624|premature birth
99774|NCT02444611|neonates
99775|NCT02444611|BCG
99776|NCT02444611|Hepatitis B vaccine
99777|NCT02444611|vaccines
99778|NCT02444611|immunity
99779|NCT02444611|immune response
99780|NCT02444611|Bacille- Calmette-Guerin
99781|NCT02444598|wounds
99782|NCT02444598|negative-pressure wound therapy
99783|NCT02444598|conflict
99784|NCT02444598|gunshot wound
99785|NCT02444598|blast injuries
99786|NCT02444598|civilian
99787|NCT02444598|war
99788|NCT02444559|Volunteers
99789|NCT02444533|Liposomal Bupivacaine
99790|NCT02444481|Mycotic Vaginitis
99791|NCT02444455|cellular therapy
99792|NCT02444455|acute lung injury
99793|NCT02444455|acute respiratory distress snydrome
99794|NCT02444455|human umbilical cord mesenchymal stem cell
99795|NCT02444455|phase 1/2 clinical study
99796|NCT02444455|allogeneic stem cell transplantation
99797|NCT02444455|ALI
99798|NCT02444455|ARDS
99799|NCT02444442|Renal denervation
99800|NCT02444442|Blood pressure
99801|NCT02444442|Cardiovascular risk
99802|NCT02444442|Target organ damage
99803|NCT02444442|Sympathetic activity
99804|NCT02444442|Non-compliance
99805|NCT02444429|Screening renal biopsy
99806|NCT02444429|Immunosuppression
99807|NCT02444403|HIV
99808|NCT02444403|Viral hepatitis
99809|NCT02444403|HCV
99810|NCT02444403|Needle-stick injury
99811|NCT02444403|Needle/syringes
99812|NCT02444403|Structural intervention
99813|NCT02444403|Stepped wedge
99814|NCT02444403|Police
99815|NCT02444403|Occupational safety
99816|NCT02444403|Police Training
99817|NCT02444390|Failed non steroidal aromatases inhibitors
99818|NCT02444390|Eligible for everolimus+exemestane
99819|NCT02444364|diabetes
99820|NCT02444364|bone loss
99821|NCT02444364|Bone Density
99822|NCT02444325|group prenatal care
99823|NCT02444325|CenteringPregnancy
99824|NCT02444325|diabetes
99825|NCT02444312|Caregiving
99826|NCT02444312|Benefit Finding
99827|NCT02444312|Writing Intervention
99828|NCT02444273|liver diseases
99829|NCT02444273|liver transplantation
99830|NCT02444273|preoperative care
99831|NCT02444273|physical therapy
99832|NCT02444260|Inguinal Hernia,
99833|NCT02444260|Local Anesthesia
99834|NCT02444260|Randomized Clinical trial
99835|NCT02444260|HERNIOPLASTY
99836|NCT02444221|Atrial Fibrillation
99837|NCT02444221|Rivaroxaban
99838|NCT02444221|Stroke
99839|NCT02444195|gynecologic cancer
99840|NCT02444195|guided imagery
99841|NCT02444195|postoperative distress
99842|NCT02444195|perioperative distress
99843|NCT02444143|Kidney
99844|NCT02444143|Immunosuppression
99845|NCT02444143|Transplant
99846|NCT02444130|multifocality
99847|NCT02444130|monovision
99848|NCT02444117|neurophysiology
99849|NCT02444104|Left Ventricular Assist Device
99850|NCT02444091|Chronic Fatigue Syndrome
99851|NCT02444091|Myalgic Encephalomyelitis (ME)
99852|NCT02444091|Cyclophosphamide
99853|NCT02444091|Immunomodulatory treatment
99854|NCT02444091|CFS
99855|NCT02444078|Alzheimer Disease
99856|NCT02444078|Dementia
99857|NCT02444078|Physical activity
99858|NCT02444078|Functional ability
99859|NCT02444078|Disability
99860|NCT02444078|Functional limitation
99861|NCT02444065|Cognitive behavior therapy
99862|NCT02444065|Motivational interviewing
99863|NCT02444065|Bulimia nervosa
99864|NCT02444065|Rapid response
99865|NCT02444013|Contrast induced nephropathy
99866|NCT02444000|chemotherapy
99867|NCT02444000|PCV
99868|NCT02444000|radiotherapy
99869|NCT02444000|post operative treatment
99870|NCT02444000|anaplastic gliomas
99871|NCT02444000|1p/19q codeletion
99872|NCT02444000|cognition
99873|NCT02443987|Tension-Free Vaginal Tape
99874|NCT02443961|Bronchopulmonary dysplasia
99875|NCT02443961|pulmonary hypertension
99876|NCT02443961|stem cell therapy
99877|NCT02443961|mesenchymal stem cells
99878|NCT02443961|very low weight preterm babies
99879|NCT02443922|type 2 diabetes
99880|NCT02443922|beta cell function
99881|NCT02443922|meal tolerance test (MTT)
99882|NCT02443922|maximal stimulation test (MaxStim)
99883|NCT02443922|method standardization
99884|NCT02443922|insulin secretion
99885|NCT02443922|prediabetes
99886|NCT02443922|insulin sensitivity
99887|NCT02443922|glimepiride
99888|NCT02443922|sitagliptin
99889|NCT02443922|metformin
99890|NCT02443909|Holmium Laser
99891|NCT02443909|Kidney Stones
99892|NCT02443909|RIRS
99893|NCT02443883|stomach cancer
99894|NCT02443844|BPH
99895|NCT02443844|bladder cancer
99896|NCT02443844|treatment
99897|NCT02443844|recurrence
99898|NCT02443844|progression
99899|NCT02443831|high risk relapsed CD19+ hematological malignancies
99900|NCT02443766|Integrative Medicine
99901|NCT02443766|Alternative Medicine
99902|NCT02443766|Complementary Medicine
99903|NCT02443766|Meditation Retreat
99904|NCT02443766|Ignatian Retreat
99905|NCT02443766|Single Photon Emission Computed Tomography (SPECT)
99906|NCT02443766|Functional Magnetic Resonance Imaging (fMRI)
99907|NCT02443766|Wellbeing
99908|NCT02443766|General Health
99909|NCT02443740|First in human
99910|NCT02443740|Single Ascending Dose Study
99911|NCT02443740|Safety and Tolerability
99912|NCT02443740|Pharmacokinetics
99913|NCT02443740|Plasma
99914|NCT02443740|Cerebrospinal Fluid
99915|NCT02443714|Needle-Free Jet Injection
99916|NCT02443714|Insulin Lispro
99917|NCT02443714|pharmacokinetics
99918|NCT02443714|pharmacodynamics
99919|NCT02442674|Hyponatremia
99920|NCT02442674|Euvolemic
99921|NCT02442674|Hypervolemic
99922|NCT02442674|Serum sodium
99923|NCT02442674|Dilutional hyponatremia
99924|NCT02442674|Electrolyte abnormality
99925|NCT02442674|Electrolyte imbalance
99926|NCT02442674|Metabolic disease
99927|NCT02442674|Water-Electrolyte Imbalance
99928|NCT02442648|Renal Transplantation
99929|NCT02442648|Carfilzomib
99930|NCT02442648|Kyprolis
99931|NCT02442648|Desensitization
99932|NCT02442622|de Quervain's disease
99933|NCT02442622|de Quervain's tenosynovitis.
99934|NCT02442622|ASTYM
99935|NCT02442622|de Quervain's treatment
99936|NCT02442609|internet
99937|NCT02442609|anesthesia
99938|NCT02442609|information
99939|NCT02442609|surgery
99940|NCT02442609|question
99941|NCT02442596|Abdominal sepsis
99942|NCT02442596|Sepsis
99943|NCT02442596|Septic shock
99944|NCT02442596|Epidemiology
99945|NCT02442596|Etiology
99946|NCT02442596|Microbiology
99947|NCT02442596|Abdomen
99948|NCT02442596|Intra-abdominal
99949|NCT02442596|Infection
99950|NCT02442596|Gastrointestinal tract
99951|NCT02442596|Perforation
99952|NCT02442596|Peritonitis
99953|NCT02442596|Pancreas
99954|NCT02442596|Biliary tract
99955|NCT02442596|Megacolon
99956|NCT02442583|colorectal cancer
99957|NCT02442583|survivor
99958|NCT02442583|exercise
99959|NCT02442583|physical activity
99960|NCT02442583|sedentary
99961|NCT02442570|alpha B-crystallin
99962|NCT02442570|immune tolerance
99963|NCT02442557|alpha B-crystallin
99964|NCT02442557|immune tolerance
99965|NCT02442518|placenta accreta
99966|NCT02442518|placenta previa
99967|NCT02442518|ultrasound
99968|NCT02442505|Atrial Fibrillation; Pacemaker; Device-detected
99969|NCT02442492|sildenafil
99970|NCT02442492|IUGR
99971|NCT02442492|FGR
99972|NCT02442492|STRIDER
99973|NCT02442479|exercise
99974|NCT02442479|resistance training
99975|NCT02442479|muscle strength
99976|NCT02442479|muscle hypertrophy
99977|NCT02443636|Depression
99978|NCT02443636|Mental Health
99979|NCT02443636|Registry
99980|NCT02443636|Reliability
99981|NCT02443636|Post Traumatic Stress Disorder
99982|NCT02443636|Bipolar Disorder
99983|NCT02443636|Mood disorder
99984|NCT02443636|Suicide
99985|NCT02443610|Postpartum Hemorrhage
99986|NCT02443610|Venous Thromboembolism
99987|NCT02443610|Pregnancy
99988|NCT02443597|ultrasound
99989|NCT02443597|trisomy screening
99990|NCT02443597|obesity
99991|NCT02443584|depression
99992|NCT02443584|pharmacogenetics
99993|NCT02443584|pharmacogenomics
99994|NCT02443584|major depressive disorder
99995|NCT02443584|genetics
99996|NCT02443584|anti-depressants
99997|NCT02443571|observational study
99998|NCT02443558|Robotics
99999|NCT02443558|Cerebral cortex
100000|NCT02443558|Brain waves
100001|NCT02443558|Electroencephalography
100002|NCT02443558|Rehabilitation
100003|NCT02443558|Brain-Computer Interfaces
100004|NCT02443545|Iron overload
100005|NCT02443545|Sickle cell disease
100006|NCT02443545|Deferiprone
100007|NCT02443545|Ferriprox
100008|NCT02443545|Iron chelation
100009|NCT02443519|Mindfulness
100010|NCT02443519|MBCT
100011|NCT02443519|Cognitive Therapy
100012|NCT02443519|Disability
100013|NCT02443428|Breast Cancer
100014|NCT02443402|Non diabetic hyperglycemia
100015|NCT02443389|nephrotoxic
100016|NCT02443389|Fluid overload
100017|NCT02443389|Acute renal failure
100018|NCT02443389|Prematurity
100019|NCT02443389|Risk factors
100020|NCT02443389|Epidemiology
100021|NCT02443324|immuno-oncology
100022|NCT02443324|Vascular Endothelial Growth Factor (VEGF)
100023|NCT02443324|angiogenesis
100024|NCT02443324|PD-1
100025|NCT02443324|carcinoma of the bladder
100026|NCT02443324|carcinoma of the urethra
100027|NCT02443324|carcinoma of the ureter
100028|NCT02443324|carcinoma of the renal pelvis
100029|NCT02443324|carcinoma of the biliary tract
100030|NCT02443298|ABBV-066
100031|NCT02443298|BI 655066
100032|NCT02443298|risankizumab
100033|NCT02443259|NAPI
100034|NCT02443259|late preterm
100035|NCT02443207|Toothache
100036|NCT02443207|Quality of life
100037|NCT02443207|Oral Health
100038|NCT02443207|Children
100039|NCT02443194|depression
100040|NCT02443194|glioblastoma
100041|NCT02443181|Essential tremor; closed-loop DBS
100042|NCT02443168|Pharmacokinetic
100043|NCT02443168|Healthy
100044|NCT02443168|Male
100045|NCT02443168|AG-221
100046|NCT02443168|[14C]
100047|NCT02443168|Single dose
100048|NCT02443168|Oral
100049|NCT02443168|Intravenous
100050|NCT02443142|mild TBI
100051|NCT02443142|concussion
100052|NCT02443142|post-concussion syndrome
100053|NCT02443103|pilot study
100054|NCT02443103|guanabenz acetate
100055|NCT02443090|secondary hypogonadism
100056|NCT02443090|sexual dysfunction
100057|NCT02443090|erectile dysfunction
100058|NCT02443064|Pharmacokinetics/pharmacodynamics
100059|NCT02443064|vancomycin
100060|NCT02443064|blood stream infections
100061|NCT02443064|Chinese patients
100062|NCT02443064|MRSA
100063|NCT02443038|patient fall
100064|NCT02443038|yoga
100065|NCT02443038|balance
100066|NCT02443012|Diabetic Macular Edema
100067|NCT02443012|Nepafenac
100068|NCT02443012|Laser therapy
100069|NCT02443012|Clinically significant macular edema
100070|NCT02443012|Adjunct Treatment
100071|NCT02443012|Topical Nepafenac
100072|NCT02442986|weaning failure
100073|NCT02442986|polyneuropathy
100074|NCT02442986|encephalopathy
100075|NCT02442986|sepsis
100076|NCT02442947|stress when dressed
100077|NCT02442947|protective garment
100078|NCT02442947|work clothes
100079|NCT02442934|Critical Care
100080|NCT02442934|Critical Care Nursing
100081|NCT02442934|Discomfort
100082|NCT02442934|Sleep deprivation
100083|NCT02442934|Noise
100084|NCT02442934|Thirst
100085|NCT02442934|Pain
100086|NCT02442895|mature oocytes
100087|NCT02442895|antral follicles count
100088|NCT02442895|follicle stimulating hormone
100089|NCT02442895|antimullerian hormone
100090|NCT02442882|Brain Concussion
100091|NCT02442882|Balance
100092|NCT02442882|Locomotion
100093|NCT02442882|Mild Traumatic Brain Injury
100094|NCT02442869|Suicide
100095|NCT02442817|DPP-4 Inhibitor
100096|NCT02442817|Linagliptin
100097|NCT02442817|SDF1-α
100098|NCT02442804|Pomegranate
100099|NCT02442804|Stroke
100100|NCT02442804|Neuropsychology
100101|NCT02442791|Cardiac arrest
100102|NCT02442791|GLP-1
100103|NCT02442791|Neuroprotection
100104|NCT02442752|Drug therapy
100105|NCT02442739|Ketamine
100106|NCT02442739|Prevention of depression
100107|NCT02442726|Heat Injury
100108|NCT02442726|Humans
100109|NCT02442726|Laser Stimulation
100110|NCT02442726|Quantitative Sensory Testing
100111|NCT02442726|Reaction Time
100112|NCT02442726|Secondary Hyperalgesia
100113|NCT02442726|Thermal Thresholds
100114|NCT02442713|Polysomnograph
100115|NCT02442713|fluvoxamine
100116|NCT02442700|HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir
100117|NCT02442440|anisodamine
100118|NCT02442440|septic shock
100119|NCT02442427|Respiratory syncytial virus
100120|NCT02442427|Palivizumab
100121|NCT02442427|Bronchiolitis
100122|NCT02442427|Treatment
100123|NCT02442414|Cancer
100124|NCT02442414|Advanced Solid Tumors
100125|NCT02442414|EGFR
100126|NCT02442414|HER2
100127|NCT02442414|HER3
100128|NCT02442414|HER4
100129|NCT02442414|ALK mutations
100130|NCT02442414|irreversible tyrosine kinase inhibitor
100131|NCT02442414|Metastatic Non Small Cell Lung Cancer
100132|NCT02442414|Gastric Cancer
100133|NCT02442414|Colorectal Cancer
100134|NCT02442388|pain
100135|NCT02442388|root canal therapy
100136|NCT02442388|endodontics
100137|NCT02442388|file
100138|NCT02442375|head and neck cancer
100139|NCT02442375|accelerated radiotherapy
100140|NCT02442375|dose reduction
100141|NCT02442375|dose de-escalation
100142|NCT02442375|elective lymph nodes
100143|NCT02442375|FDG-PET
100144|NCT02442349|Phase II, Open Label, Single-arm study, Safety and Efficacy of AZD9291, Asia Pacific, NSCLC with T790M mutation within the Epidermal Growth Factor Receptor Gene
100145|NCT02442310|deferiprone
100146|NCT02442310|deferiprone delayed release formulation
100147|NCT02442310|pharmacokinetics
100148|NCT02442297|Glioblastoma
100149|NCT02442297|T cells Expressing HER2-specific Chimeric Antigen Receptors
100150|NCT02442297|HER2-specific T cells
100151|NCT02442297|intracranial injection
100152|NCT02442284|Chronic Hepatitis C
100153|NCT02442284|Interferon-Free
100154|NCT02442284|Hepatitis C Genotype 1
100155|NCT02442284|Hepatitis C Virus
100156|NCT02442284|Hepatitis C
100157|NCT02442284|Cirrhosis
100158|NCT02442271|Chronic Hepatitis C
100159|NCT02442271|Hepatitis C Treatment Naive
100160|NCT02442271|Hepatitis C Genotype 1
100161|NCT02442271|Hepatitis C Treatment Experienced
100162|NCT02442271|Hepatitis C Virus
100163|NCT02442258|Renal Impairment
100164|NCT02442219|gluten
100165|NCT02442219|Tetramer
100166|NCT02442206|QVA149, cardiac function, ventricular enddiastolic volume, hyperinflated COPD patients
100167|NCT02442154|early tracheostomy
100168|NCT02442154|severe head injury
100169|NCT02442154|endotracheal intubation
100170|NCT02442141|Near-Infrared Spectroscopy
100171|NCT02442141|Cerebral
100172|NCT02442141|Infants
100173|NCT02442141|Anesthesia
100174|NCT02442141|Neurodevelopmental
100175|NCT02442128|Fentany
100176|NCT02442128|intubation
100177|NCT02442128|sevoflurane
100178|NCT02442128|children
100179|NCT02442128|Propofol
100180|NCT02442115|Autism
100181|NCT02442115|Autism Spectrum Disorder (ASD)
100182|NCT02442115|Tummy Troubles
100183|NCT02442115|Constipation
100184|NCT02442115|GI Disorders
100185|NCT02442115|Gastrointestinal Disorders
100186|NCT02442115|Gastrointestinal
100187|NCT02442115|Oxidative Stress
100188|NCT02442115|Stomach problems
100189|NCT02442115|Behaviors
100190|NCT02442115|Autistic
100191|NCT02442115|ASD
100192|NCT02442115|MET gene
100193|NCT02442115|GID
100194|NCT02442115|Pediatric
100195|NCT02442115|Pediatric GI disorders
100196|NCT02442115|Children with Autism
100197|NCT02442115|functional constipation
100198|NCT02442102|deglutition disorders
100199|NCT02442102|therapeutics
100200|NCT02442102|rehabilitation
100201|NCT02442102|outcome assessment
100202|NCT02442102|intubation
100203|NCT02442102|critical care
100204|NCT02442102|larynx
100205|NCT02442102|voice
100206|NCT02442089|mHealth
100207|NCT02442089|eHealth
100208|NCT02442089|Health Systems
100209|NCT02442089|Health Technology
100210|NCT02442089|No Show
100211|NCT02442089|Non-attendance
100212|NCT02442089|Chile
100213|NCT02442089|Randomized controlled trial
100214|NCT02442089|Efficiency, Organizational
100215|NCT02442089|Pediatric Hospitals
100216|NCT02442089|Global Health
100217|NCT02442089|Referral and Consultation
100218|NCT02442089|Health Care Systems
100219|NCT02442089|Community Health Systems
100220|NCT02442089|Health Information Systems
100221|NCT02442089|Integrated Health Care Systems
100222|NCT02442089|Community Medicine
100223|NCT02442076|Skin vibration
100224|NCT02442076|Acupuncture needle vibration
100225|NCT02442050|CABG
100226|NCT02442050|valve surgery
100227|NCT02442050|cardioplegia
100228|NCT02442050|heart surgery
100229|NCT02442050|cardiac surgery
100230|NCT02442050|Cardio-Pulmonary Bypass
100231|NCT02442050|myocardial arrest
100232|NCT02442050|coronary artery bypass graft
100233|NCT02442050|CPB
100234|NCT02442037|cellular therapy
100235|NCT02442037|active ulcerative colitis
100236|NCT02442037|phase 1/2 clinical study
100237|NCT02442037|human umbilical cord mesenchymal stem cell
100238|NCT02442037|allogeneic stem cell transplantation
100239|NCT02442037|UC
100240|NCT02442024|diabetes mellitus
100241|NCT02442024|diet
100242|NCT02442024|nutrient sensing
100243|NCT02442011|Hematology Biobank
100244|NCT02441998|Colorectal Cancer
100245|NCT02441998|Diminutive Polyps
100246|NCT02441998|Narrow Band Imaging
100247|NCT02441998|Colonic Polyps
100248|NCT02441998|colonoscopy
100249|NCT02441998|diagnostic imaging
100250|NCT02441998|optical diagnosis
100251|NCT02441985|Primary orthostatic tremor
100252|NCT02441946|cyclin-dependent kinase (CDK) 4/6 inhibitor
100253|NCT02441946|CDK 4 and 6 inhibitor
100254|NCT02441907|Diabetic Macular Edema
100255|NCT02441907|Ocular Cytokines
100256|NCT02441907|Triamcinolone Acetonide
100257|NCT02441881|Radiofrequency ablation
100258|NCT02441881|varicose veins
100259|NCT02441881|endothermal ablation
100260|NCT02441881|RFITT
100261|NCT02441881|Venefit
100262|NCT02441842|β-blocker
100263|NCT02441842|ACE inhibitor
100264|NCT02441842|Stress
100265|NCT02441842|Craniotomy
100266|NCT02441842|Postop hypertension
100267|NCT02441842|neurosurgical patients
100268|NCT02441829|Renal Impairment
100269|NCT02441816|wet AMD
100270|NCT02441816|neovascular AMD
100271|NCT02441803|Leukemia
100272|NCT02441803|Acute myeloid leukemia
100273|NCT02441803|AML
100274|NCT02441803|Refractory
100275|NCT02441803|Allogeneic hematopoietic stem cell transplantation
100276|NCT02441803|AHSCT
100277|NCT02441803|Busulfan
100278|NCT02441803|Busulfex
100279|NCT02441803|Myleran
100280|NCT02441803|Fludarabine
100281|NCT02441803|Fludarabine Phosphate
100282|NCT02441803|Fludara
100283|NCT02441803|Clofarabine
100284|NCT02441803|Clofarex
100285|NCT02441803|Clolar
100286|NCT02441803|Total body irradiation
100287|NCT02441803|TBI
100288|NCT02441803|XRT
100289|NCT02441803|Thymoglobulin
100290|NCT02441803|ATG (Rabbit)
100291|NCT02441803|Rabbit antithymocyte Globulin
100292|NCT02441803|Rabbit Antilymphocyte Globulin
100293|NCT02441803|Rabbit ATG
100294|NCT02441803|rATG
100295|NCT02441803|Stem cell infusion
100296|NCT02441803|Cyclophosphamide
100297|NCT02441803|Cytoxan
100298|NCT02441803|Neosar
100299|NCT02441803|Tacrolimus
100300|NCT02441803|Prograf
100301|NCT02441803|Mycophenolate mofetil
100302|NCT02441803|MMF
100303|NCT02441803|CellCept
100304|NCT02441803|Decitabine
100305|NCT02441803|Dacogen
100306|NCT02441803|Cytarabine
100307|NCT02441803|Ara-C
100308|NCT02441803|Cytosar
100309|NCT02441803|DepoCyt
100310|NCT02441803|Cytosine Arabinosine Hydrochloride
100311|NCT02441803|Idarubicin
100312|NCT02441803|Idamycin
100313|NCT02441790|5th metacarpal
100314|NCT02441790|EAROM
100315|NCT02441790|standard immobilization
100316|NCT02441790|Boxer's Fracture
100317|NCT02441790|hand function
100318|NCT02441790|DASH
100319|NCT02441790|trauma
100320|NCT02441777|retinal imaging
100321|NCT02441777|optical imaging
100322|NCT02441777|optical coherence tomography
100323|NCT02441777|polarization sensitive coherence tomography
100324|NCT02441764|Halaven
100325|NCT02441764|Eribulin Mesylate
100326|NCT02441764|locally advanced or metastatic breast cancer
100327|NCT02441751|Electrocardiography
100328|NCT02441751|Hemorrhage
100329|NCT02441751|Monitoring, Intraoperative
100330|NCT02441738|Atrial Fibrillation
100331|NCT02441738|Hybrid Ablation
100332|NCT02441738|Catheter Ablation
100333|NCT02441686|Multiple Myeloma
100334|NCT02441673|Postanaesthetic shivering
100335|NCT02441673|Subarachnoid block
100336|NCT02441673|Tramadol
100337|NCT02441673|Nefopam
100338|NCT02441621|fluid responsiveness
100339|NCT02441621|diastolic dysfunction
100340|NCT02441621|left ventricular
100341|NCT02441556|thrombectomy
100342|NCT02441556|rt-PA
100343|NCT02441556|stroke
100344|NCT02441556|endovascular treatment
100345|NCT02441556|randomized
100346|NCT02441530|vitamin D
100347|NCT02441517|Xtandi
100348|NCT02441517|Metastatic Castration Resistant Prostate Cancer
100349|NCT02441517|Metastatic
100350|NCT02441517|Prostate Cancer
100351|NCT02441517|Chemotherapy
100352|NCT02441517|Castration-resistant
100353|NCT02441517|Enzalutamide
100354|NCT02441504|Exercise training
100355|NCT02441504|microvascular rarefaction
100356|NCT02441478|cooperative behavior, therapy adherence, fMRI
100357|NCT02441452|Nuss procedure
100358|NCT02441452|postoperative care
100359|NCT02441452|early ambulation
100360|NCT02441426|Cognitive development
100361|NCT02441426|Diarrheal disease
100362|NCT02441426|Enteric infections
100363|NCT02441426|Malnutrition
100364|NCT02441426|Vaccine Response
100365|NCT02441426|Enteropathy
100366|NCT02441426|Antibiotic use
100367|NCT02441426|Micronutrients
100368|NCT02441426|Breast feeding
100369|NCT02441426|Gut inflammation
100370|NCT02441413|HRCT
100371|NCT02441413|High Resolution Computed Tomography scans
100372|NCT02441413|Functional Respiratory Imaging
100373|NCT02441413|FRI
100374|NCT02441413|Computed Tomography
100375|NCT02441413|CT
100376|NCT02441413|Bronchiolitis Obliterans Syndrome
100377|NCT02441413|BOS
100378|NCT02441413|Lung Transplant
100379|NCT02441400|GERD
100380|NCT02441400|LES Pressure
100381|NCT02441400|Electrical Stimulation
100382|NCT02441387|depression
100383|NCT02441387|elderly
100384|NCT02441387|remission
100385|NCT02441387|treatment response
100386|NCT02441387|predictors of response
100387|NCT02441387|cognitive decline
100388|NCT02441387|structural neuroimage
100389|NCT02441387|genetic polymorphism
100390|NCT02441387|psychoeducation
100391|NCT02441374|Stroke
100392|NCT02441374|Hemiparesis
100393|NCT02441374|Upper limb
100394|NCT02441348|Voice Therapy
100395|NCT02441348|Muscle Tension Dysphonia
100396|NCT02441348|Lesions
100397|NCT02441309|Metastatic and/or Recurrent Osteosarcoma
100398|NCT02441283|Hepatitis C
100399|NCT02441283|Sustained virologic response
100400|NCT02441283|Hepatitis C virus
100401|NCT02441283|Direct Acting Antiviral
100402|NCT02441283|Chronic hepatitis C
100403|NCT02441257|Gastroesophageal Reflux
100404|NCT02441257|Laryngeal Mask Airway
100405|NCT02441257|Control Ventilation
100406|NCT02441257|Spontaneous Ventilation
100407|NCT02441205|High Intensity Interval Training
100408|NCT02441192|physical training
100409|NCT02441192|aerobic training
100410|NCT02441192|resistance training
100411|NCT02441179|acute intermittent hypoxia
100412|NCT02441179|rehabilitation
100413|NCT02441179|spinal cord injury
100414|NCT02441166|Bone marrow tryptase
100415|NCT02441166|cutaneous mastocytosis
100416|NCT02441140|Stage III Ovarian Cancer
100417|NCT02441140|Stage IV Ovarian Cancer
100418|NCT02441127|free gingival graft
100419|NCT02441127|diode laser
100420|NCT02441127|donor site
100421|NCT02441127|mucogingival surgery
100422|NCT02441101|Cardiac Resynchronization therapy
100423|NCT02441075|patients
100424|NCT02441075|BMT
100425|NCT02441075|cyclosporine
100426|NCT02441075|tacrolimus
100427|NCT02441075|HSCT
100428|NCT02441049|Latino
100429|NCT02441049|Hispanic
100430|NCT02441049|Diet
100431|NCT02441049|Family health
100432|NCT02441049|Promotora
100433|NCT02441049|Intervention
100434|NCT02441036|Gene expression and protein production
100435|NCT02441023|type 2 diabetes mellitus
100436|NCT02441023|nutritional therapy
100437|NCT02441023|health education
100438|NCT02441023|self-management
100439|NCT02441023|multimedia
100440|NCT02440997|aromatherapy, peppermint
100441|NCT02440984|enteric nervous system
100442|NCT02440984|anorectal disorder
100443|NCT02440984|barostat anorectal
100444|NCT02440984|physiology
100445|NCT02440984|spina bifida
100446|NCT02440971|Adaptive Servo Ventilation
100447|NCT02440971|Acute decompensated heart failure
100448|NCT02440971|SleepMinder
100449|NCT02440971|ApneaLink Plus
100450|NCT02440971|Sleep disordered breathing
100451|NCT02440971|Natriuretic peptide
100452|NCT02440932|low Phenylalanine diet
100453|NCT02440932|PKU supplements
100454|NCT02440932|diet induced thermogenesis
100455|NCT02440932|appetite
100456|NCT02440932|body weight
100457|NCT02440919|Respiratory mechanics
100458|NCT02440919|Oxygenation
100459|NCT02440919|Suction
100460|NCT02440919|Mechanical ventilation
100461|NCT02440919|Respiratory therapy
100462|NCT02440919|Capnography
100463|NCT02440919|Pulmonary Ventilation
100464|NCT02440906|Asthma
100465|NCT02440906|Cerebrovascular Disease
100466|NCT02440906|Intracranial Injury
100467|NCT02440906|Neoplasms
100468|NCT02440906|Heart Failure
100469|NCT02440906|HIV/AIDs
100470|NCT02440906|Hereditary and Degenerative Diseases of the Central Nervous System
100471|NCT02440906|Disorders of the Peripheral Nervous System
100472|NCT02440906|Rheumatoid Arthritis and Other Inflammatory Polyarthropathies
100473|NCT02440906|History of hepatitis C
100474|NCT02440906|Schizophrenia
100475|NCT02440906|Episodic Mood Disorders
100476|NCT02440906|Delusional Disorders
100477|NCT02440906|Other Non-Organic Psychoses
100478|NCT02440906|Organic Psychotic Conditions
100479|NCT02440906|Neurotic Disorders
100480|NCT02440906|Other Non-Psychotic Mental Disorders
100481|NCT02440867|theta burst stimulation
100482|NCT02440867|Social Cognition
100483|NCT02440867|MRSI
100484|NCT02440867|Schizophrenia
100485|NCT02440867|transcranial magnetic stimulation
100486|NCT02440841|VA106483
100487|NCT02440841|fedovapagon
100488|NCT02440841|drug-drug interaction
100489|NCT02440841|DDI
100490|NCT02440841|males
100491|NCT02440841|rifampicin
100492|NCT02440841|rifampin
100493|NCT02440841|itraconazole
100494|NCT02440841|CYP3A4
100495|NCT02440841|pharmacokinetics
100496|NCT02440841|PK
100497|NCT02440815|Psychotherapy
100498|NCT02440815|Problem Solving Therapy (PST)
100499|NCT02440815|Depression
100500|NCT02440815|Major Depression
100501|NCT02440815|Major Depressive Disorder
100502|NCT02440815|Late Life Depression
100503|NCT02440815|Multimodal imaging
100504|NCT02440815|Magnetic Resonance Imaging (MRI)
100505|NCT02440815|Cerebral blood flow
100506|NCT02440815|Cortical atrophy
100507|NCT02440815|White matter lesion
100508|NCT02440763|Natural History
100509|NCT02440737|Newly diagnosed
100510|NCT02440737|Cancer patient
100511|NCT02440737|Caregiver
100512|NCT02440737|Support person
100513|NCT02440724|winged stents
100514|NCT02440724|Self-expandable Metal Stents(SEMS)
100515|NCT02440724|partial covered
100516|NCT02440724|uncovered
100517|NCT02440724|endoscopic insertion
100518|NCT02440672|Osteoarthritis
100519|NCT02440672|TKA
100520|NCT02440672|Degenerative Knee Disease
100521|NCT02440659|Chronic Kidney Disease
100522|NCT02440659|Hemodialysis
100523|NCT02440659|Peritoneal Dialysis
100524|NCT02440646|Computed tomography angiography
100525|NCT02440646|Quantitative coronary angiography
100526|NCT02440646|Coronary artery disease
100527|NCT02440646|Natural history of atherosclerosis
100528|NCT02440646|Radiocontrast-induced thyroid dysfunction
100529|NCT02440646|Contrast-induced nephropathy
100530|NCT02440646|Plaque burden
100531|NCT02440646|Glagovian artery remodeling
100532|NCT02440646|Radiation dose
100533|NCT02440646|SYNTAX score
100534|NCT02440646|Fractional flow reserve
100535|NCT02440620|Heart failure related to medical treatment of breast cancer
100536|NCT02440607|Randomization
100537|NCT02440607|cognitive aids types
100538|NCT02440607|aids
100539|NCT02440594|Primary Care
100540|NCT02440594|Depression
100541|NCT02440594|Elderly
100542|NCT02440555|diabetes, capillary blood glucose, self-administered questionnaire
100543|NCT02440542|Nerve block
100544|NCT02440542|Ankle
100545|NCT02440542|Talus
100546|NCT02440542|Pain, Postoperative
100547|NCT02440516|Standardized
100548|NCT02440516|Physical therapy
100549|NCT02440516|occupational therapy
100550|NCT02440516|quality of life
100551|NCT02440516|disability
100552|NCT02440516|activities of daily living
100553|NCT02440516|ambulatory therapy
100554|NCT02440516|multiple sclerosis
100555|NCT02440464|Multiple Myeloma
100556|NCT02440464|Allogeneic Transplant
100557|NCT02440464|Maintenance Therapy
100558|NCT02440464|Anti-Myeloma Agents
100559|NCT02440464|Hematologic Disorders
100560|NCT02440438|Clostridium difficile, recurrence, relapse, antibodies, immune response, prognosis
100561|NCT02440425|platinum resistant
100562|NCT02440425|recurrent
100563|NCT02440425|persistent
100564|NCT02440425|epithelial
100565|NCT02440425|ovarian
100566|NCT02440425|fallopian tube
100567|NCT02440425|primary peritoneal
100568|NCT02440425|carcinoma
100569|NCT02440412|Massage
100570|NCT02440412|Stress
100571|NCT02440412|salivary cortisol
100572|NCT02440360|chronic homelessness
100573|NCT02440347|local anesthesia
100574|NCT02440347|articaine
100575|NCT02440347|AMSA
100576|NCT02440334|cryosurgery
100577|NCT02440334|ultrasonography
100578|NCT02440282|patients
100579|NCT02440256|Cost-effectiveness
100580|NCT02440256|Opioid substitution treatment
100581|NCT02440256|Integrated care
100582|NCT02440256|HIV
100583|NCT02440256|HAART
100584|NCT02440256|Testing
100585|NCT02440256|Linkage to care
100586|NCT02440256|Treatment adherence
100587|NCT02440230|adjuvant endocrine therapy
100588|NCT02440230|safety
100589|NCT02440230|Exemestane
100590|NCT02440230|ovarian function suppression
100591|NCT02440230|anastrozole
100592|NCT02440204|sevoflurane
100593|NCT02440204|remifentanil
100594|NCT02440204|intubation without using muscle relaxants
100595|NCT02440178|leukemia
100596|NCT02440178|induction
100597|NCT02440178|prophylaxis
100598|NCT02440178|antifungal
100599|NCT02440178|micafungin
100600|NCT02440178|phase II
100601|NCT02440165|nutrition
100602|NCT02440165|nurse
100603|NCT02440165|intervention
100604|NCT02440165|malnutrition
100605|NCT02440126|Multiple Sclerosis
100606|NCT02440126|immunological
100607|NCT02440126|biomarkers
100608|NCT02440126|observational
100609|NCT02440126|Relapsing
100610|NCT02440126|Remitting Multiple Sclerosis
100611|NCT02440100|Phase 1
100612|NCT02440100|Multiple doses of PF-06648671
100613|NCT02440100|safety, tolerability, PK
100614|NCT02440100|plasma and CSF abeta
100615|NCT02440100|drug interaction
100616|NCT02440074|Lumbar pain
100617|NCT02440074|Mesenchymal Stem Cells
100618|NCT02440061|Ghrelin
100619|NCT02440061|age and weight matched controls
100620|NCT02440048|extraction
100621|NCT02440048|Bond Apatite
100622|NCT02440035|Healthy Participants
100623|NCT02440035|Ad35.RSV.FA2
100624|NCT02440035|JNJ-61187191
100625|NCT02439996|Kawasaki disease IVIG DNA variation
100626|NCT02439970|kidney transplant allograft
100627|NCT02439970|recipients
100628|NCT02439944|Nicotine Patch
100629|NCT02439944|Nicotine Mouth Spray
100630|NCT02439944|Smoking Cessation
100631|NCT02439944|Quit Smoking
100632|NCT02439944|Abstinence
100633|NCT02439944|Dependence
100634|NCT02439944|Nicotine
100635|NCT02439944|Tobacco
100636|NCT02439944|Transdermal Nicotine Replacement Therapy
100637|NCT02439944|Functional Magnetic Resonance Imaging
100638|NCT02439944|Neuroimaging
100639|NCT02439944|Cue Reactivity
100640|NCT02439944|Resting State
100641|NCT02439944|BOLD fMRI
100642|NCT02439905|inflammatory cytokine
100643|NCT02439905|protective effect
100644|NCT02439905|Dexmedetomidine
100645|NCT02439905|Precedex
100646|NCT02439905|one lung ventilation
100647|NCT02439905|ischemia-reperfusion
100648|NCT02439892|Radiotherapy
100649|NCT02439892|Exercise
100650|NCT02439892|Diet therapy
100651|NCT02439892|Rehabilitation
100652|NCT02439892|Patient Compliance
100653|NCT02439892|Feasibility Studies
100654|NCT02439892|Sample Size
100655|NCT02439892|Patient satisfaction
100656|NCT02439853|primary progressive aphasia
100657|NCT02439853|progressive nonfluent aphasia
100658|NCT02439853|progressive aphasia
100659|NCT02439853|frontotemporal dementia
100660|NCT02439853|frontotemporal lobar degeneration
100661|NCT02439827|Lifestyle
100662|NCT02439827|Intervention
100663|NCT02439827|Motor Activity
100664|NCT02439827|Mediating Variables
100665|NCT02439827|Mental Health
100666|NCT02439827|Obesity
100667|NCT02439827|Adolescent Health
100668|NCT02439827|School
100669|NCT02439827|Health Promotion
100670|NCT02439827|Brazil
100671|NCT02439801|PEEP
100672|NCT02439801|compliance
100673|NCT02439801|peak airway pressures
100674|NCT02439788|Neuroblastoma
100675|NCT02439788|Natural Killer T Cells
100676|NCT02439788|Gene Therapy
100677|NCT02439788|Chimeric Antigen Receptor
100678|NCT02439775|Uncontrolled hypertension
100679|NCT02439775|Renal denervation
100680|NCT02439762|Veterans
100681|NCT02439762|Cognitive Behavioral Therapy
100682|NCT02439749|Uncontrolled hypertension
100683|NCT02439749|Renal denervation
100684|NCT02439736|Traumatic Brain Injury
100685|NCT02439736|Head Injury
100686|NCT02439723|Regorafenib
100687|NCT02439723|Lean body mass
100688|NCT02439723|Proton pump inhibitors pharmacokinetics
100689|NCT02439684|HbA1c
100690|NCT02439684|Diagnostic accuracy
100691|NCT02439684|Diabetes Mellitus
100692|NCT02439684|Chinese
100693|NCT02439684|Impaired fasting glucose
100694|NCT02439671|Transition Support Program for young adults
100695|NCT02439658|genetic research
100696|NCT02439645|genetic research
100697|NCT02439606|GlideRite
100698|NCT02439606|Stylet
100699|NCT02439606|Parker
100700|NCT02439606|orotracheal
100701|NCT02439606|intubation
100702|NCT02439606|GlideScope
100703|NCT02439593|Pancreas
100704|NCT02439593|chemoradiotherapy
100705|NCT02439593|hyperthermia
100706|NCT02439580|Patients
100707|NCT02439580|After Surgery
100708|NCT02439567|Cirrhosis
100709|NCT02439567|Chronic hepatitis C
100710|NCT02439567|Clinically significant portal hypertension
100711|NCT02439567|Portal hypertension
100712|NCT02439567|Elastography
100713|NCT02439567|Antiviral therapy
100714|NCT02439541|cellular therapy
100715|NCT02439541|Chronic ischemic heart disease
100716|NCT02439541|phase 1/2 clinical study
100717|NCT02439541|human umbilical cord mesenchymal stem cell
100718|NCT02439541|ischemic heart disease
100719|NCT02439541|allogeneic stem cell transplantation
100720|NCT02439528|pulmonary fibrosis
100721|NCT02439528|syndrome
100722|NCT02439528|genetic
100723|NCT02439528|emphysema
100724|NCT02439515|post-acute stroke
100725|NCT02439515|functional electrical stimulation
100726|NCT02439515|biofeedback
100727|NCT02439515|balance
100728|NCT02439515|cycling
100729|NCT02439515|rehabilitation
100730|NCT02439515|gait
100731|NCT02439476|Multiple myeloma
100732|NCT02439476|ASCT
100733|NCT02439476|plerixafor
100734|NCT02439476|stem cell mobilization
100735|NCT02439476|Salvage ASCT using plerixafor-based stem cell mobilization in relapsed multiple myeloma
100736|NCT02439450|lung
100737|NCT02439450|cancer
100738|NCT02439450|gp96
100739|NCT02439450|vaccine
100740|NCT02439450|immunotherapy
100741|NCT02439450|Heat Biologics
100742|NCT02439450|Nivolumab
100743|NCT02439450|checkpoint inhibitor
100744|NCT02439385|Curcumin
100745|NCT02439385|Avastin
100746|NCT02439385|FOLFIRI
100747|NCT02439385|Colorectal cancer
100748|NCT02439385|Unresectable metastasis
100749|NCT02439346|Advanced solid tumors
100750|NCT02439346|Docetaxel
100751|NCT02439346|mitogen-activated protein (MAP) kinase-interacting serine / threonine-protein kinase 1, also known as Mnk1 (MKNK1 inhibitor)
100752|NCT02439346|Taxanes
100753|NCT02439346|Non-small cell lung cancer
100754|NCT02439333|Acute exacerbation of chronic obstructive pulmonary disease
100755|NCT02439333|Nasal high flow therapy
100756|NCT02439333|Oxygen therapy
100757|NCT02439307|Rifaximin
100758|NCT02439307|Minimal hepatic encephalopathy
100759|NCT02439294|Recent acute myocardial infarction
100760|NCT02439294|Obstructive sleep apnée (syndrome)
100761|NCT02439294|Ventricular remodeling
100762|NCT02439294|Continuous Positive Airway Pressure
100763|NCT02439281|Ropivacaine
100764|NCT02439281|Anesthesia adjuncts
100765|NCT02439281|clonidine
100766|NCT02439281|laparoscopic appendectomy
100767|NCT02439281|rectus sheath block
100768|NCT02439242|stroke volume, haemodynamic, fluid resucitation
100769|NCT02439216|Muscular Dystrophies
100770|NCT02439216|Musculoskeletal Diseases
100771|NCT02439216|Nervous System Diseases
100772|NCT02439216|Neuromuscular Diseases
100773|NCT02439216|Duchenne muscular dystrophy
100774|NCT02439216|DMD
100775|NCT02439216|dystrophin
100776|NCT02439216|dystrophy
100777|NCT02439216|Duchenne
100778|NCT02439203|Parkinson Disease
100779|NCT02439203|Levodopa Induced Dyskinesia (LID)
100780|NCT02439203|Dyskinesia
100781|NCT02439177|Blood glucose monitoring system
100782|NCT02439177|System Accuracy
100783|NCT02439164|sedation
100784|NCT02439164|eloquent area glioma
100785|NCT02439164|neurologic function
100786|NCT02439151|Extracorporeal Membrane Oxygenation
100787|NCT02439138|Waldenstrom's Macroglobulinemia
100788|NCT02439125|levodopa
100789|NCT02439125|dyskinesia
100790|NCT02439125|parkinsons disease
100791|NCT02439125|PD
100792|NCT02439112|Exercise
100793|NCT02439112|Physical Function
100794|NCT02439112|Physical Activity
100795|NCT02439112|Quality of Life
100796|NCT02439112|Pain
100797|NCT02439112|Bone Disease
100798|NCT02439086|rectal cancer
100799|NCT02439086|neoadjuvant chemoradiotherapy
100800|NCT02439086|long course radiotherapy
100801|NCT02439086|response
100802|NCT02439047|reconstructive surgery
100803|NCT02439047|abdominal surgery
100804|NCT02439034|pain management
100805|NCT02439034|brachytherapy
100806|NCT02439008|liver metastases of colorectal cancer
100807|NCT02439008|metastases of melanoma or renal cancer
100808|NCT02438969|Alcohol
100809|NCT02438969|Alcohol Dependence
100810|NCT02438969|Stress
100811|NCT02438969|Fear Conditioning
100812|NCT02438917|Hepatitis C
100813|NCT02438917|Cirrhosis
100814|NCT02438917|Biomarkers
100815|NCT02438917|Fibrosis
100816|NCT02438904|Blood And Marrow Transplantation
100817|NCT02438904|Stem cell transplantation
100818|NCT02438904|SCT
100819|NCT02438904|Poor graft function
100820|NCT02438904|CD34+ cell infusion
100821|NCT02438865|Upper Tract Urothelial Carcinoma
100822|NCT02438865|Intravesical Chemotherapy
100823|NCT02438865|Epirubicin
100824|NCT02438865|Urothelial Carcinoma
100825|NCT02438800|Postpartum Period
100826|NCT02438787|Ankylosing Spondylitis
100827|NCT02438787|Ustekinumab
100828|NCT02438787|Golimumab
100829|NCT02438787|STELARA
100830|NCT02438774|Post-harvest practices , complementary foods
100831|NCT02438774|aflatoxins and fumonisins exposure,
100832|NCT02438774|Maize, breast milk
100833|NCT02438774|child growth, Tanzania
100834|NCT02438761|Acute Myeloid Leukemia
100835|NCT02438761|Myelodysplastic Syndrome
100836|NCT02438761|PIK/Akt/mTor
100837|NCT02438748|Oxidized Phosphatidylcholines
100838|NCT02438735|ovarian endometriomas
100839|NCT02438735|AMH
100840|NCT02438735|ovarian reserve
100841|NCT02438670|Artificial Pancreas
100842|NCT02438670|Type 1 Diabetes
100843|NCT02438670|MPC
100844|NCT02438670|PID
100845|NCT02438631|placenta
100846|NCT02438631|placental passage
100847|NCT02438605|Nellix
100848|NCT02438605|EVAS
100849|NCT02438605|EVAR
100850|NCT02438605|Dynamic CT
100851|NCT02438605|Dyna CT
100852|NCT02438592|Continuum of care
100853|NCT02438579|Hypertonic saline
100854|NCT02438579|nasal irrigation
100855|NCT02438579|gargling
100856|NCT02438579|URTI
100857|NCT02438566|Tranexamic Acid
100858|NCT02438566|Blood Loss
100859|NCT02438566|Total Hip Replacement
100860|NCT02438566|Bilateral Knee Replacement
100861|NCT02438540|acupuncture
100862|NCT02438540|obesity
100863|NCT02438540|type 2 diabetic mellitus
100864|NCT02438540|insulin sensitivity
100865|NCT02438540|metformin
100866|NCT02438540|inflammatory factor
100867|NCT02438540|adipokines
100868|NCT02438540|lipid profile
100869|NCT02438501|low-dose involved field radiotherapy
100870|NCT02438501|recurrent
100871|NCT02438501|advanced
100872|NCT02438501|follicular lymphoma
100873|NCT02438462|Pulmonary Embolism
100874|NCT02438462|Soluble Fibrin
100875|NCT02438462|D-Dimers
100876|NCT02438462|Clinical Probability Score
100877|NCT02438462|Imaging
100878|NCT02438449|breast reconstruction
100879|NCT02438449|mastectomy
100880|NCT02438449|health-related quality of life
100881|NCT02438449|Health Utilities Index
100882|NCT02438449|HUI
100883|NCT02438449|prospective
100884|NCT02438449|quality-adjusted life years
100885|NCT02438449|QALY
100886|NCT02438410|infliximab
100887|NCT02438410|remicade
100888|NCT02438410|IBD
100889|NCT02438410|Colitis, Ulcerative
100890|NCT02438371|pregnancy
100891|NCT02438371|preterm labor
100892|NCT02438371|tocolysis
100893|NCT02438293|rhinovirus
100894|NCT02438293|cardiac surgery
100895|NCT02438293|paediatric
100896|NCT02438293|respiratory infection
100897|NCT02438293|children
100898|NCT02438280|Orthodontic
100899|NCT02438280|Orthodontic treatment
100900|NCT02438280|Accelerated orthodontics
100901|NCT02438280|Vibration
100902|NCT02438241|Pain Measurement
100903|NCT02438241|Electric Stimulation
100904|NCT02438241|Spirometry
100905|NCT02438241|Manometry
100906|NCT02438228|cardiac output
100907|NCT02438228|transpulmonary thermodilution
100908|NCT02438228|pulse contour analysis
100909|NCT02438228|G09.330.380.124
100910|NCT02438215|PD
100911|NCT02438215|Parkinson's Disease
100912|NCT02438189|Type 1 Diabetes
100913|NCT02438189|Hypoglycemia
100914|NCT02438189|Hyperglycemia
100915|NCT02438189|Artificial Pancreas
100916|NCT02438163|Theta Burst Stimulation
100917|NCT02438150|Disaster
100918|NCT02438150|Training
100919|NCT02438137|Obstructive Sleep Apnea
100920|NCT02438137|OSA
100921|NCT02438137|sleep apnea
100922|NCT02438137|snoring
100923|NCT02438137|dimethyl fumarate
100924|NCT02438137|CPAP
100925|NCT02438137|continuous positive airway pressure
100926|NCT02438124|Parkinson's disease
100927|NCT02438124|Rhythmic auditory stimulation
100928|NCT02438124|Gait
100929|NCT02438098|Rivaroxaban
100930|NCT02438098|Obesity
100931|NCT02438098|Bariatric surgery
100932|NCT02438098|Pharmacokinetics
100933|NCT02438098|Pharmacodynamics
100934|NCT02438085|acute coronary syndromes
100935|NCT02438085|outcome
100936|NCT02438085|medical management
100937|NCT02438085|comorbidities
100938|NCT02438085|registry
100939|NCT02438072|antidepressive agent
100940|NCT02438072|drug metabolism
100941|NCT02438072|CYP450
100942|NCT02438072|P-glycoprotein
100943|NCT02438072|Phenotypic study
100944|NCT02438059|Inequality in health
100945|NCT02438059|workplace health promotion
100946|NCT02438059|internet
100947|NCT02438059|mobile app
100948|NCT02438059|weight loss
100949|NCT02438059|intervention
100950|NCT02438059|randomized controlled trial
100951|NCT02438046|Connective Tissue Grafts
100952|NCT02438046|Wound healing
100953|NCT02438046|Biomaterials
100954|NCT02438046|Pain
100955|NCT02438046|Clinical Trials
100956|NCT02438046|Mucogingival Surgery
100957|NCT02438033|Deep Brain Stimulation
100958|NCT02438033|Globus Pallidus
100959|NCT02438033|GPi
100960|NCT02438033|PC+S
100961|NCT02438020|Acanthosis nigricans
100962|NCT02438020|obesity
100963|NCT02438020|children
100964|NCT02438020|metformin
100965|NCT02437942|Athletic injuries
100966|NCT02437942|chronic
100967|NCT02437942|rehabilitation
100968|NCT02437942|diagnosis
100969|NCT02437942|biomechanics
100970|NCT02437916|Melanoma
100971|NCT02437916|Non-small Cell Lung Cancer (NSCLC)
100972|NCT02437916|Squamous Cell Carcinoma
100973|NCT02437916|Carcinoma
100974|NCT02437916|Head and Neck
100975|NCT02437916|Transitional Cell Carinoma (TCC)
100976|NCT02437916|Bladder
100977|NCT02437916|Colorectal
100978|NCT02437916|Colorectal Cancer (CRC)
100979|NCT02437903|voluma temporal, facial, volume loss
100980|NCT02437877|Respiration
100981|NCT02437877|Learning
100982|NCT02437877|Speech
100983|NCT02437877|Language and Hearing Sciences
100984|NCT02437799|Pulse oximeter
100985|NCT02437799|Caesarean section
100986|NCT02437799|hypotension
100987|NCT02437799|Spinal anaesthesia
100988|NCT02437773|OCD
100989|NCT02437747|clinical trial
100990|NCT02437708|regenerative endodontics
100991|NCT02437708|platelet rich fibrin
100992|NCT02437695|Robotic Surgical Procedures
100993|NCT02437695|Trendelenburg Position
100994|NCT02437682|Gastro-esophageal Reflux Disease
100995|NCT02437682|Proton pump inhibitor
100996|NCT02437669|Intranasal
100997|NCT02437669|Hydromorphone
100998|NCT02437669|Pediatric
100999|NCT02437669|Emergency department
101000|NCT02437656|Radiochemotherapy
101001|NCT02437656|Metformin
101002|NCT02437656|Rectal cancer
101003|NCT02437617|Advanced cancers
101004|NCT02437617|Tumor tissue
101005|NCT02437617|Genomic profile test
101006|NCT02437617|Analysis of treatment outcomes
101007|NCT02437617|Molecular profiling
101008|NCT02437617|Molecular alteration
101009|NCT02437591|ASP2819
101010|NCT02437591|PAR-101
101011|NCT02437591|OPT-80
101012|NCT02437591|Inflammatory Bowel Disease (IBD)
101013|NCT02437591|Clostridium difficile Infection (CDI)
101014|NCT02437591|fidaxomicin
101015|NCT02437591|Dificlir
101016|NCT02437578|vitamin d
101017|NCT02437578|fertility
101018|NCT02437578|markers
101019|NCT02437578|endocrine disruption
101020|NCT02437578|reproduction
101021|NCT02437552|Cardiac Surgery, Coronary Artery Bypass, Exercise Movement Techniques
101022|NCT02437526|Cure
101023|NCT02437526|Analytic treatment interruption
101024|NCT02437513|Dysphagia
101025|NCT02437513|Aspiration
101026|NCT02437513|Laryngeal cancer
101027|NCT02437474|vegan diet
101028|NCT02437474|lacto-ovo-vegetarian diet
101029|NCT02437474|cancer
101030|NCT02437474|tumor remission
101031|NCT02437461|knee synovitis
101032|NCT02437461|triamcinolone hexacetonide
101033|NCT02437461|treatment response
101034|NCT02437448|Mass spectrometry
101035|NCT02437448|Exhaled breath analysis
101036|NCT02437435|assisted reproduction
101037|NCT02437435|physical therapy
101038|NCT02437435|manual therapy
101039|NCT02437435|uterine artery
101040|NCT02437435|Vascularization Index (VI)
101041|NCT02437435|Doppler ultrasonography
101042|NCT02437435|vocal
101043|NCT02437409|Ischemic, Acute
101044|NCT02437357|Psychotherapy, Group
101045|NCT02437357|Metacognition
101046|NCT02437357|Cognitive Bias
101047|NCT02437331|Advanced heart failure
101048|NCT02437331|diseased experience
101049|NCT02437318|HR+
101050|NCT02437318|HER2-negative
101051|NCT02437318|advanced breast cancer
101052|NCT02437318|alpelisib
101053|NCT02437318|fulvestrant
101054|NCT02437318|PI3K
101055|NCT02437318|Phase III
101056|NCT02437318|ER+
101057|NCT02437318|PgR+
101058|NCT02437318|men
101059|NCT02437318|postmenopausal
101060|NCT02437318|aromatase inhibitor
101061|NCT02437318|neoplasms
101062|NCT02437305|Melanoma
101063|NCT02437305|People of Color
101064|NCT02437279|Palpable
101065|NCT02437279|Stage III
101066|NCT02437279|Skin melanoma
101067|NCT02437279|Ipilimumab
101068|NCT02437279|Nivolumab
101069|NCT02437279|Surgery
101070|NCT02437253|Mucopolysaccharidosis
101071|NCT02437253|Inflammation
101072|NCT02437253|Tumor necrosis factor - alpha inhibitor
101073|NCT02437240|Pilates-based exercise
101074|NCT02437240|respiratory mechanics
101075|NCT02437240|cardiopulmonary physical therapy
101076|NCT02437240|sternotomy
101077|NCT02437175|pelvic pain
101078|NCT02437175|quality of life
101079|NCT02437175|adenomyosis
101080|NCT02437162|Axial Spondyloarthritis
101081|NCT02437162|Ustekinumab
101082|NCT02437162|Golimumab
101083|NCT02437162|Stelara
101084|NCT02437149|Texting and driving
101085|NCT02437149|Teenager and driving
101086|NCT02437149|Distracted Driving Campaign
101087|NCT02437123|mHealth
101088|NCT02437123|Indigenous
101089|NCT02437123|HIV prevention
101090|NCT02437123|substance use
101091|NCT02437110|Amyotrophic Lateral Sclerosis
101092|NCT02437110|Virus
101093|NCT02437110|Antiretroviral Therapy
101094|NCT02437071|Radiotherapy
101095|NCT02437071|Ablation
101096|NCT02437071|Pembrolizumab
101097|NCT02437071|15-069
101098|NCT02437071|Metastatic Colorectal Cancer Patients
101099|NCT02437032|GDF-9
101100|NCT02437032|BMP-15
101101|NCT02437032|Steroids
101102|NCT02437032|Apoptosis rate
101103|NCT02437032|Endocrinology
101104|NCT02437019|PCI-32765
101105|NCT02437019|Ibrutinib
101106|NCT02437019|Early access program
101107|NCT02437019|Chronic lymphocytic leukemia
101108|NCT02437019|Relapsed or refractory chronic lymphocytic leukemia
101109|NCT02437006|stroke
101110|NCT02437006|exercise capacity
101111|NCT02436993|Neoadjuvant Treatment
101112|NCT02436993|Carboplatin
101113|NCT02436993|Paclitaxel
101114|NCT02436993|Pertuzumab
101115|NCT02436993|Trastuzumab
101116|NCT02436993|Bevacizumab
101117|NCT02436980|premedication
101118|NCT02436980|ERCP
101119|NCT02436980|midazolam
101120|NCT02436980|tramadol
101121|NCT02436980|cognitive
101122|NCT02436928|H7N9 Influenza
101123|NCT02436928|Avian influenza A
101124|NCT02436928|cell culture derived
101125|NCT02436915|Slow gait
101126|NCT02436915|Executive function
101127|NCT02436915|Transcranial direct current stimulation
101128|NCT02436876|Osteosynthesis
101129|NCT02436876|Complications
101130|NCT02436876|Infection or Inflammation
101131|NCT02436876|Orthopedic
101132|NCT02436876|Device
101133|NCT02436876|Fracture
101134|NCT02436863|Laminectomy
101135|NCT02436863|Laminoplasty
101136|NCT02436863|Internal fixation
101137|NCT02436863|deformity
101138|NCT02436850|Thoracentesis
101139|NCT02436850|Pocket Ultrasound Device
101140|NCT02436850|Ultrasound
101141|NCT02436850|Soroka University Medical Center
101142|NCT02436850|Physical Examination
101143|NCT02436850|Ethical Committee
101144|NCT02436824|topical patch
101145|NCT02436824|chronic low back pain
101146|NCT02436811|Health literacy
101147|NCT02436811|Pregnant women
101148|NCT02436811|Feeding behaviour
101149|NCT02436811|Oral health
101150|NCT02436811|Child
101151|NCT02436798|QT prolongation
101152|NCT02436798|Genomic biomarkers
101153|NCT02436785|music therapy
101154|NCT02436785|pain management
101155|NCT02436785|self efficacy
101156|NCT02436785|patient education
101157|NCT02436785|relaxation
101158|NCT02436746|Von Recklinghausen's disease
101159|NCT02436746|Bourneville's disease
101160|NCT02436746|Cognitive variability
101161|NCT02436746|Loss of heterozygosity
101162|NCT02436733|pleural mesothelioma
101163|NCT02436733|phase II
101164|NCT02436733|randomized
101165|NCT02436733|surgery
101166|NCT02436733|chemotherapy
101167|NCT02436733|feasibility
101168|NCT02436694|Dexamethasone
101169|NCT02436694|Perineural
101170|NCT02436655|aortic stenosis
101171|NCT02436655|normal ejection fraction
101172|NCT02436655|asymptomatic
101173|NCT02436629|Red beetroot juice
101174|NCT02436629|High intensity intermittent exercise
101175|NCT02436629|Nitrite
101176|NCT02436629|Soccer
101177|NCT02436616|EEG
101178|NCT02436616|Preterm Infants
101179|NCT02436616|Neonate
101180|NCT02436616|wireless
101181|NCT02436603|Irritable Bowel Syndrome
101182|NCT02436603|IBS
101183|NCT02436603|Mind-Body Training
101184|NCT02436603|Integrative Medicine
101185|NCT02436603|FODMAP
101186|NCT02436590|osteoarthritis
101187|NCT02436590|knee
101188|NCT02436590|pulsed electromagnetic fields
101189|NCT02436590|PEMF
101190|NCT02436577|ticagrelor orodispersible tablet
101191|NCT02436577|ticagrelor immediate-release tablet
101192|NCT02436577|bioequivalence
101193|NCT02436577|Phase I
101194|NCT02436577|healthy Japanese subjects
101195|NCT02436564|pancreas
101196|NCT02436564|stem cells
101197|NCT02436564|tumours
101198|NCT02436564|in vitro models
101199|NCT02436564|organoids
101200|NCT02436564|cancer,
101201|NCT02436564|bile duct
101202|NCT02436564|liver
101203|NCT02436538|anti-Müllerian hormone (AMH)
101204|NCT02436538|Mullerian anomalies
101205|NCT02436538|ICSI
101206|NCT02436447|Renal Impairment, Renal function, MTP-131, Bendavia™
101207|NCT02436434|Pulsed radiofrequency, osteoarthritis
101208|NCT02436395|gastric cancer
101209|NCT02436395|gastrectomy
101210|NCT02436395|laparotomy
101211|NCT02436395|SSIs
101212|NCT02436395|povidone-iodine
101213|NCT02436395|normal saline
101214|NCT02436369|diabetic patients
101215|NCT02436369|flaxseed
101216|NCT02436369|lipid profile
101217|NCT02436369|cardiovascular risc factors
101218|NCT02436343|left ventricular functions
101219|NCT02436343|pregnancy
101220|NCT02436343|obesity
101221|NCT02436330|Exergaming, Weight management
101222|NCT02436317|Point Of Care Ultrasonography
101223|NCT02436317|Soroka University Medical Center
101224|NCT02436317|Heart Failure
101225|NCT02436317|cardiovascular
101226|NCT02436278|Gait speed
101227|NCT02436278|Mortality
101228|NCT02436278|Morbidity
101229|NCT02436265|Neuraxial
101230|NCT02436265|Caudal
101231|NCT02436265|Block
101232|NCT02436265|Anesthesia
101233|NCT02436265|Dexamethasone
101234|NCT02436252|Myelodysplastic Syndrome
101235|NCT02436252|MDS
101236|NCT02436226|PCOS
101237|NCT02436226|Clomiphene citrate resistant
101238|NCT02436226|HCG
101239|NCT02436213|workload
101240|NCT02436213|oxygen level
101241|NCT02436213|oxygen consumption
101242|NCT02436213|breathing reserve
101243|NCT02436213|ventilatory efficiency
101244|NCT02436200|Intermittent Claudication
101245|NCT02436200|IC
101246|NCT02436200|Peripheral Arterial Disease
101247|NCT02436200|Peripheral Vascular Disease
101248|NCT02436200|Peripheral Arterial Occlusive Disease
101249|NCT02436187|NSTEMI
101250|NCT02436187|excess mortality
101251|NCT02436187|evidence-based care
101252|NCT02436187|MINAP
101253|NCT02436161|Heart Failure
101254|NCT02436161|Comorbidity
101255|NCT02436161|Patient Care Management
101256|NCT02436161|Primary Health Care
101257|NCT02436161|Delivery of Health Care, Integrated
101258|NCT02436148|PEQ validation study, Finland
101259|NCT02436122|Prostate cancer
101260|NCT02436122|Preoperative
101261|NCT02436122|Glycemic control
101262|NCT02436122|Hemoglobin A1c
101263|NCT02436122|Pathologic outcomes
101264|NCT02436122|Oncological outcomes
101265|NCT02436122|Treatment Outcome
101266|NCT02436122|Hemoglobin A1c Protein, Human
101267|NCT02436096|Pain
101268|NCT02436096|Sleep
101269|NCT02436070|Pediatrics
101270|NCT02436070|Emergency Medicine
101271|NCT02436070|Text messaging
101272|NCT02436044|Hepatocellular Carcinoma
101273|NCT02436044|Locally advanced stge
101274|NCT02436044|HAIC
101275|NCT02436044|FOLFOX4
101276|NCT02436044|Locally advanced
101277|NCT02436018|Sedation
101278|NCT02436018|Low pulse oximetry
101279|NCT02436018|Upper gastrointestinal endoscopy
101280|NCT02436018|WEI NASAL JET
101281|NCT02435979|wrist
101282|NCT02435979|proximal strengthening
101283|NCT02435979|hand therapy
101284|NCT02435953|Hepatocellular Carcinoma,TACE,Chemoembolization, RFA,Intermediate-stage
101285|NCT02435940|inherited retinal degenerative disease
101286|NCT02435940|retinitis pigmentosa
101287|NCT02435940|Usher
101288|NCT02435940|Leber
101289|NCT02435940|Bardet-Biedl
101290|NCT02435940|Batten
101291|NCT02435940|Best
101292|NCT02435940|cone dystrophy
101293|NCT02435940|cone-rod dystrophy
101294|NCT02435940|choroideremia
101295|NCT02435940|congenital night blindness
101296|NCT02435940|enhanced s-cone
101297|NCT02435940|cone monochromacy
101298|NCT02435940|Goldmann-Favre
101299|NCT02435940|Kearns-Sayre
101300|NCT02435940|Refsum
101301|NCT02435940|retinoschisis
101302|NCT02435940|rod-cone dystrophy
101303|NCT02435940|rod dystrophy
101304|NCT02435940|rod monochromacy
101305|NCT02435940|Sorsby pseudoinflammatory dystrophy
101306|NCT02435940|stargardt
101307|NCT02435940|achromatopsia
101308|NCT02435940|juvenile inherited macular degeneration
101309|NCT02435940|cone dichromacy
101310|NCT02435940|cone trichromacy
101311|NCT02435940|Charcot-Marie-Tooth
101312|NCT02435940|albipunctate dystrophy
101313|NCT02435901|Reduced Intensity Conditioning Regimen
101314|NCT02435888|Resting energy expenditure
101315|NCT02435888|Predictive equations
101316|NCT02435888|Overweight
101317|NCT02435875|hypertension
101318|NCT02435875|perioperative
101319|NCT02435875|baroreflex sensitivity
101320|NCT02435862|Vitreolysis of the Vitreous
101321|NCT02435849|Pediatric, ALL, Cell therapy
101322|NCT02435810|Neuroinflammation
101323|NCT02435810|Infections
101324|NCT02435797|nicorandil
101325|NCT02435797|primary percutaneous coronary intervention
101326|NCT02435797|acute ST segment elevation myocardial infarction
101327|NCT02435797|thrombus aspiration
101328|NCT02435784|2-COM
101329|NCT02435745|Ehlers-Danlos Syndrome
101330|NCT02435745|Obstructive Sleep Apnea
101331|NCT02435745|Prevalence
101332|NCT02435745|Aortic Aneurysm
101333|NCT02435719|HCAIs
101334|NCT02435719|Handgel
101335|NCT02435719|Hospital
101336|NCT02435719|Effectiveness
101337|NCT02435706|Dental implants
101338|NCT02435706|surgical flap
101339|NCT02435706|esthetics
101340|NCT02435706|alveolar process
101341|NCT02435693|pharmaceutical care
101342|NCT02435680|MCS110; carboplatin; gemcitabine; TNBC; TAMs
101343|NCT02435667|Resistance Training
101344|NCT02435667|Exercise
101345|NCT02435667|Heart Failure preserved Ejection Fraction
101346|NCT02435654|Genes Polymorphisms
101347|NCT02435654|Plasma Concentration
101348|NCT02435602|endoscopy, gastrointestinal
101349|NCT02435602|cancer screening
101350|NCT02435576|Acute toxicity
101351|NCT02435576|Late toxicity
101352|NCT02435576|NTCP models
101353|NCT02435563|Anti-HIV Agents
101354|NCT02435563|cardiovascular agents
101355|NCT02435563|drug interactions
101356|NCT02435537|analgesia
101357|NCT02435537|intrathecal
101358|NCT02435537|opioids
101359|NCT02435537|morphine
101360|NCT02435537|dexmedetomidine
101361|NCT02435524|Breast Feeding, Exclusive
101362|NCT02435524|Infant Nutrition
101363|NCT02435524|Burkina Faso
101364|NCT02435511|agent-based modeling
101365|NCT02435511|community resources
101366|NCT02435511|simulation modeling
101367|NCT02435511|information intervention
101368|NCT02435511|clinic-to-community linkages
101369|NCT02435485|degerative lumbar spondylolisthesis
101370|NCT02435485|rehabilitation
101371|NCT02435485|balance
101372|NCT02435472|Active Surveillance
101373|NCT02435472|Exercise
101374|NCT02435472|Prostate cancer
101375|NCT02435472|Life style
101376|NCT02435472|Survey
101377|NCT02435472|Personalized exercise
101378|NCT02435472|Exercise trainer
101379|NCT02435433|liver cancer
101380|NCT02435420|Total Hip Arthroplasty
101381|NCT02435420|EMPERION Modular Stem
101382|NCT02435420|Survivorship
101383|NCT02435355|Sleep apnea
101384|NCT02435355|education
101385|NCT02435355|compliance
101386|NCT02435355|CPAP
101387|NCT02435342|ShK-186
101388|NCT02435342|dalazatide
101389|NCT02435342|psoriasis
101390|NCT02435342|Kv1.3,
101391|NCT02435342|autoimmune
101392|NCT02435316|Education
101393|NCT02435290|prediction
101394|NCT02435290|prescribing error
101395|NCT02435290|risk factors
101396|NCT02435277|Diabetes
101397|NCT02435212|New formulation, deferasirox, chelation, iron overload, compliance, satisfaction, palatability, PRO, PK, safety, PK/PD, ICL670
101398|NCT02435186|p53 gene
101399|NCT02435186|chemotherapy
101400|NCT02435186|recurrent
101401|NCT02435186|epithelial
101402|NCT02435186|ovarian cancer
101403|NCT02435186|fallopian tube cancer
101404|NCT02435186|primary peritoneal cancer
101405|NCT02435173|APDS; PASLI; PI3Kdelta
101406|NCT02435108|MET poisitivity is defined as at least half of tumor cells show weak, moderate or high staining
101407|NCT02435095|Schizophrenia
101408|NCT02435095|Maintenance treatment, Intermittent treatment
101409|NCT02435095|Brain volume
101410|NCT02435095|Antipsychotics
101411|NCT02435082|Concussion
101412|NCT02435082|Vascular Assessment
101413|NCT02435082|Vascular Regulation
101414|NCT02435082|mild Traumatic Brain Injury, mTBI
101415|NCT02435082|Traumatic Brain Injury, TBI
101416|NCT02435082|Cerebrovascular Regulation
101417|NCT02435082|Cerebral Blood Flow
101418|NCT02435082|Cerebral Blood Flow Velocity, CBFV
101419|NCT02435082|Cerebral Blood Flow Velocity Variability
101420|NCT02435082|Cerebrovascular Assessment
101421|NCT02435069|cecostomy
101422|NCT02435069|appendicostomy
101423|NCT02435056|medication overuse headache
101424|NCT02435056|health care system
101425|NCT02435030|NP-C
101426|NCT02435030|LSD
101427|NCT02435030|lysosomal storage disorder
101428|NCT02435030|lysosomal storage disease
101429|NCT02435030|NPC2
101430|NCT02435030|NPC1
101431|NCT02435030|Niemann-Pick Type C
101432|NCT02435030|Niemann-Pick,
101433|NCT02435030|Arimoclomol
101434|NCT02435017|kidney disease
101435|NCT02435017|recommended dietary allowances
101436|NCT02435017|nutrition assessment
101437|NCT02435017|food
101438|NCT02435017|dietary proteins
101439|NCT02435017|Vitamin D
101440|NCT02435017|dietary fats
101441|NCT02435017|ethnology
101442|NCT02435017|Continental Population Groups
101443|NCT02435017|Phosphorus, dietary
101444|NCT02435017|Phosphorus/analysis
101445|NCT02434991|trouble swallowing
101446|NCT02434991|food sticking
101447|NCT02434991|Achalasia
101448|NCT02434965|Neonates
101449|NCT02434965|hypoxic-ischemic encephalopathy
101450|NCT02434965|human placental-derived stem cells
101451|NCT02434965|autologous
101452|NCT02434952|Malaria, Falciparum
101453|NCT02434952|G6PD deficiency
101454|NCT02434952|Primaquine
101455|NCT02434952|Asia
101456|NCT02434926|fetoscopy
101457|NCT02434926|fetal surgery
101458|NCT02434926|anesthetic complications
101459|NCT02434913|Proximal interphalangeal joint deformity
101460|NCT02434913|Arthroplasty
101461|NCT02434822|Cholera
101462|NCT02434822|Shanchol™
101463|NCT02434822|Cholera Vaccine
101464|NCT02434809|Respiratory Motion-Corrected Cone-Beam CT
101465|NCT02434809|Radiation
101466|NCT02434809|14-225
101467|NCT02434796|Intimate Partner Violence
101468|NCT02434796|Gender-Based Violence
101469|NCT02434796|Gender
101470|NCT02434796|HIV
101471|NCT02434783|Blood circulation
101472|NCT02434783|Blood vessels
101473|NCT02434783|Mitochondria
101474|NCT02434783|Muscle, skeletal
101475|NCT02434783|Legs
101476|NCT02434783|Energy metabolism
101477|NCT02434731|Procedural pain
101478|NCT02434731|Phlebotomy
101479|NCT02434731|Intellectual Disability
101480|NCT02434731|Child
101481|NCT02434731|Buzzy
101482|NCT02434705|Eosinophilic
101483|NCT02434692|Primary Open Angle Glaucoma
101484|NCT02434692|POAG
101485|NCT02434692|Glaucoma
101486|NCT02434692|Cataract
101487|NCT02434692|Surgery
101488|NCT02434692|Ocular Pressure
101489|NCT02434679|antibiotics resistance integrons
101490|NCT02434679|neonatology newborns
101491|NCT02434679|digestive acquisition
101492|NCT02434679|dynamic of the acquisition of integrons
101493|NCT02434627|Becker
101494|NCT02434627|Dystrophy
101495|NCT02434601|Non-carious cervical lesions
101496|NCT02434601|Randomized clinical trial
101497|NCT02434601|Permanent dental restoration
101498|NCT02434601|Dentin
101499|NCT02434601|Adhesion
101500|NCT02434601|Restoration
101501|NCT02434601|Sensitivity
101502|NCT02434601|Prophylaxis
101503|NCT02434601|Randomized
101504|NCT02434575|Lower Urinary Tract Symptoms
101505|NCT02434575|Prostatic artery embolisation
101506|NCT02434575|Transurethral resection of the prostate
101507|NCT02434575|Benign prostatic hyperplasia
101508|NCT02434575|Benign prostatic enlargement
101509|NCT02434549|Randomized Controlled Trial
101510|NCT02434549|Placebo Controlled
101511|NCT02434549|Double Blinded
101512|NCT02434549|Botulinum Toxin Type A
101513|NCT02434549|Adults
101514|NCT02434549|Pain
101515|NCT02434549|Spasticity
101516|NCT02434549|Cerebral Palsy, Spastic
101517|NCT02434549|Dysport
101518|NCT02434536|Chronic Obstructive Pulmonary Disease
101519|NCT02434536|Disease Exacerbation Clinical Prediction Rule
101520|NCT02434536|Decision Analysis
101521|NCT02434523|laryngeal sensory neuropathy
101522|NCT02434510|Infection
101523|NCT02434510|Total Knee Arthroplasty
101524|NCT02434510|Total Hip Arthroplasty
101525|NCT02434510|Splash Basins
101526|NCT02434497|LDL-C
101527|NCT02434497|HoFH
101528|NCT02434497|Hyperlipidemia
101529|NCT02434484|Symbenda
101530|NCT02434484|Non-Hodgkin's lymphomas
101531|NCT02434484|Chronic lymphocytic leukemia
101532|NCT02434484|Multiple myeloma
101533|NCT02434484|Bendamustine Hydrochloride
101534|NCT02434458|fibromyalgia,
101535|NCT02434458|polyneuropathy
101536|NCT02434458|small fiber neuropathy
101537|NCT02434458|rheumatoid arthritis
101538|NCT02434458|sudomotor
101539|NCT02434406|Anxiety
101540|NCT02434406|Anxiety disorders
101541|NCT02434406|Mental health
101542|NCT02434406|Postpartum period
101543|NCT02434406|maternal welfare
101544|NCT02434406|internet
101545|NCT02434406|intervention studies
101546|NCT02434406|feasibility studies
101547|NCT02434406|randomized controlled trial
101548|NCT02434406|patient acceptance of health care
101549|NCT02434393|Depression
101550|NCT02434393|Late Life Depression
101551|NCT02434393|LLD
101552|NCT02434393|amyloid imaging
101553|NCT02434393|biomarkers
101554|NCT02434380|Vitamin D
101555|NCT02434380|Bone mineral content
101556|NCT02434380|Knee-heel length
101557|NCT02434380|Middle East
101558|NCT02434367|Cancer
101559|NCT02434354|Clinical stage III (nodal and/or intransit disease) or resectable stage IV melanoma (MEL), with or without prior treatment
101560|NCT02434328|AMD
101561|NCT02434328|CNV
101562|NCT02434328|IVT
101563|NCT02434315|Diabetes Mellitus
101564|NCT02434315|Sensing Technology
101565|NCT02434289|Older adults
101566|NCT02434289|Dietary protein
101567|NCT02434289|Resistance exercise
101568|NCT02434289|Feasibility study
101569|NCT02434289|Physical functioning
101570|NCT02434289|Real-life setting
101571|NCT02434250|Open angle glaucoma
101572|NCT02434250|Ocular hypertension
101573|NCT02434250|Cataract
101574|NCT02434250|Selective Laser Trabeculoplasty
101575|NCT02434250|Eximer Laser Trabeculectomy
101576|NCT02434250|Phacoemulsification Cataract Extraction
101577|NCT02434224|Music therapy
101578|NCT02434224|premature infant
101579|NCT02434224|brain development
101580|NCT02434198|pulmonary rehabilitation
101581|NCT02434198|balance assessment
101582|NCT02434198|Chronic Obstructive Pulmonary Disease
101583|NCT02434185|Musculoskeletal Physiological Phenomena
101584|NCT02434185|Postmenopause
101585|NCT02434185|Muscle Strength
101586|NCT02434185|Absorptiometry, Photon
101587|NCT02434172|HIV
101588|NCT02434172|Cryptococcus
101589|NCT02434172|Lateral Flow Assay
101590|NCT02434172|sub-Saharan Africa
101591|NCT02434172|Screening
101592|NCT02434172|treatment
101593|NCT02434172|cryptococcal meningitis
101594|NCT02434120|MRI
101595|NCT02434120|Orbital neoplasm
101596|NCT02434107|Sentinel Lymph Node Biopsy
101597|NCT02434107|Lymph Node Excision
101598|NCT02434094|Diabetes Assistant (DiAs)
101599|NCT02434094|Continuous Glucose Monitor (CGM)
101600|NCT02434094|Insulin Pump
101601|NCT02434094|Human Factors
101602|NCT02434094|Focus Group
101603|NCT02434094|Artificial Pancreas (AP)
101604|NCT02434094|eDAPT (electronic Diabetes Artificial Pancreas Training)
101605|NCT02434081|NSCLC
101606|NCT02434081|IIIA/B
101607|NCT02434068|kidney calculi
101608|NCT02434068|followup studies
101609|NCT02434042|probiotic
101610|NCT02434042|children
101611|NCT02434042|gastrointestinal
101612|NCT02434042|upper respiratory
101613|NCT02434016|Diaphragm
101614|NCT02434016|Mechanical ventilation
101615|NCT02434003|3D reconstruction
101616|NCT02434003|AIS
101617|NCT02434003|Computer models
101618|NCT02434003|Spinal Deformity
101619|NCT02433990|Congenital Heart Disease
101620|NCT02433990|Acquired Cardiovascular Disease
101621|NCT02433977|Asthma
101622|NCT02433977|Obesity
101623|NCT02433977|conjugated linolenic acid
101624|NCT02433977|nitrate
101625|NCT02433977|nitrite
101626|NCT02433977|nutritional supplements
101627|NCT02433964|laser
101628|NCT02433964|LED
101629|NCT02433964|PRICE
101630|NCT02433964|pain
101631|NCT02433964|edema
101632|NCT02433951|exercise tolerance
101633|NCT02433925|resveratrol
101634|NCT02433925|oxidative stress
101635|NCT02433925|inflammation
101636|NCT02433873|Microbiota
101637|NCT02433873|Body weight
101638|NCT02433873|Digestive system
101639|NCT02433847|mosapride
101640|NCT02433821|Mechanical Neck Pain
101641|NCT02433821|Pain
101642|NCT02433821|Function
101643|NCT02433821|Quality of life
101644|NCT02433821|Pilates
101645|NCT02433795|Marginal zone B-cell lymphoma
101646|NCT02433795|bendamustine plus rituximab
101647|NCT02433782|Haemophilia
101648|NCT02433782|Arthropathy
101649|NCT02433782|Pain
101650|NCT02433782|Range of motion
101651|NCT02433782|Miofascial techniques
101652|NCT02433743|HIV/AIDS
101653|NCT02433743|RUTF
101654|NCT02433743|fat free mass
101655|NCT02433743|anemia
101656|NCT02433743|zinc
101657|NCT02433743|Senegal
101658|NCT02433717|schizophrenia
101659|NCT02433717|schizoaffective disorder
101660|NCT02433717|pharmacogenetics
101661|NCT02433717|pharmacokinetics
101662|NCT02433717|event-related potentials
101663|NCT02433717|paliperidone
101664|NCT02433691|(An)aerobic exercise
101665|NCT02433691|memory training
101666|NCT02433691|cognitive benefits
101667|NCT02433652|Dengue Vaccine
101668|NCT02433639|advanced biliary tract cancer, TH-302
101669|NCT02433613|Pulmonary Vein Isolation
101670|NCT02433613|Phased Radiofrequency Ablation
101671|NCT02433574|radiosurgery
101672|NCT02433574|Neoadjuvant Therapy
101673|NCT02433548|Analgesia
101674|NCT02433548|Emergency medicine
101675|NCT02433548|Anesthesia, Regional
101676|NCT02433535|severe asthma
101677|NCT02433535|simvastatin
101678|NCT02433535|allergic airway inflammation
101679|NCT02433522|ANCA-associated vasculitides
101680|NCT02433522|Maintenance treatment
101681|NCT02433522|Rituximab
101682|NCT02433522|Granulomatosis with polyangiitis
101683|NCT02433522|Microscopic polyangiitis
101684|NCT02433509|acute ischemic stroke
101685|NCT02433509|umbilical cord blood
101686|NCT02433496|Opioid
101687|NCT02433483|Adolescent
101688|NCT02433483|Children
101689|NCT02433483|Microtransplant
101690|NCT02433483|Leukemia
101691|NCT02433457|Healthy Volunteers
101692|NCT02433457|CC-292
101693|NCT02433457|Open-Label
101694|NCT02433457|Bioavailability Pharmacokinetics
101695|NCT02433457|Phase I
101696|NCT02433444|Biosensing Techniques
101697|NCT02433431|mindfulness
101698|NCT02433431|psychological stress
101699|NCT02433431|immune marker
101700|NCT02433431|wellness programs
101701|NCT02433431|mobile applications
101702|NCT02433431|cortisol
101703|NCT02433405|Serum Amyloid A
101704|NCT02433405|Fetuin-A
101705|NCT02433405|gingival crevicular fluid
101706|NCT02433405|serum
101707|NCT02433405|periodontal diseases
101708|NCT02433392|drug-eluting beads
101709|NCT02433392|irinotecan hydrochloride
101710|NCT02433353|PTSD
101711|NCT02433353|posttraumatic stress disorder
101712|NCT02433353|venlafaxine
101713|NCT02433353|EMDR
101714|NCT02433353|eye movement desensitization reprocessing
101715|NCT02433353|antidepressant
101716|NCT02433353|psychotherapy
101717|NCT02433340|Tolerability
101718|NCT02433340|Methotrexate
101719|NCT02433340|Safety
101720|NCT02433327|Paediatric Early Warning System
101721|NCT02433327|trigger tool
101722|NCT02433327|screening tool
101723|NCT02433327|risk assessment
101724|NCT02433327|early recognition
101725|NCT02433301|chemotherapy
101726|NCT02433301|GEJ cancer
101727|NCT02433301|PET/MR-imaging
101728|NCT02433288|smart phone-based
101729|NCT02433288|rosuvastatin
101730|NCT02433288|duration of treatment
101731|NCT02433288|Treatment adherence
101732|NCT02433223|outreach nursing
101733|NCT02433223|respiratory nursing guidelines
101734|NCT02433197|Testicular cancer
101735|NCT02433197|Germ cell cancer
101736|NCT02433197|Physical exercise
101737|NCT02433197|Cancer-related fatigue
101738|NCT02433197|Chemotherapy
101739|NCT02433197|Clinical rules
101740|NCT02433197|Metabolomics
101741|NCT02433184|Etanercept
101742|NCT02433184|treat to target
101743|NCT02433184|Disease Modifying Antirheumatic Drugs (DMARDs)
101744|NCT02433171|regrowth
101745|NCT02433171|radiosurgery
101746|NCT02433171|radiation necrosis
101747|NCT02433158|Rivipansel
101748|NCT02433158|GMI-1070
101749|NCT02433158|Selectin Inhibitor
101750|NCT02433158|SCD
101751|NCT02433158|VOC
101752|NCT02433145|ADHD in preschoolers
101753|NCT02433145|neuropsychological functions
101754|NCT02433145|behavior inhibition
101755|NCT02433145|family function and parenting
101756|NCT02433132|Cystic fibrosis
101757|NCT02433132|Adults
101758|NCT02433132|Atypical form
101759|NCT02433132|Nasal brushing
101760|NCT02433132|Epithelial cells
101761|NCT02433132|Ion transport
101762|NCT02433106|Balance
101763|NCT02433106|Exercise
101764|NCT02433054|deep vein thrombosis
101765|NCT02433054|chronic venous disease
101766|NCT02433054|May-Thurner syndrome
101767|NCT02433054|venous stent
101768|NCT02433041|Postoperative delirium
101769|NCT02433041|Cortisol
101770|NCT02433041|NSE
101771|NCT02433041|S-100beta
101772|NCT02433041|MMSE
101773|NCT02433041|Nu-DESC
101774|NCT02433041|ICDSC
101775|NCT02433041|DOS
101776|NCT02433041|Haloperidol
101777|NCT02433041|Ketamine
101778|NCT02433041|Combination of Haloperidol and Ketamine
101779|NCT02433041|Placebo
101780|NCT02433041|Prevention of
101781|NCT02433028|MS key phases of disease evolution
101782|NCT02433028|MS New Treatment Options
101783|NCT02433015|Electronic Cigarette
101784|NCT02433002|eGFR
101785|NCT02433002|CKD
101786|NCT02433002|Cystatin
101787|NCT02433002|Creatinine
101788|NCT02433002|Albuminuria
101789|NCT02432989|Exercise Therapy
101790|NCT02432989|Concussion Management
101791|NCT02432989|Concussion Recovery
101792|NCT02432976|Quality of Life
101793|NCT02432976|Cardiac Surgery
101794|NCT02432976|Coronary Artery Bypass Graft Surgery
101795|NCT02432976|Incretin mimetic
101796|NCT02432976|Exenatide
101797|NCT02432937|Corever
101798|NCT02432937|hypertension
101799|NCT02432885|cardiac magnetic resonance
101800|NCT02432885|myocardial fibrosis
101801|NCT02432885|muscular dystrophies
101802|NCT02432820|Prostate Cancer
101803|NCT02432768|Anaplerotic diet
101804|NCT02432768|McArdle Disease
101805|NCT02432768|Glycogen Storage Disease
101806|NCT02432768|Triheptanoin
101807|NCT02432755|home-based rehabilitation
101808|NCT02432755|stroke
101809|NCT02432755|combination therapy
101810|NCT02432755|client-centered approach
101811|NCT02432755|post-acute
101812|NCT02432742|hyaluronic acid, comparative study, NLF
101813|NCT02432729|smoking cessation
101814|NCT02432729|smoking abstinence
101815|NCT02432729|clinical, biological and functional changes
101816|NCT02432729|one year
101817|NCT02432729|healthy smokers
101818|NCT02432729|quit smoking
101819|NCT02432703|Social Anxiety Disorder
101820|NCT02432703|JNJ-42165279
101821|NCT02432690|Neoplasms
101822|NCT02432677|tDCS
101823|NCT02432677|Opioid
101824|NCT02432677|Pain
101825|NCT02432677|Pain threshold
101826|NCT02432651|oxidative stress
101827|NCT02432651|hops
101828|NCT02432651|xanthohumol
101829|NCT02432651|DNA damage
101830|NCT02432651|cancer
101831|NCT02432625|Osteogenesis Imperfecta
101832|NCT02432625|Collagen
101833|NCT02432625|Brittle Bone Disorder
101834|NCT02432625|Rare Disease Clinical Research Network
101835|NCT02432625|COL1A2
101836|NCT02432599|F18-choline
101837|NCT02432586|T1DM
101838|NCT02432586|Diabetes
101839|NCT02432586|Child
101840|NCT02432586|Toddler
101841|NCT02432573|timing
101842|NCT02432560|Lymphangioleiomyomatosis
101843|NCT02432560|LAM
101844|NCT02432560|rare lung
101845|NCT02432560|Rare Lung Disease
101846|NCT02432547|Diabetic
101847|NCT02432547|Macular Oedema
101848|NCT02432547|Retinopathy
101849|NCT02432521|stroke
101850|NCT02432521|transcranial magnetic stimulation (TMS)
101851|NCT02432521|Electroencephalography (EEG)
101852|NCT02432521|Cerebrovascular Accident
101853|NCT02432521|Brain Vascular Accident
101854|NCT02432508|acupuncture
101855|NCT02432508|laser
101856|NCT02432508|uremic pruritus
101857|NCT02432508|randomized clinical trial
101858|NCT02432482|Tobacco
101859|NCT02432482|Cigarette
101860|NCT02432482|HIV
101861|NCT02432482|Treatment
101862|NCT02432482|Mobile
101863|NCT02432482|Smartphone
101864|NCT02432469|coronary artery bypass
101865|NCT02432469|medication adherence
101866|NCT02432469|secondary prevention
101867|NCT02432469|mobile applications
101868|NCT02432443|Motor Skills
101869|NCT02432443|Pre-literacy Skills
101870|NCT02432443|Early Intervention
101871|NCT02432430|N05.300.150.410
101872|NCT02432430|practice guideline
101873|NCT02432430|D20.215.894.899.290.130
101874|NCT02432430|Health Knowledge, Attitudes, Practice
101875|NCT02432417|Glioblastoma
101876|NCT02432417|Autophagy
101877|NCT02432417|EGFR
101878|NCT02432417|EGFRvIII
101879|NCT02432417|Chloroquine
101880|NCT02432417|Radiotherapy
101881|NCT02432417|Temozolomide
101882|NCT02432404|HSV-2
101883|NCT02432404|Contraceptive Vaginal Ring
101884|NCT02432365|Paclitaxel
101885|NCT02432365|Cisplatin
101886|NCT02432365|Cervical cancer
101887|NCT02432365|Radical hysterectomy
101888|NCT02432365|Neoadjuvant
101889|NCT02432339|immune system
101890|NCT02432339|RENIN-ANGIOTENSIN SYSTEM
101891|NCT02432326|Neoplasms
101892|NCT02432300|Traumatic Brain Injury
101893|NCT02432300|Alexithymia
101894|NCT02432300|Emotions
101895|NCT02432287|aging
101896|NCT02432287|metformin
101897|NCT02432287|prediabetes
101898|NCT02432274|E7080
101899|NCT02432274|Lenvatinib
101900|NCT02432274|Solid malignancies
101901|NCT02432274|Osteosarcoma
101902|NCT02432274|Differentiated Thyroid Cancer
101903|NCT02432261|spermatogenesis
101904|NCT02432261|androgen
101905|NCT02432261|male contraception
101906|NCT02432248|DHEA
101907|NCT02432248|live birth rate
101908|NCT02432248|poor ovarian responder
101909|NCT02432196|Mitral Valve Repair
101910|NCT02432196|Transapical
101911|NCT02432196|artificial chordae
101912|NCT02432183|individual
101913|NCT02432144|MPS 7
101914|NCT02432144|Sly Syndrome
101915|NCT02432144|MPS VII
101916|NCT02432144|Enzyme Replacement Therapy
101917|NCT02432144|Rare Disease
101918|NCT02432144|Mucopolysaccharidosis Type 7
101919|NCT02432144|Lysosomal Storage Disease
101920|NCT02432144|Metabolic Disorder
101921|NCT02432092|Cardiomegaly
101922|NCT02432092|Cardiovascular Diseases
101923|NCT02432092|Heart Diseases
101924|NCT02432092|Systolic dysfunction
101925|NCT02432092|Diastolic dysfunction
101926|NCT02432092|Ventricular hypertrophy
101927|NCT02432092|Heart failure
101928|NCT02432079|Abnormalities, Multiple
101929|NCT02432079|Asplenia
101930|NCT02432079|Bilary Atresia
101931|NCT02432079|Birth Defect
101932|NCT02432079|Cardiovascular Abnormalities
101933|NCT02432079|Cardiovascular Diseases
101934|NCT02432079|Congenital Abnormalities
101935|NCT02432079|Congenital Heart Disease
101936|NCT02432079|Dextrocardia Syndrome
101937|NCT02432079|Disturbed Internal Organ Positioning
101938|NCT02432079|Genetics
101939|NCT02432079|Genetic Testing
101940|NCT02432079|Heart Defects, Congenital
101941|NCT02432079|Heart Diseases
101942|NCT02432079|Heterotaxy syndrome
101943|NCT02432079|Intestinal malrotation
101944|NCT02432079|Laterality
101945|NCT02432079|Left Atrial Isomerism
101946|NCT02432079|Pediatrics
101947|NCT02432079|Polysplenia
101948|NCT02432079|Right Atrial Isomerism
101949|NCT02432079|Splenic Diseases
101950|NCT02432079|Cilia
101951|NCT02432079|Situs inversus
101952|NCT02432079|Dextrocardia
101953|NCT02432066|Smoking
101954|NCT02432066|Smoking Cessation
101955|NCT02432053|FK506
101956|NCT02432053|Advagraf
101957|NCT02432053|Tacrolimus
101958|NCT02432053|Transplantation
101959|NCT02432040|chronic plaque psoriasis
101960|NCT02432040|psoriasis
101961|NCT02432040|atorvastatin
101962|NCT02432040|psoriasis area and severity index
101963|NCT02432040|betamethasone valerate
101964|NCT02431988|Relapsed
101965|NCT02431988|refractory
101966|NCT02431988|DLBCL
101967|NCT02431975|HIV
101968|NCT02431975|infant
101969|NCT02431975|antiretroviral therapy, highly active
101970|NCT02431975|antiretroviral agents
101971|NCT02431962|Lung Cancer
101972|NCT02431962|Screening
101973|NCT02431962|Computed Tomography
101974|NCT02431949|Music
101975|NCT02431949|Amusia
101976|NCT02431936|Stress
101977|NCT02431936|Blood Pressure
101978|NCT02431936|Salt Sensitivity
101979|NCT02431936|Renin-Angiotensin-Aldosterone System
101980|NCT02431936|Sympathetic Nervous System
101981|NCT02431923|Sequelae
101982|NCT02431923|Seroprevalence
101983|NCT02431923|Household Contacts
101984|NCT02431910|Electromyography
101985|NCT02431910|Baropodometry
101986|NCT02431910|Torque
101987|NCT02431897|Pelvic Organ Prolapse
101988|NCT02431897|Pelvic Floor Disorders
101989|NCT02431897|Therapy, Estrogen Replacement
101990|NCT02431897|Estrogens, Conjugated
101991|NCT02431871|Developmental dysplasia of the hip
101992|NCT02431871|Hip dysplasia
101993|NCT02431871|Occlusal defect
101994|NCT02431858|Nerve block
101995|NCT02431858|Catheter
101996|NCT02431858|Catheter over needle
101997|NCT02431858|Femoral Nerve
101998|NCT02431858|Anaesthesia
101999|NCT02431858|[E04.525.210.550]
102000|NCT02431858|[E02.148]
102001|NCT02431845|Obsessive-Compulsive Disorder
102002|NCT02431845|Pharmacogenetics
102003|NCT02431832|Elderly
102004|NCT02431819|Peripheral Arterial Disease
102005|NCT02431819|Progressive compressive stockings
102006|NCT02431793|Opioids
102007|NCT02431780|Neonatal Seizures
102008|NCT02431780|Decision Support Algorithm
102009|NCT02431780|EEG
102010|NCT02431741|Presence of at least one exuding malignant (fungating) wound in need for antimicrobial treatment
102011|NCT02431728|Melatonin
102012|NCT02431728|Post-acute withdrawal symptoms
102013|NCT02431728|Anxiety
102014|NCT02431728|Depression
102015|NCT02431728|Insomnia
102016|NCT02431728|Stress
102017|NCT02431728|Substance withdrawal syndrome
102018|NCT02431702|Paliperidone Palmitate
102019|NCT02431702|Oral Antipsychotics
102020|NCT02431702|Schizophrenia
102021|NCT02431702|Psychotic Disorders
102022|NCT02431702|Cognition in Schizophrenia
102023|NCT02431702|Brain intracortical myelin volume
102024|NCT02431702|Personal and Social Performance
102025|NCT02431702|Disease Modification
102026|NCT02431663|refractory convulsive status epilepticus
102027|NCT02431663|ketamine
102028|NCT02431663|conventional anesthetics
102029|NCT02431663|children
102030|NCT02431650|Induced blood stage malaria
102031|NCT02431650|Transmission
102032|NCT02431650|Mosquito feeding
102033|NCT02431650|OZ439
102034|NCT02431650|Primaquine
102035|NCT02431650|Piperaquine
102036|NCT02431650|Artefonomel
102037|NCT02431637|Induced blood stage malaria
102038|NCT02431637|Transmission
102039|NCT02431637|Standard membrane feeding assay
102040|NCT02431624|Healthy Volunteer
102041|NCT02431585|abdominal pain
102042|NCT02431585|gluten free diet
102043|NCT02431585|functional gastrointestinal disorders
102044|NCT02431572|Intracranial Tumors
102045|NCT02431572|Glioblastoma
102046|NCT02431572|Melanoma
102047|NCT02431559|Ovarian Cancer
102048|NCT02431559|Motolimod
102049|NCT02431559|Immunotherapy
102050|NCT02431559|PD-L1
102051|NCT02431559|MEDI4736
102052|NCT02431559|Pegylated
102053|NCT02431559|Liposomal
102054|NCT02431559|Doxorubicin
102055|NCT02431559|PLD
102056|NCT02431559|TLR-8
102057|NCT02431559|Durvalumab
102058|NCT02431546|Cardiology
102059|NCT02431546|Vascular
102060|NCT02431546|CAD
102061|NCT02431546|Duke
102062|NCT02431546|Cardiac Rehabilitation
102063|NCT02431546|Prevention
102064|NCT02431546|CVD
102065|NCT02431546|Mobile Health
102066|NCT02431546|Exercise
102067|NCT02431533|IBS-D
102068|NCT02431533|diarrhea predominant
102069|NCT02431520|Patient Compliance
102070|NCT02431520|HPV-DNA probes
102071|NCT02431520|Papanicolaou test
102072|NCT02431520|Cervical cancer
102073|NCT02431507|apnea
102074|NCT02431507|sleep apnea
102075|NCT02431507|magnetic sleep apnea device
102076|NCT02431507|hyoid bone
102077|NCT02431455|Bariatric Surgery
102078|NCT02431455|obesity, morbid
102079|NCT02431455|incentive spirometry
102080|NCT02431442|Heterozygous
102081|NCT02431442|MC4R deficiency
102082|NCT02431442|associated
102083|NCT02431429|leishmaniasis
102084|NCT02431429|miltefosine
102085|NCT02431429|spermiogram
102086|NCT02431416|females
102087|NCT02431416|ghrelin
102088|NCT02431416|GnRH
102089|NCT02431416|randomized, controlled study
102090|NCT02431416|children
102091|NCT02431390|RAPAELⓇ Smart Glove digital treatment system
102092|NCT02431390|Rehabilitation
102093|NCT02431390|Stroke
102094|NCT02431390|Upper limbs
102095|NCT02431377|infant formula
102096|NCT02431364|KPT-335
102097|NCT02431364|Verdinexor
102098|NCT02431364|Karyopharm
102099|NCT02431364|First-in-Human
102100|NCT02431364|Adult Subjects
102101|NCT02431351|KPT-330
102102|NCT02431351|Karyopharm
102103|NCT02431351|Selinexor
102104|NCT02431351|SIER
102105|NCT02431351|Myelodysplastic Syndrome (MDS)
102106|NCT02431351|Erythropoietin (EPO)
102107|NCT02431351|Refractory
102108|NCT02431338|Remote ischemic conditioning
102109|NCT02431338|Cost-effectiveness analysis
102110|NCT02431325|HIV
102111|NCT02431325|Atherosclerosis
102112|NCT02431325|Microbial Translocation
102113|NCT02431325|Teduglutide
102114|NCT02431325|Gastrointestinal Permeability
102115|NCT02431325|Inflammation
102116|NCT02431312|Chronic HBV
102117|NCT02431312|immunotherapy
102118|NCT02431312|DNA vaccine
102119|NCT02431312|electroporation
102120|NCT02431286|nausea and vomiting, postoperative
102121|NCT02431286|emesis, postoperative
102122|NCT02431273|TDF
102123|NCT02431273|FTC
102124|NCT02431273|MVC
102125|NCT02431273|TDF-FTC
102126|NCT02431273|TDF-FTC-MVC
102127|NCT02431273|IVR
102128|NCT02431273|ARV
102129|NCT02431260|solid tumor
102130|NCT02431260|lymphoma
102131|NCT02431260|BET bromodomain inhibitor
102132|NCT02431260|BRD
102133|NCT02431260|Diffuse large B-cell lymphoma (DLBCL)
102134|NCT02431260|Burkitt's lymphoma
102135|NCT02431260|c-MYC
102136|NCT02431260|colorectal cancer
102137|NCT02431260|Non-small cell lung cancer
102138|NCT02431260|Pancreatic adenocarcinoma
102139|NCT02431260|castration-resistant prostate cancer
102140|NCT02431260|breast cancer
102141|NCT02431260|NUT midline carcinoma
102142|NCT02431260|leukemia
102143|NCT02431260|acute myeloid leukemia (AML)
102144|NCT02431260|atypical chronic myeloid leukemia (aCML)
102145|NCT02431260|myelodysplastic syndrome (MDS)
102146|NCT02431260|myeloproliferative neoplasms
102147|NCT02431260|myelofibrosis (MF)
102148|NCT02431260|multiple myeloma (MM)
102149|NCT02431260|CMML
102150|NCT02431260|MDS/MPN-U
102151|NCT02431260|RARS-T
102152|NCT02431247|Immunodeficiency Virus Type 1, Human
102153|NCT02431247|Darunavir
102154|NCT02431247|Cobicistat
102155|NCT02431247|Tenofovir Alafenamide
102156|NCT02431247|Emtricitabine
102157|NCT02431247|Tenofovir Disoproxil Fumarate
102158|NCT02431234|Type 2 diabetes
102159|NCT02431234|Arterial calcification
102160|NCT02431234|Mediacalcosis
102161|NCT02431234|Calcium score
102162|NCT02431221|perhexiline
102163|NCT02431221|HCM
102164|NCT02431221|Hypertrophic Cardiomyopathy
102165|NCT02431221|CPEX
102166|NCT02431195|obesity
102167|NCT02431195|bariatric surgery
102168|NCT02431195|physical activity
102169|NCT02431195|eating habits
102170|NCT02431156|presbyopia
102171|NCT02431156|monovision
102172|NCT02431156|activities of daily living,
102173|NCT02431156|pseudophakic
102174|NCT02431130|Training Program
102175|NCT02431091|Optical Coherence Tomography
102176|NCT02431078|CTCs
102177|NCT02431078|ZEB1
102178|NCT02431078|gastric cancer
102179|NCT02431065|Rectus sheath block
102180|NCT02431065|Single port laparoscopy
102181|NCT02431026|induced mild hypothermia
102182|NCT02431026|cervical cooling collar
102183|NCT02431026|mri brain thermometry
102184|NCT02431026|MRI thermometry
102185|NCT02431026|rate-of-cooling
102186|NCT02431026|Excel Cryo Cooling Collar
102187|NCT02431013|Drug-drug interaction
102188|NCT02431013|Pharmacokinetics
102189|NCT02430961|Critical Care
102190|NCT02430961|Palliative Care
102191|NCT02430948|Screening
102192|NCT02430948|Shared Decision Making
102193|NCT02430935|Psychosis
102194|NCT02430935|Psychosis NOS
102195|NCT02430935|Schizophrenia
102196|NCT02430935|Schizoaffective Disorder
102197|NCT02430935|Early Intervention
102198|NCT02430896|Neuropsychological
102199|NCT02430896|neuroimaging
102200|NCT02430896|genetic markers
102201|NCT02430896|treatment response predictor
102202|NCT02430883|pain, RIRS, kidney
102203|NCT02430870|Drug therapy
102204|NCT02430844|acute kidney injury
102205|NCT02430844|radiographic contrast
102206|NCT02430844|critically ill
102207|NCT02430844|biomarker
102208|NCT02430818|ketamine
102209|NCT02430818|emergency medicine
102210|NCT02430818|orthopedics
102211|NCT02430805|hypertension
102212|NCT02430805|microinflammation and oxidative stress
102213|NCT02430805|renal disease
102214|NCT02430805|heart failure
102215|NCT02430805|genetics markers
102216|NCT02430805|genomics markers
102217|NCT02430805|proteomics markers
102218|NCT02430792|Prostatic Neoplasms
102219|NCT02430792|Exercise
102220|NCT02430792|Football
102221|NCT02430792|Quality of Life
102222|NCT02430779|irreversible electroporation
102223|NCT02430779|Unresectable Renal Pelvic and Ureteral Neoplasms
102224|NCT02430766|irreversible electroporation
102225|NCT02430766|Unresectable Lymph Node Metastases
102226|NCT02430753|irreversible electroporation
102227|NCT02430753|Lung Neoplasms
102228|NCT02430753|Respiratory Function Insufficiency
102229|NCT02430740|Fertilization in Vitro
102230|NCT02430740|antagonist protocol
102231|NCT02430740|antral follicle count
102232|NCT02430740|Anti-Mullerian Hormone
102233|NCT02430740|Reproductive Techniques, Assisted
102234|NCT02430714|Thyroid Cancer
102235|NCT02430714|Lenvima
102236|NCT02430714|Post-marketing surveillance
102237|NCT02430714|LEN01T
102238|NCT02430714|All-Patient Investigation
102239|NCT02430714|Lenvatinib Mesylate
102240|NCT02430701|irreversible electroporation
102241|NCT02430701|Unresectable Esophageal Neoplasms
102242|NCT02430688|irreversible electroporation
102243|NCT02430688|Unresectable Extremities
102244|NCT02430675|irreversible electroporation
102245|NCT02430675|Unresectable Laryngeal Neoplasms
102246|NCT02430662|irreversible electroporation
102247|NCT02430662|Unresectable Gallbladder Neoplasms
102248|NCT02430649|irreversible electroporation
102249|NCT02430649|Unresectable Prostatic Neoplasms
102250|NCT02430636|irreversible electroporation
102251|NCT02430636|Unresectable Stomach Neoplasms
102252|NCT02430623|irreversible electroporation
102253|NCT02430623|Unresectable Urinary Neoplasms
102254|NCT02430610|irreversible electroporation
102255|NCT02430610|Unresectable Uterine Cervical Neoplasms
102256|NCT02430597|irreversible electroporation
102257|NCT02430597|Hilus Pulmonary Neoplasms
102258|NCT02430545|Glasdegib
102259|NCT02430545|PF-04449913
102260|NCT02430545|Drug-drug interaction
102261|NCT02430545|CYP3A4 inducer
102262|NCT02430545|Pharmacokinetics
102263|NCT02430532|INSPIRE
102264|NCT02430532|SPMS
102265|NCT02430532|Tecfidera
102266|NCT02430532|BG00012
102267|NCT02430519|Furcation defects
102268|NCT02430519|PRF
102269|NCT02430519|Guided Tissue Regeneration
102270|NCT02430519|Allograft
102271|NCT02430493|ACS
102272|NCT02430480|Multiparametric MRI
102273|NCT02430480|Prostatectomy
102274|NCT02430480|Focal Prostate Cancer
102275|NCT02430480|Normal Testosterone
102276|NCT02430480|Non Metastatic
102277|NCT02430454|ICU
102278|NCT02430454|decision making
102279|NCT02429388|Heart failure
102280|NCT02429388|Spironolactone
102281|NCT02429388|Diuretics
102282|NCT02429375|Mocetinostat (MGCD0103)
102283|NCT02429375|Brentuximab Vedotin (SGN-35)
102284|NCT02429375|Relapsed
102285|NCT02429375|Refractory
102286|NCT02429323|induction
102287|NCT02429323|pediatrics
102288|NCT02429323|sevoflurane
102289|NCT02429323|intubation time
102290|NCT02429310|Intermittent Claudication
102291|NCT02429310|IC
102292|NCT02429310|Peripheral Arterial Disease
102293|NCT02429310|Peripheral Vascular Disease
102294|NCT02429310|Peripheral Arterial Occlusive Disease
102295|NCT02429310|Lower Limb Arterial Disease
102296|NCT02429310|Supervised Exercise Therapy
102297|NCT02429310|Supervised Exercise Programme
102298|NCT02429310|Exercise Therapy
102299|NCT02429297|Hypertension
102300|NCT02429297|Diabetes
102301|NCT02429297|mHealth
102302|NCT02429297|Interactive Voice Response
102303|NCT02429297|Bolivia
102304|NCT02429297|Chronic disease
102305|NCT02429284|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
102306|NCT02429284|Pulmonary Endarterectomy (PEA)
102307|NCT02429284|Pulmonary Thromboendarterectomy (PTE)
102308|NCT02429284|Pulmonary Hypertension
102309|NCT02429284|Balloon Pulmonary Angioplasty (BPA)
102310|NCT02429271|undergoing thrombolysis
102311|NCT02429245|Knee
102312|NCT02429245|Knee osteoarthritis
102313|NCT02429245|Knee replacement
102314|NCT02429232|Pioglitazone
102315|NCT02429232|Linagliptin
102316|NCT02429232|Diabetes mellitus
102317|NCT02429232|Diabetic macular edema
102318|NCT02429232|Kidney
102319|NCT02430402|Climatotherapy
102320|NCT02430389|hemodynamic stability
102321|NCT02430389|remifentanil
102322|NCT02430376|Non-Muscle Myosin
102323|NCT02430363|pembrolizumab
102324|NCT02430363|MK-3475
102325|NCT02430363|Glioblastoma
102326|NCT02430363|Gliosarcoma
102327|NCT02430363|Suppressor of the PI3K/Akt pathways
102328|NCT02430363|Pictilisib
102329|NCT02430363|GDC-0941
102330|NCT02430363|BEZ235
102331|NCT02430363|NVP-BEZ235
102332|NCT02430363|Ipatasertib
102333|NCT02430363|GDC-0068
102334|NCT02430311|Chinese Patients
102335|NCT02430285|biliary stone
102336|NCT02430285|cholelithiasis
102337|NCT02430285|pancreatitis
102338|NCT02430285|EUS
102339|NCT02430285|ERCP
102340|NCT02430285|early
102341|NCT02430285|choledocholithiasis
102342|NCT02430272|Child
102343|NCT02430272|outpatient
102344|NCT02430272|premedication
102345|NCT02430259|rifapentine
102346|NCT02430259|isoniazid
102347|NCT02430259|QuantiFERON Gold In-Tube
102348|NCT02430259|tuberculin skin test
102349|NCT02430207|Pulmonary Embolism
102350|NCT02430207|Temporary Pacing
102351|NCT02430207|Femoral Vein
102352|NCT02430207|Subclavian Vein
102353|NCT02430168|Stone
102354|NCT02430168|RIRs
102355|NCT02430168|PCNL
102356|NCT02430168|Pain
102357|NCT02430155|condom-loaded Foley's catheter
102358|NCT02430155|Bakri balloon
102359|NCT02430155|primary atonic postpartum hemorrhage
102360|NCT02430142|microcirculation
102361|NCT02430142|oxygen uptake
102362|NCT02430142|hypoxia
102363|NCT02430142|adenosine
102364|NCT02430142|central venous saturation
102365|NCT02430142|hypoxanthine
102366|NCT02430142|laserdoppler
102367|NCT02430103|Breast Cancer
102368|NCT02430103|Preservation of Ovarian Reserve Function
102369|NCT02430090|regionel anesthesia
102370|NCT02430090|levobupivacaine
102371|NCT02430090|ceserean section
102372|NCT02430077|Hepatic Steatosis
102373|NCT02430051|sensory processing
102374|NCT02430051|oral care
102375|NCT02430051|electrodermal activity
102376|NCT02430051|cooperation
102377|NCT02430051|anxiety
102378|NCT02430051|distress
102379|NCT02430051|stress
102380|NCT02430051|behavior
102381|NCT02430051|occupational therapy
102382|NCT02430038|transperineal ultrasound
102383|NCT02430038|labour
102384|NCT02430038|sonopartogram
102385|NCT02430038|prediction model
102386|NCT02430025|Cardiovascular Diseases
102387|NCT02430025|Vascular Diseases
102388|NCT02430025|Acute Coronary Syndrome
102389|NCT02430025|Chest Pain
102390|NCT02430025|Heart Diseases
102391|NCT02430025|Myocardial Ischemia
102392|NCT02430025|Pathologic Processes
102393|NCT02430012|coronary artery bypass grafting
102394|NCT02430012|quality improvement
102395|NCT02430012|secondary preventions
102396|NCT02429986|Adaptive Servo-Ventilation
102397|NCT02429986|Chronic Heart Failure
102398|NCT02429986|Central Sleep Apnea Syndrome
102399|NCT02429986|Central and Obstructive Sleep Apnea Syndrome
102400|NCT02429986|Complex Sleep Apnea Syndrome
102401|NCT02429986|Hunter-Cheyne-Stokes Breathing
102402|NCT02429986|Periodic Breathing
102403|NCT02429973|Osteosarcoma
102404|NCT02429960|Nociception
102405|NCT02429960|Analgesia
102406|NCT02429960|Intraoperative
102407|NCT02429960|Monitoring
102408|NCT02429947|Charcot Marie Tooth disease
102409|NCT02429947|CMT
102410|NCT02429947|HMSN
102411|NCT02429947|HMN
102412|NCT02429947|HSN
102413|NCT02429934|Systemic Lupus Erythematosus (SLE)
102414|NCT02429934|Abatacept (Orencia)
102415|NCT02429934|Arthritis
102416|NCT02429921|dietary intervention
102417|NCT02429921|arsenic poisoning
102418|NCT02429921|high-Se lentils
102419|NCT02429895|Methotrexate
102420|NCT02429895|Efficacy
102421|NCT02429895|Safety
102422|NCT02429882|Ankylosing Spondyloarthritis; non-radiographic axial spondyloarthritis
102423|NCT02429843|Non-squamous cell lung cancer
102424|NCT02429843|Non-squamous non-small cell lung cancer
102425|NCT02429843|vascular endothelial growth factor (VEGF)
102426|NCT02429843|TRC105
102427|NCT02429830|gastroesophageal reflux disease
102428|NCT02429830|GERD
102429|NCT02429830|obesity
102430|NCT02429830|LSG
102431|NCT02429830|Laparoscopic Sleeve Gastrectomy
102432|NCT02429817|Pulmonary aerosol distribution
102433|NCT02429817|SPECT-CT analysis
102434|NCT02429817|High flow nasal cannula
102435|NCT02429817|Vibrating-mesh nebulizer
102436|NCT02429817|Jet nebulizer
102437|NCT02429791|two-drug regimen
102438|NCT02429791|virologically-suppressed
102439|NCT02429791|dolutegravir plus rilpivirine
102440|NCT02429791|integrase inhibitor
102441|NCT02429791|protease inhibitor
102442|NCT02429791|NNRTI-sparing
102443|NCT02429791|non-nucleoside reverse transcriptase inhibitor
102444|NCT02429791|HIV
102445|NCT02429791|nucleoside reverse transcriptase inhibitors
102446|NCT02429752|inspiratory muscle training
102447|NCT02429752|low back pain
102448|NCT02429752|respiration
102449|NCT02429752|breathing
102450|NCT02429739|Working Memory Training, computerized
102451|NCT02429739|Dyslexia
102452|NCT02429739|Reading fluency
102453|NCT02429739|Reading comprehension
102454|NCT02429726|malignant pleural effusion, p53 gene therapy, cisplatin
102455|NCT02429713|tourniquet
102456|NCT02429713|total knee arthroplasty
102457|NCT02429713|blood loss
102458|NCT02429674|Depression
102459|NCT02429674|Adolescence
102460|NCT02429648|AF
102461|NCT02429635|Exercise
102462|NCT02429635|lifestyle diseases
102463|NCT02429635|well-being
102464|NCT02429596|antiepileptic drugs
102465|NCT02429596|generic substitution
102466|NCT02429570|meclofenamate
102467|NCT02429570|15-068
102468|NCT02429557|autonomic failure
102469|NCT02429557|orthostatic hypotension
102470|NCT02429557|compression garments
102471|NCT02429557|treatment
102472|NCT02429544|Breast cancer
102473|NCT02429544|Stage IV breast cancer
102474|NCT02429544|Metastatic
102475|NCT02429544|Residential group programs
102476|NCT02429544|Questionnaires
102477|NCT02429544|Surveys
102478|NCT02429544|EEG
102479|NCT02429544|Computer testing
102480|NCT02429544|Saliva test
102481|NCT02429544|Study diary
102482|NCT02429544|Actigraph
102483|NCT02429531|Pneumovax 23
102484|NCT02429531|Typhim Vi
102485|NCT02429531|allohemagglutinins
102486|NCT02429518|leishmaniasis
102487|NCT02429518|miltefosine
102488|NCT02429518|EKG
102489|NCT02429492|Pathophysiology
102490|NCT02429492|Spinal interneurons
102491|NCT02429492|Electrophysiology
102492|NCT02429492|EMG
102493|NCT02429492|transcranial magnetic stimulation (TMS)
102494|NCT02429479|Advance Care Planning
102495|NCT02429479|Living Will
102496|NCT02429479|Family Caregiver
102497|NCT02429479|Advance Directive
102498|NCT02429479|Surrogate Decision Maker
102499|NCT02429479|Proxy
102500|NCT02429479|Self-Efficacy
102501|NCT02429466|testicular germ cell tumor
102502|NCT02429466|ovarian germ cell tumor
102503|NCT02429466|platinum refractory
102504|NCT02429466|cisplatin
102505|NCT02429466|SGI110
102506|NCT02429466|Guadecitabine
102507|NCT02429453|Warfarin
102508|NCT02429453|Traumatic intracranial hemorrhage
102509|NCT02429453|prothrombin complex concentrate
102510|NCT02429453|fresh frozen plasma
102511|NCT02429453|Spontaneous intracranial hemorrhage
102512|NCT02429427|Primary Breast Cancer
102513|NCT02429427|Celecoxib
102514|NCT02429414|Surgical Procedure
102515|NCT02429414|Fiberoptic bronchoscopy
102516|NCT02429414|FOB
102517|NCT02429414|Non-Video Double Lumen Tube
102518|NCT02429414|DLT
102519|NCT02429414|Video Double Lumen Tube
102520|NCT02429414|VDLT
102521|NCT02429401|binge drinking
102522|NCT02429401|heavy drinking
102523|NCT02429154|spectroscopy, near-infrared
102524|NCT02429154|Infant
102525|NCT02429154|Anesthesia, general
102526|NCT02429128|Polycystic Ovary Syndrome (PCOS)
102527|NCT02429115|peer mentoring
102528|NCT02429115|chronic kidney disease
102529|NCT02429115|quality of life
102530|NCT02429115|pcori
102531|NCT02429115|caregiver burden
102532|NCT02429102|Phase 1
102533|NCT02429102|Healthy subjects
102534|NCT02429102|Pharmacokinetics of MT-8554
102535|NCT02429089|recurrent
102536|NCT02429089|metastatic
102537|NCT02429063|Solid Tumors
102538|NCT02429050|Chronic Obstructive Pulmonary Disease
102539|NCT02429050|Dyspnea
102540|NCT02429050|Breathlessness
102541|NCT02429050|Morphine
102542|NCT02429050|Opioid
102543|NCT02429050|Symptom Management
102544|NCT02429037|p53
102545|NCT02429037|gene therapy
102546|NCT02429037|head and neck cancer
102547|NCT02429024|Diabetes Mellitus
102548|NCT02429024|A1c
102549|NCT02429011|depression
102550|NCT02429011|MRI
102551|NCT02429011|treatment-resistant
102552|NCT02429011|imaging
102553|NCT02429011|ketamine
102554|NCT02428985|Riociguat
102555|NCT02428985|Adempas
102556|NCT02428985|soluble guanylate cyclase (sGC) stimulator
102557|NCT02428985|Pulmonary arterial hypertension
102558|NCT02428985|Japan
102559|NCT02428985|Post-marketing surveillance
102560|NCT02428972|brain tumor
102561|NCT02428972|quality of life
102562|NCT02428972|cognition
102563|NCT02428972|anesthetic technique
102564|NCT02428959|Amyl Nitrite
102565|NCT02428959|High Resolution Manometry
102566|NCT02428946|Insulin Sensitivity
102567|NCT02428946|obesity
102568|NCT02428946|dopamine
102569|NCT02428933|Brown Adipose Tissue
102570|NCT02428933|Obesity
102571|NCT02428933|Insulin Sensitivity
102572|NCT02428933|Dopamine
102573|NCT02428920|cardiovascular health
102574|NCT02428920|behavior change
102575|NCT02428920|community-based
102576|NCT02428920|prevention
102577|NCT02428907|simulation training
102578|NCT02428907|minimal sedation
102579|NCT02428907|colonoscopy
102580|NCT02428907|patient satisfaction
102581|NCT02428907|teamwork
102582|NCT02428907|team training
102583|NCT02428907|patient safety
102584|NCT02428881|onabotulinumtoxin A
102585|NCT02428868|hip fracture
102586|NCT02428868|anemia
102587|NCT02428868|blood transfusion
102588|NCT02428868|tranexamic acid
102589|NCT02428868|intravenous iron
102590|NCT02428855|Cholangiocarcinoma
102591|NCT02428842|Cervical cancer
102592|NCT02428842|Tumor biopsies
102593|NCT02428842|Standard treatment
102594|NCT02428842|Molecular profile
102595|NCT02428842|Next Generation Sequencing
102596|NCT02428829|hip
102597|NCT02428829|replacement
102598|NCT02428829|arthroplasty
102599|NCT02428829|total
102600|NCT02428829|orthopaedic
102601|NCT02428829|rehabiliation
102602|NCT02428829|physiotherapy
102603|NCT02428829|therapy
102604|NCT02428816|differential diagnosis
102605|NCT02428816|multimodal MRI
102606|NCT02428816|Parkinson's Disease
102607|NCT02428816|Multiple System Atrophy
102608|NCT02428803|Peritoneal Dialysis
102609|NCT02428777|Hysteroscopy
102610|NCT02428751|Lymphoma, Large B-Cell, Diffuse
102611|NCT02428751|liposomal doxorubicin
102612|NCT02428751|doxorubicin
102613|NCT02428751|event-free survival
102614|NCT02428738|Influenza Vaccine
102615|NCT02428738|Text Message
102616|NCT02428673|Osteopenia
102617|NCT02428673|spinal muscular atrophy
102618|NCT02428673|cerebral palsy
102619|NCT02428673|muscular dystrophy
102620|NCT02428673|spina bifida
102621|NCT02428673|Rett Syndrome
102622|NCT02428660|Polypharmacy
102623|NCT02428660|Chronic conditions
102624|NCT02428660|Drug Therapy Problems
102625|NCT02428660|Medication Therapy Management
102626|NCT02428660|Medication-Related Problems
102627|NCT02428660|CYP3A4
102628|NCT02428660|CYP3A5
102629|NCT02428660|Drug-drug interactions
102630|NCT02428660|Drug-gene interactions
102631|NCT02428660|Drug-drug-gene interactions
102632|NCT02428660|Adverse Drug Reactions
102633|NCT02428660|Activities of Daily Living
102634|NCT02428647|growth
102635|NCT02428647|plasma zinc concentration
102636|NCT02428634|Cardiovascular health promotion
102637|NCT02428634|Children
102638|NCT02428634|School intervention
102639|NCT02428621|early orthodontic treatment
102640|NCT02428621|activator
102641|NCT02428621|removable appliance
102642|NCT02428621|Twicare®
102643|NCT02428621|Herbst appliance
102644|NCT02428608|Glabellar Lines
102645|NCT02428608|Botulinum toxin, Type A
102646|NCT02428582|endovascular treatment
102647|NCT02428582|arterial occlusive disease
102648|NCT02428582|bare metal stent
102649|NCT02428582|polytetrafluoroethylene covered stent
102650|NCT02428569|shared decision making
102651|NCT02428569|patient education
102652|NCT02428569|decision aids
102653|NCT02428556|Decision making
102654|NCT02428543|FLT3-ITD patients in first complete remission
102655|NCT02428517|acute lymphoblastic leukemia
102656|NCT02428517|allogeneic hematopoietic stem cell transplantation
102657|NCT02428517|alternative hematopoietic stem cell donor
102658|NCT02428517|busulfan
102659|NCT02428517|antithymocyte globulin
102660|NCT02428504|Questionnaire
102661|NCT02428491|Diphtheria
102662|NCT02428491|Tetanus
102663|NCT02428491|Pertussis
102664|NCT02428491|Poliomyelitis
102665|NCT02428491|Hepatitis B
102666|NCT02428491|DTaP-IPV-Hep B-PRP-T Combined Vaccine (Hexaxim™)
102667|NCT02428452|autism
102668|NCT02428452|Autism SPectrum Disorder
102669|NCT02428452|early intervention
102670|NCT02428452|infant
102671|NCT02428452|toddler
102672|NCT02428452|early identification
102673|NCT02428452|pivotal response training (PRT)
102674|NCT02428452|control group
102675|NCT02428452|treatment group
102676|NCT02428452|at risk
102677|NCT02428452|social communication
102678|NCT02428452|positive affect
102679|NCT02428452|smiling
102680|NCT02428439|genetic markers
102681|NCT02428439|predictors
102682|NCT02428439|Antidepressive Agents
102683|NCT02428439|Suicidal Ideation
102684|NCT02428439|Adolescent
102685|NCT02428426|Mucosal Microbiome
102686|NCT02428426|gastric intestinal metaplasia
102687|NCT02428426|duodenum
102688|NCT02428413|Waste Anesthetic Gas (WAG)
102689|NCT02428387|caregivers
102690|NCT02428387|intervention
102691|NCT02428387|health related quality of life
102692|NCT02428387|dementia
102693|NCT02428374|MRI
102694|NCT02428374|Ventricular function, left
102695|NCT02428309|Tregs
102696|NCT02428296|Clinical Trial
102697|NCT02428296|Congenital Malformations
102698|NCT02428296|Overgrowth
102699|NCT02428296|Pilot Drug Treatment Trial
102700|NCT02428257|hip fracture
102701|NCT02428257|elderly
102702|NCT02428257|continous spinal anesthesia
102703|NCT02428257|hypobaric bupivacaine
102704|NCT02428257|isobaric bupivacaine
102705|NCT02428257|hypotension
102706|NCT02428244|Smoking
102707|NCT02428244|Cessation
102708|NCT02428244|Trauma
102709|NCT02428244|Fracture
102710|NCT02428244|Complications
102711|NCT02428218|Randomized
102712|NCT02428218|Ages 10-17
102713|NCT02428218|Pediatrics
102714|NCT02428218|Placebo controlled
102715|NCT02428218|Relapse-Remitting
102716|NCT02428218|Multiple Sclerosis
102717|NCT02428218|Safety
102718|NCT02428218|Efficacy
102719|NCT02428218|BG00012
102720|NCT02428179|Surgical site infection
102721|NCT02428179|Intraoperative briefings
102722|NCT02428179|Mortality
102723|NCT02428179|Wound closure
102724|NCT02428179|Surgical procedure
102725|NCT02428166|crosslinking
102726|NCT02428166|keratoconus
102727|NCT02428166|keratometry
102728|NCT02428166|pachymetry
102729|NCT02428166|pentacam
102730|NCT02428153|static stretching
102731|NCT02428153|dynamic stretching
102732|NCT02428153|muscle-tendon unit
102733|NCT02428153|ultrasound
102734|NCT02428153|Subjects
102735|NCT02428140|ischemic stroke
102736|NCT02428140|atrial fibrillation
102737|NCT02428140|etiologic investigations
102738|NCT02428140|secondary prevention
102739|NCT02428140|anticoagulation
102740|NCT02428140|arrhythmias
102741|NCT02428140|embolic stroke, undetermined etiology
102742|NCT02428140|implantable loop recorder
102743|NCT02428140|external loop recorder
102744|NCT02428062|Post-operative complications
102745|NCT02428062|Mild cognitive impairment
102746|NCT02428062|Delirium
102747|NCT02428036|TBI-1401(HF10)
102748|NCT02428036|HF10
102749|NCT02428036|HSV-1
102750|NCT02428036|Oncolytic virus
102751|NCT02428036|Oncolytic virotherapy
102752|NCT02428036|Phase I
102753|NCT02428036|Melanoma
102754|NCT02428036|Intratumoral administration
102755|NCT02428023|Thalassemia
102756|NCT02428023|trait
102757|NCT02428023|coronary
102758|NCT02428023|stroke
102759|NCT02427997|Virtual Reality
102760|NCT02427997|Treadmill
102761|NCT02427997|Multiple Sclerosis
102762|NCT02427984|Internal Left Hip Prosthesis
102763|NCT02427984|Internal Right Hip Prosthesis
102764|NCT02427958|Drug Therapy
102765|NCT02427945|Information provision
102766|NCT02427932|Pharmacokinetics (PK)
102767|NCT02427932|Pharmacodynamics (PD)
102768|NCT02427919|G-CSF
102769|NCT02427919|G-CSF receptor
102770|NCT02427919|AML
102771|NCT02427919|refractory AML
102772|NCT02427919|Neutropenic fever
102773|NCT02427919|salvage chemotherapy
102774|NCT02427906|cirrhosis
102775|NCT02427906|gut microbiota
102776|NCT02427906|transjugular portosystemic shunt
102777|NCT02427906|hepatic encephalopathy
102778|NCT02427893|immunotherapy
102779|NCT02427893|Vemurafenib
102780|NCT02427893|Cobimetinib
102781|NCT02427880|Edema
102782|NCT02427880|Nephrotic syndrome
102783|NCT02427880|Acetazolamide
102784|NCT02427880|Furosemide
102785|NCT02427867|remote ischemic preconditioning
102786|NCT02427867|non cardiac surgery
102787|NCT02427867|myocardial ischemia
102788|NCT02427854|Major delivery complications
102789|NCT02427854|Perineal injuries
102790|NCT02427854|episiotomy
102791|NCT02427789|Physical exercise
102792|NCT02427789|Biomarkers
102793|NCT02427789|Neuroprotection
102794|NCT02427789|ergospirometry
102795|NCT02427789|Major Depressive Disorder
102796|NCT02427763|Removable Orthodontic Appliance;
102797|NCT02427763|malocclusion
102798|NCT02427763|Streptococcus mutans
102799|NCT02427763|Lactobacillus
102800|NCT02427763|Epithelium
102801|NCT02427737|Magnetic Resonance Imaging
102802|NCT02427737|Patient satisfaction
102803|NCT02427737|Diagnostic Imaging
102804|NCT02427711|Reduction of blood loss for revisions of knee arthroplasty
102805|NCT02427711|blood transfusions
102806|NCT02427711|Readmission
102807|NCT02427711|Bipolar sealer
102808|NCT02427672|antisocial behavior
102809|NCT02427672|aggression
102810|NCT02427672|transcranial direct current stimulation
102811|NCT02427672|dorsolateral prefrontal cortex
102812|NCT02427672|associated risk factors
102813|NCT02427659|VRD
102814|NCT02427659|Virtual Reality as Distraction during Procedure
102815|NCT02427659|Burn Wound Care
102816|NCT02427646|Kinematics
102817|NCT02427646|Botulinum toxin type A
102818|NCT02427633|recovery position
102819|NCT02427633|comatose
102820|NCT02427633|resource limited
102821|NCT02427620|Lymphoma
102822|NCT02427620|Mantle cell lymphoma
102823|NCT02427620|MCL
102824|NCT02427620|B-lymphocyte antigen
102825|NCT02427620|CD20
102826|NCT02427620|Ibrutinib
102827|NCT02427620|PCI-32765
102828|NCT02427620|Imbruvica
102829|NCT02427620|Rituximab
102830|NCT02427620|Rituxan
102831|NCT02427620|Cyclophosphamide
102832|NCT02427620|Cytoxan
102833|NCT02427620|Neosar
102834|NCT02427620|Vincristine
102835|NCT02427620|Mesna
102836|NCT02427620|Mesnex
102837|NCT02427620|Dexamethasone
102838|NCT02427620|Decadron
102839|NCT02427620|Doxorubicin
102840|NCT02427620|Doxorubicin hydrochloride
102841|NCT02427620|Adriamycin PFS
102842|NCT02427620|Adriamycin RDF
102843|NCT02427620|Adriamycin
102844|NCT02427620|Rubex
102845|NCT02427620|G-CSF
102846|NCT02427620|Filgrastim
102847|NCT02427620|Neupogen
102848|NCT02427620|Methotrexate
102849|NCT02427620|Cytarabine
102850|NCT02427620|Ara-C
102851|NCT02427620|Cytosar
102852|NCT02427620|DepoCyt
102853|NCT02427620|Cytosine arabinosine hydrochloride
102854|NCT02427620|Citrovorum
102855|NCT02427620|Leucovorin
102856|NCT02427620|Wellcovorin
102857|NCT02427607|Epilepsy
102858|NCT02427607|Perampanel
102859|NCT02427594|Kidney Diseases
102860|NCT02427594|Renal Insufficiency, Chronic
102861|NCT02427594|Dietary nonvolatile acid load
102862|NCT02427594|Blood pressure
102863|NCT02427594|Urine net acid excretion
102864|NCT02427568|Anxiety
102865|NCT02427568|MDMA
102866|NCT02427568|Life-threatening illness
102867|NCT02427568|psychotherapy
102868|NCT02427542|Randomized Controlled Trial
102869|NCT02427529|hcg
102870|NCT02427503|asthma
102871|NCT02427503|sinonasal polyposis
102872|NCT02427503|eosinophilic bronchial inflammation
102873|NCT02427503|endoscopic sinus surgery
102874|NCT02427490|Palliative Care
102875|NCT02427490|Caregivers
102876|NCT02427490|Medical Oncology
102877|NCT02427464|diabetic
102878|NCT02427464|neuropathy
102879|NCT02427464|shooting pain
102880|NCT02427464|burning pain
102881|NCT02427464|pins and needles pain
102882|NCT02427464|foot pain
102883|NCT02427464|ViroMed
102884|NCT02427438|video
102885|NCT02427438|handout
102886|NCT02427438|home program
102887|NCT02427438|stabilization
102888|NCT02427438|strengthening
102889|NCT02427438|core
102890|NCT02427425|Transcutaneous Electric Nerve Stimulation
102891|NCT02427425|Pain
102892|NCT02427412|Tranexamic Acid
102893|NCT02427412|Knee Arthroplasty
102894|NCT02427412|Blood loss
102895|NCT02427412|Blood transfusion
102896|NCT02427412|Thrombolic complication
102897|NCT02427412|Total blood loss 24 h after ended surgery.
102898|NCT02427412|Total blood loss 2 days after ended surgery.
102899|NCT02427386|Endometriosis
102900|NCT02427386|Pelvic pain
102901|NCT02427386|Homeopathy
102902|NCT02427386|RCT
102903|NCT02427373|bioavailability
102904|NCT02427373|fish oil
102905|NCT02427373|krill oil
102906|NCT02427360|Retrospective Studies
102907|NCT02427360|Clinical Efficacy
102908|NCT02427321|Cystoscopy
102909|NCT02427321|Bladder cancer
102910|NCT02427321|Bladder imaging
102911|NCT02427308|leishmaniasis
102912|NCT02427308|miltefosine
102913|NCT02427308|pregnancy
102914|NCT02427269|Barrett's Esophagus
102915|NCT02427269|Esophageal Cancer
102916|NCT02427269|Intramucosal Adenocarcinoma
102917|NCT02427230|Pelvic Floor Muscle Training
102918|NCT02427230|Neuromuscular Electrical Stimulation
102919|NCT02427230|Urinary Incontinence
102920|NCT02427230|Spinal Cord Injury
102921|NCT02427204|Hepatitis C infection
102922|NCT02427204|Hepatitis C treatment
102923|NCT02427191|Chronic plantar fasciitis
102924|NCT02427191|Heel pain
102925|NCT02427178|Allogeneic Hematopoietic Stem Cell Transplantation
102926|NCT02427178|MNGIE
102927|NCT02427178|Stem Cell transplant
102928|NCT02427113|TMD
102929|NCT02427113|Music Medicine
102930|NCT02427113|Vibroacousitc Therapy
102931|NCT02427100|Homeless
102932|NCT02427100|Randomized Controlled Trial
102933|NCT02427100|Diet
102934|NCT02427100|Physical Activity
102935|NCT02427087|Nonalcoholic fatty liver
102936|NCT02427087|Physical activity
102937|NCT02427087|NAFLD
102938|NCT02427087|Anthropometry
102939|NCT02427087|Body Composition
102940|NCT02427048|Clinical Practice Guidelines
102941|NCT02427022|evidence based practices, critical time intervention
102942|NCT02426944|atrial fibrillation
102943|NCT02426944|cardioembolic event
102944|NCT02426944|stroke
102945|NCT02426944|left atrial appendage closure
102946|NCT02426944|novel anticoagulants
102947|NCT02426931|retrograde intrarenal surgery
102948|NCT02426931|flexible ureteroscopy
102949|NCT02426931|renal calculi
102950|NCT02426892|Solid Tumors
102951|NCT02426892|HPV-16 Positive Incurable Solid Tumors
102952|NCT02426892|ISA101
102953|NCT02426892|HPV-16 vaccination
102954|NCT02426892|Nivolumab
102955|NCT02426892|BMS-936558
102956|NCT02426892|Opdivo
102957|NCT02426879|three-field lymphadenectomy
102958|NCT02426879|cervical metastases
102959|NCT02426879|esophagectomy
102960|NCT02426853|Cancer Prevention
102961|NCT02426853|Sun protection
102962|NCT02426853|Photograph
102963|NCT02426853|UV photograph
102964|NCT02426853|Ultraviolet
102965|NCT02426853|Pamphlets
102966|NCT02426853|Handouts
102967|NCT02426853|Questionnaires
102968|NCT02426853|Surveys
102969|NCT02426853|Skin cancer risk behaviors
102970|NCT02426840|Adverse bone health
102971|NCT02426840|Bone demineralization
102972|NCT02426840|HIV-infection
102973|NCT02426840|Children
102974|NCT02426840|Adolescents
102975|NCT02426840|Calcium
102976|NCT02426840|Vitamin D
102977|NCT02426840|Supplementation
102978|NCT02426814|Patient Compliance
102979|NCT02426814|Mobile Applications
102980|NCT02426801|Patient Compliance
102981|NCT02426801|Mobile Applications
102982|NCT02426801|Medication Adherence
102983|NCT02426788|medically unexplained
102984|NCT02426788|fibromyalgia
102985|NCT02426788|PoTS
102986|NCT02426788|non-cardiac chest pain
102987|NCT02426788|CFS
102988|NCT02426788|IBS
102989|NCT02426788|functional neurological
102990|NCT02426788|chronic pain
102991|NCT02426788|hyperventilation
102992|NCT02426762|skin sealant
102993|NCT02426762|laparoscopic surgery
102994|NCT02426762|surgical site infection
102995|NCT02426762|wound healing
102996|NCT02426736|Shoulder Joint
102997|NCT02426736|Arthroscopy
102998|NCT02426736|Ambulatory surgical procedures
102999|NCT02426736|Pain, Postoperative
103000|NCT02426736|Brachial Plexus Block
103001|NCT02426736|Corticosteroid
103002|NCT02426736|Dexamethasone
103003|NCT02426736|Bupivacaine
103004|NCT02426736|Perineural
103005|NCT02426710|ablation, atrial flutter, intracardiac echocardiography
103006|NCT02426697|bone metastasis, radiotherapy, pain, prevention
103007|NCT02426684|End Stage Renal Disease
103008|NCT02426684|Kidney Transplant
103009|NCT02426684|Desensitization
103010|NCT02426684|Highly Sensitized
103011|NCT02426684|Antibodies
103012|NCT02426671|neuromodulation
103013|NCT02426671|Minimum Masking Level
103014|NCT02426645|Biomarkers
103015|NCT02426645|Sepsis
103016|NCT02426645|Multi organ dysfunction
103017|NCT02426645|Immunomonitoring
103018|NCT02426645|CEUS
103019|NCT02426632|Healthy
103020|NCT02426632|JNJ-53718678
103021|NCT02426606|Lentils
103022|NCT02426606|Post-prandial
103023|NCT02426606|Glycemic response
103024|NCT02426606|Insulin response
103025|NCT02426606|Diabetes
103026|NCT02426606|Mixed meal
103027|NCT02426606|Glycemia
103028|NCT02426606|Slowly digestible starch
103029|NCT02426606|Post-prandial glycemia
103030|NCT02426593|CHF
103031|NCT02426593|Heart Failure
103032|NCT02426567|Crohn's Disease
103033|NCT02426567|Exclusive Enteral Nutrition
103034|NCT02426567|Dietary Treatment
103035|NCT02426567|Gut microbiota
103036|NCT02426541|Diabetes Mellitus
103037|NCT02426541|Dapagliflozin
103038|NCT02426541|Placebo
103039|NCT02426541|Insulin resistance
103040|NCT02426541|Insulin sensitivity
103041|NCT02426476|heart rate variability
103042|NCT02426476|biofeedback
103043|NCT02426476|chronic pain
103044|NCT02426476|Veterans
103045|NCT02426463|Neonatal intensive care
103046|NCT02426463|need for intratracheal intubation
103047|NCT02426437|Acute Exacerbation of COPD (AECOPD)
103048|NCT02426437|COPD
103049|NCT02426437|Emphysema
103050|NCT02426437|Chronic Bronchitis
103051|NCT02426424|c-PAP
103052|NCT02426398|EEG
103053|NCT02426372|Ulcerative Colitis
103054|NCT02426372|Inflammatory Bowel Disease
103055|NCT02426346|Adolescent; Adolescent obesity; Community-based; Overweight
103056|NCT02426307|Thrombosis
103057|NCT02426307|Cardiovascular disease
103058|NCT02426307|Oral anticoagulation
103059|NCT02426307|bioprosthesis
103060|NCT02426307|Multidetector Computed Tomography
103061|NCT02426268|cardiac surgery
103062|NCT02426268|cerebral oximetry
103063|NCT02426268|lower extremity oximetry
103064|NCT02426255|Severe trauma
103065|NCT02426255|traumatic Brain injury
103066|NCT02426255|Hemorrhage
103067|NCT02426242|brain-injury
103068|NCT02426242|extubation
103069|NCT02426229|SSc
103070|NCT02426229|systemic sclerosis
103071|NCT02426229|cutaneous systemic sclerosis
103072|NCT02426216|prostate cancer
103073|NCT02426216|chemoprevention
103074|NCT02426216|biomarker
103075|NCT02426203|Echocardiography
103076|NCT02426177|postpartum hypertension
103077|NCT02426177|labetalol in postpartum hypertension
103078|NCT02426177|nifedipine in postpartum hypertension
103079|NCT02426125|carcinoma of the bladder
103080|NCT02426125|carcinoma of the urethra
103081|NCT02426125|carcinoma the of ureter
103082|NCT02426125|carcinoma of the renal pelvis
103083|NCT02426125|transitional cell carcinoma
103084|NCT02426125|transitional cell tumor
103085|NCT02426125|RANGE
103086|NCT02426125|bladder cancer
103087|NCT02426099|Resistant hypertension
103088|NCT02426099|diabetes mellitus
103089|NCT02426099|Spironolactone
103090|NCT02426099|African
103091|NCT02426086|Myelofibrosis
103092|NCT02426086|JNJ-63935937
103093|NCT02426086|Imetelstat
103094|NCT02426073|Inflammaging
103095|NCT02426047|seizures
103096|NCT02426047|epilepsy
103097|NCT02426047|catamenial
103098|NCT02426047|ketogenic diet
103099|NCT02426047|modified Atkins diet
103100|NCT02426047|intractable epilepsy
103101|NCT02426047|medically refractory epilepsy
103102|NCT02426047|adult
103103|NCT02426047|medium chain triglyceride
103104|NCT02426034|Advanced
103105|NCT02426034|Metastatic
103106|NCT02425995|ACL
103107|NCT02425995|Hidden lesions of the medial meniscus
103108|NCT02425995|Chronic knee instability
103109|NCT02425995|Intercondylar and posteromedial arthroscopy
103110|NCT02425995|Arthroscopic Posteromedial and Intercondylar portal
103111|NCT02425995|Diagnosis capacity of hidden lesions of the medial meniscus
103112|NCT02425982|Tennis Elbow
103113|NCT02425982|Lateral elbow pain
103114|NCT02425982|Latera epicondylitis
103115|NCT02425930|gastric cancer
103116|NCT02425930|complement system
103117|NCT02425930|overal survival
103118|NCT02425904|Langerhans Cell Histiocytosis
103119|NCT02425865|UC, IBD
103120|NCT02425839|shear wave elastography
103121|NCT02425839|surface electromyogram
103122|NCT02425839|masseter
103123|NCT02425826|Parapsoriasis
103124|NCT02425826|Plaque Psoriasis
103125|NCT02425826|CC-10004
103126|NCT02425826|Apremilast
103127|NCT02425826|Moderate Plaque Psoriasis
103128|NCT02425826|Safety
103129|NCT02425787|Loss of a child
103130|NCT02425787|Grief
103131|NCT02425774|Prucalopride
103132|NCT02425774|Vagus Nerve Stimulation
103133|NCT02425774|Postoperative Ileus
103134|NCT02425761|Cerebrospinal Fluid Shunts
103135|NCT02425761|Randomized Controlled Trial
103136|NCT02425748|γδ T Cell, non small lung cancer, Without EGFR Mutation
103137|NCT02425735|Immunotherapy, γδ T Cell, heptocellular liver cancer
103138|NCT02425722|ASP0456
103139|NCT02425722|linaclotide
103140|NCT02425722|chronic constipation
103141|NCT02425696|right-to-left shunt
103142|NCT02425696|contrast-enhanced transcranial Doppler
103143|NCT02425696|migraine
103144|NCT02425696|silent cerebral infarction
103145|NCT02425683|Colon Cancer
103146|NCT02425683|Rectal Cancer
103147|NCT02425683|Colorectal Cancer
103148|NCT02425683|Stage IIIC Colorectal Cancer
103149|NCT02425670|Brain attack
103150|NCT02425670|stroke
103151|NCT02425670|Ischemic stroke
103152|NCT02425670|stem cell therapy
103153|NCT02425657|Education
103154|NCT02425657|Training
103155|NCT02425657|Fast track
103156|NCT02425657|Colonoscopy
103157|NCT02425644|relapsing multiple sclerosis
103158|NCT02425631|SI joint fusion
103159|NCT02425631|SI joint pain
103160|NCT02425631|SI joint
103161|NCT02425631|SI joint treatment
103162|NCT02425631|SI joint disease
103163|NCT02425631|Sacroiliac joint
103164|NCT02425631|Simmetry
103165|NCT02425566|autonomic nervous system
103166|NCT02425566|hypertension
103167|NCT02425566|ganglionic blocker
103168|NCT02425566|trimethaphan
103169|NCT02425566|splanchnic circulation
103170|NCT02425566|capacitance
103171|NCT02425553|Diet
103172|NCT02425553|Reflux
103173|NCT02425553|Dyspepsia
103174|NCT02425553|Symptoms
103175|NCT02425553|Alcohol
103176|NCT02425540|Pelvic MRI
103177|NCT02425527|Brain Injuries
103178|NCT02425527|Traumatic Brain Injury
103179|NCT02425527|Video Games
103180|NCT02425514|Anterior cervical discectomy and fusion
103181|NCT02425514|NovoMax
103182|NCT02425514|Bioactive Glass-ceramic Intervertebral Spacer
103183|NCT02425501|Aflibercept
103184|NCT02425501|anti-VEGF
103185|NCT02425488|Nursing
103186|NCT02425488|Outcome and Process Assessment
103187|NCT02425488|Cardiac Resynchronization Therapy Devices
103188|NCT02425488|Heart Failure
103189|NCT02425488|Education
103190|NCT02425475|Dermoscopy
103191|NCT02425449|succinylcholine
103192|NCT02425449|depolarizing muscle relaxants
103193|NCT02425449|pharmacologic effects
103194|NCT02425410|Diabetes Mellitus
103195|NCT02425410|Insulin-Dependent
103196|NCT02425410|Virus Diseases
103197|NCT02425410|Questionnaires
103198|NCT02425410|Risk assessment
103199|NCT02425410|Genome-Wide Association Study
103200|NCT02425397|Ototoxicity
103201|NCT02425397|platinum derivatives
103202|NCT02425397|paediatrics
103203|NCT02425397|oncology
103204|NCT02425397|clinical research
103205|NCT02425384|adolescent
103206|NCT02425384|physical activity
103207|NCT02425384|accelerometer
103208|NCT02425358|cell therapy
103209|NCT02425358|BMC
103210|NCT02425358|timing
103211|NCT02425345|Physical Activity
103212|NCT02425345|National Institute of Aging Go4Life
103213|NCT02425345|Postmenopausal Women
103214|NCT02425345|Balance
103215|NCT02425345|Strength
103216|NCT02425345|Exercise
103217|NCT02425345|Cardiovascular Disease
103218|NCT02425345|Stroke
103219|NCT02425345|Mortality
103220|NCT02425345|Myocardial Infarction
103221|NCT02425345|Falls
103222|NCT02425345|Venous Thromboembolic Event
103223|NCT02425345|Peripheral Artery Disease
103224|NCT02425345|Physical Function
103225|NCT02425345|Mobility
103226|NCT02425345|Coronary Artery Bypass Graft (CABG)
103227|NCT02425345|Percutaneous Coronary Intervention (PCI)
103228|NCT02425345|Hip Fractures
103229|NCT02425345|Cardiovascular Mortality
103230|NCT02425332|Spinal Cord Injury
103231|NCT02425332|adaptive control
103232|NCT02425332|assessment
103233|NCT02425332|assist-as-needed
103234|NCT02425332|walking ability
103235|NCT02425332|Lokomat
103236|NCT02425306|peptide
103237|NCT02425306|vaccine
103238|NCT02425306|adjuvant
103239|NCT02425306|polyICLC
103240|NCT02425306|cyclophosphamide
103241|NCT02425306|Montanide ISA-51
103242|NCT02425267|Telerehabilitation
103243|NCT02425241|Vaccine
103244|NCT02425241|DNA
103245|NCT02425241|HIV-1
103246|NCT02425241|Serum amyloid P component (SAP)
103247|NCT02425241|Clinical trial
103248|NCT02425241|Vaccination
103249|NCT02425241|Prophylaxis
103250|NCT02425241|Adult male
103251|NCT02425228|targeted biopsy
103252|NCT02425228|conventional biopsy
103253|NCT02425228|cognitive biopsy
103254|NCT02425215|Hyperbaric Oxygen Treatment
103255|NCT02425215|Late radiation injury
103256|NCT02425215|Adult
103257|NCT02425215|Malignancy
103258|NCT02425215|Quality of Life
103259|NCT02425215|Chronic Pain
103260|NCT02425202|pediatric
103261|NCT02425202|obstructive sleep apnea
103262|NCT02425202|tonsillectomy
103263|NCT02425202|analgesia
103264|NCT02425176|botulinum toxin
103265|NCT02425176|sialorrhoea
103266|NCT02425176|drooling
103267|NCT02425163|Prostate Cancer
103268|NCT02425163|Shear Wave Elastography
103269|NCT02425163|Prostate
103270|NCT02425163|Prostate Biopsy
103271|NCT02425150|Keratoconus
103272|NCT02425150|Corneal crosslinking
103273|NCT02425150|Corneal biomechanics
103274|NCT02425150|Corneal densitometry
103275|NCT02425150|Scheimpflug photography
103276|NCT02425111|Drug therapy
103277|NCT02425098|Drug therapy
103278|NCT02425085|retinectomy
103279|NCT02425085|endodiathermy
103280|NCT02425085|inferior
103281|NCT02425085|retinal redetachment
103282|NCT02425072|Cancer
103283|NCT02425072|Brain
103284|NCT02425072|Lung
103285|NCT02425072|Small-cell
103286|NCT02425059|irreversible electroporation
103287|NCT02425059|Unresectable Rectal Neoplasms
103288|NCT02425046|family
103289|NCT02425033|POEM
103290|NCT02425033|Minimally invasive surgery
103291|NCT02425033|Achalasia
103292|NCT02425033|Spastic esophageal disorders
103293|NCT02425020|Supplement
103294|NCT02425020|performance
103295|NCT02425020|whey
103296|NCT02425020|meat
103297|NCT02425020|protein
103298|NCT02424994|Morbidity
103299|NCT02424994|Mortality
103300|NCT02424994|Health care utilization
103301|NCT02424994|Cohort
103302|NCT02424994|Epidemiology
103303|NCT02424994|Cardiovascular diseases
103304|NCT02424968|Healthy Stem Cell Donor
103305|NCT02424955|Liver cancer
103306|NCT02424955|Hepatocellular Carcinoma
103307|NCT02424955|Liver imaging
103308|NCT02424955|Stereotactic Ablative Radiotherapy
103309|NCT02424955|SABR
103310|NCT02424929|Deep Brain Stimulation
103311|NCT02424916|Onco-dermatology
103312|NCT02424916|stage IIIc
103313|NCT02424916|adoptive transfer
103314|NCT02424916|immunotherapy
103315|NCT02424903|infection
103316|NCT02424903|prosthesis
103317|NCT02424903|hip
103318|NCT02424903|knee
103319|NCT02424903|shoulder
103320|NCT02424877|rheumatoid arthritis
103321|NCT02424877|drug treatment
103322|NCT02424877|compliance
103323|NCT02424877|outcome
103324|NCT02424864|4D PET-CT
103325|NCT02424851|myeloma
103326|NCT02424851|multiple myeloma
103327|NCT02424851|chronic kidney disease
103328|NCT02424851|renal failure
103329|NCT02424851|bortezomib
103330|NCT02424851|Velcade
103331|NCT02424851|thalidomide
103332|NCT02424851|bendamustine
103333|NCT02424851|dexamethasone
103334|NCT02424851|serum free light chains
103335|NCT02424851|proteosomal inhibition
103336|NCT02424851|immunomodulatory
103337|NCT02424825|diet
103338|NCT02424825|cooking
103339|NCT02424825|multiple sclerosis
103340|NCT02424825|fatigue
103341|NCT02424812|handwashing
103342|NCT02424812|behavior
103343|NCT02424799|Urticaria
103344|NCT02424799|SYK Inhibitor
103345|NCT02424786|Adherence
103346|NCT02424786|Polypharmacy
103347|NCT02424786|Elderly
103348|NCT02424786|Chronic kidney disease
103349|NCT02424734|Late-onset Sepsis
103350|NCT02424708|Reduced Glutathione
103351|NCT02424708|Intranasal
103352|NCT02424708|(in)GSH
103353|NCT02424708|Parkinson's Disease
103354|NCT02424708|Glutathione
103355|NCT02424708|Uptake
103356|NCT02424708|central nervous system
103357|NCT02424695|Cortical arousal intensity
103358|NCT02424695|RLS
103359|NCT02424695|Heart rate
103360|NCT02424695|Blood pressure
103361|NCT02424695|PLMs
103362|NCT02424630|sono-guided interscalene brachial plexus block
103363|NCT02424630|arthroscopy-guided suprascapular nerve block
103364|NCT02424630|arthroscopic rotator cuff repair
103365|NCT02424630|postoperative pain
103366|NCT02424591|Anesthesia Recovery Period
103367|NCT02424591|Spinal Fusion
103368|NCT02424552|severe asthma
103369|NCT02424552|vitamin D
103370|NCT02424552|treatment
103371|NCT02424539|Seasonal
103372|NCT02424539|Fluticasone Furoate
103373|NCT02424539|Perennial
103374|NCT02424539|Allergic Rhinitis
103375|NCT02424539|Nasal Spray
103376|NCT02424526|cerebral palsy
103377|NCT02424526|treadmill training
103378|NCT02424526|walking
103379|NCT02424487|Initial pressure
103380|NCT02424487|changes of intracuff pressure
103381|NCT02424487|infants and children
103382|NCT02424474|cell free fetal DNA
103383|NCT02424474|general population
103384|NCT02424474|screening
103385|NCT02424474|trisomy 21
103386|NCT02424474|IVF
103387|NCT02424435|Friedreich Ataxia
103388|NCT02424435|FRDA
103389|NCT02424422|Corrective Orthodontics
103390|NCT02424422|CBCT
103391|NCT02424422|Rapid Maxillary Expansion
103392|NCT02424422|Cone Beam Computed Tomography
103393|NCT02424422|Hyrax Expansion
103394|NCT02424422|Craniofacial Sutures
103395|NCT02424409|Asthma
103396|NCT02424409|Relapse
103397|NCT02424409|Therapeutic counselling
103398|NCT02424409|Protocol of care
103399|NCT02424396|Interleukin 2, IL2
103400|NCT02424396|Relapsing Remitting Multiple Sclerosis
103401|NCT02424396|Autoimmune diseases
103402|NCT02424396|Regulatory T cells, Tregs
103403|NCT02424370|Aortic stenosis
103404|NCT02424370|TAVR
103405|NCT02424370|Frailty
103406|NCT02424370|Elderly
103407|NCT02424357|Adjustable strabismus surgery
103408|NCT02424357|suture contamination
103409|NCT02424357|5%povidone iodine
103410|NCT02424344|COPD
103411|NCT02424331|Chronic Obstructive Pulmonary Disease
103412|NCT02424331|Respiratory mechanics
103413|NCT02424331|Plethysmography
103414|NCT02424331|Diaphragm
103415|NCT02424331|Respiratory muscles
103416|NCT02424331|Breathing exercises
103417|NCT02424292|Breast cancer
103418|NCT02424292|Physcial activity/exercise
103419|NCT02424292|anti-hormonal treatment
103420|NCT02424279|pancreatic cancer
103421|NCT02424279|pain
103422|NCT02424279|splanchnicectomy
103423|NCT02424266|Tear film
103424|NCT02424266|Imaging
103425|NCT02424266|Tomogrophy
103426|NCT02424266|dry eye
103427|NCT02424201|uterine atony
103428|NCT02424175|Fecal Transplant
103429|NCT02424175|Primary Sclerosing Cholangitis
103430|NCT02424175|Fecal Microbiota Transplantation
103431|NCT02424110|bipolar radiofrequency ablation
103432|NCT02424110|argon beam coagulator
103433|NCT02424097|Prevention
103434|NCT02424071|melatonin's
103435|NCT02424071|quality of recovery
103436|NCT02424032|Neck pain
103437|NCT02424032|stabilization exercise
103438|NCT02424032|connective tissue massage
103439|NCT02424006|keratoplasty
103440|NCT02424006|bioengineered cornea
103441|NCT02424006|donor cornea
103442|NCT02423993|Type 1 diabetes mellitus
103443|NCT02423993|Continuous subcutaneous insulin infusion
103444|NCT02423993|Quality of life
103445|NCT02423993|Therapeutic education
103446|NCT02423993|Insulin pump
103447|NCT02423941|Liver Transplantation
103448|NCT02423941|Retrograde Reperfusion
103449|NCT02423941|Graft dysfunction
103450|NCT02423941|Randomized study
103451|NCT02423928|immunotherapy
103452|NCT02423928|cryoablation
103453|NCT02423928|prostate cancer
103454|NCT02423928|dendritic cell
103455|NCT02423915|Leukemia
103456|NCT02423915|Lymphoma
103457|NCT02423915|Advanced hematologic malignancies
103458|NCT02423915|Graft versus host disease
103459|NCT02423915|GVHD
103460|NCT02423915|Fucosylated umbilical cord blood Regulatory T cells
103461|NCT02423915|CB
103462|NCT02423915|Tregs
103463|NCT02423915|T cells
103464|NCT02423915|Cord blood transplant
103465|NCT02423915|Total body radiation
103466|NCT02423915|TBI
103467|NCT02423915|Radiation therapy
103468|NCT02423915|XRT
103469|NCT02423915|Rituximab
103470|NCT02423915|Rituxan
103471|NCT02423915|Fludarabine
103472|NCT02423915|Fludarabine phosphate
103473|NCT02423915|Fludara
103474|NCT02423915|Cyclophosphamide
103475|NCT02423915|Cytoxan
103476|NCT02423915|Neosar
103477|NCT02423915|Mycophenolate
103478|NCT02423915|Mycophenolate mofetil
103479|NCT02423915|MMF
103480|NCT02423915|CellCept
103481|NCT02423915|Sirolimus
103482|NCT02423915|Rapamune
103483|NCT02423915|G-CSF
103484|NCT02423915|Filgrastim
103485|NCT02423915|Neupogen
103486|NCT02423889|Hypofractionated radiotherapy
103487|NCT02423889|SBRT
103488|NCT02423863|Cancer
103489|NCT02423863|Immunotherapy
103490|NCT02423863|Intratumoral Injection
103491|NCT02423863|Multicenter Study
103492|NCT02423863|Autovaccination
103493|NCT02423863|Solid Tumors
103494|NCT02423850|Diabetic foot ulcers
103495|NCT02423850|Leg ulcers
103496|NCT02423850|Ulcer healing
103497|NCT02423850|Ulcer measurement
103498|NCT02423850|Ulcer area
103499|NCT02423850|Ulcer volume
103500|NCT02423850|3D measurement
103501|NCT02423837|follicular lymphoma
103502|NCT02423837|bendamustine
103503|NCT02423837|rituximab
103504|NCT02423798|Diabetes
103505|NCT02423798|Glucose sensor
103506|NCT02423798|Sensor accuracy and performance
103507|NCT02423798|CGM
103508|NCT02423759|Chemoprevention
103509|NCT02423733|depression
103510|NCT02423733|dysthymia
103511|NCT02423733|cognitive behavioural therapy
103512|NCT02423733|CBT
103513|NCT02423733|problem-solving therapy
103514|NCT02423733|PST
103515|NCT02423733|waitlist
103516|NCT02423733|secondary mental health care
103517|NCT02423733|mental health
103518|NCT02423733|e-therapy
103519|NCT02423733|computerized therapy
103520|NCT02423668|cataract surgery
103521|NCT02423668|biometry
103522|NCT02423668|second eye refinement
103523|NCT02423668|effective lens position
103524|NCT02423642|Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
103525|NCT02423616|MIP
103526|NCT02423616|Hand Grip
103527|NCT02423616|Correlation
103528|NCT02423616|Inspiratory Pressure
103529|NCT02423616|Hand Grip Force
103530|NCT02423603|Triple Negative Breast Cancer
103531|NCT02423603|Metastatic
103532|NCT02423603|AKT Inhibitor
103533|NCT02423603|Advanced
103534|NCT02423603|AZD5363
103535|NCT02423603|Paclitaxel
103536|NCT02423603|PAKT
103537|NCT02423590|Squamous
103538|NCT02423590|Lung
103539|NCT02423590|Apatorsen
103540|NCT02423577|antiviral
103541|NCT02423577|influenza
103542|NCT02423577|challenge
103543|NCT02423564|Probiotic
103544|NCT02423564|Digesta-Lac
103545|NCT02423564|Occasional Constipation
103546|NCT02423564|Constipation
103547|NCT02423551|Gut microbiota
103548|NCT02423551|Intestinal permeability
103549|NCT02423551|Gut barrier integrity
103550|NCT02423525|glioblastoma
103551|NCT02423525|astrocytoma
103552|NCT02423525|oligodendroglioma
103553|NCT02423525|mixed oligoastrocytoma
103554|NCT02423525|low grade gliomas
103555|NCT02423525|brain metastases
103556|NCT02423525|meningiomas
103557|NCT02423525|leptomeningeal metastases
103558|NCT02423512|Inflammatory Bowel Diseases
103559|NCT02423512|Vedolizumab
103560|NCT02423512|Ulcerative Colitis
103561|NCT02423512|Crohn's Disease
103562|NCT02423512|MADCAM1
103563|NCT02423512|integrin alpha4beta7
103564|NCT02423499|Autism Spectrum Disorder
103565|NCT02423499|Bipolar Disorder
103566|NCT02423499|Emotions
103567|NCT02423460|Ulcerative Colitis
103568|NCT02423460|Healthy Controls
103569|NCT02423460|Crohn's Disease
103570|NCT02423434|Corneal Confocal Microscopy
103571|NCT02423434|Diabetes Mellitus
103572|NCT02423434|Type 1 Diabetes Mellitus
103573|NCT02423434|Type 2 Diabetes Mellitus
103574|NCT02423434|Diabetic Neuropathy
103575|NCT02423434|Diabetes Complications
103576|NCT02423382|silicone oil
103577|NCT02423382|retinal saturation
103578|NCT02423382|retinal blood flow
103579|NCT02423382|retinal detachment
103580|NCT02423369|S-100B protein
103581|NCT02423369|Neuron-specific Enolase
103582|NCT02423356|breast cancer
103583|NCT02423356|sarcoma
103584|NCT02423356|lymphoma
103585|NCT02423356|echocardiography
103586|NCT02423356|cardiotoxicity
103587|NCT02423356|pharmacogenetics
103588|NCT02423356|doxorubicin
103589|NCT02423356|chemotherapy
103590|NCT02423291|PMLBCL
103591|NCT02423291|Brentuximab Vedotin
103592|NCT02423291|CD30-positive
103593|NCT02423291|Mediastinal Lymphoma
103594|NCT02423278|gastrectomy
103595|NCT02423278|lymphadenectomy
103596|NCT02423278|gastric cancer
103597|NCT02423278|adjuvant chemotherapy
103598|NCT02423278|overall survival
103599|NCT02423265|Chronic total coronary occlusions
103600|NCT02423265|Ranolazine
103601|NCT02423252|Critical illness
103602|NCT02423252|Intervention
103603|NCT02423252|RCT
103604|NCT02423252|Relaxation
103605|NCT02423252|Guided imagery
103606|NCT02423252|Touch/Massage
103607|NCT02423252|Music listening
103608|NCT02423252|Neuropeptides
103609|NCT02423252|Inflammatory molecules
103610|NCT02423252|Post-traumatic stress
103611|NCT02423252|Critical care nurse
103612|NCT02423252|Psychocognitive nursing intervention
103613|NCT02423252|Interpersonal support
103614|NCT02423213|OCT
103615|NCT02423213|image-guided surgery
103616|NCT02423213|ophthalmic surgery
103617|NCT02423187|Stomach ulcer
103618|NCT02423187|Duodenal ulcer
103619|NCT02423187|Rabeprazole
103620|NCT02423187|Recurrence
103621|NCT02423161|OCT
103622|NCT02423161|image-guided surgery
103623|NCT02423161|vitreoretinal surgery
103624|NCT02423161|corneal surgery
103625|NCT02423148|Lung Cancer
103626|NCT02423096|biomarker
103627|NCT02423096|neuroendocrine
103628|NCT02423096|metabolite
103629|NCT02423096|cognitive functioning
103630|NCT02423096|clinical symptoms
103631|NCT02423096|schizophrenia
103632|NCT02423083|Neuroprotection
103633|NCT02423083|Multiple Sclerosis
103634|NCT02423083|Clinical Trial
103635|NCT02423083|Safety and Tolerability
103636|NCT02423070|Cell-free DNA
103637|NCT02423070|Acute Rejection
103638|NCT02423070|Thoracic Organ Transplantation
103639|NCT02423070|Non-Invasive Testing
103640|NCT02423070|Chronic Rejection
103641|NCT02423057|Pharmacodynamics
103642|NCT02423057|DNA Methylation
103643|NCT02423057|Pharmacokinetics
103644|NCT02423057|Nucleoside Analogue
103645|NCT02423057|Epigenetics
103646|NCT02423044|Anxiety
103647|NCT02423044|fMRI
103648|NCT02423044|Virtual Reality
103649|NCT02423044|Shock Threat
103650|NCT02423044|Healthy Volunteer
103651|NCT02423031|Physiological Measures
103652|NCT02423031|Emotional Context
103653|NCT02423031|Pediatric
103654|NCT02423031|Distresss Screening
103655|NCT02423005|Stress urinary incontinence
103656|NCT02423005|Neurotech Vital Compact
103657|NCT02423005|1h Provacative Pad Test
103658|NCT02423005|Neuroelectrical Muscle Stimulation (NEMS)
103659|NCT02422992|Iron metabolism
103660|NCT02422992|MRI
103661|NCT02422992|risk factors
103662|NCT02422992|haptoglobin phenotype
103663|NCT02422953|Stunting
103664|NCT02422953|Wasting
103665|NCT02422953|Underweight
103666|NCT02422927|C-Reactive Protein
103667|NCT02422927|Endothelial Microparticles
103668|NCT02422927|Endothelium
103669|NCT02422927|Nutraceutical
103670|NCT02422927|Cholesterol
103671|NCT02422888|ST elevation myocardial infarction
103672|NCT02422888|Percutaneous coronary intervention
103673|NCT02422888|Endothelial function
103674|NCT02422888|Ticagrelor
103675|NCT02422888|Prasugrel
103676|NCT02422875|Sjögren's Syndrome
103677|NCT02422875|Scleroderma
103678|NCT02422875|Myositis
103679|NCT02422875|Juvenile Idiopathic Arthritis
103680|NCT02422875|Rheumatoid Arthritis
103681|NCT02422875|Inflammatory Arthritis
103682|NCT02422875|Undifferentiated Connective Tissue Disease
103683|NCT02422875|Idiopathic thrombocytopenic purpura
103684|NCT02422875|Graft vs Host Disease
103685|NCT02422875|Autoimmune Lymphoproliferative Syndrome
103686|NCT02422875|Immunoglobulin G4 (IgG4)-related disease
103687|NCT02422875|Hepatitis C
103688|NCT02422875|Epstein Barr Virus (infectious mononucleosis - EBV)
103689|NCT02422875|Sepsis
103690|NCT02422875|Guillain-Barre syndrome
103691|NCT02422875|Mycoplasma pneumoniae
103692|NCT02422875|Human Immunodeficiency Virus
103693|NCT02422862|Physiotherapy
103694|NCT02422862|Manual Therapy
103695|NCT02422849|Patient admission
103696|NCT02422836|photodamage
103697|NCT02422836|fine lines
103698|NCT02422836|wrinkles
103699|NCT02422836|dyschromia
103700|NCT02422823|anesthesia
103701|NCT02422823|volumes
103702|NCT02422823|articaine
103703|NCT02422823|Inferior alveolar nerve block
103704|NCT02422797|HIV
103705|NCT02422797|NNRTI-sparing
103706|NCT02422797|two-drug regimen
103707|NCT02422797|nucleoside reverse transcriptase inhibitors
103708|NCT02422797|protease inhibitor
103709|NCT02422797|integrase inhibitor
103710|NCT02422797|non-nucleoside reverse transcriptase inhibitor
103711|NCT02422797|dolutegravir plus rilpivirine
103712|NCT02422797|virologically-suppressed
103713|NCT02422784|Vitamin D insufficient
103714|NCT02422784|rooibos tea
103715|NCT02422784|calcium
103716|NCT02422758|hypothermia
103717|NCT02422758|perioperative nursing
103718|NCT02422758|prewarming
103719|NCT02422758|prevention and control
103720|NCT02422745|Cocoa extract multivitamins cardiovascular disease cancer
103721|NCT02422732|NF1
103722|NCT02422732|Children
103723|NCT02422732|Reading disability
103724|NCT02422732|Morphological and functional MRI
103725|NCT02422732|Genetic analysis
103726|NCT02422719|Chronic myeloid leukemia
103727|NCT02422719|Intolerance
103728|NCT02422719|Resitance
103729|NCT02422719|Radotinib
103730|NCT02422693|hydrotherapy
103731|NCT02422693|aquatic
103732|NCT02422680|Quality assurance
103733|NCT02422680|Caecum intubation rate
103734|NCT02422680|Patient satisfaction
103735|NCT02422667|Orthopedics
103736|NCT02422667|Outcome Assessment
103737|NCT02422628|EGFR inhibitor
103738|NCT02422628|EGFR mutation
103739|NCT02422628|EGFR
103740|NCT02422628|adenocarcinoma
103741|NCT02422628|EGFR TKI
103742|NCT02422628|treatment
103743|NCT02422628|Non small cell
103744|NCT02422615|HR-positive
103745|NCT02422615|HER2-negative
103746|NCT02422615|Advanced breast cancer
103747|NCT02422615|LEE011
103748|NCT02422615|ribociclib
103749|NCT02422615|fulvestrant
103750|NCT02422615|faslodex
103751|NCT02422615|CDK
103752|NCT02422615|CDK4
103753|NCT02422615|CDK6
103754|NCT02422615|CDK4/6
103755|NCT02422615|CDK4/6 inhibitor
103756|NCT02422615|Phase III
103757|NCT02422615|ER-positive
103758|NCT02422615|PR-positive
103759|NCT02422615|Postmenopausal
103760|NCT02422615|Men
103761|NCT02422602|Patients
103762|NCT02422602|treated by Rivaroxaban
103763|NCT02422589|ALK-positive advanced tumors,
103764|NCT02422589|midazolam,
103765|NCT02422589|warfarin,
103766|NCT02422589|ceritinib,
103767|NCT02422589|ALK,
103768|NCT02422589|CYP3A-4,
103769|NCT02422589|Drug drug intereaction
103770|NCT02422563|neoadjuvant chemotherapy
103771|NCT02422563|FIGO IB2, FIGO IIB
103772|NCT02422563|chemo-radiation
103773|NCT02422563|dose dense chemotherapy
103774|NCT02422563|cisplatin
103775|NCT02422563|paclitaxel
103776|NCT02422563|carboplatin
103777|NCT02422563|ifosfamide
103778|NCT02422550|MRI
103779|NCT02422550|15-073
103780|NCT02422550|participants undergoing radiation therapy
103781|NCT02422524|Hepatic, impairment, PA-824, Tuberculosis, Pharmacokinetics, Safety
103782|NCT02422511|Genome Sequencing
103783|NCT02422511|Exome Sequencing
103784|NCT02422511|Newborn Screening
103785|NCT02422511|Childhood Onset Genetic Conditions
103786|NCT02422498|Treated with Concurrent Cisplatin
103787|NCT02422498|Treated with Radiation Therapy
103788|NCT02422498|Homologous Recombination Repair Status
103789|NCT02422498|Biomarker of Response
103790|NCT02422498|15-032
103791|NCT02422498|Patients
103792|NCT02422485|Salsalate
103793|NCT02422446|Endothelial function
103794|NCT02422446|Eicosapentaenoic acid
103795|NCT02422446|Triglycerides
103796|NCT02422433|EGD
103797|NCT02422433|OFDI
103798|NCT02422433|Barrett's Esophagus
103799|NCT02422433|Imaging
103800|NCT02422420|Diabetes Prevention
103801|NCT02422420|Financial Incentives
103802|NCT02422420|Medicaid
103803|NCT02422420|Motivation
103804|NCT02422381|NSCLC
103805|NCT02422381|lung cancer
103806|NCT02422381|Gemzar
103807|NCT02422381|Pembrolizumab
103808|NCT02422381|Anti-PD-1
103809|NCT02422381|Immunotherapy
103810|NCT02422368|Graves' ophthalmopathy
103811|NCT02422368|Antioxidant
103812|NCT02422368|Activity
103813|NCT02422368|Severity
103814|NCT02422355|hip
103815|NCT02422355|femoral neck
103816|NCT02422355|Garden classification
103817|NCT02422355|healing
103818|NCT02422355|cut-out
103819|NCT02422355|iatrogenic fracture
103820|NCT02422355|implant
103821|NCT02422355|rotational stability
103822|NCT02422355|minimal invasive
103823|NCT02422329|Advanced Cancers
103824|NCT02422329|Constipation
103825|NCT02422329|Recurrent cancer
103826|NCT02422329|Locally advanced cancer
103827|NCT02422329|Metastatic cancer
103828|NCT02422329|Video
103829|NCT02422329|Fact sheet
103830|NCT02422329|Questionnaires
103831|NCT02422329|Surveys
103832|NCT02422303|Depression
103833|NCT02422303|Gynecoligical surgery
103834|NCT02422303|Ketamine
103835|NCT02422290|Obsessive Compulsive Disorder
103836|NCT02422290|Ketamine
103837|NCT02422290|Glutamate
103838|NCT02422290|OCD treatment
103839|NCT02422290|OCD medication
103840|NCT02422277|Cystoprostatectomy
103841|NCT02422277|Sexual function
103842|NCT02422277|Phosphodiestrase 5 inhibitors
103843|NCT02422277|Low intensity extracorporeal shock wave therapy
103844|NCT02422277|Erectile dysfunction
103845|NCT02422277|Penile rehabilitation
103846|NCT02422212|metabolism
103847|NCT02422212|Diet Induced Thermogenesis
103848|NCT02422212|weight regain
103849|NCT02422212|energy expenditure
103850|NCT02422212|bariatric
103851|NCT02422186|Depressive Disorder, Treatment-Resistant
103852|NCT02422186|Esketamine
103853|NCT02422186|Oral Antidepressant
103854|NCT02422186|Elderly Participants
103855|NCT02422134|Pregnancy
103856|NCT02422134|implantation
103857|NCT02422134|Cytokine
103858|NCT02422108|RANKL
103859|NCT02422082|Osteopenia
103860|NCT02422082|Lactobacillus reuteri
103861|NCT02422082|Volumetric bone mineral density
103862|NCT02422056|Cleft Palate
103863|NCT02422056|Hemorrhage
103864|NCT02422056|Palatoplasty
103865|NCT02422043|adolescence
103866|NCT02422030|Male Volunteers
103867|NCT02422017|Leg ulcer
103868|NCT02422017|wound
103869|NCT02422017|topical timolol
103870|NCT02422004|Rehabilitation
103871|NCT02422004|Weight-bearing
103872|NCT02422004|Range of motion
103873|NCT02421978|Cognitive dysfunction
103874|NCT02421978|Inflammation
103875|NCT02421978|Fatigue
103876|NCT02421978|Decreased motivation
103877|NCT02421965|Schizophrenia
103878|NCT02421965|Schizoaffective Disorder
103879|NCT02421965|Bipolar Disorder
103880|NCT02421965|Major Depressive Disorder
103881|NCT02421965|Mobile Application
103882|NCT02421965|Smartphone
103883|NCT02421965|SMI
103884|NCT02421965|Illness Self-Management
103885|NCT02421965|EHealth
103886|NCT02421965|E-Health
103887|NCT02421965|Health Technology
103888|NCT02421965|mHealth
103889|NCT02421965|m-Health
103890|NCT02421939|ASP2215
103891|NCT02421939|Relapsed Acute Myeloid Leukemia
103892|NCT02421939|FLT3 Mutation
103893|NCT02421939|Refractory Acute Myeloid Leukemia
103894|NCT02421939|Acute Myeloid Leukemia (AML)
103895|NCT02421874|Patient care team
103896|NCT02421874|Care management
103897|NCT02421874|Electronic health records
103898|NCT02421861|anxiety
103899|NCT02421861|intensive care unit
103900|NCT02421861|critical care
103901|NCT02421848|Body composition
103902|NCT02421848|Sarcopenia
103903|NCT02421848|Cirrhotic with Ascites
103904|NCT02421796|n Non-Celiac Wheat Sensitivity
103905|NCT02421796|Malnutrition
103906|NCT02421796|Celiac disease
103907|NCT02421796|Irritable Bowel Syndrome
103908|NCT02421783|Non-celiac wheat sensitivity
103909|NCT02421783|Multiple food allergy
103910|NCT02421783|Body mass index
103911|NCT02421783|Osteoporosis
103912|NCT02421757|Transcutaneous Magnetic Stimulation
103913|NCT02421757|placebo
103914|NCT02421744|rehabilitation
103915|NCT02421744|Multiple Sclerosis
103916|NCT02421744|mobility
103917|NCT02421744|gait
103918|NCT02421744|task-oriented training
103919|NCT02421731|Rehabilitation
103920|NCT02421731|Gait
103921|NCT02421718|Acute toxicity
103922|NCT02421718|Late toxicity
103923|NCT02421718|Prediction models
103924|NCT02421679|PTSD
103925|NCT02421679|Military-related PTSD and other related conditions
103926|NCT02421679|open-label extension
103927|NCT02421653|Micronutrient powders
103928|NCT02421653|MNP
103929|NCT02421653|Weaning
103930|NCT02421653|Home fortification
103931|NCT02421653|Iodine
103932|NCT02421653|Iodine deficiency
103933|NCT02421653|Iodine Deficiency Disorder
103934|NCT02421653|IDD
103935|NCT02421653|Infant
103936|NCT02421653|Growth
103937|NCT02421653|Iodised oil
103938|NCT02421627|moxibustion
103939|NCT02421627|irritable bowel syndrome
103940|NCT02421627|Magnetic Resonance Imaging
103941|NCT02421614|acute respiratory failure
103942|NCT02421614|lung
103943|NCT02421614|enteral feeding
103944|NCT02421614|feeding composition
103945|NCT02421614|olive
103946|NCT02421614|high fat
103947|NCT02421549|Remote Monitoring
103948|NCT02421549|Remote Care
103949|NCT02421549|Cardiac Resynchronization Therapy
103950|NCT02421549|Pacemaker
103951|NCT02421549|Implantable Cardioverter Defibrillator
103952|NCT02421523|Exercise
103953|NCT02421523|Strength training
103954|NCT02421510|High level of sugar (glucose) in the blood
103955|NCT02421484|Phase I clinical trial
103956|NCT02421484|stem cell
103957|NCT02421484|mesenchymal stromal cell
103958|NCT02421484|mesenchymal stem cell
103959|NCT02421471|Actinic Keratosis
103960|NCT02421471|topical treatment
103961|NCT02421471|ingenol mebutate
103962|NCT02421432|trananal TME
103963|NCT02421432|safety
103964|NCT02421432|efficacy
103965|NCT02421432|difficult cases
103966|NCT02421419|flexor tendon entrapment
103967|NCT02421419|snapping finger
103968|NCT02421419|trigger digits
103969|NCT02421419|trigger thumb
103970|NCT02421393|Bone quality
103971|NCT02421393|Bone strength
103972|NCT02421393|Fractures
103973|NCT02421393|Muscle strength
103974|NCT02421393|Gait and balance
103975|NCT02421393|Musculo-skeletal symptoms
103976|NCT02421393|Falls
103977|NCT02421380|Hyperpolarized Pyruvate
103978|NCT02421380|MRI
103979|NCT02421380|14-205
103980|NCT02421354|Myeloproliferative Diseases
103981|NCT02421354|Post-Essential Thrombocythemia Myelofibrosis
103982|NCT02421354|Post-Polycythemia Vera Myelofibrosis
103983|NCT02421354|MF
103984|NCT02421354|Nivolumab
103985|NCT02421354|BMS-936558
103986|NCT02421354|Questionnaire
103987|NCT02421354|Survey
103988|NCT02421354|Phone call
103989|NCT02421341|Heart, Cardiovascular
103990|NCT02421341|Pulmonary
103991|NCT02421341|Skeletal Muscle
103992|NCT02421341|Exercise
103993|NCT02421315|OCD
103994|NCT02421315|Functional Magnetic Resonance Imaging (fMRI)
103995|NCT02421315|Magnetic Resonance Imaging (MRI)
103996|NCT02421289|CYP2B6 polymorphism
103997|NCT02421289|efavirenz
103998|NCT02421289|Thai
103999|NCT02421289|HIV-infected patient
104000|NCT02421289|pharmacogenomic
104001|NCT02421263|Psilocybin
104002|NCT02421263|Pharmacologic Actions
104003|NCT02421263|Psychotropic Drugs
104004|NCT02421224|Smoking Cessation
104005|NCT02421224|Incentives
104006|NCT02421224|Health Behavior
104007|NCT02421224|Smoking
104008|NCT02421224|Work-site
104009|NCT02421211|Hepatitis C, Chronic
104010|NCT02421211|Simeprevir
104011|NCT02421211|Ledipasvir
104012|NCT02421211|Sofosbuvir
104013|NCT02421198|Intervention Studies
104014|NCT02421185|Carcinoma, Hepatocellular
104015|NCT02421185|JNJ 42756493
104016|NCT02421185|a pan-Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor
104017|NCT02421172|Hidradenitis Suppurativa
104018|NCT02421159|HIV/AIDS
104019|NCT02421159|vulnerable populations
104020|NCT02421159|heterosexuals at high risk
104021|NCT02421159|peer-driven intervention
104022|NCT02421159|tailored intervention
104023|NCT02421159|African-American
104024|NCT02421159|Latino/Hispanic
104025|NCT02421159|Seek, test, treat, and retain (STTR)
104026|NCT02421159|Brooklyn
104027|NCT02421133|Care transition program
104028|NCT02421133|Patient readmission
104029|NCT02421133|Transition Nurse
104030|NCT02421133|Stepped wedge
104031|NCT02421133|elderly
104032|NCT02421081|CD34
104033|NCT02421081|CD133
104034|NCT02421081|CD309
104035|NCT02421081|Radial Artery
104036|NCT02421081|Ulnar Artery
104037|NCT02421081|Lymphoid Cell
104038|NCT02421081|blood levels
104039|NCT02421081|endothelial progenitor cells
104040|NCT02421081|stem cells
104041|NCT02421068|Paracetamol
104042|NCT02421068|Fentanyl
104043|NCT02421068|Phenobarbital
104044|NCT02421068|Doxapram
104045|NCT02421068|Midazolam
104046|NCT02421068|Sildenafil
104047|NCT02421068|Levetiracetam
104048|NCT02421068|Pharmacokinetics
104049|NCT02421068|Pharmacology
104050|NCT02421068|Fluconazole
104051|NCT02421068|Ibuprofen
104052|NCT02421055|Bariatric Surgery
104053|NCT02421055|Gastric Bypass
104054|NCT02421055|Sleeve Gastrectomy
104055|NCT02421055|Gastroplasty
104056|NCT02421042|Hepatic Impairment
104057|NCT02421042|Hepatic Function
104058|NCT02421029|gadolinium
104059|NCT02421029|calcium disodium ethylenediaminetetraacetic acid (EDTA)
104060|NCT02421029|heavy metal toxicity
104061|NCT02421016|De novo stenosis
104062|NCT02421016|bioresorbable polymer coating
104063|NCT02421016|bioresorbable polymer backbone
104064|NCT02421003|heart surgery blood
104065|NCT02420990|ADHD
104066|NCT02420990|Adolescents
104067|NCT02420990|Substance Use Disorders
104068|NCT02420977|radiotracer
104069|NCT02420964|injectable
104070|NCT02420964|teaching methods
104071|NCT02420951|Knee
104072|NCT02420951|Arthroplasty
104073|NCT02420951|Bupivacaine
104074|NCT02420951|Anesthetics, Local
104075|NCT02420938|Leukemia
104076|NCT02420938|Chronic Lymphocytic Leukemia
104077|NCT02420938|CLL
104078|NCT02420938|Small Lymphocytic Lymphoma
104079|NCT02420938|SLL
104080|NCT02420938|Refractory/relapsed
104081|NCT02420938|High-risk molecular features
104082|NCT02420938|Rituximab
104083|NCT02420938|Rituxan
104084|NCT02420938|Urelumab
104085|NCT02420925|Gastroparesis
104086|NCT02420925|Celiac Plexus Block
104087|NCT02420912|Leukemia
104088|NCT02420912|Chronic Lymphocytic Leukemia
104089|NCT02420912|CLL
104090|NCT02420912|Relapsed
104091|NCT02420912|Refractory
104092|NCT02420912|High-risk
104093|NCT02420912|Untreated
104094|NCT02420912|Nivolumab
104095|NCT02420912|BMS-936558
104096|NCT02420912|Opdivo
104097|NCT02420912|Ibrutinib
104098|NCT02420912|PCI-32765
104099|NCT02420912|Imbruvica
104100|NCT02420899|IVUS
104101|NCT02420899|ACS
104102|NCT02420886|In Vitro culture of human embryos
104103|NCT02420873|Leukemia
104104|NCT02420873|Hematological malignancy
104105|NCT02420873|Myelofibrosis
104106|NCT02420873|MF
104107|NCT02420873|Blastic plasmacytoid dendritic cell neoplasm
104108|NCT02420873|BPDCN
104109|NCT02420873|CD56 tumor marker
104110|NCT02420873|Acute myeloid leukemia
104111|NCT02420873|AML
104112|NCT02420873|Natural-killer leukemia
104113|NCT02420873|Acute lymphoblastic leukemia
104114|NCT02420873|ALL
104115|NCT02420873|CD56 expressing hematological malignancy
104116|NCT02420873|IMGN901
104117|NCT02420873|Lorvotuzumab mertansine
104118|NCT02420860|Myeloma
104119|NCT02420860|Multiple myeloma
104120|NCT02420860|MM
104121|NCT02420860|Post autologous stem cell transplantation
104122|NCT02420860|ASCT
104123|NCT02420860|Elotuzumab
104124|NCT02420860|Lenalidomide
104125|NCT02420860|CC-5013
104126|NCT02420860|Revlimid
104127|NCT02420860|Dexamethasone
104128|NCT02420860|Decadron
104129|NCT02420860|Diphenhydramine
104130|NCT02420860|Benadryl
104131|NCT02420860|Ranitidine
104132|NCT02420860|Ranitidine hydrochloride
104133|NCT02420860|Zantac
104134|NCT02420860|Symptom questionnaire
104135|NCT02420860|Survey
104136|NCT02420847|Bladder cancer
104137|NCT02420847|Urothelial cancer
104138|NCT02420847|Transitional cell carcinoma of the urothelium
104139|NCT02420847|Metastatic
104140|NCT02420847|Locally unresectable
104141|NCT02420847|Ixazomib
104142|NCT02420847|Gemcitabine
104143|NCT02420847|Gemcitabine hydrochloride
104144|NCT02420847|Gemzar
104145|NCT02420847|Doxorubicin
104146|NCT02420847|Doxorubicin hydrochloride
104147|NCT02420847|Adriamycin PFS
104148|NCT02420847|Adriamycin RDF
104149|NCT02420847|Adriamycin
104150|NCT02420847|Rubex
104151|NCT02420808|CAD
104152|NCT02420808|STEMI
104153|NCT02420808|non STEMI
104154|NCT02420808|Unstable angina
104155|NCT02420808|Greece
104156|NCT02420795|Lymphoma
104157|NCT02420795|Non-Hodgkin's Lymphoma
104158|NCT02420795|Relapsed/Refractory
104159|NCT02420795|NHL
104160|NCT02420795|Mantle cell lymphoma
104161|NCT02420795|MCL
104162|NCT02420795|Diffuse large B-cell lymphoma
104163|NCT02420795|DLBCL
104164|NCT02420795|Transformed large cell lymphoma
104165|NCT02420795|TLCL
104166|NCT02420795|ONC201
104167|NCT02420795|Phone call
104168|NCT02420782|Pharmacokinetics
104169|NCT02420782|ASP6282
104170|NCT02420782|Pharmacodynamics
104171|NCT02420782|Drug-drug interaction
104172|NCT02420782|Midazolam
104173|NCT02420782|Safety and tolerability
104174|NCT02420782|Healthy volunteers
104175|NCT02420782|Itraconazole
104176|NCT02420769|CA 125
104177|NCT02420769|Progesterone
104178|NCT02420769|Doppler
104179|NCT02420769|Corpus Luteum
104180|NCT02420743|PTD
104181|NCT02420717|Leukemia
104182|NCT02420717|Acute Lymphoblastic Leukemia
104183|NCT02420717|ALL
104184|NCT02420717|Philadelphia Chromosome (Ph)-Like
104185|NCT02420717|Relapsed
104186|NCT02420717|Refractory
104187|NCT02420717|6-mercaptopurine
104188|NCT02420717|Mercaptopurine
104189|NCT02420717|6-MP
104190|NCT02420717|Purinethol
104191|NCT02420717|Ruxolitinib
104192|NCT02420717|Jakafi
104193|NCT02420717|INCB018424
104194|NCT02420717|INC424
104195|NCT02420717|Dasatinib
104196|NCT02420717|BMS-354825
104197|NCT02420717|Sprycel
104198|NCT02420717|Rituximab
104199|NCT02420717|Rituxan
104200|NCT02420717|G-CSF
104201|NCT02420717|Filgrastim
104202|NCT02420717|Neupogen
104203|NCT02420717|Pegfilgrastim
104204|NCT02420717|Neulasta
104205|NCT02420717|PEG-G-CSF
104206|NCT02420717|Methotrexate
104207|NCT02420717|Cytarabine
104208|NCT02420717|Ara-C
104209|NCT02420717|Cytosar
104210|NCT02420717|DepoCyt
104211|NCT02420717|Cytosine
104212|NCT02420717|Arabinosine Hydrochloride
104213|NCT02420717|Cyclophosphamide
104214|NCT02420717|Cytoxan
104215|NCT02420717|Neosar
104216|NCT02420717|Mesna
104217|NCT02420717|Mesnex
104218|NCT02420717|Doxorubicin
104219|NCT02420717|Doxorubucin hydrochloride
104220|NCT02420717|Adriamycin PFS
104221|NCT02420717|Adriamycin RDF
104222|NCT02420717|Adriamycin
104223|NCT02420717|Rubex
104224|NCT02420717|Vincristine
104225|NCT02420717|Dexamethasone
104226|NCT02420717|Decadron
104227|NCT02420717|Solumedrol
104228|NCT02420717|Methylprednisolone
104229|NCT02420717|Depo-medrol
104230|NCT02420717|Medrol
104231|NCT02420717|Solu-medrol
104232|NCT02420717|Prednisone
104233|NCT02420717|Leucovorin
104234|NCT02420717|Citrovorum
104235|NCT02420717|Wellcovorin
104236|NCT02420704|IVF
104237|NCT02420704|endometrial thickness
104238|NCT02420704|cleavage stage embryo
104239|NCT02420704|blastocyst stage embryo
104240|NCT02420704|Ongoing pregnancy rate
104241|NCT02420691|Gastrointestinal cancer
104242|NCT02420691|Foregut neuroendocrine tumors
104243|NCT02420691|NET
104244|NCT02420691|Thymic
104245|NCT02420691|Bronchopulmonary
104246|NCT02420691|Gastric
104247|NCT02420691|Duodenal
104248|NCT02420691|Pancreatic
104249|NCT02420691|LEE011
104250|NCT02420665|Cervical Cancer
104251|NCT02420665|Cervical Dysplasia
104252|NCT02420665|Abnormal Pap test
104253|NCT02420665|Positive human papillomavirus test
104254|NCT02420665|HPV
104255|NCT02420665|Visual inspection with acetic acid
104256|NCT02420665|VIA
104257|NCT02420665|Colposcopy
104258|NCT02420665|Proflavine
104259|NCT02420665|Acetic acid
104260|NCT02420665|High-Resolution Microendoscopy
104261|NCT02420665|HRME
104262|NCT02420665|Phone call
104263|NCT02420613|Diffuse Intrinsic Pontine Glioma
104264|NCT02420613|DIPG
104265|NCT02420613|Newly Diagnosed
104266|NCT02420613|Progressive
104267|NCT02420613|Pediatrics
104268|NCT02420613|Vorinostat
104269|NCT02420613|SAHA
104270|NCT02420613|Suberoylanilide Hydroxamic Acid
104271|NCT02420613|MSK-390
104272|NCT02420613|Zolinza
104273|NCT02420613|Temsirolimus
104274|NCT02420613|CCI-779
104275|NCT02420613|Torisel
104276|NCT02420613|Radiation therapy
104277|NCT02420613|XRT
104278|NCT02420600|Circulating tumor cells
104279|NCT02420600|Head and neck cancer
104280|NCT02420600|PD-1
104281|NCT02420600|natural killer cells
104282|NCT02420600|cytotoxic T lymphocytes
104283|NCT02420587|Prostate Cancer
104284|NCT02420587|Adenocarcinoma of the prostate
104285|NCT02420587|Castration resistant prostate cancer metastatic to bone
104286|NCT02420587|mCRPC
104287|NCT02420587|AMG 208
104288|NCT02420587|Questionnaire
104289|NCT02420587|Survey
104290|NCT02420561|Depression
104291|NCT02420561|Substance-Related Disorders
104292|NCT02420561|Mental Health
104293|NCT02420535|Dementia
104294|NCT02420535|Alzheimer's Disease
104295|NCT02420535|Caregivers
104296|NCT02420535|Behavioral
104297|NCT02420535|Caregiver burden
104298|NCT02420496|Parental nutrition
104299|NCT02420496|associated
104300|NCT02420470|diabetes
104301|NCT02420470|neural and vessel alteration
104302|NCT02420470|prodromal stage
104303|NCT02420457|Fitness devices
104304|NCT02420418|Tobacco use disorder and bipolar disorders
104305|NCT02420418|N-acetylcysteine
104306|NCT02420418|Oxidative stress
104307|NCT02420418|inflammation
104308|NCT02420405|Gene testing
104309|NCT02420405|Endobronchial ultrasound (EBUS)
104310|NCT02420405|Next-generation sequencing (NGS)
104311|NCT02420405|Small biopsies
104312|NCT02420379|DMD
104313|NCT02420379|Duchenne muscular dystrophy
104314|NCT02420379|eteplirsen
104315|NCT02420379|Dystrophin
104316|NCT02420379|exon 51
104317|NCT02420353|muscle atrophy
104318|NCT02420353|growth hormone
104319|NCT02420353|ACL tear
104320|NCT02420340|Serious Mental Illness
104321|NCT02420340|Psychosocial Rehabilitation
104322|NCT02420327|nicotine
104323|NCT02420327|galantamine
104324|NCT02420327|attention
104325|NCT02420327|cognition
104326|NCT02420327|non-smoker
104327|NCT02420314|Ascorbate
104328|NCT02420314|Ascorbic acid
104329|NCT02420314|Vitamin C
104330|NCT02420314|NSCLC
104331|NCT02420314|Non Small Cell Lung Cancer
104332|NCT02420314|carboplatin
104333|NCT02420314|paclitaxel
104334|NCT02420288|Pregnancy
104335|NCT02420288|Fetoplacental growth
104336|NCT02420288|Physical exercise
104337|NCT02420288|Pregnant
104338|NCT02420288|Placental development
104339|NCT02420288|Active pregnancy
104340|NCT02420275|brain injury
104341|NCT02420275|blue enriched withe bright light therapy
104342|NCT02420275|sequel fatigue
104343|NCT02420236|Exercise therapy
104344|NCT02420236|Resistance training
104345|NCT02420236|Multidisciplinary treatment
104346|NCT02420223|Recipients
104347|NCT02420197|Exercise therapy
104348|NCT02420197|Resistance training
104349|NCT02420197|Multidisciplinary treatment
104350|NCT02420171|In Vitro
104351|NCT02420171|embryo quality
104352|NCT02420171|Intracytoplasmic sperm injection
104353|NCT02420158|Irritable Bowel Syndrome
104354|NCT02420158|Vagal nerve stimulation
104355|NCT02420158|Quality of life
104356|NCT02420119|Iron Therapy
104357|NCT02420119|serum phosphates
104358|NCT02420119|vitamin D
104359|NCT02420106|cervical dystonia
104360|NCT02420106|neck pain
104361|NCT02420106|OMM
104362|NCT02420106|spasmodic torticollis
104363|NCT02420067|von Hippel-Lindau disease
104364|NCT02420067|Endolymphatic sac tumors
104365|NCT02420067|Audiological examination
104366|NCT02420067|MRI
104367|NCT02420067|Surveillance
104368|NCT02420054|intermittent fasting
104369|NCT02420054|alternate day fasting
104370|NCT02420054|diabetes mellitus
104371|NCT02420054|non-alcoholic fatty liver disease
104372|NCT02420054|insulin sensitivity
104373|NCT02420041|Sacroiliac Joint Injection
104374|NCT02420041|Fluoroscopy
104375|NCT02420041|Ultrasound
104376|NCT02419989|Nontuberculous Mycobacteria
104377|NCT02419963|microbiome
104378|NCT02419963|biomarkers
104379|NCT02419963|Vitamin D
104380|NCT02419963|Serotonin
104381|NCT02419950|inguinal hernia
104382|NCT02419950|TEP
104383|NCT02419950|chronic pain
104384|NCT02419950|male sex
104385|NCT02419950|mesh fixation
104386|NCT02419950|quality of life
104387|NCT02419950|national register
104388|NCT02419911|gastrointestinal
104389|NCT02419911|gynecologic
104390|NCT02419911|urologic
104391|NCT02419911|bariatric
104392|NCT02419911|laparoscopic surgery
104393|NCT02419898|Feasibility
104394|NCT02419885|finger amputation
104395|NCT02419885|composite graft
104396|NCT02419885|adipo-fascia flap
104397|NCT02419859|Diabetes Mellitus
104398|NCT02419859|Diabetes Mellitus, Type 2
104399|NCT02419859|Glucose Metabolism Disorders
104400|NCT02419859|Metabolic Diseases
104401|NCT02419859|Endocrine System Diseases
104402|NCT02419859|Insulin
104403|NCT02419859|Continuous subcutaneous insulin infusion (CSII)
104404|NCT02419859|Insulin pumps
104405|NCT02419846|Informed Decision Making
104406|NCT02419846|Prostate
104407|NCT02419846|Cancer
104408|NCT02419833|non-STEMI
104409|NCT02419833|immediate
104410|NCT02419833|delayed
104411|NCT02419833|PCI
104412|NCT02419807|Near Infrared Fluorescence Imaging
104413|NCT02419807|Indocyanine Green
104414|NCT02419807|axillary lymph node mapping
104415|NCT02419807|Mastectomy, Segmental
104416|NCT02419807|Sentinel Lymph Node Biopsy
104417|NCT02419807|Lumpectomy
104418|NCT02419768|Long-range autocorrelations
104419|NCT02419768|Variability
104420|NCT02419768|Physical Exercise
104421|NCT02419768|Parkinson's Disease
104422|NCT02419768|ICF
104423|NCT02419755|Infant leukemia
104424|NCT02419755|ALL
104425|NCT02419755|AML
104426|NCT02419755|Biphenotypic leukemia
104427|NCT02419755|Pediatric
104428|NCT02419729|Vulvovaginal atrophy
104429|NCT02419729|Menopause
104430|NCT02419729|Fractional CO2 laser
104431|NCT02419729|Estrogen cream
104432|NCT02419716|colorectal cancer
104433|NCT02419716|Colorectal cancer screening
104434|NCT02419677|radiofrequency ablation
104435|NCT02419677|cytokine-induced killer cells
104436|NCT02419677|colorectal cancer iver metastases
104437|NCT02419664|pituitary
104438|NCT02419664|pituitary adenomas
104439|NCT02419664|Ga-PET
104440|NCT02419664|Acromegaly
104441|NCT02419664|TSHomas
104442|NCT02419664|Cushing
104443|NCT02419651|out patient hysteroscopy
104444|NCT02419638|relapsing-remitting MS
104445|NCT02419638|lesions
104446|NCT02419638|treatment
104447|NCT02419573|cardiac arrest
104448|NCT02419573|cardiopulmonary resuscitation
104449|NCT02419573|laryngeal tube
104450|NCT02419573|endotracheal intubation
104451|NCT02419573|non-traumatic Out of Hospital Cardiac Arrest (OOHCA)
104452|NCT02419560|Relapsed
104453|NCT02419560|Laboratory biomarker research
104454|NCT02419560|Pharmacologic study
104455|NCT02419560|Bruton's tyrosine kinase inhibitor
104456|NCT02419560|BCL-2 inhibitor
104457|NCT02419547|Ventricular tachycardia
104458|NCT02419547|ventricular tachycardia ablation
104459|NCT02419547|effects of anesthesia on VT induction
104460|NCT02419547|programed stimulation
104461|NCT02419534|Pediatric, fissure in ano
104462|NCT02419495|Advanced cancers
104463|NCT02419495|Malignant neoplasms
104464|NCT02419495|Paclitaxel
104465|NCT02419495|Taxol
104466|NCT02419495|Eribulin
104467|NCT02419495|E7389
104468|NCT02419495|Doxorubicin
104469|NCT02419495|Doxorubicin Hydrochloride
104470|NCT02419495|Adriamycin PFS
104471|NCT02419495|Adriamycin RDF
104472|NCT02419495|Adriamycin
104473|NCT02419495|Rubex
104474|NCT02419495|Cyclophosphamide
104475|NCT02419495|Cytoxan
104476|NCT02419495|Neosar
104477|NCT02419495|Pemetrexed
104478|NCT02419495|LY231514
104479|NCT02419495|Alimta
104480|NCT02419495|MTA
104481|NCT02419495|Multitargeted Antifolate
104482|NCT02419495|NSC-698037
104483|NCT02419495|Topotecan
104484|NCT02419495|Hycamtin
104485|NCT02419495|Selinexor
104486|NCT02419495|KPT-330
104487|NCT02419495|Carboplatin
104488|NCT02419495|Paraplatin
104489|NCT02419495|Irinotecan
104490|NCT02419495|CPT-11
104491|NCT02419495|Camptosar
104492|NCT02419495|5-FU
104493|NCT02419495|Fluorouracil
104494|NCT02419495|5-Fluorouracil
104495|NCT02419495|Adrucil
104496|NCT02419495|Efudex
104497|NCT02419495|Capecitabine
104498|NCT02419495|Xeloda
104499|NCT02419495|Oxaliplatin
104500|NCT02419495|Eloxatin
104501|NCT02419495|Olaparib
104502|NCT02419495|Lynparza
104503|NCT02419495|Pembrolizumab
104504|NCT02419495|Keytruda
104505|NCT02419495|MK-3475
104506|NCT02419495|SCH-900475
104507|NCT02419482|Exercise therapy
104508|NCT02419482|Reproductive Physiological Processes
104509|NCT02419482|Fertility
104510|NCT02419469|Leukemia
104511|NCT02419469|Precursor-B acute lymphoblastic leukemia
104512|NCT02419469|ALL
104513|NCT02419469|Lymphoblastic lymphoma
104514|NCT02419469|LL
104515|NCT02419469|Lymphoma
104516|NCT02419469|Cytarabine
104517|NCT02419469|Ara-C
104518|NCT02419469|Cytosar
104519|NCT02419469|DepoCyt
104520|NCT02419469|Cytosine Arabinosine Hydrochloride
104521|NCT02419469|Daunorubicin
104522|NCT02419469|Daunorubicin Hydrochloride
104523|NCT02419469|Cerubidine
104524|NCT02419469|Daunomycin
104525|NCT02419469|DNR
104526|NCT02419469|Vincristine
104527|NCT02419469|Prednisone
104528|NCT02419469|PEG asparginase
104529|NCT02419469|Pegaspargase
104530|NCT02419469|Oncaspar
104531|NCT02419469|Polyethylene glycol conjugated lasparaginase-H
104532|NCT02419469|Ofatumumab
104533|NCT02419469|Arzerra
104534|NCT02419469|Rituximab
104535|NCT02419469|Rituxan
104536|NCT02419469|Methotrexate
104537|NCT02419469|Cyclophosphamide
104538|NCT02419469|Cytoxan
104539|NCT02419469|Neosar
104540|NCT02419469|Mercaptopurine
104541|NCT02419469|6-mercaptopurine
104542|NCT02419469|Purinethol
104543|NCT02419469|6-MP
104544|NCT02419469|Doxorubicin
104545|NCT02419469|Doxorubicin hydrochloride
104546|NCT02419469|Adriamycin PFS
104547|NCT02419469|Adriamycin RDF
104548|NCT02419469|Adriamycin
104549|NCT02419469|Rubex
104550|NCT02419469|Dexamethasone
104551|NCT02419469|Decadron
104552|NCT02419469|Thioguanine
104553|NCT02419469|6-thioguanine
104554|NCT02419443|inguinal hernia repair, chronic pain
104555|NCT02419430|well-being
104556|NCT02419430|stress
104557|NCT02419430|resilience
104558|NCT02419430|self-compassion
104559|NCT02419391|RSV Vaccines
104560|NCT02419391|Respiratory Syncytial Virus Vaccines
104561|NCT02419365|Primary Ciliary Dyskinesia (PCD)
104562|NCT02419352|Cognitive function
104563|NCT02419326|couples
104564|NCT02419326|relationships
104565|NCT02419326|binge eating
104566|NCT02419326|eating disorder
104567|NCT02419326|couple therapy
104568|NCT02419313|Tremor
104569|NCT02419313|Parkinson
104570|NCT02419313|botulinum
104571|NCT02419313|Xeomin
104572|NCT02419287|ALK
104573|NCT02419287|crizotinib
104574|NCT02419274|asthma
104575|NCT02419274|phenotype
104576|NCT02419274|childhood
104577|NCT02419274|adulthood
104578|NCT02419261|knee surgery
104579|NCT02419261|anterior cruciate ligament surgery
104580|NCT02419261|nerve block
104581|NCT02419235|Refractory hypertension
104582|NCT02419235|Homoeopathy
104583|NCT02419235|Homoeopathic complex
104584|NCT02419235|Amylenum nitrosum 6cH
104585|NCT02419235|Crataegus oxyacantha 6cH
104586|NCT02419235|Natrum muriaticum 6cH
104587|NCT02419235|Scutellaria lateriflora 6cH
104588|NCT02419209|Low sexual desire
104589|NCT02419209|Perimenopause
104590|NCT02419209|Homeopathy
104591|NCT02419209|Hypoactive Sexual Desire Disorder
104592|NCT02419183|Mild Cognitive Impairment
104593|NCT02419183|Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR)
104594|NCT02419183|Rey Auditory Verbal Learning Test (RAVLT)
104595|NCT02419183|Word List Recall (WLR)
104596|NCT02419157|Cervical lesions
104597|NCT02419157|Clinical trial
104598|NCT02419157|Self-etch adhesive
104599|NCT02419144|older adults;
104600|NCT02419144|oral hygiene;
104601|NCT02419144|adapted motivational interviewing
104602|NCT02419118|Myeloma
104603|NCT02419118|monoclonal antibody
104604|NCT02419118|Daratumumab
104605|NCT02419105|Falls
104606|NCT02419105|hypogonadal men
104607|NCT02419105|Seniors
104608|NCT02419105|Testosterone
104609|NCT02419105|Colecalciferol
104610|NCT02419092|Inflammation
104611|NCT02419092|Insulin resistance
104612|NCT02419092|Bariatric surgery
104613|NCT02419053|Surgical safety checklist
104614|NCT02419053|perioperative complications
104615|NCT02419053|pediatric
104616|NCT02419040|shoulder pain
104617|NCT02419040|rotator cuff
104618|NCT02419040|calcific tendonitis
104619|NCT02419040|barbotage
104620|NCT02419027|GI Flora
104621|NCT02419014|cranial electrotherapy
104622|NCT02419014|cranial electrical stimulation
104623|NCT02419014|restless legs syndrome
104624|NCT02418962|PfSPZ Vaccine
104625|NCT02418949|hand
104626|NCT02418949|rehabilitation
104627|NCT02418949|active movement training
104628|NCT02418949|passive cyclical stretching
104629|NCT02418936|Waardenburg syndrome
104630|NCT02418936|Large vestibular aqueduct syndrome
104631|NCT02418936|Diagnosis
104632|NCT02418936|copy number variation
104633|NCT02418936|Multiplex polymerase chain reaction
104634|NCT02418910|bipolar
104635|NCT02418910|self assessment
104636|NCT02418910|prospective randomized trial
104637|NCT02418897|Fatigue
104638|NCT02418897|multiple sclerosis
104639|NCT02418897|neuromuscular junction
104640|NCT02418897|SFEMG
104641|NCT02418871|cataract
104642|NCT02418871|presbyopia
104643|NCT02418858|Essential tremor
104644|NCT02418858|DBS
104645|NCT02418832|Azoospermia
104646|NCT02418832|Rete Testis
104647|NCT02418832|TEFNA
104648|NCT02418806|Family Caregivers
104649|NCT02418806|Psychotherapy Group
104650|NCT02418793|Hemophilia
104651|NCT02418793|Factor VII
104652|NCT02418793|Factor VIIa
104653|NCT02418793|Inhibitors
104654|NCT02418793|Long Acting
104655|NCT02418728|obesity
104656|NCT02418728|adipose tissue lipolysis
104657|NCT02418728|lipolysis
104658|NCT02418728|microdialysis
104659|NCT02418728|atrial natriuretic peptide
104660|NCT02418702|depression
104661|NCT02418702|suicide
104662|NCT02418702|ketamine
104663|NCT02418702|rapid intravenous bolus
104664|NCT02418702|sub-anesthetic dose
104665|NCT02418702|double-blind placebo control
104666|NCT02418676|Human insulin
104667|NCT02418676|Hydroxypropyl-beta-cyclodextrin
104668|NCT02418676|Pressure Ulcer
104669|NCT02418676|Wound Healing
104670|NCT02418676|Gel
104671|NCT02418663|fluid responsiveness
104672|NCT02418663|enhanced recovery program
104673|NCT02418650|volunteers
104674|NCT02418637|worksite
104675|NCT02418637|screen
104676|NCT02418637|migrant
104677|NCT02418637|agricultural
104678|NCT02418637|worker
104679|NCT02418637|hypertension
104680|NCT02418637|Hyperlipidemia
104681|NCT02418637|diabetes
104682|NCT02418637|feasibility
104683|NCT02418624|breast cancer 1, early onset (BRCA1)
104684|NCT02418624|breast cancer 2, early onset (BRCA2)
104685|NCT02418624|homologous recombination deficiency
104686|NCT02418624|carboplatin
104687|NCT02418624|olaparib
104688|NCT02418611|Aorta
104689|NCT02418611|Thoracic
104690|NCT02418611|Aortic dissection
104691|NCT02418611|Rupture
104692|NCT02418611|Type B
104693|NCT02418611|DeBakey type III
104694|NCT02418611|Endovascular
104695|NCT02418598|Adeno-associated virus
104696|NCT02418598|Aromatic L-amino acid decarboxylase
104697|NCT02418598|AAV-hAADC-2
104698|NCT02418598|AAV-2
104699|NCT02418598|Gene Therapy
104700|NCT02418598|Gene Transfer
104701|NCT02418598|Parkinson Disease
104702|NCT02418598|Basal Ganglia Disease
104703|NCT02418598|Brain Disease
104704|NCT02418585|Treatment-resistant Depression
104705|NCT02418585|Esketamine
104706|NCT02418585|Placebo
104707|NCT02418585|Oral Antidepressant
104708|NCT02418559|Healthy
104709|NCT02418559|JNJ-63623872
104710|NCT02418559|Japanese Adult Participants
104711|NCT02418533|infertility
104712|NCT02418533|in vitro fertilization
104713|NCT02418533|fertility
104714|NCT02418533|preimplantation genetic screening
104715|NCT02418533|embryo
104716|NCT02418533|PGS
104717|NCT02418533|Eeva
104718|NCT02418533|IVF
104719|NCT02418481|γδ T Cell
104720|NCT02418481|breast cancer
104721|NCT02418481|her2-
104722|NCT02418481|er-
104723|NCT02418481|pr-
104724|NCT02418468|COPD, FEV1, indacaterol
104725|NCT02418455|MPS 7
104726|NCT02418455|Sly Syndrome
104727|NCT02418455|MPS VII
104728|NCT02418455|Enzyme Replacement Therapy
104729|NCT02418455|Rare Disease
104730|NCT02418455|Mucopolysaccharidosis type 7
104731|NCT02418455|Lysosomal Storage Disease
104732|NCT02418455|Metabolic Disorder
104733|NCT02418442|Systemic Arthritis
104734|NCT02418442|Oligoarthritis
104735|NCT02418442|Polyarthritis (Rheumatoid Factor Negative)
104736|NCT02418442|Polyarthritis (Rheumatoid Factor Positive)
104737|NCT02418442|Psoriatic Arthritis
104738|NCT02418442|Enthesitis Related Arthritis (ERA)
104739|NCT02418442|Undifferianted Arthritis
104740|NCT02418429|fat oxidation
104741|NCT02418429|hunger
104742|NCT02418429|resistant starch
104743|NCT02418429|whey protein
104744|NCT02418377|Obesity
104745|NCT02418377|Genetics
104746|NCT02418377|Whole exome sequencing
104747|NCT02418377|Children
104748|NCT02418351|RRMS
104749|NCT02418325|RRMS
104750|NCT02418312|histamine-2 receptor antagonist
104751|NCT02418312|peptic ulcer
104752|NCT02418312|thienopyridine
104753|NCT02418312|prevention
104754|NCT02418299|urinary incontinence
104755|NCT02418299|Er:YAG laser
104756|NCT02418286|Low Back Pain
104757|NCT02418286|Korean Rehabilitation Clinic
104758|NCT02418286|Patient Registry
104759|NCT02418273|denosumab
104760|NCT02418273|pediatric
104761|NCT02418273|rheumatology
104762|NCT02418273|osteoporosis
104763|NCT02418273|glucocorticoid
104764|NCT02418260|Humerus
104765|NCT02418260|shaft
104766|NCT02418260|diaphyseal
104767|NCT02418260|fractures
104768|NCT02418247|radioactive iodine therapy
104769|NCT02418247|ablation
104770|NCT02418247|thyroid cancer
104771|NCT02418234|Non-small Cell Lung Cancer
104772|NCT02418234|circulating tumor DNA
104773|NCT02418234|T790M
104774|NCT02418234|amplification refractory mutation system
104775|NCT02418234|digital droplet PCR
104776|NCT02418221|histamine, biogenic amines, diamine oxidase
104777|NCT02418195|Depression
104778|NCT02418195|Ketamine
104779|NCT02418195|Suicide Attempt
104780|NCT02418195|Suicidal Ideation
104781|NCT02418195|Suicidality
104782|NCT02418182|Analgesic
104783|NCT02418182|Pain Control
104784|NCT02418182|IVF
104785|NCT02418182|Tylenol
104786|NCT02418182|Acetaminophen
104787|NCT02418182|Egg Retrieval
104788|NCT02418182|iv vitro Fertilization
104789|NCT02418117|Stereolitographic guide
104790|NCT02418117|flapless surgery
104791|NCT02418117|dental implants
104792|NCT02418091|patients with moderate DKD and uncontrolled HTN
104793|NCT02418065|Physical exercises
104794|NCT02418065|Oral nutritional supplementation
104795|NCT02418065|Multimodal
104796|NCT02418065|Hemodialysis
104797|NCT02418065|Protein-Energy Wasting
104798|NCT02418052|esophageal cancer
104799|NCT02418052|minimally invasive esophagectomy
104800|NCT02418052|anastomotic leak
104801|NCT02418052|neck flexion
104802|NCT02418039|Minimal hepatic encephalopathy
104803|NCT02418039|Nutrition
104804|NCT02418013|Frailty
104805|NCT02418013|Umbilical cord blood
104806|NCT02418013|Plasma
104807|NCT02418013|Randomized trial
104808|NCT02418013|Double-blinded trial
104809|NCT02418013|Placebo-controlled trial
104810|NCT02417974|Prevention
104811|NCT02417974|Recurrence
104812|NCT02417974|Fecal Microbiota Therapy
104813|NCT02417961|Asthma,
104814|NCT02417961|Bronchial Diseases,
104815|NCT02417961|Respiratory Tract Diseases,
104816|NCT02417961|Lung Diseases,
104817|NCT02417961|Obstructive Lung Diseases,
104818|NCT02417961|Benralizumab
104819|NCT02417909|Obesity
104820|NCT02417909|quality of life
104821|NCT02417909|teenagers
104822|NCT02417909|psychological impact
104823|NCT02417896|Acute kidney injury
104824|NCT02417896|Spironolactone
104825|NCT02417883|Furosemide
104826|NCT02417883|Interstitial Fibrosis
104827|NCT02417870|Transplantation
104828|NCT02417870|interleukin-2
104829|NCT02417870|IL-2
104830|NCT02417870|Kidney
104831|NCT02417870|Renal
104832|NCT02417857|Single İncision Laparoscopic Surgery
104833|NCT02417857|Conventional Laparoscopic Surgery
104834|NCT02417792|psoriasis
104835|NCT02417792|microbiota
104836|NCT02417766|Genetic Testing
104837|NCT02417766|Secondary Findings
104838|NCT02417766|Immune-Mediated Disorders
104839|NCT02417766|Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal in
104840|NCT02417766|Whole Exome Sequencing
104841|NCT02417753|PARACENTESIS
104842|NCT02417753|STAT3 Antisense Oligonucleotide
104843|NCT02417753|Ascites
104844|NCT02417753|AZD9150
104845|NCT02417753|Surgical Resection
104846|NCT02417740|Portal Hypertension
104847|NCT02417740|Portal Fibrosis
104848|NCT02417740|Liver Disease
104849|NCT02417740|Varices
104850|NCT02417740|Splenomegaly
104851|NCT02417727|MEMORY TESTING
104852|NCT02417727|Biomarkers
104853|NCT02417727|Learning
104854|NCT02417714|Computed Tomography
104855|NCT02417714|Radiation Reduction
104856|NCT02417714|Iterative Reconstruction
104857|NCT02417688|carotid atherosclerosis, PET imaging agent
104858|NCT02417675|Option B+
104859|NCT02417675|Adherence Club
104860|NCT02417675|Postpartum
104861|NCT02417675|Breastfeeding
104862|NCT02417675|Mother-to-child transmission
104863|NCT02417662|NSCLC
104864|NCT02417662|Stereotactic Ablative Radiotherapy
104865|NCT02417662|Radiotherapy
104866|NCT02417662|Randomised
104867|NCT02417662|Controlled
104868|NCT02417662|Oligometastatic
104869|NCT02417610|Polynucleotide
104870|NCT02417610|Hyaluronic acid
104871|NCT02417610|Intra articular injection
104872|NCT02417597|hepatitis E
104873|NCT02417571|Chronic kidney disease
104874|NCT02417571|Blood pressure
104875|NCT02417571|ambulatory blood pressure
104876|NCT02417571|glomerular filtration rate
104877|NCT02417519|Coffee
104878|NCT02417519|Chlorogenic acid
104879|NCT02417519|Insulin
104880|NCT02417519|Appetite
104881|NCT02417519|Metabolomics
104882|NCT02417506|Acute pain
104883|NCT02417506|Herbal
104884|NCT02417506|VAS
104885|NCT02417506|Stop watch
104886|NCT02417493|Food allergy
104887|NCT02417493|self-management
104888|NCT02417493|epinephrine self-injection
104889|NCT02417493|ntervention
104890|NCT02417493|adolescents
104891|NCT02417467|Electronic cigarette
104892|NCT02417467|E-cigarette
104893|NCT02417467|Smoking cessation
104894|NCT02417454|probiotic
104895|NCT02417454|stress
104896|NCT02417454|emotion psychophysiology
104897|NCT02417454|brain-body-gut interactions
104898|NCT02417441|TiLE
104899|NCT02417441|Embryo Assessment
104900|NCT02417441|Pregnancy
104901|NCT02417441|Implantation
104902|NCT02417441|Fertilization
104903|NCT02417428|Muscle function
104904|NCT02417428|Functional capacity
104905|NCT02417415|Supine hypertension
104906|NCT02417415|Autonomic failure
104907|NCT02417415|Heat intolerance
104908|NCT02417415|Orthostatic hypotension
104909|NCT02417415|Heat stress
104910|NCT02417402|back pain
104911|NCT02417402|low back pain
104912|NCT02417402|chronic low back pain
104913|NCT02417389|primary hyperparathyroidism
104914|NCT02417389|hypercalcemia
104915|NCT02417389|osteoporosis
104916|NCT02417389|bone turnover
104917|NCT02417389|bone mineral density
104918|NCT02417389|fractures
104919|NCT02417376|Coronary heart disease
104920|NCT02417376|Periodontitis
104921|NCT02417376|C-reactive protein
104922|NCT02417376|Blood pressure
104923|NCT02417363|biomarkers
104924|NCT02417363|renal disease
104925|NCT02417363|periodontitis
104926|NCT02417324|medulloblastoma
104927|NCT02417324|ependymoma
104928|NCT02417324|pineoblastoma
104929|NCT02417324|CNS-PNET
104930|NCT02417311|Engineered Heart Tissue (EHT)
104931|NCT02417311|human induced pluripotent stem cells (hiPSC)
104932|NCT02417298|ketamine
104933|NCT02417298|pain
104934|NCT02417298|sickle cell disorder
104935|NCT02417285|Non-Hodgkin's Lymphoma
104936|NCT02417285|Diffused Large B-Cell Lymphoma
104937|NCT02417285|Phase 1B
104938|NCT02417285|Open-Label
104939|NCT02417285|Safety and Efficacy
104940|NCT02417285|CC-122
104941|NCT02417285|Obinutuzumab
104942|NCT02417285|GA101
104943|NCT02417285|Relapsed
104944|NCT02417285|Refractory
104945|NCT02417272|Total Disc Replacement
104946|NCT02417272|Anterior Cervical Decompression and Fusion
104947|NCT02417259|Spectroscopy, Near-Infrared
104948|NCT02417246|pharmacokinetics
104949|NCT02417246|pharmacodynamics
104950|NCT02417246|pharmacogenetics
104951|NCT02417233|HIV-positive
104952|NCT02417233|adherence
104953|NCT02417233|engagement to care
104954|NCT02417233|mHealth
104955|NCT02417233|SMS
104956|NCT02417233|peer navigation
104957|NCT02417233|retention
104958|NCT02417207|hepatitis B immune globulin (HBIG)
104959|NCT02417207|liver transplantation
104960|NCT02417207|hepatitis B
104961|NCT02417207|entecavir
104962|NCT02417194|Renal cell carcinoma
104963|NCT02417194|hemoglobin A1c protein
104964|NCT02417194|Pathologic outcomes
104965|NCT02417194|Oncological outcomes
104966|NCT02417194|Nephrectomy
104967|NCT02417181|Physician assistants
104968|NCT02417181|Out-of-hours medical care
104969|NCT02417181|Primary healthcare
104970|NCT02417181|Emergency Medical Services
104971|NCT02417155|Autonomic Nerve System
104972|NCT02417155|Epinephrin
104973|NCT02417155|Hyperventilation
104974|NCT02417155|Hypoventilation
104975|NCT02417064|Treatment-resistant Depression
104976|NCT02417064|Esketamine
104977|NCT02417064|Placebo
104978|NCT02417064|Oral Antidepressant
104979|NCT02417051|Psychological Resilience
104980|NCT02417051|Perceived Stress
104981|NCT02417051|Psychological Stress
104982|NCT02417051|Disaster Worker
104983|NCT02417051|Superstorm Sandy
104984|NCT02417051|Mental Health
104985|NCT02417051|Prevention
104986|NCT02417038|Postoperative Respiratory Monitoring
104987|NCT02417038|Neuraxial Opioid Administration for Cesarean Delivery
104988|NCT02417025|Military
104989|NCT02417025|Health Service Delivery
104990|NCT02417025|Telepsychology
104991|NCT02417025|Prolonged Exposure
104992|NCT02417025|Off-duty Activity of Military Personnel
104993|NCT02417012|lifestyle
104994|NCT02417012|exercise
104995|NCT02417012|physical activity
104996|NCT02417012|diet
104997|NCT02417012|glycemic control
104998|NCT02417012|hba1c
104999|NCT02417012|glucose lowering drugs
105000|NCT02416999|glioma
105001|NCT02416999|high-grade glioma
105002|NCT02416960|female infertility
105003|NCT02416960|glycemic index
105004|NCT02416960|leptin
105005|NCT02416960|ghrelin
105006|NCT02416960|overweight
105007|NCT02416960|obesity
105008|NCT02416960|in vitro fertilization
105009|NCT02416947|Soluble Corn Fiber
105010|NCT02416947|Osteoporosis
105011|NCT02416947|Bone Loss
105012|NCT02416921|Facebook
105013|NCT02416921|Weight Gain Prevention
105014|NCT02416921|Women's Health
105015|NCT02416921|Online
105016|NCT02416921|Weight Gain
105017|NCT02416921|Weight Loss
105018|NCT02416921|Female Contraception
105019|NCT02416921|Obesity
105020|NCT02416921|Body Weight
105021|NCT02416921|Internet
105022|NCT02416882|active
105023|NCT02416882|not active
105024|NCT02416882|normal body weight
105025|NCT02416869|Dexamethasone
105026|NCT02416869|Lower third molar surgery
105027|NCT02416856|Aphasia
105028|NCT02416856|Brain
105029|NCT02416856|Stimulation
105030|NCT02416856|Communication
105031|NCT02416856|Stroke
105032|NCT02416856|Speech Disorders
105033|NCT02416856|Communications Disorders
105034|NCT02416856|Neurobehavioral Manifestations
105035|NCT02416856|Neurologic Manifestations
105036|NCT02416856|Nervous System Diseases
105037|NCT02416856|Signs and Symptoms
105038|NCT02416843|Adipose tissue
105039|NCT02416843|metabolism
105040|NCT02416843|inflammation
105041|NCT02416843|post-prandial
105042|NCT02416843|human
105043|NCT02416830|embolization
105044|NCT02416830|visceral Aneurysms
105045|NCT02416830|Prospective Registry
105046|NCT02416817|Thrombelastography
105047|NCT02416817|Massive Transfusion
105048|NCT02416817|Major Trauma
105049|NCT02416817|Blood products
105050|NCT02416817|Thromboelastometry
105051|NCT02416804|buprenorphine
105052|NCT02416804|transdermal system
105053|NCT02416804|Pain, postoperative
105054|NCT02416804|Quality of life
105055|NCT02416804|Spinal stenosis
105056|NCT02416804|Posterior lumbar fusion
105057|NCT02416791|robotic therapy
105058|NCT02416791|transcranial direct current stimulation
105059|NCT02416778|COPD
105060|NCT02416778|Chronic Obstructive Pulmonary Disease
105061|NCT02416778|Iron deficiency
105062|NCT02416778|6 Minute-Walking-Test
105063|NCT02416765|Closed-loop strategy
105064|NCT02416765|Artificial pancreas
105065|NCT02416765|Postprandial glucose
105066|NCT02416765|Insulin
105067|NCT02416765|Glucagon
105068|NCT02416765|Hypoglycemia
105069|NCT02416765|Type 1 diabetes
105070|NCT02416752|remifentanil
105071|NCT02416752|head and neck surgery
105072|NCT02416752|recovery pofile
105073|NCT02416752|Opioid induced hyperalgesia
105074|NCT02416752|post operative pain
105075|NCT02416739|EGFR mutated lung cancer
105076|NCT02416726|Gene testing
105077|NCT02416726|Next-generation sequecing
105078|NCT02416726|Primary tumor
105079|NCT02416726|Metastatic lymph node
105080|NCT02416726|Peripheral blood
105081|NCT02416713|Driving
105082|NCT02416713|Teens
105083|NCT02416713|Texting
105084|NCT02416713|Cellphone
105085|NCT02416713|DriveID
105086|NCT02416713|Motor vehicle accident
105087|NCT02416700|Dental prosthesis
105088|NCT02416700|Patients
105089|NCT02416700|Osseointegrated implants
105090|NCT02416674|abdominal wall
105091|NCT02416674|vascularized composite allotransplantation
105092|NCT02416661|Gaucher Disease type 1
105093|NCT02416661|Lymphatic Diseases
105094|NCT02416661|Lipid Metabolism, Inborn Errors
105095|NCT02416661|Lipid Metabolism Disorders
105096|NCT02416661|Lipidoses
105097|NCT02416648|Adult HIV patients
105098|NCT02416648|Knowledge
105099|NCT02416648|Attitudes
105100|NCT02416648|Sexual behaviors
105101|NCT02416635|Liver Neoplasms
105102|NCT02416635|Circulating Tumor Cells
105103|NCT02416622|XLRS
105104|NCT02416622|maculoschisis
105105|NCT02416622|retinal degeneration
105106|NCT02416622|RS1
105107|NCT02416622|adeno-associated virus
105108|NCT02416622|gene therapy
105109|NCT02416622|AAV
105110|NCT02416609|Locally advanced pancreatic cancer
105111|NCT02416609|Stereotactic Body Radiotherapy
105112|NCT02416609|Chemopotentiator
105113|NCT02416609|Low dose radiotherapy
105114|NCT02416609|Hyper-Radiosensitivity
105115|NCT02416596|ICSI
105116|NCT02416596|IVF
105117|NCT02416596|hysteroscopy
105118|NCT02416596|Supervision
105119|NCT02416596|In-vitro Fertilization
105120|NCT02416583|membrane sweeping
105121|NCT02416583|dinoprostone
105122|NCT02416583|nulliparas
105123|NCT02416583|labor induction
105124|NCT02416570|Clarithromycin
105125|NCT02416544|Overweight
105126|NCT02416544|Obesity
105127|NCT02416544|Caloric Restriction
105128|NCT02416544|Diet, Reducing
105129|NCT02416544|Diet, Sodium-Restricted
105130|NCT02416544|Body Weight Changes
105131|NCT02416544|Energy intake
105132|NCT02416544|Feeding Behavior
105133|NCT02416531|Vulvar lichen sclerosus
105134|NCT02416531|Photodynamic therapy
105135|NCT02416531|Low-level laser therapy
105136|NCT02416531|Clobetasol propionate
105137|NCT02416518|Cancer
105138|NCT02416518|Malignancy
105139|NCT02416518|Genomic
105140|NCT02416518|Molecular
105141|NCT02416479|medication adherence
105142|NCT02416479|outcomes
105143|NCT02416479|intervention
105144|NCT02416479|randomized controlled trial
105145|NCT02416466|Colorectal cancer
105146|NCT02416466|Liver metastases
105147|NCT02416466|Breast cancer
105148|NCT02416466|Gastric cancer
105149|NCT02416466|Pancreas cancer
105150|NCT02416466|Carcinoembryonic antigen
105151|NCT02416466|CAR-T
105152|NCT02416466|Immunotherapy
105153|NCT02416453|Healthy
105154|NCT02416453|Ebola viruses
105155|NCT02416453|Ebola Viral Disease (EVD)
105156|NCT02416453|Filoviruses
105157|NCT02416453|Monovalent vaccine
105158|NCT02416453|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
105159|NCT02416453|Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
105160|NCT02416453|Safety
105161|NCT02416453|Immunogenicity
105162|NCT02416440|South African
105163|NCT02416440|urban African
105164|NCT02416440|diabetes
105165|NCT02416440|prevalence
105166|NCT02416440|risk factors
105167|NCT02416440|genetics
105168|NCT02416427|Atorvastatin
105169|NCT02416427|TAZ
105170|NCT02416427|Hippo pathway
105171|NCT02416427|ki67
105172|NCT02416401|healthy
105173|NCT02416401|aging
105174|NCT02416401|cognition
105175|NCT02416401|age-related cognitive decline
105176|NCT02416362|Postural Balance
105177|NCT02416362|Electromyography
105178|NCT02416362|Torque
105179|NCT02416349|Stroke
105180|NCT02416349|Stretching
105181|NCT02416349|Respiratory muscle
105182|NCT02416349|Ventilatory pattern
105183|NCT02416349|Optoelectronic plethysmography
105184|NCT02416336|sentinel lymph node
105185|NCT02416336|lymphoscintigraphy
105186|NCT02416336|intraoperative gamma camera
105187|NCT02416310|TEAS
105188|NCT02416310|cesarean section
105189|NCT02416310|gastrointestinal function
105190|NCT02416297|malocclusion
105191|NCT02416297|accelerated tooth movement
105192|NCT02416297|Tomography
105193|NCT02416297|Extraction
105194|NCT02416258|Psoriasis
105195|NCT02416232|melanoma
105196|NCT02416232|dabrafenib
105197|NCT02416232|trametinib
105198|NCT02416232|BRAF V600E/K mutation
105199|NCT02416219|Cricoid cartilage, cricoid pressure, obstetric
105200|NCT02416206|Multiple myeloma
105201|NCT02416206|hematopoietic stem cell transplant
105202|NCT02416193|Diabetes
105203|NCT02416193|Cognition
105204|NCT02416193|Functioning
105205|NCT02416180|EVOHALER
105206|NCT02416180|Asthma
105207|NCT02416180|SERETIDE
105208|NCT02416180|DISKUS Inhaler
105209|NCT02416180|MDI
105210|NCT02416154|interferon-epsilon
105211|NCT02416154|female reproductive tract
105212|NCT02416154|neopterin
105213|NCT02416154|menstrual cycle
105214|NCT02416115|PONV
105215|NCT02416115|ramosetron
105216|NCT02416115|naloxone
105217|NCT02416089|Tampostat
105218|NCT02416089|Tamponade
105219|NCT02416089|Postpartum hemorrhage
105220|NCT02416076|Ulthera® System
105221|NCT02416076|Ultherapy®
105222|NCT02416076|Ulthera, Inc.
105223|NCT02416050|Cocaine
105224|NCT02416050|Dependence
105225|NCT02416050|Abstinence
105226|NCT02416050|Prediction
105227|NCT02416050|Model
105228|NCT02416050|Humans
105229|NCT02416050|MRI
105230|NCT02416050|Cognitive
105231|NCT02416050|Impulsivity
105232|NCT02416050|Craving
105233|NCT02416037|ARDS
105234|NCT02416037|prone position
105235|NCT02416037|PEEP
105236|NCT02416037|mechanical ventilation
105237|NCT02416024|angiotensin converting enzyme inhibitor
105238|NCT02416024|anesthesia
105239|NCT02416011|e-cigarette
105240|NCT02416011|nicotine dependence
105241|NCT02415998|TEE
105242|NCT02415985|pharmacokinetics of rifabutin
105243|NCT02415985|HIV/TB co-infection
105244|NCT02415985|resource limited setting
105245|NCT02415985|AUC
105246|NCT02415985|Cmax
105247|NCT02415985|Cmin
105248|NCT02415985|Ctrough
105249|NCT02415972|ultrasound imaging
105250|NCT02415972|acute ischemic stroke
105251|NCT02415972|cerebral perfusion measurement in acute ischemic stroke
105252|NCT02415959|Exocrine Pancreatic Insufficiency
105253|NCT02415946|regenerative medicine
105254|NCT02415946|bone substitutes
105255|NCT02415946|sinus floor augmentation
105256|NCT02415933|Burkina Faso
105257|NCT02415933|West Africa
105258|NCT02415933|Children
105259|NCT02415933|Child Abuse
105260|NCT02415933|Child Mental Health
105261|NCT02415933|Economic Empowerment
105262|NCT02415933|Women's Empowerment
105263|NCT02415933|Domestic Violence
105264|NCT02415933|Child and Family Well-being
105265|NCT02415933|Child Separation
105266|NCT02415933|Child Labor
105267|NCT02415933|Child Maltreatment
105268|NCT02415920|Investigating oxytocin's effects
105269|NCT02415920|human communication
105270|NCT02415881|Panitumumab
105271|NCT02415881|Optical Imaging
105272|NCT02415868|Vaginal Microbiota
105273|NCT02415842|Supra-seasonal influenza vaccine
105274|NCT02415842|Pandemic
105275|NCT02415842|Exploratory
105276|NCT02415842|Protein epitopes
105277|NCT02415842|Laboratory evaluation
105278|NCT02415842|Retrospective
105279|NCT02415829|Neoajuvant chemotherapy
105280|NCT02415816|Pediatric
105281|NCT02415816|Whole body DWI MRI
105282|NCT02415803|low-dose ticagrelor
105283|NCT02415803|clopidogrel
105284|NCT02415803|Chinese patients with NSTE-ACS
105285|NCT02415803|platelet reactivity
105286|NCT02415803|inhibition of platelet aggregation
105287|NCT02415790|E2027
105288|NCT02415790|Healthy Adult and Elderly Subjects
105289|NCT02415790|Pharmacokinetics/Pharmacodynamics
105290|NCT02415738|Near infrared spectroscopy
105291|NCT02415738|Cerebral oxygenation
105292|NCT02415738|Acute respiratory distress syndrom
105293|NCT02415738|Prone positioning
105294|NCT02415712|Pharmacotherapy
105295|NCT02415686|Dravet syndrome
105296|NCT02415686|Sudden Unexpected Death in Epilepsy (SUDEP)
105297|NCT02415686|Arrhythmias
105298|NCT02415673|Orthodontics
105299|NCT02415673|Nitinol
105300|NCT02415660|trigger point dry needling
105301|NCT02415660|thoracic spine manipulation
105302|NCT02415660|deep cervical extensor muscle
105303|NCT02415660|deep cervical flexor muscle
105304|NCT02415660|shear wave elastography
105305|NCT02415647|children
105306|NCT02415647|mental health
105307|NCT02415647|family genetic study
105308|NCT02415621|metastatic
105309|NCT02415621|castration resistant
105310|NCT02415621|abiraterone therapy
105311|NCT02415582|Hypertension
105312|NCT02415582|Bloodpressure
105313|NCT02415582|Post-exercise hypotension
105314|NCT02415582|Combined exercise
105315|NCT02415582|Aerobic exercise
105316|NCT02415582|Resistance exercise
105317|NCT02415582|Aging
105318|NCT02415582|Elderly
105319|NCT02415582|Ambulatory blood pressure monitoring
105320|NCT02415569|bowel cleansing
105321|NCT02415569|bisacodyl
105322|NCT02415569|polyethyleneglycol
105323|NCT02415569|colonoscopy
105324|NCT02415569|the bristol stool form scale
105325|NCT02415556|Type 2 Diabetes Mellitus
105326|NCT02415556|Intranasal Insulin
105327|NCT02415556|Placebo
105328|NCT02415556|Memory
105329|NCT02415556|Gait
105330|NCT02415556|Non diabetic older controls
105331|NCT02415517|Cognitive training
105332|NCT02415517|Cognitive impairment
105333|NCT02415517|Heart failure
105334|NCT02415517|Cognition
105335|NCT02415504|Care transition
105336|NCT02415504|Behavioural and psychological symptoms of dementia
105337|NCT02415504|BPSD
105338|NCT02415504|Dementia
105339|NCT02415504|Persons with dementia
105340|NCT02415504|Discharge processes
105341|NCT02415491|TGA
105342|NCT02415491|ASO
105343|NCT02415491|magnetic resonance imaging (MRI)
105344|NCT02415491|young adulthood
105345|NCT02415478|Chronic obstructive pulmonary disease (COPD)
105346|NCT02415478|endoscopic lung volume reduction
105347|NCT02415478|Endobronchial valve
105348|NCT02415478|physical capacity
105349|NCT02415478|quality of life
105350|NCT02415465|Knee
105351|NCT02415465|Replacement
105352|NCT02415452|relationship
105353|NCT02415452|retinal artery lesions
105354|NCT02415452|long-term outcomes
105355|NCT02415439|Safety
105356|NCT02415439|tolerability
105357|NCT02415439|pharmacokinetics
105358|NCT02415439|adult
105359|NCT02415439|volunteers
105360|NCT02415413|Smoldering multiple myeloma
105361|NCT02415413|Carfilzomib
105362|NCT02415413|Lenalidomide
105363|NCT02415413|Melphalan
105364|NCT02415413|Dexamethasone
105365|NCT02415413|Autologous stem cell transplantation
105366|NCT02415361|Parents
105367|NCT02415361|Follow-Up Studies
105368|NCT02415309|Melatonin
105369|NCT02415309|Lumbar medial branch block (LMBB)
105370|NCT02415309|Anxiety
105371|NCT02415309|Interventional Pain
105372|NCT02415309|Pain Procedure
105373|NCT02415296|gambling disorder
105374|NCT02415296|screening model
105375|NCT02415296|online gambling
105376|NCT02415296|clinical validation
105377|NCT02415257|Vestibular schwannoma
105378|NCT02415257|acoustic neuroma
105379|NCT02415257|cerebellopontine angle tumour
105380|NCT02415257|gentamicin
105381|NCT02415257|rehabilitation
105382|NCT02415257|postural balance
105383|NCT02415244|ultrasound
105384|NCT02415231|focusing on healthy individuals and the effect that humor or sittying quietly may have on CRP levels
105385|NCT02415205|Pain and stress assessment in premature infants
105386|NCT02415192|safety data
105387|NCT02415192|hypertension therapy
105388|NCT02415179|Newly diagnosed asthma
105389|NCT02415179|peripheral airway function
105390|NCT02415127|Interferon gamma
105391|NCT02415114|Coenzyme Q10
105392|NCT02415114|Resveratrol
105393|NCT02415114|Statin
105394|NCT02415101|Adenocarcinoma
105395|NCT02415101|Squamous cell carcinoma
105396|NCT02415101|Gastroesophageal Junction
105397|NCT02415088|Nerve block
105398|NCT02415075|Return to work, state of subjective health, medical rehabilitation, motivational interviewing
105399|NCT02415062|Parkinson's disease
105400|NCT02415062|dementia
105401|NCT02415036|HCC
105402|NCT02415036|ICC
105403|NCT02415036|Percutaneous hepatic perfusion
105404|NCT02414997|RIPC (remote ischemic preconditioning)
105405|NCT02414997|primary hypertension stage I
105406|NCT02414997|vascular function
105407|NCT02414997|microRNA-126
105408|NCT02414997|microRNA-34a
105409|NCT02414984|Rheumatoid Arthritis
105410|NCT02414984|Golimumab
105411|NCT02414984|Observational
105412|NCT02414984|Compliance
105413|NCT02414971|cancer related fatigue
105414|NCT02414971|prostate cancer
105415|NCT02414971|mitochondria
105416|NCT02414932|ketamine
105417|NCT02414932|electroconvulsive therapy
105418|NCT02414932|glutamate
105419|NCT02414906|Goal Directed Therapy
105420|NCT02414906|Acute Kidney Injury
105421|NCT02414880|Sugammadex
105422|NCT02414880|Neostigmine
105423|NCT02414880|Rocuronium
105424|NCT02414880|Cirrhosis
105425|NCT02414880|Liver resection
105426|NCT02414880|Neuromuscular
105427|NCT02414841|radiocephalic
105428|NCT02414841|arteriovenous fistula
105429|NCT02414841|AVF
105430|NCT02414841|hemodialysis
105431|NCT02414841|PRT-201
105432|NCT02414841|vonapanitase
105433|NCT02414841|vascular access
105434|NCT02414841|kidney
105435|NCT02414841|renal
105436|NCT02414841|PATENCY-2
105437|NCT02414789|erythema migrans
105438|NCT02414789|Lyme
105439|NCT02414789|early diagnosis
105440|NCT02414789|skin biomarkers
105441|NCT02414789|proteomics diagnostic
105442|NCT02414789|mass spectrometry
105443|NCT02414750|Vemurafenib/cobimetinib (GDC-0973)
105444|NCT02414750|Melanoma
105445|NCT02414750|Positron Emission Tomography
105446|NCT02414750|Tumor Characteristics
105447|NCT02414750|Response monitoring
105448|NCT02414750|Resistance prediction
105449|NCT02414750|molecular targeted therapy
105450|NCT02414711|Depression
105451|NCT02414711|Primary care
105452|NCT02414711|General Practitioners
105453|NCT02414685|poor-prognosis germ cell cancer, paclitaxel, ifosfamid and cisplatin regimen, tumor marker decline
105454|NCT02414672|psychosocial intervention
105455|NCT02414672|advanced lung cancer
105456|NCT02414672|caregivers
105457|NCT02414672|self-care
105458|NCT02414633|Psoriatic Arthritis
105459|NCT02414620|Efficacy
105460|NCT02414620|Dental Vibe Unit
105461|NCT02414620|Reduction
105462|NCT02414620|Elimination
105463|NCT02414620|Dental Anesthetic Injection
105464|NCT02414607|Elderberry juice
105465|NCT02414607|Alzheimer's
105466|NCT02414607|Inflammation
105467|NCT02414555|Fluid Management
105468|NCT02414516|HDAC
105469|NCT02414516|Epigenetic
105470|NCT02414516|Histone
105471|NCT02414516|Acetylation
105472|NCT02414503|oxytocin
105473|NCT02414503|social cognition
105474|NCT02414490|CIDP
105475|NCT02414477|tobacco toxicants
105476|NCT02414477|smokeless tobacco
105477|NCT02414477|nitrosamines
105478|NCT02414477|tobacco specific nitrosamines (TSNAs)
105479|NCT02414464|tooth bleaching
105480|NCT02414464|adolescent
105481|NCT02414464|clinical trial
105482|NCT02414451|Propranolol
105483|NCT02414425|Fecal Incontinence
105484|NCT02414425|Botulinum Toxin A
105485|NCT02414425|Rectal injection
105486|NCT02414412|Ulmus macrocarpa water extract
105487|NCT02414412|immunity
105488|NCT02414399|post-discharge mortality
105489|NCT02414399|morbidity and mortality prevention
105490|NCT02414399|azithromycin
105491|NCT02414399|linear growth
105492|NCT02414386|Vitamin D
105493|NCT02414386|Continuous Renal Replacement Therapy
105494|NCT02414386|Multi Organ Failure
105495|NCT02414386|Acute Kidney Injury
105496|NCT02414386|Critical Care
105497|NCT02414386|Citrate anticoagulation
105498|NCT02414373|urination
105499|NCT02414373|analgesia, epidural
105500|NCT02414373|local anesthetics
105501|NCT02414360|Review Literature as Topic
105502|NCT02414347|Dementia
105503|NCT02414347|Tauopathies
105504|NCT02414347|Brain Diseases
105505|NCT02414347|Central Nervous System Diseases
105506|NCT02414347|Mild Cognitive Impairment
105507|NCT02414347|Nervous System Diseases
105508|NCT02414347|Neurodegenerative Disease
105509|NCT02414334|Oligometastases
105510|NCT02414334|Stereotactic ablative radiotherapy (SABR)
105511|NCT02414334|Metastatic tumours
105512|NCT02414308|Erectile dysfunction, Peyronie's disease, stem cell
105513|NCT02414295|Stem cell
105514|NCT02414295|Kleinfelter syndrome
105515|NCT02414295|Azoospermia
105516|NCT02414295|Sterility
105517|NCT02414295|Infertility
105518|NCT02414282|Dementia
105519|NCT02414282|Brain Diseases
105520|NCT02414282|mild cognitive impairment
105521|NCT02414282|Central Nervous System Diseases
105522|NCT02414282|Neurodegenerative Disease
105523|NCT02414269|modified T cells
105524|NCT02414269|cyclophosphamide
105525|NCT02414269|CAR T cells
105526|NCT02414269|15-007
105527|NCT02414269|CAR
105528|NCT02414269|immunotherapy
105529|NCT02414256|breast surgery
105530|NCT02414230|fronto-temporal dementia
105531|NCT02414230|Tauopathies
105532|NCT02414230|Nervous System Diseases
105533|NCT02414230|Neurodegenerative Diseases
105534|NCT02414204|Arteriovenous Fistulas (AVFS)
105535|NCT02414204|Hemodialysis Fistula Maturation (HFM)
105536|NCT02414204|Flow-Mediated Dilation (FMD)
105537|NCT02414204|Nitroglycerin-Mediated (NMD)
105538|NCT02414204|Venous Plethysmography (VP)
105539|NCT02414191|Feedback
105540|NCT02414191|Temperature management
105541|NCT02414191|Anesthesia
105542|NCT02414178|Dementia
105543|NCT02414178|Brain Diseases
105544|NCT02414178|Central Nervous System Diseases
105545|NCT02414178|Mild Cognitive Impairment
105546|NCT02414178|nervous system diseases
105547|NCT02414178|Neurodegenerative Disease
105548|NCT02414165|Recurrence
105549|NCT02414139|Non Small Cell Lung
105550|NCT02414139|cMET
105551|NCT02414126|Heart failure
105552|NCT02414126|child
105553|NCT02414126|work of breathing
105554|NCT02414126|cardiac function
105555|NCT02414126|sleep
105556|NCT02414126|polysomnography
105557|NCT02414126|CPAP
105558|NCT02414087|flat foot
105559|NCT02414087|therapeutic effect
105560|NCT02414087|insoles
105561|NCT02414087|children
105562|NCT02414061|Postprandial glycemia
105563|NCT02414061|metabolic health measures
105564|NCT02414048|Hypoxia
105565|NCT02414048|Head and neck cancer
105566|NCT02414035|atrial fibrillation
105567|NCT02414035|anticoagulation
105568|NCT02414035|Dabigatran
105569|NCT02413996|Virtual Reality Therapy
105570|NCT02413996|Rehabilitation
105571|NCT02413996|Total Knee Replacement
105572|NCT02413996|Knee Arthroplasty
105573|NCT02413996|Exercise
105574|NCT02413996|Arthritis
105575|NCT02413996|Rheumatic Disease
105576|NCT02413970|OSA
105577|NCT02413970|Neurostimulation
105578|NCT02413970|Hypoglossal nerve
105579|NCT02413970|Tongue
105580|NCT02413970|Upper airway stimulation
105581|NCT02413970|Surgery
105582|NCT02413957|Elderly Patients
105583|NCT02413957|Medication Safety
105584|NCT02413957|Pharmaceutical Care
105585|NCT02413957|Medication Reconciliation
105586|NCT02413931|tuberculosis
105587|NCT02413931|MDR-TB
105588|NCT02413866|body composition
105589|NCT02413866|anthropometry
105590|NCT02413840|COPD
105591|NCT02413840|Baduanjin qigong
105592|NCT02413840|depression
105593|NCT02413840|anxiety
105594|NCT02413827|Yervoy™, CDX-1401
105595|NCT02413801|Psoriasis
105596|NCT02413801|PDUS
105597|NCT02413788|adolescent idiopathic scoliosis
105598|NCT02413788|inflammatory markers
105599|NCT02413788|exercise
105600|NCT02413749|Psoriatic Arthritis
105601|NCT02413723|intubation
105602|NCT02413723|critical care
105603|NCT02413723|laryngoscope
105604|NCT02413723|videolaryngoscope
105605|NCT02413723|intratracheal
105606|NCT02413658|Phenytoin
105607|NCT02413658|Skin graft donor site
105608|NCT02413658|Clean surgical site
105609|NCT02413658|Wound model
105610|NCT02413632|HIV-positive MSM (men who have sex with men)
105611|NCT02413632|asymptomatic sexually transmitted infections
105612|NCT02413632|screening
105613|NCT02413606|follow up care
105614|NCT02413606|satisfaction with care
105615|NCT02413593|HCV genotype 3 (GT-3)
105616|NCT02413593|HCV
105617|NCT02413593|Sustained Virologic Response
105618|NCT02413593|Direct Acting Antiviral
105619|NCT02413593|GS-7977
105620|NCT02413593|GS-5885
105621|NCT02413593|Ribavirin
105622|NCT02413593|Sofosbuvir
105623|NCT02413593|Ledipasvir
105624|NCT02413593|Hepatitis C
105625|NCT02413593|Hepatitis C, Chronic
105626|NCT02413554|acetylcholinesterase inhibitors
105627|NCT02413554|rivastigmine patch
105628|NCT02413554|post-operational delirium
105629|NCT02413528|Patient Compliance
105630|NCT02413528|Mobile Applications
105631|NCT02413489|Lymphoma, Mantle-Cell
105632|NCT02413489|Lymphoma, Large B-Cell, Diffuse
105633|NCT02413489|Lymphoma, Follicular
105634|NCT02413489|Daratumumab
105635|NCT02413476|robotic-assisted gastrectomy
105636|NCT02413476|laparoscopic-assisted gastrectomy
105637|NCT02413476|gastric cancer
105638|NCT02413450|induced Pluripotent Stem Cells (iPSC)
105639|NCT02413450|Channelopathies
105640|NCT02413450|Catecholaminergic
105641|NCT02413450|Arrhythmogenic
105642|NCT02413437|contrast-enhanced ultrasound
105643|NCT02413437|biopsy
105644|NCT02413424|sucralose
105645|NCT02413411|Arthroplasty
105646|NCT02413411|Osteoarthritis
105647|NCT02413411|Replacement
105648|NCT02413411|Intervention
105649|NCT02413385|lifestyle intervention
105650|NCT02413385|physical activity
105651|NCT02413385|exercise
105652|NCT02413385|eHealth
105653|NCT02413385|technology
105654|NCT02413385|coaching
105655|NCT02413385|healthy eating
105656|NCT02413372|First Line Therapy
105657|NCT02413372|NASH
105658|NCT02413333|Contact lens solution
105659|NCT02413320|TNBC, breast cancer, neoadjuvant, carboplatin, docetaxel, paclitaxel, doxorubicin, cyclophosphamide
105660|NCT02413307|Compassion Focused Therapy
105661|NCT02413281|Healthy Volunteer
105662|NCT02413281|Abuse Liability
105663|NCT02413281|ALKS 5461
105664|NCT02413281|Alkermes
105665|NCT02413255|Drug therapy
105666|NCT02413242|S. aureus
105667|NCT02413242|P. aeruginosa
105668|NCT02413242|Colonization
105669|NCT02413242|Pneumonia
105670|NCT02413242|ICU
105671|NCT02413216|Tic Disorder
105672|NCT02413216|Tourette
105673|NCT02413216|Motor tic
105674|NCT02413216|Vocal tic
105675|NCT02413216|Habit reversal training
105676|NCT02413216|CBIT
105677|NCT02413216|TicHelper
105678|NCT02413216|Behavior Therapy
105679|NCT02413203|lipidomics
105680|NCT02413203|ex vivo human whole blood assay
105681|NCT02413203|celecoxib
105682|NCT02413203|selective COX-2 inhibitor
105683|NCT02413164|Schizophrenia
105684|NCT02413164|Mental Health
105685|NCT02413164|Physical Therapy
105686|NCT02413164|Quality of life
105687|NCT02413164|Metabolic Syndrome
105688|NCT02413164|Stigma
105689|NCT02413164|Positive and negative symptoms
105690|NCT02413151|Exercise training
105691|NCT02413151|Cardiac resynchronization therapy
105692|NCT02413151|Autonomic nervous system modulation
105693|NCT02413151|Chronic Heart failure
105694|NCT02413138|GHD
105695|NCT02413112|Aging
105696|NCT02413112|Sarcopenia
105697|NCT02413112|Resistance training
105698|NCT02413112|Strength
105699|NCT02413112|Muscle mass
105700|NCT02413086|diabetic foot ulcer
105701|NCT02413086|early-stage amputation
105702|NCT02413086|external therapy of herbs chitosan
105703|NCT02413086|wound surface healing
105704|NCT02413073|whole body vibration
105705|NCT02413073|kidney disease
105706|NCT02413034|antibiotic
105707|NCT02413021|Acute Myeloid Leukemia
105708|NCT02413021|Acute Lymphoid Leukemia
105709|NCT02413021|deferasirox
105710|NCT02412995|sea buckthorn
105711|NCT02412995|strawberry
105712|NCT02412995|glucose response
105713|NCT02412995|satiety
105714|NCT02412995|metabolomics
105715|NCT02412995|intake biomarker
105716|NCT02412956|mHealth
105717|NCT02412904|follicular stimulating hormone
105718|NCT02412904|human menopausal gonadotrophin
105719|NCT02412904|Recombinant follicular stimulating hormone (rFSH)
105720|NCT02412904|Gonadotrophin releasing hormone (GnRH) antagonists
105721|NCT02412904|GnRH agonist
105722|NCT02412904|in vitro fertilization
105723|NCT02412904|controled ovarian stimulation
105724|NCT02412904|number of mature oocytes
105725|NCT02412891|introduction of urinary catheter
105726|NCT02412865|mhealth
105727|NCT02412852|neuropathy
105728|NCT02412826|pancreatitis
105729|NCT02412826|acoustic
105730|NCT02412826|sensor
105731|NCT02412813|hypersensitivity
105732|NCT02412813|metal sensitivity
105733|NCT02412813|arthroplasty
105734|NCT02412813|implant-related hypersensitivity
105735|NCT02412813|metal-on-metal implants
105736|NCT02412813|knee revision
105737|NCT02412800|Extravascular lung water
105738|NCT02412800|Pulmonary vascualr permeability index
105739|NCT02412800|Liver transplantation
105740|NCT02412774|diet beverages
105741|NCT02412774|water
105742|NCT02412774|diabetes
105743|NCT02412774|weight loss
105744|NCT02412774|insulin sensitivity
105745|NCT02412761|Anti-hypertensive medications
105746|NCT02412761|Pediatrics
105747|NCT02412761|N-of-1 trial
105748|NCT02412748|Non-Resident
105749|NCT02412748|Fathers
105750|NCT02412748|African American
105751|NCT02412735|Chronic Lumbar Back Pain
105752|NCT02412735|Low back pain
105753|NCT02412735|Back pain
105754|NCT02412735|Degenerative Disc Disease
105755|NCT02412735|Injection of Degenerated Lumbar Disc
105756|NCT02412735|Intervertebral Disc Degeneration
105757|NCT02412735|Bone Diseases
105758|NCT02412735|Musculoskeletal Diseases
105759|NCT02412735|Nervous System Diseases
105760|NCT02412735|Neurologic Manifestations
105761|NCT02412735|Pain
105762|NCT02412735|Spinal Diseases
105763|NCT02412735|Stem Cells
105764|NCT02412735|Adult Stem Cells
105765|NCT02412735|Allogeneic Mesenchymal Precursor cells (MPCs)
105766|NCT02412735|Mesoblast
105767|NCT02412735|Hyaluronic Acid
105768|NCT02412735|Pharmaceutical Solutions
105769|NCT02412735|Adjuvants, Immunologic
105770|NCT02412735|Immunologic Factors
105771|NCT02412735|Pharmacologic Actions
105772|NCT02412735|Protective Agents
105773|NCT02412735|rexlemestrocel-L
105774|NCT02412735|Viscosupplements
105775|NCT02412722|Drug therapy
105776|NCT02412709|Long QT Syndrome
105777|NCT02412709|LQTS
105778|NCT02412709|genetic testing
105779|NCT02412709|ECG
105780|NCT02412709|saliva testing
105781|NCT02412696|placental morphology
105782|NCT02412696|CPAP
105783|NCT02412696|placental secretory function
105784|NCT02412592|HBeAg positive
105785|NCT02412592|interferon
105786|NCT02412592|peginterferon
105787|NCT02412592|HBeAg seroconversion
105788|NCT02412592|sustained viral response
105789|NCT02412592|relapse
105790|NCT02412579|HCC
105791|NCT02412579|Liver Cancer
105792|NCT02412566|cholestasis
105793|NCT02412566|growth failure
105794|NCT02412566|intravenous fat emulsion
105795|NCT02412566|SMOF
105796|NCT02412514|polio
105797|NCT02412514|inactivated poliovirus vaccine
105798|NCT02412514|oral poliovirus vaccine
105799|NCT02412514|IPV
105800|NCT02412514|OPV
105801|NCT02412462|Phase I
105802|NCT02412462|Clusterin
105803|NCT02412462|Epithelial-to-Mesenchymal Transition (EMT)
105804|NCT02412462|Circulating Tumor Cells (CTC)
105805|NCT02412462|EMT and Stem Cell Biomarkers
105806|NCT02412462|Pharmacokinetics
105807|NCT02412449|Pharmacokinetics
105808|NCT02412449|Anemia
105809|NCT02412449|Chronic kidney disease
105810|NCT02412449|CKD
105811|NCT02412449|Renal impairment
105812|NCT02412449|Chronic renal insufficiency
105813|NCT02412449|Ferrous sulfate
105814|NCT02412449|Iron
105815|NCT02412449|End stage renal disease
105816|NCT02412449|Dialysis
105817|NCT02412449|Oral anemia treatment
105818|NCT02412449|Bioavailability
105819|NCT02412449|Erythropoietin
105820|NCT02412449|Hypoxia-inducible factor
105821|NCT02412449|Volunteers
105822|NCT02412410|laborist
105823|NCT02412410|efficacy
105824|NCT02412410|sleep
105825|NCT02412410|fatigue
105826|NCT02412410|SAFTE
105827|NCT02412410|cognition
105828|NCT02412397|Shoulder
105829|NCT02412384|Lung Neoplasms
105830|NCT02412384|Circulating Tumor Cells
105831|NCT02412371|previously untreated
105832|NCT02412371|PARP inhibitor
105833|NCT02412371|radiotherapy
105834|NCT02412371|paclitaxel
105835|NCT02412371|ABT-888
105836|NCT02412371|stage III
105837|NCT02412371|first line
105838|NCT02412371|carboplatin
105839|NCT02412371|veliparib
105840|NCT02412371|non-small cell lung cancer
105841|NCT02412358|toothbrushing
105842|NCT02412358|plaque control
105843|NCT02412358|gingivitis
105844|NCT02412345|Erectile Dysfunction
105845|NCT02412345|Shockwave therapy
105846|NCT02412345|Renal Transplant
105847|NCT02412345|Male
105848|NCT02412345|Renal Transplant Recipients
105849|NCT02412332|advanced COPD (stage III)
105850|NCT02412332|Adult stem cells
105851|NCT02412332|Cell therapy
105852|NCT02412319|HBeAg positive chronic hepatitis B
105853|NCT02412319|HBeAg serum conversion rate
105854|NCT02412319|HBeAg serum disappearance rate
105855|NCT02412319|HBeAg and HBsAg titer
105856|NCT02412306|Amgen
105857|NCT02412293|Perinatal
105858|NCT02412293|neonatal
105859|NCT02412293|newborn
105860|NCT02412293|mortality
105861|NCT02412189|Anesthesia
105862|NCT02412189|Blood pressure
105863|NCT02412189|Plasma volume
105864|NCT02412189|Vasopressor agents
105865|NCT02412189|Continuous noninvasive hemoglobin measurement
105866|NCT02412189|Coronary artery bypass
105867|NCT02412176|pacemaker
105868|NCT02412176|dyssynchrony
105869|NCT02412176|apical pacing
105870|NCT02412176|mid-septum
105871|NCT02412098|Hepatic Impairment
105872|NCT02412085|golimumab
105873|NCT02412085|ulcerative colitis
105874|NCT02412085|steroid-dependent
105875|NCT02412072|Endometrial hyperplasia
105876|NCT02412072|Progesterone
105877|NCT02412072|LNG-IUS
105878|NCT02412072|dilatation & curettage
105879|NCT02412072|endometrial aspiration sampling
105880|NCT02412046|Pressure ulcer
105881|NCT02412046|Interface pressure
105882|NCT02412046|Pressure mapping device
105883|NCT02412046|Ischemia reperfusion
105884|NCT02412046|Monitoring
105885|NCT02412046|Microvascularization
105886|NCT02412033|vaginal misoprostol
105887|NCT02412007|spastic diplegia;cerebral palsy;activity based therapy
105888|NCT02411981|Lung Clearance Index
105889|NCT02411981|Non cystic fibrosis Bronchiectasis
105890|NCT02411981|Multiple Breath Nitrogen Washout
105891|NCT02411968|Cryosurgery
105892|NCT02411968|Carcinoma, renal cell
105893|NCT02411968|Diagnostic Imaging
105894|NCT02411968|Diagnostic techniques, urological
105895|NCT02411968|Radionuclide imaging
105896|NCT02411968|Follow up
105897|NCT02411903|Clopidogrel-drug interactions
105898|NCT02411890|postoperative pain
105899|NCT02411890|femoral nerve block
105900|NCT02411890|adductor canal block
105901|NCT02411890|anterior cruciate ligament reconstruction
105902|NCT02411877|Acute ischemic stroke
105903|NCT02411877|Mild hypothermia
105904|NCT02411877|Stroke
105905|NCT02411877|Hypothermia
105906|NCT02411877|Cerebral infarction
105907|NCT02411877|Ischemia
105908|NCT02411877|Cerebrovascular disorder
105909|NCT02411877|Brain disease
105910|NCT02411877|Central nervous system disease
105911|NCT02411877|Nervous system disease
105912|NCT02411877|Vascular disease
105913|NCT02411877|Cardiovascular disease
105914|NCT02411877|Brain infarction
105915|NCT02411877|Brain ischemia
105916|NCT02411877|Pathologic process
105917|NCT02411877|Body temperature change
105918|NCT02411877|Signs and symptoms
105919|NCT02411864|IVIM
105920|NCT02411864|brain
105921|NCT02411864|diffusion-weighted imaging
105922|NCT02411851|Actinic Keratoses
105923|NCT02411838|Multiple sclerosis
105924|NCT02411838|calorie restriction
105925|NCT02411838|adipokines
105926|NCT02411812|Orthodontic Appliances, Functional
105927|NCT02411812|Herbst Appliance
105928|NCT02411812|Malocclusion, Angle Class II
105929|NCT02411760|MRI
105930|NCT02411747|Medical
105931|NCT02411747|Urology
105932|NCT02411747|Randomized Controlled Trial
105933|NCT02411747|Endoscopy
105934|NCT02411747|Cystoscopy
105935|NCT02411721|Anxiety
105936|NCT02411721|Dog Intervention
105937|NCT02411721|MRI
105938|NCT02411721|Children
105939|NCT02411695|Adolescent
105940|NCT02411695|Otsuka,
105941|NCT02411695|Brexpiprazole
105942|NCT02411669|Patient centred care
105943|NCT02411656|Breast cancer
105944|NCT02411656|Metastatic inflammatory breast cancer
105945|NCT02411656|MIBC
105946|NCT02411656|IBC
105947|NCT02411656|Breast carcinoma
105948|NCT02411656|Metastatic
105949|NCT02411656|MK-3475
105950|NCT02411656|Keytruda
105951|NCT02411656|Pembrolizumab
105952|NCT02411656|SCH-900475
105953|NCT02411630|PrEP
105954|NCT02411630|HIV Prevention
105955|NCT02411578|T1D
105956|NCT02411578|Type 1 diabetes
105957|NCT02411578|Mini-dose glucagon
105958|NCT02411578|adults
105959|NCT02411578|non-severe hypoglycemia
105960|NCT02411565|epithelial
105961|NCT02411565|ovarian
105962|NCT02411565|fallopian tube
105963|NCT02411565|primary peritoneal carcinoma
105964|NCT02411565|peritoneal
105965|NCT02411565|ovary
105966|NCT02411500|Healthy
105967|NCT02411500|Male
105968|NCT02411500|Pharmacokinetics
105969|NCT02411474|stem cell transplantation (SCT)
105970|NCT02411461|Pediatric obesity
105971|NCT02411461|pseudohypoparathyroidism
105972|NCT02411461|Albright Hereditary Osteodystrophy
105973|NCT02411435|rifampin
105974|NCT02411435|drug interaction
105975|NCT02411435|pharmacokinetics
105976|NCT02411435|cabotegravir
105977|NCT02411422|intubation
105978|NCT02411422|cardiopulmonary resuscitation
105979|NCT02411422|manikins
105980|NCT02411409|Health Information Technology (HIT)
105981|NCT02411409|self-care
105982|NCT02411383|Diaphragm pacing
105983|NCT02411383|Respiratory assistance
105984|NCT02411383|Lung transplant
105985|NCT02411357|Contraception
105986|NCT02411357|Unintended pregnancy
105987|NCT02411357|HIV risk
105988|NCT02411357|Sexually transmitted infections
105989|NCT02411357|Women
105990|NCT02411357|Pregnancy
105991|NCT02411357|Neonatal health
105992|NCT02411357|Drug use
105993|NCT02411357|Drug treatment
105994|NCT02411357|Opioids
105995|NCT02411344|HER2+/HR+
105996|NCT02411344|breast cancer
105997|NCT02411331|Lock Solution
105998|NCT02411331|Catheter related blood stream infections
105999|NCT02411331|Central venous catheter infection
106000|NCT02411331|Intravenous Drug Delivery Systems
106001|NCT02411331|Coagulase-negative staphylococci infection
106002|NCT02411331|Ethanol lock solution
106003|NCT02411331|Vancomycin lock solution
106004|NCT02411279|Heart failure
106005|NCT02411279|telemonitoring
106006|NCT02411279|intrusive sensors
106007|NCT02411279|intrusive devices
106008|NCT02411279|Heart failure stage II
106009|NCT02411279|Heart failure stage III
106010|NCT02411279|heart disease
106011|NCT02411253|IL2
106012|NCT02411253|Interleukin 2
106013|NCT02411253|IL-2
106014|NCT02411253|Auto-immune disease
106015|NCT02411253|Insulin
106016|NCT02411253|Diabetes
106017|NCT02411253|Regulatory T cells
106018|NCT02411253|Treg
106019|NCT02411253|Immunoregulation
106020|NCT02411253|Immune tolerance
106021|NCT02411253|Immunotherapy
106022|NCT02411240|Air filtration
106023|NCT02411240|cardiovascular health
106024|NCT02411240|cognition
106025|NCT02411240|particulate matter
106026|NCT02411240|mitochondrial DNA
106027|NCT02411227|Neuropsychologic Testing
106028|NCT02411227|Neurocognitive
106029|NCT02411227|Virtual Reality
106030|NCT02411227|Rehabilitation
106031|NCT02411227|Driving
106032|NCT02411175|Constipation
106033|NCT02411175|Homeopathy
106034|NCT02411162|atopic dermatitis
106035|NCT02411162|FLIM
106036|NCT02411162|chronic plaque psoriasis
106037|NCT02411162|healthy volunteers
106038|NCT02411162|GSK2894512
106039|NCT02411162|Skin residency
106040|NCT02411149|Adductor Canal Block
106041|NCT02411149|Total Knee Arthroplasty
106042|NCT02411123|PGx
106043|NCT02411123|pharmacogenetics
106044|NCT02411123|depression
106045|NCT02411123|anxiety
106046|NCT02411123|Neuropsychiatric diseases
106047|NCT02411123|IDgenetix
106048|NCT02411123|AltheaDx
106049|NCT02411097|Deep venous thromboembolism
106050|NCT02411097|Femoral nerve block
106051|NCT02411097|Total knee arthroplasty
106052|NCT02411084|Graft vs Host Disease
106053|NCT02411084|Immune System Diseases
106054|NCT02411084|Dipeptidyl Peptidase 4
106055|NCT02411084|CD4-Positive T-Lymphocytes
106056|NCT02411084|Hematopoietic Stem Cell Transplantation
106057|NCT02411071|HIV-1
106058|NCT02411071|antiretroviral treatment
106059|NCT02411071|low viral load
106060|NCT02411071|low-level viremia
106061|NCT02411058|information
106062|NCT02411058|incentives
106063|NCT02411045|Indirect incentives
106064|NCT02411045|Exercise more
106065|NCT02411019|Phase 2 follow up
106066|NCT02411019|Cervical Intraepithelial Neoplasia
106067|NCT02411019|Adult
106068|NCT02411019|Safety
106069|NCT02411019|Efficacy
106070|NCT02410941|Randomized controlled trial
106071|NCT02410941|Practice management
106072|NCT02410941|tomography, x-ray computed/adverse effects
106073|NCT02410941|Clinical decision support
106074|NCT02410941|Computerized clinical decision support
106075|NCT02410941|Decision support systems, clinical
106076|NCT02410941|Health Expenditures
106077|NCT02410941|Physician's practice patterns
106078|NCT02410941|Unnecessary Procedures/economics
106079|NCT02410941|Physician's Practice Patterns/economics
106080|NCT02410941|Diffusion of innovation
106081|NCT02410941|Decision Support Models
106082|NCT02410941|Clinical Prediction Rules
106083|NCT02410915|Rehabilitation
106084|NCT02410915|Robotics
106085|NCT02410902|Autism
106086|NCT02410876|Bladder
106087|NCT02410876|neurogenic lower urinary tract dysfunction
106088|NCT02410876|benign prostatic obstruction
106089|NCT02410863|Stage III or IV with BRAF V600E/K mutation
106090|NCT02410850|Oral Appliance
106091|NCT02410850|objective adherence
106092|NCT02410850|cardiovascular events
106093|NCT02410850|cardiovascular mortality
106094|NCT02410850|cerebrovascular mortality
106095|NCT02410850|cost effectiveness
106096|NCT02410837|lung lesion
106097|NCT02410837|biopsy
106098|NCT02410837|bronchoscopy
106099|NCT02410811|Sickle Cell Disease (SCD)
106100|NCT02410811|Cardiac Magnetic Resonance Imaging (CMR)
106101|NCT02410811|Cardiomyopathy
106102|NCT02410811|Pulmonary Hypertension
106103|NCT02410785|obesity,
106104|NCT02410785|body weight,
106105|NCT02410785|overweight,
106106|NCT02410785|weight loss,
106107|NCT02410785|polyglucosamine,
106108|NCT02410785|L112
106109|NCT02410785|caloric restriction
106110|NCT02410785|physical activity
106111|NCT02410746|pain
106112|NCT02410746|surgery
106113|NCT02410733|melanoma
106114|NCT02410733|Lipo-MERIT
106115|NCT02410733|cancer vaccine
106116|NCT02410733|RB_0003-01
106117|NCT02410733|BioNTech
106118|NCT02410733|BioNTech RNA Pharmaceuticals
106119|NCT02410733|BioNTech RNA
106120|NCT02410733|RNA
106121|NCT02410720|Colonoscopy Preparation
106122|NCT02410720|Polyethylene Glycols
106123|NCT02410720|Mobile application
106124|NCT02410720|Software
106125|NCT02410720|Compliance
106126|NCT02410720|Patient Compliance
106127|NCT02410720|Adherence
106128|NCT02410707|procedural sedation
106129|NCT02410707|procedural pain
106130|NCT02410707|procedural anxiolysis
106131|NCT02410655|Uterine atony
106132|NCT02410655|Postpartum hemorrhage
106133|NCT02410655|Vaginal delivery
106134|NCT02410655|Uterotonic
106135|NCT02410655|Oxytocin
106136|NCT02410655|Bolus
106137|NCT02410655|Evidence-based
106138|NCT02410655|Protocol
106139|NCT02410642|cardiopulmonary bypass
106140|NCT02410629|Stroke
106141|NCT02410616|Psychotherapy
106142|NCT02410616|Comparative Effectiveness Research
106143|NCT02410616|Randomized Controlled Trial
106144|NCT02410616|Secondary Care
106145|NCT02410603|Chemotherapy
106146|NCT02410577|89Zr-J591
106147|NCT02410577|15-002
106148|NCT02410564|insomnia
106149|NCT02410564|Sleep
106150|NCT02410564|CBT-I intervention
106151|NCT02410564|SHUTi
106152|NCT02410551|Myeloproliferative Diseases
106153|NCT02410551|Myeloproliferative Neoplasms
106154|NCT02410551|MPN
106155|NCT02410551|Myelofibrosis
106156|NCT02410551|Polycythemia vera
106157|NCT02410551|PV
106158|NCT02410551|Essential thrombocythemia
106159|NCT02410551|Allogeneic stem cell transplantation
106160|NCT02410551|Allo TP
106161|NCT02410551|Pacritinib
106162|NCT02410551|Busulfan
106163|NCT02410551|Busulfex
106164|NCT02410551|Myleran
106165|NCT02410551|Questionnaires
106166|NCT02410551|Surveys
106167|NCT02410551|Phone calls
106168|NCT02410525|hyperlipidemia
106169|NCT02410525|positron emission tomography
106170|NCT02410499|Drug therapy
106171|NCT02410473|Congenital Heart Disease
106172|NCT02410473|Point-of-care coagulation monitoring
106173|NCT02410447|Shock waves
106174|NCT02410434|Stigma
106175|NCT02410434|lesbian
106176|NCT02410434|gay
106177|NCT02410434|bisexual
106178|NCT02410434|transgender
106179|NCT02410421|Individualized Medicine
106180|NCT02410421|Functional Neuroimaging
106181|NCT02410421|Robotic Proceedure
106182|NCT02410421|Transcranial Magnetic Stimulation, Repetitive
106183|NCT02410421|Transcranial Direct Current Stimulation Monocentric
106184|NCT02410421|Compariative Cross-Over 3 Arms Study Randomized, Single-Blind Method
106185|NCT02410408|Patient Safety
106186|NCT02410408|App
106187|NCT02410408|Root Cause Analysis
106188|NCT02410408|Patient Safety Certification
106189|NCT02410382|cancer
106190|NCT02410382|radiation therapy
106191|NCT02410382|chemotherapy
106192|NCT02410382|dexamethasone
106193|NCT02410382|corticosteroids
106194|NCT02410330|Therapeutic ultrasound
106195|NCT02410330|Angiographic recanalization rate
106196|NCT02410330|Salvagability index
106197|NCT02410330|Sonothrombolysis
106198|NCT02410317|Postoperative pain
106199|NCT02410317|Postoperative morphine consumption
106200|NCT02410317|Emergency cesarean delivery
106201|NCT02410317|Ropivacaine
106202|NCT02410317|Local anesthetic wound 48-hours infusion
106203|NCT02410317|Emergency cesarean section
106204|NCT02410304|Rheumatoid arthritis / ultrasonography / synovitis
106205|NCT02410265|guided self-help
106206|NCT02410265|student mental health
106207|NCT02410265|task shifting
106208|NCT02410265|prevention
106209|NCT02410252|continuous temperature monitoring
106210|NCT02410252|patient self-management
106211|NCT02410252|iThermonitor
106212|NCT02410252|Home monitoring
106213|NCT02410239|Cerebral Adrenoleukodystrophy
106214|NCT02410239|cALD
106215|NCT02410200|Pediatrics
106216|NCT02410187|stereotactic body radiotherapy
106217|NCT02410174|Renal Cell Carcinoma
106218|NCT02410174|RCC
106219|NCT02410174|Stereotactic Body Radiotherapy
106220|NCT02410174|SBRT
106221|NCT02410161|ketone
106222|NCT02410161|α-linolenic acid
106223|NCT02410161|flaxseed
106224|NCT02410161|aging
106225|NCT02410161|β-hydroxybutyrate
106226|NCT02410161|acetoacetate
106227|NCT02410161|omega-3 fatty acids
106228|NCT02410161|ketogenesis
106229|NCT02410148|open-angle glaucoma
106230|NCT02410148|papilledema
106231|NCT02410148|non-invasive ICP
106232|NCT02410148|Intracranial pressure
106233|NCT02410135|Lower Urinary Tract Symptoms
106234|NCT02410135|Sleep Disturbance
106235|NCT02410096|exercise-induced asthma
106236|NCT02410096|cold chamber
106237|NCT02410096|exercise challenge
106238|NCT02410096|cold air challenge
106239|NCT02410096|oil supplementation
106240|NCT02410096|middle-chain and Polyunsaturated Fatty Acids
106241|NCT02410070|Distal radial fracture
106242|NCT02410070|pronator quadratus
106243|NCT02410070|mini-approach
106244|NCT02410070|volar plating
106245|NCT02410070|open reduction and internal fixation
106246|NCT02410057|growth
106247|NCT02410057|formula
106248|NCT02410057|protein
106249|NCT02410057|alpha-lactalbumin
106250|NCT02410057|amino acids
106251|NCT02410044|Patient Reported Outcomes
106252|NCT02409992|Children with ODD and low prosocial emotions
106253|NCT02409979|colonoscopy
106254|NCT02409979|carbon dioxide
106255|NCT02409979|water exchange
106256|NCT02409979|discomfort
106257|NCT02409979|colonoscopy pain
106258|NCT02409966|periodontitis
106259|NCT02409966|therapeutics
106260|NCT02409966|quality of life
106261|NCT02409966|fear
106262|NCT02409966|anxiety
106263|NCT02409966|pain
106264|NCT02409953|volunteers
106265|NCT02409927|Medium-chain triglycerides
106266|NCT02409927|Metabolism
106267|NCT02409927|Ketones
106268|NCT02409927|Lipids
106269|NCT02409927|Emulsification
106270|NCT02409914|Insulin Resistance
106271|NCT02409914|Brain metabolism
106272|NCT02409914|PET
106273|NCT02409914|MRI
106274|NCT02409901|Physical Activity
106275|NCT02409901|Exercise Rehabilitation
106276|NCT02409901|Kidney Function
106277|NCT02409901|Employment
106278|NCT02409901|Kidney Transplant
106279|NCT02409875|early intervention
106280|NCT02409875|obesity
106281|NCT02409875|body weight
106282|NCT02409875|body mass index
106283|NCT02409875|overnutrition
106284|NCT02409875|early promoters, genetic
106285|NCT02409862|oxytocin
106286|NCT02409862|socioemotional functioning
106287|NCT02409862|aging
106288|NCT02409849|Octreotide LAR
106289|NCT02409849|Neuroendocrine carcinomas
106290|NCT02409849|unresectable or metastatic
106291|NCT02409849|Disease-free survival
106292|NCT02409823|adverse drug reactions
106293|NCT02409823|adherence to treatment
106294|NCT02409823|quality of life
106295|NCT02409823|clinical status
106296|NCT02409784|Brain metabolism
106297|NCT02409784|Ketones
106298|NCT02409784|Ketogenic diet
106299|NCT02409784|TEP scan
106300|NCT02409758|Voice disorders
106301|NCT02409758|Hoarseness
106302|NCT02409758|Therapy
106303|NCT02409745|endometrial scratch
106304|NCT02409745|IVF
106305|NCT02409745|randomized controlled study
106306|NCT02409745|Prospective controlled trial
106307|NCT02409745|Different time to perform endometrial scratch
106308|NCT02409745|In vitro fertilization
106309|NCT02409745|embryo transfer
106310|NCT02409732|Actinic cheilitis
106311|NCT02409732|Photodynamic therapy
106312|NCT02409732|Levulan
106313|NCT02409732|Blue light
106314|NCT02409719|Arthritis, Degenerative
106315|NCT02409719|Recovery of function
106316|NCT02409706|Paediatric
106317|NCT02409706|Critical care
106318|NCT02409706|Micronutrients
106319|NCT02409680|Preterm birth
106320|NCT02409680|Low dose aspirin
106321|NCT02409667|plaque, psoriasis
106322|NCT02409641|IOL
106323|NCT02409628|Non-melanoma Skin Cancer
106324|NCT02409628|Basal Cell Carcinoma
106325|NCT02409628|Squamous Cell Carcinoma
106326|NCT02409628|Surgical excision
106327|NCT02409628|EktoTherix
106328|NCT02409628|Secondary intention healing
106329|NCT02409628|Acute wound repair
106330|NCT02409628|Tissue repair scaffold
106331|NCT02409615|Complementary therapies
106332|NCT02409615|Hypnosis
106333|NCT02409615|Healing Touch
106334|NCT02409602|Ultrasonography, Doppler, Color
106335|NCT02409602|Postpartum hemorrhage
106336|NCT02409602|Bilateral iliac artery ligation
106337|NCT02409602|Dorsal clitoral artery
106338|NCT02409576|EWS
106339|NCT02409576|OS
106340|NCT02409576|RMS
106341|NCT02409550|Allergic Rhinitis
106342|NCT02409550|Asthma
106343|NCT02409550|Children
106344|NCT02409550|Control
106345|NCT02409537|Asymptomatic hypercholesterolemia,
106346|NCT02409537|cardiovascular risk,
106347|NCT02409537|total antioxidant capacity
106348|NCT02409537|red wine polyphenol content
106349|NCT02409537|vitamin E.
106350|NCT02409537|resveratrol
106351|NCT02409511|Type 1 Diabetic
106352|NCT02409511|Type 2 Diabetic
106353|NCT02409511|Hypertension
106354|NCT02409511|Renal Injury
106355|NCT02409511|Diabetic retinopathy
106356|NCT02409498|pudendal nerve block
106357|NCT02409498|vaginal reconstructive surgery
106358|NCT02409485|self-management
106359|NCT02409485|head and neck cancer
106360|NCT02409485|psychosocial intervention
106361|NCT02409485|couples
106362|NCT02409472|randomized clinical trial
106363|NCT02409433|lacosamide
106364|NCT02409433|phenytoin
106365|NCT02409394|Subjects
106366|NCT02409303|Autism Spectrum Disorder
106367|NCT02409303|Screening
106368|NCT02409303|Preventive intervention
106369|NCT02409303|Risk
106370|NCT02409277|Self-Management
106371|NCT02409277|Asthma
106372|NCT02409264|Insomnia
106373|NCT02409264|Females
106374|NCT02409264|Homeopathy
106375|NCT02409251|Antinuclear antibody (ANA)
106376|NCT02409251|Overuse
106377|NCT02409251|Rheumatologists
106378|NCT02409251|Quality of care
106379|NCT02409238|Mild Cognitive Impairment
106380|NCT02409238|Insulin Resistance
106381|NCT02409238|Diabetes Mellitus, Type 2
106382|NCT02409225|remote monitoring
106383|NCT02409225|ICD
106384|NCT02409225|CRT-D
106385|NCT02409199|Gastric Carcinoma
106386|NCT02409199|apatinib
106387|NCT02409173|Metabolic syndrome
106388|NCT02409173|Sleep disorders
106389|NCT02409173|Bariatric Surgery
106390|NCT02409173|Noninvasive ventilation
106391|NCT02409173|Inflammation
106392|NCT02409173|Quality of life
106393|NCT02409160|Severe Obesity
106394|NCT02409160|Sleep Disorders
106395|NCT02409160|Bariatric Surgery
106396|NCT02409160|Inflammation
106397|NCT02409160|Quality of Life
106398|NCT02409134|Bone Marrow Transplantation
106399|NCT02409134|Hematologic Malignancies
106400|NCT02409134|Adults
106401|NCT02409134|Cognition
106402|NCT02409121|hematopoietic cell transplantation
106403|NCT02409121|caregivers
106404|NCT02409121|health information technology
106405|NCT02409121|patient-centered care
106406|NCT02409069|Transcutaneous vagus nerve stimulation
106407|NCT02409069|P300
106408|NCT02409069|Memory task
106409|NCT02409056|intervention
106410|NCT02409056|translation
106411|NCT02409056|workplace
106412|NCT02409056|CVD
106413|NCT02409056|CDSMP
106414|NCT02409043|Stroke
106415|NCT02409043|Ischemic stroke
106416|NCT02409043|Hemorrhagic stroke
106417|NCT02409043|Biomarkers
106418|NCT02409043|Angiotensins
106419|NCT02409017|insulin drip
106420|NCT02409017|labor
106421|NCT02409004|Drug-drug interaction
106422|NCT02408991|Chronic lower limb ischemia
106423|NCT02408991|Art-Assist Device
106424|NCT02408991|Neupogen
106425|NCT02408926|Pertussis
106426|NCT02408926|Pregnancy
106427|NCT02408926|Humoral immune response
106428|NCT02408926|Functionality
106429|NCT02408926|Vaccination
106430|NCT02408913|Immunity
106431|NCT02408913|Ebola Virus
106432|NCT02408913|Ebola Hemorrhagic Fever
106433|NCT02408913|Healthy
106434|NCT02408913|Filovirus
106435|NCT02408900|Spasticity
106436|NCT02408900|Primary Lateral Sclerosis
106437|NCT02408900|Elastography
106438|NCT02408900|Ultrasound
106439|NCT02408887|Thyroidectomy
106440|NCT02408887|pCND
106441|NCT02408887|QOL
106442|NCT02408887|Outcomes
106443|NCT02408887|Screening
106444|NCT02408874|Nanoparticles
106445|NCT02408874|Inflammatory Response
106446|NCT02408874|Silver
106447|NCT02408874|Lung Function
106448|NCT02408874|Lung Microbiome
106449|NCT02408835|negative pressure wound therapy
106450|NCT02408835|lymphadenectomy
106451|NCT02408835|wound healing
106452|NCT02408809|Orthopaedic Smoking Cessation Discussion
106453|NCT02408809|Smoking Cessation
106454|NCT02408809|Randomized Controlled Trial
106455|NCT02408796|Acute otitis media with tympanostomy tubes
106456|NCT02408757|ultrasound
106457|NCT02408757|cerebral perfusion
106458|NCT02408757|cerebrospinal fluid drainage
106459|NCT02408744|nephroprotection
106460|NCT02408744|pirfenidone
106461|NCT02408744|polymorphisms
106462|NCT02408718|Mobility
106463|NCT02408718|walking aids
106464|NCT02408718|falls
106465|NCT02408718|gait and balance
106466|NCT02408705|Endogenous Glucose Production
106467|NCT02408705|Hypoglycemic clamp
106468|NCT02408705|Tracer to Tracee Technique
106469|NCT02408705|Type 1 diabetes mellitus
106470|NCT02408692|Emergency contraception
106471|NCT02408692|Obese BMI
106472|NCT02408692|Normal BMI
106473|NCT02408679|Vitamin D
106474|NCT02408679|Vitamin D Deficiency
106475|NCT02408679|Vitamin D Insufficiency
106476|NCT02408679|Healthy adults
106477|NCT02408679|Predictive questionnaire
106478|NCT02408640|Internet-Based
106479|NCT02408640|Treatment
106480|NCT02408549|Lacosamide
106481|NCT02408549|Vimpat
106482|NCT02408549|Epilepsy
106483|NCT02408549|Children
106484|NCT02408549|Primary Generalized Tonic Clonic seizures
106485|NCT02408549|Idiopathic Generalized Epilepsy
106486|NCT02408549|Adults
106487|NCT02408536|chemotherapy
106488|NCT02408536|hormone therapy
106489|NCT02408536|borderline
106490|NCT02408536|low-grade
106491|NCT02408536|serous ovarian cancer
106492|NCT02408523|Lacosamide
106493|NCT02408523|Vimpat
106494|NCT02408523|Epilepsy
106495|NCT02408523|Children
106496|NCT02408523|Primary Generalized Tonic Clonic seizures
106497|NCT02408523|Idiopathic Generalized Epilepsy
106498|NCT02408523|Adults
106499|NCT02408510|Volunteers
106500|NCT02408471|Arthritis
106501|NCT02408471|Rheumatoid Arthritis
106502|NCT02408471|Systemic Lupus Erythematosus
106503|NCT02408471|Osteoarthritis
106504|NCT02408471|Autoimmune Diseases
106505|NCT02408471|Connective Tissue Diseases
106506|NCT02408471|Immune System Diseases
106507|NCT02408471|Joint Diseases
106508|NCT02408471|Musculoskeletal Diseases
106509|NCT02408471|Rheumatic Diseases
106510|NCT02408445|body composition
106511|NCT02408445|Klinefelter syndrome
106512|NCT02408445|XXY
106513|NCT02408445|sex chromosome variation
106514|NCT02408445|sex chromsome aneuploidy
106515|NCT02408432|Blood And Marrow Transplantation
106516|NCT02408432|Left ventricular dysfunction
106517|NCT02408432|LV
106518|NCT02408432|Heart failure secondary to chemotherapy with anthracyclines
106519|NCT02408432|Allogeneic human mesenchymal stem cells
106520|NCT02408432|hMSCs
106521|NCT02408432|Standard of care drugs for heart failure
106522|NCT02408406|TNM Finding v7
106523|NCT02408393|Surgery
106524|NCT02408393|Paravertebral block
106525|NCT02408393|Chronic pain
106526|NCT02408380|biomarker
106527|NCT02408380|disease progression
106528|NCT02408367|Training
106529|NCT02408367|Cognition
106530|NCT02408367|Multiple Sclerosis
106531|NCT02408341|Propofol, Induction anesthesia, Doppler tissue imaging
106532|NCT02408315|induction of labor
106533|NCT02408315|safety
106534|NCT02408315|pharmacokinetic
106535|NCT02408315|misoprostol
106536|NCT02408250|algorithm
106537|NCT02408250|critical illness
106538|NCT02408250|early exercise
106539|NCT02408250|feasibility
106540|NCT02408250|intensive care unit
106541|NCT02408250|physical therapy
106542|NCT02408237|Transcranial direct current stimulation (tDCS)
106543|NCT02408237|tDCS for domiciliary use
106544|NCT02408237|Healthy Participants
106545|NCT02408224|ACS
106546|NCT02408185|infections
106547|NCT02408185|multidrug resistant Gram negative bacteria (MDR-GNB)
106548|NCT02408185|Skin infections
106549|NCT02408185|Pneumonia
106550|NCT02408185|Bacteriemia
106551|NCT02408185|Nosocomial infections
106552|NCT02408172|hypertension
106553|NCT02408172|Sleep apnea syndrome
106554|NCT02408172|Amlodipine
106555|NCT02408172|metoprolol
106556|NCT02408159|Live, attenuated virus varicella-zoster vaccine
106557|NCT02408159|Zostavax
106558|NCT02408159|herpes zoster
106559|NCT02408159|shingles
106560|NCT02408133|Breast Cancer
106561|NCT02408133|elderly
106562|NCT02408133|quality of life
106563|NCT02408133|exercise
106564|NCT02408120|Hyperglycemia
106565|NCT02408120|Hypoglycemia
106566|NCT02408107|Physical activity
106567|NCT02408107|Randomized controlled trial
106568|NCT02408094|Rheumatoid Arthritis
106569|NCT02408094|Heat-dampness and blood stasis syndrome
106570|NCT02408094|Protein markers
106571|NCT02408081|Depression
106572|NCT02408081|Family functioning
106573|NCT02408081|Family Focused Nursing
106574|NCT02408081|Quality of life
106575|NCT02408068|subjects
106576|NCT02408029|Focus
106577|NCT02408029|Testing Performance
106578|NCT02408029|CORA Hemostasis System
106579|NCT02408003|Transesophageal
106580|NCT02408003|Echocardiography
106581|NCT02408003|Milrinone
106582|NCT02408003|Levosimendan
106583|NCT02408003|Strain
106584|NCT02408003|Deformation
106585|NCT02408003|Diastole
106586|NCT02407964|Drug-Induced Liver Injury
106587|NCT02407964|DILI
106588|NCT02407938|dysphagia
106589|NCT02407938|reflux symptoms
106590|NCT02407938|retrosternal pain
106591|NCT02407925|Optical diagnosis
106592|NCT02407899|LADA
106593|NCT02407899|saxagliptin
106594|NCT02407899|vitamin D3
106595|NCT02407899|C-Peptide
106596|NCT02407873|aged of 75 years or more
106597|NCT02407860|breast feeding
106598|NCT02407860|sucking
106599|NCT02407860|dysfunction
106600|NCT02407860|Latch assessment tool
106601|NCT02407860|visual analogic scale
106602|NCT02407860|infant physiology
106603|NCT02407847|Nurse practitioners
106604|NCT02407847|Primary healthcare
106605|NCT02407847|Emergency Medical Services
106606|NCT02407847|Substitution of care
106607|NCT02407834|Biofilms
106608|NCT02407834|Dentures
106609|NCT02407834|Denture Cleansers
106610|NCT02407834|Castor Oil
106611|NCT02407834|Stomatitis
106612|NCT02407821|Controlled Clinical Trials, Randomized
106613|NCT02407821|Kidney Failure
106614|NCT02407821|Renal Insufficiency, Chronic
106615|NCT02407821|Dialysis, Renal
106616|NCT02407821|Peritoneal Dialysis
106617|NCT02407821|Hemodialysis
106618|NCT02407821|Depressive Symptoms
106619|NCT02407821|Selective Serotonin Reuptake Inhibitors
106620|NCT02407821|Antidepressants
106621|NCT02407821|Escitalopram
106622|NCT02407795|stereotactic radiotherapy
106623|NCT02407795|pain reduction
106624|NCT02407795|quality of life
106625|NCT02407782|Scabies
106626|NCT02407782|children
106627|NCT02407782|cluster
106628|NCT02407782|permethrin
106629|NCT02407782|Ivermectin
106630|NCT02407769|Liver transplantation
106631|NCT02407769|Liver cirrhosis
106632|NCT02407769|Branched chain amino acids
106633|NCT02407769|Late evening supplementation
106634|NCT02407769|Nutritional status
106635|NCT02407756|Eczema
106636|NCT02407743|postoperative pain
106637|NCT02407743|surgery
106638|NCT02407743|pain resolution
106639|NCT02407743|pain intensity
106640|NCT02407743|persistent postsurgical pain
106641|NCT02407743|pain-related genes
106642|NCT02407743|analgesic
106643|NCT02407704|Exercise
106644|NCT02407704|Physical activity
106645|NCT02407704|GABA
106646|NCT02407704|Venlafaxine
106647|NCT02407704|fMRI
106648|NCT02407704|Spectroscopy
106649|NCT02407704|Reward system
106650|NCT02407704|BDNF
106651|NCT02407704|Sleep
106652|NCT02407704|Cognitive function
106653|NCT02407704|Biomarkers
106654|NCT02407704|Aerobic exercise
106655|NCT02407665|Tai Chi
106656|NCT02407665|fMRI
106657|NCT02407639|insufflation
106658|NCT02407639|abdominal pain
106659|NCT02407626|ischemia
106660|NCT02407626|cardiac surgery
106661|NCT02407626|volatile anesthetic
106662|NCT02407626|total intravenous anesthesia
106663|NCT02407613|breast cancer
106664|NCT02407613|MR-HIFU
106665|NCT02407613|ablation
106666|NCT02407613|non-invasive treatment
106667|NCT02407600|EMEND for Injection
106668|NCT02407600|5HT-3
106669|NCT02407600|Fosaprepitant
106670|NCT02407561|rectal
106671|NCT02407561|adenocarcinoma
106672|NCT02407561|DecisionDx
106673|NCT02407548|cholesterol efflux
106674|NCT02407548|dyslipidemia
106675|NCT02407522|Metabolic Syndrome
106676|NCT02407522|black rice
106677|NCT02407483|Laparoscopy
106678|NCT02407483|Training Programs
106679|NCT02407470|Severe Aplastic Anemia (SAA), Hematopoietic Stem Cells, HSC Transplantation
106680|NCT02407470|ATG, Mesenchymal Stem Cells, Transdifferentiation,
106681|NCT02407444|Proximal hip fracture
106682|NCT02407444|Elderly patients
106683|NCT02407444|Physiotherapy
106684|NCT02407444|Leg cycling ergometer
106685|NCT02407418|spinal manipulation
106686|NCT02407418|muscle strength dynamometer
106687|NCT02407418|muscle strength
106688|NCT02407379|Laser
106689|NCT02407379|periodontitis
106690|NCT02407379|scaling root planing
106691|NCT02407379|bacteria
106692|NCT02407379|PMN
106693|NCT02407366|Inoperable stage III non-small cell lung cancer
106694|NCT02407366|EGFR mutation
106695|NCT02407366|Icotinib
106696|NCT02407366|Radiotherapy
106697|NCT02407366|Chemoradiotherapy
106698|NCT02407353|Phase 1
106699|NCT02407353|Double blind
106700|NCT02407353|Placebo-Controlled
106701|NCT02407353|Parallel Design
106702|NCT02407353|CSF Aβ Concentrations
106703|NCT02407353|PF-06648671
106704|NCT02407340|Alcohol Withdrawal Delirium
106705|NCT02407327|Circulating tumour cells in Advanced Non Small Cell Lung Cancer
106706|NCT02407314|Peripheral Arterial Disease
106707|NCT02407314|Optical Coherence Tomography
106708|NCT02407314|Ticagrelor
106709|NCT02407314|Aspirin
106710|NCT02407314|Claudication
106711|NCT02407314|Clopidogrel
106712|NCT02407288|OCD
106713|NCT02407262|asthma
106714|NCT02407262|black seed
106715|NCT02407262|Nigella sativa
106716|NCT02407262|supplementation
106717|NCT02407236|Ustekinumab
106718|NCT02407236|Inflammatory Bowel Diseases (IBD)
106719|NCT02407236|Colitis, Ulcerative
106720|NCT02407223|Nonradiographic Axial Spondylitis, Ankylosing
106721|NCT02407223|Ustekinumab
106722|NCT02407210|Azilsartan，Olmesartan Medoxomil
106723|NCT02407197|T1 mapping
106724|NCT02407197|CMR
106725|NCT02407197|Outcome
106726|NCT02407197|multicenter
106727|NCT02407184|Microbiota
106728|NCT02407184|Microbiome
106729|NCT02407145|retropubic
106730|NCT02407145|midurethral sling
106731|NCT02407145|polyvinylidene fluoride
106732|NCT02407119|H. pylori eradication
106733|NCT02407119|Atrophy
106734|NCT02407119|Intestinal metaplasia
106735|NCT02407119|Endoscopic resection
106736|NCT02407106|BLIS K12
106737|NCT02407106|streptococcus
106738|NCT02407093|Body Composition
106739|NCT02407093|Military
106740|NCT02407093|High-Intensity Functional Training
106741|NCT02407093|Army Physical Fitness
106742|NCT02407093|CrossFit
106743|NCT02407002|Nitroglycerin
106744|NCT02407002|Safety
106745|NCT02406976|Exercise
106746|NCT02406976|Morbidity Obesity
106747|NCT02406963|telemedicine
106748|NCT02406950|Sitagliptin
106749|NCT02406950|Endothelium
106750|NCT02406950|Ischemia-Reperfusion Injury
106751|NCT02406950|human
106752|NCT02406924|pin
106753|NCT02406924|particulated graft
106754|NCT02406924|bone augmentation
106755|NCT02406924|vertical augmentation
106756|NCT02406924|horizontal augmentation
106757|NCT02406911|platelet
106758|NCT02406911|ticagrelor
106759|NCT02406911|clopidogrel
106760|NCT02406911|end stage renal disease
106761|NCT02406911|hemodialysis
106762|NCT02406859|Spinal Cord Injury
106763|NCT02406859|Constipation
106764|NCT02406859|Fecal Incontinence
106765|NCT02406859|Neurogenic Bowel
106766|NCT02406859|Bowel Biofeedback
106767|NCT02406859|Manometry
106768|NCT02406846|Pancreatic Neoplasms
106769|NCT02406846|Circulating Tumor Cells
106770|NCT02406833|glaucoma
106771|NCT02406833|trabeculectomy
106772|NCT02406807|chronic low back pain
106773|NCT02406807|HVLA manipulation
106774|NCT02406794|Breast cancer
106775|NCT02406794|Hormonal therapy
106776|NCT02406794|Aromatase inhibitors
106777|NCT02406794|Estrogen deprivation
106778|NCT02406794|Myalgia
106779|NCT02406794|Arthralgia
106780|NCT02406794|Carpal tunnel syndrome
106781|NCT02406794|Pressure pain threshold
106782|NCT02406794|Neuromuscular taping
106783|NCT02406794|Kinesio taping
106784|NCT02406781|Efficacy of MK 3475 with Metronomic Cyclophosphamide
106785|NCT02406781|Advanced Sarcomas
106786|NCT02406781|Leiomyosarcoma
106787|NCT02406781|Undifferentiated Sarcoma
106788|NCT02406781|Other Sarcoma
106789|NCT02406781|GIST
106790|NCT02406781|Osteosarcoma
106791|NCT02406768|normal controls
106792|NCT02406742|CC-122
106793|NCT02406742|Pharmacokinetics
106794|NCT02406742|Safety
106795|NCT02406742|Ibrutinib
106796|NCT02406742|Obinutuzumab
106797|NCT02406742|GA101
106798|NCT02406742|Chronic Lymphocytic Leukemia
106799|NCT02406742|Small Lymphocytic Lymphoma
106800|NCT02406703|local anesthesia
106801|NCT02406703|regional anesthetic
106802|NCT02406690|Endometrial Insufficiency
106803|NCT02406690|Endometrial Receptivity
106804|NCT02406677|Acute Coronary Syndromes, ACS, Myocardial Infarction, STEMI, NSTEMI, MI, Co-Payments, Copay, Cost Sharing
106805|NCT02406638|3D Pelvic floor USG
106806|NCT02406638|Mid-Urethral Sling
106807|NCT02406638|TVT
106808|NCT02406638|TVT-O
106809|NCT02406638|TVT-S
106810|NCT02406612|Vascular Closure Device
106811|NCT02406612|Femoral Artery Closure
106812|NCT02406573|Sensitivity
106813|NCT02406547|Serrated lesion
106814|NCT02406547|sessile serrated adenoma
106815|NCT02406547|Narrow Band Imaging
106816|NCT02406547|Colonoscopy
106817|NCT02406547|colorectal neoplasms
106818|NCT02406521|Metastatic renal cell carcinoma
106819|NCT02406521|mRCC
106820|NCT02406482|sex work, Kazakhstan, microfinance, drug use
106821|NCT02406443|Type 2 Diabetes, DPP-4 inhibitors, renal sodium excretion
106822|NCT02406339|Physical Therapy
106823|NCT02406339|Rehabilitation
106824|NCT02406339|Neuromuscular Electrical Stimulation
106825|NCT02406339|Muscle Strength
106826|NCT02406300|Hip Fracture
106827|NCT02406300|Regional Anesthesia
106828|NCT02406300|Peripheral Nerve Blocks
106829|NCT02406300|Post-operative Mortality
106830|NCT02406300|Cognitive Dysfunction
106831|NCT02406300|Quality of Life
106832|NCT02406274|Mammography
106833|NCT02406274|Contrast Enhanced Spectral Mammography
106834|NCT02406274|Palpable Breast Abnormalities
106835|NCT02406274|15-053
106836|NCT02406248|NSTEMI
106837|NCT02406222|Relapsed
106838|NCT02406222|Refractory
106839|NCT02406222|Pomalidomide
106840|NCT02406222|Dexamethasone
106841|NCT02406222|Cyclophosphamide
106842|NCT02406209|uveitis
106843|NCT02406209|acute uveitis
106844|NCT02406209|anterior uveitis
106845|NCT02406209|NS2
106846|NCT02406209|Aldeyra
106847|NCT02406209|prednisolone acetate
106848|NCT02406157|diabetic macular edema
106849|NCT02406157|micropulse
106850|NCT02406157|laser
106851|NCT02406157|subthreshold
106852|NCT02406144|Multiple Myeloma
106853|NCT02406131|Peripheral Vascular Diseases
106854|NCT02406131|Ischemic Preconditioning
106855|NCT02406131|Inflammation
106856|NCT02406131|Angioplasty
106857|NCT02406131|Restenosis
106858|NCT02406131|RCT
106859|NCT02406118|transanal TME quality
106860|NCT02406118|CRM
106861|NCT02406105|tremor
106862|NCT02406105|Parkinson disease
106863|NCT02406105|functional radioablation
106864|NCT02406105|Cyber Knife radiosurgery
106865|NCT02406079|tracheotomy
106866|NCT02406079|procalcitonin
106867|NCT02406079|sepsis
106868|NCT02406053|lung cancer
106869|NCT02406053|antioxidants
106870|NCT02406053|oxidative damage
106871|NCT02406040|Protein synthesis
106872|NCT02406040|Protein breakdown
106873|NCT02406040|Muscle
106874|NCT02406040|Energy restriction
106875|NCT02406027|Alzheimer's Disease
106876|NCT02406027|JNJ-54861911
106877|NCT02406027|Placebo
106878|NCT02406001|peri-implantitis
106879|NCT02406001|osseous defects
106880|NCT02406001|implant surface decontamination
106881|NCT02406001|bone grafting
106882|NCT02406001|surgical therapy
106883|NCT02406001|porous titanium granules
106884|NCT02406001|reconstruction
106885|NCT02405988|Emergency Treatment
106886|NCT02405988|Morphine Derivates
106887|NCT02405988|Heroin
106888|NCT02405988|Antidotes
106889|NCT02405988|Administration, Intravenous
106890|NCT02405988|Pharmacology
106891|NCT02405988|Naloxone
106892|NCT02405988|Healthy volunteers
106893|NCT02405962|Acceptance and Commitment Therapy
106894|NCT02405962|Childhood asthma
106895|NCT02405962|Randomized controlled trial
106896|NCT02405962|Training parents
106897|NCT02405910|advanced
106898|NCT02405910|non-squamous
106899|NCT02405910|first line therapy
106900|NCT02405897|flexible bronchoscopy
106901|NCT02405897|transbronchial lung biopsy
106902|NCT02405897|forceps
106903|NCT02405884|Glaucoma
106904|NCT02405884|Renal Insufficiency, Chronic
106905|NCT02405884|Low Tension Glaucoma
106906|NCT02405884|Ocular Hypertension
106907|NCT02405858|Metastatic Castration-Resistant Prostate Cancer
106908|NCT02405858|Abiraterone Acetate
106909|NCT02405858|ZYTIGA
106910|NCT02405858|Prednisolone
106911|NCT02405845|Atherosclerosis
106912|NCT02405845|Internal Carotid Artery
106913|NCT02405845|Free-floating thrombus
106914|NCT02405845|Ulcerated plaque
106915|NCT02405845|FFT
106916|NCT02405819|Cancer
106917|NCT02405819|Oncology
106918|NCT02405819|Survivorship
106919|NCT02405819|Care
106920|NCT02405819|Plan
106921|NCT02405780|Rheumatoid
106922|NCT02405780|Arthritis
106923|NCT02405767|Diabetic foot ulcer
106924|NCT02405754|CAD
106925|NCT02405754|Clinical Utility
106926|NCT02405754|Personalized Medicine
106927|NCT02405728|PICC
106928|NCT02405728|BLOODSTREAM INFECTIONS
106929|NCT02405728|VASCULAR ACCESS
106930|NCT02405702|Infection
106931|NCT02405702|Knee
106932|NCT02405702|knee replacement
106933|NCT02405676|Lymphoma
106934|NCT02405676|non-Hodgkin
106935|NCT02405676|B-lymphocytes
106936|NCT02405676|Child
106937|NCT02405676|Multicenter study
106938|NCT02405663|blood loss
106939|NCT02405663|caesarean section
106940|NCT02405663|placental delivery
106941|NCT02405650|CKD, chronic kidney disease, CRIC
106942|NCT02405637|Feeding intolerance
106943|NCT02405637|Simulated amniotic fluid
106944|NCT02405637|Necrotizing enterocolitis
106945|NCT02405585|Pancreatic Cancer
106946|NCT02405585|Immunotherapy
106947|NCT02405585|Vaccine Therapy
106948|NCT02405572|formula-fed
106949|NCT02405572|infants
106950|NCT02405546|Nasal intubation
106951|NCT02405546|Counterclockwise rotation
106952|NCT02405533|AHCC
106953|NCT02405533|nutritional supplement
106954|NCT02405533|HPV
106955|NCT02405520|human papillomavirus vaccine
106956|NCT02405520|condylomata acuminata
106957|NCT02405507|Gastrointestinal Discomfort
106958|NCT02405507|Wheat germ
106959|NCT02405507|Constipation
106960|NCT02405507|Glycaemic Index
106961|NCT02405507|Blood Cholesterol Level
106962|NCT02405507|Glycaemic Response
106963|NCT02405507|Cholesterol
106964|NCT02405507|PAC-SYM
106965|NCT02405507|Gut Microbiota
106966|NCT02405468|blood microbiota
106967|NCT02405468|coronary disease
106968|NCT02405468|myocardial infarction
106969|NCT02405455|cervical incompetence
106970|NCT02405455|cerclage
106971|NCT02405455|cervical pessary
106972|NCT02405416|Hepatocellular Carcinoma
106973|NCT02405416|Blood Loss
106974|NCT02405416|Haemorrhage
106975|NCT02405416|Vascular Control
106976|NCT02405403|amyotrophic lateral sclerosis disease
106977|NCT02405403|PET
106978|NCT02405403|microglial activation
106979|NCT02405390|Storz C-Mac®
106980|NCT02405390|Pediatric Airway
106981|NCT02405390|Cervical Spine Injury
106982|NCT02405390|Trauma Airway Management
106983|NCT02405377|contrast-induced nephropathy
106984|NCT02405377|hydration
106985|NCT02405377|Percutaneous coronary intervention
106986|NCT02405364|Multiple Myeloma
106987|NCT02405364|Carfilzomib
106988|NCT02405364|Lenalidomide
106989|NCT02405364|Dexamethasone
106990|NCT02405364|Patient up to 65 years
106991|NCT02405364|initial management
106992|NCT02405351|Telemedicine, Stroke, Working Memory, Cognitive Training
106993|NCT02405338|AML
106994|NCT02405325|physical activity
106995|NCT02405325|multilevel
106996|NCT02405325|cost-effectiveness
106997|NCT02405325|older adults
106998|NCT02405312|communication
106999|NCT02405312|palliative care
107000|NCT02405312|death
107001|NCT02405299|child
107002|NCT02405299|disorders inhibition
107003|NCT02405299|neuropsychology
107004|NCT02405299|rehabilitation
107005|NCT02405299|ADHD
107006|NCT02405299|assessment of neurocognitive rehabilitations in ADHD in children
107007|NCT02405273|Lung Cancer
107008|NCT02405273|Surgery
107009|NCT02405273|COPD
107010|NCT02405273|Rehabilitation
107011|NCT02405247|NSCLC
107012|NCT02405247|T790M
107013|NCT02405247|EGFR
107014|NCT02405247|TKI
107015|NCT02405247|Resistance
107016|NCT02405247|Non Small Cell Lung Cancer
107017|NCT02405247|AZD9291
107018|NCT02405234|Radial Head Arthroplasty
107019|NCT02405182|Magnetic Resonance Imaging
107020|NCT02405182|MRI
107021|NCT02405182|Biomarker
107022|NCT02405169|Implantology
107023|NCT02405169|oral surgery
107024|NCT02405169|bone level changes
107025|NCT02405169|marginal bone level
107026|NCT02405156|Letrozole
107027|NCT02405156|misoprostol
107028|NCT02405156|second trimester miscarriage
107029|NCT02405143|Controlled clinical trial
107030|NCT02405143|Electric Stimulation Therapy
107031|NCT02405117|Bipolar Disorder
107032|NCT02405117|Behavior Therapy
107033|NCT02405117|Technology Assisted
107034|NCT02405117|Mobile Phone
107035|NCT02405117|Smartphone
107036|NCT02405104|osteoarthritis
107037|NCT02405104|hip
107038|NCT02405104|knee
107039|NCT02405104|total hip arthroplasty
107040|NCT02405104|total knee arthroplasty
107041|NCT02405104|post operative pain management
107042|NCT02405078|Lymphoma
107043|NCT02405078|Diffuse Large B-cell Lymphoma
107044|NCT02405078|DLBCL
107045|NCT02405078|Relapsed/Refractory
107046|NCT02405078|Fluorodeoxyglucose-positron emission tomography/computed tomography
107047|NCT02405078|FDG-PET/CT
107048|NCT02405078|18F-Fluorodeoxyglucose
107049|NCT02405078|Blood draws
107050|NCT02405078|Chemotherapy
107051|NCT02405039|DED
107052|NCT02405039|Disease
107053|NCT02405013|Africa
107054|NCT02405013|Hepatitis C
107055|NCT02405013|HIV
107056|NCT02405013|Antiviral treatment
107057|NCT02405013|Adults
107058|NCT02405013|HCV genotype 1
107059|NCT02405013|HCV genotype 2
107060|NCT02405013|HCV genotype 4
107061|NCT02404974|physical activity
107062|NCT02404948|coronary artery disease
107063|NCT02404948|diagnosis
107064|NCT02404948|non-invasive
107065|NCT02404935|Metastatic colorectal cancer
107066|NCT02404935|cetuximab
107067|NCT02404935|maintenance
107068|NCT02404922|Safety/Efficacy Study
107069|NCT02404922|Randomized
107070|NCT02404922|Double Blind
107071|NCT02404883|Cancer
107072|NCT02404883|decisional conflict
107073|NCT02404883|online
107074|NCT02404883|decision-aid tool
107075|NCT02404870|Diabetes
107076|NCT02404870|Phosphate
107077|NCT02404870|Fibroblast Growth Factor 23 (FGF23)
107078|NCT02404870|Vitamin D
107079|NCT02404870|PTH
107080|NCT02404857|Post stroke
107081|NCT02404857|BCI
107082|NCT02404857|Reeducation
107083|NCT02404857|Hand movement
107084|NCT02404831|Physiotherapy
107085|NCT02404831|Pulmonary Rehabilitation
107086|NCT02404831|Exercise
107087|NCT02404831|Telerehab
107088|NCT02404818|Radiation
107089|NCT02404818|Cardiac
107090|NCT02404818|Hodgkin's lymphoma
107091|NCT02404805|dolutegravir
107092|NCT02404805|simeprevir
107093|NCT02404805|HIV
107094|NCT02404805|HCV
107095|NCT02404792|Frail Elderly
107096|NCT02404792|IGF-1
107097|NCT02404779|ICU
107098|NCT02404779|Deep sedation
107099|NCT02404779|Mechanical ventilation
107100|NCT02404779|Traumatic brain injury
107101|NCT02404779|Intracranial hypertension
107102|NCT02404779|Cisatracurium
107103|NCT02404779|Neuromuscular Blocking Agent
107104|NCT02404779|Randomization versus placebo
107105|NCT02404766|manual therapy
107106|NCT02404766|cervical
107107|NCT02404766|range of movement
107108|NCT02404753|Locally advanced gastric cancer
107109|NCT02404753|Laparoscopic distal D2 gastrectomy
107110|NCT02404753|Neoadjuvant chemotherapy
107111|NCT02404740|VP shunted
107112|NCT02404740|Normal intracranial pathology
107113|NCT02404740|patients
107114|NCT02404727|Osteoarthritis, Hip
107115|NCT02404727|acetabular fixation
107116|NCT02404727|dual mobility cup
107117|NCT02404727|Radiostereometric Analysis
107118|NCT02404727|Dual-Energy Radiographic Absorptiometry
107119|NCT02404727|Accelerometry
107120|NCT02404727|total hip arthroplasty
107121|NCT02404727|intra-prosthetic dislocation
107122|NCT02404662|Alcohol use disorder
107123|NCT02404662|Depression
107124|NCT02404662|Mood disorders
107125|NCT02404662|Bipolar disorder
107126|NCT02404662|Supportive text messages
107127|NCT02404623|Vitamin D
107128|NCT02404623|Respiratory Morbidity
107129|NCT02404623|prematurity
107130|NCT02404610|propofol
107131|NCT02404610|moderate procedural sedation
107132|NCT02404610|deep procedural sedation
107133|NCT02404610|memory
107134|NCT02404610|emergency department
107135|NCT02404597|Cardiac output
107136|NCT02404597|Low blood pressure
107137|NCT02404597|Total Body Surface Area (TBSA)
107138|NCT02404584|Metastatic kidney cancer
107139|NCT02404545|Hernia
107140|NCT02404545|Mesh
107141|NCT02404545|Ileal conduit
107142|NCT02404532|OPC-14597 Digital
107143|NCT02404532|Aripiprazole
107144|NCT02404532|Medical Information Device #1 System (MIND1)
107145|NCT02404532|Ingestible Event Marker
107146|NCT02404519|Vitamin K
107147|NCT02404519|Menaquinone-7
107148|NCT02404519|Matrix Gla Protein
107149|NCT02404519|Vascular stiffness
107150|NCT02404506|Eribulin
107151|NCT02404506|Breast Cancer
107152|NCT02404506|Elderly Patient
107153|NCT02404506|Phase II Trial
107154|NCT02404506|HER2-neg
107155|NCT02404506|adenocarcinoma
107156|NCT02404493|Atopic Dermatitis
107157|NCT02404441|Phase I/II, PDR001, Checkpoint inhibitor, PD-1, PD-L1
107158|NCT02404428|active surveillance
107159|NCT02404428|MRI
107160|NCT02404428|diet
107161|NCT02404415|catheter ablation
107162|NCT02404415|genomics
107163|NCT02404402|Traumatic Brain Injury
107164|NCT02404402|Light Emitting Diodes
107165|NCT02404402|Cognition
107166|NCT02404402|Neuromodulation
107167|NCT02404402|PTSD
107168|NCT02404402|Neurorehabilitation
107169|NCT02404402|Veterans
107170|NCT02404402|Sleep
107171|NCT02404389|Actinic keratosis, patients, topical, lesion count, clearance rate
107172|NCT02404376|STEMI
107173|NCT02404376|Reperfusion Injury
107174|NCT02404376|Myocardial Infarction
107175|NCT02404376|Myocardial Ischemia
107176|NCT02404376|Remote Ischemic Conditioning
107177|NCT02404376|Exenatide
107178|NCT02404376|Glucagon-Like Peptide-1 (GLP-1)
107179|NCT02404376|Acute Coronary Syndrome
107180|NCT02404376|Cardioprotection
107181|NCT02404363|Clopidogrel
107182|NCT02404363|Pancreatic Cancer
107183|NCT02404363|Efficacy
107184|NCT02404363|Chemotherapy
107185|NCT02404363|Microparticles
107186|NCT02404363|Disease free survival
107187|NCT02404363|First line chemotherapy
107188|NCT02404350|Psoriatic Arthritis, Arthritis, Psoriatic, Psoriatic Arthropathy
107189|NCT02404311|HIV
107190|NCT02404311|AIDS
107191|NCT02404311|Vaccine
107192|NCT02404298|Transcriptome analysis
107193|NCT02404298|peripheral blood
107194|NCT02404298|chronic inflammatory demyelinating polyradiculoneuropathy
107195|NCT02404298|auto immune diseases
107196|NCT02404298|IVIg
107197|NCT02404272|Neonate
107198|NCT02404272|oral feeding disorder
107199|NCT02404272|full oral feeding
107200|NCT02404272|training
107201|NCT02404272|quality of health care
107202|NCT02404259|pharmacokinetics
107203|NCT02404259|TDF
107204|NCT02404259|HIV-infected children
107205|NCT02404259|Thai
107206|NCT02404259|non-nucleoside reverse transcriptase inhibitor (NNRTI)
107207|NCT02404259|ritonavir-boosted protease inhibitor (bPI)
107208|NCT02404259|less than eighteen years old
107209|NCT02404246|Bipolar
107210|NCT02404246|Peers
107211|NCT02404246|DBSA
107212|NCT02404220|Syk inhibitor
107213|NCT02404220|Blood malignancy
107214|NCT02404220|Leukemia
107215|NCT02404207|Prevention
107216|NCT02404194|schizophrenia
107217|NCT02404194|psychosis
107218|NCT02404194|at risk
107219|NCT02404194|prodrome
107220|NCT02404194|attenuated psychosis syndrome
107221|NCT02404181|Validation Studies
107222|NCT02404181|EEG
107223|NCT02404142|Trachel intubation
107224|NCT02404142|IDS score
107225|NCT02404142|Videoaryngoscopy
107226|NCT02404142|Glidescope® Titanium®
107227|NCT02404142|NMBA
107228|NCT02404142|Curare (Atracurium)
107229|NCT02404129|Fall
107230|NCT02404129|Turn 180 test
107231|NCT02404129|elderly
107232|NCT02404129|balance
107233|NCT02404090|Obesity
107234|NCT02404090|Weight Loss
107235|NCT02404090|Knee Osteoarthritis
107236|NCT02404090|Subchondral Mineralization
107237|NCT02404077|Patients
107238|NCT02404077|undergoing
107239|NCT02404077|ICU
107240|NCT02404051|Breast cancer
107241|NCT02404051|HER2Negative
107242|NCT02404051|hormone receptor positive (HR+)
107243|NCT02404051|Metastatic
107244|NCT02404051|Locally Advanced
107245|NCT02404051|fulvestrant
107246|NCT02404051|everolimus
107247|NCT02404051|exemestane
107248|NCT02404038|choice
107249|NCT02404038|young women
107250|NCT02404038|adolescent girls
107251|NCT02404038|preference
107252|NCT02404025|Eltrombopag
107253|NCT02404025|rabbit anti-thymocyte globulin
107254|NCT02404025|additive effect
107255|NCT02404025|cyclosporine A
107256|NCT02404012|iron deficiency
107257|NCT02404012|sleeve gastrectomy
107258|NCT02404012|gastric bypass
107259|NCT02404012|bariatric surgery
107260|NCT02403973|Patient hotel
107261|NCT02403973|Patient Satisfaction
107262|NCT02403973|Perioperative care
107263|NCT02403973|IN2005E
107264|NCT02403947|Multiple Sclerosis
107265|NCT02403947|Bone-marrow
107266|NCT02403947|Stem cells
107267|NCT02403947|Cell therapy
107268|NCT02403934|Airway Management
107269|NCT02403934|deep sedation
107270|NCT02403934|Jaw elevation device
107271|NCT02403921|biomarker
107272|NCT02403908|radiofrequency denervation, pulmonary hypertension
107273|NCT02403882|behavioral economics
107274|NCT02403882|food pantry
107275|NCT02403882|food choice
107276|NCT02403869|Metastatic breast cancer
107277|NCT02403869|Monotherapy
107278|NCT02403869|chemotherapy
107279|NCT02403869|second line
107280|NCT02403869|treatment
107281|NCT02403869|Her 2 negative
107282|NCT02403856|calcifying tendinitis
107283|NCT02403856|Needle lavage
107284|NCT02403856|Shoulder
107285|NCT02403856|Corticosteroid injection
107286|NCT02403856|Ultrasound-guided
107287|NCT02403817|Video Games
107288|NCT02403804|Dietary supplements
107289|NCT02403804|serum choline
107290|NCT02403804|women
107291|NCT02403791|Acute Respiratory Distress Syndrome
107292|NCT02403778|Melanoma
107293|NCT02403778|Malignant Melanoma
107294|NCT02403752|dementia
107295|NCT02403752|Alzheimer's disease
107296|NCT02403752|exercise
107297|NCT02403739|Growth
107298|NCT02403700|bone remodeling
107299|NCT02403700|bone resorption
107300|NCT02403700|three-dimensional imaging
107301|NCT02403700|clinical trial
107302|NCT02403700|dental implant
107303|NCT02403700|maxilla
107304|NCT02403700|bone healing
107305|NCT02403635|HSV
107306|NCT02403635|Herpes
107307|NCT02403635|volunteers
107308|NCT02403635|drug-drug interaction
107309|NCT02403609|cognitive assessment
107310|NCT02403609|Brain Performance Test
107311|NCT02403609|Lumosity
107312|NCT02403609|test-retest reliability
107313|NCT02403609|computerized assessment
107314|NCT02403596|Hip replacement
107315|NCT02403596|rivaroxaban
107316|NCT02403596|exacyl
107317|NCT02403596|blood loss
107318|NCT02403583|HIV Transmission
107319|NCT02403583|Prevention of Mother to Child Transmission
107320|NCT02403583|Serodiscordancy
107321|NCT02403583|Home-based testing
107322|NCT02403583|Home-based counseling
107323|NCT02403583|Linkage to care
107324|NCT02403583|Couples HIV Testing and Counseling
107325|NCT02403583|Acceptance of repeat HIV testing during pregnancy
107326|NCT02403583|Retention in care
107327|NCT02403570|Multiple Sclerosis, MRI, rotating frame
107328|NCT02403544|Clinical Trial, Phase I
107329|NCT02403544|Concurrent Chemoradiation
107330|NCT02403544|Oxaliplatin
107331|NCT02403544|Capecitabine
107332|NCT02403544|Carcinoma, Hepatocellular
107333|NCT02403531|Esophageal cancer
107334|NCT02403531|Chemoradiotherapy
107335|NCT02403531|induction chemotherapy
107336|NCT02403505|Prostate Cancer
107337|NCT02403505|SNP
107338|NCT02403505|Single Nucleotide Polymorphism
107339|NCT02403505|Genetics
107340|NCT02403505|Pharmacogenomic
107341|NCT02403505|Pharmacogenetic
107342|NCT02403505|gene
107343|NCT02403505|genome
107344|NCT02403505|genotype
107345|NCT02403505|genotyping
107346|NCT02403505|Oncology
107347|NCT02403505|Chemotherapy
107348|NCT02403505|Personalize
107349|NCT02403505|Individualize
107350|NCT02403492|Children
107351|NCT02403492|Obesity
107352|NCT02403492|Cardiovascular
107353|NCT02403492|Sleep
107354|NCT02403492|Apnea
107355|NCT02403492|Obstructive
107356|NCT02403466|Medical errors
107357|NCT02403466|Communication
107358|NCT02403466|Resident sign-out
107359|NCT02403453|Radiculopathy
107360|NCT02403453|Myelopathy
107361|NCT02403453|Spondylosis
107362|NCT02403453|Herniated Nucleus Pulposus
107363|NCT02403453|C3-C7
107364|NCT02403453|Osteophytes
107365|NCT02403453|Neurological deficit
107366|NCT02403427|Bolus calculator
107367|NCT02403427|Insulin pump
107368|NCT02403427|basal-bolus insulin therapy
107369|NCT02403401|Pregnancy prevention
107370|NCT02403388|Patient safety
107371|NCT02403388|Primary care
107372|NCT02403388|Incident reporting
107373|NCT02403388|Pluridisciplinary care offices
107374|NCT02403388|Risk management
107375|NCT02403388|Assessment
107376|NCT02403310|adverse-risk AML
107377|NCT02403310|poor-risk karyotype
107378|NCT02403310|cytogenetic abnormality
107379|NCT02403310|poor-risk mutations
107380|NCT02403310|antecedent hematologic disorder
107381|NCT02403310|treatment related AML
107382|NCT02403297|Bleeding gums
107383|NCT02403297|Gum inflammation
107384|NCT02403297|Saliva
107385|NCT02403284|insulin resistance
107386|NCT02403284|lipid metabolism
107387|NCT02403284|glucose metabolism
107388|NCT02403284|high fat diets
107389|NCT02403271|Pharmacyclics
107390|NCT02403271|PCYC
107391|NCT02403271|Ibrutinib
107392|NCT02403271|Durvalumab (MEDI4736)
107393|NCT02403271|Relapsed Refractory Solid Tumor
107394|NCT02403271|Non-Small Cell Lung Cancer
107395|NCT02403271|NSCLC
107396|NCT02403271|Squamous
107397|NCT02403271|Squamous NSCLC
107398|NCT02403271|Squamous Non-Small Cell Lung Cancer
107399|NCT02403271|Immunotherapy
107400|NCT02403271|IMBRUVICA®
107401|NCT02403271|Tumor Immunotherapy
107402|NCT02403271|Anti-PD-L1
107403|NCT02403271|Lung Cancer
107404|NCT02403258|acupuncture
107405|NCT02403258|plum-blossom needle
107406|NCT02403258|tourette syndrome
107407|NCT02403258|randomized controlled trial
107408|NCT02403245|Social interactions
107409|NCT02403245|Dementia
107410|NCT02403245|Social stimulation
107411|NCT02403245|Direct observation
107412|NCT02403232|Autologous adipose-derived stem cells
107413|NCT02403219|Dry eye
107414|NCT02403219|Botulinum toxin A
107415|NCT02403219|Orbicularis muscle of the eye
107416|NCT02403193|Adenosine A2a receptor antagonist
107417|NCT02403193|NSCLC
107418|NCT02403193|PBF-509
107419|NCT02403193|Immunotherapy
107420|NCT02403193|adenosine
107421|NCT02403193|PDR001
107422|NCT02403193|immune checkpoint inhibitors
107423|NCT02403193|Programmed Death-1 (PD-1) receptor
107424|NCT02403193|Adenosine A2a receptor (A2AR)
107425|NCT02403180|Visual Performance
107426|NCT02402101|tDCS
107427|NCT02402101|Dopamine
107428|NCT02402101|PET
107429|NCT02402088|stress
107430|NCT02402088|food cues
107431|NCT02402088|obesity
107432|NCT02402075|muscle motor evoked potentials
107433|NCT02402075|spinal motor evoked potentials
107434|NCT02402075|D-wave
107435|NCT02402075|brain tumor surgery
107436|NCT02402075|intraoperative neuromonitoring
107437|NCT02402062|pNET
107438|NCT02403154|Anterior pelvic ring
107439|NCT02403154|Internal fixation
107440|NCT02403154|External fixation
107441|NCT02403154|Orthopaedic
107442|NCT02403154|Orthopedic
107443|NCT02403154|pubic rami
107444|NCT02403128|362.17
107445|NCT02403102|Magnetic Resonance Imaging
107446|NCT02403102|Myeloma
107447|NCT02403102|Autograft
107448|NCT02403089|MAIT (Mucosal-Associated Invariant T) cells
107449|NCT02403089|Gut microbiota
107450|NCT02403089|Preterm birth
107451|NCT02403089|Hematopoietic stem cell transplantation
107452|NCT02403089|Microbial infections
107453|NCT02403050|Neoplasm Staging
107454|NCT02403050|Radiotherapy
107455|NCT02403050|Fiducial Markers
107456|NCT02403037|Breast Neoplasms
107457|NCT02403037|Auricular Therapy
107458|NCT02403037|Acupressure
107459|NCT02403037|Chemotherapy
107460|NCT02403037|Nausea
107461|NCT02403037|Vomiting
107462|NCT02403024|Colon cancer
107463|NCT02403024|rectal cancer
107464|NCT02403024|exercise
107465|NCT02403024|physical activity
107466|NCT02403024|metabolic health
107467|NCT02403011|Congenital Muscular Torticollis
107468|NCT02403011|Manual Therapy
107469|NCT02403011|Infant
107470|NCT02402998|Primacy immune thrombocytopenia
107471|NCT02402998|Adults
107472|NCT02402998|Eltrombopag
107473|NCT02402998|Long-term remission
107474|NCT02402985|nutritional support
107475|NCT02402985|diet therapy
107476|NCT02402985|protein diet
107477|NCT02402985|isocaloric diet
107478|NCT02402972|adjuvant chemotherapy
107479|NCT02402972|intraportal chemotherapy
107480|NCT02402972|prevention
107481|NCT02402959|Insomnia
107482|NCT02402959|Traditional Chinese Medicine
107483|NCT02402959|herbal medicine
107484|NCT02402959|cohort study
107485|NCT02402959|individualized treatment
107486|NCT02402959|TCM pattern differentiation
107487|NCT02402920|Lung Cancer
107488|NCT02402920|Small Cell Lung Cancer
107489|NCT02402920|SCLC
107490|NCT02402920|Limited-Stage Small-Cell Lung Cancer
107491|NCT02402920|LS-SCLC
107492|NCT02402920|Extensive-Stage Small-Cell Lung Cancer
107493|NCT02402920|ES-SCLC
107494|NCT02402920|MK-3475
107495|NCT02402920|Keytruda
107496|NCT02402920|Pembrolizumab
107497|NCT02402920|SCH-900475
107498|NCT02402920|Etoposide
107499|NCT02402920|VePesid
107500|NCT02402920|Cisplatin
107501|NCT02402920|Platinol-AQ
107502|NCT02402920|Platinol
107503|NCT02402920|CDDP
107504|NCT02402920|Carboplatin
107505|NCT02402920|Radiation therapy
107506|NCT02402920|XRT
107507|NCT02402907|cesarean section
107508|NCT02402907|chlorhexidine gluconate
107509|NCT02402907|CHG
107510|NCT02402907|surgical site infection
107511|NCT02402907|obstetrics
107512|NCT02402907|infection prevention
107513|NCT02402907|pregnancy
107514|NCT02402881|venous thromboembolism
107515|NCT02402881|deep venous thrombosis
107516|NCT02402881|pulmonary embolism
107517|NCT02402881|blood clots
107518|NCT02402855|Couverture Maladie Universelle
107519|NCT02402855|Couverture Maladie Universelle-Complémentaire
107520|NCT02402855|free health care
107521|NCT02402842|gastrointestinal oncology
107522|NCT02402842|immunology
107523|NCT02402842|taxane
107524|NCT02402764|Triple Negative Breast Cancer (TNBC)
107525|NCT02402764|Breast - Female
107526|NCT02402764|Breast - Male
107527|NCT02402764|Metastatic Triple Negative Breast Cancer
107528|NCT02402764|Receptor Tyrosine-protein Kinase erbB-2 (HER2) Negative
107529|NCT02402764|Erythroblastosis virus oncogene B (erbB)
107530|NCT02402751|Volunteers
107531|NCT02402725|Relapsed Multiple Myeloma
107532|NCT02402699|HBV
107533|NCT02402699|HBC
107534|NCT02402647|Hoarding
107535|NCT02402647|Compulsive Hoarding
107536|NCT02402595|Drug-drug interaction
107537|NCT02402595|Healthy Volunteers
107538|NCT02402595|Pharmacokinetics
107539|NCT02402595|deuterated dextromethorphan
107540|NCT02402595|dextromethorphan
107541|NCT02402595|dextromethorphan with quinidine
107542|NCT02402595|deuterated dextromethorphan with quinidine
107543|NCT02402595|itraconazole
107544|NCT02402582|Family-Centered Empowerment Model
107545|NCT02402582|Quality of life
107546|NCT02402582|Perceived stress
107547|NCT02402582|Anxiety
107548|NCT02402582|Myocardial infarction
107549|NCT02402582|Clinical trial
107550|NCT02402582|Iran
107551|NCT02402543|preemptive analgesia
107552|NCT02402543|anorectal surgery
107553|NCT02402543|gabapentin
107554|NCT02402543|neurontin
107555|NCT02402543|ketamine
107556|NCT02402543|acetaminophen
107557|NCT02402543|tylenol
107558|NCT02402543|postoperative pain
107559|NCT02402543|postoperative narcotic usage
107560|NCT02402543|dexamethasone
107561|NCT02402543|decadron
107562|NCT02402530|Neridronic Acid
107563|NCT02402530|Neridronate
107564|NCT02402530|CRPS
107565|NCT02402530|RSD
107566|NCT02402517|Diabetes Prevention
107567|NCT02402517|Obesity Prevention
107568|NCT02402491|Dual Antiplatelet Treatment
107569|NCT02402491|In-Stent Restenosis
107570|NCT02402478|Clinical Cohort
107571|NCT02402478|Electronic Health Records
107572|NCT02402478|Prognosis
107573|NCT02402478|Stable Coronary Artery Disease
107574|NCT02402439|Type 1 diabetes
107575|NCT02402439|diabetes mellitus
107576|NCT02402439|pancreatic islet transplant
107577|NCT02402439|beta cell replacement
107578|NCT02402426|Brain Health
107579|NCT02402426|Brain Research
107580|NCT02402426|Alzheimer's Disease
107581|NCT02402426|Neurodegenerative Disease
107582|NCT02402426|Parkinson's Disease
107583|NCT02402426|Dementia
107584|NCT02402426|Stroke
107585|NCT02402426|PTSD
107586|NCT02402426|Multiple Sclerosis
107587|NCT02402400|NSTEMI
107588|NCT02402361|Neuropathic pain
107589|NCT02402361|Diabetic Neuropathy
107590|NCT02402348|head and neck squamous cell carcinoma
107591|NCT02402309|Sjögren-Larsson Syndrome
107592|NCT02402309|SLS
107593|NCT02402309|Ichthyosis
107594|NCT02402309|FALDH Deficiency
107595|NCT02402309|Neuro-ichthyosis
107596|NCT02402309|Fatty Alcohol:NAD+ Oxidoreductase Deficiency
107597|NCT02402309|Fatty Aldehyde Dehydrogenase Deficiency Disease
107598|NCT02402309|Congenital Icthyosis Mental Retardation Spasticity Syndrome
107599|NCT02402309|Spastic Neurologic Disorder
107600|NCT02402309|Oligophrenia
107601|NCT02402283|Bioequivalency
107602|NCT02402283|two metronidazole-containing products
107603|NCT02402270|Colonoscopy
107604|NCT02402270|Preparation
107605|NCT02402257|Central Venous Catheter
107606|NCT02402257|Simulation-based Mastery Learning
107607|NCT02402257|Medical Education
107608|NCT02402257|Patient Outcomes
107609|NCT02402257|Bloodstream Infection Due to Central Venous Catheter
107610|NCT02402257|Pneumothorax
107611|NCT02402257|Inadvertent Arterial Puncture
107612|NCT02402205|Implementation; TF-CBT; adjudicated youth; RTF; trauma
107613|NCT02402192|corifollitropin alfa
107614|NCT02402192|recombinant FSH
107615|NCT02402192|HP-hMG
107616|NCT02402192|time-lapse
107617|NCT02402192|kinetics of development
107618|NCT02402179|protein quality
107619|NCT02402153|evaluation of subcutaneous EEG recording
107620|NCT02402140|tacrolimus blood concentration
107621|NCT02402140|pharmaceutical intervention
107622|NCT02402140|intrasubject variability
107623|NCT02402127|Contact lenses
107624|NCT02402127|Lubricity
107625|NCT02401997|sperm
107626|NCT02401997|oxidative stress
107627|NCT02401997|sexual abstinence
107628|NCT02401971|Thalidomide
107629|NCT02401971|Irinotecan
107630|NCT02401971|Second Line
107631|NCT02401945|Macular Degeneration
107632|NCT02401919|Nursing
107633|NCT02401919|Hospital
107634|NCT02401919|Communication
107635|NCT02401919|Patient Participation
107636|NCT02401919|Individualised Care
107637|NCT02401893|aging
107638|NCT02401893|influenza vaccine
107639|NCT02401893|immune responses
107640|NCT02401867|transgender
107641|NCT02401867|female-to-male
107642|NCT02401867|cervical cancer
107643|NCT02401867|HPV
107644|NCT02401867|sexual health
107645|NCT02401854|atrial fibrillation
107646|NCT02401854|hypertension
107647|NCT02401854|risk factors
107648|NCT02401854|primary care
107649|NCT02401854|elderly
107650|NCT02401815|Gastrointestinal Stromal Tumors
107651|NCT02401815|KIT
107652|NCT02401815|Biomarkers
107653|NCT02401815|PLX9486
107654|NCT02401815|PLX3397
107655|NCT02401802|Colonoscopy
107656|NCT02401802|Diet
107657|NCT02401802|Polyethylene glycols
107658|NCT02401802|Efficacy
107659|NCT02401802|Personal satisfaction
107660|NCT02401802|Colorectal cancer screening
107661|NCT02401789|oral surgery
107662|NCT02401789|Implantology
107663|NCT02401776|heart rate
107664|NCT02401776|blood pressure
107665|NCT02401776|caffeine
107666|NCT02401776|energy drink
107667|NCT02401763|biomarker
107668|NCT02401737|Hepatitis B
107669|NCT02401724|Hemispatial neglect
107670|NCT02401724|Transcranial direct current stimulation
107671|NCT02401724|Rehabilitation
107672|NCT02401698|Stroke
107673|NCT02401698|Transcranial Magnetic Stimulation
107674|NCT02401698|Neuronal Plasticity
107675|NCT02401698|Rehabilitation
107676|NCT02401685|breast cancer
107677|NCT02401685|sentinel lymph node biopsy
107678|NCT02401685|axillary lymph node clearance
107679|NCT02401685|axillary lymph node dissection
107680|NCT02401685|macrometastases
107681|NCT02401685|axillary radiotherapy
107682|NCT02401685|POSNOC
107683|NCT02401672|TMS
107684|NCT02401672|nicotine dependence
107685|NCT02401672|smoking cessation
107686|NCT02401659|remote monitoring
107687|NCT02401659|satisfaction
107688|NCT02401659|telemonitoring
107689|NCT02401659|quality of life
107690|NCT02401633|Cardio-Pulmonary-Resuscitation
107691|NCT02401633|Advanced Cardiac Life Support
107692|NCT02401633|Compression-Only CPR
107693|NCT02401633|Chest compression CPR
107694|NCT02401620|AR: arthritis rheumatoid
107695|NCT02401620|DMARDs: Disease-modifying antirheumatic drugs
107696|NCT02401620|ACR. American College of Rheumatology
107697|NCT02401620|EULAR: European League against rheumatology
107698|NCT02401607|stress
107699|NCT02401607|emergency physicians
107700|NCT02401607|health care workers
107701|NCT02401607|biomarkers
107702|NCT02401607|questionnaires
107703|NCT02401607|anxiety
107704|NCT02401607|depression
107705|NCT02401607|burn-out
107706|NCT02401594|Non-major orthopaedic surgery
107707|NCT02401594|deep vein thrombosis
107708|NCT02401542|Urothelial Cell Carcinoma
107709|NCT02401542|UCC
107710|NCT02401542|bladder cancer
107711|NCT02401542|B-701
107712|NCT02401542|FGFR3
107713|NCT02401542|invasive bladder cancer
107714|NCT02401542|targeted therapy
107715|NCT02401542|Transitional Cell Carcinoma
107716|NCT02401542|TCC
107717|NCT02401542|Phase 2
107718|NCT02401542|second line therapy
107719|NCT02401542|monoclonal antibody
107720|NCT02401542|docetaxel
107721|NCT02401542|combination therapy
107722|NCT02401529|Dexamethasone
107723|NCT02401529|Prednisolone
107724|NCT02401529|Tonsillectomy Nausea
107725|NCT02401529|Pain, Postoperative
107726|NCT02401529|Postoperative Nausea and Vomiting
107727|NCT02401529|Randomized controlled trial
107728|NCT02401529|Post-tonsillectomy pain
107729|NCT02401529|delayed feeding
107730|NCT02401516|Postural Reprogramming Insole
107731|NCT02401516|Blood Pressure
107732|NCT02401516|Posture
107733|NCT02401516|Quality Of Life
107734|NCT02401516|General Functional Capacity
107735|NCT02401516|Respiratory Muscles Strength
107736|NCT02401516|Flexibility
107737|NCT02401516|Arterial Systemic Hypertension
107738|NCT02401503|CLL
107739|NCT02401477|helicobacter pylori
107740|NCT02401477|ilaprazole
107741|NCT02401477|eradication
107742|NCT02401477|dual therapy
107743|NCT02401477|high dose therapy
107744|NCT02401425|Letrozole
107745|NCT02401425|Misoprostol
107746|NCT02401425|First-Trimester
107747|NCT02401425|Pretreatment
107748|NCT02401386|Fibromyalgia, The Lu Eight Brocades
107749|NCT02401373|Vaccines
107750|NCT02401373|Ebola Virus Disease
107751|NCT02401347|PALB2 mutation
107752|NCT02401347|BRIP1 mutation
107753|NCT02401347|BARD1 mutation
107754|NCT02401347|Rad51c mutation
107755|NCT02401347|PTEN mutation
107756|NCT02401347|CHEK2 mutation
107757|NCT02401347|ATM mutation
107758|NCT02401347|NBN mutation
107759|NCT02401347|Rad51d mutation
107760|NCT02401347|Rad50 mutation
107761|NCT02401347|MRE11 mutation
107762|NCT02401347|FANC mutation
107763|NCT02401347|HRD assay score
107764|NCT02401347|ATR mutation
107765|NCT02401295|Relapsed multiple myeloma
107766|NCT02401256|Efavirenz
107767|NCT02401256|metabolism
107768|NCT02401256|pharmacokinetics changes
107769|NCT02401230|Human Immunodeficiency Virus
107770|NCT02401230|Acquired Immune Deficiency Syndrome Virus
107771|NCT02401230|Pre-exposure Prophylaxis
107772|NCT02401204|Bacterial transmission
107773|NCT02401204|Surveillance
107774|NCT02401204|Neonatal
107775|NCT02401204|Drug Resistance
107776|NCT02401178|FLG-FADS genes variations-LCPUFA-atopic dermatitis
107777|NCT02401165|GADD34
107778|NCT02401165|Unfolded Protein Response
107779|NCT02401165|Anti-citrullinated protein antibodies
107780|NCT02401100|Rectal Neoplasms
107781|NCT02401061|ITP
107782|NCT02401061|Thrombocytopenia
107783|NCT02401035|candidate for acid suppression therapy
107784|NCT02401035|presumptive diagnosis of GERD
107785|NCT02401035|clinical diagnosis of suspected GERD
107786|NCT02401035|symptomatic GERD
107787|NCT02401035|endoscopically proven GERD
107788|NCT02401022|smoking
107789|NCT02401022|smoking cessation
107790|NCT02401022|cigarette
107791|NCT02400996|Endocrine Pancreas
107792|NCT02400996|Pancreatic Endocrine Neoplasm
107793|NCT02400983|ACAP, Automatic Algorithm
107794|NCT02400970|Polymerase Chain Reaction
107795|NCT02400970|fertility preservation
107796|NCT02400957|silver nanoparticles
107797|NCT02400957|demineralization
107798|NCT02400957|brackets
107799|NCT02400944|MSK Tobacco Cessation Program
107800|NCT02400944|smoking exposure
107801|NCT02400944|15-047
107802|NCT02400905|PAD
107803|NCT02400905|PVD
107804|NCT02400905|SFA stent
107805|NCT02400879|bispectral index
107806|NCT02400879|cardiac surgery
107807|NCT02400879|recovery
107808|NCT02400879|remifentanil
107809|NCT02400866|cancer patients receiving moderately emetogenic chemotherapy
107810|NCT02400827|Polymerase Chain Reaction
107811|NCT02400827|fertility preservation
107812|NCT02400801|endometriosis
107813|NCT02400801|infertility
107814|NCT02400801|assisted reproductive technology
107815|NCT02400775|Pharmacotherapy
107816|NCT02400749|moderate to severe non-pustular palmo-plantar psoriasis
107817|NCT02400736|Individual Placement and Support
107818|NCT02400736|Supported Employment
107819|NCT02400736|Employment
107820|NCT02400736|Vocational Rehabilitation
107821|NCT02400736|Veterans
107822|NCT02400736|Patient Aligned Care Team
107823|NCT02400723|behavioral intervention
107824|NCT02400723|relaxation
107825|NCT02400723|Veterans
107826|NCT02400723|geriatric
107827|NCT02400684|AFSr classification
107828|NCT02400684|laparoscopy
107829|NCT02400658|breast cancer
107830|NCT02400658|early-stage
107831|NCT02400658|IORT
107832|NCT02400658|brachytherapy
107833|NCT02400645|laparoscopic hysterectomy
107834|NCT02400645|robotic assisted hysterectomy
107835|NCT02400632|drug-eluting balloon
107836|NCT02400632|in-stent restenosis
107837|NCT02400619|shockwaves
107838|NCT02400619|Physiotherapy
107839|NCT02400619|Botulinum toxin
107840|NCT02400606|constructing VPs
107841|NCT02400606|knowledge and skills transfer
107842|NCT02400580|Laparoscopic Hysterectomy
107843|NCT02400580|IV acetaminophen
107844|NCT02400580|Postoperative pain control
107845|NCT02400580|Surgery
107846|NCT02400567|Luminal
107847|NCT02400567|Post menopausal
107848|NCT02400567|Breast conservation
107849|NCT02400567|Neoadjuvant
107850|NCT02400554|Indian, North American
107851|NCT02400554|Oklahoma
107852|NCT02400554|Female
107853|NCT02400554|health promotion
107854|NCT02400541|Anorexia nervosa
107855|NCT02400541|Cognitive remediation therapy
107856|NCT02400515|Exercise
107857|NCT02400515|Exercise Therapy
107858|NCT02400515|Diabetes Mellitus, Type 2
107859|NCT02400502|Schizophrenia
107860|NCT02400502|Treatment
107861|NCT02400502|Meditation
107862|NCT02400502|Mindfulness
107863|NCT02400502|Stress reactivity
107864|NCT02400502|First Episode Psychosis
107865|NCT02400502|Coping
107866|NCT02400489|Heart Valve Replacement Surgery
107867|NCT02400489|Perimount
107868|NCT02400489|Edwards
107869|NCT02400476|HER2 +
107870|NCT02400476|Breast Cancer
107871|NCT02400476|Neratinib
107872|NCT02400450|Pre-diabetes
107873|NCT02400450|prediabetes
107874|NCT02400450|glycated hemoglobin
107875|NCT02400450|hemoglobin A1c
107876|NCT02400450|LDL cholesterol
107877|NCT02400450|Cholesterol
107878|NCT02400450|metabolic function
107879|NCT02400450|vascular function
107880|NCT02400450|functional food
107881|NCT02400437|Waldenstrom's Macroglobulinemia
107882|NCT02400424|Stereotactic lung radiation therapy
107883|NCT02400424|Radiochemotherapy
107884|NCT02400424|Unresectable stage III Non-Small Cell lung Carcinoma
107885|NCT02400424|Peripheral primary tumor
107886|NCT02400411|Carbohydrate
107887|NCT02400411|Glycemic response
107888|NCT02400411|insulin
107889|NCT02400411|whole grain
107890|NCT02400411|meal
107891|NCT02400359|fMRI
107892|NCT02400359|Magnetic Resonance Imaging
107893|NCT02400359|endocrinology
107894|NCT02400359|MRI
107895|NCT02400359|obesity
107896|NCT02400359|weight loss
107897|NCT02400359|lorcaserin
107898|NCT02400333|ticagrelor orodispersible tablet
107899|NCT02400333|ticagrelor immediate-release tablet
107900|NCT02400333|relative bioavailability
107901|NCT02400333|Phase I
107902|NCT02400333|healthy subjects
107903|NCT02400307|Phase 1
107904|NCT02400307|Renally Impaired
107905|NCT02400294|Critical care
107906|NCT02400294|Mechanical ventilation
107907|NCT02400294|Ventilator associated pneumonia
107908|NCT02400294|Oral care
107909|NCT02400268|Enterobacteriaceae
107910|NCT02400268|Bloodstream
107911|NCT02400268|Bacteremia
107912|NCT02400268|Recurrence
107913|NCT02400268|Reinfection
107914|NCT02400229|coronary artery disease
107915|NCT02400229|stable chest pain
107916|NCT02400229|intermediate pretest probability
107917|NCT02400229|pragmatic randomised controlled trial
107918|NCT02400229|coronary computed tomography
107919|NCT02400229|angiography
107920|NCT02400229|invasive coronary angiography
107921|NCT02400216|Chronic Hepatitis C
107922|NCT02400216|Cirrhosis
107923|NCT02400216|Liver Biopsy
107924|NCT02400216|Microbiome
107925|NCT02400203|hemp oil,
107926|NCT02400203|hemp
107927|NCT02400203|fatty acids
107928|NCT02400203|omega-6
107929|NCT02400203|omega-3
107930|NCT02400203|blood pressure
107931|NCT02400203|blood lipids
107932|NCT02400190|radiation
107933|NCT02400190|lumpectomy
107934|NCT02400190|favorable biology
107935|NCT02400190|omission
107936|NCT02400125|Patient Registry
107937|NCT02400125|Coronary Artery Bypass
107938|NCT02400125|Cardiac Valve Annuloplasty
107939|NCT02400112|Vancomycin
107940|NCT02400086|neuroligical or neuromuscular diseases
107941|NCT02400086|bacterial respiratory tract flora
107942|NCT02400086|long term tracheostomy
107943|NCT02400047|Paediatric surgery
107944|NCT02400034|midurethral sling
107945|NCT02400034|Voiding trial
107946|NCT02400034|stress urinary incontinence
107947|NCT02399995|Quality of Life
107948|NCT02399995|Hepatectomy
107949|NCT02399995|15-057
107950|NCT02399982|Smartphone Application
107951|NCT02399982|mobile mental health
107952|NCT02399982|Binge Eating
107953|NCT02399982|Cognitive behavioral therapy
107954|NCT02399982|Eating Disorder treatment
107955|NCT02399982|Cognitive behavioral therapy guided self-help
107956|NCT02399982|self-monitoring
107957|NCT02399982|eating disorders
107958|NCT02399982|ecological momentary intervention
107959|NCT02399969|Low back pain
107960|NCT02399969|Acupuncture therapy
107961|NCT02399969|Acupuncture, ear
107962|NCT02399956|Lactation
107963|NCT02399956|Pediatric malignancies
107964|NCT02399956|Cancer survivor
107965|NCT02399917|Leukemia
107966|NCT02399917|Acute Myeloid Leukemia
107967|NCT02399917|Refractory
107968|NCT02399917|Relapsed
107969|NCT02399917|AML
107970|NCT02399917|Myelodysplastic Syndrome (MDS).
107971|NCT02399917|MDS
107972|NCT02399917|High-risk
107973|NCT02399917|5-azacytidine
107974|NCT02399917|Azacitidine
107975|NCT02399917|5-aza
107976|NCT02399917|Vidaza
107977|NCT02399917|5-AZC
107978|NCT02399917|AZA-CR
107979|NCT02399917|Ladakamycin
107980|NCT02399917|NSC-102816
107981|NCT02399917|Azacytidine
107982|NCT02399917|Lirilumab
107983|NCT02399917|Phone call
107984|NCT02399891|Remodeling
107985|NCT02399891|Prognosis
107986|NCT02399891|Incidence
107987|NCT02399891|Quality Assurance
107988|NCT02399891|Ejection Fraction
107989|NCT02399891|Sudden Death
107990|NCT02399800|pancreatitis, chronic
107991|NCT02399800|endosonography
107992|NCT02399761|AADC deficiency, newborn screening
107993|NCT02399735|NK cells
107994|NCT02399735|Liver Transplantation
107995|NCT02399735|Hepatocellular Carcinoma Recurrence
107996|NCT02399722|Negative Pressure Wound Therapy, polymeric membrane dressing, wounds
107997|NCT02399670|Total hip arthroplasty
107998|NCT02399670|degenerative joint disease
107999|NCT02399670|Femoral offset
108000|NCT02399670|Patient reported outcome
108001|NCT02399657|diabetes mellitus
108002|NCT02399657|macular edema
108003|NCT02399657|hard exudate
108004|NCT02399657|intravitreal injections
108005|NCT02399657|dexamethasone
108006|NCT02399657|implant
108007|NCT02399644|pain
108008|NCT02399644|rehabilitation
108009|NCT02399644|exercise
108010|NCT02399644|psychological
108011|NCT02399644|intervention
108012|NCT02399631|Perioperative treatment
108013|NCT02399631|Laparoscopic surgery
108014|NCT02399618|Clostridium difficile Infection
108015|NCT02399618|Fecal Microbiota Transplantation
108016|NCT02399618|Freeze-dried
108017|NCT02399618|Acid-resistant Capsules
108018|NCT02399592|Platinum resistant
108019|NCT02399579|cat allergy
108020|NCT02399579|symptom score
108021|NCT02399566|erlotinib
108022|NCT02399566|pemetrexed
108023|NCT02399566|maintenance therapy
108024|NCT02399527|Vascular Anomalies
108025|NCT02399527|Lymphatic Anomalies
108026|NCT02399527|Lymphatic Malformation
108027|NCT02399514|Sleep
108028|NCT02399514|emphysema
108029|NCT02399514|coils
108030|NCT02399514|lung volume reduction
108031|NCT02399501|2D ultrasound
108032|NCT02399501|3D ultrasound
108033|NCT02399501|sonohysterography
108034|NCT02399501|hysteroscopy
108035|NCT02399501|Uterine factor of infertility
108036|NCT02399475|Levothyroxine
108037|NCT02399475|Liothyronine
108038|NCT02399475|Thyrotropin Releasing Hormone
108039|NCT02399475|Aging
108040|NCT02399475|Hypothyroidism
108041|NCT02399475|Thyroid diseases
108042|NCT02399449|iron
108043|NCT02399449|pharmacokinetics
108044|NCT02399436|Community-Based Participatory Research
108045|NCT02399436|Community-Institutional Relations
108046|NCT02399423|diabetes
108047|NCT02399423|metabolism
108048|NCT02399423|cardiovascular disease
108049|NCT02399423|weight gain
108050|NCT02399423|weight loss
108051|NCT02399423|european
108052|NCT02399423|south asian
108053|NCT02399423|obesity
108054|NCT02399410|cytoreductive surgery
108055|NCT02399410|hipec
108056|NCT02399410|perioperative chemotherapy
108057|NCT02399410|peritoneal carcinomatosis
108058|NCT02399410|bevacizumab
108059|NCT02399410|colorectal surgery
108060|NCT02399384|Cardiac Magnetic Resonance (CMR)
108061|NCT02399358|Drug induced Hyponatremia
108062|NCT02399358|Cyclophosphamide
108063|NCT02399358|Hyponatremia
108064|NCT02399358|Cyclophosphamide induced Hyponatremia
108065|NCT02399345|Treatment naive
108066|NCT02399345|Hepatitis C Genotype 1
108067|NCT02399319|anterior pelvic ring
108068|NCT02399319|symphysis disruption
108069|NCT02399293|Cognitive training
108070|NCT02399293|Cognitive rehabilitation
108071|NCT02399293|Acquired brain injury
108072|NCT02399293|N-back
108073|NCT02399293|Visual Search
108074|NCT02399293|Cognitive transfer
108075|NCT02399280|Meal pattern
108076|NCT02399280|weight loss
108077|NCT02399280|high caloric intake
108078|NCT02399280|Dinner
108079|NCT02399280|Lunch
108080|NCT02399267|mechanical ventilation
108081|NCT02399267|weaning
108082|NCT02399267|critically ill
108083|NCT02399267|spontaneous breathing trial
108084|NCT02399267|screening
108085|NCT02399267|invasive ventilation
108086|NCT02399267|SBT technique
108087|NCT02399254|Pulmonary Rehabilitation
108088|NCT02399228|radiation therapy
108089|NCT02399228|chemotherapy
108090|NCT02399228|head and neck cancer
108091|NCT02399202|Renal impairment, osilodrostat, LCI699
108092|NCT02399189|Primary central nervous system lymphoma
108093|NCT02399189|rituximab
108094|NCT02399189|Methotrexate and Temozolomide
108095|NCT02399189|autologous stem cell transplantation
108096|NCT02399189|Carmustine and thiotepa
108097|NCT02399176|Osteoporosis
108098|NCT02399176|Yoga
108099|NCT02399150|acute abdomen
108100|NCT02399150|Pain
108101|NCT02399150|stress biomarker
108102|NCT02399137|Pancreatic Cancer
108103|NCT02399137|Front-line Pancreatic Cancer
108104|NCT02399137|Metastatic Pancreatic Cancer
108105|NCT02399137|Gemcitabine
108106|NCT02399137|Nab-paclitaxel
108107|NCT02399137|Abraxane
108108|NCT02399137|Free IGF-1
108109|NCT02399137|Heregulin
108110|NCT02399124|RCC
108111|NCT02399124|Renal Cell Carcinoma
108112|NCT02399124|Kidney tumors
108113|NCT02399111|Prevena Incision Management System (PIMS)
108114|NCT02399111|Surgical Site Infection (SSI)
108115|NCT02399085|DLBCL
108116|NCT02399085|CD19
108117|NCT02399085|monoclonal antibody
108118|NCT02399085|MOR00208
108119|NCT02399085|MOR208
108120|NCT02399059|recurrence
108121|NCT02399033|Xihuang Capsules
108122|NCT02399033|hepatocellular carcinoma
108123|NCT02399033|Recurrence
108124|NCT02399033|hepatectomy
108125|NCT02398994|Clinical Trials Unit
108126|NCT02398994|Pediatric
108127|NCT02398968|Iron
108128|NCT02398968|RURTIs
108129|NCT02398968|CARIFS
108130|NCT02398968|children
108131|NCT02398955|Drug-Eluting Stents
108132|NCT02398955|Coronary Artery Disease
108133|NCT02398955|Sirolimus
108134|NCT02398955|Absorbable Implants
108135|NCT02398903|Morbid obesity
108136|NCT02398903|bariatric surgery
108137|NCT02398903|sleeve gastrectomy
108138|NCT02398903|Roux-en-Y gastric bypass
108139|NCT02398903|hormonal contraception
108140|NCT02398903|combined oral contraceptive
108141|NCT02398903|progestin contraceptive desogestrel
108142|NCT02398903|pharmacokinetics
108143|NCT02398825|Chronic myeloid leukemia
108144|NCT02398825|Chronic phase
108145|NCT02398825|Adults
108146|NCT02398825|Ponatinib
108147|NCT02398825|Imatinib resistant
108148|NCT02398760|Low Back Pain
108149|NCT02398760|Clinical Instability
108150|NCT02398760|Motor Control Exercises
108151|NCT02398760|Clinical Tests
108152|NCT02398734|sonolysis
108153|NCT02398734|carotid endarterectomy
108154|NCT02398734|stroke prevention
108155|NCT02398734|brain infarction
108156|NCT02398721|FNAC
108157|NCT02398721|Small Incidental Thyroid Nodules
108158|NCT02398708|Hematopoietic Stem Cell Transplantation
108159|NCT02398708|Graft versus Host Disease
108160|NCT02398695|Plaque
108161|NCT02398695|Saliva
108162|NCT02398695|Caries
108163|NCT02398682|electronic alerts
108164|NCT02398682|acute kidney injury
108165|NCT02398682|NHS
108166|NCT02398682|mortality
108167|NCT02398669|Obesity
108168|NCT02398669|Lorcaserin hydrochloride
108169|NCT02398669|APD356
108170|NCT02398669|Pediatric
108171|NCT02398669|Pharmacokinetics
108172|NCT02398656|Minor Ischemic Stroke
108173|NCT02398643|Acute Exacerbation of COPD
108174|NCT02398643|COPD
108175|NCT02398643|Emphysema
108176|NCT02398643|Chronic Bronchitis
108177|NCT02398630|Histerosalpingography
108178|NCT02398630|MRI
108179|NCT02398630|Magnetic Resonance Imaging
108180|NCT02398630|HSG
108181|NCT02398630|Diagnostico Maipu
108182|NCT02398630|Imaging
108183|NCT02398630|Carrascosa Patricia
108184|NCT02398617|Heart Failure
108185|NCT02398617|End of Life Care
108186|NCT02398617|Decision Making
108187|NCT02398604|Pediatrics
108188|NCT02398604|HLHS
108189|NCT02398591|Healthy
108190|NCT02398591|JNJ 53718678
108191|NCT02398552|metastatic renal cell carcinoma
108192|NCT02398552|sunitinib
108193|NCT02398552|schedule 2weeks on/1 week off
108194|NCT02398526|Observational study
108195|NCT02398526|Bone metastases
108196|NCT02398526|Hormone Refractory Prostatic Cancer
108197|NCT02398526|Xofigo
108198|NCT02398526|Radium-223
108199|NCT02398500|First-in-human
108200|NCT02398500|anti-VEGF
108201|NCT02398500|neovascular AMD (nvAMD)
108202|NCT02398435|Auto-inflammatory disease
108203|NCT02398435|Still's disease
108204|NCT02398435|Arthritis Rheumatoid
108205|NCT02398435|IL-18
108206|NCT02398435|interleukin-18
108207|NCT02398435|IL-18 binding protein
108208|NCT02398422|Autonomic nervous system
108209|NCT02398422|Auditory processing disorder
108210|NCT02398422|Social behavior
108211|NCT02398409|stroke
108212|NCT02398409|Injury, Brain, Traumatic
108213|NCT02398409|Family Caregivers
108214|NCT02398409|TBI (Traumatic Brain Injury)
108215|NCT02398409|Informal Caregivers
108216|NCT02398370|ED
108217|NCT02398357|anticoagulation
108218|NCT02398357|Zelen-designed randomized controlled trial
108219|NCT02398331|Spinal cord injuries
108220|NCT02398331|Sexual function
108221|NCT02398331|Sexual response
108222|NCT02398331|Sexuality
108223|NCT02398331|Women
108224|NCT02398318|neurosurgery
108225|NCT02398318|deep brain stimulation
108226|NCT02398318|exposure response prevention
108227|NCT02398305|Cardiac catheterisation
108228|NCT02398305|Radial access
108229|NCT02398305|Compression
108230|NCT02398305|Terumo TR Band
108231|NCT02398305|radial artery
108232|NCT02398305|diagnostic
108233|NCT02398279|schizophrenia
108234|NCT02398279|L-Arginine
108235|NCT02398279|nitric oxide
108236|NCT02398279|drug augmentation
108237|NCT02398253|weight maintenance
108238|NCT02398253|cognitive behavior therapy
108239|NCT02398253|successful weight loss
108240|NCT02398227|Battered Women
108241|NCT02398227|Trauma
108242|NCT02398227|Domestic Violence
108243|NCT02398214|Sleep
108244|NCT02398214|Infants
108245|NCT02398214|Toddlers
108246|NCT02398214|Behavioral intervention
108247|NCT02398175|Pediatric polytrauma
108248|NCT02398175|thoracic injuries
108249|NCT02398162|Scrub Typhus in Pediatric
108250|NCT02398162|Immunology
108251|NCT02398136|intervention
108252|NCT02398136|ketamine
108253|NCT02398136|PTSD
108254|NCT02398136|treatment
108255|NCT02398136|posttraumatic stress disorder
108256|NCT02398123|Transversus Abdominis Plane
108257|NCT02398123|caudal block
108258|NCT02398123|postoperative pain
108259|NCT02398123|children
108260|NCT02398084|mastication
108261|NCT02398084|cashews
108262|NCT02398084|walnuts
108263|NCT02398084|participants
108264|NCT02398071|Positive Expiratory Pressure
108265|NCT02398071|Exercise Recovery
108266|NCT02398071|COPD
108267|NCT02398058|trabectedin
108268|NCT02398058|olaparib
108269|NCT02398058|sarcoma
108270|NCT02398058|bone tumor
108271|NCT02398045|Obsessive-compulsive disorder
108272|NCT02398045|cognitive behavioural therapy
108273|NCT02398045|computerised
108274|NCT02398032|sleep apnea
108275|NCT02398032|hypertension
108276|NCT02398032|mechanosensitivity
108277|NCT02398032|chemosensitivity
108278|NCT02398032|adhesion factors
108279|NCT02398019|CPB
108280|NCT02398019|OXIRIS®
108281|NCT02398019|SIRS
108282|NCT02398019|AKI
108283|NCT02398019|Cytokines
108284|NCT02398019|LPS
108285|NCT02398006|Clavicle [mh]
108286|NCT02398006|Fracture Healing [mh]
108287|NCT02398006|Fractures, Bone [mh]
108288|NCT02398006|Treatment outcome [mh]
108289|NCT02398006|Conservative treatment [tw]
108290|NCT02397980|Caregivers
108291|NCT02397967|NF1
108292|NCT02397967|children
108293|NCT02397967|reading disabilities
108294|NCT02397954|idiopathic polypoidal choroidal vasculopathy
108295|NCT02397954|IPCV
108296|NCT02397954|Zimura®
108297|NCT02397954|Avastin®
108298|NCT02397954|Eylea®
108299|NCT02397954|Lucentis®
108300|NCT02397928|Malignant Pleural Mesothelioma
108301|NCT02397928|Treatment
108302|NCT02397928|Minimal toxicity
108303|NCT02397928|TTFields
108304|NCT02397928|Tumor Treating Fields
108305|NCT02397928|Novocure
108306|NCT02397928|Pemetrexed
108307|NCT02397928|Carboplatin
108308|NCT02397928|Cisplatin
108309|NCT02397915|Nasal Spray
108310|NCT02397915|Fluticasone Furoate
108311|NCT02397915|Attributes
108312|NCT02397915|Single Dose
108313|NCT02397915|Allergic Rhinitis
108314|NCT02397915|Mometasone Furoate
108315|NCT02397915|Questionnaire
108316|NCT02397915|Preference
108317|NCT02397889|posttraumatic stress disorder
108318|NCT02397889|PTSD
108319|NCT02397889|ketamine
108320|NCT02397889|trauma
108321|NCT02397889|treatment
108322|NCT02397889|New York
108323|NCT02397889|NYC
108324|NCT02397876|Food Allergy
108325|NCT02397876|Cows Milk Allergy
108326|NCT02397850|depression, chronic, psychotherapy, telephone, feasibility
108327|NCT02397837|Bipolar Disorder
108328|NCT02397837|Cognition
108329|NCT02397785|chronic pelvic pain
108330|NCT02397785|electrical stimulation
108331|NCT02397785|pelvic floor rehabilitation
108332|NCT02397785|neuromodulation
108333|NCT02397772|Soil-transmitted helminths
108334|NCT02397772|Intestinal Nematodes
108335|NCT02397772|Hookworm
108336|NCT02397772|Ascaris
108337|NCT02397772|Mass Treatment
108338|NCT02397772|Kenya
108339|NCT02397746|osteoarthritis
108340|NCT02397746|avascular necrosis
108341|NCT02397746|ankylosis
108342|NCT02397746|protrusio acetabuli
108343|NCT02397746|rheumatoid arthritis
108344|NCT02397746|correction of functional deformity
108345|NCT02397746|revision procedures
108346|NCT02397720|Leukemia
108347|NCT02397720|Acute myeloid leukemia
108348|NCT02397720|AML
108349|NCT02397720|Refractory/ relapsed
108350|NCT02397720|5-azacytidine
108351|NCT02397720|Azacitidine
108352|NCT02397720|5-aza
108353|NCT02397720|Vidaza
108354|NCT02397720|5-AZC
108355|NCT02397720|AZA-CR
108356|NCT02397720|Ladakamycin
108357|NCT02397720|NSC-102816
108358|NCT02397720|Azacytidine
108359|NCT02397720|Nivolumab
108360|NCT02397720|BMS-936558
108361|NCT02397720|Phone calls
108362|NCT02397694|Adult
108363|NCT02397694|HIV
108364|NCT02397694|naive
108365|NCT02397655|stroke
108366|NCT02397655|ischemia
108367|NCT02397655|atherosclerosis
108368|NCT02397655|ultrasonography
108369|NCT02397590|Fimasartan
108370|NCT02397564|scar
108371|NCT02397564|ICD-10 CM:L90.5
108372|NCT02397538|Fimasartan
108373|NCT02397447|Momordica Charantia
108374|NCT02397447|Insulin secretion
108375|NCT02397447|Insulin sensitivity
108376|NCT02397434|assessment of QOL (EORTC QLQ-C30)
108377|NCT02397421|Heart failure
108378|NCT02397421|Diabetes
108379|NCT02397421|Left ventricular remodelling
108380|NCT02397421|SGLT-2 inhibitors
108381|NCT02397395|Renal Impairment
108382|NCT02397395|End-stage Renal Disease
108383|NCT02397395|Simeprevir
108384|NCT02397395|Daclatasvir
108385|NCT02397382|Psoriasis
108386|NCT02397382|Guselkumab
108387|NCT02397382|Cytochromes P450
108388|NCT02397369|Education and evaluate post intervention KAP
108389|NCT02397356|ketamine
108390|NCT02397343|Reduction of secondary hyperalgesia and/-or local inflammation
108391|NCT02397304|Intra-muscular triglyceride use
108392|NCT02397291|Pregnancy
108393|NCT02397291|IUGR
108394|NCT02397265|Type 1 diabetes
108395|NCT02397265|Hypoglycaemia
108396|NCT02397265|Closed loop insulin pump
108397|NCT02397265|Artificial pancreas
108398|NCT02397265|Exercise
108399|NCT02397265|Mixed meals
108400|NCT02397265|Bihormonal pump
108401|NCT02397252|Human Papillomavirus
108402|NCT02397252|Screening
108403|NCT02397252|Self-collection test
108404|NCT02397252|Pap test
108405|NCT02397226|Radiofrequency ablation
108406|NCT02397226|Plethysmography
108407|NCT02397226|Duplex ultrasound
108408|NCT02397226|High ligation/stripping
108409|NCT02397213|Ciclosporin
108410|NCT02397213|Acute Kidney injury
108411|NCT02397213|Cardiac surgery
108412|NCT02397213|Ischemia
108413|NCT02397213|Safety
108414|NCT02397213|Cystatin C
108415|NCT02397200|Growth
108416|NCT02397200|low weight
108417|NCT02397200|low height
108418|NCT02397200|Nutritional Supplementation
108419|NCT02397174|Polycystic Ovary syndrome
108420|NCT02397174|hypocaloric diet
108421|NCT02397174|Ovarian Cysts
108422|NCT02397174|Ovarian Diseases
108423|NCT02397174|Obesity
108424|NCT02397174|Mediterranean Diet
108425|NCT02397135|genomic markers
108426|NCT02397083|Endometrial Cancer
108427|NCT02397083|Endometrial hyperplasia
108428|NCT02397083|Intrauterine device
108429|NCT02397083|IUD
108430|NCT02397083|Levonorgestrel intrauterine device
108431|NCT02397083|LIUD
108432|NCT02397083|Mirena
108433|NCT02397083|Everolimus
108434|NCT02397083|Afinitor
108435|NCT02397083|Zortress
108436|NCT02397083|RAD001
108437|NCT02397083|Questionnaires
108438|NCT02397083|Survey
108439|NCT02397083|Quality of life
108440|NCT02397083|QOL
108441|NCT02397070|Jaw exercise
108442|NCT02397070|Occlusal splint
108443|NCT02397070|Treatment
108444|NCT02397070|Muscular pain
108445|NCT02397070|Mandibular movement
108446|NCT02397044|Implants, stability, loading
108447|NCT02397031|borderline personality disorder
108448|NCT02397031|mindfulness
108449|NCT02397018|stroke
108450|NCT02397018|cord blood
108451|NCT02397018|umbilical cord blood
108452|NCT02397018|hematopoietic stem cells
108453|NCT02397018|acute ischemic stroke
108454|NCT02396992|Oropharyngeal Dysphagia
108455|NCT02396992|Aspiration pneumonia
108456|NCT02396992|Malnutrition
108457|NCT02396992|Oral Health
108458|NCT02396992|Bacterial colonization
108459|NCT02396992|Aging
108460|NCT02396940|3D
108461|NCT02396940|Three-dimensional
108462|NCT02396940|Laparoscopy
108463|NCT02396940|Inguinal hernia repair
108464|NCT02396927|3D
108465|NCT02396927|Three-dimensional
108466|NCT02396927|laparoscopy
108467|NCT02396927|cholecystectomy
108468|NCT02396901|early goal direct therapy
108469|NCT02396901|preventive strategies
108470|NCT02396901|cardiac surgery
108471|NCT02396888|Blood vessel
108472|NCT02396888|Fibroplasia
108473|NCT02396888|Wound healing
108474|NCT02396888|Insulin
108475|NCT02396836|Hand hygiene
108476|NCT02396836|Hand decontamination
108477|NCT02396836|Microbial load
108478|NCT02396836|Hand coverage
108479|NCT02396836|Glove juice technique
108480|NCT02396836|Ayliffe technique
108481|NCT02396836|6 step technique
108482|NCT02396823|Blood pressure regulation
108483|NCT02396823|Respiratory Muscle Training
108484|NCT02396797|Sick leave
108485|NCT02396797|Mental Health
108486|NCT02396797|Coping
108487|NCT02396797|Social Support
108488|NCT02396797|Subjective Health Complaints
108489|NCT02396784|child overweight
108490|NCT02396784|child obesity
108491|NCT02396784|prevention
108492|NCT02396784|targeted intervention
108493|NCT02396784|development of overweight
108494|NCT02396771|Uterine
108495|NCT02396771|Massage
108496|NCT02396771|Compression
108497|NCT02396732|Aspirin
108498|NCT02396732|Enoxaparin
108499|NCT02396732|Thromboprophylaxis
108500|NCT02396732|Trauma
108501|NCT02396732|Venous thromboembolism
108502|NCT02396693|Newborn
108503|NCT02396693|non invasive ventilation
108504|NCT02396680|Ragweed Allergy
108505|NCT02396680|Rhinoconjunctivitis
108506|NCT02396680|Immunotherapy
108507|NCT02396680|Ragweed-SPIRE
108508|NCT02396641|Best Supportive Care
108509|NCT02396628|Graft-versus-Host Disease (GvHD)
108510|NCT02396628|resistance to therapy
108511|NCT02396628|allogeneic stem cell transplantation
108512|NCT02396628|Ruxolitinib
108513|NCT02396615|Ad libitum energy intake
108514|NCT02396615|Appetite
108515|NCT02396589|stroke rehabilitation
108516|NCT02396589|barriers to independence
108517|NCT02396589|environmental support
108518|NCT02396550|Expectations
108519|NCT02396537|Children
108520|NCT02396537|Midazolam
108521|NCT02396537|Lidocaine
108522|NCT02396537|Intranasal
108523|NCT02396524|Chronic Disease
108524|NCT02396524|Lifestyle Intervention
108525|NCT02396524|Health Promotion
108526|NCT02396524|Sport Mentorship
108527|NCT02396524|Men
108528|NCT02396524|Health Technology
108529|NCT02396524|Prevention
108530|NCT02396524|Exercise
108531|NCT02396524|Diet
108532|NCT02396472|social support
108533|NCT02396459|Triac
108534|NCT02396459|MCT8
108535|NCT02396459|Allan-Herndon-Dudley Syndrome
108536|NCT02396433|Halaven
108537|NCT02396433|BRCA
108538|NCT02396433|E7449
108539|NCT02396420|BPH
108540|NCT02396420|prostatic hyperplasia
108541|NCT02396420|enlarged prostate
108542|NCT02396420|benign prostatic hypertrophy
108543|NCT02396407|Chlorine water treatment
108544|NCT02396407|Point-of-use water treatment
108545|NCT02396407|Household water treatment with safe storage
108546|NCT02396407|Handwashing with soap
108547|NCT02396407|Hand hygiene
108548|NCT02396407|Latrines
108549|NCT02396407|Child potties
108550|NCT02396407|Intestinal parasitic infection
108551|NCT02396407|Soil-transmitted helminths
108552|NCT02396407|Water
108553|NCT02396407|Sanitation
108554|NCT02396407|Handwashing
108555|NCT02396407|Diarrhea
108556|NCT02396407|Herd immunity
108557|NCT02396407|Helminths
108558|NCT02396394|HIV
108559|NCT02396394|ART Adherence
108560|NCT02396394|Retention in Care
108561|NCT02396394|Pregnant Women
108562|NCT02396394|Postpartum Women
108563|NCT02396381|Candidate modified risk tobacco product
108564|NCT02396381|Conventional cigarette
108565|NCT02396381|Exposure response
108566|NCT02396381|Smoking
108567|NCT02396381|Tobacco Heating System
108568|NCT02396368|Prostate cancer
108569|NCT02396368|Bone metastatic Castration-Resistant Prostate Cancer
108570|NCT02396368|Radium 223
108571|NCT02396368|Tasquinimod
108572|NCT02396355|flow cytometry
108573|NCT02396342|Hemophilia B, gene therapy
108574|NCT02396303|General: To compare Carbetocin and Oxytocin for the control of PPH.
108575|NCT02396290|acne scar
108576|NCT02396290|fractional carbon dioxide laser
108577|NCT02396290|platelet rich plasma
108578|NCT02396264|Mediterranean Diet
108579|NCT02396264|Ovarian Cysts
108580|NCT02396264|Treatment
108581|NCT02396264|Ovarian Diseases
108582|NCT02396264|normocaloric diet
108583|NCT02396225|voriconazole
108584|NCT02396225|inhalation
108585|NCT02396225|aerosol
108586|NCT02396225|epithelial lining fluid
108587|NCT02396225|concentration
108588|NCT02396225|pharmacokinetic
108589|NCT02396199|Abdominal aortic aneurysm
108590|NCT02396199|Endovascular
108591|NCT02396199|Juxtarenal
108592|NCT02396199|Pararenal
108593|NCT02396199|Fenestrated
108594|NCT02396173|disability
108595|NCT02396173|vocational
108596|NCT02396173|rehabilitation
108597|NCT02396173|prediction
108598|NCT02396160|overactive bladder
108599|NCT02396160|urinary incontinence
108600|NCT02396160|nocturia
108601|NCT02396160|urinary frequency
108602|NCT02396147|Drug therapy
108603|NCT02396095|female
108604|NCT02396095|cancer
108605|NCT02396082|care coordination
108606|NCT02396082|quality of life
108607|NCT02396082|community-based
108608|NCT02396082|care quality
108609|NCT02396082|Long term care placement
108610|NCT02396082|memory care
108611|NCT02396082|Neuropsychiatric behaviors
108612|NCT02396056|Guided Bone Regeneration
108613|NCT02396056|Gingival Mesenchymal Stem Cells
108614|NCT02395991|gadoxetic acid
108615|NCT02395991|transient dyspnea
108616|NCT02395965|Osteopathic manipulative medicine
108617|NCT02395965|Osteopathic manipulative treatment
108618|NCT02395952|cornea
108619|NCT02395952|epithelial defect
108620|NCT02395952|amniotic membrane
108621|NCT02395939|Cryobiopsy
108622|NCT02395939|Radial EBUS
108623|NCT02395939|Guide Sheath
108624|NCT02395939|Peripheral pulmonary lesions
108625|NCT02395887|Spinal stenosis
108626|NCT02395887|Spinal decompression
108627|NCT02395887|Postural balance
108628|NCT02395887|Neurogenic claudication
108629|NCT02395848|recurrent
108630|NCT02395848|infection
108631|NCT02395835|body mass index
108632|NCT02395835|methylation
108633|NCT02395835|PPAR gamma
108634|NCT02395835|pregnancy
108635|NCT02395822|AML
108636|NCT02395822|Relapsed
108637|NCT02395822|Refractory
108638|NCT02395796|epidural
108639|NCT02395796|labor analgesia
108640|NCT02395796|pressure monitoring
108641|NCT02395783|Preterm infants
108642|NCT02395783|diagnosis of cerebral white matter injury
108643|NCT02395770|Shoulder
108644|NCT02395770|Rotator cuff
108645|NCT02395770|Rehabilitation
108646|NCT02395770|Motor control
108647|NCT02395757|Age Related Macular Degeneration (AMD)
108648|NCT02395757|Microperimetry
108649|NCT02395757|Diagnostic
108650|NCT02395731|dual eligible
108651|NCT02395731|care coordination
108652|NCT02395731|community-based
108653|NCT02395731|care quality
108654|NCT02395731|care needs
108655|NCT02395731|health services
108656|NCT02395731|care management
108657|NCT02395731|low income
108658|NCT02395731|Neuropsychiatric behaviors
108659|NCT02395718|elderly
108660|NCT02395718|quick diagnostic unit
108661|NCT02395718|short stay unit
108662|NCT02395718|randomised controlled trial
108663|NCT02395679|Dendritic cell-based immunotherapy
108664|NCT02395666|Neuroblastoma in remission
108665|NCT02395666|Relapsed Neuroblastoma
108666|NCT02395666|Refractory Neuroblastoma
108667|NCT02395653|Pediatric
108668|NCT02395653|Postoperative
108669|NCT02395653|Pain Management
108670|NCT02395627|Hormone Therapy Resistant
108671|NCT02395627|Estrogen Receptor-Positive
108672|NCT02395627|Estrogen Receptor-Negative
108673|NCT02395614|tissue expander
108674|NCT02395614|breast reconstruction
108675|NCT02395601|B-Cell Lymphoma
108676|NCT02395601|EZH2 Inhibitor
108677|NCT02395601|Phase 1
108678|NCT02395497|Penile Transplant
108679|NCT02395497|VCA
108680|NCT02395497|CTA
108681|NCT02395497|Penis
108682|NCT02395497|Amputation
108683|NCT02395497|Immunosuppression
108684|NCT02395497|Composite Tissue
108685|NCT02395497|Male
108686|NCT02395497|Humans
108687|NCT02395497|Allotransplantation
108688|NCT02395458|Sequential therapy
108689|NCT02395458|Triple therapy
108690|NCT02395458|Eradication
108691|NCT02395393|Acute rejection
108692|NCT02395393|Chronic rejection
108693|NCT02395393|Confocal microscopy
108694|NCT02395380|CRP
108695|NCT02395380|Postoperative complication
108696|NCT02395380|Length of stay
108697|NCT02395367|Prognosis
108698|NCT02395367|Risk Factors
108699|NCT02395354|Endoscopic treatment
108700|NCT02395354|Stenosis
108701|NCT02395354|Crohn's Disease
108702|NCT02395354|balloon dilatation
108703|NCT02395354|self-expanding metallic stent
108704|NCT02395354|chronic transmural inflammation
108705|NCT02395354|steady narrowing of the intestinal lumen
108706|NCT02395341|reproductive hormones
108707|NCT02395341|cancer survivors
108708|NCT02395341|endocrine function
108709|NCT02395341|antral follicle counts
108710|NCT02395341|female infertility due to diminished ovarian reserve
108711|NCT02395341|perimenopause
108712|NCT02395341|premature menopause
108713|NCT02395328|Orphans and vulnerable children (OVC)
108714|NCT02395328|Home visiting intervention
108715|NCT02395328|South Africa
108716|NCT02395328|Program evaluation
108717|NCT02395315|Diabetes Mellitus
108718|NCT02395315|Osseointegration
108719|NCT02395315|Bone vascularity
108720|NCT02395315|Primary implant stability
108721|NCT02395289|Cognitive-Based Compassion Training (CBCT)
108722|NCT02395289|HIV-related clinical outcomes
108723|NCT02395289|Stress and stress-related psychological adjustment
108724|NCT02395289|Stress-related inflammatory biomarkers
108725|NCT02395276|Congenital Heart Defects
108726|NCT02395276|Hypoxic Ischemic Brain Injury
108727|NCT02395276|Hypothermia Therapy
108728|NCT02395276|Pediatrics
108729|NCT02395237|Fed Conditions
108730|NCT02395224|Follow-up studies
108731|NCT02395224|Prognosis
108732|NCT02395224|Palliative care
108733|NCT02395224|Chemotherapy, adjuvant
108734|NCT02395224|Cost-benefit analysis
108735|NCT02395224|Population
108736|NCT02395224|Antineoplastic agents/Adverse effects
108737|NCT02395224|Terminal care
108738|NCT02395224|Medical futility
108739|NCT02395224|Survival rate
108740|NCT02395224|Norway
108741|NCT02395198|hepatitis c virus
108742|NCT02395198|opioid substitution treatment
108743|NCT02395172|avelumab
108744|NCT02395172|MSB0010718C
108745|NCT02395172|Non-Small Cell Lung Cancer
108746|NCT02395172|Anti-PD-L1
108747|NCT02395159|vascular surgery patients
108748|NCT02395159|wound management
108749|NCT02395133|Eczema
108750|NCT02395120|Dental Care
108751|NCT02395120|Caregiver Illness Perception
108752|NCT02395120|Common Sense Model of Self-Regulation
108753|NCT02395120|Dental Access
108754|NCT02395120|Referral letter
108755|NCT02395120|Dental Caries
108756|NCT02395107|Aortic Valve Stenosis
108757|NCT02395107|Functional Capacity
108758|NCT02395107|Cardiomyopathies
108759|NCT02395107|Endomyocardial Fibrosis
108760|NCT02395107|Cardiovascular Diseases
108761|NCT02395107|Heart Diseases
108762|NCT02395107|Heart Valve Diseases
108763|NCT02395107|Atrial Fibrillation
108764|NCT02395107|Hypertrophy
108765|NCT02395107|Hypertrophy, Left Ventricular
108766|NCT02395107|Diastology
108767|NCT02395081|pregnancy
108768|NCT02395081|Mongolia
108769|NCT02395081|Vitamin D
108770|NCT02395081|preeclampsia
108771|NCT02395068|Pharmacokinetics
108772|NCT02395068|Nimotuzumab
108773|NCT02395068|Safety
108774|NCT02395068|Effcacy
108775|NCT02395068|Irinotecan
108776|NCT02395029|PD
108777|NCT02395003|Obesity
108778|NCT02395003|Pediatric
108779|NCT02394977|CPR
108780|NCT02394977|Cardio first angle
108781|NCT02394977|Clinical trial
108782|NCT02394951|chemotherapy
108783|NCT02394938|Music therapy
108784|NCT02394912|vena cava filter
108785|NCT02394899|SCD
108786|NCT02394899|early childhood intervention
108787|NCT02394899|parental stress
108788|NCT02394899|neurocognition
108789|NCT02394873|Deep Second-Degree Burn Wound
108790|NCT02394847|propofol
108791|NCT02394847|electroconvulsive therapy
108792|NCT02394847|anesthesia
108793|NCT02394834|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, Bevacizumab
108794|NCT02394795|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, Bevacizumab
108795|NCT02394782|Multiple sclerosis, relapsing-remitting
108796|NCT02394782|Rebif
108797|NCT02394782|Interferon beta-1a
108798|NCT02394782|RebiSmart®2.0
108799|NCT02394782|MSdialog™
108800|NCT02394769|Colorectal Cancer
108801|NCT02394743|Glomerular Filtration Rate
108802|NCT02394730|HIV, d-dimer, hs-CRP, activated T-lymphocytes
108803|NCT02394704|Rumination
108804|NCT02394704|Sensory processing
108805|NCT02394704|Non-pharmacological intervention
108806|NCT02394704|Depression
108807|NCT02394704|Anxiety
108808|NCT02394704|PTSD
108809|NCT02394665|Glioblastoma
108810|NCT02394665|Gliosarcoma
108811|NCT02394665|GBM
108812|NCT02394626|Recurrent glioblastoma
108813|NCT02394626|Surgery
108814|NCT02394626|Complete resection of enhancing tumor
108815|NCT02394626|Survival
108816|NCT02394626|Quality of life
108817|NCT02394613|Glaucoma
108818|NCT02394613|DARC
108819|NCT02394613|Diagnosis
108820|NCT02394600|rhinitis
108821|NCT02394600|allergy
108822|NCT02394587|mindfulness
108823|NCT02394587|MBSR
108824|NCT02394587|SCD
108825|NCT02394587|experimental
108826|NCT02394548|Locally advanced, inoperable non-small cell lung carcinoma
108827|NCT02394548|Limited stage small cell lung carcinoma
108828|NCT02394548|Acute esophagitis
108829|NCT02394548|Intensity-modulated radiation therapy
108830|NCT02394535|Pancreatic Cancer
108831|NCT02394535|Adenocarcinoma of the pancreas
108832|NCT02394535|Locally Advanced Pancreatic Cancer
108833|NCT02394535|Abraxane
108834|NCT02394535|Nab-Paclitaxel
108835|NCT02394535|Paclitaxel (Protein-Bound)
108836|NCT02394535|ABI-007
108837|NCT02394535|Radiation therapy
108838|NCT02394535|XRT
108839|NCT02394535|Capecitabine
108840|NCT02394535|Xeloda
108841|NCT02394535|Questionnaires
108842|NCT02394535|Surveys
108843|NCT02394522|Malaria
108844|NCT02394522|Spatial Repellents
108845|NCT02394522|Plasmodium
108846|NCT02394509|Epilepsy Memory Problems
108847|NCT02394509|Self-Management
108848|NCT02394496|Fulvestrant
108849|NCT02394496|Lapatinib
108850|NCT02394496|Aromatase Inhibitor
108851|NCT02394496|metastatic breast cancer
108852|NCT02394483|Single ascending dose
108853|NCT02394483|double blind
108854|NCT02394470|congestion
108855|NCT02394470|total body water
108856|NCT02394470|bioimpedentiometry
108857|NCT02394470|lung ultrasound
108858|NCT02394470|diuretics
108859|NCT02394470|dyspnea
108860|NCT02394470|pulmonary B lines
108861|NCT02394470|deuterium
108862|NCT02394457|Postdural puncture headache
108863|NCT02394457|Epidural Blood Patch
108864|NCT02394457|Cosyntropin
108865|NCT02394457|PDPH
108866|NCT02394457|Regional anesthesia
108867|NCT02394457|Lumbar puncture
108868|NCT02394457|ACTH
108869|NCT02394457|Tetracosactin
108870|NCT02394444|Intervention program
108871|NCT02394444|Parenting stress
108872|NCT02394444|Parental mental health
108873|NCT02394444|Preterm infant's development
108874|NCT02394431|Sickle Cell Disease
108875|NCT02394431|Echocardiography
108876|NCT02394431|Speckle tracking
108877|NCT02394392|Medication satisfaction
108878|NCT02394392|Quality of life
108879|NCT02394392|Drug compliance
108880|NCT02394366|Skin oxygenation
108881|NCT02394366|peripheral perfusion
108882|NCT02394353|bariatrics
108883|NCT02394353|transient elastography
108884|NCT02394314|MEDI0382, diabetes
108885|NCT02394301|Efficacy of Novel Drug Combinations for Relief of Psoriasis
108886|NCT02394288|Cardiac Troponin
108887|NCT02394288|Perioperative Period
108888|NCT02394288|surgery
108889|NCT02394262|Biological Markers
108890|NCT02394262|Multidetector Computed Tomography
108891|NCT02394249|Insulin Resistance
108892|NCT02394249|Cognition
108893|NCT02394249|Affect
108894|NCT02394249|Insulin
108895|NCT02394249|Lipids
108896|NCT02394236|exercise training
108897|NCT02394223|Cancer
108898|NCT02394223|Prostate
108899|NCT02394223|PSA
108900|NCT02394223|Biopsies
108901|NCT02394223|FFOCT procedure
108902|NCT02394210|Multiple myeloma asymptomatic relapse symptomatic relapse
108903|NCT02394210|IMW Consensus Panel
108904|NCT02394210|anti-MM therapy
108905|NCT02394197|Plasmodium vivax
108906|NCT02394197|Mexico
108907|NCT02394197|treatment
108908|NCT02394197|chloroquine
108909|NCT02394197|primaquine
108910|NCT02394197|14-day treatment (T14)
108911|NCT02394197|intermittent single doses (ISD)
108912|NCT02394184|transcatheter aortic valve replacement
108913|NCT02394171|Physical Activity
108914|NCT02394171|Social Cohesion
108915|NCT02394171|Intervention Development
108916|NCT02394171|Ethnic Minorities
108917|NCT02394171|Nutrition
108918|NCT02394158|Recurrent Gestational Diabetes Mellitus
108919|NCT02394158|Prevention
108920|NCT02394158|Metformin
108921|NCT02394145|platelet
108922|NCT02394145|ticagrelor
108923|NCT02394145|clopidogrel
108924|NCT02394145|end stage renal disease
108925|NCT02394145|hemodialysis
108926|NCT02394145|genetics
108927|NCT02394132|Lentigo maligna
108928|NCT02394132|Imiquimod
108929|NCT02394132|Radiotherapy
108930|NCT02394054|vasopressin
108931|NCT02394054|intranasal administration
108932|NCT02394054|healthy sample
108933|NCT02394041|acupuncture
108934|NCT02394041|cervical dystocia
108935|NCT02394041|caesarean section
108936|NCT02394041|obstetric labor
108937|NCT02394041|randomized controlled trial
108938|NCT02394015|Platinum-sensitive Recurrent Ovarian Cancer
108939|NCT02394002|EEG, burst-suppression, N20, SEP, median nerve, facilitation
108940|NCT02393911|vestibulitis
108941|NCT02393911|microbiome
108942|NCT02393872|Prevention
108943|NCT02393859|ALL
108944|NCT02393859|High-risk first relapse B-precursor ALL
108945|NCT02393859|Precursor Cell Lymphoblastic Leukemia
108946|NCT02393859|Neoplasms
108947|NCT02393859|Lymphoproliferative Disorders
108948|NCT02393859|Immunoproliferative Disorders
108949|NCT02393859|Antibodies, Bispecific
108950|NCT02393846|ankle sprain
108951|NCT02393846|topical ketoprofen
108952|NCT02393846|non-steroidal anti-inflammatory drug
108953|NCT02393846|emergency department
108954|NCT02393833|Vascular endothelial growth factor (VEGF)
108955|NCT02393833|Vascular cell adhesion molecule-1 (VCAM-1)
108956|NCT02393833|HER2-ECD
108957|NCT02393807|Chronic Obstructive Pulmonary Disease
108958|NCT02393794|BRCA1
108959|NCT02393794|BRCA2
108960|NCT02393794|TNBC
108961|NCT02393781|severe sepsis
108962|NCT02393781|septic shock
108963|NCT02393781|adrenomedullin
108964|NCT02393781|organ dysfunction
108965|NCT02393703|exosomes
108966|NCT02393703|15-015
108967|NCT02393664|Thoracoscopy
108968|NCT02393664|Recovery
108969|NCT02393664|Tracheal intubation
108970|NCT02393638|Endoscopic Sphincterotomy
108971|NCT02393625|NSCLC, ALK-positive
108972|NCT02393586|Tuberculosis
108973|NCT02393586|Whole blood Bactericidal Activity
108974|NCT02393586|WBA
108975|NCT02393586|Faropenem
108976|NCT02393573|Insulin Resistance
108977|NCT02393573|Protein balance
108978|NCT02393573|Surgery
108979|NCT02393573|Post operative complications
108980|NCT02393573|metformin
108981|NCT02393573|Pre-diabetes
108982|NCT02393573|Fasting blood glucose
108983|NCT02393547|obesity
108984|NCT02393534|Primary Care
108985|NCT02393534|Health Services Research
108986|NCT02393534|Telemedicine
108987|NCT02393521|Vibration
108988|NCT02393521|Pressure Pain Threshold
108989|NCT02393521|Trigger Points
108990|NCT02393521|Neck Pain
108991|NCT02393508|transfusion, red blood cell
108992|NCT02393508|transfusion reaction
108993|NCT02393508|quality of life
108994|NCT02393443|oxytocin
108995|NCT02393443|healthy sample
108996|NCT02393443|intranasal administration
108997|NCT02393443|learning
108998|NCT02393417|Verruca vulgaris
108999|NCT02393417|Common Warts
109000|NCT02393378|Drug Therapy
109001|NCT02393365|Hepatitis C
109002|NCT02393365|HCV
109003|NCT02393365|screening
109004|NCT02393352|Body Composition
109005|NCT02393352|Autonomic Nervous System
109006|NCT02393352|Oxygen
109007|NCT02393352|Randomized Controlled Trial
109008|NCT02393300|tranexamic acid
109009|NCT02393300|blood loss
109010|NCT02393300|topical administration
109011|NCT02393300|intravenous administration
109012|NCT02393248|alterations in FGF or FGFR
109013|NCT02393248|squamous non-small cell lung cancer
109014|NCT02393248|gastric cancer
109015|NCT02393248|urothelial cancer
109016|NCT02393248|endometrial cancer
109017|NCT02393248|multiple myeloma
109018|NCT02393248|MPN
109019|NCT02393235|unexplained infertility
109020|NCT02393235|tubal infertility
109021|NCT02393235|pulsatility index
109022|NCT02393235|resistance index
109023|NCT02393235|fertile women
109024|NCT02393222|Dialysis
109025|NCT02393222|Cerebrovascular disease
109026|NCT02393222|ESRD
109027|NCT02393209|Drug therapy
109028|NCT02393196|colloid preloading
109029|NCT02393196|colloid coloading
109030|NCT02393183|Antioxidant
109031|NCT02393183|Graves' ophthalmopathy
109032|NCT02393183|Thyroid eye disease
109033|NCT02393183|Severity score
109034|NCT02393183|Activity score
109035|NCT02393183|Quality of life
109036|NCT02393144|Labor analysis
109037|NCT02393144|Transperineal ultrasound imaging
109038|NCT02393144|Labor curve
109039|NCT02393131|Brain Metastases
109040|NCT02393131|Whole Brain Radiotherapy
109041|NCT02393131|Neurocognitive function
109042|NCT02393118|Assistive technology
109043|NCT02393118|Non-surgical visual prosthetic
109044|NCT02393118|sensory substitution
109045|NCT02393118|BrainPort
109046|NCT02393118|Blindness
109047|NCT02393118|Assistive device
109048|NCT02393105|Breast Cancer
109049|NCT02393079|Traumatic Brain Injury
109050|NCT02393079|Cognitive
109051|NCT02393053|Gingival Recession
109052|NCT02393053|Case-Control Studies
109053|NCT02393053|Adipose Tissue
109054|NCT02393040|Alopecia
109055|NCT02393040|Androgenetic Alopecia
109056|NCT02393040|Alopecia, Male Pattern
109057|NCT02393040|Hair loss
109058|NCT02393040|Platelet-Rich Plasma
109059|NCT02393040|Alopecia, Female Pattern
109060|NCT02393040|placebo
109061|NCT02393040|double-blind
109062|NCT02393014|65 years old or older
109063|NCT02393014|hospitalized in
109064|NCT02393014|geriatrics
109065|NCT02393001|skin cancer
109066|NCT02393001|suspicious lesion
109067|NCT02393001|skin biopsy
109068|NCT02393001|noninvasive
109069|NCT02393001|screening
109070|NCT02392962|proprioception
109071|NCT02392962|countermovement jump
109072|NCT02392962|postural balance
109073|NCT02392949|Spine
109074|NCT02392949|mobilization
109075|NCT02392936|according to the definition of the Comité Technique des Infections Nosocomiales et Liées aux Soins (2007)
109076|NCT02392923|health related quality of life
109077|NCT02392910|Iron Sucrose
109078|NCT02392910|Mortality
109079|NCT02392910|Hospitalization
109080|NCT02392897|meal frequency
109081|NCT02392897|eating frequency
109082|NCT02392897|ingestive frequency
109083|NCT02392897|Positive energy balance
109084|NCT02392897|Satiation
109085|NCT02392884|Human Immunodeficiency Virus
109086|NCT02392884|Acquired Immunodeficiency Syndrome
109087|NCT02392884|Cognitive Rehabilitation
109088|NCT02392884|Minority Health
109089|NCT02392884|Vulnerable Populations
109090|NCT02392884|Underserved, Patients
109091|NCT02392884|Medication Adherence
109092|NCT02392884|Medication Compliance
109093|NCT02392884|Medication Non-compliance
109094|NCT02392884|Medication Persistence
109095|NCT02392884|Medication Non-Adherence
109096|NCT02392871|Metastatic melanoma
109097|NCT02392871|Palliative radiotherapy
109098|NCT02392845|Drug combination
109099|NCT02392845|Accelerated chemotherapy
109100|NCT02392845|Mathematical model
109101|NCT02392845|Hematotoxicity
109102|NCT02392845|Individualized dosage
109103|NCT02392832|long-lasting microbial larvicide
109104|NCT02392832|intervention
109105|NCT02392832|cluster randomised controlled trial
109106|NCT02392832|Anopheles mosquito
109107|NCT02392806|Continuous positive airway pressure
109108|NCT02392806|CPAP
109109|NCT02392806|Bubble CPAP
109110|NCT02392806|Extubation failure
109111|NCT02392806|Preterm infant
109112|NCT02392767|L-Arginine
109113|NCT02392767|Pycnogenol
109114|NCT02392767|vitamin K2
109115|NCT02392767|vitamin B
109116|NCT02392767|endothelial function
109117|NCT02392767|hypertension
109118|NCT02392767|Homocystein >10
109119|NCT02392754|Screening
109120|NCT02392754|Atrial Fibrillation
109121|NCT02392754|ECG
109122|NCT02392754|Primary care
109123|NCT02392741|Physical Activity
109124|NCT02392741|Microcirculation
109125|NCT02392741|Pregnancy Outcome
109126|NCT02392741|Obesity
109127|NCT02392741|Pregnancy
109128|NCT02392715|Inspiratory muscle training
109129|NCT02392715|General exercise training
109130|NCT02392715|pulmonary rehabilitation
109131|NCT02392715|chronic obstructive pulmonary disease
109132|NCT02392702|Subjects
109133|NCT02392702|Safety/Efficacy Study
109134|NCT02392702|Randomized
109135|NCT02392702|Open Label
109136|NCT02392689|procalcitonin
109137|NCT02392689|biomarker
109138|NCT02392689|antibiotic therapy
109139|NCT02392689|emergency department
109140|NCT02392689|cardiology
109141|NCT02392689|in vitro diagnostics
109142|NCT02392676|Ovarian cancer
109143|NCT02392676|Platinum
109144|NCT02392676|Somatic BRCA mutation
109145|NCT02392676|Homologous recombination repair
109146|NCT02392663|Sputum clearance
109147|NCT02392663|Cough severity
109148|NCT02392663|Hypertonic saline
109149|NCT02392663|Acid hyaluronic
109150|NCT02392663|Tolerability
109151|NCT02392637|Biliary Tract Cancer
109152|NCT02392637|Intrahepatic cholangiocarcinoma
109153|NCT02392637|Extrahepatic cholangiocarcinoma,
109154|NCT02392637|Gallbladder cancer
109155|NCT02392637|Metastatic
109156|NCT02392637|Unresectable
109157|NCT02392637|Abraxane
109158|NCT02392637|Nab-Paclitaxel
109159|NCT02392637|Paclitaxel (Protein-Bound)
109160|NCT02392637|ABI-007
109161|NCT02392637|Cisplatin
109162|NCT02392637|Platinol-AQ
109163|NCT02392637|Platinol
109164|NCT02392637|CDDP
109165|NCT02392637|Gemcitabine
109166|NCT02392637|Gemcitabine Hydrochloride
109167|NCT02392637|Gemzar
109168|NCT02392637|Phone calls
109169|NCT02392611|Estrogen Receptor Positive Breast Cancer
109170|NCT02392585|Leiomyoma of uterus
109171|NCT02392585|Hemostasis, Surgical
109172|NCT02392585|Prevention of Surgical Blood Loss
109173|NCT02392585|mechanical uterine tourniquet
109174|NCT02392572|Leukemia
109175|NCT02392572|Acute myelogenous leukemia
109176|NCT02392572|AML
109177|NCT02392572|Myelodysplastic syndrome
109178|NCT02392572|MDS
109179|NCT02392572|Acute lymphoblastic leukemia
109180|NCT02392572|ALL
109181|NCT02392572|Relapsed
109182|NCT02392572|Refractory
109183|NCT02392572|ONC201
109184|NCT02392559|Hypercholesterolemia
109185|NCT02392559|Elevated Cholesterol
109186|NCT02392559|High Cholesterol
109187|NCT02392559|Heterozygous Familial Hypercholesterolemia
109188|NCT02392559|PCSK9 mutations
109189|NCT02392559|Paediatric
109190|NCT02392559|pediatric
109191|NCT02392559|Childhood Familial Hypercholesterolemia
109192|NCT02392533|ultrasound
109193|NCT02392520|severe OHSS
109194|NCT02392520|antagonist administration
109195|NCT02392520|conventional treatment
109196|NCT02392442|Bronchoalveolar Lavage
109197|NCT02392442|Bronchoscopy
109198|NCT02392442|Endotoxin Instillation
109199|NCT02392442|Immunophenotype
109200|NCT02392442|miRNA
109201|NCT02392390|Topical Dynamic Phototherapy
109202|NCT02392390|Microbiota
109203|NCT02392351|Hypertension
109204|NCT02392351|Renal Denervation
109205|NCT02392338|Atrial fibrillation
109206|NCT02392338|Ablation
109207|NCT02392338|Hybrid
109208|NCT02392312|kidney transplant
109209|NCT02392312|ATG-F
109210|NCT02392286|Corticosteroid
109211|NCT02392273|migraine
109212|NCT02392273|cluster headache
109213|NCT02392273|primary headache
109214|NCT02392273|Ausanil
109215|NCT02392273|capsicum annuum
109216|NCT02392221|Crohn's disease (CD)
109217|NCT02392221|Pediatric
109218|NCT02392221|Inflammatory Bowel Disease
109219|NCT02392208|telavancin
109220|NCT02392208|end-stage renal disease
109221|NCT02392208|ESRD
109222|NCT02392208|pharmacokinetics
109223|NCT02392208|hemodialysis
109224|NCT02392208|chronic kidney disease
109225|NCT02392208|CKD
109226|NCT02392208|dialysis
109227|NCT02392208|Vibativ
109228|NCT02392195|Plagiocephaly
109229|NCT02392182|lung
109230|NCT02392169|neuroendocrine
109231|NCT02392169|ADHD
109232|NCT02392169|heredity
109233|NCT02392169|cognitive function
109234|NCT02392143|colorectal cancer screening
109235|NCT02392104|International Normalized Ratio
109236|NCT02392104|Warfarin
109237|NCT02392078|Procedural Success
109238|NCT02392078|Progression
109239|NCT02392078|Quality of Life
109240|NCT02392052|caregivers
109241|NCT02392039|Lymphoma
109242|NCT02392039|Diffuse Large B-cell Lymphoma
109243|NCT02392039|Mantle Cell Lymphoma
109244|NCT02392039|Grade 3B Follicular Lymphoma
109245|NCT02392039|Burkitt Lymphoma
109246|NCT02392039|Peripheral T cell Lymphoma NOS
109247|NCT02392039|NK/T cell Lymphoma
109248|NCT02392039|Transformed Lymphoma
109249|NCT02392039|Aggressive lymphoma
109250|NCT02392039|Bone pain
109251|NCT02392039|Pegfilgrastim
109252|NCT02392039|Neulasta
109253|NCT02392039|PEG-G-CSF
109254|NCT02392039|Loratadine
109255|NCT02392039|Placebo
109256|NCT02392039|Sugar pill
109257|NCT02392039|Questionnaires
109258|NCT02392039|Surveys
109259|NCT02392013|older adult falls
109260|NCT02392013|home hazards
109261|NCT02392013|home barriers
109262|NCT02392000|chronic insomnia
109263|NCT02392000|Veterans Health
109264|NCT02391974|Hyaluronic acid
109265|NCT02391974|Periodontal pockets
109266|NCT02391974|Periodontitis
109267|NCT02391948|Cerebral palsy
109268|NCT02391948|Gross motor delay
109269|NCT02391935|Chronic Effect of Ultraviolet Radiation on Normal Skin (Photo-aging)
109270|NCT02391922|out of hospital cardiac arrest
109271|NCT02391922|first aid
109272|NCT02391909|Vaccine
109273|NCT02391883|clopidogrel therapy
109274|NCT02391883|platelet aggregation inhibitor
109275|NCT02391883|adverse event
109276|NCT02391870|depression
109277|NCT02391870|mindfulness
109278|NCT02391870|pregnancy
109279|NCT02391870|prevention
109280|NCT02391870|cognitive behavioral therapy
109281|NCT02391857|cardiopulmonary resuscitation
109282|NCT02391857|Gastric emptying
109283|NCT02391844|Knee
109284|NCT02391844|Post-Operative Pain
109285|NCT02391844|Xartemis
109286|NCT02391831|SMA
109287|NCT02391831|Spinal Muscular Atrophy
109288|NCT02391831|Neuromuscular disease
109289|NCT02391818|balance
109290|NCT02391818|quality of life
109291|NCT02391818|chemotherapy
109292|NCT02391818|neuropathy
109293|NCT02391818|cancer
109294|NCT02391779|High normal blood pressure
109295|NCT02391779|Stage I
109296|NCT02391766|Self-management
109297|NCT02391766|Caregiving
109298|NCT02391766|Quality of life
109299|NCT02391766|Empowerment
109300|NCT02391753|levator avulsion
109301|NCT02391753|transperineal ultrasound
109302|NCT02391753|levator hiatus
109303|NCT02391727|SYN004
109304|NCT02391727|cetuximab
109305|NCT02391714|pain assessment
109306|NCT02391714|patient satisfaction
109307|NCT02391714|Visual Analog Scale
109308|NCT02391714|contraceptive devices
109309|NCT02391714|nulliparity
109310|NCT02391662|Metastatic Pancreatic Adenocarcinoma
109311|NCT02391662|Elderly
109312|NCT02391662|Nab-paclitaxel
109313|NCT02391662|Gemcitabine
109314|NCT02391649|schizophrenia
109315|NCT02391649|bibliotherapy program
109316|NCT02391649|problem-solving
109317|NCT02391649|family caregivers
109318|NCT02391649|randomized controlled trial
109319|NCT02391636|Postpartum Hemorrhage
109320|NCT02391636|carbetocin
109321|NCT02391636|oxytocin
109322|NCT02391623|Multiple Ascending Dose
109323|NCT02391623|Healthy Subjects
109324|NCT02391623|Hyperlipidemia
109325|NCT02391623|Lipid Metabolism Disorders
109326|NCT02391623|Metabolic Diseases
109327|NCT02391610|birth cohort study
109328|NCT02391610|environmental exposures
109329|NCT02391610|birth defects
109330|NCT02391610|pregnant outcomes
109331|NCT02391610|children development
109332|NCT02391545|Follicular Lymphoma
109333|NCT02391545|Previously Untreated
109334|NCT02391519|Pregnancy
109335|NCT02391519|High altitude
109336|NCT02391519|vasoreactivity
109337|NCT02391519|myometrial arteries
109338|NCT02391506|First CMC joint
109339|NCT02391506|Osteoarthritis
109340|NCT02391506|Cartilage Replacement
109341|NCT02391506|First CMC Joint Osteoarthritis
109342|NCT02391506|Damaged Articular Surface
109343|NCT02391493|bilinguals
109344|NCT02391493|language control
109345|NCT02391493|executive functions
109346|NCT02391493|functional MRI
109347|NCT02391493|stimulation mapping
109348|NCT02391493|brain tumors
109349|NCT02391480|Bromodomain Inhibitor
109350|NCT02391480|Cancer
109351|NCT02391454|Neoplasms
109352|NCT02391454|Cell Phones
109353|NCT02391454|Motor Activity
109354|NCT02391454|Feasibility
109355|NCT02391441|Pulmonary
109356|NCT02391441|Arterial
109357|NCT02391441|Hypertension
109358|NCT02391441|Lung
109359|NCT02391441|Transplantation
109360|NCT02391441|MRI
109361|NCT02391428|ADHD
109362|NCT02391428|omega3
109363|NCT02391402|Brain injury
109364|NCT02391402|TBI
109365|NCT02391402|PTSD
109366|NCT02391402|Polytrauma
109367|NCT02391389|preterm infant
109368|NCT02391376|superficial heat
109369|NCT02391376|hot pack
109370|NCT02391376|thermotherapy
109371|NCT02391376|physiotherapy
109372|NCT02391376|Schober Test
109373|NCT02391363|anxiety
109374|NCT02391363|worry
109375|NCT02391337|Atrial fibrillation
109376|NCT02391337|Quality of life
109377|NCT02391337|Left ventricular ejection fraction
109378|NCT02391337|Diastolic function
109379|NCT02391337|Echocardiography
109380|NCT02391337|Beta-blockers
109381|NCT02391337|Digoxin
109382|NCT02391311|tDCS
109383|NCT02391311|Cognitive remediation therapy
109384|NCT02391298|Multiple Sclerosis
109385|NCT02391298|stress
109386|NCT02391298|meditation
109387|NCT02391298|attention
109388|NCT02391272|recombinant human thrombopoietin
109389|NCT02391272|immune thrombocytopenia
109390|NCT02391272|pregnancy
109391|NCT02391246|central nervous system tumours
109392|NCT02391246|[18F]-fluorodeoxyglucose
109393|NCT02391233|Effectiveness intervention
109394|NCT02391233|Cost-effectiveness intervention
109395|NCT02391233|HIV prevention
109396|NCT02391233|Sexually transmitted infections prevention
109397|NCT02391233|Multimedia evidence-based intervention
109398|NCT02391233|Drug-users
109399|NCT02391233|Black/African-American women
109400|NCT02391233|Probation
109401|NCT02391233|HIV testing
109402|NCT02391194|AVB-620
109403|NCT02391194|stage I
109404|NCT02391194|newly diagnosed
109405|NCT02391194|breast cancer
109406|NCT02391194|stage II
109407|NCT02391194|stage III
109408|NCT02391194|ductal carcinoma in situ
109409|NCT02391181|Bioequivalence
109410|NCT02391181|Iron Status
109411|NCT02391155|follicular flushing
109412|NCT02391155|IVF
109413|NCT02391155|poor responders
109414|NCT02391155|oocyte retrival
109415|NCT02391142|heart failure
109416|NCT02391142|cardiac sympathetic nerve block
109417|NCT02391142|sympathetic nervous system
109418|NCT02391090|asthma
109419|NCT02391090|hypoxia
109420|NCT02391090|forced exhaled nitric oxide
109421|NCT02391090|inflammation
109422|NCT02391077|PrePex
109423|NCT02391077|Male Circumcision
109424|NCT02391077|Bacterial Load
109425|NCT02391064|cognition
109426|NCT02391064|brief computerized cognitive assessment
109427|NCT02391064|impairment prediction
109428|NCT02391051|prostate cancer
109429|NCT02391051|focal brachytherapy
109430|NCT02391051|PSA
109431|NCT02391051|Biological marker
109432|NCT02391038|MLN0264
109433|NCT02391038|Advanced gastrointestinal carcinoma
109434|NCT02391025|Metastatic
109435|NCT02391025|Prostate Cancer
109436|NCT02391025|Castrate Resistant
109437|NCT02391012|Ulcerative colitis
109438|NCT02391012|Crohns disease
109439|NCT02391012|Microbial transplantation
109440|NCT02390986|Cancer
109441|NCT02390986|Malignant Neoplasm
109442|NCT02390986|Anti-cancer drug
109443|NCT02390947|Colorectal Cancer
109444|NCT02390947|Famitinib
109445|NCT02390934|Radium 223
109446|NCT02390934|bone metastases
109447|NCT02390908|alcohol use
109448|NCT02390908|hazardous drinking
109449|NCT02390908|behavioral intervention
109450|NCT02390908|ART adherence
109451|NCT02390908|viral load
109452|NCT02390908|CD4
109453|NCT02390895|Minimally-invasive endoscopic repair
109454|NCT02390895|fetal surgery
109455|NCT02390895|outcome
109456|NCT02390895|Foetus
109457|NCT02390869|relapse
109458|NCT02390869|progression
109459|NCT02390804|postoperative pain
109460|NCT02390804|hysterectomy
109461|NCT02390804|single-port access laparoscopy
109462|NCT02390804|multi-port access laparoscopy
109463|NCT02390804|TLH
109464|NCT02390778|secondary traumatic stress
109465|NCT02390778|vicarious trauma
109466|NCT02390778|secondary distress
109467|NCT02390765|Stress Response
109468|NCT02390765|Binge Eating
109469|NCT02390765|Eating Behavior
109470|NCT02390765|Obesity
109471|NCT02390765|Disordered Eating
109472|NCT02390752|Maximum Tolerated Dose
109473|NCT02390752|Dose Escalation
109474|NCT02390752|Acute Lymphocytic Leukemia
109475|NCT02390752|Acute Myelogenous Leukemia
109476|NCT02390739|Immunotherapy
109477|NCT02390739|Gene Therapy
109478|NCT02390739|Metastatic Cancer
109479|NCT02390713|hepatectomy
109480|NCT02390713|post-operative liver failure
109481|NCT02390713|portal vein
109482|NCT02390713|portal flow
109483|NCT02390713|portal pressure
109484|NCT02390713|modulation
109485|NCT02390713|surgical device
109486|NCT02390700|Rheumatoid Arthritis
109487|NCT02390700|Observational
109488|NCT02390700|Golimumab
109489|NCT02390700|SIMPONI
109490|NCT02390700|Intravenous Infusion
109491|NCT02390661|seroma
109492|NCT02390661|accelerated partial breast irradiation (APBI)
109493|NCT02390661|breast lumpectomy
109494|NCT02390661|breast cancer
109495|NCT02390635|Leukemia
109496|NCT02390635|Acute myeloid leukemia
109497|NCT02390635|AML
109498|NCT02390635|Acute promyelocytic leukemia
109499|NCT02390635|APL
109500|NCT02390635|Extramedullary leukemia
109501|NCT02390635|EML
109502|NCT02390635|Whole body magnetic resonance imaging
109503|NCT02390635|MRI
109504|NCT02390635|Positron emission tomography/ computed tomography
109505|NCT02390635|PET/CT
109506|NCT02390635|18F-FDG
109507|NCT02390635|Gadolinium contrast agent
109508|NCT02390609|Healthy
109509|NCT02390609|Ibrutinib
109510|NCT02390609|Bioavailability
109511|NCT02390596|Kawasaki disease
109512|NCT02390596|anti Interleukin 1 treatment
109513|NCT02390596|anakinra
109514|NCT02390596|resistance to IVIg
109515|NCT02390596|coronary aneurysms
109516|NCT02390596|phase II trial
109517|NCT02390583|Internet dependence
109518|NCT02390583|Sleep disorders
109519|NCT02390583|pathological gambling
109520|NCT02390570|Patient Capacity
109521|NCT02390544|children
109522|NCT02390544|bone marrow transplant
109523|NCT02390544|pharmacokinetics
109524|NCT02390531|Retinopathy of Prematurity
109525|NCT02390531|Bevacizumab
109526|NCT02390531|ROP
109527|NCT02390505|vitamin C
109528|NCT02390505|CRPS
109529|NCT02390505|Upper limb surgery
109530|NCT02390479|Sclerostin
109531|NCT02390479|OPG
109532|NCT02390479|RANKL
109533|NCT02390453|mild cognitive impairment
109534|NCT02390453|randomized controlled trial
109535|NCT02390453|cognitive training
109536|NCT02390453|exercise training
109537|NCT02390453|cognition
109538|NCT02390453|physical performance
109539|NCT02390453|disability
109540|NCT02390453|mood
109541|NCT02390440|Pain management
109542|NCT02390440|Exparel
109543|NCT02390440|Rib fracture
109544|NCT02390427|Metastatic Breast Cancer
109545|NCT02390427|Advanced Breast Cancer
109546|NCT02390427|Recurrent Breast Cancer
109547|NCT02390414|Myelodysplastic syndromes (MDS)
109548|NCT02390388|pudendal block
109549|NCT02390388|Hypospadias
109550|NCT02390388|caudal block
109551|NCT02390388|child
109552|NCT02390388|analgesia
109553|NCT02390336|Osteoarthritis of the hip
109554|NCT02390336|Pain
109555|NCT02390336|Range of Motion
109556|NCT02390336|Physical Function
109557|NCT02390336|Manual Therapy
109558|NCT02390310|male circumcision
109559|NCT02390310|Shang Ring
109560|NCT02390310|male circumcision device
109561|NCT02390310|prevention
109562|NCT02390310|voluntary medical male circumcision (VMMC)
109563|NCT02390284|RGCD
109564|NCT02390284|Glaucoma Suspect
109565|NCT02390232|gut microbiota
109566|NCT02390232|Non Alcoholic Steato Hepatitis
109567|NCT02390232|Steatohepatitis
109568|NCT02390232|Escherichia coli
109569|NCT02390232|colibactin
109570|NCT02390206|Stroke
109571|NCT02390206|Spasticity
109572|NCT02390206|Botulinum Toxin type A
109573|NCT02390206|Dysport
109574|NCT02390193|Chronic kidney disease
109575|NCT02390193|Dialysis
109576|NCT02390193|Sleep
109577|NCT02390193|Pulmonary function
109578|NCT02390193|Polysomnography
109579|NCT02390193|Upper airway
109580|NCT02389127|Cirrhosis
109581|NCT02389127|Diabetes Mellitus, Type 2
109582|NCT02389127|Glycosylated hemoglobin A1c
109583|NCT02389127|Glucose
109584|NCT02389101|Lymphoma
109585|NCT02389101|68Ga-DOTANOC PET/CT
109586|NCT02389101|Somatostatin receptor
109587|NCT02389101|MRI
109588|NCT02389101|Diffusion weighted imaging
109589|NCT02389101|Early treatment response
109590|NCT02390128|iodine
109591|NCT02390128|thyroid
109592|NCT02390128|TSH
109593|NCT02390128|pregnancy
109594|NCT02390128|nutrition
109595|NCT02390128|diet
109596|NCT02390102|Anemia
109597|NCT02390102|Severe aortic stenosis
109598|NCT02390102|Red blood cell transfusion
109599|NCT02390102|Erythropoietin
109600|NCT02390089|Dysphagia
109601|NCT02390089|Cough
109602|NCT02390089|Aspiration pneumonia
109603|NCT02390024|Mechanical Ventilation
109604|NCT02390024|Asynchronies
109605|NCT02390024|Cognition
109606|NCT02390011|Advanced Solid Tumor
109607|NCT02389998|Functional Pain
109608|NCT02389998|Abdominal Pain
109609|NCT02389998|Irritable Bowel Syndrome
109610|NCT02389998|IBS
109611|NCT02389998|Functional Dyspepsia
109612|NCT02389998|FGID
109613|NCT02389998|Functional Gastrointestinal Disorders
109614|NCT02389959|HHT
109615|NCT02389959|Hereditary Hemorrhagic Telangiectasia
109616|NCT02389959|epistaxis
109617|NCT02389959|nose bleeds
109618|NCT02389959|nasal bleeding
109619|NCT02389959|Avastin
109620|NCT02389959|bevacizumab
109621|NCT02389946|Drug eluting coronary stents
109622|NCT02389946|Sirolimus
109623|NCT02389946|Bioabsorbable polymer
109624|NCT02389946|DES
109625|NCT02389933|Multiple Patient Program, LCZ696, heart failure, heart failure with reduced ejection fraction, HF-rEF
109626|NCT02389894|Embolic Protection Device
109627|NCT02389894|Stroke
109628|NCT02389894|Brain Infarction
109629|NCT02389894|atheroma
109630|NCT02389894|Aortic Valve Replacement
109631|NCT02389881|Drug therapy
109632|NCT02389868|Lovastatin
109633|NCT02389868|Proteome
109634|NCT02389868|Blood platelets
109635|NCT02389855|Progression
109636|NCT02389855|Quality of Life
109637|NCT02389816|Drug therapy
109638|NCT02389790|Crohn's Disease
109639|NCT02389764|Breast cancer
109640|NCT02389764|Metastatic inflammatory breast cancer
109641|NCT02389764|MIBC
109642|NCT02389764|HER2-negative
109643|NCT02389764|Breast carcinoma
109644|NCT02389764|BIBF 1120
109645|NCT02389764|Nintedanib
109646|NCT02389764|Phone call
109647|NCT02389751|Esophageal Cancer
109648|NCT02389751|Esophageal carcinoma
109649|NCT02389751|Adenocarcinoma or squamous cell carcinoma of the gastroesophageal junction
109650|NCT02389751|Adenocarcinoma or squamous cell carcinoma of the cervical esophagus
109651|NCT02389751|Adenocarcinoma or squamous cell carcinoma of thoracic esophagus
109652|NCT02389751|Ganetespib
109653|NCT02389751|Carboplatin
109654|NCT02389751|Paraplatin
109655|NCT02389751|Paclitaxel
109656|NCT02389751|Taxol
109657|NCT02389725|peripheral intravenous access
109658|NCT02389725|tourniquet techniques
109659|NCT02389712|Bipolar Disorder
109660|NCT02389712|Mayo Clinic
109661|NCT02389699|Intermediate and high grade ductal carcinoma in situ （DCIS）
109662|NCT02389686|Ductal carcinoma in situ （DCIS）
109663|NCT02389686|Nipple-sparing mastectomy (NSM)
109664|NCT02389686|Intraoperative radiotherapy (IORT)
109665|NCT02389686|INTRABEAM
109666|NCT02389673|Intermediate and high grade ductal carcinoma in situ （DCIS）
109667|NCT02389660|Depression, Blended Cognitive Behavioural Therapy, Internet intervention
109668|NCT02389621|Elective invasive procedures
109669|NCT02389608|Transcranial direct current stimulation
109670|NCT02389608|functional electrical stimulation
109671|NCT02389608|hemiparesis
109672|NCT02389608|electromyography
109673|NCT02389608|balance
109674|NCT02389595|HIV
109675|NCT02389595|vaccine
109676|NCT02389595|T cell
109677|NCT02389582|platelet function; dabigatran;enoxaparin
109678|NCT02389569|Biomaterial
109679|NCT02389569|Dental caries
109680|NCT02389569|Composite
109681|NCT02389543|KPT-330
109682|NCT02389543|Selinexor
109683|NCT02389543|Multiple Myeloma
109684|NCT02389543|Relapsed/refractory
109685|NCT02389543|Lenalidomide
109686|NCT02389543|Dexamethasone
109687|NCT02389543|Karyopharm
109688|NCT02389530|glioma
109689|NCT02389530|neoplasms
109690|NCT02389504|Exertion
109691|NCT02389504|Efficacy of Treatment
109692|NCT02389491|high density formula
109693|NCT02389491|heart defects
109694|NCT02389491|infant
109695|NCT02389478|oropharyngeal
109696|NCT02389478|breastmilk
109697|NCT02389478|colostrum
109698|NCT02389478|human milk
109699|NCT02389478|premature infant
109700|NCT02389465|Depression
109701|NCT02389465|Geriatric
109702|NCT02389426|Multiple Sclerosis
109703|NCT02389426|Cerebral hemodynamics
109704|NCT02389426|Cerebral hypoperfusion
109705|NCT02389426|Cerebral circulation
109706|NCT02389413|PQ912
109707|NCT02389413|Glutaminy Cyclase (QC)
109708|NCT02389413|QC - Inhibitor
109709|NCT02389400|adult with Langerhans cell histiocytosis
109710|NCT02389400|newly diagnosed
109711|NCT02389400|methotrexate
109712|NCT02389400|cytosine arabinoside
109713|NCT02389387|Dialysis Facilities
109714|NCT02389387|African Americans
109715|NCT02389387|Racial Disparity
109716|NCT02389387|Kidney Transplantation
109717|NCT02389387|Community-based Participatory Research
109718|NCT02389387|Coalition
109719|NCT02389348|Induced blood stage malaria
109720|NCT02389335|type 1diabetes
109721|NCT02389335|IFN γ
109722|NCT02389335|IL-2
109723|NCT02389335|TNF α
109724|NCT02389322|ESAT6
109725|NCT02389322|CFP10
109726|NCT02389322|skin test
109727|NCT02389322|diagnostic test
109728|NCT02389309|Solid tumors
109729|NCT02389309|Advanced tumors
109730|NCT02389309|Temsirolimus
109731|NCT02389309|CCI-779
109732|NCT02389309|Torisel
109733|NCT02389309|Dasatinib
109734|NCT02389309|BMS-354825
109735|NCT02389309|Sprycel
109736|NCT02389309|Cyclophosphamide
109737|NCT02389309|Cytoxan
109738|NCT02389309|Neosar
109739|NCT02389283|Rheumatoid arthritis
109740|NCT02389283|ultrasound joint count
109741|NCT02389270|Neurotrophins
109742|NCT02389270|Nerve Growth Factor
109743|NCT02389270|Brain-Derived Neurotrophic Factor
109744|NCT02389270|Urinary Biomarkers
109745|NCT02389270|Children
109746|NCT02389257|volunteers
109747|NCT02389231|interleukine 2
109748|NCT02389231|warm autoimmune hemolytic anemia
109749|NCT02389231|CD8 regulatory T cells
109750|NCT02389218|atrial fibrillation
109751|NCT02389218|cryoablation
109752|NCT02389218|catheter ablation
109753|NCT02389192|Ebola
109754|NCT02389192|Mono-clonal Antibody
109755|NCT02389179|Vitamin D Deficiency
109756|NCT02389153|secondary prevention coronary heart disease
109757|NCT02389153|myocardial infarction
109758|NCT02389153|cardiovascular risk factors
109759|NCT02389153|collaborative care
109760|NCT02389153|quality of life
109761|NCT02389153|patients´ satisfaction with treatment
109762|NCT02389140|Blood flow
109763|NCT02389140|Glucose
109764|NCT02389140|lactic acid
109765|NCT02389088|Granulosa Cell
109766|NCT02389088|Androgens
109767|NCT02389088|FSH
109768|NCT02389088|Ovary
109769|NCT02389075|intraepithelial lymphocytes
109770|NCT02389075|microbiome
109771|NCT02389075|colon mucosa
109772|NCT02389049|Primary Ciliary Dyskinesia
109773|NCT02389049|Kartagener Syndrome
109774|NCT02389023|surgical site infection
109775|NCT02389023|infrainguinal bypass
109776|NCT02389023|incisional wound vacuum assisted closure
109777|NCT02389023|Prevena
109778|NCT02389010|Umbilical Cord Blood
109779|NCT02389010|Diabetic Foot
109780|NCT02389010|Ulcer
109781|NCT02389010|Cost
109782|NCT02389010|Effectiveness
109783|NCT02389010|Safety
109784|NCT02389010|Platelet Gel
109785|NCT02389010|Cord Blood Platelet Gel
109786|NCT02389010|Adverse Event
109787|NCT02388997|mild asthma
109788|NCT02388997|young adults
109789|NCT02388997|rhinovirus
109790|NCT02388971|Drug therapy
109791|NCT02388919|anlotinib
109792|NCT02388919|Cancer
109793|NCT02388919|NSCLC
109794|NCT02388919|Non-small Cell Lung Cancer
109795|NCT02388880|ITPR
109796|NCT02388880|CPP
109797|NCT02388880|TBI
109798|NCT02388880|traumatic brain injury
109799|NCT02388880|cerebral perfusion pressure
109800|NCT02388880|intrathoracic pressure regulator
109801|NCT02388841|Pulmonary embolism, Computed tomographic pulmonary
109802|NCT02388815|Diabetes Mellitus
109803|NCT02388815|Sensing Technology
109804|NCT02388802|Infertility
109805|NCT02388802|Transplant
109806|NCT02388802|IVF
109807|NCT02388802|Hysterectomy
109808|NCT02388802|Absolute uterine infertility
109809|NCT02388789|sensory receptors
109810|NCT02388789|balance control
109811|NCT02388789|gait
109812|NCT02388789|temperature
109813|NCT02388776|ROTEM
109814|NCT02388776|Fibrinogen
109815|NCT02388763|Contact lenses
109816|NCT02388750|nausea
109817|NCT02388750|vomiting
109818|NCT02388750|radiation
109819|NCT02388750|anti-emetic drug
109820|NCT02388737|Drug therapy
109821|NCT02388724|Drug therapy
109822|NCT02388711|Dementia
109823|NCT02388711|Transitional Care
109824|NCT02388711|Caregiver
109825|NCT02388698|HPV DNA
109826|NCT02388698|PET-CT
109827|NCT02388698|Recurrent cervical cancer
109828|NCT02388698|chemoradiation
109829|NCT02388685|peripheral arterial disease
109830|NCT02388685|exercise
109831|NCT02388685|perfusion
109832|NCT02388685|energetics
109833|NCT02388685|magnetic resonance imaging
109834|NCT02388685|magnetic resonance spectroscopy
109835|NCT02388659|MRS Biomarkers
109836|NCT02388581|Helicobactor pylori, Hp
109837|NCT02388581|mucosa-associated lymphoid tissue-type lymphoma, MALToma
109838|NCT02388542|cardiovascular disease
109839|NCT02388542|education
109840|NCT02388542|peer mentor
109841|NCT02388529|Heart Failure
109842|NCT02388529|Bendavia™
109843|NCT02388529|MTP-131
109844|NCT02388516|Bangladesh
109845|NCT02388516|Vitamin D
109846|NCT02388516|Acute Respiratory Infections
109847|NCT02388516|Infancy
109848|NCT02388516|Pregnancy
109849|NCT02388503|Blood glucose
109850|NCT02388490|Brentuximabvedotin
109851|NCT02388490|EBV
109852|NCT02388490|Lymphoma
109853|NCT02388477|rotator cuff repair
109854|NCT02388477|Doxycycline
109855|NCT02388464|Congestive Heart Failure
109856|NCT02388464|Bendavia™
109857|NCT02388464|MTP-131
109858|NCT02388451|Mild Cognitive Impairment
109859|NCT02388438|demineralized bone matrix
109860|NCT02388412|Positron emission tomography
109861|NCT02388412|Tissue background ratio
109862|NCT02388412|Optical coherence tomography
109863|NCT02388412|Thin cap fibroous atheroma
109864|NCT02388412|Vulnerability
109865|NCT02388412|Acute coronary syndrome
109866|NCT02388399|Optical coherence tomography
109867|NCT02388399|Axial Plaque Stress
109868|NCT02388399|Wall Shear Stress
109869|NCT02388399|Vulnerability
109870|NCT02388386|Telemedicine
109871|NCT02388386|Mobile Health
109872|NCT02388360|Prostaglandin analogs
109873|NCT02388360|Corneal biomechanics
109874|NCT02388360|Corneal Hysteresis
109875|NCT02388360|Glaucoma, Open-Angle
109876|NCT02388334|Caregivers
109877|NCT02388334|Quality of life
109878|NCT02388334|Quality of care
109879|NCT02388321|Analgesia
109880|NCT02388321|pediatrics
109881|NCT02388321|pain management
109882|NCT02388308|Prostate cancer
109883|NCT02388308|Image-guided radiotherapy
109884|NCT02388308|Ultrasound guidance
109885|NCT02388295|Multiple System Atrophy (MSA), PET imaging, myeloperoxidase (MPO) inhibitor
109886|NCT02388282|dynamic intrinsic PEEP
109887|NCT02388282|diaphragm echography
109888|NCT02388282|respiratory mechanics
109889|NCT02388256|colon
109890|NCT02388256|colorectal
109891|NCT02388256|cancer
109892|NCT02388256|neoplasm
109893|NCT02388243|Brief intervention
109894|NCT02388243|Low and middle income countries (LMIC)
109895|NCT02388243|eLearning
109896|NCT02388243|Screening
109897|NCT02388243|Capacity Building
109898|NCT02388243|Primary Health Care
109899|NCT02388243|Education, Medical
109900|NCT02388243|Education, Nursing
109901|NCT02388243|Education, Professional
109902|NCT02388243|Community Health Workers
109903|NCT02388230|Breast cancer
109904|NCT02388230|Elastography
109905|NCT02388230|Ultrasound imaging
109906|NCT02388230|Quantification of toxicity
109907|NCT02388230|Side-effects
109908|NCT02388217|chronic pain
109909|NCT02388217|cannabis
109910|NCT02388217|Approved for cannabis treatment by Israeli ministry of health
109911|NCT02388217|Unrelieved chronic pain
109912|NCT02388204|Gait
109913|NCT02388204|Locomotion
109914|NCT02388204|Freezing
109915|NCT02388191|Contraception
109916|NCT02388191|Naproxen
109917|NCT02388191|Intrauterine devices
109918|NCT02388191|Pain Control
109919|NCT02388165|Staphylococcal Vaccine
109920|NCT02388165|Post-operative Surgical Site Infection
109921|NCT02388165|Spinal Surgery
109922|NCT02388165|MRSA
109923|NCT02388165|Staphylococcus aureus
109924|NCT02388139|acute myocardial infarction
109925|NCT02388139|renal artery stenosis
109926|NCT02388113|Exercise therapy
109927|NCT02388113|Time factors
109928|NCT02388074|Lung Cancer
109929|NCT02388074|Porphyrin
109930|NCT02388074|Fluorescence
109931|NCT02388074|Diagnostic
109932|NCT02388074|Sputum Cytology
109933|NCT02388074|Early Detection
109934|NCT02388048|Leukemia
109935|NCT02388048|Chronic
109936|NCT02388048|High-risk
109937|NCT02388048|ofatumumab
109938|NCT02388048|ibrutinib
109939|NCT02388048|Lymphoblastic
109940|NCT02388035|profiles changes
109941|NCT02388035|microorganisms
109942|NCT02388035|cefotaxime
109943|NCT02388035|SBP
109944|NCT02388035|Egyptian
109945|NCT02388035|effective antibiotics
109946|NCT02388009|bioconjugate vaccine
109947|NCT02388009|safety
109948|NCT02388009|immunogenicity
109949|NCT02388009|shigellosis
109950|NCT02387970|Dental implants
109951|NCT02387970|Partial edentulism
109952|NCT02387970|Immediate/delayed provisionalization
109953|NCT02387957|Wet AMD
109954|NCT02387957|subfoveal choroidal neovascularization
109955|NCT02387957|Fovista®
109956|NCT02387957|Avastin®
109957|NCT02387957|Lucentis®
109958|NCT02387957|Eylea®
109959|NCT02387944|Children
109960|NCT02387944|Cyanotic congenital heart defect
109961|NCT02387944|Cardiopulmonary Bypass
109962|NCT02387944|Thromboelastometry
109963|NCT02387944|Platelet Function Tests
109964|NCT02387931|Adolescent
109965|NCT02387931|Endometriosis
109966|NCT02387931|Diet
109967|NCT02387931|Nutrition
109968|NCT02387931|Pain
109969|NCT02387918|Tonsillectomy
109970|NCT02387918|postoperative vomiting (POV)
109971|NCT02387918|Dexamethasone
109972|NCT02387918|Acupuncture
109973|NCT02387905|Stereotactic spinal radiosurgery
109974|NCT02387905|Spinal Cord Diseases
109975|NCT02387905|Vertebral body compression fracture
109976|NCT02387905|SSRS
109977|NCT02387905|Brief Pain Inventory
109978|NCT02387905|MD Anderson Symptom Inventory - Spine Tumor
109979|NCT02387905|MDASI-SP
109980|NCT02387905|Questionnaires
109981|NCT02387905|Survey
109982|NCT02387879|Multiple Myeloma
109983|NCT02387879|PASS
109984|NCT02387879|Observational
109985|NCT02387879|Non-interventional
109986|NCT02387879|Relapse
109987|NCT02387879|Refractory
109988|NCT02387879|CC-5013
109989|NCT02387879|Lenalidomide
109990|NCT02387879|Turkey
109991|NCT02387866|Pharmacokinetic
109992|NCT02387866|Healthy Volunteers
109993|NCT02387866|Male
109994|NCT02387866|Japanese
109995|NCT02387866|Caucasian
109996|NCT02387866|AG-221
109997|NCT02387840|Brain
109998|NCT02387840|Cancer
109999|NCT02387840|Neurofibromatosis type 1
110000|NCT02387840|NF1
110001|NCT02387840|Magnetic resonance fingerprinting
110002|NCT02387840|MRF
110003|NCT02387827|long bout physical activity
110004|NCT02387827|short bout physical activity
110005|NCT02387827|Caloric Restriction
110006|NCT02387775|esophageal cooling device
110007|NCT02387775|post cardiac arrest
110008|NCT02387775|targetted temperature management
110009|NCT02387775|therapeutic hypothermia
110010|NCT02387775|cooling
110011|NCT02387775|rewarming
110012|NCT02387762|Acalabrutinib
110013|NCT02387749|diabetic peripheral neuropathy
110014|NCT02387749|mesenchymal stem cells
110015|NCT02387736|BPD
110016|NCT02387736|DBT
110017|NCT02387736|Dialectical Behaviour Therapy
110018|NCT02387736|Borderline Personality Disorder
110019|NCT02387736|Suicide
110020|NCT02387736|Non-suicidal self injury
110021|NCT02387736|NSSI
110022|NCT02387736|Randomized Control trials
110023|NCT02387736|treatment
110024|NCT02387710|arousal threshold
110025|NCT02387710|phenotype
110026|NCT02387710|tiagabine
110027|NCT02387710|slow wave sleep
110028|NCT02387684|chronic hepatitis B
110029|NCT02387684|interferon
110030|NCT02387684|peginterferon
110031|NCT02387684|HBsAg loss
110032|NCT02387658|peripheral arterial disease
110033|NCT02387658|claudication
110034|NCT02387658|translesional pressure gradient
110035|NCT02387658|pressure wire
110036|NCT02387658|six minute walk
110037|NCT02387658|superficial femoral artery
110038|NCT02387658|pressure gradient
110039|NCT02387658|endovascular
110040|NCT02387645|Endometrium
110041|NCT02387645|Endometrial Neoplasms
110042|NCT02387645|Early detection
110043|NCT02387645|Carcinoma of Endometrium
110044|NCT02387645|Gynaecological Cancer
110045|NCT02387606|Respiratory Syncytial Virus Infections
110046|NCT02387606|Placebo
110047|NCT02387606|Antiviral activity
110048|NCT02387606|JNJ-53718678
110049|NCT02387593|Adenoma
110050|NCT02387593|Colonoscopy
110051|NCT02387593|Screening
110052|NCT02387580|Malaria
110053|NCT02387580|Bioavailability
110054|NCT02387580|Formulation
110055|NCT02387541|Postoperative cognitive dysfunction
110056|NCT02387528|MIndfulness
110057|NCT02387528|Primary Health Care
110058|NCT02387463|chronic hepatitis B
110059|NCT02387463|antiviral therapy
110060|NCT02387463|peginterferon
110061|NCT02387463|HBeAg seroconversion
110062|NCT02387463|HBsAg loss
110063|NCT02387450|Claudication
110064|NCT02387450|Maximal walking distance
110065|NCT02387450|Morbi-mortality
110066|NCT02387437|ARDS
110067|NCT02387437|EIT
110068|NCT02387437|recruitment maneuvers
110069|NCT02387424|depression
110070|NCT02387424|mindfulness
110071|NCT02387424|pregnancy
110072|NCT02387424|prevention
110073|NCT02387424|cognitive behavioral therapy
110074|NCT02387411|heart failure
110075|NCT02387411|aerobic exercise
110076|NCT02387411|strength training
110077|NCT02387411|cardiopulmonary rehabilitation
110078|NCT02387411|high-intensity exercise training
110079|NCT02387333|Radical cystectomy
110080|NCT02387333|Urinary diversion
110081|NCT02387333|Ileal conduit
110082|NCT02387333|Parastomal hernia
110083|NCT02387333|Prophylactic mesh
110084|NCT02387333|Mesh stoma reinforcement technique
110085|NCT02387320|Anxiety
110086|NCT02387320|Pain
110087|NCT02387320|Nausea
110088|NCT02387320|Fatigue
110089|NCT02387320|Sleep Disturbance
110090|NCT02387320|Breast Cancer
110091|NCT02387320|Surgery
110092|NCT02387294|immunogenicity
110093|NCT02387294|reduced dos
110094|NCT02387294|Phase III
110095|NCT02387294|tolerability
110096|NCT02387294|safety
110097|NCT02387281|Freezing of gait
110098|NCT02387242|Tuberculosis
110099|NCT02387242|Whole blood Bactericidal Activity
110100|NCT02387242|WBA
110101|NCT02387242|Rifampicin
110102|NCT02387229|Atrial Fibrillation
110103|NCT02387229|Stroke
110104|NCT02387229|Neurocognitive decline
110105|NCT02387229|Rivaroxaban
110106|NCT02387229|Acetylsalicylic acid
110107|NCT02387229|Anticoagulation
110108|NCT02387216|NSCLC
110109|NCT02387216|Non-Small Cell Lung Cancer
110110|NCT02387216|heregulin
110111|NCT02387216|ErbB3
110112|NCT02387216|docetaxel
110113|NCT02387216|pemetrexed
110114|NCT02387203|Pseudomyxoma Peritonei
110115|NCT02387203|Appendiceal cancer
110116|NCT02387203|CRS/HIPEC
110117|NCT02387203|PMP
110118|NCT02387190|Heart Failure
110119|NCT02387190|Lung function test
110120|NCT02387190|Telenursing
110121|NCT02387190|Morbidity
110122|NCT02387190|Mortality
110123|NCT02387190|Quality of life
110124|NCT02387164|Type 1 diabetes
110125|NCT02387164|Islet autoantibodies
110126|NCT02387164|glutamate decarboxylase autoantibodies (GADA)
110127|NCT02387164|Immune tolerance
110128|NCT02387164|Prediabetes
110129|NCT02387164|Glucose tolerance
110130|NCT02387164|glutamate decarboxylase
110131|NCT02387164|Prevention
110132|NCT02387164|Children
110133|NCT02387151|Mesenchymal Stromal Cells
110134|NCT02387151|Rejection
110135|NCT02387112|End stage heart disease
110136|NCT02387112|Ventricular assist device
110137|NCT02387099|Stage IIIB
110138|NCT02387099|Stage IV
110139|NCT02387099|Recurrent
110140|NCT02387099|Metastatic
110141|NCT02387086|gefitinib
110142|NCT02387086|thalidomide
110143|NCT02387086|NSCLC
110144|NCT02387086|EGFR mutation
110145|NCT02387073|outcome assessment
110146|NCT02387073|self-reported
110147|NCT02387073|patient
110148|NCT02387073|clinical outcome
110149|NCT02387060|Anesthesia
110150|NCT02387060|Spinal and Epidural
110151|NCT02387060|Adverse Effect
110152|NCT02387060|Complications
110153|NCT02387034|Osteoarthritis
110154|NCT02387034|Sedentary
110155|NCT02387034|Physical activity
110156|NCT02387034|Health related quality of life
110157|NCT02387021|analgesia
110158|NCT02387021|nerve block
110159|NCT02387021|Total knee replacement
110160|NCT02386995|depth of anesthesia monitors
110161|NCT02386995|deep brain stimulation
110162|NCT02386969|Neuropathic Pain
110163|NCT02386969|repetitive transcranial magnetic stimulation (rTMS)
110164|NCT02386956|manual therapy
110165|NCT02386956|muscle chains
110166|NCT02386956|Dynamic stretching
110167|NCT02386956|Active stretching
110168|NCT02386930|Cognitive behavior therapy
110169|NCT02386930|Lifestyle modification
110170|NCT02386930|HbA1c
110171|NCT02386930|Carbohydrates
110172|NCT02386891|food intake
110173|NCT02386891|indoor thermal environment
110174|NCT02386878|Orphans and vulnerable children (OVC)
110175|NCT02386878|Program Evaluation
110176|NCT02386878|HIV Prevention
110177|NCT02386878|Psychosocial Wellbeing
110178|NCT02386878|Adolescents
110179|NCT02386852|Ginseng
110180|NCT02386852|Ginkgo Biloba
110181|NCT02386852|cardiovascular reactivity
110182|NCT02386852|cognition
110183|NCT02386826|INC280
110184|NCT02386826|c-MET Inhibitors
110185|NCT02386826|bevacizumab
110186|NCT02386826|Avastin
110187|NCT02386826|C-Met proto-oncogene
110188|NCT02386800|primary myelofibrosis
110189|NCT02386800|chronic idiopathic myelofibrosis,
110190|NCT02386800|post polycythemia vera myelofibrosis,
110191|NCT02386800|post essential thrombocythaemia myelofibrosis.
110192|NCT02386787|Ultrasonography
110193|NCT02386787|Non-elective surgery
110194|NCT02386787|Anesthesia
110195|NCT02386774|In vivo confocal microscopy
110196|NCT02386774|corneal disease
110197|NCT02386774|Blepharitis
110198|NCT02386774|Lacrimal Apparatus Diseases
110199|NCT02386774|Microscopy, Confocal
110200|NCT02386748|Cesarean section
110201|NCT02386748|Chewing gums
110202|NCT02386748|Intestinal motility
110203|NCT02386735|Corticosteroid treatment
110204|NCT02386735|COPD
110205|NCT02386735|Primary Health Care
110206|NCT02386735|Randomized controlled trial
110207|NCT02386722|Adherence of inhaled medication
110208|NCT02386722|pharmaceutical care intervention
110209|NCT02386683|Protective mechanical ventilation
110210|NCT02386683|ventilator-induced lung injury
110211|NCT02386683|neurosurgery
110212|NCT02386657|Sickle Cell Disease
110213|NCT02386657|Vaso-occlusive crisis
110214|NCT02386657|Emergency management
110215|NCT02386631|gait
110216|NCT02386631|orthotics
110217|NCT02386631|kinetics
110218|NCT02386631|hallux valgus
110219|NCT02386631|bunions
110220|NCT02386618|colorectal cancer
110221|NCT02386618|laterally spreading tumors
110222|NCT02386618|endoscopic mucosal resestion
110223|NCT02386618|local residual neoplasia
110224|NCT02386605|recovery
110225|NCT02386605|rehabilitation
110226|NCT02386553|NURTURE
110227|NCT02386540|Community Health Workers
110228|NCT02386540|Community Health Workers: utilization
110229|NCT02386540|Emergency Service
110230|NCT02386540|Primary Health Care/utilization
110231|NCT02386540|Health Services Accessibility
110232|NCT02386514|sexually transmitted infection
110233|NCT02386514|gonorrhea
110234|NCT02386514|chlamydia
110235|NCT02386514|presumptive therapy
110236|NCT02386462|laryngeal mask airway
110237|NCT02386462|circulatory reflexes
110238|NCT02386436|GSK2330811
110239|NCT02386436|Dose Escalation
110240|NCT02386436|Safety
110241|NCT02386436|First Time in Human
110242|NCT02386436|Pharmacodynamics
110243|NCT02386436|Pharmacokinetics
110244|NCT02386423|RLS
110245|NCT02386423|Willis-Ekbom
110246|NCT02386384|pregnancy failure
110247|NCT02386358|Chronic Chagas Disease
110248|NCT02386358|Randomized Clinical Trial double blind
110249|NCT02386358|Benznidazole vs Placebo
110250|NCT02386358|Adult patients
110251|NCT02386345|FIRM procedure
110252|NCT02386319|Melatonin
110253|NCT02386319|Analgesic
110254|NCT02386319|Surgery
110255|NCT02386319|Pharmacokinetic
110256|NCT02386280|Primary Prevention
110257|NCT02386280|Substance-Related Disorders
110258|NCT02386280|Family
110259|NCT02386254|premorbid
110260|NCT02386254|scoring system
110261|NCT02386254|ECOG
110262|NCT02386254|ICU
110263|NCT02386254|morbidity
110264|NCT02386254|mortality
110265|NCT02386241|brain tumor
110266|NCT02386228|miRNA
110267|NCT02386228|posthemorrhagic hydrocephalus (PHH)
110268|NCT02386215|HIV self-testing
110269|NCT02386215|randomized controlled trial
110270|NCT02386215|Kenya
110271|NCT02386189|Continuity of Patient Care
110272|NCT02386189|Health Records, Personal
110273|NCT02386189|Veterans
110274|NCT02386189|Patient Participation
110275|NCT02386189|Chronic Disease
110276|NCT02386137|MR-HIFU
110277|NCT02386137|HIFU
110278|NCT02386137|Fibroid treatment
110279|NCT02386137|MR Perfusion
110280|NCT02386137|CEUS perfusion
110281|NCT02386137|Diffusion weighted imaging
110282|NCT02386137|ARFI
110283|NCT02386137|Fibroid stiffness
110284|NCT02386124|frailty
110285|NCT02386124|elderly
110286|NCT02386124|acute coronary syndrome
110287|NCT02386124|acute heart failure
110288|NCT02386124|arrhythmias
110289|NCT02386111|Sutent
110290|NCT02386085|Osteopathic Manipulative Medicine
110291|NCT02386085|Osteopathic Manipulation
110292|NCT02386085|adverse effects
110293|NCT02386085|side effects
110294|NCT02386085|undesirable effects
110295|NCT02386072|Betanis®
110296|NCT02386072|Myrbetriq®
110297|NCT02386072|Quality of Life
110298|NCT02386072|Antimuscarinics
110299|NCT02386072|Betmiga®
110300|NCT02386072|Overactive Bladder
110301|NCT02386072|Observational
110302|NCT02386059|ondansetron
110303|NCT02386059|dexamethasone
110304|NCT02386059|vitrectomy
110305|NCT02386059|local anesthesia
110306|NCT02386046|Caffeine use
110307|NCT02386046|Normative data
110308|NCT02385968|Modic
110309|NCT02385968|Microbiology
110310|NCT02385968|Immunology
110311|NCT02385942|u-health
110312|NCT02385942|chronic wound management
110313|NCT02385942|pressure ulcer
110314|NCT02385929|Head and Neck Cancer
110315|NCT02385929|Intervention
110316|NCT02385929|Rehabilitation
110317|NCT02385929|Late Effects
110318|NCT02385929|Dysphagia
110319|NCT02385916|EstroSense
110320|NCT02385916|estrogen
110321|NCT02385903|Flammacerium
110322|NCT02385903|Ischemic wound
110323|NCT02385903|Lower limb
110324|NCT02385903|Arteriopathy
110325|NCT02385903|Amputation
110326|NCT02385903|Dressing
110327|NCT02385838|Nutrition labelling
110328|NCT02385838|Front-of-pack nutrition labels
110329|NCT02385838|Purchasing intentions
110330|NCT02385838|Nutritional quality
110331|NCT02385838|Randomized controlled trial (RCT)
110332|NCT02385812|Lung Cancer
110333|NCT02385812|Mesothelioma
110334|NCT02385812|Asbestos
110335|NCT02385812|Screening
110336|NCT02385799|Autism Spectrum Disorder
110337|NCT02385799|Behavior
110338|NCT02385799|sertraline
110339|NCT02385799|treatment
110340|NCT02385786|mindfulness-based cognitive therapy
110341|NCT02385786|depression
110342|NCT02385786|treatment
110343|NCT02385786|mindfulness meditation
110344|NCT02385786|psychotherapy
110345|NCT02385773|colostrum
110346|NCT02385773|Immunoglobulin Y (IgY)
110347|NCT02385760|Facial Acne
110348|NCT02385747|perimenopausal bleeding
110349|NCT02385747|postmenopausal bleeding
110350|NCT02385747|hysteroscopy
110351|NCT02385747|Steroid receptors
110352|NCT02385734|Multiple gingival recession
110353|NCT02385734|Concentrated growth factor
110354|NCT02385734|Coronally advanced flap
110355|NCT02385695|Disc Degeneration Disease
110356|NCT02385695|DDD
110357|NCT02385695|multilevel lumbar Disc Degeneration Disease
110358|NCT02385669|vaccine
110359|NCT02385669|peptide
110360|NCT02385669|ipilimumab
110361|NCT02385669|Yervoy
110362|NCT02385669|Montanide ISA-51
110363|NCT02385643|alcohol dependence
110364|NCT02385643|abstinence
110365|NCT02385643|relapse prevention
110366|NCT02385643|mobile support system
110367|NCT02385630|Longitudinal Studies
110368|NCT02385630|Esophagectomy
110369|NCT02385630|Gastrectomy
110370|NCT02385630|Hunger
110371|NCT02385630|Appetite
110372|NCT02385630|Glucagon-like Peptide 1
110373|NCT02385630|Peptide YY
110374|NCT02385630|Ghrelin
110375|NCT02385630|Satiety Response
110376|NCT02385630|Feeding Behavior
110377|NCT02385630|Meals
110378|NCT02385630|Postprandial Period
110379|NCT02385617|Glucagon-Like Peptide 1
110380|NCT02385617|Peptide YY
110381|NCT02385617|Ghrelin
110382|NCT02385617|Satiety Response
110383|NCT02385617|Appetite
110384|NCT02385617|Hunger
110385|NCT02385617|Somatostatin
110386|NCT02385617|Octreotide
110387|NCT02385617|Anastomosis, Roux-en-Y
110388|NCT02385617|Digestive System Surgical Procedures
110389|NCT02385617|Pharmacologic Actions
110390|NCT02385617|Physiological Effects of Drugs
110391|NCT02385617|Endocrine System Diseases
110392|NCT02385617|Enteroendocrine Cells
110393|NCT02385617|Gastrointestinal Agents
110394|NCT02385604|Positron-Emission Tomography
110395|NCT02385604|Neoadjuvant Therapy
110396|NCT02385604|Chemoradiotherapy
110397|NCT02385604|Esophagectomy
110398|NCT02385604|Response Evaluation Criteria in Solid Tumors
110399|NCT02385604|Treatment Outcome
110400|NCT02385604|Survival
110401|NCT02385604|Recurrence
110402|NCT02385604|Disease-Free Survival
110403|NCT02385604|Progression-Free Survival
110404|NCT02385604|Prognosis
110405|NCT02385604|Neoplasm Grading
110406|NCT02385604|Adenocarcinoma
110407|NCT02385604|Squamous Cell Carcinoma
110408|NCT02385604|Neoplasm Metastasis
110409|NCT02385591|physical activity
110410|NCT02385591|Latinos
110411|NCT02385591|overweight
110412|NCT02385591|SMS
110413|NCT02385591|mHealth
110414|NCT02385578|VS (vessel plus surface) classification system
110415|NCT02385578|Magnified endoscopy with narrow band imaging (ME-NBI)
110416|NCT02385578|the rate of detection
110417|NCT02385552|colonoscopy
110418|NCT02385552|quality improvement
110419|NCT02385552|adenoma detection rate
110420|NCT02385526|Vagus Nerve Stimulation
110421|NCT02385526|ASCEND
110422|NCT02385526|VNS Titration to Improve Tolerance and Accelerate Adaptation
110423|NCT02385513|Immunogenicity
110424|NCT02385487|Myocardial Infarction
110425|NCT02385487|Inflammation
110426|NCT02385487|Critical Illness
110427|NCT02385487|Necrosis
110428|NCT02385487|Sepsis
110429|NCT02385487|Respiratory Insufficiency
110430|NCT02385487|Myocardial Ischemia
110431|NCT02385487|Cardiovascular Diseases
110432|NCT02385487|Heart Diseases
110433|NCT02385487|Vascular Diseases
110434|NCT02385474|silver diamine fluoride
110435|NCT02385474|randomized clinical trial
110436|NCT02385474|caries
110437|NCT02385474|children
110438|NCT02385474|fluoride
110439|NCT02385448|dienogest
110440|NCT02385448|combined oral contraceptive pills
110441|NCT02385448|endometriosis
110442|NCT02385435|caudal block
110443|NCT02385422|secondary prophylaxis
110444|NCT02385422|Propranolol
110445|NCT02385422|Carvedilol
110446|NCT02385422|comparative effectiveness research
110447|NCT02385409|Patient Blood Management
110448|NCT02385409|Preoperative anemia
110449|NCT02385409|Hip replacement
110450|NCT02385409|Knee replacement
110451|NCT02385396|Polycystic Ovary Syndrome
110452|NCT02385396|Infertility
110453|NCT02385396|Myo-inositol
110454|NCT02385396|Intracytoplasmic sperm injection
110455|NCT02385383|Patient Blood Management
110456|NCT02385383|Preoperative anemia
110457|NCT02385383|IV Iron
110458|NCT02385357|Muscle function
110459|NCT02385357|Anaerobic power
110460|NCT02385357|Muscle damage
110461|NCT02385331|Neutrophils
110462|NCT02385331|necroptosis
110463|NCT02385331|apoptosis
110464|NCT02385305|Pressure support ventilation
110465|NCT02385305|respiratory drive
110466|NCT02385305|Physiology
110467|NCT02385279|CAD
110468|NCT02385279|ACS
110469|NCT02385279|All comers
110470|NCT02385279|PCI
110471|NCT02385266|Interstitial cystitis with Painful Bladder Syndrome
110472|NCT02385266|Urological Chronic Pelvic Pain Syndrome
110473|NCT02385253|Training
110474|NCT02385253|Primary Health Care
110475|NCT02385253|Skin Cancer
110476|NCT02385253|Primary Care Physicians
110477|NCT02385253|Surveillance
110478|NCT02385253|Education
110479|NCT02385214|Malignant
110480|NCT02385214|Melanoma
110481|NCT02385214|Cancer
110482|NCT02385214|Surgery
110483|NCT02385188|Extramammary Paget's disease
110484|NCT02385188|Vulva
110485|NCT02385188|Genital, female
110486|NCT02385188|imiquimod
110487|NCT02385175|Eustachian tube
110488|NCT02385175|test accuracy
110489|NCT02385175|clinical test
110490|NCT02385175|questionnaire
110491|NCT02385162|Mucolipidoses
110492|NCT02385162|Metabolic Diseases
110493|NCT02385162|Lysosomal Storage Diseases
110494|NCT02385149|resilience
110495|NCT02385149|challenge test
110496|NCT02385149|whole grain wheat
110497|NCT02385149|metabolic flexibility
110498|NCT02385149|cardio-metabolic
110499|NCT02385149|liver and adipose tissue
110500|NCT02385136|NSCLC
110501|NCT02385136|Radiotherpy
110502|NCT02385136|Temozolomide
110503|NCT02385123|ex-vivo
110504|NCT02385123|Influenza
110505|NCT02385123|plasmablasts
110506|NCT02385110|Leukemia
110507|NCT02385110|Hemophagocytic lymphohistiocytosis
110508|NCT02385110|HLH
110509|NCT02385110|Alemtuzumab
110510|NCT02385110|CAMPATH-1H
110511|NCT02385110|Campath
110512|NCT02385110|Etoposide
110513|NCT02385110|VePesid
110514|NCT02385110|Dexamethasone
110515|NCT02385110|Decadron
110516|NCT02385110|Methotrexate
110517|NCT02385110|Phone call
110518|NCT02385071|Healthy
110519|NCT02385071|Simeprevir
110520|NCT02385071|Bioavailability
110521|NCT02385058|Helminthiasis
110522|NCT02385058|Amoebiasis
110523|NCT02385058|Mebendazole
110524|NCT02385058|Quinfamide
110525|NCT02385058|Mexican population
110526|NCT02385019|Allogeneic hematopoietic stem cell transplantation
110527|NCT02385019|Graft vs host disease
110528|NCT02385019|Regulatory T cells
110529|NCT02385006|Thromboelastography
110530|NCT02385006|simulatneous pancreas-kidney transplantation
110531|NCT02384993|Alzheimer's Disease
110532|NCT02384993|Dementia
110533|NCT02384993|aerobic exercise
110534|NCT02384993|physical activity
110535|NCT02384993|exercise
110536|NCT02384993|neuroimaging
110537|NCT02384980|Intermittent Claudication
110538|NCT02384980|Functional Electrical Stimulation
110539|NCT02384954|Lymphoma
110540|NCT02384954|indolent B Cell
110541|NCT02384954|non-Hodgkin Lymphoma
110542|NCT02384954|Cancer
110543|NCT02384954|Immunotherapy
110544|NCT02384954|Relapsed
110545|NCT02384954|Refractory
110546|NCT02384954|Rituximab
110547|NCT02384954|Interleukin-15
110548|NCT02384954|Absolute Lymphocyte Count
110549|NCT02384954|White Blood Cell
110550|NCT02384954|Follicular Lymphoma
110551|NCT02384954|Marginal Zone Lymphoma
110552|NCT02384954|Small Lymphocytic Lymphoma
110553|NCT02384954|Lymphoplasmacytic Lymphoma
110554|NCT02384928|Acupuncture
110555|NCT02384928|Pharmacopuncture
110556|NCT02384928|Usual Care
110557|NCT02384902|glycemic index
110558|NCT02384902|diabetic nephropathy
110559|NCT02384902|low glycemic load
110560|NCT02384902|inflammation
110561|NCT02384876|pediatric
110562|NCT02384876|intraoperative arterial hypotension
110563|NCT02384876|ephedrine
110564|NCT02384876|general anesthesia
110565|NCT02384863|Chest Pain
110566|NCT02384863|Acute Coronary Syndrome
110567|NCT02384863|Cardiac
110568|NCT02384863|Emergency Department
110569|NCT02384863|Cardiac Testing
110570|NCT02384863|Healthcare Utilization
110571|NCT02384863|Patient Centered Outcomes
110572|NCT02384863|Shared Decision Making
110573|NCT02384863|Unnecessary hospital admissions
110574|NCT02384863|Decision Aid
110575|NCT02384850|metastatic
110576|NCT02384837|national Cather Lad
110577|NCT02384837|Interventional Imaging Training Base
110578|NCT02384811|Esophageal squamous cell carcinoma
110579|NCT02384811|postoperative radiotherapy
110580|NCT02384759|cancer, colorectal,
110581|NCT02384746|metastatic breast cancer
110582|NCT02384746|ER-positive
110583|NCT02384746|HER2-negative
110584|NCT02384746|Fulvestrant
110585|NCT02384746|MLN9708
110586|NCT02384733|Radiation induced morbidity, recurrence
110587|NCT02384694|cardiorespiratory fitness
110588|NCT02384694|weight
110589|NCT02384694|quality of life
110590|NCT02384694|depression
110591|NCT02384694|menopausal symptoms
110592|NCT02384694|exercise barriers
110593|NCT02384694|executive functions
110594|NCT02384681|Speech intelligibility
110595|NCT02384681|Short-term memory
110596|NCT02384681|Working memory
110597|NCT02384681|Perceived mental task load
110598|NCT02384668|Cholecalciferol
110599|NCT02384668|Vitamin D3
110600|NCT02384668|Arterial stiffness
110601|NCT02384668|Quality of Life
110602|NCT02384668|Bone density and geometry
110603|NCT02384668|Muscle strength and balance
110604|NCT02384655|Preterms
110605|NCT02384655|Breastfeeding
110606|NCT02384655|Lactation
110607|NCT02384655|Macronutrients
110608|NCT02384642|Adolescent Health
110609|NCT02384642|Democratic Republic of Congo
110610|NCT02384642|Sexual Violence
110611|NCT02384616|Lung Volume Measurements
110612|NCT02384616|airway resistance
110613|NCT02384616|general anesthesia
110614|NCT02384564|Laryngoscopy
110615|NCT02384564|Video Laryngoscopy
110616|NCT02384564|Tracheal intubation
110617|NCT02384551|GERD
110618|NCT02384551|diet
110619|NCT02384551|carbohydrate
110620|NCT02384551|obesity
110621|NCT02384538|Arthritis
110622|NCT02384538|Osteoarthritis
110623|NCT02384538|Joint diseases
110624|NCT02384538|Osteoarthritis, Hand
110625|NCT02384538|Musculoskeletal diseases
110626|NCT02384538|Rheumatic diseases
110627|NCT02384525|Septic AKI
110628|NCT02384525|CRRT
110629|NCT02384525|BIA
110630|NCT02384512|Parkinson's disease
110631|NCT02384512|akinesia
110632|NCT02384512|Azilect®
110633|NCT02384512|Rasagiline
110634|NCT02384512|Combination therapy with L-dopa
110635|NCT02384512|Wearing-off Questionnaire-32
110636|NCT02384512|Quality of life
110637|NCT02384512|Daily practice
110638|NCT02384460|Simplex
110639|NCT02384460|Recessive Dystrophic
110640|NCT02384460|Junctional non-Herlitz
110641|NCT02384460|Epidermolysis Bullosa
110642|NCT02384447|above knee amputation
110643|NCT02384447|sciatic nerve
110644|NCT02384447|ultrasonography
110645|NCT02384447|histology
110646|NCT02384408|menopause
110647|NCT02384408|drospirenone
110648|NCT02384408|tibolone
110649|NCT02384408|Bcl-2
110650|NCT02384408|steroid receptors
110651|NCT02384395|Dolutegravir
110652|NCT02384395|Abacavir
110653|NCT02384395|Lamivudine
110654|NCT02384395|acute HIV infection
110655|NCT02384395|human leukocyte antigen
110656|NCT02384395|latent HIV reservoir
110657|NCT02384395|integrase-based regimen
110658|NCT02384395|viremia
110659|NCT02384395|antiretroviral therapy
110660|NCT02384395|fixed dose combination
110661|NCT02384382|Cancer of the Prostate
110662|NCT02384356|Non-communicable diseases
110663|NCT02384356|Chronic disease
110664|NCT02384356|Mobile health
110665|NCT02384356|Diabetes Mellitus
110666|NCT02384356|Hypertension
110667|NCT02384356|Bolivia
110668|NCT02384356|Longitudinal survey
110669|NCT02384356|Health indicators
110670|NCT02384356|Primary care
110671|NCT02384356|Ambulatory care
110672|NCT02384343|Dexmedetomidine
110673|NCT02384343|Cesarean section
110674|NCT02384343|Anesthesia, Spinal
110675|NCT02384343|Anesthesia, Epidural
110676|NCT02384304|randomized controlled trial
110677|NCT02384304|alcohol
110678|NCT02384304|internet
110679|NCT02384304|internet based therapy
110680|NCT02384304|cognitive behavior therapy
110681|NCT02384278|alcohol use disorder
110682|NCT02384278|internet
110683|NCT02384278|cognitive behavior therapy
110684|NCT02384278|relapse prevention
110685|NCT02384265|Diabetes
110686|NCT02384265|Disparities
110687|NCT02384265|Behavioral
110688|NCT02384265|Text messaging
110689|NCT02384265|Social networks
110690|NCT02384265|African American
110691|NCT02384265|Female
110692|NCT02384252|obese cardiomyopathy
110693|NCT02384252|mitochondria
110694|NCT02384252|contractile dysfunction
110695|NCT02384226|mobile application
110696|NCT02384226|postpartum
110697|NCT02384226|weight loss
110698|NCT02384187|Gabapentin
110699|NCT02384187|PONV
110700|NCT02384187|Adenotonsillectomy
110701|NCT02384187|Pediatrics
110702|NCT02384174|Aging
110703|NCT02384174|Resistant starch
110704|NCT02384174|Dietary fibre
110705|NCT02384174|Immune system
110706|NCT02384174|Bacteria
110707|NCT02384174|older subjects
110708|NCT02384122|Angiodysplasias
110709|NCT02384122|Sandostatin LAR
110710|NCT02384122|Gastrointestinal
110711|NCT02384122|Somatostatin
110712|NCT02384122|Octreotide
110713|NCT02384096|stimulation
110714|NCT02384096|implantable
110715|NCT02384096|pulse generator
110716|NCT02384096|back pain
110717|NCT02384096|chronic pain
110718|NCT02384096|leg pain
110719|NCT02384083|Multiple Myeloma
110720|NCT02384083|Pethema
110721|NCT02384083|Filanesib
110722|NCT02384083|Pomalidomide
110723|NCT02384044|Sensitivity
110724|NCT02383979|Phantom limb pain
110725|NCT02383979|Mirror therapy
110726|NCT02383979|Elective amputation
110727|NCT02383979|Residual limb pain
110728|NCT02383979|Functional MRI
110729|NCT02383953|twins
110730|NCT02383953|IBD
110731|NCT02383953|UC
110732|NCT02383953|CD
110733|NCT02383875|nutrition economics
110734|NCT02383875|food expenditure
110735|NCT02383875|nutritional quality
110736|NCT02383875|low income
110737|NCT02383862|Sleep
110738|NCT02383862|Pain
110739|NCT02383862|Anxiety
110740|NCT02383862|Depression
110741|NCT02383862|Fatigue
110742|NCT02383862|PROMIS
110743|NCT02383862|primary care
110744|NCT02383836|Patent Foramen Ovale
110745|NCT02383823|glucose, cholesterol, estrogen, gender, age
110746|NCT02383810|Chemotherapy Induced Diarrhea (CID)
110747|NCT02383771|Ticagrelor
110748|NCT02383771|Aspirin
110749|NCT02383771|Peri-operative treatment
110750|NCT02383758|Behavioral Symptoms
110751|NCT02383758|Child Development Disorders, Pervasive
110752|NCT02383758|Bowel Incontinence
110753|NCT02383758|Constipation
110754|NCT02383745|Acute EEG
110755|NCT02383745|status epilepticus
110756|NCT02383745|seizure
110757|NCT02383706|Sleep Apnea, Obstructive
110758|NCT02383706|Pregnancy
110759|NCT02383706|Obesity, Morbid
110760|NCT02383706|Complications, pregnancy
110761|NCT02383693|depression
110762|NCT02383693|Repetitive Transcranial Magnetic Stimulation
110763|NCT02383693|tolerability
110764|NCT02383693|efficiency
110765|NCT02383693|TMS
110766|NCT02383693|refractory
110767|NCT02383680|Methotrexate therapy
110768|NCT02383654|Amyotrophic Lateral Sclerosis
110769|NCT02383654|Autologous Adipose-Tissue Derived Stem Cells (ADSCs)
110770|NCT02383641|Lipid Metabolism
110771|NCT02383641|Inborn Errors
110772|NCT02383641|Cholesterol Ester Storage Disease
110773|NCT02383628|ICG Dye
110774|NCT02383628|endoscopic neurosurgery
110775|NCT02383628|tissue perfusion
110776|NCT02383602|6,000 Thai MSM and TG from study sites in Bangkok, Chiang Mai, Chonburi and Songkhla
110777|NCT02383550|Multiple Sclerosis
110778|NCT02383550|Cognition
110779|NCT02383498|Overall Response Rate
110780|NCT02383498|Immune Activation
110781|NCT02383498|Tumor Infiltrating Lymphocytes
110782|NCT02383498|T Cell Response
110783|NCT02383485|arterial stiffness
110784|NCT02383472|Concussion
110785|NCT02383472|Mild Traumatic Brain Injury
110786|NCT02383472|MTBI
110787|NCT02383472|LED
110788|NCT02383472|Light Emitting Diode
110789|NCT02383472|Headache
110790|NCT02383472|Brain Concussion
110791|NCT02383446|Echeclon
110792|NCT02383446|Elan
110793|NCT02383446|TTA
110794|NCT02383446|Transtibial Amputee
110795|NCT02383394|second trimesteric pregnancy loss
110796|NCT02383368|Pharmacokinetics
110797|NCT02383368|ASP4132
110798|NCT02383368|Lymphoma
110799|NCT02383368|Refractory Solid Tumors
110800|NCT02383355|Persistent immune activation
110801|NCT02383355|Platelet hyperreactivity
110802|NCT02383342|Pain Processing
110803|NCT02383342|Genetic Factors
110804|NCT02383342|Biomarkers
110805|NCT02383329|malnutrition
110806|NCT02383329|Underweight
110807|NCT02383329|Oral Nutrition Supplements
110808|NCT02383329|Children
110809|NCT02383316|Insulin sensitivity
110810|NCT02383316|Metabolism
110811|NCT02383316|Noonan syndrome
110812|NCT02383316|Shp2
110813|NCT02383303|savings
110814|NCT02383303|assets
110815|NCT02383303|material hardship
110816|NCT02383303|poverty
110817|NCT02383303|Individual Development Account
110818|NCT02383264|feeding intolerance
110819|NCT02383264|preterm infants
110820|NCT02383264|near infrared spectroscopy
110821|NCT02383238|Dapagliflozin
110822|NCT02383238|diabetes mellitus
110823|NCT02383238|vascular
110824|NCT02383225|American Indian
110825|NCT02383225|Adolescent
110826|NCT02383225|Prevention
110827|NCT02383212|Advanced cancerous growth
110828|NCT02383173|end of life
110829|NCT02383173|palliative care
110830|NCT02383173|implementation
110831|NCT02383160|low-intensity pulsed ultrasound
110832|NCT02383160|nonunion
110833|NCT02383160|scaphoid
110834|NCT02383147|Adult
110835|NCT02383147|Aged
110836|NCT02383147|Alpha Rhythm
110837|NCT02383147|Auditory Cortex
110838|NCT02383147|Chronic
110839|NCT02383147|Electroencephalography
110840|NCT02383147|Female
110841|NCT02383147|Humans
110842|NCT02383147|Male
110843|NCT02383147|Neurofeedback
110844|NCT02383147|Prospective Studies
110845|NCT02383147|Questionnaires
110846|NCT02383147|Tinnitus
110847|NCT02383147|Treatment Outcome
110848|NCT02383095|Schizophrenia
110849|NCT02383095|Art-therapy
110850|NCT02383095|Visual organization
110851|NCT02382042|Rural Health
110852|NCT02382042|Veterans
110853|NCT02382042|Substance Abuse
110854|NCT02382003|Anxiety
110855|NCT02382003|Cognitive bias
110856|NCT02382003|Telemedicine
110857|NCT02381990|Prostate
110858|NCT02381990|PSA
110859|NCT02381990|FUSION
110860|NCT02381990|Ultrasound
110861|NCT02381990|MRI
110862|NCT02381990|Cancer
110863|NCT02381990|Cryotherapy
110864|NCT02381990|Outcomes
110865|NCT02381990|Recurrence
110866|NCT02381990|QOL, Quality of Life
110867|NCT02381990|Urinary function
110868|NCT02381990|Sexual Function
110869|NCT02383069|Pulmonary rehabilitation
110870|NCT02383069|Asthma
110871|NCT02383069|Children
110872|NCT02383069|Teenager
110873|NCT02383069|Physical capacity
110874|NCT02383056|wound
110875|NCT02383056|secondary intention healing
110876|NCT02383056|lower extremity
110877|NCT02383030|Breast cancer
110878|NCT02383030|Metastatic
110879|NCT02383030|HER2 negative
110880|NCT02383030|postmenopausal
110881|NCT02383030|maintenance therapy
110882|NCT02383030|fulvestrant
110883|NCT02383017|Multi-ingredient performance supplement, High Intensity Interval Training, Concurrent training
110884|NCT02383004|myringotomy tubes
110885|NCT02383004|acupuncture
110886|NCT02383004|emergence delirium
110887|NCT02383004|pediatrics
110888|NCT02383004|general anesthesia
110889|NCT02382991|Moderately active amputees
110890|NCT02382991|C-leg Compact
110891|NCT02382991|Knee prosthesis
110892|NCT02382991|Kenevo
110893|NCT02382991|Microprocessor controlled knee
110894|NCT02382991|Amputation
110895|NCT02382991|3C60
110896|NCT02382991|TGUG
110897|NCT02382991|LCI
110898|NCT02382991|QUEST
110899|NCT02382991|SF-36
110900|NCT02382952|Abdominal surgery
110901|NCT02382952|Pelvic surgery
110902|NCT02382952|Stoma takedown
110903|NCT02382952|Bowel resection
110904|NCT02382952|Lysis of abdominal adhesions
110905|NCT02382926|capacitive electrocardiography
110906|NCT02382926|Eulerian Magnification Method
110907|NCT02382900|quadrivalent
110908|NCT02382900|vaccine
110909|NCT02382887|intubation
110910|NCT02382887|difficult airway
110911|NCT02382887|fiberscopy
110912|NCT02382887|Airtraq
110913|NCT02382887|general anesthesia
110914|NCT02382874|Idiopathic nephrotic syndrome
110915|NCT02382874|adipose derived mesenchymal stromal cell
110916|NCT02382874|Focal segmental glomerulosclerosis
110917|NCT02382861|Neurally adjusted ventilatory assist
110918|NCT02382861|Weaning
110919|NCT02382861|Mechanical ventilation
110920|NCT02382861|Extubation
110921|NCT02382848|Eating Disorders
110922|NCT02382848|Bulimia Nervosa
110923|NCT02382848|Nightmares
110924|NCT02382848|Post Traumatic Stress Disorder
110925|NCT02382835|metal-on-metal
110926|NCT02382809|Alveolar osteitis
110927|NCT02382809|Third molar
110928|NCT02382809|Dry socket
110929|NCT02382809|Mouthwash
110930|NCT02382809|third molar extraction
110931|NCT02382783|Rheumatoid Arthritis
110932|NCT02382783|Disease Activity
110933|NCT02382783|Flare
110934|NCT02382783|Management of Flares
110935|NCT02382783|Pfizer
110936|NCT02382744|Saphenous Nerve
110937|NCT02382744|Nerve Block
110938|NCT02382744|Ultrasound guided
110939|NCT02382744|Neurostimulation
110940|NCT02382744|Regional Anesthesia
110941|NCT02382744|Ropivacaine
110942|NCT02382744|Foot Surgery
110943|NCT02382744|Nerve Stimulation
110944|NCT02382744|Ankle Surgery
110945|NCT02382718|fish allergy
110946|NCT02382718|parvalbumin
110947|NCT02382718|immunotherapy
110948|NCT02382718|mCyp c 1
110949|NCT02382705|capsule endoscopy
110950|NCT02382705|battery life
110951|NCT02382705|completion rate
110952|NCT02382705|diagnostic yield
110953|NCT02382640|Drug therapy
110954|NCT02382614|Endobronchial Valve
110955|NCT02382614|Minimally Invasive
110956|NCT02382614|Intrabronchial Valves
110957|NCT02382614|Digital Thoracic Drainage System
110958|NCT02382614|Spiration Valve System
110959|NCT02382614|Prolonged Air Leak
110960|NCT02382614|Persistent Air Leak
110961|NCT02382601|Pregnancy
110962|NCT02382601|IUGR
110963|NCT02382601|Small for gestational age
110964|NCT02382562|Depression
110965|NCT02382562|Asthma
110966|NCT02382562|Urticaria
110967|NCT02382549|vaccine
110968|NCT02382549|peptide
110969|NCT02382549|dabrafenib
110970|NCT02382549|trametinib
110971|NCT02382549|Montanide ISA-51
110972|NCT02382549|MEKINIST
110973|NCT02382549|Tafinlar
110974|NCT02382536|Diabetes
110975|NCT02382536|Insulin therapy
110976|NCT02382536|insulin pump
110977|NCT02382536|Infusion sets
110978|NCT02382523|acthar
110979|NCT02382523|proteinuria
110980|NCT02382523|IgA nephropathy
110981|NCT02382484|Hypertension Resistant to Conventional Therapy
110982|NCT02382471|atherosclerotic
110983|NCT02382471|BDNF
110984|NCT02382471|Follistatin
110985|NCT02382471|Irisin
110986|NCT02382432|Anesthesia
110987|NCT02382432|dexmedetomidine
110988|NCT02382432|pethidine
110989|NCT02382432|shivering
110990|NCT02382432|spinal
110991|NCT02382406|MK-3475
110992|NCT02382406|Pembrolizumab
110993|NCT02382406|Carboplatin
110994|NCT02382406|Nab-paclitaxel
110995|NCT02382393|cognitive assessment
110996|NCT02382393|Brain Performance Test
110997|NCT02382393|Lumosity
110998|NCT02382393|concurrent validity
110999|NCT02382393|computerized assessment
111000|NCT02382380|Magnetic Resonance Imaging
111001|NCT02382380|Contrast Agent
111002|NCT02382380|Gadoterate
111003|NCT02382341|ACL
111004|NCT02382341|BIOSURE
111005|NCT02382341|HEALICOIL
111006|NCT02382341|PEEK
111007|NCT02382341|In-Growth
111008|NCT02382315|fear of cancer recurrence
111009|NCT02382315|psychosocial intervention
111010|NCT02382315|randomized controlled clinical trial
111011|NCT02382302|U-health
111012|NCT02382302|chronic wound management
111013|NCT02382289|Radiofrequency
111014|NCT02382289|monopolar
111015|NCT02382289|bipolar
111016|NCT02382289|Sacroiliac Joint Arthropathy
111017|NCT02382289|three different modalities
111018|NCT02382263|Advanced pancreatic cancer
111019|NCT02382263|Fragile
111020|NCT02382263|Nab-paclitaxel
111021|NCT02382237|denutrition in Head and Neck cancer or oesophageal cancer
111022|NCT02382224|generalized anxiety disorder
111023|NCT02382224|anxiety
111024|NCT02382224|worry exposure
111025|NCT02382224|treatment
111026|NCT02382211|CMV
111027|NCT02382198|droooling, sialorrhea, parkinson's disease, parkinsons
111028|NCT02382185|Cardiac output
111029|NCT02382120|carbon dioxide
111030|NCT02382120|cardiac output
111031|NCT02382120|ventilation
111032|NCT02382120|thermodilution
111033|NCT02382107|TB
111034|NCT02382107|Tuberculosis
111035|NCT02382107|Diagnostic study
111036|NCT02382094|curative intention
111037|NCT02382094|radiation Therapy
111038|NCT02382094|health related quality of life
111039|NCT02382055|Eating Disorders
111040|NCT02382055|Psychotherapy
111041|NCT02382055|Anorexia Nervosa
111042|NCT02382055|Treatment
111043|NCT02381964|cerebral blood flow
111044|NCT02381964|cognitive function
111045|NCT02381964|vitamins
111046|NCT02381964|energy expenditure
111047|NCT02381964|NIRS
111048|NCT02381964|Indirect calorimetry
111049|NCT02381938|inactivity
111050|NCT02381938|behavior change
111051|NCT02381938|worksite wellness
111052|NCT02381938|child care
111053|NCT02381925|CT
111054|NCT02381925|Scintigraphy
111055|NCT02381925|Ultrasound
111056|NCT02381899|chronic lymphocytic leukemia
111057|NCT02381899|bendamustine
111058|NCT02381899|rituximab
111059|NCT02381886|IDHR132 mutations
111060|NCT02381886|IDH305
111061|NCT02381886|IDH
111062|NCT02381886|IDH1
111063|NCT02381886|AML
111064|NCT02381886|Acute Myeloid Leukemia
111065|NCT02381886|Leukemia
111066|NCT02381886|Myeloid
111067|NCT02381886|Acute
111068|NCT02381886|MDS
111069|NCT02381886|Myelodysplastic Syndrome
111070|NCT02381886|Glioma
111071|NCT02381886|Oligodendroglioma
111072|NCT02381886|Astrocytoma
111073|NCT02381886|Glioblastoma
111074|NCT02381886|Cholangiocarcinoma
111075|NCT02381886|Solid Tumors
111076|NCT02381873|Arthroplasty
111077|NCT02381873|Replacement
111078|NCT02381873|Knee
111079|NCT02381873|Osteoarthritis
111080|NCT02381847|gastric cancer
111081|NCT02381847|intraperitoneal chemoperfusion
111082|NCT02381834|Urine Specimen Collection
111083|NCT02381834|Infant
111084|NCT02381834|Neonate
111085|NCT02381834|Bacterial Infection
111086|NCT02381821|junctional zone
111087|NCT02381821|Implantation
111088|NCT02381821|Intracytoplasmic sperm injection
111089|NCT02381717|ultrasound
111090|NCT02381717|bupivacaine
111091|NCT02381717|femoral nerve block
111092|NCT02381717|pain reduction
111093|NCT02381678|Heart Valve Replacement
111094|NCT02381678|Perimount 2900
111095|NCT02381678|China
111096|NCT02381678|Perimount 6900P
111097|NCT02381626|HEPA filter
111098|NCT02381626|14-247
111099|NCT02381613|Fish
111100|NCT02381613|Herring
111101|NCT02381613|Meat
111102|NCT02381613|Beef
111103|NCT02381600|vitamin D
111104|NCT02381600|aging
111105|NCT02381600|cognitive function
111106|NCT02381600|depression
111107|NCT02381600|executive function
111108|NCT02381574|Lumbar Total Disk Replacement
111109|NCT02381522|remote ischemic preconditioning
111110|NCT02381509|inferior vena cava filters
111111|NCT02381496|ACT-453859
111112|NCT02381496|ACT-463036
111113|NCT02381496|Setipiprant
111114|NCT02381496|Tolerability
111115|NCT02381496|safety
111116|NCT02381496|pharmacodynamics
111117|NCT02381496|pharmacokinetics
111118|NCT02381457|Microdeletion Syndrome
111119|NCT02381457|Aneuploidy
111120|NCT02381457|22q
111121|NCT02381457|Non-Invasive Prenatal Screening
111122|NCT02381457|DiGeorge Syndrome
111123|NCT02381444|Quality of life
111124|NCT02381444|Jejunal Percutaneous Endoscopic Gastrostomy
111125|NCT02381444|Observational Study
111126|NCT02381444|Levodopa Carbidopa Intestinal Gel
111127|NCT02381444|Advanced Parkinson's Disease
111128|NCT02381431|imaging
111129|NCT02381431|diagnostic
111130|NCT02381431|pediatrics
111131|NCT02381418|Influenza
111132|NCT02381418|Vaccine
111133|NCT02381418|Committee for Medicinal Products for Human Use (CHMP) criteria
111134|NCT02381392|emergency medicine
111135|NCT02381392|infrared
111136|NCT02381392|intravenous
111137|NCT02381379|CML
111138|NCT02381379|peginterferon
111139|NCT02381379|stop
111140|NCT02381379|BCR-ABL
111141|NCT02381366|Mesenchymal Stem Cells
111142|NCT02381366|Human Umbilical Cord Blood
111143|NCT02381366|Premature Infants
111144|NCT02381366|Bronchopulmonary Dysplasia
111145|NCT02381366|Chronic Lung Disease
111146|NCT02381366|Cell Therapy
111147|NCT02381353|Enucleation
111148|NCT02381353|Evisceration
111149|NCT02381353|Exparel
111150|NCT02381353|bupivacaine
111151|NCT02381340|Obesity
111152|NCT02381340|Bariatric surgery
111153|NCT02381340|Gastric plication
111154|NCT02381340|Minimal invasive surgery
111155|NCT02381340|gastrointestinal hormones
111156|NCT02381340|food-reward
111157|NCT02381340|satiety
111158|NCT02381340|microbiota
111159|NCT02381327|Speed of eating
111160|NCT02381327|body weight
111161|NCT02381327|food intake
111162|NCT02381314|B7-H3-expressing neoplasms
111163|NCT02381301|Biological Markers
111164|NCT02381301|Multidetector Computed Tomography
111165|NCT02381288|Drug therapy
111166|NCT02381262|Fitbit
111167|NCT02381249|Esophagectomy
111168|NCT02381249|Gastrectomy
111169|NCT02381249|Octreotide
111170|NCT02381249|Somatostatin
111171|NCT02381249|Appetite
111172|NCT02381249|Hunger
111173|NCT02381249|Glucagon-Like Peptide 1
111174|NCT02381249|Peptide YY
111175|NCT02381249|Reinforcement
111176|NCT02381249|Reward
111177|NCT02381249|Psychological Phenomena and Processes
111178|NCT02381249|Gastrointestinal Agents
111179|NCT02381249|Nutritional Status
111180|NCT02381249|Pancreaticoduodenectomy
111181|NCT02381249|Whipple Procedure
111182|NCT02381210|Congo Red Dot Test
111183|NCT02381197|Congo Red Dot Test
111184|NCT02381171|myofacial pain
111185|NCT02381171|neuromodulation
111186|NCT02381171|repetitive transcranial magnetic stimulation
111187|NCT02381171|electroacupuncture
111188|NCT02381158|Wheezing
111189|NCT02381158|Children
111190|NCT02381145|Polyphenols
111191|NCT02381145|Resveratrol
111192|NCT02381145|Epigallocatechin-gallate
111193|NCT02381145|Insulin sensitivity
111194|NCT02381145|mitochondrial function
111195|NCT02381145|lipid oxidation
111196|NCT02381145|tissue lipolysis
111197|NCT02381119|dietary services
111198|NCT02381119|personalized advice
111199|NCT02381119|biological markers
111200|NCT02381106|arterial contractility
111201|NCT02381106|Uterine contractility
111202|NCT02381080|B-Cell Chronic Lymphocytic Leukemia
111203|NCT02381080|Chronic Lymphocytic Leukemia
111204|NCT02381080|Small Lymphocytic Lymphoma
111205|NCT02381080|Marginal Zone Lymphoma
111206|NCT02381080|Mantle Cell Lymphoma
111207|NCT02381080|Follicular Lymphoma
111208|NCT02381080|Waldenstrom's Macroglobulinemia
111209|NCT02381080|Ibrutinib
111210|NCT02381080|IMBRUVICA
111211|NCT02381080|PCI-32765
111212|NCT02381080|JNJ-54179060
111213|NCT02381067|Cervical Fusion
111214|NCT02381067|NuCel
111215|NCT02381067|Amniotic Allograft
111216|NCT02381067|Prospective
111217|NCT02381054|Patient reported outcomes
111218|NCT02381041|Rhinoplasty
111219|NCT02381041|Topical Vasonconstrictor
111220|NCT02381041|Cocaine
111221|NCT02381041|Adrenaline
111222|NCT02381028|Atopic eczema
111223|NCT02381028|Human milk
111224|NCT02381028|Topical treatment
111225|NCT02381028|Children
111226|NCT02381015|Genetic testing
111227|NCT02381015|Genomic testing
111228|NCT02381015|Chemoprevention
111229|NCT02381015|Prostate Specific Antigen
111230|NCT02381015|Prostate Cancer
111231|NCT02381015|Predictive Genetic Testing
111232|NCT02381015|Genetic Counseling
111233|NCT02381015|Prostate-Specific Antigen
111234|NCT02381002|Serum ferritin, physical exercise, Diet
111235|NCT02380989|Ayurveda
111236|NCT02380989|Acute pain
111237|NCT02380989|Sports Injury
111238|NCT02380963|Soy
111239|NCT02380963|Obesity
111240|NCT02380963|Weight Loss
111241|NCT02380963|Muscle
111242|NCT02380963|Cardiovascular Disease
111243|NCT02380963|Colorado Diet
111244|NCT02380937|real-time MRI
111245|NCT02380937|electrophysiology study
111246|NCT02380937|atrial flutter
111247|NCT02380937|ablation
111248|NCT02380937|active tracking
111249|NCT02380924|subjects
111250|NCT02380911|Dyslipidemia
111251|NCT02380911|Global cardiovascular risk
111252|NCT02380911|Statins
111253|NCT02380911|Educational interventions
111254|NCT02380885|severe mental illness
111255|NCT02380885|social cognition
111256|NCT02380885|intervention
111257|NCT02380872|Gingival recession
111258|NCT02380872|fibrin
111259|NCT02380872|connective tissue
111260|NCT02380872|gingival crevicular fluid
111261|NCT02380872|matrix metalloproteinase
111262|NCT02380872|cytokine
111263|NCT02380859|problems of gait and balance
111264|NCT02380820|Mattress
111265|NCT02380820|Preventing bed sores
111266|NCT02380820|Skin pressure
111267|NCT02380807|Paraspinal Muscles
111268|NCT02380807|Trigger Points
111269|NCT02380807|Randomized Controlled Trial
111270|NCT02380807|Mobility Limitation
111271|NCT02380794|Danshen Gegen Capsule
111272|NCT02380768|Supraglottic airway
111273|NCT02380768|Laryngeal mask airway
111274|NCT02380768|Children
111275|NCT02380755|Flow-mediated dilatation
111276|NCT02380755|Clomiphene citrate
111277|NCT02380755|sICAM-1
111278|NCT02380755|sVCAM-1
111279|NCT02380755|sE- Selectin
111280|NCT02380755|Endothelial function
111281|NCT02380755|Cardiovascular risk
111282|NCT02380755|Endocrine System Diseases
111283|NCT02380755|Selective Estrogen Receptor Modulators
111284|NCT02380755|Estrogen Receptor Modulators
111285|NCT02380755|Infertility, Male
111286|NCT02380755|Endothelial Progenitor Cells
111287|NCT02380755|Obesity
111288|NCT02380755|Testosterone
111289|NCT02380742|Pessary
111290|NCT02380742|Pain
111291|NCT02380742|EMLA
111292|NCT02380742|lidocaine
111293|NCT02380742|prilocaine
111294|NCT02380729|Health care delivery
111295|NCT02380729|Human Phenotype Ontology
111296|NCT02380729|Mutation prioritization
111297|NCT02380729|Next Generation Sequencing
111298|NCT02380729|Mutation detection
111299|NCT02380729|Bioinformatic analysis
111300|NCT02380729|Quality of life
111301|NCT02379884|Mechanical ventilation
111302|NCT02379884|Elderly
111303|NCT02379884|Mortality
111304|NCT02379884|Health services
111305|NCT02380703|aggression
111306|NCT02380703|dementia
111307|NCT02380703|Alzheimer's disease
111308|NCT02380703|pain
111309|NCT02380703|depression
111310|NCT02380703|caregiver
111311|NCT02380703|behavioral health
111312|NCT02380703|counseling
111313|NCT02380690|self-management
111314|NCT02380690|peer support
111315|NCT02380690|social support
111316|NCT02380664|swimmers
111317|NCT02380664|adolescent swimmers
111318|NCT02380664|whole-body vibration
111319|NCT02380664|bone and bones
111320|NCT02380664|body composition
111321|NCT02380625|Ebola
111322|NCT02380625|EVD
111323|NCT02380625|Adaptive design
111324|NCT02380625|therapeutics
111325|NCT02380612|Second Degree Burn Injuries
111326|NCT02380599|Spinal Manipulation
111327|NCT02380599|Mobilization
111328|NCT02380599|Autonomic Nervous System
111329|NCT02380573|methylene blue
111330|NCT02380573|fMRI
111331|NCT02380560|myometrial thickness
111332|NCT02380560|Preterm premature rupture of membranes
111333|NCT02380560|Preterm Labour
111334|NCT02380547|Sonography
111335|NCT02380547|Diaphragmatic function
111336|NCT02380547|Non invasive ventilation
111337|NCT02380547|Critical care patients
111338|NCT02380547|Extubation after 24 hours of invasive ventilation
111339|NCT02380534|High level of Lp(a)
111340|NCT02380521|Exenatide once weekly
111341|NCT02380521|T2DM
111342|NCT02380521|IMT
111343|NCT02380521|Atherogenic lipoproteins
111344|NCT02380508|BCG study
111345|NCT02380495|Adolescents
111346|NCT02380495|Respiratory Pathology
111347|NCT02380482|Traumatic brain injury
111348|NCT02380482|Myocardial dysfunction
111349|NCT02380482|Transthoracic echocardiography
111350|NCT02380482|Speckle tracking
111351|NCT02380469|Caregivers
111352|NCT02380469|Cancer
111353|NCT02380469|Information
111354|NCT02380469|Intervention
111355|NCT02380469|Randomised trial
111356|NCT02380443|colorectal cancer
111357|NCT02380443|KRAS mutant
111358|NCT02380443|BRAF mutant
111359|NCT02380443|metastatic
111360|NCT02380443|liver metastasis
111361|NCT02380443|AlloStim®
111362|NCT02380443|cryoablation
111363|NCT02380443|cancer vaccine
111364|NCT02380443|immunotherapy
111365|NCT02380430|Ambulatory surgery
111366|NCT02380430|Pain management
111367|NCT02380430|Nausea and vomiting management
111368|NCT02380430|Questionnaire
111369|NCT02380430|Survey
111370|NCT02380430|Management
111371|NCT02380404|Edentulous maxilla
111372|NCT02380391|Platelet reactivity
111373|NCT02380391|Acute coronary syndrome
111374|NCT02380391|Antiplatelet treatment
111375|NCT02380391|Antiretroviral treatment
111376|NCT02380391|HIV
111377|NCT02380365|lung transplantation
111378|NCT02380365|electrocardiography
111379|NCT02380365|macrolides
111380|NCT02380365|QTc interval
111381|NCT02380365|arrhythmia
111382|NCT02380352|antibiotic stewardship
111383|NCT02380352|non-inferiority
111384|NCT02380352|randomized controlled trial
111385|NCT02380313|Metastatic Castration-Resistant Prostate Cancer
111386|NCT02380313|Enzalutamide
111387|NCT02380313|Abiraterone
111388|NCT02380313|Dose-Finding
111389|NCT02380313|Afuresertib
111390|NCT02380287|interleukin-17
111391|NCT02380287|maximum tolerated dose
111392|NCT02380287|novel monoclonal antibody
111393|NCT02380274|Prostate Cancer
111394|NCT02380274|Castration-resistant Prostate Cancer
111395|NCT02380274|Metastatic Prostate Cancer
111396|NCT02380222|Systemic mastocytosis
111397|NCT02380222|Patient-reported outcome (PRO)
111398|NCT02380209|breast cancer
111399|NCT02380209|CEST MRI
111400|NCT02380183|anesthesia
111401|NCT02380183|nerve block
111402|NCT02380183|needle guidance
111403|NCT02380170|sepsis
111404|NCT02380170|urinary tract infection
111405|NCT02380170|resistance
111406|NCT02380170|pathogens
111407|NCT02380170|mortality
111408|NCT02380170|health economics
111409|NCT02380157|Blood pressure
111410|NCT02380157|Potassium, Dietary
111411|NCT02380157|Renin-angiotensin-aldosterone system
111412|NCT02380157|Sympathetic nervous system
111413|NCT02380144|carotenoid
111414|NCT02380144|bioavailability
111415|NCT02380144|beta-cryptoxanthin
111416|NCT02380144|flavonoid
111417|NCT02380144|hesperidin
111418|NCT02380144|narirutin
111419|NCT02380144|randomized cross-over
111420|NCT02380144|Pharmacokinetics
111421|NCT02380144|micronutrients
111422|NCT02380144|Oranges/Orange Juice
111423|NCT02380131|XELOX
111424|NCT02380131|Herceptin
111425|NCT02380131|Potentially Resectable Gastric Cancer
111426|NCT02380118|emergency
111427|NCT02380118|emergency medicine
111428|NCT02380118|sedation
111429|NCT02380118|acute agitation
111430|NCT02380092|Knee
111431|NCT02380092|Post-Market Surveillance
111432|NCT02380092|Legion
111433|NCT02380092|Verilast
111434|NCT02380092|Degenerative Joint Disease
111435|NCT02380079|Homozygous Sickle Cell Disease S/Beta 0 Thalassemia
111436|NCT02380053|Beta-blocker
111437|NCT02380053|Cardiopulmonary exercise testing
111438|NCT02380027|Prostate biopsy
111439|NCT02380027|MRI
111440|NCT02380027|transrectal
111441|NCT02380027|Detection
111442|NCT02380001|Postoperative pain
111443|NCT02380001|Dexketoprofen trometamol
111444|NCT02380001|third molar surgery
111445|NCT02379962|biobanking
111446|NCT02379962|research participation
111447|NCT02379962|China
111448|NCT02379949|virtual reality exposure therapy
111449|NCT02379949|social phobia
111450|NCT02379949|social anxiety disorder
111451|NCT02379949|cognitive behavioral therapy
111452|NCT02379936|Classification
111453|NCT02379936|HIE
111454|NCT02379936|Infections
111455|NCT02379936|Lactate dehydrogenase
111456|NCT02379936|Intensive Care
111457|NCT02379871|Thoracic Spinal Manipulation, Autonomic Nervous System
111458|NCT02379858|GI tract recovery
111459|NCT02379858|hospital discharge
111460|NCT02379832|preeclampsia
111461|NCT02379832|preterm birth
111462|NCT02379832|pregnancy
111463|NCT02379832|placenta
111464|NCT02379832|intra-uterine growth restriction
111465|NCT02379832|fetal growth restriction
111466|NCT02379832|ultrasound
111467|NCT02379832|doppler
111468|NCT02379832|biomarkers
111469|NCT02379832|serum
111470|NCT02379832|PAPP-A
111471|NCT02379832|PlGF
111472|NCT02379832|sFlt-1
111473|NCT02379832|endoglin
111474|NCT02379793|LEO 80185 gel
111475|NCT02379793|calcipotriol
111476|NCT02379793|betamethasone
111477|NCT02379754|vestibular schwannoma
111478|NCT02379754|acoustic neuroma
111479|NCT02379754|cerebellopontine angle tumour
111480|NCT02379754|gentamicin
111481|NCT02379754|rehabilitation
111482|NCT02379754|postural balance
111483|NCT02379741|Antibodies
111484|NCT02379741|Antibodies, Monoclonal
111485|NCT02379741|Antineoplastic agent
111486|NCT02379741|Physiological effects of drugs
111487|NCT02379741|Therapeutic uses
111488|NCT02379741|Clinical Trial, Phase I
111489|NCT02379741|Immunotherapy, Active
111490|NCT02379741|CD40 Antigen
111491|NCT02379741|Immunologic Factors
111492|NCT02379741|Injections, Intralesional
111493|NCT02379728|positional therapy
111494|NCT02379728|tennis ball technique
111495|NCT02379728|sleep pregnancy
111496|NCT02379728|supine position
111497|NCT02379728|supine
111498|NCT02379728|sleep position
111499|NCT02379728|low birth weight
111500|NCT02379728|stillbirth
111501|NCT02379728|intrauterine growth restriction
111502|NCT02379715|Remifentanil
111503|NCT02379715|smooth induction
111504|NCT02379715|desflurane
111505|NCT02379689|psychosocial state
111506|NCT02379637|N-acetylcysteine
111507|NCT02379637|adults
111508|NCT02379637|cough and cold
111509|NCT02379572|5-ALA
111510|NCT02379572|Intraoperative MRI
111511|NCT02379572|Extent of resection
111512|NCT02379559|prostate cancer
111513|NCT02379559|African-American
111514|NCT02379559|Metabolic Syndrome
111515|NCT02379559|Exercise
111516|NCT02379559|Men's Health
111517|NCT02379546|reflex, oculocardiac
111518|NCT02379546|monitoring, intraoperative
111519|NCT02379520|recurrent cancer
111520|NCT02379520|refractory cancer
111521|NCT02379520|virus specific T-cells
111522|NCT02379520|gene therapy
111523|NCT02379520|HPV
111524|NCT02379507|mild to moderate
111525|NCT02379468|Diabetic
111526|NCT02379468|Foot
111527|NCT02379468|Ulcer
111528|NCT02379455|Polypharmacy
111529|NCT02379455|Geriatrics
111530|NCT02379455|Elderly
111531|NCT02379455|Drug review
111532|NCT02379442|Graft-Versus-Host Disease
111533|NCT02379442|Corticosteroids
111534|NCT02379442|Mesenchymal Stromal Cell
111535|NCT02379442|Adoptive Cellular Therapy
111536|NCT02379429|Specimen Collection
111537|NCT02379429|Urine
111538|NCT02379429|Blood
111539|NCT02379429|Saliva
111540|NCT02379416|Drug Efflux
111541|NCT02379416|Taxanes
111542|NCT02379416|Combination
111543|NCT02379416|Bcr-Abl Kinase Inhibitors
111544|NCT02379416|Neoplasms
111545|NCT02379403|Flavonoid
111546|NCT02379403|Vascular
111547|NCT02379403|Biomarkers
111548|NCT02379403|Arterial Stiffness
111549|NCT02379403|Nutrigenomics
111550|NCT02379364|Physiotherapy
111551|NCT02379364|Patellofemoral Pain Syndrome
111552|NCT02379364|Manual therapy
111553|NCT02379351|Non-stress Test
111554|NCT02379351|Fetal Monitoring
111555|NCT02379351|Telemedicine
111556|NCT02379338|Dopamine D3 receptor
111557|NCT02379312|Foams
111558|NCT02379312|Satiety
111559|NCT02379312|Appetite
111560|NCT02379247|HER-2 Negative
111561|NCT02379247|Metastatic Breast Cancer
111562|NCT02379234|CVVH
111563|NCT02379234|Renal replacement therapy
111564|NCT02379234|High fidelity simulation
111565|NCT02379234|Nurse training
111566|NCT02379208|Visual Field Tests
111567|NCT02379208|Ocular Hypertension
111568|NCT02379208|Glaucoma, Open-Angle
111569|NCT02379208|Quality of Life
111570|NCT02379208|Glaucoma progression
111571|NCT02379208|Early glaucoma
111572|NCT02379208|Frequency Doubling Technology (FDT)
111573|NCT02379208|RareBit
111574|NCT02379208|Octopus 900 perimetry
111575|NCT02379182|dysphagia
111576|NCT02379182|VitalStim
111577|NCT02379182|electrical stimulation
111578|NCT02379169|macular pigment optical density, age related macular degeneration, dry eye, vision
111579|NCT02379156|Quadriplegia
111580|NCT02379156|Spinal Cord Injury
111581|NCT02379156|Body Temperature Regulation
111582|NCT02379156|Mild Cognitive Impairment
111583|NCT02379143|SWD, EPA, SAFE PRACTICE
111584|NCT02379130|Premature
111585|NCT02379130|Family Nurture Intervention
111586|NCT02379091|Drug therapy
111587|NCT02379078|Shared decision-making
111588|NCT02379078|Priority setting
111589|NCT02379078|Patient decision aid
111590|NCT02379078|Interprofessional care
111591|NCT02379078|Diabetes mellitus
111592|NCT02379078|Patient education
111593|NCT02379078|Medical informatics
111594|NCT02379078|Toolkit development
111595|NCT02379078|Study protocol
111596|NCT02379078|User-centred design
111597|NCT02379078|Qualitative methods
111598|NCT02379013|Fatigue
111599|NCT02379013|functional MRI
111600|NCT02378987|cerebral palsy
111601|NCT02378987|language
111602|NCT02378987|acoustic
111603|NCT02378987|motor speech
111604|NCT02378987|follow-up
111605|NCT02378974|Cerebral Infarction
111606|NCT02378974|Mesenchymal Stem Cells
111607|NCT02378974|Stroke
111608|NCT02378948|Esophagectomy
111609|NCT02378948|Nutrition
111610|NCT02378948|Oral feeding
111611|NCT02378948|Enteral feeding
111612|NCT02378948|Pulmonary complications
111613|NCT02378948|Anastomotic leakage
111614|NCT02378948|Quality of life
111615|NCT02378896|Cognitive Behavioral Therapy
111616|NCT02378883|Apollo
111617|NCT02378883|Onyx
111618|NCT02378883|arteriovenous malformation
111619|NCT02378883|AVM
111620|NCT02378883|Onyx™ Liquid Embolic System
111621|NCT02378883|Apollo™ Onyx™ Delivery Micro Catheter
111622|NCT02378883|Brain Diseases
111623|NCT02378870|CRPC
111624|NCT02378857|Univentricular heart defect
111625|NCT02378857|Fontan circulation
111626|NCT02378831|diagnosing sleep
111627|NCT02378818|Schizophrenia
111628|NCT02378818|Negative symptoms
111629|NCT02378818|Lack of motivation
111630|NCT02378818|Cognitive characterization
111631|NCT02378818|Computational psychiatry
111632|NCT02378818|Depression
111633|NCT02378805|Alport syndrome
111634|NCT02378805|thin basement membrane disease
111635|NCT02378805|familial benign hematuria
111636|NCT02378792|PINS VNS Refractory Epilepsy
111637|NCT02378779|Premature ejaculation
111638|NCT02378779|general practice
111639|NCT02378779|sexual dysfunction
111640|NCT02378766|tailored web-based intervention
111641|NCT02378766|health behavior
111642|NCT02378766|hiv comorbidities
111643|NCT02378766|online trial
111644|NCT02378753|Ebola
111645|NCT02378753|Sierra Leone
111646|NCT02378753|vaccine
111647|NCT02378753|rVSVΔG-ZEBOV
111648|NCT02378740|Anesthesia
111649|NCT02378740|Cervical Fusion
111650|NCT02378740|Quality of Recovery
111651|NCT02378740|Ketamine Infusion
111652|NCT02378714|Smoking Cessation
111653|NCT02378714|Major Depressive Disorder
111654|NCT02378714|Nicotine Dependence
111655|NCT02378714|Varenicline
111656|NCT02378714|Behavioral Activation Therapy
111657|NCT02378714|Cigarette Smoking
111658|NCT02378701|Leukemia
111659|NCT02378701|Myelodysplastic syndrome
111660|NCT02378701|MDS
111661|NCT02378701|Low- or intermediate-1-risk
111662|NCT02378701|Chronic Myelomonocytic Leukemia -1
111663|NCT02378701|CMML-1
111664|NCT02378701|Quality of Life in Myelodysplasia Scale
111665|NCT02378701|QUALMS-1
111666|NCT02378701|Anemia Subset of FACT
111667|NCT02378701|FACT-An
111668|NCT02378701|Questionnaires
111669|NCT02378701|Surveys
111670|NCT02378688|Crohn's Disease
111671|NCT02378675|Adipocytokines
111672|NCT02378662|Peritoneal Dialysis
111673|NCT02378662|End Stage Renal Disease
111674|NCT02378662|Anemia
111675|NCT02378649|Pulmonary Hypertension
111676|NCT02378623|paradoxical embolism
111677|NCT02378623|lead thrombus
111678|NCT02378623|ICD
111679|NCT02378623|Pacemaker
111680|NCT02378623|Cognitive decline
111681|NCT02378623|Stroke
111682|NCT02378623|TIA
111683|NCT02378597|Resiliency burnout stress
111684|NCT02378571|Medication adherence
111685|NCT02378571|Hospital readmissions
111686|NCT02378558|Breast Surgery
111687|NCT02378545|Sepsis
111688|NCT02378545|Hyperoxia
111689|NCT02378545|Sepsis Six
111690|NCT02378545|Oxygen delivery
111691|NCT02378532|Glioblastoma
111692|NCT02378532|Chloroquine
111693|NCT02378532|Autophagy
111694|NCT02378532|EGFRvIII
111695|NCT02378532|Radiotherapy
111696|NCT02378532|Temozolomide
111697|NCT02378519|Low back pain,
111698|NCT02378519|neck pain,
111699|NCT02378519|chronic pain
111700|NCT02378519|SSED
111701|NCT02378519|Pilot project
111702|NCT02378519|interactive web-based self-help programme
111703|NCT02378519|CBT-coaching
111704|NCT02378519|physiotherapy
111705|NCT02378493|Antibiogramme
111706|NCT02378493|Antibiofilmogramme
111707|NCT02378467|Cystic Fibrosis
111708|NCT02378467|Hypertonic Saline
111709|NCT02378467|Inhaled Saline
111710|NCT02378467|Digestive System Diseases
111711|NCT02378467|Genetic Diseases, Inborn
111712|NCT02378467|Lung Diseases
111713|NCT02378467|Pancreatic Diseases
111714|NCT02378467|Pathologic Processes
111715|NCT02378467|Respiratory Tract Diseases
111716|NCT02378454|Lung Clearance Index
111717|NCT02378454|Cystic Fibrosis
111718|NCT02378454|Multiple Breath Nitrogen Washout
111719|NCT02378441|volunteers
111720|NCT02378428|Neuroblastoma
111721|NCT02378415|Depression
111722|NCT02378402|Creatine
111723|NCT02378402|heart failure
111724|NCT02378402|lipid
111725|NCT02378402|MRS
111726|NCT02378402|myocardium
111727|NCT02378324|Attendance
111728|NCT02378324|Screening without fee
111729|NCT02378311|Bike
111730|NCT02378311|Bicycle
111731|NCT02378311|Scooter
111732|NCT02378311|Handlebar
111733|NCT02378285|recent lateral humeral epicondylitis
111734|NCT02378285|platelet-rich plasma
111735|NCT02378285|infiltration
111736|NCT02378285|tennis elbow
111737|NCT02378285|ultrasonography
111738|NCT02378272|Care Manager
111739|NCT02378272|Primary Care
111740|NCT02378272|Depressive symptoms
111741|NCT02378272|quality of life
111742|NCT02378272|return to work
111743|NCT02378246|Iodine
111744|NCT02378246|Double-Blind Method
111745|NCT02378246|Randomized Controlled Tria
111746|NCT02378233|Iodine
111747|NCT02378233|Double-Blind Method
111748|NCT02378233|Randomized Controlled Trial
111749|NCT02378220|Home Care Agencies
111750|NCT02378220|Home Health Care Agencies
111751|NCT02378220|Home Health Care Nursing
111752|NCT02378220|Home Health Nurses
111753|NCT02378220|CYP 2D6
111754|NCT02378220|CYP 2C9
111755|NCT02378220|CYP 2C19
111756|NCT02378220|CYP 3A4
111757|NCT02378220|CYP 3A5
111758|NCT02378194|in stage 3 or 4 steps
111759|NCT02378168|postconditioning
111760|NCT02378168|six month follow up
111761|NCT02378168|cardiac event
111762|NCT02378168|non-cardiac event
111763|NCT02378155|cardioversion
111764|NCT02378155|atrial fibrillation
111765|NCT02378129|Dentin Sensitivity
111766|NCT02378129|Dentin Desensitizing Agents
111767|NCT02378129|Glass Ionomer Cements
111768|NCT02378129|Randomized Controlled Trial
111769|NCT02378103|Aortic Dissection
111770|NCT02378103|Chinese XinJiang Province
111771|NCT02378077|Obesity
111772|NCT02378077|Insulin Resistance
111773|NCT02378064|Fluorodeoxyglucose F18
111774|NCT02378064|Positron-Emission Tomography and Computed Tomography
111775|NCT02378064|Plaque, Atherosclerotic
111776|NCT02378064|Renin-Angiotensin System
111777|NCT02378038|PNT2258
111778|NCT02378038|Richter's Transformation
111779|NCT02378038|NHL
111780|NCT02378038|Non-Hodgkin's Lymphoma
111781|NCT02378038|Lymphoma
111782|NCT02378038|DLBCL
111783|NCT02378038|Diffuse Large B-cell Lymphoma
111784|NCT02378038|Lymphoma, Large B-cell, Diffuse
111785|NCT02378038|Lymphoma, Non-Hodgkin
111786|NCT02378038|Lymphoma, B-cell
111787|NCT02378025|Chronic Pain
111788|NCT02378025|Veterans
111789|NCT02378025|Gulf War Illness
111790|NCT02377973|growth,
111791|NCT02377973|infancy,
111792|NCT02377973|children,
111793|NCT02377973|diet,
111794|NCT02377973|breastfeeding
111795|NCT02377973|complementary feeding
111796|NCT02377973|early life programming
111797|NCT02377973|tracking
111798|NCT02377973|physical activity
111799|NCT02377960|SMS
111800|NCT02377960|text message
111801|NCT02377960|mHealth
111802|NCT02377960|IMB
111803|NCT02377947|Lactulose Retention Enema
111804|NCT02377947|Hepatic Encephalopathy, Grade 3 or 4 West Haven Criteria
111805|NCT02377947|The Retro Study
111806|NCT02377934|Pulmonary Hypertension
111807|NCT02377934|Cardiac MRT
111808|NCT02377934|Radiotherapy
111809|NCT02377921|GNE Myopathy
111810|NCT02377921|GNEM
111811|NCT02377921|HIBM
111812|NCT02377921|Nonaka
111813|NCT02377921|Hereditary Inclusion Body Myopathy
111814|NCT02377921|DMRV
111815|NCT02377882|Intra-operative neuromonitoring
111816|NCT02377882|Neuromuscular blocking agent
111817|NCT02377882|Rocuronium
111818|NCT02377882|Thyroid surgery
111819|NCT02377856|acute hepatitis C
111820|NCT02377856|treatment
111821|NCT02377856|SVR
111822|NCT02377843|vaccine
111823|NCT02377843|physician training
111824|NCT02377843|adolescent health
111825|NCT02377817|positional therapy
111826|NCT02377817|tennis ball technique
111827|NCT02377817|sleep in pregnancy
111828|NCT02377817|supine
111829|NCT02377817|polysomnography
111830|NCT02377817|sleep position
111831|NCT02377817|supine position
111832|NCT02377804|dry needling
111833|NCT02377804|spasticity
111834|NCT02377804|pain
111835|NCT02377791|tacrolimus
111836|NCT02377791|Cytochrome P-450 CYP3A
111837|NCT02377791|Kidney transplant
111838|NCT02377791|FK506
111839|NCT02377791|Prograf
111840|NCT02377791|Rejection
111841|NCT02377791|Gene Polymorphism
111842|NCT02377765|Neuromodulation
111843|NCT02377765|Detrusor overactivity
111844|NCT02377765|Urinary urgency
111845|NCT02377765|Urgency urinary incontinence
111846|NCT02377726|Randomized Controlled Trial
111847|NCT02377726|Alcohol
111848|NCT02377726|Internet
111849|NCT02377726|Internet based therapy
111850|NCT02377726|Cognitive behavioral therapy
111851|NCT02377713|KHK6640
111852|NCT02377713|Phase 1
111853|NCT02377713|Japanese
111854|NCT02377713|single dose
111855|NCT02377713|Alzheimer's disease
111856|NCT02377687|Emergency surgery
111857|NCT02377687|HRQoL
111858|NCT02377687|Elderly
111859|NCT02377648|Cardiac Allograft Vasculopathy
111860|NCT02377648|Heart Transplant
111861|NCT02377648|Bioresorbable Vascular Scaffold
111862|NCT02377635|Arsenic
111863|NCT02377635|Arsenicosis
111864|NCT02377609|Dry Blood Spot (DBS)
111865|NCT02377609|Validation
111866|NCT02377609|Tacrolimus
111867|NCT02377609|Bioanalytical assay method cross-validation
111868|NCT02377596|Feeding
111869|NCT02377596|difficulties
111870|NCT02377596|disorders
111871|NCT02377596|childhood
111872|NCT02377596|eating
111873|NCT02377557|Dermatologic Agent
111874|NCT02377531|early glucose screen, perinatal outcome
111875|NCT02377505|Treatment-Resistant Schizophrenia
111876|NCT02377505|Deep Brain Stimulation
111877|NCT02377466|Spontaneous Preterm Labor
111878|NCT02377466|GSK221149
111879|NCT02377466|Retosiban
111880|NCT02377453|stroke
111881|NCT02377453|participation
111882|NCT02377453|brain imaging
111883|NCT02377453|biomechanical
111884|NCT02377440|ACE inhibitor
111885|NCT02377427|pharmacokinetics
111886|NCT02377427|pediatric
111887|NCT02377427|Mepolizumab
111888|NCT02377427|subcutaneous
111889|NCT02377427|eosinophilic asthma
111890|NCT02377427|pharmacodynamics
111891|NCT02377414|Retosiban
111892|NCT02377414|Infusion
111893|NCT02377414|Pharmacokinetics
111894|NCT02377414|Safety
111895|NCT02377414|GSK2847065
111896|NCT02377414|Preterm labor
111897|NCT02377401|healthy volunteer
111898|NCT02377401|Zanamivir
111899|NCT02377401|pharmacokinetics
111900|NCT02377401|intravenous
111901|NCT02377388|diabetes mellitus
111902|NCT02377388|platelet function testing
111903|NCT02377388|acute coronary syndromes
111904|NCT02377388|saxagliptin
111905|NCT02377375|Deep Brain Stimulation
111906|NCT02377375|OCD
111907|NCT02377336|GS-6615
111908|NCT02377336|coronary heart disease
111909|NCT02377336|angina pectoris
111910|NCT02377336|late sodium current
111911|NCT02377336|myocardial ischemia
111912|NCT02377336|coronary artery disease
111913|NCT02377336|chronic stable angina
111914|NCT02377323|Multiple Sclerosis
111915|NCT02377323|Patient-reported outcomes
111916|NCT02377323|Employment status
111917|NCT02377323|Quality of Life
111918|NCT02377323|Cognition
111919|NCT02377323|Rebif
111920|NCT02377297|dental atraumatic restorative treatment
111921|NCT02377297|primary tooth
111922|NCT02377297|occlusal restoration
111923|NCT02377297|glass-ionomer cement
111924|NCT02377271|Bosentan
111925|NCT02377245|Juvenile
111926|NCT02377245|Inflammatory
111927|NCT02377245|Rheumatism
111928|NCT02377245|Pediatric-Onset inflammatory diseases
111929|NCT02377206|PET
111930|NCT02377206|[18F]DPA-714
111931|NCT02377206|cognitive decline
111932|NCT02377193|kidney transplant
111933|NCT02377193|luminex method
111934|NCT02377193|simulect ATG
111935|NCT02377193|immunosuppression
111936|NCT02377180|musculoskeletal pain
111937|NCT02377180|regional anesthesia
111938|NCT02377180|diagnostic nerve block
111939|NCT02377180|intramuscular capsaicin
111940|NCT02377180|referred pain
111941|NCT02377180|hyperalgesia
111942|NCT02377180|experimental pain
111943|NCT02377180|central hypersensitivity
111944|NCT02377180|human experimental pain
111945|NCT02377154|keratometry
111946|NCT02377154|verion
111947|NCT02377154|iol
111948|NCT02377154|intraocular lens
111949|NCT02377154|iolmaster
111950|NCT02377154|lenstar
111951|NCT02377154|pentacam
111952|NCT02377154|IOL calculation
111953|NCT02377154|VERION Image Guided System
111954|NCT02377141|Oesophageal Variceal Bleed
111955|NCT02377141|TIPSS
111956|NCT02377141|Endoscopic Variceal Band Ligation
111957|NCT02377141|Decompensated Liver Disease
111958|NCT02377128|Study
111959|NCT02377128|focus
111960|NCT02377128|ovarian
111961|NCT02377128|reserve
111962|NCT02377115|Postoperative delirium
111963|NCT02377115|Postoperative cognitive decline
111964|NCT02377115|Postoperative cognitive dysfunction
111965|NCT02377115|Risk assessment
111966|NCT02377115|Tablet computer
111967|NCT02377115|Clinical screening tool
111968|NCT02377089|Trigeminal Nerve Stimulation
111969|NCT02377089|Post-Traumatic Stress Disorder
111970|NCT02377063|colonic flora
111971|NCT02377063|microbiomes
111972|NCT02377050|Nutritional support
111973|NCT02377037|Sitting
111974|NCT02377037|Standing
111975|NCT02377037|Transitions
111976|NCT02376998|Thoracic Aorta
111977|NCT02376998|Trauma
111978|NCT02376998|Endovascular
111979|NCT02376959|Anxiety
111980|NCT02376959|Complementary Therapies
111981|NCT02376959|energy therapies
111982|NCT02376933|vertebral bodies
111983|NCT02376933|vertebral fracture
111984|NCT02376933|vertebral augmentation
111985|NCT02376933|radiotherapy
111986|NCT02376933|vertebroplasty
111987|NCT02376933|kyphoplasty
111988|NCT02376920|occular melanoma
111989|NCT02376920|melanoma of eye
111990|NCT02376920|DecisionDx-UM
111991|NCT02376907|distal malignant biliary obstruction
111992|NCT02376907|endoscopic retrograde cholangiopancreatography
111993|NCT02376907|endoscopic ultrasound
111994|NCT02376907|gastric outlet obstruction
111995|NCT02376907|stent
111996|NCT02376881|Erythropoietin -Methanol - Optic Neuropathy
111997|NCT02376855|Health Services Accessibility
111998|NCT02376842|severe sepsis infection
111999|NCT02376829|Orthodontic
112000|NCT02376829|Orthodontic Treatment
112001|NCT02376829|Clear Aligners
112002|NCT02376829|Malocclusion
112003|NCT02376816|DMD
112004|NCT02376816|muscular dystrophy
112005|NCT02376816|dystrophin
112006|NCT02376803|Randomized controlled trial
112007|NCT02376803|Warfarin
112008|NCT02376803|Time in therapeutic range
112009|NCT02376803|Bleeding
112010|NCT02376803|Thromboembolic
112011|NCT02376803|Hemorrhage
112012|NCT02376803|Anticoagulant
112013|NCT02376803|TTR
112014|NCT02376803|Chronobiology
112015|NCT02376803|Chronotherapeutic
112016|NCT02376803|Coumadin
112017|NCT02376803|INR
112018|NCT02376803|International normalized ratio
112019|NCT02376803|RCT
112020|NCT02376790|Psoriatic Arthritis
112021|NCT02376790|Arthritis, Psoriasis
112022|NCT02376790|Etanercept
112023|NCT02376790|Enbrel
112024|NCT02376790|Methotrexate
112025|NCT02376790|Minimal Disease Activity
112026|NCT02376777|Anticoagulants
112027|NCT02376777|Antithrombins
112028|NCT02376777|Atrial Fibrillation
112029|NCT02376777|Intracranial haemorrhage
112030|NCT02376777|Gastrointestinal haemorrhage
112031|NCT02376777|Myocardial infarction
112032|NCT02376777|Stroke
112033|NCT02376777|Venous thrombosis
112034|NCT02376777|Primary care
112035|NCT02376751|Cholesteryl Ester Storage Disease
112036|NCT02376751|Acid lipase disease
112037|NCT02376751|Cholesterol ester hydrolase deficiency
112038|NCT02376751|LIPA Deficiency
112039|NCT02376751|Wolman disease
112040|NCT02376751|Lysosomal Storage Disease
112041|NCT02376725|Goniosynechialysis
112042|NCT02376712|Acute Kidney Injury
112043|NCT02376712|Differential diagnosis
112044|NCT02376712|Urinary indices
112045|NCT02376712|Renal Blood Flow
112046|NCT02376712|Transesophageal Echocardiography
112047|NCT02376699|CD40 Antigen
112048|NCT02376699|Drug Therapy
112049|NCT02376699|Follicular Lymphoma
112050|NCT02376699|Hodgkin Disease
112051|NCT02376699|Immunotherapy
112052|NCT02376699|Indolent Lymphoma
112053|NCT02376699|Lymphoma
112054|NCT02376699|Lymphoma, B-Cell
112055|NCT02376699|Lymphoma, Large B-Cell, Diffuse
112056|NCT02376699|Lymphoma, Non-Hodgkin
112057|NCT02376699|Monoclonal Antibody
112058|NCT02376699|Neoplasms
112059|NCT02376699|Neoplasm Metastasis
112060|NCT02376699|Solid tumor
112061|NCT02376686|sleep Quality
112062|NCT02376686|Depression
112063|NCT02376686|Music
112064|NCT02376686|quality of life
112065|NCT02376673|Pediatric Health Literacy
112066|NCT02376673|Home Literacy Orientation
112067|NCT02376673|safe sleep
112068|NCT02376647|Patients
112069|NCT02376647|ARDS diagnosis
112070|NCT02376621|omega-3 based dietary supplements
112071|NCT02376621|Bioavailability
112072|NCT02376595|Rocuronium
112073|NCT02376595|Pharmacokinetics
112074|NCT02376595|Pharmacodynamics
112075|NCT02376582|HIV/AIDS vaccine
112076|NCT02376582|helminth infection
112077|NCT02376582|Impact of co-infection
112078|NCT02376556|Dry eye syndrome
112079|NCT02376556|Blepharoplasty
112080|NCT02376556|Muller muscle resection surgery
112081|NCT02376517|Health Behavior
112082|NCT02376517|Melanin Index
112083|NCT02376517|Spectrophotometry
112084|NCT02376517|Sun Protective Clothing
112085|NCT02376517|Education
112086|NCT02376517|Primary Prevention
112087|NCT02376439|siblings
112088|NCT02376439|overweight
112089|NCT02376439|adolescent
112090|NCT02376426|Healthy
112091|NCT02376426|Ebola viruses
112092|NCT02376426|Ebola Viral Disease (EVD)
112093|NCT02376426|Filoviruses
112094|NCT02376426|Monovalent vaccine
112095|NCT02376426|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
112096|NCT02376426|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
112097|NCT02376426|Safety
112098|NCT02376426|Immunogenicity
112099|NCT02376413|Morbidity
112100|NCT02376413|The Breast Cancer Treatment Outcome Scale
112101|NCT02376413|Disease free survival
112102|NCT02376413|Positivity cavity margin rate
112103|NCT02376413|Harvard/NSABP/RTOG breast cosmesis grading scale
112104|NCT02376400|Healthy
112105|NCT02376400|Ebola viruses
112106|NCT02376400|Ebola Viral Disease (EVD)
112107|NCT02376400|Filoviruses
112108|NCT02376400|Monovalent vaccine
112109|NCT02376400|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
112110|NCT02376400|Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
112111|NCT02376400|Safety
112112|NCT02376400|Immunogenicity
112113|NCT02376374|transmission
112114|NCT02376374|vaccine
112115|NCT02376361|Surveillance
112116|NCT02376348|VMMC
112117|NCT02376348|Adult males
112118|NCT02376348|HIV Prevention
112119|NCT02376348|Africa
112120|NCT02376335|Fatigue
112121|NCT02376335|Primary Biliary Cirrhosis
112122|NCT02376335|Rituximab
112123|NCT02376335|PBC-40
112124|NCT02376296|metastatic prostate cancer
112125|NCT02376296|castrate resistant prostate cancer
112126|NCT02376296|CRPC
112127|NCT02376296|hormone sensitive prostate cancer
112128|NCT02376283|STEMI
112129|NCT02376283|NSTEMI
112130|NCT02376283|PPCI
112131|NCT02376244|High intensity Interval Exercise training
112132|NCT02376244|Cardiac rehabilitation
112133|NCT02376244|cardiac revascularisation
112134|NCT02376244|Percutaneous coronary interventions
112135|NCT02376244|Cardiac surgery
112136|NCT02376231|EOC Epithelial ovarian cancer
112137|NCT02376231|Surgery
112138|NCT02376231|nil macroscopic residual disease
112139|NCT02376231|Stage 3/4 Epithelial Ovarian Cancer requiring surgery
112140|NCT02376205|Anterior Cervical Discectomy and Fusion
112141|NCT02376205|Dysphagia
112142|NCT02376192|Microcirculation
112143|NCT02376192|Sidestream Dark Field (SDF) Imaging
112144|NCT02376192|Spinal Anesthesia
112145|NCT02376192|Phenylephrine
112146|NCT02376166|Prostate Cancer
112147|NCT02376140|micronutrient deficiency
112148|NCT02376140|24-H recall
112149|NCT02376140|West Africa
112150|NCT02376140|Food consumption
112151|NCT02376127|Dynamic Contrast-Enhanced Perfusion
112152|NCT02376127|14-203
112153|NCT02376114|ocular blood flow
112154|NCT02376114|ginkgo biloba
112155|NCT02376114|glaucoma
112156|NCT02376114|vasospasm
112157|NCT02376062|Continuing Medical Education
112158|NCT02376062|Chronic Diseases
112159|NCT02376062|Nepal
112160|NCT02376062|Implementation Research
112161|NCT02376049|Atopic Dermatitis
112162|NCT02376049|Eczema
112163|NCT02376049|AD
112164|NCT02376036|Normal healthy volunteer
112165|NCT02376023|Cervical Cancer
112166|NCT02376023|Women
112167|NCT02376023|Latina
112168|NCT02376023|Chile
112169|NCT02376023|Text Message
112170|NCT02376023|Technology
112171|NCT02376023|Screening
112172|NCT02376023|Cancer Prevention
112173|NCT02376023|Health Disparities
112174|NCT02376023|Mobile Health
112175|NCT02376010|atherosclerosis
112176|NCT02376010|coronary artery disease
112177|NCT02376010|cardiac CT
112178|NCT02376010|computed tomographic angiography
112179|NCT02375971|intravitreal ranibizumab
112180|NCT02375971|laser ablation therapy
112181|NCT02375971|retinopathy of prematurity
112182|NCT02375971|preterm infants
112183|NCT02375971|RAINBOW
112184|NCT02375958|PCA062, Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer, pCAD, pcadherin, solid-tumors
112185|NCT02375945|lymphedema
112186|NCT02375945|post operative compression treatment
112187|NCT02375945|compression therapy
112188|NCT02375945|adjustable fulcro wraps
112189|NCT02375945|edema
112190|NCT02375932|Electronic Medical Records
112191|NCT02375932|Primary Health Care
112192|NCT02375932|Diabetes Mellitus, Type 2
112193|NCT02375919|PERC rule
112194|NCT02375919|emergency department
112195|NCT02375919|pulmonary embolism
112196|NCT02375906|HDV, hepatitis delta
112197|NCT02375893|Coronary disease
112198|NCT02375893|Bile acids
112199|NCT02375893|Gut microbiota
112200|NCT02375893|Risk factors
112201|NCT02375893|Atherosclerosis
112202|NCT02375854|preterm
112203|NCT02375854|acute kidney injury
112204|NCT02375854|biomarkers
112205|NCT02375854|chronic kidney disease
112206|NCT02375841|Communication
112207|NCT02375841|Physicians
112208|NCT02375841|Patients
112209|NCT02375841|Caregivers
112210|NCT02375841|15-034
112211|NCT02375828|Acceptability
112212|NCT02375828|Phase 3
112213|NCT02375828|Neonatal diabetes
112214|NCT02375815|statin
112215|NCT02375815|decision aid
112216|NCT02375802|Stem cells
112217|NCT02375789|Migraine Headache
112218|NCT02375789|Cooling
112219|NCT02375789|Intranasal
112220|NCT02375789|Rhinochill
112221|NCT02375724|COPD
112222|NCT02375711|Chronic renal disease
112223|NCT02375711|Hepatitis B vaccine
112224|NCT02375711|Biological Aging
112225|NCT02375685|Uveitis
112226|NCT02375685|Non-infectious Uveitis
112227|NCT02375685|Intermediate Uveitis
112228|NCT02375685|Posterior Uveitis
112229|NCT02375685|Behçet's disease uveitis
112230|NCT02375672|Pembrolizumab
112231|NCT02375672|MK-3475
112232|NCT02375607|Pain management
112233|NCT02375581|Radiotherapy
112234|NCT02375581|Icotinib
112235|NCT02375568|mesenchymal stem cells
112236|NCT02375555|Multiple Myeloma
112237|NCT02375516|Drug abuse
112238|NCT02375503|Calcium
112239|NCT02375503|Vitamin D
112240|NCT02375503|Parathyroid Hormone
112241|NCT02375503|Bone
112242|NCT02375503|Microarchitecture
112243|NCT02375490|Exercise
112244|NCT02375490|Eating Behavior
112245|NCT02375490|Preschool Child
112246|NCT02375490|Early Childcare Center
112247|NCT02375490|Obesity
112248|NCT02375490|Physical Literacy
112249|NCT02375477|Clostridium difficile
112250|NCT02375477|C. difficile
112251|NCT02375477|adherence
112252|NCT02375464|neuroendocrine tumor
112253|NCT02375464|carcinoid tumor
112254|NCT02375438|nutrition
112255|NCT02375438|mitochondrial cytopathy
112256|NCT02375438|malnutrition
112257|NCT02375438|energy intake
112258|NCT02375438|nutritional risk
112259|NCT02375425|BV, HSV
112260|NCT02375425|contraceptive
112261|NCT02375425|ex vivo challenge model
112262|NCT02375412|heart rate variability
112263|NCT02375412|post-operative outcome
112264|NCT02375373|Gut Microbiota
112265|NCT02375347|Gut Microbiota
112266|NCT02375321|OSA
112267|NCT02375321|Depression
112268|NCT02375321|Quality of Life
112269|NCT02375321|CPAP
112270|NCT02375308|Hypnotherapy; Cognitive Behavioral Therapy; Efficacy
112271|NCT02375295|struvite
112272|NCT02375295|infection
112273|NCT02375295|stones
112274|NCT02375295|calculi
112275|NCT02375295|antibiotics
112276|NCT02375282|ambulation
112277|NCT02375282|cardiac rehabilitation
112278|NCT02375269|Visceral Surgery
112279|NCT02375269|Comprehensive Complication Index
112280|NCT02375269|Patient undergoing abdominal surgery
112281|NCT02375230|Neonatal Resuscitation
112282|NCT02375230|Respiratory Function Tests
112283|NCT02375230|Neonatal Simulation
112284|NCT02375230|Resuscitation Teaching
112285|NCT02375178|anti-infective agents
112286|NCT02375178|local/therapeutic use
112287|NCT02375178|chlorhexidine
112288|NCT02375178|dental desinfectants
112289|NCT02375178|polyhexamethylene biguanide
112290|NCT02375178|mouthrinse
112291|NCT02375152|neurosurgery
112292|NCT02375152|capsulotomy
112293|NCT02375113|Obesity prevention
112294|NCT02375113|Soy supplementation
112295|NCT02375074|Supported Employment
112296|NCT02375074|Vocational Rehabilitation
112297|NCT02375074|Youth
112298|NCT02375074|Sick leave
112299|NCT02375074|Disability
112300|NCT02375074|Coping
112301|NCT02375074|Work
112302|NCT02375074|Occupational
112303|NCT02375074|Labor market participation
112304|NCT02375074|Randomized Controlled Trial
112305|NCT02375061|Best Possible Self
112306|NCT02375061|Positive Psychology
112307|NCT02375061|Optimism
112308|NCT02375061|Positive Technologies
112309|NCT02375061|Future thinking
112310|NCT02375061|Pain Catastrophizing
112311|NCT02374983|Gamma Knife Radiosurgery
112312|NCT02374983|Radiation Dosimetry
112313|NCT02374957|leg pain
112314|NCT02374957|claudication
112315|NCT02374931|desmoid
112316|NCT02374931|FES-PET
112317|NCT02374931|aggressive fibromatosis
112318|NCT02374918|Mild traumatic brain injury
112319|NCT02374918|Concussion
112320|NCT02374918|Sleep problems
112321|NCT02374918|Brain imaging
112322|NCT02374918|fMRI
112323|NCT02374905|drinksmeter
112324|NCT02374905|alcohol counselling
112325|NCT02374892|Intervention
112326|NCT02374892|Congenital Heart Disease
112327|NCT02374892|Adolescent
112328|NCT02374892|Education
112329|NCT02374892|Self-management
112330|NCT02374866|Obesity
112331|NCT02374866|Morbid Obesity
112332|NCT02374866|Therapeutic education
112333|NCT02374840|Pharmacogenomics
112334|NCT02374840|Adverse Drug Reactions
112335|NCT02374840|Pharmacogenetics
112336|NCT02374827|complete salpingectomy
112337|NCT02374827|standard tubal ligation
112338|NCT02374827|cesarean delivery
112339|NCT02374827|feasibility
112340|NCT02374827|safety
112341|NCT02374827|partial salpingectomy
112342|NCT02374801|CRT-D device
112343|NCT02374801|Severe HF (NYHA Class III or ambulatory IV)
112344|NCT02374801|Stable, optimal drug regimen
112345|NCT02374801|Sinus rhythm
112346|NCT02374801|Heart Failure
112347|NCT02374775|axial plaque stress
112348|NCT02374775|pressure
112349|NCT02374775|pressure gradient
112350|NCT02374775|coronary plaque
112351|NCT02374775|plaque rupture
112352|NCT02374775|acute coronary syndrome
112353|NCT02374775|acute myocardial infarction
112354|NCT02374775|computational fluid dynamics
112355|NCT02374775|coronary computed tomography angiography
112356|NCT02374775|wall shear stress
112357|NCT02374762|Arteriovenous Fistula
112358|NCT02374762|Hemodialysis
112359|NCT02374762|Vascular Access
112360|NCT02374749|Axial Spondyloarthritis
112361|NCT02374749|Education
112362|NCT02374749|Co-morbidities
112363|NCT02374749|Nurse
112364|NCT02374736|recipients
112365|NCT02374736|Subclinical Antibody-mediated rejection (ABMR)
112366|NCT02374736|Intravenous immunoglobulins (IVIg)
112367|NCT02374736|Donor-specific antibodies (DSA)
112368|NCT02374723|improve
112369|NCT02374723|vision
112370|NCT02374697|Second opinion
112371|NCT02374684|Anti-Inflammatory Agents, Non-Steroidal
112372|NCT02374671|Near Vision
112373|NCT02374671|Reading Vision
112374|NCT02374671|Reading Glasses
112375|NCT02374671|Reading
112376|NCT02374671|Readers
112377|NCT02374619|eccentric exercise
112378|NCT02374619|pro-oxidants
112379|NCT02374619|free radicals
112380|NCT02374619|adults
112381|NCT02374619|children
112382|NCT02374606|outcomes measures
112383|NCT02374606|strength measurement
112384|NCT02374606|disease progression
112385|NCT02374567|geriatric psychiatry
112386|NCT02374567|pharmacovigilance
112387|NCT02374554|Respiratory Rate
112388|NCT02374554|Structured Light Plethysmography
112389|NCT02374554|Capnography
112390|NCT02374541|Patient Navigation
112391|NCT02374541|Health Disparities
112392|NCT02374541|Coordination of Services
112393|NCT02374541|Early Intervention (Education)
112394|NCT02374541|Health Services Accessibility
112395|NCT02374541|Patient Advocacy
112396|NCT02374528|Negative pressure wound therapy
112397|NCT02374528|wound
112398|NCT02374528|split-thickness skin grafting
112399|NCT02374502|Spondylarthropathies
112400|NCT02374502|Motor Activity
112401|NCT02374502|Physical Therapists
112402|NCT02374502|Accelerometry
112403|NCT02374476|VT
112404|NCT02374476|Refractory VT
112405|NCT02374476|VT Storm
112406|NCT02374476|Ventricular Fibrillation
112407|NCT02374476|V Fib
112408|NCT02374476|VF
112409|NCT02374463|Balance
112410|NCT02374463|Fall Risk
112411|NCT02374463|Older Adults
112412|NCT02374463|Tai Chi
112413|NCT02374463|Multimodal Balance Intervention
112414|NCT02374450|Malaria
112415|NCT02374450|Surveillance study
112416|NCT02374450|Adverse Events of Specific Interest (AESI)
112417|NCT02374450|Children
112418|NCT02374450|Infants
112419|NCT02374450|Meningitis
112420|NCT02374450|Epidemiology
112421|NCT02374450|Serious Adverse Events (SAE)
112422|NCT02374450|Africa
112423|NCT02374398|Tranexamic Acid
112424|NCT02374398|Blood Loss
112425|NCT02374398|Aquamantys System
112426|NCT02374398|TKA
112427|NCT02374372|hemodialysis
112428|NCT02374372|beta microglobulin
112429|NCT02374372|amyloidosis
112430|NCT02374307|Falls
112431|NCT02374307|home-care services
112432|NCT02374307|older people
112433|NCT02374307|falls-prevention
112434|NCT02374281|Newborn
112435|NCT02374281|Neonatal Screening
112436|NCT02374281|Autonomic Nervous System
112437|NCT02374281|Pain
112438|NCT02374281|non-nutritive sucking
112439|NCT02374281|sucrose administration
112440|NCT02374281|nociceptive action
112441|NCT02374281|Electro acoustical characteristics of crying
112442|NCT02374255|Advanced cancer
112443|NCT02374255|goals of care
112444|NCT02374255|quality of care
112445|NCT02374255|end of life discussions
112446|NCT02374242|Brain
112447|NCT02374242|Metastases
112448|NCT02374242|Immunotherapy
112449|NCT02374242|Intracranial response
112450|NCT02374242|Nivolumab
112451|NCT02374242|Ipilimumab
112452|NCT02374242|Biomarkers
112453|NCT02374242|Immune related response criteria
112454|NCT02374229|pulmonary hypertension
112455|NCT02374229|pulmonary artery denervation
112456|NCT02374229|mitral valve disease
112457|NCT02374216|Dental Implants
112458|NCT02374216|Periodontal Bone Loss
112459|NCT02374216|Implant-Supported Dental Prosthesis
112460|NCT02374216|Dental Prosthesis Failure
112461|NCT02374203|Critical Illness
112462|NCT02374203|Mechanical ventilator
112463|NCT02374203|Indirect Calorimetry
112464|NCT02374164|Drug therapy
112465|NCT02374151|intrauterine pressure catheter
112466|NCT02374151|electrohysterography
112467|NCT02374138|psychosocial stress
112468|NCT02374099|Breast Cancer
112469|NCT02374099|Her2 -
112470|NCT02374099|ER+
112471|NCT02374099|CC-486 (ORAL AZACITIDINE)
112472|NCT02374099|Metastatic Breast Cancer
112473|NCT02374099|Oralazacitidine
112474|NCT02374099|Fulvestrant
112475|NCT02374099|Epigenetics
112476|NCT02374021|rheumatoid arthritis
112477|NCT02374008|Peripheral nerve block
112478|NCT02374008|Total knee Arthroplasty
112479|NCT02374008|Dexamethasone
112480|NCT02373995|Graves
112481|NCT02373995|Orbithopaty
112482|NCT02373995|euthyroidism
112483|NCT02373995|microbiome
112484|NCT02373943|vitamin A
112485|NCT02373943|human
112486|NCT02373943|bioavailability
112487|NCT02373943|fortified maize
112488|NCT02373943|cross-over
112489|NCT02373943|beta-carotene
112490|NCT02373930|Dolutegravir
112491|NCT02373930|safety
112492|NCT02373930|Rilpivirine
112493|NCT02373930|fixed dose combination
112494|NCT02373930|relative bioavailability
112495|NCT02373865|Diabetes mellitus type 2
112496|NCT02373865|nocturnal hypoglycemia
112497|NCT02373865|metformin monotherapy
112498|NCT02373800|Induced
112499|NCT02373800|pre-term labor
112500|NCT02373787|Resorbable
112501|NCT02373787|Collagen membrane
112502|NCT02373787|NobelReplace CC
112503|NCT02373774|infant
112504|NCT02373774|lumbar puncture
112505|NCT02373774|patient safety
112506|NCT02373774|ultrasound
112507|NCT02373735|stroke volume variation
112508|NCT02373735|radical cystectomy
112509|NCT02373735|blood loss
112510|NCT02373735|postoperative complications
112511|NCT02373696|Pain
112512|NCT02373696|Caesarean section
112513|NCT02373670|Positive deviance
112514|NCT02373670|Peer mentors
112515|NCT02373657|trachoma
112516|NCT02373657|soil transmitted helminths
112517|NCT02373657|water
112518|NCT02373657|hand washing
112519|NCT02373592|Diabetic Neuropathies
112520|NCT02373592|Thermometry
112521|NCT02373592|Diabetes Mellitus, Type 2
112522|NCT02373592|Foot Ulcer
112523|NCT02373592|Telemedicine
112524|NCT02373579|omega-3 fatty acids
112525|NCT02373579|methotrexate
112526|NCT02373579|hepatotoxicity
112527|NCT02373566|burns
112528|NCT02373566|dermal substitute
112529|NCT02373566|scar quality
112530|NCT02373566|reconstruction
112531|NCT02373566|wound healing
112532|NCT02373566|wound closure
112533|NCT02373553|posture
112534|NCT02373553|postural
112535|NCT02373553|kinetics
112536|NCT02373540|spinal cord stimulation
112537|NCT02373540|chronic pain
112538|NCT02373540|failed back surgery syndrome
112539|NCT02373501|caesarean delivery
112540|NCT02373501|uterine incision repair
112541|NCT02373488|Constipation
112542|NCT02373488|connective tissue manipulation
112543|NCT02373488|abdominal massage
112544|NCT02373488|bowel movements
112545|NCT02373488|quality of life
112546|NCT02373475|spine surgery
112547|NCT02373475|prone position
112548|NCT02373475|intraoperative lung protective strategies
112549|NCT02373475|postoperative pulmonary complications
112550|NCT02373449|Ketamine
112551|NCT02373449|fMRI
112552|NCT02373449|refractory neuropathic pain
112553|NCT02373436|Upper Extremity
112554|NCT02373436|Rehabilitation
112555|NCT02373397|Wound healing
112556|NCT02373397|nerve regeneration
112557|NCT02373397|re-epithelialization
112558|NCT02373397|corneal epithelium
112559|NCT02373397|laser corneal surgery
112560|NCT02373384|Radiolucent renal stones
112561|NCT02373384|Oral dissolution therapy
112562|NCT02373384|Systemic chemolysis
112563|NCT02373384|Renal uric acid stones
112564|NCT02373384|Alkalinization
112565|NCT02373358|Complex trauma
112566|NCT02373358|Yoga
112567|NCT02373345|psychological factors
112568|NCT02373345|functional disability
112569|NCT02373345|pain thresholds
112570|NCT02373345|tolerance thresholds
112571|NCT02373345|motor adaptations
112572|NCT02373345|natural course
112573|NCT02373332|platelets
112574|NCT02373332|12-lipoxygenase
112575|NCT02373332|fatty acids
112576|NCT02373332|DGLA
112577|NCT02373332|DHA
112578|NCT02373332|EPA
112579|NCT02373332|12-LOX
112580|NCT02373319|Cardiovascular risk
112581|NCT02373319|Cholesterol
112582|NCT02373319|Hypertension
112583|NCT02373319|Diabetes
112584|NCT02373319|Smoking
112585|NCT02373319|Preventive Medicine
112586|NCT02373319|Epidemiology
112587|NCT02373319|Public Health
112588|NCT02373319|Diet
112589|NCT02373319|Physical Activity
112590|NCT02373306|Risk stratification
112591|NCT02373306|ICD intervention
112592|NCT02373306|occurrence during one-year follow-up after NIPS
112593|NCT02373293|Acute pancreatitis
112594|NCT02373280|Helicobacter pylori
112595|NCT02373280|tailored therapy
112596|NCT02373280|eradication
112597|NCT02373241|Anemia, Sickle Cell
112598|NCT02373241|Sickle Cell Disease
112599|NCT02373241|Kidney Disease
112600|NCT02373241|Hypertension
112601|NCT02373241|Proteinuria
112602|NCT02373241|Losartan
112603|NCT02373241|Antihypertensive Agents
112604|NCT02373241|Blood Pressure
112605|NCT02373111|Anti-aging
112606|NCT02373111|Isoflavones
112607|NCT02373111|Astaxanthine
112608|NCT02373111|Skin aging
112609|NCT02373098|Fingolimod,cytokine,chemokine,RRMS
112610|NCT02373085|Asymptomatic Bacteriuria
112611|NCT02373085|Kidney transplant recipients
112612|NCT02373085|Pyelonephritis
112613|NCT02373072|Pakinson's Disease, Movement Disorders
112614|NCT02373033|Folate
112615|NCT02373033|folic acid
112616|NCT02373033|intervention trial
112617|NCT02373033|folate status
112618|NCT02373033|women in childbearing age
112619|NCT02373033|food folate
112620|NCT02372994|chronic disease
112621|NCT02372994|continuity of patient care
112622|NCT02372994|patient engagement
112623|NCT02372994|cost effectiveness analysis
112624|NCT02372994|user-centred design
112625|NCT02372994|Interdisciplinary Health Team
112626|NCT02372994|Medical Informatics
112627|NCT02372994|Patient-centred care
112628|NCT02372942|efficacy
112629|NCT02372942|prevention
112630|NCT02372890|Otorhinolaryngeal Neoplasms
112631|NCT02372890|Cancer of Head and Neck
112632|NCT02372890|Head and Neck Squamous Cell Carcinoma
112633|NCT02372890|Positron Emission Tomography
112634|NCT02372890|PET/CT
112635|NCT02372890|FDG
112636|NCT02372877|Sickle Cell Disease
112637|NCT02372877|Hemoglobin (Hb) S Disease
112638|NCT02372877|Hb S Disease
112639|NCT02372877|Congenital Hemolytic Anemia
112640|NCT02372864|Ovariectomy
112641|NCT02372864|Mindfulness
112642|NCT02372864|Postmenopause
112643|NCT02372864|Hot Flashes
112644|NCT02372851|Arsenic
112645|NCT02372851|Household water treatment
112646|NCT02372851|Point of use water treatment
112647|NCT02372851|Water Quality
112648|NCT02372851|Total Urinary Arsenic
112649|NCT02372851|West Bengal
112650|NCT02372851|Thermotolerant coliforms
112651|NCT02372851|Compliance
112652|NCT02372851|Diarrhoea
112653|NCT02372825|Free iliac crest transfer
112654|NCT02372825|Bone reconstruction
112655|NCT02372825|Ankle reconstruction
112656|NCT02372825|Heel reconstruction
112657|NCT02372812|effect of dexamethasone
112658|NCT02372812|general surgery
112659|NCT02372812|post operative
112660|NCT02372786|7% lidocaine / 7% tetracaine cream
112661|NCT02372786|2,5% lidocaine / 2,5% prilocaine cream
112662|NCT02372773|Frontotemporal Dementia
112663|NCT02372773|MAPT
112664|NCT02372773|PGRN
112665|NCT02372773|C9ORF72
112666|NCT02372760|Bronchoscopic anesthesia lidocaine
112667|NCT02372760|Spray Catheter
112668|NCT02372760|brochoalveolar lavage
112669|NCT02372747|Totally laparoscopic gastrectomy
112670|NCT02372747|laparoscopic distal gastrectomy
112671|NCT02372747|Intracorporeal anastomosis
112672|NCT02372747|Delta-Shaped Anastomosis
112673|NCT02372747|Billroth II Anastomosis
112674|NCT02372747|Gastric cancer
112675|NCT02372721|acute kidney injury
112676|NCT02372656|Simvastatin, Metformin, Chronic periodontitis
112677|NCT02372643|clitoris
112678|NCT02372643|sexuality
112679|NCT02372643|vascularization
112680|NCT02372643|doppler
112681|NCT02372643|ultrasound
112682|NCT02372643|reference
112683|NCT02372643|female
112684|NCT02372643|Pilot Projects
112685|NCT02372643|Vagina/ultrasonography
112686|NCT02372643|Urethra/ultrasonography
112687|NCT02372643|Regional Blood Flow/physiology
112688|NCT02372643|Arteries/ultrasonography
112689|NCT02372643|Clitoris/ultrasonography
112690|NCT02372643|Reference values
112691|NCT02372643|Clitoris/blood supply
112692|NCT02372617|cerebral palsy
112693|NCT02372617|hip
112694|NCT02372617|luxation
112695|NCT02372617|subluxation
112696|NCT02372604|Chronic spontaneous urticaria
112697|NCT02372604|Levocetirizine
112698|NCT02372604|H1-antihistamine
112699|NCT02372604|Fourfold dosage
112700|NCT02372604|Efficacy
112701|NCT02372604|Tolerance
112702|NCT02372604|UAS7 (Urticaria activity score)
112703|NCT02372604|resistant
112704|NCT02372591|Quantitative Sensory Testing
112705|NCT02372591|Hydromorphone
112706|NCT02372591|Buprenorphine
112707|NCT02372578|Painful diabetic peripheral neuropathy (PDPN)
112708|NCT02372578|ASP3662
112709|NCT02372565|African American
112710|NCT02372565|Women
112711|NCT02372565|Physical Activity
112712|NCT02372565|Social Media
112713|NCT02372565|Exercise
112714|NCT02372565|Facebook
112715|NCT02372565|Text message
112716|NCT02372539|dexamethasone
112717|NCT02372526|Glucagon-like Peptide-1
112718|NCT02372526|Glucose-dependent insulinotropic peptide
112719|NCT02372526|Glucagon
112720|NCT02372526|Peptide YY 3-36
112721|NCT02372526|Ghrelin
112722|NCT02372526|Body Weight
112723|NCT02372526|Obesity
112724|NCT02372526|Overnutrition
112725|NCT02372526|Overweight
112726|NCT02372526|Gastrointestinal Agents
112727|NCT02372526|GLP-1 secretagogue
112728|NCT02372513|Cholesteryl Ester Storage Disease
112729|NCT02372513|Children
112730|NCT02372513|Liver disease
112731|NCT02372474|POF
112732|NCT02372474|ESS
112733|NCT02372474|stem cell therapy
112734|NCT02372461|Amoxicillin
112735|NCT02372461|Placebo
112736|NCT02372435|PJI
112737|NCT02372422|Twins
112738|NCT02372422|Twin gestation
112739|NCT02372422|Preterm birth
112740|NCT02372422|Prevention
112741|NCT02372396|PTSD
112742|NCT02372396|Psychotherapy
112743|NCT02372396|OEF/OIF
112744|NCT02372396|Veterans
112745|NCT02372383|Cystic Fibrosis
112746|NCT02372383|Pharmacokinetics
112747|NCT02372383|Pharmacodynamics
112748|NCT02372383|Nontuberculous Mycobacteria
112749|NCT02372383|Treatment
112750|NCT02372357|chemotherapy
112751|NCT02372357|stem cell transplantation
112752|NCT02372344|the effect of food timing on PK
112753|NCT02372344|the effect of food timing on Safety and Tolerability
112754|NCT02372344|AZD0585
112755|NCT02372344|Japanese
112756|NCT02372331|pancreaticoduodenectomy
112757|NCT02372331|ERAS
112758|NCT02372331|Whipple's operation
112759|NCT02372331|Fast track
112760|NCT02372318|opiod receptor modulator nalmefene
112761|NCT02372318|cue-reactivity
112762|NCT02372318|fMRI
112763|NCT02372318|resting-state networks
112764|NCT02372292|cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure
112765|NCT02372279|Embryo development
112766|NCT02372279|Implantation
112767|NCT02372279|In vitro fertilization
112768|NCT02372266|Infant, Newborn
112769|NCT02372266|hospital discharge
112770|NCT02372266|Early newborn discharge
112771|NCT02372266|Newborn length of stay
112772|NCT02372266|Maternity length of stay
112773|NCT02372253|verapamil
112774|NCT02372253|type 1 diabetes
112775|NCT02372253|diabetes
112776|NCT02372253|beta cells
112777|NCT02372253|beta cell function
112778|NCT02372253|insulin
112779|NCT02372214|Endovascular Procedures
112780|NCT02372214|3D printing
112781|NCT02372214|Simulation
112782|NCT02372214|Training
112783|NCT02372214|Learning curve
112784|NCT02372214|Education
112785|NCT02372201|irritable bowel disease
112786|NCT02372201|microbiota
112787|NCT02372201|hydro colon therapy
112788|NCT02372201|food intolerance
112789|NCT02372175|Dengue
112790|NCT02372162|Hepatocellular Carcinoma
112791|NCT02372162|Molecular Diagnostics
112792|NCT02372162|Sorafenib
112793|NCT02372162|Therapeutic chemoembolization
112794|NCT02372162|Next-generation sequencing
112795|NCT02372162|Sequence analysis, DNA
112796|NCT02372162|Sequence analysis, RNA
112797|NCT02372162|Metabolomics
112798|NCT02372123|Dysmenorrhea
112799|NCT02372123|Primary dysmenorrhea
112800|NCT02372123|physiotherapy
112801|NCT02372123|massage
112802|NCT02372123|connective tissue massage
112803|NCT02372123|connective tissue manipulation
112804|NCT02372084|Hepatic impairment,
112805|NCT02372084|osilodrostat,
112806|NCT02372084|LCI699
112807|NCT02372032|Herniation
112808|NCT02372032|Discectomy
112809|NCT02372032|Ozone
112810|NCT02372019|Social Anxiety Disorder
112811|NCT02372019|Social Phobia
112812|NCT02372019|Reconsolidation
112813|NCT02372019|Cognitive Bias Modification
112814|NCT02372019|Interpretation Bias
112815|NCT02371980|Drug therapy
112816|NCT02371928|Shoulder
112817|NCT02371928|Instability
112818|NCT02371928|Neuromuscular
112819|NCT02371928|Physiotherapy
112820|NCT02371928|Exercise
112821|NCT02371928|Dislocation
112822|NCT02371928|Recurrence
112823|NCT02371915|Rural access
112824|NCT02371915|Telehealth
112825|NCT02371902|Elbow pain
112826|NCT02371902|lateral epicondylitis
112827|NCT02371902|conservative treatment
112828|NCT02371902|shock wave treatment
112829|NCT02371902|therapeutic ultrasound
112830|NCT02371850|Bioequivalence
112831|NCT02371850|Therapeutic Equivalency
112832|NCT02371824|Magnetic Resonance Imaging
112833|NCT02371824|Bone Marrow
112834|NCT02371824|Hip
112835|NCT02371824|Lumbar Vertebrae
112836|NCT02371785|Peripheral Arterial Disease
112837|NCT02371785|Critical Limb Ischemia
112838|NCT02371785|Claudication
112839|NCT02371785|Percutaneous Vascular Intervention
112840|NCT02371785|Peripheral Vascular Intervention
112841|NCT02371772|Warfarin
112842|NCT02371772|Self Care
112843|NCT02371772|Conventional care
112844|NCT02371733|pulmonary arterial hypertension
112845|NCT02371733|aerobic exercise training
112846|NCT02371733|upper extremity
112847|NCT02371733|exercise capacity
112848|NCT02371694|Lipid
112849|NCT02371694|Carbohydrate counting
112850|NCT02371694|Adolescent
112851|NCT02371694|Continuous glucose monitoring
112852|NCT02371694|Insulin requirements
112853|NCT02371681|HR2E/RIPE
112854|NCT02371681|South Africa
112855|NCT02371681|Time to Positivity/TTP
112856|NCT02371681|FDG-PET/CT
112857|NCT02371668|Influenza A
112858|NCT02371668|H1N1
112859|NCT02371668|Challenge Model
112860|NCT02371668|Human Immunoglobulin and H1N1
112861|NCT02371668|Efficacy and Safety in H1N1
112862|NCT02371655|Bowel cleansing
112863|NCT02371655|CTcolonography
112864|NCT02371655|Bowel preparation
112865|NCT02371655|Faecal and fluid tagging
112866|NCT02371642|Echocardiography
112867|NCT02371629|Anticholinergic
112868|NCT02371629|Antimuscarinic
112869|NCT02371629|Chronic Obstructive Airway Disease
112870|NCT02371629|Chronic Obstructive Lung Disease
112871|NCT02371629|Chronic Obstructive Pulmonary Disease
112872|NCT02371629|COPD
112873|NCT02371629|LAMA
112874|NCT02371629|Lung Disease
112875|NCT02371629|Lung Diseases, Obstructive
112876|NCT02371629|Lung Function
112877|NCT02371629|Muscarinic receptor antagonist
112878|NCT02371629|Pulmonary Disease, Chronic Obstructive
112879|NCT02371629|Respiratory Tract Diseases
112880|NCT02371603|Prolyl hydroxylase inhibitor
112881|NCT02371603|GSK1278863
112882|NCT02371603|Anemia
112883|NCT02371603|Drug interaction
112884|NCT02371590|cancer
112885|NCT02371590|lenalidomide
112886|NCT02371590|obinutuzumab
112887|NCT02371590|CLL
112888|NCT02371577|Revlimid
112889|NCT02371551|Diffusion Magnetic Resonance Imaging
112890|NCT02371551|Medical Sonography
112891|NCT02371551|Computed Tomography, X-Ray
112892|NCT02371538|stem cell transplant
112893|NCT02371538|human breastmilk
112894|NCT02371525|adherence
112895|NCT02371525|prevention
112896|NCT02371512|Mitral Valve Insufficiency
112897|NCT02371499|Irritable Bowel Syndrome
112898|NCT02371499|Lactobacillus casei dg
112899|NCT02371499|microbiota
112900|NCT02371486|cesarean section defect
112901|NCT02371486|implantation
112902|NCT02371486|ivf
112903|NCT02371473|Acetazolamide
112904|NCT02371473|Central Sleep Apnea
112905|NCT02371473|Opium Abuse
112906|NCT02371460|Neonatal Prematurity
112907|NCT02371460|Omega-3 Fatty Acids
112908|NCT02371460|Breastfeeding
112909|NCT02371447|bladder cancer
112910|NCT02371447|recurrent non-muscle invasive bladder cancer
112911|NCT02371447|VPM1002BC
112912|NCT02371447|BCG therapy
112913|NCT02371369|Pigmented Villonodular Synovitis
112914|NCT02371369|Giant Cell Tumors of the Tendon Sheath
112915|NCT02371369|Tenosynovial Giant Cell Tumour
112916|NCT02371369|PLX3397
112917|NCT02371369|Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor
112918|NCT02371330|Thrombocytopenia
112919|NCT02371330|Neonate
112920|NCT02371330|PFA-100
112921|NCT02371330|Neo-BAT
112922|NCT02371330|Hemorrhage
112923|NCT02371317|Randomized clinical trial
112924|NCT02371317|Early medical intervention
112925|NCT02371317|Intervention studies
112926|NCT02371317|Blood pressure
112927|NCT02371317|Stress Management
112928|NCT02371304|local therapy
112929|NCT02371304|adjuvant chemoradiotherapy
112930|NCT02371304|rectal preserving
112931|NCT02371291|Memory Flexibility
112932|NCT02371278|Leucine
112933|NCT02371278|Protein
112934|NCT02371278|Diet
112935|NCT02371278|Muscle protein synthesis
112936|NCT02371265|HIV
112937|NCT02371265|Mozambique
112938|NCT02371265|antenatal care
112939|NCT02371265|adherence
112940|NCT02371265|retention
112941|NCT02371265|pregnancy
112942|NCT02371265|HIV-positive mothers retained in ART after 90 days
112943|NCT02371252|Osteoporosis
112944|NCT02371252|Bisphosphonates
112945|NCT02371252|Alendronate
112946|NCT02371252|Bone mineral density
112947|NCT02371252|Bone markers
112948|NCT02371239|Glucose regulation
112949|NCT02371239|Glucose
112950|NCT02371239|Lipids
112951|NCT02371226|MPS I
112952|NCT02371213|Social Networking
112953|NCT02371213|Mobile phone
112954|NCT02371213|Antenatal Care
112955|NCT02371213|Health education
112956|NCT02371213|Maternal outcome
112957|NCT02371213|Neonatal outcome
112958|NCT02371174|HER2-Negative Inoperable or Recurrent Breast Cancer
112959|NCT02371174|Japan
112960|NCT02371174|Eribulin Mesylate
112961|NCT02371135|Gut Microbiome
112962|NCT02371135|15-016
112963|NCT02370121|Gymnema Sylvestre
112964|NCT02370121|Insulin Secretion
112965|NCT02370121|Insulin Sensitivity
112966|NCT02370121|Central Obesity
112967|NCT02370108|electrical muscle stimulation
112968|NCT02370108|parkinson's disease
112969|NCT02370108|rest tremor
112970|NCT02370108|tremor reduction
112971|NCT02370095|ARDS
112972|NCT02370095|Acute Lung Injury
112973|NCT02370095|Acute Respiratory Failure
112974|NCT02370082|lumpectomy
112975|NCT02370082|breast conserving surgery
112976|NCT02371083|Pelvic organ prolapse managed by vaginal pessary
112977|NCT02370979|Dolutegravir
112978|NCT02370979|Proviral HIV-1 DNA
112979|NCT02370979|Reservoir
112980|NCT02370953|Toric IOL alignment
112981|NCT02370953|VERION digital marker
112982|NCT02370953|Manual ink-marking
112983|NCT02370953|Randomized controlled trial
112984|NCT02370940|Iron bioavailability
112985|NCT02370940|phytate
112986|NCT02370940|serum iron curve
112987|NCT02370940|hepcidin
112988|NCT02370940|iron status
112989|NCT02370914|Concussion
112990|NCT02370888|Lenalidomide
112991|NCT02370888|Hematopoietic Stem Cell Transplantation
112992|NCT02370888|Peripheral Blood Stem Cell Transplantation
112993|NCT02370862|Spinal Cord Injury
112994|NCT02370862|Neurogenic Bowel
112995|NCT02370862|Bowel Evacuation
112996|NCT02370862|Gut Motility
112997|NCT02370849|nimotuzumab
112998|NCT02370849|gastric adenocarcinoma
112999|NCT02370849|Cisplatin
113000|NCT02370849|S-1
113001|NCT02370849|epidermal growth factor receptor
113002|NCT02370836|distress
113003|NCT02370823|Osteoarthritis
113004|NCT02370823|Knee
113005|NCT02370810|tinnitus treatment, internet-intervention, CBT
113006|NCT02370797|IOERT
113007|NCT02370797|Radiation
113008|NCT02370797|Single fraction
113009|NCT02370797|Lumpectomy
113010|NCT02370797|Radiation therapy
113011|NCT02370797|Avera
113012|NCT02370784|early diffuse scleroderma
113013|NCT02370784|Raynaud
113014|NCT02370758|Quantiferon-CMV
113015|NCT02370758|Quantiferon-Monitor
113016|NCT02370758|Solid Organ Transplants
113017|NCT02370758|CMV Disease
113018|NCT02370745|Incretin
113019|NCT02370745|GLP-1
113020|NCT02370745|Skeletal muscle metabolism
113021|NCT02370745|Microvascular recruitment
113022|NCT02370745|Amino Acids
113023|NCT02370745|Microvascular blood flow
113024|NCT02370732|Alcohol
113025|NCT02370732|Bariatric Surgery
113026|NCT02370732|Roux en Y Gastric bypass
113027|NCT02370732|Alcohol impairment
113028|NCT02370732|Alcohol reinforcement
113029|NCT02370732|Alcohol pharmacokinetics
113030|NCT02370719|Diabetes mellitus
113031|NCT02370719|Randomized controlled trial
113032|NCT02370719|Primary care
113033|NCT02370719|Physical activity
113034|NCT02370719|Lifestyle
113035|NCT02370719|Blood glucose
113036|NCT02370719|Mobile health
113037|NCT02370719|Hb A1c
113038|NCT02370719|Self-management
113039|NCT02370706|PIM447
113040|NCT02370706|LGH447
113041|NCT02370706|PIM inhibitor
113042|NCT02370706|LEE011
113043|NCT02370706|CDK 4/6 inhibitor
113044|NCT02370706|ruxolitinib
113045|NCT02370706|INC424
113046|NCT02370706|Jakavi®
113047|NCT02370706|Jakafi®
113048|NCT02370706|INCB18424
113049|NCT02370706|JAK inhibitor
113050|NCT02370706|myelofibrosis
113051|NCT02370706|PMF
113052|NCT02370706|PPV-MF
113053|NCT02370706|PET-MF
113054|NCT02370693|mycophenolate
113055|NCT02370693|lung scarring
113056|NCT02370680|Antiplatelet
113057|NCT02370680|Antiplatelet therapy
113058|NCT02370680|platelet turnover
113059|NCT02370680|high platelet turnover
113060|NCT02370680|platelet aggregation
113061|NCT02370680|cardiovascular disease
113062|NCT02370680|coronary artery disease
113063|NCT02370680|diabetes mellitus
113064|NCT02370667|Exercise
113065|NCT02370667|Magnetic Resonance Imaging
113066|NCT02370654|COPD
113067|NCT02370654|Tai chi
113068|NCT02370654|Pulmonary rehabilitation
113069|NCT02370641|urolithin A
113070|NCT02370641|microflora
113071|NCT02370628|percutaneous vertebroplasty
113072|NCT02370628|facet block
113073|NCT02370602|Drug therapy
113074|NCT02370589|Ebola
113075|NCT02370537|omega-3 carboxylic acid
113076|NCT02370498|Gastric cancer
113077|NCT02370498|Gastroesophageal junction cancer
113078|NCT02370472|Ultrasound
113079|NCT02370472|Image
113080|NCT02370472|Learning Tool
113081|NCT02370472|Ultrasound Guide Procedures
113082|NCT02370472|Simulated Setting
113083|NCT02370459|Papillomavirus Vaccines
113084|NCT02370459|Immunization
113085|NCT02370459|Quality Improvement
113086|NCT02370459|Adolescent Health Services
113087|NCT02370446|Medication Log
113088|NCT02370446|15-008
113089|NCT02370433|Spinal Cord Injury
113090|NCT02370433|Neurogenic Bowel
113091|NCT02370433|Bowel Evacuation
113092|NCT02370420|Platelet-rich plasma
113093|NCT02370420|Osteoarthritis
113094|NCT02370407|surgical education
113095|NCT02370407|minimally invasive surgical procedures
113096|NCT02370407|laparoscopic simulation
113097|NCT02370407|robotic simulation
113098|NCT02370407|medical education
113099|NCT02370394|Intimate Partner Violence
113100|NCT02370394|Perinatal Women
113101|NCT02370394|Mental Health
113102|NCT02370316|metacognition
113103|NCT02370316|MRI
113104|NCT02370316|Psychotherapy
113105|NCT02370251|Fat Emulsions, Intravenous
113106|NCT02370251|Parenteral-Nutrition-Associated Liver Disease
113107|NCT02370251|Cholestasis
113108|NCT02370251|Omegaven
113109|NCT02370251|Fish Oil
113110|NCT02370238|Triple negative metastatic breast cancer
113111|NCT02370238|Cancer Stem Cells
113112|NCT02370225|sjogren's syndrome
113113|NCT02370225|aerobic exercise
113114|NCT02370225|fatigue
113115|NCT02370212|Creatine
113116|NCT02370212|interval training
113117|NCT02370212|effects on performance
113118|NCT02370173|PTSD
113119|NCT02370173|Stress
113120|NCT02370173|Sleep Problems
113121|NCT02370173|Brain imaging
113122|NCT02370173|fMRI
113123|NCT02370147|smoking reduction intervention
113124|NCT02370147|no intention to quit
113125|NCT02370147|randomized controlled trial
113126|NCT02370147|telephone follow-up intervention
113127|NCT02370030|sepsis
113128|NCT02370030|citrulline
113129|NCT02370030|endothelial
113130|NCT02370030|toxemia
113131|NCT02370030|endothelial determination of progression
113132|NCT02370030|with vs without citrulline
113133|NCT02370017|Autologous Ex vivo-expanded NK cell enriched lymphocytes
113134|NCT02370004|Asthma
113135|NCT02370004|RFST
113136|NCT02370004|Bronchial Diseases
113137|NCT02370004|Respiratory Tract Diseases
113138|NCT02370004|Lung Diseases, Obstructive
113139|NCT02370004|Lung Diseases
113140|NCT02369991|latissimus dorsi flap
113141|NCT02369991|bone transport
113142|NCT02369991|bone reconstruction
113143|NCT02369991|tibia
113144|NCT02369991|tibial fracture
113145|NCT02369978|Trypanocidal therapy
113146|NCT02369978|Benznidazole
113147|NCT02369978|Nifurtimox
113148|NCT02369978|Polymerase chain reaction
113149|NCT02369978|Randomized trial
113150|NCT02369965|HIV-1
113151|NCT02369965|AIDS
113152|NCT02369965|Albuvirtide
113153|NCT02369965|Treatment-experienced
113154|NCT02369965|Fusion inhibitor
113155|NCT02369939|anal carcinoma
113156|NCT02369939|hyperthermia
113157|NCT02369939|radiotherapy
113158|NCT02369939|chemotherapy
113159|NCT02369939|radiochemotherapy
113160|NCT02369926|multiple sclerosis
113161|NCT02369926|telemedicine
113162|NCT02369926|remote monitoring
113163|NCT02369926|lisinopril
113164|NCT02369900|Esmolol
113165|NCT02369900|Septic Shock
113166|NCT02369900|Hypotension
113167|NCT02369900|Tachycardia
113168|NCT02369887|MSM/TG who agree to start PrEP
113169|NCT02369874|Head and Neck cancer; MEDI4736; Tremelimumab
113170|NCT02369822|Vitamin C
113171|NCT02369822|convulsions status
113172|NCT02369822|EEG
113173|NCT02369822|children
113174|NCT02369809|Ischemia
113175|NCT02369796|Drug therapy
113176|NCT02369770|Stroke
113177|NCT02369770|Robotics
113178|NCT02369770|Ankle
113179|NCT02369770|Active Stretching
113180|NCT02369770|Passive Stretching
113181|NCT02369770|Range of Motion
113182|NCT02369744|Ureteral calculus
113183|NCT02369744|Ureterolithiasis
113184|NCT02369744|Ureteral stone
113185|NCT02369744|Kidney stone
113186|NCT02369744|Medical expulsive therapy
113187|NCT02369744|tamsulosin
113188|NCT02369744|silodosin
113189|NCT02369744|rapaflo
113190|NCT02369744|flomax
113191|NCT02369679|upper limb
113192|NCT02369679|lymphedema
113193|NCT02369666|Inflammation
113194|NCT02369666|Lycopene
113195|NCT02369666|Exercise
113196|NCT02369653|Anticoagulation
113197|NCT02369614|rTMS - repetitive transcranial magnetic stimulation
113198|NCT02369614|CAPS - Clinician Administered PTSD Scale
113199|NCT02369601|amniorrhexis
113200|NCT02369601|Ruptured membranes
113201|NCT02369601|Alfa-fetoprotein
113202|NCT02369562|Dental implants
113203|NCT02369562|Periodontal Bone Loss
113204|NCT02369549|Chronic Kidney Disease (CKD)
113205|NCT02369549|Micro-particle curcumin
113206|NCT02369549|Albuminuria
113207|NCT02369536|NAFLD
113208|NCT02369536|nutraceutical mixture
113209|NCT02369523|Primary Total Knee Arthroplasty
113210|NCT02369510|spinal anesthesia
113211|NCT02369510|epinephrine
113212|NCT02369510|bupivacaine
113213|NCT02369510|repeat cesarean
113214|NCT02369484|Stage IIIb/ IV NSCLC harbouring HER2 exon 20 mutations
113215|NCT02369471|Cannabidivarin
113216|NCT02369471|CBDV
113217|NCT02369471|GWP42006
113218|NCT02369432|Drug carriers
113219|NCT02369432|Polymeric microparticles
113220|NCT02369432|Preferential accumulation in inflamed skin
113221|NCT02369432|Atopic dermatitis
113222|NCT02369432|Pilosebaceous follicles
113223|NCT02369432|Selective drug delivery
113224|NCT02369432|Drug reservoir
113225|NCT02369419|frailty
113226|NCT02369419|Heart failure
113227|NCT02369419|cardiac resynchronization therapy
113228|NCT02369406|Botswana
113229|NCT02369406|Immunology
113230|NCT02369406|Antiretroviral Therapy
113231|NCT02369393|Internet based treatment
113232|NCT02369393|Depression
113233|NCT02369393|Efficacy
113234|NCT02369393|Cost-effectiveness
113235|NCT02369393|Behavioral Activation
113236|NCT02369393|Physical Activity
113237|NCT02369393|Self-applied
113238|NCT02369393|Ecological Momentary Assessment
113239|NCT02369367|Malignant Gliomas
113240|NCT02369367|Glioblastoma Multiforme
113241|NCT02369367|Gliosarcoma
113242|NCT02369367|Anaplastic Astrocytoma
113243|NCT02369367|Anaplastic Oligodendroglioma
113244|NCT02369367|Anaplastic Oligoastrocytoma
113245|NCT02369367|Camptosar
113246|NCT02369367|Irinotecan
113247|NCT02369367|CPT-11
113248|NCT02369367|Lenalidomide
113249|NCT02369367|Revlimid
113250|NCT02369367|CC-5013
113251|NCT02369354|Kidney Transplant
113252|NCT02369354|African Americans
113253|NCT02369341|Southern Hemisphere influenza vaccine
113254|NCT02369341|Elderly
113255|NCT02369341|Seasonal flu
113256|NCT02369341|Fluarix Tetra
113257|NCT02369341|Adults
113258|NCT02369341|Immunogenicity
113259|NCT02369341|Reactogenicity
113260|NCT02369341|Influenza
113261|NCT02369315|child development
113262|NCT02369315|music training
113263|NCT02369315|self-regulation
113264|NCT02369315|exposure to violence
113265|NCT02369276|neck dissection surgery
113266|NCT02369276|shoulder disability
113267|NCT02369276|musculoskeletal ultrasonography
113268|NCT02369263|Deep Vein Thrombosis
113269|NCT02369263|DVT
113270|NCT02369263|Leg Swelling
113271|NCT02369263|Leg Pain
113272|NCT02369263|Blood Clot
113273|NCT02369250|regeneration
113274|NCT02369250|surgical therapy
113275|NCT02369250|furcation defect
113276|NCT02369211|acetaminophen
113277|NCT02369172|Herpes
113278|NCT02369172|volunteers
113279|NCT02369172|drug-drug interaction
113280|NCT02369120|patient education
113281|NCT02369120|pain cognitions
113282|NCT02369107|acupuncture
113283|NCT02369107|chemotherapy-induced nausea and vomiting
113284|NCT02369094|Frailty
113285|NCT02369094|Frail elderly
113286|NCT02369094|Acupressure
113287|NCT02369094|Pragmatic Randomised Controlled Trial
113288|NCT02369081|Hypertension
113289|NCT02369055|Rehabilitation
113290|NCT02369029|Phase I
113291|NCT02369029|Dose escalation
113292|NCT02369029|NUT-midline carcinoma
113293|NCT02369029|Acute Leucemia
113294|NCT02369029|Lymphoma
113295|NCT02369029|Melanoma
113296|NCT02369029|Myeloma
113297|NCT02369029|HCC
113298|NCT02369029|NSCLC
113299|NCT02369016|indolent Non-Hodgkin lymphoma
113300|NCT02369016|rituximab-refractory
113301|NCT02369003|Deep Brain Stimulation
113302|NCT02369003|Schwann Cells
113303|NCT02368990|NSCLC
113304|NCT02368990|T790M
113305|NCT02368990|EGFR
113306|NCT02368990|TKI Resistance
113307|NCT02368990|Non Small Cell Lung Cancer
113308|NCT02368990|AZD9291
113309|NCT02368990|Clovis
113310|NCT02368977|Colonoscopy
113311|NCT02368977|Polyps
113312|NCT02368977|Adenomas
113313|NCT02368964|double triggering
113314|NCT02368964|Oocyte maturation
113315|NCT02368964|GNRH Agonist
113316|NCT02368964|hCG
113317|NCT02368964|IVF treatment
113318|NCT02368964|immature oocytes
113319|NCT02368951|Phase 1
113320|NCT02368951|Solid Tumors
113321|NCT02368951|FGFR2
113322|NCT02368951|Antibody drug conjugate
113323|NCT02368938|Cardiovascular risk factors
113324|NCT02368938|Prospective study
113325|NCT02368938|Mortality
113326|NCT02368938|Cardiovascular events
113327|NCT02368938|Asymptomatic target organ damage
113328|NCT02368938|elderly Chinese
113329|NCT02368925|Rhytids
113330|NCT02368925|Skin Laxity
113331|NCT02368912|Phase 1
113332|NCT02368912|ASP1707
113333|NCT02368912|Dose escalation
113334|NCT02368912|Food effect
113335|NCT02368912|Maximum tolerated dose (MTD)
113336|NCT02368912|Healthy subjects
113337|NCT02368912|Single ascending dose
113338|NCT02368912|Multiple ascending dose
113339|NCT02368899|technology
113340|NCT02368899|information science
113341|NCT02368899|health care
113342|NCT02368873|prevention
113343|NCT02368847|Aged
113344|NCT02368847|Psychiatric Hospitals
113345|NCT02368821|cytotrophoblast
113346|NCT02368821|syncytiotrophoblast
113347|NCT02368821|placentas
113348|NCT02368821|intrauterine growth restriction
113349|NCT02368821|preeclampsia
113350|NCT02368821|placenta accrete
113351|NCT02368808|orphans and vulnerable children
113352|NCT02368808|South Africa
113353|NCT02368808|peer support group
113354|NCT02368795|Endoscopic Retrograde Cholangiopancreatography
113355|NCT02368795|Pancreatic duct stenting
113356|NCT02368795|Post-ERCP pancreatitis
113357|NCT02368782|transient evoked otoacoustic emissions
113358|NCT02368782|distortion product otoacoustic emissions
113359|NCT02368782|ketamine
113360|NCT02368782|propofol
113361|NCT02368782|child
113362|NCT02368756|dme
113363|NCT02368704|Endoplasmic Reticulum
113364|NCT02368678|Halitosis
113365|NCT02368678|Sulfur compounds
113366|NCT02368678|Periodontitis
113367|NCT02368678|Periodontal treatment
113368|NCT02368600|lifestyle intervention
113369|NCT02368600|gestational diabetes mellitus
113370|NCT02368600|Chinese
113371|NCT02368600|prevention
113372|NCT02368587|intracoronary infusion
113373|NCT02368587|intravenous infusion
113374|NCT02368587|Wharton's jelly-derived mesenchymal stem cells
113375|NCT02368587|ischemic Cardiomyopathy
113376|NCT02368587|heart function
113377|NCT02368548|Pharmaceutical care
113378|NCT02368548|Emergency Service
113379|NCT02368535|teamwork
113380|NCT02368509|sensory test
113381|NCT02368509|olfaction
113382|NCT02368509|gustation
113383|NCT02368509|taste
113384|NCT02368509|cancer
113385|NCT02368496|Long-term parenteral nutrition
113386|NCT02368496|HR-pQCT
113387|NCT02368496|DXA
113388|NCT02368496|Bone trophicity
113389|NCT02368457|Mandibular osteoradionecrosis
113390|NCT02368457|Tocopherol
113391|NCT02368457|pentoxifylline
113392|NCT02368457|vitamine E
113393|NCT02368457|wounds and injuries
113394|NCT02368457|antioxidants
113395|NCT02368457|free radical scavengers
113396|NCT02368457|radiation-protective agents
113397|NCT02368457|vasodilatadors agents
113398|NCT02368457|osteonecrosis
113399|NCT02368457|mandible
113400|NCT02368457|extraoral fistula
113401|NCT02368457|exposed bone
113402|NCT02368457|necrotic bone
113403|NCT02368457|head and neck radiotherapy
113404|NCT02368444|Posttraumatic Stress
113405|NCT02368444|Sleep
113406|NCT02368431|Alcohol Use Disorder
113407|NCT02368431|Alcoholism
113408|NCT02368431|Alcohol Dependence
113409|NCT02368431|Zonisamide
113410|NCT02368431|Alcoholic Intoxication
113411|NCT02368431|Drinking Behaviors
113412|NCT02368431|Anticonvulsants
113413|NCT02368418|Cardiovascular disease
113414|NCT02368418|Rural health
113415|NCT02368418|China
113416|NCT02368418|Cohort study
113417|NCT02368392|in-hospital cardiac arrest
113418|NCT02368392|quality of life after cardiac arrest
113419|NCT02368392|survival after cardiac arrest
113420|NCT02368392|resources for cardiac arrest
113421|NCT02368379|Metyrapone
113422|NCT02368379|ACTH stimulation test
113423|NCT02368314|Deep vein thrombosis
113424|NCT02368314|Prophylaxis
113425|NCT02368314|Sodium enoxaparin
113426|NCT02368288|chronic hepatitic B
113427|NCT02368288|peginterferon
113428|NCT02368288|HBsAg
113429|NCT02368288|entecavir
113430|NCT02368262|Cerebral Palsy
113431|NCT02368262|Risk factors
113432|NCT02368262|Child
113433|NCT02368262|urinary incontinence
113434|NCT02368236|Early Detection of Cancer
113435|NCT02368236|Intervention Studies
113436|NCT02368236|Randomized Controlled Trial
113437|NCT02368236|Colorectal Neoplasms
113438|NCT02368236|Colonic Neoplasms
113439|NCT02368223|Children
113440|NCT02368223|Rehabilitation
113441|NCT02368223|Telerehabilitation
113442|NCT02368223|Upper limb therapy
113443|NCT02368197|dialysis fistula
113444|NCT02368197|cephalic arch stenosis
113445|NCT02368197|balloon angioplasty
113446|NCT02368197|drug eluting balloon
113447|NCT02368184|noninvasive physiologic monitoring
113448|NCT02368184|acute decompensated heart failure (ADHF)
113449|NCT02368158|myocard infarction
113450|NCT02368158|arrhythmia
113451|NCT02368158|fitness of driving
113452|NCT02368145|stroke
113453|NCT02368145|acute stroke
113454|NCT02368145|post stroke depression
113455|NCT02368132|Caregivers
113456|NCT02368132|Dementia
113457|NCT02368106|patient registry
113458|NCT02368106|radiation oncology
113459|NCT02368106|technology assessment
113460|NCT02368093|Rheumatoid arthritis
113461|NCT02368080|Lung Clearance Index
113462|NCT02368080|Cystic Fibrosis
113463|NCT02368080|Multiple Breath Nitrogen Washout
113464|NCT02368054|Epinephrine
113465|NCT02368054|Bupivacaine
113466|NCT02368054|Stroke Volume
113467|NCT02368054|Cardiac Output
113468|NCT02368054|Heart Rate
113469|NCT02368054|Hemodynamics
113470|NCT02368054|Total Peripheral Resistance
113471|NCT02368054|Blood Pressure
113472|NCT02368054|Paracervical block
113473|NCT02368054|LiDCO
113474|NCT02368054|Adrenaline
113475|NCT02368054|Conization
113476|NCT02368054|PulsCO
113477|NCT02368028|Plaque
113478|NCT02368028|Saliva
113479|NCT02368028|Dental Caries
113480|NCT02368015|Penetration
113481|NCT02368015|Cefazolin
113482|NCT02368015|Hepatic cyst
113483|NCT02368002|obesity
113484|NCT02368002|diet, reducing
113485|NCT02367989|Glucose response
113486|NCT02367989|Insulin response
113487|NCT02367989|Satiety
113488|NCT02367963|Peer education
113489|NCT02367963|Comprehensive health intervention
113490|NCT02367963|Lifestyle
113491|NCT02367963|Adult
113492|NCT02367963|Mid age
113493|NCT02367963|Male
113494|NCT02367963|Female
113495|NCT02367963|Human
113496|NCT02367963|Clinical trial
113497|NCT02367963|Prevention and control
113498|NCT02367963|Cardiovascular Disease
113499|NCT02367963|Behavior
113500|NCT02367963|Risk Factors
113501|NCT02367963|Healthy lifestyle
113502|NCT02367963|Healthy people program
113503|NCT02367963|Peer-group
113504|NCT02367937|Phase I drug-drug interaction
113505|NCT02367898|Cognitive Training
113506|NCT02367898|Lumosity
113507|NCT02367898|Crossword Puzzles
113508|NCT02367885|Prevention
113509|NCT02367872|Drug therapy
113510|NCT02367859|ameloblastoma
113511|NCT02367859|BRAF
113512|NCT02367859|odontogenic cancer
113513|NCT02367859|adamantinoma
113514|NCT02367846|Calcium Tracer
113515|NCT02367846|Oral Contraceptives
113516|NCT02367846|Contraceptive Vaginal Ring
113517|NCT02367846|Impact of contraceptives on bone health using 41Ca
113518|NCT02367833|Insulin-like growth factor-1
113519|NCT02367833|Combined oral contraceptive
113520|NCT02367833|Contraceptive Vaginal Ring
113521|NCT02367833|Transdermal Contraceptive
113522|NCT02367807|HIV prevention
113523|NCT02367807|PrEP
113524|NCT02367807|young men who have sex with men
113525|NCT02367807|Truvada
113526|NCT02367768|trauma blue
113527|NCT02367768|major trauma
113528|NCT02367768|cohort study
113529|NCT02367768|prognostic factor
113530|NCT02367768|Healing Time
113531|NCT02367768|Post Operative
113532|NCT02367755|cardiopulmonary resuscitation
113533|NCT02367755|cardiac arrest
113534|NCT02367755|therapeutic hypothermia
113535|NCT02367755|propofol
113536|NCT02367755|lorazepam
113537|NCT02367755|cerebral perfusion
113538|NCT02367755|electroencephalography
113539|NCT02367742|Diet
113540|NCT02367742|Physical Activity
113541|NCT02367742|NAFLD
113542|NCT02367703|Mini-laparoscopy
113543|NCT02367703|hysterectomy
113544|NCT02367703|Benign uterine diseases
113545|NCT02367703|Operative time
113546|NCT02367690|Diabetes
113547|NCT02367690|Foot Ulcers
113548|NCT02367690|DFU
113549|NCT02367690|KPT-330
113550|NCT02367690|Selinexor
113551|NCT02367690|Karyopharm
113552|NCT02367677|Photo
113553|NCT02367664|Japanese encephalitis
113554|NCT02367664|immunogenicity
113555|NCT02367664|safety
113556|NCT02367664|vaccine
113557|NCT02367651|Soft tissue sarcoma
113558|NCT02367651|Pazopanib
113559|NCT02367651|Tyrosine kinase inhibitor
113560|NCT02367599|PrEP
113561|NCT02367599|Pre exposure Prophylaxis
113562|NCT02367599|Truvada
113563|NCT02367599|CCTG
113564|NCT02367599|595
113565|NCT02367599|Vitamin D
113566|NCT02367599|Bone mineral density
113567|NCT02367521|TBI Depression
113568|NCT02367521|co-morbid psychiatric symptoms
113569|NCT02367508|advance care planning
113570|NCT02367508|coping skills
113571|NCT02367508|mindfulness
113572|NCT02367508|meditation
113573|NCT02367508|cancer
113574|NCT02367508|adult
113575|NCT02367508|caregivers
113576|NCT02367508|oncology providers
113577|NCT02367508|advance directives
113578|NCT02367508|anxiety
113579|NCT02367508|depression
113580|NCT02367508|quality of life
113581|NCT02367508|pilot project
113582|NCT02367495|Coronary Restenosis
113583|NCT02367495|restenosis
113584|NCT02367495|paclitaxel-coated balloon
113585|NCT02367495|drug-eluting stent
113586|NCT02367495|drug-coated balloon
113587|NCT02367495|coronary angiography
113588|NCT02367482|rGBM
113589|NCT02367482|Recurrent GBM
113590|NCT02367482|Recurrent Glioblastoma
113591|NCT02367469|recurrent brain tumors
113592|NCT02367469|brain tumors
113593|NCT02367469|Newly diagnosed brain tumors
113594|NCT02367456|MDS
113595|NCT02367456|AML
113596|NCT02367456|CMML
113597|NCT02367443|radiotherapy
113598|NCT02367443|therapeutic use
113599|NCT02367443|Radiation
113600|NCT02367443|non-small cell lung cancer
113601|NCT02367443|chemotherapy
113602|NCT02367417|Revision
113603|NCT02367417|Knee Joint
113604|NCT02367417|PMCF
113605|NCT02367378|Minimally invasive surgery
113606|NCT02367365|Neovascular Age-Related Macular Degeneration
113607|NCT02367365|anti-vascular endothelial growth factor
113608|NCT02367365|neovascular lesion morphology
113609|NCT02367365|indocyanine green angiography
113610|NCT02367365|persistent disease activity
113611|NCT02367352|Drug therapy
113612|NCT02367352|dose escalation
113613|NCT02367352|dose expansion
113614|NCT02367339|Critical Care
113615|NCT02367339|Nursing staff
113616|NCT02367339|Medical staff
113617|NCT02367339|Extended-spectrum betalactamase
113618|NCT02367339|Digestive tract colonization
113619|NCT02367339|Cross-contamination
113620|NCT02367326|score
113621|NCT02367326|inflammatory bowel disease
113622|NCT02367326|crohn's disease
113623|NCT02367326|ulcerative colitis
113624|NCT02367326|clinical response
113625|NCT02367326|thiopurines
113626|NCT02367313|Symptomatic Human Rhinovirus Infection
113627|NCT02367313|Moderate to Severe Asthma
113628|NCT02367313|Antiviral
113629|NCT02367313|Cold
113630|NCT02367313|Aviragen Therapeutics, Inc.
113631|NCT02367313|Aviragen Therapeutics
113632|NCT02367313|Aviragen
113633|NCT02367287|Diet
113634|NCT02367287|Phenotype
113635|NCT02367287|Immunology
113636|NCT02367287|Microbiota
113637|NCT02367287|Metabolomics
113638|NCT02367287|Physical activity
113639|NCT02367287|Neuroendocrine system
113640|NCT02367287|Nutritional Physiological Phenomena
113641|NCT02367248|Brain hemorrhage
113642|NCT02367248|Cerebral Hemorrhage
113643|NCT02367248|Deferoxamine
113644|NCT02367248|Xingnaojing injection
113645|NCT02367248|Hematoma edema
113646|NCT02367235|robotic
113647|NCT02367235|sacrocolpopexy
113648|NCT02367235|Colpassist
113649|NCT02367235|vaginal positioning device
113650|NCT02367209|FD MRI
113651|NCT02367209|COPD
113652|NCT02367209|SPECT/CT
113653|NCT02367209|DCE MRI
113654|NCT02367196|CC-90002
113655|NCT02367196|Monoclonal
113656|NCT02367196|Antibody
113657|NCT02367196|CD47
113658|NCT02367196|Advanced
113659|NCT02367196|Solid Cancers
113660|NCT02367196|Hematologic Cancers
113661|NCT02367183|Crohn's Disease
113662|NCT02367183|Active Crohn's Disease
113663|NCT02367183|GED-0301
113664|NCT02367183|Endoscopic
113665|NCT02367183|Double-Blind
113666|NCT02367183|IBD
113667|NCT02367183|Mongersen
113668|NCT02367170|respiratory dysfunction
113669|NCT02367170|chronic critical illness
113670|NCT02367170|diaphragm weakness
113671|NCT02367170|sepsis
113672|NCT02367170|ventilator dependance
113673|NCT02367118|chronic rhinosinusitis without nasal polyps prednisone
113674|NCT02367105|Obesity
113675|NCT02367105|Hypogonadism
113676|NCT02367105|Frailty
113677|NCT02367066|patients
113678|NCT02367066|glycaemic control on metformin
113679|NCT02367040|Clinical trial, Phase III
113680|NCT02367040|Phosphatidylinositol-3-kinase
113681|NCT02367040|Non-Hodgkin's lymphoma
113682|NCT02367040|Indolent B-cell non-Hodgkin's lymphoma
113683|NCT02367027|Biological Availability
113684|NCT02367027|Relative Bioavailability Trial
113685|NCT02367014|Mitochondrial Myopathy
113686|NCT02367014|Primary Mitochondrial Disease
113687|NCT02367014|Bendavia™
113688|NCT02367014|elamipretide
113689|NCT02367001|general practitioner
113690|NCT02367001|screening
113691|NCT02367001|participation
113692|NCT02367001|organized screening
113693|NCT02366988|Chronic pancreatitis
113694|NCT02366988|Clinical Trial
113695|NCT02366988|Bile stricture
113696|NCT02366988|Endoscopy
113697|NCT02366988|Surgery
113698|NCT02366975|BPH/LUTS
113699|NCT02366975|TRT
113700|NCT02366975|Metabolic Syndrome
113701|NCT02366962|Influenza
113702|NCT02366962|Vaccine
113703|NCT02366962|ASP7374
113704|NCT02366949|Phase 1
113705|NCT02366949|Solid tumors
113706|NCT02366949|Breast cancer
113707|NCT02366949|Paclitaxel
113708|NCT02366949|MPS-1 inhibitor
113709|NCT02366949|Oncology
113710|NCT02366884|malignant
113711|NCT02366884|atavistic chemotherapy
113712|NCT02366884|cancer
113713|NCT02366858|19 gauge
113714|NCT02366858|22 gauge
113715|NCT02366858|core tissue
113716|NCT02366806|Breast Cancer
113717|NCT02366806|AJCC Stage 1, 2, 3
113718|NCT02366806|Educational Design
113719|NCT02366806|Radiation Therapy Treatment
113720|NCT02366793|accessory mobilization, nerve mobilization.
113721|NCT02366780|Lactation
113722|NCT02366780|Breastmilk
113723|NCT02366780|Macronutrients
113724|NCT02366767|Insulin Infusion Systems
113725|NCT02366767|Continuous Glucose Monitors
113726|NCT02366754|Transcranial Magnetic Stimulation
113727|NCT02366741|SCLC
113728|NCT02366741|Neuro-cognitive function
113729|NCT02366741|PCI
113730|NCT02366741|Hippocampal sparing
113731|NCT02366676|Recurrent cystitis
113732|NCT02366676|hyaluronic acid
113733|NCT02366676|chondroitin sulphate
113734|NCT02366663|Non-Hodgkin's lymphoma
113735|NCT02366663|autologous stem cell transplantation
113736|NCT02366663|radioimmunotherapy
113737|NCT02366663|Zevalin
113738|NCT02366663|Lymphoma
113739|NCT02366663|Lymphoma, Large B-Cell, Diffuse
113740|NCT02366663|Lymphoma, Non-Hodgkin
113741|NCT02366663|Immune System Diseases
113742|NCT02366663|Immunoproliferative Disorders
113743|NCT02366663|Lymphatic Diseases
113744|NCT02366663|Lymphoma, B-Cell
113745|NCT02366663|Lymphoproliferative Disorders
113746|NCT02366663|Neoplasms
113747|NCT02366663|Neoplasms by Histologic Type
113748|NCT02366663|Antibodies, Monoclonal
113749|NCT02366663|Immunologic Factors
113750|NCT02366663|Pharmacologic Actions
113751|NCT02366663|Physiological Effects of Drugs
113752|NCT02366637|COPD
113753|NCT02366637|Sputum
113754|NCT02366546|Adoptive cell transfer
113755|NCT02366546|Cell therapy
113756|NCT02366546|Immunotherapy
113757|NCT02366546|NY-ESO-1
113758|NCT02366546|Esophageal cancer
113759|NCT02366546|Melanoma
113760|NCT02366546|Head and neck cancer
113761|NCT02366546|Ovarian cancer
113762|NCT02366546|Synovial sarcoma
113763|NCT02366546|TCR gene therapy
113764|NCT02366533|Linkage to care
113765|NCT02366533|HIV
113766|NCT02366533|Efficacy of linkage to care program
113767|NCT02366520|Child
113768|NCT02366520|Child Behavior
113769|NCT02366520|Dental Anxiety/prevention & control
113770|NCT02366520|Dental Anxiety/psychology
113771|NCT02366520|Cooperative Behavior
113772|NCT02366520|Dental Care/psychology*
113773|NCT02366520|Humans
113774|NCT02366520|Videotape Recording
113775|NCT02366507|hypotension
113776|NCT02366507|doppler
113777|NCT02366507|shock
113778|NCT02366494|prostate cancer
113779|NCT02366494|treatment response
113780|NCT02366494|androgen deprivation therapy
113781|NCT02366481|Vitamin K
113782|NCT02366481|Vitamin K2
113783|NCT02366481|Menaquinone-7
113784|NCT02366481|Osteocalcin
113785|NCT02366481|Adults
113786|NCT02366481|Obesity
113787|NCT02366481|Insulin resistance
113788|NCT02366481|Insulin sensitivity
113789|NCT02366481|Beta-cell function
113790|NCT02366481|Prediabetes
113791|NCT02366468|Diabetic macular edema
113792|NCT02366468|Visual impairment
113793|NCT02366442|dual/multitasking
113794|NCT02366442|Executive function
113795|NCT02366442|Affective function
113796|NCT02366442|Balance
113797|NCT02366416|Exercise, Physical
113798|NCT02366403|PTSD
113799|NCT02366403|Meditation
113800|NCT02366403|Yoga
113801|NCT02366403|Cognitive Therapy
113802|NCT02366390|Psychoeducative
113803|NCT02366390|HADS
113804|NCT02366390|COPD
113805|NCT02366390|dyspnea
113806|NCT02366364|NRX-1074
113807|NCT02366364|NMDA Receptor Modulator
113808|NCT02366364|Major Depressive Disorder
113809|NCT02366364|Glycine Site Modulator
113810|NCT02366312|Keratocystic odontogenic tumor
113811|NCT02366312|KCOT
113812|NCT02366273|Diabetes
113813|NCT02366273|Psoriasis
113814|NCT02366273|Inflammation
113815|NCT02366273|Insulin-resistance
113816|NCT02366247|Polyethylene Glycol Thymosin alpha1
113817|NCT02366247|Adefovir
113818|NCT02366247|Hepatitis B e Antigens positive
113819|NCT02366208|Polyethylene Glycol Thymosin alpha1
113820|NCT02366208|Adefovir
113821|NCT02366208|Hepatitis B e Antigens positive
113822|NCT02366195|T-VEC
113823|NCT02366195|CD8+ cell density
113824|NCT02366195|objective response rate
113825|NCT02366195|unresected
113826|NCT02366195|Melanoma
113827|NCT02366130|Breast cancer
113828|NCT02366130|Hormone-positive bone-dominant metastatic breast cancer
113829|NCT02366130|Ra-223 dichloride
113830|NCT02366130|Xofigo
113831|NCT02366130|Radium-223 chloride
113832|NCT02366130|Radium-223 dichloride
113833|NCT02366130|Alpharadin
113834|NCT02366130|Denosumab
113835|NCT02366130|AMG 162
113836|NCT02366130|Prolia
113837|NCT02366130|Hormone therapy
113838|NCT02366117|Quirc
113839|NCT02366117|Quality Indiciator in Rehabilitative Care
113840|NCT02366104|Cardiovascular Diseases
113841|NCT02366104|Aged
113842|NCT02366104|Primary Prevention
113843|NCT02366052|Histologically confirmed NASH
113844|NCT02366052|Hepatocyte Injury determined by M30 antigen
113845|NCT02366026|HIV
113846|NCT02366013|HIV
113847|NCT02366013|HIV Prevention
113848|NCT02366013|HIV Vaccine
113849|NCT02366013|Healthy
113850|NCT02366000|Parent-child communication
113851|NCT02366000|Health risk behaviors
113852|NCT02366000|Randomized controlled trial
113853|NCT02365987|interesterified
113854|NCT02365987|postprandial
113855|NCT02365974|arterial stiffness
113856|NCT02365974|resistant hypertension
113857|NCT02365974|sympathetic system
113858|NCT02365974|blood pressure
113859|NCT02365974|transcutaneous electrical nerve stimulation
113860|NCT02365961|Hip Arthroscopy
113861|NCT02365948|Pharmacokinetics
113862|NCT02365948|Certolizumab Pegol
113863|NCT02365948|Healthy Chinese subjects
113864|NCT02365935|adjuvant chemotherapy
113865|NCT02365922|FTLD, PSP, CBD, PPA, FTD, FTD-ALS, CBS, ALS, svPPA, nfvPPA, oPSP
113866|NCT02365883|Prostate Cancer
113867|NCT02365883|Transrectal Imaging
113868|NCT02365870|Anxiety Disorders
113869|NCT02365870|Parkinson Disease
113870|NCT02365870|rotigotine
113871|NCT02365857|spinal anesthesia
113872|NCT02365857|caesarian section
113873|NCT02365857|Dexmedetomidine
113874|NCT02365844|Narrow Band Imaging
113875|NCT02365844|oropharyngeal carcinoma
113876|NCT02365831|MBC
113877|NCT02365831|breast
113878|NCT02365831|metastatic
113879|NCT02365831|cancer
113880|NCT02365831|HER2
113881|NCT02365818|Bladder Cancer
113882|NCT02365805|BRCA 1 levels
113883|NCT02365805|HER2 Negative
113884|NCT02365792|Clinical Decision Support
113885|NCT02365792|Clinical Practice Guidelines
113886|NCT02365792|Emergency Medical Services
113887|NCT02365779|salpingectomy
113888|NCT02365779|optical biopsy
113889|NCT02365779|Cellvizio®
113890|NCT02365766|MK-3475
113891|NCT02365766|Gemcitabine
113892|NCT02365766|Cisplatin
113893|NCT02365766|Pembrolizumab
113894|NCT02365766|Neoadjuvant Bladder Cancer
113895|NCT02365753|lower transverse cesarean delivery
113896|NCT02365753|Pregnant women
113897|NCT02365740|Type 1 Diabetes mellitus
113898|NCT02365740|Gastric Emptying
113899|NCT02365740|Insulin Infusion Pump
113900|NCT02365701|Functional Dyspepsia
113901|NCT02365688|Open Abdominal Surgical Procedure
113902|NCT02365675|Pemphigus
113903|NCT02365675|Pemphigoid
113904|NCT02365675|Wound Healing
113905|NCT02365675|Itch
113906|NCT02365675|Pain
113907|NCT02365675|Wound dressing
113908|NCT02365675|Topical treatment
113909|NCT02365662|Solid Tumor types likely to exhibit elevated levels of Epidermal Growth Factor Receptor
113910|NCT02365662|Solid Tumors
113911|NCT02365662|Cancer
113912|NCT02365662|Oncology
113913|NCT02365649|Crohn's Disease
113914|NCT02365623|Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
113915|NCT02365623|TMC207
113916|NCT02365623|Bedaquiline
113917|NCT02365610|Cannabidivarin
113918|NCT02365610|CBDV
113919|NCT02365610|GWP42006
113920|NCT02365597|Urothelial Cancer
113921|NCT02365597|JNJ-42756493
113922|NCT02365597|Tyrosine Kinase Inhibitor
113923|NCT02365532|drug-induced long QT syndrome
113924|NCT02365532|DILQTS
113925|NCT02365532|prolonged QT
113926|NCT02365519|LME636
113927|NCT02365519|dry eye disease
113928|NCT02365519|efficacy
113929|NCT02365519|ocular discomfort
113930|NCT02365506|Congenital Long QT Syndrome
113931|NCT02365506|LQTS
113932|NCT02365506|Long QT2 Syndrome
113933|NCT02365506|LQT2
113934|NCT02365506|Sudden Cardiac Death
113935|NCT02365493|Methicillin-Resistant Staphylococcus aureus (MRSA)
113936|NCT02365467|TEVAR
113937|NCT02365467|Thoracic Aneurysm
113938|NCT02365467|Endovascular Aortic Repair
113939|NCT02365467|Type B Dissection
113940|NCT02365454|TAA
113941|NCT02365441|GIST
113942|NCT02365441|Advanced
113943|NCT02365428|Maternal welfare
113944|NCT02365402|chronic hepatitis B
113945|NCT02365402|peginterferon
113946|NCT02365402|sustained viral response
113947|NCT02365402|entecavir
113948|NCT02365402|HBeAg
113949|NCT02365337|Vitamin D
113950|NCT02365337|time lapse monitoring
113951|NCT02365337|embryo
113952|NCT02365324|culinary skills
113953|NCT02365324|menu planning
113954|NCT02365324|grocery shopping
113955|NCT02365324|children
113956|NCT02365324|healthy eating
113957|NCT02365324|physical activity
113958|NCT02365272|pharmacokinetics
113959|NCT02365272|aminoglycosides
113960|NCT02365246|atopic dermatitis
113961|NCT02365246|immunoadsorption
113962|NCT02365233|Type II Diabetes
113963|NCT02365233|Nonalcoholic fatty liver
113964|NCT02365194|Ventral Hernia
113965|NCT02365194|Prehabilitation
113966|NCT02365181|Shoulder arthroplasty
113967|NCT02365168|Fish allergy
113968|NCT02365155|Frailty
113969|NCT02365155|Heart failure
113970|NCT02365155|Physical activity
113971|NCT02365155|Cognitive state
113972|NCT02365142|Knee Osteoarthritis
113973|NCT02365142|Mesenchimal stem cell
113974|NCT02365142|Osteoarthritis
113975|NCT02365129|BRITE adipose tissue
113976|NCT02365129|physical activity
113977|NCT02365129|Thermogenesis
113978|NCT02365129|Body Temperature Regulation
113979|NCT02365129|Energy Metabolism
113980|NCT02365116|Peer Mentorship
113981|NCT02365116|Psychiatric Hospitalization
113982|NCT02365116|Suicide Risk
113983|NCT02365103|Anemia, Iron-Deficiency
113984|NCT02365103|Iron, Bioavailability
113985|NCT02365103|Hepcidins
113986|NCT02365103|Intestinal, Absorption
113987|NCT02365103|Isotope Labeling, Stable
113988|NCT02365077|Adverse Effect of Glucocorticoids
113989|NCT02365077|Femur Head Necrosis
113990|NCT02365077|Susceptibility
113991|NCT02365077|GWAS
113992|NCT02365025|Sleep patterns
113993|NCT02365025|Electronic Media Exposure
113994|NCT02365025|Parental Intervention
113995|NCT02364934|rocuronium
113996|NCT02364934|sex
113997|NCT02364934|elderly
113998|NCT02364934|Close-loop infusion system
113999|NCT02364921|venous ulcer
114000|NCT02364921|wound healing
114001|NCT02364921|compression bandages
114002|NCT02364908|systemic lupus erythematosus
114003|NCT02364908|antimalarials
114004|NCT02364908|therapeutic education
114005|NCT02364908|Coping questionnaire
114006|NCT02364908|MASRI questionnaire
114007|NCT02364908|morisky medication adherence scale
114008|NCT02364908|lupus Quality Of Life
114009|NCT02364908|internal medicine
114010|NCT02364895|Mailed invitation
114011|NCT02364895|Fecal Occult Blood Test
114012|NCT02364895|Screening
114013|NCT02364869|P-cresyl sulfate
114014|NCT02364869|Indoxyl sulfate
114015|NCT02364869|Intestine
114016|NCT02364869|Endothelial function
114017|NCT02364856|Autonomic Nervous System
114018|NCT02364856|Cerebral Palsy
114019|NCT02364856|Pain
114020|NCT02364856|Children
114021|NCT02364843|Threonine
114022|NCT02364843|enteral feedings
114023|NCT02364843|infants
114024|NCT02364843|amino acid
114025|NCT02364843|requirements
114026|NCT02364830|Pimpinella anisum L.
114027|NCT02364830|Peppermint oil
114028|NCT02364830|Irritable Bowel Syndrome
114029|NCT02364817|Attention Deficit Disorder with Hyperactivity
114030|NCT02364817|Alcohol Dependence
114031|NCT02364817|Adults
114032|NCT02364817|Treatment outcome
114033|NCT02364817|Mental Health
114034|NCT02364791|pulmonary resection
114035|NCT02364791|chest tube
114036|NCT02364791|segmentectomy
114037|NCT02364791|lobectomy
114038|NCT02364778|CAD
114039|NCT02364765|Maxillofacial Orthognathic Surgery
114040|NCT02364765|Hemoglobin
114041|NCT02364765|Red Blood Cells
114042|NCT02364765|Hematocrit
114043|NCT02364765|Blood Platelets
114044|NCT02364765|Body Weight
114045|NCT02364765|Operative Time
114046|NCT02364765|Age Groups
114047|NCT02364765|Gender
114048|NCT02364726|Acupuncture
114049|NCT02364726|Paclitaxel
114050|NCT02364726|15-011
114051|NCT02364700|stroke, robotics, hand rehabilitation
114052|NCT02364674|HRCT
114053|NCT02364674|High Resolution Computed Tomography scans
114054|NCT02364674|Functional Respiratory Imaging
114055|NCT02364674|FRI
114056|NCT02364674|Computed Tomography
114057|NCT02364674|CT
114058|NCT02364674|Bronchiolitis Obliterans
114059|NCT02364674|BOS
114060|NCT02364674|Lung Transplant
114061|NCT02364661|Hepatitis B virus
114062|NCT02364661|Metabolovirus
114063|NCT02364648|Endothelium, vascular
114064|NCT02364648|MitoQ
114065|NCT02364648|Mitochondria
114066|NCT02364648|Oxidative Stress
114067|NCT02364648|Chronic Renal Insufficiency
114068|NCT02364648|Cardiovascular Disease
114069|NCT02364635|Phase I pharmacokinetics and safety study
114070|NCT02364622|flexible intubating stylet
114071|NCT02364622|double-lumen endobronchial tube
114072|NCT02364596|Staphylococcus aureus vaccine
114073|NCT02364596|Staphylococcal infection
114074|NCT02364570|CVD
114075|NCT02364570|Hyperglycemia
114076|NCT02364570|Postprandial
114077|NCT02364570|Vascular Function
114078|NCT02364531|Prostatic Neoplasms
114079|NCT02364531|Prostate Cancer
114080|NCT02364531|Metastatic
114081|NCT02364531|Observational
114082|NCT02364531|Abiraterone Acetate
114083|NCT02364531|ZYTIGA
114084|NCT02364518|Snoring
114085|NCT02364518|snoreplasy
114086|NCT02364518|Tranquill
114087|NCT02364518|Sutures
114088|NCT02364505|caregivers
114089|NCT02364492|[C04.588.180]
114090|NCT02364440|skin laxity
114091|NCT02364440|Ultherapy™ System
114092|NCT02364440|rhytids
114093|NCT02364427|Pulse wave velocity
114094|NCT02364427|Arterial stiffness
114095|NCT02364427|AKI
114096|NCT02364401|Atrial Fibrillation
114097|NCT02364401|Catheter ablation
114098|NCT02364388|breast imaging diagnosis
114099|NCT02364388|breast ultrasound
114100|NCT02364388|Imagio
114101|NCT02364388|Seno Medical Instruments, Inc.
114102|NCT02364388|Seno
114103|NCT02364388|opto-acoustics
114104|NCT02364388|OA
114105|NCT02364336|Chronic Hepatitis B
114106|NCT02364310|Hypertension
114107|NCT02364310|baroreceptor stimulation
114108|NCT02364310|Hypertension resistant
114109|NCT02364297|Bleeding gastric varices
114110|NCT02364297|Transjugular intrahepatic portosystemic shunt (TIPS)
114111|NCT02364297|Injection of adhesives
114112|NCT02364271|High-sensitive troponin
114113|NCT02364271|Coronary Artery Calcium Score
114114|NCT02364271|TIMI score
114115|NCT02364271|Heart-type fatty acid binding protein
114116|NCT02364271|Major adverse cardiac event
114117|NCT02364271|HEART score
114118|NCT02364245|Cerebral Palsy.
114119|NCT02364245|Upper Extremity
114120|NCT02364245|Kinect
114121|NCT02364245|Virtual reality
114122|NCT02364219|prewarming
114123|NCT02364219|perioperative hypothermia
114124|NCT02364219|microdialysis
114125|NCT02364219|tissue oxygen saturation
114126|NCT02364219|cytoreductive surgery
114127|NCT02364206|newly diagnosed glioblastoma
114128|NCT02364206|p38 MAPK inhibitor
114129|NCT02364206|temozolomide
114130|NCT02364206|radiotherapy
114131|NCT02364193|Intrathoracic blood volume
114132|NCT02364193|Extravascular lung water
114133|NCT02364154|biomarker
114134|NCT02364154|screening
114135|NCT02364154|coloscopy
114136|NCT02364141|stroke
114137|NCT02364141|upper extremity
114138|NCT02364141|motor learning
114139|NCT02364141|rehabilitation
114140|NCT02364115|Spinal metastases
114141|NCT02364115|Spinal metastatic disease
114142|NCT02364115|Stereotactic Body Radiotherapy
114143|NCT02364115|Response
114144|NCT02364115|Bone metastases
114145|NCT02364089|Adrenal Incidentaloma
114146|NCT02364089|Subclinical Cushing's syndrome
114147|NCT02364089|Hypertension
114148|NCT02364089|Cardiovascular Risk Factors
114149|NCT02364089|Metabolic Syndrome
114150|NCT02364089|Surgery of adrenal tumor
114151|NCT02364063|Urinary incontinence
114152|NCT02364063|cerebral palsy
114153|NCT02364063|urotherapy
114154|NCT02364063|child
114155|NCT02364037|intrauterine device
114156|NCT02364037|subdermal implant
114157|NCT02364037|contraceptive counseling
114158|NCT02364024|Colon and rectum carcinoma
114159|NCT02364024|Immune response
114160|NCT02364024|Biomarker
114161|NCT02364024|Prognosis
114162|NCT02364011|Biomechanics
114163|NCT02364011|Primary Total Knee Arthroplasty
114164|NCT02364011|TKA Bearings
114165|NCT02364011|Osteoarthritis
114166|NCT02364011|Total Knee Replacement
114167|NCT02363998|detoxification
114168|NCT02363998|agonist taper
114169|NCT02363998|methadone step down
114170|NCT02363998|buprenorphine step down
114171|NCT02363998|opioid withdrawal syndrome
114172|NCT02363959|Hyperbaric Oxygen
114173|NCT02363959|Lung Transplantation
114174|NCT02363959|Central Airway Stenosis
114175|NCT02363959|Airway Exudative Plaques
114176|NCT02363959|Hyperbaric Oxygen Therapy
114177|NCT02363959|Post-Lung Transplantation
114178|NCT02363959|Airway Ischemia
114179|NCT02363959|Endobronchial Biopsy
114180|NCT02363959|Bronchoscopy
114181|NCT02363946|alpha-1 antitrypsin
114182|NCT02363946|AATD
114183|NCT02363933|Perampanel
114184|NCT02363933|Seizures
114185|NCT02363920|COPD patients
114186|NCT02363907|diabetes mellitus
114187|NCT02363907|pediatric
114188|NCT02363907|continuous glucose monitoring system
114189|NCT02363907|CGM
114190|NCT02363855|Neoplasm Metastasis
114191|NCT02363855|Metastatic castration-resistant prostate cancer
114192|NCT02363855|Castration-resistant prostate cancer (CRPC)
114193|NCT02363842|Pressure Ulcer
114194|NCT02363842|Skin IQ MCM coverlet
114195|NCT02363842|Pressure redistribution surfaces
114196|NCT02363829|clinical stages IIA, IIB, IIIA, IIIB, IVA
114197|NCT02363829|invasive carcinoma
114198|NCT02363829|uterine cervix
114199|NCT02363790|Ventral Hernia
114200|NCT02363790|Laparoscopic
114201|NCT02363764|respiratory sampling
114202|NCT02363751|Bellini
114203|NCT02363751|Metastatic
114204|NCT02363751|Chemotherapy
114205|NCT02363751|Bevacizumab
114206|NCT02363738|Bipolar Disorder
114207|NCT02363738|Bipolar Depression
114208|NCT02363738|Inflammation
114209|NCT02363738|Bipolar
114210|NCT02363725|Acute myocardial infarction
114211|NCT02363725|Inflammation
114212|NCT02363725|CRP
114213|NCT02363725|Colchicine
114214|NCT02363712|Osteoarthritis, knee
114215|NCT02363712|therapy
114216|NCT02363712|shoe
114217|NCT02363712|Randomized Controlled Trial
114218|NCT02363699|cholelithiasis
114219|NCT02363699|Cytokines
114220|NCT02363699|under general anesthesia
114221|NCT02363673|Autism Spectrum Disorder
114222|NCT02363673|Children
114223|NCT02363673|Homoeopathy
114224|NCT02363660|HIV-uninfected
114225|NCT02363647|medullary thyroid cancer
114226|NCT02363647|thyroid cancer
114227|NCT02363647|personalized therapy
114228|NCT02363647|personalized chemotherapy
114229|NCT02363647|individualized treatment
114230|NCT02363634|magnesium status
114231|NCT02363634|sleep quality
114232|NCT02363608|Canine-Assisted
114233|NCT02363608|15-010
114234|NCT02363608|post surgery patients
114235|NCT02363595|Genomic Predictors
114236|NCT02363595|14-277
114237|NCT02363569|post coital bleeding
114238|NCT02363569|vaginal bleeding
114239|NCT02363556|Cervical Dilation
114240|NCT02363556|Dilation and Evacuation
114241|NCT02363556|Misoprostol
114242|NCT02363556|Misoprostol-Dilapan
114243|NCT02363556|Abortion
114244|NCT02363530|cataract surgery
114245|NCT02363530|cornea protect
114246|NCT02363530|xerophthalmia
114247|NCT02363530|Corneal clarity
114248|NCT02363517|Hepatitis
114249|NCT02363517|Viral
114250|NCT02363517|Non-A
114251|NCT02363517|Non-B
114252|NCT02363517|Parenterally-Transmitted
114253|NCT02363504|Magnetic Resonance Imaging
114254|NCT02363504|Noradrenaline
114255|NCT02363504|locus coeruleus
114256|NCT02363504|memory
114257|NCT02363465|skin thickness
114258|NCT02363465|high-frequency ultrasound
114259|NCT02363452|Aicardi-Goutières syndrome
114260|NCT02363452|Reverse transcriptase inhibitors
114261|NCT02363452|open single study
114262|NCT02363452|interferon signature
114263|NCT02363426|intravaginal culture
114264|NCT02363426|in vitro fertilization
114265|NCT02363426|blastocyst
114266|NCT02363426|pregnancy
114267|NCT02363413|NIV
114268|NCT02363413|Overlap Syndrom
114269|NCT02363413|home
114270|NCT02363413|hospital
114271|NCT02363400|Nasopharyngeal carcinoma (NPC)
114272|NCT02363400|Epstein-Barr virus (EBV)
114273|NCT02363400|radiotherapy (RT)
114274|NCT02363400|Plasma EBV DNA(pEBV DNA)
114275|NCT02363400|Adjuvant Chemotherapy
114276|NCT02363387|HIV
114277|NCT02363387|antiretroviral medications
114278|NCT02363387|incentives
114279|NCT02363374|Rectal cancer stage II
114280|NCT02363374|Rectal cancer stage III
114281|NCT02363374|Multimodality treatment of locally advanced rectal cancer
114282|NCT02363348|L arginine
114283|NCT02363348|Preeclampsia
114284|NCT02363335|GLP-1
114285|NCT02363335|Phosphodiesterase Inhibitor
114286|NCT02363335|GLP
114287|NCT02363322|Medical Countermeasures
114288|NCT02363322|VHF
114289|NCT02363322|EVD
114290|NCT02363309|13C
114291|NCT02363309|Stable Isotopes
114292|NCT02363309|Acetate
114293|NCT02363309|Breath Tests
114294|NCT02363309|Palmitate
114295|NCT02363296|Brain Cooling - Selected
114296|NCT02363296|Brain Cooling Helmet
114297|NCT02363296|Repetitive TMS (rTMS)
114298|NCT02363270|Analgesia
114299|NCT02363270|ketamine
114300|NCT02363257|Smoke free bus policy
114301|NCT02363257|BEST commuters
114302|NCT02363257|BEST employee
114303|NCT02363244|Pap,HPVDNA
114304|NCT02363218|Liver Neoplasms
114305|NCT02363218|Stereotactic Body Radiotherapy
114306|NCT02363218|CyberKnife
114307|NCT02363192|Pharmacy
114308|NCT02363179|Emergency Service, Hospital
114309|NCT02363140|Musculoskeletal System
114310|NCT02363127|Reproductive Techniques
114311|NCT02363127|Infertility
114312|NCT02363127|Reproductive Techniques Assisted
114313|NCT02363088|cervical screening
114314|NCT02363088|uptake
114315|NCT02363088|SMS messages
114316|NCT02363088|text messages
114317|NCT02363088|reminder
114318|NCT02363075|dexamfetamine sulphate
114319|NCT02363075|severe asthenia
114320|NCT02363075|glioma
114321|NCT02363075|MFI-20
114322|NCT02363075|double-blind
114323|NCT02363075|stabilisation phase
114324|NCT02363062|frontotemporal lobar degeneration
114325|NCT02363062|genes
114326|NCT02363062|whole exome sequencing
114327|NCT02363049|Colectomy
114328|NCT02363049|primary tumor resection
114329|NCT02363049|Asymptomatic primary colon cancer
114330|NCT02363049|Unresectable synchronous liver metastasis
114331|NCT02363049|TNM Staging Primary Tumor (T)
114332|NCT02363049|Unresectable
114333|NCT02363023|Ventilator associated pneumonia
114334|NCT02363023|Bronchoalveolar lavage
114335|NCT02363010|Obesity
114336|NCT02363010|Weight loss
114337|NCT02363010|Overweight
114338|NCT02362997|Classical Hodgkin Lymphoma (cHL)
114339|NCT02362997|Diffuse Large B Cell Lymphoma (DLBCL)
114340|NCT02362997|Peripheral T-cell lymphoma (PTCL)
114341|NCT02362984|DLBS1033
114342|NCT02362984|acute ischemic stroke
114343|NCT02362984|MRS
114344|NCT02362984|mNIHSS
114345|NCT02362919|Influenza vaccination
114346|NCT02362919|Elderly individuals
114347|NCT02362919|Prospective cohort study
114348|NCT02362919|response
114349|NCT02362906|pneumonia
114350|NCT02362906|pediatrics
114351|NCT02362893|Hypertension
114352|NCT02362893|Adherence
114353|NCT02362893|Direct Observed Therapy (DOT)
114354|NCT02362893|RCT
114355|NCT02362854|dental implant
114356|NCT02362854|laser
114357|NCT02362854|diode laser
114358|NCT02362854|peri-implantitis
114359|NCT02362854|bacterial count
114360|NCT02362828|Post-Dural Puncture Headache
114361|NCT02362828|Blood Patch, epidural
114362|NCT02362828|Obstetrics
114363|NCT02362828|European Society of Anaesthesiology (ESA)
114364|NCT02362828|epidemiology
114365|NCT02362828|Accidental Dural Puncture (ADP)
114366|NCT02362828|Anaesthesia
114367|NCT02362828|childbirth complication
114368|NCT02362828|epidural analgesia
114369|NCT02362828|postdural puncture headache
114370|NCT02362828|prophylactic epidural blood patch
114371|NCT02362828|epidural
114372|NCT02362776|NMR spectroscopy
114373|NCT02362776|metabolic changes
114374|NCT02362776|blood plasma
114375|NCT02362776|biomarker
114376|NCT02362776|cancer
114377|NCT02362750|comparative effectiveness
114378|NCT02362750|survivorship
114379|NCT02362750|Patient-Centered Outcomes Research
114380|NCT02362685|Metabolic myopathies
114381|NCT02362685|Exercise testing
114382|NCT02362685|Blood sample
114383|NCT02362685|Muscle biopsy
114384|NCT02362685|Genetic analysis
114385|NCT02362685|Cycloergometer
114386|NCT02362685|Grip-test
114387|NCT02362685|Exercise physiology
114388|NCT02362685|Muscle physiology
114389|NCT02362659|non-valvular
114390|NCT02362659|atrial fibrillation
114391|NCT02362659|percutaneous coronary intervention
114392|NCT02362646|Heart Failure
114393|NCT02362646|Left Ventricular Assist Device
114394|NCT02362646|Heart Transplantation
114395|NCT02362646|Cardiomyopathy, Destination Therapy
114396|NCT02362646|Cell Therapy
114397|NCT02362646|Bridge to Transplant
114398|NCT02362594|PD1
114399|NCT02362594|PDL1
114400|NCT02362581|Prophylaxis treatment
114401|NCT02362581|On demand treatment
114402|NCT02362581|Severe hemophilia A
114403|NCT02362581|Moderate hemophilia A
114404|NCT02362568|Intubation; Difficult
114405|NCT02362555|Ossification of nuchal ligament
114406|NCT02362490|chronic hepatitis B
114407|NCT02362490|interferon
114408|NCT02362490|Nucleotide analogues
114409|NCT02362490|HBsAg
114410|NCT02362464|Multi-epitope
114411|NCT02362464|Tarp Peptide
114412|NCT02362464|Dendritic Cell Vaccine
114413|NCT02362464|D0 Prostate Cancer
114414|NCT02362451|Dendritic Cell Vaccine
114415|NCT02362451|Multi Epitope Tarp Peptide
114416|NCT02362451|Autolougous Dendritic Cell
114417|NCT02362451|D0 Prostate Cancer
114418|NCT02362451|Vaccine Therapy
114419|NCT02362438|Intrathecal
114420|NCT02362438|AAVp Mediated Gene Transfer
114421|NCT02362438|Phase 1
114422|NCT02362438|Safety Study
114423|NCT02362438|Giant Axonal Neuropathy
114424|NCT02362425|Neuromuscular Disease
114425|NCT02362425|Clinical Trial
114426|NCT02362425|Ryanodine Receptor Type 1
114427|NCT02362425|Myopathy
114428|NCT02362412|FK949E
114429|NCT02362412|quetiapine
114430|NCT02362412|bipolar depression
114431|NCT02362412|bipolar disorder
114432|NCT02362412|major depressive episodes
114433|NCT02362373|epilepsy
114434|NCT02362373|contraception
114435|NCT02362373|drug interaction
114436|NCT02362360|Ostomy
114437|NCT02362334|dual Sheimpflug analyzer
114438|NCT02362334|intraocular lens power
114439|NCT02362334|optical low-coherence reflectometry
114440|NCT02362321|[C10.228.140.300.535.450.400.120]
114441|NCT02362295|palliative care
114442|NCT02362295|vulnerable population
114443|NCT02362295|qualitative research
114444|NCT02362282|stroke
114445|NCT02362282|walking
114446|NCT02362282|cognition
114447|NCT02362282|rehabilitation
114448|NCT02362256|Opioid detoxification
114449|NCT02362256|Opioid antagonist induction
114450|NCT02362256|Conscious sedation
114451|NCT02362243|low back pain
114452|NCT02362243|low back injury
114453|NCT02362243|firefighter
114454|NCT02362243|prevention
114455|NCT02362243|physical fitness
114456|NCT02362243|exercise training
114457|NCT02362243|worksite
114458|NCT02362243|web-based
114459|NCT02362165|multiple myeloma
114460|NCT02362165|cyclophosphamide
114461|NCT02362165|bortezomib
114462|NCT02362165|doxorubicin
114463|NCT02362165|peripheral neuropathy
114464|NCT02362152|Actinic keratosis
114465|NCT02362152|Solar keratosis
114466|NCT02362152|Field treatment
114467|NCT02362152|Ingenol mebutate
114468|NCT02362152|Picato
114469|NCT02362126|Endoscopic full thickness resection
114470|NCT02362126|EFTR
114471|NCT02362126|FTRD
114472|NCT02362126|OTSC
114473|NCT02362087|pain
114474|NCT02362061|junctional zone
114475|NCT02362061|implantation
114476|NCT02362061|three D ultraosund
114477|NCT02362061|Assisted Reproductive Technology
114478|NCT02362061|Pregnancy
114479|NCT02362035|Bruton tyrosine kinase inhibitor
114480|NCT02362035|Btk
114481|NCT02362035|B-Cell Malignancies
114482|NCT02362035|Mantle Cell
114483|NCT02362035|Multiple Myeloma
114484|NCT02362035|CLL
114485|NCT02362035|SLL
114486|NCT02362035|DLBCL
114487|NCT02362035|Follicular
114488|NCT02362035|Waldenstrom
114489|NCT02362035|Burkitt lymphoma
114490|NCT02362035|marginal zone lymphomas
114491|NCT02362035|hairy cell leukemia
114492|NCT02362035|B cell acute lymphoid leukemia
114493|NCT02362035|Acalabrutinib
114494|NCT02362035|ACP-196
114495|NCT02362009|Myomas
114496|NCT02362009|Leiomyomas
114497|NCT02362009|Fibromas
114498|NCT02361970|sepsis
114499|NCT02361970|gamma delta T cells
114500|NCT02361970|immunosuppression
114501|NCT02361944|oxygen
114502|NCT02361944|hyperoxia
114503|NCT02361944|reactive oxygen species
114504|NCT02361944|oxidative stress
114505|NCT02361944|oxidative damage
114506|NCT02361944|endothelial function
114507|NCT02361944|vascular reactivity
114508|NCT02361944|mitochondrial function
114509|NCT02361944|surgery
114510|NCT02361944|anesthesia
114511|NCT02361944|kidney injury
114512|NCT02361944|renal failure
114513|NCT02361944|delirium
114514|NCT02361944|myocardial injury
114515|NCT02361944|arrythmia
114516|NCT02361931|accelerating healing
114517|NCT02361931|diabetic chronic wounds
114518|NCT02361931|diabetic patients
114519|NCT02361931|diabetic chronic ulcers
114520|NCT02361931|Wagner grade II
114521|NCT02361931|infection
114522|NCT02361931|necrosis
114523|NCT02361931|erythema
114524|NCT02361931|mild drainage
114525|NCT02361905|fibroid
114526|NCT02361905|cellular leiomyomas
114527|NCT02361905|GnRH analogue
114528|NCT02361905|ulipristal acetate
114529|NCT02361892|ovarian reserve
114530|NCT02361892|infertility
114531|NCT02361892|leiomyomas
114532|NCT02361892|ulipristal acetate
114533|NCT02361879|fibroids
114534|NCT02361879|gnrh analogue
114535|NCT02361879|ulipristal acetate
114536|NCT02361879|hysteroscopy
114537|NCT02361840|Troponin I
114538|NCT02361840|Pediatric shock
114539|NCT02361827|Vitamin D
114540|NCT02361827|IVF outcome
114541|NCT02361814|flexor tendon
114542|NCT02361814|finger
114543|NCT02361814|amniotic membrane
114544|NCT02361814|allograft
114545|NCT02361814|tendon injury
114546|NCT02361801|cardiac surgery
114547|NCT02361801|dobutamine
114548|NCT02361788|neonatal hyperbilirubinemia
114549|NCT02361788|etiology
114550|NCT02361788|incidence
114551|NCT02361788|risk factors
114552|NCT02361762|Executive Function
114553|NCT02361762|Theory of Mind
114554|NCT02361762|Individual Differences
114555|NCT02361762|Social Skills
114556|NCT02361762|Executive Control
114557|NCT02361710|Vitamin D
114558|NCT02361710|pregnancy rate
114559|NCT02361710|eFET
114560|NCT02361697|pediatric multiple sclerosis
114561|NCT02361697|clinically isolated syndrome in children
114562|NCT02361697|biomarker
114563|NCT02361697|magnetic resonance imaging
114564|NCT02361697|diffusion weighted imaging
114565|NCT02361684|cost-effectiveness
114566|NCT02361684|blended treatment
114567|NCT02361684|Internet based treatment
114568|NCT02361684|Efficacy
114569|NCT02361684|Depression
114570|NCT02361684|cognitive behavioural therapy
114571|NCT02361645|nonsteroidal antiinflammatory drugs
114572|NCT02361645|prostaglandin E2
114573|NCT02361645|vitrectomy
114574|NCT02361606|adolescents
114575|NCT02361606|cognitive behavioral internet intervention
114576|NCT02361593|endoscopic sclerotherapy, esophageal varices, transparent cap
114577|NCT02361567|Post Operative Pain
114578|NCT02361567|Addiction
114579|NCT02361528|Septic shock
114580|NCT02361528|Severe sepsis
114581|NCT02361528|GM-CSF
114582|NCT02361528|Immunosuppression
114583|NCT02361528|Hospital-acquired infections
114584|NCT02361528|ICU-acquired infections
114585|NCT02361528|HLA-DR
114586|NCT02361528|Monocytes
114587|NCT02361515|Prostate
114588|NCT02361515|Hypofractionated radiotherapy
114589|NCT02361515|Stereotactic irradiation
114590|NCT02361515|Spacer
114591|NCT02361515|Rectal and bladder toxicities
114592|NCT02361476|Anaesthesia
114593|NCT02361476|Children
114594|NCT02361476|Clonidine
114595|NCT02361476|Sevoflurane
114596|NCT02361476|Postoperative agitation
114597|NCT02361476|Prevention
114598|NCT02361476|Pharmacokinetics
114599|NCT02361476|Safety
114600|NCT02361463|Laparoscopy;
114601|NCT02361463|Training;
114602|NCT02361463|Three-Dimensional
114603|NCT02361450|Faecal incontinence
114604|NCT02361450|Spina Bifida
114605|NCT02361450|Enema
114606|NCT02361450|Constipation
114607|NCT02361450|Myelomeningocele
114608|NCT02361450|Human
114609|NCT02361437|diabetes type II
114610|NCT02361437|diabetic ulcers
114611|NCT02361424|PXT00864
114612|NCT02361424|mild AD
114613|NCT02361424|phase 2a
114614|NCT02361359|Arthroplasty
114615|NCT02361346|CD20
114616|NCT02361346|immunotoxin
114617|NCT02361346|NHL
114618|NCT02361346|non-Hodgkin's lymphoma
114619|NCT02361346|lymphoma
114620|NCT02361346|cancer
114621|NCT02361346|antibodies
114622|NCT02361346|immunotherapy
114623|NCT02361346|safety
114624|NCT02361346|pharmacokinetics
114625|NCT02361346|maximum tolerated dose
114626|NCT02361346|MT-3724
114627|NCT02361346|relapsed
114628|NCT02361346|refractory
114629|NCT02361346|leukemia
114630|NCT02361346|CLL
114631|NCT02361346|SLL
114632|NCT02361320|Pancreatic cancer
114633|NCT02361320|Pancreatic ductal adenocarcinoma
114634|NCT02361320|PDAC
114635|NCT02361320|Computed tomography
114636|NCT02361320|CT
114637|NCT02361320|Questionnaire
114638|NCT02361320|Survey
114639|NCT02361268|end-stage renal disease
114640|NCT02361268|hemodialysis
114641|NCT02361268|yoga
114642|NCT02361268|mind-body medicine
114643|NCT02361268|meditation
114644|NCT02361242|PXT00864
114645|NCT02361242|mild AD
114646|NCT02361242|phase 2a
114647|NCT02361138|SHR3824 Type 2 diabetes mellitus SGLT2
114648|NCT02361125|Fatigue
114649|NCT02361125|Cancer related fatigue
114650|NCT02361125|Methylphenidate
114651|NCT02361125|Methylphenidate Hydrochloride
114652|NCT02361125|Ritalin
114653|NCT02361125|Concerta
114654|NCT02361125|Fatigue evaluations
114655|NCT02361086|castration-resistant prostate cancer
114656|NCT02361086|CYP17
114657|NCT02361086|P450c17a
114658|NCT02361086|lyase
114659|NCT02361073|Stress-induced cardiomyopathy
114660|NCT02361073|ERP
114661|NCT02361034|Safety and pharmacokinetics of drug in healthy volunteers
114662|NCT02361021|Critical Care
114663|NCT02361021|Non invasive ventilation
114664|NCT02361021|Electrical impedance tomography
114665|NCT02361021|End expiratory lung volume
114666|NCT02361021|Lung ultrasound score
114667|NCT02361008|Infundibular Ventricular Septal Defect
114668|NCT02361008|occlusion
114669|NCT02361008|TEE-guided
114670|NCT02361008|asymmetric occluder
114671|NCT02361008|surgical repair
114672|NCT02360982|Delirium
114673|NCT02360982|regional anesthesia
114674|NCT02360982|general anesthesia
114675|NCT02360969|strabismus
114676|NCT02360969|surgical procedure
114677|NCT02360969|anesthesia
114678|NCT02360969|squint
114679|NCT02360969|child
114680|NCT02360956|Olmesartan medoxomil
114681|NCT02360956|Epicardial adipose tissue
114682|NCT02360956|Multidetector Computed Tomography
114683|NCT02360943|elderly patients
114684|NCT02360943|Pulmonary embolism
114685|NCT02360943|Anticoagulant treatments
114686|NCT02360930|Acute Lymphoblastic Leukemia
114687|NCT02360930|Pharmacokinetics
114688|NCT02360930|Vincristine
114689|NCT02360917|Cognitive Dysfunction
114690|NCT02360917|Cancer Survivorship
114691|NCT02360891|multimodal biomarkers
114692|NCT02360891|prognosis
114693|NCT02360891|endophenotypes
114694|NCT02360878|DJBS
114695|NCT02360878|Duodenal-jejunal bypass sleeve
114696|NCT02360878|Duodenal-jejunal bypass liner
114697|NCT02360878|Endobarrier
114698|NCT02360878|Obesity
114699|NCT02360878|Type 2 diabetes
114700|NCT02360878|Incretin hormones
114701|NCT02360878|Postprandial glucose metabolism
114702|NCT02360813|Cognitive remediation therapy
114703|NCT02360813|Psychiatric rehabilitation
114704|NCT02360813|Forensic mental health
114705|NCT02360813|Forensic psychiatry
114706|NCT02360813|Clinical psychology
114707|NCT02360813|Randomized controlled trial
114708|NCT02360813|Principle driven intervention
114709|NCT02360813|Psychological Intervention
114710|NCT02360813|Cognitive enhancement
114711|NCT02360800|Bleeding
114712|NCT02360800|Heart Surgery
114713|NCT02360800|Ascending Aorta Replacement
114714|NCT02360787|Almonds
114715|NCT02360787|Energy restriction
114716|NCT02360787|Obesity
114717|NCT02360787|Body weight
114718|NCT02360787|Body fat
114719|NCT02360787|Blood pressure
114720|NCT02360787|Cognitive function
114721|NCT02360774|Canagliflozin
114722|NCT02360774|Obesity
114723|NCT02360774|Weight Loss
114724|NCT02360774|Body Weight
114725|NCT02360774|Body Weight Changes
114726|NCT02360774|Overweight
114727|NCT02360774|Sodium-glucose transporter subtype 2 inhibitor
114728|NCT02360761|Lung cancer;Elderly;Sublobar resection;Lobectomy
114729|NCT02360696|Duodenal Eosinophilia
114730|NCT02360696|Functional Dyspepsia
114731|NCT02360696|Mucosal Eosinophilia
114732|NCT02360683|Subthalamic neurostimulation
114733|NCT02360657|Alzheimer's Disease
114734|NCT02360657|Alzheimer Dementia
114735|NCT02360657|JNJ-54861911
114736|NCT02360657|Beta Secretase Inhibitor
114737|NCT02360631|smoking
114738|NCT02360631|quit smoking
114739|NCT02360631|smoking treatment
114740|NCT02360618|Bladder Cancer
114741|NCT02360618|Metformin
114742|NCT02360618|Simvastatin
114743|NCT02360618|Combination Therapy
114744|NCT02360605|colorectal cancer screening
114745|NCT02360605|low literacy
114746|NCT02360605|community clinics
114747|NCT02360605|Fecal Immunochemical Test
114748|NCT02360566|Psychosis
114749|NCT02360566|Schizophrenia
114750|NCT02360566|Participatory Video
114751|NCT02360566|Narrative
114752|NCT02360540|Pulmonary Embolism
114753|NCT02360540|Diagnostic strategy
114754|NCT02360540|Exclusion
114755|NCT02360540|Clinical probability
114756|NCT02360540|Implicit Judgment (Gestalt)
114757|NCT02360540|PERC
114758|NCT02360501|nasopharyngeal carcinoma
114759|NCT02360501|induction chemotherapy
114760|NCT02360501|docetaxel
114761|NCT02360501|xeloda
114762|NCT02360475|Vaccine
114763|NCT02360475|Immunogenicity
114764|NCT02360475|Safety
114765|NCT02360475|Respiratory syncytial virus (RSV)
114766|NCT02360475|Reactogenicity
114767|NCT02360462|Transcranial Direct Current Stimulation
114768|NCT02360462|tDCS
114769|NCT02360462|Hallux Valgus
114770|NCT02360462|Chronic Pain
114771|NCT02360449|Pivotal Response Treatment
114772|NCT02360449|Applied Behavior Analysis
114773|NCT02360449|Peer Initiation
114774|NCT02360449|Social Skills Group
114775|NCT02360436|Rett
114776|NCT02360436|MeCP2
114777|NCT02360436|Glutathione
114778|NCT02360436|Cysteine
114779|NCT02360436|ROS
114780|NCT02360384|wireless motility capsule
114781|NCT02360332|Autism
114782|NCT02360332|transition to adulthood
114783|NCT02360332|employment
114784|NCT02360332|High School Seniors
114785|NCT02360319|First episode or recent onset
114786|NCT02360293|Internet
114787|NCT02360293|Exercise
114788|NCT02360280|Depressive Disorder, Treatment-Resistant
114789|NCT02360267|Bipolar Disorder
114790|NCT02360267|Pediatric
114791|NCT02360267|Offspring
114792|NCT02360267|Depression
114793|NCT02360267|Mania
114794|NCT02360267|Children of parents who suffer from Bipolar disorder
114795|NCT02360228|tACS
114796|NCT02360228|tDCS
114797|NCT02360228|sham
114798|NCT02360228|auditory hallucinations
114799|NCT02360228|Schizophrenia
114800|NCT02360228|Schizoaffective Disorder
114801|NCT02360176|single port surgery
114802|NCT02360176|bariatric surgery
114803|NCT02360176|sleeve gastrectomy
114804|NCT02360176|randomise prospective study
114805|NCT02360176|complication rate
114806|NCT02360150|cardiac angiography
114807|NCT02360150|cardiac MRI
114808|NCT02360137|carotids
114809|NCT02360137|plaque
114810|NCT02360137|characteristics
114811|NCT02360137|stroke
114812|NCT02360111|GVHD Prophylaxis
114813|NCT02360111|Cyclophosphamide
114814|NCT02360111|Renal Insufficiency
114815|NCT02360111|Hematopoietic Stem Cell Transplant
114816|NCT02360111|14-273
114817|NCT02360098|Emergence from Anesthesia
114818|NCT02360098|Anterior temporal lobectomy
114819|NCT02360098|Amygdalohippocampectomy
114820|NCT02360098|Anesthesia
114821|NCT02360085|Cervical Myelopathy
114822|NCT02360085|Hypotension
114823|NCT02360072|child
114824|NCT02360072|allergic rhinitis
114825|NCT02360072|asthma
114826|NCT02360072|nitric oxide
114827|NCT02360072|bronchial hyper-responsiveness
114828|NCT02360059|Breast cancer
114829|NCT02360059|Neuropathy
114830|NCT02360059|Paclitaxel
114831|NCT02360059|Metformin
114832|NCT02360059|Metformin ER
114833|NCT02360059|Placebo
114834|NCT02360059|Sugar pill
114835|NCT02360059|Questionnaires
114836|NCT02360059|Sensory tests
114837|NCT02360059|Fine-motor tests
114838|NCT02360059|Surveys
114839|NCT02360020|coronary stent
114840|NCT02360020|outcome
114841|NCT02360007|opioids
114842|NCT02360007|buprenorphine
114843|NCT02360007|interim treatment
114844|NCT02360007|opioid dependence
114845|NCT02359994|hemostasis
114846|NCT02359981|Weight loss, Fitness
114847|NCT02359968|resectable esophageal
114848|NCT02359968|junctional cancer
114849|NCT02359968|FOLFOX
114850|NCT02359968|paclitaxel-carboplatin
114851|NCT02359942|Helicobacter pylori infection
114852|NCT02359942|Eradication
114853|NCT02359942|Urea breath test
114854|NCT02359929|graft versus host disease
114855|NCT02359929|GVHD
114856|NCT02359890|Interventional
114857|NCT02359890|Radiofrequency ablation
114858|NCT02359890|Paroxysmal Atrial Fibrillation
114859|NCT02359877|pegylated interferon beta
114860|NCT02359877|Volunteers
114861|NCT02359838|Hematologic Malignancy
114862|NCT02359838|Geriatric Assessment
114863|NCT02359838|Geriatric Oncology
114864|NCT02359838|Frailty
114865|NCT02359812|Stroke
114866|NCT02359812|Hemiplegia
114867|NCT02359812|Upper extremity
114868|NCT02359812|Muscle hypertonia
114869|NCT02359812|Arm
114870|NCT02359812|Hand
114871|NCT02359799|Cerebral palsy
114872|NCT02359799|Ankle
114873|NCT02359773|Magnetocardiography
114874|NCT02359773|Myocardial Infarction
114875|NCT02359773|Non-ischaemic chest pain
114876|NCT02359760|Rapid orthodontics
114877|NCT02359760|accelerated orthodontics
114878|NCT02359760|Piezocision
114879|NCT02359760|flapless corticotomies
114880|NCT02359760|minimaly invasive
114881|NCT02359747|free gDNA
114882|NCT02359747|culture media
114883|NCT02359734|Patient safety
114884|NCT02359734|Medication errors
114885|NCT02359734|Smart infusion pump
114886|NCT02359721|Colony forming units Antimicrobial agents
114887|NCT02359721|Microbial colonization
114888|NCT02359695|Poor ovarian response
114889|NCT02359695|IVF
114890|NCT02359695|Growth hormone
114891|NCT02359643|Kawasaki disease
114892|NCT02359617|continuous glucose sensor
114893|NCT02359617|subcutaneous insulin infusion
114894|NCT02359617|closed-loop glucose control
114895|NCT02359617|type 1 diabetes
114896|NCT02359604|infant
114897|NCT02359604|ppi
114898|NCT02359604|proton pump inhibitor
114899|NCT02359604|microbiome
114900|NCT02359604|Microbiota
114901|NCT02359578|lymphatic system
114902|NCT02359578|occlusion pressure
114903|NCT02359578|Indocyanine Green
114904|NCT02359526|Chronic Diabetic Macular Edema
114905|NCT02359526|Iluvien
114906|NCT02359526|Intra-vitreal injections
114907|NCT02359526|Pilot study
114908|NCT02359513|bulimia
114909|NCT02359513|serotoninergic brain activity
114910|NCT02359513|fluoxetine
114911|NCT02359513|serotoninergic antidepressant
114912|NCT02359513|brain serotonin profile
114913|NCT02359513|positon emission tomography
114914|NCT02359500|68Ga- DOTATOC
114915|NCT02359500|Diagnosis
114916|NCT02359500|Somatostatin Receptor-Positive Neuroendocrine Tumors
114917|NCT02359487|Namibia
114918|NCT02359487|Alcohol
114919|NCT02359487|HIV
114920|NCT02359487|Sexual risk
114921|NCT02359474|high-risk soft tissue sarcoma
114922|NCT02359474|trabectedin
114923|NCT02359461|Vascular function
114924|NCT02359461|Pulsatile cuts
114925|NCT02359461|Type 2 diabetes
114926|NCT02359461|Endothelium
114927|NCT02359461|Cardiovascular risk
114928|NCT02359461|Vasomotricity
114929|NCT02359461|FMD (Flow Mediated Dilatation)
114930|NCT02359435|Helicobacter pylori
114931|NCT02359435|Proton pump inhibitor
114932|NCT02359435|Eradication
114933|NCT02359396|Randomized open-label study
114934|NCT02359396|Chinese Herbal
114935|NCT02359396|Constipation/drug therapy
114936|NCT02359383|pleural disease
114937|NCT02359383|infecTion
114938|NCT02359383|chest physiotherapy
114939|NCT02359370|Laryngoscopy
114940|NCT02359370|Tracheal Intubation
114941|NCT02359370|Lidocaine
114942|NCT02359370|Magnesium Sulphate
114943|NCT02359370|Cardiovascular Physiological Phenomena
114944|NCT02359331|Helicobacter pylori
114945|NCT02359331|resistance
114946|NCT02359331|rescue therapy
114947|NCT02359318|White spot lesion
114948|NCT02359318|Resin Infiltration
114949|NCT02359318|Icon
114950|NCT02359318|Debonding
114951|NCT02359318|Enamel damages
114952|NCT02359318|Enamel
114953|NCT02359318|Orthodontics
114954|NCT02359266|Mood
114955|NCT02359266|Vitamin D deficiency
114956|NCT02359266|Adjuvant treatment
114957|NCT02359253|Stroke
114958|NCT02359253|Hemiplegia
114959|NCT02359253|Muscle Spasticity
114960|NCT02359253|Upper extremity
114961|NCT02359253|Arm
114962|NCT02359253|Hand
114963|NCT02359253|Passive stretching
114964|NCT02359253|Muscle Stretching Exercises
114965|NCT02359253|Occupational Therapy
114966|NCT02359253|Physical Therapy
114967|NCT02359227|Chronic Heart Failure
114968|NCT02359227|Natriuretic Peptides
114969|NCT02359227|Cenderitide
114970|NCT02359214|Vitamin D
114971|NCT02359214|Cardiovascular disease
114972|NCT02359214|Diabetes
114973|NCT02359214|Obesity
114974|NCT02359214|Cardiometabolic
114975|NCT02359214|Bone disease
114976|NCT02359201|Nicotine replacement therapy
114977|NCT02359201|craving
114978|NCT02359201|Healthy moderately dependant smokers
114979|NCT02359188|Vagus Nerve Stimulation
114980|NCT02359175|Pain
114981|NCT02359175|Pain Measurement
114982|NCT02359175|VAS
114983|NCT02359175|Visual Analog Pain Scale
114984|NCT02359175|Analgesics
114985|NCT02359175|Opioid
114986|NCT02359175|Epidural analgesia
114987|NCT02359175|VATS
114988|NCT02359175|Video-assisted Thoracic Surgery
114989|NCT02359175|Lobectomy
114990|NCT02359175|Wedge Resection
114991|NCT02359175|Segmental Resection
114992|NCT02359162|NK/T-cell lymphoma
114993|NCT02359162|induction chemotherapy
114994|NCT02359162|survival
114995|NCT02359149|Intravitreal injections
114996|NCT02359149|Nurses
114997|NCT02359149|Physicians
114998|NCT02359136|Arthroplasty, Replacement, Hip
114999|NCT02359136|Anesthesia, Local
115000|NCT02359136|Ropivacaine
115001|NCT02359136|Randomized controlled trial
115002|NCT02359110|laparoscopy
115003|NCT02359110|postoperative pain
115004|NCT02359110|gynecology
115005|NCT02359110|gabapentin
115006|NCT02359071|handoff
115007|NCT02359071|signoff
115008|NCT02359071|handover
115009|NCT02359071|sign-out
115010|NCT02359071|shift change
115011|NCT02359071|Emergency Department
115012|NCT02359045|Omega-3-carboxylic acids,
115013|NCT02359045|Phase I,
115014|NCT02359045|Healthy Subjects,
115015|NCT02359045|Pharmacokinetics,
115016|NCT02359045|Relative bioavailability
115017|NCT02359032|Healthy subjects
115018|NCT02359032|Pharmacokinetics of ASP6858
115019|NCT02359032|ASP6858
115020|NCT02359032|Pharmacodynamics of ASP6858
115021|NCT02359006|Analgesia
115022|NCT02359006|pain analgesia
115023|NCT02359006|methadone
115024|NCT02359006|opiates
115025|NCT02358993|Urinary Tract Infections
115026|NCT02358993|Catheter-Related Infections
115027|NCT02358993|Pelvic Reconstructive Surgery
115028|NCT02358993|Urogynecology
115029|NCT02358993|Urinary catheterization
115030|NCT02358993|Post-operative Infections
115031|NCT02358993|Methenamine hippurate
115032|NCT02358980|Multiple Myeloma
115033|NCT02358980|Cast Nephropathy
115034|NCT02358980|Acute kidney injury
115035|NCT02358980|KIDNEY THERAPY
115036|NCT02358980|HFR
115037|NCT02358967|ESRD
115038|NCT02358967|dyslipidemia
115039|NCT02358967|oxidative stress
115040|NCT02358967|inflammation
115041|NCT02358967|Hemodialysis
115042|NCT02358967|CKD
115043|NCT02358954|quantitative sensory testing
115044|NCT02358954|contact heat evoked potentials
115045|NCT02358954|vection stimulation
115046|NCT02358954|3D-turntable
115047|NCT02358954|Volunteers
115048|NCT02358941|ADHD, neurofeedback, computerized cognitive training, school
115049|NCT02358928|NAFLD
115050|NCT02358928|Metabolic syndrome
115051|NCT02358928|Hepatic Magnetic Resonance Spectroscopy
115052|NCT02358928|Obesity
115053|NCT02358902|Transcranial Direct Current Stimulation
115054|NCT02358902|Exercise
115055|NCT02358902|Fibromyalgia
115056|NCT02358876|Parkinson's disease
115057|NCT02358876|Deep brain stimulation
115058|NCT02358876|Bradykinesia
115059|NCT02358850|Tonsillectomy
115060|NCT02358850|Adenoidectomy
115061|NCT02358837|elastosonography
115062|NCT02358837|comparing conventional sonography with ductosonography
115063|NCT02358824|Hypertension
115064|NCT02358824|CKD-828
115065|NCT02358824|Telmisartan
115066|NCT02358824|S-amlodipine
115067|NCT02358824|Pharmacokinetic
115068|NCT02358811|Obstructive Sleep Apnea
115069|NCT02358811|Voxel-Based Morphometry
115070|NCT02358811|Polysomnography
115071|NCT02358811|Magnetic resonance imaging
115072|NCT02358798|Time evolution of respiratory function
115073|NCT02358798|Longitudinal multicenter monitoring of large cohorts
115074|NCT02358798|Preschool aged children
115075|NCT02358798|Detection of cystic fibrosis in neonatal period
115076|NCT02358772|stroke
115077|NCT02358772|thrombolysis
115078|NCT02358772|STEMO
115079|NCT02358759|Abnormal zygote fertilization
115080|NCT02358759|3PNs correction
115081|NCT02358759|Giant oocyte management
115082|NCT02358759|triploidy fertilization
115083|NCT02358759|Maternal nucleus removal
115084|NCT02358746|epicardial catheter ablation
115085|NCT02358733|POR
115086|NCT02358733|IMSI
115087|NCT02358720|bone metastases
115088|NCT02358707|ibuprofen phonophoresis
115089|NCT02358707|High performance liquid chromatography
115090|NCT02358694|IBS
115091|NCT02358694|IBS-D
115092|NCT02358694|SBI
115093|NCT02358681|Intranasal
115094|NCT02358681|Ketorolac
115095|NCT02358681|Pediatric
115096|NCT02358681|Migraine
115097|NCT02358681|Headache
115098|NCT02358655|Oral anticoagulant
115099|NCT02358655|Knowledge translation
115100|NCT02358655|Emergency department
115101|NCT02358642|Rate of Pneumonia
115102|NCT02358642|Mortality rate
115103|NCT02358603|Chronotropic Incompetence
115104|NCT02358603|Heart Failure
115105|NCT02358564|IBS
115106|NCT02358564|Irritable Bowel Syndrome
115107|NCT02358564|Visceral Hypersensitivity
115108|NCT02358564|Permeability
115109|NCT02358564|Small Bowel
115110|NCT02358564|Lactulose
115111|NCT02358564|Mannitol
115112|NCT02358551|Pacemaker
115113|NCT02358551|Axillary Vein
115114|NCT02358551|Subclavian vein
115115|NCT02358551|Clinical Study
115116|NCT02358551|Cardiovascular implantable electronic devices
115117|NCT02358538|PCDH19
115118|NCT02358538|ganaxolone
115119|NCT02358538|neurosteroid
115120|NCT02358538|CDKL5
115121|NCT02358538|LGS
115122|NCT02358538|CSWS
115123|NCT02358512|Intensive Care
115124|NCT02358512|Recovery of Function
115125|NCT02358512|Survivors
115126|NCT02358512|Outcome Assessment (Health Care)
115127|NCT02358512|Medical Economics
115128|NCT02358499|triazoles
115129|NCT02358499|fungi
115130|NCT02358499|transplantation, hematopoietic stem cell
115131|NCT02358499|leukemia
115132|NCT02358499|pediatrics
115133|NCT02358499|pharmacokinetics
115134|NCT02358499|bone marrow failure syndrome
115135|NCT02358486|Functional Dyspepsia
115136|NCT02358486|Acupuncture
115137|NCT02358486|Functional MRI
115138|NCT02358473|Nonsmall Cell Lung Cancer
115139|NCT02358473|NSCLC
115140|NCT02358473|Non-Small-Cell Lung Carcinoma
115141|NCT02358473|Carcinoma, Non-Small Cell Lung
115142|NCT02358473|KW-0761
115143|NCT02358473|Mogamulizumab
115144|NCT02358460|neonatal
115145|NCT02358460|respiratory
115146|NCT02358460|mechanical ventilation
115147|NCT02358447|total knee arthroplasty
115148|NCT02358447|total knee prothesis
115149|NCT02358447|Spectrometry, X-Ray Emission
115150|NCT02358447|SPECT/CT
115151|NCT02358447|measurement of TKA component position
115152|NCT02358434|Implant
115153|NCT02358421|Rotterdam's diagnostic criteria of PCOS
115154|NCT02358421|Risk of OHSS
115155|NCT02358356|midgut
115156|NCT02358356|pancreatic
115157|NCT02358356|neuroendocrine
115158|NCT02358356|advanced
115159|NCT02358356|unresectable low
115160|NCT02358356|intermediate grade
115161|NCT02358356|mNETs
115162|NCT02358356|pNETs
115163|NCT02358343|Comorbid Depression
115164|NCT02358343|Major Depressive Disorder
115165|NCT02358343|Dysthymia
115166|NCT02358343|Cognitive Behavioral therapy (CBT)
115167|NCT02358343|Sertraline
115168|NCT02358343|Engagement Interview
115169|NCT02358343|End Stage Renal Disease (ESRD)
115170|NCT02358343|Hemodialysis
115171|NCT02358317|Autism
115172|NCT02358317|Postural Stability
115173|NCT02358317|Exergaming
115174|NCT02358317|White Matter
115175|NCT02358252|Heart Rate Variability
115176|NCT02358252|orthostatic hypotension
115177|NCT02358252|stroke
115178|NCT02358252|integrated intelligent biosensor system
115179|NCT02358239|dizziness and vertigo
115180|NCT02358239|emergency department (ED)
115181|NCT02358239|clinical trial
115182|NCT02358239|acupuncture
115183|NCT02358226|Substance-Related Disorders
115184|NCT02358226|Human Immunodeficiency Virus
115185|NCT02358226|Alcoholism
115186|NCT02358226|South Africa
115187|NCT02358226|Men
115188|NCT02358226|Soccer
115189|NCT02358226|Vocational Training
115190|NCT02358213|reproductibility
115191|NCT02358174|Hemorrhoids
115192|NCT02358174|MMP
115193|NCT02358174|NGAL
115194|NCT02358174|Matrix Metalloproteinases
115195|NCT02358161|Pancreatic cancer
115196|NCT02358161|LDE225
115197|NCT02358161|Gemcitabine
115198|NCT02358161|nab paclitaxel
115199|NCT02358148|Acute Coronary Syndrome
115200|NCT02358148|Chest Pain
115201|NCT02358148|ACS
115202|NCT02358148|Risk Stratification Score
115203|NCT02358148|HEART Score
115204|NCT02358148|Modified TIMI
115205|NCT02358148|Coronary Artery Disease
115206|NCT02358148|Risk Factors
115207|NCT02358148|Myocardial Infarction
115208|NCT02358135|Pragmatic
115209|NCT02358135|Equivalency
115210|NCT02358135|Teledermatology
115211|NCT02358109|Cost-Benefit Analysis, Exercise,Women,Diseases/Prevention
115212|NCT02358096|Chronic Kidney Disease
115213|NCT02358096|Type 2 Diabetes
115214|NCT02358096|ASP8232
115215|NCT02358070|Hepatocellular Carcinoma
115216|NCT02358057|Deep sedation
115217|NCT02358057|Dexmedetomidine
115218|NCT02358057|Emergency Service, Hospital
115219|NCT02358031|PD-1
115220|NCT02358031|PD-L1
115221|NCT02358018|68Ga-DOTATOC
115222|NCT02358018|PET/CT scan
115223|NCT02358018|14-226
115224|NCT02357992|Lung cancer
115225|NCT02357992|Non-small cell lung cancer
115226|NCT02357992|NSCLC
115227|NCT02357992|Squamous cell carcinoma
115228|NCT02357992|Adenocarcinoma with or without BAC features
115229|NCT02357992|Large cell carcinoma with or without neuroendocrine features
115230|NCT02357992|Neuroendocrine carcinoma
115231|NCT02357992|Bronchioloalveolar cell carcinoma
115232|NCT02357992|Stereotactic radiotherapy (SRT)
115233|NCT02357992|SRT
115234|NCT02357992|Stereotactic ablative radiotherapy
115235|NCT02357992|SABR
115236|NCT02357992|Radiation therapy
115237|NCT02357992|XRT
115238|NCT02357979|caries
115239|NCT02357979|prevention
115240|NCT02357979|laser
115241|NCT02357979|fluoride
115242|NCT02357966|Staph
115243|NCT02357966|antibody
115244|NCT02357940|Eczema
115245|NCT02357940|Skin Irritation
115246|NCT02357927|fears of recurrence
115247|NCT02357927|cancer
115248|NCT02357927|brief intervention
115249|NCT02357927|telephone counseling
115250|NCT02357927|following primary cancer treatment
115251|NCT02357914|Ultrasound
115252|NCT02357914|Shoulder
115253|NCT02357914|Spinal Cord Injury
115254|NCT02357914|Fluoroscopy
115255|NCT02357888|Nicotine replacement therapy
115256|NCT02357888|craving
115257|NCT02357862|Cardiovascular Diseases
115258|NCT02357862|Heart Diseases
115259|NCT02357862|Heart Valve Diseases
115260|NCT02357862|Mitral Valve Annuloplasty
115261|NCT02357862|Tricuspid Valve Insufficiency
115262|NCT02357823|Pneumococcal vaccine
115263|NCT02357823|HIV infection
115264|NCT02357823|13-valent Pneumococcal Conjugate Vaccine
115265|NCT02357823|23-valent Pneumococcal Polysaccharide Vaccine
115266|NCT02357784|Sacral Neuromodulation
115267|NCT02357784|SNM
115268|NCT02357784|Dual Incontinence
115269|NCT02357784|Current Perception Threshold Testing
115270|NCT02357784|CPT Testing
115271|NCT02357784|Fecal Incontinence
115272|NCT02357784|Urinary Incontinence
115273|NCT02357784|Afferent Nerve Sensation
115274|NCT02357784|InterStim
115275|NCT02357771|misalignment of the two dental arches
115276|NCT02357771|mal-align teeth
115277|NCT02357758|Antibiotic Prophylaxis
115278|NCT02357758|Urinary Microbiota
115279|NCT02357745|neopterin
115280|NCT02357745|plasma
115281|NCT02357745|urine
115282|NCT02357745|saliva
115283|NCT02357745|menopause
115284|NCT02357745|periodontitis
115285|NCT02357732|Metastatic Melanoma
115286|NCT02357719|Sleep Apnea Syndromes
115287|NCT02357719|Polysomnography
115288|NCT02357719|Holter ECG
115289|NCT02357719|Thoracic impedance
115290|NCT02357719|Heart rate variability
115291|NCT02357719|Nasal flow
115292|NCT02357693|nausea, postoperative
115293|NCT02357693|postoperative nausea
115294|NCT02357693|postoperative vomiting
115295|NCT02357693|vomiting, postoperative
115296|NCT02357641|acute coronary disease, echographic strain analysis, cut off
115297|NCT02357602|Participants
115298|NCT02357602|HIV-1 negative
115299|NCT02357589|3D
115300|NCT02357589|laparoscopy
115301|NCT02357589|cholecystectomy
115302|NCT02357563|fibroid
115303|NCT02357563|GnRH analogue
115304|NCT02357563|ulipristal acetate
115305|NCT02357537|Telemedicine
115306|NCT02357524|Effects on coagulation tests in healthy volunteers
115307|NCT02357511|sensitivity
115308|NCT02357511|specificity
115309|NCT02357511|novel blood pressure monitor
115310|NCT02357511|Saturation
115311|NCT02357498|pituitary
115312|NCT02357498|adenoma
115313|NCT02357498|transsphenoidal surgery
115314|NCT02357485|ADSC
115315|NCT02357485|osteoarthritis
115316|NCT02357485|knee
115317|NCT02357485|adipose
115318|NCT02357472|Reproductive aging
115319|NCT02357472|DHEA
115320|NCT02357472|poor ovarian responder
115321|NCT02357459|Osteoarthritis
115322|NCT02357459|Knee
115323|NCT02357459|Pain
115324|NCT02357459|Steroid
115325|NCT02357459|Intra-articular
115326|NCT02357459|Injection
115327|NCT02357420|Diabetes Mellitus
115328|NCT02357420|Delayed Gastric Emptying
115329|NCT02357420|Vomiting
115330|NCT02357420|Gastroparesis
115331|NCT02357420|Gastrointestinal Motility Disorder
115332|NCT02357407|fluoroquinolones
115333|NCT02357407|pharmacokinetic
115334|NCT02357407|infections
115335|NCT02357368|HIV-negative
115336|NCT02357329|fat taste
115337|NCT02357329|food preference
115338|NCT02357329|consumption
115339|NCT02357329|free fatty acids
115340|NCT02357316|Taste responses of healthy individuals
115341|NCT02357303|Randomized controlled trial
115342|NCT02357303|Endoscopy
115343|NCT02357303|Gastric mucosa
115344|NCT02357303|Simethicone
115345|NCT02357303|Acetylcysteine
115346|NCT02357290|mania
115347|NCT02357290|temper tantrum
115348|NCT02357290|irritability
115349|NCT02357290|mood
115350|NCT02357290|bipolar
115351|NCT02357277|Osteoporosis
115352|NCT02357277|Glucocorticoids
115353|NCT02357277|Postmenopausal
115354|NCT02357238|Uveitis
115355|NCT02357238|Infectious
115356|NCT02357225|Pompe disease
115357|NCT02357225|Pyridostigmine
115358|NCT02357212|Non-St elevation acute coronary syndrome
115359|NCT02357199|Mouth Diseases
115360|NCT02357199|Renal Insufficiency, Chronic
115361|NCT02357199|Intervention Studies
115362|NCT02357186|Mild head injury - clinical decision rule - Child
115363|NCT02357173|smoking
115364|NCT02357173|nicotine
115365|NCT02357173|tobacco products
115366|NCT02357173|electronic cigarette
115367|NCT02357147|Amatuximab
115368|NCT02357147|Pemetrexed
115369|NCT02357147|Cisplatin
115370|NCT02357147|Unresectable Malignant Pleural Mesothelioma
115371|NCT02357147|ARTEMIS
115372|NCT02357134|Advanced cancers
115373|NCT02357134|Primary or secondary lung involvement
115374|NCT02357134|Dyspnea
115375|NCT02357134|Difficulty breathing
115376|NCT02357134|Stationary cycle test
115377|NCT02357134|Questionnaires
115378|NCT02357134|Surveys
115379|NCT02357134|High flow oxygen
115380|NCT02357134|High flow air
115381|NCT02357134|Low flow oxygen
115382|NCT02357134|Low flow air
115383|NCT02357108|Supportive Care
115384|NCT02357108|treatment options
115385|NCT02357108|doctor's compassion
115386|NCT02357095|Caesarean Scar Pregnancy
115387|NCT02357095|uterine artery chemo-embolization
115388|NCT02357095|treatment
115389|NCT02357030|Gulf War Illness
115390|NCT02357030|nutrients
115391|NCT02357030|methylphenidate
115392|NCT02357030|mitochondria
115393|NCT02356991|Famitinib
115394|NCT02356991|Phase II
115395|NCT02356991|NSCLC
115396|NCT02356978|Rare disease
115397|NCT02356978|Crigler-Najjar disease
115398|NCT02356978|Paediatric
115399|NCT02356978|Experimental device
115400|NCT02356965|Third molar extraction
115401|NCT02356965|Wisdom tooth extraction
115402|NCT02356952|Metabolic Syndrome X
115403|NCT02356952|Low Glycemic Index Mediterranean Diet
115404|NCT02356952|Low Glycemic Index Diet
115405|NCT02356952|Randomized Clinical Trial
115406|NCT02356926|Adverse events
115407|NCT02356926|Medical errors
115408|NCT02356926|Emergency department
115409|NCT02356926|Cross checking
115410|NCT02356900|interval training
115411|NCT02356900|hyperbaric oxygen
115412|NCT02356900|VO2 max
115413|NCT02356900|altitude
115414|NCT02356900|exercise performance
115415|NCT02356900|mitochondrial oxidative capacity
115416|NCT02356900|mitochondrial biogenesis
115417|NCT02356861|treatment
115418|NCT02356861|photobiomodulation
115419|NCT02356861|Veterans
115420|NCT02356861|brain-injury
115421|NCT02356861|TBI
115422|NCT02356861|PTSD
115423|NCT02356848|self-care
115424|NCT02356848|self-monitoring
115425|NCT02356848|secondary prevention
115426|NCT02356848|foot ulcer
115427|NCT02356809|Gene therapy, plasmid, vegf, systemic scleroderma,secondary raynaud's phenomenon
115428|NCT02356757|self-care
115429|NCT02356757|self-monitoring
115430|NCT02356757|medication adherence
115431|NCT02356757|diet
115432|NCT02356757|physical activity
115433|NCT02356757|primary prevention
115434|NCT02356744|Maternal outcome
115435|NCT02356744|Fetal outcome
115436|NCT02356744|bariatric surgery
115437|NCT02356744|Third Trimester
115438|NCT02356731|seizures,
115439|NCT02356731|quality of life
115440|NCT02356640|Celiac plexus neurolysis
115441|NCT02356640|Celiac ganglion neurolysis
115442|NCT02356640|Pancreatic cancer
115443|NCT02356627|Occupational therapy
115444|NCT02356627|Adaptive intervention
115445|NCT02356627|Home-based
115446|NCT02356627|Assistive Technology
115447|NCT02356627|Home modification
115448|NCT02356627|Clinical effectiveness
115449|NCT02356627|Cost-effectiveness
115450|NCT02356627|Cost-utility
115451|NCT02356614|Lap Band
115452|NCT02356601|MRI
115453|NCT02356601|Lumbar spine
115454|NCT02356601|Ultrasound
115455|NCT02356575|surgery
115456|NCT02356575|chemotherapy
115457|NCT02356575|radiation
115458|NCT02356575|Acupuncture
115459|NCT02356575|16-947
115460|NCT02356562|Hepatitis C
115461|NCT02356562|Interferon-Free
115462|NCT02356562|Treatment Experienced
115463|NCT02356562|Chronic Hepatitis C
115464|NCT02356562|Hepatitis C Virus
115465|NCT02356510|myocardial infarction
115466|NCT02356510|TIMI flow
115467|NCT02356510|culprit lesion
115468|NCT02356510|culprit vessel
115469|NCT02356497|Bone metastases
115470|NCT02356497|Metastatic bone disease
115471|NCT02356497|Multi-trial facility
115472|NCT02356458|Mantle cell lymphoma
115473|NCT02356458|Relapsed
115474|NCT02356458|Refractory
115475|NCT02356458|Cancer
115476|NCT02356458|Lymphoma
115477|NCT02356458|Ibrutinib Imbruvica
115478|NCT02356458|Bortezomib Velcade
115479|NCT02356432|non-valvular atrial fibrillation
115480|NCT02356432|cerebral microbleeds
115481|NCT02356432|warfarin
115482|NCT02356432|NOACs
115483|NCT02356432|acute ischemic stroke
115484|NCT02356406|Radiosurgery
115485|NCT02356406|Celiac Plexus
115486|NCT02356406|Pain
115487|NCT02356406|Quality of Life
115488|NCT02356393|Desalinated Sea Water
115489|NCT02356393|Magnesium
115490|NCT02356393|Drinking Water
115491|NCT02356367|telemonitoring
115492|NCT02356367|Adaptive servo-ventilation
115493|NCT02356354|molecular factors
115494|NCT02356354|cutaneous innervation
115495|NCT02356354|skin biopsy
115496|NCT02356354|post-burn scar
115497|NCT02356315|Brain
115498|NCT02356315|Brain Stem
115499|NCT02356315|Spinal Cord
115500|NCT02356315|Neurophysiology
115501|NCT02356315|Magnetic Resonance Imaging
115502|NCT02356289|Hypertrophic Cardiomyopathy
115503|NCT02356263|stressful events
115504|NCT02356263|psychological stress
115505|NCT02356263|life experiences
115506|NCT02356250|liver biopsy f 4
115507|NCT02356237|Episiotomy
115508|NCT02356237|Obstetric Anal Sphincter Injury
115509|NCT02356224|SHR3824 Type 2 diabetes mellitus SGLT2
115510|NCT02356211|falls
115511|NCT02356185|Alcohol Drinking
115512|NCT02356185|Injecting drug
115513|NCT02356185|Antiretroviral therapy
115514|NCT02356185|sub-Saharan Africa
115515|NCT02356172|Quality of Life
115516|NCT02356172|Depression
115517|NCT02356172|Kallmann Syndrome
115518|NCT02356172|Hypogonadotropic Hypogonadism
115519|NCT02356159|Hematopoietic Stem Cell Transplant
115520|NCT02356159|Lymphoma
115521|NCT02356159|Leukemia
115522|NCT02356159|Unrelated Donors
115523|NCT02356146|Kidney transplantation
115524|NCT02356146|genotype
115525|NCT02356146|tacrolimus
115526|NCT02356146|CYP3A5
115527|NCT02356133|Near-Infrared Spectroscopy
115528|NCT02356094|glaucoma
115529|NCT02356094|primary open angle glaucoma
115530|NCT02356094|cornea
115531|NCT02356068|liver transplantation, rotem, bleeding, transfusion
115532|NCT02356055|activities of daily living
115533|NCT02356055|massed practice
115534|NCT02356055|occupational therapy
115535|NCT02356029|Cardiopulmonary Arrest
115536|NCT02356029|Emergency Medical Services
115537|NCT02356029|Medical Futility
115538|NCT02356029|Decision Making
115539|NCT02356029|Emotional Stress
115540|NCT02356029|Burnout, Professional
115541|NCT02356016|Sarcopenic Obesity
115542|NCT02356016|community dwelling elderly women
115543|NCT02356016|electromyostimulation
115544|NCT02356016|exercise
115545|NCT02356016|dietary supplements
115546|NCT02356003|Tourette Syndrome
115547|NCT02356003|Children
115548|NCT02356003|Tics
115549|NCT02355977|Chronic periodontitis
115550|NCT02355977|Minocycline
115551|NCT02355977|Surface and root planning
115552|NCT02355977|Pocket depth
115553|NCT02355977|Sulcus bleeding index
115554|NCT02355977|Prevotella intermedia
115555|NCT02355912|Transfemoral
115556|NCT02355873|heparin-coated
115557|NCT02355873|surface-treated polyacrylonitrile membrane hemofilter
115558|NCT02355873|critical ill
115559|NCT02355873|acute kidney injury
115560|NCT02355873|chronic kidney disease
115561|NCT02355873|continuous renal replacement therapy
115562|NCT02355834|Fecal Incontinence (FI)
115563|NCT02355834|Inflammatory bowel disease (IBD)
115564|NCT02355834|bowel control
115565|NCT02355834|Chronic diarrhoea
115566|NCT02355834|rectal inflammation
115567|NCT02355821|cellular aging
115568|NCT02355821|vascular aging
115569|NCT02355821|bone metabolism
115570|NCT02355821|collagen type 1 C-telopeptide
115571|NCT02355821|nuclear factor kappa-B ligand (RANKL)
115572|NCT02355821|pulse wave velocity
115573|NCT02355821|telomerase activity
115574|NCT02355795|weight change
115575|NCT02355795|diet
115576|NCT02355795|dietary fat
115577|NCT02355795|feeding design
115578|NCT02355782|TMA, aHUS, TTP, stem cell transplant-associated TMA
115579|NCT02355769|heart failure
115580|NCT02355769|renal failure
115581|NCT02355769|prognosis
115582|NCT02355769|impedance cardiography
115583|NCT02355717|children, bone
115584|NCT02355717|Simple obesity
115585|NCT02355717|cardiovascular disease
115586|NCT02355717|osteoporosis
115587|NCT02355717|diabetes
115588|NCT02355704|Kidney Transplantation
115589|NCT02355704|Atorvastatin
115590|NCT02355704|C-Reactive Protein
115591|NCT02355704|Biopsy
115592|NCT02355704|Interleukin
115593|NCT02355652|Total knee arthroplasty
115594|NCT02355652|IKS Score
115595|NCT02355652|cemented, uncemented
115596|NCT02355626|Anxiety
115597|NCT02355626|level of anxiety
115598|NCT02355626|delirium
115599|NCT02355626|agitation
115600|NCT02355626|tools for measuring anxiety
115601|NCT02355626|neuroendocrine system
115602|NCT02355613|Radiosurgery, brain, metastases
115603|NCT02355600|Oocyte
115604|NCT02355600|Tamoxifen
115605|NCT02355600|Fertility preservation
115606|NCT02355587|melanoma
115607|NCT02355587|cutaneous melanoma
115608|NCT02355587|DecisionDx-Melanoma
115609|NCT02355574|melanoma
115610|NCT02355574|cutaneous melanoma
115611|NCT02355574|DecisionDx-Melanoma
115612|NCT02355561|Bioavailability
115613|NCT02355561|Healthy Participants
115614|NCT02355561|JNJ-54861911
115615|NCT02355561|Food Effect
115616|NCT02355535|refractory
115617|NCT02355535|intolerant
115618|NCT02355535|solid tumors
115619|NCT02355535|lymphoma
115620|NCT02355522|saline infusion sonohysterography
115621|NCT02355509|Acarbose
115622|NCT02355509|Postprandial lipemia
115623|NCT02355509|Cardiovascular risk
115624|NCT02355496|Cost Control
115625|NCT02355496|Data Display
115626|NCT02355496|Diagnostic Tests, Routine
115627|NCT02355496|Physician's Practice Patterns
115628|NCT02355470|Sexual assault
115629|NCT02355470|Alcohol consumption
115630|NCT02355470|Intimate partner violence
115631|NCT02355457|troponin
115632|NCT02355457|myocardial infarction
115633|NCT02355457|acs
115634|NCT02355457|AMI
115635|NCT02355457|biomarker
115636|NCT02355457|BACC
115637|NCT02355457|high-sensitivity
115638|NCT02355431|EGFR
115639|NCT02355431|mutation
115640|NCT02355405|lung ultrasound
115641|NCT02355405|atelectasis
115642|NCT02355405|thoracic computed Tomography
115643|NCT02355379|Adjuvant chemotherapy in colonic adenocarcinoma in elderly
115644|NCT02355366|Offspring
115645|NCT02355366|significant mood symptoms
115646|NCT02355353|DWI-MRI
115647|NCT02355353|resectable liver metastases
115648|NCT02355340|Bone mineral density
115649|NCT02355340|Childhood cancer survivors
115650|NCT02355314|ICU patients
115651|NCT02355314|Doppler-based renal
115652|NCT02355301|ICF, impairment, activity, satisfaction, quality of care
115653|NCT02355288|Coronary Artery Disease
115654|NCT02355288|Diabetes Mellitus
115655|NCT02355288|Minimally Invasive Cardiac Surgery
115656|NCT02355288|Percutaneous Coronary Intervention
115657|NCT02355275|Home Exercise
115658|NCT02355275|Resistance Exercise
115659|NCT02355262|Insurance Coverage
115660|NCT02355262|Insurance Continuity
115661|NCT02355249|traditional three incisions
115662|NCT02355249|minimally invasive thoracol-laparoscopic esophagectomy
115663|NCT02355249|MIE
115664|NCT02355249|esophageal cancer
115665|NCT02355236|Naxozol
115666|NCT02355236|LDQ
115667|NCT02355236|GSRS
115668|NCT02355236|Osteoarthritis
115669|NCT02355236|Gastroprotective
115670|NCT02355223|Tuberculosis
115671|NCT02355223|Infection Control
115672|NCT02355223|Transmission
115673|NCT02355197|antioxidants
115674|NCT02355197|Gestational diabetes mellitus
115675|NCT02355197|oxidative stress
115676|NCT02355158|pain
115677|NCT02355158|diabetic neuropathy
115678|NCT02355158|pain in feet
115679|NCT02355145|type 2 diabetes, add-on diabetes therapy, rationale
115680|NCT02355132|Medicaid
115681|NCT02355132|public insurance
115682|NCT02355132|cardiovascular disease
115683|NCT02355132|prevention
115684|NCT02355132|community health centers
115685|NCT02355132|electronic health records
115686|NCT02355132|cancer prevention
115687|NCT02355080|HIV
115688|NCT02355080|HCV
115689|NCT02355067|parenting
115690|NCT02355067|postpartum depression
115691|NCT02355067|mothers
115692|NCT02355067|infants
115693|NCT02355067|depression
115694|NCT02355054|Recurrent
115695|NCT02355041|diet
115696|NCT02355041|body weight
115697|NCT02355041|eating
115698|NCT02355041|meal replacement
115699|NCT02355028|LHA510
115700|NCT02355028|PoC
115701|NCT02355028|Age-related macular degeneration
115702|NCT02354976|omega-3 carboxylic acid
115703|NCT02354963|Poor ovarian response
115704|NCT02354963|Salvador/Warts/Hippo pathway
115705|NCT02354963|Follicular activation
115706|NCT02354963|Poor ovarian reserve
115707|NCT02354950|GSK1265744
115708|NCT02354950|healthy controls
115709|NCT02354950|pharmacokinetic
115710|NCT02354950|Hepatic Impairment
115711|NCT02354937|Pharmacokinetics
115712|NCT02354937|GSK1265744
115713|NCT02354937|Severe Renal Impairment
115714|NCT02354911|Immunomodulation
115715|NCT02354872|Nicotine
115716|NCT02354859|Cystic Fibrosis
115717|NCT02354859|Gallium Nitrate
115718|NCT02354859|IV Gallium
115719|NCT02354859|Pseudomonas aeruginosa
115720|NCT02354833|Hypotension
115721|NCT02354833|Cesarean Delivery
115722|NCT02354833|Phenylephrine
115723|NCT02354833|Spinal Anesthesia
115724|NCT02354833|Norepinephrine
115725|NCT02354807|BAT activation
115726|NCT02354807|quantitative PET imaging
115727|NCT02354807|Mirabegron effect on BAT
115728|NCT02354794|arginine
115729|NCT02354794|supplementation
115730|NCT02354794|metabolic syndrome
115731|NCT02354794|endothelial function
115732|NCT02354781|DMD
115733|NCT02354781|muscular dystrophy
115734|NCT02354781|Follistatin
115735|NCT02354742|Echocardiography
115736|NCT02354742|EGDT
115737|NCT02354742|Sepsis
115738|NCT02354716|esophagus
115739|NCT02354716|upper GI
115740|NCT02354716|endoscopy
115741|NCT02354716|endoFLIP
115742|NCT02354716|functional luminal imaging
115743|NCT02354716|esophageal stricture
115744|NCT02354716|narrow esophagus
115745|NCT02354716|narrow caliber esophagus
115746|NCT02354716|esophageal narrowing
115747|NCT02354716|eosinophilic esophagitis
115748|NCT02354716|Zenkers diverticulum
115749|NCT02354716|Schatzki ring
115750|NCT02354703|alcoholism, treatment, serotonin transporter
115751|NCT02354677|Bronchial epithelium
115752|NCT02354677|COPD
115753|NCT02354677|Repair
115754|NCT02354677|Remodelling
115755|NCT02354677|Club Cells
115756|NCT02354664|respiratory test
115757|NCT02354664|respiratory muscle endurance
115758|NCT02354664|spirometry
115759|NCT02354651|Pompe disease
115760|NCT02354651|mechanical ventilation
115761|NCT02354651|diaphragm pacing
115762|NCT02354638|Perceptions
115763|NCT02354638|Education and evaluate post intervention KAP
115764|NCT02354625|Schwann cells
115765|NCT02354599|Randomized, double-blind, placebo-controlled, single-dose subcutaneous administration study
115766|NCT02354586|gBRCAmut
115767|NCT02354586|BRCA
115768|NCT02354586|PARP inhibitor
115769|NCT02354586|HRD
115770|NCT02354586|Ovarian cancer
115771|NCT02354586|Serous Epithelial
115772|NCT02354586|Fallopian Tube
115773|NCT02354586|Primary Peritoneal
115774|NCT02354560|Erythromycin
115775|NCT02354560|Familial Adenomatous Polyposis (FAP)
115776|NCT02354560|APC gene
115777|NCT02354560|nonsense mutations
115778|NCT02354534|cervical dysplasia
115779|NCT02354534|HPV
115780|NCT02354534|Treatment
115781|NCT02354534|preinvasive
115782|NCT02354534|cervix
115783|NCT02354534|vaginal suppository
115784|NCT02354534|Johns Hopkins
115785|NCT02354534|Cornelia Trimble
115786|NCT02354534|abnormal pap
115787|NCT02354534|CIN
115788|NCT02354521|Protein
115789|NCT02354521|Mechanical ventilation
115790|NCT02354521|Children
115791|NCT02354521|Outcomes
115792|NCT02354508|acromegaly
115793|NCT02354508|GH
115794|NCT02354508|IGF-1
115795|NCT02354508|pasireotide LAR
115796|NCT02354495|Indirect calorimetry
115797|NCT02354495|Protein
115798|NCT02354495|Mechanical ventilation
115799|NCT02354495|Respiratory failure
115800|NCT02354469|TBI
115801|NCT02354469|Mild Traumatic Brain Injury
115802|NCT02354469|Post-Concussion Syndrome
115803|NCT02354469|Recovery of Function
115804|NCT02354469|Motor Activity
115805|NCT02354469|Diffusion Tensor Imaging
115806|NCT02354469|Neural Injury
115807|NCT02354469|Biomarkers
115808|NCT02354456|atrial fibrillation
115809|NCT02354456|epidemiology
115810|NCT02354456|antiocaogulation
115811|NCT02354430|pregnancy
115812|NCT02354430|low back pain
115813|NCT02354430|sick leave,
115814|NCT02354430|motor activity
115815|NCT02354404|Ebola virus
115816|NCT02354404|Filoviridae Infections
115817|NCT02354404|Hemorrhagic Fever, Ebola
115818|NCT02354404|Viral Diseases
115819|NCT02354404|Hemorrhagic Fevers, Viral
115820|NCT02354365|PEEP adjustment
115821|NCT02354365|Tidal Volume
115822|NCT02354365|Driving Pressure
115823|NCT02354365|Compliance
115824|NCT02354339|Metabolic Syndrome
115825|NCT02354339|Irvingia gabonensis
115826|NCT02354339|African mango
115827|NCT02354339|Insulin resistance
115828|NCT02354313|MANTLE CELL LYMPHOMA (MCL)
115829|NCT02354313|Lenalidomide (Len)
115830|NCT02354313|Rituximab
115831|NCT02354313|ASCT
115832|NCT02354313|Revlimid
115833|NCT02354313|High dose chemotherapy
115834|NCT02354313|transplant
115835|NCT02354261|Basal Cell Carcinoma Nevus Syndrome
115836|NCT02354261|BCCNS
115837|NCT02354261|BCC
115838|NCT02354261|itraconazole
115839|NCT02354261|basal cell carcinoma
115840|NCT02354261|locally advanced basal cell carcinoma
115841|NCT02354248|TST
115842|NCT02354248|TMS
115843|NCT02354248|Stroke patients
115844|NCT02354248|EMG
115845|NCT02354235|MT-2412
115846|NCT02354235|MP-513
115847|NCT02354235|TA-7284
115848|NCT02354235|Teneligliptin
115849|NCT02354235|Canagliflozin
115850|NCT02354222|MT-2412
115851|NCT02354222|MP-513
115852|NCT02354222|TA-7284
115853|NCT02354222|Teneligliptin
115854|NCT02354222|Canagliflozin
115855|NCT02354183|Commitment strategies
115856|NCT02354183|Motivation
115857|NCT02354183|DBT skills
115858|NCT02354183|Self-harm
115859|NCT02354183|Brief intervention
115860|NCT02354170|Central Serous Chorioretinopathy, CSC
115861|NCT02354157|children dietary pattern
115862|NCT02354157|control rules
115863|NCT02354157|instrumental learning
115864|NCT02354157|food reinforcement
115865|NCT02354144|Human papillomavirus
115866|NCT02354144|Carrageenan
115867|NCT02354144|Microbicide
115868|NCT02354144|Anal HPV infection
115869|NCT02354131|Ovarian cancer
115870|NCT02354131|Niraparib
115871|NCT02354131|Bevacizumab
115872|NCT02354131|PARP
115873|NCT02354131|Phase 2 randomized
115874|NCT02354105|Axial Spondyloarthritis
115875|NCT02354105|Radiographic Axial Spondyloarthritis
115876|NCT02354105|Non-radiographic Axial Spondyloarthritis
115877|NCT02354105|Ankylosing spondylitis
115878|NCT02354105|Diagnosis
115879|NCT02354105|Cimzia
115880|NCT02354105|CZP
115881|NCT02354105|Certolizumab Pegol
115882|NCT02354105|CDP870
115883|NCT02354092|cervical dilation
115884|NCT02354092|pain
115885|NCT02354092|paracervical block
115886|NCT02354092|osmotic dilators
115887|NCT02354079|Low LDL-C
115888|NCT02354079|Target Identification
115889|NCT02354079|Genetic
115890|NCT02354079|Endocrinology
115891|NCT02354079|Cardiovascular Disease
115892|NCT02354066|Hallux valgus surgery
115893|NCT02354066|forefoot surgery
115894|NCT02354066|brake response time
115895|NCT02354066|foot orthoses
115896|NCT02354053|HIV
115897|NCT02354053|Triumeq
115898|NCT02354053|vulnerable populations
115899|NCT02354040|Stroke, Myocardial Infarction, Adherence, Health Literacy, Implementation, Developing Country
115900|NCT02354027|SHR3824 metformin drug-drug interaction
115901|NCT02354014|Multidrug-Resistant Tuberculosis
115902|NCT02354014|Bedaquiline
115903|NCT02354014|TMC207
115904|NCT02354001|schizophrenia
115905|NCT02354001|mental illness
115906|NCT02354001|serm
115907|NCT02354001|raloxifene
115908|NCT02354001|clinical trial
115909|NCT02353988|AR-positive
115910|NCT02353988|Androgen Antagonists
115911|NCT02353988|Bicalutamide
115912|NCT02353988|TNBC
115913|NCT02353988|metastatic
115914|NCT02353975|SHR3824
115915|NCT02353975|food effect
115916|NCT02353975|mass
115917|NCT02353975|balance
115918|NCT02353975|Phase I
115919|NCT02353962|neglect
115920|NCT02353962|exergames
115921|NCT02353949|Mild cognitive impairment
115922|NCT02353949|Alzheimer
115923|NCT02353949|PET
115924|NCT02353949|Amyloid
115925|NCT02353949|Frontotemporal
115926|NCT02353871|Moderate to Severe
115927|NCT02353858|Rectal Cancer
115928|NCT02353858|Hyperthermia
115929|NCT02353858|Radiochemotherapy
115930|NCT02353858|Chemoradiotherapy
115931|NCT02353858|Deep regional hyperthermia
115932|NCT02353858|pathologic complete response
115933|NCT02353858|Regression Grade
115934|NCT02353858|Locally advanced rectal cancer
115935|NCT02353858|complete response
115936|NCT02353806|Amlodipine besylate
115937|NCT02353806|Breast milk
115938|NCT02353806|Pharmacokinetics
115939|NCT02353806|Chronic hypertension
115940|NCT02353806|Pregnancy
115941|NCT02353793|Hypothermia
115942|NCT02353793|(Poly) Trauma
115943|NCT02353793|Emergency Room
115944|NCT02353793|Warming Blanket
115945|NCT02353780|Rheumatoid arthritis
115946|NCT02353780|TNF inhibitors
115947|NCT02353702|Diaphragmatic function
115948|NCT02353702|sniff-test
115949|NCT02353702|pulmonary complications
115950|NCT02353702|upper abdominal surgery
115951|NCT02353663|Rheumatic heart disease
115952|NCT02353663|Rheumatic fever
115953|NCT02353663|Mitral regurgitation
115954|NCT02353663|Aortic regurgitation
115955|NCT02353663|Mitral stenosis
115956|NCT02353650|Q10
115957|NCT02353650|ubiquinol
115958|NCT02353611|tooth
115959|NCT02353611|bleaching
115960|NCT02353585|vitamin K-antagonist
115961|NCT02353585|novel oral anticoagulants
115962|NCT02353585|apixaban
115963|NCT02353585|dabigatran
115964|NCT02353585|rivaroxaban
115965|NCT02353585|edoxaban
115966|NCT02353585|direct oral anticoagulants
115967|NCT02353559|acute leukemia
115968|NCT02353559|traumatic stress
115969|NCT02353559|quality of life
115970|NCT02353559|symptom burden
115971|NCT02353559|psychosocial oncology
115972|NCT02353559|palliative care
115973|NCT02353559|intervention
115974|NCT02353559|hematological malignancies
115975|NCT02353559|supportive care
115976|NCT02353546|affective symptoms
115977|NCT02353546|cancer
115978|NCT02353546|depression
115979|NCT02353546|palliative care
115980|NCT02353546|pilot trial
115981|NCT02353546|psychotherapy
115982|NCT02353533|adenoma
115983|NCT02353533|EMR
115984|NCT02353533|FTRD
115985|NCT02353533|non- lifting
115986|NCT02353533|colon
115987|NCT02353442|Pain
115988|NCT02353442|Rotator cuff
115989|NCT02353442|Stretching
115990|NCT02353442|Mobilization
115991|NCT02353442|Scapula
115992|NCT02353442|Posterior capsule
115993|NCT02353416|Mediterranean Diet
115994|NCT02353416|Low-Glycemic Index
115995|NCT02353416|AGEs
115996|NCT02353403|Fructo-oligosaccharides
115997|NCT02353403|Sugar-reduced foods
115998|NCT02353403|Postprandial glucose response
115999|NCT02353390|presyncope
116000|NCT02353390|syncope
116001|NCT02353390|adolescent
116002|NCT02353390|young adult
116003|NCT02353390|immunization
116004|NCT02353390|vaccination
116005|NCT02353390|water consumption
116006|NCT02352558|Multiple Myeloma
116007|NCT02352558|Lymphoma
116008|NCT02352558|Acute Myeloid Leukemia
116009|NCT02352558|Myelo-Dysplastic Syndrome
116010|NCT02352558|Chronic Myeloid Leukemia
116011|NCT02352558|Chronic Lymphocytic Leukemia
116012|NCT02352532|Dry Needling
116013|NCT02352532|Shear Wave Elastography
116014|NCT02352532|Ultrasound
116015|NCT02352493|PNH
116016|NCT02352493|RNAi therapeutic
116017|NCT02352480|Non Healing Wound
116018|NCT02352467|Non Healing Wound
116019|NCT02352454|Non Healing Wound
116020|NCT02352428|Skin Cancer
116021|NCT02352428|Secondary Prevention
116022|NCT02352428|Population Screening
116023|NCT02352402|CABG
116024|NCT02352402|Ticagrelor
116025|NCT02352402|Graft
116026|NCT02352402|Patency
116027|NCT02352389|Childhood
116028|NCT02352389|Cancer
116029|NCT02352389|Genetic mutations
116030|NCT02352376|Noninvasive ventilation
116031|NCT02352376|Heart rate variability
116032|NCT02352376|Thoracic surgery
116033|NCT02353364|Advanced maternal age
116034|NCT02353364|Aneuploidy
116035|NCT02353325|Iron deficiency
116036|NCT02353325|Iron fortification
116037|NCT02353325|Iron encapsulation
116038|NCT02353312|Diastolic
116039|NCT02353312|Biopterin
116040|NCT02353312|Therapeutic Use
116041|NCT02353312|Drug Therapy
116042|NCT02353312|Quality of Life
116043|NCT02353299|Cognition
116044|NCT02353299|Balance
116045|NCT02353273|WH-1,Diabetic Foot,Ulcer
116046|NCT02353234|Phenolics
116047|NCT02353234|Aleurone
116048|NCT02353234|Bioavailability
116049|NCT02353234|Pharmacokinetics
116050|NCT02353221|Early arthritis
116051|NCT02353221|undiferentiated arthritis
116052|NCT02353182|abdominal
116053|NCT02353182|lower extremity
116054|NCT02353169|changes in myocardial repolarization in healthy children
116055|NCT02353156|Hemorrhoidectomy
116056|NCT02353156|postoperative pain
116057|NCT02353156|Sitz bath
116058|NCT02353156|Electronic bidet
116059|NCT02353143|Acute Myeloid Leukemia
116060|NCT02353143|AML
116061|NCT02353143|Relapsed
116062|NCT02353143|Refractory
116063|NCT02353143|MEN1112
116064|NCT02353143|Monoclonal antibody
116065|NCT02353130|autism spectrum disorders
116066|NCT02353130|memantine
116067|NCT02353130|cortical metrics
116068|NCT02353130|sensory testing
116069|NCT02353078|Eosinophilic Esophagitis (EOE)
116070|NCT02353065|Colles' Fracture
116071|NCT02353065|ultrasonography
116072|NCT02353052|morphology standards
116073|NCT02353013|protein intake
116074|NCT02353013|body composition
116075|NCT02352974|Diamyd
116076|NCT02352974|Diabetes
116077|NCT02352974|Juvenile Diabetes
116078|NCT02352974|Diabetes Type 1
116079|NCT02352974|Type 1 Diabetes
116080|NCT02352974|Autoimmune Diabetes
116081|NCT02352974|Insulin Dependent Diabetes
116082|NCT02352974|Type 1 Diabetes Mellitus
116083|NCT02352974|rhGAD65
116084|NCT02352974|GAD65
116085|NCT02352974|GAD-Alum
116086|NCT02352974|Diabetes Mellitus
116087|NCT02352974|Diabetes mellitus Type 1
116088|NCT02352974|Glucose Metabolism Disorders
116089|NCT02352974|Metabolic Diseases
116090|NCT02352974|Vitamin D
116091|NCT02352961|Unrecognised condition
116092|NCT02352922|Laparoscopy
116093|NCT02352922|Robotic Surgical Procedures
116094|NCT02352922|Hysterectomy
116095|NCT02352922|Anesthetics, Local
116096|NCT02352922|Bupivacaine
116097|NCT02352922|Pain, Postoperative
116098|NCT02352896|Leigh syndrome
116099|NCT02352896|Mitochondrial disorders
116100|NCT02352896|EPI743
116101|NCT02352896|Vincerinone
116102|NCT02352870|Feasibility study
116103|NCT02352870|Randomised controlled trial
116104|NCT02352870|Cognitive behavioural therapy
116105|NCT02352870|Psychological distress
116106|NCT02352870|Cognitive illness representations
116107|NCT02352870|Common sense model
116108|NCT02352857|Fructo-oligosaccharides
116109|NCT02352857|Sugar-reduced foods
116110|NCT02352857|Postprandial glucose response
116111|NCT02352805|Extracorporeal circulation, ventricular assist device
116112|NCT02352792|Local control
116113|NCT02352779|Cancer Survivor
116114|NCT02352766|Thyroid cancer
116115|NCT02352766|Thyroid nodules
116116|NCT02352766|Palpable nodules
116117|NCT02352766|FNA
116118|NCT02352753|Amgen, OI, Bone
116119|NCT02352740|arginine
116120|NCT02352740|supplementation
116121|NCT02352740|metabolic syndrome
116122|NCT02352740|nitric oxide
116123|NCT02352727|Nocturnal hypokinesia
116124|NCT02352727|Accelerometers
116125|NCT02352714|Adolescents
116126|NCT02352714|Women's Health
116127|NCT02352714|Contraception
116128|NCT02352714|Reproduction
116129|NCT02352714|Comparative Effectiveness Research
116130|NCT02352714|Pregnancy Prevention
116131|NCT02352714|Intrauterine Device
116132|NCT02352701|helicobacter pylori
116133|NCT02352701|ilaprazole
116134|NCT02352701|eradication
116135|NCT02352701|triple therapy
116136|NCT02352688|elderly
116137|NCT02352688|enhanced recovery after surgery
116138|NCT02352662|Congenital Heart Disease
116139|NCT02352662|Point-of-care coagulation monitoring
116140|NCT02352662|Rotaional Thromboelastometry
116141|NCT02352649|Peripheral nerve injury
116142|NCT02352649|Neurotmesis
116143|NCT02352649|Gene therapy
116144|NCT02352649|Plasmid
116145|NCT02352649|Nerve regeneration therapy
116146|NCT02352610|carpometacarpal joints
116147|NCT02352597|PCOS
116148|NCT02352597|Phytoestrogens
116149|NCT02352597|ovulation induction
116150|NCT02352584|QIV
116151|NCT02352584|Quadrivalent Influenza Vaccine
116152|NCT02352584|Influenza vaccine
116153|NCT02352584|Vaccination
116154|NCT02352363|Parkinson's Disease
116155|NCT02352363|Motor fluctuations
116156|NCT02352363|levodopa
116157|NCT02352363|inhaled drugs
116158|NCT02352363|OFF episodes
116159|NCT02352350|Pre-Hospital Cardiac Arrest
116160|NCT02352350|Blood Lactate Level
116161|NCT02352350|Neurological Injury
116162|NCT02352337|cancer
116163|NCT02352337|pancreatic cancer
116164|NCT02352337|metastatic pancreatic cancer
116165|NCT02352324|cardiac output
116166|NCT02352324|coronary artery bypass grafting
116167|NCT02352324|minimally invasive hemodynamic monitoring
116168|NCT02352324|fluid responsiveness
116169|NCT02352272|sleep extension
116170|NCT02352272|attention
116171|NCT02352272|physical performance
116172|NCT02352259|Liver metastases of colorectal cancer Electrochemotherapy
116173|NCT02352259|Bleomycin
116174|NCT02352259|Electrochemotherapy
116175|NCT02352246|intermittent sprinting
116176|NCT02352246|abdominal fat mass
116177|NCT02352246|type 2 diabetes
116178|NCT02352246|postmenopausal women
116179|NCT02352233|retroview colonoscope
116180|NCT02352233|retroflexion colonoscopy
116181|NCT02352233|colonoscopy
116182|NCT02352207|Neonatal respiratory distress
116183|NCT02352207|prenatal lung malformation
116184|NCT02352207|KRAS mutation
116185|NCT02352207|pregnant woman
116186|NCT02352194|Multiple Sclerosis, Physical therapy, Physical capacity, Fatigue
116187|NCT02352181|Cirrhosis, transplantation, transfusion, Rotem®
116188|NCT02352168|allergic rhinitis；airway inflammation；hyperreactivity
116189|NCT02352155|haemostasis
116190|NCT02352142|Separation stress
116191|NCT02352142|Family Nurture
116192|NCT02352142|Maternal Confidence
116193|NCT02352142|Maternal Competence
116194|NCT02352142|Calming Cycle
116195|NCT02352142|Kangaroo Care
116196|NCT02352142|Infant Neurodevelopment
116197|NCT02352142|Infant Psychological Development
116198|NCT02352142|Post-partum depression
116199|NCT02352142|Mother-infant Co-regulation
116200|NCT02352116|Postoperative Experience
116201|NCT02352116|Postoperative Behavioral Changes
116202|NCT02352116|Maladaptive Behavioral Changes
116203|NCT02352103|prostate cancer
116204|NCT02352103|Urinary continence
116205|NCT02352103|robotic assisted radical prostatectomy
116206|NCT02352103|Vattikuti Urology Institute (VIP) radical prostatectomy
116207|NCT02352103|Retzius sparing radical prostatectomy
116208|NCT02352090|Contraception, oral
116209|NCT02352090|Ethinyl Estradiol
116210|NCT02352090|Estradiol Valerate
116211|NCT02352090|Dienogest
116212|NCT02352090|Insulin resistance
116213|NCT02352090|Chronic inflammation
116214|NCT02352090|Coagulation
116215|NCT02352051|attention deficit-hyperactivity disorder (ADHD).
116216|NCT02352051|executive functions
116217|NCT02352038|malocclusion
116218|NCT02352038|low-level laser therapy
116219|NCT02352025|S-equol
116220|NCT02352025|breast cancer
116221|NCT02352025|triple negative
116222|NCT02352012|Interventional Treatment
116223|NCT02352012|Refractory Pneumothorax
116224|NCT02352012|Bronchoscope
116225|NCT02351999|Atrial fibrillation
116226|NCT02351999|Transseptal puncture
116227|NCT02351999|Atrial fibrillation ablation
116228|NCT02351986|subacromial impingement
116229|NCT02351986|physical therapy
116230|NCT02351986|cryotherapy
116231|NCT02351960|Drug therapy
116232|NCT02351960|GERD
116233|NCT02351960|Dexlansoprazole
116234|NCT02351947|stroke
116235|NCT02351947|Cerebrovascular accident
116236|NCT02351947|rehabilitation
116237|NCT02351947|motor learning
116238|NCT02351947|fMRI
116239|NCT02351947|plasticity
116240|NCT02351934|colorectal surgery
116241|NCT02351934|volume status
116242|NCT02351921|transcranial magnetic stimulation
116243|NCT02351921|spinal cord injury
116244|NCT02351921|motor cortex
116245|NCT02351921|somatosensory cortex
116246|NCT02351895|infection control
116247|NCT02351895|Prevention of hospital acquired infection
116248|NCT02351856|laminopathy
116249|NCT02351804|US-guided peripheral nerve block
116250|NCT02351804|Anesthetics, Local
116251|NCT02351804|duration
116252|NCT02351804|Sensation
116253|NCT02351804|adductor canal block
116254|NCT02351804|lower limb
116255|NCT02351804|Adjuvants, Anesthesia
116256|NCT02351778|Developing Countries
116257|NCT02351778|Quality of Life
116258|NCT02351778|Mixed Methods
116259|NCT02351778|Validation
116260|NCT02351778|Caregiver Burden
116261|NCT02351726|aortic valve replacement
116262|NCT02351726|aortic stenosis
116263|NCT02351726|aortic steno-insufficiency
116264|NCT02351713|primary prevention
116265|NCT02351687|Moderate Acute Malnutrition
116266|NCT02351674|Heart Rate
116267|NCT02351674|Percutaneous coronary intervention
116268|NCT02351674|outcome
116269|NCT02351648|readmission
116270|NCT02351648|care transition
116271|NCT02351635|Calprotectin
116272|NCT02351635|Diagnosis
116273|NCT02351609|smoking cessation
116274|NCT02351609|patient navigation
116275|NCT02351609|financial incentives
116276|NCT02351609|health disparities
116277|NCT02351596|Core Stability
116278|NCT02351596|Balance
116279|NCT02351596|Core Control
116280|NCT02351505|Small Cell Lung Cancer
116281|NCT02351492|Bile duct obstruction
116282|NCT02351492|intraoperative cholangiography
116283|NCT02351492|MRCP
116284|NCT02351479|hula
116285|NCT02351479|breast cancer
116286|NCT02351479|female
116287|NCT02351479|hawaii
116288|NCT02351479|physical activity
116289|NCT02351479|cervical cancer
116290|NCT02351479|ovarian cancer
116291|NCT02351479|endometrial cancer
116292|NCT02351466|Brain Growth and Development
116293|NCT02351466|Cognition
116294|NCT02351466|Children
116295|NCT02351466|Continuous Glucose Monitoring
116296|NCT02351466|MRI
116297|NCT02351466|Functional MRI
116298|NCT02351440|duloxetine
116299|NCT02351414|Osteoarthritis
116300|NCT02351414|Ankylosis
116301|NCT02351414|Revision procedures
116302|NCT02351414|Correction of functional deformity
116303|NCT02351414|Rheumatoid arthritis
116304|NCT02351414|Arthritis
116305|NCT02351388|Alzheimer's disease
116306|NCT02351388|Depressive symptoms
116307|NCT02351388|Neuropsychiatric symptoms
116308|NCT02351388|Behavioral and Psychological Symptoms of Dementia
116309|NCT02351388|Neuromodulation
116310|NCT02351388|Transcranial Direct Current Stimulation
116311|NCT02351375|microbiota
116312|NCT02351375|small intestine
116313|NCT02351375|diet
116314|NCT02351375|feces
116315|NCT02351362|Retention
116316|NCT02351362|Attrition
116317|NCT02351362|Incentive
116318|NCT02351362|Pregnant women
116319|NCT02351349|frailty
116320|NCT02351349|CKD
116321|NCT02351349|Physical Therapy Modalities
116322|NCT02351349|Elder Nutritional Physiological Phenomena
116323|NCT02351336|Threatened preterm birth
116324|NCT02351336|Fetal adrenal gland volume
116325|NCT02351336|Fetal zone enlargement
116326|NCT02351336|Prediction of preterm birth
116327|NCT02351297|High protein diet
116328|NCT02351297|Microbiota
116329|NCT02351297|Rectal biopsies
116330|NCT02351297|Metabolomics
116331|NCT02351297|Bacterial metabolites
116332|NCT02351297|volunteers
116333|NCT02351284|HIV, vitamin D, osteoporosis
116334|NCT02351258|Pediatrics
116335|NCT02351258|Medical Oncology
116336|NCT02351258|Catheters
116337|NCT02351258|Infection
116338|NCT02351206|X-Rays
116339|NCT02351206|Magnetic Resonance Imaging
116340|NCT02351206|Sensitivity and Specificity
116341|NCT02351180|Chronic lung allograft dysfunction
116342|NCT02351180|Community-acquired respiratory viral infection
116343|NCT02351167|smoking cessation
116344|NCT02351167|counseling
116345|NCT02351167|Genetics and Genomics
116346|NCT02351141|Noble Gas MRI
116347|NCT02351141|Pulmonary Function
116348|NCT02351141|Quality of Life Questionnaires
116349|NCT02351128|lanreotide
116350|NCT02351102|Congenital CMV
116351|NCT02351102|Congenital Cytomegalovirus
116352|NCT02351063|Heart failure
116353|NCT02351063|BNP
116354|NCT02351063|home testing
116355|NCT02351063|remote monitoring
116356|NCT02351050|sonolysis, brain infarction, coronary angioplasty
116357|NCT02351037|Acute Myeloid Leukemia
116358|NCT02351037|AML
116359|NCT02351037|Ibrutinib
116360|NCT02351037|Cytarabine
116361|NCT02351037|LD-AraC
116362|NCT02351037|Azacitidine
116363|NCT02350985|Migraine
116364|NCT02350985|Migrainous Vertigo
116365|NCT02350985|Headache Disorders
116366|NCT02350985|Central Nervous System Origin Vertigo
116367|NCT02350985|Paroxysmal Vertigo
116368|NCT02350985|Adrenergic beta-Antagonist
116369|NCT02350985|Vasodilator Agent
116370|NCT02350985|Anti Arrhythmia Agent
116371|NCT02350985|Serotonin Uptake Inhibitor
116372|NCT02350985|Antidepressive Agent
116373|NCT02350985|Propranolol
116374|NCT02350985|Venlafaxine
116375|NCT02350959|Plaque
116376|NCT02350959|coronary computed tomography angiography
116377|NCT02350933|tracheal damages
116378|NCT02350920|IBD
116379|NCT02350920|Crohn's disease
116380|NCT02350920|ulcerative colitis
116381|NCT02350920|ACT
116382|NCT02350907|antimicrobial resistance
116383|NCT02350907|point-of-care testing
116384|NCT02350907|Neisseria gonorrhoeae
116385|NCT02350868|without Standard Treatment
116386|NCT02350855|Nutrition intervention
116387|NCT02350855|Palliative care
116388|NCT02350855|Public Health
116389|NCT02350855|Quality of life
116390|NCT02350855|Tailored food formula
116391|NCT02350855|Body weight
116392|NCT02350842|non-Left Bundle Branch Block morphology
116393|NCT02350842|Triple-site biventricular pacing
116394|NCT02350842|cardiac resynchronization therapy
116395|NCT02350803|distraction osteogenesis
116396|NCT02350803|mini plate
116397|NCT02350803|Lefort 1 osteotomy
116398|NCT02350790|Robotics
116399|NCT02350790|Laparoscopy
116400|NCT02350790|Endometriosis
116401|NCT02350790|Argon
116402|NCT02350790|Gynecology
116403|NCT02350777|T-cell Depleted Hematopoietic Stem Cell
116404|NCT02350777|Allogeneic Hematopoietic Stem Cell Transplantation
116405|NCT02350777|CliniMACS Cell Selection System
116406|NCT02350777|14-228
116407|NCT02350777|HSCT
116408|NCT02350764|Nivolumab
116409|NCT02350764|Lung
116410|NCT02350764|ipilimumab
116411|NCT02350764|NSCLC
116412|NCT02350764|14-137
116413|NCT02350751|Influenza, Flu, Flu A, Influenza A
116414|NCT02350738|Mild cognitive impairment
116415|NCT02350738|Dementia
116416|NCT02350738|Cognitive training
116417|NCT02350738|Cognitive rehabilitation
116418|NCT02350738|Cognitive therapy
116419|NCT02350725|Chronic Fluid Overload
116420|NCT02350647|Rotator cuff
116421|NCT02350647|Ossification
116422|NCT02350647|Suture anchors
116423|NCT02350621|cervical foraminal stenosis minimal invasive foraminotomy
116424|NCT02350582|breast cancer
116425|NCT02350582|telerehabilitation
116426|NCT02350582|strength
116427|NCT02350582|fatigue
116428|NCT02350582|quality of life
116429|NCT02350569|liver transplant
116430|NCT02350569|hepatitis C
116431|NCT02350569|Gilead
116432|NCT02350569|Communicable Diseases
116433|NCT02350569|Infection
116434|NCT02350569|Virus Diseases
116435|NCT02350569|Digestive System Diseases
116436|NCT02350569|Hepatitis
116437|NCT02350569|Hepatitis, Viral, Human
116438|NCT02350569|Liver Diseases
116439|NCT02350569|RNA Virus Infections
116440|NCT02350543|Aspirin usage
116441|NCT02350543|Transurethral resection of bladder tumor (TURBT)
116442|NCT02350530|Colorectal cancer
116443|NCT02350530|Metastatic colorectal cancer
116444|NCT02350530|Liver metastases
116445|NCT02350530|Liver resection
116446|NCT02350530|Liver ablation
116447|NCT02350530|Conversion therapy
116448|NCT02350530|FOLFOXIRI
116449|NCT02350530|Oxaliplatin
116450|NCT02350530|Irinotecan
116451|NCT02350530|Fluorouracil
116452|NCT02350530|Bevacizumab
116453|NCT02350530|RAS mutation
116454|NCT02350491|Pregnancy
116455|NCT02350491|miRNA
116456|NCT02350491|Rheumatoid Arthritis (RA)
116457|NCT02350491|Systemic Lupus Erythematosus (SLE)
116458|NCT02350465|sarcopenia
116459|NCT02350465|aging
116460|NCT02350465|myosteatosis
116461|NCT02350465|exercise
116462|NCT02350465|screening
116463|NCT02350452|laparoscopic surgery
116464|NCT02350452|diode laser
116465|NCT02350452|AMH
116466|NCT02350452|AFC
116467|NCT02350439|Coronary artery disease
116468|NCT02350439|Fractional floe reserve
116469|NCT02350400|Drug eluting beads
116470|NCT02350400|Irinotecan
116471|NCT02350400|Pharmacogenetics
116472|NCT02350400|Pharmacokinetics
116473|NCT02350374|diabetes
116474|NCT02350374|children
116475|NCT02350361|endostar
116476|NCT02350361|angiogenesis
116477|NCT02350361|EGFR-TKI
116478|NCT02350361|lung caner
116479|NCT02350348|neonates
116480|NCT02350348|infants
116481|NCT02350348|anaesthesia
116482|NCT02350348|mortality
116483|NCT02350348|adverse effects
116484|NCT02350348|Epidemiological Study
116485|NCT02350348|European Society of Anaesthesiology
116486|NCT02350335|aneurysm
116487|NCT02350335|nicotine replacement therapy
116488|NCT02350335|cerebral vasospasm
116489|NCT02350335|outcome
116490|NCT02350322|Diet
116491|NCT02350322|concentration
116492|NCT02350322|seafood
116493|NCT02350322|youths
116494|NCT02350322|Norway
116495|NCT02350322|Nutrient status in blood
116496|NCT02350322|Inflammatory markers
116497|NCT02350309|Insomnia Disorder
116498|NCT02350309|E2006
116499|NCT02350309|Multiple Sleep Latency Test
116500|NCT02350296|headache
116501|NCT02350296|dental pain
116502|NCT02350296|neuralgia
116503|NCT02350296|dysmenorrhoea
116504|NCT02350296|muscular and osteoarticular pain
116505|NCT02350283|Acute Ischemic Stroke
116506|NCT02350283|Endovascular therapy
116507|NCT02350283|Solitaire
116508|NCT02350283|Standard Medical Management
116509|NCT02350270|cognitively healthy individuals
116510|NCT02350257|cognitive behavior therapy
116511|NCT02350257|child
116512|NCT02350257|randomized controlled trial
116513|NCT02350257|internet
116514|NCT02350244|musculoskeletal diseases
116515|NCT02350244|eyestrain
116516|NCT02350244|occupational diseases
116517|NCT02350244|computer work
116518|NCT02350244|muscle stretching exercise
116519|NCT02350244|computer software application
116520|NCT02350244|MSDs
116521|NCT02350231|preterm birth
116522|NCT02350231|Twin pregnancy
116523|NCT02350231|progesterone
116524|NCT02350218|Transplantation
116525|NCT02350218|Living donor
116526|NCT02350218|Eglandin
116527|NCT02350218|Alprostadil
116528|NCT02350205|Burn wounds
116529|NCT02350205|Burns
116530|NCT02350205|Skin substitute
116531|NCT02350192|ehealth
116532|NCT02350192|intervention
116533|NCT02350192|effectiveness
116534|NCT02350192|randomized controlled trial
116535|NCT02350166|colorectal cancer
116536|NCT02350166|hepatectomy
116537|NCT02350166|laparoscopic surgery
116538|NCT02350166|laparotomy
116539|NCT02350166|complications
116540|NCT02350153|Mortality
116541|NCT02350153|Morbidity
116542|NCT02350153|Incidence
116543|NCT02350153|Prevalence
116544|NCT02350140|HIV
116545|NCT02350140|Prevention of mother-to-child HIV transmission
116546|NCT02350140|PMTCT
116547|NCT02350140|mobile health (mHealth)
116548|NCT02350140|mobile phone
116549|NCT02350140|text messaging
116550|NCT02350140|short message services (SMS)
116551|NCT02350127|dementia
116552|NCT02350127|clinical trial
116553|NCT02350127|behavioral intervention
116554|NCT02350127|exercise
116555|NCT02350127|complementary and alternative medicine
116556|NCT02350127|cognition
116557|NCT02350127|function
116558|NCT02350127|quality of life
116559|NCT02350114|Heart failure
116560|NCT02350114|6 Minute Walk Test
116561|NCT02350088|fast-track surgery
116562|NCT02350075|short implants
116563|NCT02350075|sinus floor elevation
116564|NCT02350075|randomized controlled trial
116565|NCT02350036|Preeclampsia
116566|NCT02350036|placental protein 13
116567|NCT02350036|Uterine artery doppler
116568|NCT02350023|alopecia areata
116569|NCT02350023|betamethasone
116570|NCT02350023|latanoprost
116571|NCT02350023|topical steroid
116572|NCT02350023|prostaglandin
116573|NCT02350010|Etiology
116574|NCT02350010|Prognostic risk factors
116575|NCT02350010|Intracerebral Hemorrhage
116576|NCT02350010|non-invasive imaging
116577|NCT02350010|CT angiography
116578|NCT02349997|central sleep apnea
116579|NCT02349997|Cheyne-Stokes respiration
116580|NCT02349997|obstructive sleep apnea
116581|NCT02349997|chronic heart failure
116582|NCT02349997|fluid shift
116583|NCT02349919|postinfectious cough, postviral cough
116584|NCT02349906|non-malignant diseases, allogeneic stem cell transplantation
116585|NCT02349854|pruritus
116586|NCT02349854|itch
116587|NCT02349854|skin
116588|NCT02349854|scalp
116589|NCT02349854|seborrheic dermatitis
116590|NCT02349828|antiviral
116591|NCT02349828|herpes simplex virus
116592|NCT02349828|herpes
116593|NCT02349828|burn patients
116594|NCT02349828|HSV
116595|NCT02349828|acyclovir
116596|NCT02349815|Drug Utilization Study
116597|NCT02349802|Auto-injector Device, device-related injection, Auto-injector
116598|NCT02349789|Gait
116599|NCT02349789|Cerebellum
116600|NCT02349789|Non invasive electrical stimulation
116601|NCT02349789|tDCS
116602|NCT02349789|TMS
116603|NCT02349789|Balance
116604|NCT02349763|Dexamethasone
116605|NCT02349763|Hypersensitivity reaction
116606|NCT02349763|Paclitaxel
116607|NCT02349750|Endometrial Scratch Injury
116608|NCT02349750|Unexplained infertility
116609|NCT02349750|intrauterine insemenation
116610|NCT02349750|ovulation induction
116611|NCT02349737|Bioelectrical Impedance Analysis
116612|NCT02349737|Body composition
116613|NCT02349737|ICD
116614|NCT02349724|CEA
116615|NCT02349724|CAR T
116616|NCT02349711|probiotic
116617|NCT02349711|allergy
116618|NCT02349711|immune
116619|NCT02349698|CAR T
116620|NCT02349698|Leukemia
116621|NCT02349698|Lymphoma
116622|NCT02349685|Helicobacter pylori
116623|NCT02349685|Personalized therapy
116624|NCT02349685|antimicrobial susceptibility
116625|NCT02349685|rescue therapy
116626|NCT02349685|culture
116627|NCT02349672|HIE
116628|NCT02349672|Neonates
116629|NCT02349633|EGFRm - Epidermal Growth Factor Receptor Mutation
116630|NCT02349633|Advanced EGFRm (del19 or L858R +/- T790M NSCLC
116631|NCT02349581|Anesthetics, Local
116632|NCT02349581|Mastectomy
116633|NCT02349581|Neuralgia
116634|NCT02349581|Nerve block
116635|NCT02349542|Liposomal Bupivacaine
116636|NCT02349542|Simultaneous Bilateral Total Knee Arthroplasty
116637|NCT02349542|Safety
116638|NCT02349529|Epilepsy
116639|NCT02349529|psychosocial
116640|NCT02349503|Adrenocortical function
116641|NCT02349503|Adrenal hyperplasia, Congenital
116642|NCT02349503|21-hydroxylase deficiency
116643|NCT02349503|Adrenogenital Syndrome
116644|NCT02349503|Adolescents
116645|NCT02349503|Female
116646|NCT02349503|Hyperplasia
116647|NCT02349503|Adrenal Gland Diseases
116648|NCT02349503|Congenital Abnormalities
116649|NCT02349503|Adrenocortical Hyperfunction
116650|NCT02349503|Disorders of Sex Development
116651|NCT02349503|Endocrine System Diseases
116652|NCT02349503|Genetic Diseases, Inborn
116653|NCT02349503|Gonadal Disorders
116654|NCT02349503|Metabolic Diseases
116655|NCT02349503|Metabolism, Inborn Errors
116656|NCT02349503|Pathologic Processes
116657|NCT02349503|Steroid Metabolism, Inborn Errors
116658|NCT02349503|Urogenital Abnormalities
116659|NCT02349503|Corticotropin Releasing Factor
116660|NCT02349490|gastrointestinal hemorrhage
116661|NCT02349490|endoscopy
116662|NCT02349490|hemostasis
116663|NCT02349451|Efficacy
116664|NCT02349451|Methotrexate
116665|NCT02349451|Safety
116666|NCT02349373|Overuse injury
116667|NCT02349373|Running related injury
116668|NCT02349373|Running pattern
116669|NCT02349360|safety
116670|NCT02349360|tolerability
116671|NCT02349321|physical or sexual intimate partner violence
116672|NCT02349321|adolescents
116673|NCT02349321|primary prevention
116674|NCT02349321|randomised controlled trial
116675|NCT02349321|school
116676|NCT02349321|South Africa
116677|NCT02349321|parenting
116678|NCT02349282|muscle strength
116679|NCT02349282|physical performance
116680|NCT02349282|vitamin D3
116681|NCT02349282|Cholecalciferol
116682|NCT02349282|Calcifediol
116683|NCT02349269|Atrial fibrillation
116684|NCT02349269|CABG
116685|NCT02349269|Stroke
116686|NCT02349256|MUS
116687|NCT02349256|British South Asians
116688|NCT02349256|Somatic Symptoms
116689|NCT02349256|Qualitative interviews
116690|NCT02349243|obese
116691|NCT02349243|weight loss
116692|NCT02349243|entacapone
116693|NCT02349217|Breast cancer
116694|NCT02349217|Breast cancer survivors
116695|NCT02349217|Breast cancer partners
116696|NCT02349217|Mindfulness-Based Relationship Enhancement
116697|NCT02349217|MBRE
116698|NCT02349217|Standard of care
116699|NCT02349217|Pain Assessment
116700|NCT02349217|Questionnaires
116701|NCT02349217|Surveys
116702|NCT02349217|Neurocognitive Tests
116703|NCT02349217|Cortisol Tests
116704|NCT02349217|Saliva tests
116705|NCT02349217|Interviews
116706|NCT02349217|Meditation
116707|NCT02349217|Yoga
116708|NCT02349217|Self-help materials
116709|NCT02349204|Simulator
116710|NCT02349204|Music
116711|NCT02349204|Mozart Effect
116712|NCT02349191|Alzheimers
116713|NCT02349191|dementia
116714|NCT02349191|omental transposition
116715|NCT02349191|neurological
116716|NCT02349152|Cardiopulmonary bypass
116717|NCT02349152|Heart surgery
116718|NCT02349126|Hepatitis B
116719|NCT02349126|HBV infection
116720|NCT02349126|Hepatitis B Surface Antigen
116721|NCT02349113|estrogen, aging
116722|NCT02349087|EEG
116723|NCT02349087|cardiac arrest
116724|NCT02349087|resuscitation
116725|NCT02349087|seizures
116726|NCT02349061|Systemic Lupus Erythematosus
116727|NCT02349061|Ustekinumab
116728|NCT02349048|Hepatitis C virus
116729|NCT02349048|Hepatitis C virus genotype 1
116730|NCT02349048|Chronic Hepatitis C Virus Genotype 1 Infection
116731|NCT02349048|Liver fibrosis
116732|NCT02349048|Cirrhosis
116733|NCT02349048|Simeprevir
116734|NCT02349048|Daclatasvir
116735|NCT02349048|Sofosbuvir
116736|NCT02349035|Transradial amputee
116737|NCT02349022|[89Zr]Df-IAB2M
116738|NCT02349022|Prostate cancer
116739|NCT02349022|PET scan
116740|NCT02349009|systemic sclerosis
116741|NCT02349009|scleroderma
116742|NCT02348970|mandibular advancement devices ONIRIS®
116743|NCT02348970|obstructive sleep apnea and hypopneas
116744|NCT02348957|Chronic myeloid leukemia
116745|NCT02348957|Dasatinib
116746|NCT02348957|Any line
116747|NCT02348957|Chronic phase
116748|NCT02348944|Biological markers
116749|NCT02348944|Cartilage
116750|NCT02348840|Midwives
116751|NCT02348840|Pregnant Women
116752|NCT02348827|Unipolar depression
116753|NCT02348827|Family Therapies
116754|NCT02348827|Psychoeducation
116755|NCT02348827|Family psychoeducation
116756|NCT02348814|NAFLD, NASH
116757|NCT02348788|Vivax
116758|NCT02348788|Malaria
116759|NCT02348788|artemether-lumefantrine
116760|NCT02348788|chloroquine
116761|NCT02348788|RCT
116762|NCT02348749|18F-MFBG Imaging
116763|NCT02348749|14-138
116764|NCT02348736|airway
116765|NCT02348736|videolaryngoscope
116766|NCT02348697|Cartilage Defect in the Knee
116767|NCT02348697|MACT
116768|NCT02348684|Breast Cancer
116769|NCT02348658|Pharmacological therapy
116770|NCT02348645|Pilot projects
116771|NCT02348645|Feasibility studies
116772|NCT02348645|Intervention studies
116773|NCT02348645|Orthopedics
116774|NCT02348645|Orthopedic Procedures
116775|NCT02348645|Neurosurgical Procedures
116776|NCT02348645|Neurosurgery
116777|NCT02348645|Spine
116778|NCT02348645|Spinal Fusion
116779|NCT02348645|Spondylodesis
116780|NCT02348645|Spondylosyndesis
116781|NCT02348645|Laminectomy
116782|NCT02348645|Foraminotomy
116783|NCT02348645|Decompression, surgical
116784|NCT02348645|Low Back Pain
116785|NCT02348645|Quality of Life
116786|NCT02348580|teaching
116787|NCT02348580|education
116788|NCT02348580|active learning
116789|NCT02348580|time on task
116790|NCT02348580|financial education
116791|NCT02348580|social education
116792|NCT02348580|rights based education
116793|NCT02348580|primary school
116794|NCT02348580|life-skills
116795|NCT02348567|Health care, accreditation, unannounced survey, cluster randomized controlled trial, quality improvement, organisational development
116796|NCT02348554|obesity
116797|NCT02348554|energy expenditure
116798|NCT02348554|daily living physical activity
116799|NCT02348554|smartphone
116800|NCT02348554|accelerometry
116801|NCT02348554|prediction algorithm
116802|NCT02348528|Multiple Myeloma
116803|NCT02348528|Relapsed
116804|NCT02348528|Refractory
116805|NCT02348528|Lenalidomide
116806|NCT02348528|Dexamethasone
116807|NCT02348528|open-label
116808|NCT02348528|CC-5013-MM-021
116809|NCT02348502|HBsAg loss
116810|NCT02348502|interferon
116811|NCT02348502|HBV reaction
116812|NCT02348502|Hepatitis B
116813|NCT02348489|AML
116814|NCT02348489|Acute Myeloid Leukemia
116815|NCT02348489|SGI-110
116816|NCT02348489|DNA Hypomethylating Agen
116817|NCT02348437|Pronator quadratus
116818|NCT02348437|Distal radius fracture
116819|NCT02348437|Repair
116820|NCT02348437|Volar plating
116821|NCT02348437|PRWE
116822|NCT02348424|genitourinary
116823|NCT02348424|Neisseriaceae
116824|NCT02348424|pharyngeal
116825|NCT02348424|Solithromycin
116826|NCT02348411|Medication-refractory
116827|NCT02348398|Cervical Cancer
116828|NCT02348398|Recurrent cervical cancer
116829|NCT02348398|Squamous cervical cancer
116830|NCT02348398|Adenocarcinoma of the cervix
116831|NCT02348398|Adenosquamous cervical cancer
116832|NCT02348398|Persistent cervical cancer
116833|NCT02348398|Pazopanib
116834|NCT02348398|GW786034
116835|NCT02348398|Topotecan
116836|NCT02348398|Hycamtin
116837|NCT02348385|amphetamine
116838|NCT02348385|cigarette smokers
116839|NCT02348359|Vascular Endothelial Growth Factor (VEGF)
116840|NCT02348359|Platelet Derived Growth Factor (PDGF)
116841|NCT02348359|AMD
116842|NCT02348346|self-disinfecting surfaces
116843|NCT02348346|titanium dioxide
116844|NCT02348281|triple negative breast cancer
116845|NCT02348281|androgen receptor
116846|NCT02348281|bicalutamide
116847|NCT02348268|Neck Pain
116848|NCT02348268|Myofascial release
116849|NCT02348268|Manual therapy
116850|NCT02348242|Intensive care
116851|NCT02348242|corneal damage
116852|NCT02348242|prevention
116853|NCT02348242|nursing protocol
116854|NCT02348229|Enhanced recovery after surgery
116855|NCT02348229|laparoscopic gastrectomy
116856|NCT02348229|advanced gastric cancer
116857|NCT02348229|C-reactive,visceral proteins
116858|NCT02348177|Human immunideficiency virus
116859|NCT02348177|Tuberculosis
116860|NCT02348177|superboosting
116861|NCT02348177|lopinavir/ritonavir 1:1
116862|NCT02348177|Pediatric TB/HIV co-infection
116863|NCT02348164|Carotenoids
116864|NCT02348164|absorption
116865|NCT02348164|citrus
116866|NCT02348151|COPD
116867|NCT02348151|SWTi
116868|NCT02348151|Treadmill
116869|NCT02348138|Isometric Handgrip
116870|NCT02348112|stress urinary incontinence
116871|NCT02348112|Altis 522
116872|NCT02348112|urinary incontinence
116873|NCT02348099|Diabetes
116874|NCT02348099|Lipohypertrophy
116875|NCT02348099|Ultrasound
116876|NCT02348073|Epilepsy
116877|NCT02348073|Attention Deficit Disorders
116878|NCT02348073|VAYARIN
116879|NCT02348073|Children
116880|NCT02348073|Polyunsaturated n-3 fatty acid supplementation
116881|NCT02348034|Surgical Site Infection (SSI)
116882|NCT02348034|Negative Pressure Wound Therapy (NPWT)
116883|NCT02348008|MK-3475
116884|NCT02348008|Pembrolizumab
116885|NCT02348008|Bevacizumab
116886|NCT02347995|Exercise
116887|NCT02347995|Protein
116888|NCT02347995|Nutrition
116889|NCT02347995|Stroke
116890|NCT02347982|Turkey
116891|NCT02347982|Epidemiologic
116892|NCT02347969|antioxidant
116893|NCT02347969|skin radiance
116894|NCT02347969|skin elasticity
116895|NCT02347969|skin firmness
116896|NCT02347969|skin hydration
116897|NCT02347956|robot surgery
116898|NCT02347956|reduced port
116899|NCT02347956|single-site
116900|NCT02347956|safety
116901|NCT02347956|feasibility
116902|NCT02347930|acute kidney injury
116903|NCT02347930|ultrasound technology
116904|NCT02347904|Esophageal cancer
116905|NCT02347904|Adjuvant treatment
116906|NCT02347904|S-1
116907|NCT02347904|Oxaliplatin
116908|NCT02347904|Feasibility
116909|NCT02347891|Inflammatory Myositis
116910|NCT02347891|Dermatomyositis
116911|NCT02347891|Polymyositis
116912|NCT02347891|Muscle Pain
116913|NCT02347891|Myositis
116914|NCT02347891|Refractory myositis
116915|NCT02347878|leukemia
116916|NCT02347878|lymphoma
116917|NCT02347878|lumbar puncture
116918|NCT02347878|intrathecal treatment
116919|NCT02347878|post-lumbar puncture headache
116920|NCT02347865|osteoporosis post menopausal women
116921|NCT02347826|coned wires, wire lift,
116922|NCT02347826|patient
116923|NCT02347826|discomfort
116924|NCT02347813|squamous cell carcinoma
116925|NCT02347813|pioglitazone
116926|NCT02347813|PPARgamma
116927|NCT02347813|skin cancer
116928|NCT02347774|Chronic Obstructive Pulmonary Disease
116929|NCT02347774|COPD
116930|NCT02347761|Chronic Obstructive Pulmonary Disease
116931|NCT02347748|Pain
116932|NCT02347748|Anesthesia Recovery Period
116933|NCT02347748|Postoperative Period
116934|NCT02347748|Adaptation, Psychological
116935|NCT02347748|Relaxation
116936|NCT02347748|Stress, Psychological
116937|NCT02347735|Colorectal carcinoma
116938|NCT02347735|Anastomotic leakage
116939|NCT02347735|Markers
116940|NCT02347735|Diagnosis
116941|NCT02347722|biomarkers
116942|NCT02347722|diagnosis
116943|NCT02347722|etiology of heart failure
116944|NCT02347709|Diabetic Foot Ulcer
116945|NCT02347709|DFU
116946|NCT02347709|Type 2 Diabetes
116947|NCT02347709|Neuropathy
116948|NCT02347696|Diet
116949|NCT02347696|Physical Activity
116950|NCT02347696|Trial
116951|NCT02347696|Lipidomics
116952|NCT02347696|Occidental Diseases
116953|NCT02347657|Homozygous for the F508del CFTR Mutation
116954|NCT02347566|COPD
116955|NCT02347566|Physical Activity
116956|NCT02347566|Accelerometer
116957|NCT02347540|Heart Failure
116958|NCT02347540|Diastolic Dysfunction
116959|NCT02347540|Pre-Eclampsia
116960|NCT02347540|Endothelial dysfunction
116961|NCT02347540|Biological Markers
116962|NCT02347540|MicroRNAs
116963|NCT02347540|Circulating cells
116964|NCT02347488|ETT Holder, bite guard, airway, endotracheal tube
116965|NCT02347462|BiPAP
116966|NCT02347449|Early-stage Breast cancer, node positive
116967|NCT02347449|Prognosis
116968|NCT02347449|Oncotype Dx
116969|NCT02347436|Transurethral Resection of Prostate
116970|NCT02347423|Poliomyelitis immunization
116971|NCT02347423|primary series
116972|NCT02347371|Heart transplant
116973|NCT02347371|Cardiac allograft vasculopathy
116974|NCT02347371|Chronic rejection
116975|NCT02347371|Immunosuppressant therapy
116976|NCT02347345|HCV, injection drug use
116977|NCT02347280|clostridium difficile
116978|NCT02347280|colitis
116979|NCT02347280|colon
116980|NCT02347267|Beverages sweetened caloric, no caloric
116981|NCT02347267|Weight
116982|NCT02347267|Fat percentage
116983|NCT02347267|Body Composition
116984|NCT02347267|Blood pressure
116985|NCT02347267|Sugar
116986|NCT02347267|Sodium
116987|NCT02347267|Dietary intake
116988|NCT02347228|OB318
116989|NCT02347228|Advanced Solid Malignancies
116990|NCT02347228|Antrodia cinnamomea
116991|NCT02347228|Antrodia camphorata
116992|NCT02347202|Counseling
116993|NCT02347163|triple neg
116994|NCT02347163|breast cancer
116995|NCT02347163|zoledronate
116996|NCT02347163|mevalonate pathway
116997|NCT02347124|smoking cessation
116998|NCT02347124|oral health care
116999|NCT02347124|tobacco quitlines
117000|NCT02347098|plaque
117001|NCT02347098|LDL
117002|NCT02347098|statin
117003|NCT02347098|endothelial
117004|NCT02347098|apheresis
117005|NCT02347098|acute coronary artery syndrome
117006|NCT02347033|Sertraline
117007|NCT02347033|Selective Serotonin Reuptake Inhibitor (SSRI)
117008|NCT02347033|Cognitive Behavioural Therapy (CBT)
117009|NCT02347033|Increasing Access to Psychological Therapies (IAPT)
117010|NCT02347020|Obesity
117011|NCT02347020|Metabolic Disorders
117012|NCT02347007|Obesity
117013|NCT02347007|Overweight
117014|NCT02347007|Body Weight
117015|NCT02347007|Cardiovascular Diseases
117016|NCT02347007|Cholesterol
117017|NCT02347007|Almonds
117018|NCT02347007|Visceral Adiposity
117019|NCT02347007|Quality of Life
117020|NCT02347007|Hispanic Americans
117021|NCT02347007|African Continental Ancestry Group
117022|NCT02347007|Metabolic Syndrome X
117023|NCT02346994|Body Weight
117024|NCT02346994|Obesity in Adolescence
117025|NCT02346994|Obesity in Childhood
117026|NCT02346994|Childhood Onset Obesity
117027|NCT02346994|Childhood Obesity
117028|NCT02346994|Child Obesity
117029|NCT02346994|Adolescent Obesity
117030|NCT02346994|Teenagers
117031|NCT02346994|Teens
117032|NCT02346994|Youth
117033|NCT02346994|Adolescents
117034|NCT02346994|Adolescence
117035|NCT02346968|Kidney Transplantation
117036|NCT02346968|Delayed Graft Function
117037|NCT02346968|C-terminal fragment of agrin
117038|NCT02346968|Dialysis
117039|NCT02346955|Cancer
117040|NCT02346955|Oncology
117041|NCT02346955|cCAM Biotherapeutics Ltd
117042|NCT02346955|Immunomodulatory therapy
117043|NCT02346955|CM-24
117044|NCT02346955|Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1)
117045|NCT02346955|NSCLC (adenocarcinoma)
117046|NCT02346955|Uveal
117047|NCT02346955|Acral
117048|NCT02346955|Mucosal
117049|NCT02346955|Cutaneous
117050|NCT02346955|Colorectal
117051|NCT02346955|Gastric
117052|NCT02346955|Ovarian
117053|NCT02346955|Bladder
117054|NCT02346955|MK-6018-001
117055|NCT02346929|Hematoma block
117056|NCT02346929|distal radius fracture reduction
117057|NCT02346929|ultrasound
117058|NCT02346929|ultrasound guided hematoma block
117059|NCT02346929|traditional hematoma block for analgesia
117060|NCT02346929|bupivacaine
117061|NCT02346929|pain reduction
117062|NCT02346929|wrist fracture
117063|NCT02346890|Volunteer
117064|NCT02346877|Enbrel
117065|NCT02346877|Rheumatoid Arthritis
117066|NCT02346864|head elevated position
117067|NCT02346864|preterm
117068|NCT02346864|three-stair-position
117069|NCT02346838|Prediabetes, prebiotics, metabolic endotoxemia
117070|NCT02346825|P-CIMT
117071|NCT02346825|Pediatric Constraint Induced Movement Therapy
117072|NCT02346825|Hemiparesis
117073|NCT02346825|Cerebral Palsy
117074|NCT02346825|Infants
117075|NCT02346825|Toddlers
117076|NCT02346825|Children
117077|NCT02346786|Drinking Water
117078|NCT02346786|Mineral water
117079|NCT02346786|Sports
117080|NCT02346786|Accident prevention
117081|NCT02346747|Stage III
117082|NCT02346747|Stage IV
117083|NCT02346747|Ovarian Cancer
117084|NCT02346747|Maintenance
117085|NCT02346747|Immunotherapy
117086|NCT02346747|primary peritoneal cancer
117087|NCT02346747|fallopian tube cancer
117088|NCT02346747|endometrioid ovarian cancer
117089|NCT02346747|high-grade serous ovarian cancer
117090|NCT02346734|Multiple Sclerosis
117091|NCT02346734|Telerehablitation
117092|NCT02346721|Sofosbuvir
117093|NCT02346721|SOF/GS-5816
117094|NCT02346721|GS-5816
117095|NCT02346721|Hepatitis C
117096|NCT02346721|HCV
117097|NCT02346721|Cirrhosis
117098|NCT02346708|Parkinson's
117099|NCT02346708|TMS
117100|NCT02346708|Kluger
117101|NCT02346695|LV deformation
117102|NCT02346695|Endothelial glycocalyx
117103|NCT02346695|Coronary flow reserve
117104|NCT02346682|major depression disorder
117105|NCT02346682|biochemistry
117106|NCT02346682|TCM diagnosis
117107|NCT02346682|Neurological
117108|NCT02346682|metabonomics
117109|NCT02346682|neuroimaging
117110|NCT02346669|Microbiota
117111|NCT02346669|Diabetes Mellitus, Type 2
117112|NCT02346669|Obesity
117113|NCT02346617|CMV
117114|NCT02346617|T cell therapy
117115|NCT02346604|exercise
117116|NCT02346591|Positive psychology
117117|NCT02346591|Wellbeing
117118|NCT02346591|Stress reduction
117119|NCT02346591|Relaxation
117120|NCT02346591|Gratitude
117121|NCT02346591|Mobile app
117122|NCT02346591|Intervention
117123|NCT02346591|Altruism
117124|NCT02346591|Psychological well-being
117125|NCT02346591|Social well-being
117126|NCT02346591|Physical well-being
117127|NCT02346591|Workplace engagement
117128|NCT02346552|laparoscopic Cholecystectomy
117129|NCT02346552|laparoscope holder
117130|NCT02346552|Nissen fundoplication
117131|NCT02346552|paraesophageal hernia
117132|NCT02346552|sleeve surgery
117133|NCT02346539|Nicotine
117134|NCT02346539|Depression
117135|NCT02346526|Prostate Cancer
117136|NCT02346526|Castration-resistant prostate cancer
117137|NCT02346526|Castration-resistant prostate cancer metastatic to bone
117138|NCT02346513|Hip Replacement Arthroplasty
117139|NCT02346513|Ceramic on Metal Articulation
117140|NCT02346513|Serum level of Cobalt and Chromium
117141|NCT02346500|Benign Prostatic Hyperplasia
117142|NCT02346500|Lower urinary tract symptoms
117143|NCT02346500|Photoselective laser vaporization of the prostate
117144|NCT02346500|Transrectal Ultrasound
117145|NCT02346487|children
117146|NCT02346474|Subcutaneous Fat
117147|NCT02346474|Visceral Fat
117148|NCT02346461|Hereditary Inclusion Body Myopathy (HIBM)
117149|NCT02346461|Sialic Acid
117150|NCT02346461|GNE Myopathy
117151|NCT02346461|N-Acetyl-D-mannosamine (ManNAc)
117152|NCT02346461|GNE Gene
117153|NCT02346448|endoscopic sphincterotomy
117154|NCT02346448|balloon dilation
117155|NCT02346448|adverse events
117156|NCT02346448|pancreatitis
117157|NCT02346448|bleeding
117158|NCT02346435|small renal mass
117159|NCT02346435|active surveillance
117160|NCT02346422|Heart Failure
117161|NCT02346422|Cardiomyopathies
117162|NCT02346422|Heart Diseases
117163|NCT02346422|Cardiovascular Diseases
117164|NCT02346422|Cardiomegaly
117165|NCT02346422|Gene Therapy
117166|NCT02346396|neuropathic pain
117167|NCT02346396|neurostimulation
117168|NCT02346396|ambulatory use
117169|NCT02346396|tDCS
117170|NCT02346383|back pain
117171|NCT02346383|neuromodulation
117172|NCT02346383|spinal peripheral neuromodulation
117173|NCT02346383|spinal cord stimulation
117174|NCT02346383|postlaminectomy pain syndrome
117175|NCT02346370|Recurrent, previously treated, locally advanced or metastatic NSCLC (non small cell lung cancer)
117176|NCT02346357|hip arthroscopy
117177|NCT02346357|analgesia
117178|NCT02346344|type 2 diabetes
117179|NCT02346344|beta cell function
117180|NCT02346344|meal tolerance test
117181|NCT02346344|maximum stimulation test
117182|NCT02346344|method standardization
117183|NCT02346344|insulin secretion
117184|NCT02346344|prediabetes
117185|NCT02346344|insulin sensitivity
117186|NCT02346318|Radiotherapy
117187|NCT02346318|Adverse Effect
117188|NCT02346318|Dermatitis or Eczema
117189|NCT02346292|COPD
117190|NCT02346292|Spirometry
117191|NCT02346292|severe and very severe COPD
117192|NCT02346292|COPD exacerbations
117193|NCT02346292|therapy schemes
117194|NCT02346292|therapy changes
117195|NCT02346279|Multiple Sclerosis
117196|NCT02346279|Rehabilitation
117197|NCT02346279|Questionnaire
117198|NCT02346279|Patient-Reported Outcome
117199|NCT02346279|Responsiveness
117200|NCT02346279|Minimal Important Clinical Difference
117201|NCT02346266|Stroke
117202|NCT02346266|Stroke Prevention
117203|NCT02346266|Children
117204|NCT02346266|Education
117205|NCT02346240|Certolizumab Pegol
117206|NCT02346240|Cimzia
117207|NCT02346240|Psoriasis
117208|NCT02346227|Human Papillomavirus
117209|NCT02346227|Uterine cervix
117210|NCT02346227|Infection
117211|NCT02346227|Antiviral Drug
117212|NCT02346227|Therapeutic use
117213|NCT02346214|Gestational Age
117214|NCT02346214|Anterior Lens Capsule Vascularity
117215|NCT02346214|Preterm
117216|NCT02346214|Method-comparison
117217|NCT02346188|blood lead, iron, zinc, child, cognition, behavior, Mexico
117218|NCT02346175|SHR3824 Type 2 diabetes mellitus SGLT2
117219|NCT02346162|Pre-pregnancy
117220|NCT02346162|Weight management
117221|NCT02346136|Tai Chi
117222|NCT02346136|Cluster randomized controlled trial
117223|NCT02346136|Intervention
117224|NCT02346136|Elderly
117225|NCT02346136|Mobility
117226|NCT02346136|Health care utilization
117227|NCT02346123|Chagas disease
117228|NCT02346123|Polymorphisms
117229|NCT02346123|Biomarkers
117230|NCT02346097|Cardiac Resynchronization Therapy
117231|NCT02346097|Heart Failure
117232|NCT02346097|Ejection Fraction
117233|NCT02346097|Narrow
117234|NCT02346097|Pacemaker
117235|NCT02346097|Electrophysiology
117236|NCT02346097|Electrical activation mapping
117237|NCT02346097|Coronary Sinus
117238|NCT02346097|Mapping
117239|NCT02346097|QRS
117240|NCT02346097|QRS width
117241|NCT02346097|Pacing Interval
117242|NCT02346097|Left Ventricular Lead
117243|NCT02346097|Cardiac CT
117244|NCT02346097|Echocardiography
117245|NCT02346097|Myocardial Scintigraphy
117246|NCT02346097|6 Minutes Walk Test
117247|NCT02346097|Imaging
117248|NCT02346097|Left ventricular ejection fraction
117249|NCT02346097|Epicardial veins
117250|NCT02346097|Resynchronization
117251|NCT02346097|ImagingCRT
117252|NCT02346097|Optimal electrical resynchronization
117253|NCT02346097|Cardiac computed tomography
117254|NCT02346071|Bodily distress syndrome
117255|NCT02346071|Medically unexplained symptoms
117256|NCT02346071|Functional somatic symptoms
117257|NCT02346071|Functional somatic syndromes
117258|NCT02346071|Treatment
117259|NCT02346071|Acceptance and Commitment Therapy
117260|NCT02346045|hypertension
117261|NCT02346032|second line
117262|NCT02346006|Exercise
117263|NCT02346006|Visual Acuity
117264|NCT02346006|Blood Vessels
117265|NCT02346006|Retina
117266|NCT02346006|Choroid
117267|NCT02345993|formoterol/beclomethasone in asthmatic crisis
117268|NCT02345993|asthmatic crisis treatment
117269|NCT02345967|diabetes mellitus requiring insulin
117270|NCT02345954|Uterus Prolapse
117271|NCT02345954|Laparoscopic Sacropexy
117272|NCT02345954|Laparoscopic Hysteropexy
117273|NCT02345928|Safety
117274|NCT02345928|Efficacy
117275|NCT02345928|CNTO 7160
117276|NCT02345928|Healthy
117277|NCT02345928|Asthma
117278|NCT02345928|Atopic Dermatitis
117279|NCT02345876|Dyslexia, Medial olivocochlear system, Maturation, Auditory Processing
117280|NCT02345863|CLL
117281|NCT02345850|Acute Leukemia
117282|NCT02345850|Myelodysplasia
117283|NCT02345850|GVHD Prophylaxis
117284|NCT02345850|Chronic GVHD
117285|NCT02345824|CDK4/6 Inhibitor
117286|NCT02345824|LEE011
117287|NCT02345824|Recurrent Glioblastoma
117288|NCT02345824|Anaplastic Glioma
117289|NCT02345824|Ribociclib
117290|NCT02345759|CKD patients
117291|NCT02345759|protein-restricted diets
117292|NCT02345759|compliance
117293|NCT02345759|psychological aspects
117294|NCT02345707|Cabotegravir
117295|NCT02345707|Human Immunodeficiency Virus
117296|NCT02345707|Bioavailability
117297|NCT02345707|Pharmacokinetics
117298|NCT02345694|Obstructive Sleep Apnea Syndrome
117299|NCT02345694|Gait
117300|NCT02345694|Posture
117301|NCT02345694|Continuous Positive Airway Pressure
117302|NCT02345681|furosemide
117303|NCT02345681|under strict conditions
117304|NCT02345681|normalize
117305|NCT02345681|ICU patients
117306|NCT02345681|fluid balance
117307|NCT02345668|Transdiagnostic Internet-based Protocol
117308|NCT02345668|Treatment as Usual (TAU)
117309|NCT02345655|Substances consumption
117310|NCT02345655|Opiate
117311|NCT02345655|Family practice
117312|NCT02345629|Refractory cancer pain
117313|NCT02345629|Cordotomy
117314|NCT02345629|Sharpness pain sensory testing
117315|NCT02345629|Heat pain sensory testing
117316|NCT02345629|Symptom questionnaire
117317|NCT02345629|Advanced cancers
117318|NCT02345629|Pain
117319|NCT02345616|Cardiac surgery
117320|NCT02345616|Pulmonary hypertension
117321|NCT02345616|Nitric oxide
117322|NCT02345616|Induction anesthesia
117323|NCT02345577|Kidney transplantation
117324|NCT02345577|Stochastic whole body vibration therapy
117325|NCT02345577|Muscle strength
117326|NCT02345577|Intramuscular lipid content
117327|NCT02345577|Intramyocellular lipid content
117328|NCT02345577|Short Physical Performance Battery Test
117329|NCT02345577|Prospective, randomised , double blind,placebo-controlled trial
117330|NCT02345577|Physical Therapy Modalities
117331|NCT02345551|Exercise
117332|NCT02345551|Sleep
117333|NCT02345551|Telemedicine
117334|NCT02345551|Behavior
117335|NCT02345551|Shift work
117336|NCT02345512|Falls
117337|NCT02345499|Radical cystectomy
117338|NCT02345499|Laparoscopy
117339|NCT02345486|Pilot Projects
117340|NCT02345486|Plasmalyte A
117341|NCT02345486|Ringer's lactate
117342|NCT02345486|Sodium Chloride
117343|NCT02345486|Critical Care
117344|NCT02345486|"Resuscitation"
117345|NCT02345473|Bladder cancer
117346|NCT02345473|Circulating cancer cells
117347|NCT02345421|LAL D
117348|NCT02345421|CESD
117349|NCT02345421|NASH
117350|NCT02345421|NAFLD
117351|NCT02345421|Wilson's
117352|NCT02345421|Niemann Pick
117353|NCT02345421|Familial Hypercholesterolemia
117354|NCT02345395|Brain Aneurysm
117355|NCT02345395|Pterional Craniotomy
117356|NCT02345395|MiniPterional Craniotomy
117357|NCT02345395|Transpalpebral Approach
117358|NCT02345395|Unruptured Brain Aneurysm
117359|NCT02345382|Advanced acute leukemia
117360|NCT02345356|Pharmacogenomics
117361|NCT02345356|Warfarin
117362|NCT02345356|Caribbean Hispanics
117363|NCT02345356|Polymorphisms
117364|NCT02345356|Dosing Algorithm
117365|NCT02345278|Immunotherapy
117366|NCT02345278|Allergic rhinitis/rhinoconjunctivitis
117367|NCT02345252|HIV
117368|NCT02345226|HIV
117369|NCT02345213|DLB
117370|NCT02345213|Dementia with Lewy bodies
117371|NCT02345213|Lewy Body Disease
117372|NCT02345213|Dementia
117373|NCT02345213|E2020
117374|NCT02345213|Donepezil
117375|NCT02345213|Aricept
117376|NCT02345200|dystrophy
117377|NCT02345200|body composition
117378|NCT02345200|malnutrition
117379|NCT02345174|zirconium
117380|NCT02345174|oncology
117381|NCT02345174|mAb
117382|NCT02345174|receptor occupancy
117383|NCT02345174|dose
117384|NCT02345174|PET
117385|NCT02345174|HER3
117386|NCT02345174|89-Zr
117387|NCT02345174|biodistribution
117388|NCT02345174|tumours
117389|NCT02345161|Triple Therapy
117390|NCT02345161|Formoterol
117391|NCT02345161|Respiratory
117392|NCT02345161|COPD
117393|NCT02345161|Budesonide
117394|NCT02345161|Vilanterol
117395|NCT02345161|Fluticasone Furoate
117396|NCT02345161|Umeclidinium
117397|NCT02345161|Lung Function
117398|NCT02345148|Healthy
117399|NCT02345148|Esketamine
117400|NCT02345148|JNJ-54135419
117401|NCT02345122|At-risk Drinking
117402|NCT02345122|Depression
117403|NCT02345122|Anxiety
117404|NCT02345122|Alcohol Drinking
117405|NCT02345109|weight
117406|NCT02345109|total body water
117407|NCT02345109|body fat
117408|NCT02345109|muscle mass
117409|NCT02345109|bone mass
117410|NCT02345109|BMI
117411|NCT02345109|visceral fat
117412|NCT02345109|calories
117413|NCT02345083|Frailty
117414|NCT02345083|Pre-frailty
117415|NCT02345083|Fit
117416|NCT02345083|Robust
117417|NCT02345083|Elderly
117418|NCT02345083|Sociodemography status
117419|NCT02345083|Functional status
117420|NCT02345083|Cognitive status
117421|NCT02345083|Nutrition status
117422|NCT02345083|Comorbidity
117423|NCT02345083|Polypharmacy
117424|NCT02345083|Mortality
117425|NCT02345083|Depression status
117426|NCT02345083|Health-related quality of life
117427|NCT02345083|Fall incidence
117428|NCT02345083|Hospitality
117429|NCT02345057|Diabetic Nephropathy
117430|NCT02345057|mineralocorticoid receptor antagonist
117431|NCT02345057|CS-3150
117432|NCT02345057|Japanese
117433|NCT02345044|Essential hypertension
117434|NCT02345044|mineralocorticoid receptor antagonist
117435|NCT02345044|CS-3150
117436|NCT02345044|Japanese
117437|NCT02345031|hearing loss
117438|NCT02345031|speech-in-noise
117439|NCT02345018|Mechano-chemical ablation
117440|NCT02345018|Treatment large varicose veins
117441|NCT02345018|Below-knee and branches
117442|NCT02345018|Endovenous
117443|NCT02345005|Vascular diseases
117444|NCT02345005|Aneurysm
117445|NCT02345005|Treatment Efficacy
117446|NCT02345005|Medical device
117447|NCT02345005|Population Register
117448|NCT02344979|NSCLC
117449|NCT02344979|Chemotherapy
117450|NCT02344979|thrombocytopenia
117451|NCT02344979|rhTPO
117452|NCT02344940|operable
117453|NCT02344940|premenopausal
117454|NCT02344940|endocrine therapy
117455|NCT02344940|safety
117456|NCT02344940|tamoxifen
117457|NCT02344940|toremifene
117458|NCT02344927|Cancer
117459|NCT02344927|End-of-life care
117460|NCT02344927|Clinically-assisted hydration
117461|NCT02344914|dental support
117462|NCT02344914|second stage of labor
117463|NCT02344901|non-valvular atrial fibrillation
117464|NCT02344901|stroke prevention
117465|NCT02344901|novel oral anticoagulants
117466|NCT02344901|warfarin
117467|NCT02344888|PCOS
117468|NCT02344888|Clomiphene citrate resistant
117469|NCT02344888|Prednisolone
117470|NCT02344823|cirrhosis
117471|NCT02344823|erectile dysfunction
117472|NCT02344823|portal hypertension
117473|NCT02344797|Perioperative
117474|NCT02344797|Postoperative Complications/prevention & control
117475|NCT02344784|ADD
117476|NCT02344784|ADHD
117477|NCT02344784|PPI
117478|NCT02344771|Endothelial dysfunction
117479|NCT02344771|General Surgery
117480|NCT02344771|Perioperative Care
117481|NCT02344745|Lavender
117482|NCT02344745|Aromatherapy
117483|NCT02344745|Urodynamics
117484|NCT02344732|epithelium, cornea, diabetes, vitrectomy, oxygen
117485|NCT02344719|cirrhosis
117486|NCT02344719|portal hypertension
117487|NCT02344719|taurin
117488|NCT02344706|Emergency Care, Prehospital
117489|NCT02344706|Coma
117490|NCT02344706|Electroencephalography
117491|NCT02344693|Electroencephalography
117492|NCT02344654|Fluorescence
117493|NCT02344654|Cholangiography
117494|NCT02344654|Indocyanine Green
117495|NCT02344654|Cholecystectomy, Laparoscopic
117496|NCT02344615|nerve stimulator
117497|NCT02344615|ultrasound
117498|NCT02344602|Diabetic Nephropathy
117499|NCT02344602|Diabetes Mellitus
117500|NCT02344602|Diabetes Complications
117501|NCT02344602|Uric Acid
117502|NCT02344602|Febuxostat
117503|NCT02344602|Uloric
117504|NCT02344602|Glomerular Filtration Rate
117505|NCT02344602|Kidney Disease
117506|NCT02344602|Vascular Disease
117507|NCT02344602|Cardiovascular Diseases
117508|NCT02344602|Endothelial Function
117509|NCT02344602|Arterial Stiffness
117510|NCT02344602|Pharmacologic Actions
117511|NCT02344602|Gout Suppressants
117512|NCT02344602|Therapeutic Uses
117513|NCT02344602|Free Radical Scavengers
117514|NCT02344602|Antioxidants
117515|NCT02344602|Protective Agents
117516|NCT02344602|Physiological Effects of Drugs
117517|NCT02344602|Angiotensin II Infusion
117518|NCT02344602|Flow-mediated Dilation
117519|NCT02344602|Flow-mediated Constriction
117520|NCT02344602|Nitroglycerin
117521|NCT02344602|Hyperglycemia
117522|NCT02344602|Renin-angiotensin-aldosterone System
117523|NCT02344602|Nitric Oxide
117524|NCT02344602|cGMP
117525|NCT02344602|Oxidative Stress
117526|NCT02344602|Renal Haemodynamic Function
117527|NCT02344602|Inulin Clearance
117528|NCT02344602|PAH Clearance
117529|NCT02344602|Skin Biopsy
117530|NCT02344602|T1R mRNA Expression
117531|NCT02344602|Cytokines
117532|NCT02344602|Chemokines
117533|NCT02344589|ACB
117534|NCT02344589|Adductor Canal Block
117535|NCT02344589|Peripheral Nerve Block
117536|NCT02344576|heart failure
117537|NCT02344576|heart-assist devices
117538|NCT02344576|decision making
117539|NCT02344576|decision support techniques
117540|NCT02344576|hospice care
117541|NCT02344576|palliative care
117542|NCT02344576|caregivers
117543|NCT02344563|volunteers
117544|NCT02344550|metastatic breast cancer
117545|NCT02344550|HER2 negative
117546|NCT02344550|hormone-receptor positive
117547|NCT02344537|Lyme DIsease
117548|NCT02344537|Kundalini Yoga
117549|NCT02344498|Liver cirrhosis
117550|NCT02344498|Antiviral agents
117551|NCT02344498|Liver diseases
117552|NCT02344472|MBC
117553|NCT02344472|HER2
117554|NCT02344472|CTC
117555|NCT02344472|endocrine therapy
117556|NCT02344472|Pertuzumab
117557|NCT02344472|Trastuzumab
117558|NCT02344472|HER2 therapy
117559|NCT02344446|physical therapy intervention
117560|NCT02344433|Family health history
117561|NCT02344433|Genetic literacy
117562|NCT02344433|Health literacy
117563|NCT02344433|Relational agent
117564|NCT02344433|Common chronic conditions
117565|NCT02344420|Heart Failure
117566|NCT02344420|CRT
117567|NCT02344407|Zaire Ebola Virus Disease
117568|NCT02344394|Atrial Fibrillation
117569|NCT02344394|Anti-Arrhythmia Agents
117570|NCT02344394|Catheter Ablation
117571|NCT02344394|surgical hybrid ablation
117572|NCT02344368|Sucrose
117573|NCT02344368|Anesthesia
117574|NCT02344368|Blood specimen collection
117575|NCT02344368|Injections, Intravenous
117576|NCT02344355|Ascorbic Acid
117577|NCT02344355|temozolomide
117578|NCT02344355|radiation
117579|NCT02344342|telemonitoring
117580|NCT02344290|HIV
117581|NCT02344290|Cardiovascular Disease
117582|NCT02344290|Myocardial Infarction
117583|NCT02344290|Inflammation
117584|NCT02344290|Statin
117585|NCT02344290|Computerized Tomography
117586|NCT02344290|Cholesterol
117587|NCT02344277|Subcutaneaous Implantable Cardiac Defibrillator
117588|NCT02344277|Brugada syndrome
117589|NCT02344277|Effectiveness
117590|NCT02344277|Safety
117591|NCT02344264|US guided nerve block
117592|NCT02344264|Total hip Arthroplasty
117593|NCT02344264|NCFL
117594|NCT02344264|nervus cutaneous femoralis lateralis
117595|NCT02344251|Drug study
117596|NCT02344251|Medication compliance
117597|NCT02344238|Medication compliance
117598|NCT02344238|Technology
117599|NCT02344238|Drug study
117600|NCT02344186|diabetes, endoplasmic reticulum stress, obesity, GLP1 analogs
117601|NCT02344160|Total Hip Arthroplasty
117602|NCT02344160|THA
117603|NCT02344095|recurrent, persistent
117604|NCT02344069|Fibrinogen
117605|NCT02344056|Having Lunch
117606|NCT02344056|Skipping Lunch
117607|NCT02344030|airway
117608|NCT02344030|videolaryngoscope
117609|NCT02343042|Selinexor
117610|NCT02343042|KCP-330
117611|NCT02343042|STOMP
117612|NCT02343042|Multiple Myeloma
117613|NCT02343042|Relapsed/Refractory
117614|NCT02343042|Dexamethasone
117615|NCT02343042|Pomalidomide
117616|NCT02343042|Bortezomib
117617|NCT02343042|Karyopharm
117618|NCT02343042|Lenalidomide
117619|NCT02343978|Chronic Constipation
117620|NCT02343978|CC
117621|NCT02343965|Touch-massage
117622|NCT02343965|anxiety
117623|NCT02343965|leukemia
117624|NCT02343965|haematology
117625|NCT02343965|cancerology
117626|NCT02343965|supportive care
117627|NCT02343965|complementary therapy
117628|NCT02343952|Pembrolizumab
117629|NCT02343952|MK-3475
117630|NCT02343874|Alcohol consumption
117631|NCT02343874|Primary health care
117632|NCT02343874|health care costs
117633|NCT02343874|health service utilization
117634|NCT02343861|Behavioral Research
117635|NCT02343861|Emollients
117636|NCT02343822|PRP
117637|NCT02343822|Platelet Rich Plasma
117638|NCT02343822|Lateral Epicondylitis
117639|NCT02343822|Lateral Epicondylopathy
117640|NCT02343822|Lateral Epicondylosis
117641|NCT02343822|Chronic Lateral Epicondylitis
117642|NCT02343822|PRPLE
117643|NCT02343822|Multiple PRP Injections
117644|NCT02343822|Multiple PRP
117645|NCT02343822|Platelet-Rich Plasma
117646|NCT02343822|Tennis Elbow
117647|NCT02343822|Double Blinded Randomized Controlled
117648|NCT02343822|Multiple vs Single PRP injections
117649|NCT02343822|prp tennis elbow
117650|NCT02343809|Physiotherapy
117651|NCT02343809|Lateral epicondylitis
117652|NCT02343809|Manual therapy
117653|NCT02343796|Fiberglass reinforced resins
117654|NCT02343783|Atopic Dermatitis
117655|NCT02343783|Asthma
117656|NCT02343783|Healthy
117657|NCT02343783|Skin Blisters
117658|NCT02343783|Adult Participants
117659|NCT02343744|Generalized Pustular Psoriasis
117660|NCT02343744|Erythrodermic Psoriasis
117661|NCT02343744|Guselkumab
117662|NCT02343744|CNTO1959
117663|NCT02343731|microbiome
117664|NCT02343731|hygiene hypothesis
117665|NCT02343731|human-animal interaction
117666|NCT02343731|microbiota
117667|NCT02343731|connections between human-canine microbiome
117668|NCT02343653|Malnutrition
117669|NCT02343653|Muscle mass
117670|NCT02343653|Nutrition
117671|NCT02343640|Baseball
117672|NCT02343640|Ulnar collateral ligament
117673|NCT02343614|Intermediate risk
117674|NCT02343614|Cox-2 inhibitors
117675|NCT02343588|Chinese multi-centered school based obesity intervention
117676|NCT02343575|Hyperactive delirium
117677|NCT02343575|Mixed delirium
117678|NCT02343575|Anti-psychotic
117679|NCT02343575|Haldol
117680|NCT02343575|Valproic Acid
117681|NCT02343536|Phase 1
117682|NCT02343536|Oral Azacitidine (CC-486)
117683|NCT02343536|R-CHOP
117684|NCT02343536|Diffuse Large B-cell Lymphoma
117685|NCT02343536|Grade 3B Follicular Lymphoma
117686|NCT02343536|Follicular Lymphoma
117687|NCT02343536|Transformed Lymphoma
117688|NCT02343523|Wearable device
117689|NCT02343523|Wrist-watch
117690|NCT02343523|Longitudinal monitoring
117691|NCT02343523|Congestive Heart Failure
117692|NCT02343510|Fallopian tubal cancer, high grade serous , ovarian cancer
117693|NCT02343484|pulsed radiofrequency
117694|NCT02343484|gelified ethanol
117695|NCT02343471|Whey proteins
117696|NCT02343471|Postprandial lipemia
117697|NCT02343471|Pre-meal
117698|NCT02343471|Type 2 diabetes
117699|NCT02343432|Anesthesia
117700|NCT02343432|Adverse Effect
117701|NCT02343432|Spinal
117702|NCT02343432|Epidural
117703|NCT02343419|Bronchial Hyperreactivity
117704|NCT02343419|Bronchial Provocation Tests
117705|NCT02343419|Methacholine Chloride
117706|NCT02343419|Respiratory Function Tests
117707|NCT02343419|Spirometry
117708|NCT02343419|Airway Resistance
117709|NCT02343419|Plethysmography
117710|NCT02343406|European Organization for Research and Treatment of Cancer
117711|NCT02343406|Brain Tumor Group
117712|NCT02343406|Lomustine
117713|NCT02343406|Pediatric High Grade Gliomas
117714|NCT02343406|Glioblastoma Multiforme
117715|NCT02343406|Pediatric diffuse Intrinsic Pontine Glioma
117716|NCT02343406|Children
117717|NCT02343406|Epithelial Growth Factor vIII mutation
117718|NCT02343406|Antibody Drug Conjugate
117719|NCT02343406|Temozolomide
117720|NCT02343406|recurrent glioblastoma
117721|NCT02343406|Epithelial Growth Factor
117722|NCT02343406|ABT-414
117723|NCT02343406|EORTC
117724|NCT02343406|Pediatric WHO grade III glioma
117725|NCT02343406|EGFR amplification
117726|NCT02343406|Pediatric WHO grade IV glioma
117727|NCT02343406|Brain Tumor
117728|NCT02343393|Endothelial Dysfunction
117729|NCT02343393|Biomarkers
117730|NCT02343393|Hydralazine-Isosorbide Dinitrate
117731|NCT02343380|diet-induced thermogenesis
117732|NCT02343380|glucose
117733|NCT02343380|respiratory quotient
117734|NCT02343367|Hispanic
117735|NCT02343367|overweight
117736|NCT02343367|families
117737|NCT02343367|pediatric
117738|NCT02343367|primary care
117739|NCT02343354|behavioural
117740|NCT02343354|diabetes prevention
117741|NCT02343354|physical activity
117742|NCT02343354|healthy eating
117743|NCT02343354|gestational diabetes
117744|NCT02343341|early childhood education
117745|NCT02343341|cardiovascular health
117746|NCT02343341|behavior change
117747|NCT02343341|community-based
117748|NCT02343341|family-based
117749|NCT02343341|prevention
117750|NCT02343315|low back pain
117751|NCT02343315|home exercises
117752|NCT02343315|chronic pain
117753|NCT02343315|supervised exercise
117754|NCT02343315|core stability exercises
117755|NCT02343315|spinal stabilization exercises
117756|NCT02343302|Pancreatic Fistula
117757|NCT02343289|Healthy
117758|NCT02343289|Pharmacokinetics
117759|NCT02343289|Esketamine
117760|NCT02343289|JNJ-54135419
117761|NCT02343276|Radial Spasm
117762|NCT02343263|Tonsillectomy
117763|NCT02343263|Adenotonsillectomy
117764|NCT02343263|Pain
117765|NCT02343263|Hemorrhage
117766|NCT02343237|Fibromyalgia syndrome
117767|NCT02343237|pain
117768|NCT02343237|quality of life
117769|NCT02343237|osteopathic treatment
117770|NCT02343211|Paraneoplastic Neurological Syndromes
117771|NCT02343211|Onconeural antibodies
117772|NCT02343211|Cancer
117773|NCT02343185|diaphragm
117774|NCT02343185|osteopathic treatment
117775|NCT02343185|myofascial release
117776|NCT02343172|Liposarcoma,
117777|NCT02343172|MDM2 inhibition,
117778|NCT02343172|cdk4 inhibition,
117779|NCT02343172|HDM201,
117780|NCT02343172|LEE011
117781|NCT02343133|Radiation countermeasure
117782|NCT02343133|radiomitigation
117783|NCT02343107|Obesity
117784|NCT02343107|Type 2 diabetes
117785|NCT02343107|Metabolic syndrome
117786|NCT02343107|e-coaching
117787|NCT02343107|Telehealth
117788|NCT02343094|Proteinuria
117789|NCT02343094|Lipocalin 2
117790|NCT02343094|Neutrophil gelatinase associated lipocalin
117791|NCT02343094|ELISA
117792|NCT02343081|brain neoplasm
117793|NCT02343081|bioequivalence
117794|NCT02343081|temozolomide
117795|NCT02343029|Aerobic Exercise Training
117796|NCT02343029|prevention
117797|NCT02343029|magnetic resonance spectroscopic imaging
117798|NCT02343029|psychometric tests
117799|NCT02343029|cognition
117800|NCT02343029|dementia
117801|NCT02343029|cognitive impairment
117802|NCT02343003|cooled radiofrequency ablation
117803|NCT02343003|knee pain
117804|NCT02343003|osteoarthritis
117805|NCT02343003|pain management
117806|NCT02342990|working memory training
117807|NCT02342990|home-based training
117808|NCT02342990|periventricular leukomalacia
117809|NCT02342990|bilateral cerebral palsy
117810|NCT02342990|neuropsychological profile
117811|NCT02342990|high density EEG
117812|NCT02342990|slow waves activities
117813|NCT02342977|total hip arthroplasty
117814|NCT02342964|Cystic fibrosis
117815|NCT02342964|hepatic fibrosis
117816|NCT02342964|hepatic cirrhosis
117817|NCT02342964|non-invasive methods of measurement
117818|NCT02342964|hepatic elasticity
117819|NCT02342951|Cystic fibrosis,
117820|NCT02342951|lung clearance index,
117821|NCT02342951|pulmonary function
117822|NCT02342938|Epilepsy surgery
117823|NCT02342938|High frequency activity
117824|NCT02342938|icEEG
117825|NCT02342938|fMRI
117826|NCT02342938|MEG
117827|NCT02342886|Tuberculosis
117828|NCT02342886|Multi Drug-Resistant Tuberculosis
117829|NCT02342886|Drug-sensitive Tuberculosis
117830|NCT02342886|PA-824
117831|NCT02342886|Moxifloxacin
117832|NCT02342886|Pyrazinamide
117833|NCT02342886|Rifampicin
117834|NCT02342886|Isoniazid
117835|NCT02342886|Ethambutol
117836|NCT02342886|HRZE
117837|NCT02342886|HR
117838|NCT02342886|Pretomanid
117839|NCT02342886|NC-006
117840|NCT02342886|STAND
117841|NCT02342873|ultrasound
117842|NCT02342873|nerve stimulator
117843|NCT02342860|Water
117844|NCT02342860|sanitation
117845|NCT02342860|hygiene access in school
117846|NCT02342756|ARDS, HFOV
117847|NCT02342691|Safety and efficacy of BLXA4
117848|NCT02342665|Non Hodgkin's Lymphomas
117849|NCT02342626|Prostate
117850|NCT02342626|Cancer
117851|NCT02342626|Adenocarcinoma
117852|NCT02342587|Lapatinib
117853|NCT02342561|Infection
117854|NCT02342561|Drape
117855|NCT02342561|Ioban
117856|NCT02342561|Arthroplasty
117857|NCT02342561|Knee
117858|NCT02342561|Cylinder Sampling
117859|NCT02342561|Bacteria
117860|NCT02342548|Huntington; chorea; total motor score; CAG repeat: total functional capacity; motor cognitive and behavioral symptoms
117861|NCT02342522|Cardioprotection
117862|NCT02342522|STEMI
117863|NCT02342522|PPCI
117864|NCT02342522|Myocardial reperfusion injury
117865|NCT02342522|Myocardial infarct size
117866|NCT02342509|et Control
117867|NCT02342509|inhalational sedation
117868|NCT02342509|conserve volatile anesthetics
117869|NCT02342470|prevention
117870|NCT02342470|Recurrent peptic ulcer
117871|NCT02342444|Trauma
117872|NCT02342444|Surgery
117873|NCT02342444|Enoxaparin
117874|NCT02342444|DVTs
117875|NCT02342444|Thromboembolic events
117876|NCT02342431|Thermoregulation
117877|NCT02342431|Pediatric Anesthesia
117878|NCT02342431|Cardiac Catheterization
117879|NCT02342405|Oxidative stress
117880|NCT02342405|Nitrogen oxide
117881|NCT02342405|Reactive oxygen species
117882|NCT02342392|pterygium
117883|NCT02342392|ranibizumab
117884|NCT02342392|anti-VEGF
117885|NCT02342392|recurrence
117886|NCT02342392|vascularity
117887|NCT02342392|size
117888|NCT02342366|Sodium Oxybate, Altruism, Neurostreroids, Liquid Ecstasy
117889|NCT02342340|Beans, Lentils, Bioavailability, Phytochemical Absorption
117890|NCT02342288|Intraoperative ocular pressure
117891|NCT02342275|Infantile hemangioma
117892|NCT02342275|Propranolol
117893|NCT02342275|Atenolol
117894|NCT02342275|Efficacy
117895|NCT02342275|Safety
117896|NCT02342249|Influenza A
117897|NCT02342236|Biological Markers
117898|NCT02342223|human immunodeficiency virus
117899|NCT02342223|facial lipoatrophy
117900|NCT02342223|facial lipodystrophy
117901|NCT02342223|hyaluronic acid
117902|NCT02342223|dermal filler
117903|NCT02342223|filler agent
117904|NCT02342210|Mindfulness
117905|NCT02342210|Group Therapy
117906|NCT02342197|Low responders
117907|NCT02342197|Minidose long protocol
117908|NCT02342197|Microdose flare protocol
117909|NCT02342197|Oocyte yield
117910|NCT02342171|Ebola Viral Disease
117911|NCT02342171|Convalescent Plasma
117912|NCT02342171|Developing Countries
117913|NCT02342145|beta-Thalassemia major
117914|NCT02342119|kidney transplantation
117915|NCT02342119|race disparities
117916|NCT02342119|living donor kidney transplantation
117917|NCT02342119|transplant evaluation
117918|NCT02342093|Ambulatory Blood Pressure Monitoring
117919|NCT02342093|Drospirenone
117920|NCT02342093|Oral contraceptive
117921|NCT02342080|Rehabilitation
117922|NCT02342080|Walking
117923|NCT02342080|Robotics
117924|NCT02342080|Neuronal Plasticity
117925|NCT02342054|Cancer
117926|NCT02342054|Prostate Cancer
117927|NCT02342054|Brachytherapy
117928|NCT02342054|Dose escalation
117929|NCT02342054|High Dose Rate
117930|NCT02342054|MRI-TRUS fusion
117931|NCT02342054|Detection of DILs by MRI
117932|NCT02342054|SINGLE FRACTION
117933|NCT02342041|SUVN-G3031
117934|NCT02342041|histamine 3 (H3) receptor inverse agonist
117935|NCT02342041|first in human
117936|NCT02342041|safety
117937|NCT02342041|pharmacokinetics
117938|NCT02342041|tolerability
117939|NCT02342041|single dose
117940|NCT02342041|repeat dose
117941|NCT02342028|sleep apnea
117942|NCT02342028|intermittent hypoxia
117943|NCT02342028|regulatory T cell
117944|NCT02342028|autoimmunity
117945|NCT02342002|mifepristone
117946|NCT02342002|misoprostol
117947|NCT02342002|obstetrics
117948|NCT02342002|reproductive health
117949|NCT02342002|pregnancy
117950|NCT02342002|abortion
117951|NCT02342002|missed abortion
117952|NCT02341989|Chemotherapy, adjuvant
117953|NCT02341989|Recurrence
117954|NCT02341989|Carboplatin
117955|NCT02341989|Bleomycin
117956|NCT02341989|Etoposide
117957|NCT02341989|Cisplatin
117958|NCT02341976|whole body vibration
117959|NCT02341976|pelvic floor muscle
117960|NCT02341976|urinary incontinence
117961|NCT02341976|Urinary sphincter
117962|NCT02341950|videogame
117963|NCT02341950|health
117964|NCT02341950|behavior
117965|NCT02341950|mobile
117966|NCT02341950|spinal
117967|NCT02341950|cord
117968|NCT02341950|dysfunction
117969|NCT02341911|triple negative breast cancer
117970|NCT02341911|fine line chemotherapy
117971|NCT02341898|nursing home care
117972|NCT02341898|physical restraints
117973|NCT02341898|dementia
117974|NCT02341898|implementation research
117975|NCT02341898|cluster-randomized controlled trial
117976|NCT02341885|Kidney
117977|NCT02341885|Renal replacement
117978|NCT02341885|Acute kidney injury
117979|NCT02341885|chronic kidney disease
117980|NCT02341885|Epidemiology
117981|NCT02341885|Prevalence
117982|NCT02341872|White spot lesions
117983|NCT02341872|remineralization
117984|NCT02341872|QLF
117985|NCT02341872|antibacterial
117986|NCT02341846|cancer pain
117987|NCT02341833|Anesthetic preconditioning
117988|NCT02341833|Sevoflurane
117989|NCT02341833|Liver transplantation
117990|NCT02341833|brain-death donors
117991|NCT02341820|breast cancer
117992|NCT02341820|breast conserving surgery
117993|NCT02341820|cosmesis
117994|NCT02341807|Choroideremia
117995|NCT02341807|AAV
117996|NCT02341807|Gene therapy
117997|NCT02341807|CHM
117998|NCT02341807|Adeno-associated virus
117999|NCT02341807|Adeno-associated viral vector
118000|NCT02341794|intracranial arterial disease
118001|NCT02341794|dyslipidemia
118002|NCT02341794|rosuvastatin
118003|NCT02341781|MANTLE CELL LYMPHOMA
118004|NCT02341781|Multicenter
118005|NCT02341781|Observational
118006|NCT02341781|Lenalidomide (Revlimid®)
118007|NCT02341781|Relapsed or progressed
118008|NCT02341781|Ibrutinib
118009|NCT02341768|clinical and device functional information
118010|NCT02341768|"real world ICD patient population"
118011|NCT02341742|Physical activity
118012|NCT02341742|Bone health
118013|NCT02341742|Pediatrics
118014|NCT02341742|Bone
118015|NCT02341729|semi-urgent CABG
118016|NCT02341729|reanimation
118017|NCT02341729|ticagrelor
118018|NCT02341729|crushed tablet
118019|NCT02341716|intermittent claudication
118020|NCT02341716|exercise therapy
118021|NCT02341716|physiotherapy
118022|NCT02341690|Type 2 diabetes
118023|NCT02341690|Interval Walking Training
118024|NCT02341690|Motivation
118025|NCT02341677|Prostatic Neoplasms
118026|NCT02341677|Diagnostic Techniques and Procedures
118027|NCT02341677|Magnetic Resonance Imaging
118028|NCT02341677|Ultrasonography
118029|NCT02341677|Biopsy
118030|NCT02341677|Image Fusion
118031|NCT02341664|Mobile Tablet Device
118032|NCT02341664|Outpatient Clinic
118033|NCT02341664|Tobacco
118034|NCT02341664|Health
118035|NCT02341664|Barriers
118036|NCT02341664|Prevention
118037|NCT02341664|Prescribing Practices
118038|NCT02341664|Informed Consent
118039|NCT02341664|Statin
118040|NCT02341664|Lipid Panel
118041|NCT02341664|Low Density Lipoprotein-C
118042|NCT02341664|Blood Draw
118043|NCT02341664|ACC/AHA Guidelines
118044|NCT02341664|Adult Treatment Panel Guidelines (ATPIII)
118045|NCT02341664|Atherosclerotic Cardiovascular Disease (ASCVD)
118046|NCT02341664|Cholesterol-lowering therapies
118047|NCT02341664|Cholesterol Management
118048|NCT02341664|Cardiovascular Risk
118049|NCT02341664|10-year CVD Risk
118050|NCT02341664|Labs
118051|NCT02341664|Coronary revascularization
118052|NCT02341664|Arterial revascularization
118053|NCT02341664|Imaging
118054|NCT02341651|High blood pressure
118055|NCT02341651|Cardiovascular diseases
118056|NCT02341651|Antihypertensive agents
118057|NCT02341651|Pharmacological treatment
118058|NCT02341651|Non-pharmacological treatment
118059|NCT02341651|Community health care workers
118060|NCT02341651|Treatment algorithm
118061|NCT02341651|Public and private healthcare providers
118062|NCT02341651|Strategy
118063|NCT02341651|Referral loops
118064|NCT02341651|Intervention
118065|NCT02341612|exercise-induced muscle damage
118066|NCT02341612|skeletal muscle injury recovery
118067|NCT02341612|cryotherapy
118068|NCT02341612|recovery of function
118069|NCT02341612|rehabilitation
118070|NCT02341586|Malaria
118071|NCT02341586|Cambodia
118072|NCT02341586|Iron
118073|NCT02341586|Childbearing Age
118074|NCT02341586|Women
118075|NCT02341586|Home Fortification
118076|NCT02341573|Traditional Chinese Medicine
118077|NCT02341573|Randomized Controlled Trial
118078|NCT02341560|NAION
118079|NCT02341495|Azacitidine
118080|NCT02341495|Vidaza
118081|NCT02341495|Deferasirox
118082|NCT02341495|Exjade
118083|NCT02341495|Cholecalciferol
118084|NCT02341495|Vitamin D
118085|NCT02341482|Itraconazole
118086|NCT02341482|Healthy Volunteers
118087|NCT02341482|Drug-drug interaction
118088|NCT02341482|PF-04958242
118089|NCT02341469|Burkina Faso
118090|NCT02341469|cluster randomised
118091|NCT02341469|stepped-wedge
118092|NCT02341469|IMCI
118093|NCT02341443|bilateral double mandibular fractures
118094|NCT02341443|rigid fixation
118095|NCT02341443|no-rigid fixation
118096|NCT02341443|jaw
118097|NCT02341430|hernia
118098|NCT02341430|synthetic mesh
118099|NCT02341417|Chronic Kidney Disease, Dialysis, Secondary Hyperparathyroidism, Pediatric
118100|NCT02341391|chondrocyte cells
118101|NCT02341391|Osteoarthritis
118102|NCT02341391|gene therapy
118103|NCT02341378|chondrocyte cells
118104|NCT02341378|Osteoarthritis
118105|NCT02341378|gene therapy
118106|NCT02341365|Egg donation
118107|NCT02341365|vitaminD
118108|NCT02341365|ovarian reserve
118109|NCT02341365|ovarian stimulation
118110|NCT02341326|Lung
118111|NCT02341326|COPD
118112|NCT02341326|smoking
118113|NCT02341326|Non-smoker
118114|NCT02341313|Hypoglycaemia
118115|NCT02341300|Pregnancy
118116|NCT02341300|Cast-Iron pots
118117|NCT02341300|Iron-deficiency anemia
118118|NCT02341274|Tacrolimus
118119|NCT02341274|Drug Formulation
118120|NCT02341274|Absorption
118121|NCT02341274|Bioavailability
118122|NCT02341274|Healthy Volunteer
118123|NCT02341248|Enteral Nutrition
118124|NCT02341248|Pediatrics
118125|NCT02341248|Microbiota
118126|NCT02341248|Metabolomics
118127|NCT02341235|video game
118128|NCT02341235|narrative
118129|NCT02341235|story
118130|NCT02341235|survivorship
118131|NCT02341235|cancer survivor
118132|NCT02341235|mhealth
118133|NCT02341235|physical activity
118134|NCT02341235|women
118135|NCT02341235|women's health
118136|NCT02341222|hernia prosthetic surgery
118137|NCT02341222|incisional hernia prosthesis
118138|NCT02341222|prosthesis mesh fixation
118139|NCT02341222|prosthesis mesh biocompatibility
118140|NCT02341209|CTCL
118141|NCT02341209|Sezary Syndrome (SS)
118142|NCT02341209|Mycosis Fungoides (MF)
118143|NCT02341209|Cutaneous T-cell Lymphoma
118144|NCT02341209|MF
118145|NCT02341209|SS
118146|NCT02341131|Schizophrenia
118147|NCT02341131|Cognitive Remediation
118148|NCT02341131|BDNF
118149|NCT02341118|BRCA1/2 Mutational Status
118150|NCT02341092|Traumatic brain injury
118151|NCT02341079|Total Knee Arthroplasty
118152|NCT02341079|Osteoarthritis
118153|NCT02341079|Femoral Nerve Blockade
118154|NCT02341079|Liposomal Bupivacaine
118155|NCT02341066|Cardiovascular risk score
118156|NCT02341066|Framingham risk score 2-year
118157|NCT02341066|Endothelial dysfunction
118158|NCT02341066|EndoPAT
118159|NCT02341066|Rheumatoid arthritis
118160|NCT02341053|SMA
118161|NCT02341053|Neuromuscular disability
118162|NCT02341040|wheat allergy
118163|NCT02341040|food allergy
118164|NCT02341040|pediatric
118165|NCT02341027|Immediate postpartum contraception
118166|NCT02341027|Contraceptive implants
118167|NCT02341027|Breastfeeding
118168|NCT02341027|Jadelle
118169|NCT02341027|Lactation
118170|NCT02341027|Levonorgestrel
118171|NCT02341014|Carfilzomib
118172|NCT02341014|Romidepsin
118173|NCT02341014|Lenalidomide
118174|NCT02341014|Lymphomas
118175|NCT02341014|14-179
118176|NCT02341001|Bariatric surgery
118177|NCT02341001|Sleeve gastrectomy
118178|NCT02341001|Text messaging
118179|NCT02341001|Weight loss
118180|NCT02341001|BAROS
118181|NCT02341001|Follow-up care
118182|NCT02340975|Gastric Adenocarcinoma
118183|NCT02340975|Gastroesophageal Junction Adenocarcinoma
118184|NCT02340975|Immunotherapy
118185|NCT02340975|Antibodies, Monoclonal
118186|NCT02340975|Tremelimumab
118187|NCT02340975|MEDI4736
118188|NCT02340923|DMD
118189|NCT02340923|Duchenne Muscular Dystrophy
118190|NCT02340923|EIM
118191|NCT02340910|spasticity
118192|NCT02340910|whole body vibration
118193|NCT02340910|walking
118194|NCT02340871|Neurogenetics
118195|NCT02340871|genetic testing
118196|NCT02340845|breast,colon, ovary, uterus, cervix, lung
118197|NCT02340845|Treatments
118198|NCT02340806|epidural bolus
118199|NCT02340806|pain management
118200|NCT02340806|labor analgesia
118201|NCT02340793|Weight loss
118202|NCT02340767|Suspicious Occlusal Caries
118203|NCT02340754|mindfulness
118204|NCT02340754|meditation
118205|NCT02340754|stress, psychological
118206|NCT02340754|quality of life
118207|NCT02340754|randomized controlled trial
118208|NCT02340741|carbon dioxide
118209|NCT02340741|postoperative cerebrovascular complications
118210|NCT02340741|air embolism
118211|NCT02340728|Stent Placement
118212|NCT02340728|Biliary Obstruction
118213|NCT02340728|14-260
118214|NCT02340715|Anal canal
118215|NCT02340715|Brain
118216|NCT02340715|Breast
118217|NCT02340715|Cervix
118218|NCT02340715|Esophagus
118219|NCT02340715|Gynecology
118220|NCT02340715|Head and Neck
118221|NCT02340715|Lung
118222|NCT02340715|Pancreas
118223|NCT02340715|Primary liver or liver metastases
118224|NCT02340715|Prostate cancer
118225|NCT02340715|Sarcoma
118226|NCT02340702|COPD and heart failure
118227|NCT02340689|PH
118228|NCT02340689|PH type 1
118229|NCT02340689|Primary Hyperoxaluria
118230|NCT02340689|Hyperoxaluria
118231|NCT02340689|Primary Oxalosis
118232|NCT02340689|PH type 2
118233|NCT02340689|PH type 3
118234|NCT02340689|Genetic testing for PH
118235|NCT02340689|Genetic testing for Primary Hyperoxaluria
118236|NCT02340689|Hereditary study for PH
118237|NCT02340689|Hereditary study for Primary Hyperoxaluria
118238|NCT02340689|AGXT
118239|NCT02340689|GRHPR
118240|NCT02340689|HOGA1
118241|NCT02340676|chronic graft-versus-host-disease
118242|NCT02340663|dental orthotic
118243|NCT02340663|bite splint
118244|NCT02340663|oral parafunction
118245|NCT02340663|clenching
118246|NCT02340663|grinding
118247|NCT02340650|suspicious bladder lesion, normal bladder tissue
118248|NCT02340585|Next Generation Neuroform Stent System
118249|NCT02340585|Wide Neck, Intracranial, Saccular Aneurysms
118250|NCT02340585|Cerebral Aneurysms
118251|NCT02340572|Healthy Subjects
118252|NCT02340559|meta-cognition
118253|NCT02340559|positive symptoms
118254|NCT02340559|early phases
118255|NCT02340559|schizophrenia
118256|NCT02340533|adenomyosis
118257|NCT02340481|Diarrhea
118258|NCT02340481|Flatulence
118259|NCT02340481|Abdominal discomfort
118260|NCT02340481|Loperamide hydrochloride
118261|NCT02340481|Simethicone
118262|NCT02340481|Placebo
118263|NCT02340442|arteriovenous ratio
118264|NCT02340442|retinal flicker stimulation
118265|NCT02340442|Dynamic vessel analyzer
118266|NCT02340416|orthopedic surgeries
118267|NCT02340416|general anesthesia
118268|NCT02340403|Neuropathy
118269|NCT02340403|Oxaliplatin
118270|NCT02340403|Insula
118271|NCT02340403|choline
118272|NCT02340390|G7 Acetabular System
118273|NCT02340377|core body temperature
118274|NCT02340377|whole-body hyperthermia
118275|NCT02340377|rectal body temperature
118276|NCT02340364|Hospital Readmissions
118277|NCT02340364|Patient Navigation
118278|NCT02340351|acupuncture
118279|NCT02340351|auricular acupuncture
118280|NCT02340351|NADA
118281|NCT02340351|anxiety
118282|NCT02340351|depression
118283|NCT02340299|High Frequency Oscillation Ventilation
118284|NCT02340299|Nasal Continuous Positive Airway Pressure
118285|NCT02340299|Airway Extubation
118286|NCT02340299|Prematurity
118287|NCT02340273|tendinopathy
118288|NCT02340273|ultrasound
118289|NCT02340273|pain
118290|NCT02340273|heat
118291|NCT02340273|strength
118292|NCT02340273|LITUS
118293|NCT02340273|long duration
118294|NCT02340273|therapeutic ultrasound
118295|NCT02340273|tendonopathy
118296|NCT02340260|Exercise
118297|NCT02340260|Risk factors
118298|NCT02340260|Exercise therapy
118299|NCT02340260|Hemoglobin A, Glycosylated
118300|NCT02340208|Non-Small Cell Lung Cancer
118301|NCT02340208|Neoplasms
118302|NCT02340208|Immunoconjugate
118303|NCT02340208|Tumor microenvironment alkalinization
118304|NCT02340195|Kidney impairment
118305|NCT02340182|gut flora
118306|NCT02340182|antibiotics
118307|NCT02340182|systemic immune response
118308|NCT02340182|Volunteers
118309|NCT02340091|facial nasolabial fold wrinkles
118310|NCT02340078|the facial nasolabial fold
118311|NCT02340065|colonoscopy
118312|NCT02340065|adenoma detection rate
118313|NCT02340065|Endocuff-assisted colonoscopy
118314|NCT02340052|postoperative pain treatment
118315|NCT02340039|Polyphenol
118316|NCT02340039|Fruit
118317|NCT02340039|Metabolic
118318|NCT02340026|Delay in motor skill development
118319|NCT02340000|acute sinusitis
118320|NCT02340000|amoxicillin/clavulanate
118321|NCT02340000|adults
118322|NCT02340000|outcomes
118323|NCT02339961|Systemic Sclerosis
118324|NCT02339961|Pulmonary hypertension
118325|NCT02339961|Lung Doppler Signals
118326|NCT02339948|Locally confined
118327|NCT02339935|Autism Spectrum Disorder
118328|NCT02339935|Autism
118329|NCT02339909|Screening
118330|NCT02339909|Incentives
118331|NCT02339896|rabies
118332|NCT02339896|modified TRC intradermal rabies vaccine
118333|NCT02339896|SPEEDA
118334|NCT02339883|Physiological Measures
118335|NCT02339883|MRI
118336|NCT02339883|Magnetic Resonance Imaging (MRI)
118337|NCT02339883|Cognitive Testing
118338|NCT02339857|coronary artery bypass grafting
118339|NCT02339857|saphenous vein
118340|NCT02339857|grafts
118341|NCT02339844|glutamate
118342|NCT02339844|dopamine
118343|NCT02339844|cognition
118344|NCT02339844|cortical thickness
118345|NCT02339844|ppi
118346|NCT02339844|p50
118347|NCT02339831|Knee
118348|NCT02339831|Arthroplasty
118349|NCT02339831|CPM
118350|NCT02339831|Camoped
118351|NCT02339831|Active vs Passive Motion Device
118352|NCT02339805|Minimal residual disease, NGS, NHL, DNA sequencing
118353|NCT02339792|COMPREHENSIVE GERIATRIC ASSESSMENT (CGA)
118354|NCT02339792|MEDICATION APPROPRIATENESS PRESCRIBING
118355|NCT02339792|DRUG INTERACTIONS
118356|NCT02339792|E-LEARNING
118357|NCT02339779|fat grafting
118358|NCT02339779|fat injection
118359|NCT02339779|lipoaspirate
118360|NCT02339779|fat transfer
118361|NCT02339779|lipofilling
118362|NCT02339779|liposculpturing
118363|NCT02339779|lipoinjection
118364|NCT02339779|lipotransfer
118365|NCT02339779|breast reconstruction
118366|NCT02339766|Cesarean
118367|NCT02339766|Quadratus Lumborum Block
118368|NCT02339766|Analgesia
118369|NCT02339766|Ultrasonography
118370|NCT02339727|Omega-3
118371|NCT02339727|Omega-6
118372|NCT02339714|allergic rhinitis
118373|NCT02339714|acupuncture
118374|NCT02339714|moxibustion
118375|NCT02339714|efficacy
118376|NCT02339714|safety
118377|NCT02339649|sepsis
118378|NCT02339649|septic shock
118379|NCT02339649|ICU
118380|NCT02339649|long-term outcome
118381|NCT02339649|neurocognitive
118382|NCT02339649|inflammatory
118383|NCT02339649|MRI
118384|NCT02339649|EEG
118385|NCT02339649|brain imaging
118386|NCT02339649|serum biomarkers
118387|NCT02339649|CSF
118388|NCT02339636|subclinical, enthesitis, synovitis
118389|NCT02339623|Threatened preterm birth - fetal adrenal gland volume
118390|NCT02339610|Osteoarthritis
118391|NCT02339610|Post-traumatic Arthritis
118392|NCT02339584|OAG
118393|NCT02339584|OHT
118394|NCT02339532|HER2-positive
118395|NCT02339532|non-metastatic
118396|NCT02339532|TOP2A
118397|NCT02339519|Laryngeal Masks
118398|NCT02339506|stress
118399|NCT02339506|ACTH
118400|NCT02339506|cosyntropin
118401|NCT02339506|baroreflex sensitivity
118402|NCT02339506|cardiovagal
118403|NCT02339480|Massage therapy
118404|NCT02339480|Simple obesity
118405|NCT02339480|Energy metabolism
118406|NCT02339480|Mechanism
118407|NCT02339467|decreased outdoor walking ability
118408|NCT02339467|Older adult
118409|NCT02339454|Cardiac Shock wave therapy
118410|NCT02339454|stable angina
118411|NCT02339454|exercise tolerance
118412|NCT02339441|Systemic sclerosis
118413|NCT02339428|Colonoscopy
118414|NCT02339428|diagnostic
118415|NCT02339428|diclophenac
118416|NCT02339428|randomized controlled trial
118417|NCT02339402|Cystic fibrosis, Myotonic dystrophy, Noonan, Huntingtons
118418|NCT02339363|mindfulness
118419|NCT02339363|adolescents
118420|NCT02339363|working memory
118421|NCT02339363|stress
118422|NCT02339363|anxiety
118423|NCT02339311|The study focus is on lifestyle changes and patient activation in diabetic patients by regular monthly visit by the CHRs
118424|NCT02339298|Music Therapy
118425|NCT02339285|tACS
118426|NCT02339285|Major Depressive Disorder
118427|NCT02339285|MDD
118428|NCT02339285|mood symptoms
118429|NCT02339285|sham
118430|NCT02339272|meiosis
118431|NCT02339272|synapsis
118432|NCT02339272|recombination
118433|NCT02339272|sperm aneuploidy
118434|NCT02339259|Rickettsial disease
118435|NCT02339259|Febrile
118436|NCT02339259|Murine typhus
118437|NCT02339259|Scrub typhus
118438|NCT02339259|Diagnostic test
118439|NCT02339259|Clinical features
118440|NCT02339233|Epidural Stimulation
118441|NCT02339220|Constraint-Induced Movement Therapy
118442|NCT02339220|Physical Therapy
118443|NCT02339220|Rehabilitation
118444|NCT02339220|Occupational Therapy
118445|NCT02339220|Fitness Training
118446|NCT02339220|Recovery of Function
118447|NCT02339220|Neuroplasticity
118448|NCT02339220|Exercise Therapy
118449|NCT02339220|Brain Injuries
118450|NCT02339220|Traumatic Brain Injury
118451|NCT02339220|Physical Therapy Modalities
118452|NCT02339220|Neuroimaging
118453|NCT02339194|complete denture
118454|NCT02339194|quality of life
118455|NCT02339194|patient satisfaction
118456|NCT02339155|Anthrax Vaccine Adsorbed
118457|NCT02339155|Raxibacumab
118458|NCT02339155|Immunogenicity
118459|NCT02339103|arteriovenous anastomoses
118460|NCT02339103|accidental hypothermia
118461|NCT02339103|rewarming
118462|NCT02339090|VRS-317
118463|NCT02339090|Growth Hormone Deficiency
118464|NCT02339090|Long Acting Recombinant Growth Hormone
118465|NCT02339090|Long Acting Growth Hormone
118466|NCT02339090|Pediatric Growth Hormone Deficiency
118467|NCT02339090|Growth Hormone Replacement Therapy
118468|NCT02339090|Versartis
118469|NCT02339090|Xten
118470|NCT02339090|Human Growth Hormone
118471|NCT02339090|somavaratan
118472|NCT02339090|growth failure
118473|NCT02339077|Group B Streptococcus, stillborn
118474|NCT02339064|Parkinson's disease,
118475|NCT02339064|apomorphine
118476|NCT02339064|Apokyn
118477|NCT02339064|dopamine agonist
118478|NCT02339064|levodopa
118479|NCT02339064|advanced
118480|NCT02339064|PD
118481|NCT02339064|carbidopa
118482|NCT02339064|pramipexole
118483|NCT02339064|ropinirole
118484|NCT02339064|rotigotine
118485|NCT02339064|MAO-B inhibitors
118486|NCT02339064|COMT inhibitors
118487|NCT02339064|off
118488|NCT02339064|dyskinesia
118489|NCT02339051|Basic Science
118490|NCT02339038|Community Based Research
118491|NCT02339038|Hepatitis C Virus and Human Immunodeficiency Virus
118492|NCT02339038|Ledipasvir/Sofosbuvir
118493|NCT02339038|Fixed Dose Combination
118494|NCT02339038|Sustained Viral Response
118495|NCT02339025|Cohort
118496|NCT02339025|Participation
118497|NCT02339025|Biobank
118498|NCT02339012|Genome Wide Association
118499|NCT02339012|Biomarkers
118500|NCT02339012|Methylation
118501|NCT02339012|Phenotype
118502|NCT02339012|Cytometry
118503|NCT02338999|Autoimmunity Pathogenesis
118504|NCT02338999|Arteriosclerosis
118505|NCT02338999|Adult
118506|NCT02338986|High Titer Antibodies
118507|NCT02338986|Convalescent Volunteers
118508|NCT02338986|Apheresis
118509|NCT02338986|Males
118510|NCT02338986|Quantitative IgG
118511|NCT02338973|Macular Edema
118512|NCT02338973|Rod-Cone Dystrophy
118513|NCT02338973|Inherited Retinal Degeneration
118514|NCT02338973|Enhanced S-Cone Syndrom
118515|NCT02338973|Interferon Gamma
118516|NCT02338960|HSDD Female
118517|NCT02338960|Sexual Desire Disorder
118518|NCT02338960|decreased desire
118519|NCT02338960|female sexual dysfunction
118520|NCT02338947|Frailty
118521|NCT02338947|Cardiopulmonary Bypass
118522|NCT02338947|Coronary artery bypass surgery
118523|NCT02338947|Mortality
118524|NCT02338947|Morbidity
118525|NCT02338921|triple combination therapy
118526|NCT02338921|sitagliptin
118527|NCT02338921|dapagliflozin
118528|NCT02338921|lobeglitazone
118529|NCT02338908|dry needling
118530|NCT02338908|trigger point
118531|NCT02338908|eccentric exercise
118532|NCT02338895|acute kidney injury, oliguria,renal ultrasound
118533|NCT02338882|Lenses
118534|NCT02338882|Intraocular
118535|NCT02338856|Obesity
118536|NCT02338830|Twins
118537|NCT02338830|Preterm labor
118538|NCT02338830|Progesterone
118539|NCT02338830|Short cervix
118540|NCT02338804|mix vaccine, breast neoplasms, immunotherapy
118541|NCT02338778|mix vaccine, liver neoplasms, immunotherapy
118542|NCT02338752|mix vaccine, pancreatic neoplasms, immunotherapy
118543|NCT02338739|Retention
118544|NCT02338739|Lost to follow up
118545|NCT02338739|Adaptive strategies
118546|NCT02338739|Dynamic regime
118547|NCT02338739|Sequentially randomized trial
118548|NCT02338739|Sequential multiple assignment randomized trial
118549|NCT02338739|Engagement in care
118550|NCT02338739|Kenya
118551|NCT02338726|urinary incontinence
118552|NCT02338726|pelvic floor
118553|NCT02338726|quality of life
118554|NCT02338726|elderly women
118555|NCT02338713|Drug therapy
118556|NCT02338700|mix vaccine, prostate carcinoma, immunotherapy
118557|NCT02338687|Calcium
118558|NCT02338687|Dietary supplements
118559|NCT02338687|Hypertension, Pregnancy-Induced
118560|NCT02338687|Pre-Eclampsia
118561|NCT02338687|Nutritional education
118562|NCT02338687|Diet therapy
118563|NCT02338687|Diet records
118564|NCT02338687|Hospitalization
118565|NCT02338687|Maternal mortality
118566|NCT02338635|ER stress
118567|NCT02338635|Peritoneal Dialysis
118568|NCT02338622|olaparib
118569|NCT02338622|AZD5363
118570|NCT02338622|intrapatient dose escalation
118571|NCT02338622|advanced solid tumours
118572|NCT02338609|TSC-associated SEGA,
118573|NCT02338609|height,
118574|NCT02338609|weight,
118575|NCT02338609|Tanner Stage,
118576|NCT02338609|growth development,
118577|NCT02338609|everolimus,
118578|NCT02338609|RAD001
118579|NCT02338557|MRP, MIRROR THERAPY, STROKE
118580|NCT02338518|gastric cancer
118581|NCT02338518|neoadjuvant chemotherapy
118582|NCT02338518|efficacy
118583|NCT02338518|safety
118584|NCT02338505|Robotic Surgery
118585|NCT02338505|Telelap-ALFX
118586|NCT02338505|Gynecological disease
118587|NCT02338453|Social Anxiety
118588|NCT02338453|Attention Modification
118589|NCT02338453|Dot-Probe
118590|NCT02338453|GCBT
118591|NCT02338362|Corticosteroids
118592|NCT02338362|Bronchodilator Agents
118593|NCT02338362|Intraocular Pressure
118594|NCT02338323|Hyperuricemia
118595|NCT02338323|Renal Function
118596|NCT02338323|Chronic kidney disease
118597|NCT02338323|Febuxostat
118598|NCT02338323|Benzbromarone
118599|NCT02338297|Hepatocellular Carcinoma
118600|NCT02338297|Arterioportal shunts
118601|NCT02338297|Transarterial Chemoembolization
118602|NCT02338297|Ethanol
118603|NCT02338297|Gelfoam
118604|NCT02338297|Polyvinyl Alcohol Foam Embolization Particles (PVA)
118605|NCT02338284|increased intracranial pressure
118606|NCT02338284|optic nerve sheath diameter
118607|NCT02338271|Low back pain
118608|NCT02338271|Mesenchymal stromal stem cell
118609|NCT02338271|Hyaluronic acid
118610|NCT02338219|postpartum pelvic floor
118611|NCT02338206|infertility
118612|NCT02338193|GDM
118613|NCT02338193|T2DM
118614|NCT02338193|prediabetes
118615|NCT02338180|dental caries
118616|NCT02338180|risk assessment
118617|NCT02338180|approximal sealant
118618|NCT02338180|permanent molar
118619|NCT02338180|preventive dentistry
118620|NCT02338180|adolescent
118621|NCT02338154|Aortic Valve Replacement
118622|NCT02338154|Aortic Stenosis
118623|NCT02338154|EDWARDS INTUITY
118624|NCT02338141|cervical cancer
118625|NCT02338141|colposcopy
118626|NCT02338141|human papillomavirus
118627|NCT02338141|human immunodeficiency virus
118628|NCT02338128|peritoneal dialysis
118629|NCT02338128|hyperuricemia
118630|NCT02338128|cardiovascular
118631|NCT02338128|Febuxostat
118632|NCT02338089|Uterine contraction
118633|NCT02338089|Oxytocin desensitization
118634|NCT02338063|Adolescent Risk Behavior
118635|NCT02338063|Emotion Regulation
118636|NCT02338063|Health Promotion
118637|NCT02338063|Intervention
118638|NCT02338063|Mental Health
118639|NCT02338050|ALL
118640|NCT02338050|Moxetumomab Pasudotox
118641|NCT02338050|Moxe
118642|NCT02338050|CAT-8015, HA22
118643|NCT02338024|Enrollment in HIV care
118644|NCT02338024|Recently detected HIV-positive
118645|NCT02338024|specialized health care clinics
118646|NCT02338024|Ukraine
118647|NCT02337998|Neurology
118648|NCT02337998|Sports Medicine
118649|NCT02337972|diabetic macular edema
118650|NCT02337972|Intravitreal injection
118651|NCT02337972|conjunctival flora
118652|NCT02337959|Healthy Volunteers
118653|NCT02337946|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, First-line
118654|NCT02337933|Metabolic Syndrome
118655|NCT02337933|Central Obesity
118656|NCT02337933|Insulin Sensitivity
118657|NCT02337933|Ursolic Acid
118658|NCT02337933|Triterpenoid
118659|NCT02337894|Protein kinetics
118660|NCT02337894|liver steatosis
118661|NCT02337868|dose-ranging,double blind,female,healthy,HydroVax,male,Placebo-Controlled,Vaccine,West Nile Virus
118662|NCT02337855|Intestinal
118663|NCT02337855|Pichia pastoris
118664|NCT02337855|S. mansoni
118665|NCT02337855|Schistosomiasis
118666|NCT02337855|Sm-TSP-2/Alhydrogel
118667|NCT02337855|Sm-TSP-2/Alhydrogel/GLA-AF
118668|NCT02337855|vaccine
118669|NCT02337842|NoV, CIN-1, GII4. Norovirus, challenge, FUT-2 gene, HBGA-blocking Ab
118670|NCT02337829|CLL
118671|NCT02337829|SLL
118672|NCT02337829|Btk
118673|NCT02337829|Chronic Lymphocytic Leukemia
118674|NCT02337829|Small Lymphocytic Lymphoma
118675|NCT02337829|Leukemia
118676|NCT02337829|Lymphoma
118677|NCT02337829|Lymphocytic
118678|NCT02337829|ACP-196
118679|NCT02337829|acalabrutinib
118680|NCT02337816|Endometriosis
118681|NCT02337816|Metabolomics
118682|NCT02337803|Physical Activity
118683|NCT02337790|Hypertension
118684|NCT02337790|Heart Failure
118685|NCT02337790|Fluids
118686|NCT02337777|Magnetic Resonance Imaging
118687|NCT02337777|Magnetic Resonance Angiography
118688|NCT02337777|Diffusion Tensor Imaging
118689|NCT02337777|IDEAL
118690|NCT02337777|T2* mapping
118691|NCT02337777|Magnetic ResonanceCine
118692|NCT02337777|BOLD
118693|NCT02337777|phase contrast
118694|NCT02337777|diffusion-weighted imaging
118695|NCT02337777|Functional Magnetic Resonance Imaging
118696|NCT02337712|Small cell lung cancer
118697|NCT02337712|Radiotherapy
118698|NCT02337712|Dose fractionation
118699|NCT02337686|Keytruda
118700|NCT02337686|pembrolizumab
118701|NCT02337686|immune effector function
118702|NCT02337686|pembrolizumab monotherapy
118703|NCT02337686|ex vivo T-cell-specific cytokines profiling
118704|NCT02337686|immune effector Tcell:Treg ratio
118705|NCT02337686|immunological changes
118706|NCT02337686|immune response
118707|NCT02337673|Postoperative Pulmonary Complication
118708|NCT02337673|Electrical Impedance Tomography
118709|NCT02337673|Splenectomy
118710|NCT02337673|Gastric surgery
118711|NCT02337673|Gastrectomy
118712|NCT02337673|Pancreatic surgery
118713|NCT02337673|Pancreatectomy
118714|NCT02337673|Liver surgery
118715|NCT02337673|Hemihepatectomy
118716|NCT02337673|Cholecystectomy
118717|NCT02337673|Acute Respiratory Distress Syndrome
118718|NCT02337673|Hypoxemia
118719|NCT02337673|Atelectasis
118720|NCT02337673|Pulmonary obstruction
118721|NCT02337673|Pneumonia
118722|NCT02337673|Pneumothorax
118723|NCT02337673|Pleural effusion
118724|NCT02337673|Pulmonary edema
118725|NCT02337621|sunken chest
118726|NCT02337621|caved-in chest
118727|NCT02337621|chest deformity
118728|NCT02337621|sunken sternum
118729|NCT02337608|moderate to severe ulcerative colitis
118730|NCT02337608|GLPG1205
118731|NCT02337595|CD45RA-depletion
118732|NCT02337595|TCR-alpha/beta depletion
118733|NCT02337595|Hematopoietic Stem Cell Transplantation
118734|NCT02337595|immune reconstitution
118735|NCT02337595|Graft Enhancement, Immunologic
118736|NCT02337595|Immunocompromized Host
118737|NCT02337491|Recurrent
118738|NCT02337452|Hereditary cancer-causing mutation
118739|NCT02337452|Gene mutation
118740|NCT02337452|Family member with genetic mutation
118741|NCT02337452|Questionnaire
118742|NCT02337452|Surveys
118743|NCT02337452|Registry
118744|NCT02337452|Database
118745|NCT02337452|Communication
118746|NCT02337413|Constipation
118747|NCT02337374|Urodynamics
118748|NCT02337374|Midurethral sling
118749|NCT02337374|Transobturator tape (TOT)
118750|NCT02337374|Tension free vaginal tape (TVT)
118751|NCT02337361|risky alcohol use
118752|NCT02337361|pregnancy
118753|NCT02337348|coronary stents
118754|NCT02337335|Hemodialyisis
118755|NCT02337335|Predictive Model
118756|NCT02337335|ESAs
118757|NCT02337335|patients
118758|NCT02337322|Acquired Immune Deficiency Syndrome Virus
118759|NCT02337322|HIV
118760|NCT02337322|HIV-1
118761|NCT02337322|Antiretroviral treatment
118762|NCT02337322|HIV Advanced Disease
118763|NCT02337322|AIDS
118764|NCT02337322|Dolutegravir
118765|NCT02337322|Darunavir
118766|NCT02337296|Motivational Interviewing
118767|NCT02337296|Cognitive Behavioral Therapy
118768|NCT02337296|Cancer
118769|NCT02337296|Oral Agents
118770|NCT02337296|Adherence
118771|NCT02337270|Tuberculosis
118772|NCT02337270|Vaccine
118773|NCT02337270|Aerosol
118774|NCT02337270|Adenovirus
118775|NCT02337270|Immunogenicity
118776|NCT02337244|Osteoarthritis
118777|NCT02337244|Rheumatoid arthritis
118778|NCT02337244|Traumatic arthritis
118779|NCT02337244|Polyarthritis
118780|NCT02337244|Total knee arthroplasty
118781|NCT02337192|Orthodontic, Photochemoterapy
118782|NCT02337166|alveolar bone loss
118783|NCT02337166|periodontal attachment loss
118784|NCT02337153|Orthodontique Bone Stretching
118785|NCT02337140|TAVI
118786|NCT02337140|complete AV-block
118787|NCT02337140|HV-interval
118788|NCT02337140|permanent pacemaker
118789|NCT02337140|valve implantation
118790|NCT02337140|severe
118791|NCT02337140|conduction
118792|NCT02337140|disorders
118793|NCT02337114|Acceptance and Commitment Therapy
118794|NCT02337101|Brain concussion
118795|NCT02337101|Mild Traumatic Brain Injury
118796|NCT02337101|Post-concussion symptoms
118797|NCT02337101|Therapy
118798|NCT02337101|Randomised controlled trial
118799|NCT02337101|Cognitive assessment
118800|NCT02337088|delayed cord clamping
118801|NCT02337075|condition
118802|NCT02337075|preventing
118803|NCT02337075|physical activity
118804|NCT02337049|Preeclampsia. Cardiovascular Disease (CVD) Risk.
118805|NCT02337036|Liver transplantation
118806|NCT02337036|Child
118807|NCT02337036|Tacrolimus
118808|NCT02337036|Pharmacokinetic
118809|NCT02337023|Brain scintigraphy
118810|NCT02336997|skin regeneration
118811|NCT02336997|mechanical stretch
118812|NCT02336984|Ductal carcinoma in situ (DCIS)
118813|NCT02336958|cervical plexus
118814|NCT02336958|regional anesthesia
118815|NCT02336958|ultrasound
118816|NCT02336958|carotid surgery
118817|NCT02336932|vitamin d
118818|NCT02336932|free hormone
118819|NCT02336932|surgical stress
118820|NCT02336919|discharge
118821|NCT02336919|mHealth
118822|NCT02336919|telehealth
118823|NCT02336919|text messaging
118824|NCT02336906|Lower urinary tract dysfunction
118825|NCT02336906|constipation
118826|NCT02336893|Communication Barriers
118827|NCT02336893|Total Communication Methods
118828|NCT02336893|Quality Improvement
118829|NCT02336893|Quality of Health Care
118830|NCT02336893|Critical Care
118831|NCT02336867|Complex anal fistula, clip,
118832|NCT02336854|pharmacokinetics
118833|NCT02336841|Guided Self-Help
118834|NCT02336841|Peer Mentoring
118835|NCT02336841|Anorexia Nervosa
118836|NCT02336841|Eating Disorders
118837|NCT02336828|MEWS
118838|NCT02336828|deteriorate
118839|NCT02336828|oncology
118840|NCT02336828|ICU
118841|NCT02336828|predicting outcomes
118842|NCT02336828|MEWS in predicting outcomes in oncology patients
118843|NCT02336815|Multiple myeloma
118844|NCT02336815|Karyopharm
118845|NCT02336815|KPT-330
118846|NCT02336815|Selinexor
118847|NCT02336815|Refractory
118848|NCT02336815|Bortezomib
118849|NCT02336815|Carfilzomib
118850|NCT02336815|Lenalidomide
118851|NCT02336815|Pomalidomide
118852|NCT02336815|Dexamethasone
118853|NCT02336815|STORM
118854|NCT02336815|CD38
118855|NCT02336802|Anxiety
118856|NCT02336802|Fear
118857|NCT02336802|Avoidance
118858|NCT02336776|Chronic Kidney Disease
118859|NCT02336776|Electrical Stimulation
118860|NCT02336737|breast cancer
118861|NCT02336737|sentinel lymph node biopsy
118862|NCT02336724|gastrointestinal stromal tumor
118863|NCT02336724|famitinib
118864|NCT02336698|Osteoarthritis
118865|NCT02336698|Pain
118866|NCT02336698|Fulranumab
118867|NCT02336698|JNJ-42160443
118868|NCT02336698|Monotherapy
118869|NCT02336698|Hip
118870|NCT02336698|Knee
118871|NCT02336698|Joint replacement surgery
118872|NCT02336685|Osteoarthritis
118873|NCT02336685|Pain
118874|NCT02336685|Fulranumab
118875|NCT02336685|JNJ-42160443
118876|NCT02336685|Adjunctive therapy
118877|NCT02336685|Opioid
118878|NCT02336685|Hip
118879|NCT02336685|Knee
118880|NCT02336685|Joint replacement surgery
118881|NCT02336672|Pancreatic adenocarcinoma
118882|NCT02336672|Cryothermoablation
118883|NCT02336633|Huntington disease
118884|NCT02336633|Neurodegenerative disease
118885|NCT02336633|Volumetric MRI
118886|NCT02336633|31P MR spectroscopy
118887|NCT02336633|metabolism
118888|NCT02336633|Caudate atrophy
118889|NCT02336620|Severe sepsis, Balanced Salt Solution, Normal Saline
118890|NCT02336581|Acceptance and Commitment Therapy
118891|NCT02336581|Mindfulness
118892|NCT02336581|Inpatients
118893|NCT02336581|Psychiatric Hospitalization
118894|NCT02336568|PTSD, Oxytocin
118895|NCT02336542|diagnosis of Tuberculosis
118896|NCT02336542|ESAT6
118897|NCT02336542|CFP10
118898|NCT02336542|skin test
118899|NCT02336542|diagnostic test
118900|NCT02336529|postoperative
118901|NCT02336477|non-dystrophic myotonias
118902|NCT02336477|paramyotonia congenita
118903|NCT02336477|myotonia congenita
118904|NCT02336477|Mexiletine
118905|NCT02336477|Randomized clinical trial
118906|NCT02336451|ALK-positive
118907|NCT02336451|NSCLC
118908|NCT02336451|brain metastasis
118909|NCT02336451|metastatic to the brain and/or to leptomeninges.
118910|NCT02336425|Asthma
118911|NCT02336412|Medication adherence
118912|NCT02336399|HBsAg loss, interferon, HBV reaction
118913|NCT02336386|Bortezomib
118914|NCT02336373|Hemoglobin SC disease
118915|NCT02336373|hydroxyurea
118916|NCT02336373|quality of life
118917|NCT02336373|viscosity
118918|NCT02336373|red cell density
118919|NCT02336347|Pharmacokinetics
118920|NCT02336347|Healthy Volunteers
118921|NCT02336347|deuterated dextromethorphan
118922|NCT02336347|deuterated dextromethorphan with quinidine
118923|NCT02336282|Adult survivor of acute lymphoblastic leukemia
118924|NCT02336282|Executive dysfunction
118925|NCT02336282|Transcranial direct current stimulation
118926|NCT02336282|Cancer prevention and control
118927|NCT02336269|Pharmacogenomics
118928|NCT02336256|inguinal hernia repair
118929|NCT02336256|totally extraperitoneal (TEP)
118930|NCT02336256|single incision laparoscopic surgery (SILS)
118931|NCT02336256|plasma total antioxidant status
118932|NCT02336243|docosahexaenoic acid
118933|NCT02336243|premature birth
118934|NCT02336243|placentation disorders
118935|NCT02336243|preeclampsia
118936|NCT02336243|fetal growth
118937|NCT02336230|GVHD
118938|NCT02336191|living donor liver transplantation
118939|NCT02336191|graft function
118940|NCT02336191|thromboelastometry
118941|NCT02336165|Glioblastoma
118942|NCT02336165|Immunotherapy
118943|NCT02336165|T Cell
118944|NCT02336165|PD-L1
118945|NCT02336165|MEDI4736
118946|NCT02336165|Radiation
118947|NCT02336165|Radiotherapy
118948|NCT02336165|GBM
118949|NCT02336100|Diagnostic technique and procedure
118950|NCT02336074|HIV
118951|NCT02336074|Vaccine
118952|NCT02336074|Cure
118953|NCT02336074|Early Intervention
118954|NCT02336074|Infection
118955|NCT02336074|Primary infection
118956|NCT02336074|Reservoir
118957|NCT02336074|Vorinostat
118958|NCT02336074|HDAC
118959|NCT02336022|general anesthesia
118960|NCT02336009|wrist arthritis
118961|NCT02336009|total wrist arthroplasty
118962|NCT02335970|Pain
118963|NCT02335970|Range of motion
118964|NCT02335970|Quality of life
118965|NCT02335944|non small cell lung cancer,
118966|NCT02335944|NSCLC,
118967|NCT02335944|EGF816,
118968|NCT02335944|INC280,
118969|NCT02335944|tyrosine kinase inhibitor,
118970|NCT02335944|c-MET
118971|NCT02335918|Opdivo®
118972|NCT02335866|Platelet rich fibrin
118973|NCT02335866|Gingival Recession
118974|NCT02335853|urinary bladder
118975|NCT02335853|nerve growth factor
118976|NCT02335853|overactive bladder
118977|NCT02335827|irreversible electroporation
118978|NCT02335827|renal tumor
118979|NCT02335801|heart failure
118980|NCT02335801|growth hormone
118981|NCT02335801|testosterone
118982|NCT02335801|insulin resistance
118983|NCT02335801|thyroid hormones
118984|NCT02335801|survival
118985|NCT02335788|Therapeutic
118986|NCT02335788|Embolization
118987|NCT02335736|infertility
118988|NCT02335684|Heart-assist devices
118989|NCT02335684|exercise capacity
118990|NCT02335671|Early Stage Breast Cancer
118991|NCT02335671|Breast Conserving Surgery
118992|NCT02335671|Breast Cancer Stage I
118993|NCT02335671|Breast Cancer Stage II
118994|NCT02335645|ACL reconstruction
118995|NCT02335645|Running Mechanics
118996|NCT02335645|Physical Therapy
118997|NCT02335645|Knee
118998|NCT02335645|Video Analysis
118999|NCT02335645|Body Weight Supported Treadmill
119000|NCT02335632|Hepatitis
119001|NCT02335632|Probiotics
119002|NCT02335632|Lipopolysaccharides
119003|NCT02335632|Cytokines
119004|NCT02335632|Alcoholics
119005|NCT02335593|Hemodialysis patients
119006|NCT02335593|Zinc
119007|NCT02335593|Anemia
119008|NCT02335593|Oxidative stress
119009|NCT02335580|Prognosis
119010|NCT02335554|Subthreshold
119011|NCT02335554|Employees
119012|NCT02335554|Internet
119013|NCT02335554|Mobile
119014|NCT02335554|cognitive-behavioral
119015|NCT02335515|Gastroretentive System
119016|NCT02335515|Gastric Retention Time (GRT)
119017|NCT02335515|capsule
119018|NCT02335515|Soctec
119019|NCT02335515|Gastroenterology
119020|NCT02335476|optical coherence tomography
119021|NCT02335463|optical coherence tomography
119022|NCT02335450|exercise
119023|NCT02335450|motivational interviewing
119024|NCT02335424|P-D1
119025|NCT02335424|PD-1
119026|NCT02335424|PD1
119027|NCT02335424|P-DL1
119028|NCT02335424|PD-L1
119029|NCT02335424|PDL-1
119030|NCT02335424|PDL1
119031|NCT02335424|Bladder cancer
119032|NCT02335411|Gastric cancer
119033|NCT02335411|Gastroesophageal junction cancer
119034|NCT02335411|PD1
119035|NCT02335411|PDL1
119036|NCT02335398|methadone
119037|NCT02335398|chronic pain
119038|NCT02335398|noncancer pain
119039|NCT02335398|cancer pain
119040|NCT02335398|QTc prolongation
119041|NCT02335372|Cervical cancer
119042|NCT02335372|Cervical neoplasia
119043|NCT02335372|Cervical cancer screening
119044|NCT02335372|Colposcopy
119045|NCT02335372|Wide-field white light imaging
119046|NCT02335372|Wide-field fluorescence imaging
119047|NCT02335372|Acetic acid
119048|NCT02335372|Proflavine solution
119049|NCT02335333|Delayed Graft Function
119050|NCT02335333|Slow Graft Function
119051|NCT02335333|Renal Transplant
119052|NCT02335333|Extended Criteria Donor
119053|NCT02335333|Biomarker of Aging
119054|NCT02335333|Kidney Transplant
119055|NCT02335320|VHC
119056|NCT02335320|IL28-B
119057|NCT02335320|point of care
119058|NCT02335307|Pain
119059|NCT02335307|CYP2D6
119060|NCT02335294|Pain
119061|NCT02335294|abdominoplasty
119062|NCT02335294|PCA
119063|NCT02335281|Standardized Fecal Microbiota Transplantation
119064|NCT02335281|Inflammatory Bowel Disease
119065|NCT02335281|Ulcerative Colitis
119066|NCT02335281|Crohn's Disease
119067|NCT02335268|MDS classified as IPSS low/int-1
119068|NCT02335242|Sildenafil
119069|NCT02335242|Magnetic Resonance Imaging
119070|NCT02335242|Dermatology
119071|NCT02335242|Pediatrics
119072|NCT02335190|Sacroiliac joint
119073|NCT02335190|Radiofrequency ablation
119074|NCT02335190|Ultrasound
119075|NCT02335177|Falls
119076|NCT02335177|Elderly
119077|NCT02335177|Physical activities
119078|NCT02335177|Technologies for autonomy
119079|NCT02335177|Impact of intervention
119080|NCT02335177|autonomy
119081|NCT02335177|physical activity program
119082|NCT02335151|Circulating Tumor Cells
119083|NCT02335151|Anesthesia and immunity
119084|NCT02335151|Cell Search System
119085|NCT02335138|HIV
119086|NCT02335138|MSM
119087|NCT02335138|Couples
119088|NCT02335138|Home Testing
119089|NCT02335138|Sexual Agreements
119090|NCT02335112|irreversible electroporation
119091|NCT02335112|Unresectable Head and Neck Neoplasms
119092|NCT02335099|hemodialysis
119093|NCT02335099|vascular access
119094|NCT02335099|vascular access patency
119095|NCT02335099|ticagrelor
119096|NCT02335099|brilinta
119097|NCT02335073|Prognosis
119098|NCT02335060|cannabis
119099|NCT02335060|Marijuana
119100|NCT02335060|THC
119101|NCT02335060|N-acetylcysteine
119102|NCT02335060|Psychotic Disorders
119103|NCT02335047|reliability
119104|NCT02335047|clinical test
119105|NCT02335047|physical therapy
119106|NCT02335034|Osteoarthritis
119107|NCT02335034|Knee
119108|NCT02335034|Education
119109|NCT02335034|Quality of life
119110|NCT02335034|Treatment outcome
119111|NCT02335034|Musculoskeletal pain
119112|NCT02334995|solitery rectal ulcer
119113|NCT02334995|biofeedback
119114|NCT02334995|dissynergy
119115|NCT02334982|Drug therapy
119116|NCT02334969|ischemic stroke；Naoxintong Capsule
119117|NCT02334956|MRI
119118|NCT02334956|Executive Deficits
119119|NCT02334943|Immune Activation
119120|NCT02334943|HIV-1 infected subjects
119121|NCT02334943|Undetectable viral load
119122|NCT02334943|Causes of Immune Activation in HIV-1 infected patients
119123|NCT02334943|Forms of Immune Activation
119124|NCT02334943|Emergent non-AIDS related comorbidities
119125|NCT02334930|propranolol
119126|NCT02334930|betablocker
119127|NCT02334930|angiogenesis
119128|NCT02334917|Suture Comparison
119129|NCT02334891|congestive heart failure
119130|NCT02334891|heart failure, diastolic
119131|NCT02334891|heart failure, systolic
119132|NCT02334891|elderly frail
119133|NCT02334891|guideline adherence
119134|NCT02334878|Stem Cells
119135|NCT02334878|Mesenchymal
119136|NCT02334826|multivessel coronary artery disease
119137|NCT02334826|revascularization
119138|NCT02334826|bioresorbable vascular scaffold
119139|NCT02334826|percutaneous coronary intervention
119140|NCT02334826|coronary artery bypass grafting
119141|NCT02334800|Palbociclib, PD-0332991, Hepatic Impairment
119142|NCT02334761|Biopsy
119143|NCT02334735|Melanoma
119144|NCT02334735|Immunotherapy
119145|NCT02334735|DC Vaccine
119146|NCT02334735|Adjuvant Therapy
119147|NCT02334735|Immunogenicity
119148|NCT02334696|Vascular Access
119149|NCT02334683|Comparison
119150|NCT02334683|Botulinum toxin treatments
119151|NCT02334683|Ultrasound
119152|NCT02334683|Electrophysiologic
119153|NCT02334683|Spasticity
119154|NCT02334683|Focal dystonia
119155|NCT02334670|cryptococcal meningitis
119156|NCT02334670|HIV
119157|NCT02334670|AIDS
119158|NCT02334670|Fluconazole
119159|NCT02334657|non-aneurysmal
119160|NCT02334644|Treatment
119161|NCT02334644|Natural Health Product
119162|NCT02334644|Anxiety
119163|NCT02334592|the effect of tanning
119164|NCT02334592|vitamin D production
119165|NCT02334579|Radiation
119166|NCT02334579|Stereotactic Radiosurgery
119167|NCT02334579|Radiotherapy
119168|NCT02334579|Prostate Tumor
119169|NCT02334579|Prostate Surgery
119170|NCT02334579|CyberKnife
119171|NCT02334566|PTSD
119172|NCT02334566|Refugee children mental health
119173|NCT02334566|community health care
119174|NCT02334553|COPD
119175|NCT02334553|Chronic bronchitis
119176|NCT02334553|Cystic fibrosis
119177|NCT02334553|Bronchoconstriction
119178|NCT02334553|Perfluorocarbons
119179|NCT02334553|Carbon dioxide
119180|NCT02334527|metastatic urothelial carcinoma (UC)
119181|NCT02334527|LCCC 1406
119182|NCT02334527|Lineberger
119183|NCT02334527|palbociclib
119184|NCT02334514|Influenza
119185|NCT02334514|Viral shedding
119186|NCT02334514|oseltamivir
119187|NCT02334514|Polymerase Chain Reaction
119188|NCT02334501|Healthy Volunteers
119189|NCT02334462|Assays
119190|NCT02334462|Antibody
119191|NCT02334462|Reactogenicity
119192|NCT02334462|Mosquito
119193|NCT02334462|Responses
119194|NCT02334449|healthy volunteers
119195|NCT02334410|fractures
119196|NCT02334410|immobilisation
119197|NCT02334410|paraplegia
119198|NCT02334410|tetraplegia
119199|NCT02334397|Prenatal Exercise
119200|NCT02334397|Prenatal Education
119201|NCT02334397|Pregnancy
119202|NCT02334397|Exercise and Birth Outcomes
119203|NCT02334397|Education and Birth Outcomes
119204|NCT02334397|Maternal Quality of Life
119205|NCT02334397|Birth Satisfaction
119206|NCT02334371|Magnetic Resonance Imaging
119207|NCT02334371|Positron-Emission Tomography
119208|NCT02334332|Caregiver
119209|NCT02334293|Omegaven
119210|NCT02334293|parenteral nutrition
119211|NCT02334293|liver disease
119212|NCT02334293|liver injury
119213|NCT02334280|Community mental health
119214|NCT02334280|Health coach
119215|NCT02334280|Weight loss
119216|NCT02334280|Fitness
119217|NCT02334280|Serious mental illness
119218|NCT02334280|Health promotion
119219|NCT02334254|safety
119220|NCT02334254|rivaroxaban
119221|NCT02334254|ticagrel
119222|NCT02334254|triple antithrombotic regimen
119223|NCT02334254|undergoing PCI
119224|NCT02334241|Sorbact
119225|NCT02334241|Best local Cares
119226|NCT02334241|DFU
119227|NCT02334202|Adolescent
119228|NCT02334202|Obesity/Psychology
119229|NCT02334202|Loss of Control Eating
119230|NCT02334202|Child
119231|NCT02334202|Female
119232|NCT02334202|Follow-Up Studies
119233|NCT02334202|Health Behavior
119234|NCT02334202|Health Education
119235|NCT02334202|Humans
119236|NCT02334202|Intervention Studies
119237|NCT02334202|Prospective Studies
119238|NCT02334202|Psychotherapy
119239|NCT02334202|Risk Factors
119240|NCT02334202|Weight Loss
119241|NCT02334202|Weight Gain
119242|NCT02334202|Military
119243|NCT02334163|Hepatic Encephalopathy
119244|NCT02334163|Nitazoxanide
119245|NCT02334163|Serum ammonia
119246|NCT02334150|combined spinal-epidural analgesia
119247|NCT02334150|pelvic floor muscle
119248|NCT02334150|postpartum electrophysiological function
119249|NCT02334111|Parenting Support for Mothers in Recovery
119250|NCT02334111|Neonatal Abstinence Syndrome
119251|NCT02334111|Social Determinants of Health
119252|NCT02334111|Child Development
119253|NCT02334111|Child Abuse
119254|NCT02334111|Child Neglect
119255|NCT02334111|Primary Care
119256|NCT02334098|Aggression
119257|NCT02334098|Omega-3 supplementation
119258|NCT02334098|Neurocognition
119259|NCT02334098|Attention
119260|NCT02334098|Antisocial
119261|NCT02334059|opioid sparing
119262|NCT02334059|ketamine
119263|NCT02334059|obese
119264|NCT02334059|magnesium
119265|NCT02334046|tracheal extubation
119266|NCT02334046|remifentanil
119267|NCT02334033|hypertension
119268|NCT02334033|blood pressure
119269|NCT02334033|cystatin C
119270|NCT02334033|real-life
119271|NCT02334033|kidney
119272|NCT02334020|Mental illness
119273|NCT02334020|training
119274|NCT02334020|support
119275|NCT02334020|Mental Health
119276|NCT02334007|venous thromboembolism prophylaxis
119277|NCT02334007|deep vein thrombosis
119278|NCT02334007|pulmonary embolism
119279|NCT02334007|lung resection
119280|NCT02334007|low molecular weight heparin
119281|NCT02333968|Cancer pain
119282|NCT02333968|Self-management
119283|NCT02333968|Randomized controlled trial
119284|NCT02333942|Aging
119285|NCT02333942|Diagnostic Equipment
119286|NCT02333929|rivaroxaban
119287|NCT02333929|NOAC
119288|NCT02333929|anti-Xa activity
119289|NCT02333929|method comparison
119290|NCT02333929|LCMS
119291|NCT02333903|Obesity
119292|NCT02333903|Sleeve gastrectomy
119293|NCT02333903|Personalized physical activity program
119294|NCT02333903|Body Composition
119295|NCT02333903|Fat mass
119296|NCT02333903|Lean mass
119297|NCT02333890|breast
119298|NCT02333851|Type 2 diabetes mellitus treatment
119299|NCT02333851|Hospitalized patients
119300|NCT02333838|Cord Cell Transplantation
119301|NCT02333838|High risk myeloid malignancies
119302|NCT02333799|Tuberculosis
119303|NCT02333799|MDR-TB
119304|NCT02333799|XDR-TB
119305|NCT02333799|Multi-drug resistant
119306|NCT02333799|Extensively drug resistant
119307|NCT02333799|Bedaquiline
119308|NCT02333799|PA-824
119309|NCT02333799|Linezolid
119310|NCT02333799|TB
119311|NCT02333799|Pretomanid
119312|NCT02333799|TMC-207
119313|NCT02333799|NiX-TB
119314|NCT02333773|irreversible electroporation
119315|NCT02333773|Portal venous tumor emboli
119316|NCT02333734|Type 2 diabetes
119317|NCT02333734|Interval training
119318|NCT02333734|Insulin resistance
119319|NCT02333734|fat metabolism
119320|NCT02333721|Stomach Neoplasms
119321|NCT02333721|Laparoscopy
119322|NCT02333695|SCI, Spinal Cord Injury, Stroke
119323|NCT02333669|Lung fluid absorption disorders
119324|NCT02333669|Neonatal respiratory distress syndrome
119451|NCT02332902|Everolimus
119325|NCT02333669|Single nucleotide polymorphism
119326|NCT02333669|SCNN1A
119327|NCT02333630|asthma
119328|NCT02333617|Manual Therapy
119329|NCT02333617|Physical Therapy
119330|NCT02333617|Dry Needling
119331|NCT02333617|Gluteus Medius
119332|NCT02333604|cancer
119333|NCT02333604|cancer survivor ship
119334|NCT02333604|psychosocial needs
119335|NCT02333604|cancer experience
119336|NCT02333604|metastatic breast cancer
119337|NCT02333604|multiple myeloma
119338|NCT02333604|chronic myeloid leukemia
119339|NCT02333604|breast cancer
119340|NCT02333604|Prostate
119341|NCT02333604|Colon
119342|NCT02333604|Kidney
119343|NCT02333604|Lung
119344|NCT02333604|Melanoma
119345|NCT02333604|Caregiver
119346|NCT02333552|Frailty
119347|NCT02333552|Pre-frailty
119348|NCT02333552|Fit
119349|NCT02333552|Robust
119350|NCT02333552|Elderly
119351|NCT02333552|Sociodemography status
119352|NCT02333552|Functional status
119353|NCT02333552|Cognitive status
119354|NCT02333552|Nutrition status
119355|NCT02333552|Comorbidity
119356|NCT02333552|Mortality
119357|NCT02333552|Depression status
119358|NCT02333526|ulcerative colitis
119359|NCT02333526|Clostidium difficile-associated colitis
119360|NCT02333526|Syndecan-1
119361|NCT02333526|biomarker
119362|NCT02333474|mix vaccine, lung neoplasms, immunotherapy
119363|NCT02333435|Prostatectomy
119364|NCT02333435|Omega-3 fatty acids
119365|NCT02333435|Quality of life
119366|NCT02333435|inflammation
119367|NCT02333435|cellular proliferation
119368|NCT02333422|NIRS Neurofeedback
119369|NCT02333422|Attention Deficit Hyperactivity Disorder
119370|NCT02333422|Near Infrared Spectroscopy
119371|NCT02333422|ADHD
119372|NCT02333409|Cancer of pancreas
119373|NCT02333409|Acupuncture
119374|NCT02333409|Pain
119375|NCT02333396|Navigator
119376|NCT02333396|Intervention Study
119377|NCT02333396|Randomized Controlled Trial
119378|NCT02333396|Pediatric Intensive Care Unit
119379|NCT02333396|Decision Making
119380|NCT02333383|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score
119381|NCT02333383|EAMs
119382|NCT02333383|Adalimumab
119383|NCT02333370|Advanced breast cancer
119384|NCT02333370|Hormone receptor positive
119385|NCT02333370|HER2-negative
119386|NCT02333370|LEE011,
119387|NCT02333370|Letrozole
119388|NCT02333370|Tamoxifen
119389|NCT02333370|Fulvestrant
119390|NCT02333370|Postmenopausal Asian women
119391|NCT02333370|Pre and Postmenopausal Japanese women
119392|NCT02333344|prosthetic fixation
119393|NCT02333331|Sarcopenia, muscle wasting, elderly, strength, physical function, muscle, gait speed
119394|NCT02333305|Ataxia with Oculomotor Apraxia type 1
119395|NCT02333305|CoQ10
119396|NCT02333305|hypoalbuminemia
119397|NCT02333266|Candida bloodstream infection
119398|NCT02333266|Detection fungal cells
119399|NCT02333266|Fiber-Optic Surface Plasmon Resonance (FO-SPR)
119400|NCT02333253|poor responders
119401|NCT02333253|GnRH antagonist
119402|NCT02333253|Conventional protocol
119403|NCT02333240|Pregnancy
119404|NCT02333240|Postnatal Care
119405|NCT02333240|Blood Pressure Monitoring, Home
119406|NCT02333240|Self Care
119407|NCT02333240|Pregnancy Complications, Cardiovascular
119408|NCT02333240|Qualitative Research
119409|NCT02333240|Antihypertensive Agents
119410|NCT02333214|Virtual Reality Therapy
119411|NCT02333214|Video Game
119412|NCT02333214|Physical Exercise
119413|NCT02333214|Aged
119414|NCT02333214|Frailty
119415|NCT02333201|Deglutition Disorders
119416|NCT02333201|Dysphagia
119417|NCT02333201|Mechanical Ventilation
119418|NCT02333201|Sepsis
119419|NCT02333175|Parkinson's disease, Late stage
119420|NCT02333149|Melatonin
119421|NCT02333071|HSDD
119422|NCT02333071|Female Sexual Desire Disorder
119423|NCT02333058|ALL
119424|NCT02333058|AML
119425|NCT02333058|MDS
119426|NCT02333058|JMML
119427|NCT02333045|HIV-negative
119428|NCT02333045|Women
119429|NCT02333045|At-risk
119430|NCT02333019|risk
119431|NCT02333006|Anosognosia
119432|NCT02332993|FPP (Fermented Papaya Preparation)
119433|NCT02332993|Negative Pressure Therapy
119434|NCT02332993|Wound Vac
119435|NCT02332993|Wound
119436|NCT02332993|Type II Diabetic
119437|NCT02332954|Depression
119438|NCT02332954|Major Depressive Disorder
119439|NCT02332954|Cognition
119440|NCT02332954|Cognitive symptoms
119441|NCT02332954|vortioxetine
119442|NCT02332954|real life
119443|NCT02332954|naturalistic
119444|NCT02332915|apraxia
119445|NCT02332915|aphasia
119446|NCT02332915|rehabilitation
119447|NCT02332915|efficacy
119448|NCT02332915|intensity
119449|NCT02332902|Neurofibroma
119450|NCT02332902|NF-1
119452|NCT02332902|mTOR inhibitor
119453|NCT02332863|Pancreatic cancer
119454|NCT02332863|Image guided radiation therapy
119455|NCT02332863|Fiducial marker placement
119456|NCT02332863|Endoscopic ultrasound
119457|NCT02332850|Relapsed
119458|NCT02332850|Refractory
119459|NCT02332837|informed consent, public led trials, shared decision making,
119460|NCT02332824|Pharmacological therapy
119461|NCT02332798|Multiple ascending doses
119462|NCT02332798|safety
119463|NCT02332798|tolerability
119464|NCT02332798|pharmacokinetics
119465|NCT02332798|cognitive impairment associated with schizophrenia (CIAS)
119466|NCT02332785|Colon Serrated Polyps
119467|NCT02332785|Serrated polyp
119468|NCT02332785|Hyperplastic polyps above sigmoid colon
119469|NCT02332785|Sessile serrated adenoma
119470|NCT02332785|Traditional serrated adenoma
119471|NCT02332785|Colonoscopy
119472|NCT02332785|Endoscopy
119473|NCT02332785|Data collection
119474|NCT02332785|Data review
119475|NCT02332772|Colon Polyps
119476|NCT02332772|Large polyps
119477|NCT02332772|Flat lesions
119478|NCT02332772|Endoscopy
119479|NCT02332772|Colonoscopic resection
119480|NCT02332772|Colonoscopy
119481|NCT02332772|Data review
119482|NCT02332772|Data collection
119483|NCT02332668|PD1
119484|NCT02332668|PD-1
119485|NCT02332668|PDL1
119486|NCT02332668|PD-L1
119487|NCT02332655|Sturge-Weber syndrome
119488|NCT02332655|SWS
119489|NCT02332655|Drug resistant epilepsy
119490|NCT02332629|Glucocorticoid
119491|NCT02332629|Endothelial barrier
119492|NCT02332629|Glycocalyx
119493|NCT02332629|Knee arthroplasty, total
119494|NCT02332616|Glucocorticoid
119495|NCT02332616|Complement activation
119496|NCT02332616|Knee arthroplasty, total
119497|NCT02332603|Glucocorticoid
119498|NCT02332603|Glucose homeostasis
119499|NCT02332603|Knee arthroplasty, total
119500|NCT02332603|Hip arthroplasty, total
119501|NCT02332564|Circulation, Collateral
119502|NCT02332564|Coronary Artery Disease
119503|NCT02332564|Internal Mammary-Coronary Artery Anastomosis
119504|NCT02332564|Ischemia
119505|NCT02332538|LASER
119506|NCT02332538|PROSTATE
119507|NCT02332538|BIPOLAR
119508|NCT02332538|HYPERPLASIA
119509|NCT02332538|VAPORIZATION
119510|NCT02332525|Oral Vibrational Stimulation
119511|NCT02332525|Cognitive Function
119512|NCT02332525|Mild Cognitive Impairment
119513|NCT02332525|cognitive normal elderly
119514|NCT02332512|Non-squamous non-small cell lung cancer
119515|NCT02332512|Wild-type EGFR
119516|NCT02332512|3rd/4th line treatment
119517|NCT02332512|apatinib
119518|NCT02332499|Anlotinib
119519|NCT02332499|Metastatic Colorectal Cancer （mCRC）
119520|NCT02332499|ALTER0703
119521|NCT02332447|Tonic-clonic seizures
119522|NCT02332447|Naloxone
119523|NCT02332447|SUDEP
119524|NCT02332421|canine retraction
119525|NCT02332421|acceleration of tooth movement
119526|NCT02332421|dentoalveolar distraction osteogenesis
119527|NCT02332408|vertebral hemangioma
119528|NCT02332408|conventional radiotherapy
119529|NCT02332408|Cyber Knife radiotherapy
119530|NCT02332408|randomized trial
119531|NCT02332408|radioablation
119532|NCT02332395|pain
119533|NCT02332395|pain catastrophizing
119534|NCT02332395|cesarean section
119535|NCT02332369|Cataract
119536|NCT02332356|Crohn Disease
119537|NCT02332356|Inflammatory Bowel Diseases
119538|NCT02332356|Disease Attributes
119539|NCT02332343|Retina
119540|NCT02332343|Retinal pigment epithelium
119541|NCT02332317|Advanced cancer
119542|NCT02332317|Early integration
119543|NCT02332317|Palliative rehabilitation
119544|NCT02332304|Respiratory Distress Syndrome, Newborn
119545|NCT02332291|Depression
119546|NCT02332291|Geriatrics
119547|NCT02332291|Elderly
119548|NCT02332291|MRI
119549|NCT02332291|Antidepressants
119550|NCT02332278|Cesarean section
119551|NCT02332278|Early feeding
119552|NCT02332265|Food Security
119553|NCT02332265|Microfinance
119554|NCT02332265|Village Savings and Loans
119555|NCT02332265|HIV
119556|NCT02332265|Quasi-experimental design
119557|NCT02332265|Malawi
119558|NCT02332265|Structural intervention
119559|NCT02332252|Surgical Wound Infection
119560|NCT02332252|Electrocautery
119561|NCT02332252|Scalpel
119562|NCT02332239|depression
119563|NCT02332239|violence
119564|NCT02332239|emergency department
119565|NCT02332239|text message
119566|NCT02332239|mhealth
119567|NCT02332213|Volatile organic compounds
119568|NCT02332213|Nanosensor technology
119569|NCT02332213|GC-MS
119570|NCT02332213|Breath-testing
119571|NCT02332213|Digestive cancer
119572|NCT02332213|Precancerous lesions
119573|NCT02332213|Colorectal cancer
119574|NCT02332213|Adenoma
119575|NCT02332213|Gastric cancer
119576|NCT02332213|Atrophic gastritis
119577|NCT02332213|OLGIM
119578|NCT02332200|Spondylolysis
119579|NCT02332200|Spondylolisthesis
119580|NCT02332200|Low Back Pain
119581|NCT02332174|pharmacokinetics
119582|NCT02332174|food effect
119583|NCT02332174|sex effect
119584|NCT02332174|tolerability
119585|NCT02332135|microwave ablation
119586|NCT02332135|maintenance hemodialysis
119587|NCT02332135|mild-to-moderate Secondary Hyperparathyroidism
119588|NCT02332122|COPD
119589|NCT02332122|Chronic Obstructive Pulmonary Disease
119590|NCT02332122|Aspergillus fumigatus
119591|NCT02332122|Bronchiectasis
119592|NCT02332122|Sensitization
119593|NCT02332122|Vitamin D
119594|NCT02332109|Fuchs endothelial dystrophy
119595|NCT02332109|oedema
119596|NCT02332109|sodium chloride
119597|NCT02332109|hyaluronan
119598|NCT02332109|sodium hyaluronate
119599|NCT02332070|acute kidney injury
119600|NCT02332070|coronary angiography
119601|NCT02332070|cardiac surgery
119602|NCT02332070|adverse events
119603|NCT02332070|iodinated contrast
119604|NCT02332070|Thoracic Surgery
119605|NCT02332057|IUD,Diclofenac , Lidocaine
119606|NCT02332031|Sorafenib, levothyroxine, drug interaction, pharmacokinetics, healthy volunteer
119607|NCT02331992|Continuous Positive Airway Pressure
119608|NCT02331966|FGF-23
119609|NCT02331966|GROWTH FACTORS RECEPTORS
119610|NCT02331966|RECURRENCES
119611|NCT02331953|spine surgery
119612|NCT02331953|cerebral oximetry
119613|NCT02331953|postoperative delirium
119614|NCT02331940|Chronic obstructive pulmonary disease
119615|NCT02331940|sleeping oxygen saturation
119616|NCT02331940|sleep quality
119617|NCT02331927|colorectal cancer
119618|NCT02331927|marker-driven
119619|NCT02331927|bevacizumab
119620|NCT02331927|aflibercept
119621|NCT02331927|cytokines
119622|NCT02331927|angiogenic factors
119623|NCT02331927|CAF
119624|NCT02331914|GIST
119625|NCT02331914|Bio-databank
119626|NCT02331862|urinary tract infection
119627|NCT02331862|methylprednisolone
119628|NCT02331849|Eosinophilic esophagitis (EoE)
119629|NCT02331849|GERD
119630|NCT02331849|esophageal motility
119631|NCT02331836|adenoma detection rate
119632|NCT02331836|polyp detection rate
119633|NCT02331836|withdrawal time
119634|NCT02331836|coecal and ileum intubation rate
119635|NCT02331797|endoscope
119636|NCT02331797|microscope
119637|NCT02331797|transcanal
119638|NCT02331719|intracerebral hemorrhage
119639|NCT02331719|subcortical intracerebral hemorrhage
119640|NCT02331719|ICH
119641|NCT02331719|parafascicular minimally invasive subcortical access
119642|NCT02331693|EGFR
119643|NCT02331693|CAR T cells
119644|NCT02331693|glioma
119645|NCT02331680|Undergoing Hemodialysis
119646|NCT02331680|Undergoing Hemodiafiltration
119647|NCT02331667|Diet
119648|NCT02331667|Vitamin-D
119649|NCT02331667|Meat
119650|NCT02331667|Fatty fish
119651|NCT02331667|Iodine
119652|NCT02331667|fatty acid
119653|NCT02331667|Intervention study
119654|NCT02331667|Wechsler Preschool and Primary Scale of Intelligence
119655|NCT02331667|Strengths and Difficulties Questionnaire
119656|NCT02331667|Nine hole peg test
119657|NCT02331654|Chronic pain
119658|NCT02331654|Direct Current Stimulation
119659|NCT02331641|hepatectomy
119660|NCT02331641|hepatic resection
119661|NCT02331628|TBI Traumatic Brain Injury
119662|NCT02331628|HO Heterotopic Ossification
119663|NCT02331628|NHO Neurogenic Heterotopic Ossification
119664|NCT02331628|ESWT Extracorporeal Shock Wave Therapy
119665|NCT02331615|Traumatic Brain Injury
119666|NCT02331615|Executive function difficulties
119667|NCT02331615|Transcranial direct current stimulation
119668|NCT02331602|atrial fibrillation
119669|NCT02331602|anticoagulation
119670|NCT02331602|inflammation
119671|NCT02331589|Fatigue
119672|NCT02331589|Panax ginseng
119673|NCT02331589|Chronic hepatitis
119674|NCT02331589|Non-alcoholic Fatty Liver Disease
119675|NCT02331589|Adiponectin
119676|NCT02331563|dexmedetomidine
119677|NCT02331550|Low-Grade Squamous Intraepithelial Lesions
119678|NCT02331524|exercise
119679|NCT02331524|daily activity
119680|NCT02331485|Prevention of wound infection and wound complication
119681|NCT02331472|interstitial cystitis
119682|NCT02331472|biomarker
119683|NCT02331459|mood
119684|NCT02331459|cognitive state
119685|NCT02331459|physical activity
119686|NCT02331459|frailty
119687|NCT02331394|Chinese herbs
119688|NCT02331394|lung cancer
119689|NCT02331394|quality of life
119690|NCT02331355|amputation, hand, forearm, arm, traumatic, transplantation
119691|NCT02331342|Agreement of NICOM and Innocor
119692|NCT02331329|Accuracy of NICOM
119693|NCT02331329|precision of NICOM
119694|NCT02331316|obesity
119695|NCT02331316|diet
119696|NCT02331316|weight
119697|NCT02331316|hunger
119698|NCT02331316|public led trial
119699|NCT02331264|Cardiac Toxicity
119700|NCT02331264|Metal on Metal Hip Implants
119701|NCT02331186|Obesity
119702|NCT02331186|Bariatric surgery
119703|NCT02331186|Urinary incontinence
119704|NCT02331186|Pelvic floor
119705|NCT02331173|XLRS
119706|NCT02331173|RS1
119707|NCT02331173|maculoschisis
119708|NCT02331160|Pregnancy
119709|NCT02331160|Breech Presentation
119710|NCT02331160|Version, fetal
119711|NCT02331160|Musculoskeletal Manipulations
119712|NCT02331160|Medicine, Traditional
119713|NCT02331134|Tissue
119714|NCT02331134|Hematopoietic Stem Cell
119715|NCT02331134|Melanoma
119716|NCT02331134|Squamous Head and Neck Cancer
119717|NCT02331121|children
119718|NCT02331121|parents
119719|NCT02331121|internet
119720|NCT02331121|video
119721|NCT02331121|training
119722|NCT02331121|interactive
119723|NCT02331082|Infant Mortality
119724|NCT02331082|Under-two mortality
119725|NCT02331082|Maternal Mortality
119726|NCT02331082|Implementation Research
119727|NCT02331082|Health Systems Strengthening
119728|NCT02331082|Chronic Disease Management
119729|NCT02331082|Commuity Health Workers
119730|NCT02331069|radial neuropathy
119731|NCT02331056|Stroke volume variation
119732|NCT02331056|fluid responsiveness
119733|NCT02331056|One-lung ventilation
119734|NCT02331056|thoracotomy
119735|NCT02331030|brachio-axillary
119736|NCT02331030|brachio-basilic
119737|NCT02331030|interfascial plane block
119738|NCT02331030|Pecs II block
119739|NCT02331030|supraclavicular brachial plexus block
119740|NCT02331017|Bimodal
119741|NCT02331017|Cochlear Implant
119742|NCT02331017|Hearing aid
119743|NCT02331017|Auditory Perception
119744|NCT02331004|Frail Elderly
119745|NCT02331004|Motor Skills
119746|NCT02331004|Upper Extremity
119747|NCT02330991|glioblastoma
119748|NCT02330991|relapse
119749|NCT02330991|Temozolomide
119750|NCT02330991|glioblastoma at first relapse
119751|NCT02330965|clinical research
119752|NCT02330965|mechanistic studies
119753|NCT02330965|blood draw
119754|NCT02330965|CSF by lumbar puncture (optional)
119755|NCT02330952|Double-blind method
119756|NCT02330952|Randomized Controlled trials
119757|NCT02330939|Postprandial glycemia
119758|NCT02330939|Momounsaturated fatty acids
119759|NCT02330939|Saturated fatty acids
119760|NCT02330939|Glycemic index
119761|NCT02330939|Glycemic load
119762|NCT02330939|Sensor augmented pump system
119763|NCT02330926|Combined modality treatment
119764|NCT02330926|Diet therapy
119765|NCT02330926|Exercise therapy
119766|NCT02330926|Ibuprofen
119767|NCT02330926|Dietary supplements
119768|NCT02330913|total gastrectomy
119769|NCT02330913|intracorporeal
119770|NCT02330913|totally laparoscopic
119771|NCT02330913|esophagojejunostomy
119772|NCT02330913|anastomosis
119773|NCT02330900|Implantable cardioverter defibrillator
119774|NCT02330900|Electromagnetic interference
119775|NCT02330900|Cell phone
119776|NCT02330887|Maternal Mortality
119777|NCT02330887|Institutional Birth Rate
119778|NCT02330887|Neonatal Mortality Rate
119779|NCT02330887|Preterm Birth
119780|NCT02330887|Stillbirth
119781|NCT02330887|Infant, Small for Gestational Age
119782|NCT02330887|Nepal
119783|NCT02330887|Implementation Research
119784|NCT02330887|Global Health
119785|NCT02330874|Risk
119786|NCT02330874|score
119787|NCT02330874|readmission
119788|NCT02330874|ICU
119789|NCT02330861|Coronary Circulation
119790|NCT02330848|Obesity
119791|NCT02330848|Walnuts
119792|NCT02330848|Endothelial Function
119793|NCT02330848|Adults at risk
119794|NCT02330835|school
119795|NCT02330835|bus
119796|NCT02330835|school bus
119797|NCT02330835|driver
119798|NCT02330835|training
119799|NCT02330835|behavior
119800|NCT02330835|management
119801|NCT02330835|interactive
119802|NCT02330835|computer
119803|NCT02330809|headache
119804|NCT02330809|hunger intensity
119805|NCT02330809|public led online trial
119806|NCT02330809|water intake
119807|NCT02330783|Metastatic Renal Cell Carcinoma
119808|NCT02330783|Third-line treatment
119809|NCT02330783|Sorafenib
119810|NCT02330783|Bevacizumab
119811|NCT02330770|GnRHa trigger
119812|NCT02330770|Luteal phase support
119813|NCT02330770|OHSS
119814|NCT02330757|Frozen-thawed embryo transfer
119815|NCT02330757|FET protocols
119816|NCT02330705|Intrauterine insemination
119817|NCT02330705|IUI
119818|NCT02330705|HCG
119819|NCT02330679|Major Depression, Neuroimaging, Desvenlafaxine, Machine learning
119820|NCT02330653|Colitis
119821|NCT02330653|Fecal Microbiota Transplant
119822|NCT02330653|Ulcerative colitis
119823|NCT02330653|inflammatory bowel disease
119824|NCT02330640|CABG
119825|NCT02330640|antiplatelet therapy
119826|NCT02330640|ticagrelor
119827|NCT02330614|personality
119828|NCT02330614|bleaching
119829|NCT02330588|Obesity
119830|NCT02330588|Prevention
119831|NCT02330588|Pediatric
119832|NCT02330588|Parents
119833|NCT02330588|Primary Care
119834|NCT02330588|eHealth
119835|NCT02330588|Internet
119836|NCT02330562|Marizomib
119837|NCT02330562|Bevacizumab
119838|NCT02330562|Avastin
119839|NCT02330562|Grade IV malignant glioma
119840|NCT02330562|proteasome inhibitor
119841|NCT02330562|glioblastoma
119842|NCT02330562|brain tumor
119843|NCT02330562|malignant glioma
119844|NCT02330562|brain cancer
119845|NCT02330562|gliosarcoma
119846|NCT02330562|BEV
119847|NCT02330536|Circulatory and Respiratory Physiological Phenomena
119848|NCT02330536|Thoracoscopy
119849|NCT02330510|Alzheimer's Disease
119850|NCT02330510|White Matter Hyperintensities
119851|NCT02330510|Vascular Cognitive Impairment
119852|NCT02330510|Amyloid Imaging
119853|NCT02330510|Transient Ischemic Attack
119854|NCT02330484|Community management， incentives, Medication Adherence
119855|NCT02330471|conization
119856|NCT02330471|LLETZ
119857|NCT02330471|cervical dysplasia
119858|NCT02330471|cervical intraepithelial neoplasia
119859|NCT02330458|Inflammatory Bowel Disease
119860|NCT02330458|Crohn's disease
119861|NCT02330458|Pediatric IBD
119862|NCT02330458|small bowel ultrasound
119863|NCT02330458|infliximab
119864|NCT02330419|Naltrexone
119865|NCT02330406|Dipeptidyl-Peptidase 4 Inhibitors
119866|NCT02330406|LDL Cholesterol
119867|NCT02330406|Glycosylated Hemoglobin
119868|NCT02330406|Diabetes Mellitus
119869|NCT02330406|Coronary Disease
119870|NCT02330380|psoriasis, comparative effects, inflammation
119871|NCT02330354|preschool
119872|NCT02330354|behavior change
119873|NCT02330354|social marketing
119874|NCT02330354|child care providers
119875|NCT02330354|nutrition
119876|NCT02330354|child care centers
119877|NCT02330354|physical activity
119878|NCT02330341|Glucose Intolerance
119879|NCT02330341|Artemisia dracunculus
119880|NCT02330341|Insulin
119881|NCT02330328|Chest Pain
119882|NCT02330328|Telemetry
119883|NCT02330315|transcranial direct current stimulation
119884|NCT02330315|transcranial ultrasound
119885|NCT02330315|non-invasive brain stimulation
119886|NCT02330250|Systemic Lupus Erythematosus
119887|NCT02330250|Pharmaceutical care
119888|NCT02330250|Pharmaceutical services
119889|NCT02330250|Medication adherence
119890|NCT02330224|Blood pressure
119891|NCT02330224|Lipids
119892|NCT02330224|Cardiovascular
119893|NCT02330224|Health services
119894|NCT02330224|Hypertension
119895|NCT02330211|Colitis
119896|NCT02330211|Fecal Microbiota Transplant
119897|NCT02330211|Crohn's Disease
119898|NCT02330211|inflammatory bowel disease
119899|NCT02330198|self-reported outcome instrument
119900|NCT02330185|spinal anesthesia
119901|NCT02330185|ultrasonography
119902|NCT02330185|anatomical landmark
119903|NCT02330159|Pilonidal
119904|NCT02330159|Quality of Life
119905|NCT02330133|mid-life women
119906|NCT02330133|unintended pregnancy
119907|NCT02330133|STI/HIV prevention
119908|NCT02330133|intervention
119909|NCT02330133|interactive
119910|NCT02330133|CD-ROM
119911|NCT02330133|multimedia
119912|NCT02330133|video
119913|NCT02330120|peak airway pressure
119914|NCT02330120|airway resistance
119915|NCT02330120|sedation
119916|NCT02330120|intensive care
119917|NCT02330094|aSAH
119918|NCT02330094|SAH
119919|NCT02330081|pathogen reduction technology
119920|NCT02330081|whole blood
119921|NCT02330081|Platelets
119922|NCT02330081|Mirasol
119923|NCT02330042|Diabetes
119924|NCT02330042|OCT
119925|NCT02330042|Angiography
119926|NCT02330042|Diabetic retinopathy
119927|NCT02330029|Irritable bowel syndrome,
119928|NCT02330029|Pinaverium
119929|NCT02330029|Herbal medication for IBS,
119930|NCT02330029|Tong Xie Yao Fang (Formula for pain and diarrhea)
119931|NCT02330003|Influenza
119932|NCT02330003|Influenza vaccine
119933|NCT02330003|Split influenza vaccine
119934|NCT02330003|Seasonal influenza vaccine
119935|NCT02329990|phosphorus intake
119936|NCT02329977|duodenal-biliary reflux
119937|NCT02329964|Rocuronium
119938|NCT02329964|Sugammadex
119939|NCT02329964|Succinylcholine
119940|NCT02329964|Cisatracurium
119941|NCT02329964|Neostigmine
119942|NCT02329964|acceleromyography (TOF-Watch®)
119943|NCT02329912|postoperative ileus
119944|NCT02329912|SmartPill
119945|NCT02329912|gastrointestinal transit
119946|NCT02329912|prokinetic drugs
119947|NCT02329886|chronic diseases
119948|NCT02329886|risk factors
119949|NCT02329886|health outcomes
119950|NCT02329873|Acute exacerbation of chronic obstructive pulmonary disease
119951|NCT02329873|Older adults
119952|NCT02329873|Respiratory rehabilitation exercise
119953|NCT02329847|Hematologic Neoplasms
119954|NCT02329847|JNJ54179060
119955|NCT02329847|Ibrutinib
119956|NCT02329847|Nivolumab
119957|NCT02329821|lactate
119958|NCT02329821|hartmann solution
119959|NCT02329821|hepatocellular carcinoma
119960|NCT02329808|TDM
119961|NCT02329808|dried blood spot
119962|NCT02329808|immunosuppressive
119963|NCT02329808|antifungal
119964|NCT02329769|Duchenne muscular dystrophy
119965|NCT02329769|DMD
119966|NCT02329769|BioMarin
119967|NCT02329769|PRO044
119968|NCT02329730|diagnosis of Tuberculosis (TB)
119969|NCT02329730|ESAT6
119970|NCT02329730|CFP10
119971|NCT02329730|Phase IIa Clinical Trial
119972|NCT02329704|IUI/AIH
119973|NCT02329704|Semen preparation
119974|NCT02329704|Semen processing
119975|NCT02329704|ICSI/IVF
119976|NCT02329704|ART
119977|NCT02329704|Density Gradient
119978|NCT02329704|Swimming down
119979|NCT02329704|hyaluronan affinity testing
119980|NCT02329704|Sperm vitality testin
119981|NCT02329691|safety climate
119982|NCT02329691|surgery
119983|NCT02329678|Apicomarginal defects
119984|NCT02329678|clinical study/trial
119985|NCT02329678|collagen membrane
119986|NCT02329678|guided tissue regeneration
119987|NCT02329678|endodontic microsurgery
119988|NCT02329652|Neuroprosthesis
119989|NCT02329652|Functional Electrical Stimulation
119990|NCT02329639|bevacizumab
119991|NCT02329639|paclitaxel
119992|NCT02329639|pharmacogenetics
119993|NCT02329639|breast cancer
119994|NCT02329561|Pharmacokinetics
119995|NCT02329561|Opioid
119996|NCT02329561|Geriatric
119997|NCT02329561|Pharmacodynamics
119998|NCT02329548|Alizarin
119999|NCT02329548|Orthostatic
120000|NCT02329548|POTS
120001|NCT02329548|Tilt table testing
120002|NCT02329548|Syncope
120003|NCT02329548|Anxiety
120004|NCT02329522|Haemodynamics
120005|NCT02329522|Chronic obstructive pulmonary disease
120006|NCT02329522|Ultrasonic Cardiac Output Monitor
120007|NCT02329522|severity
120008|NCT02329509|operative procedures
120009|NCT02329483|Infertility
120010|NCT02329483|Ovulation induction
120011|NCT02329483|Low-dose step-up protocol
120012|NCT02329483|Ovarian high responder
120013|NCT02329483|Androgens
120014|NCT02329483|Androstenedione
120015|NCT02329483|Testosterone
120016|NCT02329483|rhFSH
120017|NCT02329457|double-blind, randomized, intradermal, VZVv, HSCT
120018|NCT02329431|child mental health, mental health services, Latino families
120019|NCT02329340|child safety
120020|NCT02329340|injury
120021|NCT02329340|prevention
120022|NCT02329340|computer
120023|NCT02329340|internet
120024|NCT02329327|Factor Xa Inhibitors
120025|NCT02329327|Major
120026|NCT02329327|Bleeding
120027|NCT02329327|Anticoagulant
120028|NCT02329301|malaria
120029|NCT02329301|malaria, falciparum
120030|NCT02329301|antimalarials
120031|NCT02329262|exercise
120032|NCT02329262|mentors
120033|NCT02329262|health education
120034|NCT02329262|obesity
120035|NCT02329249|smoking cessation
120036|NCT02329249|coach-supported
120037|NCT02329249|tobacco use cessation
120038|NCT02329249|online
120039|NCT02329249|internet-based
120040|NCT02329249|tailored
120041|NCT02329223|Chronic spontaneous uriticaria
120042|NCT02329223|Omalizumab
120043|NCT02329197|Infertility
120044|NCT02329197|Invitro fertilization
120045|NCT02329145|renal denervation
120046|NCT02329132|diabetic macular edema
120047|NCT02329132|VEGF
120048|NCT02329132|ranibizumab
120049|NCT02329132|oxygen consumption
120050|NCT02329054|Ebola Virus Disease
120051|NCT02329054|Antivirals
120052|NCT02329054|Mortality
120053|NCT02329054|Viral load
120054|NCT02329054|Proof-of-concept
120055|NCT02329054|Phase II trial
120056|NCT02329054|Guinea
120057|NCT02329054|Adults
120058|NCT02329054|Children
120059|NCT02329041|videolaryngoscope
120060|NCT02329041|double-lumen tube
120061|NCT02329041|intubation
120062|NCT02329028|Emergency Care, Prehospital
120063|NCT02329028|Electroencephalography
120064|NCT02329028|Coma
120065|NCT02329015|stress
120066|NCT02329015|alternative
120067|NCT02329015|complementary
120068|NCT02329015|self-regulation
120069|NCT02329002|Retinoblastoma
120070|NCT02329002|Second primary tumor
120071|NCT02329002|Screening
120072|NCT02329002|Magnetic resonance imaging
120073|NCT02328989|prematurity
120074|NCT02328989|short cervix
120075|NCT02328989|twin pregnancy
120076|NCT02328989|pessary
120077|NCT02328963|Cytomegalovirus infection and disease
120078|NCT02328963|CMV-seropositive recipients
120079|NCT02328963|Everolimus
120080|NCT02328963|preemptive strategy
120081|NCT02328963|mTOR inhibitor
120082|NCT02328898|Polymer free stent
120083|NCT02328898|percutaneous coronary intervention
120084|NCT02328885|high-risk acute leukemia
120085|NCT02328885|graft versus leukemia
120086|NCT02328885|DLI
120087|NCT02328885|UCBT
120088|NCT02328872|screening
120089|NCT02328872|cervical screening
120090|NCT02328872|Human Papillomavirus (HPV)
120091|NCT02328872|cancer prevention
120092|NCT02328859|Gait
120093|NCT02328859|Rehabilitation
120094|NCT02328859|Virtual Reality
120095|NCT02328833|Depression
120096|NCT02328833|Clinical Practice Guideline
120097|NCT02328833|Implementation
120098|NCT02328833|Primary Care
120099|NCT02328833|Computerized Guideline
120100|NCT02328820|Fractional Flow Reserve, Myocardial
120101|NCT02328820|Coronary Flow Reserve
120102|NCT02328807|adenocarcinoma
120103|NCT02328807|prostate
120104|NCT02328807|ENCAGE™
120105|NCT02328807|focal bipolar radiofrequency ablation
120106|NCT02328807|radiofrequency ablation (RFA)
120107|NCT02328807|radiotherapy
120108|NCT02328794|smoking cessation
120109|NCT02328794|behavioral economics
120110|NCT02328794|e-cigarettes
120111|NCT02328794|NRT
120112|NCT02328781|vertebral artery stenosis
120113|NCT02328781|drug-eluting stent
120114|NCT02328703|Reiki
120115|NCT02328703|Neuropathic Pain
120116|NCT02328703|Military Service Members
120117|NCT02328703|Extermity Trauma
120118|NCT02328690|binaural beat technology
120119|NCT02328690|sound technology
120120|NCT02328690|cardiovascular stress response
120121|NCT02328690|military
120122|NCT02328690|music
120123|NCT02328690|anxiety
120124|NCT02328690|stress
120125|NCT02328677|Colorectal cancer
120126|NCT02328677|rectosigmoid
120127|NCT02328677|rectum
120128|NCT02328677|colon
120129|NCT02328664|Endoscopic resection
120130|NCT02328664|Pathology
120131|NCT02328664|Rescue surgery
120132|NCT02328651|Mild and Moderate Severe Patients With hand_foot-mouth Disease
120133|NCT02328638|ASD
120134|NCT02328625|Scleroderma
120135|NCT02328625|Device
120136|NCT02328625|ADRCs
120137|NCT02328625|adipose derived regenerative cells
120138|NCT02328625|hand
120139|NCT02328547|fecal microbiota transplantation
120140|NCT02328547|diarrhea-predominant
120141|NCT02328534|ICSI/IVF
120142|NCT02328534|Semen processing
120143|NCT02328534|Semen preparation
120144|NCT02328534|Swim down
120145|NCT02328534|Density gradient
120146|NCT02328534|Silica solution
120147|NCT02328521|Neointima
120148|NCT02328521|Tomography, Optical Coherence
120149|NCT02328521|drug-eluting stents
120150|NCT02328521|Nicorandil
120151|NCT02328508|hyperbaric oxygen therapy
120152|NCT02328508|diabetic foot ulcer
120153|NCT02328508|wound healing
120154|NCT02328508|inflammation
120155|NCT02328508|glycemic control
120156|NCT02328508|amputation
120157|NCT02328508|bacterial infection
120158|NCT02328508|quality of life
120159|NCT02328495|Misoprostol, Office hysteroscopy ,Pain
120160|NCT02328469|aseptic meningitis
120161|NCT02328469|tick-borne encephalitis
120162|NCT02328469|Lyme neuroborreliosis
120163|NCT02328469|inflammation
120164|NCT02328469|outcome
120165|NCT02328443|CYP3A
120166|NCT02328443|Metabolomics
120167|NCT02328404|Vitamin D
120168|NCT02328404|deficiency
120169|NCT02328404|hypovitaminosis D
120170|NCT02328404|Biodal
120171|NCT02328404|25 hydroxy Vitamin D
120172|NCT02328404|25hydroxyvitamin D
120173|NCT02328404|25(OH)D
120174|NCT02328404|PCOS
120175|NCT02328404|insulin resistance
120176|NCT02328404|BMI
120177|NCT02328404|chromium levels
120178|NCT02328404|vitamin D 3
120179|NCT02328404|cholecalciferol
120180|NCT02328404|50,000 IU
120181|NCT02328365|Colorectal Cancer
120182|NCT02328365|Comorbidity
120183|NCT02328365|Perioperative Care
120184|NCT02328365|Surgery
120185|NCT02328352|Buckypaper (BP) of Multi-Walled Carbon Nanotubes (MWCNTs)
120186|NCT02328352|surgical hernia prosthesis
120187|NCT02328352|abdominal wall defects surgery
120188|NCT02328352|prosthesis adhesion
120189|NCT02328352|disaster preparation and recovery hernia
120190|NCT02328352|Abdominal Wall Disaster Surgery
120191|NCT02328352|Fixation of prosthetic materials in general surgery
120192|NCT02328326|Diabetes
120193|NCT02328326|diabetes self-management
120194|NCT02328326|patient activation
120195|NCT02328326|social support
120196|NCT02328313|Cancer
120197|NCT02328313|Breast Cancer
120198|NCT02328313|Geriatric
120199|NCT02328313|Advance Age
120200|NCT02328313|Exercise
120201|NCT02328313|Physical Activity
120202|NCT02328313|Genetic Marker
120203|NCT02328313|p16
120204|NCT02328313|Chemotherapy
120205|NCT02328313|Breast Cancer Treatment
120206|NCT02328287|Spinal Fusion
120207|NCT02328287|Revision Surgery
120208|NCT02328287|Pseudarthrosis
120209|NCT02328287|Cell Therapy
120210|NCT02328287|Bone Graft
120211|NCT02328235|skeletal muscle, metabolism, physiology
120212|NCT02328222|Early steroid withdrawal
120213|NCT02328222|Acute allograft rejection
120214|NCT02328222|Mycophenolate
120215|NCT02328222|Tacrolimus
120216|NCT02328222|Basiliximab
120217|NCT02328196|Outcome and Process Assessment (Health Care)
120218|NCT02328196|Rasch analysis
120219|NCT02328196|Meal time performance
120220|NCT02328183|polymyxin B
120221|NCT02328183|carbapenem resistant bacteria
120222|NCT02328170|immunoglobulin E, food hypersensitivities, child, allergens
120223|NCT02328144|Hemorrhoidectomy
120224|NCT02328144|Postoperative pain
120225|NCT02328144|Metronidazole
120226|NCT02328118|Lucentis
120227|NCT02328118|Ranibizumab
120228|NCT02328118|Triamcinolone Acetonide
120229|NCT02328118|Vitrectomy
120230|NCT02328118|PDR
120231|NCT02328079|Facial Palsy (acute), Acyclovir, Prednisolone
120232|NCT02328066|NBI
120233|NCT02328066|NICE classification
120234|NCT02328066|deep submucosal invasion
120235|NCT02328066|Colonic Polyps [C23.300.825.411.235]
120236|NCT02328066|Colonoscopy [E01.370.372.250.250.200]
120237|NCT02328053|fungal keratitis
120238|NCT02328053|collagen cross linking
120239|NCT02328040|Diabetes Mellitus, Type 1
120240|NCT02328040|Closed loop
120241|NCT02328040|Artificial Pancreas
120242|NCT02328040|Insulin
120243|NCT02328040|Sitagliptin
120244|NCT02328040|Januvia
120245|NCT02328014|Bruton tyrosine kinase inhibitor
120246|NCT02328014|Btk
120247|NCT02328014|B-Cell Malignancies
120248|NCT02328014|Mantle Cell
120249|NCT02328014|Multiple Myeloma
120250|NCT02328014|CLL
120251|NCT02328014|SLL
120252|NCT02328014|DLBCL
120253|NCT02328014|Folicular
120254|NCT02328014|Waldenstrom
120255|NCT02328014|B-All
120256|NCT02327988|cryotherapy
120257|NCT02327988|laser therapy
120258|NCT02327988|eccentric exercise
120259|NCT02327988|delayed onset muscle soreness
120260|NCT02327988|muscle damage
120261|NCT02327988|dynamometry
120262|NCT02327988|electromyography
120263|NCT02327923|Laparoscopic cholecystectomy
120264|NCT02327923|lidocaine infusion
120265|NCT02327923|Esmolol infusion
120266|NCT02327923|Postoperative opioid consumption
120267|NCT02327923|Multimodal analgesia
120268|NCT02327910|Elderly patients，
120269|NCT02327910|General anesthesia，
120270|NCT02327910|Transcutaneous partial pressure of carbon dioxide(TcPCO2)，
120271|NCT02327910|Train-of-four(TOF)，
120272|NCT02327910|Extubation
120273|NCT02327910|，Respiratory events
120274|NCT02327897|Atopic Asthma
120275|NCT02327897|Exposures
120276|NCT02327897|Disease Progression
120277|NCT02327884|Genetics
120278|NCT02327884|Dry Mouth
120279|NCT02327884|Sjogren's Syndrome
120280|NCT02327884|Gland Dysfuntion
120281|NCT02327884|Induced Pluripotent Stem Cell (iPS) Cell Lines
120282|NCT02327871|Therapeutic hypothermia
120283|NCT02327871|patients
120284|NCT02327871|Safety, Efficacy
120285|NCT02327845|natural history, biomarkers, phenotype, genotype
120286|NCT02327832|Confirmation
120287|NCT02327832|safety
120288|NCT02327793|Perfusion
120289|NCT02327793|Blood pressure
120290|NCT02327767|Active Assistance
120291|NCT02327767|Resonance
120292|NCT02327767|Stroke
120293|NCT02327767|Arm Rehabilitation
120294|NCT02327741|Dual antiplatelet therapy
120295|NCT02327741|clopidogrel
120296|NCT02327741|percutaneous coronary intervention
120297|NCT02327728|blepharospasm
120298|NCT02327728|botulinum A
120299|NCT02327728|injection pattern
120300|NCT02327728|tear
120301|NCT02327715|Hepatitis B virus
120302|NCT02327715|Emtricitabine
120303|NCT02327715|Pregnancy
120304|NCT02327715|Vertical transmission
120305|NCT02327702|Hepatitis B, chronic
120306|NCT02327702|Emtricitabine
120307|NCT02327702|Pregnancy
120308|NCT02327689|Hepatitis B virus
120309|NCT02327689|Cirrhosis
120310|NCT02327689|Emtricitabine
120311|NCT02327689|Adefovir dipivoxil
120312|NCT02327676|Hepatitis B, chronic
120313|NCT02327676|Emtricitabine
120314|NCT02327676|Child
120315|NCT02327663|Hepatitis B, chronic
120316|NCT02327663|Emtricitabine
120317|NCT02327663|Adefovir dipivixil
120318|NCT02327663|HBeAg
120319|NCT02327637|Preterm Premature Rupture of the Membranes
120320|NCT02327637|Bedrest
120321|NCT02327637|Physical Activity
120322|NCT02327585|Executive function training
120323|NCT02327585|child
120324|NCT02327559|childbirth
120325|NCT02327559|mindfulness
120326|NCT02327559|fear of labor
120327|NCT02327559|labor pain
120328|NCT02327559|coping
120329|NCT02327559|self-efficacy
120330|NCT02327559|childbirth satisfaction
120331|NCT02327559|depression
120332|NCT02327546|Pharmacokinetics
120333|NCT02327546|Anemia
120334|NCT02327546|Chronic kidney disease
120335|NCT02327546|CKD
120336|NCT02327546|Chronic renal insufficiency
120337|NCT02327546|Renal impairment
120338|NCT02327546|Ferrous sulfate
120339|NCT02327546|Iron
120340|NCT02327546|Drug-drug interaction
120341|NCT02327546|End stage renal disease
120342|NCT02327546|Dialysis
120343|NCT02327546|Erythropoietin
120344|NCT02327546|Oral anemia treatment
120345|NCT02327546|Hypoxia-induciable factor
120346|NCT02327546|HIF
120347|NCT02327546|Hypoxia-induciable factor prolyl-hydroxylase inhibitor
120348|NCT02327546|HIF-PHI
120349|NCT02327533|generalized aggressive periodontitis
120350|NCT02327533|microarray analysis
120351|NCT02327520|Clostridium difficile infection
120352|NCT02327520|burden
120353|NCT02327520|nationwide study
120354|NCT02327520|South East Asia
120355|NCT02327520|Thailand
120356|NCT02327520|Epidemiology
120357|NCT02327520|Outcome Assessment (Health Care) [N04.761.559.590]
120358|NCT02327507|children
120359|NCT02327507|fluoridated toothpaste
120360|NCT02327507|health education
120361|NCT02327507|Medicaid
120362|NCT02327494|Neuromuscular blockade
120363|NCT02327494|Laparoscopy
120364|NCT02327494|Oxygen measurements
120365|NCT02327481|Stomach Neoplasms Laparoscopy
120366|NCT02327442|chemokine receptor
120367|NCT02327442|galium
120368|NCT02327442|dosimetry
120369|NCT02327442|glioma
120370|NCT02327403|Proteinuria
120371|NCT02327403|Kidney transplantation
120372|NCT02327403|Allograft dysfunction
120373|NCT02327403|B7-1
120374|NCT02327403|Belatacept
120375|NCT02327377|Irritable bowel syndrome
120376|NCT02327377|Intervention studies
120377|NCT02327377|Visceral pain
120378|NCT02327377|Chronic pain
120379|NCT02327377|Abdominal pain
120380|NCT02327377|Dyspepsia
120381|NCT02327377|Nausea
120382|NCT02327377|Nociception
120383|NCT02327377|Parents
120384|NCT02327377|Coping behavior
120385|NCT02327377|Anxiety
120386|NCT02327377|Depression
120387|NCT02327377|Catastrophization
120388|NCT02327377|Reinforcement (psychology)
120389|NCT02327377|Self efficacy
120390|NCT02327377|Health services overutilization
120391|NCT02327377|Questionnaires
120392|NCT02327377|Self report
120393|NCT02327377|Health surveys
120394|NCT02327377|Prospective studies
120395|NCT02327377|Adolescent health
120396|NCT02327377|Mental health services
120397|NCT02327377|Health services accessibility
120398|NCT02327377|Health diaries
120399|NCT02327377|National Institute of Child Health and Human Development (U.S.)
120400|NCT02327377|Telemedicine
120401|NCT02327377|E-Health
120402|NCT02327377|Web-based intervention
120403|NCT02327377|Parenting education
120404|NCT02327325|Low Back Pain
120405|NCT02327325|Exercise
120406|NCT02327325|Cognitive Behavioral Therapy
120407|NCT02327325|Aged
120408|NCT02327299|Iron deficiency
120409|NCT02327299|Iron fortification
120410|NCT02327286|Diabetes Mellitus
120411|NCT02327286|Gestational diabetes
120412|NCT02327273|subjects
120413|NCT02327221|Crohn Disease
120414|NCT02327221|Cell therapy
120415|NCT02327221|Regulatory T lymphocytes
120416|NCT02327221|Treg
120417|NCT02327221|Autologous
120418|NCT02327221|Antigen specific T regulatory lymphocytes
120419|NCT02327208|Military Training
120420|NCT02327208|Whey Protein
120421|NCT02327208|Body Composition
120422|NCT02327182|MT-4666
120423|NCT02327182|α7 nicotinic acetylcholine receptor agonist
120424|NCT02327182|Alzheimer's Disease
120425|NCT02327182|Cognitive function
120426|NCT02327182|Dementia
120427|NCT02327182|Central Nervous System Agents
120428|NCT02327169|Drug therapy
120429|NCT02327156|Dexmedetomidine
120430|NCT02327104|mindfulness
120431|NCT02327104|tobacco dependence
120432|NCT02327104|relapse prevention
120433|NCT02327091|Alfacalcidol
120434|NCT02327091|Falls
120435|NCT02327091|Handgrip
120436|NCT02327091|Muscle strength
120437|NCT02327091|Sarcopenia
120438|NCT02327065|EUS
120439|NCT02327065|FNA
120440|NCT02327065|FNB
120441|NCT02327052|Chagas disease
120442|NCT02327052|longitudinal global strain
120443|NCT02327052|speckle tracking
120444|NCT02327026|Out-of-hospital cardiac arrest
120445|NCT02327026|Bag-valve-mask ventilation
120446|NCT02327026|Tracheal intubation
120447|NCT02326961|osteoarthritis
120448|NCT02326961|knee
120449|NCT02326961|adipose derived regenerative cells
120450|NCT02326961|ADRC
120451|NCT02326961|Celution
120452|NCT02326961|arthritis
120453|NCT02326948|Gallbladder cancer
120454|NCT02326948|Case-control study
120455|NCT02326948|Risk factor
120456|NCT02326948|Alcohol consumption
120457|NCT02326948|Polypoid lesions of gallbladder
120458|NCT02326948|Biliary stone
120459|NCT02326935|MS
120460|NCT02326935|Multiple Sclerosis, Relapsing-Remitting
120461|NCT02326935|Multiple Sclerosis, Chronic Progressive
120462|NCT02326935|Myelitis
120463|NCT02326922|Dysfunctional uterine bleeding
120464|NCT02326922|Metraplant-E
120465|NCT02326922|Levonorgestrel-releasing intrauterine device
120466|NCT02326922|Endometrial decidualization
120467|NCT02326909|Upper Urinary Tract
120468|NCT02326909|Optical Coherence Tomography
120469|NCT02326909|Transitional Cell Carcinoma
120470|NCT02326909|Urothelial Cell Carcinoma
120471|NCT02326909|Diagnostic accuracy
120472|NCT02326896|intubation
120473|NCT02326896|intensive care unit
120474|NCT02326896|MACOCHA Score
120475|NCT02326870|laparoscopic Cholecystectomy
120476|NCT02326870|laparoscope holder
120477|NCT02326870|gynecological laparoscopy procedures
120478|NCT02326870|fundoplication surgery
120479|NCT02326870|laparoscopic adnexal surgery
120480|NCT02326870|excision of endometriosis lesion
120481|NCT02326870|diagnostic laparoscopy procedures
120482|NCT02326870|right hemicolectomy
120483|NCT02326870|Diaphragmatic hernia
120484|NCT02326857|Distribution of Molecular Profiles in Latin American Women
120485|NCT02326857|AJCC 7 Clinical Stage II to III
120486|NCT02326857|Breast Cancer Observational Study
120487|NCT02326857|Prospective Cohort
120488|NCT02326857|Epidemiological, Histological, and Clinical Data
120489|NCT02326844|Germline BRCA1/2 Mutations (gBRCAm)
120490|NCT02326844|DNA Damaging Agents
120491|NCT02326844|FOX03a, 53BP1 and RAD51
120492|NCT02326818|Dystonia
120493|NCT02326818|Botulinum Toxin
120494|NCT02326818|Musician's Dystonia
120495|NCT02326818|Spasticity
120496|NCT02326792|Exercise
120497|NCT02326792|Training
120498|NCT02326792|Low back Pain
120499|NCT02326792|Physical Therapy
120500|NCT02326779|esophageal cancer
120501|NCT02326779|aspirin
120502|NCT02326779|survival
120503|NCT02326740|Pyoderma Gangrenosum
120504|NCT02326740|Classic Pyoderma Gangrenosum
120505|NCT02326727|Epidural Analgesia
120506|NCT02326727|Natural Killer Cells
120507|NCT02326675|Etoposide
120508|NCT02326675|Cryotherapy
120509|NCT02326662|spinal cord injury
120510|NCT02326662|neural stem cells
120511|NCT02326662|paraplegia
120512|NCT02326662|transplantation
120513|NCT02326649|cardiac output
120514|NCT02326610|Small for gestational age (SGA)
120515|NCT02326610|Human growth hormone (hGH)
120516|NCT02326597|Hydroxyurea
120517|NCT02326597|Bone marrow transplant
120518|NCT02326597|Chronic blood transfusion
120519|NCT02326597|Treatment options for sickle cell disease
120520|NCT02326597|Decision making
120521|NCT02326584|Acute Myeloid Leukemia
120522|NCT02326584|Antibody-Drug Conjugate
120523|NCT02326584|CD33 Antigen
120524|NCT02326584|Drug Therapy
120525|NCT02326584|Acute Myelogenous Leukemia
120526|NCT02326571|EEG
120527|NCT02326571|Cortical Spreading Depression
120528|NCT02326571|Cerebral Hemorrhage
120529|NCT02326571|miRNA
120530|NCT02326571|Reactivity in EEG
120531|NCT02326571|Multimodal monitoring
120532|NCT02326558|zero ischemia
120533|NCT02326558|microwave
120534|NCT02326558|ablation
120535|NCT02326558|enucleation
120536|NCT02326558|renal cell carcinoma
120537|NCT02326545|Video Games
120538|NCT02326545|Child
120539|NCT02326545|Adolescent
120540|NCT02326532|Rheumatoid Arthritis
120541|NCT02326532|Veterans
120542|NCT02326506|Extracorporeal Membrane Oxygenation
120543|NCT02326506|Cardiopulmonary Bypass
120544|NCT02326493|Cardiac Resynchronization Therapy
120545|NCT02326493|LV lead position
120546|NCT02326493|Device programming
120547|NCT02326493|Optimization
120548|NCT02326493|Vectorcardiography
120549|NCT02326480|Childhood Obesity
120550|NCT02326480|Genetics
120551|NCT02326467|chlorhexidine
120552|NCT02326467|safety
120553|NCT02326467|bath
120554|NCT02326467|rash
120555|NCT02326467|infant
120556|NCT02326441|advanced malignancies
120557|NCT02326441|refractory therapies
120558|NCT02326441|phase 1
120559|NCT02326428|Stroke
120560|NCT02326428|Cerebrovascular Accident
120561|NCT02326428|Brain ischemia
120562|NCT02326428|Intravenous thrombolysis
120563|NCT02326428|Stroke thrombectomy
120564|NCT02326428|Stent-retriever
120565|NCT02326415|Acute Appendicitis
120566|NCT02326415|Appendectomy
120567|NCT02326415|Fast-Track
120568|NCT02326415|Clinical Pathway
120569|NCT02326402|Circulatory support
120570|NCT02326402|Extracorporeal circulatory support
120571|NCT02326402|Extracorporeal bypass
120572|NCT02326389|Cognitive functioning
120573|NCT02326363|substance abuse
120574|NCT02326363|Mental Health Disorders
120575|NCT02326350|Acute Respiratory Distress syndrome
120576|NCT02326350|Aspirin
120577|NCT02326298|Certolizumab Pegol
120578|NCT02326298|Cimzia
120579|NCT02326298|Psoriasis
120580|NCT02326285|induction therapy
120581|NCT02326285|NSCLC
120582|NCT02326285|Non-small Cell Lung Cancer
120583|NCT02326285|curative surgery
120584|NCT02326272|Certolizumab Pegol
120585|NCT02326272|Cimzia
120586|NCT02326272|Psoriasis
120587|NCT02326259|Diabetic Retinopathy
120588|NCT02326259|Disease Progression
120589|NCT02326246|MRI
120590|NCT02326246|active surveillance
120591|NCT02326207|Infant, Newborn
120592|NCT02326207|Neonatal intensive care unit
120593|NCT02326207|Ventilator circuit
120594|NCT02326194|Safety,immunogenicity,Ebola
120595|NCT02326181|respiratory muscle training
120596|NCT02326181|respiratory muscle strength
120597|NCT02326181|respiratory endurance test
120598|NCT02326181|6-minute walking test
120599|NCT02326142|Premature Obstetric Labor
120600|NCT02326142|Premature Birth
120601|NCT02326103|alcoholic
120602|NCT02326103|hepatitis
120603|NCT02326103|cirrhosis
120604|NCT02326103|cholesterol metabolites
120605|NCT02326103|ciprofloxacin
120606|NCT02326077|sonopartogram
120607|NCT02326077|transperineal ultrasound
120608|NCT02326077|intrapartum ultrasound
120609|NCT02326077|labor
120610|NCT02326077|delivery
120611|NCT02326077|partogram
120612|NCT02326077|ultrasound
120613|NCT02326051|Antiphospholipid syndrome
120614|NCT02326051|APS
120615|NCT02326051|LMWH
120616|NCT02326038|Memory
120617|NCT02326038|Attention
120618|NCT02326038|MCI
120619|NCT02326038|Ritalin
120620|NCT02325999|Endoscopic Submucosal Dissection
120621|NCT02325999|Laparoscopic Regional Lymph node Dissection
120622|NCT02325999|early gastric cancer
120623|NCT02325999|Disease-free survival
120624|NCT02325986|radiotherapy
120625|NCT02325986|esophageal carcinoma
120626|NCT02325986|chemotherapy
120627|NCT02325973|STEMI
120628|NCT02325973|IMR
120629|NCT02325973|FFR
120630|NCT02325973|microcirculatory
120631|NCT02325960|exenatide
120632|NCT02325960|insulin glargine
120633|NCT02325947|Post stroke hand paresis brain injury
120634|NCT02325934|Stribild
120635|NCT02325934|pharmacokinetics
120636|NCT02325934|Crushing
120637|NCT02325934|Drip feed
120638|NCT02325921|Magnetic Resonance Imaging
120639|NCT02325921|Diffusion Weighted MRI
120640|NCT02325921|Diffusion Tensor Imaging
120641|NCT02325908|Hemodialysis
120642|NCT02325908|Estimated Dry Weight
120643|NCT02325895|Osteoporosis
120644|NCT02325895|Dried plum
120645|NCT02325895|functional food
120646|NCT02325869|Acute Coronary Syndrome, Coronary Occlusion, catheter
120647|NCT02325856|Hemodialysis
120648|NCT02325856|Body Composition Monitor
120649|NCT02325830|Functional mitral regurgitation
120650|NCT02325830|Secondary mitral regurgitation
120651|NCT02325830|Percutaneous mitral repair
120652|NCT02325817|The purpose is to observe and evaluate the safety and efficacy of drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.
120653|NCT02325804|overweight and obesity
120654|NCT02325804|adipose tissue
120655|NCT02325804|weight loss program
120656|NCT02325804|low-calorie diet
120657|NCT02325804|circuit-based exercise
120658|NCT02325804|metabolic cardiovascular syndrome
120659|NCT02325765|congential cardiac surgery
120660|NCT02325765|nuclearsome
120661|NCT02325765|systemic inflammation response syndrome
120662|NCT02325752|readmission
120663|NCT02325752|chronic diseases
120664|NCT02325739|FGF401, PDR001, PD-1, FGFR4, FGF19, HCC
120665|NCT02325726|Cardiac surgery
120666|NCT02325726|Extracorporeal circulation
120667|NCT02325726|Renal failure
120668|NCT02325713|ODT-PZQ
120669|NCT02325713|Bio-availability
120670|NCT02325713|Praziquantel
120671|NCT02325713|Cysticide
120672|NCT02325713|Pharmacokinetics
120673|NCT02325687|Obstructive Sleep Apnea
120674|NCT02325687|Arthroplasty, Replacement, Knee
120675|NCT02325687|Cerebrospinal Fluid
120676|NCT02325687|Inflammation
120677|NCT02325687|TNF-alpha
120678|NCT02325687|Interleukin-6 (IL-6)
120679|NCT02325687|Interleukin-8 (IL-8)
120680|NCT02325687|Interleukin-10 (IL-10)
120681|NCT02325687|Cytokines
120682|NCT02325687|Neurotrophins
120683|NCT02325687|BDNF
120684|NCT02325687|Beta-NGF
120685|NCT02325687|Proteomic Analysis
120686|NCT02325674|Lipodystrophy
120687|NCT02325674|Metreleptin Registry
120688|NCT02325635|Adenoma Detection
120689|NCT02325635|Adenoma Prediction
120690|NCT02325596|Chronic rhinosinusitis
120691|NCT02325596|microRNA
120692|NCT02325596|dendritic cell
120693|NCT02325596|helper T cell
120694|NCT02325583|Intraoral 30% glucose, newborn, MRI
120695|NCT02325544|dissociative seizures,
120696|NCT02325544|psychogenic nonepileptic seizures
120697|NCT02325531|implementation strategies
120698|NCT02325531|diabetes mellitus
120699|NCT02325531|cardiovascular disease
120700|NCT02325531|community health centers
120701|NCT02325531|quality improvement
120702|NCT02325531|translational medical research
120703|NCT02325518|Open-angle glaucoma (OAG)
120704|NCT02325518|Ocular hypertension (OHT)
120705|NCT02325518|AZORGA®
120706|NCT02325518|COSOPT®
120707|NCT02325492|bariatric surgery
120708|NCT02325492|NASH
120709|NCT02325492|ARAMCHOL
120710|NCT02325479|Low Molecular Weight (LMWH) Heparin ICSI Enaoxaprin sodium
120711|NCT02325466|Peripheral Artery Disease
120712|NCT02325466|Type 2 Diabetes
120713|NCT02325466|Blood Viscosity
120714|NCT02325466|Ticagrelor
120715|NCT02325466|Aspirin
120716|NCT02325453|Robotic Surgery
120717|NCT02325453|Laparoscopic Surgery
120718|NCT02325453|Minimally Invasive Surgery
120719|NCT02325453|Robotic Gastrectomy
120720|NCT02325453|Laparoscopic Gastrectomy
120721|NCT02325453|Open Gastrectomy
120722|NCT02325453|Gastric Surgery
120723|NCT02325440|RRMS (relapsing remitting multiple sclerosis)
120724|NCT02325440|Cluster of differentiation 49d (CD49d)
120725|NCT02325440|immune function
120726|NCT02325440|disease activity
120727|NCT02325427|stroke
120728|NCT02325427|rehabilitation
120729|NCT02325427|upper limb
120730|NCT02325427|TMS
120731|NCT02325427|tDCS
120732|NCT02325414|Osteoporosis
120733|NCT02325414|Spinal Cord Injury
120734|NCT02325414|Bone Diseases
120735|NCT02325414|Metabolic Bone Diseases
120736|NCT02325414|Musculoskeletal Diseases
120737|NCT02325414|Spinal Cord Diseases
120738|NCT02325414|Central Nervous System Diseases
120739|NCT02325414|Nervous System Diseases
120740|NCT02325414|Nervous System
120741|NCT02325414|Wounds and Injuries
120742|NCT02325414|Bone Density Conservation Agents
120743|NCT02325414|Physiological Effects of Drugs
120744|NCT02325414|Pharmacologic Actions
120745|NCT02325414|Department of Defense
120746|NCT02325388|pressure ulcer
120747|NCT02325388|decubitus ulcer
120748|NCT02325388|bed sore
120749|NCT02325388|continuous pressure mapping
120750|NCT02325388|interface pressure imaging
120751|NCT02325375|Amyotrophic Lateral Sclerosis
120752|NCT02325375|spinal fluid
120753|NCT02325375|CD163
120754|NCT02325362|Cystic fibrosis
120755|NCT02325362|CFTR
120756|NCT02325362|F508del mutation
120757|NCT02325362|Miglustat
120758|NCT02325362|Total Chloride Secretion
120759|NCT02325362|Nasal Potential Difference
120760|NCT02325349|Angiogenesis
120761|NCT02325349|Integrins
120762|NCT02325349|RGD PET/CT
120763|NCT02325349|FDG PET/CT
120764|NCT02325349|Predictive value
120765|NCT02325349|Therapeutic response
120766|NCT02325349|Efficacy
120767|NCT02325349|Tolerability
120768|NCT02325336|Medication Errors
120769|NCT02325336|nurses
120770|NCT02325336|hospital
120771|NCT02325323|stomach cancer
120772|NCT02325323|gastric intestinal metaplasia
120773|NCT02325323|prospective cohort
120774|NCT02325323|low grade dysplasia
120775|NCT02325323|high grade dysplasia
120776|NCT02325323|prognosis factor
120777|NCT02325323|gastric cancer risks
120778|NCT02325310|Vaccine strain excretion in breast milk
120779|NCT02325310|Postpartum vaccination
120780|NCT02325310|Breastfeeding women
120781|NCT02325310|Measles-mumps-rubella vaccine
120782|NCT02325310|Breast milk
120783|NCT02325310|Vaccinology
120784|NCT02325297|Intensive care unit
120785|NCT02325258|Sepsis diagnosis
120786|NCT02325258|Sepsis drug therapy
120787|NCT02325258|Sepsis outcome
120788|NCT02325245|Frailty
120789|NCT02325245|Pre-frailty
120790|NCT02325245|Metformin
120791|NCT02325245|Elderly
120792|NCT02325245|Quality of life
120793|NCT02325245|Handgrip
120794|NCT02325245|Gait speed
120795|NCT02325245|Myostatin
120796|NCT02325219|Psoriasis
120797|NCT02325219|CNTO 1959
120798|NCT02325219|Guselkumab
120799|NCT02325219|Placebo
120800|NCT02325180|ACT
120801|NCT02325180|Plasmodium falciparum
120802|NCT02325180|malaria
120803|NCT02325180|efficacy
120804|NCT02325180|Indonesia
120805|NCT02325167|informal caregivers
120806|NCT02325167|mental stress
120807|NCT02325167|quality of life
120808|NCT02325167|psychotherapeutic intervention
120809|NCT02325128|social anxiety
120810|NCT02325128|exposure therapy
120811|NCT02325128|extinction
120812|NCT02325128|sleep-dependent memory consolidation
120813|NCT02325115|well-being, mental health, schizophrenia, quality of life
120814|NCT02325089|Elderly
120815|NCT02325089|Obstructive Sleep Apnea
120816|NCT02325089|Mandibular advancement oral appliance
120817|NCT02325089|Hypertension
120818|NCT02325089|Cardiovascular disease
120819|NCT02325089|Quality of life
120820|NCT02325076|Airway Management
120821|NCT02325076|intubation
120822|NCT02325076|pulmonary function test
120823|NCT02325050|Healthy
120824|NCT02325050|Ebola viruses
120825|NCT02325050|Ebola Viral Disease (EVD)
120826|NCT02325050|Filoviruses
120827|NCT02325050|monovalent vaccine
120828|NCT02325050|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
120829|NCT02325050|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
120830|NCT02325050|Safety
120831|NCT02325050|Immunogenicity
120832|NCT02325024|Sativex
120833|NCT02325024|GW-1000-02
120834|NCT02325024|Nabiximols
120835|NCT02325024|Pharmacokinetics
120836|NCT02325024|Renal Insufficiency
120837|NCT02325024|Chronic Kidney Failure
120838|NCT02325011|Sativex
120839|NCT02325011|GW-1000-02
120840|NCT02325011|Nabiximols
120841|NCT02325011|Fluconazole
120842|NCT02325011|Pharmacokinetics
120843|NCT02325011|Drug-drug interaction
120844|NCT02324998|Radical Prostatectomy
120845|NCT02324998|Prostate Cancer
120846|NCT02324998|PARP inhibition
120847|NCT02324998|Olaparib
120848|NCT02324998|Degarelix
120849|NCT02324998|Neoadjuvant
120850|NCT02324998|Pharmacodynamics
120851|NCT02324998|Pharmacokinetics
120852|NCT02324998|Biomarkers
120853|NCT02324985|muscle soreness
120854|NCT02324972|Atopic dermatitis
120855|NCT02324972|Eczema
120856|NCT02324972|AD
120857|NCT02324972|AQX-1125
120858|NCT02324972|SHIP1
120859|NCT02324946|Sleep Apnea Syndromes
120860|NCT02324946|Perioperative Period
120861|NCT02324946|Mass Screening
120862|NCT02324920|Syncope
120863|NCT02324920|Closed Loop Stimulation
120864|NCT02324920|CLS
120865|NCT02324894|screening
120866|NCT02324894|MRI
120867|NCT02324881|smartphone
120868|NCT02324881|application
120869|NCT02324881|pain management
120870|NCT02324868|Bandages
120871|NCT02324868|Catheter
120872|NCT02324855|Autogenic drainage
120873|NCT02324855|Positive expiratory pressure
120874|NCT02324855|Airway clearance technique
120875|NCT02324855|Quality of life
120876|NCT02324855|Exacerbations
120877|NCT02324855|Chest physiotherapy
120878|NCT02324829|Total joint replacement
120879|NCT02324829|Physiotherapy
120880|NCT02324829|Kalman filtering
120881|NCT02324829|Kinematic modeling
120882|NCT02324829|Hidden Markov model
120883|NCT02324829|Motion segmentation
120884|NCT02324790|OSA, Oral Pressure Therapy (OPT)
120885|NCT02324764|transradial coronary angiography
120886|NCT02324764|radial artery occlusion
120887|NCT02324764|coronary heart disease
120888|NCT02324764|Glidesheath Slender
120889|NCT02324738|Mefloquine/Dihydroartemisinin-piperaquine
120890|NCT02324738|drug interaction
120891|NCT02324725|naltrexone
120892|NCT02324725|neuroimaging
120893|NCT02324725|heroin
120894|NCT02324725|addiction
120895|NCT02324725|dependence
120896|NCT02324725|opioid
120897|NCT02324725|Vivitrol®
120898|NCT02324725|functional magnetic resonance imaging
120899|NCT02324699|Vedolizumab
120900|NCT02324699|Corticosteroids
120901|NCT02324699|Prednisone
120902|NCT02324699|Crohn's disease
120903|NCT02324686|Warfarin
120904|NCT02324686|International Normalized Ratio
120905|NCT02324686|Vitamin K
120906|NCT02324673|Treatment-resistant seizures
120907|NCT02324660|screening procedure
120908|NCT02324660|peak expiratory flow
120909|NCT02324660|respiratory health screening questionnaire
120910|NCT02324647|Urinary steroid profiling
120911|NCT02324647|Adrenal incidentaloma
120912|NCT02324647|Adrenocortical carcinoma
120913|NCT02324647|cost-effectiveness
120914|NCT02324621|protocol specific
120915|NCT02324595|Ovarian Cancer
120916|NCT02324595|Laparoscopy
120917|NCT02324595|Neoadjuvant Chemotherapy
120918|NCT02324595|Robotic
120919|NCT02324595|Interval Debulking Surgery
120920|NCT02324582|Urinary Bladder Neoplasms
120921|NCT02324582|Mycobacterium bovis
120922|NCT02324582|Programmed Cell Death 1 Receptor
120923|NCT02324582|pembrolizumab
120924|NCT02324569|Pharmacological therapy
120925|NCT02324556|Rectal Cancer
120926|NCT02324556|Surgery
120927|NCT02324556|Laparoscopy
120928|NCT02324517|response to various potential therapies as managed by lab assays
120929|NCT02324478|autonomic nervous system
120930|NCT02324478|heart rate variability
120931|NCT02324478|laparoscopic surgery
120932|NCT02324478|general anesthesia
120933|NCT02324478|photoplethysmography
120934|NCT02324439|ovarian cancer
120935|NCT02324439|flaxseed
120936|NCT02324439|dietary supplement
120937|NCT02324439|organic dietary supplement
120938|NCT02324439|recurrence
120939|NCT02324426|Parkinson's Disease
120940|NCT02324426|Reduced Glutathione
120941|NCT02324426|CNS
120942|NCT02324426|Glutathione
120943|NCT02324426|Uptake
120944|NCT02324426|Intranasal
120945|NCT02324426|(in)GSH
120946|NCT02324387|Breast Cancer
120947|NCT02324387|Molecular breast imaging
120948|NCT02324387|MBI
120949|NCT02324387|Tc99m sestamibi
120950|NCT02324387|Neoadjuvant chemotherapy
120951|NCT02324387|NAC
120952|NCT02324374|colon cancer
120953|NCT02324361|Pediatric
120954|NCT02324361|Obesity
120955|NCT02324361|Intervention
120956|NCT02324361|Information and Communication Technologies
120957|NCT02324361|Social Media
120958|NCT02324361|Text Messaging
120959|NCT02324361|Mobile Health
120960|NCT02324335|Oral Mucositis
120961|NCT02324335|Brilacidin
120962|NCT02324335|Chemoradiation
120963|NCT02324322|Device: Robotic Exoskeleton
120964|NCT02324296|small cell lung cancer
120965|NCT02324296|extended disease
120966|NCT02324296|limited disease
120967|NCT02324296|chemotherapy
120968|NCT02324296|cisplatin
120969|NCT02324296|etoposide
120970|NCT02324296|ifosfamide
120971|NCT02324283|one-lung ventilation, oxygenation
120972|NCT02324270|Pain due to ankle sprain
120973|NCT02324244|Cytomegalovirus
120974|NCT02324244|critical patient
120975|NCT02324244|ICU
120976|NCT02324244|immunocompetent
120977|NCT02324244|clinical suspicion
120978|NCT02324244|risk factors
120979|NCT02324218|Diabetes mellitus
120980|NCT02324218|Hepatitis B
120981|NCT02324218|Incidence
120982|NCT02324192|Ultrasonography
120983|NCT02324192|clinical
120984|NCT02324192|hand
120985|NCT02324166|cefazolin
120986|NCT02324166|lidocaine
120987|NCT02324153|Post-operative Delirium
120988|NCT02324114|Cancer
120989|NCT02324075|sanitation, toilet, urban, behavior change
120990|NCT02324062|Cancer Genetics
120991|NCT02324062|Multi-gene cancer panel testing
120992|NCT02324049|MPS IIIB
120993|NCT02324049|Mucopolysaccharidosis
120994|NCT02324049|Mucopolysaccharidosis type IIIB
120995|NCT02324049|Sanfilippo Syndrome
120996|NCT02324049|Metabolism, Inborn Errors
120997|NCT02324049|Metabolic Diseases
120998|NCT02324049|Genetic Diseases, Inborn
120999|NCT02324049|Carbohydrate Metabolism, Inborn Errors
121000|NCT02324049|Connective Tissue Diseases
121001|NCT02324049|Lysosomal Storage Diseases
121002|NCT02324049|Mucinoses
121003|NCT02324049|Mucopolysaccharidoses
121004|NCT02324049|Pathologic Processes
121005|NCT02324023|ultrasound
121006|NCT02324023|perfusion
121007|NCT02324023|endoscopic
121008|NCT02324010|gastric emptying
121009|NCT02324010|glycemia
121010|NCT02324010|appetite
121011|NCT02324010|incretin hormones
121012|NCT02323997|HPV
121013|NCT02323997|cervical cancer
121014|NCT02323997|human papillomavirus
121015|NCT02323997|cervical pre-cancer
121016|NCT02323997|cervical neoplasia
121017|NCT02323945|acute intermittent hypoxia
121018|NCT02323945|incomplete spinal cord injury
121019|NCT02323945|strength
121020|NCT02323945|walking
121021|NCT02323945|breathing
121022|NCT02323919|myocardial infarction
121023|NCT02323919|coronary artery bypass graft (CABG)
121024|NCT02323919|angioplasty
121025|NCT02323919|exercise
121026|NCT02323919|cardiac patient
121027|NCT02323919|physical activity
121028|NCT02323906|Hepatocellular
121029|NCT02323906|Carcinoma
121030|NCT02323906|Phase 1
121031|NCT02323906|CC-122
121032|NCT02323906|Sorafenib,
121033|NCT02323906|Nexavar
121034|NCT02323906|Unresectable Hepatocellular Carcinoma
121035|NCT02323906|Unresectable HCCAdvanced,
121036|NCT02323906|Hepatocellular Carcinoma
121037|NCT02323906|liver cancer
121038|NCT02323893|Positron Emission Tomography
121039|NCT02323893|Cancer Immunotherapy
121040|NCT02323867|Transplant
121041|NCT02323867|Alternative Donor
121042|NCT02323854|primary, recurrent, metastatic lung tumor, ablation
121043|NCT02323841|cervical cancer
121044|NCT02323841|neoadjuvant chemotherapy
121045|NCT02323841|Adverse Effects
121046|NCT02323815|child acute malnutrition prevention
121047|NCT02323815|behavior change communication
121048|NCT02323815|lipid-based nutrient supplement
121049|NCT02323815|screening coverage
121050|NCT02323763|Magnetic Resonance Imaging
121051|NCT02323763|Bipolar Disorder
121052|NCT02323763|Suicidal Ideation
121053|NCT02323698|acute intermittent hypoxia
121054|NCT02323698|incomplete spinal cord injury
121055|NCT02323685|DCI
121056|NCT02323685|Delayed Cerebral Ischemia
121057|NCT02323685|SAH
121058|NCT02323685|Subarachnoid Hemorrhage
121059|NCT02323685|Aneurysmal Subarachnoid Hemorrhage
121060|NCT02323685|Cerebral Ischemia
121061|NCT02323685|Brain Ischemia
121062|NCT02323659|Mycosis Fungoides
121063|NCT02323659|Cutaneous T-Cell Lymphoma
121064|NCT02323659|Interferon
121065|NCT02323659|Methotrexate
121066|NCT02323646|uterine fibroids
121067|NCT02323646|leiomyoma
121068|NCT02323646|fibroid tumor
121069|NCT02323646|fibroma
121070|NCT02323633|Pediatric Attention Deficit Hyperactivity Disorder
121071|NCT02323620|Acute myocardial Infarction
121072|NCT02323620|bone marrow
121073|NCT02323620|stem cells
121074|NCT02323620|cardiovascular disease
121075|NCT02323620|mortality
121076|NCT02323581|Thoracoabdominal
121077|NCT02323581|Aneurysm
121078|NCT02323581|Endovascular
121079|NCT02323581|Stent-Graft
121080|NCT02323568|ovarian cancer
121081|NCT02323568|quality of life
121082|NCT02323568|remission more than 3 years
121083|NCT02323555|Cancer
121084|NCT02323555|chemotherapy
121085|NCT02323555|Targeted therapy
121086|NCT02323555|Day Hospital
121087|NCT02323542|Starch
121088|NCT02323542|cereal products
121089|NCT02323542|glucose kinetics
121090|NCT02323542|blood glucose
121091|NCT02323542|blood insulin
121092|NCT02323529|Orfadin
121093|NCT02323529|Nitisinone
121094|NCT02323529|NTBC
121095|NCT02323503|CRT-D
121096|NCT02323503|replacement
121097|NCT02323503|primary prevention
121098|NCT02323503|ventricular tachyarrhythmias
121099|NCT02323490|meniscus repair
121100|NCT02323490|bone marrow stimulation
121101|NCT02323477|cellular therapy
121102|NCT02323477|chronic ischemic heart disease
121103|NCT02323477|phase 1/2 clinical study
121104|NCT02323477|human umbilical cord multipotent stem cell
121105|NCT02323477|human umbilical cord mesenchymal stem cell
121106|NCT02323477|ischemic heart disease
121107|NCT02323477|bone marrow mononuclear cell
121108|NCT02323477|allogeneic stem cell transplantation
121109|NCT02323438|biomarkers of tobacco exposure
121110|NCT02323438|exposure
121111|NCT02323438|tobacco
121112|NCT02323438|nicotine
121113|NCT02323438|nicotine gum
121114|NCT02323438|electronic cigarette
121115|NCT02323438|e-cig
121116|NCT02323425|stroke
121117|NCT02323425|Remote ischemic postconditioning
121118|NCT02323425|symptomatic atherosclerotic intracranial arterial stenosis
121119|NCT02323412|Low back pain
121120|NCT02323412|Chronic
121121|NCT02323412|Modic Changes
121122|NCT02323412|MRI
121123|NCT02323412|epigenetics
121124|NCT02323412|antibiotics
121125|NCT02323412|randomized placebo controlled trial
121126|NCT02323386|Dynamic RSA
121127|NCT02323386|Knee
121128|NCT02323386|Total Knee Arthroplasty
121129|NCT02323386|Kinematic Analysis
121130|NCT02323373|Arthroplasty, Replacement, Knee
121131|NCT02323373|Tranexamic Acid
121132|NCT02323373|Drug Administration Routes
121133|NCT02323360|SBRT
121134|NCT02323360|TACE
121135|NCT02323360|TAE
121136|NCT02323321|heart transplant
121137|NCT02323321|heart preservation
121138|NCT02323321|beating heart transplant
121139|NCT02323295|Malignant bone tumors
121140|NCT02323282|Dose-response relationship
121141|NCT02323282|Drug
121142|NCT02323256|cochlear implant
121143|NCT02323256|deafness
121144|NCT02323256|audiometry
121145|NCT02323256|speech perception
121146|NCT02323256|severe to profound deafness restored with cochlear implantation
121147|NCT02323243|Detrusor striated sphincter dyssynergia
121148|NCT02323243|Temporary urethral stent
121149|NCT02323217|Imidazoline Receptor 2
121150|NCT02323217|(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole
121151|NCT02323217|BU99008
121152|NCT02323217|Radionuclide Imaging
121153|NCT02323217|Molecular Imaging
121154|NCT02323217|Healthy Volunteers
121155|NCT02323217|Alzheimer Disease
121156|NCT02323204|posttraumatic stress
121157|NCT02323178|Chronic myelomonocytic leukemia
121158|NCT02323178|thrombocytopenia
121159|NCT02323178|eltrombopag
121160|NCT02323152|women
121161|NCT02323152|high risk
121162|NCT02323139|High risk MDS
121163|NCT02323139|Azacitidine
121164|NCT02323139|LDE255
121165|NCT02323126|Non small cell lung cancer,
121166|NCT02323126|NSCLC,
121167|NCT02323126|EGFR-mutated,
121168|NCT02323126|EGF816,
121169|NCT02323126|INC280,
121170|NCT02323126|Nivolumab,
121171|NCT02323126|EGFR-T790M NSCLC,
121172|NCT02323126|EGFR wild-type (wt),
121173|NCT02323126|cMET positive NSCLC,
121174|NCT02323126|cMET negative NSCLC
121175|NCT02323113|Drug therapy
121176|NCT02323100|cystic fibrosis
121177|NCT02323100|corrector
121178|NCT02323100|glycerol phenylbutyrate
121179|NCT02323100|nasal potential difference
121180|NCT02323087|Antibiotic resistance
121181|NCT02323087|Point of care tests
121182|NCT02323087|Primary Health Care
121183|NCT02323022|AML
121184|NCT02323022|cladribine
121185|NCT02323022|induction therapy
121186|NCT02323009|Transpulmonary pressure
121187|NCT02323009|Esophageal balloon
121188|NCT02323009|Esophageal pressure monitoring device
121189|NCT02323009|Cstat
121190|NCT02323009|Static effective compliance
121191|NCT02323009|Ventilator weaning
121192|NCT02323009|Morbidly Obese Ventilator Dependent Tracheotomized Patients
121193|NCT02322983|Cerebral Palsy
121194|NCT02322983|Dental Care
121195|NCT02322983|Conscious Sedation
121196|NCT02322983|Autonomic Nervous System
121197|NCT02322983|Nitrous Oxide
121198|NCT02322970|intracranial hypertension
121199|NCT02322970|tcd
121200|NCT02322970|non invasive
121201|NCT02322970|ICP
121202|NCT02322944|acute myocardial infarction
121203|NCT02322944|quality improvement
121204|NCT02322944|reperfusion therapy
121205|NCT02322905|informal caregivers
121206|NCT02322905|caregiving
121207|NCT02322905|psychotherapy for caregivers
121208|NCT02322905|cancer
121209|NCT02322905|emotion regulation
121210|NCT02322905|distress
121211|NCT02322905|inflammation
121212|NCT02322892|Thiamine
121213|NCT02322892|Vitamin B1
121214|NCT02322892|Coronary artery bypass grafting
121215|NCT02322892|Cardiac surgery
121216|NCT02322892|Lactate
121217|NCT02322892|Pyruvate dehydrogenase
121218|NCT02322879|acetaminophen
121219|NCT02322866|acne
121220|NCT02322853|Metastatic breast cancer
121221|NCT02322853|p38 map kinase
121222|NCT02322853|tamoxifen
121223|NCT02322853|LY2228820
121224|NCT02322853|Postmenopausal woman with advanced or metastatic breast cancer progressing on aromatase inhibitors (AI)
121225|NCT02322827|hiv/aids
121226|NCT02322788|Inhalation, Pharmacodynamic, Patients,
121227|NCT02322775|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases,
121228|NCT02322762|Type 2 diabetes mellitus
121229|NCT02322762|Anti-diabetic management patterns
121230|NCT02322749|bioequivalence
121231|NCT02322749|bioavailability
121232|NCT02322749|pharmacokinetics
121233|NCT02322749|Phase I
121234|NCT02322749|AZD6244
121235|NCT02322749|cancer
121236|NCT02322736|Metastatic Colorectal Cancer, wild type RAS, Panitumumab, Vectibix, Greece
121237|NCT02322723|Adalimumab
121238|NCT02322723|real life
121239|NCT02322723|RA
121240|NCT02322723|Humira
121241|NCT02322723|Rheumatoid Arthritis
121242|NCT02322723|effectiveness
121243|NCT02322710|non-inferiority
121244|NCT02322710|randomized
121245|NCT02322710|TulleGras
121246|NCT02322710|Urgotul
121247|NCT02322710|healing
121248|NCT02322710|surgical acute wounds
121249|NCT02322710|pain
121250|NCT02322697|Carnitine
121251|NCT02322697|hemodialysis
121252|NCT02322697|fatty acid
121253|NCT02322697|imaging
121254|NCT02322697|heart
121255|NCT02322684|Bougie
121256|NCT02322684|Air-Q
121257|NCT02322684|Insertion
121258|NCT02322671|chewable tablet
121259|NCT02322671|montelukast sodium
121260|NCT02322671|healthy adult subjects
121261|NCT02322671|relative bioavailability
121262|NCT02322671|GW483100
121263|NCT02322593|Gastric Cancer
121264|NCT02322593|Gastrointestinal Diseases
121265|NCT02322593|Gastrointestinal Neoplasms
121266|NCT02322593|First Line Treatment
121267|NCT02322593|Antineoplastic Agents
121268|NCT02322580|anti-TNF
121269|NCT02322580|therapeutic drug monitoring
121270|NCT02322580|immunogenicity
121271|NCT02322554|electronic health records
121272|NCT02322554|Qualified Clinical Data Registry
121273|NCT02322554|PQRS
121274|NCT02322554|quality reporting
121275|NCT02322554|cellular based products
121276|NCT02322554|bioengieered skin
121277|NCT02322554|USWR
121278|NCT02322528|Non-invasive instruments
121279|NCT02322528|Environment
121280|NCT02322528|Wavefront
121281|NCT02322528|Placido Disk
121282|NCT02322528|Ellipsometer
121283|NCT02322528|Thermal Imaging
121284|NCT02322515|Knee
121285|NCT02322515|Proprioception
121286|NCT02322515|Electromyography
121287|NCT02322515|Taping
121288|NCT02322502|laryngeal mask airway
121289|NCT02322502|desflurane
121290|NCT02322502|sevoflurane
121291|NCT02322502|propofol
121292|NCT02322489|microcurent
121293|NCT02322489|pain
121294|NCT02322489|flexibility
121295|NCT02322463|patients who were admitted to the pediatric ED
121296|NCT02322411|Stroke
121297|NCT02322411|Deglutition
121298|NCT02322411|Deglutition disorders
121299|NCT02322411|Resistance training
121300|NCT02322385|Autosomal Dominant Polycystic Kidney Disease
121301|NCT02322385|PKD 1 gene
121302|NCT02322385|PKD 2 gene
121303|NCT02322385|Truncational mutation
121304|NCT02322385|Hypomorphic mutation
121305|NCT02322372|femoral blockade
121306|NCT02322372|bupivacaine
121307|NCT02322346|posttonsillectomy pain
121308|NCT02322346|levobupivacaine
121309|NCT02322320|Multiple Myeloma
121310|NCT02322320|Lenalidomide
121311|NCT02322320|Maintenance Therapy
121312|NCT02322320|Progression
121313|NCT02322320|Long-term
121314|NCT02322320|Anti-Myeloma Agents
121315|NCT02322320|Hematologic Disorders
121316|NCT02322307|Inflammatory Bowel Disease
121317|NCT02322307|Crohn's Disease
121318|NCT02322307|Ulcerative Colitis
121319|NCT02322307|Colitis
121320|NCT02322307|PRO
121321|NCT02322307|Patient-centric
121322|NCT02322307|HealthPROMISE
121323|NCT02322294|Protein
121324|NCT02322294|mung bean
121325|NCT02322294|glucose
121326|NCT02322294|triglycerides
121327|NCT02322294|insulin
121328|NCT02322294|body weight,
121329|NCT02322294|DXA scan
121330|NCT02322281|cancer
121331|NCT02322281|metastatic
121332|NCT02322281|locally advanced
121333|NCT02322281|lung
121334|NCT02322281|non-small cell lung cancer
121335|NCT02322281|NSCLC
121336|NCT02322281|epidermal growth factor receptor
121337|NCT02322281|EGFR
121338|NCT02322281|T790M
121339|NCT02322281|CO-1686
121340|NCT02322281|unresectable
121341|NCT02322281|recurrent
121342|NCT02322281|EGFR-directed therapy
121343|NCT02322281|irreversible EGFR inhibitor
121344|NCT02322281|TIGER
121345|NCT02322281|Rociletinib
121346|NCT02322268|Type 2 Diabetes Mellitus
121347|NCT02322268|Cosmos Caudatus
121348|NCT02322268|Ulam Raja
121349|NCT02322268|Metabolomic profiling
121350|NCT02322268|antioxidant
121351|NCT02322255|Natural History Study
121352|NCT02322255|Non-interventional Study
121353|NCT02322255|Observational Study
121354|NCT02322255|Heterotopic ossification
121355|NCT02322255|Fibrodysplasia Ossificans Progressiva
121356|NCT02322255|FOP disease progression
121357|NCT02322255|FOP flare-up progression
121358|NCT02322255|Clementia
121359|NCT02322255|Myositosis Ossificans Progressiva
121360|NCT02322255|Munchmeyer's Disease
121361|NCT02322255|FOP
121362|NCT02322255|Palovarotene
121363|NCT02322229|VMT
121364|NCT02322229|sVMA
121365|NCT02322229|vitrectomy
121366|NCT02322229|ocriplasmin
121367|NCT02322216|Allergies
121368|NCT02322216|Ocular
121369|NCT02322203|Niacin
121370|NCT02322203|Cholesterol
121371|NCT02322203|High-Density Lipoprotein
121372|NCT02322203|Low-Density Lipoprotein
121373|NCT02322203|Lipoproteins
121374|NCT02322190|Steroid Failure
121375|NCT02322190|Immunomodulation
121376|NCT02322190|Corticosteroid Therapy
121377|NCT02322177|Inborn Error of Metabolism
121378|NCT02322177|Pregnancy
121379|NCT02322177|Methylmalonic Acidemia
121380|NCT02322177|Urea Cycle Disorder
121381|NCT02322164|Skin
121382|NCT02322164|TEMPERATURE
121383|NCT02322164|Placebo
121384|NCT02322151|Filgrastim
121385|NCT02322151|Neupogen
121386|NCT02322151|Transplant
121387|NCT02322151|Breast Feeding
121388|NCT02322151|Concentration
121389|NCT02322125|walking
121390|NCT02322125|locomotion
121391|NCT02322125|rehabilitation
121392|NCT02322112|Dietary Fiber
121393|NCT02322112|Gastrointestinal Microbiome
121394|NCT02322112|Overweight and Obesity
121395|NCT02322112|Personalized Nutrition
121396|NCT02322112|Inflammation
121397|NCT02322112|Metabolism
121398|NCT02322099|human immunodeficiency virus
121399|NCT02322099|bone diseases
121400|NCT02322099|osteopenia
121401|NCT02322099|osteoporosis
121402|NCT02322099|fracture
121403|NCT02322099|bone turnover
121404|NCT02322099|alendronate
121405|NCT02322099|antiretroviral
121406|NCT02322060|IVA, ovary tissue grafting, POI
121407|NCT02322034|chronic heart failure
121408|NCT02322034|multiple neurohormonal axis disequilibrium
121409|NCT02322034|growth hormone deficiency
121410|NCT02322034|Insulin-like growth factor-1 (IGF-1)
121411|NCT02322034|metabolic deficiency syndrome
121412|NCT02322034|interval training
121413|NCT02322021|E2609
121414|NCT02322021|Mild Cognitive Impairment
121415|NCT02322021|Mild to Moderate Dementia
121416|NCT02322021|Alzheimer's Disease
121417|NCT02322021|Prodromal Alzheimer's Disease
121418|NCT02321982|Mohs surgery
121419|NCT02321982|Preoperative consultation
121420|NCT02321969|Chemoprevention
121421|NCT02321969|Colorectal adenomatous polyp
121422|NCT02321969|Green tea extract
121423|NCT02321956|ASA class 1,2
121424|NCT02321956|age 1-6 years
121425|NCT02321956|General anesthesia with ETT
121426|NCT02321930|Rheumatoid Arthritis
121427|NCT02321930|Musculoskeletal Ultrasound
121428|NCT02321930|Tofacitinib
121429|NCT02321930|biomarker
121430|NCT02321904|Confocal microscopy
121431|NCT02321904|Cornea
121432|NCT02321904|Neuropathy
121433|NCT02321904|Detection
121434|NCT02321904|Diabetes
121435|NCT02321839|neovascular age-related macular degeneration
121436|NCT02321839|Ranibizumab
121437|NCT02321839|Treat and extend
121438|NCT02321813|quality of life
121439|NCT02321813|colorectal cancer
121440|NCT02321813|definitive RCT
121441|NCT02321813|complex intervention
121442|NCT02321800|S-649266
121443|NCT02321800|complicated urinary tract infection
121444|NCT02321800|cefiderocol
121445|NCT02321800|acute uncomplicated pyelonephritis
121446|NCT02321800|Gram-negative pathogens
121447|NCT02321800|imipenem/cilastatin
121448|NCT02321787|Anesthesia, Caudal
121449|NCT02321787|Ultrasonography
121450|NCT02321774|Stress
121451|NCT02321774|Virtual Reality
121452|NCT02321774|Wearable Sensor
121453|NCT02321774|Wellness
121454|NCT02321761|Amantadine hydrochloride
121455|NCT02321761|Rehabilitation
121456|NCT02321761|Acquired Brain Injury
121457|NCT02321761|TBI
121458|NCT02321748|HSV
121459|NCT02321748|Herpes
121460|NCT02321748|volunteers
121461|NCT02321748|drug-drug interaction
121462|NCT02321735|Long-Term Survivor
121463|NCT02321735|Genomic
121464|NCT02321735|Survivorship
121465|NCT02321735|Quality of Life
121466|NCT02321722|Colonoscopy
121467|NCT02321696|physiotherapy
121468|NCT02321696|manual therapy
121469|NCT02321696|acupuncture
121470|NCT02321696|eccentric exercise
121471|NCT02321670|operative technique
121472|NCT02321644|CC-90001
121473|NCT02321644|PHARMACOKINETICS
121474|NCT02321644|PHARMACODYNAMICS
121475|NCT02321644|HEALTHY SUBJECTS
121476|NCT02321644|SINGLE DOSE
121477|NCT02321644|MULTIPLE DOSE
121478|NCT02321644|PUNCH BIOPSY
121479|NCT02321631|Malnourished
121480|NCT02321631|Head and Neck Cancer
121481|NCT02321631|Surgery
121482|NCT02321618|Hypertension
121483|NCT02321618|High Blood Pressure
121484|NCT02321618|African American men
121485|NCT02321618|Black men
121486|NCT02321618|barbershop
121487|NCT02321605|Best Possible Self
121488|NCT02321605|Positive Psychology
121489|NCT02321605|Optimism
121490|NCT02321605|Positive Technology
121491|NCT02321605|Future Thinking
121492|NCT02321592|Hodgkin Lymphoma
121493|NCT02321592|AFM13
121494|NCT02321592|Natural Killer Cells
121495|NCT02321553|metabolic syndrome
121496|NCT02321553|glucose
121497|NCT02321553|cholesterol
121498|NCT02321553|brown rice
121499|NCT02321553|inflammation
121500|NCT02321553|oxidative stress
121501|NCT02321540|Lung Cancer
121502|NCT02321540|Non-small cell lung cancer
121503|NCT02321540|NSCLC
121504|NCT02321540|Epidermal growth factor receptor mutations
121505|NCT02321540|EGFR
121506|NCT02321540|Recurrent non-small cell lung cancer
121507|NCT02321540|Ibrutinib
121508|NCT02321540|PCI-32765
121509|NCT02321540|Imbruvica
121510|NCT02321527|Breast Cancer
121511|NCT02321527|Microbubble contrast-enhanced ultrasound
121512|NCT02321527|CEUS
121513|NCT02321527|Sentinel lymph nodes
121514|NCT02321527|SLN
121515|NCT02321527|Perflutren Protein-Type A Microspheres Injectable Suspension
121516|NCT02321527|OPTISON™
121517|NCT02321527|Ultrasound
121518|NCT02321527|Breast biopsy
121519|NCT02321527|Radioactive seed
121520|NCT02321527|Phone call
121521|NCT02321527|Fine needle aspiration
121522|NCT02321527|FNA
121523|NCT02321501|Head and Neck Cancer
121524|NCT02321501|Lung Cancer
121525|NCT02321501|Non small cell lung
121526|NCT02321501|NSCLC
121527|NCT02321501|Metastatic
121528|NCT02321501|Locally advanced
121529|NCT02321501|Metastatic solid tumors
121530|NCT02321501|Anaplastic lymphoma kinase
121531|NCT02321501|ALK
121532|NCT02321501|Ceritinib
121533|NCT02321501|LDK378
121534|NCT02321501|Zykadia
121535|NCT02321501|Everolimus
121536|NCT02321501|Afinitor
121537|NCT02321501|Zortress
121538|NCT02321501|RAD001
121539|NCT02321501|Pharmacokinetic
121540|NCT02321501|PK
121541|NCT02321501|Biomarker testing
121542|NCT02321475|Psycho-emotional symptoms
121543|NCT02321462|preparation
121544|NCT02321423|Nail Dystrophy
121545|NCT02321423|Plantar Keratoderma
121546|NCT02321423|Palmar Keratoderma
121547|NCT02321423|Leukokeratosis
121548|NCT02321423|Cysts
121549|NCT02321423|Pain
121550|NCT02321423|KRT17
121551|NCT02321423|KRT16
121552|NCT02321423|KRT6A
121553|NCT02321423|KRT6B
121554|NCT02321423|KRT6C
121555|NCT02321397|oxycodone naloxone combination
121556|NCT02321397|severe chronic and non-malignant pain
121557|NCT02321397|Malignant and non-malignant pain that requires around-the clock opioid therapy
121558|NCT02321358|Behavior Change
121559|NCT02321358|Objectively Measured Physical Activity
121560|NCT02321358|Survivorship
121561|NCT02321345|Allogeneic Stem Cell Transplant
121562|NCT02321345|Hematological Malignancies
121563|NCT02321345|Palliative Care
121564|NCT02321345|Supportive care
121565|NCT02321332|Palmar hyperhidrosis
121694|NCT02320799|global mental health
121566|NCT02321332|Endoscopic thoracic sympathectomy
121567|NCT02321319|chronic pain
121568|NCT02321319|pediatric
121569|NCT02321293|curcumin
121570|NCT02321293|lung cancer
121571|NCT02321293|TKI
121572|NCT02321267|AMD
121573|NCT02321267|PCV
121574|NCT02321267|RAP
121575|NCT02321267|RVO
121576|NCT02321267|DME
121577|NCT02321267|ERM
121578|NCT02321267|MH
121579|NCT02321267|mCNV
121580|NCT02321254|Stroke
121581|NCT02321254|Upper limb
121582|NCT02321254|Robotics
121583|NCT02321254|Electromyography
121584|NCT02321254|Rehabilitation
121585|NCT02321241|Wet-AMD
121586|NCT02321241|Refractory patients to ranibizumab
121587|NCT02321241|Real life
121588|NCT02321241|Switch
121589|NCT02321241|Aflibercept
121590|NCT02321228|Salpingectomy
121591|NCT02321228|Delayed oophorectomy
121592|NCT02321228|Salpingo-oophorectomy
121593|NCT02321228|Quality of life
121594|NCT02321228|Ovarian cancer
121595|NCT02321228|BRCA
121596|NCT02321215|AECOPD
121597|NCT02321215|COPD
121598|NCT02321215|education
121599|NCT02321202|omega-3
121600|NCT02321202|Progression
121601|NCT02321202|parenteral nutrition
121602|NCT02321150|Pterygium
121603|NCT02321150|Pterygiums
121604|NCT02321150|Pterygia
121605|NCT02321150|Graft
121606|NCT02321150|Autograft
121607|NCT02321150|Excision
121608|NCT02321150|Surgery
121609|NCT02321150|Eye
121610|NCT02321150|electrocautery
121611|NCT02321150|polyglactin
121612|NCT02321124|Constipation
121613|NCT02321124|connective tissue manipulation
121614|NCT02321124|conservative therapy
121615|NCT02321124|massage
121616|NCT02321124|randomized controlled trial
121617|NCT02321111|Insulin signaling and glucose disposal in muscle
121618|NCT02321111|Hepatic insulin sensitivity
121619|NCT02321111|TLR4 signaling and inflammatory gene expression
121620|NCT02321111|Plasma cytokine concentration
121621|NCT02321111|Intramyocellular diacylglycerol and ceramide content
121622|NCT02321098|Onychomycosis
121623|NCT02321098|antifungal
121624|NCT02321072|oxygen
121625|NCT02321072|hypoxia
121626|NCT02321072|hyperoxia
121627|NCT02321072|critical care
121628|NCT02321072|intensive care
121629|NCT02321059|incisional hernia
121630|NCT02321059|hernia
121631|NCT02321059|abdominal wall strength
121632|NCT02321059|validation
121633|NCT02321059|physical activity
121634|NCT02321046|Non-Small Cell Lung Cancer, NSCLC, Epidermal growth factor receptor, EGFR
121635|NCT02321033|glycemic index
121636|NCT02321033|inactivity
121637|NCT02321033|insulin sensitivity
121638|NCT02321033|metabolic flexibility
121639|NCT02321033|arterial stiffness
121640|NCT02321033|young men
121641|NCT02320994|stroke
121642|NCT02320994|aftercare
121643|NCT02320981|GERD
121644|NCT02320981|EGD
121645|NCT02320981|pH testing
121646|NCT02320981|eosinophilic esophagitis
121647|NCT02320981|impedance testing
121648|NCT02320955|autologous bone flap
121649|NCT02320955|decompressive craniectomy
121650|NCT02320955|malignant brain swelling
121651|NCT02320955|patient specific implant
121652|NCT02320955|bone resorption
121653|NCT02320955|aseptic bone necrosis
121654|NCT02320942|Bone Marrow Transplantation
121655|NCT02320942|Exercise
121656|NCT02320942|Rehabilitation
121657|NCT02320942|Cancer
121658|NCT02320929|irrigation
121659|NCT02320929|tenosynovitis
121660|NCT02320929|purulent
121661|NCT02320929|closed-catheter
121662|NCT02320929|flexor tendon
121663|NCT02320903|Criminal Justice
121664|NCT02320903|Juvenile Delinquency
121665|NCT02320890|transcranial direct current stimulation
121666|NCT02320890|tDCS
121667|NCT02320890|Mild Cognitive Impairment
121668|NCT02320890|MCI
121669|NCT02320864|muscle strength
121670|NCT02320864|muscle weakness
121671|NCT02320864|hospitalization
121672|NCT02320864|surgery
121673|NCT02320864|total knee replacement
121674|NCT02320851|Somatoform disorder
121675|NCT02320851|Functional vertigo/dizziness
121676|NCT02320851|Chronic subjective dizziness
121677|NCT02320838|Transcutaneous Electric Nerve Stimulation
121678|NCT02320838|Electric Stimulation Therapy
121679|NCT02320838|Unmodulated Alternating Currents
121680|NCT02320838|Neural Conduction
121681|NCT02320838|Pain Threshold
121682|NCT02320825|Stereotactic Radiosurgery (SRS)
121683|NCT02320825|Single-Fraction
121684|NCT02320825|Hypofractionated
121685|NCT02320825|Spinal surgery
121686|NCT02320825|14-233
121687|NCT02320799|interpersonal psychotherapy
121688|NCT02320799|HIV
121689|NCT02320799|women
121690|NCT02320799|gender based violence
121691|NCT02320799|mental health
121692|NCT02320799|africa
121693|NCT02320799|kenya
121695|NCT02320799|HIV treatment adherence
121696|NCT02320786|Power mobility
121697|NCT02320786|Wheelchair skills training
121698|NCT02320786|Spinal Cord Injury
121699|NCT02320773|Overactive Bladder
121700|NCT02320773|Quality of Life
121701|NCT02320773|Betanis®
121702|NCT02320773|Betmiga®
121703|NCT02320773|Observational
121704|NCT02320773|Myrbetriq®
121705|NCT02320747|Volunteers
121706|NCT02320734|surgical rating scale
121707|NCT02320734|neuromuscular relaxation
121708|NCT02320734|Anaesthesia
121709|NCT02320734|minimally invasive esophagectomy
121710|NCT02320708|Molar,third; Teeth,wisdom; Pain, Postoperative; Dental Surgery; Third molar extraction
121711|NCT02320643|Partially absorbable mesh
121712|NCT02320617|Lung Neoplasms
121713|NCT02320617|diffusion weighted MRI
121714|NCT02320617|ADC value
121715|NCT02320617|treatment effect
121716|NCT02320604|Liposomal amphotericin B
121717|NCT02320604|AmBisome
121718|NCT02320604|Pharmacokinetics
121719|NCT02320604|Obesity
121720|NCT02320604|Bariatric surgery
121721|NCT02320578|Neoadjuvant Chemoptherapy
121722|NCT02320578|Laparoscopy 3D
121723|NCT02320578|Cervical cancer
121724|NCT02320565|Endometrial Cancer
121725|NCT02320565|Laparoscopy 3D
121726|NCT02320552|Nutritional assessment
121727|NCT02320539|MicroRNA
121728|NCT02320539|Cerebrospinal fluid
121729|NCT02320526|Exercise
121730|NCT02320526|Training
121731|NCT02320526|Interval training
121732|NCT02320526|Systemic inflammation
121733|NCT02320526|Glucose disposal
121734|NCT02320526|Insulin sensitivity
121735|NCT02320526|Glucose effectiveness
121736|NCT02320513|Exercise
121737|NCT02320461|diabetes mellitus
121738|NCT02320461|cardiovascular diseases
121739|NCT02320461|cohort studies
121740|NCT02320461|hypertension
121741|NCT02320461|obesity
121742|NCT02320461|smoking
121743|NCT02320461|social class
121744|NCT02320422|liver transplant
121745|NCT02320422|medication adherence
121746|NCT02320422|intervention
121747|NCT02320409|Subjects
121748|NCT02320383|CLL
121749|NCT02320357|Platelet activation
121750|NCT02320357|CD40 ligand
121751|NCT02320357|CD154
121752|NCT02320357|Interferon alpha
121753|NCT02320357|clopidogrel
121754|NCT02320318|Irritable Bowel Syndrome
121755|NCT02320318|Colon, irritable
121756|NCT02320318|Bowel disease
121757|NCT02320318|Diarrhea
121758|NCT02320279|Fetal Heart Rate
121759|NCT02320279|Fetal EKG
121760|NCT02320279|FHR tracing
121761|NCT02320279|fetal R-waves
121762|NCT02320266|Deep Brain Stimulation Surgery
121763|NCT02320253|Diabetes
121764|NCT02320253|Obesity
121765|NCT02320253|Primary Care
121766|NCT02320253|Lifestyle Intervention
121767|NCT02320240|antidepressants
121768|NCT02320240|acute kidney injury
121769|NCT02320240|SNRI
121770|NCT02320240|renal failure
121771|NCT02320240|duloxetine
121772|NCT02320240|CNODES
121773|NCT02320188|modification of treatment planned
121774|NCT02320188|Exercise
121775|NCT02320175|family centered rounds
121776|NCT02320175|patient safety
121777|NCT02320175|errors
121778|NCT02320175|adverse events
121779|NCT02320175|concordance
121780|NCT02320175|patient experience
121781|NCT02320149|acne
121782|NCT02320123|Terminal Care
121783|NCT02320123|Decision Making
121784|NCT02320123|Communication
121785|NCT02320110|Irisin
121786|NCT02320110|Adiponectin
121787|NCT02320110|Leptin
121788|NCT02320110|Insulin resistance
121789|NCT02320110|Body Mass Index
121790|NCT02320110|Obesity
121791|NCT02320110|Metabolic Syndrome
121792|NCT02320110|Lipid Profile
121793|NCT02320110|Diabetes Mellitus
121794|NCT02320084|HT-1
121795|NCT02320084|Hereditary Tyrosinemia, Type I
121796|NCT02320084|hypertyrosinemia type 1
121797|NCT02320084|Orfadin
121798|NCT02320084|Long term safety
121799|NCT02320084|Hereditary Tyrosinemia Type 1
121800|NCT02320032|Alkermes
121801|NCT02320032|Schizophrenia
121802|NCT02320032|Aripiprazole
121803|NCT02320032|Aripiprazole lauroxil
121804|NCT02320032|ALKS 9072
121805|NCT02320006|hydrotubation
121806|NCT02320006|incomplete fallopian tube obstructive infertility
121807|NCT02320006|Acupuncture
121808|NCT02319993|Suan-Zao-Ren Tang
121809|NCT02319993|Tian-wang-bu-xin-dan
121810|NCT02319993|Traditional Chinese Medicine
121811|NCT02319993|Herbs
121812|NCT02319993|Quality of life
121813|NCT02319967|community health worker
121814|NCT02319967|emergency
121815|NCT02319967|asthma
121816|NCT02319941|Inhibition of Platelet Reactivity
121817|NCT02319941|ticagrelor
121818|NCT02319941|clopidogrel
121819|NCT02319941|Pharmacodynamics
121820|NCT02319941|Pharmacokinetics
121821|NCT02319915|tranexamic acid
121822|NCT02319915|knee prosthesis
121823|NCT02319915|pharmacokinetic profile
121824|NCT02319863|hepatocellular carcinoma
121825|NCT02319863|prognosis
121826|NCT02319850|sarcopenia
121827|NCT02319850|screening
121828|NCT02319850|geriatrics
121829|NCT02319850|muscle
121830|NCT02319850|aging
121831|NCT02319850|ultrasound
121832|NCT02319798|Crohn's disease
121833|NCT02319798|ulcerative colitis
121834|NCT02319798|Inflammatory bowel disease
121835|NCT02319798|IBD
121836|NCT02319772|Healthy volunteers
121837|NCT02319772|Ebola virus
121838|NCT02319772|Filovirus
121839|NCT02319759|Psoriatic Arthritis
121840|NCT02319759|Guselkumab
121841|NCT02319759|Ustekinumab
121842|NCT02319759|Placebo
121843|NCT02319694|Basal Ganglia
121844|NCT02319694|Behavior
121845|NCT02319694|Behavioral
121846|NCT02319694|Brain
121847|NCT02319694|Cognitive
121848|NCT02319694|Computer Simulation
121849|NCT02319694|Cues
121850|NCT02319694|Data
121851|NCT02319694|Deep Brain Stimulation
121852|NCT02319694|Disease
121853|NCT02319681|Caregivers
121854|NCT02319681|Anxiety
121855|NCT02319681|Depression
121856|NCT02319655|Epiretinal membrane
121857|NCT02319655|Macular pucker
121858|NCT02319655|Membrane peeling
121859|NCT02319655|pars plana vitrectomy
121860|NCT02319655|Air
121861|NCT02319655|balanced salt solution
121862|NCT02319655|Intraoperative OCT
121863|NCT02319655|Hyporeflectivity
121864|NCT02319655|Retina
121865|NCT02319642|Rheumatoid Arthritis
121866|NCT02319642|TNFα antagonist
121867|NCT02319642|Certolizumab pegol
121868|NCT02319642|Chinese patients
121869|NCT02319642|Open-label
121870|NCT02319629|Morbid obesity,
121871|NCT02319629|Cholelithiasis
121872|NCT02319629|Bariatric surgery
121873|NCT02319629|Ursodiol
121874|NCT02319577|NSCLC
121875|NCT02319577|EGFR
121876|NCT02319577|vinorelbine
121877|NCT02319577|gefitinib
121878|NCT02319564|Wheeze
121879|NCT02319564|Asthma
121880|NCT02319564|Randomized Trial
121881|NCT02319564|Pre-school aged children
121882|NCT02319525|lupus nephritis
121883|NCT02319525|lupus
121884|NCT02319525|decision-making
121885|NCT02319525|minorities
121886|NCT02319525|immunosuppressive medications
121887|NCT02319525|decision-aid
121888|NCT02319525|treatment
121889|NCT02319525|Decision conflict
121890|NCT02319525|SLE
121891|NCT02319486|Retinoblastoma
121892|NCT02319486|carboplatin
121893|NCT02319473|system of care
121894|NCT02319473|acute myocardial infarction
121895|NCT02319473|registry
121896|NCT02319473|Primary PCI
121897|NCT02319473|Fibrinolytic therapy
121898|NCT02319460|Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding
121899|NCT02319460|Warfarin Reversal
121900|NCT02319447|Living Donation
121901|NCT02319447|Kidney Transplantation
121902|NCT02319421|Alarm fatigue
121903|NCT02319395|Parkinson's Disease
121904|NCT02319395|Behaviour addiction
121905|NCT02319395|Dopamine agonist
121906|NCT02319395|Genetic.
121907|NCT02319382|Parkinson Disease
121908|NCT02319382|[18F]DPA-714
121909|NCT02319382|Positron emission tomography (PET)
121910|NCT02319382|Neuroinflammation
121911|NCT02319343|Glucocorticoid
121912|NCT02319343|Quadriceps muscle function
121913|NCT02319343|Knee arthroplasty, total
121914|NCT02319330|HIV
121915|NCT02319330|Adherence
121916|NCT02319330|Mental health
121917|NCT02319330|Depression
121918|NCT02319330|Women
121919|NCT02319330|Mobile phone technology
121920|NCT02319330|eHealth
121921|NCT02319330|India
121922|NCT02319304|Pelvic Radiotherapy
121923|NCT02319304|Rectal Adenocarcinoma
121924|NCT02319265|sepsis
121925|NCT02319265|antioxidant
121926|NCT02319265|melatonin
121927|NCT02319265|inflammation
121928|NCT02319239|Prostate neoplasms
121929|NCT02319239|Urogenital neoplasms
121930|NCT02319239|Genital neoplasms, male
121931|NCT02319239|Radiation therapy
121932|NCT02319239|PSA
121933|NCT02319239|DW-MRI, diffusion weighted MRI
121934|NCT02319239|Intra-fractional movement
121935|NCT02319239|Hypofractionated radiotherapy
121936|NCT02319239|Stereotactic
121937|NCT02319239|Toxicity due to radiotherapy
121938|NCT02319239|Quality of life
121939|NCT02319213|Intra-abdominal pressure,
121940|NCT02319213|intraocular pressure,
121941|NCT02319213|abdominal hypertension,
121942|NCT02319213|laparoscopy,
121943|NCT02319213|critical care
121944|NCT02319200|Chemoprevention
121945|NCT02319200|Decompensation of cirrhosis
121946|NCT02319200|Hepatocellular Carcinoma
121947|NCT02319200|Death
121948|NCT02319200|Efficacy
121949|NCT02319200|Safety
121950|NCT02319187|Esophageal Neoplasms
121951|NCT02319161|intravenous regional anesthesia
121952|NCT02319135|Acute Myeloid Leukemia
121953|NCT02319122|Cerebral Palsy
121954|NCT02319122|Muscle structure
121955|NCT02319122|Strength training
121956|NCT02319096|Whole body vibration therapy
121957|NCT02319096|pelvic floor muscle training
121958|NCT02319096|stress urinary incontinence
121959|NCT02319083|CABG
121960|NCT02319083|Coronary artery bypass surgery
121961|NCT02319083|Coronary artery bypass grafting
121962|NCT02319083|Coronary surgery
121963|NCT02319083|Myocardial infarction
121964|NCT02319083|Coronary artery disease
121965|NCT02319083|Off-pump
121966|NCT02319083|EuroSCORE
121967|NCT02319070|Cost
121968|NCT02319070|Clinical Outcomes
121969|NCT02319070|Quality of Life
121970|NCT02319070|On Demand Treatment
121971|NCT02319070|Secondary Prophylaxis
121972|NCT02319057|Healthy volunteer study
121973|NCT02319044|Head and neck cancer; SCCHN
121974|NCT02319005|Cardiomyopathy
121975|NCT02319005|Heart Failure
121976|NCT02319005|FAC
121977|NCT02319005|Amyloid
121978|NCT02319005|Transthyretin
121979|NCT02319005|TTR
121980|NCT02319005|RNAi therapeutic
121981|NCT02318953|Telemedicine
121982|NCT02318953|Ambulatory Surgical Procedures
121983|NCT02318953|Postoperative Care
121984|NCT02318953|Cost Effectiveness
121985|NCT02318953|Mobile Applications
121986|NCT02318953|Health Services Research
121987|NCT02318953|Breast Reconstruction
121988|NCT02318940|ultrasound guided
121989|NCT02318940|femoral vein
121990|NCT02318940|central venous catheter
121991|NCT02318940|pediatric
121992|NCT02318927|Deep Brain Stimulation
121993|NCT02318914|Pyoderma Gangrenosum
121994|NCT02318914|Classic Pyoderma Gangrenosum
121995|NCT02318888|Small bowel obstruction, Surgery, Colorectal cancer
121996|NCT02318875|Inflammation
121997|NCT02318875|swell
121998|NCT02318875|pain
121999|NCT02318875|functional impairment
122000|NCT02318875|stiffness
122001|NCT02318862|reflux
122002|NCT02318862|GERD
122003|NCT02318862|EGD
122004|NCT02318862|pH testing
122005|NCT02318849|designated organ donor, college students
122006|NCT02318836|hepatic, hepatic impairment, lofexidine
122007|NCT02318823|social neuroscience
122008|NCT02318823|emotion
122009|NCT02318823|face recognition
122010|NCT02318823|empathy
122011|NCT02318823|beer
122012|NCT02318823|alcohol
122013|NCT02318823|social cognition
122014|NCT02318810|Muscle relaxants
122015|NCT02318797|Chronic disease
122016|NCT02318797|Mental Health
122017|NCT02318797|Behavioral Health
122018|NCT02318797|Community mental health centers
122019|NCT02318797|Intervention studies
122020|NCT02318797|Mixed methods
122021|NCT02318797|Qualitative research
122022|NCT02318784|neuroendocrine malignancies
122023|NCT02318784|pancreatic neuroendocrine tumors (PNETs)
122024|NCT02318784|gastrointestinal (GI) carcinoids
122025|NCT02318784|carfilzomib
122026|NCT02318784|Kyprolis
122027|NCT02318784|proteasome inhibitors
122028|NCT02318758|This is a healthy volunteer study.
122029|NCT02318745|Family Therapy
122030|NCT02318745|Substance abuse prevention
122031|NCT02318745|Minority
122032|NCT02318745|randomized trials
122033|NCT02318745|outcome research
122034|NCT02318745|adolescent treatment
122035|NCT02318732|violence
122036|NCT02318719|Post-Herpetic Neuralgia
122037|NCT02318706|Diabetic Peripheral Neuropathic Pain
122038|NCT02318641|oxygen consumption
122039|NCT02318641|retinal oximetry
122040|NCT02318628|Cardio ankle vascular index
122041|NCT02318628|CAVI
122042|NCT02318628|pulse wave velocity
122043|NCT02318628|PWV
122044|NCT02318628|Non invasive arterial structure assessment
122045|NCT02318615|Breast Neoplasm
122046|NCT02318615|Lymphedema
122047|NCT02318615|Autologous flap
122048|NCT02318615|lattismus dorsi flap
122049|NCT02318602|Lennox-Gastaut syndrome
122050|NCT02318602|Dravet syndrome
122051|NCT02318602|Treatment-resistant seizures
122052|NCT02318576|Multiple Sclerosis
122053|NCT02318563|Treatment-resistant seizures
122054|NCT02318537|Treatment-resistant seizures
122055|NCT02318472|Microdialysis
122056|NCT02318472|Patient related outcome
122057|NCT02318472|Heel rise test
122058|NCT02318472|Immobilization
122059|NCT02318446|Anti-epileptic drugs
122060|NCT02318446|Folic acid
122061|NCT02318446|Homocysteine
122062|NCT02318433|DRF
122063|NCT02318433|PTOA
122064|NCT02318433|dexamethasone
122065|NCT02318420|Obstetrics
122066|NCT02318420|Partogram
122067|NCT02318420|ePartogram
122068|NCT02318420|eHealth
122069|NCT02318420|Low-income
122070|NCT02318420|Quality of care
122071|NCT02318420|Perinatal death
122072|NCT02318420|Maternal death
122073|NCT02318420|Cesarean section
122074|NCT02318420|Health information technology
122075|NCT02318394|advanced solid tumors; immunotherapy; OX40; immuno-oncology
122076|NCT02318381|suprascapular nerve
122077|NCT02318381|rotator cuff tear
122078|NCT02318381|suprascapular neuropathy
122079|NCT02318381|superior transverse scapular ligament
122080|NCT02318355|hemodilution
122081|NCT02318355|hemorrhage
122082|NCT02318355|trauma
122083|NCT02318355|lactate
122084|NCT02318355|base deficit
122085|NCT02318355|randomized control trial
122086|NCT02318329|FGFR2b, FGFR2, FGFR, bladder neoplasms, esophageal cancer
122087|NCT02318316|Exhaled breath condensate
122088|NCT02318316|allogeneic stem cell transplantation
122089|NCT02318316|pulmonary complications
122090|NCT02318290|Analgesia
122091|NCT02318290|Critical Care
122092|NCT02318290|Hypnotics and Sedatives
122093|NCT02318251|Power, rate of force development
122094|NCT02318251|involuntary
122095|NCT02318251|reflexive
122096|NCT02318238|evaluation
122097|NCT02318238|exercise tolerance
122098|NCT02318238|healthy children
122099|NCT02318238|6MWT
122100|NCT02318225|Misoprostol
122101|NCT02318225|Office hysteroscopy
122102|NCT02318225|Pain
122103|NCT02318212|Cervical dilatation
122104|NCT02318199|emergence agitation
122105|NCT02318199|intracranial surgery
122106|NCT02318199|general anesthesia
122107|NCT02318199|incidence
122108|NCT02318199|risk factor
122109|NCT02318186|pharmacokinetic analysis
122110|NCT02318186|remodulin
122111|NCT02318186|trepostinil
122112|NCT02318186|pulmonary arterial hypertension
122113|NCT02318173|Cervical dilatation
122114|NCT02318160|Autoimmune Thyroiditis
122115|NCT02318160|Oxidative Status
122116|NCT02318160|Children
122117|NCT02318147|Severe acute pancreatitis
122118|NCT02318147|Fecal Microbiota Transplantation
122119|NCT02318147|Bacterial Translocation
122120|NCT02318147|Infectious Complications
122121|NCT02318134|Severe acute pancreatitis
122122|NCT02318134|Fecal Microbiota Transplantation
122123|NCT02318134|Intestinal barrier dysfunction
122124|NCT02318134|Intestinal flora
122125|NCT02318121|Labor, prolonged labor, augmentation of labor
122126|NCT02318108|Organizational Innovation
122127|NCT02318108|Primary Health Care
122128|NCT02318095|Cancer of the pancreas
122129|NCT02318082|Chronic versus Graft Host Disease
122130|NCT02318069|immune response
122131|NCT02318069|TBE-vaccine
122132|NCT02318069|elderly
122133|NCT02318069|additional doses
122134|NCT02318056|hand
122135|NCT02318056|burns
122136|NCT02318056|thermal
122137|NCT02318056|dressing
122138|NCT02318056|Aquacel®
122139|NCT02318056|Mepilex® Transfer Ag
122140|NCT02318056|Xeroform®
122141|NCT02318056|Bacitracin®
122142|NCT02318056|partial thickness
122143|NCT02318056|epithelialization
122144|NCT02318056|wound healing
122145|NCT02318056|scar
122146|NCT02318056|scarring
122147|NCT02318043|adenosine monophosphate
122148|NCT02318043|histamine
122149|NCT02318043|bronchial provocation test
122150|NCT02318043|asthma symptom score
122151|NCT02318043|asthma control
122152|NCT02318030|Transplant
122153|NCT02318030|Adaptive Immunity
122154|NCT02318030|EBV
122155|NCT02318030|Medication Adherence
122156|NCT02318030|Tacrolimus
122157|NCT02318030|PTLD
122158|NCT02318017|adhd
122159|NCT02318017|global network
122160|NCT02318017|eeg
122161|NCT02318004|telemonitoring
122162|NCT02317991|gastroesophageal adenocarcinoma
122163|NCT02317991|nab-paclitaxel
122164|NCT02317991|Abraxane
122165|NCT02317991|ramucirumab
122166|NCT02317991|Cyramza
122167|NCT02317991|GE junction
122168|NCT02317913|Kawasaki disease
122169|NCT02317913|Epidemiology
122170|NCT02317913|Incidence
122171|NCT02317913|Coronary arterial lesions
122172|NCT02317913|Shanghai
122173|NCT02317887|Gene Transfer
122174|NCT02317887|X-Linked
122175|NCT02317887|Retinoschisis
122176|NCT02317887|AAV Vector
122177|NCT02317848|Diagnosis
122178|NCT02317848|prognostic marker
122179|NCT02317848|polygraphy
122180|NCT02317848|echocardiography
122181|NCT02317848|ECG
122182|NCT02317809|Healthy
122183|NCT02317809|Pergoveris
122184|NCT02317809|Bioequivalence
122185|NCT02317809|Infertility
122186|NCT02317770|lidocaine, esophago-gastro-duodenoscopy
122187|NCT02317757|elderly cancer patients, chemotherapy toxicity
122188|NCT02317731|bowel preparation
122189|NCT02317718|serum vitamin D levels
122190|NCT02317718|IVF
122191|NCT02317718|ovarian reserve
122192|NCT02317718|25 OHD3
122193|NCT02317718|pregnancy outcome
122194|NCT02317666|polypharmacy
122195|NCT02317666|drug burden index
122196|NCT02317666|aged
122197|NCT02317666|medication review
122198|NCT02317666|cholinergic agents
122199|NCT02317640|Testosterone
122200|NCT02317640|Electrical Stimulation
122201|NCT02317640|Stand Training
122202|NCT02317614|Incentives
122203|NCT02317614|Smartphone
122204|NCT02317614|Mobile intervention
122205|NCT02317614|eDOT
122206|NCT02317614|Adherence reinforcement
122207|NCT02317614|Drug users
122208|NCT02317588|Oxylipins
122209|NCT02317588|Flax oil
122210|NCT02317588|Fish oil
122211|NCT02317562|Peripheral neuropathy
122212|NCT02317562|Disimmune disease
122213|NCT02317562|Neurology chronic disease
122214|NCT02317562|Rare disease
122215|NCT02317549|sepsis
122216|NCT02317549|septic shock
122217|NCT02317549|vasodilatory shock
122218|NCT02317549|circulatory shock
122219|NCT02317549|Systemic Inflammatory Response Syndrome
122220|NCT02317549|SIRS
122221|NCT02317549|infection
122222|NCT02317549|toxemia
122223|NCT02317549|gut barrier breakdown
122224|NCT02317549|autodigestion
122225|NCT02317549|multiorgan failure
122226|NCT02317549|MOF
122227|NCT02317549|multiorgain dysfunction syndrome
122228|NCT02317549|MODS
122229|NCT02317549|hyperlactatemia
122230|NCT02317549|tissue hypoxia
122231|NCT02317536|Muscle function
122232|NCT02317536|L-Carnitine
122233|NCT02317536|Carnipure
122234|NCT02317536|DXA
122235|NCT02317536|anabolism
122236|NCT02317536|6 minute walk
122237|NCT02317536|dynamometry
122238|NCT02317536|muscle biopsy
122239|NCT02317523|Dementia
122240|NCT02317523|Caregiver
122241|NCT02317523|Cardiovascular Disease
122242|NCT02317523|Stress
122243|NCT02317523|Depression
122244|NCT02317523|Anxiety
122245|NCT02317523|Heart Disease
122246|NCT02317523|Carer
122247|NCT02317523|Care Giver
122248|NCT02317523|Caregiving
122249|NCT02317523|Psychotherapy
122250|NCT02317523|Therapy
122251|NCT02317523|Behavioral Activation
122252|NCT02317523|Education
122253|NCT02317523|Intervention
122254|NCT02317523|CBT
122255|NCT02317523|Cognitive-Behavior Therapy
122256|NCT02317510|Combined anesthesia
122257|NCT02317510|General anesthesia
122258|NCT02317510|Laparoscopic cholecystectomy
122259|NCT02317497|Neurocritical care
122260|NCT02317497|Severe Stroke
122261|NCT02317497|Ischemic stroke
122262|NCT02317497|Intracerebral hemorrhage
122263|NCT02317497|Subarachnoid hemorrhage
122264|NCT02317497|Sedation
122265|NCT02317497|RASS
122266|NCT02317497|BIS
122267|NCT02317445|helicobacter pylori
122268|NCT02317445|eradication therapy
122269|NCT02317445|major adverse cardiac events
122270|NCT02317445|long-term outcome
122271|NCT02317445|To explore the significance of Hp eradication therapy in preventing major adverse cardiac events (MACE) and upper gastrointestinal bleeding (UGIB).
122272|NCT02317432|Depression
122273|NCT02317432|Anxiety
122274|NCT02317432|Disability
122275|NCT02317432|Ethnic Minority
122276|NCT02317432|Elders
122277|NCT02317419|Solid Cancers
122278|NCT02317393|Nuclear medicine
122279|NCT02317393|Positron emission tomography
122280|NCT02317393|avb3 integrin expression
122281|NCT02317380|Self-Affirmation
122282|NCT02317380|Weight Loss
122283|NCT02317380|Self vs. Other
122284|NCT02317380|Cancer Risk and Prevention
122285|NCT02317367|Construct Validity
122286|NCT02317367|Self-Affirmation
122287|NCT02317367|Alcohol Consumption
122288|NCT02317367|Breast Cancer
122289|NCT02317354|X-Linked
122290|NCT02317354|Retinoschisis
122291|NCT02317341|Fatigue
122292|NCT02317341|Ketamine
122293|NCT02317341|Cancer
122294|NCT02317328|Retinal Images
122295|NCT02317328|Adaptive Optics
122296|NCT02317263|MS
122297|NCT02317250|Alzheimer's disease
122298|NCT02317250|Alzheimer disease
122299|NCT02317250|MDC
122300|NCT02317250|Mild Decline in Cognition
122301|NCT02317250|MCI
122302|NCT02317250|Dementia
122303|NCT02317250|PET
122304|NCT02317250|FDG-PET
122305|NCT02317250|FDG
122306|NCT02317250|amyloid
122307|NCT02317250|amyloid imaging
122308|NCT02317250|CMS
122309|NCT02317250|Coverage with Evidence Development
122310|NCT02317250|CED
122311|NCT02317250|MCI-ID
122312|NCT02317224|3-Hole approach
122313|NCT02317224|extended thymectomy
122314|NCT02317224|myasthenia gravis
122315|NCT02317224|safety
122316|NCT02317224|effectiveness
122317|NCT02317198|Elderly
122318|NCT02317198|P2Y12 inhibitors
122319|NCT02317198|clopidogrel
122320|NCT02317198|ticagrelor
122321|NCT02317172|Saliva substitute
122322|NCT02317172|Edible gel
122323|NCT02317172|Xerostomia
122324|NCT02317172|Diabetes Mellitus
122325|NCT02317172|Hypertension
122326|NCT02317133|Tregs
122327|NCT02317133|bacterial translocation
122328|NCT02317133|cytokines
122329|NCT02317107|Gait
122330|NCT02317107|Mild Traumatic Brain Injury
122331|NCT02317107|Post-Concussion Syndrome
122332|NCT02317107|Recovery of Function
122333|NCT02317107|Locomotion
122334|NCT02317107|Motor Activity
122335|NCT02317068|sick sinus syndrome
122336|NCT02317068|paroxysmal atrial fibrillation
122337|NCT02317068|atrial pacing
122338|NCT02317068|high atrial base rate pacing
122339|NCT02317055|MRI
122340|NCT02317055|Oxygenation
122341|NCT02317055|nirs
122342|NCT02317029|Cardioversion
122343|NCT02317029|Cardiac Arrythmias
122344|NCT02317029|Myocardial Injury
122345|NCT02317029|Defibrillators
122346|NCT02317029|Biomarkers
122347|NCT02317016|oncology
122348|NCT02317016|cancer
122349|NCT02317016|non small cell lung cancer
122350|NCT02317016|anticancer drug
122351|NCT02317016|pharmacokinetics
122352|NCT02317016|AZD9291
122353|NCT02317016|rosuvastatin
122354|NCT02317016|EGFR genes
122355|NCT02317003|physical exercise
122356|NCT02317003|sedentarity
122357|NCT02317003|general practice
122358|NCT02317003|family medicine
122359|NCT02317003|pedometer
122360|NCT02316977|Reproducibility of Results
122361|NCT02316964|AML
122362|NCT02316964|acute myeloid leukemia
122363|NCT02316964|decitabine
122364|NCT02316951|Postoperative
122365|NCT02316951|Pain
122366|NCT02316951|Symptoms
122367|NCT02316951|Video recording
122368|NCT02316951|Orthopedic surgery
122369|NCT02316938|kidney transplant, renal transplant, biopsy, biopsies, donor specific antibodies
122370|NCT02316912|allergy
122371|NCT02316899|ASP0456
122372|NCT02316899|constipation
122373|NCT02316899|linaclotide
122374|NCT02316899|irritable bowel syndrome (IBS)
122375|NCT02316886|Bioresorbable Vascular scaffold
122376|NCT02316886|Vulnerable Plaque
122377|NCT02316886|Insignificant Stenosis
122378|NCT02316873|music training, rhythm
122379|NCT02316847|Cluster Seizures
122380|NCT02316847|Seizures
122381|NCT02316847|Clusters
122382|NCT02316847|Acute repetitive seizures
122383|NCT02316834|Fallopian Tube Cancer
122384|NCT02316834|Ovarian Cancer
122385|NCT02316834|Peritoneal Cancer
122386|NCT02316834|BMN 673
122387|NCT02316834|Talazoparib tosylate
122388|NCT02316821|Diabetes Mellitus
122389|NCT02316821|Diabetes Mellitus, Type 2
122390|NCT02316821|Diabetic Nephropathies
122391|NCT02316821|Kidney Diseases
122392|NCT02316821|Renal Insufficiency, Chronic
122393|NCT02316821|Diabetes Complications
122394|NCT02316821|Endocrine System Diseases
122395|NCT02316821|Glucose Metabolism Disorders
122396|NCT02316821|Metabolic Diseases
122397|NCT02316821|Renal Insufficiency
122398|NCT02316821|Urologic Diseases
122399|NCT02316821|bardoxolone methyl
122400|NCT02316756|Phase 1, Single-Dose Escalation, Double Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, PF-06648671, Plasma Abeta
122401|NCT02316691|Graves Disease
122402|NCT02316691|Rituximab
122403|NCT02316678|Patient Preference
122404|NCT02316665|Type 1 diabetes
122405|NCT02316665|Sleep apnea syndrome
122406|NCT02316665|Nocturnal glycemia
122407|NCT02316665|Continuous glucose monitoring system
122408|NCT02316665|Continuous positive airway pressure
122409|NCT02316665|Sleep habits
122410|NCT02316639|Neuromuscular Training
122411|NCT02316639|Skeletally Immature
122412|NCT02316639|Knee Rehabilitation
122413|NCT02316600|elderly
122414|NCT02316600|Robust volunteers for the first phase;
122415|NCT02316600|tele-monitoring
122416|NCT02316600|self-management
122417|NCT02316600|Patient 65 and over
122418|NCT02316600|Presenting a frailty syndrome for the second phase
122419|NCT02316587|Computerized Tomography
122420|NCT02316587|Magnetic Resonance Imaging
122421|NCT02316587|Echocardiography
122422|NCT02316587|Right Heart Catheterization
122423|NCT02316574|Alcohol dependence
122424|NCT02316574|Cognitive Behavioral Therapy
122425|NCT02316574|Functional neuroimaging
122426|NCT02316535|colorectal cancer
122427|NCT02316535|stage II/III
122428|NCT02316535|elderly
122429|NCT02316535|adjuvant chemotherapy
122430|NCT02316535|capecitabine
122431|NCT02316535|non-inferiority
122432|NCT02316496|Cancer
122433|NCT02316496|Colorectal
122434|NCT02316496|Metastatic
122435|NCT02316496|Thrid-line
122436|NCT02316496|Irinotecan
122437|NCT02316496|Cetuximab
122438|NCT02316470|Clostridium difficile
122439|NCT02316470|Valneva
122440|NCT02316470|Phase 2
122441|NCT02316470|Healthy adults
122442|NCT02316457|TNBC
122443|NCT02316457|Breast Cancer
122444|NCT02316457|Warehouse
122445|NCT02316457|Mutanome
122446|NCT02316457|RNA
122447|NCT02316457|Vaccine
122448|NCT02316444|Hepatitis B vaccine HIV infection
122449|NCT02316418|Hairstetics™ anchoring system
122450|NCT02316418|hair extensions
122451|NCT02316392|Helium
122452|NCT02316392|MRI
122453|NCT02316392|Lung transplantation
122454|NCT02316379|Respiratory
122455|NCT02316314|Friedreich's Ataxia
122456|NCT02316314|Cardiomyopathy
122457|NCT02316301|Misoprostol, pain, office hysteroscopy
122458|NCT02316249|pelvic organ prolapse
122459|NCT02316249|Atrophy of Vagina
122460|NCT02316249|Gellhorn pessary
122461|NCT02316249|Ring with support pessary
122462|NCT02316249|Estrace cream
122463|NCT02316249|vaginitis with pessary
122464|NCT02316249|vaginal ulceration with pessary
122465|NCT02316249|vaginal erosion with pessary
122466|NCT02316249|pessary complications
122467|NCT02316249|vaginal bleeding with pessary
122468|NCT02316223|asthma
122469|NCT02316223|high-risk
122470|NCT02316223|adult
122471|NCT02316223|elderly
122472|NCT02316223|care coordination
122473|NCT02316223|community health worker
122474|NCT02316223|electronic medical record
122475|NCT02316197|DNA-PK Inhibitor
122476|NCT02316197|advanced solid tumors
122477|NCT02316197|Chronic lymphocytic Leukemia
122478|NCT02316197|Phase I, first-in-human
122479|NCT02316197|dose escalation
122480|NCT02316197|dose expansion
122481|NCT02316197|safety profile
122482|NCT02316197|tolerability
122483|NCT02316197|PK
122484|NCT02316197|antitumor activity
122485|NCT02316197|maximum tolerated dose
122486|NCT02316197|M3814
122487|NCT02316184|Alcohol
122488|NCT02316158|Burden
122489|NCT02316158|Mental illness
122490|NCT02316158|Stress
122491|NCT02316158|Social support
122492|NCT02316145|ADHD
122493|NCT02316145|Autism spectrum condition
122494|NCT02316145|Tourette's disorder
122495|NCT02316145|Internet-based
122496|NCT02316145|chat
122497|NCT02316145|coach
122498|NCT02316119|bleeding risk, acute coronary syndrome, platelet agregation,
122499|NCT02316106|Smoldering multiple myeloma (SMM)
122500|NCT02316106|Daratumumab
122501|NCT02316080|dental bleaching
122502|NCT02316080|dentin sensitivity
122503|NCT02316080|biomaterials
122504|NCT02316067|Spinal cord
122505|NCT02316067|Wounds and Injuries
122506|NCT02316067|Rehabilitation
122507|NCT02316054|type 2 diabetes mellitus
122508|NCT02316054|coronary microvascular disease
122509|NCT02316054|coronary artery disease
122510|NCT02316054|myocardial perfusion imaging
122511|NCT02316054|prognosis
122512|NCT02316054|atherosclerosis
122513|NCT02316054|myocardial ischemia
122514|NCT02316054|coronary heart disease
122515|NCT02316041|Femtosecond laser
122516|NCT02316041|Small incision lenticule extraction (SMILE)
122517|NCT02316028|decitabine
122518|NCT02316028|colorectal cancer
122519|NCT02316028|hepatic arterial infusion
122520|NCT02316015|Child, Hospitalized
122521|NCT02316015|Nutritional status
122522|NCT02315976|chronic stable angina pectoris
122523|NCT02315976|propatyl nitrate
122524|NCT02315976|Seattle Angina Questionnaire
122525|NCT02315911|Tonsillectomy
122526|NCT02315911|Adenoidectomy
122527|NCT02315911|Adenoidpharyngoplasty
122528|NCT02315911|OSA
122529|NCT02315885|healthy volunteers
122530|NCT02315885|social drinkers
122531|NCT02315885|alcohol
122532|NCT02315872|Multiple Sclerosis
122533|NCT02315872|Acthar Gel
122534|NCT02315872|ACTH
122535|NCT02315872|Fatigue
122536|NCT02315859|suction work
122537|NCT02315833|Migraine
122538|NCT02315833|Aura
122539|NCT02315820|Macrosomia
122540|NCT02315820|Induction of labor
122541|NCT02315820|Expectant management
122542|NCT02315820|Shoulder dystocia
122543|NCT02315794|aesthetic outcome
122544|NCT02315794|titanium abutment
122545|NCT02315794|zirconia abutment
122546|NCT02315768|CLL
122547|NCT02315768|Chronic Lymphocytic Leukemia
122548|NCT02315768|Ibrutinib
122549|NCT02315768|Obinutuzumab
122550|NCT02315768|Cancer
122551|NCT02315755|Metastatic renal cell carcinoma, targeted molecular therapy
122552|NCT02315716|Multiple Myeloma
122553|NCT02315716|Carfilzomib
122554|NCT02315703|Healthy
122555|NCT02315703|Acquired Immuno-Deficiency Syndrome
122556|NCT02315703|Acquired Immunodeficiency Syndrome Virus
122557|NCT02315703|adenovirus serotype 26
122558|NCT02315703|Ad26.Mos.HIV
122559|NCT02315703|Modified Vaccinia Ankara
122560|NCT02315703|Glycoprotein
122561|NCT02315703|Adjuvant
122562|NCT02315703|Vaccine
122563|NCT02315703|Placebo
122564|NCT02315690|malaria, Swaziland, reactive case detection, focal mass drug administration
122565|NCT02315677|Epistaxis
122566|NCT02315677|Nasal Intubation
122567|NCT02315677|Maxillofacial surgery
122568|NCT02315664|Physical activity
122569|NCT02315664|Exercise
122570|NCT02315664|Osteoarthritis
122571|NCT02315664|Knee
122572|NCT02315664|Arthritis
122573|NCT02315638|Adeno-associated viral vectors
122574|NCT02315638|Adeno-associated virus
122575|NCT02315638|AAV
122576|NCT02315638|AAV8
122577|NCT02315638|ddRNAi
122578|NCT02315638|shRNA
122579|NCT02315638|RNAi
122580|NCT02315638|Hepatitis
122581|NCT02315638|Chronic Hepatitis C
122582|NCT02315638|HCV
122583|NCT02315638|CHC
122584|NCT02315638|Genotype 1
122585|NCT02315625|MEN1
122586|NCT02315625|VHL
122587|NCT02315625|Neoplasm
122588|NCT02315625|NF1
122589|NCT02315625|mTOR
122590|NCT02315612|CD-22 Expressing Tumor
122591|NCT02315612|Chimeric Antigen Receptor
122592|NCT02315612|Adoptive Immunotherapy
122593|NCT02315612|ALL
122594|NCT02315612|Lymphoma
122595|NCT02315599|Replication Competent Retrovirus (RCR)
122596|NCT02315599|Replication Competent Lentivirus (RCL)
122597|NCT02315599|T Cell Persistence
122598|NCT02315586|Idiopathic Pulmonary Fibrosis
122599|NCT02315586|Apoliprotein A-1
122600|NCT02315573|Carpal Tunnel Syndrome
122601|NCT02315573|Anesthetics, Local
122602|NCT02315573|Pain Perception
122603|NCT02315573|Pain Measurement
122604|NCT02315573|Analgesia
122605|NCT02315573|Lidocaine
122606|NCT02315573|Bupivacaine
122607|NCT02315560|bedwetting
122608|NCT02315547|Microbiota
122609|NCT02315547|Airway infection
122610|NCT02315547|Bronchiectasis
122611|NCT02315547|Airway inflammation
122612|NCT02315547|Oxidative stress
122613|NCT02315547|Matrix metalloproteinase
122614|NCT02315534|GBM
122615|NCT02315534|Malignant Glioma
122616|NCT02315521|lower urinary tract obstruction
122617|NCT02315521|posterior urethral valves
122618|NCT02315521|urethral atresia
122619|NCT02315521|Prune Belly Syndrome
122620|NCT02315521|Megalo-urethra
122621|NCT02315521|Fetal renal function
122622|NCT02315521|Prenatal Diagnosis
122623|NCT02315521|Ultrasound
122624|NCT02315482|autonomic nervous system
122625|NCT02315482|heart rate variability
122626|NCT02315482|prostatectomy
122627|NCT02315482|steep trendelenburg
122628|NCT02315482|pneumoperitoneum
122629|NCT02315482|Intervention Affecting Autonomic Nervous System
122630|NCT02315456|capsulorhexis
122631|NCT02315456|IOL centration
122632|NCT02315443|Stroke
122633|NCT02315443|Ischemia
122634|NCT02315443|Prehospital
122635|NCT02315443|NA-1
122636|NCT02315443|Modified Rankin Scale
122637|NCT02315417|Pyoderma Gangrenosum
122638|NCT02315417|Classic Pyoderma Gangrenosum
122639|NCT02315404|Obscure gastrointestinal bleeding
122640|NCT02315404|Overt gastrointestinal bleeding
122641|NCT02315404|Occult gastrointestinal bleeding
122642|NCT02315404|Enteroscopy
122643|NCT02315378|Anxiety, Acute Trauma
122644|NCT02315352|Healthy
122645|NCT02315352|L-PZQ
122646|NCT02315352|PZQ
122647|NCT02315352|MSC2499550A
122648|NCT02315352|Praziquantel
122649|NCT02315326|Ibrutinib,
122650|NCT02315326|Imbruvica™
122651|NCT02315326|Bruton's Tyrosine Kinase (BTK) Inhibitor
122652|NCT02315326|HD-MTX
122653|NCT02315326|14-184
122654|NCT02315300|ECG, CGM, Hypoglycaemia, Sudden Cardiac Death
122655|NCT02315287|Triple combination
122656|NCT02315287|Metformin
122657|NCT02315287|Sitagliptin
122658|NCT02315287|Pioglitazone
122659|NCT02315287|Lobeglitazone
122660|NCT02315274|Type 1 diabetes
122661|NCT02315274|Pregnancy
122662|NCT02315274|Glycemic variability
122663|NCT02315274|Between visit contact
122664|NCT02315261|Epidural analgesia
122665|NCT02315261|Pain score
122666|NCT02315248|bone density
122667|NCT02315222|Nutriomics
122668|NCT02315222|Dietary supplements
122669|NCT02315222|Scaling and root planing
122670|NCT02315222|full mouth disinfection
122671|NCT02315209|Inguinal Hernia, Quality of Life, Mesh
122672|NCT02315183|Post cardiac surgery
122673|NCT02315170|diabetic retinopathy
122674|NCT02315170|age-related macular edema
122675|NCT02315157|Partial Response
122676|NCT02315144|COPD
122677|NCT02315144|bronchodilation
122678|NCT02315092|Diabetic Foot Ulcers
122679|NCT02315092|Bacteria
122680|NCT02315092|Fluorescence
122681|NCT02315079|Ocular Inflammation
122682|NCT02315079|Matrix Metalloproteinase 9
122683|NCT02315066|Immunotherapy
122684|NCT02315066|PF-04518600
122685|NCT02315066|PF-05082566
122686|NCT02315066|solid tumors
122687|NCT02315066|tumors
122688|NCT02315066|neoplasm metastasis
122689|NCT02315066|Phase 1
122690|NCT02315066|hepatocellular carcinoma
122691|NCT02315066|HCC
122692|NCT02315066|Liver cancer
122693|NCT02315066|melanoma
122694|NCT02315066|clear cell renal cell carcinoma
122695|NCT02315066|RCC
122696|NCT02315066|kidney cancer
122697|NCT02315066|head and neck squamous cell carcinoma
122698|NCT02315066|HNSCC
122699|NCT02315066|head and neck cancer
122700|NCT02315066|cervical cancer
122701|NCT02315066|cancer of the cervix
122702|NCT02315066|gastric cancer
122703|NCT02315066|stomach cancer
122704|NCT02315066|non small cell lung cancer
122705|NCT02315066|NSCLC
122706|NCT02315066|lung cancer
122707|NCT02315066|urothelial bladder carcinoma
122708|NCT02315066|bladder cancer
122709|NCT02315066|OX40
122710|NCT02315066|4-1BB
122711|NCT02315053|NSCLC
122712|NCT02315053|CCRT
122713|NCT02315053|FDG PET/CT
122714|NCT02315040|Intrauterine insemination (IUI)
122715|NCT02315040|Insemination method
122716|NCT02315040|Slow release insemination (SRI)
122717|NCT02315040|EVIE
122718|NCT02315040|Pregnancy rate
122719|NCT02315001|Liraglutide
122720|NCT02315001|GLP-1
122721|NCT02315001|Ischaemic heart disease
122722|NCT02315001|Coronary heart disease
122723|NCT02315001|Chronic stable angina
122724|NCT02314988|Tranexamic acid
122725|NCT02314988|Antifibrinolytic
122726|NCT02314988|Perioperative blood loss
122727|NCT02314988|Postoperative drain output
122728|NCT02314988|Allogenic transfusion
122729|NCT02314949|T-regulatory cells
122730|NCT02314949|Tolerogenic protocol
122731|NCT02314949|immunomodulation
122732|NCT02314936|Constipation
122733|NCT02314936|Polydextrose
122734|NCT02314936|Dietary Fiber
122735|NCT02314936|Fiber
122736|NCT02314936|Colonic Transit Time
122737|NCT02314936|PAC-SYM
122738|NCT02314910|Innervation
122739|NCT02314910|Jaw Bone
122740|NCT02314910|Implants
122741|NCT02314910|Stereognostic
122742|NCT02314910|Osseoperception
122743|NCT02314871|perioperative analgesia
122744|NCT02314871|minimal residual disease
122745|NCT02314871|cancer recurrence
122746|NCT02314871|epidural
122747|NCT02314871|morphine
122748|NCT02314871|piritramide
122749|NCT02314871|colon
122750|NCT02314871|cancer
122751|NCT02314871|circulating cancer cells
122752|NCT02314871|colon cancer surgery
122753|NCT02314845|Pulmonary Atelectasis
122754|NCT02314845|Pulmonary Ventilation
122755|NCT02314845|Anesthesia, General
122756|NCT02314845|Electric Impedance
122757|NCT02314845|Tomography, Spiral Computed
122758|NCT02314845|Intraoperative Period
122759|NCT02314832|femoral nerve block
122760|NCT02314832|adductor canal block
122761|NCT02314832|tinetti score
122762|NCT02314832|2- Results to time to up and go (TUG ) test
122763|NCT02314832|3- Results to Tinetti test
122764|NCT02314832|4- Ambulation distance
122765|NCT02314832|5- Pain scores at rest and with movement
122766|NCT02314819|colorectal cancer
122767|NCT02314793|Pharmacokinetics
122768|NCT02314793|ASP2205
122769|NCT02314741|poem
122770|NCT02314741|per oral endoscopic myotomy
122771|NCT02314741|achalasia
122772|NCT02314728|Bishop Score
122773|NCT02314728|Induction of Labor
122774|NCT02314728|Cervical Ripening
122775|NCT02314728|Unfavorable Cervix
122776|NCT02314728|Mode of Delivery
122777|NCT02314728|C-Section
122778|NCT02314728|Cesarean Section
122779|NCT02314715|Osteoarthritis Knee
122780|NCT02314702|Osteoarthritis
122781|NCT02314702|Avascular necrosis
122782|NCT02314702|Ankylosis
122783|NCT02314702|Protrusio acetabuli
122784|NCT02314702|Painful hip dysplasia
122785|NCT02314702|Rheumatoid arthritis
122786|NCT02314702|Correction of functional deformity
122787|NCT02314702|Revision procedures
122788|NCT02314663|hypercholesterolaemia
122789|NCT02314663|medication adherence
122790|NCT02314663|primary health care
122791|NCT02314637|DPP-IV inhibitor
122792|NCT02314611|osteoarthritis
122793|NCT02314611|avascular necrosis
122794|NCT02314611|ankylosis
122795|NCT02314611|protrusio acetabuli
122796|NCT02314611|painful hip dysplasia
122797|NCT02314611|rheumatoid arthritis
122798|NCT02314611|correction of functional deformity
122799|NCT02314611|revision procedures
122800|NCT02314572|Multifocal Intraocular Lens
122801|NCT02314572|Binocular Trifocality
122802|NCT02314572|Cataract Surgery
122803|NCT02314572|Spectacle Independence
122804|NCT02314572|Intermediate Vision
122805|NCT02314572|Photopic Vision
122806|NCT02314572|Mesopic Vision
122807|NCT02314572|Scotopic Vision
122808|NCT02314572|Binocular Vision
122809|NCT02314559|propofol
122810|NCT02314559|colonoscopy
122811|NCT02314507|Gua sha
122812|NCT02314481|NSCLC
122813|NCT02314481|Clonal dominance
122814|NCT02314481|Clonal evolution
122815|NCT02314481|Intratumour heterogeneity
122816|NCT02314481|Genomic instability
122817|NCT02314481|Drug resistance
122818|NCT02314481|Immunotherapy
122819|NCT02314481|PDL1
122820|NCT02314481|BRAF V600
122821|NCT02314481|ALK
122822|NCT02314481|RET
122823|NCT02314481|HER2 amplification
122824|NCT02314481|MPDL3280A
122825|NCT02314481|Vemurafenib
122826|NCT02314481|Alectinib
122827|NCT02314481|T-DM1
122828|NCT02314481|Trastuzumab emtansine
122829|NCT02314481|TRACERX
122830|NCT02314455|Eosinophilic Esophagitis
122831|NCT02314455|EoE
122832|NCT02314455|dysphagia
122833|NCT02314442|LDL-C
122834|NCT02314442|RNAi therapeutic
122835|NCT02314416|wounds, stem cells, collagen matrix, maturation
122836|NCT02314403|ESRD
122837|NCT02314390|Depression
122838|NCT02314390|Mindfulness
122839|NCT02314390|MBCT
122840|NCT02314364|Non-small cell lung cancer
122841|NCT02314364|Metastatic
122842|NCT02314364|EGFR
122843|NCT02314364|ALK
122844|NCT02314364|ROS1
122845|NCT02314364|Stereotactic Body Radiation Therapy
122846|NCT02314351|migraine disorders
122847|NCT02314351|migraine with aura
122848|NCT02314351|migraine without aura
122849|NCT02314351|pain management
122850|NCT02314351|emergency department
122851|NCT02314325|Factor VIII deficiency
122852|NCT02314325|Arthropathy
122853|NCT02314325|MRI
122854|NCT02314325|XRay
122855|NCT02314325|Joint
122856|NCT02314325|HJHS
122857|NCT02314312|Kidney transplantation
122858|NCT02314312|ECD
122859|NCT02314299|Macular edema
122860|NCT02314299|Macular degeneration
122861|NCT02314299|MTP-131
122862|NCT02314299|Ocuvia™
122863|NCT02314286|Rosuvastatin
122864|NCT02314286|severe preeclampsia
122865|NCT02314286|48 hours following delivery
122866|NCT02314260|labour induction
122867|NCT02314260|cervical length
122868|NCT02314260|trans-vaginal assessment of cervical length
122869|NCT02314260|Bishop score
122870|NCT02314247|PTCL
122871|NCT02314247|CTCL
122872|NCT02314247|Peripheral T-cell Lymphoma
122873|NCT02314247|Cutaneous T-cell Lymphoma
122874|NCT02314247|Karyopharm
122875|NCT02314247|KPT-330
122876|NCT02314247|Selinexor
122877|NCT02314221|Exoskeletal-assisted walking
122878|NCT02314208|spastic paraplegia
122879|NCT02314208|metabolism
122880|NCT02314208|oxysterols
122881|NCT02314208|neurogenetics
122882|NCT02314195|Obsessive Compulsive Disorder
122883|NCT02314195|Music Therapy/methods
122884|NCT02314195|Combined Modality Therapy
122885|NCT02314195|Anxiety Disorders/therapy
122886|NCT02314182|Rectal adenocarcinoma
122887|NCT02314182|unresectable
122888|NCT02314182|surgery
122889|NCT02314182|chemotherapy
122890|NCT02314143|dabrafenib
122891|NCT02314143|MEK
122892|NCT02314143|trametinib
122893|NCT02314143|BRAF
122894|NCT02314143|melanoma
122895|NCT02314143|Oncology
122896|NCT02314104|Surgical procedures, Minimally invasive
122897|NCT02314104|Nerve block
122898|NCT02314104|Anesthetics, Local
122899|NCT02314078|Caesarean section
122900|NCT02314078|Emergency
122901|NCT02314078|Anaesthesia
122902|NCT02314065|Severe health anxiety
122903|NCT02314065|Somatic symptom disorder
122904|NCT02314065|Illness anxiety disorder
122905|NCT02314065|Cognitive behavioral therapy
122906|NCT02314065|Internet
122907|NCT02314065|Exposure
122908|NCT02314013|uncomplicated diverticulitis, economic cost, hospital stay
122909|NCT02313974|Lupus Nephritis Treatment
122910|NCT02313974|Renal Biopsy in Lupus
122911|NCT02313974|Lupus Flare
122912|NCT02313961|ST elevation myocardial infarction
122913|NCT02313961|Reperfusion injury
122914|NCT02313961|Remote ischaemic conditioning
122915|NCT02313909|Rivaroxaban
122916|NCT02313909|Xarelto
122917|NCT02313909|Aspirin
122918|NCT02313909|ASA
122919|NCT02313909|Oral Anticoagulant
122920|NCT02313909|Blood Thinner
122921|NCT02313909|Stroke
122922|NCT02313909|Ischemic Stroke
122923|NCT02313909|Cryptogenic Stroke
122924|NCT02313909|Embolic stroke of undetermined source
122925|NCT02313909|ESUS
122926|NCT02313909|Transient Ischemic Attack
122927|NCT02313909|Thromboembolism
122928|NCT02313909|Cerebrovascular Disease
122929|NCT02313883|periodontitis
122930|NCT02313883|taurolidine (PerioSept(r))
122931|NCT02313883|scaling and root planing
122932|NCT02313870|Bullous pemphigoid
122933|NCT02313870|superpotent topical steroids
122934|NCT02313870|methotrexate
122935|NCT02313870|safety
122936|NCT02313857|Viralym-C
122937|NCT02313857|Viral infections post HSCT
122938|NCT02313857|Virus-specific T cells
122939|NCT02313844|BK virus
122940|NCT02313844|Virus specific T cells
122941|NCT02313844|Viral infections
122942|NCT02313831|autonomic nervous system
122943|NCT02313831|ventilatory anaerobic threshold
122944|NCT02313831|oxygen consumption
122945|NCT02313831|metabolic profile
122946|NCT02313831|exercise training
122947|NCT02313831|expiratory flow limitation
122948|NCT02313818|Posttraumatic Stress Disorder
122949|NCT02313818|Cognitive Processing Therapy
122950|NCT02313818|Active Duty Military
122951|NCT02313805|Insulin initiation
122952|NCT02313805|Insulin checklist
122953|NCT02313792|Hematopoietic stem cell transplantation
122954|NCT02313792|Palifermin
122955|NCT02313740|Influenza
122956|NCT02313740|Influenza Vaccines
122957|NCT02313714|heart failure, heart transplant, electrical stimulation
122958|NCT02313688|adenocarcinomas of esophagogastric junction
122959|NCT02313688|resection margin
122960|NCT02313688|length
122961|NCT02313688|prognosis
122962|NCT02313675|carpal tunnel syndrome
122963|NCT02313675|opioid analgesics
122964|NCT02313675|postoperative pain
122965|NCT02313675|IV tylenol
122966|NCT02313675|IV toradol
122967|NCT02313649|liver
122968|NCT02313649|fibrosis
122969|NCT02313649|elastography
122970|NCT02313649|ShearWave Elastography
122971|NCT02313649|ultrasound
122972|NCT02313610|Retreatment Pulmonary Tuberculosis, Qinbudan,
122973|NCT02313584|dabigatran
122974|NCT02313571|Epidural Analgesia
122975|NCT02313571|Pain
122976|NCT02313558|dentifrice
122977|NCT02313558|gingivitis
122978|NCT02313558|dental plaque
122979|NCT02313519|Infections
122980|NCT02313519|anastomotic leakage
122981|NCT02313506|Physical activity
122982|NCT02313506|Exercise
122983|NCT02313506|Osteoarthritis
122984|NCT02313506|Knee
122985|NCT02313506|Arthritis
122986|NCT02313441|remote ischemic preconditioning
122987|NCT02313428|Diabetic Foot Ulcer
122988|NCT02313428|Topical Oxygen Therapy
122989|NCT02313428|Medicaid Recipients
122990|NCT02313428|Standard of Care
122991|NCT02313363|Health care systems
122992|NCT02313363|Mobile applications
122993|NCT02313363|Self-care
122994|NCT02313363|Diabetes mellitus
122995|NCT02313363|Smartphone
122996|NCT02313350|Sciatica,
122997|NCT02313350|herniated disc,
122998|NCT02313350|chemonucleolysis.
122999|NCT02313337|Administration route
123000|NCT02313337|Preanesthetic medication
123001|NCT02313337|Sedation
123002|NCT02313324|Coccydynia
123003|NCT02313324|Extracorporeal shock wave therapy
123004|NCT02313324|Disability
123005|NCT02313311|Cleavage pattern, timing parameter, time-lapse
123006|NCT02313272|neoplasms
123007|NCT02313272|high-grade glioma
123008|NCT02313272|recurrent glioma
123009|NCT02313272|glioma
123010|NCT02313272|Hypofractionated Stereotactic Irradiation (HFSRT)
123011|NCT02313272|Bevacizumab
123012|NCT02313272|Pembrolizumab
123013|NCT02313272|recurrent high-grade glioma
123014|NCT02313272|Grade III malignant glioma
123015|NCT02313272|Grade IV malignant glioma
123016|NCT02313272|brain and nervous system
123017|NCT02313220|Obesity
123018|NCT02313220|Dapagliflozin
123019|NCT02313220|Exenatide
123020|NCT02313220|Combination treatment
123021|NCT02313220|Type 2 diabetes
123022|NCT02313181|breastfeeding
123023|NCT02313181|lactation
123024|NCT02313181|newborn
123025|NCT02313168|difficult airway; prediction, FRONT score.
123026|NCT02313155|Prevention
123027|NCT02313129|Infertility
123028|NCT02313129|Rheumatoid Arthritis
123029|NCT02313116|Lumpectomy
123030|NCT02313116|Breast cancer
123031|NCT02313116|Optical coherence tomography
123032|NCT02313116|Tumor margin
123033|NCT02313116|Imaging
123034|NCT02313103|ESRD
123035|NCT02313103|End Stage Renal Disease
123036|NCT02313103|Normal Healthy Volunteers
123037|NCT02313103|Renally Impaired
123038|NCT02313077|Healthy
123039|NCT02313077|Ebola viruses
123040|NCT02313077|Ebola Viral Disease (EVD)
123041|NCT02313077|Filoviruses
123042|NCT02313077|monovalent vaccine
123043|NCT02313077|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
123044|NCT02313077|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
123045|NCT02313077|Safety
123046|NCT02313077|Immunogenicity
123047|NCT02313051|metastatic breast cancer, everolimus
123048|NCT02313038|Coronary heart disease
123049|NCT02313038|Percutaneous Coronary Intervention
123050|NCT02313038|Drug Eluting Stents
123051|NCT02313012|Maximum Tolerated Dose
123052|NCT02313012|Solid Tumors
123053|NCT02313012|Locally Advanced Tumors
123054|NCT02313012|Metastatic Solid Tumors
123055|NCT02313012|Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors
123056|NCT02313012|Melanoma
123057|NCT02313012|Colorectal Carcinomas Papillary
123058|NCT02313012|Thyroid carcinomas
123059|NCT02313012|Pancreatic ductal Adenocarcinomas
123060|NCT02313012|Non -small cell lung cancer [NSCLC]
123061|NCT02312999|laparotomy
123062|NCT02312999|plasma-Lyte
123063|NCT02312999|volulyte
123064|NCT02312999|close loop
123065|NCT02312999|abdominal surgery
123066|NCT02312986|infection
123067|NCT02312986|colonization
123068|NCT02312986|antibiotic resistance
123069|NCT02312973|Chronic kidney disease
123070|NCT02312973|Pharmacokinetics
123071|NCT02312973|Hemodialysis
123072|NCT02312973|Peritoneal dialysis
123073|NCT02312973|Erythropoietin
123074|NCT02312934|Chemo brain
123199|NCT02312167|inflammatory
123075|NCT02312934|Chemotherapy-related cognitive impairment
123076|NCT02312934|CRCI
123077|NCT02312934|Breast cancer
123078|NCT02312934|Chemo fog
123079|NCT02312934|Nicotine
123080|NCT02312934|Transdermal nicotine
123081|NCT02312921|managed healthcare
123082|NCT02312921|child
123083|NCT02312921|dental care
123084|NCT02312908|REM Sleep Behavior Disorder
123085|NCT02312908|Parkinson Disease
123086|NCT02312908|Placebos
123087|NCT02312908|Randomized Controlled Trial
123088|NCT02312908|Double-Blind Method
123089|NCT02312908|Clinical Trial
123090|NCT02312869|Mechanical Ventilation
123091|NCT02312869|Burn patients
123092|NCT02312843|Mild Cognitive Impairment
123093|NCT02312843|Cognitive disorders
123094|NCT02312843|Prediabetes
123095|NCT02312843|Exercise
123096|NCT02312817|Carcinoma, Hepatocellular
123097|NCT02312817|Liver Neoplasms
123098|NCT02312817|Liver Disease
123099|NCT02312817|Early Detection of Cancer
123100|NCT02312817|Comparative Effectiveness Research
123101|NCT02312791|Radiation
123102|NCT02312791|Prognosis
123103|NCT02312791|Palliative Care
123104|NCT02312778|non-specific low back pain
123105|NCT02312778|center of pressure
123106|NCT02312778|spinal lumbar manipulation
123107|NCT02312778|high velocity and low amplitude manipulation
123108|NCT02312778|postural control
123109|NCT02312752|Intra-epidermal stimulation in healthy control subjects
123110|NCT02312739|pain assessment
123111|NCT02312739|pain measurement
123112|NCT02312739|patient satisfaction
123113|NCT02312739|anxiety
123114|NCT02312739|analgesia and anesthesia
123115|NCT02312739|female sterilization
123116|NCT02312726|mixed methods
123117|NCT02312726|visual analog scale
123118|NCT02312726|verbal rating score
123119|NCT02312726|pain assessment
123120|NCT02312726|patient satisfaction
123121|NCT02312726|contraceptive devices
123122|NCT02312726|postpartum
123123|NCT02312713|Osteoarthritis
123124|NCT02312713|Knee Osteoarthritis
123125|NCT02312700|empowerment
123126|NCT02312700|communication
123127|NCT02312700|shared decision making
123128|NCT02312687|XLH
123129|NCT02312687|FGF23
123130|NCT02312687|KRN23
123131|NCT02312674|pancreatic carcinoma
123132|NCT02312674|hepatocellular carcinoma
123133|NCT02312674|palliative therapy
123134|NCT02312674|oral nutritional supplements
123135|NCT02312674|quality of life
123136|NCT02312674|nutritional status
123137|NCT02312661|ovarian cancer
123138|NCT02312661|metformin
123139|NCT02312661|carboplatin
123140|NCT02312661|paclitaxel
123141|NCT02312648|Functional Capacity
123142|NCT02312648|Physical Exertion
123143|NCT02312648|Patient Care
123144|NCT02312648|Early mobilization
123145|NCT02312635|cognitive rehabilitation, traumatic brain injury
123146|NCT02312596|non-healing wound
123147|NCT02312596|diabetic foot ulcer
123148|NCT02312596|platelet rich plasma
123149|NCT02312583|depression
123150|NCT02312583|cognitive-behavior intervention
123151|NCT02312570|non-healing wounds
123152|NCT02312570|pressure ulcer
123153|NCT02312570|platelet rich plasma
123154|NCT02312531|HBV
123155|NCT02312531|Intrauterine infection
123156|NCT02312531|hepatitis B immunoglobulin
123157|NCT02312531|immune barrier
123158|NCT02312531|virus replication
123159|NCT02312531|placenta
123160|NCT02312518|non-healing wounds
123161|NCT02312518|venous stasis
123162|NCT02312518|ulcer
123163|NCT02312518|platelet rich plasma
123164|NCT02312505|cardiac output monitoring
123165|NCT02312505|semi-invasive pulse contour analysis
123166|NCT02312505|transpulmonary thermodilution
123167|NCT02312492|fatty acid kinetics
123168|NCT02312440|tranexamic acid
123169|NCT02312440|blood loss
123170|NCT02312440|topical administration
123171|NCT02312440|intravenous administration
123172|NCT02312401|MRI
123173|NCT02312401|14-172
123174|NCT02312388|central venous catheters
123175|NCT02312362|HFDS
123176|NCT02312362|ab interno
123177|NCT02312362|MIGS
123178|NCT02312362|surgery
123179|NCT02312349|Celiac Disease
123180|NCT02312349|Gluten free elaborated food
123181|NCT02312336|ST Elevation Myocardial Infarction
123182|NCT02312336|Transcoronary Cooling
123183|NCT02312258|Ixazomib
123184|NCT02312258|Newly diagnosed
123185|NCT02312219|HIV
123186|NCT02312219|Inflammation
123187|NCT02312219|Atherosclerosis
123188|NCT02312219|Positron-Emission Tomography
123189|NCT02312219|Imaging
123190|NCT02312219|fluorodeoxyglucose
123191|NCT02312193|hypertension
123192|NCT02312193|myogenic tone
123193|NCT02312167|endomicroscopy
123194|NCT02312167|optical biopsy
123195|NCT02312167|exploratory surgery
123196|NCT02312167|resection surgery
123197|NCT02312167|robot-assisted
123198|NCT02312167|peritoneum carcinosis
123200|NCT02312167|rectum cancer
123201|NCT02312167|liver cancer
123202|NCT02312167|ovarian cancer
123203|NCT02312167|digestive cancer
123204|NCT02312167|pancreas cancer
123205|NCT02312167|duodenum cancer
123206|NCT02312128|distal radius fractures
123207|NCT02312128|early mobilization
123208|NCT02312128|postoperative treatment
123209|NCT02312128|outcome
123210|NCT02312115|Renal transplant
123211|NCT02312115|Kidney transplant
123212|NCT02312115|DGF
123213|NCT02312102|myelodysplastic syndrome
123214|NCT02312102|acute myeloid leukemia
123215|NCT02312102|allogeneic stem cell transplantation
123216|NCT02312089|Luteal phase support, ICSI, GnRHa
123217|NCT02312076|Luteal phase support, ICSI, GnRHa
123218|NCT02312063|DPP-4 inhibitor
123219|NCT02312063|sulfonylurea
123220|NCT02312037|Relapsed CD33 AML
123221|NCT02312037|Refractory CD33 AML
123222|NCT02312037|Relapsed CD33 APL
123223|NCT02312037|Refractory CD33 APL
123224|NCT02312037|Relapsed CD33 MDS
123225|NCT02312037|Refractory CD33 MDS
123226|NCT02312024|CytoSorb adsorber
123227|NCT02312024|sepsis
123228|NCT02312024|cytokines
123229|NCT02312024|hemofiltration
123230|NCT02312024|hemadsorption
123231|NCT02312024|inflammation
123232|NCT02312011|Myotonic Dystrophy
123233|NCT02312011|DM1
123234|NCT02312011|Adult onset
123235|NCT02312011|Neuromuscular Disease
123236|NCT02312011|DMPKRx
123237|NCT02311998|Leukemia
123238|NCT02311998|CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
123239|NCT02311998|ALL
123240|NCT02311998|Chronic Myeloid Leukemia Lymphoid Blast Phase
123241|NCT02311998|CML
123242|NCT02311998|Bosutinib
123243|NCT02311998|SKI-606
123244|NCT02311998|Inotuzumab Ozogamicin
123245|NCT02311998|CMC-544
123246|NCT02311998|Phone Call
123247|NCT02311985|Liver cirrhosis
123248|NCT02311985|Blood coagulation
123249|NCT02311985|Thromboelastography
123250|NCT02311985|Blood transfusion
123251|NCT02311985|Catheterization, central venous
123252|NCT02311959|Breast
123253|NCT02311959|Invasive carcinoma
123254|NCT02311959|In situ carcinoma
123255|NCT02311959|Mastectomy
123256|NCT02311959|Nipple areola
123257|NCT02311959|Reconstruction
123258|NCT02311959|Local recurrence
123259|NCT02311946|Palbociclib, Rabeprazole, Proton Pump Inhibitor, Drug Interaction Study, DDI
123260|NCT02311829|Quality of life, PNES, Epilepsy,
123261|NCT02311816|Bacterial infection, empiric antibiotic therapy
123262|NCT02311790|cis-C16:1n7 supplement
123263|NCT02311790|trans-C16:1n7 supplement
123264|NCT02311790|palmitoleic acid supplement
123265|NCT02311751|Autism Spectrum Disorder
123266|NCT02311751|Executive Function
123267|NCT02311751|rTMS (Repetitive Transcranial Magnetic Stimulation)
123268|NCT02311751|MRI (Magnetic Resonance Imaging)
123269|NCT02311751|Healthy Subjects
123270|NCT02311738|Exercise and Genes in Obese (EGO)
123271|NCT02311725|narrative communication
123272|NCT02311725|depression
123273|NCT02311725|antidepressant augmentation
123274|NCT02311725|primary care
123275|NCT02311712|Esophageal cancer
123276|NCT02311712|Early detection
123277|NCT02311712|Cytological examination
123278|NCT02311699|Gender
123279|NCT02311699|Physical Violence
123280|NCT02311699|Sexual Violence
123281|NCT02311699|HIV
123282|NCT02311699|AIDS
123283|NCT02311699|Prevention
123284|NCT02311699|Community Intervention
123285|NCT02311699|Ethiopia
123286|NCT02311699|Intimate Partner Violence
123287|NCT02311686|Ethanol
123288|NCT02311686|Fatty acid ethyl esters
123289|NCT02311686|Ethyl glucoronide
123290|NCT02311686|Ethyl sulphate
123291|NCT02311686|Pharmacokinetics
123292|NCT02311673|Prader-Willi Syndrome
123293|NCT02311673|obesity
123294|NCT02311673|hyperphagia
123295|NCT02311647|Tamoxifen
123296|NCT02311647|Uterine cavity
123297|NCT02311647|endometrium
123298|NCT02311634|Electrical pudendal nerve stimulation
123299|NCT02311634|Transvaginal electrical stimulation
123300|NCT02311634|Urge urinary incontinence
123301|NCT02311634|Comparative study
123302|NCT02311608|acute variceal hemorrhage
123303|NCT02311608|terlipressin
123304|NCT02311608|somatostatin
123305|NCT02311608|octreotide
123306|NCT02311608|comparative effectiveness research
123307|NCT02311595|gastric cancer
123308|NCT02311595|laparoscope
123309|NCT02311569|JAK2
123310|NCT02311569|Mirabegron
123311|NCT02311569|Primary myelofibrosis
123312|NCT02311569|beta-3-mimetic drugs
123313|NCT02311569|Myeloproliferative neoplasm
123314|NCT02311569|Essential thrombocythemia
123315|NCT02311569|Polycythemia vera
123316|NCT02311569|Betmiga
123317|NCT02311569|JAK2-V617F
123318|NCT02311543|Axillary Lymph Node Dissection (ALND)
123319|NCT02311543|Breast Cancer
123320|NCT02311543|TachoSil®
123321|NCT02311543|Lymphatic Drainage
123322|NCT02311543|Surgical Sealing Patch
123323|NCT02311491|nano crystalline
123324|NCT02311491|archwire
123325|NCT02311465|Palliative Care
123326|NCT02311439|Locally advanced pancreatic cancer
123327|NCT02311439|Chemotherapy
123328|NCT02311439|Radiotherapy
123329|NCT02311426|Rehabilitation; Functional outcome
123330|NCT02311413|Allergic rhinoconjunctivitis
123331|NCT02311400|Emotion
123332|NCT02311400|Self-Affirmation
123333|NCT02311400|Alcohol Consumption
123334|NCT02311387|Incidence
123335|NCT02311387|Prevalence
123336|NCT02311387|Human
123337|NCT02311387|Mastomys
123338|NCT02311387|Serosurvey
123339|NCT02311374|Human Brain
123340|NCT02311374|Sleep
123341|NCT02311374|EEG
123342|NCT02311374|Magnetic Resonance Imaging (MRI)
123343|NCT02311374|Apparent Diffusion Coefficient
123344|NCT02311361|Anti-PDL1
123345|NCT02311361|Anti-CTLA4
123346|NCT02311361|Streostatic Body Radiation Therapy (SBRT)
123347|NCT02311348|Biopsy
123348|NCT02311348|Pain
123349|NCT02311335|Hypertriglyceridemia
123350|NCT02311335|Atherosclerosis
123351|NCT02311335|Genectic Variants
123352|NCT02311335|Hyperalphalipoproteinemia
123353|NCT02311335|Dyslipidemia
123354|NCT02311322|Growth Disorder
123355|NCT02311322|Growth
123356|NCT02311322|Exome Sequencing
123357|NCT02311244|All-cause mortality
123358|NCT02311244|Cardiovascular mortality
123359|NCT02311244|Myocardial infarction
123360|NCT02311244|Stroke
123361|NCT02311244|Dialysis
123362|NCT02311218|oral, microbiota, lactobacillus reuteri,
123363|NCT02311205|Transarterial Chemoembolization (TACE)
123364|NCT02311205|Hepatocellular carcinoma (HCC)
123365|NCT02311205|Metastasis
123366|NCT02311205|Sorafenib
123367|NCT02311192|Vitreous Haze
123368|NCT02311192|Ocular ultrasound
123369|NCT02311192|B scan
123370|NCT02311192|Uveitis
123371|NCT02311179|Prosthesis fixation
123372|NCT02311179|hip arthroplasty
123373|NCT02311166|Hip dysplasia
123374|NCT02311166|Soft tissue
123375|NCT02311166|Hip
123376|NCT02311166|Self-report
123377|NCT02311166|Physical activity
123378|NCT02311140|cystic fibrosis
123379|NCT02311140|nasal lavage
123380|NCT02311140|inflammation
123381|NCT02311140|Interleukin (IL)-6
123382|NCT02311140|IL-8
123383|NCT02311140|pulmonary function
123384|NCT02311127|Peripherally Inserted Central Catheters
123385|NCT02311127|Securement device
123386|NCT02311114|Program Evaluation
123387|NCT02311114|Telehomecare
123388|NCT02311114|Chronic Obstructive Pulmonary Disease
123389|NCT02311114|Heart Failure
123390|NCT02311114|LHINs
123391|NCT02311114|Local Health Integrative Network
123392|NCT02311114|OTN
123393|NCT02311114|Ontario Telemedicine Network
123394|NCT02311101|bladder cancer
123395|NCT02311101|mitomycin
123396|NCT02311101|BCG
123397|NCT02311101|intravesical
123398|NCT02311101|non-muscle invasive
123399|NCT02311062|training, soccer, eccentric, lengthening, unstable, squatting
123400|NCT02311036|Post Acute Care(PAC)
123401|NCT02311036|Cerebrovascular diseases
123402|NCT02311010|transplant
123403|NCT02311010|immunosuppressive drug
123404|NCT02310984|Early breast cancer
123405|NCT02310984|Lumpectomy
123406|NCT02310984|Breast conserving surgery
123407|NCT02310984|Radiotherapy
123408|NCT02310984|Cosmesis
123409|NCT02310971|Adenocarcinoma, resected
123410|NCT02310958|Lapraroscopic surgical procedure
123411|NCT02310958|infant
123412|NCT02310958|complications
123413|NCT02310958|inguinal hernia
123414|NCT02310958|hernia recurrence
123415|NCT02310945|pain
123416|NCT02310945|central nervous system sensitization
123417|NCT02310945|physiotherapy
123418|NCT02310932|mental health
123419|NCT02310932|cardiovascular disease
123420|NCT02310932|diabetes
123421|NCT02310932|hypertension
123422|NCT02310932|high blood pressure
123423|NCT02310919|Infertility
123424|NCT02310919|In vitro fertilization
123425|NCT02310919|IVF
123426|NCT02310906|Duchenne muscular dystrophy
123427|NCT02310906|Exon Skipping
123428|NCT02310867|hand transplantation, amputation
123429|NCT02310854|anterior cruciate ligament rupture
123430|NCT02310854|autograft
123431|NCT02310854|reconstruction
123432|NCT02310854|orthopedic surgery
123433|NCT02310854|dynamic intraligament stabilization
123434|NCT02310828|Cluster headache
123435|NCT02310828|Migrainous neuralgia
123436|NCT02310828|Horton's headache
123437|NCT02310828|Histaminic cephalalgia
123438|NCT02310802|IVF
123439|NCT02310802|ICSI
123440|NCT02310763|Duchenne Muscular Dystrophy, myostatin
123441|NCT02310737|cesarean section
123442|NCT02310737|facial incision
123443|NCT02310737|postoperative pain
123444|NCT02310724|youth onset type 2 diabetes
123445|NCT02310724|insulin sensitivity
123446|NCT02310724|beta cell function
123447|NCT02310724|macrovascular comorbidities
123448|NCT02310724|microvascular comorbidities
123449|NCT02310711|Breast
123450|NCT02310711|Mastectomy
123451|NCT02310711|Lumpectomy
123452|NCT02310711|Breast Therapy
123453|NCT02310698|Ultrasound
123454|NCT02310698|Enhanced Mammography
123455|NCT02310698|14-240
123456|NCT02310685|Cardivascular risks (hypertension, sedentary, overweight)
123457|NCT02310685|Cardiovascular age
123458|NCT02310685|E-health wellness program
123459|NCT02310685|Prevention
123460|NCT02310685|Community pharmacists
123461|NCT02310685|Lifestyle change
123462|NCT02310685|Cardiometabolic age
123463|NCT02310672|Pulmonary Arterial Hypertension
123464|NCT02310633|TBI
123465|NCT02310633|memory disorder
123466|NCT02310633|injury, brain, traumatic
123467|NCT02310633|rehabilitation
123468|NCT02310607|Post-partum women
123469|NCT02310581|Bunionectomy
123470|NCT02310568|PF 06372865
123471|NCT02310568|generalized anxiety disorder
123472|NCT02310568|outpatient
123473|NCT02310568|safety
123474|NCT02310568|efficacy
123475|NCT02310568|suboptimal response
123476|NCT02310555|Metabolic surgery
123477|NCT02310529|Maternal depression
123478|NCT02310529|Interpersonal Psycotherapy
123479|NCT02310503|Mohs Surgery
123480|NCT02310490|Nasolabial Folds
123481|NCT02310477|regorafenib, cohort, metastatic colorectal cancer
123482|NCT02310438|Music therapy
123483|NCT02310438|stroke
123484|NCT02310438|hemiparesis
123485|NCT02310438|neurologic music therapy
123486|NCT02310412|INTERCEPT
123487|NCT02310412|platelet
123488|NCT02310412|pathogen inactivation
123489|NCT02310412|platelet components stored
123490|NCT02310412|therapeutic efficacy
123491|NCT02310399|Auditory Brainstem Implant
123492|NCT02310399|Deafness
123493|NCT02310399|Hearing Loss
123494|NCT02310399|ABI
123495|NCT02310386|Fibromyalgia
123496|NCT02310386|Electromagnetic field therapy
123497|NCT02310386|Randomized controlled trial
123498|NCT02310373|Nicotine-free hookah
123499|NCT02310373|Waterpipe
123500|NCT02310373|Smoking
123501|NCT02310373|Sympathetic
123502|NCT02310321|Acute Myeloid Leukemia
123503|NCT02310321|Cytarabine
123504|NCT02310321|Idarubicin
123505|NCT02310321|ASP2215
123506|NCT02310308|Xylitol
123507|NCT02310308|Magnolia
123508|NCT02310308|chewing gum
123509|NCT02310295|Diabetic retinopathy
123510|NCT02310295|Macular edema
123511|NCT02310295|Anti-VEGF
123512|NCT02310295|Triamcinolone
123513|NCT02310282|Telemedicine
123514|NCT02310282|Emergency medicine
123515|NCT02310282|Stroke
123516|NCT02310282|Stroke syndromes
123517|NCT02310269|Cushing's disease,
123518|NCT02310269|pasireotide s.c.
123519|NCT02310269|Signifor
123520|NCT02310256|Mitochondria, muscle
123521|NCT02310256|Exercise
123522|NCT02310256|Blood Flow Velocity
123523|NCT02310243|Acute myeloid leukemia
123524|NCT02310243|Acute lymphoblastic leukemia
123525|NCT02310243|MLL-rearranged leukemia
123526|NCT02310243|Palbociclib (PD-0332991-00)
123527|NCT02310230|Endoscopy, Upper
123528|NCT02310230|Minute Ventilation
123529|NCT02310230|Tidal Volume
123530|NCT02310230|Respiratory Rate
123531|NCT02310217|Hypertension
123532|NCT02310217|Cognitive impairment
123533|NCT02310217|Biomarkers
123534|NCT02310191|ischemic stroke
123535|NCT02310191|carotid stenting
123536|NCT02310191|MRI diffusion weighted imaging
123537|NCT02310191|Laboratory marker
123538|NCT02310178|weight loss
123539|NCT02310178|sleeve gastrectomy
123540|NCT02310178|gastric bypass
123541|NCT02310178|gastric banding
123542|NCT02310178|bariatric procedures
123543|NCT02310178|cohort
123544|NCT02310178|morbid obesity
123545|NCT02310178|medical and economical impact
123546|NCT02310178|severe obesity
123547|NCT02310165|Paracentesis
123548|NCT02310165|Ascites
123549|NCT02310152|Child
123550|NCT02310152|Adolescent
123551|NCT02310152|Parents
123552|NCT02310152|Cognitive Therapy
123553|NCT02310152|Cognitive Behavior Therapy
123554|NCT02310152|Anxiety
123555|NCT02310113|NIRS
123556|NCT02310113|transfusion
123557|NCT02310113|RBC
123558|NCT02310087|male infertility
123559|NCT02310087|spermatogenesis
123560|NCT02310087|antioxidants
123561|NCT02310087|DNA damage
123562|NCT02310087|mitochondrial membrane potential
123563|NCT02310087|apoptosis
123564|NCT02310061|Dialysis
123565|NCT02310061|ESRD
123566|NCT02310061|lung congestion
123567|NCT02310061|heart failure
123568|NCT02310061|LW-US
123569|NCT02310009|Exercise
123570|NCT02310009|IL-1RA
123571|NCT02310009|Beta-cell function
123572|NCT02310009|Type 2 Diabetes
123573|NCT02309996|Randomized Controlled Trial
123574|NCT02309996|Intervention Studies
123575|NCT02309996|Inservice Training
123576|NCT02309996|Personnel Management
123577|NCT02309996|Work place
123578|NCT02309996|Work accommodation
123579|NCT02309996|Job modification
123580|NCT02309996|Supervision
123581|NCT02309996|Administration
123582|NCT02309996|Return to Work
123583|NCT02309996|Industrial Psychology
123584|NCT02309996|Human Engineering
123585|NCT02309996|Risk Management
123586|NCT02309996|Organization and Administration
123587|NCT02309996|Work Disability
123588|NCT02309996|Occupational Diseases
123589|NCT02309996|Occupational Injury
123590|NCT02309996|Occupational Health
123591|NCT02309996|Occupational Exposure
123592|NCT02309996|Sick Leave
123593|NCT02309996|Absenteeism
123594|NCT02309996|Employee Health
123595|NCT02309983|bone turnover
123596|NCT02309983|muscle atrophy
123597|NCT02309983|fiber
123598|NCT02309957|Knee Cartilage Repair, Osteochondral Defects, BioMatrix CRD
123599|NCT02309944|Wound Healing
123600|NCT02309944|Obesity
123601|NCT02309944|Gynecologic Surgery
123602|NCT02309944|Gynecologic Neoplasms
123603|NCT02309944|Surgical Complications
123604|NCT02309931|Right hemicolectomy
123605|NCT02309931|Side-to-side anastomosis
123606|NCT02309931|Orocecal time
123607|NCT02309931|Antipersitaltic
123608|NCT02309931|Isoperistaltic
123609|NCT02309931|Laparoscopic colectomy
123610|NCT02309931|Right laparoscopic hemicolectomy
123611|NCT02309918|acute HCV Genotype 1 Infection
123612|NCT02309918|HCV RNA
123613|NCT02309918|LDV/SOF FDC
123614|NCT02309905|inmates
123615|NCT02309905|skin lesion
123616|NCT02309905|telemedicine
123617|NCT02309892|Non-Small Cell Lung Cancer
123618|NCT02309892|Neoplasms
123619|NCT02309892|Immunoconjugate
123620|NCT02309892|Tumor microenvironment alkalinization
123621|NCT02309879|Intravenous lidocaine
123622|NCT02309879|Magnesium sulphate
123623|NCT02309879|Mastectomy
123624|NCT02309879|Pain
123625|NCT02309827|Inflammatory bowel disease
123626|NCT02309723|Alzheimer's Disease
123627|NCT02309723|Mild Cognitive Impairment
123628|NCT02309723|Neuroimaging
123629|NCT02309723|Diagnostic Tool
123630|NCT02309697|Development
123631|NCT02309697|Assessments
123632|NCT02309697|Premature birth
123633|NCT02309684|Diabetic Foot Ulcer (DFU)
123634|NCT02309684|Venous Leg Ulcer (VLU)
123635|NCT02309658|cervix neoplasm
123636|NCT02309658|hENT1 protein, human
123637|NCT02309658|Chemotherapy
123638|NCT02309645|fibrin sealant
123639|NCT02309645|CSF leak
123640|NCT02309619|esophageal cancer
123641|NCT02309619|esophagectomy
123642|NCT02309619|quality of life
123643|NCT02309593|osteoarthritis
123644|NCT02309593|avascular necrosis
123645|NCT02309593|ankylosis
123646|NCT02309593|protrusio acetabuli
123647|NCT02309593|painful hip dysplasia
123648|NCT02309593|rheumatoid arthritis
123649|NCT02309593|correction of functional deformity
123650|NCT02309593|revision procedures
123651|NCT02309580|Ibrutinib
123652|NCT02309580|14-227
123653|NCT02309567|Anti-p53 antibody
123654|NCT02309567|PET/CT
123655|NCT02309567|Lung Cancer
123656|NCT02309567|FDG
123657|NCT02309554|Contraception
123658|NCT02309554|Post coital test
123659|NCT02309554|Vaginal
123660|NCT02309554|Diaphragm
123661|NCT02309541|middle ear implant
123662|NCT02309541|feedback manager
123663|NCT02309541|Sound quality
123664|NCT02309502|diabetic retinopathy
123665|NCT02309502|retina
123666|NCT02309502|Laser
123667|NCT02309502|Pascal
123668|NCT02309489|Family Planning Services
123669|NCT02309489|Maternal Health Services
123670|NCT02309489|Breast Feeding
123671|NCT02309489|Contraception
123672|NCT02309489|Postnatal care
123673|NCT02309489|Postpartum contraception
123674|NCT02309489|Exclusive breastfeeding
123675|NCT02309489|Postpartum Period
123676|NCT02309476|diffuse diabetic macular oedema
123677|NCT02309476|Pascal
123678|NCT02309476|Laser
123679|NCT02309476|DMO
123680|NCT02309437|Nasopharyngeal carcinoma
123681|NCT02309437|Pain
123682|NCT02309437|Oxycodone
123683|NCT02309437|Opioids
123684|NCT02309437|Oral Mucositis
123685|NCT02309411|Pediatric
123686|NCT02309385|uveitis
123687|NCT02309385|acute uveitis
123688|NCT02309385|anterior uveitis
123689|NCT02309385|dexamethasone sodium phosphate
123690|NCT02309385|non-infectious uveitis
123691|NCT02309385|DSP-Visulex
123692|NCT02309385|Aciont
123693|NCT02309346|clindamycin
123694|NCT02309346|septic abortion
123695|NCT02309307|safety and performance
123696|NCT02309294|Patch Test
123697|NCT02309281|Eylea
123698|NCT02309268|left atrial appendage closure
123699|NCT02309255|Secondary coronary prevention
123700|NCT02309255|Psychosocial factors
123701|NCT02309255|Cardiac rehabilitation
123702|NCT02309229|sputum colour
123703|NCT02309229|cystic fibrosis
123704|NCT02309229|pollution
123705|NCT02309190|Transpulmonary pressure - morbid obesity
123706|NCT02309177|Pancreatic Cancer
123707|NCT02309177|Breast Cancer
123708|NCT02309177|Metastatic Breast Cancer
123709|NCT02309177|nab-Paclitaxel
123710|NCT02309177|Gemcitabine
123711|NCT02309177|Carboplatin
123712|NCT02309177|Non-Small Cell Lung Cancer
123713|NCT02309177|Lung Cancer
123714|NCT02309177|mBC
123715|NCT02309177|NSCLC
123716|NCT02309177|Triple-negative Breast Cancer
123717|NCT02309177|Hormone Receptor Positive
123718|NCT02309177|ER+
123719|NCT02309177|PR+
123720|NCT02309177|TNBC
123721|NCT02309177|Nivolumab
123722|NCT02309177|PD-1
123723|NCT02309177|Check-point Inhibitor/s
123724|NCT02309177|Immune Check-point Inhibitor/s
123725|NCT02309177|Anti-PD-1
123726|NCT02309177|BMS-936558
123727|NCT02309125|immediate gradual loading
123728|NCT02309099|Acoustic Neuroma
123729|NCT02309099|Vestibular Schwannoma
123730|NCT02309099|Meniere's Disease
123731|NCT02309060|narrative communication
123732|NCT02309060|depression
123733|NCT02309060|primary care
123734|NCT02309060|treatment development
123735|NCT02309034|Overweight
123736|NCT02309034|Obesity
123737|NCT02309034|Cardiometabolic risk factors
123738|NCT02309034|Adolescents
123739|NCT02309034|Exercise
123740|NCT02309021|craving
123741|NCT02309008|Pharmacokinetics
123742|NCT02308995|Endometriosis
123743|NCT02308995|Laparoscopy
123744|NCT02308995|Barbed sutures
123745|NCT02308982|encephalitis
123746|NCT02308982|meningoencephalitis
123747|NCT02308982|encephalomyelitis
123748|NCT02308982|brain inflammation
123749|NCT02308982|intravenous immunoglobulin
123750|NCT02308982|randomised controlled trial
123751|NCT02308982|Central Nervous System Diseases
123752|NCT02308982|Central Nervous System Infection
123753|NCT02308969|altered state of consciousness
123754|NCT02308969|functional magnetic resonance imaging (fMRI)
123755|NCT02308969|hallucination
123756|NCT02308969|model psychosis
123757|NCT02308969|serotonin receptor
123758|NCT02308969|LSD
123759|NCT02308956|task sharing
123760|NCT02308956|task shifting
123761|NCT02308956|community mental health care
123762|NCT02308956|primary care
123763|NCT02308956|Developing country
123764|NCT02308956|Sub-Saharan Africa
123765|NCT02308956|non-inferiority trial
123766|NCT02308917|IBD
123767|NCT02308917|Crohn's
123768|NCT02308917|Ulcerative
123769|NCT02308917|Colitis
123770|NCT02308904|Infertility
123771|NCT02308904|Thalassemia
123772|NCT02308904|Iron overload
123773|NCT02308904|Pituitary Iron Load
123774|NCT02308904|Oxidative Stress
123775|NCT02308904|REPRODUCTIVE CAPACITY AND ASSOCIATION TO IRON BURDEN AND CHELATION PATTERNS IN THALASSEMIA MAJOR PATIENTS
123776|NCT02308891|pancreatitis
123777|NCT02308891|ERCP
123778|NCT02308878|Opioid abuse
123779|NCT02308878|Cognitive Therapy
123780|NCT02308878|Executive Function
123781|NCT02308878|Mobile Health
123782|NCT02308878|Rehabilitation
123783|NCT02308865|Early palliative care
123784|NCT02308865|Lung cancer
123785|NCT02308865|Quality of life
123786|NCT02308852|bi-manual , motor skill learning , stroke , chronic patients,neuro-rehabilitative robot
123787|NCT02308839|Aneurysm
123788|NCT02308839|Aorta
123789|NCT02308839|Abdominal
123790|NCT02308800|diabetic foot ulcer
123791|NCT02308787|platelet depletion
123792|NCT02308787|apheresis
123793|NCT02308774|osteomyelitis, diabetic foot infection
123794|NCT02308735|gestation
123795|NCT02308735|diabetes
123796|NCT02308735|ethanol
123797|NCT02308722|Borderline resectable
123798|NCT02308709|Radiotherapy
123799|NCT02308709|Pulmonary Functional Imaging
123800|NCT02308709|Computed Tomography (CT)
123801|NCT02308709|Image Registration
123802|NCT02308709|Functional Image-guided Radiotherapy
123803|NCT02308696|Older Adults
123804|NCT02308696|Aging in Place
123805|NCT02308683|hscrp
123806|NCT02308683|hgba1c
123807|NCT02308683|diabetes mellitus
123808|NCT02308644|Diabetic Retinopathy
123809|NCT02308644|intravitreal bevacizumab
123810|NCT02308644|Contrast Sensitivity
123811|NCT02308631|Endoscopic, Colostomy, Colopexy
123812|NCT02308618|Achilles tendon rupture
123813|NCT02308618|Rehabilitation
123814|NCT02308618|Immobilization
123815|NCT02308618|Muscle architecture
123816|NCT02308618|Functionality
123817|NCT02308618|Neuromuscular parameters
123818|NCT02308618|Weight-Bearing
123819|NCT02308605|SMARTCap
123820|NCT02308592|Pregnancy
123821|NCT02308592|Depression
123822|NCT02308592|Antidepressant Use
123823|NCT02308592|Decision Aid
123824|NCT02308566|Intracranial Embolism
123825|NCT02308566|Ultrasonography, Doppler, Transcranial
123826|NCT02308553|BRAF V600 wildtype
123827|NCT02308553|cutaneous malignant melanoma
123828|NCT02308553|nintedanib
123829|NCT02308553|paclitaxel
123830|NCT02308553|kinase inhibitor
123831|NCT02308527|Children
123832|NCT02308527|Young adults
123833|NCT02308514|cryostimulation
123834|NCT02308488|prone IMRT to breast, level III & Supraclavicular
123835|NCT02308488|acute toxicity of prone IMRT to breast, level III & SCV
123836|NCT02308462|children of mentally ill parents
123837|NCT02308462|family intervention
123838|NCT02308462|randomized controlled trial
123839|NCT02308410|Tourniquet
123840|NCT02308410|Postoperative outcome
123841|NCT02308410|Total knee arthroplasty
123842|NCT02308397|non coeliac gluten sensitivity
123843|NCT02308397|gluten
123844|NCT02308397|bread
123845|NCT02308384|iFOBT
123846|NCT02308384|FIT
123847|NCT02308384|general practice
123848|NCT02308384|early diagnosis
123849|NCT02308371|critically ill pediatric patients
123850|NCT02308371|fluid resuscitation
123851|NCT02308358|Osteochondral Defect
123852|NCT02308358|Femoral condyle osteochondral defect
123853|NCT02308319|Hepatocellular carcinoma, Recurrence
123854|NCT02308306|Chronic pain
123855|NCT02308306|Opioid analgesics
123856|NCT02308306|Prediction study
123857|NCT02308306|Pharmaco-EEG
123858|NCT02308293|Type 1 Diabetes Mellitus
123859|NCT02308293|Hypoglycemia unawareness
123860|NCT02308293|Lactate
123861|NCT02308293|high intensity interval exercise
123862|NCT02308293|MRS
123863|NCT02308280|High-risk myeloma
123864|NCT02308280|Non myeloablative allogeneic transplantation
123865|NCT02308280|Bortezomib
123866|NCT02308267|Cystic Fibrosis
123867|NCT02308267|Mucosal immunity
123868|NCT02308254|Blood pressure
123869|NCT02308254|Gastric emptying
123870|NCT02308254|Glycemia
123871|NCT02308254|Appetite
123872|NCT02308254|Incretin Hormones
123873|NCT02308254|Superior mesenteric artery blood low
123874|NCT02308241|Ribavirin
123875|NCT02308241|Human Papillomavirus (HPV)
123876|NCT02308241|Recurrent/Metastatic (R/M)
123877|NCT02308241|14-211
123878|NCT02308228|Aging
123879|NCT02308228|Hypertrophy
123880|NCT02308228|Metformin
123881|NCT02308228|Strength
123882|NCT02308228|Muscle
123883|NCT02308215|Retina
123884|NCT02308215|AMD
123885|NCT02308215|OCT
123886|NCT02308202|PTSD
123887|NCT02308202|treatment
123888|NCT02308202|virtual reality
123889|NCT02308202|doxazosin
123890|NCT02308189|Exercise
123891|NCT02308163|Rheumatoid Arthritis
123892|NCT02308163|ASP015K
123893|NCT02308150|transcatheter aortic valve replacement
123894|NCT02308150|asian pacific
123895|NCT02308150|asian
123896|NCT02308111|Primary Biliary Cirrhosis
123897|NCT02308111|PBC
123898|NCT02308111|Cirrhosis
123899|NCT02308111|Liver
123900|NCT02308085|Premenopausal
123901|NCT02308085|endocrine responsive
123902|NCT02308085|Breast
123903|NCT02308085|Pregnancy
123904|NCT02308072|Squamous Cell Carcinoma
123905|NCT02308072|Head and Neck Cancer
123906|NCT02308072|Locally Advanced
123907|NCT02308072|Olaparib
123908|NCT02308072|Cisplatin
123909|NCT02308072|IMRT
123910|NCT02308072|Chemoradiotherapy
123911|NCT02308072|PARP
123912|NCT02308072|HNSCC
123913|NCT02307994|infertility
123914|NCT02307942|Randomized Clinical Trials
123915|NCT02307942|gastric banding
123916|NCT02307942|calorie restriction
123917|NCT02307942|SPPB
123918|NCT02307942|physical performance
123919|NCT02307942|elderly
123920|NCT02307916|tympanic membrane perforation
123921|NCT02307916|ear drum
123922|NCT02307916|hole
123923|NCT02307903|end-stage renal failure (ESRF)
123924|NCT02307890|Liver Transplantation
123925|NCT02307864|Healthy
123926|NCT02307864|QT interval
123927|NCT02307864|QTc interval
123928|NCT02307864|Electrocardiogram
123929|NCT02307864|Tramadol hydrochloride
123930|NCT02307864|Moxifloxacin
123931|NCT02307864|Placebo
123932|NCT02307838|Multiple Sclerosis, MS, RRMS, relapsing forms of multiple sclerosis, fingolimod, FTY720, Gilenya
123933|NCT02307825|Azithromycin
123934|NCT02307825|Endoscopic sinus surgery
123935|NCT02307799|tobacco
123936|NCT02307799|spirometry
123937|NCT02307799|cohort study
123938|NCT02307799|case-control study
123939|NCT02307799|prevalence
123940|NCT02307773|Upper Gastrointestinal Endoscopy
123941|NCT02307773|Pharyngeal Anesthesia
123942|NCT02307773|Lidocaine
123943|NCT02307773|Belching
123944|NCT02307773|Retching
123945|NCT02307773|Tolerance
123946|NCT02307747|infection in ICU
123947|NCT02307734|Lay Health Workers
123948|NCT02307734|Chinese
123949|NCT02307734|Vietnamese
123950|NCT02307734|Tobacco Use
123951|NCT02307734|Intervention
123952|NCT02307734|Behavior Change
123953|NCT02307734|Social Networks
123954|NCT02307734|Asians
123955|NCT02307721|Emergency Treatment
123956|NCT02307721|Morphine Derivates
123957|NCT02307721|Heroin
123958|NCT02307721|Antidotes
123959|NCT02307721|Administration, Intranasal
123960|NCT02307721|Pharmacology
123961|NCT02307721|Naloxone
123962|NCT02307721|Healthy volunteers
123963|NCT02307695|Saxagliptin
123964|NCT02307695|Type 1 Diabetes
123965|NCT02307695|Glycemic variability
123966|NCT02307695|C-Peptide
123967|NCT02307682|AMD
123968|NCT02307682|CNV
123969|NCT02307682|IVT
123970|NCT02307643|Systemic lupus erythematosus
123971|NCT02307630|124I-Humanized 3F8
123972|NCT02307630|PET Imaging
123973|NCT02307630|13-147
123974|NCT02307617|Major depressive disorder
123975|NCT02307617|MDD
123976|NCT02307617|healthy control
123977|NCT02307617|selective serotonin reuptake inhibitor
123978|NCT02307617|SSRI
123979|NCT02307617|depression
123980|NCT02307617|transcranial magnetic stimulation
123981|NCT02307617|TMS
123982|NCT02307617|magnetic resonance spectroscopy
123983|NCT02307617|MRS
123984|NCT02307617|adolescent
123985|NCT02307617|mild MDD
123986|NCT02307617|mild depression
123987|NCT02307617|cortical excitability
123988|NCT02307617|cortical inhibition
123989|NCT02307617|cortical silent period
123990|NCT02307617|motor threshold
123991|NCT02307617|intracortical facilitation
123992|NCT02307617|intracortical inhibition
123993|NCT02307617|motor cortex
123994|NCT02307617|dorsolateral prefrontal cortex
123995|NCT02307617|DLPFC
123996|NCT02307617|thumb twitch
123997|NCT02307617|gamma aminobutyric acid
123998|NCT02307617|GABA
123999|NCT02307617|glutamate
124000|NCT02307617|single pulse
124001|NCT02307617|paired pulse
124002|NCT02307604|Brain tumor
124003|NCT02307604|Biomarkers
124004|NCT02307604|Screening
124005|NCT02307578|Perampanel
124006|NCT02307578|Fycompa
124007|NCT02307578|Primary Generalized Tonic-Clonic Seizures
124008|NCT02307578|E2007-G000-332
124009|NCT02307578|E2007
124010|NCT02307565|Midodrine
124011|NCT02307565|Blood pressure
124012|NCT02307565|Orthostatic hypotension
124013|NCT02307565|Spinal Cord Injury
124014|NCT02307565|Sympathetic vascular control
124015|NCT02307565|Cerebral blood flow velocity
124016|NCT02307565|Cognition function tasks
124017|NCT02307565|Quality of Life
124018|NCT02307565|MRI
124019|NCT02307565|fMRI
124020|NCT02307552|Imaging
124021|NCT02307552|ultrasound
124022|NCT02307552|prostate
124023|NCT02307552|cancer
124024|NCT02307552|diagnostic tool
124025|NCT02307552|catheter
124026|NCT02307552|urethra
124027|NCT02307552|digital rectal exam
124028|NCT02307526|Hypotension, Postural
124029|NCT02307513|APREMILAST (CC-10004)
124030|NCT02307513|CC-10004
124031|NCT02307513|Efficacy
124032|NCT02307513|Safety
124033|NCT02307513|Phase 3
124034|NCT02307513|Behçet's Disease
124035|NCT02307487|TC-3 Gel
124036|NCT02307487|MMC
124037|NCT02307487|NMIBC
124038|NCT02307487|Non Muscle Invasive Bladder Cancer
124039|NCT02307487|Hydrogel Reverse thermal gelation
124040|NCT02307487|Drug retention
124041|NCT02307487|Urinary Bladder Neoplasms
124042|NCT02307487|Urologic Neoplasms
124043|NCT02307487|Urinary Bladder Diseases
124044|NCT02307487|Urologic Diseases
124045|NCT02307474|Kidney
124046|NCT02307474|Renal Cell Carcinoma
124047|NCT02307474|Cancer
124048|NCT02307474|Pilot
124049|NCT02307474|Pazopanib
124050|NCT02307474|stereotactic body radiation therapy
124051|NCT02307474|SBRT
124052|NCT02307461|Phase 1
124053|NCT02307461|Bioequivalence
124054|NCT02307461|Pharmacokinetics
124055|NCT02307461|Food
124056|NCT02307461|Healthy Adult
124057|NCT02307435|non union fracture
124058|NCT02307435|bone defect
124059|NCT02307435|mesenchymal stem cell
124060|NCT02307435|cryopreservation
124061|NCT02307383|SDD (Selective Digestive Decolonization)
124062|NCT02307383|OXA 48
124063|NCT02307383|carbapenemase
124064|NCT02307383|probiotics
124065|NCT02307331|Total Hip Replacement
124066|NCT02307318|Radial Artery
124067|NCT02307318|Hemostasis
124068|NCT02307318|Angiography
124069|NCT02307292|Superficial femoral artery
124070|NCT02307292|Self Expanding Stent System
124071|NCT02307253|EUS-guided biopsy, EUS-FNB
124072|NCT02307240|NMC
124073|NCT02307188|Atrial Fibrillation
124074|NCT02307188|Atrial Flutter
124075|NCT02307188|Multipolar Catheter
124076|NCT02307188|Atrial Arrhythmia
124077|NCT02307162|COPD
124078|NCT02307136|intensive care units
124079|NCT02307136|emergency department
124080|NCT02307123|Prehospital emergency care (MeSH)
124081|NCT02307123|Emergency medical services (MeSH)
124082|NCT02307123|Helicopter emergency medical service, Critical care (MeSH)
124083|NCT02307123|Airway management (MeSH)
124084|NCT02307123|Endotracheal intubation (MeSH)
124085|NCT02307123|Patient outcome
124086|NCT02307110|Diabetes Mellitus 1
124087|NCT02307110|long-term intensified insulin therapy
124088|NCT02307110|diabetic retinopathy
124089|NCT02307110|diabetic macular edema
124090|NCT02307097|Randomised Controlled Trial
124091|NCT02307097|Cognitive-Behavioural Bibliotherapy
124092|NCT02307097|Social Anxiety Disorder
124093|NCT02307097|Cognitive-Behavioural Therapy
124094|NCT02307097|IAPT
124095|NCT02307084|surgical site infection
124096|NCT02307084|long saphenous vein
124097|NCT02307084|coronary artery bypass grafting
124098|NCT02307058|Prostate Cancer
124099|NCT02307045|Arterial stiffness
124100|NCT02307045|Endothelial Glycocalyx
124101|NCT02307032|Atrial Fibrillation Relapses Prediction
124102|NCT02307032|P wave Signal Averaged ECG
124103|NCT02307032|P wave Wavelets
124104|NCT02307032|Strain
124105|NCT02307032|Tissue Doppler Imaging
124106|NCT02307019|Caregivers
124107|NCT02307019|Apraxias
124108|NCT02307019|Stroke
124109|NCT02307019|Cerebral Stroke
124110|NCT02307019|Rehabilitation
124111|NCT02307019|Pragmatic Clinical Trials as Topic
124112|NCT02306993|Sickle Cell Disease (SCD)
124113|NCT02306993|Sickle Cell Trait (SCT)
124114|NCT02306967|oral cancer
124115|NCT02306967|oral dysplasia
124116|NCT02306954|Kidney Cancer
124117|NCT02306954|High Dose IL-2
124118|NCT02306954|SBRT
124119|NCT02306928|Septic shock
124120|NCT02306928|Intensive care unit
124121|NCT02306928|Therapeutic drug monitoring
124122|NCT02306928|Pharmacokinetics
124123|NCT02306928|Critically ill
124124|NCT02306915|Lipegfilgrastim, Lonquex, Japanese Bridging
124125|NCT02306863|Parkinson's Disease
124126|NCT02306863|whole-body vibration
124127|NCT02306863|WBV
124128|NCT02306850|immunotherapy
124129|NCT02306850|PD-1 inhibitor
124130|NCT02306850|programmed death 1 inhibitor
124131|NCT02306850|neoadjuvant
124132|NCT02306850|pembrolizumab
124133|NCT02306850|MK-3475
124134|NCT02306837|lymphoma, consolidation chemotherapy, auto-HSCT
124135|NCT02306759|analgesia
124136|NCT02306759|ketamine
124137|NCT02306759|pain
124138|NCT02306746|Enteral nutrition
124139|NCT02306746|randomised control trial
124140|NCT02306746|Critical care
124141|NCT02306746|Outcome
124142|NCT02306733|Post partum hemorrhage
124143|NCT02306733|Ergometrine
124144|NCT02306733|Oxytocin
124145|NCT02306733|Obstetrics
124146|NCT02306694|hemophilia
124147|NCT02306694|bone disease
124148|NCT02306694|clinical study
124149|NCT02306694|biomarkers
124150|NCT02306668|Dry eye
124151|NCT02306655|Coital incontinence
124152|NCT02306655|Incidence
124153|NCT02306655|quality of life
124154|NCT02306629|Systemic Lupus Erythematosus
124155|NCT02306590|amyotrophic lateral sclerosis
124156|NCT02306590|survival time
124157|NCT02306590|ALS Functional Rating Scale
124158|NCT02306590|quality of life
124159|NCT02306590|survival
124160|NCT02306577|STRIBILD
124161|NCT02306577|HIV
124162|NCT02306577|Illicit dgug user
124163|NCT02306564|ICSI
124164|NCT02306564|cabergoline
124165|NCT02306564|Subendometrial vascularity
124166|NCT02306551|Offspring
124167|NCT02306551|Attachment
124168|NCT02306551|Risk development
124169|NCT02306551|Resilience
124170|NCT02306538|edema
124171|NCT02306538|inflammation
124172|NCT02306538|scar
124173|NCT02306538|ejection fraction
124174|NCT02306538|volumes
124175|NCT02306512|Melanoma In Situ
124176|NCT02306512|Lentigo Maligna
124177|NCT02306512|Confocal Microscopy
124178|NCT02306512|Direct Immunofluorescence
124179|NCT02306499|VARICOCELE-AZOOSPERMIA-ICSI
124180|NCT02306460|Neurobehavioral Manifestations
124181|NCT02306460|POCD
124182|NCT02306460|Atrial Fibrillation
124183|NCT02306460|Anti-Arrhythmia
124184|NCT02306460|Atrial Appendage Closure
124185|NCT02306434|childbirth fear
124186|NCT02306434|Internet CBT
124187|NCT02306434|counselling
124188|NCT02306434|antenatal care
124189|NCT02306434|postnatal care
124190|NCT02306434|childbirth
124191|NCT02306434|Cognitive behavioural therapy
124192|NCT02306421|RPH with the simplified Milligan-Morgan surgery
124193|NCT02306421|mixed hemorrhoids
124194|NCT02306421|the effectiveness and safety
124195|NCT02306421|A multi center clinical trial
124196|NCT02306395|endometrial local injury
124197|NCT02306395|repeated implatation failure
124198|NCT02306395|embyo transfer
124199|NCT02306382|endoanal ultrasonography
124200|NCT02306382|drainage
124201|NCT02306382|perianal abscess
124202|NCT02306382|fistulas
124203|NCT02306382|incontience
124204|NCT02306369|ICBT
124205|NCT02306369|IBS
124206|NCT02306369|FGID
124207|NCT02306369|functional abdominal pain
124208|NCT02306369|Adolescents
124209|NCT02306369|Children
124210|NCT02306369|Treatment
124211|NCT02306369|CBT
124212|NCT02306369|Exposure
124213|NCT02306369|Cognitive Behavior Therapy
124214|NCT02306369|Internet
124215|NCT02306369|Computerized
124216|NCT02306369|Abdominal Pain
124217|NCT02306369|Functional Pain
124218|NCT02306369|Functional Disorders
124219|NCT02306343|rapid acting insulin
124220|NCT02306343|insulin injection
124221|NCT02306343|insulin delivery
124222|NCT02306343|local heating
124223|NCT02306343|experimental device
124224|NCT02306343|pre and post meal glucose level
124225|NCT02306330|Malditof
124226|NCT02306330|Malditof MS
124227|NCT02306330|matrix-assisted laser desorption ionization-time
124228|NCT02306330|identifying pathogens
124229|NCT02306330|randomized diagnostic trial
124230|NCT02306304|Abdominal aortic aneurysm
124231|NCT02306304|Abdominal aortic aneurism
124232|NCT02306304|AAA
124233|NCT02306304|Screening
124234|NCT02306304|duplex ultra sound
124235|NCT02306304|Israeli Arab men
124236|NCT02306304|family physician
124237|NCT02306291|AML
124238|NCT02306291|Acute myeloid leukemia
124239|NCT02306291|E-selectin
124240|NCT02306291|relapse refractory
124241|NCT02306291|elderly newly diagnosed
124242|NCT02306291|induction
124243|NCT02306278|gabapentin
124244|NCT02306278|postoperative pain
124245|NCT02306278|vomiting
124246|NCT02306278|nausea
124247|NCT02306252|Cancer
124248|NCT02306252|Older Adult
124249|NCT02306252|Geriatric
124250|NCT02306252|Function
124251|NCT02306252|Functional Deficit
124252|NCT02306252|Occupational Therapy
124253|NCT02306252|Physical Therapy
124254|NCT02306252|Supportive Care
124255|NCT02306252|Oncology
124256|NCT02306252|physiology
124257|NCT02306252|Geriatric Assessment
124258|NCT02306252|Health Services for the Aged
124259|NCT02306252|Physical Therapy Specialty
124260|NCT02306226|TAVI
124261|NCT02306226|Aortic stenosis
124262|NCT02306226|Transcatheter aortic valve replacement
124263|NCT02306226|Transcatheter aortic valve implantation
124264|NCT02306226|Transfemoral access
124265|NCT02306200|Aorta
124266|NCT02306200|Aortic Disease
124267|NCT02306200|Abdominal Aortic Aneurysm (AAA)
124268|NCT02306200|Thoracic Aortic Aneurysm (TAA)
124269|NCT02306200|Aortic Stenosis
124270|NCT02306200|Aortic Valve Repair (AVR)
124271|NCT02306200|Bicuspid Aortic Valve (BAV)
124272|NCT02306187|The changes of bone mineral density and bone turnover markers
124273|NCT02306174|Hoarding
124274|NCT02306135|Cancer
124275|NCT02306135|Tumor
124276|NCT02306135|Everolimus
124277|NCT02306135|mTOR
124278|NCT02306135|Temsirolimus
124279|NCT02306135|Sirolimus
124280|NCT02306135|Rapamycin
124281|NCT02306122|medication adherence
124282|NCT02306122|choice architecture
124283|NCT02306122|pharmacy home
124284|NCT02306109|Motor Rehabilitation Treatment
124285|NCT02306109|Intensive versus standard
124286|NCT02306109|Motor Disability
124287|NCT02306096|prognostic and predictive biomarkers
124288|NCT02306096|RNA-sequencing
124289|NCT02306096|pathological complete response
124290|NCT02306096|minimal residual disease
124291|NCT02306096|molecular subtype
124292|NCT02306096|gene expression profiling
124293|NCT02306096|mutation screening
124294|NCT02306096|BRCA
124295|NCT02306096|translational research
124296|NCT02306096|genomics
124297|NCT02306096|transcriptomics
124298|NCT02306096|proteomics
124299|NCT02306096|metabolomics
124300|NCT02306096|liquid biopsy
124301|NCT02306096|circulating tumor cells
124302|NCT02306096|circulating tumor DNA
124303|NCT02306044|Bleeding
124304|NCT02306044|Platelet indices
124305|NCT02306044|Platelet aggregometry
124306|NCT02306044|Bleeding questionnaire
124307|NCT02306031|diclofenac
124308|NCT02306031|macular thickness
124309|NCT02306031|phacoemulsification
124310|NCT02306031|OCT(Optical coherence tomography )
124311|NCT02306031|diabetic
124312|NCT02306018|liver transplantation
124313|NCT02306018|cardiac output
124314|NCT02306005|diabetes mellitus type 1, insulin therapy, lipoproteins, HDL
124315|NCT02305966|advanced arthritis
124316|NCT02305966|shoulder
124317|NCT02305953|Psoriasis
124318|NCT02305953|Vascular Inflammation
124319|NCT02305953|Coronary Atherosclerosis
124320|NCT02305953|Ascending aorta
124321|NCT02305953|PET scan
124322|NCT02305953|Cytokine
124323|NCT02305953|Chemokine
124324|NCT02305927|Vitamin D
124325|NCT02305927|Pregnant women
124326|NCT02305914|acute pancreatitis
124327|NCT02305914|chronic pancreatitis
124328|NCT02305914|pancreatic cancer
124329|NCT02305914|pancreatic disease-associated portal hypertension
124330|NCT02305914|autoimmune pancreatitis
124331|NCT02305914|PaO2/FiO2＜200
124332|NCT02305914|diabetes mellitus
124333|NCT02305914|blood lipid
124334|NCT02305914|local complications
124335|NCT02305914|quality of life
124336|NCT02305862|Coronary Arteriosclerosis
124337|NCT02305862|Carotid Atherosclerotic Plaque
124338|NCT02305862|Rosuvastatin
124339|NCT02305849|ASP015K
124340|NCT02305849|Rheumatoid Arthritis
124341|NCT02305836|Electroacupuncture
124342|NCT02305836|Alzheimer's disease
124343|NCT02305836|alzheimer
124344|NCT02305836|cognitive impairment
124345|NCT02305823|psychosis
124346|NCT02305823|antipsychotic agents
124347|NCT02305823|treatment
124348|NCT02305823|effectiveness
124349|NCT02305784|Cystic fibrosis
124350|NCT02305784|Pulmonary exacerbation
124351|NCT02305784|inflammation
124352|NCT02305784|Chitinase
124353|NCT02305784|cytokine
124354|NCT02305784|Cystic fibrosis related diabetes
124355|NCT02305758|fluorouracil
124356|NCT02305758|irinotecan
124357|NCT02305758|colon cancer
124358|NCT02305758|veliparib
124359|NCT02305758|FOLFIRI
124360|NCT02305758|previously untreated
124361|NCT02305758|ABT-888
124362|NCT02305758|first line
124363|NCT02305758|metastatic colorectal cancer
124364|NCT02305758|PARP inhibitor
124365|NCT02305758|5-FU
124366|NCT02305758|rectal cancer
124367|NCT02305758|colorectal cancer
124368|NCT02305758|leucovorin
124369|NCT02305732|Chikungunya virus
124370|NCT02305732|CHIKV
124371|NCT02305732|Dengue virus
124372|NCT02305732|DENV
124373|NCT02305732|pathogen inactivation
124374|NCT02305732|platelets
124375|NCT02305732|Puerto Rico
124376|NCT02305706|insertion
124377|NCT02305706|patient comfort
124378|NCT02305667|Laryngoscope
124379|NCT02305667|Macintosh
124380|NCT02305667|Glidescope®
124381|NCT02305667|King Vision™
124382|NCT02305667|Airtraq®
124383|NCT02305667|intubation
124384|NCT02305667|double lumen tube
124385|NCT02305654|Penis cancer
124386|NCT02305654|Chemotherapy
124387|NCT02305654|Chemoradiotherapy
124388|NCT02305654|Surgery
124389|NCT02305654|Phase III
124390|NCT02305602|extracellular matrix
124391|NCT02305589|postoperative delirium
124392|NCT02305589|sugammadex
124393|NCT02305589|cholinesterase inhibitor
124394|NCT02305589|hip fracture surgery
124395|NCT02305550|Nitric Oxide
124396|NCT02305524|endotracheal intubation
124397|NCT02305511|Catheterization
124398|NCT02305511|Peripheral
124399|NCT02305498|Yoga
124400|NCT02305498|14-059
124401|NCT02305485|NeoVas
124402|NCT02305485|Bioresorbable Coronary Scaffold
124403|NCT02305485|Sirolimus
124404|NCT02305485|Randomized Controlled Trial
124405|NCT02305472|NeoVas
124406|NCT02305472|Bioresorbable Coronary Scaffold
124407|NCT02305472|Sirolimus
124408|NCT02305472|Registry Trial
124409|NCT02305459|SIRT
124410|NCT02305459|microcatheter
124411|NCT02305459|primary liver tumor
124412|NCT02305459|secondary liver tumor
124413|NCT02305459|radioembolisation
124414|NCT02305459|QLQ-C30
124415|NCT02305459|CIRSE
124416|NCT02305433|elderly
124417|NCT02305433|functional-based physiotherapy
124418|NCT02305433|frailty syndrome
124419|NCT02305433|osteoporotic hip fractures
124420|NCT02305433|home-based physiotherapy
124421|NCT02305433|home-dwelling
124422|NCT02305433|intervention
124423|NCT02305433|randomised controlled trial
124424|NCT02305433|costs of social and health care
124425|NCT02305433|quality of life
124426|NCT02305433|physical functioning
124427|NCT02305433|mobility
124428|NCT02305433|nutrition
124429|NCT02305394|ketamine
124430|NCT02305394|Electroconvulsive Therapy
124431|NCT02305394|Cognitive Function
124432|NCT02305342|Uncomplicated UTI
124433|NCT02305342|Enoxacin
124434|NCT02305303|Quality of life
124435|NCT02305303|post-traumatic stress disorder
124436|NCT02305303|trauma
124437|NCT02305238|Eylea,
124438|NCT02305238|Aflibercept
124439|NCT02305238|Treat and Extend regimen
124440|NCT02305238|Age-related macular degeneration
124441|NCT02305212|Working Memory
124442|NCT02305199|Diabetes Mellitus, Type 2
124443|NCT02305199|Hartmann's solution
124444|NCT02305186|Immunotherapy
124445|NCT02305186|Neoadjuvant
124446|NCT02305186|Resectable
124447|NCT02305186|Borderline resectable
124448|NCT02305173|dexamethasone
124449|NCT02305173|pulmonary function
124450|NCT02305173|spirometry
124451|NCT02305173|mastectomy
124452|NCT02305160|Respiratory distress syndrome
124453|NCT02305160|Pulmonary surfactant
124454|NCT02305160|Mortality
124455|NCT02305160|Prematurity
124456|NCT02305147|Parkinson Disease
124457|NCT02305147|Biomarkers
124458|NCT02305147|Prognostic factors
124459|NCT02305147|Prodromal features
124460|NCT02305147|Disease progression
124461|NCT02305134|Tipepidine, GIRK
124462|NCT02305121|Trochanteric fracture
124463|NCT02305121|Nail
124464|NCT02305121|Fracture reduction
124465|NCT02305121|Antirotation
124466|NCT02305121|trochanteric area with diaphyseal extension
124467|NCT02305121|trochanteric area with femoral shaft
124468|NCT02305043|non-interventional
124469|NCT02305043|advanced gastric cancer
124470|NCT02305043|Trastuzumab
124471|NCT02305043|HER2
124472|NCT02304991|Peanut
124473|NCT02304991|Food Allergy
124474|NCT02304978|colorectal cancer
124475|NCT02304978|Tissular factor
124476|NCT02304978|TF
124477|NCT02304965|LVAD
124478|NCT02304952|Lateral epicondylalgia
124479|NCT02304952|Pain
124480|NCT02304952|Function
124481|NCT02304952|Physiotherapy
124482|NCT02304952|Quality of Life
124483|NCT02304939|Norepinephrine
124484|NCT02304939|Intensive Care
124485|NCT02304939|Changeovers
124486|NCT02304939|Smart pumps
124487|NCT02304939|Quick change
124488|NCT02304939|Double pumping
124489|NCT02304939|Shock
124490|NCT02304926|Dyslipidemia
124491|NCT02304926|Simvastatin
124492|NCT02304926|Ezetimibe
124493|NCT02304926|Lipid profile
124494|NCT02304926|Inflammation
124495|NCT02304926|Oxidative stress
124496|NCT02304926|Endothelial function
124497|NCT02304900|cataract
124498|NCT02304887|Osteoporosis
124499|NCT02304887|Bone mineral densisty
124500|NCT02304887|Renal function
124501|NCT02304887|CKD-MBD
124502|NCT02304874|Ferritins
124503|NCT02304874|Iron Overload
124504|NCT02304874|Metabolic Syndrome
124505|NCT02304874|Venesection therapy
124506|NCT02304874|Volunteers
124507|NCT02304861|cataract
124508|NCT02304861|viscoelastic (OVD) technology
124509|NCT02304861|endothelial cell count
124510|NCT02304861|endothelial cell pattern
124511|NCT02304861|central corneal edema
124512|NCT02304848|Parkinson's Disease
124513|NCT02304848|DBS
124514|NCT02304848|Deep Brain Stimulation
124515|NCT02304848|Subthalamic Nucleus
124516|NCT02304822|kidney stones
124517|NCT02304822|retrograde intrarenal surgery
124518|NCT02304822|ciprofloxacin
124519|NCT02304822|prophylaxis
124520|NCT02304822|systemic inflammatory response syndrome
124521|NCT02304809|metastatic or unresectable locally advanced malignancies.
124522|NCT02304809|genomic alterations
124523|NCT02304809|biological vemurafenib targets BRAF
124524|NCT02304809|genomic.
124525|NCT02304796|Anxiety Disorders
124526|NCT02304796|Group Psychotherapy
124527|NCT02304796|Cognitive-Behavioral Therapy
124528|NCT02304796|Dance/Movement Therapy
124529|NCT02304796|CBT
124530|NCT02304796|DMT
124531|NCT02304796|Unified Protocol
124532|NCT02304783|Renal colic, Piroxicam
124533|NCT02304757|differentiated thyroid cancer
124534|NCT02304757|bone mineral density
124535|NCT02304757|thyroid stimulating hormone suppression
124536|NCT02304731|Physical Exercise, Atmospheric Pollution, Cognition.
124537|NCT02304718|GDM
124538|NCT02304718|pregnancy outcome
124539|NCT02304718|obesity
124540|NCT02304718|exercise
124541|NCT02304718|overweight
124542|NCT02304640|fatigue
124543|NCT02304640|chemotherapy
124544|NCT02304640|breast cancer
124545|NCT02304640|supportive care
124546|NCT02304640|Singapore
124547|NCT02304523|Colonoscopy preparation
124548|NCT02304523|Bowel cleansing
124549|NCT02304523|Colon cleansing
124550|NCT02304523|Colonoscopy
124551|NCT02304523|CDFR0612
124552|NCT02304523|CDFR0613
124553|NCT02304510|Prevalence
124554|NCT02304510|Menorrhagia
124555|NCT02304497|Diabetes mellitus
124556|NCT02304497|Platelet rich fibrin
124557|NCT02304497|growth factor
124558|NCT02304445|Radiotherapy
124559|NCT02304445|Chemoembolization
124560|NCT02304406|prevalence of ALK rearrangement, NSCLC, MENA
124561|NCT02304367|TIO
124562|NCT02304367|ENS
124563|NCT02304367|FGF23
124564|NCT02304367|KRN23
124565|NCT02304354|rheumatoid arthritis
124566|NCT02304354|T lymphocytes
124567|NCT02304354|rituximab
124568|NCT02304341|critical illness
124569|NCT02304341|disease progression
124570|NCT02304341|child
124571|NCT02304341|severity of illness index
124572|NCT02304341|monitoring
124573|NCT02304328|SAH
124574|NCT02304328|WFNS
124575|NCT02304328|hWFNS
124576|NCT02304328|grading
124577|NCT02304315|HBV-related liver transplantation
124578|NCT02304315|Hepatitis B Immuno Globulin
124579|NCT02304302|Memantine
124580|NCT02304302|Episodic Memory
124581|NCT02304302|CVLT
124582|NCT02304302|Hippocampus dependent memory
124583|NCT02304302|Short-term memory
124584|NCT02304263|tenofovir
124585|NCT02304263|aging
124586|NCT02304263|renal function
124587|NCT02304263|HIV
124588|NCT02304263|frailty
124589|NCT02304237|Premature Birth
124590|NCT02304237|progesterone
124591|NCT02304224|sepsis
124592|NCT02304224|melatonin
124593|NCT02304224|Human Leukocyte Antigen-DR
124594|NCT02304224|outcome
124595|NCT02304211|Microdosing
124596|NCT02304211|Phase 0
124597|NCT02304211|Exploratory Investigational New Drug (IND)
124598|NCT02304211|Intra-Arterial
124599|NCT02304211|PET Imaging
124600|NCT02304185|Healthy
124601|NCT02304185|Acquired Immuno-Deficiency Syndrome
124602|NCT02304185|Acquired Immunodeficiency Syndrome Virus
124603|NCT02304185|Glycoprotein
124604|NCT02304185|Adjuvant
124605|NCT02304185|Vaccine
124606|NCT02304185|Placebo
124607|NCT02304172|Thyroidectomy
124608|NCT02304172|Thunderbeat
124609|NCT02304159|HCV
124610|NCT02304159|Genotype 3
124611|NCT02304159|Treatment naive
124612|NCT02304159|Treatment experienced
124613|NCT02304146|Foam
124614|NCT02304146|UGFS
124615|NCT02304146|Stripping
124616|NCT02304146|Incompetence
124617|NCT02304120|proprioception
124618|NCT02304120|postural control
124619|NCT02304120|sensorimotor training
124620|NCT02304120|uncontrolled manifold
124621|NCT02304029|epilepsy
124622|NCT02304029|seizures
124623|NCT02304003|Shoulder tendinopathy
124624|NCT02304003|Subacromial impingement syndrome
124625|NCT02304003|Rotator cuff tendinopathy
124626|NCT02304003|Supraspinatus tendinopathy
124627|NCT02303964|Trauma
124628|NCT02303964|Hemorrhage
124629|NCT02303964|Plasma
124630|NCT02303964|Shock
124631|NCT02303964|Polytrauma
124632|NCT02303912|relapsed epithelial ovarian cancer,
124633|NCT02303912|relapsed fallopian tube cancer
124634|NCT02303912|relapsed primary peritoneal cancer.
124635|NCT02303860|Healthy volunteer study
124636|NCT02303808|Hyperosmolar agents
124637|NCT02303808|Hypertonic saline
124638|NCT02303808|Airway clearance techniques
124639|NCT02303808|Positive Expiratory Pressure
124640|NCT02303808|Autogenic drainage
124641|NCT02303795|bioprosthetic mitral valve
124642|NCT02303795|valvular heart disease
124643|NCT02303795|anticoagulant agents
124644|NCT02303795|NOACs
124645|NCT02303795|rivaroxaban
124646|NCT02303795|warfarin
124647|NCT02303769|Lower Urinary Track Syndrome
124648|NCT02303769|Harnal
124649|NCT02303769|Tamsulosin HCL 0.4mg
124650|NCT02303743|Bowel preparation; colonoscopy; Smartphone application
124651|NCT02303730|Diabetes
124652|NCT02303730|Non-alcoholic Fatty Liver Disease
124653|NCT02303717|Left main
124654|NCT02303717|PCI
124655|NCT02303717|DES
124656|NCT02303704|Multiperfusion set
124657|NCT02303704|Myocardial protection
124658|NCT02303704|Coronary Artery Bypass Grafting
124659|NCT02303691|anxiety
124660|NCT02303691|attention bias modification
124661|NCT02303691|computer
124662|NCT02303678|D2C7
124663|NCT02303678|Randazzo
124664|NCT02303678|Bigner
124665|NCT02303678|Pro00053325
124666|NCT02303678|recurrent malignant glioma
124667|NCT02303665|TCM multi-channel therapy
124668|NCT02303665|ART failure
124669|NCT02303639|implantable cardioverter defibrillator
124670|NCT02303639|antiarrhythmic medication
124671|NCT02303639|catheter ablation
124672|NCT02303626|BCX4161
124673|NCT02303626|Prophylaxis
124674|NCT02303626|Prevention
124675|NCT02303626|HAE
124676|NCT02303626|Hereditary Angioedema
124677|NCT02303600|Sub-acute cough
124678|NCT02303587|Severe mycoplasma pneumoniae
124679|NCT02303587|pneumonia
124680|NCT02303587|children
124681|NCT02303574|AZD7986, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect, First-in-human, Single Ascending Dose, Multiple Ascending Dose, Healthy Subjects
124682|NCT02303548|Sodium Bicarbonate
124683|NCT02303535|Congenital heart disease
124684|NCT02303535|European Paediatric Cardiac Code Short List
124685|NCT02303535|Specific Procedure Definitions
124686|NCT02303535|OPCS
124687|NCT02303535|paediatric
124688|NCT02303535|pediatric
124689|NCT02303522|ALL, pediatric, leukemia, childhood, lymphoblastic, lymphoma, acute, Precursor Cell
124690|NCT02303509|Healthy Subjects
124691|NCT02303509|Mild to moderate Psoriasis
124692|NCT02303509|Subjects
124693|NCT02303496|platelet rich plasma
124694|NCT02303470|Exercise
124695|NCT02303457|CO2 laser surgery
124696|NCT02303457|open surgery
124697|NCT02303457|multicenter prospective
124698|NCT02303457|randomized
124699|NCT02303457|controlled clinical studies
124700|NCT02303457|T1N0 squamous cell carcinoma of glottis with anterior commissure involved
124826|NCT02302820|Advance Care Planning
124701|NCT02303444|Progressive radioactive iodine refractory differentiated thyroid carcinoma
124702|NCT02303431|Pediatric
124703|NCT02303431|Pharmacokinetics (PK)
124704|NCT02303431|Pharmacodynamics (PDy)
124705|NCT02303431|Anticoagulant
124706|NCT02303431|Safety
124707|NCT02303418|Obstetrics
124708|NCT02303405|Glucose Control
124709|NCT02303405|Inflammation
124710|NCT02303379|Training Protocol
124711|NCT02303379|Cardiac Rehabilitation
124712|NCT02303379|High-Intensity Interval Training
124713|NCT02303379|Continuous Training
124714|NCT02303379|Pyramid Training
124715|NCT02303379|Physical Performance
124716|NCT02303353|Breast cancer
124717|NCT02303353|Ovarian cancer
124718|NCT02303353|Lung cancer
124719|NCT02303353|Colon cancer
124720|NCT02303353|Gastric cancer
124721|NCT02303353|Pancreatic cancer
124722|NCT02303353|Rectum cancer
124723|NCT02303353|Plasmacytoma
124724|NCT02303340|Cone Beam Computed Tomography
124725|NCT02303340|Para Thyroid Hormone
124726|NCT02303340|Dual Energy X-ray Absorptiometry
124727|NCT02303340|Digital Imaging and Communication in Medicine
124728|NCT02303275|Heart Failure
124729|NCT02303275|Congestive Heart Failure
124730|NCT02303275|Lifestyle Change
124731|NCT02303236|Exercise
124732|NCT02303197|head and neck cancer
124733|NCT02303197|chemoradiotherapy
124734|NCT02303197|radioactive stomatitis
124735|NCT02303184|RVO
124736|NCT02303184|ME
124737|NCT02303184|Central Subfield Thickness
124738|NCT02303184|OCT
124739|NCT02303184|optical coherence tomography
124740|NCT02303184|cystoid macular edema
124741|NCT02303184|subretinal fluid
124742|NCT02303184|Eylea
124743|NCT02303184|aflibercept
124744|NCT02303184|anti-VEGF
124745|NCT02303171|Antiphospholipid syndrome
124746|NCT02303171|APS
124747|NCT02303171|Warfarin
124748|NCT02303158|Alzheimer's Disease
124749|NCT02303158|Biomarkers
124750|NCT02303158|Depression
124751|NCT02303158|dementia
124752|NCT02303158|cerebrospinal fluid
124753|NCT02303158|neuropsychological
124754|NCT02303145|Breast Cancer, Survivors
124755|NCT02303119|LNH
124756|NCT02303119|CD20+
124757|NCT02303119|follicular
124758|NCT02303106|AUC exposure to lamotrigine
124759|NCT02303080|whey protein microgels
124760|NCT02303080|thermogenesis
124761|NCT02303067|Cardiac
124762|NCT02303067|Computed Tomography
124763|NCT02303067|Coronary Artery Disease
124764|NCT02303054|Prostate Cancer
124765|NCT02303054|Focal Ablation
124766|NCT02303054|MRI-US Fusion Biopsy
124767|NCT02303054|Focal Therapy
124768|NCT02303028|Pediatric
124769|NCT02303028|CNS Tumor
124770|NCT02303028|Solid Tumour
124771|NCT02303015|Germ cell cancer
124772|NCT02303015|Late toxicity
124773|NCT02303015|Renal impairment
124774|NCT02303015|Cardiovascular disease
124775|NCT02302963|Diabetes Mellitus, Type 1 (T1DM)
124776|NCT02302963|Diabetes Assistant (DiAs)
124777|NCT02302963|Artificial Pancreas (AP) System
124778|NCT02302963|Closed-Loop Control (CLC)
124779|NCT02302963|Unified Safety System (USS) Virginia
124780|NCT02302963|Sensor Augmented Pump (SAP)
124781|NCT02302963|Low Blood Glucose Index (LBGI)
124782|NCT02302963|Continuous Glucose Monitor (CGM)
124783|NCT02302963|inControl Diabetes Management Platform
124784|NCT02302950|HIV infection
124785|NCT02302950|raltegravir use
124786|NCT02302950|women
124787|NCT02302937|Inguinal Hernia
124788|NCT02302937|Primary
124789|NCT02302937|laparoscopic surgery
124790|NCT02302937|single port surgery
124791|NCT02302911|Early intervention
124792|NCT02302898|Roux-en-Y Gastric Bypass Surgery
124793|NCT02302898|Weight Regain
124794|NCT02302885|cancer-free 18-60 year old men and women
124795|NCT02302859|Cancer Prevention
124796|NCT02302859|Tobacco Use Cessation
124797|NCT02302859|HIV-positive
124798|NCT02302859|Nicotine patch
124799|NCT02302859|NRT
124800|NCT02302859|Questionnaire
124801|NCT02302859|Survey
124802|NCT02302859|Smartphone
124803|NCT02302859|Counseling
124804|NCT02302859|Saliva test
124805|NCT02302859|Saliva cotinine test
124806|NCT02302859|Nicotine replacement therapy
124807|NCT02302859|Smoking abstinence
124808|NCT02302859|Aids
124809|NCT02302846|Leukemia
124810|NCT02302846|Acute myeloid leukemia
124811|NCT02302846|AML
124812|NCT02302846|High-risk myelodysplastic syndrome
124813|NCT02302846|MDS
124814|NCT02302846|Ixazomib
124815|NCT02302846|MLN9708
124816|NCT02302833|Neuroendocrine tumors
124817|NCT02302833|Pheochromocytomas
124818|NCT02302833|Paragangliomas
124819|NCT02302833|Unresectable
124820|NCT02302833|Metastatic
124821|NCT02302833|Cabozantinib
124822|NCT02302833|XL-184
124823|NCT02302833|XL184
124824|NCT02302833|Questionnaire
124825|NCT02302833|Survey
124827|NCT02302820|Nurse Care Coordination
124828|NCT02302820|Comparative Effectiveness
124829|NCT02302820|Advance Directive
124830|NCT02302820|Decision Aides
124831|NCT02302781|Reasons for Dropout
124832|NCT02302781|Subfertility
124833|NCT02302781|IVF
124834|NCT02302781|NON IVF
124835|NCT02302742|Triple Negative Breast Cancer
124836|NCT02302742|TNBC
124837|NCT02302742|Hereditary Breast and Ovarian Cancer
124838|NCT02302742|HBOC
124839|NCT02302742|Prospective Registry
124840|NCT02302729|Micronutrient intervention
124841|NCT02302729|Responsive feeding intervention
124842|NCT02302729|School readiness intervention
124843|NCT02302677|bile acids
124844|NCT02302677|sleeve gastrectomy
124845|NCT02302677|obesity
124846|NCT02302677|GLP-1
124847|NCT02302677|FGF-19
124848|NCT02302664|Achilles
124849|NCT02302664|Platelet Rich Plasma
124850|NCT02302664|Patient reported outcome measure
124851|NCT02302664|Orthopaedic trauma
124852|NCT02302664|Musculoskeletal
124853|NCT02302664|Tendon
124854|NCT02302664|Sports Injury
124855|NCT02302664|Heel-Rise Endurance Test
124856|NCT02302651|high intensity focused ultrasound
124857|NCT02302651|osteoid osteoma
124858|NCT02302651|bone tumor
124859|NCT02302638|single-step media
124860|NCT02302638|embryo development
124861|NCT02302638|blastocyst formation
124862|NCT02302638|embryo utilization
124863|NCT02302625|Cognitive behavior therapy
124864|NCT02302612|chronic conditions
124865|NCT02302612|complex patients
124866|NCT02302612|engagement
124867|NCT02302612|activation
124868|NCT02302586|Thoracic paravertebral block
124869|NCT02302586|Patient controlled analgesia
124870|NCT02302586|Video Assisted Thoracoscopic Surgery
124871|NCT02302586|Postoperative acute pain
124872|NCT02302586|Chronic pain
124873|NCT02302573|placenta accreta
124874|NCT02302573|contrast-enhanced unltrasound
124875|NCT02302573|pregnancy
124876|NCT02302573|MRI
124877|NCT02302573|sonovue
124878|NCT02302547|HIV-DNA
124879|NCT02302547|dual therapy
124880|NCT02302547|NRTI
124881|NCT02302547|virological control
124882|NCT02302547|truvada®
124883|NCT02302534|scoliosis
124884|NCT02302534|MRI (Magnetic Resonance Imaging)
124885|NCT02302521|MRI
124886|NCT02302508|pharmacokinetics
124887|NCT02302508|drug metabolism
124888|NCT02302508|platelet reactivity
124889|NCT02302508|carboxylesterase
124890|NCT02302508|cytochromes p450
124891|NCT02302508|type 2 diabetes
124892|NCT02302508|active metabolite
124893|NCT02302495|Carfilzomib weekly
124894|NCT02302495|and Melphalan and Prednisone
124895|NCT02302482|Alzheimer's disease or related disorders
124896|NCT02302482|Functional autonomy level
124897|NCT02302482|Cognitive function
124898|NCT02302482|Predictive factors
124899|NCT02302469|Lenalidomide
124900|NCT02302469|Hematology
124901|NCT02302469|Waldenstrom Macroglobulinemia
124902|NCT02302456|Immediate postpartum hemorrhage
124903|NCT02302456|tranexamic acid
124904|NCT02302456|prevention
124905|NCT02302430|Cohesion
124906|NCT02302430|Oxytocin
124907|NCT02302430|ROTC
124908|NCT02302430|Virtual-reality
124909|NCT02302417|Asthma
124910|NCT02302417|Asthma-COPD Overlap Syndrome
124911|NCT02302417|Clinical Questionnaire
124912|NCT02302417|COPD
124913|NCT02302417|ACOS
124914|NCT02302404|FTIH
124915|NCT02302404|pharmacodynamics
124916|NCT02302404|pharmacokinetics
124917|NCT02302404|GSK2982772
124918|NCT02302404|safety
124919|NCT02302404|Repeat dose
124920|NCT02302404|tolerability
124921|NCT02302378|Hypotension
124922|NCT02302378|Anesthesia, Spinal [E03.155.086.331]
124923|NCT02302365|white blood cell depletion
124924|NCT02302365|apheresis
124925|NCT02302352|Probiotics
124926|NCT02302352|Immune system
124927|NCT02302339|Advanced melanoma
124928|NCT02302339|Unresectable melanoma
124929|NCT02302339|Metastatic melanoma
124930|NCT02302339|Targeted Treatment for melanoma
124931|NCT02302339|GPNMB
124932|NCT02302339|CDX-011
124933|NCT02302339|Glembatumumab vedotin
124934|NCT02302339|Antibody-drug-conjugate
124935|NCT02302339|Skin neoplasm
124936|NCT02302339|Varlilumab
124937|NCT02302339|CDX-1127
124938|NCT02302326|reticulum endoplasmic stress
124939|NCT02302326|Polycystic Ovary Syndrome
124940|NCT02302326|mitochondrial function
124941|NCT02302326|insulin resistance
124942|NCT02302326|inflammation
124943|NCT02302326|myoinositol
124944|NCT02302326|metformin
124945|NCT02302326|oxidative stress
124946|NCT02302313|healthy volunteers
124947|NCT02302313|critical awareness
124948|NCT02302313|hypnosis
124949|NCT02302313|Analgesia Nociception Index
124950|NCT02302313|numerical verbal scale
125075|NCT02301624|efficacy
124951|NCT02302313|Determine the validity of the index (ANI)
124952|NCT02302313|nociception in critical awareness
124953|NCT02302300|Cardiac surgery
124954|NCT02302300|Preventive non-invasive ventilation
124955|NCT02302287|Chronic kidney disease
124956|NCT02302287|mediterranean diet
124957|NCT02302287|low-protein diet
124958|NCT02302287|ketoacids
124959|NCT02302287|intestinal microbiota
124960|NCT02302274|Brugada Syndrome
124961|NCT02302274|ARVC
124962|NCT02302274|flecainide
124963|NCT02302274|ST elevation
124964|NCT02302261|Pulsus paradoxus
124965|NCT02302235|Glioblastoma multigorme
124966|NCT02302235|Ketogenic Diet
124967|NCT02302235|radiotherapy
124968|NCT02302235|chemotherapy
124969|NCT02302235|safety
124970|NCT02302235|efficiency
124971|NCT02302209|oxytocin
124972|NCT02302209|schizophrenia
124973|NCT02302209|autism spectrum disorder
124974|NCT02302183|Hypoxemic, Respiratory distress, infant
124975|NCT02302157|Cervical spinal cord injury
124976|NCT02302157|AST-OPC1
124977|NCT02302157|SCiStar
124978|NCT02302157|OPC1
124979|NCT02302157|Neural cell
124980|NCT02302157|Trauma spinal cord
124981|NCT02302157|stemcell transplant
124982|NCT02302157|Cervical spine injury
124983|NCT02302157|Paralysis
124984|NCT02302157|Quadriplegia
124985|NCT02302157|Tetraplegia
124986|NCT02302157|Spine injury
124987|NCT02302157|oligodendrocyte progenitor cell
124988|NCT02302157|Subacute spinal cord injury
124989|NCT02302144|Postural Instability (falling)
124990|NCT02302144|Gait Disturbances (e.g., freezing)
124991|NCT02302144|Bradykinesia (slowness of movement), rigidity
124992|NCT02302118|esophageal carcinoma
124993|NCT02302118|kardia carcinoma
124994|NCT02302092|Drug Therapy
124995|NCT02302079|ASP8232
124996|NCT02302079|Diabetes Mellitus
124997|NCT02302079|ranibizumab
124998|NCT02302079|Diabetic Macular Edema
124999|NCT02302066|Drug therapy
125000|NCT02302053|Hair thinning, hair loss, alopecia, women, oral supplement
125001|NCT02302040|Adolescent
125002|NCT02302027|withdrawal therapy
125003|NCT02302027|oxygen therapy
125004|NCT02302001|Breast augmentation
125005|NCT02302001|Breast implants
125006|NCT02302001|Silicone implants
125007|NCT02302001|Breast surgery
125008|NCT02301975|Adult
125009|NCT02301975|asthma
125010|NCT02301975|Fluticasone Propionate
125011|NCT02301975|Adolescents
125012|NCT02301975|Salmeterol
125013|NCT02301975|Vilanterol
125014|NCT02301975|ELLIPTA
125015|NCT02301975|ACCUHALER/DISKUS
125016|NCT02301975|Non-inferior
125017|NCT02301975|Fluticasone Furoate
125018|NCT02301962|panitumumab
125019|NCT02301962|previously treated
125020|NCT02301962|metastatic colorectal cancer
125021|NCT02301962|fully human antibody
125022|NCT02301962|wild-type KRAS and wild-type NRAS
125023|NCT02301949|gastrointestinal bleeding
125024|NCT02301949|vascular malformation
125025|NCT02301949|thalidomide retreatment
125026|NCT02301936|Sickle Cell Disease
125027|NCT02301936|Gilead
125028|NCT02301936|Hepatitis C
125029|NCT02301923|Continuous Positive Airway Pressure
125030|NCT02301910|Myocardial Infarction
125031|NCT02301910|Fibrinolysis
125032|NCT02301910|Fortelyzin
125033|NCT02301871|MNP
125034|NCT02301871|MET
125035|NCT02301871|Soft tissue mobilization
125036|NCT02301871|DNF
125037|NCT02301871|Static Stretching
125038|NCT02301858|molecular pathology
125039|NCT02301858|functional genomics
125040|NCT02301858|lung cancer
125041|NCT02301858|primary tumor
125042|NCT02301858|metastases
125043|NCT02301845|Respiration, artificial
125044|NCT02301832|acute compartment swelling (ACS)
125045|NCT02301832|near-infrared spectroscopy (NIRS)
125046|NCT02301767|MRI
125047|NCT02301767|Risk Factor
125048|NCT02301767|background Parenchymal Enhancement
125049|NCT02301767|(IMAGINE) Study
125050|NCT02301741|chronic low back pain
125051|NCT02301728|breast milk
125052|NCT02301728|short chain fatty acids
125053|NCT02301728|maternal diet
125054|NCT02301715|Intranasal oxytocin
125055|NCT02301715|Emotion regulation
125056|NCT02301715|Attachment
125057|NCT02301702|Maternal Immunization
125058|NCT02301702|Tdap
125059|NCT02301702|Td
125060|NCT02301702|Pertussis
125061|NCT02301689|Heart failure
125062|NCT02301689|Chronic heart failure
125063|NCT02301689|Sleep disordered breathing
125064|NCT02301689|Sleep apnea
125065|NCT02301689|Positive Airway Pressure
125066|NCT02301676|Geriatrics; Cognitive impairment; Interviews, Telephone
125067|NCT02301650|Hepatitis B virus
125068|NCT02301650|pregnancy
125069|NCT02301650|nucleoside (acid) analogs
125070|NCT02301650|children
125071|NCT02301650|safety
125072|NCT02301624|gMG
125073|NCT02301624|Myasthenia Gravis
125074|NCT02301624|safety
125076|NCT02301598|femtosecond laser
125077|NCT02301598|anterior lamellar keratoplasty
125078|NCT02301598|atomic-force microscopy
125079|NCT02301585|shock, septic
125080|NCT02301585|hemodynamics
125081|NCT02301585|algorithms
125082|NCT02301533|HIV infection
125083|NCT02301533|antiretroviral therapy
125084|NCT02301533|adherence
125085|NCT02301533|men who have sex with men
125086|NCT02301520|Vitamin D
125087|NCT02301520|Iodine
125088|NCT02301520|Lead
125089|NCT02301520|Thyroid function
125090|NCT02301520|point-of-care test
125091|NCT02301494|CTCL
125092|NCT02301494|Mycosis Fungoides
125093|NCT02301494|Cutaneous T-cell Lymphoma
125094|NCT02301494|MF
125095|NCT02301494|topical therapy
125096|NCT02301494|early stage
125097|NCT02301455|hypertension treatment
125098|NCT02301455|stroke prevention
125099|NCT02301403|smoking
125100|NCT02301403|cessation
125101|NCT02301403|tobacco
125102|NCT02301390|INTERVENE
125103|NCT02301390|Ventricular tachycardia
125104|NCT02301390|India
125105|NCT02301364|Buparlisib (BKM120)
125106|NCT02301364|14-177
125107|NCT02301338|Videoconferencing
125108|NCT02301338|Following Surgery
125109|NCT02301338|14-213
125110|NCT02301299|stroke
125111|NCT02301299|barriers
125112|NCT02301299|community
125113|NCT02301286|Acetylsalicylic acid
125114|NCT02301286|Colon cancer
125115|NCT02301286|Survival
125116|NCT02301273|Intensive care unit
125117|NCT02301273|Physiotherapy
125118|NCT02301273|Upright position
125119|NCT02301273|Exercise
125120|NCT02301273|Long term follow up of ICU survivors
125121|NCT02301260|Processing Speed
125122|NCT02301260|Intervention
125123|NCT02301260|Multiple Sclerosis
125124|NCT02301260|Cognition
125125|NCT02301247|Multiple Sclerosis, Progressive
125126|NCT02301247|cognition
125127|NCT02301247|memory
125128|NCT02301247|treatment
125129|NCT02301234|Osteoarthritis
125130|NCT02301234|Pain
125131|NCT02301234|Fulranumab
125132|NCT02301234|JNJ-42160443
125133|NCT02301234|Adjunctive therapy
125134|NCT02301234|Celecoxib
125135|NCT02301234|Hip
125136|NCT02301234|Knee
125137|NCT02301234|Joint replacement surgery
125138|NCT02301221|Fecal Microbiota Transplantation
125139|NCT02301221|Slow Transit Constipation
125140|NCT02301221|Colonic motility
125141|NCT02301195|Therapeutic Horseback Riding
125142|NCT02301169|Pain
125143|NCT02301143|Pancreatic Neoplasms
125144|NCT02301143|Pancreatic Cancer
125145|NCT02301143|Locally advanced pacriatic cancer
125146|NCT02301143|nab-Paclitaxel
125147|NCT02301143|Abraxane
125148|NCT02301143|Gemcitabine
125149|NCT02301143|ABI-007
125150|NCT02301130|advanced solid tumors
125151|NCT02301130|solid tumors
125152|NCT02301130|mogamulizumab
125153|NCT02301130|non-small cell lung
125154|NCT02301130|pancreatic
125155|NCT02301130|head and neck
125156|NCT02301117|Renal
125157|NCT02301117|Kidney Diseases
125158|NCT02301117|Urologic Diseases
125159|NCT02301117|Renal Insufficiency
125160|NCT02301117|Renal Impairment
125161|NCT02301117|Pharmacokinetics
125162|NCT02301117|Advance Solid Tumor
125163|NCT02301117|Creatinine Clearance
125164|NCT02301117|Kidney Neoplasms
125165|NCT02301117|Renal Tumor
125166|NCT02301117|Kidney
125167|NCT02301117|Urology
125168|NCT02301117|Pharmacologic Action
125169|NCT02301104|Liver Neoplasms
125170|NCT02301104|Hepatic
125171|NCT02301104|TAS-102
125172|NCT02301104|mCRC
125173|NCT02301104|Liver Impairment
125174|NCT02301104|Pharmacologic Actions
125175|NCT02301104|Liver Diseases
125176|NCT02301104|Liver
125177|NCT02301104|LFT
125178|NCT02301104|Advanced Solid Tumor
125179|NCT02301104|Pharmacokinetics
125180|NCT02301091|HCC PVTT TACE RFA
125181|NCT02301078|Dupuytren disease
125182|NCT02301078|needle aponeurotomy
125183|NCT02301078|collagenase
125184|NCT02301065|Viral
125185|NCT02301065|Infection
125186|NCT02301065|Allogeneic Stem Cell Transplant
125187|NCT02301052|hemorrhoids
125188|NCT02301052|Allium Ampeloprasum
125189|NCT02301052|herbal medicine
125190|NCT02301052|traditional persian medicine
125191|NCT02301000|Clostridium difficile
125192|NCT02301000|Intestinal microbiota therapy
125193|NCT02300987|Teratoma,
125194|NCT02300987|Germ Cell tumor,
125195|NCT02300987|incurable teratoma,
125196|NCT02300987|CDK4/6,
125197|NCT02300987|LEE011
125198|NCT02300948|Pregnancy
125199|NCT02300948|Perinatal Vitamins
125200|NCT02300948|folate
125201|NCT02300935|trametinib
125202|NCT02300935|nab-paclitaxel
125203|NCT02300935|Mekinist
125204|NCT02300935|Abraxane
125205|NCT02300935|unresectable
125206|NCT02300935|metastatic
125207|NCT02300896|exercise
125208|NCT02300896|physical fitness
125209|NCT02300896|geriatrics
125210|NCT02300870|Acute rejection, myocardial blood flow
125211|NCT02300831|NSCLC
125212|NCT02300831|Lung Cancer
125213|NCT02300831|SELECT-1
125214|NCT02300831|SELECT-2
125215|NCT02300831|selumetinib
125216|NCT02300831|biomarker
125217|NCT02300831|NIS
125218|NCT02300831|Observational study
125219|NCT02300831|Disease registry
125220|NCT02300831|Clinical Outcomes
125221|NCT02300818|Hipertension ocular, Glaucoma, Magnetotherapy, seawater
125222|NCT02300805|Endometrial volume , VOCAL , Endometrial , Metrorrhagia
125223|NCT02300792|honey, hepatitis A
125224|NCT02300779|Colonoscopy
125225|NCT02300779|Diabetes Mellitus
125226|NCT02300779|Diet
125227|NCT02300779|Polyethylene glycols
125228|NCT02300779|Efficacy
125229|NCT02300779|Personal satisfaction
125230|NCT02300766|Cerebellar Mutism Syndrome
125231|NCT02300766|Posterior Fossa Tumor
125232|NCT02300766|Pediatric cancer
125233|NCT02300766|Neurosurgical techniques
125234|NCT02300727|Mucositis
125235|NCT02300727|Neoplasms
125236|NCT02300727|CANCER
125237|NCT02300727|Curcumin
125238|NCT02300727|Drug Therapy
125239|NCT02300727|ANTINEOPLASTIC AGENTS
125240|NCT02300675|therapeutic patient education
125241|NCT02300675|patient adherence
125242|NCT02300675|empowerment
125243|NCT02300675|breast cancer
125244|NCT02300675|oral adjuvant endocrine therapy
125245|NCT02300675|side effects
125246|NCT02300636|Knee joint
125247|NCT02300636|Muscle strength
125248|NCT02300636|anterior cruciate ligament
125249|NCT02300610|Ureteral Diseases
125250|NCT02300610|Urinary Bladder Diseases
125251|NCT02300610|Transitional Cell Carcinoma
125252|NCT02300610|Bladder
125253|NCT02300610|Carcinoma
125254|NCT02300610|Renal
125255|NCT02300610|Pelvis
125256|NCT02300610|Ureter
125257|NCT02300610|Urethra
125258|NCT02300597|ADHD
125259|NCT02300597|Autism Spectrum Disorders
125260|NCT02300597|controlled
125261|NCT02300597|Internet based
125262|NCT02300597|coaching
125263|NCT02300558|LQT3
125264|NCT02300558|long QT syndrome
125265|NCT02300558|congenital long QT
125266|NCT02300558|sudden cardiac death
125267|NCT02300532|Malignant Glioma
125268|NCT02300532|Glioblastoma Multiforme
125269|NCT02300519|Haemophilia
125270|NCT02300519|numerical models
125271|NCT02300519|thrombin generation
125272|NCT02300519|volunteers
125273|NCT02300519|endogenous thrombin potential
125274|NCT02300506|Malignant Glioma
125275|NCT02300506|Glioblastoma multiforme
125276|NCT02300493|among college students
125277|NCT02300480|pain
125278|NCT02300480|calot's triangle
125279|NCT02300480|local block
125280|NCT02300480|analgesia
125281|NCT02300480|patient controlled intravenous analgesia
125282|NCT02300454|in-stent restenosis
125283|NCT02300454|percutaneous coronary intervention
125284|NCT02300454|balloon
125285|NCT02300428|iron deficiency
125286|NCT02300389|high risk prostate cancer radiotherapy hypofractionation
125287|NCT02300376|GFR
125288|NCT02300376|Bayesian model
125289|NCT02300376|plasma clearance
125290|NCT02300376|Calcium edetate de sodium
125291|NCT02300376|Inulin
125292|NCT02300337|laryngeal tube
125293|NCT02300337|cuff pressure
125294|NCT02300337|leakage
125295|NCT02300337|laryngeal mask
125296|NCT02300324|bioavailability
125297|NCT02300324|Beneforte
125298|NCT02300324|sulforaphane
125299|NCT02300272|Practice-related learning
125300|NCT02300272|Sleep
125301|NCT02300272|Pain
125302|NCT02300272|Circadian Rhythm
125303|NCT02300272|Older Adults
125304|NCT02300246|alveolar socket preservation
125305|NCT02300246|tooth extraction
125306|NCT02300246|platelet concentrates
125307|NCT02300246|growth factors
125308|NCT02300207|Electroacupuncture
125309|NCT02300207|Cardiovascular function
125310|NCT02300207|Orthostatic tolerance
125311|NCT02300207|Head-down bed rest
125312|NCT02300194|Pain management
125313|NCT02300168|bariatric surgery; neuromuscular blockade
125314|NCT02300155|Pregnancy
125315|NCT02300155|Morning Sickness
125316|NCT02300155|nausea and vomiting
125317|NCT02300155|hyperemesis gravidarum
125318|NCT02300155|perinatal vitamins
125319|NCT02300142|HSV
125320|NCT02300142|Herpes
125321|NCT02300142|genital infection
125322|NCT02300142|vaccine
125323|NCT02300090|COPD, Exacerbation, respiratory disease, lung disease, breathlessness, dyspnoea, sputum, wheezing, cough
125324|NCT02300077|fentanyl, morphine
125325|NCT02300077|methadone
125326|NCT02300051|Compulsive sexual behavior
125327|NCT02300051|Intervention
125328|NCT02300051|Short term psychodynamic group psychotherapy
125329|NCT02300051|Sexual addiction
125330|NCT02300051|Hypersexual behavior
125331|NCT02300012|Anterior cruciate ligament
125332|NCT02300012|Performance based investigations
125333|NCT02299973|irritable bowel syndrome
125334|NCT02299973|fecal microbiota transplantation
125335|NCT02299973|bloating
125336|NCT02299960|EndoPAT
125337|NCT02299960|NICOM
125338|NCT02299960|circulating endothelial cells
125339|NCT02299908|Hernia, Inguinal
125340|NCT02299908|Herniorrhaphy
125341|NCT02299908|Abdominal Wall
125342|NCT02299908|Analgesia
125343|NCT02299908|Pain, Postoperative
125344|NCT02299895|setting approach
125345|NCT02299895|health promotion
125346|NCT02299895|organization
125347|NCT02299895|implementation research
125348|NCT02299895|qualitative study
125349|NCT02299895|comparison
125350|NCT02299882|Posterior spine surgery
125351|NCT02299882|infection
125352|NCT02299882|vancomycin
125353|NCT02299882|surgical wound infection
125354|NCT02299856|Magnetic Resonance Imaging
125355|NCT02299856|Diagnostic Imaging
125356|NCT02299843|RFA
125357|NCT02299843|ALPPS
125358|NCT02299843|hepatectomy
125359|NCT02299843|morbidity and mortality
125360|NCT02299830|neoplasm
125361|NCT02299830|central airway
125362|NCT02299830|obstruction
125363|NCT02299791|clinic-level interventions
125364|NCT02299791|quality improvement
125365|NCT02299791|translational medical research
125366|NCT02299791|community health centers
125367|NCT02299765|Advanced Non-small Cell Lung Cancer (NSCLC)
125368|NCT02299765|EGFR Mutation
125369|NCT02299765|gefitinib
125370|NCT02299765|chemotherapy
125371|NCT02299739|Herbal Medicine
125372|NCT02299739|Complementary Therapies
125373|NCT02299739|Liver Function Tests
125374|NCT02299739|Risk Factors
125375|NCT02299726|acute heart failure
125376|NCT02299726|MRA
125377|NCT02299726|emergency department
125378|NCT02299713|acupuncture
125379|NCT02299713|knee pain
125380|NCT02299700|Janssen Autism Knowledge Engine
125381|NCT02299700|Autism Spectrum Disorder
125382|NCT02299661|Hypoxia inducible factor prolyl hydroxylase inhibitor.
125383|NCT02299661|Erythropoietin stimulating agent
125384|NCT02299661|Chronic renal disease
125385|NCT02299661|renal anemia
125386|NCT02299635|PF-03084014
125387|NCT02299635|Notch Alterations
125388|NCT02299609|C14.280.647.500
125389|NCT02299596|Colorectal neoplasm
125390|NCT02299596|Physical activity
125391|NCT02299583|prevention
125392|NCT02299583|early intervention
125393|NCT02299583|trauma-informed practice
125394|NCT02299570|Clostridium difficile
125395|NCT02299570|C diff
125396|NCT02299570|CDI
125397|NCT02299570|CDAD
125398|NCT02299570|Fecal transplant
125399|NCT02299570|Fecal Microbiota Transplant
125400|NCT02299570|Diarrhea
125401|NCT02299570|FMT
125402|NCT02299570|Microbiota restoration therapy
125403|NCT02299570|Microbiota suspension
125404|NCT02299570|Fecal bacteriotherapy
125405|NCT02299570|C diff diarrhea
125406|NCT02299505|LDK378
125407|NCT02299505|ceritinib
125408|NCT02299505|Alk+
125409|NCT02299505|Alk positive
125410|NCT02299505|NSCLC
125411|NCT02299505|lung Cancer
125412|NCT02299492|Mental Health Services
125413|NCT02299479|insulin pump
125414|NCT02299479|continuous glucose monitor
125415|NCT02299479|activity monitor
125416|NCT02299466|parenteral nutrition
125417|NCT02299466|complications
125418|NCT02299466|indications
125419|NCT02299466|long-term administration
125420|NCT02299466|HTPN
125421|NCT02299453|Telemedicine
125422|NCT02299453|Interpersonal Psychotherapy (IPT)
125423|NCT02299440|treatment of acute suicidal ideation
125424|NCT02299440|ketamine
125425|NCT02299440|low-dose ketamine
125426|NCT02299414|Pregnancy
125427|NCT02299414|Chronic hypertension
125428|NCT02299401|Medical abortion
125429|NCT02299401|Induced abortion
125430|NCT02299401|Pregnancy test
125431|NCT02299401|Semi-quantitative pregnancy test
125432|NCT02299388|Type 2 Diabetes Mellitus
125433|NCT02299388|Hypertension
125434|NCT02299388|ambulatory blood pressure monitoring
125435|NCT02299388|Endothelial Dysfunction
125436|NCT02299388|Pulse pressure
125437|NCT02299388|Renin-angiotensin system
125438|NCT02299388|heart rate variability
125439|NCT02299375|Phase II clinical study
125440|NCT02299375|losmapimod
125441|NCT02299375|exacerbations
125442|NCT02299375|COPD
125443|NCT02299375|eosinophil sub-group
125444|NCT02299362|Early Onset Scoliosis
125445|NCT02299362|EOS
125446|NCT02299362|Pulmonary function
125447|NCT02299362|Infantile Idiopathic Scoliosis
125448|NCT02299362|MCGR
125449|NCT02299362|Magnetically controlled growing rods
125450|NCT02299362|Growing rods
125451|NCT02299362|Growth friendly spine surgery
125452|NCT02299362|Cast
125453|NCT02299310|Chronic kidney disease, Anti-hypertensive drugs
125454|NCT02299297|Alopecia Areata
125455|NCT02299284|Spastic
125456|NCT02299284|Hemiplegia
125457|NCT02299245|telomere
125458|NCT02299245|telomerase
125459|NCT02299245|statin
125460|NCT02299245|percutaneous coronary intervention
125461|NCT02299245|acute coronary syndrome
125462|NCT02299232|dexmedetomidine
125463|NCT02299232|sedation
125464|NCT02299232|MRI
125465|NCT02299219|Adolescent
125466|NCT02299219|Internet Self-Management
125467|NCT02299219|Managing Cancer
125468|NCT02299193|cognitive behavioral therapy for insomnia
125469|NCT02299193|sleep hygiene
125470|NCT02299180|Advanced care planning
125471|NCT02299180|End of life care
125472|NCT02299167|Perianal surgery
125473|NCT02299167|hyperbaric bupivacaine
125474|NCT02299167|saddle block
125475|NCT02299115|Vigabatrin
125476|NCT02299115|Prednisolone
125477|NCT02299102|Aspiration Procedures
125478|NCT02299102|Bone Marrow
125479|NCT02299102|To compare powered ported bone marrow aspiration procedures to manual standard bone marrow aspiration procedures
125480|NCT02299089|acromegaly
125481|NCT02299089|neuroendocrine tumour (NET)
125482|NCT02299089|carcinoid syndrome
125483|NCT02299089|octreotide
125484|NCT02299089|Sandostatin LAR
125485|NCT02299076|Tobacco smoking cessation
125486|NCT02299076|Motivation
125487|NCT02299063|Mitochondria
125488|NCT02299063|Dexmedetomidine
125489|NCT02299063|Heart Defects, Congenital
125490|NCT02299050|Type 2 Diabetes
125491|NCT02299050|T2DM
125492|NCT02299050|Cycloset
125493|NCT02299050|Glycemic Control
125494|NCT02299050|GLP-1
125495|NCT02299024|opioids
125496|NCT02299024|health literacy
125497|NCT02299011|Biomatrix drug eluting stent
125498|NCT02299011|Orsiro drug eluting stent
125499|NCT02299011|Coronary artery disease
125500|NCT02298985|curcumin; schizophrenia; neuroprotection
125501|NCT02298946|Anti-PD1 Therapy
125502|NCT02298946|Anti-Tumor Immunity
125503|NCT02298946|Liver Metastatic
125504|NCT02298946|B7-DC Fc Fushion Protein
125505|NCT02298933|Complement Inhibition
125506|NCT02298933|Platelet Refractoriness
125507|NCT02298933|Eculizumab
125508|NCT02298907|colorectal cancer
125509|NCT02298907|surgery
125510|NCT02298907|cardiopulmonary exercise testing
125511|NCT02298907|perioperative
125512|NCT02298907|fitness
125513|NCT02298894|Low Density Lipoprotein (LDL)
125514|NCT02298894|Lipoprotein
125515|NCT02298894|Nuclear Magnetic Resonance (NMR)
125516|NCT02298894|Vertical Auto Profile (VAP)
125517|NCT02298894|Ion mobility
125518|NCT02298894|Apoliproprotein B (ApoB)
125519|NCT02298881|Dry Eye
125520|NCT02298881|Microbiome
125521|NCT02298855|Gynaecological cancer
125522|NCT02298855|Nurse-led care
125523|NCT02298855|Aftercare
125524|NCT02298855|Patient self-management
125525|NCT02298855|Quality of life
125526|NCT02298855|Relapse free interval
125527|NCT02298855|Watch and wait
125528|NCT02298842|Healthy Adults
125529|NCT02298829|curvature
125530|NCT02298829|bend
125531|NCT02298816|Monoclonal gammopathy of undetermined significance (MGUS)
125532|NCT02298816|Smoldering multiple myeloma (SMM)
125533|NCT02298816|Multiple myeloma (MM)
125534|NCT02298816|Waldenstroms Macroglobulinemia (WM)
125535|NCT02298816|Monoclonal B-cell lymphocytosis (MBL)
125536|NCT02298816|Chronic lymphocytic leukemia (CLL)
125537|NCT02298816|B-Cell Non-Hodgkin lymphoma (NHL)
125538|NCT02298816|B-Cell Hematologic Malignancies
125539|NCT02298816|immunization
125540|NCT02298816|Vaccination
125541|NCT02298816|Influenza, Human
125542|NCT02298816|Pneumonia
125543|NCT02298790|Dietary Habits
125544|NCT02298790|Circadian
125545|NCT02298790|Metabolism
125546|NCT02298790|Feeding Behavior
125547|NCT02298738|Atrial fibrillation, hypertension, vitamin D
125548|NCT02298725|Insulin Resistance
125549|NCT02298725|Obesity
125550|NCT02298725|US Dietary Guidelines
125551|NCT02298712|Iduronidase
125552|NCT02298712|Lysosomal Storage Diseases
125553|NCT02298712|Genetic Diseases, Inborn
125554|NCT02298712|Metabolism, Inborn Errors
125555|NCT02298699|Lysosomal Storage Diseases
125556|NCT02298699|Hereditary Diseases
125557|NCT02298686|Inborn Errors of Metabolism
125558|NCT02298686|Lysosomal Storage Diseases
125559|NCT02298686|Metabolism Errors, Inborn
125560|NCT02298673|Lipid Metabolism, Inborn Errors
125561|NCT02298673|Hereditary Disease
125562|NCT02298673|Inborn Genetic Diseases
125563|NCT02298660|Autonomic Dysreflexia
125564|NCT02298660|Spinal Cord Injury
125565|NCT02298660|OnabotulinumtoxinA
125566|NCT02298660|Neurogenic detrusor overactivity
125567|NCT02298660|Urodynamics
125568|NCT02298660|Cardiovascular
125569|NCT02298660|Quality of life
125570|NCT02298660|Blood pressure
125571|NCT02298660|Twenty-four hour ambulatory blood pressure monitoring
125572|NCT02298647|Lysosomal Storage Diseases
125573|NCT02298634|Lysosomal Storage Diseases
125574|NCT02298634|Lipogranulomatosis
125575|NCT02298608|Renal mass
125576|NCT02298608|Kidney cancer
125577|NCT02298608|Irreversibel Electroporation
125578|NCT02298608|Ablation
125579|NCT02298608|Safety
125580|NCT02298608|Efficacy
125581|NCT02298608|IRE
125582|NCT02298595|Carcinoma
125583|NCT02298595|Squamous
125584|NCT02298595|Oropharyngeal
125585|NCT02298595|HPV
125586|NCT02298595|Resectable
125587|NCT02298582|safety
125588|NCT02298582|procedural pain
125589|NCT02298582|intranasal fentanyl
125590|NCT02298582|elderly
125591|NCT02298569|patient discharge
125592|NCT02298569|hospital readmission
125593|NCT02298569|postnatal care
125594|NCT02298569|Home Care Services
125595|NCT02298569|Cost-Benefit Analysis
125596|NCT02298569|Personal satisfaction
125597|NCT02298569|Community Care Networks
125598|NCT02298556|Hypertension
125599|NCT02298556|Diabetes Mellitus
125600|NCT02298556|ACE Inhibitors
125601|NCT02298556|Calcium Channel Blockers
125602|NCT02298517|Morbid obesity
125603|NCT02298517|bariatric surgery
125604|NCT02298517|Respiratory muscle endurance
125605|NCT02298517|Respiratory muscle strength
125606|NCT02298517|spirometry
125607|NCT02298517|physiotherapy
125608|NCT02298478|Self-help
125609|NCT02298478|Computer-aided Treatment
125610|NCT02298478|Internet
125611|NCT02298478|Flying phobia
125612|NCT02298478|minimal contact therapies
125613|NCT02298478|Cognitive-Behavioural Treatment
125614|NCT02298478|Waiting list control group
125615|NCT02298465|ESWL
125616|NCT02298465|distal ureteric stone
125617|NCT02298465|transgluteal
125618|NCT02298465|supine ESWL
125619|NCT02298439|NAFLD
125620|NCT02298426|Body Constitution Classification
125621|NCT02298426|Health Management
125622|NCT02298426|Obese Population
125623|NCT02298374|Rehabilitation
125624|NCT02298374|Evaluation studies
125625|NCT02298374|Home care services
125626|NCT02298361|Adolescent
125627|NCT02298361|Child
125628|NCT02298361|Child Health Services/organization & administration*
125629|NCT02298361|Child, Preschool
125630|NCT02298361|Cohort Studies
125631|NCT02298361|Community Health Centers/organization & administration
125632|NCT02298361|Community Health Centers/standards
125633|NCT02298361|Electronic Health Records
125634|NCT02298361|Feasibility Studies
125635|NCT02298361|Female
125636|NCT02298361|Health Services Accessibility/economics
125637|NCT02298361|Humans
125638|NCT02298361|Infant
125639|NCT02298361|Infant, Newborn
125640|NCT02298361|Insurance Coverage
125641|NCT02298361|Insurance Coverage/statistics & numerical data
125642|NCT02298361|Insurance Coverage/trends
125643|NCT02298361|Insurance, Health
125644|NCT02298361|Insurance, Health/legislation & jurisprudence
125645|NCT02298361|Insurance, Health/statistics & numerical data
125646|NCT02298361|Insurance, Health/trends
125647|NCT02298361|Logistic Models
125648|NCT02298361|Longitudinal Studies
125649|NCT02298361|Male
125650|NCT02298361|Medicaid
125651|NCT02298361|Medicaid/statistics & numerical data
125652|NCT02298361|Medicaid/trends
125653|NCT02298361|Medicaid/utilization
125654|NCT02298361|Medically Uninsured
125655|NCT02298361|Medicare/statistics & numerical data
125656|NCT02298361|Medicare/trends
125657|NCT02298361|Medicare/utilization
125658|NCT02298361|Multivariate Analysis
125659|NCT02298361|Oregon
125660|NCT02298361|Patient Protection and Affordable Care Act
125661|NCT02298361|Patient-Centered Care
125662|NCT02298361|Pediatrics/legislation & jurisprudence
125663|NCT02298361|Pediatrics/standards
125664|NCT02298361|Population Surveillance/methods
125665|NCT02298361|Primary Health Care/economics
125666|NCT02298361|Quality Assurance, Health Care/legislation & jurisprudence
125667|NCT02298361|Quality Assurance, Health Care/methods
125668|NCT02298361|Quality Indicators, Health Care
125669|NCT02298361|Retrospective Studies
125670|NCT02298361|Socioeconomic Factors
125671|NCT02298361|United States
125672|NCT02298361|Young Adult
125673|NCT02298348|Neuroblastoma
125674|NCT02298348|NANT
125675|NCT02298348|Sorafenib
125676|NCT02298348|Relapse
125677|NCT02298335|Prednisone
125678|NCT02298335|idiopathic nephrotic syndrome
125679|NCT02298335|prospective
125680|NCT02298309|TB
125681|NCT02298309|HIV
125682|NCT02298309|Test and Treat
125683|NCT02298309|Linkage
125684|NCT02298283|Hodgkin lymphoma
125685|NCT02298283|HL
125686|NCT02298283|brentuximab vedotin
125687|NCT02298270|Neurofibromatosis
125688|NCT02298270|NF I
125689|NCT02298270|NF 2
125690|NCT02298270|Schwannomatosis
125691|NCT02298270|Stress Management
125692|NCT02298270|Resiliency
125693|NCT02298270|Skype
125694|NCT02298244|Pulmonary Hypertension
125695|NCT02298244|Atrial Fibrillation
125696|NCT02298244|Pulmonary Arterial Denervation
125697|NCT02298244|Safety
125698|NCT02298244|Pulmonary Arterial GP Ablation
125699|NCT02298231|Traumatic Brain Injury
125700|NCT02298231|Balance
125701|NCT02298231|TBI
125702|NCT02298231|Veterans
125703|NCT02298231|Virtual Reality
125704|NCT02298166|Acute myeloid leukemia
125705|NCT02298166|FLT3 mutations
125706|NCT02298166|Crenolanib
125707|NCT02298140|SMS reminders
125708|NCT02298140|Provider's compliance
125709|NCT02298140|malaria
125710|NCT02298127|smoking cessation
125711|NCT02298127|auricular acupressure
125712|NCT02298127|primary care settings
125713|NCT02298127|randomized controlled trial
125714|NCT02298114|electrical stimulation
125715|NCT02298114|intensive care unit
125716|NCT02298114|muscular atrophy
125717|NCT02298101|Aerosol delivery
125718|NCT02298101|Lung deposition
125719|NCT02298101|SPECT
125720|NCT02298101|subjects
125721|NCT02298075|Immune thrombocytopenia
125722|NCT02298075|Primary
125723|NCT02298075|Thrombopoietin receptor agonist
125724|NCT02298062|Kawasaki disease coronary artery lesion, IVIG- resistant, Infliximab
125725|NCT02298049|fMRI
125726|NCT02298049|reward
125727|NCT02298049|satiation
125728|NCT02298036|Health Anxiety
125729|NCT02298036|Urgent Care
125730|NCT02298036|Medically Unexplained
125731|NCT02298023|adipose derived mesenchymal stem cell
125732|NCT02298023|allogeneic stem cell
125733|NCT02298023|Rotator cuff tear
125734|NCT02297997|sarcopenia
125735|NCT02297997|cetylpyridinium chloride
125736|NCT02297984|Neuroglobin
125737|NCT02297984|HIF-α
125738|NCT02297984|Acute ischemic stroke
125739|NCT02297984|Prognosis
125740|NCT02297932|Exercise
125741|NCT02297919|Web-based education, Adolescent, Obesity
125742|NCT02297906|Intranasal
125743|NCT02297906|Ketorolac
125744|NCT02297906|Pharmacokinetics
125745|NCT02297906|Pediatric
125746|NCT02297880|low calorie sweetener satiety, intake, hunger
125747|NCT02297815|antibiotic use
125748|NCT02297815|effectiveness
125749|NCT02297815|acute respiratory infections
125750|NCT02297815|pediatrics
125751|NCT02297776|cardiac arrest
125752|NCT02297776|biomarker
125753|NCT02297776|microRNA
125754|NCT02297776|circRNA
125755|NCT02297776|NSE
125756|NCT02297776|CPC
125757|NCT02297750|The focus of the study is double-wire technique versus single wire technique in patients undergoing ERCP with biliary cannulation as the primary objective.
125758|NCT02297737|Tai Chi
125759|NCT02297698|Breast cancer, NeuVax
125760|NCT02297685|Transcutaneous electrical nerve stimulation (TENS)
125761|NCT02297685|Interferential currents therapy
125762|NCT02297685|Therapeutic exercises
125763|NCT02297685|Low back pain
125764|NCT02297685|Rehabilitation
125765|NCT02297672|breast cancer
125766|NCT02297672|brachytherapy
125767|NCT02297672|partial breast radiotherapy
125768|NCT02297672|palladium 103
125769|NCT02297659|damage control
125770|NCT02297659|resuscitation
125771|NCT02297659|laparotomy
125772|NCT02297646|Prevention
125773|NCT02297646|Exercise
125774|NCT02297646|Health
125775|NCT02297646|Endurance
125776|NCT02297633|COPD
125777|NCT02297633|reactive oxygen metabolites
125778|NCT02297620|SGLT-2 inhibitor
125779|NCT02297620|Elderly patients
125780|NCT02297620|ASP1941
125781|NCT02297607|Esophageal Cancer
125782|NCT02297607|Esophagectomy
125783|NCT02297581|Geriatrics [MeSH]
125784|NCT02297581|Osteoporotic fractures [MeSH]
125785|NCT02297581|Hip fractures [MeSH]
125786|NCT02297581|Cost benefit analysis [MeSH]
125787|NCT02297581|Quality of life [MeSH]
125788|NCT02297581|Mortality [MeSH]
125789|NCT02297581|Complications
125790|NCT02297568|Breast-fed infant
125791|NCT02297568|vitamin D supplementation
125792|NCT02297568|Lactation
125793|NCT02297555|Obesity
125794|NCT02297555|Metabolic Syndrome
125795|NCT02297555|ENDOBARRIER®
125796|NCT02297542|Influenza Vaccine
125797|NCT02297529|unresected, Melanoma, expanded access, EU
125798|NCT02297490|Environmental Exposure Chamber
125799|NCT02297490|Specific Immunotherapy
125800|NCT02297490|SIT
125801|NCT02297490|SCIT
125802|NCT02297464|Risk
125803|NCT02297438|breast cancer
125804|NCT02297438|postmenopausal women
125805|NCT02297438|estrogen-receptor positive
125806|NCT02297438|HER2 negative
125807|NCT02297438|locoregionally recurrent
125808|NCT02297438|metastatic
125809|NCT02297425|NSCLC, Non-Small Cell Lung Cancer, EGFRm, Epidermal Grown Factor Receptor mutation
125810|NCT02297399|Colonoscopy
125811|NCT02297399|Diabetes Mellitus
125812|NCT02297399|Polyethylene glycols
125813|NCT02297399|Ascorbate
125814|NCT02297399|Personal satisfaction
125815|NCT02297386|[18F] Dihydro-testosterone
125816|NCT02297386|PET Scan
125817|NCT02297386|MRI
125818|NCT02297386|14-185
125819|NCT02297360|Hair loss, hair thinning, women, marine protein supplement
125820|NCT02297334|CytoSorb(TM)
125821|NCT02297334|cytokines
125822|NCT02297334|inflammation
125823|NCT02297334|cardiac surgery
125824|NCT02297334|extracorporeal bypass
125825|NCT02297321|tattoos
125826|NCT02297321|laser
125827|NCT02297321|whitening
125828|NCT02297321|patch
125829|NCT02297295|Sequelae of; Amputation, Traumatic, Limb, Lower
125830|NCT02297282|Depression
125831|NCT02297282|Behavioural Activation
125832|NCT02297269|Deep vein thrombosis
125833|NCT02297269|Surgery
125834|NCT02297269|gastrointestinal malignancy
125835|NCT02297230|Locally Advanced Breast Cancer
125836|NCT02297191|volunteer
125837|NCT02297191|pilot study
125838|NCT02297191|adults
125839|NCT02297165|anorexic
125840|NCT02297165|olfactory stimulation
125841|NCT02297165|autobiographical memories recovery
125842|NCT02297152|Premature ejaculation treatment
125843|NCT02297152|Sexual dysfunction
125844|NCT02297152|Intravaginal Ejaculatory Latency time
125845|NCT02297152|Masturbation aid
125846|NCT02297152|Ejaculatory disorders
125847|NCT02297113|patients
125848|NCT02297113|departement
125849|NCT02297113|requiring Rapid Sequence Intubation (RSI)
125850|NCT02297100|women
125851|NCT02297100|interstitial cystitis
125852|NCT02297100|bladder pain syndrome
125853|NCT02297100|botox
125854|NCT02297100|onabotulinum toxin A
125855|NCT02297074|Bread
125856|NCT02297074|Glycemic index
125857|NCT02297074|Glycemic load
125858|NCT02297074|Insulinemic index
125859|NCT02297074|Satiety
125860|NCT02297074|Gastrointestinal hormones
125861|NCT02297061|Hip fracture
125862|NCT02297061|Thrombelastography
125863|NCT02297061|Blood loss
125864|NCT02297048|Potassium intake
125865|NCT02297048|Progesterone
125866|NCT02297048|steroidogenesis
125867|NCT02297048|RU486
125868|NCT02297048|Synachtene test
125869|NCT02297022|Deep Brain Stimulation
125870|NCT02297022|obesity
125871|NCT02297022|Prader-Willi syndrome
125872|NCT02296996|BRAF V600
125873|NCT02296996|Rechallenge
125874|NCT02296996|Combination
125875|NCT02296996|Dabrafenib
125876|NCT02296996|Trametinib
125877|NCT02296944|Childrens
125878|NCT02296944|tempanoplasty
125879|NCT02296944|tympanic membrane perforation
125880|NCT02296944|retrospective
125881|NCT02296944|cohort
125882|NCT02296918|CLL
125883|NCT02296918|SLL
125884|NCT02296918|PLL
125885|NCT02296918|Chronic Lymphocytic Leukemia
125886|NCT02296918|Small Lymphocytic Lymphoma
125887|NCT02296918|Prolymphocytic Leukemia
125888|NCT02296918|ACP-196
125889|NCT02296918|acalabrutinib
125890|NCT02296905|Hepatic Impairment
125891|NCT02296905|Hepatitis C Virus Infection
125892|NCT02296853|Severe Hepatic Impairment
125893|NCT02296840|analgesia
125894|NCT02296840|non-steroidal anti-inflammatory drugs
125895|NCT02296840|narcotic-containing pain medication
125896|NCT02296788|Gut Microbiota
125897|NCT02296775|Rheumatoid arthritis
125898|NCT02296775|Rituximab
125899|NCT02296775|Pharmacokinetics
125900|NCT02296736|computerised tomography (CT) scan
125901|NCT02296736|diagnostic accuracy
125902|NCT02296736|Pancreatic head malignancy
125903|NCT02296710|mitral valve
125904|NCT02296710|valve surgery
125905|NCT02296710|echocardiography
125906|NCT02296697|Pressure Ulcer
125907|NCT02296697|Low Level Laser Therapy
125908|NCT02296697|Dressings
125909|NCT02296632|Telemedicine
125910|NCT02296632|Patient Reported Outcomes
125911|NCT02296593|lactate
125912|NCT02296593|continuous lactate monitoring
125913|NCT02296593|continuous blood glucose monitoring
125914|NCT02296593|EIRUS
125915|NCT02296593|blood glucose
125916|NCT02296593|cardiac surgery
125917|NCT02296593|central veinous catheter
125918|NCT02296593|microdialysis
125919|NCT02296554|SLAP Repair
125920|NCT02296554|Biceps Tenodesis
125921|NCT02296528|Feeding Tube Dependent
125922|NCT02296502|DSM Diagnosis
125923|NCT02296450|Quality of Life (QoL)
125924|NCT02296450|Assessment
125925|NCT02296450|14-236
125926|NCT02296450|Patients and Survivors
125927|NCT02296411|Asthma, Anticholinergics
125928|NCT02296385|volunteers
125929|NCT02296333|Acetaminophen, ondansetron
125930|NCT02296307|Aged
125931|NCT02296307|Algorithms
125932|NCT02296307|CA-125 Antigen/blood*
125933|NCT02296307|Chi-Square Distribution
125934|NCT02296307|Early Detection of Cancer*
125935|NCT02296307|Feasibility Studies
125936|NCT02296307|Female
125937|NCT02296307|Humans
125938|NCT02296307|Logistic Models
125939|NCT02296307|Mass Screening/methods*
125940|NCT02296307|Middle Aged
125941|NCT02296307|Neoplasm Grading
125942|NCT02296307|Neoplasm Invasiveness
125943|NCT02296307|Neoplasm Staging
125944|NCT02296307|Ovarian Neoplasms/diagnosis*
125945|NCT02296307|Ovarian Neoplasms/epidemiology
125946|NCT02296307|Ovarian Neoplasms/immunology
125947|NCT02296307|Ovarian Neoplasms/ultrasonography
125948|NCT02296307|Pilot Projects
125949|NCT02296307|Predictive Value of Tests
125950|NCT02296307|Prevalence
125951|NCT02296307|Prognosis
125952|NCT02296307|Prospective Studies
125953|NCT02296307|Quebec/epidemiology
125954|NCT02296307|Tumor Burden
125955|NCT02296294|Bioimpedance Spectroscopy, Body Composition Monitor, Fluid Therapy
125956|NCT02296268|stroke
125957|NCT02296268|aerobic exercise
125958|NCT02296268|screening
125959|NCT02296268|prescription
125960|NCT02296255|cervical cancer screening
125961|NCT02296255|young women vaccination
125962|NCT02296255|impact of HPV vaccination on screening
125963|NCT02296216|have been treated or not treated by Gamma Knife Radiosurgery
125964|NCT02296203|cetuximab rechallenge
125965|NCT02296177|evidence-based intervention
125966|NCT02296177|mammography
125967|NCT02296177|underserved population
125968|NCT02296164|PROVe
125969|NCT02296164|CTCL
125970|NCT02296164|Mechlorethamine
125971|NCT02296164|Cutaneous T-cell lymphoma
125972|NCT02296164|Mycosis fungoides cutaneous T-cell lymphoma
125973|NCT02296164|Valchlor
125974|NCT02296164|Dermatology
125975|NCT02296164|MF-CTCL
125976|NCT02296164|Mycosis Fungoides
125977|NCT02296164|Oncology
125978|NCT02296125|Advanced Non-Small Cell Lung Cancer; EGFRm+; AZD9291; TKI; Phase III
125979|NCT02296099|retropubic suburethral sling
125980|NCT02296099|stress urinary incontinence
125981|NCT02296099|liposomal bupivacaine
125982|NCT02296086|Geriatrics [MeSH]
125983|NCT02296086|Hip fractures [MeSH]
125984|NCT02296086|China [MeSH]
125985|NCT02296086|Early ambulation [MeSH]
125986|NCT02296086|Immobilization [MeSH]
125987|NCT02296073|Pediatric intensive care unit
125988|NCT02296073|Sedation
125989|NCT02296073|Dexmedetomidine
125990|NCT02296073|mechanical ventilation
125991|NCT02296047|COPD, central drive, bronchodilators
125992|NCT02296021|helicobacter pylori
125993|NCT02296021|berberine-containing quadruple therapy
125994|NCT02296021|bismuth-containing quadruple therapy
125995|NCT02296008|high resolution manometry
125996|NCT02296008|children
125997|NCT02296008|congenital anorectal disorder
125998|NCT02296008|surgery
125999|NCT02295995|Aged
126000|NCT02295995|Exercise
126001|NCT02295995|Veterans
126002|NCT02295995|Adherence
126003|NCT02295995|Clinical Trials, Randomized
126004|NCT02295982|Laparoscopic nephrectomy
126005|NCT02295982|one day surgery
126006|NCT02295969|Rhinitis
126007|NCT02295969|Conjunctivitis
126008|NCT02295969|Grass pollen
126009|NCT02295969|Sublingual tablet
126010|NCT02295969|Allergen immunotherapy
126011|NCT02295969|Safety
126012|NCT02295956|Pancreatic Cancer
126013|NCT02295956|Pancreatic adenocarcinoma
126014|NCT02295956|Preoperative therapy
126015|NCT02295956|Questionnaires
126016|NCT02295956|Surveys
126017|NCT02295956|Exercises
126018|NCT02295956|Stretching
126019|NCT02295956|Walking
126020|NCT02295956|Nutrition counseling
126021|NCT02295956|Resistance exercise bands
126022|NCT02295956|Phone calls
126023|NCT02295956|Booklet
126024|NCT02295956|Pamphlet
126025|NCT02295930|colorectal cancer,
126026|NCT02295930|bevacizumab
126027|NCT02295930|cetuximab
126028|NCT02295930|folfoxiri
126029|NCT02295930|kras wild type
126030|NCT02295904|perineum
126031|NCT02295904|videoanalysis
126032|NCT02295865|Psoriasis
126033|NCT02295865|Toreforant
126034|NCT02295865|JNJ-38518168
126035|NCT02295852|Low-sodium calcium enriched diet
126036|NCT02295852|Low-sodium diet
126037|NCT02295852|Glucose and lipid metabolims
126038|NCT02295839|Sleep
126039|NCT02295839|Acute Lymphoblastic Leukemia
126040|NCT02295839|Fatigue
126041|NCT02295839|Sleep hygiene
126042|NCT02295839|Relaxation
126043|NCT02295839|RCT
126044|NCT02295800|HIV
126045|NCT02295800|PMTCT
126046|NCT02295800|Antenatal Care
126047|NCT02295787|Depression
126048|NCT02295787|Suicide
126049|NCT02295787|Suicidal Ideation
126050|NCT02295787|Ketamine
126051|NCT02295787|Late-Life
126052|NCT02295761|motor activity
126053|NCT02295761|obesity
126054|NCT02295761|overweight
126055|NCT02295761|intervention study
126056|NCT02295761|health promotion
126057|NCT02295761|lifestyle counseling
126058|NCT02295761|adherence
126059|NCT02295735|Skin, safety, wounds, intensive care
126060|NCT02295722|eligible for high-dose therapy and stem cell transplantation
126061|NCT02295709|ultrasound
126062|NCT02295709|cervical Transformational Epidural Steroid Injection
126063|NCT02295696|Adults, dialogue tools, outpatient clinic visits
126064|NCT02295644|Therapeutic ultrasound
126065|NCT02295592|hemorrhoids
126066|NCT02295592|The recurrence rate
126067|NCT02295592|PPH
126068|NCT02295592|TSTstarr+
126069|NCT02295566|Nitric Oxide
126070|NCT02295566|Pseudomonas Aeruginosa
126071|NCT02295566|Biofilm
126072|NCT02295553|Ketamine
126073|NCT02295553|Propofol
126074|NCT02295553|Children
126075|NCT02295553|Pediatrics
126076|NCT02295553|Upper endoscopy
126077|NCT02295514|Sepsis
126078|NCT02295514|Septic shock
126079|NCT02295501|Pathogen inactivation
126080|NCT02295501|ebola
126081|NCT02295501|convalescent plasma
126082|NCT02295501|EBOV
126083|NCT02295501|amotosalen
126084|NCT02295501|Provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
126085|NCT02295488|hymenoptera puncture
126086|NCT02295462|nursing homes
126087|NCT02295462|person-centered care
126088|NCT02295462|inappropriate prescriptions
126089|NCT02295462|cluster-randomised controlled trial
126090|NCT02295462|antipsychotic drugs
126091|NCT02295449|Prostate cancer
126092|NCT02295449|Contrast-enhanced ultrasound
126093|NCT02295436|minodronic acid
126094|NCT02295436|pharmacokinetics
126095|NCT02295436|tolerability
126096|NCT02295436|food
126097|NCT02295436|age
126098|NCT02295436|Chinese subjects
126099|NCT02295410|Assessment, PTSD, Veterans
126100|NCT02295397|Food provocation
126101|NCT02295397|Matrix effect
126102|NCT02295397|ED05
126103|NCT02295397|Allergy
126104|NCT02295397|Proton Pump Inhibitor
126105|NCT02295384|Polypharmacy
126106|NCT02295384|Medication Therapy Management
126107|NCT02295371|Drug therapy
126108|NCT02295371|Patient safety
126109|NCT02295371|Polydrug therapy
126110|NCT02295319|Discharge
126111|NCT02295319|Acute Admission Unit
126112|NCT02295319|Randomized Controlled Trial
126113|NCT02295306|OSA, polysomnography, ExSpiron monitor
126114|NCT02295293|Rhus
126115|NCT02295293|Cholesterol
126116|NCT02295293|Triglycerides
126117|NCT02295293|Lipids
126118|NCT02295293|Medicine, Traditional
126119|NCT02295293|Herbal medicine
126120|NCT02295280|headache
126121|NCT02295267|Food allergy
126122|NCT02295267|Walnut
126123|NCT02295267|Components
126124|NCT02295267|Allergens
126125|NCT02295241|Sarcopenia, muscles, aging
126126|NCT02295228|Vitamin D, Vitamin D deficiency, Hip Arthroplasty
126127|NCT02295215|chagas disease
126128|NCT02295215|exercise
126129|NCT02295215|baroreflex sensitivity
126130|NCT02295163|Stellate ganglion block
126131|NCT02295163|hot flushes
126132|NCT02295163|androgen deprivation therapy
126133|NCT02295163|prostate cancer
126134|NCT02295150|Nadroparin
126135|NCT02295150|Anti-Xa activity
126136|NCT02295124|Nausea
126137|NCT02295111|electro-acupuncture
126138|NCT02295111|chronic pelvic pain
126139|NCT02295111|patient practitioner interactions
126140|NCT02295111|TCM health consultation
126141|NCT02295111|meridian balanced method acupuncture
126142|NCT02295085|Cohort, Prospective, Biospecimens
126143|NCT02295072|Exercise-based Randomized Controlled Trial
126144|NCT02295072|Brain structure
126145|NCT02295072|Brain function
126146|NCT02295072|Cognitive function
126147|NCT02295072|Physical fitness
126148|NCT02295072|Body Mass Index
126149|NCT02295072|Cardiovascular disease risk factors
126150|NCT02295072|Mental health
126151|NCT02295072|Stress
126152|NCT02295072|Neurology
126153|NCT02295072|Obesity
126154|NCT02295072|brain
126155|NCT02295072|risk factors
126156|NCT02295072|bone
126157|NCT02295072|bones
126158|NCT02295072|body composition
126159|NCT02295059|Breast cancer
126160|NCT02295059|ERPR negative
126161|NCT02295059|HER-2/neu overexpression positive or negative
126162|NCT02295033|Boost versus no boost irradiation of early breast cancer
126163|NCT02294955|catheter ablation
126164|NCT02294955|atrial fibrillation
126165|NCT02294942|RNTA06
126166|NCT02294942|RANCAD
126167|NCT02294929|catheter ablation
126168|NCT02294929|cryoballoon
126169|NCT02294903|Focal radiofrequency ablation
126170|NCT02294903|Prostate cancer
126171|NCT02294903|Encage
126172|NCT02294864|focus: pulsed radiofrequency (E02.779.468.599)
126173|NCT02294825|deep endometriosis;
126174|NCT02294825|colorectal endometriosis
126175|NCT02294825|surgery
126176|NCT02294825|medical treatment
126177|NCT02294825|fertility
126178|NCT02294812|Hearing Loss
126179|NCT02294812|Speech Perception
126180|NCT02294812|Cognitive Training
126181|NCT02294812|Cognitive Fitness
126182|NCT02294812|Memory, Short-Term
126183|NCT02294799|Temporomandibular Joint Disorders
126184|NCT02294799|Magnetic Ressonance Imaging
126185|NCT02294799|Complementary Therapy
126186|NCT02294799|Physical Therapy Modalities.
126187|NCT02294786|Randomised
126188|NCT02294786|Octreotide
126189|NCT02294786|Diarrhoea
126190|NCT02294786|Phase II
126191|NCT02294786|Capecitabine
126192|NCT02294786|Quality of life
126193|NCT02294786|Metastatic breast cancer
126194|NCT02294786|HER2
126195|NCT02294786|Lapatinib
126196|NCT02294786|Diarrhoea diary
126197|NCT02294773|Infertility
126198|NCT02294773|Intrauterine insemination
126199|NCT02294773|Luteinizing hormone surge
126200|NCT02294760|Irritable Bowel Syndrome
126201|NCT02294760|Sacral Nerve Stimulation
126202|NCT02294760|Symptoms
126203|NCT02294760|Quality of Life
126204|NCT02294734|functional respiratory capacity
126205|NCT02294734|High-resolution computed tomography
126206|NCT02294734|GSK2269557
126207|NCT02294734|acute exacerbation of COPD
126208|NCT02294734|lung capacity
126209|NCT02294708|macula-off retinal detachment
126210|NCT02294708|scleral buckle
126211|NCT02294708|persistent sub-foveal fluid
126212|NCT02294708|postoperative postures
126213|NCT02294708|optical coherence tomography (OCT)
126214|NCT02294695|Empiric antibiotic therapy
126215|NCT02294682|uncomplicated urogenital gonorrhea
126216|NCT02294682|Bacterial Type II Topoisomerase Inhibitors (BTI)
126217|NCT02294682|antibiotics
126218|NCT02294682|GSK2140944
126219|NCT02294682|N. gonorrhoeae
126220|NCT02294656|CYSTOID MACULAR EDEMA
126221|NCT02294643|sarpogrelate
126222|NCT02294591|Bipolar Disorder
126223|NCT02294591|Depression
126224|NCT02294591|Acetylcystein
126225|NCT02294591|Oxidative Stress
126226|NCT02294591|Urine
126227|NCT02294578|Biomarkers
126228|NCT02294578|saliva
126229|NCT02294578|mRNA
126230|NCT02294565|Sentinel Lymph Node Biopsy
126231|NCT02294565|Breast Cancer
126232|NCT02294565|Lymphatic Mapping
126233|NCT02294552|Cyclophosphamide
126234|NCT02294552|Leukemia
126235|NCT02294552|Lymphoma
126236|NCT02294552|Myelodysplastic Syndromes
126237|NCT02294552|Chronic Lymphocytic Leukemia
126238|NCT02294552|Immunosuppressive Agents
126239|NCT02294552|Immune System Diseases
126240|NCT02294552|Busulfan
126241|NCT02294552|Fludarabine
126242|NCT02294552|Tacrolimus
126243|NCT02294552|Mycophenolate mofetil
126244|NCT02294552|Antineoplastic Agents, Alkylating
126245|NCT02294552|Myeloablative Agonists
126246|NCT02294552|Hematopoietic Stem Cell Transplantation
126247|NCT02294552|Allogeneic
126248|NCT02294526|Diet
126249|NCT02294526|Sardine
126250|NCT02294526|Type 2 diabetes
126251|NCT02294513|Alzheimer disease
126252|NCT02294513|Dementia
126253|NCT02294513|Hearing loss
126254|NCT02294513|Correction of hearing impairment
126255|NCT02294513|Hearing aids
126256|NCT02294513|Communication
126257|NCT02294513|Family caregivers
126258|NCT02294513|Third-party disability
126259|NCT02294500|ovarian function
126260|NCT02294500|female
126261|NCT02294500|Genital Function
126262|NCT02294487|influenza
126263|NCT02294487|pneumococcal
126264|NCT02294487|pneumonia
126265|NCT02294487|vaccine
126266|NCT02294487|immunization
126267|NCT02294487|#CAImmun
126268|NCT02294487|Immuno-oncology
126269|NCT02294487|supportive care
126270|NCT02294487|vaccination
126271|NCT02294487|meningococcal
126272|NCT02294487|HIB
126273|NCT02294461|Enzalutamide
126274|NCT02294461|Androgen receptor
126275|NCT02294461|Prostate cancer
126276|NCT02294461|Xtandi
126277|NCT02294448|Cervical radiculopathy
126278|NCT02294448|Neck pain
126279|NCT02294448|Qishe pill
126280|NCT02294448|raditional Chinese medicine
126281|NCT02294448|healthy Chinese subject
126282|NCT02294448|Population Pharmacokinetics
126283|NCT02294448|Personalized Medicine
126284|NCT02294448|Individualized Medicine
126285|NCT02294435|Thoracoabdominal Aneurysms
126286|NCT02294435|Endovascular
126287|NCT02294435|Ps-ide
126288|NCT02294435|Early Feasibility
126289|NCT02294435|Aneurysm
126290|NCT02294435|Aortic Aneurysm, Thoracic
126291|NCT02294435|Aortic Aneurysm
126292|NCT02294435|Aortic Diseases
126293|NCT02294435|Cardiovascular Diseases
126294|NCT02294435|Vascular Diseases
126295|NCT02294435|Pararenal aneurysm
126296|NCT02294435|Juxtarenal aneurysm
126297|NCT02294435|Aortic dissection
126298|NCT02294435|Short neck infrarenal aneurysm
126299|NCT02294435|Type 4 thoracoabdominal
126300|NCT02294435|TAAA
126301|NCT02294422|Loss of resistance
126302|NCT02294422|Pilot balloon
126303|NCT02294422|Cuff pressure
126304|NCT02294422|Endotracheal tube
126305|NCT02294409|social anxiety
126306|NCT02294409|psychosis
126307|NCT02294409|CBT
126308|NCT02294409|randomized
126309|NCT02294409|CRT
126310|NCT02294396|Anticholinergic
126311|NCT02294396|Overactive Bladder (OAB)
126312|NCT02294396|Mirabegron
126313|NCT02294396|YM178
126314|NCT02294383|Pelvic Floor Biomechanics
126315|NCT02294383|Tissue Elasticity
126316|NCT02294383|Tactile Imaging
126317|NCT02294370|type 2 diabetes
126318|NCT02294370|continuous glucose monitoring
126319|NCT02294357|carfilzomib
126320|NCT02294357|proteasome inhibitor
126321|NCT02294357|multiple myeloma
126322|NCT02294357|relapsed/refractory
126323|NCT02294344|double filtration plasmapheresis
126324|NCT02294344|ANCA-Associated Vasculitis
126325|NCT02294305|Depression
126326|NCT02294305|Social Anxiety
126327|NCT02294305|Social Phobia
126328|NCT02294305|Major Depression
126329|NCT02294305|Vortioxetine
126330|NCT02294279|cough, wheeze, dyspnoea
126331|NCT02294240|Pregnant, malnourished, energy dense biscuits, low birth weight
126332|NCT02294227|AIN457, psoriatic arthritis, chronic inflammatory disease, loading regimen, secukinumab, self-injection
126333|NCT02294214|malaria
126334|NCT02294214|Spatial Repellents
126335|NCT02294214|Plasmodium
126336|NCT02294201|Malaria
126337|NCT02294201|Spatial Repellents
126338|NCT02294201|Plasmodium
126339|NCT02294188|Malaria
126340|NCT02294188|Spatial Repellents
126341|NCT02294188|Plasmodium
126342|NCT02294175|larva
126343|NCT02294175|debridement
126344|NCT02294175|lower extremity or diabetic foot ulcer
126345|NCT02294175|biofilm
126346|NCT02294175|infection
126347|NCT02294175|chronic wound
126348|NCT02294149|chemotherapy
126349|NCT02294149|Omega 3
126350|NCT02294136|HIV
126351|NCT02294136|HCV
126352|NCT02294136|Adherence
126353|NCT02294136|Psychiatric
126354|NCT02294136|Behavioral
126355|NCT02294136|Intervention
126356|NCT02294110|failure
126357|NCT02294110|spinal anesthesia
126358|NCT02294071|acetaminophen
126359|NCT02294071|ibuprofen
126360|NCT02294058|MS
126361|NCT02294058|RMS
126362|NCT02294058|Multiple Sclerosis
126363|NCT02294058|Relapsing Multiple Sclerosis
126364|NCT02294045|Knee
126365|NCT02294045|Healthy
126366|NCT02294045|arthroscopy
126367|NCT02294045|MRI
126368|NCT02294045|amplification
126369|NCT02294045|sounds
126370|NCT02294045|pre-operative
126371|NCT02294045|analyzing
126372|NCT02294032|Bcells
126373|NCT02294032|kidney allograft dysfunction
126374|NCT02294032|antibody mediated rejection
126375|NCT02294019|ibuprofen 400 mg
126376|NCT02294019|actual use
126377|NCT02294019|compliance
126378|NCT02294006|pancreatic
126379|NCT02294006|neuroendocrine
126380|NCT02294006|everolimus
126381|NCT02294006|metformin
126382|NCT02294006|octreotide
126383|NCT02293941|liver inflammation
126384|NCT02293928|Hybrid coronary revascularization
126385|NCT02293928|Antiplatelet therapy
126386|NCT02293928|Aspirin
126387|NCT02293928|Clopidogrel
126388|NCT02293889|Knee osteoarthritis
126389|NCT02293889|Pain
126390|NCT02293889|Vitamin D
126391|NCT02293889|Physical activity
126392|NCT02293889|Pilot study
126393|NCT02293889|Qualitative Interview
126394|NCT02293889|Obesity
126395|NCT02293889|Older adults
126396|NCT02293876|Corneal Diseases
126397|NCT02293876|Corneal Ulcer
126398|NCT02293876|Nursing Diagnosis
126399|NCT02293876|Intensive Care Units
126400|NCT02293876|Nursing
126401|NCT02293876|Randomized Clinical Trial
126402|NCT02293837|interleukin-6 (IL-6) receptor inhibitor
126403|NCT02293824|Infant, Premature
126404|NCT02293824|Caffeine
126405|NCT02293824|Pharmacokinetics
126406|NCT02293824|Metabolism
126407|NCT02293772|Bedrest
126408|NCT02293772|Appetite
126409|NCT02293759|BPH- LASER- PROSTATE- BLEEDING TENDENCY
126410|NCT02293746|Obstructive Sleep Apnea
126411|NCT02293746|OSA
126412|NCT02293746|neurostimulation
126413|NCT02293746|hypoglossal nerve
126414|NCT02293746|tongue
126415|NCT02293746|upper airway stimulation
126416|NCT02293746|surgery
126417|NCT02293733|Retrospective
126418|NCT02293733|EGFR
126419|NCT02293733|mutation
126420|NCT02293733|TKI
126421|NCT02293733|NSCLC
126422|NCT02293707|Castration-resistant prostate cancer
126423|NCT02293707|Therapeutic vaccine
126424|NCT02293707|Telomerase vaccine
126425|NCT02293694|DMPA-SC: depo medroxyprogesterone acetate sub-cutaneous
126426|NCT02293694|DMPA-IM: depo medroxyprogesterone acetate intramuscular
126427|NCT02293681|Spondylitis, Ankylosing
126428|NCT02293681|Infliximab
126429|NCT02293681|Non-steroidal anti-inflammatory drugs
126430|NCT02293681|Disease-modifying anti-rheumatic drugs
126431|NCT02293668|poor responders
126432|NCT02293655|ADHD
126433|NCT02293655|inattention
126434|NCT02293655|hyperactivity
126435|NCT02293655|methylphenidate
126436|NCT02293642|primary cancers of the breast
126437|NCT02293642|primary cancers of the kidney
126438|NCT02293642|primary cancers of the lung
126439|NCT02293642|primary cancers of the prostate
126440|NCT02293629|Subjects
126441|NCT02293616|ICU
126442|NCT02293616|Respiratory Failure
126443|NCT02293616|Weakness
126444|NCT02293616|Nitrate supplementation
126445|NCT02293603|cardiomyopathy
126446|NCT02293603|cardiosphere-derived stem cells
126447|NCT02293603|intracoronary infusion
126448|NCT02293603|adult stem cells
126449|NCT02293603|heart disease
126450|NCT02293603|ventricular dysfunction
126451|NCT02293603|pathological processes
126452|NCT02293603|cardiovascular diseases
126453|NCT02293603|heart failure
126454|NCT02293590|Certolizumab pegol
126455|NCT02293590|DMARD
126456|NCT02293590|Joint injection
126457|NCT02293590|Glucocorticoids
126458|NCT02293564|Erosive Osteoarthritis
126459|NCT02293564|Osteoarthritis
126460|NCT02293564|Osteoarthritis of the Hand
126461|NCT02293538|Symptoms of Contact Lens Related Discomfort
126462|NCT02293512|Tinnitus
126463|NCT02293512|Coping
126464|NCT02293512|Psycho-educational intervention
126465|NCT02293499|asthma
126466|NCT02293499|adolescent
126467|NCT02293499|intervention
126468|NCT02293486|Antioxidants
126469|NCT02293486|Protein Carbonylation
126470|NCT02293486|Malondialdehyde
126471|NCT02293486|Punicaceae
126472|NCT02293486|Athletic Performance
126473|NCT02293460|Peripheral neuropathy
126474|NCT02293460|Disimmune disease
126475|NCT02293460|Neurology Chronic disease
126476|NCT02293460|Rare disease
126477|NCT02293447|Uterine
126478|NCT02293447|Fibroid
126479|NCT02293447|Embolization
126480|NCT02293447|Leiomyoma
126481|NCT02293447|Lidocaine
126482|NCT02293447|Pain
126483|NCT02293434|Malnutrition
126484|NCT02293434|Status Nutritional Weight
126485|NCT02293434|Pediatric intensive care
126486|NCT02293408|MPS IIIB
126487|NCT02293408|Mucopolysaccharidosis
126488|NCT02293408|Mucopolysaccharidosis type IIIB
126489|NCT02293408|Sanfilippo Syndrome
126490|NCT02293395|Acute Coronary Syndrome
126491|NCT02293395|Myocardial infarction
126492|NCT02293395|Unstable angina
126493|NCT02293395|Acetylsalicylic acid
126494|NCT02293395|Rivaroxaban
126495|NCT02293395|JNJ-39039039
126496|NCT02293395|Bay 59-7939
126497|NCT02293395|Xarelto
126498|NCT02293395|Clopidogrel
126499|NCT02293395|Ticagrelor
126500|NCT02293395|Plavix
126501|NCT02293395|Brilinta
126502|NCT02293395|Effient
126503|NCT02293382|MPS IIIB
126504|NCT02293382|Mucopolysaccharodosis III
126505|NCT02293382|Mucopolysaccharidosis type IIIB
126506|NCT02293382|Sanfilippo Syndrome
126507|NCT02293343|histamine profile
126508|NCT02293343|IgE Antibodies
126509|NCT02293330|continuous versus intermittent bolus sciatic nerve block
126510|NCT02293317|Influenza Prime universal vaccine M-001 Multimeric
126511|NCT02293291|Gulf war illness
126512|NCT02293278|MVPA
126513|NCT02293278|sedentary behaviour
126514|NCT02293278|PA intervention
126515|NCT02293278|preschool
126516|NCT02293278|gross motor
126517|NCT02293278|anthropometrics
126518|NCT02293278|day care
126519|NCT02293265|mepolizumab
126520|NCT02293265|omalizumab
126521|NCT02293265|SB-240563
126522|NCT02293265|Severe Asthma
126523|NCT02293265|reslizumab
126524|NCT02293252|Home Telemonitoring
126525|NCT02293239|electromyostimulation
126526|NCT02293239|cachexia
126527|NCT02293239|cancer
126528|NCT02293213|Category D
126529|NCT02293213|Category X
126530|NCT02293213|Electronic Medical Records
126531|NCT02293213|Long Acting Reversible Contraception
126532|NCT02293187|vitamin D
126533|NCT02293187|muscle performance
126534|NCT02293187|falls
126535|NCT02293161|Interleukin-7 Receptor α
126536|NCT02293161|monoclonal antibody
126537|NCT02293148|Prolyl hydroxylase inhibitor
126538|NCT02293148|QTc
126539|NCT02293148|Anemia
126540|NCT02293148|erythropoiesis stimulating agent
126541|NCT02293148|GSK1278863
126542|NCT02293135|Type 2 diabetes ; endothelium stimulation
126543|NCT02293122|Agreement
126544|NCT02293122|Repeatability
126545|NCT02293122|Reproducibility
126546|NCT02293096|Genotype
126547|NCT02293096|CYP2D6
126548|NCT02293096|ADRB1
126549|NCT02293057|Adolescent
126550|NCT02293057|Juvenile Justice
126551|NCT02293057|Drug Use
126552|NCT02293057|Marijuana
126553|NCT02293057|Gender Responsive
126554|NCT02293057|Girls
126555|NCT02293057|HIV
126556|NCT02293057|Sexual Risk
126557|NCT02293044|Sensitivity
126558|NCT02293031|maxillofacial bone defects
126559|NCT02293031|alveolar ridge atrophy
126560|NCT02293031|gene-activated matrix
126561|NCT02293031|VEGF gene
126562|NCT02293031|DNA plasmid
126563|NCT02293031|bone gene therapy
126564|NCT02293005|Lung Cancer
126565|NCT02293005|Mesothelioma
126566|NCT02293005|Unresectable malignant pleural mesothelioma
126567|NCT02293005|MPM
126568|NCT02293005|Alisertib
126569|NCT02293005|MLN8237
126570|NCT02292992|Electrical impedance tomography
126571|NCT02292992|Nasal Pillow Continuous Positive Airway Pressure(CPAP)
126572|NCT02292992|High Flow Nasal Cannula
126573|NCT02292992|extubation
126574|NCT02292979|HL
126575|NCT02292966|Hepatitis C
126576|NCT02292966|Hepatitis
126577|NCT02292966|Asunaprevir
126578|NCT02292966|Daclatasvir
126579|NCT02292966|Beclabuvir
126580|NCT02292966|Neurocognitive function
126581|NCT02292966|Brain metabolites
126582|NCT02292966|Direct acting antiviral therapy
126583|NCT02292953|ICSI
126584|NCT02292953|Ovum Pickup
126585|NCT02292953|Embryo Transfer
126586|NCT02292940|patient outcome assessment
126587|NCT02292940|electronic health records
126588|NCT02292888|Doppler VTI TEE SV volume responsiveness
126589|NCT02292875|Grass Allergy
126590|NCT02292875|Rhinoconjunctivitis
126591|NCT02292875|Environmental Exposure Unit
126592|NCT02292875|Immunotherapy
126593|NCT02292875|ToleroMune Grass
126594|NCT02292849|Depression
126595|NCT02292823|STEMI
126596|NCT02292823|heart attack
126597|NCT02292823|stent
126598|NCT02292823|Bare Metal Stent
126599|NCT02292823|myocardial infarction
126600|NCT02292823|PCI
126601|NCT02292784|infants
126602|NCT02292784|retosiban
126603|NCT02292784|Preterm Labor
126604|NCT02292784|long-term safety follow-up
126605|NCT02292771|Spontaneous Preterm Labor
126606|NCT02292771|retosiban
126607|NCT02292771|GSK221149
126608|NCT02292771|atosiban
126609|NCT02292745|locally advanced pancreatic cancer
126610|NCT02292745|chemotherapy
126611|NCT02292745|stereotactic radiotherapy
126612|NCT02292732|Pharmacokinetics
126613|NCT02292732|Solid Tumors
126614|NCT02292732|Safety
126615|NCT02292732|Trametinib
126616|NCT02292732|MEK Inhibitor
126617|NCT02292732|Combined Oral Contraceptive
126618|NCT02292732|Trametinib's Metabolite M5
126619|NCT02292732|Norethindrone
126620|NCT02292732|Ethinyl Estradiol
126621|NCT02292719|Hepatitis C Virus
126622|NCT02292719|Genotype 2
126623|NCT02292719|Chronic Hepatitis C
126624|NCT02292719|Genotype 3
126625|NCT02292719|Non-cirrhotic
126626|NCT02292719|Cirrhotic
126627|NCT02292706|HCV Cirrhosis registry
126628|NCT02292706|Cirrhosis
126629|NCT02292706|Hepatitis C
126630|NCT02292693|intubation
126631|NCT02292680|dentin
126632|NCT02292680|environmental exposures
126633|NCT02292680|neurodevelopmental outcomes
126634|NCT02292667|Transversus Abdominis Plane Block
126635|NCT02292667|Postoperative Pain Management
126636|NCT02292667|Open Repair of Aortic Abdominal Aneurysm
126637|NCT02292641|Lower Gastrointestinal Tract
126638|NCT02292641|Rectum
126639|NCT02292641|Diagnostic Imaging
126640|NCT02292641|Magnetic Resonance Imaging
126641|NCT02292641|Pelvic Exenteration
126642|NCT02292641|Neoplasms
126643|NCT02292641|Adenocarcinoma
126644|NCT02292641|Carcinoma
126645|NCT02292602|preschool
126646|NCT02292602|obesity
126647|NCT02292602|health disparities
126648|NCT02292602|intervention
126649|NCT02292589|Traumatic Brain Injury
126650|NCT02292589|Post concussion syndrome
126651|NCT02292589|Transcranial Direct Current Stimulation
126652|NCT02292589|Neuromodulation
126653|NCT02292576|volunteers
126654|NCT02292563|Nurse; Colonoscopy; Polyp; Adenoma;
126655|NCT02292550|Non-small cell lung cancer,
126656|NCT02292550|ALK translocation,
126657|NCT02292550|ALK-positive,
126658|NCT02292550|NSCLC,
126659|NCT02292550|LEE011,
126660|NCT02292550|CDK4/6 inhibitor,
126661|NCT02292550|EML4-ALK
126662|NCT02292537|Spinal Muscular Atrophy
126663|NCT02292537|SMA
126664|NCT02292537|SMN
126665|NCT02292537|SMNRx
126666|NCT02292537|ISIS-SMNRx
126667|NCT02292537|ISIS-SMN Rx
126668|NCT02292537|ISIS 396443
126669|NCT02292537|Cherish
126670|NCT02292537|IONIS-SMNRx
126671|NCT02292537|IONIS-SMN Rx
126672|NCT02292511|subjective cognitive impairment
126673|NCT02292511|mind-motor intervention
126674|NCT02292511|square-stepping exercise
126675|NCT02292511|older adults
126676|NCT02292498|imaging, diagnostic
126677|NCT02292485|Lung Cancer Screening
126678|NCT02292485|LCS
126679|NCT02292485|Survey
126680|NCT02292485|Questionnaire
126681|NCT02292485|Texas Academy of Family Physicians
126682|NCT02292472|masticatory muscles
126683|NCT02292446|Polycythemia Vera
126684|NCT02292446|Hematologic Diseases
126685|NCT02292446|Myeloproliferative Disorders
126686|NCT02292446|INC424
126687|NCT02292446|Ruxolitinib
126688|NCT02292433|Phase 1
126689|NCT02292433|type 2 diabetes
126690|NCT02292433|monotherapy
126691|NCT02292433|PF-04937319
126692|NCT02292420|pulse oximetry plethymographic waveform
126693|NCT02292420|area under curve
126694|NCT02292420|amplitude
126695|NCT02292394|Depression
126696|NCT02292394|Depressive symptoms
126697|NCT02292394|Prevention
126698|NCT02292394|Caregivers
126699|NCT02292394|Telephone intervention
126700|NCT02292368|Head and Neck Cancer
126701|NCT02292368|Xerostomia
126702|NCT02292368|Radiation-induced Xerostomia
126703|NCT02292368|Acupuncture
126704|NCT02292368|Nasopharyngeal cancer
126705|NCT02292368|Radiation therapy
126706|NCT02292368|XRT
126707|NCT02292368|Electroencephalogram
126708|NCT02292368|EEG
126709|NCT02292368|Xerostomia questionnaire
126710|NCT02292368|XQ
126711|NCT02292368|MD Anderson Symptom Inventory - Head & Neck
126712|NCT02292368|MDASI-HN
126713|NCT02292368|Questionnaires
126714|NCT02292368|Surveys
126715|NCT02292355|Temporomandibular Joint Disorders
126716|NCT02292355|posture
126717|NCT02292355|pain
126718|NCT02292355|clinical trial
126719|NCT02292355|Pilates
126720|NCT02292342|Flow mediated dilatation
126721|NCT02292329|flow-mediated dilation
126722|NCT02292329|Acai polyphenols
126723|NCT02292316|middle-aged and aged adults
126724|NCT02292316|fall in the previous year
126725|NCT02292303|Zinc/pharmacokinetics
126726|NCT02292290|Diabetes
126727|NCT02292290|Liraglutide
126728|NCT02292290|Ramadan
126729|NCT02292290|fasting
126730|NCT02292277|Ticagrelor
126731|NCT02292277|Pharmacokinetics
126732|NCT02292277|Platelet Aggregation
126733|NCT02292277|Platelet Function Tests
126734|NCT02292251|Stroke
126735|NCT02292251|Transcranial direct current stimulation
126736|NCT02292238|Alzheimer's disease
126737|NCT02292238|benfotiamine
126738|NCT02292238|glucose
126739|NCT02292238|Amyloid
126740|NCT02292225|Phase 1b, CLL/SLL, PI3K
126741|NCT02292199|Hypertension
126742|NCT02292199|TENS
126743|NCT02292199|Sympathetic and Parasympathetic nervous system
126744|NCT02292186|Cardiomyopathy
126745|NCT02292186|Heart Failure
126746|NCT02292186|FAC
126747|NCT02292186|Amyloid
126748|NCT02292186|Transthyretin
126749|NCT02292186|TTR
126750|NCT02292186|RNAi therapeutic
126751|NCT02292173|Liver Neoplasms
126752|NCT02292173|Liver Diseases
126753|NCT02292173|Digestive System Diseases
126754|NCT02292173|Advanced
126755|NCT02292173|Mitogen-Activated Protein Kinase (MEK) Inhibitor
126756|NCT02292173|Kinase Inhibitor
126757|NCT02292147|Cerebral anoxia
126758|NCT02292147|Functional outcome
126759|NCT02292134|Sleep quality
126760|NCT02292134|Sleep architecture
126761|NCT02292134|Intensive care unit
126762|NCT02292134|Light
126763|NCT02292134|Noise
126764|NCT02292134|Earplug
126765|NCT02292134|Sleep mask
126766|NCT02292121|Obesity
126767|NCT02292121|Intestinal permeability
126768|NCT02292121|Adipose tissue inflammation
126769|NCT02292121|Low grade systemic inflammation
126770|NCT02292121|Bariatric surgery
126771|NCT02292108|Hypnosis
126772|NCT02292108|self-hypnosis
126773|NCT02292108|obesity
126774|NCT02292108|high food impulsiveness
126775|NCT02292095|anesthesia
126776|NCT02292095|transverse abdominis plane block
126777|NCT02292095|patient controlled intravenous analgesia
126778|NCT02292082|Nerve Block
126779|NCT02292082|Rehabilitation
126780|NCT02292082|Knee Replacement, Total
126781|NCT02291991|Safety
126782|NCT02291991|Tolerability
126783|NCT02291991|Pharmacokinetics
126784|NCT02291991|Pharmacodynamics
126785|NCT02291991|Immunogenecity
126786|NCT02291978|back pain
126787|NCT02291978|facet joint
126788|NCT02291978|spine
126789|NCT02291965|hematopoietic cell transplant
126790|NCT02291952|Circadian Misalignment, Forced Desynchrony, Metabolism, Meal-timing, Circadian
126791|NCT02291926|Human Umbilical Cord Mesenchymal Stem Cell
126792|NCT02291926|Mesenchymal Stem Cell
126793|NCT02291926|Osteoarthritis
126794|NCT02291913|ER-Positive Breast Cancer
126795|NCT02291913|HER2-Negative Breast Cancer
126796|NCT02291913|everolimus
126797|NCT02291913|anti-estrogen therapy
126798|NCT02291913|PR-Positive Breast Cancer
126799|NCT02291913|Afinitor
126800|NCT02291900|avascular necrosis, talus, medial femoral condyle
126801|NCT02291874|Diabetes
126802|NCT02291874|Ipragliflozin
126803|NCT02291874|GLP-1 receptor agonist
126804|NCT02291861|Dyskinesias
126805|NCT02291861|Movement Disorders
126806|NCT02291861|Central Nervous System Diseases
126807|NCT02291861|Nervous System Diseases
126808|NCT02291861|Neurologic Manifestations
126809|NCT02291861|Signs and Symptoms
126810|NCT02291848|Multiple Myeloma
126811|NCT02291848|Cytotoxic T-lymphocytes
126812|NCT02291809|HIV/AIDS
126813|NCT02291809|Pediatric
126814|NCT02291809|Vaccine
126815|NCT02291809|HIV-1 Immunogen
126816|NCT02291796|Bezafibrate
126817|NCT02291796|Hyperfibrinogenemia
126818|NCT02291796|Inflammatory response
126819|NCT02291796|Acute myocardial infarction
126820|NCT02291796|Mayor cardiovascular events
126821|NCT02291770|Chronic Graft-Versus-Host Disease
126822|NCT02291770|Mesenchymal Stromal Cells
126823|NCT02291744|TFS (time to failure of strategy)
126824|NCT02291731|Autologous serum eye drops
126825|NCT02291731|Silicone-hydrogel contact lens
126826|NCT02291731|Persistent epithelial defects
126827|NCT02291731|Corneal epithelial defects
126828|NCT02291718|Suspected or confirmed
126829|NCT02291718|TAA
126830|NCT02291718|Computed tomography angiography
126831|NCT02291718|CTA
126832|NCT02291718|Contrast agent
126833|NCT02291718|Radiation dose
126834|NCT02291718|Thoracoabdominal aortic aneurysm
126835|NCT02291705|Ultrasound, rectus sheath block, children, inguinal hernia
126836|NCT02291666|Cytochromes p450
126837|NCT02291666|drug metabolism
126838|NCT02291666|pharmacokinetics
126839|NCT02291666|diabetes
126840|NCT02291666|probe markers
126841|NCT02291614|Amgen
126842|NCT02291614|Phase 1
126843|NCT02291614|Clinical Trial
126844|NCT02291614|Oncology
126845|NCT02291614|GI adenocarcinoma
126846|NCT02291614|Immunotherapy
126847|NCT02291536|THC and CBD
126848|NCT02291536|Attentional blink
126849|NCT02291523|Fecal transplant
126850|NCT02291484|Computed tomography
126851|NCT02291484|Coronary angiography
126852|NCT02291484|Coronary artery disease
126853|NCT02291484|Perfusion imaging
126854|NCT02291484|Comparative effectiveness
126855|NCT02291484|Randomized controlled trial
126856|NCT02291484|Cost-effectiveness
126857|NCT02291445|Peppermint oil
126858|NCT02291445|Menthol
126859|NCT02291445|Volatile oil
126860|NCT02291445|Plant oil
126861|NCT02291445|Visceral pain
126862|NCT02291445|Abdominal pain
126863|NCT02291445|Irritable bowel syndrome (IBS)
126864|NCT02291445|Colonic disease
126865|NCT02291419|ticagrelor
126866|NCT02291419|non-cardiac surgery
126867|NCT02291419|elevated troponin
126868|NCT02291419|myocardial injury
126869|NCT02291406|Hysterectomy
126870|NCT02291406|Insulin resistance
126871|NCT02291406|Metabolism
126872|NCT02291380|Chronic Migraine
126873|NCT02291380|Botulinum Toxin Type A for Injection
126874|NCT02291354|Fecal Microbiota Transplantation
126875|NCT02291354|Soluble Dietary Fiber
126876|NCT02291354|Slow Transit Constipation
126877|NCT02291315|Triple Stable Isotope
126878|NCT02291263|Polio
126879|NCT02291263|Inactivated polio vaccine
126880|NCT02291263|IPV
126881|NCT02291263|oral polio vaccine
126882|NCT02291250|anthocyanin
126883|NCT02291250|blackcurrant
126884|NCT02291250|greencurrant
126885|NCT02291250|glucose
126886|NCT02291250|polyphenol
126887|NCT02291250|post prandial glucose
126888|NCT02291237|hypertrophic cardiomyopathy
126889|NCT02291237|hcm
126890|NCT02291237|hocm
126891|NCT02291237|hypertrophic myocardiopathy
126892|NCT02291237|hypertrophic obstructive cardiomyopathies
126893|NCT02291237|cardiomyopathy
126894|NCT02291237|hypertrophic
126895|NCT02291237|familial hypertrophic cardiomyopathy
126896|NCT02291237|genetic heart disease
126897|NCT02291237|echocardiography
126898|NCT02291237|cardiopulmonary exercise testing
126899|NCT02291237|exercise Capacity
126900|NCT02291237|heart failure
126901|NCT02291237|angina
126902|NCT02291237|dyspnea
126903|NCT02291237|diastolic dysfunction
126904|NCT02291237|microvascular ischemia
126905|NCT02291237|late sodium current inhibitor
126906|NCT02291237|GS-6615
126907|NCT02291237|late INA
126908|NCT02291224|dual protection
126909|NCT02291224|pregnancy
126910|NCT02291224|reproductive health
126911|NCT02291224|sexually transmitted diseases
126912|NCT02291224|condoms
126913|NCT02291224|contraception
126914|NCT02291224|adolescent health services
126915|NCT02291198|colorectal cancer
126916|NCT02291198|natural killer cell activity
126917|NCT02291198|screening
126918|NCT02291198|NK cells
126919|NCT02291159|stroke
126920|NCT02291159|spasticity
126921|NCT02291159|dry needling
126922|NCT02291159|upper motor neuron syndrome
126923|NCT02291159|motor function
126924|NCT02291146|gardening
126925|NCT02291146|cooking
126926|NCT02291146|nutrition education
126927|NCT02291146|Hispanic Americans
126928|NCT02291133|Primary liver tumors
126929|NCT02291133|Bleomycin
126930|NCT02291133|Electrochemotherapy
126931|NCT02291107|Gait orthosis
126932|NCT02291107|Lokomat
126933|NCT02291107|Robotic Rehabilitation
126934|NCT02291094|Intravenous lidocaine
126935|NCT02291094|Mastectomy
126936|NCT02291094|Pain
126937|NCT02291081|HIV, AIDS
126938|NCT02291081|antiretroviral therapy
126939|NCT02291081|aging
126940|NCT02291081|heart failure
126941|NCT02291081|coronary heart disease
126942|NCT02291081|myocardial infarction
126943|NCT02291081|HIV-associated neurocognitive disorders
126944|NCT02291042|Bladder
126945|NCT02291042|Surgery
126946|NCT02291029|Sjögren's syndrome, CFZ533, ESSDAI
126947|NCT02291016|COPD
126948|NCT02291016|chronic obstructive pulmonary disease
126949|NCT02291003|circadian
126950|NCT02291003|sleep
126951|NCT02290977|RT, TACE
126952|NCT02290964|Acute normovolemic hemodilution
126953|NCT02290964|allogeneic transfusion
126954|NCT02290938|adolescents
126955|NCT02290938|Native American
126956|NCT02290938|alcohol use
126957|NCT02290938|drug use
126958|NCT02290938|cultural
126959|NCT02290938|traditional activities
126960|NCT02290938|cultural identification
126961|NCT02290925|biscuit containing Salacia reticulate
126962|NCT02290925|randomised controlled trial
126963|NCT02290912|Alzheimer's disease prevention lifestyle intervention
126964|NCT02290899|Attention Deficit Hyperactivity Disorder (ADHD)
126965|NCT02290886|safety evaluation
126966|NCT02290886|intravenous administration
126967|NCT02290886|3 doses of autologous MSC
126968|NCT02290886|ALS
126969|NCT02290834|Chemotherapy related cognitive impairment
126970|NCT02290834|Chemo-brain
126971|NCT02290808|physical
126972|NCT02290808|activity
126973|NCT02290808|exercise
126974|NCT02290808|new-parents
126975|NCT02290808|intervention
126976|NCT02290808|theory-based
126977|NCT02290795|Vitreopapillary traction
126978|NCT02290782|toxicity
126979|NCT02290782|outcome
126980|NCT02290782|TARGIT
126981|NCT02290782|quality of life
126982|NCT02290782|intraoperative radiotherapy (IORT)
126983|NCT02290769|Guide wire cannulation ERCP
126984|NCT02290769|Time of cannulation
126985|NCT02290769|Rapid exchange guide wire
126986|NCT02290769|Guide wire
126987|NCT02290756|Early child development
126988|NCT02290756|Link Workers
126989|NCT02290756|Community Birth attendants
126990|NCT02290756|Parenting Program
126991|NCT02290730|Lower trapezius
126992|NCT02290730|Kinesio taping
126993|NCT02290717|ultraviolet therapy
126994|NCT02290717|non segmental
126995|NCT02290717|vitiligo
126996|NCT02290717|topical corticosteroid
126997|NCT02290717|laser
126998|NCT02290717|fractional
126999|NCT02290717|CO2
127000|NCT02290717|carbon dioxide
127001|NCT02290717|UVB
127002|NCT02290704|oxygen saturation
127003|NCT02290704|retinal vessels
127004|NCT02290704|thyroid associated ophthalmopathy
127005|NCT02290691|Needle Free, Influenza
127006|NCT02290678|Pilot Study
127007|NCT02290678|Adventure-based Programming
127008|NCT02290665|enema
127009|NCT02290652|Sexual function in Orthopaedic patients
127010|NCT02290639|Posttraumatic Stress
127011|NCT02290639|Posttraumatic Stress Disorder
127012|NCT02290639|Military
127013|NCT02290639|Primary Care
127014|NCT02290639|Cognitive Behavioral Therapy
127015|NCT02290639|Prolonged Exposure
127016|NCT02290639|Cognitive Processing Therapy
127017|NCT02290639|Behavioral Health Optimization Program
127018|NCT02290639|Behavioral Health Consultant
127019|NCT02290626|Elemental diet
127020|NCT02290626|semi-solid diet
127021|NCT02290626|gastric emptying
127022|NCT02290626|GER
127023|NCT02290626|PEG
127024|NCT02290613|pulmonary hypertension
127025|NCT02290613|systemic sclerosis
127026|NCT02290587|social cognitive
127027|NCT02290587|theory of mind
127028|NCT02290587|cognitive impairment
127029|NCT02290587|functional MRI
127030|NCT02290587|brain activation network
127031|NCT02290561|Prostatic Neoplasms
127032|NCT02290561|Therapeutics
127033|NCT02290561|Magnetic Resonance Imaging
127034|NCT02290561|Ultrasonography
127035|NCT02290561|High Intensity Focused Ultrasound
127036|NCT02290561|Image Fusion
127037|NCT02290548|high flow nasal cannula
127038|NCT02290548|extubation failure
127039|NCT02290535|obstructive pulmonary disease
127040|NCT02290535|children
127041|NCT02290535|teenager
127042|NCT02290535|EIT (Electrical Impedance Tomography)
127043|NCT02290496|Insomnia
127044|NCT02290496|Depression
127045|NCT02290496|Teen
127046|NCT02290496|SSRI
127047|NCT02290496|CBT
127048|NCT02290496|Youth
127049|NCT02290470|Nausea
127050|NCT02290470|Vomiting
127051|NCT02290457|resistance training
127052|NCT02290457|trunk muscle strength
127053|NCT02290457|physical fitness
127054|NCT02290457|adolescent
127055|NCT02290444|Acute Relapsing Multiple Sclerosis
127056|NCT02290444|Relapsing-Remitting Multiple Sclerosis
127057|NCT02290444|Multiple Sclerosis, Chronic Progressive
127058|NCT02290431|LBH589,
127059|NCT02290431|panobinostat,
127060|NCT02290431|bortezomib,
127061|NCT02290431|dexamethasone,
127062|NCT02290431|Phase II
127063|NCT02290418|Roux-en-Y Gastric Bypass
127064|NCT02290418|Omega-Loop Gastric Bypass
127065|NCT02290418|"Mini-Gastric Bypass"
127066|NCT02290405|insomnia
127067|NCT02290405|primary insomnia
127068|NCT02290405|chronic insomnia
127069|NCT02290392|African American
127070|NCT02290392|Environmental Factor
127071|NCT02290392|Transcriptome
127072|NCT02290392|Cardiovascular Disease
127073|NCT02290392|Hypertension
127074|NCT02290353|Engagement
127075|NCT02290353|Motivation
127076|NCT02290353|Exergaming
127077|NCT02290340|Respiratory Syncytial Virus, RSV
127078|NCT02290327|Stress ulcer bleeding
127079|NCT02290327|proton pump inhibitors
127080|NCT02290327|pneumonia
127081|NCT02290327|clostridium difficile infection
127082|NCT02290262|Heart disease
127083|NCT02290262|Phase one rehabilitation
127084|NCT02290223|Chronic pain
127085|NCT02290223|Analgesics, Opioid
127086|NCT02290223|Cognitive Therapy
127087|NCT02290223|Behavior Therapy
127088|NCT02290223|Mindfulness
127089|NCT02290223|Psychophysiology
127090|NCT02290223|Biofeedback, Psychology
127091|NCT02290184|type 2 diabetes
127092|NCT02290184|cardiovascular disease prevention
127093|NCT02290184|lifestyle intervention
127094|NCT02290184|physical activity
127095|NCT02290184|weight loss
127096|NCT02290184|nutrition
127097|NCT02290184|Filipinos
127098|NCT02290184|culturally appropriate
127099|NCT02290158|treatment outcomes
127100|NCT02290158|Malocclusion/therapy
127101|NCT02290145|docetaxel, cisplatin, 5-FU, cyclinD1
127102|NCT02290132|acute lymphoblastic leukemia
127103|NCT02290132|lymphoblastic lymphoma
127104|NCT02290132|stem-cell transplant
127105|NCT02290132|T-cell lymphoma
127106|NCT02290119|Primary PCL-retaining Total Knee Arthroplasty
127107|NCT02290119|Intraoperative Sensors
127108|NCT02290119|Ligament Balancing
127109|NCT02290119|Clinical Outcomes
127110|NCT02290106|obesity
127111|NCT02290106|insulin sensitivity
127112|NCT02290106|statin (HMG-CoA Reductase Inhibitor)
127113|NCT02290106|fatty liver
127114|NCT02290093|Cathartics
127115|NCT02290093|Colonoscopy
127116|NCT02290093|Polyethylene Glycols
127117|NCT02290093|Elderly
127118|NCT02290080|acute myocardial infarction (AMI)
127119|NCT02290080|acute coronary syndrome (ACS)
127120|NCT02290080|ST-segment elevation myocardial infarction (STEMI)
127121|NCT02290080|Non ST-segment elevation myocardial infarction (NSTEMI)
127122|NCT02290080|Ischemic Reperfusion injury (IR-injury)
127123|NCT02290080|Biomarkers
127124|NCT02290080|Oxygen
127125|NCT02290080|Apoptosis
127126|NCT02290080|Fluorescence-activated cell sorting (FACS)
127127|NCT02290080|Flow cytometry
127128|NCT02290080|Matrix metalloproteinase (MMP)
127129|NCT02290067|blood glucose monitoring system
127130|NCT02290067|system accuracy
127131|NCT02290054|analgesia, epidural
127132|NCT02290054|urinary retention
127133|NCT02290041|mesenchymal stem cells
127134|NCT02290041|Virus of human immunodeficiency Infection
127135|NCT02290028|CRT-D therapy
127136|NCT02290028|quadripolar left ventricular lead
127137|NCT02290015|Single Photon Emission Computed Tomography; Acupuncture
127138|NCT02289989|Atopic dermatitis
127139|NCT02289989|Oregano
127140|NCT02289989|ADQ score
127141|NCT02289989|EASI score
127142|NCT02289989|Reflectance confocal microscopy
127143|NCT02289976|talar avascular necrosis
127144|NCT02289976|osteochondrosis dissecans
127145|NCT02289976|femoral condyle
127146|NCT02289950|Ovarian Cancer in in first relapse
127147|NCT02289950|Platinum-Sensitive
127148|NCT02289937|Postoperative pain
127149|NCT02289937|regional anaesthesia
127150|NCT02289937|total hip replacement
127151|NCT02289937|nervus cutaneous femoral lateralis
127152|NCT02289924|wet AMD
127153|NCT02289911|ultrasound
127154|NCT02289898|1st-line metastatic pancreatic ductal adenocarcinoma
127155|NCT02289885|trauma
127156|NCT02289885|examination
127157|NCT02289885|knowledge
127158|NCT02289885|paramedic
127159|NCT02289820|RSV
127160|NCT02289820|Older adults
127161|NCT02289820|MEDI7510
127162|NCT02289820|Vaccine
127163|NCT02289807|Nasopharyngeal carcinoma
127164|NCT02289807|Concurrent chemoradiotherapy
127165|NCT02289807|intermediate risk
127166|NCT02289807|intensity-modulated radiotherapy
127167|NCT02289794|Bioconjugate vaccine
127168|NCT02289794|Urinary tract infections
127169|NCT02289755|Urine Oxalate
127170|NCT02289755|Nephrolithiasis
127171|NCT02289755|Kidney Stones
127172|NCT02289755|Hyperoxaluria
127173|NCT02289755|Enteric Hyperoxaluria
127174|NCT02289755|Idiopathic Hyperoxaluria
127175|NCT02289755|Urological Diseases
127176|NCT02289755|Kidney Diseases
127177|NCT02289742|Dailies AquaComfort Plus® Multifocal (DACP MF)
127178|NCT02289742|Dailies AquaComfort Plus® Toric (DACP Toric)
127179|NCT02289742|tear film stability
127180|NCT02289742|Non-Invasive Keratograph Break-Up Time (NIK-BUT)
127181|NCT02289729|Duodopa
127182|NCT02289729|Advanced Parkinson's Disease
127183|NCT02289729|Levodopa/Carbidopa intestinal gel
127184|NCT02289716|Osteoarthritis
127185|NCT02289716|Pain
127186|NCT02289716|Fulranumab
127187|NCT02289716|JNJ-42160443
127188|NCT02289716|Monotherapy
127189|NCT02289716|Hip
127190|NCT02289716|Knee
127191|NCT02289716|Joint replacement surgery
127192|NCT02289703|End-Stage Renal Disease
127193|NCT02289703|Healthy
127194|NCT02289703|Rivaroxaban
127195|NCT02289703|BAY 59-7939
127196|NCT02289703|JNJ-39039039
127197|NCT02289703|Xarelto
127198|NCT02289703|Hemodialysis
127199|NCT02289703|Blood Coagulation
127200|NCT02289703|Pharmacokinetics
127201|NCT02289690|Veliparib
127202|NCT02289690|PARP - Poly (ADP) ribose polymerase
127203|NCT02289690|ABT-888
127204|NCT02289690|Extensive Stage Smal Cell Lung Cancer
127205|NCT02289677|intubation
127206|NCT02289677|child
127207|NCT02289677|resuscitation
127208|NCT02289677|simulation
127209|NCT02289677|Endotracheal
127210|NCT02289664|intubation
127211|NCT02289651|intubation
127212|NCT02289638|intubation
127213|NCT02289625|Obstructive Sleep Apnea
127214|NCT02289625|cognition
127215|NCT02289625|neurovascular function
127216|NCT02289625|brain metabolism
127217|NCT02289625|exercise training
127218|NCT02289612|Risk for Type 2 Diabetes Mellitus
127219|NCT02289612|Fibre
127220|NCT02289612|Postprandial Glucose
127221|NCT02289612|Postprandial Insulin
127222|NCT02289612|Postprandial Acetaminophen
127223|NCT02289612|Satiety
127224|NCT02289599|Healthy Japanese Subjects
127225|NCT02289599|E2307
127226|NCT02289599|Pharmacokinetics
127227|NCT02289547|chemotherapy
127228|NCT02289547|stomach neoplasms
127229|NCT02289521|Transcranial Direct Current stimulation
127230|NCT02289521|Executive function
127231|NCT02289521|Bilingualism
127232|NCT02289521|Dorsolateral Prefrontal Cortex
127233|NCT02289508|Heart Failure
127234|NCT02289508|Hemodynamics
127235|NCT02289508|Echocardiography
127236|NCT02289508|Diagnostic techniques and procedures
127237|NCT02289508|Ultrasonography
127238|NCT02289508|USCOM
127239|NCT02289495|Single Dose Escalation
127240|NCT02289495|Repeat Dose Escalation
127241|NCT02289495|GSK2838232
127242|NCT02289495|Ritonavir
127243|NCT02289482|Ritonavir
127244|NCT02289482|Safety
127245|NCT02289482|Continuation Single Dose Escalation
127246|NCT02289482|GSK2838232
127247|NCT02289456|Phase II, LOCALLY ADVANCED OR METASTATIC NON SMALL
127248|NCT02289456|CELL LUNG CANCER (NSCLC) AND AN
127249|NCT02289456|EASTERN COOPERATIVE ONCOLOGY GROUP
127250|NCT02289456|PERFORMANCE STATUS OF 2
127251|NCT02289456|(ABOUND.PS2)
127252|NCT02289456|LOCALLY ADVANCED OR METASTATIC NON SMALL
127253|NCT02289456|CELL LUNG CANCER (NSCLC) SUBJECTS THAT AE NOT CANDIDATES FOR RADIATION OR CURATIVE SURGERY
127254|NCT02289443|complete dentures
127255|NCT02289443|10-year follow-up
127256|NCT02289443|patient report outcomes
127257|NCT02289417|Ulcerative Colitis
127258|NCT02289417|Inflammatory Bowel Disease
127259|NCT02289391|Dexmedetomidine
127260|NCT02289391|Inflammatory factor
127261|NCT02289391|Inflammatory mediator
127262|NCT02289391|Cytokines
127263|NCT02289391|Asthma
127264|NCT02289365|Radiodermatitis
127265|NCT02289365|Breast cancer
127266|NCT02289365|Radiotherapy
127267|NCT02289313|obesity prevention
127268|NCT02289313|CBPR
127269|NCT02289313|high risk youth
127270|NCT02289313|school health
127271|NCT02289287|Self-Management
127272|NCT02289287|Stroke
127273|NCT02289287|Intervention
127274|NCT02289287|Group Processes
127275|NCT02289261|Chronic pain
127276|NCT02289261|Morphine
127277|NCT02289261|Dexmedetomidine
127278|NCT02289235|Ginger
127279|NCT02289235|Medicine, traditional
127280|NCT02289235|Herbal medicine
127281|NCT02289222|Relapsed/Refractory
127282|NCT02289222|MK-3475 & Pomalidomide
127283|NCT02289222|Immunotherapy
127284|NCT02289209|head and neck cancer
127285|NCT02289209|reirradiation
127286|NCT02289209|MK-3475
127287|NCT02289209|Anti-PD-1 monoclonal antibody
127288|NCT02289209|Squamous cell carcinoma
127289|NCT02289209|Keytruda
127290|NCT02289209|pembrolizumab
127291|NCT02289196|Vaccine
127292|NCT02289183|Stomach Neoplasms
127293|NCT02289183|Laparoscopy
127294|NCT02289183|Billroth I Operation
127295|NCT02289170|Chronic low back pain
127296|NCT02289170|Heating and cooling combination therapeutic device
127297|NCT02289170|Heating and cooling combination therapy
127298|NCT02289170|Contrast therapy
127299|NCT02289131|oral care
127300|NCT02289105|Advance Directive
127301|NCT02289105|Active Choice
127302|NCT02289105|Decision making
127303|NCT02289053|Colorectal Cancer
127304|NCT02289040|Acute Kidney Injury
127305|NCT02289040|Microvesicles
127306|NCT02289040|microRNA
127678|NCT02286726|Acute myeloid leukemia
127307|NCT02289040|Paediatric cardiac surgery
127308|NCT02289027|Ebola, Ebolavirus
127309|NCT02289014|online intervention
127310|NCT02289014|stress management
127311|NCT02289014|cognitive behavioral therapy
127312|NCT02289014|acceptance and mindfulness based intervention
127313|NCT02289001|patient simulation
127314|NCT02289001|simulation
127315|NCT02289001|teamwork
127316|NCT02289001|interdisciplinary health team
127317|NCT02289001|healthcare team
127318|NCT02289001|nursing
127319|NCT02289001|training programs
127320|NCT02288988|GERD
127321|NCT02288988|Short Esophagus
127322|NCT02288988|Minimally Invasive Surgery
127323|NCT02288988|Collis gastroplasty
127324|NCT02288975|hemoadsorption
127325|NCT02288975|extracorporeal blood purification
127326|NCT02288975|CytoSorb
127327|NCT02288975|hemofiltration
127328|NCT02288975|SIRS
127329|NCT02288975|sepsis
127330|NCT02288975|septic shock
127331|NCT02288975|membranes
127332|NCT02288975|ICU
127333|NCT02288975|dialysis
127334|NCT02288975|adsorption
127335|NCT02288962|dopamine agonists
127336|NCT02288962|cabergoline
127337|NCT02288949|mechanical ventilation, stratificacion, lung severity
127338|NCT02288936|Hormone-refractory prostate cancer
127339|NCT02288936|Enzalutamide
127340|NCT02288936|TMPRSS2-ETS fusion gene
127341|NCT02288923|Total knee arthroplasty
127342|NCT02288923|Femoral nerve block
127343|NCT02288923|Local infiltration analgesia
127344|NCT02288910|Liver Perfusion
127345|NCT02288910|DynaCT Perfusion
127346|NCT02288910|Radioembolization
127347|NCT02288910|Chemoembolization
127348|NCT02288884|Complications
127349|NCT02288884|Cesarean Section
127350|NCT02288884|Wound
127351|NCT02288884|Infection (Following Delivery)
127352|NCT02288871|aortic valve replacement
127353|NCT02288871|aortic valve bioprosthesis
127354|NCT02288871|hemodynamics
127355|NCT02288858|Hair thinning
127356|NCT02288819|loop diuretics
127357|NCT02288819|heart failure
127358|NCT02288819|natriuresis
127359|NCT02288819|urinary analysis
127360|NCT02288793|attitudes
127361|NCT02288793|knowledge
127362|NCT02288793|examination
127363|NCT02288754|DNA in Tumors
127364|NCT02288741|high-dose chemotherapy
127365|NCT02288741|autologous blood stem-cell transplantation
127366|NCT02288741|induction chemotherapy
127367|NCT02288741|elderly patients
127368|NCT02288728|Proximal gastrectomy
127369|NCT02288728|quality of life
127370|NCT02288728|mortality
127371|NCT02288728|morbidity
127372|NCT02288715|cerebral perfusion pressure
127373|NCT02288715|septic encephalopathy
127374|NCT02288676|genomics
127375|NCT02288676|molecular markers
127376|NCT02288676|genetic mutations
127377|NCT02288676|high-grade serous cancer
127378|NCT02288676|ovarian cancer
127379|NCT02288676|endometrial cancer
127380|NCT02288676|driver mutations
127381|NCT02288676|passenger mutations
127382|NCT02288676|molecular screening
127383|NCT02288598|Stammering
127384|NCT02288598|Brain stimulation
127385|NCT02288585|plant sterols
127386|NCT02288585|blood lipids
127387|NCT02288572|metabolic syndrome X
127388|NCT02288572|obesity
127389|NCT02288572|insulin resistance
127390|NCT02288572|dyslipidemia
127391|NCT02288572|probiotic bacteria
127392|NCT02288546|nutritional status
127393|NCT02288546|pesticides
127394|NCT02288546|nitrate
127395|NCT02288533|Minimally Conscious State
127396|NCT02288533|tDCS
127397|NCT02288520|Methotrexate
127398|NCT02288520|Therapeutic strategy
127399|NCT02288507|sorafenib, yttrium-90 radioembolization
127400|NCT02288494|hypoalbuminemia
127401|NCT02288494|-acid base balance
127402|NCT02288494|acid base disorders
127403|NCT02288494|critical ill
127404|NCT02288494|Stewart approach
127405|NCT02288494|human albumin infusion
127406|NCT02288481|Tuberculosis
127407|NCT02288481|TBA-354
127408|NCT02288481|Pulmonary Tuberculosis
127409|NCT02288481|TB
127410|NCT02288468|Parkinson's Disease
127411|NCT02288455|SUI, incontinence, sphincter
127412|NCT02288429|pharmacokinetics
127413|NCT02288429|cystic fibrosis
127414|NCT02288429|critical illness
127415|NCT02288403|Aerobic Exercise
127416|NCT02288403|Oxygen Consumption
127417|NCT02288403|Blood Pressure
127418|NCT02288390|VAP
127419|NCT02288390|Oral care
127420|NCT02288390|Chlorhexidine
127421|NCT02288390|Miswak (Sewak)
127422|NCT02288377|Lanreotide
127423|NCT02288377|Duodeno-pancreatic neuroendocrine tumours
127424|NCT02288377|Maintenance treatment
127425|NCT02288351|Roux-en-Y gastric bypass
127426|NCT02288325|Fetzima
127427|NCT02288325|Relapse-prevention
127428|NCT02288325|Placebo-controlled
127429|NCT02288299|Instrumental cough assistance
127430|NCT02288299|positive pressure insufflation maneuver
127431|NCT02288299|home mechanical ventilation
127432|NCT02288299|prospective evaluation
127433|NCT02288260|Acute Coronary Syndrome
127434|NCT02288260|Russian ACS Registry
127435|NCT02288260|ticagrelor
127436|NCT02288247|Metastatic Castration Resistant Prostate Cancer
127437|NCT02288247|Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
127438|NCT02288247|Chemotherapy- Naïve
127439|NCT02288247|Metastatic
127440|NCT02288247|Castration-resistant
127441|NCT02288247|Prostate Cancer
127442|NCT02288247|Enzalutamide
127443|NCT02288247|Xtandi
127444|NCT02288247|Docetaxel
127445|NCT02288247|Prednisolone
127446|NCT02288234|Registry
127447|NCT02288195|Neoadjuvant Chemotherapy
127448|NCT02288195|Preoperative radiotherapy
127449|NCT02288195|Chemoradiotherapy
127450|NCT02288195|Capecitabine
127451|NCT02288195|Oxaliplatin
127452|NCT02288182|Sinus augmentation procedure
127453|NCT02288169|Symptom management
127454|NCT02288169|palliative care
127455|NCT02288117|PMCF
127456|NCT02288117|Post Market Clinical Follow up
127457|NCT02288117|SP-CL
127458|NCT02288117|anatomic stem
127459|NCT02288104|Interventional Radiology
127460|NCT02288104|Liver
127461|NCT02288104|Kidney
127462|NCT02288104|Confocal endomicroscopy
127463|NCT02288104|Optical Biopsy
127464|NCT02288104|Scanner
127465|NCT02288104|Fluoroscopy
127466|NCT02288104|CT
127467|NCT02288104|Computed Tomography
127468|NCT02288104|Radiofrequency Ablation
127469|NCT02288104|Fluorescein
127470|NCT02288091|ALS
127471|NCT02288091|Inosine
127472|NCT02288091|Uric acid
127473|NCT02288091|Urate
127474|NCT02288091|Glutathione
127475|NCT02288091|Biomarker
127476|NCT02288091|Oxidative stress
127477|NCT02288091|Oxidative damage
127478|NCT02288091|proof-of-concept
127479|NCT02288078|unresectable colorectal cancer
127480|NCT02288078|regorafenib
127481|NCT02288078|Steroid
127482|NCT02288078|fatigue and malaise
127483|NCT02288078|Phase 2 randomized, controlled trial (RCT)
127484|NCT02288052|Handwriting
127485|NCT02288052|Motor learning
127486|NCT02288039|Pulmonary
127487|NCT02288026|Carcinoma, Non-Small-Cell Lung
127488|NCT02288026|Lung Neoplasms
127489|NCT02288026|Carcinoma, Bronchogenic
127490|NCT02288026|Bronchial Neoplasms
127491|NCT02288013|Cesarean section
127492|NCT02288013|uterine closure technique
127493|NCT02288013|materials used
127494|NCT02288000|Alzheimer
127495|NCT02288000|Memantine
127496|NCT02288000|biomarkers
127497|NCT02288000|battery
127498|NCT02288000|cognition
127499|NCT02288000|imaging
127500|NCT02288000|neuropsychology
127501|NCT02287987|Renal function
127502|NCT02287987|Off-clamp
127503|NCT02287987|Partial nephrectomy
127504|NCT02287987|Robotic
127505|NCT02287987|Hylar clamping
127506|NCT02287948|Balance
127507|NCT02287948|Multiple Sclerosis
127508|NCT02287948|Nintendo Wii Fit
127509|NCT02287935|Karydakis procedure
127510|NCT02287935|Limberg flap
127511|NCT02287935|recurrent pilonidal sinus
127512|NCT02287896|RhD-negative pregnant woman
127513|NCT02287896|anti-RhD antibody
127514|NCT02287883|Patient activation and engagement
127515|NCT02287883|Patient reported outcomes
127516|NCT02287883|Accountable Care Organizations
127517|NCT02287883|Chronic illness
127518|NCT02287883|Vulnerable population
127519|NCT02287883|Comparison of approaches
127520|NCT02287870|Epidural anesthesia
127521|NCT02287870|Chloroprocaine
127522|NCT02287870|Lidocaine
127523|NCT02287844|Xylo-oligosaccharides
127524|NCT02287844|Immunonutrition
127525|NCT02287844|Prebiotics
127526|NCT02287844|Lipopolysaccharides
127527|NCT02287844|Cytokines
127528|NCT02287805|craniosynostosis
127529|NCT02287805|simple form
127530|NCT02287805|complex form
127531|NCT02287805|diagnostic
127532|NCT02287805|announcement
127533|NCT02287805|impacts
127534|NCT02287792|Infective endocarditis
127535|NCT02287792|18-FDG PET/CT
127536|NCT02287792|Impact
127537|NCT02287792|Patient's managment
127538|NCT02287792|Diagnostic
127539|NCT02287753|vascular occlusion test
127540|NCT02287753|near infrared spectroscopy
127541|NCT02287740|Exercise
127542|NCT02287714|Instep plantar fasciotomy
127543|NCT02287701|bladder cancer
127544|NCT02287701|MRI
127545|NCT02287701|PET
127546|NCT02287688|safety of Meningococcal quadrivalent CRM-197 conjugate vaccine
127547|NCT02287688|Children 2-23 months of age
127548|NCT02287675|Sentinel Node
127549|NCT02287662|Transcatheter Aortic Valve Replacement
127550|NCT02287649|Immune thrombocytopenia
127551|NCT02287649|Fc gamma RIIIA V/F158 polymorphism
127552|NCT02287649|Rituximab
127553|NCT02287649|autoreactive B and T cells
127554|NCT02287649|ITP
127555|NCT02287610|RA
127556|NCT02287610|Delayed-release prednisone
127557|NCT02287610|Immediate-release prednisone
127558|NCT02287610|Non-interventional
127559|NCT02287571|comfort
127560|NCT02287571|satisfaction
127561|NCT02287558|HHT
127562|NCT02287558|CASE4Z14
127563|NCT02287558|Pomalidomide
127564|NCT02287545|open angle glaucoma
127565|NCT02287545|corneal biomechanics
127566|NCT02287545|trabeculectomy
127567|NCT02287506|diagnosis, strategy
127568|NCT02287480|Ebolavirus Vaccines
127569|NCT02287467|Antiviral
127570|NCT02287467|IVIG
127571|NCT02287467|Hemagglutination inhibition (HAI)
127572|NCT02287467|Antibody
127573|NCT02287454|Multiple Sclerosis, cognitive rehabilitation, REHACOP
127574|NCT02287376|Migraine with and without aura
127575|NCT02287350|pain
127576|NCT02287350|moderate pain
127577|NCT02287350|mild pain
127578|NCT02287350|acute pain
127579|NCT02287350|mild acute pain
127580|NCT02287350|moderate acute pain
127581|NCT02287350|mild or moderate acute pain
127582|NCT02287350|NSAID
127583|NCT02287350|nonsteroidal anti-inflammatory drug
127584|NCT02287337|Neck pain
127585|NCT02287324|Cervicalgia
127586|NCT02287311|EBV positive diseases
127587|NCT02287311|cytotoxic T lymphocytes
127588|NCT02287285|Type 2 Diabetes Mellitus
127589|NCT02287285|Gastric Bypass Surgery
127590|NCT02287285|Exendin9
127591|NCT02287272|COPD- cimetidine- drug-drug interaction
127592|NCT02287233|Myelogenous Leukemia
127593|NCT02287233|Untreated AML
127594|NCT02287233|Treatment Naive AML
127595|NCT02287220|Non-Contact Oximetry
127596|NCT02287220|video plethysmography
127597|NCT02287220|oxygen desaturation
127598|NCT02287168|Peritoneal lavage
127599|NCT02287168|Dissemination
127600|NCT02287168|Gastrectomy
127601|NCT02287168|Cytology
127602|NCT02287168|Lavage
127603|NCT02287155|Health Promotion
127604|NCT02287155|Intervention Study
127605|NCT02287155|Occupational Therapy
127606|NCT02287155|Rural Population
127607|NCT02287155|Quality of life
127608|NCT02287155|Sense of coherence
127609|NCT02287129|Potentially R0 - resectable AEG and primary tumor category
127610|NCT02287129|Histologically confirmed AEG I-III
127611|NCT02287129|Functional operability
127612|NCT02287129|Intense FDG tracer uptake of the tumor
127613|NCT02287116|preterm infants
127614|NCT02287116|CPAP
127615|NCT02287116|BPD
127616|NCT02287116|invasive mechanical ventilation
127617|NCT02287116|we aimed determine that affect the rate of BPD and death of NCPAP therapy with nasal prongs or nasal mask as the initial treatment for RDS.
127618|NCT02287103|Skipping Breakfast
127619|NCT02287038|PTSD
127620|NCT02287038|ADHD
127621|NCT02287038|Comorbidity
127622|NCT02287038|Combat Trauma
127623|NCT02287038|Cognitive Deficit
127624|NCT02286986|Epilepsy
127625|NCT02286986|Dravet syndrome
127626|NCT02286986|Seizures
127627|NCT02286986|Intractable Epilepsy
127628|NCT02286986|Medically Refractory Epilepsy
127629|NCT02286973|Tranexamic acid
127630|NCT02286947|DMD
127631|NCT02286947|exon 51
127632|NCT02286947|dystrophin
127633|NCT02286947|dystrophy
127634|NCT02286947|Eteplirsen
127635|NCT02286947|Duchenne
127636|NCT02286934|Carvedilol
127637|NCT02286934|CYP2D6
127638|NCT02286934|Isoproterenol Sensitivity Test
127639|NCT02286921|Testosterone
127640|NCT02286921|Enzalutamide
127641|NCT02286921|Abiraterone
127642|NCT02286921|Androgen Ablative Therapies
127643|NCT02286921|Bipolar Androgen Therapy
127644|NCT02286908|Ejection fraction, Global Strain, Mechanical dispersion
127645|NCT02286895|rotavirus
127646|NCT02286895|rotavirus vaccine
127647|NCT02286895|Mali
127648|NCT02286895|EPI vaccines
127649|NCT02286882|Single Ascending Dose
127650|NCT02286882|healthy subjects
127651|NCT02286869|mechanical ventilation
127652|NCT02286869|autonomic nervous system
127653|NCT02286869|heart rate variability
127654|NCT02286869|cardioventilatory coupling
127655|NCT02286856|malnutrition, diet intervention, Nutritional Assessment
127656|NCT02286843|89Zr-trastuzumab
127657|NCT02286843|PET/CT
127658|NCT02286843|14-156
127659|NCT02286830|osteolysis
127660|NCT02286830|zoledronic acid
127661|NCT02286830|osteonecrosis
127662|NCT02286830|bone markers
127663|NCT02286830|low-dose CT
127664|NCT02286791|Prevention of dementia
127665|NCT02286791|Mindful awareness program
127666|NCT02286791|Mild cognitive impairment
127667|NCT02286791|Mindfulness
127668|NCT02286791|Elderly
127669|NCT02286791|Cognitive decline
127670|NCT02286765|Ulthera System
127671|NCT02286765|Ultherapy
127672|NCT02286739|Total Knee Arthroplasty
127673|NCT02286739|Rotational Alignment
127674|NCT02286739|Intraoperative Sensors
127675|NCT02286739|Patient Outcomes
127676|NCT02286739|Soft Tissue Balance
127677|NCT02286726|Leukemia
127679|NCT02286726|AML
127680|NCT02286726|CPX-351
127681|NCT02286726|Phone call
127682|NCT02286713|Lung Cancer Screening
127683|NCT02286713|heavy smokers
127684|NCT02286713|state-based smoking cessation quitlines
127685|NCT02286713|patient decision aid
127686|NCT02286713|low-dose computed tomography
127687|NCT02286713|LDCT
127688|NCT02286713|standard educational information
127689|NCT02286700|dermatitis, eczema, itch, moisturizer, amino acid
127690|NCT02286687|Advanced Cancers
127691|NCT02286687|Germline mutations
127692|NCT02286687|Metastatic cancer
127693|NCT02286687|Talazoparib Tosylate
127694|NCT02286687|BMN 673
127695|NCT02286687|Phone call
127696|NCT02286674|mYpas
127697|NCT02286674|anxiety
127698|NCT02286674|distraction
127699|NCT02286674|inhalation induction
127700|NCT02286648|clinical signs
127701|NCT02286648|child
127702|NCT02286648|pulpotomy
127703|NCT02286583|RTM
127704|NCT02286583|Female breast cancer
127705|NCT02286557|Methylphenidate
127706|NCT02286557|Multiple Sclerosis
127707|NCT02286557|Cognitive Fatigue
127708|NCT02286544|Myocardial Infarction
127709|NCT02286544|Oxygen
127710|NCT02286544|Inflammation
127711|NCT02286544|Acute coronary syndrome (ACS)
127712|NCT02286544|ST-segment elevation myocardial infarction (STEMI)
127713|NCT02286544|Reperfusion injury (IR-injury)
127714|NCT02286544|Biomarkers
127715|NCT02286544|Normoxemia
127716|NCT02286544|Salmonella typhi
127717|NCT02286544|Vaccine-induced inflammation
127718|NCT02286544|Soluble markers of apoptosis
127719|NCT02286544|Leukocyte subset distribution
127720|NCT02286544|Matrix metalloproteinase (MMP)
127721|NCT02286544|Biological Markers
127722|NCT02286531|: Low grade glioma
127723|NCT02286531|PET
127724|NCT02286531|FET
127725|NCT02286531|MRI
127726|NCT02286531|Standardized uptake value
127727|NCT02286453|Osteoarthritis of The knee
127728|NCT02286453|Benjakul
127729|NCT02286453|Alternative Medicine
127730|NCT02286440|Depression
127731|NCT02286440|Genotyping
127732|NCT02286440|Pharmacokinetic
127733|NCT02286440|Pharmacodynamic
127734|NCT02286414|Oral anticoagulants, Geriatrics, General Practitioner, Safety, Misuse
127735|NCT02286401|myocardial perfusion
127736|NCT02286401|coronary atherosclerosis
127737|NCT02286401|coronary blood flow
127738|NCT02286401|fractional flow reserve
127739|NCT02286401|coronary flow reserve
127740|NCT02286388|Deep carious lesion
127741|NCT02286388|incomplete caries removal
127742|NCT02286388|antibacterial adhesive system
127743|NCT02286388|dental composite resin
127744|NCT02286388|pulp vitality preservation
127745|NCT02286388|randomized controlled trial
127746|NCT02286375|health-social partnership
127747|NCT02286375|self-efficacy
127748|NCT02286349|Neuromodulation Attention Deficit Hyperactivity Disorder
127749|NCT02286336|minimum effective concentration
127750|NCT02286336|ropivacaine
127751|NCT02286336|ultrasound-guided supraclavicular block
127752|NCT02286323|Intubation, Endotracheal
127753|NCT02286310|Exercise
127754|NCT02286310|Kinematics
127755|NCT02286297|Intubation
127756|NCT02286284|Early severe preeclampsia
127757|NCT02286284|Angiogenic factor
127758|NCT02286284|Apheresis
127759|NCT02286271|Seizure detection
127760|NCT02286258|Inulin
127761|NCT02286258|Ca-EDTA
127762|NCT02286258|Gd-DOTA
127763|NCT02286258|Chronic kidney disease
127764|NCT02286258|glomerular filtration rate measurement
127765|NCT02286245|Triage
127766|NCT02286245|Hotline
127767|NCT02286245|Primary Health Care
127768|NCT02286245|Emergency Medical Service Communication Systems
127769|NCT02286232|Chronic low back pain
127770|NCT02286232|stretching exercises
127771|NCT02286206|Clozapine
127772|NCT02286206|Psychotropic Drugs
127773|NCT02286206|Antipsychotic Agents
127774|NCT02286206|Psychotic Disorders
127775|NCT02286206|Schizophrenia
127776|NCT02286206|Adverse Effects
127777|NCT02286206|Drug Monitoring
127778|NCT02286180|near infrared spectroscopy
127779|NCT02286180|NIRS
127780|NCT02286180|intern
127781|NCT02286167|modified-Atkins diet
127782|NCT02286167|ketogenic diet
127783|NCT02286167|central nervous system malignancy
127784|NCT02286167|glioma
127785|NCT02286154|Hydroxyurea
127786|NCT02286154|Sickle Cell
127787|NCT02286154|Pharmacokinetics
127788|NCT02286154|dynamics
127789|NCT02286154|genomics
127790|NCT02286128|Type 2 diabetes
127791|NCT02286128|RAGE
127792|NCT02286128|osteoblast
127793|NCT02286115|Chronic Pelvic Pain
127794|NCT02286115|Interstitial Cystitis
127795|NCT02286115|Vulvodynia
127796|NCT02286115|Dyspareunia
127797|NCT02286115|Pelvic Floor Dysfunction
127798|NCT02286115|Emotional Processing
127799|NCT02286089|dry-AMD
127800|NCT02286089|Geographic Atrophy
127801|NCT02286076|endometrioma
127802|NCT02286076|laparoscopy
127803|NCT02286076|ovarian reserve
127804|NCT02286037|Secondary Hyperalgesia
127805|NCT02286037|Method
127806|NCT02286037|Pin-prick
127807|NCT02286037|Monofilament
127808|NCT02285998|Influenza
127809|NCT02285985|Adipose tissue
127810|NCT02285985|Inflammation
127811|NCT02285985|.Obesity
127812|NCT02285933|stroke
127813|NCT02285933|physical therapy specialty
127814|NCT02285933|exercise therapy
127815|NCT02285933|virtual reality
127816|NCT02285933|man-machine systems
127817|NCT02285933|randomized control trial
127818|NCT02285933|inpatients
127819|NCT02285933|rehabilitation
127820|NCT02285920|hemodialysis
127821|NCT02285920|spironolactone
127822|NCT02285920|cardiac fibrosis
127823|NCT02285920|diastolic function
127824|NCT02285881|diabetes treatment
127825|NCT02285881|personalized medicine
127826|NCT02285881|shared decision making
127827|NCT02285881|goal setting
127828|NCT02285868|Orthopedic rehabilitation
127829|NCT02285868|Rehabilitation outcomes
127830|NCT02285868|Physical therapy
127831|NCT02285868|Physical therapy outcomes
127832|NCT02285855|Lung Cancer
127833|NCT02285855|Non small cell lung cancer
127834|NCT02285855|Stereotactic body radiotherapy
127835|NCT02285855|SBRT
127836|NCT02285855|XRT
127837|NCT02285855|Radiation therapy
127838|NCT02285855|Metformin
127839|NCT02285855|Metformin ER
127840|NCT02285855|Placebo
127841|NCT02285855|Sugar pill
127842|NCT02285855|Lung adenocarcinoma
127843|NCT02285855|Genotypes
127844|NCT02285855|Genetic mutations
127845|NCT02285842|osteoarthritis
127846|NCT02285842|avascular necrosis
127847|NCT02285842|ankylosis
127848|NCT02285842|protrusio acetabuli
127849|NCT02285842|painful hip dysplasia
127850|NCT02285842|rheumatoid arthritis
127851|NCT02285842|correction of functional deformity
127852|NCT02285842|revision procedures
127853|NCT02285751|high on treatment platelet reactivity
127854|NCT02285751|acetylsalicylic acid
127855|NCT02285751|clopidogrel
127856|NCT02285751|prasugrel
127857|NCT02285751|ticagrelor
127858|NCT02285751|critically ill
127859|NCT02285751|pharmacokinetic
127860|NCT02285751|pharmacodynamics
127861|NCT02285738|solid tumor, cancer, simvastatin, aspirin, blood clot, VTE, venous thromboembolism
127862|NCT02285712|Peripheral venous catheter
127863|NCT02285712|ultrasound
127864|NCT02285712|nurse
127865|NCT02285712|Intensive Care Units
127866|NCT02285699|Selective Serotonin Reuptake Inhibitors
127867|NCT02285686|troponin
127868|NCT02285686|biomarkers
127869|NCT02285686|myocardial infarction
127870|NCT02285686|critical illness
127871|NCT02285673|umbilical cord, mesenchymal stem cell
127872|NCT02285621|Scoliosis
127873|NCT02285621|Spine deformity
127874|NCT02285621|Brace
127875|NCT02285621|3D
127876|NCT02285608|Medication adherence
127877|NCT02285608|Patient education
127878|NCT02285608|Mood disorders
127879|NCT02285608|Economic assessment
127880|NCT02285608|Mixed methods
127881|NCT02285556|drug carving changes during rehabilitation
127882|NCT02285556|community
127883|NCT02285556|DNA
127884|NCT02285543|TPF induction chemotherapy, randomized, trial,OSCC
127885|NCT02285530|head and neck squamous cell carcinoma, GDF15, TPF
127886|NCT02285504|Postpartum depression
127887|NCT02285465|Healthy volunteers
127888|NCT02285465|Pharmacokinetics
127889|NCT02285465|Pharmacodynamics
127890|NCT02285465|ASP3700
127891|NCT02285452|physiologcal phenomena
127892|NCT02285452|.HRV Parameters
127893|NCT02285452|respiratory activity
127894|NCT02285452|thorax wraps
127895|NCT02285439|Pediatric Oncology
127896|NCT02285439|Ras/Raf pathway
127897|NCT02285439|Low-Grade Glioma
127898|NCT02285439|MEK inhibitor
127899|NCT02285426|i-scan
127900|NCT02285426|histology
127901|NCT02285413|Melanoma
127902|NCT02285413|Dendritic cells
127903|NCT02285413|Cisplatin
127904|NCT02285413|Vaccine
127905|NCT02285413|Immunotherapy
127906|NCT02285400|COPD
127907|NCT02285400|CPAP
127908|NCT02285400|Central Drive
127909|NCT02285348|Ataxia Telangiectasia
127910|NCT02285348|cerebrospinal fluid
127911|NCT02285348|inflammation
127912|NCT02285348|proteomic analysis
127913|NCT02285309|Cardiac Surgery
127914|NCT02285309|Diastolic Dysfunction
127915|NCT02285309|Enoximone
127916|NCT02285296|geriatric assessment
127917|NCT02285296|Caregivers
127918|NCT02285296|Needs Assessment
127919|NCT02285296|oncology nursing
127920|NCT02285296|frail elderly
127921|NCT02285296|Medical, psychologic and sociologic approach
127922|NCT02285270|Circadian rhythm
127923|NCT02285270|Adipose tissue, brown
127924|NCT02285270|Metabolism
127925|NCT02285257|Sepsis, Severe sepsis, septic shock, epidemiology, outcome
127926|NCT02285231|Anti-hyperglycemic effect
127927|NCT02285192|18F-FDG Injection
127928|NCT02285192|Positron Lymphography
127929|NCT02285192|Lymphatic Mapping
127930|NCT02285192|sentinel lymph nodes
127931|NCT02285192|PET/CT
127932|NCT02285192|14-222
127933|NCT02285179|GDC-0032
127934|NCT02285179|Pi3K inhibitor
127935|NCT02285179|tamoxifen
127936|NCT02285179|hormone receptor positive
127937|NCT02285179|dose escalation
127938|NCT02285179|RECIST
127939|NCT02285179|pharmacodynamic
127940|NCT02285166|Pharmaocological therapy
127941|NCT02285153|acetylsalicylic acid
127942|NCT02285153|intensive care unit
127943|NCT02285153|mortality
127944|NCT02285153|Post mortem examination
127945|NCT02285153|bleeding
127946|NCT02285114|HIV
127947|NCT02285114|emtricitabine
127948|NCT02285114|FTC
127949|NCT02285114|tenofovir
127950|NCT02285114|TDF
127951|NCT02285114|TAF
127952|NCT02285114|antiretroviral
127953|NCT02285114|pharmacokinetic
127954|NCT02285114|PK
127955|NCT02285114|adolescents
127956|NCT02285114|children
127957|NCT02285114|pediatric
127958|NCT02285114|Gilead
127959|NCT02285101|arginine auxotrophic tumors
127960|NCT02285101|PEG-BCT-100
127961|NCT02285101|arginase
127962|NCT02285075|temocillin
127963|NCT02285075|PD/PD
127964|NCT02285075|T>MIC
127965|NCT02285062|R-CHOP chemotherapy
127966|NCT02285062|DLBCL front line therapy
127967|NCT02285062|gene expression profiling (GEP) activated B-cell (ABC) type DLBCL biomarkers
127968|NCT02285062|Activated B-Cell (ABC) type
127969|NCT02285062|Diffuse Large B-Cell Lymphoma, not otherwise specified
127970|NCT02285062|Diffuse Large B-Cell Lymphoma, associated with chronic inflammation
127971|NCT02285062|Diffuse Large B-Cell Lymphoma, Epstein-Barr virus positive (EBS+) of the elderly
127972|NCT02285062|Diffuse Large B-Cell Lymphoma, T-cell / histiocyte-rich
127973|NCT02285049|Chronic urticaria
127974|NCT02285049|Urticaria Control Test
127975|NCT02285023|Chronic urticaria
127976|NCT02285023|CU-Q2oL
127977|NCT02285010|pregabalin
127978|NCT02285010|postoperative pain
127979|NCT02285010|abdominal hysterectomy
127980|NCT02284984|Antibodies, Monoclonal
127981|NCT02284984|mabthera
127982|NCT02284984|benlysta
127983|NCT02284984|Antinuclear Antibodies
127984|NCT02284958|walking
127985|NCT02284958|pedometer
127986|NCT02284932|COPD
127987|NCT02284932|atrophy
127988|NCT02284932|muscle
127989|NCT02284906|Drug therapy
127990|NCT02284867|uterine natural killer cells
127991|NCT02284867|CD16
127992|NCT02284867|CD56
127993|NCT02284867|Preterm labour
127994|NCT02284815|Gluten
127995|NCT02284815|T1D
127996|NCT02284815|Remission
127997|NCT02284789|Hemophilia
127998|NCT02284776|Therapeutic education
127999|NCT02284750|Bifurcation lesion
128000|NCT02284750|Percutaneous coronary intervention
128001|NCT02284737|Pulmonary arterial hypertension
128002|NCT02284711|salpingectomy, ovarian reserve, coagulation technique
128003|NCT02284685|Mental Health Services
128004|NCT02284646|Ankylosing spondylitis
128005|NCT02284646|Physical training program
128006|NCT02284633|EGFR mutation
128007|NCT02284633|Liquid biopsies
128008|NCT02284633|Lung cancer
128009|NCT02284633|erlotinib
128010|NCT02284620|anesthesia
128011|NCT02284620|nerve block
128012|NCT02284620|infltration
128013|NCT02284581|MBC
128014|NCT02284581|metastatic
128015|NCT02284581|breast
128016|NCT02284581|observational
128017|NCT02284581|disease management
128018|NCT02284529|high-risk stage-Ⅱ Colorectal Cancer,Orectalip,oxaliplatin
128019|NCT02284503|MI reduction
128020|NCT02284503|intensive statin treatment
128021|NCT02284503|NSTE-ACS
128022|NCT02284490|Brain Metastases
128023|NCT02284477|Insulin resistance
128024|NCT02284477|Pulmonary function
128025|NCT02284477|Phthalates
128026|NCT02284464|Kidney transplant
128027|NCT02284464|Immunosuppression
128028|NCT02284464|Steroid withdrawal
128029|NCT02284464|Donor specific antibodies
128030|NCT02284451|HIV/AIDS and HIV Testing Knowledge
128031|NCT02284438|ETT
128032|NCT02284438|Biofilm
128033|NCT02284438|Mechanical ventilation
128034|NCT02284438|Critical illness
128035|NCT02284438|Ventilator-associated pneumonia
128036|NCT02284412|Neostigmine
128037|NCT02284412|Sugammadex
128038|NCT02284399|aneuploidy
128039|NCT02284399|Trisomy 21
128040|NCT02284399|NIPT
128041|NCT02284386|Total knee arthroplasty
128042|NCT02284360|wound healing
128043|NCT02284360|APOSEC™
128044|NCT02284360|Safety
128045|NCT02284334|mitochondrial diseases
128046|NCT02284334|nutrition
128047|NCT02284334|glycemic index
128048|NCT02283255|Fontan
128049|NCT02283255|Exercise
128050|NCT02283255|Pulmonary Function
128051|NCT02283255|Aerobic Capacity
128052|NCT02283255|Skeletal Muscle
128053|NCT02283242|Cholinergic Antagonists
128054|NCT02283242|Inflammation
128055|NCT02283242|Oxidative Stress
128056|NCT02283229|Plagiocephaly
128057|NCT02283229|torticollis
128058|NCT02283229|occlusal defect
128059|NCT02283216|neuromodulation
128060|NCT02283216|noninvasive
128061|NCT02283216|plasticity
128062|NCT02283216|transcranial magnetic stimulation
128063|NCT02283216|hearing
128064|NCT02283216|hyperacusis
128065|NCT02283203|Paracetamol
128066|NCT02283203|Management of fever
128067|NCT02283203|Infections
128068|NCT02283190|Asparaginase
128069|NCT02283190|Glutamine
128070|NCT02283164|Occupational health
128071|NCT02283164|Hazardous material handling
128072|NCT02283151|Very Low Carbohydrate Diet
128073|NCT02283151|Overweight/obese
128074|NCT02283138|FLV, VOCAL, PA-RI, preterm fetuses, RDS
128075|NCT02282098|Atrial fibrillation
128076|NCT02282098|Arrhythmias, Cardiac
128077|NCT02282098|Stroke
128078|NCT02282098|agents, anti inflammatory
128079|NCT02282098|D-dimer
128080|NCT02282098|C-reactive protein
128081|NCT02282085|Medication Non-Adherence
128082|NCT02282085|Antipsychotic
128083|NCT02284308|NSCLC
128084|NCT02284295|chronic obstructive pulmonary disease
128085|NCT02284295|silica dust
128086|NCT02284295|aromatic hydrocarbons
128087|NCT02284295|genetic
128088|NCT02284295|occupational
128089|NCT02284282|Spinal Morphine
128090|NCT02284282|Laparoscopic GI-surgery
128091|NCT02284282|Post-operative pain
128092|NCT02284243|Bunion
128093|NCT02284243|Bunionectomy
128094|NCT02284243|Pain
128095|NCT02284243|Analgesia
128096|NCT02284243|dexmedetomidine
128097|NCT02284243|intranasal
128098|NCT02284191|Radiology
128099|NCT02284191|Acute Medicine
128100|NCT02284191|Emergency Medicine
128101|NCT02284191|Cardiology
128102|NCT02284178|mechanical ventilation
128103|NCT02284178|aspiration
128104|NCT02284178|suctioning
128105|NCT02284178|secretions
128106|NCT02284178|ventilator-associated events
128107|NCT02284152|bottle feeding
128108|NCT02284152|feeding behavior
128109|NCT02284152|infants
128110|NCT02284152|mothers
128111|NCT02284152|responsive feeding
128112|NCT02284152|maternal feeding practices
128113|NCT02284152|maternal feeding styles
128114|NCT02284139|EGF ointment
128115|NCT02284139|EGFR inhibitor
128116|NCT02284139|Skin side effect
128117|NCT02284126|Vancomycin
128118|NCT02284126|Anti-Infective Agents, Local
128119|NCT02284126|Craniotomy
128120|NCT02284126|surgical site infection
128121|NCT02284126|wound prophylaxis
128122|NCT02284126|Anti-Bacterial Agents
128123|NCT02284126|Neurosurgical Procedures
128124|NCT02284126|Administration, Topical
128125|NCT02284126|Antibiotic Prophylaxis
128126|NCT02284126|antibiotics
128127|NCT02284126|prophylaxis
128128|NCT02284126|neurosurgery
128129|NCT02284126|Bacterial Infections
128130|NCT02284126|Central Nervous System Infections
128131|NCT02284087|transcranial magnetic stimulation
128132|NCT02284087|movement disorders
128133|NCT02284074|Lipopolysaccharide (LPS)
128134|NCT02284074|Biomarkers
128135|NCT02284074|Chemokines
128136|NCT02284074|Cytokines
128137|NCT02284074|Gene Expression
128138|NCT02284074|Nasal Challenge
128139|NCT02284074|Inflammation
128140|NCT02284074|Nasal
128141|NCT02284074|Nasosorption
128142|NCT02284074|Respiratory
128143|NCT02284048|Ticagrelor
128144|NCT02284048|Coronary Flow Reserve
128145|NCT02284009|New-onset type 1 diabetes mellitus
128146|NCT02284009|Albiglutide
128147|NCT02283905|amphotericin-B
128148|NCT02283905|continuously infused
128149|NCT02283905|voriconazole
128150|NCT02283892|respiratory complaints
128151|NCT02283892|dyspnea
128152|NCT02283892|cough
128153|NCT02283892|checklist
128154|NCT02283879|Human Umbilical Cord Mesenchymal Stem Cell
128155|NCT02283879|Mesenchymal Stem Cell
128156|NCT02283879|Cerebral hemorrhage
128157|NCT02283853|Pediatrics
128158|NCT02283749|NCSLC
128159|NCT02283749|lung cancer
128160|NCT02283749|non small cell lung cancer
128161|NCT02283749|bone metastases
128162|NCT02283749|maintenance
128163|NCT02283736|Chronic periodontitis
128164|NCT02283736|Probiotics
128165|NCT02283736|Non- surgical treatment
128166|NCT02283723|older adults, goal attainment, optimal aging
128167|NCT02283710|Pentoxifylline
128168|NCT02283710|Aminotransferase
128169|NCT02283710|Steatohepatitis
128170|NCT02283697|hypertension
128171|NCT02283697|high blood pressure
128172|NCT02283697|sodium
128173|NCT02283697|prevention
128174|NCT02283697|dietary sodium
128175|NCT02283697|salt
128176|NCT02283684|LASER
128177|NCT02283684|PROSTATE
128178|NCT02283684|BIPOLAR
128179|NCT02283684|HYPERPLASIA
128180|NCT02283684|VAPORIZATION
128181|NCT02283580|COPD
128182|NCT02283580|Healthy adults
128183|NCT02283580|Resistance training
128184|NCT02283580|Elastic bands
128185|NCT02283580|Limb muscle function
128186|NCT02283580|Volunteers
128187|NCT02283554|Periodontal Surgery
128188|NCT02283554|Periodontal Regeneration
128189|NCT02283554|Growth factors
128190|NCT02283554|Clinical trials
128191|NCT02283541|Gait
128192|NCT02283541|late life depression
128193|NCT02283541|mind-body therapies
128194|NCT02283515|chronic periodontitis
128195|NCT02283515|local drug delivery
128196|NCT02283515|rosuvastatin
128197|NCT02283515|osseo-differentiation
128198|NCT02283502|Uterine fibroid
128199|NCT02283502|magnetic resonance imaging
128200|NCT02283502|ultrasound
128201|NCT02283502|non-invasive therapy
128202|NCT02283489|Recombinant Human Endostatin Adenovirus
128203|NCT02283489|Head and Neck Malignant Tumor
128204|NCT02283489|clinical trial
128205|NCT02283489|randomized
128206|NCT02283489|Endostatin
128207|NCT02283489|gene therapy
128208|NCT02283476|efficacy and safety
128209|NCT02283437|Bibliotherapy
128210|NCT02283437|Problem-solving
128211|NCT02283437|Randomized Controlled Trial
128212|NCT02283437|Schizophrenia Spectrum Disorders
128213|NCT02283437|Family Caregivers
128214|NCT02283385|Elder abuse
128215|NCT02283385|Intervention
128216|NCT02283385|Treatment
128217|NCT02283385|Detection
128218|NCT02283359|Distal Esophagus
128219|NCT02283359|Esophageal
128220|NCT02283359|Gastric
128221|NCT02283359|Carcinoma
128222|NCT02283359|Adenocarcinoma
128223|NCT02283359|Stomach
128224|NCT02283359|Gastro-esophageal junction
128225|NCT02283359|Recurrent
128226|NCT02283359|Metastatic
128227|NCT02283359|Unresectable
128228|NCT02283346|Prostate Cancer
128229|NCT02283346|HDR brachytherapy
128230|NCT02283346|hypo fractionated external beam radiotherapy
128231|NCT02283346|toxicity
128232|NCT02283346|biochemical control
128233|NCT02283333|Behavioral Activation
128234|NCT02283333|Therapeutic Exposure
128235|NCT02283333|Mental Health
128236|NCT02283333|Veterans
128237|NCT02283333|Complicated Grief
128238|NCT02283333|Military
128239|NCT02283333|Treatment
128240|NCT02283333|Cognitive Therapy
128241|NCT02283333|Bereavement
128242|NCT02283333|Complicated Bereavement
128243|NCT02283099|Ebola virus, vaccination, phase I, healthy volunteers
128244|NCT02283086|Quality Improvement
128245|NCT02283086|Physician Feedback
128246|NCT02283073|Diagnosis
128247|NCT02283060|Atripla
128248|NCT02283060|Stribild
128249|NCT02283060|HIV
128250|NCT02283060|Sleep architecture
128251|NCT02283060|Neuropsychological performance
128252|NCT02283047|cardiovascular risk, obesity, interval training, diet
128253|NCT02283021|expression of L-type calcium subunits
128254|NCT02282995|Functional dyspepsia
128255|NCT02282995|symptom response
128256|NCT02282982|Immunoprophylaxis
128257|NCT02282982|Palivizumab
128258|NCT02282969|Cancer Prevention
128259|NCT02282969|Smokers
128260|NCT02282969|Quit smoking
128261|NCT02282969|Interviews
128262|NCT02282969|Questionnaires
128263|NCT02282969|Surveys
128264|NCT02282969|Lung cancer screening
128265|NCT02282969|Patient decision aid
128266|NCT02282943|endometriosis
128267|NCT02282943|CO2 laser vapourisation
128268|NCT02282943|Harmonic scalpel
128269|NCT02282943|AFS stage I-III
128270|NCT02282930|ACTH
128271|NCT02282930|Acthar
128272|NCT02282930|IgA
128273|NCT02282930|Progressive
128274|NCT02282930|Nephropathy
128275|NCT02282930|renal function
128276|NCT02282917|NF2
128277|NCT02282917|Vestibular Schwannoma
128278|NCT02282917|Schwannoma
128279|NCT02282917|Meningioma
128280|NCT02282904|Bone Marrow Transplant
128281|NCT02282904|Subablative Conditioning
128282|NCT02282904|Graft Versus Host Disease
128283|NCT02282904|Non-Myeloablative
128284|NCT02282904|Reduced Intensity
128285|NCT02282891|propofol
128286|NCT02282891|ketofol
128287|NCT02282878|High Sodium Diet
128288|NCT02282878|Low Sodium Diet
128289|NCT02282878|MS
128290|NCT02282865|Emergence agitation, Heart rate variability (HRV)
128291|NCT02282839|Head and neck cancer
128292|NCT02282839|Glutamine
128293|NCT02282839|Oral mucositis
128294|NCT02282839|Quality of life
128295|NCT02282813|Parathyroid Diseases
128296|NCT02282813|Renal Insufficiency
128297|NCT02282813|Kidney Failure, Chronic
128298|NCT02282813|Hyperparathyroidism, Secondary
128299|NCT02282813|Vitamin D
128300|NCT02282813|Hyperparathyroidism
128301|NCT02282813|Kidney Diseases
128302|NCT02282813|Kidney Failure
128303|NCT02282813|Renal Insufficiency, Chronic
128304|NCT02282787|local anesthesia
128305|NCT02282787|peribulbar anesthesia
128306|NCT02282787|DEXMEDETOMIDINE
128307|NCT02282787|vitreoretinal surgery
128308|NCT02282774|Vitreoretinal surgery
128309|NCT02282735|neuroblastoma
128310|NCT02282735|end-of-life
128311|NCT02282735|decision-making
128312|NCT02282735|parent
128313|NCT02282735|child
128314|NCT02282735|prognosis
128315|NCT02282735|preferences
128316|NCT02282735|childhood cancer
128317|NCT02282735|oncology
128318|NCT02282722|cancer
128319|NCT02282722|palliative
128320|NCT02282722|chemotherapy
128321|NCT02282722|metastatic
128322|NCT02282722|colorectal
128323|NCT02282722|communication
128324|NCT02282722|informed consent
128325|NCT02282722|video
128326|NCT02282722|education
128327|NCT02282722|oncology
128328|NCT02282722|patient-centered
128329|NCT02282722|outcomes research
128330|NCT02282709|Immunity
128331|NCT02282657|extracorporreal
128332|NCT02282657|CO2 removal
128333|NCT02282657|ARDS
128334|NCT02282657|lung
128335|NCT02282657|Protective ventilation
128336|NCT02282631|active school travel
128337|NCT02282631|active travel
128338|NCT02282631|incentive scheme
128339|NCT02282631|children
128340|NCT02282631|school
128341|NCT02282631|behaviour change
128342|NCT02282618|Cardiac Sympathetic Blockade
128343|NCT02282592|Metabolic syndrome
128344|NCT02282592|case-control study
128345|NCT02282592|Breast cancer
128346|NCT02282566|Muscle protein synthesis
128347|NCT02282514|autoimmune diseases
128348|NCT02282514|stem cells
128349|NCT02282514|autologous hematopoietic stem cell transplantation
128350|NCT02282514|Stiff Person Syndrome (SPS)
128351|NCT02282501|leptin levels
128352|NCT02282501|ghrelin levels
128353|NCT02282462|Chest tube
128354|NCT02282449|Venous access device
128355|NCT02282449|Port catheters
128356|NCT02282449|Chemotherapy
128357|NCT02282410|severe hemophilia A
128358|NCT02282410|moderately severe hemophilia A
128359|NCT02282410|Recombinant Human Coagulation Factor VIII
128360|NCT02282410|standard prophylaxis
128361|NCT02282397|Diabetes Mellitus
128362|NCT02282371|Cetuximab
128363|NCT02282371|BYL719
128364|NCT02282371|IMRT (Intensity-Modulated Radiation Therapy)
128365|NCT02282371|14-116
128366|NCT02282358|Mocetinostat
128367|NCT02282358|14-106
128368|NCT02282345|Breast cancer
128369|NCT02282345|BRCA deleterious mutation
128370|NCT02282345|Invasive adenocarcinoma of the breast
128371|NCT02282345|BMN 673
128372|NCT02282345|Talazoparib tosylate
128373|NCT02282319|spinal or intravenous dexmedetomidine
128374|NCT02282293|Chemoprevention
128375|NCT02282293|Malaria
128376|NCT02282293|Uganda
128377|NCT02282293|Dihydroartemisinin-piperaquine
128378|NCT02282293|Trimethoprim-sulfamethoxazole
128379|NCT02282293|Human Immunodeficiency Virus
128380|NCT02282267|Epidermal growth factor receptor
128381|NCT02282267|Droplet digital PCR
128382|NCT02282254|Type 1 diabetes
128383|NCT02282254|Hypoglycemia unawareness
128384|NCT02282254|Nocturnal hypoglycemia
128385|NCT02282254|Closed-loop strategy
128386|NCT02282254|Artificial pancreas
128387|NCT02282254|Glucagon
128388|NCT02282254|Hypoglycemia
128389|NCT02282254|Insulin
128390|NCT02282241|Melatonin
128391|NCT02282241|Sleep
128392|NCT02282241|Delirium
128393|NCT02282215|Fever
128394|NCT02282215|Induction chemotherapy
128395|NCT02282215|Infection
128396|NCT02282215|Leukemia
128397|NCT02282215|Myeloid progenitor cells
128398|NCT02282215|Neutropenia
128399|NCT02282202|Sputum
128400|NCT02282202|Bronchiectasis
128401|NCT02282202|Chronic Obstructive Pulmonary Disease
128402|NCT02282202|Airway clearance therapy
128403|NCT02282202|Oscillatory Positive Expiratory Pressure
128404|NCT02282189|Sputum
128405|NCT02282189|Airway clearance therapy
128406|NCT02282189|Oscillatory Positive Expiratory Pressure
128407|NCT02282189|Chronic Obstructive Pulmonary Disease
128408|NCT02282176|Neonates
128409|NCT02282176|Preterm
128410|NCT02282176|Azithromycin
128411|NCT02282176|Ureaplasma
128412|NCT02282176|Chronic Lung disease
128413|NCT02282176|Bronchopulmonary dysplasia
128414|NCT02282150|Fatigue
128415|NCT02282150|Quality of Life
128416|NCT02282150|Hydrocortisone
128417|NCT02282150|Ecological Momentary Assessments
128418|NCT02282124|weight
128419|NCT02282124|self-management
128420|NCT02282124|exercise
128421|NCT02282046|type 2 diabetes mellitus
128422|NCT02282046|dental implant
128423|NCT02282020|BRCA, ovarian, platinum, chemotherapy,
128424|NCT02282007|Quality of life
128425|NCT02281994|PEMF
128426|NCT02281994|odontoid fracture
128427|NCT02281994|IDE
128428|NCT02281994|prospective
128429|NCT02281955|Human Papillomavirus
128430|NCT02281955|Oropharynx
128431|NCT02281955|Oropharyngeal Squamous Cell Carcinoma
128432|NCT02281955|Squamous Cell Carcinoma
128433|NCT02281955|Radiation Therapy
128434|NCT02281955|Chemotherapy
128435|NCT02281955|p16
128436|NCT02281929|Alcoholic hepatitis
128437|NCT02281929|corticotherapy
128438|NCT02281929|antibiotherapy
128439|NCT02281929|survival
128440|NCT02281929|infection
128441|NCT02281929|hepato renal syndrome
128442|NCT02281916|Crohn disease
128443|NCT02281916|Immunotherapy
128444|NCT02281916|Helminth antigen
128445|NCT02281890|neurodevelopmental disability
128446|NCT02281877|Total Knee Arthroplasty (TKA)
128447|NCT02281877|Gene Expression
128448|NCT02281851|Endogenous antioxidants
128449|NCT02281851|Antioxidant supplements
128450|NCT02281851|Vitamin Supplements
128451|NCT02281851|Exercise adaptations
128452|NCT02281851|Oxidative stress
128453|NCT02281851|Redox regulation
128454|NCT02281851|Cycling - exercise
128455|NCT02281838|Stroke
128456|NCT02281838|Hypertension
128457|NCT02281825|Attention-Deficit and Hyperactivity Disorder
128458|NCT02281825|Anxiety
128459|NCT02281825|Impulsivity
128460|NCT02281825|Computer Games
128461|NCT02281825|Depression
128462|NCT02281812|Ablation Technique
128463|NCT02281812|Breast cancer
128464|NCT02281812|Stage 1
128465|NCT02281812|Lumpectomy
128466|NCT02281799|Azathioprine (AZA)
128467|NCT02281799|6-mercaptopurine (6-MP)
128468|NCT02281799|Thiopurine-S-methyltransferase (TPMT)
128469|NCT02281799|Xanthine oxidase (XO)
128470|NCT02281799|6-thioguanine (6-TGN)
128471|NCT02281799|6-methyl-mercaptopurine (6-MMP)
128472|NCT02281799|inflammatory bowel disease (IBD)
128473|NCT02281799|acute pancreatitis (AP)
128474|NCT02281799|inosine triphosphate pyrophosphohydrolase (ITPA)
128475|NCT02281799|rheumatoid arthritis (RA)
128476|NCT02281799|systemic lupus erythematosis (SLE)
128477|NCT02281799|Crohn's disease (CD)
128478|NCT02281799|ulcerative colitis (UC)
128479|NCT02281760|Histiocytosis
128480|NCT02281760|Non Langerhans Cell Histiocytosis
128481|NCT02281760|BRAF Inhibitor
128482|NCT02281747|Biologic Therapy
128483|NCT02281747|Rheumatoid Arthritis
128484|NCT02281747|Arthroplasty
128485|NCT02281708|normogram
128486|NCT02281708|recurrence
128487|NCT02281708|adjuvant chemotherapy
128488|NCT02281708|disease free survival
128489|NCT02281708|Quality of life
128490|NCT02281682|Keratosis, Actinic
128491|NCT02281682|Treatment Outcome
128492|NCT02281682|cost-effectiveness
128493|NCT02281682|economic evaluation
128494|NCT02281682|imiquimod
128495|NCT02281682|photodynamic therapy
128496|NCT02281682|topical fluorouracil
128497|NCT02281682|ingenol mebutate
128498|NCT02281643|Coinfection
128499|NCT02281643|Buruli ulcer
128500|NCT02281643|Tuberculosis
128501|NCT02281643|Mansonella perstans
128502|NCT02281630|Chronic Constipation
128503|NCT02281630|CC
128504|NCT02281578|Sex Workers
128505|NCT02281578|Prevention
128506|NCT02281565|attitudes
128507|NCT02281565|blood donation
128508|NCT02281565|blood shortage
128509|NCT02281552|Tofacitinib, CP-690,550, Janis kinase, JAK inhibitor, modified release, Xeljanz
128510|NCT02281539|Phantom Limb Pain
128511|NCT02281539|Augmented Reality
128512|NCT02281539|Myoelectric control
128513|NCT02281539|Virtual reality
128514|NCT02281539|electromyography
128515|NCT02281539|pattern recognition
128516|NCT02281539|neurorehabilitation
128517|NCT02281513|Nutrition
128518|NCT02281487|tubal carcinoma
128519|NCT02281487|ovarian carcinoma
128520|NCT02281487|tubectomy
128521|NCT02281487|hysterectomy
128522|NCT02281487|dysplastic changes
128523|NCT02281487|Anti Mullerian Hormone
128524|NCT02281487|Tubal Intraepithelial Carcinoma
128525|NCT02281487|Salpingectomy
128526|NCT02281461|PrePex
128527|NCT02281461|Infants
128528|NCT02281461|Early infants
128529|NCT02281461|Children
128530|NCT02281461|Circumcision
128531|NCT02281461|HIV
128532|NCT02281461|AIDS
128533|NCT02281461|Non surgical
128534|NCT02281435|Male Circumcision
128535|NCT02281435|HIV Prevention
128536|NCT02281435|Screen Failure Subjects
128537|NCT02281435|PrePex with Incision
128538|NCT02281409|Mogamulizumab (KW-0761)
128539|NCT02281409|14-135
128540|NCT02281396|safety
128541|NCT02281396|rabies vaccine
128542|NCT02281396|MRC-5 cell
128543|NCT02281383|Bacillus Calmette-Guérin (BCG)
128544|NCT02281383|14-174
128545|NCT02281370|eltrombopag
128546|NCT02281370|cyclosporine
128547|NCT02281370|drug-drug interaction
128548|NCT02281370|pharmacokinetics
128549|NCT02281370|SB-497115
128550|NCT02281357|Asthma
128551|NCT02281357|Reactive Airways
128552|NCT02281357|Repiratory Tract Disease
128553|NCT02281357|Obstructive Lung Disease
128554|NCT02281357|Lung Diseases
128555|NCT02281344|induced blood stage malaria infection
128556|NCT02281318|Asthma control
128557|NCT02281318|Lung function
128558|NCT02281318|Health-related quality of life
128559|NCT02281318|Mepolizumab
128560|NCT02281318|Severe Eosinophilic asthma
128561|NCT02281292|Diabetic Macular Edema
128562|NCT02281292|Intravitreal
128563|NCT02281292|Retina
128564|NCT02281292|Ophthalmology
128565|NCT02281292|Lucentis
128566|NCT02281292|OCT
128567|NCT02281253|L-carnitine
128568|NCT02281253|fibre
128569|NCT02281253|bakery product
128570|NCT02281253|insulin resistance
128571|NCT02281240|Hematopoietic Stem Cell Transplantation
128572|NCT02281214|lung cancer, mutations
128573|NCT02281214|patients
128574|NCT02281214|mutations
128575|NCT02281175|Benzodiazepine withdrawal
128576|NCT02281175|PASSE-65+ program
128577|NCT02281175|Psychosocial (non-pharmacological) intervention
128578|NCT02281175|Cognitive-Behavioral Therapy (CBT)
128579|NCT02281175|Older adults
128580|NCT02281149|breast cancer
128581|NCT02281149|radiotherapy
128582|NCT02281149|intensity modulation
128583|NCT02281149|toxicity
128584|NCT02281136|Actinic keratosis
128585|NCT02281110|Diagnostic coronary catheterization
128586|NCT02281110|Multi-vessel coronary disease
128587|NCT02281110|Percutaneous Coronary Intervention
128588|NCT02281110|Instantaneous wave free ratio
128589|NCT02281110|Fractional flow reserve
128590|NCT02281097|Postural Orthostatic Tachycardia Syndrome
128591|NCT02281097|POTS
128592|NCT02281097|Vagal Stimulation
128593|NCT02281084|myelodysplastic syndromes
128594|NCT02281084|MDS
128595|NCT02281084|azacitidine
128596|NCT02281084|oral azacitidine (CC-486)
128597|NCT02281084|decitabine
128598|NCT02281084|intermediate-1
128599|NCT02281084|intermediate-2 and high risk myelodysplastic syndromes (MDS)
128600|NCT02281084|proliferative chronic myelomonocytic leukemia (CMML)
128601|NCT02281084|Durvalumab
128602|NCT02281084|MEDI4736
128603|NCT02281084|hronic, Durvalumab, MEDI4736
128604|NCT02281084|iHMA (injectable hypomethylating agents)
128605|NCT02281084|PD-L1
128606|NCT02281032|Palliative Care
128607|NCT02281032|Nursing Homes
128608|NCT02281032|interRAI Palliative Care instrument
128609|NCT02281032|Older adults
128610|NCT02280980|Stroke
128611|NCT02280980|Postural Balance
128612|NCT02280980|Oculomotor and Gaze Stability Exercises
128613|NCT02280980|Rehabilitation
128614|NCT02280980|Physical therapy
128615|NCT02280980|Outpatient
128616|NCT02280967|Adolescent
128617|NCT02280967|Attitude
128618|NCT02280967|Condom
128619|NCT02280967|Human Papillomavirus Vaccines
128620|NCT02280967|Primary prevention
128621|NCT02280967|School Health
128622|NCT02280954|Solid Tumor
128623|NCT02280915|female
128624|NCT02280915|subjects
128625|NCT02280902|auto-immune diseases
128626|NCT02280902|inflammatory diseases
128627|NCT02280902|risk factors
128628|NCT02280902|infections
128629|NCT02280902|cohort study
128630|NCT02280889|quality of life
128631|NCT02280889|nevus or scar
128632|NCT02280889|stigmatization
128633|NCT02280889|scar
128634|NCT02280876|MS
128635|NCT02280876|Demyelinating Autoimmune Diseases
128636|NCT02280876|CNS
128637|NCT02280876|Nervous System Diseases
128638|NCT02280850|Angina
128639|NCT02280837|GLP-1
128640|NCT02280824|Transcaval
128641|NCT02280824|TAVR
128642|NCT02280824|AMPLATZER(R) Occluder
128643|NCT02280811|HPV positive
128644|NCT02280811|Metastatic
128645|NCT02280811|Diet
128646|NCT02280811|Screening
128647|NCT02280811|Risk Factors
128648|NCT02280811|Colorectal adenoma
128649|NCT02280811|Refractory
128650|NCT02280811|Immunotherapy
128651|NCT02280811|Reproductive Cancers
128652|NCT02280798|ERA
128653|NCT02280772|glucomannan
128654|NCT02280772|obesity
128655|NCT02280772|children
128656|NCT02280772|overweight
128657|NCT02280772|adolescents
128658|NCT02280772|treatment
128659|NCT02280759|diarrhea, gelatin tannate, acute gastroenteritis
128660|NCT02280733|Qualified Clinical Data Registry
128661|NCT02280733|Quality Measures
128662|NCT02280733|Meaningful Use Stage 2
128663|NCT02280733|Electronic Health Records
128664|NCT02280733|Clinical Data Research Network
128665|NCT02280733|Real world data
128666|NCT02280720|titanium-nitride-oxide-coated stent
128667|NCT02280720|everolimus-eluting stent
128668|NCT02280720|optical coherence tomography
128669|NCT02280720|strut coverage
128670|NCT02280681|reproductive medicine
128671|NCT02280681|artificial gametes
128672|NCT02280681|patient preference
128673|NCT02280681|decision making
128674|NCT02280668|muscle
128675|NCT02280668|muscle repair
128676|NCT02280668|tissue repair
128677|NCT02280668|eccentric exercise
128678|NCT02280668|force loss
128679|NCT02280668|icing
128680|NCT02280668|cold therapy
128681|NCT02280668|DOMS
128682|NCT02280668|soreness
128683|NCT02280668|recovery
128684|NCT02280655|Blood Transfusions
128685|NCT02280642|Human papillomavirus
128686|NCT02280642|Cervical cancer
128687|NCT02280642|Genital warts
128688|NCT02280642|Vaccine
128689|NCT02280642|Immunogenicity
128690|NCT02280564|motivational interviewing
128691|NCT02280564|problem solving skills
128692|NCT02280564|family communication
128693|NCT02280564|technology support
128694|NCT02280564|cell phone system
128695|NCT02280551|adolescent
128696|NCT02280551|alcohol
128697|NCT02280551|parent
128698|NCT02280551|epidemiology
128699|NCT02280538|Knee Osteoarthritis
128700|NCT02280538|Intra-Articular Hyaluronic Acid
128701|NCT02280538|disease modifying
128702|NCT02280525|Leukemia
128703|NCT02280525|Chronic Lymphocytic Leukemia
128704|NCT02280525|CLL
128705|NCT02280525|Natural Killer Cells
128706|NCT02280525|NK
128707|NCT02280525|Umbilical Cord Blood
128708|NCT02280525|UCB
128709|NCT02280525|Lenalidomide
128710|NCT02280525|CC-5013
128711|NCT02280525|Revlimid
128712|NCT02280525|Rituximab
128713|NCT02280525|Rituxan
128714|NCT02280525|Fludarabine
128715|NCT02280525|Fludarabine phosphate
128716|NCT02280525|Fludara
128717|NCT02280525|Cyclophosphamide
128718|NCT02280525|Cytoxan
128719|NCT02280525|Neosar
128720|NCT02280512|noninvasive cardiac output measurement(NICOM)
128721|NCT02280512|Leg fractures
128722|NCT02280512|Near-Infrared Spectroscopy (NIRS)
128723|NCT02280512|Intensive care unit(ICU)
128724|NCT02280486|saxagliptin
128725|NCT02280486|glimepiride
128726|NCT02280486|metformin monotherapy
128727|NCT02280421|HSV
128728|NCT02280421|Herpes
128729|NCT02280421|volunteers
128730|NCT02280421|drug-drug interaction
128731|NCT02280421|transplant
128732|NCT02280382|splinting
128733|NCT02280369|posture detection
128734|NCT02280369|healthy subjects
128735|NCT02280356|Radiation Therapy
128736|NCT02280356|Brachytherapy
128737|NCT02280356|14-163
128738|NCT02280343|forced oscillation tecnique
128739|NCT02280343|lung function
128740|NCT02280343|asbestosis
128741|NCT02280330|Iodine Deficiency
128742|NCT02280330|Micronutrient Powder
128743|NCT02280330|Hypothyroidism
128744|NCT02280304|Stress Disorders, Post-Traumatic
128745|NCT02280304|Concussion, Mild
128746|NCT02280304|Brain Injuries
128747|NCT02280304|Community Integration
128748|NCT02280304|Meditation
128749|NCT02280304|Magnetic Resonance Imaging
128750|NCT02280278|colon cancer
128751|NCT02280278|cytokine-induced killer cell immunotherapy
128752|NCT02280265|hemophilia A
128753|NCT02280265|standard prophylaxis
128754|NCT02280265|Recombinant Human Coagulation Factor VIII for injection
128755|NCT02280265|ADVATE
128756|NCT02280265|Pediatric
128757|NCT02280252|Locally-advanced Breast Cancer
128758|NCT02280252|LABC
128759|NCT02280252|breast cancer
128760|NCT02280252|breast
128761|NCT02280252|cancer
128762|NCT02280252|metastasis
128763|NCT02280252|metastatic
128764|NCT02280252|tumor
128765|NCT02280252|radiation
128766|NCT02280252|radiation therapy
128767|NCT02280252|radiotherapy
128768|NCT02280252|paclitaxel
128769|NCT02280239|Fever
128770|NCT02280239|Acetaminophen
128771|NCT02280239|Body Temperature Regulation
128772|NCT02280239|Critical Illness
128773|NCT02280239|Hypotension
128774|NCT02280200|claudication
128775|NCT02280200|ankle foot orthoses
128776|NCT02280200|community walking exercise
128777|NCT02280187|InductOs
128778|NCT02280187|rhBMP-2
128779|NCT02280187|Retrospective
128780|NCT02280187|France
128781|NCT02280187|Fusion
128782|NCT02280187|real world use
128783|NCT02280174|Apo B-48
128784|NCT02280174|TRL
128785|NCT02280174|Linagliptin
128786|NCT02280148|Propofol
128787|NCT02280148|gastroscopy and colonoscopy
128788|NCT02280148|driving simulator
128789|NCT02280148|driving ability
128790|NCT02280148|cognitive function
128791|NCT02280148|patients
128792|NCT02280122|activated matrix metalloproteinase 8
128793|NCT02280122|untreated moderate/severe chronic periodontitis
128794|NCT02280122|saliva
128795|NCT02280122|sensitivity/specificity
128796|NCT02280109|Tenofovir
128797|NCT02280109|Healthy Volunteers
128798|NCT02280109|HIV
128799|NCT02280109|pharmacokinetics of tenofovir gel and film
128800|NCT02280096|Cognitive function
128801|NCT02280096|Multiple sclerosis
128802|NCT02280096|4-aminopyridine
128803|NCT02280096|Fatigue
128804|NCT02280083|Spasticity, Post-Stroke
128805|NCT02280083|Botulinum toxin type A for Injection
128806|NCT02280083|upper limb spasticity
128807|NCT02280070|resectable rectal cancer
128808|NCT02280070|SOX
128809|NCT02280070|mFOLFOX6
128810|NCT02280070|neoadjuvant
128811|NCT02280057|PCOS
128812|NCT02280057|metformin
128813|NCT02280057|obesity
128814|NCT02280057|randomized controlled trial
128815|NCT02280044|Campylobacter jejuni
128816|NCT02280044|rifaximin
128817|NCT02280044|antibiotic prophylaxis
128818|NCT02280044|dysentery
128819|NCT02280044|diarrhea
128820|NCT02280031|Twin Pregnancy
128821|NCT02280031|Pregnancy Complications
128822|NCT02280018|Healthy
128823|NCT02280018|JNJ-49122944
128824|NCT02280018|Placebo
128825|NCT02280005|Dialysis
128826|NCT02280005|Renal Failure
128827|NCT02280005|Wearable
128828|NCT02280005|Artificial Kidney
128829|NCT02280005|Hemodialysis
128830|NCT02279992|Malignant Glioma
128831|NCT02279992|Brain Neoplasms, Malignant
128832|NCT02279992|Brain metastasis
128833|NCT02279979|PHP
128834|NCT02279979|Cardiogenic Shock
128835|NCT02279979|Percutaneous
128836|NCT02279979|Ventricular Assist
128837|NCT02279979|Heart Pump
128838|NCT02279979|Catheter
128839|NCT02279979|Thoratec Corporation
128840|NCT02279940|rivaroxaban
128841|NCT02279940|stroke
128842|NCT02279940|transient ischemic attack
128843|NCT02279940|ischemia
128844|NCT02279927|Ureteroscopy
128845|NCT02279901|Obstructive Sleep Apnea
128846|NCT02279901|CPAP
128847|NCT02279901|Continuous positive airway pressure
128848|NCT02279901|CPAP compliance
128849|NCT02279901|Telemedicine
128850|NCT02279901|Automated response mechanisms
128851|NCT02279901|Patient engagement
128852|NCT02279901|OSA
128853|NCT02279888|Pulmonary Artery Pressure Monitoring
128854|NCT02279888|Implantable Hemodynamic Monitor
128855|NCT02279875|Tuberculosis
128856|NCT02279875|Drug-Sensitive Tuberculosis
128857|NCT02279875|Linezolid
128858|NCT02279875|HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol)
128859|NCT02279875|Pulmonary Tuberculosis
128860|NCT02279875|TB
128861|NCT02279849|multi-level intervention
128862|NCT02279849|price discounts
128863|NCT02279849|communication
128864|NCT02279849|low income population
128865|NCT02279849|dietary intervention
128866|NCT02279849|obesity prevention
128867|NCT02279849|store-based intervention
128868|NCT02279836|Patients with any indication for colonoscopy in the U.S.A.
128869|NCT02279823|androgen
128870|NCT02279823|alopecia
128871|NCT02279823|CB-03-01
128872|NCT02279823|solution
128873|NCT02279823|topical
128874|NCT02279810|organ shortage
128875|NCT02279810|attitudes to organ transplantation
128876|NCT02279797|bone marrow
128877|NCT02279797|attitude
128878|NCT02279771|colorectal anastomosis
128879|NCT02279771|anastomotic leak
128880|NCT02279771|ileostomy
128881|NCT02279771|complications
128882|NCT02279758|Neuroendocrine Tumors
128883|NCT02279758|The Mammalian Target of Rapamycin (mTOR)
128884|NCT02279758|metformin
128885|NCT02279693|Raypilot dosimetry
128886|NCT02279693|CBCT (cone beam computed tomography)
128887|NCT02279654|Lenalidomide
128888|NCT02279654|Revlimid
128889|NCT02279654|Transfusion-dependent
128890|NCT02279654|international Prognostic Scoring System (IPSS) low
128891|NCT02279654|Intermediate-1-risk
128892|NCT02279654|MDS
128893|NCT02279654|Isolated del(5q)
128894|NCT02279654|Prospective
128895|NCT02279654|Non-interventional
128896|NCT02279654|Post-authorization safety study (PASS)
128897|NCT02279654|Disease registry
128898|NCT02279628|cesarean section
128899|NCT02279628|spinal anesthesia
128900|NCT02279628|continuous wound infiltration
128901|NCT02279628|intrathecal morphine
128902|NCT02279628|oral morphine
128903|NCT02279615|Overactive Bladder
128904|NCT02279615|Benign Prostatic Hyperplasia
128905|NCT02279615|Combination Therapy
128906|NCT02279615|β3-Adrenoceptor Agonist
128907|NCT02279615|Mirabegron
128908|NCT02279615|Myrbetriq
128909|NCT02279615|α-Adrenoceptor Antagonist
128910|NCT02279615|Tamsulosin
128911|NCT02279615|Flomax
128912|NCT02279602|Pancreatic
128913|NCT02279602|Gastrointestional
128914|NCT02279589|hyporesponsiveness
128915|NCT02279589|vaccination
128916|NCT02279589|recommendations
128917|NCT02279589|improvement
128918|NCT02279589|schedule
128919|NCT02279589|fractional dose
128920|NCT02279589|conjugate polysaccharide vaccine
128921|NCT02279576|Penile squamous cell carcinoma
128922|NCT02279576|Pazopanib
128923|NCT02279576|Weekly paclitaxel
128924|NCT02279550|hip fracture, elderly
128925|NCT02279537|Wet age-related macular Degeneration (Wet-AMD)
128926|NCT02279537|Naïve patients
128927|NCT02279537|Real life
128928|NCT02279537|Aflibercept
128929|NCT02279524|NASH
128930|NCT02279511|Alzheimer
128931|NCT02279485|Healthy Subjects
128932|NCT02279485|Bioequivalence
128933|NCT02279485|Fasted
128934|NCT02279485|Fed
128935|NCT02279433|Neoplasms
128936|NCT02279433|Lung Neoplasms
128937|NCT02279433|Colorectal Neoplasms
128938|NCT02279433|Neuroendocrine Tumors
128939|NCT02279433|Pancreatic Neoplasms
128940|NCT02279407|omega-3 carboxylic acid
128941|NCT02279394|Smoldering myeloma
128942|NCT02279394|Smoldering Multiple Myeloma
128943|NCT02279381|Chlorhexidine
128944|NCT02279381|Kangaroo mother care
128945|NCT02279381|RCT
128946|NCT02279342|Coronary artery disease
128947|NCT02279342|hyperuricemia
128948|NCT02279342|coronary plaque volume
128949|NCT02279342|IVUS
128950|NCT02279316|Dalcroze eurhythmics
128951|NCT02279316|home exercise
128952|NCT02279316|vitamin D
128953|NCT02279316|mild cognitive impairment
128954|NCT02279316|MCI
128955|NCT02279316|mild dementia
128956|NCT02279290|Childhood trauma
128957|NCT02279264|ph
128958|NCT02279264|RightSpot Infant
128959|NCT02279264|Feeding Tube
128960|NCT02279264|RightBio Metrics
128961|NCT02279264|placement
128962|NCT02279264|Nasogastric Tube
128963|NCT02279264|NG
128964|NCT02279264|infant
128965|NCT02279251|Anxiety
128966|NCT02279251|adolescents
128967|NCT02279251|school-based
128968|NCT02279251|low-intensity CBT
128969|NCT02279225|Phototherapy
128970|NCT02279225|Laser
128971|NCT02279225|Fibromyalgia
128972|NCT02279225|DTM/ TMD
128973|NCT02279225|Pain
128974|NCT02279212|Critical illness
128975|NCT02279212|pain
128976|NCT02279212|quality of life
128977|NCT02279199|hemophilia
128978|NCT02279199|joint health
128979|NCT02279199|motor development
128980|NCT02279199|motor proficiency
128981|NCT02279173|Pediatric
128982|NCT02279173|Immune Thrombocytopenia (ITP)
128983|NCT02279173|Amgen
128984|NCT02279147|Systemic Inflammatory Response Syndrome
128985|NCT02279147|Jaundice, Obstructive
128986|NCT02279147|anti-inflammatory
128987|NCT02279134|StageⅡB-Ⅲ esophageal cancer
128988|NCT02279134|adjuvant radiotherapy
128989|NCT02279134|adjuvant chemoradiotherapy
128990|NCT02279121|central venous catheter
128991|NCT02279121|Taurolidine
128992|NCT02279121|lock-therapy
128993|NCT02279108|sentinel lymph node
128994|NCT02279108|indocyanine green
128995|NCT02279108|fluorescence method
128996|NCT02279108|radioisotope conventional method
128997|NCT02279108|breast cancer
128998|NCT02279095|Open-label extension study
128999|NCT02279095|Clinical trial Phase 2
129000|NCT02279095|Efficacy and safety
129001|NCT02279095|Heterotopic ossification
129002|NCT02279095|Fibrodysplasia Ossificans Progressiva
129003|NCT02279095|Flare-up
129004|NCT02279095|Palovarotene
129005|NCT02279095|Retinoic acid receptor agonist
129006|NCT02279095|Retinoic acid receptor gamma agonist
129007|NCT02279095|Clementia
129008|NCT02279095|Myositis Ossificans Progressiva
129009|NCT02279095|Munchmeyer's Disease
129010|NCT02279095|FOP
129011|NCT02279069|stroke
129012|NCT02279069|walking
129013|NCT02279069|rehabilitation
129014|NCT02279043|IUD
129015|NCT02279043|IUC
129016|NCT02279043|birth control
129017|NCT02279043|contraception
129018|NCT02279043|online
129019|NCT02279030|ablation
129020|NCT02279017|Mobile Technology
129021|NCT02279017|Diet and Fitness
129022|NCT02279004|Plasma Genotyping
129023|NCT02279004|NSCLC
129024|NCT02279004|Melanoma
129025|NCT02278978|urothelial carcinoma
129026|NCT02278978|BIBF1120
129027|NCT02278965|Breast Cancer
129028|NCT02278965|Early Stage
129029|NCT02278939|diabetes prevention
129030|NCT02278939|Filipinos
129031|NCT02278939|lifestyle intervention
129032|NCT02278926|Ultrasound
129033|NCT02278926|Lypo-hypertrophy
129034|NCT02278913|inpatient
129035|NCT02278913|hospital
129036|NCT02278913|randomized trial
129037|NCT02278913|diabetes
129038|NCT02278913|analogs
129039|NCT02278913|human insulin
129040|NCT02278900|communication
129041|NCT02278900|shared decision-making
129042|NCT02278887|melanoma
129043|NCT02278887|TIL treatment
129044|NCT02278887|tumor infiltrating lymphocytes
129045|NCT02278887|ipilimumab
129046|NCT02278887|interleukin 2
129047|NCT02278887|non-myeloablative
129048|NCT02278887|randomization
129049|NCT02278874|Trisomy 13
129050|NCT02278874|Trisomy 18
129051|NCT02278874|Trisomy 21
129052|NCT02278874|Sex Chromosome Abnormalities
129053|NCT02278874|Monosomy X
129054|NCT02278874|XXX
129055|NCT02278874|XXY
129056|NCT02278874|XYY
129057|NCT02278861|actinic keratosis
129058|NCT02278861|tretinoin
129059|NCT02278861|isotretinoin
129060|NCT02278861|cryotherapy
129061|NCT02278861|sun protection factor
129062|NCT02278861|clinical clearance
129063|NCT02278848|Computerised gait analysis
129064|NCT02278848|Ultrasound measurement of cerebral pulsatility
129065|NCT02278848|MRI flow
129066|NCT02278848|Urinary incontinence scale
129067|NCT02278848|Subtractive lumbar puncture
129068|NCT02278835|Cardiac valve
129069|NCT02278809|physical activity
129070|NCT02278809|screen time
129071|NCT02278809|vegetables
129072|NCT02278809|fruit
129073|NCT02278809|snacks
129074|NCT02278809|softdrink
129075|NCT02278809|water
129076|NCT02278809|fruit juice
129077|NCT02278809|parenting practices
129078|NCT02278809|online videos
129079|NCT02278809|intervention mapping protocol
129080|NCT02278796|Diffuse large B-cell lymphomas (DLBC)
129081|NCT02278796|Follicular lymphomas (FL)
129082|NCT02278796|Mantle cell lymphomas (MCL)
129083|NCT02278770|diverticular disease
129084|NCT02278770|MRI
129085|NCT02278770|visceral and subcutaneous fat
129086|NCT02278770|adipokines
129087|NCT02278757|Metabolic syndrome
129088|NCT02278757|Weight loss
129089|NCT02278757|Obesity
129090|NCT02278757|Hypertension
129091|NCT02278757|Dyslipidemia
129092|NCT02278744|Single-Fraction Stereotactic Radiosurgery
129093|NCT02278744|Salvage Re-Irradiation
129094|NCT02278744|14-054
129095|NCT02278731|Physical activity
129096|NCT02278731|Rehabilitation
129097|NCT02278731|Older adults
129098|NCT02278731|Pilates
129099|NCT02278731|Proprioceptive neuromuscular facilitation
129100|NCT02278705|childhood obesity
129101|NCT02278705|childhood overweight
129102|NCT02278705|primary care
129103|NCT02278705|weight management
129104|NCT02278692|Vitamin K
129105|NCT02278692|Calciphylaxis
129106|NCT02278692|Calcific uremic arteriolopathy
129107|NCT02278692|Dialysis
129108|NCT02278692|End-stage renal disease
129109|NCT02278653|Restaging
129110|NCT02278653|Watchful Waiting
129111|NCT02278653|Quality of Life
129112|NCT02278653|Manometry
129113|NCT02278601|Breakthrough pain
129114|NCT02278575|antithrombin, Atenativ, preeclampsia, blood flow.
129115|NCT02278549|Spinal kinematics
129116|NCT02278536|Trisomy 13
129117|NCT02278536|Trisomy 18
129118|NCT02278536|Trisomy 21
129119|NCT02278536|Sex Chromosome Abnormalities
129120|NCT02278536|Monosomy X
129121|NCT02278536|XXX
129122|NCT02278536|XXY
129123|NCT02278536|XYY
129124|NCT02278510|topotecan
129125|NCT02278510|convection-enhanced delivery
129126|NCT02278510|CED
129127|NCT02278510|High Grade Glioma
129128|NCT02278484|sinus infections
129129|NCT02278484|sinusitis
129130|NCT02278484|chronic sinusitis
129131|NCT02278484|rhinosinusitis
129132|NCT02278484|allergic sinusitis
129133|NCT02278484|allergic rhinitis
129134|NCT02278484|chronic rhinosinusitis
129135|NCT02278484|sinus disease in children
129136|NCT02278484|sinus balloon dilation
129137|NCT02278484|balloon dilatation
129138|NCT02278484|sinus disease
129139|NCT02278484|pediatric
129140|NCT02278471|combination pill
129141|NCT02278471|polypill
129142|NCT02278471|primary prevention
129143|NCT02278445|Systemic Sclerosis
129144|NCT02278445|Pulmonary hypertension
129145|NCT02278445|Lung Doppler Signals
129146|NCT02278432|risk assessment
129147|NCT02278432|pharmacovigilance
129148|NCT02278432|pharmacoepidemiology
129149|NCT02278432|drug toxicity
129150|NCT02278432|adverse drug reaction reporting system
129151|NCT02278432|omeprazole
129152|NCT02278419|Hepatitis C
129153|NCT02278419|Simeprevir
129154|NCT02278419|Sofosbuvir
129155|NCT02278419|Healthy
129156|NCT02278406|Parkinson's Disease
129157|NCT02278406|Deep brain stimulator
129158|NCT02278406|dbs
129159|NCT02278393|Japanese healthy volunteers
129160|NCT02278393|High LDL-C
129161|NCT02278393|dairy drinks
129162|NCT02278393|phytosterols
129163|NCT02278341|ASP1517
129164|NCT02278341|FG-4592
129165|NCT02278341|Anemia
129166|NCT02278341|End Stage Renal Disease (ESRD)
129167|NCT02278341|Erythropoetin Stimulating Agents (ESAs)
129168|NCT02278341|Chronic Kidney Disease
129169|NCT02278341|Hematopoetic Agents
129170|NCT02278341|HIF-PH inhibitor
129171|NCT02278341|Hemoglobin
129172|NCT02278341|Dialysis
129173|NCT02278341|roxadustat
129174|NCT02278328|dose titration study
129175|NCT02278328|electrophysiology
129176|NCT02278315|Multiple Myeloma
129177|NCT02278315|Radiopharmaceutical
129178|NCT02278315|Therapy
129179|NCT02278315|Phase 1
129180|NCT02278263|tranexamic acid
129181|NCT02278263|enhanced recovery
129182|NCT02278263|arthroplasty
129183|NCT02278263|perioperative care
129184|NCT02278198|thyroid cancer
129185|NCT02278172|vitamin D
129186|NCT02278172|athletes
129187|NCT02278172|fitness
129188|NCT02278159|end-stage kidney disease
129189|NCT02278159|peritoneal dialysis
129190|NCT02278159|home hemodialysis
129191|NCT02278159|technique survival
129192|NCT02278159|patient survival
129193|NCT02278133|metastatic,
129194|NCT02278133|Colorectal cancer,
129195|NCT02278133|WNT974,
129196|NCT02278133|LGX818,
129197|NCT02278133|cetuximab,
129198|NCT02278133|BRAF-mutant,
129199|NCT02278133|mCRC,
129200|NCT02278133|BRAFV600-mutant,
129201|NCT02278133|KRAS
129202|NCT02278120|HR-positive
129203|NCT02278120|HER2-negative
129204|NCT02278120|Advanced breast cancer
129205|NCT02278120|Letrozole
129206|NCT02278120|Anastrozole
129207|NCT02278120|Tamoxifen
129208|NCT02278120|Goserelin
129209|NCT02278120|CDK
129210|NCT02278120|CDK4
129211|NCT02278120|CDK6
129212|NCT02278120|CDK4/6
129213|NCT02278120|Phase III
129214|NCT02278120|ER-positive
129215|NCT02278120|PR-positive
129216|NCT02278120|Premenopausal
129217|NCT02278094|OSAS
129218|NCT02278094|Adult
129219|NCT02278094|Home-based
129220|NCT02278094|Genioglossus
129221|NCT02278094|Inspiratory muscle
129222|NCT02278094|Exercise
129223|NCT02278081|Rhinitis (nasal obstruction) and GERD
129224|NCT02278068|Type 2 diabetes
129225|NCT02278055|Radium-223
129226|NCT02278055|14-098
129227|NCT02278055|Prostate Cancer Clinical Trials Consortium
129228|NCT02278016|procalcitonin
129229|NCT02278016|interleukin-6
129230|NCT02278016|agiotensininⅡ
129231|NCT02278003|Amnesic
129232|NCT02278003|Propofol
129233|NCT02278003|12-006
129234|NCT02277977|sepsis
129235|NCT02277977|septic shock
129236|NCT02277977|contrast-enhanced ultrasound
129237|NCT02277977|microcirculation
129238|NCT02277964|RRMS
129239|NCT02277964|Natalizumab
129240|NCT02277964|Fingolimod
129241|NCT02277964|Treatment Change
129242|NCT02277964|Disease Activity
129243|NCT02277925|Pelvic Organ Prolapse
129244|NCT02277925|Vaginal mesh exposure rates
129245|NCT02277925|Vaginal suture exposure rates
129246|NCT02277912|ICH
129247|NCT02277912|Stroke
129248|NCT02277912|Navigated
129249|NCT02277912|Placebo
129250|NCT02277912|TMS
129251|NCT02277899|childhood obesity
129252|NCT02277899|overweight
129253|NCT02277899|communication
129254|NCT02277899|primary care
129255|NCT02277899|weight management
129256|NCT02277899|communication methods
129257|NCT02277899|patient-centered communication
129258|NCT02277886|sodium alginate
129259|NCT02277886|esomeprazole
129260|NCT02277886|GERD
129261|NCT02277873|moon
129262|NCT02277873|parturition
129263|NCT02277873|moon phases
129264|NCT02277860|Exercise
129265|NCT02277847|Idarubicin
129266|NCT02277847|Cytosine arabinoside
129267|NCT02277847|Efficacy
129268|NCT02277847|Safety
129269|NCT02277821|Essential Hypertension
129270|NCT02277821|Central Blood Pressure
129271|NCT02277821|Microcirculation
129272|NCT02277821|Endothelium Stimulation
129273|NCT02277808|Pneumocystis
129274|NCT02277808|Nebulizer
129275|NCT02277808|Pentamidine
129276|NCT02277795|Early infant male circumcision
129277|NCT02277795|HIV
129278|NCT02277795|Prevention
129279|NCT02277795|AccuCirc
129280|NCT02277795|Kenya
129281|NCT02277795|Providers
129282|NCT02277795|Parents
129283|NCT02277782|Labor
129284|NCT02277782|Analgesia
129285|NCT02277756|high functioning autism
129286|NCT02277756|endogenous modulation systems
129287|NCT02277730|Hypotension
129288|NCT02277717|cancer
129289|NCT02277717|metastasis
129290|NCT02277717|HER2
129291|NCT02277717|trastuzumab
129292|NCT02277717|duocarmycin
129293|NCT02277717|SYD985
129294|NCT02277717|antibody-drug conjugate
129295|NCT02277717|ADC
129296|NCT02277717|trastuzumab vc-seco-DUBA
129297|NCT02277704|PTSD
129298|NCT02277704|Military-related PTSD and other related conditions
129299|NCT02277691|Pharmacological therapy
129300|NCT02277678|Pruritus
129301|NCT02277665|Cannabis Use Disorder
129302|NCT02277665|Tobacco Use
129303|NCT02277665|Treatment
129304|NCT02277639|Transplant related mortality
129305|NCT02277639|Graft versus host disease
129306|NCT02277639|Bone marrow transplant
129307|NCT02277613|stem cells
129308|NCT02277587|Plenadren
129309|NCT02277587|Addison's disease
129310|NCT02277587|Hydrocortisone
129311|NCT02277587|Cortisone Acetate
129312|NCT02277587|Monocytes
129313|NCT02277587|Natural Killer cells
129314|NCT02277587|Immunological profile
129315|NCT02277587|Inflammation
129316|NCT02277574|Rheumatoid arthritis
129317|NCT02277574|Arthritis
129318|NCT02277574|Joint diseases
129319|NCT02277574|Musculoskeletal diseases
129320|NCT02277548|chemotherapy
129321|NCT02277548|radiation therapy
129322|NCT02277535|Malnutrition in the ICU (caloric deficit >4000 kcal or 150 g protein deficit) or >48hrs of admission without receiving nutrition
129323|NCT02277470|pharmacokinetics, Golimumab, IBD
129324|NCT02277444|Methotrexate
129325|NCT02277444|Anti-TNFα Antibody
129326|NCT02277444|Golimumab
129327|NCT02277444|Pediatric Participants
129328|NCT02277379|cardiac surgery ; hemorrhage ; transfusion requirements
129329|NCT02277366|Lung Neoplasms
129330|NCT02277366|Bronchoscopy
129331|NCT02277366|Early Detection of Cancer
129332|NCT02277353|Fluid responsiveness
129333|NCT02277353|NICOM
129334|NCT02277353|Prone Position
129335|NCT02277353|Stroke Volume Variation
129336|NCT02277327|Hospitalization
129337|NCT02277327|Readmissions
129338|NCT02277327|Medical complexity
129339|NCT02277301|Pilot study
129340|NCT02277301|Randomised Controlled Trial
129341|NCT02277301|Parenting
129342|NCT02277301|Paediatrics
129343|NCT02277301|Mental Health
129344|NCT02277275|Branched chain amino acid, high protein diet, weight loss
129345|NCT02277262|peritonitis patients
129346|NCT02277236|sarcopenia
129347|NCT02277236|aging
129348|NCT02277236|insulin resistance
129349|NCT02277236|screening
129350|NCT02277184|Intermediate Risk HNSCC
129351|NCT02277184|High Risk HNSCC
129352|NCT02277184|Previously Untreated, Locally Advanced HNSCC
129353|NCT02277184|Undifferentiated carcinoma
129354|NCT02277184|Poorly differentiated carcinoma of the oral cavity
129355|NCT02277184|Poorly differentiated carcinoma of the oropharynx
129356|NCT02277184|Poorly differentiated carcinoma of the larynx
129357|NCT02277184|Poorly differentiated carcinoma of the hypopharynx
129358|NCT02277158|Rectal cancer
129359|NCT02277158|S-1
129360|NCT02277158|Chemoradiotherapy
129361|NCT02277158|Phase I
129362|NCT02277145|radiation-induced pulmonary fibrosis
129363|NCT02277145|MSCs
129364|NCT02277132|Fetal growth restriction
129365|NCT02277132|Sildenafil
129366|NCT02277080|Pain, opioids, immune system, endocrine system, quality of life
129367|NCT02277067|PPH
129368|NCT02277041|PPH
129369|NCT02277002|Cabin Air Filtration
129370|NCT02277002|Particulate Matter
129371|NCT02277002|Commuter Exposure
129372|NCT02277002|Traffic Related Air Pollution
129373|NCT02276989|Chronic Pain
129374|NCT02276989|Compliance Marker
129375|NCT02276989|Narcotic Abuse
129376|NCT02276989|Opioid related disorders
129377|NCT02276989|Opiate substitution treatment
129378|NCT02276989|Buprenorphrine
129379|NCT02276989|Suboxone
129380|NCT02276989|Lyrica
129381|NCT02276989|Pregabalin
129382|NCT02276989|Acetazolamide
129383|NCT02276989|Quinine
129384|NCT02276989|Compliance
129385|NCT02276976|crebral white matter lesions
129386|NCT02276976|brain networks
129387|NCT02276976|MRI
129388|NCT02276976|DTI
129389|NCT02276976|fMRI
129390|NCT02276976|cognitive impairment
129391|NCT02276976|gene
129392|NCT02276963|Transverse myelitis, optic neuritis, neuromyelitis optica
129393|NCT02276950|Cardiac Surgery
129394|NCT02276950|Epidemiologic Methods
129395|NCT02276950|Blood Transfusions
129396|NCT02276937|Recombinant Sendai virus
129397|NCT02276937|fibroblast growth factor-2
129398|NCT02276937|treadmill
129399|NCT02276924|Laser Confocal Microscopy
129400|NCT02276924|Superior Urinary Tract Tumors
129401|NCT02276898|pediatric
129402|NCT02276898|lung clearance index
129403|NCT02276898|Multiple Breath Washout
129404|NCT02276898|Hypertonic Saline
129405|NCT02276885|breast
129406|NCT02276885|cancer
129407|NCT02276885|breast cancer
129408|NCT02276885|prone
129409|NCT02276885|partial breast irradiation
129410|NCT02276885|PBI
129411|NCT02276872|pediatric
129412|NCT02276872|treprostinil
129413|NCT02276872|transition
129414|NCT02276872|Remodulin
129415|NCT02276859|dual-wave bolus
129416|NCT02276859|square bolus
129417|NCT02276859|normal bolus
129418|NCT02276859|standard bolus
129419|NCT02276859|high-protein meal
129420|NCT02276859|prandial insulin requirement
129421|NCT02276846|Palpitate-Eluting Balloon
129422|NCT02276846|Bifurcation
129423|NCT02276846|OCT
129424|NCT02276846|Transluminal
129425|NCT02276820|Adenovirus
129426|NCT02276820|Virus specific T cells
129427|NCT02276820|Viral infections
129428|NCT02276807|Depression
129429|NCT02276807|Behavioral Symptoms
129430|NCT02276807|Mental Disorders
129431|NCT02276807|Depressive Disorder
129432|NCT02276807|suicidal ideation
129433|NCT02276807|primary health care
129434|NCT02276807|Veterans
129435|NCT02276794|Low back pain
129436|NCT02276794|Thrust manipulation
129437|NCT02276794|Spinal manipulation
129438|NCT02276794|Joint mobilization
129439|NCT02276794|Non-thrust manipulation
129440|NCT02276794|proprioception
129441|NCT02276794|Postural stability
129442|NCT02276794|Baropodometry
129443|NCT02276781|PAD
129444|NCT02276781|Peripheral Arterial Disease
129445|NCT02276781|Biomarkers
129446|NCT02276768|rectal distension
129447|NCT02276768|rectal compliance
129448|NCT02276768|visceral pain
129449|NCT02276768|pain intensity
129450|NCT02276768|barostat
129451|NCT02276768|distender
129452|NCT02276768|VAS (Visual Analog Scale)
129453|NCT02276768|rectal sensory threshold
129454|NCT02276768|analgesia
129455|NCT02276768|trimebutine
129456|NCT02276768|pain management
129457|NCT02276768|peripheral
129458|NCT02276768|colon cancer
129459|NCT02276768|H2S (hydrogen sulfide)
129460|NCT02276729|Upper limb
129461|NCT02276729|Rehabilitation
129462|NCT02276729|Occupational Therapy
129463|NCT02276729|Mirror Box Therapy
129464|NCT02276690|iron deficiency
129465|NCT02276690|dosage of hepcidin
129466|NCT02276690|usual biomarker (ferritin and transferrin saturation)
129467|NCT02276690|mass spectrometry
129468|NCT02276690|immuno-detection
129469|NCT02276690|anaemia in intensive care unit
129470|NCT02276664|lung cancer prevention
129471|NCT02276560|main tumor ranging from less than 3cm (T1 up to 7cm (T3)
129472|NCT02276547|Mitral
129473|NCT02276547|Regurgitation
129474|NCT02276547|Heart valve
129475|NCT02276547|Transcatheter
129476|NCT02276547|Transapical
129477|NCT02276547|Functional
129478|NCT02276547|Degenerative
129479|NCT02276547|Symptomatic, severe mitral valve regurgitation, high risk for open mitral valve surgery
129480|NCT02276495|pain management for total knee arthroplasty
129481|NCT02276469|severe mental illness
129482|NCT02276443|Breast Cancer
129483|NCT02276443|Triple-negative breast cancer
129484|NCT02276443|TNBC
129485|NCT02276443|Molecular testing
129486|NCT02276443|Standard chemotherapy
129487|NCT02276443|Ultrasound
129488|NCT02276430|Testicular cancer
129489|NCT02276430|Survivor
129490|NCT02276430|Cardiovascular disease
129491|NCT02276430|Risk factors
129492|NCT02276417|Sepsis
129493|NCT02276417|Surgical ICU
129494|NCT02276313|Peripheral
129495|NCT02276313|Infrainguinal
129496|NCT02276313|Drug Releasing Balloon
129497|NCT02276313|Drug Eluting Balloon
129498|NCT02276287|Adherence
129499|NCT02276287|HAART
129500|NCT02276287|HIV
129501|NCT02276287|Illness Perception
129502|NCT02276287|IPQ-R
129503|NCT02276235|catgut embedding
129504|NCT02276235|obese women
129505|NCT02276235|obesity-related hormones
129506|NCT02276222|Chronic Obstructive Pulmonary Disease
129507|NCT02276222|COPD
129508|NCT02276157|cholangioscopy
129509|NCT02276105|Carpal Tunnel Syndrome
129510|NCT02276105|Quality of Life
129511|NCT02276105|EQ-5D
129512|NCT02276105|SF-12
129513|NCT02276105|Michigan Hand Questionnaire
129514|NCT02276092|Community-acquired pneumonia
129515|NCT02276092|Pragmatic study
129516|NCT02276092|Multi-center
129517|NCT02276092|Time-dependent bias
129518|NCT02276092|antimicrobial stewardship
129519|NCT02276092|prospective audit and feedback
129520|NCT02276079|Mild Traumatic Brain Injury
129521|NCT02276079|Aerobic Exercise
129522|NCT02276079|Brain-Derived Neurotrophic Factor
129523|NCT02276066|kidney dysfunction
129524|NCT02276066|chronic critical illness
129525|NCT02276066|sepsis
129526|NCT02276066|Glomerular filtration rate
129527|NCT02276053|Epilepsy
129528|NCT02276053|Brain tumor
129529|NCT02276053|lacosamide (LCM)
129530|NCT02276053|Anti-Epileptic Drugs (AEDs)
129531|NCT02276040|Arthroplasty
129532|NCT02276040|Knee Replacement
129533|NCT02276040|Analgesia
129534|NCT02276040|pain
129535|NCT02276027|adenocarcinoma lung cancer,squamous cell lung carcinoma, NSCLC
129536|NCT02276014|Beta carotene
129537|NCT02276014|Retinol
129538|NCT02276001|Adult Volunteers
129539|NCT02275988|Adult Volunteers
129540|NCT02275975|Adult Volunteers
129541|NCT02275962|Adult Volunteers
129542|NCT02275949|SAH (Subarachnoid Hemorrhage)
129543|NCT02275949|Cerebral Vasospasm
129544|NCT02275949|Acupuncture
129545|NCT02275936|N91115
129546|NCT02275936|Cavosonstat
129547|NCT02275910|Solid Tumors
129548|NCT02275910|E7090
129549|NCT02275897|Lower Segmental Caesarean Section (LSCS)
129550|NCT02275897|Speed of Injection
129551|NCT02275897|Spinal Anaesthesia
129552|NCT02275897|Anesthesia
129553|NCT02275884|Parkinson Disease
129554|NCT02275884|Cacao
129555|NCT02275884|Biogenic amines
129556|NCT02275884|Xanthines
129557|NCT02275884|Neurodegenerative Diseases
129558|NCT02275871|Breast Cancer
129559|NCT02275858|balloon assisted enteroscopy
129560|NCT02275858|terminal ileum intubation
129561|NCT02275845|metformin
129562|NCT02275845|prevention
129563|NCT02275819|Heart Failure
129564|NCT02275819|Exercise
129565|NCT02275819|Echocardiography
129566|NCT02275741|Vaccine
129567|NCT02275741|Antibody response
129568|NCT02275741|relaps rate
129569|NCT02275741|expanded disability status scale
129570|NCT02275728|Menopause
129571|NCT02275728|Stress Urinary Incontinence
129572|NCT02275728|EMG Biofeedback
129573|NCT02275728|Pelvic Floor Muscle Training
129574|NCT02275728|Quality of life
129575|NCT02275728|Physical Therapie
129576|NCT02275715|autism spectrum disorder (ASD)
129577|NCT02275715|feeding problems
129578|NCT02275702|Dexamethasone
129579|NCT02275702|Quality of recovery questionnaire
129580|NCT02275702|QoR-40
129581|NCT02275702|Lung cancer
129582|NCT02275702|Video-assisted thoracoscopic
129583|NCT02275689|Rotator cuff
129584|NCT02275689|Tendinosis
129585|NCT02275689|Impingement
129586|NCT02275689|radiofrequency
129587|NCT02275676|Inflammatory bowel disease
129588|NCT02275676|Nutritional Status
129589|NCT02275676|Malnutrition
129590|NCT02275676|Resting Energy Expenditure
129591|NCT02275663|relapsed AML
129592|NCT02275663|refractory AML
129593|NCT02275663|azacytidine
129594|NCT02275650|calcidiol
129595|NCT02275650|25(oh)d
129596|NCT02275650|nbUVB
129597|NCT02275650|cyp27A1
129598|NCT02275650|cyp27B1
129599|NCT02275650|vitamin D
129600|NCT02275637|Implantable Cardioverter-Defibrillators
129601|NCT02275637|Ventricular Fibrillation
129602|NCT02275637|ventricular Tachycardia
129603|NCT02275611|oxytocin
129604|NCT02275611|alcohol withdrawal
129605|NCT02275611|alcohol dependence
129606|NCT02275611|alcoholism
129607|NCT02275585|Portal vein
129608|NCT02275585|Thrombosis
129609|NCT02275585|Cirrhosis
129610|NCT02275481|Chronic obstructive pulmonary disease
129611|NCT02275481|COPD
129612|NCT02275481|Emphysema
129613|NCT02275481|Chronic bronchitis
129614|NCT02275468|Chronic Kidney Disease
129615|NCT02275468|eGFR slope
129616|NCT02275468|Herbal medicine Fu-zheng-qu-zhuo Oral liquid
129617|NCT02275442|EPICES scale
129618|NCT02275442|Precarious situation
129619|NCT02275442|Rural parturient women
129620|NCT02275442|Access to care
129621|NCT02275442|Global Initiative for Sentinel E-health Network on Grid
129622|NCT02275442|General practice
129623|NCT02275429|Metabolic Diseases
129624|NCT02275429|Athletes
129625|NCT02275429|Running
129626|NCT02275429|Selenium
129627|NCT02275429|Zinc
129628|NCT02275429|Iron Metabolism Disorders
129629|NCT02275429|Water-Electrolyte Imbalance
129630|NCT02275429|Hyperkalemia
129631|NCT02275429|Hypernatremia
129632|NCT02275429|Selenium levels before and after the race
129633|NCT02275429|Levels of other electrolytes and markers
129634|NCT02275390|mental illness
129635|NCT02275390|psychoeducation
129636|NCT02275390|nurse-led clinic
129637|NCT02275390|randomized controlled trial
129638|NCT02275377|Breathing Exercises; Autonomic Control; Blood Pressure.
129639|NCT02275351|alopecia
129640|NCT02275351|topical
129641|NCT02275351|Samumed
129642|NCT02275325|Posture
129643|NCT02275325|Unilateral vestibular deafferentation
129644|NCT02275325|Medical management
129645|NCT02275325|Preoperative vestibular rehabilitation
129646|NCT02275325|Neural plasticity
129647|NCT02275286|sarcoma
129648|NCT02275273|Adnexal Masses
129649|NCT02275273|Magnetic Resonance Imaging
129650|NCT02275273|Anatomopathology
129651|NCT02275247|Stellate ganglion block
129652|NCT02275247|Aneurysm surgery
129653|NCT02275247|Cognitive recovery
129654|NCT02275247|Cerebral vasospasm
129655|NCT02275234|cardiac arrest
129656|NCT02275234|psychological intervention
129657|NCT02275221|Hepatitis B (HBV)
129658|NCT02275221|Hepatitis C (HCV)
129659|NCT02275195|hepatitis
129660|NCT02275195|alcohol
129661|NCT02275182|Dexmedetomidine
129662|NCT02275169|follicle stimulating hormone treatment
129663|NCT02275169|azoospermia nonobstructive
129664|NCT02275169|male infertility
129665|NCT02275169|follicle stimulating hormone
129666|NCT02275156|Subjects with normal renal function or severe renal impairment (RI) or end stage renal disease (ESRD) receiving hemodialysis
129667|NCT02275143|Computed Tomography of Thorax, Abdomen and Pelvis
129668|NCT02275143|cancer patients
129669|NCT02275143|coronary angiogram evaluation
129670|NCT02275130|glottic insufficiency
129671|NCT02275130|calcium hydroxyapatite
129672|NCT02275130|augmentation of vocal cords with injection technique
129673|NCT02275117|Migraine Disorders
129674|NCT02275117|ALD403
129675|NCT02275104|Ventricular arrhythmias
129676|NCT02275104|Persistent atrial fibrillation
129677|NCT02275104|Ablation guidance
129678|NCT02275104|Software
129679|NCT02275104|MRI (Magnetic resonance imaging)
129680|NCT02275091|Children
129681|NCT02275091|Cholesterol
129682|NCT02275078|COPD
129683|NCT02275078|Action Plan
129684|NCT02275078|Telesystem
129685|NCT02275078|New technology
129686|NCT02275065|HIV-1 Infected
129687|NCT02275065|Adults
129688|NCT02275065|Treatment Naive
129689|NCT02275052|shuttle walk test
129690|NCT02275052|umeclidinium
129691|NCT02275052|beta2-agonist
129692|NCT02275052|exercise endurance time
129693|NCT02275052|anticholinergic
129694|NCT02275052|combination product
129695|NCT02275052|vilanterol
129696|NCT02275052|exercise
129697|NCT02275052|COPD
129698|NCT02275026|General Anesthesia, Postoperative Delirium, Recovery
129699|NCT02274974|incisional
129700|NCT02274974|infiltration
129701|NCT02274974|cs
129702|NCT02274974|lidocaine
129703|NCT02274974|epinephrine
129704|NCT02274974|Adverse Reaction to Topical or Infiltrative Lidocaine
129705|NCT02274922|Campylobacter diagnosis,
129706|NCT02274922|immuno-chromatographic test, ELISA, PCR, culture, stool
129707|NCT02274922|ELISA,
129708|NCT02274922|PCR,
129709|NCT02274922|culture, stool
129710|NCT02274909|electromyography
129711|NCT02274909|aged
129712|NCT02274909|muscle strength
129713|NCT02274909|wavelet analysis
129714|NCT02274909|pilates
129715|NCT02274909|proprioceptive neuromuscular facilitation
129716|NCT02274857|FIRMap
129717|NCT02274857|Rotor
129718|NCT02274857|FIRM-guided procedure
129719|NCT02274857|REAFFIRM
129720|NCT02274805|Brown adipose tissue
129721|NCT02274805|Neck surgery
129722|NCT02274779|Prostate Cancer,Oligometastasis,Radiotherapy,Hormonotherapy
129723|NCT02274766|Levodopa-Induced Dyskinesia
129724|NCT02274766|LID
129725|NCT02274766|Parkinsonism
129726|NCT02274766|Parkinson's Disease
129727|NCT02274727|Biomarker
129728|NCT02274727|Stroke
129729|NCT02274727|Etiology
129730|NCT02274727|Outcome
129731|NCT02274675|Stroke
129732|NCT02274675|Robot-assisted therapy
129733|NCT02274675|Rehabilitation
129734|NCT02274623|Bone Neoplasms
129735|NCT02274623|Hypocalcemia
129736|NCT02274623|Hyperparathyroidism, Secondary
129737|NCT02274610|docetaxel
129738|NCT02274610|Pharmacokinetic
129739|NCT02274597|hypothermia
129740|NCT02274597|pre-hospital
129741|NCT02274597|epitympanic
129742|NCT02274597|temperature
129743|NCT02274584|Hodgkin's lymphoma
129744|NCT02274584|Anaplastic large cell lymphoma
129745|NCT02274584|CD30 positive lymphoma
129746|NCT02274584|Peripheral T/Natural Killer (NK) cell lymphoma
129747|NCT02274519|multiple myeloma
129748|NCT02274519|plasma cell disorder
129749|NCT02274519|autologous stem cell transplant
129750|NCT02274506|Blood And Marrow Transplantation
129751|NCT02274506|Leukemia
129752|NCT02274506|Lymphoma
129753|NCT02274506|CD19-specific T cells
129754|NCT02274506|Acute lymphoblastic leukemia
129755|NCT02274506|ALL
129756|NCT02274506|Biphenotypic leukemia
129757|NCT02274506|Non-Hodgkin's Lymphoma
129758|NCT02274506|NHL
129759|NCT02274506|Diffuse large B-cell lymphoma
129760|NCT02274506|Small lymphocytic lymphoma
129761|NCT02274506|Follicular lymphoma
129762|NCT02274506|Mantle cell lymphoma
129763|NCT02274506|Chronic lymphocytic leukemia
129764|NCT02274506|CLL
129765|NCT02274493|da Vinci® robotic surgical system
129766|NCT02274493|latissimus dorsi muscle flap harvest procedures
129767|NCT02274493|breast reconstruction
129768|NCT02274493|scalp reconstruction
129769|NCT02274493|upper extremity reconstruction
129770|NCT02274493|lower extremity reconstruction
129771|NCT02274480|MRI
129772|NCT02274480|Diffusion Weighted Imaging
129773|NCT02274480|14-191
129774|NCT02274467|Tsui Test
129775|NCT02274467|Labour
129776|NCT02274467|Epidural catheter
129777|NCT02274454|Uterine contraction
129778|NCT02274454|Oxytocin desensitization
129779|NCT02274428|intraventricular hemorrhage
129780|NCT02274415|Streptococcus pneumoniae
129781|NCT02274415|Sickle cell disease
129782|NCT02274415|Immunogenicity
129783|NCT02274415|Antibody response
129784|NCT02274402|Prednisone
129785|NCT02274402|Glucocorticoids
129786|NCT02274402|pharmacokinetics
129787|NCT02274389|Pulmonary Multi-drug Resistant Tuberculosis
129788|NCT02274389|Bedaquiline
129789|NCT02274389|Sirturo
129790|NCT02274389|Observational
129791|NCT02274389|Prospective
129792|NCT02274363|Psoriasis
129793|NCT02274363|Plaque
129794|NCT02274363|Chronic
129795|NCT02274350|prostate cancer
129796|NCT02274350|radiation therapy
129797|NCT02274350|sexual side effects
129798|NCT02274337|Epidermal Growth Factor Receptor
129799|NCT02274337|Tyrosine Kinase Inhibitor
129800|NCT02274337|T790M mutation
129801|NCT02274324|parkinson
129802|NCT02274324|duodopa
129803|NCT02274324|diet
129804|NCT02274324|proteins
129805|NCT02274324|amino acids
129806|NCT02274311|Acromegaly
129807|NCT02274311|SERM
129808|NCT02274311|Clomiphene
129809|NCT02274285|Tetanus
129810|NCT02274285|Diphtheria
129811|NCT02274285|Pertussis
129812|NCT02274285|Poliomyelitis
129813|NCT02274285|Bacterial meningitis
129814|NCT02274285|DTaP-IPV/Hib Combination vaccine
129815|NCT02274272|lactobacillus reuteri
129816|NCT02274272|type 2 diabetes
129817|NCT02274246|Segmentation
129818|NCT02274246|GIMIAS® program
129819|NCT02274246|Atrial fibrillation
129820|NCT02274246|Left atrial fibrosis
129821|NCT02274246|Healthy volunteers
129822|NCT02274233|Chelation
129823|NCT02274233|Iron Overload
129824|NCT02274233|Thalassemia
129825|NCT02274233|Transfusion
129826|NCT02274233|Iron Chelation
129827|NCT02274220|systemic inflammation
129828|NCT02274220|glucose metabolism
129829|NCT02274220|glucose-insulin ratio
129830|NCT02274207|Silver dressing
129831|NCT02274207|NPWT
129832|NCT02274207|DMF
129833|NCT02274207|foot
129834|NCT02274194|CPAP
129835|NCT02274194|Nasal mask
129836|NCT02274194|Oronasal mask
129837|NCT02274194|Mucociliary clearance
129838|NCT02274194|breathing route
129839|NCT02274155|Head and Neck Cancer
129840|NCT02274155|anti-OX40 antibody
129841|NCT02274155|MEDI6469
129842|NCT02274155|Immunotherapy
129843|NCT02274142|dentinal caries
129844|NCT02274142|occlusal
129845|NCT02274142|occluso-proximal
129846|NCT02274116|acute intermittent hypoxia
129847|NCT02274116|walking
129848|NCT02274116|spasticity
129849|NCT02274116|incomplete spinal cord injury
129850|NCT02274116|breathing
129851|NCT02274116|strength
129852|NCT02274090|Metformin
129853|NCT02274090|Pocket depth
129854|NCT02274090|moderate periodontitis
129855|NCT02274090|severe periodontitis
129856|NCT02274077|length of stay
129857|NCT02274077|nausea
129858|NCT02274077|emesis
129859|NCT02274077|bowel function
129860|NCT02274077|pain scores
129861|NCT02274077|narcotic pain medication
129862|NCT02274077|post operative period
129863|NCT02274064|Retention
129864|NCT02274064|Blood Donor Motivation
129865|NCT02274025|Patient diagnosed with lung cancer
129866|NCT02274012|Gastric
129867|NCT02274012|Gastroesophageal Junction
129868|NCT02274012|Gastroesophageal Cancer
129869|NCT02274012|Esophageal Cancer
129870|NCT02274012|Metastatic
129871|NCT02274012|HER2 amplified
129872|NCT02274012|Afatinib
129873|NCT02273999|pulsed electromagnetic fields
129874|NCT02273999|post operative morbidity
129875|NCT02273999|third molar
129876|NCT02273999|extraction
129877|NCT02273999|pain
129878|NCT02273986|Adult Volunteers
129879|NCT02273934|Home-based rehabilitation
129880|NCT02273934|Activities of daily living
129881|NCT02273934|Restorative care
129882|NCT02273934|Reablement
129883|NCT02273934|Everyday rehabilitation
129884|NCT02273921|Dementia, Diagnosis, Electroencephalography
129885|NCT02273908|Low-Back Pain
129886|NCT02273908|Neuropathic Pain
129887|NCT02273908|Pregabalin
129888|NCT02273895|Scopolamine, AD, EEG, MCI
129889|NCT02273882|RSV
129890|NCT02273882|RSVH
129891|NCT02273882|Infant
129892|NCT02273882|Gestational Age
129893|NCT02273882|wGA
129894|NCT02273882|PRETERM
129895|NCT02273856|Chronic Lymphocytic Leukaemia (CLL)
129896|NCT02273856|Indolent Non Hodgkin's Lymphoma (iNHL)
129897|NCT02273843|Preterm
129898|NCT02273843|late-onset sepsis
129899|NCT02273843|Vitamin D
129900|NCT02273843|Dose
129901|NCT02273843|Interleukin-6
129902|NCT02273843|Tumor necrosis factor-alpha
129903|NCT02273830|oxygen therapy
129904|NCT02273830|COPD
129905|NCT02273830|exercise
129906|NCT02273804|Topiramate
129907|NCT02273804|Obesity
129908|NCT02273804|Children
129909|NCT02273804|Adolescents
129910|NCT02273791|Frozen-thawed embryo transfer
129911|NCT02273791|FET protocols
129912|NCT02273739|solid tumor
129913|NCT02273739|intrahepatic cholangiocarcinoma
129914|NCT02273739|ICC
129915|NCT02273739|chondrosarcoma
129916|NCT02273739|angioimmunoblastic T-cell lymphoma
129917|NCT02273739|AITL
129918|NCT02273739|IDH
129919|NCT02273739|glioma
129920|NCT02273739|solid tumor, including intrahepatic cholangiocarcinoma and chondrosarcoma
129921|NCT02273726|Anemia
129922|NCT02273726|Chronic Kidney Disease
129923|NCT02273726|Dialysis
129924|NCT02273726|hemodialysis
129925|NCT02273726|peritoneal dialysis
129926|NCT02273726|hemoglobin
129927|NCT02273726|End stage renal disease
129928|NCT02273726|Stable Dialysis
129929|NCT02273726|erythropoietins
129930|NCT02273726|erythropoiesis stimulating agent
129931|NCT02273713|Esophageal cancer
129932|NCT02273713|Metastasized
129933|NCT02273713|Nab-paclitaxel
129934|NCT02273713|Toxicity
129935|NCT02273713|First line treatment
129936|NCT02273713|Phase Ib/II
129937|NCT02273700|Xarelto®
129938|NCT02273700|protein/peptide profiles
129939|NCT02273687|diaphragm movement
129940|NCT02273687|ultrasound
129941|NCT02273687|emergency room
129942|NCT02273674|Borderline Personality Disorder
129943|NCT02273674|Transcranial Magnetic Stimulation, Repetitive
129944|NCT02273648|national
129945|NCT02273648|multicenter
129946|NCT02273648|observational registry
129947|NCT02273648|Orsiro Drug Eluting Stent
129948|NCT02273648|Stenting Treatment of coronary artery disease
129949|NCT02273648|coronary revascularization
129950|NCT02273648|PCI
129951|NCT02273648|STEMI
129952|NCT02273648|NSTEMI
129953|NCT02273648|Ischemia
129954|NCT02273648|Angina
129955|NCT02273648|Acute Myocardial Infarction
129956|NCT02273648|Small Vessels
129957|NCT02273648|Chronic Total Occlusion
129958|NCT02273622|hydroxytyrosol
129959|NCT02273622|dietary supplement
129960|NCT02273622|gene expression regulation
129961|NCT02273609|Atrial fibrillation
129962|NCT02273609|Anticoagulation
129963|NCT02273609|Vitamin K antagonists
129964|NCT02273609|INR control
129965|NCT02273583|of the extremity
129966|NCT02273570|Hyperparathyroidism, Secondary
129967|NCT02273570|Anemia
129968|NCT02273570|Vascular Stiffness
129969|NCT02273570|Vascular Calcification
129970|NCT02273323|Flow mediated dilation
129971|NCT02273323|tea
129972|NCT02273323|blood pressure
129973|NCT02273297|Body composition
129974|NCT02273297|Body size
129975|NCT02273284|Pain, Pediatrics, Botulinum Toxin injections, Buzzy
129976|NCT02273271|FLT-PET
129977|NCT02273271|DWI-MRI
129978|NCT02273232|Peripheral Arterial Disease
129979|NCT02273232|Peripheral Vascular Disease
129980|NCT02273232|Claudication
129981|NCT02273232|Remote Ischemic Preconditioning
129982|NCT02273232|EQ-5D
129983|NCT02273232|Symptoms free distance
129984|NCT02273232|ABI
129985|NCT02273232|micro vessel formation
129986|NCT02273219|Uveal
129987|NCT02273219|Melanoma
129988|NCT02273219|Advanced uveal melanoma
129989|NCT02273206|Depression
129990|NCT02273206|Breast Cancer Screening
129991|NCT02273206|Cervical Cancer Screening
129992|NCT02273206|Colorectal Cancer Screening
129993|NCT02273154|major depressive disorder
129994|NCT02273154|Efficacy and safety of buspirone add-one treatment in patients with major depression disorder
129995|NCT02273154|buspirone
129996|NCT02273154|paroxetine
129997|NCT02273154|anxiety
129998|NCT02273128|Osteoporosis
129999|NCT02273128|Chronic Periodontitis
130000|NCT02273128|Calcitonin gene Polymorphism
130001|NCT02273115|induction
130002|NCT02273115|Foley catheter
130003|NCT02273115|oxytocin
130004|NCT02273102|Acute Myelogenous Leukemia
130005|NCT02273102|AML
130006|NCT02273102|Myelodysplastic Syndromes
130007|NCT02273102|MDS
130008|NCT02273102|Tranylcypromine
130009|NCT02273102|TCP
130010|NCT02273102|ATRA
130011|NCT02273102|Tretinoin
130012|NCT02273089|Obstructive sleep apnea
130013|NCT02273089|arterial stiffness
130014|NCT02273089|CPAP
130015|NCT02273089|excessive daytime sleepiness
130016|NCT02273089|pulse wave velocity
130017|NCT02273063|PTSD
130018|NCT02273063|MDD
130019|NCT02273063|TMS
130020|NCT02273063|5Hz
130021|NCT02273050|Type 2 Diabetes Mellitus, Dipeptidyl-Peptidase 4 Inhibitors, Saxagliptin, Metformin, Endocrine System Diseases
130022|NCT02273037|Labour
130023|NCT02273037|Birth asphyxia
130024|NCT02273037|Fetal Heart Rate Monitor
130025|NCT02273037|Doppler Fetal Heart Rate Monitor
130026|NCT02273037|Pinard Horn
130027|NCT02273037|Pediatrics
130028|NCT02273037|Uganda
130029|NCT02273024|Exercise
130030|NCT02273024|Quality of Life
130031|NCT02273024|Fatigue
130032|NCT02273024|Symptoms
130033|NCT02273024|Prehabilitation
130034|NCT02273024|Aerobic Capacity
130035|NCT02272998|FGFR, RET, KIT
130036|NCT02272985|cerebral blood flow
130037|NCT02272985|hemodialysis
130038|NCT02272972|"fluoroscopy[MeSH], education, medical[MeSH]"
130039|NCT02272959|Anxiety/Anxiety disorders, Clinical trials, treatment, cognition, computer/Internet technology
130040|NCT02272907|Bariatric Surgery
130041|NCT02272907|Laparoscopy
130042|NCT02272907|Weight Loss Surgery
130043|NCT02272907|Staple Line Reinforcement
130044|NCT02272894|Gastric Cancer
130045|NCT02272894|D2 Lymphadenectomy
130046|NCT02272894|Superior Mesenteric Vein Lymph Node
130047|NCT02272855|HF10
130048|NCT02272855|HSV-1
130049|NCT02272855|Ipilimumab
130050|NCT02272855|Oncolytic virus
130051|NCT02272855|Phase II
130052|NCT02272855|Stage IIIB melanoma
130053|NCT02272855|Stage IIIC melanoma
130054|NCT02272855|Stage IV melanoma
130055|NCT02272855|Unresectable malignant melanoma
130181|NCT02272257|Cost
130056|NCT02272855|Metastatic malignant melanoma
130057|NCT02272855|Combination treatment
130058|NCT02272855|Intratumoral injection
130059|NCT02272842|Nepal
130060|NCT02272842|Cobalamin
130061|NCT02272842|Neurodevelopment
130062|NCT02272842|Stunting
130063|NCT02272842|Growth
130064|NCT02272790|Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
130065|NCT02272777|Myelogenous
130066|NCT02272777|Chronic
130067|NCT02272777|BCR-ABL Positive
130068|NCT02272751|cancer survivorship
130069|NCT02272751|exercise
130070|NCT02272751|relaxation
130071|NCT02272751|mindfulness
130072|NCT02272725|ultramarathon
130073|NCT02272725|ibuprofen
130074|NCT02272725|acute kidney injury
130075|NCT02272725|exercise-associated hyponatremia
130076|NCT02272725|exertion
130077|NCT02272712|cancer survivor
130078|NCT02272712|computerized treatment
130079|NCT02272712|symptom management
130080|NCT02272699|Esophageal Squamous Cell Carcinoma
130081|NCT02272699|Nimotuzumab
130082|NCT02272699|Neoadjuvant treatment
130083|NCT02272686|Lymphoma
130084|NCT02272686|Blood And Marrow Transplantation
130085|NCT02272686|Post Autologous Stem Cell Transplantation
130086|NCT02272686|SCT
130087|NCT02272686|B-cell lymphoma
130088|NCT02272686|Ibrutinib
130089|NCT02272686|PCI-32765
130090|NCT02272686|Imbruvica
130091|NCT02272660|preemptive analgesia
130092|NCT02272660|parecoxib sodium
130093|NCT02272660|total knee arthroplasty
130094|NCT02272660|total hip arthroplasty
130095|NCT02272647|Normal Healthy Volunteers
130096|NCT02272634|COPD
130097|NCT02272595|Biologic Markers
130098|NCT02272595|Molecular testing
130099|NCT02272595|Advanced cancers
130100|NCT02272595|Molecular information
130101|NCT02272595|Molecular profiling
130102|NCT02272595|Genetic Mutation
130103|NCT02272569|glaucoma
130104|NCT02272569|glaucoma drainage device
130105|NCT02272569|glaucoma shunt
130106|NCT02272530|Endothelial NO-synthase
130107|NCT02272530|red blood cell
130108|NCT02272530|erythrocytes
130109|NCT02272530|Peripheral Blood Mononuclear Cell
130110|NCT02272530|cardiovascular disease
130111|NCT02272517|Vortioxetine
130112|NCT02272517|Cognition
130113|NCT02272504|HCC
130114|NCT02272504|AFP
130115|NCT02272504|AFP-L3
130116|NCT02272504|DCP
130117|NCT02272504|Surveillance
130118|NCT02272504|biomarkers
130119|NCT02272478|AML
130120|NCT02272478|MDS
130121|NCT02272465|pre-hospital resuscitation, helicopter, trauma
130122|NCT02272452|High resolution magic angle spinning Nuclear magnetic resonance
130123|NCT02272452|Nuclear magnetic resonance
130124|NCT02272452|Spectroscopy
130125|NCT02272452|Primary brain tumors
130126|NCT02272452|Gliomas
130127|NCT02272452|extemporaneous analysis
130128|NCT02272439|Bisphenol A
130129|NCT02272439|phthalates
130130|NCT02272439|infertility
130131|NCT02272439|human
130132|NCT02272426|Stroke
130133|NCT02272426|Exercise Training
130134|NCT02272426|Cognitive Training
130135|NCT02272426|Quality of Life
130136|NCT02272400|image guided radiation therapy
130137|NCT02272400|partial breast irradiation
130138|NCT02272400|breast cancer
130139|NCT02272400|breast
130140|NCT02272400|cancer
130141|NCT02272400|breast preservation
130142|NCT02272400|IGRT
130143|NCT02272400|PBI
130144|NCT02272374|Hemodialysis
130145|NCT02272374|Arteriovenous fistula
130146|NCT02272374|Tunneled cuffed catheter
130147|NCT02272374|Arteriovenous graft
130148|NCT02272374|Elderly
130149|NCT02272374|Very elderly
130150|NCT02272348|Therapeutic education
130151|NCT02272348|Functional insulin therapy
130152|NCT02272335|Breast Cancer
130153|NCT02272335|Health Disparities
130154|NCT02272335|Psychosocial Intervention
130155|NCT02272335|Cancer Survivors
130156|NCT02272322|Anterior prolapse
130157|NCT02272296|Injections, Jet
130158|NCT02272296|pharmacology
130159|NCT02272296|Insulin Aspart
130160|NCT02272296|Equipment and Supplies
130161|NCT02272283|PCI optimization
130162|NCT02272283|Coronary Remodeling
130163|NCT02272283|Drug-Eluting Stent
130164|NCT02272283|Optical Coherence Tomography
130165|NCT02272283|Intravascular Ultrasound
130166|NCT02272283|Strut Coverage
130167|NCT02272283|Strut Apposition
130168|NCT02272283|Vascular Healing Pattern
130169|NCT02272257|Musculoskeletal Pain
130170|NCT02272257|Physical Therapists
130171|NCT02272257|Drug Prescriptions
130172|NCT02272257|Humans
130173|NCT02272257|Physical Therapy Modalities
130174|NCT02272257|Referral and Consultation
130175|NCT02272257|Workers' Compensation
130176|NCT02272257|United States
130177|NCT02272257|Primary Care
130178|NCT02272257|Health Services Research
130179|NCT02272257|Triage
130180|NCT02272257|Acute
130182|NCT02272257|Occupational Health
130183|NCT02272244|Colorectal Cancer
130184|NCT02272244|Cancer Screening
130185|NCT02272244|Decision Support
130186|NCT02272244|Navigation
130187|NCT02272231|women's health
130188|NCT02272231|vaginosis, bacterial
130189|NCT02272231|african americans
130190|NCT02272205|Hip replacement
130191|NCT02272205|Knee replacement
130192|NCT02272205|Knee infection
130193|NCT02272205|Hip infection
130194|NCT02272205|Antibiotic prophylaxis
130195|NCT02272192|autism
130196|NCT02272192|autism spectrum disorder
130197|NCT02272192|intensive intervention
130198|NCT02272192|early intervention
130199|NCT02272192|Early Start Denver Model
130200|NCT02272179|adolescence
130201|NCT02272179|suicidality
130202|NCT02272179|depression
130203|NCT02272127|EGFR tyrosine kinase inhibitor
130204|NCT02272088|physical activity
130205|NCT02272088|energy expenditure
130206|NCT02272088|compensatory mechanisms
130207|NCT02272088|adolescent
130208|NCT02272075|screeening
130209|NCT02272062|Coronary artery disease
130210|NCT02272062|Angina
130211|NCT02272062|Shared decision-making
130212|NCT02272062|Patient preferences
130213|NCT02272062|Percutaneous coronary intervention
130214|NCT02272062|Coronary artery bypass graft
130215|NCT02272049|Respiratory
130216|NCT02272036|Colonoscopy
130217|NCT02272036|Colonoscopy preparation
130218|NCT02272036|screening
130219|NCT02272036|New media
130220|NCT02272036|SMS
130221|NCT02272036|Short message service
130222|NCT02272023|alcohol
130223|NCT02272023|women
130224|NCT02272023|motivational interviewing
130225|NCT02271984|Healthy
130226|NCT02271984|Praziquantel
130227|NCT02271984|L-PZQ
130228|NCT02271984|PZQ
130229|NCT02271984|MSC2499550A
130230|NCT02271984|Bioavailability
130231|NCT02271984|Pharmacokinetics
130232|NCT02271971|Psoriasis
130233|NCT02271971|Vitamin D
130234|NCT02271971|Metabolic syndrome
130235|NCT02271971|Insulin resistance
130236|NCT02271971|Cholesterol
130237|NCT02271971|Methotrexate
130238|NCT02271971|Dyslipidemia
130239|NCT02271971|PASI
130240|NCT02271971|Psoriasis Area Severity Index
130241|NCT02271958|Mifepristone
130242|NCT02271958|Endometriosis
130243|NCT02271945|aggressive lymphoma, DLBCL, NHL
130244|NCT02271932|appendicitis
130245|NCT02271932|non-operative management
130246|NCT02271932|children
130247|NCT02271932|pediatric
130248|NCT02271919|Cancer Prevention
130249|NCT02271919|Tobacco Use Cessation
130250|NCT02271919|Nicotine replacement therapy
130251|NCT02271919|NRT
130252|NCT02271919|Varenicline
130253|NCT02271919|Chantix
130254|NCT02271919|Nicotine lozenge
130255|NCT02271919|Placebo tablet
130256|NCT02271919|Placebo patch
130257|NCT02271919|Questionnaire
130258|NCT02271919|Survey
130259|NCT02271919|Counseling
130260|NCT02271906|Lung Cancer
130261|NCT02271906|Non small cell lung cancer
130262|NCT02271906|NSCLC
130263|NCT02271906|Adenocarcinoma
130264|NCT02271906|Squamous cell carcinoma
130265|NCT02271906|BIBW 2992
130266|NCT02271906|Afatinib
130267|NCT02271893|Chemotherapy-induced peripheral neuropathy
130268|NCT02271880|Medication nonadherence
130269|NCT02271802|Butyrate
130270|NCT02271802|Interorgan metabolism
130271|NCT02271802|Short-chain fatty acids
130272|NCT02271802|Gut production
130273|NCT02271776|Insulin Sensitivity
130274|NCT02271763|cricothyroid membrane
130275|NCT02271763|ultrasound
130276|NCT02271750|IGF, Neurotrophic factors, Dementia, spinal fluid
130277|NCT02271737|Newborn
130278|NCT02271737|infection
130279|NCT02271737|community health
130280|NCT02271724|CIDP
130281|NCT02271724|MMN
130282|NCT02271724|Spinal fluid
130283|NCT02271724|CD163
130284|NCT02271724|CD19
130285|NCT02271711|Brain Cancer
130286|NCT02271711|Brain tumor
130287|NCT02271711|Recurrent posterior fossa tumors
130288|NCT02271711|Central nervous system
130289|NCT02271711|CNS
130290|NCT02271711|Artificial antigen- presenting cells
130291|NCT02271711|aAPC
130292|NCT02271711|Natural killer cells
130293|NCT02271711|NK
130294|NCT02271711|Ommaya reservoir
130295|NCT02271698|Knee arthroplasty
130296|NCT02271698|Dexamethasone
130297|NCT02271698|Acute pain
130298|NCT02271698|Chronic pain
130299|NCT02271685|Diagnostic Information
130300|NCT02271685|Risk Perception
130301|NCT02271659|Prostate
130302|NCT02271659|external beam radiotherapy
130303|NCT02271659|brachytherapy boost
130304|NCT02271659|economical evaluation
130305|NCT02271646|paravertebral block
130306|NCT02271646|ultrasound guided
130307|NCT02271633|Nitrate
130308|NCT02271633|Bioavailability
130309|NCT02271633|Sports
130310|NCT02271620|1 prevalence
130311|NCT02271620|2 children
130312|NCT02271620|3 local allergic rhinitis
130313|NCT02271607|moxibustion
130314|NCT02271555|electroconvulsive therapy
130315|NCT02271555|sevoflurane
130316|NCT02271555|remifentanil
130317|NCT02271542|Propofol
130318|NCT02271542|Polymorphism
130319|NCT02271542|UGT1A9
130320|NCT02271542|CYP2B6
130321|NCT02271529|Peripheral Vascular Disease
130322|NCT02271529|Femoral Artery
130323|NCT02271529|Drug-Eluting Stent
130324|NCT02271490|Assisted Reproductive Technique
130325|NCT02271490|ICSI
130326|NCT02271490|Acrosome Reaction
130327|NCT02271490|Pregnancy outcome
130328|NCT02271477|Fluid replacement
130329|NCT02271477|Trans-Thoracic Echocardiography
130330|NCT02271477|Spinal Anesthesia
130331|NCT02271477|Empirical Volemic Repletion
130332|NCT02271464|Metastatic colorectal cancer
130333|NCT02271464|Ist line therapy
130334|NCT02271464|metronimic therapy
130335|NCT02271464|bevacizumab
130336|NCT02271451|concussion
130337|NCT02271438|Healthy
130338|NCT02271438|Ibrutinib
130339|NCT02271438|Moxifloxacin
130340|NCT02271438|Cardiac Repolarization
130341|NCT02271438|Electrocardiogram
130342|NCT02271438|QTc interval
130343|NCT02271399|venous thromboembolism
130344|NCT02271399|total knee arthroplasty
130345|NCT02271386|Evidence-Based Practice
130346|NCT02271386|Provider Education
130347|NCT02271373|Vision, Ocular
130348|NCT02271373|Physical activity
130349|NCT02271373|Schoolchildren
130350|NCT02271373|Intervention Studies
130351|NCT02271360|infertility ICSI OHSS Calcium Dobesilate Cabergoline
130352|NCT02271334|Asthma
130353|NCT02271334|Albuterol
130354|NCT02271321|dementia
130355|NCT02271321|white noise
130356|NCT02271321|agitation
130357|NCT02271321|saliva cortisol
130358|NCT02271308|elastic band resistance training
130359|NCT02271308|nursing home residents
130360|NCT02271308|muscle strength
130361|NCT02271308|flexibility
130362|NCT02271308|quality of life
130363|NCT02271308|ease of care
130364|NCT02271295|Cirrhosis
130365|NCT02271295|Child B
130366|NCT02271295|decompensation
130367|NCT02271295|mortality
130368|NCT02271295|portal thrombosis
130369|NCT02271295|anticoagulation
130370|NCT02271269|glaucoma
130371|NCT02271269|medication adherence
130372|NCT02271269|financial incentives
130373|NCT02271269|behavioral economics
130374|NCT02271256|Functional intimate apparel
130375|NCT02271256|Adolescent Idiopathic scoliosis
130376|NCT02271243|Central line-associated bloodstream infections
130377|NCT02271243|mucosal barrier injury
130378|NCT02271243|laboratory-confirmed bloodstream infection
130379|NCT02271217|Post stroke
130380|NCT02271217|Ischemic stroke
130381|NCT02271126|ECMO
130382|NCT02271126|Heparin
130383|NCT02271126|Thromboelastography
130384|NCT02271126|Bleeding complications
130385|NCT02271074|HIV
130386|NCT02271074|Care
130387|NCT02271074|Treatment
130388|NCT02271074|Retention
130389|NCT02271074|Implementation Science
130390|NCT02271048|telemedicine
130391|NCT02271048|ultrasonography
130392|NCT02271048|echocardiography
130393|NCT02271035|VUR
130394|NCT02271022|ACS, Acute Coronary Syndromes
130395|NCT02271022|NSTEMI
130396|NCT02271022|MI, Myocardial Infarction
130397|NCT02270996|antibiotic, antimicrobial, stewardship, child
130398|NCT02270983|Opioid-Induced Constipation
130399|NCT02270983|Linaclotide
130400|NCT02270983|Linzess
130401|NCT02270944|Group B Strep
130402|NCT02270944|GBS
130403|NCT02270944|vaccine comparability
130404|NCT02270918|Xa inhibitor
130405|NCT02270918|Prothrombin complex concentrate
130406|NCT02270918|anticoagulation
130407|NCT02270905|meniscus
130408|NCT02270905|meniscectomy
130409|NCT02270905|decellularised
130410|NCT02270905|xenograft
130411|NCT02270892|Ulthera, Ulthera System, Ultherapy
130412|NCT02270866|aphasia
130413|NCT02270866|stroke
130414|NCT02270853|ApneaLink
130415|NCT02270853|bronchial carcinoma
130416|NCT02270853|sleep apnea screening
130417|NCT02270840|cardiac resynchronization therapy
130418|NCT02270801|recombinant human thrombopoietin
130419|NCT02270801|immune thrombocytopenia
130420|NCT02270801|pregnancy
130421|NCT02270775|Questionnaire
130422|NCT02270775|Translation
130423|NCT02270762|Early Physical Exercise
130424|NCT02270762|Early Passive Exercise
130425|NCT02270762|Alveolar Recruitment
130426|NCT02270762|Electrical Impedance Tomography
130427|NCT02270762|Oxygenation
130428|NCT02270762|Ventilation
130429|NCT02270684|Total Knee Arthroplasty
130430|NCT02270684|Home monitoring
130431|NCT02270671|Social Anxiety
130432|NCT02270671|Social Phobia
130433|NCT02270671|Depression
130434|NCT02270671|Attention Bias Modification Training
130435|NCT02270658|continuous positive airway pressure
130436|NCT02270658|hypertension
130437|NCT02270658|sleep apnea
130438|NCT02270606|Rectum
130439|NCT02270541|Telemedicine
130440|NCT02270541|Prehospital
130441|NCT02270541|Emergency Medicine
130442|NCT02270541|Stroke
130443|NCT02270515|Patient-Centered Care
130444|NCT02270515|Medical Home
130445|NCT02270502|critically illness
130446|NCT02270502|intensive care unit
130447|NCT02270502|outcome
130448|NCT02270502|frailty
130449|NCT02270476|Cystic Fibrosis
130450|NCT02270476|Infant
130451|NCT02270476|Toddler
130452|NCT02270476|Children
130453|NCT02270476|Newborn screening
130454|NCT02270437|total knee arthroplasty
130455|NCT02270437|cocktail analgesia
130456|NCT02270437|morphine consumption
130457|NCT02270424|Pulmonary Disease, Chronic Obstructive
130458|NCT02270424|Medicine, Chinese Traditional
130459|NCT02270424|Humans
130460|NCT02270424|Treatment Outcome
130461|NCT02270398|Exercise
130462|NCT02270398|Balance
130463|NCT02270398|Gait
130464|NCT02270398|Community
130465|NCT02270398|Rehabilitation
130466|NCT02270398|Dual-task
130467|NCT02270385|pressure ulcer
130468|NCT02270385|nursing home
130469|NCT02270385|prevention program
130470|NCT02270372|Advanced breast carcinoma
130471|NCT02270372|Advanced ovarian carcinoma
130472|NCT02270372|MUC1
130473|NCT02270372|vaccine
130474|NCT02270372|Phase 1b
130475|NCT02270359|Myocardial Infarction
130476|NCT02270359|CAD
130477|NCT02270346|Allogeneic HSCT, Inspiratory Muscle Training, Exercise Capacity
130478|NCT02270333|sarcoidosis
130479|NCT02270333|inspiratory muscle strength
130480|NCT02270333|exercise capacity
130481|NCT02270333|quality of life
130482|NCT02270320|Tai Chi Chuan
130483|NCT02270320|cognitive function
130484|NCT02270320|motor function
130485|NCT02270320|MRI
130486|NCT02270294|Ischemic stroke
130487|NCT02270294|Thai traditional massage
130488|NCT02270294|Vascular function
130489|NCT02270294|Cerebral blood flow
130490|NCT02270294|Cerebrovascular reactivity
130491|NCT02270268|Irritable bowel syndrome
130492|NCT02270268|Gut microbiota
130493|NCT02270268|Soluble dietary fiber
130494|NCT02270255|embolization
130495|NCT02270255|analgesia
130496|NCT02270242|PCI
130497|NCT02270242|DAPT
130498|NCT02270242|ticagrelor
130499|NCT02270242|aspirin
130500|NCT02270216|isolated systolic hypertension
130501|NCT02270216|exercise pressor responses
130502|NCT02270203|si joint
130503|NCT02270203|si joint injury
130504|NCT02270203|si joint treatment
130505|NCT02270203|si joint inflammation
130506|NCT02270203|si joint problems
130507|NCT02270203|si joint symptoms
130508|NCT02270203|hypermobile joint
130509|NCT02270203|si joint arthritis
130510|NCT02270203|si joint pain treatment
130511|NCT02270203|inflamed si joint
130512|NCT02270203|si joint sclerosis
130513|NCT02270203|locked si joint
130514|NCT02270203|si joint injuries
130515|NCT02270203|si joint disease
130516|NCT02270203|si joint infection
130517|NCT02270203|sacroiliac joint pelvic pain
130518|NCT02270203|sacroiliac joint arthritis treatment
130519|NCT02270203|si joint pain
130520|NCT02270203|si joint injections
130521|NCT02270177|Headache
130522|NCT02270177|Telemedicine
130523|NCT02270177|Videoconsultation
130524|NCT02270177|Headache-referrals
130525|NCT02270164|Lipids
130526|NCT02270164|Cholesterol
130527|NCT02270164|Dietary Supplements
130528|NCT02270164|Cynara scolymus
130529|NCT02270164|Safety
130530|NCT02270151|Atrial fibrillation
130531|NCT02270151|Screening
130532|NCT02270151|Primary care
130533|NCT02270151|Diagnostic
130534|NCT02270138|physical activity
130535|NCT02270138|music
130536|NCT02270138|sedentary lifestyle
130537|NCT02270125|nasal mucosa
130538|NCT02270125|chronic hypertrophic rhinosinusitis
130539|NCT02270125|mucotomy
130540|NCT02270125|nanoparticles
130541|NCT02270125|scanning electron microscopy
130542|NCT02270125|Raman microspectroscopy
130543|NCT02270125|nasal polyposis
130544|NCT02270112|atrial fibrillation
130545|NCT02270112|atrial electrophysiology
130546|NCT02270112|stroke
130547|NCT02270112|vascular stiffness
130548|NCT02270073|Psychotherapy process
130549|NCT02270073|Change mechanisms
130550|NCT02270073|Mindfulness
130551|NCT02270073|Micro-interventions
130552|NCT02270073|Mindfulness interventions
130553|NCT02270073|Progressive muscle relaxation
130554|NCT02270060|Music Therapy
130555|NCT02270060|Sickle Cell Disease
130556|NCT02270060|Pain
130557|NCT02270047|Ad libitum energy intake
130558|NCT02270047|Appetite sensation
130559|NCT02270021|Pap smear
130560|NCT02270021|Screening
130561|NCT02270021|Women
130562|NCT02270021|Human papillomavirus
130563|NCT02270021|Cervical precancer
130564|NCT02270021|Guideline adherence
130565|NCT02270008|anal incontinence
130566|NCT02270008|pregnancy-associated pelvic floor disorders
130567|NCT02269995|Hepatocellular
130568|NCT02269995|Carcinoma
130569|NCT02269969|Aminoglycoside
130570|NCT02269969|Pharmacokinetics
130571|NCT02269969|Once daily dosing
130572|NCT02269943|Metastatic nasopharyngeal carcinoma
130573|NCT02269943|oral azacitidine
130574|NCT02269943|oral AZA
130575|NCT02269943|CC-486
130576|NCT02269943|metastatic
130577|NCT02269943|recurrent
130578|NCT02269943|nasopharyngeal carcinoma
130579|NCT02269943|nasal
130580|NCT02269943|solid tumors
130581|NCT02269943|locally advanced
130582|NCT02269943|rare head and neck cancer
130583|NCT02269943|nasopharynx
130584|NCT02269943|single chemotherapy agent
130585|NCT02269943|Epstein-Barr Virus (EBV) + nasopharyngeal carcinoma
130586|NCT02269943|EBV-DN
130587|NCT02269943|Celgene
130588|NCT02269943|Sponsor-study
130589|NCT02269943|oral chemotherapy
130590|NCT02269943|phase 2
130591|NCT02269943|oral Vidaza
130592|NCT02269943|EBV promoter methylation
130593|NCT02269943|hypomethylation
130594|NCT02269943|tumor infiltrating lymphocytes (TILs)
130595|NCT02269943|EBV gene expression
130596|NCT02269943|neoplasms
130597|NCT02269917|Human Immunodeficiency Virus Type 1
130598|NCT02269917|Emerald
130599|NCT02269917|Darunavir
130600|NCT02269917|Cobicistat
130601|NCT02269917|Emtricitabine
130602|NCT02269917|Tenofovir Alafenamide
130603|NCT02269891|Menopausal symptoms
130604|NCT02269891|Peri-menopause
130605|NCT02269891|Nu Femme
130606|NCT02269891|Labisia pumila
130607|NCT02269891|Eurycoma longifolia
130608|NCT02269891|Hot flash
130609|NCT02269891|Joint pain
130610|NCT02269852|seasonal trivalent inactivated influenza vaccine
130611|NCT02269852|immunogenicity
130612|NCT02269852|safety
130613|NCT02269852|cross-reactivity
130614|NCT02269852|Northern hemisphere 2013-2014 formulation
130615|NCT02269839|Tinnitus
130616|NCT02269839|rTMS
130617|NCT02269813|MammaPrint
130618|NCT02269813|BluePrint
130619|NCT02269813|TargetPrint
130620|NCT02269774|Atrial Fibrillation
130621|NCT02269774|Obstructive Sleep Apnea
130622|NCT02269774|Atrial Premature Complexes
130623|NCT02269774|Pulmonary Vein Isolation
130624|NCT02269774|Mueller Manoeuvre
130625|NCT02269761|Emergency Departments
130626|NCT02269761|Chest
130627|NCT02269761|Lung
130628|NCT02269761|Cough
130629|NCT02269761|Dyspnea
130630|NCT02269761|Wheezing
130631|NCT02269761|Ultrasound
130632|NCT02269761|Ultrasonography
130633|NCT02269657|Scoliosis
130634|NCT02269657|Postural balance
130635|NCT02269657|Lordosis
130636|NCT02269657|Kyphosis
130637|NCT02269657|X-rays
130638|NCT02269631|Weight loss
130639|NCT02269631|Epidemiology
130640|NCT02269631|Nutrition
130641|NCT02269618|Telehealth, Home-based, rehabilitation
130642|NCT02269605|HIV reservoir
130643|NCT02269605|Bryostatin
130644|NCT02269592|MGUS
130645|NCT02269592|Smoldering Myeloma
130646|NCT02269592|Chronic Lymphocytic leukemia
130647|NCT02269592|Acute Myeloid Leukemia
130648|NCT02269592|Myeloproliferative neoplasms
130649|NCT02269592|Waldenstrom Macroglobulinemia
130650|NCT02269592|Monoclonal Gammopathy of Undermined Significance
130651|NCT02269592|Monoclonal B cell lymphocytosis
130652|NCT02269592|Smoldering Multiple Myeloma
130653|NCT02269592|Myelodysplastic syndromes
130654|NCT02269579|Newly Diagnosed AML
130655|NCT02269579|Secondary AML
130656|NCT02269579|Relapsed/Refractory AML
130657|NCT02269579|Relapsed/Refractory ALL
130658|NCT02269566|allergic rhinitis
130659|NCT02269566|immunotherapy
130660|NCT02269553|Migraine
130661|NCT02269553|Headache
130662|NCT02269514|adoption
130663|NCT02269514|electronic cigarettes
130664|NCT02269514|e-cigarettes
130665|NCT02269514|combustible cigarettes
130666|NCT02269514|nicotine polacrilex
130667|NCT02269514|own brand cigarette
130668|NCT02269514|subjective measures
130669|NCT02269514|pharmacokinetics
130670|NCT02269514|pharmacodynamics
130671|NCT02269488|Safety
130672|NCT02269488|Tolerability
130673|NCT02269488|MEDI3250
130674|NCT02269488|Japanese children
130675|NCT02269475|Efficacy
130676|NCT02269475|Safety
130677|NCT02269475|Tolerability
130678|NCT02269475|MEDI3250
130679|NCT02269475|Japanese children
130680|NCT02269449|transradial intervention
130681|NCT02269449|radial artery
130682|NCT02269410|Bariatric Surgery
130683|NCT02269410|Nitrogen Balance
130684|NCT02269410|Body composition
130685|NCT02269410|Protein supplementation
130686|NCT02269410|Satiety
130687|NCT02269410|Adherence
130688|NCT02269397|Epilepsy
130689|NCT02269397|Seizures
130690|NCT02269397|Diagnosis
130691|NCT02269397|Diagnostic
130692|NCT02269397|Inflammation
130693|NCT02269384|Pain
130694|NCT02269384|Memory
130695|NCT02269384|Pressure Pain Threshold
130696|NCT02269384|Electromyography
130697|NCT02269384|Heart Rate Variability
130698|NCT02269319|ABSSSI
130699|NCT02269319|MRX-I
130700|NCT02269319|Acute Bacterial Skin and Skin Structure Infections
130701|NCT02269306|PCOS
130702|NCT02269306|clomiphene citrate
130703|NCT02269306|AMH
130704|NCT02269306|visceral fat area
130705|NCT02269306|HOMA-IR
130706|NCT02269293|Selinexor (KPT-330)
130707|NCT02269293|Paclitaxel
130708|NCT02269293|Carboplatin
130709|NCT02269293|14-110
130710|NCT02269280|Leukemia
130711|NCT02269280|Myelodysplastic syndrome
130712|NCT02269280|MDS
130713|NCT02269280|Low or intermediate-1 risk
130714|NCT02269280|Transfusion-dependent
130715|NCT02269280|Transfusion-independent
130716|NCT02269280|Best supportive care
130717|NCT02269280|BSC
130718|NCT02269280|Azacitidine
130719|NCT02269280|5-Azacytidine
130720|NCT02269280|5-AZA
130721|NCT02269280|Vidaza
130722|NCT02269280|5-AZC
130723|NCT02269280|AZA-CR
130724|NCT02269280|Ladakamycin
130725|NCT02269280|NSC-102816
130726|NCT02269280|Azacytidine
130727|NCT02269280|Decitabine
130728|NCT02269280|Dacogen
130729|NCT02269254|Comparative Study
130730|NCT02269254|Knee Prosthesis
130731|NCT02269254|Prosthesis Design
130732|NCT02269254|Treatment Outcome
130733|NCT02269254|Follow-Up Studies
130734|NCT02269254|Arthroplasty, Replacement, Knee/methods
130735|NCT02269241|contraception
130736|NCT02269241|hormonal oral contraceptive agents
130737|NCT02269241|hormonal oral contraceptive
130738|NCT02269241|oral contraceptive
130739|NCT02269241|drospirenone
130740|NCT02269241|LF111
130741|NCT02269241|birth control
130742|NCT02269150|Recipients
130743|NCT02269150|Transplantation
130744|NCT02269137|status epileptics
130745|NCT02269137|prognosis
130746|NCT02269137|risk factor
130747|NCT02269137|outcome
130748|NCT02269098|type 2 diabetes
130749|NCT02269098|hyperglycemia
130750|NCT02269098|Emergency Department
130751|NCT02269098|Patient Education as Topic
130752|NCT02269098|Drug Therapy
130753|NCT02269085|Lymphoma
130754|NCT02269085|Mantle cell lymphoma
130755|NCT02269085|MCL
130756|NCT02269085|Relapsed or refractory
130757|NCT02269085|Ibrutinib
130758|NCT02269085|PCI-32765
130759|NCT02269085|Imbruvica
130760|NCT02269085|Carfilzomib
130761|NCT02269072|Natriuretic Peptide
130762|NCT02269046|acupuncture
130763|NCT02269046|moxibustion
130764|NCT02269046|hyperlipidemias
130765|NCT02269046|effectiveness
130766|NCT02269033|Breast cancer
130767|NCT02269033|Patient Navigation
130768|NCT02269033|Health Disparities
130769|NCT02269033|Latinas
130770|NCT02269033|Breast Imaging Reporting and Data System, BI-RADS
130771|NCT02269033|underserved
130772|NCT02269020|Squamous Cell Carcinoma of the Epi-larynx
130773|NCT02269007|safety, tolerance, quadrivalent influenza vaccine
130774|NCT02268994|ferric citrate
130775|NCT02268994|Chronic kidney disease
130776|NCT02268994|Anemia
130777|NCT02268981|Oxymizer
130778|NCT02268981|Oxygen conserving device
130779|NCT02268981|Conventional nasal cannula (CNC)
130780|NCT02268981|Idiopathic pulmonary fibrosis
130781|NCT02268968|Topical Lidocaine
130782|NCT02268968|Nasal CPAP
130783|NCT02268968|Pain
130784|NCT02268968|Preterm Infants
130785|NCT02268968|Salivary cortisol
130786|NCT02268955|Biliary Colic
130787|NCT02268955|Abdominal pain
130788|NCT02268955|Intravenous Ibuprofen
130789|NCT02268916|diabetes
130790|NCT02268916|physical activity
130791|NCT02268916|participation
130792|NCT02268903|Pulmonary Embolism
130793|NCT02268903|Right Ventricle failure
130794|NCT02268903|Diuretics
130795|NCT02268890|Multiple Myeloma
130796|NCT02268890|Bortezomib
130797|NCT02268890|Velcade
130798|NCT02268877|ultrasonography
130799|NCT02268877|emergency department
130800|NCT02268864|Hepatitis C Chronic
130801|NCT02268864|Simeprevir
130802|NCT02268864|Daclatasvir
130803|NCT02268851|Mantle Cell Lymphoma
130804|NCT02268851|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
130805|NCT02268838|E6007
130806|NCT02268838|Healthy Japanese male subjects
130807|NCT02268812|Pain Management
130808|NCT02268812|Europe
130809|NCT02268812|Intrathecal
130810|NCT02268799|Cardioversion
130811|NCT02268799|High Sensitivity Troponin T (Hs-Trop T)
130812|NCT02268799|Brain Natriuretic Peptide (BNP)
130935|NCT02268071|Primary care
130813|NCT02268799|Neutrophil Gelatinase-associated Lipocalin (NGAL)
130814|NCT02268786|Preimplantation Genetic Screening
130815|NCT02268786|Blastocyst
130816|NCT02268786|Vitrification
130817|NCT02268786|In vitro fertilization
130818|NCT02268786|non-invasive prenatal testing
130819|NCT02268786|next generation sequencing
130820|NCT02268747|skin squamous cell cancer panHER inhibitor Dacomitinib
130821|NCT02268734|Sporadic Medullary Thyroid Cancer Vandetanib miRNA
130822|NCT02268721|Pilot study
130823|NCT02268721|Frail elderly
130824|NCT02268721|Malnutrition
130825|NCT02268721|Functionality
130826|NCT02268721|Life quality
130827|NCT02268721|Health care technology
130828|NCT02268708|COPD
130829|NCT02268708|Surgery, Thoracic
130830|NCT02268695|Recurrent/Metastatic HNSCC
130831|NCT02268695|Taxanes
130832|NCT02268682|Educator-Guided
130833|NCT02268682|Patient-Guided
130834|NCT02268682|Standard of Care (Control)
130835|NCT02268669|primary angioplasty
130836|NCT02268669|post-thrombolysis angioplasty
130837|NCT02268669|ST elevation acute myocardial infarction
130838|NCT02268643|breast cancer
130839|NCT02268643|screening
130840|NCT02268643|ultrasound
130841|NCT02268643|risk model
130842|NCT02268630|Post-thrombotic syndrome
130843|NCT02268630|Chronic thromboembolic pulmonary hypertension
130844|NCT02268630|Anticoagulation
130845|NCT02268630|Rivaroxaban
130846|NCT02268617|Treadmill
130847|NCT02268617|Walking
130848|NCT02268617|Gait
130849|NCT02268617|Exercise
130850|NCT02268578|Transcranial Direct Current Stimulation
130851|NCT02268578|TDCS
130852|NCT02268578|Memory Dysfunction
130853|NCT02268578|Depression
130854|NCT02268565|sleep, insomnia, inflammation, pain
130855|NCT02268565|Insomnia symptom induction/placebo
130856|NCT02268565|Insomnia symptom induction/aspirin
130857|NCT02268552|Type 1 Spinal Muscular Atrophy
130858|NCT02268539|pilot study
130859|NCT02268539|atrial fibrillation
130860|NCT02268539|ablation
130861|NCT02268539|implanted loop recorder
130862|NCT02268526|Safety, efficacy, pharmacokinetics, CSJ148, HCMV, HCMV viral load,
130863|NCT02268526|immunogenicity
130864|NCT02268513|Cardiovascular Disease
130865|NCT02268513|Social network
130866|NCT02268513|South Asians
130867|NCT02268487|Early Improvement
130868|NCT02268487|Depression
130869|NCT02268487|Antidepressant
130870|NCT02268474|532nm
130871|NCT02268474|Excel V
130872|NCT02268474|Cutera
130873|NCT02268474|Laser
130874|NCT02268474|Laser Light
130875|NCT02268474|PDL
130876|NCT02268474|595nm
130877|NCT02268474|Flash Lamp
130878|NCT02268461|Post-Stroke Spasticity
130879|NCT02268448|itch atopic dermatitis
130880|NCT02268422|Healthy volunteer
130881|NCT02268422|crossover
130882|NCT02268422|open-label
130883|NCT02268422|randomised
130884|NCT02268422|bioequivalence
130885|NCT02268422|pharmacokinetic study
130886|NCT02268357|Dental Anxiety
130887|NCT02268357|Tooth Extraction
130888|NCT02268357|Propranolol
130889|NCT02268344|nerve regeneration
130890|NCT02268344|spinal accessory nerve
130891|NCT02268344|shoulder function
130892|NCT02268344|head neck cancer
130893|NCT02268344|electrical stimulation
130894|NCT02268318|Japanese Subjects, High LDL-C, fermented-dairy products, phytosterols
130895|NCT02268292|Metabolic syndrome
130896|NCT02268292|Diabetes
130897|NCT02268292|Muscle strength
130898|NCT02268292|Aerobic exercise
130899|NCT02268292|Bicycle
130900|NCT02268292|Brain-derived neurotrophic factor
130901|NCT02268266|brain injury, early rehabilitation, tilt table
130902|NCT02268214|Dapagliflozin
130903|NCT02268214|Efficacy
130904|NCT02268214|Safety
130905|NCT02268214|Add on to insulin
130906|NCT02268214|Oral Antidiabetic
130907|NCT02268214|Type 1 diabetes
130908|NCT02268201|immunosuppressive therapy
130909|NCT02268201|tacrolimus
130910|NCT02268188|Cancer Survivors
130911|NCT02268175|prostate adenocarcinoma
130912|NCT02268175|advanced prostate cancer
130913|NCT02268175|high risk prostate cancer
130914|NCT02268162|Lung Neoplasms
130915|NCT02268162|Bronchoscopy
130916|NCT02268162|Virtual Bronchoscopic Navigation(VBN)
130917|NCT02268162|Fluoroscopy
130918|NCT02268162|Endobronchial Ultrasonography with a Guide Sheath(EBUS-GS)
130919|NCT02268162|Diagnosis
130920|NCT02268123|Male Infertility
130921|NCT02268123|Sperm DNA Fragmentation
130922|NCT02268123|Sperm Abnormality
130923|NCT02268110|diastasis recti
130924|NCT02268110|physiotherapy
130925|NCT02268110|exercise therapy
130926|NCT02268110|abdominal binding
130927|NCT02268097|patella
130928|NCT02268097|total knee arthroplasty
130929|NCT02268097|resection
130930|NCT02268084|PTSD
130931|NCT02268084|TMS
130932|NCT02268084|EEG
130933|NCT02268071|Hypertension
130934|NCT02268071|Stopping antihypertensive treatment
130936|NCT02268071|White coat hypertension
130937|NCT02268071|Masked Hypertension
130938|NCT02268045|Non-Hodgkin Lymphoma
130939|NCT02268045|DLBCL
130940|NCT02268045|Diffuse large b-cell lymphoma
130941|NCT02268032|hormone replacement therapy
130942|NCT02268019|hypospadias
130943|NCT02268019|dehiscence
130944|NCT02268019|urethral stricture
130945|NCT02268019|side effects
130946|NCT02268006|rectal carcinoma
130947|NCT02268006|preoperative radiochemotherapy
130948|NCT02268006|IMRT
130949|NCT02268006|SIB
130950|NCT02267980|Electroconvulsive therapy; sevoflurane; ketamine
130951|NCT02267954|Calories
130952|NCT02267954|Fast Food Literacy
130953|NCT02267928|Symptom Assessment
130954|NCT02267915|Relapsed or refractory patients with mantle-cell lymphoma
130955|NCT02267915|Progression after high-dose chemotherapy and autologous HPT
130956|NCT02267902|Volunteers
130957|NCT02267889|Ganglionated plexi
130958|NCT02267850|Photobiomodulation
130959|NCT02267850|Orthodontic treatment
130960|NCT02267850|Malocclusion
130961|NCT02267850|OrthoPulse™
130962|NCT02267837|Alignment phase
130963|NCT02267837|Photobiomodulation
130964|NCT02267837|Orthodontic treatment
130965|NCT02267837|Malocclusion
130966|NCT02267837|OrthoPulse™
130967|NCT02267824|Alignment phase
130968|NCT02267824|Photobiomodulation
130969|NCT02267824|Orthodontic treatment
130970|NCT02267824|Malocclusion
130971|NCT02267824|OrthoPulse™
130972|NCT02267811|Photobiomodulation
130973|NCT02267811|Orthodontic treatment
130974|NCT02267811|Malocclusion
130975|NCT02267811|OrthoPulse™
130976|NCT02267798|Stroke
130977|NCT02267798|Rehabilitation
130978|NCT02267798|Arm motor recovery
130979|NCT02267798|biological biomarkers
130980|NCT02267785|exercise
130981|NCT02267785|mild cognitive impairment
130982|NCT02267785|Parkinson's Disease
130983|NCT02267720|Dental Atraumatic Restorative Treatment
130984|NCT02267720|Glass ionomer cement
130985|NCT02267720|Occlusal-proximal leasons
130986|NCT02267720|Primary molars
130987|NCT02267707|nab®-paclitaxel
130988|NCT02267707|ABI-007
130989|NCT02267707|Abraxane
130990|NCT02267707|Advanced Pancreatic Cancer
130991|NCT02267707|Cholestatic Hyperbilirubinemia
130992|NCT02267707|Bile Duct Obstruction
130993|NCT02267707|Pancreatic Cancer
130994|NCT02267668|concussion
130995|NCT02267668|sports concussion
130996|NCT02267668|exercise therapy
130997|NCT02267655|Inhaled Nitric Oxide (iNO)
130998|NCT02267655|Pulmonary Hypertension (PH)
130999|NCT02267655|Chronic Obstructive Pulmonary Disease (COPD)
131000|NCT02267655|Long Term Oxygen Therapy (LTOT)
131001|NCT02267655|Idiopathic Pulmonary Fibrosis (IPF)
131002|NCT02267629|OCD
131003|NCT02267616|Levonorgestrel intrauterine device (LNG IUD)
131004|NCT02267616|Etonogestrel (ENG) Implant
131005|NCT02267616|Contraception
131006|NCT02267564|patellar dislocation
131007|NCT02267564|medial patellofemoral ligament
131008|NCT02267564|tibial tubercle transfer
131009|NCT02267551|robotic surgery
131010|NCT02267551|simulation
131011|NCT02267538|Delirium
131012|NCT02267538|Cardiac Surgical Procedures
131013|NCT02267538|Postoperative Complications
131014|NCT02267538|Dexmedetomidine
131015|NCT02267538|Prevention
131016|NCT02267525|Gastroparesis
131017|NCT02267525|Diabetic
131018|NCT02267525|Idiopathic
131019|NCT02267512|Kidney Transplant Patients
131020|NCT02267512|ATG-F
131021|NCT02267499|cognitive training
131022|NCT02267499|physical training
131023|NCT02267499|exercise games
131024|NCT02267499|novelty serious games
131025|NCT02267499|computer training
131026|NCT02267499|mild cognitive impairment
131027|NCT02267499|mild dementia
131028|NCT02267499|healthy elderly
131029|NCT02267486|Alzheimer Dementia, AD
131030|NCT02267486|patients
131031|NCT02267486|cognitive
131032|NCT02267460|Peyronie's disease
131033|NCT02267460|penile plaque
131034|NCT02267460|penile curvature
131035|NCT02267447|Cardiovascular diseases
131036|NCT02267447|Clinical prediction rule
131037|NCT02267447|Population projection
131038|NCT02267447|Risk stratification
131039|NCT02267447|Health behavior
131040|NCT02267408|Heart valve prosthesis
131041|NCT02267408|Anticoagulation
131042|NCT02267408|Warfarin
131043|NCT02267395|Musicians, Injuries
131044|NCT02267369|online
131045|NCT02267369|social media
131046|NCT02267369|online social network
131047|NCT02267369|physical activity
131048|NCT02267369|message
131049|NCT02267330|Gonadal Radiation Exposure
131050|NCT02267330|Fluoroscopic Imaging
131051|NCT02267330|Trauma Surgery
131052|NCT02267330|Pelvis fractures
131053|NCT02267330|Femur fractures
131054|NCT02267317|Insulin signaling and glucose disposal in muscle
131055|NCT02267317|Hepatic insulin sensitivity
131056|NCT02267317|TLR4 signaling and inflammatory gene expression
131057|NCT02267317|Plasma cytokine concentration
131058|NCT02267317|Intramyocellular diacylglycerol and ceramide content
131059|NCT02267304|volunteers
131060|NCT02267291|Cardiac Catheterization
131061|NCT02267291|Echocardiography
131062|NCT02267291|Noninvasive Ventilation
131063|NCT02267291|Positive-Pressure Respiration
131064|NCT02267291|Ventricular Function
131065|NCT02267278|Myeloproliferative Diseases
131066|NCT02267278|Myelofibrosis
131067|NCT02267278|MF
131068|NCT02267278|Primary or post essential thrombocythemia/polycythemia vera
131069|NCT02267278|Ruxolitinib
131070|NCT02267278|Jakafi
131071|NCT02267278|INCB018424
131072|NCT02267278|INC424
131073|NCT02267278|Pracinostat
131074|NCT02267278|Questionnaire
131075|NCT02267278|Survey
131076|NCT02267265|educational intervention
131077|NCT02267265|language development
131078|NCT02267265|universal newborn hearing screening
131079|NCT02267265|postpartum
131080|NCT02267265|parental attachment
131081|NCT02267265|loss to follow-up
131082|NCT02267265|hearing loss
131083|NCT02267265|achievement gap
131084|NCT02267265|language gap
131085|NCT02267265|school readiness
131086|NCT02267239|essential oils
131087|NCT02267239|chlorhexidine
131088|NCT02267239|microscopy, confocal
131089|NCT02267239|immersion
131090|NCT02267239|antiseptic
131091|NCT02267200|biomarkers，pulmonary arterial hypertension
131092|NCT02267187|Craniomaxillofacial (CMF)
131093|NCT02267187|Battle-injured (BI)
131094|NCT02267187|Facial Trauma
131095|NCT02267187|Fat Grafts
131096|NCT02267187|Autogenous Fat Transfers (AFT)
131097|NCT02267187|Wounded Warriors
131098|NCT02267174|Implementation
131099|NCT02267174|quality improvement
131100|NCT02267174|patient safety
131101|NCT02267174|handoffs
131102|NCT02267174|intensive care unit
131103|NCT02267174|postoperative care
131104|NCT02267174|simulation
131105|NCT02267161|agenesis
131106|NCT02267161|corpus callosum
131107|NCT02267161|prenatal diagnosis
131108|NCT02267148|Non-alcoholic fatty liver disease
131109|NCT02267148|Fatty liver
131110|NCT02267148|Steatosis
131111|NCT02267148|Fibrosis
131112|NCT02267148|Liver Stiffness
131113|NCT02267148|Cirrhosis
131114|NCT02267148|Genetics
131115|NCT02267148|Single Nucleotide Polymorphism
131116|NCT02267135|scalp psoriasis, plaque psoriasis, secukinumab, AIN457, biologic, monoclonal antibody, psoriasis, AIN457A
131117|NCT02267096|lung cancer screening
131118|NCT02267083|soft tissue sarcoma
131119|NCT02267070|cognitive training
131120|NCT02267070|aerobic exercise
131121|NCT02267070|neurotrophic factors
131122|NCT02267070|randomized controlled trial
131123|NCT02267057|Pain measurement
131124|NCT02267057|Pain assessment
131125|NCT02267057|Pain management
131126|NCT02267057|Analgesia
131127|NCT02267057|Analgesics
131128|NCT02267057|Depressive symptoms
131129|NCT02267057|Alzheimer disease
131130|NCT02267057|Vascular dementia
131131|NCT02267057|Multi-infarct dementia
131132|NCT02267057|Frontotemporal lobar degeneration
131133|NCT02267057|Lewy body disease
131134|NCT02267031|cognitive dysfunction
131135|NCT02267031|mechanical ventilation
131136|NCT02267031|hyperoxia
131137|NCT02267031|hypocapnia
131138|NCT02267018|nCPAP
131139|NCT02267018|High-Frequency Oscillator Ventilation
131140|NCT02267018|Diaphragm Electrical Activity
131141|NCT02266979|peritoneal dialysis
131142|NCT02266979|nursing staff
131143|NCT02266979|nursing activities
131144|NCT02266979|Personnel Downsizing
131145|NCT02266953|Dietary services
131146|NCT02266953|Public Health Nursing
131147|NCT02266953|Preschool child
131148|NCT02266940|pharmacokinetics
131149|NCT02266901|leaks after bariatric surgery
131150|NCT02266901|fistulae after bariatric surgery
131151|NCT02266901|abdominal abcesses and bariatric surgery
131152|NCT02266901|endoscopic drainage of abcesses
131153|NCT02266901|percutaneous drainage of abcesses
131154|NCT02266901|gastric bypass
131155|NCT02266901|sleeve gastrectomy
131156|NCT02266901|necrotic collection and bariatric surgery
131157|NCT02266888|B cells
131158|NCT02266888|lung transplant recipient
131159|NCT02266888|rituximab
131160|NCT02266888|placebo
131161|NCT02266888|standard of care
131162|NCT02266836|Stroke
131163|NCT02266836|Cerebrovascular accident
131164|NCT02266836|Upper Extremity
131165|NCT02266836|Cerebral Infarction
131166|NCT02266836|Brain Infarction
131167|NCT02266836|Brain Ischemia
131168|NCT02266836|Cerebrovascular Disorders
131169|NCT02266836|Cardiovascular Diseases
131170|NCT02266836|Nervous System Diseases
131171|NCT02266836|Central Nervous System Diseases
131172|NCT02266784|smoking, smoking cessation, contingency management, ADHD
131173|NCT02266771|Negative Pressure Wound Therapy, Wound VAC, Instillation
131174|NCT02266758|Gestational Diabetes
131175|NCT02266758|Obesity
131176|NCT02266758|Pregnancy
131177|NCT02266719|Aortic Aneurysm, Abdominal [C14.907.055.239.075]
131178|NCT02266693|Cognitive Behavioural Therapy
131179|NCT02266693|Internet Based
131180|NCT02266693|CBT
131181|NCT02266693|Transdiagnostic
131182|NCT02266693|MDD
131183|NCT02266693|PD
131184|NCT02266693|SAD
131185|NCT02266693|GAD
131186|NCT02266693|iCBT
131187|NCT02266680|Social Anxiety
131188|NCT02266680|Yoga
131189|NCT02266667|NEMOT device
131190|NCT02266667|pediatrics
131191|NCT02266667|surgery
131192|NCT02266667|progressive scoliosis
131193|NCT02266654|Emergency Medical Services
131194|NCT02266654|Lactic Acid
131195|NCT02266654|Sepsis
131196|NCT02266641|one-carbon metabolism
131197|NCT02266641|folate
131198|NCT02266641|choline
131199|NCT02266641|DNA methylation
131200|NCT02266641|imprint marker
131201|NCT02266641|cancer risks
131202|NCT02266602|IORT
131203|NCT02266602|Breast Cancer
131204|NCT02266589|coagulopathy
131205|NCT02266589|hydrocortisone
131206|NCT02266589|organ failure
131207|NCT02266589|hemodynamic improvement induced by hydrocortisone
131208|NCT02266563|Traumatic Brain Injury
131209|NCT02266563|Chronic Traumatic Encephalopathy
131210|NCT02266563|Mild Cognitive Impairment
131211|NCT02266563|PET imaging
131212|NCT02266563|tauopathy
131213|NCT02266563|amyloid
131214|NCT02266446|anxiety disorders
131215|NCT02266446|cognitive bias modification
131216|NCT02266446|primary care
131217|NCT02266446|attention
131218|NCT02266446|interpretation
131219|NCT02266446|computer
131220|NCT02266433|DeQuervains Tenosynovitis
131221|NCT02266433|Lateral Epicondylitis
131222|NCT02266433|Tennis Elbow
131223|NCT02266433|Trigger Finger
131224|NCT02266433|Tenosynovitis
131225|NCT02266433|Inflammatory Disease
131226|NCT02266433|Dexamethasone
131227|NCT02266433|Ketorolac
131228|NCT02266433|Toradol
131229|NCT02266420|Triple negative breast cancer
131230|NCT02266420|immuno-histochemistery
131231|NCT02266420|genomic profiles
131232|NCT02266407|Revision TKA
131233|NCT02266407|Septic
131234|NCT02266407|Aseptic
131235|NCT02266407|Transfusion
131236|NCT02266407|Blood Loss
131237|NCT02266381|PCNL
131238|NCT02266381|MPCNL
131239|NCT02266381|guidance
131240|NCT02266381|puncture
131241|NCT02266368|Ureteral stents
131242|NCT02266368|Double J stent
131243|NCT02266368|Antimicoreal coated stent
131244|NCT02266368|USSQ
131245|NCT02266368|UTI
131246|NCT02266355|Oxaliplatin
131247|NCT02266355|Omalizumab
131248|NCT02266329|controlled clinical trial
131249|NCT02266329|randomized controlled clinical trial
131250|NCT02266290|ADHESIVE TAPE
131251|NCT02266290|ANKLE INJURY
131252|NCT02266290|POSTURAL BALANCE
131253|NCT02266290|FUNCTIONAL ANKLE INSTABILITY
131254|NCT02266277|electronic health record, utilization
131255|NCT02266277|randomized controlled trial
131256|NCT02266277|pragmatic clinical trial
131257|NCT02266277|influenza, prevention and control
131258|NCT02266277|pneumococcal vaccines
131259|NCT02266277|qualitative research
131260|NCT02266225|Chronic disease management
131261|NCT02266225|Physical activity
131262|NCT02266225|Fall prevention
131263|NCT02266225|Strength and balance exercise
131264|NCT02266199|questionnaire
131265|NCT02266199|quality assurance
131266|NCT02266199|qualitative Verification
131267|NCT02266199|conservative patients
131268|NCT02266199|interview
131269|NCT02266160|tinnitus
131270|NCT02266160|local anaesthetic
131271|NCT02266160|EMLA cream 5%
131272|NCT02266147|Low Grade B-cell Lymphoma
131273|NCT02266134|implementation
131274|NCT02266134|measurement based care
131275|NCT02266134|standardized
131276|NCT02266134|tailored
131277|NCT02266121|Multiple Sclerosis
131278|NCT02266121|MS
131279|NCT02266121|Cognitive deficits
131280|NCT02266121|Motor deficits
131281|NCT02266121|Fatigue
131282|NCT02266121|Nervous System Diseases
131283|NCT02266121|Brain Diseases
131284|NCT02266121|Brain stimulation
131285|NCT02266121|Working memory
131286|NCT02266121|Motor learning
131287|NCT02266121|Central Nervous System Diseases
131288|NCT02266121|Neuropsychological rehabilitation
131289|NCT02266108|Sexually Transmitted Infections
131290|NCT02266108|Female Sex Workers
131291|NCT02266095|Osteoarthritis
131292|NCT02266095|Thumb spica splint
131293|NCT02266095|Oval-8 splint
131294|NCT02266095|Tee-Pee splint
131295|NCT02266069|implementation
131296|NCT02266069|anticipatory care planning
131297|NCT02266069|symptom assessment
131298|NCT02266069|interdisciplinary collaboration
131299|NCT02266056|deep neuromuscular block
131300|NCT02266056|sugammadex
131301|NCT02266056|laparoscopic colorectal surgery
131302|NCT02266056|hemodynamic change
131303|NCT02266043|Upper airway obstruction
131304|NCT02266017|pain
131305|NCT02266017|coping
131306|NCT02266017|mhealth
131307|NCT02266017|cancer
131308|NCT02266004|transcranial direct current stimulation
131309|NCT02266004|neuromodulation
131310|NCT02265978|Emotional Self-Awareness
131311|NCT02265978|Positive Coping
131312|NCT02265978|Help-Seeking
131313|NCT02265926|filtering facepiece respirators
131314|NCT02265926|N95 masks
131315|NCT02265926|pandemic response
131316|NCT02265926|pregnant healthcare workers
131317|NCT02265900|Positron Emission Tomography
131318|NCT02265900|Dopamine
131319|NCT02265900|Parkinson's Disease
131320|NCT02265887|Pulmonary Hypertension
131321|NCT02265887|Africa
131322|NCT02265887|Heart Disease
131323|NCT02265887|Echocardiography
131324|NCT02265861|Polycystic ovary syndrome; Vascular endothelial growth factor; Angiotensin-Ⅱ; Ovarian hyperstimulation syndrome
131325|NCT02265848|Spinal cord stimulation
131326|NCT02265848|Chronic pain
131327|NCT02265848|Chronic low back pain
131328|NCT02265848|Radiculopathy
131329|NCT02265848|Complex Regional Pain Syndrome (CRPS)
131330|NCT02265848|High Frequency stimulation
131331|NCT02265822|melatonin
131332|NCT02265822|midazolam
131333|NCT02265822|children
131334|NCT02265809|Interleukin 2
131335|NCT02265809|Type 1 diabetes
131336|NCT02265809|T regulatory cells
131337|NCT02265809|Adaptive trial
131338|NCT02265796|deferred percutaneous coronary intervention
131339|NCT02265796|fractional flow reserve
131340|NCT02265783|Focus of Study: Healthy Volunteers
131341|NCT02265757|Behavioral Intervention
131342|NCT02265757|Mild Cognitive Impairment
131343|NCT02265757|HABIT
131344|NCT02265757|Cognitive Rehabilitation
131345|NCT02265757|Multi-Component Intervention
131346|NCT02265731|acute myeloid leukemia
131347|NCT02265731|small lymphocytic lymphoma
131348|NCT02265731|relapsed chronic lymphocytic leukemia
131349|NCT02265731|refractory multiple myeloma
131350|NCT02265731|refractory small lymphocytic lymphoma
131351|NCT02265731|relapsed multiple myeloma
131352|NCT02265731|Lymphoma, Non-Hodgkin
131353|NCT02265731|refractory chronic lymphocytic leukemia
131354|NCT02265731|Lymphoproliferative Disorders
131355|NCT02265731|relapsed small lymphocytic lymphoma
131356|NCT02265731|Lymphatic Diseases
131357|NCT02265718|Healthy
131358|NCT02265718|elderly volunteers
131359|NCT02265614|PGS
131360|NCT02265614|blastocyst
131361|NCT02265614|human
131362|NCT02265614|IVF
131363|NCT02265614|vitrification
131364|NCT02265614|single embryo transfer
131365|NCT02265601|advance care planning
131366|NCT02265601|living wills
131367|NCT02265601|end of life
131368|NCT02265601|cancer
131369|NCT02265588|Inflammatory bowel disease (IBD)
131370|NCT02265588|Ulcerative colitis
131371|NCT02265588|Crohn's disease
131372|NCT02265588|Children
131373|NCT02265588|Adolescents
131374|NCT02265588|Anxiety
131375|NCT02265588|Depression
131376|NCT02265588|Cognitive behavioral therapy
131377|NCT02265562|Hysterectomy
131378|NCT02265562|Misoprostol
131379|NCT02265562|Blood loss
131380|NCT02265549|Metastases,
131381|NCT02265549|Neoplasm
131382|NCT02265549|Cerebral
131383|NCT02265523|Arthroplasties, Replacement, Knee
131384|NCT02265458|Respiratory failure
131385|NCT02265458|NIV
131386|NCT02265458|Musical intervention
131387|NCT02265445|Carbapenems therapy/ESBL infections/Deescalation
131388|NCT02265445|due to ESBL-PE
131389|NCT02265432|Physical activity
131390|NCT02265432|Sedentary behavior
131391|NCT02265419|hyperinflammation, Cytosorb
131392|NCT02265354|Tobacco Smoking Cessation
131393|NCT02265354|Computer tailored health communication
131394|NCT02265354|messaging
131395|NCT02265354|collective intelligence
131396|NCT02265354|recommender systems
131397|NCT02265354|machine learning
131398|NCT02265328|Severe Alcoholic Hepatitis in 'Extremis'
131399|NCT02265328|Bovine Colostrum
131400|NCT02265328|Glucocorticoids
131401|NCT02265276|NAFLD, Diabetes, Glitazone
131402|NCT02265250|magnetic resonance imaging
131403|NCT02265250|positron emission tomography
131404|NCT02265237|Compensated Cirrhosis
131405|NCT02265237|Hepatitis C
131406|NCT02265237|Hepatitis C Genotype 4
131407|NCT02265237|Chronic Hepatitis C
131408|NCT02265198|Pulmonary Contusion
131409|NCT02265198|ARDS
131410|NCT02265198|Respiratory Failure
131411|NCT02265172|Physiotherapy
131412|NCT02265172|Orthopaedic
131413|NCT02265172|Primary care
131414|NCT02265146|Lipid Core Plaques (LCPs)
131415|NCT02265146|Vulnerable Plaque
131416|NCT02265146|Near Infrared Spectroscopy
131417|NCT02265107|endothelial function
131418|NCT02265107|physical training
131419|NCT02265107|exercise
131420|NCT02265107|coronary artery bypass
131421|NCT02265094|Autism Spectrum Disorder
131422|NCT02265094|Development
131423|NCT02265094|Memory
131424|NCT02265094|ERD
131425|NCT02265068|Acute coronary syndrome (ACS), Ticagrelor
131426|NCT02265029|fibromyalgia
131427|NCT02265029|rheumatism
131428|NCT02265029|fatigue syndrom
131429|NCT02265029|pain
131430|NCT02265029|spa treatment in rheumatology
131431|NCT02265016|coronary artery disease
131432|NCT02265016|acute coronary syndrome
131433|NCT02265016|angina pectoris
131434|NCT02265016|non-ST-segment elevation myocardial infarction
131435|NCT02265016|red blood cells
131436|NCT02265016|erythrocytes
131437|NCT02265003|red blood cells
131438|NCT02265003|endothelial function
131439|NCT02265003|nitric oxide pool in red blood cells
131440|NCT02265003|nitric oxide poll in blood plasma
131441|NCT02265003|nitric oxide synthase III - expression
131442|NCT02265003|oxidative status
131443|NCT02265003|nitric oxide signalling
131444|NCT02264990|cisplatin
131445|NCT02264990|paclitaxel
131446|NCT02264990|Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)
131447|NCT02264990|Non-squamous
131448|NCT02264990|Non-small cell lung cancer
131449|NCT02264990|pemetrexed
131450|NCT02264990|carboplatin
131451|NCT02264990|Metastatic
131452|NCT02264990|veliparib
131453|NCT02264964|Hemodialysis
131454|NCT02264964|End-Stage Kidney Disease
131455|NCT02264964|Central Venous Catheterization
131456|NCT02264964|Digital Subtraction Angiography
131457|NCT02264951|Short fatty acids
131458|NCT02264951|2-oleoyl glycerol
131459|NCT02264951|GLP-1 secretion
131460|NCT02264951|C8-diet oil
131461|NCT02264951|GIP secretion
131462|NCT02264925|Essential tremor
131463|NCT02264925|Deep brain stimulation (DBS)
131464|NCT02264925|Ventral intermediate Thalamus (VIM)
131465|NCT02264925|Local field potentials (LFPs)
131466|NCT02264925|Closed loop therapy
131467|NCT02264912|antiplatelet drugs, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy
131468|NCT02264899|Alzheimer's disease
131469|NCT02264899|Mild Cognitive Impairment
131470|NCT02264873|Relapse
131471|NCT02264873|Autologous stem cell transplant
131472|NCT02264847|Clomiphene Citrate
131473|NCT02264847|Ovulation trigger
131474|NCT02264847|Human chorionic gonadotrophin
131475|NCT02264834|epidural
131476|NCT02264834|primiparous patient
131477|NCT02264834|deambulation
131478|NCT02264821|analgesia
131479|NCT02264821|caesarean
131480|NCT02264821|wound infiltration
131481|NCT02264821|intrathecal morphine.
131482|NCT02264795|Cesarean section
131483|NCT02264795|Lidocaine
131484|NCT02264769|pregnancy
131485|NCT02264769|postpartum hemorrhage
131486|NCT02264769|Cesarean delivery
131487|NCT02264769|carbetocin
131488|NCT02264756|Community-acquired pneumonia
131489|NCT02264756|Pragmatic clinical trial
131490|NCT02264756|Antimicrobial stewardship
131491|NCT02264756|length of stay
131492|NCT02264756|stepped-wedge design
131493|NCT02264756|time-dependent bias
131494|NCT02264704|MS
131495|NCT02264704|Exercise
131496|NCT02264704|Training
131497|NCT02264704|Multiple sclerosis
131498|NCT02264704|Immune response
131499|NCT02264704|Neurotrophin
131500|NCT02264704|Cytokine
131501|NCT02264704|Fatigue
131502|NCT02264678|ATM deficient
131503|NCT02264652|Refractory
131504|NCT02264652|Partial
131505|NCT02264652|Epilepsy
131506|NCT02264626|acute respiratory failure
131507|NCT02264626|noninvasive ventilation
131508|NCT02264626|sedation
131509|NCT02264626|patient/ventilator interaction
131510|NCT02264600|Restless Legs Syndrome, Apelin, Oxidative Stress
131511|NCT02264535|Allergy
131512|NCT02264535|Skin test
131513|NCT02264535|Ginkgolides Meglumine Injection
131514|NCT02264509|Arterial Insufficiency
131515|NCT02264509|Human Immunodeficiency Virus
131516|NCT02264509|Atherosclerosis
131517|NCT02264509|Ankle-brachial index
131518|NCT02264509|HAART
131519|NCT02264496|Colorectal cancer
131520|NCT02264496|Exercise
131521|NCT02264496|CPEX
131522|NCT02264496|Exercise, Physical
131523|NCT02264496|Exercise, Aerobic
131524|NCT02264496|Surgery
131525|NCT02264483|Pneumonia in COPD exacerbation
131526|NCT02264470|Prediction
131527|NCT02264470|Falls
131528|NCT02264470|Stroke
131529|NCT02264457|Lenses, Intraocular
131530|NCT02264444|Cholecystectomy, visualization, single incision
131531|NCT02264431|Obesity
131532|NCT02264431|Obstructive Sleep Apnea
131533|NCT02264431|Sleep Habits
131534|NCT02264431|Bariatric Surgery
131535|NCT02264431|Cohort
131536|NCT02264418|Solid tumours
131537|NCT02264405|Autoimmune diseases
131538|NCT02264405|Systemic sclerosis
131539|NCT02264405|Autologous Hematopoietic stem cell transplant
131540|NCT02264379|Oligometastases
131541|NCT02264379|Prostate Cancer
131542|NCT02264379|Stereotactic Radiotherapy
131543|NCT02264379|Hypo fractionation
131544|NCT02264379|Normal fractionation
131545|NCT02264353|Obstructive
131546|NCT02264353|Sleep Apnea
131547|NCT02264353|Arousal threshold
131548|NCT02264353|Donepezil
131549|NCT02264340|Tension-type headache
131550|NCT02264340|relaxation techniques
131551|NCT02264340|physiotherapy
131552|NCT02264327|Motivational Interviewing
131553|NCT02264327|Evidence Based Practice
131554|NCT02264327|Online Simulation
131555|NCT02264327|Workforce development
131556|NCT02264327|Training
131557|NCT02264314|Aged
131558|NCT02264314|Hearing Aids
131559|NCT02264314|Rehabilitation
131560|NCT02264288|Peripheral Arterial Disease
131561|NCT02264288|Diabetic Foot
131562|NCT02264275|Aerobic Exercise
131563|NCT02264275|Exercise
131564|NCT02264275|Exergame
131565|NCT02264275|Behavior
131566|NCT02264275|Video Game
131567|NCT02264275|Inflammatory Bowel Disease
131568|NCT02264275|Children
131569|NCT02264275|Adolescents
131570|NCT02264275|Pediatric
131571|NCT02264275|Physical Fitness
131572|NCT02264223|Bioavailability
131573|NCT02264223|Isoflavones
131574|NCT02264223|Plasma
131575|NCT02264223|Human
131576|NCT02264223|Processing
131577|NCT02264223|Cross-over
131578|NCT02263950|Cancer
131579|NCT02263950|Malignant Neoplasm
131580|NCT02263950|Artemether
131581|NCT02263950|Sublingual
131582|NCT02263950|Neoplastic disease
131583|NCT02263950|Solid Tumour
131584|NCT02263950|Anti-cancer drug
131585|NCT02263950|Chemotherapy
131586|NCT02263950|LON002
131587|NCT02263885|Parkinson's Disease
131588|NCT02263885|ExAblate
131589|NCT02263885|MRgFUS
131590|NCT02263859|Obstructive Sleep Apnea
131591|NCT02263846|Breast cancer
131592|NCT02263846|Menopause
131593|NCT02263846|Estradiol
131594|NCT02263846|Follicle stimulating hormone
131595|NCT02263820|Acute Kidney Injury
131596|NCT02263820|Acute Renal Failure
131597|NCT02263807|Patella luxation
131598|NCT02263794|Bronchial Thermoplasty
131599|NCT02263755|CHB, cohort, fibroscan
131600|NCT02263742|Healthcare choice and outcomes
131601|NCT02263742|Peer-led whole health
131602|NCT02263742|Mental Illness
131603|NCT02263742|Peer Health Navigation
131604|NCT02263742|Health care Coordination
131605|NCT02263716|Physical Activity
131606|NCT02263716|Intensive Care
131607|NCT02263716|Activities of Daily Living
131608|NCT02263716|Delirium
131609|NCT02263716|Sepsis
131610|NCT02263716|Mechanical Ventilation
131611|NCT02263716|Critical Care
131612|NCT02263716|Critical Illness
131613|NCT02263716|Aging
131614|NCT02263716|Accelerometery
131615|NCT02263703|HPV vaccine, children, immunocompromised
131616|NCT02263677|diabetes
131617|NCT02263677|fatty liver
131618|NCT02263664|microcirculation
131619|NCT02263664|esophagectomy
131620|NCT02263664|side stream dark field
131621|NCT02263664|microcirculatory derangements
131622|NCT02263651|Breast cancer
131623|NCT02263651|Mastectomy
131624|NCT02263651|Seroma
131625|NCT02263651|Quilting suture
131626|NCT02263638|hereditary haemochromatosis
131627|NCT02263638|rheumatism
131628|NCT02263638|anakinra
131629|NCT02263625|Indication
131630|NCT02263625|Differences
131631|NCT02263612|Incisional Hernia
131632|NCT02263612|Complications
131633|NCT02263612|Long-term
131634|NCT02263586|Ironman
131635|NCT02263586|Triathlon
131636|NCT02263573|PEP'C-R
131637|NCT02263573|Endurance parameters
131638|NCT02263573|Maximal cardio-respiratory function
131639|NCT02263573|Older seniors
131640|NCT02263573|Over 70
131641|NCT02263547|teriflunomide
131642|NCT02263547|colestipol hcl
131643|NCT02263534|stress urinary incontinence
131644|NCT02263534|tension free vaginal tape
131645|NCT02263534|single incision minisling
131646|NCT02263534|midurethral sling
131647|NCT02263508|Talimogene Laherparepvec
131648|NCT02263508|pembrolizumab
131649|NCT02263508|KEYNOTE-034
131650|NCT02263508|MASTERKEY-265
131651|NCT02263495|HER2-Negative
131652|NCT02263482|muscle training
131653|NCT02263482|walking test
131654|NCT02263482|chronic heart failure
131655|NCT02263482|functional capacity
131656|NCT02263443|bowel preparation
131657|NCT02263443|gynecologic surgery
131658|NCT02263443|laparotomy
131659|NCT02263391|transmission
131660|NCT02263391|prevention
131661|NCT02263391|women
131662|NCT02263391|childbearing age
131663|NCT02263391|HIV testing
131664|NCT02263391|testing strategy
131665|NCT02263378|HPV, L-SIL
131666|NCT02263352|Diabetes, Periodontitis, Oxidative stress, Antioxidant
131667|NCT02263339|Exercise
131668|NCT02263339|MRI
131669|NCT02263313|Safety and efficacy
131670|NCT02263313|Combo stent
131671|NCT02263313|Late loss thrombosis
131672|NCT02263313|Late loss catch up
131673|NCT02263300|Fiberoptic Intubation
131674|NCT02263300|Medical student
131675|NCT02263300|Virtual larynx
131676|NCT02263300|Didactic Training
131677|NCT02263300|Medical Education
131678|NCT02263287|Alzheimer Disease
131679|NCT02263287|Lewy Body Disease
131680|NCT02263261|dermal matrix
131681|NCT02263235|Alzheimer disease (AD)
131682|NCT02263235|diagnosis biomarkers
131683|NCT02263235|cerebrospinal fluid (CSF)
131684|NCT02263235|targeted quantitative proteomics
131685|NCT02263235|mass spectrometry
131686|NCT02263235|stable isotope-labelled leucine
131687|NCT02263183|Metabolic risk
131688|NCT02263183|Abdominally overweight
131689|NCT02263131|Influenza
131690|NCT02263131|Influenza vaccine
131691|NCT02263131|Split influenza vaccine
131692|NCT02263131|Seasonal influenza vaccine
131693|NCT02263118|breastfeeding
131694|NCT02263118|rural
131695|NCT02263118|m-health
131696|NCT02263118|mHealth
131697|NCT02263118|Patojitos
131698|NCT02263118|Guatemala
131699|NCT02263118|exclusive breastfeeding
131700|NCT02263118|mobile
131701|NCT02263118|eHealth
131702|NCT02263118|e-health
131703|NCT02263105|recurrent high-grade gliomas
131704|NCT02263105|cisplatin (CDDP)
131705|NCT02263105|temozolomide (TMZ)
131706|NCT02263092|Cortical excitability
131707|NCT02263092|Plasticity
131708|NCT02263092|Healthy subjects
131709|NCT02263040|influenza vaccine
131710|NCT02263040|adult
131711|NCT02263040|immunogenicity
131712|NCT02263040|reactogenicity
131713|NCT02263027|influenza vaccine
131714|NCT02263027|adult
131715|NCT02263027|safety
131716|NCT02263027|reactogenicity
131717|NCT02263014|Breast Cancer
131718|NCT02263014|Contralateral Prophylactic Mastectomy
131719|NCT02263014|Questionnaires
131720|NCT02263014|Surveys
131721|NCT02263014|Psychosocial
131722|NCT02263001|Auricular therapy
131723|NCT02263001|Acupuncture
131724|NCT02263001|Acute, sub-acute pain
131725|NCT02263001|Auricular Acupuncture Needles
131726|NCT02262988|knee
131727|NCT02262988|joint replacement
131728|NCT02262988|total knee
131729|NCT02262988|cell therapy
131730|NCT02262975|Alzheimer's disease
131731|NCT02262936|Aged
131732|NCT02262936|Deamino Arginine Vasopressin
131733|NCT02262936|Fesoterodine
131734|NCT02262936|Randomized Controlled Trial
131735|NCT02262910|metastatic castration-resistant prostate cancer
131736|NCT02262910|CRPC
131737|NCT02262897|small cell lung cancer
131738|NCT02262897|chemotherapy
131739|NCT02262897|Nab-paclitaxel
131740|NCT02262871|Cystic fibrosis
131741|NCT02262871|High-flow nasal oxygen cannula
131742|NCT02262871|Non-invasive ventilation
131743|NCT02262871|Respiratory distress
131744|NCT02262871|Oxygen therapy
131745|NCT02262832|Diabetes
131746|NCT02262832|Leptin
131747|NCT02262832|Lipodystrophy
131748|NCT02262832|Hypertriglyceridemia
131749|NCT02262819|Skin Blister
131750|NCT02262819|Immune Response
131751|NCT02262819|Suction Device
131752|NCT02262819|Anti-Microbial
131753|NCT02262819|Killed Microbe
131754|NCT02262806|Lipodystrophy
131755|NCT02262806|Leptin
131756|NCT02262806|Hypertriglyceridemia
131757|NCT02262806|Diabetes
131758|NCT02262767|Phase 1, Randomized, Double Blind, Placebo-Controlled, Single-Dose Escalation, Safety, Tolerability, Pharmacokinetic, PF-06649751, Trimethobenzamide
131759|NCT02262728|Hepatitis C, Chronic
131760|NCT02262728|Simeprevir
131761|NCT02262728|Daclatasvir
131762|NCT02262728|Sofosbuvir
131763|NCT02262728|Decompensated Liver Disease
131764|NCT02262715|Oseltamivir
131765|NCT02262715|VX-787
131766|NCT02262689|GSK2256294
131767|NCT02262689|normoxic
131768|NCT02262689|hypoxic
131769|NCT02262689|Pulmonary artery systolic pressure (PASP)
131770|NCT02262676|Stroke prevention on Atrial Fibrillation
131771|NCT02262676|Prevention and Control
131772|NCT02262676|Stroke
131773|NCT02262507|Brain
131774|NCT02262507|Hearing
131775|NCT02262507|MTBI
131776|NCT02262468|retrospective analysis
131777|NCT02262455|Serous tumor
131778|NCT02262455|Granulosa tumor
131779|NCT02262455|Clear Cell tumor
131780|NCT02262455|Endometrial cancer
131781|NCT02262455|Advanced solid tumors
131782|NCT02262455|Adenocarcinoma
131783|NCT02262455|Prostate cancer
131784|NCT02262455|Head and Neck cancer
131785|NCT02262455|Lung cancer
131786|NCT02262455|Non-small cell lung cancer
131787|NCT02262455|Small cell lung cancer
131788|NCT02262455|Gastric cancer
131789|NCT02262455|Kidney cancer
131790|NCT02262455|Pancreatic cancer
131791|NCT02262455|Breast cancer
131792|NCT02262455|Colorectal cancer
131793|NCT02262455|Bladder cancer
131794|NCT02262455|Esophagus cancer
131795|NCT02262455|Liver cancer
131796|NCT02262455|Hepatobiliary cancer
131797|NCT02262455|Skin cancer
131798|NCT02262442|flexible bronchoscopy
131799|NCT02262442|anaesthetics
131800|NCT02262442|transcutaneous pCO2
131801|NCT02262442|capillary pCO2
131802|NCT02262442|special atomizing set
131803|NCT02262416|GnRH agonist
131804|NCT02262416|IVF
131805|NCT02262403|Hookworm
131806|NCT02262403|Helminths
131807|NCT02262403|Treg
131808|NCT02262403|Immune regulation
131809|NCT02262403|Vietnam
131810|NCT02262403|Allergic diseases
131811|NCT02262377|Group Medical Visits
131812|NCT02262377|Integrative Medicine
131813|NCT02262377|Chronic Pain
131814|NCT02262377|Depression
131815|NCT02262377|MBSR
131816|NCT02262377|Mindfulness Based Stress Reduction
131817|NCT02262377|Web based
131818|NCT02262377|Virtual Patient Advocate
131819|NCT02262377|Internet Based
131820|NCT02262351|Atrial Fibrillation
131821|NCT02262351|Screening
131822|NCT02262351|Family Practice
131823|NCT02262351|Novel screening technologies
131824|NCT02262325|Non-small cell
131825|NCT02262325|Lung Cancer
131826|NCT02262325|Chemoradiation
131827|NCT02262286|Brain Injury
131828|NCT02262273|women
131829|NCT02262273|platinum sensitive
131830|NCT02262273|recurrent
131831|NCT02262273|serous
131832|NCT02262273|ovarian cancer
131833|NCT02262273|BRCA
131834|NCT02262273|PARP
131835|NCT02262273|Olaparib
131836|NCT02262260|Diabetic macular edema, DME, ranibizumab, wait and extend
131837|NCT02262247|Transoral
131838|NCT02262247|Oropharynx
131839|NCT02262247|Hypopharynx
131840|NCT02262247|Endoscopic
131841|NCT02262247|TORS
131842|NCT02262247|Endoscopic Transoral
131843|NCT02262247|Larynx
131844|NCT02262234|Spinal cord injury
131845|NCT02262234|Chronic pain
131846|NCT02262234|Education
131847|NCT02262208|Glycemic variability, exercise, diabetes
131848|NCT02262182|Atelectasis, Respiratory physiotherapy, end expiratory pressure, EzPAP®, cardiac surgery
131849|NCT02262169|Non-Bleeding Peptic Ulcers, DLBS2411, Ulcer Healing
131850|NCT02262156|Cognitive Behavioral Therapy
131851|NCT02262156|Selective serotonin reuptake inhibitor
131852|NCT02262156|depression
131853|NCT02262156|epilepsy
131854|NCT02262130|Omalizumab
131855|NCT02262130|Efficacy
131856|NCT02262130|Safety
131857|NCT02262117|IVF, pregnancy, immune endometrial profile, personalization of treatment
131858|NCT02262104|Exercise
131859|NCT02262104|dementia
131860|NCT02262104|nursing home
131861|NCT02262078|Preserved Ejection Fraction
131862|NCT02262065|implant
131863|NCT02262065|allergy
131864|NCT02262065|particle
131865|NCT02262065|cytokine
131866|NCT02262052|Deep vein thrombosis
131867|NCT02262052|Diagnostic management
131868|NCT02262052|Recurrent
131869|NCT02262052|MRI
131870|NCT02262052|Ipsilateral
131871|NCT02262039|living
131872|NCT02262039|kidney
131873|NCT02262039|donors
131874|NCT02262013|Pediatric Obesity
131875|NCT02262013|Lifestyle Intervention
131876|NCT02262013|Family-based Intervention
131877|NCT02262013|Motivational Interviewing
131878|NCT02262000|Non Small Cell Lung Cancer
131879|NCT02262000|Surgically inoperable
131880|NCT02262000|Radiation Therapy
131881|NCT02261987|Autogenic drainage
131882|NCT02261987|Resistive inspiratory manoeuvre
131883|NCT02261987|Computerized respiratory sounds
131884|NCT02261987|Airway clearance techniques
131885|NCT02261987|Mucus clearances
131886|NCT02261974|Vaginal laxity
131887|NCT02261961|resistance exercise
131888|NCT02261961|Juven
131889|NCT02261961|exercise training
131890|NCT02261961|interleukin-1
131891|NCT02261961|insulin-like growth factor
131892|NCT02261948|Cardiac Failure
131893|NCT02261948|Severe Heart Failure
131894|NCT02261935|Family caregiver
131895|NCT02261935|Home care nursing practice
131896|NCT02261935|Palliative care
131897|NCT02261935|End of life care
131898|NCT02261935|Family caregiver quality of life
131899|NCT02261935|Family caregiver grief symptoms
131900|NCT02261935|Family caregiver burden
131901|NCT02261935|Family caregiver preparedness for caregiving
131902|NCT02261935|Family caregiver perceived social supports
131903|NCT02261935|Family caregiver health status
131904|NCT02261935|Family caregiver satisfaction with healthcare provided
131905|NCT02261909|Emergency Medicine
131906|NCT02261909|diagnosis
131907|NCT02261896|cyst
131908|NCT02261896|pancreatic cyst
131909|NCT02261896|EUS-FNA
131910|NCT02261896|antibiotic prophylaxis
131911|NCT02261883|PPHN
131912|NCT02261870|MRI, T2 quantification
131913|NCT02261857|Obstructive Sleep Apnea
131914|NCT02261857|Craniofacial Abnormalities
131915|NCT02261857|Pediatrics
131916|NCT02261857|Computer-Aided Design
131917|NCT02261857|Continuous Positive Airway Pressure
131918|NCT02261857|Three-Dimensional Printing
131919|NCT02261857|Additive Manufacturing
131920|NCT02261844|Hepatocellular carcinoma
131921|NCT02261844|Metastatic colorectal cancer
131922|NCT02261844|Metabolism
131923|NCT02261844|Hepatic function
131924|NCT02261831|bacterial
131925|NCT02261831|gut
131926|NCT02261831|type 2 diabetes.
131927|NCT02261831|16S rDNA gene
131928|NCT02261831|intestinal crypt
131929|NCT02261818|depression
131930|NCT02261818|aging
131931|NCT02261818|health services
131932|NCT02261792|Postural headache treatment
131933|NCT02261792|Spontaneous intracranial hypotension
131934|NCT02261792|Epidural blood patch
131935|NCT02261792|Trendelenburg position
131936|NCT02261792|Head-Down Tilt
131937|NCT02261792|Blood Patch, Epidural
131938|NCT02261753|epilepsy surgery, outcome, ketogenic diet, ortical dysplasia
131939|NCT02261740|Pelvic Pain
131940|NCT02261740|Genital Pain
131941|NCT02261727|COPD
131942|NCT02261727|Theophylline
131943|NCT02261727|Oral corticosteroids
131944|NCT02261727|COPD exacerbations
131945|NCT02261714|Pancreatic cancer, resected
131946|NCT02261714|Vaccine
131947|NCT02261714|KRAS
131948|NCT02261701|shoulder surgery
131949|NCT02261701|rotator cuff injury
131950|NCT02261701|rehabilitation
131951|NCT02261701|function
131952|NCT02261701|pain
131953|NCT02261701|quality of life
131954|NCT02261675|dexmedetomidine
131955|NCT02261675|sevoflurane
131956|NCT02261675|MAC bar
131957|NCT02261675|drug interaction
131958|NCT02261675|anesthesia
131959|NCT02261649|Cerebellar tumor
131960|NCT02261649|Non-malignant low-grade cerebellar astrocytomas
131961|NCT02261610|PCT algorithm
131962|NCT02261610|Antibiotic
131963|NCT02261610|Pulmonary embolism
131964|NCT02261597|insomnia, inflammation, stress
131965|NCT02261545|n-3 fatty acid
131966|NCT02261545|Sirt-1
131967|NCT02261545|AdipoR1
131968|NCT02261545|AdipoR2
131969|NCT02261545|MCP-1
131970|NCT02261545|Adiponectin
131971|NCT02261545|Resistin
131972|NCT02261545|T2DM
131973|NCT02261506|Intensive care
131974|NCT02261506|bacteremia
131975|NCT02261506|bloodstream infection
131976|NCT02261506|antimicrobial
131977|NCT02261506|mortality
131978|NCT02261506|antimicrobial stewardship
131979|NCT02261480|Parvovirus B19 Infection
131980|NCT02261454|postoperative ileus
131981|NCT02261454|gum chewing
131982|NCT02261454|postoperative care
131983|NCT02261454|abdominal surgery
131984|NCT02261454|child
131985|NCT02261441|Cardiovascular disease
131986|NCT02261441|Hypertension
131987|NCT02261441|Diabetes
131988|NCT02261441|Smoking
131989|NCT02261441|Hypercholesterolemia
131990|NCT02261441|Cardiovascular risk factor
131991|NCT02261428|Nasotracheal suction, tracheal access
131992|NCT02261415|blood transfusion
131993|NCT02261415|blood loss
131994|NCT02261415|feasibility
131995|NCT02261415|outcome
131996|NCT02261415|liver resection
131997|NCT02261402|Adherence
131998|NCT02261402|Morisky Medication Adherence Scale
131999|NCT02261402|Beliefs about Medicines Questionnaire
132000|NCT02261402|Medication Possession Ratio
132001|NCT02261402|Medication-Related Problems
132002|NCT02261402|Pharmacist
132003|NCT02261402|Pharmacist Intervention
132004|NCT02261402|Pharmacy
132005|NCT02261402|Pharmacy Service
132006|NCT02261402|Pharmacy Practice
132007|NCT02261402|Hypertension
132008|NCT02261402|Antihypertensive Agents
132009|NCT02261402|Anticoagulants
132010|NCT02261402|Statins
132011|NCT02261402|Dyslipidemia
132012|NCT02261389|breast cancer
132013|NCT02261389|follow-up
132014|NCT02261389|tumor markers
132015|NCT02261376|pharmacokinetics
132016|NCT02261337|Sarcopenia
132017|NCT02261324|Percutaneous coronary intervention
132018|NCT02261311|Breast
132019|NCT02261194|depression
132020|NCT02261194|age-related macular degeneration
132021|NCT02261194|self-care
132022|NCT02261194|self-help
132023|NCT02261181|head neck cancer XONRID radiation induced dermatitis
132024|NCT02261168|Circadian Rhythm
132025|NCT02261051|Palliative Care
132026|NCT02261051|Hospice
132027|NCT02261051|End of Life
132028|NCT02261051|Health Service Utilization
132029|NCT02261051|Quality of Life
132030|NCT02261038|total knee arthroplasty
132031|NCT02261038|total knee prothesis
132032|NCT02261038|X-Ray
132033|NCT02261038|Kanekasu radiographs
132034|NCT02261038|femoral component rotation
132035|NCT02261038|effects
132036|NCT02261025|aspirin
132037|NCT02260908|Trauma
132038|NCT02260908|Thromboprophylaxis
132039|NCT02260908|Intracranial haemorrhage
132040|NCT02260908|Deep vein thrombosis
132041|NCT02260856|RCT
132042|NCT02260856|Epiphysiodesis
132043|NCT02260856|Tantalum beads
132044|NCT02260856|Patient centered outcome data
132045|NCT02260856|Cost effective analysis
132046|NCT02260843|Insomnia
132047|NCT02260843|Sleeping
132048|NCT02260843|Quality
132049|NCT02260817|Prostate Cancer
132050|NCT02260817|11C Choline
132051|NCT02260817|PET Imaging
132052|NCT02260791|Rheumatoid
132053|NCT02260791|Arthritis
132054|NCT02260778|Learning Collaborative
132055|NCT02260778|Treat-to-Target
132056|NCT02260778|Arthritis, Rheumatoid
132057|NCT02260765|Treatment as Usual = TAU
132058|NCT02260726|femoroacetabular impingement
132059|NCT02260726|morphometry
132060|NCT02260726|dynamic
132061|NCT02260726|magnetic resonance imaging
132062|NCT02260726|ultrasound
132063|NCT02260726|screening
132064|NCT02260726|diagnosis
132065|NCT02260700|Healthy
132066|NCT02260700|Bioavailability
132067|NCT02260700|Alzheimer's Disease
132068|NCT02260700|JNJ-54861911
132069|NCT02260687|Aflibercept
132070|NCT02260687|Anti-VEGF
132071|NCT02260674|Alzheimer's Disease
132072|NCT02260674|JNJ-54861911
132073|NCT02260674|Placebo
132074|NCT02260661|AZD8835
132075|NCT02260661|Fulvestrant
132076|NCT02260661|Breast Cancer
132077|NCT02260661|PIK3CA Gene Mutation
132078|NCT02260622|Restenosis
132079|NCT02260622|Critical Limb Ischemia
132080|NCT02260622|Infrainguinal Percutaneous Transluminal Angioplasty
132081|NCT02260622|Rivaroxaban
132082|NCT02260622|Clopidogrel
132083|NCT02260609|Complex Wound
132084|NCT02260609|Diabetic Foot Ulcer
132085|NCT02260609|DFU
132086|NCT02260609|GrafixCORE
132087|NCT02260609|Exposed tendon
132088|NCT02260609|Exposed bone
132089|NCT02260609|Allograft tissue
132090|NCT02260570|tolcapone
132091|NCT02260570|mild traumatic brain injury
132092|NCT02260570|MRI
132093|NCT02260570|memory
132094|NCT02260557|Systemic Sclerosis
132095|NCT02260557|Raynaud's Phenomenon
132096|NCT02260531|Metastatic breast cancer and brain metastases
132097|NCT02260531|HER-2 Positive Breast Cancer
132098|NCT02260531|ER-Positive PR-Positive HER-2 Negative Breast Cancer
132099|NCT02260531|ER-Negative PR-Negative HER2-Negative Breast Cancer
132100|NCT02260518|Gestational weight gain
132101|NCT02260518|Lifestyle intervention
132102|NCT02260518|Pregnancy
132103|NCT02260518|Postpartum
132104|NCT02260518|Physical activity
132105|NCT02260518|Nutrition
132106|NCT02260505|Gastrointestinal Stromal Tumors
132107|NCT02260505|Non-metastatic
132108|NCT02260505|KIT +
132109|NCT02260505|Imatinib
132110|NCT02260505|Adjuvant treatment
132111|NCT02260505|High risk of recurrence
132112|NCT02260505|Tyrosine kinase inhibitor
132113|NCT02260505|Disease Free Survival
132114|NCT02260505|Overall survival
132115|NCT02260505|Time To Secondary Resistance
132116|NCT02260505|Safety profile
132117|NCT02260505|Quality of Life during treatment
132118|NCT02260479|skin disinfection
132119|NCT02260479|bacterial colonization
132120|NCT02260479|perioperative
132121|NCT02260479|chlorehexidine
132122|NCT02260466|Amyloidosis
132123|NCT02260466|echocardiography
132124|NCT02260466|magnetic resonance imaging
132125|NCT02260466|radionuclide imaging
132126|NCT02260427|elective surgery
132127|NCT02260427|undergoing general anesthesia
132128|NCT02260427|elderly adult patients
132129|NCT02260414|Endogenous Thrombin Potential
132130|NCT02260414|Lymphoma
132131|NCT02260414|Multiple Myeloma
132132|NCT02260414|tinzaparin
132133|NCT02260414|thrombin generation
132134|NCT02260414|Thromboplastin generation tests
132135|NCT02260388|CSPN
132136|NCT02260388|neuropathy
132137|NCT02260388|pain
132138|NCT02260388|pain management
132139|NCT02260375|Mesenchymal stromal cells; liver transplantation; tolerance.
132140|NCT02260349|Prostatic Neoplasms
132141|NCT02260349|Prostate cancer
132142|NCT02260349|surgical margins
132143|NCT02260349|indocyanine green
132144|NCT02260349|characterization
132145|NCT02260349|prostatectomy
132146|NCT02260349|peroperative
132147|NCT02260349|detection
132148|NCT02260297|Actigraphy
132149|NCT02260297|overweight and obese adults
132150|NCT02260297|sleep disorders
132151|NCT02260258|Cardiac Arrest, NMB, Neuromuscular Blockade, Rocuronium
132152|NCT02260219|Ahmed implant
132153|NCT02260219|Neovascular Glaucoma
132154|NCT02260219|Intraocular pressure
132155|NCT02260206|Pericardial Effusion
132156|NCT02260206|Colchicine
132157|NCT02260206|arrhythmia Recurrence
132158|NCT02260206|pericardiocentesis
132159|NCT02260193|anemia
132160|NCT02260193|end stage renal disease
132161|NCT02260193|chronic kidney disease
132162|NCT02260193|CKD
132163|NCT02260193|dialysis
132164|NCT02260193|chronic renal insufficiency
132165|NCT02260193|renal impairment
132166|NCT02260193|erythropoietin
132167|NCT02260193|kidney
132168|NCT02260193|oral anemia treatment
132169|NCT02260193|hemoglobin
132170|NCT02260193|hypoxia-inducible factor
132171|NCT02260193|HIF
132172|NCT02260193|hypoxia-inducible factor propyl-hydroxylase inhibitor
132173|NCT02260193|HIF-PHI
132174|NCT02260193|pharmacokinetics
132175|NCT02260154|Duspatalin
132176|NCT02260154|mebeverine
132177|NCT02260154|cholecystectomy
132178|NCT02260154|gastrointestinal spasm
132179|NCT02260154|abdominal pain
132180|NCT02260154|dyspepsia
132181|NCT02260154|antispasmodics
132182|NCT02260128|postoperative ileus
132183|NCT02260128|chewing gum
132184|NCT02259712|Women
132185|NCT02259712|Pelvic floor disorders
132186|NCT02259712|Urinary incontinence
132187|NCT02259712|Fecal incontinence
132188|NCT02259712|Physical Therapy Modalities
132189|NCT02259699|Ovarian Cancer
132190|NCT02259699|Intraperitoneal chemotherapy
132191|NCT02259699|Intravenous chemotherapy
132192|NCT02259699|decision making
132193|NCT02259686|Apelin
132194|NCT02259686|volunteers
132195|NCT02259660|obstructive sleep apnea
132196|NCT02259660|osa
132197|NCT02259660|breathing
132198|NCT02259660|snoring
132199|NCT02259660|respiratory
132200|NCT02259660|exercise
132201|NCT02259660|inspiratory muscle strength training
132202|NCT02259660|expiratory muscle strength training
132203|NCT02259634|Patient Navigation
132204|NCT02259634|Motivational Interviewing
132205|NCT02259634|Formerly Incarcerated
132206|NCT02259634|Health Education
132207|NCT02259634|Quality of Life
132208|NCT02259634|Healthcare Utilization
132209|NCT02259608|Trained innate immunity
132210|NCT02259608|Heterologous effects of BCG on immunity
132211|NCT02259595|Hearing Loss
132212|NCT02259595|Sensorineural Hearing Loss
132213|NCT02259595|Noise-Induced Hearing Loss
132214|NCT02259595|Antioxidant
132215|NCT02259595|NAC
132216|NCT02259595|N-acetylcysteine
132217|NCT02259595|HPN-07
132218|NCT02259582|Phase 2
132219|NCT02259582|histologically
132220|NCT02259582|confirmed
132221|NCT02259582|malignancy
132222|NCT02259582|metastatic
132223|NCT02259582|pemetrexed
132224|NCT02259582|carboplatin
132225|NCT02259582|carcinoma
132226|NCT02259582|non small cell lung
132227|NCT02259582|lung neoplasms
132228|NCT02259582|lung diseases
132229|NCT02259569|Gastric insufflation
132230|NCT02259569|I-gel
132231|NCT02259569|Peak airway pressure
132232|NCT02259569|Pressure-controlled ventilation
132233|NCT02259569|Volume-Controlled Ventilation
132234|NCT02259569|pediatric patient
132235|NCT02259543|gingival recession
132236|NCT02259543|soft tissue
132237|NCT02259543|root biomodification
132238|NCT02259543|root coverage
132239|NCT02259543|citric acid
132240|NCT02259543|tetracycline
132241|NCT02259517|ADHD
132242|NCT02259517|Intuniv
132243|NCT02259517|Non-stimulant
132244|NCT02259517|Guanfacine extended-release
132245|NCT02259517|Vyvanse
132246|NCT02259517|Stimulant
132247|NCT02259517|Lisdexamfetamine
132248|NCT02259504|aneurysms
132249|NCT02259491|Wound Healing
132250|NCT02259491|Honey
132251|NCT02259491|Skin Grafts
132252|NCT02259491|Free tissue transfer
132253|NCT02259478|Intravenous Immunoglobulin (IVIG)
132254|NCT02259478|Hemolysis
132255|NCT02259478|Transfusion Medicine
132256|NCT02259478|Pharmacovigilance
132257|NCT02259465|microbiota
132258|NCT02259465|FODMAP
132259|NCT02259465|oligofructose
132260|NCT02259465|Magnetic Resonance Imaging
132261|NCT02259465|Metabolomics
132262|NCT02259465|Diet
132263|NCT02259452|Radiation Therapy
132264|NCT02259413|Hemodialysis
132265|NCT02259413|End-stage renal disease
132266|NCT02259413|Exercise
132267|NCT02259413|Physical Function
132268|NCT02259400|NIV
132269|NCT02259400|NSIPPV
132270|NCT02259400|BiPAP
132271|NCT02259348|Hematological malignancies
132272|NCT02259348|Allogeneic hematopoietic cell transplant
132273|NCT02259348|Refractory hematologic malignancy
132274|NCT02259348|Relapsed hematologic malignancy
132275|NCT02259335|weaning from mechanical ventilation
132276|NCT02259335|extracorporeal CO2 removal
132277|NCT02259335|post-extubation failure
132278|NCT02259322|Bariatric surgery
132279|NCT02259322|Weight loss surgery
132280|NCT02259322|Behavioral weight loss treatment
132281|NCT02259322|Cognitive behavioral therapy
132282|NCT02259322|Behavioral treatment
132283|NCT02259322|Obesity
132284|NCT02259322|Morbid obesity
132285|NCT02259322|Binge eating
132286|NCT02259322|Binge eating disorder
132287|NCT02259322|Loss of control eating
132288|NCT02259322|Overeating
132289|NCT02259309|misoprostol
132290|NCT02259309|mucosal
132291|NCT02259309|cervical
132292|NCT02259309|immune
132293|NCT02259309|buccal
132294|NCT02259309|vaginal
132295|NCT02259283|achalasia
132296|NCT02259283|per oral endoscopic myotoymy
132297|NCT02259283|endoscopy
132298|NCT02259270|Acid suppressive therapy
132299|NCT02259270|Appropriateness
132300|NCT02259270|Long term treatment
132301|NCT02259270|Risk factors
132302|NCT02259270|Hospitalisation
132303|NCT02259270|Non-critically ill
132304|NCT02259270|Adult
132305|NCT02259257|carotid arteriosclerosis
132306|NCT02259257|contrast-enhanced ultrasound
132307|NCT02259257|neovascularization
132308|NCT02259257|quantitative analysis
132309|NCT02259257|3D/4D imaging
132310|NCT02259257|CEUS
132311|NCT02259257|Vasa vasorum
132312|NCT02259231|RTA 408
132313|NCT02259231|RTA 408 Capsules
132314|NCT02259231|Myeloid-derived suppressor cells (MDSDs)
132315|NCT02259231|iNOS
132316|NCT02259231|Melanoma
132317|NCT02259231|Checkpoint inhibitor
132318|NCT02259231|omaveloxolone
132319|NCT02259218|Biomarker
132320|NCT02259218|Radiation
132321|NCT02259205|platelet activating factor
132322|NCT02259205|inflammatory markers
132323|NCT02259205|yogurt
132324|NCT02259205|olive oil
132325|NCT02259205|platelet aggregation
132326|NCT02259205|oxidative stress
132327|NCT02259205|endothelial damage
132328|NCT02259205|bioactive lipids
132329|NCT02259192|deaf adult
132330|NCT02259192|single-sided
132331|NCT02259192|cochlear implant
132332|NCT02259179|Obesity
132333|NCT02259179|Overweight
132334|NCT02259179|Contrave
132335|NCT02259179|Antiobesity agents
132336|NCT02259179|Antiobesity drugs
132337|NCT02259179|Weight loss drug
132338|NCT02259179|Bioequivalence
132339|NCT02259179|Pharmacokinetic
132340|NCT02259153|Lipids
132341|NCT02259153|Non Cholesterol Sterols
132342|NCT02259153|Oxysterols
132343|NCT02259153|Cholesterol Metabolism
132344|NCT02259140|cerebral palsy
132345|NCT02259140|randomized controlled trial
132346|NCT02259140|hip dislocation
132347|NCT02259140|hip subluxation
132348|NCT02259140|patient centered outcomes
132349|NCT02259140|cost effectiveness analysis
132350|NCT02259088|DME, macular edema, vision impairment, Chinese, diabetes
132351|NCT02259075|Migraine with aura
132352|NCT02259075|Migraine without aura
132353|NCT02259075|Headache disorders
132354|NCT02259075|Botulinum Toxin Type A
132355|NCT02259075|Sphenopalatine Ganglion Block
132356|NCT02259075|Autonomic Nerve Block
132357|NCT02259036|child anxiety
132358|NCT02259036|worries
132359|NCT02259036|fears
132360|NCT02259036|talk therapy
132361|NCT02259023|Stress Perception
132362|NCT02259023|Discretionary Calories
132363|NCT02259023|Health
132364|NCT02258997|sickle cell disease
132365|NCT02258958|venous thromboembolism prophylaxis
132366|NCT02258958|deep venous thrombosis
132367|NCT02258958|pulmonary embolus
132368|NCT02258958|thoracic surgery
132369|NCT02258958|lung resection
132370|NCT02258958|incidence
132371|NCT02258945|Type 1 diabetes
132372|NCT02258945|CSII
132373|NCT02258945|Continuous subcutaneous insulin infusion
132374|NCT02258945|Insulin pump
132375|NCT02258945|Nutrition
132376|NCT02258945|Eating behaviours
132377|NCT02258945|Quality of life
132378|NCT02258945|Cardiometabolic risks
132379|NCT02258945|Liverpool
132380|NCT02258945|NHS
132381|NCT02258945|Metabolomics
132382|NCT02258945|Observational
132383|NCT02258945|Lipoproteins
132384|NCT02258945|Lipids
132385|NCT02258945|Food
132386|NCT02258945|Food diary
132387|NCT02258945|Cross-Sectional
132388|NCT02258932|Type 1 diabetes
132389|NCT02258932|CSII
132390|NCT02258932|Continuous subcutaneous insulin infusion
132391|NCT02258932|Insulin pump
132392|NCT02258932|Nutrition
132393|NCT02258932|Eating behaviours
132394|NCT02258932|Quality of life
132395|NCT02258932|Cardiometabolic risks
132396|NCT02258932|Liverpool
132397|NCT02258932|NHS
132398|NCT02258932|Metabolomics
132399|NCT02258932|Observational
132400|NCT02258932|Lipoproteins
132401|NCT02258932|Lipids
132402|NCT02258932|Food
132403|NCT02258932|Food diary
132404|NCT02258932|Longitudinal
132405|NCT02258919|Intracerebral hemorrhage
132406|NCT02258919|Decompressive craniectomy
132407|NCT02258919|Randomized controlled trial
132408|NCT02258919|Acute stroke
132409|NCT02258893|Nitrogen Dioxide
132410|NCT02258893|Parts per billion
132411|NCT02258880|Acute Stroke
132412|NCT02258880|Outcome Measures
132413|NCT02258880|Physical Performance
132414|NCT02258867|Uveitis
132415|NCT02258867|Behcet's Disease Uveitis
132416|NCT02258867|Behcet's Disease
132417|NCT02258854|Uveitis
132418|NCT02258854|Non-infectious Uveitis
132419|NCT02258854|Intermediate Uveitis
132420|NCT02258854|Posterior Uveitis
132421|NCT02258854|Panuveitis
132543|NCT02257983|hearing
132422|NCT02258854|Behçet's disease uveitis
132423|NCT02258841|domestic violence
132424|NCT02258841|mental health
132425|NCT02258841|safety planning
132426|NCT02258815|pediatric
132427|NCT02258815|haploidentical
132428|NCT02258815|stem cell transplantation
132429|NCT02258802|psychoeducational intervention
132430|NCT02258802|nutrition intervention
132431|NCT02258802|malnutrition
132432|NCT02258802|micronutrient deficiency
132433|NCT02258802|nutrition transition
132434|NCT02258789|Stroke, rehabilitation, spatial neglect
132435|NCT02258763|Pneumonia
132436|NCT02258763|Child
132437|NCT02258763|Outcome
132438|NCT02258763|Antibiotics
132439|NCT02258763|Etiology
132440|NCT02258737|Case management
132441|NCT02258737|psychiatric hospitalization
132442|NCT02258737|discharge
132443|NCT02258724|Adult
132444|NCT02258724|Registry
132445|NCT02258724|Grown-up congenital heart disease
132446|NCT02258711|Bipolar disorder
132447|NCT02258711|Psychoeducation
132448|NCT02258711|Smart-phone monitoring
132449|NCT02258685|Gut microbiota composition
132450|NCT02258672|Preoperative rehabilitation
132451|NCT02258672|Minimally invasive surgery
132452|NCT02258672|Functional capacity
132453|NCT02258646|Exercise
132454|NCT02258646|Rehabilitation
132455|NCT02258646|Telemedicine
132456|NCT02258646|Treatment Outcome
132457|NCT02258646|Costs and Cost Analysis
132458|NCT02258646|Physical Therapists
132459|NCT02258646|Adaptation, Psychological
132460|NCT02258568|Cigarette Smoking
132461|NCT02258568|Pregnancy
132462|NCT02258568|Postpartum smoking relapse
132463|NCT02258568|Romania
132464|NCT02258555|Chronic lymphocytic leukemia (CLL)
132465|NCT02258555|Follicular lymphoma (FL)
132466|NCT02258555|Small Lymphocytic Lymphoma (SLL)
132467|NCT02258555|Phosphatidylinositol 3 kinase (PI3K)
132468|NCT02258555|Marginal Zone Lymphoma (MZL)
132469|NCT02258542|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
132470|NCT02258529|Cancer
132471|NCT02258529|Indolent Non-Hodgkin Lymphoma
132472|NCT02258529|FL
132473|NCT02258529|SLL
132474|NCT02258503|Numerical scale
132475|NCT02258503|Pain in elderly patients admitted in emergency department
132476|NCT02258490|chronic myeloid leukemia
132477|NCT02258490|myelodysplastic syndrome
132478|NCT02258490|acute myeloid leukemia
132479|NCT02258490|CD34+ cell mobilization therapy
132480|NCT02258490|graft versus host disease
132481|NCT02258490|allogeneic hematopoietic stem cell
132482|NCT02258490|G-CSF
132483|NCT02258464|Breast Cancer
132484|NCT02258451|Breast Cancer
132485|NCT02258438|Sedentary Behavior
132486|NCT02258425|Homeless Women
132487|NCT02258425|Parolees
132488|NCT02258425|Probationers
132489|NCT02258425|Community Drug Treatment
132490|NCT02258425|Recidivism
132491|NCT02258412|antimicrobial
132492|NCT02258412|efficacy
132493|NCT02258412|hand
132494|NCT02258412|hygiene
132495|NCT02258412|bacteria
132496|NCT02258373|Diabetes Mellitus
132497|NCT02258373|Continuous Glucose Monitoring
132498|NCT02258360|Thromboelastometry
132499|NCT02258360|Haemostasis
132500|NCT02258360|Hypothermia
132501|NCT02258360|Heart Arrest
132502|NCT02258334|Influenza
132503|NCT02258334|Fluzone® Quadrivalent, Influenza Vaccine
132504|NCT02258334|Fluzone® Intradermal, Influenza Vaccine
132505|NCT02258334|Fluzone® High-Dose, Influenza Vaccine
132506|NCT02258295|Lateral Humeral Epicondylitis
132507|NCT02258295|Tendinitis
132508|NCT02258295|Tendinosis
132509|NCT02258295|Athletic Injuries
132510|NCT02258295|Elbow Joint
132511|NCT02258295|Sports Medicine
132512|NCT02258204|Cerebral Infarct
132513|NCT02258204|Thrombolysis
132514|NCT02258204|Tissue-type plasminogen activator
132515|NCT02258204|Neuroprotection
132516|NCT02258204|Anesthetic agent
132517|NCT02258204|Magnetic resonance imaging
132518|NCT02258191|NIV
132519|NCT02258191|COPD
132520|NCT02258191|telemonitoring
132521|NCT02258165|ovarian cancer
132522|NCT02258165|imaging
132523|NCT02258165|gated PET/CT scan
132524|NCT02258152|PDD
132525|NCT02258152|Parkinson's Disease Dementia
132526|NCT02258152|patients taking a cholinesterase inhibitor.
132527|NCT02258126|overweight children
132528|NCT02258126|hepatic fat
132529|NCT02258126|exercise
132530|NCT02258126|nutritional education program
132531|NCT02258126|cardiometabolic risk
132532|NCT02258087|Prostate, Cancer, Brachytherapy, HDR, LDR, monotherapy
132533|NCT02258048|Cirrhosis
132534|NCT02258035|vitamin D binding protein (DBP)
132535|NCT02258022|Wounds and Injuries
132536|NCT02258022|Sepsis
132537|NCT02257996|Psychoanalytic Psychotherapy
132538|NCT02257996|Telepsychology
132539|NCT02257996|Online Therapy
132540|NCT02257996|Web conferencing
132541|NCT02257996|RCT
132542|NCT02257996|HIPAA
132544|NCT02257983|noise
132545|NCT02257983|oxidative stress
132546|NCT02257970|Lymphedema
132547|NCT02257970|edema
132548|NCT02257970|swelling
132549|NCT02257931|infection
132550|NCT02257931|bacteria
132551|NCT02257931|gram-negative
132552|NCT02257931|HSCT
132553|NCT02257931|allogeneic
132554|NCT02257931|autologous
132555|NCT02257931|recipients, of all ages, for any indications
132556|NCT02257918|antibiotic,antimicrobial,AZD0914,Ceftriaxone,drug-resistant,sexually transmitted infection,urogenital gonorrhoea
132557|NCT02257905|AL Amyloidosis
132558|NCT02257905|Amyloidosis
132559|NCT02257905|allogeneic
132560|NCT02257905|HSCT
132561|NCT02257892|CTLA4
132562|NCT02257892|PI3KCD
132563|NCT02257892|MAG T1
132564|NCT02257892|Rare Immune Disorders
132565|NCT02257892|Genetic Testing
132566|NCT02257879|Midazolam
132567|NCT02257879|CYP3A
132568|NCT02257879|Loperamide
132569|NCT02257866|Autoimmunity
132570|NCT02257866|Adult and Pediatric Disease
132571|NCT02257866|Vasculitis
132572|NCT02257866|Rheumatic Disease
132573|NCT02257853|Caregiver Stress
132574|NCT02257853|Cancer Caregivers
132575|NCT02257853|Yoga-Based Stress Reduction Intervention
132576|NCT02257853|HSCT Caregivers
132577|NCT02257827|Hypofractionated schedule
132578|NCT02257827|Intensity Modulated Radiotherapy
132579|NCT02257827|Conformal radiotherapy
132580|NCT02257801|Memory
132581|NCT02257801|Cognition
132582|NCT02257801|Execute Function
132583|NCT02257801|Attention
132584|NCT02257801|Mood
132585|NCT02257762|Ready-to-use supplementary food (RUSF)
132586|NCT02257762|Lipid-based nutrient supplement (LNS)
132587|NCT02257762|Multiple micronutrients (MMN)
132588|NCT02257762|Complementary feeding
132589|NCT02257762|Home fortification
132590|NCT02257762|Efficacy/impact
132591|NCT02257762|Infant and young child feeding (IYCF)
132592|NCT02257762|Cambodia
132593|NCT02257762|Cluster randomised controlled trial
132594|NCT02257749|Concussion
132595|NCT02257749|Persistent Symptoms
132596|NCT02257749|Children
132597|NCT02257749|Exercise
132598|NCT02257749|Adolescents
132599|NCT02257749|Active Rehabilitation
132600|NCT02257749|Education
132601|NCT02257736|Prostatic neoplasms
132602|NCT02257736|JN56021927
132603|NCT02257736|ZYTIGA
132604|NCT02257736|Prednisone
132605|NCT02257736|Abiraterone acetate
132606|NCT02257736|Apalutamide
132607|NCT02257723|Inpatient care
132608|NCT02257723|Complementary and alternative medicine
132609|NCT02257723|Integrated medicine
132610|NCT02257710|national
132611|NCT02257710|Multicenter
132612|NCT02257710|Observational registry
132613|NCT02257710|Orsiro Drug Eluting Stent (DES)
132614|NCT02257710|Stenting
132615|NCT02257710|Treatment of coronary artery disease
132616|NCT02257710|Coronary revascularization
132617|NCT02257710|Coronary Intervention
132618|NCT02257710|STEMI
132619|NCT02257710|NSTEMI
132620|NCT02257710|Ischemia
132621|NCT02257710|Angina
132622|NCT02257710|Acute Myocardial Infarction (AMI)
132623|NCT02257710|Small Vessels
132624|NCT02257710|Chronic Total Occlusion
132625|NCT02257684|ALL
132626|NCT02257684|LBL
132627|NCT02257658|Men who have Sex with Men
132628|NCT02257658|HIV-positive
132629|NCT02257658|Syphilis
132630|NCT02257658|Contingency Management
132631|NCT02257619|Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
132632|NCT02257593|macronutrient
132633|NCT02257593|malnutrition
132634|NCT02257593|birth weight
132635|NCT02257593|protein leverage
132636|NCT02257580|E-Aminocaproic Acid
132637|NCT02257580|Bilateral Varus Rotational Osteotomy
132638|NCT02257580|Blood Loss and Transfusion
132639|NCT02257580|Complications
132640|NCT02257580|Safety
132641|NCT02257554|expectations
132642|NCT02257541|BGJ398
132643|NCT02257541|Imatinib Mesylate
132644|NCT02257541|14-140
132645|NCT02257502|aflibercept
132646|NCT02257502|iodiopathic choroidal neovascularization
132647|NCT02257502|young patient
132648|NCT02257476|carfilzomib
132649|NCT02257476|advanced solid malignancies
132650|NCT02257476|advanced solid cancers
132651|NCT02257476|prostate
132652|NCT02257476|bladder
132653|NCT02257476|colon
132654|NCT02257476|breast
132655|NCT02257476|lung
132656|NCT02257463|COPD
132657|NCT02257463|inspiratory muscle training
132658|NCT02257463|dyspnea
132659|NCT02257463|Quality of Life
132660|NCT02257450|Primary Aldosteronism
132661|NCT02257450|Hyperaldosteronism
132662|NCT02257437|Ready-to-use supplementary food (RUSF)
132663|NCT02257437|Lipid-based nutrient supplement (LNS)
132664|NCT02257437|Multiple micronutrients (MMN)
132665|NCT02257437|Complementary feeding
132666|NCT02257437|Home fortification
132667|NCT02257437|Acceptability
132668|NCT02257437|Infant and young child feeding (IYCF)
132669|NCT02257437|Cambodia
132670|NCT02257437|Cross-over studies
132671|NCT02257411|child
132672|NCT02257411|ear based
132673|NCT02257411|Proseal LMA
132674|NCT02257398|GSK2140944
132675|NCT02257398|TQTc
132676|NCT02257398|Moxifloxacin
132677|NCT02257385|indacaterol
132678|NCT02257385|efficacy
132679|NCT02257385|FEV1
132680|NCT02257385|ELLIPTA
132681|NCT02257385|non inferiority
132682|NCT02257385|vilanterol
132683|NCT02257385|COPD
132684|NCT02257385|safety
132685|NCT02257385|tiotropium
132686|NCT02257385|umeclidinium bromide
132687|NCT02257385|GSK573719
132688|NCT02257372|FEV1
132689|NCT02257372|DPI
132690|NCT02257372|ICS/LABA
132691|NCT02257372|UMEC
132692|NCT02257372|COPD
132693|NCT02257359|Epelsiban
132694|NCT02257359|Pharmacokinetics
132695|NCT02257359|Healthy Female Volunteers
132696|NCT02257359|Safety
132697|NCT02257359|Tolerability
132698|NCT02257359|Oxytocin
132699|NCT02257346|Pregnancy
132700|NCT02257346|Lidocaine
132701|NCT02257346|Quality
132702|NCT02257346|Recovery
132703|NCT02257333|Retinal Vein Occlusion
132704|NCT02257333|Atherosclerosis
132705|NCT02257333|Risk Factors
132706|NCT02257333|Major Adverse Cardiovascular Events
132707|NCT02257307|ROP
132708|NCT02257307|retinopathy
132709|NCT02257307|Referral warranted retinopathy
132710|NCT02257281|Sodium lauryl sulfate
132711|NCT02257281|Skin irritants
132712|NCT02257281|inflammation
132713|NCT02257281|therapeutic ultrasound
132714|NCT02257268|health behavior; risk factors;
132715|NCT02257255|cesarean section
132716|NCT02257255|pain, postoperative/diagnosis
132717|NCT02257255|pain measurement/methods
132718|NCT02257242|Bendamustine
132719|NCT02257242|Rituximab
132720|NCT02257242|Vincristine sulfate
132721|NCT02257242|Vincristine sulfate liposome injection
132722|NCT02257242|Phase I
132723|NCT02257242|Escalation With Overdose Control
132724|NCT02257229|Feet, deformity, correction, management, gait
132725|NCT02257203|Dietary sucrose
132726|NCT02257190|Glycemic control
132727|NCT02257190|Exercise
132728|NCT02257164|anterior cruciate ligament reconstruction
132729|NCT02257164|femoral nerve block
132730|NCT02257164|articular injection and obturator nerve block
132731|NCT02257151|Volunteers
132732|NCT02257138|Leukemia
132733|NCT02257138|Myeloproliferative Diseases
132734|NCT02257138|Acute Myeloid Leukemia
132735|NCT02257138|AML
132736|NCT02257138|Ruxolitinib
132737|NCT02257138|Jakafi
132738|NCT02257138|INCB018424
132739|NCT02257138|INC424
132740|NCT02257138|Decitabine
132741|NCT02257138|Dacogen
132742|NCT02257138|Post myeloproliferative neoplasm
132743|NCT02257138|Post MPN-AML
132744|NCT02257125|rehabilitation
132745|NCT02257125|virtual reality
132746|NCT02257125|stroke
132747|NCT02257125|upper extremity
132748|NCT02257125|arm
132749|NCT02257125|feedback
132750|NCT02257125|reward
132751|NCT02257060|Endocardial Ablation
132752|NCT02257060|Atrial Flutter
132753|NCT02257060|Cavotricuspid Isthmus
132754|NCT02256995|Pregnancy
132755|NCT02256995|Preeclampsia
132756|NCT02256995|Eclampsia
132757|NCT02256995|Proteinuria
132758|NCT02256982|unresectable intrahepatic cholangiocarcinoma
132759|NCT02256982|resectable intrahepatic cholangiocarcinoma
132760|NCT02256956|Pharmacogenetics of Amitriptyline
132761|NCT02256943|Pharmacogenetics of Amitriptyline
132762|NCT02256904|Alignment
132763|NCT02256904|Kinematic
132764|NCT02256904|knee
132765|NCT02256904|satisfaction
132766|NCT02256904|function
132767|NCT02256904|survivorship
132768|NCT02256891|Rotator cuff tear
132769|NCT02256891|Rotator cuff injury
132770|NCT02256891|Shoulder pain
132771|NCT02256891|Shoulder injury
132772|NCT02256865|Sleep Restriction
132773|NCT02256865|Insulin Resistance
132774|NCT02256865|Testosterone
132775|NCT02256865|Cortisol
132776|NCT02256839|Tuberculosis
132777|NCT02256839|TB
132778|NCT02256683|atrial fibrillation
132779|NCT02256683|atrial flutter
132780|NCT02256683|Atrial-Appendage Thrombus
132781|NCT02256683|Thrombus resolution
132782|NCT02256683|Dabigatran
132783|NCT02256683|Phenprocoumon
132784|NCT02256683|Transesophageal Echocardiography
132785|NCT02256670|Hormone Receptor Positive
132786|NCT02256618|neonatal encephalopathy
132787|NCT02256618|hypoxic-ischemic encephalopathy
132788|NCT02256618|newborn infants
132789|NCT02256618|neonates
132790|NCT02256618|umbilical cord blood cells
132791|NCT02256592|inflammation
132792|NCT02256592|microbiome
132793|NCT02256592|immune activation
132794|NCT02256592|fecal microbiota transplantation
132795|NCT02256592|dysbiosis
132796|NCT02256579|TDF:Tenofovir, Urine beta2microglobulin
132797|NCT02256566|cognitive training
132798|NCT02256566|depression
132799|NCT02256566|bipolar depression
132800|NCT02256566|anxiety
132801|NCT02256566|ptsd
132802|NCT02256566|generalized anxiety
132803|NCT02256566|social phobia
132804|NCT02256514|therapeutic vaccine
132805|NCT02256501|Dilated cardiomyopathy pediatric heart failure cell therapy
132806|NCT02256449|Coronary artery disease; angioplasty; bioresorbable device
132807|NCT02256436|P-D1
132808|NCT02256436|PD-1
132809|NCT02256436|PD1
132810|NCT02256436|P-DL1
132811|NCT02256436|PD-L1
132812|NCT02256436|PDL-1
132813|NCT02256436|PDL1
132814|NCT02256436|Bladder cancer
132815|NCT02256423|Ibuprofen
132816|NCT02256423|healthy volunteer study
132817|NCT02256423|pharmacokinetics
132818|NCT02256410|low back pain
132819|NCT02256410|chronic pain
132820|NCT02256410|sensitization
132821|NCT02256410|treatment
132822|NCT02256410|trigger points
132823|NCT02256397|Asthma
132824|NCT02256384|Respiration Rate
132825|NCT02256384|Respiratory Acoustic Monitor
132826|NCT02256384|postoperative
132827|NCT02256371|Neuropathic pain
132828|NCT02256371|Hypnosis
132829|NCT02256371|Relaxation
132830|NCT02256358|child, ketamine, midazolam
132831|NCT02256319|Deep brain stimulation
132832|NCT02256319|Dexmedetomidine
132833|NCT02256319|Propofol
132834|NCT02256293|Type 1 Diabetes
132835|NCT02256280|Neuromuscular blockade
132836|NCT02256280|Thoracic surgery
132837|NCT02256254|Oxidative stress
132838|NCT02256254|Simvastatin
132839|NCT02256228|Analgesia
132840|NCT02256228|Local infiltration analgesia
132841|NCT02256228|Pain, relief
132842|NCT02256228|Pain, Postoperative
132843|NCT02256228|Intra-peritoneal analgesia
132844|NCT02256228|Ropivacaine
132845|NCT02256228|Saline
132846|NCT02256228|Therapeutic Uses
132847|NCT02256228|Analgesics, Non-Narcotic
132848|NCT02256228|Analgesics
132849|NCT02256228|Opioids
132850|NCT02256228|Morphine
132851|NCT02256228|Pain
132852|NCT02256228|Postoperative Complications
132853|NCT02256228|Physiological Effects of Drugs
132854|NCT02256228|Anesthetics, Local
132855|NCT02256228|Anesthetic
132856|NCT02256228|Cytoreductive
132857|NCT02256228|Surgery
132858|NCT02256228|Cancer
132859|NCT02256215|Vitamin D
132860|NCT02256163|Thoracic Aortic Aneurysm (TAA)
132861|NCT02256163|gene
132862|NCT02256163|familial TAA
132863|NCT02256163|blood collection
132864|NCT02256137|Frailty phenotype
132865|NCT02256137|Physical fitness
132866|NCT02256137|Childhood cancer
132867|NCT02256137|Late onset of chronic health conditions
132868|NCT02256137|Physical frailty
132869|NCT02256124|Neurofibromatosis type 1
132870|NCT02256124|NF1
132871|NCT02256124|Cognition
132872|NCT02256124|Learning problems
132873|NCT02256124|Lamotrigine
132874|NCT02256124|Transcranial magnetic stimulation
132875|NCT02256124|TMS
132876|NCT02256098|Comparative Study
132877|NCT02256098|Knee Prosthesis
132878|NCT02256098|Prosthesis Design
132879|NCT02256098|Treatment Outcome
132880|NCT02256098|Follow-Up Studies
132881|NCT02256098|Arthroplasty, Replacement, Knee/methods
132882|NCT02256085|Dissociative
132883|NCT02256085|Dissociation
132884|NCT02256085|Depersonalization
132885|NCT02256085|Depersonalization Disorder
132886|NCT02256085|Transcranial Magnetic Stimulation
132887|NCT02256085|TMS
132888|NCT02256085|DPD
132889|NCT02256085|rTMS
132890|NCT02256085|Behavioral Symptoms
132891|NCT02256072|aging, geriatrics, aging in place, home services
132892|NCT02256033|Mild hepatic impairment
132893|NCT02256033|Healthy volunteer
132894|NCT02256033|Istradefylline
132895|NCT02256020|Wheel-chair dependent, music aerobic exercise, depression, insomnia
132896|NCT02256007|Videogames; stroke
132897|NCT02255981|macular, degeneration, acupuncture, visual acuity, OCT
132898|NCT02255968|Normal Volunteers
132899|NCT02255968|Safety
132900|NCT02255968|Pharmacokinetics
132901|NCT02255955|naproxen sodium codeine
132902|NCT02255955|paracetamol codeine
132903|NCT02255955|disk surgery
132904|NCT02255929|Benign Essential Tremor
132905|NCT02255929|Tremor
132906|NCT02255929|Neurologic Manifestations
132907|NCT02255929|Nervous System Diseases
132908|NCT02255929|Movement Disorders
132909|NCT02255929|Central Nervous System Diseases
132910|NCT02255916|oncology
132911|NCT02255916|psychology
132912|NCT02255916|cancer
132913|NCT02255916|music
132914|NCT02255916|sound-bed
132915|NCT02255877|Bi lateral knee surgery
132916|NCT02255877|uni compartmental
132917|NCT02255864|Stents
132918|NCT02255864|Angioplasty
132919|NCT02255864|Coronary Vessels
132920|NCT02255864|Coronary Artery Disease
132921|NCT02255864|Angina Pectoris
132922|NCT02255864|Myocardial Ischemia
132923|NCT02255864|Myocardial Infarction
132924|NCT02255864|Myocardial Revascularization
132925|NCT02255851|selected for TAVR by heart team consensus
132926|NCT02255851|treated with CE-Marked TAVR devices
132927|NCT02255799|traumatic brain injury
132928|NCT02255799|TBI
132929|NCT02255799|brain injury
132930|NCT02255799|memory
132931|NCT02255799|verbal memory deficits
132932|NCT02255799|memory problems
132933|NCT02255799|cognition
132934|NCT02255799|cognitive impairment
132935|NCT02255799|neuropsychiatric symptoms
132936|NCT02255799|donepezil
132937|NCT02255799|acetylcholinesterase inhibitor
132938|NCT02255786|Group Therapy
132939|NCT02255786|Parents
132940|NCT02255786|Autism
132941|NCT02255786|Quality of Life
132942|NCT02255773|Head and Neck Cancer
132943|NCT02255773|HNC
132944|NCT02255773|Moderate to severe fatigue
132945|NCT02255773|Computerized tasks
132946|NCT02255773|Questionnaires
132947|NCT02255773|Surveys
132948|NCT02255773|Disease-free adult males
132949|NCT02255773|Cancer survivors
132950|NCT02255760|MEDI3902, Safety, Pharmacokinetics
132951|NCT02255747|infants and children with constipation
132952|NCT02255734|Volunteers
132953|NCT02255695|posture
132954|NCT02255695|child
132955|NCT02255695|prevention
132956|NCT02255695|muscle strength
132957|NCT02255695|muscle stretching exercises
132958|NCT02255695|exercise therapy
132959|NCT02255695|disease management
132960|NCT02255695|musculoskeletal pain
132961|NCT02255695|adolescent
132962|NCT02255695|spinal curvatures
132963|NCT02255682|physical activity
132964|NCT02255682|statin therapy
132965|NCT02255682|diabetes mellitus
132966|NCT02255682|cardiovascular disease
132967|NCT02255682|Q10-supplementation
132968|NCT02255643|motor cortex stimulation
132969|NCT02255643|chronic neuropathic pain
132970|NCT02255630|salbutamol
132971|NCT02255630|exercise-induced bronchoconstriction
132972|NCT02255630|anaerobic power
132973|NCT02255604|Allergic Rhinitis
132974|NCT02255604|Allergen immunotherapy
132975|NCT02255591|Hip surgery anesthesia
132976|NCT02255591|Perioperative analgesia
132977|NCT02255565|Quillivant
132978|NCT02255552|DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
132979|NCT02255500|Total knee arthroplasty
132980|NCT02255487|surgical device
132981|NCT02255487|surgical irrigation device
132982|NCT02255487|surgical site infection prophylaxis
132983|NCT02255474|pediatrics
132984|NCT02255474|refractive error - myopia
132985|NCT02255474|contact lenses
132986|NCT02255474|intervention
132987|NCT02255435|RTA 408
132988|NCT02255435|RTA 408 Capsules
132989|NCT02255435|Oxidative Stress
132990|NCT02255435|Mitochondrial dysfunction
132991|NCT02255435|omaveloxolone
132992|NCT02255422|omaveloxolone
132993|NCT02255422|RTA 408 capsules
132994|NCT02255422|mitochondrial myopathies
132995|NCT02255383|Osteoarthritis
132996|NCT02255383|Rheumatoid Arthritis
132997|NCT02255383|Traumatic Arthritis
132998|NCT02255383|Polyarthritis
132999|NCT02255383|Total Knee Arthroplasty
133000|NCT02255370|Curcumin. Crohn's disease. Post-operative recurrence. Thiopurines . Rutgeerts endoscopic score
133001|NCT02255357|Oxytocin
133002|NCT02255357|Vasopressin
133003|NCT02255357|Cocaine
133004|NCT02255344|Acute Coronary Syndromes
133005|NCT02255344|Risk Model
133006|NCT02255344|National Registry
133007|NCT02255344|Comprehensive Care Program
133008|NCT02255344|Major Cardiovascular Events
133009|NCT02255331|Arthroplasty
133010|NCT02255331|Replacement
133011|NCT02255331|Hip
133012|NCT02255318|Taurolock®
133013|NCT02255318|infections related to chambers implantable catheter
133014|NCT02255318|patients with cancer receiving parenteral nutrition
133015|NCT02255305|CDI
133016|NCT02255305|C difficile
133017|NCT02255305|C diff
133018|NCT02255305|Clostridium difficile
133019|NCT02255253|Telmisartan
133020|NCT02255253|Hydrochlorothiazide
133021|NCT02255253|Efficacy
133022|NCT02255253|hypertension
133023|NCT02255253|high sodium intake
133024|NCT02255240|breast cancer
133025|NCT02255240|cancer
133026|NCT02255240|survivorship
133027|NCT02255240|cancer survivor
133028|NCT02255240|physical activity
133029|NCT02255240|video game
133030|NCT02255240|women
133031|NCT02255240|women's health
133032|NCT02255227|vaccination
133033|NCT02255227|randomized
133034|NCT02255227|anti-pneumococcal
133035|NCT02255227|Pneumo 23
133036|NCT02255227|Prevenar 13
133037|NCT02255227|Chronic Inflammatory Bowel Disease
133038|NCT02255188|Haemostas, prosthesis
133039|NCT02255175|Reproductive Affective Disorder
133040|NCT02255175|Depression
133041|NCT02255175|Perimenopause
133042|NCT02255175|Estrogen
133043|NCT02255175|Estradiol treatment
133044|NCT02255175|Mood Disorders
133045|NCT02255175|Estrogen Replacement Therapy
133046|NCT02255175|Sex Steroids
133047|NCT02255175|Depressive disorder
133048|NCT02255175|Mental Disorders
133049|NCT02255175|Estradiol
133050|NCT02255175|Hormones
133051|NCT02255175|Physiological effects of drugs
133052|NCT02255175|Reproductive Control Agents
133053|NCT02255162|Acute Myeloid Leukemia (AML)
133054|NCT02255162|Acute Myelocytic Leukemia
133055|NCT02255162|Acute Myelogenous Leukemia
133056|NCT02255162|Acute Granulocytic Leukemia
133057|NCT02255162|Acute Non-Lymphocytic Leukemia
133058|NCT02255136|Interleukin
133059|NCT02255136|Immunoglobulin
133060|NCT02255136|Homeopathy
133061|NCT02255136|Allergic Rhinitis
133062|NCT02255136|Asthma
133063|NCT02255110|Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
133064|NCT02255110|TH-302
133065|NCT02255110|Doxorubicin
133066|NCT02255110|Evofosfamide
133067|NCT02255097|PD-1
133068|NCT02255097|PD1
133069|NCT02255097|PD-L1
133070|NCT02255097|PDL1
133071|NCT02255084|Cervical cancer screening
133072|NCT02255084|High Risk Human papillomavirus Infection
133073|NCT02255084|vaginal self-sampling
133074|NCT02255084|pap smear
133075|NCT02255084|general practitioner
133076|NCT02255071|GERD
133077|NCT02255071|Neiguan
133078|NCT02255071|Acupressure
133079|NCT02255071|P6
133080|NCT02255032|uveitis
133081|NCT02255032|macular edema
133082|NCT02255032|UME
133083|NCT02255032|posterior uveitis
133084|NCT02255032|anterior uveitis
133085|NCT02255032|panuveitis
133086|NCT02255032|intermediate uveitis
133087|NCT02255032|noninfectious uveitis
133088|NCT02255032|triamcinolone acetonide
133089|NCT02255032|suprachoroidal space
133090|NCT02255032|injection
133091|NCT02255032|microneedle
133092|NCT02255032|intravitreal injection
133093|NCT02255032|corticosteroid
133094|NCT02255032|CME
133095|NCT02255032|choroid
133096|NCT02255032|retina
133097|NCT02255032|microinjection
133098|NCT02255032|SCS
133099|NCT02255006|volunteer
133100|NCT02255006|BMI(25 kg/m2)
133101|NCT02254980|Total hip arthroplasty
133102|NCT02254980|Cemented acetabular cup
133103|NCT02254980|Vitamin-E
133104|NCT02254980|Radiostereometry
133105|NCT02254980|Fixation of cemented acetabular component in total hip arthroplasty
133106|NCT02254967|Aged
133107|NCT02254967|Fidaxomicin
133108|NCT02254967|Clostridium Difficile
133109|NCT02254967|Vancomycin
133110|NCT02254954|glioblastoma
133111|NCT02254941|Metastatic Colon Cancer
133112|NCT02254941|Monoclonal antibodies
133113|NCT02254941|Chemotherapy
133114|NCT02254941|First line
133115|NCT02254928|poor ovarian response
133116|NCT02254928|controlled ovarian stimulation
133117|NCT02254928|randomised clinical trial
133118|NCT02254928|corifollitropin alfa
133119|NCT02254928|recombinant follicle-stimulating hormone (rFSH)
133120|NCT02254928|human menopausal gonadotropin (HMG)
133121|NCT02254915|Synergo
133122|NCT02254915|RITE
133123|NCT02254915|SHTC
133124|NCT02254915|Non Muscle Invasive Bladder Cancer
133125|NCT02254915|NMIBC
133126|NCT02254915|Superficial Bladder Cancer
133127|NCT02254915|Urothelial Cell Cancer
133128|NCT02254915|Transitional Cell Cancer
133129|NCT02254915|Mitomycin
133130|NCT02254902|sedentary lifestyle
133131|NCT02254902|physical activity
133132|NCT02254902|Somali women
133133|NCT02254902|prevention
133134|NCT02254876|Stroke
133135|NCT02254876|Hemiplegia
133136|NCT02254876|Painful shoulder Syndrome
133137|NCT02254876|NeuroMuscolar Taping
133138|NCT02254863|Adrenoleukodystrophy
133139|NCT02254863|Batten Disease
133140|NCT02254863|Hunter Syndrome
133141|NCT02254863|Krabbe
133142|NCT02254863|Metachromatic Leukodystrophy
133143|NCT02254863|ALD
133144|NCT02254863|MLD
133145|NCT02254863|PMD
133146|NCT02254850|Mesoglycan
133147|NCT02254850|Metabolic Syndrome
133148|NCT02254850|Flow Mediated Dilation
133149|NCT02254824|Xuezhikang
133150|NCT02254824|atorvastatin
133151|NCT02254785|poor prognosis
133152|NCT02254785|castrate-resistant prostate cancer
133153|NCT02254785|cabazitaxel
133154|NCT02254785|abiraterone
133155|NCT02254785|enzalutamide
133156|NCT02254733|CBSST
133157|NCT02254733|Schizoaffective Disorder
133158|NCT02254733|Psychotic Disorder
133159|NCT02254733|Cognitive Behavioral Therapy
133160|NCT02254733|Social Skills Training
133161|NCT02254733|Assertive Community Treatment
133162|NCT02254694|sagittal balance
133163|NCT02254694|posture
133164|NCT02254694|lumbar lordosis
133165|NCT02254694|high heeled shoes
133166|NCT02254681|low-dose radiotherapy
133167|NCT02254681|gemcitabine
133168|NCT02254681|cisplatin
133169|NCT02254681|cholangiocarcinoma
133170|NCT02254668|intima
133171|NCT02254668|thickness
133172|NCT02254668|transplantation
133173|NCT02254668|cardiology
133174|NCT02254668|immunosuppression
133175|NCT02254655|puerarin
133176|NCT02254655|rheumatoid arthritis
133177|NCT02254655|atherosclerosis
133178|NCT02254655|carotid intima-media thickness
133179|NCT02254629|Fecal microflora
133180|NCT02254629|IBS
133181|NCT02254629|Sequential treatment
133182|NCT02254629|Probiotic
133183|NCT02254629|Laxative
133184|NCT02254616|Stroke Rehabilitation
133185|NCT02254616|Hybrid therapy
133186|NCT02254616|Mirror Therapy
133187|NCT02254616|Transcranial Direct Current Stimulation
133188|NCT02254603|Obesity, ayuveda yoga exercise, acupuncture.
133189|NCT02254590|IEDL
133190|NCT02254590|irrigation endoscopic decompressive laminotomy
133191|NCT02254590|irrigation endoscopic decompression
133192|NCT02254590|minimally invasive spine surgery
133193|NCT02254590|endoscopic decompression
133194|NCT02254590|spinal stenosis
133195|NCT02254577|Infertility
133196|NCT02254577|Progesterone
133197|NCT02254577|ART
133198|NCT02254577|IVF
133199|NCT02254577|FET
133200|NCT02254577|FBT
133201|NCT02254577|Frozen Embryo Transfer
133202|NCT02254551|relapsed multiple myeloma
133203|NCT02254551|refractory multiple myeloma
133204|NCT02254551|LDE225
133205|NCT02254551|Sonidegib
133206|NCT02254551|bortezomib
133207|NCT02254551|smoothened (SMO) inhibitors
133208|NCT02254551|Velcade
133209|NCT02254473|Knee
133210|NCT02254473|Osteoarthritis
133211|NCT02254447|ATACAND
133212|NCT02254447|GW615775
133213|NCT02254447|Candesartan cilexetil
133214|NCT02254447|relative bio-availability
133215|NCT02254447|fasting
133216|NCT02254434|single-dose
133217|NCT02254434|fasting
133218|NCT02254434|eltrombopag 50 mg
133219|NCT02254434|pharmacokinetic
133220|NCT02254434|healthy volunteers
133221|NCT02254434|Open-label
133222|NCT02254421|Respiratory Syncytial Virus (RSV)
133223|NCT02254421|Antiviral
133224|NCT02254421|Hematopoietic Cell Transplant (HCT)
133225|NCT02254421|Lower respiratory tract infection
133226|NCT02254408|Respiratory Syncytial Virus (RSV)
133227|NCT02254408|Antiviral
133228|NCT02254408|Hematopoietic Cell Transplant (HCT)
133229|NCT02254408|Upper respiratory tract infection
133230|NCT02254382|diastolic heart failure
133231|NCT02254356|drug-eluting stent, paclitaxel-eluting stent, peripheral artery disease, peripheral vascular disease, superficial femoral artery, popliteal artery
133232|NCT02254343|stroke rehabilitation
133233|NCT02254343|robot-assisted therapy
133234|NCT02254330|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
133235|NCT02254317|Impaired Glucose Tolerance
133236|NCT02254317|Oral Glucose Tolerance Test
133237|NCT02254317|Grape Seed Extract
133238|NCT02254304|Relapsing multiple sclerosis
133239|NCT02254304|Clinically isolated syndrome
133240|NCT02254304|RMS
133241|NCT02254304|CIS
133242|NCT02254304|RebiSmart™
133243|NCT02254304|Rebif®
133244|NCT02254304|Interferon beta-1a
133245|NCT02254252|Slow coronary flow phenomenon
133246|NCT02254252|Angina pectoris
133247|NCT02254252|chest pain
133248|NCT02254252|nicroandil
133249|NCT02254213|Intra-individual stability, EEG
133250|NCT02254200|exercise
133251|NCT02254200|fat oxidation
133252|NCT02254200|indirect calorimetry
133253|NCT02254200|insulin sensitivity
133254|NCT02254200|weight management
133255|NCT02253810|Dysplasia, Congenital Hip
133256|NCT02253810|Osteotomy
133257|NCT02253810|Blood Transfusion
133258|NCT02253810|Tranexamic Acid
133259|NCT02253758|Magnetic Resonance Imaging
133260|NCT02253758|Electroencephalography
133261|NCT02253758|Conscious Sedation
133262|NCT02253758|Deep Sedation
133263|NCT02253758|Arousal
133264|NCT02253758|Consciousness
133265|NCT02253745|ADHD
133266|NCT02253745|Attention Deficit/ Hyperactivity Disorder
133267|NCT02253732|MicroRNAs
133268|NCT02253732|exercise
133269|NCT02253732|skeletal muscle
133270|NCT02253732|metabolism
133271|NCT02253719|cervical neoplasia
133272|NCT02253719|cervical cancer'
133273|NCT02253719|visual inspection acetic acid
133274|NCT02253719|cryotherapy
133275|NCT02253706|bronchoscopy
133276|NCT02253706|hypoxia
133277|NCT02253706|oxygen supplementation
133278|NCT02253706|safety
133279|NCT02253693|Hemophilia A
133280|NCT02253693|Hemophilic arthropathy
133281|NCT02253693|Accelerometry
133282|NCT02253680|Osteoarthritis
133283|NCT02253680|Total knee replacement
133284|NCT02253680|Enhanced recovery
133285|NCT02253680|Compression bandages
133286|NCT02253667|Palliative care
133287|NCT02253667|Lung disease
133288|NCT02253667|Acute Respiratory Distress Syndrome
133289|NCT02253667|High-flow oxygen nasal cannula
133290|NCT02253667|Dyspnoea
133291|NCT02253667|Opioids
133292|NCT02253654|Chronic Kidney Disease
133293|NCT02253654|Anemia
133294|NCT02253654|Hemodialysis
133295|NCT02253654|Red Blood Cell Transfusion
133296|NCT02253641|African American, Women
133297|NCT02253641|Weight Loss
133298|NCT02253628|Coffee
133299|NCT02253628|Gastrin
133300|NCT02253628|Alpha-amylase
133301|NCT02253628|Cortisol
133302|NCT02253628|Self-reported gastrointestinal symptoms
133303|NCT02253628|Self-reported stress
133304|NCT02253628|Blood pressure
133305|NCT02253615|Aging
133306|NCT02253615|Resistance training
133307|NCT02253615|Muscle strength
133308|NCT02253615|Functional performance
133309|NCT02253615|Postural balance
133310|NCT02253602|Esophageal Neoplasms
133311|NCT02253602|Lymph Nodes
133312|NCT02253602|USPIO
133313|NCT02253602|Magnetic Resonance Imaging
133314|NCT02253576|infant
133315|NCT02253576|bronchiolitis
133316|NCT02253576|hypertonic saline
133317|NCT02253537|Tuberculosis
133318|NCT02253537|TB
133319|NCT02253524|Metoclopramide
133320|NCT02253524|Dimenhydrinate
133321|NCT02253524|emergency medicine
133322|NCT02253511|Hepatocellular carcinoma
133323|NCT02253511|Hepotectomy
133324|NCT02253511|Recurrence-free survival
133325|NCT02253511|Overall survival
133326|NCT02253485|Mother-to-child transmission
133327|NCT02253446|Dysmenorrhea
133328|NCT02253446|Piroxicam
133329|NCT02253446|Diclofenac Sodium
133330|NCT02253446|Emergency department
133331|NCT02253433|asthma
133332|NCT02253433|environmental triggers
133333|NCT02253433|home-based intervention
133334|NCT02253433|asthma home visits
133335|NCT02253420|Phase 1
133336|NCT02253420|Advanced solid tumor
133337|NCT02253420|PI3 Kinase inhibitor
133338|NCT02253420|Drug-drug Interaction
133339|NCT02253394|Pulmonary Arterial Hypertension (PAH)
133340|NCT02253394|Ambrisentan
133341|NCT02253394|Spironolactone
133342|NCT02253394|Selective Endothelin A (ETA) inhibition
133343|NCT02253394|Aldosterone antagonism
133344|NCT02253394|Cardiac output (CO)
133345|NCT02253394|Right ventricular (RV) function
133346|NCT02253394|Heart failure
133347|NCT02253394|Quality of life
133348|NCT02253394|Pro-inflammatory cytokine
133349|NCT02253394|Interleukin-6 (IL-6)
133350|NCT02253394|Troponin-I
133351|NCT02253394|N-terminal pro-brain natriuretic peptide (NT-BNP)
133352|NCT02253394|Collagen metabolism
133353|NCT02253394|N-terminal procollagen type I
133354|NCT02253394|Collagen III
133355|NCT02253394|Echocardiography
133356|NCT02253394|WHO Functional Class
133357|NCT02253394|Cardiopulmonary Exercise Test with Innocor
133358|NCT02253394|Peak oxygen consumption (pVO2)
133359|NCT02253394|Liver function markers (AST/ALT)
133360|NCT02253394|Renal function markers (creatinine and potassium)
133361|NCT02253381|lateral decubitus position
133362|NCT02253381|hypotension
133363|NCT02253381|cesarean section
133364|NCT02253329|Neuromuscular electrical stimulation
133365|NCT02253329|Ageing
133366|NCT02253329|Protein ingestion
133367|NCT02253316|Multiple Myeloma
133368|NCT02253316|Autologous Stem Cell Transplantation
133369|NCT02253316|Ixazomib
133370|NCT02253316|Lenalidomide
133371|NCT02253316|Dexamethasone
133372|NCT02253277|CML, Ph+ ALL
133373|NCT02253251|Breast Cancer
133374|NCT02253251|Cancer Risk
133375|NCT02253251|Family Breast and Ovarian Cancer
133376|NCT02253251|Genetic Cancer Risk
133377|NCT02253251|Cancer Treatment
133378|NCT02253251|Familial multiple primary cancer risk
133379|NCT02253238|Head and Neck Cancer
133380|NCT02253238|Dehydration
133381|NCT02253238|Sensor-based home monitoring
133382|NCT02253238|Radiation therapy
133383|NCT02253238|RT
133384|NCT02253238|XRT
133385|NCT02253238|Oropharyngeal cancer
133386|NCT02253238|Hypopharyngeal cancer
133387|NCT02253238|Nasopharyngeal cancer
133388|NCT02253238|Salivary gland cancer
133389|NCT02253238|Oral cavity cancer
133390|NCT02253238|Questionnaires
133391|NCT02253238|Surveys
133392|NCT02253238|Quality of life
133393|NCT02253238|QOL
133394|NCT02253238|Phone calls
133395|NCT02253238|Self-monitoring devices
133396|NCT02253238|CYberinfrastructure for COmparative effectiveness REsearch
133397|NCT02253238|CYCORE
133398|NCT02253238|Emergency room visits
133399|NCT02253238|ER
133400|NCT02253238|Emergency room visits with hospitalization
133401|NCT02253238|ERHV
133402|NCT02253225|Bipolar Disorder
133403|NCT02253225|Major Depression
133404|NCT02253225|Rumination
133405|NCT02253225|Self Processing
133406|NCT02253173|VVA
133407|NCT02253173|Painful Sex
133408|NCT02253173|Postmenopausal
133409|NCT02253160|MNCs
133410|NCT02253160|Mononuclear Cells
133411|NCT02253160|Apheresis
133412|NCT02253160|Spectra Optia
133413|NCT02253134|Syncopal events
133414|NCT02253134|Palpitation events
133415|NCT02253121|COPD
133416|NCT02253121|acute exacerbation
133417|NCT02253121|glucocorticoid therapy
133418|NCT02253121|hyperglycemia
133419|NCT02253108|DES
133420|NCT02253108|Angina pectoris
133421|NCT02253108|Stent
133422|NCT02253108|Optical coherence tomography
133423|NCT02253108|Stent thrombosis
133424|NCT02253056|Fasting
133425|NCT02253056|Caloric Restriction
133426|NCT02253056|Focus is to observe effects of fasting in healthy volunteers.
133427|NCT02253043|Alzheimer's Disease
133428|NCT02253030|AMD
133429|NCT02253030|OCT
133430|NCT02253030|Angiography
133431|NCT02253030|Macular degeneration
133432|NCT02253017|Therapeutic strategies
133433|NCT02253017|Pediatrics
133434|NCT02253017|Cataract
133435|NCT02253017|Surgery
133436|NCT02253017|Intra-ocular lens
133437|NCT02252991|Breast cancer
133438|NCT02252991|Fatigue
133439|NCT02252991|Physical activity
133440|NCT02252965|Diabetes Mellitus, Type 2
133441|NCT02252965|Metformin XR
133442|NCT02252965|Metformin IR
133443|NCT02252952|Sugar Sweetened Beverages, Diet Beverages, ectopic fat, Functional MRI
133444|NCT02252926|Anesthetics, Local
133445|NCT02252926|Bupivacaine
133446|NCT02252926|Lozenge
133447|NCT02252926|Administration, Topical
133448|NCT02252900|Brain damages
133449|NCT02252900|MRI
133450|NCT02252900|infectious endocarditis
133451|NCT02252887|Gemcitabine,
133452|NCT02252887|Trastuzumab
133453|NCT02252887|Pertuzumab
133454|NCT02252887|14-124
133455|NCT02252874|balance
133456|NCT02252874|visual function
133457|NCT02252874|community-dwelling older adults
133458|NCT02252874|action video-game
133459|NCT02252822|Eating Disorders
133460|NCT02252822|Self Help
133461|NCT02252822|Anonymous CBT
133462|NCT02252809|inflammation endotoxin anti-TNF corticosteroids
133463|NCT02252796|Non-small Cell Lung Cancer
133464|NCT02252796|Radiotherapy Therapy
133465|NCT02252783|Coronary Artery Disease
133466|NCT02252783|Myocardial Ischemia
133467|NCT02252783|Coronary Disease
133468|NCT02252783|Heart Diseases
133469|NCT02252783|Cardiovascular Diseases
133470|NCT02252783|Arteriosclerosis
133471|NCT02252783|Arterial Occlusive Diseases
133472|NCT02252783|Vascular Diseases
133473|NCT02252770|ASA
133474|NCT02252770|ASLD
133475|NCT02252770|UCD
133476|NCT02252757|mHealth, hypertension, atherosclerotic disease, diabetes, obesity, metabolic syndrome, cardiotoxins, cardiomyopathy, dsypnea
133477|NCT02252744|dry eye disease
133478|NCT02252744|rheumatoid arthritis
133479|NCT02252731|Phase I
133480|NCT02252731|FG-4592
133481|NCT02252731|Warfarin
133482|NCT02252731|Pharmacokinetics
133483|NCT02252731|Pharmacodynamics
133484|NCT02252705|Pulmonary arterial hypertension
133485|NCT02252705|Mortality
133486|NCT02252705|Survival
133487|NCT02252692|Bioavailability
133488|NCT02252692|pharmacokinetics
133489|NCT02252692|enalapril
133490|NCT02252692|enalaprilat
133491|NCT02252679|Bone Turnover Markers
133492|NCT02252679|Calcium Isotopes
133493|NCT02252666|MS
133494|NCT02252666|balance
133495|NCT02252666|standing
133496|NCT02252666|control
133497|NCT02252666|movement
133498|NCT02252653|Cardiomyopathy
133499|NCT02252653|Heart Failure
133500|NCT02252653|FAC
133501|NCT02252653|Amyloid
133502|NCT02252653|Transthyretin (TTR)
133503|NCT02252640|Plasmodium Falciparum
133504|NCT02252640|Malaria
133505|NCT02252640|Vaccine
133506|NCT02252640|Plasmodium
133507|NCT02252640|Falciparum
133508|NCT02252614|naproxen sodium+codein, paracetamol+codein,lumbar disc surgery
133509|NCT02252601|Cystic Fibrosis
133510|NCT02252601|Hearing Loss
133511|NCT02252601|High Frequency Digit Triplet Test
133512|NCT02252588|COPD
133513|NCT02252588|Bacteria
133514|NCT02252562|Hand hygiene
133515|NCT02252562|Hospital acquired infections (HAI)
133516|NCT02252562|Healthcare acquired infections (HCAI)
133517|NCT02252536|alcohol use disorder
133518|NCT02252536|alcoholism
133519|NCT02252536|alcohol dependence
133520|NCT02252536|drinking alcohol
133521|NCT02252523|Feasibility study
133522|NCT02252497|hip arthroplasty
133523|NCT02252497|Tranexamic acid
133524|NCT02252497|randomized control trial
133525|NCT02252484|prostate cancer
133526|NCT02252484|prostatectomy
133527|NCT02252484|weight loss
133528|NCT02252484|prevent weight gain
133529|NCT02252471|alcohol-exposed pregnancy
133530|NCT02252471|nicotine-exposed pregnancy
133531|NCT02252471|tobacco-exposed pregnancy
133532|NCT02252471|alcohol
133533|NCT02252471|contraception
133534|NCT02252471|smoking
133535|NCT02252471|pregnancy
133536|NCT02252471|HIV
133537|NCT02252471|prevention
133538|NCT02252458|Opioid induced hyperalgesia
133539|NCT02252458|Fentanyl
133540|NCT02252432|KETAMINE
133541|NCT02252432|METHADONE
133542|NCT02252432|POSTOPERATIVE PAIN
133543|NCT02252432|OPIOID REQUIREMENTS
133544|NCT02252432|Length of hospital stay
133545|NCT02252432|Perioperative outcomes
133546|NCT02252419|Postoperative Period
133547|NCT02252419|Anesthesia, General
133548|NCT02252419|Intubation, Intratracheal
133549|NCT02252419|Dexamethasone
133550|NCT02252419|Acetaminophen
133551|NCT02252406|Stable Angina
133552|NCT02252406|Metabolic Syndrome
133553|NCT02252406|Women
133554|NCT02252406|Biomarkers
133555|NCT02252367|Phosphodiesterase 5 Inhibitors
133556|NCT02252367|BPH/LUTS
133557|NCT02252354|Drug therapy
133558|NCT02252341|smoking
133559|NCT02252341|inflammation
133560|NCT02252341|oxidative stress
133561|NCT02252341|NAC
133562|NCT02252341|treatment
133563|NCT02252328|Uveitis
133564|NCT02252328|Simvastatin
133565|NCT02252328|Visual acuity
133566|NCT02252328|Corticosteroids
133567|NCT02252328|Immunosuppression
133568|NCT02252302|Exercise-induced bronchoconstriction
133569|NCT02252302|Air pollution
133570|NCT02252302|Exercise
133571|NCT02252302|Inhaled beta-2-agonist
133572|NCT02252302|Cognitive Function
133573|NCT02252289|Asthma
133574|NCT02252289|children
133575|NCT02252289|fluctuation analysis
133576|NCT02252289|exacerbations
133577|NCT02252276|Manual therapy
133578|NCT02252276|proprioception
133579|NCT02252276|exercises
133580|NCT02252276|ankle sprain
133581|NCT02252250|rectal cancer
133582|NCT02252250|laparoscopic
133583|NCT02252250|NOTES
133584|NCT02252237|Prednisone
133585|NCT02252237|Prednisolone
133586|NCT02252237|Methylprednisolone
133587|NCT02252237|Glucocorticoids
133588|NCT02252237|pharmacokinetics
133589|NCT02252211|EphA2 positive cancer
133590|NCT02252211|DS-8895a monoclonal antibody
133591|NCT02252172|Multiple Myeloma
133592|NCT02252172|Daratumumab
133593|NCT02252172|JNJ-54767414
133594|NCT02252172|Lenalidomide
133595|NCT02252172|Dexamethasone
133596|NCT02252159|Polycythemia
133597|NCT02252159|Polycythemia Vera
133598|NCT02252159|Hematologic Diseases
133599|NCT02252159|Myeloproliferative Disorders
133600|NCT02252159|Bone Marrow Diseases
133601|NCT02252159|Hydroxyurea
133602|NCT02252159|Antineoplastic Agents
133603|NCT02252159|Therapeutic Uses
133604|NCT02252159|Pharmacologic Actions
133605|NCT02252159|Antisickling Agents
133606|NCT02252159|Hematologic Agents
133607|NCT02252159|Enzyme Inhibitors
133608|NCT02252159|Molecular Mechanisms of Pharmacological Action
133609|NCT02252159|Nucleic Acid Synthesis Inhibitors
133610|NCT02252146|DLBCL
133611|NCT02252146|MYD88 L265P
133612|NCT02252146|Lymphoma
133613|NCT02252146|Diffuse Large B Cell Lymphoma
133614|NCT02252146|Idera
133615|NCT02252146|IMO 8400
133616|NCT02252133|Contact lenses
133617|NCT02252133|Myopia
133618|NCT02252107|Decitabine
133619|NCT02252107|Hematopoietic stem cell transplantation (HSCT)
133620|NCT02252107|Conditioning
133621|NCT02252107|AML
133622|NCT02252081|metformin
133623|NCT02252081|cardiovascular disease
133624|NCT02252081|Chronic Kidney Disease
133625|NCT02252081|Metabolic Syndrome
133626|NCT02252042|Squamous cell carcinoma
133627|NCT02252042|Head and neck carcinoma
133628|NCT02252042|PD1
133629|NCT02252042|PD-1
133630|NCT02252042|PDL1
133631|NCT02252042|PD-L1
133632|NCT02252029|Rotavirus
133633|NCT02252029|Vaccine
133634|NCT02252003|Children
133635|NCT02252003|Pain
133636|NCT02252003|Pain scale evaluation
133637|NCT02251964|IMID
133638|NCT02251964|Interstitial Pneumonitis
133639|NCT02251964|rituximab
133640|NCT02251964|Immuno PET
133641|NCT02251964|PET/CT
133642|NCT02251951|Cancer
133643|NCT02251951|Stomach
133644|NCT02251951|Gastro-Esophageal Junction
133645|NCT02251951|Salvage treatment
133646|NCT02251951|Nab-paclitaxel
133647|NCT02251925|infertility froze emberyo transfer hormone replacement
133648|NCT02251912|Alcohol dependence
133649|NCT02251912|Alcohol withdrawal
133650|NCT02251912|Alcohol
133651|NCT02251912|Alcoholism
133652|NCT02251912|Oxytocin
133653|NCT02251912|OT
133654|NCT02251912|Intranasal administration
133655|NCT02251847|cholesterol
133656|NCT02251834|Healthcare Disparities
133657|NCT02251834|stroke
133658|NCT02251834|Hispanic Americans
133659|NCT02251834|community health worker
133660|NCT02251834|Mobile Health
133661|NCT02251834|Transient Ischemic Attack (TIA)
133662|NCT02251834|hypertension
133663|NCT02251834|Randomized Controlled Trial
133664|NCT02251834|high cholesterol
133665|NCT02251834|behavioral
133666|NCT02251834|exercise
133667|NCT02251834|diabetes
133668|NCT02251834|diet
133669|NCT02251808|Parkinson's Disease, Deep brain stimulation
133670|NCT02251743|ADHD
133671|NCT02251743|Attention-Deficit/Hyperactivity Disorder
133672|NCT02251743|neurofeedback
133673|NCT02251743|EEG
133674|NCT02251730|radiation therapy,Smoking pattern,head and neck cancer
133675|NCT02251717|renal transplant
133676|NCT02251704|Malaria
133677|NCT02251704|MTI
133678|NCT02251704|Surveillance study
133679|NCT02251704|Africa
133680|NCT02251704|RTSS, adjuvant
133681|NCT02251704|Epidemiology
133682|NCT02251691|Compliance
133683|NCT02251678|Plaque
133684|NCT02251678|Psoriasis
133685|NCT02251678|Biomarkers
133686|NCT02251678|CRP
133687|NCT02251678|αTNF
133688|NCT02251678|Interleuken
133689|NCT02251665|Acute ischemic stroke
133690|NCT02251665|Acute intracerebral hemorrhage
133691|NCT02251665|Transient ischemic attack
133692|NCT02251652|Actinic
133693|NCT02251639|Oral cancer
133694|NCT02251639|Pre-cancer
133695|NCT02251639|Widefield Fluorescence Imaging
133696|NCT02251639|VELScope
133697|NCT02251639|Point Spectroscopy System
133698|NCT02251639|Oral brush biopsy
133699|NCT02251639|Questionnaire
133700|NCT02251639|Survey
133701|NCT02251639|Diagnostic aid
133702|NCT02251639|Screening
133703|NCT02251626|MGH
133704|NCT02251626|Burn patient
133705|NCT02251626|Adult
133706|NCT02251626|CoQ10
133707|NCT02251626|Ubiquinol
133708|NCT02251600|Pediatric
133709|NCT02251600|Adolescent
133710|NCT02251600|Deflazacort
133711|NCT02251561|contact lenses
133712|NCT02251561|contact lens solution
133713|NCT02251561|corneal staining
133714|NCT02251561|fluorescein
133715|NCT02251548|Chronic lymphocytic leukemia
133716|NCT02251548|Leukemia
133717|NCT02251535|kinematic analysis
133718|NCT02251535|femoral rollback
133719|NCT02251535|mobile bearing
133720|NCT02251535|cruciate retaining Primary Total Knee Arthroplasty
133721|NCT02251496|Malnutrition
133722|NCT02251496|Chronic obstructive pulmonary disease
133723|NCT02251496|Nutrition Therapy
133724|NCT02251496|Oral Nutrition Supplement
133725|NCT02251496|Food
133726|NCT02251483|DIBS
133727|NCT02251483|SIBO
133728|NCT02251470|stroke
133729|NCT02251470|balance
133730|NCT02251470|exer-gaming
133731|NCT02251470|home-based exercises
133732|NCT02251470|Wii
133733|NCT02251470|postural balance
133734|NCT02251470|Nintendo
133735|NCT02251470|balance board
133736|NCT02251470|Wii-Fit
133737|NCT02251470|home
133738|NCT02251470|feasibility
133739|NCT02251457|Myotonia Congenita
133740|NCT02251457|ranolazine
133741|NCT02251457|Ohio State
133742|NCT02251457|Open Label
133743|NCT02251457|Paramyotonia Congenita
133744|NCT02251431|diabetes mellitus
133745|NCT02251431|chronic kidney disease
133746|NCT02251431|diastolic function
133747|NCT02251431|cardiac fibrosis
133748|NCT02251431|cardiac strain
133749|NCT02251431|cardiac biomarker
133750|NCT02251431|renal biomarker
133751|NCT02251418|Foot ulcer, diabetic
133752|NCT02251418|ESWT (Extracorporeal Shockwave Therapy)
133753|NCT02251418|Endocrinology
133754|NCT02251418|Dermatology
133755|NCT02251418|Wound healing
133756|NCT02251418|Ischemia
133757|NCT02251418|Neovascularization, Physiologic
133758|NCT02251418|Pain management
133759|NCT02251405|Melamine
133760|NCT02251405|Melamine tableware
133761|NCT02251392|chamomilla
133762|NCT02251392|matricaria
133763|NCT02251392|chamomile
133764|NCT02251392|chamomila
133765|NCT02251392|recutita
133766|NCT02251392|Breast Neoplasms
133767|NCT02251392|head and neck neoplasms
133768|NCT02251392|radiotherapy
133769|NCT02251366|Age-Related Macular Degeneration
133770|NCT02251353|breast cancer, intervention to metastasis
133771|NCT02251314|BRAF mutant melanoma
133772|NCT02251314|circulation tumour DNA
133773|NCT02251314|tumour heterogeneity
133774|NCT02251314|liquid biopsy
133775|NCT02251288|H7N9 pandemic, inactivated influenza vaccine (pIIV),MF59 adjuvant, live attenuated influenza vaccine (pLAIV)
133776|NCT02251275|Autosomal Dominant Polycystic Kidney Disease
133777|NCT02251262|Pacemaker
133778|NCT02251262|Endocarditis
133779|NCT02251262|18FDG-PET-CT
133780|NCT02251262|Diagnostic accuracy
133781|NCT02251262|Pacing or defibrillation lead
133782|NCT02251236|Stribild
133783|NCT02251236|Genvoya
133784|NCT02251236|elvitegravir
133785|NCT02251236|Cerebrospinal Fluid
133786|NCT02251236|HIV
133787|NCT02251093|mycosis
133788|NCT02251093|vulvovaginal candidiasis
133789|NCT02251093|lcr35
133790|NCT02251093|Lcr Regenerans®
133791|NCT02251080|adherence
133792|NCT02251080|internet-based
133793|NCT02251054|Overactive Bladder
133794|NCT02251054|Multimedia
133795|NCT02251054|Behavioral Therapy
133796|NCT02251041|Liver
133797|NCT02251041|Transplantation
133798|NCT02251041|Ischemia-reperfusion
133799|NCT02251041|Effectiveness
133800|NCT02251028|whiplash, prevention, pain, cognitive-behavioural therapy
133801|NCT02251015|Postural balance
133802|NCT02251015|Temporomandibular disorders
133803|NCT02251015|splints
133804|NCT02250989|Endothelial disfunction
133805|NCT02250989|Intercellular Adhesion Molecule-1
133806|NCT02250989|Vascular Cell Adhesion Molecule-1
133807|NCT02250989|8-epi-prostaglandin F2alpha
133808|NCT02250989|Nitric Oxide
133809|NCT02250989|Plasminogen Activator Inhibitor 1
133810|NCT02250989|Endothelin-1
133811|NCT02250989|Tumor Necrosis Factor-alpha
133812|NCT02250989|Glucose
133813|NCT02250989|Insulin
133814|NCT02250989|C-peptide
133815|NCT02250989|C-reactive protein
133816|NCT02250989|3-nitrotyrosine
133817|NCT02250963|Dobutamine Stress Echocardiography
133818|NCT02250963|Computed tomography coronary angiography
133819|NCT02250950|self-determination theory
133820|NCT02250950|motivational interviewing
133821|NCT02250950|exercise
133822|NCT02250950|physical activity
133823|NCT02250937|Acute Myeloid Leukemia
133824|NCT02250937|AML
133825|NCT02250937|Myelodysplastic Syndrome
133826|NCT02250937|MDS
133827|NCT02250937|Stem Cell Transplantation
133828|NCT02250937|Busulfan
133829|NCT02250937|Busulfex
133830|NCT02250937|Myleran
133831|NCT02250937|Fludarabine
133832|NCT02250937|Fludarabine Phosphate
133833|NCT02250937|Fludara
133834|NCT02250937|Cladribine
133835|NCT02250937|Leustatin
133836|NCT02250937|2-CdA
133837|NCT02250937|G-CSF
133838|NCT02250937|Filgrastim
133839|NCT02250937|Neupogen
133840|NCT02250937|Methotrexate
133841|NCT02250911|Caregivers of patients
133842|NCT02250911|CCC = Care for the Cancer Caregivers
133843|NCT02250911|MCP-C = Meaning-Centered Psychotherapy for Cancer Caregivers
133844|NCT02250911|14-208
133845|NCT02250898|Post Breast Surgery
133846|NCT02250898|Myofascial Massage
133847|NCT02250898|Pain
133848|NCT02250898|Mobility Limitations
133849|NCT02250885|Selinexor
133850|NCT02250885|phase 2
133851|NCT02250885|Gabrail
133852|NCT02250872|Cisplatin
133853|NCT02250872|Nephrotoxicity
133854|NCT02250872|Gemigliptin
133855|NCT02250872|DPP4 inhibitor
133856|NCT02250846|EGFR mutations
133857|NCT02250846|asymptomatic brain metastases
133858|NCT02250846|EGFR-TKI
133859|NCT02250846|Erlotinib
133860|NCT02250833|Hypertension
133861|NCT02250833|CKD-828
133862|NCT02250833|Telmisartan
133863|NCT02250833|S-amlodipine
133864|NCT02250833|Pharmacokinetic
133865|NCT02250820|Pediatric
133866|NCT02250820|Sedation
133867|NCT02250820|Transthoracic echocardiography
133868|NCT02250820|TTE
133869|NCT02250820|Dexmedetomidine
133870|NCT02250820|Pentobarbital
133871|NCT02250807|Chronic hepatitis C
133872|NCT02250807|Genotype 4 chronic hepatitis C
133873|NCT02250807|Simeprevir
133874|NCT02250807|Sofosbuvir
133875|NCT02250794|diabetes mellitus
133876|NCT02250794|inpatient management
133877|NCT02250794|metformin
133878|NCT02250794|sitagliptin
133879|NCT02250768|GM-CSF, repeated implantation failure
133880|NCT02250755|MRI perfusion
133881|NCT02250755|therapeutic response
133882|NCT02250755|chemotherapy
133883|NCT02250755|brain metastases
133884|NCT02250742|ultrasound imaging
133885|NCT02250742|acupuncture
133886|NCT02250742|back muscles
133887|NCT02250742|spine
133888|NCT02250742|muscle strength
133889|NCT02250729|anaphylaxis
133890|NCT02250729|pholcodine
133891|NCT02250729|neuromuscular blocking agents
133892|NCT02250716|CIN1
133893|NCT02250716|HIV seropositive women
133894|NCT02250716|Cryotherapy
133895|NCT02250703|Premedication
133896|NCT02250690|idiopathic PD
133897|NCT02250690|Hoehn and Yahr stage I to III
133898|NCT02250690|stable medication usage
133899|NCT02250690|age 40 to 80 years
133900|NCT02250690|absence of cognitive impairment
133901|NCT02250677|physical activity
133902|NCT02250677|Statin therapy
133903|NCT02250677|cardiovascular disease
133904|NCT02250677|diabetes mellitus
133905|NCT02250664|Biomarkers of exposure
133906|NCT02250664|Compensatory smoking
133907|NCT02250664|Nicotine dependence
133908|NCT02250664|Reduced nicotine cigarettes
133909|NCT02250664|Tobacco withdrawal
133910|NCT02250664|Women
133911|NCT02250664|Health disparities
133912|NCT02250664|Vulnerable populations
133913|NCT02250612|SYL040012
133914|NCT02250612|bamosiran
133915|NCT02250612|siRNA
133916|NCT02250612|RNAi
133917|NCT02250612|Glaucoma
133918|NCT02250612|Ocular hypertension
133919|NCT02250599|Metastatic Nasopharyngeal Carcinoma
133920|NCT02250599|treatment
133921|NCT02250586|concerned significant other
133922|NCT02250586|internet-delivered cognitive-behavioral therapy,
133923|NCT02250586|treatment-refusing problem gambler
133924|NCT02250534|Biomarkers of exposure
133925|NCT02250534|Compensatory smoking
133926|NCT02250534|Nicotine dependence
133927|NCT02250534|Reduced nicotine cigarettes
133928|NCT02250534|Tobacco withdrawal
133929|NCT02250534|Women
133930|NCT02250534|Health disparities
133931|NCT02250534|Vulnerable populations
133932|NCT02250521|BMI < 50 kg/m2
133933|NCT02250521|Mallampatti class: III-IV
133934|NCT02250521|Reduced mouth opening < 4 cm
133935|NCT02250521|Neck circumference > 40 cm for females and > 43 cm for males
133936|NCT02250521|Thyromental distance < 6 cm
133937|NCT02250521|Ratio of the patient's height to thyromental distance ≥ 23.5
133938|NCT02250521|Sternomental distance < 12 cm
133939|NCT02250443|Inclusion Body Myositis (IBM)
133940|NCT02250430|acne
133941|NCT02250365|stroke, acute
133942|NCT02250365|upper extremity
133943|NCT02250365|rehabilitation
133944|NCT02250365|electric stimulation therapy
133945|NCT02250339|Child Mental Health
133946|NCT02250339|Parenting
133947|NCT02250339|Family Issues
133948|NCT02250326|Cancer of the lung
133949|NCT02250326|lung neoplasm
133950|NCT02250326|NSCLC - non-small cell lung cancer
133951|NCT02250326|Nonsquamou
133952|NCT02250326|squamous
133953|NCT02250326|squamous NSCLC
133954|NCT02250326|Tumor
133955|NCT02250326|locally advanced NSCLC
133956|NCT02250326|metastatic NSCLC
133957|NCT02250326|advanced lung cancer
133958|NCT02250326|metastatic lung cancer
133959|NCT02250326|non-squamous NSCLC
133960|NCT02250326|lung cancer
133961|NCT02250326|Abraxane
133962|NCT02250326|ABI-007
133963|NCT02250326|nab-paclitaxel
133964|NCT02250326|albumin-bound paclitaxel
133965|NCT02250326|taxanes
133966|NCT02250326|CC-486
133967|NCT02250326|oral azacitidine
133968|NCT02250326|azacitidine
133969|NCT02250326|second line treatment of lung cancer
133970|NCT02250326|second line treatment
133971|NCT02250326|Celgene
133972|NCT02250326|abound.2L
133973|NCT02250326|third line treatment
133974|NCT02250326|durvalumab
133975|NCT02250326|immunotherapy
133976|NCT02250326|MEDI4736
133977|NCT02250313|prostate cancer
133978|NCT02250287|autosomal dominant polycystic kidney disease
133979|NCT02250287|magnetic resonance imaging parameters
133980|NCT02250287|magnetic resonance elastography
133981|NCT02250287|apparent diffusion coefficient
133982|NCT02250287|blood oxygen level determinations
133983|NCT02250287|diffusion weighted imaging
133984|NCT02250274|Immune response to influenza vaccine
133985|NCT02250274|PCR confirmed Influenza A virus
133986|NCT02250274|PCR confirmed Influenza B virus
133987|NCT02250261|walking
133988|NCT02250261|cycling
133989|NCT02250261|intervention
133990|NCT02250261|physical activity
133991|NCT02250261|environment
133992|NCT02250261|promotion
133993|NCT02250248|Degenerative disc disease
133994|NCT02250248|Lumbar spine
133995|NCT02250209|Gastric Cancer
133996|NCT02250209|HER2-positive
133997|NCT02250209|Trastuzumab
133998|NCT02250209|XELOX
133999|NCT02250209|Stage III
134000|NCT02250209|D2 Gastrectomy
134001|NCT02250196|Bowel preparation
134002|NCT02250196|Polyethylene glycol with ascorbic acid
134003|NCT02250196|Sodium picosulfate with magnesium citrate
134004|NCT02250183|Medihoney
134005|NCT02250183|Santyl
134006|NCT02250183|Burns
134007|NCT02250144|Patellofemoral pain syndrome
134008|NCT02250144|Feet orthoses
134009|NCT02250144|KOOS
134010|NCT02250131|cardiopulmonary bypass
134011|NCT02250118|pleural
134012|NCT02250118|effusion
134013|NCT02250118|breast
134014|NCT02250118|cancer
134015|NCT02250092|Cerebral Palsy
134016|NCT02250092|Hemiparesis
134017|NCT02250092|Stroke
134018|NCT02250092|Non-Invasive Brain Stimulation
134019|NCT02250092|Transcranial Direct Current Stimulation
134020|NCT02250092|Constraint-Induced Movement Therapy
134021|NCT02250092|Diffusion Tensor Imaging
134022|NCT02250092|Congenital Hemiparesis
134023|NCT02250053|stage II and stage III colon cancer survivors, who have completed curative treatment i.e., surgical resection and chemotherapy for their colon cancer
134024|NCT02250040|Stroke
134025|NCT02250040|Rehabilitation
134026|NCT02250040|Physiotherapy
134027|NCT02250040|Functional Recovery
134028|NCT02250027|acute bronchitis
134029|NCT02250027|acute exacerbations of chronic bronchitis
134030|NCT02250001|HCV
134031|NCT02249962|prospective
134032|NCT02249962|cohort
134033|NCT02249936|Volunteers
134034|NCT02249923|Pulmonary Arterial Hypertension (PAH)
134035|NCT02249923|Pulmonary Vascular Disease (PVD)
134036|NCT02249923|Registry
134037|NCT02249923|Pediatric
134038|NCT02249884|radiodermatitis
134039|NCT02249884|head and neck neoplasms
134040|NCT02249884|Breast Neoplasms
134041|NCT02249884|Urea
134042|NCT02249884|Matricaria
134043|NCT02249884|chamomilla
134044|NCT02249884|chamomile
134045|NCT02249858|cervical spine
134046|NCT02249858|OMT
134047|NCT02249858|HVLA
134048|NCT02249858|ultrasound
134049|NCT02249845|dehydration
134050|NCT02249845|children
134051|NCT02249845|gastroenteritis
134052|NCT02249832|stroke
134053|NCT02249832|CVA
134054|NCT02249832|cerebrovascular accident
134055|NCT02249832|cerebral stroke
134056|NCT02249832|robotic therapy
134057|NCT02249832|anklebot
134058|NCT02249832|physical therapy
134059|NCT02249819|stroke
134060|NCT02249819|aphasia
134061|NCT02249819|CVA
134062|NCT02249819|apraxia
134063|NCT02249819|cerebrovascular accident
134064|NCT02249819|cerebral stroke
134065|NCT02249819|speech therapy
134066|NCT02249819|aphasia therapy
134067|NCT02249819|non-invasive brain stimulation
134068|NCT02249819|transcranial direct current stimulation
134069|NCT02249819|tDCS
134070|NCT02249806|Pulmonary Hypertension
134071|NCT02249806|Chronic thromboembolic pulmonary hypertension
134072|NCT02249806|Pulmonary arterial hypertension
134073|NCT02249806|Outcome
134074|NCT02249793|circadian
134075|NCT02249793|oscillation
134076|NCT02249793|clock
134077|NCT02249793|human
134078|NCT02249793|social behavior
134079|NCT02249793|cell phone with internet access (so-called smartphone)
134080|NCT02249793|social sensing
134081|NCT02249793|behavioral feature
134082|NCT02249793|Ginger.io
134083|NCT02249793|blood pressure
134084|NCT02249793|metabolism
134085|NCT02249793|metabolomics
134086|NCT02249793|gut bacteria
134087|NCT02249793|microbiome
134088|NCT02249780|Parathyroid gland angiography
134089|NCT02249780|Parathyroid gland indocyanine green angiography
134090|NCT02249780|Parathyroid gland indocyanine green fluoroscopy
134091|NCT02249754|Nutrition education
134092|NCT02249754|Maternal counselling
134093|NCT02249754|Complementary feeding
134094|NCT02249754|Infant growth
134095|NCT02249754|Micronutrients
134096|NCT02249754|Tanzania
134097|NCT02249715|Parkinson
134098|NCT02249715|TMS
134099|NCT02249715|BNA
134100|NCT02249702|trabectedin
134101|NCT02249702|uterine leiomyosarcoma
134102|NCT02249676|Autologous mesenchymal stem cells
134103|NCT02249676|neuromyelitis optica
134104|NCT02249676|treatment
134105|NCT02249663|Bioequivalence
134106|NCT02249650|metastatic colorectal cancer
134107|NCT02249650|TSB-9-W1
134108|NCT02249624|Twin to twin transfusion syndrome
134109|NCT02249624|Developmental disabilities
134110|NCT02249624|Magnetic resonance imaging
134111|NCT02249611|Physical activity
134112|NCT02249611|mobile activity sensor and feedback system
134113|NCT02249611|self-management of health
134114|NCT02249572|Vestibular schwannoma
134115|NCT02249572|Radiosurgery
134116|NCT02249572|Neurosurgery
134117|NCT02249572|Randomized
134118|NCT02249533|Spot Light
134119|NCT02249533|High School RIO
134120|NCT02249533|Concussion
134121|NCT02249533|Injury Prevention
134122|NCT02249533|Football
134123|NCT02249533|Pop Warner
134124|NCT02249533|High School
134125|NCT02249533|Middle School
134126|NCT02249520|Magnetic Resonance Imaging
134127|NCT02249520|MRI
134128|NCT02249520|Positron Emission Tomography
134129|NCT02249520|PET
134130|NCT02249520|PET-MR
134131|NCT02249520|mMR
134132|NCT02249507|Resistant Hypertension
134133|NCT02249507|Aerobic Exercise
134134|NCT02249494|Nutritional Knowledge
134135|NCT02249494|Nutritional Counseling
134136|NCT02249481|Anaesthetic
134137|NCT02249481|total knee replacement
134138|NCT02249481|Femoral nerve catheter
134139|NCT02249481|Adductor canal catheter
134140|NCT02249377|Baker's Cyst
134141|NCT02249325|group B Streptococcus colonization
134142|NCT02249325|Probiotic
134143|NCT02249325|Pregnancy
134144|NCT02249299|ADHD,
134145|NCT02249299|Cannabis,
134146|NCT02249299|Sativex,
134147|NCT02249299|Endocannabinoid,
134148|NCT02249299|Cognition
134149|NCT02249286|Child Centered Counseling
134150|NCT02249286|Home based food production
134151|NCT02249286|Nutrition
134152|NCT02249286|Health
134153|NCT02249286|IYCF
134154|NCT02249260|Exercise, cardiac rehabilitation, quality of life
134155|NCT02249234|Scrotal pain
134156|NCT02249234|Botox
134157|NCT02249221|Influenza vaccine
134158|NCT02249221|Vaccination
134159|NCT02249221|cell-culture based influenza vaccine
134160|NCT02249221|cell culture derived influenza vaccine
134161|NCT02249221|CCIV
134162|NCT02249208|Breast Cancer
134163|NCT02249208|Sentinel Lymph Node
134164|NCT02249208|Neoadjuvant Chemotherapy
134165|NCT02249208|Clinically Node-Positive with biopsy-proven cN1
134166|NCT02249208|False-negative Rate
134167|NCT02249195|ECG loop recorder, pregnant women, arrhythmias
134168|NCT02249169|IBS
134169|NCT02249156|Health economics
134170|NCT02249156|Financial incentives
134171|NCT02249156|Health care spending
134172|NCT02249143|Continuous positive airway pressure
134173|NCT02249143|Prematurity
134174|NCT02249143|Respiratory distress syndrome
134175|NCT02249143|Bronchopulmonary dysplasia
134176|NCT02249078|Crohn's Disease
134177|NCT02249013|Ovarian Cancer
134178|NCT02248974|End-Stage Heart Failure
134179|NCT02248974|Left Ventricular Assist Device
134180|NCT02248974|Decision Aid
134181|NCT02248974|Medical Decision-Making
134182|NCT02248948|Omega-3
134183|NCT02248948|ADHD
134184|NCT02248948|Quality of Life
134185|NCT02248948|Inattention
134186|NCT02248948|Hyperactivity
134187|NCT02248935|Robotic Assisted Laparoscopic Sacrocolpopexy
134188|NCT02248935|Y Mesh
134189|NCT02248935|Pelvic Organ Prolapse
134190|NCT02248922|Cystic Fibrosis, Pseudomonas aeruginosa, Lung Clearance Index, Multiple Breath Washout, Inhaled Tobramycin, Inhaled Antibiotics.
134191|NCT02248909|COPD, Primary Care, Spirometry, Risk factors
134192|NCT02248870|femoral neck
134193|NCT02248857|UMS
134194|NCT02248857|medication schedule
134195|NCT02248857|diabetes
134196|NCT02248857|drug labeling
134197|NCT02248831|Dyspnea
134198|NCT02248831|Acute decompensated heart failure
134199|NCT02248831|Doppler ultrasound
134200|NCT02248831|Lung Doppler signals
134201|NCT02248805|colon cancer
134202|NCT02248805|colorectal carcinoma
134203|NCT02248805|stage IV colorectal cancer
134204|NCT02248779|Diabetes Risk
134205|NCT02248779|14-202
134206|NCT02248753|Atrial fibrillation
134207|NCT02248753|Electrical cardioversion
134208|NCT02248753|Pharmacological cardioversion
134209|NCT02248753|Rhythm control
134210|NCT02248753|Rate control
134211|NCT02248740|chronic venous insufficiency
134212|NCT02248740|varicose vein
134213|NCT02248740|small saphenous vein
134214|NCT02248701|Testosterone
134215|NCT02248701|Testosterone enanthate
134216|NCT02248701|Testosterone undecanoate
134217|NCT02248701|Testosterone 17 beta-cypionate
134218|NCT02248701|Methyltestosterone
134219|NCT02248701|Androgens
134220|NCT02248701|Hormones
134221|NCT02248701|Hormone Substitutes, and Hormone Antagonists
134222|NCT02248701|Physiologic Effects of Drugs
134223|NCT02248701|Pharmacologic Actions
134224|NCT02248701|Antineoplastic Agents, Hormonal
134225|NCT02248701|Antineoplastic Agents
134226|NCT02248701|Therapeutic Uses
134227|NCT02248701|Anabolic Agents
134228|NCT02248701|Testosterone Replacement Therapy
134229|NCT02248701|Dual Energy X ray Absorptiometry
134230|NCT02248701|Lean Tissue Mass
134231|NCT02248701|Body Composition
134232|NCT02248701|Lipid and Glucose profile
134233|NCT02248701|Muscle Strength
134234|NCT02248701|5-alpha Reductase
134235|NCT02248701|Muscle Mass
134236|NCT02248701|Bone Mineral Density
134237|NCT02248701|Adipose Tissue
134238|NCT02248701|Body Fat
134239|NCT02248701|Density, Bone
134240|NCT02248701|Bone Formation
134241|NCT02248701|Bone Resorption
134242|NCT02248701|Bone Density Conservation Agents
134243|NCT02248701|Magnetic Resonance Imaging
134244|NCT02248701|Muscle, Skeletal
134245|NCT02248701|Bone and Bones
134246|NCT02248701|Gait
134247|NCT02248701|Walking
134248|NCT02248701|Locomotion
134249|NCT02248701|Motor Activity
134250|NCT02248688|Bariatric Embolization
134251|NCT02248688|Gastric Artery Emboliziation
134252|NCT02248688|Left Gastric Artery Embolization
134253|NCT02248688|Morbid Obesity
134254|NCT02248688|Obesity
134255|NCT02248688|Weight Loss
134256|NCT02248688|Ghrelin
134257|NCT02248688|Embolization
134258|NCT02248675|sleep disorders
134259|NCT02248675|insomnia
134260|NCT02248675|suicidal ideation
134261|NCT02248675|Depression
134262|NCT02248675|Depressive disorders
134263|NCT02248675|PTSD
134264|NCT02248675|anxiety disorders
134265|NCT02248675|suicide
134266|NCT02248675|cognitive behavioral therapy
134267|NCT02248662|DCIS
134268|NCT02248662|PCORI
134269|NCT02248662|ductal carcinoma in situ
134270|NCT02248662|radiation
134271|NCT02248662|oncology
134272|NCT02248662|patient-centered
134273|NCT02248662|decision aid
134274|NCT02248662|decision-making
134275|NCT02248649|Parkinson's disease
134276|NCT02248649|Exercise therapy
134277|NCT02248649|Mild cognitive impairment
134278|NCT02248636|Alzheimer's disease
134279|NCT02248636|Cholinesterase inhibitor
134280|NCT02248636|Discontinuation
134281|NCT02248623|Anaesthesia
134282|NCT02248623|Isolated forearm test
134283|NCT02248623|Responsiveness
134284|NCT02248623|Laryngoscopy
134285|NCT02248623|Intubation
134286|NCT02248610|Pulmonary embolism
134287|NCT02248610|PE
134288|NCT02248610|Deep vein thrombosis
134289|NCT02248610|DVT
134290|NCT02248610|Rivaroxaban
134291|NCT02248610|Venous thromboembolism
134292|NCT02248610|Chronic thromboembolic pulmonary hypertension
134293|NCT02248610|Post thrombotic limb syndrome
134294|NCT02248610|Root cause analysis
134295|NCT02248571|breast cancer
134296|NCT02248571|advanced
134297|NCT02248571|inoperable
134298|NCT02248571|metastatic
134299|NCT02248571|HER2/neu-negative
134300|NCT02248571|hormone receptor positive
134301|NCT02248571|HR+
134302|NCT02248571|female
134303|NCT02248571|postmenopausal
134304|NCT02248558|Contest
134305|NCT02248558|Crowdsourcing
134306|NCT02248558|Innovation
134307|NCT02248558|Randomized controlled trial
134308|NCT02248558|China
134309|NCT02248558|Social entrepreneurship
134310|NCT02248545|Non-Celiac Wheat Sensitivity
134311|NCT02248545|Autoimmune diseases
134312|NCT02248545|Anti-nuclear antibodies
134313|NCT02248545|Celiac disease
134314|NCT02248545|Irritable bowel syndrome
134315|NCT02248519|Gastric cancer
134316|NCT02248519|Gastrectomy
134317|NCT02248519|Laparoscopy
134318|NCT02248506|Candidiasis
134319|NCT02248493|Pain, Postoperative
134320|NCT02248493|Paracetamol
134321|NCT02248493|Administration, Intravenous
134322|NCT02248493|Anti-Inflammatory Agents, Non-Steroidal
134323|NCT02248493|Child
134324|NCT02248493|Adolescent
134325|NCT02248467|Testosterone replacement therapy
134326|NCT02248428|multiple myeloma
134327|NCT02248428|Clarithromycin
134328|NCT02248428|CTd
134329|NCT02248415|Cardioplegic Solutions
134330|NCT02248415|Myocardial Ischemia
134331|NCT02248389|carcinoma, renal cell
134332|NCT02248389|ablation
134333|NCT02248389|laparoscopic surgery
134334|NCT02248389|high intensity focused ultrasound
134335|NCT02248376|Uterine synechiae Scraping surgery Natural miscarriage
134336|NCT02248363|Rehabilitation
134337|NCT02248363|Effectiveness
134338|NCT02248363|Determinants
134339|NCT02248363|Prediction
134340|NCT02248350|prostate cancer
134341|NCT02248350|physical activity
134342|NCT02248350|exercise
134343|NCT02248350|intervention
134344|NCT02248350|side effects
134345|NCT02248350|androgen deprivation therapy
134346|NCT02248337|Colon preparation; Colonoscopy; Inflammatory bowel disease
134347|NCT02248324|Age-related macular degeneration, genetic polymorphisms
134348|NCT02248298|Ablative fractional laser
134349|NCT02248298|Actinic keratosis
134350|NCT02248298|Efficacy
134351|NCT02248298|Photodynamic therapy
134352|NCT02248298|Short incubation time
134353|NCT02248285|multiplex
134354|NCT02248285|polymerase chain reaction
134355|NCT02248285|PCR
134356|NCT02248285|BioFire Diagnostics
134357|NCT02248285|Infectious gastroenteritis
134358|NCT02248285|Diarrheal disease
134359|NCT02248285|Emergency department
134360|NCT02248285|rapid diagnostics
134361|NCT02248285|FilmArray
134362|NCT02248285|FilmArray GI Panel
134363|NCT02248272|Polycystic ovary syndrome
134364|NCT02248272|Type 2 Diabetes
134365|NCT02248272|Hyperinsulinemia
134366|NCT02248272|Meal frequency
134367|NCT02248246|Hemostasis
134368|NCT02248246|Harmonic ACE®+7 Shears
134369|NCT02248246|Laparoscopic
134370|NCT02248246|Inferior mesenteric artery
134371|NCT02248246|Inferior mesenteric vein
134372|NCT02248246|Observational
134373|NCT02248233|nimodipine
134374|NCT02248233|acute massive cerebral infarction
134375|NCT02248233|Cerebral Infarction
134376|NCT02248233|optimal therapeutic time window
134377|NCT02248233|optimal dose
134378|NCT02248233|multi-center
134379|NCT02248194|Dysfunction uterine bleeding
134380|NCT02248194|Hysteroscopic endometrial ablation
134381|NCT02248194|Tactile endometrial ablation
134382|NCT02248194|Hysteroscopic difficulties
134383|NCT02248194|Quality of life
134384|NCT02248194|Satisfaction
134385|NCT02248090|Phase 1
134386|NCT02248090|Safety
134387|NCT02248090|Tolerability
134388|NCT02248090|Pharmacokinetics
134389|NCT02248090|Ascending Doses
134390|NCT02248090|Estrogen Receptor Positive
134391|NCT02248090|Her2 Negative
134392|NCT02248090|Advanced Breast Cancer
134393|NCT02248064|Chronic obstructive pulmonary disease
134394|NCT02248064|Long term oxygen therapy
134395|NCT02248064|Auto-titrating oxygen system
134396|NCT02248064|Intelligent oxygen therapy
134397|NCT02248064|Idiopathic pulmonary fibrosis
134398|NCT02248025|Fluid responsiveness
134399|NCT02248025|capillary refill time
134400|NCT02248025|microcirculation
134401|NCT02248025|circulatory failure
134402|NCT02248025|passive leg raising
134403|NCT02248012|Gastroenteropancreatic
134404|NCT02248012|Neuroendocrine carcinoma
134405|NCT02248012|Chemotherapy
134406|NCT02247999|Cervical Cancer
134407|NCT02247999|HIV/AIDS
134408|NCT02247999|HPV
134409|NCT02247999|Biomarkers
134410|NCT02247999|Screening
134411|NCT02247986|Conduct Disorder
134412|NCT02247986|Methylphenidate
134413|NCT02247986|Disruptive Behavior Disorders
134414|NCT02247947|CPR
134415|NCT02247934|Primary sclerosing cholangitis
134416|NCT02247934|PSC
134417|NCT02247921|caregiver delivered rehabilitation
134418|NCT02247921|nurse-organized service
134419|NCT02247921|disabled stroke patients
134420|NCT02247908|Cigarette smoking
134421|NCT02247908|Smoke
134422|NCT02247908|Smoking
134423|NCT02247908|Tobacco Use
134424|NCT02247895|ICU Acquired weakness
134425|NCT02247895|Critical illness
134426|NCT02247895|Mechanical ventilation
134427|NCT02247882|Osteoarthritis
134428|NCT02247882|Patient Education
134429|NCT02247882|Aquatic Exercise
134430|NCT02247882|kinetic
134431|NCT02247869|HL
134432|NCT02247869|Hodgkin Lymphoma
134433|NCT02247869|First line therapy
134434|NCT02247856|nebulizers,
134435|NCT02247856|noninvasive ventilation
134436|NCT02247856|COPD
134437|NCT02247856|scintigraphy,
134438|NCT02247856|aerosol
134439|NCT02247843|Sickle Cell Disease (SCD)
134440|NCT02247843|Gene Therapy
134441|NCT02247843|Lentiviral Vector
134442|NCT02247843|Beta Globin
134443|NCT02247830|Radiodermatitis
134444|NCT02247830|Head and neck neoplasms
134445|NCT02247830|Radiotherapy
134446|NCT02247830|Urea
134447|NCT02247830|Matricaria
134448|NCT02247830|Breast Neoplasms
134449|NCT02247830|chamomilla
134450|NCT02247830|chamomile
134451|NCT02247778|clavicle
134452|NCT02247778|surgical intervention
134453|NCT02247778|mini-incision
134454|NCT02247778|plate osteosynthesis
134455|NCT02247752|hepatitis
134456|NCT02247752|HBV
134457|NCT02247752|chronic hepatitis
134458|NCT02247752|HCC
134459|NCT02247752|cirrhosis
134460|NCT02247752|quantitative HBsAg
134461|NCT02247752|HBsAg inactive carriers
134462|NCT02247739|HAE
134463|NCT02247739|Hereditary Angioedema
134464|NCT02247739|Prophylaxis
134465|NCT02247726|RSV
134466|NCT02247726|Third Trimester
134467|NCT02247726|Maternal Immunization
134468|NCT02247713|PET
134469|NCT02247713|radiotherapy
134470|NCT02247713|international
134471|NCT02247713|NSCLC
134472|NCT02247713|overall survival
134473|NCT02247713|low and middle income countries
134474|NCT02247700|Pediatrics
134475|NCT02247700|ARDS
134476|NCT02247700|ARF
134477|NCT02247700|ALI
134478|NCT02247700|Respiratory
134479|NCT02247700|Mechanical ventilation
134480|NCT02247700|Ventilation
134481|NCT02247700|Noninvasive monitoring
134482|NCT02247700|electrical impedance tomography
134483|NCT02247700|EIT
134484|NCT02247687|HIV-1
134485|NCT02247687|antiretroviral treatment
134486|NCT02247687|viral load
134487|NCT02247674|Stroke, Cerebrovascular accident, Rehabilitation, Upper extremity
134488|NCT02247661|Femoral neck fracture,surgical approach, limp, abductor strenght, trochanteric pain
134489|NCT02247648|tramadol
134490|NCT02247648|shoulder surgery
134491|NCT02247648|pain
134492|NCT02247648|interscalen block
134493|NCT02247648|BUPRENORPHINE/HYDROMORPHONE [VA Drug Interaction]
134494|NCT02247635|Treatment adherence
134495|NCT02247635|Behavioral model of health care
134496|NCT02247635|Healthy lifestyle
134497|NCT02247635|Chronic metabolic diseases
134498|NCT02247635|Metabolic syndrome
134499|NCT02247635|Obesity
134500|NCT02247622|telomeres
134501|NCT02247622|PSC
134502|NCT02247609|B cell lymphoma
134503|NCT02247609|non-Hodgkin's lymphoma
134504|NCT02247609|Burkitt lymphoma
134505|NCT02247609|diffused large B cell lymphoma
134506|NCT02247609|B cell malignancy
134507|NCT02247596|Resveratrol
134508|NCT02247596|obesity
134509|NCT02247596|insulin resistance
134510|NCT02247596|energy expenditure
134511|NCT02247596|diabetes
134512|NCT02247570|Vestibular Rehabilitation
134513|NCT02247570|PTSD
134514|NCT02247570|DSM-IV
134515|NCT02247557|IC/PBS
134516|NCT02247557|VAS
134517|NCT02247557|Botulinum Toxin A
134518|NCT02247557|Lipotoxin
134519|NCT02247544|STS, leiomyosarcoma, liposarcoma, trabectedin
134520|NCT02247518|Male
134521|NCT02247518|Volunteers
134522|NCT02247492|International
134523|NCT02247492|Multicenter
134524|NCT02247492|Observational registry
134525|NCT02247492|Orsiro Drug Eluting Stent (DES)
134526|NCT02247492|Stenting
134527|NCT02247492|Treatment of coronary artery disease
134528|NCT02247492|Coronary revascularization
134529|NCT02247492|Percutaneous Coronary Intervention (PCI)
134530|NCT02247492|STEMI
134531|NCT02247492|NSTEMI
134532|NCT02247492|Ischemia
134533|NCT02247492|Angina
134534|NCT02247492|Acute Myocardial Infarction (AMI)
134535|NCT02247492|Small Vessels
134536|NCT02247492|Chronic Total Occlusion (CTO
134537|NCT02247466|Neuromuscular Blockade
134538|NCT02247466|Laparoscopy
134539|NCT02247453|lung cancer
134540|NCT02247453|clinical trial
134541|NCT02247453|screening
134542|NCT02247453|microRNA
134543|NCT02247453|biomarkers
134544|NCT02247440|HCV
134545|NCT02247440|HIV
134546|NCT02247440|Thailand
134547|NCT02247440|pegylated interferon
134548|NCT02247440|ribavirin
134549|NCT02247427|Heart failure
134550|NCT02247427|Super responder
134551|NCT02247414|Cirrhosis
134552|NCT02247414|Hypertension
134553|NCT02247414|venous thrombosis
134554|NCT02247414|Warfarin
134555|NCT02247414|Splenectomy
134556|NCT02247414|Azygoportal Disconnection
134557|NCT02247414|Laparoscopy
134558|NCT02247401|non-responder
134559|NCT02247401|Egypt
134560|NCT02247401|HCV
134561|NCT02247401|null responder
134562|NCT02247401|Genotype 4
134563|NCT02247401|compensated cirrhosis
134564|NCT02247401|naive
134565|NCT02247401|treatment experienced
134566|NCT02247401|hepatitis c
134567|NCT02247401|relapser
134568|NCT02247401|hepatitis infection
134569|NCT02247401|partial responder
134570|NCT02247401|Cirrhosis
134571|NCT02247388|Alcohol Dependence
134572|NCT02247388|Alcoholism
134573|NCT02247388|AB-CASI
134574|NCT02247388|Emergency Department
134575|NCT02247362|Safety
134576|NCT02247362|Immunogenicity
134577|NCT02247336|colorectal cancer
134578|NCT02247336|early detection of cancer
134579|NCT02247297|Pancreatic stone protein (PSP)
134580|NCT02247297|premature rupture of membranes (PPROM)
134581|NCT02247297|amniotic infection syndrome (AIS)
134582|NCT02247297|hemolysis, elevated liver enzymes, and low platelets (HELLP)
134583|NCT02247297|preeclampsia
134584|NCT02247297|pregnancy
134585|NCT02247271|peer coaches
134586|NCT02247245|CHF
134587|NCT02247245|AF
134588|NCT02247245|SR
134589|NCT02247245|HFREF
134590|NCT02247245|CRT
134591|NCT02247219|Health education
134592|NCT02247219|Health services research
134593|NCT02247206|Tourette Syndrome
134594|NCT02247206|tic disorders
134595|NCT02247206|behavior therapy
134596|NCT02247206|web-based videoconferencing
134597|NCT02247206|VoIP
134598|NCT02247193|Botulinum Toxin
134599|NCT02247193|Botox
134600|NCT02247193|Craniofacial deformity
134601|NCT02247167|obstructive sleep apnoea, oxidative stress, FMD
134602|NCT02247128|Transcatheter Aortic Valve Implantation (TAVI)
134603|NCT02247128|Transcatheter Aortic Valve Replacement (TAVR)
134604|NCT02247128|Aortic Valve Disease
134605|NCT02247128|Aortic Stenosis
134606|NCT02247128|Myocardial Infarction
134607|NCT02247128|Ischemic stroke
134608|NCT02247128|Bleeding
134609|NCT02247128|Thrombosis
134610|NCT02247128|Myocardial Ischemia
134611|NCT02247128|Heart Diseases
134612|NCT02247128|Cardiovascular Diseases
134613|NCT02247128|Vascular Diseases
134614|NCT02247128|Embolism and Thrombosis
134615|NCT02247128|Aspirin
134616|NCT02247128|Clopidogrel
134617|NCT02247128|Prasugrel
134618|NCT02247128|Ticagrelor
134619|NCT02247128|Antithrombotic treatment
134620|NCT02247128|Oral anticoagulation
134621|NCT02247128|Warfarin
134622|NCT02247128|Platelet Aggregation Inhibitors
134623|NCT02247128|Genetic Testing
134624|NCT02247128|Cytochrome P450 2C19 (CYP2C19)
134625|NCT02247128|Prostaglandin-endoperoxide synthase 2(PTGS2)
134626|NCT02247115|endoscopic ultrasound
134627|NCT02247115|endoscopic retrograde cholangiopancreatography
134628|NCT02247115|competency
134629|NCT02247089|Night Shift work
134630|NCT02247089|Stress
134631|NCT02247089|Autonomic nervous system (ANS)
134632|NCT02247089|Heart rate variability (HRV)
134633|NCT02247089|Pre-ejection period (PEP)
134634|NCT02247089|Inflammation
134635|NCT02247089|Pro-inflammatory cytokines
134636|NCT02247089|Massage Therapy
134637|NCT02247050|Costs and Cost Analysis
134638|NCT02247050|Professional Practice
134639|NCT02247050|Attitude of Health Personnel
134640|NCT02247050|Health Knowledge, Attitudes, and Practice
134641|NCT02247050|Decision Making
134642|NCT02247050|Practice Guidelines as Topic
134643|NCT02247050|Physician-Patient Relations
134644|NCT02247050|Physician's Role
134645|NCT02247050|Health Care
134646|NCT02247050|Quality of Health Care
134647|NCT02247050|Quality Assurance
134648|NCT02247050|Physicians, Primary Care
134649|NCT02247050|Evidence-Based Medicine
134650|NCT02247050|Evidence-Based Practice
134651|NCT02247050|Decision Support Systems, Clinical
134652|NCT02247050|Reminder Systems
134653|NCT02247050|Judgment
134654|NCT02247050|Cognition
134655|NCT02247050|Patient Care
134656|NCT02247050|Health Services Misuse
134657|NCT02247050|Unnecessary Procedures
134658|NCT02247050|Prescribing Patterns, Physician
134659|NCT02247050|Inappropriate Prescribing
134660|NCT02247050|Over Prescribing
134661|NCT02247050|Low Back Pain
134662|NCT02247050|Sinusitis
134663|NCT02247050|Infections, Upper Respiratory
134664|NCT02247050|Generalized Headache
134665|NCT02247050|Imaging, Diagnostic
134666|NCT02247050|Antibiotics
134667|NCT02247050|Humans
134668|NCT02247050|Overuse of Low-Value Services
134669|NCT02247050|Pragmatic Trial
134670|NCT02247050|Stepped Wedge Design
134671|NCT02247050|Cluster Randomized Trial
134672|NCT02247050|Choosing Wisely
134673|NCT02247037|Triple Negative Breast Cancer
134674|NCT02247037|Patient Derived Xenograft
134675|NCT02247037|Neoadjuvant Chemotherapy
134676|NCT02247037|Therapeutic Resistance
134677|NCT02247011|bone mineral density
134678|NCT02247011|25(OH)D
134679|NCT02246985|Processed foods
134680|NCT02246985|Carotenoids in plasma, urine and faeces
134681|NCT02246985|alpha-carotene
134682|NCT02246985|beta-carotene
134683|NCT02246985|Vitamin A
134684|NCT02246985|Lycopene
134685|NCT02246985|Gut absorption
134686|NCT02246985|Bread
134687|NCT02246985|Mayonnaise
134688|NCT02246985|Bioavailability
134689|NCT02246985|Fruits and Vegetables
134690|NCT02246985|Inflammation
134691|NCT02246985|Oxidative Stress
134692|NCT02246972|PTSD
134693|NCT02246972|Military sexual trauma
134694|NCT02246972|Veterans
134695|NCT02246972|Women in the military
134696|NCT02246972|Sexual assault
134697|NCT02246946|pleural effusion
134698|NCT02246946|chest tube
134699|NCT02246946|respiratory therapy
134700|NCT02246946|intermittent positive-pressure breathing
134701|NCT02246946|lung function
134702|NCT02246946|pulmonary complications
134703|NCT02246920|Bioequivalence
134704|NCT02246920|Allergic Rhinitis
134705|NCT02246907|Health related quality of life
134706|NCT02246855|Subjects
134707|NCT02246842|Volunteers
134708|NCT02246829|wet AMD, SD-OCT, intravitreal injection, central retinal thickness,
134709|NCT02246816|Short Bowel Syndrome
134710|NCT02246816|SBS
134711|NCT02246816|Chronic Diarrhea
134712|NCT02246816|Short Bowel
134713|NCT02246816|Short Gut
134714|NCT02246816|Short Gut Syndrome
134715|NCT02246816|Anti-Diarrheal
134716|NCT02246816|Opium Tincture
134717|NCT02246816|loperamide
134718|NCT02246816|diphenoxylate
134719|NCT02246816|ileostomies
134720|NCT02246816|tincture of opium
134721|NCT02246816|DTO
134722|NCT02246816|codeine
134723|NCT02246816|morphine
134724|NCT02246816|opiate
134725|NCT02246803|paroxysmal atrial fibrillation, CABG, pulmonary vein isolation
134726|NCT02246790|ablation, CABG
134727|NCT02246790|Long-standing persistent Atrial Fibrillation
134728|NCT02246777|Glaucoma
134729|NCT02246764|Ocular hypertension.
134730|NCT02246764|Glaucoma
134731|NCT02246751|postural control
134732|NCT02246751|Targeted Training
134733|NCT02246751|cerebral palsy
134734|NCT02246751|sensorimotor control
134735|NCT02246751|trunk segments
134736|NCT02246725|Colorectal Neoplasms
134737|NCT02246725|Depression
134738|NCT02246725|Intestinal Neoplasms
134739|NCT02246725|Gastrointestinal Neoplasms
134740|NCT02246725|Digestive System Neoplasms
134741|NCT02246725|Digestive System Diseases
134742|NCT02246725|Gastrointestinal Diseases
134743|NCT02246725|Intestinal Diseases
134744|NCT02246725|Palliative chemotherapy
134745|NCT02246725|Palliative care
134746|NCT02246725|Palliative treatment
134747|NCT02246725|Quality of life
134748|NCT02246725|Quality of life for relatives
134749|NCT02246725|Survival
134750|NCT02246712|tramadol
134751|NCT02246712|pharmacokinetics
134752|NCT02246712|enantiomers
134753|NCT02246712|metabolism
134754|NCT02246712|diabetes
134755|NCT02246699|obesity
134756|NCT02246699|overweight
134757|NCT02246699|chitosan
134758|NCT02246699|fungal chitosan
134759|NCT02246699|weight management
134760|NCT02246686|Iberogast N
134761|NCT02246686|Mild to moderate ulcerative colitis
134762|NCT02246686|add-on therapy
134763|NCT02246686|efficacy
134764|NCT02246660|Peripheral Artery Disease
134765|NCT02246660|Peripheral Arterial Disease
134766|NCT02246660|PAD
134767|NCT02246634|Colorectal Neoplasms
134768|NCT02246634|Neoplasm Metastases
134769|NCT02246634|Magnetic Resonance Imaging
134770|NCT02246634|Diffusion Weighted MRI
134771|NCT02246634|Hepatic Neoplasms
134772|NCT02246634|Tumors
134773|NCT02246634|Neoplasms, Rectal
134774|NCT02246621|MONARCH 3
134775|NCT02246595|Sepsis
134776|NCT02246595|Severe Sepsis
134777|NCT02246595|Septic Shock
134778|NCT02246595|Systemic Inflammatory Response Syndrome
134779|NCT02246595|Organ Dysfunction
134780|NCT02246582|Type 1 Diabetes
134781|NCT02246582|Type 2 Diabetes
134782|NCT02246582|Enlite 3
134783|NCT02246569|Chronic obstructive pulmonary disease (COPD)
134784|NCT02246569|endoscopic lung volume reduction
134785|NCT02246569|RePneu®Coils
134786|NCT02246569|physical capacity
134787|NCT02246569|quality of life
134788|NCT02246556|Amblyopia
134789|NCT02246556|Dichoptic
134790|NCT02246556|Virtual reality
134791|NCT02246556|Stereopsis
134792|NCT02246556|Stereo vision
134793|NCT02246556|Visual acuity
134794|NCT02246556|Binocular
134795|NCT02246543|Appetite
134796|NCT02246543|Gut Hormones
134797|NCT02246543|Protein
134798|NCT02246543|Energy Density
134799|NCT02246543|Gastric Emptying
134800|NCT02246465|Hypertrophic scar
134801|NCT02246465|Cicatrix
134802|NCT02246465|Scar prevention
134803|NCT02246465|Scar revision
134804|NCT02246452|Children and adolescents
134805|NCT02246452|Cancer
134806|NCT02246452|Malnutrition
134807|NCT02246452|BMI percentile
134808|NCT02246452|BMI-SDS
134809|NCT02246439|Gastroenteritis
134810|NCT02246439|Gastritis
134811|NCT02246439|Vomiting
134812|NCT02246439|Nausea
134813|NCT02246439|Diarrhea
134814|NCT02246413|BMI
134815|NCT02246413|Depressive symptoms
134816|NCT02246413|Integrated therapy
134817|NCT02246413|Cardiometabolic risk
134818|NCT02246413|Self-regulation
134819|NCT02246413|Behavior change
134820|NCT02246413|Precision medicine
134821|NCT02246413|Lifestyle
134822|NCT02246400|eCMP
134823|NCT02246400|eHealth
134824|NCT02246400|mHealth
134825|NCT02246400|Lifestyle intervention
134826|NCT02246400|Cardiometabolic risk reduction
134827|NCT02246400|PAMF
134828|NCT02246387|Pelvic Organ Prolapse
134829|NCT02246387|Gynecologic Surgery Procedures
134830|NCT02246387|Treatment Outcome
134831|NCT02246374|Parkinson's Disease
134832|NCT02246374|ExAblate
134833|NCT02246374|MRgFUS
134834|NCT02246361|Ankle sprain
134835|NCT02246361|Infectious colitis
134836|NCT02246361|Diverticulitis
134837|NCT02246361|Pyelonephritis
134838|NCT02246361|Prostatitis
134839|NCT02246361|Pneumonitis
134840|NCT02246361|Patient Information Leaflet (PIL)
134841|NCT02246361|Doctor Patient Communication
134842|NCT02246361|Adherence
134843|NCT02246361|Satisfaction
134844|NCT02246361|Scale
134845|NCT02246361|Doctor Patient Communication scale
134846|NCT02246361|Adherence scale
134847|NCT02246361|Satisfaction scale
134848|NCT02246348|Systemic Sclerosis
134849|NCT02246348|Pulmonary hypertension
134850|NCT02246348|Lung Doppler signals
134851|NCT02246322|Pancreatic cancer
134852|NCT02246322|Neuroendocrine tumors
134853|NCT02246322|Lymphadenopathies
134854|NCT02246322|GIST
134855|NCT02246322|Gastrointestinal wall neoplasia
134856|NCT02246309|Infertility
134857|NCT02246309|Embryo Culture
134858|NCT02246309|Laboratory Technique
134859|NCT02246296|severe acute malnutrition
134860|NCT02246296|wasting
134861|NCT02246296|kwashiorkor
134862|NCT02246296|nutrition
134863|NCT02246296|feeding
134864|NCT02246296|milk
134865|NCT02246283|schizophrenia
134866|NCT02246283|elderly
134867|NCT02246283|lifelong
134868|NCT02246283|quality of life
134869|NCT02246283|register
134870|NCT02246283|questionaire
134871|NCT02246218|Urea Cycle Disorder
134872|NCT02246218|UCD
134873|NCT02246218|GT4P
134874|NCT02246218|Buphenyl
134875|NCT02246218|Glycerol Phenylbutyrate
134876|NCT02246218|Ravicti
134877|NCT02246218|Hyperammonemia
134878|NCT02246218|Sodium Phenylbutyrate
134879|NCT02246218|GPB
134880|NCT02246218|HPN-100
134881|NCT02246205|pancreaticoduodenectomy
134882|NCT02246205|delayed gastric emptying
134883|NCT02246205|Roux en-Y reconstruction
134884|NCT02246179|Fractional laser
134885|NCT02246179|Topical anesthesia
134886|NCT02246179|Drug delivery
134887|NCT02246153|Laparoscopic gastrectomy
134888|NCT02246153|Advanced gastric cancer
134889|NCT02246153|Elderly patients
134890|NCT02246153|Morbidity
134891|NCT02246153|Mortality
134892|NCT02246127|advanced pNET
134893|NCT02246127|everolimus
134894|NCT02246127|STZ-5FU
134895|NCT02246127|treatment sequence
134896|NCT02246114|Pregnancy
134897|NCT02246114|Smoking
134898|NCT02246114|Smoking cessation
134899|NCT02246101|cardiac disease
134900|NCT02246101|cardiopulmonary disease
134901|NCT02246101|renal disease
134902|NCT02246101|albuminuria
134903|NCT02246101|cardiovascular disease
134904|NCT02246101|CVD
134905|NCT02246101|particulate matter
134906|NCT02246088|Osteoarthritis, Central Nervous System Sensitization
134907|NCT02246075|Alzheimer's disease
134908|NCT02246075|Cognition
134909|NCT02246075|Alpha-7 nAChR
134910|NCT02246062|Anxiety
134911|NCT02246062|Anesthesia
134912|NCT02246062|Evaluation
134913|NCT02246062|Preoperative care
134914|NCT02246062|Child
134915|NCT02246049|Metastatic colorectal cancer, bevacizumab, FOLFOXIRI
134916|NCT02246010|diarrhea
134917|NCT02246010|developing world
134918|NCT02246010|lactose-free diet
134919|NCT02246010|Clinical trial
134920|NCT02245997|Reduced-dose Radiotherapy
134921|NCT02245997|14-186
134922|NCT02245984|clinical competence, nursing process, nursing student
134923|NCT02245945|HIV
134924|NCT02245945|prevention
134925|NCT02245932|Pulmonary disease, Chronic Obstructive
134926|NCT02245932|Cardiovascular diseases
134927|NCT02245932|Metabolism
134928|NCT02245932|Resveratrol
134929|NCT02245919|Low Back Pain
134930|NCT02245919|Chronic Pain
134931|NCT02245919|Cognitive Behavioral Therapy
134932|NCT02245919|Primary Health Care
134933|NCT02245919|Physical Therapy
134934|NCT02245906|Brazilian fruit peel
134935|NCT02245906|Functional food
134936|NCT02245906|Cardiometabolic risk
134937|NCT02245906|Metabolic syndrome
134938|NCT02245906|Inflammation
134939|NCT02245906|Appetite
134940|NCT02245906|Gut hormone
134941|NCT02245880|cervical spine
134942|NCT02245880|intubating laryngeal mask airway
134943|NCT02245880|Glidescope videolaryngoscope
134944|NCT02245880|collar
134945|NCT02245867|Amyloidosis
134946|NCT02245867|Relapse
134947|NCT02245867|Refractory
134948|NCT02245854|diminutive polyps
134949|NCT02245854|small polyps
134950|NCT02245854|cold snare polypectomy
134951|NCT02245854|complications
134952|NCT02245854|bleeding
134953|NCT02245841|dermatomyositis
134954|NCT02245841|Acthar gel
134955|NCT02245828|healthy subjects, inhaled
134956|NCT02245815|Necrotizing enterocolitis
134957|NCT02245815|Probiotics
134958|NCT02245815|Secreting IgA
134959|NCT02245815|Preterm newborns
134960|NCT02245802|Bleeding peptic ulcer
134961|NCT02245802|Prediction model
134962|NCT02245802|Mortality
134963|NCT02245802|Prediction of in-hospital mortality for bleeding peptic ulcer
134964|NCT02245776|Incurable Neurological Disorders
134965|NCT02245776|Autologous mononuclear cell therapy
134966|NCT02245776|Stem cells
134967|NCT02245750|hysteroscopy - recurrent implantation failure
134968|NCT02245737|Alzheimer's disease
134969|NCT02245737|Dementia
134970|NCT02245737|Brain Diseases
134971|NCT02245737|Neurogenerative Diseases
134972|NCT02245737|Central Nervous System Diseases
134973|NCT02245737|Nervous System Diseases
134974|NCT02245737|Mental Disorders
134975|NCT02245737|Delirium, Dementia, Amnestic, Cognitive Disorders
134976|NCT02245737|Tauopathies
134977|NCT02245724|Mental retardation
134978|NCT02245724|Autologous mononuclear cell therapy
134979|NCT02245724|Stem cell
134980|NCT02245711|Limb Girdle Muscular Dystrophy
134981|NCT02245711|Autologous Bone Marrow Mononuclear cell therapy
134982|NCT02245711|Stem Cell
134983|NCT02245698|Chronic Stroke
134984|NCT02245698|Subacute stroke
134985|NCT02245698|Autologous Bone Marrow Mononuclear Cell therapy
134986|NCT02245698|Stem cell
134987|NCT02245685|Substitution Therapy
134988|NCT02245685|Specialized Care Center for Addicts
134989|NCT02245672|Asthma
134990|NCT02245672|fluticasone
134991|NCT02245672|salmeterol
134992|NCT02245672|CRC749
134993|NCT02245672|Diskus
134994|NCT02245672|Advair
134995|NCT02245672|FEV1
134996|NCT02245672|MGR001
134997|NCT02245620|Skeletal muscle dysfunction, MTP-131, Bendavia™
134998|NCT02245620|elamipretide
134999|NCT02245607|Psychotic Disorders
135000|NCT02245607|Cognitive Training
135001|NCT02245607|Mental Disorders
135002|NCT02245607|Schizophrenia and Disorders with Psychotic Features
135003|NCT02245594|Gastrointestinal motility
135004|NCT02245594|Motility Tracking System (MTS)
135005|NCT02245594|Transit time
135006|NCT02245594|Sleep pattern
135007|NCT02245568|Dementia
135008|NCT02245568|Alzheimer Disease
135009|NCT02245568|bvFTD
135010|NCT02245568|Frontotemporal Dementia
135011|NCT02245568|Neurodegenerative Diseases
135012|NCT02245568|Brain Diseases
135013|NCT02245568|Cognitive Disorders
135014|NCT02245516|Intraretinal Fluid
135015|NCT02245516|Subretinal Fluid
135016|NCT02245516|Retinal Vein Occlusion
135017|NCT02245516|Diabetic Macular Edema
135018|NCT02245477|Serum VEGF, FGR
135019|NCT02245425|Neck pain
135020|NCT02245425|Thoracic spine manipulation
135021|NCT02245425|Range of Motion
135022|NCT02245425|Disability
135023|NCT02245399|Weight loss
135024|NCT02245399|Diabetes
135025|NCT02245399|Cardiovascular disease (CVD) risk
135026|NCT02245399|Weight loss diet
135027|NCT02245399|mediterranean type diet
135028|NCT02245399|Canola oil
135029|NCT02245399|Low-carbohydrate diet
135030|NCT02245399|Glycemic index
135031|NCT02245373|Depression
135032|NCT02245373|Primary Care
135033|NCT02245373|Cost-effectiveness
135034|NCT02245373|Pharmacological treatment
135035|NCT02245373|Watchful-waiting or Active Monitoring.
135036|NCT02245360|GRAZAX
135037|NCT02245347|TB
135038|NCT02245347|Tuberculosis
135039|NCT02245347|MDR TB
135040|NCT02245347|Drug resistant TB
135041|NCT02245321|hemoglobin recovery
135042|NCT02245321|iron recovery
135043|NCT02245321|iron supplements
135044|NCT02245308|Tobacco use cessation
135045|NCT02245308|Homelessness
135046|NCT02245308|Veterans
135047|NCT02245295|Bronchial endoscopy
135048|NCT02245295|ultrasound
135049|NCT02245295|EBUS
135050|NCT02245295|anesthesia
135051|NCT02245295|lung cancer
135052|NCT02245295|diagnosis including staging
135053|NCT02245256|delirium
135054|NCT02245256|incidence
135055|NCT02245256|dexmedetomidine
135056|NCT02245243|Hepatic Impairment, single dose, intravenous
135057|NCT02245230|Hypertension
135058|NCT02245230|Autonomic Nervous System
135059|NCT02245230|Renin-Angiotensin System
135060|NCT02245230|Angiotensin (1-7)
135061|NCT02245230|Ganglionic Blockers
135062|NCT02245230|Trimethaphan
135063|NCT02245230|Blood Pressure
135064|NCT02245230|Hemodynamics
135065|NCT02245191|Vasopressor
135066|NCT02245191|Cesarian delivery
135067|NCT02245191|Hypotension
135068|NCT02245191|Maternal cardiac output
135069|NCT02245191|Uteroplacental blood flow
135070|NCT02245191|Cerebral fetal blood flow
135071|NCT02245191|Preeclampsia
135072|NCT02245165|Nitric oxide
135073|NCT02245165|Nitric oxide synthase
135074|NCT02245165|Gastrointestinal motility
135075|NCT02245165|Gut peptide hormones
135076|NCT02245152|child acute malnutrition
135077|NCT02245152|prevention
135078|NCT02245152|behavior change communication
135079|NCT02245152|lipid-based nutrient supplement
135080|NCT02245152|screening coverage
135081|NCT02245139|diarrhea
135082|NCT02245139|vomiting
135083|NCT02245139|fever
135084|NCT02245139|abdominal pain
135085|NCT02245139|oliguria
135086|NCT02245126|Pain, Visual analogue scale
135087|NCT02245087|atorvastatin
135088|NCT02245087|coronary artery disease
135089|NCT02245087|myocardial infarction
135090|NCT02245087|stroke
135091|NCT02245087|revascularization
135092|NCT02245074|Infantile asthma
135093|NCT02245074|Induced sputum
135094|NCT02245074|Phenotypes
135095|NCT02245074|Eosinophils
135096|NCT02245074|Neutrophils
135097|NCT02245061|pharmacoresistant focal epilepsy
135098|NCT02245061|cortical excitability
135099|NCT02245061|paired pulses
135100|NCT02245061|TMS
135101|NCT02245061|SEEG
135102|NCT02245061|DES
135103|NCT02245048|Cardiovascular Risk Stratification
135104|NCT02245048|Carotid intima-media thickness (CIMT)
135105|NCT02245048|Stress echocardiography (SE)
135106|NCT02245035|Glutathione
135107|NCT02245035|Dairy consumption
135108|NCT02245035|Brain
135109|NCT02245035|Humans
135110|NCT02245022|HIV
135111|NCT02245022|Prevention of mother to child transmission
135112|NCT02245022|Africa
135113|NCT02245022|Uganda
135114|NCT02245022|Pharmacokinetics
135115|NCT02245022|Pregnancy
135116|NCT02245022|Breastfeeding
135117|NCT02244996|Retinitis pigmentosa
135118|NCT02244996|Lycium barbarum
135119|NCT02244996|Antioxidation
135120|NCT02244996|Visual field
135121|NCT02244996|Electroretinogram
135122|NCT02244970|Mindfulness
135123|NCT02244970|Depressive mood
135124|NCT02244970|anxiety
135125|NCT02244970|early psychosis
135126|NCT02244944|nonalcoholic fatty liver disease
135127|NCT02244944|NAFLD
135128|NCT02244931|Spinal cord injuries, paraplegic, manual wheelchairs, assisting propelling device
135129|NCT02244905|Positive Deviance
135130|NCT02244905|Infection Control
135131|NCT02244905|Healthcare-Associated Infections
135132|NCT02244905|Staff Engagement
135133|NCT02244905|Cluster Randomized Controlled Trial
135134|NCT02244892|Disability glare
135135|NCT02244892|Corneal scar
135136|NCT02244892|Corneal haze
135137|NCT02244892|Scheimpflug densitometry
135138|NCT02244892|Contrast sensitivity
135139|NCT02244879|resveratrol
135140|NCT02244879|type 2 diabetes mellitus
135141|NCT02244879|inflammation
135142|NCT02244879|insulin resistance
135143|NCT02244879|body composition
135144|NCT02244879|bone mass
135145|NCT02244866|IVF
135146|NCT02244866|LH supplementation
135147|NCT02244866|ovarian stimulation
135148|NCT02244866|poor responder
135149|NCT02244840|Bidet, Sitz bath, Anal resting pressure
135150|NCT02244814|glucose
135151|NCT02244814|insulin resistance
135152|NCT02244814|dietary carbohydrate
135153|NCT02244814|dietary fat
135154|NCT02244814|adiposity
135155|NCT02244814|Air displacement plethysmography
135156|NCT02244814|Dual X-ray Absorptiometry
135157|NCT02244814|continuous glucose monitoring
135158|NCT02244775|osteo-arthritis
135159|NCT02244775|post traumatic arthritis
135160|NCT02244736|Arterial stiffness
135161|NCT02244736|Endothelial glycocalyx
135162|NCT02244736|Coronary flow reserve
135163|NCT02244723|Ventilator-Associated Pneumonia
135164|NCT02244723|diagnosis
135165|NCT02244710|Circulating Endothelial Cells
135166|NCT02244710|Endothelial Progenitor Cells
135167|NCT02244710|Acute coronary syndrome (ACS)
135168|NCT02244710|Ticagrelor
135169|NCT02244697|Stridor
135170|NCT02244697|Vocal Cord Paralysis (VCP)
135171|NCT02244697|Ultrasound (US)
135172|NCT02244684|Folate
135173|NCT02244684|Folic Acid
135174|NCT02244684|One-Carbon Nutrients
135175|NCT02244684|Epigenetics
135176|NCT02244684|Pregnancy
135177|NCT02244684|Fetal Health
135178|NCT02244658|chemotherapy-induced thrombocytopenia
135179|NCT02244658|recombinant human thrombopoietin
135180|NCT02244658|acute myelocytic leukemia
135181|NCT02244645|Low back pain, physical therapy, yoga.
135182|NCT02244632|Colorectal cancer
135183|NCT02244632|Colorectal carcinoma
135184|NCT02244632|Colorectal tumors
135185|NCT02244632|Intestinal Neoplasm
135186|NCT02244632|Gastrointestinal Neoplasm
135187|NCT02244632|Gastrointestinal disease
135188|NCT02244632|5,10-methylenetetrahydrofolate
135189|NCT02244632|Tetrahydrofolates
135190|NCT02244632|Therapeutic uses
135191|NCT02244632|Pharmacokinetics
135192|NCT02244632|Pharmacodynamics
135193|NCT02244632|Safety assessments
135194|NCT02244619|Hip replacement
135195|NCT02244619|Knee replacement
135196|NCT02244619|randomized trial
135197|NCT02244619|acetaminophen
135198|NCT02244619|post-op pain management
135199|NCT02244606|Invasive Candidiasis
135200|NCT02244606|Invasive Candida infections
135201|NCT02244606|Candidemia
135202|NCT02244606|SCY-078
135203|NCT02244606|Micafungin
135204|NCT02244606|Fluconazole
135205|NCT02244606|Echinocandin
135206|NCT02244593|breast cancer survivors
135207|NCT02244593|FAST MRI
135208|NCT02244593|mammography screening
135209|NCT02244580|Subtyping of Invasive breast cancer
135210|NCT02244567|PCOS
135211|NCT02244554|tattoo removal
135212|NCT02244554|Q-switched laser
135213|NCT02244554|Nd:YAG laser
135214|NCT02244554|nanosecond laser
135215|NCT02244554|picosecond laser
135216|NCT02244554|laser therapy
135217|NCT02244554|tattoo
135218|NCT02244554|pulsed-laser
135219|NCT02244554|laser treatment
135220|NCT02244554|remove tattoo
135221|NCT02244554|tattoo clearing
135222|NCT02244554|tattoo lightening
135223|NCT02244554|tattoo lighten
135224|NCT02244554|resistant tattoo
135225|NCT02244515|children
135226|NCT02244502|Ovarian Carcinoma
135227|NCT02244502|Treatment
135228|NCT02244502|Minimal toxicity
135229|NCT02244502|TTFields
135230|NCT02244502|Tumor Treating Fields
135231|NCT02244502|Novocure
135232|NCT02244502|Paclitaxel
135233|NCT02244502|Weekly paclitaxel
135234|NCT02244476|mouth feel
135235|NCT02244476|acoustic tribology
135236|NCT02244476|vibration spectrum
135237|NCT02244476|sensory perception
135238|NCT02244463|Anaplastic Thyroid Cancer
135239|NCT02244463|Thyroid Cancer
135240|NCT02244450|Neonatal screening
135241|NCT02244450|severe combined immunodeficiency
135242|NCT02244450|T-cell Receptor Excision Circle
135243|NCT02244437|altitude, altitude illnesses, headache
135244|NCT02244424|Infant
135245|NCT02244424|Obesity
135246|NCT02244424|Adolescent
135247|NCT02244424|Social media
135248|NCT02244424|Prevention
135249|NCT02244411|EQUAL
135250|NCT02244411|Exercise
135251|NCT02244411|Diet
135252|NCT02244411|Physical activity
135253|NCT02244411|14-164
135254|NCT02244385|vascular disease
135255|NCT02244385|pregnancy
135256|NCT02244385|chronic hypertension
135257|NCT02244385|diabetes
135258|NCT02244385|obesity
135259|NCT02244372|Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2)
135260|NCT02244372|immunity
135261|NCT02244359|Shared Decision making
135262|NCT02244359|Patient Centred care
135263|NCT02244359|Interprofessionalism
135264|NCT02244359|Home care
135265|NCT02244359|Frail elderly
135266|NCT02244164|Type 2 Diabetes
135267|NCT02244164|Incretinomimetics
135268|NCT02244164|DPP-4 inhibitors
135269|NCT02244164|Pancreas
135270|NCT02244164|PanIN
135271|NCT02244164|RMN
135272|NCT02244164|Lipasemia
135273|NCT02244151|ovulation induction,oocyte maturation timing and collection
135274|NCT02244138|Adolescent
135275|NCT02244138|Screening
135276|NCT02244138|Primary Care
135277|NCT02244138|Computer Decision Support Systems
135278|NCT02244125|Myeloma
135279|NCT02244125|Multiple Myeloma
135280|NCT02244125|Relapse
135281|NCT02244125|Refractory
135282|NCT02244125|PCD
135283|NCT02244125|IFM/DFCI 2009
135284|NCT02244125|Transplantation
135285|NCT02244125|Autologous
135286|NCT02244125|Pomalidomide
135287|NCT02244125|Immunoglobulin
135288|NCT02244125|Ig
135289|NCT02244125|Free light Chain
135290|NCT02244099|Controlled substance prescribing
135291|NCT02244099|Controlled substance treatment agreements
135292|NCT02244099|Opioid use
135293|NCT02244086|obstetric pain, bupivacaine, analgesic efficacy
135294|NCT02244073|blood glucose target
135295|NCT02244073|ICU
135296|NCT02244073|insulin
135297|NCT02244073|hypoglycemia
135298|NCT02244073|hyperglycemia
135299|NCT02244073|glycated hemoglobin
135300|NCT02244060|Vignette
135301|NCT02244060|Priming effect
135302|NCT02244021|HD
135303|NCT02244021|Hodgkin's Lymphoma
135304|NCT02244021|RELAPSED-REFRACTORY
135305|NCT02244008|Mobilization
135306|NCT02244008|Joint Range of Motion
135307|NCT02244008|Ankle
135308|NCT02244008|Manual Therapy
135309|NCT02243995|Training program
135310|NCT02243995|Resistance training
135311|NCT02243995|Endurance training
135312|NCT02243995|Muscle strength
135313|NCT02243995|Exercise capacity
135314|NCT02243995|Fatigue
135315|NCT02243995|Quality of life
135316|NCT02243982|Parkinson, dementia, FDDNP, tau, beta-amyloid
135317|NCT02243969|n-3 polyunsaturated fatty acids
135318|NCT02243969|Alpha-linolenic acid
135319|NCT02243969|Blood pressure
135320|NCT02243969|Vascular function
135321|NCT02243943|Neuromuscular block
135322|NCT02243943|neuromuscular reversal
135323|NCT02243943|postoperative conditions
135324|NCT02243943|respiratory failure
135325|NCT02243930|Sigmoidoscopy with or without cap
135326|NCT02243930|Pain during sigmoidoscopy
135327|NCT02243930|Sigmoidoscopy and time
135328|NCT02243904|Autonomic nervous function
135329|NCT02243904|Blood pressure
135330|NCT02243904|Cardiovascular regulation
135331|NCT02243904|Lead
135332|NCT02243904|Occupational exposure
135333|NCT02243904|Renal function
135334|NCT02243852|Growth Hormone Deficiency (GHD)
135335|NCT02243852|Growth Hormone Replacement Therapy
135336|NCT02243852|Fibroblast Growth Factor 21 (FGF21)
135337|NCT02243852|Visceral Fat
135338|NCT02243852|Subcutaneous Fat
135339|NCT02243839|Prosthetic valve
135340|NCT02243839|Thrombosis
135341|NCT02243839|Surgery
135342|NCT02243839|Thrombolytic therapy
135343|NCT02243839|Transesophageal echocardiography
135344|NCT02243826|Lumbar puncture
135345|NCT02243826|Adults
135346|NCT02243826|Nitrous oxide
135347|NCT02243826|Procedural pain
135348|NCT02243826|Procedural anxiety
135349|NCT02243813|Psilocybin
135350|NCT02243813|Pharmacologic Actions
135351|NCT02243813|Psychotropic Drugs
135352|NCT02243800|Vitamin D
135353|NCT02243800|Rheumatoid arthritis
135354|NCT02243800|Cholecalciferol
135355|NCT02243774|Vaccination
135356|NCT02243774|Immunization
135357|NCT02243774|Randomized Controlled Trial
135358|NCT02243774|Prevention & Control
135359|NCT02243774|Preventive Measures
135360|NCT02243774|Health Promotion
135361|NCT02243774|Medicare
135362|NCT02243774|Intention Prompts
135363|NCT02243774|Letters
135364|NCT02243761|Concurrent Disorders
135365|NCT02243761|Mental Health
135366|NCT02243761|Addictions
135367|NCT02243761|Caregiver Burden
135368|NCT02243722|laryngeal electromyography
135369|NCT02243722|intrinsic laryngeal muscles
135370|NCT02243722|recurrent laryngeal nerve
135371|NCT02243722|superior laryngeal nerve
135372|NCT02243722|laryngeal sensation
135373|NCT02243722|tone language
135374|NCT02243709|Stress, alcohol craving, alcohol use disorders
135375|NCT02243670|opioid addiction
135376|NCT02243670|opioid substitution therapy
135377|NCT02243670|addiction
135378|NCT02243670|buprenorphine maintenance treatment
135379|NCT02243670|opioid dependence
135380|NCT02243670|substitution treatment
135381|NCT02243670|noncompliance
135382|NCT02243670|opiate addiction
135383|NCT02243670|Zubzolv® maintenance
135384|NCT02243670|adherence monitoring
135385|NCT02243670|directly observed therapy
135386|NCT02243670|medication adherence
135387|NCT02243670|adherence
135388|NCT02243670|mobile
135389|NCT02243670|electronic monitoring
135390|NCT02243670|wireless
135391|NCT02243670|mobile device
135392|NCT02243670|artificial intelligence
135393|NCT02243670|facial recognition
135394|NCT02243670|computer vision
135395|NCT02243670|visual confirmation
135396|NCT02243670|sublingual buprenorphine/naloxone
135397|NCT02243670|nonadherence
135398|NCT02243657|ASP3652
135399|NCT02243657|Age
135400|NCT02243657|Gender
135401|NCT02243657|Pharmacokinetics
135402|NCT02243657|Pharmacodynamics
135403|NCT02243657|Phase 1
135404|NCT02243657|Multiple Ascending Doses (MAD)
135533|NCT02243072|adolescents
135405|NCT02243644|parenchymal neurocysticercosis upto five lesions
135406|NCT02243631|ATP
135407|NCT02243631|Probenecid
135408|NCT02243631|Chondrocalcinosis
135409|NCT02243527|Exercise
135410|NCT02243514|Hypertension
135411|NCT02243514|Heart failure
135412|NCT02243514|Sympathetic hyperactivity
135413|NCT02243514|Renal nerve
135414|NCT02243514|Remodeling
135415|NCT02243514|Nerve remodeling
135416|NCT02243488|Menstruation
135417|NCT02243488|MHM
135418|NCT02243488|Menstrual Hygiene Management
135419|NCT02243488|Girls Education
135420|NCT02243488|Absenteeism
135421|NCT02243488|Access to Education
135422|NCT02243488|Menstrual Health Education
135423|NCT02243488|Reusable Sanitary Product
135424|NCT02243462|Shivering
135425|NCT02243462|Hypothermia
135426|NCT02243462|Postoperative
135427|NCT02243462|Temperature
135428|NCT02243462|Forced air warmer
135429|NCT02243449|mechanical ventilation
135430|NCT02243449|weaning
135431|NCT02243449|elderly
135432|NCT02243449|critically ill
135433|NCT02243449|screening
135434|NCT02243449|spontaneous breathing trial
135435|NCT02243449|invasive ventilation
135436|NCT02243436|CLASSICAL HODGKIN LYMPHOMA
135437|NCT02243436|HODGKIN LYMPHOMA
135438|NCT02243436|LYMPHOMA
135439|NCT02243436|HL
135440|NCT02243423|Aortocaval compression
135441|NCT02243423|Cesarean Section
135442|NCT02243423|Spinal Anesthesia
135443|NCT02243423|Phenylephrine
135444|NCT02243384|Early Hepatocellular Carcinoma
135445|NCT02243384|Laparoscopic Hepatectomy
135446|NCT02243384|Radiofrequency Ablation
135447|NCT02243384|Micrometastases
135448|NCT02243358|Pancreatic, cancer
135449|NCT02243345|decompression
135450|NCT02243345|recompression
135451|NCT02243345|delayed
135452|NCT02243345|late
135453|NCT02243332|Knee
135454|NCT02243332|Pain
135455|NCT02243332|Joint
135456|NCT02243332|Rehabilitation
135457|NCT02243332|Patellofemoral Pain Syndrome
135458|NCT02243332|Anterior Knee Pain Syndrome
135459|NCT02243332|Knee Pain
135460|NCT02243332|Quadriceps
135461|NCT02243306|pharmacokinetics
135462|NCT02243306|Chronic kidney disease
135463|NCT02243306|peritoneal dialysis
135464|NCT02243306|hemoglobin
135465|NCT02243306|Anemia
135466|NCT02243306|GSK1278863
135467|NCT02243306|Prolyl hydroxylase inhibitor
135468|NCT02243306|erythropoiesis stimulating agents
135469|NCT02243293|Hepatitis C Virus
135470|NCT02243293|Hepatitis C Genotype 4
135471|NCT02243293|Hepatitis C
135472|NCT02243293|HCV
135473|NCT02243293|Hepatitis C Genotype 5
135474|NCT02243293|interferon free
135475|NCT02243293|Hepatitis C Genotype 2
135476|NCT02243293|Hepatitis C Genotype 3
135477|NCT02243293|Hepatitis C Genotype 6
135478|NCT02243293|Chronic Hepatitis C
135479|NCT02243280|Cirrhotic
135480|NCT02243280|HCV GT6
135481|NCT02243280|Hepatitis C Genotype 4 (GT 4)
135482|NCT02243280|Hepatitis C
135483|NCT02243280|HCV GT4
135484|NCT02243280|Hepatitis C Genotype 5 (GT 5)
135485|NCT02243280|Hepatitis C virus
135486|NCT02243280|HCV GT1
135487|NCT02243280|Interferon (IFN) Free
135488|NCT02243280|Hepatitis C Genotype 1 (GT1)
135489|NCT02243280|IFN free
135490|NCT02243280|HCV GT5
135491|NCT02243280|Chronic Hepatitis C
135492|NCT02243280|HCV
135493|NCT02243280|Ribavirin
135494|NCT02243280|Hepatitis C Genotype 6 (GT 6)
135495|NCT02243280|Child Pugh A
135496|NCT02243280|RBV
135497|NCT02243280|Compensated Cirrhosis
135498|NCT02243267|Colon Cancer Colon Cancer Prevention
135499|NCT02243241|Healthy volunteers
135500|NCT02243241|Opioid
135501|NCT02243241|ECG
135502|NCT02243241|QTcI
135503|NCT02243228|granulocyte-macrophage colony stimulating factor(GM-CSF)
135504|NCT02243228|Autoimmune pulmonary alveolar proteinosis (PAP)
135505|NCT02243215|Laparoscopy
135506|NCT02243215|Training
135507|NCT02243215|Off-site
135508|NCT02243215|Box trainer
135509|NCT02243215|Virtual Reality Simulator
135510|NCT02243202|Obesity
135511|NCT02243202|Overweight
135512|NCT02243202|Canagliflozin
135513|NCT02243202|Phentermine
135514|NCT02243202|INVOKANA®
135515|NCT02243189|Healthy
135516|NCT02243189|Asthma
135517|NCT02243189|JNJ-43260295
135518|NCT02243189|Nasal Allergen Challenge
135519|NCT02243176|Saxagliptin
135520|NCT02243176|Acarbose
135521|NCT02243176|Type 2 Diabetes
135522|NCT02243176|Metformin
135523|NCT02243124|Anemia
135524|NCT02243124|Transfusion
135525|NCT02243124|AML
135526|NCT02243124|MDS
135527|NCT02243124|CLL
135528|NCT02243124|p53
135529|NCT02243124|erythropoiesis
135530|NCT02243111|Systemic sclerosis, pulmonary hypertension
135531|NCT02243072|Insulin Dependent Diabetes Mellitus
135532|NCT02243072|family therapy
135534|NCT02243072|regimen adherence
135535|NCT02243072|metabolic control
135536|NCT02243059|Magnetic Resonance Imaging
135537|NCT02243059|Gadofosveset trisodium
135538|NCT02243059|Nodal imaging
135539|NCT02243033|Prostate cancer
135540|NCT02243033|Focal therapy
135541|NCT02243033|Laser therapy
135542|NCT02243033|Transrectal
135543|NCT02243033|MRI-guided
135544|NCT02243007|Resectable pancreatic cancer
135545|NCT02243007|Pancreatic Ductal Carcinoma
135546|NCT02242968|Licensed Vaccines
135547|NCT02242968|Blood Draw
135548|NCT02242968|Investigational Vaccines
135549|NCT02242968|Healthy Volunteers
135550|NCT02242968|Eligibility Screening
135551|NCT02242955|Alcohol-dependence
135552|NCT02242955|Relapse
135553|NCT02242955|Detoxification
135554|NCT02242955|Diazepam
135555|NCT02242955|Benzodiazepines
135556|NCT02242955|Anxiety
135557|NCT02242929|Nodular Basal Cell Carcinoma
135558|NCT02242929|Treatment
135559|NCT02242929|Imiquimod
135560|NCT02242929|Curettage
135561|NCT02242929|Surgery
135562|NCT02242916|reccurent Head and Neck tumors
135563|NCT02242916|re-irradiation
135564|NCT02242916|photon
135565|NCT02242916|proton
135566|NCT02242916|carbon-ion
135567|NCT02242890|intrauterine contraception (IUC)
135568|NCT02242890|social networks
135569|NCT02242890|social influence
135570|NCT02242890|diffusion of innovation
135571|NCT02242890|intrauterine device (IUD)
135572|NCT02242890|LARC
135573|NCT02242799|Malaria
135574|NCT02242799|HIV
135575|NCT02242799|Dolutegravir
135576|NCT02242799|Artemisinin
135577|NCT02242799|Pharmacokinetics
135578|NCT02242799|Interactions
135579|NCT02242773|Prostate Cancer
135580|NCT02242773|Active Surveillance
135581|NCT02242773|MRI-Guided Biopsy
135582|NCT02242773|Multi-parametric MRI
135583|NCT02242773|MP-MRI
135584|NCT02242760|acne
135585|NCT02242747|actinic keratosis
135586|NCT02242747|field cancerization
135587|NCT02242747|ingenol mebutate
135588|NCT02242747|5-fluorouracil
135589|NCT02242747|tolerability
135590|NCT02242747|safety
135591|NCT02242695|vulvovaginal candidiasis
135592|NCT02242695|vulvovaginal candidosis
135593|NCT02242695|mycotic vaginal infection
135594|NCT02242695|dequalinium chloride
135595|NCT02242695|Fluomizin
135596|NCT02242695|clotrimazole
135597|NCT02242695|canesten
135598|NCT02242656|Short Bowel Syndrome
135599|NCT02242656|SBS
135600|NCT02242656|Chronic Diarrhea
135601|NCT02242656|Short Bowel
135602|NCT02242656|Short Gut
135603|NCT02242656|Short Gut Syndrome
135604|NCT02242656|Anti-Diarrheal
135605|NCT02242656|Opium Tincture
135606|NCT02242656|loperamide
135607|NCT02242656|diphenoxylate
135608|NCT02242656|ileostomies
135609|NCT02242656|tincture of opium
135610|NCT02242656|DTO
135611|NCT02242656|codeine
135612|NCT02242656|morphine
135613|NCT02242656|opiate
135614|NCT02242643|Fluzone Quadrivalent
135615|NCT02242643|Comparator
135616|NCT02242643|Children
135617|NCT02242643|Seasonal influenza
135618|NCT02242643|Safety
135619|NCT02242643|Immunogenicity
135620|NCT02242630|Subacromial bursitis
135621|NCT02242630|Triamcinolone
135622|NCT02242630|Methylprednisolone
135623|NCT02242630|Shoulder pain
135624|NCT02242617|Adherence
135625|NCT02242617|CPAP
135626|NCT02242617|Oral Appliance
135627|NCT02242617|Mandibular Advancement Splints
135628|NCT02242617|Preference
135629|NCT02242591|Knee surgery
135630|NCT02242591|Saphenous nerve
135631|NCT02242591|Perineural block
135632|NCT02242591|Adductor Canal Block
135633|NCT02242591|Postoperative Pain
135634|NCT02242591|Mobilization
135635|NCT02242578|Negative symptoms
135636|NCT02242565|HIV prevention
135637|NCT02242565|ShangRing
135638|NCT02242565|adverse events
135639|NCT02242565|wound healing
135640|NCT02242565|voluntary medical male circumcision (VMMC)
135641|NCT02242565|medical device
135642|NCT02242565|Zambia
135643|NCT02242526|hiatal hernia, recurrence, biologic mesh, synthetic mesh
135644|NCT02242513|Pulsed mode radiofrequency
135645|NCT02242513|Plantar Fasciitis
135646|NCT02242513|Ultrasound-guided
135647|NCT02242500|Gingival recession/surgery
135648|NCT02242500|Collagen/therapeutic use
135649|NCT02242500|Root coverage
135650|NCT02242500|Treatment outcome
135651|NCT02242487|Parkinson's Disease
135652|NCT02242487|Motor fluctuations
135653|NCT02242487|levodopa
135654|NCT02242487|inhaled drugs
135655|NCT02242487|OFF episodes
135656|NCT02242474|Rheumatoid arthritis
135657|NCT02242474|Surgical Wound Infection
135658|NCT02242474|Surgical Site Infection
135659|NCT02242474|Antirheumatic Agents
135660|NCT02242474|Perioperative Care
135661|NCT02242474|Anti-TNF
135662|NCT02242474|Anti-TNF-alpha
135663|NCT02242461|COPD, Rhodiola L., clinical trial, biomarkers, spirometry
135664|NCT02242448|Healthy Volunteer
135665|NCT02242448|Contrast
135666|NCT02242409|Metastatic pancreatic cancer
135667|NCT02242409|Second Line treatment
135668|NCT02242409|Gemcitabine
135669|NCT02242409|Nab-paclitaxel
135670|NCT02242188|Breastfeeding
135671|NCT02242188|Iron supplementation
135672|NCT02242188|Psychomotor development
135673|NCT02242188|Safety
135674|NCT02242188|infants
135675|NCT02242162|phrenic nerves magnetic stimulations
135676|NCT02242149|Fat liver
135677|NCT02242149|Diabetes
135678|NCT02242149|Diacerein
135679|NCT02242149|Transient elastography
135680|NCT02242149|Treatment
135681|NCT02242136|Posttraumatic Stress Disorder
135682|NCT02242136|Aggressive Behavior
135683|NCT02242136|Appetitive Aggression
135684|NCT02242136|Treatment
135685|NCT02242136|FORNET
135686|NCT02242123|Celiac Disease
135687|NCT02242123|Gluten-free diet
135688|NCT02242123|EmA assay
135689|NCT02242123|Duodenal culture medium
135690|NCT02242110|Nightmares
135691|NCT02242110|Sleep
135692|NCT02242110|PTSD
135693|NCT02242110|Exposure, Relaxation, and Rescripting Therapy
135694|NCT02242071|Motor Neuron Disease
135695|NCT02242071|Amyotrophic Lateral Sclerosis
135696|NCT02242071|Autologous Mononuclear Cell therapy
135697|NCT02242071|Stem cells
135698|NCT02242032|dry eye disease
135699|NCT02241993|glucose sensor
135700|NCT02241993|Inter-sensor distance
135701|NCT02241967|total knee arthroplasty
135702|NCT02241967|pain
135703|NCT02241967|post-surgical pain
135704|NCT02241967|opioid
135705|NCT02241967|transcranial direct current stimulation
135706|NCT02241967|tDCS
135707|NCT02241967|brain stimulation
135708|NCT02241928|Muscular Dystrophy
135709|NCT02241928|Autologous Mononuclear cell therapy
135710|NCT02241928|Stem Cell
135711|NCT02241889|diabetes
135712|NCT02241889|closed-loop
135713|NCT02241889|bi-hormonal
135714|NCT02241889|exercise
135715|NCT02241863|bipolar disorders
135716|NCT02241863|medication adherence
135717|NCT02241863|psychological intervention
135718|NCT02241863|multifaceted intervention
135719|NCT02241850|High Intensity Training
135720|NCT02241850|Genetic Polymorphisms
135721|NCT02241850|Genome Wide association study
135722|NCT02241850|Single Nucleotide Polymorphism genotype
135723|NCT02241850|Subjects
135724|NCT02241837|heart failure
135725|NCT02241837|percutaneous
135726|NCT02241837|interventional cardiology
135727|NCT02241837|apical remodeling
135728|NCT02241837|LV dilatation
135729|NCT02241837|akinesis
135730|NCT02241837|dyskinesis
135731|NCT02241837|myocardial infarction
135732|NCT02241824|Lumbar Orthosis
135733|NCT02241824|Lumbar brace
135734|NCT02241811|Diabetic
135735|NCT02241811|Foot
135736|NCT02241811|Wound
135737|NCT02241811|Sodium pentaborate pentahydrate
135738|NCT02241811|Hydrogel
135739|NCT02241798|epilepsy
135740|NCT02241798|oxygen saturation
135741|NCT02241798|transcutaneous carbon dioxide
135742|NCT02241798|sudep
135743|NCT02241798|pre-oxygenation
135744|NCT02241733|exercise
135745|NCT02241733|pulmonary rehabilitation
135746|NCT02241733|dynamic hyperinflation
135747|NCT02241707|Varicose vein
135748|NCT02241707|Endovenous ablation
135749|NCT02241707|Compression
135750|NCT02241681|Medium Chain Triglycerides
135751|NCT02241681|Medium Chain Triglycerides metabolites
135752|NCT02241681|Peptamen 1.5
135753|NCT02241668|Brain tumor
135754|NCT02241668|3'-Deoxy-3'-18f-Fluorothymidine
135755|NCT02241668|Fluoro-L-Thymidine Positron Emission Tomography
135756|NCT02241668|FLT PET
135757|NCT02241668|Magnetic resonance imaging
135758|NCT02241668|MRI
135759|NCT02241655|Anesthesia
135760|NCT02241655|Electroencephalography
135761|NCT02241655|Burst suppression
135762|NCT02241655|Surgery
135763|NCT02241655|Delirium
135764|NCT02241655|Falls
135765|NCT02241655|Health related quality of life
135766|NCT02241642|Percutaneous vascular closure device
135767|NCT02241642|vascular closure device
135768|NCT02241642|Large hole closure device
135769|NCT02241629|motion sickness
135770|NCT02241603|Insulin resistance
135771|NCT02241603|Consummatory Reward
135772|NCT02241577|peri-implantitis
135773|NCT02241577|dental implants
135774|NCT02241577|randomized controlled trial
135775|NCT02241577|non-surgical periodontal treatment
135776|NCT02241577|will be defined by the presence of alveolar bone loss of at least 3mm, pocket depth of at least 5mm and bleeding on probing.
135777|NCT02241564|Immunosuppression
135778|NCT02241551|Borderline
135779|NCT02241551|Resectable
135780|NCT02241551|Pancreatic
135781|NCT02241551|Cancer
135782|NCT02241551|Neoadjuvant
135783|NCT02241551|Chemotheraphy
135784|NCT02241551|Gemcitabine
135785|NCT02241551|Nab-Paclitaxel
135786|NCT02241551|mFOFIRINOX
135787|NCT02241551|Sterotatic Body Radiation Therapy
135788|NCT02241538|Pilates-based exercises
135789|NCT02241525|Pulmonary
135790|NCT02241525|Thromboembolic
135791|NCT02241525|Lung
135792|NCT02241512|post-ERCP pancreatitis
135793|NCT02241512|pediatric
135794|NCT02241512|ibuprofen
135795|NCT02241499|Digestive System Diseases
135796|NCT02241499|Esophageal cancer
135797|NCT02241499|Intestinal Neoplasms
135798|NCT02241499|Gastrointestinal Neoplasms
135799|NCT02241499|Digestive System Neoplasms
135800|NCT02241499|Endoscopic response
135801|NCT02241499|Fluorouracil
135802|NCT02241499|Metabolic response
135803|NCT02241499|Oxaliplatin
135804|NCT02241499|Radiotherapy
135805|NCT02241486|Burn pain
135806|NCT02241486|Procedural pain
135807|NCT02241486|Sublingual fentanyl
135808|NCT02241486|Morphine
135809|NCT02241473|gait
135810|NCT02241473|physical activity
135811|NCT02241473|energy cost
135812|NCT02241473|efficiency
135813|NCT02241460|Premature Ejaculation
135814|NCT02241460|Lidocaine
135815|NCT02241447|aortic valve Stenosis
135816|NCT02241447|Echo
135817|NCT02241447|TAVI
135818|NCT02241447|SAVR
135819|NCT02241447|referral
135820|NCT02241434|Duchenne muscular dystrophy
135821|NCT02241434|Autologous Bone marrow Mononuclear cell therapy
135822|NCT02241434|Stem Cells
135823|NCT02241421|Impaired glucose tolerance
135824|NCT02241421|Glucose Metabolism Disorders
135825|NCT02241421|Metabolic Diseases
135826|NCT02241421|Endocrine System Diseases
135827|NCT02241421|Hyperinsulinism
135828|NCT02241421|Lipid metabolism
135829|NCT02241421|Anti Bacterial Agents
135830|NCT02241421|Gastro Intestinal Tract
135831|NCT02241395|Cerebral Palsy
135832|NCT02241395|autologous bone marrow mononuclear cells
135833|NCT02241395|stem cell
135834|NCT02241369|Aerodigestive Lesions and Malignancies
135835|NCT02241369|Human Papillomavirus
135836|NCT02241369|Squamous Cell Carcinoma
135837|NCT02241356|Down syndrome
135838|NCT02241356|visual functions
135839|NCT02241356|bifocals
135840|NCT02241356|children
135841|NCT02241356|visual acuity at near
135842|NCT02241343|Artificially and reversibly achieved with a blood pressure cuff
135843|NCT02241330|Zinc
135844|NCT02241330|deficiency
135845|NCT02241330|biofortification
135846|NCT02241330|wheat
135847|NCT02241317|Diabetes mellitus
135848|NCT02241317|Hypoglycaemia
135849|NCT02241317|staff training
135850|NCT02241317|Education
135851|NCT02241317|blood glucose
135852|NCT02241304|electromyography
135853|NCT02241304|neuromuscular blockade
135854|NCT02241291|Percutaneous Coronary Intervention
135855|NCT02241291|Registries
135856|NCT02241278|colon surgery
135857|NCT02241278|ketamine
135858|NCT02241278|patient-controlled-analgesia
135859|NCT02241278|preemptive analgesia
135860|NCT02241265|asthma
135861|NCT02241265|thermoplasty
135862|NCT02241252|ECG
135863|NCT02241252|QT interval
135864|NCT02241252|Sotalol
135865|NCT02241252|Dofetilide
135866|NCT02241252|iPhone
135867|NCT02241226|wellbeing
135868|NCT02241226|meditation
135869|NCT02241226|Ayurveda
135870|NCT02241226|yoga
135871|NCT02241226|herbs
135872|NCT02241226|health
135873|NCT02241226|longevity
135874|NCT02241226|individuals
135875|NCT02241213|Stroke
135876|NCT02241213|Aphasia
135877|NCT02241213|Broca
135878|NCT02241187|PEGPH20
135879|NCT02241187|Cetuximab
135880|NCT02241187|14-039
135881|NCT02241174|Atopic Dermatitis
135882|NCT02241161|skin eythema
135883|NCT02241161|rejuvenating cream
135884|NCT02241161|rejuvenating serum
135885|NCT02241161|antioxidant serum
135886|NCT02241135|Rav G protein
135887|NCT02241135|rabies
135888|NCT02241135|VNT
135889|NCT02241135|immunogenicity
135890|NCT02241135|PrEP vaccination
135891|NCT02241135|mRNA
135892|NCT02241135|CV7201
135893|NCT02241122|prostate cancer
135894|NCT02241122|PSA
135895|NCT02241122|MRI
135896|NCT02241122|biopsy
135897|NCT02241122|biomarker
135898|NCT02241109|aortic stenosis progression
135899|NCT02241109|aortic valve sclerosis progression
135900|NCT02241109|calcification propensity
135901|NCT02241070|mindfulness meditation
135902|NCT02241070|mental health promotion
135903|NCT02241070|worker
135904|NCT02241057|temperature profile
135905|NCT02241057|air activated 3-cell patch
135906|NCT02241057|adhesion
135907|NCT02241044|argon plasma coagulation, bleeding peptic ulcer
135908|NCT02241031|Megakaryocytic Progenitor Products
135909|NCT02241031|Hematological Diseases
135910|NCT02241031|Thrombocytopenia
135911|NCT02241018|Hematopoietic Stem Cell Transplantation
135912|NCT02241018|Mesenchymal Stem Cells
135913|NCT02241018|CD25 Monoclonal Antibody
135914|NCT02241018|Acute Graft-versus-host disease
135915|NCT02241005|Health-care associated infection
135916|NCT02241005|Skin integrity
135917|NCT02241005|Antimicrobial resistance
135918|NCT02240992|Poor Graft Function
135919|NCT02240992|Delayed platelet engraftment
135920|NCT02240992|Peripheral Blood Stem Cell
135921|NCT02240992|Mesenchymal Stem Cells
135922|NCT02240992|Allogeneic hematopoietic stem cell transplantation
135923|NCT02240979|arterial waveform
135924|NCT02240979|cardiac magnetic resonance imaging
135925|NCT02240979|echocardiography
135926|NCT02240979|intrinsic frequency measures of cardiac function
135927|NCT02240966|Testicular Neoplasms
135928|NCT02240966|Hypogonadism
135929|NCT02240966|Metabolic Syndrome
135930|NCT02240966|Treatment related late effects
135931|NCT02240953|Anticoagulation
135932|NCT02240953|Prosthetic Heart Valves
135933|NCT02240953|Acetylsalicylic acid
135934|NCT02240953|Warfarin
135935|NCT02240953|Thrombosis
135936|NCT02240940|Heart Failure
135937|NCT02240940|Volume Reduction
135938|NCT02240940|Pressure Reduction
135939|NCT02240940|Ischemic Heart Failure
135940|NCT02240940|LAD Infarct
135941|NCT02240927|Anticoagulation
135942|NCT02240927|Prosthetic Heart Valves
135943|NCT02240927|Pregnancy
135944|NCT02240927|Warfarin
135945|NCT02240927|Thrombosis
135946|NCT02240914|Iliac Vein Obstruction
135947|NCT02240914|May-Thurner Syndrome
135948|NCT02240914|Cockett Syndrome
135949|NCT02240914|Vascular Ultrasound
135950|NCT02240914|IVUS
135951|NCT02240901|Laryngeal mask airway
135952|NCT02240901|endotracheal intubation
135953|NCT02240901|postoperative pulmonary complications
135954|NCT02240901|elderly patients
135955|NCT02240888|pneumococcal
135956|NCT02240888|vaccination
135957|NCT02240888|antibody
135958|NCT02240888|response
135959|NCT02240888|immunosuppressive
135960|NCT02240888|treatment
135961|NCT02240888|inflammatory
135962|NCT02240888|rheumatic
135963|NCT02240888|disease
135964|NCT02240875|Ebola
135965|NCT02240875|Zaire
135966|NCT02240849|Neck pain
135967|NCT02240849|functional pillow
135968|NCT02240849|sleep
135969|NCT02240849|cervical lordosis
135970|NCT02240823|Erectile Function
135971|NCT02240823|Mesenchymal Stromal Cells
135972|NCT02240823|Stem Cell
135973|NCT02240797|Anorexia Nervosa
135974|NCT02240797|Neuroimaging
135975|NCT02240797|Positron emission tomography (PET)
135976|NCT02240797|[11C]PKAB
135977|NCT02240784|Porphyria
135978|NCT02240784|AIP
135979|NCT02240784|VP
135980|NCT02240784|HCP
135981|NCT02240784|Variegate
135982|NCT02240784|Coproporphyria
135983|NCT02240771|Transarterial chemotherapy
135984|NCT02240771|Thalidomide
135985|NCT02240771|Capecitabine
135986|NCT02240758|glioma, confocal laser endomicroscopy
135987|NCT02240745|Echocardiography, Stress
135988|NCT02240745|Echocardiography, Three-Dimensional
135989|NCT02240745|Coronary Artery Disease
135990|NCT02240745|Fractional Flow Reserve, Myocardial
135991|NCT02240745|Coronary Circulation
135992|NCT02240615|Epiphora
135993|NCT02240615|Lacrimal Stent
135994|NCT02240615|Lacrimal System
135995|NCT02240602|acute pain
135996|NCT02240602|postoperative
135997|NCT02240602|surgery
135998|NCT02240589|Traumatic Brain Injury
135999|NCT02240589|Memantine
136000|NCT02240589|Memory
136001|NCT02240576|surgery for nasal fracture
136002|NCT02240563|autoimmune thyroiditis
136003|NCT02240563|LLLT
136004|NCT02240563|safety
136005|NCT02240563|ultrasound
136006|NCT02240550|Open Inguinal Hernia
136007|NCT02240537|AML
136008|NCT02240537|MM
136009|NCT02240537|MDS
136010|NCT02240537|sMM
136011|NCT02240524|Gastric adenocarcinoma
136012|NCT02240524|HIPEC
136013|NCT02240524|Paclitaxel
136014|NCT02240524|Oxaliplatin
136015|NCT02240524|Capecitabine
136016|NCT02240511|Body Composition
136017|NCT02240511|Amino Acids Supplementation
136018|NCT02240511|Resistance Exercise
136019|NCT02240498|Abscess
136020|NCT02240498|Drainage
136021|NCT02240485|Pathological gambling
136022|NCT02240485|Treatment
136023|NCT02240485|Marital relationship
136024|NCT02240472|sentinel node biopsy, lymph node metastasis, survival
136025|NCT02240459|crossover study
136026|NCT02240459|placebo controlled
136027|NCT02240459|double blind
136028|NCT02240459|overactive bladder
136029|NCT02240420|Type 2 diabetes prevention in the post-partum
136030|NCT02240420|Behavior change among Latinas,
136031|NCT02240420|Health Coaching, Motivational interviewing techniques
136032|NCT02240407|Pompe Disease
136033|NCT02240407|Gene Therapy
136034|NCT02240407|Repeated dosing
136035|NCT02240407|Immune modulation
136036|NCT02240394|TCD Traumatic brain injury increased intracranial pressure
136037|NCT02240368|Depth anesthesia monitors
136038|NCT02240368|Children anesthesia
136039|NCT02240368|Bispectral monitor
136040|NCT02240368|Entropy monitor
136041|NCT02240342|Ovarian reserve
136042|NCT02240342|Poor response
136043|NCT02240342|Follicle recruitment
136044|NCT02240342|Bone marrow transplant
136045|NCT02240329|respiratory
136046|NCT02240329|cough
136047|NCT02240303|pain
136048|NCT02240303|mobility
136049|NCT02240303|brain
136050|NCT02240303|cognition
136051|NCT02240290|C14
136052|NCT02240290|Dosimetry
136053|NCT02240290|Mass balance
136054|NCT02240290|ADME
136055|NCT02240277|Septic Shock
136056|NCT02240277|Meropenem
136057|NCT02240277|Ciprofloxacin
136058|NCT02240277|Pharmacokinetics
136059|NCT02240264|Omega-3 fatty acids
136060|NCT02240264|Cognitive function
136061|NCT02240264|Academic performance
136062|NCT02240264|Mental health
136063|NCT02240264|Eye tracking
136064|NCT02240264|Krill oil
136065|NCT02240264|LCPUFA
136066|NCT02240251|Inferior Vena Cava Filter
136067|NCT02240251|IVC Filter
136068|NCT02240251|IVC filter removal
136069|NCT02240251|Excimer Laser
136070|NCT02240225|COPD;SRI;Reliability;validity;
136071|NCT02240212|second line treatment
136072|NCT02240212|oncology
136073|NCT02240212|AKT inhibitor
136074|NCT02240212|paclitaxel
136075|NCT02240212|HER2 (ErbB2) negative advanced gastric cancer
136076|NCT02240212|Afuresertib
136077|NCT02240186|Microprocessor-controlled knee
136078|NCT02240186|prosthesis
136079|NCT02240186|amputation
136080|NCT02240173|antipsychotic Jobelyn schizophrenia sorghum bicolor
136081|NCT02240160|Sativex
136082|NCT02240160|Pharmacokinetics
136083|NCT02240160|Oral pH
136084|NCT02240147|adult congenital heart disease
136085|NCT02240147|exercise capacity
136086|NCT02240147|exercise training
136087|NCT02240147|physical activity
136088|NCT02240121|Crohn's Disease
136089|NCT02240121|Rifaximin
136090|NCT02240121|Clinical remission with endoscopic response
136091|NCT02240121|Inflammatory Bowel Disease
136092|NCT02240108|Crohn's Disease
136093|NCT02240108|Rifaximin
136094|NCT02240108|Clinical remission with endoscopic response
136095|NCT02240108|Inflammatory Bowel Disease
136096|NCT02240082|Shiftwork
136097|NCT02240082|Sleep disruption
136098|NCT02240082|Stress
136099|NCT02240030|Parkinson's Disease
136100|NCT02240030|Motor fluctuations
136101|NCT02240030|levodopa
136102|NCT02240030|inhaled drugs
136103|NCT02240030|OFF episodes
136104|NCT02240017|Urothelial cancer, renal function impaired.
136105|NCT02239991|Point of care
136106|NCT02239991|perioperative hemostasis
136107|NCT02239991|thromboelastometry
136108|NCT02239991|bleeding risk
136109|NCT02239991|end-stage liver disease
136110|NCT02239991|hepatic coagulopathy
136111|NCT02239991|whole blood coagulation
136112|NCT02239978|Parkinson Disease
136113|NCT02239978|Posture Balance
136114|NCT02239978|Learning
136115|NCT02239978|Dopamine
136116|NCT02239965|Neuromuscular blockade
136117|NCT02239965|Neuromuscular monitoring
136118|NCT02239965|Focus group interview
136119|NCT02239965|Clinical observation
136120|NCT02239939|older adults, body composition, weight loss, muscle mass
136121|NCT02239926|IBS-D
136122|NCT02239913|Cocaine
136123|NCT02239913|Pharmacotherapy
136124|NCT02239913|Phentermine
136125|NCT02239913|Topiramate
136126|NCT02239913|Self-Administration
136127|NCT02239900|Liver Cancer
136128|NCT02239900|Lung Cancer
136129|NCT02239900|Adrenal Gland
136130|NCT02239900|Metastasis
136131|NCT02239900|Advanced Solid Malignancies
136132|NCT02239900|Ipilimumab
136133|NCT02239900|Yervoy
136134|NCT02239900|BMS-734016
136135|NCT02239900|MDX010
136136|NCT02239900|Stereotactic Body Radiation Therapy
136137|NCT02239900|SBRT
136138|NCT02239900|XRT
136139|NCT02239887|LAA occlusion
136140|NCT02239887|Non-valvular Atrial Fibrillation
136141|NCT02239887|Percutaneous
136142|NCT02239887|Oral Anticoagulation
136143|NCT02239887|Occluder
136144|NCT02239887|WAVECREST
136145|NCT02239874|mammographic breast density, breast disease, breast tissue
136146|NCT02239861|Bladder cancer
136147|NCT02239861|Breast cancer
136148|NCT02239861|Colorectal cancer
136149|NCT02239861|Endometrial cancer
136150|NCT02239861|Gastric cancer
136151|NCT02239861|Head and neck cancer
136152|NCT02239861|HCC
136153|NCT02239861|Lung cancer
136154|NCT02239861|Melanoma
136155|NCT02239861|Neuroblastoma
136156|NCT02239861|Sarcoma (osteo-, synovial, rhabdomyo-, etc)
136157|NCT02239861|Pancreatic cancer
136158|NCT02239861|Prostate cancer
136159|NCT02239861|Renal cell carcinoma
136160|NCT02239861|Thyroid cancer
136161|NCT02239861|cytotoxic T lymphocytes
136162|NCT02239822|Electrodes, Implanted
136163|NCT02239822|Electric Stimulation Therapy
136164|NCT02239809|Electrodes, Implanted
136165|NCT02239809|Electric Stimulation Therapy
136166|NCT02239796|transcutaneous posterior tibial nerve stimulation
136167|NCT02239796|Randomised controlled trial
136168|NCT02239796|Feasibility
136169|NCT02239783|osteoarthritis
136170|NCT02239783|avascular necrosis
136171|NCT02239783|ankylosis
136172|NCT02239783|protrusio acetabuli
136173|NCT02239783|painful hip dysplasia
136174|NCT02239783|rheumatoid arthritis
136175|NCT02239783|correction of functional deformity
136176|NCT02239783|revision procedures
136177|NCT02239770|Nicotine
136178|NCT02239770|Random Delivery
136179|NCT02239770|Smoking Cessation
136180|NCT02239770|Plasma Nicotine
136181|NCT02239770|Oral Film
136182|NCT02239757|Transradial Approach, Primary PCI, ST-segment elevation myocardial infarction
136183|NCT02239744|air pollution
136184|NCT02239744|air purification
136185|NCT02239744|intervention
136186|NCT02239744|randomized controlled trial
136187|NCT02239744|cardiovascular health
136188|NCT02239744|pulmonary health
136189|NCT02239731|EGFRI
136190|NCT02239731|Epidermal Growth Factor Receptor Inhibition
136191|NCT02239731|Skin toxicity
136192|NCT02239731|Topical
136193|NCT02239731|Doxycycline
136194|NCT02239731|Foam
136195|NCT02239731|Phase II
136196|NCT02239731|Cetuximab
136197|NCT02239731|Panitumumab
136198|NCT02239731|Vectibix
136199|NCT02239731|Erbitux
136200|NCT02239731|Rash
136201|NCT02239718|Resin bonded bridges
136202|NCT02239718|Clinical trial
136203|NCT02239718|Prospective
136204|NCT02239718|Survival
136205|NCT02239718|Oral health related quality of life
136206|NCT02239705|Trans pulmonary thermodilution
136207|NCT02239705|Hemodynamic
136208|NCT02239679|Actinic Keratosis
136209|NCT02239666|Dermatology, plaque psoriasis, biologic treatment, biologic naive
136210|NCT02239614|dengue fever
136211|NCT02239614|dengue
136212|NCT02239601|Physical Therapy
136213|NCT02239601|Physiotherapy
136214|NCT02239601|Breast Cancer
136215|NCT02239601|Chemotherapy Induced Peripheral Neuropathy (CIPN)
136216|NCT02239601|Nerve gliding exercises
136217|NCT02239601|Nerve Entrapment
136218|NCT02239575|Assorted cancers (oncology)
136219|NCT02239562|sPIF
136220|NCT02239562|synthetic PreImplantation Factor
136221|NCT02239562|Autoimmune
136222|NCT02239562|Liver
136223|NCT02239562|Hepatitis
136224|NCT02239549|Colonic Polyps
136225|NCT02239549|Polypectomy
136226|NCT02239536|neoplastic colorectal polyp
136227|NCT02239536|hot snare polypectomy
136228|NCT02239536|hot snare polypectomy after saline injection
136229|NCT02239523|Pathologic fracture
136230|NCT02239523|Insufficiency fracture
136231|NCT02239523|Secondary fracture
136232|NCT02239523|Fracture with bone fragility
136233|NCT02239523|Osteoporosis
136234|NCT02239523|Bone loss
136235|NCT02239523|Osteopenia
136236|NCT02239523|Metabolic Bone Disease
136237|NCT02239523|Fragility fracture
136238|NCT02239510|constipation
136239|NCT02239510|bowel habits
136240|NCT02239497|postoperatory pain
136241|NCT02239497|orthopaedic surgery
136242|NCT02239497|femoral block
136243|NCT02239432|Adenocarcinoma of the Lung
136244|NCT02239432|Adenocarcinoma, Bronchiolo-Alveolar
136245|NCT02239419|Critical Limb Ischemia
136246|NCT02239419|Limb Ischemia
136247|NCT02239419|Wound Care
136248|NCT02239419|Hemodialysis
136249|NCT02239419|Dialysis
136250|NCT02239419|Skin Ulceration
136251|NCT02239406|metal on metal total hip
136252|NCT02239406|avasuclar necrosis
136253|NCT02239406|acetabular revision
136254|NCT02239406|bone vascularity
136255|NCT02239393|Multiple Sclerosis
136256|NCT02239393|Mesenchymal Stem Cells
136257|NCT02239393|MSC
136258|NCT02239380|Lorazepam
136259|NCT02239380|Status Epilepticus
136260|NCT02239341|hospitalized
136261|NCT02239341|activity restriction
136262|NCT02239341|bed rest
136263|NCT02239341|antepartum
136264|NCT02239341|pregnant
136265|NCT02239341|high risk
136266|NCT02239328|Lung cancer
136267|NCT02239328|esophageal cancer
136268|NCT02239315|Breast cancers
136269|NCT02239315|Neoadjuvant chemotherapy
136270|NCT02239315|RNA Disruption Assay™ (RDA) score
136271|NCT02239315|Pathological Complete Response (pCR)
136272|NCT02239315|Fine Needle Aspiration Biopsy
136273|NCT02239302|Obstructed defaecation syndrome
136274|NCT02239302|Transperineal Ultrasound
136275|NCT02239302|Endovaginal Ultrasound
136276|NCT02239302|Evacuation Proctography
136277|NCT02239289|Low back pain
136278|NCT02239289|Rehabilitation
136279|NCT02239289|Biofeedback
136280|NCT02239289|Electromyography
136281|NCT02239289|Kinematic
136282|NCT02239276|Stiripentol
136283|NCT02239276|Dravet syndrome
136284|NCT02239276|Epilepsy
136285|NCT02239276|Epileptic Encephalopathies
136286|NCT02237300|Bulimia nervosa
136287|NCT02237300|Binge eating disorder
136288|NCT02237300|Food craving
136289|NCT02237300|Anxiety
136290|NCT02237300|Bingeing
136291|NCT02237300|Cue Exposure Therapy
136292|NCT02237300|Virtual Reality
136293|NCT02237274|Fontan circulation
136294|NCT02237274|High altitude exposure
136295|NCT02239250|Child health
136296|NCT02239250|Pneumonia
136297|NCT02239250|Diarrhoea
136298|NCT02239250|Household air pollution
136299|NCT02239250|PM2.5
136300|NCT02239250|Stove intervention
136301|NCT02239250|Biomass fuel
136302|NCT02239250|Monitoring and evaluation
136303|NCT02239250|Water filter
136304|NCT02239250|Compliance
136305|NCT02239250|Thermotolerant coliforms
136306|NCT02239250|Rwanda
136307|NCT02239224|FSHD
136308|NCT02239211|BUTEO
136309|NCT02239211|Primary sclerosing cholangitis
136310|NCT02239211|PSC
136311|NCT02239211|VAP-1
136312|NCT02239211|BTT1023
136313|NCT02239211|Human monoclonal antibody
136314|NCT02239198|HDL
136315|NCT02239198|nutrition bar
136316|NCT02239185|Laparoscopy
136317|NCT02239185|purse string
136318|NCT02239185|hernial sac
136319|NCT02239159|transcutaneous electric acupoint stimulation
136320|NCT02239159|elderly patients
136321|NCT02239133|Pelvic Organ Prolapse
136322|NCT02239133|POP
136323|NCT02239107|polycystic ovary syndrome
136324|NCT02239107|laparoscopic drilling
136325|NCT02239107|clomiphene citrate
136326|NCT02239107|n acetyl cysteine
136327|NCT02239107|insulin resistance
136328|NCT02239094|Bipolar Disorder
136329|NCT02239094|depression
136330|NCT02239094|Bipolar depression
136331|NCT02239081|Pharmacokinetics
136332|NCT02239081|Safety
136333|NCT02239068|CT, sedation, oral contrast
136334|NCT02239055|Borderline Personality Disorder
136335|NCT02239055|Mentalization Based Treatment
136336|NCT02239055|MBT Skills Training
136337|NCT02239055|Staff Nurse Perceptions
136338|NCT02239055|Acute Mental Health
136339|NCT02239042|Gingival recessions
136340|NCT02239029|Platelet rich plasma
136341|NCT02239029|Osteoarthritis of knee
136342|NCT02239029|Balance
136343|NCT02239029|Strength
136344|NCT02239016|Sickle cell disease
136345|NCT02239016|Hgb SS
136346|NCT02239016|Hgb SC
136347|NCT02239016|Sβ-Thalassemia
136348|NCT02238977|depression
136349|NCT02238977|ESRD
136350|NCT02238977|hemodialysis
136351|NCT02238951|care coordination, mobile health, chemotherapy, technology
136352|NCT02238938|piecemeal polypectomy
136353|NCT02238938|piecemeal endoscopic mucosal resection (EMR)
136354|NCT02238938|endoscopic submucosal dissection (ESD)
136355|NCT02238938|endoscopic en-bloc resection
136356|NCT02238925|Newly Diagnosed AML
136357|NCT02238925|Secondary AML
136358|NCT02238925|Relapsed/Refractory AML
136359|NCT02238925|Relapsed/Refractory ALL
136360|NCT02238925|MDS
136361|NCT02238912|tinea
136362|NCT02238886|Quality of Life
136363|NCT02238886|Enteral nutrition
136364|NCT02238886|Nutrition Therapy
136365|NCT02238886|Parenteral nutrition, total
136366|NCT02238873|lymphoma
136367|NCT02238873|neutropenia
136368|NCT02238873|pegfilgrastim
136369|NCT02238860|Hepatitis B
136370|NCT02238860|cirrhosis
136371|NCT02238860|Entacavir
136372|NCT02238860|enofovir
136373|NCT02238847|Pancreatic
136374|NCT02238847|Pancreatic Cancer
136375|NCT02238847|Preoperative Biliary Drainage
136376|NCT02238847|Neoadjuvant Therapy
136377|NCT02238834|Phase I
136378|NCT02238834|Safety and tolerability
136379|NCT02238834|Pharmacokinetic
136380|NCT02238834|Randomized
136381|NCT02238834|Double Blind
136382|NCT02238834|Placebo-Controlled
136383|NCT02238834|Single- & Multiple Dose Escalation
136384|NCT02238834|FP-025
136385|NCT02238834|MMP-12 inhibitor
136386|NCT02238821|resectable colorectal cancer
136387|NCT02238808|ER+ breast cancer
136388|NCT02238808|Luminal A
136389|NCT02238808|Estradiol
136390|NCT02238795|Purpura fulminans, Sepsis, Epidemiology, Morbidity, Therapy
136391|NCT02238782|bioavailability
136392|NCT02238782|pharmacokinetics
136393|NCT02238782|I phase
136394|NCT02238782|AZD6244
136395|NCT02238782|cancer
136396|NCT02238769|Hepatocellular Carcinoma, 18F-FluoroethylCholine PET
136397|NCT02238730|Depression
136398|NCT02238730|Depressive Disorder
136399|NCT02238730|Treatment Resistant Depressive Disorder
136400|NCT02238730|Bipolar Disorder
136401|NCT02238730|Major Depressive Disorder
136402|NCT02238730|Electroconvulsive therapy
136403|NCT02238717|Pain
136404|NCT02238717|evoked pain
136405|NCT02238717|healthy volunteer
136406|NCT02238717|pharmacodynamics
136407|NCT02238704|Adherence
136408|NCT02238704|Calcium supplementation
136409|NCT02238704|Prevention of preeclampsia
136410|NCT02238704|Adherence to calcium supplementation
136411|NCT02238691|PEEP
136412|NCT02238691|Air insufflation
136413|NCT02238691|Mask ventilation
136414|NCT02238691|Esophageal manometry
136415|NCT02238691|Esophageal impedance
136416|NCT02238652|Nursing homes
136417|NCT02238652|Dementia
136418|NCT02238652|Quality of Life
136419|NCT02238652|Geriatrics
136420|NCT02238652|Aged
136421|NCT02238652|Activities of Daily Living
136422|NCT02238652|Pain
136423|NCT02238652|Pain management
136424|NCT02238652|Advance Care Planning
136425|NCT02238652|Patient Safety
136426|NCT02238652|Costs and Cost Analysis
136427|NCT02238652|Medication Errors
136428|NCT02238652|Medical Order Entry Systems
136429|NCT02238652|Medication Reconciliation
136430|NCT02238652|Medication Therapy Management
136431|NCT02238652|Depression
136432|NCT02238652|Psychotropic Drugs
136433|NCT02238652|Informed Consent
136434|NCT02238652|Presumed Consent
136435|NCT02238652|Anxiety
136436|NCT02238652|Apathy
136437|NCT02238652|Hospitalization
136438|NCT02238652|Mortality
136439|NCT02238639|Venous thromboembolism
136440|NCT02238639|COPD exacerbations
136441|NCT02238639|Anticoagulation
136442|NCT02238639|Mortality
136443|NCT02238626|amyotrophic lateral sclerosis
136444|NCT02238626|pharmacotherapy
136445|NCT02238626|intervention
136446|NCT02238626|prospective
136447|NCT02238626|safety endpoint
136448|NCT02238626|preliminary efficacy
136449|NCT02238626|ibudilast
136450|NCT02238613|Radioactive stents
136451|NCT02238613|Brachytherapy
136452|NCT02238613|Biliary obstruction
136453|NCT02238613|Intrahepatic Cholangiocarcinoma
136454|NCT02238613|Cholangiocarcinoma of the Extrahepatic Bile Duct
136455|NCT02238613|ampullary carcinoma
136456|NCT02238587|Gandoerma Spores Powder Capsules, head-and-neck cancer.
136457|NCT02238561|non-invasive
136458|NCT02238561|measurement of oxygen
136459|NCT02238561|consumption
136460|NCT02238561|delivery
136461|NCT02238561|post-operative complications
136462|NCT02238548|immunity
136463|NCT02238548|vaccination
136464|NCT02238548|milk
136465|NCT02238522|Chronic lymphocytic leukemia
136466|NCT02238522|B-prolymphocytic leukemia
136467|NCT02238522|Non-Hodgkin's lymphoma
136468|NCT02238522|follicular lymphoma
136469|NCT02238522|mantle cell lymphoma
136470|NCT02238522|marginal zone lymphoma
136471|NCT02238522|small lymphocytic lymphoma
136472|NCT02238522|diffuse large B-cell lymphoma
136473|NCT02238522|unclassifiable lymphoma
136474|NCT02238522|T-cell lymphoma
136475|NCT02238522|Richter's syndrome
136476|NCT02238522|Waldenström's macroglobulinemia
136477|NCT02238509|Breast cancer
136478|NCT02238509|HER2 Positive
136479|NCT02238509|HER2+
136480|NCT02238509|MBC
136481|NCT02238509|Metastatic
136482|NCT02238509|Metastatic breast cancer
136483|NCT02238509|Chemotherapy
136484|NCT02238509|Lapatinib
136485|NCT02238509|Trastuzumab
136486|NCT02238509|anti HER2 therapies
136487|NCT02238496|Glioblastoma
136488|NCT02238496|Anaplastic Astrocytoma
136489|NCT02238496|Anaplastic Oligodendroglioma
136490|NCT02238496|Mixed Glioma
136491|NCT02238496|akt-Oncogene Protein
136492|NCT02238496|mTOR Protein
136493|NCT02238496|Glioma
136494|NCT02238496|Brain Neoplasms
136495|NCT02238496|Brain Tumor, Recurrent
136496|NCT02238483|Chronic Obstructive Pulmonary Disease
136497|NCT02238483|COPD patients
136498|NCT02238483|Exacerbations
136499|NCT02238483|ICS
136500|NCT02238483|LABA
136501|NCT02238470|Ischemic stroke
136502|NCT02238470|Intracerebral hemorrhage
136503|NCT02238470|Subdural hemorrhage
136504|NCT02238470|Microbleed
136505|NCT02238470|Leukoaraiosis
136506|NCT02238470|Oral anticoagulants
136507|NCT02238457|Heart failure
136508|NCT02238457|Losartan
136509|NCT02238444|Warfarin
136510|NCT02238444|Portal Vein
136511|NCT02238444|Anticoagulants
136512|NCT02238444|Cirrhosis
136513|NCT02238444|Hypertension
136514|NCT02238444|Venous Thrombosis
136515|NCT02238444|Splenectomy
136516|NCT02238431|Lucrin depot,
136517|NCT02238431|frozen embryo transfer,
136518|NCT02238431|artificial cycle,
136519|NCT02238431|pregnancy,
136520|NCT02238431|cancellation
136521|NCT02238418|Vitamin D, Calciuria, Paediatrics, Nephrology
136522|NCT02238392|paroxysmal atrial fibrillation
136523|NCT02238392|pulmonary vein isolation
136524|NCT02238392|adenosine
136525|NCT02238392|AF terminatin
136526|NCT02238379|Intranasal oxytocin
136527|NCT02238379|Social perception
136528|NCT02238379|EEG/ERP
136529|NCT02238340|Postoperatory pain
136530|NCT02238340|Oxycodone
136531|NCT02238327|Antiretroviral therapy
136532|NCT02238327|pulmonary function
136533|NCT02238327|biomarkers
136534|NCT02238301|Intrauterine growth restriction
136535|NCT02238301|BOLD effect
136536|NCT02238288|anticoagulation
136537|NCT02238288|extraction
136538|NCT02238288|epsilon amino caproic
136539|NCT02237261|Newly diagnosed symptomatic multiple myeloma
136540|NCT02237248|Adolescent Idiopathic Scoliosis
136541|NCT02237248|Functional Movement Screen
136542|NCT02237248|Y Balance Test
136543|NCT02237235|Schizophrenia
136544|NCT02237235|Schizoaffective disorder
136545|NCT02237235|Cognition
136546|NCT02237235|Magnesium
136547|NCT02237235|Imaging
136548|NCT02237235|Negative symptoms
136549|NCT02237222|Outcome Assessment
136550|NCT02237222|Gait
136551|NCT02237222|Neuromuscular Diseases
136552|NCT02237222|Psychometrics
136553|NCT02237222|Clinical Assessment Tools
136554|NCT02238054|Cardiology
136555|NCT02238054|Intracoronary angioplasty
136556|NCT02238054|Bioresorbable stent
136557|NCT02238041|Glucose monitoring
136558|NCT02238041|Intensive care unit
136559|NCT02238028|Heart rate variability
136560|NCT02238028|Blood pressure
136561|NCT02238028|Circulating biomarkers
136562|NCT02238028|Respirator
136563|NCT02238028|Fine particulate matter
136564|NCT02238015|cataract ,tear film,SS-OCT
136565|NCT02238002|shallow anterior chamber
136566|NCT02238002|narrow angle
136567|NCT02238002|SS-OCT
136568|NCT02237989|knee osteoarthritis, native collagen type 2, paracetamol
136569|NCT02237937|Depression, Affective Disorder
136570|NCT02237924|nasopharyngeal carcinoma
136571|NCT02237924|endostar
136572|NCT02237924|IMRT
136573|NCT02237924|chemoradiation
136574|NCT02237911|total knee replacement
136575|NCT02237911|rehabilitation
136576|NCT02237911|exercise program
136577|NCT02237911|total knee arthroplasty
136578|NCT02237898|Tobacco cessation
136579|NCT02237885|Military Veterans
136580|NCT02237872|Brown Adipose Tissue
136581|NCT02237859|cdiff
136582|NCT02237859|vancomycin
136583|NCT02237859|infection
136584|NCT02237859|clostridium difficile
136585|NCT02237846|osteoarthritis
136586|NCT02237846|knee
136587|NCT02237846|stem cells
136588|NCT02237846|mesenchymal
136589|NCT02237846|umbilical cord
136590|NCT02237833|septic shock
136591|NCT02237833|cerebral oximetry
136592|NCT02237833|vasopressor
136593|NCT02237833|norepinephrine
136594|NCT02237807|Fed Conditions
136595|NCT02237781|AMH
136596|NCT02237781|IVF
136597|NCT02237781|ovarian stimulation
136598|NCT02237768|Fasting conditions
136599|NCT02237755|Clomiphene citrate
136600|NCT02237755|IVF
136601|NCT02237755|Pregnancy Rates
136602|NCT02237755|Ovarian Reserve
136603|NCT02237729|healthy subjects
136604|NCT02237729|immunology
136605|NCT02237729|PK
136606|NCT02237729|Phase 1
136607|NCT02237729|bioequivalence
136608|NCT02237729|biosimilarity
136609|NCT02237729|adalimumab
136610|NCT02237729|single dose.
136611|NCT02237703|Post-traumatic Stress Disorder (PTSD)
136612|NCT02237703|Positron emission tomography (PET)
136613|NCT02237703|Neuroimaging
136614|NCT02237703|Kappa opioid receptor (KOR)
136615|NCT02237677|Post-traumatic stress disorder (PTSD)
136616|NCT02237677|Trauma
136617|NCT02237677|Neuroimaging
136618|NCT02237677|Positron emission tomography (PET)
136619|NCT02237677|[11C]OMAR
136620|NCT02237677|Endocannabinoid
136621|NCT02237664|Thoracoscopy
136622|NCT02237664|Patient-controlled analgesia
136623|NCT02237664|Paravertebral analgesia
136624|NCT02237651|anesthesia
136625|NCT02237651|bronchosocopy
136626|NCT02237651|lung transplantation
136627|NCT02237638|VEGF
136628|NCT02237638|Vaccine
136629|NCT02237638|Angiogenesis
136630|NCT02237625|Hypophosphatasia
136631|NCT02237625|HPP
136632|NCT02237599|SSEP
136633|NCT02237599|neuropraxia
136634|NCT02237599|intraoperative
136635|NCT02237599|automated
136636|NCT02237586|Plasmodium falciparum malaria
136637|NCT02237586|Malaria
136638|NCT02237586|PfSPZ Challenge
136639|NCT02237586|Controlled Human Malaria Infection (CHMI)
136640|NCT02237586|Sickle Cell Trait
136641|NCT02237586|Sporozoites
136642|NCT02237573|general practice
136643|NCT02237573|viral infections
136644|NCT02237573|consultation reports
136645|NCT02237573|drug prescription
136646|NCT02237560|MCI
136647|NCT02237560|Exergaming
136648|NCT02237560|Cognition
136649|NCT02237560|Exercise
136650|NCT02237560|Older Adults
136651|NCT02237547|spinal cord injury
136652|NCT02237547|mesenchymal
136653|NCT02237547|bone marrow
136654|NCT02237547|mononuclear cells
136655|NCT02237547|stem cells
136656|NCT02237547|umbilical cord
136657|NCT02237534|Lanthanum
136658|NCT02237534|Calcium Carbonate
136659|NCT02237534|Vascular Calcification
136660|NCT02237521|Incretin hormones
136661|NCT02237521|End-stage renal disease
136662|NCT02237521|ESRD
136663|NCT02237521|GLP-1
136664|NCT02237521|GIP
136665|NCT02237521|Insulin
136666|NCT02237521|Glucagon
136667|NCT02237469|Breast cancer.
136668|NCT02237469|Breast conserving surgery.
136669|NCT02237469|Radiotherapy.
136670|NCT02237469|Treatment planning.
136671|NCT02237469|Prone.
136672|NCT02237456|Myocardial infarction
136673|NCT02237456|Atherosclerosis
136674|NCT02237456|PCI
136675|NCT02237456|OCT
136676|NCT02237456|Optical coherence tomography
136677|NCT02237456|Stent
136678|NCT02237456|Bioresorbable stents
136679|NCT02237443|Patient Safety
136680|NCT02237430|Coronary angiography (CAG)
136681|NCT02237417|MRI
136682|NCT02237417|Imaging
136683|NCT02237417|Antipsychotic
136684|NCT02237404|Follow-Up studies
136685|NCT02237404|Biological Pacemakers
136686|NCT02237404|Telemedicine
136687|NCT02237404|Efficiency
136688|NCT02237391|High Frequency Emergency Department Visits
136689|NCT02237391|Healthcare Utilization
136690|NCT02237391|Chronic Pain
136691|NCT02237391|Interdisciplinary
136692|NCT02237378|FDG lung and RV uptake
136693|NCT02237365|neurological disability
136694|NCT02237365|tuberculous meningitis (TBM)
136695|NCT02237365|safety
136696|NCT02237365|aspirin
136697|NCT02237365|efficacy
136698|NCT02237352|Diabetes mellitus
136699|NCT02237352|Diabetic nephropathy
136700|NCT02237352|Social Factors
136701|NCT02237352|Biological Factors
136702|NCT02237352|VEGF-A
136703|NCT02237352|Tenascin C
136704|NCT02237352|Disease characterization
136705|NCT02237352|Mechanisms
136706|NCT02237352|Kidney
136707|NCT02237352|Chronic kidney disease
136708|NCT02237352|Secondary nephropathy
136709|NCT02237352|South America
136710|NCT02237352|Hispanics
136711|NCT02237352|Ecuador
136712|NCT02237352|Biomarkers
136713|NCT02237339|Allopurinol
136714|NCT02237339|Cardiac MRI (CMR)
136715|NCT02237339|Flow mediated dilatation (FMD)
136716|NCT02237339|Pulse wave analysis (PWA)
136717|NCT02237339|Endothelial function
136718|NCT02237339|Scar
136719|NCT02237339|Hypertrophy
136720|NCT02237339|Hypertension
136721|NCT02237326|Visual Inspection with Acetic Acid
136722|NCT02237326|Visual Inspection with Lugol's Iodine
136723|NCT02237326|Cervical Intraepithelial neoplasia
136724|NCT02237326|Cervical Cancer Screening
136725|NCT02237326|HIV infected women
136726|NCT02237313|psychological support
136727|NCT02237313|therapeutic education
136728|NCT02237313|vulnerability of patients
136729|NCT02237196|cat-allergic
136730|NCT02237196|cat immunotherapy
136731|NCT02237196|anti-thymic stromal lymphopoietin (anti-TSLP)
136732|NCT02237170|Sipuleucel-T
136733|NCT02237170|Castration Resistant Prostate Cancer
136734|NCT02237170|Provenge
136735|NCT02237157|pancreatic cancer
136736|NCT02237157|unresectable
136737|NCT02237157|gemcitabine
136738|NCT02237157|device
136739|NCT02237157|local delivery
136740|NCT02237157|chemoembolization
136741|NCT02237131|Endometriosis
136742|NCT02237131|Oral contraceptives
136743|NCT02237131|Laparoscopy
136744|NCT02237118|Acute
136745|NCT02237118|wound
136746|NCT02237118|management
136747|NCT02237118|measured
136748|NCT02237118|Visual analoge scale
136749|NCT02237066|OCT
136750|NCT02237066|PTA
136751|NCT02237066|Balloon
136752|NCT02237053|Energy expenditure
136753|NCT02237053|Glucagon
136754|NCT02237053|Octreotide
136755|NCT02237053|Weight loss
136756|NCT02237040|Children
136757|NCT02237040|mandible
136758|NCT02237040|condylar fracture
136759|NCT02237040|conservative treatment
136760|NCT02237040|functional treatment
136761|NCT02237027|HIV
136762|NCT02237027|Early treatment as prevention (TasP)
136763|NCT02237027|Pre-exposure prophylaxis (PrEP)
136764|NCT02237027|antiretroviral treatment
136765|NCT02237027|prevention
136766|NCT02237027|feasibility
136767|NCT02237027|female sex workers
136768|NCT02237027|Benin
136769|NCT02237027|West Africa
136770|NCT02237001|meniscal
136771|NCT02237001|meniscus
136772|NCT02237001|repair
136773|NCT02237001|knee
136774|NCT02237001|arthroscopy knee
136775|NCT02237001|horizontal
136776|NCT02236988|Apremilast
136777|NCT02236988|Healthy male subjects
136778|NCT02236988|Pharmacokinetics
136779|NCT02236949|pediatric pain
136780|NCT02236949|intervention sustainability
136781|NCT02236936|Squamous Cell Carcinoma
136782|NCT02236936|Head and neck
136783|NCT02236936|SCCHN
136784|NCT02236936|Parenteral nutrition
136785|NCT02236936|Larynx
136786|NCT02236936|Hypopharynx
136787|NCT02236936|Cavum oris
136788|NCT02236936|Radiotherapy
136789|NCT02236936|Cetuximab
136790|NCT02236936|Cisplatin
136791|NCT02236923|cardiovascular
136792|NCT02236923|surgery
136793|NCT02236923|ascending aorta
136794|NCT02236923|aortic dissection
136795|NCT02236910|somatostatin receptor positive tumour
136796|NCT02236884|rectal cancer
136797|NCT02236884|no scar
136798|NCT02236884|NOTES
136799|NCT02236884|TaTME
136800|NCT02236884|feasibility
136801|NCT02236884|safety
136802|NCT02236871|Adolescents
136803|NCT02236871|Dairy
136804|NCT02236871|Bone
136805|NCT02236858|COPD
136806|NCT02236845|Insomnia, medical device, sleep latency
136807|NCT02236806|Breast cancer
136808|NCT02236806|Adjuvant chemotherapy
136809|NCT02236806|Neoadjuvant chemotherapy
136810|NCT02236806|Cardioprotection
136811|NCT02236806|Anthracyclines
136812|NCT02236780|in vitro fertilisation
136813|NCT02236780|environmental conditions
136814|NCT02236780|pregnancy
136815|NCT02236780|live birth rate
136816|NCT02236754|dihydrotetrabenazine
136817|NCT02236754|beta cell mass
136818|NCT02236754|diabetes mellitus
136819|NCT02236702|Major Depressive Disorder
136820|NCT02236702|Anhedonia
136821|NCT02236702|Positron Emission Tomography (PET)
136822|NCT02236702|Kappa Opioid Receptor (KOR)
136823|NCT02236676|motor learning TBI
136824|NCT02236663|Intimate Partner Violence
136825|NCT02236663|Dating Violence
136826|NCT02236663|Relationships
136827|NCT02236663|Safety Planning
136828|NCT02236663|College
136829|NCT02236663|Student
136830|NCT02236663|App
136831|NCT02236650|Parental Resilience
136832|NCT02236650|Parental Stress
136833|NCT02236650|Family Adaptation
136834|NCT02236650|Autistic Disorder
136835|NCT02236650|Behavior
136836|NCT02236650|Child Behavior
136837|NCT02236650|Child Development Disorders
136838|NCT02236650|Pervasive Developmental Disabilities
136839|NCT02236650|Caregivers
136840|NCT02236650|Parents
136841|NCT02236650|Parenting
136842|NCT02236650|Primary Health Care
136843|NCT02236637|Adenocarcinoma of the Prostate
136844|NCT02236637|Registry
136845|NCT02236637|metastatic castration-resistant prostate cancer
136846|NCT02236611|COPD
136847|NCT02236611|inhaler ease of use
136848|NCT02236611|glycopyrronium
136849|NCT02236611|umeclidinium
136850|NCT02236611|novel dry powder inhaler
136851|NCT02236611|long-acting muscarinic antagonist
136852|NCT02236611|inhaler errors
136853|NCT02236598|borderline hypokalemia
136854|NCT02236598|glucose tolerance
136855|NCT02236598|insulin secretion
136856|NCT02236598|insulin sensitivity
136857|NCT02236598|fasting glucose
136858|NCT02236598|African American
136859|NCT02236585|uterine artery embolization, epidural , patient-controlled analgesia
136860|NCT02236572|Postmenopausal
136861|NCT02236572|ER-positive, PR-positive, HER2-negative
136862|NCT02236572|Low and intermediate risk
136863|NCT02236559|high flow therapy
136864|NCT02236559|high flow nasal cannula
136865|NCT02236559|acute respiratory failure
136866|NCT02236559|noninvasive ventilation
136867|NCT02236546|fluorodeoxyglucose
136868|NCT02236546|FDG
136869|NCT02236546|PET/CT
136870|NCT02236546|melanoma
136871|NCT02236546|imaging biomarkers
136872|NCT02236546|cancer imaging
136873|NCT02236520|Na+ MRI
136874|NCT02236520|salt stores
136875|NCT02236494|alcoholism
136876|NCT02236494|dangerous behavior
136877|NCT02236494|aged
136878|NCT02236494|emergency medicine
136879|NCT02236455|complementary medicine
136880|NCT02236455|state anxiety
136881|NCT02236455|acute pain
136882|NCT02236455|self-efficacy
136883|NCT02236455|surgery
136884|NCT02236455|medical music intervention
136885|NCT02236455|nature therapy
136886|NCT02236455|relaxation technique
136887|NCT02236442|Cephalalgia
136888|NCT02236442|Headache
136889|NCT02236442|Migraine
136890|NCT02236442|Pain
136891|NCT02236442|Global
136892|NCT02236442|Treatment
136893|NCT02236442|Oxygen
136894|NCT02236442|Emergency
136895|NCT02236442|Treatment of cephalalgia in emergency department
136896|NCT02236429|bacterial vaginitis
136897|NCT02236429|vaginal flora
136898|NCT02236429|microbiome
136899|NCT02236416|Dementia
136900|NCT02236416|Prevention
136901|NCT02236416|Physical Activity
136902|NCT02236403|Blepharitis , Demodex, Ivermectin, Metronidazole
136903|NCT02236390|Nightmare
136904|NCT02236390|PTSD
136905|NCT02236390|Sleep
136906|NCT02236390|Emotion Regulation
136907|NCT02236390|Exposure Relaxation and Rescripting Therapy
136908|NCT02236390|Cognitive Processing Therapy
136909|NCT02236377|ERRT
136910|NCT02236377|Nightmares
136911|NCT02236377|Sleep
136912|NCT02236377|Trauma
136913|NCT02236377|PTSD
136914|NCT02236351|patching
136915|NCT02236351|pediatric ophthalmology
136916|NCT02236338|chronic venous insufficiency
136917|NCT02236338|varicose vein
136918|NCT02236338|greater saphenous vein
136919|NCT02236299|Right Coronary Artery
136920|NCT02236299|Percutaneous Coronary Intervention
136921|NCT02236299|Diastolic Dysfunction
136922|NCT02236299|Glucagon-like peptide-1
136923|NCT02236299|GLP-1
136924|NCT02236299|Stunning
136925|NCT02236299|Cardioprotection
136926|NCT02236286|freezing of gait (FOG)
136927|NCT02236286|balance
136928|NCT02236286|gait
136929|NCT02236286|exercise
136930|NCT02236273|Human papillomavirus
136931|NCT02236273|vaccination
136932|NCT02236273|text message
136933|NCT02236273|reminder
136934|NCT02236247|ivabradine
136935|NCT02236247|heart rate
136936|NCT02236247|heart failure
136937|NCT02236234|HIV
136938|NCT02236234|HPV
136939|NCT02236234|Clinical trial
136940|NCT02236234|outcome
136941|NCT02236195|Urothelial
136942|NCT02236195|Bladder
136943|NCT02236195|HDAC
136944|NCT02236195|MGCD0103
136945|NCT02236195|Mocetinostat
136946|NCT02236195|CREBBP
136947|NCT02236195|EP300
136948|NCT02236195|Mirati
136949|NCT02236195|MethylGene
136950|NCT02236143|Healthy
136951|NCT02236130|pediatric regional
136952|NCT02236117|heart rate variability
136953|NCT02236117|children
136954|NCT02236117|progressive test
136955|NCT02236104|neuromuscular disorders
136956|NCT02236104|mechanical insufflation-exsufflation
136957|NCT02236104|respiratory parameters
136958|NCT02236104|plethysmography opto electronic
136959|NCT02236104|Vital capacity
136960|NCT02236091|cerebral palsy
136961|NCT02236091|stroke
136962|NCT02236091|traumatic brain injury
136963|NCT02236065|Umbilical cord blood
136964|NCT02236065|Granulocyte-colony stimulating factor
136965|NCT02236065|Brain injury
136966|NCT02236065|Neurodegenerative disorder
136967|NCT02236065|Efficacy
136968|NCT02236065|Safety
136969|NCT02236052|Influenza
136970|NCT02236052|Human
136971|NCT02236052|RNA Virus Infections
136972|NCT02236052|Immunologic
136973|NCT02236052|Immunogenic Factors
136974|NCT02236052|Physiological Effects of Drugs
136975|NCT02236052|Virus diseases
136976|NCT02236052|Orthomyxoviridae Infections
136977|NCT02236052|Infection
136978|NCT02236039|Diesel exhaust
136979|NCT02236039|Air pollution
136980|NCT02236039|Airway responsivness
136981|NCT02236026|Nestorone use as an IV solution on heart rate;
136982|NCT02236026|Abnormality in Heart Rate or Rhythm, Unspecified as to Time of Onset
136983|NCT02236013|ASP2215
136984|NCT02236013|Acute Myeloid Leukemia
136985|NCT02236013|Idarubicin
136986|NCT02236013|Cytarabine
136987|NCT02236000|NSABP
136988|NCT02236000|Trastuzumab Emtansine
136989|NCT02236000|T DM1
136990|NCT02236000|Neratinib
136991|NCT02236000|Metastatic Breast Cancer
136992|NCT02236000|HER2 positive
136993|NCT02236000|Dose Escalation
136994|NCT02235974|stroke
136995|NCT02235974|critical periods
136996|NCT02235974|sensitive periods
136997|NCT02235974|hemiparesis
136998|NCT02235974|upper extremity
136999|NCT02235974|physical rehabilitation
137000|NCT02235974|arm therapy
137001|NCT02235974|occupational therapy
137002|NCT02235974|physical therapy
137003|NCT02235974|task oriented training
137004|NCT02235974|patient focused
137005|NCT02235974|arm function
137006|NCT02235974|hand function
137007|NCT02235974|neurorehabilitation
137008|NCT02235974|motor learning
137009|NCT02235974|motor control
137010|NCT02235974|motor function
137011|NCT02235974|motor recovery
137012|NCT02235974|skill acquisition
137013|NCT02235974|skill training
137014|NCT02235948|arsenic induced health problem
137015|NCT02235948|modifying effects
137016|NCT02235948|folic acid
137017|NCT02235948|oxidative damage
137018|NCT02235948|clinical trial
137019|NCT02235922|Aged
137020|NCT02235922|Exercise
137021|NCT02235922|Cognition
137022|NCT02235922|Functional capacity
137023|NCT02235909|Pediatric Hypertension
137024|NCT02235909|High Blood Pressure
137025|NCT02235909|Hypertension
137026|NCT02235909|Pediatric
137027|NCT02235909|Primary Hypertension
137028|NCT02235909|Secondary Hypertension
137029|NCT02235896|risk factors, African American, lipids, blood pressure
137030|NCT02235883|Coronary artery disease
137031|NCT02235883|FFR
137032|NCT02235883|diagnosis
137033|NCT02235883|computational model
137034|NCT02235883|non-invasive
137035|NCT02235870|Weight Loss
137036|NCT02235870|Obesity
137037|NCT02235870|BMI
137038|NCT02235857|pediatric, renal transplantation, recurrence, drug-resistant
137039|NCT02235844|Mesenchymal
137040|NCT02235844|Stem Cells
137041|NCT02235844|Umbilical Cord
137042|NCT02235844|Duchenne's
137043|NCT02235844|Muscular Dystrophy
137044|NCT02235831|DACP MF
137045|NCT02235831|DAILIES AquaComfort Plus® Multifocal
137046|NCT02235831|presbyopia
137047|NCT02235831|visual performance
137048|NCT02235818|tennis elbow, treatment, lateral epicondylitis, immediate effects
137049|NCT02235805|Metabolic Syndrome
137050|NCT02235805|Obesity
137051|NCT02235805|Magnesium Supplementation
137052|NCT02235805|Vascular Stiffness
137053|NCT02235805|Vascular Function
137054|NCT02235779|ILD
137055|NCT02235779|Pulmonary fibrosis
137056|NCT02235779|Cryobiopsy
137057|NCT02235779|Transbronchial
137058|NCT02235766|Cardiac Resynchronization Therapy
137059|NCT02235766|Satellite Tele-Echocardiography
137060|NCT02235740|Open label
137061|NCT02235740|carfilzomib
137062|NCT02235740|Phase I
137063|NCT02235740|clinical activity
137064|NCT02235740|pharmacokinetics
137065|NCT02235740|afuresertib
137066|NCT02235740|relapsed
137067|NCT02235740|refractory
137068|NCT02235740|safety
137069|NCT02235740|multiple myeloma
137070|NCT02235714|Airway inflammation
137071|NCT02235714|Tetraplegia
137072|NCT02235714|Asthma
137073|NCT02235714|Exhaled breath condensate
137074|NCT02235714|Spirometry
137075|NCT02235714|Pulmonary Function Testing
137076|NCT02235701|soft tissue sarcoma
137077|NCT02235701|aldoxorubicin
137078|NCT02235701|ifosfamide
137079|NCT02235701|mesna
137080|NCT02235701|phase 1
137081|NCT02235701|INNO-206
137082|NCT02235688|aldoxorubicin
137083|NCT02235688|INNO-206
137084|NCT02235688|solid tumors
137085|NCT02235688|gemcitabine
137086|NCT02235688|phase 1
137087|NCT02235675|Angioplasty
137088|NCT02235675|Peripheral Artery Disease
137089|NCT02235675|Critical Limb Ischemia
137090|NCT02235675|CLI
137091|NCT02235675|PAD
137092|NCT02235662|HIV
137093|NCT02235662|LNG
137094|NCT02235662|IVR
137095|NCT02235662|Contraception
137096|NCT02235662|Prevention
137097|NCT02235623|Laparoscopic Surgery
137098|NCT02235623|Orchiopexy
137099|NCT02235610|Lung Transplantation
137100|NCT02235610|Ex Vivo Lung Perfusion
137101|NCT02235610|EVLP
137102|NCT02235597|patient access
137103|NCT02235597|patient centered care
137104|NCT02235597|scheduling
137105|NCT02235597|access barriers
137106|NCT02235597|improve efficiency
137107|NCT02235597|decision making tools
137108|NCT02235597|underserved
137109|NCT02235584|Incretin hormones
137110|NCT02235584|GLP-1
137111|NCT02235584|GIP
137112|NCT02235584|Dexamethasone
137113|NCT02235558|Acute Ischemic Stoke
137114|NCT02235558|Thrombectomy
137115|NCT02235558|Intraarterial Pharmacotherapy
137116|NCT02235558|Neuroprotection
137117|NCT02235545|HV Lead
137118|NCT02235545|ICD
137119|NCT02235545|CRT-D System
137120|NCT02235545|Treatment of Heart Failure
137121|NCT02235545|Treamtent of life-threatening ventricular tachyarrhythmia
137122|NCT02235545|Optisure
137123|NCT02235532|clinical trial
137124|NCT02235532|oral hygiene
137125|NCT02235532|Gingivitis
137126|NCT02235532|Aloevera
137127|NCT02235532|Toothpaste
137128|NCT02235532|anti-inflammatory agents
137129|NCT02235493|HPP
137130|NCT02235493|Soft Bones
137131|NCT02235493|low Alkaline Phosphatase
137132|NCT02235493|genetic metabolic disorder
137133|NCT02235493|alkaline phosphatase
137134|NCT02235493|tissue non-specific alkaline phosphatase
137135|NCT02235493|rickets
137136|NCT02235493|osteomalacia
137137|NCT02235467|autism
137138|NCT02235467|videomodeling
137139|NCT02235467|behavioral therapy
137140|NCT02235467|parental training
137141|NCT02235454|glaucoma
137142|NCT02235454|OCT
137143|NCT02235454|spectral domain optical coherence tomography
137144|NCT02235441|Gastrointestinal malignancy
137145|NCT02235441|Cardiopulmonary fitness
137146|NCT02235441|Chemoradiation therapy
137147|NCT02235376|Critical Care
137148|NCT02235376|Brain injured patients
137149|NCT02235376|Mechanical Ventilation
137150|NCT02235376|Weaning
137151|NCT02235376|Extubation
137152|NCT02235376|Prognostic score
137153|NCT02235376|Clinical examination
137154|NCT02235363|face lift
137155|NCT02235363|thread lift
137156|NCT02235363|retaining ligament
137157|NCT02235363|SMAS
137158|NCT02235350|Adult
137159|NCT02235350|Male
137160|NCT02235350|Female
137161|NCT02235350|Neuronal Plasticity
137162|NCT02235350|Imitative Behavior/physiology
137163|NCT02235350|Magnetic Resonance Imaging
137164|NCT02235350|Psychomotor Disorders/rehabilitation
137165|NCT02235350|Follow-up Studies
137166|NCT02235350|Video Recording
137167|NCT02235350|Physical Therapy Modalities
137168|NCT02235350|Recovery of Function
137169|NCT02235350|Action Observation Treatment
137170|NCT02235350|Mirror Neuron System
137171|NCT02235350|Stroke/rehabilitation
137172|NCT02235350|Upper Limb
137173|NCT02235337|Concussion
137174|NCT02235337|Sports related concussion
137175|NCT02235337|mTBI
137176|NCT02235337|Vitamin B
137177|NCT02235337|Riboflavin
137178|NCT02235311|Proton pump inhibitor
137179|NCT02235311|Upper gastrointestinal bleed
137180|NCT02235311|Ulcer healing
137181|NCT02235298|epicardial fat
137182|NCT02235298|diabetes
137183|NCT02235298|dapagliflozin
137184|NCT02235285|capsular contracture
137185|NCT02235285|reoperation
137186|NCT02235285|breast augmentation
137187|NCT02235246|perioperative intravenous magnesium
137188|NCT02235246|endoscopic submucosal dissection
137189|NCT02235220|Bruxism
137190|NCT02235207|sedentary work
137191|NCT02235207|musculoskeletal pain
137192|NCT02235207|neuromuscular exercise
137193|NCT02235207|physical fitness
137194|NCT02235207|quality of life
137195|NCT02235207|work ability
137196|NCT02235181|Twin Pregnancy
137197|NCT02235181|Prevention of Preterm birth
137198|NCT02235181|Short Cervix
137199|NCT02235181|Arabin cervical pessary
137200|NCT02235116|Number of patients
137201|NCT02235116|full body skin exam
137202|NCT02235116|Survey
137203|NCT02235116|preferences
137204|NCT02235090|Spinal muscular atrophy
137205|NCT02235090|Neuromuscular disorders
137206|NCT02235090|Outcome measures
137207|NCT02235090|Visit-free clinical trial design
137208|NCT02235077|Heart Failure
137209|NCT02235077|Heart Diseases
137210|NCT02235077|Cardiovascular Diseases
137211|NCT02235077|Spironolactone
137212|NCT02235077|Aldactone
137213|NCT02235025|mild COPD
137214|NCT02235025|dyspnea
137215|NCT02235025|exercise
137216|NCT02235025|respiratory mechanics
137217|NCT02235012|Schizophrenia
137218|NCT02235012|Ketamine
137219|NCT02235012|Cognitive biases
137220|NCT02235012|Uncertainty
137221|NCT02234999|Pharmacokinetics, Healthy Subjects
137222|NCT02234986|Advanced Fibrolamellar Carcinoma
137223|NCT02234947|type 1 diabetes
137224|NCT02234947|pancreas volume
137225|NCT02234934|Gene Therapy
137226|NCT02234934|X-Linked Chronic Granulomatous Disease (X-CGD)
137227|NCT02234934|Lentiviral Vector
137228|NCT02234921|Prostate
137229|NCT02234921|Adenocarcinoma
137230|NCT02234921|Metastatic
137231|NCT02234921|DRibble
137232|NCT02234921|Immunotherapy
137233|NCT02234921|Microbiome
137234|NCT02234908|Tuberculosis
137235|NCT02234908|Drug-resistant tuberculosis
137236|NCT02234908|Incentives
137237|NCT02234908|Symptom screening
137238|NCT02234895|osteoarthritis
137239|NCT02234895|knee
137240|NCT02234895|biomechanics
137241|NCT02234895|treatment
137242|NCT02234895|symptoms
137243|NCT02234869|Peginterferon Beta-1a
137244|NCT02234869|Relapsing Multiple Sclerosis
137245|NCT02234869|RMS
137246|NCT02234869|flu-like symptoms
137247|NCT02234856|Hysterectomy
137248|NCT02234856|Laparoscopy
137249|NCT02234856|Surgical assessment
137250|NCT02234856|Education
137251|NCT02234843|Pediatric
137252|NCT02234830|PCI
137253|NCT02234817|fall risk
137254|NCT02234817|balance
137255|NCT02234817|older adults
137256|NCT02234817|Tai Chi
137257|NCT02234817|Multimodal exercise intervention
137258|NCT02234804|Coronary angiography (CAG)
137259|NCT02234804|Percutaneous coronary intervention (PCI)
137260|NCT02234804|OCT
137261|NCT02234804|Stent
137262|NCT02234778|critical limb ischemia
137263|NCT02234778|autologous stromal vascular fraction
137264|NCT02234765|OSA
137265|NCT02234765|OSAS
137266|NCT02234765|Sleep apnea
137267|NCT02234765|Management
137268|NCT02234765|Primary Care
137269|NCT02234765|Sleep Unit
137270|NCT02234765|Cost-Effectiveness
137271|NCT02234765|ESS
137272|NCT02234752|Schizophrenia
137273|NCT02234752|Schizoaffective Disorder
137274|NCT02234752|Cognition
137275|NCT02234752|Cognitive Impairment
137276|NCT02234752|Galantamine
137277|NCT02234752|Memantine
137278|NCT02234739|voriconazole
137279|NCT02234739|COPD
137280|NCT02234739|invasive pulmonary aspergillosis
137281|NCT02234739|efficacy
137282|NCT02234739|safety
137283|NCT02234726|child health
137284|NCT02234726|child development
137285|NCT02234726|malnutrition
137286|NCT02234726|stunting
137287|NCT02234726|community-based health services
137288|NCT02234687|post-traumatic stress disorder
137289|NCT02234674|Pulsating suit
137290|NCT02234674|lymphedema
137291|NCT02234674|leg volume
137292|NCT02234661|Low income
137293|NCT02234661|Education
137294|NCT02234661|Poverty
137295|NCT02234661|Children
137296|NCT02234661|Parents
137297|NCT02234661|Head Start
137298|NCT02234648|Vascular Function
137299|NCT02234648|tart Montmorency cherries
137300|NCT02234648|Arterial Stiffness
137301|NCT02234648|Blood Flow
137302|NCT02234635|visual acuity
137303|NCT02234635|objective visual quality
137304|NCT02234635|multifocal intraocular lens
137305|NCT02234635|tear-film quality dynamics
137306|NCT02234622|Stress Disorders, Post-Traumatic
137307|NCT02234622|Yoga
137308|NCT02234622|Veterans
137309|NCT02234609|dentistry
137310|NCT02234609|dental caries
137311|NCT02234609|atraumatic restorative Treatment
137312|NCT02234609|effectiveness
137313|NCT02234596|Nintedanib
137314|NCT02234596|14-094
137315|NCT02234583|pain
137316|NCT02234583|fibromyalgia
137317|NCT02234570|neurocysticercosis
137318|NCT02234570|pork tapeworm
137319|NCT02234570|Taenia solium
137320|NCT02234557|Motor Control
137321|NCT02234557|Attention
137322|NCT02234557|Cognitive Control
137323|NCT02234544|vitamin D
137324|NCT02234544|absorption
137325|NCT02234544|ezetimibe
137326|NCT02234531|Virtual Reality,
137327|NCT02234531|Enhanced Feedback,
137328|NCT02234531|Stroke,
137329|NCT02234531|Rehabilitation,
137330|NCT02234531|Motor Learning
137331|NCT02234505|prosthetics
137332|NCT02234505|amputation
137333|NCT02234505|gait stability
137334|NCT02234505|step variability
137335|NCT02234505|load cell
137336|NCT02234492|Human immunodeficiency virus (HIV)
137337|NCT02234492|Statin therapy
137338|NCT02234492|Cardiovascular disease (CVD)
137339|NCT02234492|Coronary Flow Reserve (CFR)
137340|NCT02234492|Positron Emission Tomography (PET)
137341|NCT02234492|Myocardial contrast echocardiography (MCE)
137342|NCT02234479|Breast Cancer
137343|NCT02234479|Radiation Dermatitis
137344|NCT02234466|Quality of Recovery (QOR40)
137345|NCT02234466|Breast Surgery
137346|NCT02234466|Clinically significant Nausea and Vomiting
137347|NCT02234466|Postoperative Nausea and Vomiting
137348|NCT02234453|cancer
137349|NCT02234453|chemotherapy
137350|NCT02234453|home
137351|NCT02234453|blood count
137352|NCT02234453|remote
137353|NCT02234427|aspirin, atherosclerosis
137354|NCT02234414|vertebral fracture assessment (vfa)
137355|NCT02234414|vitamin D
137356|NCT02234401|Cystic Fibrosis
137357|NCT02234401|Noninvasive ventilation
137358|NCT02234401|Non invasive ventilation
137359|NCT02234401|Acute respiratory exacerbation
137360|NCT02234401|Bi level pressure support
137361|NCT02234388|connective tissue disease
137362|NCT02234388|registry
137363|NCT02234388|hospital for special surgery
137364|NCT02234375|Pulmonary embolism
137365|NCT02234375|Contrast
137366|NCT02234375|Computed tomography
137367|NCT02234375|Gadolinium
137368|NCT02234349|bile acids
137369|NCT02234349|pancreas kidney transplantation
137370|NCT02234349|incretins
137371|NCT02234349|intestinal flora
137372|NCT02234336|Echocardiography
137373|NCT02234336|hypertrophic cardiomyopathy
137374|NCT02234336|cardiomyopathy
137375|NCT02234336|magnetic resonance imaging
137376|NCT02234336|contrast
137377|NCT02234323|prophylaxis treatment
137378|NCT02234323|Hemophilia A
137379|NCT02234323|Hemophilia
137380|NCT02234323|episodic treatment
137381|NCT02234310|prophylaxis treatment
137382|NCT02234310|episodic treatment
137383|NCT02234297|Glioma
137384|NCT02234297|Tumor Paint
137385|NCT02234297|BLZ100
137386|NCT02234284|Chronic Obstructive Pulmonary Disease
137387|NCT02234284|Health Coaching
137388|NCT02234284|Health Disparities
137389|NCT02234284|Self-management
137390|NCT02234284|Chronic Disease Model
137391|NCT02234245|Follow-Up studies
137392|NCT02234245|Biological Pacemakers
137393|NCT02234245|Telemedicine
137394|NCT02234245|Efficiency
137395|NCT02234232|Hemodialysis
137396|NCT02234232|Exercise, aerobic
137397|NCT02234232|Exercise, resistance
137398|NCT02234232|Intradialytic
137399|NCT02234232|Randomized Controlled Trial
137400|NCT02234232|Safety
137401|NCT02234232|Quality of life
137402|NCT02234232|Physical performance
137403|NCT02234206|Hypospermatogenesis, Low Sperm Count, Oligozoospermia
137404|NCT02234193|wound healing
137405|NCT02234128|Ex Vivo Lung Perfusion
137406|NCT02234128|EVLP
137407|NCT02234128|Lung Transplant
137408|NCT02234128|Lung Transplantation
137409|NCT02234128|Toronto EVLP System™
137410|NCT02234128|PERFUSIX
137411|NCT02234115|Prostate Neoplasm Cancer Carcinoma
137412|NCT02234076|Posttraumatic Stress Disorder
137413|NCT02234076|Depression
137414|NCT02234076|Treatment
137415|NCT02234076|VRET
137416|NCT02234063|Hypertension
137417|NCT02234063|Chronic Kidney Disease
137418|NCT02234063|End Stage Renal Disease
137419|NCT02234063|APOL1
137420|NCT02234063|Genomics
137421|NCT02234063|Genetics
137422|NCT02234063|Community-engaged
137423|NCT02234050|Grade 2 Chordoid meningioma
137424|NCT02234050|Grade 2 Clear cell meningioma
137425|NCT02234050|Grade 2 Atypical meningioma
137426|NCT02234050|Grade 3 Papillary meningioma
137427|NCT02234050|Grade 3 Rhabdoid meningioma
137428|NCT02234050|Grade 3 Anaplastic meningioma
137429|NCT02234050|Grade 3 Malignant meningioma
137430|NCT02234037|AML
137431|NCT02233998|Plaque
137432|NCT02233998|Bleeding
137433|NCT02233998|Gums
137434|NCT02233998|Gingiva
137435|NCT02233998|Gingival Inflammation
137436|NCT02233998|Gingival Bleeding
137437|NCT02233985|bronchiolitis
137438|NCT02233985|hypertonic
137439|NCT02233985|saline
137440|NCT02233985|salbutamol
137441|NCT02233972|Pharmacokinetics
137442|NCT02233972|Ginkgolides Meglumine Injection
137443|NCT02233946|Substance Abuse
137444|NCT02233946|Prevention
137445|NCT02233946|Youth
137446|NCT02233946|Alcohol
137447|NCT02233946|Drugs
137448|NCT02233933|radiation proctitis
137449|NCT02233933|bleeding
137450|NCT02233933|therapy
137451|NCT02233868|Imaging Studies
137452|NCT02233868|Alcoholism
137453|NCT02233868|Inflammation
137454|NCT02233855|Seizures
137455|NCT02233855|Cestode
137456|NCT02233855|Hydrocephalus
137457|NCT02233855|Taenia Solium
137458|NCT02233855|Helminth
137459|NCT02233842|Qualitative Data
137460|NCT02233842|Questionnaire
137461|NCT02233829|C-11 Raclopride
137462|NCT02233829|015 PET
137463|NCT02233829|Circadian Rhythm
137464|NCT02233816|Influenza
137465|NCT02233816|Human
137466|NCT02233816|RNA Virus Infections
137467|NCT02233816|Immunologic
137468|NCT02233816|Immunogenic Factors
137469|NCT02233816|Physiological Effects of Drugs
137470|NCT02233816|Virus diseases
137471|NCT02233816|Orthomyxoviridae Infections
137472|NCT02233816|Infection
137473|NCT02233803|tolerability
137474|NCT02233803|NEUMOTEROL
137475|NCT02233803|efficacy
137476|NCT02233803|budesonide/formoterol fumarate 400/12 mcg
137477|NCT02233803|safety
137478|NCT02233803|Asthma
137479|NCT02233803|pharmacodynamics
137480|NCT02233790|Myocardial infarction
137481|NCT02233790|No-Reflow Phenomenon
137482|NCT02233790|Ticagrelor
137483|NCT02233790|Clopidogrel
137484|NCT02233790|Single-Photon Emission Computerized Tomography
137485|NCT02233777|Pregabalin
137486|NCT02233777|Bioequivalence
137487|NCT02233777|Bioavailability
137488|NCT02233777|Pharmacokinetic
137489|NCT02233777|Antiepileptic
137490|NCT02233764|iron
137491|NCT02233764|zinc
137492|NCT02233764|pearl millet
137493|NCT02233764|India
137494|NCT02233764|children
137495|NCT02233764|trial
137496|NCT02233764|randomized
137497|NCT02233751|Healthy Adult Males
137498|NCT02233738|Alcoholism
137499|NCT02233738|Substance-related disorders
137500|NCT02233738|Dual Diagnosis
137501|NCT02233725|Prostatic Neoplasms
137502|NCT02233725|Magnetic Resonance Imaging
137503|NCT02233725|MRI / Ultrasound Fusion
137504|NCT02233725|Contrast-Enhanced Ultrasound (CEUS)
137505|NCT02233712|gastric cancer, stomach neoplasms,
137506|NCT02233673|Obesity
137507|NCT02233673|Pregnancy
137508|NCT02233647|cocaine
137509|NCT02233647|phendimetrazine
137510|NCT02233647|pharmacotherapy
137511|NCT02233634|Coronary Angiography
137512|NCT02233634|Magnetic Resonance Imaging
137513|NCT02233634|Oxygen
137514|NCT02233634|Hyperoxia
137515|NCT02233634|Carbon Dioxide
137516|NCT02233634|Apnea
137517|NCT02233634|Hyperventilation
137518|NCT02233608|Prostate cancer
137519|NCT02233608|Radical prostatectomy
137520|NCT02233608|Pelvic floor muscle exercises
137521|NCT02233608|Pfilates
137522|NCT02233608|Hypopressives
137523|NCT02233608|Urinary Incontinence
137524|NCT02233595|MRI
137525|NCT02233595|PET
137526|NCT02233595|rectal cancer
137527|NCT02233595|adjuvant chemotherapy
137528|NCT02233582|altitude
137529|NCT02233582|mountain sickness
137530|NCT02233582|ibuprofen
137531|NCT02233582|hypoxia
137532|NCT02233569|Laparoscopic hernia repair
137533|NCT02233569|Ventral hernia
137534|NCT02233569|Incisional hernia
137535|NCT02233569|IPOM
137536|NCT02233556|event-related potential
137537|NCT02233556|mismatch negativity
137538|NCT02233556|NMDA
137539|NCT02233556|Glutamate
137540|NCT02233543|COPD
137541|NCT02233543|QVA149
137542|NCT02233543|nocturnal oxygen levels
137543|NCT02233543|combination bronchodilator
137544|NCT02233530|Dementia
137545|NCT02233530|Cognitive Stimulation Therapy
137546|NCT02233530|Quality of life
137547|NCT02233530|Cognitive impairment
137548|NCT02233530|Africa
137549|NCT02233530|Tanzania
137550|NCT02233530|Nigeria
137551|NCT02233530|Low- and Middle-income countries
137552|NCT02233530|Non-pharmacological intervention
137553|NCT02233530|Task-shifting
137554|NCT02233530|Cognitive screening
137555|NCT02233517|Veterans
137556|NCT02233517|Cognitive-Behavioral Therapy
137557|NCT02233517|Aggression
137558|NCT02233517|Anger
137559|NCT02233517|Posttraumatic Stress Disorder
137560|NCT02233517|Combat Disorders
137561|NCT02233491|PTDM
137562|NCT02233491|kidney transplant
137563|NCT02233491|lifestyle intervention
137564|NCT02233491|diet
137565|NCT02233491|exercise
137566|NCT02233478|Pomegranate polyphenols
137567|NCT02233478|Soy Protein
137568|NCT02233478|Ellagitannins
137569|NCT02233465|parastomal
137570|NCT02233465|hernia
137571|NCT02233465|mesh
137572|NCT02233465|parastomal hernia-repair with mesh
137573|NCT02233452|Neuropathic pain
137574|NCT02233452|Methadone
137575|NCT02233452|Ketamine
137576|NCT02233452|Multimodal analgesia
137577|NCT02233439|galactagogues
137578|NCT02233439|herbs
137579|NCT02233439|breastfeeding
137580|NCT02233439|supplements
137581|NCT02233439|Silybum marianum
137582|NCT02233439|Galega officinalis
137583|NCT02233426|allergic rhinitis
137584|NCT02233426|nasal steroid
137585|NCT02233426|hypertonic saline
137586|NCT02233426|eosinophil
137587|NCT02233426|symptom score
137588|NCT02233413|Traumatic brain injury
137589|NCT02233413|TBI
137590|NCT02233413|Low-level light therapy
137591|NCT02233413|LLLT
137592|NCT02233413|LLLT helmet
137593|NCT02233400|Acetaminophen
137594|NCT02233400|Gastric Bypass
137595|NCT02233400|Sleeve Gastrectomy
137596|NCT02233400|Pain
137597|NCT02233400|Cost
137598|NCT02233387|cervix cancer
137599|NCT02233387|[18F] HX4 PET imaging
137600|NCT02233387|hypoxia
137601|NCT02233387|phase II trial
137602|NCT02233374|Rectal Cancer
137603|NCT02233374|Magnetic Resonance Imaging
137604|NCT02233374|Positron Emission Tomography
137605|NCT02233374|pathologic complete response
137606|NCT02233374|Diffusion-weighted magnetic resonance imaging
137607|NCT02233374|Microstructural Imaging
137608|NCT02233374|FDG PET
137609|NCT02233361|Hearing rehabilitation
137610|NCT02233361|Elderly
137611|NCT02233361|Hearing aid use
137612|NCT02233322|ADHR
137613|NCT02233322|Rickets
137614|NCT02233322|Hypophosphatemia
137615|NCT02233296|pharmacokinetics
137616|NCT02233283|LH pulsatility
137617|NCT02233283|Insulin sensitivity
137618|NCT02233283|Metabolism
137619|NCT02233283|hypercaloric feeding
137620|NCT02233257|Adrenoleukodystrophy
137621|NCT02233257|Lorenzo's oil
137622|NCT02233257|erucic acid
137623|NCT02233244|Drug Interaction
137624|NCT02233205|microbubble
137625|NCT02233205|chemotherapy
137626|NCT02233205|alimentary
137627|NCT02233192|PrEP
137628|NCT02233192|conception
137629|NCT02233192|HIV
137630|NCT02233192|serodiscordant
137631|NCT02233179|Diabetic foot ulcer
137632|NCT02233153|Senior
137633|NCT02233153|Elderly
137634|NCT02233153|Acute Care
137635|NCT02233153|Emergency Surgery
137636|NCT02233140|Diabetes
137637|NCT02233140|Ankle equinus
137638|NCT02233140|ankle dorsiflexion
137639|NCT02233140|dynamic plantar pressure
137640|NCT02233140|shockwave therapy
137641|NCT02233127|Birth cohort
137642|NCT02233127|Pakistan
137643|NCT02233127|Child mortality
137644|NCT02233088|Prediabetic State
137645|NCT02233088|Hypertension
137646|NCT02233088|Enlarged Waist Elevated Triglycerides
137647|NCT02233088|HDL Cholesterol, Low Serum
137648|NCT02233062|Crohn's Disease
137649|NCT02233062|semen quality
137650|NCT02233062|enteral nutrition
137651|NCT02233062|CDAI score higher than 150
137652|NCT02233049|Children
137653|NCT02233049|adolescents
137654|NCT02233049|young adults
137655|NCT02233049|newly diagnosed
137656|NCT02233036|Young Adults
137657|NCT02233036|Transfer
137658|NCT02233036|Chronic Disease
137659|NCT02232997|Chronic kidney disease
137660|NCT02232997|contrast induced nephropathy
137661|NCT02232997|diabetes mellitus
137662|NCT02232997|congestive heart failure
137663|NCT02232997|hypertension
137664|NCT02232984|Heart Failure
137665|NCT02232984|Cardiac Resynchronization Therapy
137666|NCT02232984|CRT-D
137667|NCT02232984|Quadripolar pacing
137668|NCT02232971|glucagon
137669|NCT02232971|insulin pump
137670|NCT02232971|artificial pancreas
137671|NCT02232971|closed-loop
137672|NCT02232958|Hyperbaric Oxygen
137673|NCT02232958|Small Vessel Disease of the Brain
137674|NCT02232958|Impaired Brain Circuit Connections
137675|NCT02232945|influenza A (H1N1,H3N2)
137676|NCT02232945|influenza B virus
137677|NCT02232932|Hilar cholangiocarcinoma
137678|NCT02232932|Liver transplantation
137679|NCT02232932|Radiochemotherapy
137680|NCT02232919|Deep Brain Stimulation
137681|NCT02232906|Chronic kidney disease
137682|NCT02232906|CKD
137683|NCT02232906|non-dialysis-dependent
137684|NCT02232906|ND-CKD
137685|NCT02232906|Erythropoiesis-stimulating agent
137686|NCT02232906|Ferric carboxymaltose
137687|NCT02232906|Iron
137688|NCT02232893|Gastrointestinal Quality of Life Index (GIQLI)
137689|NCT02232893|Abdominal Discomfort
137690|NCT02232893|Abdominal Bloating
137691|NCT02232893|Laparoscopic colectomy
137692|NCT02232893|Postoperative ileus (POI)
137693|NCT02232880|hypertension
137694|NCT02232880|inflammation
137695|NCT02232867|rehabilitation
137696|NCT02232867|stroke
137697|NCT02232867|walking
137698|NCT02232867|interlimb connections
137699|NCT02232854|Depression
137700|NCT02232841|Electrical impedance tomography
137701|NCT02232841|lung imaging
137702|NCT02232789|Mephedrone
137703|NCT02232789|3,4-methylenedioxymethamphetamine
137704|NCT02232789|Abuse liability
137705|NCT02232789|Human Pharmacology
137706|NCT02232776|Losartan
137707|NCT02232776|Ig A nephropathy
137708|NCT02232776|children
137709|NCT02232776|proteinuria
137710|NCT02232763|Losartan
137711|NCT02232763|children
137712|NCT02232763|proteinuria
137713|NCT02232737|Biomarkers of exposure
137714|NCT02232737|Compensatory smoking
137715|NCT02232737|Nicotine dependence
137716|NCT02232737|Reduced nicotine cigarettes
137717|NCT02232737|Tobacco withdrawal
137718|NCT02232737|Women
137719|NCT02232737|Health disparaties
137720|NCT02232737|Vulnerable populations
137721|NCT02232724|Prostate Cancer
137722|NCT02232724|Staging
137723|NCT02232724|PET/CT
137724|NCT02232711|multiplex, polymerase chain reaction, PCR, BioFire, respiratory infection, infectious disease, point of care, CLIA waived, rapid diagnostics
137725|NCT02232698|Sensing Technology
137726|NCT02232698|Type 1 Diabetes,
137727|NCT02232685|Prostate cancer
137728|NCT02232685|Staging
137729|NCT02232685|PET/CT
137730|NCT02232672|Prostate Cancer
137731|NCT02232672|Staging
137732|NCT02232672|PET/CT
137733|NCT02232659|SynCardia
137734|NCT02232659|Total Artificial Heart
137735|NCT02232659|Biventricular heart failure
137736|NCT02232659|Ineligible for cardiac transplant
137737|NCT02232568|Patient blood management
137738|NCT02232568|RBC transfusion
137739|NCT02232568|Restrictive transfusion strategy
137740|NCT02232529|modified release formulation
137741|NCT02232529|pharmacokinetics
137742|NCT02232490|AFP
137743|NCT02232490|alpha-fetoprotein
137744|NCT02232490|cancer vaccine
137745|NCT02232490|cirrhosis
137746|NCT02232490|hepatitis
137747|NCT02232490|HCC
137748|NCT02232490|hepatocellular carcinoma
137749|NCT02232490|immunotherapy
137750|NCT02232490|liver tumor
137751|NCT02232464|Adult ADHD
137752|NCT02232464|diffusion spectrum imaging
137753|NCT02232464|resting-state fMRI
137754|NCT02232464|frontostriatal circuitries
137755|NCT02232464|frontoparietal circuitries
137756|NCT02232464|executive function
137757|NCT02232451|loop
137758|NCT02232451|ERCP
137759|NCT02232451|cannulation
137760|NCT02232451|biliary
137761|NCT02232451|wire
137762|NCT02232438|Depression
137763|NCT02232438|Psychotherapy
137764|NCT02232438|Anxiety
137765|NCT02232438|Cancer
137766|NCT02232412|Anemia
137767|NCT02232412|NIRS
137768|NCT02232412|Near Infrared Spectroscopy
137769|NCT02232412|RBC transfusion
137770|NCT02232412|critical ill
137771|NCT02232412|regional cerebral oxygen saturation
137772|NCT02232412|tissue oxygenation
137773|NCT02232386|Chronic lymphocyte leukemia
137774|NCT02232386|Adults
137775|NCT02232386|Ibrutinib
137776|NCT02232373|FODMAPs
137777|NCT02232373|microbiota
137778|NCT02232373|oligofructose
137779|NCT02232373|IBS
137780|NCT02232373|Irritable bowel syndrome
137781|NCT02232360|Atherosclerotic plaque
137782|NCT02232360|Virtual histology intravascular ultrasound
137783|NCT02232360|Plaque composition
137784|NCT02232360|Rosuvastatin
137785|NCT02232360|Fenofibrate
137786|NCT02232360|Coronary artery disease
137787|NCT02232347|traumatic brain injury
137788|NCT02232347|ketamine
137789|NCT02232347|microdialysis
137790|NCT02232347|PtiO2
137791|NCT02232347|glutamate
137792|NCT02232334|Idiopathic Gastroparesis, Nausea, Vomiting, Abdominal Pain, Gastrectomy, Osteopathy, Gastroparesis Cardinal Symptom Index, GCSI
137793|NCT02232295|Upper extremity, motor imagery, mirror therapy
137794|NCT02232282|Painful Bladder Syndrome
137795|NCT02232282|Interstitial Cystitis
137796|NCT02232282|Suprapubic Pain
137797|NCT02232282|Urinary Urgency
137798|NCT02232269|Coffee
137799|NCT02232269|Grapefruit Juice
137800|NCT02232269|Felodipine
137801|NCT02232269|Calcium Channel Blocker
137802|NCT02232269|Hemodynamics
137803|NCT02232269|CYP3A4
137804|NCT02232256|Chronic non-cancer pain
137805|NCT02232256|Insomnia
137806|NCT02232256|California poppy
137807|NCT02232256|Eschscholzia californica
137808|NCT02232256|Pain
137809|NCT02232256|Sleep quality
137810|NCT02232243|Cancer
137811|NCT02232243|Surgery
137812|NCT02232243|Hydroxychloroquine
137813|NCT02232217|Children
137814|NCT02232217|Sleep
137815|NCT02232217|Obesity
137816|NCT02232204|insomnia
137817|NCT02232204|implantable cardioverter defibrillator
137818|NCT02232204|cardiac arrhythmia
137819|NCT02232204|cognitive behavioral treatment
137820|NCT02232178|unilateral inguinal hernioplasty
137821|NCT02232165|acute spinal cord injury
137822|NCT02232165|hemodynamic therapy
137823|NCT02232165|functional outcome
137824|NCT02232126|Hospital readmissions
137825|NCT02232126|Randomized controlled trial
137826|NCT02232126|Older adults
137827|NCT02232126|Care transitions
137828|NCT02232126|Social work
137829|NCT02232113|malnutrition, inflammation, and anemia (MIA) syndrome,
137830|NCT02232113|hemodialysis,
137831|NCT02232113|erythropoietin stimulating agent (ESA),
137832|NCT02232113|cost-effectiveness,
137833|NCT02232113|pharmacokinetics,
137834|NCT02232113|endothelial dysfunction
137835|NCT02232100|Attentional bias modification
137836|NCT02232100|Chronic pain
137837|NCT02232100|Visual-probe task
137838|NCT02232100|Internet-delivered therapy
137839|NCT02232087|long-acting beta agonist (LABA)
137840|NCT02232087|corticosteroid
137841|NCT02232087|pMDI
137842|NCT02232087|inhaler
137843|NCT02232074|Patient Navigation
137844|NCT02232074|Medical Legal Partnership
137845|NCT02232074|Healthcare Disparities
137846|NCT02232061|multiple sclerosis, fingolimod,
137847|NCT02232035|diazepam
137848|NCT02232035|active phase
137849|NCT02232022|Stroke
137850|NCT02232022|Ischemic stroke
137851|NCT02232022|Atrial fibrillation
137852|NCT02232022|Insertable cardiac monitor
137853|NCT02232022|Non-cryptogenic
137854|NCT02232009|Neonate
137855|NCT02232009|Infant
137856|NCT02231983|Clinical Characteristics
137857|NCT02231983|Genetic Profiles
137858|NCT02231970|Obesity
137859|NCT02231970|Endoscopic sleeve gastroplasty
137860|NCT02231970|Weight loss
137861|NCT02231892|Repetitive TMS (rTMS)
137862|NCT02231892|Parameter Development
137863|NCT02231892|Cognitive Tasks
137864|NCT02231892|MRI (Magnetic Resonance Imaging)
137865|NCT02231879|Infections
137866|NCT02231879|Hypogammaglobulinemia
137867|NCT02231879|CXCR4
137868|NCT02231879|Myelokathexis
137869|NCT02231879|Warts
137870|NCT02231866|Filovirus
137871|NCT02231866|Healthy
137872|NCT02231866|Ebola Hemorrhagic Fever
137873|NCT02231866|Immunity
137874|NCT02231866|Ebola Virus
137875|NCT02231853|BK Virus
137876|NCT02231853|Cytotoxic T Cells
137877|NCT02231853|EBV
137878|NCT02231853|Adenovirus
137879|NCT02231853|CMV
137880|NCT02231840|Phenotypes
137881|NCT02231840|Alcohol Use
137882|NCT02231840|Alcohol
137883|NCT02231840|Alcohol Dependence
137884|NCT02231840|Genetics
137885|NCT02231827|subjects
137886|NCT02231814|Crohn's disease
137887|NCT02231814|Mild to moderate Crohn's Disease
137888|NCT02231814|Diet
137889|NCT02231814|Enteral Nutrition
137890|NCT02231801|Preterm
137891|NCT02231801|Kangaroo Care
137892|NCT02231801|Skin-to-Skin
137893|NCT02231801|Vital Sign
137894|NCT02231801|Heart Rate
137895|NCT02231801|Respiratory Rate
137896|NCT02231801|Oxygen Saturation
137897|NCT02231788|Telminuvo
137898|NCT02231788|Telmitrend
137899|NCT02231788|Hypertension
137900|NCT02231788|24hr ABPM
137901|NCT02231788|Telmisartan
137902|NCT02231788|S-amlodipine
137903|NCT02231775|Neoadjuvant
137904|NCT02231775|Dabrafenib
137905|NCT02231775|Tafinlar
137906|NCT02231775|GSK2118436
137907|NCT02231775|Trametinib
137908|NCT02231775|GSK1120212
137909|NCT02231775|Combination therapy
137910|NCT02231775|Surgery
137911|NCT02231775|Adjuvant therapy
137912|NCT02231775|Melanoma
137913|NCT02231736|Type 2 Diabetes
137914|NCT02231736|Chromosomal damage
137915|NCT02231736|Micronuclei
137916|NCT02231736|DNA damage
137917|NCT02231736|HbA1c
137918|NCT02231736|Comet Assay
137919|NCT02231736|Glycemic control
137920|NCT02231723|Digestive System Neoplasms
137921|NCT02231723|Endocrine Gland Neoplasms
137922|NCT02231723|Pancreatic neoplasms
137923|NCT02231723|Pancreatic cancer, adult
137924|NCT02231723|Pancreatic cancer
137925|NCT02231723|Pancreas cancer
137926|NCT02231723|Pancreatic diseases
137927|NCT02231723|Adenoma, Islet Cell
137928|NCT02231723|Carcinoma, Islet Cell
137929|NCT02231723|Carcinoma, Pancreatic Ductal
137930|NCT02231723|Gemcitabine
137931|NCT02231723|Gemzar
137932|NCT02231723|Nab-paclitaxel
137933|NCT02231723|Paclitaxel
137934|NCT02231723|Abraxane
137935|NCT02231723|Oxaliplatin
137936|NCT02231723|Leucovorin
137937|NCT02231723|Irinotecan
137938|NCT02231723|Fluorouracil
137939|NCT02231723|5-FU
137940|NCT02231723|MM-398
137941|NCT02231710|Severe Combined Immune Deficiency
137942|NCT02231710|Congenital T-cell Defect
137943|NCT02231710|Congenital T-cell Deficiency
137944|NCT02231710|Chronic Granulomatous Disease
137945|NCT02231710|Shwachman Diamond Syndrome
137946|NCT02231710|Diamond Blackfan Anemia
137947|NCT02231710|Dyskeratosis Congenita
137948|NCT02231710|Fanconi Anemia
137949|NCT02231710|Sickle Cell Disease
137950|NCT02231710|Thalassemia
137951|NCT02231710|Mucopolysaccharidosis
137952|NCT02231710|Sphingolipidoses
137953|NCT02231697|XLMTM
137954|NCT02231645|Parkinson's disease
137955|NCT02231645|Deep brain stimulation
137956|NCT02231645|Subthalamic nucleus
137957|NCT02231645|decision-making
137958|NCT02231645|cognition
137959|NCT02231645|behavior
137960|NCT02231632|Poliomyelitis
137961|NCT02231632|Vaccine
137962|NCT02231632|Safety
137963|NCT02231632|efficacy
137964|NCT02231619|feasibility
137965|NCT02231619|self assessment
137966|NCT02231619|medical abortion
137967|NCT02231619|low sensitivity urine pregnancy test
137968|NCT02231619|South Africa
137969|NCT02231606|Myopia Prevalence
137970|NCT02231606|Proportion of Purchase of free Spectacles
137971|NCT02231606|Proportion of Purchase of update Spectacles
137972|NCT02231606|Proportion of Wearing Spectacles
137973|NCT02231580|Neurodegenerative genetic disorder
137974|NCT02231567|hip replacement
137975|NCT02231567|neurocognitive rehabilitation
137976|NCT02231567|WOMAC questionnaire
137977|NCT02231554|low back pain
137978|NCT02231554|quality of life
137979|NCT02231554|rehabilitation
137980|NCT02231554|exercise
137981|NCT02231541|Fibromylgia
137982|NCT02231541|Magnetic Fields
137983|NCT02231541|Pain
137984|NCT02231541|Visual Analogue scale
137985|NCT02231528|anesthesia
137986|NCT02231528|central venous catheter
137987|NCT02231528|jugular vein
137988|NCT02231528|ultrasound guidance
137989|NCT02231502|Bioavailability in healthy individuals
137990|NCT02231489|Healthy
137991|NCT02231489|JNJ-42756493
137992|NCT02231489|JNJ-61818549
137993|NCT02231463|ultrasound
137994|NCT02231450|AE58054
137995|NCT02231450|Hepatic impairment
137996|NCT02231411|Delayed Cord Clamping
137997|NCT02231411|Pulmonary Ventilation
137998|NCT02231398|Cardiovascular disease
137999|NCT02231398|Pregnant women
138000|NCT02231398|Nulliparity
138001|NCT02231398|Pregnancy outcomes
138002|NCT02231398|Pregnancy complications
138003|NCT02231398|Sleep disordered breathing
138004|NCT02231385|Colorectal cancer
138005|NCT02231385|Serrated adenomas
138006|NCT02231385|Screening
138007|NCT02231385|Adenoma detection rate
138008|NCT02231385|Polypectomy
138009|NCT02231307|sublingual immunotherapy
138010|NCT02231307|birch pollen
138011|NCT02231307|allergic rhinitis / rhinoconjunctivitis
138012|NCT02231307|efficacy
138013|NCT02231281|HIV Infections
138014|NCT02231281|Acquired Immunodeficiency Syndrome
138015|NCT02231281|Immunologic Deficiency Syndromes
138016|NCT02231281|Immune System Diseases
138017|NCT02231281|Lentivirus Infections
138018|NCT02231281|Retroviridae Infections
138019|NCT02231281|Virus Diseases
138020|NCT02231281|RNA Virus Infections
138021|NCT02231281|Sexually Transmitted Diseases, Viral
138022|NCT02231281|Slow Virus Diseases
138023|NCT02231281|Therapeutic Uses
138024|NCT02231281|Pharmacologic Actions
138025|NCT02231281|Antiretroviral therapy
138026|NCT02231281|Early therapy
138027|NCT02231242|brain
138028|NCT02231242|children
138029|NCT02231242|cerebral palsy
138030|NCT02231242|bone marrow stem cells
138031|NCT02231242|intrathecal autologous total nucleated cells
138032|NCT02231242|quadriparesis
138033|NCT02231229|Pulmonary tuberculosis
138034|NCT02231229|Mycobacterium tuberculosis (MTB)
138035|NCT02231229|Drug Resistance (DR)
138036|NCT02231229|Isoniazid (INH or H)
138037|NCT02231229|Rifampicin (RIF or RMP or R)
138038|NCT02231229|Pyrazinamide (PZA or Z)
138039|NCT02231229|Ethambutol (EMB or E)
138040|NCT02231229|Fast-TB
138041|NCT02231229|Isoniazid, Rifampicin, Pyrazinamide (HRZ)
138042|NCT02231229|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
138043|NCT02231229|drug susceptibility testing (DST)
138044|NCT02231229|Acid-Fast Bacilli (AFB+)
138045|NCT02231229|Polymerase Chain Reaction (PCR)
138046|NCT02231216|rhinoseptoplasty
138047|NCT02231203|fish oil
138048|NCT02231203|omega-3 fatty acids
138049|NCT02231203|postoperative inflammatory response
138050|NCT02231203|erythrocyte function
138051|NCT02231190|muscle soreness
138052|NCT02231190|muscle function
138053|NCT02231190|Muscle damage and recovery
138054|NCT02231190|eccentric exercise
138055|NCT02231151|CPR quality assessment
138056|NCT02231151|Visual CPR assessment
138057|NCT02231151|Position relative to patient
138058|NCT02231138|Abelmoschus manihot
138059|NCT02231138|Chronic Kidney Disease
138060|NCT02231138|proteinuria
138061|NCT02231138|efficacy
138062|NCT02231138|safety
138063|NCT02231125|Abelmoschus manihot
138064|NCT02231125|IgA Nephropathy
138065|NCT02231125|proteinuria
138066|NCT02231125|efficacy
138067|NCT02231125|safety
138068|NCT02231112|Korean
138069|NCT02231112|Left side
138070|NCT02231099|recurrent pelvic organ prolapse
138071|NCT02231099|mesh
138072|NCT02231086|Chemotherapy, Adjuvant
138073|NCT02231086|Laparoscopy
138074|NCT02231086|Peritoneal Lavage
138075|NCT02231086|HIPEC
138076|NCT02231073|Freezing of gait
138077|NCT02231073|Idiopathic Parkinson's disease
138078|NCT02231073|Exercise
138079|NCT02231060|Outcome Prediction
138080|NCT02231060|Anoxic-Ischemic Encephalopathy
138081|NCT02231060|Coma
138082|NCT02231060|Vegetative State
138083|NCT02231060|Minimally Conscious State
138084|NCT02231060|Chronic Disorders of Consciousness
138085|NCT02231047|Diarrhea
138086|NCT02231047|Pneumonia
138087|NCT02231047|Child, Preschool
138088|NCT02231047|Infant
138089|NCT02231047|Dietary Supplements
138090|NCT02231047|Colostrums
138091|NCT02231047|Developing Countries
138092|NCT02231021|Diabetes Mellitus, Type 2
138093|NCT02231021|alogliptin
138094|NCT02231021|pioglitazone
138095|NCT02231021|DPP4 inhibitor
138096|NCT02231021|thiazolidinedione
138097|NCT02231008|SMS
138098|NCT02230969|peginterferon
138099|NCT02230969|relapsing
138100|NCT02230969|pegylated
138101|NCT02230969|Subcutaneous
138102|NCT02230969|Injectable
138103|NCT02230969|Multiple Sclerosis
138104|NCT02230943|rheumatoid
138105|NCT02230943|arthritis
138106|NCT02230943|osteoarthritis
138107|NCT02230943|gout
138108|NCT02230930|Parkinson's disease
138109|NCT02230930|Apomorphine
138110|NCT02230930|Infusion
138111|NCT02230930|Skin reactions
138112|NCT02230930|Subcutaneous nodules
138113|NCT02230930|Hydrocortisone
138114|NCT02230930|Massage
138115|NCT02230930|Dilution
138116|NCT02230904|Rotigotine patch
138117|NCT02230904|Neupro
138118|NCT02230904|Parkinson's Disease
138119|NCT02230891|heart failure
138120|NCT02230891|biomarkers
138121|NCT02230891|troponin
138122|NCT02230891|BNP
138123|NCT02230891|carvedilol
138124|NCT02230891|spironolactone
138125|NCT02230891|prevention
138126|NCT02230878|JNJ-42847922
138127|NCT02230878|Phase 1
138128|NCT02230878|Healthy
138129|NCT02230878|Placebo
138130|NCT02230865|Funnel chest (Pectus excavatum)
138131|NCT02230852|Telemedicine
138132|NCT02230852|Prehospital
138133|NCT02230852|Emergency Medicine
138134|NCT02230852|Stroke
138135|NCT02230839|insulin resistance
138136|NCT02230839|muscle
138137|NCT02230839|health education
138138|NCT02230839|exercise
138139|NCT02230826|Arthroplasty
138140|NCT02230826|Hip Replacement
138141|NCT02230826|Acetabular cup
138142|NCT02230826|Femoral stem
138143|NCT02230813|Cohort Study,
138144|NCT02230813|Cellulitis,
138145|NCT02230813|Skin and Soft Tissue Infection,
138146|NCT02230813|Emergency Department,
138147|NCT02230813|Clinical Prediction Rule
138148|NCT02230787|Pilot study
138149|NCT02230787|randomized clinical trial
138150|NCT02230787|periodontal disease
138151|NCT02230787|gingival recession
138152|NCT02230787|Emdogain
138153|NCT02230787|connective tissue
138154|NCT02230787|wound healing
138155|NCT02230787|inflammation
138156|NCT02230774|hydration
138157|NCT02230774|cognitive function
138158|NCT02230774|doctors
138159|NCT02230774|nurses
138160|NCT02230774|Nurses and Doctors oncall
138161|NCT02230761|steatoblepharon
138162|NCT02230761|blepharoptosis
138163|NCT02230761|dermatochalasis
138164|NCT02230761|blepharoplasty
138165|NCT02230761|periorbital
138166|NCT02230761|orbital
138167|NCT02230761|eyelid
138168|NCT02230761|eyebags
138169|NCT02230761|eye bags
138170|NCT02230748|LAA
138171|NCT02230748|LAA-Occluder
138172|NCT02230748|Atrial Fibrillation
138173|NCT02230748|AF
138174|NCT02230735|Robotic
138175|NCT02230735|Hysterectomy
138176|NCT02230735|Uterosacral
138177|NCT02230735|Bupivacaine
138304|NCT02230215|Total Knee Replacement
138178|NCT02230735|Robotic hysterectomy pain control
138179|NCT02230722|opioids
138180|NCT02230722|chronic pain
138181|NCT02230722|collaborative care
138182|NCT02230709|Neck pain
138183|NCT02230709|Myofascial pain syndrome
138184|NCT02230709|Soreness
138185|NCT02230683|Liver Cirrhosis
138186|NCT02230683|Hepatic Cirrhosis
138187|NCT02230683|Portal Hypertension
138188|NCT02230670|Liver Cirrhosis
138189|NCT02230670|Hepatic Cirrhosis
138190|NCT02230605|Delirium
138191|NCT02230605|Post Operative Delirium
138192|NCT02230605|PD
138193|NCT02230605|POD
138194|NCT02230605|Anesthesia
138195|NCT02230605|Anesthesiology
138196|NCT02230605|Post Operative Recovery
138197|NCT02230605|Post Anesthesia Care Unit
138198|NCT02230605|PACU
138199|NCT02230605|Cognition
138200|NCT02230605|Cognitive Impairment
138201|NCT02230605|Memory
138202|NCT02230605|Thinking
138203|NCT02230605|Confusion Assessment Method
138204|NCT02230605|CAM
138205|NCT02230605|Neurobics
138206|NCT02230605|Neuroplasticity
138207|NCT02230605|Lumosity
138208|NCT02230605|Brain Games
138209|NCT02230605|Cognitive Exercise
138210|NCT02230605|Cognitive Training
138211|NCT02230605|Perioperative Cognitive Protection
138212|NCT02230605|Cognitive Reserve
138213|NCT02230605|Neurobics Trial
138214|NCT02230605|Surgery
138215|NCT02230605|Elderly Patients
138216|NCT02230592|PET
138217|NCT02230592|Metabolic Glutamate Receptors
138218|NCT02230592|Brain Imaging
138219|NCT02230579|safety
138220|NCT02230579|tolerability
138221|NCT02230579|malaria
138222|NCT02230566|MPS 7
138223|NCT02230566|Sly Syndrome
138224|NCT02230566|Mucopolysaccharidosis
138225|NCT02230566|MPS VII
138226|NCT02230566|Enzyme Replacement Therapy
138227|NCT02230566|Mucopolysaccharidosis type 7
138228|NCT02230566|rare disease
138229|NCT02230566|lysosomal storage disease
138230|NCT02230566|metabolic disorder
138231|NCT02230514|Nonunion fracture
138232|NCT02230514|Long bones
138233|NCT02230514|Pseudoarthrosis
138234|NCT02230514|Cell therapy
138235|NCT02230514|Tissue engineering
138236|NCT02230514|Mesenchymal stromal cells
138237|NCT02230488|Inpatient Diabetes Management
138238|NCT02230488|Prevent <31 day readmission in patients with Diabetes
138239|NCT02230488|CDEs role in transition of care of inpatients with diabetes
138240|NCT02230475|Allergic Rhinitis
138241|NCT02230475|NMR
138242|NCT02230462|patient satisfaction
138243|NCT02230462|Mohs surgery
138244|NCT02230436|Pancreatectomy
138245|NCT02230436|Time of drain removal
138246|NCT02230423|Functional nasal surgery
138247|NCT02230423|Empty Nose Syndrome (ENS)
138248|NCT02230410|Barrett's
138249|NCT02230410|high grade dysplasia
138250|NCT02230410|ablation
138251|NCT02230410|cyrotherapy
138252|NCT02230397|skin aging
138253|NCT02230397|anti-aging cream
138254|NCT02230397|wrinkles
138255|NCT02230384|Attempt at Smoking Cessation
138256|NCT02230384|Schizophrenia or Schizoaffective disorder
138257|NCT02230384|Novel nicotinergic drug
138258|NCT02230371|Myofascial pain
138259|NCT02230371|TMD
138260|NCT02230371|5-HT3
138261|NCT02230371|Granisetron
138262|NCT02230371|Placebo-controlled
138263|NCT02230371|Patients
138264|NCT02230371|Randomized
138265|NCT02230371|Double-blind
138266|NCT02230358|carotid endarterectomy
138267|NCT02230358|cardiac output
138268|NCT02230358|trans-cranial Doppler
138269|NCT02230358|CEA
138270|NCT02230358|regional anesthesia
138271|NCT02230358|general anesthesia
138272|NCT02230345|Probiotic
138273|NCT02230345|Yoghourt
138274|NCT02230345|Inflammation
138275|NCT02230345|Metabolomics
138276|NCT02230319|Cryotherapy
138277|NCT02230319|Cold therapy
138278|NCT02230319|Peripheral Neuropathy
138279|NCT02230319|Paclitaxel
138280|NCT02230319|Breast Cancer
138281|NCT02230319|Symptom management
138282|NCT02230319|Prevention
138283|NCT02230293|ambulatory care,
138284|NCT02230293|hypertension,
138285|NCT02230293|health personnel,
138286|NCT02230293|clinical trial
138287|NCT02230280|Mobile health technology
138288|NCT02230280|Multiple chronic conditions
138289|NCT02230280|Older adults
138290|NCT02230280|Home and community care
138291|NCT02230280|Effectiveness
138292|NCT02230280|Cost analysis
138293|NCT02230280|Interprofessional Stroke Rehabilitation
138294|NCT02230267|boot camp
138295|NCT02230267|exercise
138296|NCT02230267|balance training
138297|NCT02230267|fall prevention
138298|NCT02230267|falling
138299|NCT02230267|strength training
138300|NCT02230254|Coronary Artery Disease
138301|NCT02230241|Dyslipidaemia
138302|NCT02230241|LDL-C goals
138303|NCT02230241|Guidelines
138305|NCT02230215|Visionaire
138306|NCT02230189|Asthma
138307|NCT02230189|Allergen challenge
138308|NCT02230163|Chikungunya virus
138309|NCT02230163|Human anti-CHIKV hyperimmune intravenous immunoglobulins
138310|NCT02230163|Neonates
138311|NCT02230150|Adhesion, Knowledge, Nursing
138312|NCT02230137|adolescents
138313|NCT02230137|type 1 diabetes
138314|NCT02230137|poorly controlled
138315|NCT02230137|SMS
138316|NCT02230137|Improve glycaemic control
138317|NCT02230137|HbA1c reduction
138318|NCT02230137|poorly controlled type 1 diabetic adolescents
138319|NCT02230124|Hydrocephalus
138320|NCT02230111|Women
138321|NCT02230111|Caloric restriction
138322|NCT02230111|Cognitive dietary restraint
138323|NCT02230111|Eating behaviours
138324|NCT02230111|Food habits
138325|NCT02230111|Appetite sensations
138326|NCT02230111|Stress
138327|NCT02230111|Weight management
138328|NCT02230098|remote ischemic conditioning
138329|NCT02230098|ischemic heart disease
138330|NCT02230059|Prostatic Neoplasms
138331|NCT02230059|observational Study
138332|NCT02230059|Metastatic castration-resistant prostate cancer
138333|NCT02230046|Healthy,
138334|NCT02230046|Abiraterone Acetate,
138335|NCT02230046|Bioequivalence.
138336|NCT02230033|JNJ-56021927
138337|NCT02230033|Itraconazole
138338|NCT02230033|Gemfibrozil
138339|NCT02229994|Dyspnea
138340|NCT02229994|Self-administered questionnaire
138341|NCT02229994|Chronic respiratory disease
138342|NCT02229994|COPD
138343|NCT02229994|Diffuse interstitial lung diseases
138344|NCT02229994|Pulmonary arterial hypertension
138345|NCT02229994|Cystic fibrosis
138346|NCT02229981|Lymphoma
138347|NCT02229981|B-cell Lymphomas
138348|NCT02229981|Lymphosarcoma
138349|NCT02229981|Kaposi's Sarcoma-associated Herpesvirus
138350|NCT02229981|KHSV
138351|NCT02229981|Human Immunodeficiency Virus
138352|NCT02229981|HIV
138353|NCT02229981|Epstein-Barr Virus
138354|NCT02229981|EBV
138355|NCT02229968|craniosynostosis
138356|NCT02229968|craniofacial
138357|NCT02229968|amicar
138358|NCT02229968|epsilon aminocaproic acid
138359|NCT02229968|ε-aminocaproic acid
138360|NCT02229955|Dry Eye Syndromes
138361|NCT02229942|Chronic Fatigue Syndrome (CFS)
138362|NCT02229942|Myalgic Encephalitis (ME)
138363|NCT02229942|Rituximab
138364|NCT02229942|B-lymphocyte depletion
138365|NCT02229942|B-cell depletion
138366|NCT02229929|Pruritus
138367|NCT02229929|uremic pruritus
138368|NCT02229929|kappa opioid
138369|NCT02229929|CR845
138370|NCT02229916|Testicular Neoplasms
138371|NCT02229916|Testicular Cancer
138372|NCT02229916|Cohort Study
138373|NCT02229903|OCD
138374|NCT02229864|Absorb™ BVS
138375|NCT02229864|Angioplasty
138376|NCT02229864|Bioabsorbable
138377|NCT02229864|BVS
138378|NCT02229864|Coronary Artery Disease
138379|NCT02229864|Coronary Artery Endothelial Responsiveness
138380|NCT02229864|Coronary artery restenosis
138381|NCT02229864|Coronary artery stenosis
138382|NCT02229864|Coronary scaffold
138383|NCT02229864|Coronary Stent
138384|NCT02229864|Drug eluting stents
138385|NCT02229864|Everolimus
138386|NCT02229864|Myocardial ischemia
138387|NCT02229864|Stent thrombosis
138388|NCT02229864|Stents
138389|NCT02229708|Pregnancy
138390|NCT02229708|Weight control
138391|NCT02229708|Behavioral
138392|NCT02229708|technology-based intervention
138393|NCT02229695|Trauma
138394|NCT02229695|Sepsis
138395|NCT02229695|Temporary abdominal closure
138396|NCT02229695|Bogota bag
138397|NCT02229695|Vacuum assisted closure
138398|NCT02229682|extranodal NK/T-cell lymphoma,nasal-type,
138399|NCT02229682|radiotherapy,
138400|NCT02229682|intensity-modulated radiation treatment,
138401|NCT02229682|asparaginase-based chemotherapy,
138402|NCT02229682|loco-regional control,
138403|NCT02229682|survival
138404|NCT02229656|olaparib
138405|NCT02229656|radiotherapy
138406|NCT02229656|Laryngeal SCC
138407|NCT02229656|oropharyngeal SCC
138408|NCT02229643|Traumatic brain injury
138409|NCT02229643|Neuroglobin
138410|NCT02229643|Nogo-A
138411|NCT02229643|Prognosis
138412|NCT02229630|intra-uterine growth restriction
138413|NCT02229630|MRI
138414|NCT02229630|apparent diffusion coefficient
138415|NCT02229617|Intramuscular testosterone
138416|NCT02229617|Subcutaneous testosterone
138417|NCT02229604|electroacupuncture
138418|NCT02229604|diminished ovarian reserve
138419|NCT02229604|cohort study
138420|NCT02229578|Burn pain
138421|NCT02229578|lidocaine
138422|NCT02229578|donor site pain
138423|NCT02229578|Narcotic use
138424|NCT02229565|prostate cancer
138425|NCT02229565|prostate biopsy
138426|NCT02229565|prostatectomy
138427|NCT02229526|Fish oil supplementation
138428|NCT02229526|RCT
138429|NCT02229526|High risk pregnancies
138430|NCT02229526|Twin pregnancy
138431|NCT02229526|Preterm birth
138432|NCT02229526|Intrauterine growth retardation
138433|NCT02229526|Pregnancy induced hypertension
138434|NCT02229513|postpartum hemorrhage
138435|NCT02229513|uterine atony
138436|NCT02229513|cesarean section
138437|NCT02229513|cesarean hysterectomy
138438|NCT02229513|acute blood loss anemia
138439|NCT02229513|uterotonics
138440|NCT02229513|obstetric hemorrhage
138441|NCT02229513|severe hemorrhage
138442|NCT02229513|blood transfusion
138443|NCT02229513|obstetric emergencies
138444|NCT02229513|obstetrics
138445|NCT02229513|massive hemorrhage
138446|NCT02229513|hemorrhage
138447|NCT02229513|uterine cooling
138448|NCT02229500|Propionate
138449|NCT02229500|Microbiome
138450|NCT02229500|Dietary Fibre
138451|NCT02229500|Short chain fatty acids
138452|NCT02229487|Prediabetes
138453|NCT02229487|Short sleepers
138454|NCT02229487|GLP-1
138455|NCT02229474|Dementia
138456|NCT02229474|Cognitive Stimulation Therapy
138457|NCT02229474|Quality of life
138458|NCT02229474|Cognitive impairment
138459|NCT02229474|Africa
138460|NCT02229474|Tanzania
138461|NCT02229474|Nigeria
138462|NCT02229474|Low- and Middle-income countries
138463|NCT02229474|Non-pharmacological intervention
138464|NCT02229474|Task-shifting
138465|NCT02229474|Cognitive screening
138466|NCT02229448|Immunoglobulin G
138467|NCT02229448|focus
138468|NCT02229448|study
138469|NCT02229448|detect
138470|NCT02229448|patients
138471|NCT02229435|Chronic kidney disease
138472|NCT02229435|Urological care
138473|NCT02229435|Nephrological care
138474|NCT02229409|adults
138475|NCT02229396|Diabetes Mellitus
138476|NCT02229396|Exenatide
138477|NCT02229396|Dapagliflozin
138478|NCT02229396|Diabetes medication
138479|NCT02229396|Treatment efficacy
138480|NCT02229396|Placebo
138481|NCT02229396|Metabolism
138482|NCT02229396|Cardiovascular metabolic
138483|NCT02229383|Diabetes Mellitus
138484|NCT02229383|Exenatide
138485|NCT02229383|Diabetes drug
138486|NCT02229383|Treatment efficacy
138487|NCT02229383|Placebo
138488|NCT02229383|Metabolism
138489|NCT02229383|Cardiovascilar metabolic
138490|NCT02229370|extracranial
138491|NCT02229370|carotid
138492|NCT02229370|artery
138493|NCT02229370|aneurysm
138494|NCT02229370|registry
138495|NCT02229370|CAR
138496|NCT02229357|H5N2 Vaccine
138497|NCT02229344|colitis, ulcerative
138498|NCT02229344|MOSAIK
138499|NCT02229344|REMICADE
138500|NCT02229344|Infliximab
138501|NCT02229331|haemophilia
138502|NCT02229331|arthropathy
138503|NCT02229331|pediatrics
138504|NCT02229331|ankle
138505|NCT02229331|biomechanics
138506|NCT02229305|Anxiety
138507|NCT02229305|Trauma
138508|NCT02229305|Depression
138509|NCT02229305|Problem Behavior
138510|NCT02229305|evidence-based treatments
138511|NCT02229279|Surgical Procedures, Operative
138512|NCT02229266|AML
138513|NCT02229266|high-risk AML
138514|NCT02229266|acute myeloid leukemia
138515|NCT02229266|NK cells
138516|NCT02229266|haploidentical natural killer cells
138517|NCT02229266|immunotherapy
138518|NCT02229240|Albiglutide
138519|NCT02229240|Add-on to basal-bolus insulin therapy
138520|NCT02229240|Glucagon-like peptide-1 receptor agonist
138521|NCT02229240|Type 2 diabetes mellitus
138522|NCT02229227|switch study
138523|NCT02229227|albiglutide
138524|NCT02229227|glucagon-like peptide-1 receptor agonist
138525|NCT02229227|Type 2 diabetes mellitus
138526|NCT02229227|basal-bolus insulin therapy
138527|NCT02229214|Renal function
138528|NCT02229214|Glomerular Filtration Rate
138529|NCT02229214|Kidney function
138530|NCT02229214|Qsymia
138531|NCT02229214|Iohexol
138532|NCT02229214|Serum Creatinine
138533|NCT02229214|Creatinine clearance
138534|NCT02229214|Renal Clearance
138535|NCT02229214|VI-0521
138536|NCT02229214|Healthy volunteers
138537|NCT02229201|propofol
138538|NCT02229201|sevoflurane
138539|NCT02229201|Interleukin 6
138540|NCT02229201|Interleukin 10
138541|NCT02229188|Depression; mood; cognitive training
138542|NCT02229175|Diabetic Macular Edema
138543|NCT02229175|Diabetic Retinopathy
138544|NCT02229175|Type 1 Diabetes
138545|NCT02229175|Type 2 Diabetes
138546|NCT02229175|Macular Edema
138547|NCT02229175|bevacizumab
138548|NCT02229175|intravitreal injection
138549|NCT02229175|Avastin
138550|NCT02229175|PASCAL Endpoint Management (EpM) system
138551|NCT02229175|Subthreshold focal laser treatments
138552|NCT02229162|umbilical cord
138553|NCT02229162|cesarean section
138554|NCT02229162|Blood Loss, Surgical
138555|NCT02229149|breast cancer
138556|NCT02229149|metastatic breast cancer
138557|NCT02229149|HER2+ breast cancer
138558|NCT02229136|Mouth sores from chemotherapy
138559|NCT02229136|mouth sores
138560|NCT02229136|hormone receptor-positive metastatic breast cancer
138561|NCT02229136|metastatic breast cancer
138562|NCT02229123|seizures
138563|NCT02229123|neonates
138564|NCT02229123|anticonvulsants treatment
138565|NCT02229123|levetiracetam
138566|NCT02229123|hypoxic-ischemic encephalopathy
138567|NCT02229123|electroencephalography
138568|NCT02229110|type 2 diabetes mellitus
138569|NCT02229110|e-Health
138570|NCT02229110|allocation of care
138571|NCT02229110|clinical inertia
138572|NCT02229110|quality of care
138573|NCT02229110|patient satisfaction
138574|NCT02229097|type 1 diabetes
138575|NCT02229071|Donafenib
138576|NCT02229071|HCC
138577|NCT02229071|Advanced
138578|NCT02229071|inoperable
138579|NCT02229071|Phase 1B
138580|NCT02229058|Gastric Cancer
138581|NCT02229058|Albumin Bound Paclitaxel
138582|NCT02229058|S-1
138583|NCT02229058|First Line
138584|NCT02229045|gastric caner
138585|NCT02229045|Albumin Bound Paclitaxel
138586|NCT02229045|5-FU/CF
138587|NCT02229045|taxanes naive
138588|NCT02229032|Dravet Syndrome
138589|NCT02229032|cannabidiol therapy
138590|NCT02229032|Charlotte's Web
138591|NCT02229019|Volunteers
138592|NCT02229019|Mealtime assistance
138593|NCT02229019|Older adults
138594|NCT02229019|Nutrition
138595|NCT02229019|Nursing
138596|NCT02229006|Aortic aneurysm, abdominal
138597|NCT02229006|Sodium Fluoride
138598|NCT02229006|Positron Emission Tomography
138599|NCT02228980|Influenza
138600|NCT02228980|Trivalent influenza vaccine
138601|NCT02228980|Sanofi Pasteur Shenzhen trivalent influenza vaccine
138602|NCT02228967|Alcohol Use
138603|NCT02228967|SBIRT
138604|NCT02228967|Military
138605|NCT02228967|Health Behavior
138606|NCT02228967|Emergency Room
138607|NCT02228967|Health Promotion
138608|NCT02228967|Formative Research
138609|NCT02228967|Randomized Trial
138610|NCT02228954|Clear-cell metastatic renal cell carcinoma
138611|NCT02228954|Positron-Emission Tomography
138612|NCT02228928|Peripheral Nerve Injury
138613|NCT02228928|Postherpetic Neuralgia
138614|NCT02228889|Hernia
138615|NCT02228889|Abdominal wall reconstruction
138616|NCT02228889|Abdominal wall defect
138617|NCT02228889|Porcine mesh
138618|NCT02228889|Component separation
138619|NCT02228889|Abdominal wall tumor
138620|NCT02228889|Desmoid
138621|NCT02228863|Stroke
138622|NCT02228863|Spasticity
138623|NCT02228850|Secondary Raynaud's Phenomenon
138624|NCT02228850|Secondary Raynaud's Disease
138625|NCT02228850|Scleroderma
138626|NCT02228850|Raynaud's Disease secondary to systemic sclerosis
138627|NCT02228850|CREST
138628|NCT02228850|Apricus Biosciences
138629|NCT02228850|laser doppler
138630|NCT02228850|thermography
138631|NCT02228824|Smoking
138632|NCT02228824|Non-daily smokers
138633|NCT02228824|Ecological Momentary Assessment
138634|NCT02228824|Biomarkers
138635|NCT02228798|anticoagulant
138636|NCT02228798|atrial fibrillation
138637|NCT02228798|surgery
138638|NCT02228798|oral anticoagulant
138639|NCT02228798|discontinue
138640|NCT02228798|DOAC
138641|NCT02228798|NOAC
138642|NCT02228798|blood thinner
138643|NCT02228798|interruption
138644|NCT02228772|Acute lymphoblastic Leukemia
138645|NCT02228772|Lymphoblastic lymphoma
138646|NCT02228772|B-cell Adult Acute Lymphoblastic Leukemia
138647|NCT02228772|T-cell Adult Acute Lymphoblastic Leukemia
138648|NCT02228759|Ambulatory home regional
138649|NCT02228759|adductor canal block
138650|NCT02228759|Postoperative pain
138651|NCT02228759|total knee arthroplasty
138652|NCT02228759|Home regional
138653|NCT02228759|Fast track arthroplasty
138654|NCT02228694|ADC
138655|NCT02228694|Pre installation
138656|NCT02228694|Post installation
138657|NCT02228694|Safety
138658|NCT02228694|Time
138659|NCT02228668|AVANT
138660|NCT02228668|GERCOR
138661|NCT02228668|Follow up
138662|NCT02228668|Colon cancer
138663|NCT02228668|Bevacizumab
138664|NCT02228668|Overall survival
138665|NCT02228655|Chronic Kidney Disease
138666|NCT02228655|CKD
138667|NCT02228655|Anemia of Chronic Illness
138668|NCT02228642|Type 1 diabetes
138669|NCT02228642|Type 2 diabetes
138670|NCT02228642|Hypoglycemia
138671|NCT02228642|Cognition disorders
138672|NCT02228642|Inpatient
138673|NCT02228629|Diabetes
138674|NCT02228629|Foot complications
138675|NCT02228629|plantar keratoma
138676|NCT02228629|plantar pressure
138677|NCT02228616|Constipation
138678|NCT02228616|Chronic constipation
138679|NCT02228616|Prucalopride
138680|NCT02228616|Women
138681|NCT02228603|exercise therapy
138682|NCT02228603|rehabilitation
138683|NCT02228590|Parkinson's Disease
138684|NCT02228551|Augmented renal clearance
138685|NCT02228551|non-critically ill
138686|NCT02228551|surgery
138687|NCT02228551|prevalence
138688|NCT02228551|risk factors
138689|NCT02228538|total knee arthroplasty
138690|NCT02228538|osteoarthritis
138691|NCT02228525|Selinexor (KPT-330)
138692|NCT02228525|Selective Inhibitor of Nuclear Export (SINE)
138693|NCT02228525|14-005
138694|NCT02228512|HHV8
138695|NCT02228512|PEL
138696|NCT02228512|Immune Modulation
138697|NCT02228512|CC-4047
138698|NCT02228512|IMiD
138699|NCT02228499|asthma
138700|NCT02228499|academics
138701|NCT02228499|GPA
138702|NCT02228499|attendance
138703|NCT02228447|Adolescent
138704|NCT02228447|Randomized controlled trial
138705|NCT02228447|Eating behavior
138706|NCT02228447|Physical Activity
138707|NCT02228447|Sedentary lifestyle
138708|NCT02228434|Childhood obesity, intervention, effectiveness, comparison
138709|NCT02228408|hemodialysis
138710|NCT02228408|ESRD
138711|NCT02228408|Cardiovascular Disease
138712|NCT02228408|Isosorbide Dinitrate
138713|NCT02228408|Hydralazine
138714|NCT02228395|Single ascending doses
138715|NCT02228395|pharmacokinetics
138716|NCT02228395|safety
138717|NCT02228395|tolerability
138718|NCT02228395|healthy volunteers
138719|NCT02228395|cognitive impairment associated with schizophrenia (CIAS)
138720|NCT02228382|Bosutinib
138721|NCT02228382|Chronic Myeloid Leukemia
138722|NCT02228382|CML
138723|NCT02228382|Leukemia
138724|NCT02228382|Myelogenous
138725|NCT02228382|Chronic
138726|NCT02228382|BC-ABL Positive
138727|NCT02228369|Non Small Cell Lung Cancer, EGFR, Tyrosine kinase inhibitor,EGFR mutation positive, Brain Metastasis, Leptomeningeal Metastasis
138728|NCT02228356|Neoplasm Metastasis
138729|NCT02228356|oligometastatic cancer
138730|NCT02228356|Stereotactic Body Radiation Therapy
138731|NCT02228356|SBRT
138732|NCT02228356|Real-time Tumor Tracking (RTTT)
138733|NCT02228356|ITV
138734|NCT02228356|Internal Target Volume
138735|NCT02228356|Respiratory Motion Management
138736|NCT02228356|Image-guided Radiotherapy
138737|NCT02228356|IGRT
138738|NCT02228330|Transurethral resection of bladder tumors
138739|NCT02228330|Obturator nerve reflex
138740|NCT02228330|Obturator nerve block
138741|NCT02228317|Emergency Medical Dispatch
138742|NCT02228317|Telemedicine
138743|NCT02228317|Emergency Medical Services
138744|NCT02228317|Pre-hospital
138745|NCT02228304|Wet AMD
138746|NCT02228304|Wet Age Related Macular Degeneration
138747|NCT02228304|Recurrent CNV Secondary to AMD
138748|NCT02228304|Active subfoveal CNV
138749|NCT02228291|Polyphenols
138750|NCT02228291|Endothelial function
138751|NCT02228291|Gut barrier function
138752|NCT02228278|Pediatric
138753|NCT02228278|Obesity
138754|NCT02228278|Overweight
138755|NCT02228278|Texting
138756|NCT02228278|Text message
138757|NCT02228278|SMS
138758|NCT02228278|Diet
138759|NCT02228278|Weight Loss
138760|NCT02228278|Nutrition
138761|NCT02228278|Physical activity
138762|NCT02228278|BMI z-score
138763|NCT02228278|BMI
138764|NCT02228252|Proteins
138765|NCT02228252|Postprandial lipemia
138766|NCT02228252|Pre-meal
138767|NCT02228252|Metabolic syndrome
138768|NCT02228239|Healthy
138769|NCT02228239|Esketamine
138770|NCT02228239|Mirtazapine
138771|NCT02228239|Psychomotor.
138772|NCT02228226|Arthroscopic Bankart repair
138773|NCT02228226|Bone hole
138774|NCT02228226|Ossification
138775|NCT02228226|Suture anchor
138776|NCT02228226|Shoulder dislocation
138777|NCT02228213|multiple sclerosis
138778|NCT02228213|SPMS
138779|NCT02228200|Oncology Nursing
138780|NCT02228200|Advanced Practice Nursing
138781|NCT02228200|Nurse-led care
138782|NCT02228200|Chemotherapy
138783|NCT02228174|Abnormal Uterine Bleeding associated with fibroids
138784|NCT02228174|AUB-L
138785|NCT02228174|Fibroids
138786|NCT02228174|Heavy menstrual bleeding
138787|NCT02228174|HMB
138788|NCT02228174|Myoma
138789|NCT02228174|Menorrhagia
138790|NCT02228161|Yoga
138791|NCT02228161|Work-related Stress,
138792|NCT02228161|Stress Adaptation.
138793|NCT02228148|Post linguistically deafness, severe to profound deafness
138794|NCT02228122|Chronic wounds
138795|NCT02228122|Biofilms
138796|NCT02228122|Bacteria
138797|NCT02228083|dental
138798|NCT02228083|epinephrine
138799|NCT02228083|local anesthetic
138800|NCT02228083|lidocaine
138801|NCT02228083|cardiac arrhythmias
138802|NCT02228083|procedure
138803|NCT02228070|strabismus
138804|NCT02228070|oculomotor palsy
138805|NCT02228070|abducens palsy
138806|NCT02228070|trochlear palsy
138807|NCT02228057|arterial patency
138808|NCT02228057|upper extremity
138809|NCT02228057|anastomosis
138810|NCT02228057|sensibility
138811|NCT02228057|pain
138812|NCT02228057|cold intolerance
138813|NCT02228044|suicide
138814|NCT02228044|alcohol
138815|NCT02228044|marijuana
138816|NCT02228044|HIV
138817|NCT02228044|prevention
138818|NCT02228044|adolescent
138819|NCT02228031|Mirror neurons
138820|NCT02228031|Imitation
138821|NCT02228031|Oxytocin
138822|NCT02227992|Fibrin Sealant
138823|NCT02227992|Hemostatics
138824|NCT02227992|Coagulants
138825|NCT02227966|Mild Cognitive Impairment
138826|NCT02227966|MCI
138827|NCT02227966|tDCS
138828|NCT02227966|transcranial Direct Current Stimulation
138829|NCT02227953|Alzheimer's Disease
138830|NCT02227953|AD
138831|NCT02227953|tDCS
138832|NCT02227953|transcranial direct current stimulation
138833|NCT02227927|Gastroesophageal Reflux Disease
138834|NCT02227927|GERD
138835|NCT02227927|Gastroparesis
138836|NCT02227927|Domperidone
138837|NCT02227888|CF
138838|NCT02227888|F508Del
138839|NCT02227888|Cavosonstat
138840|NCT02227888|N91115
138841|NCT02227849|insulin resistance
138842|NCT02227836|Allergy Patch testing
138843|NCT02227836|Eosinophilic Esophagitis
138844|NCT02227836|EoE
138845|NCT02227823|spinal muscular atrophy type 3
138846|NCT02227823|electromyography
138847|NCT02227823|fatigability
138848|NCT02227823|decrement
138849|NCT02227810|Prolong mechanical ventilator,
138850|NCT02227810|Electrical stimulation,
138851|NCT02227810|Activities of daily life,
138852|NCT02227810|Hospitalization outcomes.
138853|NCT02227797|stem cell transplant
138854|NCT02227797|hematopoietic stem cell transplant
138855|NCT02227797|fungal infection
138856|NCT02227797|voriconazole
138857|NCT02227797|pediatric
138858|NCT02227719|after augmentation
138859|NCT02227719|procedure
138860|NCT02227706|Fibrin Sealant
138861|NCT02227706|Hemostatics
138862|NCT02227706|Coagulants
138863|NCT02227693|Thrombocytopenia
138864|NCT02227693|Chronic Liver Disease
138865|NCT02227680|music therapy
138866|NCT02227680|massage therapy
138867|NCT02227667|MEDI4736
138868|NCT02227667|14-109
138869|NCT02227654|Ovary
138870|NCT02227654|Cancer
138871|NCT02227654|Morphology
138872|NCT02227654|Surgery
138873|NCT02227641|CMV
138874|NCT02227641|Cytomegalovirus
138875|NCT02227641|EBV
138876|NCT02227641|Epstein Barr Virus
138877|NCT02227641|virus
138878|NCT02227641|T cell
138879|NCT02227641|adoptive transfer
138880|NCT02227641|transplantation
138881|NCT02227641|allogeneic
138882|NCT02227589|adolescent,
138883|NCT02227589|alcohol abuse
138884|NCT02227589|depression,
138885|NCT02227589|cognitive behavior therapy
138886|NCT02227589|cannabis abuse
138887|NCT02227576|glioblastoma, thrombocytopenia, temozolomide, chemotherapy
138888|NCT02227563|dorsolateral prefrontal cortex
138889|NCT02227563|left superior temporal gyrus
138890|NCT02227563|auditory hallucinations
138891|NCT02227563|transcranial direct current stimulation (tDCS)
138892|NCT02227550|Atrilal fibrillation
138893|NCT02227550|anticoagulation
138894|NCT02227550|prevention of peri-procedural complication
138895|NCT02227550|catheter ablation
138896|NCT02227537|Adolescence Idiopathic Scoliosis
138897|NCT02227537|nighttime Bracing
138898|NCT02227537|Providence
138899|NCT02227524|Multiple Sclerosis
138900|NCT02227524|Walking
138901|NCT02227524|Gait
138902|NCT02227511|fruit, nuts, liver fat, insulin, glucose
138903|NCT02227511|Focus of the study is to compare the often given advice to eat fruit, containing large amount of glucose and fructose, with nuts that are more rich in fat.
138904|NCT02227485|Gingivitis
138905|NCT02227485|Diabetes mellitus
138906|NCT02227485|Medicine, Traditional
138907|NCT02227485|Herbal medicine
138908|NCT02227485|Punica granatum
138909|NCT02227446|Surgical site infection risk prevention
138910|NCT02227446|Bacterial species type and antibacterial sensitives
138911|NCT02227433|Hodgkin Lymphoma, Elderly Patients, brentuximab vedotin (BV)
138912|NCT02227407|SCI
138913|NCT02227407|SMA
138914|NCT02227407|Paralysis
138915|NCT02227394|Asthma
138916|NCT02227394|Functional Respiratory Imaging
138917|NCT02227394|Computational Fluid Dynamic
138918|NCT02227368|Myocardial Infarction
138919|NCT02227368|Peripheral Arterial disease
138920|NCT02227368|Mycardial Ischemia
138921|NCT02227368|Heart Diseases
138922|NCT02227368|Cardiovascular Diseases
138923|NCT02227368|Vascular Diseases
138924|NCT02227368|Altherosclerosis
138925|NCT02227368|Arteriosclerosis
138926|NCT02227368|Arterial Occlusive Diseases
138927|NCT02227368|Peripheral Vascular Diseases
138928|NCT02227368|Ticagrelor
138929|NCT02227368|Ticlopidine
138930|NCT02227368|Platelet Aggregation inhibitors
138931|NCT02227368|Hematologic Agents
138932|NCT02227368|Therapeutic Uses
138933|NCT02227368|Pharmacologic Actions
138934|NCT02227368|Purinegic P2Y Receptor Antagonists
138935|NCT02227368|Purinegic P2 Receptor Antagonists
138936|NCT02227368|Purinergic Antagonists
138937|NCT02227368|Purinergic Agents
138938|NCT02227368|Neurotransmitter Agents
138939|NCT02227368|Molecular Mechanisms of Pharmacological Actions
138940|NCT02227368|Physiological Effects of Drugs
138941|NCT02227368|Fibrinolytic Agents
138942|NCT02227368|Crardiovascular Agents
138943|NCT02227355|Parkinson's Disease
138944|NCT02227355|Neupro®
138945|NCT02227355|Rotigotine
138946|NCT02227355|Transdermal patch
138947|NCT02227355|NEUPART
138948|NCT02227355|Levodopa
138949|NCT02227355|Noninterventional
138950|NCT02227355|Combination therapy
138951|NCT02227329|Home parenteral Nutrition
138952|NCT02227329|Quality of Life
138953|NCT02227329|infection prevention
138954|NCT02227329|CRBSI
138955|NCT02227329|Ethanol lock therapy
138956|NCT02227316|Uterine Fibroid Embolization
138957|NCT02227316|Pain
138958|NCT02227316|UFE
138959|NCT02227316|Fibroids
138960|NCT02227316|Adenomyosis
138961|NCT02227316|Bleeding
138962|NCT02227316|IV Acetaminophen
138963|NCT02227316|IV Ibuprofen
138964|NCT02227316|Menorrhagia
138965|NCT02227316|Leiomyoma
138966|NCT02227316|Patient Satisfaction
138967|NCT02227290|Tinea Corporis
138968|NCT02227290|Ringworm
138969|NCT02227277|HIV
138970|NCT02227277|HIV-1
138971|NCT02227277|Pegintron
138972|NCT02227277|Peg-IFN-α2b
138973|NCT02227277|Viral suppression
138974|NCT02227277|ART cessation
138975|NCT02227277|Immune function
138976|NCT02227277|Innate immunity
138977|NCT02227277|Toxicity
138978|NCT02227277|Immune-based therapy
138979|NCT02227277|Treatment interruption
138980|NCT02227277|HIV Cure
138981|NCT02227277|HIV Eradication
138982|NCT02227277|BEAT-HIV
138983|NCT02227277|HIV Cure Trial
138984|NCT02227277|Cure Trial
138985|NCT02227264|Primary hyperparathyroidism
138986|NCT02227264|Calcimimetic Agents
138987|NCT02227264|Parathyroid adenomectomy
138988|NCT02227251|Diffuse large B-cell Lymphoma
138989|NCT02227251|DLBCL
138990|NCT02227251|Karyopharm
138991|NCT02227251|KPT-330
138992|NCT02227251|selinexor
138993|NCT02227238|integrase inhibitor
138994|NCT02227238|non-inferiority
138995|NCT02227238|dolutegravir
138996|NCT02227238|lopinavir/ritonavir
138997|NCT02227238|second-line treatment
138998|NCT02227238|HIV-1
138999|NCT02227238|antiretroviral therapy-experienced
139000|NCT02227225|Postoperative Delirium
139001|NCT02227186|Influenza vaccination rates
139002|NCT02227147|Neurotrophic Keratitis
139003|NCT02227108|pediatric cancer,pediatric acute lymphoblastic leukemia, lymphoblastic lymphoma, B-cell leukemia, ALL, moxetumomab pasudotox, CD22
139004|NCT02227082|radiotherapy
139005|NCT02227082|olaparib
139006|NCT02227082|breast cancer
139007|NCT02227082|locally advanced breast cancer
139008|NCT02227056|Acquired pediatric brain injury
139009|NCT02227056|Methylphenidate
139010|NCT02227056|Traumatic brain injury
139011|NCT02227056|Cerebrovascular event
139012|NCT02227056|Hypoxic ischemic brain injury
139013|NCT02227056|Function (ecologic)
139014|NCT02227004|MRI
139015|NCT02227004|Magnetic Resonance Imaging
139016|NCT02227004|pacemakers
139017|NCT02227004|ICD
139018|NCT02226965|PNT2258
139019|NCT02226965|DLBCL
139020|NCT02226965|Diffuse Large B-cell Lymphoma
139021|NCT02226965|NHL
139022|NCT02226965|Non-Hodgkin's Lymphoma
139023|NCT02226965|Lymphoma
139024|NCT02226913|Buffered
139025|NCT02226913|inferior alveolar nerve block
139026|NCT02226913|irreversible pulpitis
139027|NCT02226913|local anesthesia
139028|NCT02226913|sodium bicarbonate
139029|NCT02226900|Multivessel Coronary Artery Disease
139030|NCT02226900|Hybrid Revascularization
139031|NCT02226887|Loop ileostomy
139032|NCT02226887|Eventration
139033|NCT02226874|Dose Estimation
139034|NCT02226874|Dose Reconstruction
139035|NCT02226874|Methods
139036|NCT02226874|Fallout
139037|NCT02226874|Radiation Exposure
139038|NCT02226861|Acute Lymphoblastic Leukemia (ALL)
139039|NCT02226861|MDS
139040|NCT02226861|Chronic Myelogenous Leukemia (CML)
139041|NCT02226861|Chronic Lymphocytic Leukemia (CLL)
139042|NCT02226861|Acute Myelogenous Leukemia (AML)
139043|NCT02226848|Endothelial Progenitor Cells
139044|NCT02226848|Angiogenesis
139045|NCT02226848|Traumatic Brain Injury
139046|NCT02226835|OCT
139047|NCT02226835|Alzheimer's Disease
139048|NCT02226835|Age-Related Macular Degeneration (AMD)
139049|NCT02226822|Type 2 diabetes mellitus
139050|NCT02226809|Muscle relaxants
139051|NCT02226809|Postoperative complications, respiratory
139052|NCT02226809|General anesthesia
139053|NCT02226809|Postanesthesia care unit
139054|NCT02226809|Neuromuscular block reversal
139055|NCT02226796|Broca's Aphasia
139056|NCT02226796|Transcranial Direct Current Stimulation
139057|NCT02226783|Phase I
139058|NCT02226783|Healthy subjects
139059|NCT02226783|PK
139060|NCT02226783|PD
139061|NCT02226757|NSCLC
139062|NCT02226757|HER2-expression
139063|NCT02226757|EGFR-mutation
139064|NCT02226757|Trastuzumab
139065|NCT02226757|Paclitaxel
139066|NCT02226744|breathing
139067|NCT02226744|mind-body practices
139068|NCT02226744|yoga
139069|NCT02226744|meditation
139070|NCT02226731|Immediate postpartum hemorrhage
139071|NCT02226731|Intrauterine balloon tamponade
139072|NCT02226705|Rhinocerebral Mucormycosis
139073|NCT02226705|Surgery
139074|NCT02226705|Fungal Infection
139075|NCT02226705|Survival
139076|NCT02226692|chronic low back pain
139077|NCT02226692|prognostic factors
139078|NCT02226692|disabling low back pain
139079|NCT02226692|lumbar muscle activity
139080|NCT02226692|start back screening tool
139081|NCT02226692|physical evaluation
139082|NCT02226679|crossover
139083|NCT02226679|rollover study
139084|NCT02226679|open label
139085|NCT02226666|MRI
139086|NCT02226666|Eovist
139087|NCT02226666|MultiHance
139088|NCT02226601|drowsiness
139089|NCT02226601|loopiness
139090|NCT02226601|nausea
139091|NCT02226575|Sense of coherence
139092|NCT02226549|hepatitis C
139093|NCT02226549|Gilead
139094|NCT02226549|GS-9451
139095|NCT02226536|Posture
139096|NCT02226536|Vertigo
139097|NCT02226536|glucose metabolism
139098|NCT02226536|diet
139099|NCT02226536|scales
139100|NCT02226536|dinamic posturography
139101|NCT02226523|immunomagnetic reduction
139102|NCT02226523|acute coronary syndrome
139103|NCT02226523|serum biomarkers
139104|NCT02226484|Gastroesophageal reflux disease
139105|NCT02226484|GERD
139106|NCT02226484|Acid reflux
139107|NCT02226484|Reflux
139108|NCT02226484|Quercetin
139109|NCT02226458|Autism
139110|NCT02226458|Mitochondrial Disorders
139111|NCT02226458|EPI-743
139112|NCT02226458|EPI743
139113|NCT02226458|Rett syndrome
139114|NCT02226458|Angelman syndrome
139115|NCT02226445|Adults
139116|NCT02226445|Outpatients
139117|NCT02226432|Barthel Scale
139118|NCT02226432|Disability
139119|NCT02226432|Modified Ashworth Scale
139120|NCT02226432|Right Arm
139121|NCT02226432|Neuromodulation
139122|NCT02226432|Spasticity
139123|NCT02226432|Stroke
139124|NCT02226419|Fatty acid oxidation disorder
139125|NCT02226419|Primary carnitine deficiency
139126|NCT02226419|Exercise
139127|NCT02226419|L-carnitine treatment
139128|NCT02226419|Stable isotopes
139129|NCT02226419|Carnitine transporter deficiency
139130|NCT02226406|Early Physical Exercise
139131|NCT02226406|Alveolar Recruitment
139132|NCT02226406|Electrical Impedance Tomography
139133|NCT02226406|Oxygenation
139134|NCT02226406|Ventilation
139135|NCT02226393|Toddlers; Preschoolers; PTSD
139136|NCT02226367|prazosin
139137|NCT02226367|alcohol use disorders
139138|NCT02226367|posttraumatic stress disorder
139139|NCT02226367|PTSD
139140|NCT02226367|combat trauma
139141|NCT02226367|military
139142|NCT02226367|alpha-1 adrenoreceptor antagonist
139143|NCT02226354|Dietary vegetable oil
139144|NCT02226354|Stearidonic acid
139145|NCT02226354|Tissue
139146|NCT02226354|Fatty Acid
139147|NCT02226354|composition
139148|NCT02226341|Lupus
139149|NCT02226341|Lupus Nephritis
139150|NCT02226341|ACTHar
139151|NCT02226341|Columbia
139152|NCT02226341|Rheumatology
139153|NCT02226341|CUMC
139154|NCT02226341|Autoimmune
139155|NCT02226341|SLE
139156|NCT02226341|Proliferative Lupus Nephritis
139157|NCT02226315|noninvasive prenatal testing
139158|NCT02226302|Endometrial cancer
139159|NCT02226302|Obesity
139160|NCT02226289|bevacizumab
139161|NCT02226289|refractory
139162|NCT02226289|colorectal cancer
139163|NCT02226289|metastatic
139164|NCT02226263|Necrotizing enterocolitis
139165|NCT02226263|Probiotics
139166|NCT02226263|Preterm newborns
139167|NCT02226250|sugar-based beverage
139168|NCT02226250|Time Influence
139169|NCT02226237|urinary incontinence
139170|NCT02226237|erectile dysfunction
139171|NCT02226237|Retropubic Prostatectomy
139172|NCT02226237|Physiotherapy
139173|NCT02226224|gastrointestinal neoplasms
139174|NCT02226224|endosonography
139175|NCT02226224|in vitro
139176|NCT02226224|Staging
139177|NCT02226198|LDL-C
139178|NCT02226198|HoFH
139179|NCT02226198|Hyperlipidemia
139180|NCT02226172|Primary myelofibrosis
139181|NCT02226172|Secondary myelofibrosis
139182|NCT02226172|PMF
139183|NCT02226172|PET-MF
139184|NCT02226172|PPV-MF
139185|NCT02226172|Ruxolitinib resistant or intolerant
139186|NCT02226172|previously treated myelofibrosis
139187|NCT02226172|smoothened inhibitor
139188|NCT02226172|oral
139189|NCT02226172|single agent.
139190|NCT02226159|cervical
139191|NCT02226159|radicular pain
139192|NCT02226159|transforaminal epidural steroid injections
139193|NCT02226146|Pemphigoid Bullous
139194|NCT02226146|Bullous
139195|NCT02226146|Blisters
139196|NCT02226146|SKIN DISEASES
139197|NCT02226146|BP
139198|NCT02226120|LCZ696, chronic heart failure, open-label study, ARNI
139199|NCT02226107|Lay health worker
139200|NCT02226107|Patient navigation
139201|NCT02226107|Screening colonoscopy
139202|NCT02226107|Colon cancer
139203|NCT02226107|Training
139204|NCT02226107|Hispanic
139205|NCT02226107|Latino
139206|NCT02226094|intra-ocular pressure
139207|NCT02226094|primary open-angle glaucoma
139208|NCT02226094|intra ocular pressure
139209|NCT02226094|primary open angle glaucoma
139210|NCT02226094|glaucoma
139211|NCT02226094|deep wave trabeculoplasty
139212|NCT02226094|ocular hypertension
139213|NCT02226081|breast lesion
139214|NCT02226081|ultrasound
139215|NCT02226081|BI-RADS
139216|NCT02226081|women
139217|NCT02226081|malignancy
139218|NCT02226068|Atopic dermatitis
139219|NCT02226068|Ciclosporine
139220|NCT02226068|Extracorporal photopheresis
139221|NCT02226055|Chronic kidney disease of unknown origin
139222|NCT02226055|Chronic kidney disease of unknown aetiology
139223|NCT02226055|Sri Lanka
139224|NCT02226055|CKDu
139225|NCT02226055|Arterial stiffness
139226|NCT02226055|Cardiovascular risk
139227|NCT02226055|North Central Province
139228|NCT02226029|MRI, fat fraction, stomach, lipid emulsion
139229|NCT02226016|ptosis
139230|NCT02226016|blepharochalasis
139231|NCT02226016|dermatochalasis
139232|NCT02225990|stroke
139233|NCT02225990|stroke rehabilitation
139234|NCT02225990|stroke therapy
139235|NCT02225964|APOEε4
139236|NCT02225938|Intensive Care
139237|NCT02225938|Recovery
139238|NCT02225938|Long term outcome
139239|NCT02225938|Function
139240|NCT02225925|brachytherapy
139241|NCT02225886|Renal anaemia
139242|NCT02225886|Intravenous ascorbic acid
139243|NCT02225886|Intravenous iron administration
139244|NCT02225860|ADPKD
139245|NCT02225860|Copeptin
139246|NCT02225860|Vasopressin
139247|NCT02225860|Diet
139248|NCT02225860|Water
139249|NCT02225847|Gardening
139250|NCT02225847|Therapeutic Horticulture
139251|NCT02225847|Functional Magnetic Resonance Imaging
139252|NCT02225847|Psychometric Assessment
139253|NCT02225847|Stress
139254|NCT02225847|Depression
139255|NCT02225847|Anxiety
139256|NCT02225847|Quality of Life
139257|NCT02225847|Wellness
139258|NCT02225834|Atorvastatin, ischemic stroke, cytokines
139259|NCT02225821|Implant Removal
139260|NCT02225821|Antibiotic Prophylaxis
139261|NCT02225821|Postoperative wound infection
139262|NCT02225821|Orthopedics
139263|NCT02225808|CBT
139264|NCT02225808|autism
139265|NCT02225808|anxiety
139266|NCT02225808|treatment
139267|NCT02225808|fMRI
139268|NCT02225795|Crohn's Disease
139269|NCT02225795|Hematopoietic stem cell transplantation
139270|NCT02225795|Children
139271|NCT02225795|Young Adults
139272|NCT02225782|Alteplase; Hemodialysis Catheter; Occlusion; Renal Failure
139273|NCT02225769|fever
139274|NCT02225769|point-of-care tests
139275|NCT02225769|clinical algorithms
139276|NCT02225769|electronic support
139277|NCT02225769|host biomarkers
139278|NCT02225756|Drug therapy
139279|NCT02225756|Prevention and control
139280|NCT02225756|Healing
139281|NCT02225756|Tissue regeneration
139282|NCT02225756|Therapy
139283|NCT02225743|Hypothermia
139284|NCT02225743|Total Hip Joint Prosthesis
139285|NCT02225743|Total Knee Joint Prosthesis
139286|NCT02225717|Preterm labor
139287|NCT02225717|cervicovaginal secretions
139288|NCT02225717|markers of fetal membranes remodelling
139289|NCT02225717|Multiplex test
139290|NCT02225691|type 1 diabetes
139291|NCT02225691|type 2 diabetes
139292|NCT02225691|paired testing
139293|NCT02225678|healthy volunteers
139294|NCT02225678|asthma
139295|NCT02225678|sputum eosinophils
139296|NCT02225639|ADHD
139297|NCT02225639|Adult
139298|NCT02225613|Cruciate ligament injury
139299|NCT02225613|Balance control
139300|NCT02225613|Rehabilitation
139301|NCT02225613|Spa therapy
139302|NCT02225613|Sport
139303|NCT02225600|Borderline Personality Disorder
139304|NCT02225600|BPD
139305|NCT02225600|Intranasal oxytocin
139306|NCT02225574|Leukemia
139307|NCT02225574|Advanced phase chronic myeloid leukemia
139308|NCT02225574|refractory chronic phase chronic myeloid leukemia
139309|NCT02225574|CML
139310|NCT02225574|Accelerated phase
139311|NCT02225574|(AP)
139312|NCT02225574|Blast phase
139313|NCT02225574|(BP)
139314|NCT02225574|Philadelphia-positive acute leukemia
139315|NCT02225574|MEK-162
139316|NCT02225574|Nilotinib
139317|NCT02225574|AMN107
139318|NCT02225574|Tasigna
139319|NCT02225574|Questionnaires
139320|NCT02225574|Surveys
139321|NCT02225561|Cardiopulmonary resuscitation
139322|NCT02225561|Nitroprusside
139323|NCT02225561|Transthoracic
139324|NCT02225561|Impedances
139325|NCT02225535|low back pain
139326|NCT02225535|telehealth
139327|NCT02225535|videoconferencing
139328|NCT02225535|access to physical therapy
139329|NCT02225535|interprofessional care
139330|NCT02225535|rural health
139331|NCT02225522|Intensive Care Units, Neonatal
139332|NCT02225522|Infant, Newborn
139333|NCT02225522|Genetic Diseases, Inborn
139334|NCT02225509|Thyroid cancer
139335|NCT02225509|Thyroid cancer diagnostic
139336|NCT02225509|Thyroid nodule
139337|NCT02225509|Fine needle aspiration biopsy
139338|NCT02225509|Indeterminate cytological result
139339|NCT02225509|Molecular diagnostic
139340|NCT02225509|Transcriptomics
139341|NCT02225509|Molecular signature
139342|NCT02225496|Oropharyngeal cancer
139343|NCT02225496|Oropharynx
139344|NCT02225496|Human papilloma virus
139345|NCT02225496|HPV positive
139346|NCT02225496|Squamous cell carcinoma
139347|NCT02225496|SCC
139348|NCT02225496|Transoral robotic surgery
139349|NCT02225496|TORS
139350|NCT02225496|Intuitive Surgical da Vinci Surgical System
139351|NCT02225496|Modified barium swallow
139352|NCT02225496|MBS
139353|NCT02225496|Questionnaires
139354|NCT02225496|Surveys
139355|NCT02225496|Speech and swallowing function
139356|NCT02225470|Locally Recurrent or Metastatic Breast Cancer
139357|NCT02225457|insulin resistance
139358|NCT02225457|type 2 diabetes
139359|NCT02225457|obesity
139360|NCT02225457|polyphenols
139361|NCT02225457|adipose tissue
139362|NCT02225457|overfeeding
139363|NCT02225444|degenerative lumbosacral spine disease
139364|NCT02225444|posterolateral fusion evaluation
139365|NCT02225444|OsteoAMP growth factor
139366|NCT02225444|autograft
139367|NCT02225431|Contrast-induced nephropathy
139368|NCT02225431|Contrast-Induced acute kidney injury
139369|NCT02225431|Contrast media
139370|NCT02225431|Angiography
139371|NCT02225431|Coronary percutaneous intervention
139372|NCT02225418|Laparoscopic
139373|NCT02225418|Cholecystectomy
139374|NCT02225418|Postoperative
139375|NCT02225418|Pain
139376|NCT02225418|Quadratus lumborum
139377|NCT02225418|Ultrasound
139378|NCT02225405|Lung Cancer
139379|NCT02225405|Non-small Cell Lung Cancers
139380|NCT02225405|NCLC
139381|NCT02225405|Chemotherapy
139382|NCT02225405|Nintedanib
139383|NCT02225405|BIBF 1120
139384|NCT02225405|Cisplatin
139385|NCT02225405|Platinol-AQ
139386|NCT02225405|Platinol
139387|NCT02225405|CDDP
139388|NCT02225405|Docetaxel
139389|NCT02225405|Taxotere
139390|NCT02225392|Bronchial thermoplasty
139391|NCT02225392|Severe asthma
139392|NCT02225379|Type 1 Diabetes
139393|NCT02225379|Hypoglycemia detection
139394|NCT02225379|Non-invasive sensor
139395|NCT02225379|Nocturnal hypoglycemia
139396|NCT02225366|Melanoma
139397|NCT02225366|Metastatic
139398|NCT02225366|Antimicrobial peptide
139399|NCT02225366|LL37
139400|NCT02225366|Photographs
139401|NCT02225353|Cervical Pessaries
139402|NCT02225353|Progesterone
139403|NCT02225314|Parkinson's Disease
139404|NCT02225314|Mild Cognitive Impairment
139405|NCT02225301|Child maltreatment
139406|NCT02225301|Child Care
139407|NCT02225301|Knowledge
139408|NCT02225301|Attitude
139409|NCT02225288|Healthy Subjects
139410|NCT02225288|Japanese
139411|NCT02225288|Males
139412|NCT02225275|Leukemia
139413|NCT02225275|Chronic Lymphocytic Leukemia
139414|NCT02225275|CLL
139415|NCT02225275|Small Lymphocytic Lymphoma
139416|NCT02225275|SLL
139417|NCT02225275|Recurrent
139418|NCT02225275|Lenalidomide
139419|NCT02225275|CC-5013
139420|NCT02225275|Revlimid
139421|NCT02225275|Obinutuzumab
139422|NCT02225275|GA101
139423|NCT02225275|Gazyva
139424|NCT02225262|Prostate cancer
139425|NCT02225262|CyberKnife
139426|NCT02225262|Stereotactic
139427|NCT02225262|Radiation
139428|NCT02225236|executive functioning
139429|NCT02225236|metacognition
139430|NCT02225236|self-regulation
139431|NCT02225236|preschoolers
139432|NCT02225223|metastatic lesions
139433|NCT02225223|vertebral body
139434|NCT02225223|ablation
139435|NCT02225223|radiation
139436|NCT02225223|targeted radio-frequency ablation
139437|NCT02225223|radio-frequency targeted vertebral augmentation
139438|NCT02225223|radiofrequency kyphoplasty
139439|NCT02225223|spine
139440|NCT02225223|vertebral augmentation
139441|NCT02225223|kyphoplasty
139442|NCT02225223|spinal ablation
139443|NCT02225223|pain
139444|NCT02225223|quality of life
139445|NCT02225223|spinal tumors
139446|NCT02225210|Dexmedetomidine ,Delirium ,Haemodynamic, Mechanical ventilation
139447|NCT02225197|Perioptic
139448|NCT02225197|Stereotactic
139449|NCT02225197|Radiation
139450|NCT02225197|Benign brain tumor
139451|NCT02225197|Optic apparatus
139452|NCT02225184|Opioid Dependence
139453|NCT02225184|OPRM1
139454|NCT02225184|Outcome
139455|NCT02225184|Treatment
139456|NCT02225171|Genetic Knowledge
139457|NCT02225171|Genetic Testing
139458|NCT02225158|Immunity
139459|NCT02225158|Co-Infection
139460|NCT02225158|Parasite
139461|NCT02225158|Mycobacteria
139462|NCT02225145|Bone Marrow Transplant
139463|NCT02225145|Fertility
139464|NCT02225145|Ovary
139465|NCT02225132|Hydroxyurea
139466|NCT02225132|Sickle Cell Disease
139467|NCT02225132|Fetal Hemoglobin Induction
139468|NCT02225119|Retinal Images
139469|NCT02225119|Retinal Pigment Epithelium
139470|NCT02225106|Dopamine Receptors
139471|NCT02225106|Methylphenidate
139472|NCT02225106|Traumatic Brain Injury
139473|NCT02225106|C-11 Raclopride
139474|NCT02225106|Dopamine Release
139475|NCT02225093|Pharmacokinetics
139476|NCT02225093|Safety
139477|NCT02225093|Drug-drug interactions
139478|NCT02225093|Enzalutamide
139479|NCT02225093|Caffeine
139480|NCT02225093|Dextromethorphan
139481|NCT02225093|CYP1A2
139482|NCT02225093|CYP2D6
139483|NCT02225093|Prostate cancer
139484|NCT02225093|Phase 1
139485|NCT02225067|Patients
139486|NCT02225067|Volunteers
139487|NCT02225054|duration of analgesia
139488|NCT02225041|intensive care
139489|NCT02225041|critical care
139490|NCT02225041|child
139491|NCT02225041|family
139492|NCT02225041|survivors
139493|NCT02225028|physical activity
139494|NCT02225028|physical fitness
139495|NCT02225028|exercise program
139496|NCT02225028|telephone coaching
139497|NCT02225028|motivational counseling
139498|NCT02225028|stretching
139499|NCT02225028|fitness improvement
139500|NCT02225028|exercise coaching
139501|NCT02225028|toning
139502|NCT02225028|SCI
139503|NCT02225028|spinal cord injury
139504|NCT02225028|home-based
139505|NCT02225028|home exercise
139506|NCT02225015|Cancer
139507|NCT02225015|Breast cancer
139508|NCT02225015|Ovarian cancer
139509|NCT02225015|BRCA Mutation
139510|NCT02225015|BRCA1 Gene Mutation
139511|NCT02225015|BRCA2 Gene Mutation
139512|NCT02225015|Telephone genetic counselling
139513|NCT02225015|Cancer prevention
139514|NCT02225002|relapsed
139515|NCT02225002|refractory to standard therapy
139516|NCT02225002|no effective therapy exists
139517|NCT02224976|exercise training
139518|NCT02224963|Aging,
139519|NCT02224963|Macular Degeneration,
139520|NCT02224963|Preparation for Future Care,
139521|NCT02224963|Psychological Well-being,
139522|NCT02224963|Problem Solving
139523|NCT02224963|Prevention
139524|NCT02224963|Mental Health Promotion
139525|NCT02224950|Atopic dermatitis
139526|NCT02224950|eczema
139527|NCT02224950|alternative therapy
139528|NCT02224950|complementary therapy
139529|NCT02224950|moisturizer
139530|NCT02224937|Melatonin
139531|NCT02224937|Cognitive parameters
139532|NCT02224937|pharmacodynamic
139533|NCT02224937|pharmacokinetics
139534|NCT02224924|Experimental: autologous blood patch injection (ABPI)
139535|NCT02224924|Experimental: BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug
139536|NCT02224924|14-141
139537|NCT02224911|focal therapy
139538|NCT02224911|prostate cancer treatment
139539|NCT02224911|laser treatment
139540|NCT02224885|Interventional radiology
139541|NCT02224885|Lung
139542|NCT02224885|Liver
139543|NCT02224885|Confocal endomicroscopy
139544|NCT02224885|Optical biopsy
139545|NCT02224885|Scanner
139546|NCT02224885|Fluoroscopy
139547|NCT02224885|CT
139548|NCT02224885|Computed Tomography
139549|NCT02224885|Radiofrequency Ablation
139550|NCT02224885|Fluorescein
139551|NCT02224872|bone marrow transplant
139552|NCT02224872|thymoglobulin
139553|NCT02224872|cyclophosphamide
139554|NCT02224872|fludarabine
139555|NCT02224872|tacrolimus
139556|NCT02224872|Mycophenolic Acid Mofetil
139557|NCT02224872|chemotherapy
139558|NCT02224872|GVHD
139559|NCT02224872|haploidentical
139560|NCT02224833|appropriateness
139561|NCT02224833|elderly
139562|NCT02224833|polypharmacy
139563|NCT02224833|primary care
139564|NCT02224820|transplantation
139565|NCT02224820|sensitised patients
139566|NCT02224820|HLA-antibodies
139567|NCT02224807|breast cancer
139568|NCT02224807|diet
139569|NCT02224807|exercise
139570|NCT02224807|weight loss
139571|NCT02224794|abdominal
139572|NCT02224794|aortic
139573|NCT02224794|aneurysm
139574|NCT02224755|Heart Failure
139575|NCT02224755|Left Ventricular Assist Device
139576|NCT02224755|Ventricular Dysfunction
139577|NCT02224755|Cardiomyopathy
139578|NCT02224755|Heart Disease
139579|NCT02224755|Cardiovascular Disease
139580|NCT02224755|Heart-assist devices
139581|NCT02224755|Thoratec Corporation
139582|NCT02224703|Cannabidiol
139583|NCT02224703|CBD
139584|NCT02224703|GWP42003-P
139585|NCT02224690|Cannabidiol
139586|NCT02224690|CBD
139587|NCT02224690|Epidiolex
139588|NCT02224690|GWP42003-P
139589|NCT02224677|CFM
139590|NCT02224677|facial asymmetry
139591|NCT02224677|skin tag
139592|NCT02224677|facial tag
139593|NCT02224677|missing ear
139594|NCT02224677|small ear
139595|NCT02224677|anotia
139596|NCT02224677|microtia
139597|NCT02224677|epibulbar dermoid
139598|NCT02224677|coloboma
139599|NCT02224677|macrostomia
139600|NCT02224677|lateral cleft
139601|NCT02224677|infant
139602|NCT02224677|toddler
139603|NCT02224677|baby
139604|NCT02224677|neurodevelopment
139605|NCT02224677|cognition
139606|NCT02224677|socialization
139607|NCT02224638|skin ulcers
139608|NCT02224612|Pediatric Face Masks
139609|NCT02224612|children
139610|NCT02224573|Cannabidiol
139611|NCT02224573|CBD
139612|NCT02224573|GWP42003-P
139613|NCT02224560|Cannabidiol
139614|NCT02224560|CBD
139615|NCT02224560|Epidiolex
139616|NCT02224560|GWP42003-P
139617|NCT02224547|non-small cell lung cancer
139618|NCT02224547|lung carcinoma
139619|NCT02224547|NSCLC
139620|NCT02224534|ST elevation myocardial infarction.
139621|NCT02224534|Ticagrelor
139622|NCT02224534|Left ventricular remodeling
139623|NCT02224534|Platelet reactivity
139624|NCT02224521|FLAP inhibitor
139625|NCT02224521|Chronic Obstructive Pulmonary Disease (COPD)
139626|NCT02224521|COPD
139627|NCT02224521|Bioavailability
139628|NCT02224469|Brain-Computer Interface
139629|NCT02224469|Motor Cortex
139630|NCT02224469|Dorsolateral Prefrontal Cortex
139631|NCT02224469|Quality of Life
139632|NCT02224456|Tenofovir disoproxil fumarate
139633|NCT02224456|hepatocellular carcinoma
139634|NCT02224456|chronic hepatitis B
139635|NCT02224456|Cirrhosis
139636|NCT02224443|Dexmedetomidine,postoperative cognitive dysfunction
139637|NCT02224430|biomarker of relapse
139638|NCT02224430|schizophrenia
139639|NCT02224430|schizoaffective disorder
139640|NCT02224430|on-body sensors
139641|NCT02224430|smartphone
139642|NCT02224430|observational
139643|NCT02224417|Diabetes
139644|NCT02224417|Treatment medication adherence
139645|NCT02224417|Physical activity
139646|NCT02224417|Financial incentives
139647|NCT02224417|Outcome incentives
139648|NCT02224417|Process incentives
139649|NCT02224417|HbA1c
139650|NCT02224391|Smoking Cessation
139651|NCT02224391|Attentional bias modification
139652|NCT02224391|ABM
139653|NCT02224391|Smartphone
139654|NCT02224391|Nicotine replacement therapy
139655|NCT02224391|Nicotine patch
139656|NCT02224391|NRT
139657|NCT02224391|Questionnaires
139658|NCT02224391|Surveys
139659|NCT02224391|Saliva collection
139660|NCT02224391|Cotinine level
139661|NCT02224391|Counseling sessions
139662|NCT02224391|Electroencephalography
139663|NCT02224391|EEG
139664|NCT02224378|fluid responsiveness
139665|NCT02224378|atrial fibrillation
139666|NCT02224378|passive leg raising
139667|NCT02224378|central venous pressure
139668|NCT02224378|valvular heart surgery
139669|NCT02224365|Diabetes
139670|NCT02224365|Arterial Stiffness
139671|NCT02224365|Blood Pressure
139672|NCT02224365|Endothelial Function
139673|NCT02224365|Body Composition
139674|NCT02224365|Glycemic Control
139675|NCT02224365|Apples
139676|NCT02224365|Functional Foods
139677|NCT02224365|Polyphenols
139678|NCT02224365|Fiber
139679|NCT02224352|Electric Stimulation
139680|NCT02224352|Respiration
139681|NCT02224352|Abdominal wall
139682|NCT02224352|Lung Diseases
139683|NCT02224352|Respiratory Tract Diseases
139684|NCT02224352|COPD
139685|NCT02224339|Atherosclerosis
139686|NCT02224339|carotid plaque
139687|NCT02224339|Contrast-enhanced ultrasound
139688|NCT02224339|Major Adverse Cardiovascular Events
139689|NCT02224326|Alzheimer´s disease
139690|NCT02224326|early diagnosis
139691|NCT02224326|evoked potentials
139692|NCT02224326|near-infrared spectroscopy
139693|NCT02224313|vaginal cytokine
139694|NCT02224287|Urolithiasis
139695|NCT02224287|Kidney Stones
139696|NCT02224287|Ureteroscopy
139697|NCT02224287|Fluoroscopy
139698|NCT02224274|Antiplatelet Therapy
139699|NCT02224274|Cardiac Arrest
139700|NCT02224274|Therapeutic hypothermia
139701|NCT02224274|Myocardial infarction (STEMI and NSTEMI)
139702|NCT02224261|Axillary web syndrome
139703|NCT02224261|cording
139704|NCT02224261|physical therapy
139705|NCT02224261|breast cancer
139706|NCT02224248|cardiorespiratory fitness
139707|NCT02224248|exercise tolerance
139708|NCT02224248|exercise test
139709|NCT02224248|health behavior
139710|NCT02224248|motor activity
139711|NCT02224248|motivation
139712|NCT02224248|intention
139713|NCT02224248|self-rated health
139714|NCT02224235|Stable angina
139715|NCT02224235|PCI
139716|NCT02224235|Percutaneous Coronary Intervention
139717|NCT02224209|Carotid artery stenosis
139718|NCT02224209|High risk of hyperperfusion
139719|NCT02224209|Staged angioplasty
139720|NCT02224209|Routine single-stage stenting
139721|NCT02224196|manual ventilation
139722|NCT02224196|pressure-controlled ventilation
139723|NCT02224196|peak airway pressure
139724|NCT02224196|antral area
139725|NCT02224183|low back pain
139726|NCT02224183|yoga
139727|NCT02224183|education
139728|NCT02224183|Veterans
139729|NCT02224183|cost-effectiveness
139730|NCT02224183|military
139731|NCT02224183|back pain
139732|NCT02224170|Dexamethasone
139733|NCT02224170|Lidocaine
139734|NCT02224170|Quality of Recovery
139735|NCT02224170|Laparoscopic cholecystectomy
139736|NCT02224144|Kidney Transplantation
139737|NCT02224144|Calcitriol
139738|NCT02224144|Bone Mineral Density
139739|NCT02224144|Bone Mass and Strength
139740|NCT02224144|Vascular Calcifications
139741|NCT02224144|Hyperparathyroidism
139742|NCT02224144|Parathyroid Hormone
139743|NCT02224131|platelet function test
139744|NCT02224131|stent;
139745|NCT02224118|Healthy
139746|NCT02224118|Diabetes Mellitus, Type 2
139747|NCT02224118|CNTO 3649
139748|NCT02224092|heart health
139749|NCT02224092|general well-being
139750|NCT02224066|Aortic stenosis
139751|NCT02224066|TAVI
139752|NCT02224066|TAVR
139753|NCT02224066|Transcatheter aortic valve implantation
139754|NCT02224066|Ticagrelor
139755|NCT02224066|Antiplatelet reactivity
139756|NCT02224053|oncology, cancer, non small cell lung cancer, anticancer druge, omeprazole, healthy volunteer
139757|NCT02224001|tip plasty
139758|NCT02224001|septal cartilage
139759|NCT02223988|Patients
139760|NCT02223988|mechanical
139761|NCT02223988|ventilation
139762|NCT02223988|tracheostomy
139763|NCT02223975|Spectrum Analysis, vibrational
139764|NCT02223975|Spectrum Analysis, infrared
139765|NCT02223975|Spectrum Analysis, Raman
139766|NCT02223975|Spectrum Analysis
139767|NCT02223975|Fourier transform infrared spectroscopy
139768|NCT02223975|Raman probe
139769|NCT02223975|Optical
139770|NCT02223975|Diagnosis
139771|NCT02223975|Cancer
139772|NCT02223975|Multivariate analysis
139773|NCT02223975|Vulval Intraepithelial Neoplasia
139774|NCT02223975|Vulvar Neoplasm
139775|NCT02223975|Vulva
139776|NCT02223975|Vulvar Diseases
139777|NCT02223962|physical activity
139778|NCT02223962|COPD
139779|NCT02223962|activity monitors
139780|NCT02223949|Obesity
139781|NCT02223949|Labor complications
139782|NCT02223949|Induction of labor
139783|NCT02223949|Mechanical cervical ripening
139784|NCT02223936|nuchal translucency, neurological developpment, anxiety, depression, prenatal diagnosis, normal karyotype
139785|NCT02223923|Phase 1
139786|NCT02223923|Maximimum tolerated dose
139787|NCT02223923|ATR Inhibitor
139788|NCT02223923|Radiotherapy
139789|NCT02223910|brain computer interface
139790|NCT02223910|neurofeedback
139791|NCT02223910|functional connectivity
139792|NCT02223897|Liver transplantation
139793|NCT02223897|Biliary complication
139794|NCT02223897|mesenchymal stem cells
139795|NCT02223884|Malignant melanoma, second-line treatment, docetaxel, carboplatin
139796|NCT02223871|Malaria
139797|NCT02223871|ACT-451840
139798|NCT02223858|Health Status Disparities
139799|NCT02223858|Arthritis
139800|NCT02223858|Psychology
139801|NCT02223858|Pain Management
139802|NCT02223858|Affect
139803|NCT02223845|Music, Anxiety, IVF
139804|NCT02223832|ACT-128800
139805|NCT02223832|Safety
139806|NCT02223832|Tolerability
139807|NCT02223832|Pharmacokinetics
139808|NCT02223819|Crizotinib
139809|NCT02223819|14-063
139810|NCT02223806|Postpartum hemorrhage
139811|NCT02223806|Uterine tonus assessment
139940|NCT02223130|HIV Outcomes
139812|NCT02223806|Active management of third stage of labor
139813|NCT02223793|Vascular screening
139814|NCT02223793|Cardiovascular risk factors
139815|NCT02223793|Blood pressure
139816|NCT02223793|Lipids
139817|NCT02223793|Lifestyle
139818|NCT02223793|Identifying unknown risk
139819|NCT02223793|Low socioeconomic status
139820|NCT02223793|low threshold
139821|NCT02223780|COPD
139822|NCT02223780|palliative care
139823|NCT02223767|TMS
139824|NCT02223767|VR
139825|NCT02223767|Exposure therapy
139826|NCT02223767|TMS augmentations of exposure therapy
139827|NCT02223741|Cerebral palsy
139828|NCT02223741|GMFM-66
139829|NCT02223741|PEDI
139830|NCT02223702|Aggressive periodontitis
139831|NCT02223702|amoxicillin
139832|NCT02223702|metronidazole
139833|NCT02223702|moxifloxacin
139834|NCT02223702|nonsurgical periodontal debridement.
139835|NCT02223689|SkinAffix
139836|NCT02223676|Pharmacy
139837|NCT02223676|Length-of-stay
139838|NCT02223676|Emergency Department
139839|NCT02223650|Intermittent Exotropia
139840|NCT02223650|IXT
139841|NCT02223650|overminus
139842|NCT02223624|eccentric
139843|NCT02223624|exercise
139844|NCT02223624|heart disease
139845|NCT02223624|chronic heart failure
139846|NCT02223624|rehabilitation
139847|NCT02223611|Stage Ⅱ-ⅢA NSCLC S1 capsule Completely resection
139848|NCT02223598|Lymphoid Hematological Malignancies
139849|NCT02223585|Gut microbial
139850|NCT02223585|response
139851|NCT02223585|to protein-based
139852|NCT02223585|diet
139853|NCT02223585|challenges
139854|NCT02223585|population
139855|NCT02223533|analgesia
139856|NCT02223533|post-operative
139857|NCT02223533|wound catheter infusion
139858|NCT02223533|laparoscopic colon surgery
139859|NCT02223520|Staphylococcus aureus
139860|NCT02223520|Infection
139861|NCT02223520|Colonization
139862|NCT02223520|Transmission
139863|NCT02223520|Neonate
139864|NCT02223468|Intestinal Microbiota
139865|NCT02223468|Liver Transplant
139866|NCT02223468|Acute Rejection
139867|NCT02223468|Infection
139868|NCT02223455|Methicillin-resistant Staphylococcus aureus (MRSA)
139869|NCT02223455|Infection Control (IC)
139870|NCT02223455|Hospital-associated infections (HAI)
139871|NCT02223455|Hand Hygiene (HH)
139872|NCT02223455|Compliance
139873|NCT02223455|Health Care Workers (HCWs)
139874|NCT02223442|chronic pain
139875|NCT02223442|central analgesic drugs
139876|NCT02223442|adherence to therapy
139877|NCT02223442|side effects
139878|NCT02223442|quality of life
139879|NCT02223442|MOR-NRI drugs
139880|NCT02223429|Paternal nurturance
139881|NCT02223429|Oxytocin
139882|NCT02223429|Vasopressin
139883|NCT02223429|fMRI
139884|NCT02223429|Neurobiology
139885|NCT02223416|female
139886|NCT02223416|volunteers
139887|NCT02223403|Nitrate-rich beetroot juice
139888|NCT02223403|heart failure
139889|NCT02223403|exercise performance
139890|NCT02223403|oxygen consumption
139891|NCT02223390|South Africa
139892|NCT02223390|HIV
139893|NCT02223390|Mental health
139894|NCT02223390|Trauma
139895|NCT02223390|Women
139896|NCT02223351|HSV
139897|NCT02223351|HIV
139898|NCT02223351|Herpes
139899|NCT02223351|volunteers
139900|NCT02223351|drug-drug interaction
139901|NCT02223325|Elderly
139902|NCT02223325|Prognosis
139903|NCT02223299|Depression
139904|NCT02223299|SSRI
139905|NCT02223299|Nutritional Supplements
139906|NCT02223299|Beck Depression Scale
139907|NCT02223299|L-tyrosine
139908|NCT02223299|L-tryptophan
139909|NCT02223273|stroke,
139910|NCT02223273|quality improvement
139911|NCT02223247|solid tumors
139912|NCT02223247|cancer
139913|NCT02223221|In Vitro Fertilization
139914|NCT02223221|Intracytoplasmic Sperm Injections
139915|NCT02223221|Infertility, Female
139916|NCT02223221|Abortion, Habitual
139917|NCT02223221|recurrent pregnancy loss
139918|NCT02223221|comprehensive chromosome screening
139919|NCT02223221|preimplantation genetic screening
139920|NCT02223221|SNP array
139921|NCT02223208|PTCL
139922|NCT02223208|PTCL-NOS
139923|NCT02223208|AITL
139924|NCT02223208|ALCL
139925|NCT02223195|Juvenile Idiopathic Arthritis
139926|NCT02223195|Saliva
139927|NCT02223182|Milk Allergy,
139928|NCT02223182|Viaskin Milk,
139929|NCT02223182|Specific Immunotherapy,
139930|NCT02223182|Epicutaneous ImmunoTherapy (EPIT)
139931|NCT02223182|IgE-Mediated Cow's Milk Allergy
139932|NCT02223169|Blood Pressure
139933|NCT02223169|Hypertension
139934|NCT02223169|Cardiovascular disease
139935|NCT02223143|Lipid lowering therapy
139936|NCT02223130|HIV
139937|NCT02223130|Discrimination
139938|NCT02223130|Coping
139939|NCT02223130|Medical Mistrust
139941|NCT02223130|Cognitive Behavioral Therapy
139942|NCT02223091|complementary therapies
139943|NCT02223091|consultants
139944|NCT02223091|medical oncology
139945|NCT02223091|breast-cancer
139946|NCT02223091|education
139947|NCT02223052|CC-486
139948|NCT02223052|Oral Azacitidine
139949|NCT02223052|Soli Tumor Malignancy
139950|NCT02223052|Hematological Malignancy
139951|NCT02223052|Leukemia
139952|NCT02223052|Lymphoma
139953|NCT02223052|Multiple Myeloma
139954|NCT02223052|Acute Myeloid Leukemia
139955|NCT02223052|Myelodysplastic Syndromes
139956|NCT02223052|Neoplasms
139957|NCT02223052|Melanoma
139958|NCT02223052|Breast Cancer
139959|NCT02223052|Metastatic Breast Cancer
139960|NCT02223052|Non-Small Cell Lung Cancer
139961|NCT02223052|Small Cell Lung Cancer
139962|NCT02223052|Renal Cell Carcinoma
139963|NCT02223052|Glioblastoma Multiforme
139964|NCT02223052|Brain Cancer
139965|NCT02223052|Kidney Cancer
139966|NCT02223052|Lung cancer
139967|NCT02223052|Blood Cancer
139968|NCT02223052|Thyroid Cancer
139969|NCT02223052|Bone Cancer
139970|NCT02223052|Bone Metastasis
139971|NCT02223052|Testicular Cancer
139972|NCT02223052|Prostate Cancer
139973|NCT02223052|Bladder Cancer
139974|NCT02223052|Ovarian Cancer
139975|NCT02223052|Skin Cancer
139976|NCT02223052|Cancer general
139977|NCT02223052|Survival
139978|NCT02223052|Chemotherapy
139979|NCT02223052|Targeted Therapy
139980|NCT02223052|Genitourinary
139981|NCT02223052|MM
139982|NCT02223052|MDS
139983|NCT02223052|AML
139984|NCT02223052|NHL
139985|NCT02223052|HL
139986|NCT02223052|MBC
139987|NCT02223052|NSCLC
139988|NCT02223052|SCLC
139989|NCT02223052|GBM
139990|NCT02223039|Psoriasis
139991|NCT02223039|Dermatology
139992|NCT02223039|Monoclonal antibody
139993|NCT02222935|Balance training
139994|NCT02222935|low back pain
139995|NCT02222935|balance test
139996|NCT02222935|routine back exercise
139997|NCT02222922|ADC
139998|NCT02222922|PF-06647020
139999|NCT02222922|solid tumors
140000|NCT02222922|tumors
140001|NCT02222922|neoplasm metastasis
140002|NCT02222922|TNBC
140003|NCT02222922|triple negative breast cancer
140004|NCT02222922|NSCLC
140005|NCT02222922|non small cell lung cancer
140006|NCT02222922|advanced metastatic breast cancer
140007|NCT02222922|ovarian cancer
140008|NCT02222922|OVCA
140009|NCT02222909|Community Based Organization
140010|NCT02222909|Reverse Innovation
140011|NCT02222909|Social Services
140012|NCT02222909|Referral
140013|NCT02222909|Chronic disease
140014|NCT02222870|Influenza
140015|NCT02222870|Influenza virus vaccine
140016|NCT02222870|Quadrivalent Influenza Virus Vaccine (No Preservative)
140017|NCT02222870|Fluzone®
140018|NCT02222857|Acute retinal necrosis
140019|NCT02222857|Retinal detachment
140020|NCT02222857|Laser photocoagulation
140021|NCT02222857|Vitrectomy
140022|NCT02222844|Cancer
140023|NCT02222844|Colorectal Neoplasms
140024|NCT02222844|Colon, Sigmoid
140025|NCT02222844|Magnetic Resonance Imaging
140026|NCT02222844|General Surgery
140027|NCT02222844|Postoperative Complications
140028|NCT02222831|IVF
140029|NCT02222831|Embryo Quality
140030|NCT02222831|Time Lapse Culture
140031|NCT02222831|Preimplantation factor
140032|NCT02222805|Cord clamping
140033|NCT02222805|Iron deficiency
140034|NCT02222805|Anemia
140035|NCT02222805|Iron
140036|NCT02222805|Hyperbilirubinemia
140037|NCT02222805|Jaundice
140038|NCT02222805|Neurodevelopment
140039|NCT02222792|Staphylococci, Streptococci, P acnes and Gram-negative bacteria
140040|NCT02222740|Safety
140041|NCT02222740|Tolerability
140042|NCT02222740|Pharmacokinetics
140043|NCT02222714|ischemic stroke
140044|NCT02222714|stroke
140045|NCT02222714|APC
140046|NCT02222714|3K3A
140047|NCT02222714|3K3A-APC
140048|NCT02222714|activated protein C
140049|NCT02222714|RHAPSODY
140050|NCT02222701|composite
140051|NCT02222701|dental
140052|NCT02222701|longevity
140053|NCT02222688|cancer
140054|NCT02222688|CLL
140055|NCT02222662|Massage
140056|NCT02222662|effectiveness
140057|NCT02222662|autism
140058|NCT02222662|parent stress
140059|NCT02222649|Elderly
140060|NCT02222649|vitamin D insufficiency
140061|NCT02222649|High dose vitamin D3 supplementation
140062|NCT02222649|Polymorphism of the VDR gene
140063|NCT02222636|The efficacy and safety of intranasal dexmedetomidine
140064|NCT02222623|insulin
140065|NCT02222623|basal
140066|NCT02222623|diabetes
140067|NCT02222623|hospital
140068|NCT02222623|glucose
140069|NCT02222623|hypoglycemia
140070|NCT02222623|glargine
140071|NCT02222623|NPH
140072|NCT02222623|neutral protamine hagedorn
140073|NCT02222610|Radiation Retinopathy
140074|NCT02222597|head injury
140075|NCT02222597|infrascanner
140076|NCT02222597|intracranial hemorrhage
140077|NCT02222584|inflammatory bowel disease
140078|NCT02222584|physical activity
140079|NCT02222584|disease activity
140080|NCT02222584|quality of life
140081|NCT02222558|hypogonadism
140082|NCT02222558|Gonadal Disorders
140083|NCT02222558|Endocrine System Diseases
140084|NCT02222558|Testosterone
140085|NCT02222558|Testosterone enanthate
140086|NCT02222558|Testosterone undecanoate
140087|NCT02222558|Testosterone 17 beta-cypionate
140088|NCT02222558|Methyltestosterone
140089|NCT02222558|Androgens
140090|NCT02222558|Hormones
140091|NCT02222558|Hormones,
140092|NCT02222558|Hormone Substitutes,
140093|NCT02222558|Hormone Antagonists
140094|NCT02222558|Physiological Effects of Drugs
140095|NCT02222558|Pharmacologic Actions
140096|NCT02222558|Therapeutic Uses
140097|NCT02222558|Anabolic Agents
140098|NCT02222558|dihydrotestosterone
140099|NCT02222545|TMA, aHUS, HSCT-associated TMA, TTP
140100|NCT02222532|tetronine
140101|NCT02222532|congenital heart disease
140102|NCT02222532|cardiopulmonary bypass
140103|NCT02222532|euthyroid sick syndrome
140104|NCT02222519|statins
140105|NCT02222519|nondepolarizing muscle relaxants
140106|NCT02222519|rocuronium
140107|NCT02222519|myalgia
140108|NCT02222493|Phase 3
140109|NCT02222493|infliximab
140110|NCT02222493|rheumatoid arthritis
140111|NCT02222480|Patients
140112|NCT02222480|with mild
140113|NCT02222480|moderate
140114|NCT02222480|essential
140115|NCT02222441|Palbociclib
140116|NCT02222441|Modafinil
140117|NCT02222441|Pioglitazone
140118|NCT02222441|Pharmacokinetics
140119|NCT02222441|Drug-Drug Interaction Study
140120|NCT02222441|Healthy Volunteers
140121|NCT02222441|CYP3A Inducers
140122|NCT02222415|Muscle mass
140123|NCT02222415|Strength
140124|NCT02222415|Cross-sectional area
140125|NCT02222415|Protein
140126|NCT02222402|Quality of Life
140127|NCT02222402|Exercise
140128|NCT02222402|Functional Capacity
140129|NCT02222376|Diabetic ulcer, diabetic foot
140130|NCT02222363|Phase I
140131|NCT02222363|Iron chelator
140132|NCT02222363|Refractory advanced solid tumors
140133|NCT02222363|Dose escalation study
140134|NCT02222363|Safety and tolerability
140135|NCT02222363|Tumor response by RECIST 1.1
140136|NCT02222363|Progression-free survival
140137|NCT02222363|Overall survival Pharmacokinetics
140138|NCT02222350|type 2 diabetes mellitus
140139|NCT02222337|behavioral intervention
140140|NCT02222337|quality of life
140141|NCT02222337|breast cancer
140142|NCT02222337|Latina
140143|NCT02222337|caregiver
140144|NCT02222337|PCORI
140145|NCT02222324|QTc Interval
140146|NCT02222324|Healthy Subjects
140147|NCT02222272|cml
140148|NCT02222272|chronic myeloid leukemia
140149|NCT02222272|dasatinib
140150|NCT02222272|nilotinib
140151|NCT02222272|tki
140152|NCT02222272|second generation tki
140153|NCT02222272|2nd generation tki
140154|NCT02222259|Geriatric Oncology
140155|NCT02222259|Quality of Life
140156|NCT02222259|Comprehensive Geriatric Assessment
140157|NCT02222259|Functional Status
140158|NCT02222259|Chemotherapy
140159|NCT02222259|Older Adults
140160|NCT02222246|Sickle Cell Disease
140161|NCT02222246|Emergency Department
140162|NCT02222246|Vaso-occlusive Crisis
140163|NCT02222246|Pain Management
140164|NCT02222246|Pilot Project
140165|NCT02222207|neovascular Age-related Macular Degeneration
140166|NCT02222194|Lung cancer
140167|NCT02222194|Surgery
140168|NCT02222194|Videomediastinoscopy
140169|NCT02222181|elderly, medication adherence,pharmaceutical care
140170|NCT02222155|ANCA-associated vasculitis
140171|NCT02222155|complement
140172|NCT02222155|vasculitis
140173|NCT02222155|C5aR
140174|NCT02222142|Ischemic heart disease
140175|NCT02222142|Off pump coronary artery bypass graft
140176|NCT02222142|Isoflurane
140177|NCT02222142|Propofol
140178|NCT02222129|Randomized controlled trial
140179|NCT02222129|anesthetics-local
140180|NCT02222129|bupivacaine
140181|NCT02222129|analgesia
140182|NCT02222129|Pain, Postoperative
140183|NCT02222116|STEMI
140184|NCT02222116|BMS
140185|NCT02222116|DES
140186|NCT02222116|mesh
140187|NCT02222090|patients with atrial fibrillation (AF) recommend the use of novel oral anticoagulants (NOACs) in patients with non-valvular AF
140188|NCT02222077|Central blood pressure
140189|NCT02222077|Ambulatory blood pressure monitoring
140190|NCT02222077|Target-organ damage
140191|NCT02222077|Adolescents and young adults
140192|NCT02222051|neck pain
140193|NCT02222051|chronic pain
140194|NCT02221986|Interdisciplinary rehabilitation
140195|NCT02221986|Neurooncology
140196|NCT02221986|Physiotherapy
140197|NCT02221986|Occupational therapy
140198|NCT02221986|Neurorehabilitation
140199|NCT02221986|Glioma
140200|NCT02221960|Recurrent or metastatic solid tumors, MEDI6383, OX40
140201|NCT02221947|Alzheimer's
140202|NCT02221947|bryostatin
140203|NCT02221947|PKC epsilon
140204|NCT02221934|Pain
140205|NCT02221934|Chronic
140206|NCT02221934|Amputation
140207|NCT02221934|Phantom Pain
140208|NCT02221934|Stump Pain
140209|NCT02221908|Systolic Blood pressure < 100 mm Hg
140210|NCT02221895|postpartum appointment
140211|NCT02221895|breastfeeding
140212|NCT02221895|postpartum contraception
140213|NCT02221895|postpartum cervical cancer screening
140214|NCT02221895|postpartum depression screening
140215|NCT02221856|Conventional orthodontic treatment
140216|NCT02221856|Motion View
140217|NCT02221843|sun behavior
140218|NCT02221843|immunosuppression
140219|NCT02221843|skin neoplasms
140220|NCT02221843|sunbit
140221|NCT02221843|uv sensor
140222|NCT02221843|uv dosimeter
140223|NCT02221843|solar radiation
140224|NCT02221843|uv exposition
140225|NCT02221843|uv index
140226|NCT02221804|Physical Inactivity
140227|NCT02221804|Skeletal Muscle
140228|NCT02221804|Cachexia
140229|NCT02221791|Flavan-3-ol
140230|NCT02221791|Flavonoids
140231|NCT02221791|Epicatechin
140232|NCT02221791|Cocoa
140233|NCT02221791|Chocolate
140234|NCT02221791|Endothelial function
140235|NCT02221791|Bioavailability
140236|NCT02221778|Carcinoma, Hepatocellular
140237|NCT02221778|SBRT
140238|NCT02221765|Obesity
140239|NCT02221765|Overnutrition
140240|NCT02221765|Nutrition Disorders
140241|NCT02221765|Overweight
140242|NCT02221765|Body Weight
140243|NCT02221765|Signs and Symptoms
140244|NCT02221752|iron deficiency
140245|NCT02221752|iron deficiency anemia
140246|NCT02221752|infant
140247|NCT02221752|pregnancy
140248|NCT02221739|lung cancer
140249|NCT02221739|NSCLC
140250|NCT02221739|lung
140251|NCT02221739|cancer
140252|NCT02221739|radiation
140253|NCT02221739|immunotherapy
140254|NCT02221739|metastatic
140255|NCT02221726|Healthy
140256|NCT02221726|JNJ-35685-AAA-G-023
140257|NCT02221726|Placebo
140258|NCT02221726|Transdermal delivery device system
140259|NCT02221713|diverticulitis
140260|NCT02221713|diverticulosis
140261|NCT02221713|diverticular disease
140262|NCT02221700|Gastrointestinal cancer
140263|NCT02221700|Chemotherapy Induced Peripheral Neuropathy
140264|NCT02221700|CIPN
140265|NCT02221700|Symptom reduction
140266|NCT02221700|Massage
140267|NCT02221700|Symptom questionnaires
140268|NCT02221700|Surveys
140269|NCT02221700|Leg function and balance tests
140270|NCT02221687|synbiotic formula
140271|NCT02221687|infant formula
140272|NCT02221687|diarrhea
140273|NCT02221674|Post-surgical pain
140274|NCT02221674|Opioid
140275|NCT02221661|Alzheimer
140276|NCT02221661|cognitive impairment
140277|NCT02221661|blood test
140278|NCT02221648|Back
140279|NCT02221648|Pain
140280|NCT02221648|Muscle
140281|NCT02221635|Schizoaffective Disorder
140282|NCT02221635|Repetitive transcranial magnetic stimulation (rTMS)
140283|NCT02221622|Alzheimer's disease
140284|NCT02221622|Mild Cognitive Impairment
140285|NCT02221622|Dementia
140286|NCT02221622|Regenerative therapeutic
140287|NCT02221609|Low Back Pain, Mechanical Low Back Pain, Low Back Ache, Low Backache, Lower Back Pain, Lumbago
140288|NCT02221596|Vitamin D
140289|NCT02221596|25(OH)D
140290|NCT02221596|Aerobic training
140291|NCT02221596|Near-infrared spectroscopy
140292|NCT02221596|Diffuse correlation spectroscopy
140293|NCT02221596|MRS
140294|NCT02221583|End stage renal disease
140295|NCT02221583|Renal transplant candidate
140296|NCT02221583|Laparoscopic sleeve gastrectomy
140297|NCT02221583|Immunosuppressants
140298|NCT02221544|Parkinson's disease, rTMS, Freezing of Gait
140299|NCT02221518|OCD
140300|NCT02221518|Functional Magnetic Resonance Imaging (fMRI)
140301|NCT02221505|LOP628,
140302|NCT02221505|cKit,
140303|NCT02221505|ADC,
140304|NCT02221505|Antibody drug conjugates,
140305|NCT02221505|maytansine
140306|NCT02221466|diabetes
140307|NCT02221466|foot
140308|NCT02221466|wounds
140309|NCT02221466|nitric oxide
140310|NCT02221466|endothelium
140311|NCT02221466|infection
140312|NCT02221466|biological markers
140313|NCT02221466|observational study
140314|NCT02221466|hyperbaric oxygen
140315|NCT02221466|ulcers
140316|NCT02221466|cytokines
140317|NCT02221466|inflammation
140318|NCT02221453|Diabetic Macular Edema
140319|NCT02221453|Ocular Cytokines
140320|NCT02221453|Triamcinolone Acetonide
140321|NCT02221427|First time mothers
140322|NCT02221427|Labour progression
140323|NCT02221427|Prolonged labour
140324|NCT02221427|Oxytocin
140325|NCT02221427|Mode of delivery
140326|NCT02221427|Maternal birth outcome
140327|NCT02221427|Neonatal birth outcome
140328|NCT02221349|Sensitivity
140329|NCT02221336|Bipolar disorder
140330|NCT02221336|Daily electronic monitoring
140331|NCT02221336|Smartphones
140332|NCT02221336|Subjective and objective smartphone data
140333|NCT02221336|Feedback loop
140334|NCT02221310|targeted therapy
140335|NCT02221310|leukemia
140336|NCT02221310|MDS
140337|NCT02221310|immune therapy
140338|NCT02221284|Pharmacological therapy
140339|NCT02221258|Rheumatoid Arthritis
140340|NCT02221258|Rheumatic Disease
140341|NCT02221258|RA
140342|NCT02221258|Stem cell
140343|NCT02221258|Cell therapy
140344|NCT02221258|furestem
140345|NCT02221258|Umbilical cord Blood
140346|NCT02221258|hUCB-MSC
140347|NCT02221258|UCB-MSC
140348|NCT02221245|Esophageal cancer
140349|NCT02221245|Cancer Stem Cell
140350|NCT02221245|CSC
140351|NCT02221245|Wnt
140352|NCT02221245|Hegdehog
140353|NCT02221245|Notch
140354|NCT02221245|Signaling
140355|NCT02221245|Pathway
140356|NCT02221245|Chemo-naive
140357|NCT02221232|ZuraPrep
140358|NCT02221232|Antimicrobial
140359|NCT02221232|Bio-Science Laboratories
140360|NCT02221232|Zurex Pharma
140361|NCT02221232|Surgical/Patient preoperative skin preparation
140362|NCT02221219|infant
140363|NCT02221219|brain injury
140364|NCT02221219|renal
140365|NCT02221219|indomethacin
140366|NCT02221206|Mini-Screw implant anchorage
140367|NCT02221206|retraction of maxillary incisors
140368|NCT02221180|Bioequivalence
140369|NCT02221180|Metformin
140370|NCT02221180|Canagliflozin
140371|NCT02221180|Healthy
140372|NCT02221167|breastfeeding
140373|NCT02221167|donor milk
140374|NCT02221167|formula
140375|NCT02221167|exclusive breastfeeding
140376|NCT02221167|newborn
140377|NCT02221154|in vitro fertilization
140378|NCT02221154|ovarian hyperstimulation
140379|NCT02221154|pregnancy
140380|NCT02221115|Google Glass device
140381|NCT02221115|Evaluation
140382|NCT02221115|patient's
140383|NCT02221115|response
140384|NCT02221115|to new technology
140385|NCT02221115|clinical setting
140386|NCT02221102|edoxaban
140387|NCT02221102|aspirin
140388|NCT02221102|new oral anticoagulant
140389|NCT02221102|TIA
140390|NCT02221102|acute minor ischemic stroke
140391|NCT02221089|Effect of Retaron on imparied retinal vascular reactivity after LPS administration in healthy subjects
140392|NCT02221076|Cellvizio
140393|NCT02221076|Endomicroscopy
140394|NCT02221076|Robot-assisted procedure
140395|NCT02221076|Cervix cancer
140396|NCT02221076|Endocervix cancer
140397|NCT02221076|Endometrium cancer
140398|NCT02221076|Ovarian cancer
140399|NCT02221076|Tubal cancer
140400|NCT02221076|Colposcopy
140401|NCT02221076|Hysteroscopy
140402|NCT02221063|thiamin
140403|NCT02221063|thiamin diphosphate
140404|NCT02221063|beriberi
140405|NCT02221063|Cambodia
140406|NCT02221063|fish sauce
140407|NCT02221063|fortification
140408|NCT02221063|pregnancy
140409|NCT02221063|breastfeeding
140410|NCT02221063|childbearing age
140411|NCT02221037|PaO2/FiO2
140412|NCT02221037|Peri-operative lung injury
140413|NCT02221037|EVLWI
140414|NCT02221037|ARDS
140415|NCT02221037|PVPI
140416|NCT02221037|SOFA scores
140417|NCT02221037|GSK2862277
140418|NCT02221037|Oesophagectomy
140419|NCT02221024|Peripheral intravenous catheter
140420|NCT02221024|Peripheral intravenous lock
140421|NCT02221024|Normal saline
140422|NCT02221024|Patency
140423|NCT02221024|Management
140424|NCT02221024|of peripheral
140425|NCT02221024|intravenous catheter
140426|NCT02221011|Shock wave
140427|NCT02221011|Spasticity
140428|NCT02221011|Effect
140429|NCT02220998|Hepatitis C
140430|NCT02220998|HCV
140431|NCT02220998|cirrhosis
140432|NCT02220998|Sofosbuvir
140433|NCT02220998|Sovaldi
140434|NCT02220998|SOF/VEL
140435|NCT02220998|GS-5816
140436|NCT02220998|GS-7977
140437|NCT02220998|liver
140438|NCT02220998|Treatment naive
140439|NCT02220998|Treatment Experience
140440|NCT02220998|genotype 2
140441|NCT02220972|Epilepsy
140442|NCT02220972|Partial Onset Seizures
140443|NCT02220972|Insomnia
140444|NCT02220959|morbid obesity surgery
140445|NCT02220959|walk test
140446|NCT02220959|exercise
140447|NCT02220946|Vaginal Electrical Stimulation
140448|NCT02220933|Multiple Sclerosis
140449|NCT02220933|MS
140450|NCT02220933|EDSS
140451|NCT02220920|insulin resistance
140452|NCT02220907|MT-2412
140453|NCT02220907|MP-513
140454|NCT02220907|TA-7284
140455|NCT02220907|Teneligliptin
140456|NCT02220907|Canagliflozin
140457|NCT02220894|PD-1
140458|NCT02220894|PD1
140459|NCT02220894|PD-L1
140460|NCT02220894|PDL1
140461|NCT02220881|Hallux valgus, Mold making silicone toe separator, Toe separator
140462|NCT02220868|HIV
140463|NCT02220868|HCV
140464|NCT02220868|DAA
140465|NCT02220829|alpha-blocker
140466|NCT02220829|symptomatic urinary problems
140467|NCT02220829|radiation therapy
140468|NCT02220829|prostate cancer
140469|NCT02220816|Attention
140470|NCT02220816|Competitive
140471|NCT02220816|Training
140472|NCT02220803|Acetazolamide
140473|NCT02220803|Zonegran
140474|NCT02220803|Obstructive Sleep apnea
140475|NCT02220803|Apnea
140476|NCT02220803|Respiration Disorders
140477|NCT02220803|Sleep Disorders
140478|NCT02220803|Cardiovascular
140479|NCT02220803|Hypertension
140480|NCT02220803|Carbonic Anhydrase
140481|NCT02220803|Carbonic Anhydrase Inhibitors
140482|NCT02220803|Enzyme Inhibitors
140483|NCT02220803|Sulfonamides
140484|NCT02220803|Therapeutic Uses
140485|NCT02220803|Pharmacologic Actions
140486|NCT02220803|Vascular stifness
140487|NCT02220790|IPFN
140488|NCT02220790|Pediatric
140489|NCT02220790|Fungal
140490|NCT02220790|Biomarker Assays
140491|NCT02220790|Candida
140492|NCT02220790|Pediatric ICU patient
140493|NCT02220777|MTD (Maximum Tolerated Dose)
140494|NCT02220777|Food effect
140495|NCT02220777|Postmenopausal subjects
140496|NCT02220777|Vasectomized subjects
140497|NCT02220777|FIH (First In Humans)
140498|NCT02220777|SAD (Single Ascending Dose)
140499|NCT02220777|DDI (Drug-Drug Interaction)
140500|NCT02220764|prospective study
140501|NCT02220764|chipping
140502|NCT02220764|survival rate
140503|NCT02220764|fracture resistance
140504|NCT02220764|zirconia
140505|NCT02220751|Periodontal Attachment Loss
140506|NCT02220751|Genes
140507|NCT02220751|Saliva
140508|NCT02220751|Diagnosis
140509|NCT02220738|Alzheimer's Disease
140510|NCT02220725|Andexanet alpha
140511|NCT02220725|Anticoagulation
140512|NCT02220725|Antidote
140513|NCT02220725|Rivaroxaban
140514|NCT02220725|Anti-fXa inhibitor
140515|NCT02220725|PRT4445
140516|NCT02220725|Xarelto
140517|NCT02220725|Reversal agent
140518|NCT02220712|Aripiprazole
140519|NCT02220712|Deltoid
140520|NCT02220699|Ostoporosis
140521|NCT02220699|Primary Prevention
140522|NCT02220699|Health Promotion
140523|NCT02220699|General Practice
140524|NCT02220699|Secondary screening
140525|NCT02220699|Patients at increased risk of osteoporosis
140526|NCT02220686|VAPOR
140527|NCT02220686|smoking cessation
140528|NCT02220686|PAD
140529|NCT02220621|Intrauterine adhesion
140530|NCT02220621|crosslinked hyaluronan gel
140531|NCT02220621|hysteroscopy
140532|NCT02220621|clinical trial
140533|NCT02220608|Multiple Myeloma
140534|NCT02220608|G-CSF
140535|NCT02220608|Bortezomib
140536|NCT02220595|Stenting
140537|NCT02220595|Endarterectomy
140538|NCT02220595|Cognition
140539|NCT02220582|Cardiac Magnetic Resonance (CMR)
140540|NCT02220582|Cardiovascular Diseases
140541|NCT02220582|socio-environmental factors
140542|NCT02220582|Contextual factors
140543|NCT02220543|Cognitive behavioral therapy
140544|NCT02220543|Primary health care
140545|NCT02220543|Physical Therapy
140546|NCT02220530|Sedation.
140547|NCT02220530|Colonoscopy quality.
140548|NCT02220530|Scientific and technical quality.
140549|NCT02220530|Perceived quality (patient's satisfaction).
140550|NCT02220530|Safety
140551|NCT02220517|MRI/US fusion-guided prostate biopsy
140552|NCT02220517|MR-guided in-bore prostate biopsy
140553|NCT02220517|prostate cancer
140554|NCT02220504|schizophrenia spectrum
140555|NCT02220504|relapse
140556|NCT02220504|treatment
140557|NCT02220504|maintenance
140558|NCT02220478|hip
140559|NCT02220478|Signature
140560|NCT02220465|sedentary
140561|NCT02220465|smoking
140562|NCT02220465|cue reactivity
140563|NCT02220465|physical activity
140564|NCT02220439|rotavirus
140565|NCT02220439|immunogenicity
140566|NCT02220439|enteric vaccine
140567|NCT02220439|vaccine immunogenicity
140568|NCT02220439|rotavirus vaccine
140569|NCT02220439|gut microbiome
140570|NCT02220439|microbiome
140571|NCT02220426|Brown adipose tissue
140572|NCT02220426|Hyperpolarized xenon gas MRI
140573|NCT02220413|Breastmilk
140574|NCT02220413|Lactogenesis
140575|NCT02220413|Obesity
140576|NCT02220400|Postoperative cognitive dysfunction
140577|NCT02220400|Ketamine
140578|NCT02220400|Surgery
140579|NCT02220387|occupational COPD
140580|NCT02220387|phenotype
140581|NCT02220387|genetic
140582|NCT02220374|Osteoarthritis
140583|NCT02220374|Finger
140584|NCT02220374|Supportive
140585|NCT02220374|Tape
140586|NCT02220374|Pain
140587|NCT02220374|Function
140588|NCT02220374|Trial
140589|NCT02220335|pulmonary hypertension
140590|NCT02220335|pulmonary arterial denervation
140591|NCT02220335|left heart failure
140592|NCT02220335|6-min walk distance
140593|NCT02220322|cortical thickness
140594|NCT02220322|age
140595|NCT02220309|anxiety
140596|NCT02220309|depression
140597|NCT02220309|SAD
140598|NCT02220309|bipolar disorder II
140599|NCT02220309|PTSD
140600|NCT02220309|GAD
140601|NCT02220309|Phobia
140602|NCT02220283|Acute kidney injury,aortic dissection
140603|NCT02220257|diabetes mellitus type 1
140604|NCT02220257|remission, honeymoon
140605|NCT02220257|microangiopathy
140606|NCT02220244|multiple sclerosis (MS)
140607|NCT02220244|optic neuritis
140608|NCT02220244|visual defect
140609|NCT02220244|visual loss
140610|NCT02220244|relapsing remitting multiple sclerosis (RRMS)
140611|NCT02220244|primary progressive multiple sclerosis (PPMS)
140612|NCT02220244|secondary progressive multiple sclerosis (SPMS)
140613|NCT02220231|mediastinal mass, one-lung ventilation, capnothorax, transesophageal echocardiography
140614|NCT02220218|Healthy
140615|NCT02220218|Metformin
140616|NCT02220218|Canagliflozin
140617|NCT02220218|JNJ-28431754
140618|NCT02220205|IUD
140619|NCT02220205|training
140620|NCT02220205|simulation
140621|NCT02220192|cervical neoplasia
140622|NCT02220192|cervix
140623|NCT02220192|high-grade dysplasia
140624|NCT02220192|LEEP (loop electrosurgical excision procedure)
140625|NCT02220192|precancerous cells
140626|NCT02220192|colposcopy
140627|NCT02220166|Celiac Disease
140628|NCT02220166|Gluten
140629|NCT02220166|Gluten free diet
140630|NCT02220166|Triticum monococcum
140631|NCT02220153|Monoclonal antibody
140632|NCT02220153|subjects
140633|NCT02220153|First in human
140634|NCT02220127|Brain
140635|NCT02220127|Neoplasm Micrometastasis
140636|NCT02220127|Gamma Knife Radiosurgery
140637|NCT02220114|Infantile spasms
140638|NCT02220114|vigabatrin
140639|NCT02220114|soluble tablets
140640|NCT02220114|acceptability
140641|NCT02220114|adherence
140642|NCT02220114|pharmacokinetics
140643|NCT02220101|hypothermia
140644|NCT02220101|core temperature
140645|NCT02220101|temperature measurement methods
140646|NCT02220088|Hepatocellular Carcinoma
140647|NCT02220088|TACE
140648|NCT02220088|TACE failure
140649|NCT02220088|TACE refractoriness
140650|NCT02220088|BCLC B
140651|NCT02220075|fiberoptic, LMA, caudal block
140652|NCT02220036|Diabetic nephropathy
140653|NCT02220036|Renal function
140654|NCT02220036|Insulin resistance
140655|NCT02220036|Metabolic profile
140656|NCT02220036|Serum magnesium level
140657|NCT02220010|Post operative pancreatic fistulas
140658|NCT02220010|Pancreatic stenting
140659|NCT02219997|Cataract
140660|NCT02219997|Intraocular lens (IOL)
140661|NCT02219997|AcrySof
140662|NCT02219984|Anticoagulation
140663|NCT02219984|vitamin K antagonists
140664|NCT02219984|Warfarin
140665|NCT02219984|low molecular weight heparin
140666|NCT02219984|fondaparinux
140667|NCT02219984|antithrombotics
140668|NCT02219984|Direct oral anticoagulants
140669|NCT02219984|dabigatran
140670|NCT02219984|rivaroxaban
140671|NCT02219984|apixaban
140672|NCT02219984|edoxaban
140673|NCT02219984|atrial fibrillation
140674|NCT02219984|venous thromboembolism
140675|NCT02219971|Healthy
140676|NCT02219958|Hypertension
140677|NCT02219945|pulmonary tuberculosis; electronic nose; diagnostic accuracy
140678|NCT02219932|Fampridine
140679|NCT02219919|Carpal Tunnel Syndrome
140680|NCT02219919|Pain
140681|NCT02219919|Sensitivity
140682|NCT02219919|Pain Thresholds
140683|NCT02219919|Sensitization
140684|NCT02219919|Physical Therapy
140685|NCT02219893|Peritoneal Carcinomatosis
140686|NCT02219893|Peritoneal Metastasis
140687|NCT02219893|Colorectal Cancer
140688|NCT02219893|Cytoreductive surgery
140689|NCT02219893|HIPEC
140690|NCT02219893|Intraperitoneal treatment
140691|NCT02219893|Immunotoxin
140692|NCT02219893|MOC31PE
140693|NCT02219880|Kava
140694|NCT02219880|Anxiety
140695|NCT02219880|Generalized Anxiety Disorder
140696|NCT02219880|Psychiatric
140697|NCT02219880|Anxiolytic
140698|NCT02219880|GABA
140699|NCT02219880|Kavalactones
140700|NCT02219867|ketamine
140701|NCT02219867|MDD
140702|NCT02219841|Obesity, low-calorie diet, exercise, atrial fibrillation
140703|NCT02219828|pericarditis
140704|NCT02219828|recurrent pericarditis
140705|NCT02219828|corticosteroids
140706|NCT02219828|anakinra
140707|NCT02219815|Preoperative Care
140708|NCT02219815|Exercise Therapy
140709|NCT02219815|Cardiac Surgery
140710|NCT02219815|Frailty
140711|NCT02219802|Coronary artery disease
140712|NCT02219802|Acute myocardial infarction
140713|NCT02219802|Drug-coated balloon
140714|NCT02219802|Drug-eluting stent
140715|NCT02219776|Infection,
140716|NCT02219776|Proprionbacterium Acne,
140717|NCT02219776|Shoulder,
140718|NCT02219776|skin preparation
140719|NCT02219750|premix insuiln, basal-plus insulin
140720|NCT02219711|MGCD516
140721|NCT02219711|MET
140722|NCT02219711|AXL
140723|NCT02219711|RET
140724|NCT02219711|TRK
140725|NCT02219711|NTRK
140726|NCT02219711|DDR2
140727|NCT02219711|KDR
140728|NCT02219711|VEGFR
140729|NCT02219711|PDGFRA
140730|NCT02219711|KIT
140731|NCT02219711|Tyrosine kinase inhibitor
140732|NCT02219711|NSCLC
140733|NCT02219711|Non-small cell lung cancer
140734|NCT02219711|Head and neck cancer
140735|NCT02219711|Renal cell carcinoma
140736|NCT02219711|Prostate cancer
140737|NCT02219711|Phase 1
140738|NCT02219711|CBL
140739|NCT02219672|Triptolide wilfordii HIV-1 reservoir acute hiv infection
140740|NCT02219659|sedation strategy
140741|NCT02219659|mechanical ventilation
140742|NCT02219659|ventilator weaning
140743|NCT02219646|T2DM
140744|NCT02219646|ED
140745|NCT02219620|creative arts
140746|NCT02219620|older adults
140747|NCT02219620|intervention study
140748|NCT02219594|gemstone CT
140749|NCT02219594|320-detector row spiral CT
140750|NCT02219594|optical coherence tomography(OCT)
140751|NCT02219594|in-stent restenosis
140752|NCT02219594|coronary heart disease
140753|NCT02219581|Osteoarthritis
140754|NCT02219581|Postoperative pain
140755|NCT02219581|Total knee arthroplasty
140756|NCT02219581|Orthopaedics
140757|NCT02219581|Inflammation
140758|NCT02219568|obscure gastrointestinal bleeding, CT enterography
140759|NCT02219555|Carpal tunnel
140760|NCT02219542|cytokine Transversus Abdominis Plane Block
140761|NCT02219503|Hepatitis C
140762|NCT02219503|Chronic Hepatitis C
140763|NCT02219503|Compensated Cirrhosis
140764|NCT02219503|Cirrhotic
140765|NCT02219503|Hepatitis C Genotype 1b
140766|NCT02219503|Hepatitis C Virus
140767|NCT02219503|Interferon-Free
140768|NCT02219503|Child Pugh A
140769|NCT02219503|Ribavirin-Free
140770|NCT02219490|Non responder
140771|NCT02219490|Null responder
140772|NCT02219490|Treatment-Experienced
140773|NCT02219490|Cirrhosis
140774|NCT02219490|Relapser
140775|NCT02219490|Hepatitis C Genotype 1
140776|NCT02219490|Compensated Cirrhosis
140777|NCT02219490|Naive
140778|NCT02219477|Hepatitis C Genotype 1
140779|NCT02219477|Chronic Hepatitis C
140780|NCT02219477|Decompensated Cirrhosis
140781|NCT02219477|Interferon-Free
140782|NCT02219477|Hepatitis C
140783|NCT02219477|Hepatitis C Virus
140784|NCT02219477|Child-Pugh B
140785|NCT02219477|Cirrhosis
140786|NCT02219477|Hepatitis C Genotype 4
140787|NCT02219464|nasopharyngeal catheter
140788|NCT02219464|nasal cannula
140789|NCT02219451|Chronic heart failure
140790|NCT02219451|exercise training
140791|NCT02219451|Sympathetic modulation
140792|NCT02219451|arterial baroreflex control
140793|NCT02219425|Infertility
140794|NCT02219425|Endometrium
140795|NCT02219425|Endometrial biopsy
140796|NCT02219425|Gene expression
140797|NCT02219412|ticagrelor
140798|NCT02219412|platelet aggregation rate
140799|NCT02219412|ADP antagonist
140800|NCT02219412|antiplatelet therapy
140801|NCT02219399|Pregnancy
140802|NCT02219399|DHA
140803|NCT02219399|Gestational Length
140804|NCT02219399|Cognitive Development
140805|NCT02219386|Myofascial pain syndromes,physiotherapy,muscle stretching exercises,neck pain,dry needling
140806|NCT02219360|acute
140807|NCT02219360|exacerbation
140808|NCT02219360|chronic obstructive pulmonary disease
140809|NCT02219347|rheumatoid arthritis
140810|NCT02219347|biological markers
140811|NCT02219347|remission
140812|NCT02219347|ultrasonography
140813|NCT02219347|microarray
140814|NCT02219347|survival analysis
140815|NCT02219347|T cell
140816|NCT02219334|Children
140817|NCT02219334|Nasal suction devices
140818|NCT02219334|Suctioning
140819|NCT02219321|Pain, Opioid dependence, Lidocaine infusion
140820|NCT02219308|Contraception
140821|NCT02219308|Pain
140822|NCT02219308|Intrauterine Device
140823|NCT02219308|Paracervical Block
140824|NCT02219295|SGLT1 (sodium dependent glucose transporter)
140825|NCT02219295|Glut-transporters
140826|NCT02219295|taste receptors genes
140827|NCT02219295|sweet taste receptor T1R2T1R3
140952|NCT02218762|Respiratory
140828|NCT02219295|bitter taste receptors of the hTAS2gene family
140829|NCT02219282|laryngeal mask airway, edentulate geriatric patients
140830|NCT02219269|contraception
140831|NCT02219269|family planning
140832|NCT02219269|complex medical conditions
140833|NCT02219256|Drug therapy
140834|NCT02219243|Social Anxiety Disorder
140835|NCT02219243|Cognitive Training
140836|NCT02219243|Interpretation Modification Program
140837|NCT02219204|Acupuncture
140838|NCT02219204|Herbal treatment
140839|NCT02219191|Puerarin tablet
140840|NCT02219191|rheumatoid arthritis
140841|NCT02219191|metabolism syndrome
140842|NCT02219165|Paediatrics
140843|NCT02219165|Toxic Shock Syndrome
140844|NCT02219165|Intravenous human immunoglobulin
140845|NCT02219165|feasibility
140846|NCT02219139|Edentulous
140847|NCT02219139|Roxolid
140848|NCT02219139|SLAclive surface
140849|NCT02219139|Titanium/zirconium
140850|NCT02219113|Damage of articular cartilage
140851|NCT02219113|Cartilage degeneration
140852|NCT02219113|Intraarticular injection
140853|NCT02219113|ADRC
140854|NCT02219113|Adipose-derived regenerative cells
140855|NCT02219113|Adipose tissue
140856|NCT02219113|Stem cells
140857|NCT02219087|Total knee arthroplasty
140858|NCT02219087|Total joint arthroplasty
140859|NCT02219087|Knee replacement
140860|NCT02219087|Osteoarthritis of the knee
140861|NCT02219061|Measles
140862|NCT02219061|Meningitis C
140863|NCT02219061|waning
140864|NCT02219061|Geometric Mean Titer
140865|NCT02219061|China
140866|NCT02219048|Asthma
140867|NCT02219048|Staged withdrawal of background therapy
140868|NCT02219035|presentation with
140869|NCT02219022|Rheumatoid arthritis
140870|NCT02219022|Progressive resistance exercise
140871|NCT02219022|Pain
140872|NCT02219022|Functional capacity
140873|NCT02219022|Quality of life
140874|NCT02219022|Muscle strength
140875|NCT02219009|OPC-14597 Digital
140876|NCT02219009|Aripiprazole
140877|NCT02219009|Medical Information Device #1 System (MIND1)
140878|NCT02219009|Treatment Adherence
140879|NCT02219009|Ingestible Event Marker
140880|NCT02218996|Anxiety
140881|NCT02218996|Children
140882|NCT02218996|Adolescent
140883|NCT02218996|Effectiveness
140884|NCT02218996|Outpatient
140885|NCT02218983|trauma
140886|NCT02218983|echo
140887|NCT02218983|echocardiogram
140888|NCT02218983|ultrasound
140889|NCT02218983|inferior vena cava collapsibility
140890|NCT02218970|rehabilitation
140891|NCT02218970|strength training
140892|NCT02218970|muscle strength
140893|NCT02218970|physical fitness
140894|NCT02218957|Bariatric surgery
140895|NCT02218957|Roux-en-Y Gastric Bypass
140896|NCT02218931|Pre-eclampsia
140897|NCT02218931|Gestational diabetes
140898|NCT02218931|Stillbirth
140899|NCT02218931|Small for gestational age
140900|NCT02218931|Admission to neonatal intensive care unit
140901|NCT02218931|Obesity
140902|NCT02218931|Raised Lipids
140903|NCT02218931|High Blood Pressure
140904|NCT02218931|Cardiovascular risk
140905|NCT02218931|Insulin resistance
140906|NCT02218931|Mediterranean dietary pattern
140907|NCT02218931|Dietary interventions
140908|NCT02218918|Ground walk
140909|NCT02218918|treadmill walk
140910|NCT02218918|Functional walk capacity
140911|NCT02218918|COPD
140912|NCT02218918|Quality of Life
140913|NCT02218905|Correlation
140914|NCT02218905|Sit to stand repetitions
140915|NCT02218905|Anthropometric variables
140916|NCT02218905|Age
140917|NCT02218905|Height
140918|NCT02218905|weight
140919|NCT02218905|Gender
140920|NCT02218905|Regression
140921|NCT02218866|Bariatric surgery
140922|NCT02218866|Obesity
140923|NCT02218866|Neuropathy
140924|NCT02218853|Bipolar disorder
140925|NCT02218853|Psychosis
140926|NCT02218853|Schizophrenia
140927|NCT02218840|cigar smoker
140928|NCT02218840|smoking
140929|NCT02218840|behavioral pharmacology
140930|NCT02218840|smoking topography
140931|NCT02218827|Dry Eye
140932|NCT02218827|Inflammatory reaction
140933|NCT02218827|steroids
140934|NCT02218814|Femoral Nerve Block
140935|NCT02218814|Adductor Canal Nerve Block
140936|NCT02218801|Liver metastasis
140937|NCT02218801|Colorectal carcinoma
140938|NCT02218801|Unresectable
140939|NCT02218801|Borderline resectable
140940|NCT02218801|Initially unresectable
140941|NCT02218788|Nasolabial folds
140942|NCT02218788|Marionette lines
140943|NCT02218788|Cheek bones
140944|NCT02218788|Jaw lines
140945|NCT02218775|Kappa opioid receptor
140946|NCT02218775|Mu opioid receptor
140947|NCT02218775|LY2456302
140948|NCT02218775|Anhedonia
140949|NCT02218775|Mood and Anxiety Spectrum Disorders
140950|NCT02218762|Fluticasone propionate/salmeterol in a capsule-based inhaler
140951|NCT02218762|replicated cross-over design
140953|NCT02218762|asthma
140954|NCT02218762|safety
140955|NCT02218762|pharmacokinetics
140956|NCT02218762|Fluticasone propionate/salmeterol
140957|NCT02218762|pharmacodynamics
140958|NCT02218762|Fluticasone propionate/salmeterol in a multi-dose dry powder inhaler
140959|NCT02218736|Anhedonia
140960|NCT02218736|Mood and Anxiety Spectrum Disorders
140961|NCT02218736|CERC-501 (investigational product)
140962|NCT02218736|Kappa Opioid Receptor (KOR)
140963|NCT02218723|inhaled corticosteroid
140964|NCT02218723|UD-DPI
140965|NCT02218723|ELLIPTA DPI
140966|NCT02218723|healthy volunteer
140967|NCT02218723|Asthma
140968|NCT02218723|Fluticasone furoate
140969|NCT02218697|Immunogenicity
140970|NCT02218697|Influsplit Tetra (Fluarix Tetra) 2014/2015 season
140971|NCT02218697|Safety
140972|NCT02218697|Adults
140973|NCT02218697|Pneumovax 23/Pneumovax
140974|NCT02218697|Co-administration
140975|NCT02218697|Elderly
140976|NCT02218697|Seasonal influenza
140977|NCT02218697|Pneumococcal infection
140978|NCT02218632|Galactosaemia
140979|NCT02218632|Dysglycosylation
140980|NCT02218632|Diet
140981|NCT02218619|type 1 diabetes (T1D)
140982|NCT02218619|endoplasmic reticulum (ER) stress
140983|NCT02218619|induced pluripotential stem (iPS) cells
140984|NCT02218619|Tauroursodeoxycholic Acid (TUDCA)
140985|NCT02218606|Abiraterone Acetate
140986|NCT02218606|CABAZITAXEL
140987|NCT02218606|CASTRATION RESISTANT
140988|NCT02218606|14-046
140989|NCT02218606|Prostate Cancer Clinical Trials Consortium
140990|NCT02218580|massage therapy
140991|NCT02218580|juvenile arthritis
140992|NCT02218580|pain
140993|NCT02218554|BRONJ
140994|NCT02218528|subjects
140995|NCT02218515|Autogenous bone graft
140996|NCT02218515|Chronic periodontitis
140997|NCT02218515|Enamel matrix derivatives
140998|NCT02218515|Gingival crevicular fluid
140999|NCT02218515|Periodontal flap surgery
141000|NCT02218502|Ovarian cancer
141001|NCT02218502|Diagnosis
141002|NCT02218502|Risk of Malignancy Index
141003|NCT02218502|RMI
141004|NCT02218502|Ultrasound
141005|NCT02218502|Simple ultrasound-based rules
141006|NCT02218502|DW-MRI
141007|NCT02218502|Subjective assessment
141008|NCT02218489|Pain
141009|NCT02218489|Corticosteroid
141010|NCT02218489|Meibomian Gland Disease
141011|NCT02218489|Blepharitis
141012|NCT02218489|Eyelid
141013|NCT02218489|Ocular Discomfort
141014|NCT02218463|Vulvar disease, adhesions, topical therapy
141015|NCT02218463|Labial adhesions prepubertal girls
141016|NCT02218463|Labial agglutination
141017|NCT02218463|Labial fusion
141018|NCT02218437|Mesenchymal Stem Cells (MSC)
141019|NCT02218437|Umbilical Cord
141020|NCT02218437|thymocyte globulin (ATG)
141021|NCT02218437|Severe Aplastic Anemia (SAA)
141022|NCT02218398|airway resistance
141023|NCT02218398|lung compliance
141024|NCT02218398|Duration of mechanical ventilation
141025|NCT02218385|Nipple Aspirate Fluid
141026|NCT02218385|Breast Health Screening
141027|NCT02218385|Cytology
141028|NCT02218372|Clostridium difficile-associated Diarrhea (CDAD)
141029|NCT02218372|vancomycin
141030|NCT02218372|Clostridium difficile infection
141031|NCT02218372|fidaxomicin
141032|NCT02218359|Gram-negative pneumonia
141033|NCT02218359|Aerosol antibiotics
141034|NCT02218359|Mechanical ventilation
141035|NCT02218359|Amikacin
141036|NCT02218359|Fosfomycin
141037|NCT02218359|Pneumonia, Bacterial
141038|NCT02218359|Pneumonia
141039|NCT02218359|Bacterial Infections
141040|NCT02218359|Lung Diseases
141041|NCT02218359|Respiratory Tract Diseases
141042|NCT02218359|Respiratory Tract Infections
141043|NCT02218359|Anti-Bacterial Agents
141044|NCT02218359|Anti-Infective Agents
141045|NCT02218359|Therapeutic Uses
141046|NCT02218359|Pharmacologic Actions
141047|NCT02218359|MRSA
141048|NCT02218346|Healthy volunteers
141049|NCT02218320|HIV
141050|NCT02218320|Gut-associated lymphoid tissue
141051|NCT02218320|raltegravir
141052|NCT02218320|Isentress
141053|NCT02218320|dolutegravir
141054|NCT02218320|Tivicay
141055|NCT02218320|pharmacodynamics
141056|NCT02218294|BCX4161
141057|NCT02218294|BioCryst
141058|NCT02218294|hereditary angioedema
141059|NCT02218294|mass balance
141060|NCT02218294|kallikrein inhibitor
141061|NCT02218294|ADME
141062|NCT02218268|type I diabetes
141063|NCT02218268|healthy
141064|NCT02218268|children
141065|NCT02218268|adolescents
141066|NCT02218268|young adults
141067|NCT02218255|In Vitro Fertilization
141068|NCT02218242|Lung
141069|NCT02218242|Cancer
141070|NCT02218242|Ultrasound
141071|NCT02218242|Staging
141072|NCT02218229|shock wave
141073|NCT02218229|carpal tunnel syndrome
141074|NCT02218216|Mild Traumatic Brain Injury
141075|NCT02218203|chronic pain
141076|NCT02218203|central neuropathic pain
141077|NCT02218203|spinal cord injury
141078|NCT02218203|dextromethorphan
141079|NCT02218203|lidocaine
141080|NCT02218203|combination therapy
141081|NCT02218203|analgesia
141082|NCT02218190|Alvimopan
141083|NCT02218190|Ileus
141084|NCT02218190|Posterior spinal fusion
141085|NCT02218177|wet Age Related Macular Degeneration
141086|NCT02218177|Ranibizumab
141087|NCT02218177|Aflibercept
141088|NCT02218177|Combination Photodynamic Therapy
141089|NCT02218177|Cytokine analysis
141090|NCT02218164|metastatic
141091|NCT02218164|cutaneous
141092|NCT02218164|skin cancer
141093|NCT02218151|Hematopoietic
141094|NCT02218151|Stem Cell
141095|NCT02218151|Transplant
141096|NCT02218151|patient-centered
141097|NCT02218151|Microbiota
141098|NCT02218151|GVHD
141099|NCT02218138|Adolescent
141100|NCT02218138|Diabetes
141101|NCT02218138|Depression
141102|NCT02218138|Obesity
141103|NCT02218138|Stress
141104|NCT02218125|Healthy
141105|NCT02218125|Human immunodeficiency virus type 1 (HIV-1) infection
141106|NCT02218125|Acquired immunodeficiency syndrome (AIDS)
141107|NCT02218125|recombinant adenovirus (rAd) vector-based vaccines
141108|NCT02218125|Vaccination
141109|NCT02218125|Ad26.ENVA.01
141110|NCT02218125|Recombinant
141111|NCT02218125|Modified Vaccinia Ankara (MVA) vector-based vaccines
141112|NCT02218112|Blood pressure
141113|NCT02218112|Obesity
141114|NCT02218112|Glomerular filtration rate
141115|NCT02218112|Renal Sodium handling
141116|NCT02218099|Phase 1
141117|NCT02218099|ASP8232
141118|NCT02218099|Single dose
141119|NCT02218099|Multiple doses
141120|NCT02218086|postural control
141121|NCT02218086|postural balance
141122|NCT02218086|slackline
141123|NCT02218073|Healthy
141124|NCT02218073|JNJ-42756493
141125|NCT02218073|JNJ-61818549
141126|NCT02218073|Isotope
141127|NCT02218047|Pegylated-Proline-interferon alpha-2b (AOP2014)
141128|NCT02218047|Polycythemia Vera
141129|NCT02218047|PROUD-PV
141130|NCT02218047|CONTINUATION-PV
141131|NCT02218047|AOP Orphan
141132|NCT02218047|Polycythemia
141133|NCT02218047|Hematologic Diseases
141134|NCT02218047|Myeloproliferative Disorders
141135|NCT02218047|Bone Marrow Diseases
141136|NCT02218047|Interferon-alpha
141137|NCT02218047|Peginterferon alfa-2b
141138|NCT02218021|Alkermes
141139|NCT02218021|ALKS 33
141140|NCT02218021|ALKS 5461
141141|NCT02218021|Samidorphan
141142|NCT02218008|Major depressive disorder (MDD)
141143|NCT02218008|depression
141144|NCT02218008|Alkermes
141145|NCT02218008|ALKS 5461
141146|NCT02218008|samidorphan
141147|NCT02217995|Mindfulness-Based Cognitive Therapy
141148|NCT02217995|Mindfulness
141149|NCT02217969|Anesthesia
141150|NCT02217969|Hypotension
141151|NCT02217930|TQT
141152|NCT02217917|Healthy subjects
141153|NCT02217917|Randomized
141154|NCT02217917|Double-blind
141155|NCT02217917|Single ascending dose
141156|NCT02217917|Multiple ascending dose
141157|NCT02217878|ST-segment elevation myocardial infarction
141158|NCT02217878|non-ST-segment elevation myocardial infarction
141159|NCT02217878|ticagrelor
141160|NCT02217878|morphine
141161|NCT02217878|pharmacokinetics
141162|NCT02217878|pharmacodynamics
141163|NCT02217878|drug interactions
141164|NCT02217878|VASP assay
141165|NCT02217878|Multiple Electrode Aggregometry
141166|NCT02217878|VerifyNow
141167|NCT02217865|Colorectal Cancer
141168|NCT02217865|CRC
141169|NCT02217865|Curative resection of colorectal cancer
141170|NCT02217865|Caregivers
141171|NCT02217865|Interviews
141172|NCT02217865|Focus groups
141173|NCT02217865|Questionnaires
141174|NCT02217865|Surveys
141175|NCT02217852|hypertension
141176|NCT02217852|Tibetan
141177|NCT02217852|Nitrendipine
141178|NCT02217852|hydrochlorothiazide
141179|NCT02217852|captopril
141180|NCT02217852|Beijing hypotensive No.0
141181|NCT02217774|Computer-Aided Design/instrumentation
141182|NCT02217774|Cone-Beam Computed Tomography
141183|NCT02217774|Dental Implant
141184|NCT02217774|MGuide
141185|NCT02217761|Pharmacokinetics
141186|NCT02217761|Antifungal Agents
141187|NCT02217735|Parkinson's Disease
141188|NCT02217735|Caregivers
141189|NCT02217735|Expressive Writing
141190|NCT02217735|Complementary Medicine
141191|NCT02217735|Cortisol
141192|NCT02217696|Electroencephalography (EEG)
141193|NCT02217696|Magnetic Resonance Imaging (MRI)
141194|NCT02217696|Multimodal Neuroimaging
141195|NCT02217696|Development
141196|NCT02217696|Prediction
141197|NCT02217696|Intervention
141198|NCT02217683|Catheterization, Swan-Ganz
141199|NCT02217683|Cardiac Surgical Procedures
141200|NCT02217683|Blood Transfusion
141201|NCT02217683|Nitric Oxide
141202|NCT02217657|Smart-Touch
141203|NCT02217657|Contact force
141204|NCT02217605|NAFLD
141205|NCT02217605|Oral Fructose Challenge
141206|NCT02217605|31P MRS
141207|NCT02217605|Liver
141208|NCT02217605|Subjects
141209|NCT02217579|Weight loss
141210|NCT02217579|Appetite
141211|NCT02217579|Overweight
141212|NCT02217579|Obesity
141213|NCT02217579|Dietary fiber
141214|NCT02217579|Dietary protein
141215|NCT02217566|Prostatic neoplasms
141216|NCT02217566|Diethylstilbestrol therapy
141217|NCT02217566|Abiraterone acetate
141218|NCT02217566|Prednisone
141219|NCT02217566|Androgen deprivation therapy
141220|NCT02217553|platelet
141221|NCT02217553|P-selectin
141222|NCT02217553|platelet-fibrinogen binding
141223|NCT02217553|platelet-monocye aggregate formation
141224|NCT02217553|vitamin D
141225|NCT02217540|Shoulder, disability evaluation, physiotherapy modalities
141226|NCT02217527|crossover
141227|NCT02217501|peripheral arterial disease, antiplatelet therapy
141228|NCT02217462|pregnancy
141229|NCT02217462|gestational weight gain
141230|NCT02217462|dietary intake
141231|NCT02217462|food reward
141232|NCT02217423|Physical Therapy Modalities
141233|NCT02217423|Respiration Disorders
141234|NCT02217423|Respiratory Therapy
141235|NCT02217410|renal, de novo,
141236|NCT02217397|Apnea-hyponea Index, CPAP, Obstructive Sleep Apnea, Oral Appliance
141237|NCT02217384|Microbiome
141238|NCT02217384|DNA sequencing
141239|NCT02217384|Leptin
141240|NCT02217384|Adiponectin
141241|NCT02217384|Insulin
141242|NCT02217384|IGF-I
141243|NCT02217371|ADHD Patient
141244|NCT02217371|Healthy subjects
141245|NCT02217371|Sleepiness
141246|NCT02217371|PSG
141247|NCT02217371|MWT
141248|NCT02217371|EEG
141249|NCT02217371|cognitive tests
141250|NCT02217358|squamous cell carcinoma of the head and neck
141251|NCT02217358|NBI endoscopy
141252|NCT02217358|videoendoscopy
141253|NCT02217358|white light endoscopy
141254|NCT02217358|magnifying endoscopy
141255|NCT02217358|direct laryngoscopy
141256|NCT02217332|Sinusitis
141257|NCT02217332|Rhinosinusitis
141258|NCT02217332|CRS
141259|NCT02217332|CRSwNP
141260|NCT02217332|CSNP-E
141261|NCT02217332|Nasal polyps
141262|NCT02217332|Nasal polyposis
141263|NCT02217332|Eosinophilia
141264|NCT02217332|Asthma
141265|NCT02217319|Volatile Anesthetic
141266|NCT02217319|Cardioprotection
141267|NCT02217319|Lung surgery
141268|NCT02217319|non cardiac surgery
141269|NCT02217293|Pulsed radiofrequency
141270|NCT02217293|Ultrasound-guided
141271|NCT02217293|Carpal tunnel syndrome
141272|NCT02217280|Cervical Radiculopathy
141273|NCT02217267|Peripheral neuropathy
141274|NCT02217215|Spectroscopy
141275|NCT02217215|HPV
141276|NCT02217202|knee replacement
141277|NCT02217202|knee arthroplasty
141278|NCT02217202|revision
141279|NCT02217202|high risk
141280|NCT02217189|Zinc supplementation.
141281|NCT02217189|Oxidative stress.
141282|NCT02217189|Superoxide radical scavengers.
141283|NCT02217189|Asthenospermia.
141284|NCT02217189|Oxido-sensitive index.
141285|NCT02217137|Dry Eye
141286|NCT02217137|Rheumatoid Arthritis
141287|NCT02217137|Systemic Lupus Erythematosus
141288|NCT02217137|Tear cytokines and immune response
141289|NCT02217124|apple
141290|NCT02217124|high fiber
141291|NCT02217124|body composition
141292|NCT02217124|children
141293|NCT02217111|vocal fold nodules
141294|NCT02217111|pediatric
141295|NCT02217111|voice therapy
141296|NCT02217111|acoustic
141297|NCT02217111|aerodynamic
141298|NCT02217111|quality of life
141299|NCT02217111|Adventures in Voice
141300|NCT02217098|ART
141301|NCT02217098|Occlusal
141302|NCT02217098|Occlusoproximal
141303|NCT02217098|Primary teeth
141304|NCT02217085|Colorectal Cancer Screening
141305|NCT02217085|Colon Cancer Screening
141306|NCT02217085|Polyps
141307|NCT02217085|Colonoscopy
141308|NCT02217072|academic performance
141309|NCT02217072|cognitive development
141310|NCT02217072|children in care
141311|NCT02217072|prevention of school failure
141312|NCT02217059|Emergency Medical Services
141313|NCT02217059|Emergency Care
141314|NCT02217059|Hypertension
141315|NCT02217059|BpTRU
141316|NCT02217059|Blood pressure
141317|NCT02217046|Infection
141318|NCT02217046|prevention
141319|NCT02217046|cardiac devices
141320|NCT02217033|Breast Cancer
141321|NCT02217033|Stage I breast cancer
141322|NCT02217033|Stage II breast cancer
141323|NCT02217033|Water study
141324|NCT02217033|'R'
141325|NCT02217033|Electro-kinetically altered beverage
141326|NCT02217033|altered beverage
141327|NCT02217033|Insomnia
141328|NCT02217033|Fatigue
141329|NCT02217033|Depression
141330|NCT02217033|Adjuvant chemotherapy
141331|NCT02217020|Rectal Cancer
141332|NCT02217020|Locally advanced rectal cancer
141333|NCT02217020|Neoadjuvant
141334|NCT02217020|chemotherapy
141335|NCT02217020|FOLFOXIRI
141336|NCT02217007|Tourette
141337|NCT02217007|Tourette's
141338|NCT02217007|tic
141339|NCT02216994|Intestinal dysganglinosis
141340|NCT02216994|Hirschsprung disease
141341|NCT02216994|Hirschsprung disease allied disorders
141342|NCT02216994|diagnostic scoring system
141343|NCT02216994|Prospective study
141344|NCT02216981|Obsessive Compulsive Disorder (OCD)
141345|NCT02216981|Cognitive Behavioural Therapy (CBT)
141346|NCT02216981|Intensive therapy
141347|NCT02216981|Intensive treatment
141348|NCT02216981|Treatment Resistant
141349|NCT02216968|vegetables
141350|NCT02216968|Head Start
141351|NCT02216968|preschool
141352|NCT02216968|children
141353|NCT02216968|theater
141354|NCT02216968|puppet
141355|NCT02216942|Endodontics
141356|NCT02216942|Deciduous teeth
141357|NCT02216942|Iodoform pastes
141358|NCT02216942|Treatment Refusal
141359|NCT02216929|intubation
141360|NCT02216929|intensive care
141361|NCT02216929|withholding treatment
141362|NCT02216929|cancer
141363|NCT02216929|terminal care
141364|NCT02216929|APACHE
141365|NCT02216903|Atrial fibrillation, sleep apnea
141366|NCT02216890|Renal Cell Carcinoma
141367|NCT02216890|Mantle-Cell Lymphoma
141368|NCT02216890|Diffuse, Large B-Cell, Lymphoma
141369|NCT02216890|Follicular Lymphoma, Grade 3
141370|NCT02216890|Antibody-Drug Conjugate
141371|NCT02216890|CD70 Antigen
141372|NCT02216890|Drug Therapy
141373|NCT02216877|Chronic Kidney Disease
141374|NCT02216877|Hypomagnesemia
141375|NCT02216851|hyaluronic acid
141376|NCT02216851|no-treatment control
141377|NCT02216851|enhancement
141378|NCT02216812|Finger stiffness
141379|NCT02216812|Range of motion
141380|NCT02216812|Distal radius fracture
141381|NCT02216812|Vitamin C
141382|NCT02216799|Parenteral nutrition
141383|NCT02216799|Hyperglycemia
141384|NCT02216799|Glargine insulin
141385|NCT02216799|Regular insulin
141386|NCT02216773|Liver hypertrophy
141387|NCT02216773|Liver resection
141388|NCT02216773|Liver metastases
141389|NCT02216773|Portal vein ligation
141390|NCT02216773|Portal vein embolization
141391|NCT02216773|Radiofrequency splitting
141392|NCT02216760|Monomorphic Ventricular Tachycardia
141393|NCT02216760|Myocardial infarction
141394|NCT02216760|Dilated cardiomyopathy
141395|NCT02216760|Catheter ablation
141396|NCT02216760|Substrate mapping
141397|NCT02216760|Ripple Conduction channels
141398|NCT02216747|Idiopathic Nephrotic syndrome relapse
141399|NCT02216734|HIV/AIDS
141400|NCT02216734|Prevention of mother-to-child transmission
141401|NCT02216734|Mother support groups
141402|NCT02216734|Retention-in-care
141403|NCT02216734|Male participation
141404|NCT02216734|Anti-retroviral treatment
141405|NCT02216734|Infants
141406|NCT02216721|bone mineral density
141407|NCT02216721|bone turnover markers
141408|NCT02216721|primary aldosteronism treatment
141409|NCT02216708|Severe malnutrition
141410|NCT02216708|severe dehydration
141411|NCT02216708|cholera
141412|NCT02216695|acute kidney injury
141413|NCT02216695|epidemiology
141414|NCT02216695|mortality
141415|NCT02216682|Acetaminophen
141416|NCT02216682|Total knee replacement
141417|NCT02216682|Numeric rating scale
141418|NCT02216669|Solid tumors
141419|NCT02216669|Head and Neck Neoplasms
141420|NCT02216643|Stroke
141421|NCT02216643|Ischemic Stroke
141422|NCT02216643|Thrombectomy
141423|NCT02216643|Reperfusion Therapy
141424|NCT02216643|Treatment
141425|NCT02216630|COPD
141426|NCT02216604|Exercise
141427|NCT02216604|Pediatric oncology
141428|NCT02216604|Physical Performance
141429|NCT02216604|Quality of Life
141430|NCT02216604|Feasibility
141431|NCT02216604|during primary
141432|NCT02216604|anticancer treatment
141433|NCT02216591|HIV
141434|NCT02216591|Medication Adherence
141435|NCT02216591|Working Memory
141436|NCT02216578|tyrosine kinase inhibitor
141437|NCT02216578|progressed
141438|NCT02216578|(GIST)
141439|NCT02216565|Stroke
141440|NCT02216565|Endovascular treatment
141441|NCT02216565|Tandem carotid occlusions
141442|NCT02216565|Fibrinolysis
141443|NCT02216552|Pediatrics
141444|NCT02216552|Adolescents
141445|NCT02216552|NAFLD
141446|NCT02216552|Spectroscopy
141447|NCT02216552|Type 2 diabetes
141448|NCT02216539|All terminal
141449|NCT02216539|leading
141450|NCT02216539|indication
141451|NCT02216539|lung transplantation
141452|NCT02216526|Skin health
141453|NCT02216526|Nursing
141454|NCT02216526|Long-term care
141455|NCT02216513|subarachnoid hemorrhage
141456|NCT02216513|SAH
141457|NCT02216513|DFO
141458|NCT02216513|cerebral autoregulation
141459|NCT02216513|delayed cerebral ischemia
141460|NCT02216500|Ketogenic Therapy
141461|NCT02216500|Ketogenic Diet
141462|NCT02216487|mCRC
141463|NCT02216487|colorectal cancer
141464|NCT02216448|Arthroscopy skills
141465|NCT02216448|Knee
141466|NCT02216448|Virtual reality
141467|NCT02216448|Simulator
141468|NCT02216422|Chronic Hepatitis C
141469|NCT02216422|Hepatitis C
141470|NCT02216422|Hepatitis C Virus
141471|NCT02216422|Hepatitis C Genotype 1b
141472|NCT02216422|Interferon-Free
141473|NCT02216396|dementia
141474|NCT02216396|care home
141475|NCT02216396|agitation
141476|NCT02216396|coping
141477|NCT02216383|Post partum haemorrhage
141478|NCT02216383|Active Management of Third Stage of Labour
141479|NCT02216383|Carbetocin
141480|NCT02216383|Syntocinon
141481|NCT02216383|Syntometrine
141482|NCT02216383|Birth experience
141483|NCT02216383|Labour
141484|NCT02216370|Cryptogenic stroke /TIA
141485|NCT02216370|Atrial Fibrillation
141486|NCT02216370|Implantable Loop Recorder
141487|NCT02216370|Genetic Mutation
141488|NCT02216357|Samster's triad
141489|NCT02216357|Acetylsalicylic acid triad
141490|NCT02216357|Widal's triad
141491|NCT02216357|Francis' triad
141492|NCT02216357|Aspirin triad
141493|NCT02216357|Aspirin-induced asthma and rhinitis (AIAR)
141494|NCT02216344|Patient safety monitors
141495|NCT02216331|tuberculosis
141496|NCT02216331|PK
141497|NCT02216331|TMC207
141498|NCT02216331|bedaquiline
141499|NCT02216331|rifapentine
141500|NCT02216331|rifampicin
141501|NCT02216331|drug drug interaction
141502|NCT02216318|sleep
141503|NCT02216318|circadian
141504|NCT02216318|melatonine
141505|NCT02216318|pupil response
141506|NCT02216305|HAL-RAR
141507|NCT02216305|Hemorrhoids
141508|NCT02216305|Hemorrhoid artery ligation
141509|NCT02216305|Anal repair
141510|NCT02216305|Quality of Life
141511|NCT02216305|Postoperative Complications
141512|NCT02216292|preterm single donor milk
141513|NCT02216292|human milk
141514|NCT02216292|very lo birth weight infants
141515|NCT02216292|enteral feedings
141516|NCT02216292|NEC
141517|NCT02216279|Pulmonary
141518|NCT02216279|Hypertension
141519|NCT02216279|PH
141520|NCT02216279|PulmoBind
141521|NCT02216279|Imaging
141522|NCT02216266|Delirium
141523|NCT02216266|CAM-ICU
141524|NCT02216253|Urinary tract infection
141525|NCT02216253|Pelvic organ prolapse
141526|NCT02216253|Urinary incontinence
141527|NCT02216253|Stress urinary incontinence
141528|NCT02216253|Mixed Urinary incontinence
141529|NCT02216253|L-methionine
141530|NCT02216253|Placebo
141531|NCT02216227|MRSA
141532|NCT02216227|surgical site infection
141533|NCT02216214|Urinary Incontinence
141534|NCT02216214|Mirabegron
141535|NCT02216214|Overactive Bladder
141536|NCT02216175|Cow's milk allergy
141537|NCT02216175|Desensitisation
141538|NCT02216175|Safety
141539|NCT02216162|oncogeriatrics
141540|NCT02216162|adjuvant endocrine therapy
141541|NCT02216162|compliance
141542|NCT02216162|elderly
141543|NCT02216162|Taï Chi
141544|NCT02216162|Physical training
141545|NCT02216149|fluoropyrimidine
141546|NCT02216149|S-1
141547|NCT02216149|Teysuno
141548|NCT02216149|oxaliplatin
141549|NCT02216149|coronary artery flow
141550|NCT02216149|coronary artery dysfunction
141551|NCT02216149|gastrointestinal tract cancer
141552|NCT02216136|Mastectomy
141553|NCT02216136|Breast Cancer
141554|NCT02216136|Reconstruction
141555|NCT02216136|Lumpectomy
141556|NCT02216136|Breast Conservation Therapy
141557|NCT02216123|Tafenoquine
141558|NCT02216123|Plasmodium vivax
141559|NCT02216123|Hemolysis
141560|NCT02216123|Primaquine
141561|NCT02216123|Chloroquine
141562|NCT02216123|Glucose-6-phosphate dehydrogenase (G6PD)
141563|NCT02216123|Relapse
141564|NCT02216110|Endoscopic submucosal dissection
141565|NCT02216110|Gastrectomy
141566|NCT02216110|Survival
141567|NCT02216110|Outcome
141568|NCT02216045|Hepatitis C ,Chronic Hepatitis C ,camel milk
141569|NCT02216019|cardiac surgery
141570|NCT02216019|infectious complication
141571|NCT02216006|Atelectasis
141572|NCT02216006|Fresh gas flow
141573|NCT02216006|Prevention
141574|NCT02216006|Oxygenation
141575|NCT02216006|Anaesthesia
141576|NCT02215993|Ticagrelor
141577|NCT02215993|Prasugrel
141578|NCT02215993|VerifyNow
141579|NCT02215993|Acute coronary syndrome
141580|NCT02215980|Multiple myeloma
141581|NCT02215980|Diagnosis
141582|NCT02215980|Elderly and unfit patients
141583|NCT02215980|Lenalidomide plus steroids
141584|NCT02215967|Immunotherapy
141585|NCT02215967|Anti-BCMA-CAR
141586|NCT02215967|Gene Therapy
141587|NCT02215967|Adoptive T Cell Therapy
141588|NCT02215967|Plasma Cell Malignancy
141589|NCT02215915|Percutaneous coronary intervention
141590|NCT02215915|Drug-eluting stent
141591|NCT02215915|Intravascular ultrasound
141592|NCT02215902|ESRD
141593|NCT02215902|Hepatitis C
141594|NCT02215889|Liver metastases
141595|NCT02215889|Transplantation
141596|NCT02215876|Her 2-negative breast cancer
141597|NCT02215876|neoadjuvant doxorubicin/cyclophosphamide followed by Eribulin chemotherapy
141598|NCT02215863|Immunogenicity, Safety, MF59, Influenza vaccine, Pneumococcal vaccine
141599|NCT02215837|Gastric cancer
141600|NCT02215837|D-CIK
141601|NCT02215837|Autologous tumor lysate
141602|NCT02215811|Extracorporeal membrane oxygenation
141603|NCT02215785|Funtional constipation
141604|NCT02215785|Kiwifruit
141605|NCT02215785|Health promotion
141606|NCT02215707|PfSPZ Vaccine
141607|NCT02215707|Plasmodium falciparum
141608|NCT02215707|Malaria
141609|NCT02215707|Controlled Human Malaria Infection (CHMI)
141610|NCT02215694|Apolipoprotein A-V
141611|NCT02215694|LDL particle size
141612|NCT02215694|probiotic
141613|NCT02215694|triglyceride
141614|NCT02215681|otitis media with effusion
141615|NCT02215681|acupuncture
141616|NCT02215681|inflammatory markers
141617|NCT02215655|phosphate binder adherence
141618|NCT02215655|autonomous motivation
141619|NCT02215629|Leukemia
141620|NCT02215629|Acute Leukemia
141621|NCT02215629|Relapsed Leukemia
141622|NCT02215629|Refractory Leukemia
141623|NCT02215629|Acute Myeloid Leukemia
141624|NCT02215629|B-Cell Acute Lymphoblastic Leukemia
141625|NCT02215590|Postural balance
141626|NCT02215590|Motor Learning and Motor Control
141627|NCT02215590|Community integration
141628|NCT02215590|Quality of life
141629|NCT02215590|Functional ambulation
141630|NCT02215577|cancer, colorectal
141631|NCT02215577|hepatectomy
141632|NCT02215577|portal vein
141633|NCT02215577|embolization
141634|NCT02215577|two-stage
141635|NCT02215564|Bordetella pertussis
141636|NCT02215564|Carriage rates in young adults
141637|NCT02215551|laminectomy
141638|NCT02215538|ADHD
141639|NCT02215538|adult
141640|NCT02215538|WRAADDS
141641|NCT02215538|OROS MPH
141642|NCT02215538|emotional dysregulation
141643|NCT02215525|HCV
141644|NCT02215525|UVA
141645|NCT02215525|Herbal therapy
141646|NCT02215499|JZP-386, Xyrem, sodium oxybate
141647|NCT02215486|Head massage therapy
141648|NCT02215486|Massage therapy
141649|NCT02215486|Autonomic nervous system (ANS)
141650|NCT02215486|Heart rate variability (HRV)
141651|NCT02215486|Pre-ejection period (PEP)
141652|NCT02215473|gingivitis
141653|NCT02215473|periodontitis
141654|NCT02215473|mouth rinse
141655|NCT02215473|bacteremia
141656|NCT02215447|NAB-paclitaxel
141657|NCT02215447|Gastrointestinal Neuroendocrine Carcinomas
141658|NCT02215447|phase II
141659|NCT02215447|carboplatin
141660|NCT02215434|Libido; Sexual Dysfunction; testosterone
141661|NCT02215421|vegetables
141662|NCT02215421|dietary intake
141663|NCT02215421|preschoolers
141664|NCT02215421|parents
141665|NCT02215421|video game
141666|NCT02215408|Diabetes
141667|NCT02215408|Hyperlipidemia
141668|NCT02215408|Hypertension
141669|NCT02215408|Cardiovascular Disease
141670|NCT02215395|Nestorone
141671|NCT02215395|miconazole nitrate
141672|NCT02215382|two reversal methods
141673|NCT02215382|changes in IOP
141674|NCT02215382|heart rate
141675|NCT02215382|blood pressure
141676|NCT02215382|tracheal extubation
141677|NCT02215330|Central serous chorioretinopathy
141678|NCT02215330|Eplerenone
141679|NCT02215330|Photodynamic Therapy
141680|NCT02215330|Macula
141681|NCT02215330|Retina
141682|NCT02215317|Sleep Apnea
141683|NCT02215317|Stent
141684|NCT02215317|Coronary Artery Disease
141685|NCT02215317|Percutaneous Coronary Intervention
141686|NCT02215304|Dietary supplementation
141687|NCT02215304|Probiotics
141688|NCT02215304|Safety/Efficiency
141689|NCT02215304|Healthy infants
141690|NCT02215291|Undergoing Esophagogastroduodenoscopy (EGD) or endoscopy
141691|NCT02215278|iron biofortification
141692|NCT02215278|lpa bean
141693|NCT02215278|stable iron isotope study
141694|NCT02215278|phytic acid
141695|NCT02215265|Human papillomavirus HPV positive oropharyngeal cancer
141696|NCT02215239|health lifestyle
141697|NCT02215239|health promotion
141698|NCT02215239|occupational health
141699|NCT02215239|Work site health promotion
141700|NCT02215226|Group B Streptococcus, early onset disease, late onset disease, anticapsular antibodies, serotype specific
141701|NCT02215213|Vitamin D
141702|NCT02215213|pregnancy
141703|NCT02215213|Pakistan
141704|NCT02215200|Type 1 Diabetes TrialNet
141705|NCT02215174|Rosuvastatin
141706|NCT02215174|PK
141707|NCT02215174|Interethnic
141708|NCT02215174|Morbid obese
141709|NCT02215135|Corifollitropin alfa
141710|NCT02215135|polycystic ovarian syndrome (PCOS)
141711|NCT02215135|controlled ovarian hyperstimulation (COS)
141712|NCT02215135|GnRH antagonist protocol
141713|NCT02215135|Ovarian hyperstimulation syndrome (OHSS)
141714|NCT02215122|Fluticasone Propionate
141715|NCT02215122|Salmeterol
141716|NCT02215122|Pharmacokinetics
141717|NCT02215122|Healthy Subjects
141718|NCT02215122|MGR001
141719|NCT02215122|CRC749
141720|NCT02215122|Dry Powder Inhaler
141721|NCT02215122|generic
141722|NCT02215122|Advair Diskus
141723|NCT02215122|Seretide Accuhaler
141724|NCT02215096|enzalutamide
141725|NCT02215096|metastatic castration-resistant prostate cancer
141726|NCT02215096|GSK2636771
141727|NCT02215096|PI3K-beta
141728|NCT02215096|PTEN deficiency
141729|NCT02215083|peripheral neuropathy
141730|NCT02215083|breast cancer
141731|NCT02215083|taxane induced peripheral neuropathy
141732|NCT02215083|chemotherapy induced peripheral neuropathy
141733|NCT02215070|Allogeneic Stem Cell Transplantation
141734|NCT02215070|Acute Myeloid Leukemia
141735|NCT02215070|Acute Lymphoid Leukemia
141736|NCT02215070|Acute Non-Lymphocytic Leukemia
141737|NCT02215070|Myelodysplastic Syndrome
141738|NCT02215070|Chronic Myeloid Leukemia
141739|NCT02215070|Lymphoma
141740|NCT02215057|topical anesthesia
141741|NCT02215057|intracameral lidocaine
141742|NCT02215057|implantable collamer lens
141743|NCT02214875|Retention
141744|NCT02214862|Unclassifiable Parkinsonism, [F18]-FDDNP-PET, Tauopathy, PSP,MSA
141745|NCT02214849|Breastfeeding
141746|NCT02214849|Breastfeeding peer counseling
141747|NCT02214849|Exclusive breastfeeding
141748|NCT02214849|Formula supplementation
141749|NCT02214849|Mobile health
141750|NCT02214849|WIC program
141751|NCT02214836|kidney stones
141752|NCT02214836|ultrasound imaging
141753|NCT02214836|ureter stones
141754|NCT02214810|Bupivacaine
141755|NCT02214810|multimodal
141756|NCT02214810|exparel
141757|NCT02214810|open reduction
141758|NCT02214810|internal fixation
141759|NCT02214810|post-surgical pain control
141760|NCT02214797|Presbyopia
141761|NCT02214797|Refractive Error
141762|NCT02214797|Contact Lenses
141763|NCT02214784|Stress urinary Incontinence
141764|NCT02214784|SUI
141765|NCT02214784|Continence
141766|NCT02214771|Clostridium difficile infection CDI
141767|NCT02214771|Observational
141768|NCT02214771|Fidaxomicin recurrence
141769|NCT02214771|France
141770|NCT02214758|Home care clients, nutrition, oral health, medication
141771|NCT02214745|Israeli Arab population
141772|NCT02214745|Israeli/ethnology
141773|NCT02214732|Pregnancy
141774|NCT02214732|Postpartum
141775|NCT02214732|Mindfulness Based Cognitive Therapy
141776|NCT02214732|Depression
141777|NCT02214732|Anxiety
141778|NCT02214732|Stress
141779|NCT02214732|MBCT
141780|NCT02214732|Actigraphy
141781|NCT02214719|type 1 diabetes, insulin therapy, bolus calculator
141782|NCT02214693|patients
141783|NCT02214680|Pupil diameter
141784|NCT02214680|Brimonidine
141785|NCT02214680|Timolol
141786|NCT02214680|Combigan
141787|NCT02214667|Jail
141788|NCT02214667|co-occurring disorders
141789|NCT02214667|implementation
141790|NCT02214667|acceptability
141791|NCT02214667|feasibility
141792|NCT02214667|fidelity
141793|NCT02214628|Wet AMD
141794|NCT02214628|Choroidal neovascularization
141795|NCT02214628|Fovista®
141796|NCT02214628|E10030
141797|NCT02214628|Avastin®
141798|NCT02214628|Eylea®
141799|NCT02214602|non muscle invasive bladder cancer
141800|NCT02214602|intermediate and high risk
141801|NCT02214602|immediate single instillation
141802|NCT02214602|Intravesical chemotherapy
141803|NCT02214602|Disease prevention
141804|NCT02214576|Respiratory Distress Syndrome, Adult
141805|NCT02214576|intubation, intratracheal
141806|NCT02214576|Oxygen Inhalation Therapy
141807|NCT02214576|Positive-Pressure Respiration
141808|NCT02214576|laryngoscopy
141809|NCT02214563|Vitamin D
141810|NCT02214563|Cholecalciferol
141811|NCT02214563|Hepcidins
141812|NCT02214563|Renal Dialysis
141813|NCT02214550|Cystitis, Interstitial
141814|NCT02214550|Dysmenorrhea
141815|NCT02214550|Migraine Disorders
141816|NCT02214550|Cross Organ Sensitization
141817|NCT02214550|Pelvic Pain
141818|NCT02214550|Endometriosis
141819|NCT02214550|Contraceptives, Oral
141820|NCT02214550|Birth Control Pills
141821|NCT02214550|Painful Bladder Syndrome
141822|NCT02214550|Visceral Pain
141823|NCT02214550|Chronic Pain
141824|NCT02214524|perioperative hypothermia
141825|NCT02214524|Tympanic temperature
141826|NCT02214524|Blood loss
141827|NCT02214524|Blood Coagulation Disorders
141828|NCT02214524|Major surgery
141829|NCT02214511|major depressive disorder
141830|NCT02214511|social rejection
141831|NCT02214511|rapid facial reaction
141832|NCT02214511|facial mimicry
141833|NCT02214511|prosocial behavior
141834|NCT02214511|inflammation
141835|NCT02214511|self esteem
141836|NCT02214498|Dipper
141837|NCT02214498|Non-dipper
141838|NCT02214498|Chronopharmacology
141839|NCT02214485|frailty
141840|NCT02214485|exercise
141841|NCT02214485|intervention
141842|NCT02214472|Rumination síndrome
141843|NCT02214472|Regurgitation
141844|NCT02214472|Vomiting
141845|NCT02214472|Biofeedback
141846|NCT02214472|Electromyography
141847|NCT02214472|Abdominal accommodation
141848|NCT02214459|mHealth
141849|NCT02214459|Hypertension
141850|NCT02214459|Mobile
141851|NCT02214459|smartphone
141852|NCT02214459|diet
141853|NCT02214459|lifestyle
141854|NCT02214459|bluetooth
141855|NCT02214459|physical acitvity
141856|NCT02214459|behavior change
141857|NCT02214459|motivational interviewing
141858|NCT02214446|truth telling
141859|NCT02214446|hope
141860|NCT02214446|quality of life
141861|NCT02214446|care burden
141862|NCT02214446|children with cancer
141863|NCT02214433|Antibiotic
141864|NCT02214433|Antibiotic Resistant Bacterial Infection
141865|NCT02214381|breast cancer
141866|NCT02214381|elderly
141867|NCT02214329|Postural Balance
141868|NCT02214329|Gait
141869|NCT02214329|Fall risk
141870|NCT02214303|Allergic asthma
141871|NCT02214303|Allergic rhinitis
141872|NCT02214303|Healthy subjects
141873|NCT02214290|Cardiovascular
141874|NCT02214290|Caffeine
141875|NCT02214290|L-citrulline
141876|NCT02214290|Arterial Function
141877|NCT02214290|Hemodynamics
141878|NCT02214290|Blood Pressure
141879|NCT02214290|Pulse Wave Velocity
141880|NCT02214290|Pulse Wave Analysis
141881|NCT02214277|Embolic Protection
141882|NCT02214277|Edwards SAPIEN THV
141883|NCT02214277|Edwards SAPIEN XT
141884|NCT02214277|TAVR
141885|NCT02214277|Transfemoral
141886|NCT02214277|Transapical
141887|NCT02214277|Heart Valve Diseases
141888|NCT02214277|Heart Diseases
141889|NCT02214277|TAVI
141890|NCT02214277|Aortic Stenosis
141891|NCT02214277|Aortic Valve
141892|NCT02214277|Transcatheter Heart Valve
141893|NCT02214251|Parkinson's disease
141894|NCT02214251|freezing of gait
141895|NCT02214251|movement disorders
141896|NCT02214251|neuroscience
141897|NCT02214251|neural
141898|NCT02214251|mechanism
141899|NCT02214212|traumatic brain injury
141900|NCT02214212|TBI
141901|NCT02214212|Sleep
141902|NCT02214212|Bright White Light Therapy
141903|NCT02214212|Red Light Therapy
141904|NCT02214212|Recovery
141905|NCT02214212|Central Nervous System Diseases
141906|NCT02214212|Brain Diseases
141907|NCT02214212|Nervous System Diseases
141908|NCT02214212|Signs and Symptoms
141909|NCT02214212|Rehabilitation
141910|NCT02214212|Actigraphy
141911|NCT02214199|Shoulder Pain
141912|NCT02214199|Shoulder Impingement Syndrome
141913|NCT02214199|Exercise therapy
141914|NCT02214199|Randomized Controlled Trial
141915|NCT02214186|Pre-Eclampsia
141916|NCT02214186|Acute Kidney Injury
141917|NCT02214186|Fluid Therapy
141918|NCT02214186|Anesthesia, Spinal
141919|NCT02214173|HIV, BRM4, hydrolyzed rice bran, metabolic syndrome
141920|NCT02214160|Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
141921|NCT02214160|carnitine palmitoyltransferase (CPT I or CPT II) deficiency
141922|NCT02214160|very long chain acyl-CoA dehydrogenase (VLCAD) deficiency
141923|NCT02214160|long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency
141924|NCT02214160|trifunctional protein (TFP) deficiency
141925|NCT02214160|carnitine-acylcarnitine translocase (CACT) deficiency
141926|NCT02214160|Triheptanoin
141927|NCT02214160|UX007
141928|NCT02214160|C7
141929|NCT02214147|Alisertib
141930|NCT02214147|MLN8237
141931|NCT02214147|Relapsed/refractory lymphoma
141932|NCT02214134|Lung cancer
141933|NCT02214134|Malignant pleural mesothelioma
141934|NCT02214134|Thymic malignancy
141935|NCT02214134|Biomarkers
141936|NCT02214134|Screening
141937|NCT02214121|sickle cell anemia
141938|NCT02214121|paediatric
141939|NCT02214108|BMI
141940|NCT02214108|Obesity
141941|NCT02214108|overweight
141942|NCT02214108|child
141943|NCT02214108|Physical activity
141944|NCT02214095|Cytokines
141945|NCT02214095|interleukin-1β
141946|NCT02214095|chronic periodontitis
141947|NCT02214095|host modulation
141948|NCT02214095|glucosamine sulphate.
141949|NCT02214056|mobile screening team
141950|NCT02214056|feasibility
141951|NCT02214030|Femoral compression device
141952|NCT02214030|manual compression
141953|NCT02214030|arterial hemostasis
141954|NCT02214030|coronary intervention
141955|NCT02214030|coronary artery disease
141956|NCT02214017|diabetes
141957|NCT02214017|telemedicine
141958|NCT02214017|glycemia
141959|NCT02214017|lipids
141960|NCT02214017|blood pressure
141961|NCT02214004|Breast cancer
141962|NCT02214004|HER2
141963|NCT02214004|ER
141964|NCT02214004|Postmenopausal
141965|NCT02214004|Trastuzumab
141966|NCT02214004|Letrozole
141967|NCT02214004|Neoadjuvant endocrine treatment
141968|NCT02213991|Breast Cancer
141969|NCT02213991|Breast Conservative Surgery
141970|NCT02213991|Intraoperative Radiotherapy
141971|NCT02213991|Local Toxicity
141972|NCT02213991|Whole breast radiotherapy
141973|NCT02213965|Intravenous Catheter
141974|NCT02213965|Vasofix safety
141975|NCT02213965|Introcan safety
141976|NCT02213952|Ulcer
141977|NCT02213952|Platelet-Rich Plasma
141978|NCT02213939|Myocardial revascularization
141979|NCT02213939|Cytosorb
141980|NCT02213939|Inflammatory response
141981|NCT02213939|Cardiopulmonary bypass
141982|NCT02213926|Bruton tyrosine kinase inhibitor
141983|NCT02213926|Btk
141984|NCT02213926|Mantle Cell Lymphoma
141985|NCT02213926|MCL
141986|NCT02213926|ACP-196
141987|NCT02213926|Acalabrutinib
141988|NCT02213926|ACE-LY-004
141989|NCT02213900|delirium
141990|NCT02213900|confusion
141991|NCT02213900|surgery
141992|NCT02213900|cognitive Impairment
141993|NCT02213900|post-traumatic Stress disorder
141994|NCT02213900|depression
141995|NCT02213900|anxiety
141996|NCT02213887|Drug Interactions
141997|NCT02213887|Pantoprazole
141998|NCT02213887|Proton Pump Inhibitors
141999|NCT02213887|Psychotropic Drugs
142000|NCT02213887|Antipsychotic Agents
142001|NCT02213887|Aripiprazole
142002|NCT02213887|Asenapine
142003|NCT02213887|Clozapine
142004|NCT02213887|Lurasidone
142005|NCT02213887|Olanzapine
142006|NCT02213887|9-hydroxy-risperidone
142007|NCT02213887|Quetiapine
142008|NCT02213887|Risperidone
142009|NCT02213887|Ziprasidone
142010|NCT02213887|Valproic Acid
142011|NCT02213887|Lithium
142012|NCT02213887|Gastrins
142013|NCT02213887|Psychotic Disorders
142014|NCT02213887|Gastroesophageal Reflux
142015|NCT02213874|Pregnant Women
142016|NCT02213874|Women's Health
142017|NCT02213874|Contraception
142018|NCT02213874|Trust in Health Care
142019|NCT02213861|CTCL
142020|NCT02213861|Cutaneous T-Cell Lymphoma
142021|NCT02213861|Early-stage
142022|NCT02213861|SHAPE
142023|NCT02213861|SHP-141
142024|NCT02213861|topical
142025|NCT02213861|Histone deacetylase inhibitor
142026|NCT02213861|CAILS
142027|NCT02213861|mSWAT
142028|NCT02213861|mycosis fungoides
142029|NCT02213848|Neuromuscular blockade reversal
142030|NCT02213848|TOF ratio
142031|NCT02213848|Calcium chloride
142032|NCT02213835|Crohn's disease and Ulcerative colitis
142033|NCT02213822|genome
142034|NCT02213822|transcriptome
142035|NCT02213822|molecular
142036|NCT02213822|proteome
142037|NCT02213822|oncogenic mutations
142038|NCT02213822|sequencing
142039|NCT02213822|solid tumor
142040|NCT02213822|hematological malignancy
142041|NCT02213822|cancer
142042|NCT02213822|analysis
142043|NCT02213822|genetic
142044|NCT02213822|mutation
142045|NCT02213796|meropenem, early phase, severe sepsis and septic shock, critically ill, population pharmacokinetics
142046|NCT02213783|Imipenem
142047|NCT02213783|Febrile neutropenia
142048|NCT02213783|Gram-negative infection
142049|NCT02213783|Pharmacodynamic
142050|NCT02213783|Monte Carlo Simulation
142051|NCT02213757|Hematuria
142052|NCT02213757|Menopause
142053|NCT02213757|Urinalysis
142054|NCT02213744|HER2-positive
142055|NCT02213744|HER2+
142056|NCT02213744|HER2
142057|NCT02213744|Locally Advanced Breast Cancer
142058|NCT02213744|Metastatic Breast Cancer
142059|NCT02213744|trastuzumab
142060|NCT02213744|Herceptin
142061|NCT02213744|pertuzumab
142062|NCT02213744|ado-trastuzumab emtansine
142063|NCT02213744|TDM-1
142064|NCT02213744|Perjeta
142065|NCT02213744|Kadcyla
142066|NCT02213731|Atrial Fibrillation
142067|NCT02213731|Persistent Atrial Fibrillation
142068|NCT02213731|Cryoablation
142069|NCT02213731|Cryoballoon
142070|NCT02213731|Pulmonary Vein Isolation
142071|NCT02213718|Desflurane
142072|NCT02213718|myocardial function
142073|NCT02213718|Coronary Artery Bypass Surgery
142074|NCT02213705|SYSTEMIC SCLERODERMA
142075|NCT02213705|TRANSPLANTATION
142076|NCT02213705|ALLOGENEIC MESENCHYMAL STEM CELLS
142077|NCT02213705|ADULT
142078|NCT02213692|Liver Resection
142079|NCT02213692|Harmonic Scalpel
142080|NCT02213692|Crush-clamping
142081|NCT02213692|A Prospective Randomized Study
142082|NCT02213679|Creatine
142083|NCT02213679|Guanidinoacetic acid
142084|NCT02213679|Intervention
142085|NCT02213679|Fatigue
142086|NCT02213679|Muscle strength
142087|NCT02213666|Atrial fibrillation ablation
142088|NCT02213666|Intracardiac echocardiography
142089|NCT02213666|Thrombus
142090|NCT02213666|Left atrial appendage
142091|NCT02213666|Right atrial appendage
142092|NCT02213653|Functional iron deficiency
142093|NCT02213653|Metastatic
142094|NCT02213640|Neurologic neglect syndrome
142095|NCT02213640|post stroke
142096|NCT02213640|transcranial direct current stimulation (tDCS)
142097|NCT02213640|prismatic adaptation
142098|NCT02213627|Corifollitropin alfa, recombinant FSH, HP-hMG, apoptosis, oocyte donation
142099|NCT02213601|Yoga
142100|NCT02213601|Complementary and Alternative Medicine Interventions
142101|NCT02213601|Treatment
142102|NCT02213601|Postpartum Depression
142103|NCT02213588|Antioxidant
142104|NCT02213575|Resistent Hypertension
142105|NCT02213536|Metastatic brain cancer
142106|NCT02213536|Whole brain radiotherapy
142107|NCT02213536|Scalp sparing whole brain radiotherapy
142108|NCT02213536|Prophylactic whole brain radiotherapy
142109|NCT02213523|antioxidant
142110|NCT02213510|pacemaker
142111|NCT02213510|implantable cardioverter defibrillator
142112|NCT02213510|ICD
142113|NCT02213510|surgical wound closure
142114|NCT02213510|sutures
142115|NCT02213510|Zipline
142116|NCT02213510|Zips
142117|NCT02213510|CIED
142118|NCT02213510|cardiovascular implantable electronic devices
142119|NCT02213510|arrhythmia
142120|NCT02213497|Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.
142121|NCT02213484|aortopathy syndrome
142122|NCT02213484|aortic aneurysm
142123|NCT02213484|aortic dissection
142124|NCT02213484|connective tissue disorder
142125|NCT02213458|Pragmatic Clinical Trial
142126|NCT02213458|Family Caregivers
142127|NCT02213458|Patient Care Management
142128|NCT02213432|influenza vaccine
142129|NCT02213432|cancer
142130|NCT02213419|Cystic Tumors of the Pancreas
142131|NCT02213419|Endoscopic Ultrasound
142132|NCT02213419|Ethanol
142133|NCT02213393|undernutrition
142134|NCT02213393|nutritional status
142135|NCT02213393|elderly patients
142136|NCT02213393|protein
142137|NCT02213393|enriched products
142138|NCT02213393|recovery
142139|NCT02213393|physical function
142140|NCT02213393|quality of life
142141|NCT02213393|activities of daily living
142142|NCT02213380|delirium
142143|NCT02213380|general anesthesia
142144|NCT02213380|regional anesthesia
142145|NCT02213380|elderly patient
142146|NCT02213380|hip fracture
142147|NCT02213354|Influenza, H7N9, Elderly, Vaccine, MF59 Adjuvant
142148|NCT02213341|Milk Allergy
142149|NCT02213341|Egg Allergy
142150|NCT02213341|Peanut Allergy
142151|NCT02213341|Infant Vaccination
142152|NCT02213315|Healthy Volunteers, Rheumatoid Arthritis, mavrilimumab
142153|NCT02213302|premedication
142154|NCT02213302|preoperative anxiety
142155|NCT02213302|salivary cortisol level
142156|NCT02213302|anxiety visual analog scale
142157|NCT02213289|Gastric
142158|NCT02213289|Esophagogastric
142159|NCT02213276|Glucose infusion
142160|NCT02213276|Bone markers
142161|NCT02213276|Inflammatory markers
142162|NCT02213263|rituximab
142163|NCT02213263|follicular lymphoma
142164|NCT02213263|Non-Hodgkin lymphoma
142165|NCT02213263|Non-Hodgkin's lymphoma
142166|NCT02213224|Perindopril,Telmisartan, Efficacy, NAFLD
142167|NCT02213211|Malawi
142168|NCT02213211|Case management
142169|NCT02213211|Rapid diagnostic tests
142170|NCT02213211|Artemether lumefantrine
142171|NCT02213211|School children
142172|NCT02213211|School health services
142173|NCT02213211|Attendance
142174|NCT02213211|Anaemia
142175|NCT02213211|Parasitic diseases
142176|NCT02213198|Serious mental illness, treatment engagement, transitional care, continuity of care, shared decision making
142177|NCT02213185|Sterile water injections
142178|NCT02213185|Pain
142179|NCT02213185|VAS
142180|NCT02213185|Complementary method
142181|NCT02213172|IBS
142182|NCT02213172|Probiotic
142183|NCT02213172|Constipation
142184|NCT02213172|Bifidobacterium longum
142185|NCT02213172|Lactobacillus paracasei
142186|NCT02213172|Lallemand Health Solutions
142187|NCT02213159|Dexmedetomidine
142188|NCT02213159|bariatric surgery
142189|NCT02213159|postoperative pain
142190|NCT02213159|morphine consumption
142191|NCT02213159|Quality of recovery
142192|NCT02213133|Squamous
142193|NCT02213133|SCC
142194|NCT02213133|Carcinoma
142195|NCT02213133|KPT-330
142196|NCT02213133|SINE
142197|NCT02213133|Selinexor
142198|NCT02213133|Karyopharm
142199|NCT02213133|Karyopharm Therapeutics
142200|NCT02213133|Lung
142201|NCT02213133|Head
142202|NCT02213133|Neck
142203|NCT02213133|Esophageal
142204|NCT02213120|Vertigo, Dizziness
142205|NCT02213107|prostate
142206|NCT02213094|preeclampsia
142207|NCT02213094|pregnancy-induced hypertension
142208|NCT02213094|nicotinamide
142209|NCT02213081|Endometriosis
142210|NCT02213081|chronic pelvic pain
142211|NCT02213081|dysmenorrhea
142212|NCT02213081|dyschezia
142213|NCT02213081|bleeding
142214|NCT02213081|ulipristal
142215|NCT02213081|progesterone
142216|NCT02213068|Kidney
142217|NCT02213068|Renal
142218|NCT02213068|Transplant
142219|NCT02213068|EBV
142220|NCT02213068|Immunosuppressants
142221|NCT02213068|Belatacept
142222|NCT02213055|Lice
142223|NCT02213042|biomarker
142224|NCT02213042|Lapatinib
142225|NCT02213042|Prosigna
142226|NCT02213042|ErbB2
142227|NCT02213042|PAM50
142228|NCT02213042|HER2
142229|NCT02213042|HER2-overexpressing metastatic breast cancer
142230|NCT02213042|HER2-enriched
142231|NCT02213042|Trastuzumab
142232|NCT02213029|epelsiban
142233|NCT02213029|pharmacokinetics
142234|NCT02213029|patient reported pain / discomfort
142235|NCT02213029|pharmacodynamics
142236|NCT02213029|oxytocin infusions
142237|NCT02213029|Uterine contractions
142238|NCT02213016|Stimulation magnetic transcranial, major depression, cognitive impairment
142239|NCT02213003|islet transplantation
142240|NCT02212990|Fever
142241|NCT02212990|Antipyretics
142242|NCT02212990|Acetaminophen
142243|NCT02212990|Ibuprofen
142244|NCT02212990|Influenza vaccine
142245|NCT02212990|Influenza
142246|NCT02212990|Body temperature changes
142247|NCT02212990|Signs and symptoms
142248|NCT02212977|Port Catheter
142249|NCT02212977|Octyl 2-cyanoacrylate
142250|NCT02212977|2-octylcyanoacrylate
142251|NCT02212964|Radiation Injury
142252|NCT02212964|Radiation Necrosis
142253|NCT02212964|Ultra-high field MRI
142254|NCT02212964|Susceptibility Weighted Imaging
142255|NCT02212964|Post-treatment radiographic imaging change
142256|NCT02212912|acute ischemic stroke, performance measure, acute treatment
142257|NCT02212899|Spinal Surgery
142258|NCT02212899|Spinal Fusion
142259|NCT02212899|Deformity Correction
142260|NCT02212899|Spinal Instrumentation
142261|NCT02212886|Glatiramer acetate
142262|NCT02212886|Copaxone
142263|NCT02212886|Multiple sclerosis
142264|NCT02212886|Relapsing remitting multiple sclerosis
142265|NCT02212886|RRMS
142266|NCT02212886|GA Depot
142267|NCT02212886|Monthly injection
142268|NCT02212873|school based intervention
142269|NCT02212873|overweight
142270|NCT02212873|obese
142271|NCT02212873|BMI z score
142272|NCT02212873|fat mass
142273|NCT02212860|neoadjuvant
142274|NCT02212860|radiation
142275|NCT02212860|breast
142276|NCT02212860|cancer
142277|NCT02212860|hypofractionation
142278|NCT02212860|stereotactic
142279|NCT02212860|preoperative
142280|NCT02212834|Breast
142281|NCT02212834|Cancer
142282|NCT02212834|Surveillance
142283|NCT02212834|Imaging
142284|NCT02212834|Comparative
142285|NCT02212834|Effectiveness
142286|NCT02212808|Cluster-randomized crossover trial
142287|NCT02212808|Antimicrobial stewardship
142288|NCT02212808|Community hospitals
142289|NCT02212808|Feasibility
142290|NCT02212795|healthy
142291|NCT02212782|Healthy
142292|NCT02212769|healthy
142293|NCT02212756|healthy
142294|NCT02212717|Acute cholecystitis
142295|NCT02212717|EUS-guided gallbladder drainage
142296|NCT02212717|Percutaneous cholecystostomy
142297|NCT02212704|vestibular
142298|NCT02212704|proprioception
142299|NCT02212704|spatial orientation
142300|NCT02212704|bayesian
142301|NCT02212691|Sickle Cell
142302|NCT02212652|Bariatric surgery
142303|NCT02212652|Vitamin D deficiency
142304|NCT02212652|Vitamin D insufficiency
142305|NCT02212652|Adverse surgical outcomes
142306|NCT02212652|Clinical outcomes
142307|NCT02212639|Kaposi' s sarcoma
142308|NCT02212639|Digoxin
142309|NCT02212613|Major Depressive Disorder
142310|NCT02212613|Mental Disorders, nonpsychotic episode, antipsychotic
142311|NCT02212613|Mood Disorder, psychotic disorder
142312|NCT02212587|inhaled antibiotics
142313|NCT02212574|Wnt
142314|NCT02212574|Medulloblastoma
142315|NCT02212574|Chemotherapy
142316|NCT02212548|SpaceOAR Hydrogel Image Guided Modulated Radiotherapy
142317|NCT02212535|Sickle cell disease
142318|NCT02212535|Open monocenter study
142319|NCT02212535|Phase I/II
142320|NCT02212535|hematopoietic stem cells
142321|NCT02212535|Plerixafor
142322|NCT02212522|Diabetes Mellitus
142323|NCT02212522|Insulin-Dependent
142324|NCT02212522|Genome-Wide Association Study
142325|NCT02212522|Environment-Wide Association Study
142326|NCT02212522|Predisposition
142327|NCT02212522|Complications
142328|NCT02212483|Asthma
142329|NCT02212483|Medical Indoor Environment Counselors
142330|NCT02212483|Pediatric
142331|NCT02212483|Environment
142332|NCT02212483|Clinical effectiveness
142333|NCT02212483|Economical impact
142334|NCT02212444|plantar fasciitis
142335|NCT02212444|dynamic elastomeric fabric orthoses (DEFO)
142336|NCT02212444|feasibility
142337|NCT02212444|Physiotherapy
142338|NCT02212444|Musculoskeletal
142339|NCT02212431|Cystic Fibrosis
142340|NCT02212431|Cysteamine
142341|NCT02212431|Pharmacokinetics
142342|NCT02212405|Deep rTMS
142343|NCT02212405|Insular cortex
142344|NCT02212405|PET
142345|NCT02212405|[11C]-PHNO
142346|NCT02212392|acute pancreatitis
142347|NCT02212379|Raltegravir
142348|NCT02212379|Etravirine
142349|NCT02212379|aged, 45 and over
142350|NCT02212379|Viral load
142351|NCT02212379|Efficacy
142352|NCT02212379|Safety
142353|NCT02212366|TDCS
142354|NCT02212366|Depression
142355|NCT02212366|Brain Stimulation
142356|NCT02212366|Memory
142357|NCT02212366|Cognition
142358|NCT02212366|EEG
142359|NCT02212340|propofol
142360|NCT02212340|desflurane
142361|NCT02212340|quality of recovery
142362|NCT02212340|vitrectomy
142363|NCT02212327|Na+ MRI
142364|NCT02212327|salt stores
142365|NCT02212314|Response Inhibition, Williams Syndrome
142366|NCT02212275|ASD
142367|NCT02212275|autism
142368|NCT02212275|typical development
142369|NCT02212275|sensory testing
142370|NCT02212275|the cortical metric
142371|NCT02212249|soluble VE-cadherin
142372|NCT02212249|antibody
142373|NCT02212249|systemic slerosis
142374|NCT02212236|Distress
142375|NCT02212236|Depression
142376|NCT02212236|Anxiety
142377|NCT02212236|Stress
142378|NCT02212236|Coping
142379|NCT02212236|Illness perceptions
142380|NCT02212236|Stem cell transplantation
142381|NCT02212236|Bone marrow transplantation
142382|NCT02212223|Vitamin D
142383|NCT02212223|Serum 25-hydroxyvitamin D (25OHD)
142384|NCT02212223|Dietary supplement
142385|NCT02212223|Ethnicity
142386|NCT02212223|Immigrant
142387|NCT02212197|prostate cancer
142388|NCT02212197|leuprolide
142389|NCT02212184|Diaphragm
142390|NCT02212184|COPD
142391|NCT02212184|Musculoskeletal Manipulations
142392|NCT02212184|Ultrasonography
142393|NCT02212184|Optoelectronic Plethysmography.
142394|NCT02212158|Type 1 diabetes
142395|NCT02212158|adolescents
142396|NCT02212158|HA1c
142397|NCT02212158|psychological intervention
142398|NCT02212145|prevention
142399|NCT02212145|cardiovascular disease
142400|NCT02212145|risk factors
142401|NCT02212132|metamemory
142402|NCT02212132|memory complaints
142403|NCT02212132|performance mnemonic
142404|NCT02212132|cancer
142405|NCT02212119|Dementia
142406|NCT02212119|Paratonia
142407|NCT02212119|Caregiver Burden
142408|NCT02212119|Botulinum toxin
142409|NCT02212093|Pneumonia, mechanical ventilation, ICU, mortality
142410|NCT02212041|electronic cigarettes
142411|NCT02212041|smoking
142412|NCT02212041|schizophrenia
142413|NCT02212041|serious mental illness
142414|NCT02212028|ST-elevation myocardial infarction
142415|NCT02212028|prasugrel
142416|NCT02212028|pharmacodynamic
142417|NCT02212028|pharmacokinetic
142418|NCT02212002|Group B Streptococcus
142419|NCT02212002|Intrapartum Antibiotic Prophylaxis
142420|NCT02212002|term infants
142421|NCT02212002|vaginal delivery
142422|NCT02212002|gut microbiota
142423|NCT02212002|feeding
142424|NCT02212002|molecular analysis
142425|NCT02212002|real-time PCR
142426|NCT02211846|Pharmacokinetics
142427|NCT02211846|Mirabegron
142428|NCT02211846|Neurogenic detrusor overactivity (NDO)
142429|NCT02211846|Overactive bladder (OAB)
142430|NCT02211820|Encephalopathy
142431|NCT02211820|Imaging Studies
142432|NCT02211820|Dementia
142433|NCT02211820|Cerebellar Cortical Atrophy
142434|NCT02211794|Total Knee Arthroplasty
142435|NCT02211794|degenerative joint disease
142436|NCT02211781|Tribal Communities
142437|NCT02211781|Radiation
142438|NCT02211781|Cancer
142439|NCT02211768|Genetic Analysis
142440|NCT02211768|Biopsy
142441|NCT02211768|FDG-PET
142442|NCT02211768|FLT-PET
142443|NCT02211755|Purine Nucleoside Inhibitor
142444|NCT02211755|Proteasome Inhibitor
142445|NCT02211755|Combination Treatment
142446|NCT02211755|Solid Tumors
142447|NCT02211742|dapagliflozin
142448|NCT02211742|fasting glucose
142449|NCT02211742|postprandial glucose excursion
142450|NCT02211742|euglycemic hyperinsulinemic clamp
142451|NCT02211742|euglycemic oral glucose tolerance test
142452|NCT02211703|perioperative hypothermia
142453|NCT02211703|Epidemiology
142454|NCT02211703|Tympanic temperature
142455|NCT02211651|adipose tissue
142456|NCT02211651|placenta
142457|NCT02211651|pregnancy
142458|NCT02211651|umbilical cord
142459|NCT02211638|Drug Therapy
142460|NCT02211625|Healthy
142461|NCT02211625|Pharmacodynamics (PD)
142462|NCT02211625|Pharmacokinetics (PK)
142463|NCT02211612|Overfeeding
142464|NCT02211612|Weight gain
142465|NCT02211612|Liver fat
142466|NCT02211612|Pancreatic fat
142467|NCT02211612|Ectopic fat
142468|NCT02211612|Skeletal muscle
142469|NCT02211612|Adipose tissue
142470|NCT02211612|Gene expression
142471|NCT02211612|DNA methylation
142472|NCT02211612|Palmitate
142473|NCT02211612|Linoleic acid
142474|NCT02211612|Saturated fat
142475|NCT02211612|Polyunsaturated fat
142476|NCT02211612|Metabolism
142477|NCT02211612|Insulin sensitivity
142478|NCT02211599|protein
142479|NCT02211599|carbohydrate
142480|NCT02211599|lipid
142481|NCT02211599|oxidation
142482|NCT02211599|fat
142483|NCT02211599|sugar
142484|NCT02211599|juice
142485|NCT02211599|obesity
142486|NCT02211586|insulin glargine
142487|NCT02211586|subcutaneous injections
142488|NCT02211586|sleep respiratory quotient
142489|NCT02211573|Autonomic Nervous System, Body composition, Oxygen Uptake,
142490|NCT02211573|Water Based Physical Training.
142491|NCT02211534|Pulsed Electromagnetic Energy Fields
142492|NCT02211534|Total Knee Arthroplasty
142493|NCT02211534|Pain Intensity
142494|NCT02211521|Osteoarthritis, platelet-rich plasma, hyaluronic acid
142495|NCT02211508|fibromyalgia
142496|NCT02211508|pain
142497|NCT02211508|stimulation
142498|NCT02211482|HIV-1 infected patients
142499|NCT02211482|dual therapy
142500|NCT02211456|Endocardial pacing
142501|NCT02211456|Multi site pacing
142502|NCT02211443|Full human anti-EGFR monoclonal antibody (SCT200) ;
142503|NCT02211443|metastatic colorectal cancer （mCRC）;
142504|NCT02211443|Escalating doses ;
142505|NCT02211443|single dose and multiple doses;
142506|NCT02211443|safety, tolerability and pharmacokinetics.
142507|NCT02211430|smoking cessation
142508|NCT02211430|pregnancy
142509|NCT02211430|postpartum
142510|NCT02211430|intervention
142511|NCT02211391|Nighttime Eating
142512|NCT02211391|Protein
142513|NCT02211391|Obesity
142514|NCT02211391|Lipolysis
142515|NCT02211391|Metabolism
142516|NCT02211378|stress
142517|NCT02211378|performance
142518|NCT02211378|cortisol
142519|NCT02211365|Hypertension
142520|NCT02211365|CVD
142521|NCT02211352|blood pressure, ginseng
142522|NCT02211339|Social skills
142523|NCT02211339|Social communication
142524|NCT02211339|Cognitive communication
142525|NCT02211339|Traumatic brain injury
142526|NCT02211339|Acquired brain injury
142527|NCT02211339|Communication partner training
142528|NCT02211339|Peer partner training
142529|NCT02211339|Peer mentoring
142530|NCT02211339|Rating scales
142531|NCT02211339|Rehabilitation
142532|NCT02211326|AF or DVT
142533|NCT02211326|Age Over 60 Years, Acquired
142534|NCT02211300|glucose monitoring
142535|NCT02211300|OptiScanner
142536|NCT02211287|Dementia
142537|NCT02211287|Decision-making
142538|NCT02211287|Communication
142539|NCT02211287|Advance Care Planning
142540|NCT02211274|Quality of Life
142541|NCT02211274|Nursing Homes
142542|NCT02211274|Housing for the Elderly
142543|NCT02211274|Homes for the Aged
142544|NCT02211261|first in human
142545|NCT02211261|single dose
142546|NCT02211261|multiple dose
142547|NCT02211261|escalation
142548|NCT02211261|safety study
142549|NCT02211261|Type 2 Diabetes Mellitus
142550|NCT02211248|Cardiac Frequency Variability
142551|NCT02211248|multidisciplinary care
142552|NCT02211248|clinical trial
142553|NCT02211235|Cystic Fibrosis
142554|NCT02211235|Healthy Controls
142555|NCT02211235|Diabetes
142556|NCT02211235|Cystic Fibrosis Related Diabetes (CFRD)
142557|NCT02211235|CFRD
142558|NCT02211222|Thyroid Cancer
142559|NCT02211222|Radioiodine-Refractory
142560|NCT02211222|Differentiated
142561|NCT02211183|Massive Rotator Cuff Tear
142562|NCT02211183|Sub-acromial spacer
142563|NCT02211183|Best repair of rotator cuff
142564|NCT02211105|GastroEsophageal Reflux Disease
142565|NCT02211105|Transoral Incisionless Fundoplication
142566|NCT02211105|Laparoscopic Nissen Fundoplication
142567|NCT02211092|Family Caregivers
142568|NCT02211092|Advanced Cancer
142569|NCT02211092|Palliative Care
142570|NCT02211092|Support
142571|NCT02211092|Self Care
142572|NCT02211092|Physical Activity
142573|NCT02211079|Healthy
142574|NCT02211079|JNJ-54861911
142575|NCT02211079|Caffeine
142576|NCT02211079|Midazolam
142577|NCT02211079|Tolbutamide
142578|NCT02211079|Cytochrome P450 3A4
142579|NCT02211079|Cytochrome P450 2C9
142580|NCT02211079|Cytochrome P450 1A2
142581|NCT02211079|Alzheimer's disease
142582|NCT02211053|Organ donation
142583|NCT02211053|Brain dead
142584|NCT02211053|Levothyroxine
142585|NCT02211040|Intervention Mapping Protocol
142586|NCT02211040|physical activity
142587|NCT02211040|fruit intake
142588|NCT02211040|vegetable intake
142589|NCT02211040|computer tailoring
142590|NCT02211040|eHealth
142591|NCT02211040|self-regulation
142592|NCT02211040|goal setting
142593|NCT02211040|problem solving
142594|NCT02211040|general practice
142595|NCT02211027|Squamous Cell Carcinoma
142596|NCT02211027|Head & Neck Cancer
142597|NCT02211027|Vaccine
142598|NCT02211027|Carcinoma
142599|NCT02211027|Immunization
142600|NCT02211027|Autologous Tumor
142601|NCT02211014|Bruton tyrosine kinase inhibitor
142602|NCT02211014|Btk
142603|NCT02211014|Multiple Myeloma
142604|NCT02211014|MM
142605|NCT02211014|ACP-196
142606|NCT02211014|acalabrutinib
142607|NCT02211001|Exercise Movement Techniques
142608|NCT02211001|Exercise Therapy
142609|NCT02211001|Physical Therapy Modalities.
142610|NCT02210988|Acupuncture therapy, Acute stroke, Randomized controlled trials
142611|NCT02210975|GERD
142612|NCT02210975|LES
142613|NCT02210975|Sleeve Gastrectomy
142614|NCT02210975|Electrical Stimulation Therapy
142615|NCT02210962|early psychosis
142616|NCT02210962|chronic schizophrenia
142617|NCT02210962|first episode psychosis
142618|NCT02210962|omega-3 and omega-6 essential fatty acids
142619|NCT02210962|relapse prevention
142620|NCT02210962|efficacy
142621|NCT02210949|Blood transfusion
142622|NCT02210949|Erythropoietin
142623|NCT02210949|Iron suppletion
142624|NCT02210923|Baroreflex
142625|NCT02210923|Electrical stimulation
142626|NCT02210923|Carotid body
142627|NCT02210923|Chemoreceptors
142628|NCT02210923|Resistant hypertension
142629|NCT02210910|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff
142630|NCT02210884|Vitamin D supplementation
142631|NCT02210884|Lactation
142632|NCT02210884|25 hydroxyvitamin D
142633|NCT02210884|Breast feeding
142634|NCT02210845|Diabetes
142635|NCT02210845|Supervised Exercise
142636|NCT02210845|Weight loss
142637|NCT02210832|smoking
142638|NCT02210832|pregnancy
142639|NCT02210832|cessation
142640|NCT02210832|incentives
142641|NCT02210819|Thromboembolism
142642|NCT02210819|Embolism and Thrombosis
142643|NCT02210819|Vascular Diseases
142644|NCT02210819|Cardiovascular Diseases
142645|NCT02210819|Thrombosis
142646|NCT02210806|Asthma
142647|NCT02210806|Mild-to-moderate persistent asthma
142648|NCT02210806|Mild asthma
142649|NCT02210806|Moderate asthma
142650|NCT02210806|Persistent asthma
142651|NCT02210793|Transepithelial PRK
142652|NCT02210793|Dry eye
142653|NCT02210793|Schirmer test
142654|NCT02210793|Tear break up time
142655|NCT02210793|Dry eye after advanced surface ablation technique
142656|NCT02210754|Nicotine
142657|NCT02210754|Pharmacokinetics
142658|NCT02210754|Pharmacodynamics
142659|NCT02210754|blu e-cigs
142660|NCT02210754|Tolerability
142661|NCT02210754|Safety
142662|NCT02210754|Smoke urge
142663|NCT02210741|immune repertoire
142664|NCT02210741|Graves' disease
142665|NCT02210728|cognitive behavioral therapy
142666|NCT02210728|stimulant medication
142667|NCT02210728|efficacy
142668|NCT02210728|symptoms
142669|NCT02210728|functional outcomes
142670|NCT02210663|Breast cancer
142671|NCT02210663|PARP
142672|NCT02210663|Primary peritoneal cancer
142673|NCT02210663|Fallopian tube
142674|NCT02210663|Ovarian cancer
142675|NCT02210663|veliparib
142676|NCT02210663|ABT-888
142677|NCT02210663|BRCA
142678|NCT02210650|kidney stone
142679|NCT02210637|Appointments and Schedules
142680|NCT02210637|Outpatient Clinics, Hospital/Economics
142681|NCT02210637|Emergency Department
142682|NCT02210637|Hospitalization
142683|NCT02210637|Mortality
142684|NCT02210624|Anoxic Brain Injury
142685|NCT02210624|Autologous bone marrow derived stem cell
142686|NCT02210624|stoke
142687|NCT02210598|labor, induced
142688|NCT02210598|catheter
142689|NCT02210598|oxytocin
142690|NCT02210598|Cesarean section
142691|NCT02210572|Intestinal microbiota
142692|NCT02210572|Intestinal gas
142693|NCT02210572|Dietary intervention
142694|NCT02210572|Low-FODMAPs diet
142695|NCT02210572|Prebiotics
142696|NCT02210559|locally
142697|NCT02210559|advanced
142698|NCT02210559|pancreatic
142699|NCT02210559|cancer
142700|NCT02210559|unresectable
142701|NCT02210559|pancreatic cancer
142702|NCT02210546|breast cancer
142703|NCT02210546|intermediate risk
142704|NCT02210507|vitamin A
142705|NCT02210507|retinol
142706|NCT02210507|carotenoids
142707|NCT02210481|vitrectomy,
142708|NCT02210481|macular thinning,
142709|NCT02210481|retinal detachment,
142710|NCT02210481|epimacular membrane,
142711|NCT02210481|intravitreal glucose,
142712|NCT02210481|OCT
142713|NCT02210468|Osteoarthritis
142714|NCT02210468|Protease Inhibitors
142715|NCT02210468|Alpha-2-macroglobulin
142716|NCT02210468|Autologous treatment
142717|NCT02210468|APIC-CF
142718|NCT02210468|Pain due to Mild to Moderate osteoarthritis (OA) of the knee
142719|NCT02210455|FASD
142720|NCT02210455|pFAS
142721|NCT02210455|ARND
142722|NCT02210455|Fetal Alcohol Syndrome
142723|NCT02210455|Partial Fetal Alcohol Syndrome
142724|NCT02210455|Alcohol Related Neurodevelopmental Disorder
142725|NCT02210455|Static Encephalopathy (Alcohol Exposed)
142726|NCT02210455|Neurobehavioural Disorder (Alcohol Exposed)
142727|NCT02210442|educational games
142728|NCT02210442|clinical practice guideline
142729|NCT02210442|family medicine
142730|NCT02210442|primary health care
142731|NCT02210442|cluster clinical trial
142732|NCT02210429|Supraclavicular Block
142733|NCT02210429|Supraclavicular Catheter
142734|NCT02210429|Pediatric Anesthesia
142735|NCT02210429|Regional Anesthesia
142736|NCT02210429|Supracondylar Elbow Fracture
142737|NCT02210390|Psycho-education, Bipolar , cultural adaptation, Pakistan
142738|NCT02210377|Auto-moxibusition, intra-dialytic hypotension, hemodialysis
142739|NCT02210325|gonorrhea
142740|NCT02210325|chlamydia
142741|NCT02210325|solithromycin
142742|NCT02210299|Healthy young children (2-6 months ; 12-18 months)
142743|NCT02210286|dementia
142744|NCT02210286|magnesium
142745|NCT02210286|learning
142746|NCT02210286|memory
142747|NCT02210286|Alzheimer's disease
142748|NCT02210273|Stress Urinary Incontinence
142749|NCT02210273|SUI
142750|NCT02210260|Cancer
142751|NCT02210260|Colorectal
142752|NCT02210260|Pain relief
142753|NCT02210234|wheat bran
142754|NCT02210234|healthy immunity
142755|NCT02210234|T cells
142756|NCT02210221|TBI
142757|NCT02210195|Cannabis Treatment
142758|NCT02210195|Alcohol Treatment
142759|NCT02210195|Alcohol-Related Disorders
142760|NCT02210195|Cannabis-Related Disorders
142761|NCT02210195|Substance-Related Disorders
142762|NCT02210195|Emend
142763|NCT02210195|NK1 receptor antagonist
142764|NCT02210195|Alcohol
142765|NCT02210195|Cannabis
142766|NCT02210195|aprepitant
142767|NCT02210182|Hepatocellular carcinoma
142768|NCT02210182|Oral Pentamidine
142769|NCT02210182|Endo-exonuclease
142770|NCT02210156|Respiratory tract infection
142771|NCT02210156|Incidence
142772|NCT02210156|Dietary supplements
142773|NCT02210156|Micronutrients
142774|NCT02210156|Plant extracts
142775|NCT02210117|Kidney Cancer
142776|NCT02210117|Metastatic Renal Cell Carcinoma
142777|NCT02210117|mRCC
142778|NCT02210117|Cytoreductive Nephrectomy
142779|NCT02210117|Presurgical therapy
142780|NCT02210117|Nivolumab
142781|NCT02210117|BMS-936558
142782|NCT02210117|Bevacizumab
142783|NCT02210117|Avastin
142784|NCT02210117|Anti-VEGF monoclonal antibody
142785|NCT02210117|fhuMab-VEGF
142786|NCT02210117|Ipilimumab
142787|NCT02210117|Yervoy
142788|NCT02210117|BMS-734016
142789|NCT02210117|MDX010
142790|NCT02210104|Melanoma
142791|NCT02210104|Sarcoma
142792|NCT02210104|Mixed round cell liposarcoma
142793|NCT02210104|Advanced
142794|NCT02210104|Metastatic
142795|NCT02210104|Immunotherapy
142796|NCT02210104|Ipilimumab
142797|NCT02210104|Yervoy
142798|NCT02210104|BMS-734016
142799|NCT02210104|MDX010
142800|NCT02210104|Cyclophosphamide
142801|NCT02210104|Cytoxan
142802|NCT02210104|Neosar
142803|NCT02210104|CD4+T Cells
142804|NCT02210078|Blood And Marrow Transplantation
142805|NCT02210078|Infection
142806|NCT02210078|Cytomegalovirus
142807|NCT02210078|CMV
142808|NCT02210078|Stem cell transplant
142809|NCT02210078|Hematopoietic stem cell transplantation
142810|NCT02210078|HSCT
142811|NCT02210078|Human Leukocyte Antigen
142812|NCT02210078|HLA
142813|NCT02210078|Cytotoxic T-Lymphocytes
142814|NCT02210078|CTL
142815|NCT02210065|Leukemia
142816|NCT02210065|Lymphoma
142817|NCT02210065|Blood And Marrow Transplantation
142818|NCT02210065|Hematological malignancies
142819|NCT02210065|Cytotoxic T cells
142820|NCT02210065|CTL
142821|NCT02210065|Cytomegalovirus
142822|NCT02210065|CMV
142823|NCT02210065|Allogeneic hematopoietic stem cell transplantation
142824|NCT02210065|HSCT
142825|NCT02210052|radiofrequency ablation
142826|NCT02210039|SECM
142827|NCT02210039|Esophagus
142828|NCT02210039|Imaging
142829|NCT02210026|bubble nasal continuous positive airway pressure (Bn-CPAP)
142830|NCT02210026|work of breathing
142831|NCT02210026|pressure-rate products
142832|NCT02210013|AMH, AFC, aging, ethnicity
142833|NCT02210000|repeat dose
142834|NCT02210000|phase II
142835|NCT02210000|GCSI-DD
142836|NCT02210000|pharmacodynamics
142837|NCT02210000|gastroparesis
142838|NCT02210000|type 1 and type 2 diabetes mellitus
142839|NCT02210000|camicinal
142840|NCT02210000|GSK962040
142841|NCT02210000|symptoms
142842|NCT02210000|gut motility
142843|NCT02209974|emphysema
142844|NCT02209974|CRP
142845|NCT02209974|interleukin-8
142846|NCT02209974|dynamic hyperinflation
142847|NCT02209935|pediatric
142848|NCT02209935|acute neurologic disease
142849|NCT02209935|critical care
142850|NCT02209935|rehabilitation
142851|NCT02209935|outcome
142852|NCT02209922|tDCS, stroke, postural control
142853|NCT02209909|preoperative aspirin use
142854|NCT02209909|platelet activation
142855|NCT02209909|off pump coronary artery bypass
142856|NCT02209896|Peripheral Neuropathic Pain
142857|NCT02209896|PNP
142858|NCT02209883|sevoflurane, anesthesia, washout time,COPD
142859|NCT02209870|Cardiopulmonary resuscitation
142860|NCT02209870|Teamwork
142861|NCT02209870|electronic checklist
142862|NCT02209857|Breastcancer
142863|NCT02209857|Adjuvant chemotherapy
142864|NCT02209857|70-gene expression profile
142865|NCT02209857|MammaPrint
142866|NCT02209818|Low level laser therapy
142867|NCT02209818|Elastomeric separator
142868|NCT02209818|Placebo
142869|NCT02209818|Visual analog scale
142870|NCT02209818|Laser irradiation
142871|NCT02209766|Safety
142872|NCT02209766|Tolerability
142873|NCT02209766|Pharmacokinetics
142874|NCT02209766|Pharmacodynamics
142875|NCT02209766|D5884
142876|NCT02209766|Japanese
142877|NCT02209766|Caucasian
142878|NCT02209740|renal toxicity, HIV, antiretroviral, outcome
142879|NCT02209675|hepatitis C recurrence
142880|NCT02209675|Rejection
142881|NCT02209675|Liver Transplantation
142882|NCT02209675|Liver biopsy
142883|NCT02209662|APIC-PRP
142884|NCT02209662|Chronic Wounds
142885|NCT02209662|Diabetic foot ulcer
142886|NCT02209636|hyperphosphatemia
142887|NCT02209636|vascular dysfunction
142888|NCT02209636|chronic kidney disease
142889|NCT02209636|cardiovascular disease
142890|NCT02209636|endothelial dysfunction
142891|NCT02209610|Heart Failure
142892|NCT02209597|Major Depressive Disorder
142893|NCT02209597|MDD
142894|NCT02209597|bupropion XL
142895|NCT02209597|Wellbutrin XL
142896|NCT02209571|Breath Tests
142897|NCT02209545|fibroids, leiomyomata, blood loss, misoprostol
142898|NCT02209532|Lymph node mapping
142899|NCT02209532|Endometrial cancer
142900|NCT02209532|Uterine cancer
142901|NCT02209532|Cervical cancer
142902|NCT02209519|bacterial vaginosis
142903|NCT02209519|recurrence
142904|NCT02209519|male partner
142905|NCT02209506|MLN3126
142906|NCT02209493|Dietary intervention
142907|NCT02209493|Hypercholesterolemic adults
142908|NCT02209493|Vegetable intake
142909|NCT02209493|Functional food
142910|NCT02209493|Prevention
142911|NCT02209467|walking
142912|NCT02209467|postural balance
142913|NCT02209467|falls
142914|NCT02209454|Dexketoprofen
142915|NCT02209454|Bioavailability
142916|NCT02209454|Comparative
142917|NCT02209454|Pharmacokinetic
142918|NCT02209441|sorafenib, gastric cancer, FOLFOX4
142919|NCT02209428|Temozolomide
142920|NCT02209428|IDH mutation
142921|NCT02209428|Low grade glioma
142922|NCT02209389|breast cancer
142923|NCT02209389|cancer associated auto antibodies
142924|NCT02209389|breast cancer blood test
142925|NCT02209363|Parkinson's disease
142926|NCT02209363|OSA
142927|NCT02209363|CPAP
142928|NCT02209363|cognition
142929|NCT02209311|Alveolar Bone Loss
142930|NCT02209311|Alveolar Bone Atrophy
142931|NCT02209311|Dental Implantation
142932|NCT02209311|Bone Tissue Reconstruction
142933|NCT02209311|Sinus Lift
142934|NCT02209311|Autologous Multipotent Mesenchymal Stem Cell
142935|NCT02209311|Autologous MMSCs
142936|NCT02209311|Synthetic Tricalcium Phosphate
142937|NCT02209311|Tissue Engineered Construction
142938|NCT02209311|Oral Mucosa
142939|NCT02209285|Older adults
142940|NCT02209285|Home and community care
142941|NCT02209285|Effectiveness
142942|NCT02209285|Cost analysis
142943|NCT02209285|Stroke
142944|NCT02209285|TIA
142945|NCT02209285|Hypertension
142946|NCT02209285|Cardiovascular disease
142947|NCT02209220|Obstructive sleep apnea
142948|NCT02209220|Treatment compliance
142949|NCT02209220|Automatic positive airway pressure
142950|NCT02209220|Continuous positive airway pressure
142951|NCT02209220|Bariatric surgery
142952|NCT02209207|chronic obstructive pulmonary disease
142953|NCT02209207|endurance training
142954|NCT02209207|interval training
142955|NCT02209207|continuous training
142956|NCT02209207|walking training
142957|NCT02209194|aneurysms
142958|NCT02209194|vascular disease
142959|NCT02209194|E-liac Stent Graft
142960|NCT02209194|E-liac Stent Graft System
142961|NCT02209194|iliac aneurysm
142962|NCT02209194|branched stent graft
142963|NCT02209194|self expanding stent graft
142964|NCT02209181|dental pain
142965|NCT02209181|post-surgical dental pain
142966|NCT02209168|AMH, ACF, VIT D, Etnicity
142967|NCT02209142|Major depression
142968|NCT02209129|digital breast tomosynthesis
142969|NCT02209116|ADHD
142970|NCT02209116|QB Test
142971|NCT02209116|Activity
142972|NCT02209116|Attention
142973|NCT02209116|Children
142974|NCT02209116|Clinical Decision Making
142975|NCT02209103|Polyphenols
142976|NCT02209103|Orange
142977|NCT02209103|Sleep
142978|NCT02209103|Fatigue
142979|NCT02209090|occiput-posterior
142980|NCT02209090|occipitoposterior
142981|NCT02209090|labour
142982|NCT02209064|Subxiphoid
142983|NCT02209064|Access
142984|NCT02209051|Diabetic Foot Ulcers
142985|NCT02209051|AMNIOEXCEL
142986|NCT02209051|Wagner Grade 1 or 2 foot ulcers
142987|NCT02209051|Wound
142988|NCT02209051|Foot health
142989|NCT02209051|Ulcer
142990|NCT02209051|Foot Ulcer
142991|NCT02209051|Diabetic Foot
142992|NCT02209051|Foot Diseases
142993|NCT02209051|Skin Diseases
142994|NCT02209051|Leg Ulcer
142995|NCT02209051|Skin Ulcer
142996|NCT02209051|Diabetic Angiopathies
142997|NCT02209051|Vascular Diseases
142998|NCT02209051|Cardiovascular Diseases
142999|NCT02209051|Diabetes Complications
143000|NCT02209051|Diabetes Mellitus
143001|NCT02209051|Endocrine System Diseases
143002|NCT02209051|Diabetic Neuropathies
143003|NCT02209038|end stage renal disease
143004|NCT02209038|hemodialysis
143005|NCT02209038|dialysis
143006|NCT02209025|Atherosclerosis
143007|NCT02209025|Cholesterol
143008|NCT02209025|Cholesterol, HDL
143009|NCT02209025|Apolipoprotein A-I
143010|NCT02209025|Theobromine
143011|NCT02209012|Actinic Keratosis
143012|NCT02208999|medullary neurostimulation
143013|NCT02208999|pain
143014|NCT02208999|Precision
143015|NCT02208999|rechargeable
143016|NCT02208999|implantable
143017|NCT02208986|GnRH antagonist
143018|NCT02208986|GnRH agonist trigger
143019|NCT02208986|Oocyte donor
143020|NCT02208973|Adenosine A1 receptor antagonist
143021|NCT02208973|adenosine receptor modulator
143022|NCT02208973|Asthma
143023|NCT02208973|COPD
143024|NCT02208960|Neurodevelopment
143025|NCT02208960|Neonatal kit
143026|NCT02208960|Kenya
143027|NCT02208960|Cluster Randomized Controlled Trial
143028|NCT02208960|Chlorhexidine
143029|NCT02208960|ThermoSpot
143030|NCT02208947|advance care planning
143031|NCT02208947|decision making
143032|NCT02208947|patient engagement
143033|NCT02208947|patient education
143034|NCT02208947|financial incentives
143035|NCT02208947|behavioral economics
143036|NCT02208934|PDE10 inhibitor
143037|NCT02208934|Huntington's disease
143038|NCT02208934|phosphodiesterase 10 inhibitor
143039|NCT02208934|psychiatric disorders
143040|NCT02208921|Type 2 Diabetes
143041|NCT02208908|Oral care
143042|NCT02208908|cancer
143043|NCT02208908|palliative
143044|NCT02208908|training
143045|NCT02208895|pleural
143046|NCT02208895|glucose
143047|NCT02208895|glucometer
143048|NCT02208895|i-STAT
143049|NCT02208869|familial hypercholesterolemia
143050|NCT02208869|cholesterol
143051|NCT02208869|prevention
143052|NCT02208869|registry
143053|NCT02208869|atherosclerosis
143054|NCT02208869|treatment
143055|NCT02208869|prevalence
143056|NCT02208830|bronchiectasis
143057|NCT02208830|functional capacity
143058|NCT02208830|lung functional
143059|NCT02208817|capillary refill
143060|NCT02208817|paediatric early warning score
143061|NCT02208817|photoplethysmography
143062|NCT02208804|Colorectal Cancer Liver Metastases
143063|NCT02208791|Kidney Transplantation
143064|NCT02208791|Graft Rejection
143065|NCT02208791|Immunossupression
143066|NCT02208778|Osteoarthritis
143067|NCT02208778|Chronic Pain
143068|NCT02208778|Pain relief
143069|NCT02208765|Coronary Circulation
143070|NCT02208765|Coronary Artery Disease
143071|NCT02208765|Myocardial perfusion imaging
143072|NCT02208765|Prognosis
143073|NCT02208752|rotator cuff tears
143074|NCT02208752|ultrasound measure
143075|NCT02208752|pain
143076|NCT02208752|range of motion
143077|NCT02208752|muscle force
143078|NCT02208739|Chronic periodontitis
143079|NCT02208739|periodontal pathogens
143080|NCT02208739|inflammatory mediators
143081|NCT02208739|Non surgical periodontal therapy
143082|NCT02208739|Oral hygiene instructions
143083|NCT02208739|Polymerase chain reaction
143084|NCT02208739|Elisa
143085|NCT02208726|anxiety
143086|NCT02208726|students
143087|NCT02208726|examinations
143088|NCT02208726|Homeopathy
143089|NCT02208713|FSHD muscle derived stem cell adipose derived mesenchymal stem cell intramuscular injection
143090|NCT02208687|Social Participation
143091|NCT02208687|Fatigue
143092|NCT02208687|Self-Management
143093|NCT02208687|Rehabilitation
143094|NCT02208687|Physical therapy
143095|NCT02208687|Occupational therapy
143096|NCT02208687|Group intervention
143097|NCT02208687|Exercise
143098|NCT02208674|chronic kidney disease
143099|NCT02208674|albuminuria
143100|NCT02208674|hypertension
143101|NCT02208674|dyslipidemia
143102|NCT02208674|cardiovascular disease
143103|NCT02208674|pragmatic trial
143104|NCT02208674|cluster randomized trial
143105|NCT02208661|Morquio A syndrome
143106|NCT02208661|Mucopolysaccharidosis IV A
143107|NCT02208661|Psychological health
143108|NCT02208648|coronary calcification
143109|NCT02208648|Computed Tomography
143110|NCT02208648|Coronary artery calcium
143111|NCT02208648|calcium scores
143112|NCT02208648|post-operative mortality
143113|NCT02208635|Zinc Absorption
143114|NCT02208635|Biofortification
143115|NCT02208635|Maize
143116|NCT02208635|Zambia
143117|NCT02208635|Stable isotopes of Zn
143118|NCT02208622|Zinc absorption
143119|NCT02208622|Iron Absorption
143120|NCT02208622|Whey Protein
143121|NCT02208622|Mexico
143122|NCT02208622|Stable isotopes
143123|NCT02208609|Zinc Absorption
143124|NCT02208609|Maize
143125|NCT02208609|Amaranth
143126|NCT02208609|Guatemala
143127|NCT02208609|Stable isotopes of Zn
143128|NCT02208583|Molecular phenotypic；CRPC; personalized treatment
143129|NCT02208570|Hypotension during anesthesia induction
143130|NCT02208557|Incisional hernia
143131|NCT02208557|prevention
143132|NCT02208557|laparotomy closure
143133|NCT02208557|absorbable mesh
143134|NCT02208544|Thyroid Nodule
143135|NCT02208544|Indeterminate Cytology
143136|NCT02208544|FDG-PET/CT
143137|NCT02208544|Diagnostic Thyroid Surgery
143138|NCT02208544|Efficacy
143139|NCT02208544|Cost-Effectiveness
143140|NCT02208544|Quality-of-Life
143141|NCT02208544|Thyroidectomy
143142|NCT02208531|Early Childhood Development (ECD)
143143|NCT02208531|Psychosocial stimulation
143144|NCT02208531|Malnutrition
143145|NCT02208531|Bangladesh
143146|NCT02208531|Scaling up ECD
143147|NCT02208518|Endoscopic Ultrasound elastography
143148|NCT02208518|Quantitative elastography
143149|NCT02208518|Qualitative elastography
143150|NCT02208518|Endoscopic Ultrasound
143151|NCT02208518|Elastography
143152|NCT02208492|Levetiracetam, Carabamazepine
143153|NCT02208479|cardiac surgery
143154|NCT02208479|diaphragm dysfunction
143155|NCT02208479|mechanical ventilation weaning
143156|NCT02208479|respiratory paralysis
143157|NCT02208479|muscle weakness
143158|NCT02208479|cardiac bypass
143159|NCT02208479|valvular surgery
143160|NCT02208479|respiratory insufficiency
143161|NCT02208466|repetitive transcranial magnetic stimulation
143162|NCT02208466|rTMS
143163|NCT02208466|TMS
143164|NCT02208466|fluoxetine
143165|NCT02208453|Massive Rotator Cuff Tear
143166|NCT02208453|Local anesthesia
143167|NCT02208453|Sub-acromial spacer
143168|NCT02208440|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff
143169|NCT02208427|isoniazid, LTBI, rifapentine, TST
143170|NCT02208414|Food Allergies
143171|NCT02208388|Computed tomography perfusion
143172|NCT02208388|Fractional flow reserve
143173|NCT02208375|Breast Cancer
143174|NCT02208375|Malignant Female Reproductive System Neoplasm
143175|NCT02208375|Recurrent endometrial cancer
143176|NCT02208375|Recurrent endometrial adenocarcinoma
143177|NCT02208375|Triple negative breast cancer
143178|NCT02208375|Ovarian cancer
143179|NCT02208375|Primary peritoneal cancer
143180|NCT02208375|Fallopian tube cancer
143181|NCT02208375|Olaparib
143182|NCT02208375|AZD2014
143183|NCT02208375|AZD5363
143184|NCT02208349|intubation, video laryngoscopy, direct laryngoscopy, prehospital, emergency medical services
143185|NCT02208323|Hypoxia
143186|NCT02208323|Respiratory Distress
143187|NCT02208310|Crohn's disease
143188|NCT02208310|Vitamin D deficiency
143189|NCT02208284|Single Ascending Dose
143190|NCT02208284|healthy subjects
143191|NCT02208284|Hyperlipidemia
143192|NCT02208284|Lipid Metabolism Disorders
143193|NCT02208284|Metabolic Diseases
143194|NCT02208271|tissue necrosis
143195|NCT02208271|metal on metal total hip
143196|NCT02208271|biomarker
143197|NCT02208258|fecal incontinence, consure medical, semi formed stool, stool management system
143198|NCT02208232|IOL rotation
143199|NCT02208219|Stroke
143200|NCT02208219|Paresis
143201|NCT02208219|Upper extremity
143202|NCT02208219|Motor deficits
143203|NCT02208219|Music Therapy
143204|NCT02208219|Neurorehabilitation
143205|NCT02208206|Neuropathic pain
143206|NCT02208206|Phenotype
143207|NCT02208206|Genotype
143208|NCT02208206|Biomarkers
143209|NCT02208206|HIV
143210|NCT02208206|Diabetes mellitus
143211|NCT02208206|Breast cancer
143212|NCT02208206|Genomics
143213|NCT02208206|Quantitative sensory testing
143214|NCT02208193|Alzheimer disease Art Healing gardens Discourse analysis
143215|NCT02208180|Return of results
143216|NCT02208180|Genomics
143217|NCT02208167|Antigen Expanded Specific T Cell Therapy
143218|NCT02208167|HXTC
143219|NCT02208167|Antiretroviral Therapy
143220|NCT02208167|Acute HIV infection
143221|NCT02208167|Chronic HIV infection
143222|NCT02208167|Leukapheresis
143223|NCT02208154|ICU acquired bacteraemia
143224|NCT02208154|colonization
143225|NCT02208154|decolonization
143226|NCT02208154|selective decontamination
143227|NCT02208154|multidrug resistant bacteria
143228|NCT02208141|children
143229|NCT02208141|obesity
143230|NCT02208141|adipose tissue dysfunction
143231|NCT02208141|inflammation
143232|NCT02208141|macrophage infiltration
143233|NCT02208141|insulin resistance
143234|NCT02208141|dyslipidemia
143235|NCT02208128|Renal cell carcinoma
143236|NCT02208128|Biomarkers
143237|NCT02208128|Molecular modifications
143238|NCT02208115|Type 1 Diabetes Mellitus
143239|NCT02208115|Exercise
143240|NCT02208115|Appetite
143241|NCT02208102|atrial fibrillation, catheter ablation, blood-biomarkers
143242|NCT02208089|Keratoconus
143243|NCT02208089|Corneal collagen cross-linking
143244|NCT02208089|Photorefractive keratectomy
143245|NCT02208076|Growth disorders
143246|NCT02208076|Saizen
143247|NCT02208076|Easypod
143248|NCT02208076|Growth hormone
143249|NCT02208076|Pediatric subject
143250|NCT02208063|Bacteremia
143251|NCT02208063|Staphylococcus aureus
143252|NCT02208050|Secondary Progressive Multiple Sclerosis
143253|NCT02208050|Primary Progressive Multiple Sclerosis
143254|NCT02208050|Multiple Sclerosis
143255|NCT02208050|Upper limb function
143256|NCT02208050|Mobility
143257|NCT02208050|Fampridine
143258|NCT02208050|DASH
143259|NCT02208050|AMSQ
143260|NCT02208050|MSWS-12
143261|NCT02208050|MSIS-29
143262|NCT02208050|SF-36
143263|NCT02208050|9HPT
143264|NCT02208050|25FTW
143265|NCT02208050|JTT
143266|NCT02208037|Acute Lymphoblastic Leukemia/Lymphoma
143267|NCT02208037|Acute Myelogenous Leukemia
143268|NCT02208037|Mantel-Cell Lymphoma
143269|NCT02208037|Hematopoietic Transplant
143270|NCT02208037|GVHD Prophylaxis
143271|NCT02207998|osteoarthritis, physiotherapy, homeopathy, complex
143272|NCT02207985|Pancreatic adenocarcinoma
143273|NCT02207985|Hematopoietic stem cell transplantation
143274|NCT02207972|Pregnant
143275|NCT02207972|labor
143276|NCT02207972|Epidural
143277|NCT02207959|Gastric cancer
143278|NCT02207959|Neoplasia
143279|NCT02207959|Endoscopic imaging
143280|NCT02207959|In vivo imaging
143281|NCT02207933|anterioposterior
143282|NCT02207933|weight
143283|NCT02207933|shifting
143284|NCT02207933|training
143285|NCT02207933|patient
143286|NCT02207894|Haemophilia A, factor VIII, development of inhibitor
143287|NCT02207881|herpes labialis
143288|NCT02207881|cold sore
143289|NCT02207829|COPD
143290|NCT02207829|inhaler critical errors
143291|NCT02207829|double-dummy
143292|NCT02207829|novel dry powder inhaler
143293|NCT02207829|inhaler preference
143294|NCT02207829|tiotropium
143295|NCT02207829|umeclidinium
143296|NCT02207829|long-acting muscarinic antagonist
143297|NCT02207816|Infants
143298|NCT02207816|Efficacy
143299|NCT02207816|Children
143300|NCT02207816|Malaria
143301|NCT02207816|Plasmodium falciparum
143302|NCT02207816|Safety
143303|NCT02207816|Surveillance
143304|NCT02207816|Immunogenicity
143305|NCT02207816|RTS,S/AS01E
143306|NCT02207816|Africa
143307|NCT02207803|Brain Injuries
143308|NCT02207803|Caregivers
143309|NCT02207803|Intervention Studies
143310|NCT02207803|Latin America
143311|NCT02207790|Clinical Trial, Phase I
143312|NCT02207790|Healthy Volunteers
143313|NCT02207777|Obesity
143314|NCT02207777|Roux-en-Y gastric bypass (RYGB)
143315|NCT02207777|Type 2 Diabetes
143316|NCT02207777|Sleeve Gastrectomy (SG)
143317|NCT02207777|Biliopancreatic Diversion with Duodenal switch (BPD)
143318|NCT02207777|Laparoscopic Adjustable Gastric Banding (LAGB)
143319|NCT02207751|Chronic Kidney Disease
143320|NCT02207751|Peritoneal Dialysis Access
143321|NCT02207751|Peritoneal Dialysis Catheter
143322|NCT02207751|Catheter Function
143323|NCT02207738|acne
143324|NCT02207738|acne scar
143325|NCT02207738|microneedling radiofrequency
143326|NCT02207738|bipolar radiofrequency
143327|NCT02207725|Andexanet alpha
143328|NCT02207725|Anticoagulation
143329|NCT02207725|Antidote
143330|NCT02207725|Apixaban
143331|NCT02207725|Anti-fXa inhibitor
143332|NCT02207725|PRT4445
143333|NCT02207725|Eliquis
143334|NCT02207725|Reversal agent
143335|NCT02207712|Diabetes
143336|NCT02207712|Macular Oedema
143337|NCT02207712|Diabetic retinopathy
143338|NCT02207712|Noctura
143339|NCT02207686|CNS hemangioblastoma
143340|NCT02207686|Renal Cell Carcinoma
143341|NCT02207686|VHL germline mutation
143342|NCT02207686|VHL somatic mutation
143343|NCT02207686|Tumor development
143344|NCT02207673|epilepsy surgery
143345|NCT02207673|biomarker
143346|NCT02207673|high frequency oscillations (HFOs)
143347|NCT02207673|acute electrocorticography (aECoG)
143348|NCT02207660|cisplatin
143349|NCT02207660|Cervical cancer
143350|NCT02207660|metastasis
143351|NCT02207660|recurrence
143352|NCT02207634|High cholesterol
143353|NCT02207634|Treatment for high cholesterol
143354|NCT02207634|Lowering cholesterol
143355|NCT02207634|Lowering high cholesterol
143356|NCT02207634|Hypercholesterolemia
143357|NCT02207621|Glaucoma
143358|NCT02207608|BCG
143359|NCT02207608|hyaluronic acid
143360|NCT02207608|non-muscle invasive bladder cancer
143361|NCT02207608|non bacterial cystitis
143362|NCT02207582|depression; trns
143363|NCT02207556|AL amyloidosis
143364|NCT02207556|amyloidosis
143365|NCT02207556|light chain amyloidosis
143366|NCT02207543|Cancer
143367|NCT02207543|Palliative care
143368|NCT02207543|home
143369|NCT02207530|Head and neck cancer; SCCHN
143370|NCT02207517|convergence insufficiency
143371|NCT02207517|vision therapy
143372|NCT02207517|reading
143373|NCT02207517|attention
143374|NCT02207504|Castration-resistant Prostate Cancer
143375|NCT02207491|Glaucoma
143376|NCT02207478|Electromagnetic navigation bronchoscopy with a guide sheath
143377|NCT02207478|Transbronchial lung biopsy
143378|NCT02207478|Peripheral lung lesions
143379|NCT02207478|Solitary pulmonary nodule
143380|NCT02207452|Hyperpolarised helium-3
143381|NCT02207452|Lung Imaging
143382|NCT02207452|Magnetic Resonance Imaging
143383|NCT02207426|Healthy volunteers
143384|NCT02207413|Quadrivalent influenza vaccine
143385|NCT02207413|Safety
143386|NCT02207413|Children
143387|NCT02207413|Adults
143388|NCT02207413|Immunogenicity
143389|NCT02207322|Hematopoietic stem cell transplantation (HSCT)
143390|NCT02207322|autologous stem cell transplant
143391|NCT02207322|allogeneic stem cell transplant
143392|NCT02207309|high-risk soft tissue sarcoma
143393|NCT02207309|pazopanib
143394|NCT02207309|retroperitoneal soft tissue sarcoma
143395|NCT02207309|visceral soft tissue sarcoma
143396|NCT02207309|votrient
143397|NCT02207270|Angina
143398|NCT02207270|Coronary artery disease
143399|NCT02207270|Costs
143400|NCT02207270|Cost minimization
143401|NCT02207270|Percutaneous coronary intervention
143402|NCT02207270|Randomized trial
143403|NCT02207270|Risk score
143404|NCT02207270|Same day discharge
143405|NCT02207270|Unstable angina
143406|NCT02207257|PER977
143407|NCT02207257|anticoagulation reversal
143408|NCT02207257|pharmacokinetics
143409|NCT02207257|edoxaban
143410|NCT02207257|whole blood clotting time
143411|NCT02207257|D-dimer
143412|NCT02207257|prothrombin fragments 1 and 2
143413|NCT02207257|tissue factor pathway inhibitor
143414|NCT02207257|prothrombin time
143415|NCT02207244|Psoriasis
143416|NCT02207244|Plaque-type psoriasis
143417|NCT02207244|Guselkumab
143418|NCT02207244|Adalimumab
143419|NCT02207244|CNTO 1959
143420|NCT02207244|Monoclonal antibody
143421|NCT02207231|Psoriasis
143422|NCT02207231|Plaque-type psoriasis
143423|NCT02207231|Guselkumab
143424|NCT02207231|Adalimumab
143425|NCT02207231|CNTO 1959
143426|NCT02207231|Monoclonal antibody
143427|NCT02207192|obesity, lung volumes, postural changes
143428|NCT02207179|Intraoperative
143429|NCT02207179|Cancer margin
143430|NCT02207179|Spectroscopy
143431|NCT02207179|Polarization
143432|NCT02207166|hypertension
143433|NCT02207166|device
143434|NCT02207166|errors
143435|NCT02207166|human factor engineering
143436|NCT02207166|usability engineering
143437|NCT02207153|Chronic Hemodialysis
143438|NCT02207153|Chronic Peritoneal Dialysis
143439|NCT02207127|obstructive sleep apnea
143440|NCT02207127|sleep apnea
143441|NCT02207114|Sepsis, SIRS, antibiotic use, intensive care unit
143442|NCT02207101|Young athletes
143443|NCT02207101|Cardiac endurance
143444|NCT02207101|Herbal
143445|NCT02207101|Ejection Fraction
143446|NCT02207101|Basic Research
143447|NCT02207101|Cardiovascular Injury
143448|NCT02207088|Compensated Cirrhosis
143449|NCT02207088|dialysis
143450|NCT02207088|Hepatitis C Virus
143451|NCT02207088|Severe Renal Impairment
143452|NCT02207088|Renal impairment
143453|NCT02207088|cirrhosis
143454|NCT02207088|Chronic Hepatitis C
143455|NCT02207088|Hepatitis C
143456|NCT02207088|End-stage renal disease
143457|NCT02207088|Hepatitis C Genotype 1
143458|NCT02207088|renal disease
143459|NCT02207075|SPMS
143460|NCT02207075|Myelin Water Fraction
143461|NCT02207075|activated microglia
143462|NCT02207036|Tobacco
143463|NCT02207036|cigarettes
143464|NCT02207036|cessation
143465|NCT02207036|intervention
143466|NCT02207036|young adults
143467|NCT02207036|Internet
143468|NCT02207036|social media
143469|NCT02207036|mobile health
143470|NCT02207023|Stroke
143471|NCT02207023|Telehealth
143472|NCT02207023|Rehabilitation
143473|NCT02207023|Stroke Coach
143474|NCT02207023|Randomized controlled trial
143475|NCT02207023|Lifestyle behaviours
143476|NCT02207023|Secondary prevention
143477|NCT02207023|Chronic disease self-management
143478|NCT02207010|Glioblastoma
143479|NCT02207010|GBM
143480|NCT02207010|first recurrence
143481|NCT02206997|perioperative hypothermia
143482|NCT02206997|prewarming
143483|NCT02206997|treatment guideline
143484|NCT02206958|Toileting disability
143485|NCT02206958|Functional urinary incontinence
143486|NCT02206958|Urinary incontinence
143487|NCT02206958|Frailty
143488|NCT02206958|Physical activity
143489|NCT02206932|Hepatitis C
143490|NCT02206932|HIV
143491|NCT02206932|Simeprevir
143492|NCT02206932|Sofosbuvir
143493|NCT02206919|Flow mediated dilation
143494|NCT02206919|Magnetic Resonance Imaging MRI
143495|NCT02206919|Diabetes
143496|NCT02206919|Endothelial dysfunction
143497|NCT02206919|Popliteal artery
143498|NCT02206919|Atherosclerosis
143499|NCT02206919|Cardiovascular disease
143500|NCT02206919|Vascular disease
143501|NCT02206906|Medication Adherence
143502|NCT02206906|Incentives
143503|NCT02206906|Real-time Medication Monitoring
143504|NCT02206880|Thoracic Surgery
143505|NCT02206880|Delirium
143506|NCT02206880|Cardiopulmonary Bypass
143507|NCT02206880|Intensive Care
143508|NCT02206854|Pharmakokinetic
143509|NCT02206854|capsules
143510|NCT02206854|R-Flurbiprofen
143511|NCT02206841|fibrosis
143512|NCT02206841|markers
143513|NCT02206828|HERNIA
143514|NCT02206828|SYMCHRO
143515|NCT02206828|SOFRADIM
143516|NCT02206828|REGISTRY
143517|NCT02206828|SYMBOTEX
143518|NCT02206802|Alopecia
143519|NCT02206802|Androgenetic Alopecia
143520|NCT02206802|Female Pattern Hair Loss
143521|NCT02206802|Hair Loss
143522|NCT02206802|Minoxidil
143523|NCT02206802|Hair Thinning
143524|NCT02206776|OCD
143525|NCT02206750|Controlled Human exposure study
143526|NCT02206750|Air Pollution
143527|NCT02206750|Cardiovascular
143528|NCT02206750|Social factors
143529|NCT02206750|Cognitive function
143530|NCT02206724|Metastatic prostate cancer
143531|NCT02206698|Intraabdominal Injury
143532|NCT02206698|CT Abdomen and Pelvis
143533|NCT02206698|Pediatric trauma
143534|NCT02206698|blunt abdominal injury
143535|NCT02206698|blunt trauma
143536|NCT02206698|clinical prediction model
143537|NCT02206633|dehydration
143538|NCT02206607|Phase 1
143539|NCT02206607|bioavailability
143540|NCT02206607|type 2 diabetes mellitus
143541|NCT02206607|PF-04937319
143542|NCT02206581|dehydration
143543|NCT02206568|diabetes mellitus
143544|NCT02206568|phase 1
143545|NCT02206568|insulin lispro
143546|NCT02206568|male subjects
143547|NCT02206555|HIV
143548|NCT02206555|prevention
143549|NCT02206555|prophylaxis
143550|NCT02206555|antiretroviral
143551|NCT02206555|biomedical
143552|NCT02206555|bio-behavioural
143553|NCT02206555|evaluation
143554|NCT02206555|demonstration study
143555|NCT02206542|acupuncture,frozen shoulder,robot,sonography,MRI
143556|NCT02206529|obesity
143557|NCT02206529|child
143558|NCT02206529|weight management
143559|NCT02206529|behavioral
143560|NCT02206529|social networks
143561|NCT02206529|social support
143562|NCT02206503|LENALIDOMIDE
143563|NCT02206503|BIOCHEMICAL PROGRESSION
143564|NCT02206503|RELAPSED/REFRACTORY MM
143565|NCT02206503|WITHOUT CRAB
143566|NCT02206490|Gulf War Illness
143567|NCT02206490|treatment
143568|NCT02206490|dextromethorphan
143569|NCT02206490|naltrexone
143570|NCT02206477|breast capsular contructure
143571|NCT02206477|dimethyl sulfoxide
143572|NCT02206477|radiotherapy
143573|NCT02206477|breast reconstruction
143574|NCT02206464|A/Anhui/1/2013 (H7N9)
143575|NCT02206464|Antibody Response
143576|NCT02206464|Avian Influenza
143577|NCT02206464|A/Shanghai/2/2013 (H7N9)
143578|NCT02206464|Immunogenicity
143579|NCT02206451|Assay
143580|NCT02206451|Infection
143581|NCT02206451|Direct Skin Feed
143582|NCT02206451|Midgut
143583|NCT02206451|Parasite
143584|NCT02206438|supraglottic airway devices
143585|NCT02206438|the classic laryngeal mask airway
143586|NCT02206438|the self-pressurised air-Q intubating laryngeal airway in adult patients
143587|NCT02206438|elective surgery of short duration (less than 2 hr) undergoing general anesthesia using supraglottic airway in adult patients
143588|NCT02206425|multiple myeloma
143589|NCT02206425|Relapsed/refractory
143590|NCT02206425|Ixazomib
143591|NCT02206425|Proteasome inhibitor
143592|NCT02206425|Oral
143593|NCT02206412|high mobility group box 1
143594|NCT02206412|prognostic biomarker
143595|NCT02206412|off-pump coronary artery bypass graft
143596|NCT02206412|patients
143597|NCT02206373|creatinine
143598|NCT02206373|glomerular filtration rate
143599|NCT02206373|renal insufficiency, chronic
143600|NCT02206360|Pancreatic Cancer
143601|NCT02206360|Pancreatic Cancer Screening
143602|NCT02206360|Pancreas Cancer
143603|NCT02206360|Pancreatic Adenocarcinoma
143604|NCT02206360|Pancreatic Adenocarcinoma screening
143605|NCT02206360|Familial Pancreatic Cancer
143606|NCT02206360|BRCA 1/2
143607|NCT02206360|HNPCC
143608|NCT02206360|Lynch Syndrome
143609|NCT02206360|Hereditary Pancreatitis
143610|NCT02206360|FAMMM
143611|NCT02206360|Familial atypical multiple mole melanoma
143612|NCT02206360|Peutz Jeghers Syndrome
143613|NCT02206360|MRI
143614|NCT02206360|Magnetic Resonance Imaging
143615|NCT02206360|EUS
143616|NCT02206360|Endoscopic Ultrasound
143617|NCT02206360|Early detection
143618|NCT02206360|Screening
143619|NCT02206308|Chimeric anti-CD20 monoclonal antibody(SCT400)
143620|NCT02206308|escalating doses
143621|NCT02206308|safety
143622|NCT02206308|pharmacokinetics and pharmacodynamics
143623|NCT02206295|selexipag
143624|NCT02206295|ACT-333679
143625|NCT02206243|Benign prostatic hyperplasia
143626|NCT02206243|BPH
143627|NCT02206230|glioblastoma
143628|NCT02206230|radiotherapy
143629|NCT02206230|hypofractionated radiotherapy
143630|NCT02206204|Selexipag
143631|NCT02206204|ACT-333679
143632|NCT02206152|Diabetes
143633|NCT02206152|Hypoglycemia
143634|NCT02206152|Unawareness
143635|NCT02206152|HAAF
143636|NCT02206126|Obstructive sleep apnea
143637|NCT02206126|Weight loss
143638|NCT02206126|Obesity
143639|NCT02206126|Sympathetic activity
143640|NCT02206126|Metabolic profile
143641|NCT02206126|Endothelial function
143642|NCT02206113|Standing workstation
143643|NCT02206100|PER977
143644|NCT02206100|enoxaparin
143645|NCT02206100|anticoagulation reversal
143646|NCT02206100|whole blood clotting time
143647|NCT02206087|PER977
143648|NCT02206087|heparin
143649|NCT02206087|anticoagulation reversal
143650|NCT02206087|whole blood clotting time
143651|NCT02206048|Cervix Carcinoma
143652|NCT02206048|Cervical adenocarcinoma in situ
143653|NCT02206048|AIS
143654|NCT02206048|Cervical intraepithelial neoplasia
143655|NCT02206048|CIN
143656|NCT02206048|microinvasive carcinoma of the cervix
143657|NCT02206048|cold knife cone of the cervix
143658|NCT02206048|CKC
143659|NCT02206048|High-Resolution Microendoscopy
143660|NCT02206048|HRME
143661|NCT02206048|Proflavine
143662|NCT02206022|Central Venous Catheter
143663|NCT02206022|Remifentanil
143664|NCT02206022|local anesthesia
143665|NCT02206022|pain
143666|NCT02205996|Type 2 diabetes
143667|NCT02205996|Hypoglycaemia
143668|NCT02205996|Platelets
143669|NCT02205996|Inflammation
143670|NCT02205983|enrolling
143671|NCT02205983|adult
143672|NCT02205983|volunteers
143673|NCT02205970|TENS
143674|NCT02205970|Dysmenorrhea
143675|NCT02205970|analgesia
143676|NCT02205970|interactive
143677|NCT02205957|anesthesiology and intensive care, quality, training
143678|NCT02205944|chronic kidney disease
143679|NCT02205944|hemodialysis
143680|NCT02205944|vascular access
143681|NCT02205944|arteriovenous fistula
143682|NCT02205944|forearm exercise
143683|NCT02205931|Epilepsy
143684|NCT02205931|Ketogenic diet
143685|NCT02205931|Antiepileptic drugs
143686|NCT02205931|Randomised controlled trial
143687|NCT02205905|PER977
143688|NCT02205905|metabolic disposition
143689|NCT02205905|mass balance
143690|NCT02205905|metabolites
143691|NCT02205905|radiolabeled
143692|NCT02205892|natural product
143693|NCT02205892|clinical trial
143694|NCT02205879|pregabalin
143695|NCT02205879|patients
143696|NCT02205879|treatment
143697|NCT02205853|Oncology Service Hospital
143698|NCT02205853|Patient-centred
143699|NCT02205853|Exercise
143700|NCT02205853|Neoplasms
143701|NCT02205853|Rehabilitation
143702|NCT02205853|Qualitative Research
143703|NCT02205853|Health Plan Implementation
143704|NCT02205853|Quality of Health Care
143705|NCT02205853|Guidelines
143706|NCT02205853|Quality of Life
143707|NCT02205827|whole blood clotting time
143708|NCT02205814|Osteoarthritis, Knee
143709|NCT02205814|Arthritis
143710|NCT02205814|WOMAC
143711|NCT02205814|Injections, intra-articular
143712|NCT02205814|Fasitibant
143713|NCT02205814|MEN 16132
143714|NCT02205762|Langerhans cell histiocytosis
143715|NCT02205749|biobanks
143716|NCT02205749|informed consent
143717|NCT02205749|health literacy
143718|NCT02205736|Breast health education
143719|NCT02205736|Latino women
143720|NCT02205736|Group education
143721|NCT02205736|Breast cancer
143722|NCT02205723|Asthma
143723|NCT02205723|Asthma exacerbations
143724|NCT02205723|Pediatric
143725|NCT02205697|Fruit
143726|NCT02205697|Vegetable
143727|NCT02205684|Physical activity
143728|NCT02205684|Exercise
143729|NCT02205684|High intensity training
143730|NCT02205684|Schizophrenia
143731|NCT02205684|Symptoms
143732|NCT02205684|Well-being
143733|NCT02205684|Cognition
143734|NCT02205684|Hippocampal volume
143735|NCT02205684|Neuroplasticity
143736|NCT02205684|Smoking
143737|NCT02205684|Substance use
143738|NCT02205684|Metabolic indices
143739|NCT02205671|caregiving
143740|NCT02205671|chronic illness
143741|NCT02205671|patient education
143742|NCT02205671|self management
143743|NCT02205658|Sensory Processing
143744|NCT02205658|Autism
143745|NCT02205645|medial
143746|NCT02205645|meniscus
143747|NCT02205645|scaffold
143748|NCT02205645|repair
143749|NCT02205645|tear
143750|NCT02205645|injury
143751|NCT02205619|Residual cementum
143752|NCT02205619|root surface instrumentation
143753|NCT02205619|ultrasonic scaling
143754|NCT02205619|air polishing with glycine
143755|NCT02205593|psoriasis
143756|NCT02205593|atopic dermatitis
143757|NCT02205593|eczema
143758|NCT02205593|patient education
143759|NCT02205593|stress reduction
143760|NCT02205593|quality of life
143761|NCT02205554|Analgesia
143762|NCT02205554|Pharmacokinetics
143763|NCT02205554|Treatment
143764|NCT02205541|Eculizumab
143765|NCT02205541|Shiga-toxin
143766|NCT02205541|hemolytic and uremic syndrome
143767|NCT02205541|pediatric
143768|NCT02205476|Phase 2
143769|NCT02205476|open-label
143770|NCT02205476|safety
143771|NCT02205476|hypertrophic scar revision surgery
143772|NCT02205463|Esophagus
143773|NCT02205463|Gastroesophageal Junction
143774|NCT02205463|Stomach
143775|NCT02205463|Gastric
143776|NCT02205463|Cancer
143777|NCT02205463|HER2
143778|NCT02205463|Metastatic
143779|NCT02205463|Adenocarcinoma
143780|NCT02205450|Prader-Willi Syndrome
143781|NCT02205450|Growth Hormone
143782|NCT02205450|Children
143783|NCT02205437|Schizophrenia
143784|NCT02205437|Psychosis
143785|NCT02205437|Antipsychotics
143786|NCT02205437|Treatment response
143787|NCT02205437|Metabolic side effects
143788|NCT02205437|Gene expression
143789|NCT02205437|RNA
143790|NCT02205437|Genes
143791|NCT02205424|Ischaemic stroke
143792|NCT02205424|Alzheimer's disease
143793|NCT02205424|Brain volume
143794|NCT02205424|Cortical thickness
143795|NCT02205424|Magnetic Resonance Imaging
143796|NCT02205411|heart assist device
143797|NCT02205411|ventricular assist device
143798|NCT02205398|INC280
143799|NCT02205398|c-MET inhibitor
143800|NCT02205398|cetuximab
143801|NCT02205398|metastatic colorectal cancer
143802|NCT02205398|head and neck
143803|NCT02205398|squamous cell carcinoma
143804|NCT02205398|resistance to cetuximab/panitumumab
143805|NCT02205385|Neuroma
143806|NCT02205385|Amputee
143807|NCT02205385|Amputation Stump
143808|NCT02205385|Assessment, Pain
143809|NCT02205372|Diabetic Nephropathy
143810|NCT02205359|AdaptivCRT
143811|NCT02205359|aCRT
143812|NCT02205346|obstructive sleep apnea
143813|NCT02205333|Advanced Solid tumors
143814|NCT02205333|Diffuse Large B-cell Lymphoma
143815|NCT02205333|programmed death 1
143816|NCT02205333|programmed dealth ligand 1
143817|NCT02205333|cytotoxic T-lymphocyte-associated antigen-4
143818|NCT02205333|OX40 ligand
143819|NCT02205320|Pegfilgrastim
143820|NCT02205320|Pharmacokinetics
143821|NCT02205320|Pharmacodynamics
143822|NCT02205320|Healthy volunteers
143823|NCT02205307|Rectal cancer
143824|NCT02205307|Rectal neoplasm
143825|NCT02205307|Colorectal surgery
143826|NCT02205307|Anastomosis
143827|NCT02205294|Osteopathic treatment
143828|NCT02205294|Deep Vein Thrombosis
143829|NCT02205294|Proximal Leg DVT
143830|NCT02205281|Overweight
143831|NCT02205281|Obese
143832|NCT02205281|Pregnancy
143833|NCT02205281|Weight Gain
143834|NCT02205281|Weight Loss
143835|NCT02205268|Attention Deficit Disorder with Hyperactivity
143836|NCT02205268|Attention Deficit Hyperactivity Disorder
143837|NCT02205268|Biofeedback
143838|NCT02205268|Neurofeedback Training
143839|NCT02205268|Prefrontal Cortex
143840|NCT02205268|Near infrared spectroscopy
143841|NCT02205255|AECOPD
143842|NCT02205255|Chronic Obstructive Pulmonary Disease
143843|NCT02205255|Acute exacerbation
143844|NCT02205255|Hospitalization
143845|NCT02205255|Azithromycin
143846|NCT02205255|Macrolides
143847|NCT02205255|Randomized Controlled Trial
143848|NCT02205255|Placebo
143849|NCT02205255|Economic Impact
143850|NCT02205255|Cost-effectiveness
143851|NCT02205255|EQ5D
143852|NCT02205242|AECOPD
143853|NCT02205242|Chronic Obstructive Pulmonary Disease
143854|NCT02205242|Acute exacerbation
143855|NCT02205242|Hospitalization
143856|NCT02205242|Azithromycin
143857|NCT02205242|Macrolides
143858|NCT02205242|Randomized Controlled Trial
143859|NCT02205242|Placebo
143860|NCT02205242|Physical Activity
143861|NCT02205242|PRO-Active
143862|NCT02205242|Activity Monitor
143863|NCT02205216|tDCS
143864|NCT02205216|FOG
143865|NCT02205216|Freezing of Gait
143866|NCT02205216|Parkinson
143867|NCT02205216|Rehabilitation
143868|NCT02205203|Anxiety
143869|NCT02205203|Social Anxiety
143870|NCT02205203|Social Phobia
143871|NCT02205203|Separation Anxiety
143872|NCT02205203|Generalized Anxiety
143873|NCT02205203|GAD
143874|NCT02205203|Phobia
143875|NCT02205203|Panic
143876|NCT02205203|Agoraphobia
143877|NCT02205203|Obsessive Compulsive Disorder
143878|NCT02205203|OCD
143879|NCT02205203|Child
143880|NCT02205203|Adolescent
143881|NCT02205203|Smartphone
143882|NCT02205203|Teen
143883|NCT02205203|Youth
143884|NCT02205190|Fimasartan
143885|NCT02205177|Anxiety
143886|NCT02205177|Social Anxiety
143887|NCT02205177|Social Phobia
143888|NCT02205177|Separation Anxiety
143889|NCT02205177|Generalized Anxiety
143890|NCT02205177|GAD
143891|NCT02205177|Phobia
143892|NCT02205177|Panic
143893|NCT02205177|Agoraphobia
143894|NCT02205177|Obsessive Compulsive Disorder
143895|NCT02205177|OCD
143896|NCT02205177|Child
143897|NCT02205177|Adolescent
143898|NCT02205177|Smartphone
143899|NCT02205177|Teen
143900|NCT02205177|Youth
143901|NCT02205164|palonosetron
143902|NCT02205164|aprepitant
143903|NCT02205164|CINV
143904|NCT02205164|AML
143905|NCT02205164|multiple-days
143906|NCT02205151|Fimasartan
143907|NCT02205138|Spinal Fusion
143908|NCT02205138|Lumbar Interbody Fusion
143909|NCT02205138|Degenerative Disc Disease
143910|NCT02205138|Cell Therapy
143911|NCT02205138|Bone Graft
143912|NCT02205125|polyp
143913|NCT02205125|colon
143914|NCT02205125|polypectomy
143915|NCT02205125|snare
143916|NCT02205112|intravenous nemonoxacin
143917|NCT02205112|community-acquired pneumonia
143918|NCT02205099|Schizophrenia
143919|NCT02205047|Neoadjuvant chemotherapy
143920|NCT02205034|Prader Willi
143921|NCT02205008|advanced gastric cancer
143922|NCT02205008|serosal invasion
143923|NCT02205008|peritoneal recurrence
143924|NCT02205008|intraperitoneal chemotherapy
143925|NCT02204995|Osteoarthritis
143926|NCT02204995|Thumb
143927|NCT02204995|LRTI
143928|NCT02204995|Trapeziectomy
143929|NCT02204982|Phase 3, Follicular Lymphoma, FL, PI3K
143930|NCT02204956|Smoking cessation
143931|NCT02204956|Tobacco use cessation
143932|NCT02204956|Psychiatric comorbidity
143933|NCT02204930|Haemostat
143934|NCT02204930|Liver surgery
143935|NCT02204930|Primary liver cancer
143936|NCT02204930|Metastatic liver cancer
143937|NCT02204930|Benign liver disease such as adenoma
143938|NCT02204930|Hepatitis-related or alcoholic-related liver cirrhosis
143939|NCT02204930|Living donation for liver transplant
143940|NCT02204917|Ultrasound
143941|NCT02204917|Ultrasound Contrast Agents
143942|NCT02204917|Optison
143943|NCT02204917|contrast enhanced Voiding Urosonography
143944|NCT02204917|ceVUS
143945|NCT02204917|Vesicoureteral Reflux
143946|NCT02204917|Children
143947|NCT02204917|Kidney
143948|NCT02204917|Bladder
143949|NCT02204917|Urethra
143950|NCT02204917|Voiding Cystourethrography
143951|NCT02204917|VCUG
143952|NCT02204917|Safety
143953|NCT02204917|Urinary tract
143954|NCT02204904|X-linked Adrenoleukodystrophy
143955|NCT02204904|Hematopoietic Stem Cells
143956|NCT02204891|Abdominal pain
143957|NCT02204891|Abdominal discomfort
143958|NCT02204891|Flatulence
143959|NCT02204891|Diarrhea
143960|NCT02204891|Bacterial overgrowth
143961|NCT02204891|Cytokines
143962|NCT02204865|Sleep-Disordered Breathing
143963|NCT02204865|Sleep Apnoea
143964|NCT02204865|Heart failure
143965|NCT02204839|T1DM, Exercise, Hypoglycaemia
143966|NCT02204826|Effects of Korean Red Ginseng on semen parameters in male infertility patients: a randomized, placebo-controlled, double-blind clinical study
143967|NCT02204813|Gastric Bypass
143968|NCT02204813|RYGB
143969|NCT02204813|GLP-1
143970|NCT02204813|Xenin
143971|NCT02204813|Insulin Secretion
143972|NCT02204813|Glucose Homeostasis
143973|NCT02204813|Vertical Sleeve
143974|NCT02204813|Lap Band
143975|NCT02204800|Tumor growth rate in maximal dimension, biomarker assessment based on driver gene alterations (specifically CRG)
143976|NCT02204774|aortic aneurysm
143977|NCT02204774|obstructive sleep apnea
143978|NCT02204735|Meal Time
143979|NCT02204735|Weight Loss
143980|NCT02204735|Circadian Rhythm
143981|NCT02204709|obese
143982|NCT02204709|obesity
143983|NCT02204709|metabolic syndrome
143984|NCT02204709|omega-3 fatty acids
143985|NCT02204709|fish
143986|NCT02204696|sleep apnea
143987|NCT02204696|obstructive sleep apnea
143988|NCT02204696|sleepiness
143989|NCT02204696|quality of life
143990|NCT02204683|AMD
143991|NCT02204683|Neovascularization
143992|NCT02204683|macular degeneration
143993|NCT02204683|wet macular degeneration
143994|NCT02204683|vitrectomy
143995|NCT02204670|Irisin
143996|NCT02204670|Obesity
143997|NCT02204670|Exercise
143998|NCT02204670|Myokine
143999|NCT02204670|Impaired Glucose Tolerance
144000|NCT02204657|Continuous glucose monitoring in GDM
144001|NCT02204631|Head and Neck Cancer
144002|NCT02204618|single sided deafness
144003|NCT02204618|Asymmetrical hearing loss
144004|NCT02204618|Cost-utility
144005|NCT02204618|Tinnitus
144006|NCT02204618|Cochlear implants
144007|NCT02204618|Bone conduction device
144008|NCT02204618|Dichotic hearing
144009|NCT02204618|Squelch effect.
144010|NCT02204605|patients
144011|NCT02204605|puzzling
144012|NCT02204605|conditions
144013|NCT02204579|Autosomal Dominant Hypocalcemia
144014|NCT02204579|Hypocalcemia
144015|NCT02204579|ADH
144016|NCT02204579|Hypoparathyroidism
144017|NCT02204566|OFDI
144018|NCT02204566|RF Ablation
144019|NCT02204566|Atrial Fibrillation
144020|NCT02204566|Imaging
144021|NCT02204566|Esophagus
144022|NCT02204553|Multiple Myeloma
144023|NCT02204553|Panobinostat
144024|NCT02204553|LBH589
144025|NCT02204553|Expanded Access
144026|NCT02204553|EAP, ETP
144027|NCT02204553|Expanded Treatment
144028|NCT02204553|Bortezomib
144029|NCT02204553|HDAC
144030|NCT02204553|histone deacetylace inhibitor
144031|NCT02204540|Webcams, video monitoring, compliance, adherence
144032|NCT02204527|hypertension
144033|NCT02204527|diabetes mellitus
144034|NCT02204527|vitamin D
144035|NCT02204501|Aviragen Therapeutics, Inc.
144036|NCT02204501|Aviragen Therapeutics
144037|NCT02204501|Aviragen
144038|NCT02204488|Osteoarthritis
144039|NCT02204488|Thumb
144040|NCT02204488|Total joint arthroplasty
144041|NCT02204488|Trapeziectomy
144042|NCT02204462|PET
144043|NCT02204462|Positron Emission Tomography
144044|NCT02204462|Breast Cancer
144045|NCT02204462|Imaging
144046|NCT02204449|cardiac rehabilitation
144047|NCT02204449|peer mentorship
144048|NCT02204449|healthcare utilization
144049|NCT02204449|continuity of cardiac care
144050|NCT02204436|hyperpigmentation
144051|NCT02204436|depigmenting treatment
144052|NCT02204436|hand
144053|NCT02204423|Upper extremity dysfunction
144054|NCT02204423|Trans-Radial Percutaneous Coronary Interventions
144055|NCT02204410|ADHD
144056|NCT02204410|Attention Deficit Hyperactivity Disorder
144057|NCT02204410|DESR
144058|NCT02204410|Deficient Emotional Self-Regulation
144059|NCT02204410|Emotional Dysregulation
144060|NCT02204410|Omega-3 Fatty Acids
144061|NCT02204410|Fish Oil
144062|NCT02204397|Type 1 Diabetes mellitus
144063|NCT02204397|INGAP
144064|NCT02204397|Ustekinumab
144065|NCT02204384|Dietary fiber
144066|NCT02204384|Dietary Supplements
144067|NCT02204384|Type 2 diabetes
144068|NCT02204384|Postprandial Period
144069|NCT02204384|Plasma insulin
144070|NCT02204384|Plasma glucose
144071|NCT02204384|Area Under Curve
144072|NCT02204384|Soluble fiber
144073|NCT02204371|Pazopanib
144074|NCT02204371|hereditary haemorrhagic telangiectasia
144075|NCT02204371|bleeding
144076|NCT02204319|provoked or non-provoked vulvar vestibulitis
144077|NCT02204319|low level laser light device
144078|NCT02204293|Adult-Onset Still´s Disease
144079|NCT02204293|Canakinumab
144080|NCT02204293|Joint involvement
144081|NCT02204293|AOSD
144082|NCT02204280|UbA52;diabetic nephropathy ;diabetic;ELISA
144083|NCT02204267|Stroke
144084|NCT02204267|atrial fibrillation
144085|NCT02204267|ECG
144086|NCT02204241|Multiple myeloma
144087|NCT02204241|Diagnosis
144088|NCT02204241|CCyd
144089|NCT02204228|osteoarthritis
144090|NCT02204228|rheumatoid arthritis
144091|NCT02204228|post traumatic arthritis
144092|NCT02204228|avascular necrosis
144093|NCT02204228|severe fractures
144094|NCT02204215|Weakness
144095|NCT02204215|Mechanical Ventilation
144096|NCT02204215|Acupuncture Therapy
144097|NCT02204202|acute lung transplant rejection
144098|NCT02204202|neutrophilic lung inflammation
144099|NCT02204202|positron emission tomography imaging
144100|NCT02204202|[18F] fluorodeoxyglucose
144101|NCT02204202|[18F] ISO-1
144102|NCT02204189|acute pancreatitis
144103|NCT02204189|gastrointestinal dysfunction
144104|NCT02204189|TongFuSan
144105|NCT02204189|ShenQue acupoint
144106|NCT02204150|Optical Coherence Tomography
144107|NCT02204150|Barrett's Esophagus
144108|NCT02204150|Esophagus
144109|NCT02204150|Imaging
144110|NCT02204124|Whipple procedure
144111|NCT02204111|Palliative Treatment
144112|NCT02204111|Trabectedin
144113|NCT02204111|Patient Reported Outcome
144114|NCT02204085|Refractory acute myeloid leukemia
144115|NCT02204085|Relapsed acute myeloid leukemia
144116|NCT02204020|Acute Myeloid Leukemia (AML)
144117|NCT02204020|Myelodysplastic Syndrome (MDS)
144118|NCT02204020|allogeneic
144119|NCT02204020|5-azacytidine (5-aza)
144120|NCT02204020|hematopoietic
144121|NCT02204020|transplantation
144122|NCT02204020|transplant
144123|NCT02204020|graft-versus-tumor
144124|NCT02204020|graft-versus-host disease (GVHD)
144125|NCT02204020|epigenetic
144126|NCT02204020|maintenance
144127|NCT02204020|hypomethylation
144128|NCT02204020|relapse
144129|NCT02204007|Acetabular Shell
144130|NCT02204007|Total Hip Arthroplasty
144131|NCT02204007|3D imaging
144132|NCT02203994|extracorporal shock wave therapy (ESWT)
144133|NCT02203994|spasticity
144134|NCT02203994|spinal cord injury
144135|NCT02203981|normal Eyes
144136|NCT02203968|Fibrinogen replacement
144137|NCT02203968|Trauma coagulopathy
144138|NCT02203968|Hypofibrinogenemia
144139|NCT02203968|Early trauma coagulopathy
144140|NCT02203968|Haemorrhage
144141|NCT02203968|Fibrinogen concentrate
144142|NCT02203968|Feasibility trial
144143|NCT02203968|Clinical trials
144144|NCT02203942|Bacterial Vaginosis
144145|NCT02203942|Vulvovaginal Candidiasis
144146|NCT02203942|Trichomoniasis
144147|NCT02203929|Macular Holes
144148|NCT02203929|Progression
144149|NCT02203916|Drug therapy
144150|NCT02203890|Growth
144151|NCT02203890|Hematology
144152|NCT02203890|Hydration
144153|NCT02203890|Oxidation
144154|NCT02203890|Infection
144155|NCT02203890|Inflammation
144156|NCT02203890|Guatemalan children
144157|NCT02203851|BI 655066
144158|NCT02203851|risankizumab
144159|NCT02203838|Schizophrenia
144160|NCT02203838|Schizophrenic
144161|NCT02203838|Schizophrenias
144162|NCT02203838|Risperidone
144163|NCT02203838|Long-acting Risperidone
144164|NCT02203838|Atrigel
144165|NCT02203838|Subcutaneous
144166|NCT02203825|Acute Myeloid Leukemia
144167|NCT02203825|NKG2D
144168|NCT02203825|Multiple Myeloma
144169|NCT02203825|Cell Therapy
144170|NCT02203799|Peanut Allergy
144171|NCT02203799|Anaphylaxis
144172|NCT02203799|Desensitization
144173|NCT02203799|Food Allergy
144174|NCT02203799|Oral Immunotherapy
144175|NCT02203786|amphetamine
144176|NCT02203786|d1 and d2 receptors
144177|NCT02203786|dopamine antagonists
144178|NCT02203786|pathological gambling
144179|NCT02203786|priming
144180|NCT02203786|reinforcement
144181|NCT02203773|AML
144182|NCT02203773|Treatment Naive AML
144183|NCT02203773|ABT-199
144184|NCT02203773|GDC-0199
144185|NCT02203773|Untreated AML
144186|NCT02203773|Acute Myelogenous Leukemia
144187|NCT02203773|Myelogenous Leukemia
144188|NCT02203760|Relapsed or metastatic uterine leiomyosarcomas or carcinosarcomas
144189|NCT02203734|Pregnancy
144190|NCT02203734|Depression
144191|NCT02203734|Massage
144192|NCT02203708|BPD (Borderline Personality Disorder)
144193|NCT02203708|Mother/child
144194|NCT02203695|Salvage Radiation Therapy (SRT)
144195|NCT02203695|Enzalutamide
144196|NCT02203682|Graves' orbitopathy
144197|NCT02203682|Graves´ ophthalmopathy
144198|NCT02203682|Thyroid eye disease
144199|NCT02203682|Thyroid-associated ophthalmopathy
144200|NCT02203682|Doxycycline
144201|NCT02203682|EUGOGO
144202|NCT02203682|CAS
144203|NCT02203669|breast reconstruction
144204|NCT02203669|occupational therapy
144205|NCT02203669|physical therapy
144206|NCT02203669|upper extremity morbidity
144207|NCT02203656|intervention studies
144208|NCT02203656|nutrition
144209|NCT02203656|exercise
144210|NCT02203656|testosterone
144211|NCT02203656|patient readmission
144212|NCT02203630|Septic shock
144213|NCT02203630|Vasopressor Agents
144214|NCT02203630|Phenylephrine
144215|NCT02203630|Norepinephrine
144216|NCT02203630|Tachycardia
144217|NCT02203630|Heart Rate
144218|NCT02203630|Arrhythmia
144219|NCT02203630|Catecholamine
144220|NCT02203617|anticipatory guidance
144221|NCT02203617|baby books
144222|NCT02203617|safety
144223|NCT02203591|surgical skin prep
144224|NCT02203591|CHG
144225|NCT02203591|IPA
144226|NCT02203552|Breast Cancer
144227|NCT02203539|circadian rhythm
144228|NCT02203539|light exposure
144229|NCT02203539|exercise capacity
144230|NCT02203539|endurance
144231|NCT02203539|strength
144232|NCT02203539|reaction
144233|NCT02203526|Tyrosine Kinase Inhibitor
144234|NCT02203526|ABC DLBCL
144235|NCT02203526|Lymphoma in Brain and CNS
144236|NCT02203526|Diffuse Large B-Cell Lymphomas in CNS
144237|NCT02203513|p53 Dysfunction
144238|NCT02203513|Cell Cycle Arrest
144239|NCT02203513|Checkpoint Kinases
144240|NCT02203513|DNA Damage Repair Pathways
144241|NCT02203513|Hereditary Breast and Ovarian Cancer Syndrome
144242|NCT02203461|ART, HIV, insulin resistance
144243|NCT02203435|code blue
144244|NCT02203435|Cardiopulmonary Resuscitation
144245|NCT02203435|APACHE
144246|NCT02203422|Immune Thrombocytopenia
144247|NCT02203422|Recombinant Human Thrombopoietin
144248|NCT02203422|Cyclosporin A
144249|NCT02203409|liver tumor
144250|NCT02203409|Two stage hepatectomy
144251|NCT02203409|Hypertrophy
144252|NCT02203409|laparoscopy
144253|NCT02203409|ALPPS
144254|NCT02203396|SAA
144255|NCT02203396|Immunosuppressive treatment
144256|NCT02203396|ATG
144257|NCT02203396|Cyclosporine
144258|NCT02203396|Levamisole
144259|NCT02203383|Cardiac Resynchronization Therapy
144260|NCT02203383|Central Sleep Apnoea
144261|NCT02203383|Sleep Disordered Breathing
144262|NCT02203383|Heart Failure
144263|NCT02203383|Hypercapnic Ventilatory Response
144264|NCT02203357|hepatitis B
144265|NCT02203357|hepatitis B vaccine
144266|NCT02203357|immunogenicity
144267|NCT02203357|adults
144268|NCT02203318|cryptorchidism, undescended testis, hypertrophy of contralateral testis
144269|NCT02203305|Unilateral hearing loss
144270|NCT02203305|Single Sided Deafness
144271|NCT02203305|Asymmetric hearing loss
144272|NCT02203292|Traumatic Brain Injury
144273|NCT02203292|Blood Transfusion
144274|NCT02203279|Chair-side hard relining
144275|NCT02203279|complete denture
144276|NCT02203279|patients' satisfaction
144277|NCT02203279|supporting tissues
144278|NCT02203279|autopolymerized reline resins
144279|NCT02203279|heat cured relining material
144280|NCT02203266|Medication Adherence
144281|NCT02203266|Patient Compliance
144282|NCT02203253|solid tumor
144283|NCT02203253|chemotherapy-induced delayed nausea and vomiting
144284|NCT02203253|thalidomide
144285|NCT02203253|prevention
144286|NCT02203240|Cacao
144287|NCT02203240|Polyphenols
144288|NCT02203240|Prediabetic State
144289|NCT02203240|Blood Glucose
144290|NCT02203240|Glucose Intolerance
144291|NCT02203240|Diabetes Mellitus, Type 2
144292|NCT02203240|Obesity
144293|NCT02203240|Muscle, Skeletal
144294|NCT02203240|Endotoxins
144295|NCT02203240|Gut Permeability
144296|NCT02203240|Incretins
144297|NCT02203240|Metabolic Flexibility
144298|NCT02203227|Dietary supplements
144299|NCT02203227|Cotinine level
144300|NCT02203227|Malondialdehyde
144301|NCT02203227|Chronic smokers
144302|NCT02203227|Hyperlipidemia
144303|NCT02203214|Ligamys
144304|NCT02203214|ACL
144305|NCT02203214|healing
144306|NCT02203201|Not-celiac gluten sensitivity
144307|NCT02203201|Celiac Disease
144308|NCT02203201|Gluten-free diet
144309|NCT02203201|EMA assay
144310|NCT02203201|Duodenal culture medium
144311|NCT02203175|propofol
144312|NCT02203175|pretreatment
144313|NCT02203175|mixture
144314|NCT02203162|cough
144315|NCT02203162|cough reflex sensitivity
144316|NCT02203162|electronic cigarette
144317|NCT02203162|capsaicin
144318|NCT02203136|Bladder cancer
144319|NCT02203136|Muscle invasive bladder cancer
144320|NCT02203136|MIBC
144321|NCT02203136|Biopsy specimen molecular profiling
144322|NCT02203136|Bladder surgery
144323|NCT02203136|Magnetic resonance imaging
144324|NCT02203136|MRI
144325|NCT02203136|Trans urethral resection of bladder
144326|NCT02203110|simultaneous bacterial and viral pneumonia
144327|NCT02203097|Target controlled infusion
144328|NCT02203097|propofol
144329|NCT02203097|cerebral vasoreactivity
144330|NCT02203097|arterial stiffness
144331|NCT02203097|Transcranial Doppler
144332|NCT02203097|SphygmoCor
144333|NCT02203084|Cystic Fibrosis
144334|NCT02203084|Diabetes Mellitus Type I
144335|NCT02203084|Chronic Renal Insufficiency
144336|NCT02203084|The influence of socioeconomic variables upon outcome in children with three chronic medical diseases.
144337|NCT02203071|sports
144338|NCT02203071|injury
144339|NCT02203071|knee
144340|NCT02203071|pain
144341|NCT02203071|cartilage
144342|NCT02203058|Inspiratory capacity
144343|NCT02203058|Positive-pressure respiration
144344|NCT02203058|Exercise
144345|NCT02203058|Activities of daily living
144346|NCT02203058|COPD.
144347|NCT02203045|Total Knee Arthroplasty
144348|NCT02203032|Psoriasis
144349|NCT02203032|Plaque-type psoriasis
144350|NCT02203032|Guselkumab
144351|NCT02203032|Ustekinumab
144352|NCT02203032|CNTO 1959
144353|NCT02203032|Monoclonal antibody
144354|NCT02203019|Dexmedetomidine
144355|NCT02203019|Propofol
144356|NCT02203019|Sepsis
144357|NCT02203019|Mechanical Ventilation
144358|NCT02203019|Respiratory Failure
144359|NCT02203006|HIV,
144360|NCT02203006|infection,
144361|NCT02203006|cohort
144362|NCT02202967|Aspirin
144363|NCT02202967|Intestinal bleeding
144364|NCT02202967|Misoprostol
144365|NCT02202967|NSAIDs
144366|NCT02202967|Small intestine
144367|NCT02202967|Video capsule endoscopy
144368|NCT02202954|Stroke
144369|NCT02202954|Muscle Spasticity
144370|NCT02202954|Rehabilitation
144371|NCT02202928|Colorectal cancer
144372|NCT02202928|DC-CIK
144373|NCT02202928|Autologous tumor lysate
144374|NCT02202902|Cushing's syndrome
144375|NCT02202902|cardiac steatosis
144376|NCT02202902|intramyocardial triglyceride content
144377|NCT02202902|1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging
144378|NCT02202902|Left Ventricularly hypertrophy
144379|NCT02202889|Adolescents
144380|NCT02202889|Bone mass
144381|NCT02202889|Calcium
144382|NCT02202889|Perceived milk intolerance
144383|NCT02202889|lactose maldigestion
144384|NCT02202863|Dietary intervention
144385|NCT02202863|Wine grape pomace flour
144386|NCT02202863|Metabolic Syndrome
144387|NCT02202863|Oxidative stress
144388|NCT02202863|Antioxidants
144389|NCT02202863|Fiber
144390|NCT02202785|Drug therapy
144391|NCT02202772|Urothelial
144392|NCT02202772|Cisplatin
144393|NCT02202772|Gemcitabine
144394|NCT02202772|Cabazitaxel
144395|NCT02202772|Bladder
144396|NCT02202772|Carcinoma
144397|NCT02202772|Bacillus Calmette-Guerin
144398|NCT02202772|Intravesical
144399|NCT02202772|Recurrent
144400|NCT02202772|Non-muscle
144401|NCT02202772|Invasive
144402|NCT02202772|Cancer
144403|NCT02202759|Drug therapy
144404|NCT02202746|Breast cancer
144405|NCT02202746|Metastatic breast cancer
144406|NCT02202746|MBC
144407|NCT02202746|HER2 positive
144408|NCT02202746|HER2+
144409|NCT02202746|Estrogen receptor positive
144410|NCT02202746|ER+
144411|NCT02202746|Triple negative
144412|NCT02202746|FGFR1
144413|NCT02202746|11q
144414|NCT02202746|FGF aberrant
144415|NCT02202746|Biomarker negative
144416|NCT02202746|FGF non-aberrant
144417|NCT02202733|cooking skills
144418|NCT02202733|eating out
144419|NCT02202733|foods prepared away from home
144420|NCT02202720|Sevoflurane
144421|NCT02202720|RASS score
144422|NCT02202720|Sedation
144423|NCT02202720|Minimal alveolar concentration (MAC)
144424|NCT02202694|CBT, Psychosis, cultural adaptation, Pakistan
144425|NCT02202681|Duodenum
144426|NCT02202681|Optical Frequency Domain Imaging (OFDI)
144427|NCT02202681|Optical Coherence Tomography
144428|NCT02202681|Imaging
144429|NCT02202681|Celiac Disease
144430|NCT02202668|Foot ulcer, diabetic
144431|NCT02202668|Spectrum analysis, Raman
144432|NCT02202655|non- small cell lung cancer;
144433|NCT02202655|lymphocyte subsets
144434|NCT02202616|COPD,
144435|NCT02202616|QVA149,
144436|NCT02202616|Tiotropium,
144437|NCT02202616|FDC,
144438|NCT02202616|GlycOpyrronium With IndacatERol,
144439|NCT02202616|POWER
144440|NCT02202590|SECM
144441|NCT02202590|Esophagus
144442|NCT02202590|Eosinophilic Esophagitis
144443|NCT02202590|Allergy
144444|NCT02202577|Surgical site infection
144445|NCT02202577|Surgical site antisepsis
144446|NCT02202577|Cesarean Delivery
144447|NCT02202564|hepatocellular carcinoma
144448|NCT02202564|liver transplantation
144449|NCT02202564|adenovirus-thymidine kinase
144450|NCT02202564|gene therapy
144451|NCT02202551|Levodopa Induced Dyskinesia
144452|NCT02202551|LID
144453|NCT02202551|Parkinsonism
144454|NCT02202551|Parkinson's Disease
144455|NCT02202538|SCI
144456|NCT02202538|Indego
144457|NCT02202538|Walking
144458|NCT02202499|pharmacotherapy
144459|NCT02202473|Oxymatrine Capsules, lamivudine, chronic Hepatitis B
144460|NCT02202447|EC1169
144461|NCT02202447|prostate cancer
144462|NCT02202447|EC0652
144463|NCT02202421|Autism
144464|NCT02202421|Applied Behavior Analysis
144465|NCT02202395|Hydroxytriptolide
144466|NCT02202395|Rheumatoid Arthritis
144467|NCT02202395|Methotrexate
144468|NCT02202395|T8
144469|NCT02202395|LTS
144470|NCT02202369|Multimodal Analgesia
144471|NCT02202369|Pain Management
144472|NCT02202356|RSV
144473|NCT02202356|Respiratory Syncytial Virus
144474|NCT02202343|Nutrition
144475|NCT02202343|Food
144476|NCT02202343|Security
144477|NCT02202343|School
144478|NCT02202343|Health
144479|NCT02202317|Liver Cancer
144480|NCT02202317|Hepatic Tumors
144481|NCT02202317|Primary Liver Tumors
144482|NCT02202317|Metastastic Liver Tumors
144483|NCT02202317|Yttrium-90
144484|NCT02202317|Y-90
144485|NCT02202291|Raynaud's phenomenon, Vasospasm, Genetics
144486|NCT02202278|ovarian hyperstimulation
144487|NCT02202278|Oxidative Stress
144488|NCT02202278|IMA
144489|NCT02202278|OHSS
144490|NCT02202278|ICSI
144491|NCT02202278|long agonist protocol
144492|NCT02202278|TAC
144493|NCT02202278|TOS
144494|NCT02202278|OSI
144495|NCT02202278|MDA
144496|NCT02202265|Heart Diseases
144497|NCT02202252|Patient comfort
144498|NCT02202252|Drains
144499|NCT02202252|Breast cancer
144500|NCT02202252|Modified radical mastectomy
144501|NCT02202252|Seroma
144502|NCT02202200|Melanoma
144503|NCT02202200|BRAF mutated
144504|NCT02202174|supraglottic airway
144505|NCT02202174|children
144506|NCT02202174|safety
144507|NCT02202174|efficacy
144508|NCT02202161|pharmacokinetic
144509|NCT02202161|intestinal bile acid transporter inhibitor
144510|NCT02202161|metformin
144511|NCT02202161|sitagliptin
144512|NCT02202161|GSK2330672
144513|NCT02202161|pharmacodynamic
144514|NCT02202148|Fibroscan
144515|NCT02202148|alcohol dependence
144516|NCT02202148|alcohol withdrawal
144517|NCT02202148|controlled attenuation parameter
144518|NCT02202148|BDNF
144519|NCT02202135|complicated skin and soft tissue infections (cSSTI)
144520|NCT02202135|skin infection
144521|NCT02202135|ceftaroline
144522|NCT02202135|wound infection
144523|NCT02202135|cellulitis
144524|NCT02202135|burn infection
144525|NCT02202135|bacterial infection
144526|NCT02202135|vancomycin
144527|NCT02202122|Femoral Neck Fractures
144528|NCT02202122|Obstructive Sleep Apnea
144529|NCT02202122|Perioperative Complications
144530|NCT02202109|Screen
144531|NCT02202109|self-sampler
144532|NCT02202109|cervical, cancer
144533|NCT02202109|women
144534|NCT02202109|community health workers
144535|NCT02202109|Hispanic/ Latinas
144536|NCT02202109|Haitian
144537|NCT02202109|Focus of study is cervical cancer
144538|NCT02202083|Oxytocin
144539|NCT02202083|Cook Balloon
144540|NCT02202070|onabotulinumtoxinA
144541|NCT02202070|Temporomandibular Joint Disorders
144542|NCT02202070|Bruxism
144543|NCT02202070|Temporomandibular Joint Dysfunction Syndrome
144544|NCT02202070|Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint
144545|NCT02202057|respiratory sensation
144546|NCT02202057|somatosensation
144547|NCT02202057|resistive load
144548|NCT02202057|magnitude estimation
144549|NCT02202044|Bladder Cancer
144550|NCT02202018|Knowledge Translation
144551|NCT02202018|Chronic Kidney Disease
144552|NCT02202018|Dialysis
144553|NCT02202018|Home dialysis
144554|NCT02202018|Cluster randomized trial
144555|NCT02202005|Bioequivalence
144556|NCT02201979|breast
144557|NCT02201979|ptosis
144558|NCT02201979|sagging
144559|NCT02201979|implant
144560|NCT02201979|lift
144561|NCT02201966|low back pain
144562|NCT02201966|pediatric
144563|NCT02201966|gymnasts
144564|NCT02201953|Sofosbuvir
144565|NCT02201953|Velpatasvir
144566|NCT02201953|SOF/VEL
144567|NCT02201953|GS-5816
144568|NCT02201953|Hepatitis C
144569|NCT02201953|HCV
144570|NCT02201953|Cirrhosis
144571|NCT02201953|Genotype 3
144572|NCT02201940|Sofosbuvir
144573|NCT02201940|SOF/VEL
144574|NCT02201940|Velpatasvir
144575|NCT02201940|Hepatitis C
144576|NCT02201940|HCV
144577|NCT02201940|cirrhosis
144578|NCT02201927|galvanic vestibular stimulation
144579|NCT02201927|right parietal lobe lesion
144580|NCT02201927|egocentric space
144581|NCT02201901|Sofosbuvir
144582|NCT02201901|Velpatasvir
144583|NCT02201901|SOF/VEL
144584|NCT02201901|GS-5816
144585|NCT02201901|Hepatitis C
144586|NCT02201901|HCV
144587|NCT02201901|Cirrhosis
144588|NCT02201901|CPT-B
144589|NCT02201888|Schizophrenia
144590|NCT02201888|Rehabilitation
144591|NCT02201888|Cognition
144592|NCT02201875|hypoxia
144593|NCT02201875|exercise
144594|NCT02201875|periodic breathing
144595|NCT02201875|hypercapnia
144596|NCT02201875|apneas
144597|NCT02201875|cardiac failure
144598|NCT02201862|Aneuploidy
144599|NCT02201862|Down Syndrome
144600|NCT02201862|amniocentesis
144601|NCT02201862|chronic villus sampling
144602|NCT02201862|Trisomy
144603|NCT02201862|non-invasive prenatal testing
144604|NCT02201862|Chromosome disorders
144605|NCT02201849|Alkermes
144606|NCT02201849|ALKS 8700
144607|NCT02201810|smoking cessation
144608|NCT02201810|quit line
144609|NCT02201810|nicotine replacement therapy
144610|NCT02201810|tobacco intervention
144611|NCT02201797|Reproducibility of Results
144612|NCT02201797|Liver neoplasm
144613|NCT02201797|Neoplasm metastasis
144614|NCT02201797|Regional Perfusion
144615|NCT02201797|Perfusion Magnetic Resonance Imaging
144616|NCT02201784|Subarachnoid block
144617|NCT02201784|intrathecal
144618|NCT02201784|spinal anesthesia
144619|NCT02201784|isobaric
144620|NCT02201784|levobupivacaine
144621|NCT02201784|ropivacaine
144622|NCT02201771|CABG
144623|NCT02201771|Antiplatelet
144624|NCT02201771|Ticagrelor
144625|NCT02201758|Inflammatory Bowel Disease (IBD), ulcerative colitis (UC), flaxseed lignan-enriched complex (FLC)
144626|NCT02201732|Incomplete miscarriage
144627|NCT02201732|Hysteroscopy
144628|NCT02201732|curettage, pregnancy
144629|NCT02201732|RCT
144630|NCT02201719|Adenomyosis
144631|NCT02201719|Dysmenorrhea
144632|NCT02201719|Chronic pelvic pain
144633|NCT02201719|Infertility
144634|NCT02201719|Sensitivity histology
144635|NCT02201719|womens health
144636|NCT02201719|junction zone
144637|NCT02201706|Retinal detachment
144638|NCT02201706|silicone oil
144639|NCT02201706|retinectomy
144640|NCT02201693|Crohn's disease,
144641|NCT02201693|pediatric GETAID (Therapeutic study group of inflammatory bowel diseases of the child),
144642|NCT02201693|enteral nutrition,
144643|NCT02201693|randomized multicenter study
144644|NCT02201680|anxiety
144645|NCT02201680|preoperative
144646|NCT02201667|non-ST elevation acute coronary syndrome
144647|NCT02201667|myocardial perfusion
144648|NCT02201667|magnetic Resonance Imaging
144649|NCT02201667|antiplatelet
144650|NCT02201641|Indirect pulp capping
144651|NCT02201641|reversible pulpitis
144652|NCT02201641|periapical radiolucency
144653|NCT02201641|periapical radiographs
144654|NCT02201641|cone beam computed tomography
144655|NCT02201641|calcium silicate cements
144656|NCT02201641|glass ionomer cements
144657|NCT02201641|caries
144658|NCT02201628|Oesophageal
144659|NCT02201628|Nasopharyngeal
144660|NCT02201628|temperature
144661|NCT02201628|Intubation, endotracheal
144662|NCT02201628|Pediatric
144663|NCT02201628|Anesthesia
144664|NCT02201628|Hypothermia
144665|NCT02201615|Perineal Massage; Episiotomy; Perineal Laceration
144666|NCT02201602|sulphonylureas
144667|NCT02201602|gliclazide
144668|NCT02201602|glibenclamide
144669|NCT02201589|Lesions in the ascending thoracic aorta
144670|NCT02201576|Chronic antibody-mediated rejection,
144671|NCT02201576|transplant rejection, kidney transplantation,
144672|NCT02201576|proteasome inhibitor,
144673|NCT02201576|anti-HLA antibodies,
144674|NCT02201576|immunosuppressive agents
144675|NCT02201563|Adverse radiation effects (ARE)
144676|NCT02201563|Radiosurgery
144677|NCT02201563|Brain metastases
144678|NCT02201563|Minocycline
144679|NCT02201537|Ultrasound functional imaging
144680|NCT02201537|Chronic kidney Nephropathy
144681|NCT02201524|Phase 2
144682|NCT02201524|randomized
144683|NCT02201524|double-blind
144684|NCT02201524|placebo
144685|NCT02201524|plaque
144686|NCT02201524|psoriasis
144687|NCT02201524|safety
144688|NCT02201524|efficacy
144689|NCT02201524|JAK
144690|NCT02201524|janus kinase
144691|NCT02201524|moderate
144692|NCT02201524|severe
144693|NCT02201511|relative bioavailbility
144694|NCT02201511|food effect
144695|NCT02201511|pharmacokinetics
144696|NCT02201511|ALTERATION OF COGNITIVE FUNCTIONS
144697|NCT02201485|Budd-Chiari syndrome
144698|NCT02201485|percutaneous recanalization
144699|NCT02201485|treatment
144700|NCT02201485|reocclusion
144701|NCT02201485|patency
144702|NCT02201472|liver
144703|NCT02201472|mre
144704|NCT02201472|mri
144705|NCT02201472|neonatal
144706|NCT02201472|mr touch
144707|NCT02201459|Peg-IFN, nilotinib, MR4.5, CML, chronic phase, first-line
144708|NCT02201433|breastfeeding
144709|NCT02201433|fathers
144710|NCT02201433|preterm newborns
144711|NCT02201433|partner influence
144712|NCT02201394|Antiplatelet
144713|NCT02201394|Ticagrelor
144714|NCT02201394|Platelets
144715|NCT02201394|Thrombosis
144716|NCT02201394|Coronary artery disease
144717|NCT02201394|Coronary artery disease.
144718|NCT02201381|Cancer
144719|NCT02201381|Cancer Treatments
144720|NCT02201381|Cancer Palliative Care
144721|NCT02201381|Metabolic
144722|NCT02201381|Metabolism
144723|NCT02201381|Existing Medicines
144724|NCT02201381|Licensed Medicines
144725|NCT02201381|Quality of Life
144726|NCT02201381|Real World
144727|NCT02201381|Breast Cancer
144728|NCT02201381|Triple Negative Breast Cancer
144729|NCT02201381|Colon Cancer
144730|NCT02201381|Prostrate Cancer
144731|NCT02201381|Brain Cancer
144732|NCT02201381|Ovarian Cancer
144733|NCT02201381|Pancreatic Cancer
144734|NCT02201381|AML
144735|NCT02201381|CML
144736|NCT02201381|Leukemea
144737|NCT02201381|Metformin
144738|NCT02201381|Statins
144739|NCT02201381|Mebendazole
144740|NCT02201381|Doxycycline
144741|NCT02201381|Ibuprofen
144742|NCT02201381|Metastatic
144743|NCT02201368|Triglycerides; Lipid Metabolism; Fatty Acids.
144744|NCT02201355|Head and Neck cancer
144745|NCT02201342|Fontan
144746|NCT02201342|Pharmacokinetics
144747|NCT02201342|Pharmacodynamics
144748|NCT02201342|Exercise capacity
144749|NCT02201342|Maximal Oxygen Consumption
144750|NCT02201342|Vascular function
144751|NCT02201342|EndoPAT
144752|NCT02201342|Myocardial performance
144753|NCT02201316|Healthy adult human subjects
144754|NCT02201316|Mosapride citrate anhydrous
144755|NCT02201316|Bioequivalence
144756|NCT02201316|Dyspepsia
144757|NCT02201303|CD11b
144758|NCT02201303|Children
144759|NCT02201303|Neutrophils
144760|NCT02201303|Respiratory Syncytial Virus
144761|NCT02201303|CXCR2
144762|NCT02201303|CXCL1
144763|NCT02201303|Danirixin
144764|NCT02201290|Chronic immune thrombocytopenic purpura, ITP, eltrombopag olamine, thrombopoietin receptor agonist, pediatrics
144765|NCT02201277|IVC
144766|NCT02201277|IVC Filter
144767|NCT02201277|Filter
144768|NCT02201277|Option
144769|NCT02201277|Denali
144770|NCT02201277|filter tilt
144771|NCT02201277|filter migration
144772|NCT02201277|filter fracture
144773|NCT02201277|filter thrombus
144774|NCT02201277|filter penetration
144775|NCT02201264|myocardial infarction
144776|NCT02201264|Angioplasty
144777|NCT02201264|Stent
144778|NCT02201251|Epilepsy
144779|NCT02201251|Topiramate
144780|NCT02201251|Levetiracetam
144781|NCT02201251|Pediatric
144782|NCT02201212|TSC1
144783|NCT02201212|TSC2
144784|NCT02201212|Tuberous Sclerosis Complex
144785|NCT02201212|MTOR
144786|NCT02201186|honey enema for pouchitis
144787|NCT02201160|NAFLD
144788|NCT02201160|Fatty acid composition
144789|NCT02201160|Omega 3 supplementation
144790|NCT02201160|Metabolism
144791|NCT02201134|Cardiac arrest
144792|NCT02201134|Therapeutic hypothermia
144793|NCT02201134|Sevoflurane
144794|NCT02201134|Sedation
144795|NCT02201134|Patient resuscitated from cardiac arrest
144796|NCT02201134|Requiring sedation
144797|NCT02201134|Adult patients
144798|NCT02201134|Patient covered by french health care system
144799|NCT02201095|caesarean section
144800|NCT02201095|perioperative hypothermia
144801|NCT02201095|active warming
144802|NCT02201095|forced air warming
144803|NCT02201095|conduction mattress warming
144804|NCT02201095|thermal comfort
144805|NCT02201095|Prevention of
144806|NCT02201069|nutrition
144807|NCT02201069|physical activity
144808|NCT02201069|sleep
144809|NCT02201069|weight loss
144810|NCT02201056|Drug Therapy
144811|NCT02201043|ankylosing spondylitis
144812|NCT02201043|thalidomide
144813|NCT02200952|OHSS
144814|NCT02200952|Oocytes triggering
144815|NCT02200952|GnRh agonist triggering
144816|NCT02200952|Luteal phase supplementation
144817|NCT02200952|recombinant LH
144818|NCT02200900|High flow nasal cannula
144819|NCT02200900|Continuous Positive Airway Pressure
144820|NCT02200900|Respiratory physiology
144821|NCT02200887|Dyskinesia
144822|NCT02200887|Slow Wave Sleep
144823|NCT02200874|disease related malnutrition
144824|NCT02200874|influence of Nutrition Support Team
144825|NCT02200874|length of hospital stay
144826|NCT02200874|quality of life
144827|NCT02200874|body composition
144828|NCT02200874|health care costs
144829|NCT02200861|sedation,
144830|NCT02200861|tooth extraction,
144831|NCT02200848|Lenalidomide
144832|NCT02200848|Ibrutinib
144833|NCT02200848|Rituximab
144834|NCT02200848|CLL
144835|NCT02200848|SLL
144836|NCT02200835|aortic dissection
144837|NCT02200835|Chinese patients
144838|NCT02200835|gender differences
144839|NCT02200822|neurohumoral blocker therapy
144840|NCT02200822|renin-angiotensin-aldosterone system (RAAS)
144841|NCT02200822|RAAS-blocker
144842|NCT02200822|beta blocker
144843|NCT02200822|spironolactone
144844|NCT02200822|angiotensin converting enzyme inhibitor (ACE-I)
144845|NCT02200822|angiotensin receptor blocker (ARB)
144846|NCT02200822|cardiac resynchronization therapy (CRT)
144847|NCT02200822|heart failure
144848|NCT02200822|dyssynchrony
144849|NCT02200822|left bundle branch block
144850|NCT02200809|MR-guided therapy
144851|NCT02200809|Focal laser ablation
144852|NCT02200809|Prostate cancer
144853|NCT02200796|Dietary Protein
144854|NCT02200796|Satiety
144855|NCT02200796|Food Intake
144856|NCT02200796|Thermic Effect of Food
144857|NCT02200796|Diet Induced Thermogenesis
144858|NCT02200783|Cardiac catheterization
144859|NCT02200783|Radiation Protection
144860|NCT02200783|Radial artery
144861|NCT02200783|Femoral artery
144862|NCT02200770|NMO, NMOSD, Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders, autoimmune, demyelination, MEDI-551, monoclonal antibody, Devic's syndrome, B-cell
144863|NCT02200744|Procedural sedation
144864|NCT02200744|emergency department
144865|NCT02200744|adults
144866|NCT02200744|propofol
144867|NCT02200744|recall assessment
144868|NCT02200731|Childhood cancer
144869|NCT02200731|Psychosocial intervention
144870|NCT02200731|Family
144871|NCT02200731|Siblings
144872|NCT02200731|Childhood cancer survivors
144873|NCT02200731|Cogntive Behavioural
144874|NCT02200731|Manualized
144875|NCT02200718|Multiple Sclerosis Pediatric MS NeuroVax Vaccine Therapeutic
144876|NCT02200705|cryoablation, cryotherapy, breast cancer
144877|NCT02200692|plasma transfusion
144878|NCT02200692|allergic transfusion reaction
144879|NCT02200692|transfusion reaction
144880|NCT02200692|blood transfusion
144881|NCT02200692|Solvent detergent plasma
144882|NCT02200679|Autism spectrum disorders
144883|NCT02200679|Prevalence
144884|NCT02200679|Diagnosis
144885|NCT02200679|Screen
144886|NCT02200679|Risk Factor
144887|NCT02200679|SRS
144888|NCT02200679|ASRS
144889|NCT02200666|Type 2 diabetes mellitus
144890|NCT02200666|Diabetes
144891|NCT02200666|Forxiga
144892|NCT02200666|Long-term use
144893|NCT02200627|Type 2 diabetes mellitus
144894|NCT02200627|Diabetes
144895|NCT02200627|Forxiga
144896|NCT02200627|Elderly
144897|NCT02200601|Seipher Wellness
144898|NCT02200601|algorithm
144899|NCT02200601|secure samples of SGC waveform
144900|NCT02200601|volunteers
144901|NCT02200601|validation
144902|NCT02200601|heart health algorithm
144903|NCT02200588|psychosis
144904|NCT02200588|schizophrenia
144905|NCT02200549|pulmonary rehabilitation
144906|NCT02200549|inspiratory muscle training
144907|NCT02200549|exercise training
144908|NCT02200523|EEG
144909|NCT02200523|electrode
144910|NCT02200510|Anemia, Sickle Cell
144911|NCT02200510|Transition to Adult Care
144912|NCT02200510|Self Care
144913|NCT02200510|Personal Electronic Health Records
144914|NCT02200510|Adolescent
144915|NCT02200510|Young Adult
144916|NCT02200510|Disease Management
144917|NCT02200510|Physician-Patient Relations
144918|NCT02200484|obesity
144919|NCT02200484|adolescents, females
144920|NCT02200484|child development
144921|NCT02200484|weight loss programs
144922|NCT02200484|child rearing
144923|NCT02200484|parenting
144924|NCT02200471|Cosmetic dermatology
144925|NCT02200471|near-infrared
144926|NCT02200471|patient preference
144927|NCT02200471|physician preference
144928|NCT02200445|Ulcerative colitis
144929|NCT02200445|Inflammatory bowel disease
144930|NCT02200445|Interleukin 2
144931|NCT02200445|Interleukin-2
144932|NCT02200445|IL-2
144933|NCT02200445|Regulatory T Cells
144934|NCT02200445|Tregs
144935|NCT02200445|T-Lymphocytes, Regulatory
144936|NCT02200432|Smoking Cessation
144937|NCT02200432|Persuasive Communication Tailoring
144938|NCT02200432|Health Behavior Change
144939|NCT02200432|Patient decision support
144940|NCT02200419|Rotem
144941|NCT02200419|Point of care coagulation tests
144942|NCT02200419|Cardiac surgery
144943|NCT02200419|Vascular surgery
144944|NCT02200419|Cardiopulmonary bypass
144945|NCT02200419|Blood products
144946|NCT02200419|Transfusion
144947|NCT02200419|Viscoelastic coagulation
144948|NCT02200406|Desvenlafaxine
144949|NCT02200406|Opioid-dependent
144950|NCT02200406|Addiction
144951|NCT02200406|Depression
144952|NCT02200406|Methadone
144953|NCT02200406|Comorbidity
144954|NCT02200393|Spinal cord injury
144955|NCT02200393|Tetraplegia
144956|NCT02200393|Ventilator
144957|NCT02200367|Primary health care
144958|NCT02200367|Computer communication network
144959|NCT02200367|Depression
144960|NCT02200328|Clostridium difficile infection
144961|NCT02200328|Diarrhea
144962|NCT02200328|Flagyl
144963|NCT02200328|Metronidazole
144964|NCT02200315|Stomach neoplasms
144965|NCT02200315|Surgical site infection
144966|NCT02200315|Laparoscopic gastrectomy
144967|NCT02200315|Antimicrobial prophylaxis
144968|NCT02200289|Birth cohort
144969|NCT02200289|Ghana
144970|NCT02200289|Biomass
144971|NCT02200289|Cook stove
144972|NCT02200289|Oxidative stress
144973|NCT02200289|Lung development
144974|NCT02200263|ocular albinism (OA)
144975|NCT02200263|oculocutaneous albinism (OCA)
144976|NCT02200263|macular pigment
144977|NCT02200263|visual function
144978|NCT02200237|EV71 Vaccine
144979|NCT02200211|Amblyopia
144980|NCT02200198|undernutrition
144981|NCT02200198|abdominal surgery
144982|NCT02200198|respiratory muscles
144983|NCT02200198|muscles strength
144984|NCT02200198|pulmonary complication
144985|NCT02200198|perioperative care
144986|NCT02200185|post traumatic pain
144987|NCT02200185|titrated morphine
144988|NCT02200185|nebulised morphine
144989|NCT02200172|Cancer
144990|NCT02200172|Melatonin
144991|NCT02200172|Delirium
144992|NCT02200172|Feasibility Studies
144993|NCT02200172|Palliative Care
144994|NCT02200159|Sedation
144995|NCT02200159|Dexmedetomidine
144996|NCT02200159|ICU
144997|NCT02200159|Delirium
144998|NCT02200146|sarcoidosis
144999|NCT02200146|treatment
145000|NCT02200146|lung
145001|NCT02200146|glucocorticoids
145002|NCT02200146|hydroxychloroquine
145003|NCT02200133|Hematopoietic cell transplant (HCT) survivors
145004|NCT02200133|Survivorship Care Plan
145005|NCT02200107|Osteoarthritis Knee
145006|NCT02200107|Self Care
145007|NCT02200107|Treatment Outcome
145008|NCT02200107|Patient Education as Topic
145009|NCT02200107|Physical Therapy Modalities
145010|NCT02200081|Extensive disease
145011|NCT02200081|After first line therapy
145012|NCT02200081|Immuno therapy
145013|NCT02200068|Perceived Efficacy of Patient Physician Interactions
145014|NCT02200068|Patient Reported Outcomes
145015|NCT02200068|Personal Health Record
145016|NCT02200055|Electrical Bioimpedance
145017|NCT02200055|Major Intra-abdominal Surgical Procedures
145018|NCT02200055|Total Body Volume
145019|NCT02200055|Fluid Resuscitation
145020|NCT02200029|Intrahepatic Cholestasis
145021|NCT02200016|Postoperative pain
145022|NCT02200016|Regional anesteshia
145023|NCT02200016|Nerve catheters
145024|NCT02200016|Sciatic nerve catheters
145025|NCT02200003|attention bias modification, anxiety, event-related potentials
145026|NCT02199990|cognitive function; propofol; etomidate;
145027|NCT02199977|Malaria
145028|NCT02199977|Antimalarial subsidy
145029|NCT02199977|Malaria rapid diagnostic test (RDT)
145030|NCT02199977|public-private partnership
145031|NCT02199964|Dry eye
145032|NCT02199964|environmental stress
145033|NCT02199964|artificial tears
145034|NCT02199964|cyclosporin
145035|NCT02199964|Restasis
145036|NCT02199951|Uncomplicated Malaria
145037|NCT02199951|dihydroartemisinin
145038|NCT02199951|piperaquine
145039|NCT02199925|Autism
145040|NCT02199925|Autism spectrum
145041|NCT02199925|Autism children
145042|NCT02199912|cachexia
145043|NCT02199912|nutrition
145044|NCT02199912|cancer
145045|NCT02199912|colorectal tumor
145046|NCT02199834|diabetes
145047|NCT02199834|peer support
145048|NCT02199834|personalized feedback report
145049|NCT02199795|stroke
145050|NCT02199795|hemiplegia
145051|NCT02199795|footdrop
145052|NCT02199795|electrical stimulation
145053|NCT02199769|Clinical decision support
145054|NCT02199769|Diabetes screening
145055|NCT02199756|Uterine contractions
145056|NCT02199756|Indomethacin
145057|NCT02199756|Nanovectors
145058|NCT02199743|schizophrenia
145059|NCT02199743|schizoaffective
145060|NCT02199743|cognition
145061|NCT02199743|lurasidone
145062|NCT02199743|Latuda
145063|NCT02199717|Physical Activity
145064|NCT02199717|Accelerometer
145065|NCT02199717|Exercise
145066|NCT02199717|Obesity
145067|NCT02199717|BMI
145068|NCT02199704|Parenting
145069|NCT02199704|Psychosis
145070|NCT02199704|Schizophrenia
145071|NCT02199704|Delusions
145072|NCT02199704|Hallucinations
145073|NCT02199691|Meningitis
145074|NCT02199691|Meningococcal Meningitis
145075|NCT02199691|MenACYW conjugate vaccine
145076|NCT02199691|MENVEO vaccine
145077|NCT02199691|Adacel®
145078|NCT02199691|GARDASIL®
145079|NCT02199639|Haemophilia
145080|NCT02199639|Arthropathy
145081|NCT02199639|Range of Movement
145082|NCT02199639|Strength
145083|NCT02199639|Proprioception
145084|NCT02199639|Gait
145085|NCT02199639|Quality of Life
145086|NCT02199613|HIV
145087|NCT02199613|antiretroviral therapy
145088|NCT02199587|Medical clown
145089|NCT02199587|Growth hormone
145090|NCT02199587|Precocious puberty
145091|NCT02199548|Adolescent
145092|NCT02199548|Decision-making
145093|NCT02199548|Social network
145094|NCT02199535|operating room,
145095|NCT02199535|risk factors
145096|NCT02199535|anesthesiologists
145097|NCT02199509|Levetiracetam
145098|NCT02199509|Cranial Dystonia
145099|NCT02199509|Oromandibular Dystonia
145100|NCT02199496|Malabsorption
145101|NCT02199496|Enteropathy
145102|NCT02199496|Diarrhea
145103|NCT02199496|IL-23
145104|NCT02199496|IL-12
145105|NCT02199483|Energy Expenditure
145106|NCT02199483|Behavioral Weight Loss Treatment
145107|NCT02199483|Neurocognitive Function
145108|NCT02199483|Weight Loss
145109|NCT02199470|β-CELLS,
145110|NCT02199470|MIXED MEAL TEST,
145111|NCT02199470|C-PEPTİDE
145112|NCT02199431|Lu AF11167
145113|NCT02199431|Interaction
145114|NCT02199405|Spondylosis, Massage Therapy, Exercise Therapy ,Treatment Efficacy
145115|NCT02199392|P-glycoprotein
145116|NCT02199392|Healthy Volunteers
145117|NCT02199379|renal impairment
145118|NCT02199379|disease severity
145119|NCT02199366|Cardiac MRI
145120|NCT02199366|Radiation
145121|NCT02199366|Proton Radiation
145122|NCT02199366|Breast Cancer
145123|NCT02199353|Activities of daily living, Occupational Therapy, Dementia
145124|NCT02199340|Exercise testing
145125|NCT02199340|Children
145126|NCT02199340|Exercise capacity
145127|NCT02199327|Conjunctival-corneal intraepithelial neoplasia
145128|NCT02199327|Mitomycin C
145129|NCT02199327|Interferon alfa 2b
145130|NCT02199314|intra
145131|NCT02199314|operative
145132|NCT02199314|neurophysiologic
145133|NCT02199314|monitoring
145134|NCT02199314|transcranial
145135|NCT02199314|motor
145136|NCT02199314|evoked
145137|NCT02199314|potential
145138|NCT02199314|anesthesia
145139|NCT02199314|pulses
145140|NCT02199301|Kidney transplantation
145141|NCT02199301|Tolerance induction
145142|NCT02199301|Immunosuppression withdrawal
145143|NCT02199301|Bone marrow transplantation
145144|NCT02199301|Transplantation conditioning
145145|NCT02199301|Hematopoietic stem cell transplantation
145146|NCT02199301|Living donor
145147|NCT02199301|Haplotype
145148|NCT02199301|Immune tolerance
145149|NCT02199275|Non-urgent surgery
145150|NCT02199275|General anesthesia
145151|NCT02199275|Enterocyte damage
145152|NCT02199275|Intestinal fatty acid-binding protein
145153|NCT02199262|Intensive care unit
145154|NCT02199262|Incidents
145155|NCT02199262|prevention
145156|NCT02199262|music
145157|NCT02199262|reflexology
145158|NCT02199249|open anatomic reduction
145159|NCT02199249|syndesmosis screw fixation, syndesmosis Tightrope fixation
145160|NCT02199236|High-Dose-Rate Brachytherapy
145161|NCT02199236|oral capecitabine
145162|NCT02199236|infusional 5-FU
145163|NCT02199236|Questionnaires
145164|NCT02199236|14-104
145165|NCT02199210|Massive transfusion protocols
145166|NCT02199210|Self-regulatory learning
145167|NCT02199210|Forethought
145168|NCT02199210|Clinical expertise
145169|NCT02199210|Simulation
145170|NCT02199210|Education
145171|NCT02199184|Leukemia
145172|NCT02199184|Burkitt leukemia
145173|NCT02199184|Burkitt-like leukemia/lymphoma
145174|NCT02199184|Newly diagnosed
145175|NCT02199184|Relapsed/refractory
145176|NCT02199184|Ofatumumab
145177|NCT02199184|Arzerra
145178|NCT02199184|Etoposide
145179|NCT02199184|VePesid
145180|NCT02199184|Doxorubicin
145181|NCT02199184|Doxorubicin Hydrochloride
145182|NCT02199184|Adriamycin PFS
145183|NCT02199184|Adriamycin RDF
145184|NCT02199184|Adriamycin
145185|NCT02199184|Rubex
145186|NCT02199184|Vincristine
145187|NCT02199184|Cyclophosphamide
145188|NCT02199184|Cytoxan
145189|NCT02199184|Neosar
145190|NCT02199184|Prednisone
145191|NCT02199184|Rituximab
145192|NCT02199184|Rituxan
145193|NCT02199184|DA-EPOCH
145194|NCT02199184|Pegfilgrastim
145195|NCT02199184|Neulasta
145196|NCT02199184|PEG-G-CSF
145197|NCT02199184|G-CSF
145198|NCT02199184|Filgrastim
145199|NCT02199184|Neupogen
145200|NCT02199184|Phone calls
145201|NCT02199171|hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin
145202|NCT02199171|intraperitoneal (IP) chemotherapy
145203|NCT02199171|cytoreductive surgery
145204|NCT02199158|iridoplasty
145205|NCT02199158|angle
145206|NCT02199158|glaucoma
145207|NCT02199158|anterior chamber
145208|NCT02199158|laser treatment
145209|NCT02199132|Nasopharyngeal Carcinoma
145210|NCT02199119|children
145211|NCT02199119|television
145212|NCT02199119|exercise
145213|NCT02199119|food intake
145214|NCT02199119|appetite
145215|NCT02199119|satiation
145216|NCT02199093|MeSH terms:
145217|NCT02199093|Apraxias
145218|NCT02199093|Apraxia, Ideomotor
145219|NCT02199093|Stroke
145220|NCT02199093|Cerebral Stroke
145221|NCT02199093|Rehabilitation
145222|NCT02199093|Occupational therapy
145223|NCT02199093|Treatment Outcome
145224|NCT02199093|Activities of Daily Living
145225|NCT02199054|Snack Foods
145226|NCT02199054|Safflower Oil
145227|NCT02199054|Soy
145228|NCT02199054|Postmenopausal women
145229|NCT02199054|Metabolic Syndrome
145230|NCT02199041|Cord Blood
145231|NCT02199041|Haploidentical
145232|NCT02199041|Reduced Intensity Regimen
145233|NCT02199028|hyaluronidase
145234|NCT02199028|infusion sets
145235|NCT02199028|insulin pump
145236|NCT02199028|Continuous glucose monitor
145237|NCT02199015|Dysarthria
145238|NCT02199015|Electrical Stimulation
145239|NCT02199015|Lateral Cord Stimulation
145240|NCT02199015|Spasticity
145241|NCT02199015|Treatment
145242|NCT02199002|acid pocket
145243|NCT02199002|GERD
145244|NCT02199002|Barrett
145245|NCT02198963|Skin irritation potential of RUT058-60.
145246|NCT02198950|sepsis
145247|NCT02198950|diagnosis
145248|NCT02198950|biomarker
145249|NCT02198937|smokers
145250|NCT02198937|non-smokers
145251|NCT02198924|sequential administration
145252|NCT02198924|pain control
145253|NCT02198924|inflammation control
145254|NCT02198924|function recovery
145255|NCT02198911|Habituation
145256|NCT02198911|Orosensory cues
145257|NCT02198911|Satiation
145258|NCT02198885|FAST
145259|NCT02198885|Thoracoabdominal Trauma
145260|NCT02198885|Prehospital care
145261|NCT02198885|ultrasound
145262|NCT02198885|NanoMaxx Ultrasound
145263|NCT02198885|RP-Xpress
145264|NCT02198872|Autonomic Nervous System, Body composition, Oxygen Uptake,
145265|NCT02198872|Water Based Physical Training, Land Based Physical Training.
145266|NCT02198859|Prostate Cancer
145267|NCT02198859|Lithium
145268|NCT02198859|Androgen
145269|NCT02198859|PSA
145270|NCT02198833|Urinary Tract Infection
145271|NCT02198833|Bacteriuria
145272|NCT02198833|Transurethral Foley Catheter
145273|NCT02198833|Suprapubic Foley Catheter
145274|NCT02198833|Spinal Cord injury
145275|NCT02198820|Femoral Neck Fractures
145276|NCT02198820|Perioperative Care
145277|NCT02198820|Perioperative Period
145278|NCT02198820|Postoperative Complications
145279|NCT02198794|Dyskinesias
145280|NCT02198794|Movement Disorders
145281|NCT02198794|Central Nervous System Diseases
145282|NCT02198794|Nervous System Diseases
145283|NCT02198794|Neurologic Manifestations
145284|NCT02198794|Signs and Symptoms
145285|NCT02198781|atrial fibrilation
145286|NCT02198781|atrial-ventricula
145287|NCT02198781|right ventricle
145288|NCT02198781|left ventricle
145289|NCT02198781|surrogate marker
145290|NCT02198781|ventricular dysfunction
145291|NCT02198781|pacing
145292|NCT02198768|ankle fracture
145293|NCT02198768|ankle fracture-dislocation
145294|NCT02198768|prospective
145295|NCT02198768|observational
145296|NCT02198755|high resolution ultrasound
145297|NCT02198755|osteomyelitis
145298|NCT02198716|Percutaneous coronary intervention
145299|NCT02198716|Elderly
145300|NCT02198716|Angina
145301|NCT02198703|Probiotics
145302|NCT02198703|AB-Life
145303|NCT02198703|LDL-cholesterol
145304|NCT02198703|Hypercholesterolemia
145305|NCT02198690|Mammography, Older women, decision making
145306|NCT02198664|Characterized Peanut Allergen
145307|NCT02198664|Peanut
145308|NCT02198664|OIT
145309|NCT02198664|Oral Desensitization
145310|NCT02198664|Peanut Allergen
145311|NCT02198664|Peanut-Allergic Children
145312|NCT02198664|Children
145313|NCT02198664|Peanut-Allergic Adults
145314|NCT02198651|Magnetic Resonance Imaging
145315|NCT02198651|Taper
145316|NCT02198651|Anti-rheumatic drugs
145317|NCT02198651|Arthritis
145318|NCT02198651|Rheumatoid Arthritis
145319|NCT02198651|Drug Level
145320|NCT02198651|Flare
145321|NCT02198651|Ultrasound
145322|NCT02198651|Reduced dose
145323|NCT02198651|Remission
145324|NCT02198651|Adalimumab
145325|NCT02198651|Biomarker
145326|NCT02198638|Influenza
145327|NCT02198638|Vaccination rate
145328|NCT02198638|Hospital acquired infection
145329|NCT02198625|Moderate FiO2
145330|NCT02198625|Protective lung ventilation
145331|NCT02198625|Postoperative pulmonary complications
145332|NCT02198625|Positive end-expiratory pressure
145333|NCT02198625|recruitment maneuvers
145334|NCT02198599|Multiple sclerosis
145335|NCT02198599|Stroke
145336|NCT02198599|Nursing
145337|NCT02198599|Mobility
145338|NCT02198599|Rehabilitation
145339|NCT02198586|Alzheimer's, MRI, APOE
145340|NCT02198573|malaria
145341|NCT02198573|K13
145342|NCT02198573|pfmrp1
145343|NCT02198573|Myanmar
145344|NCT02198560|Normal (Eyes without pathologies)
145345|NCT02198547|Local anesthetic adjuvant,
145346|NCT02198547|Magnesium solfatus,
145347|NCT02198547|Sciatic block
145348|NCT02198534|visual acuity
145349|NCT02198534|Landolt C
145350|NCT02198534|ETDRS charts
145351|NCT02198534|Freiburg Visual Acuity Test
145352|NCT02198534|FrACT
145353|NCT02198534|Comparison
145354|NCT02198534|acceptance
145355|NCT02198534|Test retest reliability
145356|NCT02198534|duration
145357|NCT02198534|questionnaire
145358|NCT02198521|Patients undergoing staged bilateral open Carpal Tunnel Release (CTR) have no difference in overall pain intensity of pain between sides.
145359|NCT02198482|Acute Myeloid Leukemia (AML)
145360|NCT02198482|Volasertib
145361|NCT02198482|High-risk Myelodysplastic Syndrome (MDS)
145362|NCT02198469|actinic cheilitis
145363|NCT02198469|Er:YAG ablative fractional laser
145364|NCT02198469|methyl aminolevulinate photodynamic therapy
145365|NCT02198456|pulmonary arterial hypertension
145366|NCT02198430|Haemophilia
145367|NCT02198430|Arthropathy
145368|NCT02198430|Range of motion
145369|NCT02198430|Strength
145370|NCT02198430|Proprioception
145371|NCT02198430|Gait
145372|NCT02198430|Quality of Life.
145373|NCT02198417|Polycystic Ovary Syndrome
145374|NCT02198417|PCOS
145375|NCT02198417|Acne
145376|NCT02198417|Infertility
145377|NCT02198417|Irregular menses
145378|NCT02198417|Irregular period
145379|NCT02198417|Mitochondria
145380|NCT02198417|Metabolism
145381|NCT02198378|premixed nitrous oxide and oxygen
145382|NCT02198378|pain
145383|NCT02198378|prehospital setting
145384|NCT02198378|acute coronary syndrome
145385|NCT02198365|mRNA,
145386|NCT02198365|DNA,
145387|NCT02198365|integrated HPV DNA
145388|NCT02198365|human papillomavirus,
145389|NCT02198365|cervical neoplasia
145390|NCT02198300|dedicated bifurcation stent
145391|NCT02198300|sirolimus eluting stent
145392|NCT02198261|alopecia
145393|NCT02198261|androgenetic alopecia
145394|NCT02198261|hair loss
145395|NCT02198261|minoxidil
145396|NCT02198261|5% minoxidil foam
145397|NCT02198261|male pattern hair loss
145398|NCT02198209|liraglutide
145399|NCT02198209|GLP-1
145400|NCT02198209|liver glucokinase
145401|NCT02198170|Healthy Volunteers
145402|NCT02198157|duration of second stage
145403|NCT02198157|urinary catheterization
145404|NCT02198157|epidural anaesthesia
145405|NCT02198144|Hypertension
145406|NCT02198144|High Blood Pressure
145407|NCT02198144|African American Men
145408|NCT02198144|Black Men
145409|NCT02198118|breast cancer
145410|NCT02198118|physiotherapy
145411|NCT02198118|radiotherapy
145412|NCT02198105|PAD
145413|NCT02198105|femoropoliteal stenosis/occlusion
145414|NCT02198105|cutting-balloon
145415|NCT02198105|drug-coated-balloon
145416|NCT02198092|familial adenomatous polyposis
145417|NCT02198092|multiple adenomatous polyposis
145418|NCT02198092|lynch syndrome
145419|NCT02198092|hnpcc
145420|NCT02198092|colorectal cancer
145421|NCT02198092|genetic syndrome
145422|NCT02198092|epigenomics
145423|NCT02198092|septin9
145424|NCT02198079|non-tuberculous mycobacteria
145425|NCT02198079|Pediatrics
145426|NCT02198079|Cystic Fibrosis
145427|NCT02198066|Sternotomy incision
145428|NCT02198066|Silver dressing
145429|NCT02198066|Sternal wound infection
145430|NCT02198040|Elbow
145431|NCT02198040|Joint disease
145432|NCT02198040|Hemophilia
145433|NCT02198040|Physiotherapy modalities
145434|NCT02198027|Percutaneous nephrolithotomy
145435|NCT02198027|postoperative analgesia
145436|NCT02198027|peritubal block
145437|NCT02198027|pain
145438|NCT02198027|Visual Analog Pain Scale
145439|NCT02198014|Knee
145440|NCT02198014|Joint disease
145441|NCT02198014|Haemophilia
145442|NCT02198014|Physiotherapy modalities
145443|NCT02198001|Platelets
145444|NCT02198001|fibrin
145445|NCT02198001|growth factors
145446|NCT02198001|bisphosphonates
145447|NCT02198001|tooth extraction
145448|NCT02197988|Surgery
145449|NCT02197988|Abdominal
145450|NCT02197988|Epidural Anesthesia
145451|NCT02197988|Transversus Abdominis Plane Block
145452|NCT02197988|TAP block
145453|NCT02197975|Healthy Volunteers
145454|NCT02197962|Osteoarthritis
145455|NCT02197962|Radial shockwaves
145456|NCT02197936|Peristalsis
145457|NCT02197936|ultrasound
145458|NCT02197923|Menorrhagia
145459|NCT02197923|Dysmenorrhea
145460|NCT02197923|Pelvic pain
145461|NCT02197923|expression profiling
145462|NCT02197923|uterine biopsies
145463|NCT02197923|serum hormones
145464|NCT02197897|Tamoxifen citrate
145465|NCT02197897|Bladder Cancer
145466|NCT02197884|Healthy
145467|NCT02197884|JNJ-54861911
145468|NCT02197884|Cytochrome P450 3A4 inhibitor
145469|NCT02197884|Itraconazole
145470|NCT02197884|Clarithromycin
145471|NCT02197884|Alzheimer's disease
145472|NCT02197871|COPD
145473|NCT02197871|malnutrition
145474|NCT02197871|nutrition supplementation
145475|NCT02197858|invasive arterial pressure
145476|NCT02197858|extended hemodynamic monitoring
145477|NCT02197858|propofol
145478|NCT02197858|remifentanil
145479|NCT02197845|sickle cell disease
145480|NCT02197845|hydroxyurea
145481|NCT02197845|patient navigator
145482|NCT02197845|community health worker
145483|NCT02197845|public health worker
145484|NCT02197845|fetal hemoglobin
145485|NCT02197845|health services research
145486|NCT02197832|Frozen thawed embryo transfer
145487|NCT02197832|Endometrial injury
145488|NCT02197832|Ongoing pregnancy rates
145489|NCT02197780|Diagnostic accuracy
145490|NCT02197780|Fecal biomarker
145491|NCT02197780|Clinical Decision Rule
145492|NCT02197780|Cohort Study
145493|NCT02197767|fibrillary GN
145494|NCT02197767|rituximab
145495|NCT02197767|Rituxan
145496|NCT02197767|MabThera
145497|NCT02197767|Zytux
145498|NCT02197754|pharmacokinetics
145499|NCT02197754|polyphenol metabolites
145500|NCT02197754|lean individuals
145501|NCT02197754|obese individuals
145502|NCT02197728|hysterectomy, uterine manipulator, thermal damage, laparoscopy, colpotomy
145503|NCT02197715|Pregnancy
145504|NCT02197715|Contraceptive Methods
145505|NCT02197715|Family Planning Services
145506|NCT02197702|RCT
145507|NCT02197702|asthma
145508|NCT02197702|pediatric
145509|NCT02197702|virus
145510|NCT02197702|corticosteroid
145511|NCT02197689|Personalized Medication Management
145512|NCT02197689|Medication Adherence
145513|NCT02197689|SMS Medication Reminder
145514|NCT02197663|acupuncture
145515|NCT02197663|stroke
145516|NCT02197663|Randomized Controlled Trial
145517|NCT02197650|ALL l-asparaginase encapsulated erythrocytes
145518|NCT02197624|Non-heme iron absorption; HFE
145519|NCT02197611|Haemophilia
145520|NCT02197611|Adherence of Treatment
145521|NCT02197611|Knowledge of Illness
145522|NCT02197611|Medical-patient Relationship
145523|NCT02197611|Illness Behavior
145524|NCT02197611|Treatment Difficulties.
145525|NCT02197598|nalmefene, alcohol consumption, liver effects
145526|NCT02197585|Male patients
145527|NCT02197585|Age > 18 year
145528|NCT02197585|Primary hernia
145529|NCT02197585|glue
145530|NCT02197572|Drug therapy
145531|NCT02197559|Ischemic Stroke, restenosis,bare-metal stents, drug -eluting stents
145532|NCT02197546|Injection pain
145533|NCT02197546|local anesthesia
145534|NCT02197546|acupuncture
145535|NCT02197481|BiClamp forceps hepatectomy
145536|NCT02197481|Clamp crushing technique
145537|NCT02197481|Liver parenchyma transection
145538|NCT02197481|Randomized controlled trial
145539|NCT02197468|Gut microbiome
145540|NCT02197468|Necrotizing enterocolitis
145541|NCT02197468|Antibiotics
145542|NCT02197429|Vulvodynia
145543|NCT02197429|Acupuncture
145544|NCT02197429|Provoked Vestibulodynia
145545|NCT02197429|Vulvar Vestibulitis
145546|NCT02197429|Vulvar Pain
145547|NCT02197429|Dyspareunia
145548|NCT02197429|Female Sexual Function
145549|NCT02197403|Dexmedetomidine
145550|NCT02197403|Sedation
145551|NCT02197403|Paradoxical excitement response
145552|NCT02197403|Alcohol drinkers
145553|NCT02197390|Childhood obesity
145554|NCT02197390|Latino
145555|NCT02197390|Hispanic
145556|NCT02197377|Laryngeal mask airway, edentulous geriatric patient
145557|NCT02197364|Interstitial Lung Disease
145558|NCT02197364|Diagnosis
145559|NCT02197364|Krebs Von Den Lungen-6
145560|NCT02197351|stomach neoplasms
145561|NCT02197351|narrow band imaging
145562|NCT02197351|gastroscopy
145563|NCT02197338|cholangiopancreatography, endoscopic retrograde
145564|NCT02197325|NSTEMI and STEMI
145565|NCT02197312|yttrium-oxide
145566|NCT02197312|Y-TZP
145567|NCT02197312|bridge
145568|NCT02197312|NobelProcera
145569|NCT02197312|Shaded Zirconia
145570|NCT02197273|Total knee arthroplasty
145571|NCT02197273|Total shoulder arthroplasty
145572|NCT02197273|Total hip arthroplasty
145573|NCT02197273|Total joint arthroplasty
145574|NCT02197273|Hip replacement
145575|NCT02197273|Knee replacement
145576|NCT02197273|Shoulder replacement
145577|NCT02197260|Periodontitis
145578|NCT02197260|amoxicillin
145579|NCT02197260|metronidazole
145580|NCT02197260|case management
145581|NCT02197247|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, rifampicin, CYP P450 inducer, EGFR genes
145582|NCT02197234|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, simvastatin, EGFR genes
145583|NCT02197208|Frozen-thawed embryo transfer
145584|NCT02197208|natural cycle
145585|NCT02197208|spontaneous ovulation
145586|NCT02197208|hCG induced natural cycles
145587|NCT02197182|Bacterial Vaginosis (BV)
145588|NCT02197182|Amsel's criteria
145589|NCT02197182|Pap smear
145590|NCT02197169|Brain
145591|NCT02197169|Brain Cancer
145592|NCT02197169|Brain Neoplasms
145593|NCT02197169|Central Nervous System Diseases
145594|NCT02197169|Central Nervous System Neoplasms
145595|NCT02197169|CNS
145596|NCT02197169|Conditionally Replication-Competent Adenovirus
145597|NCT02197169|DNX-2401
145598|NCT02197169|Delta-24-RGD
145599|NCT02197169|Glioma
145600|NCT02197169|Glioblastoma
145601|NCT02197169|Gliosarcoma
145602|NCT02197169|Interferon gamma
145603|NCT02197169|Malignant brain tumor
145604|NCT02197169|Neoplasms, Neuroepithelial
145605|NCT02197169|Neuroectodermal Tumors
145606|NCT02197169|Neoplasms, Germ Cell and Embryonal
145607|NCT02197169|Neoplasms by Histologic Type
145608|NCT02197169|Neoplasms, Glandular and Epithelial
145609|NCT02197169|Neoplasms, Nerve Tissue
145610|NCT02197169|Nervous System Diseases
145611|NCT02197169|Alcyone Lifesciences
145612|NCT02197169|AMC™
145613|NCT02197169|Cannula
145614|NCT02197169|Alcyone MEMS Cannula (AMC™) System
145615|NCT02197143|esomeprazole
145616|NCT02197143|ranitidine
145617|NCT02197143|hydrotalcid
145618|NCT02197143|treatment of dyspepsia
145619|NCT02197143|emergancy medicine
145620|NCT02197130|Huntington; chorea; total motor score; CAG repeat: total functional capacity; motor cognitive and behavioral symptoms
145621|NCT02197117|ST-segment elevation myocardial infarction (STEMI); thrombolysis, remote ischemic conditioning, myocardial infarct size, cardioprotection
145622|NCT02197065|hip fracture
145623|NCT02197065|myocardial ischemia
145624|NCT02197065|statin
145625|NCT02197065|surgery
145626|NCT02197065|troponin
145627|NCT02197065|complication
145628|NCT02197065|arthroplasty
145629|NCT02197065|hip
145630|NCT02197065|knee
145631|NCT02197065|orthopedic
145632|NCT02197065|atorvastatin
145633|NCT02197065|cardiovascular
145634|NCT02197039|Peptic ulcer hemorrhage, second-look endoscopy
145635|NCT02197000|BRCA mutation
145636|NCT02197000|Breast cancer
145637|NCT02197000|Estrogen metabolism
145638|NCT02197000|3,3-Diindolylmethane
145639|NCT02197000|Breast density
145640|NCT02196987|Pain
145641|NCT02196987|Catheter
145642|NCT02196987|Urethra
145643|NCT02196987|Urination
145644|NCT02196974|bronchoscopy
145645|NCT02196974|lung nodule
145646|NCT02196974|diagnosis
145647|NCT02196974|cryobiopsy
145648|NCT02196961|Merkel cell carcinoma
145649|NCT02196961|Ipilimumab
145650|NCT02196961|Adjuvant
145651|NCT02196948|Supraspinatus, tendinopathy, pain, disability, EPTE
145652|NCT02196935|Cholangitis
145653|NCT02196935|Choledocholithiasis
145654|NCT02196935|Gastrointestinal Neoplasms
145655|NCT02196935|Medically underserved area
145656|NCT02196935|Anesthesia
145657|NCT02196922|Chronic Heart Failure
145658|NCT02196922|Telehealth
145659|NCT02196922|Self Management
145660|NCT02196909|HIBM
145661|NCT02196909|GNE
145662|NCT02196870|Airway pressure stress index
145663|NCT02196870|Transpulmonary pressure stress index
145664|NCT02196870|Acute Respiratory Failure
145665|NCT02196870|Chest wall elastance
145666|NCT02196870|Lung stress
145667|NCT02196857|Leukemia
145668|NCT02196857|Acute myeloid leukemia
145669|NCT02196857|AML
145670|NCT02196857|High risk myelodysplastic syndrome
145671|NCT02196857|MDS
145672|NCT02196857|FLT3-ITD mutation
145673|NCT02196857|Azacytidine
145674|NCT02196857|5-Azacytidine
145675|NCT02196857|5-AZA
145676|NCT02196857|Vidaza
145677|NCT02196857|5-AZC
145678|NCT02196857|AZA-CR
145679|NCT02196857|Ladakamycin
145680|NCT02196857|NSC-102816
145681|NCT02196857|Sorafenib
145682|NCT02196857|Nexavar
145683|NCT02196857|BAY 43-9006
145684|NCT02196844|Lung cancer
145685|NCT02196844|Hatha Yoga
145686|NCT02196844|Questionnaires
145687|NCT02196844|Surveys
145688|NCT02196844|Walk Test
145689|NCT02196844|Caregiver
145690|NCT02196831|Human immunodeficiency virus (HIV)
145691|NCT02196831|Nonalcoholic fatty liver disease (NAFLD)
145692|NCT02196831|Nonalcoholic steatohepatitis (NASH)
145693|NCT02196831|Growth hormone releasing hormone
145694|NCT02196831|tesamorelin
145695|NCT02196805|bioequivalence
145696|NCT02196805|imported PROBUCOL table
145697|NCT02196805|Lorelco
145698|NCT02196805|marketed PROBUCOL tablet
145699|NCT02196805|Chang Tai
145700|NCT02196792|Joint Diseases
145701|NCT02196792|Musculoskeletal Diseases
145702|NCT02196792|radiostereometric analysis
145703|NCT02196779|Abdominoplasty
145704|NCT02196779|circulation
145705|NCT02196779|skin
145706|NCT02196779|dissection
145707|NCT02196779|laser
145708|NCT02196779|fluorescence
145709|NCT02196779|imaging
145710|NCT02196753|Positron emission tomography combined with computed tomography
145711|NCT02196753|PET CT
145712|NCT02196753|Cardiovascular Implantable Electronic Device
145713|NCT02196753|Infective endocarditis
145714|NCT02196753|Generator pocket infection
145715|NCT02196753|Fever of unknown origin
145716|NCT02196740|periapical periodontitis,primary teeth
145717|NCT02196727|Postoperative pain
145718|NCT02196727|Multimodal analgesia
145719|NCT02196727|Bascom Cleft Lift
145720|NCT02196727|Day-case.
145721|NCT02196714|Japanese Healthy Volunteers
145722|NCT02196701|methotrexate
145723|NCT02196701|adalimumab
145724|NCT02196701|biologic
145725|NCT02196701|psoriasis
145726|NCT02196701|Tumor necrosis factor (TNF)-α inhibitor
145727|NCT02196688|subjects with mCRC who failed at least 2nd line therapy
145728|NCT02196610|End-Stage Renal Disease,
145729|NCT02196610|arterial or vascular stiffness,
145730|NCT02196610|hemodialysis,
145731|NCT02196610|Pulse wave velocity
145732|NCT02196610|Renal insufficiency,
145733|NCT02196610|tonometry
145734|NCT02196597|anorectal manometry
145735|NCT02196571|GDM
145736|NCT02196571|Exercise
145737|NCT02196571|Diabetes
145738|NCT02196571|Pregnancy
145739|NCT02196558|Rheumatoid Arthritis
145740|NCT02196558|Japanese subjects
145741|NCT02196532|retinal nerve fiber layer thickness
145742|NCT02196532|optical coherence tomography
145743|NCT02196532|migraine
145744|NCT02196506|OPC-34712
145745|NCT02196506|brexpiprazole
145746|NCT02196506|Major Depressive Disorder
145747|NCT02196506|Adjunctive Treatment
145748|NCT02196506|Anxious Distress
145749|NCT02196493|Productive
145750|NCT02196493|Cough
145751|NCT02196493|Bronchitis
145752|NCT02196493|Azithromycin
145753|NCT02196467|myoblast
145754|NCT02196467|transplantation
145755|NCT02196467|strength
145756|NCT02196467|tacrolimus
145757|NCT02196467|immunosuppression
145758|NCT02196454|HPV vaccine
145759|NCT02196454|vaccination
145760|NCT02196454|immunization
145761|NCT02196454|video
145762|NCT02196454|health education
145763|NCT02196454|communication
145764|NCT02196441|deep topical fornix nerve block
145765|NCT02196441|topical anesthesia
145766|NCT02196441|implantable contact lens procedure
145767|NCT02196428|Ambient Assisted Living (AAL)
145768|NCT02196428|Telemonitoring
145769|NCT02196428|Teleconsultation
145770|NCT02196415|Hindfoot Alignment
145771|NCT02196415|Rearfoot
145772|NCT02196415|Malalignment
145773|NCT02196415|biplanar radiography
145774|NCT02196415|3D measurement
145775|NCT02196376|Postural orthostatic syndrome
145776|NCT02196376|orthostatic intolerance
145777|NCT02196376|autonomic dysfunction
145778|NCT02196350|personalized treatment
145779|NCT02196350|prevention
145780|NCT02196350|improved diagnosis
145781|NCT02196337|Iodine deficiency
145782|NCT02196324|Prurigo Nodularis
145783|NCT02196324|Atopic Dermatitis
145784|NCT02196324|Lichen-simplex chronicus
145785|NCT02196311|Supracondylar humerus fractures, external fixation, open reduction, and internal fixation.
145786|NCT02196298|physical therapy
145787|NCT02196298|gait
145788|NCT02196298|pediatric rehabilitation
145789|NCT02196298|gross motor function
145790|NCT02196298|participation
145791|NCT02196285|Double
145792|NCT02196285|Viral
145793|NCT02196285|Vaccine
145794|NCT02196285|Measles
145795|NCT02196285|Rubella
145796|NCT02196285|Safety
145797|NCT02196285|Efficacy
145798|NCT02196285|Imunogenicity
145799|NCT02196259|Pre-Post
145800|NCT02196233|Trigger Finger
145801|NCT02196233|Prospective Clinical Research
145802|NCT02196233|Randomized
145803|NCT02196233|Questionnaires
145804|NCT02196233|Transverse
145805|NCT02196233|Longitudinal
145806|NCT02196207|Severe Hemophilia A
145807|NCT02196207|Previously Untreated Patients
145808|NCT02196207|Hemophilia Inhibitor Formation
145809|NCT02196207|Long-Acting Factor VIII
145810|NCT02196207|Prophylaxis
145811|NCT02196155|plantar fasciitis
145812|NCT02196155|Botulinum toxin A
145813|NCT02196155|Cortisone
145814|NCT02196155|RCT
145815|NCT02196142|Cortisol
145816|NCT02196142|Alcohol Craving
145817|NCT02196142|Alcohol Dependence
145818|NCT02196129|low back pain
145819|NCT02196129|pharmacoacupuncture
145820|NCT02196129|sinbaro-3
145821|NCT02196116|Alzheimer disease
145822|NCT02196116|amyloid load
145823|NCT02196116|educational level
145824|NCT02196116|cognitive performances
145825|NCT02196103|TOLAC
145826|NCT02196103|PROM
145827|NCT02196103|Previous Cesarian section
145828|NCT02196103|Mechanical cervical ripening
145829|NCT02196090|OCD, Exposure and Response Prevention, Vagal Stimulation
145830|NCT02196077|Budesonide and formoterol inhalation aerosol
145831|NCT02196064|HIV HCV antiretroviral
145832|NCT02196051|Insulin resistance
145833|NCT02196051|Exercise
145834|NCT02196051|de novo lipogenesis
145835|NCT02196051|NAFLD
145836|NCT02196051|Magnetic Resonance Spectroscopy
145837|NCT02196038|heart failure
145838|NCT02196025|Insomnia
145839|NCT02196012|overweight
145840|NCT02196012|obesity
145841|NCT02196012|Technology
145842|NCT02196012|College Students
145843|NCT02195986|vaginal dryness
145844|NCT02195986|vaginal and/or vulvar irritation/itching
145845|NCT02195986|dysuria
145846|NCT02195986|vaginal pain and bleeding associated with sexual activity
145847|NCT02195986|vaginal atrophy
145848|NCT02195973|ovarian cancer
145849|NCT02195973|platinum resistant
145850|NCT02195973|LED225
145851|NCT02195973|Sonidegib
145852|NCT02195973|Paclitaxel
145853|NCT02195960|skin toxicity, radiotherapy, antioxidants
145854|NCT02195947|Growth hormone
145855|NCT02195947|IVF/ICSI
145856|NCT02195947|Poor responder
145857|NCT02195947|Antagonist protocol
145858|NCT02195934|Cardiovascular disease, blood orange juice, anthocyanins
145859|NCT02195895|Teriparatide
145860|NCT02195895|Alendronate
145861|NCT02195895|Alendronic Acid
145862|NCT02195895|Osteoporosis
145863|NCT02195895|Bone Fracture
145864|NCT02195895|Bone Loss
145865|NCT02195895|Spinal Cord Injury
145866|NCT02195895|Bone Diseases
145867|NCT02195895|Metabolic Bone Diseases
145868|NCT02195895|Musculoskeletal Diseases
145869|NCT02195895|Spinal Cord Diseases
145870|NCT02195895|Central Nervous System Diseases
145871|NCT02195895|Nervous System Diseases
145872|NCT02195895|Nervous System
145873|NCT02195895|Wounds and Injuries
145874|NCT02195895|Bone Density Conservation Agents
145875|NCT02195895|Physiological Effects of Drugs
145876|NCT02195895|Pharmacologic Actions
145877|NCT02195882|strength training
145878|NCT02195882|scapular stabilization
145879|NCT02195882|kayakers.
145880|NCT02195869|PCYC1129
145881|NCT02195869|PCYC1129CA
145882|NCT02195869|1129
145883|NCT02195869|Ibrutinib
145884|NCT02195869|PCI32765
145885|NCT02195869|IMBRUVICA
145886|NCT02195869|Pharmacyclics
145887|NCT02195869|PCYC
145888|NCT02195869|GVHD
145889|NCT02195869|Steroid dependent
145890|NCT02195869|refractory
145891|NCT02195869|chronic
145892|NCT02195869|graft versus host disease
145893|NCT02195869|chronic graft versus host disease
145894|NCT02195869|immunology
145895|NCT02195856|Diabetes
145896|NCT02195856|Nitrate
145897|NCT02195856|Nitrite
145898|NCT02195856|Hepatic
145899|NCT02195856|MRI
145900|NCT02195856|Incretin
145901|NCT02195856|Insulin
145902|NCT02195856|Glucose
145903|NCT02195843|CRT-D
145904|NCT02195843|Heart Failure
145905|NCT02195843|Middle East
145906|NCT02195843|Quadripolar
145907|NCT02195830|Sepsis
145908|NCT02195830|ultrasound
145909|NCT02195830|inferior vena cava collapsibility
145910|NCT02195778|Health Literacy
145911|NCT02195778|Adult
145912|NCT02195778|UAE
145913|NCT02195778|Disease
145914|NCT02195778|Age
145915|NCT02195765|Chronic Periodontitis
145916|NCT02195765|Periodontal disease
145917|NCT02195752|Compounded pain cream
145918|NCT02195752|Ordinary care
145919|NCT02195752|Compounding
145920|NCT02195752|Topical treatment
145921|NCT02195752|Analgesia
145922|NCT02195739|smoking
145923|NCT02195739|smoking cessation
145924|NCT02195739|cardiovascular disease
145925|NCT02195739|pharmacological intervention
145926|NCT02195739|UK primary care population
145927|NCT02195739|nicotine replacement therapy
145928|NCT02195700|Dyskinesias
145929|NCT02195700|Movement Disorders
145930|NCT02195700|Central Nervous System Diseases
145931|NCT02195700|Nervous System Diseases
145932|NCT02195700|Neurologic Manifestations
145933|NCT02195700|Signs and Symptoms
145934|NCT02195661|Epilepsy
145935|NCT02195661|Electroencephalogram
145936|NCT02195661|children
145937|NCT02195661|sedation
145938|NCT02195648|Tension-Type Headache
145939|NCT02195648|Physical Therapy Modalities
145940|NCT02195648|Musculoskeletal Manipulations
145941|NCT02195648|Sub-occipital muscle inhibition technique
145942|NCT02195609|Vasomotor Symptoms Associated With Menopause
145943|NCT02195609|Menopause
145944|NCT02195609|Hot Flashes
145945|NCT02195609|Postmenopausal Women
145946|NCT02195596|Alzheimer disease, exercise, cognition
145947|NCT02195570|contingency management
145948|NCT02195570|smoking cessation
145949|NCT02195570|prenatal tobacco exposure
145950|NCT02195570|maternal smoking
145951|NCT02195531|Adherence
145952|NCT02195518|Chronic Hepatitis B
145953|NCT02195518|Tenofovir disoproxil fumarate
145954|NCT02195518|Failure of multiple NAs treatment
145955|NCT02195479|Multiple Myeloma
145956|NCT02195479|Bortezomib
145957|NCT02195479|Velcade
145958|NCT02195479|Melphalan
145959|NCT02195479|Prednisone
145960|NCT02195479|Daratumumab
145961|NCT02195453|Non-small cell lung cancer
145962|NCT02195453|FACT-L scale
145963|NCT02195453|Yangzhengxiaoji
145964|NCT02195440|Hepatitis C virus, cirrhosis
145965|NCT02195414|NeoVas
145966|NCT02195414|Bioresorbable scaffold
145967|NCT02195414|Sirolimus
145968|NCT02195414|First-in-Man
145969|NCT02195401|autism, cleanroom, immune dysregulation, toxins
145970|NCT02195388|Arterial stiffness,
145971|NCT02195388|endothelial function,
145972|NCT02195388|autonomic nervous system,
145973|NCT02195388|acute coronary syndrome,
145974|NCT02195388|arterial hypertension,
145975|NCT02195388|pulse wave velocity,
145976|NCT02195388|augmentation index,
145977|NCT02195388|arterial stiffness index,
145978|NCT02195388|heart rate variability,
145979|NCT02195388|heart rate turbulence,
145980|NCT02195388|vascular endothelial growth factor,
145981|NCT02195388|asymmetric dimethylarginine
145982|NCT02195375|Chronic Obstructive Pulmonary Disease
145983|NCT02195375|FEV1 ≤ 50%
145984|NCT02195349|Tuberculin Purified Protein Derivative
145985|NCT02195349|Delayed Type Hypersensitivity
145986|NCT02195349|Biopsy
145987|NCT02195349|Induration
145988|NCT02195349|First time in human
145989|NCT02195349|T-cells
145990|NCT02195349|LAG-3
145991|NCT02195349|safety
145992|NCT02195349|GSK2831781
145993|NCT02195349|psoriasis
145994|NCT02195323|autologous bone marrow mesenchymal stem cells chronic kidney disease
145995|NCT02195310|Sternotomy
145996|NCT02195310|Surgical site Occurences
145997|NCT02195310|Negative Pressure Wound Therapy
145998|NCT02195310|Surgical Site Infection
145999|NCT02195297|cellulitis
146000|NCT02195297|anticellulitis
146001|NCT02195284|Inhaler preference
146002|NCT02195284|Overall inhaler error
146003|NCT02195284|DISKUS/ACCUHALER
146004|NCT02195284|MDI
146005|NCT02195284|TURBUHALER
146006|NCT02195284|ELLIPTA
146007|NCT02195284|Ease of use
146008|NCT02195284|Critical inhaler error
146009|NCT02195271|Melatonin
146010|NCT02195271|Transcranial Direct Current Stimulation
146011|NCT02195271|Neuroplasticity
146012|NCT02195271|Analgesia
146013|NCT02195271|Pain
146014|NCT02195245|CO2 filter
146015|NCT02195245|anesthesia
146016|NCT02195245|device
146017|NCT02195232|Venous Thromboembolic Events in Cancer Patients
146018|NCT02195232|Thromboembolism of Vein in Colorectal Cancer
146019|NCT02195232|Thromboembolism of Vein in Pancreatic Cancer
146020|NCT02195232|Thromboembolism of Vein in Non-small Cell Lung Cancer
146021|NCT02195219|conservative
146022|NCT02195219|treatment
146023|NCT02195219|surgical
146024|NCT02195219|Acromioclavicular
146025|NCT02195219|Joint
146026|NCT02195219|dislocation
146027|NCT02195206|Hyperpolarized gas magnetic resonance imaging
146028|NCT02195206|Hyperpolarized Xenon-129 magnetic resonance imaging
146029|NCT02195206|Lung Imaging
146030|NCT02195206|Healthy Adults
146031|NCT02195193|Health Services Research
146032|NCT02195193|Acute Coronary Syndromes
146033|NCT02195193|Depression
146034|NCT02195193|Integrated care
146035|NCT02195180|Pancreas
146036|NCT02195180|adenocarcinoma
146037|NCT02195180|cancer
146038|NCT02195180|asparaginase
146039|NCT02195180|erythrocytes
146040|NCT02195180|red blood cell
146041|NCT02195180|Encapsulation
146042|NCT02195180|folfox
146043|NCT02195180|gemcitabine
146044|NCT02195154|18F-DTBZ
146045|NCT02195141|Preoperative Chemoradiotherapy
146046|NCT02195141|Locally Advanced Rectal Cancer
146047|NCT02195141|boost
146048|NCT02195141|IMRT
146049|NCT02195102|transcatheter aortic valve Replacement
146050|NCT02195089|Treatment of Cervical Intraepithelial Neoplasia(CIN3)
146051|NCT02195076|Lung cancer
146052|NCT02195076|Breast Cancer
146053|NCT02195076|Biosensors
146054|NCT02195076|Volatile Organic Compounds
146055|NCT02195076|Odor
146056|NCT02195076|Urine Sample
146057|NCT02195076|Exhaled Breath Samples
146058|NCT02195063|Pain management
146059|NCT02195063|Scar care
146060|NCT02195063|Wound care
146061|NCT02195063|UDT
146062|NCT02195063|Urinary drug testing
146063|NCT02195037|Delayed Cord Clamping
146064|NCT02195024|pacemaker
146065|NCT02195024|magnetic resonance imaging
146066|NCT02195024|MRI conditional
146067|NCT02195024|pacemaker leads
146068|NCT02195011|Regorafenib
146069|NCT02195011|90Y
146070|NCT02195011|Radioembolization
146071|NCT02195011|SIR-Spheres Microspheres
146072|NCT02195011|Metastatic Colorectal Cancer
146073|NCT02195011|Liver Metastases
146074|NCT02195011|SIRT
146075|NCT02195011|Refractory
146076|NCT02194985|Fabry disease
146077|NCT02194985|Lysosomal storage disease
146078|NCT02194985|migalastat HCl
146079|NCT02194985|AT1001
146080|NCT02194972|constipation
146081|NCT02194972|colon transit time
146082|NCT02194972|gut microbiota
146083|NCT02194972|soluble dietary fiber
146084|NCT02194972|disturbance of gut microbiota in constipation
146085|NCT02194959|Patient Navigation
146086|NCT02194959|Screening Colonoscopy
146087|NCT02194959|Colorectal Cancer Screening
146088|NCT02194959|African Americans
146089|NCT02194946|Chronic Kidney Disease,
146090|NCT02194946|End-Stage Renal Disease,
146091|NCT02194946|Traditional Chinese Medicine,
146092|NCT02194946|dialysis initiation.
146093|NCT02194933|Schizophrenia
146094|NCT02194933|Mental Disorders, Antipsychotic,
146095|NCT02194933|Psychotic disorder, Impulsivity
146096|NCT02194907|Emotional Aging
146097|NCT02194907|Neurofeedback
146098|NCT02194894|Acetaminophen, Non-alcoholic Fatty Liver Disease (NAFLD)
146099|NCT02194881|Cystic fibrosis
146100|NCT02194881|CFTR
146101|NCT02194881|G551D mutation
146102|NCT02194881|Novel treatments
146103|NCT02194881|Potentiator
146104|NCT02194881|Ivacaftor
146105|NCT02194868|Allogeneic hematopoietic stem cell transplantation,
146106|NCT02194868|Immunoregulatory T lymphocytes,
146107|NCT02194868|acute graft versus host disease
146108|NCT02194855|rocuronium
146109|NCT02194855|cisatracurium
146110|NCT02194855|pharmacokinetic
146111|NCT02194842|metastatic
146112|NCT02194842|prostate cancer
146113|NCT02194816|Parkinson's Disease
146114|NCT02194816|PD
146115|NCT02194816|Complementary and Alternative
146116|NCT02194816|CAM
146117|NCT02194790|Chronic Kidney Disease
146118|NCT02194790|Diabetic Nephropathy
146119|NCT02194790|Integrated Chronic Kidney Disease Care
146120|NCT02194725|Stress and Coping Model
146121|NCT02194725|Coping
146122|NCT02194712|circulating anodic antigen
146123|NCT02194686|cilostazol
146124|NCT02194686|progenitor cells
146125|NCT02194686|cardiovascular disease
146126|NCT02194686|risk factors
146127|NCT02194686|angiogenesis
146128|NCT02194686|biological markers
146129|NCT02194686|endothelial function
146130|NCT02194660|Fractures Liaison Service
146131|NCT02194660|Osteoporosis
146132|NCT02194660|Fracture
146133|NCT02194660|Medication adherence
146134|NCT02194647|Osteoporosis
146135|NCT02194647|Medication Monitoring
146136|NCT02194647|Education
146137|NCT02194647|Adherence
146138|NCT02194647|Management
146139|NCT02194595|type 2 diabetes
146140|NCT02194595|beta-cell function
146141|NCT02194595|GLP-1
146142|NCT02194595|insulin
146143|NCT02194582|FSGS
146144|NCT02194582|NS
146145|NCT02194582|Kidney disease
146146|NCT02194582|Kidney failure
146147|NCT02194582|Renal disease
146148|NCT02194582|nephrotic syndrome
146149|NCT02194582|focal segmental glomerulosclerosis
146150|NCT02194582|familial kidney disease
146151|NCT02194582|minimal change disease
146152|NCT02194582|proteinuria
146153|NCT02194543|Cataract
146154|NCT02194543|HD 3D
146155|NCT02194543|Microscope
146156|NCT02194530|Peanut allergy
146157|NCT02194530|Allergic/atopic individuals
146158|NCT02194530|Non allergic individuals
146159|NCT02194530|Allergic individuals receiving xolair therapy
146160|NCT02194517|diabetes
146161|NCT02194517|diet control toolset
146162|NCT02194517|food exchanges
146163|NCT02194517|CHO
146164|NCT02194517|FP
146165|NCT02194504|Metabolic health
146166|NCT02194504|Phenotyping
146167|NCT02194504|Abdominal obesity
146168|NCT02194504|Abdominal adiposity
146169|NCT02194504|Liver fat
146170|NCT02194504|Belly fat
146171|NCT02194491|[11C]AS2471907
146172|NCT02194491|ASP3662
146173|NCT02194491|Positron Emission Tomography (PET)
146174|NCT02194491|Brain enzyme occupancy
146175|NCT02194478|Stress
146176|NCT02194478|Meditation
146177|NCT02194478|Mind body
146178|NCT02194439|Acute Graft Versus Host Disease
146179|NCT02194439|Affect
146180|NCT02194439|Anti-inflammatory
146181|NCT02194439|Anti-inflammatory Agents
146182|NCT02194439|Antigen-Presenting Cells
146183|NCT02194439|Alloantigen
146184|NCT02194439|Allogeneic
146185|NCT02194439|Allograft rejection
146186|NCT02194439|Allograft Tolerance
146187|NCT02194439|Antigens
146188|NCT02194439|Autoimmunity
146189|NCT02194439|Biomarkers
146190|NCT02194439|Biospecimen Repository
146191|NCT02194439|BMT
146192|NCT02194439|Bone Marrow Transplantation
146193|NCT02194439|Cell Transplantation
146194|NCT02194439|Cells
146195|NCT02194439|Clonal Expansion
146196|NCT02194439|Complex
146197|NCT02194439|Cytokine
146198|NCT02194439|Data
146199|NCT02194439|Development
146200|NCT02194439|Environment
146201|NCT02194439|Failure (biologic function)
146202|NCT02194439|Genomics
146203|NCT02194439|Graft-vs-Host Disease
146204|NCT02194439|Graft-vs-Leukemia
146205|NCT02194439|GVHD
146206|NCT02194439|GVL
146207|NCT02194439|Hematopoietic
146208|NCT02194439|Hematopoietic Stem Cell Transplantation
146209|NCT02194439|HCT
146210|NCT02194439|HSCT
146211|NCT02194439|IL-33 Receptor
146212|NCT02194439|Immune Reconstitution
146213|NCT02194439|Immune Response
146214|NCT02194439|Inflammatory
146215|NCT02194439|Modeling
146216|NCT02194439|Novel
146217|NCT02194439|Novel therapeutics
146218|NCT02194439|Outcome
146219|NCT02194439|Pathway interactions
146220|NCT02194439|Peptides
146221|NCT02194439|Prevent
146222|NCT02194439|Process
146223|NCT02194439|Production
146224|NCT02194439|Proteomics
146225|NCT02194439|Regulatory T-Lymphocyte
146226|NCT02194439|Response
146227|NCT02194439|Role
146228|NCT02194439|Signal
146229|NCT02194439|ST2
146230|NCT02194439|Transduction
146231|NCT02194439|T-cell response
146232|NCT02194439|T-cell Activation
146233|NCT02194439|T-Lymphocytes
146234|NCT02194439|Tissues
146235|NCT02194400|RSLV-132
146236|NCT02194400|Systemic Lupus Erythematosus
146237|NCT02194400|Lupus
146238|NCT02194400|SLE
146239|NCT02194400|Resolve
146240|NCT02194387|Breast Cancer
146241|NCT02194387|Ovarian Cancer
146242|NCT02194387|Triple negative breast cancer
146243|NCT02194387|TNBC
146244|NCT02194387|BRCA-positive survivor
146245|NCT02194387|High-grade serous ovarian cancer
146246|NCT02194387|HGSOC
146247|NCT02194387|Female biological relative of a BRCA positive TNBC or HGSOC survivor
146248|NCT02194387|Cancer survivors
146249|NCT02194387|Employees at MD Anderson
146250|NCT02194387|Multi-phase Optimization Strategy
146251|NCT02194387|MOST
146252|NCT02194387|Energy balance interventions
146253|NCT02194387|EB
146254|NCT02194387|Telephone Coaching
146255|NCT02194387|Text Messaging
146256|NCT02194387|Resistance Training
146257|NCT02194387|Daily Self-Monitoring
146258|NCT02194387|Weekly Self-Monitoring
146259|NCT02194387|Email Coaching
146260|NCT02194387|Questionnaires
146261|NCT02194387|Surveys
146262|NCT02194374|Leukemia
146263|NCT02194374|Chronic lymphocytic leukemia
146264|NCT02194374|CLL
146265|NCT02194374|Small lymphocytic lymphoma
146266|NCT02194374|SLL
146267|NCT02194374|B cell
146268|NCT02194374|ROR1-specific T cells
146269|NCT02194374|Fludarabine
146270|NCT02194374|Fludarabine Phosphate
146271|NCT02194374|Fludara
146272|NCT02194374|Cyclophosphamide
146273|NCT02194374|Cytoxan
146274|NCT02194374|Neosar
146275|NCT02194374|Rituximab
146276|NCT02194374|Rituxan
146277|NCT02194374|Bendamustine
146278|NCT02194374|Bendamustine Hydrochloride
146279|NCT02194374|Bendamustine HCL
146280|NCT02194374|CEP-18083
146281|NCT02194374|SDX-105
146282|NCT02194374|Treanda
146283|NCT02194231|Mesothelioma
146284|NCT02194231|MPM
146285|NCT02194231|Trabectedin
146286|NCT02194192|prevention of hypotension
146287|NCT02194192|spinal anesthesia
146288|NCT02194192|cesarean section
146289|NCT02194192|ephedrine
146290|NCT02194192|ondansetron
146291|NCT02194140|ultrasound
146292|NCT02194140|iodinated contrast material
146293|NCT02194140|computed tomography
146294|NCT02194114|Chronic Renal Failure
146295|NCT02194114|End-Stage Renal Disease
146296|NCT02194114|Nitrogen Balance
146297|NCT02194114|Dietary Protein Intake
146298|NCT02194101|oxygen delivery
146299|NCT02194101|proximal femoral fracture
146300|NCT02194101|goal-directed therapy
146301|NCT02194062|Chronic rhinosinusitis with polyps
146302|NCT02194062|Nasal steroids
146303|NCT02194062|Functional endoscopic sinus surgery
146304|NCT02194062|SNOT-22
146305|NCT02194062|Lund-Kennedy
146306|NCT02194036|Ownership of body
146307|NCT02194036|Bodily and mental balance
146308|NCT02194036|Learning
146309|NCT02194036|Body image
146310|NCT02194036|Sensations
146311|NCT02194036|Expectations
146312|NCT02194023|chlorhexidine digluconate
146313|NCT02194023|gingivitis
146314|NCT02194023|cetylpyridinium chloride
146315|NCT02194023|mouthrinse
146316|NCT02194023|dental plaque
146317|NCT02194023|de novo
146318|NCT02194023|in vivo
146319|NCT02194010|Outcome Measure
146320|NCT02194010|Patient Reported Questionnaires
146321|NCT02193984|Diabetes
146322|NCT02193984|Peer support
146323|NCT02193984|Hispanic
146324|NCT02193984|Latino
146325|NCT02193971|Acute coronary syndrome
146326|NCT02193971|Drug eluting stent
146327|NCT02193971|Everolimus
146328|NCT02193971|Prasugrel
146329|NCT02193958|Acute Myeloid Leukemia
146330|NCT02193958|Chronic Myelomonocytic Leukemia
146331|NCT02193958|Myelodysplastic Syndrome
146332|NCT02193932|EEG triggered
146333|NCT02193932|fMRI
146334|NCT02193932|epilepsy
146335|NCT02193932|intractable
146336|NCT02193919|psoriasis
146337|NCT02193906|Cognitive training
146338|NCT02193906|Multiple sclerosis
146339|NCT02193906|Cognitive deficits
146340|NCT02193893|cell-based therapy
146341|NCT02193893|autologous bone marrow-derived stem/progenitor cells
146342|NCT02193893|stem cell infusion, stem cell transplantation
146343|NCT02193893|biological therapy with neurotrophic factors
146344|NCT02193893|bioactive neurotrophic factors
146345|NCT02193867|LIPA
146346|NCT02193867|Wolman Disease
146347|NCT02193867|Wolman Phenotype
146348|NCT02193867|Acid Lipase Deficiency
146349|NCT02193867|Acid Cholesteryl Hydrolase
146350|NCT02193867|Acid Lipase Disease Deficiency, type 2
146351|NCT02193867|Cholesteryl Ester Storage Disease (CESD)
146352|NCT02193867|Cholesteryl Ester Hydrolase Deficiency
146353|NCT02193867|Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
146354|NCT02193867|LAL Deficiency
146355|NCT02193867|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
146356|NCT02193867|Wolman Disease (early onset LAL Deficiency)
146357|NCT02193867|Related Disorders:
146358|NCT02193867|Non-alcoholic Fatty Liver Disease (NAFLD)
146359|NCT02193867|Non-alcoholic Steatohepatitis (NASH)
146360|NCT02193867|Alcoholic Liver Disease
146361|NCT02193867|Cryptogenic Cirrhosis
146362|NCT02193867|Niemann-Pick Disease (NPD) Type C
146363|NCT02193867|Chanarin Dorfman Syndrome
146364|NCT02193854|Telemedicine
146365|NCT02193854|Mobile phone
146366|NCT02193854|Rural physicians
146367|NCT02193854|Mongolia
146368|NCT02193841|Simple bone cyst
146369|NCT02193841|Unicameral bone cyst
146370|NCT02193828|Dupuytren's nodules
146371|NCT02193815|psoriasis
146372|NCT02193815|plaque
146373|NCT02193815|vulgaris
146374|NCT02193815|phase 1
146375|NCT02193815|randomized
146376|NCT02193815|double-blind
146377|NCT02193815|topical
146378|NCT02193815|safety
146379|NCT02193802|Crohn's disease
146380|NCT02193802|small bowel (SB)
146381|NCT02193802|capsule endoscopy
146382|NCT02193802|ileocolonoscopy
146383|NCT02193802|anti-TNF-alpha antibodies
146384|NCT02193789|Anastomosis site structure
146385|NCT02193789|Stent insertion
146386|NCT02193789|Stent migration
146387|NCT02193776|Tuberculosis
146388|NCT02193776|Multi Drug-Resistant Tuberculosis
146389|NCT02193776|Drug-Sensitive Tuberculosis
146390|NCT02193776|Pa-824
146391|NCT02193776|Bedaquiline
146392|NCT02193776|Moxifloxacin
146393|NCT02193776|Pyrazinamide
146394|NCT02193776|Nitroimidazole
146395|NCT02193776|Quinolone
146396|NCT02193776|Pretomanid
146397|NCT02193776|NC-005
146398|NCT02193763|pediatric
146399|NCT02193763|lumbar puncture
146400|NCT02193763|ultrasonography
146401|NCT02193763|efficacy
146402|NCT02193750|Crohn's Disease
146403|NCT02193724|Heritable Retinoblastoma
146404|NCT02193724|Familial Retinoblastoma
146405|NCT02193724|Pluripotent Stem Cells
146406|NCT02193698|POEMS syndrome
146407|NCT02193698|lenalidomide
146408|NCT02193685|(HAEC) Hirschsprung Associated Entrocolistis
146409|NCT02193685|(HD) Hirschsprung Disease
146410|NCT02193685|(IBD) Inflammatory Bowel Disease
146411|NCT02193685|Children
146412|NCT02193672|Advanced cancers
146413|NCT02193672|PET/CT
146414|NCT02193672|Positron emission tomography / computed tomography
146415|NCT02193672|[18F]Fluciclatide
146416|NCT02193672|Chemotherapy
146417|NCT02193672|Phone calls
146418|NCT02193659|breakfast cereal
146419|NCT02193659|omega-3
146420|NCT02193659|cholesterol
146421|NCT02193659|lipidic profile
146422|NCT02193659|consumption
146423|NCT02193659|acceptability
146424|NCT02193646|Colonoscopy
146425|NCT02193646|Adenoma
146426|NCT02193646|ADR
146427|NCT02193646|Screening Colon Cancer
146428|NCT02193620|Analgesic
146429|NCT02193620|Narcotics
146430|NCT02193620|Opioids
146431|NCT02193620|Pain relief after surgery
146432|NCT02193607|Occult stress incontinence
146433|NCT02193607|Pelvic Organ Prolapse
146434|NCT02193607|Surgical Intervention
146435|NCT02193607|TVT-O(Tension-free vaginal tape-obturator)
146436|NCT02193607|Improved Reconstructive Pelvic Surgery
146437|NCT02193607|Combined Surgery
146438|NCT02193607|Two-step Approach
146439|NCT02193607|Prophylactic Incontinence Procedure
146440|NCT02193607|Randomized Controlled Trial
146441|NCT02193594|Preoperative concurrent chemoradiotherapy
146442|NCT02193594|Neoadjuvant chemoradiotherapy
146443|NCT02193594|Gastroesophageal junction adenocarcinoma
146444|NCT02193568|Supratentorial Glioma
146445|NCT02193568|Craniotomy
146446|NCT02193555|Presbyopia
146447|NCT02193555|Refractive error correction
146448|NCT02193555|Contact lenses
146449|NCT02193542|regional anesthesia
146450|NCT02193542|general anesthesia
146451|NCT02193542|obstetric
146452|NCT02193529|sleeve gastrectomy, dietary intake, morbid obesity.
146453|NCT02193503|cancer
146454|NCT02193503|solid tumors
146455|NCT02193503|gene therapy
146456|NCT02193503|cell therapy
146457|NCT02193503|encapsulation
146458|NCT02193490|DNase, Pulmozyme, dry eye disease, treatment
146459|NCT02193464|inflammatory bowel disease, registry, incidence, Korea
146460|NCT02193451|Lower urinary tract symptoms
146461|NCT02193451|Male LUTS
146462|NCT02193451|Voiding dysfunction
146463|NCT02193451|Benign prostate obstruction
146464|NCT02193451|Detrusor underactivity
146465|NCT02193438|Heart rate variability
146466|NCT02193438|Resting energy expenditure
146467|NCT02193438|Facial thermography
146468|NCT02193438|Blood pressure
146469|NCT02193438|Spices ingestion
146470|NCT02193425|Brain
146471|NCT02193425|Connectivity
146472|NCT02193425|PET
146473|NCT02193425|fcMRI
146474|NCT02193425|18FDG
146475|NCT02193412|analgesia nociception index
146476|NCT02193412|heart rate variability
146477|NCT02193412|autonomic nervous system
146478|NCT02193412|specificity
146479|NCT02193412|systemic venous return
146480|NCT02193412|pulse pressure variation
146481|NCT02193412|Intraoperative Monitoring
146482|NCT02193399|Stem cell transplantation
146483|NCT02193399|Fatigue
146484|NCT02193399|Physiotherapy
146485|NCT02193399|Quality of Life
146486|NCT02193399|Cancer
146487|NCT02193399|Psychosocial aspects
146488|NCT02193386|Cerebral Palsy
146489|NCT02193386|Physical Therapy
146490|NCT02193386|gait analysis
146491|NCT02193386|gross motor function
146492|NCT02193373|Osteopathic Manipulative Medicine
146493|NCT02193373|Autonomic Nervous System
146494|NCT02193373|Heart Rate Variability
146495|NCT02193373|Sub-Occipital Release
146496|NCT02193373|Rib-Raising
146497|NCT02193373|Stellate Ganglion Release
146498|NCT02193360|Inflammation
146499|NCT02193360|PBC
146500|NCT02193347|Immunotherapy
146501|NCT02193347|Adult
146502|NCT02193334|Hepatocyte Growth Factor
146503|NCT02193334|HGF
146504|NCT02193334|KP-100IT
146505|NCT02193334|Intrathecal injection
146506|NCT02193321|Atrial Fibrillation
146507|NCT02193321|Amniotic Membrane
146508|NCT02193295|Weight Reduction
146509|NCT02193295|Caloric Restriction
146510|NCT02193295|Euglycemic Hyperinsulinemic Clamp
146511|NCT02193295|Magnetic Resonance Spectroscopy
146512|NCT02193269|Abstinent cocaine users
146513|NCT02193269|minocycline
146514|NCT02193269|antibiotic
146515|NCT02193256|varenicline
146516|NCT02193256|prazosin
146517|NCT02193256|cigarette smoking
146518|NCT02193256|alcohol drinking
146519|NCT02193256|sleep
146520|NCT02193256|dreams
146521|NCT02193243|Congenital Heart Disease
146522|NCT02193243|Six Minute Walk Test
146523|NCT02193243|Exercise Testing
146524|NCT02193243|Peak oxygen uptake
146525|NCT02193230|Atopic dermatitis, Feasibility, Adherence to treatment
146526|NCT02193204|Alcohol dependence
146527|NCT02193204|Stress
146528|NCT02193204|Cytokines
146529|NCT02193204|Depressive Symptomatology
146530|NCT02193191|Plerixafor
146531|NCT02193191|13-229
146532|NCT02193152|Advanced Non-Small Cell Lung Cancer
146533|NCT02193152|NSCLC
146534|NCT02193152|Pazopanib
146535|NCT02193126|Long term foster care
146536|NCT02193126|child abuse and neglect
146537|NCT02193126|trauma
146538|NCT02193113|Diabetic Macular Edema
146539|NCT02193113|DME
146540|NCT02193113|Plasma Kallikrein inhibitor
146541|NCT02193113|KVD001
146542|NCT02193113|KVD001-001
146543|NCT02193113|Intravitreal
146544|NCT02193113|IVT
146545|NCT02193113|Diabetes mellitus
146546|NCT02193087|Drug therapy
146547|NCT02193074|Spinal Muscular Atrophy
146548|NCT02193074|SMA
146549|NCT02193074|SMN
146550|NCT02193074|SMNRx
146551|NCT02193074|ISIS-SMNRx
146552|NCT02193074|ISIS-SMN Rx
146553|NCT02193074|ISIS 396443
146554|NCT02193074|Endear
146555|NCT02193074|IONIS-SMNRx
146556|NCT02193074|IONIS-SMN Rx
146557|NCT02193061|Rotavirus
146558|NCT02193061|immunological behavior
146559|NCT02193061|Rotarix
146560|NCT02193061|RotaTeq
146561|NCT02193061|vaccine interchangeability
146562|NCT02193035|Microparticles
146563|NCT02193035|Severe aortic stenosis
146564|NCT02193035|Calcified aortic stenosis
146565|NCT02193035|transcatheter aortic valve replacement
146566|NCT02193022|Bangladesh, PKDL, Visceral Leishmaniasis, Children, Miltefosine
146567|NCT02192996|VLBW preterm
146568|NCT02192996|GUT microbiota
146569|NCT02192996|probiotics supplementation
146570|NCT02192996|immune compounds
146571|NCT02192970|Retinal detachment
146572|NCT02192970|Proliferative vitreoretinopathy
146573|NCT02192957|cardioversion
146574|NCT02192957|electrical cardioversion
146575|NCT02192957|atrial fibrillation
146576|NCT02192957|cardioversion protocol
146577|NCT02192944|ECG
146578|NCT02192944|Pharmacokinetic profile
146579|NCT02192892|Young children
146580|NCT02192892|Acceptability
146581|NCT02192892|Food intake
146582|NCT02192892|Energy dense porridge
146583|NCT02192879|thoracic epidural
146584|NCT02192879|continuous paravertebral catheter
146585|NCT02192879|PCA
146586|NCT02192879|liver resection
146587|NCT02192879|pain management
146588|NCT02192853|Diabetes Mellitus
146589|NCT02192853|Glucagon-like peptide 1
146590|NCT02192853|Dipeptidyl peptidase 4
146591|NCT02192853|Dipeptidyl peptidase 4 inhibitor
146592|NCT02192853|sitagliptin
146593|NCT02192853|Enzyme activity
146594|NCT02192840|provisional T stenting
146595|NCT02192840|dedicated bifurcation stent
146596|NCT02192827|Pediatric
146597|NCT02192827|Asthma
146598|NCT02192827|Exacerbation
146599|NCT02192827|Dexamethasone
146600|NCT02192827|Peak flow
146601|NCT02192814|Lacosamide
146602|NCT02192814|LCM
146603|NCT02192814|Epilepsy
146604|NCT02192814|Partial-onset seizures
146605|NCT02192814|iv
146606|NCT02192801|Classic Bladder Exstrophy
146607|NCT02192801|Renal function
146608|NCT02192801|GFR
146609|NCT02192801|Proteinuria
146610|NCT02192788|SBRT
146611|NCT02192788|Oligometastases
146612|NCT02192788|Prostate Cancer
146613|NCT02192775|Measles virus
146614|NCT02192775|Sodium Iodide Symporter
146615|NCT02192775|Cyclophosphamide
146616|NCT02192775|Refractory multiple myeloma
146617|NCT02192749|autism
146618|NCT02192749|umbilical cord
146619|NCT02192749|mesenchymal
146620|NCT02192749|stem cells
146621|NCT02192736|asthma
146622|NCT02192736|umbilical cord
146623|NCT02192736|mesenchymal
146624|NCT02192736|stem cells
146625|NCT02192736|trophic factors
146626|NCT02192710|outpatient surgery
146627|NCT02192710|anaesthesia
146628|NCT02192710|midazolam
146629|NCT02192710|electronic tab
146630|NCT02192697|safety
146631|NCT02192697|pharmacokinetics
146632|NCT02192697|tolerability
146633|NCT02192697|ASP8273
146634|NCT02192697|Non-small Cell Lung Cancer
146635|NCT02192697|T790M resistance mutation
146636|NCT02192697|NSCLC
146637|NCT02192697|Epidermal Growth Factor Receptor mutations
146638|NCT02192697|irreversible EGFR inhibitor
146639|NCT02192697|antitumor activity
146640|NCT02192697|EGFR
146641|NCT02192684|obstructive sleep apnea
146642|NCT02192684|insulin sensitivity
146643|NCT02192684|cardiovascular risk
146644|NCT02192684|positive airway pressure therapy
146645|NCT02192671|hepatocellular carcinoma
146646|NCT02192671|radiofrequency ablation
146647|NCT02192671|hepatic resection
146648|NCT02192671|portal hypertension
146649|NCT02192671|Milan criteria
146650|NCT02192671|randomized critical trial
146651|NCT02192619|APL
146652|NCT02192619|acute promyelocytic leukemia
146653|NCT02192619|AML M3
146654|NCT02192606|Laparoscopy
146655|NCT02192606|3D Visual System
146656|NCT02192606|Total Hysterectomy
146657|NCT02192567|Advanced solid malignant tumor
146658|NCT02192567|phase 1
146659|NCT02192567|oncology
146660|NCT02192554|OPC-34712
146661|NCT02192554|brexpiprazole
146662|NCT02192554|Dementia
146663|NCT02192554|Alzheimer's Disease
146664|NCT02192554|Cognitive Disorders
146665|NCT02192554|Memory
146666|NCT02192554|Agitation
146667|NCT02192541|Urothelial Carcinomas
146668|NCT02192541|Non-Squamous Non-Small Cell Lung Carcinomas
146669|NCT02192541|Refractory Gastrointestinal Carcinomas
146670|NCT02192541|Hsp90 Inhibitor
146671|NCT02192541|Sarcomas
146672|NCT02192528|vitamin D
146673|NCT02192528|25-hydroxyvitamin D
146674|NCT02192528|1,25-dihydroxyvitamin D
146675|NCT02192528|MACCE
146676|NCT02192528|mortality
146677|NCT02192528|cardiac
146678|NCT02192528|cerebrovascular
146679|NCT02192515|Healthy Subjects
146680|NCT02192515|Japanese Adult
146681|NCT02192489|Chronic Cutaneous Sarcoidosis
146682|NCT02192489|Cutaneous Sarcoidosis
146683|NCT02192489|Skin Sarcoidosis
146684|NCT02192489|Sarcoidosis
146685|NCT02192476|Stroke, subluxation
146686|NCT02192450|Diabetes Mellitus
146687|NCT02192450|Hypoglycaemia
146688|NCT02192450|Glucose Metabolism Disorders
146689|NCT02192450|Metabolic Diseases
146690|NCT02192450|Endocrine System Diseases
146691|NCT02192450|Autoimmune Diseases
146692|NCT02192450|Insulin
146693|NCT02192450|Hypoglycaemic Agents
146694|NCT02192450|Physiological Effetcs of Drugs
146695|NCT02192437|methionine
146696|NCT02192437|cysteine
146697|NCT02192437|sulfur amino acid restriction
146698|NCT02192424|beta-cell function,
146699|NCT02192424|type 2 diabetes,
146700|NCT02192424|intermittent insulin
146701|NCT02192411|lidocaine
146702|NCT02192411|tumescent
146703|NCT02192411|endovenous
146704|NCT02192411|laser
146705|NCT02192411|pain
146706|NCT02192398|Pain
146707|NCT02192398|Pain management
146708|NCT02192398|Neck
146709|NCT02192398|Back
146710|NCT02192372|creatinine
146711|NCT02192372|glomerular filtration rate
146712|NCT02192372|metabolic syndrome
146713|NCT02192346|metastatic
146714|NCT02192346|refractory
146715|NCT02192346|progressive
146716|NCT02192320|Atorvastatin
146717|NCT02192320|Atorvastatin and Dexamethasone
146718|NCT02192320|Chronic Subdural Hematoma
146719|NCT02192320|conservative treatment
146720|NCT02192307|Sensitivity
146721|NCT02192294|Bosutinib
146722|NCT02192294|absolute bioavailability
146723|NCT02192281|Physical activity
146724|NCT02192281|Recess
146725|NCT02192281|Accelerometer
146726|NCT02192281|Play
146727|NCT02192255|diabetes type 2
146728|NCT02192255|primary care
146729|NCT02192255|chronic disease care improvement
146730|NCT02192255|adherence, randomized trial
146731|NCT02192255|BP control
146732|NCT02192255|lipid control
146733|NCT02192255|glucose control
146734|NCT02192255|natural language processing.
146735|NCT02192242|acute ischemic pain
146736|NCT02192242|model
146737|NCT02192242|S100
146738|NCT02192242|interleukine 6
146739|NCT02192216|Body composition
146740|NCT02192216|Chemotherapy
146741|NCT02192216|Muscle mass
146742|NCT02192216|Muscle function
146743|NCT02192216|Exercise
146744|NCT02192177|Apoptosis
146745|NCT02192177|intrahepatic cholestasis
146746|NCT02192177|obstetric outcomes
146747|NCT02192164|plaque psoriasis
146748|NCT02192164|smoking
146749|NCT02192164|etanercept
146750|NCT02192151|Analgesic
146751|NCT02192151|Narcotics
146752|NCT02192151|Opioids
146753|NCT02192151|Non-scheduled substanse
146754|NCT02192138|Pleural effusion
146755|NCT02192138|Pleural fluid
146756|NCT02192138|Thoracentesis
146757|NCT02192138|Intrapleural pressure
146758|NCT02192138|Pleural manometry
146759|NCT02192125|stroke
146760|NCT02192125|rehabilitation
146761|NCT02192125|balance
146762|NCT02192125|training
146763|NCT02192125|posture
146764|NCT02192086|Kidney transplantation
146765|NCT02192060|Biofilm
146766|NCT02192060|Triclosan
146767|NCT02192060|Crossover
146768|NCT02192060|Clinical trial
146769|NCT02192034|Colonoscopy
146770|NCT02192034|Colon cancer
146771|NCT02192034|screening
146772|NCT02192034|navigation
146773|NCT02192021|CTCL
146774|NCT02192021|Cutaneous T-cell Lymphoma
146775|NCT02192021|Mycosis Fungoides
146776|NCT02192008|Challenge
146777|NCT02192008|Re-challenge
146778|NCT02192008|Controlled Infection
146779|NCT02192008|Enteric fever
146780|NCT02191982|Cancer
146781|NCT02191982|Chemotherapy
146782|NCT02191982|Fatigue
146783|NCT02191982|Elderly
146784|NCT02191982|Geriatric
146785|NCT02191982|Any Cancer
146786|NCT02191982|Cancer Treatment
146787|NCT02191982|Weakness
146788|NCT02191982|Tiredness
146789|NCT02191969|Chemotherapy
146790|NCT02191969|Adjuvant Chemotherapy
146791|NCT02191969|Cancer Therapy
146792|NCT02191969|Fatigue
146793|NCT02191969|Physical Activity
146794|NCT02191969|Physical Function
146795|NCT02191969|Tiredness
146796|NCT02191969|Colon Cancer
146797|NCT02191969|Rectal Cancer
146798|NCT02191969|Walk With Ease
146799|NCT02191969|Colorectal Cancer
146800|NCT02191969|Geriatric Assessment
146801|NCT02191969|Geriatric
146802|NCT02191969|Elderly
146803|NCT02191956|Disruptive behavior disorders
146804|NCT02191956|Early Onset
146805|NCT02191956|Young Children
146806|NCT02191956|Parenting
146807|NCT02191956|Behavioral Parent Training
146808|NCT02191943|caries
146809|NCT02191943|proximal
146810|NCT02191943|non-cavitated
146811|NCT02191943|fluoridation
146812|NCT02191878|Liver Cancer
146813|NCT02191878|Liver Neoplasms
146814|NCT02191878|Liver Epithelial Neoplasms
146815|NCT02191878|Liver Cancer, malignant
146816|NCT02191839|cardiac surgery
146817|NCT02191839|alpha 1 antitrypsin
146818|NCT02191839|inflammation
146819|NCT02191839|post operative bleeding
146820|NCT02191839|organ function
146821|NCT02191826|Transthyretin
146822|NCT02191826|TTR
146823|NCT02191826|Amyloidosis
146824|NCT02191826|SOM0226
146825|NCT02191826|Familiar Amyloid Polyneuropathy
146826|NCT02190747|Intervention study
146827|NCT02190747|Clinical trial Phase 2
146828|NCT02190747|Efficacy and safety
146829|NCT02190747|Heterotopic ossification
146830|NCT02190747|Flare-up
146831|NCT02190747|Palovarotene
146832|NCT02190747|Retinoic acid receptor agonist
146833|NCT02190747|Retinoic acid receptor gamma agonist
146834|NCT02190747|Clementia
146835|NCT02190747|Myositis Ossificans Progressiva
146836|NCT02190747|Munchmeyer's Disease
146837|NCT02190747|FOP
146838|NCT02191774|Medical abortion
146839|NCT02191774|Home abortion
146840|NCT02191683|Anaemia
146841|NCT02191683|Pregnancy
146842|NCT02191683|Foetal programming
146843|NCT02191683|Epigenetics
146844|NCT02191683|Non-communicable diseases
146845|NCT02191683|Tanzania
146846|NCT02191657|HIV
146847|NCT02191657|deferiprone
146848|NCT02191657|iron chelation
146849|NCT02191631|OCD
146850|NCT02191631|adolescents
146851|NCT02191631|pediatric
146852|NCT02191631|internet
146853|NCT02191631|online
146854|NCT02191631|CBT
146855|NCT02191618|Aneurysm
146856|NCT02191618|Intracranial Aneurysm
146857|NCT02191618|Vascular Diseases
146858|NCT02191618|Cardiovascular Diseases
146859|NCT02191618|Intracranial Arterial Diseases
146860|NCT02191618|Cerebrovascular Disorders
146861|NCT02191618|Brain Diseases
146862|NCT02191618|Central Nervous System Diseases
146863|NCT02191618|Nervous System Diseases
146864|NCT02191605|Computerized Brief Intervention
146865|NCT02191592|Tinnitus
146866|NCT02191592|EMA
146867|NCT02191592|Bothersome
146868|NCT02191566|Stomach Cancer
146869|NCT02191553|mindfulness meditation
146870|NCT02191553|alpha rhythm
146871|NCT02191553|EEG
146872|NCT02191553|brain mapping
146873|NCT02191553|emotion
146874|NCT02191553|attention
146875|NCT02191527|PMTCT
146876|NCT02191527|HIV
146877|NCT02191527|Syphilis
146878|NCT02191527|Anemia during pregnancy
146879|NCT02191527|Point of care diagnostics
146880|NCT02191514|Prehospital
146881|NCT02191514|EMS
146882|NCT02191514|EMD
146883|NCT02191514|Stroke
146884|NCT02191514|Dispatch
146885|NCT02191501|Obesity Treatment
146886|NCT02191501|Endoscopy
146887|NCT02191501|Pyloric Suturing
146888|NCT02191501|Pyloric restriction
146889|NCT02191488|Fluorescence
146890|NCT02191488|Brain Tumors
146891|NCT02191488|Brain Metastases
146892|NCT02191488|Malignant Glioma
146893|NCT02191488|Brain Lesions
146894|NCT02191475|sepsis shock
146895|NCT02191475|Tigecycline
146896|NCT02191475|Piperacillin / tazobactam
146897|NCT02191475|Abdominal infection
146898|NCT02191462|Pharmacokinetics
146899|NCT02191462|Niagen
146900|NCT02191462|Nicotinamide riboside
146901|NCT02191436|Haemophilia
146902|NCT02191436|Adherence
146903|NCT02191436|Family Functioning
146904|NCT02191436|Quality of Life
146905|NCT02191436|Anxiety
146906|NCT02191436|Illness Behavior
146907|NCT02191436|Coping Strategies
146908|NCT02191423|postpartum Depression
146909|NCT02191423|Diadic psychotherapy
146910|NCT02191423|Oxytocin
146911|NCT02191423|fMRI
146912|NCT02191423|attachment
146913|NCT02191423|empathy
146914|NCT02191410|Video-assisted thoracoscopic surgery
146915|NCT02191410|one-lung ventilation
146916|NCT02191410|continuous positive-airway ventilation
146917|NCT02191410|high-frequency positive-pressure ventilation
146918|NCT02191410|stroke volume variation
146919|NCT02191410|fluid responsiveness
146920|NCT02191397|Escitalopram
146921|NCT02191397|Major depressive disorder
146922|NCT02191397|Non-inferiority
146923|NCT02191397|Bupropion
146924|NCT02191371|oxygenation
146925|NCT02191371|microcirculation
146926|NCT02191371|one-lung ventilation
146927|NCT02191371|thoracic surgery
146928|NCT02191358|Cytochrome drug interactions
146929|NCT02191358|Drug-drug interaction
146930|NCT02191358|Drug-gene interaction
146931|NCT02191358|Drug-drug-gene interaction
146932|NCT02191358|Drug Metabolism
146933|NCT02191358|Elderly
146934|NCT02191358|Geriatric medicine
146935|NCT02191358|Geriatrics
146936|NCT02191358|Personalized medicine
146937|NCT02191358|Pharmacist
146938|NCT02191358|Pharmacogenetics
146939|NCT02191358|Pharmacogenomics
146940|NCT02191358|Pharmacokinetics
146941|NCT02191358|Polymorphism
146942|NCT02191358|Polypharmacy
146943|NCT02191358|Precision medicine
146944|NCT02191358|Seniors
146945|NCT02191358|YouScript
146946|NCT02191358|CYP2C9
146947|NCT02191358|CYP2C19
146948|NCT02191358|CYP2D6
146949|NCT02191358|CYP3A4
146950|NCT02191358|CYP3A5
146951|NCT02191358|VKORC1
146952|NCT02191358|Amitriptyline
146953|NCT02191358|Aripiprazole
146954|NCT02191358|Atomoxetine
146955|NCT02191358|Carvedilol
146956|NCT02191358|Celecoxib
146957|NCT02191358|Citalopram
146958|NCT02191358|Clobazam
146959|NCT02191358|Clomipramine
146960|NCT02191358|Clopidogrel
146961|NCT02191358|Clozapine
146962|NCT02191358|Codeine
146963|NCT02191358|Desipramine
146964|NCT02191358|Dextromethorphan
146965|NCT02191358|Diazepam
146966|NCT02191358|Doxepin
146967|NCT02191358|Escitalopram
146968|NCT02191358|Esomeprazole
146969|NCT02191358|Fesoterodine
146970|NCT02191358|Flecainide
146971|NCT02191358|Fluoxetine
146972|NCT02191358|Flurbiprofen
146973|NCT02191358|Fluvoxamine
146974|NCT02191358|Haloperidol
146975|NCT02191358|Hydrocodone
146976|NCT02191358|Ibuprofen
146977|NCT02191358|Iloperidone
146978|NCT02191358|Imipramine
146979|NCT02191358|Indomethacin
146980|NCT02191358|Meloxicam
146981|NCT02191358|Metoprolol
146982|NCT02191358|Mexiletine
146983|NCT02191358|Nortriptyline
146984|NCT02191358|Omeprazole
146985|NCT02191358|Oxycodone
146986|NCT02191358|Paroxetine
146987|NCT02191358|Perphenazine
146988|NCT02191358|Phenobarbital
146989|NCT02191358|Phenytoin
146990|NCT02191358|Pimozide
146991|NCT02191358|Piroxicam
146992|NCT02191358|Proguanil
146993|NCT02191358|Propafenone
146994|NCT02191358|Propranolol
146995|NCT02191358|Risperidone
146996|NCT02191358|Sertraline
146997|NCT02191358|Tetrabenazine
146998|NCT02191358|Thioridazine
146999|NCT02191358|Timolol
147000|NCT02191358|Tolterodine
147001|NCT02191358|Torsemide
147002|NCT02191358|Tramadol
147003|NCT02191358|Trimipramine
147004|NCT02191358|Venlafaxine
147005|NCT02191358|Voriconazole
147006|NCT02191358|Vortioxetine
147007|NCT02191345|guided imagery
147008|NCT02191345|burnout
147009|NCT02191345|compassion fatigue
147010|NCT02191345|state anxiety
147011|NCT02191267|CTE
147012|NCT02191267|Positron Emission Topography
147013|NCT02191267|Tau
147014|NCT02191267|Beta-amyloid
147015|NCT02191267|Magnetic Resonance Imaging
147016|NCT02191267|Magnetic Resonance Spectroscopy
147017|NCT02191267|Diffusion Tensor Imaging
147018|NCT02191150|Anaemia, Chronic Kidney Disease, Switching, Aranesp, Darbepoetin Alfa, Epoetin Alfa Biosimilars, Haemodialysis.
147019|NCT02191137|Pulmonary Hypertension,Riociguat,Living with Pulmonary Hypertension Questionnaire
147020|NCT02191124|Measurement-based care
147021|NCT02191124|Unipolar depression
147022|NCT02191124|Outpatients
147023|NCT02191111|Pharmacist
147024|NCT02191111|Pharmacy practice
147025|NCT02191111|Patient care
147026|NCT02191111|Community pharmacy
147027|NCT02191111|Hypertension
147028|NCT02191111|Diabetes
147029|NCT02191111|Dyslipidemia
147030|NCT02191111|Pharmaceutical care
147031|NCT02191098|HIV
147032|NCT02191098|ART
147033|NCT02191072|urticaria,omalizumab
147034|NCT02191059|Non Small Cell Lung Cancer
147035|NCT02191059|Wild Type EGFR
147036|NCT02191059|Icotinib
147037|NCT02191059|Second-line Treatment
147038|NCT02191046|nasal irrigation
147039|NCT02191046|sinusitis
147040|NCT02191046|children
147041|NCT02191046|buffered hypertonic saline
147042|NCT02191046|nasal irrigation device
147043|NCT02191033|cigarette smoking
147044|NCT02191033|tobacco use cessation products
147045|NCT02191020|Total Glucosides of Paeony(TGP)
147046|NCT02191020|Acitretin Capsules
147047|NCT02191020|Psoriasis Vulgaris
147048|NCT02190994|Hydrocortisone
147049|NCT02190994|Pituitary adenomas
147050|NCT02190994|Replacement therapy
147051|NCT02190981|Small bowel obstruction
147052|NCT02190981|Ultrasound
147053|NCT02190981|Emergency department
147054|NCT02190968|Mindfulness Based Cognitive Therapy
147055|NCT02190968|Internet interventions
147056|NCT02190968|Residual depressive symptoms
147057|NCT02190968|Depressive relapse prevention
147058|NCT02190903|delirium
147059|NCT02190903|hip fracture
147060|NCT02190903|general anesthesia
147061|NCT02190903|spinal anesthesia
147062|NCT02190903|postoperative complications
147063|NCT02190877|Heart Failure
147064|NCT02190877|Impedance
147065|NCT02190877|Fluids
147066|NCT02190851|urinary disorders
147067|NCT02190851|Parkinson's disease
147068|NCT02190838|Melanoma
147069|NCT02190838|Melatonin
147070|NCT02190838|Metformin
147071|NCT02190838|Dacarbazine
147072|NCT02190812|wrist muscle strength
147073|NCT02190799|Corona Virus
147074|NCT02190799|Convalescent plasma
147075|NCT02190799|Serology
147076|NCT02190786|Hyperuricemia
147077|NCT02190773|Chronic Periodontitis, Aggressive Periodontitis, RANKL/OPG ratio, Gingival crevicular fluid
147078|NCT02190734|Stroke
147079|NCT02190734|Pusher Syndrome
147080|NCT02190734|Lateropulsion
147081|NCT02190734|Pushing Behaviors
147082|NCT02190734|Burke Lateropulsion Scale
147083|NCT02190721|Neutropenia
147084|NCT02190708|PQ912
147085|NCT02190708|Midazolam
147086|NCT02190708|Omeprazole
147087|NCT02190708|Pharmacokinetics
147088|NCT02190708|Drug Interaction
147089|NCT02190682|postoperative
147090|NCT02190682|chronic
147091|NCT02190682|pain
147092|NCT02190682|software
147093|NCT02190656|Rectal cancer
147094|NCT02190656|Anterior Resection Syndrome
147095|NCT02190656|Functional outcomes
147096|NCT02190643|Smoking
147097|NCT02190643|HIV
147098|NCT02190643|Latino
147099|NCT02190643|Cessation
147100|NCT02190643|Nicotine patch
147101|NCT02190617|Asthma
147102|NCT02190617|Guidelines
147103|NCT02190617|Community Health Worker
147104|NCT02190604|FEV1- Forced Expiratory volume
147105|NCT02190604|LCI - Lung Clearance Index
147106|NCT02190604|CFTR - cystic fibrosis transmembrane conductance regulator
147107|NCT02190591|epidural
147108|NCT02190591|pregnant
147109|NCT02190591|Cesarean Section
147110|NCT02190591|forceps
147111|NCT02190591|vaginal
147112|NCT02190565|pregnancy, lactation, food supplement, anaemia
147113|NCT02190552|Brain
147114|NCT02190552|Brain Clot
147115|NCT02190552|Brain Diseases
147116|NCT02190552|Brain Infarction
147117|NCT02190552|Cerebral Ischemia
147118|NCT02190552|Cerebrovascular Disorders
147119|NCT02190552|EmboTrap® Revascularization Device
147120|NCT02190552|EmboTrap
147121|NCT02190552|Ischemia
147122|NCT02190552|Ischemic
147123|NCT02190552|Ischemic Stroke
147124|NCT02190552|Mechanical Thrombectomy
147125|NCT02190552|Neurovascular Intervention
147126|NCT02190552|Revascularization
147127|NCT02190552|Stent Retriever
147128|NCT02190552|Stroke
147129|NCT02190552|Vascular Diseases
147130|NCT02190539|Breast cancer
147131|NCT02190539|complementary medicine
147132|NCT02190539|homeopathy
147133|NCT02190539|quality of life
147134|NCT02190526|mesalamine
147135|NCT02190526|amitriptyline
147136|NCT02190526|Severity of Illness Index
147137|NCT02190500|stroke
147138|NCT02190500|tpa
147139|NCT02190500|emergency medical service
147140|NCT02190500|ems
147141|NCT02190500|mobile
147142|NCT02190500|ct scan
147143|NCT02190474|fibromyalgia
147144|NCT02190474|juvenile fibromyalgia
147145|NCT02190474|juvenile primary fibromyalgia syndrome (JPFS)
147146|NCT02190474|adolescent pain
147147|NCT02190474|mindfulness
147148|NCT02190474|MBSR
147149|NCT02190461|Early Respiratory Rehabilitation
147150|NCT02190461|Chronic Obstructive Pulmonary Disease
147151|NCT02190461|Re-admitted patients
147152|NCT02190461|Open clinical trial
147153|NCT02190461|Exacerbations
147154|NCT02190448|galactogogue
147155|NCT02190448|lactation
147156|NCT02190448|milk production
147157|NCT02190448|breastfeeding
147158|NCT02190435|Computer-assisted navigation
147159|NCT02190435|ADAPT
147160|NCT02190435|Intramedullary nail
147161|NCT02190435|Intertrochanteric femur fracture
147162|NCT02190422|reproductive technologies, assisted
147163|NCT02190422|echocardiography
147164|NCT02190422|cardiology
147165|NCT02190422|pediatrics
147166|NCT02190409|Dental Implant,
147167|NCT02190396|Calcium
147168|NCT02190396|Vitamin D
147169|NCT02190396|Placental calcification.
147170|NCT02190383|Tic-Disorder, Tourette-Disorder, Habit Reversal Training
147171|NCT02190370|Tic-Disorder, Tourette-Disorder, Resources activation
147172|NCT02190357|Cirrhosis
147173|NCT02190344|Eight
147174|NCT02190344|Channel
147175|NCT02190344|Paddle
147176|NCT02190344|Coil
147177|NCT02190344|MRI
147178|NCT02190344|Prostate
147179|NCT02190344|Healthy Male
147180|NCT02190331|Detraining
147181|NCT02190331|Neck
147182|NCT02190331|Exercise
147183|NCT02190331|Posture
147184|NCT02190331|Rehabilitation
147185|NCT02190318|peritoneal dialysis；
147186|NCT02190318|residual renal function；
147187|NCT02190318|RAAS
147188|NCT02190279|Prostate Specific Membrane Antigen
147189|NCT02190279|Radiolabeled PET Agent
147190|NCT02190279|Imaging
147191|NCT02190279|NaF
147192|NCT02190266|Extrapulmonary
147193|NCT02190266|Immunodeficiency
147194|NCT02190266|Genetics
147195|NCT02190266|Infection
147196|NCT02190266|Fungal
147197|NCT02190253|Renal Threshold
147198|NCT02190253|Liver Transplant
147199|NCT02190253|Transplantation
147200|NCT02190253|Hepatitis E
147201|NCT02190240|Complementary and Alternative Medicine
147202|NCT02190240|Integrative Medicine
147203|NCT02190240|Pain Management
147204|NCT02190227|Breast Cancer
147205|NCT02190227|Chemotherapy
147206|NCT02190227|Neoadjuvant
147207|NCT02190227|RNA Disruption Assay
147208|NCT02190227|Biopsies
147209|NCT02190227|Response
147210|NCT02190214|Hyperthyroidism
147211|NCT02190214|Hypothyroidism
147212|NCT02190214|Autoimmune thyroid disorders
147213|NCT02190214|Iodine deficiency
147214|NCT02190214|Genetic susceptibility
147215|NCT02190201|videolaryngoscope
147216|NCT02190201|double lumen intubation
147217|NCT02190188|wedge insoles,
147218|NCT02190188|knee brace,
147219|NCT02190188|orthotic device
147220|NCT02190188|goal
147221|NCT02190162|Patients undergoing tonsillectomy with or without adenoidectomy
147222|NCT02190149|Factor VIII Deficiency
147223|NCT02190149|Factor FIX Deficiency
147224|NCT02190136|obesity
147225|NCT02190136|protein-rich whole foods diet
147226|NCT02190136|aerobic fitness
147227|NCT02190136|resistance training
147228|NCT02190136|stretching/yoga training
147229|NCT02190136|glycemia
147230|NCT02190136|mood state
147231|NCT02190123|Acute Coronary Syndrome (ACS)
147232|NCT02190123|Oral antiplatelets (ticagrelor, prasugrel, clopidogrel) (OAP)
147233|NCT02190123|Treatment persistence.
147234|NCT02190110|Pulmonary embolism
147235|NCT02190110|diagnosis
147236|NCT02190110|emergency medicine
147237|NCT02190110|ultrasonography
147238|NCT02190097|PCOS
147239|NCT02190097|insulin sensitivity
147240|NCT02190097|paleolithic diet
147241|NCT02190084|apathy
147242|NCT02190084|Alzheimer's
147243|NCT02190084|executive function
147244|NCT02190071|EUS-FNA
147245|NCT02190071|cytopathology
147246|NCT02190071|slide smear
147247|NCT02190058|safety
147248|NCT02190058|pharmacokinetics
147249|NCT02190058|DS-1971a
147250|NCT02190045|Balance
147251|NCT02190045|gait
147252|NCT02190045|Wii-Fit
147253|NCT02190019|Mild Cognitive Impairment
147254|NCT02190019|apathy
147255|NCT02190019|executive function
147256|NCT02190006|Polycystic ovarian syndrome
147257|NCT02190006|Follicle output rate
147258|NCT02190006|preovulatory count
147259|NCT02190006|ICSI
147260|NCT02189993|Mortality
147261|NCT02189993|Long term follow-up
147262|NCT02189993|Parenteral Nutrition, Total
147263|NCT02189980|Nausea
147264|NCT02189980|Post-operative
147265|NCT02189967|non-small cell lung cancer
147266|NCT02189967|radiotherapy
147267|NCT02189967|accelerated fractionation
147268|NCT02189967|conventional fractionation
147269|NCT02189967|postoperative
147270|NCT02189954|elderly; laryngeal masks; postoperative complications
147271|NCT02189941|Deferiprone
147272|NCT02189941|Deferiprone sustained-release tablets
147273|NCT02189941|Pharmacokinetics
147274|NCT02189902|Vitamin D
147275|NCT02189889|Active preoperative anemia management
147276|NCT02189889|Erythrocyte transfusion
147277|NCT02189889|RBC transfusion
147278|NCT02189889|Red cell transfusion
147279|NCT02189889|Transfusion in cardiac surgery
147280|NCT02189889|Anemia treatment with erythropoietin
147281|NCT02189889|Anemic cardiac surgery patients
147282|NCT02189889|Erythrocyte stimulating agent (ESA)
147283|NCT02189889|Iron deficiency anemia
147284|NCT02189889|EPO
147285|NCT02189889|Feraheme
147286|NCT02189876|HIV Prevention
147287|NCT02189876|Behavioral Intervention
147288|NCT02189876|Condom Use
147289|NCT02189876|African American
147290|NCT02189876|Sexually Transmitted Disease
147291|NCT02189876|Sexually Transmitted Infection
147292|NCT02189876|Internet
147293|NCT02189863|Driving Simulator
147294|NCT02189863|Air Optix Aqua
147295|NCT02189863|AOAMF
147296|NCT02189850|colonoscopy
147297|NCT02189850|pediatric
147298|NCT02189837|Raised cholesterol
147299|NCT02189837|Cholesterol
147300|NCT02189837|Elevated Cholesterol
147301|NCT02189837|Hyperlipidemias
147302|NCT02189837|Dyslipidemias
147303|NCT02189837|Lipid Metabolism Disorders
147304|NCT02189837|Metabolic Diseases
147305|NCT02189811|IPV
147306|NCT02189811|OPV
147307|NCT02189811|tOPV
147308|NCT02189811|bOPV
147309|NCT02189811|Polio
147310|NCT02189811|Endgame
147311|NCT02189811|Pakistan
147312|NCT02189798|Cochlear Implant
147313|NCT02189798|HiRes™ 90K Advantage implant
147314|NCT02189798|Cochlear Implantation
147315|NCT02189798|HiFocus™ Mid-Scala electrode
147316|NCT02189798|Listening Benefits
147317|NCT02189798|Adults
147318|NCT02189798|Cochlear Implant Benefit
147319|NCT02189798|Electrical Stimulation
147320|NCT02189798|Electro-Acoustic Stimulation (EAS)
147321|NCT02189785|social
147322|NCT02189785|rejection
147323|NCT02189785|acceptance
147324|NCT02189785|PET
147325|NCT02189785|opioid
147326|NCT02189785|fMRI
147327|NCT02189785|reward
147328|NCT02189785|exclusion
147329|NCT02189772|ADHD
147330|NCT02189772|Inattention
147331|NCT02189772|MDX
147332|NCT02189759|Hypothermia
147333|NCT02189759|Hyperthermia
147334|NCT02189759|Kangaroo Mother Care
147335|NCT02189759|Newborn
147336|NCT02189746|Hypothermia
147337|NCT02189746|Newborn
147338|NCT02189746|Hyperthermia
147339|NCT02189746|Kangaroo mother care
147340|NCT02189720|Amifampridine Phosphate
147341|NCT02189720|Amifampridine
147342|NCT02189720|3,4-Diaminopyridine Phosphate
147343|NCT02189720|3,4-Diaminopyridine
147344|NCT02189720|3,4-DAP
147345|NCT02189720|LEMS
147346|NCT02189720|CMS
147347|NCT02189720|Lambert-Eaton Myasthenic Syndrome
147348|NCT02189720|Congenital Myasthenic Syndrome
147349|NCT02189720|Neuromuscular disorders
147350|NCT02189720|Neuromuscular
147351|NCT02189720|eye movement
147352|NCT02189720|electromyography
147353|NCT02189720|EMG
147354|NCT02189720|Expanded Access
147355|NCT02189720|Firdapse®
147356|NCT02189720|Downbeat Nystagmus
147357|NCT02189707|Gastrointestinal disorder
147358|NCT02189707|Constipation
147359|NCT02189707|Probiotics
147360|NCT02189707|Dietary supplement
147361|NCT02189694|Type 1 diabetes
147362|NCT02189694|Hypoglycemia
147363|NCT02189694|Insulin
147364|NCT02189694|Glucagon
147365|NCT02189694|Closed-loop system
147366|NCT02189694|Artificial pancreas
147367|NCT02189681|spinal anaesthesia
147368|NCT02189681|ultrasound
147369|NCT02189681|paramedian
147370|NCT02189668|Appendicitis
147371|NCT02189668|Non-operative
147372|NCT02189668|Children
147373|NCT02189668|Appendicolith
147374|NCT02189668|fecalith
147375|NCT02189668|Pediatrics
147376|NCT02189655|shivering spinal anesthesia
147377|NCT02189629|Acne vulgaris
147378|NCT02189629|Safety
147379|NCT02189629|Face
147380|NCT02189629|Trunk
147381|NCT02189616|asthma management
147382|NCT02189616|SMS reminder
147383|NCT02189616|SMS consultation
147384|NCT02189603|hepatitis E
147385|NCT02189603|Immunogenicity
147386|NCT02189603|vaccine
147387|NCT02189603|safety
147388|NCT02189590|supraglottic airway
147389|NCT02189590|children
147390|NCT02189590|fiberoptic guided tracheal intubation
147391|NCT02189590|air-Q
147392|NCT02189590|i-gel
147393|NCT02189577|Chronic Obstructive Pulmonary disease
147394|NCT02189577|COPD
147395|NCT02189538|Infections, Enteral nutrition, SIRS, critically ill
147396|NCT02189525|traumatic brain injury
147397|NCT02189525|sports head injury
147398|NCT02189525|sports concussion
147399|NCT02189512|brain-death organ donors
147400|NCT02189512|intestinal manipulation
147401|NCT02189512|monocytes
147402|NCT02189499|Stents
147403|NCT02189499|Angioplasty
147404|NCT02189499|Coronary Vessels
147405|NCT02189499|Coronary Artery Disease
147406|NCT02189499|Angina Pectoris
147407|NCT02189499|Myocardial Ischemia
147408|NCT02189499|Myocardial Infarction
147409|NCT02189499|Myocardial Revascularization
147410|NCT02189486|Prostate Cancer
147411|NCT02189486|Radical Prostatectomy
147412|NCT02189486|Prostate biopsy
147413|NCT02189486|Upgrading
147414|NCT02189486|Upgrading Reference set
147415|NCT02189473|metastatic epidural spinal cord compression
147416|NCT02189473|motor function
147417|NCT02189473|ambulatory status
147418|NCT02189473|pain
147419|NCT02189473|quality of life
147420|NCT02189473|overall survival
147421|NCT02189473|local control
147422|NCT02189473|toxicity
147423|NCT02189460|Cognition
147424|NCT02189447|Keratoconus
147425|NCT02189447|Ectasia
147426|NCT02189447|Corneal Cross-linking
147427|NCT02189421|peroral cholangioscopy
147428|NCT02189421|ultra-slim upper endoscope
147429|NCT02189421|multibending endoscope
147430|NCT02189408|Platelet rich plasma
147431|NCT02189408|Autologous conditioned plasma
147432|NCT02189408|Outerbridge
147433|NCT02189395|Type 2 diabetes
147434|NCT02189395|Uncontrolled blood glucose
147435|NCT02189395|insulin
147436|NCT02189395|glargine
147437|NCT02189395|NPH
147438|NCT02189382|Sensitivity
147439|NCT02189356|Pregnancy-related low back and pelvic pain
147440|NCT02189356|exercise program
147441|NCT02189356|nurse
147442|NCT02189343|Multiple Myeloma
147443|NCT02189343|Relapsed and Refractory
147444|NCT02189343|Refractory Disease
147445|NCT02189343|Progressive Disease
147446|NCT02189343|Pomalidomide
147447|NCT02189343|Dexamethasone
147448|NCT02189343|Proteasome Inhibitor
147449|NCT02189343|Ricolinostat
147450|NCT02189304|Healthy volunteers
147451|NCT02189291|Indwelling catheter
147452|NCT02189291|Hospital stay
147453|NCT02189291|Urinary tract infection
147454|NCT02189291|Sacrocolpopexy
147455|NCT02189278|Breast Cancer
147456|NCT02189278|Surveillance
147457|NCT02189278|Mammography
147458|NCT02189278|Adherence
147459|NCT02189265|Live birth [MeSH]
147460|NCT02189265|Infant [MeSH]
147461|NCT02189265|Infant, newborn [MeSH]
147462|NCT02189265|Second-hand smoke
147463|NCT02189265|Tobacco smoke pollution [MeSH]
147464|NCT02189265|Smoke-free
147465|NCT02189265|Smoke-free policy [MeSH]
147466|NCT02189226|probe-based confocal laser endomicroscopy (pCLE), early gastric cancer (EGC), endoscopic submucosal dissection (ESD), margin
147467|NCT02189213|anxiety
147468|NCT02189213|SSRI
147469|NCT02189213|biomarker
147470|NCT02189213|sleep
147471|NCT02189213|children
147472|NCT02189213|adolescents
147473|NCT02189213|young adults
147474|NCT02189200|nutritional counseling
147475|NCT02189200|oat bran
147476|NCT02189200|dyslipidemia
147477|NCT02189200|cardiovascular disease
147478|NCT02189187|Weight Loss
147479|NCT02189187|Body Weight Changes
147480|NCT02189187|Body Weight
147481|NCT02189187|Magnetic Resonance Imaging
147482|NCT02189187|Emotions
147483|NCT02189187|Emotion regulation
147484|NCT02189187|Health Behavior
147485|NCT02189187|Eating behavior
147486|NCT02189174|Solid tumor,
147487|NCT02189174|breast cancer,
147488|NCT02189174|lung cancer,
147489|NCT02189174|endometrial cancer
147490|NCT02189161|anal intraepithelial neoplasia
147491|NCT02189161|AIN
147492|NCT02189161|Radiofrequency Ablation
147493|NCT02189161|RFA
147494|NCT02189148|Prediction
147495|NCT02189148|Preeclampsia
147496|NCT02189148|Preterm birth
147497|NCT02189148|Pregnancy
147498|NCT02189148|Placenta
147499|NCT02189148|Intra-uterine growth restriction
147500|NCT02189148|fetal growth restriction
147501|NCT02189148|Ultrasound
147502|NCT02189148|Doppler
147503|NCT02189148|Biomarkers
147504|NCT02189148|PAPP-A
147505|NCT02189148|Placental growth factor (PlGF)
147506|NCT02189109|glioblastoma
147507|NCT02189109|multiforme
147508|NCT02189109|radiation
147509|NCT02189109|radiation therapy
147510|NCT02189096|Sepsis
147511|NCT02189096|National Early Warning Score
147512|NCT02189096|Lactate
147513|NCT02189083|Leiomyoma
147514|NCT02189083|Medicine, Chinese Traditional
147515|NCT02189083|Randomized Controlled Trial
147516|NCT02189070|Follow-up
147517|NCT02189070|Percutaneous coronary intervention
147518|NCT02189070|Patient preference
147519|NCT02189070|DUTCH PEERS
147520|NCT02189070|TWENTE
147521|NCT02189057|Bipolar
147522|NCT02189057|Unipolar
147523|NCT02189057|Genotyping
147524|NCT02189057|Pharmacokinetic
147525|NCT02189057|Pharmacodynamic
147526|NCT02189044|aged;
147527|NCT02189044|breathing exercises;
147528|NCT02189044|muscle strength.
147529|NCT02189031|Upper limb Amputee
147530|NCT02189031|Targeted Muscle Reinnervation
147531|NCT02189031|Prosthetic
147532|NCT02189018|Peripheral arterial disease
147533|NCT02189018|Endovascular
147534|NCT02189018|Exercise
147535|NCT02189018|Perfusion
147536|NCT02189018|Functional capacity
147537|NCT02189005|High blood sugar
147538|NCT02189005|High HbA1C
147539|NCT02189005|hyperglycemia
147540|NCT02189005|Pre-Diabetes
147541|NCT02189005|Natural Supplement for Diabetes
147542|NCT02188992|Sepsis
147543|NCT02188992|Immune activation
147544|NCT02188992|Systemic Inflammation
147545|NCT02188992|Emergency Medicine
147546|NCT02188992|Critical Care
147547|NCT02188979|airway
147548|NCT02188979|equipment - laryngoscopes
147549|NCT02188979|intubation - tracheal
147550|NCT02188979|obesity.
147551|NCT02188966|Geographic Information System
147552|NCT02188966|Emergency Care Information Systems
147553|NCT02188966|Telemedicine
147554|NCT02188966|Emergency Hospital Service
147555|NCT02188953|aflatoxin
147556|NCT02188953|Kenya
147557|NCT02188940|Asthma
147558|NCT02188940|Obesity
147559|NCT02188940|Clinical control
147560|NCT02188940|Exercise
147561|NCT02188940|Weight-loss
147562|NCT02188927|Advanced notification letter
147563|NCT02188927|Standard invitation
147564|NCT02188927|Participation rate
147565|NCT02188927|Colonoscopy
147566|NCT02188927|Screening
147567|NCT02188927|Colorectal Neoplasms
147568|NCT02188927|Digestive System Diseases
147569|NCT02188914|Inhalant use disorder
147570|NCT02188914|Positron emission tomography
147571|NCT02188914|Magnetic Resonance Imaging
147572|NCT02188914|Executive functions assessment
147573|NCT02188914|Transcriptome
147574|NCT02188901|HCC
147575|NCT02188901|Sonazoid
147576|NCT02188901|Ultrasonography
147577|NCT02188901|Screening
147578|NCT02188888|septic shock
147579|NCT02188888|esmolol
147580|NCT02188888|tachycardia
147581|NCT02188888|betablockers
147582|NCT02188875|Fitbit One
147583|NCT02188875|wearable sensor
147584|NCT02188875|wearable device
147585|NCT02188875|web-based intervention
147586|NCT02188875|SMS text messages
147587|NCT02188875|randomized controlled trial
147588|NCT02188875|physical activity
147589|NCT02188875|behavioral intervention
147590|NCT02188875|text message prompts
147591|NCT02188875|text messaging
147592|NCT02188875|technology
147593|NCT02188875|exercise
147594|NCT02188862|Rheumatic heart disease
147595|NCT02188862|Acute rheumatic fever
147596|NCT02188862|Group A streptococcal disease
147597|NCT02188862|Streptococcus pyogenes
147598|NCT02188862|Genetics
147599|NCT02188862|Oceania
147600|NCT02188849|creatine
147601|NCT02188849|resistance training
147602|NCT02188849|older women
147603|NCT02188849|muscle strength
147604|NCT02188823|prediabetes
147605|NCT02188823|obesity
147606|NCT02188823|mindful eating
147607|NCT02188823|positive affect
147608|NCT02188823|low carbohydrate
147609|NCT02188823|ketogenic
147610|NCT02188823|diet
147611|NCT02188810|PAL
147612|NCT02188810|fluviral
147613|NCT02188810|healthy volunteer
147614|NCT02188810|adjuvant
147615|NCT02188810|TH1 immune response
147616|NCT02188797|homeless
147617|NCT02188797|young adults
147618|NCT02188797|substance use
147619|NCT02188797|HIV risk
147620|NCT02188797|sexual risk behavior
147621|NCT02188797|group motivational interviewing
147622|NCT02188771|Moderate to Severe OA
147623|NCT02188771|VAS score of ≥ 5
147624|NCT02188771|grade III-IV Kellgren Lawrence of OA
147625|NCT02188771|subjects who failed conservative treatment
147626|NCT02188771|subjects who candidates for total knee replacement (TKR)
147627|NCT02188771|subject 45 and 75 years old
147628|NCT02188771|subject is experiencing pain in the intended study knee with a VAS score of ≥ 5
147629|NCT02188771|subject has a Body Mass Index (BMI) between 18.5 and 35
147630|NCT02188758|iron
147631|NCT02188758|hepcidin-25
147632|NCT02188758|pulmonary exacerbation
147633|NCT02188758|interleukin-6
147634|NCT02188745|metastatic
147635|NCT02188745|locally advanced
147636|NCT02188745|ER+
147637|NCT02188745|Estrogen therapy
147638|NCT02188745|Estradiol therapy
147639|NCT02188732|Community Mental Health
147640|NCT02188732|Serious Mental Illness
147641|NCT02188732|Medical Comorbidity
147642|NCT02188732|Self-Management
147643|NCT02188732|Automated Telehealth
147644|NCT02188732|Early Mortality
147645|NCT02188719|Donor-Alloantigen-Reactive Regulatory T Cell Therapy
147646|NCT02188719|Tregs
147647|NCT02188719|Cell- and Tissue-Based Therapy
147648|NCT02188719|Immunotherapy, Adoptive
147649|NCT02188719|Liver Transplantation
147650|NCT02188706|Leukemia
147651|NCT02188706|Acute myeloid leukemia
147652|NCT02188706|AML
147653|NCT02188706|Myelodysplastic syndrome
147654|NCT02188706|MDS
147655|NCT02188706|Relapsed or refractory
147656|NCT02188706|Decitabine
147657|NCT02188706|Dacogen
147658|NCT02188706|Carboplatin
147659|NCT02188706|Paraplatin
147660|NCT02188706|Arsenic Trioxide
147661|NCT02188706|ATO
147662|NCT02188706|Trisenox
147663|NCT02188680|fructose test
147664|NCT02188667|Chronic Noncancer Pain
147665|NCT02188667|Musculoskeletal Pain
147666|NCT02188667|Neuropathic Pain
147667|NCT02188667|Headache Pain
147668|NCT02188654|psoriatic arthritis
147669|NCT02188654|inflammation
147670|NCT02188654|metabolic syndrome
147671|NCT02188654|metformin
147672|NCT02188641|Psoriatic arthritis
147673|NCT02188641|inflammation
147674|NCT02188641|obesity
147675|NCT02188641|diet
147676|NCT02188641|exercise
147677|NCT02188628|Motor recovery, robotics, stroke rehabilitation
147678|NCT02188615|Squamous Cell Esophageal Carcinoma
147679|NCT02188615|minimally invasive esophagectomy
147680|NCT02188615|laparoscopy
147681|NCT02188615|thoracoscopy
147682|NCT02188576|Craniofacial Surgery
147683|NCT02188576|tranexamic acid
147684|NCT02188576|Antifibrinolytic
147685|NCT02188563|Smoking cessation
147686|NCT02188563|Head and neck neoplasms
147687|NCT02188563|Lung neoplasms
147688|NCT02188563|Thoracic neoplasms
147689|NCT02188563|Radiation
147690|NCT02188550|relapse or refractory or persistent epithelial ovarian fallopian tube
147691|NCT02188550|primary peritoneal carcinoma or endometrial cancer
147692|NCT02188537|Myeloma
147693|NCT02188537|proteasome inhibitor-nonresponsive myeloma
147694|NCT02188537|Nelfinavir
147695|NCT02188537|bortezomib
147696|NCT02188537|bortezomib-sensitizing drug
147697|NCT02188524|balance, exercise, compensatory stepping, tai chi
147698|NCT02188511|E-Cigarettes
147699|NCT02188511|Lung
147700|NCT02188511|Non-Smokers
147701|NCT02188511|Lung Biology
147702|NCT02188472|Oxidative Stress
147703|NCT02188472|antibiotics
147704|NCT02188446|Radical cystectomy
147705|NCT02188446|Bladder cancer
147706|NCT02188446|Smoking cessation
147707|NCT02188446|Alcohol cessation
147708|NCT02188446|Postoperative complications
147831|NCT02187900|Tripterygium Wilfordii HOOK. f.
147832|NCT02187900|Mycophenolate mofetil
147709|NCT02188433|Effectiveness of quit immediately (QI) and cut down to quit (CDTQ) interventions in achieving smoking abstinence
147710|NCT02188420|PAS
147711|NCT02188420|TMS
147712|NCT02188420|Stroke
147713|NCT02188420|Paired Associative Stimulation
147714|NCT02188420|Transcranial Magnetic Stimulation
147715|NCT02188407|thoracotomy
147716|NCT02188407|one-lung ventilation (OLV)
147717|NCT02188407|total intravenous anaesthesia (TIVA)
147718|NCT02188407|volatile induced and maintained anaesthesia (VIMA)
147719|NCT02188407|cytokines
147720|NCT02188407|interleukine (IL)
147721|NCT02188394|migraine,
147722|NCT02188394|pressure pain,
147723|NCT02188394|anesthetic blocks
147724|NCT02188394|patients
147725|NCT02188381|Resistant Hypertension
147726|NCT02188381|Uncontrolled Hypertension
147727|NCT02188368|Pomalidomide
147728|NCT02188368|Lenalidomide refractory
147729|NCT02188368|multiple myeloma
147730|NCT02188355|Ultimaster
147731|NCT02188355|registry
147732|NCT02188355|DES
147733|NCT02188355|DAPT
147734|NCT02188329|Early care and education
147735|NCT02188329|ECE
147736|NCT02188329|workforce
147737|NCT02188329|child care
147738|NCT02188329|caregivers
147739|NCT02188329|home-based providers
147740|NCT02188329|center-based providers
147741|NCT02188316|Cold forceps polypectomy
147742|NCT02188316|Diminutive colorectal polyp
147743|NCT02188316|Hot biopsy forceps electrocauterization
147744|NCT02188316|Jumbo forceps.
147745|NCT02188290|Haploidentical donor
147746|NCT02188290|Unrelated donor
147747|NCT02188290|Umbilical cord blood
147748|NCT02188290|Graft versus host disease
147749|NCT02188290|Transplant-related mortality
147750|NCT02188290|Hematologic malignancy
147751|NCT02188290|Hematopoietic Stem Cell Transplantation
147752|NCT02188251|Activamp
147753|NCT02188251|Gynostemma pentaphyllum
147754|NCT02188251|Body weight
147755|NCT02188251|Fat Loss
147756|NCT02188251|Metabolic markers
147757|NCT02188251|Overweight participants
147758|NCT02188251|DXA
147759|NCT02188251|AMPK
147760|NCT02188238|saliva
147761|NCT02188238|protein
147762|NCT02188238|oral health
147763|NCT02188238|film
147764|NCT02188238|pellicle
147765|NCT02188225|Hot flash
147766|NCT02188225|Acupuncture
147767|NCT02188225|Fluoxetine
147768|NCT02188225|Quality of life
147769|NCT02188199|Hip
147770|NCT02188199|Knee
147771|NCT02188199|Hip replacement
147772|NCT02188199|Knee replacement
147773|NCT02188199|Total Joint
147774|NCT02188186|triple combination
147775|NCT02188186|metformin
147776|NCT02188186|sitagliptin
147777|NCT02188186|thiazolidinedione
147778|NCT02188160|Pain
147779|NCT02188160|Corticosteroid
147780|NCT02188160|Dry Eye
147781|NCT02188160|Hyperemia
147782|NCT02188160|Ocular Discomfort
147783|NCT02188147|Syncope
147784|NCT02188147|Sudden Cardiac Arrest
147785|NCT02188147|Sudden Cardiac Death
147786|NCT02188147|Cardiac Arrest
147787|NCT02188147|Emergency Service
147788|NCT02188147|Emergency Department
147789|NCT02188147|Ambulatory Electrocardiography
147790|NCT02188147|Holter
147791|NCT02188147|Holter Electrocardiography
147792|NCT02188147|Holter Monitoring
147793|NCT02188134|Adverse events,
147794|NCT02188134|adverse drug reactions,
147795|NCT02188134|medication error,
147796|NCT02188134|noncompliance
147797|NCT02188108|quality of life
147798|NCT02188108|QOL
147799|NCT02188108|urolithiasis
147800|NCT02188108|nephrolithiasis
147801|NCT02188108|kidney stones
147802|NCT02188108|patient-reported outcomes
147803|NCT02188069|Non-atherosclerotic Coronary Artery Disease
147804|NCT02188056|Venous
147805|NCT02188056|Thromboembolic
147806|NCT02188056|Pulmonary embolism
147807|NCT02188043|Alcohol use disorder
147808|NCT02188043|Motivational Intervention
147809|NCT02188043|Health expenditures
147810|NCT02188043|efficacy study
147811|NCT02188030|musculoskeletal symptom
147812|NCT02188030|industrial workers
147813|NCT02188030|physical-activity program
147814|NCT02188030|resistance training
147815|NCT02188030|randomized controlled trial
147816|NCT02188017|prednisone, methotrexate, sarcoidosis, azathioprine
147817|NCT02188004|HPV
147818|NCT02188004|genital warts
147819|NCT02187991|metastatic breast cancer
147820|NCT02187991|Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer
147821|NCT02187991|Estrogen Receptor-positive (ER+) breast cancer
147822|NCT02187991|Triple Negative breast cancer
147823|NCT02187991|alisertib
147824|NCT02187991|paclitaxel
147825|NCT02187978|Early total enteral feeding (ETEF)
147826|NCT02187978|Conventional enteral feeding (CEF)
147827|NCT02187978|VLBW infants
147828|NCT02187978|NEC
147829|NCT02187978|Preterm infants
147830|NCT02187926|Drug therapy
147833|NCT02187887|alcohol
147834|NCT02187887|young adult veterans
147835|NCT02187887|brief intervention
147836|NCT02187887|online
147837|NCT02187887|perceived norms
147838|NCT02187835|complexity
147839|NCT02187835|electroencephalogram
147840|NCT02187835|entropy
147841|NCT02187835|negative symptoms
147842|NCT02187835|schizophrenia.
147843|NCT02187822|Brain
147844|NCT02187822|Advanced solid tumors
147845|NCT02187822|Fractionated Stereotactic Radiotherapy (FSRT)
147846|NCT02187822|Brain lesions
147847|NCT02187822|Primary solid malignancy
147848|NCT02187796|HIV
147849|NCT02187796|Dementia
147850|NCT02187796|HAND
147851|NCT02187796|COGNISION System
147852|NCT02187796|ERP
147853|NCT02187796|event-related potentials
147854|NCT02187783|Solid malignancy,
147855|NCT02187783|Hematologic malignancy,
147856|NCT02187783|Mutations,
147857|NCT02187783|Amplifications,
147858|NCT02187783|Signature,
147859|NCT02187783|CDK4,
147860|NCT02187783|CDK6,
147861|NCT02187783|CDK4/6,
147862|NCT02187783|Cyclin D1,
147863|NCT02187783|CCND1,
147864|NCT02187783|Cyclin D3,
147865|NCT02187783|CCND3,
147866|NCT02187783|p16 mutation,
147867|NCT02187783|CDKN2A,
147868|NCT02187783|LEE011,
147869|NCT02187783|Breast cancer,
147870|NCT02187783|Ovarian cancer,
147871|NCT02187783|Lymphoma,
147872|NCT02187783|Mesothelioma,
147873|NCT02187783|Pancreatic neuroendocrine,
147874|NCT02187783|Leukemia
147875|NCT02187783|Tumor
147876|NCT02187757|Dyslipidemia
147877|NCT02187757|High cholesterol
147878|NCT02187757|High LDL
147879|NCT02187757|Triglycerides
147880|NCT02187744|Biosimilars
147881|NCT02187744|Non-inferiority
147882|NCT02187744|Neoadjuvant Setting
147883|NCT02187744|Early Breast Cancer
147884|NCT02187744|PK
147885|NCT02187744|Phase 3
147886|NCT02187744|Trastuzumab
147887|NCT02187744|Herceptin
147888|NCT02187744|HER2 Positive
147889|NCT02187731|Multiple Myeloma
147890|NCT02187731|Functional Imaging
147891|NCT02187731|PET/CT
147892|NCT02187731|Diffusion Weighted MRI
147893|NCT02187718|Sentinel Lymph Node Biopsy
147894|NCT02187718|Local Anaesthesia
147895|NCT02187692|schizophrenia;
147896|NCT02187692|meta-cognition;
147897|NCT02187692|general functioning;
147898|NCT02187692|positive symptoms;
147899|NCT02187692|insight;
147900|NCT02187679|Tourette Syndrome
147901|NCT02187679|Tourette's Syndrome
147902|NCT02187679|Chronic Vocal Tic
147903|NCT02187679|Vocal Tic
147904|NCT02187666|Cervical
147905|NCT02187666|Lumbar
147906|NCT02187666|Spine
147907|NCT02187666|Spinal Disease
147908|NCT02187653|IOM
147909|NCT02187653|IONM
147910|NCT02187653|Intraoperative Monitoring
147911|NCT02187653|Intraoperative Neuromonitoring
147912|NCT02187653|Spine
147913|NCT02187653|Lumbar
147914|NCT02187653|Cervical
147915|NCT02187640|Acupressure
147916|NCT02187640|Self-administration
147917|NCT02187640|Psychiatric in-patients
147918|NCT02187640|Constipation
147919|NCT02187640|Self-administered acupressure program
147920|NCT02187640|Sham control group
147921|NCT02187614|Acute Renal colic
147922|NCT02187614|Acute Ureteric Colic
147923|NCT02187614|Renal or Ureteral Calculi
147924|NCT02187614|Urolithiasis
147925|NCT02187614|Kidney or Ureteral stones
147926|NCT02187549|Hyaluronic Acid
147927|NCT02187549|Osteoarthritis
147928|NCT02187549|Knee
147929|NCT02187549|Hyaluronan
147930|NCT02187549|Viscoelastic
147931|NCT02187549|Hydrogel
147932|NCT02187510|Hemodynamics
147933|NCT02187510|Premature Infant
147934|NCT02187510|Umbilical cord
147935|NCT02187510|Milking
147936|NCT02187510|Delayed clamping
147937|NCT02187471|pain
147938|NCT02187471|fibromyalgia
147939|NCT02187445|Sickle Cell Disease
147940|NCT02187445|Budesonide inhalation suspension
147941|NCT02187445|Acute Chest Syndrome
147942|NCT02187419|Sleep
147943|NCT02187419|Menopause
147944|NCT02187419|Hypnosis
147945|NCT02187419|Relaxation
147946|NCT02187419|Hypnotic Relaxation Therapy
147947|NCT02187419|Hot Flash
147948|NCT02187406|athletic tape
147949|NCT02187406|tennis
147950|NCT02187406|warm-up exercise
147951|NCT02187393|Epithelial cell function of cells from individuals with various genotypes
147952|NCT02187302|nanopharmaceutical,
147953|NCT02187289|NCSG
147954|NCT02187289|Compression bandages
147955|NCT02187289|devices
147956|NCT02187289|Night time compression
147957|NCT02187289|Breast cancer treatment side effects
147958|NCT02187289|Compression therapy
147959|NCT02187289|Reid Sleeve
147960|NCT02187289|Comprefit
147961|NCT02187289|Medassist
147962|NCT02187289|Tribute
147963|NCT02187289|Comprilan
147964|NCT02187276|Predictive factors of response
147965|NCT02187276|mild and moderate
147966|NCT02187276|Alzheimer disease
147967|NCT02187276|mixed dementia
147968|NCT02187276|APOE
147969|NCT02187276|polymorphisms of CYP 2D6
147970|NCT02187263|hereditary cardiomyopathy,
147971|NCT02187263|inflammatory cardiomyopathy,
147972|NCT02187263|registry,
147973|NCT02187263|biomaterial,
147974|NCT02187263|clinical trial
147975|NCT02187263|Patients
147976|NCT02187250|PCOS
147977|NCT02187250|PDE-4 inhibitor
147978|NCT02187250|roflumilast
147979|NCT02187250|liraglutide
147980|NCT02187250|metformin
147981|NCT02187250|obesity
147982|NCT02187224|Alcohol Dependence
147983|NCT02187224|Post-Traumatic stress disorder (PTSD)
147984|NCT02187224|Progesterone
147985|NCT02187211|Alcohol Dependence
147986|NCT02187211|Minocycline
147987|NCT02187198|Opioid Dependence
147988|NCT02187198|Buprenorphine
147989|NCT02187185|Inflammatory biomarkers
147990|NCT02187185|Periodontitis
147991|NCT02187172|Psoriasis
147992|NCT02187172|Cardiovascular Disease
147993|NCT02187172|Vascular Inflammation
147994|NCT02187172|Lipid Biomarkers
147995|NCT02187172|FDG-PET/CT
147996|NCT02187159|pain
147997|NCT02187159|fibromyalgia
147998|NCT02187146|Vitamin D
147999|NCT02187146|Infertility
148000|NCT02187146|IVF
148001|NCT02187146|ART
148002|NCT02187133|Relapsed
148003|NCT02187133|Refractory
148004|NCT02187120|Wounds and Injuries
148005|NCT02187120|Acute Coagulopathy
148006|NCT02187120|Tranexamic Acid
148007|NCT02187120|Emergency Medical Services
148008|NCT02187107|HIV
148009|NCT02187107|AIDS
148010|NCT02187107|TMC114
148011|NCT02187107|Ritonavir
148012|NCT02187107|Norvir
148013|NCT02187107|Darunavir
148014|NCT02187081|HCC
148015|NCT02187081|RFA
148016|NCT02187081|Sorafenib
148017|NCT02187081|Tumore recurrence
148018|NCT02187081|Overall survival
148019|NCT02187068|Anaesthetics iv
148020|NCT02187068|Dexmedetomidine
148021|NCT02187068|Pharmacokinetic
148022|NCT02187042|sunitinib
148023|NCT02187042|call center
148024|NCT02187042|management of patients
148025|NCT02187042|nurses
148026|NCT02187042|metastatic renal carcinoma
148027|NCT02187029|Hyperuricemia
148028|NCT02187029|gout
148029|NCT02187029|serum uric acid
148030|NCT02187016|Gingivitis
148031|NCT02187016|plaque
148032|NCT02187016|interproximal cleaning
148033|NCT02187016|dental floss
148034|NCT02187003|Sickle Cell Anemia
148035|NCT02187003|Sickle Cell Disease
148036|NCT02187003|Sickle Cell Disorders
148037|NCT02187003|pain crisis
148038|NCT02187003|vaso-occlusive crisis
148039|NCT02187003|rivipansel
148040|NCT02187003|GMI-1070
148041|NCT02187003|selectin inhibitor
148042|NCT02187003|SCD
148043|NCT02187003|VOC
148044|NCT02186977|immunogenicity
148045|NCT02186977|safety
148046|NCT02186977|proof of concept
148047|NCT02186951|ventilator-associated pneumonia
148048|NCT02186951|cardiac arrests with shockable rhythm
148049|NCT02186951|Mild therapeutic hypothermia
148050|NCT02186951|preventive antibiotics
148051|NCT02186938|head and neck cancer
148052|NCT02186938|patients requiring a free flap surgery
148053|NCT02186925|Kidney Cancer
148054|NCT02186925|Prostate Cancer
148055|NCT02186925|Bladder Cancer
148056|NCT02186912|edentulous
148057|NCT02186912|Nobel Active
148058|NCT02186912|Nobel Procera
148059|NCT02186912|IBO
148060|NCT02186912|CAD/CAM
148061|NCT02186886|Ulcerative Colitis
148062|NCT02186886|Golimumab
148063|NCT02186886|Physiological Intermolecular Modification Spectroscopy
148064|NCT02186886|PIMS
148065|NCT02186873|Ankylosing Spondylitis
148066|NCT02186873|Golimumab
148067|NCT02186873|SIMPONI
148068|NCT02186834|Relapsed
148069|NCT02186834|Refractory
148070|NCT02186834|Myeloma
148071|NCT02186821|hematological malignancy
148072|NCT02186821|solid tumor malignancy
148073|NCT02186821|mutation
148074|NCT02186821|translocation
148075|NCT02186821|rearrangement
148076|NCT02186821|amplification
148077|NCT02186821|ALK
148078|NCT02186821|ROS1
148079|NCT02186821|NSCLC
148080|NCT02186821|B-cell lymphoma
148081|NCT02186795|Arthroplasty
148082|NCT02186795|Replacement, Hip
148083|NCT02186782|Clomiphene citrate
148084|NCT02186782|Estradiol
148085|NCT02186782|Endometrial thickness
148086|NCT02186756|Fibromyalgia
148087|NCT02186756|Complementary Therapies
148088|NCT02186756|Biofeedback
148089|NCT02186756|Randomized controlled trial
148090|NCT02186756|Relaxation Therapy
148091|NCT02186743|Irritable Bowel Syndrome
148092|NCT02186743|IBS
148093|NCT02186743|Diet
148094|NCT02186743|Food sensitivity
148095|NCT02186730|Computerised Cognitive Behaviour Therapy
148096|NCT02186730|Adolescents
148097|NCT02186730|Depression
148098|NCT02186730|Low Mood
148099|NCT02186704|Atrial Fibrillation
148100|NCT02186704|Implantable Defibrillators
148101|NCT02186704|Implanted Electrodes
148102|NCT02186691|pulmonary valve replacement
148103|NCT02186691|tetralogy of Fallot
148104|NCT02186652|obese
148105|NCT02186652|children
148106|NCT02186652|adolescents
148107|NCT02186652|GERD
148108|NCT02186652|pharmacokinetic
148109|NCT02186639|exhaled breath
148110|NCT02186639|volatile organic compounds (VOCs)
148111|NCT02186639|SESI-MS
148112|NCT02186626|West Nile Virus, vaccine
148113|NCT02186613|Breast Feeding
148114|NCT02186613|Telephone
148115|NCT02186613|Education
148116|NCT02186613|Primary Health Care
148117|NCT02186600|Low bone mass
148118|NCT02186600|Post-menopausal women
148119|NCT02186600|Bone mineral density
148120|NCT02186600|Bone structure
148121|NCT02186600|Bone turnover
148122|NCT02186600|Bone-loading exercises
148123|NCT02186600|Optimal calcium and vitamin D
148124|NCT02186600|risedronate
148125|NCT02186574|Non-Hodgkin
148126|NCT02186574|Lymphoma
148127|NCT02186574|Hepatitis B
148128|NCT02186574|Tenofovir
148129|NCT02186574|Viread
148130|NCT02186561|intracranial aneurysm
148131|NCT02186561|brain aneurysm
148132|NCT02186522|Sepsis
148133|NCT02186522|Septic shock
148134|NCT02186522|Critical care
148135|NCT02186522|Immune dysfunction
148136|NCT02186522|Inflammatory markers
148137|NCT02186522|Neutrophil
148138|NCT02186522|Monocyte
148139|NCT02186522|Tregs
148140|NCT02186470|Breast Cancer
148141|NCT02186470|Early Stage Breast Cancer
148142|NCT02186457|Pancreatoduodenectomy
148143|NCT02186457|Whipple
148144|NCT02186444|newly diagnosed prostate cancer
148145|NCT02186444|prostate
148146|NCT02186431|Contact lenses
148147|NCT02186418|sickle cell disease
148148|NCT02186418|sickle cell anemia
148149|NCT02186418|hemoglobinopathies
148150|NCT02186418|hematopoietic stem cell
148151|NCT02186418|gene transfer
148152|NCT02186418|gene therapy
148153|NCT02186392|Depression
148154|NCT02186392|Anxiety
148155|NCT02186392|Stroke
148156|NCT02186392|Cerebral Infarction
148157|NCT02186392|Sleep disorders
148158|NCT02186392|Circadian Rhythm disorders
148159|NCT02186392|Circadian Light
148160|NCT02186392|Light therapy
148161|NCT02186392|Melatonin
148162|NCT02186392|Sleep
148163|NCT02186392|Sleep apnea
148164|NCT02186392|Coagulation disturbances
148165|NCT02186392|Bone metabolism
148166|NCT02186392|Rehabilitation
148167|NCT02186392|Mood disorders
148168|NCT02186392|Mental disorders
148169|NCT02186392|Neurologic Manifestations
148170|NCT02186392|Signs and Symptoms Cerebrovascular Disorders
148171|NCT02186392|Brain Diseases
148172|NCT02186392|Vascular Disease
148173|NCT02186392|Brain Infarction
148174|NCT02186392|Brain Ischemia
148175|NCT02186379|Obesity
148176|NCT02186379|Obesity Prevention
148177|NCT02186379|Childhood obesity prevention
148178|NCT02186379|Rapid Eating Style
148179|NCT02186366|Anxiety Disorders, Massage Therapy, Treatment Efficacy
148180|NCT02186353|Whole grains
148181|NCT02186353|Food processing
148182|NCT02186353|Cardiometabolic risk factors
148183|NCT02186327|Integrative Health Coaching
148184|NCT02186314|atrial fibrillation, heart failure, pacemaker
148185|NCT02186301|cancer
148186|NCT02186301|metastatic
148187|NCT02186301|locally advanced
148188|NCT02186301|lung
148189|NCT02186301|non-small cell lung cancer
148190|NCT02186301|NSCLC
148191|NCT02186301|epidermal growth factor receptor
148192|NCT02186301|EGFR
148193|NCT02186301|T790M
148194|NCT02186301|CO-1686
148195|NCT02186301|unresectable
148196|NCT02186301|recurrent
148197|NCT02186301|EGFR-directed therapy
148198|NCT02186301|irreversible EGFR inhibitor
148199|NCT02186301|TIGER
148200|NCT02186301|rociletinib
148201|NCT02186288|Critical Care
148202|NCT02186288|High-flow nasal cannula oxygen
148203|NCT02186288|Electrical impedance tomography
148204|NCT02186288|End expiratory lung volume
148205|NCT02186288|End expiratory lung impedance
148206|NCT02186288|Diaphragmatic ultrasound
148207|NCT02186275|Crohn
148208|NCT02186275|vitamin D
148209|NCT02186275|remission
148210|NCT02186275|inflammation
148211|NCT02186275|tolerance
148212|NCT02186262|Glioma
148213|NCT02186262|MRI
148214|NCT02186262|Rotating frame relaxation
148215|NCT02186262|DWI
148216|NCT02186262|treatment response
148217|NCT02186236|Detection of Oncogenic Tumor Mutations
148218|NCT02186236|blood
148219|NCT02186236|urine
148220|NCT02186236|14-114
148221|NCT02186223|Pulmonary Embolism
148222|NCT02186223|PE
148223|NCT02186223|DVT
148224|NCT02186223|Deep Vein Thrombosis
148225|NCT02186223|VTE
148226|NCT02186223|Venous Thromboembolism
148227|NCT02186223|prophylaxis
148228|NCT02186223|thromboprophylaxis
148229|NCT02186223|contraindications to thromboprophylaxis
148230|NCT02186223|prophylactic
148231|NCT02186223|prevention
148232|NCT02186223|Inferior vena cava filter
148233|NCT02186223|IVC filter
148234|NCT02186223|filter
148235|NCT02186223|prevention of pulmonary embolism
148236|NCT02186223|trauma
148237|NCT02186223|critically-ill
148238|NCT02186210|microcirculation
148239|NCT02186210|off-pump coronary artery bypass surgery
148240|NCT02186210|tissue oxygen saturation
148241|NCT02186210|vascular occlusion test
148242|NCT02186210|recovery slope
148243|NCT02186197|Volume Responsiveness
148244|NCT02186184|Myopia progression
148245|NCT02186184|Orthokeratology
148246|NCT02186171|Osteoporosis in men
148247|NCT02186158|Pneumonia
148248|NCT02186158|Elderly
148249|NCT02186158|Ascorbic acid
148250|NCT02186158|Vitamin C
148251|NCT02186158|Hospitalized patient
148252|NCT02186132|heart rate
148253|NCT02186132|neostigmine
148254|NCT02186132|atropine
148255|NCT02186132|dosage
148256|NCT02186093|Coronary Artery Disease
148257|NCT02186093|Angina, Stable
148258|NCT02186093|Fractional Flow Reserve, Myocardial
148259|NCT02186093|Coronary Angiography
148260|NCT02186080|diabetes mellitus
148261|NCT02186080|metabolic endotoxemia
148262|NCT02186080|gemigliptin
148263|NCT02186080|DPP-4 inhibitor
148264|NCT02186067|Hypertension
148265|NCT02186067|Uncontrolled Hypertension
148266|NCT02186054|Abdominal-Pelvic MRI (magnetic resonance image)
148267|NCT02186054|T2W (T2 weighted)
148268|NCT02186054|FSE Flex (recently developed MRI pulse sequence)
148269|NCT02186054|Enhanced single shot FSE (fast spin echo).
148270|NCT02186028|oral daily supplementation with vitamin D for 6 months
148271|NCT02186015|Metastatic Breast Cancer
148272|NCT02186015|MBC
148273|NCT02186015|Vitamin D Supplementation
148274|NCT02186015|Symptom Management
148275|NCT02186002|ACT-451840
148276|NCT02186002|Safety
148277|NCT02186002|Tolerability
148278|NCT02186002|Pharmacokinetics
148279|NCT02185989|Critical Illness/*rehabilitation
148280|NCT02185989|Humans
148281|NCT02185989|*Intensive Care Units
148282|NCT02185989|Muscle Weakness/diagnosis/*etiology/physiopathology/prevention & control
148283|NCT02185989|Polyneuropathies/diagnosis/*etiology/physiopathology
148284|NCT02185976|preoperative anxiety
148285|NCT02185976|paediatric patients
148286|NCT02185976|Cartoon
148287|NCT02185963|Diabetes
148288|NCT02185963|Dyslipidemia
148289|NCT02185963|HDL function
148290|NCT02185963|Cholesterol efflux
148291|NCT02185963|MCA assay
148292|NCT02185963|MCP-1
148293|NCT02185950|Burn
148294|NCT02185950|Skin graft
148295|NCT02185950|Elasticity
148296|NCT02185950|Skin
148297|NCT02185950|Physical therapy modalities
148298|NCT02185937|imatinib
148299|NCT02185937|gastrectomy
148300|NCT02185937|gastrointestinal stromal tumor
148301|NCT02185937|pharmacokinetics
148302|NCT02185924|PARECOXIB
148303|NCT02185924|CONTINUOUS FEMORAL BLOCK
148304|NCT02185911|chronic kidney disease,
148305|NCT02185911|anaemia correction/maintenance,
148306|NCT02185911|non dialysis,
148307|NCT02185898|electronic cigarettes
148308|NCT02185898|e-cigarettes
148309|NCT02185898|combustible cigarettes
148310|NCT02185898|second-hand smoke
148311|NCT02185898|environmental tobacco smoke
148312|NCT02185898|tobacco-burning
148313|NCT02185885|Ischemic stroke
148314|NCT02185885|Embolic stroke
148315|NCT02185885|Postoperative Cognitive Dysfunction
148316|NCT02185885|Cardiac Bypass Surgery
148317|NCT02185885|Cardiac Anaesthesia
148318|NCT02185872|Exercise
148319|NCT02185872|Physical Fitness
148320|NCT02185872|Body Composition, Beneficial
148321|NCT02185859|Lidocaine
148322|NCT02185859|Magnesium
148323|NCT02185859|Mastectomy
148324|NCT02185859|Functional Recovery
148325|NCT02185846|Fed condition
148326|NCT02185833|Fasting condition
148327|NCT02185820|Multiple myeloma
148328|NCT02185820|Relapsed and/or refractory
148329|NCT02185820|CPD
148330|NCT02185807|cataract
148331|NCT02185807|surgery
148332|NCT02185807|consent process
148333|NCT02185807|video-assisted
148334|NCT02185794|HCV genotype 1 (GT-1)
148335|NCT02185794|HCV genotype 2 (GT-2)
148336|NCT02185794|HCV genotype 3 (GT-3)
148337|NCT02185794|HCV genotype 4 (GT-4)
148338|NCT02185794|HCV
148339|NCT02185794|Sustained Virologic Response
148340|NCT02185794|Direct Acting Antiviral
148341|NCT02185794|Combination Therapy
148342|NCT02185794|Open Label
148343|NCT02185794|Hepatitis
148344|NCT02185794|Hepatitis, Chronic
148345|NCT02185794|Hepatitis C
148346|NCT02185794|Hepatitis C, Chronic
148347|NCT02185794|Liver Diseases
148348|NCT02185794|Digestive System Diseases
148349|NCT02185794|Hepatitis, Viral, Human
148350|NCT02185794|Virus Diseases
148351|NCT02185794|Enterovirus Infections
148352|NCT02185794|Picornaviridae Infections
148353|NCT02185794|RNA Virus Infections
148354|NCT02185794|Flaviviridae Infections
148355|NCT02185794|Antiviral Agents
148356|NCT02185794|Anti-Infective Agents
148357|NCT02185794|Therapeutic Uses
148358|NCT02185794|Pharmacologic Actions
148359|NCT02185794|Antimetabolites
148360|NCT02185794|Molecular Mechanisms of Pharmacological Action
148361|NCT02185781|Phase I
148362|NCT02185781|Adoptive immunotherapy
148363|NCT02185781|Enriched and expanded autologous natural killer (NK) cells
148364|NCT02185781|Ph+ acute lymphoblastic leukemia
148365|NCT02185781|≥60 years
148366|NCT02185781|Not eligible for other post-CHR treatment modalities
148367|NCT02185768|Liver cancer
148368|NCT02185755|Internet-Based Glucose Monitoring System
148369|NCT02185755|Type 2 Diabetes
148370|NCT02185742|HIV
148371|NCT02185742|jail
148372|NCT02185742|detainee
148373|NCT02185742|Linkage and Retention
148374|NCT02185742|Treatment as Prevention
148375|NCT02185742|Strength Based Case Management
148376|NCT02185742|releases
148377|NCT02185729|Intravenous Feeding
148378|NCT02185729|Lipid Emulsions, Intravenous
148379|NCT02185716|Transversus abdominis plane block
148380|NCT02185716|levobupivacaine
148381|NCT02185690|Lung cancer
148382|NCT02185690|Non small cell lung cancer
148383|NCT02185690|non squamous
148384|NCT02185690|pemetrexed
148385|NCT02185690|carboplatin
148386|NCT02185690|binimetinib
148387|NCT02185690|chemotherapy
148388|NCT02185690|combination chemotherapy
148389|NCT02185690|Phase 1
148390|NCT02185690|Princess Margaret Cancer Centre
148391|NCT02185690|carcinoma
148392|NCT02185677|dysexecutive syndrome
148393|NCT02185677|multiple system atrophy
148394|NCT02185677|imaging study
148395|NCT02185664|internal jugular vein
148396|NCT02185664|landmark
148397|NCT02185664|ultrasound
148398|NCT02185664|static
148399|NCT02185664|cardiac surgery
148400|NCT02185651|Pompe Disease
148401|NCT02185651|Enzyme Replacement Therapy
148402|NCT02185651|Infusion Associated Reaction
148403|NCT02185638|obesity
148404|NCT02185638|herbal bioactive compounds
148405|NCT02185638|appetite
148406|NCT02185638|GLP-1
148407|NCT02185638|ghrelin
148408|NCT02185638|CCK
148409|NCT02185599|colposcopy
148410|NCT02185599|CIN
148411|NCT02185599|cervical neoplasia
148412|NCT02185599|cervical dysplasia
148413|NCT02185599|cervical cancer
148414|NCT02185599|CIN2+
148415|NCT02185573|Bulk fill
148416|NCT02185573|SonicFill
148417|NCT02185573|resin composite application
148418|NCT02185573|class II restoration
148419|NCT02185560|Sorafenib
148420|NCT02185560|Differentiated Thyroid Carcinoma,
148421|NCT02185560|Japan
148422|NCT02185560|Post Marketing Surveillance
148423|NCT02185560|Drug Use Investigation
148424|NCT02185547|women
148425|NCT02185534|Clopidogrel, Zyllt, Plavix, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence
148426|NCT02185521|Hemodynamics
148427|NCT02185521|Medical Informatics
148428|NCT02185508|IONM
148429|NCT02185508|Lumbar Disk Disease
148430|NCT02185508|Degenerative Spine Disease
148431|NCT02185508|Radiculopathy
148432|NCT02185508|Intraoperative Neurophysiological Monitoring
148433|NCT02185508|Somatosensory Evoked Potentials
148434|NCT02185508|Electromyography
148435|NCT02185482|Psychological counselling
148436|NCT02185482|Randomized single blind study
148437|NCT02185482|Depression
148438|NCT02185482|Diabetes
148439|NCT02185469|Corneal Endothelial Cell Loss
148440|NCT02185469|pneumatic retinopexy
148441|NCT02185469|vitrectomy
148442|NCT02185443|SBRT
148443|NCT02185443|radiation
148444|NCT02185443|Neoplasm Metastasis
148445|NCT02185443|Colorectal Neoplasms
148446|NCT02185443|Anal Canal
148447|NCT02185443|Neuroendocrine Tumors
148448|NCT02185417|Hypertension
148449|NCT02185417|Diuretic
148450|NCT02185417|Comparative Effectiveness Research
148451|NCT02185417|Point of Care Research
148452|NCT02185391|Coronary Disease
148453|NCT02185391|Audience Response System
148454|NCT02185365|T1-rho MRI
148455|NCT02185365|dGEMRIC MRI
148456|NCT02185365|DDH
148457|NCT02185365|Developmental dysplasia of the hip
148458|NCT02185352|Bevacizumab
148459|NCT02185352|Brain Metastases
148460|NCT02185352|Breast Cancer
148461|NCT02185352|Chemotherapy
148462|NCT02185352|Whole Brain Radiotherapy
148463|NCT02185339|Respiratory mechanics
148464|NCT02185339|Respiratory function test
148465|NCT02185339|Hemodynamics
148466|NCT02185326|Poor responders
148467|NCT02185326|Poor ovarian response
148468|NCT02185326|IVF/ICSI
148469|NCT02185326|Microflare protocol
148470|NCT02185326|Growth hormone
148471|NCT02185326|Oral contraceptive pills
148472|NCT02185300|GSK1349572
148473|NCT02185300|granule
148474|NCT02185300|pediatric
148475|NCT02185300|CONTREX mineral water
148476|NCT02185300|free-acid
148477|NCT02185300|chelating
148478|NCT02185300|cations
148479|NCT02185300|divalent
148480|NCT02185300|dolutegravir
148481|NCT02185300|dispersible tablet
148482|NCT02185300|relative bioavailability
148483|NCT02185274|Transsexualism
148484|NCT02185274|Cross-sex hormone treatment
148485|NCT02185274|Sex hormones
148486|NCT02185274|Mood
148487|NCT02185274|Stress
148488|NCT02185274|Cortisol
148489|NCT02185274|Cardiovascular
148490|NCT02185274|Metabolome
148491|NCT02185261|Relapse
148492|NCT02185261|Minimal residual disease
148493|NCT02185261|Graft-versus-host disease
148494|NCT02185261|Acute leukemia
148495|NCT02185261|Interferon Alfa-2b
148496|NCT02185248|Pediatric Obesity
148497|NCT02185248|Body Mass Index
148498|NCT02185248|Weight Perception
148499|NCT02185248|Counseling
148500|NCT02185248|Health Behavior
148501|NCT02185235|Electrical stimulation
148502|NCT02185235|Biofeedback
148503|NCT02185222|Vitamin D
148504|NCT02185222|Cholecalciferol
148505|NCT02185222|25-hydroxyvitamin D
148506|NCT02185222|Memory complaint
148507|NCT02185222|Subjective memory complaint
148508|NCT02185222|Mild cognitive impairment
148509|NCT02185222|Preventive therapy
148510|NCT02185222|Cognitive disorders
148511|NCT02185196|Vitamin D,
148512|NCT02185196|Severe pneumonia,
148513|NCT02185196|Under-five children,
148514|NCT02185196|Randomised
148515|NCT02185196|Controlled
148516|NCT02185196|Trial (RCT)
148517|NCT02185196|Morbidity
148518|NCT02185170|Prostate
148519|NCT02185170|Cancer
148520|NCT02185170|Medical Device
148521|NCT02185170|Fluorescence
148522|NCT02185157|elderly
148523|NCT02185157|dual-task training
148524|NCT02185157|aerobic training
148525|NCT02185157|gait
148526|NCT02185157|cognition
148527|NCT02185144|HIV, mental health, substance abuse
148528|NCT02185131|Major Depressive Disorder
148529|NCT02185131|Alcohol Use Disorder
148530|NCT02185092|exacerbations
148531|NCT02185092|COPD
148532|NCT02185092|pneumonia
148533|NCT02185092|probiotic
148534|NCT02185079|labor
148535|NCT02185079|epidural
148536|NCT02185040|Lupus, Systemic Lupus, SLE
148537|NCT02185027|Oral anticoagulants
148538|NCT02185027|Surgery
148539|NCT02185027|Haemorrhage
148540|NCT02185027|Emergency
148541|NCT02185014|Crohn's Disease
148542|NCT02185001|Medial patellofemoral ligament
148543|NCT02185001|MPFL
148544|NCT02185001|Repair
148545|NCT02185001|Patellar dislocation
148546|NCT02185001|Knee
148547|NCT02184988|Glabellar Lines
148548|NCT02184988|Botulinum purifies neurotoxin, Type A (DWP-450)
148549|NCT02184975|cold knife conization
148550|NCT02184975|lateral hemostatic sutures
148551|NCT02184975|cervix
148552|NCT02184949|PCI
148553|NCT02184949|Coronary angioplasty
148554|NCT02184949|Percutaneous transluminal coronary angioplasty
148555|NCT02184949|PTCA
148556|NCT02184936|CT Angiography, CT Perfusion, Ischemic Stroke, Collaterals
148557|NCT02184910|atrophic gastritis, pepsinogen, Helicobacter pylori
148558|NCT02184884|off-pump coronary artery bypass surgery, clopidogrel responsiveness, ischemic outcome
148559|NCT02184871|intrahepatic cholangiocarcinoma
148560|NCT02184871|RNAseq
148561|NCT02184871|risk factors
148562|NCT02184871|asbestos
148563|NCT02184845|single tooth implant
148564|NCT02184845|supported restoration(s)
148565|NCT02184845|maxillary lateral incisor
148566|NCT02184845|mandibular central incisor
148567|NCT02184845|lateral incisor
148568|NCT02184845|areas of the mouth
148569|NCT02184819|coronary artery bypass graft
148570|NCT02184819|left ventricular dysfunction
148571|NCT02184819|low cardiac output syndrome
148572|NCT02184819|levosimendan
148573|NCT02184819|mortality
148574|NCT02184819|inotropic agents
148575|NCT02184819|cardiac mechanical assist devices
148576|NCT02184819|renal replacement therapy
148577|NCT02184819|mechanical ventilation duration
148578|NCT02184819|ICU stay
148579|NCT02184806|Ovarian tissue transplantation
148580|NCT02184806|Cryopreserved ovarian tissue
148581|NCT02184793|mechanical ventilation
148582|NCT02184793|semirecumbent position
148583|NCT02184793|electronic monitoring device
148584|NCT02184780|Neurodevelopment
148585|NCT02184780|General Anaesthesia
148586|NCT02184780|Infants
148587|NCT02184780|Epidural
148588|NCT02184780|Spinal
148589|NCT02184780|Anxiety and depression
148590|NCT02184754|Magnetic endoscope imaging
148591|NCT02184754|single-balloon-enteroscopy
148592|NCT02184741|IVIG
148593|NCT02184741|Unexplained Recurrent miscarriage
148594|NCT02184741|Recurrent abortion
148595|NCT02184741|Intravenous immunoglobulin
148596|NCT02184728|end-tidal CO2
148597|NCT02184728|capnometer
148598|NCT02184715|virtual reality system, children, developmental delay
148599|NCT02184676|Type 1 diabetes
148600|NCT02184676|risk assessment
148601|NCT02184676|immunological marker
148602|NCT02184676|children
148603|NCT02184676|relatives
148604|NCT02184676|autoantibodies
148605|NCT02184676|lymphocytes
148606|NCT02184676|T cells
148607|NCT02184676|epitopes
148608|NCT02184676|Children born to mother/father with type 1 diabetes and their parents
148609|NCT02184663|Unresectable
148610|NCT02184663|Pancreatic cancer
148611|NCT02184663|GERCOR
148612|NCT02184663|Adapted physical activity (APA)
148613|NCT02184663|Quality of life
148614|NCT02184663|Fatigue
148615|NCT02184650|Premature infants
148616|NCT02184650|Nutritional status
148617|NCT02184650|Polyunsaturated fatty acids status
148618|NCT02184637|Malaria
148619|NCT02184637|Artemisinin-based Combination Therapies (ACT)
148620|NCT02184624|BREEZHALER
148621|NCT02184624|DISKUS/ACCUHALER
148622|NCT02184624|MDI
148623|NCT02184624|Inhaler preference
148624|NCT02184624|Overall inhaler error
148625|NCT02184624|HANDIHALER
148626|NCT02184624|Ease of use
148627|NCT02184624|TURBUHALER
148628|NCT02184624|ELLIPTA
148629|NCT02184624|Critical inhaler error
148630|NCT02184611|lung function
148631|NCT02184611|Umeclidinium
148632|NCT02184611|GSK573719
148633|NCT02184611|anticholinergic
148634|NCT02184611|novel dry powder inhaler
148635|NCT02184611|long-acting muscarinic receptor antagonist
148636|NCT02184611|Chronic Obstructive Pulmonary Disease
148637|NCT02184598|ADHD
148638|NCT02184598|Cognitive training
148639|NCT02184598|fMRI
148640|NCT02184598|Cognitive function
148641|NCT02184585|bioavailability
148642|NCT02184585|Dutasteride
148643|NCT02184585|crossover design
148644|NCT02184585|healthy male volunteers
148645|NCT02184585|tamsulosin hydrochloride
148646|NCT02184572|Rubella
148647|NCT02184572|Healthy children
148648|NCT02184572|Measles
148649|NCT02184572|Safety
148650|NCT02184572|Mumps
148651|NCT02184572|12 to 15 months
148652|NCT02184572|Immunogenicity
148653|NCT02184507|insulin resistance
148654|NCT02184507|blood glucose
148655|NCT02184507|CABG
148656|NCT02184507|oxidative stress
148657|NCT02184494|Parkinson's Disease
148658|NCT02184494|Multiple Sclerosis
148659|NCT02184494|Fatigue
148660|NCT02184494|Resting Energy Expenditure
148661|NCT02184494|Whole Body Vibration
148662|NCT02184494|Exercise
148663|NCT02184494|Blood Lactate
148664|NCT02184481|Depression
148665|NCT02184481|Anxiety
148666|NCT02184481|Working memory
148667|NCT02184481|Rumination
148668|NCT02184481|Cognitive training
148669|NCT02184481|Executive functioning
148670|NCT02184468|Cardiac Arrest
148671|NCT02184468|Out-of-Hospital Cardiac Arrest
148672|NCT02184468|Firefighters
148673|NCT02184468|Police
148674|NCT02184468|Defibrillators
148675|NCT02184468|Survival
148676|NCT02184455|Diabetic
148677|NCT02184455|Chronic Ulcer
148678|NCT02184455|Wound Healing
148679|NCT02184455|Leg
148680|NCT02184442|SAPIEN
148681|NCT02184442|TAVR
148682|NCT02184442|THV
148683|NCT02184442|Aortic Stenosis
148684|NCT02184442|Heart Valve Disease
148685|NCT02184442|Aortic Valve
148686|NCT02184442|Retroflex
148687|NCT02184442|Ascendra
148688|NCT02184429|First in human
148689|NCT02184429|single ascending dose study
148690|NCT02184429|multiple ascending dose study
148691|NCT02184429|safety and tolerability
148692|NCT02184429|pharmacokinetics
148693|NCT02184429|food effect
148694|NCT02184429|Parkinson's Disease
148695|NCT02184416|Inlyta
148696|NCT02184416|axitinib
148697|NCT02184416|Sutent
148698|NCT02184416|sunitinib
148699|NCT02184416|renal
148700|NCT02184390|Internet
148701|NCT02184390|Education
148702|NCT02184377|quantitative laryngeal electromyography
148703|NCT02184377|cricothyroid muscle
148704|NCT02184377|unilateral vocal fold paralysis
148705|NCT02184377|superior laryngeal nerve
148706|NCT02184377|lexical tone
148707|NCT02184377|Mandarin
148708|NCT02184221|Deep-brain magnetic stimulation
148709|NCT02184221|Brain derived neurotropic factor
148710|NCT02184221|Effectiveness
148711|NCT02184221|Safety
148712|NCT02184208|ARDS
148713|NCT02184208|ALI
148714|NCT02184208|mechanical ventilation
148840|NCT02183272|Ketamine
148841|NCT02183272|Emergency Department
148715|NCT02184195|BRCA, metastatic adenocarcinoma pancreas, maintenance olaparib monotherapy, first line platinum chemotherapy, pancreatic cancer, PARP inhibitor
148716|NCT02184169|hemodynamics
148717|NCT02184169|neonatal
148718|NCT02184169|cardiac disease
148719|NCT02184169|congenital heart disease
148720|NCT02184169|volumetric oxygen consumption
148721|NCT02184117|Fractional Flow Reserve, Myocardial
148722|NCT02184117|Adenosine
148723|NCT02184117|Contrast Media
148724|NCT02184104|caffeine
148725|NCT02184104|pharmacokinetics
148726|NCT02184104|pharmacodynamics
148727|NCT02184026|nightmare
148728|NCT02184026|PTSD
148729|NCT02184026|trauma
148730|NCT02184026|children
148731|NCT02184026|Children Age 8 to 13
148732|NCT02184013|Atrial fibrillation
148733|NCT02184013|Catheter ablation
148734|NCT02184013|Delayed gadolinium enhanced MRI
148735|NCT02184013|C-metahydroxyepherdrine (HED) PET scan
148736|NCT02184013|ECGI mapping
148737|NCT02184013|Atrial Fibrosis
148738|NCT02184013|Atrial sympathetic denervation
148739|NCT02184000|strain elastography
148740|NCT02184000|hepatopathy
148741|NCT02184000|liver fibrosis
148742|NCT02183987|Knowledge Translation
148743|NCT02183987|Chronic Kidney Disease
148744|NCT02183987|Dialysis
148745|NCT02183987|Intent-to-defer
148746|NCT02183987|Early dialysis
148747|NCT02183987|Cluster randomized trial
148748|NCT02183974|otitis media with effusion
148749|NCT02183974|Laryngopharyngeal Reflux
148750|NCT02183961|otitis media with effusion
148751|NCT02183961|peptest
148752|NCT02183961|restech
148753|NCT02183961|oropharyngeal pH monitoring
148754|NCT02183961|laryngopharyngeal reflux
148755|NCT02183948|treatment
148756|NCT02183948|mask face exoressions
148757|NCT02183948|genier
148758|NCT02183935|Obesity
148759|NCT02183935|Diabetes
148760|NCT02183935|Metabolic syndrome
148761|NCT02183935|Gut hormones
148762|NCT02183935|Adipokines
148763|NCT02183935|Appetite
148764|NCT02183935|Adolescent
148765|NCT02183896|Femoroacetabular impingement (FAI)
148766|NCT02183896|Chondral lesions
148767|NCT02183896|Hip
148768|NCT02183896|Microfracture
148769|NCT02183896|Platelet-rich plasma (PRP)
148770|NCT02183883|Non-small cell lung cancer
148771|NCT02183883|NSCLC
148772|NCT02183883|Afatinib
148773|NCT02183883|Intra-tumour heterogeneity
148774|NCT02183883|Clonal dominance
148775|NCT02183883|Drug resistance
148776|NCT02183883|EGFR
148777|NCT02183883|HER2
148778|NCT02183883|Phase 2
148779|NCT02183870|lung cancer
148780|NCT02183870|adenocarcinoma
148781|NCT02183870|NSCLC
148782|NCT02183870|ROS1
148783|NCT02183870|ROS1 translocation
148784|NCT02183870|crizotinib
148785|NCT02183870|phase II
148786|NCT02183857|children
148787|NCT02183857|congenital heart disease
148788|NCT02183844|Medical Informatics
148789|NCT02183844|Patient-Centered
148790|NCT02183844|Healthcare Preferences
148791|NCT02183844|Health Education
148792|NCT02183844|Quality Improvement
148793|NCT02183844|Weight Loss
148794|NCT02183844|Personal Satisfaction
148795|NCT02183844|Humans
148796|NCT02183844|Cognition
148797|NCT02183844|Body Weight
148798|NCT02183818|Smoking
148799|NCT02183818|COPD
148800|NCT02183818|Non-Smokers
148801|NCT02183818|Smokers
148802|NCT02183805|triple negative breast cancer
148803|NCT02183805|autologous hematopoietic stem-cell transplantation
148804|NCT02183779|post-occlusive hyperaemia
148805|NCT02183779|laser-speckle contrast imaging
148806|NCT02183779|epoxyeicosatrienoic acid
148807|NCT02183779|nitrous oxide
148808|NCT02183753|LAIV
148809|NCT02183753|Flumist
148810|NCT02183753|wood smoke
148811|NCT02183740|Education
148812|NCT02183740|Nurses
148813|NCT02183740|Nursing homes
148814|NCT02183740|Fecal incontinence
148815|NCT02183740|Cluster-randomized controlled trial
148816|NCT02183727|ACL
148817|NCT02183727|knee injury
148818|NCT02183727|anterior cruciate ligament
148819|NCT02183597|Magnetic Resonance Imaging
148820|NCT02183597|Data Accuracy
148821|NCT02183597|Reproducibility of Results
148822|NCT02183597|Diagnosis
148823|NCT02183558|PCOS
148824|NCT02183558|GDM
148825|NCT02183558|OGTT
148826|NCT02183558|Glucose metabolism
148827|NCT02183519|Cough
148828|NCT02183519|Reflex
148829|NCT02183519|Voluntary
148830|NCT02183519|Healthy older adults
148831|NCT02183519|Parkinson's disease
148832|NCT02183519|Respiratory kinematics
148833|NCT02183519|Cueing
148834|NCT02183454|intracoronary stent
148835|NCT02183454|drug eluting stent
148836|NCT02183454|sirolimus
148837|NCT02183454|endothelial progenitor cells
148838|NCT02183272|Depression
148839|NCT02183272|Suicidal Ideation
148842|NCT02183207|percutaneous endoscopic gastrostomy
148843|NCT02183207|Introducer method
148844|NCT02182999|Hallux valgus surgery
148845|NCT02182999|wound infiltration
148846|NCT02182999|pain
148847|NCT02182986|Biomarkers
148848|NCT02182986|Post-Transplant Lymphoproliferative Disorders (PTLDs)
148849|NCT02182973|neonatal abstinence syndrome, infant opiate withdrawal
148850|NCT02182947|Pediatric
148851|NCT02182947|Inflammatory Bowel Disease
148852|NCT02182947|capsule endoscopy
148853|NCT02182947|MRI
148854|NCT02182947|Crohn's Disease
148855|NCT02182947|Indeterminant Colitis
148856|NCT02182947|Small bowel Crohn's Disease
148857|NCT02182908|Aneurysm of abdominal aorta
148858|NCT02182908|18F-fluorodesoxyglucose (FDG-F18)
148859|NCT02182843|Cellentra ACDF
148860|NCT02182817|General Anaesthesia
148861|NCT02182817|Neurocognitive Development
148862|NCT02182817|Behaviour
148863|NCT02182804|Confocal Laser Endomicroscopy
148864|NCT02182804|Narrow Band Imaging
148865|NCT02182804|Lugol Chromoendoscopy
148866|NCT02182804|Esophageal Neoplasm
148867|NCT02182804|Head and Neck Cancer
148868|NCT02181777|Psychosis
148869|NCT02181777|Schizophrenia
148870|NCT02181777|Social Skills
148871|NCT02181777|Therapy
148872|NCT02181764|XLH
148873|NCT02181751|Child Sexual Abuse
148874|NCT02181751|CSA
148875|NCT02181751|Treatment
148876|NCT02181751|Prevention
148877|NCT02181751|PTSD
148878|NCT02181751|Post Traumatic Stress Disorder
148879|NCT02181751|Depression
148880|NCT02181751|Anxiety
148881|NCT02181751|Quality of Life
148882|NCT02181751|Attachment
148883|NCT02181751|Cognitive Behavioural Therapy
148884|NCT02181751|Group Therapy
148885|NCT02181725|Chronic Pain
148886|NCT02181725|Adolescent
148887|NCT02181725|Graded Exposure
148888|NCT02181712|Bronchiolitis obliterans
148889|NCT02181712|lung transplant
148890|NCT02181712|mesenchymal stem cell
148891|NCT02181712|cell therapy
148892|NCT02182687|Hepatocellular carcinoma (HCC)
148893|NCT02182687|Orthotopic liver transplant
148894|NCT02182687|Bridge to transplant
148895|NCT02182687|stereotactic body radiation therapy (SBRT)
148896|NCT02182687|trans-arterial chemoembolization (TACE)
148897|NCT02182596|Acute Myeloid Leukemia
148898|NCT02182596|First relapsing AML
148899|NCT02182466|Colon capsule endoscopy
148900|NCT02182466|Colonoscopy
148901|NCT02182466|Screening colonoscopy
148902|NCT02182440|SA-AKI
148903|NCT02182440|Sepsis
148904|NCT02182440|AKI
148905|NCT02182440|Recombinant Alkaline Phosphatase
148906|NCT02182440|recAP
148907|NCT02182167|Drug Induced Hepatitis (DIH)
148908|NCT02182167|Toxic Liver
148909|NCT02182167|Drug Induced Liver Injury (DILI)
148910|NCT02182115|Staphylococcus aureus infection
148911|NCT02182115|Decolonization
148912|NCT02182115|Surgical site infection
148913|NCT02181894|Infant
148914|NCT02181894|Newborn
148915|NCT02181894|Neonate
148916|NCT02181894|Intubation
148917|NCT02181894|Neonatal resuscitation
148918|NCT02181842|Pharmacological therapy
148919|NCT02181829|Whole Lung IMRT
148920|NCT02181829|14-075
148921|NCT02181816|Pharmacological therapy
148922|NCT02181790|psoriasis
148923|NCT02181790|palmoplantar
148924|NCT02181790|acitretin
148925|NCT02181790|retinoids
148926|NCT02181790|laser treatment
148927|NCT02181686|Heart Failure
148928|NCT02181686|Iperia ICD family
148929|NCT02181686|Sentus QP left ventricular lead
148930|NCT02181686|Quadripolar CRT-D system
148931|NCT02181673|Psoriatic arthritis
148932|NCT02181673|Golimumab
148933|NCT02181673|Simponi
148934|NCT02181660|AML
148935|NCT02181660|Acute myeloid leukemia
148936|NCT02181660|ASP2215
148937|NCT02181634|Advanced Cholangiocarcinoma
148938|NCT02181634|Metastatic Cholangiocarcinoma
148939|NCT02181634|CCA
148940|NCT02181634|Bile Duct Cancer
148941|NCT02181634|Nab-Paclitaxel
148942|NCT02181634|Abraxane®
148943|NCT02181634|Gemcitabine
148944|NCT02181634|Gemzar®
148945|NCT02181608|Alcohol Dependence
148946|NCT02181608|Fear Conditioning
148947|NCT02181608|Stress
148948|NCT02181608|Alcohol
148949|NCT02181595|Reading
148950|NCT02181595|FACIT-SP
148951|NCT02181595|Primary Ovarian Insufficiency
148952|NCT02181582|Health Humans
148953|NCT02181582|Receptor Occupancy
148954|NCT02181569|Addiction Severity Index
148955|NCT02181569|Addiction
148956|NCT02181569|Sleep Measures
148957|NCT02181569|Sleep Disorders
148958|NCT02181556|colorectal cancer
148959|NCT02181556|Metastatic
148960|NCT02181543|Clonidine
148961|NCT02181543|Psychomotor agitation
148962|NCT02181543|Anesthesia recovery period
148963|NCT02181543|Tonsillectomy
148964|NCT02181543|Child, preschool
148965|NCT02181478|Total Body Irradiation
148966|NCT02181478|Human Mesenchymal Stromal Cells
148967|NCT02181478|hMSC
148968|NCT02181478|Cyclophosphamide
148969|NCT02181478|Fludarabine
148970|NCT02181478|Dimethyl Sulfoxide
148971|NCT02181478|DMSO
148972|NCT02181478|Cyclosporine
148973|NCT02181478|Mycophenolate Mofetil
148974|NCT02181478|MMF
148975|NCT02181478|Granulocyte- Colony Stimulating Factor
148976|NCT02181478|G-CSF
148977|NCT02181478|GVHD
148978|NCT02181478|Cancer
148979|NCT02181478|feasibility
148980|NCT02181452|liver
148981|NCT02181452|fibrosis
148982|NCT02181452|ShearWave Elastography
148983|NCT02181452|ultrasound
148984|NCT02181426|Knee Arthroscopy
148985|NCT02181413|Drug therapy
148986|NCT02181413|TOURMALINE
148987|NCT02181413|ixazomib
148988|NCT02181400|diabetic retinopathy
148989|NCT02181400|diabetic macular edema
148990|NCT02181400|diabetic macular oedema
148991|NCT02181400|near infrared light therapy
148992|NCT02181387|labor pain
148993|NCT02181387|acetaminophen
148994|NCT02181374|atrial fibrillation
148995|NCT02181374|NT-proBNP
148996|NCT02181374|Cardioembolic Stroke
148997|NCT02181361|atrial fibrillation
148998|NCT02181361|cardioembolic stroke
148999|NCT02181361|Hirudin
149000|NCT02181361|aspirin
149001|NCT02181361|warfarin
149002|NCT02181348|Vitamin E, Hemoglobin, mild anemia
149003|NCT02181296|Shoulder arthroscopy
149004|NCT02181296|Interscalene block
149005|NCT02181296|Drug concentration
149006|NCT02181296|0.1% ropivacaine or 0.2% ropivacaine
149007|NCT02181283|alcohol
149008|NCT02181283|prescribed drugs
149009|NCT02181283|National Guard
149010|NCT02181270|NAFLD
149011|NCT02181270|obesity
149012|NCT02181270|ck18
149013|NCT02181270|blood lipids
149014|NCT02181270|high intensity exercise training
149015|NCT02181270|individuals
149016|NCT02181270|>5% liver fat
149017|NCT02181257|Bronchiolitis Obliterans Syndrome
149018|NCT02181257|Lung Transplantation
149019|NCT02181257|Extracorporeal Photopheresis
149020|NCT02181257|Methoxsalen
149021|NCT02181244|egg
149022|NCT02181244|oatmeal
149023|NCT02181244|atherogenic dyslipidemia
149024|NCT02181244|glycosylated hemoglobin
149025|NCT02181244|inflammatory markers
149026|NCT02181231|depression
149027|NCT02181231|older adult
149028|NCT02181231|buprenorphine
149029|NCT02181231|Effexor XR
149030|NCT02181231|treatment resistant
149031|NCT02181231|venlafaxine
149032|NCT02181231|Saint Louis
149033|NCT02181231|late life
149034|NCT02181231|major depression
149035|NCT02181192|biochemical recurrence
149036|NCT02181192|prostate carcinoma
149037|NCT02181192|prostate cancer
149038|NCT02181192|PSA
149039|NCT02181192|postoperative
149040|NCT02181192|radiotherapy
149041|NCT02181192|imaging diagnostic
149042|NCT02181192|PET/CT
149043|NCT02181192|social economic aspects
149044|NCT02181192|quality of life
149045|NCT02181179|yoga
149046|NCT02181179|exercise intervention
149047|NCT02181179|smoking
149048|NCT02181179|stress
149049|NCT02181179|mind-body
149050|NCT02181179|intervention
149051|NCT02181166|Breast Neoplasms
149052|NCT02181166|Mastectomy
149053|NCT02181166|Myofascial pain syndromes
149054|NCT02181166|Physical Therapy Modalities
149055|NCT02181153|inflammatory bowel disease
149056|NCT02181153|siblings
149057|NCT02181140|fine needle aspiration
149058|NCT02181140|core biopsy
149059|NCT02181140|endoscopic ultrasound
149060|NCT02181140|space occupying process mediastinal, perigastral, perihilar
149061|NCT02181140|suspect lymph nodes mediastinal, perigastral or perihilar
149062|NCT02181140|diagnostic accuracy of EUS guided core biopsy
149063|NCT02181127|bionic pancreas
149064|NCT02181127|artificial pancreas
149065|NCT02181127|insulin
149066|NCT02181127|glucagon
149067|NCT02181127|continuous glucose monitoring (CGM)
149068|NCT02181127|outpatient
149069|NCT02181127|insulin pump
149070|NCT02181127|glucagon pump
149071|NCT02181114|Coaching
149072|NCT02181114|Educational Materials
149073|NCT02181114|Expert System
149074|NCT02181114|Living Donor Kidney Transplant
149075|NCT02181088|Malaria
149076|NCT02181088|Plasmodium falciparum
149077|NCT02181088|RH5
149078|NCT02181075|ThermoDox
149079|NCT02181075|High Intensity Focused Ultrasound
149080|NCT02181075|Lyso thermosensitive Liposomal
149081|NCT02181075|Non invasive drug delivery
149082|NCT02181075|Hepatic metastatic disease
149083|NCT02181075|Liver tumour(s)
149084|NCT02181075|Targeted Release of Chemotherapy
149085|NCT02181062|Stroke
149086|NCT02181062|Stroke prevention
149087|NCT02181062|older adults
149088|NCT02181062|self efficacy
149089|NCT02181062|walking
149090|NCT02181062|minorities
149091|NCT02181062|minority older adults
149092|NCT02181062|hypertension
149093|NCT02181062|high blood pressure
149094|NCT02181062|elderly
149095|NCT02181062|sedentary lifestyle
149096|NCT02181049|Childhood cancer survivors
149097|NCT02181049|Cardiac
149098|NCT02181049|Vascular
149099|NCT02181049|Cardiovascular
149100|NCT02181049|Late-sequelae
149101|NCT02181036|Family work shop
149102|NCT02181036|speech developmental delays
149103|NCT02181036|children
149104|NCT02181023|COPD
149105|NCT02181023|Hyperinflation
149106|NCT02181023|Aclidinium
149107|NCT02181023|Glycopyrronium
149108|NCT02181023|Volume distribution
149109|NCT02181023|Anticholinergic
149110|NCT02181023|Pharmacokinetics
149111|NCT02181023|Single Breath Nitrogen Test
149112|NCT02181023|Phase III
149113|NCT02181010|African American
149114|NCT02181010|Adolescents
149115|NCT02181010|Urban
149116|NCT02181010|Food Desert
149117|NCT02181010|Food Insecurity
149118|NCT02181010|Obesity
149119|NCT02181010|Baltimore City
149120|NCT02181010|Peer mentors
149121|NCT02181010|Multi level
149122|NCT02181010|Policy
149123|NCT02181010|Caregivers
149124|NCT02181010|Systems
149125|NCT02181010|Agent Based Model
149126|NCT02181010|Systems Dynamic Model
149127|NCT02181010|Corner Store
149128|NCT02181010|Carryout
149129|NCT02181010|Recreation Center
149130|NCT02181010|Text Messaging
149131|NCT02181010|Social Media
149132|NCT02181010|Mapping
149133|NCT02180997|α1-blockers
149134|NCT02180997|antimuscarinic agent
149135|NCT02180984|Binge Eating
149136|NCT02180984|Obesity
149137|NCT02180984|TMS
149138|NCT02180984|Neuroimage
149139|NCT02180984|Neuromodulation
149140|NCT02180984|Biomarkers
149141|NCT02180984|Eating Disorders
149142|NCT02180984|Cognition
149143|NCT02180984|Endocrine
149144|NCT02180984|Hormones
149145|NCT02180984|BDNF
149146|NCT02180984|Inflammatory biomarkers
149147|NCT02180971|Multi-detector computed tomography angiography
149148|NCT02180971|Coronary vessel distensibility
149149|NCT02180971|Coronary spasm
149150|NCT02180958|cerebral arteriovenous malformations
149151|NCT02180958|cAVM
149152|NCT02180958|ONYX
149153|NCT02180945|dAVF
149154|NCT02180945|Arteriovenous fistula
149155|NCT02180945|ONYX
149156|NCT02180919|Telemonitoring
149157|NCT02180919|COPD
149158|NCT02180919|Heart failure
149159|NCT02180919|Exacerbation
149160|NCT02180919|Respiratory failure
149161|NCT02180919|Prevention
149162|NCT02180919|Self monitoring
149163|NCT02180906|Fasciitis
149164|NCT02180906|Gangrene
149165|NCT02180906|Fasciitis, Necrotizing
149166|NCT02180906|Soft Tissue Infections
149167|NCT02180906|Fournier's Gangrene
149168|NCT02180906|Streptococcal septic shock syndrome
149169|NCT02180906|Flesh eating bacteria
149170|NCT02180906|Meleneys ulcer
149171|NCT02180906|Wounds and Injuries
149172|NCT02180906|Streptococcus pyogenes
149173|NCT02180906|Staphylococcus aureus
149174|NCT02180906|Immunopathogenesis
149175|NCT02180906|Soft Tissue Infections/blood
149176|NCT02180906|Necrosis/blood
149177|NCT02180906|Necrosis/diagnosis
149178|NCT02180906|Necrosis/mortality
149179|NCT02180906|Necrosis/surgery
149180|NCT02180906|Prognosis
149181|NCT02180906|Risk Factors
149182|NCT02180906|Bacterial Infections
149183|NCT02180906|Infection
149184|NCT02180906|Skin Diseases, Bacterial
149185|NCT02180906|Observational study
149186|NCT02180906|Biological markers
149187|NCT02180880|Neuralgia
149188|NCT02180880|Spinal cord
149189|NCT02180880|Oxcarbazepine
149190|NCT02180880|Pregabalin
149191|NCT02180880|Drug therapy
149192|NCT02180880|Algorithms
149193|NCT02180854|Early warning score
149194|NCT02180854|Rapid response systems
149195|NCT02180854|Medical emergency team
149196|NCT02180841|soy
149197|NCT02180841|hypertension
149198|NCT02180841|HDL-C
149199|NCT02180841|cholesterol efflux
149200|NCT02180841|cardiovascular disease
149201|NCT02180815|Obstructive Sleep Apnea
149202|NCT02180815|Obstructive Sleep Apnea due to primary tongue base closure
149203|NCT02180815|Minimally invasive surgery
149204|NCT02180815|ReVENT Sleep Apnea System
149205|NCT02180815|Tongue implants
149206|NCT02180802|obese adolescents
149207|NCT02180802|BMI ≥ 95th percentile for age and gender
149208|NCT02180789|tamsulosin,
149209|NCT02180789|benign prostatic hyperplasia,
149210|NCT02180789|α1-adrenoceptor antagonists
149211|NCT02180763|Primary Immunodeficiency, PID
149212|NCT02180750|Children
149213|NCT02180750|HIV
149214|NCT02180750|orphans
149215|NCT02180737|dexmedetomedine
149216|NCT02180737|sedation
149217|NCT02180737|interventional radiology
149218|NCT02180724|Bruton tyrosine kinase inhibitor
149219|NCT02180724|Btk
149220|NCT02180724|Waldenström Macroglobulinemia
149221|NCT02180724|WM
149222|NCT02180724|Waldenström
149223|NCT02180724|Macroglobulinemia
149224|NCT02180711|Bruton tyrosine kinase inhibitor
149225|NCT02180711|Btk
149226|NCT02180711|Follicular Lymphoma
149227|NCT02180711|FL
149228|NCT02180711|acalabrutinib
149229|NCT02180711|ACP-196
149230|NCT02180672|Obstructive sleep apnea syndrome
149231|NCT02180672|OSA
149232|NCT02180672|sleep apnea
149233|NCT02180672|nasal steroids
149234|NCT02180672|corticosteroids
149235|NCT02180646|GLP-1
149236|NCT02180646|GIP
149237|NCT02180646|second meal phenomena
149238|NCT02180646|type 2 diabetes
149239|NCT02180633|Idiopathic Macular Hole
149240|NCT02180620|GIP
149241|NCT02180620|GLP-1
149242|NCT02180620|exercise timing
149243|NCT02180620|resistance exercise
149244|NCT02180620|glucose concentrations
149245|NCT02180607|depression
149246|NCT02180607|social
149247|NCT02180607|rejection
149248|NCT02180607|acceptance
149249|NCT02180607|fMRI
149250|NCT02180607|reward
149251|NCT02180607|exclusion
149252|NCT02180581|Infections
149253|NCT02180581|Allergy
149254|NCT02180581|Immune function
149255|NCT02180581|Microbiota
149256|NCT02180581|Infant
149257|NCT02180568|Ground-glass-opacity (GGO)
149258|NCT02180568|Lung localization
149259|NCT02180568|Lipiodol
149260|NCT02180568|Hook wire
149261|NCT02180568|Video assisted thoracic surgery (VATS)
149262|NCT02180542|stroke
149263|NCT02180542|Ischemic stroke
149264|NCT02180542|Cerebral infarction
149265|NCT02180542|recurrent stroke
149266|NCT02180542|atrial fibrillation
149267|NCT02180542|premature atrial complexes
149268|NCT02180542|heart rhythm monitoring
149269|NCT02180542|left atrial function
149270|NCT02180542|carotid artery
149271|NCT02180542|plaque morphology
149272|NCT02180529|methylphenidate, elderly, mild cognitive impairment
149273|NCT02180464|psoriasis, topical
149274|NCT02180438|HIV-2
149275|NCT02180425|acne
149276|NCT02180425|lipid
149277|NCT02180425|tretinoin
149278|NCT02180425|isotretinoin
149279|NCT02180412|Acute porphyria
149280|NCT02180412|Hemin
149281|NCT02180399|Sepsis
149282|NCT02180399|Capillary blood lactate
149283|NCT02180399|Serial measurement of capillary
149284|NCT02180386|Audiovisual distraction
149285|NCT02180386|Pediatric dentistry
149286|NCT02180360|Capoeira training
149287|NCT02180360|Range of motion
149288|NCT02180360|Flexibility
149289|NCT02180360|beginners
149290|NCT02180347|Pediatrics
149291|NCT02180347|Contact lenses
149292|NCT02180334|Gastric Emptying
149293|NCT02180334|Gastrointestinal Motility
149294|NCT02180334|Incretins
149295|NCT02180334|Glucagon-Like Peptide 1
149296|NCT02180334|Diabetes Mellitus
149297|NCT02180321|Tranexamic acid
149298|NCT02180321|pharmacokinetics
149299|NCT02180321|craniosynostosis
149300|NCT02180308|Head cancer
149301|NCT02180308|Neck cancer
149302|NCT02180308|MRI
149303|NCT02180308|PET
149304|NCT02180282|Acne Treatment
149305|NCT02180269|Healthy
149306|NCT02180269|JNJ-54861911
149307|NCT02180269|Alzheimer's disease
149308|NCT02180256|IVF
149309|NCT02180256|ICSI
149310|NCT02180256|Embryo transfer
149311|NCT02180256|Assisted reproduction
149312|NCT02180256|Endometrial injury
149313|NCT02180256|Endometrial scratching
149314|NCT02180243|meditation
149315|NCT02180243|acupuncture
149316|NCT02180243|Gulf War Veterans' Illness
149317|NCT02180243|Gulf War health education
149318|NCT02180230|Short implants
149319|NCT02180230|prospective multicenter study
149320|NCT02180230|maxilla & mandible
149321|NCT02180217|LCI699
149322|NCT02180217|Cushing's disease
149323|NCT02180204|Cerebral Infarction
149324|NCT02180204|Ischemic Stroke
149325|NCT02180204|Thrombolysis
149326|NCT02180191|Gut microbiota
149327|NCT02180178|microvascular disease
149328|NCT02180178|coronary artery disease
149329|NCT02180178|Coronary artery disease, with or without microvascular dysfuntion
149330|NCT02180152|Perinatal outcomes
149331|NCT02180113|Cirrhotic patients
149332|NCT02180113|Fibroscan
149333|NCT02180113|Liver Stiffness Measurement
149334|NCT02180113|Oesophageal Varices
149335|NCT02180113|Portal Hypertension
149336|NCT02180113|Spleen Stiffness Measurement
149337|NCT02180087|Cardiac surgery
149338|NCT02180087|Post-operative pain
149339|NCT02180087|Kétoprofène
149340|NCT02180087|Minimum analgesic dose
149341|NCT02180087|Morphin consumption
149342|NCT02180087|Morphin secondary effects
149343|NCT02180087|Patient comfort and satisfaction
149344|NCT02180087|Renal fonction
149345|NCT02180074|Hydrogen Sulfide Pools,
149346|NCT02180061|PD1
149347|NCT02180061|PD-1
149348|NCT02180061|PDL1
149349|NCT02180061|PD-L1
149350|NCT02180035|diet therapy
149351|NCT02180035|symbiotic
149352|NCT02180035|dyslipidemia
149353|NCT02180035|gastrointestinal symptoms
149354|NCT02180035|body composition
149355|NCT02180035|adherence
149356|NCT02180035|HIV
149357|NCT02180035|HAART
149358|NCT02180022|Quercetin
149359|NCT02180022|Endothelial function
149360|NCT02180022|Onion peel extract
149361|NCT02180022|volunteers
149362|NCT02179996|Vaccination
149363|NCT02179996|Very preterm-born infants
149364|NCT02179996|Hib immunisation
149365|NCT02179996|Pertussis immunisation
149366|NCT02179983|Bronchiectasis
149367|NCT02179983|rehabilitation
149368|NCT02179983|exercise
149369|NCT02179983|exacerbations
149370|NCT02179970|Advanced pancreatic cancer
149371|NCT02179970|Advanced ovarian cancer
149372|NCT02179970|Advanced colorectal cancer
149373|NCT02179970|Metastatic pancreatic cancer
149374|NCT02179970|Metastatic ovarian cancer
149375|NCT02179970|Metastatic colorectal cancer
149376|NCT02179957|Stenoses
149377|NCT02179957|Ischaemia
149378|NCT02179957|haemodynamics
149379|NCT02179957|fractional flow reserve (FFR)
149380|NCT02179957|computed tomography (CT)
149381|NCT02179957|cardiac
149382|NCT02179944|medication abortion
149383|NCT02179944|serum hCG
149384|NCT02179918|Advanced Solid Tumors
149385|NCT02179905|MRI
149386|NCT02179905|Heart rate variability
149387|NCT02179905|Fatty acid
149388|NCT02179892|anesthesia
149389|NCT02179892|surgery
149390|NCT02179892|pain
149391|NCT02179879|labor,epidural,analgesia
149392|NCT02179853|Kawasaki disease
149393|NCT02179853|Anakinra
149394|NCT02179853|IL-1
149395|NCT02179840|Cerebral microvascular circulation
149396|NCT02179840|Cerebral autoregulation
149397|NCT02179814|bulimia nervosa
149398|NCT02179814|dopamine
149399|NCT02179814|reward
149400|NCT02179814|catechol-O-methyltransferase
149401|NCT02179814|gene
149402|NCT02179814|catecholamines
149403|NCT02179814|alpha-methyl-para-tyrosine
149404|NCT02179814|magnetic resonance imaging
149405|NCT02179801|Abdominal aortic aneurysm
149406|NCT02179801|AAA
149407|NCT02179801|Screening
149408|NCT02179788|lactation
149409|NCT02179788|breastfeeding
149410|NCT02179788|human milk
149411|NCT02179788|insulin
149412|NCT02179788|metformin
149413|NCT02179788|prediabetes
149414|NCT02179788|pre-diabetes
149415|NCT02179788|insulin resistance
149416|NCT02179762|cancer survivor
149417|NCT02179762|prostate cancer
149418|NCT02179762|exercise
149419|NCT02179762|Active surveillance
149420|NCT02179762|EASE
149421|NCT02179749|Alcohol-Related Disorders
149422|NCT02179749|Substance-Related Disorders
149423|NCT02179749|Mental Disorders
149424|NCT02179749|Mifepristone
149425|NCT02179749|Glucocorticoid Antagonists
149426|NCT02179749|Alcohol Treatment
149427|NCT02179749|Alcohol
149428|NCT02179736|Correction of moderate to severe nasolabial folds
149429|NCT02179723|wound healing
149430|NCT02179723|cosmetic results
149431|NCT02179723|trocar incision
149432|NCT02179710|adherence
149433|NCT02179710|cystic fibrosis
149434|NCT02179710|adolescents
149435|NCT02179710|adults
149436|NCT02179697|Groups:
149437|NCT02179697|Group 1 (2 Treatment Arms (Randomized between 2 treatments))
149438|NCT02179697|Treatment 1: Surgery + Bracing
149439|NCT02179697|Treatment 2: Bracing Alone
149440|NCT02179697|Group 2
149441|NCT02179697|The patient will decide which group is best for themselves.
149442|NCT02179684|Cranial Nerve fascial paresis
149443|NCT02179671|Lung cancer; NSCLC
149444|NCT02179658|Clostridium
149445|NCT02179658|Infections
149446|NCT02179658|Difficile
149447|NCT02179658|Vancomycin
149448|NCT02179658|Fidaxomicin
149449|NCT02179632|disclosure
149450|NCT02179632|conflicts of interest
149451|NCT02179632|trust
149452|NCT02179632|patient doctor relationship
149453|NCT02179593|Maxillary expansion
149454|NCT02179593|Orthognathic surgery
149455|NCT02179593|Symmetry
149456|NCT02179593|Palatal expansion technique
149457|NCT02179593|Maxilla abnormality
149458|NCT02179580|Traditional Chinese Medicine
149459|NCT02179580|Clinical trial
149460|NCT02179580|Good Clinical Practice
149461|NCT02179567|Metastatic NSCLC
149462|NCT02179567|Elderly
149463|NCT02179567|1st Line
149464|NCT02179567|Bevacizumab-based treatment
149465|NCT02179541|Otitis media with effusion, viscosity, RGB (red-green-blue).
149466|NCT02179515|Immune Response
149467|NCT02179515|Maximum Tolerated Dose
149468|NCT02179515|Vaccine Therapy
149469|NCT02179515|Increased Expression of Brachyury
149470|NCT02179515|Immunotherapy
149471|NCT02179489|Peritoneal carcinomatosis
149472|NCT02179489|HIPEC
149473|NCT02179489|controlled clinical trial
149474|NCT02179489|colorectal cancer
149475|NCT02179476|Facet joint
149476|NCT02179476|facet joint pain
149477|NCT02179476|facet joint disease
149478|NCT02179476|lumbar pain
149479|NCT02179476|back pain
149480|NCT02179463|Gastric Cancer
149481|NCT02179463|Neoadjuvant chemotherapy
149482|NCT02179463|Response Evaluation
149483|NCT02179437|TIVA
149484|NCT02179437|Propofol
149485|NCT02179437|Postoperative pain
149486|NCT02179437|Liver resection surgery
149487|NCT02179437|Retrospective study
149488|NCT02179424|smoking cessation interventions
149489|NCT02179398|Fever without source
149490|NCT02179398|Antibiotic prescription
149491|NCT02179398|Serious bacterial infection
149492|NCT02179385|Type 2 diabetes
149493|NCT02179385|Type II diabetes
149494|NCT02179359|Sickle Cell Disease
149495|NCT02179359|Thalassemia
149496|NCT02179359|Diamond Blackfan Anemia
149497|NCT02179359|hematologic disorders
149498|NCT02179359|stem cell transplant
149499|NCT02179346|cartilage defect
149500|NCT02179346|hip
149501|NCT02179346|impingement
149502|NCT02179320|Myofascial Pain Syndrome
149503|NCT02179320|Dry needling
149504|NCT02179320|Clinical Trial
149505|NCT02179307|muscle hypertrophy
149506|NCT02179307|strength
149507|NCT02179307|resistance training
149508|NCT02179307|exercise
149509|NCT02179307|physical fitness
149510|NCT02179307|health
149511|NCT02179307|physical conditioning
149512|NCT02179294|Pain relief
149513|NCT02179294|Labour
149514|NCT02179294|Child birth
149515|NCT02179294|Anaesthetics
149516|NCT02179268|Antidepressants
149517|NCT02179268|bone mineral density
149518|NCT02179268|bone turnover markers
149519|NCT02179255|DOR
149520|NCT02179255|Premature Ovarian Failure (POF)
149521|NCT02179255|Ovarian Failure
149522|NCT02179255|Human Growth Hormone
149523|NCT02179242|cardiac rehab
149524|NCT02179242|heart failure
149525|NCT02179242|KCCQ
149526|NCT02179242|6 minute walk test
149527|NCT02179242|readmission
149528|NCT02179229|Kidney transplantation
149529|NCT02179229|pCresol
149530|NCT02179229|Immunosuppressant drugs
149531|NCT02179216|Orthostatic hypotension in the elderly
149532|NCT02179216|Efficacity of Hydration
149533|NCT02179216|Difference between hydratation and venous contention
149534|NCT02179177|Vaso-occlusive crisis
149535|NCT02179177|Reduction in hospitalizations
149536|NCT02179177|Sickle Cell Disease
149537|NCT02179151|Prader-Willi Syndrome
149538|NCT02179151|Obesity
149539|NCT02179151|Hyperphagia
149540|NCT02179125|COPD
149541|NCT02179125|Endobronchial treatment
149542|NCT02179112|Surgery
149543|NCT02179112|Specialties, Surgical
149544|NCT02179112|Geography, Medical
149545|NCT02179112|Developing Countries
149546|NCT02179112|Developed Countries
149547|NCT02179112|Laparotomy
149548|NCT02179112|Outcome and Process Assessment (Health Care)
149549|NCT02179112|Treatment Outcome
149550|NCT02179112|Quality of Health Care
149551|NCT02179099|overactive bladder
149552|NCT02179099|OAB
149553|NCT02179099|urgency
149554|NCT02179099|botulinum toxin
149555|NCT02179099|BTX
149556|NCT02179099|botox
149557|NCT02179099|intravesical
149558|NCT02179099|TheraCoat
149559|NCT02179099|TCGel
149560|NCT02179099|TC-3 Gel
149561|NCT02179060|Sudden cardiac arrest, RhinoChill -cooling, MRI
149562|NCT02179047|SYNTAX ,NGAL,Cystatin C,Galectin-3,Copeptin.MR-ProANP,sST2.
149563|NCT02179034|tobacco
149564|NCT02179034|electronic cigarettes
149565|NCT02179034|menthol
149566|NCT02179021|Thromboelastometry
149567|NCT02179021|Haemostasis
149568|NCT02179021|Hypothermia
149569|NCT02179021|Heart arrest
149570|NCT02179008|Santen
149571|NCT02179008|Eye
149572|NCT02179008|Glaucoma
149573|NCT02179008|Ocular hypertension
149574|NCT02178982|mechanical ventilation
149575|NCT02178982|ARDS
149576|NCT02178982|Ventilator strategy
149577|NCT02178982|outcome
149578|NCT02178943|Molecular Diagnostics
149579|NCT02178943|Heart Transplantation
149580|NCT02178943|Risk Factors
149581|NCT02178943|Prognosis
149582|NCT02178930|HIV
149583|NCT02178930|cardiovascular disease
149584|NCT02178930|self-management
149585|NCT02178930|HIV co-morbidities
149586|NCT02178930|self-efficacy
149587|NCT02178930|coronary heart disease risk
149588|NCT02178930|quality of life
149589|NCT02178904|Ischemia
149590|NCT02178904|Dual Energy Computed Tomography
149591|NCT02178904|Computed Tomographic Perfusion
149592|NCT02178904|Fractional Flow Rate
149593|NCT02178904|Invasive Coronary Angiography
149594|NCT02178904|Coronary Artery Stenosis
149595|NCT02178891|short implants
149596|NCT02178891|Nobel Biocare
149597|NCT02178891|partially edentulous
149598|NCT02178891|maxilla or mandible
149599|NCT02178878|Labor pain and progress, variation, genetic
149600|NCT02178865|translocation
149601|NCT02178839|Non Alcoholic Fatty Liver Disease(NAFLD)
149602|NCT02178839|β- glucan
149603|NCT02178839|Appetite
149604|NCT02178839|Insulin Resistance
149605|NCT02178826|Nocturnal Enuresis
149606|NCT02178826|Rapid Maxillary Expansion
149607|NCT02178826|Orthodontics
149608|NCT02178826|Polysomnography
149609|NCT02178826|Quality of life
149610|NCT02178813|Minocycline
149611|NCT02178813|Neuroprotection
149612|NCT02178813|Stroke
149613|NCT02178787|cerebral blood flow
149614|NCT02178787|near infrared spectroscopy
149615|NCT02178787|transcranial Doppler
149616|NCT02178787|diabetes mellitus
149617|NCT02178787|cerebral autoregulation
149618|NCT02178774|Near-Infrared Spectroscopy (NIRS)
149619|NCT02178774|spinal anesthesia
149620|NCT02178774|cesarean section
149621|NCT02178761|Erectile dysfunction
149622|NCT02178761|Lower Urinary Tract Symptoms
149623|NCT02178761|Peripheral Arterial Disease
149624|NCT02178761|Angioplasty
149625|NCT02178761|Multidetector Computed Tomography
149626|NCT02178748|Tuberculosis
149627|NCT02178748|Phase II
149628|NCT02178748|MVA85A
149629|NCT02178748|Schistosoma mansoni
149630|NCT02178735|pelvic organ prolapse, vaginal mesh, urodynamic studies
149631|NCT02178709|Pancreatic
149632|NCT02178709|Cancer
149633|NCT02178709|Resectable
149634|NCT02178683|TACROLIMUS
149635|NCT02178683|MYCOPHENOLATE MOFETIL
149636|NCT02178683|FLUDARABINE
149637|NCT02178683|HLA-MATCHED
149638|NCT02178683|MIS-MATCHED
149639|NCT02178657|Stroke
149640|NCT02178657|Cell therapy
149641|NCT02178657|Bone marrow
149642|NCT02178605|rhBMP-2
149643|NCT02178605|arthrodesis
149644|NCT02178605|cervical
149645|NCT02178592|integrase inhibitor
149646|NCT02178592|Mycobacterium tuberculosis
149647|NCT02178592|rifampicin-sensitive
149648|NCT02178592|dolutegravir
149649|NCT02178592|antiretroviral therapy-naïve
149650|NCT02178592|HIV-1 infection
149651|NCT02178592|efavirenz
149652|NCT02178592|co-infection
149653|NCT02178579|Heart Failure
149654|NCT02178579|Cardiac Toxicity
149655|NCT02178579|Multiple Myeloma
149656|NCT02178579|Bortezomib
149657|NCT02178579|Carfilzomib
149658|NCT02178566|COPD
149659|NCT02178566|Trepostinil
149660|NCT02178566|Pulmonary Rehabilitation
149661|NCT02178553|Thoracotomy
149662|NCT02178553|Pain
149663|NCT02178540|Human factors, TOBI® Podhaler™, Instructions For use, IFU, CF patients
149664|NCT02178527|Geriatrics
149665|NCT02178527|Accidental Falls
149666|NCT02178527|Podiatry
149667|NCT02178527|Exercise Therapy
149668|NCT02178527|Orthotic Devices
149669|NCT02178527|Foot
149670|NCT02178501|OMEGA-3 PUFA
149671|NCT02178501|type 2 diabetes
149672|NCT02178501|cardiovascular diseases
149673|NCT02178475|NHL
149674|NCT02178475|Breast Cancer
149675|NCT02178423|children, ultrasound, central catheter
149676|NCT02178410|Atrial Fibrillation
149677|NCT02178410|Vitamin D3
149678|NCT02178410|Omega-3 fatty acids
149679|NCT02178410|Fish oil
149680|NCT02178397|erlotinib
149681|NCT02178397|lung cancer
149682|NCT02178397|EGFR mutation
149683|NCT02178384|Loading Forces
149684|NCT02178384|Removable partial dentures
149685|NCT02178384|Bilateral distal extension
149686|NCT02178371|Upper extremity
149687|NCT02178371|Physical therapy modalities
149688|NCT02178358|transforming growth factor beta (TGF-β)
149689|NCT02178345|MRI
149690|NCT02178345|14-126
149691|NCT02178332|Children
149692|NCT02178332|socio-emotional
149693|NCT02178332|socio-emotional skills
149694|NCT02178332|psychiatric symptoms
149695|NCT02178332|SDQ
149696|NCT02178332|Finland
149697|NCT02178332|School
149698|NCT02178332|School community
149699|NCT02178332|Teacher
149700|NCT02178332|Whole school approach
149701|NCT02178332|Intervention
149702|NCT02178332|Effectiveness study
149703|NCT02178332|Cluster randomised trial
149704|NCT02178319|portal hypertension
149705|NCT02178319|Randomized clinical trial
149706|NCT02178319|laparoscopic
149707|NCT02178319|open
149708|NCT02178267|Newborn, preterm, probiotic, resistant microorganisms
149709|NCT02178254|Pseudomonas aeruginosa, ZTI-101, phosphonic acid derivative, Monurol, fosfomycin tromethamine
149710|NCT02178228|Anastomotic Leaks
149711|NCT02178228|Bowel Resection
149712|NCT02178228|Postoperative Complication
149713|NCT02178215|atopic dermatitis
149714|NCT02178215|skin barrier function
149715|NCT02178215|transepidermal water loss
149716|NCT02178215|skin pH
149717|NCT02178215|stratum corneum hydration
149718|NCT02178215|sebum
149719|NCT02178215|wrinkle
149720|NCT02178202|Harmonic technique, Low Back Pain, McKenzie exercise, Pain, Disability
149847|NCT02177513|Pharmacodynamics
149721|NCT02178189|prenatal opioid exposure
149722|NCT02178189|infant
149723|NCT02178189|weight gain
149724|NCT02178189|infant formula
149725|NCT02178150|Magnesium
149726|NCT02178150|Insulin Resistance
149727|NCT02178150|Lipid profile
149728|NCT02178150|Sex hormones
149729|NCT02178150|Inflammatory factors
149730|NCT02178111|episiotomy, vaginal delivery, randomized, perineum
149731|NCT02178098|LDL
149732|NCT02178098|Cholesterol
149733|NCT02178085|glaucoma
149734|NCT02178085|phase-contrast MRI
149735|NCT02178085|blood flow
149736|NCT02178085|cerebrospinal fluid
149737|NCT02178072|HNSCC
149738|NCT02178059|Healthy volunteers, pharmacokinetic, inhalation
149739|NCT02178046|Gingivitis
149740|NCT02178033|adenoma detection rate, screening colonoscopy
149741|NCT02178020|Knee Arthroplasty
149742|NCT02178020|Osteolysis
149743|NCT02178020|Radiolucent Lines
149744|NCT02177994|Elective Cesarean Section
149745|NCT02177994|Antibiotic prophylaxis
149746|NCT02177994|Timing of Antibiotic prophylaxis
149747|NCT02177994|post cesarean section infection
149748|NCT02177981|Remote Ischemic Preconditioning
149749|NCT02177981|Coronary Artery Bypass Grafting
149750|NCT02177981|Diffusion Weighted Magnetic Resonance Imaging
149751|NCT02177981|Resting State Functional Magnetic Resonance Imaging
149752|NCT02177981|Postoperative Cognitive Dysfunction
149753|NCT02177968|fall
149754|NCT02177968|elderly
149755|NCT02177968|characteristics
149756|NCT02177955|Third Molar
149757|NCT02177955|Anty-anxiety drugs
149758|NCT02177955|hemodynamic
149759|NCT02177955|Benzodiazepines
149760|NCT02177929|Spinal cord injury,
149761|NCT02177929|adaptive sport,
149762|NCT02177929|dynamometry,
149763|NCT02177929|electromyography,
149764|NCT02177929|force platform.
149765|NCT02177916|lung transplantation
149766|NCT02177903|hypothermia
149767|NCT02177903|surgical site infection
149768|NCT02177903|opioid usage
149769|NCT02177903|blood loss
149770|NCT02177903|pain severity
149771|NCT02177903|anxiety
149772|NCT02177903|Length of Stay
149773|NCT02177877|Epilepsy
149774|NCT02177877|Seizures
149775|NCT02177877|Wrist accelerometer
149776|NCT02177877|Epilepsy diary
149777|NCT02177877|Seizure detection
149778|NCT02177877|Biosensor
149779|NCT02177851|Iron bio-availability
149780|NCT02177851|Hepcidin
149781|NCT02177851|Iron absorption
149782|NCT02177812|Oncology
149783|NCT02177812|LSD1
149784|NCT02177812|GSK2879552
149785|NCT02177812|Acute myeloid leukemia
149786|NCT02177799|Gastroenteritis
149787|NCT02177799|Hospitalized
149788|NCT02177799|Children
149789|NCT02177786|Diabetic Kidney Disease
149790|NCT02177786|Gilead
149791|NCT02177760|SCID
149792|NCT02177760|severe combined immunodeficiency
149793|NCT02177760|maternal engraftment
149794|NCT02177760|aGVHD prophylaxis
149795|NCT02177760|sirolimus
149796|NCT02177734|Adjuvant
149797|NCT02177734|Safety
149798|NCT02177734|Influenza
149799|NCT02177734|H7N9
149800|NCT02177734|Immunogenicity
149801|NCT02177734|Adults
149802|NCT02177721|Raxibacumab
149803|NCT02177721|anthrax
149804|NCT02177721|anti-toxin
149805|NCT02177695|Bladder Cancer
149806|NCT02177695|Neoadjuvant Chemotherapy
149807|NCT02177695|Coexpression Extrapolation
149808|NCT02177695|COXEN
149809|NCT02177695|S1314
149810|NCT02177695|SWOG
149811|NCT02177682|AKT inhibitor
149812|NCT02177682|Afuresertib
149813|NCT02177682|multiple myeloma
149814|NCT02177669|Normal, healthy individuals without ocular disease
149815|NCT02177669|Ages 20-89
149816|NCT02177669|English speaking
149817|NCT02177669|Visual acuity better than 20/25
149818|NCT02177656|heart failure
149819|NCT02177656|self-care
149820|NCT02177656|self-care maintenance
149821|NCT02177656|self-care management
149822|NCT02177656|self-efficacy
149823|NCT02177656|quality of life
149824|NCT02177656|symptoms
149825|NCT02177643|Diabetes
149826|NCT02177643|Diacerein
149827|NCT02177630|myocarditis, myocardial inflammation, imaging, magnetic resonance
149828|NCT02177617|Cervical Dystonia
149829|NCT02177617|Botox
149830|NCT02177578|Subventricular Zone
149831|NCT02177578|progenitor cell
149832|NCT02177578|radiation therapy
149833|NCT02177578|temozolomide
149834|NCT02177565|Non-union
149835|NCT02177565|fracture
149836|NCT02177565|bone marrow stem cells
149837|NCT02177552|Esophageal cancer
149838|NCT02177552|Gastric cancer
149839|NCT02177539|cycloplegia
149840|NCT02177539|refraction in children
149841|NCT02177539|cycloplegic agents
149842|NCT02177539|cycloplegic schemes
149843|NCT02177539|cyclopentolate
149844|NCT02177526|CT
149845|NCT02177526|MRI
149846|NCT02177513|Cannabis
149848|NCT02177513|Marijuana
149849|NCT02177513|Cannabinoids
149850|NCT02177513|Vaporized
149851|NCT02177474|depressive symptoms
149852|NCT02177474|perceived social support
149853|NCT02177474|coronary heart disease
149854|NCT02177474|peer support
149855|NCT02177474|women
149856|NCT02177279|Wheat bran cereals, bran phytochemicals, phytochemicals bioavailability
149857|NCT02177240|GlideScope®
149858|NCT02177240|GlideRite®
149859|NCT02177240|Flex-it®
149860|NCT02177240|Difficult intubation
149861|NCT02177227|Total Knee Arthroplasty (TKA)
149862|NCT02177227|Attune
149863|NCT02177227|Primary Total Knee Prosthesis
149864|NCT02177227|TruMatch
149865|NCT02177188|Hypovolaemic shock
149866|NCT02177188|Monitoring
149867|NCT02177188|Haemorrhage
149868|NCT02177188|Transthoracic Echocardiography
149869|NCT02177175|Carvedilol
149870|NCT02177175|Anthracycline
149871|NCT02177175|HER2
149872|NCT02177175|14-099
149873|NCT02177136|PSC
149874|NCT02177123|glaucoma shunt
149875|NCT02177123|glaucoma drainage device
149876|NCT02177110|advanced melanoma
149877|NCT02177110|metastatic melanoma
149878|NCT02177110|fresh frozen tissue
149879|NCT02177110|FFPE tissue
149880|NCT02177097|Pain
149881|NCT02177097|Infection
149882|NCT02177097|Inflammation
149883|NCT02177097|Prosthesis
149884|NCT02177084|PTNS
149885|NCT02177084|rectal cancer
149886|NCT02177084|low anterior resection syndrome
149887|NCT02177071|CROHN DISEASE
149888|NCT02177071|INFLIXIMAB
149889|NCT02177071|COMBINATION THERAPY
149890|NCT02177071|steroid free remission
149891|NCT02177071|anti-metabolites
149892|NCT02177058|Nursing homes
149893|NCT02177058|Hospitalizations
149894|NCT02177032|Rabies vaccines
149895|NCT02177032|intradermal
149896|NCT02177032|human rabies immunoglobulins
149897|NCT02177019|frequent headaches
149898|NCT02177019|personalized health plan
149899|NCT02176993|Acute stroke
149900|NCT02176993|Therapeutic Hypothermia
149901|NCT02176980|HCV
149902|NCT02176980|hepatitis C
149903|NCT02176980|alcohol
149904|NCT02176980|integrated care
149905|NCT02176941|Telomere Length
149906|NCT02176941|Arterial Aging
149907|NCT02176941|Endothelial Progenitor Cells
149908|NCT02176941|Inflammation
149909|NCT02176941|Atherosclerosis
149910|NCT02176889|Lactospore
149911|NCT02176889|Bacillus coagulans
149912|NCT02176889|Safety
149913|NCT02176889|Probiotic
149914|NCT02176889|Healthy Adults
149915|NCT02176889|Tolerability
149916|NCT02176876|rheumatoid arthritis
149917|NCT02176876|RA
149918|NCT02176876|GS-5745
149919|NCT02176876|MMP9
149920|NCT02176876|phase 1
149921|NCT02176863|FORCE
149922|NCT02176863|post-polio syndrome
149923|NCT02176863|Flebogamma
149924|NCT02176863|Immune Globulin Intravenous
149925|NCT02176863|IGIV
149926|NCT02176837|subarachnoid hemorrhage
149927|NCT02176837|vasospasm
149928|NCT02176837|nitrite
149929|NCT02176837|sodium nitrite
149930|NCT02176811|Non-alcoholic Fatty Liver Disease
149931|NCT02176811|Betatrophin
149932|NCT02176785|Sleep
149933|NCT02176785|Transcranial Electric Stimulation
149934|NCT02176720|Glioma
149935|NCT02176720|Glioblastoma
149936|NCT02176720|Glioblastoma multiforme
149937|NCT02176720|GBM
149938|NCT02176720|Recurrence
149939|NCT02176720|PET
149940|NCT02176720|FDOPA
149941|NCT02176707|Lung Function
149942|NCT02176707|Exercise Capacity
149943|NCT02176694|persistent asthma
149944|NCT02176694|adherence
149945|NCT02176694|text message reminders
149946|NCT02176655|Delayed Alcohol Induced Headache
149947|NCT02176642|Urinary Urge Incontinence
149948|NCT02176642|Posterior Tibial Nerve Stimulation
149949|NCT02176642|PTNS
149950|NCT02176642|Neuromodulation
149951|NCT02176642|Oxybutynin
149952|NCT02176642|Anticholinergic Medication
149953|NCT02176629|Virtual Reality
149954|NCT02176629|mild cognitive impairment
149955|NCT02176629|Alzheimer's disease
149956|NCT02176603|phenylketonuria, endothelial dysfunction, CKD
149957|NCT02176590|PATHS Social Emotional Learning
149958|NCT02176590|Coping Power
149959|NCT02176590|Power PATH
149960|NCT02176590|Head Start
149961|NCT02176486|Drug therapy
149962|NCT02176473|Depression
149963|NCT02176460|Knee Osteoarthritis
149964|NCT02176460|Double-blind
149965|NCT02176460|placebo-controlled
149966|NCT02176460|randomized
149967|NCT02176460|colchicine
149968|NCT02176434|End stage renal disease
149969|NCT02176434|Transplantation
149970|NCT02176434|Tolerance
149971|NCT02176408|Major Depressive Disorder
149972|NCT02176408|Depression
149973|NCT02176408|MDD
149974|NCT02176408|Exercise
149975|NCT02176408|Physical Activity
149976|NCT02176408|Treatment
149977|NCT02176408|Behavioral Activation
149978|NCT02176395|Acute Ischemic Stroke
149979|NCT02176395|Randomized Controlled Trial
149980|NCT02176395|Traditional Chinese Medicine
149981|NCT02176395|Proteomics
149982|NCT02176369|Non small cell lung cancer (NSCLC)
149983|NCT02176369|Lung tumor in advanced phase
149984|NCT02176330|Randomised Controlled Trial
149985|NCT02176330|Virtual Clinic
149986|NCT02176330|ePAQ-PF
149987|NCT02176330|Pelvic Floor Disorders
149988|NCT02176330|Economic Analysis
149989|NCT02176317|Autism Spectrum Disorder
149990|NCT02176317|ASD
149991|NCT02176317|Umbilical cord blood
149992|NCT02176317|Autologous cord blood
149993|NCT02176317|cord blood
149994|NCT02176304|knee
149995|NCT02176304|arthritis
149996|NCT02176304|injections
149997|NCT02176304|corticosteroids
149998|NCT02176291|Buprenorphine
149999|NCT02176291|Receptors, opioid
150000|NCT02176291|Receptors, opioid kappa and mu
150001|NCT02176278|Diabetic Kidney Disease
150002|NCT02176278|Diabetes
150003|NCT02176278|Asian
150004|NCT02176278|Joint Asia Diabetes Evaluation (JADE) Program
150005|NCT02176265|CAD
150006|NCT02176265|PCI
150007|NCT02176265|bioactive coronary stent
150008|NCT02176265|OCT
150009|NCT02176226|Major Depressive Disorder
150010|NCT02176226|Anxiety Disorders
150011|NCT02176226|Behavior Therapy
150012|NCT02176226|Technology Assisted
150013|NCT02176226|Mobile Phone
150014|NCT02176226|Cellular Phone
150015|NCT02176226|Smartphone
150016|NCT02176226|App
150017|NCT02176213|Relapsed
150018|NCT02176213|Refractory
150019|NCT02176213|Multiple Myeloma
150020|NCT02176213|Pomalidomide
150021|NCT02176213|Cyclophosphamide
150022|NCT02176213|Dexamethasone
150023|NCT02176174|Ethnic group
150024|NCT02176174|Cardiovascular disease
150025|NCT02176174|Atherosclerosis
150026|NCT02176161|Prostate Cancer
150027|NCT02176161|Prostate Cancer Recurrent
150028|NCT02176148|cutaneous lupus
150029|NCT02176148|systemic lupus
150030|NCT02176148|systemic therapy
150031|NCT02176148|medication
150032|NCT02176135|HIV
150033|NCT02176135|HAART suppressed
150034|NCT02176135|Auranofin
150035|NCT02176135|HIV latent reservoir
150036|NCT02176057|trachoma
150037|NCT02176044|Nitric Oxide
150038|NCT02176044|Sodium Nitroprusside
150039|NCT02176044|Spatial Working Memory
150040|NCT02176044|Psychosis
150041|NCT02176044|Schizophrenia
150042|NCT02176031|Graft Versus Host Disease
150043|NCT02176018|Episodic Migraine
150044|NCT02176018|Migraine
150045|NCT02176018|Headache
150046|NCT02175979|postoperative ileus
150047|NCT02175979|anastomotic leak
150048|NCT02175979|colorectal surgery
150049|NCT02175979|inflammation
150050|NCT02175953|caregiver burden
150051|NCT02175953|stress
150052|NCT02175953|depression
150053|NCT02175953|dementia
150054|NCT02175927|Helicobacter pylori
150055|NCT02175927|Treatment Failure
150056|NCT02175927|second-line therapy
150057|NCT02175914|Erythromycin
150058|NCT02175914|Familial Adenomatous Polyposis (FAP).
150059|NCT02175914|APC gene
150060|NCT02175914|nonsense mutations
150061|NCT02175901|helicobacter pylori eradication
150062|NCT02175901|antibiotic
150063|NCT02175888|Iron bio availability
150064|NCT02175888|Hepcidin
150065|NCT02175888|Iron absorption
150066|NCT02175875|ticagrelor
150067|NCT02175875|platelet function test
150068|NCT02175875|comatose
150069|NCT02175875|PCI
150070|NCT02175875|naso-gastric tube
150071|NCT02175862|Helicopter Emergency Medical Service
150072|NCT02175862|Trauma
150073|NCT02175862|Early retirement
150074|NCT02175862|ISS
150075|NCT02175862|Quality of life
150076|NCT02175849|Multi-Drug Resistant Tuberculosis
150077|NCT02175849|Social Network Analysis
150078|NCT02175836|Arrhythmic Sudden Cardiac Death
150079|NCT02175836|Heart Failure
150080|NCT02175836|Risk Stratification
150081|NCT02175836|Autonomic Nervous System
150082|NCT02175836|Heart Rate
150083|NCT02175836|Repolarization
150084|NCT02175823|Cancer survivors
150085|NCT02175823|circadian rhythm
150086|NCT02175823|Elderly Patients
150087|NCT02175823|frailty
150088|NCT02175810|Obesity
150089|NCT02175810|Bariatric surgery
150090|NCT02175810|physical activity
150091|NCT02175810|cardiopulmonary exercise test
150092|NCT02175797|Pacemaker, leads and MRI exam
150093|NCT02175784|Blood glucose
150094|NCT02175784|insulin
150095|NCT02175784|ipragliflozin
150096|NCT02175784|SGLT2 inhibitor
150097|NCT02175732|Type 1 Diabetes
150098|NCT02175732|Distress
150099|NCT02175719|Torticollis
150100|NCT02175719|rimabotulinumtoxinB
150101|NCT02175693|Torticollis
150102|NCT02175693|rimabotulinumtoxinB
150103|NCT02175680|HIV-1
150104|NCT02175680|HIV
150105|NCT02175680|Treatment Substitution
150106|NCT02175680|PRO 140
150107|NCT02175680|PRO140
150108|NCT02175680|CytoDyn
150109|NCT02175680|Amarex
150110|NCT02175667|Global postural reeducation
150111|NCT02175667|Stabilometry
150112|NCT02175667|Postural Sway
150113|NCT02175667|Range of motion
150114|NCT02175667|Personality traits
150115|NCT02175654|metastatic colorectal cancer
150116|NCT02175654|RAS/BRAF mutation
150117|NCT02175654|Regorafenib
150118|NCT02175654|FOLFOXIRI
150119|NCT02175654|Bevacizumab
150120|NCT02175641|Healthy lifestyle Intervention
150121|NCT02175641|Serious Mental Illness
150122|NCT02175641|Effectiveness trial
150123|NCT02175641|Supportive housing
150124|NCT02175641|Racial and Ethnic Health Disparities
150125|NCT02175628|Ultrasound
150126|NCT02175628|Breast
150127|NCT02175628|Angiography
150128|NCT02175615|CYCLOSPORINE
150129|NCT02175615|ACUTE GRAFT VERSUS HOST DISEASE
150130|NCT02175615|PROPHYLAXIS
150131|NCT02175615|CHILDREN
150132|NCT02175615|HAEMATOPOIETIC STEM CELL TRANSPLANT
150133|NCT02175589|Familial Mediterranean Fever
150134|NCT02175589|Monozygous
150135|NCT02175589|MEFV
150136|NCT02175589|Colchicine
150137|NCT02175589|Serum Amyloid A
150138|NCT02175563|Chest
150139|NCT02175563|Compression
150140|NCT02175550|partially edentulous
150141|NCT02175550|maxilla
150142|NCT02175550|implants
150143|NCT02175550|Conical connection
150144|NCT02175550|Nobel Biocare
150145|NCT02175550|NobelReplace
150146|NCT02175550|Immediate loading
150147|NCT02175550|One- stage surgery
150148|NCT02175550|Two- stage surgery
150149|NCT02175550|supported restoration
150150|NCT02175550|patients
150151|NCT02175537|Diabetes Mellitus, Type II
150152|NCT02175537|Disease management
150153|NCT02175537|Obesity
150154|NCT02175537|Social Network
150155|NCT02175537|Chronic disease
150156|NCT02175537|Prevention and control
150157|NCT02175537|Education
150158|NCT02175524|nut chewing
150159|NCT02175511|Home Blood Pressure
150160|NCT02175511|Computerized physician order entry (CPOE)
150161|NCT02175511|Telemonitoring
150162|NCT02175511|Hypertension
150163|NCT02175498|Homoeopathy Similimum female infertility
150164|NCT02175472|Parkinson's disease
150165|NCT02175472|Light therapy
150166|NCT02175472|Circadian rhythm
150167|NCT02175446|Breast cancer
150168|NCT02175446|HER2Negative
150169|NCT02175446|Second line treatment
150170|NCT02175446|HER2-
150171|NCT02175446|MBC
150172|NCT02175446|Metastatic
150173|NCT02175446|Metastatic breast cancer
150174|NCT02175446|bevacizumab
150175|NCT02175446|eribulin
150176|NCT02175446|Human Epidermal Growth Factor Receptor 2-Negative
150177|NCT02175433|Refractory or relapsed chronic lymphocytic leukemia (CLL) prolymphocytic leukemia (PLL)
150178|NCT02175433|Relapsed lymphoid malignancy
150179|NCT02175433|Refractory lymphoid malignancy
150180|NCT02175433|Pharmacokinetics of AGS67E
150181|NCT02175433|hairy cell leukemia (HCL)
150182|NCT02175433|AGS67C
150183|NCT02175433|non-Hodgkin lymphoma (NHL)
150184|NCT02175433|AGS67E
150185|NCT02175420|BCG
150186|NCT02175420|Salmonella
150187|NCT02175420|Trained immunity
150188|NCT02175420|Non-specific effect vaccines
150189|NCT02175407|Healthy subjects
150190|NCT02175407|ASP1707
150191|NCT02175407|Itraconazole
150192|NCT02175381|Metastatic NSCLC
150193|NCT02175381|Elderly
150194|NCT02175381|1st Line
150195|NCT02175381|Platinum-based treatment
150196|NCT02175368|total etch protocol
150197|NCT02175368|direct filling therapy
150198|NCT02175329|CAD/CAM, three-unit posterior bridges, zirconia framework
150199|NCT02175277|Myelodysplastic Syndrome (MDS)
150200|NCT02175277|Darbepoetin alfa
150201|NCT02175277|low risk MDS
150202|NCT02175277|intermediate-1 risk MDS
150203|NCT02175277|International Prognostic Scoring System (IPSS)
150204|NCT02175264|Isolated non syndromic CDH
150205|NCT02175251|rTMS
150206|NCT02175251|Schizophrenia
150207|NCT02175251|high frequency rTMS
150208|NCT02175251|low frequency rTMS
150209|NCT02175251|AHRS
150210|NCT02175251|SAPS SANS PANSS
150211|NCT02175251|GAF
150212|NCT02175251|UKU
150213|NCT02175225|Brain hemorrhage
150214|NCT02175225|Cerebral hemorrhage
150215|NCT02175225|Bleeding in the brain
150216|NCT02175225|Deferoxamine
150217|NCT02175225|iDEF trial
150218|NCT02175212|Patients with prostate adenocarcinoma
150219|NCT02175199|Contact lens
150220|NCT02175199|Vision care
150221|NCT02175199|Daily wear
150222|NCT02175199|Color contact lens
150223|NCT02175186|Gastritis
150224|NCT02175186|Gastroduodenal Ulcer
150225|NCT02175186|Percutaneous Coronary Revascularization
150226|NCT02175186|Dual Antiplatelet Therapy
150227|NCT02175173|Epileptic encephalopathy, Lennox-Gastaut type
150228|NCT02175160|Driver reaction time
150229|NCT02175134|tuberculosis
150230|NCT02175134|peritonitis
150231|NCT02175134|laparoscopy
150232|NCT02175108|Cerebral palsy
150233|NCT02175108|Adolescents
150234|NCT02175108|Adults
150235|NCT02175108|Diet
150236|NCT02175108|Activity
150237|NCT02175108|Metabolic Syndrome
150238|NCT02175095|regorafenib
150239|NCT02175095|fluorothymidine
150240|NCT02175095|positron emission tomography
150241|NCT02175095|metastatic colorectal cancer
150242|NCT02175082|Parkinson Disease
150243|NCT02175082|Exercise
150244|NCT02175082|Rehabilitation
150245|NCT02175082|Physical Therapy
150246|NCT02175082|Cycling
150247|NCT02175069|Shoulder surgery
150248|NCT02175056|First In Human
150249|NCT02175056|CAPS, SoJIA, AOSD, Bechet Disease, Rheumatoid arthritis
150250|NCT02175043|atrial fibrillation, catheter ablation, recurrence
150251|NCT02175030|Emergency contraception
150252|NCT02175030|Levonorgestrel IUD
150253|NCT02175030|Copper IUD
150254|NCT02175017|ONO-4538
150255|NCT02175017|Advanced non-small cell lung cancer
150256|NCT02175004|FAP
150257|NCT02175004|Familial Amyloid Polyneuropathy
150258|NCT02175004|TTR
150259|NCT02175004|Transthyretin
150260|NCT02175004|Amyloidosis
150261|NCT02174978|Malaria vaccine
150262|NCT02174952|Parenting interventions
150263|NCT02174952|ADHD
150264|NCT02174952|Family functioning
150265|NCT02174952|Parent Training
150266|NCT02174939|cilostazol
150267|NCT02174939|progenitor cells
150268|NCT02174939|coronary artery disease
150269|NCT02174939|myocardial infarction
150270|NCT02174939|angiogenesis
150271|NCT02174939|biological markers
150272|NCT02174939|endothelial function
150273|NCT02174913|Awakening time
150274|NCT02174913|Bispectral index
150275|NCT02174913|clinical signs
150276|NCT02174913|neurophysiologic monitoring
150277|NCT02174913|spine surgery
150278|NCT02174900|G6PD deficiency
150279|NCT02174900|safety
150280|NCT02174900|transmission
150281|NCT02174887|pancreatic adenocarcinoma
150282|NCT02174887|liver metastases
150283|NCT02174861|Chronic Migraine
150284|NCT02174848|Pantothenate Kinase-Associated Neurodegeneration
150285|NCT02174848|PKAN
150286|NCT02174848|Neurodegeneration with Brain Iron Accumulation
150287|NCT02174848|NBIA
150288|NCT02174848|Deferiprone
150289|NCT02174848|Ferriprox
150290|NCT02174835|Pharmacokinetics
150291|NCT02174835|Healthy Volunteers
150292|NCT02174835|deuterated dextromethorphan
150293|NCT02174835|deuterated dextromethorphan with quinidine
150294|NCT02174822|Drug-drug interaction
150295|NCT02174822|Pharmacokinetics
150296|NCT02174822|Healthy Volunteers
150297|NCT02174822|deuterated dextromethorphan
150298|NCT02174822|deuterated dextromethorphan with quinidine
150299|NCT02174809|Pregnancy
150300|NCT02174809|Gestational Weight Gain
150301|NCT02174809|Primary Care
150302|NCT02174809|Guidelines
150303|NCT02174796|Pectus excavatum
150304|NCT02174796|cardiac output
150305|NCT02174796|transthoracic impedancemetry
150306|NCT02174783|Weight Loss
150307|NCT02174783|Diet, Mediterranean
150308|NCT02174783|Diet, Reducing
150309|NCT02174783|protein sparing modified diet
150310|NCT02174744|Pain in elderly patients having communication disorders
150311|NCT02174744|Numerical scale
150312|NCT02174744|Algoplus® scale
150313|NCT02174744|Doloplus® scale
150314|NCT02174731|Renal,
150315|NCT02174731|CKD,
150316|NCT02174731|Epoetin alfa,
150317|NCT02174731|Roxadustat,
150318|NCT02174731|dialysis,
150319|NCT02174731|anemia
150320|NCT02174718|Cholecalciferol
150321|NCT02174718|Transdermal patch
150322|NCT02174705|vaccination
150323|NCT02174705|pain management
150324|NCT02174705|sucrose
150325|NCT02174705|rotavirus
150326|NCT02174666|Aglycones
150327|NCT02174666|Isoflavones
150328|NCT02174666|Red clover
150329|NCT02174666|Osteopenia
150330|NCT02174666|Menopause
150331|NCT02174666|Bone turnover
150332|NCT02174666|Bone mineral density
150333|NCT02174640|Coffee
150334|NCT02174640|Polyphenolics
150335|NCT02174627|Renal,
150336|NCT02174627|CKD,
150337|NCT02174627|Roxadustat,
150338|NCT02174627|anemia,
150339|NCT02174627|non-dialysis
150340|NCT02174614|Cocaine use disorder
150341|NCT02174601|bowel preparation
150342|NCT02174601|coolprep
150343|NCT02174601|colonoscopy
150344|NCT02174601|prediction model
150345|NCT02174588|sedation, propofol, midazolam
150346|NCT02174575|Hepatectomy
150347|NCT02174562|Type 2 diabetes
150348|NCT02174562|Mild Cognitive Impairment
150349|NCT02174549|Hypoxia
150350|NCT02174549|Embolization
150351|NCT02174549|Tirapazamine
150352|NCT02174549|Hepatocellular carcinoma
150353|NCT02174523|pharmacokinetic
150354|NCT02174523|lurasidone
150355|NCT02174523|multiple dose
150356|NCT02174510|pharmacokinetic
150357|NCT02174510|lurasidone
150358|NCT02174510|single dose
150359|NCT02174497|Pediatric Colonoscopy
150360|NCT02174497|Bowel Preparation
150361|NCT02174497|Safety
150362|NCT02174497|Tolerability
150363|NCT02174484|Pacemaker
150364|NCT02174484|Remote monitoring
150365|NCT02174484|Remote follow-up
150366|NCT02174484|Home monitoring
150367|NCT02174484|Periodic IEGM
150368|NCT02174484|Intracardiac electrogram
150369|NCT02174471|Aortic Stenosis
150370|NCT02174471|Aortic Valve Replacement
150371|NCT02174471|T1 Mapping
150372|NCT02174471|Extracellular Volume Fraction
150373|NCT02174471|Cardiovascular Magnetic Resonance
150374|NCT02174471|Diffuse Myocardial Fibrosis
150375|NCT02174458|Bariatric surgery; Body contouring; Quality of life
150376|NCT02174445|Patients with CML in chronic phase
150377|NCT02174445|Imatinib
150378|NCT02174445|Nilotinib
150379|NCT02174432|Itch
150380|NCT02174432|Chronic Itch
150381|NCT02174432|Nalbupine
150382|NCT02174419|Itch
150383|NCT02174419|Chronic Itch
150384|NCT02174419|nalbuphine
150385|NCT02174406|Ultrasound
150386|NCT02174406|Digital Breast Tomosynthesis
150387|NCT02174406|14-119
150388|NCT02174367|Chronic plaque psoriasis
150389|NCT02174367|Liver fibrosis
150390|NCT02174367|Fatty liver disease
150391|NCT02174367|Non-alcoholic fatty liver disease
150392|NCT02174367|Transient elastography
150393|NCT02174367|Fibroscan
150394|NCT02174367|Procollagen-3 N-Terminal peptide
150395|NCT02174367|Alanine aminotransferase
150396|NCT02174367|Liver function tests
150397|NCT02174354|Psoriasis
150398|NCT02174354|Methotrexate
150399|NCT02174354|Methotrexate Polyglutamates
150400|NCT02174354|Injury of Liver
150401|NCT02174341|Chikungunya fever
150402|NCT02174341|Chikungunya Virus
150403|NCT02174328|See incidence of Pre-Eclampsia in acetylsalicylic acid group
150404|NCT02174328|See incidence of Pre-Eclampsia in placebo group
150405|NCT02174289|Heart Failure
150406|NCT02174289|Cardiac Resynchronisation Therapy
150407|NCT02174289|Transseptal left ventricular endocardial lead
150408|NCT02174250|PD
150409|NCT02174237|Phase 1, safety, tolerability, PK, PD
150410|NCT02174224|Violence
150411|NCT02174224|At-risk youth
150412|NCT02174224|Intentional Injury
150413|NCT02174224|Violence Intervention
150414|NCT02174224|Youth
150415|NCT02174224|recidivism
150416|NCT02174198|Immediate implant
150417|NCT02174198|bone graft
150418|NCT02174198|immediate restoration
150419|NCT02174185|bladder cancer
150420|NCT02174185|conduit diversion
150421|NCT02174185|orthotopic neobladder
150422|NCT02174185|health-related quality of life
150423|NCT02174185|validated questionnaire
150424|NCT02174146|leptin
150425|NCT02174146|visfatin
150426|NCT02174146|chronic periodontitis
150427|NCT02174146|diabetes mellitus
150428|NCT02174146|non-surgical periodontal therapy
150429|NCT02174133|left ventricular assist device
150430|NCT02174133|endothelial function
150431|NCT02174133|microvascular perfusion
150432|NCT02174133|microparticles
150433|NCT02174107|Health economics
150434|NCT02174107|Percutaneous vertebroplasty
150435|NCT02174107|Radiation therapy
150436|NCT02174107|Painful spine metastases
150437|NCT02174081|mechanical ventilation, ARDS, Ventilator strategy, outcome
150438|NCT02174068|Paracetamol
150439|NCT02174068|Nefopam
150440|NCT02174068|Pharmacokinetic
150441|NCT02174068|Drug interaction
150442|NCT02174055|Depression
150443|NCT02174055|14-101
150444|NCT02174029|Atrophy
150445|NCT02174029|Ventilator
150446|NCT02174029|Induced
150447|NCT02174029|Diaphragm
150448|NCT02174029|Dysfunction
150449|NCT02174016|Intensive Care Units
150450|NCT02174016|Pediatric
150451|NCT02174003|whole body hyperthermia
150452|NCT02174003|depression
150453|NCT02174003|fibromyalgia
150454|NCT02174003|rheumatoid arthritis
150455|NCT02174003|perimenopausal symptoms
150456|NCT02174003|open treatment
150457|NCT02173990|adenocarcinoma
150458|NCT02173990|colon and/or rectum
150459|NCT02173977|GnRH Agonist
150460|NCT02173977|GnRH Antagonist
150461|NCT02173977|OHSS
150462|NCT02173964|fluorodeoxyglucose
150463|NCT02173964|positron emission tomography
150464|NCT02173964|computed tomography
150465|NCT02173964|bowel
150466|NCT02173964|pinaverium bromide
150467|NCT02173951|young minimally transfused beta thalassemia major
150468|NCT02173951|labile plasma iron (LPI)
150469|NCT02173951|Transferrin saturation (TSAT)
150470|NCT02173951|Deferiprone
150471|NCT02173951|Transfusional iron loading rate
150472|NCT02173951|Transfusion units
150473|NCT02173938|Smokers
150474|NCT02173938|outpatient
150475|NCT02173938|Tobacco Dependence Treatment Program
150476|NCT02173873|Age related macular degeneration
150477|NCT02173873|central retinal vein occlusion
150478|NCT02173860|Coronary artery disease
150479|NCT02173860|Valvular heart disease
150480|NCT02173860|Fractional flow reserve
150481|NCT02173860|Coronary artery bypass surgery
150482|NCT02173860|Coronary graft failure or patency
150483|NCT02173847|anvil-shaped corneal graft
150484|NCT02173847|penetrating keratoplasty
150485|NCT02173847|femtosecond laser
150486|NCT02173847|laser welding
150487|NCT02173834|Brown Adipose Tissue
150488|NCT02173834|Weight
150489|NCT02173834|Sympathetic Nervous System
150490|NCT02173756|chemotherapy
150491|NCT02173756|mucositis
150492|NCT02173756|systemic opioids
150493|NCT02173756|morphine
150494|NCT02173743|plasma, calcific tendinitis, rotator cuff, PRP
150495|NCT02173704|Meningitis
150496|NCT02173704|Infants
150497|NCT02173704|Meningococcal B Recombinant Vaccine
150498|NCT02173626|Mindfulness
150499|NCT02173613|infection lung elderly patients
150500|NCT02173600|Cardiovascular risk
150501|NCT02173600|Primary prevention
150502|NCT02173600|Intensive dietary counselling
150503|NCT02173600|Physical exercise
150504|NCT02173587|Anti-inflammation, Rheumatoid arthritis, Thick shell mussel lipid extract, Chinese
150505|NCT02173574|Hepatitis C Virus, Viral, Antiviral, Infection, Infectious disease, alisporivir, EDP239, DEB025
150506|NCT02173561|Posttraumatic Stress Disorder
150507|NCT02173561|Cognitive Processing Therapy
150508|NCT02173561|combat
150509|NCT02173561|military
150510|NCT02173561|CPT
150511|NCT02173561|group therapy
150512|NCT02173548|heart failure
150513|NCT02173548|HFpEF
150514|NCT02173548|diastole
150515|NCT02173548|diastolic heart failure
150516|NCT02173548|inflammation
150517|NCT02173548|interleukin-1
150518|NCT02173548|C-reactive protein
150519|NCT02173522|Prostate cancer
150520|NCT02173522|Prostate artery embolization
150521|NCT02173522|Robot-assisted laparoscopic radical prostatectomy
150522|NCT02173496|Wet age-related macular degeneration
150523|NCT02173496|Assessment modalities for preclinical, pre-symptomatic ARMD
150524|NCT02173457|Chiglitazar
150525|NCT02173457|Sitagliptin
150526|NCT02173457|diabetes
150527|NCT02173457|type 2 diabetes
150528|NCT02173444|in-vitro fertilization
150529|NCT02173444|ovarian stimulation
150530|NCT02173431|BMI
150531|NCT02173431|Pressure
150532|NCT02173431|Bedsore
150533|NCT02173418|Postoperative pain
150534|NCT02173418|Acute postoperative pain
150535|NCT02173418|Chronic postoperative pain
150536|NCT02173418|Shoulder pain
150537|NCT02173418|Thoracotomy
150538|NCT02173418|Thoracoscopy
150539|NCT02173405|Myofascial Pain Syndromes
150540|NCT02173405|Pelvic pain
150541|NCT02173405|Trigger points + injections
150542|NCT02173405|Myofascial Trigger Point Pain
150543|NCT02173405|Trigger Point Pain, Myofascial
150544|NCT02173405|Botulinum Toxins, Type A
150545|NCT02173405|Botulinum Neurotoxin A
150546|NCT02173405|Botulinum Toxin Type A
150547|NCT02173405|Clostridium botulinum A Toxin
150548|NCT02173405|Clostridium Botulinum Toxin Type A
150549|NCT02173405|Oculinum
150550|NCT02173379|Absorb™ BVS
150551|NCT02173379|Angioplasty
150552|NCT02173379|Bioabsorbable
150553|NCT02173379|BVS
150554|NCT02173379|Coronary Artery Disease
150555|NCT02173379|Coronary Artery Endothelial Responsiveness
150556|NCT02173379|Coronary artery restenosis
150557|NCT02173379|Coronary artery stenosis
150558|NCT02173379|Coronary scaffold
150559|NCT02173379|Coronary Stent
150560|NCT02173379|Drug eluting stents
150561|NCT02173379|Everolimus
150562|NCT02173379|Myocardial ischemia
150563|NCT02173379|Stent thrombosis
150564|NCT02173379|Stents
150565|NCT02173353|Ultrasound use during radiation therapy for Pancreas cancer
150566|NCT02173314|Long term foster care
150567|NCT02173314|child abuse and neglect
150568|NCT02173262|Breast
150569|NCT02173236|Dental Implant Platform Switching
150570|NCT02173236|Early Dental Implant Loading
150571|NCT02173210|Premature birth
150572|NCT02173210|Premature delivery
150573|NCT02173210|Metabolomics
150574|NCT02173210|Microbiota
150575|NCT02173210|Genetics
150576|NCT02173210|17 hydroxyprogesterone caproate
150577|NCT02173197|Occupational Therapy
150578|NCT02173197|Complex patients
150579|NCT02173197|Occupational performance problem
150580|NCT02173197|Rehabilitation Complexity Scale
150581|NCT02173184|bacterial vaginosis
150582|NCT02173184|Gynevac Lactobacillus vaccine
150583|NCT02173171|Melanoma
150584|NCT02173145|idiopathic pulmonary fibrosis
150585|NCT02173145|cough
150586|NCT02173145|immunomodulation
150587|NCT02173145|macrolide
150588|NCT02173119|Hepatocellular
150589|NCT02173119|Carcinoma
150590|NCT02173119|HCC
150591|NCT02173119|lipiodol
150592|NCT02173093|Neuroblastoma
150593|NCT02173093|Osteosarcoma
150594|NCT02173093|Solid tumor
150595|NCT02173093|Immunotherapy targeting GD2
150596|NCT02173093|Bispecific antibodies
150597|NCT02173093|Activated T cells
150598|NCT02173080|autosomal dominant polycystic liver disease
150599|NCT02173080|autosomal dominant polycystic kidney disease
150600|NCT02173080|quality of life
150601|NCT02173080|patient reported outcome tool
150602|NCT02173067|Diabetes mellitus
150603|NCT02173067|Epinephrine
150604|NCT02173067|Anesthesia, Dental
150605|NCT02173067|lidocaine
150606|NCT02173067|Ambulatory Surgical Procedures
150607|NCT02173054|Acne
150608|NCT02173054|Moisturizer
150609|NCT02173054|Efficacy
150610|NCT02173054|Irritation
150611|NCT02173041|Prevention and Awareness Groups (PAG),
150612|NCT02173041|Substance Use Disorder,
150613|NCT02173041|Community based intervention
150614|NCT02173028|Beta Blocker Intolerance;
150615|NCT02173028|Remote Patient Management system;
150616|NCT02173028|Cardiac Resynchronization Therapy
150617|NCT02173015|accidental falls
150618|NCT02173015|older adults
150619|NCT02173015|long-term care
150620|NCT02173015|nursing home
150621|NCT02173015|postural balance
150622|NCT02173002|Telemedicine
150623|NCT02173002|Patient empowerment
150624|NCT02173002|Integrated care
150625|NCT02172989|Near-infrared fluorescence
150626|NCT02172989|Indocyanine green, ICG
150627|NCT02172989|Radio-guided surgery
150628|NCT02172989|breast cancer
150629|NCT02172976|pancreas cancer
150630|NCT02172976|neoadjuvant chemotherapy
150631|NCT02172976|Folfirinox
150632|NCT02172976|gemcitabine
150633|NCT02172963|Stem Cell Transplantation
150634|NCT02172963|Decidual Stromal Cells
150635|NCT02172937|Stem Cell Transplantation
150636|NCT02172937|Decidual Stromal Cells
150637|NCT02172924|Stem Cell Transplantation
150638|NCT02172924|Decidual Stromal Cells
150639|NCT02172911|Cervical cancer
150640|NCT02172911|Papillomavirus
150641|NCT02172911|Chemoradiation
150642|NCT02172911|Recurrent cervical cancer
150643|NCT02172911|Persistent cervical cancer
150644|NCT02172885|Mesenchymal stem cell based therapy
150645|NCT02172885|cell infusion
150646|NCT02172872|Newly diagnosed
150647|NCT02172872|AML
150648|NCT02172872|Elderly
150649|NCT02172872|Decitabine
150650|NCT02172872|Transplant
150651|NCT02172859|lumiVida™, cognition, mood, sleep, tryptophane
150652|NCT02172820|cardiac rehabilitation
150653|NCT02172820|contingency management
150654|NCT02172768|pharmacokinetics
150655|NCT02172768|alternate dosing
150656|NCT02172768|micafungin
150657|NCT02172755|Eslicarbazepine acetate
150658|NCT02172755|BIA 2-093
150659|NCT02172742|Eslicarbazepine acetate
150660|NCT02172742|BIA 2-093
150661|NCT02172729|adductor canal block
150662|NCT02172729|healthy volunteers
150663|NCT02172729|US-guided peripheral nerve block
150664|NCT02172729|lower limb
150665|NCT02172729|duration
150666|NCT02172729|Muscle Strength
150667|NCT02172729|Anesthetics, Local
150668|NCT02172729|Sensation
150669|NCT02172703|TBI
150670|NCT02172703|SAH
150671|NCT02172703|ICP
150672|NCT02172703|non invasive measurement
150673|NCT02172690|Gastric Cancer
150674|NCT02172690|Laparoscopic Staging
150675|NCT02172690|Cytology
150676|NCT02172690|Peritoneal Metastases
150677|NCT02172664|noncarious cervical lesions
150678|NCT02172664|dental adhesive
150679|NCT02172664|retention
150680|NCT02172664|enamel margin discoloration
150681|NCT02172664|self etch
150682|NCT02172664|selective etch procedures
150683|NCT02172651|Vitamin D
150684|NCT02172651|Stage I-III colon cancer
150685|NCT02172651|Stage IV colon cancer
150686|NCT02172651|Resectable liver metastases
150687|NCT02172638|Enhanced Recovery After Surgery
150688|NCT02172638|ERAS
150689|NCT02172638|Fast-Track
150690|NCT02172638|Ovarian cancer
150691|NCT02172638|Gynecologic surgery
150692|NCT02172638|Gynecology oncology
150693|NCT02172638|Median length of stay
150694|NCT02172638|Readmission rate
150695|NCT02172638|Surgery related complications
150696|NCT02172638|Cost
150697|NCT02172625|Athletic performance
150698|NCT02172625|Running
150699|NCT02172625|Dietary supplementation
150700|NCT02172625|Quality of life
150701|NCT02172625|Running performance
150702|NCT02172625|oxidative damage
150703|NCT02172612|Anticholinergic drugs
150704|NCT02172599|sit-stand workstation
150705|NCT02172599|workplace
150706|NCT02172599|multi-component intervention
150707|NCT02172599|randomised control trial design
150708|NCT02172599|physical activity
150709|NCT02172599|sitting
150710|NCT02172599|sedentary behaviour
150711|NCT02172599|process evaluation
150712|NCT02172599|health
150713|NCT02172365|Chronic myeloid leukemia
150714|NCT02172365|Allogeneic hematopoietic cell transplantation
150715|NCT02172365|Tyrosine kinase inhibitor
150716|NCT02172365|TKI failure
150717|NCT02172183|cognitive-behavioral therapy, adolescents, ADHD.
150718|NCT02172092|Diabetes
150719|NCT02172092|Ketoacidosis
150720|NCT02172092|fluid shift
150721|NCT02172079|shoulder impingement, manual therapy, pain, motion.
150722|NCT02172066|Posttraumatic Stress Disorder
150723|NCT02172066|Childhood maltreatment
150724|NCT02172053|Workplace
150725|NCT02172053|Industrial workers
150726|NCT02172053|Resistance exercise
150727|NCT02172053|Fatigue
150728|NCT02172053|Occupational risk
150729|NCT02172053|Physical therapy
150730|NCT02172040|High blood pressure
150731|NCT02172040|Systolic blood pressure
150732|NCT02172040|Diastolic blood pressure
150733|NCT02172040|Antihypertensive
150734|NCT02172014|Mechanical Ventilation
150735|NCT02172014|Sedation
150736|NCT02172014|Fentanyl
150737|NCT02172014|Midazolam
150738|NCT02172014|Comfort behavior scale
150739|NCT02172001|IDA
150740|NCT02172001|Iron deficiency
150741|NCT02172001|iron deficiency anemia and who are intolerant or unresponsive to oral iron therapy
150742|NCT02171988|Postural Orthostatic Tachycardia Syndrome
150743|NCT02171988|propranolol
150744|NCT02171988|bisoprolol
150745|NCT02171988|pyridostigmine
150746|NCT02171975|Spinal anaesthesia
150747|NCT02171975|Ultrasound pre-procedure guided
150748|NCT02171975|Paramedian spinal
150749|NCT02171962|Zilver® PTX® Drug-Eluting Peripheral Stent
150750|NCT02171962|Above-the-Knee Femoropopliteal Artery
150751|NCT02171962|Chinese patient
150752|NCT02171949|Chronic hepatitis
150753|NCT02171949|Hepatic cirrhosis
150754|NCT02171936|Pain
150755|NCT02171936|Precariousness
150756|NCT02171936|EPICES Score
150757|NCT02171936|CETD
150758|NCT02171923|depression
150759|NCT02171910|Cholangiopancreatography, Endoscopic Retrograde
150760|NCT02171910|Sedation
150761|NCT02171871|EFFECTS,
150762|NCT02171871|PASSIVE SMOKING ,
150763|NCT02171871|RESPIRATORY SYSTEM MECHANICS,
150764|NCT02171871|DIFFERENT BODY POSITIONS.
150765|NCT02171858|Stroke
150766|NCT02171858|National Institutes of Health Stroke Scale
150767|NCT02171858|Serum high sensitivity C-Reactive Protein
150768|NCT02171845|Male foetuses of 10 to 37 weeks
150769|NCT02171819|Influenza
150770|NCT02171819|Avian
150771|NCT02171819|H5N1
150772|NCT02171819|Vaccine
150773|NCT02171390|Hypogonadism
150774|NCT02171390|Endothelial dysfunction
150775|NCT02171390|Insulin resistance
150776|NCT02171390|Inflammation
150777|NCT02171390|Testosterone replacement therapy
150778|NCT02171377|COPD
150779|NCT02171377|electrical stimulation
150780|NCT02171377|Rehabilitation
150781|NCT02171377|exercise test
150782|NCT02171364|Atrial fibrillation, Virtual ablation, electrocardiography, electroanatomical mapping data
150783|NCT02171351|sympathetic nerve reactivity
150784|NCT02171351|neuromuscular electrostimulation
150785|NCT02171338|Procalcitonin
150786|NCT02171338|Antibiotic therapy
150787|NCT02171338|Lower respiratory tract diseases
150788|NCT02171325|irinotecan
150789|NCT02171325|Small Cell Lung Cancer
150790|NCT02171312|Dizziness
150791|NCT02171312|Imbalance
150792|NCT02171286|KRAS
150793|NCT02171286|EGFR
150794|NCT02171286|BRAF
150795|NCT02171286|NRAS and HRAS
150796|NCT02171286|PIK3CA
150797|NCT02171286|RAS-RAF-MEK-MAPK
150798|NCT02171286|HER2
150799|NCT02171286|IDH1 and IDH2
150800|NCT02171286|ALK
150801|NCT02171286|TP53
150802|NCT02171286|c-KIT
150803|NCT02171286|STAT1&3
150804|NCT02171286|PDGFRA
150805|NCT02171286|Metastatic colorectal cancer
150806|NCT02171286|Advanced non-small cell lung cancer
150807|NCT02171286|Advanced melanoma
150808|NCT02171286|Gastrointestingal Struma Tumor
150809|NCT02171286|Candidate genes implicated as potential prognostic and predictive biomarkers in patients with solid tumours
150810|NCT02171286|Circulating Tumor DNA
150811|NCT02171273|Sleep
150812|NCT02171273|Aging
150813|NCT02171273|Metabolism
150814|NCT02171273|Circadian
150815|NCT02171273|Genetic
150816|NCT02171273|Alertness
150817|NCT02171260|Tumors
150818|NCT02171260|Lymphomas
150819|NCT02171260|Solid Tumors
150820|NCT02171260|Pediatric
150821|NCT02171247|coronary computed tomographic angiography
150822|NCT02171247|contrast
150823|NCT02171234|Epilepsy
150824|NCT02171234|BIA 2-093
150825|NCT02171234|Eslicarbazepine acetate
150826|NCT02171221|Refractory or relapsed tumors
150827|NCT02171221|Antimetabolites, Antineoplastic
150828|NCT02171221|Fluorouracil
150829|NCT02171195|Eslicarbazepine acetate
150830|NCT02171195|BIA 2-093
150831|NCT02171195|Epilepsy
150832|NCT02171182|Qutenza
150833|NCT02171182|8% capsaicin patch
150834|NCT02171182|Non-interventional
150835|NCT02171182|Post-operative peripheral neuropathic pain
150836|NCT02171182|Observational
150837|NCT02171182|Czech Republic
150838|NCT02171143|ASP2409
150839|NCT02171143|Rheumatoid Arthritis
150840|NCT02171143|methotrexate
150841|NCT02171130|Diabetes Mellitus
150842|NCT02171130|Hypoglycemia
150843|NCT02171130|Glucagon
150844|NCT02171130|Anti-glucagon Antibody
150845|NCT02171130|Immunogenicity
150846|NCT02171117|Acute Myeloid Leukemia
150847|NCT02171117|microtransplantation
150848|NCT02171117|elderly patients
150849|NCT02171117|HLA-mismatched
150850|NCT02171117|donor
150851|NCT02171117|Peripheral
150852|NCT02171117|stem cell
150853|NCT02171117|infusion
150854|NCT02171104|allogeneic hematopoietic cell transplantation
150855|NCT02171104|bone marrow transplantation
150856|NCT02171104|Mucopolysaccharidosis I
150857|NCT02171104|Mucopolysaccharidosis II
150858|NCT02171104|Mucopolysaccharidosis VI
150859|NCT02171104|Mucopolysaccharidosis VII
150860|NCT02171104|Hurler syndrome
150861|NCT02171104|Hunter syndrome
150862|NCT02171104|Maroteaux Lamy syndrome
150863|NCT02171104|Sly syndrome
150864|NCT02171104|Glycoprotein Metabolic Disorders
150865|NCT02171104|Alpha Mannosidosis
150866|NCT02171104|Fucosidosis
150867|NCT02171104|Aspartylglucosaminuria
150868|NCT02171104|Adrenoleukodystrophy
150869|NCT02171104|Peroxisomal Disorders
150870|NCT02171104|Osteopetrosis
150871|NCT02171104|Sphingolipidosis
150872|NCT02171104|Gangliosidosis
150873|NCT02171104|Globoid Cell Leukodystrophy
150874|NCT02171104|Metachromatic Leukodystrophy
150875|NCT02171104|Niemann Pick B
150876|NCT02171104|Niemann Pick C subtype 2
150877|NCT02171104|I-cell disease
150878|NCT02171104|Mucolipidosis
150879|NCT02171104|Wolmans disease
150880|NCT02171104|Sanfilippo syndrome
150881|NCT02171104|Sandhoff disease
150882|NCT02171104|Inherited Metabolic
150883|NCT02171091|endotracheal
150884|NCT02171091|intubation
150885|NCT02171091|airway
150886|NCT02171091|inflammation
150887|NCT02171078|Breast Cancer
150888|NCT02171078|Breast Neoplasms
150889|NCT02171078|Health Services Research
150890|NCT02171078|Surveillance
150891|NCT02171078|Diagnostic Imaging
150892|NCT02171078|Magnetic Resonance Imaging
150893|NCT02171078|Mammography
150894|NCT02171078|Toxicity
150895|NCT02171078|Adverse Effects
150896|NCT02171078|Side Effects
150897|NCT02171078|Recurrence
150898|NCT02171065|NIRS/IVUS
150899|NCT02171065|multimodality imaging
150900|NCT02171065|PROSPECT
150901|NCT02170961|Acute heart failure
150902|NCT02170961|RAAS
150903|NCT02170961|MMP3
150904|NCT02170961|MMP12
150905|NCT02170961|Polymorphysm
150906|NCT02170948|ultrasound-guided regional anesthesia
150907|NCT02170948|nerve block
150908|NCT02170948|ankle block
150909|NCT02170948|dexmedetomidine
150910|NCT02170948|Precedex
150911|NCT02170948|ankle surgery
150912|NCT02170948|forefoot surgery
150913|NCT02170948|duration
150914|NCT02170948|anesthetic duration following ankle block for forefoot surgery
150915|NCT02170883|asthma
150916|NCT02170883|mHealth
150917|NCT02170883|cluster randomized controlled trial
150918|NCT02170883|pharmacy practice
150919|NCT02170883|pharmacist
150920|NCT02170857|Hyaluronic acid
150921|NCT02170857|infra-bony defects
150922|NCT02170857|chronic periodontitis
150923|NCT02170857|experimental
150924|NCT02170857|radiographic
150925|NCT02170857|clinical
150926|NCT02170857|periodontal surgical treatment
150927|NCT02170857|open flap curettage
150928|NCT02170818|Education
150929|NCT02170818|Curriculum
150930|NCT02170818|Anesthesiology
150931|NCT02170818|Operating Rooms
150932|NCT02170779|multiple sclerosis
150933|NCT02170779|spasticity
150934|NCT02170779|stretching
150935|NCT02170779|exercise
150936|NCT02170779|rehabilitation
150937|NCT02170714|Acute severe colitis
150938|NCT02170714|Children
150939|NCT02170714|Infliximab
150940|NCT02170714|colectomy
150941|NCT02170688|IV contrast
150942|NCT02170688|contrast dosing
150943|NCT02170662|male pattern hair loss
150944|NCT02170662|androgenetic alopecia
150945|NCT02170662|bimatoprost
150946|NCT02170649|BIA 2-093
150947|NCT02170649|Eslicarbazepine acetate
150948|NCT02170558|Trabecular Metal
150949|NCT02170558|Metal reduction CT
150950|NCT02170558|TM- Ardis
150951|NCT02170545|avascular necrosis
150952|NCT02170545|humeral head fracture
150953|NCT02170545|proximal arm fracture
150954|NCT02170545|arthroplasty
150955|NCT02170532|asthma
150956|NCT02170519|pulmonary hypertension
150957|NCT02170493|Insole Sensor
150958|NCT02170493|Optimial Limb Loading
150959|NCT02170493|42IIIB
150960|NCT02170493|IIIC
150961|NCT02170493|Lower Extremity Fractures
150962|NCT02170467|Intestinal permeability - Anorexia nervosa- Re feeding - auto-antibodies α-MSH
150963|NCT02170454|neuromodulation
150964|NCT02170454|swallowing
150965|NCT02170454|magnetic stimulation
150966|NCT02170454|healthy subjects
150967|NCT02170441|Tuberculosis
150968|NCT02170441|Multi-drug resistant tuberculosis
150969|NCT02170441|Extensively drug-resistant tuberculosis
150970|NCT02170441|Drug-resistant tuberculosis
150971|NCT02170441|Mycobacterial Growth Indicator Tube Drug Susceptibility Test
150972|NCT02170441|Line Probe Assay
150973|NCT02170441|Microscopic Observation Drug Susceptibility Assay
150974|NCT02170441|Pyrosequencing
150975|NCT02170428|growth,
150976|NCT02170428|infancy,
150977|NCT02170428|children,
150978|NCT02170428|diet,
150979|NCT02170428|breastfeeding
150980|NCT02170428|complementary feeding
150981|NCT02170428|early life programming
150982|NCT02170428|tracking
150983|NCT02170428|physical activity
150984|NCT02170415|Persistent post-surgical pain
150985|NCT02170415|Breast surgery
150986|NCT02170415|Complex intervention
150987|NCT02170415|Pain treatment
150988|NCT02170376|Parkinson's disease (PD)
150989|NCT02170376|BIA 9-1067
150990|NCT02170376|Opicapone
150991|NCT02170363|Heart Failure
150992|NCT02170363|Ventricular Dysfunction
150993|NCT02170363|Cardiomyopathies
150994|NCT02170363|Heart Disease
150995|NCT02170363|Cardiovascular Disease
150996|NCT02170363|Heart-assist devices
150997|NCT02170311|Z-213, Ferric carboxymaltose, Iron, Iron-deficiency-anemia
150998|NCT02170298|ADHD
150999|NCT02170298|Attention Deficit Hyperactivity Disorder
151000|NCT02170298|Vyvanse
151001|NCT02170298|Lisdexamfetamine
151002|NCT02170285|perinatal stroke
151003|NCT02170285|hemiparetic cerebral palsy
151004|NCT02170285|brain stimulation
151005|NCT02170285|tDCS
151006|NCT02170285|constraint-induced movement therapy
151007|NCT02170285|hand arm bimanual intensive therapy
151008|NCT02170259|Tension-type headache
151009|NCT02170259|Depression
151010|NCT02170259|Anxiety
151011|NCT02170259|Manual therapy
151012|NCT02170259|Spinal manipulation
151013|NCT02170259|Patients diagnosed with tension-type headache
151014|NCT02170246|Acute HIV infection
151015|NCT02170246|Central nervous system
151016|NCT02170246|Antiretroviral therapy
151017|NCT02170246|Telmisartan
151018|NCT02170246|Cerebrospinal fluid
151019|NCT02170220|Drug therapy
151020|NCT02170207|Pharmacological therapy
151021|NCT02170194|smart phone apps
151022|NCT02170194|subthreshold PTSD
151023|NCT02170194|resilience enhancement
151024|NCT02170194|military veterans
151025|NCT02170194|natural disasters
151026|NCT02170194|terrorism
151027|NCT02170194|shootings
151028|NCT02170194|fMRI
151029|NCT02170194|physiology
151030|NCT02170181|SBRT
151031|NCT02170181|prostate cancer
151032|NCT02170181|lung cancer
151033|NCT02170181|bladder cancer
151034|NCT02170181|kidney cancer
151035|NCT02170181|oligometastatic disease
151036|NCT02170168|Community health services
151037|NCT02170168|Models, organizational
151038|NCT02170168|Referral and consultation
151039|NCT02170168|Palliative medicine
151040|NCT02170168|Terminal care
151041|NCT02170142|MRI
151042|NCT02170142|perinatal brain
151043|NCT02170142|development, neonates
151044|NCT02170103|segment elevation myocardial infarctions (STEMIs),
151045|NCT02170103|sonothrombolysis
151046|NCT02170103|reperfusion
151047|NCT02170103|percutaneous intervention (PCI),
151048|NCT02170103|antithrombotic therapy,
151049|NCT02170103|antiplatelet therapy,
151050|NCT02170090|adjuvant chemotherapy
151051|NCT02170090|cholangiocarcinoma
151052|NCT02170090|muscle invasive gall bladder carcinoma
151053|NCT02170090|translational research
151054|NCT02170090|multidisciplinary
151055|NCT02170090|AIO, DGAV, DGVS
151056|NCT02170077|Epilepsy
151057|NCT02170077|BIA 2-093
151058|NCT02170064|Epilepsy
151059|NCT02170064|BIA 2-093
151060|NCT02170051|negative symptoms
151061|NCT02170051|cognition
151062|NCT02170051|functioning
151063|NCT02170051|defeatist attitudes
151064|NCT02170051|psychosocial treatment
151065|NCT02170038|Drug Kinetics
151066|NCT02170025|Cystic fibrosis
151067|NCT02170025|delta F508
151068|NCT02170025|Safety
151069|NCT02170025|Tolerability
151070|NCT02170025|Sweat Chloride
151071|NCT02170025|Pharmacokinetics
151072|NCT02170012|Multiple dose
151073|NCT02170012|safety
151074|NCT02170012|tolerability
151075|NCT02170012|PK
151076|NCT02169973|Healthy
151077|NCT02169973|Positron Emission Tomography
151078|NCT02169973|11C-MK-3168
151079|NCT02169973|JNJ-42165279
151080|NCT02169973|Human Brain
151081|NCT02169895|Parkinson's disease (PD)
151082|NCT02169895|Opicapone
151083|NCT02169895|Bia 9-1067
151084|NCT02169882|Tuberculous meningitis
151085|NCT02169882|Rifampicin
151086|NCT02169882|Dose finding study
151087|NCT02169882|Pharmacokinetics
151088|NCT02169869|intrauterine device, postpartum, contraception, Mirena, Paragard, intrauterine system
151089|NCT02169856|Cholecystectomy
151090|NCT02169856|Laparoscopic
151091|NCT02169856|Postoperative Nausea and Vomiting
151092|NCT02169843|Dexmedetomidine,
151093|NCT02169843|agitation,
151094|NCT02169843|AFPS,
151095|NCT02169843|NRS,
151096|NCT02169843|mean arterial pressure
151097|NCT02169843|heart rate(HR)
151098|NCT02169830|vestibular migraines, nortriptyline and topiramate
151099|NCT02169791|hematologic malignancies
151100|NCT02169778|Weight loss
151101|NCT02169778|Intermittent energy restriction
151102|NCT02169778|Metabolic compensation
151103|NCT02169778|Diet therapy
151104|NCT02169765|Hepatocellular Carcinoma
151105|NCT02169765|Liver Cancer
151106|NCT02169752|Pre-Pulmonary Atrial Hypertension
151107|NCT02169739|ischemic preconditioning
151108|NCT02169739|remote ischemic preconditioning
151109|NCT02169739|ischemic stroke
151110|NCT02169739|white matter disease
151111|NCT02169739|cerebral small vessel disease
151112|NCT02169739|cognitive decline
151113|NCT02169739|leukoaraiosis
151114|NCT02169739|diffusion tensor imaging
151115|NCT02169739|white matter hyper intensity score
151116|NCT02169739|European scale of age-related white matter change
151117|NCT02169713|Healthy subjects
151118|NCT02169713|Mirabegron
151119|NCT02169713|Solifenacin
151120|NCT02169713|Tamsulosin HCl
151121|NCT02169700|Ischemic compression
151122|NCT02169700|Myofascial trigger points
151123|NCT02169700|Post-needling soreness
151124|NCT02169687|Thyroid, HIFU, hyperfunctioning, autonomous
151125|NCT02169674|Hepatitis B
151126|NCT02169674|Vaccine
151127|NCT02169674|Immunogenicity
151128|NCT02169661|Oxidative stress
151129|NCT02169661|Lipid peroxides
151130|NCT02169661|Phytochemicals
151131|NCT02169661|Ready meals
151132|NCT02169661|Beetroot
151133|NCT02169661|Blood pressure
151134|NCT02169648|macular edema
151135|NCT02169648|branch retinal vein occlusion
151136|NCT02169648|central retinal vein occlusion
151137|NCT02169648|ranibizumab
151138|NCT02169648|cytokines
151139|NCT02169648|visual acuity
151140|NCT02169648|central macular thickness
151141|NCT02169635|macular buckle
151142|NCT02169635|high myopia
151143|NCT02169635|posterior staphyloma
151144|NCT02169609|Neuroblastoma
151145|NCT02169609|Immunotherapy
151146|NCT02169609|Dinutuximab
151147|NCT02169596|Acute Coronary Syndrome
151148|NCT02169596|Nitric oxide
151149|NCT02169596|Ticagrelor
151150|NCT02169596|Antiplatelet agents
151151|NCT02169596|Endothelial function
151152|NCT02169583|GSK1325756
151153|NCT02169583|Safety
151154|NCT02169583|Bioavailability
151155|NCT02169583|Pharmacokinetics
151156|NCT02169570|Type 2 Diabetes Mellitus
151157|NCT02169570|Pulmonary Tuberculosis
151158|NCT02169570|Vitamin D
151159|NCT02169570|Calcium
151160|NCT02169531|Diabetes Mellitus Type 2
151161|NCT02169531|Hyperglycemia
151162|NCT02169531|Immunotherapy
151163|NCT02169531|Autologous
151164|NCT02169518|PON1 activity
151165|NCT02169518|HDL functionality
151166|NCT02169518|LDL oxidation
151167|NCT02169518|Type 1 diabetes
151168|NCT02169518|Type 2 diabetes
151169|NCT02169518|Obesity
151170|NCT02169518|Bariatric surgery
151171|NCT02169505|Lymphoma
151172|NCT02169505|Hodgkin lymphoma
151173|NCT02169505|HL
151174|NCT02169505|CD30 positive Hodgkin Lymphoma
151175|NCT02169505|Anaplastic large cell lymphoma
151176|NCT02169505|ALCL
151177|NCT02169505|Allogeneic Stem Cell Transplantation
151178|NCT02169505|ASCT
151179|NCT02169505|Graft-versus-host disease
151180|NCT02169505|GVHD
151181|NCT02169505|Brentuximab Vedotin
151182|NCT02169505|SGN-35
151183|NCT02169505|Adcetris
151184|NCT02169492|Thrombectomy
151185|NCT02169492|Stroke
151186|NCT02169492|ReVive SE
151187|NCT02169479|Parkinson's disease (PD)
151188|NCT02169479|Opicapone
151189|NCT02169479|BIA 9-1067
151190|NCT02169466|Parkinson's disease (PD)
151191|NCT02169466|Opicapone
151192|NCT02169466|BIA 9-1067
151193|NCT02169453|Parkinson's disease (PD)
151194|NCT02169453|BIA 9-1067
151195|NCT02169453|Opicapone
151196|NCT02169440|Parkinson's disease (PD)
151197|NCT02169440|BIA 9-1067
151198|NCT02169440|Opicapone
151199|NCT02169427|Parkinson's disease (PD)
151200|NCT02169427|BIA 9-1067
151201|NCT02169427|Opicapone
151202|NCT02169414|Parkinson's disease (PD)
151203|NCT02169414|BIA 9-1067
151204|NCT02169414|Opicapone
151205|NCT02169388|Gut microflora
151206|NCT02169388|colorectal cancer
151207|NCT02169388|Chemotherapy
151208|NCT02169388|Immunity
151209|NCT02169388|Nutrition
151210|NCT02169362|Burns
151211|NCT02169362|Thermal burns
151212|NCT02169362|Second degree burns
151213|NCT02169362|Partial thickness burns
151214|NCT02169362|Deep partial thickness burns
151215|NCT02169362|Acute burns
151216|NCT02169362|Burn wounds
151217|NCT02169336|Bunion
151218|NCT02169336|Bunionectomy
151219|NCT02169336|Pain
151220|NCT02169336|Analgesia
151221|NCT02169336|dexmedetomidine
151222|NCT02169336|intranasal
151223|NCT02169323|Non-eosinophilic Asthma
151224|NCT02169323|Inhaled corticosteroids
151225|NCT02169323|Step-down
151226|NCT02169310|Traumatic Brain Injury
151227|NCT02169310|Decision-Making
151228|NCT02169310|Dopaminergic Network
151229|NCT02169310|Brain Imaging
151230|NCT02169310|Non-Invasive Brain Stimulation
151231|NCT02169297|Pain Management
151232|NCT02169297|Anesthesia: Nerve Block
151233|NCT02169258|coronary artery disease
151234|NCT02169258|peripheral artery disease
151235|NCT02169258|percutaneous transluminal angioplasty
151236|NCT02169258|coronary angiography
151237|NCT02169258|revascularization
151238|NCT02169258|gene polymorphisms
151239|NCT02169258|microRNAs
151240|NCT02169232|Awake intubation
151241|NCT02169232|Videolaryngoscope
151242|NCT02169232|Fiberoptic
151243|NCT02169206|Frozen shoulder
151244|NCT02169206|scapulothoracic angle
151245|NCT02169206|scapulohumeral angle
151246|NCT02169206|acromiohumeral distance
151247|NCT02169206|center equator distance
151248|NCT02169206|shoulder radiography
151249|NCT02169193|microaspiration
151250|NCT02169193|mechanical ventilation
151251|NCT02169193|enteral feeding
151252|NCT02169193|99m technetium
151253|NCT02169193|pepsin
151254|NCT02169180|Ibrutinib
151255|NCT02169180|IMBRUVICA
151256|NCT02169180|PCI-32765
151257|NCT02169180|JNJ-54179060
151258|NCT02169180|Lymphoma, Mantle-cell
151259|NCT02169167|Diabetes complications
151260|NCT02169167|Diabetic foot
151261|NCT02169167|Foot ulcer
151262|NCT02169167|Wound healing
151263|NCT02169167|Wound infection
151264|NCT02169141|pharmacokinetics
151265|NCT02169141|pharmacodynamics
151266|NCT02169141|MDR-TB
151267|NCT02169141|Levofloxacin
151268|NCT02169141|Capreomycin
151269|NCT02169102|Low power laser
151270|NCT02169102|Pulpitis
151271|NCT02169102|Pain
151272|NCT02169076|Ventricular Assist Device, Cardiac Resynchronization Therapy
151273|NCT02169050|Vitamin D deficiency
151274|NCT02169050|Inflammation
151275|NCT02169050|Obesity
151276|NCT02169037|Rotor
151277|NCT02169037|FIRM
151278|NCT02169037|Paroxysmal Atrial Fibrillation
151279|NCT02169037|Atrial tachyarrhythmia
151280|NCT02169037|Ablation
151281|NCT02169037|Contact mapping
151282|NCT02169037|Clinical trial
151283|NCT02169037|Signal processing.
151284|NCT02169024|prenatal care
151285|NCT02169024|group care
151286|NCT02169024|Expect With Me
151287|NCT02169024|evaluation studies
151288|NCT02169024|group prenatal care
151289|NCT02169011|Breast reconstruction
151290|NCT02169011|Breast cancer
151291|NCT02168998|Medical clown
151292|NCT02168998|Pediatric emergency medicine
151293|NCT02168985|Child violence
151294|NCT02168985|HIV AIDS conflicted couples
151295|NCT02168985|Intimate partner violence
151296|NCT02168985|Tanzania
151297|NCT02168985|Marriage counseling
151298|NCT02168985|Child maltreatment
151299|NCT02168985|Couples communication
151300|NCT02168972|atrial fibrillation
151301|NCT02168972|global
151302|NCT02168972|radiofrequency RF ablation
151303|NCT02168972|left atrium anatomical and electrophysiological mapping
151304|NCT02168959|Femoral Nerve Block
151305|NCT02168959|Pain Control
151306|NCT02168959|Tibial Plateau Fracture
151307|NCT02168959|Prospective
151308|NCT02168959|Randomized
151309|NCT02168933|psoriasis
151310|NCT02168933|nail
151311|NCT02168933|laser
151312|NCT02168933|excimer
151313|NCT02168933|treatment
151314|NCT02168920|Alzeheimer
151315|NCT02168894|Peripheral neuropathy
151316|NCT02168894|Chemotherapy-Induced Peripheral Neuropathy
151317|NCT02168894|Cancer Survivors
151318|NCT02168894|Acupuncture
151319|NCT02168894|Electrical stimulation
151320|NCT02168894|Nerve function tests
151321|NCT02168894|Hand function tests
151322|NCT02168894|Balance tests
151323|NCT02168894|Questionnaires
151324|NCT02168894|Surveys
151325|NCT02168881|labour
151326|NCT02168881|induction
151327|NCT02168881|misoprostol
151328|NCT02168881|dinoprostone
151329|NCT02168868|Autoimmune Diseases
151330|NCT02168868|Child Development Disorders, Pervasive
151331|NCT02168868|Inflammation
151332|NCT02168868|Risk Factors
151333|NCT02168855|Smoking cessation
151334|NCT02168855|Non-daily smokers
151335|NCT02168855|Ecological Momentary Assessment
151336|NCT02168855|nicotine replacement therapy
151337|NCT02168842|Parkinson
151338|NCT02168842|Parkinson Disease
151339|NCT02168842|Parkinson's Disease
151340|NCT02168829|AF ablation
151341|NCT02168829|Anticoagulation AF ablation
151342|NCT02168829|Stroke prevention
151343|NCT02168816|Osteomyelitis
151344|NCT02168816|Diabetes
151345|NCT02168816|Foot Infection
151346|NCT02168803|abnormal cholesterol
151347|NCT02168790|amniotic membrane holder, aminiotic membrane transplantation
151348|NCT02168777|Patients with Cancer
151349|NCT02168751|one lung ventilation
151350|NCT02168751|inflammatory response
151351|NCT02168751|thoracic surgery
151352|NCT02168738|nutrition
151353|NCT02168725|briciclib
151354|NCT02168725|Dose escalation
151355|NCT02168725|Maximum tolerated dose
151356|NCT02168712|Coronary Heart Disease
151357|NCT02168712|Interval exercise training
151358|NCT02168712|Continuous exercise training
151359|NCT02168712|Quality of life
151360|NCT02168712|Safety
151361|NCT02168699|children
151362|NCT02168699|infants
151363|NCT02168699|musculocutaneous nerve
151364|NCT02168699|ultrasonography
151365|NCT02168686|alpha1-antitrypsin deficiency
151366|NCT02168686|alpha1AT
151367|NCT02168686|A1AT
151368|NCT02168686|ADVM-043
151369|NCT02168686|gene therapy
151370|NCT02168686|gene transfer vector
151371|NCT02168673|COPD
151372|NCT02168673|Cigarette Smoke
151373|NCT02168673|Smoker
151374|NCT02168673|Nonsmoker
151375|NCT02168673|ODF2
151376|NCT02168673|Cilia
151377|NCT02168660|Obesity
151378|NCT02168660|Insulin Resistance
151379|NCT02168660|Vitamin D Deficiency
151380|NCT02168660|Children
151381|NCT02168660|Adolescents
151382|NCT02168647|Excessive gestational weight gain
151383|NCT02168647|Insulin resistance
151384|NCT02168647|Physical activity
151385|NCT02168647|Behavioral prenatal lifestyle intervention
151386|NCT02168647|Reduced carbohydrate intake
151387|NCT02168647|Self-determination theory
151388|NCT02168647|Motivational interviewing
151389|NCT02168621|Chronic periodontitis
151390|NCT02168621|Non-surgical therapy
151391|NCT02168621|Ultrasonic debridement
151392|NCT02168621|Scaling and root planing
151393|NCT02168608|hepatic ischemia reperfusion injury
151394|NCT02168608|ischemia precondition
151395|NCT02168608|remote ischemia precondition
151396|NCT02168608|anti-inflammation
151397|NCT02168595|healthy volunteers, GMI-1271
151398|NCT02168582|Physical Therapy Modalities
151399|NCT02168582|Prognosis
151400|NCT02168582|Patient Selection
151401|NCT02168569|treatment
151402|NCT02168569|artemisin-based combinations
151403|NCT02168569|children
151404|NCT02168556|Urodynamics, Anxiety
151405|NCT02168517|Obesity
151406|NCT02168517|Pain
151407|NCT02168517|Fertility
151408|NCT02168478|Neo-Synalar
151409|NCT02168478|Patch Test
151410|NCT02168478|Sodium lauryl sulfate
151411|NCT02168478|Saline
151412|NCT02168478|Presensitization
151413|NCT02168465|self-efficacy
151414|NCT02168465|self-management
151415|NCT02168465|web-based intervention research
151416|NCT02168452|Neoadjuvant chemotherapy
151417|NCT02168452|Indocyanine green (ICG)
151418|NCT02168452|Radioisotope (RI)
151419|NCT02168452|Near infrared fluorescence camera
151420|NCT02168439|Dexmedetomidine
151421|NCT02168439|Midazolam
151422|NCT02168413|cortical excitability
151423|NCT02168413|robotized TMS
151424|NCT02168413|EEG
151425|NCT02168413|EMG
151426|NCT02168387|atelectasis
151427|NCT02168387|continuous high frequency oscillator
151428|NCT02168387|acetylcysteine
151429|NCT02168387|dornase alfa
151430|NCT02168374|Glass ionomer cement
151431|NCT02168374|Indirect pulp therapy
151432|NCT02168361|cirrhosis
151433|NCT02168322|growth factors
151434|NCT02168322|periodontal regeneration
151435|NCT02168322|modefied perforated membranes
151436|NCT02168296|Pharmacokinetics
151437|NCT02168296|Blood glucose
151438|NCT02168296|subjects
151439|NCT02168283|cardiovascular disease
151440|NCT02168283|hypertension
151441|NCT02168257|Nasal Cannula
151442|NCT02168244|psoriasis
151443|NCT02168244|biologics
151444|NCT02168244|subcutaneous
151445|NCT02168244|pain
151446|NCT02168244|heat
151447|NCT02168244|ice
151448|NCT02168231|Complex abdominal wall hernia
151449|NCT02168231|Biologic mesh
151450|NCT02168231|Strattice
151451|NCT02168218|protein synthesis
151452|NCT02168218|intrahepatic fat
151453|NCT02168218|lean body mass
151454|NCT02168218|IGF1
151455|NCT02168218|energy metabolism
151456|NCT02168205|Healthy volunteer
151457|NCT02168205|Pharmacokinetics
151458|NCT02168205|Pomalyst
151459|NCT02168205|Pomalidomide
151460|NCT02168205|Food effect
151461|NCT02168205|smoker
151462|NCT02168192|Breaking bad news skills
151463|NCT02168192|Communications skills
151464|NCT02168192|Medical education
151465|NCT02168192|Obstetrics
151466|NCT02168192|Simulation
151467|NCT02168166|Neurological Disorders
151468|NCT02168166|Neuroscience
151469|NCT02168166|Neuropsychology
151470|NCT02168166|EEG
151471|NCT02168166|Cognitive remediation
151472|NCT02168166|Cognitive Response
151473|NCT02168153|Chiropractic Manipulative Therapy
151474|NCT02168153|Reaction Times
151475|NCT02168153|Response Times
151476|NCT02168153|Special Forces
151477|NCT02168153|Biomechanical Assessments
151478|NCT02168114|Duchenne Muscular Dystrophy
151479|NCT02168114|Exercise
151480|NCT02168114|Optical Imaging
151481|NCT02168114|Magnetic Resonance
151482|NCT02168101|MLN9708
151483|NCT02168101|allogeneic stem cell transplant
151484|NCT02168101|multiple myeloma
151485|NCT02168101|ixazomib
151486|NCT02168101|autologous stem cell transplant
151487|NCT02168088|Sudden unexplained death
151488|NCT02168062|Supportive Therapy
151489|NCT02168062|Androgen Deprivation Therapy
151490|NCT02168049|cardiac, respiratory, monitoring
151491|NCT02168036|lung disease
151492|NCT02168036|mediastinal lymph node
151493|NCT02168036|bronchoscopy
151494|NCT02168036|Endobronchial-Guided Transbronchial Needle Aspiration
151495|NCT02168023|surgical site infection
151496|NCT02168023|dialkylcarbamoylchloride impregnated dressing
151497|NCT02168023|caesarean section
151498|NCT02168023|wound dehiscence
151499|NCT02167984|esophageal swallow
151500|NCT02167984|gastroesophageal reflux
151501|NCT02167984|esophageal impedance
151502|NCT02167984|newborn
151503|NCT02167984|preterm
151504|NCT02167971|traumatic brain injury
151505|NCT02167971|diffuse axonal injury
151506|NCT02167971|repetitive transcranial magnetic stimulation
151507|NCT02167971|neuromodulation
151508|NCT02167971|cognitive rehabilitation
151509|NCT02167945|Naïve
151510|NCT02167945|Hepatitis C
151511|NCT02167945|Non responder
151512|NCT02167945|Relapser
151513|NCT02167945|Null responder
151514|NCT02167945|Treatment-Experienced
151515|NCT02167945|Cirrhosis
151516|NCT02167945|Hepatitis C Genotype 1
151517|NCT02167945|Compensated Cirrhosis
151518|NCT02167945|Hepatitis C Virus
151519|NCT02167932|Breast Cancer
151520|NCT02167932|Walk With Ease
151521|NCT02167932|Physical Activity
151522|NCT02167932|Walking
151523|NCT02167932|Younger Women
151524|NCT02167932|Cancer
151525|NCT02167932|p16
151526|NCT02167932|Aging
151527|NCT02167932|Biomarkers
151528|NCT02167932|Biomarkers of Aging
151529|NCT02167932|Chemotherapy
151530|NCT02167932|Chemotherapy Treatment
151531|NCT02167932|Adjuvant Chemotherapy
151532|NCT02167932|Neoadjuvant Chemotherapy
151533|NCT02167919|Prostate
151534|NCT02167919|Men
151535|NCT02167919|Hyperplasia
151536|NCT02167893|Pharmacological therapy
151537|NCT02167867|body contouring
151538|NCT02167867|circumference reduction
151539|NCT02167867|body shaping
151540|NCT02167867|low level laser
151541|NCT02167854|LJM716
151542|NCT02167854|BYL719 [Alpelisib]
151543|NCT02167854|TRASTUZUMAB
151544|NCT02167854|HER2+
151545|NCT02167854|14-057
151546|NCT02167841|Breech presentation,
151547|NCT02167841|External cephalic version,
151548|NCT02167841|Maternal posture,
151549|NCT02167841|Pregnancy,
151550|NCT02167841|Caesarean section.
151551|NCT02167828|HIV
151552|NCT02167828|AIDS
151553|NCT02167828|treatment adherence
151554|NCT02167828|social network
151555|NCT02167802|severe infection, pediatrics, sub-optimal care, term care
151556|NCT02167789|HF, diagnosis
151557|NCT02167763|contraception
151558|NCT02167763|IUD
151559|NCT02167763|copper
151560|NCT02167750|cognitive
151561|NCT02167750|phytochmicals
151562|NCT02167750|caffeine
151563|NCT02167750|cognitive performance after ingestion of test beverage
151564|NCT02167737|Accident Prevention
151565|NCT02167737|Accidental Falls
151566|NCT02167737|Geriatric Health Services
151567|NCT02167737|Gender Differences
151568|NCT02167698|Pediatric acute respiratory distress syndrome
151569|NCT02167698|Mechanical ventilation
151570|NCT02167698|Airway pressure release ventilation
151571|NCT02167698|Conventional low-tidal volume ventilation
151572|NCT02167672|total abdominal hysterectomy, total laparoscopic hysterectomy, vaginal hysterectomy
151573|NCT02167659|Lymphedema
151574|NCT02167659|Breast cancer
151575|NCT02167659|Bioimpedance Spectroscopy
151576|NCT02167659|L-Dex
151577|NCT02167646|Soft tissue defect
151578|NCT02167646|dorsal branch of the digital nerve
151579|NCT02167646|dorsal branch of the digital artery
151580|NCT02167646|dorsal digital flap
151581|NCT02167633|Radiosurgery
151582|NCT02167633|Laminectomy
151583|NCT02167633|Radiotherapy
151584|NCT02167633|Spinal Cord Compression
151585|NCT02167633|Neoplasm Metastasis
151586|NCT02167633|Randomized Controlled Trial
151587|NCT02167607|Purple Potatoes
151588|NCT02167607|Polyphenolics
151589|NCT02167581|Maxillofacial surgery
151590|NCT02167581|Epithelial odontogenic tumours
151591|NCT02167568|corpus callosum agenesis/dysgenesis
151592|NCT02167568|mental deficiency/ Intellectual deficiency
151593|NCT02167568|genetic and phenotypic characterization
151594|NCT02167555|Wild Blueberries
151595|NCT02167555|Polyphenolics
151596|NCT02167542|Severe hypoxemic respiratory failure
151597|NCT02167542|Fiberoptic bronchoscopy
151598|NCT02167542|Noninvasive possitive pressure ventilation
151599|NCT02167542|Continuous positive airway pressure
151600|NCT02167529|Quality of life-Thyroidectomy-Morbidity
151601|NCT02167516|Xinfeng capsule
151602|NCT02167516|Knee osteoarthritis
151603|NCT02167516|Randomized controlled trials
151604|NCT02167516|Double-blind
151605|NCT02167490|BC; conservative surgery; SNB; AD; axillary US imaging
151606|NCT02167477|Intubation, Endotracheal
151607|NCT02167464|Hypertension
151608|NCT02167451|stem cell transplant
151609|NCT02167451|GVHD prevention
151610|NCT02167438|Cesarean
151611|NCT02167438|Section
151612|NCT02167438|second
151613|NCT02167438|stage
151614|NCT02167438|labor
151615|NCT02167425|People who Inject Drugs
151616|NCT02167425|HIV
151617|NCT02167425|Methadone
151618|NCT02167425|Sub Saharan Africa
151619|NCT02167425|Tanzania
151620|NCT02167425|Implementation Science
151621|NCT02167412|POTS
151622|NCT02167412|Syncope
151623|NCT02167386|Men who have sex with men (MSM)
151624|NCT02167386|Black/African-American
151625|NCT02167360|adult patients
151626|NCT02167360|B-cell ALL
151627|NCT02167360|chemo-refractory
151628|NCT02167360|relapsed after allogeneic SCT
151629|NCT02167360|ineligible for allogeneic SCT
151630|NCT02167347|CBT, Psychosis, cultural adaptation, Pakistan
151631|NCT02167334|panendoscopy
151632|NCT02167334|preoxygenation
151633|NCT02167334|non invasive ventilation
151634|NCT02167295|betel nut
151635|NCT02167295|dependence
151636|NCT02167295|withdraw
151637|NCT02167295|deprivation test
151638|NCT02167269|enclosed afferent reservoir
151639|NCT02167269|Jackson Rees system
151640|NCT02167269|anesthesia breathing circuit
151641|NCT02167269|spontaneous breathing
151642|NCT02167269|pediatric anesthesia
151643|NCT02167230|Coronary Artery Disease
151644|NCT02167230|Percutaneous Coronary Intervention
151645|NCT02167230|Bifurcation
151646|NCT02167230|Jailed-balloon technique
151647|NCT02167217|Duchenne Muscular Dystrophy
151648|NCT02167217|Corticosteroids
151649|NCT02167217|Infants
151650|NCT02167217|Young Children
151651|NCT02167217|Toddlers
151652|NCT02167165|Atrial Fibrillation
151653|NCT02167165|Digoxin
151654|NCT02167165|SNP
151655|NCT02167139|Rheumatoid Arthritis, Adalimumab
151656|NCT02167126|Athletic Performance;
151657|NCT02167126|Muscle Strength;
151658|NCT02167126|Isometric Contraction;
151659|NCT02167126|Kinesio Taping
151660|NCT02167100|HIV
151661|NCT02167100|Highly Active Antiretroviral Therapy
151662|NCT02167100|Patient Care
151663|NCT02167100|Patient Care Management
151664|NCT02167100|Lost to Follow-Up
151665|NCT02167087|Sentinel node mapping
151666|NCT02167087|lymphatic mapping
151667|NCT02167087|lymphatic metastasis
151668|NCT02167087|Aberrant lymphatic drainage
151669|NCT02167087|indocyanine green
151670|NCT02167087|ICG
151671|NCT02167087|near infrared
151672|NCT02167087|colon cancer
151673|NCT02167087|laparoscopic surgery
151674|NCT02167074|Diagnostic accuracy
151675|NCT02167074|Endoscopic Ultrasound-Guided Fine Needle Aspiration
151676|NCT02167074|EUS-FNA
151677|NCT02167074|Endoscopic Ultrasound-Guided Fine Needle Biopsy
151678|NCT02167074|EUS-FNB
151679|NCT02167074|Pancreatic mass
151680|NCT02167074|Lymph node
151681|NCT02167048|Attention Deficit Hyperactivity Disorders
151682|NCT02167048|Executive Function
151683|NCT02167048|Methylphenidate
151684|NCT02167048|Psychostimulants
151685|NCT02167048|Adolescent
151686|NCT02167048|Child
151687|NCT02167048|Working Memory
151688|NCT02167048|Prefrontal Cortex
151689|NCT02167048|Attention
151690|NCT02167048|Cognitive Function
151691|NCT02167048|Inhibition
151692|NCT02167035|Open-Angle Glaucoma
151693|NCT02167035|Ocular Hypertension
151694|NCT02167022|intense therapy
151695|NCT02167022|brain plasticity
151696|NCT02167022|Perception-Action approach
151697|NCT02167009|ARTERY EMBOLIZATION
151698|NCT02167009|BPH
151699|NCT02166970|Hilar tumor
151700|NCT02166970|Metal stent
151701|NCT02166970|Single
151702|NCT02166970|Multiple
151703|NCT02166957|Esophageal disruption
151704|NCT02166957|anterograde-retrograde endoscopy
151705|NCT02166957|rendez-vous technique
151706|NCT02166957|NOTES
151707|NCT02166957|recanalization
151708|NCT02166957|dilatations
151709|NCT02166957|Stenting
151710|NCT02166957|radiation therapy
151711|NCT02166957|head and neck carcinoma
151712|NCT02166944|amyotrophic lateral sclerosis
151713|NCT02166944|ALS functional ration scale
151714|NCT02166944|TAR-DNA-binding protein-43
151715|NCT02166944|tamoxifen
151716|NCT02166944|mTOR
151717|NCT02166931|Essence of Chicken
151718|NCT02166931|stress
151719|NCT02166931|cognitive function
151720|NCT02166918|Schizophrenia
151721|NCT02166918|Real-Life Functioning
151722|NCT02166918|Schizophrenia Endophenotypes
151723|NCT02166892|Childhood obesity
151724|NCT02166892|Plate
151725|NCT02166892|Food consumption
151726|NCT02166879|Obstructive Sleep Apnea-Hypopnea Syndrome
151727|NCT02166879|Obstructive sleep apnea
151728|NCT02166879|OSA
151729|NCT02166879|Chart review
151730|NCT02166879|Questionnaire
151731|NCT02166879|Survey
151732|NCT02166853|Acute respiratory distress syndrome (ARDS)
151733|NCT02166853|Sevoflurane
151734|NCT02166853|Mechanical ventilation
151735|NCT02166853|Intensive Care Unit (ICU)
151736|NCT02166853|Prospective study
151737|NCT02166853|Lung injury
151738|NCT02166853|Gas exchange
151739|NCT02166853|Inflammation
151740|NCT02166853|Receptor for advanced glycation end-produts (RAGE)
151741|NCT02166853|sRAGE
151742|NCT02166827|TMS
151743|NCT02166827|Cognitive Stimulation
151744|NCT02166827|NeuroAD
151745|NCT02166801|Cerebral palsy
151746|NCT02166801|Children
151747|NCT02166801|Early Intervention
151748|NCT02166801|Communication
151749|NCT02166801|Gross motor function
151750|NCT02166801|Hand function
151751|NCT02166788|metastatic melanoma
151752|NCT02166788|groin lymph nodes
151753|NCT02166788|surgery
151754|NCT02166788|lymphadenectomy
151755|NCT02166762|Cardiac Resynchronization Therapy
151756|NCT02166762|Biventricular implantable cardioverter defibrillators
151757|NCT02166762|Heart failure
151758|NCT02166762|Cardiomyopathy
151759|NCT02166762|QLV
151760|NCT02166762|LV lead placement
151761|NCT02166762|Arrhythmia
151762|NCT02166749|Hysterectomy, long term follow up, subjective outcome
151763|NCT02166736|Instantaneous wave Free Ratio
151764|NCT02166736|Fractional Flow Reserve
151765|NCT02166723|persistent atrial fibrillation
151766|NCT02166723|Cryoballoon ablation
151767|NCT02166710|Knee arthroplasty
151768|NCT02166710|Adductor canal block
151769|NCT02166710|Quadriceps strength
151770|NCT02166697|Pharmacological therapy
151771|NCT02166684|Do-it-yourself devices
151772|NCT02166684|User-experiences
151773|NCT02166684|Health behavior
151774|NCT02166684|Self-measurement
151775|NCT02166684|Methodology, Evaluation
151776|NCT02166684|Personal health records
151777|NCT02166684|Blood Glucose Self-Monitoring
151778|NCT02166684|Self Blood Pressure Monitoring
151779|NCT02166658|Patients with breast or lung cancer and recurrent or progressive brain
151780|NCT02166658|metastases
151781|NCT02166645|patient positioning
151782|NCT02166645|premature infant
151783|NCT02166645|mechanical ventilation
151784|NCT02166645|airway extubation
151785|NCT02166632|Knee arthroplasty
151786|NCT02166632|Exparel
151787|NCT02166632|Bupivacaine liposome
151788|NCT02166632|Total knee replacement
151789|NCT02166632|Pain control
151790|NCT02166619|Stroke
151791|NCT02166619|Rehabilitation
151792|NCT02166619|Electric stimulation therapy
151793|NCT02166619|Neuroplasticity
151794|NCT02166567|intracytoplasmic sperm injection
151795|NCT02166567|Male infertility
151796|NCT02166567|apoptosis
151797|NCT02166567|flow cytometry and sorting
151798|NCT02166567|DNA fragmentation
151799|NCT02166554|Adhesions
151800|NCT02166554|Hyaluronan
151801|NCT02166554|Gynaecological surgery
151802|NCT02166554|Clinical outcomes
151803|NCT02166541|cerebral palsy, spastic, diplegic,
151804|NCT02166541|children,
151805|NCT02166541|intervention study,
151806|NCT02166541|manipulation, spinal
151807|NCT02166541|randomized controlled trial
151808|NCT02166528|female pelvic floor dysfunction
151809|NCT02166528|pelvic organ prolaps
151810|NCT02166528|urinary incontinence
151811|NCT02166528|massively parallel sequencing
151812|NCT02166515|cervical cancer
151813|NCT02166515|ovarian cancer
151814|NCT02166515|endometrial cancer
151815|NCT02166515|high-throughput sequencing
151816|NCT02166502|pediatric
151817|NCT02166502|HIV
151818|NCT02166502|prevention
151819|NCT02166502|prophylaxis
151820|NCT02166502|nevirapine
151821|NCT02166489|autologous mesenchymal stem cells
151822|NCT02166489|polycystic kidney disease
151823|NCT02166489|intravenous injection
151824|NCT02166489|CRF
151825|NCT02166450|Denture stomatitis
151826|NCT02166450|Dentures
151827|NCT02166450|Denture wearers
151828|NCT02166437|osteoporosis
151829|NCT02166437|BMD
151830|NCT02166437|teriparatide
151831|NCT02166437|bisphosphonate
151832|NCT02166437|denosmab
151833|NCT02166424|Pregnancy
151834|NCT02166424|Depression
151835|NCT02166424|omega-3 fatty acids
151836|NCT02166411|Myomectomy ,Laparoscopy , Barbed sutures
151837|NCT02166398|Amlodipine basylate, Losartan potassium
151838|NCT02166359|Icodextrin
151839|NCT02166359|Triglyceride
151840|NCT02166346|Transverse myelitis
151841|NCT02166333|vitamin D
151842|NCT02166333|falls
151843|NCT02166333|high risk of falling
151844|NCT02166333|insufficient or deficient serum vitamin D levels
151845|NCT02166333|10-25 ng/ml
151846|NCT02166307|formaldehyde; Maillard Reaction; cross-linkage; human aging
151847|NCT02166294|Foot
151848|NCT02166294|Ulcer
151849|NCT02166294|Diabetes
151850|NCT02166294|Amputation
151851|NCT02166294|Limb salvage
151852|NCT02166281|Insomnia
151853|NCT02166281|Anxiety
151854|NCT02166281|Depression
151855|NCT02166281|Restless leg syndrome
151856|NCT02166281|Aromatase inhibitor
151857|NCT02166281|Body composition
151858|NCT02166268|Allergic rhinoconjunctivitis
151859|NCT02166268|Allergic rhinitis
151860|NCT02166268|Allergy
151861|NCT02166268|Grass pollen
151862|NCT02166242|non-small cell lung cancer
151863|NCT02166242|thioredoxin reductase
151864|NCT02166216|Prolonged high intensity exercise
151865|NCT02166216|Healthy subjects
151866|NCT02166216|Cardiovascular risk markers
151867|NCT02166216|Troponin
151868|NCT02166216|Leisure sports athletes
151869|NCT02166216|Cycling
151870|NCT02166216|CT coronary angiography
151871|NCT02166216|Outcomes
151872|NCT02166190|Pancreatic
151873|NCT02166190|cholangiocarcinoma
151874|NCT02166190|radiofrequency ablation
151875|NCT02166164|Pain
151876|NCT02166164|Secondary hyperalgesia
151877|NCT02166164|thermal sensitization
151878|NCT02166164|Catastrophization
151879|NCT02166164|Anxiety
151880|NCT02166125|gastric bypass
151881|NCT02166125|sleeve gastrectomy
151882|NCT02166125|esophageal stent
151883|NCT02166125|suturing
151884|NCT02166112|Hernia of Abdominal Wall
151885|NCT02166112|Biologic implant
151886|NCT02166112|Infected Hernioplasty Mesh
151887|NCT02165020|Prostate
151888|NCT02165020|Hypofractionated radiotherapy
151889|NCT02165020|Hyaluronic acid
151890|NCT02165020|Spacer
151891|NCT02165020|Rectum toxicity
151892|NCT02165020|Rectal toxicities after hypofractionated irradiation and injection of hyaluronic acid in patients with low- to intermediate-risk Prostate Cancer
151893|NCT02164994|Astigmatism, arcuate incisions, astigmatic keratotomy
151894|NCT02164968|Device investigation
151895|NCT02164955|Pomalidomide
151896|NCT02164955|Multiple Myeloma
151897|NCT02164955|Relapsed, Refractory
151898|NCT02164955|Observational
151899|NCT02164955|Imnovid
151900|NCT02164955|Registry
151901|NCT02164955|Post-approval
151902|NCT02164955|Safety
151903|NCT02164929|TAP block
151904|NCT02164929|Paravertebral block
151905|NCT02164929|Epidural
151906|NCT02164929|Laparoscopic colectomy
151907|NCT02164916|BRAF Mutant
151908|NCT02164916|Metastatic
151909|NCT02164903|Quality of Life
151910|NCT02164903|Chronic Myeloid Leukemia
151911|NCT02164903|Imatinib
151912|NCT02164903|Dasatinib
151913|NCT02164877|Dietary fiber
151914|NCT02164851|shock, emergencies, inflammation, infection
151915|NCT02164851|pathologic process
151916|NCT02166047|Hepatitis B
151917|NCT02166047|HBV
151918|NCT02166047|GS-9620
151919|NCT02166047|TLR-7 Agonist
151920|NCT02166034|children
151921|NCT02166034|fruit
151922|NCT02166034|vegetable
151923|NCT02166034|diet
151924|NCT02166034|school
151925|NCT02166034|garden
151926|NCT02166021|Multiple Sclerosis (MS)
151927|NCT02166021|Stem Cells
151928|NCT02166008|Repamipide
151929|NCT02166008|Dual antiplatelet
151930|NCT02166008|Peptic ulcer
151931|NCT02165995|Brain Tumor
151932|NCT02165995|Glioma
151933|NCT02165995|Tumor resection
151934|NCT02165995|Navigated Transcranial Magnetic Stimulation
151935|NCT02165995|nTMS
151936|NCT02165995|Brain mapping
151937|NCT02165995|Motor function
151938|NCT02165995|Speech function
151939|NCT02165995|Speech mapping
151940|NCT02165969|tumor
151941|NCT02165969|inflammatory process
151942|NCT02165969|fracture
151943|NCT02165969|defect
151944|NCT02165956|Cereals
151945|NCT02165956|Obesity
151946|NCT02165956|Complementary Feeding
151947|NCT02165930|Bioavailability
151948|NCT02165930|oxycodone
151949|NCT02165930|ethanol interaction
151950|NCT02165930|healthy volunteers
151951|NCT02165917|Endometriosis
151952|NCT02165917|Adhesions
151953|NCT02165917|Hyalobarrier®
151954|NCT02165917|Hyaluronic acid
151955|NCT02165917|Antiadhesion agent
151956|NCT02165917|Adhesionbarrier
151957|NCT02165917|Pregnancy rate
151958|NCT02165904|Analyze clinical efficacy of subarachnoid administration of
151959|NCT02165904|"autologous BMSC expanded in vitro"
151960|NCT02165878|Chronic kidney disease(CKD)
151961|NCT02165865|hand transplantation
151962|NCT02165865|hand allotransplantation
151963|NCT02165865|upper extremity transplantation
151964|NCT02165865|upper extremity amputation
151965|NCT02165865|hand amputation
151966|NCT02165865|vascularized composite allotransplantation
151967|NCT02165865|composite tissue allotransplantation
151968|NCT02165865|variance component analysis (VCA)
151969|NCT02165865|composite tissue allograft (CTA)
151970|NCT02165852|ampulla of Vater
151971|NCT02165852|adenoma
151972|NCT02165852|papillectomy
151973|NCT02165852|injection
151974|NCT02165852|non-injection
151975|NCT02165826|Drug therapy
151976|NCT02165774|sacral neuromodulation, neurogenic lower urinary tract dysfunction
151977|NCT02165761|Hemodialysis
151978|NCT02165761|End Stage Renal Disease
151979|NCT02165761|Vascular Graft
151980|NCT02165722|Influenza
151981|NCT02165722|HPV
151982|NCT02165722|Tdap
151983|NCT02165722|MCV
151984|NCT02165722|vaccination
151985|NCT02165722|adolescents
151986|NCT02165696|compression bandage, manual lymphatic drainage, lymphedema, breast cancer, qualitative research.
151987|NCT02165683|Cancer
151988|NCT02165683|Pediatric
151989|NCT02165683|PET Scan
151990|NCT02165670|Ischemic heart disesase
151991|NCT02165670|Myocardial infarction
151992|NCT02165670|Angina pectoris
151993|NCT02165657|Excimer laser
151994|NCT02165657|UVB
151995|NCT02165657|Psoriasis
151996|NCT02165644|Subarachnoid Hemorrhage
151997|NCT02165644|Vasospasm
151998|NCT02165644|Acetazolamide
151999|NCT02165618|frailty
152000|NCT02165618|geriatric, elderly
152001|NCT02165618|polypharmacy
152002|NCT02165605|external beam radiotherapy
152003|NCT02165605|breast cancer
152004|NCT02165592|Hemophilia
152005|NCT02165592|Arthropathy
152006|NCT02165592|Range of Motion
152007|NCT02165592|Strength
152008|NCT02165592|Proprioception
152009|NCT02165592|Gait
152010|NCT02165592|Quality of Life
152011|NCT02165579|procalcitonin
152012|NCT02165579|biomarkers
152013|NCT02165579|Osteomyelitis
152014|NCT02165579|diabetes
152015|NCT02165579|foot ulcer(s)
152016|NCT02165579|Infectious Disease Society of America stage 3 infection
152017|NCT02165566|intensive insulin therapy
152018|NCT02165566|critical care patients
152019|NCT02165566|blood glucose concentration>180 mg/dl
152020|NCT02165553|Hibiscus sabdariffa calyces
152021|NCT02165553|Blood Pressure
152022|NCT02165553|Vascular Function
152023|NCT02165553|Inflammation
152024|NCT02165553|Cardiometabolic risk markers
152025|NCT02165553|Systemic antioxidant capacity
152026|NCT02165540|Doula
152027|NCT02165540|Pain management
152028|NCT02165540|Miscarriage
152029|NCT02165540|Abortion
152030|NCT02165514|spinal curvatures
152031|NCT02165488|ketamine
152032|NCT02165488|abuse
152033|NCT02165488|abdominal discomfort
152034|NCT02165488|cholangiopathy
152035|NCT02165462|Haemophilia
152036|NCT02165462|Arthropathy
152037|NCT02165462|Bilateral deficit phenomenon
152038|NCT02165462|Proprioception
152039|NCT02165449|ketamine
152040|NCT02165449|major depression
152041|NCT02165449|imaging
152042|NCT02165449|gene expression
152043|NCT02165423|pediatric
152044|NCT02165423|solid organ transplant
152045|NCT02165423|parents
152046|NCT02165423|heart
152047|NCT02165423|kidney
152048|NCT02165423|liver
152049|NCT02165410|Autism, mental retardation, Magnetic Resonance Imaging
152050|NCT02165397|Ibrutinib
152051|NCT02165397|Pharmacyclics
152052|NCT02165397|PCYC
152053|NCT02165397|Lymphoma
152054|NCT02165397|Btk inhibitor
152055|NCT02165397|WM
152056|NCT02165397|Rituximab
152057|NCT02165397|Rituxan
152058|NCT02165397|Waldenström's
152059|NCT02165397|Waldenstrom Macroglobulinemia
152060|NCT02165397|non-Hodgkin lymphoma
152061|NCT02165397|NHL
152062|NCT02165384|tympanostomy
152063|NCT02165384|myringotomy
152064|NCT02165384|otitis media
152065|NCT02165384|ear tubes
152066|NCT02165384|ear infection
152067|NCT02165358|BMD
152068|NCT02165358|LGMD2I
152069|NCT02165358|Calf enlargement
152070|NCT02165358|Muscular dystrophy
152071|NCT02165358|MRI
152072|NCT02165306|epilepsy
152073|NCT02165280|Pelvic Organ Prolapse
152074|NCT02165280|Surgery
152075|NCT02165254|physical activity
152076|NCT02165254|coronary heart disease
152077|NCT02165254|exercise
152078|NCT02165254|affect
152079|NCT02165254|mind/body therapies
152080|NCT02165254|stress, psychological
152081|NCT02165241|Hypertension
152082|NCT02165241|Cardiac remodeling
152083|NCT02165241|Immune system
152084|NCT02165202|HIV Pre-exposure Prophylaxis;
152085|NCT02165202|long-acting injectable;
152086|NCT02165202|HIV PrEP;
152087|NCT02165202|biomedical HIV prevention research
152088|NCT02165189|Simeprevir
152089|NCT02165189|Sofosbuvir
152090|NCT02165189|Ribavirin
152091|NCT02165189|Hepatitits C
152092|NCT02165189|Hepatitis C virus ribonucleic acid
152093|NCT02165176|cannabis
152094|NCT02165176|toxicology
152095|NCT02165176|intoxication
152096|NCT02165150|Elastic Band
152097|NCT02165150|Institutional Elders
152098|NCT02165150|Functional Fitness
152099|NCT02165150|Sleep Quality
152100|NCT02165150|Depression
152101|NCT02165137|trauma
152102|NCT02165137|major trauma
152103|NCT02165137|multiple trauma
152104|NCT02165137|outcome
152105|NCT02165137|quality
152106|NCT02165137|process Management
152107|NCT02165137|emergency room
152108|NCT02165137|trauma center
152109|NCT02165124|Obesity
152110|NCT02165124|Morbid Obesity
152111|NCT02165124|Bariatric Surgery
152112|NCT02165124|Embolization
152113|NCT02165124|Minimally Invasive
152114|NCT02165124|Weight Loss
152115|NCT02165111|Scleroderma, Systemic
152116|NCT02165111|Raynaud Disease
152117|NCT02165111|Botulinum Toxins, Type A
152118|NCT02165085|Biomarkers
152119|NCT02165085|Ehlers-Danlos syndrome, vascular type
152120|NCT02165085|Pathophysiology
152121|NCT02165072|Inferior vena cava
152122|NCT02165072|Kidney injury
152123|NCT02165072|Ultrasound
152124|NCT02165059|Nausea
152125|NCT02165059|Vomiting
152126|NCT02165059|Functional dyspepsia
152127|NCT02165059|Bloating
152128|NCT02165059|Regurgitation
152129|NCT02165059|Retching
152130|NCT02164799|Shock
152131|NCT02164799|Predicting diagnosis
152132|NCT02164799|Predicting adverse outcomes
152133|NCT02164786|Acute severe disease
152134|NCT02164786|Intensive care unit
152135|NCT02164786|adult
152136|NCT02164786|cohort study
152137|NCT02164786|metabolomics
152138|NCT02164786|NMR
152139|NCT02164786|High Performance Liquid Chromatography
152140|NCT02164773|sevoflurane
152141|NCT02164773|pediatric
152142|NCT02164773|lower abdominal surgery
152143|NCT02164773|caudal
152144|NCT02164773|magnesium sulfate
152145|NCT02164773|Magnesium Sulfate Causing Adverse Effects in Therapeutic Use
152146|NCT02164773|Agitation States as Acute Reaction to Exceptional Stress
152147|NCT02164760|burns
152148|NCT02164760|dermal substitute
152149|NCT02164760|scar quality
152150|NCT02164760|reconstruction
152151|NCT02164760|wound healing
152152|NCT02164760|wound closure
152153|NCT02164734|surfactant
152154|NCT02164721|Heart failure
152155|NCT02164721|Chemotherapy-induced cardiomyopathy
152156|NCT02164721|Cardiac resynchronization therapy
152157|NCT02164708|mindfulness meditation, mental health, self-criticism
152158|NCT02164682|Hypospadias repair
152159|NCT02164682|Caudal block
152160|NCT02164682|Postoperative complications
152161|NCT02164669|Inflammation
152162|NCT02164669|Coronary artery bypass graft
152163|NCT02164669|Magnetic Resonance Imaging
152164|NCT02164643|Alzheimer's disease
152165|NCT02164643|Mild Cognitive Impairment
152166|NCT02164630|Temporomandibular Joint Disorder
152167|NCT02164630|TMD
152168|NCT02164630|Hope
152169|NCT02164630|Resilience
152170|NCT02164630|Cognitive Behavior Therapy
152171|NCT02164617|Dementia
152172|NCT02164617|Wheelchair-bound seniors
152173|NCT02164617|Long-term care facilities
152174|NCT02164617|Elastic band exercise
152175|NCT02164617|Functional fitness
152176|NCT02164617|Daily life function
152177|NCT02164617|Depression
152178|NCT02164617|Problem behaviors
152179|NCT02164604|ranibizumab
152180|NCT02164604|intravitreal therapy
152181|NCT02164604|ROP
152182|NCT02164604|Plus disease
152183|NCT02164604|stage 3 plus
152184|NCT02164591|gastroparesis
152185|NCT02164591|gastric electrical stimulator
152186|NCT02164591|GES
152187|NCT02164591|vomiting
152188|NCT02164591|nausea
152189|NCT02164591|bloating
152190|NCT02164591|postprandial fullness
152191|NCT02164591|epigastric pain
152192|NCT02164552|PCOS
152193|NCT02164552|vitamin D
152194|NCT02164552|insulin resistance
152195|NCT02164552|glycemic control
152196|NCT02164539|GSK573719
152197|NCT02164539|asthma
152198|NCT02164539|UMEC
152199|NCT02164539|FF
152200|NCT02164539|GSK2829332
152201|NCT02164539|persistent obstruction
152202|NCT02164539|GW685698
152203|NCT02164539|Fluticasone Furoate
152204|NCT02164539|COPD
152205|NCT02164539|umeclidinium bromide
152206|NCT02164526|Pulmonary Hypertension
152207|NCT02164526|Left Heart Disease
152208|NCT02164526|Heart failure
152209|NCT02164526|Registry
152210|NCT02164526|China
152211|NCT02164513|COPD
152212|NCT02164513|umeclidinium
152213|NCT02164513|fluticasone furoate
152214|NCT02164513|vilanterol
152215|NCT02164513|triple therapy
152216|NCT02164513|exacerbation
152217|NCT02164487|B1 adolescents Eating disorders Thaimine
152218|NCT02164461|Adenocarcinoma
152219|NCT02164461|Carcinoma
152220|NCT02164461|Carcinoma, Squamous Cell
152221|NCT02164461|Uterine Cervical Neoplasms
152222|NCT02164461|Small Cell Lung Carcinoma
152223|NCT02164461|Carcinoma, Small Cell
152224|NCT02164461|Carcinoma, Adenosquamous
152225|NCT02164461|Neoplasms, Glandular and Epithelial
152226|NCT02164461|Neoplasms by Histologic Type
152227|NCT02164461|Neoplasms
152228|NCT02164461|Neoplasms, Squamous Cell
152229|NCT02164461|Uterine Neoplasms
152230|NCT02164461|Genital Neoplasms, Female
152231|NCT02164461|Urogenital Neoplasms
152232|NCT02164461|Neoplasms by Site
152233|NCT02164461|Uterine Cervical Diseases
152234|NCT02164461|Uterine Diseases
152235|NCT02164461|Genital Diseases, Female
152236|NCT02164448|dexmedetomidine
152237|NCT02164448|postoperative bowel movement
152238|NCT02164448|laparoscopic gastrectomy
152239|NCT02164435|Uncontrolled hypertension
152240|NCT02164435|Renal denervation
152241|NCT02164435|Renal artery
152242|NCT02164422|Alcohol
152243|NCT02164422|Drinkers
152244|NCT02164422|Guanfacine
152245|NCT02164383|Smoking Cessation
152246|NCT02164383|Smoking
152247|NCT02164383|Nicotine
152248|NCT02164357|Ischaemic Stroke
152249|NCT02164357|Main artery occlusion
152250|NCT02164357|Endovascular treatment
152251|NCT02164357|Intravenous Thrombolytic Therapy
152252|NCT02164344|HIV
152253|NCT02164344|Gut
152254|NCT02164344|probiotics
152255|NCT02164344|immune activation
152256|NCT02164305|Rotator cuff muscle
152257|NCT02164305|Excitability
152258|NCT02164305|Proprioception
152259|NCT02164305|Kinematics
152260|NCT02164305|Muscle activity
152261|NCT02164305|Electromyography
152262|NCT02164292|Liver tumor
152263|NCT02164292|ALPPS
152264|NCT02164292|Two-stage hepatectomy
152265|NCT02164292|Morbidity
152266|NCT02164292|Hypertrophy
152267|NCT02164279|Microalbuminuria
152268|NCT02164279|diabetic nephropathy
152269|NCT02164279|type I diabetes
152270|NCT02164279|early predictive urinary biomarkers
152271|NCT02164240|Gastrointestinal Stromal Tumor
152272|NCT02164227|anxiety
152273|NCT02164227|breathing exercise
152274|NCT02164227|labour
152275|NCT02164201|Type A Aortic Dissection (where the use of BioFoam is limited to the anastomotic site)
152276|NCT02164188|Stress
152277|NCT02164188|Well-being
152278|NCT02164188|Functional magnetic resonance imaging
152279|NCT02164188|Positive psychology
152280|NCT02164175|HeRO Graft
152281|NCT02164162|Parkinson's disease, Lokomat, gait training, rehabilitation.
152282|NCT02164149|Colon cancer
152283|NCT02164149|Quality of surgery
152284|NCT02164149|Length of tumour feeding artery
152285|NCT02164123|Autonomic effects
152286|NCT02164123|spinal mobilization
152287|NCT02164123|clinical trial
152288|NCT02164097|ICE
152289|NCT02164097|ODSH
152290|NCT02164097|platelet recovery
152291|NCT02164097|recurrent solid tumor
152292|NCT02164084|acne
152293|NCT02164071|Haematological malignancy
152294|NCT02164071|Elderly
152295|NCT02164071|Health Status
152296|NCT02164071|Scale validation
152297|NCT02164058|Myocardial infarction
152298|NCT02164058|STEMI
152299|NCT02164058|ST elevation MI
152300|NCT02164058|Acute MI
152301|NCT02164019|Pathologic Fractures
152302|NCT02164019|hip replacements
152303|NCT02164019|12-287
152304|NCT02164006|Hodgkin's
152305|NCT02163980|dexmedetomidine
152306|NCT02163980|caudal block
152307|NCT02163980|children
152308|NCT02163980|children (1-6 years) undergoing ambulatory orchipexy
152309|NCT02163967|cranial electrical stimulation
152310|NCT02163967|CES
152311|NCT02163967|heart rate variability
152312|NCT02163967|parasympathetic
152313|NCT02163967|Vagal
152314|NCT02163954|platelet
152315|NCT02163954|ticagrelor
152316|NCT02163954|clopidogrel
152317|NCT02163954|end stage renal disease
152318|NCT02163954|hemodialysis
152319|NCT02163941|PTSD
152320|NCT02163941|empathy
152321|NCT02163941|meditation
152322|NCT02163941|compassion
152323|NCT02163941|inflammation
152324|NCT02163941|oxytocin
152325|NCT02163941|fMRI
152326|NCT02163928|Antioxidants
152327|NCT02163928|Carotenoids
152328|NCT02163928|Diet
152329|NCT02163915|Drug therapy
152330|NCT02163889|Candida
152331|NCT02163889|Blood culture
152332|NCT02163889|Antifungal therapy
152333|NCT02163889|Sepsis
152334|NCT02163876|spine
152335|NCT02163876|injury
152336|NCT02163876|trauma
152337|NCT02163876|spine injury
152338|NCT02163876|cervical spine injury
152339|NCT02163876|cervical spine
152340|NCT02163876|stemcells transplantation
152341|NCT02163863|Peripheral arterial disease (PAD)
152342|NCT02163863|Peripheral vascular disease (PVD)
152343|NCT02163863|Biomimetic stent
152344|NCT02163863|Helical centerline
152345|NCT02163837|sleep quality
152346|NCT02163837|physical activity
152347|NCT02163837|daytime sleepiness
152348|NCT02163837|actigraphy
152349|NCT02163837|quality of life
152350|NCT02163824|postsurgical
152351|NCT02163824|postoperative
152352|NCT02163824|ocular
152353|NCT02163824|cataract
152354|NCT02163824|inflammation
152355|NCT02163824|pain
152356|NCT02163824|corticosteroid
152357|NCT02163811|Self-management
152358|NCT02163811|Functional status
152359|NCT02163811|Depression
152360|NCT02163798|Tai Chi
152361|NCT02163798|Walking
152362|NCT02163798|Physical activity
152363|NCT02163798|Randomized controlled trial
152364|NCT02163798|Chinese population
152365|NCT02163798|Exercise
152366|NCT02163798|Body composition
152367|NCT02163798|Cardiovascular risk factor
152368|NCT02163798|Energy expenditure
152369|NCT02163798|Fitness
152370|NCT02163798|SF-12
152371|NCT02163785|Inferior rectal cancer
152372|NCT02163785|Abdominoperineal resection
152373|NCT02163785|Miles operation
152374|NCT02163785|Supine Miles operation
152375|NCT02163785|Prone Miles operation
152376|NCT02163785|Total mesorectal excision
152377|NCT02163785|Circumferential radial margin
152378|NCT02163746|Hidradenitis suppurativa
152379|NCT02163733|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, EGFR sensitivity mutation, food effect
152380|NCT02163720|ovarian cancer
152381|NCT02163720|fallopian tube or primary peritoneal
152382|NCT02163720|relapse
152383|NCT02163720|platinum-sensitive
152384|NCT02163720|Yondelis®-Caelyx®
152385|NCT02163707|Psilocybin
152386|NCT02163707|Pharmacokinetics
152387|NCT02163694|Breast Cancer
152388|NCT02163694|Carboplatin
152389|NCT02163694|BRCA2
152390|NCT02163694|BRCA Mutation
152391|NCT02163694|BRCA1
152392|NCT02163694|ABT-888
152393|NCT02163694|Paclitaxel
152394|NCT02163694|Metastatic Breast Cancer
152395|NCT02163694|PARP
152396|NCT02163694|Genetic breast cancer
152397|NCT02163694|Veliparib
152398|NCT02163694|Locally recurrent
152399|NCT02163694|PARP Inhibitor
152400|NCT02163694|HER2-negative
152401|NCT02163668|Yoga
152402|NCT02163668|Bone turnover markers
152403|NCT02163668|Bone strength
152404|NCT02163668|Bone mineral density
152405|NCT02163655|preeclampsia, very high blood pressure, diuretics
152406|NCT02163642|Bronchiectasis
152407|NCT02163642|Immunity
152408|NCT02163629|Psychotherapeutic intervention
152409|NCT02163629|stress management
152410|NCT02163629|cardiac transplantation
152411|NCT02163629|quality of life
152412|NCT02163616|Primary postpartum hemorrhage
152413|NCT02163616|PPH
152414|NCT02163616|uterine atony
152415|NCT02163616|high fever
152416|NCT02163616|hyperpyrexia
152417|NCT02163616|shock index
152418|NCT02163590|Spinal mobilisation
152419|NCT02163590|Pressure pain threshold
152420|NCT02163590|Thoracic spine
152421|NCT02163577|X-linked hypophosphatemia
152422|NCT02163577|XLH
152423|NCT02163577|FGF23
152424|NCT02163577|KRN23
152425|NCT02163564|Adolescent
152426|NCT02163564|Depression
152427|NCT02163564|Insomnia
152428|NCT02163551|dyspnea
152429|NCT02163551|respiratory sensation
152430|NCT02163551|event-related potentials
152431|NCT02163551|spinal cord injury
152432|NCT02163538|energy device
152433|NCT02163538|laparoscopic
152434|NCT02163538|hysterectomy
152435|NCT02163538|enseal
152436|NCT02163538|ligasure
152437|NCT02163538|raw tlx
152438|NCT02163525|Fibroids
152439|NCT02163525|Myomas
152440|NCT02163525|leiomyomata
152441|NCT02163525|menorrhagia
152442|NCT02163525|Acessa Procedure
152443|NCT02163525|Radiofrequency Ablation (RFA)
152444|NCT02163525|GFA
152445|NCT02163525|Acessa
152446|NCT02163512|Hepatic cirrhosis
152447|NCT02163512|Ascites
152448|NCT02163512|Beta blockers treatment
152449|NCT02163486|I-gel
152450|NCT02163486|oropharyngeal leak pressure
152451|NCT02163486|head position
152452|NCT02163460|ventral hernia
152453|NCT02163460|seroma
152454|NCT02163460|drainage
152455|NCT02163460|infection
152456|NCT02163447|Chemoprevention
152457|NCT02163447|Malaria
152458|NCT02163447|Uganda
152459|NCT02163447|Sulfadoxine-pyrimethamine
152460|NCT02163447|Dihydroartemisinin-piperaquine
152461|NCT02163434|pregnancy
152462|NCT02163434|nausea
152463|NCT02163434|vomiting
152464|NCT02163434|hyperemesis
152465|NCT02163434|treatment
152466|NCT02163434|gabapentin
152467|NCT02163434|metoclopramide
152468|NCT02163434|safety
152469|NCT02163421|Drug therapy
152470|NCT02163408|MRI
152471|NCT02163408|Plaque Characterization
152472|NCT02163395|Ceramic implant
152473|NCT02163382|Nava
152474|NCT02163382|Non Invasive Ventilation
152475|NCT02163356|neuroblastoma
152476|NCT02163356|recurrent
152477|NCT02163356|resistant
152478|NCT02163343|Serum metal ion levels
152479|NCT02163343|Cathcart/Corail hemiarthroplasty
152480|NCT02163343|Hip replacement
152481|NCT02163291|advanced gastric cancer
152482|NCT02163291|neoadjuvant chemotherapy
152483|NCT02163291|safety
152484|NCT02163291|feasibility
152485|NCT02163278|DBPR108
152486|NCT02163278|DPP4
152487|NCT02163278|Diabetes
152488|NCT02163278|Glucagon-like peptide-1 (GLP-1)
152489|NCT02163278|Incretins
152490|NCT02163239|FloShield
152491|NCT02163239|MID
152492|NCT02163239|Minimally invasive surgery
152493|NCT02163239|Minimally Invasive devices
152494|NCT02163239|Robot-assisted Laparoscopic Surgery
152495|NCT02163239|Single-site Laparoscopic Surgery
152496|NCT02163239|Single Incision Laparoscopic Surgery
152497|NCT02163239|Cannula
152498|NCT02163239|Blunt Obturator
152499|NCT02163239|Cholecystectomy
152500|NCT02163239|Benign hysterectomy
152501|NCT02163239|Salpingo-oophorectomy
152502|NCT02163226|Bone metastases
152503|NCT02163226|Hypofractionated Radiation Therapy
152504|NCT02163226|Standard Radiation Therapy
152505|NCT02163226|XRT
152506|NCT02163226|Pain control
152507|NCT02163226|Palliation of symptoms
152508|NCT02163226|Questionnaire
152509|NCT02163226|Survey
152510|NCT02163213|diarrhea
152511|NCT02163213|irritable bowel syndrome
152512|NCT02163200|Bedsores
152513|NCT02163200|pressure
152514|NCT02163200|hip
152515|NCT02163187|Neuromodulation (SNM)
152516|NCT02163187|sphincter preservation
152517|NCT02163187|rectal polyp
152518|NCT02163187|InterStimTM
152519|NCT02163187|14-100
152520|NCT02163174|neonatal
152521|NCT02163174|pentoxifylline
152522|NCT02163174|randomized controlled trial
152523|NCT02163161|Phase I
152524|NCT02163161|Open Label
152525|NCT02163161|Single dose
152526|NCT02163161|Crossover
152527|NCT02163161|Bioavailability
152528|NCT02163161|Fasting
152529|NCT02163161|Fed
152530|NCT02163161|PF-04965842
152531|NCT02163161|Healthy
152532|NCT02163122|Cat Allergy
152533|NCT02163122|Feld1
152534|NCT02163109|Oxygen consumption
152535|NCT02163109|Pulmonary gas exchange
152536|NCT02163109|Cardiac output
152537|NCT02163070|whey protein
152538|NCT02163070|malnutrition
152539|NCT02163070|oxidative stress
152540|NCT02163070|hemodialysis
152541|NCT02163057|Head and neck squamous cell cancer
152542|NCT02163057|Papillomavirus
152543|NCT02163031|heart transplant
152544|NCT02163031|radial approach
152545|NCT02163031|catheterization
152546|NCT02163005|GDL contrast agent
152547|NCT02162992|Antibodies, Antinuclear
152548|NCT02162992|SS-A antigen
152549|NCT02162992|Lupus Erythematosus, Systemic
152550|NCT02162992|Atrioventricular Block
152551|NCT02162992|Sudden death
152552|NCT02162979|Parkinson's disease
152553|NCT02162979|PD
152554|NCT02162979|dyskinesia
152555|NCT02162979|treatment
152556|NCT02162979|motor complications
152557|NCT02162966|colistin
152558|NCT02162966|ICU
152559|NCT02162966|critical care
152560|NCT02162953|eye disease
152561|NCT02162953|retinal
152562|NCT02162953|best1
152563|NCT02162940|low back pain
152564|NCT02162940|epidural steroid injection
152565|NCT02162940|statin
152566|NCT02162940|quality of life
152567|NCT02162927|muscular strength
152568|NCT02162927|muscular endurance
152569|NCT02162927|muscular power
152570|NCT02162927|rowing
152571|NCT02162927|CrossFit
152572|NCT02162927|dietary nitrate
152573|NCT02162914|Intra-hepatic
152574|NCT02162914|Hilar
152575|NCT02162914|Locally Advanced
152576|NCT02162914|Non Resectable
152577|NCT02162914|Metastatic
152578|NCT02162914|Regorafenib
152579|NCT02162914|Placebo
152580|NCT02162901|Diabetes prevention
152581|NCT02162875|Schistosoma mansoni
152582|NCT02162875|treatment
152583|NCT02162875|school children
152584|NCT02162875|adults
152585|NCT02162862|Inflammatory Bowel Disease
152586|NCT02162862|Physical Illness
152587|NCT02162862|Wellbutrin
152588|NCT02162849|Tobacco Use Cessation
152589|NCT02162849|Smoking Cessation
152590|NCT02162849|Cancer Prevention
152591|NCT02162849|Behavioral Counseling
152592|NCT02162849|Nicotine Replacement Therapy
152593|NCT02162849|NRT
152594|NCT02162849|Nicotine patch
152595|NCT02162849|Placebo patch
152596|NCT02162849|Placebo pill
152597|NCT02162849|Sugar pill
152598|NCT02162849|Varenicline
152599|NCT02162849|Chantix
152600|NCT02162849|Questionnaires
152601|NCT02162849|Surveys
152602|NCT02162849|Saliva test
152603|NCT02162836|Prostatic Neoplasms, Castration-Resistant
152604|NCT02162836|Metastatic Castration-Resistant Prostate Cancer
152605|NCT02162836|Prostate Cancer
152606|NCT02162836|Androgen Receptor
152607|NCT02162836|JNJ-56021927
152608|NCT02162823|The MeSH name is Carcinoma, Pancreatic Ductal
152609|NCT02162810|hypospadias
152610|NCT02162797|HIV
152611|NCT02162797|AIDS
152612|NCT02162797|zinc
152613|NCT02162797|zinc supplement
152614|NCT02162797|immunological deficiency
152615|NCT02162771|Advanced Follicular Lymphoma
152616|NCT02162758|Drug therapy
152617|NCT02162745|Bronchiolitis
152618|NCT02162745|Normal saline solution
152619|NCT02162745|Hypertonic solution
152620|NCT02162745|Nasal irrigation
152621|NCT02162680|local anesthesia
152622|NCT02162680|intravenous catheter
152623|NCT02162654|neuroprotection
152624|NCT02162654|ischemic preconditioning
152625|NCT02162654|cerebral aneurysm
152626|NCT02162628|Pelvic Floor Disorder
152627|NCT02162628|Pelvic Organ Prolapse
152628|NCT02162628|Sexual Dysfunction
152629|NCT02162628|Mesh
152630|NCT02162628|POP
152631|NCT02162628|Transvaginal
152632|NCT02162628|Total Repair
152633|NCT02162628|Uterine Prolapse
152634|NCT02162628|Cystocele
152635|NCT02162628|Rectocele
152636|NCT02162628|Enterocele
152637|NCT02162628|Vaginal Vault Prolapse
152638|NCT02162628|Native Tissue Repair
152639|NCT02162628|Repair Augmented with Mesh
152640|NCT02162628|Pathological Conditions, Anatomical
152641|NCT02162628|Exair Prolapse Repair System
152642|NCT02162628|Vaginal Mesh
152643|NCT02162628|Transvaginal Mesh
152644|NCT02162615|Pelvic Floor Disorder
152645|NCT02162615|Pelvic Organ Prolapse
152646|NCT02162615|Sexual Dysfunction
152647|NCT02162615|Mesh
152648|NCT02162615|POP
152649|NCT02162615|Transvaginal
152650|NCT02162615|Anterior
152651|NCT02162615|Posterior
152652|NCT02162615|Apical
152653|NCT02162615|Uterine Prolapse
152654|NCT02162615|Cystocele
152655|NCT02162615|Rectocele
152656|NCT02162615|Enterocele
152657|NCT02162615|Vaginal Vault Prolapse
152658|NCT02162615|Native Tissue Repair
152659|NCT02162615|Repair Augmented with Mesh
152660|NCT02162615|Pathological Conditions, Anatomical
152661|NCT02162615|Restorelle Direct Fix
152662|NCT02162615|Vaginal Mesh
152663|NCT02162615|Transvaginal Mesh
152664|NCT02162576|asthma
152665|NCT02162576|asthma control
152666|NCT02162576|healthcare utilization costs
152667|NCT02162576|community hotspots
152668|NCT02162576|public health research
152669|NCT02162563|Colorectal cancer
152670|NCT02162563|Chemotherapy
152671|NCT02162563|Anti-EGFR
152672|NCT02162563|Liver metastases
152673|NCT02162563|R0 R1 liver resection
152674|NCT02162563|Resectability of liver
152675|NCT02162563|Liver expert panel
152676|NCT02162550|Type 2 Diabetes
152677|NCT02162550|Cardiovascular Disease
152678|NCT02162550|Hyperglycemia
152679|NCT02162550|Carotid Plaque
152680|NCT02162550|Endothelial function
152681|NCT02162550|Incretins
152682|NCT02162550|Atherosclerosis
152683|NCT02162537|Strategy
152684|NCT02162537|Radiotherapy
152685|NCT02162537|Chemotherapy
152686|NCT02162537|Cisplatin
152687|NCT02162524|aerobic exercise
152688|NCT02162524|obesity
152689|NCT02162524|energy balance
152690|NCT02162511|Haplocompatible
152691|NCT02162511|Stem cell transplant
152692|NCT02162511|Borderline organ function
152693|NCT02162511|Alternative donor stem cell transplant
152694|NCT02162498|Peer support
152695|NCT02162498|Adherence
152696|NCT02162498|Exclusive breastfeeding
152697|NCT02162498|Early infant diagnosis
152698|NCT02162498|Stigma and disclosure
152699|NCT02162472|videocapillaroscopy, psoriasis, systemic agent
152700|NCT02162459|Adolescent
152701|NCT02162459|supplements
152702|NCT02162459|strength
152703|NCT02162459|whey protein
152704|NCT02162459|bench press strength
152705|NCT02162459|squat strength
152706|NCT02162420|severe aplastic anemia
152707|NCT02162420|Hematopoietic Stem Cell Transplant
152708|NCT02162381|Humphrey visual fields
152709|NCT02162381|methylphenidate
152710|NCT02162381|attention deficit disorder
152711|NCT02162381|MoCa questionnaire
152712|NCT02162368|laryngeal mask, prone position, spine surgery
152713|NCT02162342|upper extremity
152714|NCT02162342|muscle activity
152715|NCT02162342|kinematics
152716|NCT02162342|motion capture
152717|NCT02162342|Electromyography
152718|NCT02162329|Breast Cancer
152719|NCT02162329|Cognitive function
152720|NCT02162329|Questionnaires
152721|NCT02162329|Surveys
152722|NCT02162329|Electroencephalography
152723|NCT02162329|EEG
152724|NCT02162329|Magnetic resonance imaging
152725|NCT02162329|fMRI
152726|NCT02162329|Tibetan meditation
152727|NCT02162329|Quality of life
152728|NCT02162329|QOL
152729|NCT02162303|Atherosclerosis
152730|NCT02162303|Vascular
152731|NCT02162303|Cardiovascular
152732|NCT02162303|Coronary artery disease
152733|NCT02162303|Imaging
152734|NCT02162303|PET
152735|NCT02162303|Scan
152736|NCT02162303|anti-inflammatory
152737|NCT02162277|To decrease
152738|NCT02162277|number
152739|NCT02162277|osteoporotic
152740|NCT02162277|patients in
152741|NCT02162277|Kami-Ina area
152742|NCT02162277|Nagano prefecture
152743|NCT02162264|Alzheimer's Disease
152744|NCT02162264|donepezil hydrochloride
152745|NCT02162251|Alzheimer's Disease
152746|NCT02162251|donepezil hydrochloride
152747|NCT02162238|zinc
152748|NCT02162238|diet
152749|NCT02162238|water
152750|NCT02162238|morbidity
152751|NCT02162238|growth
152752|NCT02162225|Erythrocyte Deformability
152753|NCT02162225|Platelet Activation
152754|NCT02162225|Platelet Aggregation
152755|NCT02162225|Nitrite
152756|NCT02162225|Sickle Cell Anemia
152757|NCT02162225|Diet Therapy
152758|NCT02162199|Antibiotic
152759|NCT02162199|Antibiotic Resistant Bacterial Infection
152760|NCT02162186|Arthroplasty, Replacement, Hip/methods
152761|NCT02162186|Hip Joint/physiopathology
152762|NCT02162186|Hip Joint/radiography
152763|NCT02162186|Hip Joint/surgery
152764|NCT02162186|Hip Prosthesis
152765|NCT02162186|Outcome Assessment (Health Care)
152766|NCT02162186|Female
152767|NCT02162186|Male
152768|NCT02162186|Adult
152769|NCT02162173|Familial adenomatous polyposis syndrome
152770|NCT02162173|Non-ampullary polyp
152771|NCT02162173|Ampullary polyp
152772|NCT02162173|Narrow band imaging endoscopy
152773|NCT02162173|Confocal laser endomicroscopy
152774|NCT02162160|probiotic
152775|NCT02162160|post-menopausal
152776|NCT02162160|atrophic vaginitis
152777|NCT02162147|patient safety
152778|NCT02162147|pediatrics
152779|NCT02162147|emergency medicine
152780|NCT02162134|cholecystectomy
152781|NCT02162134|laparoscopic
152782|NCT02162134|postoperative
152783|NCT02162134|ileus
152784|NCT02162134|chewing gum
152785|NCT02162095|Chronic obstructive pulmonary disease
152786|NCT02162095|Coronary artery disease
152787|NCT02162095|Coronary calcium score
152788|NCT02162043|Glaucoma
152789|NCT02162043|Perimetry
152790|NCT02162043|Diagnostic self-evaluation
152791|NCT02162043|Screening
152792|NCT02162043|Visual fields
152793|NCT02162017|Acute ischemic stroke
152794|NCT02162017|Acute intracerebral haemorrhage
152795|NCT02162017|Head position
152796|NCT02162017|Lying flat head position
152797|NCT02162017|Sitting up head position
152798|NCT02162017|Death
152799|NCT02162017|Disability
152800|NCT02162017|Clinical trial
152801|NCT02162004|Type 1 diabetes
152802|NCT02162004|Continuous Glucose Monitoring
152803|NCT02162004|Insulin pump
152804|NCT02162004|Sensor-augmented pump
152805|NCT02162004|Continuous correction of high blood glucose
152806|NCT02161991|aprepitant
152807|NCT02161991|non-small cell lung cancer
152808|NCT02161978|antiangiogenic
152809|NCT02161978|cancer
152810|NCT02161978|vascular
152811|NCT02161978|biomarker
152812|NCT02161965|Anticoagulation
152813|NCT02161965|Coronary and peripheral calcification
152814|NCT02161965|Arterial stiffness
152815|NCT02161965|Biomarker
152816|NCT02161952|Fibrosis, necroinflammation, hepatitis C chronic
152817|NCT02161926|Obesity
152818|NCT02161926|dietary restrictions
152819|NCT02161926|metabolism
152820|NCT02161926|nutrition
152821|NCT02161926|elderly
152822|NCT02161874|edentulism
152823|NCT02161874|dental implants
152824|NCT02161874|clinical study
152825|NCT02161874|endosseous
152826|NCT02161874|randomized
152827|NCT02161874|crestal bone level
152828|NCT02161874|T3
152829|NCT02161874|Nanotite Certain
152830|NCT02161874|Nanotite Certain Prevail
152831|NCT02161874|Tapered
152832|NCT02161861|tripeptide FEE
152833|NCT02161861|fertilization rates
152834|NCT02161861|embryos
152835|NCT02161861|oocytes
152836|NCT02161835|Congenital myotonia
152837|NCT02161835|Myotonia congenita
152838|NCT02161835|Thomsons disease
152839|NCT02161835|Becker type
152840|NCT02161835|Training
152841|NCT02161835|Exercise
152842|NCT02161822|locally advanced rectal cancer, neoadjuvant chemoradiation
152843|NCT02161809|MVPA
152844|NCT02161809|Healthy Eating
152845|NCT02161809|children
152846|NCT02161809|childhood obesity
152847|NCT02161796|Phase 1
152848|NCT02161796|FG-4592
152849|NCT02161796|Age/gender comparison
152850|NCT02161783|Hematopoietic stem cell transplant
152851|NCT02161770|oncology, cancer, neoplasm, anticancer drug, pharmacokinetics, area under curve, AZD9291, solid tumour, mild hepatic impairment, moderate hepatic impairment
152852|NCT02161757|Asthma
152853|NCT02161757|Reactive Airways
152854|NCT02161757|Respiratory Tract Disease
152855|NCT02161757|Obstructive Lung Disease
152856|NCT02161757|Lung Diseases
152857|NCT02161744|Adipose derived stem cells
152858|NCT02161744|Stromal vascular fraction cells
152859|NCT02161744|Pulmonary Function Tests
152860|NCT02161744|Chronic Obstructive Pulmonary Disease
152861|NCT02161718|Alkermes
152862|NCT02161718|Schizophrenia
152863|NCT02161718|Alcohol Use Disorder
152864|NCT02161718|ALKS 3831
152865|NCT02161705|Immediate breast reconstruction
152866|NCT02161705|pain control
152867|NCT02161705|post mastectomy pain control
152868|NCT02161679|Antibody drug conjugate
152869|NCT02161679|IMMU-132
152870|NCT02161679|Triple-negative breast cancer
152871|NCT02161679|Safety and tolerability
152872|NCT02161679|Progression Free Survival (PFS)
152873|NCT02161666|Obesity
152874|NCT02161666|Gastric Bypass
152875|NCT02161666|Bariatric Surgery
152876|NCT02161666|Incretin Function
152877|NCT02161666|Islet Function
152878|NCT02161653|Severe alcoholic hepatitis
152879|NCT02161653|survival
152880|NCT02161653|oxidative stress
152881|NCT02161627|spinal cord stimulation
152882|NCT02161627|automatic control
152883|NCT02161614|hormone replacement therapy
152884|NCT02161614|Dopplervelocimetry
152885|NCT02161614|Flow-mediated dilation
152886|NCT02161614|menopause
152887|NCT02161614|Estradiol valerate
152888|NCT02161601|Cricoid pressure
152889|NCT02161601|Rapid Sequence Induction
152890|NCT02161562|chronic spontaneous urticaria, CSU, chronic idiopathic urticaria, CIU, hives, angioedema, itch
152891|NCT02161523|mast cells, lung cancer, cancer associated fibroblasts (CAF)
152892|NCT02161497|Medical History Taking
152893|NCT02161497|Electronic Health Records
152894|NCT02161497|Pediatrics
152895|NCT02161497|Parents
152896|NCT02161484|Peripheral Nerve Block
152897|NCT02161484|Total Hip Replacement
152898|NCT02161471|Atria, Heart
152899|NCT02161471|Function, Atrial
152900|NCT02161471|Heart Defects, Congenital
152901|NCT02161471|Cardiovascular Abnormalities
152902|NCT02161471|Congenital Abnormalities
152903|NCT02161471|Tetralogy, Fallot
152904|NCT02161471|Transposition of Great Arteries
152905|NCT02161471|Coarctation of the Aorta
152906|NCT02161458|Escitalopram
152907|NCT02161458|Amyloid Beta
152908|NCT02161458|Cerebrospinal Fluid
152909|NCT02161445|impedance
152910|NCT02161445|pep
152911|NCT02161445|tevg
152912|NCT02161445|dyspnea
152913|NCT02161445|AHF
152914|NCT02161445|BNP
152915|NCT02161419|Small Cell Lung Carcinoma,
152916|NCT02161419|First line
152917|NCT02161419|Extensive disease
152918|NCT02161419|Small cell lung cancer
152919|NCT02161406|Scleroderma
152920|NCT02161393|Physical Activity
152921|NCT02161393|Pulmonary Rehabilitation
152922|NCT02161393|Chronic obstructive pulmonary disease
152923|NCT02161380|Gene therapy
152924|NCT02161380|Mitochondrial Genes
152925|NCT02161380|Leber's
152926|NCT02161380|AAV2 Viral vectors
152927|NCT02161367|colorectal surgery
152928|NCT02161367|postoperative ileus
152929|NCT02161367|simethicone
152930|NCT02161367|randomized controlled trial
152931|NCT02161367|double blind
152932|NCT02161367|pilot study
152933|NCT02161367|anti-foaming agent
152934|NCT02161367|abdominal pain
152935|NCT02161367|abdominal distention
152936|NCT02161367|nausea vomiting
152937|NCT02161367|flatus
152938|NCT02161367|bowel movement
152939|NCT02161367|placebo
152940|NCT02161367|postoperative complications
152941|NCT02161367|polydimethylsiloxane
152942|NCT02161367|hydrated silica gel
152943|NCT02161367|gas bubbles
152944|NCT02161367|intestinal tract
152945|NCT02161354|Dental Pain
152946|NCT02161354|Acute Pain
152947|NCT02161354|Mild Pain
152948|NCT02161354|Moderate Pain
152949|NCT02161341|Bacterial microbiome
152950|NCT02161341|Gene expression
152951|NCT02161315|SAID, Progestogens, nSAID-resistanced, LSBC
152952|NCT02161302|Endometriosis
152953|NCT02161302|Transcranial Direct Current Stimulation
152954|NCT02161302|tDCS
152955|NCT02161302|Near Infrared Spectroscopy
152956|NCT02161302|NIRS
152957|NCT02161302|Chronic Pelvic Pain
152958|NCT02161289|100 HIV-negagtve MSM
152959|NCT02161263|LASIK
152960|NCT02161263|Satisfaction
152961|NCT02161237|Acute rejection
152962|NCT02161237|Advagraf
152963|NCT02161237|Renal function
152964|NCT02161224|Phase 1
152965|NCT02161224|FG-4592
152966|NCT02161224|Single dose
152967|NCT02161224|Moderate hepatic impairment
152968|NCT02161211|alcohol
152969|NCT02161211|anxiety
152970|NCT02161198|Panax ginseng CA
152971|NCT02161198|ginsan
152972|NCT02161198|polysaccharide
152973|NCT02161198|immunity
152974|NCT02161198|natural killer cell
152975|NCT02161185|Epilepsy
152976|NCT02161185|seizure cluster
152977|NCT02161185|acute repetitive seizures
152978|NCT02161185|open-label
152979|NCT02161185|intranasal Midazolam
152980|NCT02161185|USL261
152981|NCT02161185|Upsher-Smith
152982|NCT02161172|Mild traumatic brain injury
152983|NCT02161172|Cognitive outcome
152984|NCT02161172|Psychological outcome
152985|NCT02161133|Veterans
152986|NCT02161133|neuropsychology
152987|NCT02161133|fatigue
152988|NCT02161133|Chronic Multisymptom Illness
152989|NCT02161133|Gulf War Illness
152990|NCT02161133|behavioral treatment
152991|NCT02161120|IBS, irritable bowel syndrome, functional gastrointestinal disorder, diet, bread, rye, FODMAP, microbiota
152992|NCT02161107|Grass
152993|NCT02161107|Allergy
152994|NCT02161107|rhinoconjunctivitis
152995|NCT02161107|rhinitis
152996|NCT02161107|asthma
152997|NCT02161094|Community management incentives
152998|NCT02161081|Myocardial ischemia
152999|NCT02161081|Coronary artery disease
153000|NCT02161081|Myocardial CT perfusion
153001|NCT02161081|Modified scan protocol
153002|NCT02161081|Diagnostic performance
153003|NCT02161081|Radiation dose
153004|NCT02161068|ADPKD
153005|NCT02161068|Chart Review
153006|NCT02161068|PKD Genotyping
153007|NCT02161055|Insulin
153008|NCT02161055|Hyperglycemia
153009|NCT02161055|Postoperative Mortality
153010|NCT02161055|Intensive insulin therapy
153011|NCT02161055|Non-intensive insulin therapy
153012|NCT02161055|Brain Injuries
153013|NCT02161055|Wounds and Injuries
153014|NCT02161055|Craniocerebral Trauma
153015|NCT02161055|Trauma, Nervous System
153016|NCT02161042|Blood transfusion
153017|NCT02161042|Storage Lesion
153018|NCT02161042|Endothelial dysfunction
153019|NCT02161042|Nitric Oxide
153020|NCT02161029|Gastric tumor
153021|NCT02161003|Fecal Incontinence
153022|NCT02161003|Posterior Sagittal Ano-rectoplasty
153023|NCT02161003|Mesenchymal Stem Cell
153024|NCT02160990|Obesity
153025|NCT02160977|Surgical procedures
153026|NCT02160977|Minimally invasive
153027|NCT02160977|Arthroplasty
153028|NCT02160977|Knee
153029|NCT02160964|Inferior Vena Cava
153030|NCT02160951|Multiple Myeloma,
153031|NCT02160951|Phase I,
153032|NCT02160951|PIM,
153033|NCT02160951|Japanese patients,
153034|NCT02160951|LGH447
153035|NCT02160938|microarray
153036|NCT02160938|prenatal
153037|NCT02160938|copy number variant
153038|NCT02160938|CNV
153039|NCT02160938|microdeletion
153040|NCT02160938|microduplication
153041|NCT02160938|genetic
153042|NCT02160899|High Lipoprotein(a)
153043|NCT02160847|children
153044|NCT02160847|pediatric obesity
153045|NCT02160847|parent training
153046|NCT02160847|home-based
153047|NCT02160847|nutrition
153048|NCT02160847|physical activity
153049|NCT02160847|parent-child interaction
153050|NCT02160847|parenting
153051|NCT02160834|Sedentary behavior
153052|NCT02160834|Physical activity
153053|NCT02160834|Obesity
153054|NCT02160834|Mobile health
153055|NCT02160834|Smartphone
153056|NCT02160834|Time spent sedentary
153057|NCT02160821|Transversus Abdominis Plane Block
153058|NCT02160821|Caudal Epidural
153059|NCT02160821|Pediatric Pain control
153060|NCT02160821|Pain control for Lower Abdominal Surgery
153061|NCT02160795|Periconceptional
153062|NCT02160795|Folic Acid
153063|NCT02160795|Leukemia
153064|NCT02160795|Childhood Cancer
153065|NCT02160769|Tear Lipid Thickness
153066|NCT02160769|Pterygium surgery
153067|NCT02160756|Healthy
153068|NCT02160756|JNJ-56021927
153069|NCT02160756|JNJ-56142060
153070|NCT02160756|ARN-509
153071|NCT02160730|Cushings disease
153072|NCT02160730|R-roscovitine
153073|NCT02160717|Turner Syndrome
153074|NCT02160717|Diabetes
153075|NCT02160704|Sperm density
153076|NCT02160704|Testosterone
153077|NCT02160704|Hypogonadism
153078|NCT02160652|Ureteral Obstruction
153079|NCT02160652|HYDRONEPHROSIS
153080|NCT02160652|nephrostomy tube
153081|NCT02160639|diabetes self management education
153082|NCT02160639|diabetes self management support
153083|NCT02160639|type 2 diabetes
153084|NCT02160626|Seborrheic keratosis
153085|NCT02160626|A101
153086|NCT02160613|Osteoprotegerin
153087|NCT02160613|Biomarker
153088|NCT02160613|Chronic periodontitis
153089|NCT02160613|Open flap debridement
153090|NCT02160561|mechanical
153091|NCT02160561|ventilation
153092|NCT02160561|acute
153093|NCT02160561|respiratory
153094|NCT02160561|failure
153095|NCT02160548|Organophosphate, insectiside, Salbutamol, Atropine
153096|NCT02160535|Mild Traumatic Brain Injury
153097|NCT02160535|Concussion
153098|NCT02160535|Post Concussive Headache
153099|NCT02160522|Intubation
153100|NCT02160522|cuff
153101|NCT02160522|cuffed
153102|NCT02160522|endotracheal
153103|NCT02160522|tube
153104|NCT02160522|pressure
153105|NCT02160522|pediatric
153106|NCT02160522|child
153107|NCT02160522|children
153108|NCT02160522|emergency
153109|NCT02160509|real time, ultrasonography, handheld
153110|NCT02160496|Weight Loss
153111|NCT02160496|Obesity
153112|NCT02160496|Overweight
153113|NCT02160496|Diet, Reducing
153114|NCT02160496|Lipids
153115|NCT02160483|Chronic pelvic pain
153116|NCT02160483|Endometriosis
153117|NCT02160457|Cerebral palsy
153118|NCT02160457|Instrumented gait analysis
153119|NCT02160457|Gait Deviation Index
153120|NCT02160444|CBT
153121|NCT02160444|Parent Training
153122|NCT02160444|Anxiety Disorders in Children
153123|NCT02160431|Children
153124|NCT02160431|OCD
153125|NCT02160431|CBT
153126|NCT02160431|Neuropsychological profiles
153127|NCT02160405|Iron levels
153128|NCT02160392|HIV
153129|NCT02160392|female
153130|NCT02160392|genital tract
153131|NCT02160379|roux-en-Y-gastric bypass
153132|NCT02160379|brain responses to food
153133|NCT02160379|gastrointestinal hormones
153134|NCT02160379|bile acids
153135|NCT02160366|Advanced Cancers
153136|NCT02160366|Molecular profiling
153137|NCT02160366|Biomarker data
153138|NCT02160366|Data analysis
153139|NCT02160366|Tumor marker
153140|NCT02160340|Posterior Vitreous Detachment
153141|NCT02160340|Vitreomacular Traction
153142|NCT02160340|Vitreous
153143|NCT02160314|stress urinary incontinence, SUI, pessary
153144|NCT02160301|pain
153145|NCT02160301|postoperative
153146|NCT02160301|multimodal
153147|NCT02160301|satisfaction
153148|NCT02160301|narcotic
153149|NCT02160288|Botox
153150|NCT02160288|obstructed defecation syndrome
153151|NCT02160288|ODS
153152|NCT02160288|Outlet-Type Constipation
153153|NCT02160288|injection
153154|NCT02160275|Artificial pancreas
153155|NCT02160275|Bi-hormonal closed loop
153156|NCT02160275|Diabetes Type 1
153157|NCT02160249|Schizophrenia
153158|NCT02160249|Psychotic disorders
153159|NCT02160249|Schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder or schizophreniform disorder) using DSM-IV criteria
153160|NCT02160236|dexketoprofen trometamol
153161|NCT02160236|tenoxicam
153162|NCT02160236|postoperative pain
153163|NCT02160223|sugammadex
153164|NCT02160223|neostigmine
153165|NCT02160223|obstructive sleep apnea
153166|NCT02160197|Ankle Fractures
153167|NCT02160197|Fracture Fixation
153168|NCT02160197|Early Ambulation
153169|NCT02160197|Fracture Healing
153170|NCT02160197|Return to Work
153171|NCT02160171|Decision Support Algorithm
153172|NCT02160171|Neonatal Seizures
153173|NCT02160171|EEG
153174|NCT02160158|Fesoterodine
153175|NCT02160158|SR3
153176|NCT02160158|SR4
153177|NCT02160158|bioavailability
153178|NCT02160158|pharmacokinetics
153179|NCT02160158|sprinkle
153180|NCT02160158|applesauce
153181|NCT02160145|Chronic Kidney Disease
153182|NCT02160145|Autosomal Dominant Polycystic Kidney Disease
153183|NCT02160119|Autism Spectrum Disorders
153184|NCT02160119|Emotion
153185|NCT02160119|Attention
153186|NCT02160119|Event-related potential
153187|NCT02160119|Functional neuroimaging
153188|NCT02160119|Diffusion Tensor Imaging
153189|NCT02160119|Development
153190|NCT02160106|Cancer
153191|NCT02160106|advanced solid tumors
153192|NCT02160106|metastatic
153193|NCT02160106|phase I
153194|NCT02160106|transforming growth factor beta
153195|NCT02160106|TGF-β
153196|NCT02160106|first-in-human
153197|NCT02160106|TEW-7197
153198|NCT02160106|activin receptor-like kinase 5
153199|NCT02160106|ALK5
153200|NCT02160106|Smad2
153201|NCT02160106|Smad3
153202|NCT02160106|phospho-Smad
153203|NCT02160106|phospho Smad
153204|NCT02160106|psmad
153205|NCT02160106|serine / threonine kinase inhibitor
153206|NCT02160106|pharmacokinetics
153207|NCT02160106|MedPacto
153208|NCT02160106|National OncoVenture
153209|NCT02160093|sarcopenia
153210|NCT02160093|frailty
153211|NCT02160093|chronic disease control
153212|NCT02160093|aging psychology
153213|NCT02160080|Boceprevir;
153214|NCT02160080|Liver pre-transplant
153215|NCT02160067|Healthy Volunteers
153216|NCT02160067|Pharmacokinetics
153217|NCT02160054|tacrolimus
153218|NCT02160054|cyclosporine
153219|NCT02160054|Graceptor®
153220|NCT02160054|kidney transplantation
153221|NCT02160041|Solid tumor malignancy
153222|NCT02160041|hematologic malignancy
153223|NCT02160041|mutation
153224|NCT02160041|translocations
153225|NCT02160041|amplifications,
153226|NCT02160041|fusions
153227|NCT02160041|signature
153228|NCT02160041|FGFR
153229|NCT02160041|ligand
153230|NCT02160041|BGJ398
153231|NCT02160028|Information
153232|NCT02160028|Pain
153233|NCT02160028|Stress
153234|NCT02160028|Fear
153235|NCT02160028|Placebo analgesia
153236|NCT02160002|Incubator Weaning
153237|NCT02160002|Moderately Preterm Infants
153238|NCT02160002|Growth Velocity
153239|NCT02159976|Helicobacter pylori
153240|NCT02159963|FSHD
153241|NCT02159963|HIT
153242|NCT02159963|Training
153243|NCT02159963|Exercise
153244|NCT02159963|10-20-30 interval training
153245|NCT02159937|cancer
153246|NCT02159937|in vitro
153247|NCT02159937|peptides
153248|NCT02159937|dendritic cells
153249|NCT02159924|Smartphone measurements
153250|NCT02159924|Orientation
153251|NCT02159924|Range of motion
153252|NCT02159924|Median nerve neurodynamic test
153253|NCT02159924|Posture
153254|NCT02159924|Thoracic spine
153255|NCT02159924|Shoulder girdle
153256|NCT02159911|Cervical
153257|NCT02159911|Hysteroscopy
153258|NCT02159911|Misoprostol
153259|NCT02159911|Oral
153260|NCT02159898|Esophageal Cancer
153261|NCT02159898|Dysphagia
153262|NCT02159898|Regurgitation
153263|NCT02159885|obstructive sleep apnea
153264|NCT02159885|adherence
153265|NCT02159885|telemedicine
153266|NCT02159885|auto-titrating continuous positive airway pressure
153267|NCT02159872|Leukemia
153268|NCT02159872|Myelodysplastic Syndrome
153269|NCT02159872|MDS
153270|NCT02159872|Omacetaxine
153271|NCT02159872|Synribo
153272|NCT02159872|Homoharringtonine
153273|NCT02159859|ertapenem
153274|NCT02159859|pharmacokinetic
153275|NCT02159859|pharmacodynamics
153276|NCT02159859|hemodialysis
153277|NCT02159859|requires hemodialysis three times a week
153278|NCT02159846|Herbs
153279|NCT02159846|Diabetes Mellitus
153280|NCT02159846|HbA1c
153281|NCT02159846|Lipid Profile
153282|NCT02159833|Food allergy
153283|NCT02159833|Diagnosis
153284|NCT02159807|Pain control
153285|NCT02159807|labor
153286|NCT02159807|epidural
153287|NCT02159807|pregnant
153288|NCT02159794|Transcatheter Aortic Valve Replacement
153289|NCT02159794|Aortic valve stenosis
153290|NCT02159794|Severe aortic stenosis
153291|NCT02159768|tracheal intubation
153292|NCT02159742|Adult subjects
153293|NCT02159742|history
153294|NCT02159742|treatment
153295|NCT02159742|photodynamic therapy
153296|NCT02159716|Subjects
153297|NCT02159703|T1-2 N2 M0,
153298|NCT02159703|stage IVa SCCA
153299|NCT02159703|oropharynx
153300|NCT02159703|negative for PNI,
153301|NCT02159703|negative surgical margins
153302|NCT02159690|prostate cancer
153303|NCT02159690|prostatectomy
153304|NCT02159690|localized prostate cancer
153305|NCT02159677|EIM
153306|NCT02159664|didgeridoo
153307|NCT02159664|sleep apnea
153308|NCT02159664|drug induced sleep endoscopy
153309|NCT02159651|tacrolimus
153310|NCT02159651|interstitial pneumonia
153311|NCT02159651|prograf
153312|NCT02159638|Diabetes Mellitus
153313|NCT02159638|Diabetes Mellitus, Type 1
153314|NCT02159638|Diabetes Mellitus, Insulin-Dependent
153315|NCT02159638|Endocrine System Diseases
153316|NCT02159638|Blood glucose
153317|NCT02159638|Blood Glucose, Self-Monitoring
153318|NCT02159625|Abdominal Compression Elastic Support
153319|NCT02159625|Hemodialysis
153320|NCT02159625|hypotension
153321|NCT02159625|occurrence rate
153322|NCT02159612|FSHD
153323|NCT02159612|MRI
153324|NCT02159612|Disease progression
153325|NCT02159586|gastroparesis
153326|NCT02159586|gastric electrical stimulator
153327|NCT02159586|GES
153328|NCT02159586|vomiting
153329|NCT02159586|nausea
153330|NCT02159586|bloating
153331|NCT02159586|postprandial fullness
153332|NCT02159586|epigastric pain
153333|NCT02159547|migraine, emergency department, dexketoprofen, placebo
153334|NCT02159521|deep vein thrombosis
153335|NCT02159521|post-thrombotic syndrome
153336|NCT02159521|chronic deep vein thrombosis
153337|NCT02159508|nutritional status
153338|NCT02159508|nutritional intervention
153339|NCT02159508|handgrip strength
153340|NCT02159508|patient-generated subjective global assessment
153341|NCT02159508|chemoradiotherapy
153342|NCT02159508|survival
153343|NCT02159469|Hypogonadism
153344|NCT02159469|Testosterone enanthate
153345|NCT02159443|Hu14.18K322A
153346|NCT02159443|Human anti-human antibodies (HAHA)
153347|NCT02159443|Pretreatment anti-therapeutic antibodies (PATA)
153348|NCT02159417|Evolution of the sport, HbA1C, IMC
153349|NCT02159391|Accident Prevention
153350|NCT02159391|Alcohol Drinking
153351|NCT02159391|Substance-Related Disorders
153352|NCT02159391|Motivational Interviewing
153353|NCT02159391|Adult
153354|NCT02159391|Humans
153355|NCT02159391|Intervention Studies
153356|NCT02159391|Recurrence
153357|NCT02159391|Risk Factors
153358|NCT02159391|Trauma Centers
153359|NCT02159391|Wounds and Injuries/epidemiology
153360|NCT02159391|Wounds and Injuries/etiology*
153361|NCT02159391|Wounds and Injuries/prevention & control*
153362|NCT02159378|Gestational Diabetes
153363|NCT02159378|Fructosamines
153364|NCT02159378|Insulin treatment
153365|NCT02159339|DNA methylation
153366|NCT02159313|Biological Availability
153367|NCT02159300|Fibromyalgia
153368|NCT02159300|Pain
153369|NCT02159287|ischemic stroke
153370|NCT02159287|atrial fibrillation
153371|NCT02159287|bridging therapy
153372|NCT02159274|Late symptoms
153373|NCT02159274|Shoulder function
153374|NCT02159274|Cosmetic results
153375|NCT02159274|EORTC
153376|NCT02159274|Lymphoedema
153377|NCT02159261|Personal Satisfaction
153378|NCT02159248|pancreatic, gemcitabine, radiation, tolfenamic acid
153379|NCT02159235|cadmium
153380|NCT02159235|lead
153381|NCT02159235|mercury
153382|NCT02159235|zinc
153383|NCT02159235|endostatin
153384|NCT02159235|angiostatin
153385|NCT02159235|VEGF
153386|NCT02159235|CAD
153387|NCT02159235|osteopontin
153388|NCT02159209|Acute Kidney Injury
153389|NCT02159209|Adverse Drug Reaction
153390|NCT02159209|Acute Kidney Failure
153391|NCT02159209|Kidney
153392|NCT02159209|Kidneys
153393|NCT02159196|mechanical ventilation
153394|NCT02159196|nebulisation
153395|NCT02159196|respiratory failure
153396|NCT02159170|Use of NGF injection as a model of non-inflammatory neuropathic pain in healthy subjects
153397|NCT02159157|breast cancer, exercise
153398|NCT02159144|Brown adipose tissue
153399|NCT02159144|Subcutaneous white adipose tissue
153400|NCT02159144|White adipose tissue
153401|NCT02159131|ethinyl estradiol
153402|NCT02159131|GSK1265744
153403|NCT02159131|pharmacokinetics
153404|NCT02159131|oral contraceptive
153405|NCT02159131|oral contraceptive containing levonorgestrel and ethinyl estradiol
153406|NCT02159131|levonorgestrel
153407|NCT02159118|bone marrow aspiration
153408|NCT02159118|bone marrow biopsy
153409|NCT02159118|OnControl
153410|NCT02159118|powered bone marrow aspiration and biopsy device
153411|NCT02159118|standard manual bone marrow aspiration and biopsy device
153412|NCT02159105|postpartum hemorrhage
153413|NCT02159105|postsurgical bleeding
153414|NCT02159105|abdominal ultrasound
153415|NCT02159105|FAST scan
153416|NCT02159105|non-invasive hemoglobin measurement
153417|NCT02159092|Waterpipe
153418|NCT02159092|Smoking cessation
153419|NCT02159092|Contingency management
153420|NCT02159092|Dependence
153421|NCT02159079|Sepsis
153422|NCT02159079|Severe Sepsis
153423|NCT02159079|Septic Shock
153424|NCT02159079|Conservative Fluid Management
153425|NCT02159079|Fluid Balance
153426|NCT02159079|Fluid Restriction
153427|NCT02159066|Melanoma
153428|NCT02159053|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, secukinumab, self-injection
153429|NCT02159040|Int-2 MDS
153430|NCT02159027|Human Immunodeficiency Virus
153431|NCT02159027|AIDS Dementia Complex
153432|NCT02159014|Physical activity intervention
153433|NCT02159014|Aerobic dance
153434|NCT02159014|Nutritional intervention
153435|NCT02159014|Online participation
153436|NCT02159014|Primary Care settings
153437|NCT02159014|General Practice Physical Activity Questionnaire GPPAQ
153438|NCT02159014|Qrisk2
153439|NCT02159014|QDS Diabetes
153440|NCT02159001|clozapine
153441|NCT02159001|ECT
153442|NCT02159001|PANSS
153443|NCT02159001|schizoaffective disorder
153444|NCT02159001|schizophrenia
153445|NCT02159001|treatment
153446|NCT02158988|Gastric cancer
153447|NCT02158988|cancer of the esophagogastric junction
153448|NCT02158988|peritoneal carcinomatosis
153449|NCT02158988|hyperthermic intraperitoneal chemotherapy
153450|NCT02158988|HIPEC
153451|NCT02158962|Partner abuse
153452|NCT02158962|Abuse African Caribbean women
153453|NCT02158962|Intimate Partner Violence
153454|NCT02158949|alcohol
153455|NCT02158949|mHealth
153456|NCT02158949|SBIRT
153457|NCT02158936|thrombocytopenia
153458|NCT02158936|myelodysplastic syndromes (MDS)
153459|NCT02158936|thrombopoietin
153460|NCT02158936|azacitidine
153461|NCT02158936|Eltrombopag
153462|NCT02158923|ventilation
153463|NCT02158923|lung
153464|NCT02158923|lung complications
153465|NCT02158923|postoperative complications
153466|NCT02158923|perioperative lung protective ventilation
153467|NCT02158910|Alzheimer's disease
153468|NCT02158884|Major extremity trauma
153469|NCT02158884|wounded warriors
153470|NCT02158884|IDEO
153471|NCT02158884|return to run
153472|NCT02158871|Education
153473|NCT02158871|Early intervention
153474|NCT02158871|Workplace
153475|NCT02158871|Stigma
153476|NCT02158871|Mental Health Literacy
153477|NCT02158858|Phase 1
153478|NCT02158858|Oncology
153479|NCT02158858|BET Inhibitor
153480|NCT02158845|endometriosis
153481|NCT02158845|blood coagulation
153482|NCT02158845|levonorgestrel
153483|NCT02158845|GnRH agonist
153484|NCT02158845|progesterone-releasing intrauterine device
153485|NCT02158832|Lymphoedema
153486|NCT02158832|Edema
153487|NCT02158832|Oedema
153488|NCT02158832|Cancer
153489|NCT02158832|Breast Cancer
153490|NCT02158819|Visionaire
153491|NCT02158819|Health Economics
153492|NCT02158819|Degenerative arthritis
153493|NCT02158819|total knee arthroplasty
153494|NCT02158806|Venous ulcer, varicose ulcer, gravitational ulcer, aspirin
153495|NCT02158793|face transplant
153496|NCT02158793|Craniomaxillofacial Allotransplantation
153497|NCT02158793|facial disfigurement
153498|NCT02158793|facial trauma
153499|NCT02158754|coronary artery disease
153500|NCT02158754|gene expression score
153501|NCT02158754|Corus CAD
153502|NCT02158754|coronary artery disease diagnosis
153503|NCT02158754|coronary artery disease economics
153504|NCT02158741|Self-Management
153505|NCT02158741|Home Visits
153506|NCT02158702|Relapsed Myeloma Patients
153507|NCT02158702|Relapsed after use of Bortezomib and Lenalidomide
153508|NCT02158702|Pomalidomide and Dexamethasone
153509|NCT02158702|Efficacy and Safety
153510|NCT02158689|Poor responders
153511|NCT02158689|letrozole
153512|NCT02158689|human menopausal gonadotropin
153513|NCT02158676|Roux-en-y gastric bypass
153514|NCT02158676|Inflammatory markers
153515|NCT02158676|Nutritional status
153516|NCT02158676|Fatty acids
153517|NCT02158676|Glucose
153518|NCT02158676|Prebiotic
153519|NCT02158676|Synbiotic
153520|NCT02158663|Transcranial Magnetic Stimulation
153521|NCT02158663|TMS
153522|NCT02158663|PTSD
153523|NCT02158650|informed consent
153524|NCT02158650|video-based
153525|NCT02158637|PRO-CTCAE
153526|NCT02158637|Patient-Reported Outcomes
153527|NCT02158637|Common Terminology Criteria for Adverse Events
153528|NCT02158637|Questionnaire
153529|NCT02158637|Adverse Events
153530|NCT02158637|Symptoms
153531|NCT02158611|Individual Counseling service
153532|NCT02158611|Group Counseling service
153533|NCT02158585|Lamotrigine
153534|NCT02158585|Lamictal
153535|NCT02158585|Anticonvulsant
153536|NCT02158585|Ménière's disease
153537|NCT02158585|Vertigo attack
153538|NCT02158585|Dizziness
153539|NCT02158585|Vestibular disorder
153540|NCT02158572|prevention of pregnancy
153541|NCT02158546|Major Depressive Disorder
153542|NCT02158546|Depression
153543|NCT02158546|Alkermes
153544|NCT02158546|ALKS 5461
153545|NCT02158546|Samidorphan
153546|NCT02158533|Major Depressive Disorder
153547|NCT02158533|Depression
153548|NCT02158533|Alkermes
153549|NCT02158533|ALKS 5461
153550|NCT02158533|Samidorphan
153551|NCT02158507|metastatic
153552|NCT02158507|triple negative breast cancer (TNBC)
153553|NCT02158507|Veliparib
153554|NCT02158507|Lapatinib
153555|NCT02158507|estrogen receptor (ER) negative
153556|NCT02158507|progesterone receptor (PR) negative
153557|NCT02158507|human epidermal growth factor receptor 2 (HER-2-Neu) negative
153558|NCT02158494|Cranial Nerve Noninvasive Neuromodulation
153559|NCT02158494|Portable Neuromodulation Stimulator (PoNS)
153560|NCT02158494|Balance and Gait Training
153561|NCT02158494|Breathing Awareness Training
153562|NCT02158481|Vascular function
153563|NCT02158481|Dietary ingredients
153564|NCT02158481|Acute glucose load
153565|NCT02158481|Oxidative stress
153566|NCT02158468|STEMI, reperfusion, preconditioning, postconditioning, reperfusion injury, myocardial salvage
153567|NCT02158455|CABG
153568|NCT02158455|Saphenous vein
153569|NCT02158455|Radial artery
153570|NCT02158442|Diabetes
153571|NCT02158442|Lower limb infection
153572|NCT02158442|Significant wound infections
153573|NCT02158442|Intravenous antibiotics
153574|NCT02158442|Timentin
153575|NCT02158429|substance use disorders
153576|NCT02158429|pregnancy
153577|NCT02158429|maternal attachment
153578|NCT02158429|paternal attachment
153579|NCT02158429|three dimensional ultrasound
153580|NCT02158416|platelet
153581|NCT02158416|transfusion
153582|NCT02158416|ThromboLUX
153583|NCT02158416|corrected count increment
153584|NCT02158416|thrombocytopenic
153585|NCT02158403|HeartMate II
153586|NCT02158403|heart assist device
153587|NCT02158403|pump thrombosis
153588|NCT02158403|hypercoagulable disorder
153589|NCT02158403|thrombus
153590|NCT02158403|Thoratec Corporation
153591|NCT02158390|Down syndrome
153592|NCT02158390|Language intervention
153593|NCT02158390|Communication intervention
153594|NCT02158377|Dental implants
153595|NCT02158377|Trabecular Metal dental implants
153596|NCT02158377|TSV dental implants
153597|NCT02158377|Zimmer Dental
153598|NCT02158377|Implant stability
153599|NCT02158377|Implant stability quotient (ISQ)
153600|NCT02158377|Resonance Frequency Analysis (RFA)
153601|NCT02158364|Pharmacological therapy
153602|NCT02158351|Simple steatosis (SS)
153603|NCT02158351|Non-alcoholic steatohepatitis (NASH)
153604|NCT02158351|Gut microbiota (GM)
153605|NCT02158351|Non alcoholic fatty liver disease (NAFLD)
153606|NCT02158338|asthma
153607|NCT02158338|maternal bonding
153608|NCT02158338|maternal bonding disruptions
153609|NCT02158338|mother-infant interaction
153610|NCT02158312|neuroplasticity
153611|NCT02158273|Alcohol
153612|NCT02158273|Relapse
153613|NCT02158260|Capsule endoscopy
153614|NCT02158260|Patient position changing
153615|NCT02158234|squamous cell carcinoma
153616|NCT02158234|head and neck cancer
153617|NCT02158234|paranasal sinuses
153618|NCT02158234|nasal cavity
153619|NCT02158234|nasopharynx
153620|NCT02158234|oropharynx
153621|NCT02158234|oral cavity
153622|NCT02158234|larynx
153623|NCT02158234|hypopharynx
153624|NCT02158234|salivary glands
153625|NCT02158234|cervical lymph nodes
153626|NCT02158208|before any treatment
153627|NCT02158208|at the diagnosis
153628|NCT02158182|Hepatic Encephalopathy
153629|NCT02158182|Acute Variceal Bleeding
153630|NCT02158182|Cirrhosis
153631|NCT02158130|Physical Inactivity
153632|NCT02158130|Aerobic Exercise Detraining
153633|NCT02158130|Body Weight
153634|NCT02158130|Energy Expenditure
153635|NCT02158130|Metabolic Syndrome
153636|NCT02158117|Emergency Treatment
153637|NCT02158117|Morphine Derivates
153638|NCT02158117|Heroin
153639|NCT02158117|Antidotes
153640|NCT02158117|Administration, Intranasal
153641|NCT02158091|Chronic Lymphocytic Leukemia
153642|NCT02158078|Diabetes Mellitus
153643|NCT02158078|Diabetes Mellitus, Type 2
153644|NCT02158078|Glucose Metabolism Disorders
153645|NCT02158078|Metabolic Diseases
153646|NCT02158078|Endocrine System Diseases
153647|NCT02158078|Insulin
153648|NCT02158078|Continuous subcutaneous insulin infusion (CSII)
153649|NCT02158078|Insulin pumps
153650|NCT02158065|Chronic obstructive pulmonary disease (COPD)
153651|NCT02158065|physical activity
153652|NCT02158065|PROactive
153653|NCT02158065|telecoaching
153654|NCT02158052|HLA matched
153655|NCT02158052|bone marrow transplantation
153656|NCT02158052|kidney transplantation
153657|NCT02158039|Intraductal Papillary Mucinous Neoplasm
153658|NCT02158039|Mucinous Cystic Neoplasm
153659|NCT02158039|Endoscopic Ultrasound
153660|NCT02158039|Ethanol
153661|NCT02158026|Follicular sensitivity index
153662|NCT02158026|ICSI
153663|NCT02158026|IVF
153664|NCT02157987|telangietasia hereditary hemorragic
153665|NCT02157987|epistaxis
153666|NCT02157987|safety
153667|NCT02157987|quality of life
153668|NCT02157987|bevacizumab
153669|NCT02157987|spray
153670|NCT02157948|postmenopausal osteoporosis
153671|NCT02157948|osteoporosis
153672|NCT02157948|postmenopausal
153673|NCT02157948|denosumab
153674|NCT02157948|women
153675|NCT02157935|COPD, turbuhaler, pMDI
153676|NCT02157922|Cystic fibrosis
153677|NCT02157922|mucolytic
153678|NCT02157922|mucociliary clearance
153679|NCT02157922|lung clearance
153680|NCT02157909|Lens fit
153681|NCT02157909|contact lenses
153682|NCT02157909|myopia
153683|NCT02157896|Acute ischemic stroke
153684|NCT02157896|Vascular endothelial growth factor
153685|NCT02157896|Endostatin
153686|NCT02157883|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, intraconazole, EGFR sensitivity mutation
153687|NCT02157870|Ovary
153688|NCT02157870|ovarian cancer
153689|NCT02157870|biologic therapy
153690|NCT02157870|platinum-resistant
153691|NCT02157870|platinum-refractory ovarian cancer
153692|NCT02157870|platinum-resistant ovarian cancer
153693|NCT02157870|paclitaxel
153694|NCT02157870|tgDCC-E1A
153695|NCT02157870|E1A
153696|NCT02157870|Taxol
153697|NCT02157857|NSCLC, SCLC, lung cancer, EBUS-TBNA
153698|NCT02157844|Obstructive Sleep Apnea
153699|NCT02157844|Chronic Obstructive Pulmonary Disease
153700|NCT02157844|Obesity
153701|NCT02157844|Hepatic fat metabolism
153702|NCT02157844|fat digestion
153703|NCT02157844|whole body protein synthesis
153704|NCT02157844|protein digestion
153705|NCT02157844|amino acid metabolism
153706|NCT02157844|adipose tissue fat metabolism
153707|NCT02157844|lipolysis
153708|NCT02157831|Subjects with Clinical Benefit After a Single Infusion of CP - 870, 893
153709|NCT02157805|Meat processes
153710|NCT02157805|Amino acids bioavailability
153711|NCT02157805|Digestion rate
153712|NCT02157805|Protein synthesis
153713|NCT02157805|Aging
153714|NCT02157805|Sarcopenia
153715|NCT02157792|Solid Tumor
153716|NCT02157792|Advanced Solid Tumor
153717|NCT02157779|Veterans
153718|NCT02157779|Anger
153719|NCT02157779|Cognitive Behavioral Therapy
153720|NCT02157779|Treatment
153721|NCT02157766|Mental Health
153722|NCT02157766|Asthma
153723|NCT02157766|Mindfulness
153724|NCT02157766|Compassion
153725|NCT02157766|Meditation
153726|NCT02157753|Osteoporotic fracture
153727|NCT02157753|treatment for osteoporosis
153728|NCT02157753|adherence and compliance
153729|NCT02157701|Dietary herbs
153730|NCT02157701|Polyherbal capsule
153731|NCT02157701|Functional exercise capacity
153732|NCT02157701|Joint health
153733|NCT02157688|folliculitis decalvans
153734|NCT02157688|Staphylococcus Aureus
153735|NCT02157688|antibiotics
153736|NCT02157675|Delayed onset muscle soreness
153737|NCT02157675|Muscle damage
153738|NCT02157675|Eccentric exercise
153739|NCT02157636|Phase 1
153740|NCT02157636|Oncology
153741|NCT02157636|BET Inhibitor
153742|NCT02157623|Basal Cell Nevus Syndrome
153743|NCT02157623|Gorlin's Syndrome
153744|NCT02157610|Cervical Cancer
153745|NCT02157610|Cervical Cancer Survivors
153746|NCT02157610|Smoking Cessation
153747|NCT02157610|Motivation And Problem-Solving
153748|NCT02157610|MAPS
153749|NCT02157610|Saliva test
153750|NCT02157610|Self help materials
153751|NCT02157610|Pamphlets
153752|NCT02157610|Texas Quitline
153753|NCT02157610|Nicotine patch
153754|NCT02157610|Questionnaires
153755|NCT02157610|Surveys
153756|NCT02157610|Telephone counseling sessions
153757|NCT02157571|prulifloxacin
153758|NCT02157571|AECB
153759|NCT02157571|Levofloxacin
153760|NCT02157545|muscle relaxants
153761|NCT02157545|pyridostigmine
153762|NCT02157545|pharmacodynamics
153763|NCT02157545|potency
153764|NCT02157532|Severe stroke
153765|NCT02157532|IV tPA
153766|NCT02157532|mechanical thrombectomy
153767|NCT02157519|Oral Chemotherapy
153768|NCT02157519|Cancer
153769|NCT02157506|Acute Heart failure
153770|NCT02157506|Hemodynamics
153771|NCT02157506|Pharmacokinetics
153772|NCT02157506|Renal Function
153773|NCT02157493|American Indian
153774|NCT02157493|Adolescents
153775|NCT02157493|Entrepreneurship
153776|NCT02157493|Paraprofessional
153777|NCT02157493|Life skills
153778|NCT02157480|glucose profile
153779|NCT02157480|continuous glucose monitoring
153780|NCT02157480|electrostimulation
153781|NCT02157441|Postpartum Hemorrhage
153782|NCT02157441|Placenta Previa
153783|NCT02157441|uterine cavity
153784|NCT02157402|Adolescent
153785|NCT02157376|SUP
153786|NCT02157376|Upper GI bleeding
153787|NCT02157376|Seriously ill patients
153788|NCT02157350|Eye Diseases
153789|NCT02157350|Proliferative Diabetic Retinopathy
153790|NCT02157350|Retinal Vessel Geometry
153791|NCT02157350|Retinal Oxymetry
153792|NCT02157350|Retina Ischemia
153793|NCT02157350|Panretinal Photocoagulation
153794|NCT02157350|Lasers, Semiconductor
153795|NCT02157350|Fluorescein Angiography
153796|NCT02157337|aortic surgery
153797|NCT02157337|postoperative acute kidney injury
153798|NCT02157337|statin
153799|NCT02157337|the patient undergoing aortic surgery
153800|NCT02157324|Bruton tyrosine kinase inhibitor
153801|NCT02157324|Btk
153802|NCT02157311|HIV-1
153803|NCT02157311|simplification,
153804|NCT02157311|treatment discontinuation
153805|NCT02157311|virological success
153806|NCT02157311|four days a week
153807|NCT02157298|Japanese patients with type 2 diabetes with inadequate glycemic control on insulin
153808|NCT02157285|Unintended pregnancy in adolescence
153809|NCT02157285|LARC
153810|NCT02157285|contraception
153811|NCT02157272|Antiphospholipid
153812|NCT02157272|Syndrome
153813|NCT02157272|Rivaroxaban
153814|NCT02157272|Warfarin
153815|NCT02157272|Thrombosis
153816|NCT02157272|Treatment
153817|NCT02157246|hypoxia
153818|NCT02157246|rectal cancer
153819|NCT02157207|antioxidants
153820|NCT02157207|Caucasians
153821|NCT02157207|healthy
153822|NCT02157207|African Americans
153823|NCT02157207|vascular
153824|NCT02157207|aging
153825|NCT02157207|racial differences
153826|NCT02157181|HCL variant
153827|NCT02157181|HCL relapse
153828|NCT02157181|Risk stratified
153829|NCT02157168|Affordable Care Act
153830|NCT02157168|Medically underserved minorities
153831|NCT02157168|Community health workers
153832|NCT02157168|Health disparities among Mexican origin
153833|NCT02157142|Severe aortic stenosis
153834|NCT02157142|Aortic valve stenosis
153835|NCT02157142|Transcatheter aortic valve replacement
153836|NCT02157129|Tracheostomy
153837|NCT02157129|inflammation
153838|NCT02157129|mucous congestion
153839|NCT02157129|inhalation therapy
153840|NCT02157129|phospholipids
153841|NCT02157116|Dose-Dense Chemotherapy
153842|NCT02157103|GBM
153843|NCT02157103|Glioblastoma
153844|NCT02157103|Bevacizumab
153845|NCT02157103|Avastin
153846|NCT02157103|Subcutaneous
153847|NCT02157090|HSL of lips
153848|NCT02157090|perioral skin
153849|NCT02157090|duration of HSL symptoms not more than three days
153850|NCT02157090|not acyclovir or other cold sore therapies
153851|NCT02157077|Eye diseases
153852|NCT02157077|Vision Impairment and Blindness
153853|NCT02157077|Eyes and Vision
153854|NCT02157077|Seniors
153855|NCT02157077|Neovascular Age-Related Macular Degeneration (AMD)
153856|NCT02157077|Retinal Disease
153857|NCT02157038|whiplash
153858|NCT02157038|neck pain
153859|NCT02157038|chronic pain
153860|NCT02157038|motor vehicle accident
153861|NCT02157038|car accident
153862|NCT02157038|MRI
153863|NCT02157038|DNA
153864|NCT02157038|RNA
153865|NCT02157025|Humphrey visual fields
153866|NCT02157025|perimetry
153867|NCT02157025|pediatrics
153868|NCT02156973|cardiac computed tomography
153869|NCT02156973|Image quality
153870|NCT02156947|Power Doppler sonography
153871|NCT02156947|cholecystitis, adhesion
153872|NCT02156934|autologous stress urinary incontinence muscle derived cells
153873|NCT02156908|cognitive remediation
153874|NCT02156895|Korean PMS of Axitinib
153875|NCT02156895|Metastatic RCC ; 2nd line only
153876|NCT02156882|TB
153877|NCT02156882|Tuberculosis
153878|NCT02156882|MaTuTU - Maputo Tuberculosis Trial Unit
153879|NCT02156882|Clinical Trial Capacity Development
153880|NCT02156869|Prostate cancer
153881|NCT02156869|Screening
153882|NCT02156869|Decision aids
153883|NCT02156856|hemodynamic monitoring
153884|NCT02156856|cardiac output
153885|NCT02156856|cardiac surgery
153886|NCT02156843|Diabetic Kidney Disease
153887|NCT02156843|Nephropathy
153888|NCT02156843|Diabetic Nephropathy
153889|NCT02156843|Kidney Disease
153890|NCT02156843|Type 2 Diabetes
153891|NCT02156817|Amplitude integrated electroencephalogram
153892|NCT02156817|Heart rate variability
153893|NCT02156817|Respiratory rate variability
153894|NCT02156817|Preterm Infants
153895|NCT02156817|Length of Hospital Stay
153896|NCT02156791|Seasonal allergic rhinoconjunctivitis
153897|NCT02156791|Grass pollen
153898|NCT02156791|Allergen specific immunotherapy
153899|NCT02156778|Post-Stroke Disease Management
153900|NCT02156778|Post-Stroke Complication
153901|NCT02156778|Risk Factor Control
153902|NCT02156778|Quality-of-Life
153903|NCT02156765|Atrial Fibrillation
153904|NCT02156765|Screening
153905|NCT02156765|Stroke patients
153906|NCT02156739|Liver Neoplasms
153907|NCT02156739|Liver lesions
153908|NCT02156739|Benign liver lesions
153909|NCT02156739|Malignant liver lesions
153910|NCT02156739|Contrast-Enhanced Magnetic Resonance Imaging
153911|NCT02156739|MRI
153912|NCT02156739|Gadoxetate
153913|NCT02156739|Eovist
153914|NCT02156739|Gadopentetate Dimeglumine
153915|NCT02156739|Magnevist
153916|NCT02156726|chronic lymphocytic leukemia
153917|NCT02156726|fludarabine
153918|NCT02156726|rituximab
153919|NCT02156726|elderly
153920|NCT02156726|comorbid
153921|NCT02156726|FCR
153922|NCT02156726|CIRS
153923|NCT02156713|Hemiparesis
153924|NCT02156713|Occupational Therapy
153925|NCT02156700|shear wave elastography
153926|NCT02156700|haemangiomas
153927|NCT02156700|metastases
153928|NCT02156700|hepatocellular carcinoma
153929|NCT02156700|focal nodular hyperplasia
153930|NCT02156700|cholangiocellular carcinoma
153931|NCT02156674|Maroteaux-Lamy Syndrome
153932|NCT02156674|mucopolysaccharide VI
153933|NCT02156674|MPS VI
153934|NCT02156648|Invasive ductal
153935|NCT02156648|HER2-neu positive
153936|NCT02156635|Rehabilitation
153937|NCT02156635|Direct Current Stimulation
153938|NCT02156635|Acute Stroke
153939|NCT02156622|HIV
153940|NCT02156622|Depression
153941|NCT02156622|Measurement-based care
153942|NCT02156622|Outcomes
153943|NCT02156622|Viral load
153944|NCT02156609|HeartMate PHP
153945|NCT02156609|HeartMate PHP CE Mark
153946|NCT02156609|Percutaneous coronary intervention
153947|NCT02156609|PCI
153948|NCT02156609|Percutaneous ventricular assist
153949|NCT02156609|Thoratec Corporation
153950|NCT02156596|renal colic
153951|NCT02156596|nebulised morphine
153952|NCT02156596|Intravenous NSAID
153953|NCT02156583|Ventricular Assist Device
153954|NCT02156583|Skeletal Muscle
153955|NCT02156583|Frailty
153956|NCT02156583|Older adults
153957|NCT02156570|Hepatitis C
153958|NCT02156570|Acute/early chronic
153959|NCT02156570|Recently acquired
153960|NCT02156570|Directly acting antiviral therapy
153961|NCT02156570|Sofosbuvir
153962|NCT02156570|Ribavirin
153963|NCT02156531|Anxiety
153964|NCT02156531|Youth Anxiety
153965|NCT02156531|CBM
153966|NCT02156531|Cognitive Bias Modification
153967|NCT02156531|Adolescents
153968|NCT02156505|stent
153969|NCT02156505|gastric outlet obstruction
153970|NCT02156505|restenosis
153971|NCT02156479|CMV
153972|NCT02156479|T-Track CMV
153973|NCT02156479|allo-HSCT
153974|NCT02156479|CMI
153975|NCT02156466|Psoriasis
153976|NCT02156466|MSB0010841
153977|NCT02156466|Anti-IL17A/F Nanobody
153978|NCT02156466|M1095
153979|NCT02156453|Functional recovery
153980|NCT02156453|Total knee arthroplasty
153981|NCT02156440|Ostearthritis
153982|NCT02156440|Knee
153983|NCT02156440|SierraSil
153984|NCT02156414|Prostatectomy
153985|NCT02156414|Extended Lymphadenectomy
153986|NCT02156414|Pelvic lymph node dissection
153987|NCT02156414|Prostatic Neoplasm
153988|NCT02156414|Prospective Studies
153989|NCT02156401|Venous thromboembolism
153990|NCT02156401|Deep vein thrombosis
153991|NCT02156401|Pulmonary embolism
153992|NCT02156401|Cohort study/epidemiology
153993|NCT02156401|Outcome
153994|NCT02156401|Prognosis
153995|NCT02156375|Healthy
153996|NCT02156375|Ustekinumab
153997|NCT02156375|STELARA®
153998|NCT02156362|Thyroid carcinoma
153999|NCT02156362|predictive factors
154000|NCT02156362|refractory
154001|NCT02156362|Differentiated
154002|NCT02156362|follicular origin
154003|NCT02156349|Diabetes
154004|NCT02156336|Diabetic Peripheral Neuropathic Pain
154005|NCT02156336|Ranexa
154006|NCT02156336|Ranolazine
154007|NCT02156336|Neurology
154008|NCT02156284|Fear; Thoracic Surgery; Nursing Care; Preoperative Care
154009|NCT02156271|Insomnia
154010|NCT02156258|Imaging
154011|NCT02156258|Mammography
154012|NCT02156232|hepatic encephalopathy (HE)
154013|NCT02156232|vericeal bleeding
154014|NCT02156232|spontaneous portosystemic shunts (SPSS)
154015|NCT02156232|transjugular intrahepatic portosystemic shunt (TIPS)
154016|NCT02156232|embolization
154017|NCT02156180|exhaled breath
154018|NCT02156180|volatile organic compounds
154019|NCT02156180|surgery
154020|NCT02156180|chemotherapy
154021|NCT02156180|radiotherapy
154022|NCT02156167|Otosclerosis, cochlear implant, acoustic stimulation
154023|NCT02156141|Kennedy's disease
154024|NCT02156141|Spinal and bulbar muscular atrophy
154025|NCT02156141|High Intensity Training
154026|NCT02156141|High Intensity Interval Training
154027|NCT02156141|HIT
154028|NCT02156141|HIIT
154029|NCT02156141|Training
154030|NCT02156141|Exercise
154031|NCT02156141|10-20-30
154032|NCT02156128|Cognitive therapy
154033|NCT02156115|Lymphangiomatosis
154034|NCT02156115|Lymphangiogenesis
154035|NCT02156115|Smooth Muscle Cell
154036|NCT02156115|Vascular Anomalies
154037|NCT02156102|Genetic Disorders
154038|NCT02156102|Sickle Cell Disease
154039|NCT02156102|African American
154040|NCT02156102|Leg Ulcers
154041|NCT02156102|Skin
154042|NCT02156089|fMRI
154043|NCT02156089|Reward Processing
154044|NCT02156089|Nutrition
154045|NCT02156089|Omega-3 Fatty Acids
154046|NCT02156089|ADHD
154047|NCT02156063|Recurrent Pregnancy Loss
154048|NCT02156063|Recurrent Miscarriage
154049|NCT02156063|Miscarriage
154050|NCT02156063|Pregnancy Loss
154051|NCT02156063|Repeated Pregnancy Loss
154052|NCT02156037|Hispanic
154053|NCT02156037|clinical decision support
154054|NCT02156037|diabetes
154055|NCT02156037|Hba1c
154056|NCT02156037|psychosocial
154057|NCT02156024|clinical trials
154058|NCT02156024|Gastrodia and Uncaria Drink
154059|NCT02156011|In vivo knee joint kinematics
154060|NCT02156011|In vivo knee joint loading
154061|NCT02156011|Video-fluoroscopy
154062|NCT02156011|Instrumented implants
154063|NCT02156011|Optical motion capture
154064|NCT02156011|Ground reaction forces
154065|NCT02156011|Electromyography
154066|NCT02155998|prostate adenocarcinoma, locally advanced prostate cancer with high and very high risk of recurrence, adjuvant endocrine treatment, prostate specific antigen
154067|NCT02155972|Bipolar
154068|NCT02155972|Depression
154069|NCT02155972|Probiotic
154070|NCT02155972|ALIGN
154071|NCT02155972|HAMD
154072|NCT02155972|STAI
154073|NCT02155972|YMRS
154074|NCT02155972|CGI
154075|NCT02155972|SDS
154076|NCT02155972|WHOQOL-BREF
154077|NCT02155972|C-SSRS
154078|NCT02155972|TSES
154079|NCT02155959|astigmatism
154080|NCT02155959|cataract
154081|NCT02155959|toric
154082|NCT02155959|lens
154083|NCT02155946|Aging
154084|NCT02155946|Alzheimer's Disease/Dementia
154085|NCT02155946|Cognitive Disorders
154086|NCT02155946|Imaging
154087|NCT02155946|Magnetic Resonance Imaging (MRI)
154088|NCT02155946|Neurology
154089|NCT02155946|Physical Medicine & Rehabilitation
154090|NCT02155946|transcranial direct current stimulation
154091|NCT02155920|Ependymoma
154092|NCT02155920|Anaplastic Ependymoma
154093|NCT02155894|Rheumatoid arthritis, treat to target, telemedicine
154094|NCT02155881|Drug therapy
154095|NCT02155868|Cerebral near-infrared spectroscopy monitoring
154096|NCT02155868|Postoperative complications
154097|NCT02155868|Cardiac surgery
154098|NCT02155855|type 1 diabetes, home glucose monitor, upload, cloud
154099|NCT02155842|exercise therapy
154100|NCT02155829|PTSD
154101|NCT02155829|TBI
154102|NCT02155829|Riluzole
154103|NCT02155829|Rilutek
154104|NCT02155829|augmentation
154105|NCT02155829|supplement
154106|NCT02155829|double blinded
154107|NCT02155829|clinical trial
154108|NCT02155829|placebo
154109|NCT02155829|RCT
154110|NCT02155829|Randomized Control Trial
154111|NCT02155816|inflammation
154112|NCT02155816|lipoproteins
154113|NCT02155816|omega 3
154114|NCT02155816|omega 7
154115|NCT02155803|Sarcoidosis-Associated Calcium Dysregulation
154116|NCT02155803|Sarcoidosis-Associated hypercalciuria
154117|NCT02155803|hypercalcemia
154118|NCT02155803|hypercalciuria
154119|NCT02155803|nephrocalcinosis
154120|NCT02155803|nephrolithiasis
154121|NCT02155803|interstitial nephritis
154122|NCT02155803|glomerulonephritis
154123|NCT02155803|acute kidney disease
154124|NCT02155803|chronic kidney disease
154125|NCT02155790|safety, performance, hypertension, renal denervation
154126|NCT02155777|BRCA1
154127|NCT02155777|BRCA2
154128|NCT02155777|Risk-reducing surgery
154129|NCT02155777|Oral Contraceptives
154130|NCT02155764|tooth
154131|NCT02155764|extraction
154132|NCT02155764|alveolar socket
154133|NCT02155764|socket preservation
154134|NCT02155764|ridge preservation
154135|NCT02155764|bone graft
154136|NCT02155764|tricalcium phosphate
154137|NCT02155764|octacalcium phosphate
154138|NCT02155764|xenograft
154139|NCT02155764|bio oss
154140|NCT02155751|Obesity prevention
154141|NCT02155751|Nutrition and exercise in pregnancy
154142|NCT02155751|Postpartum
154143|NCT02155751|Maternal obesity risk
154144|NCT02155738|IV acetaminophen
154145|NCT02155738|Postoperative pain
154146|NCT02155738|Pelvic organ prolapse surgery
154147|NCT02155738|Pelvic organ prolapse repair
154148|NCT02155725|PPH
154149|NCT02155725|fibrinogen
154150|NCT02155725|vaginal delivery
154151|NCT02155699|UHR, Remediation, Exercise, Intervention, Psychosis
154152|NCT02155686|Elderly
154153|NCT02155686|Prevention
154154|NCT02155686|Multiple chronic disease
154155|NCT02155686|Telemonitoring
154156|NCT02155686|Geriatric teleexpertise
154157|NCT02155686|Home heath care
154158|NCT02155686|Medico-economics
154159|NCT02155660|Obstructive Lung Diseases
154160|NCT02155660|Chronic Obstructive Pulmonary Disease
154161|NCT02155660|Lung Disease
154162|NCT02155660|Bronchial Diseases
154163|NCT02155660|COPD Exacerbation
154164|NCT02155660|Respiratory Tract Diseases
154165|NCT02155647|Carcinoma, Merkel Cell
154166|NCT02155647|MSB0010718C
154167|NCT02155647|avelumab
154168|NCT02155647|anti PD-L1
154169|NCT02155647|JAVELIN Merkel 200
154170|NCT02155634|Newly Diagnosed Multiple Myeloma
154171|NCT02155634|Multiple Myeloma
154172|NCT02155634|Lenalidomide
154173|NCT02155634|Revlimid
154174|NCT02155634|Phase III
154175|NCT02155634|Phase IIIb
154176|NCT02155634|Plasma Cell Dyscrasia
154177|NCT02155621|cancer genomics
154178|NCT02155621|precision medicine
154179|NCT02155621|metastatic cancer
154180|NCT02155621|clinical decision-making
154181|NCT02155608|ADHD
154182|NCT02155608|neuromodulation
154183|NCT02155608|trigeminal nerve stimulation
154184|NCT02155608|cognition
154185|NCT02155582|Solid tumors
154186|NCT02155569|Cesarean, extraperitoneal
154187|NCT02155569|Cesarean
154188|NCT02155569|Pain
154189|NCT02155517|TCI,Schnider Model, Cortinez Model, BIS, Cardiac Output.
154190|NCT02155504|Healthy volunteers
154191|NCT02155504|Pharmacokinetics
154192|NCT02155504|ASP3700
154193|NCT02155504|Itraconazole
154194|NCT02155504|Drug-drug interaction
154195|NCT02155491|venous, thromboembolism, embolism, DVT, Pulmonary Embolism, thrombosis
154196|NCT02155465|Ruxolitinib
154197|NCT02155465|Erlotinib
154198|NCT02155465|EGFR-mutant
154199|NCT02155465|14-043
154200|NCT02155452|ALA
154201|NCT02155452|Malignant gliomas
154202|NCT02155439|Prospective, randomized controlled trial - pilot study
154203|NCT02155413|Acute pain
154204|NCT02155413|Audit
154205|NCT02155413|Safety
154206|NCT02155413|Tolerability
154207|NCT02155387|EVLW
154208|NCT02155387|EVLWI
154209|NCT02155387|PVPI
154210|NCT02155387|MICS
154211|NCT02155374|Glucocorticoid induced hyperglycemia, insulin, chemotherapy
154212|NCT02155361|Diabetes mellitus
154213|NCT02155361|Diabetes complications
154214|NCT02155361|Pain
154215|NCT02155309|scopolamine
154216|NCT02155309|motion
154217|NCT02155309|sickness
154218|NCT02155296|positive youth development
154219|NCT02155296|restorative practices
154220|NCT02155296|school climate
154221|NCT02155296|social competency
154222|NCT02155283|Chronic Low Back Pain
154223|NCT02155283|Mild-to-Moderate Chronic Low Back Pain
154224|NCT02155283|Continuous Passive Motion Devices
154225|NCT02155270|Cataract
154226|NCT02155270|Incision
154227|NCT02155270|Precut
154228|NCT02155270|Corneal
154229|NCT02155270|OCT
154230|NCT02155270|Intraoperative OCT
154231|NCT02155270|Imaging
154232|NCT02155270|Astigmatism
154233|NCT02155270|Clear corneal incision
154234|NCT02155257|Osteoarthritis
154235|NCT02155244|CBDS
154236|NCT02155244|ERCP
154237|NCT02155244|Dindo-Clavien classification
154238|NCT02155231|Male with history of anal sex with men or previous participants of the MSM VCT study
154239|NCT02155218|Magnetic Resonance Angiography
154240|NCT02155218|Contrast Media
154241|NCT02155192|CNTO1959PSO2001
154242|NCT02155192|C0743T08
154243|NCT02155192|C0743T09
154244|NCT02155192|C0743T12
154245|NCT02155192|Psoriasis
154246|NCT02155192|Pharmacogenomics
154247|NCT02155166|Levonorgestrel-releasing intrauterine system
154248|NCT02155166|anesthesia
154249|NCT02155166|pain
154250|NCT02155166|nulliparous
154251|NCT02155140|enteral feeding
154252|NCT02155140|Discharged
154253|NCT02155140|surgical resection of an upper gastrointestinal malignancy
154254|NCT02155140|Nutritional supplementation via a jejunostomy
154255|NCT02155127|chronic kidney disease
154256|NCT02155127|physical function
154257|NCT02155114|Hepcidins
154258|NCT02155114|Homeostasis
154259|NCT02155114|Iron/administration & dosage
154260|NCT02155114|Biological Markers/blood
154261|NCT02155101|Efficacy
154262|NCT02155101|Safety
154263|NCT02155101|Darunavir
154264|NCT02155101|HIV-1 RNA level
154265|NCT02155101|Cameroon
154266|NCT02155088|Locally Advanced
154267|NCT02155088|Metastatic
154268|NCT02155088|Recurrent
154269|NCT02155088|Pancreas
154270|NCT02155075|Breast neoplasm
154271|NCT02155075|Breast implants
154272|NCT02155075|Mammography
154273|NCT02155075|Breast imaging
154274|NCT02155075|Imaging augmented breast
154275|NCT02155062|Nutritional biomarker
154276|NCT02155062|Dietary assessment
154277|NCT02155062|Whole grain
154278|NCT02155062|Wheat
154279|NCT02155062|Rye
154280|NCT02155062|Alkylresorcinol
154281|NCT02155062|Urine
154282|NCT02155049|TED
154283|NCT02155049|Prostaglandin Analogues
154284|NCT02155036|exercise
154285|NCT02155036|rehabilitation
154286|NCT02155036|kidney function
154287|NCT02155036|cardiovascular disease risk
154288|NCT02155010|Dexmedetomidine
154289|NCT02155010|Spinal anesthesia
154290|NCT02154971|HIV Seropositivity
154291|NCT02154971|Audiometry
154292|NCT02154971|Hearing Loss
154293|NCT02154958|Follicular output rate
154294|NCT02154958|IVF
154295|NCT02154958|ICSI
154296|NCT02154932|Myomectomy, Misoprostol
154297|NCT02154906|periodontal disease
154298|NCT02154906|periodontitis
154299|NCT02154893|Ultrasound
154300|NCT02154893|Laser
154301|NCT02154893|Therapeutic exercise
154302|NCT02154893|Rehabilitation
154303|NCT02154893|Osteoarthritis
154304|NCT02154880|HIV
154305|NCT02154880|lung
154306|NCT02154880|aging
154307|NCT02154867|IBS-D
154308|NCT02154867|FMT
154309|NCT02154867|metagenomics
154310|NCT02154867|gut microbiome
154311|NCT02154854|Renal
154312|NCT02154854|Transplantation
154313|NCT02154854|Tacrolimus
154314|NCT02154854|Arterial stiffness
154315|NCT02154854|Vascular fibrose plasma markers
154316|NCT02154841|Postoperative
154317|NCT02154841|nutrition
154318|NCT02154841|taste
154319|NCT02154841|perception
154320|NCT02154841|preference
154321|NCT02154841|choice
154322|NCT02154828|Children
154323|NCT02154828|aged
154324|NCT02154828|3 to 6 years
154325|NCT02154815|End Stage Renal Disease
154326|NCT02154815|Renal transplantation
154327|NCT02154815|Dialysis
154328|NCT02154815|Pre-emptive transplantation
154329|NCT02154815|Psychological adjustment
154330|NCT02154815|Quality of life.
154331|NCT02154776|LEE011,
154332|NCT02154776|buparlisib,
154333|NCT02154776|letrozole,
154334|NCT02154776|HR +,
154335|NCT02154776|HER2 - negative,
154336|NCT02154776|post-menopausal,
154337|NCT02154776|breast cancer,
154338|NCT02154776|CDK 4/6,
154339|NCT02154776|PI3K,
154340|NCT02154776|MTD
154341|NCT02154763|Bariatric surgery
154342|NCT02154763|Bariatrics
154343|NCT02154763|Local anesthetic
154344|NCT02154763|Ropivacaine
154345|NCT02154763|Intraperitoneal
154346|NCT02154750|Atrioventricular delay
154347|NCT02154750|AV delay
154348|NCT02154750|Pacemaker
154349|NCT02154750|Sick Sinus Syndrome
154350|NCT02154750|Bradycardia
154351|NCT02154750|PR interval
154352|NCT02154750|Atrioventricular block
154353|NCT02154750|AV block
154354|NCT02154750|Echocardiography
154355|NCT02154750|Arrhythmia
154356|NCT02154750|AV optimization
154357|NCT02154737|Pancreatic
154358|NCT02154737|Gemcitabine
154359|NCT02154737|Gemzar
154360|NCT02154737|erlotinib
154361|NCT02154737|Tarceva
154362|NCT02154711|mitochondrial disease
154363|NCT02154711|magnetic resonance imaging
154364|NCT02154711|magnetic resonance spectroscopy
154365|NCT02154711|creatine
154366|NCT02154711|phosphocreatine
154367|NCT02154685|Smoking
154368|NCT02154685|Nicotine
154369|NCT02154685|Addiction
154370|NCT02154685|Cessation
154371|NCT02154620|Distal radius fracture
154372|NCT02154620|wrist fracture
154373|NCT02154620|volar plate
154374|NCT02154620|surgical treatment
154375|NCT02154620|plaster immobilisation
154376|NCT02154607|oral lichen planus
154377|NCT02154607|recurrence
154378|NCT02154607|Treatment
154379|NCT02154607|cancer
154380|NCT02154607|Primary disease Management
154381|NCT02154594|Acacia
154382|NCT02154594|Chlorhexidine
154383|NCT02154594|Gingivitis
154384|NCT02154594|Orthodontic appliances.
154385|NCT02154581|Dental implants
154386|NCT02154581|Esthetic score
154387|NCT02154581|Immediate implants
154388|NCT02154581|Gingival biotype
154389|NCT02154568|Hyperpolarized gas MRI
154390|NCT02154542|Nava
154391|NCT02154542|Mechanical ventilation
154392|NCT02154477|hypogonadotropic hypogonadism
154393|NCT02154464|Morphine-sparing
154394|NCT02154464|Paracetamol
154395|NCT02154464|Obesity
154396|NCT02154464|Gastric banding
154397|NCT02154425|Cimzia®
154398|NCT02154425|CZP
154399|NCT02154425|Breastfeeding
154400|NCT02154425|Nursing
154401|NCT02154425|Autoimmune diseases and pregnancy
154402|NCT02154412|Respiration
154403|NCT02154412|Motor control
154404|NCT02154412|Blood Pressure
154405|NCT02154412|Orthostatic Hypotension
154406|NCT02154386|bone augmentation
154407|NCT02154386|tooth extraction
154408|NCT02154386|dental implant
154409|NCT02154360|HIV infection
154410|NCT02154360|NK-1R antagonists
154411|NCT02154360|aprepitant
154412|NCT02154360|ritonavir boosting
154413|NCT02154347|Type 2 Diabetes Mellitus
154414|NCT02154347|HbA1c
154415|NCT02154334|Allergic Rhinitis
154416|NCT02154334|Healthy
154417|NCT02154334|Esketamine
154418|NCT02154334|Mometasone
154419|NCT02154334|Oxymetazoline
154420|NCT02154334|Phase 1
154421|NCT02154308|Influenza
154422|NCT02154308|Influenza vaccine
154423|NCT02154308|Split influenza vaccine
154424|NCT02154308|Seasonal influenza vaccine
154425|NCT02154282|hepatic encephalopathy
154426|NCT02154282|covert hepatic encephalopathy
154427|NCT02154282|cirrhosis
154428|NCT02154269|Chagas disease
154429|NCT02154269|G-CSF
154430|NCT02154269|Cell therapy
154431|NCT02154256|walking
154432|NCT02154256|incentives
154433|NCT02154256|exercise
154434|NCT02154256|habits
154435|NCT02154230|weight loss
154436|NCT02154230|sulphate-bicarbonate-calcium water
154437|NCT02154230|gut microbiota
154438|NCT02154230|body composition
154439|NCT02154230|bile salts
154440|NCT02154191|Lumbosacral Region
154441|NCT02154191|Sedentary Lifestyle
154442|NCT02154191|Surgical Procedure, Operative
154443|NCT02154178|empiric antifungal therapy
154444|NCT02154178|biomarkers
154445|NCT02154178|invasive fungal infection
154446|NCT02154178|Candida
154447|NCT02154165|Neonatal hyperbilirubinemia
154448|NCT02154165|Phototherapy
154449|NCT02154165|Light emitting diodes
154450|NCT02154165|Blue light
154451|NCT02154165|Turquoise light
154452|NCT02154152|Bed wetting
154453|NCT02154152|Primary Enuresis
154454|NCT02154152|Frequency
154455|NCT02154152|Efficacy
154456|NCT02154152|Homoeopathic Medicine
154457|NCT02154152|Causticum 200c
154458|NCT02154139|Pharmacological therapy
154459|NCT02154113|Syneron
154460|NCT02154113|Velashape
154461|NCT02154113|ELOS
154462|NCT02154113|Ultrashape
154463|NCT02154100|Metabolic Syndrome
154464|NCT02154100|Arterial Stiffness
154465|NCT02154100|Blood Pressure
154466|NCT02154100|Endothelial Function
154467|NCT02154100|Tart Cherries
154468|NCT02154087|Venous leg ulcer
154469|NCT02154087|Ulcer
154470|NCT02154087|Venous stasis
154471|NCT02154087|Compression
154472|NCT02154074|Dexmedetomidine perioperative blood glucose and insulin
154473|NCT02154061|Flu Vaccine, Intestinal Microbiome, Antibiotics
154474|NCT02154035|Viral Suppression
154475|NCT02154035|Functional Cure
154476|NCT02154022|PK
154477|NCT02154009|Autonomic Nervous System
154478|NCT02154009|Catecholamines
154479|NCT02154009|Dysautonomia
154480|NCT02154009|Parasympathetic Cholinergic System
154481|NCT02154009|Sympathetic Adrenergic System
154482|NCT02153996|Malaria Immunity Longevity
154483|NCT02153983|Obesity
154484|NCT02153983|Colchicine
154485|NCT02153983|Inflammation
154486|NCT02153983|Metabolic Syndrome
154487|NCT02153983|Dyslipidemia
154488|NCT02153970|Clinical Outcomes Measures
154489|NCT02153970|Proxy Reported Outcome
154490|NCT02153970|Pediatric
154491|NCT02153970|Neuromuscular Disease
154492|NCT02153970|Cerebral Palsy
154493|NCT02153957|Exercise
154494|NCT02153957|Memory
154495|NCT02153957|BDNF
154496|NCT02153957|Zamzee
154497|NCT02153957|QOL
154498|NCT02153944|Startle
154499|NCT02153944|Induced-Threat
154500|NCT02153944|Memory
154501|NCT02153944|Stimulant
154502|NCT02153944|Cognitive Interference
154503|NCT02153931|Children's Tumor Foundation
154504|NCT02153931|Social Support
154505|NCT02153931|Online
154506|NCT02153931|Anxiety
154507|NCT02153931|Depression
154508|NCT02153918|Surgery
154509|NCT02153918|Neoadjuvant
154510|NCT02153918|CD8 Cell Infiltrate Response
154511|NCT02153918|CD4 Cell Infiltrate Response
154512|NCT02153918|Vaccine
154513|NCT02153905|Adoptive Cell Therapy
154514|NCT02153905|Metastatic Melanoma
154515|NCT02153905|Metastatic Cancer
154516|NCT02153905|Renal Cancer
154517|NCT02153892|Functional Mitral Regurgitation
154518|NCT02153892|Heart Failure
154519|NCT02153892|Ventricular Reshaping
154520|NCT02153879|HDL
154521|NCT02153879|Niacin
154522|NCT02153879|Fenofibrate
154523|NCT02153879|Diabetes
154524|NCT02153879|Metabolomics
154525|NCT02153866|rotavirus vaccine
154526|NCT02153840|Stable Plaque Psoriasis
154527|NCT02153827|Shoulder
154528|NCT02153827|Eccentric Training
154529|NCT02153827|Subacromial Impingement Syndrome
154530|NCT02153814|Infertility
154531|NCT02153814|In vitro fertilization
154532|NCT02153814|Endometrial injury
154533|NCT02153801|High Ligation, Low ligation, Genito-urinary function, laparoscopy, rectal cancer, aterior resection, Total mesorectal Excision, anastomotic leak.
154534|NCT02153788|Insomnia
154535|NCT02153788|HIV
154536|NCT02153775|Progressive muscle relaxation
154537|NCT02153775|Cigarette
154538|NCT02153775|Smoking
154539|NCT02153775|Craving
154540|NCT02153762|Atopic Dermatitis
154541|NCT02153762|AD
154542|NCT02153723|Treatment trial
154543|NCT02153710|Aphasia
154544|NCT02153710|Anomia
154545|NCT02153697|solar lentigines
154546|NCT02153697|Q-switches Laser
154547|NCT02153697|bleaching cream
154548|NCT02153684|smoking
154549|NCT02153684|small airway dysfunction
154550|NCT02153684|mild COPD
154551|NCT02153684|dyspnea
154552|NCT02153684|exercise
154553|NCT02153684|clinical outcomes
154554|NCT02153671|LAIV H5N2
154555|NCT02153671|Influenza vaccine
154556|NCT02153671|Russia
154557|NCT02153658|PrePex
154558|NCT02153658|Odor
154559|NCT02153658|Cleaning technique
154560|NCT02153658|Male Circumcision
154561|NCT02153658|HIV
154562|NCT02153658|AIDS
154563|NCT02153658|Chlorhexidine
154564|NCT02153658|Soap
154565|NCT02153645|Parkinson's Disease
154566|NCT02153645|Levodopa Induced Dyskinesias (LID)
154567|NCT02153645|Dyskinesias
154568|NCT02153645|Parkinsonism
154569|NCT02153632|Parkinson's Disease
154570|NCT02153632|Levodopa Induced Dyskinesia (LID)
154571|NCT02153632|LID
154572|NCT02153632|Parkinsonism
154573|NCT02153632|Dyskinesia
154574|NCT02153619|Grief
154575|NCT02153619|bereavement
154576|NCT02153619|questionnaires
154577|NCT02153619|therapy sessions
154578|NCT02153619|14-102
154579|NCT02153606|Glycerin Suppositories
154580|NCT02153606|Enteral Nutrition
154581|NCT02153606|Enterocolitis, Necrotizing
154582|NCT02153606|Infant, Premature
154583|NCT02153606|Meconium
154584|NCT02153593|Clinical trial
154585|NCT02153593|Randomized
154586|NCT02153593|Fibrin glue
154587|NCT02153593|Tranexamic acid
154588|NCT02153593|Blood loss
154589|NCT02153567|Functional dyspepsia
154590|NCT02153567|symptom response
154591|NCT02153567|postprandial fullness
154592|NCT02153567|Anxiety
154593|NCT02153567|Depression
154594|NCT02153528|Bangladesh
154595|NCT02153528|Rimfapicin
154596|NCT02153515|Finger prick with diabetic lancet
154597|NCT02153515|Fingerprick
154598|NCT02153515|Fresh
154599|NCT02153515|Your own blood
154600|NCT02153515|autologous blood
154601|NCT02153515|Dry eyes
154602|NCT02153515|Sjogren's disease with dry eyes
154603|NCT02153515|Persistent corneal epithelial defects
154604|NCT02153515|Chronic corneal ulcers
154605|NCT02153463|Tourette Syndrome
154606|NCT02153463|Persistent Tic Disorder
154607|NCT02153463|Physical Activity
154608|NCT02153463|Quality of Life
154609|NCT02153450|pancreatic cancer
154610|NCT02153450|Radiation
154611|NCT02153450|Metformin
154612|NCT02153450|Pancreatic Adenocarcinomas
154613|NCT02153411|Asthma control
154614|NCT02153398|Gastric ulcer (GU)
154615|NCT02153398|Duodenal ulcer (DU)
154616|NCT02153398|Anastomotic ulcer (AU)
154617|NCT02153398|Non-erosive reflux esophagitis disease (NERD)
154618|NCT02153398|Reflux esophagitis (RE)
154619|NCT02153398|Zollinger-Ellison syndrome
154620|NCT02153385|Yoga, heart rate variability, stress, mood, women
154621|NCT02153372|large bone defect, bone marrow-derived mononuclear cells
154622|NCT02153359|asthma
154623|NCT02153359|HEPA
154624|NCT02153359|air pollutants
154625|NCT02153359|lung function
154626|NCT02153359|home environment
154627|NCT02153359|respiratory symptoms
154628|NCT02153359|diet
154629|NCT02153346|indirect cost
154630|NCT02153346|asthma
154631|NCT02153333|Human rotavirus (HRV) vaccine
154632|NCT02153333|Serologic response
154633|NCT02153333|Porcine circovirus type 1 (PCV-1)
154634|NCT02153333|Laboratory evaluations
154635|NCT02153320|HBsAg
154636|NCT02153320|Persistence of the immune response
154637|NCT02153320|Adjuvants
154638|NCT02153294|low tidal volume
154639|NCT02153294|high tidal volume
154640|NCT02153294|protective ventilation
154641|NCT02153294|ARDS
154642|NCT02153281|Depression
154643|NCT02153281|Positron Emission Tomography (PET)
154644|NCT02153281|MAO-B
154645|NCT02153268|Safety
154646|NCT02153268|efficacy
154647|NCT02153268|BonoFill
154648|NCT02153268|bone filler
154649|NCT02153268|autologous adipose tissue derived cells (HATDCs)
154650|NCT02153268|Bone augmentation
154651|NCT02153268|sinus augmentation
154652|NCT02153268|Bone grafting after removal of cysts from jaws
154653|NCT02153255|Morquio
154654|NCT02153255|Mucopolysaccharidosis
154655|NCT02153255|Galactosamine-6-Sulfatase
154656|NCT02153255|GALNS
154657|NCT02153242|Pacing
154658|NCT02153242|Haemodynamics
154659|NCT02153242|Pilot
154660|NCT02153229|Histological diagnosis of MPM
154661|NCT02153229|epitheliod subtype
154662|NCT02153229|limited to the hemithorax
154663|NCT02153229|macroscopically complete resection of the tumor
154664|NCT02153203|Autism spectrum disorder
154665|NCT02153203|Problem behavior
154666|NCT02153190|Type 1 Diabetes,
154667|NCT02153190|T1DM,
154668|NCT02153190|Artificial Pancreas
154669|NCT02153177|Randomized Controlled Trial (RCT)
154670|NCT02153177|RCT
154671|NCT02153177|rotator cuff tear
154672|NCT02153177|NSAIDs
154673|NCT02153177|non-steroidal anti-inflammatory drugs
154674|NCT02153177|rotator cuff repair
154675|NCT02153164|Enthalpy
154676|NCT02153164|Trendelenberg position
154677|NCT02153164|Mechanical ventilation
154678|NCT02153138|vegetarian diet
154679|NCT02153138|vegan
154680|NCT02153138|cardiovascular diseases
154681|NCT02153138|endothelial function
154682|NCT02153138|carotid intima-media thickness
154683|NCT02153112|Drug therapy
154684|NCT02153099|Drug therapy
154685|NCT02153086|Pharmacological therapy
154686|NCT02153073|Pharmacological therapy
154687|NCT02153060|immune thrombocytopenia
154688|NCT02153060|dexamethasone
154689|NCT02153060|efficacy
154690|NCT02153060|safety
154691|NCT02153047|Smoking cessation
154692|NCT02153047|Spirometry
154693|NCT02153047|Primary health care
154694|NCT02153034|Buruli ulcer
154695|NCT02153034|Mycobacterium ulcerans disease
154696|NCT02153034|M. ulcerans disease
154697|NCT02153021|anthropometric parameters;
154698|NCT02153021|biochemical parameters;
154699|NCT02153021|inflammatory markers
154700|NCT02153021|neuropeptide markers
154701|NCT02153021|phototherapy
154702|NCT02153008|Strep throat
154703|NCT02152956|AML
154704|NCT02152956|leukemia
154705|NCT02152956|myelogenous
154706|NCT02152956|myeloid
154707|NCT02152956|refractory
154708|NCT02152956|MDS
154709|NCT02152956|Myelodysplastic
154710|NCT02152943|Breast Cancer
154711|NCT02152943|Advanced Metastatic Breast Cancer
154712|NCT02152943|Solid Tumors
154713|NCT02152943|Advanced Solid Tumors
154714|NCT02152943|Everolimus
154715|NCT02152943|Afinitor
154716|NCT02152943|Zortress
154717|NCT02152943|RAD001
154718|NCT02152943|Trastuzumab
154719|NCT02152943|Herceptin
154720|NCT02152943|Letrozole
154721|NCT02152943|Femara
154722|NCT02152930|Fish oil supplements
154723|NCT02152930|Supervised Exercise Training
154724|NCT02152930|Walking distance
154725|NCT02152930|Hemorheological factors
154726|NCT02152930|Cardiovascular risk
154727|NCT02152904|Peptic ulcer bleeding
154728|NCT02152904|rebleeding
154729|NCT02152904|mortality
154730|NCT02152904|nationwide
154731|NCT02152891|Emergency Medical Services
154732|NCT02152891|Elderly
154733|NCT02152878|transcranial direct current stimulation
154734|NCT02152878|non invasive brain stimulation
154735|NCT02152878|bipolar disorder
154736|NCT02152878|depression
154737|NCT02152865|medication
154738|NCT02152852|Type 2 Diabetes
154739|NCT02152826|Sensitivity
154740|NCT02152813|Electrical stimulation, exercise, stroke , rehabilitation
154741|NCT02152787|emergence agitation
154742|NCT02152787|propofol
154743|NCT02152787|strabismus surgery
154744|NCT02152787|children
154745|NCT02152787|elective strabismus surgery
154746|NCT02152761|bimagrumab,
154747|NCT02152761|BYM338,
154748|NCT02152761|hip fracture,
154749|NCT02152761|elderly,
154750|NCT02152761|controlled clinical trial,
154751|NCT02152761|randomized,
154752|NCT02152761|muscle wasting (atrophy)
154753|NCT02152748|glioblastoma
154754|NCT02152748|morphological and molecular changes
154755|NCT02152748|progression
154756|NCT02152748|therapy-resistance
154757|NCT02152722|Breath test
154758|NCT02152722|Volatile Organic Compounds
154759|NCT02152722|VOC
154760|NCT02152722|oxidative stress
154761|NCT02152722|radiation biodosimetry
154762|NCT02152722|metabolomics
154763|NCT02152722|GCxGC TOF-MS
154764|NCT02152709|Safety
154765|NCT02152709|Immunogenicity
154766|NCT02152709|Vaccine
154767|NCT02152709|Hepatitis B
154768|NCT02152657|Spinal cord injury
154769|NCT02152657|Stem cell transplantation
154770|NCT02152657|Mesenchymal stem cell
154771|NCT02152644|amyloidosis-carpal tunnel
154772|NCT02152631|Therapy, Platinum, Kras +
154773|NCT02152618|Serious emotional disturbance
154774|NCT02152618|foster care
154775|NCT02152618|child protective services
154776|NCT02152605|SGRQ
154777|NCT02152605|vilanterol
154778|NCT02152605|long-acting beta2-agonist
154779|NCT02152605|long-acting muscarinic antagonist
154780|NCT02152605|COPD
154781|NCT02152605|umeclidinium
154782|NCT02152592|Postoperative pain
154783|NCT02152592|Ambulatory surgery
154784|NCT02152592|NSAIDS
154785|NCT02152592|CR Oxycodone
154786|NCT02152592|Compliance to study medication
154787|NCT02152579|Stable Angina
154788|NCT02152553|Biomarker
154789|NCT02152553|Glucocorticoids
154790|NCT02152553|Metabolism
154791|NCT02152553|Pharmacology
154792|NCT02152553|Metabolomics
154793|NCT02152540|TBI
154794|NCT02152540|Transcranial Magnetic Stimulation, Repetitive
154795|NCT02152540|magnetic resonance imaging functional
154796|NCT02152540|Quality of life
154797|NCT02152540|Executive Function
154798|NCT02152540|Veterans
154799|NCT02152501|obese
154800|NCT02152501|overweight
154801|NCT02152501|exercise
154802|NCT02152501|energy expenditure differences
154803|NCT02152501|relative reinforcing values (RRV)
154804|NCT02152501|food
154805|NCT02152501|physical activity
154806|NCT02152501|biological
154807|NCT02152501|neurobehavioral
154808|NCT02152501|behavioral
154809|NCT02152488|cerebral blood flow
154810|NCT02152488|position
154811|NCT02152488|cervical spine
154812|NCT02152475|Blue-LED
154813|NCT02152475|Curcumin
154814|NCT02152475|PDT
154815|NCT02152475|Oral disinfection
154816|NCT02152462|exergaming
154817|NCT02152462|breast cancer
154818|NCT02152462|African American women
154819|NCT02152462|obesity
154820|NCT02152423|enoxaparin
154821|NCT02152423|Enoxamed
154822|NCT02152423|lovenox
154823|NCT02152423|anti Xa
154824|NCT02152423|acute coronary syndrome
154825|NCT02152410|acupuncture
154826|NCT02152410|renal colic
154827|NCT02152358|Cytomegalovirus
154828|NCT02152358|Herpes simplex virus
154829|NCT02152358|ICU
154830|NCT02152358|mechanical ventilation
154831|NCT02152358|mortality
154832|NCT02152358|ventilator-free days
154833|NCT02152358|PCR
154834|NCT02152345|kidney
154835|NCT02152345|renal
154836|NCT02152345|transplant
154837|NCT02152345|belatacept
154838|NCT02152345|delayed graft function
154839|NCT02152345|thymoglobulin
154840|NCT02152345|tacrolimus
154841|NCT02152345|kidney function
154842|NCT02152345|immunosuppression
154843|NCT02152345|NGAL
154844|NCT02152332|JNJ-54861912
154845|NCT02152332|RSC-385896
154846|NCT02152332|MTS-0385896A
154847|NCT02152332|Phase 1
154848|NCT02152332|Moxifloxacin
154849|NCT02152332|Placebo
154850|NCT02152332|Healthy
154851|NCT02152319|Parkinson's disease
154852|NCT02152319|Telemedicine
154853|NCT02152319|Telehealth
154854|NCT02152319|Kinesia
154855|NCT02152319|Tremor
154856|NCT02152319|Bradykinesia
154857|NCT02152319|Dyskinesia
154858|NCT02152306|Fimasartan
154859|NCT02152306|Fimasartan and Amlodipine
154860|NCT02152306|Antihypertension
154861|NCT02152267|Temporomandibular
154862|NCT02152267|Musculoskeletal Diseases
154863|NCT02152267|Electrical Stimulation of the Brain
154864|NCT02152267|Prefrontal Cortex
154865|NCT02152254|Metastatic Cancer
154866|NCT02152254|Molecular Profiling
154867|NCT02152254|Genomic alteration analysis of the tumor
154868|NCT02152254|Advanced Cancer Therapy
154869|NCT02152254|Gene mutations
154870|NCT02152254|Tumor biopsy
154871|NCT02152254|Personalized medicine
154872|NCT02152241|IBD
154873|NCT02152241|Crohn
154874|NCT02152241|Colitis
154875|NCT02152241|Function
154876|NCT02152176|pain
154877|NCT02152176|analgesia
154878|NCT02152176|morphine
154879|NCT02152176|PCA
154880|NCT02152176|Nurse
154881|NCT02152163|Assessing the efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients
154882|NCT02152150|iron
154883|NCT02152150|anemia
154884|NCT02152150|bio-fortification
154885|NCT02152150|children
154886|NCT02152150|India
154887|NCT02152124|Acromegaly
154888|NCT02152124|Acromegaly treatment
154889|NCT02152124|Long-acting somatostatin analogs
154890|NCT02152124|Pegvisomant
154891|NCT02152124|Insulin sensitivity
154892|NCT02152124|Gut hormones
154893|NCT02152124|Lipid metabolism
154894|NCT02152124|Adipokines
154895|NCT02152111|Obesity
154896|NCT02152111|Coconut flour
154897|NCT02152111|Diet quality
154898|NCT02152111|Cardiovascular risk factor
154899|NCT02152085|Walking
154900|NCT02152085|Mobility
154901|NCT02152085|Neuromuscular electrical stimulation
154902|NCT02152085|Multiple sclerosis
154903|NCT02152059|Small cell lung cancer
154904|NCT02152059|BIBF1120
154905|NCT02152059|nintedanib
154906|NCT02152059|platinum-sensitive
154907|NCT02152033|Substance Abuse
154908|NCT02152033|Continuing Care
154909|NCT02152033|Recovery
154910|NCT02152033|Substance Abuse Treatment
154911|NCT02152033|Parent
154912|NCT02152033|Family
154913|NCT02152033|Young Adult
154914|NCT02152007|pachyonychia congenita
154915|NCT02151994|BIA 5-1058
154916|NCT02151994|hypertension
154917|NCT02151994|chronic heart failure
154918|NCT02151994|cardiovascular disorders
154919|NCT02151981|Advanced Non-Small Cell Lung Cancer; T790M Mutation Positive
154920|NCT02151942|elective endovascular AAA repair
154921|NCT02151929|myocardial infarction
154922|NCT02151929|primary PCI
154923|NCT02151929|stent
154924|NCT02151916|dental caries
154925|NCT02151916|early childhood caries
154926|NCT02151916|topical fluorides
154927|NCT02151916|fluoride varnish
154928|NCT02151903|NHL
154929|NCT02151903|Immunocytokine
154930|NCT02151903|Lymphoma
154931|NCT02151903|Non-Hodgkin
154932|NCT02151903|B-cell
154933|NCT02151903|IL (interleukin)
154934|NCT02151890|POF
154935|NCT02151890|ESS
154936|NCT02151890|stem cell
154937|NCT02151877|Ischemia/reperfusion injury
154938|NCT02151864|liver cancer
154939|NCT02151864|cirrhosis
154940|NCT02151864|Child-Pugh A
154941|NCT02151864|Hedgehog
154942|NCT02151851|Rheumatoid Arthritis
154943|NCT02151851|TNFα antagonist
154944|NCT02151851|Certolizumab Pegol
154945|NCT02151851|Chinese patients
154946|NCT02151838|HIV-infected pregnant women who request HAART from the TRCSPMTCT
154947|NCT02151825|Gut microbiota
154948|NCT02151825|Probiotics
154949|NCT02151825|Prebiotics
154950|NCT02151825|Synbiotic
154951|NCT02151825|Bifidobacterium lactis BB-12
154952|NCT02151825|Lactobacillus acidophilus LA-5
154953|NCT02151825|Lactobacillus casei 431
154954|NCT02151825|Inulin
154955|NCT02151825|GOS
154956|NCT02151825|Body Weight
154957|NCT02151825|Overweight
154958|NCT02151825|Adiposity
154959|NCT02151825|Obesity
154960|NCT02151825|ANGPTL4
154961|NCT02151786|Pharmacological therapy
154962|NCT02151773|Pharmacological therapy
154963|NCT02151760|Metastatic Prostate Cancer
154964|NCT02151747|breast neoplasms, BRCA1, Sanger, NGS, Next generation sequencing
154965|NCT02151721|Vorinostat
154966|NCT02151721|Gefitinib
154967|NCT02151721|BIM polymorphism
154968|NCT02151721|EGFR-TKI resistance
154969|NCT02151708|accommodation, emptying,motilitone
154970|NCT02151682|chronic pain
154971|NCT02151682|opioid
154972|NCT02151669|Mediterranean diet
154973|NCT02151669|Smoking/tobacco
154974|NCT02151669|Spirometry
154975|NCT02151656|Schizophrenia
154976|NCT02151656|Mental disorders
154977|NCT02151656|Antipsychotic Drugs
154978|NCT02151643|Dialysis Dependent Chronic Kidney Disease
154979|NCT02151630|wart
154980|NCT02151630|verruca vulgaris
154981|NCT02151630|topical therapy
154982|NCT02151630|pyruvic acid
154983|NCT02151630|salicylic acid
154984|NCT02151617|Multiple dose
154985|NCT02151617|safety
154986|NCT02151617|tolerability
154987|NCT02151617|PK
154988|NCT02151591|Quit smoking
154989|NCT02151591|Quit drinking
154990|NCT02151578|Impact of home management of malaria and pneumonia on child mortality
154991|NCT02151578|home management of malaria and pneumonia
154992|NCT02151565|back pain
154993|NCT02151565|sciatica
154994|NCT02151565|electrotherapy
154995|NCT02151565|HTEMS
154996|NCT02151565|TENS
154997|NCT02151552|lung inflammation
154998|NCT02151552|positron emission tomography
154999|NCT02151552|inducible nitric oxide synthase
155000|NCT02151513|Cancer-associated pain
155001|NCT02151513|Immune function
155002|NCT02151500|Medically Unexplained Symptoms (MUPS)
155003|NCT02151500|Somatoform disorders
155004|NCT02151500|Chronic pain
155005|NCT02151500|Somatic symptoms
155006|NCT02151500|Emotional processing
155007|NCT02151500|Primary Care
155008|NCT02151487|Supraclavicular block
155009|NCT02151487|Ropivacaine
155010|NCT02151487|Dexamethasone
155011|NCT02151487|Clonidine
155012|NCT02151461|Diabetes
155013|NCT02151461|Type 2 Diabetes
155014|NCT02151435|Idiopathic Pulmonary Fibrosis
155015|NCT02151435|Biomarkers
155016|NCT02151435|Forced Vital Capacity
155017|NCT02151435|Diffusion Capacity for Carbon Monoxide
155018|NCT02151435|Prognosis
155019|NCT02151422|Adults
155020|NCT02151422|age 18-65
155021|NCT02151422|physician-diagnosed
155022|NCT02151422|persistent asthma
155023|NCT02151396|ADHD, hyperactivity, inattention, working memory
155024|NCT02151383|Acute heart failure,
155025|NCT02151383|RELAX−AHF−PEDIATRIC PK
155026|NCT02151357|first in man
155027|NCT02151357|dose escalating
155028|NCT02151357|MTD
155029|NCT02151357|DLT
155030|NCT02151331|Chronic care model
155031|NCT02151331|Mood disorders
155032|NCT02151331|Adaptive implementation
155033|NCT02151279|Shrimp allergy
155034|NCT02151279|Chitosan
155035|NCT02151279|fining agent
155036|NCT02151266|Heart failure
155037|NCT02151266|Exercise
155038|NCT02151266|Cognitive training
155039|NCT02151253|Nocturia
155040|NCT02151253|Daytime sleepiness
155041|NCT02151240|herpes zoster, Foscarnet Sodium, Acyclovir, Postherpetic neuralgia
155042|NCT02151227|Meta-Analysis
155043|NCT02151227|Metabolic Syndrome
155044|NCT02151227|Magnesium
155045|NCT02151227|Dose Response Effect
155046|NCT02151227|Systematic Review
155047|NCT02151214|Palliative Phase of Cancer
155048|NCT02151214|Quality of life
155049|NCT02151214|Parenteral nutrition
155050|NCT02151214|Undernutrition
155051|NCT02151201|pregnancy vaccination influenza education
155052|NCT02151149|NSCLC advanced non-small cell lung cancer squamous adenocarcinoma large cell carcinoma lung cancer elderly first line treatment abraxane carbo nab-paclitaxel
155053|NCT02151136|Sucrose
155054|NCT02151136|Pain
155055|NCT02151123|Colonic Neoplasms
155056|NCT02151123|Colon Cancer
155057|NCT02151123|Microbiome
155058|NCT02151110|Healthy Male
155059|NCT02151110|Healthy Female of non child bearing potential
155060|NCT02151097|Prostatectomy
155061|NCT02151097|Prostate cancer
155062|NCT02151097|Cerenkov Luminescence Imaging
155063|NCT02151084|randomized
155064|NCT02151084|selumetinib
155065|NCT02151084|tablets
155066|NCT02151084|cisplatin
155067|NCT02151084|gemcitabine
155068|NCT02151084|non-resectable
155069|NCT02151084|recurrent
155070|NCT02151084|metstatic
155071|NCT02151071|Breast Cancer
155072|NCT02151071|Mastectomy, Segmental
155073|NCT02151071|Breast Conserving Surgery
155074|NCT02151071|Cerenkov Luminescence Imaging
155075|NCT02151071|Beta particle detection
155076|NCT02151058|Staining
155077|NCT02151058|Intensity
155078|NCT02151058|Area
155079|NCT02151045|Epidural infiltration of Corticoids
155080|NCT02151045|L3-L4 stage
155081|NCT02151045|On contact of disco radicular conflict
155082|NCT02151045|Scan control
155083|NCT02151032|Colorectal Cancer
155084|NCT02151032|Colorectal cancer screening
155085|NCT02151032|Multimedia
155086|NCT02151032|Booklet
155087|NCT02151032|Pamphlet
155088|NCT02151032|Audio CD
155089|NCT02151032|Video with animated images
155090|NCT02151032|Video with non-moving images
155091|NCT02151032|Questionnaires
155092|NCT02151032|Surveys
155093|NCT02151006|DHEA
155094|NCT02151006|IVF
155095|NCT02151006|ICSI
155096|NCT02150993|Africa
155097|NCT02150993|Antiretroviral Treatment
155098|NCT02150993|HIV-2
155099|NCT02150993|firsts line ART
155100|NCT02150993|Adults
155101|NCT02150980|Fractures
155102|NCT02150980|burden of fractures
155103|NCT02150980|orthopaedic fractures
155104|NCT02150980|orthopaedic injuries
155105|NCT02150980|orthopaedic trauma
155106|NCT02150980|observational study
155107|NCT02150980|outcomes of fracture care
155108|NCT02150980|epidemiology
155109|NCT02150967|cholangiocarcinoma,
155110|NCT02150967|FGFR2 gene fusion,
155111|NCT02150967|FGFR genetic alteration
155112|NCT02150954|induction of labor
155113|NCT02150954|pitocin
155114|NCT02150954|foley bulb
155115|NCT02150941|Upper gastrointestinal tract
155116|NCT02150941|Endoscopy
155117|NCT02150941|Endoscopic Hemostasis
155118|NCT02150915|Acupoints
155119|NCT02150915|Acupuncture therapy
155120|NCT02150915|Median nerve
155121|NCT02150915|Biomechanics
155122|NCT02150902|Catheter ablation for atrial fibrillation
155123|NCT02150902|treatment for atrial fibrillation
155124|NCT02150902|comparison of catheter ablation techniques for atrial fibrillation
155125|NCT02150889|insulin resistance
155126|NCT02150889|lipid metabolism
155127|NCT02150889|diabetes
155128|NCT02150876|DES
155129|NCT02150876|SDF
155130|NCT02150876|MACE
155131|NCT02150876|SYNERGY
155132|NCT02150863|actinic keratosis
155133|NCT02150863|field cancerization
155134|NCT02150863|organ transplant patients
155135|NCT02150850|Femoral Fractures
155136|NCT02150850|Subtrochanteric Fractures
155137|NCT02150850|Osteoporotic Fractures
155138|NCT02150850|Fractures, Spontaneous
155139|NCT02150850|Stress Fractures
155140|NCT02150850|Bone Fractures
155141|NCT02150850|Hip Fractures
155142|NCT02150850|Osteoporosis
155143|NCT02150837|Obesity
155144|NCT02150837|Weight Loss
155145|NCT02150837|Meal replacements
155146|NCT02150837|Weight maintenance
155147|NCT02150798|Diet Therapy
155148|NCT02150798|Diet, Carbohydrate Restricted
155149|NCT02150798|Fatty Acids, Omega 3
155150|NCT02150798|Oximetry
155151|NCT02150798|phase angle
155152|NCT02150798|Triglycerides, blood
155153|NCT02150798|Lipids, blood
155154|NCT02150798|Hand Strength
155155|NCT02150798|Body Composition
155156|NCT02150798|Electric Impedance
155157|NCT02150785|Thrombolysis
155158|NCT02150785|Safety of Streptokinase
155159|NCT02150785|tissue plasminogen activator tPA
155160|NCT02150785|Stroke treatment
155161|NCT02150759|Dexmedetomidine
155162|NCT02150759|Ketamine
155163|NCT02150759|Pain
155164|NCT02150746|Pancreatic ductal adenocarcinoma
155165|NCT02150746|Pancreatic cancer
155166|NCT02150746|PDAC
155167|NCT02150746|Circulating tumor cells
155168|NCT02150720|Hip fractures
155169|NCT02150720|Clinical Trial
155170|NCT02150720|Randomized
155171|NCT02150720|Fibrin glue
155172|NCT02150720|Tranexamic acid
155173|NCT02150720|Blood loss
155174|NCT02150681|preconception
155175|NCT02150681|pregnancy
155176|NCT02150681|postpartum
155177|NCT02150681|women
155178|NCT02150668|ADHD
155179|NCT02150668|Homework
155180|NCT02150668|School
155181|NCT02150668|Organization
155182|NCT02150668|Time-management
155183|NCT02150616|Pulmonary hypertension
155184|NCT02150616|Interstitial lung disease
155185|NCT02150616|Pulmonary fibrosis
155186|NCT02150603|Heart defects, congenital
155187|NCT02150603|Patient-reported outcomes
155188|NCT02150603|Health status
155189|NCT02150603|Factors, psychosocial
155190|NCT02150603|Health behavior
155191|NCT02150603|Quality of life
155192|NCT02150603|Sense of coherence
155193|NCT02150603|Illness perceptions
155194|NCT02150603|Depression
155195|NCT02150603|Anxiety
155196|NCT02150590|airway disease
155197|NCT02150590|bronchitis
155198|NCT02150590|emphysema
155199|NCT02150590|lung
155200|NCT02150577|Screening
155201|NCT02150577|Mood Stabilizers
155202|NCT02150577|Computer delivered psychotherapy
155203|NCT02150577|Peer Support
155204|NCT02150577|Telepsychiatry
155205|NCT02150577|Implementation
155206|NCT02150577|Rural
155207|NCT02150564|Malignant gliomas
155208|NCT02150564|Sono RCT
155209|NCT02150551|Crohn disease
155210|NCT02150551|ulcerative colitis
155211|NCT02150551|mesenchymal stromal cells
155212|NCT02150551|inflammatory bowel diseases
155213|NCT02150538|Cardiac Resynchronization therapy
155214|NCT02150538|Minimized Right ventricular pacing
155215|NCT02150538|Prolonged AV conduction
155216|NCT02150525|breast cancer
155217|NCT02150525|vaginal dryness
155218|NCT02150525|dyspareunia
155219|NCT02150525|genital irritation
155220|NCT02150512|Septic shock
155221|NCT02150512|Critically ill patients
155222|NCT02150512|Transpulmonary thermodilution
155223|NCT02150512|Fluid resuscitation
155224|NCT02150499|Acute Asthma exacerbation
155225|NCT02150473|rheumatoid Arthritis
155226|NCT02150460|ophthalmic surgery, peribulbar local anaesthesia
155227|NCT02150447|Gastric cancer bleeding
155228|NCT02150447|Proton pump inhibitor
155229|NCT02150434|Oxygen therapy
155230|NCT02150434|Hypoxemia
155231|NCT02150434|COPD
155232|NCT02150434|Closed-loop
155233|NCT02150434|Automated titration,
155234|NCT02150382|hypertension
155235|NCT02150382|rural
155236|NCT02150382|China
155237|NCT02150382|protocol-based treatment
155238|NCT02150343|Cat allergy
155239|NCT02150343|Rhinoconjunctivitis
155240|NCT02150330|Dehydroepiandrosterone
155241|NCT02150330|DHEAS
155242|NCT02150330|Gene expression of cumulus cells.
155243|NCT02150330|Folliculogenesis.
155244|NCT02150330|Oocyte maturation.
155245|NCT02150330|Ovarian hyper-stimulation protocol.
155246|NCT02150330|Artificial reproduction technology.
155247|NCT02150317|Carcinoma, Hepatocellular
155248|NCT02150317|Chemoembolization, Therapeutic
155249|NCT02150317|Sorafenib
155250|NCT02150278|Driving
155251|NCT02150278|Alcohol consumption
155252|NCT02150278|Risk perception
155253|NCT02150252|Clinical trial
155254|NCT02150252|Ischemic stroke
155255|NCT02150252|Bu-Yang-Huan-Wu Tang (BYHWT）
155256|NCT02150252|Gait parameter
155257|NCT02150252|Quality of life
155258|NCT02150239|pain
155259|NCT02150239|postoperative
155260|NCT02150213|Adrenocortical Adenoma,
155261|NCT02150213|Endometrial Stromal sarcomas
155262|NCT02150213|BGG492
155263|NCT02150187|Androgenetic Alopecia
155264|NCT02150187|Male
155265|NCT02150187|Baldness
155266|NCT02150187|hair loss pattern
155267|NCT02150174|Schizophrenia
155268|NCT02150174|Episodic memory deficits
155269|NCT02150148|breast cancer
155270|NCT02150148|prostate cancer
155271|NCT02150148|colorectal cancer
155272|NCT02150148|small intestine cancer
155273|NCT02150148|thyroid cancer
155274|NCT02150148|Hodgkin lymphoma
155275|NCT02150148|non-Hodgkin lymphoma
155276|NCT02150148|endometrial cancer
155277|NCT02150148|kidney cancer
155278|NCT02150148|cervical cancer
155279|NCT02150148|diet
155280|NCT02150148|exercise
155281|NCT02150148|physical activity
155282|NCT02150148|garden
155283|NCT02150135|Pancreatic cancer
155284|NCT02150135|Quality of life
155285|NCT02150135|Pain
155286|NCT02150122|Vitamin D
155287|NCT02150122|Serum 25-hydroxyvitamin D (25OHD)
155288|NCT02150122|Adolescents
155289|NCT02150096|chronic non-specific low back pain
155290|NCT02150096|clinical trial
155291|NCT02150096|disability
155292|NCT02150096|women
155293|NCT02150083|midurethral sling
155294|NCT02150083|voiding study
155295|NCT02150083|voiding trial
155296|NCT02150083|retrograde voiding trial
155297|NCT02150070|Healthy subjects
155298|NCT02150070|ASP2408
155299|NCT02150070|Rheumatoid arthritis
155300|NCT02150070|Safety and Tolerability
155301|NCT02150070|Pharmacokinetics
155302|NCT02150057|knee osteoarthritis unicompartmental unloading brace
155303|NCT02150031|prevention and control
155304|NCT02150031|chlorhexidine
155305|NCT02150031|therapeutic irrigation
155306|NCT02150031|mouthwashes
155307|NCT02150031|culture
155308|NCT02150018|- Critical Care
155309|NCT02150018|Non invasive ventilation
155310|NCT02150018|Electrical impedance tomography
155311|NCT02150018|End expiratory lung volume
155312|NCT02150018|End expiratory lung impedance
155313|NCT02150005|periodontal diseases
155314|NCT02150005|cardiovascular diseases
155315|NCT02150005|periodontitis treatment
155316|NCT02149992|gestational diabetes
155317|NCT02149992|myoinositol
155318|NCT02149979|Incision
155319|NCT02149979|Wound Closure
155320|NCT02149979|Laser Tissue Soldering
155321|NCT02149966|safety and tolerability
155322|NCT02149966|pharmacokinetic study
155323|NCT02149953|Pregnancy
155324|NCT02149953|Glycine requirements
155325|NCT02149953|Indicator Amino Acid Oxidation (IAAO) method
155326|NCT02149953|Stable isotopes
155327|NCT02149940|Elderly
155328|NCT02149940|Frailty
155329|NCT02149940|Polypharmacy
155330|NCT02149940|Medication review
155331|NCT02149940|Clinical pharmacy services
155332|NCT02149927|EEG
155333|NCT02149927|fMRI
155334|NCT02149927|connectivity
155335|NCT02149927|sevoflurane
155336|NCT02149914|Ryodoraku
155337|NCT02149914|Meridian energy
155338|NCT02149914|Heart rate variability
155339|NCT02149914|Autonomic Nervous System
155340|NCT02149914|GERD
155341|NCT02149901|Pure Autonomic Failure
155342|NCT02149901|Multiple System Atrophy
155343|NCT02149901|Pseudoephedrine
155344|NCT02149901|Water
155345|NCT02149901|Osmopressor
155346|NCT02149888|HIV
155347|NCT02149888|Pre-Exposure Prophylaxis
155348|NCT02149888|PrEP
155349|NCT02149888|Human Immunodeficiency Virus
155350|NCT02149875|Acute ischemic stroke
155351|NCT02149875|Dl-3-n-butylphthalide
155352|NCT02149875|Cerebrolysin
155353|NCT02149862|Bladder cancer
155354|NCT02149862|Diagnostic
155355|NCT02149862|Infrared
155356|NCT02149862|Spectrum
155357|NCT02149862|Urina
155358|NCT02149862|Patients with an indication of partial or total bladder resection
155359|NCT02149862|or
155360|NCT02149862|"Lithiasic patients should be operated a urinary calculation, without catheter double J"
155361|NCT02149849|Ipsilateral shoulder pain
155362|NCT02149849|Surgical positioning
155363|NCT02149849|Lung cancer
155364|NCT02149849|Thoracotomy
155365|NCT02149849|Video assisted thoracic surgery
155366|NCT02149836|major depressive disorder
155367|NCT02149836|depression
155368|NCT02149836|treatment resistent depression
155369|NCT02149823|Oxytocin, Social Cognition
155370|NCT02149823|Borderline Personality Disorder
155371|NCT02149823|Schizotypal Personality Disorder
155372|NCT02149823|Social Cognition
155373|NCT02149823|BPD
155374|NCT02149823|SPD
155375|NCT02149823|MASC
155376|NCT02149810|MDD
155377|NCT02149784|Metastasis colorectal cancer
155378|NCT02149784|Chemotherapy
155379|NCT02149784|Resection of primary tumor
155380|NCT02149771|hepatocellular carcinoma
155381|NCT02149771|portal vein tumor thrombosis
155382|NCT02149771|stents
155383|NCT02149771|chemoembolization
155384|NCT02149758|Cyclooxygenase two inhibitors
155385|NCT02149758|Etoricoxib
155386|NCT02149758|Periodontitis
155387|NCT02149758|Superoxide dismutase
155388|NCT02149758|Saliva
155389|NCT02149732|Limbal stem cell deficiency
155390|NCT02149732|Cultivated oral mucosal cell sheet transplantation
155391|NCT02149732|Ocular surface reconstruction
155392|NCT02149719|Peanut allergy
155393|NCT02149719|Desensitisation
155394|NCT02149719|Safety
155395|NCT02149706|Secondary Progress Multiple Sclerosis
155396|NCT02149706|SPMS
155397|NCT02149706|Multiple Sclerosis
155398|NCT02149706|NeuroVax
155399|NCT02149693|Flipped classroom
155400|NCT02149693|High-fidelity simulation
155401|NCT02149693|Medical education reform
155402|NCT02149693|Medical teamwork
155403|NCT02149693|Resuscitation training
155404|NCT02149680|Post-dural puncture headache
155405|NCT02149680|epidural blood patch
155406|NCT02149680|labour analgesia
155407|NCT02149680|epidural analgesia
155408|NCT02149667|osteoarthritis
155409|NCT02149667|avascular necrosis
155410|NCT02149667|ankylosis
155411|NCT02149667|protrusio acetabuli
155412|NCT02149667|painful hip dysplasia
155413|NCT02149667|rheumatoid arthritis
155414|NCT02149667|correction of functional deformity
155415|NCT02149667|revision procedures
155416|NCT02149654|Transcatheter aortic valve implantation
155417|NCT02149654|Transcatheter aortic valve replacement
155418|NCT02149654|Engager transcatheter aortic valve implantation system
155419|NCT02149654|Engager bioprosthesis
155420|NCT02149615|idiopathic intracranial hypertension
155421|NCT02149615|optic disc swelling
155422|NCT02149615|antiacne medication
155423|NCT02149615|isotretinoin
155424|NCT02149602|involvement of bilateral parapharyngeal spaces
155425|NCT02149589|ARDS
155426|NCT02149589|PEEP
155427|NCT02149589|Recruitment manoeuvres
155428|NCT02149589|Lung Morphology
155429|NCT02149576|Retrospective Review
155430|NCT02149576|Pilot Study
155431|NCT02149576|Early Stage NSCLC
155432|NCT02149576|Post-Surgical Surveillance
155433|NCT02149576|Re-intervention Rates
155434|NCT02149550|Plasmodium falciparum
155435|NCT02149550|malaria
155436|NCT02149537|sickle cell disease
155437|NCT02149537|sickle cell anemia
155438|NCT02149537|hydroxyurea
155439|NCT02149537|Nigeria
155440|NCT02149537|low income country
155441|NCT02149537|middle income country
155442|NCT02149537|developing country
155443|NCT02149524|HER2 Positive Breast Cancer
155444|NCT02149524|Trastuzumab
155445|NCT02149524|Biosimilar
155446|NCT02149498|Parkinson
155447|NCT02149498|EEG
155448|NCT02149498|BNA
155449|NCT02149485|PGD,
155450|NCT02149485|follow up
155451|NCT02149459|Radiotherapy
155452|NCT02149459|Ketosis
155453|NCT02149459|Metformin
155454|NCT02149459|Magnetic Resonance Imaging
155455|NCT02149459|Metabolome
155456|NCT02149459|Insulin
155457|NCT02149459|recurrent brain tumors
155458|NCT02149459|gliomas
155459|NCT02149459|glioblastomas
155460|NCT02149459|astrocytomas
155461|NCT02149446|Left sided pancreatic resections
155462|NCT02149446|Distal pancreatic resections
155463|NCT02149446|Reinforced staple line
155464|NCT02149446|Post operative pancreatic fistula
155465|NCT02149433|Pneumocystis Jiroveci
155466|NCT02149433|Steroids
155467|NCT02149433|Infants
155468|NCT02149420|primary Sjögren's syndrome, pharmacodynamics
155469|NCT02149394|Thirst
155470|NCT02149394|Ice
155471|NCT02149394|Water
155472|NCT02149394|Perioperative Nursing
155473|NCT02149394|Recovery Room
155474|NCT02149381|Depression
155475|NCT02149381|treatment as usual
155476|NCT02149381|CBASP
155477|NCT02149381|befriending
155478|NCT02149355|teeth position
155479|NCT02149355|jaw alignment
155480|NCT02149342|Actinic keratoses
155481|NCT02149342|Daylight-PDT
155482|NCT02149342|Hexylaminolaevulinate
155483|NCT02149342|HAL
155484|NCT02149342|Methylaminolaevulinate
155485|NCT02149342|MAL
155486|NCT02149342|Hyperspectral imaging
155487|NCT02149329|fever
155488|NCT02149329|neutropenia
155489|NCT02149329|febrile neutropenia
155490|NCT02149329|carbapenem
155491|NCT02149329|imipenem
155492|NCT02149329|meropenem
155493|NCT02149329|antibiotic stewardship
155494|NCT02149329|hematology
155495|NCT02149329|oncology
155496|NCT02149290|Heart Failure
155497|NCT02149290|Six minute walk test
155498|NCT02149277|Infertility
155499|NCT02149277|IVF
155500|NCT02149277|Embryo transfer
155501|NCT02149251|Pre-genetic diagnosis
155502|NCT02149251|ICSI
155503|NCT02149238|flavanols
155504|NCT02149238|cardiovascular effects
155505|NCT02149238|nutrition-nutrition interaction
155506|NCT02149225|Actively personalized peptide vaccinations
155507|NCT02149225|Newly diagnosed Glioblastoma
155508|NCT02149225|Concurrent to first line temozolomide maintenance therapy
155509|NCT02149212|Iliac
155510|NCT02149212|Vein
155511|NCT02149212|Stent
155512|NCT02149160|Histone deacetylase inhibitor
155513|NCT02149160|Frontotemporal dementia
155514|NCT02149160|Granulin
155515|NCT02149147|physical activity
155516|NCT02149147|environmental factors
155517|NCT02149147|variety
155518|NCT02149147|MVPA
155519|NCT02149095|treprostinil
155520|NCT02149082|Intracranial hematoma
155521|NCT02149082|traumatic brain injury
155522|NCT02149082|Near infrared spectroscopy
155523|NCT02149082|NIRS
155524|NCT02149056|Platelets/Lymphocytes Rate;Serological Index;
155525|NCT02149043|inflammatory bowel disease
155526|NCT02149043|ulcerative colitis
155527|NCT02149043|thermography
155528|NCT02149043|endoscopy
155529|NCT02149043|CRP
155530|NCT02149017|amyloid plaque
155531|NCT02149017|Positron-Emission Tomography
155532|NCT02149017|radiopharmaceuticals
155533|NCT02149004|Human immunodeficiency virus (HIV)
155534|NCT02149004|Prevention
155535|NCT02149004|Long-term life
155536|NCT02149004|Cure
155537|NCT02149004|Cohort
155538|NCT02148965|motor activity
155539|NCT02148965|clinical trials
155540|NCT02148965|pregnancy
155541|NCT02148965|hypertension
155542|NCT02148965|cohort studies
155543|NCT02148952|Maternal Health
155544|NCT02148952|Maternal Death
155545|NCT02148952|Maternal Morbidity
155546|NCT02148952|Stillbirth
155547|NCT02148952|Neonatal Mortality
155548|NCT02148952|Quality Improvement
155549|NCT02148952|Resource Limited Settings
155550|NCT02148952|Checklist
155551|NCT02148952|Safe Childbirth
155552|NCT02148939|ischemic stroke
155553|NCT02148939|Antiplatelet Effects
155554|NCT02148939|aspirin
155555|NCT02148939|metamizole
155556|NCT02148939|dipyrone
155557|NCT02148900|Marfan syndrome
155558|NCT02148900|blood test
155559|NCT02148900|aortic root size
155560|NCT02148900|Marfan related disorders
155561|NCT02148874|pregnant
155562|NCT02148874|flu shot
155563|NCT02148874|influenza
155564|NCT02148874|vaccine
155565|NCT02148848|Osteoporosis
155566|NCT02148848|Femoral neck fracture
155567|NCT02148848|hemiarthroplasty
155568|NCT02148835|Omega-3 Index
155569|NCT02148835|Bioavailability
155570|NCT02148835|Eicosapentaenoic acid
155571|NCT02148835|Docosahexaenoic acid
155572|NCT02148835|Fortified food
155573|NCT02148822|Visceral leishmaniasis
155574|NCT02148822|kala azar
155575|NCT02148822|malnutrition
155576|NCT02148822|stunting
155577|NCT02148822|thinness
155578|NCT02148822|Leishmania donovani
155579|NCT02148796|Wheezing
155580|NCT02148796|Lower respiratory tract illness
155581|NCT02148796|Asthma
155582|NCT02148796|Atopy
155583|NCT02148783|Traumatic brain injury
155584|NCT02148783|Attention deficit and memory problems
155585|NCT02148783|Methylphenidate
155586|NCT02148783|Dopamine receptor imaging
155587|NCT02148783|Motivation and reward
155588|NCT02148783|Positron emission tomography
155589|NCT02148783|Transcranial magnetic stimulation
155590|NCT02148770|rt-fmri
155591|NCT02148770|self-control
155592|NCT02148770|eating behaviour
155593|NCT02148770|overweight
155594|NCT02148770|neurofeedback
155595|NCT02148757|DVT
155596|NCT02148731|Colon cancer
155597|NCT02148731|Elderly patients
155598|NCT02148718|Crohn's Disease
155599|NCT02148705|fire/flame
155600|NCT02148705|scalds
155601|NCT02148705|contact
155602|NCT02148679|Heart Failure
155603|NCT02148679|Diet
155604|NCT02148653|Cardiometabolic risk
155605|NCT02148653|Diet
155606|NCT02148653|Dietary prevention
155607|NCT02148653|Functional diet
155608|NCT02148653|Functional foods
155609|NCT02148653|Metabolic Syndrome
155610|NCT02148653|Overweight
155611|NCT02148627|antibody
155612|NCT02148627|autoimmune
155613|NCT02148601|Fecal microbiota transplantation
155614|NCT02148601|Recurrent C. difficile infection
155615|NCT02148601|Colonoscopy
155616|NCT02148601|Randomized clinical trial
155617|NCT02148588|Central Post Stroke Pain
155618|NCT02148588|Nerve block
155619|NCT02148575|Palliative Care
155620|NCT02148575|Self-management
155621|NCT02148575|Breast Cancer
155622|NCT02148549|Borderline resectable pancreatic cancer
155623|NCT02148549|R0 resection
155624|NCT02148549|Resection rate
155625|NCT02148549|Optimal schedule
155626|NCT02148523|Medication Adherence
155627|NCT02148523|High Blood Pressure
155628|NCT02148523|Diabetes
155629|NCT02148523|Statins
155630|NCT02148510|human
155631|NCT02148510|sleep apnea
155632|NCT02148510|adults
155633|NCT02148510|oral appliance
155634|NCT02148510|efficacy
155635|NCT02148510|safety
155636|NCT02148510|polygraphy
155637|NCT02148510|bruxism
155638|NCT02148510|cost
155639|NCT02148497|volunteers
155640|NCT02148484|PTSD
155641|NCT02148484|Cognitive Behavioral Treatment
155642|NCT02148484|Child Sexual Abuse
155643|NCT02148471|Nonalcoholic fatty liver disease
155644|NCT02148471|Steatosis
155645|NCT02148471|Nonalcoholic steatohepatitis
155646|NCT02148458|Intermittent fasting
155647|NCT02148458|Mediterranean diet
155648|NCT02148458|overweight
155649|NCT02148458|Calorie restriction
155650|NCT02148445|smoking cessation
155651|NCT02148445|tobacco use cessation products
155652|NCT02148445|nicotine
155653|NCT02148432|sleep apnea syndrome, fiberoptic bronchoscopy, IV sedation
155654|NCT02148419|quality of life
155655|NCT02148419|maltreatment
155656|NCT02148419|neglect
155657|NCT02148419|childhood
155658|NCT02148406|Yoga
155659|NCT02148406|Mind-body therapies
155660|NCT02148406|Fatigue
155661|NCT02148406|Colorectal cancer
155662|NCT02148406|Depressive symptoms
155663|NCT02148380|Lung adenocarcinoma,EGFR mutation, chemotherapy, gefitinib
155664|NCT02148367|Traumatic brain injury
155665|NCT02148367|Endothelial progenitor cells
155666|NCT02148367|Cerebrovascular reactivity
155667|NCT02148367|Angiogenesis
155668|NCT02148354|Depression
155669|NCT02148354|Self-applied treatment
155670|NCT02148354|Internet
155671|NCT02148354|Support by the therapist
155672|NCT02148354|Cognitive-Behavioural Treatment
155673|NCT02148354|Positive Psychology
155674|NCT02148354|Behavioral Activation
155675|NCT02148328|Healthy participants
155676|NCT02148328|Immunogenicity
155677|NCT02148328|Influenza
155678|NCT02148328|Prevention
155679|NCT02148328|Safety
155680|NCT02148315|physical activity
155681|NCT02148315|children
155682|NCT02148315|school
155683|NCT02148315|garden
155684|NCT02148302|Venous Leg Ulcerations
155685|NCT02148302|Epidermal Grafts
155686|NCT02148302|Chronic wounds
155687|NCT02148302|Clinical trial
155688|NCT02148302|Protease levels in chronic wounds
155689|NCT02148289|COPD, beetroot, dietary nitrate, nitric oxide
155690|NCT02148276|Social harm detection
155691|NCT02148276|Instrument development
155692|NCT02148276|HIV-related clinical trials
155693|NCT02148276|Substance abuse
155694|NCT02148276|Research participation
155695|NCT02148263|Contact Lenses
155696|NCT02148263|Neophytes
155697|NCT02148263|Contact Lens Adaptation
155698|NCT02148263|Randomized
155699|NCT02148250|Type 2 diabetes
155700|NCT02148250|Insulin resistance
155701|NCT02148250|High insulin requirements
155702|NCT02148250|U 500
155703|NCT02148237|Breastfeeding duration
155704|NCT02148237|Puerto Rican mothers
155705|NCT02148237|WIC program
155706|NCT02148237|Home-based individual breastfeeding consultation
155707|NCT02148224|glycemic index
155708|NCT02148224|body composition
155709|NCT02148211|Fluarix Quadrivalent
155710|NCT02148211|Fluarix
155711|NCT02148211|FluLaval
155712|NCT02148211|FluLaval Quadrivalent
155713|NCT02148211|Pregnancy Registry
155714|NCT02148211|Pregnancy outcome
155715|NCT02148185|Crohn's disease
155716|NCT02148172|Knee
155717|NCT02148172|plyometrics
155718|NCT02148172|motor learning
155719|NCT02148172|psychological factors
155720|NCT02148159|anorexia
155721|NCT02148159|cachexia
155722|NCT02148159|cancer
155723|NCT02148159|unintentional weigh loss
155724|NCT02148159|gastrointestinal tract
155725|NCT02148159|adults
155726|NCT02148146|short bowel syndrome
155727|NCT02148146|intestinal failure
155728|NCT02148146|total parenteral nutrition associated cholestasis
155729|NCT02148133|Thrombocytopenia
155730|NCT02148133|Eltrombopag
155731|NCT02148133|Aplastic Anemia (AA)
155732|NCT02148133|Thrombopoietin
155733|NCT02148094|HIV
155734|NCT02148094|AIDS
155735|NCT02148094|India
155736|NCT02148094|Prevention
155737|NCT02148094|Female sex workers
155738|NCT02148094|PrEP
155739|NCT02148094|Pre-exposure prophylaxis
155740|NCT02148094|Truvada
155741|NCT02148094|Tenofovir
155742|NCT02148081|pediatrics, critical illness, recovery, function, health
155743|NCT02148068|Obesity
155744|NCT02148068|Bariatric Surgery
155745|NCT02148068|Roux-en-y Gastric Bypass
155746|NCT02148068|Sleeve Gastrectomy
155747|NCT02148055|spontaneous intrauterine death
155748|NCT02148055|fetal MRI
155749|NCT02148055|autopsy
155750|NCT02148042|Anorexia
155751|NCT02148042|Generalized anxiety
155752|NCT02148042|Fear
155753|NCT02148029|Deep vein thrombosis
155754|NCT02148029|Post thrombotic syndrome
155755|NCT02148029|Thrombus resolution
155756|NCT02148016|Corneal disorders
155757|NCT02148016|Chemical injury
155758|NCT02148016|Pterygium
155759|NCT02148016|Refractive error
155760|NCT02148016|Myopia
155761|NCT02148016|Hyperopia
155762|NCT02148016|Cornea
155763|NCT02148016|Monocular
155764|NCT02148016|Transparent
155765|NCT02148016|Transplantation
155766|NCT02148016|Visual function
155767|NCT02147990|cancer
155768|NCT02147990|metastatic
155769|NCT02147990|locally advanced
155770|NCT02147990|lung
155771|NCT02147990|non-small cell lung cancer
155772|NCT02147990|NSCLC
155773|NCT02147990|epidermal growth factor receptor
155774|NCT02147990|EGFR
155775|NCT02147990|T790M
155776|NCT02147990|CO-1686
155777|NCT02147990|unresectable
155778|NCT02147990|recurrent
155779|NCT02147990|EGFR-directed therapy
155780|NCT02147990|irreversible EGFR inhibitor
155781|NCT02147990|TIGER
155782|NCT02147990|Rociletinib
155783|NCT02147977|Renal Dialysis
155784|NCT02147977|Arrhythmias Cardiac
155785|NCT02147977|Death Sudden Cardiac
155786|NCT02147977|Fatty Acids Omega 3
155787|NCT02147964|intratesticular androgens
155788|NCT02147964|testosterone
155789|NCT02147964|dutasteride
155790|NCT02147964|gonadotropin suppression
155791|NCT02147964|male contraception
155792|NCT02147964|spermatogenesis
155793|NCT02147951|Melanoma
155794|NCT02147938|France
155795|NCT02147938|Tacrolimus
155796|NCT02147938|Prograf
155797|NCT02147938|Observational
155798|NCT02147938|Advagraf
155799|NCT02147925|Non-alcoholic fatty liver disease
155800|NCT02147925|Glucagon-like peptide-1 receptor agonists
155801|NCT02147925|Diabetes mellitus, type 2
155802|NCT02147912|Depression
155803|NCT02147912|COPD
155804|NCT02147912|Aerobic Exercise
155805|NCT02147912|Anxiety
155806|NCT02147912|Quality of life
155807|NCT02147912|neurocognitive functioning
155808|NCT02147886|Bioblast, Randomized, parallel-group, and dose-controlled
155809|NCT02147873|MDS
155810|NCT02147873|CMML
155811|NCT02147873|myelodysplastic syndrome
155812|NCT02147873|chronic myelomonocytic leukemia
155813|NCT02147873|TL32711
155814|NCT02147873|TL32711-0094
155815|NCT02147873|azacitidine
155816|NCT02147873|birinapant
155817|NCT02147873|higher risk
155818|NCT02147873|naive
155819|NCT02147873|double blind
155820|NCT02147873|placebo
155821|NCT02147873|placebo controlled
155822|NCT02147873|randomized
155823|NCT02147860|Diabetes Mellitus, Type 1
155824|NCT02147860|Artificial Pancreas Project (APP)
155825|NCT02147860|Diabetes Assistant (DiAs)
155826|NCT02147860|Closed-Loop Control (CLC)
155827|NCT02147860|Continuous Glucose Monitor (CGM)
155828|NCT02147860|Insulin Pump
155829|NCT02147847|Presbycusis
155830|NCT02147847|Hearing In Noise
155831|NCT02147847|Hearing Impairment
155832|NCT02147847|Hearing Loss
155833|NCT02147847|Aging
155834|NCT02147847|Plasticity
155835|NCT02147847|Video Games
155836|NCT02147847|Perceptual Learning
155837|NCT02147834|deferred percutaneous coronary intervention
155838|NCT02147834|fractional flow reserve
155839|NCT02147795|Patient Blood Management
155840|NCT02147795|Red Blood Cell Transfusion Practice
155841|NCT02147795|Patient Safety
155842|NCT02147795|Anemia
155843|NCT02147795|Clinical Outcome
155844|NCT02147795|perioperative care
155845|NCT02147782|chronic renal insufficient, renal osteodystrophy, bone mineral density, bone turnover, kidney function
155846|NCT02147769|cerebral autoregulation
155847|NCT02147769|preterm
155848|NCT02147769|near-infrared spectroscopy
155849|NCT02147756|Skin pigmentation, skin texture disorders, fractional laser, CO2, fractional CO2, Syneron, Solta.
155850|NCT02147743|Adolescents
155851|NCT02147743|Family-Based treatment
155852|NCT02147743|Multidimensional Family Therapy
155853|NCT02147730|chronic pain
155854|NCT02147717|preterm newborns
155855|NCT02147717|Transfontanellar ultrafast doppler
155856|NCT02147717|Acupuncture
155857|NCT02147717|perioperative pain
155858|NCT02147717|surgery of the ductus arteriosus
155859|NCT02147665|Hookah
155860|NCT02147665|waterpipe
155861|NCT02147665|smoking
155862|NCT02147665|sympathetic
155863|NCT02147652|moderate dementia
155864|NCT02147652|severe dementia
155865|NCT02147652|Alzheimer's disease
155866|NCT02147652|Vascular dementia
155867|NCT02147652|agitation
155868|NCT02147652|personalized music therapy
155869|NCT02147626|preeclampsia
155870|NCT02147626|cardiovascular disease
155871|NCT02147626|health behaviors
155872|NCT02147626|behavioral intervention
155873|NCT02147626|web-based
155874|NCT02147626|Hypertension
155875|NCT02147626|Post-partum Weight Retention
155876|NCT02147600|adalimumab
155877|NCT02147600|biologicals
155878|NCT02147600|immunogenicity
155879|NCT02147574|slow-transit constipation
155880|NCT02147574|laparoscope Sub-total Colectomy
155881|NCT02147574|anti-peristaltic anastomosis
155882|NCT02147522|community health worker
155883|NCT02147522|promotoras
155884|NCT02147522|self-care behaviors activation
155885|NCT02147522|depression
155886|NCT02147522|low-income patients
155887|NCT02147522|safety-net care
155888|NCT02147509|Dry eye
155889|NCT02147509|Therapeutic bandage contact lenses
155890|NCT02147509|The quality of life
155891|NCT02147496|Food intake
155892|NCT02147496|Appetite
155893|NCT02147496|Blood glucose
155894|NCT02147496|Insulin
155895|NCT02147496|Dairy
155896|NCT02147496|Milk
155897|NCT02147483|Mindfulness
155898|NCT02147483|Alcohol use disorders
155899|NCT02147470|cirrhosis of the liver
155900|NCT02147470|Acute kidney injury
155901|NCT02147457|Prematurity
155902|NCT02147457|Extremely low birth weight
155903|NCT02147457|Phenotyping
155904|NCT02147444|Rivaroxaban
155905|NCT02147444|Non-valvular atrial fibrillation
155906|NCT02147444|NOAC
155907|NCT02147444|Xa inhibitor
155908|NCT02147418|Head and neck cancer
155909|NCT02147418|Throat cancer
155910|NCT02147418|Human papillomavirus
155911|NCT02147418|HPV
155912|NCT02147418|Exosome
155913|NCT02147418|Diagnostic
155914|NCT02147418|Early Detection
155915|NCT02147405|FDG PET/CT Scan
155916|NCT02147405|Lymph Node Biopsy
155917|NCT02147405|Apheresis
155918|NCT02147392|PET Imaging
155919|NCT02147379|Bipolar Disorder
155920|NCT02147379|Cognition
155921|NCT02147379|Euthymic
155922|NCT02147379|Lurasidone
155923|NCT02147366|Hypertension,ambulatory pressure,autonomic function,music
155924|NCT02147353|External Genital Warts
155925|NCT02147353|Sinecatechins
155926|NCT02147353|Cryotherapy
155927|NCT02147340|Heart Failure patients
155928|NCT02147340|Remote Patient Management
155929|NCT02147340|External Sensors
155930|NCT02147327|vitamin D
155931|NCT02147327|cord blood
155932|NCT02147327|neonatal sepsis
155933|NCT02147327|neonatal morbidity
155934|NCT02147314|diabetes
155935|NCT02147314|glucometer
155936|NCT02147314|Yofimeter
155937|NCT02147314|diabetes monitoring
155938|NCT02147275|hypertension
155939|NCT02147275|cerebral oxygen saturation
155940|NCT02147275|near-infrared spectroscopy
155941|NCT02147275|cognitive function
155942|NCT02147262|chronic atrophic acrodermatitis
155943|NCT02147262|Lyme borreliosis
155944|NCT02147262|molecular characteristics
155945|NCT02147262|outcome
155946|NCT02147249|erythema migrans
155947|NCT02147249|Lyme borreliosis
155948|NCT02147249|inflammation
155949|NCT02147249|outcome
155950|NCT02147236|autism
155951|NCT02147236|pervasive developmental disorders
155952|NCT02147236|social skills intervention
155953|NCT02147223|flavanols
155954|NCT02147223|sex-related cardiovascular effects
155955|NCT02147210|Chronic transplant glomerulopathy
155956|NCT02147210|antibody mediated rejection
155957|NCT02147210|Ephrin-B1
155958|NCT02147184|SSRI
155959|NCT02147184|serotonin transporter
155960|NCT02147184|DXA
155961|NCT02147184|pQCT
155962|NCT02147184|bone mass
155963|NCT02147184|adolescents
155964|NCT02147171|Retinal ageing, macular pigment, visual function
155965|NCT02147145|GIST
155966|NCT02147145|endoscopy
155967|NCT02147145|endoscopic ultrasound
155968|NCT02147132|Cigarette
155969|NCT02147132|Methadone
155970|NCT02147132|Smoking
155971|NCT02147132|Cessation
155972|NCT02147132|Varenicline
155973|NCT02147132|Nicotine
155974|NCT02147106|Neuroendocrine tumor
155975|NCT02147106|Videoconsultation
155976|NCT02147106|Feasibility
155977|NCT02147080|prevention or control
155978|NCT02147067|microvascular angina
155979|NCT02147067|coronary microvascular disease
155980|NCT02147067|coronary physiology
155981|NCT02147067|ranolazine
155982|NCT02147054|Organophosphate poisoning
155983|NCT02147054|Intermediate syndrome
155984|NCT02147054|Rocuronium
155985|NCT02147041|diabetes mellitus
155986|NCT02147041|hyperlipidemia
155987|NCT02147041|green tea
155988|NCT02147041|epigallocatechin gallate
155989|NCT02147028|whole brain RT
155990|NCT02147028|hippocampal sparing
155991|NCT02147028|neurocognitive function
155992|NCT02147015|Acute Exacerbations
155993|NCT02147015|Corticosteroids
155994|NCT02147015|Chronic Obstructive Pulmonary Disease
155995|NCT02147015|Doses
155996|NCT02147002|Chronic Kidney Disease
155997|NCT02147002|Cardiovascular Complications
155998|NCT02146989|Cerebral Palsy
155999|NCT02146989|child
156000|NCT02146989|upper extremity
156001|NCT02146989|strength, reproducibility
156002|NCT02146976|postoperative
156003|NCT02146976|sleep quality
156004|NCT02146976|propofol
156005|NCT02146976|sevoflurane
156006|NCT02146950|LCS-12
156007|NCT02146950|Intrauterine Device (IUD)
156008|NCT02146950|Intrauterine System (IUS)
156009|NCT02146950|Levonorgestrel
156010|NCT02146950|Pearl Index
156011|NCT02146950|Hormonal Contraception
156012|NCT02146937|active surveillance
156013|NCT02146937|MRI/transrectal ultrasound fusion guided biopsy
156014|NCT02146937|biopsy
156015|NCT02146911|Smoking Cessation Medication
156016|NCT02146911|Smoking Treatment
156017|NCT02146911|Tobacco Treatment
156018|NCT02146911|Quitting Smoking
156019|NCT02146911|Bupropion
156020|NCT02146911|Varenicline
156021|NCT02146911|Efficacy
156022|NCT02146911|Pharmacogenetics of Smoking Treatment
156023|NCT02146911|Genetics analysis
156024|NCT02146911|Smoking Personality
156025|NCT02146911|Dependence
156026|NCT02146911|Addiction
156027|NCT02146911|Cigarettes
156028|NCT02146911|Primary Care Physicians
156029|NCT02146911|Biochemical Confirmation
156030|NCT02146898|spinal anesthesia
156031|NCT02146898|hypotension
156032|NCT02146898|pregnancy
156033|NCT02146872|Coronary Artery Disease
156034|NCT02146872|Myocardial Infarction
156035|NCT02146872|Atherosclerosis
156036|NCT02146872|High-Throughput Nucleotide Sequencing
156037|NCT02146872|Sequence Analysis, DNA
156038|NCT02146872|Genetic Testing
156039|NCT02146872|Genetic Linkage
156040|NCT02146859|residual neuromuscular blockade
156041|NCT02146846|cml
156042|NCT02146833|castrate-resistant prostate cancer
156043|NCT02146833|prostate cancer
156044|NCT02146833|Karyopharm
156045|NCT02146833|KPT-330
156046|NCT02146833|selinexor
156047|NCT02146820|Pigmented Lesions, Skin Pigment, Picosecond Laser, Syneron
156048|NCT02146807|Tattoos, Picosecond Laser, Syneron
156049|NCT02146742|ASP1707
156050|NCT02146742|Japanese subjects
156051|NCT02146742|Safety
156052|NCT02146742|Pharmacokinetics
156053|NCT02146742|Pharmacodynamics
156054|NCT02146729|Randomized
156055|NCT02146729|Thoracolumbar fractures
156056|NCT02146729|Spine Trauma
156057|NCT02146729|Percutaneous Pedicle Screw Fixation
156058|NCT02146729|Functional Outcome
156059|NCT02146716|RESC, alcohol withdrawal syndrome
156060|NCT02146703|biliary tract neoplasm
156061|NCT02146703|gemcitabine
156062|NCT02146703|S-1
156063|NCT02146690|pathology
156064|NCT02146690|newborn
156065|NCT02146690|osteopathic manipulative treatment
156066|NCT02146690|pain
156067|NCT02146677|prematurity
156068|NCT02146677|newborns
156069|NCT02146677|pain
156070|NCT02146677|cost
156071|NCT02146664|Acute NSTEMI
156072|NCT02146664|DLBS1033
156073|NCT02146664|SPECT
156074|NCT02146664|Infarct size
156075|NCT02146664|Left ventricular function
156076|NCT02146638|post operative analgesia, morphine, fentanyl
156077|NCT02146573|Intensive Care Units, Pediatric
156078|NCT02146573|Communication
156079|NCT02146573|Health personnel
156080|NCT02146573|Decision making
156081|NCT02146573|Critical Care
156082|NCT02146573|Length of Stay
156083|NCT02146573|Iatrogenic Disease
156084|NCT02146560|Surgery
156085|NCT02146560|Non-cardiac
156086|NCT02146560|Elective
156087|NCT02146560|Adult
156088|NCT02146560|Patients
156089|NCT02146560|Troponin
156090|NCT02146560|Myocardial
156091|NCT02146560|Injury
156092|NCT02146560|Postoperative
156093|NCT02146560|Recovery
156094|NCT02146560|Outcome
156095|NCT02146547|depot, oral, antipsychotics, paliperidone, aripiprazole
156096|NCT02146521|z-axis limited CT
156097|NCT02146521|computed tomography
156098|NCT02146521|CT
156099|NCT02146521|abdominal non-traumatic pain and tenderness
156100|NCT02146521|emergency patients
156101|NCT02146508|Esophageal cancer
156102|NCT02146508|Radiofrequency, catheter ablation
156103|NCT02146508|Endoscopic mucosal resection
156104|NCT02146508|Esophageal squamous dysplasia
156105|NCT02146508|Cancer prevention
156106|NCT02146482|back pain
156107|NCT02146482|low back pain
156108|NCT02146482|sit-stand workstation
156109|NCT02146482|standing desk
156110|NCT02146469|varicella vaccination
156111|NCT02146443|Manual dexterity
156112|NCT02146443|hand to eye coordination
156113|NCT02146443|stress
156114|NCT02146443|fatigue
156115|NCT02146430|pain
156116|NCT02146430|fibromyalgia
156117|NCT02146417|Low pressure pneumoperitoneum
156118|NCT02146417|Deep neuromuscular block
156119|NCT02146404|Type 1 Diabetes Mellitus
156120|NCT02146404|Hypoglycemia unawareness
156121|NCT02146404|1H MRS
156122|NCT02146404|Lactate
156123|NCT02146352|Pancreatic pseudocyst
156124|NCT02146339|nutrition
156125|NCT02146339|milk
156126|NCT02146339|polar lipids
156127|NCT02146339|cardiometabolic risk
156128|NCT02146300|birch pollen
156129|NCT02146300|allergy
156130|NCT02146300|breathing
156131|NCT02146300|pattern
156132|NCT02146300|exposure
156133|NCT02146287|cycled light
156134|NCT02146287|preterm infants
156135|NCT02146287|infant neurodevelopment
156136|NCT02146287|infant sleep
156137|NCT02146274|PROSPER
156138|NCT02146274|Stroke
156139|NCT02146274|Ischemic Stroke
156140|NCT02146261|Volunteers
156141|NCT02146261|Japanese
156142|NCT02146261|Males
156143|NCT02146248|hysterosalpingography, DMPA, combined oral contraceptive, tubal patency
156144|NCT02146235|Music Therapy
156145|NCT02146235|Pulmonary Disease
156146|NCT02146235|COPD
156147|NCT02146235|Music Visualization
156148|NCT02146235|Therapeutic Singing
156149|NCT02146235|Wind-playing
156150|NCT02146235|Lung Condition
156151|NCT02146196|Heart failure
156152|NCT02146196|robotic assisted gait therapy
156153|NCT02146183|Stevio glycosides
156154|NCT02146183|sport
156155|NCT02146183|glycogen
156156|NCT02146170|Sample Acquisition
156157|NCT02146170|Generic and Epigenetic Alterations
156158|NCT02146170|Mig6 Expression
156159|NCT02146170|Proteomic Analysis
156160|NCT02146170|Genomic Analysis
156161|NCT02146144|Idiopathic epimacular membrane
156162|NCT02146144|internal limiting membrane peeling
156163|NCT02146144|microscotomas
156164|NCT02146131|Peripheral pulmonary lesions
156165|NCT02146131|Solitary pulmonary lesions
156166|NCT02146131|Multiple pulmonary lesions
156167|NCT02146118|Erlotinib
156168|NCT02146118|Silybin-phytosome
156169|NCT02146118|EGFR mutant lung adenocarcinoma
156170|NCT02146092|lung resection
156171|NCT02146092|incentive spirometry
156172|NCT02146092|physiotherapy
156173|NCT02146092|quality improvement
156174|NCT02146092|outcomes
156175|NCT02146092|post operative complications
156176|NCT02146066|GBM
156177|NCT02146066|Brain tumor
156178|NCT02146066|glioblastoma
156179|NCT02146066|Brain tumor WHO grade IV
156180|NCT02146053|healthy participants
156181|NCT02146053|gastrointestinal side-effects associated with oral iron
156182|NCT02146040|anticoagulation
156183|NCT02146040|atrial fibrillation
156184|NCT02146040|cardioversion
156185|NCT02146040|complications
156186|NCT02146040|hemorrhage
156187|NCT02146040|medications
156188|NCT02146040|thromboembolism
156189|NCT02146040|TIA
156190|NCT02146040|stroke
156191|NCT02146040|treatment
156192|NCT02146027|HIV
156193|NCT02146027|Lactobacillus casei Shirota
156194|NCT02146027|NK cell
156195|NCT02146027|CD4
156196|NCT02146027|Lymphocyte
156197|NCT02146027|Cell activation
156198|NCT02146027|Antiretroviral therapy
156199|NCT02146027|Immune discordants
156200|NCT02146014|cigarette smoking, smoking
156201|NCT02146001|sedentary behavior
156202|NCT02146001|physical activity
156203|NCT02146001|older adults
156204|NCT02145988|DLBS1033
156205|NCT02145988|Peripheral arterial disease
156206|NCT02145988|Ankle-brachial index
156207|NCT02145975|Severe postoperative pain
156208|NCT02145975|Morphine
156209|NCT02145975|Fentanyl
156210|NCT02145975|Time to titration of pain
156211|NCT02145975|Pain and PACU
156212|NCT02145975|Anesthesiology
156213|NCT02145962|diabetic foot ulcer healing
156214|NCT02145962|magnetic therapy
156215|NCT02145962|safety and efficacy
156216|NCT02145962|wound care
156217|NCT02145949|aging
156218|NCT02145949|clinical
156219|NCT02145949|translational
156220|NCT02145949|functional mobility
156221|NCT02145949|total knee arthroplasty
156222|NCT02145936|fatty acid
156223|NCT02145923|Hodgkin Lymphoma
156224|NCT02145923|Non-Hodgkin's Lymphomas
156225|NCT02145923|Allogeneic Mesenchymal Stem Cell Transplantation
156226|NCT02145923|Autologous Peripheral Blood Stem Cell Transplantation
156227|NCT02145923|Neutropenic Enterocolitis
156228|NCT02145923|Myeloablative Chemotherapy
156229|NCT02145923|Bone Marrow Aplasia
156230|NCT02145897|CLI
156231|NCT02145884|hemangioma
156232|NCT02145884|birthmark
156233|NCT02145884|strawberry hemangioma
156234|NCT02145884|timolol
156235|NCT02145871|Radical Cystectomy
156236|NCT02145871|Perioperative Fluid Management
156237|NCT02145871|EV1000
156238|NCT02145871|14-069
156239|NCT02145858|Chest tube, chest drainage, chest tube clogging, retained blood complications, hemothorax, tamponade, heart surgery, pleural effusion, intensive care
156240|NCT02145845|critical limb ischemia
156241|NCT02145845|wound healing
156242|NCT02145845|amputation
156243|NCT02145832|TINN
156244|NCT02145832|Pharmacokinetic
156245|NCT02145832|Neonates
156246|NCT02145832|Antifungal
156247|NCT02145832|Fluconazole
156248|NCT02145832|Micafungin
156249|NCT02145806|Urinary incontinence
156250|NCT02145806|Validation study
156251|NCT02145806|Pregnant women
156252|NCT02145806|Postpartum period
156253|NCT02145793|primary care
156254|NCT02145793|pediatrics
156255|NCT02145793|parenting
156256|NCT02145793|education
156257|NCT02145780|Overfeeding
156258|NCT02145780|Fat distribution
156259|NCT02145780|Subcutaneous and visceral adipose tissue
156260|NCT02145780|Insulin sensitivity
156261|NCT02145780|Insulin resistance
156262|NCT02145780|Peripheral and hepatic insulin sensitivity
156263|NCT02145780|Stable isotopes
156264|NCT02145780|Lipid oxidation
156265|NCT02145780|Energy expenditure
156266|NCT02145780|Muscle and subcutaneous adipose tissue gene expression
156267|NCT02145754|erythema migrans
156268|NCT02145754|Lyme borreliosis
156269|NCT02145754|Borrelia burgdorferi
156270|NCT02145754|skin culture
156271|NCT02145754|culture media
156272|NCT02145728|Non-specific chronic low back pain
156273|NCT02145728|Cognitive functional therapy
156274|NCT02145728|Exercise classes
156275|NCT02145702|ESRD
156276|NCT02145702|Kidney Failure
156277|NCT02145702|Exercise
156278|NCT02145702|Cognitive impairment
156279|NCT02145637|Cancer, Lung cancer, Head and neck squamous cell carcinoma, Afatinib, Ruxolitinib, EGFR, JAK, STAT
156280|NCT02145624|pertussis
156281|NCT02145624|maternal vaccination
156282|NCT02145624|maternal immunisation
156283|NCT02145624|immune response
156284|NCT02145611|hypertension, diabetes, endothelial function
156285|NCT02145598|Multiple Myeloma
156286|NCT02145598|Revlimid
156287|NCT02145598|Lenalidomide maintenance
156288|NCT02145585|Cardiac surgery
156289|NCT02145585|Robotic pharmacological anesthesia
156290|NCT02145585|Anesthesia
156291|NCT02145546|Pacing dependent
156292|NCT02145546|Atrial Fibrillation
156293|NCT02145546|Amiodarone
156294|NCT02145546|Propafenone
156295|NCT02145546|Sotalol
156296|NCT02145546|AF burden
156297|NCT02145533|MMP
156298|NCT02145533|NGAL
156299|NCT02145533|Arterial Aneurysms
156300|NCT02145520|bronchiolitis
156301|NCT02145507|Leukoreduction
156302|NCT02145507|Red Blood Cell post-leukoreduction recovery
156303|NCT02145507|Packed red blood cell post storage hemolysis
156304|NCT02145507|Red blood cell recovery
156305|NCT02145507|Plasma clotting factors
156306|NCT02145507|2,3-DPG rejuvenation
156307|NCT02145494|SBRT (stereotactic body radiotherapy)
156308|NCT02145494|Focal boost
156309|NCT02145494|Prostate
156310|NCT02145481|coronary artery disease
156311|NCT02145481|decision quality
156312|NCT02145481|decision making
156313|NCT02145481|survey
156314|NCT02145481|measure development
156315|NCT02145481|patient-centered care
156316|NCT02145481|cardiology
156317|NCT02145481|heart disease
156318|NCT02145468|Myocardial infarction
156319|NCT02145468|Acute coronary syndrome
156320|NCT02145468|Cardiovascular disease
156321|NCT02145468|p38 mitogen-activated protein kinase (MAPK) inhibitor
156322|NCT02145468|NSTEMI
156323|NCT02145468|Losmapimod
156324|NCT02145468|STEMI
156325|NCT02145455|Arthroplasty, Replacement, Knee/methods
156326|NCT02145455|Knee Joint/physiopathology
156327|NCT02145455|Knee Joint/radiography
156328|NCT02145455|Knee Joint/surgery
156329|NCT02145455|Knee Prosthesis
156330|NCT02145455|Outcome Assessment (Health Care)
156331|NCT02145455|Female
156332|NCT02145455|Male
156333|NCT02145455|Adult
156334|NCT02145442|Impaired fasting glucose
156335|NCT02145442|Prediabetes
156336|NCT02145442|Obesity
156337|NCT02145442|Overweight
156338|NCT02145442|Insulin sensitivity
156339|NCT02145442|Weight loss
156340|NCT02145442|Nutritional supplement
156341|NCT02145442|Waist
156342|NCT02145442|Body composition
156343|NCT02145429|Prevention of depression and anxiety disorder
156344|NCT02145429|Depression Prevention
156345|NCT02145416|Imaging
156346|NCT02145416|Chemoradiotherapy
156347|NCT02145403|Allogeneic Transplantation
156348|NCT02145403|Carfilzomib
156349|NCT02145403|Relapse
156350|NCT02145403|Graft-Versus-Host Disease
156351|NCT02145403|Multiple Myeloma
156352|NCT02145403|Lymphoma
156353|NCT02145403|Leukemia
156354|NCT02145390|Bladder Cancer
156355|NCT02145390|Bladder Carcinoma
156356|NCT02145390|Transition Cell Cancer
156357|NCT02145390|TCC
156358|NCT02145390|Muscle Invasive Bladder Carcinoma
156359|NCT02145377|Cholera
156360|NCT02145377|Vaccine
156361|NCT02145377|Mali
156362|NCT02145364|Ulthera System®
156363|NCT02145364|Ultherapy®
156364|NCT02145364|Ulthera, Inc.
156365|NCT02145351|HFpEF
156366|NCT02145351|Heart failure
156367|NCT02145351|Heart failure with preserved ejection fraction
156368|NCT02145351|Chronotropic incompetence
156369|NCT02145338|Urinary tract infection
156370|NCT02145338|Clean intermittent self-catheterisation
156371|NCT02145338|Antibiotic prophylaxis
156372|NCT02145325|Kidney transplant
156373|NCT02145325|Regulatory T cells
156374|NCT02145325|Leukopheresis
156375|NCT02145325|Immune cells
156376|NCT02145325|Stem Cells
156377|NCT02145325|Tolerance
156378|NCT02145273|Maternal Depression
156379|NCT02145273|Interpersonal Psychotherapy
156380|NCT02145273|School Readiness
156381|NCT02145260|Hemodialysis
156382|NCT02145260|Hypotension
156383|NCT02145260|Hospitalization
156384|NCT02145208|BPH
156385|NCT02145195|Vitamin D
156386|NCT02145195|Children
156387|NCT02145195|Supplements
156388|NCT02145195|Cardiometabolic markers
156389|NCT02145195|Immune defense
156390|NCT02145195|Bone turnover
156391|NCT02145195|Muscle strength
156392|NCT02145182|DGF
156393|NCT02145182|Dialysis
156394|NCT02145182|Kidney
156395|NCT02145182|Kidney Transplantation
156396|NCT02145182|eGFR
156397|NCT02145182|Complement
156398|NCT02145182|Eculizumab
156399|NCT02145169|procedural sedation
156400|NCT02145169|emergence reaction
156401|NCT02145169|nitrous oxide
156402|NCT02145169|ketamine
156403|NCT02145156|HPV vaccination
156404|NCT02145156|Tailored health messaging
156405|NCT02145143|Radioiodine (RAI) Incorporation
156406|NCT02145143|Vemurafenib
156407|NCT02145143|14-031
156408|NCT02145130|Skin
156409|NCT02145130|Tissue-engineering
156410|NCT02145130|Autologous
156411|NCT02145130|Dermis
156412|NCT02145130|Epidermis
156413|NCT02145117|MBSR
156414|NCT02145117|fMRI
156415|NCT02145117|PTH
156416|NCT02145091|Psilocybin
156417|NCT02145091|Hallucinogens
156418|NCT02145091|Pharmacologic Actions
156419|NCT02145091|Central Nervous System Agents
156420|NCT02145091|Therapeutic Uses
156421|NCT02145091|Psychotropic Drugs
156422|NCT02145065|paclitaxel coated balloon
156423|NCT02145065|restenosis
156424|NCT02145065|Femoropopliteal artery disease
156425|NCT02145052|Fascial closure
156426|NCT02145052|Interrupted suture
156427|NCT02145052|Running suture
156428|NCT02145052|Continuous suture
156429|NCT02145039|Acute Lymphoblastic Leukemia (ALL)
156430|NCT02145039|Acute Myelogenous Leukemia (AML)
156431|NCT02145039|Burkitt's lymphoma
156432|NCT02145039|Natural killer cell malignancies
156433|NCT02145039|Chronic myelogenous leukemia
156434|NCT02145039|Myelodysplastic syndrome
156435|NCT02145039|Large-cell lymphoma
156436|NCT02145039|Hodgkin lymphoma
156437|NCT02145039|Multiple myeloma
156438|NCT02145039|Chronic lymphocytic leukemia (CLL)
156439|NCT02145039|Small lymphocytic lymphoma (SLL)
156440|NCT02145039|Marginal zone B-cell lymphoma
156441|NCT02145039|Follicular lymphoma
156442|NCT02145039|Lymphoplasmacytic lymphoma
156443|NCT02145039|Mantle-cell lymphoma
156444|NCT02145039|Prolymphocytic leukemia
156445|NCT02145039|Refractory leukemia
156446|NCT02145039|MDS
156447|NCT02145039|Bone marrow failure syndromes
156448|NCT02145039|Myeloproliferative syndromes
156449|NCT02145013|portal hypertension, hepatocellular carcinoma, resection
156450|NCT02145000|Rotavirus
156451|NCT02145000|Gastroenteritis
156452|NCT02145000|Diarrhea
156453|NCT02145000|Vaccine
156454|NCT02145000|Niger
156455|NCT02144974|Total pelvic exenteration.
156456|NCT02144961|breast reconstruction
156457|NCT02144961|Deep Inferior Epigastric Artery Perforator (DIEP)
156458|NCT02144961|Indocyanine Green Angiography (IGA)
156459|NCT02144961|autologous tissue transfer
156460|NCT02144948|diabetes
156461|NCT02144935|pediatrics
156462|NCT02144922|Hypertension
156463|NCT02144922|Statin
156464|NCT02144909|Diabetes self management
156465|NCT02144909|support group
156466|NCT02144909|semi structured support group
156467|NCT02144883|telephone counseling
156468|NCT02144870|Tic-Disorder, Tourette-Disorder, Habit Reversal Training, Resources activation
156469|NCT02144844|Antepartum depressive symptoms
156470|NCT02144844|Antepartum depression
156471|NCT02144844|Cognitive behavioral intervention
156472|NCT02144844|Feasibility
156473|NCT02144844|randomized clinical trial
156474|NCT02144831|TIA
156475|NCT02144831|stroke prevention
156476|NCT02144831|ASA
156477|NCT02144831|clopidogrel
156478|NCT02144831|dual antiplatelet treatment
156479|NCT02144753|IBS-C
156480|NCT02144753|Constipation
156481|NCT02144753|IBS
156482|NCT02144740|Flow-mediated dilation
156483|NCT02144688|Human Immunodeficiency Virus
156484|NCT02144688|HIV
156485|NCT02144688|Cognitive symptoms
156486|NCT02144688|Cognitive evaluation
156487|NCT02144688|Neuropsychological testing
156488|NCT02144688|Quality of life
156489|NCT02144688|Anxiety
156490|NCT02144688|Viral load
156491|NCT02144688|Antiretroviral
156492|NCT02144688|Cerebrospinal fluid
156493|NCT02144688|Lumbar puncture
156494|NCT02144688|Magnetic resonance imaging
156495|NCT02144688|MRI
156496|NCT02144649|Prostate Cancer
156497|NCT02144649|Tangerine Juice
156498|NCT02144649|Tomato Juice
156499|NCT02144623|Chronic Lymphocytic Leukemia
156500|NCT02144623|Valproate
156501|NCT02144623|Cluster of differentiation antigen 20
156502|NCT02144623|Lymphomas
156503|NCT02144623|B-cell lymphomas
156504|NCT02144623|Translational research
156505|NCT02144623|Monoclonal antibodies
156506|NCT02144610|CLI
156507|NCT02144597|morbid obesity
156508|NCT02144597|gastric bypass
156509|NCT02144597|bariatrics
156510|NCT02144597|diet
156511|NCT02144597|caloric restriction
156512|NCT02144597|liver fat
156513|NCT02144597|appetite
156514|NCT02144584|ischemic stroke
156515|NCT02144584|memantine
156516|NCT02144584|upper extremity weakness
156517|NCT02144584|motor recovery
156518|NCT02144558|Sperm parameters
156519|NCT02144558|Spinal cord injuries
156520|NCT02144558|Oxidative stress
156521|NCT02144558|Inflammatory syndrome
156522|NCT02144545|Surgery
156523|NCT02144545|Morbid Obesity
156524|NCT02144545|Bariatric surgery
156525|NCT02144545|Sleeve gastrectomy
156526|NCT02144545|Bougie Size
156527|NCT02144545|Distance from pylorus
156528|NCT02144545|Hormones
156529|NCT02144545|Gastric remanent
156530|NCT02144532|Ehlers-Danlos syndrome
156531|NCT02144532|hypermobility
156532|NCT02144532|Compression garment
156533|NCT02144532|pain
156534|NCT02144532|isokinetic evaluation
156535|NCT02144506|Elderly, home-based exercises programm
156536|NCT02144493|common bile duct stones
156537|NCT02144493|diverticulum
156538|NCT02144480|coronary bypass surgery
156539|NCT02144480|rehabilitation
156540|NCT02144480|exercise training
156541|NCT02144480|platelet activation
156542|NCT02144480|cardiopulmonary fitness
156543|NCT02144467|Multiple-MRI, Gene, Cognition
156544|NCT02144454|Cardiovascular disease
156545|NCT02144454|Fatty acids
156546|NCT02144454|Vascular function
156547|NCT02144454|Blood pressure
156548|NCT02144454|Plasma lipids
156549|NCT02144454|Insulin resistance
156550|NCT02144454|Endothelial activation
156551|NCT02144441|Diabetes Mellitus
156552|NCT02144441|Insulin
156553|NCT02144441|Self Administration
156554|NCT02144441|Patient Satisfaction
156555|NCT02144441|Glucose
156556|NCT02144441|Hypoglycemia
156557|NCT02144441|Hyperglycemia
156558|NCT02144415|abuse liability
156559|NCT02144415|recreational drug user
156560|NCT02144415|stimulant
156561|NCT02144415|d-amphetamine
156562|NCT02144415|ADHD
156563|NCT02144389|Arachidonic acid
156564|NCT02144389|Bilharzia
156565|NCT02144389|Mansoni
156566|NCT02144389|Schistosomiasis
156567|NCT02144389|Polyunsaturated fatty acid
156568|NCT02144376|Constipation
156569|NCT02144376|psyllium
156570|NCT02144376|ispaghula
156571|NCT02144376|Magnetic Resonance Imaging
156572|NCT02144376|MRI
156573|NCT02144376|microbiota
156574|NCT02144363|Preterm
156575|NCT02144363|RDS
156576|NCT02144363|Mechanical Ventilation
156577|NCT02144363|Extubation failure
156578|NCT02144350|hyperbaric oxygen
156579|NCT02144337|Physical activity
156580|NCT02144337|Type 1 Diabetes Mellitus
156581|NCT02144337|Children
156582|NCT02144337|Intervention
156583|NCT02144324|Maxillary protraction
156584|NCT02144324|Modified Tandem Appliance
156585|NCT02144324|Face mask therapy
156586|NCT02144324|Class III malocclusion
156587|NCT02144324|Maxillary deficiency
156588|NCT02144311|MRI
156589|NCT02144311|FDG PET/CT
156590|NCT02144311|histologic heterogeneity
156591|NCT02144311|14-061
156592|NCT02144298|microcirculation
156593|NCT02144298|coronary artery bypass grafting
156594|NCT02144298|cold blood cardioplegia
156595|NCT02144298|cristalloid cardioplegia
156596|NCT02144285|Renal dialysis
156597|NCT02144272|Antibody
156598|NCT02144272|Tumor Necrosis Factor alpha
156599|NCT02144272|Interleukin-17
156600|NCT02144233|Pain
156601|NCT02144233|Temporomandibular joint disorders
156602|NCT02144233|Occlusal adjustment
156603|NCT02144233|Therapy
156604|NCT02144233|Randomized clinical trial
156605|NCT02144233|Mastication
156606|NCT02144233|Habitual chewing side
156607|NCT02144233|Handedness preference
156608|NCT02144233|Hemimandibular retrognathia
156609|NCT02144220|Telemedicine
156610|NCT02144220|Virtual care visit
156611|NCT02144220|Remote visit
156612|NCT02144220|Video-conferencing
156613|NCT02144194|Oral Vinorelbine
156614|NCT02144194|Oral Chemotherapy
156615|NCT02144194|Metastatic Breast Cancer
156616|NCT02144194|Advanced Breast Cancer
156617|NCT02144194|Maintenance treatment
156618|NCT02144181|Ulthera® System
156619|NCT02144181|Ultherapy® Treatment
156620|NCT02144181|Ulthera, Inc.
156621|NCT02144168|Prebiotics
156622|NCT02144168|diarrhoea
156623|NCT02144168|Enteral nutrition
156624|NCT02144168|Fibre
156625|NCT02144168|Bifidobacteria
156626|NCT02144168|SCFA
156627|NCT02144155|Oxytocin
156628|NCT02144142|Microbiome
156629|NCT02144142|Atopic dermatitis
156630|NCT02144142|Eczema
156631|NCT02144142|Bacteriotherapy
156632|NCT02144129|Whole Body Electromyostimulation
156633|NCT02144129|Inflammatory Bowel Disease
156634|NCT02144129|Lean Body Mass
156635|NCT02144129|Muscle Strength
156636|NCT02144116|dance-movement therapy
156637|NCT02144116|balance
156638|NCT02144116|Fibromyalgia
156639|NCT02144103|Glaucomatous Neurodegeneration
156640|NCT02144103|Retinal Degeneration
156641|NCT02144103|Primary Open-Angle Glaucoma
156642|NCT02144103|Optic Neuropathy
156643|NCT02144103|Intraocular pressure
156644|NCT02144103|Retinal ganglion cell degeneration
156645|NCT02144103|Optic nerve atrophy
156646|NCT02144103|Subtenon injection
156647|NCT02144103|Glaucomatous damage
156648|NCT02144103|ADRC
156649|NCT02144103|Adipose-derived regenerative cells
156650|NCT02144103|Fat tissue
156651|NCT02144103|Stem cells
156652|NCT02144090|Angiography
156653|NCT02144090|Angioplasty
156654|NCT02144090|Coronary artery disease
156655|NCT02144090|Diagnostic
156656|NCT02144090|Fractional flow reserve
156657|NCT02144077|Photodynamic Therapy
156658|NCT02144077|PDT
156659|NCT02144077|non-aggressive BCC
156660|NCT02144064|Aspirin, heparin, pregnancy, recurrent miscarriage
156661|NCT02144051|solid tumor, prostate cancer, breast cancer, bladder cancer, ovarian cancer, gastric cancer, salivary duct cancer
156662|NCT02144038|multiple myeloma,
156663|NCT02144038|relapsed and refractory,
156664|NCT02144038|LGH447,
156665|NCT02144038|pan-PIM inhibitor,
156666|NCT02144038|PIM Kinase,
156667|NCT02144038|BYL719,
156668|NCT02144038|PI3K inhibitor
156669|NCT02144025|Ocular Graft-Versus-Host-Disease
156670|NCT02144025|Topical Cyclosporine
156671|NCT02143986|sepsis
156672|NCT02143986|Macrophagic activation syndrome
156673|NCT02143986|Ferritin
156674|NCT02143986|Still's disease
156675|NCT02143973|Uremic
156676|NCT02143973|Pruritus
156677|NCT02143973|Itch
156678|NCT02143973|Chronic Itch
156679|NCT02143973|Nalbuphine
156680|NCT02143960|Syneron
156681|NCT02143960|Velashape
156682|NCT02143960|ELOS
156683|NCT02143960|Zeltiq
156684|NCT02143960|Cryolipolysis
156685|NCT02143947|Orthoses
156686|NCT02143947|Foot
156687|NCT02143947|Kinematics
156688|NCT02143947|EMG
156689|NCT02143947|Biomechanics
156690|NCT02143934|Plasmodium vivax
156691|NCT02143934|Hypnozoites
156692|NCT02143934|Primaquine
156693|NCT02143934|Liver-stage
156694|NCT02143934|Blood-stage
156695|NCT02143934|Plasmodium falciparum
156696|NCT02143921|NGO zinc scale
156697|NCT02143921|compliance with WHO zinc treatment recommendations
156698|NCT02143908|Diarrhea
156699|NCT02143908|L-lysine supplementation
156700|NCT02143908|immune status
156701|NCT02143908|adults
156702|NCT02143908|Bangladesh
156703|NCT02143908|aged 18-45 years
156704|NCT02143908|urban community
156705|NCT02143882|Live attenuated influenza vaccine
156706|NCT02143882|fluenz
156707|NCT02143882|pandemrix
156708|NCT02143882|pandemic influenza vaccine
156709|NCT02143882|immunogenicity
156710|NCT02143869|Gastrointestinal cancer
156711|NCT02143869|Lung cancer
156712|NCT02143869|Bioelectrical Impedance analysis
156713|NCT02143869|Body composition
156714|NCT02143869|Perioperative
156715|NCT02143830|marrow aplasia
156716|NCT02143830|cytopenia
156717|NCT02143830|myelodysplasia
156718|NCT02143830|AML
156719|NCT02143830|bone marrow transplant
156720|NCT02143830|cytoreductive regimen
156721|NCT02143830|T-cell reduction
156722|NCT02143817|whole body vibration training
156723|NCT02143817|L-citrulline
156724|NCT02143817|hypertension
156725|NCT02143817|obesity
156726|NCT02143817|arterial function
156727|NCT02143817|arterial stiffness
156728|NCT02143817|autonomic function
156729|NCT02143817|endothelial function
156730|NCT02143804|Oncolytic virus
156731|NCT02143804|GMCSF
156732|NCT02143804|pRb
156733|NCT02143804|PDL1
156734|NCT02143804|Immunotherapy
156735|NCT02143804|Adenovirus
156736|NCT02143791|SCS
156737|NCT02143791|Burst stimulation
156738|NCT02143778|MBT
156739|NCT02143778|CSPH
156740|NCT02143778|HVPG
156741|NCT02143765|Mitiglinide
156742|NCT02143765|Acarbose
156743|NCT02143765|Type 2 Diabetes Mellitus
156744|NCT02143752|Smoking
156745|NCT02143752|Tobacco
156746|NCT02143752|Addiction
156747|NCT02143752|Mindfulness
156748|NCT02143752|Meditation
156749|NCT02143739|asthma
156750|NCT02143713|Dyspareunia
156751|NCT02143713|Endometriosis-associated pain
156752|NCT02143713|Dysmenorrhea (DYS)
156753|NCT02143713|Elagolix
156754|NCT02143713|Gonadotropin-releasing Hormone Antagonist
156755|NCT02143713|Non-menstrual Pelvic Pain (NMPP)
156756|NCT02143700|exacerbation
156757|NCT02143700|cognitive
156758|NCT02143700|chronic obstructive pulmonary disease
156759|NCT02143687|Pulmonary hypertension
156760|NCT02143687|Interstitial lung disease
156761|NCT02143687|Pulmonary fibrosis
156762|NCT02143674|Stretching exercise muscle
156763|NCT02143674|Elderly
156764|NCT02143674|Techniques and exercise
156765|NCT02143674|Physiotherapy
156766|NCT02143648|uremic
156767|NCT02143648|pruritus
156768|NCT02143648|itch
156769|NCT02143648|chronic itch
156770|NCT02143648|nalbuphine
156771|NCT02143635|HDM201,TP53wt, p53, MDM2, HDM2, advanced tumors, BLRM (Bayesian logistic regression model)
156772|NCT02143622|Head and neck cancer
156773|NCT02143609|airway disease
156774|NCT02143609|bronchitis
156775|NCT02143609|emphysema
156776|NCT02143609|lung
156777|NCT02143596|stroke
156778|NCT02143596|dehydration
156779|NCT02143596|prognosis
156780|NCT02143583|rhinoconjunctivitis
156781|NCT02143583|birch pollen
156782|NCT02143583|desensitization
156783|NCT02143583|allergen immunotherapy
156784|NCT02143570|Urinary Bladder, Overactive
156785|NCT02143570|Darifenacin
156786|NCT02143570|Physiotherapy
156787|NCT02143570|Quality of Life
156788|NCT02143557|breast milk
156789|NCT02143557|infants
156790|NCT02143557|chylothorax
156791|NCT02143557|cardiac surgery
156792|NCT02143557|modified breast milk
156793|NCT02143544|Intra-aortic balloon counterpulsation
156794|NCT02143544|Cardiac surgery
156795|NCT02143544|High-risk patients
156796|NCT02143518|Human Hookworm
156797|NCT02143518|Necator americanus
156798|NCT02143518|Hookworm
156799|NCT02143518|Hookworm Disease
156800|NCT02143518|Iron-deficiency anemia
156801|NCT02143518|Soil-transmitted helminth infection
156802|NCT02143518|Neglected Tropical Disease
156803|NCT02143518|Na-GST-1
156804|NCT02143518|CpG
156805|NCT02143479|France
156806|NCT02143479|Prograf
156807|NCT02143479|Pharmaco-epidemiology
156808|NCT02143479|Tacrolimus
156809|NCT02143479|Observational
156810|NCT02143466|Phase I
156811|NCT02143466|Safety
156812|NCT02143466|Tolerability
156813|NCT02143466|Efficacy
156814|NCT02143466|Anti-tumour
156815|NCT02143466|AZD9291
156816|NCT02143466|Osimertinib
156817|NCT02143466|MEDI4736
156818|NCT02143466|Durvalumab
156819|NCT02143466|AZD6094
156820|NCT02143466|Savolitinib
156821|NCT02143466|Selumetinib
156822|NCT02143466|Ascending Doses
156823|NCT02143466|Expansion cohorts
156824|NCT02143466|EGFR
156825|NCT02143466|Advanced Non-Small Cell Lung Cancer
156826|NCT02143466|Tyrosine Kinase Inhibitors
156827|NCT02143453|exercise
156828|NCT02143453|overweight
156829|NCT02143453|children
156830|NCT02143427|social skills training,
156831|NCT02143427|computer based,
156832|NCT02143427|social competence training,
156833|NCT02143427|Oppositional Defiant Disorder
156834|NCT02143427|peer related aggressive behavior
156835|NCT02143427|randomized controlled trial
156836|NCT02143388|Local advanced
156837|NCT02143388|high risk
156838|NCT02143388|nasopharyngeal carcinoma
156839|NCT02143362|Intraoperative wake up
156840|NCT02143362|Closed loop of target controlled infusion
156841|NCT02143362|Dexmedetomidine
156842|NCT02143362|Propofol
156843|NCT02143349|obesity
156844|NCT02143349|herbal remedies
156845|NCT02143349|metabolic disorders
156846|NCT02143336|Surgical site infections
156847|NCT02143336|Skin closure techniques
156848|NCT02143336|Colorectal surgery
156849|NCT02143323|GST, DILI, biomarker
156850|NCT02143297|Sleep Apnea/Hypopnea Syndrome
156851|NCT02143297|Pulse Oximetry
156852|NCT02143297|Nonlinear Dynamics
156853|NCT02143297|Fourier Analysis
156854|NCT02143297|Neural Networks (Computer)
156855|NCT02143271|Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
156856|NCT02143258|stenting venous sinus
156857|NCT02143258|intracranial hypertension
156858|NCT02143258|quality of life
156859|NCT02143258|headache
156860|NCT02143258|visual impairment
156861|NCT02143232|knee replacement
156862|NCT02143232|hip replacement
156863|NCT02143232|patient monitor
156864|NCT02143219|Pancreatic metastatic cancer
156865|NCT02143219|FOLFIRINOX
156866|NCT02143219|toxicity
156867|NCT02143219|efficacy
156868|NCT02143206|Chronic Obstructive Pulmonary Disease
156869|NCT02143206|Pain
156870|NCT02143206|Arthritis
156871|NCT02143206|Dyspnea
156872|NCT02143206|Exercise
156873|NCT02143206|Aerobic
156874|NCT02143193|Breastfeeding
156875|NCT02143193|Newborn
156876|NCT02143193|Formula
156877|NCT02143193|Temperature
156878|NCT02143193|Initial Bath
156879|NCT02143180|real-time tissue elastography
156880|NCT02143180|hepatic fibrosis
156881|NCT02143154|vancomycin, GBS
156882|NCT02143141|postoperative pain
156883|NCT02143141|narcotic side effects
156884|NCT02143128|score
156885|NCT02143128|postoperative
156886|NCT02143128|pain
156887|NCT02143128|nausea
156888|NCT02143128|mental status
156889|NCT02143128|tool
156890|NCT02143115|Colorectal cancer surveillance
156891|NCT02143089|CCSWI
156892|NCT02143076|Medication Adherence
156893|NCT02143076|Hydroxyurea
156894|NCT02143050|Unresectable melanoma Stage IIIC and Stage IV BRAF V600E+
156895|NCT02143024|depression
156896|NCT02143024|family
156897|NCT02143024|primary health care
156898|NCT02143011|sugar
156899|NCT02143011|sucrose
156900|NCT02143011|fruit juice
156901|NCT02143011|orange juice
156902|NCT02143011|metabolism
156903|NCT02143011|immune cell aging
156904|NCT02143011|lipids
156905|NCT02142998|GERD
156906|NCT02142998|Laparoscopic
156907|NCT02142998|sleeve
156908|NCT02142998|gastrectomy
156909|NCT02142972|Low back pain
156910|NCT02142972|Oswestry questionnaire
156911|NCT02142972|Post-partum Depression
156912|NCT02142972|Pelvic pain
156913|NCT02142959|RTA 408
156914|NCT02142959|RTA 408 Lotion
156915|NCT02142959|Breast cancer
156916|NCT02142959|Radiation therapy
156917|NCT02142959|Radiation dermatitis
156918|NCT02142959|Oxidative stress
156919|NCT02142959|Inflammation
156920|NCT02142959|omaveloxolone
156921|NCT02142933|colonization
156922|NCT02142933|screening
156923|NCT02142933|group B streptococci
156924|NCT02142933|extended-spectrum beta-lactamase
156925|NCT02142933|enterobacteriaceae
156926|NCT02142920|Healthy Volunteers
156927|NCT02142907|Breast conservative surgery
156928|NCT02142907|boost radiation
156929|NCT02142907|acute toxicity
156930|NCT02142907|cosmesis
156931|NCT02142907|local control
156932|NCT02142894|Tuberculosis
156933|NCT02142894|TB
156934|NCT02142868|Expanded Access
156935|NCT02142868|Advanced Breast Cancer
156936|NCT02142855|volunteers
156937|NCT02142855|young (18-30 y)
156938|NCT02142855|older (65-75 y)
156939|NCT02142855|age groups
156940|NCT02142842|Adipose stem cell
156941|NCT02142842|Platelet rich plasma
156942|NCT02142842|Knee Osteoarthritis
156943|NCT02142842|Injured cartilage
156944|NCT02142829|bariatric surgery, postoperative pain
156945|NCT02142777|S-equol
156946|NCT02142777|COX activity
156947|NCT02142764|Multiple Sclerosis
156948|NCT02142764|CD8+ T-cells
156949|NCT02142764|Class I Major Histocompatibility Complex (MHC)
156950|NCT02142764|pentamers
156951|NCT02142751|Escherichia coli
156952|NCT02142751|Extended-spectrum β-lactamases (ESBLs)
156953|NCT02142751|Bacteremia
156954|NCT02142751|Urinary tract infection
156955|NCT02142751|Bloodstream infection
156956|NCT02142751|Fosfomycin
156957|NCT02142751|Meropenem
156958|NCT02142751|Pharmacokinetics
156959|NCT02142751|intestinal colonization
156960|NCT02142751|Recurrence
156961|NCT02142751|multidrug resistance E.coli
156962|NCT02142751|Ceftriaxone
156963|NCT02142738|PD-1
156964|NCT02142738|PD1
156965|NCT02142738|PD-L1
156966|NCT02142738|PDL1
156967|NCT02142712|Ischemic Stroke
156968|NCT02142712|Brain Edema
156969|NCT02142712|Diphenhydramine
156970|NCT02142712|Dextromethorphan
156971|NCT02142712|Famotidine
156972|NCT02142699|Acute kidney injury
156973|NCT02142699|Cardiac surgery
156974|NCT02142699|Ischaemia reperfusion injury
156975|NCT02142699|hemearginate
156976|NCT02142686|Hysteroscopy
156977|NCT02142686|Filling pressures
156978|NCT02142673|Operative hysteroscopy
156979|NCT02142673|Filling pressure
156980|NCT02142660|Adhesion barrier system
156981|NCT02142660|Bariatric surgery
156982|NCT02142647|infant growth
156983|NCT02142647|dietary protein
156984|NCT02142647|body composition
156985|NCT02142647|gut microbiome
156986|NCT02142608|Prostate cancer
156987|NCT02142608|Ultrasound Imaging
156988|NCT02142595|dexmedetomidine
156989|NCT02142595|midazolam
156990|NCT02142595|sleep quality
156991|NCT02142595|delirium
156992|NCT02142582|Home Parenteral Nutrition
156993|NCT02142582|Compliance
156994|NCT02142582|Short Bowel Syndrome
156995|NCT02142582|Oral Rehydration Solution
156996|NCT02142569|Monacolin K
156997|NCT02142569|Cholesterol
156998|NCT02142569|Tocotrienol-enriched fraction of palm oil (TRF)
156999|NCT02142569|Chinese Red Yeast Rice (CRYR
157000|NCT02142530|NHL
157001|NCT02142530|DLBCL
157002|NCT02142530|PTCL
157003|NCT02142530|Marginal zone lymphoma
157004|NCT02142530|lymphoplasmacytic lymphoma
157005|NCT02142530|Waldenstrom's macroglobulinemia
157006|NCT02142517|pancreaticoduodenectomy, pancreatic fistula
157007|NCT02142504|Drug therapy
157008|NCT02142491|Egg allergy
157009|NCT02142491|live attenuated influenza vaccine
157010|NCT02142478|physical activity
157011|NCT02142478|behaviour change
157012|NCT02142478|exercise referral
157013|NCT02142478|self-determination theory
157014|NCT02142478|mixed-method
157015|NCT02142478|evaluation
157016|NCT02142478|qualitative
157017|NCT02141867|Surgery
157018|NCT02141867|Mortality
157019|NCT02141841|intrathecal;
157020|NCT02141841|bupivacaine;
157021|NCT02141841|concentration;
157022|NCT02141828|Leukemia
157023|NCT02141828|Advanced hematologic malignancies
157024|NCT02141828|Epizyme
157025|NCT02141828|Phase 1b
157026|NCT02141828|MLL gene
157027|NCT02141828|11q23
157028|NCT02141828|Ambiguous lineage
157029|NCT02141828|ALL
157030|NCT02141828|AML
157031|NCT02141828|Acute leukemias
157032|NCT02141828|MLL-r
157033|NCT02141763|Psoriatic Arthritis
157034|NCT02141724|Neuromuscular
157035|NCT02141724|Wheelchair
157036|NCT02141724|Pain
157037|NCT02141724|Bedsore
157038|NCT02141724|Trouble postural
157039|NCT02141711|Drug therapy
157040|NCT02141698|Drug therapy
157041|NCT02142452|Pregnancy
157042|NCT02142452|Obesity/Overweight
157043|NCT02142452|postpartum
157044|NCT02142452|mobile health
157045|NCT02142452|cardiovascular disease
157046|NCT02142439|Anorexia
157047|NCT02142439|Bulimia
157048|NCT02142439|Physical activity
157049|NCT02142439|Treatment
157050|NCT02142426|wound chronic
157051|NCT02142413|Stroke
157052|NCT02142413|Atrial fibrillation
157053|NCT02142413|Holter ECG
157054|NCT02142413|cardiac MRI
157055|NCT02142335|B-Raf, inoperable stage III melanoma, metastatic stage IV melanoma,
157056|NCT02142296|Pigment Epithelial Detachment
157057|NCT02142296|Age-related Macular degeneration
157058|NCT02142283|Mechanical thrombectomy
157059|NCT02142283|Acute ischemic stroke
157060|NCT02142283|Wake up stroke
157061|NCT02142283|Late presenting stroke
157062|NCT02142257|Obesity
157063|NCT02142257|Gastric Bypass
157064|NCT02142257|Aspiration Therapy
157065|NCT02142257|AspireAssist
157066|NCT02142244|Sentinel node biopsy
157067|NCT02142244|Near infra red light
157068|NCT02142244|Indocyanine green
157069|NCT02142244|micrometastasis
157070|NCT02142231|acupuncture
157071|NCT02142231|test anxiety
157072|NCT02142231|neuroenhancer
157073|NCT02142231|placebo
157074|NCT02142179|Asthma
157075|NCT02142179|Knowledge
157076|NCT02142179|School-Based Service
157077|NCT02142179|Adolescents
157078|NCT02142166|aneurysmal subarachnoid hemorrhage (ASH)
157079|NCT02142166|biomarker
157080|NCT02142153|First in man
157081|NCT02142153|Antifungal
157082|NCT02142153|Intravenous infusion
157083|NCT02142153|Healthy volunteers
157084|NCT02142140|Treatment of ADHD
157085|NCT02142140|Long-term treatment follow-up
157086|NCT02142127|GFT505
157087|NCT02142127|Mass balance
157088|NCT02142127|Pharmacokinetics
157089|NCT02142127|Metabolites
157090|NCT02142127|Healthy subjects
157091|NCT02142127|Healthy male volunteers
157092|NCT02142114|Intravitreal injection
157093|NCT02142114|Needle size
157094|NCT02142114|Pain
157095|NCT02142114|Intraocular pressure
157096|NCT02142114|Pain following an Intravitreal injection
157097|NCT02142101|Gut Microbiota
157098|NCT02142101|Polycystic kidney disease
157099|NCT02142101|Chronic kidney disease
157100|NCT02142101|Uremic metabolites
157101|NCT02142088|Glycaemic Control
157102|NCT02142088|Glucose Monitoring
157103|NCT02142088|Intravascular Glucose Monitoring
157104|NCT02142075|Pharmacokinetics
157105|NCT02142062|Venous outflow obstruction
157106|NCT02142062|Iliac Vein
157107|NCT02142062|Common Femoral Vein
157108|NCT02142062|Iliac Compression
157109|NCT02142049|DLBCL
157110|NCT02142049|ABC
157111|NCT02142049|GCB
157112|NCT02142049|Primary Mediastinal B-cell lymphoma
157113|NCT02142049|Pharmacyclics
157114|NCT02142049|Lenalidomide
157115|NCT02142049|lymphoma
157116|NCT02142049|Rituximab
157117|NCT02142049|EPOCH
157118|NCT02142036|Metastatic disease
157119|NCT02142036|Metastasis
157120|NCT02142036|Targeted therapy
157121|NCT02142036|Solid tumor
157122|NCT02142036|Personalized medicine
157123|NCT02142036|N-of-1 trial
157124|NCT02141997|efficacy
157125|NCT02141997|Methotrexate
157126|NCT02141997|safety
157127|NCT02141984|Korean regulatory required Postmarketing Surveillance
157128|NCT02141971|Down syndrome
157129|NCT02141971|Alzheimer's disease
157130|NCT02141971|biomarkers
157131|NCT02141971|amyloid
157132|NCT02141971|tau
157133|NCT02141945|Cancer
157134|NCT02141945|Colon Cancer
157135|NCT02141945|Colorectal Cancer
157136|NCT02141945|Neoplasm
157137|NCT02141945|Colorectal Neoplasm
157138|NCT02141945|Intestinal Neoplasms
157139|NCT02141945|Gastrointestinal Neoplasms
157140|NCT02141945|Digestive System Neoplasms
157141|NCT02141945|Neoplasms by Site
157142|NCT02141945|Neoplasms
157143|NCT02141945|Colonic Diseases
157144|NCT02141945|Digestive System Diseases
157145|NCT02141945|Gastrointestinal Diseases
157146|NCT02141945|Intestinal Diseases
157147|NCT02141945|Rectal Diseases
157148|NCT02141932|Hand-held
157149|NCT02141932|Ultrasound
157150|NCT02141932|Diagnosis
157151|NCT02141932|Cardiovascular
157152|NCT02141932|Carotid artery stenosis
157153|NCT02141919|renal cancer
157154|NCT02141880|Obesity
157155|NCT02141685|in vitro fertilization
157156|NCT02141685|assisted reproduction techniques
157157|NCT02141685|noninvasive imaging of embryos
157158|NCT02141685|time lapse imaging of embryos
157159|NCT02141685|traditional morphological grading of embryos
157160|NCT02141685|prediction of blastocysts
157161|NCT02141685|infertility
157162|NCT02141685|preimplantation genetic diagnosis
157163|NCT02141685|array-Comparative Genomic Hybridization
157164|NCT02141672|lupus nephritis
157165|NCT02141672|calcineurin inhibitors
157166|NCT02141672|voclosporin
157167|NCT02141646|adolescent risky sexual behavior, MI, BST
157168|NCT02141633|smokers
157169|NCT02141633|airway blood flow
157170|NCT02141633|fluticasone
157171|NCT02141633|echocardiogram
157172|NCT02141607|shock
157173|NCT02141607|heart failure
157174|NCT02141607|inflammation
157175|NCT02141607|biomarkers
157176|NCT02141607|cardiovascular instability
157177|NCT02141607|metabolic pathways
157178|NCT02141607|proteolysis
157179|NCT02141581|Influenza vaccine
157180|NCT02141568|Cost-effective
157181|NCT02141568|Unexplained Medical Symptoms
157182|NCT02141568|Frequent Attenders
157183|NCT02141555|misoprostol, early pregnancy loss, missed abortion
157184|NCT02141542|Metastatic Melanoma
157185|NCT02141529|Intraarticular
157186|NCT02141529|pulsed radiofrequency
157187|NCT02141529|osteoarthritis
157188|NCT02141516|Meningitis
157189|NCT02141516|vaccination
157190|NCT02141516|complement deficiency
157191|NCT02141516|asplenia
157192|NCT02141516|splenic dysfunction
157193|NCT02141503|Biomarkers
157194|NCT02141503|Alpha-Manosidosis
157195|NCT02141490|Lymph Node
157196|NCT02141490|Biopsy
157197|NCT02141490|Metastatic Nodes
157198|NCT02141490|Imaging Agent
157199|NCT02141477|Leukemia
157200|NCT02141477|Acute Myelogenous Leukemia
157201|NCT02141477|AML
157202|NCT02141477|High Risk Myelodysplastic Syndrome
157203|NCT02141477|MDS
157204|NCT02141477|Omacetaxine
157205|NCT02141477|Synribo
157206|NCT02141477|Homoharringtonine
157207|NCT02141477|Decitabine
157208|NCT02141477|Dacogen
157209|NCT02141451|DLBCL
157210|NCT02141438|Radium-223
157211|NCT02141438|Metastatic castration-resistant prostate cancer
157212|NCT02141438|CRPC
157213|NCT02141438|Phase IV
157214|NCT02141438|Safety study
157215|NCT02141425|Healthy volunteers
157216|NCT02141425|ASP015K
157217|NCT02141412|optimal dose of dexmedetomidine
157218|NCT02141412|prevent shivering
157219|NCT02141412|improve quality of emergence
157220|NCT02141412|anesthesia
157221|NCT02141412|without delay
157222|NCT02141412|recovery
157223|NCT02141386|Multiple Sclerosis
157224|NCT02141386|Cognitive remediation
157225|NCT02141386|Plasticity-based, adaptive, computerized cognitive remediation
157226|NCT02141386|Cognitive impairment
157227|NCT02141373|seroma
157228|NCT02141373|axillary
157229|NCT02141373|dissection
157230|NCT02141360|Mild Traumatic Brain Injury
157231|NCT02141321|IUD
157232|NCT02141321|Misoprostol
157233|NCT02141321|Rectal administration
157234|NCT02141308|Retina
157235|NCT02141308|Optical coherence tomography
157236|NCT02141308|Imaging
157237|NCT02141282|Oncology
157238|NCT02141282|Cancer of the blood and bone marrow
157239|NCT02141282|Chronic Lymphocytic Leukemia
157240|NCT02141269|Transthoracic echocardiogram
157241|NCT02141269|Hand-held Echocardiography
157242|NCT02141256|elderly
157243|NCT02141256|protein enrichment
157244|NCT02141256|undernutrition
157245|NCT02141217|Odontogenic (Dental) Infections
157246|NCT02141217|Dental infections, periapical abscess
157247|NCT02141217|Bacterial infection
157248|NCT02141204|HRV
157249|NCT02141204|Liquid vaccine
157250|NCT02141204|Human rotavirus vaccine
157251|NCT02141191|cystic fibrosis
157252|NCT02141191|hypertonic saline
157253|NCT02141191|nebulizer
157254|NCT02141191|nasal cannula
157255|NCT02141165|sleep apnea
157256|NCT02141165|portable monitor
157257|NCT02141165|primary care
157258|NCT02141165|cost-effectiveness
157259|NCT02141165|OSAS
157260|NCT02141139|Anti-Inflammatory Agents, Non-Steroidal
157261|NCT02141139|Inflammation
157262|NCT02141139|Perioperative Period
157263|NCT02141126|Older adults
157264|NCT02141126|Strength training
157265|NCT02141126|Muscle mass
157266|NCT02141126|Function
157267|NCT02141126|Inpatients
157268|NCT02141100|thioguanine
157269|NCT02141100|mercaptopurine
157270|NCT02141100|methotrexate
157271|NCT02141048|Parenting programme
157272|NCT02141048|Randomised controlled trial
157273|NCT02141048|South Africa
157274|NCT02141048|Positive parenting
157275|NCT02141048|Child behaviour problems
157276|NCT02141048|Implementation fidelity
157277|NCT02141048|Low- and middle-income country
157278|NCT02141035|Acetyl-l-carnitine
157279|NCT02141035|Carpal tunnel syndrome
157280|NCT02141035|Motor unit number estimation
157281|NCT02141035|Compression neuropathy
157282|NCT02141022|Multiple Sclerosis
157283|NCT02141022|Cognition
157284|NCT02141022|Cognitive Remediation
157285|NCT02141022|Gilenya
157286|NCT02141022|Computerized Cognitive Exercise
157287|NCT02141009|Vaccination, prevnar, PCV13
157288|NCT02140996|MUC-1 vector vaccine; epithelial cancers; immunotherapy; safety; antigen specific vaccine, dendritic cell activation
157289|NCT02140983|Insulin Resistance
157290|NCT02140983|Family History of Dementia
157291|NCT02140983|Cognition
157292|NCT02140970|ureteral stent
157293|NCT02140970|stent pain
157294|NCT02140970|ureteral spasm
157295|NCT02140970|NSAID
157296|NCT02140970|ibuprofen
157297|NCT02140970|placebo
157298|NCT02140970|ureteropelvic junction obstruction
157299|NCT02140970|urolithiasis
157300|NCT02140957|Toddler Bottle Use
157301|NCT02140957|Educational Intervention
157302|NCT02140957|Pediatrics
157303|NCT02140957|Iron Deficiency
157304|NCT02140944|Cord blood transplantation
157305|NCT02140944|CCR5Δ32
157306|NCT02140944|HIV cure
157307|NCT02140931|Cell therapy
157308|NCT02140931|Autologous
157309|NCT02140918|Fludrocortisone
157310|NCT02140918|Mineralocorticoids
157311|NCT02140918|Hemodynamics
157312|NCT02140918|Pharmacokinetics
157313|NCT02140905|Hemodialysis
157314|NCT02140905|Heart failure
157315|NCT02140905|Impedance
157316|NCT02140905|Fluids
157317|NCT02140879|pregnancy
157318|NCT02140879|inflammation
157319|NCT02140879|infant assessment
157320|NCT02140853|MDR gram-negative bacilli
157321|NCT02140853|Mortality
157322|NCT02140853|Therapy
157323|NCT02140840|TMTB
157324|NCT02140840|Mekinist
157325|NCT02140840|Trametinib
157326|NCT02140840|relapse
157327|NCT02140840|refractory
157328|NCT02140840|response rate
157329|NCT02140827|bowel preparation
157330|NCT02140827|instant messaging program
157331|NCT02140814|PKD
157332|NCT02140814|niacinamide
157333|NCT02140814|Vitamin B3
157334|NCT02140814|Vitamin B
157335|NCT02140801|Percutaneous coronary intervention
157336|NCT02140801|Drug-eluting stent
157337|NCT02140801|Thrombosis
157338|NCT02140788|schizophrenia
157339|NCT02140788|schizo-affective disorder
157340|NCT02140775|HIV
157341|NCT02140775|AIDS
157342|NCT02140775|Fatigue
157343|NCT02140775|armodafinil
157344|NCT02140775|Unemployment
157345|NCT02140762|Meningitis ABCWY
157346|NCT02140762|adolescents
157347|NCT02140762|accination
157348|NCT02140762|meningococcal disease
157349|NCT02140749|Bifidobacteria
157350|NCT02140749|Bristol Stool Scale
157351|NCT02140749|Constipation
157352|NCT02140749|Diet
157353|NCT02140749|Fructooligosacchardes
157354|NCT02140749|Microbiota
157355|NCT02140749|Oligofructose
157356|NCT02140736|Chemotherapy-induced anemia
157357|NCT02140736|Epoetin biosimilar
157358|NCT02140723|preoperative short course radiotherapy
157359|NCT02140723|delay of surgery
157360|NCT02140723|rectal cancer
157361|NCT02140723|TP53
157362|NCT02140723|predictive marker
157363|NCT02140723|MRT imaging
157364|NCT02140710|premature infant
157365|NCT02140710|visceral osteopathy
157366|NCT02140710|alternative medicine
157367|NCT02140710|meconium passage
157368|NCT02140710|enteral feedings
157369|NCT02140710|hospital stay
157370|NCT02140684|Real-world
157371|NCT02140684|observational
157372|NCT02140684|Nitric oxide
157373|NCT02140684|Inhaled corticosteroid
157374|NCT02140684|UK
157375|NCT02140671|asthma management
157376|NCT02140671|anti-inflammatory therapy
157377|NCT02140671|compliance
157378|NCT02140671|hospital admission
157379|NCT02140671|educations
157380|NCT02140671|self-management
157381|NCT02140671|guidelines
157382|NCT02140671|exacerbations
157383|NCT02140671|diagnostic accuracy
157384|NCT02140671|symptom control
157385|NCT02140658|ischemic stroke
157386|NCT02140658|Statins Medication Compliance
157387|NCT02140658|outcome
157388|NCT02140632|Carpal tunnel syndrome
157389|NCT02140632|Local steroid injection
157390|NCT02140632|Wrist splinting
157391|NCT02140619|ischemic stroke
157392|NCT02140619|Medication Compliance
157393|NCT02140619|outcome
157394|NCT02140606|AML
157395|NCT02140606|phase1
157396|NCT02140606|MTD
157397|NCT02140606|Cafusertib
157398|NCT02140580|Minimally-invasive surfactant therapy
157399|NCT02140541|Asthma
157400|NCT02140541|Blood eosinophils
157401|NCT02140541|Sputum eosinophils
157402|NCT02140541|Clinical predictor
157403|NCT02140541|UK primary care
157404|NCT02140541|Global Initiative for Asthma (GINA)
157405|NCT02140528|Allogenic adipose derived mesenchymal stem cell tibial fracture
157406|NCT02140515|Gonal-F Luveris Assisted Reproductive Technology Hypogonadotropic Hypogonadism
157407|NCT02140502|Enterobacterial Infections
157408|NCT02140502|Prostate cancer
157409|NCT02140502|Biopsy
157410|NCT02140502|Incidence of fluoroquinolone resistant enteric bacteria
157411|NCT02140476|Thyroid goiter
157412|NCT02140476|Papillary thyroid cancer
157413|NCT02140476|Bipolar device
157414|NCT02140476|Sealing and cutting device
157415|NCT02140476|Thyroidectomy
157416|NCT02140450|intraocular pressure, intravitreal injection, short term
157417|NCT02140437|Fulvestrant
157418|NCT02140437|Anastrozole
157419|NCT02140437|Luminal A-like
157420|NCT02140437|Postmenopausal
157421|NCT02140437|Advanced breast cancer
157422|NCT02140424|type 1 diabetes
157423|NCT02140424|osteoporosis
157424|NCT02140424|children
157425|NCT02140398|infertility
157426|NCT02140398|PCOS
157427|NCT02140398|scratching
157428|NCT02140398|endometrial receptivity
157429|NCT02140372|colchicine
157430|NCT02140372|platelet activity
157431|NCT02140372|neutrophil
157432|NCT02140359|homelessness
157433|NCT02140359|housing first
157434|NCT02140359|social networks
157435|NCT02140359|drug abuse
157436|NCT02140359|alcohol use
157437|NCT02140359|HIV
157438|NCT02140333|erlotinib
157439|NCT02140333|EGFR mutation
157440|NCT02140307|Health Promotion
157441|NCT02140307|Prevention
157442|NCT02140307|Relaxation Response
157443|NCT02140307|Meditation
157444|NCT02140307|Cortisol
157445|NCT02140281|Phase I, Healthy Volunteers
157446|NCT02140268|Phase I
157447|NCT02140268|Healthy
157448|NCT02140268|Pharmacokinetics
157449|NCT02140255|HIV Remission
157450|NCT02140242|AML
157451|NCT02140242|leukemia
157452|NCT02140242|induction treatment
157453|NCT02140242|daunorubicin
157454|NCT02140242|7+3
157455|NCT02140229|Rheumatoid Arthritis
157456|NCT02140229|Remission,
157457|NCT02140229|DAS28,
157458|NCT02140229|ACR/EULAR,
157459|NCT02140229|RAPID, Randomized study,
157460|NCT02140229|Longitudinal follow-up
157461|NCT02140216|Blood transfusion
157462|NCT02140216|Immune
157463|NCT02140216|Surgery
157464|NCT02140203|Metabolic Syndrome
157465|NCT02140203|Waist circumference
157466|NCT02140203|blood pressure
157467|NCT02140203|triglyceride
157468|NCT02140203|HDL
157469|NCT02140177|Screening
157470|NCT02140177|Adults
157471|NCT02140177|Medical Inpatients
157472|NCT02140177|Suicide
157473|NCT02140164|Cystoid Macular Edema
157474|NCT02140164|Minocycline
157475|NCT02140164|Microglia
157476|NCT02140164|Retinitis Pigmentosa
157477|NCT02140151|amd
157478|NCT02140151|non-exudative macular degeneration
157479|NCT02140151|exudative macular degeneration
157480|NCT02140151|age-related macular degeneration
157481|NCT02140151|ranibizumab
157482|NCT02140151|anti-VEGF
157483|NCT02140125|ASP2408
157484|NCT02140112|T. suis ova
157485|NCT02140112|Trichuris suis ova
157486|NCT02140112|Autism Spectrum Disorder
157487|NCT02140112|ASD
157488|NCT02140099|Mental health
157489|NCT02140099|Violence
157490|NCT02140099|Substance use
157491|NCT02140099|Adolescent
157492|NCT02140099|Prevention
157493|NCT02140086|asthma
157494|NCT02140086|Buteyko
157495|NCT02140086|remedial breathing
157496|NCT02140086|children
157497|NCT02140073|GERD
157498|NCT02140073|Omez
157499|NCT02140073|Omez DSR
157500|NCT02140073|heartburn
157501|NCT02140073|esophagitis
157502|NCT02140073|omeprazole
157503|NCT02140073|omeprazole+domperidone
157504|NCT02140060|Glaucoma
157505|NCT02140060|Ocular
157506|NCT02140060|Hypertension
157507|NCT02140060|OAG
157508|NCT02140060|POAG
157509|NCT02140060|OHT
157510|NCT02140047|Haemophilus influenza type b
157511|NCT02140047|Hib
157512|NCT02140034|Extensive Peritoneal Lavage
157513|NCT02140034|Overall Survival
157514|NCT02140034|Disease Free Survival
157515|NCT02140034|Peritoneal Recurrence Rate
157516|NCT02140034|T3 and T4 Gastric Cancer
157517|NCT02140021|Malignant Female Reproductive System Neoplasm
157518|NCT02140021|Gynecological Cancer
157519|NCT02140021|High-grade dysplasia
157520|NCT02140021|Carcinoma of the cervix
157521|NCT02140021|Carcinoma of the vagina
157522|NCT02140021|Carcinoma of the vulva
157523|NCT02140021|Invasive squamous cell carcinoma
157524|NCT02140021|Anal pap test
157525|NCT02140021|Anoscopy
157526|NCT02140008|supraglottic airway devices
157527|NCT02140008|the i-gel
157528|NCT02140008|the self-pressurised air-Q intubating laryngeal airway,
157529|NCT02140008|children
157530|NCT02139995|transfusion
157531|NCT02139995|trigger
157532|NCT02139995|critically-ill
157533|NCT02139982|hemodynamics
157534|NCT02139982|anaesthetics
157535|NCT02139982|brachial plexus
157536|NCT02139982|peripheral nerves
157537|NCT02139982|skin temperature
157538|NCT02139982|sympathetic nervous system
157539|NCT02139982|dose-response relationship
157540|NCT02139943|Diabetes Mellitus, Type 1
157541|NCT02139943|Canagliflozin
157542|NCT02139943|Continuous Glucose Monitoring
157543|NCT02139930|smoking
157544|NCT02139930|nicotine reduction
157545|NCT02139917|transitional palliative care
157546|NCT02139917|end stage renal failure
157547|NCT02139904|Mesothelioma
157548|NCT02139904|Vinorelbine
157549|NCT02139904|BRCA1
157550|NCT02139891|Cardiac Resynchronization Therapy
157551|NCT02139891|non responders
157552|NCT02139891|MultiPoint Pacing (MPP)
157553|NCT02139813|Obesity -
157554|NCT02139813|Bariatric surgery
157555|NCT02139813|Gastric bypass
157556|NCT02139800|Neonatal resuscitation
157557|NCT02139800|Extreme Low Gestational Age Newborn (ELGAN)
157558|NCT02139800|Delivery Room
157559|NCT02139800|Continuous positive airway pressure (CPAP)
157560|NCT02139800|Positive pressure ventilation (PPV)
157561|NCT02139800|Sustained inflation
157562|NCT02139787|Hypertension, obesity
157563|NCT02139787|Dietary behaviors
157564|NCT02139787|Physical activity behaviors
157565|NCT02139787|Radio story, entertainment health education
157566|NCT02139787|Immigrants
157567|NCT02139787|Somali, Latino, Hmong
157568|NCT02139787|Families with 3-18 year old children
157569|NCT02139774|Prostate Cancer
157570|NCT02139774|Elderly
157571|NCT02139774|Geriatric
157572|NCT02139774|Radiation
157573|NCT02139774|Arthritis
157574|NCT02139774|Exercise
157575|NCT02139774|Walking
157576|NCT02139774|Endocrine Therapy
157577|NCT02139774|Androgen Deprivation Therapy
157578|NCT02139774|Active Surveillance
157579|NCT02139774|Men
157580|NCT02139761|Cocaine
157581|NCT02139761|Treatment
157582|NCT02139748|Dental Implants
157583|NCT02139748|Alveolar Bone Grafting
157584|NCT02139748|Acellular Dermis
157585|NCT02139735|Temporomandibular Joint Disorders,
157586|NCT02139735|Ultrasonics,
157587|NCT02139735|Electromyography,
157588|NCT02139735|Pain Measurement,
157589|NCT02139735|Muscle Stretching Exercise
157590|NCT02139722|hepatitis B
157591|NCT02139722|hepatitis C
157592|NCT02139722|screening
157593|NCT02139722|Asian Americans
157594|NCT02139722|mobile technology
157595|NCT02139657|Rabies
157596|NCT02139657|Rabies virus
157597|NCT02139657|Rhabdoviridae
157598|NCT02139657|Rabies immune globulin
157599|NCT02139657|Rabies antibodies
157600|NCT02139657|Passive rabies immunization
157601|NCT02139631|hemodynamic
157602|NCT02139631|mechanical ventilation
157603|NCT02139631|respiration with positive pressure
157604|NCT02139618|Randomized-controlled-trial
157605|NCT02139618|Methyl-Aminolevulinate
157606|NCT02139618|Daylight
157607|NCT02139618|Photodynamic-therapy
157608|NCT02139605|D2 versus D3 Lymphadenectomy
157609|NCT02139592|Pharmacological therapy
157610|NCT02139579|chemotherapy
157611|NCT02139579|EGFR-TKI resistance
157612|NCT02139579|Bevacizumab
157613|NCT02139553|Rhythmic versus discrete movements
157614|NCT02139553|Rehabilitation
157615|NCT02139540|Treatment
157616|NCT02139527|arthroplasty
157617|NCT02139527|spinal
157618|NCT02139527|CHARITE
157619|NCT02139527|PRODISC-L
157620|NCT02139527|PRODISC
157621|NCT02139527|disc
157622|NCT02139527|replacement
157623|NCT02139527|lumbar
157624|NCT02139514|Social Skills
157625|NCT02139514|Adults
157626|NCT02139501|Recombinant Human Thrombopoietin
157627|NCT02139501|Dose and frequency
157628|NCT02139501|Immune Thrombocytopenia
157629|NCT02139488|Esophageal cancer
157630|NCT02139488|Chemoradiation
157631|NCT02139475|bowel cleansing, colorectal cancer surgery
157632|NCT02139462|FBT, fidelity, training
157633|NCT02139449|CRT, heart failure, ICD
157634|NCT02139423|Congenital cytomegalovirus infection
157635|NCT02139423|newborn universal hearing screening
157636|NCT02139410|sarcopenia
157637|NCT02139410|mortality
157638|NCT02139384|procalcitonin
157639|NCT02139384|community acquired pneumonia
157640|NCT02139384|pneumonia score
157641|NCT02139371|Positron Emission Tomography
157642|NCT02139371|Uroplasminogen Plasminogen Activator Receptor
157643|NCT02139371|Breast cancer
157644|NCT02139371|Prostate cancer
157645|NCT02139371|Urinary bladder cancer
157646|NCT02139371|Biodistribution
157647|NCT02139371|Radiation exposure
157648|NCT02139358|Breast - Female
157649|NCT02139358|Metastatic
157650|NCT02139358|HER2+
157651|NCT02139345|Osteoarthritis
157652|NCT02139345|Rheumatoid arthritis
157653|NCT02139345|Post-traumatic arthritis
157654|NCT02139345|Avascular necrosis
157655|NCT02139345|AVN
157656|NCT02139332|Attachment theory
157657|NCT02139332|Parent- child relationship
157658|NCT02139332|Child mental health
157659|NCT02139332|Behavioral health
157660|NCT02139293|vagus nerve stimulation effects on heart rate variability and peripheral blood perfusion
157661|NCT02139280|Cyclophosphamide
157662|NCT02139280|Hematopoietic
157663|NCT02139280|Stem Cell
157664|NCT02139280|Mobilization
157665|NCT02139280|Hematologic Malignancy
157666|NCT02139267|CIN3
157667|NCT02139267|Cervical Intraepithelial Neoplasia
157668|NCT02139267|High-Risk HPV
157669|NCT02139267|HPV Infection
157670|NCT02139267|Neoplasm
157671|NCT02139267|Precancerous Diseases
157672|NCT02139267|Uterine Diseases
157673|NCT02139267|Genital Diseases, Female
157674|NCT02139254|Gestational Diabetes
157675|NCT02139254|HbA1c
157676|NCT02139254|Glucose
157677|NCT02139254|First Trimenon
157678|NCT02139228|Haemophilus influenzae type b
157679|NCT02139228|persistency
157680|NCT02139228|children
157681|NCT02139228|CRM197
157682|NCT02139228|anti-PRP antibody
157683|NCT02139202|Acute
157684|NCT02139202|Myocardial
157685|NCT02139202|Infarction
157686|NCT02139202|AMI
157687|NCT02139176|couple HIV testing and counseling
157688|NCT02139176|disclosure
157689|NCT02139176|discordant
157690|NCT02139176|HIV
157691|NCT02139176|Malawi
157692|NCT02139163|Community acquired pneumonia
157693|NCT02139163|CAP
157694|NCT02139163|CAPNETZ
157695|NCT02139163|age ≥18
157696|NCT02139163|infiltrate on chest X-ray
157697|NCT02139163|cough or production of purulent sputum
157698|NCT02139163|pathologic lung auscultation
157699|NCT02139163|fever
157700|NCT02139150|FLT PET Imaging
157701|NCT02139150|3'deoxy-3' [18F] fluorothymidine ([18F] FLT)
157702|NCT02139150|CT
157703|NCT02139150|scans
157704|NCT02139150|14-050
157705|NCT02139098|sleep architecture
157706|NCT02139098|conditioning of pharmacological responses
157707|NCT02139098|insomnia
157708|NCT02139085|varicose veins
157709|NCT02139085|catheter ablation
157710|NCT02139085|Catheter Ablation, Electrical
157711|NCT02139085|Catheter Ablation, Radiofrequency
157712|NCT02139072|Anticoagulation
157713|NCT02139072|International normalized ratio
157714|NCT02139072|Warfarin
157715|NCT02139059|anuria
157716|NCT02139059|children
157717|NCT02139059|ureteroscopy
157718|NCT02139059|initial urinary drainage
157719|NCT02139059|ureteric stones
157720|NCT02139046|Drug therapy
157721|NCT02139033|Dry Eye, Dry Eye Syndrome, Retaine, KCS, Keratoconjunctivitis sicca
157722|NCT02139020|Targeted therapies
157723|NCT02139020|Plasma samples
157724|NCT02138981|Hepatocellular Carcinoma
157725|NCT02138981|Milan Criteria
157726|NCT02138968|Pre-frailty
157727|NCT02138968|Frail
157728|NCT02138968|Exercise
157729|NCT02138968|Nutritional assessment
157730|NCT02138968|Functional capacity
157731|NCT02138942|automated vascular filling
157732|NCT02138942|Learning Intravenous Resuscitator (LIR)
157733|NCT02138942|General Surgery
157734|NCT02138942|Fluid Therapy
157735|NCT02138929|Esophageal Cancer
157736|NCT02138929|Advanced adenocarcinoma of the esophagus
157737|NCT02138929|Advanced adenocarcinoma of the gastroesophageal junction
157738|NCT02138929|GEJ
157739|NCT02138929|Metastatic
157740|NCT02138929|Everolimus
157741|NCT02138929|Afinitor
157742|NCT02138929|Zortress
157743|NCT02138929|RAD001
157744|NCT02138929|LDE 225
157745|NCT02138916|Obstructive Lung Diseases
157746|NCT02138916|Chronic Obstructive Pulmonary Disease
157747|NCT02138916|Lung Disease
157748|NCT02138916|Bronchial Diseases
157749|NCT02138916|COPD Exacerbation
157750|NCT02138916|Respiratory Tract Diseases
157751|NCT02138903|weaning
157752|NCT02138903|Cardiac
157753|NCT02138903|Echocardiography
157754|NCT02138903|Mechanical Ventilation
157755|NCT02138890|Autologous Protein Solution
157756|NCT02138890|APS
157757|NCT02138890|Osteoarthritis
157758|NCT02138890|Intra Articular Injection
157759|NCT02138877|Pelviureteric junction obstruction
157760|NCT02138877|pyeloplasty
157761|NCT02138877|Neonate affected by hydronephrosis
157762|NCT02138877|obstructive uropathy
157763|NCT02138877|urinary stent
157764|NCT02138864|carbon monoxide intoxication
157765|NCT02138864|Parkinsonism
157766|NCT02138864|18F-DTBZ AV-133
157767|NCT02138838|Chronic Kidney Disease, Secondary Hyperparathyroidism, Dialysis, Pediatric
157768|NCT02138812|Phase 1
157769|NCT02138812|Solid tumors
157770|NCT02138812|Breast cancer
157771|NCT02138812|Paclitaxel
157772|NCT02138812|MPS-1 inhibitor
157773|NCT02138812|Taxanes
157774|NCT02138799|Phase I
157775|NCT02138799|Pharmacokinetics
157776|NCT02138799|Safety
157777|NCT02138799|Drug-drug interactions
157778|NCT02138799|Enzalutamide
157779|NCT02138799|Rifampin
157780|NCT02138799|CYP3A4
157781|NCT02138799|CYP2D8
157782|NCT02138799|Enzyme induction
157783|NCT02138786|Richter's Transformation
157784|NCT02138786|Richter's Syndrome
157785|NCT02138786|Karyopharm
157786|NCT02138786|selinexor
157787|NCT02138786|KPT-330
157788|NCT02138786|SIRRT
157789|NCT02138786|CLL
157790|NCT02138773|prolonged release formulation
157791|NCT02138773|adrenergic blocker
157792|NCT02138773|Bioequivalence
157793|NCT02138760|prostate cancer
157794|NCT02138760|prostate biopsy
157795|NCT02138760|magnetic resonance imaging guidance
157796|NCT02138760|detection rates
157797|NCT02138760|performance
157798|NCT02138747|Overactive bladder (OAB)
157799|NCT02138747|tolterodine ER
157800|NCT02138747|mirabegron
157801|NCT02138734|antitumor
157802|NCT02138734|BCG
157803|NCT02138734|bladder cancer
157804|NCT02138734|cancer
157805|NCT02138734|immunotherapy
157806|NCT02138734|instillation
157807|NCT02138734|interleukin-15
157808|NCT02138734|intravesical
157809|NCT02138734|naive
157810|NCT02138734|non-muscle invasive
157811|NCT02138734|transitional cell carcinoma
157812|NCT02138721|Metastatic Prostate Cancer
157813|NCT02138721|Prostatectomy
157814|NCT02138708|Pulmonary arterial hypertension,
157815|NCT02138708|congenital heart disease,
157816|NCT02138708|heart shunt,
157817|NCT02138708|acetylcholine
157818|NCT02138708|Pharmacological test of pulmonary vascular reactivity (acetylcholine) in
157819|NCT02138695|atrial fibrillation
157820|NCT02138695|catheter ablation
157821|NCT02138695|recurrence
157822|NCT02138682|DaT-SPECT scan
157823|NCT02138682|Parkinson's
157824|NCT02138682|Diagnostic
157825|NCT02138669|Cornea
157826|NCT02138669|Keratoconus
157827|NCT02138669|Steep cornea
157828|NCT02138656|Crying
157829|NCT02138656|Chiropractic
157830|NCT02138656|Infant
157831|NCT02138656|pediatric
157832|NCT02138656|Infantile colic
157833|NCT02138656|Clinical Trial
157834|NCT02138643|Achalasia
157835|NCT02138643|Megaesophagus
157836|NCT02138643|Peropal endoscopic myotomy(POEM)
157837|NCT02138643|Laparoscopic Heller myotomy
157838|NCT02138630|Exercise
157839|NCT02138617|Colon Cancer
157840|NCT02138617|Irinotecan
157841|NCT02138617|FOLFIRI
157842|NCT02138617|Genotyping
157843|NCT02138617|UGT1A1
157844|NCT02138604|chest pain
157845|NCT02138604|myocardial ischemia
157846|NCT02138604|acute myocardial dysfunction
157847|NCT02138604|plethesmography
157848|NCT02138604|non invasive dP/dt
157849|NCT02138591|vitamin d deficiency
157850|NCT02138591|cathelicidin antimicrobial peptide
157851|NCT02138591|resistin, human
157852|NCT02138591|protein, human
157853|NCT02138591|1,25-dihydroxy-16,23-diene vitamin D3
157854|NCT02138591|Cholecalciferol
157855|NCT02138591|Nutritional Status
157856|NCT02138591|length of stay
157857|NCT02138539|hyperpigmentation
157858|NCT02138539|melasma
157859|NCT02138539|sun spots
157860|NCT02138539|dark spots
157861|NCT02138526|cancer
157862|NCT02138526|pazopanib
157863|NCT02138526|food
157864|NCT02138526|pharmacokinetics
157865|NCT02138513|Mindfulness
157866|NCT02138513|MBCT
157867|NCT02138513|Cancer
157868|NCT02138513|Oncology
157869|NCT02138513|E-health
157870|NCT02138513|Cost-effectiveness
157871|NCT02138500|PF-06372865
157872|NCT02138500|phase 1
157873|NCT02138500|open-label
157874|NCT02138500|GABA-A receptor occupancy
157875|NCT02138500|positron emission tomography
157876|NCT02138500|healthy subjects
157877|NCT02138487|pelvic organ prolapse
157878|NCT02138487|reconstructive pelvic surgery
157879|NCT02138487|postoperative restrictions
157880|NCT02138487|patient satisfaction
157881|NCT02138474|Lacticum acidum homaccord
157882|NCT02138474|homeopathy
157883|NCT02138474|chronic tension-type headaches
157884|NCT02138461|glaucoma
157885|NCT02138461|bimatoprost
157886|NCT02138461|latanoprost
157887|NCT02138461|tolerability
157888|NCT02138448|Cancer Screenings
157889|NCT02138448|Health Information Technology
157890|NCT02138448|Patient Health Record
157891|NCT02138448|Preventive Services
157892|NCT02138422|colorectal cancer
157893|NCT02138383|advanced pancreatic cancer
157894|NCT02138383|pancreas
157895|NCT02138383|malignant neoplasm
157896|NCT02138383|endocrine system
157897|NCT02138357|Restless Legs Syndrome
157898|NCT02138357|Willis Ekbom Disease
157899|NCT02138357|Twitchy Legs
157900|NCT02138357|Periodic Limb Movements
157901|NCT02138357|Leg Movements
157902|NCT02138357|Augmentation
157903|NCT02138357|Requip
157904|NCT02138357|ropinirole
157905|NCT02138357|Mirapex
157906|NCT02138357|pramipexole
157907|NCT02138357|gabapentin
157908|NCT02138357|Horizant
157909|NCT02138357|Neupro
157910|NCT02138357|rotigotine
157911|NCT02138331|Diabetes Mellitus Type 1
157912|NCT02138331|Microvesicles
157913|NCT02138331|Exosomes
157914|NCT02138331|Cord Blood
157915|NCT02138331|Mesenchymal Stem Cells
157916|NCT02138305|Fractional Flow Reserve (FFR)
157917|NCT02138305|Instantaneous Wave Free Ratio (iFR)
157918|NCT02138305|Coronary Flow Reserve (CFR)
157919|NCT02138305|Hyperemic Stenosis Resistance Index (HSR)
157920|NCT02138305|Hyperemic microvascular resistance (HMR)
157921|NCT02138305|Wave intensity analysis (WIA)
157922|NCT02138305|Myocardial Perfusion
157923|NCT02138305|SPY NIRF Regional Myocardial Perfusion Analysis
157924|NCT02138253|liver transplant
157925|NCT02138253|hepatitis C
157926|NCT02138253|liver fibrosis
157927|NCT02138253|hepatic fibrosis
157928|NCT02138253|liver cirrhosis
157929|NCT02138253|hepatic cirrhosis
157930|NCT02138227|Organ donation request
157931|NCT02138227|Family decision makers
157932|NCT02138227|Communication
157933|NCT02138201|diffusion tensor imaging fiber tracking
157934|NCT02138201|magnetic resonance Imaging
157935|NCT02138201|spinal cord injury
157936|NCT02138201|neurogenic lower urinary tract dysfunction
157937|NCT02138175|bleeding
157938|NCT02138175|blood loss
157939|NCT02138175|hemoglobin
157940|NCT02138175|hemoglobin monitoring
157941|NCT02138175|noninvasive monitoring
157942|NCT02138162|Phase 1
157943|NCT02138162|Pharmacokinetics
157944|NCT02138162|Safety
157945|NCT02138162|Severe hepatic impairment
157946|NCT02138162|Enzalutamide
157947|NCT02138149|spinal cord injury
157948|NCT02138149|neurogenic lower urinary tract dysfunction
157949|NCT02138149|nerve growth factor
157950|NCT02138149|neurogenic detrusor overactivity
157951|NCT02138149|urodynamics
157952|NCT02138123|dense cataract
157953|NCT02138123|phacoemulsification
157954|NCT02138123|lens-shell technique
157955|NCT02138123|intraocular lens
157956|NCT02138110|Spinal Cord Injury (SCI)
158202|NCT02136784|buprenorphine
157957|NCT02138110|Complete (AIS A) Traumatic Acute Spinal Cord Injury
157958|NCT02138071|low back pain
157959|NCT02138071|lumbar pain
157960|NCT02138058|compulsive buying, compulsive shopping, topiramate
157961|NCT02138045|Diabetes Mellitus, Type 1
157962|NCT02138045|Diabetic Neuropathy
157963|NCT02138045|Liraglutide
157964|NCT02138032|message framing
157965|NCT02138032|smoking cessation
157966|NCT02138032|peripheral artery disease
157967|NCT02138019|corneal ulcers
157968|NCT02138019|conjunctival closure in strabismus surgery
157969|NCT02138019|surgery for retinal detachment
157970|NCT02138019|cataract surgery
157971|NCT02138019|mucous membrane grafting
157972|NCT02137954|cancer
157973|NCT02137954|pain
157974|NCT02137941|Stress
157975|NCT02137941|occupations
157976|NCT02137941|biomarkers
157977|NCT02137941|firefighters
157978|NCT02137928|Retinoblastoma
157979|NCT02137928|carboplatin
157980|NCT02137915|AMD
157981|NCT02137902|Tobacco dependence
157982|NCT02137902|Cardiovascular disease
157983|NCT02137902|Risk behaviors
157984|NCT02137902|Smoking
157985|NCT02137902|Physical activity
157986|NCT02137902|Alaska Native people
157987|NCT02137889|CLL
157988|NCT02137876|B cells
157989|NCT02137876|Thymoglubulin
157990|NCT02137876|humoral rejections
157991|NCT02137876|transplant
157992|NCT02137876|rATG
157993|NCT02137863|Contrast induced nephropathy
157994|NCT02137863|Diabetes Mellitus
157995|NCT02137863|Dexmedetomidine
157996|NCT02137837|Metastatic breast cancer
157997|NCT02137837|Invasive breast carcinoma
157998|NCT02137837|estrogen receptor-positive breast cancer
157999|NCT02137837|HER2-negative breast cancer
158000|NCT02137837|Stage IV breast cancer
158001|NCT02137837|progesterone receptor-positive breast cancer
158002|NCT02137811|cancer
158003|NCT02137811|CorrectChemo
158004|NCT02137811|assay
158005|NCT02137811|lab test
158006|NCT02137811|MICK assay
158007|NCT02137811|apoptosis
158008|NCT02137811|increase survival
158009|NCT02137811|increase response rates
158010|NCT02137811|decrease time to progression
158011|NCT02137811|chemotherapy
158012|NCT02137811|cancer treatment
158013|NCT02137798|fluoroscopy exposure
158014|NCT02137798|paroxysmal atrial fibrillation Ablation
158015|NCT02137798|fluoroscopy
158016|NCT02137798|Atrial Fibrillation Ablation
158017|NCT02137785|Actinic Keratosis
158018|NCT02137759|Glioblastoma
158019|NCT02137746|Prostate Cancer
158020|NCT02137746|Radical Prostatectomy
158021|NCT02137720|Diabetes
158022|NCT02137720|Treatment Adherence
158023|NCT02137720|Self-management
158024|NCT02137720|Emotional Distress
158025|NCT02137720|Diabetes-related Distress
158026|NCT02137707|Multiple Sclerosis, Relapsing-Remitting
158027|NCT02137707|Gilenya
158028|NCT02137707|Fingolimod
158029|NCT02137694|Papillomavirus
158030|NCT02137694|Vaginal auto-takings
158031|NCT02137694|Urinary test
158032|NCT02137681|immune thrombocytopenia
158033|NCT02137681|rituximab
158034|NCT02137681|efficacy
158035|NCT02137681|safety
158036|NCT02137642|constipation
158037|NCT02137629|Myelodysplastic syndromes
158038|NCT02137629|Vidaza
158039|NCT02137629|Observational study
158040|NCT02137629|Korea
158041|NCT02137616|psychosis
158042|NCT02137616|syndrome
158043|NCT02137616|risk
158044|NCT02137616|antipsychotic
158045|NCT02137603|Suppurative appendicitis, appendicitis, pediatric
158046|NCT02137590|Spanish Black Radish
158047|NCT02137590|Phase I detoxification enzymes
158048|NCT02137590|Phase II detoxification enzymes
158049|NCT02137590|Acetaminophen
158050|NCT02137577|drug eluting balloon catheter
158051|NCT02137551|adherence
158052|NCT02137551|healthcare costs
158053|NCT02137551|appointment based model
158054|NCT02137551|accountable care organization
158055|NCT02137512|Artificial Pancreas
158056|NCT02137460|Alzheimer's disease
158057|NCT02137460|Early diagnosis
158058|NCT02137460|Prediction
158059|NCT02137460|Biomarker
158060|NCT02137460|Imaging
158061|NCT02137447|Prevena
158062|NCT02137447|faster healing time
158063|NCT02137447|surgical site infection
158064|NCT02137434|Acute calcium
158065|NCT02137434|Dietary calcium
158066|NCT02137434|Supplementary calcium
158067|NCT02137434|Postprandial metabolism
158068|NCT02137421|Coronary artery disease
158069|NCT02137421|Metabolic syndrome
158070|NCT02137421|Resveratrol
158071|NCT02137421|β-catenin
158072|NCT02137421|Wnt signaling
158073|NCT02137421|FOXO
158074|NCT02137421|MnSOD
158075|NCT02137408|Chronic hypertension in pregnancy
158076|NCT02137408|Pre-term delivery
158077|NCT02137408|Preeclampsia
158078|NCT02137408|Endothelial Health
158079|NCT02137408|Docosahexaenoic acid (DHA)
158080|NCT02137395|Children, Dexamethasone, Sugammadex,
158081|NCT02137382|maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis
158082|NCT02137369|MDD
158083|NCT02137369|Major Depressive Disorder
158084|NCT02137369|Treatment
158085|NCT02137369|Antidepressants
158086|NCT02137369|Lexapro
158087|NCT02137369|Talk therapy
158088|NCT02137356|rectal cancer
158089|NCT02137356|rectal adenocarcinoma
158090|NCT02137356|Selinexor
158091|NCT02137356|capecitabine
158092|NCT02137356|chemoradiation
158093|NCT02137356|radiation
158094|NCT02137356|radiotherapy
158095|NCT02137356|neoadjuvant
158096|NCT02137356|locally advanced rectal cancer
158097|NCT02137343|Gastric Cancer
158098|NCT02137343|First Line Treatment Gastroesophageal Junction (GEJ)
158099|NCT02137343|Gastroesophageal Junction Cancer (GEJ)
158100|NCT02137343|GEJ Cancer
158101|NCT02137330|Obalon swallowable intragastric balloons
158102|NCT02137330|Severe obesity
158103|NCT02137330|Children
158104|NCT02137317|Pesticides
158105|NCT02137317|Personal protective equipment
158106|NCT02137317|Developing countries
158107|NCT02137317|Tropical Climate
158108|NCT02137304|cough help
158109|NCT02137304|in-exsufflation
158110|NCT02137304|neuromuscular disease
158111|NCT02137304|cough assistance optimization
158112|NCT02137304|efficient cough flow
158113|NCT02137291|Video-assisted thoracoscopic surgery (VATS)
158114|NCT02137291|Lung isolation device
158115|NCT02137291|One-lung ventilation
158116|NCT02137291|Double lumen endotracheal tube
158117|NCT02137291|Bronchial blocker
158118|NCT02137278|Syncope
158119|NCT02137278|Presyncope
158120|NCT02137278|Vasoactive drugs
158121|NCT02137278|Hypotension
158122|NCT02137278|Carotid sinus massage
158123|NCT02137278|Tilt table test
158124|NCT02137265|Azoospermia
158125|NCT02137265|Hypogonadism
158126|NCT02137265|Clomiphene
158127|NCT02137252|Invasive Breast Cancer (Stage I-III)
158128|NCT02137252|Ductal Carcinoma in Situ
158129|NCT02137252|Lobular Carcinoma in Situ
158130|NCT02137252|Lobular Carcinoma
158131|NCT02137252|Fatigue Related to Cancer Treatment
158132|NCT02137213|Opioid-induced constipation
158133|NCT02137213|Methadone
158134|NCT02137213|Naloxone
158135|NCT02137187|Atrial fibrillation
158136|NCT02137187|Heart failure
158137|NCT02137187|Catheter ablation
158138|NCT02137187|Cardiac resynchronization therapy
158139|NCT02137187|Implantable defibrillator
158140|NCT02137148|Vascular Access
158141|NCT02137148|Sonic Window
158142|NCT02137148|Ultrasound
158143|NCT02137135|chronic postoperative pain
158144|NCT02137135|menstrual cycle
158145|NCT02137122|Volunteers
158146|NCT02137109|Pediatric
158147|NCT02137096|Recurrent nasopharynx carcinoma
158148|NCT02137083|Chemotherapy
158149|NCT02137083|Endocrine therapy
158150|NCT02137083|Docetaxel
158151|NCT02137083|Fulvestrant
158152|NCT02137070|Weightloss and brain function
158153|NCT02137070|Effects of bariatric surgery on brain function
158154|NCT02137070|Reduced glucose insulin changes and brain function
158155|NCT02137057|Heart Rate Variability
158156|NCT02137057|spinal anesthesia
158157|NCT02137057|DM
158158|NCT02137057|cardiac autonomic dysfunction
158159|NCT02137044|multiple sclerosis
158160|NCT02137044|pain
158161|NCT02137044|depression
158162|NCT02137018|hernia
158163|NCT02137018|incisional hernia
158164|NCT02137018|device
158165|NCT02137018|pig
158166|NCT02137005|walking
158167|NCT02137005|gait disorders, neurologic
158168|NCT02137005|health status
158169|NCT02137005|cognition
158170|NCT02137005|quality of life
158171|NCT02137005|Transition to Adult Care
158172|NCT02136953|Obsessive-Compulsive Disorder
158173|NCT02136953|Exercise
158174|NCT02136953|Cognitive Behavior Therapy
158175|NCT02136953|Cognitive Behavioral Therapy
158176|NCT02136953|Treatment Efficacy
158177|NCT02136953|Brain-Derived Neurotrophic Factor
158178|NCT02136914|Levodopa Induced Dyskinesia
158179|NCT02136914|LID
158180|NCT02136914|Parkinsonism
158181|NCT02136901|NuSurface
158182|NCT02136901|Meniscus
158183|NCT02136901|Prosthesis
158184|NCT02136901|KOOS
158185|NCT02136888|Ponesimod
158186|NCT02136888|Safety
158187|NCT02136875|COPD
158188|NCT02136875|COPD exacerbation
158189|NCT02136862|Alport syndrome
158190|NCT02136862|kidney disease
158191|NCT02136849|severe intellectual disability, genetic, de novo exome
158192|NCT02136836|Genes, erbB-2
158193|NCT02136836|Prognosis
158194|NCT02136823|Spinal Cord Injury
158195|NCT02136810|Hypertension
158196|NCT02136810|Perioperative Care
158197|NCT02136797|CMVpp65 Specific T-cells
158198|NCT02136797|Allogeneic Hematopoietic Stem Cell Transplantation
158199|NCT02136797|14-070
158200|NCT02136784|pain
158201|NCT02136784|cold presser test
158203|NCT02136784|opioids
158204|NCT02136758|lifestyle modification
158205|NCT02136758|diet
158206|NCT02136758|exercise
158207|NCT02136758|cardiovascular disease
158208|NCT02136758|gene expression
158209|NCT02136758|obesity
158210|NCT02136745|Irritable Bowel Syndrome
158211|NCT02136745|Inflammatory Bowel Disease
158212|NCT02136745|mind body
158213|NCT02136745|intervention
158214|NCT02136745|group
158215|NCT02136745|Relaxation Response
158216|NCT02136745|genomic effects
158217|NCT02136732|chronic conditions
158218|NCT02136732|multimorbid
158219|NCT02136719|Uterine massage
158220|NCT02136719|vaginal birth
158221|NCT02136719|postpartum haemorrhage
158222|NCT02136706|Stable coronary artery disease
158223|NCT02136693|obstructed defecation
158224|NCT02136693|STARR
158225|NCT02136693|constipation
158226|NCT02136693|incontinence
158227|NCT02136693|psyllium
158228|NCT02136680|HIV disease
158229|NCT02136680|palliative care
158230|NCT02136680|educational intervention
158231|NCT02136667|Preeclampsia
158232|NCT02136667|Cardiovascular disease (CVD) risk
158233|NCT02136654|diabetes
158234|NCT02136654|ethnicity
158235|NCT02136654|South Asian
158236|NCT02136654|diabetes management
158237|NCT02136641|Anesthesia
158238|NCT02136641|Spinal Anesthesia
158239|NCT02136641|Conscious Sedation
158240|NCT02136641|Operating Rooms.
158241|NCT02136628|RTL Technique
158242|NCT02136615|hyperbaric oxygenation
158243|NCT02136615|insulin sensitivity
158244|NCT02136615|human
158245|NCT02136615|inflammation
158246|NCT02136615|adipose tissue
158247|NCT02136563|Chronic kidney disease
158248|NCT02136563|Erythropoiesis stimulating agent response index
158249|NCT02136563|Hyporesponsive anemia to erythropoiesis stimulating agent
158250|NCT02136563|Observational study
158251|NCT02136550|smoking
158252|NCT02136550|smoking cessation
158253|NCT02136550|mucociliary clearance
158254|NCT02136550|proteomics
158255|NCT02136550|miRNA
158256|NCT02136498|smoking cessation
158257|NCT02136498|varenicline
158258|NCT02136498|adherence
158259|NCT02136472|Subfertility
158260|NCT02136472|Metabolic syndrome
158261|NCT02136472|Plasma volume
158262|NCT02136472|Intima media thickness
158263|NCT02136472|Flow mediated dilatation
158264|NCT02136459|Thyroidectomy
158265|NCT02136459|Endotracheal tube
158266|NCT02136459|Voice
158267|NCT02136459|Complications
158268|NCT02136459|Patients undergoing elective thyroidectomy
158269|NCT02136446|Paravertebral block
158270|NCT02136446|Mastectomy
158271|NCT02136446|Post-operative pain
158272|NCT02136446|Echogenic
158273|NCT02136446|Peripheral nerve block catheter
158274|NCT02136433|Hand
158275|NCT02136433|Rehabilitation
158276|NCT02136433|Stroke
158277|NCT02136433|Brain-injury
158278|NCT02136433|Tablet
158279|NCT02136407|Vitamin D
158280|NCT02136407|vitamin D deficiency
158281|NCT02136407|parathyroid hormone
158282|NCT02136381|Lifestyle, interventions, retirement
158283|NCT02136368|older adults
158284|NCT02136368|multiple-modality exercise
158285|NCT02136368|mind-motor exercise
158286|NCT02136368|self-reported cognitive complaints
158287|NCT02136368|global cognitive functioning
158288|NCT02136368|mobility
158289|NCT02136368|vascular function
158290|NCT02136368|sensorimotor function
158291|NCT02136368|brain imaging
158292|NCT02136368|community-based research
158293|NCT02136368|subjective cognitive complaints
158294|NCT02136342|no available effective treatment
158295|NCT02136316|Healthy volunteers
158296|NCT02136316|ASP7962
158297|NCT02136316|pharmacokinetics
158298|NCT02136290|Weight loss
158299|NCT02136277|colorectal surgery
158300|NCT02136277|cardiac output
158301|NCT02136264|hypertension
158302|NCT02136264|dietary intervention
158303|NCT02136264|personalized nutrition
158304|NCT02136264|randomized controlled trial
158305|NCT02136251|Total Shoulder Arthroplasty
158306|NCT02136251|Glenoid anchor peg component fixation
158307|NCT02136251|Autologous bone grafting
158308|NCT02136238|amputation
158309|NCT02136238|transradial
158310|NCT02136238|prosthesis
158311|NCT02136238|terminal device
158312|NCT02136225|youth
158313|NCT02136225|gun
158314|NCT02136225|access
158315|NCT02136225|home
158316|NCT02136186|home telemonitoring
158317|NCT02136186|readmission
158318|NCT02136186|high risk
158319|NCT02136160|elementary school
158320|NCT02136160|children
158321|NCT02136160|health promotion
158322|NCT02136160|teachers
158323|NCT02136160|prevention
158324|NCT02136147|Attention Deficit Disorder with Hyperactivity
158325|NCT02136147|Neuropsychiatry
158326|NCT02136147|Drug therapy
158327|NCT02136147|Pharmacogenetics
158328|NCT02136147|Child Psychiatry
158329|NCT02136134|Multiple Myeloma
158330|NCT02136134|Plasmacytoma
158331|NCT02136134|Refractory Multiple Myeloma
158332|NCT02136134|Relapsed Multiple Myeloma
158333|NCT02136134|Daratumumab
158334|NCT02136134|VELCADE
158335|NCT02136108|Chronic pain
158336|NCT02136108|Complementary and alternative therapies
158337|NCT02136108|Mobile health
158338|NCT02136108|Medicaid
158339|NCT02136108|Patient navigation
158340|NCT02136095|Fluorescent cholangiography
158341|NCT02136095|Laparoscopic cholecystectomy
158342|NCT02136082|HIV
158343|NCT02136082|Women
158344|NCT02136082|Children
158345|NCT02136082|Nutrition
158346|NCT02136056|Sick-leave
158347|NCT02136056|Return to work
158348|NCT02136056|Self-management
158349|NCT02136056|Self-efficacy
158350|NCT02136056|Quality of Life and Well-being
158351|NCT02136056|Motivation
158352|NCT02136030|Cryptococcal meningitis
158353|NCT02136017|AEFI
158354|NCT02136017|influenza vaccine
158355|NCT02136004|arteriotomy
158356|NCT02136004|vessel closure
158357|NCT02136004|femoral access site
158358|NCT02135978|Spinal Cord Injury
158359|NCT02135978|Shoulder Pain
158360|NCT02135978|Exercise
158361|NCT02135952|Periodontitis
158362|NCT02135952|Diabetes
158363|NCT02135926|Cerebral Stroke, Stroke, Acute, Brain Infarction
158364|NCT02135913|Obese
158365|NCT02135913|Children
158366|NCT02135913|Vitamin D deficiency
158367|NCT02135913|Low HDL
158368|NCT02135900|Heliox
158369|NCT02135900|Obstructive Sleep Apnea
158370|NCT02135887|Stage III Colorectal Cancer
158371|NCT02135887|Grade 4 Neutropenia
158372|NCT02135887|MB-6
158373|NCT02135874|Leukemia
158374|NCT02135874|Mixed Phenotype Acute Leukemia
158375|NCT02135874|MPAL
158376|NCT02135874|Newly Diagnosed
158377|NCT02135874|Relapsed
158378|NCT02135874|Clofarabine
158379|NCT02135874|Clofarex
158380|NCT02135874|Clolar
158381|NCT02135874|Idarubicin
158382|NCT02135874|Idamycin
158383|NCT02135874|Cytarabine
158384|NCT02135874|Ara-C
158385|NCT02135874|Cytosar
158386|NCT02135874|DepoCyt
158387|NCT02135874|Cytosine arabinosine hydrochloride
158388|NCT02135874|Vincristine
158389|NCT02135874|Rituximab
158390|NCT02135874|Rituxan
158391|NCT02135874|Dexamethasone
158392|NCT02135874|Decadron
158393|NCT02135861|Acute decompensated heart failure
158394|NCT02135861|heart failure
158395|NCT02135861|MRI
158396|NCT02135861|trpV4 channel inhibitors
158397|NCT02135861|pulmonary oedema
158398|NCT02135822|nanoparticle albumin-bound paclitaxel
158399|NCT02135822|gemcitabine
158400|NCT02135822|advanced pancreatic cancer
158401|NCT02135796|Septic Shock
158402|NCT02135796|Severe Sepsis
158403|NCT02135796|ICU
158404|NCT02135770|heparin
158405|NCT02135770|sepsis
158406|NCT02135770|inflammation
158407|NCT02135744|Chronic Obstructive Pulmonary Disease
158408|NCT02135744|COPD
158409|NCT02135744|Readmissions
158410|NCT02135718|ELLIPTA
158411|NCT02135718|Asthma
158412|NCT02135718|Inhaler preference
158413|NCT02135718|Fluticasone furoate
158414|NCT02135718|ELLIPTA inhaler
158415|NCT02135718|Dry Powder Inhaler
158416|NCT02135692|Severe eosinophilic asthma
158417|NCT02135692|Extension study
158418|NCT02135692|Expanded access
158419|NCT02135692|Safety
158420|NCT02135692|Mepolizumab
158421|NCT02135692|Eosinophils
158422|NCT02135666|Twinrix
158423|NCT02135666|Long-term follow-up
158424|NCT02135666|Persistence
158425|NCT02135666|Hepatitis A
158426|NCT02135666|Antibody
158427|NCT02135666|Immunity
158428|NCT02135666|Hepatitis B
158429|NCT02135666|Combination vaccine
158430|NCT02135666|Adult
158431|NCT02135601|colonoscopy
158432|NCT02135601|water
158433|NCT02135601|adenoma
158434|NCT02135601|pain
158435|NCT02135575|premenopausal
158436|NCT02135575|postmenopausal
158437|NCT02135575|cardiovascular
158438|NCT02135575|exercise training
158439|NCT02135575|vascular function
158440|NCT02135575|cardiac function
158441|NCT02135575|cardiac morphology
158442|NCT02135575|health
158443|NCT02135562|endometrial cancer
158444|NCT02135562|survivor
158445|NCT02135562|obesity
158446|NCT02135562|diet
158447|NCT02135562|high protein
158448|NCT02135562|protein-sparing modified fast intervention
158449|NCT02135562|PSMF
158450|NCT02135523|ovarian cancer
158451|NCT02135523|involved-field radiation therapy
158452|NCT02135523|progression free survival
158453|NCT02135484|Prostate Cancer
158454|NCT02135484|Adenocarcinoma of the prostate
158455|NCT02135484|Castrate resistant prostate cancer
158456|NCT02135484|CRPC
158457|NCT02135484|Skeletal metastases
158458|NCT02135484|Alpharadin
158459|NCT02135484|Xofigo
158460|NCT02135484|Radium-223 chloride
158461|NCT02135484|Radium-223 dichloride
158462|NCT02135471|gingival recession
158463|NCT02135471|dental enamel proteins
158464|NCT02135471|acellular dermal matrix graft
158465|NCT02135471|tobacco
158466|NCT02135458|Heart failure
158467|NCT02135458|Telemonitoring
158468|NCT02135458|therapeutic education
158469|NCT02135458|care network
158470|NCT02135458|hospitalization
158471|NCT02135445|Drug therapy
158472|NCT02135432|Chronic Obstructive pulmonary disease, Ivacaftor
158473|NCT02135406|Adult
158474|NCT02135406|18 years or older
158475|NCT02135406|multiple myeloma
158476|NCT02135406|poor prognosis
158477|NCT02135406|relapsed/progressive disease
158478|NCT02135406|within one year of first autologous stem cell transplantation
158479|NCT02135367|PRP
158480|NCT02135367|growth factors
158481|NCT02135367|Viscosupplementation
158482|NCT02135367|injections
158483|NCT02135367|chondropathy
158484|NCT02135367|randomized controlled trial
158485|NCT02135354|AECOPD
158486|NCT02135354|Chronic Obstructive Pulmonary Disease
158487|NCT02135354|Acute exacerbation
158488|NCT02135354|Hospitalization
158489|NCT02135354|Azithromycin
158490|NCT02135354|Macrolides
158491|NCT02135354|Randomized Controlled Trial
158492|NCT02135354|Placebo
158493|NCT02135341|Detrusor Overactivity
158494|NCT02135341|Impaired Contractility
158495|NCT02135341|Botulinum Toxin A (BoNT-A)
158496|NCT02135328|Type 2 diabetes
158497|NCT02135328|Dietary behaviors
158498|NCT02135328|Physical activity behaviors
158499|NCT02135328|Radio story, entertainment health education
158500|NCT02135328|Immigrants
158501|NCT02135328|Somali, Latino, Hmong
158502|NCT02135328|Families with 3-18 year old children
158503|NCT02135315|Acute Coronary Syndrome, arterial pressure
158504|NCT02135302|hepatic
158505|NCT02135250|Traditional Chinese Medicine
158506|NCT02135211|non-small cell lung cancer (NSCLC)
158507|NCT02135211|multiple risk factor
158508|NCT02135211|lifestyle intervention
158509|NCT02135211|health behavior
158510|NCT02135211|lifestyle risk reduction
158511|NCT02135211|health related quality of life
158512|NCT02135198|GABA modulator
158513|NCT02135198|AZD7325
158514|NCT02135198|Short interval intracortical inhibition
158515|NCT02135198|volunteers
158516|NCT02135146|Hypotension
158517|NCT02135146|Kidney injury
158518|NCT02135133|Chronic Lymphocytic Leukemia
158519|NCT02135133|Small Lymphocytic Lymphoma
158520|NCT02135107|Gastroesophageal reflux disease
158521|NCT02135094|trapezius
158522|NCT02135094|upper back
158523|NCT02135094|muscle pain
158524|NCT02135094|pain relief
158525|NCT02135094|ultrasound
158526|NCT02135094|double blind
158527|NCT02135094|Sam
158528|NCT02135094|ZetrOZ
158529|NCT02135094|muscle
158530|NCT02135094|LITUS
158531|NCT02135094|low intensity therapeutic ultrasound
158532|NCT02135081|Single ventricle
158533|NCT02135081|Hypoplastic Left Heart Syndrome
158534|NCT02135081|Congenital heart lesion
158535|NCT02135081|Right or left ventricle
158536|NCT02135081|Cerebral blood flow
158537|NCT02135081|Pulmonary blood flow
158538|NCT02135081|Staged Fontan reconstruction
158539|NCT02135081|hemi Fontan/bidirectional Glenn stages
158540|NCT02135068|type 1 diabetes
158541|NCT02135068|closed loop insulin delivery systems
158542|NCT02135068|exercise
158543|NCT02135068|hypoglycemia
158544|NCT02135055|organ function
158545|NCT02135055|sedation
158546|NCT02135029|Hyperlipidemia
158547|NCT02135029|statin intolerance
158548|NCT02135016|effect-site concentration
158549|NCT02135016|propofol
158550|NCT02135016|thoracic epidural anesthesia
158551|NCT02134990|Carcinoma, Non-Small-Cell Lung
158552|NCT02134990|Docetaxel
158553|NCT02134977|Pharmacological therapy
158554|NCT02134964|Safety
158555|NCT02134964|Tolerability
158556|NCT02134964|Pharmacokinetics
158557|NCT02134964|Dose escalation
158558|NCT02134964|Randomized
158559|NCT02134964|Healthy volunteers
158560|NCT02134964|OLT1177
158561|NCT02134964|Olatec
158562|NCT02134899|Autosomal dominant polycystic kidney disease
158563|NCT02134899|cyst
158564|NCT02134899|kidney
158565|NCT02134899|liver
158566|NCT02134899|kidney transplantation
158567|NCT02134899|IF/TA
158568|NCT02134899|fibrosis
158569|NCT02134899|DSA
158570|NCT02134899|mTOR inhibitors
158571|NCT02134899|calcineurin inhibitors
158572|NCT02134873|Pain
158573|NCT02134873|Pain management
158574|NCT02134873|Hospitalized
158575|NCT02134873|Infants
158576|NCT02134873|Sucrose
158577|NCT02134847|Resident
158578|NCT02134847|Fatigue
158579|NCT02134847|Sleep deprivation
158580|NCT02134847|medical errors
158581|NCT02134808|Major Depressive Disorder
158582|NCT02134808|Creatine
158583|NCT02134808|Brain Chemistry
158584|NCT02134808|Magnetic Resonance Spectroscopy
158585|NCT02134808|Treatment Resistance
158586|NCT02134808|Selective Serotonin Reuptake Inhibitor (SSRI) Resistance
158587|NCT02134795|Parkinson's disease
158588|NCT02134782|Randomized Controlled Trial, yoga, children, chemotherapy, haematopoietic stem cell transplantation, fatigue, quality of life
158589|NCT02134769|catheter-related bloodstream infections
158590|NCT02134756|Supplement impact
158591|NCT02134756|Performance
158592|NCT02134756|Fatigue
158593|NCT02134743|dental implant
158594|NCT02134743|Surface energy
158595|NCT02134743|Hydrophilicity
158596|NCT02134743|Contact angle
158597|NCT02134743|Titanium implant roughness
158598|NCT02134743|Surface conditioning
158599|NCT02134730|FRIENDS for life
158600|NCT02134730|universal prevention
158601|NCT02134730|school children
158602|NCT02134730|anxiety
158603|NCT02134717|sarcoidosis
158604|NCT02134717|CCR5 inhibition
158605|NCT02134717|maraviroc
158606|NCT02134691|Posttraumatic Stress Disorder (PTSD)
158607|NCT02134691|Prolonged Exposure (PE)
158608|NCT02134678|self-system therapy
158609|NCT02134678|cognitive therapy
158610|NCT02134678|depression
158611|NCT02134678|psychotherapy
158612|NCT02134678|mechanisms of action
158613|NCT02134665|Vancomycin
158614|NCT02134665|severe acute pancreatitis
158615|NCT02134665|Creatinine clearance
158616|NCT02134652|Ultrasonography
158617|NCT02134652|World Health
158618|NCT02134626|Portal Hypertension
158619|NCT02134626|Hepatic Venous Pressure Gradient
158620|NCT02134626|Esophageal Varices
158621|NCT02134626|Liver Cirrhosis
158622|NCT02134626|Simvastatin
158623|NCT02134626|Nitric oxide
158624|NCT02134626|HVPG
158625|NCT02134613|99mTc-anti-TNF
158626|NCT02134613|Inflammation
158627|NCT02134613|Psoriatic arthritis
158628|NCT02134613|Rheumatoid arthritis
158629|NCT02134600|Omega-3 fatty acids
158630|NCT02134600|DHA
158631|NCT02134600|EPA
158632|NCT02134600|Docosahexaenoic acid
158633|NCT02134600|Eicosapentaenoic acid
158634|NCT02134600|Childhood cancer
158635|NCT02134600|Body composition
158636|NCT02134600|Inflammation
158637|NCT02134600|Neuropsychiatric symptoms
158638|NCT02134587|Health knowledge, attitudes, practices.
158639|NCT02134587|Adverse drug reaction reporting systems.
158640|NCT02134587|Pharmacovigilance. Product Surveillance, Postmarketing.
158641|NCT02134587|Drug-related side effects and adverse reactions.
158642|NCT02134574|Lymphoma,
158643|NCT02134574|leukemia,
158644|NCT02134574|multiple myeloma,
158645|NCT02134574|hodgkin disease
158646|NCT02134522|non alcoholic fatty liver
158647|NCT02134522|childhood obesity
158648|NCT02134522|Sleep Apnea
158649|NCT02134509|Cigarette smoking
158650|NCT02134496|hip
158651|NCT02134496|knee
158652|NCT02134496|arthroplasty
158653|NCT02134496|spinal
158654|NCT02134496|anesthesia
158655|NCT02134483|Parathyroid
158656|NCT02134483|Permanent hypocalcemia
158657|NCT02134483|Transplantation
158658|NCT02134470|saliva
158659|NCT02134470|blood
158660|NCT02134470|urine
158661|NCT02134444|Dizziness
158662|NCT02134444|Vertigo
158663|NCT02134444|Vestibular Diseases
158664|NCT02134444|Vestibular Neuritis
158665|NCT02134444|Labyrinth Diseases
158666|NCT02134444|Ear Diseases
158667|NCT02134444|Vestibular rehabilitation
158668|NCT02134444|Telerehabilitation
158669|NCT02134444|Gaze control
158670|NCT02134444|Balance
158671|NCT02134431|HIV
158672|NCT02134431|tenofovir
158673|NCT02134431|miocrobicide
158674|NCT02134431|endoscopy (colonoscopy, sigmoidoscopy)
158675|NCT02134431|adolescents
158676|NCT02134431|pediatrics
158677|NCT02134418|Schizophrenia
158678|NCT02134418|Irony
158679|NCT02134418|Hemispheric processing
158680|NCT02134418|Theory of mind
158681|NCT02134405|functional dyspepsia
158682|NCT02134405|symptoms
158683|NCT02134405|proton pump inhibitor
158684|NCT02134405|gastritis
158685|NCT02134392|C-diff
158686|NCT02134392|Clostridium difficile
158687|NCT02134392|Fecal Transplant
158688|NCT02134392|FMT
158689|NCT02134392|Fecal Microbiota Transplant
158690|NCT02134379|Thoracic Impedance
158691|NCT02134379|Diagnostic Marker
158692|NCT02134379|Bed Rest Test
158693|NCT02134379|Transthoracic Impedance
158694|NCT02134379|Heart Failure
158695|NCT02134379|HF
158696|NCT02134366|Epilepsia Partialis Continua
158697|NCT02134366|Kojewnikov's Epilepsy
158698|NCT02134366|Epilepsy
158699|NCT02134366|Clobazam
158700|NCT02134366|Focal Motor Epilepsy
158701|NCT02134366|Partial Motor Seizure
158702|NCT02134340|IGF1R
158703|NCT02134314|ESRD
158704|NCT02134314|CKD
158705|NCT02134314|Kidney Transplant
158706|NCT02134314|ECD
158707|NCT02134314|delayed graft function
158708|NCT02134301|oritavancin
158709|NCT02134301|pediatrics
158710|NCT02134301|gram positive
158711|NCT02134301|bacterial infection
158712|NCT02134301|Confirmed
158713|NCT02134301|Suspected
158714|NCT02134288|Dialysis
158715|NCT02134288|Kidney Transplant
158716|NCT02134288|immunosuppressive therapy
158717|NCT02134288|Delayed Graft Function
158718|NCT02134288|Belatacept
158719|NCT02134275|whole body vibration training
158720|NCT02134275|young adult
158721|NCT02134275|weight gain
158722|NCT02134275|obesity
158723|NCT02134275|randomized clinical trial
158724|NCT02134262|Anti-CD19 CAR Expressing T cells Therapy
158725|NCT02134262|CD19 CAR Gene-Transduced Lymphocyte
158726|NCT02134262|Adoptive Immunotherapy
158727|NCT02134262|Genetically Engineered Lymphocyte Therapy
158728|NCT02134262|Retroviral Vector
158729|NCT02134262|Burkitt Lymphoma
158730|NCT02134262|Lymphoma
158731|NCT02134262|Lymphoma, Follicular
158732|NCT02134262|Lymphoma, Non-Hodgkin
158733|NCT02134262|Lymphomatoid Granulomatosis
158734|NCT02134262|Lymphoma, B-Cell
158735|NCT02134262|Lymphoma, Large B-Cell, Diffuse
158736|NCT02134262|Lymphoma, Large-Cell, Immunoblastic
158737|NCT02134262|Lymphoma, B-Cell, Marginal Zone
158738|NCT02134262|Lymphoma, Extranodal NK-T-Cell
158739|NCT02134262|Lymphoma, Mantle-Cell
158740|NCT02134262|Neoplasms by Histologic Type
158741|NCT02134262|Neoplasms
158742|NCT02134262|Neoplasms, Experimental
158743|NCT02134262|Immune System Diseases
158744|NCT02134249|infertility
158745|NCT02134249|ICSI
158746|NCT02134249|OHSS
158747|NCT02134249|Diosmin
158748|NCT02134249|Cabergoline
158749|NCT02134210|PsO
158750|NCT02134197|Oncology
158751|NCT02134197|Solid tumors
158752|NCT02134197|Antibody drug conjugate
158753|NCT02134197|Maximum tolerated dose
158754|NCT02134171|Thrombotic microangiopathy,
158755|NCT02134171|haemolytic uremic syndrome,
158756|NCT02134171|thrombotic thrombocytopenic purpura,
158757|NCT02134171|ADAMTS13,
158758|NCT02134171|troponin,
158759|NCT02134171|plasma exchange.
158760|NCT02134158|tDCS, gait disorders, equilibrium, hemiplegic, stroke
158761|NCT02134145|Mobile Health
158762|NCT02134145|mHealth
158763|NCT02134145|Technology
158764|NCT02134132|Platelet gel
158765|NCT02134132|diabetic foot ulcer
158766|NCT02134132|umbilical cord blood
158767|NCT02134119|dietary supplement
158768|NCT02134119|endurance athletes
158769|NCT02134119|VO2max
158770|NCT02134119|red blood cells
158771|NCT02134106|Multicenter
158772|NCT02134106|Open-label
158773|NCT02134106|Randomized
158774|NCT02134106|Controlled
158775|NCT02134106|RCT
158776|NCT02134106|antibiotic
158777|NCT02134106|drug-resistant
158778|NCT02134106|Gram-negative
158779|NCT02134106|bacteria
158780|NCT02134080|Tourette Syndrome
158781|NCT02134080|FAAH-Inhibitor
158782|NCT02134080|Tics
158783|NCT02134080|Tic Disorders
158784|NCT02134067|advanced solid tumors
158785|NCT02134067|tumor
158786|NCT02134067|Dose Escalation
158787|NCT02134067|TAS-119
158788|NCT02134067|Taxane
158789|NCT02134067|Paclitaxel
158790|NCT02134067|Aurora A kinase inhibitor
158791|NCT02134067|AurA
158792|NCT02134054|Therapeutic drug monitoring
158793|NCT02134054|Biological treatment
158794|NCT02134054|IBD
158795|NCT02134041|traumatic brain injury
158796|NCT02134041|Alzheimer disease
158797|NCT02134015|Carcinoma
158798|NCT02134015|Non-Small-Cell Lung
158799|NCT02134015|Lung Neoplasms
158800|NCT02134015|Bronchogenic
158801|NCT02134015|Bronchial Neoplasms
158802|NCT02134015|Respiratory Tract Neoplasms
158803|NCT02134015|Thoracic Neoplasms
158804|NCT02134015|Neoplasms by Site
158805|NCT02134015|Neoplasms
158806|NCT02134015|Lung Diseases
158807|NCT02134015|Respiratory Tract Diseases
158808|NCT02134015|Erlotinib
158809|NCT02134015|Therapeutic Uses
158810|NCT02134015|Pharmacologic Actions
158811|NCT02134015|Molecular Mechanisms of Pharmacological Action
158812|NCT02134002|cocaine
158813|NCT02134002|disulfiram
158814|NCT02134002|beta-dopamine hydroxylase
158815|NCT02133989|Carotid stenosis
158816|NCT02133989|Stenting
158817|NCT02133989|Clopidogrel resistance
158818|NCT02133989|Stroke, ischemic
158819|NCT02133976|chronic low back pain
158820|NCT02133976|psychosocial interventions
158821|NCT02133976|mechanisms
158822|NCT02133963|depression
158823|NCT02133963|postpartum depression
158824|NCT02133963|pregnancy
158825|NCT02133963|perinatal depression
158826|NCT02133963|sleep
158827|NCT02133963|life stress
158828|NCT02133950|preimplantation genetic diagnosis
158829|NCT02133950|cryopreservation
158830|NCT02133950|pregnancy
158831|NCT02133924|Graft vs Host Disease
158832|NCT02133924|Graft vs Host Reaction
158833|NCT02133924|allogeneic bone marrow transplantation
158834|NCT02133924|allogeneic hematopoietic stem cell transplantation
158835|NCT02133924|adverse effects
158836|NCT02133898|Depression
158837|NCT02133898|MTHFR
158838|NCT02133898|L-methylfolate
158839|NCT02133885|Resistent Hypertension
158840|NCT02133885|Systolic Blood Pressure
158841|NCT02133872|Resistent Hypertension
158842|NCT02133846|4RT, CBS, PSP, CBD, TPI-287
158843|NCT02133820|Healthy Volunteer
158844|NCT02133820|Pharmacokinetics
158845|NCT02133807|Lipoprotein(a);
158846|NCT02133807|Lp(a) immunoadsorption;
158847|NCT02133807|Apheresis;
158848|NCT02133807|Coronary atherosclerosis;
158849|NCT02133807|Carotid Atherosclerosis;
158850|NCT02133807|Intima-media thickness;
158851|NCT02133807|Regression;
158852|NCT02133807|Quantitative Coronary Angiography;
158853|NCT02133807|Intravascular Ultrasound;
158854|NCT02133807|Virtual Histology;
158855|NCT02133807|Plaque;
158856|NCT02133807|Atorvastatin;
158857|NCT02133794|Hip fracture
158858|NCT02133794|Tomosynthesis
158859|NCT02133794|X-ray
158860|NCT02133794|Emergency room
158861|NCT02133781|Influenza vaccine
158862|NCT02133742|Axitinib and MK-3475
158863|NCT02133742|patients with advanced Renal Cell Cancer.
158864|NCT02133716|pain
158865|NCT02133716|premature infant
158866|NCT02133716|sucrose
158867|NCT02133716|breastfeeding
158868|NCT02133716|expressed breast milk
158869|NCT02133716|PIPP
158870|NCT02133703|Genetic counseling
158871|NCT02133703|genetic testing
158872|NCT02133703|BRCA1
158873|NCT02133703|BRCA2
158874|NCT02133703|Hereditary breast cancer
158875|NCT02133703|Hereditary ovarian cancer
158876|NCT02133690|rotavirus
158877|NCT02133690|rotavirus vaccine
158878|NCT02133690|BRV-PV
158879|NCT02133677|lung cancer and breast cancer patients with brain metastases
158880|NCT02133664|multiple sclerosis
158881|NCT02133664|cognition
158882|NCT02133664|clinical trial
158883|NCT02133664|thiotic acid
158884|NCT02133664|Omega-3 fatty acids
158885|NCT02133651|Clostridium difficile
158886|NCT02133651|Intestinal Microbiota Transplantation
158887|NCT02133651|Diarrhea
158888|NCT02133651|Fecal Microbiota Transplant
158889|NCT02133638|Delirium
158890|NCT02133638|Hypoxic Brain Damage
158891|NCT02133638|Propofol
158892|NCT02133638|S100b protein
158893|NCT02133638|Sevoflurane
158894|NCT02133625|Advanced solid tumor
158895|NCT02133625|Metastatic solid tumor
158896|NCT02133612|esophageal cancer
158897|NCT02133612|adjuvant chemotherapy
158898|NCT02133612|esophageal surgery
158899|NCT02133612|paclitaxel
158900|NCT02133612|cisplatin
158901|NCT02133586|Air pollution
158902|NCT02133586|Ozone
158903|NCT02133586|Nitrogen dioxide
158904|NCT02133586|Lung function
158905|NCT02133586|Cytokines
158906|NCT02133573|progesterone
158907|NCT02133573|congenital heart disease
158908|NCT02133573|periventricular leucomalacia
158909|NCT02133573|brain development
158910|NCT02133573|cardiac surgery
158911|NCT02133573|neurodevelopmental disability
158912|NCT02133573|fetus
158913|NCT02133573|fetal neuroprotection
158914|NCT02133560|Sickle cell
158915|NCT02133560|Thalassemia
158916|NCT02133560|Adherence
158917|NCT02133547|Nitric Oxide
158918|NCT02133547|Nose
158919|NCT02133547|Healthy Volunteers
158920|NCT02133547|Kartagener Syndrome
158921|NCT02133547|Primary Ciliary Dyskinesia
158922|NCT02133534|Chronic kidney disease
158923|NCT02133534|High cholesterol
158924|NCT02133521|DLBS1033
158925|NCT02133521|Acute ischemic stroke
158926|NCT02133521|NIHSS
158927|NCT02133521|Barthel Index
158928|NCT02133495|lower eyelid
158929|NCT02133495|retraction
158930|NCT02133469|Effectiveness
158931|NCT02133469|Prevenar
158932|NCT02133469|nasopharyngeal carriage
158933|NCT02133469|vaccine serotype
158934|NCT02133456|safety
158935|NCT02133456|influenza vaccine
158936|NCT02133456|post-marketing
158937|NCT02133443|Mechanical ventilation
158938|NCT02133443|Acute respiratory failure
158939|NCT02133443|Weaning
158940|NCT02133443|Pressure support ventilation
158941|NCT02133443|Neurally adjusted ventilatory assist
158942|NCT02133430|Postoperative delirium
158943|NCT02133417|Quantitative Transmission Ultrasound
158944|NCT02133417|QTUS
158945|NCT02133404|secondary hyperparathyroidism(SHPT)
158946|NCT02133404|Chronic kidney disease(CKD)
158947|NCT02133404|Mineral bone disease(MBD)
158948|NCT02133391|Accountable Care Organization
158949|NCT02133391|Comparative Effectiveness Research
158950|NCT02133391|Immunization/statistics & numerical data
158951|NCT02133391|Medicaid
158952|NCT02133391|Reminder Systems/economics
159082|NCT02132728|Nutrition
158953|NCT02133391|Reminder Systems/statistics & numerical data
158954|NCT02133378|Bleeding
158955|NCT02133378|Hemostatic
158956|NCT02133352|pulmonary hypertension
158957|NCT02133352|diastolic dyfunction
158958|NCT02133326|Analgesia
158959|NCT02133326|Third Molar Extraction
158960|NCT02133326|Ibuprofen
158961|NCT02133326|Acetaminophen
158962|NCT02133326|Pain Medicine
158963|NCT02133326|Nonsteroidal
158964|NCT02133326|Anti-inflammatory
158965|NCT02133313|Peritoneal Dialysis
158966|NCT02133313|Peritoneal Fibrosis
158967|NCT02133313|Glucose Transporters
158968|NCT02133274|Neoplasms
158969|NCT02133274|Early Palliative Care
158970|NCT02133274|Psychosocial Intervention
158971|NCT02133274|Symptoms
158972|NCT02133274|Quality of life
158973|NCT02133274|Depression
158974|NCT02133248|donor specific antibodies
158975|NCT02133248|B cells
158976|NCT02133248|antibody mediated rejection
158977|NCT02133248|kidney transplant
158978|NCT02133248|desensitization
158979|NCT02133235|endobronchial blocker
158980|NCT02133235|lung separation
158981|NCT02133235|vedio-assisted thoracic operation
158982|NCT02133209|migraine
158983|NCT02133209|headache
158984|NCT02133209|meditation
158985|NCT02133209|mindfulness based stress reduction
158986|NCT02133209|MBSR
158987|NCT02133196|Metastatic
158988|NCT02133196|Non-Small Cell Lung Cancer
158989|NCT02133196|NSCLC
158990|NCT02133196|Lung Cancer
158991|NCT02133170|BIPOLAR DISORDER
158992|NCT02133170|DEPRESSIVE SYMPTOMS
158993|NCT02133170|MINDFULNESS
158994|NCT02133170|PSYCHOEDUCATION
158995|NCT02133170|BIPOLAR PATIENTS WITH DEPRESSIVE SYMPTOMS
158996|NCT02133157|tumor
158997|NCT02133144|NAFLD
158998|NCT02133144|insulin resistance
158999|NCT02133144|metabolic syndrome
159000|NCT02133144|de novo lipogenesis
159001|NCT02133144|overfeeding
159002|NCT02133118|Type 2 diabetes
159003|NCT02133118|New-user design
159004|NCT02133118|Weight trajectory
159005|NCT02133118|Add-on therapy
159006|NCT02133118|Sulphonylureas.
159007|NCT02133105|Heart failure
159008|NCT02133105|Renal failure
159009|NCT02133105|Inotropic drugs
159010|NCT02133105|Levosimendan
159011|NCT02133105|Dobutamine
159012|NCT02133092|Respiratory syncytial virus
159013|NCT02133092|RSV
159014|NCT02133092|Lower respiratory tract infection
159015|NCT02133092|LRTI
159016|NCT02133092|Acute respiratory infection
159017|NCT02133092|Belgian children
159018|NCT02133066|Ultrasound
159019|NCT02133066|Lumbar Puncture
159020|NCT02133066|Spinal Tap
159021|NCT02133066|Pediatric
159022|NCT02133066|Infant
159023|NCT02133066|Bedside Ultrasonography
159024|NCT02133053|Allergic Rhinitis
159025|NCT02133053|Ectoine
159026|NCT02133053|bitop
159027|NCT02133053|Ectoin
159028|NCT02133040|Brown Adipose Tissue
159029|NCT02133027|Laparoscopic cholecystectomy
159030|NCT02133014|pancreatitis
159031|NCT02133014|laparoscopic
159032|NCT02133014|drainage
159033|NCT02133014|surgery
159034|NCT02133001|Major Depressive Disorder
159035|NCT02133001|Esketamine
159036|NCT02133001|Intranasal esketamine
159037|NCT02133001|Placebo
159038|NCT02132975|prostate
159039|NCT02132975|cancer
159040|NCT02132923|Respiratory syncytial virus
159041|NCT02132923|RSV
159042|NCT02132923|Lower respiratory tract infection
159043|NCT02132923|LRTI
159044|NCT02132923|Acute respiratory infection
159045|NCT02132923|Japanese children
159046|NCT02132897|Antiepileptic
159047|NCT02132897|Carbamazepine
159048|NCT02132897|Bio-equivalence
159049|NCT02132897|Fed
159050|NCT02132897|Crossover
159051|NCT02132832|marijuana
159052|NCT02132832|attentional bias
159053|NCT02132832|stress
159054|NCT02132832|buspirone
159055|NCT02132819|transfusion
159056|NCT02132819|feeding
159057|NCT02132819|TRAGI
159058|NCT02132819|NEC
159059|NCT02132806|class II furcation involvement
159060|NCT02132806|piezoelectric surgery
159061|NCT02132806|regeneration
159062|NCT02132806|biomaterial
159063|NCT02132793|technology
159064|NCT02132793|mobile
159065|NCT02132793|anger management
159066|NCT02132793|anger
159067|NCT02132793|PTSD
159068|NCT02132793|veterans
159069|NCT02132767|Heart surgery
159070|NCT02132767|Cardiac surgery
159071|NCT02132767|Coronary artery bypass
159072|NCT02132767|Mitral valve surgery
159073|NCT02132767|Aortic valve surgery
159074|NCT02132767|Atrial fibrillation
159075|NCT02132767|Atrial flutter
159076|NCT02132767|Cardiac arrhythmia
159077|NCT02132767|Valve surgery
159078|NCT02132741|OCT; hypertension; CKD
159079|NCT02132728|flaxseed
159080|NCT02132728|lignans
159081|NCT02132728|inflammation
159083|NCT02132728|enterolactone
159084|NCT02132728|enterodiol
159085|NCT02132689|Moderate Risk Acute Pulmonary Embolism
159086|NCT02132676|Self-Management
159087|NCT02132676|Patient Care Management
159088|NCT02132676|Peer Group
159089|NCT02132676|Disease Management
159090|NCT02132676|Health Plan Implementation
159091|NCT02132676|Diabetes Mellitus
159092|NCT02132650|Rehabilitation
159093|NCT02132650|Walking
159094|NCT02132650|Motor skills disorders
159095|NCT02132650|Electromyography
159096|NCT02132598|Lung Cancer
159097|NCT02132598|Non Small Cell
159098|NCT02132598|Brain metastases
159099|NCT02132598|c-MET
159100|NCT02132520|Hemiparesis
159101|NCT02132520|Stroke
159102|NCT02132520|Rehabilitation
159103|NCT02132520|Transcranial Magnetic Stimulation, Repetitive
159104|NCT02132520|Electroencephalography
159105|NCT02132520|Functional Neuroimaging
159106|NCT02132520|Brain-Computer Interface
159107|NCT02132507|epilepsy
159108|NCT02132507|fMRI
159109|NCT02132507|EEG
159110|NCT02132507|ICA
159111|NCT02132481|Smartphones
159112|NCT02132481|Mobile phones
159113|NCT02132481|Substance use disorder
159114|NCT02132481|Recovery Support Services
159115|NCT02132481|Ecological Momentary Assessment (EMA)
159116|NCT02132481|Ecological Momentary Intervention (EMI)
159117|NCT02132481|Randomized field experiment
159118|NCT02132481|Effectiveness
159119|NCT02132481|Post-Discharge
159120|NCT02132468|PNET
159121|NCT02132468|GI-NET
159122|NCT02132468|neuroendocrine
159123|NCT02132468|carcinoid
159124|NCT02132455|Screening colonoscopy
159125|NCT02132455|Surveillance colonoscopy
159126|NCT02132442|Children
159127|NCT02132442|Adolescents
159128|NCT02132442|Adults
159129|NCT02132442|Type 2 diabetes
159130|NCT02132442|Nonalcoholic fatty liver disease
159131|NCT02132442|Vitamin D deficiency
159132|NCT02132429|Migraine
159133|NCT02132416|Prospective study
159134|NCT02132416|Surgical management
159135|NCT02132416|Unstable thoracic cage injuries
159136|NCT02132416|Trauma
159137|NCT02132416|Ventilator support
159138|NCT02132403|pancreatic cancer
159139|NCT02132403|adenocarcinoma of the pancreas (PDAC)
159140|NCT02132403|mixed adenocarcinoma of the pancreas
159141|NCT02132403|locally advanced
159142|NCT02132403|recurrent
159143|NCT02132403|metastatic
159144|NCT02132390|Breast cancer
159145|NCT02132390|Chemotherapy induced amenorrhea
159146|NCT02132390|Goserelin
159147|NCT02132364|stroke
159148|NCT02132364|hypertension
159149|NCT02132364|secondary prevention
159150|NCT02132364|educational program
159151|NCT02132338|Type 2 Diabetes Mellitus
159152|NCT02132338|Prevention
159153|NCT02132338|Health Education
159154|NCT02132325|Pancreatic Cancer
159155|NCT02132325|Dignity Therapy
159156|NCT02132325|Palliative Care
159157|NCT02132325|Advanced Lung Cancer
159158|NCT02132325|Non-Small-Cell Lung Cancer
159159|NCT02132312|Cataract
159160|NCT02132312|Lens replacement
159161|NCT02132312|pediatric
159162|NCT02132299|Malaria
159163|NCT02132299|Plasmodium falciparum malaria
159164|NCT02132299|PfSPZ Vaccine
159165|NCT02132299|PfSPZ Challenge
159166|NCT02132299|Controlled human malaria infection (CHMI)
159167|NCT02132286|Functional magnetic resonance neuroimaging
159168|NCT02132286|Serotonin transporter gene polymorphism
159169|NCT02132286|Amygdala
159170|NCT02132286|Antidepressant
159171|NCT02132286|Quetiapine
159172|NCT02132286|Citalopram
159173|NCT02132286|imaging biomarker
159174|NCT02132260|Naftifine
159175|NCT02132260|Naftin®
159176|NCT02132260|Tinea pedis
159177|NCT02132247|Minor athletic injuries
159178|NCT02132247|Pain
159179|NCT02132247|Diclofenac
159180|NCT02132247|Topical
159181|NCT02132221|Chronic non cancer pain
159182|NCT02132221|Long term opioid therapy
159183|NCT02132221|Side effects
159184|NCT02132221|risks
159185|NCT02132221|function
159186|NCT02132221|negative benefit/risk ratio
159187|NCT02132143|Lung adenocarcinoma
159188|NCT02132143|Concurrent chemoradiotherapy
159189|NCT02132143|Sequential chemoradiotherapy
159190|NCT02132143|Progression-free survival
159191|NCT02132130|gene therapy
159192|NCT02132130|hearing loss
159193|NCT02132130|balance
159194|NCT02132130|vestibular
159195|NCT02132130|cochlear implant
159196|NCT02132104|Intrauterine adhesions
159197|NCT02132104|Asherman Syndrome
159198|NCT02132104|Amnion graft
159199|NCT02132091|Sirtuins
159200|NCT02132091|Calorie Restriction
159201|NCT02132091|Intermittent Fasting
159202|NCT02132091|Antioxidant
159203|NCT02132091|Aging
159204|NCT02132091|Metabolism
159205|NCT02132091|Mitochondria
159206|NCT02132091|Oxidative Stress
159207|NCT02132078|Lung transplant recipients
159208|NCT02132078|diverticulitis
159209|NCT02132078|immunosuppression
159210|NCT02132052|Essential Tremor
159211|NCT02132052|Multiple System Atrophy
159212|NCT02132052|Corticobasal Degeneration
159213|NCT02132052|Supranuclear Palsy, Progressive
159214|NCT02132052|Parkinson's Disease
159215|NCT02132052|PD
159216|NCT02132039|Tai Chi, dementia, caregivers
159217|NCT02132026|Aortic Stenosis
159218|NCT02132026|Denosumab
159219|NCT02132026|Alendronic Acid
159220|NCT02132026|Osteoporosis
159221|NCT02131987|Dislocation
159222|NCT02131987|Hemiarthroplasty
159223|NCT02131987|Femoral neck fracture
159224|NCT02131987|Femoral offset
159225|NCT02131987|Leg length difference
159226|NCT02131987|Wiberg angle
159227|NCT02131974|intubation, pediatric, endotracheal, cuffed ETT
159228|NCT02131961|diabetic foot
159229|NCT02131961|foot ulcer
159230|NCT02131961|foot wound
159231|NCT02131961|plantar ulcer
159232|NCT02131961|plantar wound
159233|NCT02131961|contact cast
159234|NCT02131961|collagenase
159235|NCT02131948|Insulin resistance
159236|NCT02131948|Brain insulin action
159237|NCT02131948|Type 2 Diabetes
159238|NCT02131909|unilateral cerebral palsy
159239|NCT02131909|children
159240|NCT02131909|upper-limb
159241|NCT02131909|mirror therapy
159242|NCT02131909|bimanual coordination
159243|NCT02131909|kinematics analysis
159244|NCT02131896|Type 1 Diabetes
159245|NCT02131896|Newly diagnosed
159246|NCT02131896|Lipid profile
159247|NCT02131896|Mediterranean diet
159248|NCT02131883|Health Anxiety
159249|NCT02131883|Hypochondriasis
159250|NCT02131883|Illness Anxiety Disorder
159251|NCT02131883|Somatic Symptom Disorder
159252|NCT02131883|Personality Disorders
159253|NCT02131883|Cognitive Behavioral Therapy
159254|NCT02131883|Group-CBT
159255|NCT02131883|Illness Perception
159256|NCT02131883|Cost-effectiveness
159257|NCT02131870|iron absorption
159258|NCT02131870|healthy females
159259|NCT02131870|child bearing age
159260|NCT02131857|Mindfulness
159261|NCT02131857|stress reduction
159262|NCT02131844|colorectal surgery
159263|NCT02131844|postoperative recovery
159264|NCT02131844|early mobilization
159265|NCT02131831|telomere
159266|NCT02131831|telomerase
159267|NCT02131831|cirrhosis
159268|NCT02131818|amoxicillin
159269|NCT02131818|postpartum infections
159270|NCT02131818|puerperal infection
159271|NCT02131805|skin
159272|NCT02131805|Brachytherapy
159273|NCT02131805|14-001
159274|NCT02131779|prostate cancer disparities
159275|NCT02131779|African American
159276|NCT02131779|Spiritually based intervention
159277|NCT02131779|Men's Health
159278|NCT02131779|Informed Decision Making
159279|NCT02131779|Community Based Participatory Research
159280|NCT02131779|Health Communication
159281|NCT02131779|Health Information Technology
159282|NCT02131779|Community Health Advisors
159283|NCT02131766|Diabetes Mellitus, Type 1
159284|NCT02131766|Artificial Pancreas Project (APP)
159285|NCT02131766|Diabetes Assistant (DiAs)
159286|NCT02131766|Closed-Loop Control (CLC)
159287|NCT02131753|hairy cell leukemia
159288|NCT02131753|untreated
159289|NCT02131753|cladribine subcutaneous
159290|NCT02131740|corneal
159291|NCT02131740|eye rubbing
159292|NCT02131727|hand hygiene
159293|NCT02131727|communicable diseases
159294|NCT02131727|respiratory tract infections
159295|NCT02131727|primary prevention
159296|NCT02131727|employees
159297|NCT02131714|pressure pain threshold
159298|NCT02131714|temporomandibular disorder syndrome
159299|NCT02131714|therapeutic exercise
159300|NCT02131714|conservative treatment
159301|NCT02131714|facial pain
159302|NCT02131701|Physical fitness
159303|NCT02131701|Family history of type 2 diabetes
159304|NCT02131701|Prescription of exercise
159305|NCT02131688|safety;malignant lymphoma;
159306|NCT02131675|C-peptide
159307|NCT02131675|type 1 diabetes
159308|NCT02131662|Uterine fibroids
159309|NCT02131649|Prostate Cancer
159310|NCT02131649|PET
159311|NCT02131649|MRI
159312|NCT02131649|Fluorocholine
159313|NCT02131649|Radiotherapy
159314|NCT02131649|Prostatectomy
159315|NCT02131610|Sleep apnea
159316|NCT02131610|Obstructive sleep apnea
159317|NCT02131610|Subclinical atherosclerosis
159318|NCT02131610|Epigenetics
159319|NCT02131610|T cells
159320|NCT02131597|Leukemia
159321|NCT02131597|Myelodysplastic syndrome
159322|NCT02131597|MDS
159323|NCT02131597|Higher risk
159324|NCT02131597|SGI-110
159325|NCT02131584|Leukemia
159326|NCT02131584|Chronic Lymphocytic Leukemia
159327|NCT02131584|CLL
159328|NCT02131584|Fatigue
159329|NCT02131584|Brief Fatigue Inventory
159330|NCT02131584|BFI
159331|NCT02131584|Questionnaires
159332|NCT02131584|Surveys
159333|NCT02131584|Ruxolitinib
159334|NCT02131584|Jakafi
159335|NCT02131584|INCB018424
159336|NCT02131584|INC424
159337|NCT02131571|HIV
159338|NCT02131571|bone
159339|NCT02131571|fractures
159340|NCT02131571|vitamin D
159341|NCT02131571|biomarkers
159342|NCT02131558|Endometrial cancer
159343|NCT02131558|Sentinel lymph node
159344|NCT02131558|Indocyanine green
159345|NCT02131558|Near infrared imaging
159346|NCT02131545|quetiapine
159347|NCT02131545|pharmacokinetics
159348|NCT02131545|dementia
159349|NCT02131545|delirium
159350|NCT02131545|palliative care
159351|NCT02131532|Post-stroke fatigue
159352|NCT02131532|Psychological intervention
159353|NCT02131532|Feasibility
159354|NCT02131506|Advanced HER2 positive Breast Cancer
159355|NCT02131506|pretreated breast cancer
159356|NCT02131506|advanced disease
159357|NCT02131454|asthma and COPD treatment
159358|NCT02131454|inhalation techniques
159359|NCT02131454|training of inhalation
159360|NCT02131428|Heart Failure
159361|NCT02131428|Depression
159362|NCT02131428|BNP
159363|NCT02131415|schizophrenia
159364|NCT02131415|real-life
159365|NCT02131415|long-acting injectable
159366|NCT02131415|Reliam
159367|NCT02131389|Hip
159368|NCT02131389|Arthroplasty
159369|NCT02131389|Arthroplasties
159370|NCT02131389|Prosthesis
159371|NCT02131389|Iconacy
159372|NCT02131389|Osteoarthritis
159373|NCT02131389|Arthritis
159374|NCT02131389|THA
159375|NCT02131389|THR
159376|NCT02131389|DJD
159377|NCT02131376|carcinoma, renal cell
159378|NCT02131376|partial nephrectomy
159379|NCT02131376|kidney function test
159380|NCT02131376|robotics
159381|NCT02131324|Psoriasis
159382|NCT02131311|single use
159383|NCT02131311|disposable
159384|NCT02131311|pessary
159385|NCT02131311|stress urinary incontinence
159386|NCT02131311|sui
159387|NCT02131298|Palbociclib
159388|NCT02131298|Itraconazole
159389|NCT02131298|Pharmacokinetics
159390|NCT02131298|Drug-Drug Interaction Study
159391|NCT02131298|Healthy Volunteers
159392|NCT02131285|Rehabilitation,
159393|NCT02131285|Balance,
159394|NCT02131285|Sensory strategies,
159395|NCT02131285|Multiple Sclerosis,
159396|NCT02131285|Postural control
159397|NCT02131220|No-Reflow Phenomenon
159398|NCT02131194|Cataract
159399|NCT02131194|Nutritional Supplement
159400|NCT02131181|Delirium, postoperative delirium, elderly
159401|NCT02131142|ischemic heart disease
159402|NCT02131142|CAD
159403|NCT02131129|schizophrenia
159404|NCT02131129|schizophreniform disorder
159405|NCT02131129|schizoaffective disorder
159406|NCT02131129|first episode
159407|NCT02131129|psychosis
159408|NCT02131129|cognition
159409|NCT02131116|schizophrenia
159410|NCT02131116|schizophreniform disorder
159411|NCT02131116|schizoaffective disorder
159412|NCT02131116|cognition
159413|NCT02131116|metacognition
159414|NCT02131116|insight
159415|NCT02131116|first episode psychosis
159416|NCT02131116|psychosis
159417|NCT02131103|Pharmacoinvasive strategy
159418|NCT02131090|Epidural
159419|NCT02131090|Catheter
159420|NCT02131090|Fixation
159421|NCT02131090|Device
159422|NCT02131090|Intrapartum
159423|NCT02131077|Lateral Epicondylitis
159424|NCT02131051|ectoine
159425|NCT02131051|allergic rhinitis
159426|NCT02131051|bitop
159427|NCT02131038|Ectoine
159428|NCT02131038|bitop
159429|NCT02131038|Allergic Rhinitis
159430|NCT02131012|Macular edema
159431|NCT02130999|Non-24
159432|NCT02130999|absolute bioavailability
159433|NCT02130999|tasimelteon
159434|NCT02130999|Hetlioz™
159435|NCT02130986|procalcitonin (PCT)
159436|NCT02130986|lower respiratory tract infection (LRTI)
159437|NCT02130986|antibiotic exposure
159438|NCT02130986|antibiotic decision making
159439|NCT02130986|community acquired pneumonia (CAP)
159440|NCT02130986|chronic obstructive pulmonary disease (COPD) exacerbation
159441|NCT02130986|acute asthma exacerbation
159442|NCT02130986|acute bronchitis
159443|NCT02130986|procalcitonin guideline
159444|NCT02130973|teriparatide
159445|NCT02130973|Forteo
159446|NCT02130973|Denosumab
159447|NCT02130973|Prolia
159448|NCT02130973|bone density
159449|NCT02130973|treatment
159450|NCT02130960|RMR
159451|NCT02130960|Reliability
159452|NCT02130960|Obese
159453|NCT02130960|Energy Expenditure
159454|NCT02130960|Resting Energy Expenditure
159455|NCT02130960|Resting Metabolic Rate
159456|NCT02130947|Metastatic Castration Resistant Prostate Cancer
159457|NCT02130947|Prostate Cancer
159458|NCT02130947|mCRPC
159459|NCT02130947|Pilot Study
159460|NCT02130947|UNC Lineberger
159461|NCT02130947|Exercise
159462|NCT02130934|Childhood cancer
159463|NCT02130934|anthracyclines
159464|NCT02130934|cardiotoxicity
159465|NCT02130934|cardiac MRI
159466|NCT02130934|cumulative does of at least 150 mg/m2 of anthracyclines
159467|NCT02130934|Ventricular function
159468|NCT02130921|Stigma
159469|NCT02130921|HIV
159470|NCT02130921|CHWs
159471|NCT02130921|PLH
159472|NCT02130921|Injecting Drug Users
159473|NCT02130921|FM
159474|NCT02130895|prescribing
159475|NCT02130895|STOPP Criteria
159476|NCT02130895|potentially inappropriate prescribing
159477|NCT02130895|clinical decision support
159478|NCT02130895|Electronic Medical Records
159479|NCT02130895|primary care
159480|NCT02130882|Interleukin-5
159481|NCT02130882|Monoclonal Antibody
159482|NCT02130882|Treatment
159483|NCT02130869|Autologous stem cell transplantation
159484|NCT02130869|Natural killer cells
159485|NCT02130856|Neonatal mortality
159486|NCT02130856|Neonatal kit
159487|NCT02130856|Pakistan
159488|NCT02130856|Randomized Control Trial
159489|NCT02130856|Chlorhexidine
159490|NCT02130856|ThermoSpot
159491|NCT02130856|Birth
159492|NCT02130843|URINARY INCONTINENCE
159493|NCT02130843|URODYNAMICS
159494|NCT02130843|URINARY RETENTION
159495|NCT02130843|URINARY CATHETERIZATION
159496|NCT02130830|hemorrhoids
159497|NCT02130830|Rubber band ligation
159498|NCT02130830|pain
159499|NCT02130817|Renal Transplant
159500|NCT02130817|Kidney Transplant
159501|NCT02130817|Mean flourescent Intensity
159502|NCT02130817|Delayed Graft Function
159503|NCT02130817|Antagonist of Thymocyte Cell Activation
159504|NCT02130804|Obesity
159505|NCT02130804|Adipose tissue inflammation
159506|NCT02130804|Salsalate
159507|NCT02130804|Hispanics
159508|NCT02130765|Monomorphic Ventricular Tachycardia
159509|NCT02130765|Ischemic
159510|NCT02130765|Non-ischemic
159511|NCT02130765|Catheter Ablation
159512|NCT02130752|Stomach Neoplasms
159513|NCT02130752|Operative Time
159514|NCT02130752|Gastrectomy
159515|NCT02130752|Surgical Hemorrhage
159516|NCT02130752|Mortality
159517|NCT02130752|Morbidity
159518|NCT02130739|Anesthesia
159519|NCT02130739|Epidural
159520|NCT02130739|Thoracic Nerves
159521|NCT02130739|Horner syndrome
159522|NCT02130726|Gastric cancer
159523|NCT02130726|Minimally-invasive
159524|NCT02130726|Oncological quality of resection
159525|NCT02130700|mCRPC
159526|NCT02130700|metastatic
159527|NCT02130700|castration-resistant prostate cancer
159528|NCT02130687|Type 2 Diabetes Mellitus
159529|NCT02130687|Hypertension
159530|NCT02130687|Angiotensin Converting Enzyme Inhibitors
159531|NCT02130687|Dipeptidyl Peptidase IV Inhibitors
159532|NCT02130687|Sitagliptin
159533|NCT02130687|Aprepitant
159534|NCT02130687|Ramipril
159535|NCT02130674|traumatic brain injury
159536|NCT02130674|glutamine
159537|NCT02130674|microdialysis
159538|NCT02130674|metabolism
159539|NCT02130661|drug interaction
159540|NCT02130661|healthy volunteer
159541|NCT02130661|rilapladib
159542|NCT02130661|SB-659032
159543|NCT02130661|Alzheimer's disease
159544|NCT02130661|itraconazole
159545|NCT02130648|Non-invasive Prenatal Diagnosis (NIPD)
159546|NCT02130648|Cystic Fibrosis
159547|NCT02130648|Quantitative real time MEMO-PCR
159548|NCT02130635|PI3Kd
159549|NCT02130635|Pharmacodynamics
159550|NCT02130635|dry powder inhaler
159551|NCT02130635|GSK2269557
159552|NCT02130635|safety
159553|NCT02130635|COPD subjects
159554|NCT02130622|Diabetic Gastroparesis
159555|NCT02130622|Promethazine
159556|NCT02130570|Adverse events
159557|NCT02130570|Readmissions
159558|NCT02130570|Patient Centered Medical Home (PCMH)
159559|NCT02130570|Accountable Care Organizations (ACO)
159560|NCT02130570|Medication reconciliation
159561|NCT02130570|Discharge Advocate
159562|NCT02130570|Patient engagement
159563|NCT02130570|Transitions of care
159564|NCT02130570|Transitions coach
159565|NCT02130570|Pharmacist intervention
159566|NCT02130557|Leukemia
159567|NCT02130557|Myelogenous
159568|NCT02130557|Chronic
159569|NCT02130557|BCR-ABL Positive
159570|NCT02130557|Bosutinib
159571|NCT02130557|Leukemia, Myeloid
159572|NCT02130557|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
159573|NCT02130557|Philadelphia Chromosome
159574|NCT02130557|Neoplasms by Histologic Type
159575|NCT02130557|Bone Marrow Diseases
159576|NCT02130557|Hematologic Diseases
159577|NCT02130557|Translocation, Genetic
159578|NCT02130557|Pathologic Processes
159579|NCT02130557|Imatinib
159580|NCT02130557|Therapeutic Uses
159581|NCT02130557|Pharmacologic Actions
159582|NCT02130557|Molecular Mechanisms of Pharmacological Action
159583|NCT02130466|PD1
159584|NCT02130466|PD-1
159585|NCT02130466|PDL1
159586|NCT02130466|PD-L1
159587|NCT02130453|Ischemia
159588|NCT02130453|Coronary artery disease
159589|NCT02130453|Nuclear stress test
159590|NCT02130453|Stress Echocardiogram
159591|NCT02130453|Echocardiography strain measurement
159592|NCT02130453|Ultrasound cardiac imaging
159593|NCT02130453|ReSTE
159594|NCT02130453|SPECT
159595|NCT02130453|Regadenoson
159596|NCT02130440|nasal obstruction
159597|NCT02130440|sneezing
159598|NCT02130440|itching
159599|NCT02130440|rhinorrhea
159600|NCT02130440|respiratory infections
159601|NCT02130440|wheezing
159602|NCT02130427|Adult subjects
159603|NCT02130427|NSCLC
159604|NCT02130414|Cyclosporine
159605|NCT02130414|Healthy Volunteers
159606|NCT02130414|Immunosuppressive Agents
159607|NCT02130414|CyCol
159608|NCT02130414|Pharmacokinetics
159609|NCT02130401|neuromodulation
159610|NCT02130401|caloric vestibular stimulation
159611|NCT02130401|Type 2 Diabetes
159612|NCT02130362|Adalimumab
159613|NCT02130362|Crohn's
159614|NCT02130362|Crohn's Disease
159615|NCT02130362|Registry
159616|NCT02130362|Gastrointestinal Diseases
159617|NCT02130362|Inflammatory Bowel Diseases
159618|NCT02130349|IBD
159619|NCT02130349|Crohns Disease
159620|NCT02130349|Ulcerative Colitis
159621|NCT02130349|Cohort
159622|NCT02130349|Biobank
159623|NCT02130349|Population based
159624|NCT02130349|IBDSL
159625|NCT02130336|Metabolic syndrome
159626|NCT02130336|Metabolic risk factors
159627|NCT02130336|High-intensity interval training
159628|NCT02130336|Moderate-intensity exercise
159629|NCT02130323|Cervical intraepithelial neoplasia, Imiquimod
159630|NCT02130310|Chronic ulcers
159631|NCT02130310|Venous ulcers
159632|NCT02130297|Mohs
159633|NCT02130297|scar
159634|NCT02130297|post excision
159635|NCT02130297|CO2 laser
159636|NCT02130297|laser
159637|NCT02130297|skin cancer
159638|NCT02130297|resurfacing
159639|NCT02130271|Sciatica
159640|NCT02130271|PET scan
159641|NCT02130271|MRI
159642|NCT02130271|Inflammation
159643|NCT02130271|Epidural Steroid Injection (ESI)
159644|NCT02130258|Radicular
159645|NCT02130258|Pain
159646|NCT02130258|Epidural Steroid Injection
159647|NCT02130245|Laparoscopic cholecystectomy
159648|NCT02130245|Acute cholecystitis
159649|NCT02130245|Early
159650|NCT02130245|Delayed
159651|NCT02130232|Gestational weight gain
159652|NCT02130232|Lifestyle
159653|NCT02130232|Intervention
159654|NCT02130219|ICP, intracranial hypertension, Vittamed 205
159655|NCT02130206|Plaque, Saliva, Cavities
159656|NCT02130193|Efficacy
159657|NCT02130193|Danirixin
159658|NCT02130193|EXACT-PRO
159659|NCT02130193|COPD
159660|NCT02130193|Safety
159661|NCT02130193|RD
159662|NCT02130193|CXCR2 inhibitor
159663|NCT02130193|EXACT-RS
159664|NCT02130193|PK
159665|NCT02130193|HCRU exacerbations
159666|NCT02130193|PD
159667|NCT02130167|Myopia progression
159668|NCT02130167|Low concentration atropine
159669|NCT02130154|Brown adipose Tissue
159670|NCT02130154|Ageing
159671|NCT02130154|Sympathetic Nervous Stimulation
159672|NCT02130154|Obesity
159673|NCT02130141|cocoa
159674|NCT02130141|dark chocolate
159675|NCT02130141|hypertension
159676|NCT02130141|blood pressure monitoring, ambulatory
159677|NCT02130141|flavanols
159678|NCT02130102|technology acceptance
159679|NCT02130102|ambient assisted living
159680|NCT02130102|independent living
159681|NCT02130102|quality of life
159682|NCT02130102|socioeconomic impact
159683|NCT02130102|usability of information and communication technologies
159684|NCT02130063|IDA
159685|NCT02130063|Iron deficiency
159686|NCT02130063|iron deficiency anaemia and who are intolerant or unresponsive to oral iron therapy
159687|NCT02130050|Obstructive Sleep Apnea
159688|NCT02130050|Continuous Positive Airway Pressure
159689|NCT02130050|Cardiovascular disease
159690|NCT02130050|Polysomnography
159691|NCT02130050|Metabolomic
159692|NCT02130037|APPLICATION
159693|NCT02130037|SMARTPHONE
159694|NCT02130037|BULIMIA
159695|NCT02130037|B.E.D
159696|NCT02130037|BINGE EATING DISORDER
159697|NCT02130024|Age-related macular degeneration, ranibizumab, aflibercept, geographic atrophy, inject and extend
159698|NCT02129998|Infertility
159699|NCT02129998|IVF/ICSI
159700|NCT02129998|Progesterone
159701|NCT02129998|Preimplantation Factor (PIF)
159702|NCT02129985|the newly onset type 2 diabetes
159703|NCT02129985|short-term insulin treatment
159704|NCT02129985|exenatide sequential therapy
159705|NCT02129985|beta cell function
159706|NCT02129985|glycaemic remission
159707|NCT02129972|Inflammatory Bowel Disease, colon lesions, colon capsule endoscopy
159828|NCT02129556|PD-L1 expressing
159829|NCT02129556|HER2-positive
159708|NCT02129959|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic
159709|NCT02129959|assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
159710|NCT02129946|Type 2 Diabetes
159711|NCT02129946|Resistant Starch
159712|NCT02129946|Postprandial Glucose
159713|NCT02129946|Postprandial Insulin
159714|NCT02129946|Satiety
159715|NCT02129933|EAC
159716|NCT02129933|HGD
159717|NCT02129933|Esophagus
159718|NCT02129920|Stroke
159719|NCT02129920|Cerebral Infarction
159720|NCT02129920|Atrial Fibrillation
159721|NCT02129920|Arrhythmias, Cardiac
159722|NCT02129920|Heart Diseases
159723|NCT02129920|Cardiovascular Diseases
159724|NCT02129920|Cerebrovascular Disorders
159725|NCT02129920|Brain Diseases
159726|NCT02129920|Central Nervous System Diseases
159727|NCT02129920|Nervous System Diseases
159728|NCT02129920|Vascular Diseases
159729|NCT02129920|Brain Infarction
159730|NCT02129920|Brain Ischemia
159731|NCT02129920|Anticoagulants
159732|NCT02129920|Hematologic Agents
159733|NCT02129920|Therapeutic Uses
159734|NCT02129907|Anemias
159735|NCT02129907|Iron-Deficiency
159736|NCT02129907|thrombin
159737|NCT02129894|cesarean section
159738|NCT02129894|postoperative pain
159739|NCT02129894|pregnancy
159740|NCT02129894|abdominal binder
159741|NCT02129868|Type 1 diabetes
159742|NCT02129868|Closed-loop glucose control
159743|NCT02129868|Artificial Pancreas
159744|NCT02129868|Continuous subcutaneous insulin infusion
159745|NCT02129868|Continuous glucose monitoring
159746|NCT02129842|AFib
159747|NCT02129842|AF
159748|NCT02129842|ablation
159749|NCT02129842|EndoPAT
159750|NCT02129842|Endothelial dysfunction
159751|NCT02129842|PAT
159752|NCT02129829|Cirrhosis
159753|NCT02129829|HBV
159754|NCT02129829|HIV
159755|NCT02129829|HCV
159756|NCT02129816|Female
159757|NCT02129816|Postmenopause
159758|NCT02129803|Cystic Fibrosis, high flow 20 liters per minute (LPM) humidification therapy
159759|NCT02129790|Bipolar Disorder
159760|NCT02129790|Suicidal
159761|NCT02129790|Depression
159762|NCT02129790|Self-harm
159763|NCT02129790|Psychosocial intervention
159764|NCT02129777|Drug therapy
159765|NCT02129751|able to swallow medications without difficulty
159766|NCT02129751|bupropion hydrobromide
159767|NCT02129699|NSCLC
159768|NCT02129699|stage IV
159769|NCT02129686|Chemotherapy-induced peripheral neuropathy (CIPN)
159770|NCT02129686|Acupuncture
159771|NCT02129686|Early-Stage Breast Carcinoma
159772|NCT02129686|Stage I Breast Cancer
159773|NCT02129686|Stage II Breast Cancer
159774|NCT02129686|Stage III Breast Cancer
159775|NCT02129673|Glaucoma
159776|NCT02129673|Intra-ocular pressure
159777|NCT02129673|Slow Release
159778|NCT02129673|Controlled release
159779|NCT02129647|Neurofibromatosis Type 2
159780|NCT02129647|Vestibular Schwannomas
159781|NCT02129647|Axitinib
159782|NCT02129634|Percutaneous Transluminal Angioplasty
159783|NCT02129634|Limb-salvage
159784|NCT02129634|Randomized Controlled Trial
159785|NCT02129634|Paclitaxel
159786|NCT02129621|Lipocalin
159787|NCT02129621|mineralocorticoid receptor
159788|NCT02129608|overweight
159789|NCT02129608|obese
159790|NCT02129608|central adiposity
159791|NCT02129608|Laser
159792|NCT02129608|lorcaserin
159793|NCT02129608|low level laser therapy
159794|NCT02129608|belviq
159795|NCT02129595|Resveratrol
159796|NCT02129595|Diabetes Mellitus
159797|NCT02129595|Diabetes Mellitus, Type 2
159798|NCT02129595|Insulin Resistance
159799|NCT02129595|Glucose Metabolism Disorders
159800|NCT02129595|Metabolic Diseases
159801|NCT02129595|Endocrine System Diseases
159802|NCT02129595|Hyperinsulinism
159803|NCT02129595|Anti-Inflammatory Agents, Non-Steroidal
159804|NCT02129595|Analgesics, Non-Narcotic
159805|NCT02129595|Analgesics
159806|NCT02129595|Sensory System Agents
159807|NCT02129595|Peripheral Nervous System Agents
159808|NCT02129595|Physiological Effects of Drugs
159809|NCT02129595|Pharmacologic Actions
159810|NCT02129595|Anti-Inflammatory Agents
159811|NCT02129595|Therapeutic Uses
159812|NCT02129595|Antirheumatic Agents
159813|NCT02129595|Antineoplastic Agents, Phytogenic
159814|NCT02129595|Antineoplastic Agents
159815|NCT02129595|Antioxidants
159816|NCT02129595|Molecular Mechanisms of Pharmacological Action
159817|NCT02129595|Protective Agents
159818|NCT02129595|Enzyme Inhibitors
159819|NCT02129595|Platelet Aggregation Inhibitors
159820|NCT02129595|Hematologic Agents
159821|NCT02129595|Antimutagenic Agents
159822|NCT02129595|Anticarcinogenic Agents
159823|NCT02129595|Central Nervous System Agents
159824|NCT02129595|Brown Adipose Tissue
159825|NCT02129556|Metastatic
159826|NCT02129556|Breast
159827|NCT02129556|trastuzumab-resistant
159830|NCT02129543|SCT
159831|NCT02129543|Stem Cell Transplantation
159832|NCT02129543|Stem Cell Transplant
159833|NCT02129530|Community Mobilization
159834|NCT02129530|HIV
159835|NCT02129530|Intimate Partner Violence
159836|NCT02129530|Gender Norms
159837|NCT02129504|root coverage
159838|NCT02129504|gingival recession
159839|NCT02129504|periodontal surgery
159840|NCT02129491|stroke
159841|NCT02129491|Congenital stroke
159842|NCT02129491|neonatal
159843|NCT02129491|hemiplegia
159844|NCT02129478|olanzapine
159845|NCT02129478|pediatrics
159846|NCT02129478|chemotherapy-induced nausea
159847|NCT02129478|chemotherapy-induced vomiting
159848|NCT02129465|Cytomegalovirus
159849|NCT02129465|CMV
159850|NCT02129465|pregnancy
159851|NCT02129465|transmission
159852|NCT02129452|Alzheimer disease
159853|NCT02129452|Dementia
159854|NCT02129452|Neurodegenerative Diseases
159855|NCT02129452|Tauopathies
159856|NCT02129452|Amyloid beta Peptides
159857|NCT02129452|Amyloid Plaque
159858|NCT02129452|MicroRNAs
159859|NCT02129452|Early Diagnosis
159860|NCT02129439|Antisense oligonucleotide
159861|NCT02129439|Colitis Ulcerosa
159862|NCT02129439|Ulcerative colitis
159863|NCT02129439|Phase II
159864|NCT02129439|Transcription factor GATA-3
159865|NCT02129439|intrarectal application
159866|NCT02129439|proof-of-concept
159867|NCT02129426|Sedation
159868|NCT02129426|MRI
159869|NCT02129413|Aneurysmal subarachnoid hemorrhage
159870|NCT02129413|Subarachnoid hemorrhage
159871|NCT02129413|Cerebral vasospasm
159872|NCT02129413|Ruptured aneurysm
159873|NCT02129413|Delayed Cerebral Ischemia
159874|NCT02129413|Delayed Ischemic Deficit
159875|NCT02129413|Delayed ischemic neurological deficit
159876|NCT02129413|Neurostimulation
159877|NCT02129413|Carotid body
159878|NCT02129400|Xenon-inhalation
159879|NCT02129400|Erythropoetin
159880|NCT02129400|Pharmakokinetic
159881|NCT02129400|Pharmacodynamic
159882|NCT02129400|Hemodynamic parameters
159883|NCT02129400|Inflammatory parameters
159884|NCT02129400|Growth factors
159885|NCT02129400|Oxidative stress parameters
159886|NCT02129387|Nicotine
159887|NCT02129387|Smoking Progression
159888|NCT02129387|EEG
159889|NCT02129387|Young adults
159890|NCT02129387|Light smokers
159891|NCT02129387|rs1051730 genotype
159892|NCT02129374|Spondylolysis
159893|NCT02129374|Lumbar spine
159894|NCT02129374|Young population
159895|NCT02129374|Direct repair
159896|NCT02129374|Union rate
159897|NCT02129374|Functional outcome
159898|NCT02129361|traumatic brain injury
159899|NCT02129348|Alzheimer's disease
159900|NCT02129348|psychosis
159901|NCT02129348|agitation
159902|NCT02129348|aggression
159903|NCT02129348|Lithium
159904|NCT02129348|delusions
159905|NCT02129348|hallucinations
159906|NCT02129335|glioblastoma
159907|NCT02129335|partner
159908|NCT02129335|stress
159909|NCT02129335|exercise
159910|NCT02129335|outcome
159911|NCT02129309|COPD
159912|NCT02129309|Apelin
159913|NCT02129309|agonist
159914|NCT02129309|antagonist
159915|NCT02129296|Morbid obesity
159916|NCT02129296|Gastric balloon
159917|NCT02129296|Weight loss
159918|NCT02129296|Tolerance
159919|NCT02129296|Safety
159920|NCT02129283|physicians, nurses, ICU, end-of-life, simulation training
159921|NCT02129270|Fractures of the distal radius
159922|NCT02129270|Hematoma block
159923|NCT02129270|Lidocaine
159924|NCT02129244|MDR-TB
159925|NCT02129244|HIV
159926|NCT02129244|Nurse Case Management (NCM)
159927|NCT02129231|ezetimibe/simvastatin
159928|NCT02129231|rosuvastatin
159929|NCT02129231|diabetic polyneuropathy
159930|NCT02129231|oxidative stress
159931|NCT02129231|mitochondrial dysfunction
159932|NCT02129205|solid tumors
159933|NCT02129205|triple negative breast cancer
159934|NCT02129205|PF-06650808
159935|NCT02129205|Phase 1
159936|NCT02129153|Randomized controlled trial
159937|NCT02129153|Population, School Age
159938|NCT02129140|hernia repair
159939|NCT02129140|ventral incisional hernia
159940|NCT02129140|biologic mesh
159941|NCT02129140|hernia graft
159942|NCT02129088|Healthy
159943|NCT02129088|Esketamine
159944|NCT02129088|Phase 1
159945|NCT02129088|Placebo
159946|NCT02129088|Elderly
159947|NCT02129088|Adult
159948|NCT02129036|Ovarian cancer
159949|NCT02129036|Clear cell carcinoma
159950|NCT02129036|Paclitaxel-platinum
159951|NCT02129036|Chemotherapy
159952|NCT02129036|response to chemotherapy
159953|NCT02129036|survival of clear cell ovarian carcinoma
159954|NCT02129036|Prognostic factors
159955|NCT02129023|Exergame
159956|NCT02129023|user health
159957|NCT02129023|exercise
159958|NCT02129010|subarachnoid hemorrhage
159959|NCT02129010|terson syndrome
159960|NCT02129010|CSF-proteines
159961|NCT02129010|phospho-tau
159962|NCT02129010|beta-amyloid
159963|NCT02128997|obesity, cesarean section, wound complication
159964|NCT02128984|Malnutrition
159965|NCT02128984|Dietary supplement
159966|NCT02128984|Nutritional supplement
159967|NCT02128984|Symbiotic formula
159968|NCT02128984|DHA
159969|NCT02128984|Cystic Fibrosis
159970|NCT02128984|Failure to Thrive
159971|NCT02128971|Iron supplement study
159972|NCT02128958|Hepatocellular Carcinoma
159973|NCT02128958|Child-Pugh Class B Cirrhosis
159974|NCT02128945|PET
159975|NCT02128945|Chronic lymphocytic Leukemia (CLL)
159976|NCT02128945|Diffuse Large B Cells Lymphoma (DLBCL)
159977|NCT02128945|Fludarabine
159978|NCT02128919|Schizophrenia
159979|NCT02128919|Cigarette smoking
159980|NCT02128919|Cognition
159981|NCT02128919|Craving
159982|NCT02128919|MATRICS
159983|NCT02128906|ERCC1
159984|NCT02128906|squamous cell carcinoma
159985|NCT02128906|oropharynx
159986|NCT02128906|larynx
159987|NCT02128906|hypopharynx
159988|NCT02128906|p16
159989|NCT02128906|radiotherapy
159990|NCT02128906|docetaxel
159991|NCT02128906|cetuximab
159992|NCT02128906|cisplatin
159993|NCT02128906|EGFR
159994|NCT02128906|Biomarker
159995|NCT02128906|efficacy
159996|NCT02128906|head and neck
159997|NCT02128906|tongue
159998|NCT02128906|throat
159999|NCT02128893|Isavuconazole
160000|NCT02128893|Esomeprazole
160001|NCT02128893|BAL4815
160002|NCT02128893|BAL8728
160003|NCT02128893|Healthy Subjects
160004|NCT02128880|AEP, drinking, contraception, FASD, Internet interventions
160005|NCT02128867|gastro-esophageal reflux
160006|NCT02128867|GOR
160007|NCT02128867|GER
160008|NCT02128867|airway clearance techniques
160009|NCT02128854|Diabetes Mellitus, Type 2
160010|NCT02128854|Diabetes Mellitus, Adult-Onset
160011|NCT02128854|Diabetes Mellitus, Non-Insulin-Dependent
160012|NCT02128854|Diabetes Mellitus, Noninsulin Dependent
160013|NCT02128854|Diabetes Mellitus, Type II
160014|NCT02128854|African Americans
160015|NCT02128854|Blacks
160016|NCT02128854|Non-Hispanic Blacks
160017|NCT02128854|Randomized Control Trial
160018|NCT02128854|Controlled Clinical Trial
160019|NCT02128854|Behavioral Research
160020|NCT02128854|Behavioral Medicine
160021|NCT02128841|rivaroxaban
160022|NCT02128841|Heart Valve Prosthesis Implantation
160023|NCT02128841|anticoagulants
160024|NCT02128841|Factor Xa/antagonists & inhibitors
160025|NCT02128828|AIDS Dementia Complex
160026|NCT02128828|HIV-1-Associated Cognitive Motor Complex
160027|NCT02128828|Human Immunodeficiency Virus
160028|NCT02128815|adults
160029|NCT02128815|coaching
160030|NCT02128815|type 2 diabetes
160031|NCT02128802|Obesity
160032|NCT02128802|Renal failure
160033|NCT02128802|Gastric bypass
160034|NCT02128789|Older Adults
160035|NCT02128789|Caregivers
160036|NCT02128789|Aging
160037|NCT02128789|Support
160038|NCT02128776|Children
160039|NCT02128776|Chronic illnesses
160040|NCT02128724|Lung cancer
160041|NCT02128724|BKM120
160042|NCT02128724|Hypoxia
160043|NCT02128724|Misonidazole
160044|NCT02128724|Radiotherapy
160045|NCT02128711|lung
160046|NCT02128711|cystic fibrosis
160047|NCT02128711|bacteria
160048|NCT02128711|positive diagnosis of CF,
160049|NCT02128698|Bariatric surgery
160050|NCT02128698|Protein supplementation
160051|NCT02128698|Physical activity
160052|NCT02128698|Muscle mass
160053|NCT02128698|Weight loss
160054|NCT02128698|Physical fitness
160055|NCT02128698|Muscle strength
160056|NCT02128685|Threatened miscarriage
160057|NCT02128685|Dydrogesterone
160058|NCT02128685|Randomized controlled trial
160059|NCT02128646|Pain Management
160060|NCT02128646|Exparel
160061|NCT02128646|Abdominal Hernia Repair
160062|NCT02128646|Laparoscopic Surgery
160063|NCT02128633|Dentin hypersensitivity
160064|NCT02128633|Dentin Sensitivities
160065|NCT02128620|Sexually transmitted diseases
160066|NCT02128620|Internet
160067|NCT02128620|Education
160068|NCT02128620|Appointments and Schedules
160069|NCT02128607|low back pain
160070|NCT02128607|manual therapy
160071|NCT02128607|Mulligan
160072|NCT02128607|sustained natural apophyseal glide (SNAG)
160073|NCT02128607|Kinematic spine model
160074|NCT02128568|Depression/therapy;
160075|NCT02128568|Developing Countries;
160076|NCT02128568|Interpersonal Relations;
160077|NCT02128568|Life Change Events;
160078|NCT02128568|Psychotherapy, Group;
160079|NCT02128568|Resilience, Psychological;
160080|NCT02128568|Sierra Leone;
160081|NCT02128568|Survivors/psychology;
160082|NCT02128568|Social Adjustment;
160083|NCT02128568|Social Behavior;
160084|NCT02128568|War
160085|NCT02128555|ankle arthritis
160086|NCT02128555|osteoarthritis
160087|NCT02128555|total ankle replacement
160088|NCT02128555|arthrodesis
160089|NCT02128555|quality of life
160090|NCT02128555|musculoskeletal
160091|NCT02128542|Veterans HCV
160092|NCT02128529|COPD
160093|NCT02128490|Drug therapy
160094|NCT02128477|Myocardial infarction
160095|NCT02128477|Repolarization instability
160096|NCT02128477|Ventricular fibrillation
160097|NCT02128464|Knee Osteoarthritis
160098|NCT02128464|Total Knee Arthroplasty
160099|NCT02128464|Customized Cutting Block
160100|NCT02128464|Conventional Intramedullary Cutting Guide
160101|NCT02128451|meperdine ,fentanyl, clonidine, orthopedic surgery .
160102|NCT02128425|Colorectal cancer
160103|NCT02128425|Metastatic colorectal cancer
160104|NCT02128425|FOLFOXIRI
160105|NCT02128425|FOLFOX
160106|NCT02128425|Oxaliplatin
160107|NCT02128425|irinotecan
160108|NCT02128425|Leucovorin
160109|NCT02128425|5-FU
160110|NCT02128412|Patients scheduled to undergo coronary angioplasty and stenting because of symptoms related to a single de novo coronary artery stenoses
160111|NCT02128399|antimicrobial stewardship
160112|NCT02128360|Low ovarian reserve
160113|NCT02128360|Poor responder
160114|NCT02128360|Infertility
160115|NCT02128347|Hemodialysis, Home
160116|NCT02128347|Peritoneal Dialysis
160117|NCT02128347|Telemedicine
160118|NCT02128334|Uro-Oncologists
160119|NCT02128334|PSA
160120|NCT02128334|Eligard
160121|NCT02128334|prostate carcinoma
160122|NCT02128321|Isavuconazole
160123|NCT02128321|Repaglinide
160124|NCT02128321|Caffeine
160125|NCT02128321|BAL4815
160126|NCT02128321|BAL8728
160127|NCT02128321|Healthy Subjects
160128|NCT02128308|Antituberculosis agents
160129|NCT02128308|Pharmacokinetics
160130|NCT02128295|Breast pumps, breast milk, expression, term infants
160131|NCT02128282|Cholangiocarcinoma
160132|NCT02128282|Bile duct cancer
160133|NCT02128282|Biliary tract cancer
160134|NCT02128269|Antiphospholipid (aPL)-positive
160135|NCT02128269|Antiphospholid syndrome (APS)
160136|NCT02128256|Osteomyelitis
160137|NCT02128256|Bone substitute
160138|NCT02128256|Ceramic
160139|NCT02128256|Gentamicin
160140|NCT02128230|High risk
160141|NCT02128230|Carfilzomib
160142|NCT02128191|Patent ductus arteriosus
160143|NCT02128191|Ibuprofen
160144|NCT02128191|Bronchopulmonary dysplasia
160145|NCT02128178|Morbid obesity
160146|NCT02128178|Laparoscopic surgery
160147|NCT02128178|Compression ultrasonography
160148|NCT02128178|Pulmonary embolism
160149|NCT02128178|Bleeding
160150|NCT02128165|gastric balloon
160151|NCT02128165|morbid obesity
160152|NCT02128152|stroke
160153|NCT02128152|exoskeleton
160154|NCT02128152|Ekso
160155|NCT02128152|ambulation
160156|NCT02128152|robotics
160157|NCT02128139|Infective endocarditis
160158|NCT02128139|Developing country
160159|NCT02128139|Global health
160160|NCT02128139|Cardiac surgery
160161|NCT02128139|Heart valve disease
160162|NCT02128139|Bacteremia
160163|NCT02128126|Advanced or recurrent cervical cancer
160164|NCT02128126|HPV16 positive
160165|NCT02128126|No curative treatment options
160166|NCT02128113|RTA 408
160167|NCT02128113|Cataract surgery
160168|NCT02128113|Corneal Endothelial Cells
160169|NCT02128113|omaveloxolone
160170|NCT02128100|Pancreatic Cancer
160171|NCT02128087|HIV
160172|NCT02128087|Antiretroviral (ARV)
160173|NCT02128087|co-trimoxazole
160174|NCT02128087|SMS
160175|NCT02128087|mobile Health (mHealth)
160176|NCT02128087|Adolescents
160177|NCT02128087|Uganda
160178|NCT02128087|Adherence
160179|NCT02128035|radiation protection
160180|NCT02128035|interventional cardiologist
160181|NCT02128035|percutaneous coronary intervention (PCI)
160182|NCT02128035|angiography
160183|NCT02128035|lead shield
160184|NCT02128022|Glucagon-Like Peptide 1
160185|NCT02128022|Angina Pectoris
160186|NCT02128022|Percutaneous Coronary Intervention
160187|NCT02128022|Ischemic Preconditioning
160188|NCT02128022|Myocardial Reperfusion Injury
160189|NCT02127996|Angina Pectoris
160190|NCT02127996|Percutaneous Coronary Intervention
160191|NCT02127996|Myocardial Infarction
160192|NCT02127996|Glucagon-Like Peptide 1
160193|NCT02127996|Reperfusion Injury
160194|NCT02127983|TB, HIV, case finding, access, informal providers
160195|NCT02127957|cystic fibrosis
160196|NCT02127957|exercise
160197|NCT02127957|Cystic fibrosis related diabetes
160198|NCT02127918|Electrical status epilepticus in sleep
160199|NCT02127918|Continuous spikes and waves during sleep
160200|NCT02127918|Children
160201|NCT02127918|Electroencephalogram
160202|NCT02127918|Neuropsychology
160203|NCT02127918|Development
160204|NCT02127918|Antiepileptic drugs
160205|NCT02127918|Clobazam
160206|NCT02127918|Seizures
160207|NCT02127905|Fanconi Anemia
160208|NCT02127905|compassionate treatment
160209|NCT02127905|BMT
160210|NCT02127905|HSCT
160211|NCT02127905|unrelated
160212|NCT02127905|bone marrow transplantation
160213|NCT02127905|PBSC
160214|NCT02127905|peripheral blood
160215|NCT02127905|CD34+
160216|NCT02127892|Severe Combined Immune Deficiency
160217|NCT02127892|SCID
160218|NCT02127892|HLA-matched unrelated donor
160219|NCT02127892|unrelated
160220|NCT02127892|MUD
160221|NCT02127892|bone marrow
160222|NCT02127892|cord blood
160223|NCT02127892|haplo-identical
160224|NCT02127892|peripheral blood
160225|NCT02127892|CD34+ selection
160226|NCT02127892|T cell depletion
160227|NCT02127892|HSCT
160228|NCT02127892|BMT
160229|NCT02127892|CliniMACS
160230|NCT02127879|Repetitive Transcranial Magnetic Stimulation
160231|NCT02127879|Schizophrenia
160232|NCT02127879|Negative symptoms
160233|NCT02127879|Intensive
160234|NCT02127879|Transcranial Magnetic Stimulation, Repetitive
160235|NCT02127866|Asthma, anticholinergics
160236|NCT02127853|serial cataract surgery
160237|NCT02127853|hyperalgesia
160238|NCT02127853|gabapentin
160239|NCT02127853|central sensitization
160240|NCT02127840|primary aldosteronism
160241|NCT02127840|adrenal adenoma
160242|NCT02127840|arterial hypertension
160243|NCT02127814|induced diarrhea
160244|NCT02127814|Clostridium difficile toxicity
160245|NCT02127788|Haematology
160246|NCT02127788|Micafungin
160247|NCT02127788|Observational study
160248|NCT02127788|Prophylaxis
160249|NCT02127788|Invasive Fungal Infection
160250|NCT02127788|France
160251|NCT02127762|Pain
160252|NCT02127762|Quality of Life
160253|NCT02127762|Glycemic Control
160254|NCT02127762|diabetic neuropathy
160255|NCT02127762|mindfulness
160256|NCT02127762|stress reduction
160257|NCT02127762|adult
160258|NCT02127762|chronic pain
160259|NCT02127762|depression
160260|NCT02127762|cortisol
160261|NCT02127749|antibiotics
160262|NCT02127749|gut microbiota
160263|NCT02127749|endotoxemia
160264|NCT02127749|innate immunity
160265|NCT02127723|cellulite
160266|NCT02127710|AZD6094
160267|NCT02127710|Savolitinib
160268|NCT02127710|Papillary Renal Cell Cancer
160269|NCT02127697|Asthma, poorly controlled asthma, LAMA, Long-Acting Muscarinic Antagonist, Glycopyrronium, Glycopyrronium bromide, Anticholinergic
160270|NCT02127684|diabetic macular edema
160271|NCT02127645|RADIOTHERAPY
160272|NCT02127645|TRANSANAL ENDOSCOPIC MICROSURGERY
160273|NCT02127645|LOCAL EXCISION
160274|NCT02127632|laryngeal mask Supreme
160275|NCT02127632|laparoscopic gynecologic surgery
160276|NCT02127632|Laryngeal mask during surgery
160277|NCT02127619|knee prosthesis
160278|NCT02127619|total knee replacement
160279|NCT02127619|total knee arthroplasty
160280|NCT02127619|prospective study
160281|NCT02127619|Therapeutic level IV
160282|NCT02127593|Norgestimate
160283|NCT02127593|Ethinyl estradiol
160284|NCT02127593|Norgestrel
160285|NCT02127593|Norelgestromin
160286|NCT02127593|Ortho cyclen
160287|NCT02127593|Phase 1
160288|NCT02127593|Healthy Women
160289|NCT02127580|THV
160290|NCT02127580|BAV
160291|NCT02127580|pre-dilation
160292|NCT02127580|Aortic valve stenosis
160293|NCT02127567|medical writing, reporting, randomized controlled trial
160294|NCT02127541|Localisation of Insulinoma
160295|NCT02127541|beta-cell imaging
160296|NCT02127541|exendin-4
160297|NCT02127541|68Ga-DOTA-exendin-4 PET/CT
160298|NCT02127541|111In-DOTA-exendin-4 SPECT/CT
160299|NCT02127515|Down, trisomy 21
160300|NCT02127515|NIPT
160301|NCT02127515|Amniocentesis
160302|NCT02127515|miscarriage
160303|NCT02127515|invasive
160304|NCT02127515|prenatal
160305|NCT02127515|screening.
160306|NCT02127489|Bupivacaine, caudal, rectal midazolam, children
160307|NCT02127463|AMD
160308|NCT02127463|Dry AMD
160309|NCT02127463|Non-Exudative AMD
160310|NCT02127463|MC-1101
160311|NCT02127450|Enterobacteriaceae
160312|NCT02127450|non-susceptible to carbapenem
160313|NCT02127450|carbapenemases
160314|NCT02127450|prevalence
160315|NCT02127450|screening algorithm
160316|NCT02127437|Autosomal dominant polycystic kidney disease,
160317|NCT02127437|Glomerular filtration rate,
160318|NCT02127437|Somatostatin,
160319|NCT02127437|lanreotide
160320|NCT02127424|Nurse
160321|NCT02127424|Nursing
160322|NCT02127424|Screening
160323|NCT02127424|HIV
160324|NCT02127424|Emergency Service Hospital
160325|NCT02127411|Mindfulness
160326|NCT02127411|Benzodiazepines
160327|NCT02127411|Sleep
160328|NCT02127411|Dependence
160329|NCT02127411|Relapse Prevention
160330|NCT02127398|C. difficile colitis
160331|NCT02127398|fecal microbiota transplantation
160332|NCT02127372|non-small cell
160333|NCT02127372|lung cancer
160334|NCT02127359|Metastatic
160335|NCT02127346|Chronic Periodontitis
160336|NCT02127346|Vitamin D concentration
160337|NCT02127346|Calcium concentration
160338|NCT02127333|chronic obstructive pulmonary disease
160339|NCT02127333|Coronary artery disease
160340|NCT02127333|Endothelial function
160341|NCT02127307|Myocardial sympathetic innervation
160342|NCT02127307|Heart failure (HF)
160343|NCT02127307|Nuclear imaging
160344|NCT02127307|Radiopharmaceutical
160345|NCT02127294|Foramen Ovale, Patent
160346|NCT02127294|migraine
160347|NCT02127294|transcatheter patent foramen ovale closure
160348|NCT02127294|contrast-enhanced transcranial Doppler
160349|NCT02127294|Transthoracic Echocardiography
160350|NCT02127281|Revision total knee arthroplasty
160351|NCT02127281|Revision total hip arthroplasty
160352|NCT02127281|Negative pressure wound therapy system (NPWT)
160353|NCT02127281|Drainage
160354|NCT02127255|chemotherapy
160355|NCT02127255|nausea
160356|NCT02127255|vomiting
160357|NCT02127255|cancer
160358|NCT02127242|hepatolithiasis
160359|NCT02127242|ureteroscope
160360|NCT02127242|air-pressure ballistic lithotripsy
160361|NCT02127242|hepatectomy
160362|NCT02127229|endoscopic retrograde cholangiopancreatography
160363|NCT02127229|disposable accessory cost
160364|NCT02127229|endoscopy cost analysis
160365|NCT02127216|Mobile Health
160366|NCT02127216|Diabetes
160367|NCT02127216|Self-Care of Diabetes
160368|NCT02127203|oxidative stress
160369|NCT02127203|periodontal disease
160370|NCT02127203|nitric oxide
160371|NCT02127190|nitro-fatty acids
160372|NCT02127190|anti-inflammatory
160373|NCT02127190|Nrf2 activation
160374|NCT02127190|contrast induced AKI
160375|NCT02127177|obstructive sleep apnea
160376|NCT02127177|coronary heart disease
160377|NCT02127177|continuous positive airway pressure
160378|NCT02127177|lipid profiles
160379|NCT02127177|high-sensitivity C-reactive protein
160380|NCT02127138|unprotected distal left main bifurcation lesion
160381|NCT02127138|Percutaneous coronary intervention
160382|NCT02127138|clinical study
160383|NCT02127138|Active Transfer of Plaque （ATP）
160384|NCT02127138|Provisional T Stenting
160385|NCT02127112|Ridge Augmentation
160386|NCT02127112|Bone regeneration
160387|NCT02127112|Guided Bone Regeneration
160388|NCT02127112|Partially Edentulous
160389|NCT02127099|OSA
160390|NCT02127099|obstructive
160391|NCT02127099|sleep
160392|NCT02127099|apnea
160393|NCT02127099|operation
160394|NCT02127086|Acute pain severity
160395|NCT02127086|Non-communicative patients
160396|NCT02127086|PAIN algorithm
160397|NCT02127086|Multi-dimensional Pain Assessment Tool (MOPAT)
160398|NCT02127073|Breast cancer
160399|NCT02127073|Ductal carcinoma in situ (DCIS)
160400|NCT02127073|Oxytocin
160401|NCT02127060|vitamin C
160402|NCT02127060|effectiveness
160403|NCT02127060|pain management
160404|NCT02127060|posterior lumbar interbody fusion
160405|NCT02127034|Healthy subjects
160406|NCT02127034|Mirabegron
160407|NCT02127034|Solifenacin
160408|NCT02127034|Digoxin
160409|NCT02127021|Pancreaticoduodenectomy
160410|NCT02127021|Nutritional Status
160411|NCT02127021|Quality of Life
160412|NCT02127021|Biochemical Marker
160413|NCT02127008|epidural fat
160414|NCT02127008|resection
160415|NCT02127008|spinal stenosis
160416|NCT02127008|lumbar spine
160417|NCT02126995|Fragile X Syndrome, Fra(X) Syndrome, FRAXA Syndrome
160418|NCT02126982|clopidogrel besylate
160419|NCT02126982|clopidogrel hydrogen sulfate
160420|NCT02126982|Generic clopidogrel
160421|NCT02126982|Coronary Artery Disease
160422|NCT02126969|Cancer
160423|NCT02126969|Low dose radiation
160424|NCT02126956|ACT-128800
160425|NCT02126943|PAH
160426|NCT02126943|pulmonary arterial hypertension
160427|NCT02126930|anti-infectious treatment
160428|NCT02126930|observance
160429|NCT02126930|pharmaceutical consultation
160430|NCT02126917|Phase 1
160431|NCT02126917|Alcohol
160432|NCT02126917|Hydrocodone Bitartrate
160433|NCT02126917|Pharmacokinetics
160434|NCT02126891|Cardiac functions
160435|NCT02126891|Endurance training
160436|NCT02126891|Senior athletes
160437|NCT02126852|residual paralysis,neuromuscular blockade,acceleromyography,electromyography
160438|NCT02126813|Postoperative urinary retention
160439|NCT02126813|Fast-track total hip (THA) and knee arthroplasty (TKA)
160440|NCT02126813|Urinary bladder volume
160441|NCT02126800|breast cancer
160442|NCT02126787|Anxiety disorders
160443|NCT02126787|Depressive disorders
160444|NCT02126787|Personality disorders
160445|NCT02126787|Psychodynamic psychotherapy
160446|NCT02126787|Cognitive-behavioral psychotherapy
160447|NCT02126787|Group psychotherapy
160448|NCT02126787|Day treatment
160449|NCT02126774|epilepsy
160450|NCT02126774|focal epilepsy
160451|NCT02126761|Influenza
160452|NCT02126761|elderly
160453|NCT02126761|adjuvant
160454|NCT02126748|bronchiolitis
160455|NCT02126748|Wang score
160456|NCT02126748|Sa02
160457|NCT02126748|airway clearance techniques
160458|NCT02126748|intrapulmonary percussive ventilation
160459|NCT02126748|assisted autogenic drainage
160460|NCT02126722|Helicobacter pylori
160461|NCT02126722|Gastritis
160462|NCT02126709|Povidone Iodine
160463|NCT02126709|Safety
160464|NCT02126709|Efficacy
160465|NCT02126709|Acne treatment
160466|NCT02126696|Anti-retroviral Therapy
160467|NCT02126696|Lesotho
160468|NCT02126696|Southern Africa
160469|NCT02126696|Comorbidity
160470|NCT02126696|Virologic failure
160471|NCT02126683|Hashimoto's thyroiditis
160472|NCT02126683|Plaquenil
160473|NCT02126657|Acne scars
160474|NCT02126657|70% Glycolic acid peel
160475|NCT02126644|Photoaging
160476|NCT02126644|70% glycolic acid peel
160477|NCT02126618|Lower urinary tract symptoms
160478|NCT02126618|urodynamic studies
160479|NCT02126618|diuresis
160480|NCT02126605|diabetes alert dogs
160481|NCT02126605|hypoglycemia
160482|NCT02126579|melanoma
160483|NCT02126579|neoplasms
160484|NCT02126579|Poly ICLC
160485|NCT02126579|Freund's Adjuvant
160486|NCT02126579|Metastatic melanoma
160487|NCT02126579|resiquimod
160488|NCT02126579|adjuvants
160489|NCT02126579|peptide vaccine
160490|NCT02126566|striae distensiae
160491|NCT02126553|Leukemia
160492|NCT02126553|Acute myeloid leukemia
160493|NCT02126553|AML
160494|NCT02126553|Remission
160495|NCT02126553|Lenalidomide
160496|NCT02126553|CC-5013
160497|NCT02126553|Revlimid
160498|NCT02126540|Peripheral Arterial Disease
160499|NCT02126540|Atherectomy
160500|NCT02126540|Optical Coherence Tomography
160501|NCT02126514|Beta secretase inhibitor
160502|NCT02126514|Alzheimer disease
160503|NCT02126501|weaning
160504|NCT02126501|NCPAP
160505|NCT02126501|Preterm
160506|NCT02126501|sudden wean
160507|NCT02126501|gradual pressure off wean
160508|NCT02126488|treadmill training
160509|NCT02126488|generalization
160510|NCT02126488|retention
160511|NCT02126475|"parkinson patients ON"
160512|NCT02126475|"parkinson patients OFF"
160513|NCT02126475|time estimation
160514|NCT02126475|anticipation
160515|NCT02126462|Human Hookworm
160516|NCT02126462|Necator americanus
160517|NCT02126462|Hookworm
160518|NCT02126462|Hookworm Disease
160519|NCT02126462|Iron-deficiency anemia
160520|NCT02126462|Soil-transmitted helminth infection
160521|NCT02126462|Neglected Tropical Disease
160522|NCT02126462|Na-APR-1
160523|NCT02126462|Na-GST-1
160524|NCT02126436|phantom limb pain
160525|NCT02126436|phantom limb sensation
160526|NCT02126436|acupuncture
160527|NCT02126436|randomised controlled trial
160528|NCT02126423|Drug Resistance, Microbial
160529|NCT02126410|sarcopenia
160530|NCT02126410|sleep duration
160531|NCT02126410|body composition
160532|NCT02126410|skeletal muscle
160533|NCT02126397|endometrial polyp
160534|NCT02126397|resection of endometrial polyps
160535|NCT02126397|hysteroscopy
160536|NCT02126397|bipolar electrode Versapoint
160537|NCT02126397|Laser Diode
160538|NCT02126384|Immunology
160539|NCT02126384|human
160540|NCT02126384|B-lymphocytes subsets
160541|NCT02126384|Antibody-Producing Cells
160542|NCT02126384|23 valent pneumococcal capsular polysaccharide vaccine
160543|NCT02126332|Severe acute pancreatitis
160544|NCT02126332|Epidural analgesia
160545|NCT02126332|Acute respiratory failure
160546|NCT02126332|Mechanical ventilation
160547|NCT02126332|Intensive Care Unit (ICU)
160548|NCT02126319|Cognitive-affective preparation
160549|NCT02126319|prostate cancer counseling
160550|NCT02126280|proinflammatory cytokines
160551|NCT02126280|anti-inflammatory cytokines
160552|NCT02126280|human monocytes
160553|NCT02126280|activation
160554|NCT02126280|biomarkers
160555|NCT02126280|asymptomatic atherosclerosis
160556|NCT02126267|periodontal disease
160557|NCT02126267|therapy
160558|NCT02126267|anti-bacterial agents
160559|NCT02126267|Randomized Controlled Trials
160560|NCT02126241|Heart Failure
160561|NCT02126241|Cardiac Resyncronization Therapy
160562|NCT02126241|Optimization
160563|NCT02126241|Non-invasive cardiac system
160564|NCT02126241|Impedance measured cardiac output
160565|NCT02126228|antibiotics, cesarean
160566|NCT02126215|magnetic resonance imaging
160567|NCT02126215|carbon dioxide
160568|NCT02126215|abdominal aortic aneurysm
160569|NCT02126215|post-op delirium
160570|NCT02126202|Elderly
160571|NCT02126202|Octogenarians
160572|NCT02126202|PCI
160573|NCT02126202|Myocardial infarction
160574|NCT02126202|NSTEMI
160575|NCT02126202|Unstable angina pectoris
160576|NCT02126189|Head and Neck Squamous Cell Carcinoma
160577|NCT02126189|Human Papillomavirus
160578|NCT02126189|Aetiology
160579|NCT02126189|prevalence
160580|NCT02126189|risk factors
160581|NCT02126189|clinical outcome
160582|NCT02126163|Excessive Drinking
160583|NCT02126163|Hazardous Drinking
160584|NCT02126137|HCV
160585|NCT02126137|Ezetimibe
160586|NCT02126137|Cholesterol
160587|NCT02126137|Host
160588|NCT02126124|Brainsway, dTMS, Deep Transcranial Magnetic Stimulation, Smoking Cessation
160589|NCT02126098|ANCA-associated vasculitis
160590|NCT02126098|Granulomatosis with polyangiitis
160591|NCT02126098|Microscopic polyangiitis
160592|NCT02126098|Wegner's granulomatosis
160593|NCT02126098|Eosinphilic granulomatosis with polyangiitis
160594|NCT02126085|ischemic stroke
160595|NCT02126085|recanalisation
160596|NCT02126085|sedation
160597|NCT02126072|Ethanol
160598|NCT02126072|Alcohol
160599|NCT02126072|Consumption
160600|NCT02126072|Gut wall integrity
160601|NCT02126072|Endotoxemia
160602|NCT02126059|dementia
160603|NCT02126059|behavioral and psychological symptoms
160604|NCT02126059|quality of life
160605|NCT02126046|Cord Blood Transplant
160606|NCT02126046|Haploidentical HSCT
160607|NCT02126046|Thalassemia major
160608|NCT02126033|celiac
160609|NCT02126033|telomere
160610|NCT02126033|telomerase
160611|NCT02126020|Keratoprosthesis
160612|NCT02126020|corneal melt
160613|NCT02126020|keratolysis
160614|NCT02126020|Tumor necrosis factor alpha
160615|NCT02126020|infliximab
160616|NCT02126020|matrix metalloproteinase
160617|NCT02126007|fatigue
160618|NCT02126007|HIV
160619|NCT02126007|behavioral intervention
160620|NCT02126007|sleep
160621|NCT02125981|limaprost alfadex
160622|NCT02125981|cervical myelopathy
160623|NCT02125981|surgery
160624|NCT02125968|chronic low back pain
160625|NCT02125968|video game
160626|NCT02125968|therapeutic effects
160627|NCT02125955|Pediatric
160628|NCT02125955|Overweight
160629|NCT02125955|Obesity
160630|NCT02125955|Gut microbiota
160631|NCT02125955|Adiposity
160632|NCT02125955|Prebiotic
160633|NCT02125955|Dietary fiber
160634|NCT02125942|Borderline Personality Disorder
160635|NCT02125877|Iron overload
160636|NCT02125877|Chelation
160637|NCT02125877|Thalassemia
160638|NCT02125877|Myelodysplastic syndrome (MDS)
160639|NCT02125877|Transfusional hemisiderosis
160640|NCT02125877|Deferasirox
160641|NCT02125877|ICL670
160642|NCT02125877|Dispersible tablet
160643|NCT02125877|Film-coated tablet
160644|NCT02125864|AMD
160645|NCT02125864|VEGF
160646|NCT02125864|Aflibercept
160647|NCT02125851|slurry
160648|NCT02125851|splenda
160649|NCT02125851|sucralose
160650|NCT02125851|budesonide
160651|NCT02125851|mucosal contact time
160652|NCT02125838|laryngeal mask Supreme
160653|NCT02125838|laparoscopic gynecologic surgery
160654|NCT02125838|Laryngeal mask during surgery
160655|NCT02125812|Aggressive Periodontitis
160656|NCT02125812|antimicrobial(s)
160657|NCT02125812|microbiology
160658|NCT02125773|PrEP
160659|NCT02125773|Risk score
160660|NCT02125773|Self-perception
160661|NCT02125760|Respiratory muscle training
160662|NCT02125760|stroke
160663|NCT02125760|rehabilitation
160664|NCT02125747|Respiratory muscle training; high-intensity training
160665|NCT02125721|cystinuria
160666|NCT02125721|D-penicillamine (Cuprimine®)
160667|NCT02125721|tiopronin (Thiola®)
160668|NCT02125708|preterm prelabor rupture of membranes
160669|NCT02125708|Ovula Ring
160670|NCT02125708|body-core-temperature
160671|NCT02125708|biomarkers
160672|NCT02125708|Single pregnancies
160673|NCT02125708|PPROM
160674|NCT02125708|gestation week 22 and 27
160675|NCT02125682|HDL
160676|NCT02125682|Hyperlipidemia
160677|NCT02125682|Diabetes
160678|NCT02125682|Inflammation
160679|NCT02125669|basal cell carcinoma
160680|NCT02125669|laser surgery
160681|NCT02125669|pulsed dye laser
160682|NCT02125669|randomized controlled trial
160683|NCT02125643|Exercise-induced muscle damage
160684|NCT02125643|Caffeine
160685|NCT02125643|Maximal voluntary strength
160686|NCT02125630|Metastatic breast carcer
160687|NCT02125630|Bone metastasis
160688|NCT02125630|surgery
160689|NCT02125617|Castration-resistant prostate cancer
160690|NCT02125617|Abiraterone
160691|NCT02125617|Biomarker
160692|NCT02125617|Urokinase Plasminogen Activator Receptor
160693|NCT02125617|Plasma
160694|NCT02125617|Predictive markers
160695|NCT02125604|Gastrointestinal event
160696|NCT02125591|Mild Traumatic Brain Injury
160697|NCT02125565|Arterial
160698|NCT02125565|Blood
160699|NCT02125565|Gas
160700|NCT02125565|Needle
160701|NCT02125565|Pain
160702|NCT02125565|Local
160703|NCT02125565|Anaesthesia
160704|NCT02125565|Anaesthetic
160705|NCT02125552|vascular access device
160706|NCT02125552|ultrasonography
160707|NCT02125539|Online adolescent substance abuse relapse prevention program
160708|NCT02125526|Acute myocardial infarction
160709|NCT02125526|Persisting ischemia
160710|NCT02125526|No reflow
160711|NCT02125526|Intra-aortic balloon pump
160712|NCT02125526|Exhausted autoregulation
160713|NCT02125513|neoadjuvant chemotherapy
160714|NCT02125513|ovarian cancer
160715|NCT02125513|fallopian tube carcinoma
160716|NCT02125513|peritoneal carcinoma
160717|NCT02125513|randomized study
160718|NCT02125500|HCV/HIV coinfection
160719|NCT02125500|HCV genotype 1
160720|NCT02125487|Clinical Breast Examination
160721|NCT02125487|Breast Cancer detection
160722|NCT02125487|Breast Simulator
160723|NCT02125487|Hybrid Simulation
160724|NCT02125487|Patient Simulation
160725|NCT02125487|Standardized Patient
160726|NCT02125487|Medical student education
160727|NCT02125487|Health Communication
160728|NCT02125487|Communication Barriers
160729|NCT02125487|Cultural competency
160730|NCT02125487|Cultural
160731|NCT02125487|Middle East
160732|NCT02125487|Lebanon
160733|NCT02125474|Neuroendocrine Tumors
160734|NCT02125474|Lutetium
160735|NCT02125474|Treatment Outcome
160736|NCT02125461|Locally advanced
160737|NCT02125461|Unresectable Non-Small Cell Lung Cancer
160738|NCT02125461|MEDI4736
160739|NCT02125461|PD-L1
160740|NCT02125461|Stage III Non-Small Cell Lung Cancer
160741|NCT02125461|Chemoradiation
160742|NCT02125461|Immune-mediated cancer therapy
160743|NCT02125448|Esophageal cancer
160744|NCT02125448|MRI
160745|NCT02125448|PET-CT
160746|NCT02125448|Response assessment
160747|NCT02125435|Healthy subjects
160748|NCT02125435|ASP2408
160749|NCT02125435|pharmacokinetics
160750|NCT02125396|hepatocellular carcinoma
160751|NCT02125396|liver cancer
160752|NCT02125396|transarterial chemoembolization
160753|NCT02125396|radiotherapy
160754|NCT02125396|adjuvant therapy
160755|NCT02125383|Parkinson's disease
160756|NCT02125383|Transcranial direct current stimulation
160757|NCT02125357|sequencing
160758|NCT02125357|abiraterone
160759|NCT02125357|enzalutamide
160760|NCT02125357|metastatic castration-resistant prostate cancer
160761|NCT02125357|randomized
160762|NCT02125331|Blood Pressure
160763|NCT02125318|myeloproliferative neoplasm
160764|NCT02125318|chronic myelogenous leukemia
160765|NCT02125318|polycythemia vera
160766|NCT02125318|primary myelofibrosis
160767|NCT02125318|essential thrombocythemia
160768|NCT02125318|anagrelide
160769|NCT02125318|thrombocytosis
160770|NCT02125318|GALE-401
160771|NCT02125305|Metformin
160772|NCT02125305|Pharmacokinetics/ Pharmacodynamics
160773|NCT02125214|consciousness, anesthesia, electroencephalogram, microstate, long-range dependency
160774|NCT02125201|intranasal fentanyl
160775|NCT02125201|newborn
160776|NCT02125162|BCX4161
160777|NCT02125162|BioCryst
160778|NCT02125162|hereditary angioedema
160779|NCT02125162|relative bioavailability
160780|NCT02125162|kallikrein inhibitor
160781|NCT02125149|pregnancy
160782|NCT02125149|obese
160783|NCT02125136|unresectable
160784|NCT02125136|borderline resectable
160785|NCT02125110|neurotoxicants
160786|NCT02125110|MRI
160787|NCT02125110|developing brain
160788|NCT02125097|Intracranial Aneurysm Treatment
160789|NCT02125097|Endovascular Therapy
160790|NCT02125084|Metastatic Prostate Cancer
160791|NCT02125084|Castrate-resistant
160792|NCT02125084|Enzalutamide
160793|NCT02125084|Everolimus
160794|NCT02125058|intracutaneous sutures
160795|NCT02125058|transcutaneous sutures
160796|NCT02125058|dermatological surgery
160797|NCT02125058|facial area
160798|NCT02125045|GSH
160799|NCT02125045|cardiovascular risk factors
160800|NCT02125045|endothelial dysfunction
160801|NCT02125045|oxidative stress
160802|NCT02125019|Breast Cancer
160803|NCT02125019|Taxane
160804|NCT02125019|Gait
160805|NCT02125019|Men
160806|NCT02125019|Women
160807|NCT02125006|Mindfulness
160808|NCT02125006|Breast Cancer
160809|NCT02125006|Painful Neuropathy
160810|NCT02125006|Chronic Pain
160811|NCT02125006|fMRI
160812|NCT02125006|Disability
160813|NCT02125006|Quality of Life
160814|NCT02125006|Cytokines
160815|NCT02125006|Cortisol
160816|NCT02124993|Gastrectomy
160817|NCT02124980|Opioid Substitution Treatment
160818|NCT02124980|Cognitive Behavioral Therapy
160819|NCT02124980|Mobile Health
160820|NCT02124928|stroke
160821|NCT02124928|biomarkers
160822|NCT02124928|vulnerable plaque
160823|NCT02124928|carotid endarterectomy
160824|NCT02124928|carotid artery disease
160825|NCT02124915|prosthetic socket
160826|NCT02124915|amputee
160827|NCT02124889|bariatric surgery
160828|NCT02124889|multivitamin
160829|NCT02124889|weight loss
160830|NCT02124889|adherence
160831|NCT02124876|amputee
160832|NCT02124876|prosthetics
160833|NCT02124837|lunch breaks, recovery, nature, park walking, relaxation
160834|NCT02124811|Schizophrenia
160835|NCT02124811|Clozapine
160836|NCT02124811|Minocycline
160837|NCT02124798|Subcutaneous
160838|NCT02124798|Autoinjector
160839|NCT02124798|Belimumab
160840|NCT02124798|Real-Life Use Study
160841|NCT02124798|Reliability
160842|NCT02124785|Long-term persistence
160843|NCT02124785|Havrix
160844|NCT02124785|Hepatitis A
160845|NCT02124772|v600-mutation
160846|NCT02124772|neuroblastoma
160847|NCT02124772|Trametinib
160848|NCT02124772|pediatrics
160849|NCT02124772|low grade glioma plexiform neurofibromas
160850|NCT02124746|Primary Myelofibrosis
160851|NCT02124746|Post Polycythemia Vera Myelofibrosis
160852|NCT02124746|Post Essential Thrombocythemia Myelofibrosis
160853|NCT02124746|Polycythemia Vera
160854|NCT02124746|Essential Thrombocythemia
160855|NCT02124746|blood disorders
160856|NCT02124733|Actinic Keratosis
160857|NCT02124733|Actinic Keratoses
160858|NCT02124733|AK
160859|NCT02124733|PDT
160860|NCT02124733|Photodynamic Therapy
160861|NCT02124733|Blue Light Therapy
160862|NCT02124733|ALA
160863|NCT02124733|aminolevulinic acid
160864|NCT02124733|Levulan
160865|NCT02124720|Autism spectrum disorders
160866|NCT02124720|Stereotypy
160867|NCT02124720|Repetitive behavior
160868|NCT02124707|Head and neck cancer
160869|NCT02124707|Squamous cell carcinoma
160870|NCT02124707|Metastatic
160871|NCT02124707|Recurrent
160872|NCT02124707|Phase II
160873|NCT02124707|Carboplatin
160874|NCT02124707|Paclitaxel
160875|NCT02124707|Cetuximab
160876|NCT02124694|historical trauma and unresolved grief
160877|NCT02124694|complicated grief
160878|NCT02124694|prolonged grief
160879|NCT02124694|interpersonal conflicts
160880|NCT02124694|depression
160881|NCT02124694|American Indians
160882|NCT02124694|interpersonal psychotherapy
160883|NCT02124694|traumatic grief
160884|NCT02124694|posttraumatic stress disorder
160885|NCT02124668|Xtandi
160886|NCT02124668|MDV3100
160887|NCT02124668|Progressive Castration-Resistant Prostate Cancer
160888|NCT02124668|Enzalutamide
160889|NCT02124655|Biofilms
160890|NCT02124655|Chlorhexidine
160891|NCT02124655|Microscopy, confocal
160892|NCT02124655|Dental plaque
160893|NCT02124655|Mouthwashes
160894|NCT02124642|Folate requirements
160895|NCT02124642|Pregnancy
160896|NCT02124642|Folic acid
160897|NCT02124642|DNA methylation
160898|NCT02124642|Folate biomarkers
160899|NCT02124616|spinal muscular atrophy
160900|NCT02124616|Muscular dystrophy
160901|NCT02124616|Muscle diseases
160902|NCT02124616|myasthenic syndromes
160903|NCT02124616|Polyneuropathies
160904|NCT02124616|Myopathies
160905|NCT02124603|cataract
160906|NCT02124603|prophylaxis
160907|NCT02124603|susceptibility
160908|NCT02124590|Carnitine
160909|NCT02124590|Acylcarnitine
160910|NCT02124590|Exercise
160911|NCT02124590|Exercise Intensity
160912|NCT02124590|Insulin Sensitivity
160913|NCT02124564|Lacosamide
160914|NCT02124564|Epilepsy
160915|NCT02124564|Focal, Partial-Onset Seizures with or without secondary generalization
160916|NCT02124564|Monotherapy
160917|NCT02124551|Goal-directed fluid therapy
160918|NCT02123485|Depression,
160919|NCT02123485|ECT,
160920|NCT02123485|rTMS,
160921|NCT02123485|Right prefrontal,
160922|NCT02123485|antidepressive efficacy
160923|NCT02123485|Inflammation markers
160924|NCT02123433|HIV
160925|NCT02123433|Streptococcus pneumoniae
160926|NCT02123433|13-valent conjugate pneumococcal vaccine
160927|NCT02123433|Vaccine
160928|NCT02123433|Immunological Response
160929|NCT02123433|Pneumococcal Carriage
160930|NCT02123420|Platform Switching vs Regular Platform
160931|NCT02123407|Advanced Gastric Cancer
160932|NCT02123407|Carbon Nanoparticles
160933|NCT02123407|Lymph Nodes
160934|NCT02123394|Low Back Pain
160935|NCT02123394|Mechanical Low Back Pain
160936|NCT02123394|Low Back Ache
160937|NCT02123394|Low Backache
160938|NCT02123394|Lower Back Pain
160939|NCT02123394|Lumbago
160940|NCT02123381|tumor tissue and serum biomarkers
160941|NCT02123381|cetuximab
160942|NCT02123381|preoperative radiotherapy
160943|NCT02123381|esophageal squamous cell carcinoma
160944|NCT02123368|Osteoarthritis
160945|NCT02123368|Mesenchimal stem cell
160946|NCT02123368|Knee
160947|NCT02124512|obese
160948|NCT02124512|insulin resistance
160949|NCT02124512|metabolic syndrome
160950|NCT02124499|anesthesia recovery period
160951|NCT02124499|postoperative complications
160952|NCT02124499|pain
160953|NCT02124499|pain measurement
160954|NCT02124499|postoperative nausea and vomiting
160955|NCT02124499|quality of life
160956|NCT02124499|genetic association study
160957|NCT02124486|IIH
160958|NCT02124486|Weight loss
160959|NCT02124486|Bariatric surgery
160960|NCT02124473|Resistant hypertension
160961|NCT02124473|Homeopathy
160962|NCT02124473|Blood pressure
160963|NCT02124473|Ambulatory blood pressure monitoring
160964|NCT02124460|Pediatric
160965|NCT02124460|Obesity
160966|NCT02124460|Overweight
160967|NCT02124460|Intervention
160968|NCT02124434|Laparoscopic Sleeve Gastrectomy surgery
160969|NCT02124421|Ovarian cancer
160970|NCT02124421|Cytoreductive surgery
160971|NCT02124421|Hyperthermic Intraperitoneal chemotherapy
160972|NCT02124421|Systemic chemotherapy
160973|NCT02124421|Primary peritoneal carcinoma
160974|NCT02124421|Fallopian Tube cancer
160975|NCT02124421|Intraperitoneal chemotherapy
160976|NCT02124421|IV/IP chemotherapy
160977|NCT02124421|IV chemotherapy
160978|NCT02124382|liver failure
160979|NCT02124382|liver malignancy
160980|NCT02124382|metabolic diseases
160981|NCT02124382|Pediatric liver transplanted recipients and their healthy donors
160982|NCT02124369|Pancreatic cancer
160983|NCT02124369|locally advanced
160984|NCT02124369|unresectable
160985|NCT02124343|Neutrophil
160986|NCT02124343|Exercise
160987|NCT02124343|COPD
160988|NCT02124343|Pulmonary Rehabilitation
160989|NCT02124330|Montmorillonite, proteic diet, in vitro and in vivo models
160990|NCT02124317|nanoparticle albumin-bound paclitaxel
160991|NCT02124317|S-1
160992|NCT02124317|advanced pancreatic cancer
160993|NCT02124317|objective response rate
160994|NCT02124304|Sternocleidomastoid
160995|NCT02124304|Neck pain
160996|NCT02124304|EMG
160997|NCT02124304|Perceived Exertion
160998|NCT02124304|Thera-Band
160999|NCT02124304|Cervical Paraspinals
161000|NCT02124291|In Vitro Fertilization
161001|NCT02124291|Vitrification
161002|NCT02124291|Frozen Embryo
161003|NCT02124291|Assisted Hatching
161004|NCT02124291|Pregnancy Rate
161005|NCT02124278|Single ascending dose
161006|NCT02124278|Safety and tolerability in healthy subjects
161007|NCT02124265|Oral Rehydration Therapy
161008|NCT02124252|cervical cancer screening
161009|NCT02124252|human papillomavirus testing
161010|NCT02124252|Kenya
161011|NCT02124252|implementation science
161012|NCT02124226|Chronic severe asthma, immunomodulation, methotrexate, steroids, omalizumab
161013|NCT02124213|Receptor Occupancy
161014|NCT02124213|PET
161015|NCT02124213|D1 Receptor Agonist
161016|NCT02124174|acute myelogenous leukemia (AML)
161017|NCT02124174|myelodysplastic syndrome (MDS)
161018|NCT02124161|Pneumococcal polysaccharide vaccine
161019|NCT02124161|13-valent pneumococcal conjugate vaccine
161020|NCT02124161|invasive pneumococcal disease
161021|NCT02124161|flu vaccine
161022|NCT02124148|cancer
161023|NCT02124135|Nutrition
161024|NCT02124122|Focus
161025|NCT02124122|safety
161026|NCT02124109|Rheumatic Fever
161027|NCT02124109|Acquired Heart Disease
161028|NCT02124109|Rheumatic Heart Disease
161029|NCT02124109|Endomyocardial Fibrosis
161030|NCT02124096|Zoonotic
161031|NCT02124096|Influenza
161032|NCT02124096|Infections
161033|NCT02124096|Ohio
161034|NCT02124096|Fairs
161035|NCT02124083|Niemann Pick Disease, Type C1
161036|NCT02124083|Phase I, Phase 2
161037|NCT02124083|Vorinostat
161038|NCT02124070|Cystinosis
161039|NCT02124070|Myopathy
161040|NCT02124070|Recombiant Growth Hormone
161041|NCT02124057|Liver
161042|NCT02124057|Motor Neuron Disease
161043|NCT02124044|Coinfection
161044|NCT02124044|HCV Genotype 1b
161045|NCT02124044|Interferon Free therapy
161046|NCT02124044|Liver Biopsy
161047|NCT02124044|Virological Response
161048|NCT02124031|Osteoarthritis
161049|NCT02124031|Rheumatoid Arthritis
161050|NCT02124031|Disability
161051|NCT02124031|Joint function
161052|NCT02124018|Myocardial infarction
161053|NCT02124018|Risk stratification
161054|NCT02124018|Sudden cardiac death
161055|NCT02124018|Preserved ejection fraction
161056|NCT02124018|Programmed ventricular stimulation
161057|NCT02124005|Knee surgery
161058|NCT02124005|Femoral block
161059|NCT02124005|Bupivacaine
161060|NCT02124005|Ultrasound
161061|NCT02123966|Chronic Graft-versus-Host-Disease
161062|NCT02123966|Oral mucosal disease
161063|NCT02123953|Drug therapy
161064|NCT02123940|Weaning from mechanical ventilation
161065|NCT02123940|Lung ultrasound
161066|NCT02123940|Nasal humidified high flow therapy
161067|NCT02123940|Weaning failure
161068|NCT02123940|Postextubation distress
161069|NCT02123927|Drug therapy
161070|NCT02123914|Exercise training
161071|NCT02123914|Allergic rhinitis
161072|NCT02123914|Vitamin C
161073|NCT02123914|Cytokine
161074|NCT02123914|Rhinitis symptoms
161075|NCT02123901|Mind and body Exercise
161076|NCT02123901|Flow mediated dilation
161077|NCT02123901|Diabetes
161078|NCT02123888|Prostate
161079|NCT02123888|Lung
161080|NCT02123862|Prostate Cancer
161081|NCT02123862|Breast Cancer
161082|NCT02123862|Colorectal Cancer
161083|NCT02123862|Colon Cancer
161084|NCT02123862|Rectal Cancer
161085|NCT02123862|Cancer
161086|NCT02123862|Solid Tumor
161087|NCT02123862|Metastatic
161088|NCT02123862|Circulating Tumor Cells
161089|NCT02123810|fatigue
161090|NCT02123810|motor skills
161091|NCT02123810|cardiopulmonary resuscitation
161092|NCT02123784|Rotator Cuff Tear
161093|NCT02123784|Rotator Cuff Repair
161094|NCT02123784|Biomarker
161095|NCT02123784|Predictive factors
161096|NCT02123784|Skeletal Muscle
161097|NCT02123784|Tendon
161098|NCT02123784|Subacromial Bursa
161099|NCT02123771|Focus of Study : HELICOBACTER PYLORI INFECTIONS
161100|NCT02123758|Prostatic Neoplasms
161101|NCT02123758|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
161102|NCT02123758|Prostate cancer
161103|NCT02123758|Abiraterone Acetate (ZYTIGA)
161104|NCT02123758|Prednisone
161105|NCT02123758|JNJ-56021927
161106|NCT02123745|infiltration
161107|NCT02123745|extravasation
161108|NCT02123745|peripheral intravenous therapy
161109|NCT02123732|Diabetes
161110|NCT02123732|Diabetes Mellitus
161111|NCT02123732|Herbal
161112|NCT02123732|food supplement
161113|NCT02123693|Osteopathic manipulative treatment
161114|NCT02123693|Low back pain
161115|NCT02123693|Dynamic MRI
161116|NCT02123680|expectation
161117|NCT02123680|chronic illness
161118|NCT02123680|trajectory
161119|NCT02123628|diabetic foot osteomyelitis, antibiotic treatment duration
161120|NCT02123615|Primary Immunodeficiency
161121|NCT02123615|Subdermal bloodless space
161122|NCT02123615|Subdermal injection
161123|NCT02123615|Subcutaneous injection
161124|NCT02123615|Injectable electromyography needle
161125|NCT02123615|Electrical stimulation
161126|NCT02123615|MRI with Gadolinium
161127|NCT02123602|patellofemoral pain syndrome
161128|NCT02123602|abdominal muscles
161129|NCT02123576|Hepatorenal syndrome
161130|NCT02123576|Renal failure
161131|NCT02123576|Pentoxyfylline
161132|NCT02123576|Liver transplantation
161133|NCT02123576|Cirrhosis
161134|NCT02123550|deep
161135|NCT02123550|venous
161136|NCT02123550|thrombosis
161137|NCT02123550|Doppler
161138|NCT02123550|ultrasound
161139|NCT02123550|plastic
161140|NCT02123550|surgery
161141|NCT02123550|thromboembolism
161142|NCT02123550|prevention
161143|NCT02123537|Bioness L300 Foot Drop System
161144|NCT02123537|Functional electrical stimulation
161145|NCT02123524|Superficial Vein Thrombosis
161146|NCT02123498|ear pressure
161147|NCT02123498|ear fullness
161148|NCT02123498|ear pain
161149|NCT02123498|ETD
161150|NCT02123498|laryngopharyngeal reflux
161151|NCT02123498|LPR
161152|NCT02123498|gastroesophageal reflux disease
161153|NCT02123498|GERD
161154|NCT02123498|nasopharyngeal reflux
161155|NCT02123498|acid reflux
161156|NCT02123342|health
161157|NCT02123342|older adults
161158|NCT02123342|mobile phone
161159|NCT02123329|Qatar
161160|NCT02123329|Pharmacy
161161|NCT02123329|Pharmacist
161162|NCT02123329|Smoking cessation
161163|NCT02123316|local allergic rhinitis
161164|NCT02123316|subcutaneous immunotherapy
161165|NCT02123316|house dust mite allergy
161166|NCT02123316|Dermatophagoides pteronyssinus allergy
161167|NCT02123303|Hypotension, Orthostatic Hypotension
161168|NCT02123290|Plasmodium
161169|NCT02123290|falciparum
161170|NCT02123290|malaria
161171|NCT02123290|vivax
161172|NCT02123290|DSM265
161173|NCT02123290|pharmacokinetics
161174|NCT02123290|adult
161175|NCT02123251|Incentives,
161176|NCT02123251|Diabetes,
161177|NCT02123251|Medicaid,
161178|NCT02123251|Health behavior,
161179|NCT02123251|Cost effectiveness
161180|NCT02123225|STOP-BANG
161181|NCT02123225|Obstructive sleep apnea (OSA)
161182|NCT02123225|total knee arthroplasty (TKA)
161183|NCT02123225|portable monitoring
161184|NCT02123225|sleep medicine
161185|NCT02123225|unattended sleep study
161186|NCT02123225|postoperative sleep study
161187|NCT02123212|Hepatitis C
161188|NCT02123212|Chronic Hepatitis C
161189|NCT02123212|Screening
161190|NCT02123199|COPD
161191|NCT02123186|Newborn Screening , spinal muscular atrophy
161192|NCT02123173|one lung ventilation,
161193|NCT02123173|cardiac output
161194|NCT02123173|fluid responsiveness
161195|NCT02123160|Depression
161196|NCT02123160|Dyadic therapy
161197|NCT02123160|Behavioral Problems
161198|NCT02123160|Child parent therapy
161199|NCT02123160|Affect regulation
161200|NCT02123160|Immune markers
161201|NCT02123160|Cortisol
161202|NCT02123121|Aging
161203|NCT02123121|Biogenesis
161204|NCT02123121|Cell Respiration
161205|NCT02123121|Elderly
161206|NCT02123121|Enzymes
161207|NCT02123121|Mitochondria
161208|NCT02123121|Mitochondrial DNA
161209|NCT02123121|Muscle Fatigue
161210|NCT02123121|Physical Function
161211|NCT02123121|Resveratrol
161212|NCT02123108|Simulect, Myfortic, OLT, Renal Dysfunction, Liver Transplant, Orthotopic Liver Transplantation
161213|NCT02123082|Urolithiasis
161214|NCT02123082|Kidney stones
161215|NCT02123082|Ureteral Obstruction
161216|NCT02123082|Ureteroscopes
161217|NCT02123082|Ureteroscopies
161218|NCT02123069|Autonomic nervous system
161219|NCT02123069|Blood pressure
161220|NCT02123069|Blood vessels
161221|NCT02123069|Physiological effects of drugs
161222|NCT02123069|Vascular stiffness
161223|NCT02123056|reflex fainting
161224|NCT02123056|vasovagal syncope
161225|NCT02123056|metoprolol
161226|NCT02123056|randomized clinical trial
161227|NCT02123056|quality of life
161228|NCT02123043|rehabilitation
161229|NCT02123043|wheelchair
161230|NCT02123043|older adults
161231|NCT02123043|manual wheelchair
161232|NCT02123043|motor learning
161233|NCT02123043|biomechanics
161234|NCT02123043|gross mechanical efficiency
161235|NCT02123030|Lung cancer
161236|NCT02123030|pulmonary disease
161237|NCT02123017|Bowel Evacuation
161238|NCT02123017|Colonoscopy Preparation
161239|NCT02123004|ST-Segment Elevation Myocardial Infarction
161240|NCT02123004|Percutaneous Coronary Intervention
161241|NCT02122991|spinal cord injury
161242|NCT02122991|autonomic dysreflexia
161243|NCT02122991|baroreceptor integrity
161244|NCT02122991|sympathetic integrity
161245|NCT02122991|vagal integrity
161246|NCT02122991|autonomic integrity
161247|NCT02122991|arterial stiffness
161248|NCT02122991|cognitive function
161249|NCT02122991|traumatic brain injury
161250|NCT02122991|cerebral blood flow
161251|NCT02122978|psoriasis
161252|NCT02122978|dermatology
161253|NCT02122978|mindfulness
161254|NCT02122978|self-compassion
161255|NCT02122952|Gene Transfer
161256|NCT02122952|Gene Therapy
161257|NCT02122952|Adeno-associated virus
161258|NCT02122952|Survival Motor Neuron
161259|NCT02122952|SMN
161260|NCT02122952|AAV9
161261|NCT02122926|Transitions in care
161262|NCT02122926|discharge intervention
161263|NCT02122926|RCT
161264|NCT02122926|readmission rates
161265|NCT02122926|medication adherence
161266|NCT02122926|glycemic control
161267|NCT02122926|ED visits
161268|NCT02122926|medication reconciliation
161269|NCT02122926|Coleman Transitions Coach
161270|NCT02122926|telemonitoring; hypoglycemic events
161271|NCT02122913|TRK
161272|NCT02122913|TRKA
161273|NCT02122913|TRKB
161274|NCT02122913|TRKC
161275|NCT02122913|NTRK1
161276|NCT02122913|NTRK2
161277|NCT02122913|NTRK3
161278|NCT02122913|larotrectinib
161279|NCT02122913|NTRK fusion positive
161280|NCT02122913|NTRK gene rearrangements
161281|NCT02122913|NTRK1 fusion
161282|NCT02122913|NTRK2 fusion
161283|NCT02122913|NTRK3 fusion
161284|NCT02122913|NTRK1 gene rearrangement
161285|NCT02122913|NTRK2 gene rearrangement
161286|NCT02122913|NTRK3 gene rearrangement
161287|NCT02122913|ETV6-NTRK3
161288|NCT02122913|fusion
161289|NCT02122913|tumors
161290|NCT02122913|solid tumors
161291|NCT02122913|CNS tumors
161292|NCT02122913|central nervous system tumors
161293|NCT02122913|TRK fusion
161294|NCT02122913|ETV6
161295|NCT02122913|ETV6 fusion
161296|NCT02122913|ETV6 gene rearrangement
161297|NCT02122913|solid CNS tumor
161298|NCT02122913|Advanced CNS tumor
161299|NCT02122913|Primary CNS tumor
161300|NCT02122913|Metastatic CNS tumor
161301|NCT02122913|LOXO-101
161302|NCT02122887|jewish, arab, israel, teenagers
161303|NCT02122874|Percutaneous neurostimulation; dermatome T7, type 2 diabetes
161304|NCT02122861|Melanoma
161305|NCT02122848|Heart failure
161306|NCT02122848|Exercise tolerance
161307|NCT02122848|Noninvasive ventilation
161308|NCT02122835|exercise
161309|NCT02122835|aerobic exercise
161310|NCT02122822|supratentoria glioma
161311|NCT02122809|Chiauranib, advanced solid tumors, phase 1 study
161312|NCT02122796|Breast Cancer
161313|NCT02122796|Mastectomy
161314|NCT02122796|Acupuncture
161315|NCT02122770|Drug Therapy
161316|NCT02122731|antihypertensive therapy
161317|NCT02122731|amiloride
161318|NCT02122731|add-on
161319|NCT02122731|resistant hypertension
161320|NCT02122731|blood pressure control
161321|NCT02122731|type 2 diabetes mellitus,
161322|NCT02122731|microalbuminuria.
161323|NCT02122705|Remifentanil
161324|NCT02122705|Labour analgesia
161325|NCT02122666|Metabolic Syndrome
161326|NCT02122666|Pre-diabetes
161327|NCT02122666|impaired glucose tolerance
161328|NCT02122666|Phospholipids
161329|NCT02122653|Fatigue
161330|NCT02122653|aging
161331|NCT02122653|transcranial magnetic stimulation
161332|NCT02122653|interpolated
161333|NCT02122653|twitch technique
161334|NCT02122627|Vitamin D, COPD, immunomodulation, physical function, pulmonary function
161335|NCT02122614|Chronic obstructive pulmonary disease
161336|NCT02122614|COPD
161337|NCT02122614|Pulmonary rehabilitation
161338|NCT02122614|Physical activity
161339|NCT02122614|Exercise
161340|NCT02122588|serous and endometrioid ovarian, peritoneal, fallopian tube cancer, hereditary ovarian cancer, BRCA (breast cancer gene) mutation, genetic testing
161341|NCT02122575|Inflammasome
161342|NCT02122575|Fasting
161343|NCT02122575|Sirt3
161344|NCT02122562|Ketamine
161345|NCT02122562|Major Depression
161346|NCT02122562|Alcohol
161347|NCT02122562|Alcohol Clamp
161348|NCT02122562|NMDA Antagonist
161349|NCT02122549|In-Hospital Cardiac Arrest
161350|NCT02122549|Telemetry
161351|NCT02122523|Image guided surgery
161352|NCT02122510|Analgesia, casarean section, TAP block
161353|NCT02122497|abdominal aortic aneurysm
161354|NCT02122497|aortic occlusive disease
161355|NCT02122497|cardiovascular biomarkers
161356|NCT02122497|open surgical repair
161357|NCT02122497|endovascular aortic repair
161358|NCT02122484|reperfusion damage
161359|NCT02122471|CIC
161360|NCT02122471|Constipation
161361|NCT02122471|Chronic Constipation
161362|NCT02122471|Synergy
161363|NCT02122471|Plecanatide
161364|NCT02122458|hearing impairment
161365|NCT02122458|post-traumatic stress disorder
161366|NCT02122458|traumatic brain injury
161367|NCT02122458|auditory processing disorder
161368|NCT02122445|Gluteus Maximum
161369|NCT02122445|Gluteus Medius
161370|NCT02122445|TFL
161371|NCT02122445|EMG
161372|NCT02122445|Flexion-Response Phenomenon
161373|NCT02122445|Thera-Band
161374|NCT02122445|kinesiology tape
161375|NCT02122432|teledermatology
161376|NCT02122432|dermatology
161377|NCT02122432|general practice
161378|NCT02122432|organization of care
161379|NCT02122406|Rheumatoid Arthritis
161380|NCT02122406|Depression
161381|NCT02122406|Anxiety
161382|NCT02122406|DAS28
161383|NCT02122406|HADS
161384|NCT02122380|Growth Hormone
161385|NCT02122380|Dipeptidyl Peptidase 4
161386|NCT02122380|Polycystic Ovary Syndrome
161387|NCT02122328|Twin twin transfusion syndrome
161388|NCT02122328|Sequential laser photocoagulation of communicating vessels
161389|NCT02122302|Altered gastrointestinal anatomy
161390|NCT02122302|Chronic pancreatic disease
161391|NCT02122302|Chronic pancreatic pain
161392|NCT02122302|Patient self-assessment
161393|NCT02122302|Online assessment
161394|NCT02122289|Exacerbation, QoL
161395|NCT02122276|Spinal cord injury
161396|NCT02122276|Passive motion
161397|NCT02122276|Fatigue index
161398|NCT02122276|Hypertonia
161399|NCT02122250|Diabetes
161400|NCT02122250|Health literacy
161401|NCT02122250|web intervention
161402|NCT02122224|satiety
161403|NCT02122224|satiation
161404|NCT02122224|diet quality
161405|NCT02122224|memory
161406|NCT02122224|obesity
161407|NCT02122224|protein
161408|NCT02122224|fiber
161409|NCT02122211|Sperm motility
161410|NCT02122198|Cognitive impairment
161411|NCT02122198|Executive function
161412|NCT02122198|Arterial stiffness
161413|NCT02122198|Endothelial function
161414|NCT02122198|Menopause
161415|NCT02122198|Women's health
161416|NCT02122198|Hormone therapy
161417|NCT02122198|functional MRI
161418|NCT02122159|safety
161419|NCT02122159|tolerability
161420|NCT02122159|RPE cellular therapy
161421|NCT02122159|MMD
161422|NCT02122146|ADC
161423|NCT02122146|PF-06664178
161424|NCT02122146|solid tumors
161425|NCT02122146|tumors
161426|NCT02122146|neoplasm metastasis
161427|NCT02122146|NSCLC
161428|NCT02122146|non small cell lung cancer
161429|NCT02122146|OVCA
161430|NCT02122146|ovarian cancer
161431|NCT02122146|Phase 1
161432|NCT02122146|breast cancer
161433|NCT02122133|IC aneurysms, coil embolization, PC 400, radiation exposure,
161434|NCT02122120|enteral nutrition, tube feeding, nutritional support
161435|NCT02122107|Treatment Exposure
161436|NCT02122107|Smoking History
161437|NCT02122107|14-071
161438|NCT02122068|Meditation
161439|NCT02122068|Mindfulness
161440|NCT02122068|Caregiver
161441|NCT02122068|Dementia
161442|NCT02122068|Depression
161443|NCT02122055|combined sedation
161444|NCT02122029|Lifestyle intervention
161445|NCT02122029|Bariatric surgery
161446|NCT02122029|Weight management
161447|NCT02122029|Physical activity
161448|NCT02122016|Ventilator weaning
161449|NCT02122016|Protocols
161450|NCT02122016|Computer driven weaning
161451|NCT02122016|Decision Making, Computer-Assisted
161452|NCT02122016|Therapy, Computer-Assisted
161453|NCT02122016|Respiration, Artificial
161454|NCT02122003|sorafenib
161455|NCT02122003|pazopanib
161456|NCT02122003|cross-resistance
161457|NCT02122003|TKI
161458|NCT02122003|mRCC
161459|NCT02121990|(IP) Cisplatin
161460|NCT02121990|IV/IP Paclitaxel
161461|NCT02121990|IV Bevacizumab
161462|NCT02121990|Oral Olaparib (AZD2281)
161463|NCT02121990|Optimally Debulked
161464|NCT02121990|Stage II/III
161465|NCT02121990|Ovary
161466|NCT02121990|Pertoneum
161467|NCT02121990|10-220
161468|NCT02121964|unilateral primary total hip arthroplasty
161469|NCT02121964|bilateral primary total hip arthroplasty
161470|NCT02121964|Arthritis
161471|NCT02121964|Orthopedic Disorders
161472|NCT02121964|Orthopedics
161473|NCT02121964|Surgery,
161474|NCT02121964|Orthopedic
161475|NCT02121964|arthroplasty
161476|NCT02121964|hip
161477|NCT02121964|osteoarthritis
161478|NCT02121964|capsulectomy
161479|NCT02121964|capsulotomy
161480|NCT02121951|Percutaneous Nephrostomy
161481|NCT02121951|Quadtatus Lumborum Block
161482|NCT02121951|Cancer
161483|NCT02121951|Monitored Anaesthesia Care
161484|NCT02121938|Very Low Birth Weight (VLBW)
161485|NCT02121938|Microbiome
161486|NCT02121925|Registry
161487|NCT02121899|Registry
161488|NCT02121873|breast cancer, nipple aspirate, ductal lavage, hyperplasia
161489|NCT02121860|Hepatic Impairment
161490|NCT02121860|Pharmacokinetics
161491|NCT02121860|Pharmacodynamics
161492|NCT02121808|Morbid Obesity
161493|NCT02121808|Bariatric Surgery Candidate
161494|NCT02121808|Pre-Oxygenation
161495|NCT02121808|Functional Residual Capacity
161496|NCT02121795|HIV
161497|NCT02121795|HIV-1 Positive
161498|NCT02121795|Virologically-suppressed
161499|NCT02121782|QIV
161500|NCT02121782|Quadrivalent Influenza Vaccine
161501|NCT02121782|Influenza vaccine
161502|NCT02121782|Vaccination
161503|NCT02121769|cholestasis
161504|NCT02121769|short bowel syndrome
161505|NCT02121756|Dipyridamole
161506|NCT02121756|HIV
161507|NCT02121756|Immune Markers
161508|NCT02121756|Immune Activation
161509|NCT02121756|Inflammation
161510|NCT02121743|strattice
161511|NCT02121743|colostomy
161512|NCT02121743|parastomal hernia
161513|NCT02121730|grafting kidney
161514|NCT02121730|Cancer
161515|NCT02121717|Chiglitazar,diabetes,type 2 diabetes
161516|NCT02121704|Sedation
161517|NCT02121704|Colonoscopy
161518|NCT02121704|Propofol
161519|NCT02121704|Scope guide
161520|NCT02121691|Cancer
161521|NCT02121691|Obesity
161522|NCT02121691|Body Mass Index
161523|NCT02121678|Resistance training
161524|NCT02121678|Aerobic exercise
161525|NCT02121678|Isokinetic muscle strength
161526|NCT02121678|Bicycle ergometry test
161527|NCT02121678|Subcutaneous immunoglobulin
161528|NCT02121652|lung cancer survivors
161529|NCT02121652|insomnia treatment
161530|NCT02121652|cognitive behavioral therapy
161531|NCT02121639|Metastatic Castration Resistant Prostate Cancer
161532|NCT02121639|AZD5363
161533|NCT02121639|Docetaxel
161534|NCT02121639|Prednisolone
161535|NCT02121626|Cancer
161536|NCT02121626|Chemotheraphy
161537|NCT02121626|Small Bowel Bacterial Overgrowth
161538|NCT02121626|Bile Acid Malabsorption
161539|NCT02121626|Pancreatic Insufficiency
161540|NCT02121626|Carbohydrate Malabsorption
161541|NCT02121626|Anorexia
161542|NCT02121626|Borborygmi
161543|NCT02121626|Bloating
161544|NCT02121626|Constipation
161545|NCT02121626|Diarrhoea
161546|NCT02121626|Mucositis
161547|NCT02121626|Dysphagia
161548|NCT02121626|Early satiety
161549|NCT02121626|Frequency of defaecation
161550|NCT02121626|Incontinence
161551|NCT02121626|Mucus discharge
161552|NCT02121626|Nausea
161553|NCT02121626|Nocturnal defaecation
161554|NCT02121626|Pain
161555|NCT02121626|Reflux
161556|NCT02121626|Regurgitation
161557|NCT02121626|Steatorrhoea
161558|NCT02121626|Tenesmus
161559|NCT02121626|Urgency of defaecation
161560|NCT02121626|Vomiting
161561|NCT02121626|Weight loss
161562|NCT02121626|Wind.
161563|NCT02121600|Fluorocholine (FCH)
161564|NCT02121600|Positron Emission Tomography (PET)
161565|NCT02121600|Magnetic Resonance Imaging (MRI)
161566|NCT02121587|Musculoskeletal Pain, Osteopathy, Mindfulness
161567|NCT02121574|Surgery
161568|NCT02121574|thermometers
161569|NCT02121574|Hypothermia
161570|NCT02121574|anesthesia
161571|NCT02121574|temperature
161572|NCT02121561|Shame
161573|NCT02121548|Screen
161574|NCT02121548|cervical, cancer
161575|NCT02121548|HPV
161576|NCT02121548|women
161577|NCT02121548|community health workers
161578|NCT02121548|Hispanic/ Latinas
161579|NCT02121548|Haitian
161580|NCT02121496|Depression
161581|NCT02121496|Development
161582|NCT02121496|Infant sleep
161583|NCT02121470|AKI
161584|NCT02121470|Acute Kidney Injury
161585|NCT02121470|Renal failure
161586|NCT02121470|NGAL
161587|NCT02121470|neutrophil gelatinase-associated lipocalin
161588|NCT02121470|lipocalin-2
161589|NCT02121470|siderocalin
161590|NCT02121470|Intensive care
161591|NCT02121470|ICU
161592|NCT02121470|Critical care
161593|NCT02121457|cognitive performance
161594|NCT02121457|selenium
161595|NCT02121457|brazil nuts
161596|NCT02121457|oxidative stress
161597|NCT02121444|RRMS
161598|NCT02121444|CIS
161599|NCT02121366|Endoscopic Ultrasound-Guided Fine Needle Aspiration
161600|NCT02121366|Insulinoma
161601|NCT02121366|Ethanol
161602|NCT02121366|Ablation Techniques
161603|NCT02121353|Age related macular degeneration
161604|NCT02121353|AMD
161605|NCT02121353|Wet AMD
161606|NCT02121353|Eye conditions
161607|NCT02121353|CFT
161608|NCT02121353|OCT
161609|NCT02121353|CNV
161610|NCT02121353|FA
161611|NCT02121353|Ocular
161612|NCT02121353|Eye
161613|NCT02121353|Disorder of the eye
161614|NCT02121340|Depression
161615|NCT02121340|Health disparities
161616|NCT02121340|African American
161617|NCT02121340|Geriatric
161618|NCT02121327|stroke, disease management programs, self-management
161619|NCT02121314|TB
161620|NCT02121314|bioavailability
161621|NCT02121314|HRZE
161622|NCT02121314|fasting
161623|NCT02121314|fed
161624|NCT02121301|Dry Eye
161625|NCT02121301|Dry Eye Syndrome
161626|NCT02121301|SkQ1
161627|NCT02121301|KCS
161628|NCT02121301|Keratoconjunctivitis
161629|NCT02121288|Peripheral Artery Disease
161630|NCT02121288|Myocardial Blood Flow
161631|NCT02121288|Cardiac Blood Flow
161632|NCT02121236|CBCT
161633|NCT02121236|Ultrasonic diagnosis
161634|NCT02121236|Benign radiolucent lesions
161635|NCT02121236|Histopathology
161636|NCT02121223|acute ST segment elevated myocardial infarction
161637|NCT02121223|primary percutaneous intervention
161638|NCT02121223|Stent Incomplete Apposition
161639|NCT02121197|Macular Diabetic Edema
161640|NCT02121197|Ozurdex
161641|NCT02121197|Retrospective
161642|NCT02121197|European
161643|NCT02121197|Intra-vitreal injections
161644|NCT02121184|Oxytocin
161645|NCT02121184|Labor, Obstetric
161646|NCT02121184|Non-reassuring fetal heart rate
161647|NCT02121184|Epidural
161648|NCT02121158|CSP 592
161649|NCT02121158|ICD
161650|NCT02121158|cardiovascular
161651|NCT02121158|heart
161652|NCT02121158|aging
161653|NCT02121158|chronic diseases
161654|NCT02121158|multi-site trial
161655|NCT02121158|phase 3
161656|NCT02121158|investigational device
161657|NCT02121158|cardiomyopathy
161658|NCT02121158|coronary artery disease
161659|NCT02121158|congestive heart failure
161660|NCT02121158|myocardial infarction
161661|NCT02121158|I-70
161662|NCT02121158|I70
161663|NCT02121158|elderly
161664|NCT02121158|defibrillator
161665|NCT02121145|Vivotif
161666|NCT02121145|Typherix
161667|NCT02121145|Salmonella Typhi
161668|NCT02121145|non-typhoid Salmonella
161669|NCT02121145|Salmonella Paratyphi
161670|NCT02121145|enzyme-linked immunospot assay
161671|NCT02121145|Plasmablast
161672|NCT02121132|Overweight
161673|NCT02121132|Obesity
161674|NCT02121119|Peripheral nerve block
161675|NCT02121119|Lidocaine
161676|NCT02121119|Bupivacaine
161677|NCT02121093|vibration
161678|NCT02121093|physiotherapy
161679|NCT02121093|cortex
161680|NCT02121093|muscles
161681|NCT02121067|postpartum
161682|NCT02121067|contraception
161683|NCT02121067|intrauterine device
161684|NCT02121067|intrauterine system
161685|NCT02121067|mirena
161686|NCT02121067|uterine involution
161687|NCT02121054|Antiplatelet Agents
161688|NCT02121054|Drug Resistance
161689|NCT02121041|Hypertension
161690|NCT02121041|Blood Pressure
161691|NCT02121041|Ambulatory Blood Pressure Monitoring
161692|NCT02121028|Intracranial Atherosclerotic Disease
161693|NCT02121028|Stroke
161694|NCT02121028|Transient Ischemic Attack
161695|NCT02121028|Imaging
161696|NCT02121015|Postpartum Depression
161697|NCT02121015|Depression Prevention
161698|NCT02121015|Supportive Accountability
161699|NCT02121015|Individual Internet Interventions (IIIs)
161700|NCT02121015|Internet Support Groups (ISGs)
161701|NCT02121002|Knee
161702|NCT02120989|insomnia
161703|NCT02120989|cognitive behavioral therapy for insomnia (CBT-I)
161704|NCT02120989|partner-assisted
161705|NCT02120976|Safety
161706|NCT02120976|Tolerability
161707|NCT02120976|Pharmacokinetics
161708|NCT02120976|Food-effect
161709|NCT02120976|Diabetes
161710|NCT02120963|Fatigue
161711|NCT02120963|Rheumatoid Arthritis
161712|NCT02120963|Physical Therapy
161713|NCT02120963|Person-Centred Care
161714|NCT02120950|PCV
161715|NCT02120937|amygdala
161716|NCT02120937|mindfulness
161717|NCT02120937|mood
161718|NCT02120937|emotion
161719|NCT02120937|bipolar disorder
161720|NCT02120937|parental bipolar disorder
161721|NCT02120937|adolescence
161722|NCT02120924|Moderate facial rosacea
161723|NCT02120924|Azelaic acid
161724|NCT02120924|Rosacea
161725|NCT02120911|Her2+
161726|NCT02120911|Resectable esophageal carcinoma
161727|NCT02120911|Pertuzumab
161728|NCT02120911|Trastuzumab
161729|NCT02120898|Actinic Keratosis
161730|NCT02120898|Imiquimod
161731|NCT02120898|Zyclara
161732|NCT02120885|Gastric cancer
161733|NCT02120885|minimally invasive gastrectomy
161734|NCT02120885|Physical activity intervention
161735|NCT02120859|PCI
161736|NCT02120859|Drug-eluting balloon (DEB)
161737|NCT02120859|Fractional flow reserve (FFR)
161738|NCT02120846|Stroke
161739|NCT02120846|Flywheel resistance exercise
161740|NCT02120846|Muscle function
161741|NCT02120846|Cognitive function
161742|NCT02120833|Atopic Dermatitis
161743|NCT02120820|massage
161744|NCT02120820|multisensory environment
161745|NCT02120820|challenging behaviours
161746|NCT02120820|relaxation
161747|NCT02120807|Certolizumab
161748|NCT02120807|Cisplatin
161749|NCT02120807|Pemetrexed
161750|NCT02120807|thoracic
161751|NCT02120807|13-063
161752|NCT02120794|Type 1 diabetes
161753|NCT02120794|Pediatric
161754|NCT02120794|Threshold Suspend
161755|NCT02120794|Sensor augmented pump
161756|NCT02120768|Barrier resection
161757|NCT02120768|Local recurrence
161758|NCT02120768|Complication
161759|NCT02120742|Road traffic injury prevention
161760|NCT02120742|Helmet use
161761|NCT02120742|mHealth intervention
161762|NCT02120729|Pharmacogenetics
161763|NCT02120729|CYP2D6 Mutations
161764|NCT02120729|Major Depressive Disorder
161765|NCT02120729|Psychiatric Inpatients
161766|NCT02120729|Length of Stay
161767|NCT02120729|30 Day Readmission Rate
161768|NCT02120729|Psychiatric hospital inpatients
161769|NCT02120716|HIV
161770|NCT02120716|STIs
161771|NCT02120716|Health Check Up
161772|NCT02120716|Intervention
161773|NCT02120703|Pregabalin
161774|NCT02120703|gabapentin
161775|NCT02120703|microdiscectomy
161776|NCT02120703|pain
161777|NCT02120690|pain
161778|NCT02120690|fibromyagia
161779|NCT02120690|TNS
161780|NCT02120677|skin cancer
161781|NCT02120677|basal cell carcinoma
161782|NCT02120651|Fibrin monomer
161783|NCT02120651|Tympanoplasty
161784|NCT02120651|Hemostatic sponge
161785|NCT02120638|Multidrug Resistant Tuberculosis
161786|NCT02120638|Pyrazinamide
161787|NCT02120625|radiofrequency ablation
161788|NCT02120625|neurotomy
161789|NCT02120625|facet joint
161790|NCT02120625|medial branch
161791|NCT02120625|low back pain
161792|NCT02120612|Opioid Dependence
161793|NCT02120612|Addiction
161794|NCT02120612|Naloxone
161795|NCT02120612|Naloxone Education
161796|NCT02120612|Opiate Overdose Knowledge Scale
161797|NCT02120612|OOKS
161798|NCT02120586|Elderly
161799|NCT02120586|Institutionalization
161800|NCT02120586|Sarcopenia
161801|NCT02120586|Strength training
161802|NCT02120586|Muscle mass
161803|NCT02120586|Muscle strength
161804|NCT02120586|Physical performance
161805|NCT02120573|Cardiac Arrest
161806|NCT02120573|Cardiopulmonary Resuscitation
161807|NCT02120573|Training
161808|NCT02120560|Atrial Fibrillation Ablation
161809|NCT02120560|Cerebrothromboemboli
161810|NCT02120560|Neurocognitive Function
161811|NCT02120547|Liver Insufficiency
161812|NCT02120547|Hepatic impairment
161813|NCT02120534|soluble CD14 ,serum CD88,sepsis , SIRS.
161814|NCT02120521|Sepsis and SIRS, ICU
161815|NCT02120508|stroke
161816|NCT02120508|aphasia
161817|NCT02120508|rTMS
161818|NCT02120508|Functional MRI
161819|NCT02120508|Speech training
161820|NCT02120495|condylectomy
161821|NCT02120495|TMJ function
161822|NCT02120495|intraoral approach
161823|NCT02120482|ABO isoagglutinins
161824|NCT02120482|ABO incompatible transplantation
161825|NCT02120482|immunoadsorption
161826|NCT02120482|membrane filtration
161827|NCT02120482|plasmapheresis
161828|NCT02120443|infiltration
161829|NCT02120443|extravasation
161830|NCT02120443|peripheral intravenous therapy
161831|NCT02120430|Early childhood
161832|NCT02120430|Audiovisual materials
161833|NCT02120430|Parent-child interaction
161834|NCT02120430|Parenting programs
161835|NCT02120430|Timing
161836|NCT02120417|Breast Cancer
161837|NCT02120404|septic shock, hemodynamic tolerance, esmolol
161838|NCT02120378|miscarriage
161839|NCT02120378|fetal viability
161840|NCT02120378|prematurity
161841|NCT02120365|Alcoholism
161842|NCT02120365|Heavy Drinking
161843|NCT02120365|Perampanel
161844|NCT02120352|bi-monthly
161845|NCT02120352|GSK744
161846|NCT02120352|injectable
161847|NCT02120352|long acting
161848|NCT02120352|maintenance
161849|NCT02120352|abacavir
161850|NCT02120352|every other month
161851|NCT02120352|rilpivirine
161852|NCT02120352|HIV-1 infection
161853|NCT02120352|integrase inhibitor
161854|NCT02120352|TMC278 LA
161855|NCT02120352|RPV
161856|NCT02120352|non-nucleoside reverse transcriptase inhibitor
161857|NCT02120352|LA
161858|NCT02120352|once monthly
161859|NCT02120352|GSK1265744
161860|NCT02120352|induction
161861|NCT02120352|treatment satisfication
161862|NCT02120352|once daily
161863|NCT02120352|lamivudine
161864|NCT02120352|adherence
161865|NCT02120352|TMC278
161866|NCT02120352|therapy-naive
161867|NCT02120339|Hypertension
161868|NCT02120339|PAH
161869|NCT02120326|Chronic migraine, tDCS, Transcranial direct current stimulation
161870|NCT02120313|rehabilitation
161871|NCT02120313|total knee arthroplasty
161872|NCT02120287|Border Zone Stereotactic Radiosurgery
161873|NCT02120287|Bevacizumab
161874|NCT02120287|Recurrent Glioblastoma Multiforme
161875|NCT02120287|Progressive Glioblastoma Multiforme
161876|NCT02120287|Magnetic Resonance Spectroscopy
161877|NCT02120287|Glioblastoma
161878|NCT02120287|Brain Cancer
161879|NCT02120287|Brain Tumor
161880|NCT02120287|Radiosurgery
161881|NCT02120274|RNA Virus Infections
161882|NCT02120274|Flaviviridae Infections
161883|NCT02120274|Hepatitis C
161884|NCT02120274|Hepatitis C, Chronic
161885|NCT02120274|Vitamin D
161886|NCT02120274|Cholecalciferol
161887|NCT02120274|Vitamin B 12
161888|NCT02120261|Myofascial Pain Syndrome
161889|NCT02120261|trigger point injection
161890|NCT02120248|WIC
161891|NCT02120248|Oregon
161892|NCT02120248|Breastfeeding
161893|NCT02120248|Peer Counseling
161894|NCT02120248|Exclusive Breastfeeding
161895|NCT02120235|Lysosomal storage disorders
161896|NCT02120235|LSD
161897|NCT02120235|Gaucher disease
161898|NCT02120235|Fabry disease
161899|NCT02120235|Pompe disease
161900|NCT02120235|Niemann-Pick disease
161901|NCT02120222|melanoma
161902|NCT02120209|assessment; falls; older adults; prediction scale; standardized declaration
161903|NCT02120183|Caregivers
161904|NCT02120183|Quality of life
161905|NCT02120183|Neoplasms
161906|NCT02120183|Psychotherapy, group
161907|NCT02120183|Family
161908|NCT02120183|Adaptation, psychological
161909|NCT02120183|Psycho-educational support group therapy
161910|NCT02120183|Cancer patients
161911|NCT02120170|Hemoclip, Heparin bridging therapy, colon polypectomy, warfarin
161912|NCT02120157|Acute lymphoblastic leukemia
161913|NCT02120157|Acute myeloid leukemia
161914|NCT02120157|Juvenile myelomonocytic leukemia
161915|NCT02120157|Treatment related leukemia
161916|NCT02120157|Biphenotypic leukemia
161917|NCT02120131|third molar surgery, periodontal probing depth , flap design
161918|NCT02120118|Treatment failure
161919|NCT02120105|Renal aminoaciduria
161920|NCT02120105|cystinuria
161921|NCT02120105|D-penicillamine
161922|NCT02120105|renal tubular transport
161923|NCT02120105|inborn errors
161924|NCT02120105|tiopronin
161925|NCT02120105|urolithiasis
161926|NCT02120092|ACS, Acute coronary syndrome
161927|NCT02120079|Dry Eye
161928|NCT02120066|Submacular hemorrhage
161929|NCT02120066|Vitrectomy
161930|NCT02120066|tissue- plasminogen activator
161931|NCT02120053|Immediate complete denture
161932|NCT02120053|Alveolar ridge resorption
161933|NCT02120053|Alveolar bone loss
161934|NCT02120053|Bone substitute material
161935|NCT02120053|Edentulism
161936|NCT02120027|Irritable Bowel Syndrome
161937|NCT02120027|Colon, irritable
161938|NCT02120027|Bowel disease
161939|NCT02120027|Diarrhea
161940|NCT02120014|Heart Failure
161941|NCT02120014|Heart Failure Reduced Ejection Fraction
161942|NCT02120014|Heart Failure Preserved Ejection Fraction
161943|NCT02120014|Venous Plethysmography
161944|NCT02120014|Blood Volume Study
161945|NCT02120001|Medical Devices
161946|NCT02120001|Ventilator-Associated Pneumonia (VAP)
161947|NCT02120001|Ventilator-Associated Events (VAE)
161948|NCT02120001|Endotracheal Tube
161949|NCT02120001|Microbial Diversity
161950|NCT02120001|Drug-Resistance
161951|NCT02120001|biofilms
161952|NCT02120001|endotracheal intubation
161953|NCT02120001|mechanical ventilation
161954|NCT02119988|TIPS
161955|NCT02119988|Embolization
161956|NCT02119988|Variceal rebleeding
161957|NCT02119975|Rumination
161958|NCT02119975|Working memory
161959|NCT02119975|Depression
161960|NCT02119975|Anxiety
161961|NCT02119975|Working memory training
161962|NCT02119975|Overgeneral memories
161963|NCT02119962|burnout
161964|NCT02119962|working memory
161965|NCT02119962|working memory training
161966|NCT02119962|cognitive behavioral therapy
161967|NCT02119962|executive control
161968|NCT02119949|Substance abuse
161969|NCT02119949|Addiction
161970|NCT02119949|Working memory
161971|NCT02119949|Craving
161972|NCT02119949|Impulsivity
161973|NCT02119949|Attention control
161974|NCT02119936|Stress
161975|NCT02119936|Anxiety
161976|NCT02119936|Mental Health
161977|NCT02119936|Mental Health Services
161978|NCT02119936|Maternal Mental Health
161979|NCT02119923|Depression
161980|NCT02119923|Anxiety
161981|NCT02119923|Working memory
161982|NCT02119923|Rumination
161983|NCT02119923|Cognitive training
161984|NCT02119923|Executive functioning
161985|NCT02119910|pediatric feeding disorders
161986|NCT02119910|behavioral intervention
161987|NCT02119910|treatment manual
161988|NCT02119910|feeding
161989|NCT02119910|food refusal
161990|NCT02119910|diet
161991|NCT02119897|Oropharyngeal Mucositis
161992|NCT02119897|Myeloablative Hematopoietic Cell Transplantation
161993|NCT02119897|Low Level Light Therapy
161994|NCT02119884|Gastric and Esophageal Varices
161995|NCT02119884|Hepatic Venous Pressure Gradient
161996|NCT02119884|Terlipressin
161997|NCT02119884|Octreotide
161998|NCT02119871|Cerebral air emboli, heart surgery
161999|NCT02119845|Chronic kidney disease
162000|NCT02119845|Arteriovenous fistula (AVF)
162001|NCT02119845|Hemodialysis
162002|NCT02119845|Vascular access
162003|NCT02119845|Endovascular AVF (EndoAVF)
162004|NCT02119832|Chronic kidney disease
162005|NCT02119832|Arteriovenous fistula
162006|NCT02119832|Hemodialysis
162007|NCT02119832|Vascular access
162008|NCT02119819|Weight loss
162009|NCT02119806|cardiac surgery, benzodiazepines, delirium
162010|NCT02119767|Atherosclerosis
162011|NCT02119754|Wound
162012|NCT02119754|Ulcer
162013|NCT02119754|Infected
162014|NCT02119754|Infection
162015|NCT02119741|Interdental papilla
162016|NCT02119741|hyaluronic acid
162017|NCT02119741|esthetic zone
162018|NCT02119741|black triangles
162019|NCT02119715|Breast Cancer
162020|NCT02119715|Neutropenia
162021|NCT02119715|Febrile Neutropenia
162022|NCT02119702|HIV/AIDS, perinatal HIV infection
162023|NCT02119689|Diabetes
162024|NCT02119689|Retinopathy
162025|NCT02119676|Metastatic Colorectal Cancer
162026|NCT02119676|Colon Cancer
162027|NCT02119676|Ruxolitinib
162028|NCT02119676|adenocarcinoma
162029|NCT02119676|regorafenib
162030|NCT02119676|Jakavi ®
162031|NCT02119676|Jakafi ®
162032|NCT02119676|Stivarga ®
162033|NCT02119663|Metastatic pancreatic cancer
162034|NCT02119650|Non small cell lung cancer
162035|NCT02119637|Emotion
162036|NCT02119637|Tactile Discrimination
162037|NCT02119637|Transcranial Magnetic Stimulation (TMS)
162038|NCT02119637|Somatosensory
162039|NCT02119637|Somatosensory Cortex
162040|NCT02119624|Neural Networks
162041|NCT02119624|Alcoholism
162042|NCT02119624|fMRI
162043|NCT02119624|Reward
162044|NCT02119624|Addiction
162045|NCT02119611|Deep Brain Stimulation
162046|NCT02119611|Movement Disorders
162047|NCT02119611|Parkinson's Disease
162048|NCT02119611|Dystonia
162049|NCT02119611|Essential Tremor
162050|NCT02119598|Prehospital care
162051|NCT02119598|Telemedicine
162052|NCT02119598|Ambulance-based telemedicine
162053|NCT02119585|orthotopic liver transplantation
162054|NCT02119585|ischemia reperfusion syndrome
162055|NCT02119585|cytokines
162056|NCT02119585|respiratory system elastance
162057|NCT02119585|lung elastance
162058|NCT02119585|chest wall elastance
162059|NCT02119585|shunt
162060|NCT02119585|dead space
162061|NCT02119585|acute respiratory failure
162062|NCT02119585|atelectasis
162063|NCT02119585|pleural effusion
162064|NCT02119572|diabetes,peer support
162065|NCT02119559|Circulating Tumor Cells
162066|NCT02119559|Treatment Efficiency
162067|NCT02119559|Biomarker
162068|NCT02119546|Mild CognitIve impairment
162069|NCT02119546|Alzheimer's disease
162070|NCT02119546|Cognitive function
162071|NCT02119546|Exercise training
162072|NCT02119533|brain injury
162073|NCT02119533|concussion
162074|NCT02119533|post traumatic stress
162075|NCT02119520|Periodontitis
162076|NCT02119520|Surgery
162077|NCT02119520|Growth Factors
162078|NCT02119520|Statins
162079|NCT02119507|Dental caries
162080|NCT02119507|Curodont Repair
162081|NCT02119507|P11-4
162082|NCT02119494|chronic obstructive pulmonary disease
162083|NCT02119494|phenotypes
162084|NCT02119494|categories
162085|NCT02119494|stage
162086|NCT02119494|GOLD
162087|NCT02119494|treatment
162088|NCT02119481|Mindfulness stress reduction training
162089|NCT02119481|Expressive writing condition
162090|NCT02119481|Waiting list control condition
162091|NCT02119442|Eisenmenger Syndrome, Pulmonary Arterial Hyptertension
162092|NCT02119429|Blood pressure
162093|NCT02119429|Pre-menopausal
162094|NCT02119429|Supplementation
162095|NCT02119416|Cardiovascular influences
162096|NCT02119416|caffeine
162097|NCT02119416|healthy children
162098|NCT02119403|Minimal Sedation nitrous oxide
162099|NCT02119390|adolescents
162100|NCT02119390|young adults
162101|NCT02119390|medication adherence
162102|NCT02119377|trans
162103|NCT02119377|transsexual
162104|NCT02119377|transgender
162105|NCT02119377|sistergirl
162106|NCT02119377|brotherboy
162107|NCT02119377|androgynous
162108|NCT02119377|genderqueer
162109|NCT02119364|cerebral palsy
162110|NCT02119364|working memory
162111|NCT02119364|cognitive training
162112|NCT02119351|peripheral intravenous catheters
162113|NCT02119351|blood exposure
162114|NCT02119351|blood control
162115|NCT02119351|IV catheter insertion
162116|NCT02119338|5-ala
162117|NCT02119338|5-aminolevulinic acid
162118|NCT02119338|fluorescence-guided surgery
162119|NCT02119338|glioma
162120|NCT02119338|astrocytoma
162121|NCT02119338|glioblastoma
162122|NCT02119338|oligodendroglioma
162123|NCT02119338|recurrence of glioma
162124|NCT02119325|fibre
162125|NCT02119325|overweight
162126|NCT02119325|impaired fasting glucose
162127|NCT02119312|Malaria
162128|NCT02119312|Plasmodium
162129|NCT02119312|Plasmodium falciparum
162130|NCT02119312|Clinical Trials
162131|NCT02119312|Vaccine Study
162132|NCT02119312|Drug Study
162133|NCT02119312|Malaria Clinical Trials Center
162134|NCT02119312|Seattle BioMed
162135|NCT02119312|Center for Infectious Disease Research
162136|NCT02119286|long acting beta2- receptor agonist
162137|NCT02119286|long acting muscarininc receptor antagonist
162138|NCT02119286|dry powder inhaler
162139|NCT02119286|safety
162140|NCT02119286|COPD
162141|NCT02119286|inhaled corticosteroid
162142|NCT02119286|efficacy
162143|NCT02119286|fluticasone furoate/vilanterol
162144|NCT02119286|umeclidinium bromide
162145|NCT02119273|CRSsNP
162146|NCT02119273|Steroids
162147|NCT02119273|Corticosteroids
162148|NCT02119273|Endoscopic
162149|NCT02119273|Surgery
162150|NCT02119273|Perioperative
162151|NCT02119260|First Time in Human
162152|NCT02119260|TRPV4 inhibitor
162153|NCT02119260|Heart failure
162154|NCT02119247|systemic availability , pharmacokinetics, COPD
162155|NCT02119195|composite
162156|NCT02119195|sealant
162157|NCT02119195|longevity
162158|NCT02119182|Traumatic Brain Injury
162159|NCT02119182|Biomarkers
162160|NCT02119182|Neuroimaging
162161|NCT02119182|Psychological Health
162162|NCT02119182|Comparative Effectiveness Research
162163|NCT02119156|treatment holiday
162164|NCT02119156|PGA
162165|NCT02119156|belimumab
162166|NCT02119156|Lymphostat-B
162167|NCT02119156|rebound
162168|NCT02119156|SELENA SLEDAI
162169|NCT02119156|Systemic Lupus Erythematosus
162170|NCT02119156|immunogenicity
162171|NCT02119143|common cold, immunity, oxidative stress
162172|NCT02119130|cluster randomized trial
162173|NCT02119130|interferon-gamma
162174|NCT02119130|tuberculin test
162175|NCT02119130|operational comparison
162176|NCT02119130|cost effectiveness
162177|NCT02119130|qualitative evaluation
162178|NCT02119117|mtDNA
162179|NCT02119117|aneuploidy
162180|NCT02119117|IVF
162181|NCT02119117|blastocyst
162182|NCT02119117|COQ10
162183|NCT02119091|QT prolongation
162184|NCT02119091|Chinese
162185|NCT02119091|Caucasian
162186|NCT02119091|Moxifloxacin
162187|NCT02119078|Geriatrics
162188|NCT02119078|Acute Care for Elders
162189|NCT02119078|Geriatric syndromes
162190|NCT02119078|Delirium
162191|NCT02119078|Falls
162192|NCT02119078|Polypharmacy
162193|NCT02119065|Yttrium-90 Radioembolization
162194|NCT02119065|hepatic malignancy
162195|NCT02119065|hepatic metastatic disease
162196|NCT02119039|Cross-linking
162197|NCT02119039|RGTA OTR4120 (CACICOL20)
162198|NCT02119026|metastatic colorectal cancer
162199|NCT02119026|Patients with metastatic colorectal cancer who did not receive
162200|NCT02119026|systemic treatment for their metastatic disease
162201|NCT02118987|Drug Desensitization
162202|NCT02118987|Hypersensitivity reactions to chemotherapeutic agents
162203|NCT02118974|Hysterectomy
162204|NCT02118974|Robot-assisted
162205|NCT02118974|Laparoscopy
162206|NCT02118961|Diphtheria
162207|NCT02118961|Tetanus
162208|NCT02118961|Pertussis
162209|NCT02118961|DTaP vaccine
162210|NCT02118961|Adolescents
162211|NCT02118948|abuse
162212|NCT02118948|sexual behavior
162213|NCT02118948|sexual risk reduction
162214|NCT02118948|behavioral intervention
162215|NCT02118896|Tacrolimus
162216|NCT02118896|FK506E
162217|NCT02118896|MR4
162218|NCT02118896|Advagraf
162219|NCT02118896|Kidney Transplantation
162220|NCT02118896|Renal Transplantation
162221|NCT02118896|Heart Transplantation
162222|NCT02118883|exercise
162223|NCT02118883|hydration
162224|NCT02118883|dehydration
162225|NCT02118883|rehydration
162226|NCT02118883|alkaline water
162227|NCT02118883|blood viscosity
162228|NCT02118883|plasma osmolality
162229|NCT02118883|bioimpedance
162230|NCT02118870|ACS patients
162231|NCT02118870|Older than 18 years
162232|NCT02118870|PCI
162233|NCT02118870|Combo stent
162234|NCT02118857|Microorganisms and foods
162235|NCT02118857|Fecal microbiota
162236|NCT02118857|Salivary microbiota
162237|NCT02118844|bariatric surgery
162238|NCT02118844|surgical conditions
162239|NCT02118844|deep neuromuscular blockade
162240|NCT02118831|macular degeneration
162241|NCT02118831|diabetic macular edema
162242|NCT02118831|vein occlusion
162243|NCT02118831|vascular endothelial growth factor
162244|NCT02118805|ALS
162245|NCT02118805|Myasthenia Gravis
162246|NCT02118805|Myopathy
162247|NCT02118805|Stroke
162248|NCT02118805|Parkinson's Disease
162249|NCT02118805|Bulbar
162250|NCT02118805|Orofacial
162251|NCT02118805|Ultrasound
162252|NCT02118805|Electrical Impedance Myography
162253|NCT02118792|atopic dermatitis
162254|NCT02118779|Myotonic Dystrophy Type 1
162255|NCT02118779|DM1
162256|NCT02118779|Physical Exercise
162257|NCT02118779|Cognitive Behavioural Therapy
162258|NCT02118779|Biomarkers
162259|NCT02118766|atopic dermatitis
162260|NCT02118753|ischemia-reperfusion injury
162261|NCT02118740|Autologous Stem Cells
162262|NCT02118740|Spinal Cord Injury
162263|NCT02118740|Preclinical
162264|NCT02118727|ALS
162265|NCT02118727|FTD
162266|NCT02118727|Tau
162267|NCT02118727|pNF-H/C3
162268|NCT02118714|Kidney Diseases
162269|NCT02118714|Urologic Diseases
162270|NCT02118714|Diabetes Complications
162271|NCT02118714|Diabetes Mellitus
162272|NCT02118714|Endocrine System Diseases
162273|NCT02118714|Diabetic Nephropathies
162274|NCT02118701|Shared decision making
162275|NCT02118701|Dementia
162276|NCT02118701|Long-term care
162277|NCT02118701|Nursing home
162278|NCT02118701|Care plan
162279|NCT02118636|Joint pain
162280|NCT02118636|Hormone receptor positive breast cancer
162281|NCT02118636|Estrogen
162282|NCT02118636|Androgen
162283|NCT02118623|Bipolar Disorder
162284|NCT02118623|Bipolar
162285|NCT02118623|Online intervention
162286|NCT02118623|Internet intervention
162287|NCT02118623|Self help
162288|NCT02118545|vWF
162289|NCT02118545|Liver Resection
162290|NCT02118545|Liver Dysfunction
162291|NCT02118545|Liver Regeneration
162292|NCT02118545|Postoperative Outcome
162293|NCT02118532|Atherosclerosis
162294|NCT02118532|Superficial Femoral Artery
162295|NCT02118532|Proximal Popliteal Artery
162296|NCT02118519|Bone marrow derived Mesenchymal Stem Cells
162297|NCT02118519|Knee articular cartilage injury
162298|NCT02118519|Chondrogenesis
162299|NCT02118519|orthopedics
162300|NCT02118506|Primary Parkinsonism.
162301|NCT02118506|Rehabilitation.
162302|NCT02118506|Biomechanics.
162303|NCT02118506|Neurological gait disorders.
162304|NCT02118493|Benign Biliary Stenosis
162305|NCT02118493|Laser Excision
162306|NCT02118480|Parkinson disease, cognitive rehabilitation, REHACOP
162307|NCT02118467|Shock
162308|NCT02118467|Vasopressor agents
162309|NCT02118467|Norepinephrine
162310|NCT02118467|Epinephrine
162311|NCT02118467|Phenylephrine
162312|NCT02118467|Vasopressin
162313|NCT02118467|Atrial fibrillation
162314|NCT02118467|Tachyarrhythmia
162315|NCT02118454|Medication adherence
162316|NCT02118454|Self-management
162317|NCT02118454|Depression
162318|NCT02118454|Coping
162319|NCT02118454|Social support
162320|NCT02118454|Mobile health
162321|NCT02118454|Antiretroviral treatment
162322|NCT02118428|whole blood
162323|NCT02118428|transfusion
162324|NCT02118428|Plasmodium
162325|NCT02118428|Malaria
162326|NCT02118428|Pathogen Reduction Technology
162327|NCT02118428|Whole blood transfusion
162328|NCT02118415|not eligible for surgery
162329|NCT02118415|efficacy of immunotherapy following RCTx
162330|NCT02118376|obesity; fat distribution; inflammation
162331|NCT02118363|upper limb
162332|NCT02118363|lower limb
162333|NCT02118363|monitoring
162334|NCT02118363|assessment
162335|NCT02118363|sensor
162336|NCT02118337|select advanced malignancies
162337|NCT02118324|Acute Lymphoblastic Leukemia
162338|NCT02118324|ALL
162339|NCT02118324|fitness intervention
162340|NCT02118311|Acute Leukemias
162341|NCT02118311|Burkitt's Lymphoma
162342|NCT02118311|Natural Killer Cell Malignancies
162343|NCT02118311|Chronic Myelogenous Leukemia
162344|NCT02118311|Myelodysplastic Syndrome
162345|NCT02118311|Large-Cell Lymphoma
162346|NCT02118311|Hodgkin Lymphoma
162347|NCT02118311|Multiple Myeloma
162348|NCT02118311|Chronic Lymphocytic Leukemia
162349|NCT02118311|Small Lymphocytic Lymphoma
162350|NCT02118311|Marginal Zone B-Cell Lymphoma
162351|NCT02118311|Follicular Lymphoma:
162352|NCT02118311|Lymphoplasmacytic Lymphoma
162353|NCT02118311|Mantle-Cell Lymphoma
162354|NCT02118311|Prolymphocytic Leukemia
162355|NCT02118285|Ovarian cancer
162356|NCT02118285|Fallopian cancer
162357|NCT02118285|Primary peritoneal cancer
162358|NCT02118259|Multidisciplinary review of drug prescriptions
162359|NCT02118259|Adverse drug events geriatric risk score
162360|NCT02118259|Residence for dependent elderly
162361|NCT02118246|Knee pain,Dry Needling, kinesioTape,Trigger point
162362|NCT02118233|carotid
162363|NCT02118233|stenosis
162364|NCT02118233|surgery
162365|NCT02118233|cognitive
162366|NCT02118233|unilateral
162367|NCT02118207|SCUBA diving
162368|NCT02118207|Exercise
162369|NCT02118207|Microparticles
162370|NCT02118207|Repetitive diving
162371|NCT02118207|Endothelial function
162372|NCT02118194|paraplegia
162373|NCT02118194|paralysis
162374|NCT02118194|robotics
162375|NCT02118194|walking
162376|NCT02118194|immobilization
162377|NCT02118168|HIV
162378|NCT02118168|HAART
162379|NCT02118168|Tat Protein
162380|NCT02118129|Vitamin D
162381|NCT02118129|Intervention
162382|NCT02118129|Behaviour
162383|NCT02118129|Mobile app
162384|NCT02118116|ASIST, gatekeeper, suicide, intervention, First Nations, Aboriginal, educational, prevention, safety
162385|NCT02118103|Lumbosacral Region
162386|NCT02118103|Psychomotor Performance
162387|NCT02118103|Manipulation, Spinal
162388|NCT02118090|malaria
162389|NCT02118090|Plasmodium vivax
162390|NCT02118090|drug resistance
162391|NCT02118090|chloroquine
162392|NCT02118090|Cambodia
162393|NCT02118064|G17DT
162394|NCT02118064|irinotecan
162395|NCT02118064|Colorectal Cancer
162396|NCT02118051|Infertility
162397|NCT02118051|IVF
162398|NCT02118051|Corifollitropin Alfa treatment
162399|NCT02118051|Ovarian stimulation
162400|NCT02118038|Postpartum haemorrhage
162401|NCT02118038|Sulprostone
162402|NCT02118038|Cardiac impact
162403|NCT02118038|Emotional impact
162404|NCT02118038|Cardiac magnetic imaging resonance
162405|NCT02118025|Off-pump bypass graft surgery
162406|NCT02118025|Mini extracorporeal circulation bypass surgery
162407|NCT02118012|Chlorcyclizine HCL
162408|NCT02118012|Direct Acting Antivirals
162409|NCT02118012|Ribavirin
162410|NCT02118012|Hepatitis C
162411|NCT02117999|corneal cross-linking
162412|NCT02117999|transepithelial corneal cross-linking
162413|NCT02117999|iontophoresis
162414|NCT02117999|progressive keratoconus
162415|NCT02117986|critically ill patients
162416|NCT02117986|colistin dosing
162417|NCT02117986|multidrug resistant bacteria
162418|NCT02117960|atherosclerotic
162419|NCT02117960|BMP-4
162420|NCT02117960|YKL40
162421|NCT02117960|HSP70
162422|NCT02117960|HSP27
162423|NCT02117947|child secondhand smoke
162424|NCT02117947|maternal smoking
162425|NCT02117947|tobacco
162426|NCT02117947|nicotine
162427|NCT02117947|behavioral counseling
162428|NCT02117947|low-income
162429|NCT02117947|underserved
162430|NCT02117934|HBV vaccine
162431|NCT02117934|HEPLISAV-B
162432|NCT02117934|Hepatitis B vaccine
162433|NCT02117934|Hepatitis B
162434|NCT02117934|Hepatitis
162435|NCT02117934|Hepatitis B virus (HBV)
162436|NCT02117934|Prevention and Control
162437|NCT02117934|Healthy
162438|NCT02117934|Healthy volunteers
162439|NCT02117921|Mind Body Syndrome
162440|NCT02117921|MBS
162441|NCT02117921|Chronic Pain
162442|NCT02117908|prevention
162443|NCT02117908|radiofrequency treatment
162444|NCT02117908|lung cancer ablation
162445|NCT02117895|Distal Pancreatectomy
162446|NCT02117895|Celiac Plexus
162447|NCT02117895|Resection
162448|NCT02117895|Pancreatic Cancer
162449|NCT02117895|Body and Tail
162450|NCT02117882|lateral approach, bone augmentation , sinus floor elevation
162451|NCT02117869|Grapefruit juice
162452|NCT02117856|Implant-Supported Denture
162453|NCT02117856|Single-Implant Denture
162454|NCT02117856|Patient Satisfaction
162455|NCT02117856|Edentulous Mandible
162456|NCT02117856|Dental Implants
162457|NCT02117856|Standard of Care
162458|NCT02117856|Randomized Clinical Trial
162459|NCT02117830|To determine
162460|NCT02117830|effects
162461|NCT02117830|once
162462|NCT02117830|daily
162463|NCT02117830|oral doses
162464|NCT02117830|Androxal
162465|NCT02117804|Discharge Planning
162466|NCT02117804|Decision Support
162467|NCT02117791|Riociguat, Adempas, sGC stimulator, CTEPH, Japan, PMS
162468|NCT02117765|T1D
162469|NCT02117765|ustekinumab
162470|NCT02117765|new-onset
162471|NCT02117765|diabetes
162472|NCT02117726|Sedation;
162473|NCT02117726|ARDS;
162474|NCT02117726|Mechanical ventilation
162475|NCT02117726|Hypnotics
162476|NCT02117726|Antianxiety Drugs
162477|NCT02117726|Causing
162478|NCT02117726|Adverse Effects
162479|NCT02117726|Therapeutic Use
162480|NCT02117700|fatty liver
162481|NCT02117700|obesity
162482|NCT02117700|children
162483|NCT02117700|oxidative stress
162484|NCT02117700|antioxidants
162485|NCT02117674|colonoscopy
162486|NCT02117674|adenoma detection rate
162487|NCT02117674|full spectrum colonoscopy
162488|NCT02117674|right colon retroflexion
162489|NCT02117674|feasibility
162490|NCT02117661|L-carnitine
162491|NCT02117661|Metabolic syndrome
162492|NCT02117661|Atherosclerosis
162493|NCT02117661|Coronary artery disease
162494|NCT02117661|Carotid
162495|NCT02117661|Plaque
162496|NCT02117661|Cardiovascular disease
162497|NCT02117661|Heart disease
162498|NCT02117661|Vascular disease
162499|NCT02117648|advanced cancer
162500|NCT02117648|metastatic cancer
162501|NCT02117635|Efficacy
162502|NCT02117635|Non comparative
162503|NCT02117635|Neural stem cells
162504|NCT02117635|Intracranial administration
162505|NCT02117609|Elderly
162506|NCT02117609|Nursing home
162507|NCT02117609|Functional impairment
162508|NCT02117609|High-protein oral supplement
162509|NCT02117596|Pediatric
162510|NCT02117596|Renal
162511|NCT02117596|Transplant
162512|NCT02117583|pharmacokinetics
162513|NCT02117583|relative bioavailability
162514|NCT02117583|food effects
162515|NCT02117583|oxycodone
162516|NCT02117570|Clostridium difficile
162517|NCT02117570|vaccine
162518|NCT02117557|Single-incision
162519|NCT02117557|Laparoscopy
162520|NCT02117557|Colorectal Cancer
162521|NCT02117544|Contact lens
162522|NCT02117544|Presbyopia
162523|NCT02117544|Multifocal
162524|NCT02117518|type 1 diabetes
162525|NCT02117518|autoreactive T cells
162526|NCT02117518|beta cell peptides
162527|NCT02117518|genetically modified T cells
162528|NCT02117518|mRNA electroporation
162529|NCT02117505|Biological Availability
162530|NCT02117505|JNJ-39220675
162531|NCT02117505|Healthy
162532|NCT02117505|Phase 1
162533|NCT02117492|hysterectomy
162534|NCT02117492|vaginal cuff
162535|NCT02117479|Metastatic pancreatic cancer
162536|NCT02117479|Metastatic pancreatic adenocarcinoma that is recurrent
162537|NCT02117466|cetuximab
162538|NCT02117466|PET-imaging
162539|NCT02117453|ANCA vasculitis
162540|NCT02117453|Statin
162541|NCT02117453|Subclinical markers of atherosclerosis
162542|NCT02117453|Cardiovascular events
162543|NCT02117453|Myocardial infarction
162544|NCT02117453|Stroke
162545|NCT02117453|Arterial revascularization
162546|NCT02117453|Unstable angina
162547|NCT02117453|Death
162548|NCT02117440|Lung Cancer
162549|NCT02117440|Lung Neoplasms
162550|NCT02117414|Magnetic Resonance Imaging (MRI)
162551|NCT02117388|Older adults
162552|NCT02117388|insomnia
162553|NCT02117388|CBT-I (cognitive behavioral therapy-insomnia)
162554|NCT02117388|Behavioral Therapy
162555|NCT02117388|SRT (sleep restriction therapy)
162556|NCT02117388|Cognitive Therapy
162557|NCT02117375|multiple sclerosis
162558|NCT02117375|spinal cord
162559|NCT02117375|MRI
162560|NCT02117375|longitudinal study
162561|NCT02117375|disability
162562|NCT02117362|Melanoma
162563|NCT02117362|Ipilimumab
162564|NCT02117362|Yervoy
162565|NCT02117362|Galectin
162566|NCT02117362|GR-MD-02
162567|NCT02117362|galactoarabino-rhamnogalacturonate
162568|NCT02117362|galectin-3 inhibitor
162569|NCT02117362|Providence Health & Services
162570|NCT02117362|Earle A. Chiles Research Institute
162571|NCT02117362|Robert W. Franz Cancer Center
162572|NCT02117362|Immunotherapy
162573|NCT02117349|surgical hemostasis
162574|NCT02117349|bleeding
162575|NCT02117349|fibrin sealant
162576|NCT02117349|fibrinogen
162577|NCT02117349|thrombin
162578|NCT02117349|spray dried
162579|NCT02117323|corneal opacities
162580|NCT02117323|Optical coherence tomography
162581|NCT02117284|positron emission tomography (PET)
162582|NCT02117284|Rubidium-82
162583|NCT02117284|myocardial perfusion imaging
162584|NCT02117284|automated elution system
162585|NCT02117284|controlled radioactivity delivery
162586|NCT02117271|obstructive sleep apnea
162587|NCT02117271|treatment
162588|NCT02117271|placebo
162589|NCT02117271|appearance
162590|NCT02117271|skin quality
162591|NCT02117258|Z-360, Pancreatic cancer, Pancreatic Adenocarcinoma
162592|NCT02117245|Food effect on MGCD265 bioavailability in healthy volunteers
162593|NCT02117232|colonoscopy
162594|NCT02117232|cecal intubation
162595|NCT02117232|carbon dioxide insufflation
162596|NCT02117219|Myelodysplastic syndrome
162597|NCT02117219|MDS
162598|NCT02117206|L-arginine
162599|NCT02117180|functional gastrointestinal disorders
162600|NCT02117180|FGID
162601|NCT02117180|children
162602|NCT02117180|FODMAP
162603|NCT02117154|Continuous Glucose Monitoring System
162604|NCT02117154|HbA1c
162605|NCT02117154|Diabetes Mellitus, Type 2
162606|NCT02117141|Food Effect
162607|NCT02117141|Pharmacokinetics
162608|NCT02117128|Tranexamic Acid
162609|NCT02117128|Antifibrinolytic
162610|NCT02117128|Blood transfusion
162611|NCT02117128|Total knee arthroplasty
162612|NCT02117076|Restless leg syndrome
162613|NCT02117076|RLS
162614|NCT02117076|gabapentin
162615|NCT02117076|gabapentin enacarbil
162616|NCT02117076|Neurontin
162617|NCT02117076|Horizant
162618|NCT02117050|Multiple Sclerosis
162619|NCT02117050|Rebif ®
162620|NCT02117050|Tecfidera ™
162621|NCT02117050|treatment change
162622|NCT02117024|lung
162623|NCT02117024|cancer
162624|NCT02117024|gp96
162625|NCT02117024|vaccine
162626|NCT02117024|immunotherapy
162627|NCT02117024|Heat Biologics
162628|NCT02117024|cyclophosphamide
162629|NCT02117024|vinorelbine
162630|NCT02117024|erlotinib
162631|NCT02117024|gemcitabine
162632|NCT02117024|paclitaxel
162633|NCT02117024|docetaxel
162634|NCT02117024|pemetrexed
162635|NCT02116998|GEN-004
162636|NCT02116998|Aluminum hydroxide
162637|NCT02116998|Vaccine
162638|NCT02116998|Streptococcus pneumoniae
162639|NCT02116998|Pneumococcal Infections
162640|NCT02116998|Strep pneumoniae
162641|NCT02116998|Pneumonia
162642|NCT02116985|Dual-Loop TCI
162643|NCT02116985|NI
162644|NCT02116985|Laparoscopic Cholecystectomy
162645|NCT02116972|Osteoarthritis
162646|NCT02116972|Knee
162647|NCT02116972|pain
162648|NCT02116972|steroid
162649|NCT02116972|intra-articular
162650|NCT02116972|injection
162651|NCT02116959|Systemic
162652|NCT02116959|Chemotherapy
162653|NCT02116959|Melphalan
162654|NCT02116933|Autologous Fat Grafting
162655|NCT02116933|Breast Augmentation
162656|NCT02116933|Stromal Vascular Fraction
162657|NCT02116933|Adipose Derived Stem Cell
162658|NCT02116920|CIN
162659|NCT02116920|HPV DNA
162660|NCT02116920|mRNA E6/E7
162661|NCT02116920|CIN triage
162662|NCT02116920|Cervix Biopsy
162663|NCT02116920|VIA
162664|NCT02116920|Cervix Cancer
162665|NCT02116907|Healthy
162666|NCT02116907|Male Subjects
162667|NCT02116894|Colorectal cancer
162668|NCT02116894|PF-03446962
162669|NCT02116894|regorafenib
162670|NCT02116881|Incisional hernia
162671|NCT02116881|colorectal surgery
162672|NCT02116881|bowel obstruction
162673|NCT02116868|Pupillometry
162674|NCT02116868|Pupillary reflex
162675|NCT02116868|Analgesia
162676|NCT02116868|Laparoscopic surgery
162677|NCT02116868|Total intravenous anesthesia
162678|NCT02116868|Target controlled infusion
162679|NCT02116803|solid tumors,
162680|NCT02116803|TKI258
162681|NCT02116790|acute
162682|NCT02116790|pain
162683|NCT02116764|Hematopoietic (Stem) Cell Transplantation
162684|NCT02116764|Primary Immune Deficiency Consortium
162685|NCT02116751|HIV, antiretroviral, toxicity, eGFR, tubular disease, BMD
162686|NCT02116738|flap
162687|NCT02116738|pilonidal sinus
162688|NCT02116738|vas
162689|NCT02116738|recurrence
162690|NCT02116712|LAM
162691|NCT02116712|saracatinib
162692|NCT02116712|Lymphangioleiomyomatosis
162693|NCT02116699|oropharyngeal
162694|NCT02116699|colostrum
162695|NCT02116699|mother's milk
162696|NCT02116699|premature
162697|NCT02116699|neonate
162698|NCT02116699|infection
162699|NCT02116699|necrotizing enterocolitis
162700|NCT02116699|ventilator-associated pneumonia
162701|NCT02116699|breastmilk
162702|NCT02116699|human milk
162703|NCT02116699|late-onset sepsis
162704|NCT02116699|microbiome
162705|NCT02116699|antioxidant
162706|NCT02116699|enteral feeds
162707|NCT02116686|chronic heart failure
162708|NCT02116686|Polysomnography
162709|NCT02116686|Sleep Apnea Syndromes
162710|NCT02116686|Electrocardiogram
162711|NCT02116673|Head injury
162712|NCT02116673|Concussion
162713|NCT02116673|Cognitive rest
162714|NCT02116673|Emergency department
162715|NCT02116647|Gender discrimination
162716|NCT02116647|Psychoanalysis
162717|NCT02116647|Randomized controlled trial
162718|NCT02116621|Musculoskeletal pain
162719|NCT02116621|Chronic pain
162720|NCT02116621|Patient centered outcomes research
162721|NCT02116621|Physician patient relationship
162722|NCT02116621|Mobile applications
162723|NCT02116595|volunteers
162724|NCT02116582|MDV3100
162725|NCT02116582|Xtandi
162726|NCT02116582|Abiraterone
162727|NCT02116582|Metastatic Castration-Resistant Prostate Cancer
162728|NCT02116582|Enzalutamide
162729|NCT02116569|Multiple Myeloma
162730|NCT02116569|Daratumumab
162731|NCT02116569|JNJ-54767414
162732|NCT02116569|Phase 1
162733|NCT02116569|Relapse
162734|NCT02116569|Refractory
162735|NCT02116556|Alcoholic Hepatitis
162736|NCT02116556|Bacterial Infections
162737|NCT02116556|Acute-on-Chronic Liver Failure
162738|NCT02116543|Hepatitis C
162739|NCT02116543|HCV
162740|NCT02116517|obese women
162741|NCT02116517|high LDL-C
162742|NCT02116504|Rheumatoid arthritis
162743|NCT02116504|Juvenile Idiopathic Arthritis
162744|NCT02116504|Biopharmaceutical
162745|NCT02116504|Immunogenicity
162746|NCT02116504|Anti-Drug Antibody
162747|NCT02116504|Prediction
162748|NCT02116478|plantar fasciitis
162749|NCT02116478|gastrocnemius recession
162750|NCT02116439|Violence
162751|NCT02116426|copeptin
162752|NCT02116426|troponin HS
162753|NCT02116413|fluid challenge
162754|NCT02116413|fluid resuscitation
162755|NCT02116400|Suicidal ideation
162756|NCT02116387|Proprioception
162757|NCT02116348|Cerebral palsy children
162758|NCT02116348|Cerebrolysin
162759|NCT02116348|Sleep questionnaire
162760|NCT02116348|Quality of life
162761|NCT02116348|Bayley III scale
162762|NCT02116335|arterial stiffness
162763|NCT02116335|flow-mediated dilation
162764|NCT02116335|endothelial function
162765|NCT02116335|pulse wave velocity
162766|NCT02116335|inflammation
162767|NCT02116335|oxidative stress
162768|NCT02116335|Nitric Oxide
162769|NCT02116335|Cold Pressor Test
162770|NCT02116335|physio flow
162771|NCT02116335|Bosentan
162772|NCT02116335|Endothelin Receptor
162773|NCT02116335|Endothelin-1
162774|NCT02116335|BMI
162775|NCT02116335|stress
162776|NCT02116335|blood pressure
162777|NCT02116283|smoking
162778|NCT02116283|healthy
162779|NCT02116283|smartphone
162780|NCT02116270|Renal Failure
162781|NCT02116270|Dialysis
162782|NCT02116270|Biological Aging
162783|NCT02116257|Nausea
162784|NCT02116257|Vomiting
162785|NCT02116244|Dry Eye
162786|NCT02116244|Civamide
162787|NCT02116244|Zucapsaicin
162788|NCT02116244|Neuropeptides
162789|NCT02116244|TRPV-1
162790|NCT02116231|Nasopharyngeal neoplasm;IMRT; Concurrent chemotherapy
162791|NCT02116218|Traditional Chinese Medicine
162792|NCT02116218|acupuncture
162793|NCT02116218|complementary alternative medicine
162794|NCT02116218|cancer pain
162795|NCT02116218|emergency department
162796|NCT02116205|Hantaan virus
162797|NCT02116205|Puumala virus
162798|NCT02116205|HFRS
162799|NCT02116192|Non-alcoholic Fatty Liver Disease
162800|NCT02116192|Adolescent
162801|NCT02116179|Human Immunodeficiency Virus
162802|NCT02116179|Acquired Immunodeficiency Syndrome
162803|NCT02116179|Hepatitis C
162804|NCT02116179|Hispanic
162805|NCT02116179|Criminal Justice
162806|NCT02116166|aging
162807|NCT02116166|sarcopenia
162808|NCT02116166|mitochondria
162809|NCT02116166|skeletal muscle
162810|NCT02116166|inflammation
162811|NCT02116153|Cardiac Troponin T
162812|NCT02116153|Micro-RNA
162813|NCT02116153|Sensitivity
162814|NCT02116153|Specificity
162815|NCT02116140|positron emission tomography
162816|NCT02116140|[11C]hydroxyephedrine (HED)
162817|NCT02116140|[11C]acetate
162818|NCT02116140|Adaptive Servoventilation (ASV)
162819|NCT02116140|Myocardial Energetics
162820|NCT02116140|work-metabolic index (WMI)
162821|NCT02116140|Myocardial sympathetic neuron (SN) presynaptic function continuous positive airway pressure
162822|NCT02116140|heart rate variability
162823|NCT02116140|overnight polysomnogram
162824|NCT02116140|Plasma Norepinephrine
162825|NCT02116140|Urine Normetanephrine
162826|NCT02116140|Quality of Life
162827|NCT02116127|Depression
162828|NCT02116127|Pregnancy
162829|NCT02116127|Transcranial Direct Current Stimulation
162830|NCT02116114|Pulmonary Disease, Chronic Obstructive
162831|NCT02116101|Intestinal Health
162832|NCT02116101|Prebiotics
162833|NCT02116101|Blood Lipid
162834|NCT02116088|Externalizing problem behavior, teacher training, teacher coaching, primary school, elementary school, continuing professional development, advanced training
162835|NCT02116049|Disclosure, intervention
162836|NCT02116049|HIV
162837|NCT02116049|prevention
162838|NCT02116049|Disclosure Intervention
162839|NCT02116049|Attention Control Case Management
162840|NCT02116036|Antiphospholipid Antibody Syndrome
162841|NCT02116036|Rivaroxaban
162842|NCT02116036|Thromboembolism
162843|NCT02116036|Bleeding
162844|NCT02116036|Feasibility
162845|NCT02116023|Satiety, beverage, crossover
162846|NCT02116010|Wound Infection in burned patient
162847|NCT02115971|chronic
162848|NCT02115971|functional
162849|NCT02115971|instability
162850|NCT02115971|ankle
162851|NCT02115945|chronic postoperative pain
162852|NCT02115945|total knee arthroplasty
162853|NCT02115945|femoral block
162854|NCT02115945|We aimed to compare the effects of epidural and femoral block on acute and chronic postoperative pain.
162855|NCT02115932|Diabetes Mellitus
162856|NCT02115932|Diabetes Mellitus, Type 2
162857|NCT02115932|Diabetes Complications
162858|NCT02115932|Diabetic Foot
162859|NCT02115932|Diabetic Neuropathies
162860|NCT02115932|Gait
162861|NCT02115932|Balance, Postural
162862|NCT02115932|Muscle Strength
162863|NCT02115932|Exercise Therapy
162864|NCT02115932|Physical Therapy Modalities
162865|NCT02115932|Endocrine System Diseases
162866|NCT02115932|Peripheral Nervous System Diseases
162867|NCT02115932|Metabolic Diseases
162868|NCT02115932|Glucose Metabolism Diseases
162869|NCT02115932|Quality of Life
162870|NCT02115932|Training
162871|NCT02115919|condyloma
162872|NCT02115919|HIV
162873|NCT02115893|Nitrate
162874|NCT02115893|Performance
162875|NCT02115893|Sports
162876|NCT02115880|Depression
162877|NCT02115880|Prevention
162878|NCT02115880|Adolescent
162879|NCT02115880|Child
162880|NCT02115880|Randomised Controlled Trial
162881|NCT02115880|Risk
162882|NCT02115880|Cognitive behavioural therapy
162883|NCT02115880|Group-based therapy
162884|NCT02115867|diverticular disease
162885|NCT02115867|diverticulitis
162886|NCT02115867|diverticulosis
162887|NCT02115854|usefullness of labial biopsy to distinguish between tuberculosis and sarcoidosis
162888|NCT02115841|Transcutaneous Nerve Stimulation
162889|NCT02115841|serial reaction time task
162890|NCT02115841|functional near infrared spectroscopy
162891|NCT02115841|transcranial magnetic stimulation
162892|NCT02115828|Vismodegib
162893|NCT02115828|Metastatic Castration-Resistant Prostate Cancer
162894|NCT02115828|Accessible Metastatic Lesions for Tumor Biopsy
162895|NCT02115815|Respiratory Syncytial Virus (RSV)
162896|NCT02115815|MEDI7510
162897|NCT02115789|cicatrix
162898|NCT02115789|Demonstrate
162899|NCT02115789|that there
162900|NCT02115789|is no perception of superiority
162901|NCT02115776|bacteremia
162902|NCT02115776|prophylaxis
162903|NCT02115776|antibiotics
162904|NCT02115776|dentistry
162905|NCT02115763|physically active,
162906|NCT02115763|18-35 year old men
162907|NCT02115750|CHS-0214
162908|NCT02115750|Enbrel
162909|NCT02115750|RA
162910|NCT02115750|Biosimilar
162911|NCT02115750|Etanercept
162912|NCT02115724|Low childhood SES
162913|NCT02115724|Early Life Stress
162914|NCT02115724|Endothelial function
162915|NCT02115724|Flow mediated dilation
162916|NCT02115724|Cardiovascular disease
162917|NCT02115724|Subcutaneous adipose arterioles
162918|NCT02115711|India
162919|NCT02115711|Cardiovascular risk factors
162920|NCT02115711|Community health workers
162921|NCT02115711|Hypertension
162922|NCT02115711|Diabetes
162923|NCT02115711|Smoking
162924|NCT02115698|Sarcopenia
162925|NCT02115698|Frailty
162926|NCT02115698|Ageing
162927|NCT02115698|Protein supplementation
162928|NCT02115698|Protein quality
162929|NCT02115698|Exercise training
162930|NCT02115698|Muscle protein turnover
162931|NCT02115685|spinal cord injury
162932|NCT02115685|sympathetic nervous system
162933|NCT02115685|locomotor training
162934|NCT02115685|exercise
162935|NCT02115672|Chronic myeloid leukemia
162936|NCT02115672|imatinib
162937|NCT02115672|CXCR4 antagonist
162938|NCT02115672|BL-8040
162939|NCT02115659|ADPKD
162940|NCT02115659|triptolide
162941|NCT02115646|burn
162942|NCT02115646|scar
162943|NCT02115620|Heart failure
162944|NCT02115620|Cardiac failure
162945|NCT02115620|Congestive Heart Failure
162946|NCT02115620|Cardiomyopathy
162947|NCT02115620|Myocardial Failure
162948|NCT02115620|Telemedicine
162949|NCT02115620|Telehealth
162950|NCT02115620|Remote Consultation
162951|NCT02115607|Breast cancer
162952|NCT02115607|Interstitial fluid pressure
162953|NCT02115607|Angiogenesis
162954|NCT02115607|Contrast enhanced ultrasound imaging
162955|NCT02115607|Subharmonic imaging
162956|NCT02115607|Subharmonic pressure estimation
162957|NCT02115594|metastatic breast cancer
162958|NCT02115594|estrogen receptor
162959|NCT02115594|Histone Deacetylase Inhibitors
162960|NCT02115594|Histone Deacetylases
162961|NCT02115594|HDAC inhibitors
162962|NCT02115594|selective estrogen receptor modulator
162963|NCT02115594|estrogen receptor modulator, selective
162964|NCT02115594|Estrogen receptor modulators, selective
162965|NCT02115581|Coenzyme O10
162966|NCT02115581|Children
162967|NCT02115581|Idiopathic Dilated Cardiomyopathy
162968|NCT02115555|type 1
162969|NCT02115555|diabetes
162970|NCT02115555|adolescents
162971|NCT02115555|heath information technology
162972|NCT02115542|biliary
162973|NCT02115542|liver
162974|NCT02115542|Refractory Advanced Biliary Cancers
162975|NCT02115542|gallbladder cancer
162976|NCT02115542|carcinoma
162977|NCT02115542|intra-hepatic biliary system
162978|NCT02115542|extra-hepatic biliary system
162979|NCT02115542|gall bladder
162980|NCT02115542|unresectable
162981|NCT02115542|locally advanced
162982|NCT02115542|metastatic disease
162983|NCT02115542|Bile Duct Diseases
162984|NCT02115542|Gallbladder Diseases
162985|NCT02115542|regorafenib
162986|NCT02115542|stivarga
162987|NCT02115542|Bay 73-4506
162988|NCT02115542|multikinase inhibitor
162989|NCT02115516|Malaria
162990|NCT02115516|Plasmodium falciparum malaria
162991|NCT02115516|Antimalarial chemoprophylaxis
162992|NCT02115516|PfSPZ Challenge
162993|NCT02115516|Cryopreserved Plasmodium Falciparum Sporozoites
162994|NCT02115516|PfSPZ-CVac
162995|NCT02115490|Alveolar bone
162996|NCT02115490|Bisphosphonates
162997|NCT02115490|Cone-beam CT
162998|NCT02115490|Osteoporosis
162999|NCT02115477|Uterus cancer
163000|NCT02115477|Hysterectomy
163001|NCT02115477|Lymphadenectomy
163002|NCT02115477|Lymphedema
163003|NCT02115464|Metformin
163004|NCT02115464|Non-small cell lung cancer
163005|NCT02115464|Locally advanced
163006|NCT02115464|Chemo-radiotherapy
163007|NCT02115464|Lung cancer treatment
163008|NCT02115399|Dermatitis
163009|NCT02115399|Staphylococcus
163010|NCT02115399|Staphylococcus aureus
163011|NCT02115399|Dermatitis, Atopic
163012|NCT02115399|Non-atopic controls
163013|NCT02115386|Ph+ CML, chronic myeloid leukemia
163014|NCT02115373|Hepatocellular Carcinoma
163015|NCT02115373|c-Met inhibitor
163016|NCT02115373|Phase 1b
163017|NCT02115373|Sorafenib
163018|NCT02115373|MSC2156119J
163019|NCT02115360|epidural calcitonin
163020|NCT02115360|amputation
163021|NCT02115360|postoperative pain
163022|NCT02115360|Later Complication
163023|NCT02115334|Developmental delay
163024|NCT02115334|Early Intervention
163025|NCT02115334|Home programs
163026|NCT02115334|Preschool activities
163027|NCT02115295|Leukemia
163028|NCT02115295|Acute Myeloid Leukemia
163029|NCT02115295|AML
163030|NCT02115295|High Risk Myelodysplastic Syndrome
163031|NCT02115295|HR MDS
163032|NCT02115295|Myeloid Blast Phase of Chronic Myeloid Leukemia
163033|NCT02115295|CML
163034|NCT02115295|Acute Biphenotypic Leukemia
163035|NCT02115295|Cladribine
163036|NCT02115295|Leustatin
163037|NCT02115295|2-CdA
163038|NCT02115295|Cytarabine
163039|NCT02115295|Ara-C
163040|NCT02115295|Cytosar
163041|NCT02115295|DepoCyt
163042|NCT02115295|Cytosine Arabinosine Hydrochloride
163043|NCT02115295|Idarubicin
163044|NCT02115295|Idamycin
163045|NCT02115295|Phone calls
163046|NCT02115269|Indoprocaf
163047|NCT02115269|Indomethacin
163048|NCT02115269|Caffeine
163049|NCT02115269|Prochlorperazine
163050|NCT02115269|Migraine with Aura
163051|NCT02115269|Migraine without Aura
163052|NCT02115269|Tension-Type Headache
163053|NCT02115256|External Cephalic Version
163054|NCT02115256|breech
163055|NCT02115230|Heart Failure
163056|NCT02115230|Heart Failure, Diastolic
163057|NCT02115230|Hypertension
163058|NCT02115230|Renal Denervation
163059|NCT02115230|Irrigated Radiofrequency Catheter
163060|NCT02115217|Kinestiotaping
163061|NCT02115217|Basketball players
163062|NCT02115217|Effect of kinesiotaping
163063|NCT02115217|on postural stability
163064|NCT02115191|2-octylcyanoacrylate
163065|NCT02115191|Urethrocutaneous fistulas.
163066|NCT02115191|Closure.
163067|NCT02115191|Recurrence.
163068|NCT02115178|Hemodynamic changes
163069|NCT02115178|Spinal anesthesia
163070|NCT02115178|Patient position
163071|NCT02115178|Impedance cardiography
163072|NCT02115152|Capecitabine
163073|NCT02115152|Neoadjuvant therapy
163074|NCT02115152|Early Breast Cancer
163075|NCT02115139|melanoma
163076|NCT02115139|brain
163077|NCT02115139|metastases
163078|NCT02115139|Patients with melanoma and brain metastases
163079|NCT02115113|Liver transplantation, everolimus, CNI-minimization, CNI-elimination, renal function
163080|NCT02115100|Paroxysmal atrial fibrillation
163081|NCT02115100|Persistent atrial fibrillation
163082|NCT02115100|Out of range hypertension
163083|NCT02115100|Signs of sympathetic overdrive
163084|NCT02115087|laparotomy
163085|NCT02115087|levobupivacaine
163086|NCT02115087|patient controlled analgesia
163087|NCT02115074|Low-grade gliomas
163088|NCT02115074|high-grade gliomas
163089|NCT02115074|optico-chiasmatic
163090|NCT02115074|relapsed
163091|NCT02115074|refractory
163092|NCT02115061|Gastric varices,coil,cyanoacrylate,treating gastric varices.
163093|NCT02115035|Multiple Myeloma
163094|NCT02115022|pancreatic cancer
163095|NCT02115022|resectability
163096|NCT02115022|endosonography (EUS)
163097|NCT02115022|multidetection computer tomography (MDCT)
163098|NCT02115022|staging
163099|NCT02115009|sacroiliac joint lumbopelvic ,chronic low back pain
163100|NCT02114996|mechanical ventilation
163101|NCT02114996|ischemic stroke
163102|NCT02114983|deep vein thrombosis
163103|NCT02114983|diagnostic accuracy
163104|NCT02114983|general practitioner
163105|NCT02114983|test
163106|NCT02114983|compression ultrasonography
163107|NCT02114983|ultrasound
163108|NCT02114970|Older Adults
163109|NCT02114970|Informed Consent
163110|NCT02114970|Technology
163111|NCT02114970|Tablet-delivered
163112|NCT02114957|bio-availability
163113|NCT02114957|decursin
163114|NCT02114957|decursinol angelate
163115|NCT02114957|decursinol
163116|NCT02114957|subjects
163117|NCT02114944|Do-not-intubate
163118|NCT02114944|DNI
163119|NCT02114944|Palliative treatment
163120|NCT02114944|Acute respiratory failure
163121|NCT02114944|Acute on chronic respiratory failure
163122|NCT02114944|Hypoxia
163123|NCT02114944|Respiratory acidosis
163124|NCT02114944|Hypercarbia
163125|NCT02114944|Non invasive ventilation
163126|NCT02114944|NIV
163127|NCT02114944|CPAP
163128|NCT02114944|Oxygen-therapy
163129|NCT02114944|High-flow oxygen therapy
163130|NCT02114931|arthritis
163131|NCT02114931|rheumatoid
163132|NCT02114918|obsessive compulsive disorder
163133|NCT02114918|children
163134|NCT02114918|adolescents
163135|NCT02114918|attention bias modification
163136|NCT02114905|Tourette's
163137|NCT02114905|Tic Disorder
163138|NCT02114905|CBIT
163139|NCT02114905|Dissemination
163140|NCT02114905|Occupational Therapist
163141|NCT02114892|metabolic syndrome
163142|NCT02114892|central obesity
163143|NCT02114892|resveratrol
163144|NCT02114892|insulin secretion
163145|NCT02114892|insulin sensitivity
163146|NCT02114879|Physical Therapy
163147|NCT02114879|Occupational Therapy
163148|NCT02114879|Rehabilitation
163149|NCT02114879|Older adults
163150|NCT02114879|Depression
163151|NCT02114879|Physical Functioning
163152|NCT02114827|Multiple Myeloma
163153|NCT02114814|Diabetes
163154|NCT02114814|Hispanic
163155|NCT02114814|Adult
163156|NCT02114814|Family Member
163157|NCT02114801|Cerebral Palsy;
163158|NCT02114801|Toothbrushing;
163159|NCT02114801|Dental Plaque
163160|NCT02114775|mild traumatic brain injury
163161|NCT02114775|growth hormone
163162|NCT02114775|fatigue
163163|NCT02114775|sildenafil
163164|NCT02114775|neurology
163165|NCT02114762|otitis media
163166|NCT02114762|eustachian tube
163167|NCT02114762|eustachian tube dysfunction
163168|NCT02114762|eustachian tube function testing
163169|NCT02114749|Healthy volunteers
163170|NCT02114749|Physiological variables : respiration and circulation
163171|NCT02114736|Stroke
163172|NCT02114736|Muscle spasticity
163173|NCT02114736|Stiff knee gait
163174|NCT02114736|Botulinum toxin
163175|NCT02114736|Tenotomy
163176|NCT02114723|Mediacal Taping concept
163177|NCT02114723|Neuromuscular bandage
163178|NCT02114723|Physiotherapy techniques
163179|NCT02114723|Kinesio Tape
163180|NCT02114710|coagulopathy
163181|NCT02114710|hydrocortisone
163182|NCT02114710|organ failure
163183|NCT02114697|Cancer survivorship, cardiovascular disease, stroke, TIA
163184|NCT02114658|Anaplastic and medullary thyroid carcinoma
163185|NCT02114658|Thyroid Neoplasms
163186|NCT02114645|Luteal phase support,GnRH agonist,ART cycles
163187|NCT02114632|ADHD, attention deficit/hyperactivity disorder, attention deficit disorder, inattention, cognitive skills, children, polyunsaturated fatty acids, PUFA
163188|NCT02114619|radioiodine therapy
163189|NCT02114619|Graves' disease
163190|NCT02114619|Hyperthyroidism
163191|NCT02114619|calculated dose
163192|NCT02114606|Eosinophilic Esophagitis
163193|NCT02114606|EoE
163194|NCT02114606|Cytosponge
163195|NCT02114593|Mental Health
163196|NCT02114593|Children
163197|NCT02114593|Parent support program
163198|NCT02114593|Somali families
163199|NCT02114593|Sweden
163200|NCT02114580|mild cognitive impairment
163201|NCT02114580|exercise
163202|NCT02114580|brain plasticity
163203|NCT02114580|FMRI
163204|NCT02114567|AECOPD
163205|NCT02114567|work of breathing
163206|NCT02114567|patient-ventilator synchrony
163207|NCT02114554|MELAS
163208|NCT02114554|MIDD
163209|NCT02114554|Heteroplasmy
163210|NCT02114528|Ventricular Tachycardia
163211|NCT02114528|Ventricular Arrhythmia
163212|NCT02114528|Anti-arrhythmic drugs
163213|NCT02114528|Catheter Ablation
163214|NCT02114528|ICD Shocks
163215|NCT02114515|Patient Navigators
163216|NCT02114515|Readmissions
163217|NCT02114515|Peer Coaching
163218|NCT02114502|Myeloma
163219|NCT02114502|Multiple myeloma
163220|NCT02114502|MM
163221|NCT02114502|Refractory
163222|NCT02114502|Relapsed
163223|NCT02114502|Stem Cell Transplant
163224|NCT02114502|SCT
163225|NCT02114502|Carfilzomib
163226|NCT02114502|SAHA
163227|NCT02114502|Vorinostat
163228|NCT02114502|Suberoylanilide Hydroxamic Acid
163229|NCT02114502|MSK-390
163230|NCT02114502|Zolinza
163231|NCT02114502|Gemcitabine
163232|NCT02114502|Gemcitabine Hydrochloride
163233|NCT02114502|Gemzar
163234|NCT02114502|Busulfan
163235|NCT02114502|Busulfex
163236|NCT02114502|Myleran
163237|NCT02114502|Palifermin
163238|NCT02114502|Kepivance
163239|NCT02114502|Dexamethasone
163240|NCT02114502|Decadron
163241|NCT02114502|Melphalan
163242|NCT02114502|Alkeran
163243|NCT02114502|Caphosol
163244|NCT02114502|Glutamine
163245|NCT02114502|Enterex
163246|NCT02114502|Glutapak-10
163247|NCT02114502|NutreStore
163248|NCT02114502|Resource
163249|NCT02114502|GlutaSolve
163250|NCT02114502|Sympt-X G.I.
163251|NCT02114502|Sympt-X
163252|NCT02114502|Pyridoxine
163253|NCT02114489|AOH
163254|NCT02114489|ibandronate
163255|NCT02114476|GDM
163256|NCT02114476|implant
163257|NCT02114476|diabetes mellitus
163258|NCT02114476|metabolic syndrome
163259|NCT02114463|Local analgesia system
163260|NCT02114463|Ropivacaine
163261|NCT02114463|Analgesic efficacy after operation
163262|NCT02114463|Postoperative
163263|NCT02114450|Stroke
163264|NCT02114450|Paresis
163265|NCT02114450|Gait rehabilitation
163266|NCT02114450|Human-Machine Interaction
163267|NCT02114450|Wearable Robotic Devices
163268|NCT02114437|Closed-Loop TCI
163269|NCT02114437|NI
163270|NCT02114437|Laparoscopic Cholecystectomy
163271|NCT02114424|Positional Obstructive sleep apnea syndrome (POSAS)
163272|NCT02114424|Obstructive sleep apnea syndrome (OSAS)
163273|NCT02114424|Apnea-Hypnea Index (AHI)
163274|NCT02114424|Sleep questionnaire
163275|NCT02114424|Positional sleep apnea belt
163276|NCT02114424|Adverse events
163277|NCT02114424|Compliance
163278|NCT02114385|Prevention
163279|NCT02114372|Alzheimer's disease
163280|NCT02114372|Mild Cognitive Impairment (MCI)
163281|NCT02114359|gastric cancer, elderly, chemotherapy
163282|NCT02114346|Computed Tomography Angiogram
163283|NCT02114346|Side Effects
163284|NCT02114346|Contrast-Induced Nephropathy
163285|NCT02114346|Prevention
163286|NCT02114333|Shingles vaccine
163287|NCT02114333|Immune response
163288|NCT02114333|Zoster vaccine
163289|NCT02114320|Endoscopic ultrasonography
163290|NCT02114320|Biliary drainage
163291|NCT02114320|Metal stent
163292|NCT02114307|electrical stimulation
163293|NCT02114307|venous insufficiency
163294|NCT02114307|post thrombotic syndrome
163295|NCT02114307|varicose veins
163296|NCT02114294|Patellofemoral pain syndrome
163297|NCT02114294|Anterior knee pain
163298|NCT02114294|Randomised controlled trial
163299|NCT02114294|Exercise intervention
163300|NCT02114294|Hip strengthening
163301|NCT02114294|Quadriceps based training
163302|NCT02114294|Anterior knee pain score
163303|NCT02114281|Oral Health
163304|NCT02114281|Periodontitis
163305|NCT02114281|Tooth cavities
163306|NCT02114281|Saliva
163307|NCT02114281|Halitosis
163308|NCT02114281|Mucosa
163309|NCT02114281|Chronic kidney disease
163310|NCT02114281|Inflammation
163311|NCT02114281|Nutrition
163312|NCT02114268|Respiratory Syncytial Virus, RSV
163313|NCT02114255|Influenza
163314|NCT02114255|Trained immunity
163315|NCT02114255|BCG
163316|NCT02114242|Parkinson's disease
163317|NCT02114242|multiple system atrophy
163318|NCT02114242|progressive supranuclear palsy
163319|NCT02114242|alpha-synuclein
163320|NCT02114229|Alisertib
163321|NCT02114229|MLN8237
163322|NCT02114229|AT/RT
163323|NCT02114229|MRT
163324|NCT02114190|Overweight Adolescents
163325|NCT02114190|Mindful Eating and Living
163326|NCT02114190|Family Systems
163327|NCT02114190|Body-Mass Index
163328|NCT02114190|Mindfulness
163329|NCT02114177|Hepatitis C Virus Infection
163330|NCT02114177|Simeprevir
163331|NCT02114177|Sofosbuvir
163332|NCT02114177|HCV
163333|NCT02114177|Cirrhosis
163334|NCT02114164|AirSeal
163335|NCT02114164|Trocar
163336|NCT02114164|Carbon Dioxide Exchange and Absorption
163337|NCT02114151|Hepatitis C Virus Infection
163338|NCT02114151|Simeprevir
163339|NCT02114151|Sofosbuvir
163340|NCT02114151|HCV
163341|NCT02114151|Cirrhosis
163342|NCT02114138|postoperative acute kidney injury
163343|NCT02114138|pAKI
163344|NCT02114138|stress injury on the kidney
163345|NCT02114138|chronic kidney disease
163346|NCT02114138|CKD
163347|NCT02114125|Physical activity
163348|NCT02114125|Cognitive training
163349|NCT02114112|Bronchopulmonary dysplasia
163350|NCT02114112|Continuous positive airway pressure pressure
163351|NCT02114112|Preterms
163352|NCT02114099|Kawasaki Disease
163353|NCT02114099|Aneurysm, Coronary
163354|NCT02114086|Observational Study
163355|NCT02114086|intraoperative Radiation of Breast Cancer
163356|NCT02114086|early and late effects of radiation
163357|NCT02114086|cosmesis and quality of life
163358|NCT02114073|glaucoma
163359|NCT02114073|trabeculectomy
163360|NCT02114073|cyclosporine
163361|NCT02114073|betamethasone
163362|NCT02114060|HSV
163363|NCT02114060|Herpes
163364|NCT02114060|genital infection
163365|NCT02114060|vaccine
163366|NCT02114034|Severe asthma,
163367|NCT02114034|child,
163368|NCT02114034|outcome,
163369|NCT02114021|Syndrome incidence after intubation
163370|NCT02114021|Betamethasone gel
163371|NCT02114021|lidocaine jelly
163372|NCT02114021|sore throat
163373|NCT02114021|cough
163374|NCT02114021|hoarseness of voice
163375|NCT02114008|Gastric emptying.
163376|NCT02114008|Residual gastric volume.
163377|NCT02114008|Preoperative fasting.
163378|NCT02114008|Morbid Obesity.
163379|NCT02114008|Diabetes.
163380|NCT02113995|Obesity, Morbid
163381|NCT02113995|Insulin Resistance
163382|NCT02113995|Acute-Phase Reaction
163383|NCT02113995|Gastroplasty
163384|NCT02113995|Length of Stay
163385|NCT02113995|Protocols
163386|NCT02113995|Randomized Controlled Trial.
163387|NCT02113969|Pelvic Organ Prolapse
163388|NCT02113969|Quality of Life
163389|NCT02113969|Symptoms
163390|NCT02113969|Pessary
163391|NCT02113969|Treatment
163392|NCT02113956|HIV Prevention
163393|NCT02113956|Adolescent Men who Have Sex with Men (AMSM)
163394|NCT02113956|Text-Messaging
163395|NCT02113956|Information-Motivation-Behavioral Skills(IMB)Model
163396|NCT02113917|infant, adolescent and adult Hemophagocytic Syndrome
163397|NCT02113917|Hemophagocytic lymphohistiocytosis
163398|NCT02113904|Netherton syndrome
163399|NCT02113904|Adalimumab
163400|NCT02113904|TNF-alpha
163401|NCT02113904|Orphan genetic syndrome
163402|NCT02113891|Antibody-mediated rejection
163403|NCT02113891|Complement blockade
163404|NCT02113891|Eculizumab
163405|NCT02113891|Kidney transplantation
163406|NCT02113878|Carcinoma, Squamous Cell of Head and Neck
163407|NCT02113878|Human Papillomavirus Positive Oropharyngeal Carcinoma
163408|NCT02113878|Hypopharyngeal Cancer
163409|NCT02113878|Early Invasive Cervical Squamous Cell Carcinoma
163410|NCT02113878|Carcinoma of Larynx
163411|NCT02113878|Cancer of Nasopharynx
163412|NCT02113852|Non small cell Lung Cancer
163413|NCT02113852|Heavy smokers
163414|NCT02113852|Treatment naive patients
163415|NCT02113839|Dyspnea perception
163416|NCT02113839|COPD
163417|NCT02113839|Exacerbations
163418|NCT02113839|CO2 rebreathing test
163419|NCT02113826|Pazopanib
163420|NCT02113826|Alveolar soft part sarcoma
163421|NCT02113813|irreversible EGFR inhibitor
163422|NCT02113813|Non-Small-Cell Lung Cancer
163423|NCT02113813|Midazolam
163424|NCT02113813|T790M resistance mutation
163425|NCT02113813|EGFR
163426|NCT02113813|NSCLC
163427|NCT02113813|Epidermal Growth Factor Receptor mutations
163428|NCT02113813|ASP8273
163429|NCT02113787|epilepsy
163430|NCT02113787|anticonvulsants
163431|NCT02113787|generic drugs
163432|NCT02113748|Pulmonary disease, chronic obstructive
163433|NCT02113748|Downhill walking
163434|NCT02113748|exercise
163435|NCT02113735|ARDS
163436|NCT02113735|Acute Respiratory Distress Syndrome
163437|NCT02113735|Acthar
163438|NCT02113735|ACTH
163439|NCT02113735|H.P. Acthar Gel
163440|NCT02113722|Sudden cardiac death
163441|NCT02113722|Ganglionectomy
163442|NCT02113722|Ventricular arrhythmia
163443|NCT02113722|Cardiac surgery
163444|NCT02113722|Implanted cardiac defibrillator
163445|NCT02113709|Amblyopia
163446|NCT02113709|Strabismus
163447|NCT02113709|Occlusion therapy
163448|NCT02113709|Visual improvement
163449|NCT02113696|morbid obesity
163450|NCT02113696|BMI at or above 4O kg/m2
163451|NCT02113696|ingestion of omega 3
163452|NCT02113696|inflammatory cytokines
163453|NCT02113696|biochemical factors
163454|NCT02113696|anthropometric factors
163455|NCT02113683|colo-rectal cancer
163456|NCT02113683|stomach cancer
163457|NCT02113683|melanoma
163458|NCT02113683|MMS test
163459|NCT02113683|therapy monitoring
163460|NCT02113670|stress urinary incontinence
163461|NCT02113670|abdominal leak point pressure
163462|NCT02113670|urodynamic study
163463|NCT02113657|Prostate cancer
163464|NCT02113657|Castration-resistant prostate cancer
163465|NCT02113657|CRPC
163466|NCT02113657|Metastatic
163467|NCT02113657|Hormone therapy treatment
163468|NCT02113657|Androgen deprivation therapy
163469|NCT02113657|gonadotropin-releasing hormone
163470|NCT02113657|GnRH
163471|NCT02113657|Ipilimumab
163472|NCT02113657|Yervoy
163473|NCT02113657|BMS-734016
163474|NCT02113657|MDX010
163475|NCT02113631|Hepatitis C treatment,
163476|NCT02113631|Boceprevir,
163477|NCT02113631|Telaprevir,
163478|NCT02113631|Safety
163479|NCT02113631|Effectiveness
163480|NCT02113631|Head-to-head trial
163481|NCT02113618|Cognitive function, alcohol dependence, working memory
163482|NCT02113605|Functional gastrointestinal disorders
163483|NCT02113605|FGID
163484|NCT02113605|Recurrent abdominal pain
163485|NCT02113605|Abdominal pain
163486|NCT02113605|pain-predominant functional gastrointestinal disorders
163487|NCT02113605|Pediatric pain
163488|NCT02113592|Pain management
163489|NCT02113592|Opioid use
163490|NCT02113592|Pragmatic
163491|NCT02113592|Collaborative care
163492|NCT02113592|Primary care
163493|NCT02113579|Tooth Sensitivity
163494|NCT02113566|Delayed onset muscle soreness
163495|NCT02113566|DOMS
163496|NCT02113540|coronary angiography
163497|NCT02113540|chronic stable angina
163498|NCT02113540|CIN
163499|NCT02113527|Electrogastrography
163500|NCT02113527|Functional dyspepsia
163501|NCT02113527|Gastric emptying
163502|NCT02113527|Gastrointestinal peptides
163503|NCT02113527|Rome III criteria
163504|NCT02113514|Appalachian
163505|NCT02113514|abnormal pap test
163506|NCT02113501|HGT1
163507|NCT02113501|high risk bladder cancer
163508|NCT02113501|substaging
163509|NCT02113501|repeat transurethral resection (reTUR)
163510|NCT02113501|lamina propria
163511|NCT02113475|CDT
163512|NCT02113475|PCDT
163513|NCT02113475|DVT
163514|NCT02113475|PTS
163515|NCT02113475|Quality of Life
163516|NCT02113462|Chronic kidney disease
163517|NCT02113462|Endothelial dysfunction
163518|NCT02113462|Inflammation
163519|NCT02113462|Insulin resistance
163520|NCT02113462|Tg/hdl ratio
163521|NCT02113449|Carbon Dioxide, Allergy symptoms
163522|NCT02113436|FP/SLM
163523|NCT02113436|Asthma
163524|NCT02113436|Infant
163525|NCT02113436|Efficacy
163526|NCT02113436|Safety
163527|NCT02113423|superiority, re-irradiation, IMRT, recurrent T1-2 NPC
163528|NCT02113410|osteoarthritis
163529|NCT02113410|Older adults
163530|NCT02113410|Sit 'N' Chair Yoga
163531|NCT02113410|Pain
163532|NCT02113410|Physical Function
163533|NCT02113410|Balance
163534|NCT02113410|Fatigue
163535|NCT02113410|Depression
163536|NCT02113410|Life Satisfaction
163537|NCT02113397|Cystic fibrosis
163538|NCT02113397|Microbiome
163539|NCT02113397|Sputum
163540|NCT02113397|Tobramycin
163541|NCT02113397|Colistimethate
163542|NCT02113384|Rectal cancer
163543|NCT02113384|Locally advanced rectal cancer
163544|NCT02113384|Peritoneal carcinomatosis
163545|NCT02113384|Exfoliated peritoneal cells
163546|NCT02113384|Peritoneal lavage
163547|NCT02113371|Injury Prevention
163548|NCT02113371|Health Promotion
163549|NCT02113371|Well being
163550|NCT02113371|Safety
163551|NCT02113371|Nutrition
163552|NCT02113371|Physical Activity
163553|NCT02113371|Sleep
163554|NCT02113371|Stress
163555|NCT02113358|fluid therapy
163556|NCT02113358|neurosurgery
163557|NCT02113345|metamemory
163558|NCT02113345|memory
163559|NCT02113345|mild cognitive impairment
163560|NCT02113332|Insulin injections
163561|NCT02113332|Overweight
163562|NCT02113332|Inadequate glycaemic control
163563|NCT02113319|Core Binding Factors
163564|NCT02113319|Acute Myelogenous Leukemia refractory to conventional chemotherapy
163565|NCT02113319|molecular relapse
163566|NCT02113293|phase I study
163567|NCT02113293|tolerability
163568|NCT02113293|safety
163569|NCT02113293|CyclASol®
163570|NCT02113293|eye drops
163571|NCT02113267|esophagitis
163572|NCT02113267|eosinophils
163573|NCT02113267|allergy
163574|NCT02113267|inflammation
163575|NCT02113267|corticosteroids
163576|NCT02113254|corn
163577|NCT02113254|macular pigment
163578|NCT02113254|lutein
163579|NCT02113254|zeaxanthin
163580|NCT02113254|Age Macular Degeneration
163581|NCT02113254|AMD
163582|NCT02113241|metabolic syndrome
163583|NCT02113241|forxiga
163584|NCT02113241|dapagliflozin
163585|NCT02113241|insulin secretion
163586|NCT02113241|insulin sensitivity
163587|NCT02113228|Energy metabolism
163588|NCT02113228|Stable isotopes
163589|NCT02113228|Short bowel syndrome
163590|NCT02113228|Doubly labeled water
163591|NCT02113215|aging
163592|NCT02113215|lipid metabolism
163593|NCT02113215|very low density lipoproteins
163594|NCT02113202|Optical imaging
163595|NCT02113202|Fluorescence endoscopy
163596|NCT02113202|Near infrared fluorescence
163597|NCT02113202|Familial Adenomatous Polyposis
163598|NCT02113202|IRDye800CW
163599|NCT02113202|Vascular Endothelial Growth Factor A
163600|NCT02113202|Gastrointestinal endoscopy
163601|NCT02113189|gait
163602|NCT02113189|Parkinson's disease
163603|NCT02113176|SAH
163604|NCT02113163|Type 2 diabetes
163605|NCT02113163|T2DM
163606|NCT02113163|hypertriglyceridemia
163607|NCT02113163|severe hypertriglyceridemia
163608|NCT02113163|dyslipidemia
163609|NCT02113163|triglycerides
163610|NCT02113163|lipids
163611|NCT02113163|omega-3 fatty acids
163612|NCT02113163|EPA
163613|NCT02113163|ethyl-EPA
163614|NCT02113163|Metformin
163615|NCT02113163|Glucophage
163616|NCT02113163|Lovaza
163617|NCT02113163|Vascepa
163618|NCT02113163|Epanova
163619|NCT02113163|Astra Zeneca
163620|NCT02113163|Amarin
163621|NCT02113163|GSK
163622|NCT02113150|troponin t,cystatin-c,ketamine,remifentanil
163623|NCT02113137|halitosis
163624|NCT02113137|chlorine dioxide
163625|NCT02113137|tongue cleaning
163626|NCT02113124|Chronic Brain Injury
163627|NCT02113124|Traumatic brain injury (TBI)
163628|NCT02113124|Amino Acids
163629|NCT02113124|Microbiome
163630|NCT02113098|Stroke
163631|NCT02113098|Gait
163632|NCT02113098|Rehabilitation
163633|NCT02113085|Adolescents, foster care, self-determination
163634|NCT02113072|wheezing, immune system, cytokines, probiotics, infants.
163635|NCT02113059|Liver regeneration
163636|NCT02113059|liver dysfunction
163637|NCT02113059|platelets
163638|NCT02113059|plasma
163639|NCT02113059|serum
163640|NCT02113059|platelet activation
163641|NCT02113059|morbidity
163642|NCT02113059|mortality
163643|NCT02113059|Growth factors
163644|NCT02113059|Postoperative clinical outcome
163645|NCT02113046|pancreas
163646|NCT02113046|pancreatico-jejunal anastomosis
163647|NCT02113046|postoperative pancreatic fistulae
163648|NCT02113007|Lymphoma; CNS; rituximab; temozolomide
163649|NCT02112994|Enzyme Replacement Therapy (ERT)
163650|NCT02112994|Lysosomal Storage Disease
163651|NCT02112994|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
163652|NCT02112994|Acid cholesteryl ester hydrolase deficiency, type 2
163653|NCT02112994|Acid lipase disease
163654|NCT02112994|Cholesterol ester hydrolase deficiency
163655|NCT02112994|LAL Deficiency
163656|NCT02112994|LIPA Deficiency
163657|NCT02112994|Wolman disease
163658|NCT02112994|Additional relevant MeSH terms:
163659|NCT02112994|Cholesterol Ester Storage Disease
163660|NCT02112994|Metabolic Diseases
163661|NCT02112994|Lipidoses
163662|NCT02112994|Lipid Metabolism, Inborn Errors
163663|NCT02112994|Metabolism, Inborn Errors
163664|NCT02112994|Genetic Diseases, Inborn
163665|NCT02112994|Lysosomal Storage Diseases
163666|NCT02112994|Lipid Metabolism Disorders
163667|NCT02112994|Infant, Newborn, Diseases
163668|NCT02112981|CORONARY ARTERIOSCLEROSIS
163669|NCT02112968|Myopia
163670|NCT02112968|Hyperopia
163671|NCT02112968|Presbyopia
163672|NCT02112968|Supracor
163673|NCT02112968|Zyoptix
163674|NCT02112968|Proscan
163675|NCT02112968|LASIK
163676|NCT02112955|Stroke
163677|NCT02112955|Disease management
163678|NCT02112955|Self efficacy
163679|NCT02112955|Quality of life
163680|NCT02112955|Community integration
163681|NCT02112942|Hepatitis C virus
163682|NCT02112942|HCV
163683|NCT02112929|Magnetic Resonance Imaging
163684|NCT02112929|Lung Diseases
163685|NCT02112890|Mexico
163686|NCT02112890|Adolescents
163687|NCT02112890|Hepatitis
163688|NCT02112890|Seroprevalence
163689|NCT02112890|Pertussis
163690|NCT02112890|Young adults
163691|NCT02112877|iliofemoral vein
163692|NCT02112877|venous
163693|NCT02112877|venous obstruction
163694|NCT02112838|IGA Glomerulonephritis
163695|NCT02112838|Nephritis, IGA Type
163696|NCT02112825|Exercise
163697|NCT02112825|blood pressure
163698|NCT02112825|chronic kidney disease
163699|NCT02112812|Parkinsons disease
163700|NCT02112812|Helicobacter pylori
163701|NCT02112812|Eradication
163702|NCT02112812|Levodopa response
163703|NCT02112812|Motor outcomes
163704|NCT02112812|Quality of Life
163705|NCT02112812|Open label
163706|NCT02112799|Hepatitis B
163707|NCT02112786|Overactive Bladder
163708|NCT02112773|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
163709|NCT02112760|specific stabilization exercise
163710|NCT02112760|ultrasound
163711|NCT02112760|low back pain
163712|NCT02112747|Colorectal Cancer Prevention
163713|NCT02112747|Colorectal Cancer Screening
163714|NCT02112747|ACCS
163715|NCT02112747|Lynch Syndrome
163716|NCT02112747|LS
163717|NCT02112734|vitamin D
163718|NCT02112734|food allergy
163719|NCT02112734|eczema
163720|NCT02112708|Psychotherapy, Rational-Emotive
163721|NCT02112708|Depression
163722|NCT02112708|Social Work
163723|NCT02112708|Primary Health Care
163724|NCT02112695|endurance sportswomen
163725|NCT02112695|addiction
163726|NCT02112695|undernutrition
163727|NCT02112695|[11C]diprenorphine Pet
163728|NCT02112695|pituitary region
163729|NCT02112682|Sentinel lymph node metastasis
163730|NCT02112682|Completion axillary lymph node dissection
163731|NCT02112682|Axillary radiotherapy
163732|NCT02112656|Carcinoma
163733|NCT02112656|Carcinoma, Hepatocellular
163734|NCT02112656|Neoplasms, Glandular and Epithelial
163735|NCT02112656|Neoplasms by Histologic Type
163736|NCT02112656|Neoplasms
163737|NCT02112656|Adenocarcinoma
163738|NCT02112656|Liver Neoplasms
163739|NCT02112656|Digestive System Neoplasms
163740|NCT02112656|Neoplasms by Site
163741|NCT02112656|Digestive System Diseases
163742|NCT02112656|Liver Diseases
163743|NCT02112656|Doxorubicin
163744|NCT02112656|Antibiotics, Antineoplastic
163745|NCT02112656|Antineoplastic Agents
163746|NCT02112656|Therapeutic Uses
163747|NCT02112656|Pharmacologic Actions
163748|NCT02112643|Thyroid eye disease
163749|NCT02112643|Thyroid orbitopathy
163750|NCT02112643|Graves' orbitopathy
163751|NCT02112643|Graves' ophthalmopathy
163752|NCT02112630|Hepatitis C Infection
163753|NCT02112630|HCV, genotype 1
163754|NCT02112630|End Stage Renal Disease
163755|NCT02112630|ESRD
163756|NCT02112630|Boceprevir
163757|NCT02112630|Pegylated Interferon
163758|NCT02112630|Ribavirin
163759|NCT02112617|Neuroblastoma
163760|NCT02112617|Childhood neuroblastoma
163761|NCT02112617|Ganglioneuroblastoma
163762|NCT02112617|Pediatric neuroblastoma
163763|NCT02112604|critically ill, OSA, mechanical ventilation
163764|NCT02112591|Stress urinary incontinence
163765|NCT02112591|mesh
163766|NCT02112591|tape
163767|NCT02112591|micturition dysfunction
163768|NCT02112591|urinary obstruction
163769|NCT02112591|TOT
163770|NCT02112578|Vertigo, Meclizine, dimenhydrinate, Peripheral Origin
163771|NCT02112526|de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
163772|NCT02112526|Diffuse Large B-Cell Lymphoma
163773|NCT02112526|Novo Activated B-cell (ABC)
163774|NCT02112526|Novo Activated B-cell
163775|NCT02112526|ABC DLBCL
163776|NCT02112526|DLBCL
163777|NCT02112526|Lymphoma
163778|NCT02112526|B-Cell
163779|NCT02112526|Immunoproliferative Disorders
163780|NCT02112526|Immune System Diseases
163781|NCT02112487|pulmonary arterial hypertension
163782|NCT02112487|PAH-SYMPACT
163783|NCT02112487|PAH
163784|NCT02112487|psychometric instrument
163785|NCT02112474|Failed Back Surgery Syndrome
163786|NCT02112474|Neuropathic pain
163787|NCT02112474|Leg Pain
163788|NCT02112474|Chronic Pain
163789|NCT02112474|Spinal Cord Stimulation
163790|NCT02112474|Neurostimulation
163791|NCT02112461|end of life care
163792|NCT02112448|congenital heart disease, pediatric cardiothoracic surgery
163793|NCT02112435|obstructive sleep apnea
163794|NCT02112435|mandibular advancement splint
163795|NCT02112435|active mandibular advancement splint
163796|NCT02112435|oral appliance
163797|NCT02112422|Parturients
163798|NCT02112409|Adolescent idiopathic scoliosis
163799|NCT02112409|scoliosis corrective surgery
163800|NCT02112409|autologous blood transfusion
163801|NCT02112409|cell salvage
163802|NCT02112409|acute normovolemic hemodilution
163803|NCT02112409|hemoglobin level
163804|NCT02112396|CRAFT
163805|NCT02112396|Concerned Significant Others
163806|NCT02112396|Contingency management
163807|NCT02112396|Reinforcement
163808|NCT02112396|Family Intervention
163809|NCT02112383|Procrastination
163810|NCT02112383|Cognitive behavior therapy
163811|NCT02112383|Internet interventions
163812|NCT02112383|Group intervention
163813|NCT02112383|Students
163814|NCT02112383|Randomized controlled trial
163815|NCT02112370|Ropivacaine
163816|NCT02112370|Epinephrine
163817|NCT02112370|Endoscopy
163818|NCT02112370|Robotics
163819|NCT02112370|Thyroidectomy
163820|NCT02112357|molecular profiling
163821|NCT02112357|genetic sequencing
163822|NCT02112357|personalised medicine
163823|NCT02112357|gastrointestinal cancer
163824|NCT02112331|Preterm newborns
163825|NCT02112331|Gastric lipolysis
163826|NCT02112331|Physical treatments
163827|NCT02112331|Human milk
163828|NCT02112305|Magnesium sulphate nebulized
163829|NCT02112279|Microbiota
163830|NCT02112279|c-difficile
163831|NCT02112279|colonoscopy
163832|NCT02112279|stool transplant
163833|NCT02112266|depression
163834|NCT02112266|online therapy
163835|NCT02112266|cognitive behavioural therapy
163836|NCT02112266|quality of life
163837|NCT02112266|alexithymia
163838|NCT02112266|therapy expectation and satisfaction
163839|NCT02112253|Tourette's syndrome
163840|NCT02112253|Deep brain stimulation
163841|NCT02112253|Stereotactic surgery
163842|NCT02112253|Globus pallidus interna
163843|NCT02112253|Tics
163844|NCT02112240|sentinel lymph node
163845|NCT02112240|lymphatic mapping
163846|NCT02112240|rectal tumor
163847|NCT02112227|Heart Failure
163848|NCT02112227|Transitional Care
163849|NCT02112227|Knowledge Translation
163850|NCT02112227|Outcomes
163851|NCT02112214|Helicobacter pylori treatment
163852|NCT02112214|Gastric cancer
163853|NCT02112214|Screening
163854|NCT02112175|Multiple Myeloma
163855|NCT02112175|Lenalidomide
163856|NCT02112175|Revlimid
163857|NCT02112175|MPV
163858|NCT02112175|Melphalan
163859|NCT02112175|Prednisone
163860|NCT02112175|Velcade
163861|NCT02112175|Placebo
163862|NCT02112149|Body Composition
163863|NCT02112149|Exercise
163864|NCT02112149|Survivorship
163865|NCT02112136|Autosomal Dominant Polycystic Kidney Disease (ADPKD)
163866|NCT02112136|Renal cysts
163867|NCT02112136|Chronic Kidney Diseases
163868|NCT02112136|Genetic
163869|NCT02112123|icariin
163870|NCT02112123|pharmacokinetics
163871|NCT02112123|healthy participants
163872|NCT02112097|Plaque Psoriasis.
163873|NCT02112097|Subdermal bloodless space
163874|NCT02112097|Subdermal injection
163875|NCT02112097|Subcutaneous injection
163876|NCT02112097|Injectable electromyography needle
163877|NCT02112097|Electrical stimulation
163878|NCT02112097|MRI with Gadolinium
163879|NCT02112071|Exercise
163880|NCT02112071|Diabetic kidney disease
163881|NCT02112071|vascular function
163882|NCT02112071|physical function
163883|NCT02112032|melanoma
163884|NCT02112032|advanced
163885|NCT02112019|Sjögren's Syndrome
163886|NCT02112019|Sialoendoscopy
163887|NCT02112019|Saliva
163888|NCT02112019|Dry Mouth
163889|NCT02112006|hand surgery
163890|NCT02112006|wrist surgery
163891|NCT02112006|finger surgery
163892|NCT02112006|anesthesia
163893|NCT02112006|regional anesthesia
163894|NCT02112006|postoperative pain
163895|NCT02111993|Defibrillation testing
163896|NCT02111993|Upper Limit of Vulnerability
163897|NCT02111993|ULV
163898|NCT02111993|DFT
163899|NCT02111993|ICD
163900|NCT02111993|implantable cardioverter defibrillator
163901|NCT02111993|cardiomyopathy
163902|NCT02111993|cardiac arrhythmia
163903|NCT02111993|cardiac device testing
163904|NCT02111980|CIED
163905|NCT02111980|pacemaker
163906|NCT02111980|implantable cardioverter defibrillator
163907|NCT02111980|ICD
163908|NCT02111980|radiofrequency
163909|NCT02111980|cardiac device programming
163910|NCT02111980|RF sponge detection
163911|NCT02111980|RF assure
163912|NCT02111980|cardiac internal electronic devices
163913|NCT02111980|temporary pacing
163914|NCT02111980|pulmonary thromboendarterectomy
163915|NCT02111980|pacing interference
163916|NCT02111980|Arrhythmia
163917|NCT02111954|prostate cancer
163918|NCT02111954|primary
163919|NCT02111954|recurrence
163920|NCT02111954|F-18-FCH PET/CT
163921|NCT02111954|Ga-68-NODAGA-MJ9 PET/CT
163922|NCT02111915|Maternal depression
163923|NCT02111902|Cardiovascular Disease
163924|NCT02111902|Obesity
163925|NCT02111902|Physical Activity
163926|NCT02111902|Vitamin D deficiency
163927|NCT02111902|African Americans
163928|NCT02111876|ICU, COPD, OHS, OSA, heart failure
163929|NCT02111863|Skin Cancer
163930|NCT02111863|Metastatic Melanoma
163931|NCT02111863|Adoptive Cell Therapy
163932|NCT02111863|Immunotherapy
163933|NCT02111863|Clinical Response
163934|NCT02111850|Gene Therapy
163935|NCT02111850|Tumor Regression
163936|NCT02111850|Immunotherapy
163937|NCT02111850|Adoptive Cell Therapy
163938|NCT02111824|Lung Cancer
163939|NCT02111824|Peripheral lung lesions
163940|NCT02111824|Lung biopsy
163941|NCT02111824|Minimally invasive
163942|NCT02111824|multimodality image-guided intervention system
163943|NCT02111824|MIMIG
163944|NCT02111824|Indocyanine green
163945|NCT02111824|ICG
163946|NCT02111811|Depression
163947|NCT02111811|Treatment Outcome
163948|NCT02111811|Delivery of Healthcare, Integrated
163949|NCT02111811|Employment
163950|NCT02111811|Rehabilitation
163951|NCT02111798|substance abuse treatment
163952|NCT02111798|cocaine dependence
163953|NCT02111798|contingency management; abstinence incentives
163954|NCT02111798|medication-enhanced behavioral therapy
163955|NCT02111785|Dexamethasone
163956|NCT02111785|Burr hole craniostomy
163957|NCT02111785|Chronic subdural hematoma
163958|NCT02111746|Postoperative pain
163959|NCT02111746|sternotomy
163960|NCT02111746|laparotomy
163961|NCT02111746|thoracotomy
163962|NCT02111746|mini-thoracotomy
163963|NCT02111746|truncal surgical incisions
163964|NCT02111746|local anaesthetics
163965|NCT02111746|bupivacaine
163966|NCT02111720|HIV
163967|NCT02111720|Disclosure
163968|NCT02111720|Family
163969|NCT02111720|Intervention
163970|NCT02111694|infant
163971|NCT02111694|intake
163972|NCT02111694|satiation
163973|NCT02111694|mother
163974|NCT02111694|feeding practices
163975|NCT02111694|bottle feeding
163976|NCT02111694|formula feeding
163977|NCT02111694|maternal responsiveness
163978|NCT02111694|infant cues
163979|NCT02111681|Calypso-based Deep Inspiration Breath Hold (DIBH)
163980|NCT02111681|radiation treatments
163981|NCT02111681|13-174
163982|NCT02111668|Aorta
163983|NCT02111668|Dilatation
163984|NCT02111668|Marfan syndrome
163985|NCT02111668|Genetic
163986|NCT02111668|Fbn1
163987|NCT02111655|Thrombosis
163988|NCT02111655|Arteriovenous fistulae
163989|NCT02111655|Hemodialysis
163990|NCT02111655|Doppler ultrasound
163991|NCT02111655|Vascular access blood flow
163992|NCT02111655|Surveillance
163993|NCT02111642|Pelvic organ prolapse
163994|NCT02111642|Stress urinary incontinence
163995|NCT02111642|Midurethral sling
163996|NCT02111642|Patient satisfaction
163997|NCT02111629|Vaginosis, bacterial; Candidiasis, vulvovaginal
163998|NCT02111616|cancer survivorship care
163999|NCT02111616|provider communication
164000|NCT02111616|provider care coordination
164001|NCT02111590|Immunoglobulins, Intravenous
164002|NCT02111590|Immunoglobulins, Subcutaneous
164003|NCT02111577|Immunotherapy
164004|NCT02111577|Metastatic
164005|NCT02111577|Castrate Resistant
164006|NCT02111577|Prostate Cancer
164007|NCT02111577|Biological
164008|NCT02111577|Vaccine
164009|NCT02111564|Heart Failure
164010|NCT02111564|Respiratory Insufficiency
164011|NCT02111564|Stroke Acute
164012|NCT02111564|Infectious Diseases
164013|NCT02111564|Rheumatic Diseases
164014|NCT02111564|Medically ill Patient
164015|NCT02111564|Rivaroxaban
164016|NCT02111564|Thromboembolism
164017|NCT02111564|Prophylactic Anti-Coagulation
164018|NCT02111551|Autism
164019|NCT02111551|Nicotinic agonist
164020|NCT02111551|Cognition
164021|NCT02111551|P50
164022|NCT02111551|Alpha 7
164023|NCT02111499|psoriasis plaque test
164024|NCT02111499|topical application
164025|NCT02111499|atrophy measure
164026|NCT02111486|Breakfast
164027|NCT02111486|Satiety
164028|NCT02111486|Fibre
164029|NCT02111486|Glucose
164030|NCT02111486|Gastric emptying
164031|NCT02111473|endothelial dysfunction
164032|NCT02111473|bone mineral metabolism
164033|NCT02111473|testosteron replacement treatment
164034|NCT02111460|Initially
164035|NCT02111460|Untreated
164036|NCT02111460|Distant metastatic
164037|NCT02111447|children
164038|NCT02111447|sevoflurane
164039|NCT02111447|isoflurane
164040|NCT02111447|propofol
164041|NCT02111447|anesthesia
164042|NCT02111447|MRI
164043|NCT02111447|delirium
164044|NCT02111434|visceral adiposity index
164045|NCT02111434|triglycerides / hdl cholesterol ratio
164046|NCT02111434|testosterone
164047|NCT02111421|dexmedetomidine
164048|NCT02111421|parturient
164049|NCT02111421|nonpregnant women
164050|NCT02111421|sedation
164051|NCT02111408|Sleep apnea syndromes
164052|NCT02111408|Autonomic nervous system +/- disease
164053|NCT02111408|Depression
164054|NCT02111408|Peripheral arterial disease
164055|NCT02111382|Low back pain
164056|NCT02111382|osteopathic manipulations
164057|NCT02111382|electroencephalography
164058|NCT02111369|Essential Tremor
164059|NCT02111369|Essential Vocal Tremor
164060|NCT02111369|Essential Voice Tremor
164061|NCT02111343|auditory processing disorder
164062|NCT02111343|central auditory processing disorder
164063|NCT02111343|auditory processing
164064|NCT02111343|auditory training
164065|NCT02111330|Adenosine A2a receptor antagonist
164066|NCT02111330|adenosine receptor modulator
164067|NCT02111330|Cancer
164068|NCT02111317|ASP015K
164069|NCT02111317|Pharmacokinetics
164070|NCT02111317|Healthy Subjects
164071|NCT02111304|cholera
164072|NCT02111304|diarrhea
164073|NCT02111304|secretory diarrhea
164074|NCT02111304|ORS
164075|NCT02111304|V. cholerae O1
164076|NCT02111304|iOWH032
164077|NCT02111304|children
164078|NCT02111304|pharmacokinetic
164079|NCT02111304|Bangladesh
164080|NCT02111291|Diabetic Foot Ulcers
164081|NCT02111278|Manipulation
164082|NCT02111278|Lumbar
164083|NCT02111278|Low Back Pain
164084|NCT02111278|Manual Therapy
164085|NCT02111278|Adolescents
164086|NCT02111252|Drug Therapy
164087|NCT02111239|DIEP
164088|NCT02111239|DIEP flap
164089|NCT02111239|Breast reconstruction
164090|NCT02111239|Breast Cancer
164091|NCT02111239|CTA
164092|NCT02111239|MRA
164093|NCT02111226|hypertension
164094|NCT02111226|cardiovascular disease
164095|NCT02111226|diabetes
164096|NCT02111226|chronic disease management
164097|NCT02111213|physical activity
164098|NCT02111213|Intervention
164099|NCT02111213|Attitude to Computers
164100|NCT02111200|UCD
164101|NCT02111187|LDE225
164102|NCT02111187|High risk localized prostate cancer
164103|NCT02111187|Pre-surgical
164104|NCT02111174|Neuropathy
164105|NCT02111174|Peripheral neuropathy
164106|NCT02111174|Chemotherapy-induced peripheral neuropathy
164107|NCT02111161|Randomised controlled trial (RCT)
164108|NCT02111161|Immunoglobulin
164109|NCT02111161|Patient Reported Outcome
164110|NCT02111161|Health-Related Quality of Life
164111|NCT02111161|Short Form-36 (SF-36)
164112|NCT02111148|rupture of membranes, nitrazine, urea, creatinine
164113|NCT02111122|excessive daytime sleepiness
164114|NCT02111122|Parkinson`s Disease
164115|NCT02111122|sleep-wake disturbances
164116|NCT02111122|Sodium Oxybate
164117|NCT02111109|Microcirculation
164118|NCT02111109|Trauma
164119|NCT02111109|Haemorrhage
164120|NCT02111109|Shock
164121|NCT02111070|Influenza
164122|NCT02111070|Influenza vaccine
164123|NCT02111070|Split influenza vaccine
164124|NCT02111057|Rheumatoid Arthritis
164125|NCT02111057|Total Hip Replacement
164126|NCT02111057|Flare
164127|NCT02111057|Perioperative Outcomes
164128|NCT02111044|de novo or partial responder to somatostatin analogues
164129|NCT02111031|CELLSEARCH
164130|NCT02111031|CTC
164131|NCT02111031|metastatic breast cancer
164132|NCT02111031|Registry
164133|NCT02111031|mBC
164134|NCT02111005|apoptosis
164135|NCT02111005|periodontal disease
164136|NCT02111005|smoking
164137|NCT02110979|Patient Decision Aid
164138|NCT02110979|Shared Decision Making
164139|NCT02110966|Anaesthetic effect
164140|NCT02110966|Inferior alveolar nerve block
164141|NCT02110966|Local tramadol
164142|NCT02110966|Mepivacaine
164143|NCT02110966|Symptomatic irreversible pulpitis.
164144|NCT02110927|Abdominal fat
164145|NCT02110927|Metabolic syndrome
164146|NCT02110927|Microcurrent
164147|NCT02110927|Aerobic exercise
164148|NCT02110927|Lipolysis
164149|NCT02110914|Feasibility study
164150|NCT02110914|Coaching
164151|NCT02110914|Motivational Interviewing
164152|NCT02110914|Health related quality of life
164153|NCT02110914|Adherence
164154|NCT02110901|radiocephalic
164155|NCT02110901|arteriovenous fistula
164156|NCT02110901|AVF
164157|NCT02110901|hemodialysis
164158|NCT02110901|PRT-201
164159|NCT02110901|vascular access
164160|NCT02110901|kidney
164161|NCT02110901|renal
164162|NCT02110901|vonapanitase
164163|NCT02110901|PATENCY-1
164164|NCT02110875|Healthy Volunteers
164165|NCT02110849|Prostate
164166|NCT02110849|Proton Therapy
164167|NCT02110849|Cancer
164168|NCT02110810|post-ERCP Acute Pancreatitis
164169|NCT02110810|Indomethacin
164170|NCT02110810|NSAIDs
164171|NCT02110797|RETT syndrome
164172|NCT02110797|MECP2
164173|NCT02110797|Osteoporosis
164174|NCT02110797|RANK-ligand
164175|NCT02110797|osteoprotegerin
164176|NCT02110784|Artemisinin based Combination Therapies
164177|NCT02110784|eurartesim
164178|NCT02110784|Dihydroartemisinin/Piperaquine
164179|NCT02110771|schizophrenia
164180|NCT02110771|social cognition
164181|NCT02110771|facial affects recognition
164182|NCT02110771|cognitive remediation
164183|NCT02110758|Patient Care Management
164184|NCT02110758|Patient Care Planning
164185|NCT02110758|Patient-Centered Care
164186|NCT02110758|Patient Care Team
164187|NCT02110758|Advance Care Planning
164188|NCT02110758|Delivery of Health Care
164189|NCT02110758|Evidence-based Practice
164190|NCT02110758|Health Care Costs
164445|NCT02109627|Ficlatuzumab
164191|NCT02110758|Health Care Quality, Access, and Evaluation
164192|NCT02110758|Quality of Health Care
164193|NCT02110758|Neoplasms
164194|NCT02110758|Medical Oncology
164195|NCT02110719|narcotic use
164196|NCT02110719|pain
164197|NCT02110719|constipation
164198|NCT02110719|nausea
164199|NCT02110706|Myasthenia Gravis
164200|NCT02110706|Rituximab
164201|NCT02110693|Substance Use
164202|NCT02110693|Substance Use Disorder
164203|NCT02110693|Screening
164204|NCT02110693|Brief Assessment
164205|NCT02110680|overactive bladder
164206|NCT02110680|transcutaneous electric stimulation
164207|NCT02110680|posterior tibial nerve stimulation
164208|NCT02110667|Prostate cancer
164209|NCT02110667|Prostatectomy
164210|NCT02110667|Ultrasound
164211|NCT02110667|TPUS
164212|NCT02110654|chronic rhinosinusitis
164213|NCT02110654|asthma
164214|NCT02110654|montelukast
164215|NCT02110654|surgery
164216|NCT02110654|treatment outcomes
164217|NCT02110641|Breast Cancer
164218|NCT02110641|Survivorship
164219|NCT02110641|Weight Loss
164220|NCT02110628|total gastrectomy
164221|NCT02110628|pouch
164222|NCT02110628|roux-en-y
164223|NCT02110628|quality of life
164224|NCT02110602|Nutrition
164225|NCT02110589|seizures
164226|NCT02110550|endocrown
164227|NCT02110550|marginal adaptation
164228|NCT02110550|anatomic form
164229|NCT02110550|retention loss
164230|NCT02110550|IPS.emmax crowns
164231|NCT02110537|Atrial fibrillation
164232|NCT02110537|Acupuncture
164233|NCT02110537|Recurrence
164234|NCT02110537|Electrical cardioversion
164235|NCT02110524|Peripheral Arterial Disease
164236|NCT02110498|Pancreatic cyst
164237|NCT02110498|IPMN
164238|NCT02110498|SCA
164239|NCT02110498|SPN
164240|NCT02110498|MCN
164241|NCT02110498|pancreatic cystic neoplasm
164242|NCT02110485|Appendicitis
164243|NCT02110485|Pediatric
164244|NCT02110485|Children
164245|NCT02110485|Non-operative
164246|NCT02110485|Antibiotics alone
164247|NCT02110472|Emmetropic presbyopes
164248|NCT02110472|Presbyopic
164249|NCT02110459|POL7080
164250|NCT02110459|Pharmacokinetics
164251|NCT02110446|Sjögren's syndrome
164252|NCT02110446|SS-1
164253|NCT02110446|Gan-Lu-Yin
164254|NCT02110446|Sang-Ju-Yin
164255|NCT02110446|Xuefu-Zhuyu-Decoction
164256|NCT02110433|chronic heart failure
164257|NCT02110433|BNP
164258|NCT02110433|telemedicine
164259|NCT02110433|telemonitoring
164260|NCT02110433|weight
164261|NCT02110433|education
164262|NCT02110433|self management
164263|NCT02110433|cost effectiveness
164264|NCT02110420|Safety
164265|NCT02110420|Pharmacokinetics
164266|NCT02110420|Healthy Subjects
164267|NCT02110420|First-in-Human
164268|NCT02110407|healthy young adults
164269|NCT02110407|tDCS
164270|NCT02110407|LOCATO task
164271|NCT02110407|visual-spatial learning
164272|NCT02110394|observational
164273|NCT02110394|chronic lymphocytic leukemia
164274|NCT02110394|bendamustine
164275|NCT02110381|High blood pressure
164276|NCT02110355|Metastatic melanoma
164277|NCT02110342|PF-04449913
164278|NCT02110342|[14C]PF-04449913
164279|NCT02110342|Human ADME
164280|NCT02110342|Radiolabel
164281|NCT02110342|Mass Balance
164282|NCT02110342|Pharmacokinetics
164283|NCT02110329|colorectal cancer
164284|NCT02110329|stage II and III
164285|NCT02110329|somatic quantitative molecular alterations
164286|NCT02110329|Qantitative Multiplex Pcr of Short fluorescent Fragments method (QMPSF)
164287|NCT02110290|quality of life
164288|NCT02110290|adaptive sports
164289|NCT02110290|therapeutic recreation
164290|NCT02110290|mental health
164291|NCT02110277|Ovarian Cancer
164292|NCT02110277|Epithelial ovarian cancer
164293|NCT02110264|Opioid Use
164294|NCT02110264|Incarceration
164295|NCT02110264|Vivitrol
164296|NCT02110264|Patient Navigator
164297|NCT02110264|Drug Education
164298|NCT02110238|osteoarthritis
164299|NCT02110238|knee pain
164300|NCT02110238|Supartz
164301|NCT02110238|Euflexxa
164302|NCT02110238|HA
164303|NCT02110238|hyaluronic acid
164304|NCT02110225|Cone-Rod Degenerations
164305|NCT02110225|Cone-Rod Dystrophy
164306|NCT02110225|Cone-Rod Dystrophy 2
164307|NCT02110225|Cone-Rod Retinal Dystrophy
164308|NCT02110225|Pigmentary Retinopathy
164309|NCT02110225|Retinal Cone-Rod Dystrophy
164310|NCT02110225|Rod Cone Dystrophies
164311|NCT02110225|Rod-Cone Dystrophy
164312|NCT02110225|Tapetoretinal Degeneration
164313|NCT02110212|Cataract
164314|NCT02110212|Surgery, cataract extraction
164315|NCT02110212|Optical devices, laser
164316|NCT02110186|lumbar disc herniation
164317|NCT02110186|dynamic stabilization
164318|NCT02110186|discectomy with posterior dynamic stabilization
164319|NCT02110186|discectomy alone
164320|NCT02110186|discectomy with internal fixation and fusion
164321|NCT02110069|KHE
164322|NCT02110069|Vascular anomaly
164323|NCT02110069|Kasabach-Merritt Syndrome
164324|NCT02110069|Tufted angioma
164325|NCT02110069|hemangioendothelioma
164326|NCT02110056|healthy older adults
164327|NCT02110056|tDCS
164328|NCT02110056|LOCATO task
164329|NCT02110056|visual-spatial learning
164330|NCT02110043|mild cognitive impairment (MCI)
164331|NCT02110043|tDCS
164332|NCT02110043|LOCATO task
164333|NCT02110043|visual-spatial learning
164334|NCT02110030|Transcutaneous electrical nerve stimulation (TENS)
164335|NCT02110030|Ultrasound
164336|NCT02110030|Interferential current therapy
164337|NCT02110030|Rehabilitation
164338|NCT02110030|Shoulder pain
164339|NCT02110017|Ecological task
164340|NCT02110017|fMRI
164341|NCT02110017|Schizophrenia
164342|NCT02110017|Social Cognition
164343|NCT02109978|Diabetes
164344|NCT02109978|Type 2 diabetes
164345|NCT02109978|Diabetes therapy response
164346|NCT02109978|Diabetes progression
164347|NCT02109939|MDD
164348|NCT02109939|Pharmacogenomic
164349|NCT02109939|Pharmacogenomic Testing
164350|NCT02109939|Pharmacogenomics
164351|NCT02109939|Genetic Testing
164352|NCT02109939|Genetics
164353|NCT02109939|Major Depressive Disorder
164354|NCT02109939|GeneSight
164355|NCT02109939|Assurex
164356|NCT02109939|AssureRx
164357|NCT02109939|Psychotropic
164358|NCT02109939|Randomized
164359|NCT02109939|Double Blind
164360|NCT02109939|Placebo Controlled
164361|NCT02109913|Breast Cancer
164362|NCT02109913|metastatic
164363|NCT02109913|hormone receptor positive
164364|NCT02109913|everolimus
164365|NCT02109913|biomarker
164366|NCT02109887|Pneumocystis jiroveci, cytomegalovirus, co-infection
164367|NCT02109861|Multiple Myeloma
164368|NCT02109861|Phase 0 study
164369|NCT02109861|Microdose study
164370|NCT02109861|Micro array
164371|NCT02109861|Gene expression profiling
164372|NCT02109848|keratoconus
164373|NCT02109848|post-keratoplasty
164374|NCT02109835|Diabetes
164375|NCT02109835|coronary artery disease
164376|NCT02109835|Cardiac computed tomography
164377|NCT02109835|Computed tomographics coronary angiography
164378|NCT02109835|Plaque progression
164379|NCT02109822|Cystic Fibrosis
164380|NCT02109822|Pulmonary Exacerbation
164381|NCT02109822|Lung Infection
164382|NCT02109822|Cystic Fibrosis Foundation
164383|NCT02109822|Cystic Fibrosis Foundation National Patient Registry
164384|NCT02109796|tDCS
164385|NCT02109796|Stroke
164386|NCT02109796|Force
164387|NCT02109796|Spasticity
164388|NCT02109796|Gait
164389|NCT02109796|EMG
164390|NCT02109796|Isokinetic
164391|NCT02109783|Athletes
164392|NCT02109783|Ergogenic aids
164393|NCT02109783|Caffeine
164394|NCT02109783|Nutrigenomics
164395|NCT02109783|Genotype
164396|NCT02109770|22q
164397|NCT02109770|DiGeorge
164398|NCT02109770|Angelman
164399|NCT02109770|Cri du chat
164400|NCT02109770|Miller Dieker
164401|NCT02109770|1p36
164402|NCT02109770|Phelan McDermid
164403|NCT02109770|Prader Willi
164404|NCT02109770|Wolf Hirschorn
164405|NCT02109770|Smith Magenis
164406|NCT02109770|Trisomy 21
164407|NCT02109770|Down syndrome
164408|NCT02109770|Trisomy 18
164409|NCT02109770|Edwards syndrome
164410|NCT02109770|Trisomy 13
164411|NCT02109770|Patau syndrome
164412|NCT02109770|Monosomy X
164413|NCT02109770|Turner syndrome
164414|NCT02109770|XXY
164415|NCT02109770|Klinefelter syndrome
164416|NCT02109770|XXX
164417|NCT02109770|XYY
164418|NCT02109757|Hearing conservation
164419|NCT02109757|Personal attenuation rating
164420|NCT02109757|earplug
164421|NCT02109731|Obstructive Sleep Apnea Syndrome (OSAS)
164422|NCT02109731|Sleep Apnea
164423|NCT02109718|Burns
164424|NCT02109718|Dressings
164425|NCT02109718|Outpatient Management
164426|NCT02109718|Petrolatum Jelly
164427|NCT02109718|Superficial Partial Thickness Burns
164428|NCT02109718|Less than or equal to 10% Total Body Surface Area
164429|NCT02109692|dystrophinopathies
164430|NCT02109692|muscle dystrophies
164431|NCT02109692|dystromirs
164432|NCT02109692|longitudinal study
164433|NCT02109692|miRNA
164434|NCT02109653|NSCLC,
164435|NCT02109653|Non-Small Cell Lung Cancer,
164436|NCT02109653|BRAF V600,
164437|NCT02109653|LGX818
164438|NCT02109640|Colorectal
164439|NCT02109640|Surgery
164440|NCT02109640|Laparoscopic
164441|NCT02109640|Analgesia
164442|NCT02109640|Enhanced Recovery
164443|NCT02109640|Targinact
164444|NCT02109627|Acute Myeloid Leukemia
164446|NCT02109627|High Dose Cytarabine
164447|NCT02109627|antibody
164448|NCT02109614|lipoprotein(a)
164449|NCT02109614|aortic stenosis
164450|NCT02109601|Patient Portals
164451|NCT02109601|Personal Health Records
164452|NCT02109601|Patient Engagement
164453|NCT02109601|Mobile Health
164454|NCT02109601|Tablet Computers
164455|NCT02109575|Acute Rejection
164456|NCT02109575|Cardiac Biomarkers
164457|NCT02109575|Cardiac Catheterization
164458|NCT02109575|Cardiomyopathy
164459|NCT02109575|Cell-Free DNA
164460|NCT02109575|Congenital Heart Defect
164461|NCT02109575|Congenital Heart Disease
164462|NCT02109575|Coronary Angiogram
164463|NCT02109575|Donor Specific DNA
164464|NCT02109575|Donor Specific Cell-Free DNA
164465|NCT02109575|Endomyocardial Biopsy
164466|NCT02109575|Heart Failure
164467|NCT02109575|Heart Transplant Failure
164468|NCT02109575|Heart Transplant
164469|NCT02109575|Heart Transplant Rejection
164470|NCT02109562|Schizophrenia
164471|NCT02109562|Schizophrenic
164472|NCT02109562|Schizophrenias
164473|NCT02109562|Risperidone
164474|NCT02109536|Colonoscopy
164475|NCT02109536|Looping
164476|NCT02109536|Loop recognition
164477|NCT02109536|magnetic endoscopic imager
164478|NCT02109471|corneal opacities
164479|NCT02109471|Optical coherence tomography
164480|NCT02109458|Lung nodule biopsy
164481|NCT02109432|Pedal Desk
164482|NCT02109432|Physical Activity
164483|NCT02109432|Workplace
164484|NCT02109432|Energy Expenditure
164485|NCT02109419|computerized assessments
164486|NCT02109419|mood
164487|NCT02109419|life space
164488|NCT02109419|cognition
164489|NCT02109393|Rehabilitation
164490|NCT02109393|Robot-assisted walking training
164491|NCT02109393|Treadmill
164492|NCT02109393|Lokomat
164493|NCT02109367|ovarian cancer
164494|NCT02109367|ovarian mass
164495|NCT02109367|CA-125
164496|NCT02109367|HE4
164497|NCT02109367|culdocentesis
164498|NCT02109367|biomarker(s)
164499|NCT02109354|HIV infection
164500|NCT02109354|Vaccine
164501|NCT02109341|mPC
164502|NCT02109328|Bladder cancer
164503|NCT02109328|Urothelial cancer
164504|NCT02109328|Alisertib
164505|NCT02109328|Phase 2
164506|NCT02109328|Advanced disease
164507|NCT02109289|Anti-Tumor necrosis factor alpha
164508|NCT02109289|18-FluoroDeoxyGlucose Positron Emission Tomography
164509|NCT02109289|High-sensitivity C- Reactive protein
164510|NCT02109276|Fuch's endothelial dystrophy
164511|NCT02109276|Aspheric intraocular lens
164512|NCT02109276|Higher Order Aberrations
164513|NCT02109276|Contrast Sensitivity
164514|NCT02109263|Breast-feeding
164515|NCT02109263|Saccharose
164516|NCT02109263|Breast-feeding newborn
164517|NCT02109263|cortical pain responses
164518|NCT02109263|near infrared spectroscopy (NIRS)
164519|NCT02109263|Salivary rate cortisol
164520|NCT02109263|heel lance
164521|NCT02109250|Medullary Thyroid Cancer (MTC) vandetanib caprelsa
164522|NCT02109237|Lung transplantation
164523|NCT02109237|Bronchiolitis obliterans
164524|NCT02109198|Mild Traumatic Brain Injury
164525|NCT02109185|seasonal allergic rhinitis
164526|NCT02109185|grass/tree/ragweed allergies
164527|NCT02109185|nasal congestion/stuffiness
164528|NCT02109185|rhinnorea
164529|NCT02109185|nasal itching
164530|NCT02109185|sneezing
164531|NCT02109172|Chronic Obstructive Pulmonary Disease
164532|NCT02109172|COPD
164533|NCT02109146|TACE
164534|NCT02109146|Postoperation
164535|NCT02109133|deep neuromuscular blockade
164536|NCT02109133|intraocular pressure
164537|NCT02109107|body contouring
164538|NCT02109107|body shaping
164539|NCT02109107|circumference reduction
164540|NCT02109094|insulin
164541|NCT02109094|metabolomics
164542|NCT02109081|dexamethasone
164543|NCT02109081|delirium
164544|NCT02109081|postoperative cognitive dysfunction
164545|NCT02109081|postoperative
164546|NCT02109081|elderly
164547|NCT02109068|Breast Cancer
164548|NCT02109068|Survivorship
164549|NCT02109068|Weight Loss
164550|NCT02109055|Cardiovascular Diseases
164551|NCT02109055|Thoracic Surgery
164552|NCT02109055|Exercise Therapy
164553|NCT02109016|FGFR1 amplification
164554|NCT02109016|FGF alteration
164555|NCT02109016|VEGF alteration
164556|NCT02109016|PDGF alteration
164557|NCT02109016|Tyrosine kinase inhibitor
164558|NCT02109016|VEGFR inhibitor
164559|NCT02109016|FGFR inhibitor
164560|NCT02109016|PDGFR inhibitor
164561|NCT02109016|VEGFR-FGFR inhibitor
164562|NCT02109003|tracheal cuff
164563|NCT02109003|cuff overinflation
164564|NCT02109003|cuff underinflation
164565|NCT02108990|borderline personality disorder
164566|NCT02108990|rejection
164567|NCT02108990|social pain
164568|NCT02108977|Remote Consultation
164569|NCT02108977|Teleconsultation
164570|NCT02108977|Videoconferencing
164571|NCT02108977|Genetic Counseling
164572|NCT02108977|Costs and Cost Analysis
164573|NCT02108977|Comparative Effectiveness Research
164574|NCT02108977|Telehealth
164575|NCT02108964|NSCLC,
164576|NCT02108964|Non-small Cell Lung Cancer EGFRmut,
164577|NCT02108964|EGFR TKIs (EGF816),
164578|NCT02108964|acquired T790M mutation,
164579|NCT02108964|de novo T790M mutation,
164580|NCT02108964|EGFR TKI activating mutation (i.e. L858R or ex19del),
164581|NCT02108964|Treatment naive advanced NSCLC with EGFR activating mutations
164582|NCT02108964|Locally advanced NSCLC (Stage IIIB NSCLC not amenable to definitive multi-modality therapy including surgery).
164583|NCT02108964|Metastatic NSCLC refers to Stage IV NSCLC.
164584|NCT02108951|CML
164585|NCT02108951|Ph-CML
164586|NCT02108951|leukaemia
164587|NCT02108951|leukemia
164588|NCT02108951|chronic myeloid leukemia
164589|NCT02108951|chronic myeloid leukaemia
164590|NCT02108951|TKI intolerance
164591|NCT02108951|tyrosine kinase inhibitor
164592|NCT02108951|tyrosine kinase inhibitor intolerance
164593|NCT02108912|stroke
164594|NCT02108912|gait
164595|NCT02108912|cardiovascular
164596|NCT02108899|Schizophrenia
164597|NCT02108899|Episodic memory deficits
164598|NCT02108886|preterm labor
164599|NCT02108886|montelukast
164600|NCT02108886|uterine contractions
164601|NCT02108873|Appointments and Schedules
164602|NCT02108873|Outpatient Clinics, Hospital/economics
164603|NCT02108860|Granulomatosis with polyangiitis (Wegener's)
164604|NCT02108860|Granulomatosis with polyangiitis
164605|NCT02108860|GPA
164606|NCT02108860|Wegener's granulomatosis
164607|NCT02108860|Wegener granulomatosis
164608|NCT02108860|Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
164609|NCT02108860|ANCA Associated Vasculitis
164610|NCT02108860|AAV
164611|NCT02108860|Vasculitis
164612|NCT02108860|Systemic vasculitis
164613|NCT02108860|Systemic inflammatory disease
164614|NCT02108860|Lung Diseases
164615|NCT02108860|Respiratory Tract Diseases
164616|NCT02108860|Vascular Diseases
164617|NCT02108860|Abatacept
164618|NCT02108860|CTLA4-Ig
164619|NCT02108860|Immunosuppressive agent
164620|NCT02108860|Prednisone
164621|NCT02108860|Glucocorticoids
164622|NCT02108860|Glucocorticoid
164623|NCT02108860|Corticosteroid
164624|NCT02108860|Corticosteroids
164625|NCT02108860|Treatment
164626|NCT02108860|Pharmacologic Actions
164627|NCT02108860|Therapeutic Uses
164628|NCT02108860|Anti Inflammatory Agents
164629|NCT02108847|Arthroplasty, Replacement, Hip
164630|NCT02108847|Pain, Postoperative
164631|NCT02108847|Nerve Block
164632|NCT02108847|Anesthesia, Regional
164633|NCT02108847|Fascia Iliaca Block
164634|NCT02108847|Ultrasound Guided
164635|NCT02108834|chronic postsurgery pain
164636|NCT02108834|acute pain
164637|NCT02108821|Inflammatory Bowel Diseases (IBD)
164638|NCT02108821|Crohn's Disease (CD)
164639|NCT02108821|Ulcerative Colitis (UC)
164640|NCT02108808|FFR
164641|NCT02108808|adenosine
164642|NCT02108808|Ticagrelor
164643|NCT02108769|Yoga
164644|NCT02108769|Yogic breathing
164645|NCT02108769|Saliva
164646|NCT02108769|Proteomics
164647|NCT02108769|Lipdomics
164648|NCT02108769|Nerve growth factor
164649|NCT02108769|Thirumanthiram
164650|NCT02108717|Telemedicine
164651|NCT02108717|appendicitis
164652|NCT02108717|remote consultation
164653|NCT02108704|Parkinson's Disease
164654|NCT02108704|Helicobacter pylori infection
164655|NCT02108678|Acceptance and Commitment Therapy (ACT)
164656|NCT02108678|Depression
164657|NCT02108678|Illness Management
164658|NCT02108678|Behavioral Treatment
164659|NCT02108678|Impairment
164660|NCT02108652|anti-PD-L1
164661|NCT02108652|PD-L1
164662|NCT02108652|MPDL3280A
164663|NCT02108652|PD-1
164664|NCT02108652|bladder cancer
164665|NCT02108652|atezolizumab
164666|NCT02108652|Tecentriq
164667|NCT02108626|Electronic Cigarettes
164668|NCT02108626|Lozenge
164669|NCT02108626|Nicotine
164670|NCT02108626|Tobacco
164671|NCT02108626|Dependence
164672|NCT02108626|Withdrawal
164673|NCT02108613|Androgen deprivation therapy
164674|NCT02108613|Supportive care
164675|NCT02108613|Quality of life
164676|NCT02108600|Kidney transplantation
164677|NCT02108600|Inflammation
164678|NCT02108561|Breast Cancer Heterogeneity Her2
164679|NCT02108548|ASP7657
164680|NCT02108548|Pharmacokinetics
164681|NCT02108548|Pharmacodynamics
164682|NCT02108548|Healthy Subjects
164683|NCT02108548|First in man
164684|NCT02108548|Safety
164685|NCT02108535|burns
164686|NCT02108535|dressings
164687|NCT02108535|silver sulfadiazine
164688|NCT02108535|silver compounds
164689|NCT02108535|cost
164690|NCT02108522|CMV infection
164691|NCT02108522|EBV infection
164692|NCT02108522|HHV6 virus infection
164693|NCT02108522|BK virus infection
164694|NCT02108522|Adenovirus infection
164695|NCT02108522|JC virus infection
164696|NCT02108522|allogeneic stem cell transplant
164697|NCT02108522|Virus Specific T cells
164698|NCT02108509|Chronic Pancreatitis
164699|NCT02108509|Osteopenia
164700|NCT02108509|Osteoporosis
164701|NCT02108509|Hypogonadism
164702|NCT02108509|Opioid medications
164703|NCT02108470|Oral Health Related Quality of Life (OHRQoL)
164704|NCT02108470|Oral Health Impact Profile (OHIP)
164705|NCT02108470|Dentist-Patient Relations
164706|NCT02108470|patients' participation.
164707|NCT02108470|patients' satisfaction with the consultation.
164708|NCT02108457|concurrent chemotherapy
164709|NCT02108444|hepatitis
164710|NCT02108444|hepatitis B
164711|NCT02108444|lymphoma
164712|NCT02108444|Hematologic Diseases
164713|NCT02108431|urinary diversion
164714|NCT02108431|urethral catheter
164715|NCT02108431|suprapubic tube
164716|NCT02108431|radical prostatectomy
164717|NCT02108431|robotic surgery
164718|NCT02108431|discomfort
164719|NCT02108431|pain
164720|NCT02108405|critically ill patient.
164721|NCT02108392|PXE
164722|NCT02108392|phenotype
164723|NCT02108392|eye
164724|NCT02108392|biomarkers
164725|NCT02108366|severe
164726|NCT02108366|influenza A
164727|NCT02108366|celecoxib
164728|NCT02108353|Type 2 Diabetes
164729|NCT02108353|metabolic control
164730|NCT02108353|Metabolomics
164731|NCT02108353|Circadian Rhythm
164732|NCT02108353|Melatonin
164733|NCT02108353|Biomarker
164734|NCT02108353|Clock Gene
164735|NCT02108353|PBMC
164736|NCT02108353|Cardiovascular function
164737|NCT02108353|Epigenetic modification
164738|NCT02108353|Lifestyle Intervention
164739|NCT02108340|Appendicitis
164740|NCT02108340|Diagnosis
164741|NCT02108340|Microwave radiometry
164742|NCT02108340|Ultrasonography
164743|NCT02108327|Blood loss
164744|NCT02108327|total knee arthroplasty
164745|NCT02108327|hot knife
164746|NCT02108327|cold knife
164747|NCT02108327|unipolar electrocautery
164748|NCT02108327|surgical blade
164749|NCT02108301|chronic hepatitis C-virus infection
164750|NCT02108301|renal transplantation
164751|NCT02108301|glucose tolerance
164752|NCT02108301|immunosuppression
164753|NCT02108236|acupuncture
164754|NCT02108236|chinese traditional medicine
164755|NCT02108223|ICSI
164756|NCT02108223|Suboptimal Ovarian Response
164757|NCT02108223|rLH
164758|NCT02108210|Chronic fatigue syndrome
164759|NCT02108210|Cytokines
164760|NCT02108210|Interleukin-1
164761|NCT02108210|Fatigue
164762|NCT02108210|Anakinra
164763|NCT02108184|helicobacter eradication rates
164764|NCT02108171|intranasal
164765|NCT02108171|dexmedetomidine
164766|NCT02108171|early recovery
164767|NCT02108171|suspension laryngoscopy
164768|NCT02108145|cholangiocarcinoma
164769|NCT02108145|jaundice
164770|NCT02108145|metal stent
164771|NCT02108145|PTBS
164772|NCT02108132|hemophilia
164773|NCT02108132|mesenchymal stem cells
164774|NCT02108132|in-vitro transdifferentiation
164775|NCT02108106|safety and tolerability
164776|NCT02108106|pharmacokinetic study
164777|NCT02108080|Alcohol
164778|NCT02108080|Adolescents
164779|NCT02108080|Adults
164780|NCT02108054|fMRI
164781|NCT02108054|Alcoholism
164782|NCT02108054|Phenotype
164783|NCT02108054|Imaging
164784|NCT02108041|Physicians
164785|NCT02108041|Pharmacogenetic Testing
164786|NCT02108041|Decision-Making
164787|NCT02108041|Communicative Behaviors
164788|NCT02108028|Advance Care Planning Guide
164789|NCT02108028|End-of-Life
164790|NCT02108015|Transmembrane AMPA Receptor Regulatory Protein
164791|NCT02108015|Glutamate Receptors
164792|NCT02108015|Healthy Volunteers
164793|NCT02108002|Missense Mutations
164794|NCT02108002|Hemangioblastoma
164795|NCT02108002|Histone Deacytelase Inhibitors
164796|NCT02108002|Von Hippel-Lindau Disease
164797|NCT02107989|Epilepsy
164798|NCT02107989|MRI
164799|NCT02107989|fMRI
164800|NCT02107989|MEG
164801|NCT02107976|Diabetes
164802|NCT02107976|Red Blood Cells
164803|NCT02107976|Vitamin C
164804|NCT02107976|Plasma Vitamin C Levels
164805|NCT02107963|GD2-Expressing Tumors
164806|NCT02107963|Anti-GD2 Chimeric Antigen Receptor
164807|NCT02107963|Osteosarcoma
164808|NCT02107963|Adoptive Immunotherapy
164809|NCT02107963|Sarcomas
164810|NCT02107950|Ovarian
164811|NCT02107950|Platinum Sensitive
164812|NCT02107950|Epithelial
164813|NCT02107937|serous
164814|NCT02107937|endometrioid
164815|NCT02107937|mucinous
164816|NCT02107937|epithelial ovarian cancer
164817|NCT02107924|Total
164818|NCT02107924|Knee
164819|NCT02107924|Replacment
164820|NCT02107924|Infection
164821|NCT02107924|Stimulan
164822|NCT02107911|men who have sex with men
164823|NCT02107911|non-occupational post exposure prophylaxis
164824|NCT02107911|HIV infection
164825|NCT02107859|Cystic fibrosis
164826|NCT02107859|Nonsense mutation
164827|NCT02107859|Premature stop codon
164828|NCT02107859|PTC124
164829|NCT02107859|Ataluren
164830|NCT02107820|Bladder training
164831|NCT02107820|Percutaneous Tibial nerve stimulation
164832|NCT02107820|Overactive bladder
164833|NCT02107820|Randomised controlled study
164834|NCT02107807|Influenza,
164835|NCT02107807|H5N1
164836|NCT02107807|aH5N1
164837|NCT02107807|H5N1 vaccine
164838|NCT02107807|Pandemic Influenza vaccine
164839|NCT02107807|MF59
164840|NCT02107807|Adjuvant
164841|NCT02107807|Avian flu
164842|NCT02107807|Underlying Immunosuppressive
164843|NCT02107807|immunosuppressive conditions
164844|NCT02107807|Pandemic vaccine
164845|NCT02107807|Adjuvanted vaccine
164846|NCT02107794|Grave's
164847|NCT02107794|Disease
164848|NCT02107794|Thyroid
164849|NCT02107794|Hyperthyroidism
164850|NCT02107794|Thyroidectomy
164851|NCT02107794|Radioactive
164852|NCT02107794|Iodine
164853|NCT02107794|Antithyroid
164854|NCT02107794|Shared
164855|NCT02107794|Decision
164856|NCT02107794|Making
164857|NCT02107794|Aid
164858|NCT02107794|Evidence
164859|NCT02107794|Based
164860|NCT02107794|Endocrinology
164861|NCT02107794|Mayo
164862|NCT02107794|Clinic
164863|NCT02107781|Open abdomen
164864|NCT02107781|abdominal compartment pressure
164865|NCT02107768|Stroke
164866|NCT02107768|Exercise
164867|NCT02107768|Randomized trial
164868|NCT02107768|Quality of Life
164869|NCT02107755|oligometastatic melanoma
164870|NCT02107755|melanoma
164871|NCT02107742|Injections
164872|NCT02107742|Time factors
164873|NCT02107742|Pain
164874|NCT02107742|Healthy volunteers
164875|NCT02107742|Lidocaine
164876|NCT02107729|Injections
164877|NCT02107729|Pain
164878|NCT02107729|Healthy volunteers
164879|NCT02107729|Lidocaine
164880|NCT02107716|Pain
164881|NCT02107716|Injections
164882|NCT02107716|Lidocaine
164883|NCT02107716|Healthy volunteers
164884|NCT02107703|MONARCH 2
164885|NCT02107690|Injections
164886|NCT02107690|Temperature
164887|NCT02107690|Pain
164888|NCT02107690|Healthy volunteers
164889|NCT02107690|Lidocaine
164890|NCT02107664|Radiotherapy
164891|NCT02107664|Cachexia
164892|NCT02107664|Inflammation
164893|NCT02107664|Depression
164894|NCT02107651|Bleeding
164895|NCT02107651|Anticoagulation
164896|NCT02107638|Parkinson's Disease
164897|NCT02107638|Osteopathic Manipulative Medicine
164898|NCT02107638|Falls
164899|NCT02107638|Balance
164900|NCT02107638|Motor function
164901|NCT02107625|Defecation
164902|NCT02107625|Abdominal pain
164903|NCT02107612|Mini-Dental Implant
164904|NCT02107612|Implant-Supported Dental Prosthesis
164905|NCT02107612|Minimally Invasive Surgical procedures
164906|NCT02107612|Overdentures
164907|NCT02107612|Aged
164908|NCT02107586|biceps tenodesis
164909|NCT02107586|biceps tenotomy
164910|NCT02107586|biceps tendonitis
164911|NCT02107586|biceps inflammation
164912|NCT02107586|shoulder surgery
164913|NCT02107573|Randomized Controlled Trial
164914|NCT02107573|Rotator Cuff Tear
164915|NCT02107573|Suprascapular Nerve
164916|NCT02107573|Decompression
164917|NCT02107573|Shoulder Surgery
164918|NCT02107560|Cholangitis
164919|NCT02107560|Bacteremia
164920|NCT02107560|Endotoxemia
164921|NCT02107560|Blood
164922|NCT02107560|Bile
164923|NCT02107547|Randomized Controlled Trial (RCT)
164924|NCT02107547|Type 2 SLAP lesions
164925|NCT02107547|labral tear
164926|NCT02107547|biceps tenodesis
164927|NCT02107547|shoulder surgery
164928|NCT02107547|RCT
164929|NCT02107547|Comparison between two alternative surgical procedures
164930|NCT02107534|parent training
164931|NCT02107534|homework
164932|NCT02107534|parenting stress
164933|NCT02107521|sperm morphology
164934|NCT02107521|ICSI
164935|NCT02107521|IMSI
164936|NCT02107521|implantation
164937|NCT02107521|pregnancy
164938|NCT02107508|activity energy expenditure
164939|NCT02107508|body composition
164940|NCT02107495|CHF
164941|NCT02107469|Diabetic Polyneuropathy
164942|NCT02107469|Diabetic
164943|NCT02107469|Polyneuropathy
164944|NCT02107469|Ayurvedic
164945|NCT02107469|Ayurveda
164946|NCT02107469|Neuralgia
164947|NCT02107469|Diabetic Neuralgia
164948|NCT02107469|Sida cordifolia
164949|NCT02107469|Phyllanthus Niruri
164950|NCT02107469|Phyllanthus Amarus
164951|NCT02107469|Extracts
164952|NCT02107469|Extract
164953|NCT02107469|Crude Herb
164954|NCT02107469|Crude
164955|NCT02107469|Herb
164956|NCT02107469|Herbal
164957|NCT02107469|Herbal Extract
164958|NCT02107469|Decoction
164959|NCT02107469|Churna
164960|NCT02107469|Powder
164961|NCT02107469|Bala
164962|NCT02107469|Bhumyamalaki
164963|NCT02107469|Tamalaki
164964|NCT02107456|Dry Needling, Myofascial trigger point, Upper trapezius
164965|NCT02107430|Immunotherapy
164966|NCT02107430|Prostate Cancer
164967|NCT02107430|Biological, Vaccine
164968|NCT02107417|chemotherapy
164969|NCT02107417|pain
164970|NCT02107417|paresthesia
164971|NCT02107417|Physiotherapy
164972|NCT02107417|Transcutaneous Electrical Nerve Stimulation
164973|NCT02107404|Immunotherapy
164974|NCT02107404|Prostate Cancer
164975|NCT02107404|Biological
164976|NCT02107404|Vaccine
164977|NCT02107391|Immunotherapy
164978|NCT02107391|Prostate Cancer
164979|NCT02107391|Biological
164980|NCT02107391|Vaccine
164981|NCT02107391|Androgen Deprivation Therapy
164982|NCT02107378|Immunotherapy
164983|NCT02107378|Serous
164984|NCT02107378|Relapsed
164985|NCT02107378|Platinum resistant (pt)
164986|NCT02107378|Ovarian Cancer (OvCa)
164987|NCT02107378|Biological
164988|NCT02107378|Vaccine
164989|NCT02107365|Hepatitis C
164990|NCT02107365|HCV infection
164991|NCT02107365|HCV genotype 4
164992|NCT02107365|Non-responders HCV infected patients
164993|NCT02107365|Asunaprevir
164994|NCT02107365|Daclatasvir
164995|NCT02107365|Pegylated Interferon
164996|NCT02107365|Ribavirin
164997|NCT02107352|Anti-craving medication
164998|NCT02107352|Inhibition
164999|NCT02107352|Attentional Bias
165000|NCT02107352|Event-Related Potentials
165001|NCT02107352|Relapse
165002|NCT02107339|methadone
165003|NCT02107339|hydromorphone
165004|NCT02107339|acute postoperative pain
165005|NCT02107339|chronic persistent surgical pain
165006|NCT02107326|Type 1 diabetes
165007|NCT02107326|HbA1C
165008|NCT02107326|Quality of Life
165009|NCT02107326|Hypoglycaemia
165010|NCT02107326|Self-management
165011|NCT02107326|Telemedicine
165012|NCT02107300|Obstructive Sleep Apnea Syndrome
165013|NCT02107274|Azithromycin
165014|NCT02107274|Bronchiectasis
165015|NCT02107274|Macrolide
165016|NCT02107274|Inflammation
165017|NCT02107274|Pulmonary
165018|NCT02107261|Musician's Dystonia
165019|NCT02107248|Arthroplasty
165020|NCT02107248|Replacement
165021|NCT02107248|Hip
165022|NCT02107248|Posterolateral surgery
165023|NCT02107248|Precautions
165024|NCT02107235|Chemoradiotherapy
165025|NCT02107235|cisplatin
165026|NCT02107222|COPD
165027|NCT02107222|Exacerbation
165028|NCT02107222|invasive ventilation
165029|NCT02107222|CO2-Removal
165030|NCT02107196|Irritable Bowel Syndrome
165031|NCT02107196|Colon, irritable
165032|NCT02107196|Bowel disease
165033|NCT02107196|Diarrhea
165034|NCT02107183|Oxygen therapy
165035|NCT02107183|Extubation
165036|NCT02107183|Weaning
165037|NCT02107183|Reintubation
165038|NCT02107183|Acute respiratory failure
165039|NCT02107144|trimetazidine
165040|NCT02107144|microcirculation
165041|NCT02107144|stenting
165042|NCT02107144|pressure wire
165043|NCT02107118|Stem cells
165044|NCT02107118|cardiovascular disease
165045|NCT02107118|erectile dysfunction
165046|NCT02107105|Rectal cancer
165047|NCT02107105|Adenocarcinoma of the rectum
165048|NCT02107105|Quality of Life
165049|NCT02107105|QOL
165050|NCT02107105|Post surgery
165051|NCT02107105|Pre-surgery
165052|NCT02107105|Questionnaires
165053|NCT02107105|Surveys
165054|NCT02107079|melatonin
165055|NCT02107079|bioavailability
165056|NCT02107079|pharmacokinetics
165057|NCT02107066|exercise
165058|NCT02107066|physical activity
165059|NCT02107066|ovarian cancer
165060|NCT02107066|quality of life
165061|NCT02107066|fatigue
165062|NCT02107066|weight
165063|NCT02107053|Oxidative stress,
165064|NCT02107053|hemodialysis,
165065|NCT02107053|pomegranate juice,
165066|NCT02107053|dietary supplement
165067|NCT02107053|patients
165068|NCT02107001|Lung ultrasound
165069|NCT02107001|Community acquired p neumonia (CAP)
165070|NCT02107001|Pleuritis
165071|NCT02107001|Pulmonary embolism
165072|NCT02107001|Lung Cancer
165073|NCT02106988|Lymphoma
165074|NCT02106988|NK cell lymphoma-nasal type
165075|NCT02106988|Radiation therapy
165076|NCT02106988|XRT
165077|NCT02106988|Dexamethasone
165078|NCT02106988|Decadron
165079|NCT02106988|Etoposide
165080|NCT02106988|VePesid
165081|NCT02106988|Ifosfamide
165082|NCT02106988|Ifex
165083|NCT02106988|Mesna
165084|NCT02106988|Mesnex
165085|NCT02106988|Carboplatin
165086|NCT02106988|Paraplatin
165087|NCT02106962|hemodialysis
165088|NCT02106962|fistula
165089|NCT02106962|clotting
165090|NCT02106962|tranexamic acid
165091|NCT02106962|bacitracin
165092|NCT02106949|suicide attempt, SMS monitoring, recurrence, phone, prevention control, tertiary healthcare
165093|NCT02106936|Focal Hand Dystonia
165094|NCT02106936|Depotentiation
165095|NCT02106936|Transcranial Magnetic Stimulation (TMS)
165096|NCT02106936|Rapid Paired Associative Stimulation
165097|NCT02106936|Healthy Volunteer
165098|NCT02106910|Barrett's Esophagus
165099|NCT02106910|Radiofrequency Ablation
165100|NCT02106884|Pancreatic cancer
165101|NCT02106884|Locally advanced
165102|NCT02106884|Metastatic
165103|NCT02106871|cancer
165104|NCT02106871|pancreas
165105|NCT02106871|cholangiocarcinoma
165106|NCT02106871|fatigue
165107|NCT02106871|sildenafil
165108|NCT02106871|lean mass
165109|NCT02106871|muscle
165110|NCT02106858|Stivarga / Regorafenib / Metastatic Colorectal Cancer / Metastatic or unresectable locally advanced GIST (Gastrointestinal stromal tumors)
165111|NCT02106845|Regorafenib
165112|NCT02106845|Probe substrates
165113|NCT02106845|Pharmacokinetics
165114|NCT02106845|Cancer
165115|NCT02106845|Safety
165116|NCT02106845|Advanced solid malignant tumors
165117|NCT02106832|Ciprofloxacin
165118|NCT02106832|Dry Powder for Inhalation
165119|NCT02106832|Exacerbation
165120|NCT02106832|Bronchiectasis
165121|NCT02106819|Cerebellar Ataxia
165122|NCT02106819|Emotions
165123|NCT02106819|Affective Prosody
165124|NCT02106819|Facial Expression
165125|NCT02106819|Magnetic Resonance Imaging
165126|NCT02106806|Oxidative stress
165127|NCT02106806|Zinc
165128|NCT02106806|Chemotherapy
165129|NCT02106806|Colorectal cancer
165130|NCT02106793|Chronic Rhinosinusitis
165131|NCT02106793|Mitomicin C
165132|NCT02106793|Postoperative nasal synerchia
165133|NCT02106780|Phase 1
165134|NCT02106780|Healthy subjects
165135|NCT02106780|Excretion
165136|NCT02106780|14C-labeled ASP1707
165137|NCT02106767|rosuvastatin
165138|NCT02106767|rifampin
165139|NCT02106767|pharmacokinetics
165140|NCT02106767|drug interaction
165141|NCT02106767|healthy volunteer
165142|NCT02106767|drug transporter
165143|NCT02106767|Asian
165144|NCT02106767|White
165145|NCT02106741|Pain
165146|NCT02106741|Acupressure
165147|NCT02106741|Symptoms
165148|NCT02106741|Fatigue
165149|NCT02106741|Self-administered
165150|NCT02106728|Eating Disorders
165151|NCT02106728|Family Therapy
165152|NCT02106728|Multi-Family Therapy
165153|NCT02106728|Bulimia Nervosa
165154|NCT02106728|Eating Disorder Not Otherwise Specified
165155|NCT02106702|HIV
165156|NCT02106702|detention
165157|NCT02106702|substance abuse
165158|NCT02106689|infertility, superovulation, gonadotropins, needle free injection system
165159|NCT02106676|polycystic ovary Syndrome
165160|NCT02106676|hyperandrogenism
165161|NCT02106676|cordblood
165162|NCT02106676|androgens
165163|NCT02106663|atrial fibrillation
165164|NCT02106663|paroxysmal atrial fibrillation
165165|NCT02106663|PAF
165166|NCT02106663|arrhythmia
165167|NCT02106663|atrial fibrillation ablation
165168|NCT02106663|circumferential ablation
165169|NCT02106663|CPVA
165170|NCT02106663|segmental ablation
165171|NCT02106663|PVI
165172|NCT02106663|pulmonary vein isolation
165173|NCT02106650|Relapsed PTCL
165174|NCT02106650|Refractory PTCL
165175|NCT02106637|ACS
165176|NCT02106637|Cessation
165177|NCT02106624|mechanical ventilation
165178|NCT02106611|MRI
165179|NCT02106611|stress echo
165180|NCT02106611|Clinical Assessment
165181|NCT02106611|14-017
165182|NCT02106598|Sentinel Lymph Node Mapping
165183|NCT02106598|Intraoperative Sentinel
165184|NCT02106598|Head and Neck Melanoma
165185|NCT02106598|Targeted Silica Nanoparticles
165186|NCT02106598|cRGDY-PEG-Cy5.5-C dots
165187|NCT02106598|13-249
165188|NCT02106585|Safety
165189|NCT02106585|Tolerability
165190|NCT02106585|Pharmacokinetics
165191|NCT02106585|Food-effect
165192|NCT02106585|Diabetes
165193|NCT02106572|superficial bladder cancer
165194|NCT02106572|viscum album extract
165195|NCT02106572|mistletoe extract
165196|NCT02106572|abnobaVISCUM
165197|NCT02106572|recurrence rate
165198|NCT02106559|Pleural Photodynamic Therapy
165199|NCT02106559|Pleural Malignancy
165200|NCT02106559|PDT
165201|NCT02106546|carboplatin
165202|NCT02106546|Randomized
165203|NCT02106546|veliparib
165204|NCT02106546|Advanced
165205|NCT02106546|Metastatic
165206|NCT02106546|Overall Survival
165207|NCT02106546|Squamous
165208|NCT02106546|placebo controlled
165209|NCT02106546|ABT-888
165210|NCT02106546|Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)
165211|NCT02106546|non-small cell lung cancer
165212|NCT02106546|paclitaxel
165213|NCT02106533|Coronary artery disease
165214|NCT02106533|Exercise
165215|NCT02106533|Ventilatory efficiency
165216|NCT02106520|Epistaxis
165217|NCT02106520|Bevacizumab
165218|NCT02106507|Apalutamide
165219|NCT02106507|RAD001
165220|NCT02106507|Everolimus
165221|NCT02106507|Castration-resistant
165222|NCT02106507|13-025
165223|NCT02106507|ARN-509
165224|NCT02106494|Highly emetogenic chemotherapy (HEC)
165225|NCT02106494|Chemotherapy-Induced Nausea and Vomiting (CINV)
165226|NCT02106481|TKA
165227|NCT02106481|TKR
165228|NCT02106481|Knee OA
165229|NCT02106481|pain management
165230|NCT02106481|Femoral Nerve Catheter
165231|NCT02106481|Single Shot Femoral Nerve Blocks
165232|NCT02106468|Oral Lichen Planus
165233|NCT02106468|Corticosteroid
165234|NCT02106468|Omega -3
165235|NCT02106455|Pharmacological theapy
165236|NCT02106442|Pharmacological therapy
165237|NCT02106429|Vascular Surgery
165238|NCT02106416|prostate cancer
165239|NCT02106416|bladder cancer
165240|NCT02106416|MRI
165241|NCT02106416|PET
165242|NCT02106416|perfusion
165243|NCT02106390|Meningitis, vaccination, infant
165244|NCT02106377|(DES)
165245|NCT02106338|follow-up to 10-0008, Clostridium difficile, dose-escalating, CRS3123
165246|NCT02106325|Ketamine
165247|NCT02106325|Ketlar
165248|NCT02106325|Depression
165249|NCT02106325|Antidepressants
165250|NCT02106325|Treatment
165251|NCT02106325|Acute
165252|NCT02106312|Radiotherapy
165253|NCT02106312|Myxoid liposarcoma
165254|NCT02106312|Soft tissue sarcoma
165255|NCT02106286|Cardiopulmonary exercise test
165256|NCT02106286|surgery
165257|NCT02106286|abdominal aortic aneurysm
165258|NCT02106286|anaerobic threshold
165259|NCT02106286|fitness
165260|NCT02106286|beta-blockers
165261|NCT02106273|LMA
165262|NCT02106273|Bronchial blocker
165263|NCT02106260|safety
165264|NCT02106260|pharmacokinetics (PK)
165265|NCT02106260|pharmacodynamics (PD)
165266|NCT02106260|CLS003
165267|NCT02106234|contrast induced nephropathy
165268|NCT02106234|prophylactic intravenous hydration
165269|NCT02106234|intravenous normal saline
165270|NCT02106234|acute kidney injury
165271|NCT02106221|Care coordination
165272|NCT02106221|nurse care management
165273|NCT02106221|practice facilitation
165274|NCT02106221|health information technology
165275|NCT02106182|Benign prostatic hyperplasia
165276|NCT02106182|Nocturia
165277|NCT02106182|Silodosin
165278|NCT02106182|Thrupas
165279|NCT02106169|Food allergy
165280|NCT02106169|Children and families
165281|NCT02106169|Therapeutic education
165282|NCT02106169|Quality of life
165283|NCT02106130|Mosapride citrate
165284|NCT02106130|Rebamipide
165285|NCT02106130|pharmacokinetic drug drug interaction
165286|NCT02106130|oral administration
165287|NCT02106130|healthy male subjects
165288|NCT02106104|Type 2 diabetes mellitus
165289|NCT02106104|Diabetic kidney disease
165290|NCT02106104|Diabetic nephropathy
165291|NCT02106104|Renoprotection
165292|NCT02106104|DPP-4 inhibitors
165293|NCT02106104|Linagliptin
165294|NCT02106104|SU derivatives
165295|NCT02106104|Glimepiride
165296|NCT02106078|Bipolar Disorder
165297|NCT02106078|Bipolar
165298|NCT02106078|Online Intervention
165299|NCT02106078|Internet intervention
165300|NCT02106078|Self-Help
165301|NCT02106065|Dementia
165302|NCT02106065|Caregivers
165303|NCT02106065|Neurodegenerative Diseases
165304|NCT02106065|Brain Diseases
165305|NCT02106065|Cost of Illness
165306|NCT02106065|Stress, Psychological
165307|NCT02106065|Depression
165308|NCT02106065|Vital Statistics
165309|NCT02106065|Mortality
165310|NCT02106065|Behavioral Symptoms
165311|NCT02106065|Residential Facilities
165312|NCT02106065|Emergency Medical Services
165313|NCT02106065|Long-Term Care
165314|NCT02106052|cognitive function
165315|NCT02106052|cognitive impairment
165316|NCT02106052|cognitive intervention
165317|NCT02106052|cognitive improvement
165318|NCT02106052|information processing speed
165319|NCT02106052|exercise training program
165320|NCT02106052|aerobic exercise
165321|NCT02106052|stretching and toning
165322|NCT02106052|Multiple sclerosis
165323|NCT02106052|executive function
165324|NCT02106039|diabetes mellitus
165325|NCT02106039|tuberculosis
165326|NCT02106039|management
165327|NCT02106039|randomized controlled trial
165328|NCT02106026|Breastfeeding
165329|NCT02106026|Nursing
165330|NCT02106026|Patient Education as Topic
165331|NCT02106026|Health Knowledge, Attitudes, Practice
165332|NCT02106026|Hispanic Americans.
165333|NCT02106013|HDL
165334|NCT02106013|Carotid artery intima-media thickness
165335|NCT02106013|Cholesterol efflux capacity
165336|NCT02106013|Antioxidant effect of HDL
165337|NCT02106013|Susceptibility to oxidation of HDL
165338|NCT02106013|Anti-inflammatory effect of HDL
165339|NCT02106013|Platelet aggregation inhibition by HDL
165340|NCT02106000|Post Partum
165341|NCT02106000|Inhaled Oxytocin
165342|NCT02106000|Inhalation Profiles
165343|NCT02105987|Abacavir/dolutegravir/lamivudine
165344|NCT02105987|Fixed-dose combination
165345|NCT02105987|Once daily
165346|NCT02105987|Trii
165347|NCT02105987|Single-tablet regimen
165348|NCT02105974|COPD
165349|NCT02105974|Fluticasone Furoate (FF)
165350|NCT02105974|Vilanterol (VI)
165351|NCT02105974|Dry Powder Inhaler
165352|NCT02105961|Chronic Obstructive Pulmonary Disease
165353|NCT02105961|exacerbations
165354|NCT02105961|SB240563
165355|NCT02105961|mepolizumab
165356|NCT02105961|eosinophils
165357|NCT02105948|eosinophils
165358|NCT02105948|SB240563
165359|NCT02105948|exacerbations
165360|NCT02105948|Chronic Obstructive Pulmonary Disease
165361|NCT02105948|mepolizumab
165362|NCT02105922|Frailty
165363|NCT02105922|Ageing
165364|NCT02105922|Protein supplementation
165365|NCT02105922|Protein quality
165366|NCT02105922|Exercise training
165367|NCT02105922|Sarcopenia
165368|NCT02105896|dental bonding
165369|NCT02105857|knee mobilazation
165370|NCT02105857|TKA
165371|NCT02105857|joint replacement
165372|NCT02105857|rehabilitation
165373|NCT02105844|atrial fibrillation
165374|NCT02105844|dementia
165375|NCT02105844|cognitive dysfunction
165376|NCT02105844|stroke
165377|NCT02105844|Magnetic resonance imaging
165378|NCT02105831|left ventricular assist device
165379|NCT02105831|contrast ultrasound
165380|NCT02105831|perfusion imaging
165381|NCT02105818|Self-reported questionnaire
165382|NCT02105818|Swallowing disorders
165383|NCT02105818|Systemic sclerosis
165384|NCT02105818|Drug therapy
165385|NCT02105818|Adherence to medication regime
165386|NCT02105818|Coping strategy
165387|NCT02105818|Pharmaceutical care
165388|NCT02105818|Patient safety
165389|NCT02105818|Patient oriented care
165390|NCT02105805|intention weight loss
165391|NCT02105805|heart failure
165392|NCT02105805|6-minute walk test
165393|NCT02105792|Diabetes
165394|NCT02105792|Type 2 diabetes
165395|NCT02105792|Diabetes therapy response
165396|NCT02105792|Diabetes progression
165397|NCT02105766|Sickle Cell Disease
165398|NCT02105766|Allogeneic Hematopoietic Stem Cell Transplant
165399|NCT02105766|Pentostatin (Nipent)
165400|NCT02105766|Cyclophosphamide
165401|NCT02105766|Alemtuzumab (Campath)
165402|NCT02105740|BEHAVIORAL
165403|NCT02105740|HYPNOSIS
165404|NCT02105740|ANXIETY
165405|NCT02105740|DEPRESSION
165406|NCT02105727|Dietary sodium
165407|NCT02105727|Urinary sodium excretion
165408|NCT02105727|Urinary iodine excretion
165409|NCT02105714|Diarrhoea
165410|NCT02105714|Abdominal pain
165411|NCT02105714|Bacterial
165412|NCT02105714|Protozoal
165413|NCT02105714|Helminth
165414|NCT02105675|Immunotherapy
165415|NCT02105675|Metastatic
165416|NCT02105675|Castrate Resistant
165417|NCT02105675|Prostate Cancer
165418|NCT02105675|Biological
165419|NCT02105675|Vaccine
165420|NCT02105649|cerebral palsy
165421|NCT02105649|standing
165422|NCT02105649|strengthening
165423|NCT02105623|Coronary Arteriosclerosis
165424|NCT02105623|rosuvastatin
165425|NCT02105610|volatile anesthetics
165426|NCT02105610|desflurane
165427|NCT02105610|isoflurane
165428|NCT02105610|sevoflurane
165429|NCT02105610|TIVA
165430|NCT02105610|cardiac surgery
165431|NCT02105610|mortality
165432|NCT02105610|anesthesia
165433|NCT02105610|intensive care
165434|NCT02105597|Diabetes mellitus
165435|NCT02105597|Medication adherence
165436|NCT02105597|Compliance
165437|NCT02105597|Mobile health
165438|NCT02105571|Body Weight
165439|NCT02105571|Nutrition
165440|NCT02105571|Physical Activity
165441|NCT02105571|Sleep
165442|NCT02105571|Health Promotion
165443|NCT02105571|Stress
165444|NCT02105571|Safety
165445|NCT02105558|trial of labor after cesarean
165446|NCT02105558|vaginal birth after cesarean
165447|NCT02105558|epidural vs combined spinal epidural
165448|NCT02105545|cancer
165449|NCT02105545|oncology
165450|NCT02105545|malignant
165451|NCT02105545|malignancy
165452|NCT02105545|genetics
165453|NCT02105545|genomics
165454|NCT02105545|exome
165455|NCT02105545|DNA
165456|NCT02105545|RNA
165457|NCT02105545|sequencing
165458|NCT02105545|epigenetic
165459|NCT02105545|clinically actionable findings
165460|NCT02105545|CAF
165461|NCT02105545|secondary findings
165462|NCT02105545|SF
165463|NCT02105545|single nucleotide variants
165464|NCT02105545|SNV
165465|NCT02105545|bioinformatics
165466|NCT02105545|genotype
165467|NCT02105545|The American College of Medical Genetics and Genomics
165468|NCT02105545|ACMG
165469|NCT02105532|Transfusion in gastrointestinal bleeding
165470|NCT02105519|trivalent influenza vaccine, chronic kidney disease
165471|NCT02105506|Esophagus
165472|NCT02105506|Stomach
165473|NCT02105506|Resection
165474|NCT02105506|Esophageal disease requiring surgery
165475|NCT02105506|Gastric disease requiring surgery
165476|NCT02105493|Nitroglycerin
165477|NCT02105493|Radial Artery Occlusion
165478|NCT02105493|Transradial Catheterization
165479|NCT02105480|Computer aided auscultation (CAA)
165480|NCT02105480|Phonocardiogram analysis
165481|NCT02105480|Murmur detection
165482|NCT02105480|Heart auscultation
165483|NCT02105441|cochlear implant
165484|NCT02105428|Polycystic Ovarian Syndrome (PCOS)
165485|NCT02105428|Insulin Resistance
165486|NCT02105428|Overweight, Obese Women
165487|NCT02105428|Protein Metabolism
165488|NCT02105428|Post Translational Modifications
165489|NCT02105415|Critical care
165490|NCT02105415|Emergent
165491|NCT02105415|Etomidate
165492|NCT02105415|Hemodynamics
165493|NCT02105415|Intensive care unit
165494|NCT02105415|Intubation
165495|NCT02105415|Ketamine-Propofol admixture
165496|NCT02105402|Speech sound disorders
165497|NCT02105402|Randomized Controlled Trial
165498|NCT02105402|Speech intelligibility
165499|NCT02105402|PROMPT treatment
165500|NCT02105402|Developmental motor speech disorders
165501|NCT02105402|Children
165502|NCT02105402|Functional outcomes
165503|NCT02105402|Treatment efficacy
165504|NCT02105389|fatigue
165505|NCT02105389|quality of life
165506|NCT02105389|chemotherapy
165507|NCT02105389|haematopoietic stem cell transplantation
165508|NCT02105389|children
165509|NCT02105389|pilot
165510|NCT02105389|yoga
165511|NCT02105376|depression
165512|NCT02105376|cranial nerve stimulation
165513|NCT02105376|trigeminal stimulation
165514|NCT02105350|MEK162
165515|NCT02105350|Gemcitabine
165516|NCT02105350|Oxaliplatin
165517|NCT02105350|Non-resectable
165518|NCT02105350|Recurrent or metastatic
165519|NCT02105324|bionic pancreas
165520|NCT02105324|artificial pancreas
165521|NCT02105324|insulin
165522|NCT02105324|glucagon
165523|NCT02105324|continuous glucose monitoring (CGM)
165524|NCT02105324|outpatient
165525|NCT02105324|insulin pump
165526|NCT02105324|pediatrics
165527|NCT02105324|children
165528|NCT02105324|camp
165529|NCT02105324|summer camp
165530|NCT02105311|Intraocular pressure
165531|NCT02105311|Selective laser trabeculoplasty
165532|NCT02105311|Travoprost
165533|NCT02105311|Ocular surface disease
165534|NCT02105311|Glaucoma symptom scale
165535|NCT02105298|Fluids
165536|NCT02105298|Intraoperative
165537|NCT02105298|Respiratory
165538|NCT02105298|Outcomes
165539|NCT02105298|Surgery
165540|NCT02105298|Anesthesia
165541|NCT02105259|Test
165542|NCT02105259|psychodynamic
165543|NCT02105259|Internet-delivered psychodynamic treatment
165544|NCT02105259|patients with social anxiety disorder
165545|NCT02105246|Cardiac rehabilitation
165546|NCT02105246|home based care
165547|NCT02105246|secondary prevention
165548|NCT02105246|efficacy
165549|NCT02105246|6 minute walk rates.
165550|NCT02105233|ultrasonography
165551|NCT02105233|ultrasonics
165552|NCT02105233|brain
165553|NCT02105233|surgery
165554|NCT02105220|Respiratory mechanics
165555|NCT02105220|Esophageal pressure
165556|NCT02105220|Functional residual capacity
165557|NCT02105220|positive end-expiratory pressure
165558|NCT02105194|cerebral decompression illness
165559|NCT02105181|benign biliary stricture
165560|NCT02105181|anastomotic biliary stricture after liver transplantation
165561|NCT02105181|chronic pancreatitis
165562|NCT02105181|biliary surgical procedure
165563|NCT02105181|fully covered metal stent
165564|NCT02105155|Liver transplantation,
165565|NCT02105155|Conversion (Prograf® to Advagraf®),
165566|NCT02105155|Prograf® ,
165567|NCT02105155|Advagraf® ,
165568|NCT02105155|acute rejection,
165569|NCT02105155|GFR
165570|NCT02105142|Attention deficit hyperactivity disorder
165571|NCT02105142|Interventions
165572|NCT02105142|Primary care
165573|NCT02105142|Pediatric
165574|NCT02105090|Upper gastrointestinal tract
165575|NCT02105090|Endoscopy
165576|NCT02105090|Lozenge
165577|NCT02105090|Articaine
165578|NCT02105090|Dyspepsia
165579|NCT02105090|Hematemesis
165580|NCT02105090|Abdominal pain
165581|NCT02105090|Heartburn
165582|NCT02105077|xenon
165583|NCT02105077|doping
165584|NCT02105077|anesthesia
165585|NCT02105077|mass spectrometry
165586|NCT02105077|surgery
165587|NCT02105038|distal radius fracture
165588|NCT02105038|steering
165589|NCT02105038|steering wheel spinner knob
165590|NCT02105025|insertion time
165591|NCT02105012|Mild
165592|NCT02105012|moderate persistent
165593|NCT02105012|Adult
165594|NCT02104986|non seminomateous malignant germ cell tumour (NSMGCT)
165595|NCT02104986|Dose De-escalation
165596|NCT02104986|Chemotherapy
165597|NCT02104960|Skin Surface Microscopy
165598|NCT02104960|Skin Aging
165599|NCT02104960|PROOF
165600|NCT02104895|Breast cancer
165601|NCT02104895|Early breast cancer
165602|NCT02104895|Adjuvant breast cancer
165603|NCT02104895|Accelerated partial breast irradiation
165604|NCT02104895|Intensity modulated radiotherapy
165605|NCT02104882|Glioblastoma Multiforme
165606|NCT02104882|High-Grade Glioma
165607|NCT02104882|Malignant Glioma
165608|NCT02104882|IORT
165609|NCT02104869|Influenza vaccine
165610|NCT02104856|Asthma
165611|NCT02104856|Bronchial Thermoplasty
165612|NCT02104856|Registry
165613|NCT02104856|Device
165614|NCT02104856|Alair
165615|NCT02104830|empegfilgrastim
165616|NCT02104830|pegylated filgrastim
165617|NCT02104830|neutropenia
165618|NCT02104830|febrile neutropenia
165619|NCT02104830|chemotherapy-associated neutropenia
165620|NCT02104830|breast cancer
165621|NCT02104830|docetaxel
165622|NCT02104830|doxorubicin
165623|NCT02104817|omega-3 carboxylic acid
165624|NCT02104804|Type 2 Diabetes Mellitus, Insulin, Dipeptidyl-Peptidase 4 Inhibitors, Metformin,saxagliptin,Endocrine System Diseases
165625|NCT02104791|Procalcitonin
165626|NCT02104791|intra-amniotic subclinical infection.
165627|NCT02104752|Curcumin
165628|NCT02104752|Turmeric
165629|NCT02104752|Schizophrenia
165630|NCT02104752|Cognition
165631|NCT02104752|Psychosis
165632|NCT02104739|prediabetes
165633|NCT02104739|diabetes mellitus type 2
165634|NCT02104739|exenatide
165635|NCT02104739|saxagliptin
165636|NCT02104739|exenatide ER
165637|NCT02104713|Skin Burn Degree Second
165638|NCT02104713|Second degree Burn
165639|NCT02104713|Burn wound
165640|NCT02104700|HIV
165641|NCT02104687|GTD, goal-directed haemodynamic therapy
165642|NCT02104687|CI, cardiac index
165643|NCT02104687|MAP, mean arterial pressure
165644|NCT02104687|CVP, central venous pressure
165645|NCT02104622|spinal cord injury
165646|NCT02104622|exoskeleton
165647|NCT02104622|ambulation
165648|NCT02104622|walking
165649|NCT02104622|robotics
165650|NCT02104609|Obesity
165651|NCT02104609|Emergency contraception
165652|NCT02104609|Levonorgestrel emergency contraception
165653|NCT02104583|VT
165654|NCT02104583|VF
165655|NCT02104583|Ventricular Tachycardia
165656|NCT02104583|Ventricular Fibrillation
165657|NCT02104583|shock
165658|NCT02104583|ATP
165659|NCT02104570|Fatigue
165660|NCT02104570|Proprioception
165661|NCT02104570|Shoulder
165662|NCT02104557|Sayana
165663|NCT02104557|Pregnancy
165664|NCT02104557|Contraception
165665|NCT02104557|Endometriosis-associated pain
165666|NCT02104557|PMS
165667|NCT02104557|Post Marketing Surveillance
165668|NCT02104544|DHA intake;
165669|NCT02104544|Plasma;
165670|NCT02104544|Erythrocyte;
165671|NCT02104544|Breast milk.
165672|NCT02104518|glucose-6-phosphate dehydrogenase
165673|NCT02104518|point-of-care diagnostic testing
165674|NCT02104492|multiple sclerosis
165675|NCT02104492|respiratory muscle strength
165676|NCT02104492|maximal inspiratory pressure (MIP)
165677|NCT02104492|maximal expiratory pressure (MEP)
165678|NCT02104492|respiratory muscle endurance
165679|NCT02104492|quality of life
165680|NCT02104492|qualitative research
165681|NCT02104466|acupuncture
165682|NCT02104466|pain
165683|NCT02104466|neuropathy
165684|NCT02104453|airway maneuver
165685|NCT02104440|Cytopenia
165686|NCT02104414|Liposomal Bupivacaine
165687|NCT02104414|Exparel
165688|NCT02104375|wave reflection
165689|NCT02104375|augmentation Index
165690|NCT02104375|heart rate variability
165691|NCT02104375|arterial stiffness
165692|NCT02104349|spine surgery
165693|NCT02104349|post op pain management
165694|NCT02104336|Pearson
165695|NCT02104336|EPI743
165696|NCT02104336|EPI-743
165697|NCT02104336|Vincerinone
165698|NCT02104336|Mitochondrial disorder
165699|NCT02104336|Mitochondrial disease
165700|NCT02104323|Neurofibromatosis Type 2
165701|NCT02104323|Vestibular Schwannoma
165702|NCT02104323|Other NF2-related tumors
165703|NCT02104310|malignant glioma
165704|NCT02104310|FDOPA
165705|NCT02104310|PET CT
165706|NCT02104310|radiation therapy
165707|NCT02104297|Nasal septum operation
165708|NCT02104297|agitation
165709|NCT02104284|Bronchial provocation test
165710|NCT02104284|Mannitol
165711|NCT02104284|Methacholine
165712|NCT02104284|Bronchial hyperreactivity
165713|NCT02104284|Sensitivity and specificity
165714|NCT02104271|chronic radiation proctitis
165715|NCT02104271|argon plasma coagulation
165716|NCT02104271|rectal bleeding
165717|NCT02104258|Hamstring
165718|NCT02104258|Muscle
165719|NCT02104258|Injury
165720|NCT02104258|Treatment
165721|NCT02104258|Rehabilitation
165722|NCT02104245|Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa
165723|NCT02104232|Maternal depression
165724|NCT02104219|Hypophosphatasia
165725|NCT02104219|HPP
165726|NCT02104219|bone disease
165727|NCT02104219|Soft Bones
165728|NCT02104219|low Alkaline Phosphatase
165729|NCT02104219|genetic metabolic disorder
165730|NCT02104219|alkaline phosphatase
165731|NCT02104219|tissue non-specific alkaline phosphatase
165732|NCT02104219|rickets
165733|NCT02104219|osteomalacia
165734|NCT02104193|brain metastases
165735|NCT02104193|simvastatin
165736|NCT02104193|radiation therapy
165737|NCT02104180|non-inferiority
165738|NCT02104180|randomized
165739|NCT02104180|TulleGras
165740|NCT02104180|Urgotul
165741|NCT02104180|pain
165742|NCT02104180|venous leg ulcer
165743|NCT02104180|healing
165744|NCT02104167|DDD
165745|NCT02104167|degenerative disc disease
165746|NCT02104167|cervical spine
165747|NCT02104167|fusion rate
165748|NCT02104141|DDD
165749|NCT02104141|lumbar spine
165750|NCT02104141|fusion rate
165751|NCT02104141|degenerative disc disease
165752|NCT02104128|Anhedonia
165753|NCT02104128|Dopamine
165754|NCT02104128|Bupropion
165755|NCT02104128|fMRI
165756|NCT02104128|emotional processing
165757|NCT02104128|reward
165758|NCT02104115|Stomach
165759|NCT02104115|Small bowel
165760|NCT02104115|Colon
165761|NCT02104115|MRI
165762|NCT02104115|Function
165763|NCT02104115|Gastrointestinal volumes
165764|NCT02104102|Elderly
165765|NCT02104102|mirror therapy
165766|NCT02104102|hands
165767|NCT02104089|Thoracoabdominal aortic aneurysm
165768|NCT02104089|Endovascular
165769|NCT02104089|Fenestration
165770|NCT02104089|Branch
165771|NCT02104089|Off-the-shelf
165772|NCT02104076|Bile Duct Obstructions
165773|NCT02104076|Biliary Stases
165774|NCT02104076|Biliary Tract
165775|NCT02104076|Stents
165776|NCT02104024|Kidney
165777|NCT02104024|Pancreas
165778|NCT02104024|Transplant
165779|NCT02104024|Contrast Enhanced Ultrasound
165780|NCT02104011|Angiomyolipomas in tuberous sclerosis
165781|NCT02104011|Beta-blockers
165782|NCT02104011|Anti-angiogenic therapies
165783|NCT02103998|extremely low gestational age neonate
165784|NCT02103998|hypothyroxinemia of prematurity
165785|NCT02103998|brain development
165786|NCT02103998|cerebral palsy
165787|NCT02103998|cognitive dealy
165788|NCT02103985|Healthy
165789|NCT02103985|JNJ-39823277
165790|NCT02103985|JNJ-40917006
165791|NCT02103985|Pharmacokinetics
165792|NCT02103972|All subjects of any ethnicity aged from 4 to 30 months with atopic dermatitis skin symptoms with a SCORAD equal or above 20
165793|NCT02103946|serratus
165794|NCT02103946|paravertebral
165795|NCT02103946|breast
165796|NCT02103946|cancer
165797|NCT02103946|axilla
165798|NCT02103907|balance
165799|NCT02103907|knee
165800|NCT02103907|osteoarthritis
165801|NCT02103907|physical function
165802|NCT02103894|Alzheimer's disease (AD)
165803|NCT02103894|Parkinson's disease (PD)
165804|NCT02103894|Progressive supranuclear palsy (PSP)
165805|NCT02103894|Chronic traumatic encephalopathy (CTE)
165806|NCT02103894|Frontal temporal dementia (FTD)
165807|NCT02103894|Pick's disease
165808|NCT02103894|tauopathies
165809|NCT02103881|Agitation
165810|NCT02103881|Ketamine
165811|NCT02103881|Haloperidol
165812|NCT02103881|Emergency Medical Services
165813|NCT02103881|Feeling of restlessness
165814|NCT02103881|Increased motor activity
165815|NCT02103868|Tobacco cessation
165816|NCT02103868|Zari worker
165817|NCT02103868|Behavior therapy
165818|NCT02103868|Qualitative Research
165819|NCT02103868|Mumbai
165820|NCT02103855|pancreas transplantation
165821|NCT02103855|immunosuppression
165822|NCT02103855|belatacept
165823|NCT02103829|Cigarette smoking
165824|NCT02103829|Tobacco smoking
165825|NCT02103829|Smoking, Tobacco
165826|NCT02103803|concussion
165827|NCT02103803|sports-related concussion
165828|NCT02103803|mild traumatic brain injury (mTBI)
165829|NCT02103803|eye tracking
165830|NCT02103803|oculometrics
165831|NCT02103777|high dose of caffeine
165832|NCT02103777|low dose of caffeine
165833|NCT02103777|prevention
165834|NCT02103764|Anovulatory Dysfunctional Uterine Bleeding
165835|NCT02103764|cyclic desogestrel
165836|NCT02103764|cyclic medroxyprogesterone acetate
165837|NCT02103764|lipid metabolism
165838|NCT02103764|glucose metabolism
165839|NCT02103764|endometrial histology changing
165840|NCT02103751|biomarkers
165841|NCT02103751|HPHCs
165842|NCT02103751|CVD
165843|NCT02103751|smoking
165844|NCT02103751|Smokers
165845|NCT02103751|non-smokers
165846|NCT02103738|Lucentis
165847|NCT02103738|Ranibizumab
165848|NCT02103738|Treat and Extend
165849|NCT02103738|wetAMD
165850|NCT02103738|Age related macular degeneration
165851|NCT02103699|Hepatitis C virus
165852|NCT02103699|Simeprevir
165853|NCT02103699|Ribonucleic acid
165854|NCT02103699|Sustained virologic response
165855|NCT02103686|Neuropathic pain
165856|NCT02103686|pregabalin
165857|NCT02103660|contraceptive implant
165858|NCT02103660|Depo-Medroxyprogesterone Acetate
165859|NCT02103660|Hormonal Contraception
165860|NCT02103660|progestin
165861|NCT02103647|Neuropathic pain
165862|NCT02103647|pregabalin
165863|NCT02103634|breast cancer
165864|NCT02103634|FDG PET/CT
165865|NCT02103634|MRI
165866|NCT02103634|NaF PET/MRI
165867|NCT02103634|NaF PET/CT
165868|NCT02103608|at Home Photo depilation device, Silk'n.
165869|NCT02103556|Constipation
165870|NCT02103556|Rome III criteria
165871|NCT02103556|Hemodialysis
165872|NCT02103491|Half-ironman
165873|NCT02103491|Triathlon
165874|NCT02103491|Salt
165875|NCT02103491|Exercise
165876|NCT02103491|Performance
165877|NCT02103478|Myelodysplastic Syndrome
165878|NCT02103478|MDS
165879|NCT02103465|Parkinson's Disease
165880|NCT02103465|treatment
165881|NCT02103465|old patients
165882|NCT02103465|Rotigotine
165883|NCT02103439|Hepatitis C
165884|NCT02103439|Cepeginterferon alfa
165885|NCT02103439|Peginterferon
165886|NCT02103439|Treatment
165887|NCT02103426|Cytomegalovirus
165888|NCT02103426|ASP0113
165889|NCT02103426|CMV-seropositive
165890|NCT02103426|Healthy subjects
165891|NCT02103426|CMV-seronegative
165892|NCT02103426|Dialysis
165893|NCT02103374|weaned tobacco
165894|NCT02103374|Has not submitted an exacerbation in the past 3 months
165895|NCT02103361|autoimmune disease
165896|NCT02103361|pregnancy
165897|NCT02103361|psoriasis
165898|NCT02103361|Stelara
165899|NCT02103361|ustekinumab
165900|NCT02103361|birth outcome
165901|NCT02103361|malformation
165902|NCT02103361|birth defect
165903|NCT02103348|Severe asthma
165904|NCT02103348|Sputum
165905|NCT02103348|Mucolysis
165906|NCT02103335|Myeloma
165907|NCT02103335|Multiple Myeloma
165908|NCT02103335|Pomalidomide
165909|NCT02103335|Marizomib
165910|NCT02103335|Low dose Dexamethasone
165911|NCT02103335|Relapsed
165912|NCT02103335|Refractory
165913|NCT02103309|Soft contact lenses
165914|NCT02103309|DACP
165915|NCT02103283|Diabetic Macular Edema
165916|NCT02103244|pharmacokinetics
165917|NCT02103244|safety
165918|NCT02103231|Preterm birth
165919|NCT02103231|Hypertension
165920|NCT02103231|Exercise capacity
165921|NCT02103231|Cardiovascular risk
165922|NCT02103218|HIV
165923|NCT02103218|risky sex prevention
165924|NCT02103218|intervention
165925|NCT02103205|Lactoferrin
165926|NCT02103205|Infant formula
165927|NCT02103205|Iron
165928|NCT02103179|Extrahepatic cholangiocarcinoma
165929|NCT02103179|ECC
165930|NCT02103179|VEGF signaling
165931|NCT02103140|Breast Cancer
165932|NCT02103140|Obesity
165933|NCT02103140|African American female
165934|NCT02103140|exergaming
165935|NCT02103101|polymorphism
165936|NCT02103101|ABCB1
165937|NCT02103101|P-glycoprotein
165938|NCT02103101|oral anticoagulant
165939|NCT02103101|dabigatran
165940|NCT02103101|apixaban
165941|NCT02103101|rivaroxaban
165942|NCT02103101|hemorrhagic complication
165943|NCT02103101|thrombo-embolism
165944|NCT02103101|serious adverse event
165945|NCT02103088|Prostate cancer
165946|NCT02103088|Intervention
165947|NCT02103088|Rehabilitation
165948|NCT02103088|Couple
165949|NCT02103088|Sexology
165950|NCT02103088|Urology
165951|NCT02103088|Late effects
165952|NCT02103075|spinocerebellar ataxia (SCA)
165953|NCT02103075|motor evoked potential (MEP)
165954|NCT02103075|Neuromuscular electrical stimulation (NMES)
165955|NCT02103075|silent period
165956|NCT02103075|cerebellum
165957|NCT02103062|Metastatic Colorectal Cancer
165958|NCT02103062|nab®Paclitaxel
165959|NCT02103062|Response Evaluation in Solid Tumors
165960|NCT02103062|Progression Free Survival
165961|NCT02103062|Overall Survival
165962|NCT02103062|Duration of Response
165963|NCT02103062|RAS
165964|NCT02103036|Low Back Pain
165965|NCT02103036|Core stability exercise
165966|NCT02103036|Back school
165967|NCT02103036|TENS
165968|NCT02103036|Infra- red light
165969|NCT02102997|DTS
165970|NCT02102997|Stents
165971|NCT02102997|Stent
165972|NCT02102997|DES
165973|NCT02102997|Drug eluting
165974|NCT02102997|Drug Eluting Stent (DES)
165975|NCT02102997|Drug eluting stents
165976|NCT02102997|Endothelial Progenitor Cell (EPC)
165977|NCT02102997|Endothelial progenitor cell capturing
165978|NCT02102997|Sirolimus
165979|NCT02102997|Sirolimus eluting
165980|NCT02102997|Percutaneous Coronary Intervention (PCI)
165981|NCT02102997|PCI
165982|NCT02102997|Registry
165983|NCT02102997|Registries
165984|NCT02102997|Multi center
165985|NCT02102997|Multi centre
165986|NCT02102984|distal malignancy of the extra-hepatic biliary tract
165987|NCT02102984|metallic biliary stents
165988|NCT02102984|covered biliary stents
165989|NCT02102984|uncovered biliary stents
165990|NCT02102971|liver
165991|NCT02102971|ischemia
165992|NCT02102971|reperfusion
165993|NCT02102958|diabetes
165994|NCT02102958|visual impairment
165995|NCT02102958|foot care
165996|NCT02102958|diabetes self-management education
165997|NCT02102945|Computed tomography
165998|NCT02102945|Perfusion imaging
165999|NCT02102945|Coma
166000|NCT02102945|Heart arrest
166001|NCT02102945|Brain death
166002|NCT02102906|Adult
166003|NCT02102906|Humans
166004|NCT02102906|Conversion disorder
166005|NCT02102906|Somatoform Disorders/therapy
166006|NCT02102906|Nervous System Disorders/therapy
166007|NCT02102893|for Gastroentero-Pancreatic Neuroendocrine Tumors in Taiwan
166008|NCT02102880|Genetic Association Studies
166009|NCT02102867|HIV
166010|NCT02102867|STI
166011|NCT02102867|Primary Prevention
166012|NCT02102867|Topical Microbicides
166013|NCT02102867|User Experience
166014|NCT02102867|Drug Delivery Systems
166015|NCT02102854|kidney transplantation
166016|NCT02102854|acute rejection
166017|NCT02102854|rabbit antithymocyte globulin
166018|NCT02102828|DVT
166019|NCT02102828|Total Knee Arthroplasty
166020|NCT02102815|total knee arthroplasty
166021|NCT02102815|pain control
166022|NCT02102815|dexamethasone
166023|NCT02102815|steroids
166024|NCT02102802|PTSD
166025|NCT02102802|MDMA
166026|NCT02102802|Brain activity
166027|NCT02102802|fMRI
166028|NCT02102802|Heart rate variability
166029|NCT02102802|Physiological correlate
166030|NCT02102776|Primary Pterygium
166031|NCT02102776|Mitomycin C
166032|NCT02102776|Amniotic membrane transplantation
166033|NCT02102776|Conjunctival autograft
166034|NCT02102776|Multi-center randomized clinical trial
166035|NCT02102763|Overweight
166036|NCT02102763|Obesity
166037|NCT02102763|Dietary intake
166038|NCT02102763|Physical activity levels
166039|NCT02102763|Blood pressure levels
166040|NCT02102763|Family perceptions
166041|NCT02102737|insulin resistance
166042|NCT02102737|Scintigraphy
166043|NCT02102737|Hyperinsulinemic euglycemic clamp
166044|NCT02102724|African Americans
166045|NCT02102724|Older Adults
166046|NCT02102711|VITAMIN A
166047|NCT02102711|BLOOD CONCENTRATION
166048|NCT02102711|retinopathy of prematurity
166049|NCT02102698|Tourette's Syndrome
166050|NCT02102698|Ecopipam
166051|NCT02102698|D1 Receptor
166052|NCT02102698|Phase 2
166053|NCT02102685|VAC Therapy
166054|NCT02102685|Neck Abscess
166055|NCT02102685|Traditional Therapy
166056|NCT02102685|Wound Healing
166057|NCT02102659|Nutritional Assessment
166058|NCT02102659|Oral Epithelial Cell
166059|NCT02102659|Apoptosis
166060|NCT02102633|bosutinib
166061|NCT02102633|dabigatran
166062|NCT02102633|drug interaction
166063|NCT02102633|p-glycoprotein
166064|NCT02102633|pharmacokinetics
166065|NCT02102620|intra-articular injection
166066|NCT02102620|corticosteroid
166067|NCT02102620|osteoarthritis
166068|NCT02102620|Interphalangeal joint
166069|NCT02102607|intrathecal; ropivacaine; motor blockade; local anesthetics
166070|NCT02102594|Myasthenia Gravis
166071|NCT02102594|Systemic Lupus Erythematosus
166072|NCT02102594|Rheumatoid Arthritis
166073|NCT02102594|proteasome inhibitor
166074|NCT02102594|Bortezomib
166075|NCT02102594|Velcade
166076|NCT02102594|antibody-mediated autoimmune disease
166077|NCT02102581|Tourniquet
166078|NCT02102581|Total knee arthroplasty
166079|NCT02102581|Blood loss
166080|NCT02102581|Limb swelling
166081|NCT02102581|Limb circumference
166082|NCT02102542|glycopyrrolate
166083|NCT02102542|efficacy
166084|NCT02102542|antisialagogue
166085|NCT02102529|pain
166086|NCT02102529|quality of life
166087|NCT02102516|Post operative pain management
166088|NCT02102490|Endocrine Therapy, Taxane, MONARCH 1
166089|NCT02102477|Prostatic neoplasms
166090|NCT02102477|Locally advanced
166091|NCT02102477|Radiotherapy
166092|NCT02102477|Surgery
166093|NCT02102477|Mortality
166094|NCT02102451|Interferon-free
166095|NCT02102451|Direct acting antiviral (DAA)
166096|NCT02102451|Treatment as prevention
166097|NCT02102451|Surveillance
166098|NCT02102451|Feasibility
166099|NCT02102438|Elderly patients
166100|NCT02102438|Localized HER2+ Breast Cancer
166101|NCT02102438|Omission of anthracyclines
166102|NCT02102438|Neoadjuvant chemotherapy
166103|NCT02102438|Adjuvant chemotherapy
166104|NCT02102438|Safety information
166105|NCT02102425|Peritoneal Dialysis
166106|NCT02102425|Exit site infection
166107|NCT02102425|Exit site care
166108|NCT02102425|Bandage
166109|NCT02102425|Prevention
166110|NCT02102425|Guidelines
166111|NCT02102412|crc
166112|NCT02102412|colonoscopy
166113|NCT02102412|colon cancer
166114|NCT02102399|Voice training
166115|NCT02102399|Education
166116|NCT02102399|Voice
166117|NCT02102399|Faculty
166118|NCT02102386|elective
166119|NCT02102386|carotid endarterectomy surgery
166120|NCT02102373|colonoscopy, pediatric, preparation, diet
166121|NCT02102360|microsurgery, furcation defects, periodontal disease, enamel matrix proteins, bone substitutes
166122|NCT02102347|Physical Therapy Modalities
166123|NCT02102347|osteoarthritis
166124|NCT02102334|Osteoarthritis, hip,
166125|NCT02102334|radiograpghic measurements
166126|NCT02102334|femoral offset
166127|NCT02102334|leg length discrepancy
166128|NCT02102334|cup anteversion
166129|NCT02102334|cup inclination
166130|NCT02102321|hookworm
166131|NCT02102321|albendazole
166132|NCT02102321|iron supplementation
166133|NCT02102321|democratic republic of congo
166134|NCT02102321|subsistence farmers
166135|NCT02102321|randomized control trial
166136|NCT02102321|neglected tropical disease
166137|NCT02102321|helminths
166138|NCT02102295|Gingivitis
166139|NCT02102295|antioxidant
166140|NCT02102295|dentifrice
166141|NCT02102295|Ascorbic Acid Derivative
166142|NCT02102295|L ascorbic acid 2 phosphate magnesium salt
166143|NCT02102282|Pregnancy
166144|NCT02102282|Breast Cancer
166145|NCT02102282|Chemotherapy
166146|NCT02102282|Surgery
166147|NCT02102282|Obstetric managment
166148|NCT02102256|deafness
166149|NCT02102256|congenital
166150|NCT02102256|pediatric
166151|NCT02102256|device
166152|NCT02102243|hypertension
166153|NCT02102243|blood pressure
166154|NCT02102243|sympathetic nerve activity
166155|NCT02102243|vascular oxidative stress
166156|NCT02102243|nitric oxide
166157|NCT02102243|nitric oxide synthase (eNOS)
166158|NCT02102243|endothelium
166159|NCT02102243|endothelial dysfunction
166160|NCT02102243|endothelial cell protein expression
166161|NCT02102243|microvascular blood flow
166162|NCT02102243|flow mediated dilation
166163|NCT02102243|endothelial cell collection
166164|NCT02102243|microbubbles
166165|NCT02102243|Definity
166166|NCT02102230|Sleep Initiation and Maintenance Disorders
166167|NCT02102230|marijuana abuse
166168|NCT02102230|Veterans
166169|NCT02102217|Major Abdominal Surgery
166170|NCT02102217|C-reactive protein
166171|NCT02102217|Computed Tomography
166172|NCT02102217|Quality Control
166173|NCT02102217|Postoperative complications
166174|NCT02102204|Secondary Hyperparathyroidism (SHPT), chrominc kidney disease (CKD), hemodialysis
166175|NCT02102178|oncological pain
166176|NCT02102178|therapeutic activities
166177|NCT02102178|occupational therapy.
166178|NCT02102165|Aurora
166179|NCT02102165|breast cancer
166180|NCT02102165|metastatic
166181|NCT02102165|molecular screening
166182|NCT02102165|targeted gene sequencing
166183|NCT02102165|molecular aberrations
166184|NCT02102165|exploratory
166185|NCT02102165|biomarker
166186|NCT02102152|Tobramycin Podhaler
166187|NCT02102152|bronchiectasis
166188|NCT02102152|chronic infection
166189|NCT02102152|Pseudomonas Aeruginosa
166190|NCT02102126|Renal denervation therapy
166191|NCT02102126|Aortic blood pressure
166192|NCT02102126|Blood pressure variability
166193|NCT02102126|Arterial stiffness
166194|NCT02102126|Target organ damage
166195|NCT02102126|Biomarker
166196|NCT02102100|menthol, electronic cigarette, nicotine, smoking, tobacco
166197|NCT02102074|colon and rectal tumors
166198|NCT02102074|colon cancer markers
166199|NCT02102061|overweight
166200|NCT02102061|exercise
166201|NCT02102061|nutrition
166202|NCT02102061|philosophy
166203|NCT02102048|HIV
166204|NCT02102048|diabetes
166205|NCT02102048|glucose metabolism
166206|NCT02102048|antiretroviral therapy
166207|NCT02102048|ritonavir
166208|NCT02102048|atazanavir
166209|NCT02102035|defect
166210|NCT02102035|dorsal branch of the proper digital nerve
166211|NCT02102035|dorsal digital island flap
166212|NCT02102035|sensory reconstruction.
166213|NCT02102022|argininosuccinate synthetase
166214|NCT02102022|arginine
166215|NCT02102022|arginine deiminase
166216|NCT02102009|Malnutrition
166217|NCT02102009|Dietary supplement
166218|NCT02102009|Nutritional supplement
166219|NCT02102009|Complete enteral formula
166220|NCT02102009|COPD
166221|NCT02101996|stable isotopes
166222|NCT02101996|triacylglycerol
166223|NCT02101983|Acute myeloid leukemia
166224|NCT02101983|outpatient consolidation treatment
166225|NCT02101970|Breast cancer risk
166226|NCT02101970|DHA
166227|NCT02101970|Omega-3 Fatty Acids
166228|NCT02101970|EPA
166229|NCT02101970|Weight Loss
166230|NCT02101931|Bladder Cancer
166231|NCT02101931|Laser Diagnosis
166232|NCT02101931|Amino levulinic Acid
166233|NCT02101931|Photodynamic Detection
166234|NCT02101931|spectra of urine
166235|NCT02101892|migraine
166236|NCT02101892|Amitriptyline
166237|NCT02101892|pain modulation
166238|NCT02101892|pain psychophysics
166239|NCT02101892|pain neurophysiology
166240|NCT02101892|preventive treatment
166241|NCT02101866|Bioavailability Study
166242|NCT02101866|Aviragen Therapeutics, Inc.
166243|NCT02101866|Aviragen Therapeutics
166244|NCT02101866|Aviragen
166245|NCT02101840|Substance-Related Disorders
166246|NCT02101840|Prescription Drug Misuse
166247|NCT02101840|Analgesics, Opioid
166248|NCT02101840|Oxycodone
166249|NCT02101840|Randomized Controlled Trial
166250|NCT02101840|Cross-Over Studies
166251|NCT02101840|Placebo
166252|NCT02101840|Healthy Volunteers
166253|NCT02101801|environment, recycled wastewater, carbamazepine
166254|NCT02101762|Foley
166255|NCT02101762|Catheters
166256|NCT02101762|CAUTI
166257|NCT02101762|ERASE CAUTI
166258|NCT02101749|trivalent inactivated influenza vaccine
166259|NCT02101736|Ages 16 or greater
166260|NCT02101736|Cabozantinib
166261|NCT02101736|XL184
166262|NCT02101736|Plexiform Neurofibromas
166263|NCT02101736|Neurofibromatosis
166264|NCT02101736|Pathogenetic NF1 Mutations
166265|NCT02101736|Cometriq
166266|NCT02101736|NF1
166267|NCT02101723|Zinc absorption
166268|NCT02101723|Micronutrient supplement
166269|NCT02101723|Microbiome
166270|NCT02101723|Kenya
166271|NCT02101723|Complementary foods
166272|NCT02101723|Home fortification
166273|NCT02101710|Bioequivalence
166274|NCT02101710|Isosorbide 5-mononitrate
166275|NCT02101710|Elantan
166276|NCT02101710|Imdur
166277|NCT02101710|Korean
166278|NCT02101710|Healthy
166279|NCT02101697|reduce
166280|NCT02101697|Indian health providers
166281|NCT02101684|Orteronel, Granulosa Cell Tumour
166282|NCT02101671|agitation
166283|NCT02101671|anaesthesia
166284|NCT02101671|laparoscopy
166285|NCT02101671|surgery
166286|NCT02101671|delirium
166287|NCT02101671|sedation
166288|NCT02101671|emergence
166289|NCT02101671|steep
166290|NCT02101671|trendelemburg
166291|NCT02101671|position
166292|NCT02101671|delayed
166293|NCT02101671|Confusion
166294|NCT02101671|Disorientation
166295|NCT02101645|Bioimpedance
166296|NCT02101645|Venous ulcer
166297|NCT02101645|Edema
166298|NCT02101645|LIDC
166299|NCT02101645|Electrical stimulation
166300|NCT02101632|TMD
166301|NCT02101632|bee venom
166302|NCT02101632|muscle tension
166303|NCT02101632|muscle pain
166304|NCT02101619|aortic stenosis
166305|NCT02101619|myocardial tissue
166306|NCT02101619|echocardiography
166307|NCT02101619|MRI
166308|NCT02101606|Acute Stroke
166309|NCT02101606|Cerebral Stroke
166310|NCT02101606|Brain Ischemia
166311|NCT02101606|Perfusion Imaging
166312|NCT02101606|MRI, Diffusion Weighted
166313|NCT02101606|MRI, Perfusion Weighted
166314|NCT02101593|argininosuccinate synthetase
166315|NCT02101593|arginine
166316|NCT02101593|arginine deiminase
166317|NCT02101580|argininosuccinate synthetase
166318|NCT02101580|arginine
166319|NCT02101580|arginine deiminase
166320|NCT02101567|Postpartum hemorrhage, Cesarean section, Uterotonics
166321|NCT02101554|Pediatric
166322|NCT02101554|pain indication
166323|NCT02101554|controlled release morphine
166324|NCT02101541|Atrial fibrillation
166325|NCT02101541|Arrhythmias, Cardiac
166326|NCT02101541|Heart diseases
166327|NCT02101541|Cardiovascular diseases
166328|NCT02101541|Pathological processes
166329|NCT02101528|Strength in PD patients
166330|NCT02101528|Isokinetic muscle strength
166331|NCT02101515|randomized controlled trial
166332|NCT02101515|labor complications
166333|NCT02101515|cesarean section
166334|NCT02101515|second stage
166335|NCT02101502|Healthcare,educational effectiveness, institutional capacity
166336|NCT02101489|TVT
166337|NCT02101489|Stress urinary incontinence
166338|NCT02101476|Pain
166339|NCT02101463|aortic
166340|NCT02101463|sm-FBSG
166341|NCT02101463|aneurysms
166342|NCT02101463|fenestrated
166343|NCT02101463|stent-grafts
166344|NCT02101463|Vascular
166345|NCT02101463|Endovascular
166346|NCT02101450|extra-abdominal
166347|NCT02101450|intra-abdominal
166348|NCT02101450|removal of placenta
166349|NCT02101450|cesarean section
166350|NCT02101450|bleeding
166351|NCT02101424|Overdose
166352|NCT02101424|Emergency Department
166353|NCT02101424|Supplemental Oxygen
166354|NCT02101424|Pulse Oximeter
166355|NCT02101424|Capnography
166356|NCT02101398|tDCS
166357|NCT02101398|Stroke
166358|NCT02101398|Aphasia
166359|NCT02101398|Naming
166360|NCT02101385|Genomically-Directed Therapy
166361|NCT02101385|DNA Sequencing
166362|NCT02101385|RNA Sequencing
166363|NCT02101372|first episode psychosis
166364|NCT02101372|psychoeducation
166365|NCT02101372|group therapy
166366|NCT02101333|TAKAYASU ARTERITIS
166367|NCT02101333|STEROID SPARING
166368|NCT02101333|TOCILIZUMAB
166369|NCT02101333|EFFICACY
166370|NCT02101333|SAFETY
166371|NCT02101320|surgery
166372|NCT02101320|nuclear medicine
166373|NCT02101320|Lymphoscintigraphy
166374|NCT02101320|Gamma Camera
166375|NCT02101320|SNOLL
166376|NCT02101320|breast cancer
166377|NCT02101294|carpal tunnel syndrome
166378|NCT02101294|repetitive stress disorder
166379|NCT02101281|Dry Eye
166380|NCT02101255|Dental caries
166381|NCT02101255|Curodont Repair
166382|NCT02101255|P11-4
166383|NCT02101242|Near-infrared-Spectroscopy
166384|NCT02101229|Glycemic control algorithm
166385|NCT02101229|closed loop
166386|NCT02101229|artificial pancreas
166387|NCT02101216|bioequivalence
166388|NCT02101216|pharmacokinetics
166389|NCT02101216|psoriasis
166390|NCT02101203|HSDD
166391|NCT02101190|BIA 9-1067
166392|NCT02101190|Opicapone
166393|NCT02101190|catechol-O-methyltransferase (COMT)
166394|NCT02101177|Viral Hepatitis C
166395|NCT02101177|Genotype 4
166396|NCT02101177|SVR
166397|NCT02101177|Egyptian National Program
166398|NCT02101151|Type 2 diabetes mellitus
166399|NCT02101151|vitamin D
166400|NCT02101151|cholecalciferol
166401|NCT02101151|obesity
166402|NCT02101138|Corticosteroids
166403|NCT02101138|Eosinophilia
166404|NCT02101099|Colonoscopy
166405|NCT02101099|Force
166406|NCT02101099|Monitor
166407|NCT02101099|Endoscopist
166408|NCT02101099|Conscious
166409|NCT02101099|Sedation
166410|NCT02101099|Propofol
166411|NCT02101086|umbilical cord blood
166412|NCT02101086|premature
166413|NCT02101086|autologous transfusion
166414|NCT02101086|allogeneic transfusion
166415|NCT02101060|exercise
166416|NCT02101060|aging
166417|NCT02101060|aerobic capacity
166418|NCT02101060|cardiac function
166419|NCT02101060|inflammation
166420|NCT02101047|cesarean section
166421|NCT02101047|hypotension
166422|NCT02101047|phenylephrine
166423|NCT02100982|Multimorbidity
166424|NCT02100982|Communication
166425|NCT02100982|Primary Care
166426|NCT02100982|Mental Health
166427|NCT02100969|MG
166428|NCT02100969|Hizentra
166429|NCT02100969|autoimmune neuromuscular disorder
166430|NCT02100956|chronic pain
166431|NCT02100956|neuropathic pain
166432|NCT02100943|Obstructive Sleep Apnea
166433|NCT02100930|Anti-GD2 3F8 Monoclonal Antibody
166434|NCT02100930|oral isotretinoin
166435|NCT02100930|GM-CSF
166436|NCT02100930|Sargramostim
166437|NCT02100930|13-260
166438|NCT02100917|Bioequivalence
166439|NCT02100917|Biosimilarity
166440|NCT02100917|Similarity
166441|NCT02100917|Pharmacokinetics
166442|NCT02100917|Phase I
166443|NCT02100917|Trastuzumab
166444|NCT02100917|Healthy Male Volunteers
166445|NCT02100917|Single-dose
166446|NCT02100917|HER-2
166447|NCT02100917|Oncology
166448|NCT02100904|Fibroids
166449|NCT02100904|Radiofrequency ablation
166450|NCT02100891|Ewing Sarcoma
166451|NCT02100891|Neuroblastoma
166452|NCT02100891|Rhabdomyosarcoma
166453|NCT02100891|Osteosarcoma
166454|NCT02100891|CNS tumors
166455|NCT02100891|Brain Tumors
166456|NCT02100839|hypercholesterolemia
166457|NCT02100839|apolipoprotein E
166458|NCT02100839|First in Human
166459|NCT02100839|Apolipoprotein E (ApoE)
166460|NCT02100839|Apolipoprotein E Mimetic (AEM)
166461|NCT02100800|COPD
166462|NCT02100800|Emphysema
166463|NCT02100800|MRI
166464|NCT02100800|UTE
166465|NCT02100800|Quantification
166466|NCT02100800|CT
166467|NCT02100787|tear osmolarity
166468|NCT02100787|keratitis sicca
166469|NCT02100787|ocular surface disease
166470|NCT02100787|TheraTears
166471|NCT02100774|bioavailability
166472|NCT02100774|postprandial period
166473|NCT02100774|genetic variants
166474|NCT02100774|single nucleotide polymorphisms
166475|NCT02100774|vitamin
166476|NCT02100774|carotenoid
166477|NCT02100774|lutein
166478|NCT02100774|lycopene
166479|NCT02100774|tocopherol
166480|NCT02100774|cholecalciferol
166481|NCT02100761|Voriconazole
166482|NCT02100761|Invasive pulmonary aspergillosis
166483|NCT02100761|Therapeutic drug monitoring
166484|NCT02100761|CYP genetic polymorphism
166485|NCT02100761|Efficacy
166486|NCT02100761|Safety
166487|NCT02100748|moderate to severe acute pain
166488|NCT02100748|bunionectomy
166489|NCT02100735|sedatives
166490|NCT02100735|analgesics
166491|NCT02100735|protocol
166492|NCT02100735|mechanical ventilation
166493|NCT02100735|analgosedation
166494|NCT02100683|Occluder
166495|NCT02100657|multiple myeloma
166496|NCT02100657|plitidepsin
166497|NCT02100657|APLIDIN
166498|NCT02100618|Adolescents
166499|NCT02100618|Adults
166500|NCT02100618|Immunogenicity
166501|NCT02100618|6.5 years
166502|NCT02100618|Safety
166503|NCT02100618|Antibody persistence
166504|NCT02100618|Human Papillomavirus (HPV) vaccine
166505|NCT02100605|Nasal
166506|NCT02100605|Congestion
166507|NCT02100605|Decongestion
166508|NCT02100605|Hypertonic
166509|NCT02100605|Saline solution
166510|NCT02100592|brain injury
166511|NCT02100592|coma
166512|NCT02100592|intensive care
166513|NCT02100592|early rehabilitation
166514|NCT02100566|Advance Directive
166515|NCT02100553|Postmenopausal Women
166516|NCT02100553|Obese
166517|NCT02100553|Non-obese
166518|NCT02100553|Drug Interaction with Itraconazole
166519|NCT02100553|Pharmacokinetic
166520|NCT02100540|PMS
166521|NCT02100540|hot flashes
166522|NCT02100527|safety
166523|NCT02100527|tolerability
166524|NCT02100527|pharmacokinetics
166525|NCT02100527|oral dosing
166526|NCT02100527|moderate to severe acne vulgaris
166527|NCT02100514|Primary hyperlipidemia or mixed dyslipidemia
166528|NCT02100514|high risk of cardiovascular events
166529|NCT02100514|multiple cardiovascular disease risk factors.
166530|NCT02100501|Seizure control through dietary therapy in pediatric intractable epilepsy patients.
166531|NCT02100488|Closed-loop insulin infusion
166532|NCT02100488|Postprandial glucose control
166533|NCT02100488|Glucose variability
166534|NCT02100462|Hypertension
166535|NCT02100462|Platelet activation
166536|NCT02100462|Platelet aggregation
166537|NCT02100462|Chlorthalidone
166538|NCT02100449|Atelectasis
166539|NCT02100449|Pneumonia
166540|NCT02100449|Lung ultrasound
166541|NCT02100449|Doppler
166542|NCT02100436|influenza, H3N2, H3N2v, vaccine, children, pediatric, unadjuvanted
166543|NCT02100410|Contact Lens
166544|NCT02100410|Toric
166545|NCT02100397|Enteric fever
166546|NCT02100397|Paratyphoid
166547|NCT02100397|Salmonella Paratyphi
166548|NCT02100397|Challenge study
166549|NCT02100397|Human model of infection
166550|NCT02100384|peri implant
166551|NCT02100384|Maintenance
166552|NCT02100384|Ultrasonic
166553|NCT02100384|Scalers
166554|NCT02100371|BMS-833923
166555|NCT02100371|CA194002
166556|NCT02100358|acute cholecystitis
166557|NCT02100332|Drug Therapy
166558|NCT02100319|Pharmacological therapy
166559|NCT02100293|magnesium sulfate, rocuronium
166560|NCT02100280|Neuromuscular blockade
166561|NCT02100280|Sugammadex
166562|NCT02100280|Laparoscopic surgery
166563|NCT02100280|IL-6
166564|NCT02100241|Young adult
166565|NCT02100241|Muscle Stretching Exercises
166566|NCT02100241|Range of Motion, Articular
166567|NCT02100228|apixaban
166568|NCT02100228|oral anticoagulant
166569|NCT02100228|non-valvular atrial fibrillation
166570|NCT02100228|cardioversion
166571|NCT02100215|simulation
166572|NCT02100215|competence
166573|NCT02100215|self-efficacy
166574|NCT02100215|novice nurses
166575|NCT02100202|Dietary supplements
166576|NCT02100202|Cotinine level
166577|NCT02100202|Malondialdehyde
166578|NCT02100202|Chronic smokers
166579|NCT02100202|Hyperlipidemia
166580|NCT02100176|Rehabilitation treatment
166581|NCT02100163|Ortho trauma
166582|NCT02100150|Concussion
166583|NCT02100124|reproductive life planning
166584|NCT02100124|action planning
166585|NCT02100124|contraceptive use
166586|NCT02100124|unintended pregnancy
166587|NCT02100098|Ankle fracture
166588|NCT02100098|Nerve block
166589|NCT02100098|Postoperative pain
166590|NCT02100098|Pain profile
166591|NCT02100098|Rebound pain
166592|NCT02100085|Phase 1 follow up
166593|NCT02100085|Cervical Intraepithelial Neoplasia
166594|NCT02100085|Adult
166595|NCT02100085|Safety
166596|NCT02100085|Efficacy
166597|NCT02100059|meniscectomy
166598|NCT02100059|arthroscopic partial meniscectomy
166599|NCT02100059|meniscus
166600|NCT02100046|Ethosuximide
166601|NCT02100046|Neuropathic pain
166602|NCT02100046|Pain
166603|NCT02100046|Quality of life
166604|NCT02100046|Neuropathic Pain diagnostic questionnaire ≥ 4
166605|NCT02100046|Analgesic treatment failure for at least 3 months
166606|NCT02100020|physical activity
166607|NCT02100020|exercise guidelines
166608|NCT02100020|multiple sclerosis
166609|NCT02100007|solid tumors
166610|NCT02100007|relapsed
166611|NCT02100007|advanced
166612|NCT02100007|metastatic
166613|NCT02100007|small cell lung cancer
166614|NCT02100007|ovarian cancer
166615|NCT02100007|refractory
166616|NCT02099994|HIV
166617|NCT02099994|vaccine
166618|NCT02099981|Diabetes
166619|NCT02099981|Diabetic
166620|NCT02099981|Retinopathy
166621|NCT02099981|Ophthalmology
166622|NCT02099981|Eye
166623|NCT02099981|Eyes
166624|NCT02099955|spinal cord injury
166625|NCT02099955|vitamin D deficiency
166626|NCT02099955|pulmonary function
166627|NCT02099955|metabolic diseases
166628|NCT02099942|Balloon Aortic Valvuloplasty
166629|NCT02099942|Valvuloplasty
166630|NCT02099942|Transcatheter Aortic Valve Replacement
166631|NCT02099942|Surgical Aortic Valve Replacement
166632|NCT02099929|Coffee
166633|NCT02099929|Glucose
166634|NCT02099929|Insulin
166635|NCT02099929|Diabetes
166636|NCT02099929|Type 2 Diabetes Mellitus
166637|NCT02099916|DHEA, pregnancy, ovarian reserve, AMH
166638|NCT02099903|Heart Failure
166639|NCT02099903|Heart Failure, Systolic
166640|NCT02099903|Chagas Disease
166641|NCT02099903|Chagas Cardiomyopathy
166642|NCT02099903|Renal Denervation
166643|NCT02099903|Irrigated Radiofrequency Catheter
166644|NCT02099890|Chronic Inflammation
166645|NCT02099890|Spinal Cord Injury
166646|NCT02099890|Anti-inflammatory Diet
166647|NCT02099890|Neuropathic Pain
166648|NCT02099890|Depression
166649|NCT02099890|Cognitive Impairment
166650|NCT02099890|Somatic Nerve Function
166651|NCT02099890|Autonomic Nerve Function
166652|NCT02099877|µ-opioid receptor polymorphism
166653|NCT02099877|Opioids
166654|NCT02099877|Opioid analgesia
166655|NCT02099877|Labor analgesia
166656|NCT02099838|Pioglitazone
166657|NCT02099838|Metformin
166658|NCT02099838|Type 2 Diabetes Mellitus
166659|NCT02099825|adult male
166660|NCT02099825|anxiety
166661|NCT02099825|public speaking
166662|NCT02099825|healthy controls
166663|NCT02099825|exposure therapy
166664|NCT02099825|social anxiety
166665|NCT02099825|mifepristone
166666|NCT02099825|d-cycloserine
166667|NCT02099799|Physical Activity
166668|NCT02099799|COPD Self-Management
166669|NCT02099799|Internet
166670|NCT02099799|6-Minute Walk Test
166671|NCT02099799|COPD Exacerbation
166672|NCT02099799|Health-related Quality of Life
166673|NCT02099786|hearing
166674|NCT02099786|cisplatin
166675|NCT02099786|Ototoxicity
166676|NCT02099786|Veterans
166677|NCT02099773|AAC
166678|NCT02099773|support worker
166679|NCT02099773|direct care staff
166680|NCT02099773|intellectual disability
166681|NCT02099773|learning disability
166682|NCT02099773|communication
166683|NCT02099773|adults
166684|NCT02099760|gonorrhea
166685|NCT02099760|chlamydia
166686|NCT02099760|trichomonas
166687|NCT02099747|Aplastic Anaemia
166688|NCT02099747|Eltrombopag
166689|NCT02099747|HATG
166690|NCT02099747|ATGAM
166691|NCT02099734|14-016
166692|NCT02099721|Sudden Cardiac Arrest (SCA)
166693|NCT02099721|Syncope
166694|NCT02099721|NSVT
166695|NCT02099721|PVC
166696|NCT02099721|LVEF
166697|NCT02099721|Primary Prevention
166698|NCT02099721|Secondary Prevention
166699|NCT02099721|ATP
166700|NCT02099721|shock
166701|NCT02099721|appropriate therapy
166702|NCT02099708|Pharmacological therapy
166703|NCT02099695|Hyperhidrosis
166704|NCT02099695|Oxybutynin
166705|NCT02099682|Pharmacological therapy
166706|NCT02099604|Hepatitis C - Genotype 4
166707|NCT02099604|SVR (Sustained Virological Response)
166708|NCT02099604|Vitamin D
166709|NCT02099604|Treatment Naïve
166710|NCT02099591|Constipation
166711|NCT02099591|Colonic Inertia
166712|NCT02099591|Dyschezia
166713|NCT02099591|Pharmacokinetics
166714|NCT02099591|Naloxegol
166715|NCT02099591|Paediatric
166716|NCT02099591|Opioids
166717|NCT02099591|Opioid induced constipation
166718|NCT02099591|OIC
166719|NCT02099591|Phase 1
166720|NCT02099578|Blood pressure
166721|NCT02099578|Arterial stiffness
166722|NCT02099578|Pulse wave velocity
166723|NCT02099578|Strawberries
166724|NCT02099578|Endothelial function
166725|NCT02099578|Oxidative stress
166726|NCT02099578|Postmenopausal women
166727|NCT02099565|Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
166728|NCT02099565|Statins
166729|NCT02099565|LDL-cholesterol
166730|NCT02099565|Inflammatory markers
166731|NCT02099565|Percutaneous Coronary Intervention (PCI)
166732|NCT02099552|X-Linked hypohidrotic ectodermal dysplasia
166733|NCT02099552|XLHED
166734|NCT02099552|Hypohidrotic ectodermal dysplasia
166735|NCT02099552|HED
166736|NCT02099552|Christ-Siemens-Touraine syndrome
166737|NCT02099539|absolute lymphocyte count
166738|NCT02099539|antitumor
166739|NCT02099539|cancer
166740|NCT02099539|immunotherapy
166741|NCT02099539|immunochemotherapy
166742|NCT02099539|interleukin-15
166743|NCT02099539|multiple myeloma
166744|NCT02099539|NK cell
166745|NCT02099539|refractory
166746|NCT02099539|relapsed
166747|NCT02099539|T cell
166748|NCT02099539|white blood cell count
166749|NCT02099526|cancer
166750|NCT02099526|caregiver
166751|NCT02099526|caregiving
166752|NCT02099526|care give
166753|NCT02099526|elderly
166754|NCT02099526|older adults
166755|NCT02099526|unmet needs
166756|NCT02099526|post-discharge
166757|NCT02099526|cancer symptoms
166758|NCT02099513|Mobile Technology
166759|NCT02099513|Chronic illness
166760|NCT02099513|Wireless blood pressure device
166761|NCT02099513|Wireless scale
166762|NCT02099513|Pedometer
166763|NCT02099500|Critical Limb Ischemia
166764|NCT02099500|Peripheral Vascular Disease
166765|NCT02099500|Lower Limb Ulcer
166766|NCT02099500|Gangrene
166767|NCT02099500|Amputation
166768|NCT02099500|Lower Limb Wound
166769|NCT02099487|HGG
166770|NCT02099474|HIV-1
166771|NCT02099474|HIV mother to child prevention
166772|NCT02099474|Raltegravir
166773|NCT02099474|Pharmacokinetic
166774|NCT02099435|Gastriointestinal
166775|NCT02099435|Lower gastriointestinal
166776|NCT02099435|Digestive
166777|NCT02099435|Hemostasis
166778|NCT02099435|Recurrent bleeding
166779|NCT02099435|Hemospray
166780|NCT02099409|Type 1 diabetes mellitus
166781|NCT02099409|children
166782|NCT02099409|closed loop
166783|NCT02099409|cross over
166784|NCT02099409|overnight
166785|NCT02099409|FLORENCED2
166786|NCT02099409|DANA Diabecare R pump
166787|NCT02099409|FreeStyle Navigator II
166788|NCT02099409|Dexcom G4
166789|NCT02099396|PFS,efficacy and safety,lobaplatin and gemcitabine in combination, second-line treatments on advanced osteosarcoma
166790|NCT02099383|Stroke
166791|NCT02099383|Dehydration
166792|NCT02099383|Fluid Therapy
166793|NCT02099370|Multiple Sclerosis
166794|NCT02099370|Tecfidera(R)
166795|NCT02099370|Oral medication
166796|NCT02099370|Adherence
166797|NCT02099331|Atrial Fibrillation
166798|NCT02099331|Reactive Oxygen Species
166799|NCT02099331|Cardiac Surgery
166800|NCT02099318|Rehearsal Platform
166801|NCT02099305|Adolescent; Depression
166802|NCT02099305|Early intervention (education)
166803|NCT02099305|Randomized Controlled Trial
166804|NCT02099305|Primary Prevention
166805|NCT02099305|schools
166806|NCT02099305|Health Literacy
166807|NCT02099305|Discrimination (Psychology)
166808|NCT02099305|Mental Health Services
166809|NCT02099292|lymphoma
166810|NCT02099292|high dose therapy
166811|NCT02099292|DexaBEAM
166812|NCT02099292|Rituximab
166813|NCT02099292|role of alternative salvage treatment - dexaBEAM
166814|NCT02099266|Umbilical Cord Blood (UCB) Stem Cell Transplant
166815|NCT02099266|Hyperbaric oxygen
166816|NCT02099266|Leukemia
166817|NCT02099266|Lymphoma
166818|NCT02099266|MDS
166819|NCT02099253|Age
166820|NCT02099253|Pharmacodynamics
166821|NCT02099253|dexmedetomidine
166822|NCT02099240|Osteomyelitis
166823|NCT02099240|IV Antibiotics
166824|NCT02099240|Oral Antibiotics
166825|NCT02099227|pediatric
166826|NCT02099227|soft tissue infections
166827|NCT02099227|ultrasonography
166828|NCT02099227|effectiveness
166829|NCT02099214|myocardial iron overload
166830|NCT02099214|HFE-Associated Hereditary Hemochromatosis
166831|NCT02099214|3 Tesla MRI
166832|NCT02099214|cardiological strategy in haemochromatosis
166833|NCT02099214|congestive heart failure
166834|NCT02099201|ACT-389949
166835|NCT02099162|OCT
166836|NCT02099162|Coronary
166837|NCT02099162|Stenting
166838|NCT02099149|Group B Streptococcus
166839|NCT02099149|early onset disease
166840|NCT02099149|late onset disease
166841|NCT02099149|anticapsular antibodies
166842|NCT02099149|serotype specific
166843|NCT02099123|Survival
166844|NCT02099123|Functional Disability
166845|NCT02099123|Cardiovascular Disease
166846|NCT02099123|Diabetes
166847|NCT02099123|Dementia
166848|NCT02099123|Cancer
166849|NCT02099097|3D Coping Skills Game
166850|NCT02099097|Quit smoking
166851|NCT02099097|14-062
166852|NCT02099071|ACT-389949
166853|NCT02099058|Advanced Solid Tumor
166854|NCT02099058|Neoplasm
166855|NCT02099058|Cancer
166856|NCT02099032|nutrition
166857|NCT02099032|milk
166858|NCT02099032|polar lipids
166859|NCT02099032|cardiometabolic risk
166860|NCT02099019|Coronary CT angiography; Revascularization; Decision-making
166861|NCT02098993|Sickle cell disease
166862|NCT02098993|Acute chest syndrome
166863|NCT02098993|Hemoglobinopathy
166864|NCT02098993|Hemolytic anemia
166865|NCT02098993|Heparin
166866|NCT02098993|Anticoagulant
166867|NCT02098954|TKI
166868|NCT02098954|resistance
166869|NCT02098954|erlotinib
166870|NCT02098954|combined chemotherapy
166871|NCT02098941|topiramate
166872|NCT02098941|oxcarbazepine
166873|NCT02098941|levetiracetam
166874|NCT02098941|retention rate
166875|NCT02098928|Acupuncture
166876|NCT02098928|Electro acupuncture
166877|NCT02098928|Menopause
166878|NCT02098915|gastroschisis
166879|NCT02098915|intestinal motility
166880|NCT02098915|prokinetic agents
166881|NCT02098915|intravenous metoclopramide
166882|NCT02098915|time to full enteral feeding
166883|NCT02098902|Overweight
166884|NCT02098902|Obesity
166885|NCT02098902|Overnutrition
166886|NCT02098902|Weight Loss
166887|NCT02098902|Body Weight
166888|NCT02098902|Nutrition Disorders
166889|NCT02098889|Cervix, active phase of labor, Hyoscine-N-Butylbromide (HBB)
166890|NCT02098876|neointimal tissue area
166891|NCT02098876|angulated coronary vessels
166892|NCT02098876|wall shear stress
166893|NCT02098876|zotarolimus eluting stent
166894|NCT02098876|everolimus eluting stent
166895|NCT02098863|Sickle Cell Anemia
166896|NCT02098863|Sickle Cell Disease
166897|NCT02098863|Survival
166898|NCT02098863|Mortality
166899|NCT02098863|End-Order Dysfunction
166900|NCT02098850|Staphylococcus aureus
166901|NCT02098850|bloodstream infection
166902|NCT02098850|bacteremia
166903|NCT02098837|HIV
166904|NCT02098824|vascular cognitive impairment
166905|NCT02098824|treatment
166906|NCT02098824|cerebrovascular lesions
166907|NCT02098824|memory impairment
166908|NCT02098824|executive dysfunction
166909|NCT02098824|neuronal networks
166910|NCT02098824|white matter tracts
166911|NCT02098824|monoaminergic systems
166912|NCT02098824|cholinergic systems
166913|NCT02098824|DTI
166914|NCT02098824|rs-fMRI
166915|NCT02098798|Dysplasia, Inflammatory Bowel Disease
166916|NCT02098785|VAP
166917|NCT02098785|liver
166918|NCT02098785|hepatology
166919|NCT02098785|caffeine
166920|NCT02098772|aortic valve disease
166921|NCT02098772|coronary bypass surgery
166922|NCT02098772|cardioplegic solutions
166923|NCT02098759|TSC
166924|NCT02098759|tuberous sclerosis complex
166925|NCT02098759|epilepsy
166926|NCT02098746|Pharmacological therapy
166927|NCT02098733|Pharmacological therapy
166928|NCT02098707|Stabilometric Platform
166929|NCT02098707|Rehabilitation
166930|NCT02098707|Balance Disorders
166931|NCT02098707|Falls
166932|NCT02098694|Physiotherapy
166933|NCT02098694|Outpatient clinic
166934|NCT02098681|Pectus Excavatum
166935|NCT02098668|menstrual cycle dynamics
166936|NCT02098668|PCOS
166937|NCT02098668|hyperprolactinemia
166938|NCT02098668|endometriosis
166939|NCT02098668|infertility
166940|NCT02098655|Stabilometric Platform
166941|NCT02098655|Postural instability
166942|NCT02098642|Gait Disturbances
166943|NCT02098642|Metatarsophalangeal joint
166944|NCT02098629|Myocardial infarction
166945|NCT02098629|myocardial ischemia
166946|NCT02098629|reperfusion injury
166947|NCT02098616|Hepatitis
166948|NCT02098616|Hepatitis, Chronic
166949|NCT02098616|Hepatitis C
166950|NCT02098616|Hepatitis C, Chronic
166951|NCT02098616|Liver Diseases
166952|NCT02098616|Digestive System Diseases
166953|NCT02098616|Hepatitis, Viral, Human
166954|NCT02098616|RNA Virus Infections
166955|NCT02098616|Antiviral Agents
166956|NCT02098616|Drug Resistance, Viral
166957|NCT02098590|Malaria
166958|NCT02098590|Plasmodium falciparum
166959|NCT02098577|Balance
166960|NCT02098564|hand therapy
166961|NCT02098564|activity-based training
166962|NCT02098564|hand related injuries
166963|NCT02098564|sense of coherence
166964|NCT02098551|atopic dermatitis
166965|NCT02098551|bet v 1
166966|NCT02098551|bet v 1 fragments
166967|NCT02098551|allergy
166968|NCT02098538|Regorafenib
166969|NCT02098538|13-244
166970|NCT02098525|Cryptococcal meningitis
166971|NCT02098525|HIV/AIDS
166972|NCT02098525|Antiretroviral therapy
166973|NCT02098525|Prognosis
166974|NCT02098525|Thailand
166975|NCT02098512|Brentuximab Vedotin
166976|NCT02098512|Immunotherapy
166977|NCT02098512|Relapsed Hodgkin Lymphoma
166978|NCT02098512|Refractory Hodgkin Lymphoma
166979|NCT02098512|Reduced Intensity Conditioning
166980|NCT02098512|Allogeneic Stem Cell Transplantation
166981|NCT02098486|Bile duct obstruction
166982|NCT02098486|Cholangitis
166983|NCT02098486|Moxifloxacin
166984|NCT02098486|Ceftriaxone
166985|NCT02098486|Sepsis
166986|NCT02098460|the Achilles tendon
166987|NCT02098460|intima-media thickness
166988|NCT02098447|vagus nerve stimulation effects on heart rate variability and peripheral blood perfusion
166989|NCT02098421|Induction of Labor
166990|NCT02098421|Pitocin
166991|NCT02098421|Oxytocin
166992|NCT02098421|Foley bulb
166993|NCT02098408|Ultra-high risk psychosis
166994|NCT02098408|Schizophrenia prodrome
166995|NCT02098408|Cognitive remediation
166996|NCT02098382|Cervical ripening
166997|NCT02098369|Chronic obstructive pulmonary disease (COPD)
166998|NCT02098369|Supplemental oxygen
166999|NCT02098369|Adherence
167000|NCT02098369|Telephonic education
167001|NCT02098369|Peer coaching
167002|NCT02098356|hemodialysis
167003|NCT02098356|dialysis
167004|NCT02098356|acidosis
167005|NCT02098356|bicarbonate
167006|NCT02098343|Ovarian cancer
167007|NCT02098343|Ovarian carcinoma
167008|NCT02098343|High Grade Serous Ovarian Cancer
167009|NCT02098343|Recurrent Cancer
167010|NCT02098343|Resistant Cancer
167011|NCT02098330|Vestibular neuritis
167012|NCT02098330|Vertigo
167013|NCT02098330|Head impulse test
167014|NCT02098330|Steroid
167015|NCT02098317|NAFLD
167016|NCT02098317|NASH
167017|NCT02098317|DHA
167018|NCT02098317|VITAMIN D
167019|NCT02098317|OBESITY
167020|NCT02098317|CHILDREN
167021|NCT02098304|Caries
167022|NCT02098304|ICDAS
167023|NCT02098304|Lesion activity
167024|NCT02098304|Demineralisation
167025|NCT02098304|Imaging
167026|NCT02098265|aneurysm
167027|NCT02098265|transient ischemic attack
167028|NCT02098252|brain arteriovenous malformation
167029|NCT02098252|Arteriovenous Malformations
167030|NCT02098252|AVM
167031|NCT02098252|BAVM
167032|NCT02098252|Stroke
167033|NCT02098252|Intracranial Hemorrhage
167034|NCT02098252|Congenital Abnormalities
167035|NCT02098252|Aneurysm
167036|NCT02098252|Vascular Malformations
167037|NCT02098252|Cardiovascular Abnormalities
167038|NCT02098252|Cardiovascular Diseases
167039|NCT02098252|Vascular Diseases
167040|NCT02098213|plaque psoriasis
167041|NCT02098213|DLQI
167042|NCT02098213|VQ Dermato
167043|NCT02098213|PASI
167044|NCT02098213|PASI change
167045|NCT02098213|phototherapy
167046|NCT02098213|balneotherapy
167047|NCT02098213|hydrotherapy
167048|NCT02098213|Euroquol EQ 5d scale
167049|NCT02098213|Visual analogic scale
167050|NCT02098213|SPA treatment Scale
167051|NCT02098213|PSS
167052|NCT02098200|tricuspid
167053|NCT02098200|regurgitation
167054|NCT02098200|repair
167055|NCT02098200|outcomes
167056|NCT02098187|Glomerular Filtration Rate
167057|NCT02098187|Acute Kidney Injury
167058|NCT02098174|Glomerular Filtration Rate
167059|NCT02098174|Acute kidney injury
167060|NCT02098161|Leukemia
167061|NCT02098161|Primary Myelofibrosis
167062|NCT02098161|PMF
167063|NCT02098161|Post-Polycythemia Vera Myelofibrosis
167064|NCT02098161|Post-PV MF
167065|NCT02098161|Post-Essential Thrombocytosis Myelofibrosis
167066|NCT02098161|Post-ET MF
167067|NCT02098161|LCL-161
167068|NCT02098161|Questionnaire
167069|NCT02098161|Survey
167070|NCT02098161|Phone Call
167071|NCT02098096|knee
167072|NCT02098096|arthritis
167073|NCT02098096|Veterans
167074|NCT02098096|strength
167075|NCT02098096|exercise
167076|NCT02098096|muscle
167077|NCT02098083|acute
167078|NCT02098083|stroke
167079|NCT02098083|gait
167080|NCT02098070|Knee Pain
167081|NCT02098070|Community Study
167082|NCT02098070|Knee Osteoarthritis
167083|NCT02098070|Risk Factors
167084|NCT02098057|IBS-diarrhea
167085|NCT02098044|knee osteoarthritis
167086|NCT02098044|epidemiology
167087|NCT02098044|risk factors
167088|NCT02098044|prevalence
167089|NCT02098044|professional football
167090|NCT02098031|Child Nutrition Sciences
167091|NCT02098031|Growth and Development
167092|NCT02098031|Developing Countries
167093|NCT02097992|COPD
167094|NCT02097992|airway blood flow
167095|NCT02097979|glaucoma
167096|NCT02097979|adherence
167097|NCT02097979|medication possession ratio
167098|NCT02097979|intervention
167099|NCT02097953|Daptomycin
167100|NCT02097953|Rifampin
167101|NCT02097953|P-glycoprotein
167102|NCT02097953|Pharmacokinetic
167103|NCT02097940|Postural balance
167104|NCT02097940|Athletes
167105|NCT02097940|Sports
167106|NCT02097940|Soccer
167107|NCT02097940|Physiotherapy
167108|NCT02097927|Appetite
167109|NCT02097927|Satiety
167110|NCT02097927|Energy intake
167111|NCT02097927|Saliva
167112|NCT02097927|Biomarkers
167113|NCT02097914|Secondhand smoke exposure
167114|NCT02097914|Secondhand smoke
167115|NCT02097914|Environmental Tobacco Smoke
167116|NCT02097914|Smoke-free homes
167117|NCT02097914|Smoke-free homes ban
167118|NCT02097901|Rotator Cuff
167119|NCT02097901|Injury
167120|NCT02097901|Repair
167121|NCT02097901|Microfracture
167122|NCT02097901|Healing
167123|NCT02097875|Skin cancer
167124|NCT02097875|Basal cell carcinoma
167125|NCT02097875|Squamous cell carcinoma
167126|NCT02097875|Melanoma
167127|NCT02097862|Degenerative Disc Disease
167128|NCT02097862|Disc Disease
167129|NCT02097862|Back pain
167130|NCT02097862|stem cells
167131|NCT02097862|adipose stem cells
167132|NCT02097862|ADSCs
167133|NCT02097849|vaccine
167134|NCT02097849|pneumococcal
167135|NCT02097849|meningococcal
167136|NCT02097849|tetanus diphtheria
167137|NCT02097849|immune response
167138|NCT02097836|postural control
167139|NCT02097836|Targeted Training
167140|NCT02097836|cerebral palsy
167141|NCT02097836|trunk segments
167142|NCT02097823|olanzapine
167143|NCT02097823|Nausea and vomiting
167144|NCT02097823|aprepitant
167145|NCT02097823|pediatrics
167146|NCT02097797|Inflammatory bowel disease
167147|NCT02097797|Crohn's disease
167148|NCT02097797|microbiota
167149|NCT02097797|fecal transplantation
167150|NCT02097784|cirrhosis
167151|NCT02097784|hepatorenal syndrome
167152|NCT02097784|acute kidney injury
167153|NCT02097784|diastolic function
167154|NCT02097771|laryngeal mask airway ventilation
167155|NCT02097732|Metastatic melanoma
167156|NCT02097732|Brain metastases
167157|NCT02097732|Radiation therapy
167158|NCT02097732|Immune therapy
167159|NCT02097706|Boderline Personality Disorder
167160|NCT02097706|Mental Illness
167161|NCT02097706|Cognition
167162|NCT02097693|DBS
167163|NCT02097693|quality of life
167164|NCT02097693|dystonia
167165|NCT02097693|dyskinetic cerebral palsy
167166|NCT02097680|with disturbed glucose metabolism
167167|NCT02097680|without disturbed glucose metabolism
167168|NCT02097667|Severe early onset Fetal Growth Restrictions
167169|NCT02097654|Hospital acquired
167170|NCT02097654|Elderly
167171|NCT02097641|Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells
167172|NCT02097641|Acute Respiratory Distress Syndrome
167173|NCT02097628|volume controlled ventilation
167174|NCT02097628|pressure controlled ventilation
167175|NCT02097615|soft
167176|NCT02097615|tissue
167177|NCT02097615|infections
167178|NCT02097602|Reticulated platelets
167179|NCT02097602|noncardiac surgery
167180|NCT02097602|MACCEs
167181|NCT02097602|major adverse cardiac and cerebrovascular events
167182|NCT02097602|outcome
167183|NCT02097602|High-risk or intermediate-risk noncardiac surgery
167184|NCT02097589|Health Controls
167185|NCT02097576|Chronic Rhinosinusitis
167186|NCT02097563|Mood Disorders
167187|NCT02097563|Psychosis
167188|NCT02097563|Subthreshold
167189|NCT02097563|Bipolar Disorder
167190|NCT02097550|Renal Insufficiency, Chronic
167191|NCT02097550|Kidney Failure, Chronic
167192|NCT02097550|Self Care
167193|NCT02097550|Consumer Participation
167194|NCT02097550|Patient Participation
167195|NCT02097550|Marketing
167196|NCT02097550|Consumer Health Information
167197|NCT02097511|Drug-drug interaction
167198|NCT02097511|Pharmacokinetics
167199|NCT02097511|Pharmacodynamics
167200|NCT02097498|Simulation
167201|NCT02097498|Enhance
167202|NCT02097498|Safety
167203|NCT02097498|Proficiency
167204|NCT02097498|Paramedics.
167205|NCT02097498|Airway Management
167206|NCT02097498|Intubation
167207|NCT02097459|Breast cancer
167208|NCT02097459|Endocrine therapy
167209|NCT02097459|Perimenopausal and recently postmenopausal patients
167210|NCT02097459|Early-stage hormone receptor-positive
167211|NCT02097446|cystectomy
167212|NCT02097433|Dacomitinib
167213|NCT02097433|PF299804
167214|NCT02097433|pharmacokinetics
167215|NCT02097433|healthy
167216|NCT02097433|Chinese
167217|NCT02097420|Mitral valve
167218|NCT02097381|HIV infection
167219|NCT02097381|GUT
167220|NCT02097381|microbial translocation
167221|NCT02097381|chronic inflammation
167222|NCT02097381|antiretroviral therapy
167223|NCT02097381|cART
167224|NCT02097381|HAART
167225|NCT02097381|Th17
167226|NCT02097381|Th1
167227|NCT02097381|CD4+
167228|NCT02097368|Tongue strength
167229|NCT02097368|neuromuscular
167230|NCT02097368|swallowing
167231|NCT02097355|chronic disease
167232|NCT02097355|patient portal
167233|NCT02097355|health information technology
167234|NCT02097355|patient provider communication
167235|NCT02097355|quality improvement
167236|NCT02097342|Type 2 Diabetes Mellitus
167237|NCT02097342|Insulin sensitivity- hyperinsulinemic euglycemic clamp
167238|NCT02097342|Pancreatic beta cell function
167239|NCT02097342|Linagliptin
167240|NCT02097342|Voglibose
167241|NCT02097342|Mixed meal test
167242|NCT02097342|GLP-1 response
167243|NCT02097329|bioavailability
167244|NCT02097329|antacid
167245|NCT02097329|rabeprazole
167246|NCT02097329|famotidine
167247|NCT02097329|palbociclib
167248|NCT02097316|Glycemic control
167249|NCT02097316|JewelPump accuracy
167250|NCT02097303|Prostate Cancer
167251|NCT02097303|Bone Metastasis
167252|NCT02097303|Symptomatic
167253|NCT02097303|Androgen Independent
167254|NCT02097303|Hormone Refractory
167255|NCT02097303|Castrate Resistant
167256|NCT02097303|AIPC
167257|NCT02097303|pre-chemotherapy
167258|NCT02097303|Post-chemotherapy
167259|NCT02097290|Threshold algorithms
167260|NCT02097290|CRT-D
167261|NCT02097251|Mucopolysaccharidosis Type 7
167262|NCT02097251|Sly syndrome
167263|NCT02097251|UX003
167264|NCT02097251|Enzyme Replacement Therapy
167265|NCT02097251|rare disease
167266|NCT02097251|Lysosomal Storage Disease
167267|NCT02097251|metabolic disorder
167268|NCT02097212|Tracheobronchomalacia
167269|NCT02097212|TBM
167270|NCT02097212|HyperDynamic Airway Collapse
167271|NCT02097212|HDAC
167272|NCT02097212|Obstructive Sleep Apnea
167273|NCT02097212|OSA
167274|NCT02097199|activity, osteoprotegerin, endocan, atherosclerosis, biomarker
167275|NCT02097186|Vascular disease
167276|NCT02097186|Open aortic aneurysm repair
167277|NCT02097186|Endovascular aneurysm repair
167278|NCT02097186|Carotid endartrectomy
167279|NCT02097186|Lower limb surgical revascularisation
167280|NCT02097186|Major lower limb amputation
167281|NCT02097160|childhood
167282|NCT02097160|healthy
167283|NCT02097160|vitamin D
167284|NCT02097160|bone
167285|NCT02097160|dairy products
167286|NCT02097147|Viibryd
167287|NCT02097108|HIV infection
167288|NCT02097108|Raltegravir
167289|NCT02097108|Switch
167290|NCT02097108|Hyperlipidemia
167291|NCT02097108|Women
167292|NCT02097095|Correlates of risk
167293|NCT02097095|TB
167294|NCT02097095|Tuberculosis
167295|NCT02097095|Sub-study
167296|NCT02097095|TB-018
167297|NCT02097082|Peripheral Arterial Disease
167298|NCT02097082|Intermittent Claudication
167299|NCT02097082|Vascular Diseases
167300|NCT02097082|Cardiovascular Diseases
167301|NCT02097082|Superficial Femoral Artery
167302|NCT02097069|Gestational diabetes mellitus
167303|NCT02097069|Myo-inositol
167304|NCT02097069|D-chiro-inositol
167305|NCT02097069|Insulin resistance
167306|NCT02097056|Alzheimer's disease
167307|NCT02097017|lidocaine
167308|NCT02097017|laminaria
167309|NCT02097017|dilatation and evacuation
167310|NCT02097017|pain
167311|NCT02097004|chronic hepatitis B
167312|NCT02097004|Pegasys
167313|NCT02097004|Euvax B
167314|NCT02097004|Baracrude
167315|NCT02096978|Implant
167316|NCT02096978|Stability
167317|NCT02096978|placement
167318|NCT02096978|Osteotome
167319|NCT02096965|Calcium oxalate
167320|NCT02096965|Calcium phosphate
167321|NCT02096965|Kidney stone
167322|NCT02096952|Attention-deficit/hyperactivity disorder
167323|NCT02096952|ADHD
167324|NCT02096952|Autism spectrum disorder
167325|NCT02096952|ASD
167326|NCT02096952|High-functioning ASD
167327|NCT02096952|Asperger's disorder
167328|NCT02096952|Asperger's
167329|NCT02096926|Third Molar Extraction
167330|NCT02096913|Rho-Inhibition
167331|NCT02096913|Plasticity
167332|NCT02096913|Neurological Function
167333|NCT02096913|RhoA
167334|NCT02096913|Ibuprofen
167335|NCT02096913|NSAIDs
167336|NCT02096900|Pre-medication
167337|NCT02096900|Pre-operative anxiety
167338|NCT02096887|education
167339|NCT02096887|compliance
167340|NCT02096887|risk factors
167341|NCT02096874|Peripheral retinal ischemia
167342|NCT02096874|ultra wide field fluorescein angiography
167343|NCT02096874|Bevacizumab
167344|NCT02096848|otitis media
167345|NCT02096848|microbiology
167346|NCT02096848|vaccines
167347|NCT02096835|Postoperative nausea and vomiting
167348|NCT02096835|Transcutaneous electrical acupoint stimulation
167349|NCT02096835|Gynecological laparoscopic surgery
167350|NCT02096835|Tropisetron
167351|NCT02096835|Dexamethasone
167352|NCT02096822|Facilitated tucking
167353|NCT02096822|Non nutritive sucking
167354|NCT02096822|Preterm
167355|NCT02096822|Pain relief
167356|NCT02096809|Bone Conduction
167357|NCT02096809|Hearing loss - conductive
167358|NCT02096809|Osseointegration
167359|NCT02096809|Prostheses and Implants
167360|NCT02096757|Claudication
167361|NCT02096757|Critical Limb Ischemia
167362|NCT02096757|Endovascular procedure
167363|NCT02096757|Atherosclerosis
167364|NCT02096679|Phase I, healthy, pharmacokinetics, Mass balance
167365|NCT02096666|MET Amplified Gastric/ Gastroesophageal Junction/ Esophageal Adenocarcinomas, or other solid tumors
167366|NCT02096653|sacroiliac joint
167367|NCT02096653|low back pain
167368|NCT02096653|steroid injection
167369|NCT02096627|Cataract, femtosecond laser, FLACS
167370|NCT02096614|Adoptive cell transfer
167371|NCT02096614|Cell therapy
167372|NCT02096614|Immunotherapy
167373|NCT02096614|MAGE-A4
167374|NCT02096614|Esophageal cancer
167375|NCT02096614|Melanoma
167376|NCT02096614|Head and neck cancer
167377|NCT02096614|Ovarian cancer
167378|NCT02096614|TCR gene therapy
167379|NCT02096601|Motor fluctuations
167380|NCT02096601|levodopa pharmacokinetics
167381|NCT02096601|levodopa and carbidopa solution
167382|NCT02096601|continuous subcutaneous delivery
167383|NCT02096588|Breast cancer
167384|NCT02096588|Adriamycin
167385|NCT02096588|Simvastatin
167386|NCT02096588|Statin
167387|NCT02096588|Echocardiogram
167388|NCT02096575|nitrous oxide
167389|NCT02096575|pain
167390|NCT02096562|knee welling outpatient compression stockings
167391|NCT02096549|cerebral palsy
167392|NCT02096549|Botulinum toxin
167393|NCT02096549|Propofol
167394|NCT02096549|Deep sedation
167395|NCT02096549|Bispectral index monitor
167396|NCT02096536|Neonate
167397|NCT02096536|Vancomycin
167398|NCT02096536|LC/MS-MS
167399|NCT02096536|protein binding
167400|NCT02096523|inherited platelet disorders
167401|NCT02096523|proteome
167402|NCT02096510|Addison Disease
167403|NCT02096510|Adrenal Hyperplasia Congenital
167404|NCT02096484|Metacognitive therapy
167405|NCT02096484|mindfulness meditation therapy
167406|NCT02096484|group therapy
167407|NCT02096484|generalized anxiety disorder
167408|NCT02096484|Group Based Metacognitive Therapy
167409|NCT02096484|Group Based Mindfulness Meditation Therapy
167410|NCT02096471|Neurofibromatosis Type 1 (Neurofibromas)
167411|NCT02096471|PD-0325901
167412|NCT02096471|Radiographic Response
167413|NCT02096471|Inoperable Plexiform Neurofibromas
167414|NCT02096458|Drug therapy
167415|NCT02096445|stroke
167416|NCT02096445|acute
167417|NCT02096445|rehabilitation
167418|NCT02096445|robot therapy
167419|NCT02096445|hand function
167420|NCT02096445|fine motor skills
167421|NCT02096445|neurocognitive
167422|NCT02096445|sensory
167423|NCT02096445|Perfetti
167424|NCT02096445|haptics
167425|NCT02096419|clopidogrel
167426|NCT02096419|platelet reactivity
167427|NCT02096419|acute coronary syndrome
167428|NCT02096419|tailoring therapy
167429|NCT02096419|outcome
167430|NCT02096406|Coronary artery disease
167431|NCT02096406|Coronary artery bypass grafting
167432|NCT02096406|angiotensin converting enzyme inhibitor
167433|NCT02096406|angiotensin receptor blocker
167434|NCT02096406|Surgical valve repair
167435|NCT02096406|Valve Replacement
167436|NCT02096380|Nasopharyngeal Carcinoma
167437|NCT02096380|cycle
167438|NCT02096380|induction chemotherapy
167439|NCT02096380|docetaxel
167440|NCT02096367|vibrations
167441|NCT02096367|stroke
167442|NCT02096367|posture
167443|NCT02096367|gait
167444|NCT02096367|readaptation
167445|NCT02096328|Ventilator Associated Pneumonia (VAP)
167446|NCT02096328|Lower respiratory infection
167447|NCT02096328|POL7080
167448|NCT02096328|Pseudomonas aeruginosa
167449|NCT02096328|Nosocomial pneumonia
167450|NCT02096315|POL7080
167451|NCT02096315|Pseudomonas aeruginosa
167452|NCT02096315|Non cystic fibrosis bronchiectasis
167453|NCT02096315|Exacerbation
167454|NCT02096302|Probiotics
167455|NCT02096302|Infant Formula
167456|NCT02096302|Microbiota
167457|NCT02096302|Bifidobacterium longum biovar infantis CECT7210
167458|NCT02096302|Growth
167459|NCT02096289|Relapsed Acute Myeloid Leukemia
167460|NCT02096289|Refractory Acute Myeloid Leukemia
167461|NCT02096289|Thioridazine
167462|NCT02096289|Phase I
167463|NCT02096289|Clinical Trial
167464|NCT02096276|Pregnancy Registry
167465|NCT02096276|Boostrix
167466|NCT02096276|Women
167467|NCT02096276|Cohort
167468|NCT02096276|Prospective
167469|NCT02096276|Pregnancy outcome
167470|NCT02096276|Exploratory
167471|NCT02096263|Healthy
167472|NCT02096263|Infanrix Hexa
167473|NCT02096263|Immunogenicity
167474|NCT02096263|Infants
167475|NCT02096263|Safety
167476|NCT02096237|asthma, bronchial
167477|NCT02096237|immunoadsorbents
167478|NCT02096237|apheresis
167479|NCT02096237|immunoglobulin E
167480|NCT02096211|Total hip replacement
167481|NCT02096211|Total hip arthroplasty
167482|NCT02096211|Hip joint replacement
167483|NCT02096211|Hip prosthesis replacement
167484|NCT02096198|Total Hip Replacement
167485|NCT02096198|Total Hip Arthroplasty
167486|NCT02096198|Hip Joint Replacement
167487|NCT02096198|Hip Prosthesis Replacement
167488|NCT02096185|Breast cancer
167489|NCT02096185|Surgery
167490|NCT02096185|Specimen imaging
167491|NCT02096159|Hypospadias
167492|NCT02096159|Anti-Bacterial Agents
167493|NCT02096146|Plate
167494|NCT02096146|Hallux valgus
167495|NCT02096146|Foot deformity
167496|NCT02096146|Screw
167497|NCT02096146|Tarsometatarsal angle
167498|NCT02096146|Cost effectiveness
167499|NCT02096133|Multiple sclerosis, vitamin D, HPA-axis, cortisol
167500|NCT02096120|Periodontitis
167501|NCT02096107|Everolimus
167502|NCT02096107|Graft dysfunction
167503|NCT02096107|Interstitial fibrosis
167504|NCT02096094|Antiseptics
167505|NCT02096094|Administration cutaneously
167506|NCT02096094|Chlorine compounds
167507|NCT02096094|Infection control
167508|NCT02096094|Anti-infecting agents, local
167509|NCT02096081|Glabellar Frown Lines
167510|NCT02096081|Frown Lines
167511|NCT02096081|Facial Wrinkles
167512|NCT02096068|Neuroprotection
167513|NCT02096055|Leukemia
167514|NCT02096055|Acute Myeloid Leukemia
167515|NCT02096055|AML
167516|NCT02096055|Elderly
167517|NCT02096055|SGI-110
167518|NCT02096055|Idarubicin
167519|NCT02096055|Idamycin
167520|NCT02096055|Cladribine
167521|NCT02096055|Leustatin
167522|NCT02096055|2-CdA
167523|NCT02096042|Leukemia
167524|NCT02096042|Acute Myeloid Leukemia
167525|NCT02096042|AML
167526|NCT02096042|CD30-Positive
167527|NCT02096042|Relapsed
167528|NCT02096042|Refractory
167529|NCT02096042|Brentuximab Vedotin
167530|NCT02096042|SGN-35
167531|NCT02096042|Adcetris
167532|NCT02096042|5-Azacytidine
167533|NCT02096042|Azacytidine
167534|NCT02096042|Azacitidine
167535|NCT02096042|5-aza
167536|NCT02096042|Vidaza
167537|NCT02096042|5-AZC
167538|NCT02096042|AZA-CR
167539|NCT02096042|Ladakamycin
167540|NCT02096042|NSC-102816
167541|NCT02096029|smoking
167542|NCT02096029|smoking cessation
167543|NCT02096029|nicotine replacement therapy
167544|NCT02096029|primary care
167545|NCT02096029|comparative effectiveness
167546|NCT02096016|Surveillance
167547|NCT02096016|Follow up
167548|NCT02096003|Intrathecal hydromorphone
167549|NCT02096003|Intrathecal morphine
167550|NCT02096003|Primary cesarean section
167551|NCT02096003|Analgesia
167552|NCT02095990|Facial Melasma
167553|NCT02095977|St. Jude Riata lead failure
167554|NCT02095977|implantable cardioverter-defibrillator (ICD)
167555|NCT02095977|externalized conductors
167556|NCT02095977|ventricular tachyarrythmia
167557|NCT02095977|electrophysiology
167558|NCT02095964|cardiac syndrome X
167559|NCT02095964|inflammation
167560|NCT02095964|dyslipidemia
167561|NCT02095938|schizophrenia
167562|NCT02095938|brain structure
167563|NCT02095938|treatment response
167564|NCT02095938|solian
167565|NCT02095938|gene
167566|NCT02095938|mri
167567|NCT02095912|Squamous Cell Carcinoma
167568|NCT02095899|Thoracic Surgical Procedures
167569|NCT02095873|Oral glucose tolerance test
167570|NCT02095873|Flow mediated dilatation
167571|NCT02095873|Aortal pulse wave velocity
167572|NCT02095873|Finger-fold capillary density by capillaroscopy
167573|NCT02095847|Uterine Cancer
167574|NCT02095847|Endometrial cancer
167575|NCT02095847|Hysterectomy
167576|NCT02095847|Hysteroscopy
167577|NCT02095847|High-resolution microendoscopy
167578|NCT02095847|HRME
167579|NCT02095847|Hysteroscopic-guided resection
167580|NCT02095847|Proflavine
167581|NCT02095834|Myeloma
167582|NCT02095834|Multiple Myeloma
167583|NCT02095834|Relapsed
167584|NCT02095834|Refractory
167585|NCT02095834|Carfilzomib
167586|NCT02095834|Bendamustine
167587|NCT02095834|Bendamustine Hydrochloride
167588|NCT02095834|Bendamustine HCL
167589|NCT02095834|CEP-18083
167590|NCT02095834|SDX-105
167591|NCT02095834|Treanda
167592|NCT02095834|Dexamethasone
167593|NCT02095834|Decadron
167594|NCT02095795|Exercise Therapy
167595|NCT02095782|non-small cell lung cancer
167596|NCT02095782|erlotinib
167597|NCT02095782|chemotherapy
167598|NCT02095769|Pharmacogenomics
167599|NCT02095769|Adverse Drug Reactions
167600|NCT02095743|Early breast cancer
167601|NCT02095743|Chemotherapy
167602|NCT02095743|PICC line
167603|NCT02095743|Implanted port
167604|NCT02095730|crosslinking
167605|NCT02095730|cornea
167606|NCT02095730|keratoconus
167607|NCT02095730|ectasia
167608|NCT02095730|irradiance
167609|NCT02095730|riboflavin
167610|NCT02095691|Renal Sympathetic Denervation
167611|NCT02095678|Hepatocellular Carcinoma
167612|NCT02095678|Hepatoma
167613|NCT02095678|Liver Cancer, Adult
167614|NCT02095678|Liver Cell Carcinoma
167615|NCT02095678|Liver Cell Carcinoma, Adult
167616|NCT02095678|HCC
167617|NCT02095665|ureteric stents
167618|NCT02095665|LUTS
167619|NCT02095665|lower urinary tract symptoms
167620|NCT02095587|Phase 1
167621|NCT02095587|hepatic impairment
167622|NCT02095574|GDC-0199
167623|NCT02095574|ADME
167624|NCT02095574|Relapsed
167625|NCT02095574|Refractory
167626|NCT02095574|ABT-199
167627|NCT02095574|Non-Hodgkin's Lymphoma
167628|NCT02095561|HPV self testing
167629|NCT02095561|screening uptake
167630|NCT02095561|cervical cáncer
167631|NCT02095561|cervical intraepithelial neoplasia
167632|NCT02095535|obstetric patients
167633|NCT02095535|chloraprep
167634|NCT02095535|chlorhexidine
167635|NCT02095535|drying time
167636|NCT02095522|colchicine NSTEMI endothelial function inflammation
167637|NCT02095496|sleep
167638|NCT02095496|intensive care
167639|NCT02095496|mechanical ventilation
167640|NCT02095470|Laryngoscopy
167641|NCT02095470|Equipment
167642|NCT02095470|Video Laryngoscope
167643|NCT02095457|Routine Outcome Monitoring
167644|NCT02095457|Psychotherapy
167645|NCT02095457|Alliance
167646|NCT02095457|Feedback Informed Treatment
167647|NCT02095457|Mental Health Outpatients
167648|NCT02095431|patients undergoing the liver transplantation
167649|NCT02095431|acute kidney injury
167650|NCT02095418|New-onset diabetes after transplantation (NODAT)
167651|NCT02095418|Liver transplantation
167652|NCT02095405|Supraventricular Tachycardia
167653|NCT02095405|Atrial Fibrillation
167654|NCT02095405|Electrophysiology Study
167655|NCT02095405|Programmed Electrical Stimulation
167656|NCT02095392|soluble phosphate
167657|NCT02095392|phosphorus metabolism
167658|NCT02095392|calcium metabolism
167659|NCT02095392|bone metabolism
167660|NCT02095392|human study
167661|NCT02095379|oligosecretary multiple myeloma
167662|NCT02095366|Acute Pain
167663|NCT02095366|Traumatic Pain
167664|NCT02095366|Emergency setting
167665|NCT02095366|Prehospital setting
167666|NCT02095366|Analgesia
167667|NCT02095366|Intranasal device
167668|NCT02095366|Intra veinous injection
167669|NCT02095366|Sufentanil citrate
167670|NCT02095366|Morphine Sulfate
167671|NCT02095353|Brain tumor
167672|NCT02095353|extraaxial
167673|NCT02095353|metastasis
167674|NCT02095353|glioma
167675|NCT02095353|primary brain tumor
167676|NCT02095353|secondary brain tumor
167677|NCT02095353|MRI
167678|NCT02095353|perfusion
167679|NCT02095353|dynamic contrast enhancement
167680|NCT02095353|CBV
167681|NCT02095353|CBF
167682|NCT02095353|ktrans
167683|NCT02095314|DTP-HB-Hib
167684|NCT02095314|Pentavalen
167685|NCT02095314|Pentabio
167686|NCT02095314|Booster
167687|NCT02095288|lipidomics
167688|NCT02095288|in vitro human whole blood assay
167689|NCT02095288|anti-inflammatory drugs
167690|NCT02095288|Lipidomics screening of anti-inflammatory drugs
167691|NCT02095275|BNP, acute kidney injury, fluid status
167692|NCT02095249|prostate cancer
167693|NCT02095249|radical prostatectomy
167694|NCT02095223|Knee injury
167695|NCT02095223|Meniscus injury
167696|NCT02095223|Anterior cruciate ligament injury
167697|NCT02095223|Knee ligament injury
167698|NCT02095210|PET scan
167699|NCT02095210|HER2
167700|NCT02095210|breast cancer
167701|NCT02095184|Breast Cancer
167702|NCT02095184|Postmenopausal
167703|NCT02095184|Hormone-Receptor Positive
167704|NCT02095119|Uterine cervical cancer
167705|NCT02095119|Palliative
167706|NCT02095119|Treatment
167707|NCT02095119|Monoclonal antibody
167708|NCT02095119|Nimotuzumab
167709|NCT02095106|forearm fractures
167710|NCT02095106|pediatric fractures
167711|NCT02095106|distal radius
167712|NCT02095093|Total Hip Arthroplasty
167713|NCT02095093|Navigation
167714|NCT02095093|Imageless
167715|NCT02095093|THA
167716|NCT02095093|Computer navigated
167717|NCT02095080|Leucine
167718|NCT02095080|Upper Intake Level (UL)
167719|NCT02095080|Elderly
167720|NCT02095080|Amino acids
167721|NCT02095080|Protein
167722|NCT02095067|Telemedicine
167723|NCT02095067|Emergency medical dispatch
167724|NCT02095067|Prehospital care
167725|NCT02095067|Video conference
167726|NCT02095054|Advanced Cancers
167727|NCT02095054|Advanced malignancy
167728|NCT02095054|Metastatic cancer
167729|NCT02095054|Advanced solid tumor
167730|NCT02095054|Regorafenib
167731|NCT02095054|Stivarga
167732|NCT02095054|Cetuximab
167733|NCT02095054|C225
167734|NCT02095054|Erbitux
167735|NCT02095054|IMC-C225
167736|NCT02095054|MOAB C225
167737|NCT02095054|Questionnaire
167738|NCT02095054|Survey
167739|NCT02095041|Oxygen saturation.
167740|NCT02095041|Term infants.
167741|NCT02095041|Saturation trend.
167742|NCT02095041|Histogram.
167743|NCT02095041|Public health nurse.
167744|NCT02095041|congenital heart disease screening.
167745|NCT02095015|MPS
167746|NCT02095015|Mucopolysaccharidosis
167747|NCT02095015|MPS I
167748|NCT02095015|Mucopolysaccharidosis I
167749|NCT02095015|Hurler, Hurler-Scheie, or Scheie syndrome
167750|NCT02095015|MPS II
167751|NCT02095015|Mucopolysaccharidosis II
167752|NCT02095015|Hunter syndrome
167753|NCT02095015|MPS VI
167754|NCT02095015|Mucopolysaccharidosis VI
167755|NCT02095015|Maroteaux-Lamy syndrome
167756|NCT02095015|iduronate-2-sulfatase
167757|NCT02095015|ENT
167758|NCT02095015|ear, nose and throat
167759|NCT02095002|modified valsalva maneuver, internal jugular vein
167760|NCT02094989|electrocardiogram
167761|NCT02094989|vectorcardiogram
167762|NCT02094989|telecardiology
167763|NCT02094989|linear regression
167764|NCT02094989|individual transformation matrix
167765|NCT02094989|posture
167766|NCT02094976|Prone position
167767|NCT02094976|Intra-abdominal pressure
167768|NCT02094976|Respiratory system compliance
167769|NCT02094976|Jackson table
167770|NCT02094976|Wilson frame
167771|NCT02094976|Chest roll
167772|NCT02094963|acute coronary syndrome
167773|NCT02094963|coronary disease
167774|NCT02094963|coronary artery disease
167775|NCT02094950|concurrent chemotherapy
167776|NCT02094950|concurrent radiation
167777|NCT02094937|fluticasone propionate
167778|NCT02094937|step-down regimen
167779|NCT02094937|well-controlled subjects
167780|NCT02094937|adults
167781|NCT02094937|switching regimen
167782|NCT02094937|asthma
167783|NCT02094937|fluticasone furoate
167784|NCT02094937|fluticasone furoate/Vilanterol
167785|NCT02094924|Candesartan cilexetil
167786|NCT02094924|Hypertension
167787|NCT02094924|Hydrochlorothiazide
167788|NCT02094924|Healthy adult human subjects
167789|NCT02094924|Bioequivalence
167790|NCT02094911|Prevention
167791|NCT02094911|Combined lifestyle intervention
167792|NCT02094911|Primary health care
167793|NCT02094898|Depression
167794|NCT02094898|Unipolar
167795|NCT02094898|Bipolar
167796|NCT02094898|Suicidal
167797|NCT02094859|Glucose Monitoring
167798|NCT02094846|Cellular phones
167799|NCT02094846|Type 2 diabetes
167800|NCT02094846|Glycated hemoglobin
167801|NCT02094846|glycemic control
167802|NCT02094833|Diphtheria
167803|NCT02094833|Tetanus
167804|NCT02094833|Pertussis
167805|NCT02094833|Haemophilus influenzae type b infection
167806|NCT02094833|Hepatitis B
167807|NCT02094833|DTaP-IPV-Hep - PRP-T vaccine
167808|NCT02094807|prospective study
167809|NCT02094807|surgical management
167810|NCT02094807|rib fractures
167811|NCT02094807|trauma
167812|NCT02094755|critical limb ischemia, High on-treatment platelet reactivity, HPR, aspirin, clopidogrel
167813|NCT02094742|screening program
167814|NCT02094742|metastatic breast cancer
167815|NCT02094742|molecular profile
167816|NCT02094742|gene sequencing
167817|NCT02094729|mild cognitive impairment
167818|NCT02094729|Alzheimer's disease
167819|NCT02094716|Sarcoptes
167820|NCT02094716|Scabiei
167821|NCT02094716|Scabies
167822|NCT02094716|ectoparasite
167823|NCT02094716|parasite
167824|NCT02094716|infestation
167825|NCT02094716|Renaissance
167826|NCT02094703|female
167827|NCT02094703|age 18-65 years
167828|NCT02094703|storage symptoms
167829|NCT02094703|clinical urinary tract infection
167830|NCT02094703|non complicated
167831|NCT02094690|head and neck neoplasms
167832|NCT02094690|radiotherapy
167833|NCT02094690|physical therapy
167834|NCT02094690|trismus
167835|NCT02094664|Heat
167836|NCT02094664|Humidification
167837|NCT02094664|Oxygen
167838|NCT02094651|Abnormal EEGs
167839|NCT02094638|Traditional Chinese Medicine Injection
167840|NCT02094625|Cisplatin
167841|NCT02094625|N-acetylcysteine
167842|NCT02094625|Hearing Loss
167843|NCT02094625|Otoprotection
167844|NCT02094612|Attention Deficit and Disruptive Behavior Disorders
167845|NCT02094612|Attention Deficit Disorder with Hyperactivity
167846|NCT02094612|Pediatrics
167847|NCT02094612|Patient Outcome Assessment
167848|NCT02094573|Non-small cell lung cancer
167849|NCT02094573|Non-small cell lung carcinoma
167850|NCT02094573|Epithelial lung cancer
167851|NCT02094573|Squamous cell carcinoma
167852|NCT02094573|Large cell carcinoma
167853|NCT02094573|Adenocarcinoma
167854|NCT02094573|Anaplastic lymphoma kinase (ALK)
167855|NCT02094573|Advanced Malignancies
167856|NCT02094573|Carcinoma
167857|NCT02094573|Advanced Cancers
167858|NCT02094573|AP26113
167859|NCT02094560|therapy refractory
167860|NCT02094560|endstage
167861|NCT02094560|solid tumours
167862|NCT02094547|Infant Formula
167863|NCT02094547|Cognition
167864|NCT02094547|Neurodevelopment
167865|NCT02094547|Immunity
167866|NCT02094547|Microbiota
167867|NCT02094534|Diabetes type 1
167868|NCT02094534|Oral Insulin
167869|NCT02094534|Safety
167870|NCT02094534|Tolerability
167871|NCT02094534|Phase 2a
167872|NCT02094534|Randomized
167873|NCT02094534|Blinded
167874|NCT02094534|Parallel
167875|NCT02094508|Parasitemia
167876|NCT02094508|HIV-Exposed
167877|NCT02094508|HIV-Unexposed
167878|NCT02094508|Liver Stage
167879|NCT02094508|Randomized
167880|NCT02094495|Tamoxifen
167881|NCT02094495|Breast cancer
167882|NCT02094495|Knowkedge
167883|NCT02094469|Treatment for vasospastic angina
167884|NCT02094456|diverticular disease
167885|NCT02094456|diverticular bleeding
167886|NCT02094456|endoscopic clipping
167887|NCT02094456|endoscopy
167888|NCT02094456|lower gastrointestinal bleeding
167889|NCT02094443|Chronic hepatitis C genotype 2
167890|NCT02094443|Chronic hepatitis C genotype 3
167891|NCT02094443|Cyclophilin inhibitor
167892|NCT02094443|Interferon intolerant
167893|NCT02094417|Anemia, Aplastic
167894|NCT02094417|Thrombopoietin
167895|NCT02094417|Thrombocytopenia
167896|NCT02094404|Emergency Department
167897|NCT02094404|Pediatric Early Warning Score
167898|NCT02094404|Manchester Triage System
167899|NCT02094378|Healthy
167900|NCT02094378|Esketamine
167901|NCT02094378|Cognitive functioning
167902|NCT02094352|Complex Regional Pain Syndrome
167903|NCT02094352|Pain management
167904|NCT02094352|Ketamine infusion
167905|NCT02094339|Local analgesia system
167906|NCT02094339|Ropivacaine
167907|NCT02094339|Analgesic efficacy after operation
167908|NCT02094339|Postoperative
167909|NCT02094313|Atorvastatin
167910|NCT02094313|Human Spermatozoa
167911|NCT02094313|Seminal fluid
167912|NCT02094313|Accessory Glands
167913|NCT02094313|Cholesterol
167914|NCT02094313|Gonadotropins,
167915|NCT02094313|Testosterone
167916|NCT02094300|Aorta
167917|NCT02094300|Thoracic
167918|NCT02094300|Aortic dissection
167919|NCT02094300|Rupture
167920|NCT02094300|Type B
167921|NCT02094300|DeBakey type III
167922|NCT02094300|Endovascular
167923|NCT02094261|Phase II, open label study; safety and efficacy of AZD9291; diagnosis of Epidermal Growth Factor Receptor mutation positive and T790M mutation positive NSCLC
167924|NCT02094235|Dermatitis
167925|NCT02094235|Atopic
167926|NCT02094235|Pediatric
167927|NCT02094235|Adolescent
167928|NCT02094235|Child
167929|NCT02094209|External Fixation
167930|NCT02094209|Tibial fracture
167931|NCT02094209|Fracture healing
167932|NCT02094196|Reward- based learning
167933|NCT02094196|Pavlovian-to-instrumental transfer
167934|NCT02094196|Relapse Risk
167935|NCT02094196|Positron emission tomography (PET)
167936|NCT02094196|Magnetic resonance spectroscopy (MRS)
167937|NCT02094196|Dopamine receptor availability
167938|NCT02094196|Glutamate
167939|NCT02094157|Atrial fibrillation
167940|NCT02094157|Mechanical heart valve
167941|NCT02094157|Stroke
167942|NCT02094157|Venous thromboembolism
167943|NCT02094157|Hemorrhage
167944|NCT02094144|Sedentary
167945|NCT02094144|Physical activity
167946|NCT02094144|Brisk walking
167947|NCT02094144|Postmenopausal women
167948|NCT02094144|Body composition
167949|NCT02094144|Balance
167950|NCT02094144|Muscle strength
167951|NCT02094144|Depression, bone density
167952|NCT02094144|Nutrition
167953|NCT02094144|Biological effects
167954|NCT02094131|incentive spirometry
167955|NCT02094131|flow-oriented spirometer
167956|NCT02094131|volume-oriented spirometer
167957|NCT02094131|physical therapy
167958|NCT02094131|respiratory muscle training
167959|NCT02094118|Transfusion
167960|NCT02094118|RBC
167961|NCT02094118|cardiac
167962|NCT02094118|surgery
167963|NCT02094118|transfusion related acute lung injury (TRALI)
167964|NCT02094118|transfusion associated circulatory overload (TACO)
167965|NCT02094105|esophageal cancer
167966|NCT02094105|screening
167967|NCT02094105|endoscopy
167968|NCT02094105|prevention
167969|NCT02094092|L.reuteri ProTectis DSM 17938
167970|NCT02094092|Infantile colic
167971|NCT02094092|Maternal mental health.
167972|NCT02094092|Infant crying/fussing
167973|NCT02094092|Edinburgh Postnatal Depression Scale (EPDS)
167974|NCT02094079|hypothyroidism
167975|NCT02094079|pregnancy
167976|NCT02094066|tranexamic acid
167977|NCT02094066|total hip arthroplasty
167978|NCT02094053|Down syndrome
167979|NCT02094053|regression symptoms
167980|NCT02094053|disabled activities of daily living
167981|NCT02094040|frailty
167982|NCT02094040|readmission
167983|NCT02094040|transition
167984|NCT02094040|discharge
167985|NCT02094040|primary care
167986|NCT02094027|Obesity
167987|NCT02094027|Bariatric surgery
167988|NCT02094027|Binge eating
167989|NCT02094027|Self help
167990|NCT02094014|Perceptual masking
167991|NCT02094014|Auditory stimulation
167992|NCT02094014|Speech
167993|NCT02094014|Language
167994|NCT02094014|Verbal Fluency Disorders
167995|NCT02093962|TH-302
167996|NCT02093962|TH-CR-415
167997|NCT02093962|Pemetrexed
167998|NCT02093962|Non-small cell lung cancer
167999|NCT02093962|Lung cancer
168000|NCT02093962|Evofosfamide
168001|NCT02093936|airway inflammation
168002|NCT02093936|induced sputum
168003|NCT02093936|normal values
168004|NCT02093936|lymphocyte
168005|NCT02093936|eosinophil
168006|NCT02093936|neutrophil
168007|NCT02093923|HAE
168008|NCT02093910|multiple myeloma
168009|NCT02093910|peripheral neuropathy
168010|NCT02093910|prophylaxis
168011|NCT02093884|Pregnancy
168012|NCT02093884|Pregnancy, unplanned
168013|NCT02093884|Reproductive behavior
168014|NCT02093884|Pregnancy in Adolescence
168015|NCT02093884|Text messaging
168016|NCT02093871|Ovarian cancer
168017|NCT02093871|Therapeutic hyperthermia
168018|NCT02093871|HEATT
168019|NCT02093871|whole body hyperthermia
168020|NCT02093871|hyperthermia
168021|NCT02093871|PISH
168022|NCT02093871|Verthermia
168023|NCT02093871|Phase 1 clinical trial
168024|NCT02093871|stage 3 ovarian cancer
168025|NCT02093871|stage 4 ovarian cancer
168026|NCT02093871|stage III ovarian cancer
168027|NCT02093871|stage IV ovarian cancer
168028|NCT02093871|late stage ovarian cancer
168029|NCT02093871|Core HFC
168030|NCT02093871|Lilja
168031|NCT02093871|Vertrees
168032|NCT02093871|Bastidas
168033|NCT02093871|total body hyperthermia
168034|NCT02093858|Metabolic Syndrome
168035|NCT02093845|Percutaneous coronary intervention
168036|NCT02093845|DES
168037|NCT02093845|Angina pectoris
168038|NCT02093845|Stent
168039|NCT02093832|femoral head size
168040|NCT02093832|cup size
168041|NCT02093832|Total hip arthroplasty
168042|NCT02093767|prebiotics
168043|NCT02093767|Synergy1
168044|NCT02093728|Phase I, healthy, pharmacokinetics
168045|NCT02093715|Bronchiolitis
168046|NCT02093715|FeNO
168047|NCT02093715|Asthma
168048|NCT02093715|wheezing, RSV
168049|NCT02093676|diabetes
168050|NCT02093676|type 1
168051|NCT02093676|adolescents
168052|NCT02093676|parents counselling
168053|NCT02093663|Mild
168054|NCT02093663|Moderate
168055|NCT02093650|Menopausal symptoms
168056|NCT02093650|menopause related quality of life
168057|NCT02093650|black cohosh
168058|NCT02093650|cimicifuga racemosa
168059|NCT02093650|MENQOL
168060|NCT02093650|Kupperman index
168061|NCT02093650|KI
168062|NCT02093650|liver function tests
168063|NCT02093598|pharmacokinetic
168064|NCT02093598|pharmacodynamic
168065|NCT02093598|Carcinoma, Endometrioid
168066|NCT02093598|mTOR protein
168067|NCT02093598|temsirolimus
168068|NCT02093598|torisel
168069|NCT02093598|biological marker
168070|NCT02093598|phase II
168071|NCT02093585|HIV-1
168072|NCT02093585|Abacavir
168073|NCT02093585|Platelet activation
168074|NCT02093585|Thromboelastography
168075|NCT02093585|Coagulation
168076|NCT02093572|Clock genes
168077|NCT02093572|Metabolism
168078|NCT02093572|Insulin sensitivity
168079|NCT02093559|Clinical Trial
168080|NCT02093559|Naloxone
168081|NCT02093559|Motivational Interviewing
168082|NCT02093546|Endometrial cancer
168083|NCT02093546|Endometrioid adenocarcinoma
168084|NCT02093546|Serous adenocarcinoma
168085|NCT02093546|Undifferentiated carcinoma
168086|NCT02093546|Mixed epithelial carcinoma
168087|NCT02093546|Adenocarcinoma not otherwise specified
168088|NCT02093546|NOS
168089|NCT02093546|Companion Protocol to GOG229O
168090|NCT02093546|Biomarkers
168091|NCT02093546|Circulating tumor cells
168092|NCT02093546|CTCs
168093|NCT02093546|Blood draw
168094|NCT02093546|Biopsy
168095|NCT02093533|Membranoproliferative glomerulonephritis
168096|NCT02093533|Nephrotic syndrome
168097|NCT02093533|Proteinuria
168098|NCT02093533|Alternative complement pathway
168099|NCT02093533|Complement inhibition
168100|NCT02093533|Eculizumab
168101|NCT02093520|Lumbar Spinal Stenosis
168102|NCT02093520|Spinal Stenosis
168103|NCT02093520|Neurogenic Claudication
168104|NCT02093507|newborn
168105|NCT02093507|foot deformity congenital
168106|NCT02093494|Septicemia
168107|NCT02093494|Blood culture
168108|NCT02093494|Contamination
168109|NCT02093468|Acute limb ischemia
168110|NCT02093468|ALI
168111|NCT02093468|Acute lower extremity arterial occlusion
168112|NCT02093455|Endothelial function
168113|NCT02093416|Obesity
168114|NCT02093416|Leptin
168115|NCT02093403|AML
168116|NCT02093403|Acute Myeloid Leukemia
168117|NCT02093403|Adult Acute Myeloid Leukemia with T(8;21)(Q22;Q22)
168118|NCT02093403|adult Acute Myeloid Leukemia with 11q23 (MLL) abnormalities
168119|NCT02093403|adult Acute Myeloid Leukemia with del(5q)
168120|NCT02093403|adult Acute Myeloid Leukemia with inv(16)(p13;q22)
168121|NCT02093377|acute myocardial infarction
168122|NCT02093377|sleep apnea
168123|NCT02093377|adaptive servo-ventilation
168124|NCT02093351|oncology, cancer, tumour, neoplasm, anticancer drug, pharmacokinetics, olaparib, anastrozole, tamoxifen, letrozole,
168125|NCT02093338|breast pain
168126|NCT02093338|probiotic
168127|NCT02093338|mastitis
168128|NCT02093338|lactobacillus fermentun
168129|NCT02093338|Staphylococcus
168130|NCT02093325|eltrombopag , thrombocytopenia, gynecologic cancer
168131|NCT02093312|Cancer
168132|NCT02093312|Food-delivery
168133|NCT02093312|Nutritional Intervention
168134|NCT02093312|Quality of life
168135|NCT02093312|Outpatients
168136|NCT02093286|Pentabio Vaccine
168137|NCT02093286|Safety
168138|NCT02093286|Infants
168139|NCT02093286|Booster Dose
168140|NCT02093286|DTwP/HepB/Hib
168141|NCT02093273|tOPV
168142|NCT02093273|Antibody response
168143|NCT02093273|Safety
168144|NCT02093260|Flubio Vaccine (Influenza HA)
168145|NCT02093260|Infants
168146|NCT02093260|Children
168147|NCT02093260|Safety
168148|NCT02093260|Immunogenicity
168149|NCT02093234|self care of diabetes type 2 patients
168150|NCT02093234|mobile health cell phone application impact on health
168151|NCT02093234|community health workers impact on health
168152|NCT02093221|Type 1 Diabetes Mellitus
168153|NCT02093221|Alpha1-Proteinase Inhibitor
168154|NCT02093221|Beta Cell
168155|NCT02093221|Alpha1-Antitrypsin
168156|NCT02093195|Treatment, COPD, bosentan
168157|NCT02093156|bowel preparation
168158|NCT02093156|Ottawa Score
168159|NCT02093143|Diagnostic panendoscopy of the upper airway
168160|NCT02093143|Total intravenous general anesthesia
168161|NCT02093143|Remifentanil
168162|NCT02093143|Propofol
168163|NCT02093143|Target controlled infusion
168164|NCT02093143|Direct laryngoscopy
168165|NCT02093143|Tracheoscopy
168166|NCT02093143|Oesophagoscopy
168167|NCT02093143|Ear Nose and Throat (ENT) tumor
168168|NCT02093143|Ear Nose and Throat (ENT) cancer
168169|NCT02093130|Double-blind Trial
168170|NCT02093130|Placebo-controlled
168171|NCT02093130|Pomegranate
168172|NCT02093130|Memory
168173|NCT02093130|Memory Impairment
168174|NCT02093130|Cognition
168175|NCT02093130|Ages 50-75
168176|NCT02093117|Supratentorial neurosurgery
168177|NCT02093117|Recruitment maneuver
168178|NCT02093117|Subdural pressure
168179|NCT02093117|Brain relaxation
168180|NCT02093117|Cerebral perfusion pressure
168181|NCT02093104|unresectable hepatocellular carcinoma
168182|NCT02093104|(undergoing chemoembolization and radioembolization)
168183|NCT02093091|nano-filled resin modified glass ionomer
168184|NCT02093091|clinical performance
168185|NCT02093091|class I
168186|NCT02093091|primary teeth
168187|NCT02093091|dentin bond strength
168188|NCT02093091|Filling of class I
168189|NCT02093065|severe hemophilia A
168190|NCT02093065|coated platelets
168191|NCT02093065|bleeding
168192|NCT02093052|Parenting
168193|NCT02093052|Parent child relations
168194|NCT02093052|Middle childhood outcomes
168195|NCT02093039|breast cancer screening
168196|NCT02093039|patient decision aids
168197|NCT02093039|informed decision
168198|NCT02093039|empowerment
168199|NCT02093039|randomized control trial
168200|NCT02093039|From 50 to 74 years old
168201|NCT02093039|invited to national breast cancer screening
168202|NCT02093013|asthma
168203|NCT02093013|intervention
168204|NCT02093013|medication adherence
168205|NCT02093013|inhaled corticosteroids
168206|NCT02093013|asthma control
168207|NCT02093013|integrated care
168208|NCT02092987|Hispanic
168209|NCT02092987|Dementia
168210|NCT02092987|Caregivers
168211|NCT02092987|Depressive symptoms
168212|NCT02092987|Burden
168213|NCT02092987|Pragmatic randomized trial
168214|NCT02092974|transcranial direct current stimulation (tDCS)
168215|NCT02092974|selective serotonin reuptake inhibitor (SSRI)
168216|NCT02092974|young
168217|NCT02092974|older adults
168218|NCT02092961|Rheumatoid Arthritis
168219|NCT02092961|OSKIRA
168220|NCT02092961|fostamatinib
168221|NCT02092961|CE-MRI
168222|NCT02092961|DCE-MRI
168223|NCT02092948|metastatic
168224|NCT02092948|PSCA
168225|NCT02092948|minibody
168226|NCT02092948|PET/CT
168227|NCT02092935|CDAD
168228|NCT02092935|Clostridium Difficile
168229|NCT02092896|Diabetes Mellitus
168230|NCT02092896|Diabetes Mellitus, Type 1
168231|NCT02092896|Glucose Metabolism Disorders
168232|NCT02092896|Metabolic Diseases
168233|NCT02092896|Cognitive performance
168234|NCT02092896|Hypoglycemia
168235|NCT02092896|Insulin
168236|NCT02092896|Glucagon-Like Peptide 1
168237|NCT02092896|Hypoglycemic Agents
168238|NCT02092896|Physiological Effects of Drugs
168239|NCT02092896|Pharmacologic Actions
168240|NCT02092896|Incretins
168241|NCT02092896|Hormones
168242|NCT02092883|Infantile Spasms
168243|NCT02092883|Neuroinflammation
168244|NCT02092883|PK11195
168245|NCT02092883|PET
168246|NCT02092883|ACTH
168247|NCT02092870|Chronic Wounds
168248|NCT02092870|Diabetes
168249|NCT02092870|Adipose Derived Stem Cells
168250|NCT02092870|Diabetic Foot
168251|NCT02092857|nutrient
168252|NCT02092857|nutrition
168253|NCT02092857|arachidonic acid
168254|NCT02092857|essential fatty acids
168255|NCT02092844|Menopause
168256|NCT02092844|Insomnia
168257|NCT02092844|Hot Flashes
168258|NCT02092805|VAS
168259|NCT02092805|VDS
168260|NCT02092805|HAM-D
168261|NCT02092805|Visceral pain
168262|NCT02092805|Malignancy
168263|NCT02092805|rTMS
168264|NCT02092805|Motor cortex
168265|NCT02092805|Analgesia
168266|NCT02092805|Dynorphin
168267|NCT02092766|malaria
168268|NCT02092766|anaemia
168269|NCT02092766|artesunate
168270|NCT02092753|Ketogenic diet, logi diet, breast cancer, rehabilitation
168271|NCT02092740|Testicular cancer
168272|NCT02092727|Dialysis facilities
168273|NCT02092727|African Americans
168274|NCT02092727|Racial disparity
168275|NCT02092727|Kidney Transplantation
168276|NCT02092727|Community-based Participatory Research
168277|NCT02092727|Coalition
168278|NCT02092727|Georgia
168279|NCT02092688|time to delivery
168280|NCT02092688|PROM
168281|NCT02092688|PTL
168282|NCT02092688|positive predictive value
168283|NCT02092675|Chronic obstructive pulmonary disease
168284|NCT02092675|frequent exacerbator
168285|NCT02092675|endothelial dysfunction
168286|NCT02092675|Flow mediated dilatation
168287|NCT02092675|Systemic inflammation
168288|NCT02092649|Omega-3
168289|NCT02092649|Resting metabolic rate
168290|NCT02092649|Eicosapentaenoic acid
168291|NCT02092649|Docosahexaenoic acid
168292|NCT02092636|Hybrid NIR/US imaging technique
168293|NCT02092636|NIR/US imaging
168294|NCT02092636|US imaging
168295|NCT02092636|US imaging technique
168296|NCT02092623|Female
168297|NCT02092623|Prolapse surgery with transvaginal mesh
168298|NCT02092623|Subjective outcome
168299|NCT02092584|atherosclerotic
168300|NCT02092584|IGF-1
168301|NCT02092584|IGFBP-3
168302|NCT02092558|metaplasia, dysfunction, urinary bladder, children
168303|NCT02092545|Obesity
168304|NCT02092519|EUSFNA
168305|NCT02092519|endoscopic ultrasound
168306|NCT02092519|pancreatic masses
168307|NCT02092506|H pylori
168308|NCT02092506|therapy
168309|NCT02092493|ScopeGuide
168310|NCT02092493|Colonoscopy
168311|NCT02092493|Mental workload
168312|NCT02092480|Feasibility Trial
168313|NCT02092480|Educational Intervention
168314|NCT02092480|Teenage Pregnancy
168315|NCT02092480|Boys
168316|NCT02092480|Gender sensitive interventions
168317|NCT02092480|Unintended pregnancy
168318|NCT02092480|Parents
168319|NCT02092480|Process evaluation
168320|NCT02092480|Economic costing
168321|NCT02092467|Post-marketing
168322|NCT02092467|Phase 4
168323|NCT02092467|Open-label
168324|NCT02092467|Safety Surveillance
168325|NCT02092467|CP690550
168326|NCT02092467|Xeljanz
168327|NCT02092467|oral treatment
168328|NCT02092441|Nausea
168329|NCT02092441|Vomiting
168330|NCT02092441|Antiemetic
168331|NCT02092428|Coronary Magnetic Resonance Imaging
168332|NCT02092428|CAD
168333|NCT02092428|Coronary Magnetic Resonance Angiography
168334|NCT02092428|MRA
168335|NCT02092428|3 Tesla MRI
168336|NCT02092415|Tourniquet
168337|NCT02092415|Muscle perfusion
168338|NCT02092415|Contrast ultrasound
168339|NCT02092402|Fecal transplantation
168340|NCT02092402|microbiota transplantation
168341|NCT02092402|irritable bowel syndrome
168342|NCT02092402|IBS
168343|NCT02092389|Ulcerative Colitis
168344|NCT02092389|Inflammatory Bowel Syndrome
168345|NCT02092389|Adalimumab
168346|NCT02092389|Tumor necrosis factor (TNF) alpha Antibody
168347|NCT02092389|Calprotectin
168348|NCT02092376|Bariatric surgery
168349|NCT02092376|vitamin D
168350|NCT02092376|supplementation
168351|NCT02092363|Platinum-Sensitive Ovarian Cancer
168352|NCT02092337|CAST, Hearing aids, Speech recognition, Cochlear implants
168353|NCT02092311|varicocele
168354|NCT02092311|varicocelectomy
168355|NCT02092311|complications of varicocelectomy
168356|NCT02092311|Recurrence of varicocele
168357|NCT02092311|Post-varicocelectomy testicular atrophy
168358|NCT02092311|Post-varicocelectomy hydrocele
168359|NCT02092298|Gastrointestinal cancer
168360|NCT02092298|Hyperthermic Intraperitoneal Chemoperfusion
168361|NCT02092298|HIPEC
168362|NCT02092298|Gastric carcinomatosis
168363|NCT02092298|Gastroesophageal cancer
168364|NCT02092298|Mitomycin C
168365|NCT02092298|Mitomycin
168366|NCT02092298|Cisplatin
168367|NCT02092298|Platinol-AQ
168368|NCT02092298|Platinol
168369|NCT02092298|CDDP
168370|NCT02092298|Sodium Thiosulfate
168371|NCT02092298|Tinver
168372|NCT02092233|ARIES HSV 1&2
168373|NCT02092220|Bionic Pancreas
168374|NCT02092220|Insulin
168375|NCT02092220|Glucagon
168376|NCT02092220|Continuous Glucose Monitor
168377|NCT02092194|beta 2-Microglobulin
168378|NCT02092194|Hemodiafiltration
168379|NCT02092194|convective volume
168380|NCT02092168|Opicapone
168381|NCT02092168|BIAL
168382|NCT02092142|Q fever
168383|NCT02092142|Coxiella burnetii
168384|NCT02092129|Acromegaly, surgery, histopathology, hyperprolactinaemia,
168385|NCT02092103|Premature Birth
168386|NCT02092103|Umbilical Cord Clamping
168387|NCT02092090|salt substitute
168388|NCT02092090|sodium reduction
168389|NCT02092090|stroke
168390|NCT02092090|cluster randomized trial
168391|NCT02092090|China
168392|NCT02092077|Growth Hormone-Deficient
168393|NCT02092077|recombinant human growth hormone
168394|NCT02092064|basal proteinuria
168395|NCT02092064|FMF
168396|NCT02092064|pregnancy
168397|NCT02092051|Continuous glucose monitoring
168398|NCT02092051|Type 1 diabetes
168399|NCT02092051|Insulin injections
168400|NCT02092051|Cross-over
168401|NCT02092038|glioblastoma
168402|NCT02092038|temozolomide
168403|NCT02092038|radiation therapy
168404|NCT02092038|radiotherapy
168405|NCT02092038|surgery
168406|NCT02092038|pre-operative
168407|NCT02092038|neoadjuvant
168408|NCT02092025|Pharmacological therapy
168409|NCT02092012|postoperative pain
168410|NCT02092012|dexketoprofen trometamol
168411|NCT02092012|dexmedetomidine
168412|NCT02091999|Metastatic Urothelial Cancer
168413|NCT02091999|Safety
168414|NCT02091999|AGS-22C3E
168415|NCT02091999|Nectin 4 protein, humans
168416|NCT02091999|Clinical Trial, Phase 1
168417|NCT02091999|ASG-22CE
168418|NCT02091999|ASG-22ME
168419|NCT02091999|Pharmacokinetics of ASG-22CE
168420|NCT02091986|asthma, children, budesonide pMDI
168421|NCT02091973|everolimus
168422|NCT02091973|tacrolimus
168423|NCT02091973|kidney transplantation
168424|NCT02091973|microRNA
168425|NCT02091960|Breast cancer
168426|NCT02091960|Enzalutamide
168427|NCT02091960|Xtandi
168428|NCT02091960|Androgen receptor positive
168429|NCT02091960|HER2
168430|NCT02091960|Trastuzumab
168431|NCT02091947|FMS
168432|NCT02091947|Urine incontinence
168433|NCT02091934|Alcon
168434|NCT02091934|Wavelight
168435|NCT02091934|PRK
168436|NCT02091934|Wavefront-guided
168437|NCT02091934|Wavefront-optimized
168438|NCT02091934|Myopia
168439|NCT02091934|Astigmatism
168440|NCT02091921|Critical Limb Ischemia, ticagrelor, Brilinta
168441|NCT02091908|Influenza
168442|NCT02091908|H5N1
168443|NCT02091908|aH5N1
168444|NCT02091908|H5N1 vaccine
168445|NCT02091908|Pandemic Influenza vaccine
168446|NCT02091908|MF59, Adjuvant, Avian flu
168447|NCT02091908|Underlying medical conditions
168448|NCT02091908|Underlying cardiovascular medical condition
168449|NCT02091908|Pandemic vaccine
168450|NCT02091908|Charlson Comorbidity Index (CCI)
168451|NCT02091908|Adjuvanted vaccine
168452|NCT02091895|probe-based confocal laser endomicroscopy, lower gastrointestinal disorders
168453|NCT02091882|OPC-14597 Digital
168454|NCT02091882|Aripiprazole
168455|NCT02091882|Medical Information Device #1 System (MIND1)
168456|NCT02091882|Ingestible Event Marker
168457|NCT02091869|Adolescents
168458|NCT02091869|Asthma
168459|NCT02091869|Asthma Symptoms
168460|NCT02091817|oxytocin
168461|NCT02091817|face
168462|NCT02091817|memory
168463|NCT02091804|Attachment theory
168464|NCT02091804|Parent- child relationship
168465|NCT02091804|Child mental health
168466|NCT02091804|Behavioral health
168711|NCT02090595|bipolar disorder
168467|NCT02091791|acute lumbar sciatica, lumbar traction, traction force, radicular pain, lumbar functional parameters, disc herniation
168468|NCT02091765|Sexual dysfunction.
168469|NCT02091765|Intimacy problems.
168470|NCT02091765|Breast cancer survivors.
168471|NCT02091765|Internet-based.
168472|NCT02091765|Cognitive behavioral therapy.
168473|NCT02091752|Primary Myelofibrosis
168474|NCT02091752|Hematologic Diseases
168475|NCT02091752|Myeloproliferative Disorders
168476|NCT02091752|INC424
168477|NCT02091752|Ruxolitinib
168478|NCT02091726|Circumcision
168479|NCT02091726|HIV prevention
168480|NCT02091726|Surgical device
168481|NCT02091726|Cyanoacrylate
168482|NCT02091726|Tissue Adhesive
168483|NCT02091726|voluntary
168484|NCT02091713|FMS
168485|NCT02091713|functional movement screen
168486|NCT02091700|Normal
168487|NCT02091700|Healthy
168488|NCT02091700|Normal healthy patient
168489|NCT02091674|ankle sprain
168490|NCT02091674|hyaluronic acid
168491|NCT02091661|Clinically localized prostate cancer
168492|NCT02091661|Radical retropubic prostatectomy
168493|NCT02091661|External beam radiotherapy
168494|NCT02091661|Efficacy
168495|NCT02091661|Quality of life
168496|NCT02091661|adverse events
168497|NCT02091648|Asthma
168498|NCT02091648|Stress
168499|NCT02091648|Children
168500|NCT02091648|Psychosocial Factors
168501|NCT02091648|Relaxation
168502|NCT02091648|Stress management
168503|NCT02091635|accommodation, emptying, motilitone
168504|NCT02091609|plaque removal around dental implants
168505|NCT02091596|Wound
168506|NCT02091596|Ulcer
168507|NCT02091596|Infected
168508|NCT02091596|Infection
168509|NCT02091583|Metabolic syndrome
168510|NCT02091583|Cardiovascular disease
168511|NCT02091583|High Oleic Canola Oil
168512|NCT02091583|DHA
168513|NCT02091583|β-glucan
168514|NCT02091583|Barley
168515|NCT02091583|Cholesterol
168516|NCT02091583|Lipoproteins
168517|NCT02091583|Lipids
168518|NCT02091583|Inflammation
168519|NCT02091583|Glucose
168520|NCT02091583|Insulin
168521|NCT02091583|Satiety
168522|NCT02091583|Body composition
168523|NCT02091583|Blood pressure
168524|NCT02091570|Hunger
168525|NCT02091570|Fullness
168526|NCT02091570|Satiety
168527|NCT02091570|Nutrition bar
168528|NCT02091570|Crossover
168529|NCT02091557|GnRH-a
168530|NCT02091557|endometriosis
168531|NCT02091557|chronic pelvic pain
168532|NCT02091557|VAS score
168533|NCT02091557|diagnostic accuracy
168534|NCT02091544|overweight
168535|NCT02091544|obesity
168536|NCT02091544|children
168537|NCT02091544|lifestyle intervention
168538|NCT02091531|mTOR Inhibitor MLN0128
168539|NCT02091531|PSA
168540|NCT02091531|13-143
168541|NCT02091518|MRI
168542|NCT02091518|13-239
168543|NCT02091518|volunteers
168544|NCT02091518|patients
168545|NCT02091492|Proximal humerus fracture, teriparatide
168546|NCT02091479|hæmorrhage, thrombosis
168547|NCT02091466|Hypothermia
168548|NCT02091466|Perioperative Care
168549|NCT02091466|Anesthesia
168550|NCT02091466|Spinal
168551|NCT02091466|Rewarming
168552|NCT02091453|Brain injury
168553|NCT02091453|stroke
168554|NCT02091453|cognitive rehabilitation
168555|NCT02091440|Medical Device
168556|NCT02091440|Thoracic Surgical Procedure
168557|NCT02091440|Pumps Heart Assist
168558|NCT02091440|Ventricular Assist Device
168559|NCT02091401|magnesium sulfate
168560|NCT02091375|cannabidiol
168561|NCT02091336|gestational diabetes
168562|NCT02091336|metformin
168563|NCT02091336|glyburide
168564|NCT02091336|fetal growth
168565|NCT02091336|capillar glucose
168566|NCT02091323|T2DM, gastric bypass surgery, BMI<35, obesity
168567|NCT02091310|GFT505
168568|NCT02091310|TQT
168569|NCT02091310|QT/QTc
168570|NCT02091310|Pharmacokinetic
168571|NCT02091310|Healthy subjects
168572|NCT02091310|Moxifloxacin
168573|NCT02091297|Buprenorphine
168574|NCT02091297|Suboxone
168575|NCT02091297|Subutex
168576|NCT02091297|Buprenex
168577|NCT02091297|Caesarean Delivery
168578|NCT02091284|alcoholism
168579|NCT02091284|tDCS
168580|NCT02091284|dlPFC
168581|NCT02091284|craving
168582|NCT02091284|cognition
168583|NCT02091271|Evaluation
168584|NCT02091271|Research
168585|NCT02091271|Healthy Volunteers
168586|NCT02091245|Relapsed acute lymphoblastic leukemia (ALL)
168587|NCT02091245|Refractory acute lymphoblastic leukemia (ALL)
168588|NCT02091245|Relapsed acute myelogenous leukemia (AML)
168589|NCT02091245|Refractory acute myelogenous leukemia (AML)
168590|NCT02091245|Relapsed childhood leukemia
168591|NCT02091245|Relapsed mixed lineage leukemia
168592|NCT02091245|Refractory mixed lineage leukemia
168593|NCT02091245|Relapsed biphenotypic leukemia
168594|NCT02091245|Refractory biphenotypic leukemia
168595|NCT02091245|Chronic myelogenous leukemia (CML) in blast crisis
168596|NCT02091219|Hypovitaminosis D
168597|NCT02091219|Free 25-hydroxyvitamin D
168598|NCT02091219|Total 25-hydroxyvitamin D
168599|NCT02091206|Cannabidiol
168600|NCT02091193|Krill Oil
168601|NCT02091193|Endothelial Function
168602|NCT02091193|Type II Diabetes Mellitus
168603|NCT02091180|Anesthesia
168604|NCT02091180|Recovery
168605|NCT02091180|laparoscopy
168606|NCT02091180|cholecystectomy
168607|NCT02091167|crack-cocaine addiction
168608|NCT02091167|tDCS
168609|NCT02091167|dlPFC
168610|NCT02091167|craving
168611|NCT02091167|cognition
168612|NCT02091154|Food Intake Regulation
168613|NCT02091154|Fruit
168614|NCT02091154|Vegetable
168615|NCT02091115|Constipation
168616|NCT02091115|ROMA III criteria
168617|NCT02091115|Scale Bristol
168618|NCT02091076|Silk fibroin with bioactive coating layer dressing
168619|NCT02091076|Wound healing
168620|NCT02091076|Skin graft donor
168621|NCT02091063|hematologic malignancies
168622|NCT02091063|hodgkin
168623|NCT02091063|hodgkins
168624|NCT02091063|non-hodgkin
168625|NCT02091063|non-hodgkins
168626|NCT02091063|mantle cell lymphoma
168627|NCT02091063|follicular
168628|NCT02091063|lymphoma
168629|NCT02091063|lymphoid malignancies
168630|NCT02091050|3D Brachytherapy
168631|NCT02091050|cervical cancer
168632|NCT02091050|endometrial cancer
168633|NCT02091050|vaginal vault brachytherapy
168634|NCT02091037|Atopic dermatitis
168635|NCT02091037|Bacterial colonization
168636|NCT02091011|This study is designed to efficiently provide device and battery longevity data on market released
168637|NCT02091011|Boston Scientific ICD and CRT-D (Cardiac Resynchronization Therapy Defibrillator) devices. In addition, the data collected will allow for
168638|NCT02091011|comparisons of device survival probability estimated in the Product Performance Report versus
168639|NCT02091011|those collected in the study. The data collected will also provide a better understanding on the
168640|NCT02091011|potential predictors of pulse generator battery longevity.
168641|NCT02090998|Migraine Headache
168642|NCT02090998|Menstrual Migraine
168643|NCT02090998|Vascular Headache
168644|NCT02090998|Temporal Lobe Seizure
168645|NCT02090985|Stoma
168646|NCT02090985|Peri-stomal
168647|NCT02090985|Lipomodelling
168648|NCT02090959|Duchenne muscular dystrophy
168649|NCT02090959|Dystrophinopathy
168650|NCT02090959|Nonsense mutation
168651|NCT02090959|Premature stop codon
168652|NCT02090959|Becker muscular dystrophy
168653|NCT02090959|DMD/BMD
168654|NCT02090959|PTC124
168655|NCT02090959|Ataluren
168656|NCT02090946|children with physical disabilities
168657|NCT02090946|home activity programs
168658|NCT02090946|home programmes
168659|NCT02090946|learning
168660|NCT02090946|therapeutic relationship
168661|NCT02090946|phenomenology
168662|NCT02090946|physiotherapy
168663|NCT02090946|clinicians who teach
168664|NCT02090946|parent perspective
168665|NCT02090946|parent-professional relationships
168666|NCT02090946|Parents/carers
168667|NCT02090946|long term physiotherapy needs
168668|NCT02090907|Subclinical hypothyroidism
168669|NCT02090907|Atherosclerosis
168670|NCT02090907|Cardiovascular disease
168671|NCT02090907|Endothelial function
168672|NCT02090907|Prevention
168673|NCT02090868|Non-Invasive Ventilation
168674|NCT02090868|Bi-Level Positive Airway Pressure
168675|NCT02090868|Continuous Positive Airway Pressure
168676|NCT02090868|Critical Care
168677|NCT02090868|Nutrition
168678|NCT02090868|Malnutrition
168679|NCT02090868|Staff attitudes, knowledge and beliefs
168680|NCT02090842|Milk proteins
168681|NCT02090842|Blood pressure
168682|NCT02090842|Vascular function
168683|NCT02090829|Autism
168684|NCT02090829|Oxytocin
168685|NCT02090829|Syntocinon
168686|NCT02090790|dexamethasone
168687|NCT02090790|femoral block
168688|NCT02090790|total knee arthroplasty
168689|NCT02090751|Retinal Rod Photoreceptor Cells
168690|NCT02090751|Dark Adaptation
168691|NCT02090725|fluctuating muscle weakness
168692|NCT02090725|hyporeflexia
168693|NCT02090725|autonomic Dysfunction
168694|NCT02090712|myocardial infarction
168695|NCT02090712|acute coronary syndrome
168696|NCT02090712|coronary disease
168697|NCT02090699|thalassemia major
168698|NCT02090699|chronic blood transfusion related iron overload
168699|NCT02090699|magnetic resonance imaging
168700|NCT02090699|myocardium
168701|NCT02090699|fibrosis
168702|NCT02090647|dental implant, aesthetic, implant abutment
168703|NCT02090634|HIV
168704|NCT02090634|Bipolar Disorder
168705|NCT02090634|Medication Adherence
168706|NCT02090621|Liver
168707|NCT02090621|transplantation
168708|NCT02090621|Immunosuppression
168709|NCT02090621|photopheresis
168710|NCT02090621|extracorporeal
168712|NCT02090595|anxiety
168713|NCT02090595|mindfulness
168714|NCT02090595|high risk
168715|NCT02090595|cognitive behavioral
168716|NCT02090569|Functional micro-Doppler Sonography, fmDS, dysplasia, epilepsy, neurosurgery, cerebral blood volume, echography, hemodynamics
168717|NCT02090530|Cancer Genomics
168718|NCT02090530|Tumor Sequencing
168719|NCT02090517|Nasal telangiectasis
168720|NCT02090504|alcohol withdrawal syndrome
168721|NCT02090504|treatment
168722|NCT02090504|sodium oxybate
168723|NCT02090504|oxazepam
168724|NCT02090491|autism
168725|NCT02090465|Actinic Keratosis
168726|NCT02090452|Telemedicine
168727|NCT02090452|Mobile
168728|NCT02090452|Vital signs
168729|NCT02090452|Prehospital care
168730|NCT02090452|Emergency medicine
168731|NCT02090413|multiple sclerosis
168732|NCT02090413|flushing
168733|NCT02090413|aspirin
168734|NCT02090400|Women
168735|NCT02090400|Osteoporosis, Postmenopausal
168736|NCT02090400|Bazedoxifene
168737|NCT02090400|BMD
168738|NCT02090374|Allergy
168739|NCT02090374|Asthma
168740|NCT02090374|Biomarkers
168741|NCT02090374|Chemokines
168742|NCT02090374|Cytokines
168743|NCT02090374|Eosinophil
168744|NCT02090374|Gene Expression
168745|NCT02090374|Grass pollen
168746|NCT02090374|Hay Fever
168747|NCT02090374|Human Challenge Study
168748|NCT02090374|Inflammation
168749|NCT02090374|Innate Immune Response
168750|NCT02090374|Lipopolysaccharide
168751|NCT02090374|Mucosal Lining Fluid
168752|NCT02090374|Nasal
168753|NCT02090374|Nasorption
168754|NCT02090374|Respiratory
168755|NCT02090374|Respiratory Tract Infection
168756|NCT02090374|T cells
168757|NCT02090374|Tuberculosis
168758|NCT02090374|Virus
168759|NCT02090361|collagen -elastin matrix
168760|NCT02090361|skin graft
168761|NCT02090361|loss of cutaneous substance
168762|NCT02090335|community mental health
168763|NCT02090335|health coach
168764|NCT02090335|weight loss
168765|NCT02090335|fitness
168766|NCT02090335|serious mental illness
168767|NCT02090335|health promotion
168768|NCT02090322|ROP
168769|NCT02090322|Bevacizumab
168770|NCT02090322|No inferiority
168771|NCT02090283|Epidermolysis Bullosa
168772|NCT02090283|Simplex
168773|NCT02090283|Recessive Dystrophic
168774|NCT02090283|Junctional non-Herlitz
168775|NCT02090270|hair cortisol
168776|NCT02090270|stroke
168777|NCT02090257|Heart transplant recipients who are entering into adult care.
168778|NCT02090244|PTH
168779|NCT02090244|Spinal stenosis
168780|NCT02090244|Teriparatide
168781|NCT02090231|stroke
168782|NCT02090231|dysphagia
168783|NCT02090231|rTMS
168784|NCT02090205|cardio-pulmonary bypass
168785|NCT02090205|cardiac surgery
168786|NCT02090205|lung injury prevention
168787|NCT02090205|mechanical ventilation
168788|NCT02090205|pulmonary insufficiency
168789|NCT02090192|Whole-body vibration;
168790|NCT02090192|Frail Elderly;
168791|NCT02090192|Blood flow;
168792|NCT02090192|Bone density
168793|NCT02090192|Mobility;
168794|NCT02090192|Balance;
168795|NCT02090192|Muscle strength;
168796|NCT02090192|Lower Extremity;
168797|NCT02090192|Musculoskeletal System;
168798|NCT02090192|Health Status;
168799|NCT02090192|Exercise;
168800|NCT02090192|Mechanical Oscillation
168801|NCT02090179|MPS IIIB
168802|NCT02090179|Mucopolysaccharidosis
168803|NCT02090179|Mucopolysaccharidosis type IIIB
168804|NCT02090179|Sanfilippo Syndrome
168805|NCT02090179|Metabolism, Inborn Errors
168806|NCT02090179|Metabolic Diseases
168807|NCT02090179|Genetic Diseases, Inborn
168808|NCT02090153|Advance Gastric Cancer,
168809|NCT02090153|S-1 plus leucovorin,
168810|NCT02090153|ORR,
168811|NCT02090153|OS,
168812|NCT02090153|TTP,
168813|NCT02090153|TTF,
168814|NCT02090153|Adverse events,
168815|NCT02090153|Pharmacokinetics
168816|NCT02090140|cartilage/transplantation
168817|NCT02090140|cartilage, articular/injuries
168818|NCT02090140|cartilage, articular/surgery
168819|NCT02090140|chondrocytes/cytology
168820|NCT02090140|knee injuries/surgery
168821|NCT02090140|knee joint/surgery
168822|NCT02090140|orthopedic procedures/methods
168823|NCT02090140|tissue engineering
168824|NCT02090140|tissue scaffolds
168825|NCT02090140|arthroscopy/methods
168826|NCT02090140|chondrocytes/transplantation
168827|NCT02090140|adipose tissue/cytology
168828|NCT02090140|cartilage, articular/cytology
168829|NCT02090140|chondrogenesis/physiology
168830|NCT02090140|osteogenesis/physiology
168831|NCT02090140|stem cell transplantation/methods
168832|NCT02090140|stem cells
168833|NCT02090140|tissue engineering/methods
168834|NCT02090140|cartilage, articular/pathology
168835|NCT02090140|chondrocytes/pathology
168836|NCT02090140|knee joint/pathology
168837|NCT02090140|platelet-rich plasma
168838|NCT02090114|Bipolar Androgen Therapy
168839|NCT02090114|Testosterone
168840|NCT02090114|Enzalutamide
168841|NCT02090114|Abiraterone
168842|NCT02090114|Androgen Ablative Therapies
168843|NCT02090075|cardiac Computed tomography
168844|NCT02090075|coronary calcification
168845|NCT02090075|intervention
168846|NCT02090075|warfarin
168847|NCT02090075|apixaban
168848|NCT02090062|endoscopic resection
168849|NCT02090062|H. pylori infection
168850|NCT02090049|Appetite
168851|NCT02090049|Satiety
168852|NCT02090049|Bread
168853|NCT02090049|Dietary fiber
168854|NCT02090049|Gastrointestinal hormones
168855|NCT02090049|Glycemia
168856|NCT02090049|Insulinemia
168857|NCT02090036|Efficacy
168858|NCT02090036|Safety
168859|NCT02090036|Primaquine
168860|NCT02090036|Artemether-lumefantrine
168861|NCT02090036|Gametocytes
168862|NCT02090023|Obstructive sleep apnea
168863|NCT02090023|National Health Insurance Research Database in Taiwan
168864|NCT02090023|Survival Analysis
168865|NCT02090023|Validation Studies
168866|NCT02090023|Cohort Studies
168867|NCT02089997|Pharmacological therapy
168868|NCT02089984|Cognitive Behavior Therapy
168869|NCT02089984|On-line training
168870|NCT02089958|Lapraoscopy, incisional hernia repair, mesh
168871|NCT02089945|transcatheter aortic valve implantation
168872|NCT02089945|severe aortic stenosis
168873|NCT02089945|cognition
168874|NCT02089945|functional capacity
168875|NCT02089945|quality of life
168876|NCT02089932|femoral nerve block
168877|NCT02089932|peri-neural dexmedetomidine
168878|NCT02089867|Ezetimibe
168879|NCT02089867|Plant sterol
168880|NCT02089867|Hydroxymethylglutaryl coenzyme A Reductase Inhibitors
168881|NCT02089867|Coronary artery disease
168882|NCT02089867|LDL-cholesterol
168883|NCT02089854|triple negative breast cancer
168884|NCT02089854|estrogen receptor-beta
168885|NCT02089854|endocrine therapy
168886|NCT02089841|Efficacy
168887|NCT02089841|Artemether/lumefantrine
168888|NCT02089841|Malaria
168889|NCT02089841|Children
168890|NCT02089802|RCC
168891|NCT02089789|Natural History
168892|NCT02089789|Glycosylation
168893|NCT02089789|Genetic Disorders
168894|NCT02089776|Stroke
168895|NCT02089776|fMRI
168896|NCT02089776|Real Time fMRI Feedback
168897|NCT02089763|Hepatocellular carcinoma
168898|NCT02089763|HCC
168899|NCT02089763|Pegylated recombinant human arginase
168900|NCT02089763|PEG-BCT-100
168901|NCT02089763|ASS
168902|NCT02089763|OTC
168903|NCT02089750|Low Back Pain
168904|NCT02089750|Chiropractic
168905|NCT02089750|Shoe Orthotics
168906|NCT02089711|Normal subjects
168907|NCT02089698|Kelman tip
168908|NCT02089698|Mini-flared
168909|NCT02089698|phacoemulsification
168910|NCT02089698|cataract
168911|NCT02089633|hepatocellular carcinoma
168912|NCT02089633|HCC
168913|NCT02089633|pegylated recombinant human arginase
168914|NCT02089633|PEG-BCT-100
168915|NCT02089633|oxaliplatin
168916|NCT02089633|capecitabine
168917|NCT02089620|Premenstrual syndrome
168918|NCT02089620|Oral contraceptive pills
168919|NCT02089620|Calcium Supplements
168920|NCT02089594|Hyperbaric Oxygen Treatment
168921|NCT02089594|Mild Traumatic Brain Injury
168922|NCT02089594|Persistent Post-Concussion Syndrome
168923|NCT02089581|Healthy Volunteer
168924|NCT02089581|Pharmacokinetics
168925|NCT02089581|Bioequivalence
168926|NCT02089568|Living donation
168927|NCT02089568|Antibiotics
168928|NCT02089568|Laparoscopic surgery
168929|NCT02089542|thyroidectomy
168930|NCT02089542|parathyroid surgery
168931|NCT02089542|parathyroid identification
168932|NCT02089542|methylene blue
168933|NCT02089542|near infrared fluorescence
168934|NCT02089542|intraoperative imaging
168935|NCT02089529|Axial Spondyloarthritis
168936|NCT02089529|Pain
168937|NCT02089529|NSAIDs
168938|NCT02089529|Placebo
168939|NCT02089529|Placebo intervention
168940|NCT02089529|Stress
168941|NCT02089529|Conditioning
168942|NCT02089516|Frailty
168943|NCT02089516|Accelerometry
168944|NCT02089516|Physical activity
168945|NCT02089516|validity
168946|NCT02089477|Type 2 diabetes, InterWalk, Individual Support, Motivation
168947|NCT02089412|Healthy Subjects
168948|NCT02089412|Absorption
168949|NCT02089412|High-Fat Meal
168950|NCT02089360|Advanced glycation end product
168951|NCT02089360|coronary
168952|NCT02089360|atherosclerosis
168953|NCT02089360|inflammation
168954|NCT02089360|outcome
168955|NCT02089347|Tetanus
168956|NCT02089347|Diphtheria
168957|NCT02089347|Pertussis
168958|NCT02089347|TdaP vaccine
168959|NCT02089347|DT BIK®
168960|NCT02089334|renal cell carcinoma
168961|NCT02089334|clear cell
168962|NCT02089334|renal cancer
168963|NCT02089334|metastatic renal cancer
168964|NCT02089334|Carcinoma, Renal Cell*/therapy
168965|NCT02089334|Humans
168966|NCT02089334|Kidney Neoplasms*/therapy
168967|NCT02089321|low back pain
168968|NCT02089321|lumbopelvic assessment
168969|NCT02089321|active straight leg raise
168970|NCT02089321|active hip abduction
168971|NCT02089308|Smoking cessation
168972|NCT02089308|Nicotine
168973|NCT02089308|Tobacco Use Disorder
168974|NCT02089308|Central Nervous System Agents
168975|NCT02089295|dose proportionality
168976|NCT02089295|oxycodone
168977|NCT02089269|pancreatic neoplasms
168978|NCT02089269|neoplasms
168979|NCT02089269|registry
168980|NCT02089269|advanced pancreatic cancer
168981|NCT02089269|health services research
168982|NCT02089269|epidemiology
168983|NCT02089269|Germany
168984|NCT02089269|palliative treatment
168985|NCT02089269|palliative care
168986|NCT02089243|Epilepsy,Temporal Lobe
168987|NCT02089243|Brain Diseases
168988|NCT02089230|Leukemia
168989|NCT02089230|Acute Myeloid Leukemia
168990|NCT02089230|AML
168991|NCT02089230|Advanced leukemias
168992|NCT02089230|Myelodysplastic syndrome
168993|NCT02089230|MDS
168994|NCT02089230|Acute lymphoblastic leukemia
168995|NCT02089230|ALL
168996|NCT02089230|Relapsed
168997|NCT02089230|Refractory
168998|NCT02089230|MEK 162
168999|NCT02089217|asymptomatic
169000|NCT02089217|carotid
169001|NCT02089217|stent
169002|NCT02089217|endarterectomy
169003|NCT02089217|embolic protection
169004|NCT02089217|medical management
169005|NCT02089217|hypertension
169006|NCT02089217|hyperlipidemia
169007|NCT02089217|cognition
169008|NCT02089217|risk factor control
169009|NCT02089204|Hypoxia Imaging -Guided Radiotherapy
169010|NCT02089204|PET/CT
169011|NCT02089204|simultaneous modulated accelerated radiation therapy (SMART)
169012|NCT02089191|DACP
169013|NCT02089191|DAILIES® AquaComfort Plus
169014|NCT02089191|Tear film stability
169015|NCT02089191|NIK-BUT
169016|NCT02089178|total intravenous anesthesia, inhalation anesthesia, cancer cell cytotoxicity, breast tumor
169017|NCT02089152|Diabetes
169018|NCT02089152|Melioidosis
169019|NCT02089152|stepped wedge trial
169020|NCT02089152|behaviour change
169021|NCT02089152|Education program
169022|NCT02089139|Back pain
169023|NCT02089139|Discogel
169024|NCT02089087|Rheumatoid arthritis, RA, first-in-human, single ascending dose, safety, tolerability
169025|NCT02089074|Secondary Prevention
169026|NCT02089074|Pharmacists
169027|NCT02089074|Directive Counseling
169028|NCT02089074|Medication Adherence
169029|NCT02089074|Patient Compliance
169030|NCT02089048|Amebiasis, auranofin, pharmokinetics, pharmacodynamics
169031|NCT02089035|Milk fatty acids
169032|NCT02089035|Total cholesterol
169033|NCT02089035|Vascular function
169034|NCT02089035|Blood pressure
169035|NCT02089022|Ice
169036|NCT02089022|Heat
169037|NCT02089022|Ground reaction forces
169038|NCT02089022|Electromyography
169039|NCT02089022|Lower Limb
169040|NCT02089022|Center of pressure
169041|NCT02088970|Infectious keratitis
169042|NCT02088970|Corneal cross linking
169043|NCT02088970|Topical antibiotics
169044|NCT02088957|Brivaracetam
169045|NCT02088957|Phenytoin
169046|NCT02088957|Nonconvulsive electrographic seizures
169047|NCT02088931|Tregs
169048|NCT02088931|Kidney transplantation
169049|NCT02088905|PCIT, autism, parent training, noncompliance
169050|NCT02088892|BCG challenge study
169051|NCT02088866|Tinnitus
169052|NCT02088866|Otolaryngology
169053|NCT02088853|intestinal
169054|NCT02088853|metabolic control
169055|NCT02088853|mucosa
169056|NCT02088853|human
169057|NCT02088853|diet
169058|NCT02088840|SIGNB
169059|NCT02088840|severe infections gram negative bacteria
169060|NCT02088840|stem cell transplant
169061|NCT02088827|Exercise
169062|NCT02088827|Sedentary Behaviour
169063|NCT02088827|Type 2 Diabetes
169064|NCT02088827|Older Adults
169065|NCT02088814|posttraumatic stress
169066|NCT02088814|burns
169067|NCT02088814|injuries
169068|NCT02088814|children
169069|NCT02088801|Intubation; Difficult
169070|NCT02088788|radiation
169071|NCT02088788|radiation injury
169072|NCT02088788|occupational risk
169073|NCT02088762|margin of safety
169074|NCT02088749|obesity
169075|NCT02088749|weight loss
169076|NCT02088749|treatment
169077|NCT02088749|lifestyle
169078|NCT02088723|Sleep Apnea, Obstructive
169079|NCT02088723|Sleep Apnea Syndromes
169080|NCT02088723|Polysomnography
169081|NCT02088723|Sleep
169082|NCT02088723|Patient Positioning
169083|NCT02088710|Patients´ Expectations
169084|NCT02088710|Breast Cancer
169085|NCT02088710|Adjuvant Endocrine Treatment
169086|NCT02088710|Nocebo
169087|NCT02088710|Psycho-oncology
169088|NCT02088710|Satisfaction with information
169089|NCT02088684|Hormone receptor positive, HER2 negative
169090|NCT02088671|NeuroSENSE
169091|NCT02088671|Anesthesia
169092|NCT02088671|Hypnosis
169093|NCT02088671|Desflurane
169094|NCT02088671|Propofol
169095|NCT02088658|Diabetes Mellitus, Type 2
169096|NCT02088658|Diabetes Mellitus, Adult-Onset
169097|NCT02088658|Diabetes Mellitus, Non-Insulin-Dependent
169098|NCT02088658|Diabetes Mellitus, Noninsulin Dependent
169099|NCT02088658|Diabetes Mellitus, Type II
169100|NCT02088658|African Americans
169101|NCT02088658|Blacks
169102|NCT02088658|non-Hispanic Blacks
169103|NCT02088658|Randomized Control Trial
169104|NCT02088658|Controlled Clinical Trial
169105|NCT02088658|Behavioral Research
169106|NCT02088658|Behavioral Medicine
169107|NCT02088645|Calcitonin
169108|NCT02088645|Medullary thyroid carcinoma
169109|NCT02088645|Peptide receptor radionuclide therapy
169110|NCT02088645|Gastrin
169111|NCT02088645|Cholecystokinin-2 receptor
169112|NCT02088619|psychological wellbeing
169113|NCT02088619|anxiety
169114|NCT02088619|depression
169115|NCT02088619|autonomic functioning
169116|NCT02088606|Atrial fibrillation
169117|NCT02088593|Medical Students
169118|NCT02088541|Relapsed/Refractory Acute Myeloid Leukemia
169119|NCT02088541|Acute Myeloid Leukemia
169120|NCT02088541|AML
169121|NCT02088541|Karyopharm
169122|NCT02088541|Selinexor
169123|NCT02088541|KPT-330
169124|NCT02088515|Nedaplatin
169125|NCT02088515|lung squamous cell carcinoma
169126|NCT02088502|Coronary Angiography
169127|NCT02088502|Side Effects
169128|NCT02088502|Contrast-Induced Nephropathy
169129|NCT02088502|Prevention
169130|NCT02088489|Atrial flutter
169131|NCT02088489|Thermocool catheter
169132|NCT02088489|Thermocool SF catheter
169133|NCT02088476|candidemia
169134|NCT02088476|children
169135|NCT02088476|mortality
169136|NCT02088476|risk factors
169137|NCT02088463|Mechanical LBP
169138|NCT02088463|Mobilization
169139|NCT02088463|Postpartum
169140|NCT02088450|Cardiovascular complications
169141|NCT02088450|Clinical trial
169142|NCT02088450|Elderly
169143|NCT02088450|Isolated systolic hypertension
169144|NCT02088450|Stroke
169145|NCT02088398|relative bioavailability
169146|NCT02088398|food-effect
169147|NCT02088359|cycled light, near darkness, growth
169148|NCT02088346|Stroke
169149|NCT02088346|Thrombolysis
169150|NCT02088346|Tissue plasminogen activator
169151|NCT02088346|Urokinase
169152|NCT02088346|Telemedicine
169153|NCT02088333|colorectal cancer screening
169154|NCT02088333|computer-assisted instruction
169155|NCT02088333|mHealth
169156|NCT02088333|text message
169157|NCT02088307|cardiovascular supplement
169158|NCT02088307|cardiovascular disease
169159|NCT02088307|coronary artery disease
169160|NCT02088294|obesity
169161|NCT02088294|stress
169162|NCT02088294|intuitive eating
169163|NCT02088294|guided imagery
169164|NCT02088294|adolescents
169165|NCT02088294|insulin resistance
169166|NCT02088294|latinos
169167|NCT02088294|minorities
169168|NCT02088281|Indigo naturalis, indirubin, Th1 cells, Th17 cells
169169|NCT02088255|Rehabilitation
169170|NCT02088255|Gait
169171|NCT02088255|Stroke
169172|NCT02088255|Biomechanics
169173|NCT02088229|Diabetic Macular Edema
169174|NCT02088216|N-acetylcysteine；
169175|NCT02088216|Bronchiectasis；
169176|NCT02088216|Acute exacerbations；
169177|NCT02088216|Antioxidant；
169178|NCT02088216|Anti-inflammatory
169179|NCT02088177|Cannabis
169180|NCT02088177|Cannabis Dependence
169181|NCT02088177|Cannabis Use Disorder
169182|NCT02088177|Marijuana
169183|NCT02088177|Naltrexone
169184|NCT02088177|Long Acting Injectable Naltrexone
169185|NCT02088177|Treatment
169186|NCT02088164|PSA,
169187|NCT02088164|asian men,
169188|NCT02088164|survival
169189|NCT02088151|selective laser therapy
169190|NCT02088151|retinal pigment epithelium
169191|NCT02088151|macular edema
169192|NCT02088151|diabetic retinopathy
169193|NCT02088151|central serous chorioretinopathy
169194|NCT02088151|age-related macular degeneration
169195|NCT02088151|retinal vein occlusion
169196|NCT02088138|Thoracic Surgery
169197|NCT02088138|Electrical Stimulation
169198|NCT02088138|Rehabilitation
169199|NCT02088138|Quality of Life
169200|NCT02088125|Stroke
169201|NCT02088125|Incentive Spirometry
169202|NCT02088125|Breath Stacking
169203|NCT02088125|Optoelectronic Plethysmography
169204|NCT02088112|NSCLC
169205|NCT02088099|Traumatic brain injury
169206|NCT02088099|Telehealth
169207|NCT02088099|ehealth
169208|NCT02088099|Mobile Health
169209|NCT02088099|social participation
169210|NCT02088099|patient participation
169211|NCT02088099|consumer participation
169212|NCT02088099|Patient Outcome Assessment
169213|NCT02088086|Pediatric obesity
169214|NCT02088086|Overweight
169215|NCT02088086|Body mass index
169216|NCT02088086|Primary schools
169217|NCT02088086|Secondary schools
169218|NCT02088047|Autism
169219|NCT02088047|Self-Stimulating behaviors
169220|NCT02088047|Autism Spectrum Disorders
169221|NCT02087995|Diabetes Mellitus
169222|NCT02087956|Women
169223|NCT02087956|Depression
169224|NCT02087956|Socioeconomically Disadvantaged
169225|NCT02087956|Navigation
169226|NCT02087943|Atopic Dermatitis
169227|NCT02087943|Atopic Eczema
169228|NCT02087917|hypercholesterolemia
169229|NCT02087917|cholesterol absorption inhibitor
169230|NCT02087917|placebo-controlled trial
169231|NCT02087904|Pain
169232|NCT02087904|Osteoarthritis
169233|NCT02087904|Synovitis
169234|NCT02087904|Knee
169235|NCT02087878|Hepatosplenic T-Cell Lymphoma
169236|NCT02087852|Questionnaire
169237|NCT02087852|DNA
169238|NCT02087852|saliva
169239|NCT02087852|kidney cancer
169240|NCT02087852|13-218
169241|NCT02087839|Non-Small Cell Lung Cancer
169242|NCT02087839|Lung Cancer
169243|NCT02087839|NSCLC
169244|NCT02087839|ZD6474
169245|NCT02087839|ZACTIMA
169246|NCT02087839|Vandetanib
169247|NCT02087839|Inoperable NSCLC
169248|NCT02087839|Unresectable NSCLC
169249|NCT02087839|Radiation Therapy
169250|NCT02087839|Palliative radiation therapy
169251|NCT02087839|Angiogenesis
169252|NCT02087813|neuromyelitis optica
169253|NCT02087813|optic neuritis
169254|NCT02087813|longitudinally extensive transverse myelitis
169255|NCT02087800|smoking cessation
169256|NCT02087800|smoking abstinence
169257|NCT02087800|allopregnanolone
169258|NCT02087787|bone marrow transplant
169259|NCT02087787|hematologic malignancies
169260|NCT02087761|ARIES Flu
169261|NCT02087748|DOMS
169262|NCT02087735|Cranberry
169263|NCT02087735|Proanthocyanidins
169264|NCT02087735|Urinary catabolites
169265|NCT02087722|Primary Insomnia
169266|NCT02087696|Arthritis, Rheumatoid
169267|NCT02087696|methotrexate
169268|NCT02087696|intolerance
169269|NCT02087696|poor compliance
169270|NCT02087696|contraindication
169271|NCT02087696|Tocilizumab
169272|NCT02087696|monotherapy
169273|NCT02087683|heart failure
169274|NCT02087683|vitamin D deficiency
169275|NCT02087683|ventricular function
169276|NCT02087683|cytokines
169277|NCT02087670|chronic heart failure
169278|NCT02087670|cardiac rehabilitation
169279|NCT02087670|exercise
169280|NCT02087670|Natriuretic Brain Pro-peptid
169281|NCT02087657|Peripheral Blood Stem Cell (PBSC) Transplant
169282|NCT02087657|Hyperbaric oxygen
169283|NCT02087657|Lymphoma
169284|NCT02087657|Myeloma
169285|NCT02087631|multiple sclerosis
169286|NCT02087631|quetiapine
169287|NCT02087631|remyelination
169288|NCT02087618|MCI
169289|NCT02087618|Alzheimer's
169290|NCT02087618|Dementia
169291|NCT02087618|Tablet
169292|NCT02087618|Non-Pharmacological Intervention
169293|NCT02087618|Cognition
169294|NCT02087605|Vascular stiffness, retinal vessels, target organ damage
169295|NCT02087592|hereditary breast and ovarian cancer (HBOC)
169296|NCT02087592|BRCA1/2 mutation carriers
169297|NCT02087592|Mediterranean diet
169298|NCT02087592|Structured exercise training
169299|NCT02087592|prevention
169300|NCT02087579|Psychotic Disorders
169301|NCT02087579|Schizophrenia
169302|NCT02087579|Bipolar Disorder
169303|NCT02087579|Depressive Disorder
169304|NCT02087579|Antipsychotics
169305|NCT02087579|Aripiprazole
169306|NCT02087579|Olanzapine
169307|NCT02087579|Paliperidone
169308|NCT02087579|Quetiapine
169309|NCT02087579|Risperidone
169310|NCT02087579|Capillary Concentration
169311|NCT02087566|Linezolid
169312|NCT02087566|Pharmacokinetics
169313|NCT02087566|Haemodialysis
169314|NCT02087566|Dosing adjustment
169315|NCT02087566|Eligible subjects were classified into three groups depending on their 24-h urinary creatinine clearance (CLcr) values or HD status.
169316|NCT02087566|Group 1, included 6 healthy subjects with normal renal function (CLcr ˃80 ml/min);
169317|NCT02087566|Group 2, included 6 patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine);
169318|NCT02087566|Group 3, included 6 patients on long term haemodialysis (minimum period of dialysis was 40 month while maximum period were 130 month)
169319|NCT02087553|Blood Transfusion
169320|NCT02087553|Iron
169321|NCT02087553|Packed Red Blood Cells
169322|NCT02087553|PRBC
169323|NCT02087553|NTBI
169324|NCT02087527|Cellulitis
169325|NCT02087527|Soft Tissue Infections
169326|NCT02087527|Skin Diseases, Infectious
169327|NCT02087527|Corticosteroids
169328|NCT02087527|Glucocorticoids
169329|NCT02087527|Dexamethasone
169330|NCT02087514|Blood Transfusion
169331|NCT02087514|Iron
169332|NCT02087514|Red Blood Cells
169333|NCT02087501|Abdominal Aortic Aneurysm
169334|NCT02087501|AAA
169335|NCT02087501|Abdominal Aortoiliac Aneurysm
169336|NCT02087501|Endovascular Aortic Repair
169337|NCT02087501|EVAR
169338|NCT02087488|primary insomnia
169339|NCT02087488|auricular acupuncture
169340|NCT02087462|Sciatica
169341|NCT02087462|Electroacupuncture
169342|NCT02087462|Intervertebral disc displacement
169343|NCT02087423|Locally advanced, metastatic, Non-Small Cell Lung Cancer, MEDI4736, PD-L1
169344|NCT02087397|Stem Cell
169345|NCT02087397|Erectile Dysfunction
169346|NCT02087384|Anal intraepithelial neoplasia
169347|NCT02087384|HIV
169348|NCT02087384|HPV
169349|NCT02087384|Vaccination
169350|NCT02087384|Gardasil
169351|NCT02087384|Prophylactic
169352|NCT02087358|alcohol dependence
169353|NCT02087358|Stress- correlation
169354|NCT02087358|genetic
169355|NCT02087358|CRHR1
169356|NCT02087332|Kidney damage hypertension cardiovascular diseases, congestive heart failure renal function natriuresis natriuresis monitoring
169357|NCT02087306|Adenovirus Infection
169358|NCT02087241|Stage IV Lung Cancer
169359|NCT02087228|Endometrial ablation, menorrhagia
169360|NCT02087215|diabetes mellitus
169361|NCT02087215|foot ulcer
169362|NCT02087215|boron
169363|NCT02087215|wound care
169364|NCT02087202|pain
169365|NCT02087189|ICD, CRT-D, lead
169366|NCT02087176|NSCLC
169367|NCT02087137|aging
169368|NCT02087137|memory
169369|NCT02087137|memory training
169370|NCT02087124|Whey protein
169371|NCT02087124|Postprandial lipaemia
169372|NCT02087124|Pre-meal
169373|NCT02087124|Metabolic syndrome
169374|NCT02087111|Telaprevir
169375|NCT02087111|Genotype 3 HCV
169376|NCT02087098|overactive bladder
169377|NCT02087098|solifenacin
169378|NCT02087098|quality of life
169379|NCT02087072|home visits
169380|NCT02087072|transitions of care
169381|NCT02087072|pharmacist
169382|NCT02087059|Post-Polycythemia Vera (PV) MF
169383|NCT02087059|Post-Essential Thrombocythemia (ET) MF
169384|NCT02087033|supraventricular ectopic beats
169385|NCT02087020|Joint Prosthesis
169386|NCT02087020|Prosthesis-Related Infections
169387|NCT02087020|Joint Diseases
169388|NCT02087020|Therapeutic Irrigation
169389|NCT02087020|Prostheses and Implants
169390|NCT02087020|Arthroplasty Replacement
169391|NCT02087007|Treatment for vasospastic angina
169392|NCT02086994|carbetocin, misoprostol, pre-eclampsia, pph
169393|NCT02086955|Diabetes
169394|NCT02086955|Nursing counseling
169395|NCT02086955|Foot ulceration
169396|NCT02086955|Outpatient
169397|NCT02086955|Advanced Practice Nurse
169398|NCT02086929|Trazodone
169399|NCT02086929|Venlafaxine
169400|NCT02086929|Major depressive disorder
169401|NCT02086916|Clostridium difficile
169402|NCT02086916|Prediction
169403|NCT02086916|Treatment
169404|NCT02086916|Failure
169405|NCT02086903|Ticagrelor
169406|NCT02086903|Clopidogrel
169407|NCT02086903|Platelet function test
169408|NCT02086890|retinitis pigmentosa
169409|NCT02086890|acupuncture
169410|NCT02086890|electroacupuncture
169411|NCT02086890|transcorneal electrical stimulation
169412|NCT02086890|microcurrent
169413|NCT02086864|Attention Deficit Hyperactivity Disorder
169414|NCT02086864|ADHD
169415|NCT02086864|Homeopathy
169416|NCT02086851|pediatric obesity
169417|NCT02086851|motivational interviewing
169418|NCT02086851|lifestyle intervention
169419|NCT02086838|Iron deficiency anemia
169420|NCT02086838|Pregnancy
169421|NCT02086838|Iron therapy
169422|NCT02086799|asthma
169423|NCT02086799|thyroid hormones
169424|NCT02086799|treatment
169425|NCT02086799|asthma exacerbation
169426|NCT02086773|Acute Leukemia
169427|NCT02086773|Red Cell Transfusion
169428|NCT02086760|hydronephrosis
169429|NCT02086747|Abdominal Hysterectomy, Acetaminophen, chronic pain
169430|NCT02086734|Perfusion-CT
169431|NCT02086734|mRCC
169432|NCT02086734|antiangiogenic therapy
169433|NCT02086734|response assessment
169434|NCT02086708|Sonoelastography,
169435|NCT02086708|Diffuse liver disease,
169436|NCT02086708|chronic liver disease,
169437|NCT02086708|NASH,
169438|NCT02086708|NAFLD,
169439|NCT02086708|Elevated Transaminases,
169440|NCT02086708|Liver Biopsy,
169441|NCT02086708|Fibrosis,
169442|NCT02086708|METAVIR
169443|NCT02086695|Chemotherapy
169444|NCT02086695|Cardiotoxicity
169445|NCT02086682|hemodialysis
169446|NCT02086682|dialysis
169447|NCT02086682|renal dialysis
169448|NCT02086682|clotting
169449|NCT02086682|coagulation
169450|NCT02086682|blood lines
169451|NCT02086656|liver metastases
169452|NCT02086656|colorectal cancer
169453|NCT02086656|perioperative treatment
169454|NCT02086643|Infraclavicular block
169455|NCT02086643|Brachial Plexus
169456|NCT02086643|Retroclavicular Approach
169457|NCT02086643|Complications of retroclavicular approach
169458|NCT02086643|Success of retroclavicular approach
169459|NCT02086643|Obese Patients
169460|NCT02086643|Obesity and Anesthesia
169461|NCT02086630|disparities
169462|NCT02086630|antiretroviral
169463|NCT02086630|HIV
169464|NCT02086630|barriers
169465|NCT02086630|access
169466|NCT02086630|delay
169467|NCT02086630|decline
169468|NCT02086630|discontinue
169469|NCT02086630|African American
169470|NCT02086630|Black
169471|NCT02086630|Latino
169472|NCT02086630|Hispanic
169473|NCT02086630|care continuum
169474|NCT02086630|Heart to Heart Behavioral intervention
169475|NCT02086630|Treatment as Usual
169476|NCT02086591|Non Hodgkin Lymphoma
169477|NCT02086591|Doxycycline
169478|NCT02086578|multi-beam Intensity-Modulated Radiation Therapy (IMRT)
169479|NCT02086578|14-028
169480|NCT02086565|asthma,
169481|NCT02086565|asthma control,
169482|NCT02086565|asthma-related quality of life
169483|NCT02086565|electronic health record,
169484|NCT02086565|portal,
169485|NCT02086565|health literacy
169486|NCT02086513|Graft versus Host Disease
169487|NCT02086513|Allogeneic Stem Cell Transplantation
169488|NCT02086500|Tranexamic acid
169489|NCT02086500|randomized
169490|NCT02086500|hemorrhage
169491|NCT02086500|blinded
169492|NCT02086487|NIlotinib , Suboptimal Response , Imatinib
169493|NCT02086435|Myomectomy
169494|NCT02086435|Laparoscopic myomectomy
169495|NCT02086435|Morcellation
169496|NCT02086435|Risk of dissemination
169497|NCT02086435|Uterine Sarcoma
169498|NCT02086435|Parasitic myoma
169499|NCT02086396|obesity
169500|NCT02086396|cardiovascular risk factors
169501|NCT02086396|pumpkin seed
169502|NCT02086396|diet quality
169503|NCT02086383|Pulmonary Rehabilitation
169504|NCT02086383|Self-Efficacy
169505|NCT02086383|Physical Activity
169506|NCT02086370|PBS
169507|NCT02086370|Prophylactic bilateral salpingectomy
169508|NCT02086370|Ovarian cancer prevention
169509|NCT02086370|Ovarian reserve
169510|NCT02086370|Permanent contraception
169511|NCT02086370|Surgical sterilization
169512|NCT02086344|Total Laparoscopic Hysterectomy
169513|NCT02086344|TLH
169514|NCT02086344|Ovarian reserve
169515|NCT02086344|Prophylactic bilateral salpingectomy
169516|NCT02086344|Ovarian cancer prevention
169517|NCT02086344|Ovarian cancer
169518|NCT02086344|Fallopian Tubes
169519|NCT02086318|Ovarian reserve
169520|NCT02086318|Ovarian age
169521|NCT02086318|Fertility
169522|NCT02086318|Reproductive prognosis
169523|NCT02086318|Distance to menopause
169524|NCT02086305|Transitional care
169525|NCT02086305|Supportive and palliative care
169526|NCT02086292|Injections
169527|NCT02086292|Lidocaine
169528|NCT02086292|Pain
169529|NCT02086292|Healthy volunteers
169530|NCT02086279|AMH levels
169531|NCT02086279|Ovarian reserve
169532|NCT02086279|GnRH analogue
169533|NCT02086279|Ovarian reserve after GnRH analogue
169534|NCT02086279|Ovarian reserve modification
169535|NCT02086279|Antral follicle count
169536|NCT02086279|Antral follicle count after GnRH analogue
169537|NCT02086266|Prostatectomy
169538|NCT02086266|Urinary Continence
169539|NCT02086266|Physical Therapy Modalities
169540|NCT02086266|Pelvic Floor
169541|NCT02086266|Randomized Trial.
169542|NCT02086253|Endothelin, endothelium, flow-mediated dilatation
169543|NCT02086227|Bioequivalence
169544|NCT02086214|Upper limb
169545|NCT02086214|Proprioceptive pressure therapy
169546|NCT02086214|Children
169547|NCT02086214|Assisting Hand Assessment performance
169548|NCT02086201|major depression
169549|NCT02086201|depression
169550|NCT02086201|depressive disorder
169551|NCT02086201|mental health
169552|NCT02086201|mental disorder
169553|NCT02086188|Multiple Sclerosis
169554|NCT02086188|Overactive Bladder
169555|NCT02086188|Incontinence
169556|NCT02086188|Voiding
169557|NCT02086188|Bladder Urgency
169558|NCT02086188|Pelvic Floor Exercises
169559|NCT02086175|relapsed/refractory indolent B cell non-Hodgkin lymphomas
169560|NCT02086162|Schizophrenia
169561|NCT02086162|Smoking
169562|NCT02086162|Tobacco
169563|NCT02086162|Motivation
169564|NCT02086162|Cessation Treatment
169565|NCT02086149|Quit smoking
169566|NCT02086149|Exercise
169567|NCT02086149|Tobacco
169568|NCT02086149|Smoking
169569|NCT02086136|aortic dissection
169570|NCT02086136|diagnosis
169571|NCT02086136|emergency medicine
169572|NCT02086136|d-dimer
169573|NCT02086123|Analgesia
169574|NCT02086123|Epidural Analgesia
169575|NCT02086123|Narcotic Analgesia
169576|NCT02086123|Patient Controlled Analgesia
169577|NCT02086123|Anesthesia and Analgesia
169578|NCT02086123|Anti inflammatory Analgesics
169579|NCT02086123|NSAIDS
169580|NCT02086110|probiotic
169581|NCT02086110|prebiotic
169582|NCT02086110|autism
169583|NCT02086110|oligosaccharides
169584|NCT02086110|Bifidobacterium infantis
169585|NCT02086097|pain
169586|NCT02086097|symptomatic irreversible pulpitis
169587|NCT02086097|postoperative dental pain
169588|NCT02086084|Acute Exacerbation Chronic Obstructive Pulmonary Disease
169589|NCT02086084|AECOPD
169590|NCT02086084|Non invasive ventilation
169591|NCT02086084|NIV
169592|NCT02086084|Extracorporeal carbon dioxide removal
169593|NCT02086084|ECCO2R
169594|NCT02086071|REBIOP re-biopsies advanced or metastatic NSCLC
169595|NCT02086058|overactive bladder
169596|NCT02086058|daytime urinary incontinence
169597|NCT02086058|children
169598|NCT02086058|gene expression
169599|NCT02086045|Coronary artery disease
169600|NCT02086032|Sleeping quality
169601|NCT02086032|menopause
169602|NCT02086032|climacteric
169603|NCT02086032|progestin
169604|NCT02086032|dydrogesterone
169605|NCT02086032|micronized progesterone
169606|NCT02086019|Revascularisation, octogenarian,acute coronary syndromes
169607|NCT02086006|Coronary artery disease
169608|NCT02085993|romiplostim,
169609|NCT02085993|Nplate,
169610|NCT02085993|immune thrombocytopenic purpura
169611|NCT02085967|Healthy
169612|NCT02085967|Metabolism
169613|NCT02085967|Drug-Drug Interactions
169614|NCT02085941|Head and Neck Neoplasms
169615|NCT02085941|Malignant Neoplasm of Vertebral Column
169616|NCT02085928|Tennis elbow
169617|NCT02085928|Lateral epicondylitis
169618|NCT02085928|Intratissue percutaneous electrolysis
169619|NCT02085928|Eccentric exercise
169620|NCT02085928|Ultrasonography
169621|NCT02085876|patients
169622|NCT02085876|present
169623|NCT02085876|undergo bariatric surgery
169624|NCT02085811|Kyphoplasty
169625|NCT02085811|at a single level
169626|NCT02085811|(between T11 and L5)
169627|NCT02085811|associated surgery
169628|NCT02085798|Leukemia, Myelomonocytic, Chronic, myelodysplastic syndrome, Prospective, Treatment strategy, epidemiologic data
169629|NCT02085785|weight loss
169630|NCT02085785|exercise
169631|NCT02085785|home-based
169632|NCT02085785|lower extremity amputation
169633|NCT02085785|pilot study
169634|NCT02085759|Healthy
169635|NCT02085733|Arthritis, Septic
169636|NCT02085681|Diabetic Retinopathy
169637|NCT02085681|Screening
169638|NCT02085681|Tele-medicine
169639|NCT02085681|Retinal Imaging
169640|NCT02085681|Remote diagnosis
169641|NCT02085668|Chronic Heart Failure
169642|NCT02085668|Cardio-Renal Syndrome
169643|NCT02085668|Renal Denervation
169644|NCT02085668|Symplicity
169645|NCT02085668|Sympathetic activation
169646|NCT02085655|Extranodal NK/T-cell lymphoma
169647|NCT02085655|PA-Gemox regimen
169648|NCT02085655|thalidomide
169649|NCT02085642|Stroke
169650|NCT02085642|Acupuncture
169651|NCT02085642|Gait
169652|NCT02085642|Spasticity
169653|NCT02085629|renal failure, end stage
169654|NCT02085629|renal transplantation
169655|NCT02085629|cell therapy
169656|NCT02085629|macrophages, monocyte derived
169657|NCT02085629|immune tolerance
169658|NCT02085629|ONE Study
169659|NCT02085629|immunotherapy
169660|NCT02085616|Smoking cessation
169661|NCT02085616|Tobacco cessation
169662|NCT02085616|Quitline
169663|NCT02085616|Telephone counselling
169664|NCT02085616|Intensity
169665|NCT02085603|advanced solid malignancies
169666|NCT02085590|BCG vaccine
169667|NCT02085590|Sepsis
169668|NCT02085590|Immunity
169669|NCT02085577|Morphine consumption
169670|NCT02085577|Postoperative pain
169671|NCT02085577|Ketamine
169672|NCT02085577|Side effects
169673|NCT02085577|Spine surgery
169674|NCT02085577|Chronic pain
169675|NCT02085564|Gastroesophageal-junction cancer
169676|NCT02085564|neoadjuvant chemotherapy
169677|NCT02085551|peripheral arterial occlusion
169678|NCT02085551|visceral emboli
169679|NCT02085551|limb ischemia
169680|NCT02085551|adverse events
169681|NCT02085551|Indigo System
169682|NCT02085551|aspiration
169683|NCT02085551|mechanical thrombectomy
169684|NCT02085538|renal impairment
169685|NCT02085538|AUC
169686|NCT02085538|Cmax
169687|NCT02085538|palbociclib
169688|NCT02085538|normal matched subjects
169689|NCT02085512|Post Traumatic Stress Disorder (PTSD)
169690|NCT02085512|Major Depression
169691|NCT02085512|Secondary Prevention
169692|NCT02085512|Neurocognitive Retraining
169693|NCT02085512|Randomized Controlled Trial
169694|NCT02085499|nasal ventilation
169695|NCT02085499|premature infants
169696|NCT02085499|synchronized ventilation
169697|NCT02085486|dialysis
169698|NCT02085486|av shunt
169699|NCT02085486|cannulation
169700|NCT02085486|ultrasound
169701|NCT02085486|outcome
169702|NCT02085447|Homelessness
169703|NCT02085447|Antipsychotic Drugs
169704|NCT02085447|Antipsychotics
169705|NCT02085447|Injectables
169706|NCT02085447|Long Acting Injectable Antipsychotic
169707|NCT02085447|Psychotic Disorders
169708|NCT02085447|Schizophrenia
169709|NCT02085447|Schizoaffective Disorder
169710|NCT02085447|Medication Adherence
169711|NCT02085447|Medication Non-Adherence
169712|NCT02085447|Community Mental Health Centers
169713|NCT02085421|tdcs, neuromodulation, CRT, psychosis, schizophrenia
169714|NCT02085395|Actinic Keratosis, AK, Bowen's Disease, Bowen
169715|NCT02085382|Kangaroo Mother Care(KMC), Low-birth weight, neonates
169716|NCT02085369|bariatric surgery
169717|NCT02085369|cognitive function
169718|NCT02085369|gene expression
169719|NCT02085356|HIV
169720|NCT02085356|PMTCT
169721|NCT02085356|South Africa
169722|NCT02085356|Couples
169723|NCT02085356|Male involvement
169724|NCT02085343|Exposure therapy
169725|NCT02085343|Specific phobia
169726|NCT02085343|Fear of heights
169727|NCT02085343|Acrophobia
169728|NCT02085343|Safety behavior fading
169729|NCT02085343|Anti-phobic Actions
169730|NCT02085317|Microcirculation
169731|NCT02085317|Leprosy
169732|NCT02085317|Nervous system
169733|NCT02085317|Orthogonal polarization spectral (OPS) imaging
169734|NCT02085317|Laser Doppler flowmetry
169735|NCT02085317|Iontophoresis.
169736|NCT02085304|Glioblastoma
169737|NCT02085304|GBM
169738|NCT02085304|Radiation
169739|NCT02085304|GammaKnife(R)
169740|NCT02085304|Radiosurgery
169741|NCT02085304|Gliadel(R)
169742|NCT02085304|Temozolomide
169743|NCT02085304|Temodar(R)
169744|NCT02085291|septic shock, microcirculation, fluid
169745|NCT02085278|arteriovenous malformation
169746|NCT02085278|Brain
169747|NCT02085278|AVM
169748|NCT02085278|Onyx
169749|NCT02085278|Micro catheter
169750|NCT02085278|catheter entrapment,
169751|NCT02085278|Embolization
169752|NCT02085278|Vein Of Galen
169753|NCT02085265|Alzheimer's Disease
169754|NCT02085265|Hypertension
169755|NCT02085265|Perindopril
169756|NCT02085265|Telmisartan
169757|NCT02085265|Brain atrophy
169758|NCT02085252|Drug Therapy
169759|NCT02085239|Breast Biopsy
169760|NCT02085239|Ultrasound
169761|NCT02085239|Lidocaine
169762|NCT02085239|Ropivacaine
169763|NCT02085239|Breast Lesion
169764|NCT02085226|Stroke
169765|NCT02085226|Rehabilitation
169766|NCT02085226|Creative Engagement
169767|NCT02085226|Psychosocial
169768|NCT02085226|Art
169769|NCT02085213|Retained Placenta
169770|NCT02085213|Manual Removal of Placenta
169771|NCT02085213|Glyceryl Trinitrate
169772|NCT02085200|glenohumeral internal rotation deficit
169773|NCT02085200|overhead athlete
169774|NCT02085200|shoulder exercise
169775|NCT02085200|posterior glenohumeral capsule
169776|NCT02085200|posteroinferior glenohumeral ligament
169777|NCT02085200|posterior rotator cuff
169778|NCT02085187|Pulmonary rehabilitation
169779|NCT02085187|Training
169780|NCT02085187|Counselling
169781|NCT02085187|Telemedicine
169782|NCT02085187|Videoconference
169783|NCT02085187|COPD
169784|NCT02085187|Chronic disease
169785|NCT02085187|Internet.
169786|NCT02085148|Pediatric cancer
169787|NCT02085135|depression
169788|NCT02085135|major depressive disorder
169789|NCT02085135|Alkermes
169790|NCT02085135|ALKS 5461
169791|NCT02085135|samidorphan
169792|NCT02085135|buprenorphine
169793|NCT02085109|Cardiovascular Diseases
169794|NCT02085109|HDL metabolism
169795|NCT02085109|ApoA-I
169796|NCT02085109|High fat
169797|NCT02085109|Theobromine
169798|NCT02085096|Caregivers
169799|NCT02085096|Coping Skills
169800|NCT02085083|Inflammatory Bowel Disease
169801|NCT02085083|Transition
169802|NCT02085083|Adolescent
169803|NCT02085083|Chronic Disease
169804|NCT02085083|Colitis, Ulcerative
169805|NCT02085044|malnutrition
169806|NCT02085044|children's health
169807|NCT02085044|prevention
169808|NCT02085044|ready-to-use supplementary food
169809|NCT02085044|lipid based nutrient supplement
169810|NCT02085044|chad
169811|NCT02085044|children
169812|NCT02085031|Roux-en-Y Anastomosis
169813|NCT02085031|laparoscopic surgery
169814|NCT02085031|minilaparotomy
169815|NCT02085031|stomach neoplasms
169816|NCT02085018|omeprazole, idiopathic pulmonary fibrosis
169817|NCT02084992|Congestive Heart Failure
169818|NCT02084992|Disease management
169819|NCT02084992|Hospitalization
169820|NCT02084979|Primary care mental health consultation
169821|NCT02084979|Telepsychiatry
169822|NCT02084979|Asynchronous telepsychiatry
169823|NCT02084966|Kidney
169824|NCT02084966|Transplantation
169825|NCT02084966|Imaging
169826|NCT02084966|Renal function
170076|NCT02083796|shoulder
169827|NCT02084966|Optical Coherence Tomography
169828|NCT02084940|PCOS
169829|NCT02084940|OHSS
169830|NCT02084940|GnRH antagonist
169831|NCT02084940|IVF
169832|NCT02084940|COH
169833|NCT02084914|endometrial scratching
169834|NCT02084914|pipelle
169835|NCT02084914|pregnancy rate
169836|NCT02084914|unexplained infertility
169837|NCT02084901|Biodegradable stents
169838|NCT02084901|converage
169839|NCT02084901|OCT
169840|NCT02084875|Food effect
169841|NCT02084875|pharmacokinetic
169842|NCT02084875|healthy volunteer
169843|NCT02084862|Tracheostomy
169844|NCT02084862|Ultrasound
169845|NCT02084836|fMRI obesity adolescents
169846|NCT02084797|arginine vasopressin
169847|NCT02084797|sweat sodium
169848|NCT02084797|V2 antagonist
169849|NCT02084797|running
169850|NCT02084784|Near-infrared fluorescence
169851|NCT02084784|Image guided surgery
169852|NCT02084784|Breast cancer;
169853|NCT02084784|Sentinel lymph node biopsy
169854|NCT02084784|Indocyanine green
169855|NCT02084784|Methylene blue
169856|NCT02084771|contrast nephropathy
169857|NCT02084771|contrast induced acute kidney injury
169858|NCT02084771|acute kidney injury
169859|NCT02084771|prophylaxis
169860|NCT02084771|randomized trial
169861|NCT02084758|COPD
169862|NCT02084758|nitrate supplementation
169863|NCT02084758|metabolic efficiency
169864|NCT02084745|Boston keratoprosthesis
169865|NCT02084745|Glaucoma drainage device
169866|NCT02084745|Ahmed tube shunt
169867|NCT02084732|Sorafenib, thyroid neoplasms, salicylic acid
169868|NCT02084680|Prenatal
169869|NCT02084680|Newborn care
169870|NCT02084680|mobile phones
169871|NCT02084654|prediabetes
169872|NCT02084654|exenatide
169873|NCT02084654|weight loss
169874|NCT02084654|insulin resistance
169875|NCT02084654|acute insulin response
169876|NCT02084654|insulin secretion
169877|NCT02084641|ectopic fat
169878|NCT02084641|obesity
169879|NCT02084641|triglyceride storage
169880|NCT02084641|adipocyte
169881|NCT02084641|overfeeding
169882|NCT02084641|intrahepatic fat
169883|NCT02084641|adipocyte proliferation
169884|NCT02084641|inflammation
169885|NCT02084641|macrophage
169886|NCT02084615|Aspirin
169887|NCT02084615|Postoperative hemorrhage
169888|NCT02084615|Inguinal hernia
169889|NCT02084602|artesunate
169890|NCT02084602|mefloquine
169891|NCT02084602|falciparum
169892|NCT02084602|peruvian amazon
169893|NCT02084589|PCEA, labor analgesia, background infusion, ropivacaine
169894|NCT02084576|Cystoid macular edema
169895|NCT02084576|nonsteroidal anti-inflammatory drug
169896|NCT02084576|OCT
169897|NCT02084576|phacoemulsification.
169898|NCT02084563|Acute Myeloid Leukemia
169899|NCT02084563|Myeloproliferative Neoplasms
169900|NCT02084563|Myelodysplastic Syndromes
169901|NCT02084563|Myeloproliferative/Myelodysplastic Neoplasm
169902|NCT02084563|Leukemia
169903|NCT02084563|MDS
169904|NCT02084563|MPN
169905|NCT02084563|AML
169906|NCT02084563|Chronic myelomonocytic leukemia (CMML)
169907|NCT02084563|Polycythemia Vera (PV)
169908|NCT02084563|Essential Thrombocythemia (ET)
169909|NCT02084563|Myelofibrosis (MF)
169910|NCT02084537|symptomatic
169911|NCT02084537|infected
169912|NCT02084537|necrotic collection
169913|NCT02084524|vulnerable
169914|NCT02084524|nutrition
169915|NCT02084524|cancer
169916|NCT02084524|colorectal
169917|NCT02084524|tumor
169918|NCT02084498|Automated bolus calculator (ABC)
169919|NCT02084498|Advanced carbohydrate counting (ACC)
169920|NCT02084498|Patient empowerment
169921|NCT02084485|COPD
169922|NCT02084485|LPS
169923|NCT02084472|atopic eczema
169924|NCT02084472|moisturisers
169925|NCT02084472|alternatives
169926|NCT02084472|affordable
169927|NCT02084459|Chronic pain
169928|NCT02084459|Supportive care
169929|NCT02084459|Psychosocial Circumstances
169930|NCT02084459|Autonomy support
169931|NCT02084459|Nursing intervention
169932|NCT02084446|Everolimus
169933|NCT02084446|Tacrolimus
169934|NCT02084446|Sodium Mycophenolate
169935|NCT02084446|CMV
169936|NCT02084446|Graft function
169937|NCT02084446|Acute rejection
169938|NCT02084433|MIH of the first permanent molar
169939|NCT02084407|DM1
169940|NCT02084407|Cardiopathy
169941|NCT02084407|Adult
169942|NCT02084394|CBF autoregulation, rSO2,doppler, TCD, delirium,
169943|NCT02084381|CKD5, dialysis, high porous membranes
169944|NCT02084368|combined lumbar plexus and sciatic nerve block，
169945|NCT02084368|combined spinal and epidural anesthesia
169946|NCT02084355|Significant cancer pain
169947|NCT02084355|at least numeric rating scale 4
169948|NCT02084342|desmopressin
169949|NCT02084342|tranexamic acid
169950|NCT02084342|blood loss
169951|NCT02084342|transfusion need
169952|NCT02084342|posterior scoliosis orthopedics
169953|NCT02084329|Physiotherapy
169954|NCT02084329|Physical therapy
169955|NCT02084329|neurotrauma rehabilitation
169956|NCT02084329|Rehabilitation
169957|NCT02084329|Balance
169958|NCT02084329|Balance Confidence
169959|NCT02084329|concussion
169960|NCT02084329|Post-Concussion
169961|NCT02084329|Mild Traumatic Brain Injury
169962|NCT02084316|China CDC
169963|NCT02084316|One4All testing algorithm
169964|NCT02084316|Guangxi Autonomous Region
169965|NCT02084316|Testing and Linkage to HIV Care in China
169966|NCT02084290|Crohn's disease
169967|NCT02084290|Shared Decision Making
169968|NCT02084290|Decision Aid
169969|NCT02084277|Oral health-related quality of life (OHRQoL)
169970|NCT02084277|Self-ligating brackets (SLB)
169971|NCT02084277|Conventional brackets (CB)
169972|NCT02084277|Oral Health Impact Profile-14 (OHIP-14)
169973|NCT02084277|Short Form-36 (SF-36)
169974|NCT02084264|Adolescent Idiopathic Scoliosis
169975|NCT02084264|Pediatric Scoliosis
169976|NCT02084251|safety,
169977|NCT02084251|pharmacokinetics,
169978|NCT02084251|Long acting GLP-1 analogue
169979|NCT02084238|SLE, IL-2
169980|NCT02084225|low resource
169981|NCT02084225|conflict setting
169982|NCT02084225|ultrasound guided regional anesthesia
169983|NCT02084225|acute injuries
169984|NCT02084225|pain management
169985|NCT02084225|education
169986|NCT02084225|ultrasound
169987|NCT02084225|trauma
169988|NCT02084225|emergency department
169989|NCT02084173|alcohol
169990|NCT02084173|60+ years
169991|NCT02084173|treatment
169992|NCT02084173|met
169993|NCT02084173|cra
169994|NCT02084173|multi site
169995|NCT02084173|multi country
169996|NCT02084173|questionnaire
169997|NCT02084173|random
169998|NCT02084134|pituitary adenoma
169999|NCT02084134|Pituitary Tumor
170000|NCT02084134|transsphenoidal resection
170001|NCT02084134|pituitary cyst
170002|NCT02084121|metachromatic leukodystrophy
170003|NCT02084108|Frail and dependent older adults
170004|NCT02084108|Integrated care
170005|NCT02084108|Home care
170006|NCT02084108|Multidimensional geriatric assessment
170007|NCT02084108|RAI-HC (resident assessment instrument- Home care)
170008|NCT02084108|Palliative care.
170009|NCT02084043|aerosol delivery
170010|NCT02084043|vibrating mesh nebulizer
170011|NCT02084043|breath-actuated nebulizer
170012|NCT02084043|non invasive ventilation
170013|NCT02084043|bilevel ventilator
170014|NCT02084043|single limb circuit ventilator
170015|NCT02084043|Amikacin
170016|NCT02084030|cardiac surgery
170017|NCT02084030|POCD
170018|NCT02084030|GWAS
170019|NCT02084030|Susceptibility gene
170020|NCT02084017|Surgical Site Infection
170021|NCT02084017|Vascular Surgery
170022|NCT02084017|Negative Pressure Wound Therapy
170023|NCT02084004|Type 2 diabetes mellitus
170024|NCT02084004|Berberine Hydrochloride
170025|NCT02084004|Bifidobacterium
170026|NCT02083991|NODAT
170027|NCT02083991|Renal transplantation
170028|NCT02083991|Corticosteroids avoidance
170029|NCT02083991|CNI minimization
170030|NCT02083978|Bipolar Disorder
170031|NCT02083978|Magnetic Resonance Imaging (MRI) scanning
170032|NCT02083939|Inguinal hernia
170033|NCT02083939|Mesh repair
170034|NCT02083939|Prophylactic Antibiotics
170035|NCT02083939|Herniorrhaphy
170036|NCT02083939|Laparoscopic Inguinal Hernia Repair
170037|NCT02083926|Social Anxiety Disorder
170038|NCT02083926|SAD
170039|NCT02083926|Ketamine
170040|NCT02083913|Severely obese
170041|NCT02083913|Bariatric surgery
170042|NCT02083913|Physical activity
170043|NCT02083913|Physical fitness
170044|NCT02083913|Telehealth
170045|NCT02083913|Quality of life
170046|NCT02083887|Immune response
170047|NCT02083887|Vaccine
170048|NCT02083887|Malaria
170049|NCT02083874|cannabidiol
170050|NCT02083874|CBD
170051|NCT02083874|marijuana
170052|NCT02083874|withdrawal
170053|NCT02083874|treatment
170054|NCT02083861|osteoarthritis
170055|NCT02083861|arthritis
170056|NCT02083861|musculoskeletal
170057|NCT02083861|connective tissue disease
170058|NCT02083861|ultrasound
170059|NCT02083861|pain
170060|NCT02083861|mobility
170061|NCT02083861|heat
170062|NCT02083861|strength
170063|NCT02083861|ZetrOZ
170064|NCT02083861|LITUS
170065|NCT02083861|Sam
170066|NCT02083861|grade 1
170067|NCT02083861|grade 2
170068|NCT02083848|Locoregional invasion
170069|NCT02083848|Stage IB1, IB2, IIA or IIB
170070|NCT02083835|post-operative pain
170071|NCT02083822|premature baby
170072|NCT02083822|MRI : conventional and advanced images
170073|NCT02083822|Executive function testing at 5 years of age
170074|NCT02083796|manual therapy
170075|NCT02083796|rehabilitation
170077|NCT02083796|spine
170078|NCT02083770|Hispanics
170079|NCT02083770|Patient Participation
170080|NCT02083770|Refusal to Participate
170081|NCT02083770|Education
170082|NCT02083770|Clinical Trials
170083|NCT02083757|Fluid responsiveness; Passive leg raising
170084|NCT02083744|Congestive Heart Failure
170085|NCT02083744|Self-care
170086|NCT02083744|Spanish
170087|NCT02083731|CMV infection
170088|NCT02083731|Mesenchymal Stem Cells
170089|NCT02083731|Allogeneic hematopoietic stem cell transplantation
170090|NCT02083718|Poor Graft Function
170091|NCT02083718|Peripheral Blood Stem Cell
170092|NCT02083718|Mesenchymal Stem Cells
170093|NCT02083718|Allogeneic hematopoietic stem cell transplantation
170094|NCT02083705|Chest compression, Delivery Room, NICU,
170095|NCT02083679|Carcinoma, Non-Small-Cell Lung
170096|NCT02083679|Sym004
170097|NCT02083666|Phase I
170098|NCT02083666|Dose cohorts
170099|NCT02083666|Escalating dose
170100|NCT02083666|Single dose
170101|NCT02083666|Multiple dose
170102|NCT02083666|Safety
170103|NCT02083666|Tolerability
170104|NCT02083666|Pharmacokinetics
170105|NCT02083666|Pharmacodynamics
170106|NCT02083666|volunteers
170107|NCT02083653|Metastatic Colorectal Cancer
170108|NCT02083653|Sym004
170109|NCT02083653|Best Supportive Care
170110|NCT02083653|Capecitabine
170111|NCT02083653|Fluorouracil (5-FU)
170112|NCT02083640|healthy volunteer
170113|NCT02083640|bioavailability
170114|NCT02083640|palbociclib
170115|NCT02083640|formulation
170116|NCT02083627|Pharmacokinetics
170117|NCT02083627|Drug-Drug Interaction
170118|NCT02083627|Intestinal Absorption
170119|NCT02083627|Fidaxomicin
170120|NCT02083627|Rosuvastatin
170121|NCT02083627|Multiple Doses
170122|NCT02083627|Single Doses
170123|NCT02083601|Caregivers
170124|NCT02083601|Spinal Cord Injuries
170125|NCT02083601|Psychology, Educational
170126|NCT02083601|Counseling
170127|NCT02083601|Outcome Assessment (Health Care)
170128|NCT02083588|Fibromyalgia
170129|NCT02083588|dTMS
170130|NCT02083588|pain
170131|NCT02083588|PFC
170132|NCT02083588|Subjects with Fibromyalgia
170133|NCT02083575|vitamin c
170134|NCT02083575|thalassemia major
170135|NCT02083575|iron chelation
170136|NCT02083562|Bronchopulmonary dysplasia, preterm infant
170137|NCT02083549|Massive Transfusion Protocol
170138|NCT02083536|Low Dose Fractionated Whole Abdominal Radiation Therapy
170139|NCT02083536|LDFWART
170140|NCT02083536|Docetaxel
170141|NCT02083536|Ovarian Cancer
170142|NCT02083536|Ovarian Carcinoma
170143|NCT02083536|Platinum-Resistant
170144|NCT02083523|Motivational Interview, normative feedback, adolescents
170145|NCT02083510|Colchicine
170146|NCT02083510|Hypertriglyceridemia
170147|NCT02083510|Apolipoprotein CIII
170148|NCT02083497|kick
170149|NCT02083497|taping
170150|NCT02083497|dynamic equilibrium
170151|NCT02083458|critical care
170152|NCT02083458|catheterization
170153|NCT02083458|axillary vein
170154|NCT02083445|Traumatic brain injury
170155|NCT02083445|Exercise
170156|NCT02083445|Psychology
170157|NCT02083445|Physiology
170158|NCT02083445|Progenitor cells
170159|NCT02083445|Hypoxia
170160|NCT02083432|intra-oral injections
170161|NCT02083432|CBT
170162|NCT02083432|Blood-Injury-Injection-phobia
170163|NCT02083432|DSM-IV. 300.29
170164|NCT02083419|Left Ventricular Assist Devices (LVAD)
170165|NCT02083419|Cardiac Resynchronization Devices (CRT)
170166|NCT02083406|Malaria
170167|NCT02083406|Bio-availability
170168|NCT02083393|dendritic cell
170169|NCT02083380|Plasmodium falciparum malaria
170170|NCT02083380|malaria
170171|NCT02083380|OZ439
170172|NCT02083380|piperaquine
170173|NCT02083380|PQP
170174|NCT02083354|melanoma
170175|NCT02083354|dabrafenib
170176|NCT02083354|trametinib
170177|NCT02083328|heart rate variability
170178|NCT02083328|exercise performance
170179|NCT02083315|acute pain, analgesia, respiratory drive, ventilator response to hypercapnia, pupillometry
170180|NCT02083302|campus sexual assault
170181|NCT02083302|bystander intervention
170182|NCT02083289|ONO-9054
170183|NCT02083289|ocular hypertension (OHT)
170184|NCT02083289|Open angle-glaucoma (OAG)
170185|NCT02083289|Glaucoma
170186|NCT02083289|Eye Diseases
170187|NCT02083289|Mild to moderate
170188|NCT02083276|Chlamydia trachomatis
170189|NCT02083276|Urethritis
170190|NCT02083276|Genital Diseases, Male
170191|NCT02083263|Lung function
170192|NCT02083250|Leukemia
170193|NCT02083250|Blood And Marrow Transplantation
170194|NCT02083250|Acute lymphoblastic leukemia
170195|NCT02083250|ALL
170196|NCT02083250|Acute myeloid leukemia
170197|NCT02083250|AML
170198|NCT02083250|Myelodysplastic syndrome
170199|NCT02083250|MDS
170200|NCT02083250|Allogeneic stem cell transplant
170201|NCT02083250|SCT
170202|NCT02083250|Thymoglobulin
170203|NCT02083250|ATG
170204|NCT02083250|Antithymocyte Globulin
170205|NCT02083250|Fludarabine
170206|NCT02083250|Fludarabine Phosphate
170207|NCT02083250|Fludara
170208|NCT02083250|Clofarabine
170209|NCT02083250|Clofarex
170210|NCT02083250|Clolar
170211|NCT02083250|Busulfan
170212|NCT02083250|Busulfex
170213|NCT02083250|Myleran
170214|NCT02083250|SAHA
170215|NCT02083250|Vorinostat
170216|NCT02083250|Suberoylanilide Hydroxamic Acid
170217|NCT02083250|MSK-390
170218|NCT02083250|Zolinza
170219|NCT02083237|mild cognitive impairment
170220|NCT02083237|memory training
170221|NCT02083237|healthy lifestyle
170222|NCT02083237|psychosocial support
170223|NCT02083211|Cervical cancer
170224|NCT02083211|Recurrent or persistent tumor
170225|NCT02083211|Monoclonal antibody
170226|NCT02083198|hyperchloremic acidosis
170227|NCT02083198|balanced fluids
170228|NCT02083198|plasmalyte
170229|NCT02083172|USCOM (UltraSound Cardiac Output Monitor)
170230|NCT02083172|2D echocardiography
170231|NCT02083172|agreement
170232|NCT02083172|pediatrics
170233|NCT02083133|Diabetes
170234|NCT02083133|Renal Failure
170235|NCT02083133|Dialysis
170236|NCT02083133|End Stage Renal Disease
170237|NCT02083133|Hypoglycemia
170238|NCT02083120|high flow
170239|NCT02083120|COPD
170240|NCT02083120|AIRVO
170241|NCT02083107|Postpartum hemorrhage
170242|NCT02083107|Intrapartum blood loss
170243|NCT02083107|Misoprostol
170244|NCT02083081|tobacco
170245|NCT02083081|smoking
170246|NCT02083068|Malaria, vaccine, P. vivax
170247|NCT02083055|dexmedetomidine
170248|NCT02083055|controlled hypotensive anesthesia
170249|NCT02083042|CMV
170250|NCT02083042|T-Track CMV
170251|NCT02083042|kidney transplantation
170252|NCT02083029|Asthma
170253|NCT02083029|Death
170254|NCT02083029|Mechanism
170255|NCT02083029|Syncope
170256|NCT02083029|Dive reflex
170257|NCT02083003|Pain
170258|NCT02083003|Polyamine
170259|NCT02083003|Cholecystectomy
170260|NCT02082990|Alcohol-related disorders
170261|NCT02082990|Alcohol Drinking
170262|NCT02082990|e-health
170263|NCT02082990|Alcohol Use Disorder Test
170264|NCT02082990|Quality of Life
170265|NCT02082977|Refractory
170266|NCT02082977|Phase I study, dose escalation study
170267|NCT02082977|diffuse large B cell lymphoma
170268|NCT02082977|Relapsed
170269|NCT02082977|Solid tumors
170270|NCT02082977|transformed follicular lymphoma
170271|NCT02082977|Multiple myeloma
170272|NCT02082977|GSK2816126
170273|NCT02082977|Non-Hodgkin's lymphoma
170274|NCT02082938|stroke,
170275|NCT02082938|rehabilitation,
170276|NCT02082938|hemiparesis,
170277|NCT02082938|gait training
170278|NCT02082925|Exercise training
170279|NCT02082925|Dyspnea threshold
170280|NCT02082925|6MWT
170281|NCT02082899|Allergic Conjunctivitis
170282|NCT02082899|Interleukin 1 Receptor Inhibitor
170283|NCT02082899|Environmental Exposure Chamber
170284|NCT02082899|Conjunctival Allergen Provocation Test
170285|NCT02082886|Metastasis
170286|NCT02082886|Carcinomatosis
170287|NCT02082886|Carcinosis
170288|NCT02082886|Sarcomatosis
170289|NCT02082886|CRS
170290|NCT02082886|Cytoreductive surgery
170291|NCT02082886|HIPEC
170292|NCT02082886|Heated Intraperitoneal Chemotherapy
170293|NCT02082886|Intra-abdominal
170294|NCT02082886|Sugarbaker technique
170295|NCT02082886|Mitomycin C
170296|NCT02082886|Cisplatin
170297|NCT02082886|Doxorubicin
170298|NCT02082886|Oxaliplatin
170299|NCT02082886|Melphalan
170300|NCT02082873|Quantitative EEG
170301|NCT02082873|Nonconvulsive seizures
170302|NCT02082873|ICU EEG monitoring
170303|NCT02082860|Porphyria
170304|NCT02082860|Gene therapy
170305|NCT02082860|AAV
170306|NCT02082860|Liver gene transfer
170307|NCT02082834|Endovascular aneurysm repair EVAR
170308|NCT02082834|Endoleak/diagnosis
170309|NCT02082834|VEOTM
170310|NCT02082834|Model-based iterative reconstruction (MBIR)
170311|NCT02082834|Adaptive statistical iterative reconstruction (ASIR)
170312|NCT02082834|Aortic Aneurysm
170313|NCT02082834|Low dose
170314|NCT02082834|Prospective
170315|NCT02082834|CTA
170316|NCT02082808|Dolutegravir
170317|NCT02082808|healthy volunteer
170318|NCT02082808|pharmacokinetics
170319|NCT02082808|daclatasvir
170320|NCT02082808|drug interaction
170321|NCT02082795|Breech presentation
170322|NCT02082795|External cephalic version
170323|NCT02082795|Anaesthesia
170324|NCT02082795|Qualitative
170325|NCT02082795|Pregnancy
170326|NCT02082782|Colorectal liver metastases (CRLM)
170327|NCT02082782|Tumor ablation
170328|NCT02082782|Irreversible electroporation (IRE)
170329|NCT02082782|Interventional oncology
170330|NCT02082782|NanoKnife
170331|NCT02082782|Colorectal liver metastasis, unresectable and not-thermally ablative due to location near vulnerable structures like vessels or bile ducts
170332|NCT02082769|Gout
170333|NCT02082769|Uric Acid
170334|NCT02082769|Xanthine oxidase
170335|NCT02082769|Febuxostat
170336|NCT02082756|Prediabetes
170337|NCT02082756|Berberine Hydrochloride
170338|NCT02082756|Bifidobacterium
170339|NCT02082743|Myopia
170340|NCT02082743|Outdoor activity
170341|NCT02082743|Recess outside classroom
170342|NCT02082730|CFS/ME, Chronic fatigue syndrome, Pediatric, remote mobile technology
170343|NCT02082704|Diabetes
170344|NCT02082704|Education, Patient
170345|NCT02082704|Educational Technology
170346|NCT02082691|G-202
170347|NCT02082691|Hepatocellular
170348|NCT02082678|Bipolar Disorder
170349|NCT02082678|BPD
170350|NCT02082678|Alcohol Use Disorder
170351|NCT02082678|Alcohol Abuse
170352|NCT02082678|Alcohol Dependence
170353|NCT02082678|Ondansetron
170354|NCT02082678|Cognition
170355|NCT02082678|Mood
170356|NCT02082665|rosuvastatin
170357|NCT02082665|BRAF V600
170358|NCT02082665|Melanoma
170359|NCT02082665|dabrafenib
170360|NCT02082665|midazolam
170361|NCT02082652|Etonogestrel
170362|NCT02082652|Efavirenz
170363|NCT02082652|Nevirapine
170364|NCT02082652|Pharmacokinetics
170365|NCT02082639|Adolescents
170366|NCT02082639|Havrix
170367|NCT02082639|Immunogenicity
170368|NCT02082639|Cervarix
170369|NCT02082639|Safety
170370|NCT02082626|Phase I
170371|NCT02082626|Pediatric
170372|NCT02082626|Cancer
170373|NCT02082626|Lymphoma
170374|NCT02082626|Eribulin
170375|NCT02082613|Testicular hydrocele
170376|NCT02082613|Hydrocele
170377|NCT02082613|Sclerotherapy
170378|NCT02082613|Surgery
170379|NCT02082613|Complications
170380|NCT02082587|brain metastases
170381|NCT02082587|brain mets
170382|NCT02082587|WBRT
170383|NCT02082561|transdiagnostic treatment
170384|NCT02082561|cognitive behavior therapy
170385|NCT02082561|anxiety
170386|NCT02082561|panic disorder
170387|NCT02082561|generalized anxiety disorder
170388|NCT02082561|social anxiety disorder
170389|NCT02082548|atrial fibrillation
170390|NCT02082548|anticoagulation
170391|NCT02082548|education
170392|NCT02082548|educational intervention
170393|NCT02082535|Premature Birth
170394|NCT02082535|Brain Injuries
170395|NCT02082535|Leukomalacia Periventricular
170396|NCT02082535|S100B protein human
170397|NCT02082535|Glial Fibrillary Acidic Protein
170398|NCT02082535|Magnetic Resonance Imaging
170399|NCT02082535|Developmental Disabilities
170400|NCT02082522|Cholangiocarcinoma
170401|NCT02082522|Unresectable perihilar cholangiocarcinoma
170402|NCT02082522|Klatskin tumor
170403|NCT02082522|Photodynamic therapy
170404|NCT02082522|Porfimer sodium
170405|NCT02082522|Photofrin
170406|NCT02082522|Gemcitabine
170407|NCT02082522|Cisplatin
170408|NCT02082522|Stents
170409|NCT02082522|CCA
170410|NCT02082522|PDT
170411|NCT02082522|Bile duct cancer
170412|NCT02082522|Bile duct tumor
170413|NCT02082522|Bile duct adenocarcinoma
170414|NCT02082522|Chemotherapy
170415|NCT02082509|Traumatic Brain Injury
170416|NCT02082509|Post-Concussive Symptoms
170417|NCT02082509|Brain Imaging
170418|NCT02082509|Cognition
170419|NCT02082496|Obesity
170420|NCT02082496|Obesity Genetics
170421|NCT02082496|GLP-1
170422|NCT02082496|GLP-1 Receptor Agonists
170423|NCT02082483|Kidney Transplant
170424|NCT02082483|Screening
170425|NCT02082457|Irritable Bowel Syndrome
170426|NCT02082457|Constipation
170427|NCT02082457|C-IBS
170428|NCT02082431|Sensorineural hearing loss
170429|NCT02082431|Long QT Syndrome
170430|NCT02082418|Mild cognitive impairment
170431|NCT02082418|Protein digestion
170432|NCT02082418|Tryptophan digestion
170433|NCT02082418|Cognitive function
170434|NCT02082418|Mood
170435|NCT02082418|Muscle function
170436|NCT02082418|Alpha-lactalbumin
170437|NCT02082379|Interface, aerosol, child, acceptance
170438|NCT02082366|Atrial fibrillation
170439|NCT02082366|CPVI
170440|NCT02082366|TCD
170441|NCT02082366|nMARQ
170442|NCT02082366|MES
170443|NCT02082366|microembolic signals
170444|NCT02082353|Granulomatous Disease, Chronic
170445|NCT02082353|Hematopoietic Stem Cell Transplantation
170446|NCT02082340|Tuberculosis
170447|NCT02082340|Armenia
170448|NCT02082340|Clinical trial
170449|NCT02082340|Directly Observed Therapy (DOT)
170450|NCT02082340|Self-administered drug intake
170451|NCT02082327|Fabry Disease
170452|NCT02082327|Fabry
170453|NCT02082327|Lysosomal storage disorders
170454|NCT02082327|LSD
170455|NCT02082327|Amicus
170456|NCT02082327|migalastat HCl
170457|NCT02082327|migalastat
170458|NCT02082327|AT1001
170459|NCT02082314|radiofrequency ablation
170460|NCT02082314|bone metastases
170461|NCT02082288|ICSI outcome
170462|NCT02082275|Prenatal Care
170463|NCT02082275|Obstetrics
170464|NCT02082249|carbidopa
170465|NCT02082249|Tolerability
170466|NCT02082249|levodopa
170467|NCT02082249|levodopa-carbidopa intestinal gel
170468|NCT02082249|Efficacy
170469|NCT02082249|Advanced Parkinson's Disease
170470|NCT02082249|Safety
170471|NCT02082236|Plasma concentrations
170472|NCT02082223|Quality of life
170473|NCT02082223|Deficits
170474|NCT02082223|Complex gastrointestinal surgery
170475|NCT02082197|low testosterone
170476|NCT02082184|Sensing Technology
170477|NCT02082184|Type 2 Diabetes,
170478|NCT02082171|older adults
170479|NCT02082171|physical disability
170480|NCT02082171|multidomain intervention
170481|NCT02082171|prevention
170482|NCT02082171|pilot study
170483|NCT02082171|frailty
170484|NCT02082171|mobility
170485|NCT02082171|comprehensive geriatric assessment
170486|NCT02082106|alpine skiing
170487|NCT02082106|cross country skiing
170488|NCT02082106|indoor cycling
170489|NCT02082106|physical fitness
170490|NCT02082106|training status
170491|NCT02082106|metabolic equivalent
170492|NCT02082093|Chronic Kidney Disease
170493|NCT02082093|telemedicine
170494|NCT02082054|rhinitis
170495|NCT02082054|seasonal
170496|NCT02082054|allergic
170497|NCT02082015|Neuronal plasticity
170498|NCT02082015|Transcranial magnetic stimulation
170499|NCT02082015|Stroke
170500|NCT02082015|Upper extremity
170501|NCT02082015|Function
170502|NCT02082015|Recovery
170503|NCT02082002|Multiple scerlosis
170504|NCT02082002|Fatigue
170505|NCT02082002|Sleep
170506|NCT02082002|Somnolence
170507|NCT02082002|Depression
170508|NCT02082002|Cognitive disorders
170509|NCT02081989|Diabetes
170510|NCT02081989|Renal denervation
170511|NCT02081963|Nebulized amikacin;
170512|NCT02081963|Non-Cystic Fibrosis Bronchiectasis;
170513|NCT02081963|Bacterial clearance rate of sputum；
170514|NCT02081963|Acute exacerbation.
170515|NCT02081937|chimeric antigen receptor
170516|NCT02081937|immunotherapy
170517|NCT02081937|T lymphocyte
170518|NCT02081937|mantle cell lymphoma
170519|NCT02081924|Infertility
170520|NCT02081924|Kisspeptin
170521|NCT02081924|Reproductive hormones
170522|NCT02081911|adductor canal
170523|NCT02081911|femoral
170524|NCT02081911|quadriceps
170525|NCT02081898|low calorie diet
170526|NCT02081898|BMI
170527|NCT02081898|sphingomyelin
170528|NCT02081898|L-leucine
170529|NCT02081898|L-phenylalanine
170530|NCT02081885|Tricalcium phosphate
170531|NCT02081885|Chitosan
170532|NCT02081885|Grafting, Bone
170533|NCT02081885|Mandibular Fractures
170534|NCT02081872|Pharmacogenomics
170535|NCT02081872|Target Drug Related Adverse Events (TDAE)
170536|NCT02081846|transitions of care
170537|NCT02081846|reutilization
170538|NCT02081846|home nurse visit
170539|NCT02081846|focus groups
170540|NCT02081846|quality improvement
170541|NCT02081833|acute respiratory infections
170542|NCT02081833|acute gastrointestinal infections
170543|NCT02081833|children
170544|NCT02081833|child
170545|NCT02081833|symptom diary
170546|NCT02081833|nasal swabs
170547|NCT02081833|stool samples
170548|NCT02081820|hyperglycemia
170549|NCT02081820|aneurysmal subarachnoid hemorrhage
170550|NCT02081820|glycated hemoglobin
170551|NCT02081820|outcome
170552|NCT02081820|DCI
170553|NCT02081768|Rathke's cleft cyst
170554|NCT02081768|cystic craniopharyngiomas
170555|NCT02081755|Immunosuppressive Agents
170556|NCT02081755|Liver Transplantation
170557|NCT02081742|Colonoscopy, CT colonography, Colon capsule
170558|NCT02081703|Postsurgical pain
170559|NCT02081703|Total knee arthroplasty
170560|NCT02081703|Total knee replacement
170561|NCT02081690|PAH-SYMPACT
170562|NCT02081690|psychometric instrument
170563|NCT02081664|Amalgam attributed health complaints
170564|NCT02081664|feasibility pilot study
170565|NCT02081664|integrated medical care program
170566|NCT02081664|lifestyle
170567|NCT02081638|Immune Activation
170568|NCT02081625|Duchenne muscular dystrophy
170569|NCT02081625|NS-065/NCNP-01
170570|NCT02081625|exon 53 skipping
170571|NCT02081625|morpholino
170572|NCT02081599|insulin resistance
170573|NCT02081586|CBT
170574|NCT02081586|Type 2 Diabetes
170575|NCT02081586|Diabetes Distress
170576|NCT02081586|Adherence
170577|NCT02081586|Smartphone App
170578|NCT02081586|Self-management
170579|NCT02081573|Brief CBT
170580|NCT02081573|smartphone app
170581|NCT02081573|mHealth
170582|NCT02081573|diabetes distress
170583|NCT02081573|adherence
170584|NCT02081560|pharmacokinetics
170585|NCT02081560|antibiotic
170586|NCT02081560|Gram negative
170587|NCT02081560|continuous renal replacement therapy
170588|NCT02081547|rectal carcinoma
170589|NCT02081547|recurrence
170590|NCT02081547|pathology
170591|NCT02081547|cytology
170592|NCT02081547|free cancer cells
170593|NCT02081547|survival
170594|NCT02081534|S-phosphate, hyperphosphatemia, hemodialysis, ESRD
170595|NCT02081521|behaviour change
170596|NCT02081521|diarrhoeal disease
170597|NCT02081521|handwashing
170598|NCT02081521|breastfeeding
170599|NCT02081521|diarrhoea management
170600|NCT02081508|Memory
170601|NCT02081495|Neoplasms
170602|NCT02081495|Neoplasms, Ovarian
170603|NCT02081495|Ovarian Cancer
170604|NCT02081495|Advanced or Refractory Solid Malignancies
170605|NCT02081495|Doxorubicin
170606|NCT02081495|DOXIL
170607|NCT02081495|CAELYX
170608|NCT02081469|Chronic hepatitis B
170609|NCT02081469|HBV
170610|NCT02081469|Chemotherapy
170611|NCT02081469|Reactivation
170612|NCT02081469|Prophylaxis
170613|NCT02081443|coronary artery disease
170614|NCT02081443|platelet function
170615|NCT02081443|ticagrelor
170616|NCT02081443|cangrelor
170617|NCT02081417|Trauma
170618|NCT02081417|Post traumatic stress disorder
170619|NCT02081417|substance use disorders
170620|NCT02081417|peer-delivered trauma treatment
170621|NCT02081404|Non-erosive Reflux Disease
170622|NCT02081391|Acute Pain
170623|NCT02081391|Post-operative
170624|NCT02081391|Tapentadol
170625|NCT02081391|Opioid Treatment
170626|NCT02081391|Pediatric Participants
170627|NCT02081378|CML
170628|NCT02081378|Ph+ ALL
170629|NCT02081352|Dermis
170630|NCT02081352|Diabetic foot ulcers
170631|NCT02081352|Skin substitutes
170632|NCT02081352|Decellularized
170633|NCT02081326|Diabetes Mellitus, Type One
170634|NCT02081326|Diabetes Mellitus, Type I
170635|NCT02081326|Autoimmune Diabetes
170636|NCT02081326|Insulin Dependent Diabetes Mellitus 1
170637|NCT02081326|IDDM
170638|NCT02081313|Netherton syndrome
170639|NCT02081313|Immune system
170640|NCT02081313|Skin barrier
170641|NCT02081300|Testosterone
170642|NCT02081300|Male hypogonadism
170643|NCT02081300|Low testosterone
170644|NCT02081300|LPCN 1021
170645|NCT02081300|Androgel
170646|NCT02081300|Testim
170647|NCT02081300|Testopel
170648|NCT02081300|Fortesta
170649|NCT02081300|Axiron.
170650|NCT02081300|Hypogonadism
170651|NCT02081300|Eunuchism
170652|NCT02081300|Gonadal Disorders
170653|NCT02081300|Endocrine System Diseases
170654|NCT02081300|Testosterone enanthate
170655|NCT02081300|Testosterone undecanoate
170656|NCT02081300|Testosterone 17 beta-cypionate
170657|NCT02081300|Methyltestosterone
170658|NCT02081300|Androgens
170659|NCT02081300|Hormones
170660|NCT02081300|Hormones, Hormone Substitutes, and Hormone Antagonists
170661|NCT02081300|Physiological Effects of Drugs
170662|NCT02081300|Pharmacologic Actions
170663|NCT02081300|Antineoplastic Agents, Hormonal
170664|NCT02081300|Antineoplastic Agents
170665|NCT02081300|Anabolic Agents
170666|NCT02081287|Bipolar Disorder
170667|NCT02081287|Depression
170668|NCT02081287|Inositol
170669|NCT02081287|Inositol Hexaphosphate
170670|NCT02081287|Phytic Acid
170671|NCT02081287|IP6
170672|NCT02081287|Lithium
170673|NCT02081287|Lamotrigine
170674|NCT02081274|tidal volume
170675|NCT02081274|congenital heart disease
170676|NCT02081274|mortality
170677|NCT02081261|coronary artery bypass surgery
170678|NCT02081261|acute kidney injury
170679|NCT02081261|creatinine
170680|NCT02081261|mortality
170681|NCT02081235|congenital heart disease
170682|NCT02081235|acute kidney injury
170683|NCT02081235|risk factor
170684|NCT02081235|anesthesia
170685|NCT02081222|congenital heart disease
170686|NCT02081222|rotational thromboelastometry
170687|NCT02081222|blood loss
170688|NCT02081222|transfusion requirements
170689|NCT02081209|Lipolysis
170690|NCT02081209|Cryolipolysis
170691|NCT02081209|Fat Reduction
170692|NCT02081196|Lipolysis
170693|NCT02081196|Cryolipolysis
170694|NCT02081196|Fat Reduction
170695|NCT02081144|Standard Care Condition
170696|NCT02081144|Texting + NRT Condition
170697|NCT02081131|periampullary cancer
170698|NCT02081131|pancreatic cancer
170699|NCT02081131|randomized controlled trial
170700|NCT02081131|Whipple's operation
170701|NCT02081131|laparoscopy
170702|NCT02081105|ARDS,
170703|NCT02081105|PEEP,
170704|NCT02081105|lung recruitment,
170705|NCT02081105|lung recruitability,
170706|NCT02081105|Chest-X-Ray,
170707|NCT02081105|lung imaging,
170708|NCT02081105|Pressure/Volume (PV) curve,
170709|NCT02081105|compliance,
170710|NCT02081105|respiratory mechanics
170711|NCT02081092|PAP
170712|NCT02081092|Pulmonary Alveolar Proteinosis
170713|NCT02081092|Pulmonary
170714|NCT02081092|Patients
170715|NCT02081079|HCV GT 4
170716|NCT02081079|HCV GT 5
170717|NCT02081053|metastatic lesions
170718|NCT02081053|vertebral body
170719|NCT02081053|ablation
170720|NCT02081053|targeted radio-frequency ablation
170721|NCT02081053|radio-frequency targeted vertebral augmentation
170722|NCT02081053|radiofrequency kyphoplasty
170723|NCT02081053|spine
170724|NCT02081053|vertebral augmentation
170725|NCT02081053|kyphoplasty
170726|NCT02081053|spinal ablation
170727|NCT02081053|pain
170728|NCT02081053|quality of life
170729|NCT02081040|brainstem
170730|NCT02081040|diaphragm
170731|NCT02081040|deglutition disorder
170732|NCT02081040|sonography
170733|NCT02081014|Hypoglycemia
170734|NCT02081014|Glucagon
170735|NCT02081014|Diabetes
170736|NCT02081001|Hypoglycemia
170737|NCT02081001|Glucagon
170738|NCT02081001|Artificial Pancreas
170739|NCT02080988|stroke
170740|NCT02080988|deglutition disorders
170741|NCT02080988|cough
170742|NCT02080988|aspiration pneumonia
170743|NCT02080988|diaphragm
170744|NCT02080988|respiratory function
170745|NCT02080962|non-melanoma skin cancer, radiotherapy, orthovoltage
170746|NCT02080949|brain metastases, hypofractionated stereotactic radiotherapy
170747|NCT02080936|Experimental approaches
170748|NCT02080936|Peripheral muscle Keyword
170749|NCT02080936|Rehabilitation
170750|NCT02080923|Adolescent
170751|NCT02080923|Adolescent Behavior
170752|NCT02080923|Age Factors
170753|NCT02080923|Courtship
170754|NCT02080923|Randomized Control Trial
170755|NCT02080923|Female
170756|NCT02080923|Male
170757|NCT02080923|Minority Groups/statistics & numerical data
170758|NCT02080923|Risk-Taking
170759|NCT02080923|Sex Factors
170760|NCT02080923|Sexual Behavior/statistics & numerical data
170761|NCT02080923|Substance-Related Disorders/epidemiology
170762|NCT02080923|Urban Population/statistics & numerical data
170763|NCT02080923|Violence/statistics & numerical data
170764|NCT02080923|Dating Violence
170765|NCT02080923|Dating Aggression
170766|NCT02080923|Perpetration
170767|NCT02080910|Caregiver
170768|NCT02080910|stroke
170769|NCT02080910|psychoeducation
170770|NCT02080910|problem-solving
170771|NCT02080897|non-surgical
170772|NCT02080897|palliative surgery
170773|NCT02080858|Apixaban
170774|NCT02080858|Ticagrelor
170775|NCT02080858|ASA
170776|NCT02080858|shed blood
170777|NCT02080858|perfusion chamber
170778|NCT02080845|Caffeine
170779|NCT02080845|MRI
170780|NCT02080845|Brain blood flow
170781|NCT02080845|Cognition
170782|NCT02080845|Perfusion
170783|NCT02080845|Resting functional magnetic resonance imaging (fMRI)
170784|NCT02080832|substance abuse
170785|NCT02080832|cocaine
170786|NCT02080832|impulsivity
170787|NCT02080832|serotonin
170788|NCT02080832|MRI
170789|NCT02080819|drug abuse
170790|NCT02080819|cocaine
170791|NCT02080819|impulsivity
170792|NCT02080819|dopamine
170793|NCT02080806|stroke, dysphagia, cough, mechanical insufflation exsufflation
170794|NCT02080754|Crush induction
170795|NCT02080754|Cricoid pressure
170796|NCT02080754|Sellick maneuver
170797|NCT02080754|Lung aspiration
170798|NCT02080754|Aspiration pneumonia
170799|NCT02080715|Sleep-wake
170800|NCT02080715|regulation
170801|NCT02080715|volunteers
170802|NCT02080702|GIT, Monosyn, anastomoses leakage
170803|NCT02080676|Cannabis
170804|NCT02080676|Intra ocular pressure
170805|NCT02080676|Ocular perfusion
170806|NCT02080676|Blood pressure
170807|NCT02080663|carpectomy, proximal row, long-term, wrist, arthritis
170808|NCT02080637|Single ventricle
170809|NCT02080585|Inactivity
170810|NCT02080546|Vaginal cuff dehiscence
170811|NCT02080546|Thermal Injury
170812|NCT02080546|Total laparoscopic hysterectomy
170813|NCT02080533|pulmonary arterial hypertension
170814|NCT02080533|symptoms
170815|NCT02080533|dyspnea
170816|NCT02080533|fatigue
170817|NCT02080533|sleep
170818|NCT02080520|Prevention
170819|NCT02080520|Soy
170820|NCT02080520|Fermented soy
170821|NCT02080520|Nattokinase
170822|NCT02080520|Randomized controlled trial
170823|NCT02080520|Carotid artery
170824|NCT02080520|Cognition
170825|NCT02080520|Atherothrombosis
170826|NCT02080507|rTMS
170827|NCT02080507|depression
170828|NCT02080507|ECT
170829|NCT02080494|tranexamic acid
170830|NCT02080494|orthopaedic trauma
170831|NCT02080494|pelvic fracture
170832|NCT02080494|hip fracture
170833|NCT02080494|femur fracture
170834|NCT02080494|blood loss
170835|NCT02080468|Effect
170836|NCT02080468|Ethinyl Estradiol/Norgestimate
170837|NCT02080468|Pharmacokinetics
170838|NCT02080468|Lomitapide.
170839|NCT02080442|COPD
170840|NCT02080442|Balance
170841|NCT02080442|Pulmonary Rehabilitation
170842|NCT02080416|EBV
170843|NCT02080416|KSHV
170844|NCT02080416|malignancy
170845|NCT02080416|lymphoma
170846|NCT02080416|sarcoma
170847|NCT02080416|virus-associated
170848|NCT02080403|Peri-Implantitis
170849|NCT02080403|Periodontal Diseases
170850|NCT02080403|Chlorhexidine gluconate
170851|NCT02080403|PerioChip
170852|NCT02080403|Anti-Infective Agents
170853|NCT02080403|Mouth Diseases
170854|NCT02080403|Antiseptics
170855|NCT02080390|Her 2 Positive Breast Cancer
170856|NCT02080390|Trastuzumab
170857|NCT02080390|Herceptin
170858|NCT02080390|Heart Failure
170859|NCT02080390|Echocardiography
170860|NCT02080377|Pregnancy
170861|NCT02080377|Gestational diabetes
170862|NCT02080377|Glycaemic control
170863|NCT02080377|Metformin
170864|NCT02080364|Alzheimer's disease
170865|NCT02080364|RAGE
170866|NCT02080364|ADAS-cog
170867|NCT02080364|CDR-sb
170868|NCT02080338|Orthodontic, Bracket slot, Effective, Randomized, Duration
170869|NCT02080325|weight loss
170870|NCT02080325|high protein diet
170871|NCT02080325|plant protein
170872|NCT02080325|satiety
170873|NCT02080325|soy
170874|NCT02080312|Meniere's disease
170875|NCT02080312|endolymphatic hydrops
170876|NCT02080286|spatial neglect
170877|NCT02080286|rehabilitation
170878|NCT02080286|brain stimulation
170879|NCT02080286|tDCS
170880|NCT02080286|prism adaptation
170881|NCT02080234|Lymphoma, Extranodal NK-T-Cell
170882|NCT02080234|asparaginase
170883|NCT02080234|GELOX
170884|NCT02080234|concurrent chemoradiotherapy
170885|NCT02080234|sIL-2R
170886|NCT02080221|metastatic pancreatic cancer
170887|NCT02080221|pancreatic cancer
170888|NCT02080221|metastatic
170889|NCT02080208|hypoxemia
170890|NCT02080208|high flow oxygen therapy
170891|NCT02080208|respiratory failure
170892|NCT02080182|Acute Pyelonephritis
170893|NCT02080182|Acetylcysteine
170894|NCT02080182|Pediatric
170895|NCT02080169|Intensive care unit
170896|NCT02080169|Mechanical ventilation
170897|NCT02080169|Combined sedation
170898|NCT02080156|Obstructive Sleep Apnea
170899|NCT02080156|Percutaneous Coronary Intervention
170900|NCT02080156|Coronary Artery Bypass Graft
170901|NCT02080156|Mortality
170902|NCT02080156|Questionnaire
170903|NCT02080156|Biomarker
170904|NCT02080143|Skin temperature measurements
170905|NCT02080143|Heat patch adhesion
170906|NCT02080143|Dermal irritation
170907|NCT02080130|Gastroenteritis
170908|NCT02080130|diarrhea
170909|NCT02080117|kidney transplantation
170910|NCT02080117|delayed graft function
170911|NCT02080117|creatinine
170912|NCT02080117|graft survival
170913|NCT02080104|postpartum hemorrhage
170914|NCT02080104|oxytocin
170915|NCT02080104|vaginal delivery
170916|NCT02080104|prophylactic
170917|NCT02080078|Erlotinib
170918|NCT02080078|Theophylline
170919|NCT02080078|Diarrhea
170920|NCT02080065|risk factor
170921|NCT02080065|acute kidney injury
170922|NCT02080065|liver transplantation
170923|NCT02080065|postoperative renal function
170924|NCT02080039|Spinal Cord Injury
170925|NCT02080039|Denervation
170926|NCT02080039|Electrical Stimulation
170927|NCT02080026|malaria
170928|NCT02080026|Plasmodium falciparum
170929|NCT02080000|Heart Failure
170930|NCT02080000|Cardiac Resynchronisation Therapy
170931|NCT02080000|Biventricular Pacemaker
170932|NCT02080000|Optimisation
170933|NCT02079987|Health Literacy
170934|NCT02079987|Care Transition Intervention
170935|NCT02079987|Emergency Department Population
170936|NCT02079987|Access to Care
170937|NCT02079974|endometriosis
170938|NCT02079974|pain
170939|NCT02079974|fertility
170940|NCT02079961|anemia
170941|NCT02079961|children
170942|NCT02079961|iron-fortified product
170943|NCT02079961|value chain
170944|NCT02079948|Aging
170945|NCT02079948|Cognitive Function
170946|NCT02079948|Physical Function
170947|NCT02079948|Systematic Inflammation
170948|NCT02079948|Methotrexate
170949|NCT02079948|Pain Symptoms
170950|NCT02079935|BN
170951|NCT02079935|Binge
170952|NCT02079935|overconsumption of food
170953|NCT02079935|purging
170954|NCT02079935|purge
170955|NCT02079922|Multiple Ascending Dose
170956|NCT02079922|healthy subjects
170957|NCT02079922|Hypercholesterolemia
170958|NCT02079922|Hyperlipidemias
170959|NCT02079922|Dyslipidemias
170960|NCT02079922|Lipid Metabolism Disorders
170961|NCT02079922|Metabolic Diseases
170962|NCT02079909|Alzheimer's Disease
170963|NCT02079909|Alzheimer's
170964|NCT02079896|Dialysis
170965|NCT02079844|Drug therapy
170966|NCT02079831|Adolescent obesity
170967|NCT02079831|childhood obesity
170968|NCT02079831|anthropometry
170969|NCT02079831|body weights and measures
170970|NCT02079818|visceral artery aneurysms
170971|NCT02079818|arteriovenous malformations
170972|NCT02079818|Penumbra Ruby Coil System
170973|NCT02079792|Budesonide
170974|NCT02079792|Mucosal Atomization Device
170975|NCT02079792|Head Position
170976|NCT02079779|Robotic-assisted therapy
170977|NCT02079779|Acute Stroke
170978|NCT02079779|International Classification of Functioning, Disability and Health
170979|NCT02079753|COPD, portable concentrator, oxygen sources
170980|NCT02079727|Condrosulf
170981|NCT02079727|Chondroitin sulfate
170982|NCT02079727|Celebrex
170983|NCT02079727|Knee OA
170984|NCT02079727|Knee osteoarthritis
170985|NCT02079714|Orthopaedic Trauma
170986|NCT02079714|Injury
170987|NCT02079701|pneumonia
170988|NCT02079701|pneumococcus
170989|NCT02079701|vaccine
170990|NCT02079701|23-valent pneumococcal vaccine
170991|NCT02079701|military recruits
170992|NCT02079688|Antisense oligonucleotide
170993|NCT02079688|atopic eczema
170994|NCT02079688|atopic dermatitis
170995|NCT02079688|Phase II
170996|NCT02079688|Transcription factor GATA-3
170997|NCT02079688|dermal application
170998|NCT02079688|Proof-of-Concept
170999|NCT02079662|Breast Cancer
171000|NCT02079662|Radiation Therapy
171001|NCT02079662|Radiotherapy
171002|NCT02079662|XRT
171003|NCT02079662|Aerobic Activity
171004|NCT02079662|Dietician Counseling
171005|NCT02079662|Dietary Assessment
171006|NCT02079662|Yoga
171007|NCT02079662|Cognitive Behavior Therapy
171008|NCT02079662|Smoking Cessation Counseling
171009|NCT02079662|Questionnaires
171010|NCT02079662|Surveys
171011|NCT02079662|Saliva Samples
171012|NCT02079662|Blood Samples
171013|NCT02079649|Allergic conjunctivitis
171014|NCT02079649|Red eyes
171015|NCT02079649|Eyelid swelling
171016|NCT02079649|Ragweed
171017|NCT02079649|Allergies
171018|NCT02079649|Itchy eyes
171019|NCT02079649|Ocular redness
171020|NCT02079649|Chemosis
171021|NCT02079649|Tearing
171022|NCT02079649|Watery eyes
171023|NCT02079623|Pancreatic cancer
171024|NCT02079623|Electroporation
171025|NCT02079623|Nano knife treatment
171026|NCT02079610|Depression
171027|NCT02079610|Neurofeedback
171028|NCT02079610|Amygdala
171029|NCT02079597|SIRS
171030|NCT02079597|Ninj1
171031|NCT02079597|Sepsis
171032|NCT02079597|Healthy
171033|NCT02079584|Patient Compliance
171034|NCT02079584|Target Specific Anticoagulant
171035|NCT02079584|Quality of Life
171036|NCT02079558|prevention
171037|NCT02079558|cesarean section
171038|NCT02079545|Healthy
171039|NCT02079545|Bioavailability
171040|NCT02079545|Pharmacokinetics
171041|NCT02079545|Sirukumab
171042|NCT02079545|Subcutaneous
171043|NCT02079545|Male
171044|NCT02079493|osteoarthritis
171045|NCT02079493|knee replacement
171046|NCT02079493|functional testing
171047|NCT02079467|Arthroplasty, Hip
171048|NCT02079467|Replacement, Hip
171049|NCT02079467|Postoperative Care
171050|NCT02079467|Rehabilitation
171051|NCT02079441|Anti- TNF
171052|NCT02079441|inflammatory bowel disease
171053|NCT02079441|pregnancy
171054|NCT02079441|infant
171055|NCT02079441|immunity
171056|NCT02079441|Immune function
171057|NCT02079428|Heart Failure
171058|NCT02079428|Registry
171059|NCT02079428|China
171060|NCT02079415|NICU
171061|NCT02079402|sepsis
171062|NCT02079402|septic
171063|NCT02079402|shock
171064|NCT02079402|ICU
171065|NCT02079402|intensive
171066|NCT02079402|critical
171067|NCT02079402|resuscitation
171068|NCT02079402|fluid
171069|NCT02079402|IV
171070|NCT02079402|crystalloid
171071|NCT02079402|balance
171072|NCT02079389|colon cancer
171073|NCT02079389|rectum cancer
171074|NCT02079389|laparoscopic ultrasound
171075|NCT02079389|LUS
171076|NCT02079389|Contrast enhanced ultrasound
171077|NCT02079389|CEUS
171078|NCT02079389|Peroperative TNM staging
171079|NCT02079389|screening for liver metastases
171080|NCT02079376|diabetes
171081|NCT02079363|Pancreatic Diseases
171082|NCT02079363|Pancreatic Neoplasms
171083|NCT02079363|Pancreatitis
171084|NCT02079363|DNA promoter hypermethylation
171085|NCT02079363|DNA methylation
171086|NCT02079363|Cell-free DNA
171087|NCT02079363|Plasma
171088|NCT02079324|head and neck cancer
171089|NCT02079324|gene therapy
171090|NCT02079324|stem cell therapy
171091|NCT02079324|immunotherappy
171092|NCT02079311|Patient warming
171093|NCT02079311|Active warming
171094|NCT02079311|Forced Air Warming
171095|NCT02079311|Warming blanket
171096|NCT02079272|Tomotherapy
171097|NCT02079272|Breast Cancer
171098|NCT02079272|Heart
171099|NCT02079272|Subclinical cardiac lesions
171100|NCT02079272|Myocardial lesions
171101|NCT02079272|Coronary lesions
171102|NCT02079272|Circulating biomarkers
171103|NCT02079272|Ionizing radiation
171104|NCT02079272|Heart absorbed doses
171105|NCT02079233|Basic Science
171106|NCT02079233|Safety
171107|NCT02079233|Tolerability
171108|NCT02079233|Efficacy of CLP
171109|NCT02079220|Colorectal Cancer
171110|NCT02079220|Metastatic Colorectal Cancer
171111|NCT02079194|Drug-eluting stents
171112|NCT02079194|aspirin
171113|NCT02079194|P2Y12 antagonist monotherapy
171114|NCT02079168|Keloid
171115|NCT02079168|Cicatrix
171116|NCT02079168|Keloid prevention
171117|NCT02079168|Keloid revision/excision
171118|NCT02079168|Keloidectomy
171119|NCT02079129|agreement between cMRI PVL grading and TTE PVL grading
171120|NCT02079129|Edwards Sapien TAVR
171121|NCT02079116|Obesity
171122|NCT02079116|Lipids
171123|NCT02079116|Single Photon Emission Computed Tomography
171124|NCT02079116|Functional Neuroimaging
171125|NCT02079103|Virtual reality
171126|NCT02079103|Stroke
171127|NCT02079103|Arm motor function
171128|NCT02079103|Neurorehabilitation
171129|NCT02079090|Propofol
171130|NCT02079090|Ketamine
171131|NCT02079090|Fentanyl
171132|NCT02079090|Procedural sedation
171133|NCT02079090|children
171134|NCT02079090|Emergency Department
171135|NCT02079077|HIV, Immune quiescence, ASA, Hydroxychloroquin
171136|NCT02079064|Splenectomy
171137|NCT02079064|Desflurane
171138|NCT02079064|Propofol
171139|NCT02079064|TCI
171140|NCT02079064|ROTEM
171141|NCT02079051|Obesity Physical Performance Weight loss Optifast
171142|NCT02079025|Prostate Biopsy
171143|NCT02079025|Ultrasound guided biopsy of the prostate
171144|NCT02079025|High-resolution ultrasound
171145|NCT02079012|Walking Program
171146|NCT02079012|Mental Disorders
171147|NCT02079012|Physical Activity
171148|NCT02079012|Physical Fitness
171149|NCT02079012|Anxiety
171150|NCT02079012|Depression
171151|NCT02079012|Self Determination
171152|NCT02078999|Mechanical ventilation, procalcitonin, c-reactive protein
171153|NCT02078986|Whole-Body-Electromyostimulation
171154|NCT02078986|High Intensity Resistance Exercise Training (HIT)
171155|NCT02078986|Lean Body Mass
171156|NCT02078986|Muscle Strength
171157|NCT02078973|Tolvaptan
171158|NCT02078973|L-NMMA
171159|NCT02078973|Healthy subjects
171160|NCT02078973|Nephrology
171161|NCT02078960|Chronic Phase
171162|NCT02078960|Accelerated Phase
171163|NCT02078960|CML
171164|NCT02078960|Chronic Myeloid Leukemia
171165|NCT02078947|Diastolic heart failure, Heart failure with preserved ejection fraction, exercise
171166|NCT02078934|Surgical Endoscopy
171167|NCT02078934|Morbid Obesity
171168|NCT02078934|Weight Loss
171169|NCT02078934|Bariatrics
171170|NCT02078934|Complex incisional hernia with mesh
171171|NCT02078908|Central blood pressure
171172|NCT02078908|Peripheral (brachial) blood pressure
171173|NCT02078908|Renal variables
171174|NCT02078908|Vasoactive hormones
171175|NCT02078908|Pharmacology
171176|NCT02078908|Pharmacokinetics
171177|NCT02078895|Lower Urinary tract discomfort (frequency, urgency, nocturia, dysuria) and pain associated with ureteral stent placement
171178|NCT02078882|Primary Biliary Cirrhosis
171179|NCT02078882|Ursodeoxycholic acid
171180|NCT02078882|Abatacept
171181|NCT02078882|Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)
171182|NCT02078843|NET
171183|NCT02078843|Gallium-68-DOTATATE
171184|NCT02078843|PET/CT
171185|NCT02078843|Indium-111-pentetreotide scintigraphy
171186|NCT02078843|octreoscan
171187|NCT02078843|GEP-NET
171188|NCT02078843|gastroenteropancreatic neuroendocrine tumors
171189|NCT02078830|Wound Contamination
171190|NCT02078817|Treatment-resistant
171191|NCT02078804|Colorectal cancer
171192|NCT02078804|Mortality
171193|NCT02078804|Incidence
171194|NCT02078804|Screening
171195|NCT02078804|Health-economy
171196|NCT02078791|Fibromyalgia
171197|NCT02078791|Group Problem Solving Technique
171198|NCT02078791|infiltration
171199|NCT02078778|Continuous airway pressure
171200|NCT02078778|Hypertension
171201|NCT02078778|Obstructive sleep apnea
171202|NCT02078765|hypertension
171203|NCT02078765|chronic kidneys disease
171204|NCT02078765|obstructive sleep apnea
171205|NCT02078765|24-h blood pressure
171206|NCT02078765|central blood pressure
171207|NCT02078765|peripheral blood pressure
171208|NCT02078752|ADC
171209|NCT02078752|PF-06647263
171210|NCT02078752|solid tumors
171211|NCT02078752|tumors
171212|NCT02078752|neoplasm metastasis
171213|NCT02078752|TNBC
171214|NCT02078752|Triple negative breast cancer
171215|NCT02078739|Yoga
171216|NCT02078739|COPD
171217|NCT02078739|Congestive Heart Failure
171218|NCT02078726|glucagon, screening colonoscopy
171219|NCT02078713|contraception
171220|NCT02078713|patient decision support
171221|NCT02078713|patient decision aid
171222|NCT02078713|shared decision making
171223|NCT02078713|Decision Making, Shared
171224|NCT02078713|Patient-Centered Outcomes Research
171225|NCT02078700|cancer
171226|NCT02078700|early palliative care
171227|NCT02078700|feasibility
171228|NCT02078687|very preterm
171229|NCT02078687|nutrition
171230|NCT02078687|6 year follow-up
171231|NCT02078687|growth
171232|NCT02078687|metabolic syndrome
171233|NCT02078687|allergy
171234|NCT02078687|dexa
171235|NCT02078674|H7N9
171236|NCT02078661|Keratoconjunctivitis sicca
171237|NCT02078661|Dry eye
171238|NCT02078648|Glioma Associated Antigen
171239|NCT02078648|Vaccine
171240|NCT02078648|Adult
171241|NCT02078648|Recurrent Glioblastoma
171242|NCT02078648|Immunotherapy
171243|NCT02078635|Arterial plaque
171244|NCT02078635|portfolio diet
171245|NCT02078635|dietary modification
171246|NCT02078635|dietary trials
171247|NCT02078635|Canadian Network
171248|NCT02078635|knowledge synthesis and translation
171249|NCT02078635|Magnetic resonance imaging
171250|NCT02078622|COPD
171251|NCT02078622|Respiratory Therapist
171252|NCT02078622|Case Management
171253|NCT02078622|Education
171254|NCT02078609|AML,
171255|NCT02078609|MDS,
171256|NCT02078609|PIM,
171257|NCT02078609|LGH447,
171258|NCT02078609|acute myelod leukemia,
171259|NCT02078609|myelodysplastic syndrome
171260|NCT02078596|temper outbursts
171261|NCT02078596|pediatric aggression
171262|NCT02078596|irritability
171263|NCT02078544|Cancer in Gynaecologic Oncology
171264|NCT02078505|Change in gut microbial population
171265|NCT02078505|polycystic ovary syndrome
171266|NCT02078505|gut microbiome
171267|NCT02078505|diet
171268|NCT02078479|Malignancy
171269|NCT02078479|VAS
171270|NCT02078479|LANSS
171271|NCT02078479|VDS
171272|NCT02078479|Neuropathic pain
171273|NCT02078479|rTMS
171274|NCT02078479|motor cortex
171275|NCT02078479|analgesia
171276|NCT02078466|Functional assessment
171277|NCT02078466|readmission
171278|NCT02078466|acute care
171279|NCT02078466|older medical patients
171280|NCT02078453|Dental caries
171281|NCT02078453|Diagnosis
171282|NCT02078453|Visual inspection
171283|NCT02078453|Radiographic examination
171284|NCT02078440|Type 2 Diabetes
171285|NCT02078440|Children
171286|NCT02078440|Adolescents
171287|NCT02078440|Bioavailability
171288|NCT02078440|Cycloset
171289|NCT02078440|Bromocriptine Mesylate
171290|NCT02078401|Optic pathway glioma
171291|NCT02078401|Ophthalmological screening
171292|NCT02078375|Rheumatoid Arthritis
171293|NCT02078323|Irritable Bowel Syndrome with Constipation (IBS-C)
171294|NCT02078323|Linaclotide
171295|NCT02078310|Dementia,
171296|NCT02078310|Healthy
171297|NCT02078310|geriatric
171298|NCT02078310|volunteers
171299|NCT02078310|patients
171300|NCT02078297|IL-23
171301|NCT02078297|IL-17A
171302|NCT02078297|Skin biopsies
171303|NCT02078284|platelet transfusion
171304|NCT02078258|depression，adolescent，attention bias，modification
171305|NCT02078245|Familial pancreatic cancer
171306|NCT02078245|Surveillance
171307|NCT02078245|Screening
171308|NCT02078232|fine needle aspiration under ultrasound endoscopy
171309|NCT02078232|solid pancreatic tumors
171310|NCT02078232|head of pancreas
171311|NCT02078232|19G Flex needle
171312|NCT02078232|22G standard needle
171313|NCT02078206|Critical illness
171314|NCT02078206|Neurocognition
171315|NCT02078206|Neurocognitive stimulation
171316|NCT02078206|Delirium
171317|NCT02078206|Virtual Reality
171318|NCT02078206|cognitive
171319|NCT02078206|rehabilitation
171320|NCT02078206|ICU
171321|NCT02078167|ipercholesterolemia not familiarity
171322|NCT02078154|D-Dimer
171323|NCT02078154|DVT
171324|NCT02078154|Wells score
171325|NCT02078141|18F-deoxyglucose (FDG) PET, idiopathic Dilated Cardiomyopathy
171326|NCT02078128|burn, wound healing, skin graft
171327|NCT02078089|Refractory cancer pain
171328|NCT02078076|MRI
171329|NCT02078076|free-breathing acquisitions
171330|NCT02078076|myopathy
171331|NCT02078076|fibrosis assessment
171332|NCT02078076|function
171333|NCT02078037|Intracerebral hemorrhage
171334|NCT02078037|Perihematomal edema
171335|NCT02078037|hemorrhage
171336|NCT02078037|normothermia
171337|NCT02078024|Onchocerciasis
171338|NCT02077985|autism
171339|NCT02077985|electrodermal activity
171340|NCT02077985|cooperation
171341|NCT02077985|anxiety
171342|NCT02077985|distress
171343|NCT02077985|stress
171344|NCT02077985|oral care
171345|NCT02077985|sensory processing
171346|NCT02077985|behavior
171347|NCT02077985|occupational therapy
171348|NCT02077972|PTSD
171349|NCT02077972|Military service
171350|NCT02077972|depression
171351|NCT02077972|Whole Body Hyperthermia (WBH)
171352|NCT02077959|Relapsed Multiple Myeloma
171353|NCT02077959|Refractory Multiple Myeloma
171354|NCT02077933|Solid tumors
171355|NCT02077933|renal cell carcinoma
171356|NCT02077933|pancreatic neuroendocrine tumors
171357|NCT02077933|breast cancer
171358|NCT02077933|PI3K inhibitor
171359|NCT02077933|BYL719
171360|NCT02077933|alpelisib
171361|NCT02077933|everolimus
171362|NCT02077933|exemestane
171363|NCT02077920|Ventilator-associated pneumonia VAP
171364|NCT02077920|Chlorhexidine
171365|NCT02077920|Oropharyngeal decontamination
171366|NCT02077920|Subglottic secretion drainage
171367|NCT02077894|Whole Genome Sequencing
171368|NCT02077894|Genetic Eye Disease
171369|NCT02077881|metastatic
171370|NCT02077881|metastasis
171371|NCT02077881|Pancreatic
171372|NCT02077881|Pancreas
171373|NCT02077881|Cancer
171374|NCT02077881|adenocarcinoma
171375|NCT02077868|CRC
171376|NCT02077868|mCRC
171377|NCT02077868|maintenance treatment
171378|NCT02077868|immune modulation
171379|NCT02077868|colorectal cancer
171380|NCT02077868|immunotherapy
171381|NCT02077868|metastatic
171382|NCT02077855|Sensitivity and Sensitivity
171383|NCT02077829|Implementation process
171384|NCT02077829|implementation strategy
171385|NCT02077829|Implementation research
171386|NCT02077829|evidence based practice
171387|NCT02077829|recovery
171388|NCT02077829|Illness management and recovery
171389|NCT02077816|body temperature
171390|NCT02077816|Thermometry
171391|NCT02077816|Infrared Rays
171392|NCT02077816|catheter related infection
171393|NCT02077803|Healthy
171394|NCT02077803|Canagliflozin
171395|NCT02077803|Metformin
171396|NCT02077803|Type 2 diabetes mellitus
171397|NCT02077803|Bioequivalence
171398|NCT02077803|GLUMETZA®
171399|NCT02077777|mesalazine
171400|NCT02077777|colon
171401|NCT02077777|cancer
171402|NCT02077764|heart transplantation,
171403|NCT02077764|rejection
171404|NCT02077764|cardiac vasculopathy
171405|NCT02077764|optical coherence tomography
171406|NCT02077764|speckle tracking
171407|NCT02077764|Positron Emission Tomography .
171408|NCT02077764|exercise capacity
171409|NCT02077738|effectiveness
171410|NCT02077738|elderly
171411|NCT02077738|high frequency chest wall oscillation
171412|NCT02077738|mechanical ventilation
171413|NCT02077738|pneumonia
171414|NCT02077738|randomized controlled trial
171415|NCT02077725|drug related problems
171416|NCT02077725|comprehensive medication review
171417|NCT02077725|quality of life
171418|NCT02077699|Lactobacillus casei DG
171419|NCT02077699|Irritable Bowel Syndrome
171420|NCT02077686|diabetes
171421|NCT02077686|education
171422|NCT02077686|randomized
171423|NCT02077686|prospective
171424|NCT02077673|GEJ-cancer
171425|NCT02077673|surgery
171426|NCT02077673|gastroesophageal resection
171427|NCT02077673|gastroesophageal anastomosis
171428|NCT02077673|anastomotic leakage
171429|NCT02077660|Green tea, aging, oxidation, anthropometrics.
171430|NCT02077647|Knee osteoarthritis
171431|NCT02077647|knee osteonecrosis
171432|NCT02077647|osteotomy
171433|NCT02077621|cancer-related fatigue
171434|NCT02077621|Palliative Abdominal Surgery
171435|NCT02077621|HRQL
171436|NCT02077608|In vitro fertilization
171437|NCT02077608|Embryotransfer
171438|NCT02077608|Hyaluronan
171439|NCT02077608|Pregnancy rate
171440|NCT02077608|Implantation rate
171441|NCT02077595|transcutaneous electrical nerve stimulation
171442|NCT02077595|transcranial magnetic stimulation
171443|NCT02077582|acute ischemic stroke
171444|NCT02077569|AKT inhibitor
171445|NCT02077569|AZD5363
171446|NCT02077569|Anti-tumour activity
171447|NCT02077569|Breast cancer
171448|NCT02077569|ER positive
171449|NCT02077569|Oestrogen positive
171450|NCT02077569|post menopausal
171451|NCT02077569|chemotherapy required
171452|NCT02077569|no prior cancer treatment
171453|NCT02077556|tacrolimus, everolimus, pharmacokinetics, drug interaction
171454|NCT02077530|Patients with metabolic syndrome age between 30 to 64: Central obesity (Men ≥ 90 cm Women ≥ 85 cm), Plasma triglycerides ≥ 150 mg/dL
171455|NCT02077530|HDL cholesterol Men < 40 mg/dL, Women < 50 mg/dL, Blood pressure ≥130/85 mm Hg (or treatment for hypertension),
171456|NCT02077530|Fasting plasma glucose ≥ 100 mg/dL
171457|NCT02077517|Roux en Y Gastric Bypass
171458|NCT02077517|Postoperative complications
171459|NCT02077517|Hand sewn anastomosis
171460|NCT02077517|Stapled anastomosis
171461|NCT02077491|Aged
171462|NCT02077491|Systemic Inflammatory Response Syndrome
171463|NCT02077491|Body Composition
171464|NCT02077491|Dietary Protein
171465|NCT02077465|COPD, chronic obstructive pulmonary disease; Phase 1b, Safety, Pharmacokinetics
171466|NCT02077452|Glucokinase activator
171467|NCT02077452|Phase I
171468|NCT02077452|Type 2 diabetes mellitus
171469|NCT02077439|Stroke
171470|NCT02077439|Hand
171471|NCT02077439|Upper Extremity
171472|NCT02077439|Robotics
171473|NCT02077426|Functional Capacity
171474|NCT02077426|Exercise Independence
171475|NCT02077426|Peripheral
171476|NCT02077426|Strength
171477|NCT02077413|muscle
171478|NCT02077413|eccentric exercise
171479|NCT02077413|T2 MRI
171480|NCT02077387|Inhibitory control
171481|NCT02077387|executive functioning
171482|NCT02077387|childhood obesity
171483|NCT02077387|preschool
171484|NCT02077387|snack foods
171485|NCT02077387|caloric intake
171486|NCT02077374|NAFLD
171487|NCT02077374|NASH
171488|NCT02077361|choroideremia
171489|NCT02077361|gene therapy
171490|NCT02077361|gene transfer
171491|NCT02077348|Diabetes Mellitus type I
171492|NCT02077348|Ketoacidosis
171493|NCT02077348|Insulin withdrawal
171494|NCT02077348|Growth hormone injection
171495|NCT02077348|Lipolysis and ATGL
171496|NCT02077335|Brachytherapy
171497|NCT02077335|Monotherapy
171498|NCT02077335|HDR
171499|NCT02077322|Merocel Middle Meatus Spacers
171500|NCT02077322|Silastic Middle Meatus Spacers
171501|NCT02077322|Functional Endoscopic Sinus Surgery
171502|NCT02077309|T2DM,
171503|NCT02077309|vascular inflammation,
171504|NCT02077309|18-FDG-PET,
171505|NCT02077309|plaque morphology,
171506|NCT02077309|MRI,
171507|NCT02077309|DPP-4 Inhibition
171508|NCT02077296|cytokines
171509|NCT02077296|predictive value
171510|NCT02077296|preoperative chemoradiotherapy
171511|NCT02077296|rectal cancer
171512|NCT02077283|NAFLD (non-alcoholic fatty liver disease, NAFLD)
171513|NCT02077283|urinary metabonomics
171514|NCT02077283|TCM pattern
171515|NCT02077283|"liver depression and spleen deficiency pattern,"
171516|NCT02077283|"damp-heat in the interior pattern"
171517|NCT02077270|colonoscopy
171518|NCT02077270|acupuncture
171519|NCT02077270|pain
171520|NCT02077244|patient
171521|NCT02077244|intensive care
171522|NCT02077244|follow up
171523|NCT02077244|post traumatic stress symptoms
171524|NCT02077244|randomized controlled trial
171525|NCT02077205|Diagnostic and Statistical Manual of Mental Disorders-IV/-5: Anxiety Disorders in children
171526|NCT02077179|Postpartum
171527|NCT02077179|Preeclampsia
171528|NCT02077179|Gestational Hypertension
171529|NCT02077179|Gestational Diabetes
171530|NCT02077179|Exercise Intervention
171531|NCT02077179|Dietary Intervention
171532|NCT02077179|Behavioral Intervention
171533|NCT02077179|Mobile Website
171534|NCT02077179|Mobile Application
171535|NCT02077166|DLBCL
171536|NCT02077101|HIV
171537|NCT02077101|Therapeutic vaccine
171538|NCT02077101|acceptability
171539|NCT02077101|representations
171540|NCT02077088|interventional
171541|NCT02077088|doubleblind
171542|NCT02077088|randomised
171543|NCT02077088|pediatric
171544|NCT02077088|prebiotic
171545|NCT02077088|atopic
171546|NCT02077088|dermatitis
171547|NCT02077088|infant
171548|NCT02077075|weight loss
171549|NCT02077075|healthy weight
171550|NCT02077075|overweight
171551|NCT02077075|body mass index greater that 25 kg/m2
171552|NCT02077062|hepatectomy,
171553|NCT02077062|liver regeneration
171554|NCT02077062|mediators
171555|NCT02077049|elderly
171556|NCT02077049|exercise program
171557|NCT02077049|self-training
171558|NCT02077049|mobility
171559|NCT02077049|computer-based learning games
171560|NCT02077049|serious game
171561|NCT02077049|balance
171562|NCT02077049|training adherence
171563|NCT02077049|training compliance
171564|NCT02077049|Kinect ®
171565|NCT02077049|Fit Bit ®
171566|NCT02077023|Stroke
171567|NCT02077023|Heart Attack
171568|NCT02077023|Asymptomatic Carotid Artery Disease
171569|NCT02077023|Atrial Fibrillation
171570|NCT02077010|milrinone
171571|NCT02077010|heart failure
171572|NCT02077010|cardiomyopathy
171573|NCT02077010|inhaled
171574|NCT02076997|Cancer
171575|NCT02076997|High Dose Methotrexate
171576|NCT02076984|Ventral hernia
171577|NCT02076984|Incisional hernia
171578|NCT02076984|Patient affected by ventral or incisional hernias
171579|NCT02076971|Lung transplant
171580|NCT02076971|Quantiferon
171581|NCT02076971|Immuknow
171582|NCT02076958|Implementation
171583|NCT02076958|Cancer
171584|NCT02076958|Early detection
171585|NCT02076958|Faith-based
171586|NCT02076958|Community health advisor
171587|NCT02076945|Regional anesthesia
171588|NCT02076945|Diabetic neuropathy
171589|NCT02076945|Ultrasound
171590|NCT02076919|LHA510
171591|NCT02076919|First in human
171592|NCT02076919|Safety
171593|NCT02076919|Tolerability
171594|NCT02076919|Pharmacokinetics
171595|NCT02076919|Elderly
171596|NCT02076919|Age-Related Macular Degeneration
171597|NCT02076919|AMD
171598|NCT02076919|Ocular
171599|NCT02076919|Eye drop
171600|NCT02076906|relapsed pediatric solid tumors
171601|NCT02076906|refractory pediatric solid tumors
171602|NCT02076906|high intensity focused ultrasound
171603|NCT02076893|Tonsillectomy
171604|NCT02076893|Pain management
171605|NCT02076893|Pediatrics
171606|NCT02076880|Type 2 diabetes
171607|NCT02076880|Obesity
171608|NCT02076880|Sleeve gastrectomy
171609|NCT02076880|Insulin
171610|NCT02076880|GLP-1
171611|NCT02076867|somatic symptoms and related disorders
171612|NCT02076867|somatic symptoms
171613|NCT02076867|psychodynamic psychotherapy
171614|NCT02076854|eating disorders
171615|NCT02076854|anorexia nervosa
171616|NCT02076854|treatment
171617|NCT02076854|technology
171618|NCT02076828|anemia
171619|NCT02076828|iron polymaltose complexes
171620|NCT02076828|iron zinc
171621|NCT02076815|myeloproliferative neoplasm
171622|NCT02076815|essential thrombocythemia
171623|NCT02076815|high risk patients
171624|NCT02076815|anagrelide
171625|NCT02076802|prehypertension
171626|NCT02076802|coronary atherosclerosis
171627|NCT02076802|cardiovascular disease
171628|NCT02076789|Device Replacement
171629|NCT02076789|Device Upgrade
171630|NCT02076789|Long-term Postoperative Complications
171631|NCT02076789|Resource consumption and associated costs after device replacement/upgrade
171632|NCT02076776|Stroke
171633|NCT02076776|Exercise
171634|NCT02076776|Rehabilitation
171635|NCT02076776|Neuroplasticity
171636|NCT02076776|Task Practice
171637|NCT02076763|Observational
171638|NCT02076763|Porphyria
171639|NCT02076750|Inflammatory Bowel Diseases
171640|NCT02076750|Vitamin D
171641|NCT02076750|Cholecalciferol
171642|NCT02076750|Skin Pigmentation
171643|NCT02076737|Model-based iterative reconstruction MB-IR
171644|NCT02076737|VEOTM
171645|NCT02076737|Ultra low-dose
171646|NCT02076737|Abdominal CT
171647|NCT02076737|Dose reduction
171648|NCT02076737|Adaptative statistical iterative reconstruction ASIR
171649|NCT02076737|Acute renal colic
171650|NCT02076724|Abdominal donor-site
171651|NCT02076724|Breast reconstruction
171652|NCT02076724|Synthetic mesh
171653|NCT02076724|Biological mesh
171654|NCT02076711|Aortic Stenosis
171655|NCT02076711|Myocardial efficiency
171656|NCT02076698|Deep Brain Stimulation
171657|NCT02076698|Anterior Nucleus of thalamus
171658|NCT02076698|Treatment refractory
171659|NCT02076698|Pharmacoresistant partial epilepsy
171660|NCT02076698|vagus nerve stimulation therapy
171661|NCT02076685|pharmacogenetics
171662|NCT02076685|anti-tuberculosis drug
171663|NCT02076685|genetic polymorphism
171664|NCT02076685|isoniazid
171665|NCT02076672|prevention
171666|NCT02076672|non-malignant asbestos-related disease
171667|NCT02076672|benign pleural disease
171668|NCT02076672|asbestosis
171669|NCT02076659|F8
171670|NCT02076659|IL10
171671|NCT02076659|Interleukin
171672|NCT02076659|monoclonal
171673|NCT02076659|antibody
171674|NCT02076659|Rheumatoid Arthritis
171675|NCT02076646|Interleukin
171676|NCT02076646|IL2
171677|NCT02076646|monoclonal
171678|NCT02076646|antibody
171679|NCT02076646|cytokine
171680|NCT02076646|Dacarbazine
171681|NCT02076646|metastatic
171682|NCT02076646|melanoma
171683|NCT02076646|tumor targeting
171684|NCT02076646|Dose definition
171685|NCT02076646|L19
171686|NCT02076633|L19
171687|NCT02076633|monoclonal
171688|NCT02076633|antibody
171689|NCT02076633|IL-2
171690|NCT02076633|TNFα
171691|NCT02076633|Interleukin
171692|NCT02076633|Phase II
171693|NCT02076633|metastatic melanoma
171694|NCT02076633|clinical stage III
171695|NCT02076633|Clinical stage IV M1a
171696|NCT02076620|L19
171697|NCT02076620|monoclonal
171698|NCT02076620|antibody
171699|NCT02076620|doxorubicin
171700|NCT02076620|TNFα
171701|NCT02076620|solid tumour
171702|NCT02076620|sarcoma, breast cancer, lung carcinomas, gynecological cancer
171703|NCT02076620|anthracycline
171704|NCT02076607|vertebra
171705|NCT02076607|column
171706|NCT02076607|lumbar
171707|NCT02076607|toracica
171708|NCT02076607|fracture
171709|NCT02076607|burst
171710|NCT02076568|diabetes
171711|NCT02076568|education
171712|NCT02076568|randomized
171713|NCT02076568|prospective
171714|NCT02076555|diabetes
171715|NCT02076555|education
171716|NCT02076555|randomized
171717|NCT02076555|prospective
171718|NCT02076542|diabetes
171719|NCT02076542|education
171720|NCT02076542|randomized
171721|NCT02076542|prospective
171722|NCT02076529|chemotherapy induced nausea vomiting
171723|NCT02076516|Drug-eluting Stent,Coronary Artery Disease
171724|NCT02076503|Neoplasm Staging
171725|NCT02076503|Positron-Emission Tomography
171726|NCT02076503|Magnetic Resonance Imaging
171727|NCT02076503|1-amino-3-fluorocyclobutane-1-carboxylic acid
171728|NCT02076490|Telerehabilitation, mirror therapy, phantom limb pain
171729|NCT02076477|intervention time
171730|NCT02076477|radiotherapy
171731|NCT02076477|oligometastatic
171732|NCT02076477|non-small cell lung cancer
171733|NCT02076438|antibiotics
171734|NCT02076438|diarrhea
171735|NCT02076438|c diff
171736|NCT02076438|Hospitalized patients
171737|NCT02076425|Depressive Disorder, Major
171738|NCT02076425|Child Psychiatry
171739|NCT02076425|Parent-Child Relationship
171740|NCT02076425|Therapy
171741|NCT02076399|Persistent Immune Thrombocytopenic Purpura
171742|NCT02076399|Chronic Immune Thrombocytopenic Purpura
171743|NCT02076360|Preoperative counseling
171744|NCT02076360|Patient satisfaction
171745|NCT02076360|Prolapse
171746|NCT02076360|Sacrocolpopexy
171747|NCT02076347|Metformin
171748|NCT02076347|Vitamin B12 Deficiency
171749|NCT02076347|Population Management
171750|NCT02076347|Pharmacist
171751|NCT02076334|compression, isokinetic, far-infrared
171752|NCT02076308|Acupuncture, ultrasound
171753|NCT02076295|Cognition
171754|NCT02076295|Cholinergic nicotinic receptors
171755|NCT02076295|Positron Emission Tomography
171756|NCT02076282|Stage III non-small cell lung cancer
171757|NCT02076282|Optimization
171758|NCT02076282|MRI
171759|NCT02076282|Radiotherapy
171760|NCT02076269|HRCT
171761|NCT02076269|Dry Powder Inhaler
171762|NCT02076269|COPD
171763|NCT02076269|Pharyngometry
171764|NCT02076269|Inhalation Profiles
171765|NCT02076256|helping relationships, healthy lifestyle, quality of life
171766|NCT02076243|cutaneous squamous cell carcinoma
171767|NCT02076243|SCC
171768|NCT02076243|abraxane
171769|NCT02076243|nab-paclitaxel
171770|NCT02076243|unresectable
171771|NCT02076243|metastatic
171772|NCT02076230|14C-TH-302
171773|NCT02076230|Advanced or Metastatic Solid Tumors
171774|NCT02076230|Evofosfamide
171775|NCT02076217|Highly Effective Contraception
171776|NCT02076217|Emergency Contraception
171777|NCT02076217|Birth Control
171778|NCT02076217|LARC (Long Acting Reversible Contraception)
171779|NCT02076217|HERC (Highly Effective Contraception)
171780|NCT02076204|Pregnancy
171781|NCT02076204|Postpartum programs
171782|NCT02076204|Infant health services
171783|NCT02076191|Ruxolitinib
171784|NCT02076191|Decitabine
171785|NCT02076191|Myeloproliferative Neoplasms
171786|NCT02076191|Combination Therapy
171787|NCT02076178|Pre-Exposure Prophylaxis
171788|NCT02076178|HIV integrase
171789|NCT02076178|Intramuscular Injection
171790|NCT02076178|GSK1265744
171791|NCT02076165|insomnia
171792|NCT02076165|women
171793|NCT02076152|Recurrent Glioblastoma
171794|NCT02076139|tuberculosis
171795|NCT02076139|treg
171796|NCT02076139|tolerance
171797|NCT02076139|probiotic
171798|NCT02076139|mycobacteria
171799|NCT02076126|Lung maturity
171800|NCT02076126|RDS
171801|NCT02076126|Prematurity
171802|NCT02076126|Lecithin-sphingomyelin ratio
171803|NCT02076126|Spectroscopy
171804|NCT02076126|Chemometrics
171805|NCT02076113|cervical spondylotic myelopathy
171806|NCT02076113|degenerative cervical spondylosis
171807|NCT02076113|spinal fusion
171808|NCT02076087|Subcutaneous adipose tissue
171809|NCT02076087|Lipectomy
171810|NCT02076061|COPD
171811|NCT02076061|Primary Care
171812|NCT02076061|Smoking
171813|NCT02076061|Smokers
171814|NCT02076061|ex-Smokers
171815|NCT02076061|Lung Cancer
171816|NCT02076061|Cardiovascular Disease
171817|NCT02076061|Proteomics
171818|NCT02076061|Biomarkers
171819|NCT02076061|Biobank
171820|NCT02076061|Disease Staging
171821|NCT02076061|Gold Stage
171822|NCT02076048|LCPUFA supplementation
171823|NCT02076048|Brain Imaging
171824|NCT02076048|MRI
171825|NCT02076048|MEG
171826|NCT02076035|low back pain
171827|NCT02076035|periduroscopy
171828|NCT02076035|genetic
171829|NCT02076035|genomic
171830|NCT02076035|inflammation
171831|NCT02076022|Fat Grafting
171832|NCT02076022|Pain at amputation site
171833|NCT02076022|prosthetic
171834|NCT02076009|Multiple Myeloma
171835|NCT02076009|Relapsed Multiple Myeloma
171836|NCT02076009|Refractory Multiple Myeloma
171837|NCT02076009|Daratumumab
171838|NCT02076009|Lenalidomide
171839|NCT02076009|Dexamethasone
171840|NCT02075996|pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,
171841|NCT02075983|HIV
171842|NCT02075983|Vaccine
171843|NCT02075983|Immunisation
171844|NCT02075983|DNA
171845|NCT02075983|Adverse events
171846|NCT02075983|Electroporation
171847|NCT02075983|Transcutaneous
171848|NCT02075983|GTU MultiHIV B Clade
171849|NCT02075983|Antibody
171850|NCT02075983|Intramuscular
171851|NCT02075983|Immunogenicity
171852|NCT02075970|Neonatal
171853|NCT02075970|Anemia
171854|NCT02075970|Transfusion
171855|NCT02075970|Erythropoetin
171856|NCT02075970|Epoetin Alpha
171857|NCT02075970|Red Blood Cell
171858|NCT02075970|Survival
171859|NCT02075970|Pharmacodynamics
171860|NCT02075970|Model
171861|NCT02075957|Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip
171862|NCT02075944|Aerobic exercise
171863|NCT02075944|Cognitive function
171864|NCT02075944|Executive function
171865|NCT02075944|Brain-derived neurotrophic factor
171866|NCT02075905|Barrett's Esophagus
171867|NCT02075905|Esophageal Adenocarcinoma
171868|NCT02075892|cordyceps, aerobic capacity, exercise performance, fatigue
171869|NCT02075853|Cerebral palsy
171870|NCT02075853|Pes planus
171871|NCT02075853|Calcaneal lengthening
171872|NCT02075827|Appetite, metabolism, sedentary behaviour, stress response
171873|NCT02075801|Sealant, Margins Defect, Amalgam
171874|NCT02075775|instability
171875|NCT02075749|irradiation
171876|NCT02075749|mucositis
171877|NCT02075749|triamcinolone acetonide
171878|NCT02075749|licorice
171879|NCT02075749|mucoadhesive film
171880|NCT02075710|Diet
171881|NCT02075710|Sugar
171882|NCT02075710|Cardiovascular
171883|NCT02075710|Lipid
171884|NCT02075697|psoriasis
171885|NCT02075697|biologic therapy
171886|NCT02075697|infliximab
171887|NCT02075697|etanercept
171888|NCT02075697|efalizumab
171889|NCT02075697|adalimumab
171890|NCT02075697|ustekinumab
171891|NCT02075697|methotrexate
171892|NCT02075697|cyclosporine
171893|NCT02075697|acitretin
171894|NCT02075671|Rosacea
171895|NCT02075671|Photodynamic Therapy
171896|NCT02075671|Aminolevulinic Acid
171897|NCT02075671|Papulopustular Rosacea
171898|NCT02075671|Blue Light
171899|NCT02075658|renal cell carcinoma
171900|NCT02075658|minimally invasive procedures
171901|NCT02075658|robotic nephrectomy
171902|NCT02075658|laparoscopic nephrectomy
171903|NCT02075658|pneumoperitoneum
171904|NCT02075658|trocars
171905|NCT02075658|AirSeal® IFS
171906|NCT02075632|Alclometasone dipropionate
171907|NCT02075632|Eczema
171908|NCT02075632|Psoriasis
171909|NCT02075632|Itch
171910|NCT02075619|Amlodipine
171911|NCT02075619|Healthy volunteers
171912|NCT02075619|Rosuvastatin
171913|NCT02075619|Dyslipidaemia
171914|NCT02075619|Pharmacokinetics
171915|NCT02075619|Hypertension
171916|NCT02075606|NET
171917|NCT02075606|Symptomatic response
171918|NCT02075606|Functioning NeuroEndocrine Tumours
171919|NCT02075606|midgut region
171920|NCT02075593|dolutegravir/abacavir/lamivudine fixed dose combination
171921|NCT02075593|pregnant women
171922|NCT02075593|once daily
171923|NCT02075593|antiretroviral therapy-naive
171924|NCT02075593|HIV-1 Infection
171925|NCT02075593|integrase inhibitor
171926|NCT02075580|cancer, quality of life, body-image, subcutaneous-implant
171927|NCT02075567|Diabetes Mellitus Type 1
171928|NCT02075567|Exercise
171929|NCT02075567|Insulin Reduction
171930|NCT02075567|Glucose
171931|NCT02075567|Hypoglycemia
171932|NCT02075567|Continuous Glucose Monitoring System
171933|NCT02075541|Immunogenicity
171934|NCT02075541|Observer-blind
171935|NCT02075541|Reactogenicity
171936|NCT02075541|Chronic Obstructive Pulmonary Disease
171937|NCT02075541|Safety
171938|NCT02075528|Paliperidone
171939|NCT02075528|Treatment response
171940|NCT02075528|Schizophrenia
171941|NCT02075528|Early prediction
171942|NCT02075528|Pharmacokinetics
171943|NCT02075515|Safety
171944|NCT02075515|Zoster
171945|NCT02075515|Immunogenicity
171946|NCT02075515|Adults
171947|NCT02075515|Consistency
171948|NCT02075502|claudication
171949|NCT02075502|community walking exercise
171950|NCT02075502|community-based participatory research
171951|NCT02075502|exercise adherence
171952|NCT02075502|endovascular therapy
171953|NCT02075489|Acupressure
171954|NCT02075489|Reiki
171955|NCT02075489|EEG
171956|NCT02075489|EMG
171957|NCT02075489|fatigue relief
171958|NCT02075489|veterans
171959|NCT02075476|Fracture-luxation
171960|NCT02075476|humeral proximal extremity
171961|NCT02075476|Hemiarthroplasty
171962|NCT02075476|reverse Arthroplasty
171963|NCT02075463|recombinant human erythropoietin
171964|NCT02075463|GSK1278863
171965|NCT02075463|hemodialysis
171966|NCT02075463|anemia
171967|NCT02075463|Hemoglobin
171968|NCT02075463|chronic rhEPO hyporesponsiveness
171969|NCT02075463|chronic kidney disease
171970|NCT02075463|erythropoiesis stimulating agents
171971|NCT02075463|pharmacokinetics
171972|NCT02075450|Cardiac
171973|NCT02075450|Arrest
171974|NCT02075450|Simulation
171975|NCT02075450|Feedback
171976|NCT02075437|Functional Abdominal Pain, Children
171977|NCT02075437|Finding a treatment or intervention for children
171978|NCT02075424|stress
171979|NCT02075424|cortisol
171980|NCT02075424|emergency call center
171981|NCT02075424|hospital staff
171982|NCT02075411|anterior cruciate ligament reconstruction
171983|NCT02075411|transplantation allografts
171984|NCT02075411|adolescent
171985|NCT02075411|nerve block
171986|NCT02075411|pain
171987|NCT02075398|Portable pulse oximeter
171988|NCT02075385|Dysphagia
171989|NCT02075385|speech language therapy
171990|NCT02075385|quality of life
171991|NCT02075385|induction chemotherapy
171992|NCT02075385|concurrent chemoradiotherapy
171993|NCT02075372|Chronic Total Occlusion of Coronary Artery
171994|NCT02075372|Percutaneous Coronary Intervention
171995|NCT02075372|Hybrid
171996|NCT02075372|Angioplasty
171997|NCT02075359|Total Energy Expenditure
171998|NCT02075359|Physical Activity Levels
171999|NCT02075359|Body Mass Index
172000|NCT02075359|Children
172001|NCT02075346|Patient safety monitors
172002|NCT02075320|CT
172003|NCT02075320|Chest
172004|NCT02075320|Lung
172005|NCT02075307|insulin
172006|NCT02075307|diabetes
172007|NCT02075307|obesity
172008|NCT02075307|DNA damage
172009|NCT02075307|metabolic syndrome
172010|NCT02075294|Aged
172011|NCT02075294|Hepatitis B, Chronic
172012|NCT02075294|Antiviral Agents
172013|NCT02075268|Korean
172014|NCT02075268|Healthy
172015|NCT02075268|Male
172016|NCT02075255|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids
172017|NCT02075242|HBV
172018|NCT02075229|Cochlear Implant
172019|NCT02075229|Post-lingual onset hearing loss
172020|NCT02075229|Profound hearing loss
172021|NCT02075229|Low Frequency hearing loss
172022|NCT02075229|Profound sensorineural hearing loss
172023|NCT02075229|High frequency hearing loss
172024|NCT02075229|CMS-eligible patients
172025|NCT02075216|Urinary Incontinence
172026|NCT02075216|Children
172027|NCT02075216|Bladder Exstrophy
172028|NCT02075216|Extrophy -Epispadias complex,
172029|NCT02075216|Modern staged repair,
172030|NCT02075216|Bladder neck reconstruction
172031|NCT02075203|BCG Vaccinated
172032|NCT02075177|neuroblastoma
172033|NCT02075164|Non-alcoholic Fatty Liver Disease
172034|NCT02075164|Non-alcoholic steatohepatitis
172035|NCT02075164|NAFLD
172036|NCT02075164|NASH
172037|NCT02075151|Bronchial Thermoplasty
172038|NCT02075125|Korea
172039|NCT02075125|Platelet inhibition
172040|NCT02075125|Prasugrel
172041|NCT02075125|Ticagrelor
172042|NCT02075125|ST-segment elevation myocardial infarction
172043|NCT02075112|Soy
172044|NCT02075112|Isoflavone
172045|NCT02075112|Radiation Therapy
172046|NCT02075112|Cisplatin
172047|NCT02075099|whole blood donation
172048|NCT02075099|donation water drink
172049|NCT02075099|isotonic drink
172050|NCT02075099|presyncopal and syncopal reactions
172051|NCT02075086|angiogenic switch
172052|NCT02075086|plasma cytokines
172053|NCT02075086|Colon cancer
172054|NCT02075073|Pharmacokinetics
172055|NCT02075060|low-grade
172056|NCT02075060|NMIBC
172057|NCT02075047|Bipolar I Disorder (current or most recent episode manic). Children and adolescents aged 10 to 17 years.
172058|NCT02075034|Myelodysplastic syndrome
172059|NCT02075034|MDS
172060|NCT02075034|Low risk
172061|NCT02075034|Intermediate-1 risk
172062|NCT02075034|Intermediate-2 risk
172063|NCT02075034|International Prognostic Scoring System
172064|NCT02075034|IPSS
172065|NCT02075021|relapsed
172066|NCT02075021|refractory
172067|NCT02075021|multiple myeloma
172068|NCT02075021|revlimid
172069|NCT02075021|lenalidomide
172070|NCT02075021|abraxane
172071|NCT02075021|n-paclitaxel
172072|NCT02075008|asthma
172073|NCT02075008|allergic asthma
172074|NCT02075008|QGE031
172075|NCT02075008|open-label
172076|NCT02075008|IgE
172077|NCT02075008|long-term safety
172078|NCT02074995|Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing
172205|NCT02074527|cardiac catheterization
172079|NCT02074982|chronic plaque type psoriasis, secukinumab, ustekinumab, inflammatory skin disease, scaling
172080|NCT02074969|re-operation rate
172081|NCT02074969|pertrochanteric fractures
172082|NCT02074969|GammaNail
172083|NCT02074969|PFNA
172084|NCT02074969|Tip-Apex-Distance
172085|NCT02074969|Parkers-Ratio
172086|NCT02074956|BCG Vaccinated
172087|NCT02074956|HIV Negative
172088|NCT02074943|Androgenetic Alopecia
172089|NCT02074917|anterior cruciate ligament
172090|NCT02074917|ACL
172091|NCT02074917|anterior cruciate ligament reconstruction
172092|NCT02074917|outcome assessment
172093|NCT02074917|outcome assessment, patient
172094|NCT02074917|treatment outcome
172095|NCT02074917|exercise test
172096|NCT02074917|anatomic
172097|NCT02074917|anatomical
172098|NCT02074917|single-bundle
172099|NCT02074917|force platform
172100|NCT02074917|postural balance
172101|NCT02074917|biomechanics
172102|NCT02074917|CT scan
172103|NCT02074917|X-ray computed tomography
172104|NCT02074917|tomography
172105|NCT02074917|diagnostic imaging
172106|NCT02074917|knee
172107|NCT02074917|knee injuries
172108|NCT02074917|joint instability
172109|NCT02074917|reconstructive surgical procedures
172110|NCT02074917|knee surgery
172111|NCT02074917|arthroscopy
172112|NCT02074917|athletes
172113|NCT02074917|sports medicine
172114|NCT02074917|humans
172115|NCT02074917|prospective studies
172116|NCT02074917|Randomized Controlled Trial
172117|NCT02074891|preexposure prophylaxis
172118|NCT02074891|PrEP
172119|NCT02074891|HIV
172120|NCT02074878|Breast Cancer
172121|NCT02074878|Metastatic
172122|NCT02074878|Crizotinib
172123|NCT02074878|Sunitinib
172124|NCT02074878|Xalcori
172125|NCT02074878|Sutent
172126|NCT02074839|acute myeloid leukemia
172127|NCT02074839|AML
172128|NCT02074839|myelodysplastic syndrome
172129|NCT02074839|MDS
172130|NCT02074839|hematologic malignancies
172131|NCT02074839|IDH
172132|NCT02074839|Untreated AML
172133|NCT02074839|IDH1
172134|NCT02074839|relapsed AML
172135|NCT02074839|refractory AML
172136|NCT02074813|Inspiratory muscle training
172137|NCT02074813|COPD
172138|NCT02074813|dyspnea
172139|NCT02074813|Multidimensional Dyspnea Profile questionnaire (MDP).
172140|NCT02074813|pulmonary rehabilitation
172141|NCT02074800|Healthy
172142|NCT02074800|CNTO 328
172143|NCT02074800|Sp2/0-derived CNTO 328
172144|NCT02074800|CHO-derived CNTO 328
172145|NCT02074800|Safety
172146|NCT02074800|Pharmacokinetics
172147|NCT02074774|nasal cannula, high flow oxygen therapy, pulse oximetry
172148|NCT02074761|sacroiliac joint fusion
172149|NCT02074761|SIJ fusion
172150|NCT02074761|SI joint
172151|NCT02074761|SIJ
172152|NCT02074748|Bunion
172153|NCT02074748|Foot Arch
172154|NCT02074748|Instability
172155|NCT02074735|alcohol dependence
172156|NCT02074735|alcohol abuse
172157|NCT02074709|Pain, Liposomal bupivacaine, Wound infiltration
172158|NCT02074696|brain derived neurotrophic factor
172159|NCT02074657|Immunotherapy
172160|NCT02074657|NKAEs
172161|NCT02074657|Expanded haploidentical natural killer cells
172162|NCT02074657|Activated natural killer cells
172163|NCT02074644|Prostatism
172164|NCT02074644|Randomized Controlled Trial
172165|NCT02074644|Embolization, Therapeutic
172166|NCT02074644|Hyperplasia
172167|NCT02074644|Prostatic Diseases
172168|NCT02074644|Genital Diseases, Male
172169|NCT02074631|bone mineral content
172170|NCT02074631|bone mineral density
172171|NCT02074631|bone formation
172172|NCT02074631|bone resorption
172173|NCT02074631|pamidronate
172174|NCT02074631|children
172175|NCT02074631|DXA
172176|NCT02074631|bone marrow transplant
172177|NCT02074618|Physical Therapy.
172178|NCT02074618|Exercise.
172179|NCT02074618|Rehabilitation.
172180|NCT02074618|Renal Insufficiency.
172181|NCT02074618|Quality of life.
172182|NCT02074605|Melanoma
172183|NCT02074605|Interferon
172184|NCT02074605|Cognition
172185|NCT02074592|Self assessment
172186|NCT02074592|Audit
172187|NCT02074592|Feedback
172188|NCT02074592|Quality
172189|NCT02074592|Ultrasound
172190|NCT02074592|Fetal
172191|NCT02074592|Biometry
172192|NCT02074579|Irritable Bowel Syndrome
172193|NCT02074579|Rome III criteria
172194|NCT02074579|abdominal bloating
172195|NCT02074579|natural
172196|NCT02074579|herbal
172197|NCT02074579|Kampo
172198|NCT02074579|Adult ages 18 to 65
172199|NCT02074579|Female subjects
172200|NCT02074566|Pulmonary Vein Isolation
172201|NCT02074566|Atrial fibrillation
172202|NCT02074566|Cryoballoon therapy
172203|NCT02074566|Duration
172204|NCT02074527|congenital heart disease
172206|NCT02074527|brazilian electronic registration
172207|NCT02074501|stroke
172208|NCT02074501|elderly
172209|NCT02074501|caregivers
172210|NCT02074501|empowerment
172211|NCT02074501|self-care
172212|NCT02074501|pilot study
172213|NCT02074488|balance
172214|NCT02074488|gait
172215|NCT02074462|Voriconazole
172216|NCT02074462|CRP
172217|NCT02074462|Inflammation
172218|NCT02074462|Pharmacokinetics
172219|NCT02074449|Pulmonary Arterial Hypertension
172220|NCT02074449|Right Ventricular Performance
172221|NCT02074449|Treprostinil
172222|NCT02074449|Remodulin
172223|NCT02074436|hematological malignancies
172224|NCT02074436|thrombocytopenia
172225|NCT02074436|aminocaproic acid
172226|NCT02074423|Cinnamon extract
172227|NCT02074423|Postprandial glycemia
172228|NCT02074423|Glycemic index
172229|NCT02074423|Pre-diabetes
172230|NCT02074423|Metabolic syndrome
172231|NCT02074371|coronary artery bypass surgery
172232|NCT02074371|cardiopulmonary bypass
172233|NCT02074371|ICU
172234|NCT02074371|postoperative respiratory depression
172235|NCT02074345|Drug therapy
172236|NCT02074345|Safety and immunogenicity of Hib vaccine
172237|NCT02074332|Obesity
172238|NCT02074332|Physical activity
172239|NCT02074332|Schoolchildren
172240|NCT02074332|Intervention Studies
172241|NCT02074319|Schizophrenia
172242|NCT02074319|Anti-Inflammatory
172243|NCT02074319|Methotrexate
172244|NCT02074319|Psychosis Not Otherwise Specified
172245|NCT02074306|endotracheal intubation
172246|NCT02074306|low energy ultrasound
172247|NCT02074306|sputum culture
172248|NCT02074293|Subdermal bloodless space
172249|NCT02074293|Subdermal injection
172250|NCT02074293|injectable EMG needle
172251|NCT02074293|electrical stimulation
172252|NCT02074293|MRI with Gadolinium
172253|NCT02074293|Cervical Dystonia
172254|NCT02074293|intramuscular injection
172255|NCT02074293|cervical dystonia,
172256|NCT02074280|rifaximin
172257|NCT02074280|endotoxemia
172258|NCT02074280|cirrhosis
172259|NCT02074280|advanced cirrhosis
172260|NCT02074228|Attention-deficit/hyperactivity disorder,
172261|NCT02074228|symptomatology,
172262|NCT02074228|neurocognitive endophenotype,
172263|NCT02074228|medication response
172264|NCT02074215|Mild Cognitive Impairment
172265|NCT02074215|Alzheimer's disease
172266|NCT02074215|Aerobic exercise
172267|NCT02074202|18F fluorocholine
172268|NCT02074202|18F fluorodeoxyglucose
172269|NCT02074202|hepatocellular carcinoma
172270|NCT02074202|PET CT scan
172271|NCT02074176|Attention-deficit/hyperactivity disorder
172272|NCT02074176|orexin A
172273|NCT02074176|mRNA
172274|NCT02074163|Subdermal bloodless space
172275|NCT02074163|Subdermal injection
172276|NCT02074163|injectable EMG needle
172277|NCT02074163|electrical stimulation
172278|NCT02074163|MRI with Gadolinium
172279|NCT02074163|Chronic Migraine
172280|NCT02074163|intramuscular injection
172281|NCT02074150|Subdermal bloodless space
172282|NCT02074150|Subdermal injection
172283|NCT02074150|injectable EMG needle
172284|NCT02074150|electrical stimulation
172285|NCT02074150|MRI with Gadolinium
172286|NCT02074150|Upper Limb Spasticity
172287|NCT02074150|intramuscular injection
172288|NCT02074111|Moyamoya disease
172289|NCT02074111|Intracranial atherosclerotic stroke
172290|NCT02074111|Intracranial steno-occlusive disease
172291|NCT02074111|ring finger 213 (RNF213) gene mutation
172292|NCT02074111|high-resolution MRI
172293|NCT02074098|intubation
172294|NCT02074098|Cardiopulmonary resuscitation
172295|NCT02074098|Manikin study
172296|NCT02074072|Endotracheal intubation
172297|NCT02074072|Left lateral tilt wedge
172298|NCT02074072|Maternal Cardiopulmonary Resuscitation
172299|NCT02074072|Manikin Study
172300|NCT02074020|SLE
172301|NCT02074020|Lupus
172302|NCT02074020|Lupus Erythematosus, Systemic
172303|NCT02074020|Autoimmune Diseases
172304|NCT02074020|A-623
172305|NCT02074020|Blisibimod
172306|NCT02074020|Nephritis
172307|NCT02074007|Acute Otitis Media
172308|NCT02074007|Pain
172309|NCT02074007|Ear Pain
172310|NCT02074007|Ear Ache
172311|NCT02074007|Ear infection
172312|NCT02074007|middle ear infection
172313|NCT02073994|chondrosarcoma
172314|NCT02073994|cholangiocarcinoma
172315|NCT02073994|glioma
172316|NCT02073994|advanced solid tumors
172317|NCT02073994|IDH1
172318|NCT02073994|AG-120
172319|NCT02073981|Parkinson Disease
172320|NCT02073955|Stroke
172321|NCT02073955|Validation
172322|NCT02073955|Community Health workers
172323|NCT02073955|stroke symptom questionnaire
172324|NCT02073916|Breast Cancer
172325|NCT02073916|HER2 positive Breast Cancer
172326|NCT02073903|dual handset interpreter phones
172327|NCT02073903|communication
172328|NCT02073903|14-042
172329|NCT02073890|traumatic Subarachnoid Haemorrhage
172330|NCT02073890|Head Trauma
172331|NCT02073890|Computed Tomography
172332|NCT02073877|Peri-implant dermatitis
172333|NCT02073864|Aortic valve stenosis, stenosis, intervention
172334|NCT02073851|TAVR
172335|NCT02073825|Computer-assisted interventions
172336|NCT02073825|Alcohol use disorders
172337|NCT02073825|At-risk drinking
172338|NCT02073825|Spouses
172339|NCT02073825|Military
172340|NCT02073825|Brief Intervention
172341|NCT02073773|stroke, virtual reality based therapy
172342|NCT02073760|Healthcare acquired infections
172343|NCT02073760|Cardiac Surgery
172344|NCT02073760|Sternal Superficial Wound Infection
172345|NCT02073760|Deep Sternal Infection
172346|NCT02073760|Mediastinitis
172347|NCT02073760|Thoracotomy
172348|NCT02073760|Conduit harvest or cannulation site
172349|NCT02073760|Sepsis
172350|NCT02073760|Pneumonia
172351|NCT02073747|Albuterol
172352|NCT02073747|Serum Lactate
172353|NCT02073747|Lactic Acidosis
172354|NCT02073747|Asthma
172355|NCT02073734|pelvic organ prolapse surgery
172356|NCT02073734|dexamethasone
172357|NCT02073734|postoperative nausea and vomiting
172358|NCT02073734|peroperative administration
172359|NCT02073695|Proximal humeral fracture
172360|NCT02073695|Shoulder
172361|NCT02073695|Orthopaedics
172362|NCT02073695|Neutral rotation brace
172363|NCT02073695|Polysling
172364|NCT02073669|latent tuberculosis
172365|NCT02073669|tuberculin skin test
172366|NCT02073669|Interferon gamma release assay
172367|NCT02073669|immigration
172368|NCT02073656|genotype 1
172369|NCT02073656|genotype 4
172370|NCT02073656|HIV
172371|NCT02073630|magnetoencephalography
172372|NCT02073630|non invasive brain stimulation
172373|NCT02073630|cerebellum
172374|NCT02073630|gamma rhythms
172375|NCT02073617|DynaCT
172376|NCT02073617|Aortic valve and root measurements
172377|NCT02073617|TAVR
172378|NCT02073604|Congenital mirror movements
172379|NCT02073604|SMA
172380|NCT02073604|Movement preparation
172381|NCT02073604|Movement lateralization
172382|NCT02073604|MRI
172383|NCT02073604|Transcranial magnetic stimulation
172384|NCT02073591|Children
172385|NCT02073591|Atopic Dermatitis
172386|NCT02073591|Ceradan
172387|NCT02073591|PEST
172388|NCT02073591|SCORAD
172389|NCT02073578|achalasia
172390|NCT02073578|POEM
172391|NCT02073578|peroral endoscopic myotomy
172392|NCT02073578|myotomy
172393|NCT02073578|Heller myotomy
172394|NCT02073565|intracoronary stent
172395|NCT02073565|drug eluting stent
172396|NCT02073565|sirolimus
172397|NCT02073565|endothelial progenitor cells
172398|NCT02073552|colon cleansing, bowel preparations; polyethyleneglycol
172399|NCT02073539|Chest compression
172400|NCT02073539|One accelerometer
172401|NCT02073539|Manikin Study
172402|NCT02073526|Antibodies, Monoclonal
172403|NCT02073526|Anti-TNF
172404|NCT02073526|TNF-alpha
172405|NCT02073526|Trough level
172406|NCT02073526|Drug concentration
172407|NCT02073526|ELISA
172408|NCT02073513|Spasticity, Hand Function, Cerebral Palsy, Kinesiotape
172409|NCT02073500|Peritoneal carcinomatosis
172410|NCT02073500|Peritoneal surface malignancy
172411|NCT02073500|Cytoreductive surgery
172412|NCT02073500|Hyperthermic intraperitoneal chemotherapy
172413|NCT02073500|CRS
172414|NCT02073500|HIPEC
172415|NCT02073500|Prognostic biomarker
172416|NCT02073500|Predictive biomarker
172417|NCT02073487|Neoadjuvant Breast Cancer
172418|NCT02073487|HER2 positive Breast Cancer
172419|NCT02073474|cannabinoids
172420|NCT02073474|Sativex
172421|NCT02073474|THC
172422|NCT02073474|delta-9-tetrahydrocannabinol
172423|NCT02073474|cannabidiol
172424|NCT02073474|CBD
172425|NCT02073474|Registry
172426|NCT02073474|Safety
172427|NCT02073474|MS
172428|NCT02073461|Acne Vulgaris
172429|NCT02073448|Acne Vulgaris
172430|NCT02073435|liver transplantation
172431|NCT02073435|living donor
172432|NCT02073435|Safety
172433|NCT02073422|Magnetic resonance imaging
172434|NCT02073422|Myocardial stress perfusion magnetic resonance imaging
172435|NCT02073422|Fractional flow reserve
172436|NCT02073422|Relaxometry
172437|NCT02073422|Coronary artery disease
172438|NCT02073409|Nontuberculous Mycobacteria
172439|NCT02073383|Axillary brachial plexus block
172440|NCT02073383|Ultrasound
172441|NCT02073383|Bupivacaine
172442|NCT02073344|obstructive sleep apnea
172443|NCT02073344|overhydration
172444|NCT02073344|end stage renal disease
172445|NCT02073344|renal transplantation
172446|NCT02073344|polysomnography
172447|NCT02073344|bioimpedance
172448|NCT02073344|leg fluid shift
172449|NCT02073344|neck circumference
172450|NCT02073331|Open heart surgery, cardiac repair
172451|NCT02073305|obstructive sleep apnea
172452|NCT02073305|end stage renal disease
172453|NCT02073305|cardiovascular events
172454|NCT02073240|Tuberculosis
172455|NCT02073240|Infection Control
172456|NCT02073227|Healthy Volunteers
172457|NCT02073227|Canagliflozin
172458|NCT02073227|Metformin
172459|NCT02073227|Type 2 diabetes mellitus
172460|NCT02073175|Postpartum
172461|NCT02073175|Dietary Supplements
172462|NCT02073175|Mood Symptoms
172463|NCT02073149|Iron
172464|NCT02073149|Anemia
172465|NCT02073149|Sodium Fe(III)-ethylenediaminetetraacetic acid (NaFeEDTA)
172466|NCT02073149|Ferrous compounds
172467|NCT02073149|Child, preschool
172468|NCT02073149|Kenya
172469|NCT02073123|Metastatic melanoma
172470|NCT02073123|Stage III melanoma
172471|NCT02073123|Stage IV melanoma
172472|NCT02073123|unresectable
172473|NCT02073110|Kidney cancer
172474|NCT02073110|Renal mass
172475|NCT02073110|Small renal mass
172476|NCT02073110|Optical Coherence Tomography
172477|NCT02073110|OCT
172478|NCT02073110|Diffuse Reflectance Spectroscopy
172479|NCT02073110|DRS
172480|NCT02073110|Optical Biopsy
172481|NCT02073110|OB
172482|NCT02073058|Subjects with Type 1 or Type 2 Diabetes Requiring Multiple daily Insulin Injection (MDI) or Continuous Subcutaneous Insulin Infusion (CSII)
172483|NCT02073032|Refeeding syndrome, risk factors, head and neck cancer
172484|NCT02073006|Chronic
172485|NCT02073006|Functional
172486|NCT02073006|Constipation
172487|NCT02073006|less than 3 bowel movements per week
172488|NCT02072993|Phase I, healthy, pharmacokinetics
172489|NCT02072980|DT1
172490|NCT02072980|DAILIES TOTAL1®
172491|NCT02072980|Lubricity
172492|NCT02072967|Relapsed
172493|NCT02072967|Refractory
172494|NCT02072967|Non-Hodgkin Lymphoma
172495|NCT02072967|Bendamustine
172496|NCT02072941|Advance care planning
172497|NCT02072941|Latino Health
172498|NCT02072941|Medical decision making
172499|NCT02072941|Health Literacy
172500|NCT02072941|Limited English proficiency
172501|NCT02072941|Aging
172502|NCT02072902|Cohort
172503|NCT02072902|Historical
172504|NCT02072902|Prospective
172505|NCT02072902|Medications
172506|NCT02072902|Observational
172507|NCT02072902|Glucose
172508|NCT02072902|Control
172509|NCT02072889|Cardiac Surgery
172510|NCT02072889|Internal Jugular Cannulation
172511|NCT02072889|Optimal Neck Angle
172512|NCT02072876|Stroke
172513|NCT02072876|Asymptomatic Intracranial Atherosclerotic Disease
172514|NCT02072876|Lifestyle and socio-economic risk factors
172515|NCT02072876|Clinical predictors
172516|NCT02072850|Myocardial infarction
172517|NCT02072850|Primary percutaneous coronary intervention (PCI)
172518|NCT02072850|Thrombolysis
172519|NCT02072850|Rescue PCI
172520|NCT02072850|Electrocardiogram
172521|NCT02072850|Magnetic resonance imaging
172522|NCT02072850|Area-at-risk
172523|NCT02072850|Myocardial salvage
172524|NCT02072850|Infarct size
172525|NCT02072850|Pressure wire
172526|NCT02072850|Coronary thermodilution
172527|NCT02072850|Coronary microvascular function
172528|NCT02072850|Index of microvascular resistance
172529|NCT02072850|Heart failure
172530|NCT02072850|Prognosis
172531|NCT02072837|hemodialysis, dyslipidemia, cardiovascular disease
172532|NCT02072824|Partial Onset Seizures
172533|NCT02072824|Epilepsy
172534|NCT02072824|Safety
172535|NCT02072824|Efficacy
172536|NCT02072824|Tolerability
172537|NCT02072824|Pregabalin
172538|NCT02072824|Lyrica
172539|NCT02072824|Adjunctive treatment
172540|NCT02072824|Placebo controlled
172541|NCT02072824|blinded
172542|NCT02072824|Eligibility Criteria
172543|NCT02072811|AML
172544|NCT02072798|Randomized Controlled Trial
172545|NCT02072798|Caesarean Section
172546|NCT02072798|Surgical Site Infections
172547|NCT02072798|Wound Infections
172548|NCT02072798|Infectious Morbidity
172549|NCT02072785|Adult Acute Lymphoblastic Leukemia
172550|NCT02072785|Vincristine Sulfate Liposome
172551|NCT02072785|Vincristine Sulfate
172552|NCT02072759|Insulin sensitivity
172553|NCT02072759|Metabolic flexibility
172554|NCT02072746|cirrhosis
172555|NCT02072746|alcohol
172556|NCT02072733|frailty
172557|NCT02072733|oncogeriatrics
172558|NCT02072733|Multidisciplinary intervention
172559|NCT02072733|multimorbidity
172560|NCT02072733|Comprehensive geriatric assessment
172561|NCT02072733|patients
172562|NCT02072720|Radiotherapy
172563|NCT02072720|VEGF
172564|NCT02072720|esophagus carcinoma
172565|NCT02072720|bevacizumab
172566|NCT02072707|Ventricular Tachycardia
172567|NCT02072707|RF ablation
172568|NCT02072707|Epicardial Access
172569|NCT02072707|Contact Sensor Irrigated tip catheter
172570|NCT02072694|Obesity
172571|NCT02072694|Single Photon Emission Computed Tomography
172572|NCT02072694|Functional Neuroimaging
172573|NCT02072668|sickle cell anemia
172574|NCT02072668|sickle cell disease
172575|NCT02072668|rivaroxaban
172576|NCT02072668|direct Xa inhibition
172577|NCT02072668|coagulation
172578|NCT02072668|anticoagulation
172579|NCT02072629|Antimalarials
172580|NCT02072629|Antibiotics
172581|NCT02072629|ORS Zn
172582|NCT02072629|Village Health Volunteers
172583|NCT02072629|Integrated Community Case Management
172584|NCT02072616|Circulating Tumor Cells
172585|NCT02072616|pancreatic adenocarcinoma
172586|NCT02072616|circulating tumor DNA (KRAS)
172587|NCT02072616|CA 19.9
172588|NCT02072603|Infant HIV
172589|NCT02072603|Kenya
172590|NCT02072603|HITSystem
172591|NCT02072603|EID care
172592|NCT02072603|Early Infant Diagnosis
172593|NCT02072590|Celiac disease
172594|NCT02072590|Eosinophilic esophagitis
172595|NCT02072590|Endomysial antibodies
172596|NCT02072590|Transglutaminase antibodies
172597|NCT02072590|Small-bowel
172598|NCT02072577|Nursing care, oral health, educational video, oral hygiene.
172599|NCT02072538|Stress testing
172600|NCT02072538|Troponin T
172601|NCT02072538|GRACE score
172602|NCT02072538|Outcome
172603|NCT02072525|Pertussis
172604|NCT02072525|Healthy adults
172605|NCT02072525|Tetanus
172606|NCT02072525|Human serum samples
172607|NCT02072525|Streptococcus
172608|NCT02072525|Diphtheria
172609|NCT02072525|Plasma
172610|NCT02072525|Meningococcus
172611|NCT02072512|pre- and perimenopausal HR+ advanced breast cancer
172612|NCT02072473|Re-entrant Atrioventricular Node Tachycardia
172613|NCT02072473|Unsuccessful right-sided slow pathway ablation
172614|NCT02072473|Coronary sinus / left-sided slow pathway ablation
172615|NCT02072447|absolute bioavailability,
172616|NCT02072447|microdose,
172617|NCT02072447|AMS
172618|NCT02072434|Atrial fibrillation
172619|NCT02072434|anti-coagulant
172620|NCT02072434|warfarin
172621|NCT02072434|edoxaban
172622|NCT02072434|electrical cardioversion
172623|NCT02072395|morbid obesity
172624|NCT02072395|bariatric surgery
172625|NCT02072395|gastric banding
172626|NCT02072395|gastric plication
172627|NCT02072382|Hypertension
172628|NCT02072382|Metformin
172629|NCT02072382|Ambulatory blood pressure monitor
172630|NCT02072369|stroke
172631|NCT02072369|hand
172632|NCT02072369|fingers
172633|NCT02072369|rehabilitation
172634|NCT02072369|training
172635|NCT02072356|Humanitarian Device
172636|NCT02072356|Carcinoma
172637|NCT02072356|Hepatocellular Carcinoma
172638|NCT02072356|TheraSphere®
172639|NCT02072356|HUD
172640|NCT02072343|Capnography
172641|NCT02072343|Catheters
172642|NCT02072343|Intubation
172643|NCT02072330|Hypertension, Drug therapy
172644|NCT02072317|PFS
172645|NCT02072304|mood disorder
172646|NCT02072304|depressive disorder
172647|NCT02072304|mental disorders
172648|NCT02072304|program acceptability
172649|NCT02072304|behavioral symptoms
172650|NCT02072304|suicidal ideation
172651|NCT02072304|patient adherence
172652|NCT02072265|infrared thermal image
172653|NCT02072265|wound healing
172654|NCT02072265|wound infection
172655|NCT02072252|Major Depressive Disorder
172656|NCT02072252|Generalized Anxiety Disorder
172657|NCT02072252|Mobile Phone
172658|NCT02072252|Cellular Phone
172659|NCT02072252|Mobile Application
172660|NCT02072252|Mobile Intervention
172661|NCT02072252|App
172662|NCT02072252|mHealth
172663|NCT02072252|eHealth
172664|NCT02072252|Technology Assisted
172665|NCT02072252|Internet
172666|NCT02072252|Cognitive Behavioral Therapy
172667|NCT02072252|LGBT
172668|NCT02072252|Sexual Minorities
172669|NCT02072252|Gay
172670|NCT02072252|Bisexual
172671|NCT02072252|Same Sex Attraction
172672|NCT02072252|Males
172673|NCT02072252|Men
172674|NCT02072252|Youth
172675|NCT02072252|Adolescents
172676|NCT02072252|Young Adults
172677|NCT02072239|CABG
172678|NCT02072239|Intimal Hyperplasia
172679|NCT02072239|Atherosclerosis
172680|NCT02072239|Myocardial Infarction
172681|NCT02072213|Tamsulosin,controlled release formulation
172682|NCT02072200|RA, MS, Safety, Efficacy, MR prednisone
172683|NCT02072187|Depression
172684|NCT02072187|Vitamin D
172685|NCT02072187|Complementary and Alternative Medicine
172686|NCT02072187|Supplements
172687|NCT02072187|Non Remitted Depression
172688|NCT02072161|Statin
172689|NCT02072161|LDL
172690|NCT02072161|Cholesterol
172691|NCT02072148|Human Papilloma Virus
172692|NCT02072148|Oropharyngeal Squamous Cell Carcinoma
172693|NCT02072148|Transoral Robotic Surgery
172694|NCT02072122|dry eye
172695|NCT02072122|fertility treatment
172696|NCT02072122|Meibomian gland dysfunction
172697|NCT02072122|supra physiologic estrogen level
172698|NCT02072109|Near infrared spectroscopy
172699|NCT02072109|Bolus nutrition
172700|NCT02072109|Continuous nutrition
172701|NCT02072109|Mesenteric circulation
172702|NCT02072083|dexmedetomidine
172703|NCT02072083|intranasal
172704|NCT02072083|strabismus surgery
172705|NCT02072083|premedication
172706|NCT02072083|oculocardiac reflex
172707|NCT02072070|chondrocyte cells, Osteoarthritis, gene therapy
172708|NCT02072044|Renal Cell Carcinoma（RCC）
172709|NCT02072044|Anlotinib
172710|NCT02072031|Anlotinib
172711|NCT02072031|Sunitinib
172712|NCT02072031|Renal Cell Carcinoma（RCC）
172713|NCT02072018|Peyronie's
172714|NCT02072018|Peyronie's disease
172715|NCT02072018|Treatment
172716|NCT02072018|Clinical Study
172717|NCT02071979|Chronic
172718|NCT02071979|Non-healing
172719|NCT02071979|Wounds
172720|NCT02071966|Micro-RNA, Microparticles, Ticagrelor, NSTE-ACS
172721|NCT02071940|Acral Melanoma subtypes
172722|NCT02071940|Mucosal Melanoma subtypes
172723|NCT02071927|leukemia
172724|NCT02071927|glutaminase
172725|NCT02071927|glutamine
172726|NCT02071888|Non-Hodgkin's lymphoma
172727|NCT02071888|Waldenstrom's macroglobulinemia
172728|NCT02071888|Multiple myeloma
172729|NCT02071888|glutaminase
172730|NCT02071888|glutamine
172731|NCT02071875|Vasospasm
172732|NCT02071875|Aneurysm
172733|NCT02071875|SAH
172734|NCT02071875|Nautilus NeuroWave
172735|NCT02071862|Tumor metabolism
172736|NCT02071862|Glutaminase
172737|NCT02071862|Glutamine
172738|NCT02071862|Tricarboxylic acid (TCA) cycle
172739|NCT02071849|Aortic Insufficiency
172740|NCT02071849|Aortic Regurgitation
172741|NCT02071836|web application
172742|NCT02071836|DWI intervention
172743|NCT02071836|DUI intervention
172744|NCT02071836|Experimental group: Right Turns + treatment as usual
172745|NCT02071836|Control group: Treatment as usual
172746|NCT02071823|Opicapone,
172747|NCT02071823|Parkinson,
172748|NCT02071823|Bial,
172749|NCT02071823|BIA 9-1067
172750|NCT02071810|Parkinson's disease (PD)
172751|NCT02071810|Opicapone
172752|NCT02071810|Bial
172753|NCT02071810|BIA 9-1067
172754|NCT02071797|Therapeutic Hypothermia
172755|NCT02071797|Cardiac Arrest
172756|NCT02071797|Randomised Controlled trial
172757|NCT02071797|Pilot study
172758|NCT02071771|DACP Toric
172759|NCT02071771|DAILIES® AquaComfort Plus®
172760|NCT02071771|Astigmatism
172761|NCT02071771|Toric
172762|NCT02071758|Leishmaniasis
172763|NCT02071758|Visceral leishmaniasis
172764|NCT02071758|Vaccine
172765|NCT02071758|Adjuvant
172766|NCT02071758|GLA
172767|NCT02071758|SLA
172768|NCT02071693|subthalamic nucleus
172769|NCT02071693|deep brain stimulation
172770|NCT02071693|cognition
172771|NCT02071693|white matter hyperintensities
172772|NCT02071680|atrial fibrillation
172773|NCT02071680|atrial cardiac innervation
172774|NCT02071680|catheter ablation of atrial fibrillation
172775|NCT02071680|High Frequency Stimulation
172776|NCT02071680|ganglionated plexuses
172777|NCT02071680|123I-mIBG
172778|NCT02071680|nuclear imaging
172779|NCT02071667|Chronic sinusitis
172780|NCT02071667|Nasal Polyps
172781|NCT02071654|Venus P-valve
172782|NCT02071615|Brain Activity
172783|NCT02071602|Heart attack
172784|NCT02071602|Myocardial Infarction
172785|NCT02071602|STEMI
172786|NCT02071576|Myopia
172787|NCT02071576|Hyperopia
172788|NCT02071576|Proscan
172789|NCT02071576|LASIK
172790|NCT02071576|TENEO
172791|NCT02071576|Excimer
172792|NCT02071550|laparoscopic cholecystectomy, near infrared spectroscopy, positive end expiratory pressure
172793|NCT02071498|Pillbox
172794|NCT02071498|Non-adherence
172795|NCT02071498|Applications
172796|NCT02071498|Patient safety
172797|NCT02071498|Elderly
172798|NCT02071459|L-threo DOPS (DroxiDopa)
172799|NCT02071459|Orthostatic Hypotension
172800|NCT02071459|Multiple system atrophy
172801|NCT02071446|Deep Brain Stimulation
172802|NCT02071446|Local Field Potential
172803|NCT02071446|Subthalamic Nucleus
172804|NCT02071433|Saphenous nerve block
172805|NCT02071433|Adductor canal block
172806|NCT02071433|Anterior cruciate ligament
172807|NCT02071433|Pain management
172808|NCT02071433|Day care
172809|NCT02071407|traumatic brain injury
172810|NCT02071407|sedation
172811|NCT02071407|midazolam
172812|NCT02071394|Xenon
172813|NCT02071394|Hypothermia
172814|NCT02071394|Hypoxic Ischemic Encephalopathy
172815|NCT02071394|Newborn
172816|NCT02071394|Neonate
172817|NCT02071394|Term
172818|NCT02071394|Neuroprotection
172819|NCT02071394|Cooling
172820|NCT02071394|HIE
172821|NCT02071368|Healthy
172822|NCT02071368|Canagliflozin
172823|NCT02071368|Metformin
172824|NCT02071368|JNJ-28431754
172825|NCT02071368|GLUMETZA®
172826|NCT02071368|Bioequivalence
172827|NCT02071368|Fixed Dose Combination
172828|NCT02071355|Healthy
172829|NCT02071355|Chinese participants
172830|NCT02071355|TMC435
172831|NCT02071355|Multiple oral doses
172832|NCT02071355|Pharmacokinetics
172833|NCT02071355|Safety
172834|NCT02071355|Tolerability
172835|NCT02071342|acute myocardial infarction
172836|NCT02071342|bioresorbable vascular scaffold
172837|NCT02071342|percutaneous coronary intervention
172838|NCT02071329|FP-01.1
172839|NCT02071329|Influenza A
172840|NCT02071329|Flu
172841|NCT02071329|Vaccine
172842|NCT02071329|Virus
172843|NCT02071329|H1N1
172844|NCT02071329|Challenge
172845|NCT02071316|upper gastrointestinal bleeding
172846|NCT02071316|Hexacapron
172847|NCT02071316|hemostasis
172848|NCT02071303|Pain
172849|NCT02071303|Hysteroscopy
172850|NCT02071303|Tramadol
172851|NCT02071303|Celecoxib
172852|NCT02071290|Hemorrhagic Shock
172853|NCT02071290|Remote Ischemic Conditioning
172854|NCT02071277|Mechanical ventilation
172855|NCT02071277|Airway pressure release ventilation
172856|NCT02071277|Biphasic intermittent positive airway pressure
172857|NCT02071277|Pressure-controlled ventilation
172858|NCT02071277|Lung protective ventilation
172859|NCT02071277|Spontaneous breathing
172860|NCT02071264|HIV/AIDS
172861|NCT02071264|sex work
172862|NCT02071264|reproductive health
172863|NCT02071264|human rights
172864|NCT02071264|ethics
172865|NCT02071251|Wound complications
172866|NCT02071251|Wound infection
172867|NCT02071251|Wound separation
172868|NCT02071238|Carpal tunnel
172869|NCT02071238|Carpal tunnel release
172870|NCT02071238|Risk Recall
172871|NCT02071238|Patient satisfaction
172872|NCT02071238|Pamphlet
172873|NCT02071238|Brochure
172874|NCT02071199|Gingivitis
172875|NCT02071199|Periodontitis
172876|NCT02071199|ACCS
172877|NCT02071160|HIE
172878|NCT02071160|hypothermia
172879|NCT02071160|encephalopathy
172880|NCT02071160|anti oxidants
172881|NCT02071160|MRI
172882|NCT02071147|Follow-up
172883|NCT02071147|No follow-up
172884|NCT02071147|removal
172885|NCT02071147|Randomised Controlled Trial
172886|NCT02071147|6 Weeks
172887|NCT02071134|Deep brain stimulation
172888|NCT02071134|Parkinson's disease
172889|NCT02071134|Vercise
172890|NCT02071121|BIIB061
172891|NCT02071121|Healthy
172892|NCT02071095|Human immunodeficiency virus 1
172893|NCT02071095|Combined Antiretroviral Therapy
172894|NCT02071095|Poly-ICLC
172895|NCT02071095|Adjuvant
172896|NCT02071082|HIV
172897|NCT02071082|HBV
172898|NCT02071082|Coinfection
172899|NCT02071069|Incurable colorectal cancer
172900|NCT02071069|maintenance therapy
172901|NCT02071069|Cetuximab
172902|NCT02071043|neo-adjuvant chemotherapy
172903|NCT02071043|advanced gastric cancer patients
172904|NCT02071043|para-aortic lymph node metastasis
172905|NCT02071030|CBCT
172906|NCT02071030|Third molar removal
172907|NCT02071030|Inferior alveolar nerve injury
172908|NCT02071004|acute ischemic stroke
172909|NCT02070991|pre- and post-capillary pulmonary hypertension
172910|NCT02070991|CpcPH
172911|NCT02070978|Lupus Erythematosus, Systemic
172912|NCT02070978|Atacicept 75 and 150 mg
172913|NCT02070978|LTE
172914|NCT02070952|CyberKnife
172915|NCT02070952|Stereotactic Body Radiation Therapy
172916|NCT02070952|Low and Intermediate Risk Prostate Cancer
172917|NCT02070939|Phase 1
172918|NCT02070939|Randomized
172919|NCT02070939|Double Blind
172920|NCT02070939|Placebo-Controlled
172921|NCT02070939|Single and Multiple Dose Escalation
172922|NCT02070939|Safety Tolerability
172923|NCT02070939|PK
172924|NCT02070939|PD
172925|NCT02070939|PF-06460414
172926|NCT02070913|Hypothermia
172927|NCT02070913|Acute Myocardial Infarction
172928|NCT02070913|Percutaneous Coronary Intervention
172929|NCT02070913|AMI
172930|NCT02070913|PCI
172931|NCT02070913|Therapeutic Hypothermia
172932|NCT02070900|Prevention of Mother to Child Transmission
172933|NCT02070900|PMTCT
172934|NCT02070900|Option B+
172935|NCT02070900|ART
172936|NCT02070900|Retention
172937|NCT02070900|Loss to Follow Up
172938|NCT02070900|Time to initiation
172939|NCT02070900|POC CD4
172940|NCT02070900|Clinical mentoring
172941|NCT02070900|Costing
172942|NCT02070900|HIV
172943|NCT02070900|AIDS
172944|NCT02070900|Zimbabwe
172945|NCT02070874|pain and symptom management
172946|NCT02070861|Cardiac output
172947|NCT02070861|Endtidal CO2
172948|NCT02070861|Nexfin
172949|NCT02070861|Esophageal Doppler
172950|NCT02070848|red blood cell
172951|NCT02070848|knee extension exercise
172952|NCT02070835|Diabetic Foot Ulcer
172953|NCT02070835|ReCell
172954|NCT02070822|Hepatocellular carcinoma
172955|NCT02070822|Transarterial chemoembolization
172956|NCT02070822|Magnetic resonance imaging
172957|NCT02070809|wound
172958|NCT02070809|tissue-engineered skin
172959|NCT02070796|Rotigotine
172960|NCT02070796|Transdermal Patch
172961|NCT02070796|Bioequivalence
172962|NCT02070783|depression
172963|NCT02070783|cognition
172964|NCT02070783|emotion perception
172965|NCT02070783|information processing
172966|NCT02070757|Ventilator-associated bacterial pneumonia
172967|NCT02070757|Hospital-acquired bacterial pneumonia
172968|NCT02070757|Pneumonia
172969|NCT02070757|Lung Diseases
172970|NCT02070757|Respiratory Tract Diseases
172971|NCT02070757|Respiratory Tract Infections
172972|NCT02070757|Infection
172973|NCT02070757|Ventilator-Induced Lung Injury
172974|NCT02070757|Lung Injury
172975|NCT02070744|CF
172976|NCT02070731|TAVR
172977|NCT02070731|TAVI
172978|NCT02070731|Aortic Valve Stenosis
172979|NCT02070718|hot flashes
172980|NCT02070718|menopause
172981|NCT02070718|kappa agonist
172982|NCT02070692|Contraceptive implant
172983|NCT02070692|Irregular vaginal bleeding
172984|NCT02070692|Etonogestrel implant
172985|NCT02070679|Alpha-tocopherol
172986|NCT02070679|Vitamin E
172987|NCT02070679|Contrast-Induced Acute Kidney Injury
172988|NCT02070679|Coronary angiography
172989|NCT02070666|ARDS
172990|NCT02070666|Prevention
172991|NCT02070666|Protective mechanical ventilation
172992|NCT02070666|low tidal volumes
172993|NCT02070653|Aorta
172994|NCT02070653|Aneurysm
172995|NCT02070653|Antiplatelet
172996|NCT02070640|cholecystectomy
172997|NCT02070640|cholecystitis
172998|NCT02070627|acute cholecystitis
172999|NCT02070627|acute cholangitis
173000|NCT02070627|cholecystectomy
173001|NCT02070614|sufentanil
173002|NCT02070614|metabolism
173003|NCT02070614|cytochrome P450 3A4
173004|NCT02070614|gene polymorphism
173005|NCT02070588|TBI
173006|NCT02070588|mTBI
173007|NCT02070588|MR
173008|NCT02070588|MRI
173009|NCT02070588|Pulse Sequences
173010|NCT02070588|NFL
173011|NCT02070575|PSA
173012|NCT02070575|Human Kallikrein 2
173013|NCT02070575|locally resected prostate cancer
173014|NCT02070575|biochemical recurrence
173015|NCT02070575|14-041
173016|NCT02070562|breast milk, dietary survey
173017|NCT02070536|Acute Respiratory Distress Syndrome (ARDS)
173018|NCT02070536|Receptor for advanced glycation end products (RAGE)
173019|NCT02070536|Soluble RAGE (sRAGE)
173020|NCT02070536|Gene polymorphisms
173021|NCT02070536|Biomarker
173022|NCT02070484|NuCel
173023|NCT02070484|Lumbar Spine
173024|NCT02070484|Degenerative Disease
173025|NCT02070484|Efficacy
173026|NCT02070484|Fusion
173027|NCT02070445|CABG
173028|NCT02070445|pilot
173029|NCT02070445|ultrasound
173030|NCT02070445|perioperative
173031|NCT02070445|low tidal volume ventilation
173032|NCT02070432|LUZ11
173033|NCT02070432|head and neck cancer
173034|NCT02070432|photodynamic therapy
173035|NCT02070432|Redaporfin
173036|NCT02070393|Hodgkins Disease in Young Females
173037|NCT02070393|Breast Sparing Radiation Treatments
173038|NCT02070380|confirmed brain disease
173039|NCT02070380|highly suspected brain disease
173040|NCT02070367|allodynia
173041|NCT02070367|complex regional pain syndrome
173042|NCT02070367|peripheral nerve injuries
173043|NCT02070367|clinical measurement properties
173044|NCT02070354|Obesity
173045|NCT02070354|Bariatric surgery
173046|NCT02070354|Physical Activity
173047|NCT02070354|Nutrition
173048|NCT02070354|Weight Loss
173049|NCT02070341|patient tolerability
173050|NCT02070341|quality
173051|NCT02070328|Proton Therapy
173052|NCT02070328|Registry
173053|NCT02070315|heart failure
173054|NCT02070315|liver failure
173055|NCT02070315|post liver transplant
173056|NCT02070289|Multiple dose
173057|NCT02070289|safety
173058|NCT02070289|tolerability
173059|NCT02070289|PK
173060|NCT02070276|Spinal anesthesia
173061|NCT02070276|Systemic hypotension
173062|NCT02070276|Total fluid amount
173063|NCT02070276|Non-invasive fluid responsiveness
173064|NCT02070276|Passive Leg Raising Test
173065|NCT02070263|Food allergy
173066|NCT02070263|Tree nuts
173067|NCT02070250|Stress management
173068|NCT02070250|Coping skills
173069|NCT02070250|Recently diagnosed cancer patients
173070|NCT02070250|Intervention, Psychological
173071|NCT02070237|Obesity
173072|NCT02070237|Obesity, Morbid
173073|NCT02070237|Pregnancy
173074|NCT02070237|Cesarean
173075|NCT02070237|Venous thromboembolism
173076|NCT02070237|Deep venous thrombosis
173077|NCT02070237|Pulmonary embolism
173078|NCT02070211|Psychotic Disorder
173079|NCT02070211|22q11 Deletion Syndrome
173080|NCT02070211|Fatty Acids, Omega-3
173081|NCT02070198|Poor responders, IVF, GnRH agonist, GnRH antagonist, recombinant FSH
173082|NCT02070185|caloric adjustment,liking, flavour nutrient learning, children
173083|NCT02070172|headache diagnosis
173084|NCT02070172|flexion rotation test
173085|NCT02070172|range of motion
173086|NCT02070172|upper cervical
173087|NCT02070159|coronary artery disease
173088|NCT02070159|prasugrel
173089|NCT02070159|platelet function tests
173090|NCT02070133|Chronic Bronchitis
173091|NCT02070133|Statins
173092|NCT02070133|Endothelial dysfunction
173093|NCT02070133|Systemic inflammation
173094|NCT02070133|BODE index
173095|NCT02070133|Uric acid
173096|NCT02070133|Vascular growth factors
173097|NCT02070120|Nonmuscle invasive bladder cancer (NMIBC)
173098|NCT02070120|Mitomycin C
173099|NCT02070120|Chemoresection
173100|NCT02070081|Obesity
173101|NCT02070081|Bariatric surgery
173102|NCT02070055|Maximal Rate of Fat Oxidation
173103|NCT02070055|Substrate Oxidation
173104|NCT02070055|Fat oxidation
173105|NCT02070055|Respiratory Exchange Ratio (RER)
173106|NCT02070055|Exercise
173107|NCT02070055|indirect calorimetry
173108|NCT02070055|substrate crossover
173109|NCT02070042|Overactive Bladder
173110|NCT02070042|Oxybutynin
173111|NCT02070042|Omega -3 Fatty Acid
173112|NCT02070029|Female Sexual Dysfunction (FSD)
173113|NCT02070029|Hypoactive Sexual Desire Disorder (HSDD)
173114|NCT02070029|Low libido
173115|NCT02070029|Acupuncture
173116|NCT02069977|Autism
173117|NCT02069977|Aripiprazole
173118|NCT02069977|Abilify
173119|NCT02069951|Laparoscopy
173120|NCT02069951|Training
173121|NCT02069951|Simulator
173122|NCT02069938|Subjects
173123|NCT02069912|Major Depression
173124|NCT02069912|Heart Disease
173125|NCT02069912|Hispanics
173126|NCT02069912|Collaborative Depression Care Management
173127|NCT02069899|Hemophagocytic lymphohistiocytosis (HLH) previously treated with NI-0501
173128|NCT02069886|Endocrine complications
173129|NCT02069886|transfusion dependent thalassemia
173130|NCT02069873|Post Traumatic Stress Disorder
173131|NCT02069873|Group
173132|NCT02069873|Treatment
173133|NCT02069873|Cognitive, Exposure, Skills
173134|NCT02069873|Women
173135|NCT02069873|Veterans
173136|NCT02069860|bona anchored
173137|NCT02069860|haemodialysis
173138|NCT02069860|Mastoid bone
173139|NCT02069860|nephrology
173140|NCT02069860|retroauricular anchored devices
173141|NCT02069860|permanent central venous access devices.
173142|NCT02069847|Esophageal stricture formation
173143|NCT02069847|Endoscopic mucosal resection
173144|NCT02069847|Endoscopic submucosal dissection
173145|NCT02069847|Budesonide
173146|NCT02069847|Radical endoscopic mucosal resection
173147|NCT02069847|EMR
173148|NCT02069847|ESD
173149|NCT02069834|Dolutegravir
173150|NCT02069834|Rilpivirine
173151|NCT02069834|PI- and NRTI- sparing ART regimen
173152|NCT02069834|switch study
173153|NCT02069795|concussion, athlete, speech analysis
173154|NCT02069782|Pregnancy
173155|NCT02069782|postpartum programs
173156|NCT02069782|infant health services
173157|NCT02069769|Hospice Care
173158|NCT02069769|Head and Neck cancer
173159|NCT02069769|Gynecological Oncology
173160|NCT02069769|Sarcoma
173161|NCT02069769|Melanoma
173162|NCT02069756|Duchenne
173163|NCT02069756|Becker
173164|NCT02069756|Muscular Dystrophy
173165|NCT02069743|cancer pain
173166|NCT02069730|molecular profiling
173167|NCT02069730|selinexor
173168|NCT02069730|tumor tissue
173169|NCT02069704|colorectal cancer
173170|NCT02069704|metastatic
173171|NCT02069704|first-line treatment
173172|NCT02069704|comparability
173173|NCT02069691|stroke,
173174|NCT02069691|rehabilitation,
173175|NCT02069691|leg cycling,
173176|NCT02069691|feedback,
173177|NCT02069691|virtual reality
173178|NCT02069665|pneumonia
173179|NCT02069665|pediatrics
173180|NCT02069665|viral
173181|NCT02069613|Mild traumatic injury to extremity (for controls)
173182|NCT02069613|mTBI
173183|NCT02069613|concussion
173184|NCT02069613|MEG
173185|NCT02069613|EEG
173186|NCT02069613|Blood
173187|NCT02069613|MRI
173188|NCT02069613|DTI
173189|NCT02069613|biomarkers
173190|NCT02069600|Elderly
173191|NCT02069600|CPAP
173192|NCT02069600|clinical trial
173193|NCT02069600|obstructive sleep apnea
173194|NCT02069587|PPROM
173195|NCT02069587|PREGNANCY
173196|NCT02069587|POMEGRANATE
173197|NCT02069587|OXIDATIVE STRESS
173198|NCT02069535|Cupressus arizonica
173199|NCT02069509|Friedreich's Ataxia
173200|NCT02069509|EFACTS
173201|NCT02069509|FRDA
173202|NCT02069483|smoking
173203|NCT02069483|smoker
173204|NCT02069483|text
173205|NCT02069483|smartphone
173206|NCT02069483|motivation
173207|NCT02069483|quitting
173208|NCT02069483|cessation
173209|NCT02069483|feedback
173210|NCT02069483|messages
173211|NCT02069470|Stepped wedged design
173212|NCT02069470|Early cancer diagnosis
173213|NCT02069470|Continuing medical education
173214|NCT02069431|inflammation
173215|NCT02069431|physical function
173216|NCT02069431|cognitive function
173217|NCT02069392|schizophrenia
173218|NCT02069392|cognition
173219|NCT02069392|cognitive remediation
173220|NCT02069392|nicotine
173221|NCT02069379|Metabolic syndrome
173222|NCT02069379|Insulin resistance
173223|NCT02069379|Mu-opioid system
173224|NCT02069379|Depression
173225|NCT02069379|Emotion regulation
173226|NCT02069366|Post-Traumatic Stress Disorders
173227|NCT02069366|Dronabinol
173228|NCT02069366|Extinction
173229|NCT02069366|fMRI
173230|NCT02069353|Cardiac arrest
173231|NCT02069353|Neurological injury
173232|NCT02069353|Seizures
173233|NCT02069353|Spreading depolarizations
173234|NCT02069353|Cerebral hypoperfusion
173235|NCT02069353|Brain tissue hypoxia
173236|NCT02069327|Femur
173237|NCT02069327|Fat
173238|NCT02069327|Emboli
173239|NCT02069327|Bone
173240|NCT02069327|Marrow
173241|NCT02069327|proteomic
173242|NCT02069327|proteomics
173243|NCT02069327|metabolomics
173244|NCT02069327|metabolomic
173245|NCT02069327|inflammatory
173246|NCT02069327|cytokine
173247|NCT02069327|chemokine
173248|NCT02069327|anaphlylatoxin
173249|NCT02069327|Thromboelastography
173250|NCT02069327|Medical Center of the Rockies
173251|NCT02069327|Fat Embolism Syndrome
173252|NCT02069327|Injury
173253|NCT02069327|Fracture
173254|NCT02069327|Metabolite
173255|NCT02069327|MCR
173256|NCT02069327|TEG
173257|NCT02069327|FES
173258|NCT02069301|Behavior Activation
173259|NCT02069301|Problem solving therapy
173260|NCT02069301|Depression Treatment
173261|NCT02069301|depression care integration
173262|NCT02069301|microfinance
173263|NCT02069301|livelihood
173264|NCT02069288|fludrocortisone
173265|NCT02069288|pharmacology
173266|NCT02069288|septic shock
173267|NCT02069275|Immediate mobilization
173268|NCT02069275|Bedrest
173269|NCT02069275|Coronary angiography
173270|NCT02069275|Coronary percutaneous intervention
173271|NCT02069275|Vascular access complications
173272|NCT02069275|Patients comfort
173273|NCT02069262|obscure gastrointestinal bleeding
173274|NCT02069262|laparoscopy
173275|NCT02069262|angiography
173276|NCT02069249|Preschool children
173277|NCT02069249|Sleep problems
173278|NCT02069249|Nutrition problems
173279|NCT02069249|Online intervention
173280|NCT02069249|Psychological functioning
173281|NCT02069236|Glucose-6 phosphate dehydrogenase deficiency
173282|NCT02069236|capillary
173283|NCT02069236|venous
173284|NCT02069236|genotype phenotype correlation
173285|NCT02069223|Biliopancreatic Diversion with Duodenal Switch
173286|NCT02069223|Gastrectomy
173287|NCT02069197|ketogenic diet
173288|NCT02069197|obesity
173289|NCT02069197|diabetes
173290|NCT02069197|obstructive sleep apnea
173291|NCT02069184|opioid usage requirements
173292|NCT02069184|pain
173293|NCT02069184|IV acetaminophen
173294|NCT02069184|opioid usage
173295|NCT02069184|c-section
173296|NCT02069171|Lower extremity edema
173297|NCT02069171|Lower leg lymphedema
173298|NCT02069171|Lower leg edema
173299|NCT02069171|Lymphedema
173300|NCT02069171|Pelvic lymph node dissection
173301|NCT02069171|Gynecologic Cancer Lymphedema Questionnaire
173302|NCT02069158|Advanced solid tumor
173303|NCT02069145|Hepatocellular Cancer
173304|NCT02069145|Liver Cancer
173305|NCT02069132|Warfarin
173306|NCT02069132|International Warfarin Pharmacogenetics Consortium algorithm
173307|NCT02069132|Atrial Fibrillation
173308|NCT02069132|Heart Valve Prosthesis Implantation
173309|NCT02069132|elderly
173310|NCT02069132|comorbidity
173311|NCT02069106|low density lipoprotein cholesterol
173312|NCT02069106|triglycerides
173313|NCT02069106|mixed hyperlipoproteinemia
173314|NCT02069106|Dehydroascorbic Acid
173315|NCT02069106|Eicosapentaenoic Acid
173316|NCT02069106|Fish oil
173317|NCT02069080|Positron Emission Tomograhy
173318|NCT02069080|Metastasis
173319|NCT02069067|breakthrough cancer pain
173320|NCT02069067|pain
173321|NCT02069067|neuropathic pain
173322|NCT02069067|intractable pain
173323|NCT02069067|cancer
173324|NCT02069054|asthma
173325|NCT02069054|COPD
173326|NCT02069054|airway inflammation
173327|NCT02069054|remodeling
173328|NCT02069054|cytokines
173329|NCT02069054|airway wall thickness
173330|NCT02069028|surviving sepsis campaign
173331|NCT02069028|sepsis
173332|NCT02069028|septic
173333|NCT02069028|septicemia
173334|NCT02069028|mortality
173335|NCT02069028|compliance
173336|NCT02069015|Patient education
173337|NCT02069015|Hypertension
173338|NCT02069015|Patient activation
173339|NCT02069002|Indoor Air
173340|NCT02069002|Medically unexplained symptoms
173341|NCT02069002|Randomized controlled trial
173342|NCT02069002|Cognitive-Behavioral Therapy
173343|NCT02069002|Applied relaxation
173344|NCT02068950|Head and neck cancer
173345|NCT02068950|Concurrent chemoradiotherapy
173346|NCT02068950|Progressive resistance training
173347|NCT02068950|Exercise
173348|NCT02068950|Feasibility
173349|NCT02068950|Weight loss
173350|NCT02068950|LBM
173351|NCT02068950|Body composition
173352|NCT02068937|Heart Failure
173353|NCT02068937|Therapy
173354|NCT02068937|Diuretics
173355|NCT02068937|Algorithms
173356|NCT02068924|Slow freezing
173357|NCT02068924|Vitrification
173358|NCT02068924|Single embryo transfer
173359|NCT02068911|Neuromuscular disease
173360|NCT02068911|Home ventilation
173361|NCT02068911|End tidal CO2
173362|NCT02068911|Transcutaneous CO2
173363|NCT02068911|Monitoring
173364|NCT02068885|Low carbohydrate diet
173365|NCT02068885|Low fat diet
173366|NCT02068885|Glycemic index
173367|NCT02068885|Weight loss maintenance
173368|NCT02068872|Obesity
173369|NCT02068872|Transplant
173370|NCT02068872|Sleeve Gastrectomy
173371|NCT02068872|Liver Transplantation
173372|NCT02068872|Weight Loss
173373|NCT02068846|HIV
173374|NCT02068846|Salivary Gland Disease
173375|NCT02068846|Benign Lymphoepithelial Lesion
173376|NCT02068846|BK Polyomavirus
173377|NCT02068833|Microalbuminuria
173378|NCT02068833|Gastrectomy
173379|NCT02068833|Biliopancreatic Diversion With Duodenal Switch
173380|NCT02068820|Sentinel lymph nodes
173381|NCT02068820|da Vinci
173382|NCT02068820|Firefly
173383|NCT02068820|Sentinel lymph node mapping
173384|NCT02068820|Fluorescence Imaging
173385|NCT02068820|SLN
173386|NCT02068820|SLN mapping
173387|NCT02068768|fusion
173388|NCT02068768|lateral interbody fusion system
173389|NCT02068768|lumbar spine
173390|NCT02068768|degenerative disc disease
173391|NCT02068755|anemia
173392|NCT02068755|renal impairment
173393|NCT02068755|thrombocytopenia
173394|NCT02068755|anticoagulation
173395|NCT02068755|Coronary bypass
173396|NCT02068755|Aortic valve surgery
173397|NCT02068755|Mitral valve surgery
173398|NCT02068755|red blood cell
173399|NCT02068755|platelet
173400|NCT02068755|fresh frozen plasma
173401|NCT02068755|octaplas
173402|NCT02068742|post-operative cognitive dysfunction
173403|NCT02068742|elderly
173404|NCT02068742|Mini Mental State Examination
173405|NCT02068742|Geriatric Index of Comorbidity
173406|NCT02068742|Geriatric Depression Scale
173407|NCT02068742|Trail Making Test B-A
173408|NCT02068742|Digit Span
173409|NCT02068742|Digit Symbol Substitution Test
173410|NCT02068729|degenerative disc disease
173411|NCT02068729|DDD
173412|NCT02068729|Grade 1 spondylolisthesis
173413|NCT02068729|spondylolisthesis
173414|NCT02068729|L2-S1
173415|NCT02068716|Healthcare acquired infections
173416|NCT02068716|Cardiovascular Surgery
173417|NCT02068716|Mediastinitis
173418|NCT02068716|Thoracotomy
173419|NCT02068716|Conduit harvest or cannulation site
173420|NCT02068703|survey
173421|NCT02068664|spatial neglect
173422|NCT02068664|aphasia
173423|NCT02068651|End-of-life care
173424|NCT02068651|Treatment decision making
173425|NCT02068651|Advance care planning
173426|NCT02068638|exercise
173427|NCT02068638|isotope labeling, stable
173428|NCT02068638|spectroscopy, magnetic resonance
173429|NCT02068638|monitoring, home blood glucose
173430|NCT02068638|hormones
173431|NCT02068625|retinal detachment
173432|NCT02068625|rasagiline
173433|NCT02068625|optical coherence tomography
173434|NCT02068625|visual acuity
173435|NCT02068625|neuroprotection
173436|NCT02068625|azilect
173437|NCT02068612|Executive function,
173438|NCT02068612|cardiovascular fitness,
173439|NCT02068612|cognitive function
173440|NCT02068599|Osteoarthritis
173441|NCT02068599|OA
173442|NCT02068599|Arthritis pain
173443|NCT02068573|Childhood Asthma
173444|NCT02068573|Allergy
173445|NCT02068573|House dust mites
173446|NCT02068573|Indoor air quality
173447|NCT02068547|posterior cervical fusion
173448|NCT02068547|posterior cervical decompression
173449|NCT02068534|in-depth individual interview
173450|NCT02068534|charcoal-burning suicide
173451|NCT02068521|Growth Hormone Deficiency
173452|NCT02068521|Pediatric Growth Hormone Deficiency
173453|NCT02068521|GHD
173454|NCT02068521|PGHD
173455|NCT02068521|VRS-317
173456|NCT02068521|Versartis
173457|NCT02068521|Growth disorder
173458|NCT02068521|Long acting growth hormone
173459|NCT02068521|Growth hormone
173460|NCT02068521|Weekly growth hormone dosing
173461|NCT02068521|Semi-monthly growth hormone dosing
173462|NCT02068521|Monthly growth hormone dosing
173463|NCT02068521|IGF-I
173464|NCT02068521|Short stature
173465|NCT02068521|Height velocity
173466|NCT02068521|Annual height velocity
173467|NCT02068521|Growth rate
173468|NCT02068521|Somavaratan
173469|NCT02068508|Drug therapy
173470|NCT02068495|Drug therapy
173471|NCT02068482|Uncomplicated
173472|NCT02068482|Symptomatic
173473|NCT02068456|Drug therapy
173474|NCT02068443|Drug therapy
173475|NCT02068430|Corneal Ulcers
173476|NCT02068430|cross-linking
173477|NCT02068430|UVA
173478|NCT02068430|Riboflavin
173479|NCT02068417|IIEF score
173480|NCT02068417|ED
173481|NCT02068404|Tocolysis
173482|NCT02068404|Preterm labor
173483|NCT02068404|Nifedipine
173484|NCT02068404|Pharmacokinetics
173485|NCT02068391|covert stroke
173486|NCT02068391|cerebral blood flow
173487|NCT02068391|grey matter
173488|NCT02068391|attention
173489|NCT02068391|executive function
173490|NCT02068391|aerobic exercise
173491|NCT02068352|Atopic Dermatitis, Eczema
173492|NCT02068326|Mentalization-based Treatment
173493|NCT02068326|Adolescence
173494|NCT02068326|Borderline Personality Disorder
173495|NCT02068300|1,5-anhydro-D-glucitol, hypoglycemia, surrogate marker
173496|NCT02068287|Septic Shock
173497|NCT02068287|Hemodynamic
173498|NCT02068287|Inflammatory status
173499|NCT02068287|Beta adrenergic modulation
173500|NCT02068287|Esmolol
173501|NCT02068235|Ponesimod
173502|NCT02068235|Bioavailability
173503|NCT02068235|Pharmacokinetics
173504|NCT02068235|Safety
173505|NCT02068222|Hepatitis C
173506|NCT02068222|HCV
173507|NCT02068222|Interferon Free
173508|NCT02068222|Chronic Hepatitis C
173509|NCT02068222|Hepatitis C virus
173510|NCT02068222|Hepatitis C Genotype 3
173511|NCT02068209|Outpatient hysteroscopy
173512|NCT02068209|Tramadol
173513|NCT02068196|Cancer
173514|NCT02068196|Malignant Melanoma
173515|NCT02068196|Ipilimumab
173516|NCT02068183|World Trade Center exposure
173517|NCT02068183|cardiovascular risk
173518|NCT02068183|insulin resistance
173519|NCT02068183|post-traumatic stress
173520|NCT02068183|pulmonary disease
173521|NCT02068170|QT-prolongation
173522|NCT02068170|Torsade de Pointes
173523|NCT02068170|QT-prolonging drugs
173524|NCT02068144|Cranberry Extract
173525|NCT02068131|Metastatic Colorectal Cancer
173526|NCT02068131|Novaferon
173527|NCT02068131|Recombinant anti-tumor and anti-virus protein for injection
173528|NCT02068131|xeloda
173529|NCT02068118|E health
173530|NCT02068118|Telecardiology program
173531|NCT02068118|Heart failure
173532|NCT02068105|ALKS 5461
173533|NCT02068105|samidorphan
173534|NCT02068066|Physical work requirements
173535|NCT02068066|Energy expenditure
173536|NCT02068066|Physical activity
173537|NCT02068066|Different occupational categories
173538|NCT02068066|Aerobic capacity
173539|NCT02068040|with preserved ejection fraction of >55%
173540|NCT02068027|Diabetes Mellitus
173541|NCT02068027|Pain
173542|NCT02068027|Foot pain
173543|NCT02068027|Neuropathy
173544|NCT02068014|stapplers- obesity- stomach
173545|NCT02067988|Radioembolization
173546|NCT02067988|Somatostatin receptor treatment
173547|NCT02067988|Neuroendocrine tumors
173548|NCT02067988|Liver metastases
173549|NCT02067975|tryptophan
173550|NCT02067975|kynurenic acid
173551|NCT02067975|schizophrenia
173552|NCT02067962|Juvenile idiopathic arhtritis
173553|NCT02067962|JIA
173554|NCT02067962|Gene identification
173555|NCT02067962|Whole exome sequencing
173556|NCT02067962|Next generation sequencing
173557|NCT02067962|Identification of molecular basis
173558|NCT02067962|Acceptation of both parents to participate to the study
173559|NCT02067923|T1D
173560|NCT02067923|type 1 diabetes
173561|NCT02067923|type 1 diabetes mellitus
173562|NCT02067923|juvenile diabetes
173563|NCT02067923|autoimmune diabetes
173564|NCT02067923|autoimmune
173565|NCT02067923|anti-CD3 mAb
173566|NCT02067923|mAb hOKT3g1(Ala-Ala)
173567|NCT02067923|teplizumab
173568|NCT02067910|Abatacept
173569|NCT02067910|Subcutaneous
173570|NCT02067910|Sjögren's syndrome
173571|NCT02067910|Treatment
173572|NCT02067910|Safety
173573|NCT02067910|Efficacy
173574|NCT02067897|Nails, Ingrown
173575|NCT02067897|Children
173576|NCT02067897|Ambulatory Surgical Procedures
173577|NCT02067871|neuromuscular electrical stimulation
173578|NCT02067871|low-level laser therapy
173579|NCT02067871|knee osteoarthritis
173580|NCT02067871|muscle architecture
173581|NCT02067871|functionality
173582|NCT02067871|neuromuscular parameters
173583|NCT02067845|Lesbian, queer, bisexual women
173584|NCT02067845|HIV and STI prevention
173585|NCT02067845|Resilient coping
173586|NCT02067845|Sexual stigma
173587|NCT02067845|Depression
173588|NCT02067845|Safer-sex practices
173589|NCT02067845|Safer sex self-efficacy
173590|NCT02067845|HIV/STI knowledge and testing
173591|NCT02067845|Pilot-testing
173592|NCT02067819|Tourette's
173593|NCT02067819|Tic Disorder
173594|NCT02067819|Dental Appliance
173595|NCT02067819|Oral Orthotic
173596|NCT02067819|Mouthguard
173597|NCT02067806|PASS
173598|NCT02067806|TNS
173599|NCT02067806|CES
173600|NCT02067806|CHLOROPROCAINE
173601|NCT02067793|NRX-1074
173602|NCT02067793|NMDA Receptor Modulator
173603|NCT02067793|Major Depressive Disorder
173604|NCT02067793|Glycine site modulator
173605|NCT02067767|HIV-1 infection
173606|NCT02067767|Nevirapine
173607|NCT02067767|Dolutegravir
173608|NCT02067767|Anti-retroviral agents
173609|NCT02067754|The mutation profiling of circulating free DNA
173610|NCT02067741|Post-menopausal women
173611|NCT02067741|topical application CR1447
173612|NCT02067741|endocrine responsive-HER2neg breast cancer
173613|NCT02067741|triple negative-androgen receptor positive breast cancer
173614|NCT02067728|obesity prevention
173615|NCT02067715|Tooth Discoloration
173616|NCT02067715|Bleaching Agents
173617|NCT02067715|Tooth Bleaching
173618|NCT02067689|Normal cognition in healthy adults
173619|NCT02067689|Cognitive function
173620|NCT02067689|Transcranial direct current stimulation
173621|NCT02067689|Structural Magnetic Resonance Imaging
173622|NCT02067689|Functional Magnetic Resonance Imaging
173623|NCT02067676|Campylobacter jejuni
173624|NCT02067663|Postplacental IUD placement
173625|NCT02067663|LNG-IUS
173626|NCT02067637|cancer therapy, cancer treatment
173627|NCT02067611|Phase 2, Efficacy, Safety, Osteoarthritis
173628|NCT02067598|Scapular exercises
173629|NCT02067572|oral health
173630|NCT02067572|mouthwash
173631|NCT02067572|salvia
173632|NCT02067572|hospice
173633|NCT02067572|xerostomia
173634|NCT02067572|mouth sores
173635|NCT02067559|Post Traumatic Stress Disorder
173636|NCT02067559|PTSD
173637|NCT02067559|Intensive Care Unit
173638|NCT02067559|ICU
173639|NCT02067546|constipation
173640|NCT02067520|Post C/S pain relief
173641|NCT02067507|Human Papillomavirus
173642|NCT02067507|Immunization
173643|NCT02067507|Oncogenic viruses
173644|NCT02067507|Cervical Cancer
173645|NCT02067507|Health Disparities
173646|NCT02067494|Low Back Pain
173647|NCT02067494|Chronic Pain
173648|NCT02067494|Manual Therapy
173649|NCT02067494|Randomized Clinical Trial
173650|NCT02067494|Bandages
173651|NCT02067481|Breast cancer
173652|NCT02067481|Survivors
173653|NCT02067481|Weight loss
173654|NCT02067481|Diet
173655|NCT02067481|Physical activity
173656|NCT02067468|Human Papillomavirus
173657|NCT02067468|cervical cancer
173658|NCT02067468|health services research
173659|NCT02067468|Colombia
173660|NCT02067468|Cervical Intraepithelial Neoplasia
173661|NCT02067455|Right ventricular function
173662|NCT02067455|echocardiography
173663|NCT02067455|left ventricular assist device
173664|NCT02067455|exercise
173665|NCT02067442|acetaminophen intravenous oral pain scores opioids
173666|NCT02067416|neoadjuvant
173667|NCT02067416|mammostrat
173668|NCT02067416|TLE3
173669|NCT02067416|DDR
173670|NCT02067416|breast cancer
173671|NCT02067403|Pressure-support
173672|NCT02067403|Asynchrony
173673|NCT02067377|GOLD, COPD, cachexia, BMI
173674|NCT02067364|hydrocephalus
173675|NCT02067364|CSF shunt
173676|NCT02067299|Depressive Disorder, Major
173677|NCT02067299|Major Depressive Disorder
173678|NCT02067299|Insomnia
173679|NCT02067299|JNJ-42847922
173680|NCT02067299|Placebo
173681|NCT02067221|percutaneous nephrolithotomy
173682|NCT02067221|renal calculi
173683|NCT02067221|ureteroscopy
173684|NCT02067208|Osteoarthritis
173685|NCT02067208|Cartilage
173686|NCT02067208|Musculoskeletal
173687|NCT02067208|Biomechanics
173688|NCT02067208|Subtype
173689|NCT02067208|Footwear
173690|NCT02067208|Orthotics
173691|NCT02067208|Joint Loading
173692|NCT02067195|acute myocardial infarction,contrast,coronary intervention
173693|NCT02067169|Transplantation
173694|NCT02067169|CMV infection
173695|NCT02067169|antiviral resistance
173696|NCT02067156|glioblastoma
173697|NCT02067143|Untreated philadelphia positive acute lymphoblastic leukemia
173698|NCT02067143|De novo
173699|NCT02067143|Secondary
173700|NCT02067143|Low-dose corticosteroids pretreatment
173701|NCT02067143|Pegylated asparaginase
173702|NCT02067143|Lineage-targeted risk and minimal residual disease
173703|NCT02067130|Beta Thalassemia Major
173704|NCT02067117|influenza
173705|NCT02067091|STEMI
173706|NCT02067091|Coronary
173707|NCT02067091|Bioresorbable scaffold
173708|NCT02067091|Drug eluting stent
173709|NCT02067091|Optical coherence tomography
173710|NCT02067091|Multislice computed tomography
173711|NCT02067078|nerve block
173712|NCT02067078|total knee arthroplasty
173713|NCT02067078|saphenous nerve block
173714|NCT02067078|obturator nerve block
173715|NCT02067078|pain
173716|NCT02067078|opioid consumption
173717|NCT02067065|Colonoscopy
173718|NCT02067065|Sedation
173719|NCT02067065|Propofol
173720|NCT02067065|Non-anesthesiologist propofol administration
173721|NCT02067052|Vulvar neoplasm
173722|NCT02067052|sentinel nodes
173723|NCT02067052|chemotherapy
173724|NCT02067052|radiotherapy
173725|NCT02067039|HIV testing
173726|NCT02067039|Rapid HIV test
173727|NCT02067039|HIV self-testing
173728|NCT02067039|Men who have sex with men (MSM)
173729|NCT02067039|HIV diagnosis
173730|NCT02067039|Sexual behavior
173731|NCT02067026|overweight
173732|NCT02067013|Tractional retinal detachment
173733|NCT02067013|Exudative retinal detachment
173734|NCT02067013|Macular hole
173735|NCT02067013|Neovascular glaucoma
173736|NCT02066987|Action planning, Implementation intention
173737|NCT02066974|hepatocellular carcinoma
173738|NCT02066974|genomic expression
173739|NCT02066974|radiotherapy
173740|NCT02066961|metastatic prostate cancer
173741|NCT02066961|castration-resistant prostate cancer
173742|NCT02066961|prostate cancer
173743|NCT02066948|DXA
173744|NCT02066948|MRI
173745|NCT02066948|Fitness assessment
173746|NCT02066948|Meal tolerance test
173747|NCT02066935|immunosuppression
173748|NCT02066935|medication nonadherence
173749|NCT02066935|kidney transplantation
173750|NCT02066922|Contact lenses
173751|NCT02066922|Nearsightedness
173752|NCT02066922|Corneal curvature
173753|NCT02066922|K-reading
173754|NCT02066922|High minus
173755|NCT02066922|Spectacle refraction
173756|NCT02066909|pharmacokinetics
173757|NCT02066909|safety
173758|NCT02066909|tolerability
173759|NCT02066909|healthy volunteers
173760|NCT02066909|steady state
173761|NCT02066909|multiple doses
173762|NCT02066909|Japanese subjects
173763|NCT02066896|Sjogrens Syndrome
173764|NCT02066896|Syndrome, Sjogren's
173765|NCT02066896|Sjogren Syndrome
173766|NCT02066896|Sicca Syndrome
173767|NCT02066896|Syndrome, Sicca
173768|NCT02066870|Icotinib
173769|NCT02066870|Arsenic Trioxide
173770|NCT02066870|Resistance
173771|NCT02066870|Non-small cell lung cancer
173772|NCT02066857|Wrist fracture
173773|NCT02066857|Radius fracture
173774|NCT02066857|Elderly
173775|NCT02066857|Splint
173776|NCT02066857|Cast
173777|NCT02066844|Hip Pain
173778|NCT02066844|Hip Injection
173779|NCT02066844|Hip Fracture
173780|NCT02066844|Hip Bursitis
173781|NCT02066844|Hip Arthritis
173782|NCT02066844|Hip Sciatica
173783|NCT02066818|local anesthetic
173784|NCT02066818|incision and drainage
173785|NCT02066818|pain
173786|NCT02066818|cutaneous abscess
173787|NCT02066792|Social Phobia
173788|NCT02066753|Cardiac arrest
173789|NCT02066753|Therapeutic Hypothermia
173790|NCT02066753|Cardioprotectiveness
173791|NCT02066753|Hemodynamics
173792|NCT02066740|Superficial Femoral Artery
173793|NCT02066740|Proximal Popliteal Artery
173794|NCT02066740|Everflex
173795|NCT02066740|Entrust
173796|NCT02066740|stent
173797|NCT02066727|Dexmedetomidine
173798|NCT02066727|obturator nerve block
173799|NCT02066727|lidocaine
173800|NCT02066727|EC50
173801|NCT02066714|Enterovirus Infections
173802|NCT02066714|Hand, Foot and Mouth Disease
173803|NCT02066714|Coxsackievirus Infections
173804|NCT02066714|Herpangina
173805|NCT02066714|Cognition
173806|NCT02066714|Neurocognitive
173807|NCT02066714|Sequelae
173808|NCT02066714|Outcomes
173809|NCT02066701|Barrett's esophagus
173810|NCT02066675|Metastatic
173811|NCT02066675|Locally advanced
173812|NCT02066675|Soft tissue tumors
173813|NCT02066662|Coronary or Valvular Calcification
173814|NCT02066662|Agatston Score
173815|NCT02066662|Rivaroxaban
173816|NCT02066662|Coumarin
173817|NCT02066662|Oral Anticoagulation Therapy (OAT)
173818|NCT02066662|Atrial Fibrillation
173819|NCT02066662|Pulmonary Embolism
173820|NCT02066649|portal hypertension
173821|NCT02066649|esophageal varices
173822|NCT02066649|variceal bleed
173823|NCT02066649|carvedilol
173824|NCT02066649|variceal band ligation
173825|NCT02066623|coronary artery stenosis, vascular scaffold, ABSORB
173826|NCT02066597|Deep vein thrombosis
173827|NCT02066597|thrombectomy
173828|NCT02066597|percutaneuos
173829|NCT02066584|sibling oocytes
173830|NCT02066584|glucose
173831|NCT02066584|culture media
173832|NCT02066571|Parkinson's disease
173833|NCT02066571|Freezing of gait
173834|NCT02066571|Gait
173835|NCT02066558|Carbon monoxide
173836|NCT02066558|Headache
173837|NCT02066558|Migraine
173838|NCT02066532|Breast Neoplasms
173839|NCT02066532|Breast Cancer
173840|NCT02066532|Breast Carcinoma
173841|NCT02066532|Breast tumors
173842|NCT02066532|Cancer of the Breast
173843|NCT02066532|Malignant tumor of the breast
173844|NCT02066532|HER2 positive
173845|NCT02066532|erythroblastosis virus oncogene B-2 (erbB-2)
173846|NCT02066532|Metastatic Breast Cancer
173847|NCT02066532|Secondary Breast Cancer
173848|NCT02066519|Myasthenia gravis
173849|NCT02066519|physical exercise
173850|NCT02066519|quality of life
173851|NCT02066519|muscular performance
173852|NCT02066519|fatigability
173853|NCT02066506|systemic right ventricle
173854|NCT02066506|cardiac magnetic resonance imaging
173855|NCT02066506|congenital heart disease
173856|NCT02066493|giant intracranial aneurysm, cerebrovascular bypass, flow diverter
173857|NCT02066467|Phrenic Nerve Stimulation
173858|NCT02066467|Heartfailure treatment
173859|NCT02066467|CRT-D therapy
173860|NCT02066467|Quadripolar lead
173861|NCT02066467|Lead related complication free rate
173862|NCT02066454|myeloma
173863|NCT02066454|antiXa anticoagulant
173864|NCT02066454|venous thromboembolic disease
173865|NCT02066454|iMiDs
173866|NCT02066441|Vitamin D
173867|NCT02066441|bone formation
173868|NCT02066441|resorption
173869|NCT02066441|mineral density
173870|NCT02066441|inflammation
173871|NCT02066441|flexibility
173872|NCT02066441|balance
173873|NCT02066441|elderly
173874|NCT02066428|BCG Vaccinated
173875|NCT02066428|HIV Negative
173876|NCT02066415|Chronic Migraine
173877|NCT02066389|anti-inflammatory agents
173878|NCT02066389|Joint Diseases
173879|NCT02066389|Arthritis
173880|NCT02066389|Musculoskeletal Disease
173881|NCT02066389|antirheumatic agents
173882|NCT02066363|Bioelectrical impedance
173883|NCT02066363|Parenteral nutrition
173884|NCT02066363|Malnutrition
173885|NCT02066363|Quality of life.
173886|NCT02066363|Cancer cachexia
173887|NCT02066363|Body composition
173888|NCT02066350|Diabetes type 1
173889|NCT02066350|Endothelial dysfunction
173890|NCT02066350|Pancreas transplantation
173891|NCT02066337|Ozone gel
173892|NCT02066337|Antioxidants
173893|NCT02066337|Chronic periodontitis
173894|NCT02066337|Superoxide dismutase
173895|NCT02066311|lupus
173896|NCT02066311|SLE
173897|NCT02066298|Asthma
173898|NCT02066298|Mometasone
173899|NCT02066298|Tiotropium
173900|NCT02066285|Solitary fibrous tumor
173901|NCT02066285|Extraskeletal myxoid chondrosarcoma
173902|NCT02066285|Unresectable
173903|NCT02066285|Locally advanced
173904|NCT02066285|Metastatic disease
173905|NCT02066272|IBD
173906|NCT02066272|anti-TNF
173907|NCT02066272|biosimilars
173908|NCT02066272|safety
173909|NCT02066259|colon cancer
173910|NCT02066259|cancer associated auto antibodies
173911|NCT02066259|colon cancer blood test
173912|NCT02066246|laparoscopic robot-assisted surgery
173913|NCT02066246|in steep trendelenburg position
173914|NCT02066233|Barrett's
173915|NCT02066233|esophagus
173916|NCT02066233|reflux
173917|NCT02066233|heartburn
173918|NCT02066233|screening
173919|NCT02066220|pediatric brain tumor
173920|NCT02066220|medulloblastoma
173921|NCT02066220|event-free survival (EFS)
173922|NCT02066220|progression-free survival (PFS)
173923|NCT02066220|overall survival (OS)
173924|NCT02066220|PNET
173925|NCT02066220|posterior fossa
173926|NCT02066220|chemotherapy
173927|NCT02066220|radiotherapy
173928|NCT02066220|biological profile
173929|NCT02066220|ß-catenin
173930|NCT02066155|diabetes self-management support
173931|NCT02066155|diabetes-related distress
173932|NCT02066155|parish nurses
173933|NCT02066155|peer support
173934|NCT02066129|Asthma
173935|NCT02066129|Fluticasone
173936|NCT02066090|acupuncture
173937|NCT02066090|obesity
173938|NCT02066090|metabolomics
173939|NCT02066077|Major Depressive Disorder
173940|NCT02066077|Modified Electroconvulsive Therapy
173941|NCT02066077|Cognition
173942|NCT02066077|Memory
173943|NCT02066064|Colorectal Cancer
173944|NCT02066064|Adenoma
173945|NCT02066064|Standard Colonoscopy
173946|NCT02066064|G-EYE(TM) Colonoscopy
173947|NCT02066038|chemotherapy
173948|NCT02066038|maintenance therapy
173949|NCT02066038|erlotinib
173950|NCT02066025|breast cancer
173951|NCT02066025|cancer associated auto antibodies
173952|NCT02066025|breast cancer blood test
173953|NCT02066012|Dysmetabolic Iron Overload Syndrome
173954|NCT02066012|Metabolic Syndrome X
173955|NCT02066012|Iron
173956|NCT02066012|Monocyte
173957|NCT02066012|Macrophage
173958|NCT02066012|Polarization
173959|NCT02065999|Hepatitis C, chronic
173960|NCT02065986|HIV
173961|NCT02065986|Prevention
173962|NCT02065986|Truvada
173963|NCT02065960|Feasibility study
173964|NCT02065960|Early breast cancer
173965|NCT02065960|Stereotactic body radiotherapy
173966|NCT02065960|Cyberknife
173967|NCT02065960|Pre-operative radiotherapy
173968|NCT02065947|paravertebral block, mastectomy, efficiency
173969|NCT02065934|in hospital cardiac arrest
173970|NCT02065934|in situ simulation
173971|NCT02065934|clinical audit
173972|NCT02065934|education
173973|NCT02065921|COPD cohort
173974|NCT02065921|COPD management
173975|NCT02065921|exacerbation
173976|NCT02065908|breast cancer
173977|NCT02065908|anthracyclines
173978|NCT02065908|cardiotoxicity
173979|NCT02065908|circulating microRNA
173980|NCT02065908|biomarker
173981|NCT02065908|serum
173982|NCT02065908|anthracyclines based chemotherapy
173983|NCT02065895|Physiologic Insulin Delivery (PID)
173984|NCT02065895|Closed Loop
173985|NCT02065895|Sensor
173986|NCT02065895|Insulin sensitivity
173987|NCT02065882|fibrinogen, bleeding,
173988|NCT02065869|ALL
173989|NCT02065869|AML
173990|NCT02065869|hematologic neoplasms
173991|NCT02065869|hematologic malignancies
173992|NCT02065869|primary immune deficiences
173993|NCT02065843|Anxiety
173994|NCT02065843|Third molar surgery
173995|NCT02065843|Blood pressure
173996|NCT02065843|Heart rate
173997|NCT02065843|Oxygen saturation
173998|NCT02065830|Robot
173999|NCT02065830|Spinal Cord Injury
174000|NCT02065830|Gait
174001|NCT02065830|Quality of life
174002|NCT02065830|Rehabilitation
174003|NCT02065830|Lower Limb
174004|NCT02065817|Lipid
174005|NCT02065817|Apolipoproteins
174006|NCT02065817|Cardiovascular disease risks
174007|NCT02065804|Herniorrhaphy
174008|NCT02065804|Surgical Equipment
174009|NCT02065804|Chronic Pain
174010|NCT02065804|Inguinal Herniorrhaphy
174011|NCT02065804|Laparoscopy
174012|NCT02065804|Surgical Outcome
174013|NCT02065791|Diabetes Mellitus, Type 2
174014|NCT02065791|Diabetic Nephropathies
174015|NCT02065791|Canagliflozin
174016|NCT02065791|JNJ-28431754
174017|NCT02065791|End-Stage Kidney Disease
174018|NCT02065791|Chronic Kidney Disease
174019|NCT02065791|Macroalbuminuria
174020|NCT02065752|Healthy Volunteers
174021|NCT02065752|Canagliflozin
174022|NCT02065752|Metformin
174023|NCT02065752|Type 2 diabetes mellitus
174024|NCT02065739|Healthy
174025|NCT02065739|JNJ-42165279
174026|NCT02065739|Itraconazole
174027|NCT02065739|Pharmacokinetics
174028|NCT02065713|Psoriatic arthritis, dactylitis, enthesitis
174029|NCT02065700|Methotrexate
174030|NCT02065700|insufficient responders
174031|NCT02065674|type II Diabetes mellitus
174032|NCT02065674|FBS
174033|NCT02065674|PPBS
174034|NCT02065674|HbA1c%
174035|NCT02065648|MRA
174036|NCT02065648|Syngo Native
174037|NCT02065648|Gadolinium
174038|NCT02065648|Non contrast
174039|NCT02065622|Ulcerative Colitis
174040|NCT02065609|Trastuzumab
174041|NCT02065596|Sickle Cell Disease
174042|NCT02065596|Sickle Cell Anemia
174043|NCT02065596|GvHD
174044|NCT02065596|fludarabine
174045|NCT02065583|Ileus
174046|NCT02065583|Equipment and Supplies
174047|NCT02065583|Technology
174048|NCT02065583|Acoustics
174049|NCT02065570|Crohn's Disease
174050|NCT02065557|Ulcerative Colitis
174051|NCT02065557|adalimumab
174052|NCT02065544|Type 2 diabetes mellitus
174053|NCT02065544|behavioral weight loss
174054|NCT02065544|exercise training
174055|NCT02065544|hemoglobin A1c
174056|NCT02065531|Low Back Pain
174057|NCT02065531|Chronic Pain
174058|NCT02065531|Manipulation
174059|NCT02065531|Manual Therapy
174060|NCT02065531|Randomized Controlled Trial
174061|NCT02065518|Muscle strength
174062|NCT02065518|Electrical muscle stimulation
174063|NCT02065518|Strength training
174064|NCT02065505|Spastic hemiparesis
174065|NCT02065505|Posture
174066|NCT02065505|Pilates
174067|NCT02065505|Respiratory Capacity
174068|NCT02065492|Thalassemia
174069|NCT02065492|Amlodipine
174070|NCT02065492|Chelation
174071|NCT02065492|T2*
174072|NCT02065492|MRI
174073|NCT02065492|Myocardial Iron
174074|NCT02065479|Coronary Artery Disease
174075|NCT02065479|Percutaneous Coronary Intervention
174076|NCT02065479|Genetic Polymorphism
174077|NCT02065479|Pharmacodynamic
174078|NCT02065453|lap hysterectomy
174207|NCT02064959|Hypothermia
174079|NCT02065453|Women in need of a lap hysterectomy for benign disease.
174080|NCT02065440|Ebastine/Pseudoephedrine
174081|NCT02065440|subacute cough
174082|NCT02065440|upper airway cough syndrome
174083|NCT02065427|Caregiver
174084|NCT02065427|Burden
174085|NCT02065427|Social support
174086|NCT02065427|Primary health Care
174087|NCT02065427|Home Care
174088|NCT02065427|Intervention
174089|NCT02065414|Gums
174090|NCT02065414|Gingiva
174091|NCT02065414|Gingival Inflammation
174092|NCT02065414|Gingival Bleeding
174093|NCT02065375|RTA 408
174094|NCT02065375|Ocular surgery
174095|NCT02065375|Cataract surgery
174096|NCT02065375|Ocular inflammation
174097|NCT02065375|Ocular pain
174098|NCT02065375|Eye inflammation
174099|NCT02065362|EBV positive
174100|NCT02065362|TGFbeta
174101|NCT02065362|Nasopharyngeal carcinoma
174102|NCT02065362|cytotoxic T lymphocytes
174103|NCT02065349|peripheral neuropathy
174104|NCT02065349|PDPN
174105|NCT02065349|PHN
174106|NCT02065349|pain
174107|NCT02065336|HBV
174108|NCT02065336|Hepatitis
174109|NCT02065323|Prostate Cancer
174110|NCT02065323|Metastatic
174111|NCT02065323|Hormone-sensitive
174112|NCT02065323|Androgen Deprivation Therapy (ADT)
174113|NCT02065323|Castration-Resistant Prostate Cancer (CRPC)
174114|NCT02065323|Dovitinib
174115|NCT02065323|TKI258
174116|NCT02065323|Circulating Tumor Cells
174117|NCT02065310|AGE
174118|NCT02065310|Diabetes Biomarkers
174119|NCT02065310|CEdG
174120|NCT02065284|MS
174121|NCT02065284|Ambulation
174122|NCT02065258|Asthma, Clinical control, Exercise
174123|NCT02065245|Aging Frailty, Frailty, Cardiovascular, stem cells
174124|NCT02065219|Chronic Pain
174125|NCT02065219|Inguinal Hernia
174126|NCT02065219|Outcome
174127|NCT02065219|Surgical Procedure, Operative
174128|NCT02065206|Focus groups
174129|NCT02065206|Underrepresented Minorities
174130|NCT02065206|Social Media
174131|NCT02065206|Clinical Research Careers
174132|NCT02065167|avascular necrosis of femoral head
174133|NCT02065167|cell therapy
174134|NCT02065167|Mesenchymal stem cells
174135|NCT02065154|acute myeloid leukemia
174136|NCT02065154|AML
174137|NCT02065154|acute lymphoblastic leukemia
174138|NCT02065154|ALL
174139|NCT02065154|chronic myeloid leukemia
174140|NCT02065154|CML
174141|NCT02065154|chronic lymphocytic leukemia
174142|NCT02065154|CLL
174143|NCT02065154|non-Hodgkin lymphoma
174144|NCT02065154|NHL
174145|NCT02065154|Hodgkin lymphoma
174146|NCT02065154|HL
174147|NCT02065154|myelodysplastic syndrome
174148|NCT02065154|MDS
174149|NCT02065154|myelofibrosis
174150|NCT02065154|severe aplastic anemia
174151|NCT02065141|digestion
174152|NCT02065141|absorption
174153|NCT02065141|protein
174154|NCT02065141|amino acids
174155|NCT02065141|heart failure
174156|NCT02065141|COPD
174157|NCT02065115|ice
174158|NCT02065115|cryotherapy
174159|NCT02065115|puncture
174160|NCT02065115|pain
174161|NCT02065102|Rotational atherectomy
174162|NCT02065102|Angina
174163|NCT02065102|Optical coherence tomography
174164|NCT02065102|Intravascular ultrasound
174165|NCT02065102|Coronary stent
174166|NCT02065076|Sodium Polystyrene Sulfonate
174167|NCT02065076|Kayexalate
174168|NCT02065076|Pre-dialysis
174169|NCT02065076|Outpatients
174170|NCT02065076|Hyperkalemia
174171|NCT02065076|Chronic kidney failure
174172|NCT02065076|Potassium
174173|NCT02065063|MEK inhibitor
174174|NCT02065063|PD-0332991
174175|NCT02065063|CDK4/6 inhibitor
174176|NCT02065063|palbociclib
174177|NCT02065063|NRAS wild type
174178|NCT02065063|cutaneous melanoma
174179|NCT02065063|GSK1120212
174180|NCT02065063|trametinib
174181|NCT02065063|NRAS mutant
174182|NCT02065063|BRAFV600 wild type
174183|NCT02065050|Diabetes mellitus
174184|NCT02065050|Team approach
174185|NCT02065037|Insufflation
174186|NCT02065037|Carbon Dioxide
174187|NCT02065037|Colonic Polyps
174188|NCT02065037|Colonoscopy
174189|NCT02065037|Randomized Controlled Trial
174190|NCT02065024|b-cryptoxanthin
174191|NCT02065024|plant sterols
174192|NCT02065024|serum Cholesterol
174193|NCT02065024|bone turnover markers
174194|NCT02064998|Randomized Controlled Trial
174195|NCT02064998|Alcohol
174196|NCT02064998|Internet
174197|NCT02064998|Mobile phone
174198|NCT02064998|Screening
174199|NCT02064998|Brief intervention
174200|NCT02064972|Graft vs Host Disease
174201|NCT02064972|Hematopoietic Stem Cell Transplant
174202|NCT02064972|Biological Marker
174203|NCT02064972|Circulating Endothelial Cells
174204|NCT02064972|Endothelial Dysfunction
174205|NCT02064959|Subdural Hematoma
174206|NCT02064959|Traumatic Brain Injury
174208|NCT02064946|prostate cancer
174209|NCT02064946|bone density
174210|NCT02064946|vitamin D
174211|NCT02064946|micronutrients
174212|NCT02064946|pharmacologic actions
174213|NCT02064933|Wiskott-Aldrich Syndrome
174214|NCT02064933|Hematopoietic Stem Cell Transplantation
174215|NCT02064933|Genetic Therapy
174216|NCT02064907|Drug therapy
174217|NCT02064894|children
174218|NCT02064894|analgesia
174219|NCT02064894|musculoskeletal injury
174220|NCT02064894|emergency
174221|NCT02064894|opioids
174222|NCT02064881|Postprandial lipemia
174223|NCT02064881|Diabetes
174224|NCT02064881|Metformin glycinate
174225|NCT02064881|oxidized LDL
174226|NCT02064868|AHF,
174227|NCT02064868|RLX030,
174228|NCT02064868|SOC,
174229|NCT02064868|WHF,
174230|NCT02064868|RELAX-AHF-EU
174231|NCT02064868|Renal Impairment
174232|NCT02064855|Spinal stenosis
174233|NCT02064855|Spondylolisthesis
174234|NCT02064855|Degenerative disc disease
174235|NCT02064855|Spinal fusion
174236|NCT02064855|Allograft
174237|NCT02064855|Interbody fusion
174238|NCT02064842|Healthy
174239|NCT02064842|TMC647055
174240|NCT02064842|TMC435
174241|NCT02064842|Simeprevir
174242|NCT02064842|Sovriad
174243|NCT02064842|Ritonavir (RTV)
174244|NCT02064829|Metastatic breast cancer
174245|NCT02064829|Locally recurrent breast cancer
174246|NCT02064829|Bioequivalence
174247|NCT02064829|IG-001
174248|NCT02064829|nab-paclitaxel
174249|NCT02064829|Paclitaxel
174250|NCT02064829|Pharmacokinetics
174251|NCT02064816|Multiple Sclerosis, Relapsing-Remitting
174252|NCT02064816|Interferon beta 1a
174253|NCT02064816|Rebif®
174254|NCT02064790|Gabapentin
174255|NCT02064790|Pregabalin
174256|NCT02064790|Lyrica
174257|NCT02064790|Neurontin
174258|NCT02064790|lumbar
174259|NCT02064790|cervical
174260|NCT02064738|Omega-3 fatty acids
174261|NCT02064738|Omega-6 fatty acids
174262|NCT02064738|aspirin exacerbated respiratory disease
174263|NCT02064738|AERD
174264|NCT02064738|Samter's Triad
174265|NCT02064738|nasal polyp
174266|NCT02064738|aspirin
174267|NCT02064738|diet
174268|NCT02064738|leukotriene
174269|NCT02064725|Endometrial cancer
174270|NCT02064725|Recurrent or persistent endometrial carcinoma
174271|NCT02064725|Progesterone Receptor Negative
174272|NCT02064725|Sodium cridanimod
174273|NCT02064725|Virexxa
174274|NCT02064712|Continuous Positive Airway Pressure
174275|NCT02064699|Renal transplant
174276|NCT02064699|CMV
174277|NCT02064699|Test QuantiFERON-CMV
174278|NCT02064673|prostate cancer
174279|NCT02064673|radical prostatectomy
174280|NCT02064660|Myopia
174281|NCT02064660|Children
174282|NCT02064660|Acupressure
174283|NCT02064660|Refractive error
174284|NCT02064660|Axial length
174285|NCT02064660|Korean medicine
174286|NCT02064647|Insulin Infusion Systems
174287|NCT02064647|Blood Glucose
174288|NCT02064634|Shinbaro Capsule
174289|NCT02064634|Celecoxib
174290|NCT02064634|Osteoarthritis
174291|NCT02064634|GCSB-5
174292|NCT02064634|Discontinuation rate
174293|NCT02064634|Gastrointestinal adverse event
174294|NCT02064634|NSAIDs
174295|NCT02064634|OASIS
174296|NCT02064608|Prostate
174297|NCT02064608|Cancer
174298|NCT02064608|Prostate Cancer
174299|NCT02064608|High Risk
174300|NCT02064608|Intermediate Risk
174301|NCT02064608|Early disease
174302|NCT02064608|Neoadjuvant treatment
174303|NCT02064608|Radical Prostatectomy
174304|NCT02064595|Tibial fractures.
174305|NCT02064595|Fracture fixation.
174306|NCT02064595|External fixators.
174307|NCT02064595|Intramedullary.
174308|NCT02064595|Quality of life.
174309|NCT02064582|prostate cancer, enzalutamide, radiation, hormone therapy
174310|NCT02064543|Parkinson's disease
174311|NCT02064543|gait
174312|NCT02064530|TAP block
174313|NCT02064530|dexmedetomidine
174314|NCT02064530|bupivacaine
174315|NCT02064530|postoperative analgesia
174316|NCT02064517|Necrosed Immature monoradicular Teeth , Revascularisation pulpar, MTA apical barrier, Clinical and radiographic success
174317|NCT02064504|Respiratory
174318|NCT02064504|GSK961081 (MABA)
174319|NCT02064504|healthy subjects
174320|NCT02064504|pharmacokinetics
174321|NCT02064504|GW685698 (fluticasone furoate)
174322|NCT02064491|Non-small cell lung cancer
174323|NCT02064491|EGFR mutant
174324|NCT02064491|Erlotinib
174325|NCT02064491|Treatment Beyond Progression
174326|NCT02064478|Bone anchored hearing implant
174327|NCT02064478|Bone anchored hearing device
174328|NCT02064452|behavior problems
174329|NCT02064452|children
174330|NCT02064452|prevention
174331|NCT02064452|parenting
174332|NCT02064452|online
174333|NCT02064452|pediatric
174334|NCT02064439|deep vein thrombosis
174335|NCT02064439|pulmonary embolism
174336|NCT02064439|long-term prevention of recurrent symptomatic VTE
174337|NCT02064426|Anemia of CKD on dialysis
174338|NCT02064413|Birth control
174339|NCT02064400|Rheumatoid arthritis
174340|NCT02064400|Ultrasound
174341|NCT02064400|Remission
174342|NCT02064400|Qualitative
174343|NCT02064387|Multiple Myeloma
174344|NCT02064387|BCMA expressing Lymphomas
174345|NCT02064374|Dolutegravir
174346|NCT02064374|drug interaction
174347|NCT02064374|metformin
174348|NCT02064374|pharmacokinetics
174349|NCT02064374|healthy volunteers
174350|NCT02064361|SCUBA diving
174351|NCT02064361|exercise,
174352|NCT02064361|microparticles
174353|NCT02064361|neutrophil activation,
174354|NCT02064361|high intensity exercise
174355|NCT02064335|physical activity coach, diabetic persons, health, behaviour
174356|NCT02064322|sacroiliac joint fusion
174357|NCT02064322|SIJ fusion
174358|NCT02064322|SI joint
174359|NCT02064296|Fibromyalgia Chronic Pain
174360|NCT02064270|incision care
174361|NCT02064270|Total Hip Arthroplasty
174362|NCT02064270|Total Knee Arthroplasty
174363|NCT02064270|Knee surgery
174364|NCT02064270|Hip surgery
174365|NCT02064257|autonomic nervous system
174366|NCT02064257|auditory processing disorder
174367|NCT02064257|social behavior
174368|NCT02064244|renal
174369|NCT02064244|kidney
174370|NCT02064244|creatinine
174371|NCT02064244|Inferior Vena Cava (IVC)
174372|NCT02064244|Acute Renal Failure (ARF)
174373|NCT02064244|Acute Kidney Injury (AKI)
174374|NCT02064205|pre-load
174375|NCT02064205|satiety
174376|NCT02064205|energy intake
174377|NCT02064205|appetite
174378|NCT02064192|defibrillator, implantable cardioverter
174379|NCT02064192|sudden cardiac death
174380|NCT02064192|primary prophylaxis
174381|NCT02064192|risk stratification
174382|NCT02064179|Congenital heart disease
174383|NCT02064179|Antiplatelet therapy
174384|NCT02064179|Aspirin
174385|NCT02064166|Parkinson disease
174386|NCT02064166|Multiple system atrophy
174387|NCT02064166|Intranasal
174388|NCT02064166|Insulin
174389|NCT02064153|Dialysate temperature
174390|NCT02064153|Spent dialysate
174391|NCT02064153|Toxin removal
174392|NCT02064153|Intra-dialytic hypotension
174393|NCT02064153|Inter-compartmental resistance
174394|NCT02064140|ARDS
174395|NCT02064140|Mechanical Ventilation
174396|NCT02064140|Tidal volume
174397|NCT02064140|NMBA
174398|NCT02064114|BMI >40
174399|NCT02064101|Scoliosis
174400|NCT02064101|EMG
174401|NCT02064101|Pedicle screw
174402|NCT02064101|Neuromonitoring
174403|NCT02064088|Regional anesthesia
174404|NCT02064088|TAP block
174405|NCT02064088|Pediatric anesthesia
174406|NCT02064088|analgesic effects
174407|NCT02064088|pharmacokinetics
174408|NCT02064075|Subarachnoid hemorrhage
174409|NCT02064075|vasospasm
174410|NCT02064075|Lactated Ringer's solution
174411|NCT02064075|Hydroxyethyl starch solution
174412|NCT02064062|Achilles Tendinopathy
174413|NCT02064062|Autologous Stem Cells
174414|NCT02064062|Musculoskeletal
174415|NCT02064049|Hepatitis C virus
174416|NCT02064049|People who inject drugs
174417|NCT02064049|Drug users
174418|NCT02064049|Direct acting antiviral (DAA)
174419|NCT02064049|Infectious diseases
174420|NCT02064049|Prisoners
174421|NCT02064036|Prostate Cancer
174422|NCT02064036|Radiotherapy
174423|NCT02064036|Androgen Deprivation
174424|NCT02064023|insulin pump
174425|NCT02064023|CSII
174426|NCT02064023|multiple daily injections
174427|NCT02064023|MDI
174428|NCT02064023|type 1 diabetes
174429|NCT02064023|type 2 diabetes
174430|NCT02064023|pregnancy
174431|NCT02063971|Skin aging
174432|NCT02063971|Soothing activity
174433|NCT02063971|Hyaluronic acid injections
174434|NCT02063958|Neuroendocrine tumor
174435|NCT02063958|Hsp90
174436|NCT02063945|ADHA
174437|NCT02063945|ODD
174438|NCT02063945|Conduct disorder
174439|NCT02063945|Aggression
174440|NCT02063945|Treatment
174441|NCT02063945|Methylphenidate
174442|NCT02063945|Risperidone
174443|NCT02063932|mucosal microbiome
174444|NCT02063932|H.pylori
174445|NCT02063932|intestinal metaplasia
174446|NCT02063932|gastric neoplasia
174447|NCT02063932|endomicroscopy
174448|NCT02063880|HIV-1
174449|NCT02063880|IRIS
174450|NCT02063867|HAI
174451|NCT02063867|MRSA
174452|NCT02063867|VRE
174453|NCT02063854|Drug Therapy
174454|NCT02063802|pediatric obesity
174455|NCT02063802|conjugated linoleic acid
174456|NCT02063802|CLA
174457|NCT02063802|metformin
174458|NCT02063789|Immune Thrombocytopenia
174459|NCT02063789|Immune Thrombocytopenic Purpura
174460|NCT02063789|Idiopathic Thrombocytopenic Purpura
174461|NCT02063789|Human Immunoglobulin
174462|NCT02063789|ITP
174463|NCT02063789|IVIg
174464|NCT02063789|IgIV
174465|NCT02063789|IV-Globulin SN Inj.
174466|NCT02063776|Haemodiafiltration (HDF)
174467|NCT02063776|Haemodialysis (HD)
174468|NCT02063776|Children
174469|NCT02063776|Carotid intima media thickness
174470|NCT02063776|Pulse wave velocity
174471|NCT02063776|Height standard deviation score
174472|NCT02063763|Adult patients
174473|NCT02063763|Immune primary thrombocytopenia
174474|NCT02063763|Splenectomy
174475|NCT02063763|TPO-mimetics
174476|NCT02063763|Eltrombopag
174477|NCT02063763|Romiplostim
174478|NCT02063750|Fibromyalgia
174479|NCT02063750|Muscle strength exercises
174480|NCT02063750|Pain
174481|NCT02063750|Quality of life
174482|NCT02063737|Shift work
174483|NCT02063737|Fatigue
174484|NCT02063737|Sleepiness
174485|NCT02063737|Injury
174486|NCT02063724|Invasive Breast Cancer
174487|NCT02063724|Breast Cancer
174488|NCT02063724|Immunotherapy
174489|NCT02063724|Vaccine
174490|NCT02063724|Dendritic Cell
174491|NCT02063711|Prenatal Yoga
174492|NCT02063711|Yoga, Pregnancy
174493|NCT02063711|Yoga, Fetal Response
174494|NCT02063646|polyphenols
174495|NCT02063646|memory
174496|NCT02063646|elderly
174497|NCT02063633|Thoracic malignancy, irradiation, respiratory gating system PET
174498|NCT02063620|IVRA, ketamine, lidocaine, ECG
174499|NCT02063607|Hepatitis C naive
174500|NCT02063594|Iodixanol
174501|NCT02063594|Iodinated Contrast
174502|NCT02063594|Liposome
174503|NCT02063594|Computed Tomography
174504|NCT02063594|X-ray Imaging
174505|NCT02063594|Blood pool agent
174506|NCT02063594|Biomarker
174507|NCT02063555|Tuberculosis
174508|NCT02063555|BCG
174509|NCT02063555|HIV
174510|NCT02063555|TB Vaccines
174511|NCT02063542|Postoperative cognitive changes
174512|NCT02063542|Acetylcholine in CSF
174513|NCT02063542|Surgery
174514|NCT02063529|Colorectal cancer
174515|NCT02063529|Metastatic colorectal cancer
174516|NCT02063529|Liver metastases
174517|NCT02063529|Liver resection
174518|NCT02063529|Liver ablation
174519|NCT02063529|Conversion therapy
174520|NCT02063529|FOLFOXIRI
174521|NCT02063529|Cetuximab
174522|NCT02063529|Oxaliplatin
174523|NCT02063529|Irinotecan
174524|NCT02063529|Leucovorin
174525|NCT02063516|Airway Cuff
174526|NCT02063516|Guardian
174527|NCT02063516|Proseal
174528|NCT02063516|Cuff Pressure
174529|NCT02063516|laryngeal Mask Airway
174530|NCT02063503|clinical prediction rule
174531|NCT02063503|nonspecific
174532|NCT02063503|chronic
174533|NCT02063503|low back pain
174534|NCT02063503|Non specific chronic low back pain
174535|NCT02063490|Adherence
174536|NCT02063490|dialysis
174537|NCT02063490|intervention
174538|NCT02063490|nurse-led
174539|NCT02063490|phosphate binders
174540|NCT02063490|trial
174541|NCT02063464|Tumorcidal
174542|NCT02063464|Monocytes
174543|NCT02063464|Interferons Alpha and Gamma
174544|NCT02063451|Obesity [C18.654.726.500]
174545|NCT02063451|Receptor, Opioid, mu [D12.776.543.750.100.620.550]
174546|NCT02063451|Brain [A08.186.211]
174547|NCT02063451|Affect [F01.470.047]
174548|NCT02063438|Thoracotomy
174549|NCT02063438|Pain
174550|NCT02063438|Intracostal Suture
174551|NCT02063438|Pericostal Suture
174552|NCT02063425|Motor recovery
174553|NCT02063425|Fluoxetine
174554|NCT02063425|Transcranial magnetic stimulation
174555|NCT02063425|stroke
174556|NCT02063399|NPC
174557|NCT02063399|Cancer screening
174558|NCT02063399|Plasma EBV DNA
174559|NCT02063347|innate collateral supply
174560|NCT02063347|collateral
174561|NCT02063347|coronary collateral
174562|NCT02063347|renal collateral
174563|NCT02063347|peripheral collateral
174564|NCT02063347|coronary artery disease
174565|NCT02063334|vitamin D3
174566|NCT02063334|cholecalciferol
174567|NCT02063334|calcidiol
174568|NCT02063334|25-hydroxyvitamin D
174569|NCT02063334|gene expression
174570|NCT02063334|vitamin D receptor
174571|NCT02063334|randomized controlled trial
174572|NCT02063334|men
174573|NCT02063334|adults
174574|NCT02063321|DME, diabetic retinopathy, diabetes mellitus, epidemiology
174575|NCT02063308|Oxaloacetate
174576|NCT02063308|OAA
174577|NCT02063308|AD
174578|NCT02063308|Alzheimer's Disease
174579|NCT02063295|Beloranib
174580|NCT02063295|ZGN-440
174581|NCT02063295|ZGN-440 for injectable suspension
174582|NCT02063295|ZGN-433
174583|NCT02063282|Asymptomatic
174584|NCT02063282|Carriage
174585|NCT02063282|Colonization
174586|NCT02063282|Clostridium difficile
174587|NCT02063282|Colitis
174588|NCT02063282|Rectal swab
174589|NCT02063269|rivastigmine, butyrylcholinesterase, MRI, PET
174590|NCT02063256|sperm count
174591|NCT02063256|sperm concentration
174592|NCT02063256|mobility
174593|NCT02063256|diet
174594|NCT02063256|PUFA (polyunsaturated fatty acids)
174595|NCT02063243|Keloid, hypertrophic scar
174596|NCT02063230|Phase I, healthy, pharmacokinetic, hepatic impairment
174597|NCT02063204|Phase I, healthy, pharmacokinetics, renal impairment
174598|NCT02063191|Atrial Fibrillation
174599|NCT02063191|Bundle Branch Block
174600|NCT02063165|Safflower Oil
174601|NCT02063165|Linoleic Acid
174602|NCT02063165|Dyslipidemia
174603|NCT02063165|Hypertension
174604|NCT02063139|Knemometry
174605|NCT02063126|Coenzyme Q10 plus NADH
174606|NCT02063126|maximum Heart Rate
174607|NCT02063126|Fatigue
174608|NCT02063126|Pain
174609|NCT02063126|Sleep
174610|NCT02063113|Multiple myeloma,
174611|NCT02063113|Older patient,
174612|NCT02063113|Treatment,
174613|NCT02063113|Geriatric assessment
174614|NCT02063100|Glomerulonephritis
174615|NCT02063100|proteinuria
174616|NCT02063100|shenyankangfu tablets
174617|NCT02063100|Losartan Potassium
174618|NCT02063100|efficacy
174619|NCT02063100|safety
174620|NCT02063087|Head CT
174621|NCT02063087|Head Injury
174622|NCT02063087|Pediatric
174623|NCT02063087|Emergency Department
174624|NCT02063087|Decision Aids
174625|NCT02063087|Shared Decision Making
174626|NCT02063061|extracorporeal shock wave therapy ESWT
174627|NCT02063061|erectile dysfunction
174628|NCT02063048|weight loss
174629|NCT02063048|Text Messaging
174630|NCT02063048|Short Message Service
174631|NCT02063048|Text Messages
174632|NCT02063035|lumbar spine surgery
174633|NCT02063035|thoracic spine surgery
174634|NCT02063022|Non metastatic Ewing's Sarcoma
174635|NCT02062944|Liver Transplant
174636|NCT02062944|Sirolimus
174637|NCT02062944|Rapamune
174638|NCT02062944|Immunosuppressant Therapy
174639|NCT02062944|Withdrawal
174640|NCT02062931|Primary Infertility
174641|NCT02062931|Primary Amenorrhea
174642|NCT02062931|Sex Steroid Deficiency
174643|NCT02062931|Premature Ovarian Failure (POF)
174644|NCT02062918|Abdominal belt
174645|NCT02062918|Chronic low back pain
174646|NCT02062918|Pain
174647|NCT02062918|Functional capacity
174648|NCT02062892|everolimus
174649|NCT02062892|sirolimus
174650|NCT02062892|tacrolimus
174651|NCT02062892|vascular endothelial function
174652|NCT02062892|kidney
174653|NCT02062892|Transplantation
174654|NCT02062892|biomarkers
174655|NCT02062879|pain
174656|NCT02062879|trauma
174657|NCT02062840|Whole Body Hyperthermia
174658|NCT02062840|Functional Magnetic Resonance Imaging
174659|NCT02062840|EEG
174660|NCT02062827|Glioma
174661|NCT02062801|Combined spinal epidural analgesia, labor, fetal bradycardia
174662|NCT02062788|Early Recovery After Surgery
174663|NCT02062788|Oral rehydration solution
174664|NCT02062788|Insulin resistance
174665|NCT02062788|Postoperative complication
174666|NCT02062749|Colorectal cancer
174667|NCT02062749|Colon Cancer
174668|NCT02062749|Pediatric
174669|NCT02062749|Adolescent
174670|NCT02062749|Hyperthermic Intraperitoneal Chemotherapy
174671|NCT02062749|HIPEC
174672|NCT02062749|Oxaliplatin
174673|NCT02062749|Eloxatin
174674|NCT02062736|methadone
174675|NCT02062736|heroin addiction
174676|NCT02062736|methadone maintenance treatment
174677|NCT02062736|adequate dosage of methadone
174678|NCT02062723|methadone
174679|NCT02062723|heroin addiction
174680|NCT02062723|methadone maintenance treatment
174681|NCT02062723|adequate dosage of methadone
174682|NCT02062710|cough
174683|NCT02062710|cough reflex
174684|NCT02062710|capsaicin
174685|NCT02062710|diphenhydramine
174686|NCT02062710|phenylephrine
174687|NCT02062710|dextromethorphan
174688|NCT02062710|placebo
174689|NCT02062697|Neoplasms
174690|NCT02062697|Glandular and Epithelial
174691|NCT02062697|Ovarian Neoplasms
174692|NCT02062697|Ovarian cancer
174693|NCT02062684|IgAN
174694|NCT02062684|IgA Nephropathy
174695|NCT02062684|A-623
174696|NCT02062684|Blisibimod
174697|NCT02062684|Kidney Disease
174698|NCT02062684|Persistent proteinuria
174699|NCT02062671|ADPKD
174700|NCT02062671|denervation
174701|NCT02062671|renal denervation
174702|NCT02062658|OCD
174703|NCT02062645|essential hypertension
174704|NCT02062619|Stroke
174705|NCT02062619|Aphasia
174706|NCT02062619|Acquired reading disorders
174707|NCT02062619|Central alexia
174708|NCT02062619|Computer based rehabilitation
174709|NCT02062619|Transcranial direct current stimulation
174710|NCT02062619|tDCS
174711|NCT02062619|Magnetoencephalography
174712|NCT02062619|MEG
174713|NCT02062619|Magnetic Resonance Imaging
174714|NCT02062619|MRI
174715|NCT02062606|Scoliosis
174716|NCT02062606|Spinal Curvatures
174717|NCT02062606|Spinal Diseases
174718|NCT02062606|Adolescent Idiopathic Scoliosis
174719|NCT02062606|Spinal Deformity
174720|NCT02062593|Stable angina
174721|NCT02062593|Percutaneous coronary intervention
174722|NCT02062593|Optimal medical therapy
174723|NCT02062593|Sham-control
174724|NCT02062580|Vaccine immunogenicity
174725|NCT02062580|Immune activation
174726|NCT02062554|Myocardial infarction
174727|NCT02062554|Clinical outcome
174728|NCT02062554|Flow-mediated dilation
174729|NCT02062554|Inflammation
174730|NCT02062541|functional assessment
174731|NCT02062541|rehabilitation
174732|NCT02062541|cross-sectorial cooperation
174733|NCT02062528|EPA
174734|NCT02062489|breast cancer,
174735|NCT02062489|tamoxifen,
174736|NCT02062489|ER/PR negative, ER-beta positive
174737|NCT02062463|Asthma
174738|NCT02062450|Arthroplasty
174739|NCT02062450|Hip Replacement
174740|NCT02062450|Acetabular cup
174741|NCT02062450|Dual mobility
174742|NCT02062450|Hip revision surgery
174743|NCT02062437|Arthroplasty
174744|NCT02062437|Hip Replacement
174745|NCT02062437|Ceramic
174746|NCT02062437|Acetabular cup
174747|NCT02062437|Femoral stem
174748|NCT02062424|ischemic heart disease, dietary guidelines
174749|NCT02062411|attention deficit disorder (ADHD)
174750|NCT02062411|cognitive behavioral therapy (CBT)
174751|NCT02062411|adult
174752|NCT02062398|PNP
174753|NCT02062398|Stimulation
174754|NCT02062398|Peripheral neurostimulation
174755|NCT02062372|7 T MRI
174756|NCT02062372|Radiotherapy
174757|NCT02062372|Glioblastoma
174758|NCT02062372|Biopsy
174759|NCT02062359|Malignant Melanoma
174760|NCT02062359|Metastatic Cancer
174761|NCT02062359|Gene Therapy
174762|NCT02062359|Immunotherapy
174763|NCT02062359|Tumor Regression
174764|NCT02062346|endothelin;
174765|NCT02062346|blood pressure;
174766|NCT02062346|vasculitis
174767|NCT02062333|dexmedetomidine
174768|NCT02062333|esmolol
174769|NCT02062333|stapes reflex
174770|NCT02062320|Acute Pain Service
174771|NCT02062320|postoperative analgesia
174772|NCT02062320|Caesarean Section
174773|NCT02062320|non-opioid analgesia
174774|NCT02062320|opioid analgesia
174775|NCT02062320|epidural analgesia
174776|NCT02062307|Hypogonadism
174777|NCT02062307|Asymmetric Dimethyl Arginine
174778|NCT02062307|Osteoprotegerin
174779|NCT02062307|Fibroblast Growth Factor
174780|NCT02062307|Vitamin D
174781|NCT02062281|Safety
174782|NCT02062281|Immunogenicity
174783|NCT02062281|vaccine
174784|NCT02062281|pneumococcal
174785|NCT02062281|influenza
174786|NCT02062268|KAP
174787|NCT02062268|drink driving
174788|NCT02062268|public
174789|NCT02062268|Jiangsu province
174790|NCT02062268|China
174791|NCT02062255|Asprin
174792|NCT02062255|Omega-3 Free Fatty Acids
174793|NCT02062255|Obesity
174794|NCT02062255|COX-2 inhibitor
174795|NCT02062242|Pelvic Floor
174796|NCT02062242|Physical Therapy Specialty
174797|NCT02062242|Awareness
174798|NCT02062242|Electric Stimulation
174799|NCT02062242|Palpation
174800|NCT02062229|oxidative stress
174801|NCT02062229|oxysterols
174802|NCT02062229|fatty acids
174803|NCT02062229|seminal fluid
174804|NCT02062216|Coronary artery disease
174805|NCT02062216|Percutaneous coronary intervention
174806|NCT02062216|Inflammatory receptors
174807|NCT02062203|Akebia
174808|NCT02062203|QT interval
174809|NCT02062203|TQT
174810|NCT02062203|pharmacokinetic
174811|NCT02062203|anemia
174812|NCT02062203|chronic kidney disease
174813|NCT02062203|CKD
174814|NCT02062203|chronic renal insufficiency
174815|NCT02062203|renal impairment
174816|NCT02062203|safety
174817|NCT02062164|psychosocial, healthcare, co-morbidities, extremely obese adolescents
174818|NCT02062138|rehabilitation
174819|NCT02062138|total knee arthroplasty
174820|NCT02062138|range of motion
174821|NCT02062138|continuous passive motion
174822|NCT02062138|controlled active motion
174823|NCT02062138|postoperative physical therapy
174824|NCT02062125|scleroderma
174825|NCT02062125|calcinosis
174826|NCT02062112|Bowel preparation solutions
174827|NCT02062112|Colonoscopy
174828|NCT02062112|Polyethylene glycol
174829|NCT02062086|Sarcopenia
174830|NCT02062086|Mass muscle
174831|NCT02062086|Quality of life
174832|NCT02062073|head lice
174833|NCT02062073|Hatchtech
174834|NCT02062060|Head Lice
174835|NCT02062060|Hatchtech
174836|NCT02062047|Diabetes Mellitus
174837|NCT02062047|Chronic Periodontitis
174838|NCT02062047|Root Planing
174839|NCT02062047|Cytokines
174840|NCT02062047|microbiology
174841|NCT02062047|Glycated hemoglobin
174842|NCT02062047|diabetic subjects
174843|NCT02062034|Oxidative stress
174844|NCT02062034|Mitochondrial dysfunction
174845|NCT02062034|Ubiquinone
174846|NCT02062034|Antioxidant combined therapy
174847|NCT02062034|Diabetic retinopathy
174848|NCT02062008|Positron Emission Tomography-Magnetic Resonance Imaging
174849|NCT02062008|Cardiac Disease
174850|NCT02061995|Bone Diseases
174851|NCT02061995|Metabolic Bone Diseases
174852|NCT02061995|Osteoporosis
174853|NCT02061995|Bone Fractures
174854|NCT02061995|Osteoporotic Fractures
174855|NCT02061995|Musculoskeletal Diseases
174856|NCT02061982|Do It Yourself (DIY)
174857|NCT02061982|Caffeine
174858|NCT02061982|Cognition
174859|NCT02061969|nursing home facility
174860|NCT02061969|long-term care facility
174861|NCT02061969|older patients
174862|NCT02061969|elderly patients
174863|NCT02061969|hyperglycemia
174864|NCT02061969|type 2 diabetes
174865|NCT02061943|Spasmodic dysphonia
174866|NCT02061943|Laryngeal dystonia
174867|NCT02061943|Dystonia
174868|NCT02061943|Severity
174869|NCT02061930|single tooth
174870|NCT02061930|dental implant
174871|NCT02061930|aesthetics outcome
174872|NCT02061930|long term
174873|NCT02061930|soft tissue recession
174874|NCT02061930|pink esthetic score
174875|NCT02061930|white esthetic score
174876|NCT02061917|Biomarkers
174877|NCT02061917|Tobacco
174878|NCT02061917|Tobacco-heating
174879|NCT02061917|Smokeless Tobacco
174880|NCT02061917|Snus
174881|NCT02061917|Smoking
174882|NCT02061917|Exposure
174883|NCT02061917|Quality of Life
174884|NCT02061891|Coronary Stenosis
174885|NCT02061891|Coronary Artery Disease
174886|NCT02061891|Acute coronary syndrome
174887|NCT02061891|Percutaneous Coronary Intervention
174888|NCT02061891|Multidetector Computed Tomography
174889|NCT02061878|ApoE
174890|NCT02061878|beta-amyloid
174891|NCT02061813|Hatchtech
174892|NCT02061800|Unrelated donor transplant
174893|NCT02061800|Allogenic Stem Cell Transplant
174894|NCT02061800|Adult Bone Marrow Transplant
174895|NCT02061800|Pediatric Bone Marrow Transplant
174896|NCT02061800|Related donor transplant
174897|NCT02061800|Haploidentical donor transplant
174898|NCT02061800|Peripheral blood stem cell transplantation
174899|NCT02061800|Non-malignant disease
174900|NCT02061800|Malignant disease
174901|NCT02061800|Bone marrow failure syndrome
174902|NCT02061800|Severe Aplastic Anemia
174903|NCT02061800|Severe Congenital Neutropenia
174904|NCT02061800|Amegakaryocytic Thrombocytopenia
174905|NCT02061800|Diamond-Blackfan Anemia
174906|NCT02061800|Schwachman Diamond Syndrome
174907|NCT02061800|Primary Immunodeficiency Syndrome
174908|NCT02061800|Acquired Immunodeficiency Syndrome
174909|NCT02061800|Histiocytic Syndrome
174910|NCT02061800|Familial Hemophagocytic Lymphocytosis
174911|NCT02061800|Lymphohistiocytosis
174912|NCT02061800|Macrophage Activation Syndrome
174913|NCT02061800|Langerhans Cell Histiocytosis (LCH)
174914|NCT02061800|Hemoglobinopathies
174915|NCT02061800|Reduced-Intensity Conditioning
174916|NCT02061800|Sickle Cell Disease
174917|NCT02061800|Sickle Cell-beta-thalassemia
174918|NCT02061774|acetaminophen in transforaminal lumbar interbody fusion
174919|NCT02061735|skin imaging
174920|NCT02061735|image analysis
174921|NCT02061735|infrared thermography
174922|NCT02061735|infantile hemangioma
174923|NCT02061735|three dimensional imaging
174924|NCT02061735|color imaging and analysis
174925|NCT02061735|propranolol
174926|NCT02061735|timolol
174927|NCT02061735|ontogeny
174928|NCT02061709|Rhinoconjunctivitis
174929|NCT02061709|Rhinitis
174930|NCT02061709|Seasonal
174931|NCT02061709|Ragweed
174932|NCT02061709|Allergy
174933|NCT02061696|Coronary Artery Disease
174934|NCT02061696|Coronary Disease
174935|NCT02061696|Heart disease
174936|NCT02061696|Cardiovascular Diseases
174937|NCT02061696|Arteriosclerosis
174938|NCT02061696|Atherosclerosis
174939|NCT02061696|Manual Compression
174940|NCT02061670|Ragweed
174941|NCT02061670|Allergy
174942|NCT02061670|rhinoconjunctivitis
174943|NCT02061670|rhinitis
174944|NCT02061670|asthma
174945|NCT02061618|South Asian
174946|NCT02061579|Physical Activity
174947|NCT02061566|Acute kidney injury
174948|NCT02061553|traumatic brain injury
174949|NCT02061553|TBI
174950|NCT02061553|head injury
174951|NCT02061553|brain injury
174952|NCT02061553|depression
174953|NCT02061553|anxiety
174954|NCT02061527|ADM
174955|NCT02061527|Strattice
174956|NCT02061527|Breast reconstruction
174957|NCT02061527|Immediate breast reconstruction
174958|NCT02061527|IBR
174959|NCT02061527|Acellular dermal matrix
174960|NCT02061527|Biological mesh
174961|NCT02061527|Randomized controlled trial
174962|NCT02061527|RCT
174963|NCT02061527|Breast cancer
174964|NCT02061527|Implants
174965|NCT02061527|Mastectomy
174966|NCT02061527|Direct-to-implant
174967|NCT02061501|visual cognitive deficits
174968|NCT02061488|Artificial pancreas, closed loop glucose control, model predictive control
174969|NCT02061475|Lidocaine patches
174970|NCT02061475|Pain
174971|NCT02061475|Intravenous cannulation
174972|NCT02061449|Toll-like receptor agonist
174973|NCT02061449|immunostimulation
174974|NCT02061436|chronic total occlusion, percutaneous coronary intervention
174975|NCT02061423|Invasive Breast Cancer
174976|NCT02061423|Breast Cancer
174977|NCT02061423|Immunotherapy
174978|NCT02061423|Vaccine
174979|NCT02061423|Dendritic Cell
174980|NCT02061423|Neoadjuvant
174981|NCT02061410|Elderly
174982|NCT02061397|lymphangioleiomyomatosis (LAM)
174983|NCT02061397|tuberous sclerosis complex (TSC)
174984|NCT02061397|simvastatin
174985|NCT02061397|sirolimus
174986|NCT02061397|everolimus
174987|NCT02061384|Infertility
174988|NCT02061371|stroke
174989|NCT02061371|spasticity
174990|NCT02061371|physiotherapy
174991|NCT02061371|virtual reality
174992|NCT02061358|Dengue
174993|NCT02061358|Arbovirus Infections
174994|NCT02061358|Flaviviridae Infections
174995|NCT02061358|Flavivirus Infections
174996|NCT02061358|Hemorrhagic Fevers, Viral
174997|NCT02061358|RNA Virus Infections
174998|NCT02061358|Virus Diseases
174999|NCT02061358|Pharmaceutical Solutions
175000|NCT02061358|Pharmacologic Actions
175001|NCT02061358|Therapeutic Uses
175002|NCT02061345|Prostate cancer
175003|NCT02061345|Androgen Deprivation Therapy
175004|NCT02061345|Mild Cognitive Impairment
175005|NCT02061332|Breast Cancer
175006|NCT02061332|DCIS
175007|NCT02061332|Immunotherapy
175008|NCT02061332|Vaccine
175009|NCT02061332|Dendritic Cell
175010|NCT02061306|Celiac disease
175011|NCT02061306|coeliac disease
175012|NCT02061306|microbiome
175013|NCT02061306|gluten
175014|NCT02061306|infants
175015|NCT02061306|pregnancy
175016|NCT02061306|genetic
175017|NCT02061280|Asthma
175018|NCT02061280|Clinical Trial Design
175019|NCT02061280|Electronic Data Entry
175020|NCT02061280|Mobile Devices
175021|NCT02061280|Home Spirometry
175022|NCT02061267|Metabolic Syndrome
175023|NCT02061267|Olive Oil
175024|NCT02061267|Niacin
175025|NCT02061254|Venous insufficiency
175026|NCT02061254|Lymphedema
175027|NCT02061254|Elastograph
175028|NCT02061254|Ultrasonography
175029|NCT02061254|Fibrosis
175030|NCT02061254|Dermis
175031|NCT02061254|Hypodermis
175032|NCT02061254|Skin
175033|NCT02061241|Cardiac resynchronisation therapy
175034|NCT02061241|Pacing
175035|NCT02061215|CYTOF
175036|NCT02061215|CMV
175037|NCT02061215|PCR
175038|NCT02061215|HLA
175039|NCT02061202|Sickle Cell Disease
175040|NCT02061202|Pain Crisis
175041|NCT02061202|Painful Crisis
175042|NCT02061202|Sickle Pain
175043|NCT02061189|neuromuscular disease, Spinal Muscular Atrophy, Infantile,
175044|NCT02061189|motor function measure, Hammersmith scale,
175045|NCT02061189|rehabilitation program, physical exercise
175046|NCT02061176|Hemorrhoids
175047|NCT02061176|Haemorrhoids
175048|NCT02061176|Transanal Haemorrhoidal Dearterialization
175049|NCT02061176|Transanal Hemorrhoidal Dearterialisation
175050|NCT02061176|Open Haemorrhoidectomy
175051|NCT02061176|Open Hemorrhoidectomy
175052|NCT02061150|Early onset GBS sepsis
175053|NCT02061150|Prevention
175054|NCT02061150|Maternal risk factors
175055|NCT02061137|Rett Syndrome (Mecp2 positive)
175056|NCT02061137|Fingolimod (FTY 720)
175057|NCT02061137|BDNF
175058|NCT02061137|Brain Atrophy
175059|NCT02061111|Mitochondria Function
175060|NCT02061111|TPO-antibodies
175061|NCT02061111|Subclinical Thyroid Disease
175062|NCT02061111|Thyroid Disease In Pregnancy
175063|NCT02061111|Children´s Development
175064|NCT02061098|Pomegranate
175065|NCT02061098|Cardiovascular
175066|NCT02061098|Urolithins
175067|NCT02061098|Microbiota
175068|NCT02061098|Polyphenols
175069|NCT02061098|Nutraceutical
175070|NCT02061098|Dietary supplement
175071|NCT02061085|Breast Neoplasm Metastasis
175072|NCT02061085|Receptor,HER-2
175073|NCT02061085|Eribulin
175074|NCT02061085|Furans, quetones
175075|NCT02061085|Antimitotic agent
175076|NCT02061072|pharmacokinetics
175077|NCT02061072|population pharmacokinetics
175078|NCT02061072|hemophilia
175079|NCT02061072|factor VIII
175080|NCT02061072|factor IX
175081|NCT02061046|Gait
175082|NCT02061046|Dual task
175083|NCT02061033|Hemophilia A
175084|NCT02061033|Hemophilia B
175085|NCT02061033|Von Willebrand's Disease
175086|NCT02061033|Endogen thrombin potential
175087|NCT02061033|Overall hemostatic potential
175088|NCT02061033|Microparticles
175089|NCT02061033|Fibrin clot
175090|NCT02061020|delta-9-tetrahydrocannabinol, volunteers, cannabis users
175091|NCT02061007|skin cancer
175092|NCT02060981|Randomized controlled trial
175093|NCT02060981|Primary medication adherence
175094|NCT02060981|Decision-support tool
175095|NCT02060981|Patient-centered outcomes research
175096|NCT02060981|Antihypertensive medications
175097|NCT02060981|One-on-one patient interviews
175098|NCT02060968|Promus PREMIER
175099|NCT02060968|Routine Clinical Practice
175100|NCT02060955|Glioblastoma multiforme
175101|NCT02060955|Immunotherapy
175102|NCT02060955|Bevacizumab/Irinotecan
175103|NCT02060955|ALECSAT
175104|NCT02060955|recurrent
175105|NCT02060942|Volume responsiveness mean systemic filling pressure
175106|NCT02060929|Healthy
175107|NCT02060929|Esketamine
175108|NCT02060929|Intranasal
175109|NCT02060929|Nasal Guide
175110|NCT02060929|Pharmacokinetics
175111|NCT02060903|Head Lice
175112|NCT02060903|Hatchtech
175113|NCT02060890|Glioblastoma
175114|NCT02060877|suspected lung cancer
175115|NCT02060877|diagnostic work-up
175116|NCT02060864|enzyme
175117|NCT02060864|gluten
175118|NCT02060864|food intolerance
175119|NCT02060851|EPO
175120|NCT02060851|Intravenous iron
175121|NCT02060851|iron storage
175122|NCT02060851|preterm anemia
175123|NCT02060812|ultrasound guided axillary nerve block
175124|NCT02060812|arthroscopic rotator cuff repair
175125|NCT02060812|ultrasound guided suprascapular nerve block
175126|NCT02060812|rebound phenomenon of pain
175127|NCT02060799|Dyspnea
175128|NCT02060799|Emergency Service, Hospital
175129|NCT02060799|prognosis
175130|NCT02060799|Fatal Outcome
175131|NCT02060799|Epidemiology
175132|NCT02060786|Antiplatelet; clopidogrel; acute coronary syndrome
175133|NCT02060773|Septic shock
175134|NCT02060773|Early goal directed therapy
175135|NCT02060773|Fluid resuscitation
175136|NCT02060773|Hepatic perfusion
175137|NCT02060773|Indocyanine Green
175138|NCT02060760|Prospective cohort study
175139|NCT02060760|Diagnostic accuracy
175140|NCT02060760|High sensitivity versus contemporary troponin I assay
175141|NCT02060760|Gender
175142|NCT02060760|Renal Function
175143|NCT02060734|Whiplash,
175144|NCT02060734|injection,
175145|NCT02060734|lidocaine,
175146|NCT02060734|sham needling
175147|NCT02060721|Chronic thromboembolic pulmonary hypertension (CTEPH)
175148|NCT02060695|Parkinson disease
175149|NCT02060682|Fractional Flow Reserve
175150|NCT02060682|Rapid Exchange
175151|NCT02060682|Catheter
175152|NCT02060656|Relapsed or refractory Diffuse Large B-Cell Lymphoma after R-CHOP chemotherapy
175153|NCT02060630|Surgical revascularization
175154|NCT02060630|Endovascular revascularization
175155|NCT02060630|Amputation
175156|NCT02060630|Peripheral artery disease
175157|NCT02060630|Critical limb ischemia
175158|NCT02060630|claudication
175159|NCT02060630|leg pain
175160|NCT02060630|leg ulcer
175161|NCT02060630|gangrene
175162|NCT02060617|low back pain
175163|NCT02060617|physical therapy
175164|NCT02060617|manual therapy
175165|NCT02060617|manipulation
175166|NCT02060617|exercise
175167|NCT02060617|motor control
175168|NCT02060617|regional interdependence
175169|NCT02060604|ketorolac
175170|NCT02060604|NSAIDs
175171|NCT02060604|wet macular degeneration
175172|NCT02060604|choroidal neovascularization
175173|NCT02060578|Cancer palliative care
175174|NCT02060578|Dead child
175175|NCT02060565|diagnosis
175176|NCT02060565|survival
175177|NCT02060565|non-invasive method
175178|NCT02060565|cirrhosis
175179|NCT02060565|FibroScan
175180|NCT02060526|sulfoglucosamine sulfohydrolase (SGSH)
175181|NCT02060526|recombinant human heparan N-sulfatase (rhHNS)
175182|NCT02060526|Hunter's Syndrome
175183|NCT02060526|Shire HGT
175184|NCT02060526|Lysosomal Storage Disease (LSD)
175185|NCT02060526|Sanfilippo Syndrome Type A (Sanfilippo A)
175186|NCT02060526|enzyme replacement therapy (ERT)
175187|NCT02060513|Wounded warriors
175188|NCT02060513|Battlefield infection
175189|NCT02060513|Acinetobacter
175190|NCT02060513|ESBL
175191|NCT02060513|MRSA
175192|NCT02060513|KPC
175193|NCT02060500|GERD
175194|NCT02060500|fundoplication
175195|NCT02060500|cardiaplication
175196|NCT02060500|reflux
175197|NCT02060487|pulmonary arterial hypertension
175198|NCT02060487|pulmonary hypertension
175199|NCT02060487|PAH
175200|NCT02060487|sildenafil
175201|NCT02060487|revatio
175202|NCT02060474|Allan-Herndon-Dudley Syndrome
175203|NCT02060474|MCT8
175204|NCT02060474|Triac
175205|NCT02060474|Therapeutic Trial
175206|NCT02060448|Non-suicidal self-injury
175207|NCT02060448|Self-injurious behavior
175208|NCT02060448|NSSI
175209|NCT02060448|Anxiety
175210|NCT02060448|Depression
175211|NCT02060448|Transdiagnostic
175212|NCT02060448|CBT
175213|NCT02060448|Unified Protocol
175214|NCT02060435|diffuse large B-cell lymphoma
175215|NCT02060435|Ebstein-Barr Virus
175216|NCT02060422|Epilepsy
175217|NCT02060422|Drug-resistant epilepsy
175218|NCT02060422|Seizure
175219|NCT02060422|Mindfulness
175220|NCT02060422|Stress
175221|NCT02060422|Psychotherapy
175222|NCT02060409|myelodysplastic syndrome
175223|NCT02060409|decitabine
175224|NCT02060409|spliceosome mutation
175225|NCT02060383|Cushing's disease
175226|NCT02060383|acromegaly
175227|NCT02060383|pasireotide
175228|NCT02060383|hyperglycemia
175229|NCT02060370|Genitourinary Cancer
175230|NCT02060370|Kidney Cancer
175231|NCT02060370|Metastatic Renal Cell Carcinoma
175232|NCT02060370|mRCC
175233|NCT02060370|Sunitinib
175234|NCT02060370|Sunitinib malate
175235|NCT02060370|SUO11248
175236|NCT02060370|Sutent
175237|NCT02060370|Questionnaire
175238|NCT02060370|Survey
175239|NCT02060357|Diabetes Mellitus
175240|NCT02060357|PCI
175241|NCT02060357|Drug eluting stent
175242|NCT02060357|OCT
175243|NCT02060344|Cardiovascular Disease
175244|NCT02060344|Hispanic
175245|NCT02060344|Latinos
175246|NCT02060331|Nocturia
175247|NCT02060331|Pelvic Organ Prolapse
175248|NCT02060331|Nocturnal Polyuria
175249|NCT02060331|Post-obstructive Diuresis
175250|NCT02060318|Crohn Disease
175251|NCT02060318|Regulatory T-cells
175252|NCT02060318|Infliximab
175253|NCT02060292|COPD
175254|NCT02060292|Cognitive Function
175255|NCT02060292|MRI Brain
175256|NCT02060292|Aortic Stiffness
175257|NCT02060292|Cerebrovascular disease
175258|NCT02060279|Obesity
175259|NCT02060279|Diabetes Mellitus
175260|NCT02060279|Diabetes Mellitus, Type 2
175261|NCT02060279|Prevention
175262|NCT02060279|Behavioral research
175263|NCT02060279|Metabolic Syndrome
175264|NCT02060279|Metabolic Disease
175265|NCT02060279|Overnutrition
175266|NCT02060279|Nutrition Disorders
175267|NCT02060279|Overweight
175268|NCT02060279|Body weight
175269|NCT02060279|Insulin resistance
175270|NCT02060279|Carotenoids
175271|NCT02060279|Dietary Supplement
175272|NCT02060279|Physical fitness
175273|NCT02060279|Sedentary lifestyle
175274|NCT02060240|Obesity
175275|NCT02060240|Prediabetic State
175276|NCT02060240|Sedentary Lifestyle
175277|NCT02060240|Insulin Resistance
175278|NCT02060240|Endothelium
175279|NCT02060240|Eicosanoids
175280|NCT02060240|Nitric Oxide
175281|NCT02060240|Regional Blood Flow
175282|NCT02060175|Optical coherence tomography, Drug-eluting stent, Strut coverage
175283|NCT02060162|antiretroviral therapy
175284|NCT02060162|Hepatitis C virus
175285|NCT02060149|Extensively Drug Resistant A. Baumannii
175286|NCT02060136|Electronic micturition chart, validation
175287|NCT02060123|Qigong
175288|NCT02060123|Telomerase
175289|NCT02060123|Perceived stress
175290|NCT02060123|RCT
175291|NCT02060123|Chinese
175292|NCT02060123|Abused women
175293|NCT02060123|intervention
175294|NCT02060123|Depression
175295|NCT02060110|CRT
175296|NCT02060110|HEART FAILURE
175297|NCT02060097|Anti-aging
175298|NCT02060097|High-flavanol cocoa
175299|NCT02060084|preterm;
175300|NCT02060084|Intestinal flora;
175301|NCT02060084|early Micro-feeding
175302|NCT02060084|Feeding intolerance
175303|NCT02060071|aortic stenosis
175304|NCT02060058|hepatitis C virus
175305|NCT02060058|hepatitis B virus
175306|NCT02060058|boceprevir
175307|NCT02060058|null responder
175308|NCT02060058|partial responder
175309|NCT02060058|relapser
175310|NCT02060045|bundle
175311|NCT02060045|prevention
175312|NCT02060045|Disturbance; Heart, Functional, Postoperative, Cardiac Surgery
175313|NCT02060032|Chronic periodontitis, Local drug delivery,
175314|NCT02060019|Pharmacokinetics
175315|NCT02060019|Pharmacodynamics
175316|NCT02060019|Safety
175317|NCT02060019|Tolerability
175318|NCT02060006|TB
175319|NCT02060006|IRIS
175320|NCT02059993|continuous positive airway pressure
175321|NCT02059993|hypertension
175322|NCT02059993|coronary heart disease
175323|NCT02059993|metabolic disorder
175324|NCT02059993|obstructive sleep apnea
175325|NCT02059980|OCD
175326|NCT02059980|Trichotillomania
175327|NCT02059980|Response inhibition
175328|NCT02059980|Cognitive training
175329|NCT02059967|Lung
175330|NCT02059954|Hysterectomy
175331|NCT02059941|Severe traumatic brain injury, intracranial hypertension, Latin America, observational study, outcomes assessments
175332|NCT02059928|fluid resuscitation
175333|NCT02059928|invasive pressure monitoring
175334|NCT02059915|pharmacokinetics
175335|NCT02059915|bioequivalence
175336|NCT02059915|bioavailability
175337|NCT02059915|oxycodone
175338|NCT02059902|Pain management
175339|NCT02059902|Narcotic consumption
175340|NCT02059902|Skin graft
175341|NCT02059889|Lung
175342|NCT02059876|breast cancer
175343|NCT02059876|dose dense
175344|NCT02059876|neoadjuvant treatment
175345|NCT02059876|pathologic complete response
175346|NCT02059863|cluster randomised trial
175347|NCT02059863|low and middle income countries
175348|NCT02059863|community based intervention
175349|NCT02059863|complex intervention
175350|NCT02059824|Eyelid sensation, aesthesiometer
175351|NCT02059811|Kidney Diseases
175352|NCT02059811|Renal Insufficiency, Chronic
175353|NCT02059811|Diet
175354|NCT02059811|DASH diet
175355|NCT02059811|Hypertension
175356|NCT02059811|Vascular diseases
175357|NCT02059811|Cardiovascular Diseases
175358|NCT02059811|Blood pressure
175359|NCT02059798|Myelopathy
175360|NCT02059785|Pinocembrin for Injection
175361|NCT02059785|Placebo
175362|NCT02059785|mRS
175363|NCT02059759|low-dose interleukin 2
175364|NCT02059746|cesarean section
175365|NCT02059746|vaginal birth
175366|NCT02059746|twins
175367|NCT02059746|urinary incontinence
175368|NCT02059746|sexuality
175369|NCT02059746|quality of life
175370|NCT02059733|18F-DTBZ
175371|NCT02059720|acute myeloid leukemia
175372|NCT02059720|allogeneic hematopoietic stem cell transplantation
175373|NCT02059720|autologous hematopoietic stem cell transplantation
175374|NCT02059720|maintenance treatment
175375|NCT02059720|hematopoietic stem cell transplantation
175376|NCT02059694|Eyelid surgery
175377|NCT02059694|local block/anesthesia
175378|NCT02059694|hyaluronidase
175379|NCT02059694|Bilateral upper eyelid surgery
175380|NCT02059694|Duke Eye Centre
175381|NCT02059694|Duke Aesthetic Center
175382|NCT02059668|locally advanced head and neck cancer
175383|NCT02059668|biomarkers
175384|NCT02059668|definitive treatment
175385|NCT02059668|adjuvant treatment
175386|NCT02059668|radiochemotherapy
175387|NCT02059655|Graves' disease
175388|NCT02059629|Heart failure
175389|NCT02059629|Eluna pacemaker family
175390|NCT02059629|Sentus OTW BP L left ventricular lead
175391|NCT02059629|Bradycardia
175392|NCT02059629|SADE-free rate
175393|NCT02059603|Electroacupuncture
175394|NCT02059603|Fast track program
175395|NCT02059603|Postoperative ileus
175396|NCT02059603|Laparoscopic surgery
175397|NCT02059603|Colorectal surgery
175398|NCT02059603|Randomized controlled trial
175399|NCT02059603|Hospital stay
175400|NCT02059590|14C-labeled isavuconazonium sulfate
175401|NCT02059590|Pyridinylmethyl-14C-labeled isavuconazonium sulfate
175402|NCT02059590|Healthy Subjects
175403|NCT02059590|BAL8728
175404|NCT02059590|BAL4815
175405|NCT02059577|vitamins
175406|NCT02059577|minerals
175407|NCT02059577|essential fatty acids
175408|NCT02059577|Epsom salts
175409|NCT02059577|carnitine
175410|NCT02059577|digestive enzymes
175411|NCT02059577|gluten-free casein-free diet
175412|NCT02059564|Diabetes Mellitus
175413|NCT02059564|Diabetes Mellitus, Type 2
175414|NCT02059564|Glucose Metabolism Disorders
175415|NCT02059564|Metabolic Diseases
175416|NCT02059564|Endocrine System Diseases
175417|NCT02059564|Exendin-4
175418|NCT02059551|pulmonary embolism
175419|NCT02059551|magnetic resonance imaging
175420|NCT02059551|venous ultrasonography of the legs
175421|NCT02059551|diagnostic performances
175422|NCT02059538|Obesity
175423|NCT02059538|Type 2 diabetes
175424|NCT02059538|Coronary artery diseases
175425|NCT02059538|Microbiota
175426|NCT02059538|Omics (ie transcriptomics, metabolomics, metagenomics, lipidomics)
175427|NCT02059525|observational
175428|NCT02059525|Belgium
175429|NCT02059512|ischemic heart disease,
175430|NCT02059512|autologous bone marrow mononuclear cells
175431|NCT02059512|coronary artery bypass grafting
175432|NCT02059460|Terlipressin
175433|NCT02059460|Acute kidney injury
175434|NCT02059460|Liver transplantation
175435|NCT02059460|NGAL
175436|NCT02059447|Controlled trial
175437|NCT02059447|Active control
175438|NCT02059447|Waiting, non treatment, period
175439|NCT02059447|Mindfulness Based Cognitive Therapy
175440|NCT02059447|Relaxation Therapy
175441|NCT02059421|Johrei therapy
175442|NCT02059421|Sleep
175443|NCT02059421|CBT-I
175444|NCT02059421|Critical illness
175445|NCT02059382|daily physical activity
175446|NCT02059382|exercise
175447|NCT02059382|social support
175448|NCT02059382|online social network
175449|NCT02059369|Atrial fibrillation
175450|NCT02059369|Recurrence
175451|NCT02059369|CFAE
175452|NCT02059369|linear ablation
175453|NCT02059356|Dementia
175454|NCT02059356|Alzheimer's
175455|NCT02059356|Alzheimers
175456|NCT02059356|Cognitive decline
175457|NCT02059356|Cognitive impairment
175458|NCT02059356|Memory loss
175459|NCT02059356|Memory disorder
175460|NCT02059356|Forgetfulness
175461|NCT02059356|Confusion
175462|NCT02059356|Senile
175463|NCT02059356|Demented
175464|NCT02059356|Developmental delay
175465|NCT02059356|Portal systemic shunting
175466|NCT02059356|High ammonia level
175467|NCT02059356|Elevated ammonia level
175468|NCT02059343|pharmacokinetics
175469|NCT02059343|pharmacodynamics
175470|NCT02059343|safety
175471|NCT02059343|dexmedetomidine
175472|NCT02059343|cardiopulmonary bypass
175473|NCT02059343|children
175474|NCT02059330|Japanese PK-Bridging Study
175475|NCT02059330|dose-proportionality study
175476|NCT02059330|Palbociclib
175477|NCT02059330|PD-0332991
175478|NCT02059330|healthy volunteers
175479|NCT02059304|cervical length
175480|NCT02059304|prediction of preterm delivery
175481|NCT02059291|Canakinumab, interleukin-1, Hereditary Periodic Fevers, auto-inflammatory diseases
175482|NCT02059278|Primary open angle glaucoma
175483|NCT02059278|Ocular hypertension
175484|NCT02059239|NHL
175485|NCT02059239|HL
175486|NCT02059239|Lymphoma
175487|NCT02059200|Randomised controlled trial
175488|NCT02059200|Recurrent depression
175489|NCT02059200|Mindfulness training
175490|NCT02059200|Compassion training (MBCL)
175491|NCT02059200|Fear of Compassion
175492|NCT02059200|Added value Compassion
175493|NCT02059135|Preeclampsia
175494|NCT02059135|Preterm preeclampsia
175495|NCT02059135|Pregnancy
175496|NCT02059109|Belmont
175497|NCT02059109|Rapid
175498|NCT02059109|Infuser
175499|NCT02059109|proficiency
175500|NCT02059109|proficient
175501|NCT02059109|training
175502|NCT02059096|Multiple Sclerosis
175503|NCT02059096|Repetitive transcranial magnetic stimulation (rTMS)
175504|NCT02059096|Chronic neuropathic pain
175505|NCT02059096|Cortical excitability
175506|NCT02059083|adolescent
175507|NCT02059083|cannabis
175508|NCT02059083|biofeedback
175509|NCT02059070|Nerve Block/adverse effects
175510|NCT02059070|Phrenic Nerve
175511|NCT02059070|Respiratory function
175512|NCT02059070|Pain measurement
175513|NCT02059044|patient safety
175514|NCT02059044|pharmacoepidemiology
175515|NCT02059044|health services research
175516|NCT02059044|adherence
175517|NCT02059044|information technology
175518|NCT02059031|integrase inhibitor
175519|NCT02059031|pharmacokinetics
175520|NCT02059031|HIV
175521|NCT02059031|relative bioavailability
175522|NCT02059031|food
175523|NCT02059031|GSK1265744
175524|NCT02059005|Addiction
175525|NCT02059005|Substance Use Disorder
175526|NCT02059005|Rehospitalization
175527|NCT02059005|Community Disease Management
175528|NCT02059005|Behavioral Health
175529|NCT02059005|Community Health Worker
175530|NCT02058992|Drug therapy
175531|NCT02058966|Entacapone
175532|NCT02058966|COMT val158met
175533|NCT02058966|Methamphetamine
175534|NCT02058953|Melanoma
175535|NCT02058953|skin cancer
175536|NCT02058953|brain metastases
175537|NCT02058953|craniotomy
175538|NCT02058927|HIV
175539|NCT02058927|ART
175540|NCT02058927|children
175541|NCT02058914|Sugar sweetened beverages
175542|NCT02058914|metabolism
175543|NCT02058914|endocrine
175544|NCT02058914|lipids
175545|NCT02058914|blood glucose
175546|NCT02058901|sunitinib
175547|NCT02058901|solid tumors
175548|NCT02058888|metagenomics
175549|NCT02058888|antimicrobial resistance
175550|NCT02058888|multidrug resistance
175551|NCT02058849|Mucositis
175552|NCT02058849|Beetroot
175553|NCT02058849|Head and neck cancer
175554|NCT02058836|Chronic testicular pain
175555|NCT02058836|Orchialgia
175556|NCT02058836|Botulinum toxin
175557|NCT02058836|Botox
175558|NCT02058836|Urology
175559|NCT02058823|Hypoxia
175560|NCT02058823|Sleep apnea
175561|NCT02058823|Valsartan
175562|NCT02058823|Amlodipine
175563|NCT02058823|Healthy subjects
175564|NCT02058823|Randomized
175565|NCT02058823|Cross-over
175566|NCT02058823|International
175567|NCT02058823|Sympathetic nervous system
175568|NCT02058810|nasal high flow oxygen
175569|NCT02058810|cardio-renal syndrom
175570|NCT02058810|heartfailure
175571|NCT02058797|Procrastination
175572|NCT02058797|Coherence Therapy
175573|NCT02058797|Cognitive Behavioral Therapy
175574|NCT02058797|Repertory Grid Technique
175575|NCT02058797|Cognitive Conflicts
175576|NCT02058797|Personal Dilemmas
175577|NCT02058771|Action potential duration restitution
175578|NCT02058771|Ventricular arrhythmia
175579|NCT02058771|Sudden cardiac death
175580|NCT02058771|Body-surface potential mapping
175581|NCT02058771|Electrocardiogram
175582|NCT02058758|Breast cancer
175583|NCT02058758|Magnetic resonance spectroscopy
175584|NCT02058758|Diffusion weighted imaging
175585|NCT02058745|Neuro-oncology
175586|NCT02058745|Caregivers
175587|NCT02058745|Intervention Research
175588|NCT02058745|Representational Approach
175589|NCT02058745|Cognitive Behavioral Therapy
175590|NCT02058745|Family
175591|NCT02058745|Internet
175592|NCT02058680|prostate specific antigen (PSA)
175593|NCT02058667|Breast Cancer
175594|NCT02058667|Paclitaxel
175595|NCT02058667|Helical Tomotherapy
175596|NCT02058667|Chest wall
175597|NCT02058654|Creatine
175598|NCT02058654|Functional magnetic resonance imaging (fMRI)
175599|NCT02058654|Phosphorus-31 magnetic resonance spectroscopy (31P-MRS)
175600|NCT02058641|macrophage phenotype
175601|NCT02058641|cellular accumulation
175602|NCT02058641|Type 2 diabetes mellitus
175603|NCT02058641|darapladib
175604|NCT02058641|M1/M2
175605|NCT02058641|inflammatory mediators
175606|NCT02058641|cytokines
175607|NCT02058641|cantharidin blister
175608|NCT02058628|azelaic acid
175609|NCT02058628|Clindamycin
175610|NCT02058628|Benzoyl peroxide
175611|NCT02058628|Acne vulgaris
175612|NCT02058615|Male caregivers
175613|NCT02058615|Breast cancer
175614|NCT02058615|Intervention
175615|NCT02058615|Online toolkit
175616|NCT02058602|HRCT
175617|NCT02058602|Airway morphometry
175618|NCT02058602|Resistivity
175619|NCT02058602|Inhalation Profiles
175620|NCT02058602|Inhaler
175621|NCT02058602|Pharyngometry
175622|NCT02058602|Idiopathic Pulmonary Fibrosis (IPF)
175623|NCT02058589|Immunocompromised
175624|NCT02058589|Safety
175625|NCT02058589|≥ 18 years of age
175626|NCT02058589|Renal transplant
175627|NCT02058589|Adults
175628|NCT02058589|Immunosuppressed
175629|NCT02058589|Immunogenicity
175630|NCT02058589|Herpes zoster
175631|NCT02058576|healthy subject
175632|NCT02058576|dutasteride
175633|NCT02058576|bioequivalence
175634|NCT02058576|GI198745
175635|NCT02058576|Tamsulosin
175636|NCT02058576|combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
175637|NCT02058576|tamsulosin hydrochloride
175638|NCT02058563|Measles, mumps and rubella diseases
175639|NCT02058563|Safety
175640|NCT02058563|Immunogenicity
175641|NCT02058524|Ulcerative Colitis
175642|NCT02058524|Fecal Microbiota Transplantation
175643|NCT02058498|Liver transplant
175644|NCT02058498|Physical Activity
175645|NCT02058498|Quality of Life
175646|NCT02058485|hypertension
175647|NCT02058485|dexmedetomidine
175648|NCT02058485|midazolam
175649|NCT02058485|premedication
175650|NCT02058459|Chronic obstructive pulmonary disease, targeted lung denervation, intervention, device, safety, lung function, Holaira
175651|NCT02058433|Chemotherapy
175652|NCT02058433|Individual Paclitaxel dose
175653|NCT02058433|pharmacokinetics
175654|NCT02058420|bone health
175655|NCT02058407|FTIH
175656|NCT02058407|food effect
175657|NCT02058407|GSK2793660
175658|NCT02058407|pharmacodynamics
175659|NCT02058407|pharmacokinetics
175660|NCT02058407|safety
175661|NCT02058394|Retained nuclear lens fragments
175662|NCT02058394|Phacoemulsification
175663|NCT02058394|Cataract Surgery
175664|NCT02058368|Benign Prostatic Hyperplasia
175665|NCT02058368|Quality of Life
175666|NCT02058342|Prader Willi syndrome
175667|NCT02058342|Obesity
175668|NCT02058342|Childhood
175669|NCT02058342|Family
175670|NCT02058342|Interactive games
175671|NCT02058342|Playground games
175672|NCT02058342|Exercise routine
175673|NCT02058329|Hip fracture
175674|NCT02058329|postoperative complications
175675|NCT02058329|Depression
175676|NCT02058329|Environmental Hazards
175677|NCT02058329|FIM scores
175678|NCT02058329|Falls
175679|NCT02058303|hand surgery
175680|NCT02058303|wrist surgery
175681|NCT02058303|finger surgery
175682|NCT02058303|anesthesia
175683|NCT02058303|regional anesthesia
175684|NCT02058303|postoperative pain
175685|NCT02058290|laparoscopic colectomy
175686|NCT02058277|bosutinib
175687|NCT02058277|aprepitant
175688|NCT02058277|drug interaction
175689|NCT02058277|healthy volunteers
175690|NCT02058277|pharmacokinetics
175691|NCT02058277|chronic myelogenous leukemia
175692|NCT02058251|Alcohol
175693|NCT02058251|Oxytocin
175694|NCT02058251|Stress reactivity
175695|NCT02058238|Robotic-guided spinal fusions
175696|NCT02058238|Scoliosis
175697|NCT02058238|Kyphoscoliosis
175698|NCT02058238|Spinal deformity
175699|NCT02058238|Spondylosis
175700|NCT02058225|Infant Nutrition
175701|NCT02058225|Magnetic resonance spectroscopy
175702|NCT02058225|Infant Brain Development
175703|NCT02058225|Diffusion weighted Imaging
175704|NCT02058225|Diffusion tensor tractography
175705|NCT02058212|ICSI
175706|NCT02058212|antioxidants
175707|NCT02058212|ROS
175708|NCT02058212|endometriosis
175709|NCT02058199|gastric bypass
175710|NCT02058199|rivaroxaban
175711|NCT02058199|pharmacodynamics
175712|NCT02058186|Atopic dermatitis, vitamin D supplementation, cathelicidin, Staphylococcus aureus colonization, SCORAD score
175713|NCT02058121|Eating disorders
175714|NCT02058121|Acceptance and Commitment Therapy
175715|NCT02058121|Body image
175716|NCT02058108|Chronic hepatitis B, pediatrics, antiviral treatment, telbivudine
175717|NCT02058082|Failure to Conceive Due to Infertility of Male Partner
175718|NCT02058082|DNA Damage
175719|NCT02058056|Early prophylactic
175720|NCT02058056|cranial irradiation
175721|NCT02058056|hippocampal avoidance
175722|NCT02058056|limited disease small-cell lung cancer
175723|NCT02058030|ProSeal laryngeal mask airway
175724|NCT02058030|Insertion success
175725|NCT02058030|complication
175726|NCT02058004|Microaspiration
175727|NCT02058004|ARDS
175728|NCT02058004|Hospital acquired pneumonia
175729|NCT02058004|Cricoid pressure
175730|NCT02057978|Late Lumen Loss
175731|NCT02057978|MACE
175732|NCT02057978|Death
175733|NCT02057978|TLF
175734|NCT02057978|Thrombosis(definite or probable )
175735|NCT02057965|Mesenchymal Stromal Cells
175736|NCT02057965|Allograft rejection
175737|NCT02057965|Fibrosis
175738|NCT02057952|Weight Management
175739|NCT02057952|Diabetes
175740|NCT02057952|Exercise
175741|NCT02057952|Portion Control
175742|NCT02057952|Multiple Chronic Conditions
175743|NCT02057939|Prostate cancer
175744|NCT02057939|enzalutamide
175745|NCT02057939|ADT
175746|NCT02057939|radiation
175747|NCT02057926|Membrane degradation
175748|NCT02057926|Collagen membrane bio-durability
175749|NCT02057913|Penile neoplasms
175750|NCT02057913|Chemotherapy
175751|NCT02057913|Vinflunine
175752|NCT02057913|Phase II
175753|NCT02057900|Postinfarction heart failure
175754|NCT02057900|Transplantation of human embryonic stem cell-derived cardiac progenitors
175755|NCT02057900|Tissue-engineered cellular graft
175756|NCT02057900|Fibrin hydrogel
175757|NCT02057861|diabetes mellitus
175758|NCT02057861|neuromuscular blockade
175759|NCT02057861|sugammadex
175760|NCT02057848|carbohydrate, hypoglycemia
175761|NCT02057822|Vernal keratoconjunctivitis
175762|NCT02057822|Cytokines
175763|NCT02057822|Mediators
175764|NCT02057822|Tears
175765|NCT02057809|Developmental Disabilities
175766|NCT02057809|Family-centered services
175767|NCT02057809|Pediatric rehabilitation
175768|NCT02057796|HIV-1
175769|NCT02057796|Tuberculosis
175770|NCT02057796|Systematic empiric TB treatment
175771|NCT02057796|ART
175772|NCT02057796|TB diagnosis
175773|NCT02057796|Xpert MTB/RIF®
175774|NCT02057796|Urine LAM
175775|NCT02057744|Robotic-guided surgery
175776|NCT02057744|Minimally invasive spinal surgery
175777|NCT02057744|Spinal fusion
175778|NCT02057744|Pedicle screws
175779|NCT02057705|MTM
175780|NCT02057705|myotubular myopathy
175781|NCT02057705|X-linked centronuclear myopathy
175782|NCT02057705|inherited myopathies
175783|NCT02057705|neuromuscular diseases
175784|NCT02057705|hypotonia
175785|NCT02057705|genetic mutation
175786|NCT02057679|Acute cholecystitis.
175787|NCT02057679|Amoxicillin clavulanic
175788|NCT02057653|Goal-directed fluid management
175789|NCT02057601|Local anaesthetic infiltration
175790|NCT02057601|Fractured neck of femur
175791|NCT02057601|Postoperative pain
175792|NCT02057588|ablation
175793|NCT02057575|Open Angle Glaucoma
175794|NCT02057575|Ocular Hypertension
175795|NCT02057575|Intraocular Pressure
175796|NCT02057575|AR13324
175797|NCT02057575|PG324
175798|NCT02057562|Adenoma
175799|NCT02057562|Diverticular disease
175800|NCT02057562|Diverticulosis
175801|NCT02057562|Colorectal carcinoma
175802|NCT02057562|Polyp
175803|NCT02057536|estrogen receptor positive, aromatase inhibitors, exercise,
175804|NCT02057510|Head and Neck Cancer
175805|NCT02057510|Radiation Therapy
175806|NCT02057484|long-term follow-up
175807|NCT02057484|liver transplant
175808|NCT02057484|kidney transplant
175809|NCT02057484|Advagraf
175810|NCT02057471|Adenocarcinoma
175811|NCT02057471|Anemia
175812|NCT02057471|Blood Transfusion
175813|NCT02057471|Colorectal surgery
175814|NCT02057471|Preoperative care
175815|NCT02057471|Perioperative care
175816|NCT02057471|Postoperative care
175817|NCT02057471|Iron
175818|NCT02057471|Hematinics
175819|NCT02057471|Hepcidin
175820|NCT02057471|Quality of life
175821|NCT02057471|Postoperative complications
175822|NCT02057458|arterial stiffness
175823|NCT02057458|flow-mediated dilation
175824|NCT02057458|endothelial function
175825|NCT02057458|pulse wave velocity
175826|NCT02057458|inflammation
175827|NCT02057458|oxidative stress
175828|NCT02057458|pulmonary function test
175829|NCT02057458|Cystic Fibrosis
175830|NCT02057458|Lung Disease
175831|NCT02057458|Nitric Oxide
175832|NCT02057458|Exercise Capacity
175833|NCT02057458|CF
175834|NCT02057458|Muscle Function
175835|NCT02057458|Sildenafil
175836|NCT02057458|Viagra
175837|NCT02057458|Revatio
175838|NCT02057445|cellular therapy
175839|NCT02057445|lymphoma
175840|NCT02057445|lymphoproliferative disorder
175841|NCT02057432|I-II Breast Cancer
175842|NCT02057419|contraception
175843|NCT02057419|contraceptive methods
175844|NCT02057419|sexual lubricant
175845|NCT02057419|user experience
175846|NCT02057419|adherence
175847|NCT02057419|User experience: impact on use of contraceptive methods
175848|NCT02057419|User experience: impact on use of sexual lubricants
175849|NCT02057393|Melanoma
175850|NCT02057393|Sentinel node biopsy
175851|NCT02057393|Indocyanine green
175852|NCT02057393|Real time lymphangiography
175853|NCT02057380|Paclitaxel
175854|NCT02057380|Linsitinib
175855|NCT02057380|OSI-774
175856|NCT02057380|Advanced Solid Tumor
175857|NCT02057380|Tarceva
175858|NCT02057380|Erlotinib
175859|NCT02057380|OSI-906
175860|NCT02057367|supratentorial brain tumour
175861|NCT02057367|craniotomy
175862|NCT02057354|Brain
175863|NCT02057354|Brain-Derived Neurotrophic Factor
175864|NCT02057354|Brain Mapping
175865|NCT02057354|Cognition
175866|NCT02057354|Exercise
175867|NCT02057354|Hippocampus
175868|NCT02057354|Hydrocortisone
175869|NCT02057354|Learning
175870|NCT02057354|Memory
175871|NCT02057354|Magnetic Resonance Imaging
175872|NCT02057354|Nerve Growth Factors
175873|NCT02057354|Neuroimaging
175874|NCT02057354|Physical Endurance
175875|NCT02057354|Physical Fitness
175876|NCT02057354|Resistance Training
175877|NCT02057354|Walking
175878|NCT02057341|laminopathy
175879|NCT02057315|Migraine headache
175880|NCT02057315|Photophobia
175881|NCT02057315|Phonophobia
175882|NCT02057315|Aura
175883|NCT02057315|Topical treatment
175884|NCT02057302|Xuezhikang Dyslipidemia chinese medicine RCT
175885|NCT02057289|pediatric
175886|NCT02057289|antifungal
175887|NCT02057289|bone marrow
175888|NCT02057289|AML or relapsed ALL
175889|NCT02057263|Vaccine
175890|NCT02057263|Adjuvant
175891|NCT02057263|Bisphosphonates
175892|NCT02057263|Alendronate
175893|NCT02057263|Hepatitis B vaccine
175894|NCT02057224|Renal denervation
175895|NCT02057224|Hypertension
175896|NCT02057224|Insulin resistance
175897|NCT02057224|Adipose tissue function
175898|NCT02057185|Chronic Hematological Diseases
175899|NCT02057185|work
175900|NCT02057185|job
175901|NCT02057172|glycaemic control
175902|NCT02057172|HM11260C
175903|NCT02057172|placebo
175904|NCT02057172|safety
175905|NCT02057172|tolerability
175906|NCT02057172|type 2 diabetes mellitus
175907|NCT02057172|efficacy
175908|NCT02057172|T2DM
175909|NCT02057172|glycated haemoglobin (HbA1c)
175910|NCT02057172|glycosylated haemoglobin (HbA1c)
175911|NCT02057172|Glucagon-Like Peptide-1 (GLP-1) agonists
175912|NCT02057172|blood sugar levels
175913|NCT02057172|fasting plasma glucose (FPG)
175914|NCT02057159|Secondary Progress Multiple Sclerosis
175915|NCT02057159|SPMS
175916|NCT02057159|Multiple Sclerosis
175917|NCT02057159|NeuroVax
175918|NCT02057146|PSC
175919|NCT02057146|mother-baby endoscopy
175920|NCT02057146|ERCP
175921|NCT02057146|IPMN
175922|NCT02057120|Kinesio Taping, Soccer, Hop Test, Electromyography, Athletic Performance, Muscle Strength Dynamometer
175923|NCT02057081|Stress Disorders, Post-traumatic
175924|NCT02057081|Mild Traumatic Brain Injury
175925|NCT02057081|Veterans Health
175926|NCT02057081|Veterans
175927|NCT02057081|Spouses
175928|NCT02057081|Couples
175929|NCT02057081|Psychotherapy, Group
175930|NCT02057081|Depression
175931|NCT02057081|Couples Therapy
175932|NCT02057081|Family Therapy
175933|NCT02057081|PTSD
175934|NCT02057081|posttraumatic stress disorder
175935|NCT02057068|Caregivers
175936|NCT02057068|Telemedicine
175937|NCT02057068|Sleep Disorders
175938|NCT02057068|Meditation
175939|NCT02057068|Dementia
175940|NCT02057068|Cognitive Behavioral Therapy
175941|NCT02057068|Exercise
175942|NCT02057068|Technology
175943|NCT02057055|Antibacterial soaps
175944|NCT02057055|Microbiome
175945|NCT02057055|Commensal bacteria
175946|NCT02057055|Pyrosequencing
175947|NCT02057055|Innate immunity
175948|NCT02057042|Peer Support
175949|NCT02057042|cCBT
175950|NCT02057042|primary care
175951|NCT02057029|Estrogen Receptor (ER) Positive
175952|NCT02057029|Early Stage Breast Cancer
175953|NCT02057029|Breast Cancer Index
175954|NCT02057003|HIV
175955|NCT02057003|hepatitis C virus
175956|NCT02057003|sustained virologic response
175957|NCT02057003|telaprevir
175958|NCT02057003|boceprevir
175959|NCT02057003|simeprevir
175960|NCT02057003|sofosbuvir
175961|NCT02057003|daclatasvir
175962|NCT02057003|paritaprevir
175963|NCT02057003|pegylated interferon
175964|NCT02057003|ribavirin
175965|NCT02057003|direct-acting antivirals
175966|NCT02057003|dasabuvir
175967|NCT02057003|ombitasvir
175968|NCT02057003|ledipasvir
175969|NCT02057003|velpatasvir
175970|NCT02057003|grazoprevir
175971|NCT02057003|elbasvir
175972|NCT02056990|Athletes
175973|NCT02056977|Acute Respiratory Distress Syndrome
175974|NCT02056977|Cardiac Surgical Procedure
175975|NCT02056977|Mechanical Ventilation
175976|NCT02056977|Postoperative Complications
175977|NCT02056977|Positive End-Expiratory Pressure
175978|NCT02056977|Lung Collapse
175979|NCT02056977|Respiratory Failure
175980|NCT02056977|Electrical Impedance Tomography
175981|NCT02056964|Acute Coronary Syndrome
175982|NCT02056964|Chest Pain
175983|NCT02056964|Risk Stratification
175984|NCT02056964|Clinical Decision Aid
175985|NCT02056964|Emergency Department
175986|NCT02056964|Low Risk Chest Pain
175987|NCT02056964|Non Cardiac Chest Pain
175988|NCT02056951|Rehabilitation
175989|NCT02056951|Treatment Outcome
175990|NCT02056951|Interprofessional Relations
175991|NCT02056951|Interdisciplinary Communication
175992|NCT02056951|Behavioural Exercise Therapy
175993|NCT02056951|Cognitive Therapy
175994|NCT02056951|Health Education
175995|NCT02056951|Workplace related information
175996|NCT02056951|Multicenter Study
175997|NCT02056938|Transplantation
175998|NCT02056938|kidney
175999|NCT02056938|delayed graft function
176000|NCT02056938|induction therapy
176001|NCT02056938|personalized medicine
176002|NCT02056938|First kidney transplantation
176003|NCT02056938|No anti HLA immunization prior transplantation
176004|NCT02056938|Risk of DGF higher than 40% calculated byt he score DGFS
176005|NCT02056912|lipodystrophy
176006|NCT02056912|gene
176007|NCT02056912|inborn error of metabolism
176008|NCT02056899|Preterm labor, premature birth, gabapentin
176009|NCT02056886|breast cancer, sentinel lymph node, extemporaneous, OSNA
176010|NCT02056873|deep brain stimulation
176011|NCT02056873|DBS
176012|NCT02056873|tourette
176013|NCT02056873|tourette's
176014|NCT02056873|tourette syndrome
176015|NCT02056873|TS
176016|NCT02056860|cystic fibrosis
176017|NCT02056847|Livalo, pitavastatin, hyperlipidemia, IFG
176018|NCT02056821|stroke
176019|NCT02056821|transcranial doppler
176020|NCT02056821|cerebral blood flow
176021|NCT02056821|cardiac output
176022|NCT02056821|non-invasive hemodynamic monitoring
176023|NCT02056782|Acute Myeloid Leukemia
176024|NCT02056782|AML
176025|NCT02056782|ODSH
176026|NCT02056782|ODSH-AML
176027|NCT02056782|Cantex
176028|NCT02056756|REFRACTORY OR RELAPSED
176029|NCT02056756|CBD
176030|NCT02056730|chronic hemodialysis patients
176031|NCT02056730|Hyperparathyroidism
176032|NCT02056730|Regpara
176033|NCT02056730|FGF 23
176034|NCT02056704|Dialysis Fistula
176035|NCT02056704|Dialysis Graft
176036|NCT02056704|Stenosis
176037|NCT02056704|Intravascular Ultrasound
176038|NCT02056704|Angiography
176039|NCT02056691|Resectable
176040|NCT02056691|non-metastatic
176041|NCT02056691|colorectal
176042|NCT02056691|carcinoma
176043|NCT02056691|cancer
176044|NCT02056691|neoplasm
176045|NCT02056691|exercise
176046|NCT02056691|effects
176047|NCT02056691|program
176048|NCT02056691|pre-operative
176049|NCT02056691|proliferation
176050|NCT02056691|diagnosed
176051|NCT02056691|surgery
176052|NCT02056691|biopsy
176053|NCT02056691|muscle
176054|NCT02056691|signalling
176055|NCT02056691|IGF1
176056|NCT02056691|ki67
176057|NCT02056691|p53
176058|NCT02056691|response
176059|NCT02056691|training
176060|NCT02056691|biochemical
176061|NCT02056691|pathways
176062|NCT02056691|glucose
176063|NCT02056678|cholecystitis
176064|NCT02056678|cholelithiasis
176065|NCT02056678|obstructive sleep apnea
176066|NCT02056678|acetaminophen
176067|NCT02056665|Angelman Syndrome
176068|NCT02056665|EFFICACY
176069|NCT02056665|SAFETY
176070|NCT02056665|MINOCYCLINE
176071|NCT02056665|Pediatrics population
176072|NCT02056665|Rare diseases
176073|NCT02056652|Preterm birth
176074|NCT02056652|Preterm delivery
176075|NCT02056652|short cervix
176076|NCT02056652|pessary
176077|NCT02056639|Premature birth
176078|NCT02056639|Premature delivery
176079|NCT02056639|Short cervix
176080|NCT02056639|Pessary
176081|NCT02056626|hypertension
176082|NCT02056613|Blood Donation
176083|NCT02056613|Tissue Procurement
176084|NCT02056613|Cellular Therapies
176085|NCT02056587|renal cell carcinoma
176086|NCT02056587|kidney cancer
176087|NCT02056587|bevacizumab failure
176088|NCT02056587|everolimus
176089|NCT02056574|Endovascular repair
176090|NCT02056574|Subarachnoid hemorrhage
176091|NCT02056574|Ruptured intracranial aneurysm
176092|NCT02056574|Stroke
176093|NCT02056574|Coiling
176094|NCT02056574|NA-1
176095|NCT02056561|Anesthesia
176096|NCT02056561|Oxidants
176097|NCT02056561|Antioxidants
176098|NCT02056548|preemptive antiviral treatment
176099|NCT02056548|lymphoma
176100|NCT02056548|chronic hepatitis B
176101|NCT02056535|Alcohol
176102|NCT02056535|SBIRT (Screening, Brief Intervention, Referral to Treatment)
176103|NCT02056522|Melanoma
176104|NCT02056522|Skin Cancer
176105|NCT02056509|cardiopulmonary resuscitation,Ventilation
176106|NCT02056496|Pomegranate
176107|NCT02056496|Ellagic acid
176108|NCT02056496|Pharmacokinetics
176109|NCT02056496|Urolithins
176110|NCT02056496|Bioavailability
176111|NCT02056483|neoplasms
176112|NCT02056483|rehabilitation
176113|NCT02056483|anxiety
176114|NCT02056483|depression
176115|NCT02056483|adverse effects
176116|NCT02056483|health behavior
176117|NCT02056457|Responsible fatherhood
176118|NCT02056457|Healthy marriage
176119|NCT02056457|Healthy relationships
176120|NCT02056457|Parenting
176121|NCT02056457|Economic self-sufficiency
176122|NCT02056444|Blood conservation
176123|NCT02056444|Tranexamic acid
176124|NCT02056444|Total hip arthroplasty
176125|NCT02056431|Diabetes
176126|NCT02056431|Neuropathy
176127|NCT02056431|Patient-Reported Outcomes
176128|NCT02056405|Postoperative Ileus
176129|NCT02056405|Mosapride
176130|NCT02056405|Colorectal laparoscopic surgery
176131|NCT02056405|Prolonged postoperative ileus
176132|NCT02056392|Phase I, healthy, pharmacokinetics
176133|NCT02056379|stridor
176134|NCT02056379|laryngitis
176135|NCT02056379|budesonide
176136|NCT02056379|dexamethasone
176137|NCT02056379|children
176138|NCT02056366|Cardiac Autonomic Neuropathy
176139|NCT02056353|Software
176140|NCT02056353|Algorithm
176141|NCT02056353|Cardiac surgery
176142|NCT02056327|Oral Appliance
176143|NCT02056262|Bacteria
176144|NCT02056262|microbial community
176145|NCT02056262|hygiene
176146|NCT02056249|hypoglycemia
176147|NCT02056249|Positron Emission Tomography
176148|NCT02056249|norepinephrine transporter
176149|NCT02056236|Cardiac arrest
176150|NCT02056236|Postanoxic encephalopathy
176151|NCT02056236|Electroencephalographic status epilepticus
176152|NCT02056236|EEG monitoring
176153|NCT02056236|Anti-epileptic drugs
176154|NCT02056223|Patent ductus arteriosus
176155|NCT02056223|Preterm infant
176156|NCT02056223|Paracetamol
176157|NCT02056223|Ibuprofen
176158|NCT02056210|Stem cells
176159|NCT02056210|Bone marrow
176160|NCT02056171|delirium
176161|NCT02056171|pediatrics
176162|NCT02056171|critical care
176163|NCT02056171|quetiapine
176164|NCT02056158|HIV
176165|NCT02056158|COPD
176166|NCT02056158|Emphysema
176167|NCT02056158|Smoking
176168|NCT02056119|Ventilators, mechanical
176169|NCT02056119|Aerosol Drug Therapy
176170|NCT02056119|Nebulizers
176171|NCT02056119|Equipment Contamination
176172|NCT02056119|vibrating mesh nebulizer
176173|NCT02056119|jet nebulizer
176174|NCT02056119|mechanical ventilation
176175|NCT02056119|ventilator associated event
176176|NCT02056119|ventilator associated tracheobronchitis
176177|NCT02056106|depression, Uganda, HIV, task-shifting, condom use, adherence
176178|NCT02056093|NAVA - PAV- Breathing Variability - Asynchrony
176179|NCT02056080|Breast Neoplasm
176180|NCT02056080|Receptor,HER2
176181|NCT02056080|Antineoplastic agent
176182|NCT02056080|Antibodies, monoclonal
176183|NCT02056080|Trastuzumab, Lapatinib
176184|NCT02056080|Protein kinase inhibitors
176185|NCT02056080|quinazolines
176186|NCT02056054|Autoimmune hepatitis
176187|NCT02056054|Liver transplantation
176188|NCT02056054|Hepatitis C
176189|NCT02056002|Peer-driven intervention
176190|NCT02056002|Interactive voice response system
176191|NCT02056002|Continuous Positive Airway Pressure therapy and adherence
176192|NCT02055976|PF-04950615
176193|NCT02055976|Japan
176194|NCT02055963|Head And Neck Cancer
176195|NCT02055963|Postsurgical symptom reduction
176196|NCT02055963|Minocycline
176197|NCT02055963|Dynacin
176198|NCT02055963|Minocin
176199|NCT02055963|Minocin PAC
176200|NCT02055963|Myrac
176201|NCT02055963|Solodyn
176202|NCT02055963|Placebo
176203|NCT02055963|Sugar pill
176204|NCT02055963|Questionnaires
176205|NCT02055963|Surveys
176206|NCT02055950|Kidney transplant
176207|NCT02055950|Marginal donors
176208|NCT02055950|Pulse perfusion
176209|NCT02055950|Graft function
176210|NCT02055937|mastectomy, reconstruction
176211|NCT02055924|Bruton's tyrosine kinase (BTK) Inhibition in B-cell Lymphomas
176212|NCT02055911|diabetic macular edema
176213|NCT02055911|intravitreal ranibizumab
176214|NCT02055911|f retinal ganglion cell
176215|NCT02055872|Edema
176216|NCT02055872|Hypoproteinemia
176217|NCT02055872|Albumin
176218|NCT02055872|Diuresis
176219|NCT02055872|Critical illness
176220|NCT02055859|acoustic neuromas
176221|NCT02055859|radiosurgery
176222|NCT02055859|hearing preservation
176223|NCT02055846|Androgen-independent prostate cancer
176224|NCT02055807|Atelectasis
176225|NCT02055807|Ultrasound
176226|NCT02055807|Recruitment maneuver
176227|NCT02055807|Positive end-expiratory pressure
176228|NCT02055794|perineal wound
176229|NCT02055794|perineal tear
176230|NCT02055794|perineum
176231|NCT02055794|pain
176232|NCT02055794|childbirth
176233|NCT02055781|Myelofibrosis
176234|NCT02055781|Post-Polycythemia Vera Myelofibrosis
176235|NCT02055781|Post-Essential Thrombocythemia Myelofibrosis
176236|NCT02055781|Primary Myelofibrosis
176237|NCT02055781|Polycythemia
176238|NCT02055781|Polycythemia Vera
176239|NCT02055781|Thrombocythemia, Essential
176240|NCT02055781|Thrombocythemia
176241|NCT02055781|Myeloproliferative Disorders
176242|NCT02055781|Bone Marrow Disease
176243|NCT02055781|Hematologic Diseases
176244|NCT02055781|Blood Platelet Disorders
176245|NCT02055781|Hemorrhagic Disorders
176246|NCT02055781|Splenomegaly
176247|NCT02055781|Pacritinib
176248|NCT02055781|MPN-SAF
176249|NCT02055781|MPN-SAF TSS
176250|NCT02055781|Anemia
176251|NCT02055781|Myeloproliferative
176252|NCT02055781|Myeloproliferative Neoplasm
176253|NCT02055781|Spleen
176254|NCT02055781|Spleen volume
176255|NCT02055781|Thrombocytopenia
176256|NCT02055781|SB1518
176257|NCT02055755|Diabetes
176258|NCT02055755|Wounds
176259|NCT02055755|Wound Healing
176260|NCT02055755|Diabetic Foot Ulcer
176261|NCT02055755|DFU
176262|NCT02055755|Clinical Decision Support
176263|NCT02055729|bedsore
176264|NCT02055729|bacteria
176265|NCT02055729|colonization
176266|NCT02055729|ecology
176267|NCT02055703|Healthy Subjects
176268|NCT02055690|Advanced Recurrent Ovarian Cancer
176269|NCT02055690|Pazopanib
176270|NCT02055690|Votrient
176271|NCT02055690|Fosbretabulin
176272|NCT02055677|personality profiles
176273|NCT02055677|values
176274|NCT02055677|empathy
176275|NCT02055677|quality of life
176276|NCT02055677|vegetarians
176277|NCT02055677|vegans
176278|NCT02055651|Worksite
176279|NCT02055651|Cardiovascular
176280|NCT02055651|Epidemiology
176281|NCT02055651|Risk factors
176282|NCT02055638|Intermittent Explosive Disorder
176283|NCT02055638|IED
176284|NCT02055638|Aggression
176285|NCT02055638|SRX246
176286|NCT02055638|Vasopressin 1a Receptor Antagonist
176287|NCT02055638|V1a
176288|NCT02055625|Graft-versus-host-disease
176289|NCT02055625|Immune system diseases
176290|NCT02055625|Oral
176291|NCT02055612|wet AMD
176292|NCT02055612|epidemiology
176293|NCT02055599|Wound
176294|NCT02055599|Wound Healing
176295|NCT02055599|Pressure Ulcers
176296|NCT02055599|Chronic Wounds
176297|NCT02055599|Clinical Decision Support
176298|NCT02055573|Abusive Head Trauma
176299|NCT02055573|Early Literacy
176300|NCT02055573|Parental Education
176301|NCT02055573|Low Income
176302|NCT02055560|colorectal
176303|NCT02055560|OnDose
176304|NCT02055560|MyCare
176305|NCT02055560|5-FU
176306|NCT02055560|pharmacokinetics
176307|NCT02055560|exposure
176308|NCT02055560|optimization
176309|NCT02055560|dose adjustment
176310|NCT02055521|Composite tissue allograft
176311|NCT02055521|operational tolerance
176312|NCT02055521|skin rejection
176313|NCT02055521|Hand and Face allotransplantation
176314|NCT02055508|Exercise
176315|NCT02055508|Physical Activity
176316|NCT02055508|Palliative Care
176317|NCT02055508|Lung Cancer
176318|NCT02055508|NSCLC
176319|NCT02055495|Painful flatfeet
176320|NCT02055495|Planovagus feet
176321|NCT02055495|Subtalar arthroeresis
176322|NCT02055495|Lateral column lengthening
176323|NCT02055495|Kinematic motion analysis
176324|NCT02055482|Anemia on CKD
176325|NCT02055469|Achalasia
176326|NCT02055456|Hormones
176327|NCT02055456|Androgens
176328|NCT02055456|Aplastic Anemia
176329|NCT02055456|Bone Marrow Failure Syndromes
176330|NCT02055456|Idiopathic Pulmonary Fibrosis
176331|NCT02055456|Telomere
176332|NCT02055456|Telomere Shortening
176333|NCT02055443|nuclear cardiology
176334|NCT02055443|chest pain
176335|NCT02055443|cardiac ischemia
176336|NCT02055443|shortness of breath
176337|NCT02055443|ECG
176338|NCT02055443|EKG
176339|NCT02055443|electrocardiogram
176340|NCT02055430|anuria
176341|NCT02055430|children
176342|NCT02055430|nephrostomy
176343|NCT02055430|stents
176344|NCT02055430|urinary calculi
176345|NCT02055404|astigmatism
176346|NCT02055404|toric
176347|NCT02055404|contact lenses
176348|NCT02055404|daily disposable contact lenses
176349|NCT02055404|molded mark
176350|NCT02055404|rotation mark
176351|NCT02055378|myopia
176352|NCT02055378|atropine
176353|NCT02055378|anterior chamber depth
176354|NCT02055378|auricular acupoint
176355|NCT02055378|axial length
176356|NCT02055365|Hepatitis B vaccine
176357|NCT02055326|Smoking
176358|NCT02055326|yoga
176359|NCT02055326|men
176360|NCT02055326|intervention
176361|NCT02055313|Exceptional patient
176362|NCT02055313|Cancer care
176363|NCT02055313|Lung cancer
176364|NCT02055313|Pancreatic cancer
176365|NCT02055313|Stomach cancer
176366|NCT02055313|Unexplained survival
176367|NCT02055313|still alive from 2001-2008
176368|NCT02055287|schizophrenia
176369|NCT02055287|schizoaffective disorder
176370|NCT02055274|Parkinsons
176371|NCT02055248|Genetic Counseling
176372|NCT02055248|Mobius Syndrome
176373|NCT02055248|Birth Defects
176374|NCT02055248|Congenital Malformations
176375|NCT02055248|Gene Identification
176376|NCT02055235|Brain
176377|NCT02055235|Pain
176378|NCT02055235|Yoga
176379|NCT02055222|COPD
176380|NCT02055222|Smoking
176381|NCT02055222|Idiopathic Pulmonary Fibrosis
176382|NCT02055209|Coronary Artery Calcification
176383|NCT02055209|African American
176384|NCT02055209|African-American Families
176385|NCT02055183|Registry
176386|NCT02055183|Botulinum toxin
176387|NCT02055183|Botulism Antitoxin Heptavalent- (Equine)
176388|NCT02055183|BAT®
176389|NCT02055157|Achondroplasia
176390|NCT02055157|Dwarfism
176391|NCT02055157|Bone Diseases, Developmental
176392|NCT02055157|Bone Diseases
176393|NCT02055144|NSCLC
176394|NCT02055144|VeriStrat
176395|NCT02055144|chemotherapy
176396|NCT02055144|circulating tumor cells
176397|NCT02055131|vascular access
176398|NCT02055131|hemodialysis
176399|NCT02055131|aspirin resistance
176400|NCT02055131|PFA-100
176401|NCT02055118|hunters disease
176402|NCT02055118|MPS II
176403|NCT02055118|lysosomal storage disorder
176404|NCT02055118|hunters syndrome
176405|NCT02055118|ert treatment
176406|NCT02055118|hunter's disease
176407|NCT02055118|iduronate sulfatase
176408|NCT02055118|MPS society
176409|NCT02055118|mps 2
176410|NCT02055118|enlarged adenoids
176411|NCT02055118|hunter's syndrome
176412|NCT02055118|iduronate 2 sulfatase
176413|NCT02055118|chronic ear infection
176414|NCT02055118|mucopolysaccharides
176415|NCT02055118|hunter syndrome therapy
176416|NCT02055118|hunter's syndrome treatment
176417|NCT02055118|enzyme replacement therapy
176418|NCT02055118|hunter syndrome treatment
176419|NCT02055118|elaprase
176420|NCT02055118|MPSII
176421|NCT02055118|lysosomal storage disease
176422|NCT02055118|mps diagnosis
176423|NCT02055118|mps symptoms
176424|NCT02055118|idursulfase
176425|NCT02055118|hunter disease
176426|NCT02055118|hunter's disease treatment
176427|NCT02055118|MPS2
176428|NCT02055105|Pediatric Sepsis
176429|NCT02055092|Young onset dementia
176430|NCT02055092|Quality of life
176431|NCT02055092|Specific needs
176432|NCT02055092|Healthcare resources in dementia
176433|NCT02055092|Frontotemporal dementia
176434|NCT02055092|Alzheimer's disease
176435|NCT02055092|Healthcare services
176436|NCT02055079|ADPKD
176437|NCT02055079|PKD
176438|NCT02055079|Polycystic kidney disease
176439|NCT02055079|Mammalian target of rapamycin
176440|NCT02055079|mTOR-I
176441|NCT02055079|Sirolimus
176442|NCT02055066|cancer
176443|NCT02055066|c-MET
176444|NCT02055053|Post Operative Pain
176445|NCT02055053|hernia repair
176446|NCT02055027|Sleep Apnea, Obstructive
176447|NCT02055027|Continuous Positive Airway Pressure
176448|NCT02055027|Perioperative Period
176449|NCT02055014|Endobarrier
176450|NCT02055014|Duodenal-jejunal bypass liner
176451|NCT02055014|Glucagon-like peptide-1 receptor agonist
176452|NCT02055014|Liraglutide
176453|NCT02055014|Diabesity
176454|NCT02055014|Type 2 diabetes
176455|NCT02055014|Obesity
176456|NCT02055001|gender medicine
176457|NCT02055001|platelet function
176458|NCT02055001|sex hormones
176459|NCT02055001|antiplatelet drugs
176460|NCT02055001|haemostasis
176461|NCT02054975|asthma, children, vitamin D deficiency, clinical trial
176462|NCT02054962|Pain
176463|NCT02054949|N-acetyl cysteine
176464|NCT02054949|Refractory Seizures
176465|NCT02054923|colonoscopy
176466|NCT02054923|videorecording
176467|NCT02054923|quality indicators
176468|NCT02054923|screening
176469|NCT02054923|colorectal cancer
176470|NCT02054884|Interleukin, IL2, F16, monoclonal, antibody, cytokine Paclitaxel, Merkel cell carcinoma
176471|NCT02054871|Peripheral Angioplasty
176472|NCT02054871|Remote Ischaemic Preconditioning
176473|NCT02054871|Contrast Induced Nephropathy
176474|NCT02054858|Computerized Tomography
176475|NCT02054858|Contrast enhanced
176476|NCT02054858|Acute Kidney Injury
176477|NCT02054858|Remote ischaemic preconditioning
176478|NCT02054858|RIPC
176479|NCT02054845|Body awareness therapy
176480|NCT02054845|Physical therapy
176481|NCT02054819|lung cancer
176482|NCT02054819|NSCLC
176483|NCT02054806|PD1
176484|NCT02054806|PD-1
176485|NCT02054806|PDL1
176486|NCT02054806|PD-L1
176487|NCT02054793|metastatic disease
176488|NCT02054793|non-metastatic disease
176489|NCT02054793|prostate cancer
176490|NCT02054793|castration-resistant prostate cancer
176491|NCT02054767|articaine
176492|NCT02054767|lidocaine
176493|NCT02054767|mepivacaine
176494|NCT02054767|inferior alveolar nerve block
176495|NCT02054767|irreversible pulpitis
176496|NCT02054754|Dexanabinol
176497|NCT02054754|Oral
176498|NCT02054754|Safety
176499|NCT02054754|Tolerability
176500|NCT02054754|Pharmacokinetics
176501|NCT02054728|right-heart catheterization
176502|NCT02054728|respiratory muscle training
176503|NCT02054728|inspiratory resistance
176504|NCT02054728|hemodynamics
176505|NCT02054702|Schizophrenia
176506|NCT02054702|Mental Disorders
176507|NCT02054702|Psychotic Disorders
176508|NCT02054702|Antipsychotic
176509|NCT02054702|Cognitive testing
176510|NCT02054676|mandible
176511|NCT02054676|alveolar nerve inferior
176512|NCT02054676|anatomy
176513|NCT02054676|cross-sectional
176514|NCT02054676|dental implants
176515|NCT02054676|classification
176516|NCT02054676|reliability
176517|NCT02054676|validity
176518|NCT02054663|Acute coronary syndrome
176519|NCT02054663|Coronary artery disease
176520|NCT02054663|Antiplatelet therapy
176521|NCT02054663|Ticagrelor
176522|NCT02054663|Clopidogrel
176523|NCT02054650|Chronic low back pain
176524|NCT02054650|Type 2 diabetes mellitus
176525|NCT02054650|Back pain
176526|NCT02054650|Diabetes
176527|NCT02054650|Osteopathic manual treatment
176528|NCT02054650|Osteopathic manipulative treatment
176529|NCT02054650|OMT
176530|NCT02054650|Biomarkers
176531|NCT02054650|Glycemic control
176532|NCT02054650|Kidney function
176533|NCT02054637|Bile reflux
176534|NCT02054637|Reflux esophagitis
176535|NCT02054637|Lanreotide autogel
176536|NCT02054637|Somatuline
176537|NCT02054637|Endoscopy
176538|NCT02054637|Impedancemetry
176539|NCT02054624|Obesity
176540|NCT02054624|Rural Health
176541|NCT02054624|Exercise
176542|NCT02054624|Weight loss
176543|NCT02054624|Behavior change
176544|NCT02054611|ARDS
176545|NCT02054611|Chest radiographs
176546|NCT02054611|Vignettes
176547|NCT02054611|Online educational video
176548|NCT02054585|dehydration
176549|NCT02054585|pediatric
176550|NCT02054585|glucose
176551|NCT02054585|IV fluid
176552|NCT02054572|AMG 416, ESRD, hemodialysis
176553|NCT02054559|localized
176554|NCT02054559|diffuse large B-cell lymphoma
176555|NCT02054559|R-CHOP chemotherapy
176556|NCT02054559|radiotherapy
176557|NCT02054533|Crohn's disease
176558|NCT02054533|Ulcerative colitis
176559|NCT02054533|Inflammatory bowel disease
176560|NCT02054533|Surgery
176561|NCT02054533|Anti-Tumor Necrosis Factor
176562|NCT02054533|Infection
176563|NCT02054520|Stage IV
176564|NCT02054520|metastatic melanoma
176565|NCT02054507|Children
176566|NCT02054507|Cognitive outcome
176567|NCT02054507|Prematurity
176568|NCT02054507|Care Network
176569|NCT02054507|Outpatient follow-up of cognitive development
176570|NCT02054507|Care resources
176571|NCT02054468|Muscle relaxant, Rocuronium, TIVA, Propofol
176572|NCT02054455|PPI
176573|NCT02054455|SIBO
176574|NCT02054455|LP-F19
176575|NCT02054442|cetuximab
176576|NCT02054442|methotrexate
176577|NCT02054442|squamous cell carcinoma head neck
176578|NCT02054442|palliative chemotherapy
176579|NCT02054416|non-traumatic lower limb amputation
176580|NCT02054416|AKA
176581|NCT02054416|BKA
176582|NCT02054390|Angiotensin converting enzyme inhibitor
176583|NCT02054390|inflammation
176584|NCT02054390|metabolic syndrome
176585|NCT02054390|myonecrosis
176586|NCT02054390|percutaneous coronary intervention
176587|NCT02054390|periprocedural myocardial injury
176588|NCT02054377|cystic fibrosis
176589|NCT02054377|tai chi
176590|NCT02054364|Eating Disorder
176591|NCT02054364|Anorexia Nervosa
176592|NCT02054364|Eating Disorder Not Otherwise Specified
176593|NCT02054364|Maudsley
176594|NCT02054364|Family-Based Therapy
176595|NCT02054364|FBT
176596|NCT02054364|Family Therapy
176597|NCT02054364|Cognitive Remediation Therapy
176598|NCT02054364|CRT
176599|NCT02054351|Advanced ovarian cancer
176600|NCT02054351|CLDN6 positive
176601|NCT02054325|Sclerotherapy
176602|NCT02054325|varicose veins
176603|NCT02054325|veins
176604|NCT02054273|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
176605|NCT02054247|Carpal tunnel syndrome,ultrasound,pulsed ultrasound
176606|NCT02054234|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
176607|NCT02054221|hypertrophic cardiomyopathy
176608|NCT02054221|mitral valve
176609|NCT02054208|human umbilical cord blood derived mesenchymal stem cells
176610|NCT02054208|stem cells
176611|NCT02054208|alzheimer's disease
176612|NCT02054208|cognitive ability
176613|NCT02054208|mesenchymal stem cells
176614|NCT02054208|cord blood
176615|NCT02054182|vitamin D supplementation, pneumonia, bronchiolitis
176616|NCT02054156|Cystic fibrosis (CF)
176617|NCT02054156|Azithromycin
176618|NCT02054156|Tobramycin solution for inhalation (TIS)
176619|NCT02054156|Pseudomonas aeruginosa (Pa)
176620|NCT02054156|Early Pseudomonas aeruginosa infection
176621|NCT02054156|Pulmonary exacerbation
176622|NCT02054156|Standardized anti-pseudomonal therapy
176623|NCT02054143|sevoflurane
176624|NCT02054143|cerebral vasoreactivity
176625|NCT02054143|arterial stiffness
176626|NCT02054143|Transcranial Doppler
176627|NCT02054143|SphygmoCor
176628|NCT02054130|Asthma
176629|NCT02054117|Hemorrhage
176630|NCT02054117|Intracerebral hemorrhage (ICH)
176631|NCT02054104|Lung Cancer
176632|NCT02054104|Cancer Vaccine
176633|NCT02054104|Immunotherapy
176634|NCT02054104|Adjuvant Therapy
176635|NCT02054104|Surgical Intervention
176636|NCT02054091|Preterm infants
176637|NCT02054091|Bovine colostrum
176638|NCT02054091|Feeding intolerance
176639|NCT02054091|Postnatal growth
176640|NCT02054091|Intestinal maturation
176641|NCT02054091|Necrotizing enterocolitis
176642|NCT02054065|Urinary Catheter
176643|NCT02054065|urinary tract infection
176644|NCT02054052|non-small cell lung cancer
176645|NCT02054052|malignant pleural effusion
176646|NCT02054052|bevacizumab
176647|NCT02054052|intrapleural injection
176648|NCT02054052|pericardial effusion
176649|NCT02054039|Cardiac surgery
176650|NCT02054039|Spirometry
176651|NCT02054039|Physical Therapy Modalities
176652|NCT02054039|Postoperative Complications
176653|NCT02054000|No-reflow phenomenon, tirofiban, intracoronary
176654|NCT02053974|Anthracycline
176655|NCT02053974|spironolactone
176656|NCT02053974|cardiotoxicity
176657|NCT02053948|Reversal
176658|NCT02053948|Surgical technique
176659|NCT02053948|Pursestring Wound Closure
176660|NCT02053948|Gunsight Skin Incision and Closure Technique
176661|NCT02053935|Dopamine
176662|NCT02053935|hyperglycemic clamp
176663|NCT02053935|sepsis
176664|NCT02053935|hyperglycemia
176665|NCT02053935|insulin secretion
176666|NCT02053922|caesarean section, ecbolics, postpartum hemorrhage
176667|NCT02053909|Saphenous vein graft disease
176668|NCT02053909|Coronary artery bypass graft surgery
176669|NCT02053909|Antiplatelet therapy
176670|NCT02053909|Coronary artery disease
176671|NCT02053909|Secondary prevention
176672|NCT02053909|Graft patency
176673|NCT02053896|Type I Gaucher
176674|NCT02053896|ISU302
176675|NCT02053896|Imiglucerase
176676|NCT02053883|SCI
176677|NCT02053883|spinal cord injury
176678|NCT02053883|biologic drug
176679|NCT02053883|rho
176680|NCT02053883|paralysis
176681|NCT02053883|paraplegia
176682|NCT02053883|tetraplegia
176683|NCT02053883|quadriplegia
176684|NCT02053883|trauma
176685|NCT02053883|central nervous system
176686|NCT02053883|fibrin sealant
176687|NCT02053883|neurosurgery
176688|NCT02053883|cervical
176689|NCT02053883|regeneration
176690|NCT02053883|neurotrauma
176691|NCT02053870|Adventitious lung sounds
176692|NCT02053870|Crackles
176693|NCT02053870|Wheezes
176694|NCT02053870|Sputum location
176695|NCT02053857|severe acute malnutrition
176696|NCT02053857|polyunsaturated fatty acids
176697|NCT02053857|ready-to-use therapeutic food
176698|NCT02053844|health care costs
176699|NCT02053844|quality of health care
176700|NCT02053831|plastic surgery
176701|NCT02053818|Cognitive dysfunction
176702|NCT02053818|Cardioprotection
176703|NCT02053818|Recovery
176704|NCT02053818|Renal function
176705|NCT02053818|ICU discharge
176706|NCT02053805|prostate cancer
176707|NCT02053805|BRCA1 Syndrome
176708|NCT02053805|BRCA germ-line mutation
176709|NCT02053805|Lynch syndrome
176710|NCT02053805|BRCA2 Syndrome
176711|NCT02053779|GnRH agonist
176712|NCT02053779|GnRH antagonist
176713|NCT02053779|Luteal phase
176714|NCT02053766|Mitochondrial Diseases
176715|NCT02053766|Sevoflurane
176716|NCT02053766|Dexmedetomidine (Precedex®)
176717|NCT02053766|Propofol
176718|NCT02053753|denosumab, bioequivalence
176719|NCT02053727|Rheumatoid Arthritis
176720|NCT02053727|Hepatitis B
176721|NCT02053727|Abatacept
176722|NCT02053727|Orencia
176723|NCT02053727|entecavir
176724|NCT02053701|magnetic resonance spectroscopy
176725|NCT02053701|quantification precision
176726|NCT02053701|brain
176727|NCT02053701|brain metabolites
176728|NCT02053675|septic shock
176729|NCT02053675|vasopressin
176730|NCT02053675|microcirculation
176731|NCT02053675|tissue oxygenation
176732|NCT02053675|vasopressors
176733|NCT02053675|hemodynamics
176734|NCT02053662|Bladder Cancer
176735|NCT02053649|depression
176736|NCT02053649|major depressive disorder
176737|NCT02053649|postpartum depression
176738|NCT02053649|antenatal depression
176739|NCT02053649|sleep
176740|NCT02053649|circadian
176741|NCT02053649|bright light
176742|NCT02053597|Primary breast cancer
176743|NCT02053597|Young women
176744|NCT02053597|Ovarian function
176745|NCT02053597|Sexual function
176746|NCT02053597|Eligible for adjuvant or neoadjuvant chemotherapy
176747|NCT02053597|Negative hormone-receptor status
176748|NCT02053558|Anesthesiology
176749|NCT02053558|Pain
176750|NCT02053558|TAP block
176751|NCT02053558|Gynecology
176752|NCT02053558|Postoperative
176753|NCT02053558|Analgesia
176754|NCT02053532|Trauma
176755|NCT02053532|Post-traumatic stress disorder (PTSD)
176756|NCT02053532|Imaging
176757|NCT02053532|Neuroimaging
176758|NCT02053532|F-18-fluorodeoxyglucose (FDG)
176759|NCT02053493|Heart Failure
176760|NCT02053493|Preserved Ejection Fraction
176761|NCT02053480|pyruvate kinase deficiency
176762|NCT02053480|hemolytic anemia
176763|NCT02053480|anemia
176764|NCT02053480|enzymopathy
176765|NCT02053480|jaundice
176766|NCT02053480|splenectomy
176767|NCT02053480|health-related quality of life
176768|NCT02053480|Hematologic diseases
176769|NCT02053467|eConsultation
176770|NCT02053467|Specialist care
176771|NCT02053467|Primary health care
176772|NCT02053467|Reducing wait times for specialist care
176773|NCT02053467|Reducing referral rates
176774|NCT02053454|RNAi therapeutic
176775|NCT02053441|Muscle Protein Synthesis
176776|NCT02053441|Muscle Protein Breakdown
176777|NCT02053428|Head and neck cancer
176778|NCT02053428|Percutaneous image-guided gastrostomy
176779|NCT02053428|Pain
176780|NCT02053428|Quality of life
176781|NCT02053428|Complication
176782|NCT02053415|krill oil
176783|NCT02053415|omega-3 index
176784|NCT02053415|plasma lipid profile
176785|NCT02053415|tolerance
176786|NCT02053415|young adults
176787|NCT02053402|vitamin D supplementation, persistent asthma, control
176788|NCT02053389|Patient-Physician communication
176789|NCT02053389|Decision Support Techniques
176790|NCT02053389|Health Communication
176791|NCT02053389|Physician-Patient Relationship
176792|NCT02053389|Decision Making
176793|NCT02053376|gallbladder cancer, biliary cancer, bile duct cancer, hepatobiliary cancer, Biliary Tract Carcinoma
176794|NCT02053376|Cholangiocarcinoma
176795|NCT02053363|tranexamic acid, reconstructive spine surgery
176796|NCT02053350|Clostridium difficile
176797|NCT02053350|glutamine
176798|NCT02053350|diarrhea
176799|NCT02053350|alanyl-glutamine
176800|NCT02053324|AvidinOX
176801|NCT02053311|adenocarcinoma of the prostate
176802|NCT02053311|metastatic castration-resistant prostate cancer
176803|NCT02053311|maintenance therapy
176804|NCT02053311|orteronel
176805|NCT02053311|TAK-700
176806|NCT02053298|Glaucoma
176807|NCT02053272|Diabetes
176808|NCT02053272|Glycaemic control
176809|NCT02053272|Delta-9-tetrahydrocannabivarin
176810|NCT02053272|Cannabinoids
176811|NCT02053233|stroke
176812|NCT02053233|robot-assisted therapy
176813|NCT02053233|conventional therapy
176814|NCT02053233|motor function
176815|NCT02053207|Cognitive training
176816|NCT02053207|Brain training
176817|NCT02053207|Plasticity-based training
176818|NCT02053207|Cardiac surgery
176819|NCT02053207|Preoperative
176820|NCT02053207|Cognitive function
176821|NCT02053194|Inappropriate prescribing
176822|NCT02053194|Health Education
176823|NCT02053194|Community Pharmacy Services
176824|NCT02053194|Medication Therapy Management
176825|NCT02053194|Preventive Health Services
176826|NCT02053194|Polypharmacy
176827|NCT02053194|Inappropriate prescriptions
176828|NCT02053194|Aged
176829|NCT02053181|Cadazolid
176830|NCT02053181|ACT-179811
176831|NCT02053181|Pharmacokinetics
176832|NCT02053181|Safety
176833|NCT02053181|Tolerability
176834|NCT02053155|Smoking cessation
176835|NCT02053155|perioperative complication
176836|NCT02053155|Smokerlyzer
176837|NCT02053155|smokers help line
176838|NCT02053142|Pharmacokinetics
176839|NCT02053142|Herpes simplex virus
176840|NCT02053142|Genital herpes ulcers
176841|NCT02053129|tuberculosis
176842|NCT02053129|HIV
176843|NCT02053129|pregnancy
176844|NCT02053090|Fibromyalgia
176845|NCT02053090|Group Acupuncture
176846|NCT02053090|Group Education with Stretching
176847|NCT02053090|Nociceptive Reflex Testing
176848|NCT02053090|Pain
176849|NCT02053090|Sleep
176850|NCT02053090|Fatigue
176851|NCT02053064|Neurodegenerative diseases
176852|NCT02053064|Nervous systems diseases
176853|NCT02053064|Genetic diseases, Inborn
176854|NCT02053064|Metabolic diseases
176855|NCT02053064|Gene therapy
176856|NCT02053064|Adeno Associated Virus (AAV)
176857|NCT02053025|appetite
176858|NCT02053025|overweight
176859|NCT02053025|energy intake
176860|NCT02053025|obesity
176861|NCT02053025|gut hormones
176862|NCT02052986|Fatty Acids, Omega-3
176863|NCT02052986|Omega-3 fatty acids
176864|NCT02052986|Docosahexaenoic acid (DHA)
176865|NCT02052986|Eicosapentaenoic acid (EPA)
176866|NCT02052986|Docosapentaenoic acid (DPA)
176867|NCT02052986|Omega Index
176868|NCT02052986|Omega Score
176869|NCT02052986|Cardiac Rehab
176870|NCT02052973|Streptococcus mutans
176871|NCT02052973|Natural products
176872|NCT02052947|Alzheimer's disease
176873|NCT02052947|cerebrovascular disease
176874|NCT02052947|Lewy body disease
176875|NCT02052947|MRI
176876|NCT02052947|SPECT
176877|NCT02052947|CSF
176878|NCT02052947|biomarkers
176879|NCT02052947|disability
176880|NCT02052947|Multicenter and prospective cohort study
176881|NCT02052934|Escherichia coli Infections
176882|NCT02052934|ETEC Candidate Vaccine
176883|NCT02052934|Immunogenicity
176884|NCT02052921|Observation
176885|NCT02052921|Rectal Resection
176886|NCT02052921|complete clinical response
176887|NCT02052921|neoadjuvant chemoradiotherapy.
176888|NCT02052895|Presepsin
176889|NCT02052895|Sepsis
176890|NCT02052895|SIRS
176891|NCT02052882|Romiplostim
176892|NCT02052882|Thrombocytopenia
176893|NCT02052882|13-132
176894|NCT02052869|endotracheal intubation
176895|NCT02052869|esophageal intubation
176896|NCT02052856|Tunnel Widening
176897|NCT02052856|All-Inside Suspensory Method
176898|NCT02052856|Biointerference Screw Fixation
176899|NCT02052791|Spinal Muscular Atrophy
176900|NCT02052791|SMA
176901|NCT02052791|SMN
176902|NCT02052791|SMNRx
176903|NCT02052791|ISIS-SMNRx
176904|NCT02052791|ISIS 396443
176905|NCT02052791|IONIS-SMNRx
176906|NCT02052791|IONIS-SMN Rx
176907|NCT02052778|Breast Cancer
176908|NCT02052778|Non Small Cell Lung Cancer
176909|NCT02052778|Gastric Cancer
176910|NCT02052778|Multiple Myeloma
176911|NCT02052778|FGF
176912|NCT02052778|FGFR
176913|NCT02052778|FGFR abnormality
176914|NCT02052778|TAS-120
176915|NCT02052778|Dose Escalation
176916|NCT02052739|Status Epilepticus
176917|NCT02052739|Refractory status epilepticus
176918|NCT02052739|Super-refractory status epilepticus
176919|NCT02052739|SAGE-547
176920|NCT02052739|SAGE
176921|NCT02052739|Sage Therapeutics
176922|NCT02052713|tamsulosin
176923|NCT02052713|combination capsule of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
176924|NCT02052713|dutasteride
176925|NCT02052713|dutasteride and tamsulosin combination
176926|NCT02052713|healthy subject
176927|NCT02052687|Healthy volunteer
176928|NCT02052674|Precursor to CAUTI
176929|NCT02052661|Adolescents
176930|NCT02052661|Infancy
176931|NCT02052661|Hepatitis B
176932|NCT02052661|Infanrix™ hexa
176933|NCT02052661|Hepatitis B antibodies
176934|NCT02052661|Engerix™-B Kinder
176935|NCT02052661|Safety
176936|NCT02052661|Immunogenicity
176937|NCT02052648|glioblastoma multiforme
176938|NCT02052648|glioma
176939|NCT02052648|gliosarcoma
176940|NCT02052648|malignant brain tumor
176941|NCT02052635|Percutaneous Coronary Intervention
176942|NCT02052622|submental fat reduction
176943|NCT02052596|Boostrix
176944|NCT02052596|Herpes zoster
176945|NCT02052596|Immunogenicity
176946|NCT02052596|Co-administration
176947|NCT02052596|Adults
176948|NCT02052596|Safety
176949|NCT02052583|Cardiac arrest
176950|NCT02052583|Oxymetry
176951|NCT02052583|Hypothermia
176952|NCT02052570|School Reentry after pediatric HSCT
176953|NCT02052557|Exparel
176954|NCT02052557|liposomal bupivicaine
176955|NCT02052557|post operative pain control
176956|NCT02052557|local anesthetic after surgery
176957|NCT02052557|colorectal surgery
176958|NCT02052557|marcaine
176959|NCT02052557|long acting local anesthetic
176960|NCT02052557|pain medication use after surgery
176961|NCT02052544|determination of heparin levels
176962|NCT02052544|Patients
176963|NCT02052544|requiring
176964|NCT02052544|unfractionated
176965|NCT02052518|Childhood obesity
176966|NCT02052518|Breastfeeding
176967|NCT02052518|Introduction of solids
176968|NCT02052518|Introduction of juice
176969|NCT02052505|inappropriate prescribing
176970|NCT02052505|psychiatry
176971|NCT02052505|medication quality
176972|NCT02052505|patient safety
176973|NCT02052505|medication errors
176974|NCT02052479|Polycystic Ovary Syndrome
176975|NCT02052479|PCOS
176976|NCT02052479|Secondary Amenorrhea
176977|NCT02052479|Hirsutism
176978|NCT02052479|Hyperandrogenism
176979|NCT02052479|Insulin Resistance
176980|NCT02052466|Shoulder Joint
176981|NCT02052466|Computed tomography
176982|NCT02052453|Pacemaker
176983|NCT02052453|ICD
176984|NCT02052453|Surgery
176985|NCT02052453|Electrocautery
176986|NCT02052453|Electromagnetic interference
176987|NCT02052427|Ischemic heart disease
176988|NCT02052427|Coronary artery disease
176989|NCT02052427|Chronic Heart Failure
176990|NCT02052427|Cardiovascular disease
176991|NCT02052427|adult stem cells
176992|NCT02052427|adipose derived regenerative cells
176993|NCT02052414|side effects
176994|NCT02052414|safety
176995|NCT02052414|efficacy
176996|NCT02052414|Gralise
176997|NCT02052414|Fibromyalgia
176998|NCT02052414|gabapentin
176999|NCT02052401|OLD AGE
177000|NCT02052401|Elderly
177001|NCT02052401|Domiciliary Intervention
177002|NCT02052401|Occupational Therapy
177003|NCT02052401|Rehospitalization
177004|NCT02052388|Skin Infection
177005|NCT02052388|Staph aureus
177006|NCT02052388|MRSA
177007|NCT02052388|MSSA
177008|NCT02052388|Cellulitis/Erysipelas
177009|NCT02052388|Wound Infection
177010|NCT02052388|Abscess
177011|NCT02052375|Rheumatoid Arthritis
177012|NCT02052375|ASP2408
177013|NCT02052375|methotrexate
177014|NCT02052362|absolute bioavailability
177015|NCT02052362|healthy volunteers
177016|NCT02052349|relative bioavailability
177017|NCT02052349|healthy volunteers
177018|NCT02052336|Drug-Drug interaction
177019|NCT02052336|Pharmacokinetics
177020|NCT02052323|P.f Malaria, Artemisinin resistance, ACT treatment failure
177021|NCT02052310|Anemia
177022|NCT02052310|Chronic Kidney Disease
177023|NCT02052310|Hemoglobin
177024|NCT02052310|End-Stage Renal Disease
177025|NCT02052310|Incident-Dialysis
177026|NCT02052310|Erythropoieitin
177027|NCT02052310|Erythropoieisis stimulating-agent
177028|NCT02052310|Roxadustat
177029|NCT02052310|AZD9941
177030|NCT02052310|ASP1517
177031|NCT02052297|Idiopathic Pulmonary Fibrosis (IPF)
177032|NCT02052297|dosimetry
177033|NCT02052297|Positron Emission Tomograph (PET)
177034|NCT02052284|ELBW
177035|NCT02052284|premature
177036|NCT02052284|neonate
177037|NCT02052284|skin
177038|NCT02052284|water loss
177039|NCT02052271|essential tremor
177040|NCT02052271|cerebellum
177041|NCT02052271|transcranial direct current stimulation
177042|NCT02052271|electrophysiology
177043|NCT02052258|oxytocin
177044|NCT02052219|Blisibimod
177045|NCT02052219|IgA nephropathy
177046|NCT02052219|BAFF
177047|NCT02052219|BLyS
177048|NCT02052206|osteoarthritis
177049|NCT02052206|complexe proximal humeral fracture
177050|NCT02052206|shoulder
177051|NCT02052206|shoulder replacement
177052|NCT02052206|accuracy
177053|NCT02052206|computer-assisted
177054|NCT02052206|3D
177055|NCT02052180|Carpalmetacarpal arthroplasty
177056|NCT02052180|Proximal row carpectomy
177057|NCT02052180|Post-operative pain control
177058|NCT02052180|Exparel
177059|NCT02052180|Marcaine
177060|NCT02052154|Pneumococcal infection
177061|NCT02052154|Splenectomized
177062|NCT02052154|vaccination
177063|NCT02052141|Pediatric
177064|NCT02052141|C1 inhibitor
177065|NCT02052141|HAE
177066|NCT02052141|Cinryze
177067|NCT02052141|C1 INH
177068|NCT02052141|Prevention
177069|NCT02052128|endometrial cancer
177070|NCT02052128|ovarian cancer
177071|NCT02052128|breast cancer
177072|NCT02052128|uterine sarcoma
177073|NCT02052128|uterine endometrioid adenocarcinoma
177074|NCT02052115|breast cancer
177075|NCT02052115|exercise
177076|NCT02052115|weight loss
177077|NCT02052115|executive function
177078|NCT02052115|breast cancer survivor
177079|NCT02052102|Deep inspiration breath hold
177080|NCT02052102|radiation therapy
177081|NCT02052102|Cardiac toxicity
177082|NCT02052102|Left-sided breast cancer
177083|NCT02052089|Tennis Elbow
177084|NCT02052089|lateral epicondylosis
177085|NCT02052089|lateral epicondylitis
177086|NCT02052089|Platelet-Rich Plasma
177087|NCT02052089|Extracorporeal Shockwave Therapy
177088|NCT02052089|Prolotherapy
177089|NCT02052089|Physiotherapy
177090|NCT02052076|Energy balance
177091|NCT02052076|meal pattern
177092|NCT02052076|metabolic syndrome
177093|NCT02052063|rectocele
177094|NCT02052063|intussusception
177095|NCT02052063|surgery
177096|NCT02052050|colorectal-neoplasms,deep-muscles of the back,rehabilitation
177097|NCT02052037|Type 2 Diabetes
177098|NCT02052037|Egg
177099|NCT02052037|Glycemic Control
177100|NCT02052037|Insulin sensitivity
177101|NCT02052037|Diet quality
177102|NCT02052024|Spasticity
177103|NCT02052024|Modified Ashworth Scale
177104|NCT02052024|MYOBLOC
177105|NCT02052024|Botox
177106|NCT02052024|Muscle Atrophy
177107|NCT02052011|Chest Pain
177108|NCT02052011|Microvascular Angina
177109|NCT02052011|Ranolazine
177110|NCT02052011|Emergency department
177111|NCT02052011|PET
177112|NCT02051998|Geographic atrophy
177113|NCT02051998|Age-related macular degeneration
177114|NCT02051998|Retina
177115|NCT02051998|Retinal pigment epithelium
177116|NCT02051998|Optical coherence tomography
177117|NCT02051998|Scanning laser ophthalmoscopy
177118|NCT02051985|Chronic heart failure
177119|NCT02051985|Heart decompensation
177120|NCT02051985|Aerobic exercise training
177121|NCT02051985|Functional capacity
177122|NCT02051985|Dyspnea
177123|NCT02051985|Beta-adrenergic receptor signaling
177124|NCT02051959|Phantom Limb Pain
177125|NCT02051959|Transcranial Direct Current Stimulation
177126|NCT02051959|Amputation
177127|NCT02051959|Diabetes Mellitus
177128|NCT02051946|novel drug delivery technique for glaucoma patients
177129|NCT02051933|pilon
177130|NCT02051933|tibial plafond
177131|NCT02051933|botox
177132|NCT02051933|ankle dorsiflexion
177133|NCT02051933|ankle functionality
177134|NCT02051933|ankle range of motion
177135|NCT02051920|Elastography
177136|NCT02051894|Neonates
177137|NCT02051894|Dobutamine
177138|NCT02051894|Superior Vena Cana Flow
177139|NCT02051894|Hypoxic Ischemic Encephalopathy
177140|NCT02051894|Pleth Variability Index
177141|NCT02051868|Squamous cell carcinoma of the anus
177142|NCT02051868|Anal cancer
177143|NCT02051868|Cancer of the anus
177144|NCT02051868|SCCA
177145|NCT02051868|Cisplatin-5FU
177146|NCT02051868|Carboplatin-Paclitaxel
177147|NCT02051868|inoperable
177148|NCT02051868|locally recurrent
177149|NCT02051868|metastatic
177150|NCT02051855|Neonates
177151|NCT02051855|Superior Vena Cava Flow
177152|NCT02051855|Pleth Variability Index
177153|NCT02051855|Dobutamine
177154|NCT02051855|Intensive Care
177155|NCT02051842|NAFLD
177156|NCT02051842|oxidative stress
177157|NCT02051842|malondialdehyde
177158|NCT02051816|Endotracheal Intubation
177159|NCT02051816|Apneic Oxygenation
177160|NCT02051816|Respiratory failure
177161|NCT02051803|smoking cessation
177162|NCT02051803|women
177163|NCT02051751|Solid tumors, Head and neck non squamous cell carcinoma, breast cancer, PI3K inhibitor, BYL719, paclitaxel
177164|NCT02051738|Healthy
177165|NCT02051738|Mebendazole
177166|NCT02051738|Fast-Disintegrating Chewable Formulation
177167|NCT02051738|Bioavailability
177168|NCT02051712|chronic heart failure
177169|NCT02051712|exercise training
177170|NCT02051712|preferred training
177171|NCT02051712|prevention
177172|NCT02051699|Osteoarthritis of the knee
177173|NCT02051699|Weight bearing radiograph
177174|NCT02051699|Kellgren-Lawrence classification
177175|NCT02051699|Joint space width
177176|NCT02051699|One-leg standing view
177177|NCT02051686|Acetabulum Fractures
177178|NCT02051686|Pelvic Ring Injuries
177179|NCT02051686|Tranexamic Acid
177180|NCT02051673|Kidney Transplantation
177181|NCT02051647|medical students
177182|NCT02051647|Basel University
177183|NCT02051634|Aging
177184|NCT02051634|Papaya
177185|NCT02051634|Fermented Papaya
177186|NCT02051634|Inflammation
177187|NCT02051634|Phytochemicals
177188|NCT02051634|Physical function
177189|NCT02051634|Quality of life
177190|NCT02051634|Fatigue
177191|NCT02051634|Health
177192|NCT02051621|pulmonary vein isolation
177193|NCT02051621|isthmus ablation
177194|NCT02051621|recurrence
177195|NCT02051595|heart lung machine
177196|NCT02051595|blood pump
177197|NCT02051595|cardiac surgery
177198|NCT02051595|cardiopulmonary bypass
177199|NCT02051595|circulation
177200|NCT02051556|Parkinson's disease
177201|NCT02051556|Freezing of gait
177202|NCT02051556|Asymmetry
177203|NCT02051556|Rehabilitation
177204|NCT02051556|Physical therapy
177205|NCT02051530|mood
177206|NCT02051530|empathy
177207|NCT02051530|mimicry
177208|NCT02051530|emotional reactivity
177209|NCT02051530|prosody
177210|NCT02051517|Virectomy
177211|NCT02051504|Type 1 diabetes
177212|NCT02051504|Glycated hemoglobin
177213|NCT02051504|Muscle Oxygenation
177214|NCT02051504|Exercise
177215|NCT02051504|Maximal Oxygen uptake
177216|NCT02051504|Mitochondrial respiration
177217|NCT02051504|Endocannabinoid system
177218|NCT02051504|Oxidative stress
177219|NCT02051478|manipulation
177220|NCT02051478|mobilization
177221|NCT02051478|spine
177222|NCT02051478|pressure pain
177223|NCT02051439|Varicose Veins
177224|NCT02051439|Venous Insufficiency
177225|NCT02051439|Doppler
177226|NCT02051439|Duplex
177227|NCT02051439|Valsava
177228|NCT02051426|neuropsychiatric effects
177229|NCT02051413|Major depression
177230|NCT02051413|Antidepressant drug
177231|NCT02051413|Beta-arrestin
177232|NCT02051413|Biomarker
177233|NCT02051413|Predictive factor
177234|NCT02051400|Intubation
177235|NCT02051400|Laryngoscopes
177236|NCT02051361|DAT = Dual Antiplatelet Treatment
177237|NCT02051361|Major Cardiac Adverse Events
177238|NCT02051348|Helicobacter pylori
177239|NCT02051348|Mild Indigestion
177240|NCT02051335|Drug therapy
177241|NCT02050360|Raynaud's phenomenon
177242|NCT02050360|Sildenafil
177243|NCT02050360|Systemic Sclerosis
177244|NCT02050360|Local cooling
177245|NCT02050360|Microcirculation
177246|NCT02050347|CD19.CAR-CD28zeta
177247|NCT02050347|chimeric antigen receptor
177248|NCT02050347|hematopoietic stem cell transplant
177249|NCT02050334|Phase 1
177250|NCT02050334|Healthy Volunteer
177251|NCT02050334|Safety
177252|NCT02050334|Healthy Volunteer Safety Study
177253|NCT02050282|Dyspnea
177254|NCT02050282|Prehospital
177255|NCT02050282|Biomarker
177256|NCT02050282|Heart failure
177257|NCT02050282|Triage
177258|NCT02050282|Randomized, controlled study
177259|NCT02051309|Smokers
177260|NCT02051309|Quit Smoking
177261|NCT02051309|Treatment
177262|NCT02051309|Guanfacine
177263|NCT02051283|Hepatocellular carcinoma
177264|NCT02051283|RFA
177265|NCT02051283|MRI
177266|NCT02051270|Elderly
177267|NCT02051270|Nursing homes
177268|NCT02051270|Mild cognitive impairment
177269|NCT02051244|Alzheimer's Disease
177270|NCT02051244|Retinal Nerve Fiber Layer
177271|NCT02051244|Ocular Computerized Tomography
177272|NCT02051244|Minimal Cognitive Impairment
177273|NCT02051244|Subjective Memory Loss
177274|NCT02051244|Asymptomatic Preclinical Alzheimer's Disease
177275|NCT02051231|Uterine contraction
177276|NCT02051231|Oxytocin receptors
177277|NCT02051231|Oxytocin desensitization
177278|NCT02051218|metastatic breast cancer
177279|NCT02051218|castration resistant metastatic prostate cancer
177280|NCT02051218|bone metastases
177281|NCT02051218|Denosumab
177282|NCT02051218|XGEVA
177283|NCT02051218|de-escalation
177284|NCT02051205|Parkinson's disease, risk factors, epidemiology
177285|NCT02051192|obsessive-compulsive disorder
177286|NCT02051192|Social phobia
177287|NCT02051192|Generalized anxiety disorder
177288|NCT02051192|Specific phobia
177289|NCT02051192|Separation anxiety disorder
177290|NCT02051192|Selective Mutism
177291|NCT02051192|Anxiety Disorder, Not Otherwise Specified
177292|NCT02051192|Counseling
177293|NCT02051192|Behavioral therapy
177294|NCT02051192|Psychotherapy
177295|NCT02051192|Exposure
177296|NCT02051192|Young Children
177297|NCT02051179|Repair
177298|NCT02051179|Replacement
177299|NCT02051179|Dental Amalgam
177300|NCT02051153|Modafinil
177301|NCT02051153|Cognitive
177302|NCT02051153|Performance
177303|NCT02051140|Postural Balance
177304|NCT02051140|Walking
177305|NCT02051140|Giat
177306|NCT02051140|Cognition
177307|NCT02051140|Learning
177308|NCT02051140|Memory
177309|NCT02051140|Antioxidants
177310|NCT02051140|Anti-Inflammatory Agents
177311|NCT02051140|Brain
177312|NCT02051140|Strawberry
177313|NCT02051127|Exercise
177314|NCT02051127|Physical Fitness
177315|NCT02051127|Stress, Psychological
177316|NCT02051127|Cognition
177317|NCT02051127|Psychophysiology
177318|NCT02051127|Ergometry
177319|NCT02051127|Exercise Test
177320|NCT02051127|Sedentary Lifestyle
177321|NCT02051114|Rheumatoid arthritis
177322|NCT02051088|Critical limb ischemia
177323|NCT02051088|Intermittent claudication
177324|NCT02051088|endovascular treatment
177325|NCT02051088|drug-elution
177326|NCT02051075|IVF
177327|NCT02051075|ICSI
177328|NCT02051075|Asthenospermia
177329|NCT02051075|pentoxyphylline
177330|NCT02051075|Spermatozoa
177331|NCT02051062|Pharmacokinetics
177332|NCT02051062|BAT
177333|NCT02051062|Pediatric
177334|NCT02051049|CN
177335|NCT02051049|UCD
177336|NCT02051036|moxibustion
177337|NCT02051023|keratoconjunctivitis sicca
177338|NCT02051023|dry eye
177339|NCT02051023|dry eye syndrome
177340|NCT02051023|dry eye disease
177341|NCT02051023|steroids
177342|NCT02050984|Obesity
177343|NCT02050984|Hypertension
177344|NCT02050984|Bariatric Surgery
177345|NCT02050984|Diabetes
177346|NCT02050971|Umbilical Cord Blood
177347|NCT02050971|Autologous Umbilical Cord Blood Transfusion
177348|NCT02050971|Prematurity Complications
177349|NCT02050971|Infant, Premature, Diseases
177350|NCT02050971|Infant, Newborn, Diseases
177351|NCT02050971|Hematologic Diseases
177352|NCT02050971|Lung Diseases
177353|NCT02050971|Central Nervous System Diseases
177354|NCT02050971|Gastrointestinal Tract Diseases
177355|NCT02050971|Vascular Diseases
177356|NCT02050971|Retinopathies, Neonates
177357|NCT02050971|Prevention,Treatment
177358|NCT02050932|hepcidin
177359|NCT02050932|iron bioavailability
177360|NCT02050932|iron supplementation
177361|NCT02050906|IDEA-P
177362|NCT02050906|Androgen Deprivation Therapy
177363|NCT02050893|septic shock
177364|NCT02050893|sepsis
177365|NCT02050893|fluid responsiveness
177366|NCT02050893|Midazolam
177367|NCT02050893|Propofol
177368|NCT02050893|haemodynamics
177369|NCT02050880|Normal Eyes
177370|NCT02050880|Eye; Disorder with Glaucoma
177371|NCT02050880|Eye; Disorder with Retinal Disease
177372|NCT02050880|Eye; Disorder Corneal Disease incl kerato-refractive group
177373|NCT02050867|Youth Suicide
177374|NCT02050867|Suicide
177375|NCT02050854|Aripiprazole
177376|NCT02050854|Treatment Adherence
177377|NCT02050841|Pediatric
177378|NCT02050841|patients
177379|NCT02050841|replacement
177380|NCT02050841|coagulation factors
177381|NCT02050841|plasma
177382|NCT02050841|s/d plasma
177383|NCT02050841|Octaplas
177384|NCT02050841|plasma replacement
177385|NCT02050815|MEK162
177386|NCT02050815|Hepatic impairment
177387|NCT02050815|Healthy subjects
177388|NCT02050802|Macitentan
177389|NCT02050802|Pharmacokinetics
177390|NCT02050802|Pharmacodynamics
177391|NCT02050763|HIV
177392|NCT02050763|Intimate partner violence
177393|NCT02050763|Community based prevention intervention
177394|NCT02050763|Uganda
177395|NCT02050763|Cluster randomized trial
177396|NCT02050750|Must have registered with the ICORG 06-31 TAILORx trial
177397|NCT02050737|Curative resection
177398|NCT02050737|Adjuvant chemotherapy
177399|NCT02050724|Solitary Pulmonary Nodule
177400|NCT02050724|Thoracoscopy
177401|NCT02050724|Thoracic Surgery
177402|NCT02050724|Video-Assisted
177403|NCT02050724|Radioactive Tracers
177404|NCT02050724|Radioguided surgery
177405|NCT02050724|Handheld-SPECT
177406|NCT02050711|Chronic obstructive pulmonary disease (COPD)
177407|NCT02050711|Pulmonary rehabilitation
177408|NCT02050711|Computerized respiratory sounds
177409|NCT02050698|fift metatarsal avulsion fracture
177410|NCT02050698|hard-soled shoe
177411|NCT02050698|short leg walking cast
177412|NCT02050698|protected weightbearing
177413|NCT02050672|Myoinositol
177414|NCT02050672|ART
177415|NCT02050672|EMBRYO QUALITY
177416|NCT02050646|Autoimmune hepatitis
177417|NCT02050646|Liver dysfunction
177418|NCT02050646|Elevated serum auto antibodies
177419|NCT02050633|Craniocerebral Trauma
177420|NCT02050633|Long term outcome
177421|NCT02050633|Activities of Daily Living
177422|NCT02050633|Cognitive Deficiency
177423|NCT02050633|Health Care Quality, Access, and Evaluation
177424|NCT02050633|Burden of care
177425|NCT02050620|Breast cancer, exercise and quality of life
177426|NCT02050581|Platelets are a part of the blood hat helps with clotting
177427|NCT02050581|ITP idiopathic thrombocytopenia purpura low platelet count
177428|NCT02050568|Genital prolapse
177429|NCT02050568|Genital prolapse surgery
177430|NCT02050568|Stress urinary incontinence
177431|NCT02050568|Urethral Pressure Reflectometry
177432|NCT02050542|cancer
177433|NCT02050542|prostate
177434|NCT02050542|PSA
177435|NCT02050542|biopsies
177436|NCT02050542|ultrasound
177437|NCT02050542|MRI
177438|NCT02050542|fusion of images
177439|NCT02050529|Hypertension, Pregnancy induced
177440|NCT02050529|Pre-eclampsia
177441|NCT02050529|Eclampsia
177442|NCT02050529|Labetalol
177443|NCT02050529|Hydralazine
177444|NCT02050516|Blastocyst, micro-well group culture dish
177445|NCT02050503|Mucositis
177446|NCT02050503|Breakthrough pain
177447|NCT02050503|Head Nad neck cancer
177448|NCT02050503|Intranasal transmucosal fentanyl in pectin
177449|NCT02050477|Obesity
177450|NCT02050477|Bariatric
177451|NCT02050477|Surgery
177452|NCT02050477|Sleeve
177453|NCT02050477|Gastroplasty
177454|NCT02050477|Laparoscopy
177455|NCT02050464|Alzheimer Disease
177456|NCT02050464|Frontotemporal Dementia
177457|NCT02050464|Dementia, Vascular
177458|NCT02050464|Mild Cognitive Impairment
177459|NCT02050464|Diagnosis
177460|NCT02050464|Risk factors
177461|NCT02050464|Biomarkers
177462|NCT02050464|AD
177463|NCT02050464|FTD
177464|NCT02050464|VAD
177465|NCT02050464|MCI
177466|NCT02050451|radical cystectomy
177467|NCT02050451|urinary diversion
177468|NCT02050451|nutrition
177469|NCT02050451|oral supplementation
177470|NCT02050451|enteral nutrition
177471|NCT02050438|Osteoarthritis Knee
177472|NCT02050438|Total Knee Arthroplasty
177473|NCT02050438|Quality of Life
177474|NCT02050425|OSA
177475|NCT02050425|CPAP
177476|NCT02050425|exhaled breath
177477|NCT02050399|Isometric Exercise
177478|NCT02050399|Arterial Pressure
177479|NCT02050399|Autonomic Nervous System
177480|NCT02050399|Cardiovascular system
177481|NCT02050399|Posture
177482|NCT02050386|Brain arousal systems
177483|NCT02050386|Aging
177484|NCT02050386|MRI
177485|NCT02050386|fMRI
177486|NCT02050386|Cognition
177487|NCT02050373|Mucositis
177488|NCT02050373|Stomatitis
177489|NCT02050373|Chemotherapy
177490|NCT02050373|Hematopoietic stem cell transplant
177491|NCT02050373|Laser therapy
177492|NCT02050373|Inflammatory cytokines
177493|NCT02050256|Palliative care
177494|NCT02050256|Continuing medical education
177495|NCT02050256|General practitioner
177496|NCT02050256|Electronic decision support
177497|NCT02050243|pediatrics
177498|NCT02050243|brain tumor
177499|NCT02050243|CNS
177500|NCT02050243|fluorescence
177501|NCT02050243|5ALA
177502|NCT02050230|transfusion
177503|NCT02050230|pulmonary hypertension
177504|NCT02050230|intensive care medicine
177505|NCT02050217|Helmet
177506|NCT02050217|Neurally Adjusted Ventilatory Assist
177507|NCT02050217|Children
177508|NCT02050217|Respiratory Failure
177509|NCT02050204|work to family conflict
177510|NCT02050204|supervisor support
177511|NCT02050204|long work hours
177512|NCT02050204|cardiometabolic risk
177513|NCT02050204|sleep duration
177514|NCT02050204|insomnia symptoms
177515|NCT02050178|Pancreatic Cancer
177516|NCT02050178|Stage IV Pancreatic Cancer
177517|NCT02050165|obesity
177518|NCT02050165|snacks
177519|NCT02050165|satiety
177520|NCT02050165|hunger
177521|NCT02050152|Amnesia
177522|NCT02050152|Memory
177523|NCT02050152|Implicit
177524|NCT02050152|Explicit
177525|NCT02050152|Nitrous Oxide
177526|NCT02050139|L-Cysteine
177527|NCT02050139|Peritoneal dialysis
177528|NCT02050139|Diuresis
177529|NCT02050139|Glomerular filtration rate
177530|NCT02050139|Peritoneal function
177531|NCT02050139|Inflammation
177532|NCT02050113|Complex Aortic Aneurysms
177533|NCT02050113|Thoracoabdominal Aneurysms
177534|NCT02050113|Pararenal Aortic Aneurysms
177535|NCT02050113|Juxtarenal Renal Aneurysms
177536|NCT02050113|Endovascular Branch Graft
177537|NCT02050113|Fenestrated Stent Graft
177538|NCT02050113|Abdominal Aortic Aneurysm
177539|NCT02050113|Endovascular
177540|NCT02050100|primary lung adenocarcinoma Stages I, II, IIIA, IIIB
177541|NCT02050100|squamous cell carcinoma Stages I, II, IIIA, IIIB
177542|NCT02050100|benign non-calcified pulmonary nodules
177543|NCT02050100|early detection
177544|NCT02050087|Rotator cuff
177545|NCT02050087|Rehabilitation
177546|NCT02050048|Pancreatitis
177547|NCT02050048|Endoscopic retrograde cholangiopancreatography
177548|NCT02050048|Cholangiopancreatography, Endoscopic Retrograde
177549|NCT02050048|ERCP
177550|NCT02050048|High Volume
177551|NCT02050048|Lactated Ringer
177552|NCT02050048|Intravenous Administration
177553|NCT02050048|Sphincterotomy, Endoscopic
177554|NCT02050048|Pancreas
177555|NCT02050035|Exercise Therapy
177556|NCT02050035|Endothelium, vascular
177557|NCT02050035|Blood Vessels
177558|NCT02050022|Biomarkers
177559|NCT02050022|Genomics
177560|NCT02050022|Proteomics
177561|NCT02050022|Diagnostics
177562|NCT02050022|Prognostics
177563|NCT02049996|Quality of life
177564|NCT02049996|Robotic surgery
177565|NCT02049996|Vaginal surgery
177566|NCT02049996|Prolapse repair
177567|NCT02049996|Vaginal hysterectomy
177568|NCT02049970|Supraclavicular block
177569|NCT02049957|MLN0128
177570|NCT02049944|Antibiotic Prophylaxis
177571|NCT02049944|Obesity
177572|NCT02049944|Obesity, Morbid
177573|NCT02049944|Pregnancy
177574|NCT02049944|Infection; Cesarean Section
177575|NCT02049931|osteoporosis, compression fracture, brace
177576|NCT02049918|Respiratory viruses
177577|NCT02049905|soft tissue sarcoma
177578|NCT02049905|unresectable
177579|NCT02049905|metastatic
177580|NCT02049905|locally advanced
177581|NCT02049905|sarcoma
177582|NCT02049892|Total Hip Replacement
177583|NCT02049892|Metal Ion
177584|NCT02049892|2-5 years after surgery
177585|NCT02049892|Asymptomatic
177586|NCT02049866|osteoporosis
177587|NCT02049866|premenopausal
177588|NCT02049866|denosumab
177589|NCT02049866|idiopathic
177590|NCT02049866|Idiopathic Osteoporosis in Premenopausal Women
177591|NCT02049853|acute dyspnea
177592|NCT02049853|heart failure
177593|NCT02049853|diagnostics
177594|NCT02049853|POCT analysis
177595|NCT02049853|preclinical area
177596|NCT02049840|Female sling
177597|NCT02049840|Stress Urinary Incontinence
177598|NCT02049840|Urination Disorders
177599|NCT02049840|Urologic Diseases
177600|NCT02049827|Renal transplant, BK virus
177601|NCT02049814|Drug therapy
177602|NCT02049762|novel P2Y12 inhibitors
177603|NCT02049762|aspirin
177604|NCT02049762|platelet reactivity
177605|NCT02049762|acute coronary syndrome
177606|NCT02049749|Child Behavior Problems
177607|NCT02049749|Parent Training Program
177608|NCT02049723|Gastroesophageal reflux disease
177609|NCT02049723|Knowledge
177610|NCT02049697|Healthy
177611|NCT02049697|Healthy male participants
177612|NCT02049697|14C-JNJ -39823277
177613|NCT02049697|TPI 1062
177614|NCT02049697|Tianeptine
177615|NCT02049697|Absorption
177616|NCT02049697|Metabolism
177617|NCT02049697|Excretion
177618|NCT02049697|Pharmacokinetics
177619|NCT02049658|tumor
177620|NCT02049658|cancer
177621|NCT02049645|lung cancer
177622|NCT02049645|breast cancer
177623|NCT02049632|Breast cancer
177624|NCT02049632|Sentinel Node Biopsy
177625|NCT02049632|Micrometastasis
177626|NCT02049632|Axillary lymph node dissection
177627|NCT02049619|Pharyngeal pack
177628|NCT02049619|Nausea
177629|NCT02049619|Vomiting
177630|NCT02049619|orthognathic surgery
177631|NCT02049619|maxillary osteotomy
177632|NCT02049606|LAYLA
177633|NCT02049606|Non-inferiority
177634|NCT02049606|100mm pain VAS
177635|NCT02049593|protocol specific
177636|NCT02049580|lymphoma
177637|NCT02049567|cataract, presbyopia
177638|NCT02049554|preconception care
177639|NCT02049554|women's health
177640|NCT02049541|BKM120
177641|NCT02049541|B-Cell Lymphoma
177642|NCT02049541|PI3K inhibitor
177643|NCT02049528|Food Effect
177644|NCT02049528|Pharmacokinetic
177645|NCT02049528|Healthy
177646|NCT02049528|Male
177647|NCT02049515|Phase 3
177648|NCT02049515|CLL/SLL
177649|NCT02049515|PI3K
177650|NCT02049502|ulcerative colitis
177651|NCT02049502|fecal microbiota transplantation
177652|NCT02049489|ICT-121
177653|NCT02049489|glioblastoma
177654|NCT02049489|immunotherapy
177655|NCT02049489|dendritic cell vaccine
177656|NCT02049489|CD133
177657|NCT02049476|Uveitis, Intermediate
177658|NCT02049476|Uveitis, Posterior
177659|NCT02049476|Dexamethasone
177660|NCT02049476|Immunosuppressive Agents
177661|NCT02049476|Eye Abnormalities
177662|NCT02049476|Eye Diseases
177663|NCT02049476|Ophthalmology
177664|NCT02049476|Ophthalmologic Surgical Procedures
177665|NCT02049476|Vision Disorders
177666|NCT02049476|Inflammation
177667|NCT02049463|carotid artery
177668|NCT02049463|sound
177669|NCT02049463|stenosis
177670|NCT02049463|wall
177671|NCT02049463|stroke
177672|NCT02049450|thalassemia, spleen enlargement
177673|NCT02049437|HIV
177674|NCT02049437|Immune failure
177675|NCT02049437|Tocilizumab
177676|NCT02049437|ACTEMRA
177677|NCT02049437|Antiretroviral therapy
177678|NCT02049437|HAART
177679|NCT02049411|Ketamine
177680|NCT02049411|acute cognitive dysfunction
177681|NCT02049411|geriatric patients
177682|NCT02049398|Microbiome
177683|NCT02049398|Saliva
177684|NCT02049398|Reliability
177685|NCT02049398|Oral Cavity
177686|NCT02049385|Glutamate
177687|NCT02049385|Pathophysiology
177688|NCT02049385|Depression
177689|NCT02049385|Treatment
177690|NCT02049372|complications
177691|NCT02049372|tonsillectomy
177692|NCT02049372|tonsillotomy
177693|NCT02049359|Diabetes
177694|NCT02049346|Anemia
177695|NCT02049346|Hemodialysis
177696|NCT02049346|Erythropoetin Stimulating Agents
177697|NCT02049346|Comparison
177698|NCT02049294|Prednisone
177699|NCT02049294|Eosinophils
177700|NCT02049294|Immunoglobin E (IgE)
177701|NCT02049294|Asthma
177702|NCT02049294|Bronchitis
177703|NCT02049294|Inflammation
177704|NCT02049294|Allergy
177705|NCT02049268|alcohol
177706|NCT02049268|nicotine
177707|NCT02049268|addiction
177708|NCT02049268|functional MRI
177709|NCT02049268|functional connectivity
177710|NCT02049268|brain circuits
177711|NCT02049255|All
177712|NCT02049242|Hemorrhage
177713|NCT02049242|Leiomyoma
177714|NCT02049242|Myofibroma
177715|NCT02049242|Uterine Myomectomy
177716|NCT02049242|Tourniquet
177717|NCT02049229|Stent
177718|NCT02049229|Titanium
177719|NCT02049229|drug eluting stent
177720|NCT02049229|myocardial infarction
177721|NCT02049229|stent thrombosis
177722|NCT02049216|knee
177723|NCT02049216|osteoarthritis
177724|NCT02049216|tape
177725|NCT02049216|exercise
177726|NCT02049216|rocktape
177727|NCT02049190|Advanced Prostate Cancer
177728|NCT02049190|Castration-resistant Prostate Cancer
177729|NCT02049190|Prostatic Neoplasms
177730|NCT02049190|Genital Neoplasms, Male
177731|NCT02049190|Urogenital Neoplasms
177732|NCT02049190|Neoplasms by Site
177733|NCT02049190|Neoplasms
177734|NCT02049190|Genital Diseases, Male
177735|NCT02049190|Prostatic Diseases
177736|NCT02049190|onapristone
177737|NCT02049177|Cancer
177738|NCT02049177|Epidemiology
177739|NCT02049177|Head and Neck
177740|NCT02049177|HPV
177741|NCT02049164|AR08, Vasomotor Symptoms
177742|NCT02049151|Carcinoma, Non-Small-Cell Lung
177743|NCT02049151|Tecemotide
177744|NCT02049151|Placebo
177745|NCT02049151|NSCLC
177746|NCT02049151|L-BLP25
177747|NCT02049138|Joint Diseases
177748|NCT02049138|Musculoskeletal Disease
177749|NCT02049138|Anti-inflammatory Agents
177750|NCT02049138|Antirheumatic agents
177751|NCT02049138|Arthritis
177752|NCT02049125|NGAL
177753|NCT02049125|Acute kidney injury
177754|NCT02049125|Cirrhosis
177755|NCT02049125|Hepatorenal syndrome
177756|NCT02049112|Cross-over
177757|NCT02049112|Salivary equivalent
177758|NCT02049112|Dry mouth
177759|NCT02049112|Medical device
177760|NCT02049086|SBIRT
177761|NCT02049086|Screening
177762|NCT02049086|Brief Intervention
177763|NCT02049086|Referral to Treatment
177764|NCT02049086|Pain-Management
177765|NCT02049086|Veterans
177766|NCT02049073|hearing loss
177767|NCT02049073|noise induced hearing loss
177768|NCT02049073|zonisamide
177769|NCT02049060|MPM
177770|NCT02049060|NSCLC
177771|NCT02049047|thymoma thymic carcinoma
177772|NCT02049034|GLP-1 agonist
177773|NCT02049034|Lixisenatide
177774|NCT02049034|Postprandial glucose metabolism
177775|NCT02049034|Postprandial lipid metabolism
177776|NCT02049034|Gastric emptying
177777|NCT02049034|Lipoprotein lipase activity
177778|NCT02049021|schizophrenia
177779|NCT02049021|electroconvulsive therapy
177780|NCT02049021|refractory Schizophrenia
177781|NCT02049021|super refractory schizophrenia
177782|NCT02049021|clozapine
177783|NCT02048995|Bipolar Disorder
177784|NCT02048995|Depression
177785|NCT02048995|Light Therapy
177786|NCT02048995|Contrast Sensitivity
177787|NCT02048995|Visual Evoked Potential
177788|NCT02048995|Visual or Neural Responses
177789|NCT02048995|Biomarker
177790|NCT02048982|physician prescribing
177791|NCT02048982|behavioral economics
177792|NCT02048982|primary care practice
177793|NCT02048969|hepatic encephalopathy
177794|NCT02048969|flumazenil
177795|NCT02048969|liver cirrhosis
177796|NCT02048956|knee osteoarthritis
177797|NCT02048956|hydrotherapy
177798|NCT02048930|GPRD
177799|NCT02048930|effectiveness
177800|NCT02048930|cost-effectiveness
177801|NCT02048930|Easyhaler
177802|NCT02048930|Primary care
177803|NCT02048930|DPI
177804|NCT02048917|Smoking
177805|NCT02048917|Cessation
177806|NCT02048917|Bupropion
177807|NCT02048917|Varenicline
177808|NCT02048917|Nicotine
177809|NCT02048917|Counseling
177810|NCT02048917|Tobacco
177811|NCT02048904|microalbuminuria
177812|NCT02048904|type 2 diabetes
177813|NCT02048878|Insomnia
177814|NCT02048865|VTE Cancer
177815|NCT02048852|menthol
177816|NCT02048852|nicotine
177817|NCT02048826|stroke
177818|NCT02048800|Treosulfan pharmacokinetics
177819|NCT02048800|Children
177820|NCT02048800|Any condition that requires an allogeneic HSCT
177821|NCT02048787|Renal impairment
177822|NCT02048787|Healthy volunteers
177823|NCT02048787|Clinical pharmacology study
177824|NCT02048748|Home Care Services
177825|NCT02048748|Telemedicine
177826|NCT02048696|Exercise training
177827|NCT02048696|High intensity interval training
177828|NCT02048696|left ventricular systolic function
177829|NCT02048696|G-protein related kinase 2
177830|NCT02048696|heart failure
177831|NCT02048696|myocardial infarction
177832|NCT02048696|coronary artery disease
177833|NCT02048696|beta adrenergic receptor
177834|NCT02048683|Pharmacokinetics
177835|NCT02048683|Sevoflurane
177836|NCT02048683|Burn
177837|NCT02048683|Sedation
177838|NCT02048670|Pilot study
177839|NCT02048670|Assessment of sway phase
177840|NCT02048670|Therapy trial phase
177841|NCT02048657|LMA, Foley Airway Stylet Tool (FAST), introducer-tool (I-Tool)
177842|NCT02048644|Platelets adhesion
177843|NCT02048631|oral cancer,Quality of life,Sensory
177844|NCT02048618|Active Crohn's Disease
177845|NCT02048618|GLPG0634
177846|NCT02048592|cystic fibrosis, immunonutrition, oxidative stress
177847|NCT02048566|Echocardiography, Transesophageal
177848|NCT02048566|Monitoring, Physiologic
177849|NCT02048566|Shock
177850|NCT02048553|ventriculostomy; complications in neurosurgery;catheter accuracy;
177851|NCT02048514|Aortic Aneurysm, Abdominal
177852|NCT02048514|Endovascular Procedures
177853|NCT02048501|Weight regain
177854|NCT02048501|Sustain weight loss
177855|NCT02048501|Weight loss
177856|NCT02048501|Gut hormones
177857|NCT02048488|non small cell lung cancer
177858|NCT02048488|NSCLC
177859|NCT02048488|Anaplastic lymphoma kinase
177860|NCT02048488|ALK tyrosine kinase receptor
177861|NCT02048488|ALK+
177862|NCT02048488|TRK+
177863|NCT02048488|ALK inhibitor
177864|NCT02048488|TRK inhibitor
177865|NCT02048488|tropomyosin receptor kinase
177866|NCT02048488|TRKA
177867|NCT02048488|TRKB
177868|NCT02048488|TRKC
177869|NCT02048488|advanced malignancy
177870|NCT02048475|desflurane
177871|NCT02048475|electroencephalogram
177872|NCT02048449|Reflux finding score, interrater reliability
177873|NCT02048436|Respiratory Rate
177874|NCT02048423|suicidal
177875|NCT02048397|Bronchiectasis.
177876|NCT02048384|rapamycin
177877|NCT02048384|metformin
177878|NCT02048384|pancreatic cancer
177879|NCT02048384|adenocarcinoma
177880|NCT02048384|metastatic
177881|NCT02048358|Healthy volunteers
177882|NCT02048358|first in human
177883|NCT02048358|2B3-201
177884|NCT02048358|methylprednisolone
177885|NCT02048358|CNS-targeting
177886|NCT02048358|liposomal
177887|NCT02048358|crossover
177888|NCT02048358|placebo controlled
177889|NCT02048358|active controlled
177890|NCT02048358|multiple sclerosis
177891|NCT02048358|multiple sclerosis relapse
177892|NCT02048345|ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fasted state
177893|NCT02048345|ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fed state
177894|NCT02048345|two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fasted state
177895|NCT02048345|two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fed state
177896|NCT02048332|Epstein-Barr Virus (EBV)
177897|NCT02048332|Adenovirus (ADV)
177898|NCT02048332|t-cells
177899|NCT02048332|donor
177900|NCT02048332|transplant
177901|NCT02048332|children
177902|NCT02048332|cytomegalovirus (CMV)
177903|NCT02048319|Liver cyst
177904|NCT02048319|Hepatic cyst
177905|NCT02048319|Symptomatic
177906|NCT02048319|Aspiration sclerotherapy
177907|NCT02048306|Chronic obstructive pulmonary disease (COPD)
177908|NCT02048306|Pulmonary rehabilitation
177909|NCT02048306|Family
177910|NCT02048306|Integrated care
177911|NCT02048306|Mixed methods
177912|NCT02048293|remifentanil
177913|NCT02048293|propofol
177914|NCT02048293|pharmacodynamic
177915|NCT02048293|total intravenous anesthesia
177916|NCT02048293|orotracheal intubation
177917|NCT02048293|heart rate
177918|NCT02048293|mean arterial pressure
177919|NCT02048293|Cooper intubation condition score
177920|NCT02048267|Alcoholic
177921|NCT02048267|Non alcoholic
177922|NCT02048267|Idiopathic
177923|NCT02048267|Tropical
177924|NCT02048267|Exocrine dysfunction
177925|NCT02048267|Endocrine dysfunction
177926|NCT02048267|Pain control
177927|NCT02048267|Frey's procedure
177928|NCT02048267|Duodenum preserving pancreatic head resection
177929|NCT02048254|inoperable salivary gland cancer
177930|NCT02048254|brachytherapy
177931|NCT02048254|intensity-modulated radiation therapy
177932|NCT02048241|childhood
177933|NCT02048241|temper
177934|NCT02048241|explosive
177935|NCT02048241|aggression
177936|NCT02048241|tantrums
177937|NCT02048241|oppositional
177938|NCT02048241|defiant
177939|NCT02048241|conduct
177940|NCT02048241|disruptive
177941|NCT02048241|emotional dysregulation
177942|NCT02048241|special education
177943|NCT02048228|Clopidogrel,
177944|NCT02048228|Pharmacogenetics,
177945|NCT02048228|Platelet reactivity,
177946|NCT02048228|CYP2C19,
177947|NCT02048228|point-of-care
177948|NCT02048215|thermogenesis
177949|NCT02048215|low-calorie diet
177950|NCT02048215|uncoupling-protein 3
177951|NCT02048215|beta-3 adrenoceptors
177952|NCT02048215|thermogenic drugs
177953|NCT02048202|clown
177954|NCT02048202|neonate
177955|NCT02048202|premature
177956|NCT02048176|Mutism
177957|NCT02048163|Meropenem
177958|NCT02048163|Nausea
177959|NCT02048163|Pharmacokinetics
177960|NCT02048124|25d ProCor needle
177961|NCT02048124|22 gauge
177962|NCT02048124|endoscopic ultrasonography
177963|NCT02048124|fine needle biopsies
177964|NCT02048124|Patients
177965|NCT02048124|presenting
177966|NCT02048111|Hemophilia B
177967|NCT02048111|Hemophilia A
177968|NCT02048111|Blood Coagulation Disorders, Inherited
177969|NCT02048111|Blood Coagulation Disorders
177970|NCT02048111|Hematologic Diseases
177971|NCT02048111|Coagulation Protein Disorders
177972|NCT02048111|Hemorrhagic Disorders
177973|NCT02048111|Genetic Diseases, Inborn
177974|NCT02048111|Genetic Diseases, X-Linked
177975|NCT02048098|misoprostol
177976|NCT02048098|Labor, Induced
177977|NCT02048098|Pregnancy Trimester, Second
177978|NCT02048098|Abortion, Induced
177979|NCT02048085|ACS
177980|NCT02048085|STEMI
177981|NCT02048085|Fibrinolysis
177982|NCT02048085|Pharmacodynamics
177983|NCT02048085|Pharmacokinetics
177984|NCT02048085|Plavix
177985|NCT02048085|Brilinta
177986|NCT02048085|Ticagrelor
177987|NCT02048085|Clopidogrel
177988|NCT02048072|relapsing remitting
177989|NCT02048072|multiple sclerosis
177990|NCT02048072|fingolimod
177991|NCT02048072|Gilenya
177992|NCT02048072|autonomic nervous system
177993|NCT02048059|ANG1005
177994|NCT02048059|GRN1005
177995|NCT02048059|LRP-1
177996|NCT02048059|Targeted therapy
177997|NCT02048059|Breast cancer
177998|NCT02048059|Brain metastases
177999|NCT02048059|Brain tumor
178000|NCT02048059|Blood-brain barrier
178001|NCT02048059|Trastuzumab
178002|NCT02048059|Herceptin
178003|NCT02048059|Paclitaxel
178004|NCT02048059|Taxol
178005|NCT02048059|Breast cancer with brain metastases
178006|NCT02048059|Triple Negative
178007|NCT02048059|TNBC
178008|NCT02048059|HER2-positive
178009|NCT02048059|HER2-negative
178010|NCT02048059|Metastatic brain tumors
178011|NCT02048046|ECMO
178012|NCT02048046|Nutrition therapy
178013|NCT02048033|Obesity
178014|NCT02048033|Endogastric suturing
178015|NCT02048033|Jujenal anastomosis
178016|NCT02048033|weight regain
178017|NCT02048007|Childhood mortality
178018|NCT02048007|Azithromycin
178019|NCT02048007|Mass treatment
178020|NCT02048007|Infection
178021|NCT02048007|Bacterial infections
178022|NCT02048007|Trachoma
178023|NCT02048007|Chlamydia infections
178024|NCT02048007|Malaria
178025|NCT02048007|Diarrhea
178026|NCT02048007|Respiratory Infections
178027|NCT02048007|Antibiotic resistance
178028|NCT02048007|Verbal Autopsy
178029|NCT02048007|Microbiome
178030|NCT02047994|Gastric cancer
178031|NCT02047994|Gastric cancer mortality
178032|NCT02047994|Helicobacter pylori treatment
178033|NCT02047994|Pepsinogen testing
178034|NCT02047994|Endoscopy
178035|NCT02047994|Volatile marker
178036|NCT02047981|Childhood mortality
178037|NCT02047981|Azithromycin
178038|NCT02047981|Mass treatment
178039|NCT02047981|Infection
178040|NCT02047981|Verbal Autopsy
178041|NCT02047968|Wake therapy
178042|NCT02047968|Sleep deprivation
178043|NCT02047968|Light therapy
178044|NCT02047968|Bipolar depression
178045|NCT02047968|Sleep-wake cycle
178046|NCT02047968|Major depression
178047|NCT02047968|Depression
178048|NCT02047968|Depressive Disorder
178049|NCT02047968|Major Behavioural Symptoms
178050|NCT02047968|Mood Disorders
178051|NCT02047968|Mental Disorders
178052|NCT02047968|Dyssomnias
178053|NCT02047968|Sleep Disorders
178054|NCT02047968|Affective Disorders
178055|NCT02047929|Asthma
178056|NCT02047929|Shared decision making
178057|NCT02047929|Participatory methods
178058|NCT02047929|Practice facilitator
178059|NCT02047929|Health coach
178060|NCT02047916|Neonates
178061|NCT02047916|Superior Vena Cava Flow
178062|NCT02047916|Pleth variabilty index
178063|NCT02047890|CDK inhibitor
178064|NCT02047890|BAY1000394
178065|NCT02047890|Advanced malignancies
178066|NCT02047890|Japanese
178067|NCT02047877|Respiratory Secretions
178068|NCT02047877|Tracheal Secretions
178069|NCT02047877|Bronchial Secretions
178070|NCT02047877|NonBronchoscopic BAL
178071|NCT02047877|Interleukin 10
178072|NCT02047877|Interleukin 12p70
178073|NCT02047864|Osteoporosis
178074|NCT02047864|Sarcopenia
178075|NCT02047864|Strength
178076|NCT02047864|Bone
178077|NCT02047864|Muscle
178078|NCT02047864|Creatine
178079|NCT02047825|Multiple sclerosis
178080|NCT02047825|Dexterity
178081|NCT02047825|Upper limbs
178082|NCT02047812|Laparotomy
178083|NCT02047812|General Surgery
178084|NCT02047812|Hospitals,General
178085|NCT02047812|Hospitals,High-Volume
178086|NCT02047812|Hospitals,Low-Volume
178087|NCT02047812|Outcome Assessment (Health Care)
178088|NCT02047799|elderly people, blood pressure, hypertension, vitamin D.
178089|NCT02047786|Outcome Assessment (Health Care)
178090|NCT02047786|Appendectomy
178091|NCT02047786|Child
178092|NCT02047786|Hospitals, Pediatric
178093|NCT02047786|Hospitals, General
178094|NCT02047773|bronchiectasis
178095|NCT02047773|intravenous antibiotics
178096|NCT02047773|duration of antibiotic course
178097|NCT02047773|side effects
178098|NCT02047773|bacterial load
178099|NCT02047747|Brain
178100|NCT02047747|Metastasis
178101|NCT02047747|human epidermal receptor (HER)
178102|NCT02047695|migraine with aura
178103|NCT02047695|migraine
178104|NCT02047695|case-control study
178105|NCT02047695|magnetic resonance imaging
178106|NCT02047695|brain diseases
178107|NCT02047656|Healthy volunteers, hypertension
178108|NCT02047643|Type 1 diabetes
178109|NCT02047643|Hypoglycemia
178110|NCT02047643|Accelerometer
178111|NCT02047630|Primary open angle glaucoma
178112|NCT02047630|Ocular hypertension
178113|NCT02047630|latanoprost
178114|NCT02047630|generic
178115|NCT02047630|intraocular pressure
178116|NCT02047617|Muscle Weakness
178117|NCT02047617|Exercise therapy
178118|NCT02047617|Physiotherapy
178119|NCT02047617|Critical illness
178120|NCT02047617|Intensive care
178121|NCT02047617|Mechanical ventilation
178122|NCT02047617|Rehabilitation
178123|NCT02047604|Phase 2a multiple ascending dose, Anti-Very Late Antigen-1
178124|NCT02047578|hematopoietic stem cell transplantation
178125|NCT02047565|punch biopsy
178126|NCT02047552|trauma
178127|NCT02047552|iron
178128|NCT02047552|anemia
178129|NCT02047552|red blood cell transfusion
178130|NCT02047526|Heart Failure
178131|NCT02047526|Cardiovascular disease
178132|NCT02047526|Congestive Heart Failure
178133|NCT02047500|TH-302
178134|NCT02047500|Nab-paclitaxel
178135|NCT02047500|Gemcitabine
178136|NCT02047500|Evofosfamide
178137|NCT02047461|Molybdenum cofactor deficiency (MoCD)
178138|NCT02047461|molybdenum cofactor (MoCo) biosynthesis
178139|NCT02047461|sulfite oxidase (SO)
178140|NCT02047461|xanthine dehydrogenase
178141|NCT02047461|aldehyde oxidase
178142|NCT02047461|S sulfocysteine (SSC)
178143|NCT02047448|transition of care
178144|NCT02047448|care transitions
178145|NCT02047448|readmission
178146|NCT02047448|medication
178147|NCT02047448|adherence
178148|NCT02047448|medication management
178149|NCT02047448|medication reconciliation
178150|NCT02047448|patient counseling
178151|NCT02047448|pharmacist
178152|NCT02047435|Social participation
178153|NCT02047435|Loneliness
178154|NCT02047435|General practice
178155|NCT02047435|Cultural institutions
178156|NCT02047422|Heart failure, diuretics, kidney, glomerular filtration rate
178157|NCT02047383|respiratory infection
178158|NCT02047383|physical variables
178159|NCT02047370|stretching, diaphragm, asthma, manual therapy
178160|NCT02047357|Maternal depression
178161|NCT02047357|Mother
178162|NCT02047357|Child
178163|NCT02047357|LTP
178164|NCT02047357|Learning Through Play
178165|NCT02047357|Healthy thinking
178166|NCT02047344|NSCLC
178167|NCT02047331|periarticular drug injection
178168|NCT02047331|fascia iliaca block
178169|NCT02047331|knee arthroplasty
178170|NCT02047305|ESCN
178171|NCT02047305|RFA
178172|NCT02047292|Gait analysis
178173|NCT02047292|3D videofluoroscopy
178174|NCT02047292|Femoroacetabular impingement
178175|NCT02047292|Neck-cup impingement
178176|NCT02047292|Head-neck ratio
178177|NCT02047292|Hip scores
178178|NCT02047292|Functional assessment
178179|NCT02047292|Cup size
178180|NCT02047292|Range of motion
178181|NCT02047292|Unilateral Primary
178182|NCT02047292|Secondary
178183|NCT02047279|Atrial fibrillation
178184|NCT02047279|Mitral valve
178185|NCT02047266|MICS CABG OPCABG ONCABG CAD
178186|NCT02047253|carfilzomib
178187|NCT02047253|prostate cancer
178188|NCT02047253|PSA (prostate-specific antigen)
178189|NCT02047253|CRPC (castration-resistant prostate cancer)
178190|NCT02047240|liver cirrhosis
178191|NCT02047240|glomerular filtration
178192|NCT02047240|cystatin C
178193|NCT02047227|ESPART
178194|NCT02047227|Reproductive Techniques, Assisted
178195|NCT02047227|Infertility
178196|NCT02047227|Pergoveris®
178197|NCT02047227|GONAL-f®
178198|NCT02047214|Glioblastoma multiforme
178199|NCT02047214|Glioblastoma
178200|NCT02047214|Radiotherapy
178201|NCT02047214|Temozolomide
178202|NCT02047214|TPI 287
178203|NCT02047214|Taxoid
178204|NCT02047214|Avastin
178205|NCT02047214|Bevacizumab
178206|NCT02047201|Head and neck cancer
178207|NCT02047201|PET/CT
178208|NCT02047201|induction chemotherapy
178209|NCT02047201|IMRT
178210|NCT02047188|narrow band imaging,microvessels,matrix metalloproteinase-7
178211|NCT02047162|diarrhea
178212|NCT02047162|gastroenteritis
178213|NCT02047162|antimicrobial drug resistance
178214|NCT02047162|antimicrobial agents
178215|NCT02047162|Pakistan
178216|NCT02047162|ambulatory care
178217|NCT02047162|bismuth
178218|NCT02047149|Myelogenous Leukemia
178219|NCT02047123|commercial flaxseed
178220|NCT02047123|cholesterol
178221|NCT02047123|lipidic profile
178222|NCT02047123|yoghurt
178223|NCT02047123|consumption
178224|NCT02047110|ABBV-066
178225|NCT02047110|BI 655066
178226|NCT02047110|risankizumab
178227|NCT02047071|Obstructive sleep apnea
178228|NCT02047071|Female gender
178229|NCT02047071|Continuous Positive Airway Pressure
178230|NCT02047058|biomarker
178231|NCT02047058|Q cell
178232|NCT02047058|Overall survival
178233|NCT02047058|Progression-free survival
178234|NCT02047045|severe chronic constipation
178235|NCT02047045|randomized controlled
178236|NCT02047045|electro-acupuncture
178237|NCT02047045|prucalopride
178238|NCT02047032|electroacupuncture
178239|NCT02047032|urinary incontinence
178240|NCT02047032|PFMT
178241|NCT02047032|Solifenacin
178242|NCT02047019|Drug combination
178243|NCT02047019|Nifedipine GITS
178244|NCT02047019|Candesartan Cilexetil
178245|NCT02047019|Hypertension
178246|NCT02047019|Combination therapy
178247|NCT02047006|Hemodialysis
178248|NCT02047006|Rivaroxaban
178249|NCT02047006|AUC
178250|NCT02046993|Hypertension
178251|NCT02046993|self blood pressure monitoring
178252|NCT02046993|smartphone based telemonitoring
178253|NCT02046993|primary care
178254|NCT02046967|endovenous laser ablation
178255|NCT02046967|endovenous steam ablation
178256|NCT02046967|great saphenous veins
178257|NCT02046967|quality of life
178258|NCT02046954|transesophageal echocardiography
178259|NCT02046954|tee
178260|NCT02046954|toe
178261|NCT02046954|cardiac surgery
178262|NCT02046941|aphasia
178263|NCT02046941|stroke
178264|NCT02046941|Magnetic Resonance Imaging
178265|NCT02046941|Diffusion Magnetic Resonance Imaging
178266|NCT02046928|Leukemia
178267|NCT02046928|Lymphoma
178268|NCT02046902|coronary artery disease
178269|NCT02046902|cardiac stent
178270|NCT02046902|PCI procedure
178271|NCT02046902|Patient preference
178272|NCT02046876|neck pain
178273|NCT02046876|physiotherapy
178274|NCT02046876|adapted swimming
178275|NCT02046876|therapeutic exercises
178276|NCT02046876|health education
178277|NCT02046863|Parkinson's disease
178278|NCT02046863|Tremor
178279|NCT02046863|Bradykinesia
178280|NCT02046863|Deep brain stimulation
178281|NCT02046863|Kinesia
178282|NCT02046850|Phase I, healthy, pharmacokinetics,
178283|NCT02046837|Prostate cancer
178284|NCT02046837|Exercise
178285|NCT02046837|Elderly
178286|NCT02046837|Quality of life
178287|NCT02046837|Fatigue
178288|NCT02046837|Physical fitness
178289|NCT02046837|Adherence
178290|NCT02046837|Cost-effectiveness
178291|NCT02046811|Skin neoplasms
178292|NCT02046811|Radiation
178293|NCT02046811|Screening
178294|NCT02046811|Self-examination
178295|NCT02046811|Comparative effectiveness research
178296|NCT02046811|Dermoscopy
178297|NCT02046798|Pharmacokinetics
178298|NCT02046798|ASP3652
178299|NCT02046798|14C radio-labeled
178300|NCT02046798|Phase 1
178301|NCT02046785|Fluid administration
178302|NCT02046785|Cardiac output
178303|NCT02046785|Right atrial pressure
178304|NCT02046785|Resuscitation
178305|NCT02046772|hemorrhoidectomy
178306|NCT02046772|analgesia
178307|NCT02046772|anaesthetic
178308|NCT02046772|bupivacaine
178309|NCT02046772|morphine chloride
178310|NCT02046733|SCLC
178311|NCT02046733|CTLA-4
178312|NCT02046694|acute lymphoblastic leukemia
178313|NCT02046694|ALL
178314|NCT02046694|pediatric
178315|NCT02046694|maintenance
178316|NCT02046694|allopurinol
178317|NCT02046694|6-MP
178318|NCT02046694|6-mercaptopurine
178319|NCT02046681|Medication Adherence
178320|NCT02046681|Medication Compliance
178321|NCT02046681|Medication Therapy Management
178322|NCT02046681|Side effects
178323|NCT02046681|Analgesics
178324|NCT02046681|Emergency Medicine
178325|NCT02046681|Home care
178326|NCT02046681|Aged
178327|NCT02046681|Acetaminophen
178328|NCT02046681|codeine
178329|NCT02046681|ibuprofen
178330|NCT02046681|Oxycodone
178331|NCT02046668|Osteoarthritis of knee
178332|NCT02046642|Amniotic fluid index;
178333|NCT02046642|amniotic fluid volume;
178334|NCT02046642|intervention studies;
178335|NCT02046642|maternal care patterns;
178336|NCT02046642|mother-fetus relationships;
178337|NCT02046642|rest;
178338|NCT02046642|sonography;
178339|NCT02046642|transplacental exposure
178340|NCT02046590|Propofol
178341|NCT02046590|remifentanil
178342|NCT02046590|safety
178343|NCT02046590|gastro-intestinal
178344|NCT02046590|ERCP
178345|NCT02046590|minimally invasive
178346|NCT02046590|intubation
178347|NCT02046590|ventilation
178348|NCT02046577|Acute respiratory tract infections
178349|NCT02046577|vitamin D
178350|NCT02046577|cholecalciferol
178351|NCT02046577|children
178352|NCT02046577|bronchiolitis
178353|NCT02046577|pneumonia
178354|NCT02046577|prevention
178355|NCT02046551|nicotine
178356|NCT02046551|smoking
178357|NCT02046551|atomoxetine
178358|NCT02046551|stress
178359|NCT02046525|Fecal microbiota therapy
178360|NCT02046512|Probiotics
178361|NCT02046499|Prevention, post partum haemorrhage
178362|NCT02046486|ticagrelor
178363|NCT02046486|ST elevation myocardial infarction
178364|NCT02046486|liquid formulation
178365|NCT02046447|dystonia
178366|NCT02046447|cervical dystonia
178367|NCT02046447|DYT1
178368|NCT02046447|DYT 1
178369|NCT02046447|DYT-1
178370|NCT02046447|Dystonia 1
178371|NCT02046447|fMRI
178372|NCT02046447|healthy
178373|NCT02046447|trihexyphenidyl
178374|NCT02046447|Artane
178375|NCT02046447|Apo-Trihex
178376|NCT02046447|Parkin
178377|NCT02046447|Pacitane
178378|NCT02046447|Benzhexol
178379|NCT02046447|Trihex
178380|NCT02046408|Smoking
178381|NCT02046408|5A's for smoking cessation
178382|NCT02046408|tailored health messages
178383|NCT02046408|Patient-facing information technology
178384|NCT02046408|Mobile health
178385|NCT02046408|behavioral health
178386|NCT02046395|Type 2 Diabetes
178387|NCT02046395|Hypertension
178388|NCT02046382|IV Acetaminophen
178389|NCT02046382|Cesarean Section
178390|NCT02046382|Pain, Postoperative
178391|NCT02046369|Lurasidone, Latuda, Bipolar Depression
178392|NCT02046356|hepatocellular carcinoma
178393|NCT02046356|radiofrequency ablation
178394|NCT02046356|Milan Criteria
178395|NCT02046356|recurrence
178396|NCT02046356|risk factor
178397|NCT02046343|physical activity
178398|NCT02046343|prevention
178399|NCT02046343|health disparities
178400|NCT02046343|behavior
178401|NCT02046343|community based intervention
178402|NCT02046330|Deep Brain Stimulation
178403|NCT02046330|Treatment Resistant Depression
178404|NCT02046330|Major Depressive Disorder
178405|NCT02046330|Depression
178406|NCT02046330|ECT
178407|NCT02046330|TNS
178408|NCT02046304|Sarcoma
178409|NCT02046304|Soft Tissue Sarcomas
178410|NCT02046304|STS
178411|NCT02046304|Extremity and Trunk
178412|NCT02046304|Gemcitabine
178413|NCT02046304|Gemcitabine Hydrochloride
178414|NCT02046304|Gemzar
178415|NCT02046304|External beam radiation therapy
178416|NCT02046304|EBRT
178417|NCT02046304|Radiotherapy
178418|NCT02046304|XRT
178419|NCT02046291|umbilical cord transplant
178420|NCT02046291|acute leukemia
178421|NCT02046291|UCBT
178422|NCT02046291|Hodgkin's Lymphoma
178423|NCT02046291|Lymphoid Leukemia
178424|NCT02046291|Multiple Myeloma
178425|NCT02046291|Myeloid and Monocytic Leukemia
178426|NCT02046291|Non-Hodgkin's Lymphoma
178427|NCT02046291|Hematopoietic malignancies
178428|NCT02046265|Cervical cancer prevention
178429|NCT02046226|Critical Limb Ischemia
178430|NCT02046226|Non Healing Wounds
178431|NCT02046226|Diabetic Wounds
178432|NCT02046226|Foot Ulcers
178433|NCT02046213|Metabolism and Excretion
178434|NCT02046200|ivermectin, alcoholism, alcohol use disorder, treatment
178435|NCT02046187|Ketogenic Diet
178436|NCT02046187|Brain tumor
178437|NCT02046187|Glioma
178438|NCT02046187|Glioblastoma
178439|NCT02046187|Radiation
178440|NCT02046187|Chemotherapy
178441|NCT02046187|temozolomide
178442|NCT02046174|colon
178443|NCT02046174|colorectal
178444|NCT02046174|rectal
178445|NCT02046174|cancer
178446|NCT02046174|macrobead
178447|NCT02046174|stage IV
178448|NCT02046174|metastatic
178449|NCT02046174|biological
178450|NCT02046174|mouse cells
178451|NCT02046174|new york
178452|NCT02046174|new jersey
178453|NCT02046174|clinical research
178454|NCT02046161|colon preparation
178455|NCT02046148|Maternal vaccine
178456|NCT02046148|GBS
178457|NCT02046148|pregnant women
178458|NCT02046148|IgG
178459|NCT02046148|IgA
178460|NCT02046135|Pediatric
178461|NCT02046135|Sodium bicarbonate
178462|NCT02046135|Acute kidney injury
178463|NCT02046135|Cardiac surgery
178464|NCT02046109|Repair
178465|NCT02046109|Replace
178466|NCT02046109|Composite
178467|NCT02046109|restoration
178468|NCT02046109|failing dental restoration
178469|NCT02046109|filling
178470|NCT02046109|dental
178471|NCT02046109|dentistry
178472|NCT02046096|Venous thrombosis
178473|NCT02046096|pulmonary embolism
178474|NCT02046096|vena cava, inferior
178475|NCT02046096|vena cava filters
178476|NCT02046096|venous thromboembolism
178477|NCT02046083|Teenager
178478|NCT02046083|Peanut
178479|NCT02046083|OIT (Oral Induction Tolerance)
178480|NCT02046070|MLN9708
178481|NCT02046070|Newly diagnosed
178482|NCT02046070|NDMM
178483|NCT02046070|IXAZOMIB
178484|NCT02046070|RRMM
178485|NCT02046057|Sentinel Lymph Node
178486|NCT02046057|Ultrasound Guided Needle Core Biopsy
178487|NCT02046044|Heart failure
178488|NCT02046044|Digoxin
178489|NCT02046044|Ivabradine
178490|NCT02046031|Ischemic stroke
178491|NCT02046031|safety
178492|NCT02046031|Pharmacokinetics
178493|NCT02046031|Ginkgolides Meglumine Injection
178494|NCT02046018|Maternal and Child Health
178495|NCT02046018|Rural Uganda
178496|NCT02046005|Family History
178497|NCT02046005|RA
178498|NCT02046005|Rheumatoid Arthritis
178499|NCT02046005|Genetics
178500|NCT02046005|Rheumatoid Factor
178501|NCT02046005|Shared Epitope
178502|NCT02046005|Anti-CCP
178503|NCT02045953|Healthy Subjects
178504|NCT02045953|SERETIDE
178505|NCT02045953|Pharmocokinetics
178506|NCT02045953|FLIXOTIDE
178507|NCT02045953|VENTOLIN Mini-Spacer
178508|NCT02045940|FTIH
178509|NCT02045940|safety
178510|NCT02045940|SARM
178511|NCT02045940|pharmacokinetics
178512|NCT02045927|sedation
178513|NCT02045927|BIS
178514|NCT02045927|monitoring
178515|NCT02045914|calcium ionophore
178516|NCT02045914|fertilization rate
178517|NCT02045914|poor ovarian reserve
178518|NCT02045901|Nausea
178519|NCT02045901|Vomiting
178520|NCT02045901|Pregnancy
178521|NCT02045901|Adolescent
178522|NCT02045901|Diclegis
178523|NCT02045901|Morning
178524|NCT02045901|Sickness
178525|NCT02045888|Hamstring
178526|NCT02045888|Tear
178527|NCT02045888|Muscle
178528|NCT02045888|Grade
178529|NCT02045888|adipose
178530|NCT02045888|cells
178531|NCT02045888|regenerative
178532|NCT02045888|Celution
178533|NCT02045888|stem
178534|NCT02045888|cell
178535|NCT02045888|liposuction
178536|NCT02045888|fat
178537|NCT02045875|Adherence monitoring
178538|NCT02045875|Motivational Interviewing Adherence strategies
178539|NCT02045862|Solifenacin Succinate
178540|NCT02045862|Mirabegron
178541|NCT02045862|Urinary Incontinence
178542|NCT02045862|Combination Therapy
178543|NCT02045862|Urgency
178544|NCT02045862|Nocturia
178545|NCT02045862|Overactive Bladder
178546|NCT02045849|relative bioavailability
178547|NCT02045849|itraconazole
178548|NCT02045849|GSK2140944
178549|NCT02045849|pharmacokinetics
178550|NCT02045849|tolerability
178551|NCT02045849|drug interaction
178552|NCT02045849|safety
178553|NCT02045849|elderly healthy subjects
178554|NCT02045849|food effect
178555|NCT02045836|Pneumovax 23
178556|NCT02045836|Co-administration
178557|NCT02045836|Herpes zoster
178558|NCT02045836|Immunogenicity
178559|NCT02045836|Safety
178560|NCT02045836|Adults
178561|NCT02045810|Measurement
178562|NCT02045810|nosiseption
178563|NCT02045797|Dose ranging
178564|NCT02045797|Intravenous
178565|NCT02045797|Adaptive design
178566|NCT02045797|suspected or confirmed gram-positive acute bacterial skin and skin structure infection
178567|NCT02045797|Subjects
178568|NCT02045797|infection
178569|NCT02045797|Oral
178570|NCT02045797|GSK2140944
178571|NCT02045771|Depression
178572|NCT02045771|Behavioral Activation
178573|NCT02045745|Prolonged postoperative air leaks in risk patients.
178574|NCT02045732|Multiple Sclerosis
178575|NCT02045732|MRI
178576|NCT02045719|cat´s claw
178577|NCT02045719|uncaria tomentosa
178578|NCT02045719|quality of life
178579|NCT02045719|no further therapeutic options
178580|NCT02045706|Community Health Workers
178581|NCT02045706|Service
178582|NCT02045706|Volunteerism
178583|NCT02045706|Health Behaviors
178584|NCT02045680|colorectal cancer
178585|NCT02045680|laparoscopy
178586|NCT02045680|neuromuscular block
178587|NCT02045680|oxygen delivery
178588|NCT02045667|Becker's myotonia congenita (BMC)
178589|NCT02045667|Thomson's myotonia congenita (TMC)
178590|NCT02045667|Paramyotonia Congenita (PMC)
178591|NCT02045667|Sodium Channel Myotonia (SCM)
178592|NCT02045641|cardiac surgery
178593|NCT02045641|postoperative treatment
178594|NCT02045641|pleural effusion
178595|NCT02045641|physical performance
178596|NCT02045628|Bariatric Surgery
178597|NCT02045628|Health Psychology
178598|NCT02045602|Cancer
178599|NCT02045602|Solid Tumors
178600|NCT02045602|Gemcitabine
178601|NCT02045602|Oncolytic virus
178602|NCT02045602|Metastatic
178603|NCT02045602|Pancreatic cancer
178604|NCT02045589|Cancer
178605|NCT02045589|Pancreatic adenocarcinoma
178606|NCT02045589|Locally advanced
178607|NCT02045589|Metastatic
178608|NCT02045589|Gemcitabine
178609|NCT02045589|Oncolytic virus
178610|NCT02045589|Abraxane®
178611|NCT02045576|Obstructive Sleep Apnea
178612|NCT02045576|sleep position trainer
178613|NCT02045576|oral appliance therapy
178614|NCT02045576|mandibular advancement device or splint
178615|NCT02045537|HIV
178616|NCT02045498|cpr
178617|NCT02045498|feedback
178618|NCT02045498|capnography
178619|NCT02045498|outcome
178620|NCT02045498|quality
178621|NCT02045498|resuscitation
178622|NCT02045472|Influenza
178623|NCT02045472|Monoclonal antibody
178624|NCT02045459|Microvascular Disease
178625|NCT02045459|Exercise
178626|NCT02045459|Angina
178627|NCT02045459|Chest pain
178628|NCT02045420|Idiopathic Parkinson's Disease
178629|NCT02045420|Magnetic Resonance Imaging
178630|NCT02045420|MR Venography
178631|NCT02045420|Flow Quantification
178632|NCT02045420|Susceptibility Weighted Imaging
178633|NCT02045407|Brain Death
178634|NCT02045407|Neurological Death
178635|NCT02045407|Cerebral circulatory arrest
178636|NCT02045407|Computed Tomography Angiography
178637|NCT02045394|haemoptysis
178638|NCT02045394|hemoptysis
178639|NCT02045394|airway bleeding
178640|NCT02045381|Cancer
178641|NCT02045381|MRI
178642|NCT02045368|refractory
178643|NCT02045368|intolerant
178644|NCT02045368|non-hematologic
178645|NCT02045368|solid tumors
178646|NCT02045329|Staphylococcus aureus, mupirocin, decolonization
178647|NCT02045316|Preeclampsia
178648|NCT02045316|Aquaporins
178649|NCT02045316|Placenta
178650|NCT02045303|Sub-acute wound
178651|NCT02045303|Chronic wound
178652|NCT02045303|wound
178653|NCT02045303|MIST
178654|NCT02045303|Soring
178655|NCT02045303|Contact Ultrasound
178656|NCT02045303|Noncontact ultrasound
178657|NCT02045303|Wound Care
178658|NCT02045303|VIP Ultrasound Protocol
178659|NCT02045303|Ultrasound
178660|NCT02045264|Firazyr
178661|NCT02045264|Angioedema
178662|NCT02045264|Angioedemas, Hereditary
178663|NCT02045264|Vascular Diseases
178664|NCT02045264|Cardiovascular Diseases
178665|NCT02045264|Urticaria
178666|NCT02045264|Skin Diseases, Vascular
178667|NCT02045264|Skin Diseases
178668|NCT02045264|Hypersensitivity, Immediate
178669|NCT02045264|Hypersensitivity
178670|NCT02045264|Immune System Diseases
178671|NCT02045264|Genetic Diseases, Inborn
178672|NCT02045264|Icatibant
178673|NCT02045264|Anti-Inflammatory Agents, Non-Steroidal
178674|NCT02045264|Analgesics, Non-Narcotic
178675|NCT02045264|Analgesics
178676|NCT02045264|Sensory System Agents
178677|NCT02045264|Peripheral Nervous System Agents
178678|NCT02045264|Physiological Effects of Drugs
178679|NCT02045264|Pharmacologic Actions
178680|NCT02045264|Anti-Inflammatory Agents
178681|NCT02045264|Therapeutic Uses
178682|NCT02045264|Antirheumatic Agents
178683|NCT02045264|Adrenergic beta-Antagonists
178684|NCT02045264|Adrenergic Antagonists
178685|NCT02045264|Adrenergic Agents
178686|NCT02045264|Neurotransmitter Agents
178687|NCT02045264|Molecular Mechanisms of Pharmacological Action
178688|NCT02045264|Central Nervous System Agents
178689|NCT02045251|Helicobacter pylori
178690|NCT02045251|H. pylori
178691|NCT02045251|Pylera
178692|NCT02045238|Bronchiolitis
178693|NCT02045238|Therapeutics
178694|NCT02045238|Saline Solution, Hypertonic
178695|NCT02045225|social anxiety in sexual situations
178696|NCT02045212|Ischemic Optic Neuropathy
178697|NCT02045212|Traumatic Neuropathy
178698|NCT02045212|Non Arteritic Ischemic Neuropathy (NAION)
178699|NCT02045199|Diabetic Neuropathies
178700|NCT02045199|Diabetes Mellitus
178701|NCT02045199|Diabetic Foot
178702|NCT02045199|Diabetes Complications
178703|NCT02045186|Human Papilloma Virus
178704|NCT02045186|Oropharynx
178705|NCT02045186|Oropharyngeal Squamous Cell Carcinoma
178706|NCT02045186|Squamous Cell Carcinoma
178707|NCT02045186|Radiation Therapy
178708|NCT02045186|Chemotherapy
178709|NCT02045173|Sleep apnea, Arrhythmias, Heart Failure, ICD, CRT-D, Apneascan
178710|NCT02045147|Home Bound Care Transitions
178711|NCT02045134|Post Operative Atrial Fibrillation after a cardiac surgery
178712|NCT02045082|Flocked swab
178713|NCT02045082|Traditional fiber swab
178714|NCT02045082|Herpes simplex epithelial keratitis
178715|NCT02045082|Quantitative PCR
178716|NCT02045056|Alzheimer disease
178717|NCT02045056|mild cognitive impairment
178718|NCT02045056|normal cognition
178719|NCT02045043|Sudden Cardiac Death
178720|NCT02045043|Arrhythmias
178721|NCT02045043|Congestive Heart Failure
178722|NCT02045043|Cardiomyopathy
178723|NCT02045043|Single Nucleotide Polymorphisms
178724|NCT02045043|Genomics
178725|NCT02045030|metastatic
178726|NCT02045030|colorectal
178727|NCT02045030|cancer
178728|NCT02045030|aflibercept
178729|NCT02045030|FOLFIRI
178730|NCT02045017|Multiple Myeloma
178731|NCT02045017|Relapsed Multiple Myeloma
178732|NCT02045017|Refactory Multiple Myeloma
178733|NCT02045017|Renal Insufficiency
178734|NCT02045017|Pomalidomide
178735|NCT02045017|Dexamethasone
178736|NCT02045004|Anesthesia
178737|NCT02045004|Surgery
178738|NCT02045004|Geriatrics
178739|NCT02045004|Postoperative cognitive dysfunction
178740|NCT02045004|Postoperative delirium
178741|NCT02045004|Dementia
178742|NCT02045004|Postoperative complications
178743|NCT02045004|Neurological complications
178744|NCT02045004|Psychological complications
178745|NCT02044991|Pelvic girdle pain (PGP) in pregnancy
178746|NCT02044965|urinary tract infection
178747|NCT02044965|antibiotic prophylaxis
178748|NCT02044965|probiotics
178749|NCT02044965|neurogenic bladder
178750|NCT02044965|clean intermittent catheterization
178751|NCT02044952|Crohn's Disease
178752|NCT02044952|mesalazine
178753|NCT02044952|Tripterygium Glycosides
178754|NCT02044952|induction remission
178755|NCT02044939|Sarcoidosis, pulmonary rehabilitation
178756|NCT02044900|obstructive sleep apnea
178757|NCT02044900|polysomnography
178758|NCT02044900|heart rate variability
178759|NCT02044900|mathematical biomarker
178760|NCT02044887|Physical activity
178761|NCT02044887|dementia
178762|NCT02044887|relative caregivers
178763|NCT02044887|podometer
178764|NCT02044887|cardiovascular risk
178765|NCT02044848|type 1 diabetes mellitus
178766|NCT02044835|atherosclerotic renal artery stenosis, herbal medicine
178767|NCT02044822|Chronic Lymphocytic Leukemia
178768|NCT02044822|CLL
178769|NCT02044783|Adults
178770|NCT02044783|Elderly
178771|NCT02044770|laparoscopic
178772|NCT02044770|colectomy
178773|NCT02044770|ENSEAL
178774|NCT02044757|Caffeine
178775|NCT02044757|Addiction
178776|NCT02044757|Withdrawal symptoms
178777|NCT02044757|Pediatric
178778|NCT02044757|Adolescent
178779|NCT02044757|Overweight
178780|NCT02044744|Obesity
178781|NCT02044744|Pediatric Obesity
178782|NCT02044744|Physical Activity
178783|NCT02044744|Physical Fitness
178784|NCT02044744|Primary Health Care
178785|NCT02044744|Referral and Consultation
178786|NCT02044731|Schools
178787|NCT02044731|Pediatrics
178788|NCT02044731|Obesity
178789|NCT02044731|Overweight
178790|NCT02044731|Intervention Studies
178791|NCT02044731|African Americans
178792|NCT02044731|Family
178793|NCT02044731|Body mass index
178794|NCT02044718|adverse events
178795|NCT02044718|unplanned admission intensive care
178796|NCT02044718|chart review
178797|NCT02044705|Primary Health Care
178798|NCT02044705|Pediatrics
178799|NCT02044705|Obesity
178800|NCT02044705|Overweight
178801|NCT02044705|Clinical trial
178802|NCT02044705|Hispanic Americans
178803|NCT02044705|Family
178804|NCT02044705|Body mass index
178805|NCT02044692|Hunter syndrome
178806|NCT02044692|Mucopolysaccharidosis II
178807|NCT02044692|Hunterase
178808|NCT02044666|Critical Limb Ischemia
178809|NCT02044666|Amputation
178810|NCT02044653|Phase 2
178811|NCT02044614|Hemodialysis/Peritoneal Dialysis
178812|NCT02044614|functionally anuric
178813|NCT02044614|Icodextrin
178814|NCT02044614|Kidney Disease Quality of Life
178815|NCT02044601|Lung Cancer
178816|NCT02044601|Non-small cell lung cancer
178817|NCT02044601|NSCLC
178818|NCT02044601|Squamous cell carcinoma of the lung
178819|NCT02044601|Adenocarcinoma of the lung
178820|NCT02044601|Radiation therapy
178821|NCT02044601|Proton therapy
178822|NCT02044601|XRT
178823|NCT02044601|Carboplatin
178824|NCT02044601|Paraplatin
178825|NCT02044601|Paclitaxel
178826|NCT02044601|Taxol
178827|NCT02044601|Onartuzumab
178828|NCT02044601|Erlotinib
178829|NCT02044601|Erlotinib hydrochloride
178830|NCT02044601|OSI-774
178831|NCT02044601|CP358774
178832|NCT02044601|Tarceva
178833|NCT02044588|HBsAg(+) donor
178834|NCT02044588|HBsAg(-) donor
178835|NCT02044588|Anti-hepatitis B antibody
178836|NCT02044588|Kidney allograft
178837|NCT02044575|Clock genes, circadian regulation
178838|NCT02044562|dietary nitrate
178839|NCT02044562|radiotherapy
178840|NCT02044562|nasopharyngeal carcinoma
178841|NCT02044549|Carbetocin
178842|NCT02044549|syntometrine
178843|NCT02044549|postpartum hemorrhage
178844|NCT02044549|cesarean section
178845|NCT02044536|biopsy; endoscopy; neoplasms
178846|NCT02044523|Chronic liver disease
178847|NCT02044523|Fibrosis
178848|NCT02044523|Elastography
178849|NCT02044523|Ultrasound
178850|NCT02044523|Magnetic resonance elastography
178851|NCT02044523|Diagnostic performance
178852|NCT02044523|Sensitivity and specificity
178853|NCT02044510|Multiple Sclerosis
178854|NCT02044510|Spinal Cord Injuries
178855|NCT02044510|mirabegron
178856|NCT02044510|Urodynamics
178857|NCT02044497|pharmacokinetics
178858|NCT02044497|pharmacogenomics
178859|NCT02044497|oral oxycodone
178860|NCT02044497|pediatric surgical patients
178861|NCT02044484|HIV
178862|NCT02044484|AIDS
178863|NCT02044484|Viral load
178864|NCT02044484|Primary care
178865|NCT02044471|left ventricular assist device
178866|NCT02044471|continuous flow
178867|NCT02044471|remote ischemic conditioning
178868|NCT02044471|hypertension
178869|NCT02044471|sympathetic tone
178870|NCT02044471|endothelial dysfunction
178871|NCT02044458|Foley Catheterization
178872|NCT02044458|Induction of Labor
178873|NCT02044458|5 French Stylette
178874|NCT02044445|IVF, hCG, oocyte retrieval, time interval
178875|NCT02044419|Comparative
178876|NCT02044419|Bioavailability
178877|NCT02044419|lomitapide
178878|NCT02044341|Acute Otitis Media
178879|NCT02044341|Pain
178880|NCT02044341|Ear Pain
178881|NCT02044341|Ear Ache
178882|NCT02044341|Ear infection
178883|NCT02044341|middle ear infection
178884|NCT02044302|pain
178885|NCT02044302|breast cancer
178886|NCT02044302|breast implant
178887|NCT02044302|breast reconstruction
178888|NCT02044289|depression
178889|NCT02044289|electroconvulsive therapy (ECT)
178890|NCT02044289|magnetic resonance imaging (MRI)
178891|NCT02044276|Neutropenia
178892|NCT02044276|NHL
178893|NCT02044276|Non-Hodgkin lymphomas
178894|NCT02044276|R-CHOP-21
178895|NCT02044263|Cognitive therapy
178896|NCT02044263|Behavior therapy
178897|NCT02044263|Waiting lists
178898|NCT02044263|Therapy, computer-assisted
178899|NCT02044263|Internet
178900|NCT02044250|Aspirin
178901|NCT02044250|Clopidogrel
178902|NCT02044250|Antiplatelet monotherapy
178903|NCT02044250|Drug-eluting stent
178904|NCT02044237|trichotillomania
178905|NCT02044237|online therapy
178906|NCT02044211|Heart Failure, Systolic
178907|NCT02044211|Depressive Disorder
178908|NCT02044211|Depressive Disorder, Major
178909|NCT02044211|Mood Disorder
178910|NCT02044198|Plasmodium Falciparum
178911|NCT02044198|Malaria
178912|NCT02044198|Vaccine
178913|NCT02044198|Plasmodium
178914|NCT02044198|Falciparum
178915|NCT02044185|HMGB1 Protein
178916|NCT02044185|Graft versus Host Disease
178917|NCT02044185|Immunosuppressive Agents
178918|NCT02044185|oral mucositis
178919|NCT02044172|Prostate cancer
178920|NCT02044172|Treatment
178921|NCT02044172|Screening
178922|NCT02044172|Surgery
178923|NCT02044172|Radiotherapy
178924|NCT02044172|Active monitoring
178925|NCT02044159|Hydrocortisone
178926|NCT02044159|Pediatrics
178927|NCT02044159|Adrenal Insufficiency
178928|NCT02044107|Diarrhea,
178929|NCT02044107|Pneumonia,
178930|NCT02044107|Zinc treatment,
178931|NCT02044107|Patient Compliance.
178932|NCT02044094|Opioid dependent
178933|NCT02044094|Buprenorphine
178934|NCT02044094|Suboxone Film
178935|NCT02044094|Opioid blockade
178936|NCT02044094|Hydromorphone challenge
178937|NCT02044016|Achilles tendon rupture, lengthening, validity, goniometer.
178938|NCT02044003|angioplasty
178939|NCT02044003|dissections
178940|NCT02043990|NAVA
178941|NCT02043990|noninvasive ventilation
178942|NCT02043990|infants
178943|NCT02043977|Propofol
178944|NCT02043977|Insomnia
178945|NCT02043977|Sleep disorder
178946|NCT02043977|Sleep deprivation
178947|NCT02043977|Chronic insomnia
178948|NCT02043977|Refractory insomnia
178949|NCT02043977|Primary insomnia
178950|NCT02043964|Multiple Sclerosis
178951|NCT02043964|Clinically Isolated Syndrome
178952|NCT02043964|Tears
178953|NCT02043964|Isoelectric focusing
178954|NCT02043964|Oligoclonal profile
178955|NCT02043938|Electroencephalography
178956|NCT02043938|pharmacological
178957|NCT02043925|QT-prolongation
178958|NCT02043925|Torsade de Pointes
178959|NCT02043925|drug interactions
178960|NCT02043925|psychiatry
178961|NCT02043912|QT-prolongation
178962|NCT02043912|Torsade de Pointes
178963|NCT02043912|Haloperidol
178964|NCT02043912|Drug interactions
178965|NCT02043899|Neuroblastoma
178966|NCT02043899|Positron emission tomography
178967|NCT02043899|124-iodine
178968|NCT02043899|Meta-Iodobenzylguanidine
178969|NCT02043886|Type 2 Diabetes, Postprandial Hypotension, Acarbose
178970|NCT02043873|Clinical Trial
178971|NCT02043873|Composite Restorations
178972|NCT02043873|Restorations Repair
178973|NCT02043873|Replacement Restorations
178974|NCT02043873|Operative Dentistry.
178975|NCT02043860|Multiple Myeloma
178976|NCT02043860|High Risk
178977|NCT02043860|Intermediate Risk
178978|NCT02043860|Symptomatic
178979|NCT02043847|Multiple Myeloma
178980|NCT02043847|Relapsed
178981|NCT02043847|Refractory
178982|NCT02043847|Progressive Disease
178983|NCT02043847|Symptomatic
178984|NCT02043795|Bioresorbable Vascular Scaffold System
178985|NCT02043795|Percutaneous Transluminal Angioplasty
178986|NCT02043795|Stent
178987|NCT02043769|South Africa
178988|NCT02043769|Eastern Cape
178989|NCT02043769|Child ARV
178990|NCT02043769|CLWHIV
178991|NCT02043756|Mitoxantrone Hydrochloride Liposome Injection
178992|NCT02043730|pancreatic cancer
178993|NCT02043730|locally advanced
178994|NCT02043730|unresectable cancer
178995|NCT02043717|Cystic Fibrosis
178996|NCT02043717|Vitamin D
178997|NCT02043717|Lung function
178998|NCT02043704|IV Acetaminophen
178999|NCT02043704|Vaginal Reconstruction
179000|NCT02043704|Pain, Postoperative
179001|NCT02043691|Endovascular
179002|NCT02043691|Aortic
179003|NCT02043691|Aneurysm
179004|NCT02043691|Thoracoabdominal
179005|NCT02043691|Juxtarenal
179006|NCT02043691|Suprarenal
179007|NCT02043691|Endograft
179008|NCT02043691|Fenestrated
179009|NCT02043691|Branched
179010|NCT02043691|Complex
179011|NCT02043691|Abdominal
179012|NCT02043691|Thoracic
179013|NCT02043691|Stent
179014|NCT02043691|Stentgraft
179015|NCT02043678|Phase III
179016|NCT02043678|Radium-223 dichloride
179017|NCT02043678|Abiraterone acetate
179018|NCT02043678|Combination therapy
179019|NCT02043678|Chemotherapy-naive
179020|NCT02043678|Bone metastasis
179021|NCT02043678|Castration-resistant prostate cancer (CRPC)
179022|NCT02043665|CAVATAK
179023|NCT02043665|KEYNOTE-200
179024|NCT02043665|pembrolizumab
179025|NCT02043665|lung cancer
179026|NCT02043665|bladder cancer
179027|NCT02043639|rotation
179028|NCT02043639|shoulder
179029|NCT02043639|joint
179030|NCT02043639|ROM
179031|NCT02043639|abduction,
179032|NCT02043639|internal rotation,
179033|NCT02043639|external rotation,
179034|NCT02043639|flexion
179035|NCT02043639|normal
179036|NCT02043639|joint movement
179037|NCT02043639|physical examination
179038|NCT02043626|childhood nutrition
179039|NCT02043626|physical activity
179040|NCT02043626|school wellness
179041|NCT02043626|school health
179042|NCT02043626|nutritional policies
179043|NCT02043626|childhood obesity
179044|NCT02043613|Joint pain
179045|NCT02043613|Context effects
179046|NCT02043613|Placebo effect
179047|NCT02043613|Exercise treatment
179048|NCT02043600|Colitis, ulcerative
179049|NCT02043600|Yoga
179050|NCT02043587|Acute lymphoblastic leukemia
179051|NCT02043587|Lymphoblastic leukemia
179052|NCT02043587|Lymphoblastic lymphoma
179053|NCT02043574|Aerobic Exercise
179054|NCT02043574|Treadmill Test
179055|NCT02043574|Sedentary Lifestyle
179056|NCT02043548|dermatomyositis
179057|NCT02043548|polymyositis
179058|NCT02043548|tocilizumab
179059|NCT02043548|Actemra
179060|NCT02043535|myocardial perfusion imaging
179061|NCT02043535|myocardial blood flow
179062|NCT02043535|pharmacologic stress agents
179063|NCT02043535|carbon dioxide
179064|NCT02043535|rubidium 82 radioisotope
179065|NCT02043535|positron emission tomography
179066|NCT02043522|123I-mIBG
179067|NCT02043522|SPECT Imaging
179068|NCT02043522|Phantom imaging
179069|NCT02043522|Heart failure
179070|NCT02043522|Coronary artery disease
179071|NCT02043522|Heart to mediastinum ratios
179072|NCT02043522|heart to calibration ratios
179073|NCT02043522|Myocardial blood flow
179074|NCT02043522|Myocardial blood flow researve
179075|NCT02043509|smoking cessation
179076|NCT02043509|pregnancy
179077|NCT02043509|cessation support
179078|NCT02043509|tailored text messages
179079|NCT02043509|self-help
179080|NCT02043509|MiQuit
179081|NCT02043496|Binge Eating Disorder
179082|NCT02043496|Binge Eating
179083|NCT02043496|Eating Disorders
179084|NCT02043496|Obesity
179085|NCT02043496|Psychotherapy
179086|NCT02043496|Cognitive Behavioral Therapy
179087|NCT02043483|CPAP
179088|NCT02043483|OSAS
179089|NCT02043483|CEDOC (Centro de Estudos de Doenças Crónicas)
179090|NCT02043483|FCM (Faculdade de Ciências Médicas)
179091|NCT02043483|UNL (Universidade Nova de Lisboa
179092|NCT02043483|NOVA MEDICAL SCHOOL
179093|NCT02043483|FCT (Fundação para a Ciência e Tecnologia)
179094|NCT02043470|Sinus/nasal cancer
179095|NCT02043431|Heart failure
179096|NCT02043431|Electronic medical records
179097|NCT02043431|Genomics
179098|NCT02043431|Biobank
179099|NCT02043418|HIV
179100|NCT02043418|ARV
179101|NCT02043418|Pediatric
179102|NCT02043418|Cameroon
179103|NCT02043392|intestinal anastomosis
179104|NCT02043392|non-emergent
179105|NCT02043392|intestinal revision
179106|NCT02043392|magnetic compression
179107|NCT02043392|anastomotic leak
179108|NCT02043379|congenital heart disease
179109|NCT02043379|Cardiopulmonary Bypass
179110|NCT02043379|Hypogammaglobulinemia
179111|NCT02043366|Remifentanil
179112|NCT02043366|Opioid-induced hyperalgesia
179113|NCT02043366|Postoperative pain
179114|NCT02043366|Pain Intensity
179115|NCT02043340|Periodontitis
179116|NCT02043340|Bacterial viability
179117|NCT02043340|Lactate dehydrogenase levels
179118|NCT02043340|Indocyanine green
179119|NCT02043340|Scaling and root planing
179120|NCT02043340|Antimicrobial photodynamic therapy.
179121|NCT02043327|Colonoscopy
179122|NCT02043327|assessment
179123|NCT02043327|certification,
179124|NCT02043327|simulation,
179125|NCT02043327|standard setting
179126|NCT02043301|pharmacokinetics
179127|NCT02043301|bioavailability
179128|NCT02043301|PF-04950615
179129|NCT02043288|Pancreatic cancer
179130|NCT02043288|Platinum
179131|NCT02043288|Micelle
179132|NCT02043275|resistance training
179133|NCT02043262|Elderly
179134|NCT02043262|Home-based rehabilitation
179135|NCT02043262|Activities of daily living
179136|NCT02043262|Restorative care
179137|NCT02043262|Reablement
179138|NCT02043262|Everyday rehabilitation
179139|NCT02043249|DELAYED CORD CLAMPING
179140|NCT02043249|MILKING OF CORD
179141|NCT02043249|PREMATURE INFANTS
179142|NCT02043249|LEVEL OF IgG IN NEONATES
179143|NCT02043236|Prostate cancer
179144|NCT02043236|Androgen deprivation therapy
179145|NCT02043236|Bone health
179146|NCT02043236|Bone mineral density
179147|NCT02043223|Vitamin A
179148|NCT02043223|Breast milk
179149|NCT02043223|Postpartum vitamin A supplementation
179150|NCT02043223|Infant vaccine response
179151|NCT02043210|substance use, Spanish speaking, CBT4CBT
179152|NCT02043197|Depression,
179153|NCT02043197|depressive symptoms,
179154|NCT02043197|major depressive disorder,
179155|NCT02043197|Fevarine,
179156|NCT02043197|fluvoxamine,
179157|NCT02043197|cognitive function,
179158|NCT02043197|neurological disorders,
179159|NCT02043197|sleep state
179160|NCT02043184|Neoplasms
179161|NCT02043184|Medication Adherence
179162|NCT02043184|Administration, Oral
179163|NCT02043184|Symptom Assessment
179164|NCT02043184|Neurobehavioral Manifestations
179165|NCT02043184|Depression
179166|NCT02043184|Behavioral Symptoms
179167|NCT02043184|Utilization
179168|NCT02043158|Ovarian Cancer
179169|NCT02043158|Short term survivors
179170|NCT02043158|Long term survivors
179171|NCT02043158|Biobehavioral characteristics
179172|NCT02043158|Sociodemographic characteristics
179173|NCT02043158|Questionnaire
179174|NCT02043158|Survey
179175|NCT02043158|Interview
179176|NCT02043132|reverse shoulder arthroplasty
179177|NCT02043132|Rotator cuff
179178|NCT02043132|Orthopedic joint surgery
179179|NCT02043132|Total shoulder
179180|NCT02043132|Perioperative bleeding
179181|NCT02043132|Tranexamic acid
179182|NCT02043132|Orthopedic complications
179183|NCT02043132|Hemorrhage
179184|NCT02043132|Postoperative Hemorrhage
179185|NCT02043132|Pathologic Processes
179186|NCT02043132|Arthritis
179187|NCT02043132|Joint Diseases
179188|NCT02043132|Musculoskeletal Diseases
179189|NCT02043132|Postoperative Complications
179190|NCT02043132|Antifibrinolytic Agents
179191|NCT02043132|Fibrin Modulating Agents
179192|NCT02043132|Molecular Mechanisms of Pharmacological Action
179193|NCT02043132|Pharmacologic Actions
179194|NCT02043132|Hemostatics
179195|NCT02043132|Coagulants
179196|NCT02043132|Hematologic Agents
179197|NCT02043132|Therapeutic Uses
179198|NCT02043093|Adolescent suicide prevention
179199|NCT02043093|Peer Leader prevention model
179200|NCT02043093|Universal school-based prevention
179201|NCT02043080|Tuberculosis
179202|NCT02043080|HIV
179203|NCT02043080|Xpert MTB/RIF
179204|NCT02043080|Determine TB-LAM
179205|NCT02043080|UNC
179206|NCT02043080|Zambia
179207|NCT02043080|Cost Effectiveness Analysis Curve
179208|NCT02043080|Centre for Infectious Disease Research in Zambia
179209|NCT02043067|TB
179210|NCT02043067|HIV
179211|NCT02043067|Extensively resistant TB
179212|NCT02043067|Extra pulmonary TB
179213|NCT02043054|Type 2 Diabetes Mellitus (T2DM)
179214|NCT02043054|Young Adults
179215|NCT02043054|Cardiovascular Disease (CVD)
179216|NCT02043054|GLP1 Analogue
179217|NCT02043054|DPP IV Inhibitor
179218|NCT02043054|Obesity
179219|NCT02043054|Cardiometabolic Effects
179220|NCT02043054|Cardiac MRI
179221|NCT02043028|Cardiopulmonary resuscitation
179222|NCT02043028|Chest compression
179223|NCT02043028|Advanced cardiac life support
179224|NCT02043028|Posture
179225|NCT02043015|voluntary counseling and testing (VCT)
179226|NCT02043015|couples voluntary counseling and testing (CVCT)
179227|NCT02043015|pre-exposure prophylaxis (PrEP)
179228|NCT02043015|homosexuality
179229|NCT02043015|male
179230|NCT02043015|South Africa
179231|NCT02042989|Advanced Cancers
179232|NCT02042989|Advanced solid tumor
179233|NCT02042989|Advanced p53 Mutant Malignancies
179234|NCT02042989|MLN9708
179235|NCT02042989|Vorinostat
179236|NCT02042989|SAHA
179237|NCT02042989|Suberoylanilide Hydroxamic Acid
179238|NCT02042989|MSK-390
179239|NCT02042989|Zolinza
179240|NCT02042976|Chronic obstructive pulmonary disease (COPD)
179241|NCT02042976|Mindfulness-based cognitive therapy (MBCT)
179242|NCT02042976|Behavioural intervention
179243|NCT02042976|Quality-of-life
179244|NCT02042976|Anxiety
179245|NCT02042976|Depression
179246|NCT02042976|Physical health status
179247|NCT02042963|The cohort of Asian kidney transplant recipients
179248|NCT02042963|The cohort of metabolic complication after kidney transplant
179249|NCT02042963|The biorepository of Asian kidney transplant recipients
179250|NCT02042950|Lymphoma
179251|NCT02042950|Mantle Cell Lymphoma
179252|NCT02042950|MCL
179253|NCT02042950|Relapsed
179254|NCT02042950|Refractory
179255|NCT02042950|Carfilzomib
179256|NCT02042937|Knee
179257|NCT02042937|Hip
179258|NCT02042937|Muscle Strength
179259|NCT02042937|Electromyography
179260|NCT02042937|Biomechanical Phenomena
179261|NCT02042924|Leukemia
179262|NCT02042924|Lymphoma
179263|NCT02042924|Myeloma
179264|NCT02042924|Myelodysplastic Syndrome
179265|NCT02042898|Cardiac Surgery
179266|NCT02042898|Transfusion
179267|NCT02042885|Prostate cancer
179268|NCT02042872|Spinal Cord Injury
179269|NCT02042872|Disuse Osteoporosis
179270|NCT02042872|Zoledronic acid
179271|NCT02042872|Bisphosphonates
179272|NCT02042872|Dual Energy X-ray Absorptiometry
179273|NCT02042859|EndoHPB
179274|NCT02042820|Dry Eye
179275|NCT02042781|PG545
179276|NCT02042781|Phase I
179277|NCT02042781|Progen
179278|NCT02042781|antimetastatic
179279|NCT02042781|antiangiogenic
179280|NCT02042781|advanced cancer patients
179281|NCT02042781|solid tumors
179282|NCT02042781|solid tumours
179283|NCT02042781|tumor microenvironment
179284|NCT02042768|Glucose
179285|NCT02042768|Dialysate
179286|NCT02042768|Peritoneal Dialysis
179287|NCT02042768|patients
179288|NCT02042768|non-diabetic
179289|NCT02042755|cataract
179290|NCT02042755|IOL
179291|NCT02042755|trifocal
179292|NCT02042755|FineVision
179293|NCT02042742|Cross-over studies
179294|NCT02042742|Antioxidants
179295|NCT02042742|Hydroxytyrosol
179296|NCT02042742|Punicalagin
179297|NCT02042742|Treatment outcome
179298|NCT02042742|Inflammatory markers
179299|NCT02042742|Endothelial function
179300|NCT02042742|Humans
179301|NCT02042742|Adults
179302|NCT02042742|volunteers
179303|NCT02042729|volunteer
179304|NCT02042716|preterm and term newborns
179305|NCT02042716|diagnosis of cerebral white matter damage
179306|NCT02042716|quantitative brain elasticity
179307|NCT02042716|Transfontanel ultrafast doppler
179308|NCT02042690|Acute Lymphoblastic Leukemia
179309|NCT02042690|hematopoietic stem cell transplantation
179310|NCT02042690|chemotherapy
179311|NCT02042677|ileostomy
179312|NCT02042677|1-piece
179313|NCT02042677|assessment
179314|NCT02042677|Nova
179315|NCT02042677|NovaLife
179316|NCT02042677|Dansac
179317|NCT02042651|ESWT
179318|NCT02042651|Chronic pelvic pain
179319|NCT02042651|randomized
179320|NCT02042651|sham controlled
179321|NCT02042612|Pharmacokinetics
179322|NCT02042612|Sevoflurane
179323|NCT02042612|Obesity
179324|NCT02042612|Sedation
179325|NCT02042612|ICU patients
179326|NCT02042599|Pharmacokinetics
179327|NCT02042599|Sevoflurane
179328|NCT02042599|Acute kidney injury
179329|NCT02042599|Sedation
179330|NCT02042599|ICU patients
179331|NCT02042534|stroke
179332|NCT02042534|TIA
179333|NCT02042521|Cigarette
179334|NCT02042521|Withdrawal
179335|NCT02042521|Nicotine
179336|NCT02042482|Ultra coenzyme Q10
179337|NCT02042482|L-carnitine
179338|NCT02042469|awareness, clinical research, Saudi arabia
179339|NCT02042456|breast cancer
179340|NCT02042456|dense breasts
179341|NCT02042456|mammography screening
179342|NCT02042456|Screening techniques
179343|NCT02042456|women
179344|NCT02042404|Hearing impairment
179345|NCT02042404|Hearing loss
179346|NCT02042391|PTLD
179347|NCT02042391|CD20-positive
179348|NCT02042391|solid organ transplantation
179349|NCT02042378|BRCA
179350|NCT02042378|BRCA mutation
179351|NCT02042378|germline BRCA
179352|NCT02042378|somatic BRCA
179353|NCT02042378|PARP inhibitor
179354|NCT02042378|rucaparib
179355|NCT02042378|CO-338
179356|NCT02042378|PF 01367338
179357|NCT02042378|AG 14699
179358|NCT02042378|Clovis
179359|NCT02042378|Clovis Oncology
179360|NCT02042378|RucaPanc
179361|NCT02042365|Enhanced recovery,
179362|NCT02042365|sleeve gastrectomy,
179363|NCT02042339|Hyperbaric Oxygen
179364|NCT02042339|Diabetic ulcer
179365|NCT02042339|Wound healing
179366|NCT02042339|3-D life-viz- system
179367|NCT02042339|Indocyanine green video angiography
179368|NCT02042339|Transcutaneous oxygen pressure
179369|NCT02042339|Endothelial progenitor cells
179370|NCT02042326|Arteriovenous Malformations
179371|NCT02042326|Sirolimus
179372|NCT02042326|Maxillofacial Surgery
179373|NCT02042300|XIENCE Xpedition
179374|NCT02042300|Routine Clinical Practice
179375|NCT02042300|Alpine
179376|NCT02042287|Bacterial Infections and Mycoses
179377|NCT02042287|Pharmaceutical Preparations
179378|NCT02042287|Health Occupations
179379|NCT02042274|Fish oil
179380|NCT02042274|EPA
179381|NCT02042274|DHA
179382|NCT02042274|fatty acids
179383|NCT02042274|genetic variation
179384|NCT02042274|gene expression
179385|NCT02042248|HIV
179386|NCT02042248|Acute HIV Infection
179387|NCT02042248|Chronic HIV Infection
179388|NCT02042248|AGS-004
179389|NCT02042248|Phase 1
179390|NCT02042248|Phase II
179391|NCT02042248|Antiretroviral Therapy
179392|NCT02042248|ART
179393|NCT02042248|UNC
179394|NCT02042248|Argos Therapeutics
179395|NCT02042248|The CARE Collaboratory of AIDS
179396|NCT02042248|Immunization
179397|NCT02042248|vaccination
179398|NCT02042235|prematurity
179399|NCT02042235|language
179400|NCT02042235|parent-implemented intervention
179401|NCT02042235|speech therapy
179402|NCT02042235|neurodevelopment
179403|NCT02042222|Sickle cell
179404|NCT02042222|Hydroxyurea
179405|NCT02042222|Dose prediction
179406|NCT02042222|Maximum tolerated dose
179407|NCT02042209|acute coronary syndrome
179408|NCT02042209|thoracic pain
179409|NCT02042209|prehospital
179410|NCT02042209|diagnostic score
179411|NCT02042196|endothelial function
179412|NCT02042196|women
179413|NCT02042196|estrogen deficiency
179414|NCT02042196|sex hormones
179415|NCT02042196|adiposity
179416|NCT02042196|oxidative stress
179417|NCT02042196|antioxidants
179418|NCT02042157|Quality of Life
179419|NCT02042157|Caregivers
179420|NCT02042157|Caregiver burden
179421|NCT02042157|Urinary Tract Infections
179422|NCT02042157|Bidet
179423|NCT02042157|Women's health
179424|NCT02042157|Toileting
179425|NCT02042157|Hygiene
179426|NCT02042157|Activities of Daily Living
179427|NCT02042157|Functional impairment
179428|NCT02042157|Geriatrics
179429|NCT02042144|Neoplasms, Colorectal
179430|NCT02042131|suicide
179431|NCT02042131|suicidal ideation
179432|NCT02042131|ambivalence
179433|NCT02042131|suicide ambivalence
179434|NCT02042131|reasons for living
179435|NCT02042131|reasons for dying
179436|NCT02042131|military
179437|NCT02042131|veteran
179438|NCT02042131|clinical trial
179439|NCT02042131|cognitive behavioral therapy
179440|NCT02042131|psychotherapy
179441|NCT02042131|crisis
179442|NCT02042131|Treatment As Usual (TAU)
179443|NCT02042131|Crisis Response Plan (CRP)
179444|NCT02042131|Enhanced Crisis Response Plan (E-CRP)
179445|NCT02042118|Neonatal resuscitation
179446|NCT02042118|Laryngeal Mask Airway (LMA)
179447|NCT02042118|Face mask ventilation (FMV)
179448|NCT02042118|Uganda
179449|NCT02042118|Africa
179450|NCT02042105|non-small-cell lung cancer
179451|NCT02042105|anaplastic lymphoma kinase
179452|NCT02042105|immunohistochemistry
179453|NCT02042092|Ultrasound
179454|NCT02042092|MRA
179455|NCT02042092|Large Vessel Vasculitis
179456|NCT02042092|Giant Cell Arteritis
179457|NCT02042092|Takayasu Arteritis
179458|NCT02042092|Immunological abnormalities
179459|NCT02042079|Endoscopic full-thickness resection
179460|NCT02042079|gastric subepithelial tumor
179461|NCT02042079|hybrid-NOTES
179462|NCT02042066|Resistant Hypertension
179463|NCT02042066|RH
179464|NCT02042066|RHT
179465|NCT02042066|Blood Pressure
179466|NCT02042066|Kidney
179467|NCT02042066|Shockwave
179468|NCT02042053|imaging
179469|NCT02042053|diagnostic
179470|NCT02042053|castration resistant
179471|NCT02042053|metastatic prostate cancer
179472|NCT02042053|immunotherapy
179473|NCT02042027|corneal neovascularization
179474|NCT02042027|Gamunex-C
179475|NCT02042027|IVI-g
179476|NCT02042027|anterior segment inflammation
179477|NCT02042014|Pulmonary arterial hypertension, QTI571, open label study
179478|NCT02041988|premedication
179479|NCT02041988|oral morphine
179480|NCT02041988|preemptive analgesia
179481|NCT02041975|Prebiotics
179482|NCT02041975|Gut health
179483|NCT02041975|Satisfaction
179484|NCT02041962|Care Management
179485|NCT02041962|Chronic Care Model
179486|NCT02041962|Mood Disorders
179487|NCT02041936|irreversible electroporation
179488|NCT02041936|Nanoknife
179489|NCT02041936|pancreatic cancer
179490|NCT02041923|preterm infant
179491|NCT02041923|stable infant
179492|NCT02041923|mother-infant interaction
179493|NCT02041923|health care cost
179494|NCT02041923|H-HOPE intervention
179495|NCT02041923|mother outcomes
179496|NCT02041923|infant behavioral organization
179497|NCT02041923|infant growth
179498|NCT02041897|EUS-FNA
179499|NCT02041897|Pancreatic cystic lesion
179500|NCT02041897|Diagnosis
179501|NCT02041884|Cognitive Behavioral Therapy
179502|NCT02041884|Dialectical Behavioral Therapy
179503|NCT02041884|Applied Relaxation
179504|NCT02041884|Stress-reduction
179505|NCT02041884|Smartphone application
179506|NCT02041884|ADHD
179507|NCT02041884|Randomized controlled trial
179508|NCT02041884|Psychological treatment
179509|NCT02041884|Efficacy
179510|NCT02041871|Liver Surgery
179511|NCT02041871|Hepatectomy
179512|NCT02041871|Immunonutrition
179513|NCT02041871|Cancer
179514|NCT02041871|Morbidity
179515|NCT02041871|Postoperative complication
179516|NCT02041858|Alarms
179517|NCT02041858|Physiologic Monitoring
179518|NCT02041858|Critical Care
179519|NCT02041858|Alarm fatigue
179520|NCT02041858|Adverse Events
179521|NCT02041845|Radiotherapy
179522|NCT02041845|Radiotherapy dosage
179523|NCT02041845|Dose fractionation
179524|NCT02041845|Radiotherapy, image-guided
179525|NCT02041845|Thorax
179526|NCT02041819|Neoadjuvant chemotherapy
179527|NCT02041819|Nimotuzumab
179528|NCT02041819|Nab-Paclitaxel
179529|NCT02041819|Carcinoma of Esophagus
179530|NCT02041793|Acute pancreatitis
179531|NCT02041793|Pseudocyst
179532|NCT02041780|Diagnostic
179533|NCT02041780|Liver fibrosis
179534|NCT02041780|Ishak score
179535|NCT02041780|Fibrotest
179536|NCT02041780|ShearWave elastography
179537|NCT02041780|Liver biopsies
179538|NCT02041767|Ertapenem; prostatic diffusion; antibioprophylaxy; pharmacokinetics; benign prostatic hyperplasia
179539|NCT02041741|happiness
179540|NCT02041741|well-being
179541|NCT02041741|distress
179542|NCT02041741|positive psychology
179543|NCT02041715|Virus Diseases
179544|NCT02041715|Hemorrhagic Fever, Ebola
179545|NCT02041715|Hemorrhagic Fevers, Viral
179546|NCT02041715|RNA Virus Infections
179547|NCT02041715|Filoviridae Infections
179548|NCT02041715|Mononegavirales Infections
179549|NCT02041702|Bradycardia
179550|NCT02041702|Pacemaker
179551|NCT02041702|Magnetic
179552|NCT02041702|Conditional
179553|NCT02041702|St Jude
179554|NCT02041702|Accent
179555|NCT02041702|Tendril
179556|NCT02041689|Children
179557|NCT02041689|Cancer
179558|NCT02041689|Learning
179559|NCT02041689|Education
179560|NCT02041689|Qualitative
179561|NCT02041676|Chest
179562|NCT02041676|Physiotherapy
179563|NCT02041676|Increased Inspiratory Flow Technique
179564|NCT02041676|Prematurity
179565|NCT02041676|Non Invasive Ventilation
179566|NCT02041663|brain natriuretic peptide
179567|NCT02041663|cardiac function
179568|NCT02041663|meningococcal infections
179569|NCT02041663|septic shock
179570|NCT02041663|severe sepsis
179571|NCT02041637|liver failure
179572|NCT02041637|etiology
179573|NCT02041637|liver transplantation
179574|NCT02041624|allergic
179575|NCT02041624|rhinitis
179576|NCT02041624|conjunctivitis
179577|NCT02041624|grass pollen
179578|NCT02041624|Allergen ImmunoTherapy (AIT)
179579|NCT02041624|grass mix
179580|NCT02041611|WHO grade III and IV
179581|NCT02041585|Hospital Readmission
179582|NCT02041585|Social Isolation and Hospital Readmission
179583|NCT02041585|Age and Hospital Readmission
179584|NCT02041585|Functional Status and Hospital Readmission
179585|NCT02041585|Charlson Score and Hospital Readmission
179586|NCT02041585|Length of Stay and Hospital Readmission
179587|NCT02041546|Lung lavage,
179588|NCT02041546|Surfactant,
179589|NCT02041546|Duration of mechanical
179590|NCT02041546|ventilation
179591|NCT02041520|Seropositive HIV
179592|NCT02041520|Omega 3 fatty acids
179593|NCT02041520|Oxidative stress
179594|NCT02041507|Water-aided colonoscopy
179595|NCT02041507|Water Immersion
179596|NCT02041507|Water Exchange
179597|NCT02041507|On-demand sedation
179598|NCT02041507|Unsedated colonoscopy
179599|NCT02041507|Adenoma detection rate
179600|NCT02041507|Mean adenomas per procedure
179601|NCT02041494|Hernia
179602|NCT02041494|Ventral
179603|NCT02041494|Incisional
179604|NCT02041494|Abdominal
179605|NCT02041494|Herniorrhaphy
179606|NCT02041494|Recurrence
179607|NCT02041494|Infection
179608|NCT02041494|Mesh
179609|NCT02041494|Biologic
179610|NCT02041494|Synthetic
179611|NCT02041468|ALK-positive
179612|NCT02041455|Fibromyalgia
179613|NCT02041455|Melatonin
179614|NCT02041455|Amitriptylin
179615|NCT02041455|Imune-pineal axis
179616|NCT02041442|overactive bladder
179617|NCT02041442|cystoscopy
179618|NCT02041429|Recurrent Breast Cancer
179619|NCT02041429|Advanced Breast Cancer
179620|NCT02041429|Metastatic Breast Cancer
179621|NCT02041416|Geriatric assessment
179622|NCT02041416|REDCap
179623|NCT02041416|touchscreen
179624|NCT02041416|age 65
179625|NCT02041364|Fatigue
179626|NCT02041364|Biomarkers
179627|NCT02041364|Breast Cancer
179628|NCT02041351|metastatic breast cancer
179629|NCT02041351|taxanes
179630|NCT02041351|heavily pretreated
179631|NCT02041312|Cholesterol
179632|NCT02041312|Gastric cancer
179633|NCT02041312|Stage
179634|NCT02041299|sickle cell disease
179635|NCT02041299|Iron overload
179636|NCT02041299|Deferiprone
179637|NCT02041299|Ferriprox
179638|NCT02041299|deferoxamine
179639|NCT02041299|Chelation
179640|NCT02041273|bioavailability
179641|NCT02041273|bioequivalence
179642|NCT02041273|AUC
179643|NCT02041273|Cmax
179644|NCT02041260|Adult
179645|NCT02041260|differentiated thyroid cancer (DTC),
179646|NCT02041260|poorly differentiated thyroid cancer
179647|NCT02041260|not anaplastic thyroid cancer
179648|NCT02041234|Diabetes
179649|NCT02041234|surgical treatment
179650|NCT02041234|medical treatment
179651|NCT02041221|pharmacokinetics, pharmacodynamics, asthma
179652|NCT02041208|Chronic renal anemia
179653|NCT02041208|Hemoglobin
179654|NCT02041208|Kidney transplant
179655|NCT02041195|Overweight
179656|NCT02041182|youth violence
179657|NCT02041182|doctor-patient communication
179658|NCT02041182|health risk behaviors
179659|NCT02041182|pre-visit questionnaires
179660|NCT02041130|Heart Failure
179661|NCT02041130|Heart Failure with Preserved Ejection Fraction
179662|NCT02041104|Metabolic syndrome
179663|NCT02041104|Two month intervention
179664|NCT02041104|Randomised placebo controlled parallel study
179665|NCT02041104|Beta-glucans
179666|NCT02041104|Abdominal fat
179667|NCT02041104|Dyslipidemia
179668|NCT02041104|Insulin resistance
179669|NCT02041104|Hypertension
179670|NCT02041104|Gut Microbiota Composition
179671|NCT02041104|Oral Glucose Tolerance Test
179672|NCT02041104|Lipid Profile
179673|NCT02041104|Real-Time Polymerase Chain Reaction
179674|NCT02041104|Denaturating Gradient Gel Electrophoresis
179675|NCT02041078|Liver surgery
179676|NCT02041078|Blood loss
179677|NCT02041078|CUSA
179678|NCT02041078|Hepatic transection
179679|NCT02041065|Liver transection
179680|NCT02041065|Bloodloss
179681|NCT02041065|Operation time
179682|NCT02041065|Safety
179683|NCT02041065|feasibility
179684|NCT02041026|probiotic
179685|NCT02041026|Yoghurt
179686|NCT02041026|NN20
179687|NCT02041013|Asthma
179688|NCT02041013|Health Literacy
179689|NCT02041000|COPD
179690|NCT02041000|pulmonary
179691|NCT02041000|stem cells
179692|NCT02041000|emphysema
179693|NCT02041000|lungs
179694|NCT02040987|Thorough QT study
179695|NCT02040974|immunotherapy, house dust mites, pollens, allergic rhinitis
179696|NCT02040961|Patients
179697|NCT02040961|Undergoing
179698|NCT02040961|Elective
179699|NCT02040961|Thoracic
179700|NCT02040961|Surgery
179701|NCT02040922|Antibiotics
179702|NCT02040922|Campylobacter
179703|NCT02040922|Diarrhoea
179704|NCT02040922|Enteritis
179705|NCT02040922|Microbiota
179706|NCT02040922|Calprotectin
179707|NCT02040909|sedation
179708|NCT02040909|quality of intubation
179709|NCT02040909|hypotension
179710|NCT02040909|pharmacodynamics
179711|NCT02040909|pharmacokinetics
179712|NCT02040896|computed tomography
179713|NCT02040896|emergency
179714|NCT02040896|CT scan
179715|NCT02040896|ordering behavior
179716|NCT02040896|diagnosis
179717|NCT02040896|radiation
179718|NCT02040883|Schizophrenia
179719|NCT02040883|Tandospirone
179720|NCT02040883|Cognitive Therapy
179721|NCT02040870|Non-Small Cell lung Cancer, NSCLC, ALK, LDK378
179722|NCT02040857|Breast Cancer
179723|NCT02040805|compulsive hoarding
179724|NCT02040805|clutter
179725|NCT02040805|hoarding disorder
179726|NCT02040792|COPD
179727|NCT02040792|Chronic Obstructive Pulmonary Disease
179728|NCT02040779|asthma
179729|NCT02040779|breath-actuated inhaler
179730|NCT02040779|beclomethasone
179731|NCT02040766|asthma
179732|NCT02040766|breath-actuated inhaler
179733|NCT02040766|metered dose inhaler
179734|NCT02040753|Lifestyle intervention
179735|NCT02040753|Change of body composition
179736|NCT02040753|Physical activity
179737|NCT02040753|Weight loss maintenance
179738|NCT02040727|Myokines
179739|NCT02040727|Osteokines
179740|NCT02040727|Glucose homeostasis
179741|NCT02040727|Puberty
179742|NCT02040714|femur head necrosis
179743|NCT02040714|hip
179744|NCT02040714|pediatric orthopedics
179745|NCT02040714|MRI
179746|NCT02040714|Osteonecrosis
179747|NCT02040714|Bone diseases
179748|NCT02040714|Legg Calve Perthes Syndrome
179749|NCT02040662|paravertebral block
179750|NCT02040662|thoracic epidural analgesia
179751|NCT02040662|videothoracoscopic surgery
179752|NCT02040662|lung lobectomy
179753|NCT02040649|Critical care
179754|NCT02040649|Respiration, artificial
179755|NCT02040636|Pertussis
179756|NCT02040636|Tetanus
179757|NCT02040636|Diphtheria
179758|NCT02040636|Poliomyelitis
179759|NCT02040636|Hepatitis B
179760|NCT02040636|Acellular Pertussis Vaccines
179761|NCT02040623|Chronic Graft versus Host Disease
179762|NCT02040623|Keratoconjunctivitis Sicca
179763|NCT02040610|Low Risk Prostate Cancer
179764|NCT02040610|Intermediate Risk Prostate Cancer
179765|NCT02040610|Hypofractionated
179766|NCT02040610|Image Guided Proton Therapy
179767|NCT02040584|De Novo Liver Transplant Recipients, Tacrolimus Minimisation, Everolimus, Renal Function
179768|NCT02040545|Infertility
179769|NCT02040545|In Vitro Fertilization (IVF)
179770|NCT02040545|Venopuncture-free treatment
179771|NCT02040545|Needle-free treatment
179772|NCT02040519|Overactive bladder
179773|NCT02040519|Non obstructive urinary retention
179774|NCT02040519|Sacral neuromodulation
179775|NCT02040506|Acute Myelogenous Leukemia
179776|NCT02040506|Acute Myeloid Leukemia
179777|NCT02040506|Drug therapy
179778|NCT02040506|CD98
179779|NCT02040506|Relapsed
179780|NCT02040506|Refractory
179781|NCT02040506|Monoclonal antibody
179782|NCT02040493|breast cancer
179783|NCT02040493|IORT
179784|NCT02040493|brachytherapy
179785|NCT02040480|bioavailability
179786|NCT02040480|food effect
179787|NCT02040480|formulation
179788|NCT02040480|GSK2110183
179789|NCT02040480|afuresertib
179790|NCT02040480|AKT inhibitor
179791|NCT02040441|Proteomics
179792|NCT02040441|Diabetes
179793|NCT02040441|Chronic kidney disease
179794|NCT02040441|Diabetic nephropathy
179795|NCT02040441|Diabetic retinopathy
179796|NCT02040441|Mineralocorticoid receptor antagonists
179797|NCT02040441|Spironolactone
179798|NCT02040441|Microalbuminuria
179799|NCT02040428|Cardiovascular Diseases
179800|NCT02040428|Fibrin Sealant
179801|NCT02040428|Hemostatics
179802|NCT02040428|Coagulants
179803|NCT02040402|Comparison of pneumococcal conjugated vaccine regimes
179804|NCT02040389|children
179805|NCT02040389|penile
179806|NCT02040389|inguinal
179807|NCT02040389|kidney parents
179808|NCT02040389|anxiety
179809|NCT02040376|Paediatrics
179810|NCT02040376|Medulloblastoma
179811|NCT02040376|Metformin
179812|NCT02040363|COPD
179813|NCT02040363|skeletal muscle
179814|NCT02040363|angiogenesis
179815|NCT02040363|exercise training
179816|NCT02040363|intensity
179817|NCT02040350|Pralidoxime, atropine, organophosphorous poisoning.
179818|NCT02040285|CT colonography
179819|NCT02040259|ischemic stroke
179820|NCT02040259|mechanical thrombectomy device
179821|NCT02040259|Retriever
179822|NCT02040220|CRVO, Macular edema, Aflibercept, anti-VEGF
179823|NCT02040181|renal function, creatinine clearance
179824|NCT02040168|Ventilation
179825|NCT02040168|PTSD
179826|NCT02040168|sedation
179827|NCT02040142|Hyperthermic Intraperitoneal Mitomycin c
179828|NCT02040142|HIPEC
179829|NCT02040142|Cytoreduction
179830|NCT02040116|Rapid Infusion Rituximab
179831|NCT02040103|Deep Vein Thrombosis
179832|NCT02040103|Pulmonary Embolism
179833|NCT02040103|Intermittent Pneumatic Compression
179834|NCT02040103|Pharmacologic DVT
179835|NCT02040103|Prophylaxis
179836|NCT02040103|Critically Ill Patients.
179837|NCT02040077|opioid
179838|NCT02040077|overdose
179839|NCT02040077|OD
179840|NCT02040077|opiate
179841|NCT02040077|prescription opioids
179842|NCT02040077|prescription pain medication
179843|NCT02040077|heroin
179844|NCT02040077|detoxification
179845|NCT02040077|prevention
179846|NCT02040051|intensive care units
179847|NCT02040051|mechanical ventilation
179848|NCT02040051|music therapy
179849|NCT02040038|Diabetes
179850|NCT02040038|Virtual Environment
179851|NCT02040038|Self-Management
179852|NCT02040025|hypertension
179853|NCT02040025|diabetes mellitus
179854|NCT02040025|hemoglobin A1C
179855|NCT02040025|peripheral vascular resistance
179856|NCT02040025|EECP
179857|NCT02040025|Blood pressure
179858|NCT02040025|angiogenesis
179859|NCT02040025|Coronary Artery Disease
179860|NCT02040025|Coronary Disease
179861|NCT02040025|Heart Diseases
179862|NCT02040025|Cardiovascular Diseases
179863|NCT02040012|Type 2 Diabetes Mellitus
179864|NCT02039999|chronic
179865|NCT02039999|cough
179866|NCT02039999|challenge
179867|NCT02039999|ATP
179868|NCT02039999|hypersensitivity
179869|NCT02039999|TRPA1
179870|NCT02039986|cystic fibrosis
179871|NCT02039986|CF
179872|NCT02039986|cystic fibrosis related diabetes
179873|NCT02039986|CFRD
179874|NCT02039986|kalydeco
179875|NCT02039986|ivacaftor
179876|NCT02039973|HIV
179877|NCT02039973|AIDS
179878|NCT02039973|Tanzania
179879|NCT02039973|depression
179880|NCT02039973|perinatal
179881|NCT02039973|psychotherapy
179882|NCT02039973|task-sharing
179883|NCT02039973|problem-solving
179884|NCT02039960|Epidemiology
179885|NCT02039960|Drug Abuse Warning Network (DAWN)
179886|NCT02039960|bupropion
179887|NCT02039960|abuse
179888|NCT02039947|BRAF V600K mutation
179889|NCT02039947|Metastatic Melanoma
179890|NCT02039947|BRAF V600R mutation
179891|NCT02039947|BRAF V600D mutation
179892|NCT02039947|BRAF V600E mutation
179893|NCT02039947|Brain metastases BRAF inhibitor
179894|NCT02039947|Intracranial
179895|NCT02039934|type 2 diabetes
179896|NCT02039934|exercise intervention
179897|NCT02039934|high intensity interval training
179898|NCT02039908|Tolerance to stimulant medication
179899|NCT02039895|Cutaneous T-cell lymphoma
179900|NCT02039895|Helical irradiation of the total skin
179901|NCT02039895|Refractory
179902|NCT02039895|Total skin electron beam therapy
179903|NCT02039882|Acute Coronary Syndrome (ACS)
179904|NCT02039882|Percutaneous Coronary Intervention PCI
179905|NCT02039882|Normals
179906|NCT02039882|Myocardial Infarction MI
179907|NCT02039882|Point of Care POC
179908|NCT02039882|Hypoxanthine
179909|NCT02039882|Inosine
179910|NCT02039882|HPLC High Pressure Liquid Chromatography
179911|NCT02039869|NERD
179912|NCT02039869|Non erosive reflux disease
179913|NCT02039869|functional dyspepsia
179914|NCT02039869|erosive esophagitis
179915|NCT02039869|confocal endomicroscopy
179916|NCT02039869|cell visio
179917|NCT02039869|proton pump inhibitor
179918|NCT02039869|sucralfate
179919|NCT02039856|Patient-centered medical homes
179920|NCT02039856|Primary care
179921|NCT02039856|Women's health
179922|NCT02039856|Veterans
179923|NCT02039830|female
179924|NCT02039830|aging
179925|NCT02039830|physiotherapy
179926|NCT02039830|pelvic floor
179927|NCT02039830|rehabilitation
179928|NCT02039817|pharmacokinetics
179929|NCT02039817|pharmacodynamics
179930|NCT02039817|renal impairment
179931|NCT02039778|Glioblastoma
179932|NCT02039778|High-grade Glioma
179933|NCT02039778|Brain Tums
179934|NCT02039778|Temozolomide
179935|NCT02039778|Stem cell radiation therapy
179936|NCT02039778|IMRT
179937|NCT02039778|Proton beam radiotherapy
179938|NCT02039778|Conventional external beam radiotherapy
179939|NCT02039778|Quality of Life
179940|NCT02039778|Neurocognition
179941|NCT02039765|Ocular Redness
179942|NCT02039752|Multivessel
179943|NCT02039739|Orsiro
179944|NCT02039739|Drug Eluting Stent
179945|NCT02039739|Routine Clinical Practice
179946|NCT02039739|Angioplasty, Transluminal, Percutaneous Coronary
179947|NCT02039739|Coronary Artery Disease
179948|NCT02039726|Acute Myeloid Leukemia
179949|NCT02039726|AML
179950|NCT02039726|FMS-like tyrosine kinase 3
179951|NCT02039726|FLT3-ITD
179952|NCT02039726|Quizartinib
179953|NCT02039726|Leukemia
179954|NCT02039726|Tablets
179955|NCT02039713|DeSyne
179956|NCT02039713|Angioplasty, Transluminal, Percutaneous Coronary
179957|NCT02039713|Coronary Artery Disease
179958|NCT02039687|neuropathy
179959|NCT02039687|sarcoidosis
179960|NCT02039674|PD-1
179961|NCT02039674|PD1
179962|NCT02039674|Programmed Cell Death-1
179963|NCT02039674|Programmed Cell Death 1
179964|NCT02039661|Curettage;
179965|NCT02039661|Pain Score
179966|NCT02039648|Periodontitis
179967|NCT02039648|Porphyromonas gingivalis
179968|NCT02039648|Rumex acetosa L.
179969|NCT02039648|Proanthocyanidins
179970|NCT02039635|cancer
179971|NCT02039635|cancer related fatigue
179972|NCT02039635|Korean red ginseng
179973|NCT02039635|chemotherapy
179974|NCT02039583|live birth
179975|NCT02039583|infant
179976|NCT02039583|infant, newborn
179977|NCT02039583|second-hand smoke
179978|NCT02039583|tobacco smoke pollution
179979|NCT02039583|smoke-free
179980|NCT02039583|smoke-free policy
179981|NCT02039570|haemorrhoids
179982|NCT02039570|pelvic reflux
179983|NCT02039531|Knee
179984|NCT02039531|osteoarthritis
179985|NCT02039531|plasma rich in growth factors
179986|NCT02039531|platelet rich plasma
179987|NCT02039531|hyaluronic acid
179988|NCT02039518|Progression free Survival
179989|NCT02039505|Drug therapy
179990|NCT02039479|anti-suicide
179991|NCT02039479|Lithium
179992|NCT02039479|Depression
179993|NCT02039479|suicidal Ideation/behavior
179994|NCT02039453|Colonoscopy
179995|NCT02039453|sedation
179996|NCT02039453|propofol
179997|NCT02039453|fentanyl
179998|NCT02039453|pethidine
179999|NCT02039427|Sore throat
180000|NCT02039427|Hoarseness
180001|NCT02039427|Intubation
180002|NCT02039427|Thyroidectomy
180003|NCT02039427|Ketorolac
180004|NCT02039427|Dexamethasone
180005|NCT02039414|Obesity
180006|NCT02039414|Physical Inactivity
180007|NCT02039414|Lipid Oxidation
180008|NCT02039414|Oxidative stress
180009|NCT02039414|pregnancy
180010|NCT02039414|neonatal adiposity
180011|NCT02039414|neonatal insulin sensitivity
180012|NCT02039401|ALS
180013|NCT02039401|Lou Gehrig's disease
180014|NCT02039401|neurodegenerative disease
180015|NCT02039388|Ovarian Epithelial Cancer
180016|NCT02039388|Serous Intraepithelial Carcinoma (STIC)
180017|NCT02039388|BRCA1 gene
180018|NCT02039388|BRCA2 gene
180019|NCT02039388|Mutation
180020|NCT02039388|Neoplasms
180021|NCT02039388|Glandular and Epithelial
180022|NCT02039388|Ovarian Neoplasms
180023|NCT02039388|Ovarian cancer
180024|NCT02039388|Carcinoma in situ
180025|NCT02039388|family history breast cancer
180026|NCT02039388|family history ovarian cancer
180027|NCT02039375|IV tPA
180028|NCT02039375|Thrombolysis
180029|NCT02039375|Stroke
180030|NCT02039375|Ischemic
180031|NCT02039375|Monitoring
180032|NCT02039349|Alcoholism
180033|NCT02039349|Ghrelin
180034|NCT02039349|Ghrelin Antagonism
180035|NCT02039323|Tenofovir
180036|NCT02039323|Tenofovir disoproxil
180037|NCT02039323|Maraviroc
180038|NCT02039323|Pharmacologic Actions
180039|NCT02039323|Anti-HIV agents
180040|NCT02039323|Pharmacodynamics
180041|NCT02039297|AWARE, Checklist, ICU, Outcome, Adults
180042|NCT02039284|Cerebral palsy
180043|NCT02039284|novel intervention
180044|NCT02039284|sensory electrical stimulation
180045|NCT02039284|virtual reality
180046|NCT02039284|cycling training
180047|NCT02039284|constraint-induced therapy
180048|NCT02039284|biomechanical
180049|NCT02039284|physiology
180050|NCT02039284|outcome
180051|NCT02039271|music
180052|NCT02039271|total knee replacement
180053|NCT02039271|Pain management
180054|NCT02039258|Healthy Volunteers
180055|NCT02039258|Canagliflozin
180056|NCT02039258|Metformin
180057|NCT02039258|INVOKANA®
180058|NCT02039258|Type 2 diabetes mellitus
180059|NCT02039245|Healthy Volunteers
180060|NCT02039245|Canagliflozin
180061|NCT02039245|Metformin
180062|NCT02039245|INVOKANA®
180063|NCT02039245|Type 2 Diabetes Mellitus
180064|NCT02039206|Machado Joseph disease
180065|NCT02039206|Deep TMS
180066|NCT02039206|TMS
180067|NCT02039206|Transcranial Magnetic Stimulation
180068|NCT02039206|SCA3
180069|NCT02039206|Magnetic Stimulation
180070|NCT02039206|Brainsway
180071|NCT02039193|Generalized anxiety disorder
180072|NCT02039193|cognitive behavior therapy
180073|NCT02039193|adherence
180074|NCT02039180|phase I
180075|NCT02039180|healthy volunteers
180076|NCT02039180|AZD3293
180077|NCT02039180|bioavailability
180078|NCT02039180|Pharmacokinetics
180079|NCT02039154|Exercise
180080|NCT02039154|Exercise tolerance
180081|NCT02039154|Aging
180082|NCT02039154|Physical activity
180083|NCT02039141|diabetes prevention program
180084|NCT02039141|community based interventions
180085|NCT02039141|childhood obesity
180086|NCT02039141|insulin resistance
180087|NCT02039141|glucose tolerance
180088|NCT02039141|quality of life
180089|NCT02039141|Latino youth
180090|NCT02039141|physical activity
180091|NCT02039141|nutrition
180092|NCT02039102|hormonal contraceptives
180093|NCT02039102|combined pills
180094|NCT02039102|progesterone-only contraceptives
180095|NCT02039102|body mass index
180096|NCT02039102|asthma
180097|NCT02039102|Scotland
180098|NCT02039102|women
180099|NCT02039076|Healthy
180100|NCT02039063|Crohn's Disease
180101|NCT02039050|Pulmonary Disease, Chronic Obstructive
180102|NCT02039050|Long-acting muscarinic antagonists
180103|NCT02039050|Impulse oscillometry
180104|NCT02039024|18F-DTBZ
180105|NCT02039011|Asthma
180106|NCT02039011|Long acting beta-agonists
180107|NCT02039011|Long acting muscarinic antagonists
180108|NCT02039011|Mannitol challenge
180109|NCT02038998|stroke
180110|NCT02038998|periodic acceleration
180111|NCT02038998|endothelium release
180112|NCT02038998|ischemic penumbra
180113|NCT02038998|shear stress
180114|NCT02038998|adrenomedullin
180115|NCT02038985|Endometriosis
180116|NCT02038985|Robotic Surgery
180117|NCT02038985|Diagnostic Imaging
180118|NCT02038959|Parkinson disease
180119|NCT02038959|Parkinson's
180120|NCT02038959|Parkinson's disease
180121|NCT02038959|telemedicine
180122|NCT02038959|virtual visits
180123|NCT02038959|video calls
180124|NCT02038959|video conferencing
180125|NCT02038959|virtual house calls
180126|NCT02038920|Drug Therapy
180127|NCT02038907|Norovirus, vaccination
180128|NCT02038894|Anesthetic
180129|NCT02038894|Pediatric
180130|NCT02038894|Esophagogastroduodenoscopies
180131|NCT02038894|Eosinophilic esophagitis
180132|NCT02038894|Gastroesophageal reflux disease (GERD)
180133|NCT02038894|Abdominal Pain
180134|NCT02038894|Vomiting
180135|NCT02038894|Sevofluorane
180136|NCT02038894|Propofol
180137|NCT02038894|Nasal cannula
180138|NCT02038894|Intubation
180139|NCT02038894|Endotracheal tube
180140|NCT02038868|BPH
180141|NCT02038868|ASP4901
180142|NCT02038855|Dual-diagnosis
180143|NCT02038855|Latino
180144|NCT02038855|Mental health
180145|NCT02038855|Substance use
180146|NCT02038855|HIV risk
180147|NCT02038829|COPD
180148|NCT02038803|Cystic Fibrosis Medication Adherence
180149|NCT02038790|opioid dependence
180150|NCT02038790|buprenorphine/naloxone
180151|NCT02038777|Hematologic Malignancies
180152|NCT02038764|Phase 1
180153|NCT02038764|RN168
180154|NCT02038764|Adults
180155|NCT02038764|Type 1 Diabetes
180156|NCT02038764|T1D
180157|NCT02038751|Genotyping
180158|NCT02038751|Phenotyping
180159|NCT02038751|Sleep Apnea
180160|NCT02038751|Genetic Association Studies
180161|NCT02038751|Phenotype
180162|NCT02038738|gallium
180163|NCT02038738|Ga
180164|NCT02038738|PET Scan
180165|NCT02038725|Risks
180166|NCT02038725|Risk Factors
180167|NCT02038725|ABCD2 score
180168|NCT02038725|Predictive Value of Tests
180169|NCT02038725|Risk Assessment
180170|NCT02038725|Severity of Illness Index
180171|NCT02038725|Decision Support Techniques
180172|NCT02038712|Obesity
180173|NCT02038712|Binge eating disorder
180174|NCT02038712|fMRI
180175|NCT02038712|gut hormones
180176|NCT02038686|Hip fracture
180177|NCT02038686|Unstable (31A2 and 31A3)
180178|NCT02038686|Proximal femoral nail
180179|NCT02038673|ASP5878
180180|NCT02038673|FGFR 1,2,3 and 4 inhibitor
180181|NCT02038660|Coronary Artery Disease
180182|NCT02038660|Angioplasty, Balloon
180183|NCT02038634|wrist
180184|NCT02038634|tendonitis
180185|NCT02038634|dequervain's
180186|NCT02038634|tenosynovitis
180187|NCT02038608|Parkinson
180188|NCT02038608|serotonin
180189|NCT02038608|dopamine
180190|NCT02038608|non motor
180191|NCT02038608|progression
180192|NCT02038608|PET
180193|NCT02038595|brown adipose tissue
180194|NCT02038582|HIV
180195|NCT02038582|HIV Counseling and Testing
180196|NCT02038582|Linkages to Care
180197|NCT02038582|Point of Care CD4
180198|NCT02038582|Point of Care Viral Load
180199|NCT02038543|Hyperoxaluria
180200|NCT02038543|Oxalate
180201|NCT02038543|Primary Hyperoxaluria
180202|NCT02038543|PH
180203|NCT02038530|Deep Vein Thrombosis
180204|NCT02038517|Insulin secretion
180205|NCT02038517|Insulin sensitivity
180206|NCT02038517|Orthotopic liver transplantation
180207|NCT02038517|Type 2 diabetes
180208|NCT02038517|Metabolic syndrome
180209|NCT02038517|Cardiovascular disease
180210|NCT02038504|gastrointestinal fistula
180211|NCT02038504|enteral nutrition
180212|NCT02038504|thyroid function
180213|NCT02038491|Epidural anesthesia
180214|NCT02038491|Spinal anesthesia
180215|NCT02038491|nerve blocks
180216|NCT02038491|complications
180217|NCT02038478|Sickle Cell Disease
180218|NCT02038478|Thalassemia
180219|NCT02038452|hand
180220|NCT02038452|wrist
180221|NCT02038452|carpal
180222|NCT02038452|tunnel
180223|NCT02038452|syndrome
180224|NCT02038452|pragmatic
180225|NCT02038452|randomised
180226|NCT02038452|steroid
180227|NCT02038452|splint
180228|NCT02038439|Evidence-Based Medicine
180229|NCT02038439|Evidence Retrieval
180230|NCT02038439|Knowledge Translation
180231|NCT02038439|Medical Education
180232|NCT02038413|NSCLC
180233|NCT02038413|cT1/cT2aN0M0
180234|NCT02038413|Stereotactic lung treatment
180235|NCT02038413|MAASTRO
180236|NCT02038413|age >18 years
180237|NCT02038335|immune cells
180238|NCT02038335|contraception
180239|NCT02038335|intrauterine device
180240|NCT02038335|IUD
180241|NCT02038335|copper
180242|NCT02038335|microbiota
180243|NCT02038335|DMPA
180244|NCT02038335|etonogestrel
180245|NCT02038335|subdermal implant
180246|NCT02038335|NET-EN
180247|NCT02038335|Jadelle
180248|NCT02038335|Implanon
180249|NCT02038335|Cyclofem
180250|NCT02038322|OTC Home Use Conception Aid Cervical Cap Insemination
180251|NCT02038309|Acute coronary syndrome
180252|NCT02038309|persistent platelet reactivity
180253|NCT02038296|Hepatocellular carcinoma
180254|NCT02038296|Transarterial chemoembolization
180255|NCT02038296|Gemcitabine
180256|NCT02038283|Colorectal Neoplasms
180257|NCT02038283|Early Detection of Cancer
180258|NCT02038283|Quality of Life
180259|NCT02038283|Quality-Adjusted Life Years
180260|NCT02038283|Direct Service Costs
180261|NCT02038283|Cost-Benefit Analysis
180262|NCT02038231|Adolescence
180263|NCT02038231|Substance abuse
180264|NCT02038231|Mindfulness
180265|NCT02038218|DM-CHOC-PEN
180266|NCT02038218|CNS
180267|NCT02038218|brain
180268|NCT02038218|melanoma
180269|NCT02038218|lung cancer
180270|NCT02038218|breast cancer
180271|NCT02038218|glioblastoma multiforme
180272|NCT02038218|primary brain tumors
180273|NCT02038192|Caregiver
180274|NCT02038192|Dementia
180275|NCT02038192|Long Term Care
180276|NCT02038192|Hope
180277|NCT02038192|Quality of Life
180278|NCT02038192|Intervention
180279|NCT02038179|Pre-hypertension
180280|NCT02038179|JNC 7 stage I hypertension
180281|NCT02038140|Primary Ankle Replacement
180282|NCT02038140|Total Ankle Arthroplasty
180283|NCT02038140|Total Ankle Replacement
180284|NCT02038140|Trabecular Metal Total Ankle
180285|NCT02038114|Odette Cancer Centre at Sunnybrook Health Sciences Centre
180286|NCT02038114|Toronto
180287|NCT02038114|Ontario
180288|NCT02038088|Need general anesthesia
180289|NCT02038075|suicide
180290|NCT02038075|suicidal ideation
180291|NCT02038075|military
180292|NCT02038075|veteran
180293|NCT02038075|cognitive behavioral therapy
180294|NCT02038075|behavioral therapy
180295|NCT02038075|psychotherapy
180296|NCT02038075|Brief Cognitive Behavioral Therapy (BCBT)
180297|NCT02038075|Treatement As Usual (TAU)
180298|NCT02038049|Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Magnetic Resonance Imaging, VAY736, monoclonal antibody, gadolinium [Gd]-enhancing lesions, B-Cell
180299|NCT02038036|Polycythemia Vera
180300|NCT02038036|Hematologic Diseases
180301|NCT02038036|Myeloproliferative Disorders
180302|NCT02038036|Bone Marrow Diseases
180303|NCT02038036|Hydroxyurea
180304|NCT02038036|INC424
180305|NCT02038036|Ruxolitinib
180306|NCT02038023|Iv iron in pregnant women
180307|NCT02038023|second and third trimester
180308|NCT02037997|PFS
180309|NCT02037971|Systemic Lupus Erythematosus
180310|NCT02037971|Lupus
180311|NCT02037971|Sleep disorders
180312|NCT02037971|Sleep disturbed
180313|NCT02037971|Physical exercise
180314|NCT02037971|Aerobic exercise
180315|NCT02037945|18F-Fluorocholine (18F-FCho)
180316|NCT02037945|Pet Scan
180317|NCT02037945|MRI
180318|NCT02037945|13-199
180319|NCT02037932|Aneurysm
180320|NCT02037932|Brain Aneurysm
180321|NCT02037906|Renal stones
180322|NCT02037906|SWL
180323|NCT02037880|Mucopolysaccharidosis
180324|NCT02037880|MPS
180325|NCT02037880|Sanfilippo
180326|NCT02037867|alcohol
180327|NCT02037867|type 2 diabetes
180328|NCT02037867|ALT
180329|NCT02037867|abnormal liver enzymes
180330|NCT02037867|hepatic fibrosis
180331|NCT02037867|cirrhosis
180332|NCT02037841|Asthma
180333|NCT02037841|Nursing
180334|NCT02037841|Protocol
180335|NCT02037841|PRAM
180336|NCT02037841|Length of Stay
180337|NCT02037841|Weaning
180338|NCT02037841|Clinical pathway
180339|NCT02037841|Asthma exacerbation
180340|NCT02037828|COPD
180341|NCT02037828|biomarker
180342|NCT02037828|EBC
180343|NCT02037828|FEV1
180344|NCT02037815|hyperosmolar drugs
180345|NCT02037815|mannitol
180346|NCT02037815|hypertonic saline
180347|NCT02037815|serum osmolality
180348|NCT02037815|correlation
180349|NCT02037802|caudal
180350|NCT02037802|epidural
180351|NCT02037802|pediatric
180352|NCT02037802|renal
180353|NCT02037802|transplant
180354|NCT02037802|hemodynamics
180355|NCT02037789|pain
180356|NCT02037789|low back pain
180357|NCT02037789|GWAS
180358|NCT02037789|glycomics
180359|NCT02037789|activomics
180360|NCT02037776|Rikkunshito
180361|NCT02037776|Double blind
180362|NCT02037776|Functional dyspepsia (FD)
180363|NCT02037763|Low back pain
180364|NCT02037763|GWAS
180365|NCT02037763|Glycomics
180366|NCT02037763|Activomics
180367|NCT02037763|Epigenetics
180368|NCT02037750|foster care
180369|NCT02037750|school adjustment
180370|NCT02037711|Laparoscopic
180371|NCT02037711|Levobupivacaine
180372|NCT02037711|Pediatric
180373|NCT02037711|Anesthesia
180374|NCT02037711|Instillation
180375|NCT02037711|surgeries
180376|NCT02037698|CTO
180377|NCT02037698|CT
180378|NCT02037698|Revascularization
180379|NCT02037685|Statins
180380|NCT02037685|Cholesterol lowering medications
180381|NCT02037685|Adherence
180382|NCT02037685|Motivational interviewing
180383|NCT02037685|Minority populations
180384|NCT02037672|PCOS
180385|NCT02037672|PDE-4 inhibitor
180386|NCT02037672|roflumilast
180387|NCT02037672|metformin
180388|NCT02037672|obesity
180389|NCT02037646|Colorectal cancer
180390|NCT02037646|Screening
180391|NCT02037646|Fecal occult blood
180392|NCT02037646|Fecal immunochemical test
180393|NCT02037646|Qualitative
180394|NCT02037646|Quantitative
180395|NCT02037620|Epidural Stimulation
180396|NCT02037607|Deep vein thrombosis
180397|NCT02037607|Children
180398|NCT02037607|Pediatric
180399|NCT02037607|Anti-coagulant
180400|NCT02037607|Neurosurgical procedures
180401|NCT02037607|Blood Clot
180402|NCT02037594|HIV
180403|NCT02037594|Pre-exposure prophylaxis
180404|NCT02037594|PrEP
180405|NCT02037594|MSM
180406|NCT02037594|Demonstration Project
180407|NCT02037581|integrated care
180408|NCT02037581|hometreatment
180409|NCT02037581|assertive community treatment (ACT)
180410|NCT02037581|psychosis
180411|NCT02037581|schizophrenia
180412|NCT02037581|bipolar disorder
180413|NCT02037581|first episode
180414|NCT02037568|depression
180415|NCT02037568|stress
180416|NCT02037568|caregiving
180417|NCT02037568|anxiety
180418|NCT02037568|psychoeducation intervention
180419|NCT02037568|psycho-oncology
180420|NCT02037568|allogeneic hematopoietic stem cell transplant
180421|NCT02037555|Antithrombin
180422|NCT02037555|Cardiopulmonary bypass
180423|NCT02037542|BMI, Lipid profile
180424|NCT02037529|Breast Cancer
180425|NCT02037529|Metastatic
180426|NCT02037529|Locally Recurrent
180427|NCT02037516|residual muscle weakness, respiratory events
180428|NCT02037490|Infants
180429|NCT02037490|Mothers
180430|NCT02037490|Social media
180431|NCT02037490|Obesity prevention
180432|NCT02037464|Prostate Cancer
180433|NCT02037464|Active Surveillance
180434|NCT02037464|Radical Prostatectomy
180435|NCT02037451|Parkinson's disease
180436|NCT02037451|Auditory Cueing
180437|NCT02037438|Clinical sleep medicine
180438|NCT02037438|New methodology for healthcare delivery
180439|NCT02037438|Diagnosis and treatment of sleep disorders
180440|NCT02037438|Electronic health records
180441|NCT02037438|Clinical informatics
180442|NCT02037438|Evidence-based comparative effectiveness research
180443|NCT02037438|Sleep specialists
180444|NCT02037438|Primary care providers
180445|NCT02037438|Allied health professionals
180446|NCT02037438|Patient-centered care
180447|NCT02037425|Chronic Migraine
180448|NCT02037425|onabotulinumtoxinA
180449|NCT02037425|Headache
180450|NCT02037425|Migraine
180451|NCT02037425|Neuronal regrowth
180452|NCT02037425|Botox
180453|NCT02037412|Ticagrelor
180454|NCT02037412|strut coverage
180455|NCT02037412|DES
180456|NCT02037412|ACS
180457|NCT02037412|OCT
180458|NCT02037399|Endoscopic submucosal dissection
180459|NCT02037399|early gastric cancer
180460|NCT02037399|pain relief
180461|NCT02037399|intravenous dexamethasone
180462|NCT02037399|present pain intensity
180463|NCT02037386|Side branch stent
180464|NCT02037386|Coronary bifurcation lesion
180465|NCT02037373|intra and post-op coagulopathy in patients undergoing OLT
180466|NCT02037360|Smoking
180467|NCT02037360|Cessation
180468|NCT02037334|Preterm delivery
180469|NCT02037334|Diagnostics
180470|NCT02037334|Biomechanics
180471|NCT02037321|Systematic review and meta-analysis
180472|NCT02037308|Glu298Asp polymorphism
180473|NCT02037308|Blood pressure
180474|NCT02037308|Plasma NOx
180475|NCT02037308|Beetroot
180476|NCT02037295|Gut Microbiota
180477|NCT02037295|Obesity
180478|NCT02037295|Absorption
180479|NCT02037295|Overfeeding
180480|NCT02037282|HAI Titer
180481|NCT02037282|Hemagglutination Inhibition Assays
180482|NCT02037282|Immunogenicity
180483|NCT02037282|Serum Antibody Response
180484|NCT02037269|Cerenkov Luminescence Imaging, CLI, margin status
180485|NCT02037243|behavior change
180486|NCT02037243|handwashing
180487|NCT02037243|water treatment
180488|NCT02037243|disgust
180489|NCT02037243|shame
180490|NCT02037243|neighbour
180491|NCT02037243|willingness to pay
180492|NCT02037204|IMPACT
180493|NCT02037204|Chondrons
180494|NCT02037204|Mesenchymal stem cells
180495|NCT02037204|Allogeneic MSCs
180496|NCT02037204|single-stage
180497|NCT02037204|Cartilage repair
180498|NCT02037204|Safety
180499|NCT02037204|Efficacy
180500|NCT02037191|ALOPECIA AREATA
180501|NCT02037191|TREATMENT METHOTREXATE
180502|NCT02037178|Peripheral Obliterative Arteriopathy of the legs
180503|NCT02037178|Screening by generalists
180504|NCT02037178|Ultrasound
180505|NCT02037152|Chronic pain
180506|NCT02037152|Mobile applications
180507|NCT02037152|Mindfulness
180508|NCT02037152|Meditation
180509|NCT02037152|Telemedicine
180510|NCT02037152|Cellular phone
180511|NCT02037152|Pain Management
180512|NCT02037152|Therapy, computer-assisted
180513|NCT02037139|Hearing loss
180514|NCT02037139|Tinnitus
180515|NCT02037139|Screening
180516|NCT02037139|Primary Care
180517|NCT02037113|IVUS
180518|NCT02037113|PAD
180519|NCT02037113|Femoro-popliteal disease
180520|NCT02037113|Intravascular ultrasound
180521|NCT02037087|Short Message Service
180522|NCT02037087|newborn health
180523|NCT02037087|maternal behavior
180524|NCT02037087|good household pregnancy practice
180525|NCT02037087|care seeking
180526|NCT02037074|Phosphodiesterase 10 inhibitor
180527|NCT02037022|Autism Spectrum Disorder (ASD)
180528|NCT02037022|Autism
180529|NCT02036983|Ultrasound guided
180530|NCT02036983|Bilateral Transversus abdominis Plane Block
180531|NCT02036983|Dexamethasone
180532|NCT02036983|Preperitoneal Instillation
180533|NCT02036983|Local Analgesic
180534|NCT02036983|Efficacy
180535|NCT02036983|Total Extraperitoneal Bilateral Inguinal hernia repair
180536|NCT02036970|Pulmonary Arterial Hypertension
180537|NCT02036970|PAH
180538|NCT02036970|Bardoxolone methyl
180539|NCT02036970|6-minute walk distance
180540|NCT02036970|CDDO-me
180541|NCT02036970|RTA 402
180542|NCT02036970|Pulmonary Hypertension
180543|NCT02036957|capecitabine
180544|NCT02036957|dermatologic toxicity
180545|NCT02036944|Celiac Disease
180546|NCT02036944|Celiac Sprue
180547|NCT02036944|Iron-Deficiency Anemia
180548|NCT02036931|Joint
180549|NCT02036931|Osteoarthritis
180550|NCT02036931|Avascular Necrosis
180551|NCT02036918|castrate resistant prostate cancer
180552|NCT02036918|metastatic
180553|NCT02036918|sipuleucel-T
180554|NCT02036918|lymphadenectomy
180555|NCT02036918|Excisional lymph node biopsy
180556|NCT02036905|neck pain, orthopedic manual therapy
180557|NCT02036892|Diabetes
180558|NCT02036879|Cystic Fibrosis
180559|NCT02036879|Loestrin
180560|NCT02036879|Hormone
180561|NCT02036866|knee osteoarthritis
180562|NCT02036866|grade I and II knee osteoarthritis
180563|NCT02036866|arthritis
180564|NCT02036853|Triheptanoin
180565|NCT02036853|Glut1 DS
180566|NCT02036853|Epilepsy
180567|NCT02036853|Seizures
180568|NCT02036827|Pain, Postoperative
180569|NCT02036827|Neuromuscular Blocking Agents
180570|NCT02036827|Laparoscopy
180571|NCT02036814|Hypertension
180572|NCT02036814|Nursing
180573|NCT02036814|Therapeutic compliance
180574|NCT02036814|Quality of life
180575|NCT02036814|Health education
180576|NCT02036801|ARDS
180577|NCT02036801|Lung
180578|NCT02036801|Specific Elastance
180579|NCT02036801|Pediatric patients
180580|NCT02036788|Esophageal pressure, Mechanical ventilation
180581|NCT02036762|Chronic Obstructive Pulmonary Disease
180582|NCT02036762|Thoracoabdominal Mechanics
180583|NCT02036762|Functional capacity
180584|NCT02036762|Quality of life
180585|NCT02036736|Orthopedic Surgery
180586|NCT02036736|Total hip prosthesis
180587|NCT02036736|Total knee replacement
180588|NCT02036736|Intraoperative anesthetic strategy
180589|NCT02036736|Propofol
180590|NCT02036736|Desflurane
180591|NCT02036723|Macular Degeneration
180592|NCT02036723|Eye Diseases
180593|NCT02036723|Neovascular Macular Degeneration
180594|NCT02036723|Choroidal Neovascularization
180595|NCT02036723|Geographic Atrophy
180596|NCT02036710|GLP-1
180597|NCT02036710|PYY
180598|NCT02036710|Leptin
180599|NCT02036710|Duodenal Switch
180600|NCT02036697|Cesarean section
180601|NCT02036697|spinal anesthesia
180602|NCT02036697|low dose spinal
180603|NCT02036697|bupivacaine
180604|NCT02036697|hemodynamics
180605|NCT02036697|blood pressure
180606|NCT02036697|cardiac output
180607|NCT02036684|Prostate cancer
180608|NCT02036684|Radical prostatectomy
180609|NCT02036684|Prehabilitation
180610|NCT02036684|Pelvic floor muscle exercises
180611|NCT02036671|Arteriovenous fistula
180612|NCT02036671|Fistula
180613|NCT02036671|Chronic kidney disease
180614|NCT02036671|Percutaneous
180615|NCT02036671|Kidney Disease
180616|NCT02036671|Kidney Failure, Chronic
180617|NCT02036671|Urologic Diseases
180618|NCT02036671|Renal Insufficiency, Chronic
180619|NCT02036671|Renal Insufficiency
180620|NCT02036671|CKD
180621|NCT02036671|hemodialysis
180622|NCT02036658|social anxiety
180623|NCT02036658|treatment
180624|NCT02036619|gestational diabetes
180625|NCT02036619|pregestational diabetes
180626|NCT02036619|screening
180627|NCT02036619|diagnostic criteria
180628|NCT02036619|IADPSG
180629|NCT02036593|Cardiovascular Risk Factors
180630|NCT02036580|Japan
180631|NCT02036580|Phase2
180632|NCT02036580|Safety
180633|NCT02036580|Tolerability
180634|NCT02036580|Idiopathic Pulmonary Fibrosis
180635|NCT02036580|IPF
180636|NCT02036580|CAT-354
180637|NCT02036580|Tralokinumab
180638|NCT02036541|Glaucoma Implant
180639|NCT02036541|Trabeculectomy
180640|NCT02036541|POAG
180641|NCT02036541|Primary Open Angle Glaucoma
180642|NCT02036541|Pseudoexfoliation Glaucoma
180643|NCT02036541|Pigmentary Glaucoma
180644|NCT02036528|Foot Ulcer
180645|NCT02036528|Diabetic Foot
180646|NCT02036528|Gentamicins
180647|NCT02036528|infection
180648|NCT02036502|PD1
180649|NCT02036502|PD-1
180650|NCT02036502|PDL1
180651|NCT02036502|PD-L1
180652|NCT02036476|Merkel Cell Carcinoma
180653|NCT02036476|Skin Cancer
180654|NCT02036463|Duchenne Muscular Dystrophy
180655|NCT02036463|Corticosteroids
180656|NCT02036450|atrial fibrillation
180657|NCT02036450|cardiac arrhythmia
180658|NCT02036450|stroke
180659|NCT02036450|implantable loop recorder
180660|NCT02036450|bleeding
180661|NCT02036450|anticoagulation
180662|NCT02036450|hypertension
180663|NCT02036450|diabetes
180664|NCT02036450|heart failure
180665|NCT02036450|mortality
180666|NCT02036437|Induction of Labor
180667|NCT02036437|Misoprostol
180668|NCT02036411|clomiphene citrate
180669|NCT02036411|amh
180670|NCT02036411|inhibin b
180671|NCT02036398|Percutaneous Nephrolithotomy (PCNL)
180672|NCT02036398|Nephrostomy
180673|NCT02036398|Double J stent
180674|NCT02036398|PleuraL Effusion
180675|NCT02036398|Pain
180676|NCT02035332|Excessive Uterine Bleeding
180677|NCT02035332|Menorrhagia
180678|NCT02035332|Endometrial Ablation
180679|NCT02036372|glucose
180680|NCT02036372|diabetes mellitus
180681|NCT02036372|perioperative
180682|NCT02036359|Non-small Cell Lung Cancer(NSCLC)
180683|NCT02036346|ileostomy
180684|NCT02036346|colorectal resection
180685|NCT02036346|dehydration
180686|NCT02036346|nutritional status
180687|NCT02036333|near infrared spectroscopy
180688|NCT02036333|pediatrics
180689|NCT02036307|Fish oils
180690|NCT02036307|Triglycerides
180691|NCT02036307|Blood pressure
180692|NCT02036294|Patient self-care behaviors
180693|NCT02036294|Patient activation
180694|NCT02036294|Family caregiver support
180695|NCT02036294|Patient-centered care
180696|NCT02036281|Terminally ill , histologically-confirmed advanced cancer
180697|NCT02036281|Pain unrelieved by opioids
180698|NCT02036268|Ostomy education
180699|NCT02036268|Education
180700|NCT02036268|care of ostomy site
180701|NCT02036255|Prevention, Thrombosis, Hemodialysis, Vascular access device
180702|NCT02036242|Opioid
180703|NCT02036242|Local anesthetic
180704|NCT02036242|Labor delivery
180705|NCT02036242|Safety
180706|NCT02036229|demodex
180707|NCT02036229|demodicidosis
180708|NCT02036229|rosacea
180709|NCT02036229|ivermectin
180710|NCT02036216|Hepatocellular Carcinoma；cell free tumor DNA; Mutation;
180711|NCT02036190|COPD, chronic obstructive pulmonary disease, emphysema
180712|NCT02036164|Locally advanced cervical cancer
180713|NCT02036164|Concurrent chemoradiation
180714|NCT02036164|Adjuvant chemotherapy
180715|NCT02036151|Xylitol
180716|NCT02036151|prevention
180717|NCT02036151|Mutans streptococci
180718|NCT02036151|caries
180719|NCT02036151|plaque
180720|NCT02036151|children
180721|NCT02036125|Corticosteroid
180722|NCT02036125|Ultrasound
180723|NCT02036125|Guided injection
180724|NCT02036112|Advanced Lower rectal cancer
180725|NCT02036112|Extralevator abdominoperineal excision
180726|NCT02036112|Circumferential resection margin
180727|NCT02036112|Morbidity
180728|NCT02036112|Survival
180729|NCT02036099|Dementia
180730|NCT02036099|Automobile driving
180731|NCT02036099|Accidents, traffic
180732|NCT02036086|Melanoma stage IIIB or C with BRAF mutation
180733|NCT02036086|Recurrent regional lymphadenopathy not suitable for surgery
180734|NCT02036086|Eligible for neoadjuvant vemurafenib and cobimetinib
180735|NCT02036073|erythropoietin
180736|NCT02036073|preterm
180737|NCT02036073|brain injury
180738|NCT02036073|cerebral palsy
180739|NCT02036073|PVL
180740|NCT02036060|Metastatic prostate cancer
180741|NCT02036060|Abiraterone acetate
180742|NCT02036021|pediatric anesthesia
180743|NCT02036021|perioperative respiratory events
180744|NCT02036021|days of hospitalization
180745|NCT02036021|cost of hospitalization
180746|NCT02036008|Liver metastases
180747|NCT02036008|MRI
180748|NCT02036008|Contrast Agents
180749|NCT02035995|gestational diabetes mellitus; optical coherence tomography; pregnancy; retinal nerve fiber layer.
180750|NCT02035956|IVAC MUTANOME
180751|NCT02035956|IVAC
180752|NCT02035956|personalized therapy
180753|NCT02035956|personalized immuno therapy
180754|NCT02035956|RB_0004-01
180755|NCT02035956|Ribological
180756|NCT02035956|Melanoma
180757|NCT02035956|cancer vaccine
180758|NCT02035930|Bispectral Index Monitor, Menstrual Cycle, Dexmedetomidine
180759|NCT02035891|colchicine
180760|NCT02035891|urinary albumin-to-creatinine ratio
180761|NCT02035891|carotid Intima-Media Thickness
180762|NCT02035891|overt nephropathy
180763|NCT02035891|Type 2 diabetes
180764|NCT02035878|anxiety
180765|NCT02035878|depression
180766|NCT02035878|probiotics
180767|NCT02035878|adult
180768|NCT02035878|human
180769|NCT02035878|depression anxiety stress scale
180770|NCT02035878|anxiety sensitivity index
180771|NCT02035865|Psychiatric morbidity
180772|NCT02035865|Cognitive function
180773|NCT02035865|Heart transplantation
180774|NCT02035865|Mortality
180775|NCT02035865|Cardiac allograft vasculopathy
180776|NCT02035839|Target Temperature Management
180777|NCT02035839|Cooling comatose survivors from OHCA
180778|NCT02035839|Good neurological outcome at modified Rankin Score (mRS) ≤ 3
180779|NCT02035813|metastatic breast cancer
180780|NCT02035813|circulating tumor cells
180781|NCT02035813|everolimus
180782|NCT02035813|eribulin
180783|NCT02035800|Rheumatoid Arthritis
180784|NCT02035800|Adalimumab
180785|NCT02035800|Humira
180786|NCT02035787|metformin
180787|NCT02035787|endometrial cancer
180788|NCT02035787|Lineberger Comprehensive Cancer Center
180789|NCT02035787|complex atypical hyperplasia
180790|NCT02035774|Brachial plexus block
180791|NCT02035774|Suprascapular nerve block
180792|NCT02035761|MSA
180793|NCT02035761|Shy-Dragers Syndrome
180794|NCT02035761|Possible or Probable
180795|NCT02035748|Vitreomacular traction
180796|NCT02035748|Symptomatic vitreomacular adhesion
180797|NCT02035748|Ocriplasmin
180798|NCT02035748|JETREA
180799|NCT02035735|NBI,
180800|NCT02035735|squamous cell carcinoma,
180801|NCT02035735|pharynx, larynx, surgical margins.
180802|NCT02035709|Therapy
180803|NCT02035696|influenza
180804|NCT02035696|children
180805|NCT02035696|safety
180806|NCT02035696|tolerability
180807|NCT02035696|immunogenicity
180808|NCT02035683|metabolic response
180809|NCT02035683|chemotherapy
180810|NCT02035670|diagnostic strategy
180811|NCT02035670|effectiveness
180812|NCT02035670|fever of unknown origin
180813|NCT02035657|Merkel cell carcinoma
180814|NCT02035657|MCC
180815|NCT02035631|Breast Neoplasms
180816|NCT02035631|Recurrence
180817|NCT02035631|Motor Activity
180818|NCT02035631|Diet
180819|NCT02035631|Quality of Life
180820|NCT02035579|concussion
180821|NCT02035579|mild traumatic brain injury
180822|NCT02035579|post-concussion syndrome
180823|NCT02035579|adolescents
180824|NCT02035579|sports injury
180825|NCT02035579|aerobic training
180826|NCT02035579|stretching training
180827|NCT02035566|Minority Health
180828|NCT02035566|Health Status Disparities
180829|NCT02035566|Health Care Disparities
180830|NCT02035566|Rural Health
180831|NCT02035566|Telemedicine
180832|NCT02035566|Health Services Research
180833|NCT02035566|Social Determinants of Health
180834|NCT02035566|Ecological Theory of Health
180835|NCT02035527|squamous cell carcinoma
180836|NCT02035527|head and neck
180837|NCT02035514|multiple sclerosis
180838|NCT02035514|mesenchymal stem cells
180839|NCT02035514|autologous transplantation
180840|NCT02035514|MRI efficacy
180841|NCT02035514|clinical safety
180842|NCT02035488|Dry powder inhalation
180843|NCT02035488|Bronchiectasis
180844|NCT02035488|Tobramycin
180845|NCT02035475|Prevention
180846|NCT02035475|Pelvic Lymph Node Dissection
180847|NCT02035475|Lymphoceles
180848|NCT02035475|Prostate Malignancies
180849|NCT02035475|daVinci
180850|NCT02035475|Vessel Sealer
180851|NCT02035475|EndoWrist One
180852|NCT02035449|Video laryngoscope
180853|NCT02035449|Pre-hospital
180854|NCT02035449|Endotracheal intubation
180855|NCT02035449|Difficult endotracheal intubation
180856|NCT02035449|Pre hospital Critical care
180857|NCT02035449|McGrath MAC
180858|NCT02035449|Airway device
180859|NCT02035436|Respiration, artificial
180860|NCT02035436|Critcal care
180861|NCT02035423|Vitamin D Deficiency
180862|NCT02035423|Compliance
180863|NCT02035423|Milk
180864|NCT02035410|cardiac devices
180865|NCT02035410|prevention
180866|NCT02035410|infection
180867|NCT02035397|botulinum toxin
180868|NCT02035397|Endoscopy
180869|NCT02035397|Satiation
180870|NCT02035397|Diet
180871|NCT02035397|Weight Loss
180872|NCT02035358|Metastatic
180873|NCT02035358|Recurrent
180874|NCT02035358|Refractory
180875|NCT02035358|Renal Cell Carcinoma
180876|NCT02035358|Kidney
180877|NCT02035358|clear-cell renal cancer
180878|NCT02035358|Cancer
180879|NCT02035345|Recurrent Ovarian Cancer
180880|NCT02035345|Platinum Sensitive Ovarian Cancer
180881|NCT02035293|COPD Exacerbation
180882|NCT02035293|Pulmonary embolism
180883|NCT02035293|Standardized and consensus diagnostic strategy
180884|NCT02035280|Spine
180885|NCT02035280|Deformity
180886|NCT02035280|Fusion
180887|NCT02035280|Elderly
180888|NCT02035280|SRS-22r
180889|NCT02035241|Spices
180890|NCT02035241|Herbs
180891|NCT02035241|Functional food
180892|NCT02035241|Cardiometabolic risk
180893|NCT02035241|Metabolic syndrome
180894|NCT02035241|Inflammation
180895|NCT02035241|Appetite
180896|NCT02035241|Gut hormone
180897|NCT02035228|Chronic Obstructive Pulmonary Disease
180898|NCT02035228|Lung Hyperinflation
180899|NCT02035228|Abdominal Muscle
180900|NCT02035228|Functional Electrical Stimulation
180901|NCT02035215|Hyperlipidemia, Familial Combined
180902|NCT02035215|Omega 3 acids ethylesters 90
180903|NCT02035215|Atorvastatin
180904|NCT02035176|autism
180905|NCT02035176|ADHD
180906|NCT02035176|attention deficit hyperactivity disorder
180907|NCT02035176|behavioral assessment
180908|NCT02035176|behavior
180909|NCT02035163|Atrial fibrillation
180910|NCT02035163|coronary artery bypass graft
180911|NCT02035163|cryoablation
180912|NCT02035163|ganglionic plexi
180913|NCT02035150|breakfast
180914|NCT02035150|oatmeal
180915|NCT02035150|appetite
180916|NCT02035150|cholesterol
180917|NCT02035124|Prostate
180918|NCT02035124|Metastatic
180919|NCT02035124|Refractory
180920|NCT02035124|mCRPC
180921|NCT02035111|Migraine
180922|NCT02035111|Tianshu capsule
180923|NCT02035098|cancer, pain, cluster trial, quality improvement
180924|NCT02035085|19F MRI
180925|NCT02035059|Oral Glucose Tolerance Test
180926|NCT02035059|Fibronectin
180927|NCT02035059|Adiponectin
180928|NCT02035059|Copeptin
180929|NCT02035059|Cortisol
180930|NCT02035046|Gitelman
180931|NCT02035046|Heterozygous SLC12A3 mutation
180932|NCT02035046|Blood pressure
180933|NCT02035046|Hypokalemia
180934|NCT02035020|frataxin, gamma interferon, Friedreich ataxia
180935|NCT02034994|school-based intervention
180936|NCT02034994|after school physical activity
180937|NCT02034994|sugar sweetened beverages
180938|NCT02034994|sedentary behavior
180939|NCT02034994|schoolchildren
180940|NCT02034981|metastatic or unresectable locally advanced malignancies.
180941|NCT02034981|genomic alterations.
180942|NCT02034981|biological crizotinib targets (ALK, MET, ROS1, RON, AXL).
180943|NCT02034968|Nimotuzumab
180944|NCT02034968|Nab-Paclitaxel
180945|NCT02034968|Carcinoma of Esophagus
180946|NCT02034955|Prostate Cancer
180947|NCT02034955|Adaptive Radiotherapy
180948|NCT02034955|Prostatectomy
180949|NCT02034955|Patients who had a prostatectomy
180950|NCT02034942|non-sedation
180951|NCT02034929|colon cancer
180952|NCT02034929|adenoma
180953|NCT02034929|colon polyps
180954|NCT02034916|Breast cancer
180955|NCT02034916|BRCA mutation
180956|NCT02034916|PARP inhibitor
180957|NCT02034916|BRCA 1
180958|NCT02034916|BRCA 2
180959|NCT02034903|Enteral Feeding
180960|NCT02034903|Infant, Premature
180961|NCT02034890|orthotopic neobladder
180962|NCT02034890|urinary tract infection
180963|NCT02034890|intravesical instillation
180964|NCT02034890|hyaluronic acid
180965|NCT02034877|13-valent pneunococcal conjugate vaccine
180966|NCT02034877|pneumococcal disease prevention; safety and immunogenicity study
180967|NCT02034851|Acute pyelonephritis
180968|NCT02034851|Renal scarring
180969|NCT02034851|Dexamethasone
180970|NCT02034851|Children
180971|NCT02034851|Corticoids
180972|NCT02034851|Complementary treatment
180973|NCT02034851|Prevention strategy
180974|NCT02034838|PK
180975|NCT02034838|pharmacokinetic
180976|NCT02034838|HIV-infected
180977|NCT02034838|atazanavir
180978|NCT02034838|ritonavir
180979|NCT02034786|Mesenchymal stem cell
180980|NCT02034786|Hyaluronic acid
180981|NCT02034786|Adipose Tissue
180982|NCT02034786|Filler Agent
180983|NCT02034773|Safety, Pharmacokinetics, Pharmacodynamics, Healthy Subjects
180984|NCT02034760|Frailty
180985|NCT02034760|Ageing
180986|NCT02034760|Protein supplementation
180987|NCT02034760|Protein quality
180988|NCT02034760|Gut microbiota
180989|NCT02034760|Metabolome
180990|NCT02034760|Exercise training
180991|NCT02034760|Sarcopenia
180992|NCT02034747|Advagraf
180993|NCT02034747|kidney transplant
180994|NCT02034747|Corticosteroid
180995|NCT02034747|Immunosuppressive regimen
180996|NCT02034734|Phase 1
180997|NCT02034734|ASP3652
180998|NCT02034734|Cerebrospinal fluid (CSF)
180999|NCT02034734|Multiple doses
181000|NCT02034721|Muscle damage
181001|NCT02034721|Muscle soreness
181002|NCT02034721|Muscle function
181003|NCT02034721|Innate immune function
181004|NCT02034721|Inflammation
181005|NCT02034708|Primary brain tumor
181006|NCT02034695|Diabetes mellitus
181007|NCT02034669|Acute Spinal cord Injury, Adipose derived stem cells
181008|NCT02034656|imatinib resistance
181009|NCT02034656|mutation
181010|NCT02034630|hematopoietic stem cell transplantation
181011|NCT02034617|Cognition
181012|NCT02034617|Family nursing
181013|NCT02034617|Infant, premature
181014|NCT02034617|Object attachment
181015|NCT02034617|Stress, physiological
181016|NCT02034617|Stress, psychological
181017|NCT02034604|Naftopidil
181018|NCT02034604|safety
181019|NCT02034539|peripheral artery disease
181020|NCT02034539|critical limb ischemia
181021|NCT02034539|VADOplex
181022|NCT02034539|intermittent foot compression
181023|NCT02034526|Sinus node disease
181024|NCT02034526|Atrial fibrillation
181025|NCT02034526|Pacing
181026|NCT02034500|prevention
181027|NCT02034500|Shigella sonnei
181028|NCT02034487|Delayed Puberty
181029|NCT02034487|Boys
181030|NCT02034487|Hormones
181031|NCT02034487|Polymorphism, Genetic
181032|NCT02034461|Micro-Electrodes
181033|NCT02034461|Peripheral Nerve Injury
181034|NCT02034461|Amputation
181035|NCT02034461|Spinal Cord Injury
181036|NCT02034448|CRRT
181037|NCT02034448|Renal
181038|NCT02034448|Kidney
181039|NCT02034448|adults
181040|NCT02034448|registry
181041|NCT02034448|AKI
181042|NCT02034422|Exercise
181043|NCT02034409|Knee Osteoarthritis
181044|NCT02034409|Pulsed Low Intensity Ultrasound
181045|NCT02034396|Ulcers, venous, unna's boot
181046|NCT02034370|Interscalene nerve block
181047|NCT02034370|Shoulder surgery
181048|NCT02034370|Obstructive Sleep Apnea
181049|NCT02034370|Sleep Disordered Breathing
181050|NCT02034357|Parkinson Disease
181051|NCT02034357|Sleep Disordered Breathing
181052|NCT02034357|Sleep Obstructive Apnea
181053|NCT02034357|Polysomnography
181054|NCT02034357|CPAP (continuous positive airway pressure) titration
181055|NCT02034357|CPAP (continuous positive airway pressure) treatment
181056|NCT02034344|Lupus Erythematosus, Cutaneous
181057|NCT02034344|Lupus Erythematosus, Systemic
181058|NCT02034344|Lupus Erythematosus, Discoid
181059|NCT02034344|Healthy
181060|NCT02034344|Active Cutaneous Lupus Erythematosus
181061|NCT02034344|Longitudinal Study
181062|NCT02034344|Biomarkers
181063|NCT02034344|Subacute Cutaneous Lupus Erythematosus
181064|NCT02034344|Skin Biopsy
181065|NCT02034331|Insulin Sensitivity
181066|NCT02034331|Microvascular permeability
181067|NCT02034331|Sympathetic nervous system
181068|NCT02034318|Fatigue
181069|NCT02034318|Cardiac Sympathetic Denervation
181070|NCT02034318|Parkinson Disease
181071|NCT02034305|Airway Clearance
181072|NCT02034305|Duchenne Muscular Dystrophy
181073|NCT02034305|Peak Cough Flow
181074|NCT02034279|cirrhosis
181075|NCT02034266|Type one diabetes
181076|NCT02034266|nerve damage
181077|NCT02034266|neuropathy
181078|NCT02034266|omega-3 fatty acid
181079|NCT02034266|supplementation
181080|NCT02034266|nutrition
181081|NCT02034253|duration of untreated psychosis
181082|NCT02034253|glutamate
181083|NCT02034253|functional connectivity
181084|NCT02034253|structural connectivity
181085|NCT02034253|schizophrenia
181086|NCT02034253|psychosis
181087|NCT02034227|leukemia
181088|NCT02034214|HIV
181089|NCT02034214|adolescents
181090|NCT02034188|multiple sclerosis
181091|NCT02034188|umbilical cord
181092|NCT02034188|mesenchymal
181093|NCT02034188|stem cells
181094|NCT02034175|apnea
181095|NCT02034175|hypopnea
181096|NCT02034175|polysomnography
181097|NCT02034175|respiratory
181098|NCT02034175|cheyne
181099|NCT02034162|Helminth infections
181100|NCT02034162|Helminths
181101|NCT02034162|Pediatric
181102|NCT02034162|Preschool aged
181103|NCT02034162|School aged
181104|NCT02034162|Mebendazole
181105|NCT02034162|Vermox
181106|NCT02034162|Placebo
181107|NCT02034149|chronic kidney disease
181108|NCT02034149|high risk
181109|NCT02034149|intervention
181110|NCT02034149|hypertension
181111|NCT02034149|hyperglycemia
181112|NCT02034149|hyperlipidemia
181113|NCT02034123|First time in humans
181114|NCT02034123|Small cell lung carcinoma
181115|NCT02034123|Oncology
181116|NCT02034123|GSK2879552
181117|NCT02034123|LSD1 inhibitor
181118|NCT02034110|solid tumors
181119|NCT02034110|efficacy
181120|NCT02034110|BRAF V600E mutation
181121|NCT02034110|trametinib
181122|NCT02034110|safety
181123|NCT02034110|Dabrafenib
181124|NCT02034097|ROS1
181125|NCT02034097|erlotinib
181126|NCT02034097|EGFR
181127|NCT02034097|non-small cell lung cancer
181128|NCT02034097|foretinib
181129|NCT02034084|Transradial approach,
181130|NCT02034084|Coronary angiography
181131|NCT02034071|Prader-Willi syndrome
181132|NCT02034058|Wingspan Stent System
181133|NCT02034058|Wingspan Stent
181134|NCT02034058|Intracranial Stent
181135|NCT02034058|Ischemic Stroke
181136|NCT02034058|Intracranial Atherosclerotic Disease
181137|NCT02034058|Intracranial Stenosis
181138|NCT02034032|Osteoarthritis
181139|NCT02034032|Knee
181140|NCT02034032|Arthritis
181141|NCT02034032|TKA
181142|NCT02034032|Total Knee Arthroplasty
181143|NCT02034006|pathological myopia
181144|NCT02034006|choroidal neovascularization
181145|NCT02034006|ranibizumab
181146|NCT02034006|mono-bilateral
181147|NCT02034006|poor visual acuity
181148|NCT02034006|retinal disease
181149|NCT02034006|eye disease
181150|NCT02034006|Angiogenesis Inhibitors
181151|NCT02034006|Angiogenesis Modulating Agents
181152|NCT02033980|narrow band imaging(NBI)
181153|NCT02033980|NICE classification
181154|NCT02033980|colorectal lesions
181155|NCT02033980|predicting histology
181156|NCT02033967|liver donor
181157|NCT02033967|hepatectomy
181158|NCT02033967|vasodilator
181159|NCT02033967|central venous pressure
181160|NCT02033967|stroke volume variation
181161|NCT02033954|Embolization
181162|NCT02033954|Hemorrhage
181163|NCT02033954|TIPS
181164|NCT02033954|GI Bleeding
181165|NCT02033954|AV Fistula
181166|NCT02033954|AV Malformation
181167|NCT02033954|Traumatic Vascular Injury
181168|NCT02033941|Alzheimer's Disease
181169|NCT02033941|Grapeseed Extract
181170|NCT02033941|Clinical Trial
181171|NCT02033941|Meganatural-AZ
181172|NCT02033941|anti-oligomerization
181173|NCT02033941|Phase 2
181174|NCT02033941|Dietary Supplement
181175|NCT02033941|Nutraceutical
181176|NCT02033928|Myeloma
181177|NCT02033928|MGUS (monoclonal gammopathy of undetermined significance)
181178|NCT02033928|amyloidosis
181179|NCT02033928|stem cell transplant
181180|NCT02033915|Suicide risk assessment
181181|NCT02033915|interactive discussion group
181182|NCT02033915|suicide attempt
181183|NCT02033915|self-harm
181184|NCT02033915|randomized control study
181185|NCT02033915|identifying high risk group for suicide
181186|NCT02033902|Epilepsy
181187|NCT02033863|Varicocele
181188|NCT02033863|Pelvic Congestion Syndrome
181189|NCT02033863|Pelvic Venous Incompetence
181190|NCT02033863|Ovarian Varices
181191|NCT02033850|small vessel disease
181192|NCT02033850|cognition
181193|NCT02033850|treatment
181194|NCT02033850|rehabilitation
181195|NCT02033850|attention
181196|NCT02033850|fMRI
181197|NCT02033850|vascular dementia
181198|NCT02033837|Coronary artery disease
181199|NCT02033837|Cardiac CT
181200|NCT02033837|Appropriate Use Criteria (AUC)
181201|NCT02033811|mitral regurgitation
181202|NCT02033811|MitraClip system
181203|NCT02033811|percutaneous mitral valve repair
181204|NCT02033798|Urodynamics
181205|NCT02033798|Glomerular Filtration Rate
181206|NCT02033785|Prostatic hyperplasia
181207|NCT02033759|Lymphedema
181208|NCT02033733|Post cardiac arrest
181209|NCT02033733|Postcardiac arrest therapeutic hypothermia
181210|NCT02033733|Therapeutic hypothermia protocol
181211|NCT02033733|Neuromuscular blocking agents
181212|NCT02033733|Muscle relaxants
181213|NCT02033733|Hypothermia-induced increased muscle tone
181214|NCT02033733|Microshivering
181215|NCT02033720|postcardiac arrest
181216|NCT02033720|post cardiac arrest syndrome
181217|NCT02033720|post cardiac arrest hypothermia
181218|NCT02033720|pulseless electrical activity
181219|NCT02033720|asystole
181220|NCT02033720|therapeutic hypothermia
181221|NCT02033720|therapeutic hypothermia after cardiac arrest
181222|NCT02033720|therapeutic hypothermia neurologic outcome
181223|NCT02033707|Hallucinogen
181224|NCT02033707|Cognitive effects
181225|NCT02033707|Subjective effects
181226|NCT02033694|Lipid
181227|NCT02033694|Vulnerable Plaque
181228|NCT02033694|Plaque
181229|NCT02033694|Cholesterol
181230|NCT02033694|Near Infrared Spectroscopy
181231|NCT02033694|NIRS-IVUS
181232|NCT02033694|Intravascular Ultrasound
181233|NCT02033694|Angiography
181234|NCT02033694|Coronary Imaging
181235|NCT02033681|epinephrine
181236|NCT02033681|hand
181237|NCT02033681|ischemia
181238|NCT02033681|lidocaine
181239|NCT02033681|upper extremity
181240|NCT02033668|bioavailability
181241|NCT02033668|Pharmacokinetics
181242|NCT02033668|intravenous
181243|NCT02033668|subcutaneous and intramuscular administration
181244|NCT02033668|amyloid beta
181245|NCT02033668|monoclonal antibody
181246|NCT02033655|weight loss
181247|NCT02033655|older adults
181248|NCT02033655|obesity
181249|NCT02033629|Anesthesia
181250|NCT02033629|remifentanil
181251|NCT02033629|propofol
181252|NCT02033629|target-controlled infusion
181253|NCT02033629|cardiac surgery
181254|NCT02033603|Total knee arthroplasty
181255|NCT02033603|Total knee replacement
181256|NCT02033603|Femoral Nerve Block
181257|NCT02033603|Adductor Canal Block
181258|NCT02033564|Sore Throat
181259|NCT02033564|Intubation
181260|NCT02033564|Laryngoscopy
181261|NCT02033564|Anesthesiology
181262|NCT02033564|Perioperative
181263|NCT02033564|Airway Management
181264|NCT02033551|Gastric Cancer
181265|NCT02033551|Lung Cancer
181266|NCT02033551|PARP Inhibitor
181267|NCT02033551|Ovarian Cancer
181268|NCT02033551|Solid Tumors
181269|NCT02033551|Breast Cancer
181270|NCT02033551|Colon Cancer
181271|NCT02033538|Neoadjuvant chemotherapy
181272|NCT02033538|Nab-Paclitaxel
181273|NCT02033538|Carcinoma of Esophagus
181274|NCT02033525|Chronic Meniscal Injury
181275|NCT02033525|Degenerative meniscus
181276|NCT02033525|Meniscus injury
181277|NCT02033525|Meniscal injury
181278|NCT02033525|Mesenchymal stromal cells
181279|NCT02033525|Mesenchymal stem cells
181280|NCT02033525|Advanced Therapy
181281|NCT02033525|Bone marrow
181282|NCT02033512|Post-menopause
181283|NCT02033512|Hormone Replacement Therapy
181284|NCT02033512|Nanotechnology
181285|NCT02033512|Biolipid B2
181286|NCT02033499|Blood Glucose Self-Monitoring
181287|NCT02033499|Self-Monitoring, Blood Glucose
181288|NCT02033499|Diabetes Mellitus, Type 2
181289|NCT02033499|Quality of Life
181290|NCT02033486|diffuse optical tomography
181291|NCT02033486|digital breast tomosynthesis
181292|NCT02033486|breast cancer
181293|NCT02033486|solid benign lesions
181294|NCT02033486|cysts
181295|NCT02033486|malignant lesions
181296|NCT02033473|Apelin
181297|NCT02033473|insulin
181298|NCT02033473|volunteers
181299|NCT02033460|Manual therapy
181300|NCT02033460|Exercise
181301|NCT02033460|Education
181302|NCT02033447|Prostate Cancer
181303|NCT02033434|intranasal
181304|NCT02033434|ketamine
181305|NCT02033434|analgesia
181306|NCT02033434|mountain medicine
181307|NCT02033434|pre-hospital care
181308|NCT02033434|patient transport
181309|NCT02033434|pilot study
181310|NCT02033434|mountain environment
181311|NCT02033421|Infective endocarditis
181312|NCT02033421|Therapeutic drug monitoring
181313|NCT02033408|IBD: Inflammatory Bowel Diseases
181314|NCT02033408|CD: Crohn's Disease
181315|NCT02033408|UC: Ulcerative Colitis
181316|NCT02033408|ASC: Acute Severe Colitis
181317|NCT02033408|FMT: Fecal Microbiota Transplantation
181318|NCT02033408|PUCAI: Pediatric Ulcerative Colitis Activity Index
181319|NCT02033408|Ciprofloxacin, Doxycycline, Gentamycin, amoxicillin, vancomycin, metronidazole,ciprofloxacin
181320|NCT02033369|Major depressive disorder
181321|NCT02033369|MDD
181322|NCT02033369|depression
181323|NCT02033369|pramipexole
181324|NCT02033356|adductor canal block
181325|NCT02033356|volunteers
181326|NCT02033356|US-guided peripheral nerve block
181327|NCT02033356|lower limb
181328|NCT02033356|MRI
181329|NCT02033343|Prostate Cancer
181330|NCT02033343|Real-time tracking
181331|NCT02033343|Radiotherapy
181332|NCT02033343|Dynamic Multileaf Collimator
181333|NCT02033330|phenolics
181334|NCT02033330|orange peel
181335|NCT02033330|bioavailability
181336|NCT02033304|Cesarean section
181337|NCT02033304|Pain
181338|NCT02033304|Wound hyperalgesia
181339|NCT02033291|Cerebral Small Vessel Disease
181340|NCT02033291|Blood-Brain Barrier permeability
181341|NCT02033291|Dynamic contrast enhanced Magnetic Resonance Imaging
181342|NCT02033291|Pharmacokinetic modeling
181343|NCT02033291|Reproducibility
181344|NCT02033265|Ultrasound-guided Axillary Brachial Plexus Block
181345|NCT02033265|Obesity
181346|NCT02033265|Performance time
181347|NCT02033265|Failure rate
181348|NCT02033265|Acute complications
181349|NCT02033226|Periodontitis
181350|NCT02033226|Periodontal Regeneration
181351|NCT02033226|Amniotic membrane
181352|NCT02033226|Guided tissue regeneration
181353|NCT02033226|Anti-inflammatory
181354|NCT02033226|Periodontal Therapy.
181355|NCT02033213|intraoperative
181356|NCT02033213|fluid management
181357|NCT02033213|esophageal carcinoma
181358|NCT02033213|surgery
181359|NCT02033213|gas exchange
181360|NCT02033213|tissue perfusion
181361|NCT02033200|vision
181362|NCT02033200|Stendra
181363|NCT02033200|avanafil
181364|NCT02033200|PDE5 inhibitor
181365|NCT02033200|visual acuity
181366|NCT02033200|intraocular pressure
181367|NCT02033200|pupillometry
181368|NCT02033200|color vision discrimination
181369|NCT02033200|healthy males
181370|NCT02033174|alcohol, inflammation, oxidation.
181371|NCT02033161|Functional gastrointestinal disorders
181372|NCT02033161|FGID
181373|NCT02033161|Recurrent abdominal pain
181374|NCT02033161|Abdominal pain
181375|NCT02033161|pain-related functional gastrointestinal disorders
181376|NCT02033135|Atherosclerosis
181377|NCT02033135|Intermittent claudication
181378|NCT02033135|Angioplasty
181379|NCT02033122|exercise, bronchial hyperresponsiveness, inflammation
181380|NCT02033096|stannsoporfin
181381|NCT02033096|hyperbilirubinemia
181382|NCT02033096|heme oxygenase
181383|NCT02033083|abortion
181384|NCT02033083|cervical dilation
181385|NCT02033070|RFA
181386|NCT02033057|Muscular electrostimulation, mechanically ventilated, critically ill patients, muscular weakness.
181387|NCT02033044|borderline personality disorder
181388|NCT02033044|cognitive rehabilitation
181389|NCT02033044|psychoeducation
181390|NCT02033044|psychosocial functioning
181391|NCT02033031|branch retinal vein occlusion
181392|NCT02033031|central retinal thickness
181393|NCT02033031|visual acuity
181394|NCT02033031|central reintal sensitivity
181395|NCT02033018|Aflibercept
181396|NCT02033018|Myopia
181397|NCT02033018|Complications
181398|NCT02033018|Neovascularization
181399|NCT02033018|OCT
181400|NCT02033005|Body Composition
181401|NCT02033005|Adipose Tissue
181402|NCT02033005|Intrahepatocellular Lipid
181403|NCT02033005|Infant
181404|NCT02033005|Magnetic Resonance Imaging
181405|NCT02033005|Magnetic Resonance Spectroscopy
181406|NCT02032966|outcomes
181407|NCT02032966|surgical
181408|NCT02032966|non-surgical
181409|NCT02032966|ankle
181410|NCT02032966|malleolus
181411|NCT02032966|fracture
181412|NCT02032966|tibia
181413|NCT02032966|fibula
181414|NCT02032966|bimalleolar
181415|NCT02032966|trimalleolar
181416|NCT02032953|colorectal cancer
181417|NCT02032953|protein recovery
181418|NCT02032953|perioperative nutrition
181419|NCT02032953|hyperinsulinemia
181420|NCT02032953|normoglycemia
181421|NCT02032953|hyperinsulinemic-normoglycemic clamp
181422|NCT02032953|anabolism
181423|NCT02032940|MRI, Angiography, Pulse Sequence
181424|NCT02032927|osteoarthritis
181425|NCT02032927|pain
181426|NCT02032927|opioids
181427|NCT02032914|pyogenic liver abscess
181428|NCT02032914|colon cancer
181429|NCT02032862|menopause, hot flushes, hot flashes, salvia, sage, sweating
181430|NCT02032849|ventilator associated pneumonia
181431|NCT02032849|subglottic secretion drainage
181432|NCT02032849|manual air-impingement operation
181433|NCT02032849|prolonged intubation
181434|NCT02032823|Breast Cancer
181435|NCT02032823|Adjuvant
181436|NCT02032823|Olaparib
181437|NCT02032823|BRCA 1/2
181438|NCT02032823|HER2
181439|NCT02032810|Stage III Melanoma
181440|NCT02032810|Stage IV Melanoma
181441|NCT02032810|HDAC Inhibitor
181442|NCT02032758|Occupational; Cramp(s)
181443|NCT02032719|Hypertension, Systolic, Uncontrolled
181444|NCT02032706|obstructive sleep apnea
181445|NCT02032706|position therapy
181446|NCT02032706|snoring
181447|NCT02032706|positional
181448|NCT02032693|Everycell
181449|NCT02032693|DNA damage
181450|NCT02032693|DNA inflammation
181451|NCT02032693|DNA stress
181452|NCT02032667|physical activity
181453|NCT02032667|exergames
181454|NCT02032654|antibiotics
181455|NCT02032654|flucloxacillin
181456|NCT02032654|therapy duration
181457|NCT02032654|cellulitis
181458|NCT02032654|erysipelas
181459|NCT02032654|skin infections
181460|NCT02032654|hospital
181461|NCT02032641|Non-ablative laser
181462|NCT02032641|Scar revision
181463|NCT02032641|direct brow lift
181464|NCT02032628|epigenetics
181465|NCT02032628|cancer
181466|NCT02032628|exercise
181467|NCT02032628|intensity
181468|NCT02032628|duration
181469|NCT02032615|anemia
181470|NCT02032602|Myofascial Pain Syndromes
181471|NCT02032602|Trigger Point
181472|NCT02032602|Shoulder Pain
181473|NCT02032602|Aged
181474|NCT02032576|major depressive episode, electroconvulsive therapy
181475|NCT02032563|neoadjuvant therapy
181476|NCT02032550|Localized prostate cancer
181477|NCT02032550|Patient preference
181478|NCT02032550|Treatment choice
181479|NCT02032550|Decision making
181480|NCT02032550|Patient centered outcomes
181481|NCT02032537|callmax cream
181482|NCT02032537|uremic pruritus
181483|NCT02032498|sentinel lymph nodes
181484|NCT02032498|radiocolloids
181485|NCT02032498|Indocyanine Green
181486|NCT02032498|complementarity
181487|NCT02032498|axillary lymph node dissection
181488|NCT02032485|colorectal cancer
181489|NCT02032485|Indocyanine Green
181490|NCT02032485|visualization of peritoneal metastases
181491|NCT02032472|Blood Pressure Monitoring, Ambulatory
181492|NCT02032472|Arterial Pressure
181493|NCT02032472|Hypertension Controlled
181494|NCT02032472|Pharmacies
181495|NCT02032459|Pregnancy
181496|NCT02032459|Minority Women
181497|NCT02032459|Preterm delivery
181498|NCT02032459|Fetal growth restriction
181499|NCT02032459|Preeclampsia
181500|NCT02032459|Gestational Diabetes
181501|NCT02032459|Vitamin D
181502|NCT02032433|extended-release naltrexone (Vivitrol)
181503|NCT02032433|buprenorphine-naloxone (Suboxone)
181504|NCT02032433|comparative effective
181505|NCT02032433|relapse prevention
181506|NCT02032394|Chlorhexidine
181507|NCT02032394|Povidone-iodine
181508|NCT02032394|bacteriuria
181509|NCT02032394|Urinary Catheterization
181510|NCT02032394|Urinary tract infection
181511|NCT02032381|non infectious pulmonary complications after hematopoietic cell transplant
181512|NCT02032381|functional respiratory test and exercise test
181513|NCT02032381|thoracic tomodensitometry
181514|NCT02032368|circulating tumour cell;
181515|NCT02032368|transarterial chemoembolization;
181516|NCT02032368|hepatocellular carcinoma;
181517|NCT02032368|recurrence
181518|NCT02032329|Functional Electrical Stimulation (FES)
181519|NCT02032316|Renal Stone
181520|NCT02032316|Ureteroscopy
181521|NCT02032316|Ureteral Stent
181522|NCT02032316|post-uncomplicated ureteroscopy
181523|NCT02032316|UURS
181524|NCT02032277|Oncology
181525|NCT02032277|United States Oncology - 12152
181526|NCT02032277|Alliance - AFT-04
181527|NCT02032277|Triple negative breast cancer
181528|NCT02032277|National Surgical Adjuvant Breast and Bowel Project - B-56-I
181529|NCT02032277|Grupo Español de Investigación en Cáncer de Mama - GEICAM/2014-02
181530|NCT02032277|German Breast Group - GBG 81
181531|NCT02032264|Next generation sequencing
181532|NCT02032264|Embryonic aneuploidy
181533|NCT02032251|Sperm DNA damage ejaculated spermatozoa Ginger Herbal Drug Herbal medicine
181534|NCT02032199|Gastric bypass
181535|NCT02032199|Health-related quality of life
181536|NCT02032199|SF-36
181537|NCT02032199|Questionnaire
181538|NCT02032199|Treatment guidelines
181539|NCT02032186|magnesium
181540|NCT02032186|prematurity
181541|NCT02032173|Ranibizumab
181542|NCT02032173|Diabetic Macular Edema
181543|NCT02032160|ADITEC
181544|NCT02032160|Immunology
181545|NCT02032160|Vaccines
181546|NCT02032160|Hepatitis B
181547|NCT02032160|Investigational study
181548|NCT02032160|innate and adaptive immune responses
181549|NCT02032160|Hepatitis B vaccinations
181550|NCT02032134|Cryopreserved platelets, thrombocytopenia, DMSO
181551|NCT02032121|Cancer survivors
181552|NCT02032121|Long-term cancer survivor
181553|NCT02032108|Diabetes lifestyle intervention Rwanda
181554|NCT02032095|IVIG
181555|NCT02032095|Renal transplantation
181556|NCT02032095|desensitization
181557|NCT02032056|Infections
181558|NCT02032056|Allergy
181559|NCT02032056|Immune function
181560|NCT02032056|Microbiota
181561|NCT02032056|infant
181562|NCT02032043|Filariasis
181563|NCT02032043|Onchocerciasis
181564|NCT02032043|Albendazole
181565|NCT02032043|Ivermectin
181566|NCT02032043|STH Soil Transmitted Helminth infections
181567|NCT02032043|MDA Mass Drug Administration
181568|NCT02032030|quality of Life
181569|NCT02032030|pain
181570|NCT02032030|nausea
181571|NCT02032030|falls
181572|NCT02032030|intraoperative awareness
181573|NCT02032030|anesthesia awareness
181574|NCT02032030|cognition
181575|NCT02032030|activities of daily living
181576|NCT02032030|major morbidity
181577|NCT02032030|all-cause mortality
181578|NCT02032017|Total Hip Arthroplasty
181579|NCT02032017|Gluteus medius
181580|NCT02032017|Approach
181581|NCT02032017|Rehabilitation
181582|NCT02032017|Functional outcome
181583|NCT02032004|Chronic Heart Failure
181584|NCT02032004|CHF
181585|NCT02032004|Left Ventricular Systolic Dysfunction
181586|NCT02032004|Ischemic Heart Failure
181587|NCT02032004|Nonischemic Heart Failure
181588|NCT02032004|Stem Cells
181589|NCT02032004|Allogeneic Mesenchymal Precursor Cells
181590|NCT02031991|Bioequivalence
181591|NCT02031991|Biosimilarity
181592|NCT02031991|Similarity
181593|NCT02031991|PK
181594|NCT02031991|Phase 1
181595|NCT02031991|Bevacizumab
181596|NCT02031991|Healthy Volunteers
181597|NCT02031991|Single-Dose
181598|NCT02031991|Oncology
181599|NCT02031978|Breast Feeding
181600|NCT02031978|Infant Nutrition
181601|NCT02031978|Childhood Obesity
181602|NCT02031978|Infant feeding patterns
181603|NCT02031978|WIC
181604|NCT02031952|hepatocellular carcinoma
181605|NCT02031952|hepatectomy
181606|NCT02031952|lymphadenectomy
181607|NCT02031952|complication
181608|NCT02031952|prognosis
181609|NCT02031939|Rectal cancer
181610|NCT02031939|neoadjuvant chemoradiotherapy
181611|NCT02031939|optimization
181612|NCT02031913|Chronic hepatitis B
181613|NCT02031913|Hepatic fibrosis
181614|NCT02031913|Steatosis
181615|NCT02031887|starter formula
181616|NCT02031887|stool microbiota
181617|NCT02031887|infants
181618|NCT02031887|caesarean section delivery
181619|NCT02031874|H1N1
181620|NCT02031874|HIV
181621|NCT02031874|Immunogenecity
181622|NCT02031848|weight loss
181623|NCT02031848|diet
181624|NCT02031822|Primary Headache
181625|NCT02031822|Greater Occipital Nerve
181626|NCT02031822|Ultrasound
181627|NCT02031822|Chronic Pain
181628|NCT02031822|Cervicogenic
181629|NCT02031822|Occipital Neuralgia
181630|NCT02031822|Migraine
181631|NCT02031822|Tension type headache
181632|NCT02031822|Cluster headache
181633|NCT02031809|Thoracic Surgery, Video-Assisted
181634|NCT02031770|vascular endothelial cells
181635|NCT02031757|Balance control
181636|NCT02031757|Aging
181637|NCT02031757|Balance reactions
181638|NCT02031757|Perturbation
181639|NCT02031705|Fibrillation
181640|NCT02031705|Catheter ablation
181641|NCT02031692|Benign paroxysmal positional vertigo
181642|NCT02031692|Vitamin D
181643|NCT02031692|Calcium
181644|NCT02031692|Prevention
181645|NCT02031679|Chronic Idiopathic Urticaria
181646|NCT02031666|Healthy
181647|NCT02031666|JNJ-56021927
181648|NCT02031666|ARN-509
181649|NCT02031666|Bioavailability
181650|NCT02031653|Penile Cuff Test
181651|NCT02031640|asthma
181652|NCT02031640|breath-actuated inhaler
181653|NCT02031640|metered-dose inhaler
181654|NCT02031627|lymphedema
181655|NCT02031627|lymphoedema
181656|NCT02031627|leg lymphoedema
181657|NCT02031627|lower extremity lymphoedema
181658|NCT02031627|pneumatic compression device
181659|NCT02031614|anemia
181660|NCT02031614|blood withdrawal
181661|NCT02031614|phlebotomy
181662|NCT02031614|innate immunity
181663|NCT02031614|Immune reponse
181664|NCT02031588|Study of commensal flora
181665|NCT02031588|Fluoroquinolones
181666|NCT02031575|Reproductive Health
181667|NCT02031575|Contraception
181668|NCT02031575|Public Health
181669|NCT02031575|Sexual Health
181670|NCT02031575|Adolescents
181671|NCT02031575|Mobile Health
181672|NCT02031562|Balance
181673|NCT02031562|Falls
181674|NCT02031562|Low back pain
181675|NCT02031562|Geriatric
181676|NCT02031523|endometriosis
181677|NCT02031523|dysmenorrhea
181678|NCT02031523|Sanjie analgesic capsule
181679|NCT02031523|effect/safety
181680|NCT02031497|Sweetener, insulin, body mass index, physical activity
181681|NCT02031432|cancer-related pain
181682|NCT02031432|cebranopadol
181683|NCT02031419|CC-122
181684|NCT02031419|CC-223
181685|NCT02031419|CC-292
181686|NCT02031419|Rituximab
181687|NCT02031419|Lymphoma
181688|NCT02031419|Diffuse Large B-Cell Lymphoma
181689|NCT02031380|Glaucoma
181690|NCT02031380|Open angle glaucoma
181691|NCT02031380|ocular hypertension
181692|NCT02031380|compliance
181693|NCT02031354|Lysine Chloride
181694|NCT02031328|prostate
181695|NCT02031328|radiation
181696|NCT02031328|stereotactic body radiation
181697|NCT02031315|sudden death
181698|NCT02031315|sudden cardiac arrest
181699|NCT02031302|Lotus
181700|NCT02031302|Valve
181701|NCT02031302|Real world
181702|NCT02031302|Aortic stenosis
181703|NCT02031302|High risk
181704|NCT02031289|Anemia
181705|NCT02031289|Iron deficiency
181706|NCT02031289|Cardiac surgery
181707|NCT02031289|Perioperative Care
181708|NCT02031276|ABBV-066
181709|NCT02031276|BI 655066
181710|NCT02031276|risankizumab
181711|NCT02031224|Chronic Kidney Disease
181712|NCT02031224|Restricted protein diets
181713|NCT02031224|Nutritional status
181714|NCT02031198|Alzheimer's disease
181715|NCT02031198|tau
181716|NCT02031198|dementia
181717|NCT02031198|elderly
181718|NCT02031198|cognitive
181719|NCT02031198|disease modifying
181720|NCT02031198|treatment
181721|NCT02031198|immunization
181722|NCT02031198|vaccine
181723|NCT02031172|Dry Eye Disease
181724|NCT02031172|Sjogren's Syndrome
181725|NCT02031172|Tear Film
181726|NCT02031172|Ocular Surface
181727|NCT02031172|Aqueous Tear Deficiency
181728|NCT02031159|perioperative hypothermia
181729|NCT02031159|zero heat flux
181730|NCT02031159|non-invasive measurement of body core temperature
181731|NCT02031133|Antisense
181732|NCT02031133|miR-122 antagonist
181733|NCT02031133|host factor
181734|NCT02031133|Chronic hepatitis C
181735|NCT02031133|Hepatitis C
181736|NCT02031107|stroke
181737|NCT02031107|brain stimulation
181738|NCT02031107|electroencephalography
181739|NCT02031107|functional magnetic resonance imaging
181740|NCT02031107|functional connectivity
181741|NCT02031068|active rehabilitation
181742|NCT02031068|exercise
181743|NCT02031068|concussion
181744|NCT02031055|Advanced solid tumors
181745|NCT02031042|neoadjuvant chemotherapy
181746|NCT02031042|breast cancer
181747|NCT02031042|sentinel lymph node biopsy
181748|NCT02031042|false negative rate
181749|NCT02031042|identification rate
181750|NCT02031029|personality scores
181751|NCT02031016|Chronic thoracic pain
181752|NCT02031016|Remifentanil
181753|NCT02031016|Fentanyl
181754|NCT02031016|sternotomy
181755|NCT02030990|photorefractive keratectomy
181756|NCT02030990|corneal haze
181757|NCT02030990|mitomycin-C
181758|NCT02030990|postoperative steroids
181759|NCT02030951|preterm infant behavior
181760|NCT02030951|tube feeding
181761|NCT02030951|feeding efficiency
181762|NCT02030938|breast implant
181763|NCT02030938|revision augmentation
181764|NCT02030938|stretch deformity
181765|NCT02030938|fold malposition
181766|NCT02030938|bottoming out
181767|NCT02030912|The impact of a number of different types of antibiotics
181768|NCT02030912|The emergence and persistence of antibiotic resistance
181769|NCT02030899|Cervical vertebrae
181770|NCT02030899|single
181771|NCT02030899|degenerative disease
181772|NCT02030899|Fusion
181773|NCT02030899|Sagittal angle
181774|NCT02030873|virtual simulation
181775|NCT02030873|temporal bone
181776|NCT02030873|surgical training
181777|NCT02030873|medical education
181778|NCT02030873|self-directed learning
181779|NCT02030873|final product assessment
181780|NCT02030873|cognitive load
181781|NCT02030873|reaction time
181782|NCT02030873|skills training
181783|NCT02030873|simulator metrics
181784|NCT02030808|Thoracic surgery
181785|NCT02030808|non-muscle relaxant
181786|NCT02030808|target-controlled infusion
181787|NCT02030808|remifentanil
181788|NCT02030808|surgical conditions
181789|NCT02030795|Thoracic surgery
181790|NCT02030795|Arndt® blocker
181791|NCT02030795|lung deflation
181792|NCT02030795|Disconnection technique
181793|NCT02030795|Continuous suction
181794|NCT02030795|Elective video-assisted thoracoscopic
181795|NCT02030782|depression
181796|NCT02030782|quality improvement
181797|NCT02030782|treatment
181798|NCT02030782|adolescents
181799|NCT02030769|Esophageal Neoplasms
181800|NCT02030769|Lugol's solution
181801|NCT02030769|Pronase
181802|NCT02030769|Endoscopy, Digestive System
181803|NCT02030769|Pretreatment method
181804|NCT02030756|constipation
181805|NCT02030743|Falls
181806|NCT02030743|Older adults
181807|NCT02030743|Balance
181808|NCT02030743|Mobility
181809|NCT02030743|Visual attention
181810|NCT02030730|Brief Parenting Training
181811|NCT02030730|Early Intervention
181812|NCT02030730|Child Behavior
181813|NCT02030730|Greece
181814|NCT02030717|Spinal anesthesia
181815|NCT02030717|Epidural anesthesia
181816|NCT02030717|Klonidin
181817|NCT02030717|renal cell carcinoma
181818|NCT02030691|Neonatal respiratory distress
181819|NCT02030691|nHFPV
181820|NCT02030691|nCPAP
181821|NCT02030691|cerebral tissue oxygenation
181822|NCT02030691|NIRS
181823|NCT02030665|Marijuana Dependence
181824|NCT02030665|Individualized treatment
181825|NCT02030665|Motivational Enhancement Treatment
181826|NCT02030665|Cognitive-Behavioral Treatment
181827|NCT02030665|Contingency Management
181828|NCT02030652|premature newborn
181829|NCT02030652|nasal ventilation
181830|NCT02030652|noninvasive ventilation
181831|NCT02030652|continuous positive airway pressure
181832|NCT02030626|Neuropathic pain
181833|NCT02030626|lumbar radiculopathy
181834|NCT02030626|rTMS
181835|NCT02030626|tDCS
181836|NCT02030626|placebo controlled study
181837|NCT02030613|juvenile idiopathic arthritis
181838|NCT02030613|etanercept
181839|NCT02030587|Hyperaldosteronism
181840|NCT02030587|Adrenocortical adenoma
181841|NCT02030587|Adrenalectomy
181842|NCT02030587|Catheter ablation
181843|NCT02030561|NK cells
181844|NCT02030561|trastuzumab
181845|NCT02030561|immunotherapy
181846|NCT02030548|CABG
181847|NCT02030548|dual antiplatelet therapy
181848|NCT02030548|aspirin
181849|NCT02030548|clopidogrel
181850|NCT02030548|prasugrel
181851|NCT02030548|ticagrelor
181852|NCT02030522|Post-traumatic stress disorder
181853|NCT02030522|PTSD
181854|NCT02030522|Accelerated Resolution Therapy
181855|NCT02030522|Military
181856|NCT02030522|Veterans
181857|NCT02030522|Exposure therapy
181858|NCT02030522|Eye movements
181859|NCT02030509|cancer diagnosis
181860|NCT02030496|distal radius fractures
181861|NCT02030496|Closed reduction
181862|NCT02030496|Open reduction internal fixation
181863|NCT02030496|Volar plate
181864|NCT02030496|Redislocation
181865|NCT02030496|Unstable fracture
181866|NCT02030496|Extra-articular fracture
181867|NCT02030496|Colles fracture
181868|NCT02030496|Barton fracture
181869|NCT02030470|Periodontitis, treatment, photodynamic, mid-term, bacteria
181870|NCT02030444|Neoplasms Staging
181871|NCT02030444|Bronchoscopy
181872|NCT02030444|Nuclear Medicine
181873|NCT02030444|Radiology
181874|NCT02030392|Functional abdominal pain
181875|NCT02030392|psychological intervention
181876|NCT02030392|quality of life
181877|NCT02030392|Randomized controlled trial
181878|NCT02030392|children
181879|NCT02030379|Cancer
181880|NCT02030353|Lifestyle intervention
181881|NCT02030353|Internet intervention
181882|NCT02030353|Breast neoplasms
181883|NCT02030353|Body weight
181884|NCT02030353|Body weight changes
181885|NCT02030340|urodynamic investigation
181886|NCT02030340|lower urinary tract dysfunction
181887|NCT02030340|catheter
181888|NCT02030340|air-charged
181889|NCT02030340|water filled
181890|NCT02030327|proteomics
181891|NCT02030327|multiple trauma
181892|NCT02030327|organ dysfunction
181893|NCT02030314|Chlorthalidone
181894|NCT02030314|Resistant Hypertension
181895|NCT02030314|Kidney Transplant Patients
181896|NCT02030301|Herpes Simplex Virus, Type 2
181897|NCT02030301|Herpes
181898|NCT02030301|HSV-2
181899|NCT02030288|alcohol
181900|NCT02030288|substance use
181901|NCT02030288|eHealth
181902|NCT02030275|Hypertrophic scar
181903|NCT02030275|Cicatrix
181904|NCT02030275|Scar prevention
181905|NCT02030275|Scar revision
181906|NCT02030249|Pre-diabetes
181907|NCT02030249|Obesity
181908|NCT02030249|Low calorie diet
181909|NCT02030249|Diet - reducing
181910|NCT02030249|Appetite
181911|NCT02030249|Visual analogue scale
181912|NCT02030249|Ghrelin
181913|NCT02030249|Peptide YY
181914|NCT02030249|Bone mass
181915|NCT02030249|Bone turnover
181916|NCT02030249|Muscle strength
181917|NCT02030236|hypothermia, induced
181918|NCT02030236|rewarming
181919|NCT02030236|therapeutic
181920|NCT02030236|heart arrest
181921|NCT02030236|asystole
181922|NCT02030236|frostbite
181923|NCT02030223|transversus abdominis plane block
181924|NCT02030223|inguinal hernia repair
181925|NCT02030223|acute postoperative pain
181926|NCT02030223|neuropathic pain
181927|NCT02030210|Quality improvement
181928|NCT02030210|STEMI
181929|NCT02030210|Belgium
181930|NCT02030184|Lung cancer
181931|NCT02030184|Small cell lung cancer
181932|NCT02030184|Neuroendocrine tumor
181933|NCT02030184|Rhenium
181934|NCT02030184|Re 188-P2045
181935|NCT02030171|Chronic low back pain
181936|NCT02030158|Severe sepsis
181937|NCT02030158|Septic shock
181938|NCT02030158|Early goal directed therapy
181939|NCT02030158|Individual patient data meta-analysis
181940|NCT02030145|COPD
181941|NCT02030145|Pulmonary
181942|NCT02030132|Physical activity
181943|NCT02030132|Sedentary lifestyle
181944|NCT02030132|Pedometers
181945|NCT02030132|Walking
181946|NCT02030132|Financial Incentives
181947|NCT02030132|Behavioral Economics
181948|NCT02030119|Sedentary lifestyle
181949|NCT02030119|Pedometers
181950|NCT02030119|Obesity
181951|NCT02030119|Physical Activity
181952|NCT02030119|Financial Incentives
181953|NCT02030119|Behavioral Economics
181954|NCT02030106|Cervicovaginal microbiome
181955|NCT02030106|Microbiome
181956|NCT02030106|Preterm Birth
181957|NCT02030106|Cervical Remodeling
181958|NCT02030106|Preterm delivery
181959|NCT02030106|Microbiota
181960|NCT02030093|Alcohol dependence
181961|NCT02030093|Telephone-based continuing care
181962|NCT02030093|Outcome monitoring
181963|NCT02030080|Pedometers
181964|NCT02030080|Walking
181965|NCT02030080|Financial incentives
181966|NCT02030080|Sedentary lifestyle
181967|NCT02030080|Behavioral economics
181968|NCT02030067|oncology
181969|NCT02030067|tumor
181970|NCT02030067|metastatic
181971|NCT02030041|simvastatin
181972|NCT02030041|exercise mediated cardiorespiratory fitness
181973|NCT02030041|vitamin D supplementation
181974|NCT02030028|Rheumatoid Arthritis
181975|NCT02030028|ACTH gel
181976|NCT02030015|infantile Tay-Sachs disease
181977|NCT02030015|juvenile Tay-Sachs disease
181978|NCT02030015|infantile GM1 gangliosidosis
181979|NCT02030015|juvenile GM1 gangliosidosis
181980|NCT02030015|infantile GM2 gangliosidosis
181981|NCT02030015|juvenile GM2 gangliosidosis
181982|NCT02030015|Sandhoff disease
181983|NCT02030015|gangliosidoses
181984|NCT02030015|miglustat
181985|NCT02030015|ketogenic diet
181986|NCT02030015|SYNER-G regimen
181987|NCT02030015|Syner-G
181988|NCT02030015|Zavesca
181989|NCT02030015|Tay-Sachs disease
181990|NCT02030015|Tay Sachs disease
181991|NCT02029989|Metabolic Syndrome
181992|NCT02029989|Antipsychotics
181993|NCT02029989|Schizophrenia
181994|NCT02029989|Bipolar Disorder
181995|NCT02029989|Diabetes
181996|NCT02029989|Dyslipidemia
181997|NCT02029989|Hyperlipidemia
181998|NCT02029989|Hypertension
181999|NCT02029989|Obesity
182000|NCT02029989|Medication Therapy Management
182001|NCT02029989|MTM
182002|NCT02029989|Pharmacist
182003|NCT02029989|Comprehensive Medication Management
182004|NCT02029989|CMM
182005|NCT02029989|Health Disparity
182006|NCT02029989|Monitoring
182007|NCT02029989|Point of Care Testing
182008|NCT02029989|Chronic Persistent Mental Illness
182009|NCT02029937|Squamous cell neoplasia
182010|NCT02029937|Proflavine
182011|NCT02029937|Lugol's chromoendoscopy
182012|NCT02029911|Menorrhagia
182013|NCT02029911|Excessive uterine bleeding
182014|NCT02029911|Endometrial Ablation
182015|NCT02029898|cesarean section
182016|NCT02029898|anesthesia
182017|NCT02029898|children
182018|NCT02029885|Hypertension
182019|NCT02029885|Renal Denervation
182020|NCT02029872|MRSA
182021|NCT02029872|colonization
182022|NCT02029872|decolonization
182023|NCT02029859|pregnancy (after 30 weeks of amenorhea)
182024|NCT02029859|obesity (BMI>35)
182025|NCT02029859|sleep apnea syndrom
182026|NCT02029859|preeclampsy
182027|NCT02029859|intrauterine growth restriction
182028|NCT02029820|Contrast Nephropathy
182029|NCT02029820|Prevention
182030|NCT02029820|Renalguard
182031|NCT02029794|Cervical Cancer
182032|NCT02029794|Cervical Cancer Screening
182033|NCT02029794|Low Resource setting
182034|NCT02029794|HPV
182035|NCT02029794|Self-Collection
182036|NCT02029794|VIA
182037|NCT02029781|Appendicitis
182038|NCT02029781|Laparoscopy
182039|NCT02029781|Appendectomy
182040|NCT02029781|Negative appendectomy
182041|NCT02029781|Morbidity
182042|NCT02029768|outcome
182043|NCT02029755|transversus abdominis plane block
182044|NCT02029755|local infiltration
182045|NCT02029755|ropivacaine
182046|NCT02029755|heart rate variability
182047|NCT02029755|postoperative analgesia
182048|NCT02029742|Sickle cell disease
182049|NCT02029742|Medication adherence
182050|NCT02029742|Hydroxyurea
182051|NCT02029742|Community health worker intervention
182052|NCT02029742|Sickle Cell Treatment
182053|NCT02029729|RTA 408
182054|NCT02029729|RTA 408 Capsules
182055|NCT02029729|Non-small cell lung cancer
182056|NCT02029729|Metastatic non-small cell lung cancer
182057|NCT02029729|Incurable non-small cell lung cancer
182058|NCT02029729|Refractory melanoma
182059|NCT02029729|Relapsed melanoma
182060|NCT02029716|RTA 408
182061|NCT02029716|RTA 408 Lotion
182062|NCT02029716|Oxidative stress
182063|NCT02029716|Inflammation
182064|NCT02029716|Volunteers
182065|NCT02029703|Knee Osteoarthritis
182066|NCT02029703|Knee Pain
182067|NCT02029703|Synvisc-One
182068|NCT02029690|argininosuccinate synthetase
182069|NCT02029690|arginine
182070|NCT02029690|arginine deiminase
182071|NCT02029651|Stroke
182072|NCT02029651|Hand
182073|NCT02029651|Rehabilitation
182074|NCT02029651|Game
182075|NCT02029638|Kidney Transplantation
182076|NCT02029638|Renal Transplantation
182077|NCT02029612|Tobacco Use Cessation
182078|NCT02029612|Cancer Prevention
182079|NCT02029612|HIV/AIDS
182080|NCT02029612|Questionnaires
182081|NCT02029612|Surveys
182082|NCT02029612|Nicotine patch
182083|NCT02029612|Breath test
182084|NCT02029612|Cell Phone Calls for Smoking Cessation Counseling
182085|NCT02029612|Text Message Smoking Cessation Support
182086|NCT02029573|Phase II
182087|NCT02029573|Atorvastatin
182088|NCT02029573|Temozolomide
182089|NCT02029573|Radiotherapy
182090|NCT02029573|Glioblastoma Multiforme (GBM)
182091|NCT02029534|post-operative atrial fibrillation
182092|NCT02029534|POAF
182093|NCT02029534|A-Fib
182094|NCT02029521|cystic fibrosis
182095|NCT02029521|growth Failure
182096|NCT02029521|glutathione
182097|NCT02029508|PSCC(Posterior semicircular canal)
182098|NCT02029508|BPPV(Bening paroxysmal positional vertigo)
182099|NCT02029508|Vertigo
182100|NCT02029508|Otorhinolaryngologic Diseases
182101|NCT02029495|Psoriatic Arthritis
182102|NCT02029495|Brodalumab
182103|NCT02029495|AMG 827
182104|NCT02029482|ACT-128800
182105|NCT02029469|Humeral Resurfacing
182106|NCT02029469|Humeral Resurfacing Arthroplasty
182107|NCT02029456|Massive Pulmonary embolism
182108|NCT02029456|thrombolytic therapy
182109|NCT02029456|high risk
182110|NCT02029456|elderly
182111|NCT02029443|Bruton's tyrosine kinase inhibitor
182112|NCT02029430|HIV +
182113|NCT02029430|HIV positive
182114|NCT02029430|AIDS
182115|NCT02029430|Kaposi's sarcoma
182116|NCT02029430|Sarcoma
182117|NCT02029430|tumor
182118|NCT02029430|cancer
182119|NCT02029391|Myofascial pain syndrome
182120|NCT02029391|taping
182121|NCT02029391|manual therapies
182122|NCT02029365|Infertility
182123|NCT02029365|desire for children
182124|NCT02029365|eating disorder
182125|NCT02029365|anorexia nervosa
182126|NCT02029365|bulimia nervosa
182127|NCT02029365|eating disorders not otherwise specified
182128|NCT02029352|Treatment
182129|NCT02029352|Sinecatechins
182130|NCT02029339|Negative pressure wound therapy
182131|NCT02029339|Acute wound infection
182132|NCT02029339|complicated abdominal infection
182133|NCT02029339|Cytokines
182134|NCT02029339|Matrix metalloproteinase
182135|NCT02029326|colorectal cancer, cetuximab, biomarker, prometheus
182136|NCT02029300|pediatrics
182137|NCT02029300|fiberoptic intubation
182138|NCT02029300|oral intubation
182139|NCT02029300|nasal intubation
182140|NCT02029300|children under the age of 2
182141|NCT02029287|Chronic heart failure
182142|NCT02029287|telemedicine
182143|NCT02029287|health service platform
182144|NCT02029274|Dermatomyositis
182145|NCT02029261|Burn
182146|NCT02029248|Anorectal malformation
182147|NCT02029248|fecal incontinence
182148|NCT02029248|quality of life
182149|NCT02029248|child
182150|NCT02029235|Adult
182151|NCT02029235|soft-tissue hand surgery
182152|NCT02029183|stroke, SAHS, BiPAP
182153|NCT02029170|ankle fracture
182154|NCT02029170|weightbearing
182155|NCT02029170|cast
182156|NCT02029118|Acupoint Application,Stable Angina Pectoris,herbal medicine
182157|NCT02029105|Mesothelioma,
182158|NCT02029105|Pleural diseases,
182159|NCT02029105|Mesothelin,
182160|NCT02029105|Osteopontin,
182161|NCT02029105|Hyaluronan,
182162|NCT02029105|Syndecan-1
182163|NCT02029092|International
182164|NCT02029092|Multicenter
182165|NCT02029092|Observational registry
182166|NCT02029092|Orsiro Drug Eluting Stent (DES)
182167|NCT02029092|Stenting
182168|NCT02029092|Treatment of coronary artery disease
182169|NCT02029092|Coronary revascularization
182170|NCT02029092|Percutaneous Coronary Intervention (PCI)
182171|NCT02029092|STEMI
182172|NCT02029092|NSTEMI
182173|NCT02029092|Ischemia
182174|NCT02029092|Angina
182175|NCT02029092|Acute Myocardial Infarction (AMI)
182176|NCT02029092|Small Vessels
182177|NCT02029092|Chronical Total Occlusion (CTO)
182178|NCT02029079|Malnutrition
182179|NCT02029066|actinic keratosis
182180|NCT02029066|SR-T100
182181|NCT02029066|pharmacokinetics
182182|NCT02029053|Vaginal dryness
182183|NCT02029053|Vaginal lubrication
182184|NCT02029053|Post-menopausal symptoms
182185|NCT02029053|Peri-menopausal symptoms
182186|NCT02029053|Urogenital atrophy
182187|NCT02029053|Dyspareunia
182188|NCT02029053|Painful intercourse
182189|NCT02029040|Bronchiolitis
182190|NCT02029040|Hypertonic saline
182191|NCT02029040|Emergency Department
182192|NCT02029027|Urinary Stress Incontinence
182193|NCT02029027|Urinary Mixed Incontinence
182194|NCT02029014|LAmbre
182195|NCT02029001|Solid tumor
182196|NCT02029001|Recurrent/metastatic
182197|NCT02029001|Personalized medicine
182198|NCT02029001|Genomic alteration
182199|NCT02029001|Targeted therapy
182200|NCT02029001|Nilotinib
182201|NCT02029001|Everolimus
182202|NCT02029001|Sorafenib
182203|NCT02029001|Lapatinib
182204|NCT02029001|Pazopanib
182205|NCT02028988|Intermediate Risk Prostate Cancer
182206|NCT02028962|Smoking cessation
182207|NCT02028962|Romanian adults
182208|NCT02028923|topical morphine
182209|NCT02028910|gastroenteritis
182210|NCT02028910|pediatrics
182211|NCT02028910|vomiting
182212|NCT02028897|In vitro fertilization
182213|NCT02028897|IVF
182214|NCT02028897|Embryo culture
182215|NCT02028897|Blastocyst transfer
182216|NCT02028832|pain
182217|NCT02028832|nausea/vomiting
182218|NCT02028832|anxiety
182219|NCT02028832|complementary and alternative medicine
182220|NCT02028832|pediatric
182221|NCT02028832|oncology
182222|NCT02028832|cost-effectiveness
182223|NCT02028793|Pharmaceutical Care, Taiwan, pharmacist, Workload, pressure
182224|NCT02028741|neck pain
182225|NCT02028741|transverse vertebral pressures
182226|NCT02028741|thoracic mobilization
182227|NCT02028728|International
182228|NCT02028728|Multicenter
182229|NCT02028728|Observational registry
182230|NCT02028728|Orsiro Drug Eluting Stent (DES)
182231|NCT02028728|Stenting
182232|NCT02028728|Treatment of coronary artery disease
182233|NCT02028728|Coronary revascularization
182234|NCT02028728|Percutaneous Coronary Intervention (PCI)
182235|NCT02028728|STEMI
182236|NCT02028728|NSTEMI
182237|NCT02028728|Ischemia
182238|NCT02028728|Angina
182239|NCT02028728|Acute Myocardial Infarction (AMI)
182240|NCT02028728|Small Vessels
182241|NCT02028728|Chronic Total Occlusion (CTO)
182242|NCT02028715|IV Acetaminophen
182243|NCT02028715|Ofirmev
182244|NCT02028715|Post-operative pain
182245|NCT02028702|red clover
182246|NCT02028702|menopause
182247|NCT02028702|bioactive compounds
182248|NCT02028702|isoflavones
182249|NCT02028702|phytoestrogen
182250|NCT02028676|HIV
182251|NCT02028676|Africa
182252|NCT02028676|children
182253|NCT02028676|antiretroviral therapy
182254|NCT02028676|laboratory monitoring
182255|NCT02028676|toxicity
182256|NCT02028676|CD4
182257|NCT02028676|induction maintenance
182258|NCT02028676|cotrimoxazole
182259|NCT02028676|prophylaxis
182260|NCT02028676|abacavir
182261|NCT02028676|lamivudine
182262|NCT02028676|once daily
182263|NCT02028663|P-CAB
182264|NCT02028663|APA(Acid Pump Antagonist)
182265|NCT02028650|relapse leukemia
182266|NCT02028650|DSI
182267|NCT02028637|asthma
182268|NCT02028637|toll like receptor
182269|NCT02028637|innate immunity
182270|NCT02028624|Rheumatoid arthritis
182271|NCT02028624|Mediterranean diet
182272|NCT02028624|Lifestyle intervention
182273|NCT02028624|Adiponectin
182274|NCT02028624|Telephone counseling
182275|NCT02028611|Rib fracture
182276|NCT02028611|Inverted grayscale
182277|NCT02028598|Clomipramine
182278|NCT02028598|Premature ejaculation
182279|NCT02028585|low-fat milk
182280|NCT02028585|metabolic syndrome
182281|NCT02028585|lipid profile
182282|NCT02028585|inflammation
182283|NCT02028585|oxidative stress
182284|NCT02028585|endothelial function
182285|NCT02028572|Structure function correlation
182286|NCT02028572|Optical coherence tomography
182287|NCT02028572|Retinal Nerve fibre layer thickness
182288|NCT02028572|Visual fields
182289|NCT02028572|Primary open angle glaucoma
182290|NCT02028559|stones
182291|NCT02028559|kidney
182292|NCT02028559|stone fragments
182293|NCT02028559|lithotripsy
182294|NCT02028546|atopic dermatitis, skin cleansing, cleanser, moisturizer, skin hydration
182295|NCT02028533|addiction
182296|NCT02028533|oxytocin
182297|NCT02028533|tolerability
182298|NCT02028507|Palbociclib
182299|NCT02028507|Capecitabine
182300|NCT02028507|Hormonal Receptor positive
182301|NCT02028507|HER2 negative
182302|NCT02028507|Metastatic Breast Cancer
182303|NCT02028507|Resistance to non-steroidal Aromatase inhibitors
182304|NCT02028507|Fulvestrant
182305|NCT02028507|Exemestane
182306|NCT02028481|Macular hole
182307|NCT02028481|Vitreoretinal surgery
182308|NCT02028481|Macular surgery
182309|NCT02028481|Air tamponade
182310|NCT02028468|Femoral Neck Fracture
182311|NCT02028468|Anterolateral approach
182312|NCT02028468|Trans-gluteal approach
182313|NCT02028468|Watson Jones approach
182314|NCT02028468|Hardinge approach
182315|NCT02028455|pediatric
182316|NCT02028455|young adult
182317|NCT02028455|acute lymphoblastic leukemia
182318|NCT02028455|CD19
182319|NCT02028455|leukemia
182320|NCT02028455|Chimeric Antigen Receptor
182321|NCT02028455|T cell
182322|NCT02028429|Minimal Hepatic Encephalopathy (MHE)
182323|NCT02028429|Psychometric Hepatic Encephalopathy Score (PHES)
182324|NCT02028429|Sickness Impact Profile (SIP)
182325|NCT02028429|Model for End-stage Liver Disease (MELD)
182326|NCT02028429|Child-Turcotte-Pugh score (CTP)
182327|NCT02028416|pancytopenia
182328|NCT02028416|aplastic anemia
182329|NCT02028416|ATG
182330|NCT02028416|Cyclosporin
182331|NCT02028390|wounds
182332|NCT02028390|thermal
182333|NCT02028390|temperature
182334|NCT02028390|periwound
182335|NCT02028390|camera
182336|NCT02028390|imaging
182337|NCT02028377|Adenocarcinoma
182338|NCT02028377|imaging
182339|NCT02028377|PET
182340|NCT02028377|MRI
182341|NCT02028364|Locally advanced breast cancer
182342|NCT02028364|HER2 negative
182343|NCT02028364|NSAI refractory
182344|NCT02028364|Metastatic breast cancer
182345|NCT02028364|Estrogen-receptor positive (ER+)
182346|NCT02028351|visual acuity
182347|NCT02028351|contrast sensitivity
182348|NCT02028351|cataract
182349|NCT02028351|maculopathy
182350|NCT02028312|Dry Eye
182351|NCT02028299|Pulmonary Arterial Hypertension
182352|NCT02028299|Pulmonary Vascular Resistance
182353|NCT02028299|Right Heart Catheterization
182354|NCT02028286|Rosacea
182355|NCT02028273|Neurogenesis
182356|NCT02028273|Addiction
182357|NCT02028273|Cocaine
182358|NCT02028273|MRI
182359|NCT02028273|MRS
182360|NCT02028247|Autism spectrum disorders
182361|NCT02028247|Autism
182362|NCT02028247|Asperger's syndrome
182363|NCT02028247|Pervasive developmental disability - not otherwise specified
182364|NCT02028247|obsessive-compulsive disorder
182365|NCT02028247|Social phobia
182366|NCT02028247|Generalized anxiety disorder
182367|NCT02028247|Specific phobia
182368|NCT02028247|Separation anxiety disorder
182369|NCT02028247|Counseling
182370|NCT02028247|Cognitive-behavioral therapy
182371|NCT02028247|Psychotherapy
182372|NCT02028221|Breast cancer prevention
182373|NCT02028221|metformin
182374|NCT02028221|Breast cancer risk reduction
182375|NCT02028208|Patch Test
182376|NCT02028208|Allergy Testing
182377|NCT02028208|Contact Dermatitis
182378|NCT02028208|Mercury, Aluminum or Palladium skin allergy
182379|NCT02028195|Health check
182380|NCT02028195|Health promotion
182381|NCT02028195|prevention diabetes
182382|NCT02028195|prevention cardiovascular disease
182383|NCT02028195|mental health
182384|NCT02028182|Patch Test
182385|NCT02028182|Allergy Testing
182386|NCT02028182|Contact dermatitis
182387|NCT02028182|Lyral allergen
182388|NCT02028182|Fragrance Mix allergen
182389|NCT02028169|Work Productivity
182390|NCT02028169|Anti-TNFs
182391|NCT02028169|Psoriatic Arthritis
182392|NCT02028143|Atrial Fibrillation
182393|NCT02028130|Atrial fibrillation
182394|NCT02028130|Ablation
182395|NCT02028130|Left atrial appendage occlusion
182396|NCT02028130|Stroke prevention
182397|NCT02028091|Pulse walve arrival time differences
182398|NCT02028078|Endogenous glucose production
182399|NCT02028078|Type 1 diabetes mellitus
182400|NCT02028078|hypoglycaemic clamp
182401|NCT02028078|tracer to technique
182402|NCT02028078|pharmacodynamics
182403|NCT02028078|pharmacokinetics
182404|NCT02028065|reversal of neuromuscular blockade
182405|NCT02028052|enlarged mediastinal nodes
182406|NCT02028052|enlarged hilar lymph nodes
182407|NCT02028039|Leukemia
182408|NCT02028039|Refractory Acute Lymphoblastic Leukemia
182409|NCT02028039|ALL
182410|NCT02028039|Burkitt's lymphoma
182411|NCT02028039|Lymphoblastic lymphoma
182412|NCT02028039|IPI-145
182413|NCT02028026|Depressive Disorder
182414|NCT02028026|Anxiety
182415|NCT02028026|Comorbidity
182416|NCT02028026|Magnetic Resonance Imaging
182417|NCT02028026|Magnetic Resonance Spectroscopy
182418|NCT02028026|Citalopram
182419|NCT02028026|Vilazodone
182420|NCT02028026|Serotonin Uptake Inhibitors
182421|NCT02028026|Receptor, Serotonin, 5-HT1A
182422|NCT02028013|Erectile dysfunction, sexual dysfunction, bioresonance
182423|NCT02028000|Pregnancy
182424|NCT02028000|Pregnant
182425|NCT02028000|Cesarean Section Delivery
182426|NCT02027987|valproate acid
182427|NCT02027987|traumatic brain injury
182428|NCT02027987|brain protection
182429|NCT02027987|epilepsy
182430|NCT02027974|Hip
182431|NCT02027974|Arthroplasty
182432|NCT02027974|Arthroplasties
182433|NCT02027974|Prosthesis
182434|NCT02027974|Iconacy
182435|NCT02027974|Osteoarthritis
182436|NCT02027974|Arthritis
182437|NCT02027974|THA
182438|NCT02027974|THR
182439|NCT02027974|DJD
182440|NCT02027961|Metastatic or Unresectable Melanoma, MEDI4736, dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1
182441|NCT02027948|nutritional management algorithm
182442|NCT02027948|nutritional and functional assessments
182443|NCT02027948|13-264
182444|NCT02027935|Melanoma
182445|NCT02027935|Metastatic
182446|NCT02027935|CD8+ T cells
182447|NCT02027935|White blood cell
182448|NCT02027935|Leukapheresis
182449|NCT02027935|Cyclophosphamide
182450|NCT02027935|Cytoxan
182451|NCT02027935|Neosar
182452|NCT02027935|Interleukin-2
182453|NCT02027935|Aldesleukin
182454|NCT02027935|IL-2
182455|NCT02027935|Proleukin
182456|NCT02027935|Ipilimumab
182457|NCT02027935|Yervoy
182458|NCT02027935|BMS-734016
182459|NCT02027935|MDX010
182460|NCT02027922|white spot lesion
182461|NCT02027922|caries
182462|NCT02027909|Sinus Node Dysfunction
182463|NCT02027896|Perioperative outcomes
182464|NCT02027883|Defibrillators
182465|NCT02027883|Ventricular Fibrillation Induction Testing
182466|NCT02027870|DES
182467|NCT02027870|CAD
182468|NCT02027870|EXCEL-II
182469|NCT02027870|JWMS
182470|NCT02027870|PCI
182471|NCT02027857|brain electrical impedance;
182472|NCT02027857|traumatic brain injury;
182473|NCT02027857|brain edema;
182474|NCT02027857|intracranial pressure
182475|NCT02027831|lymph nodes
182476|NCT02027818|margins
182477|NCT02027818|tumorectomy
182478|NCT02027805|Steroid-resistant
182479|NCT02027805|Graft vs Host Disease
182480|NCT02027805|Refractory acute Graft vs Host Disease
182481|NCT02027805|Hematopoietic Stem Cell Transplantation
182482|NCT02027805|Stem Cell Transplantation
182483|NCT02027805|Allogeneic Stem Cell Transplantation
182484|NCT02027805|Immune System Diseases
182485|NCT02027805|Antibodies, monoclonal
182486|NCT02027805|Immunotoxins
182487|NCT02027805|Immunosuppressive agents
182488|NCT02027779|GreenGene™ F, Previously Treated Patients
182489|NCT02027727|inflammatory bowel disease
182490|NCT02027727|infliximab
182491|NCT02027727|trough level
182492|NCT02027727|crohn's disease
182493|NCT02027727|ulcerative colitis
182494|NCT02027714|Discordant
182495|NCT02027714|Lesotho
182496|NCT02027714|Couples
182497|NCT02027714|Enhanced Prevention Package (EPP)
182498|NCT02027714|ART
182499|NCT02027714|Counseling
182500|NCT02027714|Male Circumcision
182501|NCT02027688|Oral feeding
182502|NCT02027688|Premature
182503|NCT02027688|Infants
182504|NCT02027688|Neonatal Intensive Care Unit
182505|NCT02027675|exercise
182506|NCT02027675|immune function
182507|NCT02027675|inflammation
182508|NCT02027675|immunity
182509|NCT02027675|diet
182510|NCT02027675|obesity
182511|NCT02027675|asthma
182512|NCT02027649|Bladder cancer
182513|NCT02027649|Keratin 14
182514|NCT02027649|Pronostic marker
182515|NCT02027649|Diagnostic marker
182516|NCT02027649|Noninvasive technique
182517|NCT02027636|Depression
182518|NCT02027636|Latinos
182519|NCT02027636|Mental Health
182520|NCT02027636|Disparities
182521|NCT02027623|Mechanical low back pain
182522|NCT02027623|Non-specific low back pain
182523|NCT02027623|Exercise
182524|NCT02027623|Motor skill training
182525|NCT02027610|Infant
182526|NCT02027610|Bangladesh
182527|NCT02027610|vitamin A
182528|NCT02027610|microbiota
182529|NCT02027610|vaccine
182530|NCT02027610|immunity
182531|NCT02027597|video games
182532|NCT02027597|oral health
182533|NCT02027597|social cognitive theory
182534|NCT02027597|behavior change
182535|NCT02027597|randomized trial
182536|NCT02027597|growth modeling
182537|NCT02027597|minority
182538|NCT02027597|gender
182539|NCT02027584|infant, premature
182540|NCT02027584|infant, newborn
182541|NCT02027584|choline
182542|NCT02027571|Diabetes
182543|NCT02027571|Race/Ethnicity
182544|NCT02027571|Offspring Cohort
182545|NCT02027571|African Americans
182546|NCT02027571|Prediabetes Reversal
182547|NCT02027571|Lifestyle Intervention
182548|NCT02027571|Insulin Sensitivity
182549|NCT02027571|Beta-cell Function
182550|NCT02027571|Diabetes Prevention
182551|NCT02027558|cognitive behavioral therapy
182552|NCT02027558|insomnia
182553|NCT02027558|apnea
182554|NCT02027545|cancer screening
182555|NCT02027545|decision making
182556|NCT02027519|Self-testing
182557|NCT02027519|Home-based testing
182558|NCT02027519|Lesotho
182559|NCT02027519|Discordant
182560|NCT02027506|ECG
182561|NCT02027506|aVL
182562|NCT02027506|CHRONIC STABLE ANGINA
182563|NCT02027506|T WAVE
182564|NCT02027493|Children
182565|NCT02027493|Chronic hepatitis C
182566|NCT02027493|Hansenula polymorpha
182567|NCT02027493|Pegylated interferon
182568|NCT02027493|Response rate
182569|NCT02027493|Ribavirin
182570|NCT02027493|Treatment
182571|NCT02027480|Antiretroviral Therapy (ART)
182572|NCT02027480|Biomarkers
182573|NCT02027480|Nyanza Province
182574|NCT02027480|Kenya
182575|NCT02027467|Hematopoietic stem cells
182576|NCT02027467|Herbal
182577|NCT02027467|Dietary
182578|NCT02027467|CD cells
182579|NCT02027467|Basic research
182580|NCT02027454|GSK1265744
182581|NCT02027454|HIV
182582|NCT02027454|placebo
182583|NCT02027454|cardiac repolarization
182584|NCT02027454|12-lead ECG
182585|NCT02027454|moxifloxacin
182586|NCT02027454|QTc
182587|NCT02027441|Serodiscordant
182588|NCT02027441|Lesotho
182589|NCT02027441|Home-based testing
182590|NCT02027428|Nab-paclitaxel
182591|NCT02027428|Albumin bound paclitaxel
182592|NCT02027428|Taxanes
182593|NCT02027428|Maintenance trials
182594|NCT02027428|Celgene
182595|NCT02027428|Abraxane
182596|NCT02027428|ABI-007
182597|NCT02027428|NSCLC
182598|NCT02027428|Non-Small Cell Lung Cancer
182599|NCT02027428|Cancer of the Lung
182600|NCT02027428|Carcinoma, Squamous Cell
182601|NCT02027428|Lung Neoplasms
182602|NCT02027428|Abound.sqm
182603|NCT02027415|air pollution
182604|NCT02027415|food
182605|NCT02027415|nitrites
182606|NCT02027415|nitrates
182607|NCT02027415|breath tests/methods
182608|NCT02027389|MSSA, MRSA
182609|NCT02027376|Advanced Breast Cancer
182610|NCT02027376|LDE225
182611|NCT02027376|Triple Negative
182612|NCT02027376|Hormonal Receptor negative
182613|NCT02027376|Her2 negative
182614|NCT02027363|Metastasis colorectal cancer
182615|NCT02027363|Maintenance
182616|NCT02027363|First-line treatment
182617|NCT02027363|Capecitabine
182618|NCT02027337|combined oral contraceptives
182619|NCT02027337|drospirenone
182620|NCT02027337|cyproterone
182621|NCT02027337|hemostasis
182622|NCT02027337|antioxidants
182623|NCT02027324|Surgical site infection
182624|NCT02027324|Cesarean delivery
182625|NCT02027324|Antisepsis
182626|NCT02027324|Povidone iodine
182627|NCT02027324|Chlorhexidine alcohol
182628|NCT02027324|Endometritis
182629|NCT02027311|Endoscopic Retrograde Cholangiopancreatography (ERCP)
182630|NCT02027311|Conscious Sedation
182631|NCT02027311|etomidate
182632|NCT02027311|midazolam
182633|NCT02027298|Abatacept
182634|NCT02027298|Sjogren's Syndrome
182635|NCT02027298|Rheumatoid Arthritis
182636|NCT02027285|fortified milk, aging, health status
182637|NCT02027272|Eclampsia
182638|NCT02027259|Diabetes
182639|NCT02027259|Depression
182640|NCT02027259|Group
182641|NCT02027246|spinal cord injury
182642|NCT02027246|autologous bone marrow mononuclear cells
182643|NCT02027246|stem cell therapy
182644|NCT02027233|Prevention
182645|NCT02027233|Influenza
182646|NCT02027233|Adults hospitalized
182647|NCT02027233|Vaccines
182648|NCT02027233|Effectiveness
182649|NCT02027207|Cholera
182650|NCT02027207|Oral cholera vaccine
182651|NCT02027207|Shanchol
182652|NCT02027207|Protective efficacy
182653|NCT02027207|Bangladesh
182654|NCT02027194|Allergic Rhinitis
182655|NCT02027194|Chinese herbal medicine
182656|NCT02027194|Adolescents
182657|NCT02027194|Double-blinded
182658|NCT02027194|Randomized controlled trial
182659|NCT02027168|infertility
182660|NCT02027168|elevated FSH
182661|NCT02027168|alternative treatment
182662|NCT02027168|Clear Passage Approach
182663|NCT02027168|Clear Passage Physical Therapy
182664|NCT02027155|healthy volunteers
182665|NCT02027129|Respiratory Distress Syndrome, Adult
182666|NCT02027129|Cor Pulmonale
182667|NCT02027129|High Frequency Ventilaiton
182668|NCT02027116|chronic hepatitis C
182669|NCT02027116|DNA Vaccine
182670|NCT02027116|Electroporation
182671|NCT02027116|Intramuscular (IM) Injection
182672|NCT02027103|Fetuin-A
182673|NCT02027103|OPG
182674|NCT02027103|Metformin
182675|NCT02027103|Pioglitazone
182676|NCT02027077|physical activity
182677|NCT02027077|diet
182678|NCT02027077|small change
182679|NCT02027077|behavior change
182680|NCT02027051|population genetics
182681|NCT02027025|Spasticity, Multiple sclerosis
182682|NCT02026934|Graft-Versus-Host Disease(GVHD)
182683|NCT02026934|Hematopoietic Stem Cell Transplantation.
182684|NCT02026934|Graft failure
182685|NCT02026934|Graft exhaustion
182686|NCT02026921|Phase II study,
182687|NCT02026921|Recurrent platinum-sensitive ovarian cancer
182688|NCT02026921|docetaxel
182689|NCT02026921|Carboplatin
182690|NCT02026921|Toxicity
182691|NCT02026908|Prostate Artery Embolization
182692|NCT02026908|PAE
182693|NCT02026908|Benign Prostatic Hyperplasia
182694|NCT02026908|BPH
182695|NCT02026908|Lower Urinary Tract Symptoms
182696|NCT02026908|LUTS
182697|NCT02026882|Airway, Caesarean
182698|NCT02026869|Vaginal administration, PCOS, Metformin
182699|NCT02026856|oxidative stress, sepsis, selenium
182700|NCT02026830|Diabetic foot infections
182701|NCT02026830|microorganisms
182702|NCT02026791|Supraglottic airway device
182703|NCT02026791|I-gel
182704|NCT02026791|SupremeLMA
182705|NCT02026791|Elderly patient
182706|NCT02026739|minimally invasive esophagectomy; pulmonary function
182707|NCT02026674|urineflow
182708|NCT02026674|luts
182709|NCT02026674|urine flow
182710|NCT02026674|uroflometry
182711|NCT02026674|bph
182712|NCT02026635|heart failure
182713|NCT02026635|Optivol® cardiac device
182714|NCT02026635|Medtronic CareLink
182715|NCT02026622|major depressive disorder
182716|NCT02026622|cerebrovascular reactivity
182717|NCT02026622|emotional reactivity
182718|NCT02026609|TIPS
182719|NCT02026609|Hepatic encephalopathy
182720|NCT02026609|Oral glutamine challenge
182721|NCT02026609|Psychometric tests
182722|NCT02026609|Portal hypertension
182723|NCT02026609|Cirrhosis
182724|NCT02026596|subrachnoid hemorrhage
182725|NCT02026596|secondary brain injury
182726|NCT02026570|Prosthesis
182727|NCT02026570|Falls
182728|NCT02026570|Training
182729|NCT02026544|low frequency ultrasound
182730|NCT02026544|glomerular filtration rate
182731|NCT02026492|exercise-induced bronchoconstriction
182732|NCT02026492|exercise-induced asthma
182733|NCT02026492|cold chamber
182734|NCT02026492|exercise challenge
182735|NCT02026492|cold air challenge
182736|NCT02026492|combined exercise- and cold-air challenge
182737|NCT02026492|methacholine challenge
182738|NCT02026479|full-frequency sudden hearing loss
182739|NCT02026479|post auricular injection
182740|NCT02026479|glucocorticoid
182741|NCT02026479|multi-center
182742|NCT02026466|Coronary Artery Disease
182743|NCT02026466|Chronic Total Occlusion
182744|NCT02026453|Adverse drug events
182745|NCT02026440|oral fluid collection device cotinine detection
182746|NCT02026414|PrimaVie
182747|NCT02026414|Herbal Supplement
182748|NCT02026414|Muscle biopsy
182749|NCT02026414|Energy
182750|NCT02026414|Exercise
182751|NCT02026414|Human skeletal muscle adaptation
182752|NCT02026414|Muscle function
182753|NCT02026388|PH
182754|NCT02026388|primary hyperoxaluria
182755|NCT02026388|hyperoxaluria
182756|NCT02026388|primary oxalosis
182757|NCT02026388|Primary Hyperoxaluria Type 1
182758|NCT02026388|Primary Hyperoxaluria Type 2
182759|NCT02026388|Primary Hyperoxaluria Type 3
182760|NCT02026388|Dent
182761|NCT02026388|Dents
182762|NCT02026388|Dent Disease
182763|NCT02026388|Dent 1
182764|NCT02026388|Dent 2
182765|NCT02026388|Cystinuria
182766|NCT02026388|APRT
182767|NCT02026388|APRT deficiency
182768|NCT02026388|Biobank
182769|NCT02026362|HCC
182770|NCT02026362|DC
182771|NCT02026362|CTL
182772|NCT02026349|influenza
182773|NCT02026349|flu
182774|NCT02026349|fever
182775|NCT02026349|cough
182776|NCT02026349|body aches
182777|NCT02026349|headache
182778|NCT02026349|nasal congestion
182779|NCT02026349|body pains
182780|NCT02026349|sore throat
182781|NCT02026349|fatigue
182782|NCT02026349|T-705
182783|NCT02026349|favipiravir
182784|NCT02026349|favor
182785|NCT02026349|flu symptoms
182786|NCT02026336|asthma; inflammation; electronic nose
182787|NCT02026310|glimepiride
182788|NCT02026310|metformin
182789|NCT02026310|basal insulin
182790|NCT02026310|Hemoglobin A, Glycosylated
182791|NCT02026310|glucose fluctuation
182792|NCT02026310|hypoglycemia
182793|NCT02026297|postpartum hemorrhage
182794|NCT02026297|estimated blood loss
182795|NCT02026297|coagulation
182796|NCT02026297|thromboelastography
182797|NCT02026297|tranexamic acid
182798|NCT02026284|Caesarean section
182799|NCT02026284|Anaesthesia
182800|NCT02026284|Questionnaires
182801|NCT02026245|Arthritis
182802|NCT02026245|rheumatoid
182803|NCT02026245|joints
182804|NCT02026245|swelling
182805|NCT02026245|measurement
182806|NCT02026245|movement
182807|NCT02026245|electronic
182808|NCT02026245|data
182809|NCT02026245|glove
182810|NCT02026245|goniometry
182811|NCT02026245|outcome
182812|NCT02026245|stiffness
182813|NCT02026232|Type 2 Diabetes
182814|NCT02026232|Overweight
182815|NCT02026206|Primary Dysmenorrhea
182816|NCT02026206|Pain
182817|NCT02026167|Chronic Pain
182818|NCT02026167|Mood
182819|NCT02026167|Physical Activity
182820|NCT02026154|hypertension, biomarkers, echocardiography, heart failure
182821|NCT02026128|Uveitis
182822|NCT02026128|Inflammation
182823|NCT02026128|OCT
182824|NCT02026128|Grading
182825|NCT02026115|cancer
182826|NCT02026115|hospice
182827|NCT02026115|pain
182828|NCT02026102|decision aid
182829|NCT02026102|patient decision making
182830|NCT02026102|heart failure
182831|NCT02026102|ejection fraction
182832|NCT02026102|primary prevention
182833|NCT02026102|implantable cardioverter defibrillator
182834|NCT02026102|ICD
182835|NCT02026102|pilot trial
182836|NCT02026102|patient centered health care
182837|NCT02026076|low back pain
182838|NCT02026076|traction
182839|NCT02026076|unloading
182840|NCT02026050|dexamethasone
182841|NCT02026050|intraarticular injection
182842|NCT02026050|interscalene brachial plexus block
182843|NCT02026037|Stress Disorders
182844|NCT02026037|Post-Traumatic
182845|NCT02026037|Burns
182846|NCT02026037|Brief Psychotherapy
182847|NCT02026037|Cognitive Behavior Therapy
182848|NCT02026011|alcohol use disorder
182849|NCT02026011|naltrexone
182850|NCT02026011|Asian American
182851|NCT02026011|pharmacogenetics
182852|NCT02026011|OPRM1 gene
182853|NCT02025998|ibudilast, alcoholism
182854|NCT02025985|Karyopharm
182855|NCT02025985|KPT-330
182856|NCT02025985|Selinexor
182857|NCT02025985|SIGN
182858|NCT02025985|ovarian cancer
182859|NCT02025985|endometrial cancer
182860|NCT02025985|cervical cancer
182861|NCT02025985|SINE™
182862|NCT02025985|breast cancer
182863|NCT02025985|HER2 negative
182864|NCT02025972|Cerebral palsy
182865|NCT02025972|Umbilical cord blood
182866|NCT02025972|Rehabilitation
182867|NCT02025972|Cytokine
182868|NCT02025972|Outcome
182869|NCT02025959|staff empowerment
182870|NCT02025959|Sleep Apnea
182871|NCT02025959|educational intervention
182872|NCT02025933|Children
182873|NCT02025933|Age 9-12 years
182874|NCT02025933|Overweight (iso-BMI > 25)
182875|NCT02025907|Diabetes Mellitus, Type 2
182876|NCT02025907|Canagliflozin
182877|NCT02025907|Hemoglobin A1c
182878|NCT02025907|Metformin
182879|NCT02025907|Sitagliptin
182880|NCT02025907|T2DM
182881|NCT02025907|JNJ-28431754
182882|NCT02025894|neoplastic solid tumour
182883|NCT02025894|PCVC
182884|NCT02025894|thromboembolic complications
182885|NCT02025894|infectious complications
182886|NCT02025894|risk factors
182887|NCT02025868|Africa
182888|NCT02025868|Antiretroviral Treatment
182889|NCT02025868|Adherence reinforcement
182890|NCT02025868|Third line ART
182891|NCT02025868|Second line ART
182892|NCT02025868|Virologic failure
182893|NCT02025868|Adults
182894|NCT02025855|Iatrogenic opioid abstinence syndrome
182895|NCT02025855|Methadone
182896|NCT02025855|Mechanical ventilation
182897|NCT02025855|ICU delirium
182898|NCT02025855|Continuous sedation
182899|NCT02025842|Hepatocellular carcinoma
182900|NCT02025842|Hepatitis B
182901|NCT02025829|cystic fibrosis
182902|NCT02025829|IL-17 neutrophils
182903|NCT02025803|Advanced solid tumors
182904|NCT02025790|Achalasia
182905|NCT02025790|POEM
182906|NCT02025790|Pneumatic dilatation
182907|NCT02025790|Eckardt score
182908|NCT02025777|Ulcerative Colitis
182909|NCT02025777|PillCam
182910|NCT02025777|IBD
182911|NCT02025751|Diabetes
182912|NCT02025751|Gastroparesis
182913|NCT02025751|Delayed gastric emptying
182914|NCT02025751|Nausea
182915|NCT02025751|Vomiting
182916|NCT02025751|Bloating
182917|NCT02025751|Abdominal pain
182918|NCT02025751|Early Satiety
182919|NCT02025751|Gastric stasis
182920|NCT02025751|Gastropathy
182921|NCT02025725|Gastroparesis
182922|NCT02025725|Diabetic
182923|NCT02025725|Delayed gastric emptying
182924|NCT02025725|Gastric stasis
182925|NCT02025725|Nausea
182926|NCT02025725|Vomiting
182927|NCT02025725|Bloating
182928|NCT02025725|Abdominal pain
182929|NCT02025725|Early satiety
182930|NCT02025725|Gastropathy
182931|NCT02025686|Pain
182932|NCT02025686|Inflammation
182933|NCT02025686|Hyperalgesia
182934|NCT02025686|burn injury
182935|NCT02025686|Hyperbaric Oxygen
182936|NCT02025660|Mw
182937|NCT02025660|Mycobacterium indicum prannii
182938|NCT02025660|Mycobacterium w
182939|NCT02025660|Severe sepsis
182940|NCT02025660|Septic shock
182941|NCT02025647|Mood disorders
182942|NCT02025647|Anxiety disorders
182943|NCT02025647|Eating concerns
182944|NCT02025647|Pain concerns
182945|NCT02025647|Alcohol abuse
182946|NCT02025647|Self harm
182947|NCT02025647|Mental health
182948|NCT02025647|Clinical Decision Support
182949|NCT02025634|Pain, Postoperative
182950|NCT02025634|Ofirmev
182951|NCT02025634|Acetaminophen
182952|NCT02025634|Analgesics, Non-Narcotic
182953|NCT02025634|Arthroscopy
182954|NCT02025621|coronary artery bypass grafting
182955|NCT02025621|CABG
182956|NCT02025621|mitral valve
182957|NCT02025621|LCOS
182958|NCT02025621|low cardiac output syndrome
182959|NCT02025621|levosimendan
182960|NCT02025608|Restless legs syndrome
182961|NCT02025595|Brain
182962|NCT02025595|Genes
182963|NCT02025595|Environment
182964|NCT02025595|Etiology
182965|NCT02025595|Reward
182966|NCT02025595|Satiety Response
182967|NCT02025595|Central Nervous System
182968|NCT02025595|Magnetic Resonance Imaging
182969|NCT02025595|Twins, Monozygotic
182970|NCT02025595|Overweight
182971|NCT02025595|Obesity
182972|NCT02025582|idiopathic toe walking
182973|NCT02025582|gait disorder
182974|NCT02025582|gait analysis
182975|NCT02025582|kinesio taping
182976|NCT02025582|ultrasound elastography
182977|NCT02025582|pediatric
182978|NCT02025582|children
182979|NCT02025582|muscle stiffness
182980|NCT02025582|muscle elasticity
182981|NCT02025569|chronic ankle instability
182982|NCT02025569|lateral ankle sprain
182983|NCT02025569|manual therapy
182984|NCT02025569|star excursion balance test
182985|NCT02025569|strain and counterstrain
182986|NCT02025556|High Frequency Episodic Migraine Headache
182987|NCT02025556|Episodic Migraine Headache
182988|NCT02025556|Migraine Headache
182989|NCT02025543|MRI
182990|NCT02025543|Iron overload
182991|NCT02025530|Stillbirth
182992|NCT02025530|Modifiable risk factors
182993|NCT02025517|Parkinson's disease
182994|NCT02025517|rehabilitation
182995|NCT02025517|kinematics
182996|NCT02025517|cognition
182997|NCT02025504|Colonoscopy, Looping, Sigmoid Looping, ColoWrap, Binder, Patient Satisfaction
182998|NCT02025491|Disseminated leishmaniasis
182999|NCT02025491|Liposomal Amphotericin B
183000|NCT02025491|Leishmania braziliensis
183001|NCT02025478|children
183002|NCT02025478|bone marrow transplant
183003|NCT02025478|autologous
183004|NCT02025478|allogeneic
183005|NCT02025478|breastmilk
183006|NCT02025478|hematopoietic stem cell transplantation (HSCT)
183007|NCT02025465|Atrial Fibrillation
183008|NCT02025465|Atrial Flutter
183009|NCT02025465|Metoprolol
183010|NCT02025465|Diltiazem
183011|NCT02025452|diarrhoea
183012|NCT02025452|gastroenteritis
183013|NCT02025452|rapid diagnostics
183014|NCT02025452|probiotics
183015|NCT02025452|sub-Saharan Africa
183016|NCT02025439|Traumatic Brain Injury
183017|NCT02025439|Transcranial Magnetic Stimulation
183018|NCT02025439|Amantadine
183019|NCT02025439|Vegetative State
183020|NCT02025439|Minimally Conscious State
183021|NCT02025426|Cesarean delivery
183022|NCT02025426|Spinal Anesthesia
183023|NCT02025400|Rehabilitation
183024|NCT02025400|eRehab
183025|NCT02025400|Physical Therapy
183026|NCT02025400|e-Health
183027|NCT02025400|Telemedicine
183028|NCT02025400|Telerehabilitation
183029|NCT02025400|Patient-Centered
183030|NCT02025374|spinal anesthesia
183031|NCT02025374|cesarean section
183032|NCT02025374|hyperbaric levobupivacaine
183033|NCT02025361|prostate biopsy, local anesthesia, cancer detection rate.
183034|NCT02025322|HIV/AIDS
183035|NCT02025322|Peer Mentoring
183036|NCT02025322|Medication Adherence
183037|NCT02025322|Medication Non-adherent
183038|NCT02025322|Newly diagnosed
183039|NCT02025322|HIV-positive individuals
183040|NCT02025322|HIV viral load
183041|NCT02025322|CD4 lymphocyte cell counts
183042|NCT02025322|Treatment adherence
183043|NCT02025322|Health literacy
183044|NCT02025322|Self-efficacy
183045|NCT02025309|train of four
183046|NCT02025309|neuromuscular recovery
183047|NCT02025309|sugammadex
183048|NCT02025296|Telemedicine
183049|NCT02025296|Clinical decision support system
183050|NCT02025296|Ubiquitous healthcare
183051|NCT02025296|Diabetes Care
183052|NCT02025296|Multifactorial Intervention
183053|NCT02025283|Intervertebral disc disease
183054|NCT02025283|Radiculopathy
183055|NCT02025283|Chronic pain
183056|NCT02025283|Thermocoagulation
183057|NCT02025270|Azoospermia, Spermatogonial Arrest, Maturation Arrest.
183058|NCT02025257|coronary artery disease
183059|NCT02025257|elderly
183060|NCT02025257|exercise
183061|NCT02025257|exercise-based cardiac rehabilitation
183062|NCT02025244|Key hole biopsy
183063|NCT02025244|Upper Gastrointestinal Submucosal Tumors
183064|NCT02025244|EUS-FNA
183065|NCT02025244|Mitototic Activity
183066|NCT02025244|GIST
183067|NCT02025231|reirradiation
183068|NCT02025231|recurrent glioma
183069|NCT02025231|positron emission tomography
183070|NCT02025231|amino acid tracer
183071|NCT02025218|NSCLC
183072|NCT02025218|EGFR
183073|NCT02025218|TKI
183074|NCT02025218|Re-challenge
183075|NCT02025218|Lung Cancer
183076|NCT02025218|Resistance
183077|NCT02025192|ONT-380
183078|NCT02025192|Capecitabine
183079|NCT02025192|Trastuzumab
183080|NCT02025192|Xeloda
183081|NCT02025192|Herceptin
183082|NCT02025192|HER2 positive breast cancer
183083|NCT02025192|Breast cancer
183084|NCT02025192|ARRY-380
183085|NCT02025192|Tucatinib
183086|NCT02025179|Teriparatide
183087|NCT02025179|Osteoporosis
183088|NCT02025179|Spinal Cord Injury
183089|NCT02025179|Bone Diseases
183090|NCT02025179|Metabolic Bone Diseases
183091|NCT02025179|Musculoskeletal Diseases
183092|NCT02025179|Spinal Cord Diseases
183093|NCT02025179|Central Nervous System Diseases
183094|NCT02025179|Nervous System Diseases
183095|NCT02025179|Nervous System
183096|NCT02025179|Wounds and Injuries
183097|NCT02025179|Bone Density Conservation Agents
183098|NCT02025179|Physiological Effects of Drugs
183099|NCT02025179|Pharmacologic Actions
183100|NCT02025179|Vibration
183101|NCT02025166|Pain
183102|NCT02025166|abortion
183103|NCT02025166|paracetamol
183104|NCT02025166|lornoxicam
183230|NCT02024477|endothelial dysfunction
183105|NCT02025140|Computer controlled anesthesia (CCLAD)
183106|NCT02025140|pain perception
183107|NCT02025140|Effectiveness
183108|NCT02025140|primary molars
183109|NCT02025140|Behavior
183110|NCT02025127|septic shock
183111|NCT02025127|mechanical ventilation
183112|NCT02025127|enteral nutrition
183113|NCT02025127|trophic feeding
183114|NCT02025114|NSCLC, EGFR mutation
183115|NCT02025101|Slow Coronary Flow
183116|NCT02025075|Tomography
183117|NCT02025075|Oximetry
183118|NCT02025075|Echocardiography
183119|NCT02025062|head and neck squamous cell carcinomas (HNSCCs)
183120|NCT02025062|elderly
183121|NCT02025062|cancer
183122|NCT02025062|comprehensive geriatric assessment
183123|NCT02025062|functional status
183124|NCT02025062|malnutrition
183125|NCT02025062|survival
183126|NCT02025049|pancreatitis
183127|NCT02025036|Chemoradiotherapy， Esophageal Squamous Cancer
183128|NCT02025023|Size
183129|NCT02025023|Pain
183130|NCT02025023|Resolution
183131|NCT02025023|Complications
183132|NCT02025023|Swelling
183133|NCT02025010|castration-resistant prostate cancer
183134|NCT02024997|Pancreatic malignancy
183135|NCT02024997|Radiation Therapy
183136|NCT02024984|LPFPCCPCOS
183137|NCT02024971|Drug therapy
183138|NCT02024958|Adult ICU patients
183139|NCT02024958|spontaneous breathing
183140|NCT02024958|invasive ventilation
183141|NCT02024958|non-invasive ventilation
183142|NCT02024945|Drug therapy
183143|NCT02024906|isoflavone
183144|NCT02024906|CVD
183145|NCT02024906|soy intake
183146|NCT02024906|subclinical hypothyroid
183147|NCT02024893|Humeral retroversion
183148|NCT02024893|dynamic control ratio
183149|NCT02024893|GIRD
183150|NCT02024880|in vitro fertilization
183151|NCT02024880|embryo transfer
183152|NCT02024880|transfer catheter
183153|NCT02024867|Methicillin resistent Staphylococcus aureus
183154|NCT02024867|Staphylococcus aureus
183155|NCT02024854|Kangaroo-Mother Care Method
183156|NCT02024854|Stress, Physiological
183157|NCT02024841|Gastric cancer
183158|NCT02024841|Peritoneal carcinomatosis
183159|NCT02024841|Intraperitoneal docetaxel
183160|NCT02024841|Cisplatin
183161|NCT02024841|TS-ONE
183162|NCT02024828|Infant feeding
183163|NCT02024802|Pain
183164|NCT02024802|Pain Cream
183165|NCT02024802|Nociceptive pain
183166|NCT02024802|neurologic pain
183167|NCT02024802|transdermal
183168|NCT02024802|compounding
183169|NCT02024802|compound
183170|NCT02024776|Training
183171|NCT02024776|Wellness
183172|NCT02024776|Aerobic capacity
183173|NCT02024776|Information and communication technology, surgical risk
183174|NCT02024776|Abdominal surgery
183175|NCT02024763|Energy Expenditure
183176|NCT02024763|Physical Education
183177|NCT02024763|Children
183178|NCT02024763|Randomized Controlled Trial
183179|NCT02024750|Family centered care
183180|NCT02024750|Patient centered care
183181|NCT02024750|Diabetes Mellitus, Type 1
183182|NCT02024750|Problem Recognition in Illness Self-Management (PRISM)
183183|NCT02024711|Cataract
183184|NCT02024711|Intraocular Lens
183185|NCT02024711|IOL
183186|NCT02024711|Aphakia
183187|NCT02024685|Prostate
183188|NCT02024685|Localized Prostate Cancer
183189|NCT02024685|Decision making
183190|NCT02024672|Intrauterine devices
183191|NCT02024672|IUDs
183192|NCT02024672|postpartum
183193|NCT02024672|contraception
183194|NCT02024659|nasal polyps
183195|NCT02024659|remodeling
183196|NCT02024659|inflammatory cells
183197|NCT02024659|budesonide
183198|NCT02024646|Psoriatic Arthritis
183199|NCT02024646|Brodalumab
183200|NCT02024646|AMG 827
183201|NCT02024620|depression
183202|NCT02024620|technology
183203|NCT02024620|psychotherapy
183204|NCT02024620|behavioral activation
183205|NCT02024594|Nitrous Oxide-Oxygen conscious sedation
183206|NCT02024594|Cognitive Behavioral Therapy
183207|NCT02024594|Children, Preschool
183208|NCT02024594|dental anxiety
183209|NCT02024594|Patient Cooperation
183210|NCT02024581|pediatric
183211|NCT02024581|dermatology
183212|NCT02024581|East Indian sandalwood oil
183213|NCT02024581|pox virus
183214|NCT02024568|Pregabalin
183215|NCT02024568|Arthralgia Myalgia Syndrome
183216|NCT02024568|Paclitaxel
183217|NCT02024568|Pain management
183218|NCT02024568|Breast cancer
183219|NCT02024542|Bariatric Surgery, Obesity, White Adipose Tissue
183220|NCT02024516|Type 2 diabetes
183221|NCT02024516|Pomegranate
183222|NCT02024516|Inflammation
183223|NCT02024516|lipid profiles
183224|NCT02024503|stroke
183225|NCT02024503|fMRI
183226|NCT02024503|DTI
183227|NCT02024490|vitamin D, prematurity, RDS, BPD, maternal, neonatal
183228|NCT02024477|endothelial cells
183229|NCT02024477|cellular biomarker
183231|NCT02024464|Primary open angle glaucoma
183232|NCT02024464|POAG
183233|NCT02024464|Pseudoexfoliative glaucoma
183234|NCT02024464|PXG
183235|NCT02024464|Pigmentary dispersion glaucoma
183236|NCT02024464|PDG
183237|NCT02024464|Hydrus
183238|NCT02024451|Radial shock wave
183239|NCT02024451|Acupuncture
183240|NCT02024438|metastatic gastric cancer
183241|NCT02024438|neurotoxicity
183242|NCT02024438|mFOLFOX6
183243|NCT02024438|monosialotetrahexosylganglioside Sodium Injection
183244|NCT02024425|Clinical trials
183245|NCT02024425|Adult
183246|NCT02024425|Women
183247|NCT02024425|Functional food
183248|NCT02024425|Dietary Supplements
183249|NCT02024425|Overweight
183250|NCT02024425|Obese
183251|NCT02024425|Absorptiometry, Dual X-Ray
183252|NCT02024425|Rosmarinus
183253|NCT02024425|Oligosaccharides
183254|NCT02024425|Lactulose
183255|NCT02024425|Bioactive peptide
183256|NCT02024412|metastatic colorectal cancer
183257|NCT02024412|neurotoxicity
183258|NCT02024412|mFOLFOX6
183259|NCT02024412|monosialotetrahexosylganglioside Sodium Injection
183260|NCT02024399|Pediatric Overweight/Obesity, DEXA, Fitness
183261|NCT02024386|Guanylate Cyclase
183262|NCT02024386|Pulmonary Edema of Mountaineers
183263|NCT02024386|Mountaineering
183264|NCT02024386|Performance-Enhancing Substances
183265|NCT02024386|Athletic Performance
183266|NCT02024373|chronic subdural hematoma
183267|NCT02024373|Atorvastatin
183268|NCT02024373|oral administration therapy
183269|NCT02024360|obesity
183270|NCT02024360|overweight
183271|NCT02024360|children
183272|NCT02024360|prevention
183273|NCT02024334|JIA
183274|NCT02024334|LEFLUNOMIDE
183275|NCT02024334|EFFICACY
183276|NCT02024321|abdominal surgery
183277|NCT02024321|TPN
183278|NCT02024321|blood glucose
183279|NCT02024308|acute myeloid leukemia,
183280|NCT02024308|AML1-ETO fusion protein,
183281|NCT02024308|Fludarabine,
183282|NCT02024308|recurrence
183283|NCT02024269|macular degeneration
183284|NCT02024269|stem cells
183285|NCT02024269|adipose stem cells
183286|NCT02024256|Vaginal delivery
183287|NCT02024256|Perineal swelling
183288|NCT02024256|Perineal pain
183289|NCT02024256|MgSo4
183290|NCT02024256|Magnesium sulfate
183291|NCT02024256|Cold water
183292|NCT02024243|Micro RNA
183293|NCT02024243|Wound
183294|NCT02024243|Chronic Venous Leg Ulcer
183295|NCT02024243|VLU
183296|NCT02024243|miR210
183297|NCT02024243|OSU Comprehensive Wound Center
183298|NCT02024204|World Trade Center Disaster
183299|NCT02024204|Environmental Exposure
183300|NCT02024204|Respiratory Physiology
183301|NCT02024204|Inflammation
183302|NCT02024204|Gastrointestinal Diseases
183303|NCT02024204|Sinus Symptoms
183304|NCT02024204|PTSD
183305|NCT02024204|Anxiety
183306|NCT02024204|Depression
183307|NCT02024204|Hypersensitivity
183308|NCT02024204|Spirometry
183309|NCT02024204|Oscillometry
183310|NCT02024191|glutamine
183311|NCT02024191|oxaliplatin
183312|NCT02024191|peripheral neuropathy
183313|NCT02024178|Prostate Cancer
183314|NCT02024178|Radical Prostatectomy
183315|NCT02024178|Ultrasound Imaging
183316|NCT02024165|Ultrasound
183317|NCT02024165|FSE
183318|NCT02024165|IUPC
183319|NCT02024139|Orthodontic pain
183320|NCT02024139|Chewing gum
183321|NCT02024126|Knee osteoarthritis
183322|NCT02024126|Exercise therapy
183323|NCT02024126|RCT
183324|NCT02024126|Intervention
183325|NCT02024126|Knee pain
183326|NCT02024126|Muticenter
183327|NCT02024126|Knee function
183328|NCT02024113|validation
183329|NCT02024113|model
183330|NCT02024113|metabolic profile
183331|NCT02024113|positron emission tomography
183332|NCT02024061|Adolescents
183333|NCT02024061|Obesity
183334|NCT02024061|Physical activity
183335|NCT02024061|Sedentary behavior
183336|NCT02024061|Psychosocial health
183337|NCT02024048|Pregnancy
183338|NCT02024048|OCT
183339|NCT02024048|Enhanced depth imaging
183340|NCT02024048|Choroid
183341|NCT02024035|Tomotherapy
183342|NCT02024035|Head and neck squamous celle carcinoma
183343|NCT02024035|Health economic evaluation
183344|NCT02024022|colonoscopy
183345|NCT02024022|bowel cleansing
183346|NCT02024022|polyethylene glycol
183347|NCT02024022|sodium picosulphate / magnesium citrate
183348|NCT02024009|chemoradiotherapy
183349|NCT02024009|nelfinavir
183350|NCT02024009|abraxane
183351|NCT02024009|gemcitabine
183352|NCT02024009|radiotherapy
183353|NCT02024009|capecitabine
183354|NCT02023996|HER2 positive
183355|NCT02023996|PET Imaging
183356|NCT02023996|89Zr-DFO-trastuzumab
183357|NCT02023996|13-165
183358|NCT02023983|ST-segment elevation myocardial infarction
183359|NCT02023983|Primary percutaneous coronary intervention
183360|NCT02023983|Low risk
183361|NCT02023983|Early discharge
183362|NCT02023970|Bioprosthetic heart valves, immune response, structural valve deterioration, valvular disease.
183363|NCT02023957|Interactive Health-risk assessment
183364|NCT02023957|Primary Care
183365|NCT02023957|Randomized
183366|NCT02023957|Open Label
183367|NCT02023957|Efficacy Study
183368|NCT02023944|Memory
183369|NCT02023944|Aging
183370|NCT02023944|Healthy People
183371|NCT02023944|Intervention
183372|NCT02023931|Oral mucosa
183373|NCT02023931|Nrf2 pathway
183374|NCT02023931|Broccoli Sprout Extract
183375|NCT02023931|Head and Neck Cancer
183376|NCT02023918|Growth hormone antagonism
183377|NCT02023866|Leigh Syndrome
183378|NCT02023866|Leber's hereditary optic neuropathy
183379|NCT02023866|myoclonic epilepsy
183380|NCT02023866|mitochondrial encephalomyopathy
183381|NCT02023866|Kearn-Sayre syndrome
183382|NCT02023866|POLG-related disorders
183383|NCT02023866|Neurogastrointestinal encephalopathy
183384|NCT02023840|periodontitis
183385|NCT02023840|pockets
183386|NCT02023827|Transtheoretical Model
183387|NCT02023827|Stages of change
183388|NCT02023827|Computer-tailored intervention
183389|NCT02023827|Delinquency
183390|NCT02023827|Substance abuse
183391|NCT02023827|Juvenile offender
183392|NCT02023827|Juvenile justice
183393|NCT02023827|Rise Above Your Situation (RAYS) program
183394|NCT02023801|Menorrhagia
183395|NCT02023801|Dysfunctional Uterine Bleeding
183396|NCT02023801|Endometrial Ablation
183397|NCT02023788|human umbilical cord blood-derived mesenchymal stem cells
183398|NCT02023788|bronchopulmonary dysplasia
183399|NCT02023788|respiratory tract infection
183400|NCT02023788|Premature infants
183401|NCT02023762|mitral regurgitation
183402|NCT02023762|local anaesthesia
183403|NCT02023762|percutaneous repair
183404|NCT02023749|nuts
183405|NCT02023749|metabolic syndrome
183406|NCT02023749|lipid profile
183407|NCT02023749|inflammation
183408|NCT02023749|oxidative stress
183409|NCT02023749|endothelial function
183410|NCT02023723|Energy Drink
183411|NCT02023723|Electrocardiograph
183412|NCT02023723|Hemodynamic
183413|NCT02023710|mucosal melanoma
183414|NCT02023710|Bevacizumab
183415|NCT02023710|Carboplatin
183416|NCT02023710|Paclitaxel
183417|NCT02023684|Sleeve Gastrectomy
183418|NCT02023684|Lidocaine
183419|NCT02023684|ropivacaine
183420|NCT02023658|HIV
183421|NCT02023658|pMTCT
183422|NCT02023645|lutein
183423|NCT02023645|cognition
183424|NCT02023645|neural efficiency
183425|NCT02023645|aging
183426|NCT02023632|older adults
183427|NCT02023632|physical activity
183428|NCT02023632|self-categorization
183429|NCT02023632|group dynamics
183430|NCT02023632|self-identity
183431|NCT02023619|Keratoconus
183432|NCT02023619|Astigmatism
183433|NCT02023619|Cornea
183434|NCT02023619|SD-OCT
183435|NCT02023606|Impulsive Aggression
183436|NCT02023606|ADHD
183437|NCT02023580|Viral suppression
183438|NCT02023580|Sexual risk
183439|NCT02023554|azithromycin
183440|NCT02023554|theophylline
183441|NCT02023554|CYP3A4
183442|NCT02023515|weight loss
183443|NCT02023515|metabolic syndrome
183444|NCT02023515|stress
183445|NCT02023515|obesity
183446|NCT02023502|female stress urinary incontinence
183447|NCT02023502|proteomics
183448|NCT02023502|biomarker
183449|NCT02023424|BDNF
183450|NCT02023424|GLATIRAMER ACETATE
183451|NCT02023424|RETT SYNDROME
183452|NCT02023424|COPAXONE
183453|NCT02023424|Bruria Ben-Zeev
183454|NCT02023411|Teriparatide
183455|NCT02023411|Inactive Charcot's neuroarthropathy
183456|NCT02023398|High Frequency
183457|NCT02023398|Waist circumferential reduction
183458|NCT02023385|Low Level Laser Therapy
183459|NCT02023385|LLLT
183460|NCT02023385|Waist circumferential reduction
183461|NCT02023372|NuCel
183462|NCT02023372|Lumbar Spine
183463|NCT02023372|Degenerative Disease
183464|NCT02023372|Efficacy
183465|NCT02023372|Fusion
183466|NCT02023359|Advanced breast cancer
183467|NCT02023359|Everolimus
183468|NCT02023346|Patient-Physician Communication
183469|NCT02023346|Brain cancer
183470|NCT02023346|13-253
183471|NCT02023333|Regorafenib
183472|NCT02023333|Performance Status
183473|NCT02023333|13-211
183474|NCT02023281|Depression
183475|NCT02023281|Exercise
183476|NCT02023281|Neurotransmitters
183477|NCT02023281|Catecholimines
183478|NCT02023281|EEG
183479|NCT02023255|Healthy
183480|NCT02023255|JNJ-39393406
183481|NCT02023255|Safety
183482|NCT02023255|Tolerability
183483|NCT02023255|Pharmacokinetics
183484|NCT02023242|Primary open angle glaucoma
183485|NCT02023242|POAG
183486|NCT02023242|Pseudoexfoliative glaucoma
183487|NCT02023242|PXG
183488|NCT02023242|Pigmentary glaucoma
183489|NCT02023242|PG
183490|NCT02023242|Hydrus
183491|NCT02023229|Branched chain aminoacids
183492|NCT02023229|Nutritional status
183493|NCT02023229|Hepatic encephalopathy
183494|NCT02023216|Preterm infants
183495|NCT02023216|Non-nutritive sucking
183496|NCT02023216|Pacifier
183497|NCT02023216|Gastro-esophageal reflux
183498|NCT02023216|pH-multiple intraluminal impedance
183499|NCT02023216|Apneas
183500|NCT02023216|Bradycardias
183501|NCT02023216|Hypoxic episodes
183502|NCT02023216|Polysomnographic monitoring
183503|NCT02023190|liver cirrhosis
183504|NCT02023190|liver transplant
183505|NCT02023190|nutritional status
183506|NCT02023190|bioelectrical impedance vector analysis
183507|NCT02023177|phase angle
183508|NCT02023177|liver cirrhosis
183509|NCT02023177|mortality
183510|NCT02023177|malnutrition
183511|NCT02023138|Clinical practice guideline
183512|NCT02023138|Brain injury
183513|NCT02023138|Acceptability
183514|NCT02023138|Feasibility
183515|NCT02023138|Effectiveness
183516|NCT02023112|Japanese
183517|NCT02023112|Hepatitis C
183518|NCT02023112|Treatment naive
183519|NCT02023112|Treatment experienced
183520|NCT02023112|Genotype 2
183521|NCT02023112|Ombitasvir
183522|NCT02023112|Paritaprevir
183523|NCT02023112|Ritonavir
183524|NCT02023112|Ribavirin
183525|NCT02023112|VIEKIRAX Combination Tablets
183526|NCT02023099|Hepatitis C
183527|NCT02023099|Genotype 1b
183528|NCT02023099|Cirrhotic
183529|NCT02023099|Treatment Experienced
183530|NCT02023099|Treatment Naive
183531|NCT02023099|Japanese
183532|NCT02023099|ombitasvir
183533|NCT02023099|paritaprevir
183534|NCT02023099|ritonavir
183535|NCT02023099|VIEKIRAX Combination Tablets
183536|NCT02023086|Visual field defect
183537|NCT02023086|Blood oxygenation
183538|NCT02023086|Optic nerve Head
183539|NCT02023047|Anal Fissure
183540|NCT02023047|Nifedipine
183541|NCT02023034|Parkinson's disease, Physical Therapy, Fatigue, Quality of Life
183542|NCT02023021|Pancreatic Cancer; Pancreatic Adenocarcinoma; Nab-paclitaxel; Gemcitabine; Adjuvant Therapy
183543|NCT02022995|EGFR
183544|NCT02022995|cetuximab
183545|NCT02022995|colon cancer
183546|NCT02022982|KRAS mutant Non-Small Cell Lung Cancer
183547|NCT02022982|Solid Tumors
183548|NCT02022969|atelectasis
183549|NCT02022969|SPO2 - oscillations
183550|NCT02022943|Alzheimer's
183551|NCT02022943|prevention
183552|NCT02022930|Osteoarthritis
183553|NCT02022930|Knee
183554|NCT02022917|ovarian cancer.
183555|NCT02022917|tubal cancer
183556|NCT02022917|peritoneal cancer
183557|NCT02022904|prostate cancer
183558|NCT02022904|metastatic
183559|NCT02022904|castrate resistant
183560|NCT02022891|Sickle cell disease
183561|NCT02022891|psychological support
183562|NCT02022891|quality of life
183563|NCT02022878|Chronic total occlusion
183564|NCT02022878|Percutaneous coronary intervention
183565|NCT02022878|Coronary computed tomography angiography
183566|NCT02022878|Coronary angiography
183567|NCT02022865|periodontitis
183568|NCT02022865|cytokines
183569|NCT02022865|adverse pregnancy outcome
183570|NCT02022852|Rectal Cancer
183571|NCT02022852|Concurrent Chemoradiotherapy
183572|NCT02022852|Sequential Therapy
183573|NCT02022839|mechanical ventilation, weaning
183574|NCT02022839|ultrasonography
183575|NCT02022826|Gastroparesis
183576|NCT02022826|SmartPill Monitoring System (SPM)
183577|NCT02022826|Gastric Emptying Scintigraphy (GES)
183578|NCT02022813|Energy requirements, Glucose turnover, Protein turnover
183579|NCT02022787|RCC
183580|NCT02022787|Chemokines
183581|NCT02022787|nephrectomy
183582|NCT02022787|partial nephrectomy
183583|NCT02022761|Mild or moderate asthmatics
183584|NCT02022761|Adults
183585|NCT02022761|Laninamivir
183586|NCT02022735|Deep Brain Stimulation
183587|NCT02022722|Pelvic Floor Myalgia
183588|NCT02022722|Trigger Point Injections
183589|NCT02022722|Pelvic Rehabilitation
183590|NCT02022722|Dyspareunia
183591|NCT02022709|Cognitive Behavior Therapy
183592|NCT02022709|Exposure and Response/Ritual Prevention
183593|NCT02022709|Selective Serotonin Reuptake Inhibitors
183594|NCT02022709|Psychotherapy
183595|NCT02022709|Pharmacotherapy
183596|NCT02022709|Citalopram
183597|NCT02022709|Fluoxetine
183598|NCT02022709|Paroxetine
183599|NCT02022709|Sertraline
183600|NCT02022709|Fluvoxamine
183601|NCT02022709|fMRI
183602|NCT02022709|Stop Signal Task
183603|NCT02022696|Adenosine Deaminase Deficiency
183604|NCT02022696|Gene Therapy
183605|NCT02022696|Lentiviral Vectors
183606|NCT02022683|Endoscopic lung volume reduction
183607|NCT02022683|Endobronchial valves
183608|NCT02022670|endothelial function
183609|NCT02022670|arterial stiffness
183610|NCT02022670|flow-mediated dilation
183611|NCT02022670|pulse wave velocity
183612|NCT02022670|sodium nitrite
183613|NCT02022670|aging
183614|NCT02022670|vascular diseases
183615|NCT02022657|Pre exposure prophylaxis
183616|NCT02022657|Dried blood spots
183617|NCT02022618|Hypertension
183618|NCT02022618|Target organ damage
183619|NCT02022618|polymorphism
183620|NCT02022618|Hypertensive patients
183621|NCT02022605|ERCP, trainning, trainees, EMS
183622|NCT02022579|Breast Cancer
183623|NCT02022579|Diagnosis
183624|NCT02022579|Malignant
183625|NCT02022579|Benign
183626|NCT02022579|Biopsy
183627|NCT02022566|Osteoarthritis knee
183628|NCT02022566|Osteoarthritis hip
183629|NCT02022566|Physical activity
183630|NCT02022566|accelerometer
183631|NCT02022553|rectal cancer
183632|NCT02022553|RACHEL
183633|NCT02022553|oil chemoembolization
183634|NCT02022540|Neovascular Age-Related Macular Degeneration
183635|NCT02022540|AMD
183636|NCT02022540|Macular Degeneration
183637|NCT02022540|Age-Related Macular Degeneration
183638|NCT02022540|wet AMD
183639|NCT02022540|neovascular AMD
183640|NCT02022540|exudative AMD
183641|NCT02022527|Cost-Effectiveness,
183642|NCT02022527|Heart valve prosthesis
183643|NCT02022527|Warfarin,
183644|NCT02022527|Aspirin,
183645|NCT02022527|Egypt
183646|NCT02022501|Macular Degeneration
183647|NCT02022488|Child
183648|NCT02022488|Sevoflurane
183649|NCT02022488|Emergence delirium
183650|NCT02022488|General anesthesia
183651|NCT02022488|Premedication.
183652|NCT02022475|vitamin D
183653|NCT02022475|fatigue
183654|NCT02022462|Serious mental illnesses
183655|NCT02022462|peer navigator
183656|NCT02022462|integrated health care
183657|NCT02022449|Maternal depression
183658|NCT02022449|Maternal psychosocial stress and distress
183659|NCT02022449|Maternal health outcomes
183660|NCT02022449|Social support
183661|NCT02022449|Pediatric cancer
183662|NCT02022410|CAS
183663|NCT02022410|Length of stay
183664|NCT02022410|Rehabilitation localisation
183665|NCT02022410|TKA
183666|NCT02022397|tracheal intubation
183667|NCT02022397|predicting difficult intubation
183668|NCT02022397|general anesthesia
183669|NCT02022397|difficult ventilation
183670|NCT02022384|Malignant glioma
183671|NCT02022384|Anaplastic astrocytoma
183672|NCT02022384|Glioblastoma multiforme
183673|NCT02022384|Immune
183674|NCT02022384|Immunophenotyping
183675|NCT02022384|Immune cells
183676|NCT02022384|activation state
183677|NCT02022384|Quality of live
183678|NCT02022384|translational research
183679|NCT02022358|Osteosarcoma
183680|NCT02022358|Methotrexate
183681|NCT02022358|Glucarpidase
183682|NCT02022358|Mucositis
183683|NCT02022345|Percutaneous Coronary Intervention
183684|NCT02022345|Coronary Artery Disease
183685|NCT02022345|Angioplasty
183686|NCT02022345|Offsite cardiac surgery
183687|NCT02022345|Heart disease
183688|NCT02022345|Ischemic Heart Disease
183689|NCT02022306|Hepatitis C
183690|NCT02022293|Nasopharyngeal Carcinoma
183691|NCT02022293|Radiotherapy
183692|NCT02022293|Carotid Stenosis
183693|NCT02022293|Atorvastatin
183694|NCT02022267|clubfoot
183695|NCT02022267|gait analysis
183696|NCT02022267|outcome questionaire
183697|NCT02022267|Ponseti method
183698|NCT02022241|Ovarian Hyperstimulation Syndrome
183699|NCT02022241|Luteinizing Hormone
183700|NCT02022241|Polycystic Ovarian Syndrome
183701|NCT02022241|Ovarian Yield
183702|NCT02022241|Ovarian Maturity
183703|NCT02022228|Ovarian Hyperstimulation Syndrome
183704|NCT02022228|Luteinizing Hormone
183705|NCT02022228|Polycystic Ovarian Syndrome
183706|NCT02022228|Ovarian Yield
183707|NCT02022228|Ovarian Maturity
183708|NCT02022228|Gonadotropin Releasing Hormone Agonist
183709|NCT02022228|Human Chorionic Gonadotropin
183710|NCT02022189|Dent
183711|NCT02022189|Dents
183712|NCT02022189|Dent Disease
183713|NCT02022189|Renal Biopsy
183714|NCT02022189|Kidney Biopsy
183715|NCT02022189|Clinical Biopsy
183716|NCT02022176|Nitrate
183717|NCT02022176|Nitrite
183718|NCT02022176|Nitric oxide
183719|NCT02022176|Resting metabolic rate
183720|NCT02022176|Glucose uptake
183721|NCT02022176|Insulin sensitivity
183722|NCT02022176|Reactive oxygen species production
183723|NCT02022176|inorganic nitrate
183724|NCT02022176|Sodium nitrite infusion
183725|NCT02022163|Influenza, Human
183726|NCT02022163|RNA Virus Infections
183727|NCT02022163|Respiratory Tract Diseases
183728|NCT02022163|Respiratory Tract Infections
183729|NCT02022163|Aluminum Hydroxide
183730|NCT02022163|Adjuvants, Immunologic
183731|NCT02022163|Immunogenic Factors
183732|NCT02022163|Physiological Effects of Drugs
183733|NCT02022163|Virus Diseases
183734|NCT02022163|Orthomyxoviridae Infections
183735|NCT02022163|Infection
183736|NCT02022150|Paracentesis
183737|NCT02022150|Liver Cirrhosis
183738|NCT02022150|ascites
183739|NCT02022150|body composition
183740|NCT02022137|Minimal hepatic encephalopathy
183741|NCT02022137|Hepatic encephalopathy
183742|NCT02022124|chronic low back pain
183743|NCT02022124|open-label placebo
183744|NCT02022046|chronic kidney disease
183745|NCT02022046|cardiovascular disease
183746|NCT02022046|nitric oxide
183747|NCT02022046|homocysteine
183748|NCT02022046|asymmetric dimethylarginine
183749|NCT02022046|methylation
183750|NCT02022033|Pancreatic Cancer
183751|NCT02022033|Adjuvant
183752|NCT02022033|Pancreas
183753|NCT02022033|Resected
183754|NCT02022033|Invasive adenocarcinoma
183755|NCT02022033|adenosquamous cancer
183756|NCT02022033|Intraductal papillary mucinous neoplasm
183757|NCT02022007|PCOS
183758|NCT02022007|IGT
183759|NCT02022007|DPP-4 inhibitor
183760|NCT02021006|antibiotic prophylaxis
183761|NCT02021006|vesicoureteral reflux
183762|NCT02021006|congenital abnormalities of kidney
183763|NCT02021006|renal hypodysplasia
183764|NCT02021006|chronic kidney disease
183765|NCT02020993|Nt-proBNP, newborn, preterm
183766|NCT02021981|Quality Improvement
183767|NCT02021981|Primary Care
183768|NCT02021981|Blood Pressure, High
183769|NCT02021981|Feedback
183770|NCT02021981|Knowledge
183771|NCT02021955|randomized controlled trial
183772|NCT02021955|quality of life
183773|NCT02021955|patient readmission
183774|NCT02021955|mortality
183775|NCT02021955|patient satisfaction
183776|NCT02021955|intervention studies
183777|NCT02021955|multicenter study
183778|NCT02021942|primary inoperable thymoma
183779|NCT02021942|local recurrent thymoma
183780|NCT02021942|reduction of tumor size
183781|NCT02021942|SOM230 LAR
183782|NCT02021929|Randomized Controlled Trial
183783|NCT02021929|Clinical Trial
183784|NCT02021929|sorafenib
183785|NCT02021929|Hepatopulmonary Syndrome
183786|NCT02021903|arterial hypotension
183787|NCT02021903|postprandial sleepiness
183788|NCT02021903|orthostatic hypotension
183789|NCT02021903|synucleinopathies
183790|NCT02021903|hyperglycemia
183791|NCT02021890|Dance
183792|NCT02021890|Physical activity
183793|NCT02021890|Physical fitness
183794|NCT02021890|Weight loss
183795|NCT02021877|Brain trauma
183796|NCT02021877|ICP measurement
183797|NCT02021877|cranial CT / MRI
183798|NCT02021877|Glasgow Coma Score
183799|NCT02021877|acute TBI
183800|NCT02021877|EEG
183801|NCT02021877|metabolic, proteomic, and genetic biomarkers of TBIs
183802|NCT02021877|injury mechanism
183803|NCT02021864|hypocalcemia, pregnancy, vitamin D
183804|NCT02021851|Dexamethasone,
183805|NCT02021851|Ondansetron
183806|NCT02021851|Aprepitant
183807|NCT02021851|PONV
183808|NCT02021851|Laparoscopic surgery
183809|NCT02021838|domestic violence homicide prevention
183810|NCT02021825|mitoxantrone
183811|NCT02021825|neuromyelitis optica
183812|NCT02021825|relapse
183813|NCT02021799|Gut microbiome
183814|NCT02021799|Vaginal microbiome
183815|NCT02021799|Oral microbiome
183816|NCT02021799|Human milk microbiome
183817|NCT02021799|Nutritional Status
183818|NCT02021773|Headache
183819|NCT02021773|Migraine
183820|NCT02021773|Chronic Migraine
183821|NCT02021682|Aβ
183822|NCT02021682|ABeta
183823|NCT02021682|ABeta kinetics
183824|NCT02021682|Alzheimer's Disease
183825|NCT02021682|Alzheimer's
183826|NCT02021682|amyloid beta
183827|NCT02021682|biomarker
183828|NCT02021682|dementia
183829|NCT02021682|PET/PIB
183830|NCT02021669|Antidepressive agents
183831|NCT02021669|Coronary disease
183832|NCT02021669|Depression
183833|NCT02021669|Depressive disorder
183834|NCT02021669|Fatty Acids, Omega-3
183835|NCT02021630|Obesity
183836|NCT02021630|Bariatric Surgery
183837|NCT02021630|Weight Loss
183838|NCT02021630|Physical Activity
183839|NCT02021630|Body Composition
183840|NCT02021617|Intraosseous Access
183841|NCT02021617|EZ-IO
183842|NCT02021604|Congenital Hyperinsulinism
183843|NCT02021604|HI
183844|NCT02021604|Hypoglycemia
183845|NCT02021591|Diabetes
183846|NCT02021591|Chronic disease
183847|NCT02021591|problem solving
183848|NCT02021591|self management
183849|NCT02021578|Depression
183850|NCT02021578|Mood disorder
183851|NCT02021565|Caregivers
183852|NCT02021565|Activities of Daily Living
183853|NCT02021565|Dementia
183854|NCT02021565|Veterans
183855|NCT02021565|Self-Help Devices
183856|NCT02021565|Telemedicine
183857|NCT02021552|Trauma
183858|NCT02021552|Sepsis
183859|NCT02021539|Elastography of the cervix
183860|NCT02021539|Cervical elastography
183861|NCT02021539|Predicting delivery
183862|NCT02021526|G1D
183863|NCT02021526|Glut1 Deficiency
183864|NCT02021526|Glucose Transporter Type 1 Deficiency
183865|NCT02021526|Glucose Transporter Type I Deficiency
183866|NCT02021513|SLE
183867|NCT02021513|Fish Oil
183868|NCT02021513|Omega-3
183869|NCT02021448|OHS
183870|NCT02021422|metastatic pancreatic ductal adenocarcinoma (PDAC)
183871|NCT02021422|pancreatic cancer
183872|NCT02021422|pancreas cancer
183873|NCT02021422|pancreatic adenocarcinoma
183874|NCT02021422|metastatic pancreas cancer
183875|NCT02021422|metastatic pancreatic cancer
183876|NCT02021409|Anemia on CKD
183877|NCT02021396|Rescue splenic trauma patients at high risk of splenectomy
183878|NCT02021383|Weight loss
183879|NCT02021383|Weight maintenance
183880|NCT02021383|Contingency Management
183881|NCT02021383|College students
183882|NCT02021383|Financial incentives
183883|NCT02021370|Anemia of CKD
183884|NCT02021357|Facial Pain
183885|NCT02021357|Physical Therapy Modalities
183886|NCT02021357|Temporomandibular Joint Disorders
183887|NCT02021357|Exercise Therapy
183888|NCT02021331|jaw, edentulous, partially
183889|NCT02021318|Non-dialysis
183890|NCT02021318|Roxadustat
183891|NCT02021318|ASP1517
183892|NCT02021318|Chronic Kidney Disease (CKD)
183893|NCT02021318|Anemia
183894|NCT02021318|Hemoglobin
183895|NCT02021305|Toll like Receptors
183896|NCT02021305|TLR 4
183897|NCT02021305|Urinary track infections in children
183898|NCT02021305|TLR 4 polymorphisms
183899|NCT02021305|Innate immunity
183900|NCT02021305|Defence mechanisms
183901|NCT02021305|Immune responses
183902|NCT02021292|Chronic thromboembolic pulmonary hypertension (CTEPH)
183903|NCT02021279|pelvic organ prolapse
183904|NCT02021279|MatriStem
183905|NCT02021279|pelvic floor matrix
183906|NCT02021279|ACell
183907|NCT02021279|native tissue repair
183908|NCT02021253|Endotoxemia
183909|NCT02021253|Probiotic
183910|NCT02021253|Leaky gut
183911|NCT02021253|Gut permeability
183912|NCT02021253|Liver cirrhosis
183913|NCT02021253|Liver fibrosis
183914|NCT02021253|Hepatocellular carcinoma
183915|NCT02021227|Acute respiratory failure
183916|NCT02021227|Mechanical ventilation
183917|NCT02021227|Rehabilitation
183918|NCT02021227|Exercise chair sitting
183919|NCT02021227|Weaning
183920|NCT02021227|Chronic respiratory failure
183921|NCT02021214|Methylphenidate
183922|NCT02021214|Fear extinction
183923|NCT02021214|fMRI
183924|NCT02021214|mPFC
183925|NCT02021188|Vascular inflammation
183926|NCT02021188|Atherosclerosis
183927|NCT02021188|Positron Emission Tomography
183928|NCT02021188|Molecular Imaging
183929|NCT02021188|68Ga-DOTATATE
183930|NCT02021175|Smoking Cessation
183931|NCT02021175|Korean
183932|NCT02021175|Youth
183933|NCT02021175|Adolescent
183934|NCT02021175|Dependence
183935|NCT02021175|Teen Smoking
183936|NCT02021175|Smoking and Youth
183937|NCT02021175|Youth and Tobacco
183938|NCT02021175|Cognitive-Behavioral Motivational Enhancement
183939|NCT02021175|Technology
183940|NCT02021175|Nicotine Dependence
183941|NCT02021175|Cell Phone
183942|NCT02021175|Smart Phone
183943|NCT02021175|Internet
183944|NCT02021175|Web
183945|NCT02021162|Multiple sclerosis
183946|NCT02021162|Gilenya
183947|NCT02021162|Healthy controls
183948|NCT02021162|Thalamic atrophy
183949|NCT02021162|MRI
183950|NCT02021149|Major Depressive Disorder
183951|NCT02021149|Whole Body Hyperthermia
183952|NCT02021149|Psychotherapy
183953|NCT02021149|Therapist and patient alliance
183954|NCT02021123|Anidulafungin
183955|NCT02021123|Gastric bypass
183956|NCT02021123|Morbidly obese
183957|NCT02021123|Pharmacokinetics
183958|NCT02021123|Prophylaxis
183959|NCT02021123|Yeast infection
183960|NCT02021097|Levonorgestrel；
183961|NCT02021097|Ethinyl Estradiol；
183962|NCT02021097|Oral Contraceptive
183963|NCT02021084|Familial Mediterranean Fever (FMF), probiotics
183964|NCT02021032|BPH
183965|NCT02020928|Oral Mucositis
183966|NCT02020928|chemotherapy
183967|NCT02020928|Bone Marrow Transplantation
183968|NCT02020889|eosinophils
183969|NCT02020889|SB 240563
183970|NCT02020889|Churg-Strauss Syndrome
183971|NCT02020889|quality of life
183972|NCT02020889|mepolizumab
183973|NCT02020889|safety
183974|NCT02020889|biomarkers
183975|NCT02020889|efficacy
183976|NCT02020889|corticosteroids
183977|NCT02020889|Eosinophilic granulomatosis with polyangiitis
183978|NCT02020850|Toe-Brachial Index
183979|NCT02020850|Ankle-Brachial Index
183980|NCT02020850|Systolic blood pressure
183981|NCT02020824|Acrophobia
183982|NCT02020785|proteinuria
183983|NCT02020772|primary health care
183984|NCT02020772|Physical Therapy Specialty
183985|NCT02020772|General Practitioners
183986|NCT02020772|General Practice
183987|NCT02020733|Hysterosalpingography
183988|NCT02020733|balloon catheter
183989|NCT02020733|metal cannula
183990|NCT02020733|pain assessment
183991|NCT02020694|Obesity
183992|NCT02020694|Insulin resistance
183993|NCT02020694|Vitamin D
183994|NCT02020694|Cardiovascular risk factors
183995|NCT02020681|Dental caries
183996|NCT02020681|Curodont Repair
183997|NCT02020681|P11-4
183998|NCT02020668|Pain
183999|NCT02020668|Functional capacity
184000|NCT02020668|Quality of Life
184001|NCT02020655|IL-1 alpha, Sebutape, shear- force
184002|NCT02020642|polysomnography
184003|NCT02020642|bioimpedance
184004|NCT02020642|leg fluid shift
184005|NCT02020642|neck circumference
184006|NCT02020642|Sleep Apnea Syndromes
184007|NCT02020642|Sleep Apnea, Obstructive
184008|NCT02020642|Sleep Disorders, Intrinsic
184009|NCT02020642|Sleep Disorders
184010|NCT02020642|Apnea
184011|NCT02020642|Kidney Diseases
184012|NCT02020642|Kidney Failure, Chronic
184013|NCT02020642|Renal Insufficiency, Chronic
184014|NCT02020642|Renal Insufficiency
184015|NCT02020642|Dyssomnias
184016|NCT02020629|Glucagon
184017|NCT02020629|Hypoglycemia
184018|NCT02020629|Counterregulation
184019|NCT02020603|peptic ulcer bleeding
184020|NCT02020603|hemostatic forceps
184021|NCT02020603|soft coagulation
184022|NCT02020603|argon plasma coagulation
184023|NCT02020590|Delayed-Union Fractures
184024|NCT02020590|Impaired Healing
184025|NCT02020590|Fractures
184026|NCT02020590|Orthopedics
184027|NCT02020590|Bone
184028|NCT02020590|Musculoskeletal Disorders
184029|NCT02020564|Processing Speed
184030|NCT02020564|Cognition
184031|NCT02020564|Intervention
184032|NCT02020564|Traumatic Brain Injury
184033|NCT02020564|Mild Cognitive Impairment
184034|NCT02020551|Scores During IUD insertion.
184035|NCT02020538|Thoracic surgery
184036|NCT02020538|cardiac surgery
184037|NCT02020538|acute kidney injury
184038|NCT02020538|hyperchloremia
184039|NCT02020538|intravenous fluid
184040|NCT02020486|Healthy
184041|NCT02020473|Informed consents
184042|NCT02020473|Withholding/withdrawing life support (WLS)
184043|NCT02020473|Intensive care unit (ICU)
184044|NCT02020460|post-laminectomy pain syndrome,
184045|NCT02020460|refractory,
184046|NCT02020460|refractory chronic neuropathic pain,
184047|NCT02020460|failed back surgery syndrome.
184048|NCT02020421|ischemic stroke
184049|NCT02020421|rehabilitation
184050|NCT02020421|aphasia
184051|NCT02020421|non-invasive brain stimulation
184052|NCT02020382|microRNAs
184053|NCT02020382|IBD
184054|NCT02020382|Crohn's disease
184055|NCT02020382|Ulcerative colitis
184056|NCT02020382|colonic polyps screening
184057|NCT02020382|controls
184058|NCT02020356|Alzheimer's disease
184059|NCT02020356|Neuroleptics
184060|NCT02020356|Music therapy
184061|NCT02020330|falciparum, malaria
184062|NCT02020317|drug interactions
184063|NCT02020317|Drug Monitoring
184064|NCT02020317|Potassium
184065|NCT02020317|Hyperkalemia
184066|NCT02020304|Combined spinal epidural duration
184067|NCT02020304|labor pain
184068|NCT02020291|Foxy-5
184069|NCT02020291|Wnt-5A
184070|NCT02020278|Hyponatremia
184071|NCT02020278|Euvolemic
184072|NCT02020278|Hypervolemic
184073|NCT02020278|Serum sodium
184074|NCT02020278|Dilutional hyponatremia
184075|NCT02020278|Electrolyte abnormality
184076|NCT02020278|Electrolyte imbalance
184077|NCT02020278|Metabolic disease
184078|NCT02020278|Water-Electrolyte Imbalance
184079|NCT02020265|stress and depression related symptoms
184080|NCT02020239|physical activity
184081|NCT02020239|females
184082|NCT02020239|body composition
184083|NCT02020226|TH-302
184084|NCT02020226|Solid Tumors
184085|NCT02020226|QTc
184086|NCT02020226|Cardiac
184087|NCT02020226|Evofosfamide
184088|NCT02020213|successful percentage
184089|NCT02020200|Bipolar Disorder
184090|NCT02020200|Methylphenidate
184091|NCT02020200|Cognitive Function
184092|NCT02020187|Congenital myopathy
184093|NCT02020187|Exercise
184094|NCT02020174|Preeclampsia
184095|NCT02020174|Eclampsia
184096|NCT02020174|HELLP
184097|NCT02020174|HELLP Syndrome
184098|NCT02020174|Toxemia
184099|NCT02020174|Hypertensive Disorder of Pregnancy
184100|NCT02020174|Registry
184101|NCT02020174|Pregnancy Complication
184102|NCT02020174|Pregnancy
184103|NCT02020174|Maternal Death
184104|NCT02020174|Premature
184105|NCT02020174|High Blood Pressure
184106|NCT02020174|Hypertension
184107|NCT02020148|pregnancy
184108|NCT02020148|oxytocin
184109|NCT02020148|postpartum depression
184110|NCT02020148|depression
184111|NCT02020148|pregnant women
184112|NCT02020148|mood
184113|NCT02020148|anxiety
184114|NCT02020148|hormones
184115|NCT02020148|women's health
184116|NCT02020148|mental health
184117|NCT02020148|baby blues
184118|NCT02020148|mood disorders
184119|NCT02020122|endogenous pain modulation
184120|NCT02020122|coronary artery bypass grafting
184121|NCT02020122|quantitative sensory testings
184122|NCT02020122|duloxetine
184123|NCT02020122|pregabalin
184124|NCT02020122|preemptive treatment
184125|NCT02020096|Lumbar plexus block
184126|NCT02020096|Ultrasound guidance
184127|NCT02020096|Nerve stimulator
184128|NCT02020083|VIH ; Placental transfer ; Tenofovir ; Emtricitabine ; Membrane transporter
184129|NCT02020070|Ipilimumab
184130|NCT02020070|Degarelix
184131|NCT02020070|Radical Prostatectomy
184132|NCT02020070|13-134
184133|NCT02020031|Revision knee joint
184134|NCT02020005|menthol cigarettes
184135|NCT02020005|smoking cessation
184136|NCT02019992|sepsis
184137|NCT02019992|mitochondrial DNA
184138|NCT02019992|systemic inflammation
184139|NCT02019992|outcome
184140|NCT02019979|non squamous
184141|NCT02019979|non small cell
184142|NCT02019979|lung cancer
184143|NCT02019979|metformin
184144|NCT02019927|NAION
184145|NCT02019927|Decreased vision
184146|NCT02019927|Eye trauma
184147|NCT02019927|TES
184148|NCT02019927|Electrical stimulation
184149|NCT02019927|Multiple Sclerosis
184150|NCT02019927|Optic Neuritis
184151|NCT02019914|PTSD
184152|NCT02019914|CPAP
184153|NCT02019914|OSA
184154|NCT02019901|Rheumatoid arthritis
184155|NCT02019901|Person-centered care
184156|NCT02019901|Tight control
184157|NCT02019888|Ear, Middle
184158|NCT02019888|Ear, Inner
184159|NCT02019888|Audiometry
184160|NCT02019888|Acoustic impedance tests
184161|NCT02019875|Vitamin D
184162|NCT02019875|CYP3A4
184163|NCT02019875|Calcium
184164|NCT02019862|Total hip arthroplasty
184165|NCT02019862|TRJ
184166|NCT02019862|PMCF
184167|NCT02019862|Hip stem
184168|NCT02019849|THA, Plasmafit®
184169|NCT02019836|vit D; sepsis; newborn; maternal; neonatal
184170|NCT02019823|SMS-text
184171|NCT02019823|mobile health
184172|NCT02019823|mHealth
184173|NCT02019823|treatment
184174|NCT02019823|adherence
184175|NCT02019797|aortic valve replacement
184176|NCT02019784|Cirrhosis
184177|NCT02019784|Hepatic encephalopathy
184178|NCT02019771|HIV Infection
184179|NCT02019771|Men who have sex with men
184180|NCT02019771|Chlamydia
184181|NCT02019771|Gonorrhea
184182|NCT02019745|Live attenuated influenza virus (LAIV)
184183|NCT02019745|Flu vaccine
184184|NCT02019745|FluMist
184185|NCT02019745|Smokers
184186|NCT02019745|New and emerging tobacco products
184187|NCT02019732|Mild outcomes
184188|NCT02019732|Database
184189|NCT02019732|Influenza-attributable
184190|NCT02019732|Retrospective
184191|NCT02019732|Influenza
184192|NCT02019732|United States of America (USA)
184193|NCT02019719|Hemodialysis
184194|NCT02019719|GSK1278863
184195|NCT02019719|Pharmacokinetics
184196|NCT02019719|Erythropoiesis Stimulating Agents
184197|NCT02019719|Hemoglobin
184198|NCT02019719|Recombinant Erythropoietin
184199|NCT02019719|Prolyl Hydroxylase Inhibitor
184200|NCT02019719|Anemia
184201|NCT02019719|Chronic Kidney Disease
184202|NCT02019706|Cushing Syndrome
184203|NCT02019706|Ectopic ACTH Secretion
184204|NCT02019706|Imaging
184205|NCT02019693|MET Inhibitor
184206|NCT02019693|Sporadic
184207|NCT02019693|Hereditary
184208|NCT02019693|Multifocal
184209|NCT02019693|HGF/MET Pathway
184210|NCT02019680|Endothelial Function
184211|NCT02019680|Biomarkers
184212|NCT02019680|Atherosclerosis
184213|NCT02019680|Blood Flow
184214|NCT02019680|Blood Pressure
184215|NCT02019667|GABA
184216|NCT02019667|Seizures
184217|NCT02019667|Neurotransmitters
184218|NCT02019654|Post -Traumatic Stress Disorder (PTSD)
184219|NCT02019654|Traumatic Brain Injury
184220|NCT02019654|Neuroendocrine
184221|NCT02019654|Epigenetics
184222|NCT02019641|Exercise
184223|NCT02019641|Interstitial Lung Disease
184224|NCT02019641|Pulmonary Rehabilitation
184225|NCT02019628|NK cells cytotoxicity, dietary supplementation
184226|NCT02019615|disorders of consciousness
184227|NCT02019615|minimally conscious state
184228|NCT02019615|traumatic brain injury
184229|NCT02019615|stroke
184230|NCT02019615|transcranial direct current stimulation
184231|NCT02019602|Cimzia®
184232|NCT02019602|CZP
184233|NCT02019602|Placental transfer
184234|NCT02019602|Autoimmune diseases and pregnancy
184235|NCT02019589|Secondary Amenorrhea
184236|NCT02019589|SPRY Trial
184237|NCT02019576|Metastatic renal cell carcinoma
184238|NCT02019576|mRCC
184239|NCT02019576|Clear cell
184240|NCT02019563|pediatrics
184241|NCT02019563|dental caries
184242|NCT02019563|dental pulp exposure
184243|NCT02019563|incisor
184244|NCT02019550|Multiple Sclerosis, Relapsing-Remitting
184245|NCT02019550|Rebif®Rebidose®
184246|NCT02019550|Rebiject II®
184247|NCT02019524|Stage I breast cancer
184248|NCT02019524|Stage II breast cancer
184249|NCT02019524|Stage IIIA, IIIB, and IIIC breast cancer
184250|NCT02019524|Male breast cancer
184251|NCT02019524|Ovarian cancer
184252|NCT02019511|Orthopedic surgery
184253|NCT02019511|Infections
184254|NCT02019511|Steroid
184255|NCT02019511|Fast-track
184256|NCT02019511|Total knee arthroplasty
184257|NCT02019511|Safety
184258|NCT02019498|low back pain
184259|NCT02019498|relaxation
184260|NCT02019485|Healthy
184261|NCT02019485|Tapentadol
184262|NCT02019485|Tapentadol extended-release tamper-resistant formulation
184263|NCT02019485|Tapentadol extended-release prolonged-release formulation
184264|NCT02019485|Bioequivalence
184265|NCT02019485|Fasted Conditions
184266|NCT02019472|Rheumatoid arthritis
184267|NCT02019472|CNTO 136
184268|NCT02019472|Sirukumab
184269|NCT02019472|Adalimumab
184270|NCT02019472|HUMIRA®
184271|NCT02019446|type 2 diabetes mellitus
184272|NCT02019446|onychomycosis
184273|NCT02019446|laser treatment
184274|NCT02019446|antifungal
184275|NCT02019433|THA, augment, revision, pelvis
184276|NCT02019420|Pneumonia
184277|NCT02019420|Tedizolid Phosphate
184278|NCT02019420|TR-701
184279|NCT02019407|atrial fibrillation
184280|NCT02019407|atrial flutter
184281|NCT02019407|catheter ablation
184282|NCT02019407|cavo-tricuspid isthmus block
184283|NCT02019342|blood pressure
184284|NCT02019342|mean arterial pressure
184285|NCT02019342|MAP
184286|NCT02019342|intraoperative
184287|NCT02019342|postoperative
184288|NCT02019342|anesthesia
184289|NCT02019316|Supplementation
184290|NCT02019316|Performance
184291|NCT02019316|Cognitive Function
184292|NCT02019316|Muscular Endurance
184293|NCT02019316|BioSteel
184294|NCT02019316|BCAA
184295|NCT02019316|Branched Chain Amino Acids
184296|NCT02019316|Sprint Interval Exercise
184297|NCT02019264|Diabetes
184298|NCT02019264|Cardiovascular Disease
184299|NCT02019264|Multiple Cardiovascular Risk Factors
184300|NCT02019264|Obesity
184301|NCT02019264|Overweight
184302|NCT02019264|MACE
184303|NCT02019264|Conversion to Diabetes
184304|NCT02019225|dialysis
184305|NCT02019225|hemodialysis
184306|NCT02019225|pragmatic trial
184307|NCT02019225|end stage renal disease
184308|NCT02019225|randomized clinical trial
184309|NCT02019212|99mTc-tetrofosmin
184310|NCT02019212|myocardial perfusion imaging
184311|NCT02019212|SPECT
184312|NCT02019212|radiation
184313|NCT02019186|type 1 diabetes
184314|NCT02019186|endothelial function
184315|NCT02019186|adolescents
184316|NCT02019186|vitamin C
184317|NCT02019186|vitamin E
184318|NCT02019173|exercise therapy
184319|NCT02019173|brain injury
184320|NCT02019173|postural balance
184321|NCT02019160|silver nitrate
184322|NCT02019160|sodium fluoride
184323|NCT02019160|silver diamine fluoride
184324|NCT02019160|caries
184325|NCT02019160|non-inferiority trial
184326|NCT02019147|HIE
184327|NCT02019147|Biomarker
184328|NCT02019134|chronic neck pain
184329|NCT02019134|relaxation technique
184330|NCT02019134|comparative effectiveness research
184331|NCT02019108|osteoarthritis
184332|NCT02019108|knee
184333|NCT02019108|walking
184334|NCT02019108|toeout
184335|NCT02019108|gait modification
184336|NCT02019095|Pneumonia, Ventilator-Associated
184337|NCT02019095|Respiratory Distress Syndrome, Adult
184338|NCT02019095|Pulmonary Surfactant-Associated Proteins
184339|NCT02019095|activin A
184340|NCT02019030|benign prostatic hyperplasia
184341|NCT02019030|Transurethral vaporization of prostate
184342|NCT02019017|Cluster Headache
184343|NCT02019017|Botulinum Toxin Type A
184344|NCT02019017|Sphenopalatine Ganglion Block
184345|NCT02019017|Autonomic Nerve Block
184346|NCT02018978|HIV prevention
184347|NCT02018978|Behavioral intervention
184348|NCT02018978|Community-randomized trial
184349|NCT02018965|HIV
184350|NCT02018965|Extended-release Niacin
184351|NCT02018965|Immune activation
184352|NCT02018952|Septic arthritis
184353|NCT02018952|Ultrasonography
184354|NCT02018952|Prognosis parameters
184355|NCT02018939|pharmacokinetics, doripenem, renal replacement therapy, MARS, organ replacement therapy
184356|NCT02018926|Mocetinostat
184357|NCT02018926|Azacitidine
184358|NCT02018926|Vidaza
184359|NCT02018926|Myelodysplastic syndrome
184360|NCT02018926|HDAC
184361|NCT02018926|HMA
184362|NCT02018926|MDS
184363|NCT02018900|Synbiotics
184364|NCT02018900|Intestinal permeability
184365|NCT02018900|Microbiota
184366|NCT02018900|Immune response
184367|NCT02018848|Obsessive-Compulsive Disorder
184368|NCT02018848|Attention Training
184369|NCT02018848|Attention Bias Modification
184370|NCT02018848|Dot-Probe Task
184371|NCT02018848|Randomized Controlled Trial
184372|NCT02018848|Online Treatment
184373|NCT02018848|Washing
184374|NCT02018848|Checking
184375|NCT02018822|restorative material
184376|NCT02018809|Medication Adherence
184377|NCT02018809|High Blood Pressure
184378|NCT02018809|Diabetes
184379|NCT02018809|Statins
184380|NCT02018770|Temporomandibular Disorders, Electromyogram,
184381|NCT02018770|Modalities of physiotherapy,
184382|NCT02018770|Temporomandibular dysfunction syndrome,
184383|NCT02018770|Lasers.
184384|NCT02018757|Carcinoma, Hepatocellular
184385|NCT02018757|primary liver cancer
184386|NCT02018757|primary hepatocellular carcinoma
184387|NCT02018757|transarterial chemoembolization
184388|NCT02018757|Chemoembolization, Therapeutic
184389|NCT02018757|arsenic trioxide
184390|NCT02018757|arsenous anhydride
184391|NCT02018757|diarsenic trioxide
184392|NCT02018757|randomized controlled trial
184393|NCT02018757|multicenter study
184394|NCT02018757|HCC
184395|NCT02018757|TACE
184396|NCT02018731|Becker's Muscular dystrophy
184397|NCT02018731|BMD
184398|NCT02018731|Metformin
184399|NCT02018731|L-citrulline
184400|NCT02018718|Skeletal muscle
184401|NCT02018718|Marathon
184402|NCT02018718|MRI
184403|NCT02018705|POEM
184404|NCT02018705|LHM
184405|NCT02018705|Achalasia treatment
184406|NCT02018705|LES sphincter myotomy
184407|NCT02018679|Nodular basal cell carcinoma
184408|NCT02018679|Er:YAG
184409|NCT02018679|AFL-assisted
184410|NCT02018679|MAL-PDT
184411|NCT02018653|Cancer
184412|NCT02018653|Diarrhea
184413|NCT02018653|Calcium Alumina-Silicate
184414|NCT02018653|CASAD
184415|NCT02018653|Calcium Aluminosilicate anti-diarrheal
184416|NCT02018653|Placebo
184417|NCT02018653|Sugar pill
184418|NCT02018653|Questionnaire
184419|NCT02018653|Survey
184420|NCT02018640|cancer
184421|NCT02018640|tobacco use
184422|NCT02018640|pregnancy
184423|NCT02018627|bionic pancreas
184424|NCT02018627|artificial pancreas
184425|NCT02018627|insulin
184426|NCT02018627|glucagon
184427|NCT02018627|clamp
184428|NCT02018614|Pain
184429|NCT02018614|elderly
184430|NCT02018614|aged 65 or above 65
184431|NCT02018614|communication disorders
184432|NCT02018614|Algoplus® scale
184433|NCT02018588|requirements
184434|NCT02018588|amino acid
184435|NCT02018588|tryptophan
184436|NCT02018575|lysine
184437|NCT02018575|bioavailability
184438|NCT02018575|amino acids
184439|NCT02018575|corn
184440|NCT02018562|Quality of Life
184441|NCT02018562|Talking Tracheostomy Tube
184442|NCT02018562|Speech
184443|NCT02018562|Mechanically ventilated patients
184444|NCT02018549|COPD
184445|NCT02018549|placebo
184446|NCT02018549|inhalatory profile
184447|NCT02018536|Healthy
184448|NCT02018536|TMC435
184449|NCT02018536|GSK2336805
184450|NCT02018536|Pharmacokinetic
184451|NCT02018536|Safety
184452|NCT02018536|Tolerability
184453|NCT02018523|Carcinoma, Non-Small-Cell Lung
184454|NCT02018523|Stage 3B/4
184455|NCT02018523|Maintenance Therapy
184456|NCT02018523|Lenalidomide
184457|NCT02018510|Healthy Volunteers
184458|NCT02018510|HIV
184459|NCT02018497|Essential arterial hypotension
184460|NCT02018497|Arterial hypotension
184461|NCT02018497|Low blood pressure
184462|NCT02018497|Hypotension
184463|NCT02018497|Essential arterial hypertension
184464|NCT02018497|Syncope
184465|NCT02018497|Dysautonomia
184466|NCT02018497|Stress
184467|NCT02018497|Adaptability
184468|NCT02018497|Reactivity
184469|NCT02018497|Homeostasis
184470|NCT02018497|Allostasis
184471|NCT02018497|Allostatic load
184472|NCT02018497|Distress
184473|NCT02018484|Surgery / Knee / Replacement / MRI / Specific cutting guides
184474|NCT02018471|anxiety
184475|NCT02018471|psychoeducational training
184476|NCT02018471|coping
184477|NCT02018471|relaxation
184478|NCT02018458|Dendritic cell vaccine
184479|NCT02018458|Breast Cancer
184480|NCT02018458|Doxorubicin
184481|NCT02018458|Paclitaxel
184482|NCT02018458|Cyclophosphamide
184483|NCT02018458|Carboplatin
184484|NCT02018406|Hematopoietic Growth Factors (EPO, G-CSF),
184485|NCT02018406|Neurological Diseases,
184486|NCT02018406|Neurorehabilitation,
184609|NCT02017821|Oxygen Consumption
184487|NCT02018406|Neurotrophic and Neuroprotective Effects
184488|NCT02018393|FEIBA®
184489|NCT02018367|Barrett's esophagus
184490|NCT02018367|proflavine
184491|NCT02018367|Microscopic imaging
184492|NCT02018354|Orthopaedics
184493|NCT02018354|Anterior cruciate ligament (ACL) reconstruction
184494|NCT02018354|Anterolateral ligament
184495|NCT02018354|Lateral Extra-articular Tenodesis (LET)
184496|NCT02018341|Assessment of biologic activity of a homeopathic remedy
184497|NCT02018315|G1D
184498|NCT02018315|Glut1 Disorder
184499|NCT02018315|Glucose Transporter Type 1 Disorder
184500|NCT02018315|Glucose Transporter Type I Disorder
184501|NCT02018302|G1D
184502|NCT02018302|Glut1 Deficiency
184503|NCT02018302|Glucose Transporter Type 1 Deficiency
184504|NCT02018302|Glucose Transporter Type I Deficiency
184505|NCT02018289|Triclosan coated suture
184506|NCT02018289|Surgical site infection
184507|NCT02018289|Fecal peritonitis
184508|NCT02018289|Superficial
184509|NCT02018289|incisional
184510|NCT02018276|Lidocaine
184511|NCT02018276|Magnesium
184512|NCT02018276|Functional recovery
184513|NCT02018237|Obesity
184514|NCT02018237|Nonalcoholic fatty liver disease
184515|NCT02018237|High fructose corn syrup
184516|NCT02018224|Achilles tendon rupture, operative treatment, elongation, long-term follow up.
184517|NCT02018211|delayed onset muscle soreness
184518|NCT02018211|muscle damage
184519|NCT02018211|muscle function
184520|NCT02018211|inflammation
184521|NCT02018146|Laryngeal Masks
184522|NCT02018146|Airway Management
184523|NCT02018133|CKD
184524|NCT02018133|chronic
184525|NCT02018133|kidney
184526|NCT02018133|vitamin D
184527|NCT02018120|multiple gingival recession
184528|NCT02018120|platelet rich fibrin
184529|NCT02018120|connective tissue graft
184530|NCT02018120|microsurgery
184531|NCT02018120|periodontal diseases
184532|NCT02018120|gingival recession
184533|NCT02018107|Liver Tumor Ablation
184534|NCT02018107|Liver Neoplasms
184535|NCT02018107|Positron Emission Tomography
184536|NCT02018107|Computed Tomography
184537|NCT02018094|Amputation
184538|NCT02018094|Infection
184539|NCT02018094|Skin Preparation
184540|NCT02018094|SSI
184541|NCT02018094|Stump
184542|NCT02018094|Wound
184543|NCT02018081|pharmacokinetic study : open, prospective, monocentric
184544|NCT02018068|Patient-controlled Perineural analgesia
184545|NCT02018068|Postoperative
184546|NCT02018068|Orthopedic surgery
184547|NCT02018068|"Remote Control versus at bedside care"
184548|NCT02018068|Comparative medico-economic evaluation
184549|NCT02018042|Alopecia Areata
184550|NCT02018042|AA
184551|NCT02018029|Heart failure
184552|NCT02018029|Cardiac Resynchronisation Therapy
184553|NCT02018029|collagen peptides
184554|NCT02018029|MIBG scintigraphy
184555|NCT02018016|Appendectomy
184556|NCT02018016|Hospitals,General
184557|NCT02018016|Hospitals,High-Volume
184558|NCT02018016|Hospitals,Low-Volume
184559|NCT02018016|Outcome Assessment (Health Care)
184560|NCT02017990|Renal transplantation
184561|NCT02017990|n-3 polyunsaturated fatty acids
184562|NCT02017990|Mortality
184563|NCT02017990|Graft loss
184564|NCT02017990|Rejection
184565|NCT02017977|Laparotomy
184566|NCT02017977|General Surgery
184567|NCT02017977|Hospitals,General
184568|NCT02017977|Hospitals,Rural
184569|NCT02017977|Hospitals,Urban
184570|NCT02017977|Rural Health Services
184571|NCT02017977|Geography, Medical
184572|NCT02017977|Outcome Assessment (Health Care)
184573|NCT02017951|Appendectomy
184574|NCT02017951|Hospitals,General
184575|NCT02017951|Hospitals,Rural
184576|NCT02017951|Hospitals,Urban
184577|NCT02017951|Rural Health Services
184578|NCT02017951|Geography, Medical
184579|NCT02017951|Outcome Assessment (Health Care)
184580|NCT02017938|Fatigue
184581|NCT02017938|electromyography (EMG)
184582|NCT02017938|central fatigue
184583|NCT02017938|cycling training
184584|NCT02017925|Pulmonary Rehabilitation
184585|NCT02017925|Non-Small Cell Lung Cancer
184586|NCT02017925|NSCLC
184587|NCT02017912|Mesenchymal Stromal cells
184588|NCT02017912|MSC-NTF
184589|NCT02017912|Cell therapy
184590|NCT02017912|ALS
184591|NCT02017899|prevention
184592|NCT02017899|Shigella sonnei
184593|NCT02017886|Probiotics
184594|NCT02017886|Oral health
184595|NCT02017886|Innate immunity
184596|NCT02017873|bleaching
184597|NCT02017873|smokers
184598|NCT02017873|effectiveness
184599|NCT02017873|pain
184600|NCT02017860|RAD001, everolimus, roll-over
184601|NCT02017847|oxygen consumption
184602|NCT02017847|activity monitors
184603|NCT02017847|METs
184604|NCT02017847|intensity
184605|NCT02017834|oral cavity squamous cell carcinoma
184606|NCT02017834|head and neck cancer
184607|NCT02017834|oral cancer
184608|NCT02017821|Exercise
184610|NCT02017821|mental health
184611|NCT02017808|OCT
184612|NCT02017808|Copaxone
184613|NCT02017808|Multiple sclerosis
184614|NCT02017808|relapsing-remitting
184615|NCT02017795|asthma, mixed asthma, telehealth, action plan, exacerbation
184616|NCT02017782|Dust
184617|NCT02017782|Ozone
184618|NCT02017782|Indoor air quality
184619|NCT02017782|Indoor environment
184620|NCT02017782|Indoor climate
184621|NCT02017782|Cardiovascular diseases
184622|NCT02017782|Full body exposure
184623|NCT02017782|Exposure experiment with dust and ozone
184624|NCT02017782|Acute exposure to ozone and dust
184625|NCT02017782|Respiratory outcomes
184626|NCT02017782|Cardiovascular outcomes
184627|NCT02017782|Acoustic rhinometry
184628|NCT02017782|Body inflammatory markers
184629|NCT02017782|Cytokines
184630|NCT02017782|Exhaled FeNO
184631|NCT02017782|Nasal Lavage
184632|NCT02017782|Heart rate variability
184633|NCT02017782|Blood biomarkers
184634|NCT02017782|Subjective discomfort
184635|NCT02017782|General mucosal irritation
184636|NCT02017769|Subcutaneous immunoglobulin
184637|NCT02017769|Magnetic resonance imaging
184638|NCT02017756|Carotid artery
184639|NCT02017756|Atherosclerosis
184640|NCT02017756|Vulnerable plaque
184641|NCT02017756|Magnetic resonance imaging
184642|NCT02017756|Arterial wall
184643|NCT02017704|Endorectal Brachytherapy Radiation Therapy
184644|NCT02017704|Intensity Modulated Radiation Therapy and Capecitabine
184645|NCT02017678|JX-594
184646|NCT02017678|Ovarian cancer
184647|NCT02017678|Peritoneal
184648|NCT02017678|Carcinomatosis
184649|NCT02017678|Vaccinia virus
184650|NCT02017678|Oncolytic virus
184651|NCT02017665|encephalitis
184652|NCT02017665|viral infections
184653|NCT02017665|central nervous system
184654|NCT02017652|bowel motility
184655|NCT02017652|cerebral perfusion
184656|NCT02017652|intestinal perfusion
184657|NCT02017626|Fish allergy
184658|NCT02017626|immunotherapy
184659|NCT02017626|hypoallergen
184660|NCT02017613|CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML
184661|NCT02017574|Stroke
184662|NCT02017574|Cerebral Infarction
184663|NCT02017561|Diastolic dysfunction
184664|NCT02017561|Metabolic syndrome
184665|NCT02017561|Metformin
184666|NCT02017548|advance directives, advance care planning
184667|NCT02017522|PET
184668|NCT02017522|Cardiac sarcoidosis
184669|NCT02017522|FDG
184670|NCT02017522|Cardiac MRI
184671|NCT02017509|Immunophenotype
184672|NCT02017509|Immunoscore
184673|NCT02017509|MRI
184674|NCT02017509|RNA Later
184675|NCT02017496|Breast cancer
184676|NCT02017496|locally advanced
184677|NCT02017496|neoadjuvant treatment
184678|NCT02017496|breast conserving surgery
184679|NCT02017483|ADHD,
184680|NCT02017483|emotion recognition
184681|NCT02017483|attention
184682|NCT02017470|Women Heart Health
184683|NCT02017470|Cardiovascular Disease
184684|NCT02017470|focus group
184685|NCT02017470|advisory board
184686|NCT02017470|one-on-one interview
184687|NCT02017457|Hematology
184688|NCT02017457|Acute Myelogenous Leukemia
184689|NCT02017457|Myelodysplasic syndrome
184690|NCT02017457|Allogeneic stem cell transplantation
184691|NCT02017457|Donor lymphocyte infusion
184692|NCT02017457|DLI
184693|NCT02017457|Azacytidine
184694|NCT02017457|Vidaza
184695|NCT02017457|Overall response rate
184696|NCT02017457|Relapse
184697|NCT02017444|Pseudotumor Cerebri
184698|NCT02017444|Benign Intracranial Hypertension
184699|NCT02017444|Headaches
184700|NCT02017444|Tinnitus
184701|NCT02017444|Papilledema
184702|NCT02017444|Blindness
184703|NCT02017444|Optic Disk
184704|NCT02017444|Intracranial Hypertension
184705|NCT02017444|Clinical Trial, Phase 2
184706|NCT02017444|11beta-Hydroxysteroid Dehydrogenase Type 1
184707|NCT02017444|Obesity
184708|NCT02017431|Diesel exhaust
184709|NCT02017431|Particle depleted diesel exhaust
184710|NCT02017431|Air pollution
184711|NCT02017431|Airway responsiveness
184712|NCT02017431|Allergies
184713|NCT02017418|zeaxanthin
184714|NCT02017418|visual function
184715|NCT02017418|reaction time
184716|NCT02017418|processing speed
184717|NCT02017405|Digestibility
184718|NCT02017405|Healthy volunteers
184719|NCT02017405|serum-derived bovine immunoglobulin protein isolate
184720|NCT02017405|bovine IgG
184721|NCT02017405|adults
184722|NCT02017392|postoperative agitation
184723|NCT02017392|endotracheal intubation
184724|NCT02017392|general anesthesia
184725|NCT02017379|upper gastrointestinal bleeding
184726|NCT02017379|melena
184727|NCT02017379|hematemesis
184728|NCT02017366|Surgery
184729|NCT02017366|Malnutrition
184730|NCT02017366|Nutrition, Enteral
184731|NCT02017340|Alzheimer's Disease
184732|NCT02017340|Investigator-driven clinical trial
184733|NCT02017340|Nilvadipine
184734|NCT02017340|Calcium Channel blocker
184735|NCT02017340|Elderly
184736|NCT02017340|Therapeutic Intervention
184737|NCT02017314|morbid obesity
184738|NCT02017314|postoperative pain
184739|NCT02017301|Liver Cirrhosis,Infection, Impedance, Body Composition
184740|NCT02017288|Head and Neck Cancers
184741|NCT02017288|Larynx
184742|NCT02017288|Oropharynx
184743|NCT02017288|Oral Cavity
184744|NCT02017262|Self-care
184745|NCT02017262|Patient education
184746|NCT02017236|Food Effect
184747|NCT02017236|Health subjects
184748|NCT02017223|Physical activity
184749|NCT02017197|Therapeutic Equivalency
184750|NCT02017197|Warfarin
184751|NCT02017197|Drugs, Generic
184752|NCT02017197|Anticoagulants
184753|NCT02017197|Anticoagulants [Pharmacological Action]
184754|NCT02017197|Coumarins
184755|NCT02017184|Body Temperature Regulation Sensor Noninvasive
184756|NCT02017171|Kidney Diseases
184757|NCT02017171|Diabetic Nephropathies
184758|NCT02017171|Diabetes Mellitus
184759|NCT02017171|Diabetes Complications
184760|NCT02017171|Uric acid
184761|NCT02017171|Allopurinol
184762|NCT02017171|Glomerular filtration rate
184763|NCT02017171|Coronary artery disease
184764|NCT02017158|Obesity
184765|NCT02017158|Nutrition
184766|NCT02017158|Children
184767|NCT02017145|infection
184768|NCT02017145|chloraprep
184769|NCT02017145|chlorhexidine
184770|NCT02017145|lower extremity surgery
184771|NCT02017145|antiseptic
184772|NCT02017145|bacterial colonization
184773|NCT02017132|Pomegranate
184774|NCT02017132|Blood pressure
184775|NCT02017132|Body composition
184776|NCT02017132|Weight-loss
184777|NCT02017132|Fat mass
184778|NCT02017132|Polyphenols
184779|NCT02017132|Quality of Life
184780|NCT02017106|Varicose Veins
184781|NCT02017093|CVA, rehabilitation
184782|NCT02017080|fetal thyroid ultrasound
184783|NCT02017080|fetal fT4
184784|NCT02017080|antithyroid antibodies
184785|NCT02017080|pregnancy
184786|NCT02017080|autoimmune thyroid disease
184787|NCT02017067|Resistance training
184788|NCT02017067|musculoskeletal conditions
184789|NCT02017067|RFD
184790|NCT02017041|opioid dependence, buprenorphine, smartphone, suboxone
184791|NCT02017015|Pancreatic cancer
184792|NCT02017015|Metastatic pancreatic cancer
184793|NCT02017015|treatment for pancreatic cancer
184794|NCT02017015|Abraxane clinical research trials
184795|NCT02017015|Celgene clinical research trials
184796|NCT02017002|Esophageal cancer
184797|NCT02017002|minimally invasive
184798|NCT02017002|Surgical Procedures
184799|NCT02017002|Esophagectomy
184800|NCT02016989|Bacterial keratitis
184801|NCT02016989|OTR4120
184802|NCT02016989|Matrix therapy
184803|NCT02016963|Monoclonal Antibody
184804|NCT02016963|Safety
184805|NCT02016963|Raxibacumab
184806|NCT02016963|HGS1021
184807|NCT02016963|Immunogenicity
184808|NCT02016937|Anesthesia , lactation, birth
184809|NCT02016924|Pediatrics
184810|NCT02016924|Adolescents
184811|NCT02016924|HIV
184812|NCT02016924|HIV-1
184813|NCT02016924|Treatment experienced
184814|NCT02016898|Primary open angle glaucoma
184815|NCT02016898|trabeculectomy
184816|NCT02016898|mitomycin-C
184817|NCT02016898|express mini-shunt
184818|NCT02016872|PET/CT
184819|NCT02016872|18F-FMISO
184820|NCT02016872|tumor hypoxia
184821|NCT02016872|13-186
184822|NCT02016859|IPF Immature platelet fraction
184823|NCT02016859|ICU neutropenic fever
184824|NCT02016859|hip fracture
184825|NCT02016859|critically ill
184826|NCT02016833|Ovarian Cancer
184827|NCT02016833|Cervical Cancer
184828|NCT02016833|Leukemia
184829|NCT02016833|Immunity
184830|NCT02016833|WT-1
184831|NCT02016833|Survivin
184832|NCT02016833|HPV
184833|NCT02016820|Clostridium Difficile Infection
184834|NCT02016820|Proton Pump Inhibitors
184835|NCT02016820|Histamine-2 Receptor Antagonists
184836|NCT02016820|Gastroesophageal Reflux Disease
184837|NCT02016807|Mucositis
184838|NCT02016807|Sucralfate
184839|NCT02016807|Prothelial
184840|NCT02016807|High potency sucralfate
184841|NCT02016807|Ulcerations
184842|NCT02016807|Chemotherapy induced diarrhea
184843|NCT02016807|Radiation induced mucositis
184844|NCT02016807|Chemotherapy colitis
184845|NCT02016807|Radiation colitis
184846|NCT02016807|Mucosal erosions
184847|NCT02016794|cervical
184848|NCT02016794|interbody
184849|NCT02016794|spacer
184850|NCT02016794|degenerative
184851|NCT02016794|pain
184852|NCT02016794|neck
184853|NCT02016794|decompression
184854|NCT02016794|fusion
184855|NCT02016794|implant
184856|NCT02016781|Myelodysplastic Syndrome
184857|NCT02016755|Peripheral Arterial Disease
184858|NCT02016755|Vascular Disease
184859|NCT02016755|CLI
184860|NCT02016755|Critical Limb Ischemia
184861|NCT02016755|PAD
184862|NCT02016755|AnGes
184863|NCT02016755|HGF Plasmid
184864|NCT02016755|HGF
184865|NCT02016755|Hepatocyte Growth Factor Plasmid
184866|NCT02016755|gene therapy
184867|NCT02016742|Pharmacokinetics
184868|NCT02016729|AML
184869|NCT02016716|Postmenopausal Osteoporosis
184870|NCT02016703|erythritol
184871|NCT02016703|polyol
184872|NCT02016703|laxation
184873|NCT02016703|gastrointestinal
184874|NCT02016703|tolerance
184875|NCT02016703|soft drinks
184876|NCT02016703|child
184877|NCT02016703|diarrhoea
184878|NCT02016690|Prevention of severe RSV infection
184879|NCT02016690|Respiratory syncytial virus (RSV) infection
184880|NCT02016690|Down Syndrome
184881|NCT02016690|Immunocompromised
184882|NCT02016690|Effectiveness of palivizumab
184883|NCT02016677|Breast reduction
184884|NCT02016677|Mastopexy
184885|NCT02016677|Sagging
184886|NCT02016664|Chronic Pain, Ketamine, Safety
184887|NCT02016638|Obstructive Sleep Apnea in pregnancy
184888|NCT02016638|Pregnancy induced hypertension
184889|NCT02016638|Restless leg syndrome
184890|NCT02016638|Sleep
184891|NCT02016612|Recurrent
184892|NCT02016612|Ptosis
184893|NCT02016612|Reduction
184894|NCT02016612|Mammoplasty
184895|NCT02016612|Mastopexy
184896|NCT02016599|Hypotension
184897|NCT02016599|Low blood pressure
184898|NCT02016599|Neonate
184899|NCT02016599|Extremely Low Birth Weight Infant
184900|NCT02016573|renal denervation
184901|NCT02016573|blood pressure
184902|NCT02016573|cardiovascular risk
184903|NCT02016573|target organ damage
184904|NCT02016573|sympathetic activity
184905|NCT02016547|Stroke
184906|NCT02016547|Middle Cerebral Artery
184907|NCT02016547|Thrombectomy
184908|NCT02016547|Mechanical Thrombolysis
184909|NCT02016547|Abciximab
184910|NCT02016534|MET Amplified Gastric / Gastroesophageal Junction / Esophageal Adenocarcinoma, or other solid tumors.
184911|NCT02016521|Exercise
184912|NCT02016521|Clothing
184913|NCT02016521|Core body temperature
184914|NCT02016521|Skin Temperature
184915|NCT02016521|Performance
184916|NCT02016508|Adult bone marrow stem cells
184917|NCT02016508|AMD
184918|NCT02016482|Nail Psoriasis
184919|NCT02016482|Plaque Psoriasis
184920|NCT02016456|Transcranial Magnetic Stimulation
184921|NCT02016456|Neuronavigation
184922|NCT02016456|Magnetic Resonance Imaging
184923|NCT02016443|inguinal hernia
184924|NCT02016430|TMAO
184925|NCT02016430|Gut Flora
184926|NCT02016430|Dietary Intervention
184927|NCT02016430|Choline
184928|NCT02016430|Carnitine
184929|NCT02016417|Nasopharyngeal carcinoma
184930|NCT02016417|Induction chemotherapy
184931|NCT02016417|Concurrent chemoradiotherapy
184932|NCT02016417|Gemcitabine
184933|NCT02016417|Docetaxel
184934|NCT02016404|blood pressure
184935|NCT02016404|sodium
184936|NCT02016404|salt
184937|NCT02016404|low sodium high potassium salt
184938|NCT02016404|potassium
184939|NCT02016404|Vietnam
184940|NCT02016404|randomized controlled trial
184941|NCT02016365|Transthyretin amyloidosis
184942|NCT02016365|Cardiomyopathy
184943|NCT02016365|ATTR
184944|NCT02016365|neuropathy
184945|NCT02016352|hydrocephalus
184946|NCT02016352|proteomic
184947|NCT02016352|cerebrospinal fluid
184948|NCT02016326|Colonoscopy
184949|NCT02016326|High Definition White Light
184950|NCT02016326|I-Scan
184951|NCT02016326|Adenomas
184952|NCT02016300|cartilage
184953|NCT02016300|microfracture
184954|NCT02016300|knee
184955|NCT02016300|bracing
184956|NCT02016261|Cognitive function
184957|NCT02016248|CyberKnife
184958|NCT02016248|Prostate Cancer
184959|NCT02016248|Stereotactic Body Radiation
184960|NCT02016248|SBRT
184961|NCT02016248|Radiosurgery
184962|NCT02016248|SABR
184963|NCT02016248|Stereotactic Ablative Body Radiotherapy
184964|NCT02016248|Boost
184965|NCT02016235|Dent
184966|NCT02016235|Dents
184967|NCT02016235|Dent Disease
184968|NCT02016235|Phosphorus Supplements
184969|NCT02016235|FGF 23
184970|NCT02016222|primary progressive multiple sclerosis
184971|NCT02016222|diagnosis
184972|NCT02016222|tears
184973|NCT02016222|isoelectric focusing
184974|NCT02016222|oligoclonal bands
184975|NCT02016196|TIPS
184976|NCT02016196|portal pressure
184977|NCT02016196|rifaximin
184978|NCT02016196|overt hepatic encephalopathy
184979|NCT02016196|microbiota
184980|NCT02016183|Drug Therapy
184981|NCT02016170|platelet reactivity
184982|NCT02016170|ticagrelor
184983|NCT02016170|prasugrel
184984|NCT02016157|Moxifloxacin
184985|NCT02016157|Chlorhexidine
184986|NCT02016157|In situ gel
184987|NCT02016157|Chronic periodontitis
184988|NCT02016144|Airway management; Fiber optic technology; Intubation
184989|NCT02016131|endoleak
184990|NCT02016131|EVAR
184991|NCT02016131|AAA
184992|NCT02016131|CQDSA
184993|NCT02016118|RUTI
184994|NCT02016105|plaque type psoriasis
184995|NCT02016105|equivalent efficacy
184996|NCT02016105|safety and immunogenicity
184997|NCT02016105|GP2017
184998|NCT02016105|Humira®
184999|NCT02016092|Parkinson's disease
185000|NCT02016092|biomarkers
185001|NCT02016092|blood
185002|NCT02016092|urine,
185003|NCT02016092|proteomics
185004|NCT02016092|lipidomics
185005|NCT02016092|metabolomics
185006|NCT02016079|randomized controlled trial
185007|NCT02016079|omega-3
185008|NCT02016079|nutrition
185009|NCT02016079|behavior problems
185010|NCT02016079|externalizing
185011|NCT02016079|internalizing
185012|NCT02016079|antisocial
185013|NCT02016079|aggressive
185014|NCT02016066|Healthy
185015|NCT02016066|CR6261
185016|NCT02016066|Japanese
185017|NCT02016066|Safety
185018|NCT02016066|Pharmacokinetics
185019|NCT02016066|Immunogenicity
185020|NCT02016040|Prostate cancer
185021|NCT02016040|HIFU Hemi-ablation
185022|NCT02016040|Prostate biopsies
185023|NCT02016014|Physical activity
185024|NCT02016014|Alimentation
185025|NCT02016014|Information and communication Technology
185026|NCT02016014|Arterial aging
185027|NCT02016001|fluoride
185028|NCT02016001|dental caries
185029|NCT02016001|prevention
185030|NCT02015988|Acute coronary syndrome
185031|NCT02015988|Diabetes Mellitus, Type 2
185032|NCT02015988|Hypertriglyceridemia
185033|NCT02015988|Simvastatin
185034|NCT02015988|Fenofibrate
185035|NCT02015975|patellar fracture
185036|NCT02015975|fracture of patella
185037|NCT02015975|patella
185038|NCT02015975|locking plate osteosynthesis
185039|NCT02015975|osteosynthesis
185040|NCT02015975|star-plate
185041|NCT02015975|arrow-plate
185042|NCT02015962|Hypokalemia
185043|NCT02015962|Intravenous
185044|NCT02015962|Enteral
185045|NCT02015962|post-cardiac surgery
185046|NCT02015936|stage III cancer
185047|NCT02015936|stage IV cancer
185048|NCT02015936|cancer
185049|NCT02015936|advanced stage cancer
185050|NCT02015936|Nintendo Wii training
185051|NCT02015936|exercise
185052|NCT02015936|physical training
185053|NCT02015936|physical function
185054|NCT02015936|physical fitness test
185055|NCT02015923|Colonic cancer
185056|NCT02015923|Metastasis
185057|NCT02015884|Incivility
185058|NCT02015884|Rudeness
185059|NCT02015884|Aggression
185060|NCT02015884|Violent act
185061|NCT02015884|Healthcare workers
185062|NCT02015884|Emergency unit
185063|NCT02015832|SYNTAX II Score
185064|NCT02015832|Pressure wires
185065|NCT02015832|instantaneous wave-free ratio
185066|NCT02015832|fractional flow reserve
185067|NCT02015832|intravascular ultrasound
185068|NCT02015832|Drug eluting stents
185069|NCT02015832|Stents
185070|NCT02015832|Angioplasty
185071|NCT02015832|multi slice computed tomography
185072|NCT02015806|Quality improvement
185073|NCT02015806|Randomized controlled trial
185074|NCT02015806|Medication adherence
185075|NCT02015806|RxTimer Cap
185076|NCT02015806|PillMinder
185077|NCT02015806|Take-N-Slide
185078|NCT02015806|Low-touch devices
185079|NCT02015806|Medication management
185080|NCT02015793|Crohn's Disease
185081|NCT02015793|Pharmacokinetics
185082|NCT02015780|Drug therapy
185083|NCT02015767|Drug therapy
185084|NCT02015728|Refractory
185085|NCT02015728|Recurrent
185086|NCT02015728|Brain
185087|NCT02015728|Tumor
185088|NCT02015728|Pediatric
185089|NCT02015728|Biologically Targeted Therapy
185090|NCT02015728|Sorafenib
185091|NCT02015728|Everolimus
185092|NCT02015728|Erlotinib
185093|NCT02015728|Dasatinib
185094|NCT02015728|Temozolomide
185095|NCT02015728|Etoposide
185096|NCT02015702|Physicians
185097|NCT02015702|Electronic Health Record
185098|NCT02015702|Education
185099|NCT02015663|Cystic Fibrosis
185100|NCT02015663|CF
185101|NCT02015650|Locally advanced squamous cell carcinomas of head and neck
185102|NCT02015637|Gonorrhea
185103|NCT02015637|N. gonorrhoeae
185104|NCT02015637|bacterial infection
185105|NCT02015637|Anti-Infective Agents
185106|NCT02015637|Anti-Bacterial Agents
185107|NCT02015624|Acute coronary syndromes
185108|NCT02015624|Intensive Care Unit
185109|NCT02015611|Vitamin D
185110|NCT02015611|Muscle power
185111|NCT02015611|Muscle fiber
185112|NCT02015611|Falls
185113|NCT02015611|Aging
185114|NCT02015598|Obstructive sleep apnoea
185115|NCT02015598|Antioxidant
185116|NCT02015598|drug treatment
185117|NCT02015598|oxidative stress
185118|NCT02015598|Continuous Positive Airway Pressure
185119|NCT02015572|Low back pain
185120|NCT02015572|Return to work
185121|NCT02015572|Sickness absence
185122|NCT02015572|Rehabilitation
185123|NCT02015572|Occupational intervention
185124|NCT02015546|Major Depressive Disorder
185125|NCT02015546|Vilazodone
185126|NCT02015533|Healthy
185127|NCT02015533|CR8020
185128|NCT02015533|Japanese
185129|NCT02015533|Safety
185130|NCT02015533|Pharmacokinetics
185131|NCT02015533|Immunogenicity
185132|NCT02015494|Safety
185133|NCT02015494|Immunogenicity
185134|NCT02015481|Case control, safety, tolerability, efficacy.
185135|NCT02015468|Distal radius fracture
185136|NCT02015468|Wrist fracture
185137|NCT02015468|Physiotherapy
185138|NCT02015468|Immobilization
185139|NCT02015468|Volar locking plates
185140|NCT02015468|Mobilization
185141|NCT02015455|pragmatic trial
185142|NCT02015455|stepped-wedge design
185143|NCT02015455|cluster-randomized trial
185144|NCT02015442|Sucrose in diet
185145|NCT02015429|Food intake
185146|NCT02015429|satiety
185147|NCT02015429|glycemia
185148|NCT02015429|appetite
185149|NCT02015429|blood glucose
185150|NCT02015429|yellow peas
185151|NCT02015429|fibre
185152|NCT02015429|protein
185153|NCT02015429|mixed meal
185154|NCT02015416|Melanoma
185155|NCT02015416|Ovarian cancer
185156|NCT02015416|Sarcoma
185157|NCT02015416|Non-small cell lung cancer
185158|NCT02015416|NSCLC
185159|NCT02015416|Breast cancer
185160|NCT02015390|bone defects
185161|NCT02015390|iatrogenic resection
185162|NCT02015390|titanium mesh cage
185163|NCT02015390|biomembrane
185164|NCT02015390|Masquelet technique
185165|NCT02015364|Achilles tendon
185166|NCT02015364|Rupture
185167|NCT02015364|Rehabilitation
185168|NCT02015364|Dynamic rehabilitation
185169|NCT02015351|Choroidal neovascularization
185170|NCT02015351|Vogt Koyanagi Harada Disease
185171|NCT02015351|Inflammatory choroidal neovascularization
185172|NCT02015351|Anti-VEGF
185173|NCT02015338|Hemiparesis
185174|NCT02015338|Cerebral Palsy
185175|NCT02015338|Congenital Stroke
185176|NCT02015338|Congenital Infarct
185177|NCT02015325|Water
185178|NCT02015325|Sanitation
185179|NCT02015325|Hygiene
185180|NCT02015325|Education
185181|NCT02015325|Evaluation
185182|NCT02015312|Amyloidosis
185183|NCT02015299|Diabetes
185184|NCT02015299|Pulse Wave Velocity
185185|NCT02015299|Dipeptidyl peptidase (DPP)-4 inhibitors
185186|NCT02015299|Linagliptin
185187|NCT02015299|Arterial Stiffness
185188|NCT02015299|Subclinical arterial inflammation
185189|NCT02015286|Growth disorders
185190|NCT02015286|Saizen
185191|NCT02015286|Easypod
185192|NCT02015286|Growth hormone
185193|NCT02015286|Pediatric subject
185194|NCT02015273|easypod™
185195|NCT02015273|SAIZEN®
185196|NCT02015260|human papilloma virus infection
185197|NCT02015260|Anogenital warts
185198|NCT02015260|condylomata acuminata
185199|NCT02015234|TNX-102 SL
185200|NCT02015234|bedtime
185201|NCT02015234|sublingual
185202|NCT02015234|12-month
185203|NCT02015234|long term safety
185204|NCT02015234|long term efficacy
185205|NCT02015234|Fibromyalgia
185206|NCT02015221|chronic venous insufficiency
185207|NCT02015221|venous leg ulcers
185208|NCT02015221|pneumatic compression
185209|NCT02015208|CLL
185210|NCT02015208|cytokine signaling
185211|NCT02015208|signal transduction inhibitors
185212|NCT02015208|elderly
185213|NCT02015208|p53
185214|NCT02015195|Jellyfish stings
185215|NCT02015195|Treatment
185216|NCT02015195|Humans
185217|NCT02015195|Topical Treatments
185218|NCT02015195|Pain
185219|NCT02015195|Erythema
185220|NCT02015182|Bupivacaine
185221|NCT02015182|Sensorcaine
185222|NCT02015182|Population pharmacokinetics
185223|NCT02015182|Children
185224|NCT02015182|Pediatrics
185225|NCT02015182|Transversus abdominis plane (TAP) block
185226|NCT02015182|Regional Anesthesia
185227|NCT02015169|gastric cancer
185228|NCT02015169|neoadjuvant chemotherapy
185229|NCT02015169|capecitabine
185230|NCT02015169|oxaliplatin
185231|NCT02015169|lapatinib
185232|NCT02015156|Trastuzumab
185233|NCT02015156|Healthy Male Volunteers
185234|NCT02015156|Single-Dose
185235|NCT02015156|Phase 1
185236|NCT02015156|Biosimilarity
185237|NCT02015130|Type 2 diabetes
185238|NCT02015130|hypertension
185239|NCT02015130|individual
185240|NCT02015104|Urothelial Cancinoma
185241|NCT02015104|Vaccines
185242|NCT02015104|Immunotherapy
185243|NCT02015104|TICE BCG
185244|NCT02015104|Intravesical Treatment
185245|NCT02015091|Healthy Subjects
185246|NCT02015091|Vaccine-Mediated Protection
185247|NCT02015091|Immunogenicity
185248|NCT02015091|Sporozoites
185249|NCT02015091|Parasitemia
185250|NCT02015078|Eating Behavior
185251|NCT02015078|Cancer
185252|NCT02015078|Chronic Diseases
185253|NCT02015078|Obesity
185254|NCT02015065|GIST
185255|NCT02015065|Toxicity
185256|NCT02015065|Mesenchymal Tumor
185257|NCT02015065|Clinical Activity
185258|NCT02015065|Survival
185259|NCT02015039|Occupational Therapy
185260|NCT02015039|Botulinum Toxin
185261|NCT02015039|Writer's Cramp
185262|NCT02015026|Biospecimen Repository
185263|NCT02015026|Disease Progression Pattern
185264|NCT02015026|Specimen Analysis
185265|NCT02015026|Genetic Analysis
185266|NCT02015013|Leukapheresis
185267|NCT02015013|Progenitor Cells
185268|NCT02015000|Pterygium
185269|NCT02015000|Recurrence
185270|NCT02014987|Running related injury
185271|NCT02014987|Overuse injury
185272|NCT02014987|Running pattern
185273|NCT02014974|Fractures
185274|NCT02014974|burden of fractures
185275|NCT02014974|orthopaedic fractures
185276|NCT02014974|orthopaedic injuries
185277|NCT02014974|orthopaedic trauma
185278|NCT02014974|fractures India
185279|NCT02014974|observational study
185280|NCT02014974|outcomes of fracture care
185281|NCT02014974|wait times India
185282|NCT02014974|epidemiology
185283|NCT02014948|Low Back Pain
185284|NCT02014948|Physiotherapy
185285|NCT02014935|Low-intensity Laser
185286|NCT02014935|Spasticity
185287|NCT02014935|pain,
185288|NCT02014935|Fatigue
185289|NCT02014909|KTN3379
185290|NCT02014909|Advanced cancer
185291|NCT02014909|Phase 1
185292|NCT02014909|Monoclonal antibody
185293|NCT02014909|Safety and pharmacokinetics
185294|NCT02014896|Ischemic Stroke
185295|NCT02014896|Transient Ischemic Attack
185296|NCT02014896|Transient Neurological Event
185297|NCT02014896|Atrial Fibrillation
185298|NCT02014896|Cryptogenic Stroke
185299|NCT02014896|Gene Expression
185300|NCT02014896|RNA
185301|NCT02014896|Anticoagulant
185302|NCT02014896|NOAC
185303|NCT02014896|Antiplatelet
185304|NCT02014896|Cardiac monitoring
185305|NCT02014896|Point of Care
185306|NCT02014896|tPA
185307|NCT02014896|Atheroembolic
185308|NCT02014870|Influenza
185309|NCT02014870|Vaccine
185310|NCT02014870|Virus
185311|NCT02014870|H1N1
185312|NCT02014870|Challenge
185313|NCT02014870|Vismederi
185314|NCT02014857|Smoking, gingival crevicular fluid, matrix metalloproteinases, intercellular signaling peptides and proteins, healthy volunteers
185315|NCT02014844|glioblastoma
185316|NCT02014844|aldoxorubicin
185317|NCT02014844|temozolomide
185318|NCT02014844|brain cancer
185319|NCT02014844|brain tumor
185320|NCT02014831|Squamous Cell Carcinoma of the penis
185321|NCT02014831|Stage N3
185322|NCT02014831|Metastasis
185323|NCT02014831|TIP
185324|NCT02014831|Cetuximab
185325|NCT02014831|Objective Response Rate
185326|NCT02014831|Safety profile
185327|NCT02014831|Overall Survival
185328|NCT02014831|Progression Free Survival
185329|NCT02014831|Quality of Life
185330|NCT02014805|postoperative
185331|NCT02014805|conformal
185332|NCT02014805|radiotherapy
185333|NCT02014805|thymoma
185334|NCT02014792|Haemodialysis
185335|NCT02014792|Heart rate variability
185336|NCT02014792|n-3 PUFA
185337|NCT02014779|Randomized Controlled Trial
185338|NCT02014779|Alcohol
185339|NCT02014779|Internet
185340|NCT02014779|Internet based therapy
185341|NCT02014779|Cognitive behavioral therapy
185342|NCT02014753|AMI
185343|NCT02014753|STEMI
185344|NCT02014753|ACS
185345|NCT02014740|Epicardial fat
185346|NCT02014740|Type 2 diabetes
185347|NCT02014740|Obesity
185348|NCT02014740|GLP-1 analogs
185349|NCT02014727|Malaria vaccine
185350|NCT02014727|phase 1,
185351|NCT02014727|AMA1-DiCO
185352|NCT02014701|echocardiogram
185353|NCT02014701|regional wall motion abnormalities
185354|NCT02014701|myocardial contrast
185355|NCT02014688|Normal subjects
185356|NCT02014675|ICD
185357|NCT02014675|CRT-D
185358|NCT02014675|Lead
185359|NCT02014662|Muscle function, Muscle damage and recovery, Eccentric exercise, Muscle soreness, Protein synthesis
185360|NCT02014649|Influenza treatment
185361|NCT02014649|pediatric
185362|NCT02014649|laninamivir
185363|NCT02014636|Pazopanib (GW786034)
185364|NCT02014636|MK 3475
185365|NCT02014636|Renal cell carcinoma
185366|NCT02014623|Allergic rhinitis
185367|NCT02014623|Asthma
185368|NCT02014623|Regulatory T cells
185369|NCT02014623|IgE
185370|NCT02014623|IgG4
185371|NCT02014610|Neutrophil
185372|NCT02014610|Lymphocyte
185373|NCT02014610|Eosinophil
185374|NCT02014610|Leukocyte count
185375|NCT02014610|Cardiovascular disease
185376|NCT02014610|Atherosclerosis
185377|NCT02014610|Monocyte
185378|NCT02014610|Basophil
185379|NCT02014597|Glaucoma
185380|NCT02014584|quality of life
185381|NCT02014584|safety
185382|NCT02014584|sexual function
185383|NCT02014584|male pattern hair loss (MPHL)
185384|NCT02014584|Androgenic alopecia (AGA)
185385|NCT02014584|dutasteride
185386|NCT02014584|satisfaction with hair growth
185387|NCT02014571|Safety
185388|NCT02014571|NS5B
185389|NCT02014571|pharmacokinetics (PK)
185390|NCT02014571|hepatitis C virus (HCV)
185391|NCT02014571|antiviral activity
185392|NCT02014571|GSK2878175
185393|NCT02014571|chronic hepatitis C (CHC)
185394|NCT02014558|Acute Myeloid Leukemia
185395|NCT02014558|ASP2215
185396|NCT02014545|brain metastases
185397|NCT02014545|non-small cell lung cancer
185398|NCT02014545|whole brain radiation therapy
185399|NCT02014545|lucanthone
185400|NCT02014532|Leukotriene receptor antagonist
185401|NCT02014532|Chronic periodontitis
185402|NCT02014532|Scaling and root planing
185403|NCT02014532|C- reactive protein
185404|NCT02014519|Adults
185405|NCT02014519|Hungary
185406|NCT02014519|Bordetella pertussis
185407|NCT02014519|Seroprevalence
185408|NCT02014519|Pertussis antibodies
185409|NCT02014506|Children and adolescents
185410|NCT02014506|Malignant disease
185411|NCT02014506|Non-malignant disease
185412|NCT02014506|TCRαβ depletion
185413|NCT02014506|Haploidentical hematopoietic stem cell transplantation
185414|NCT02014493|Respiration
185415|NCT02014493|Noninvasive Ventilation
185416|NCT02014493|Work of breathing
185417|NCT02014493|Infant, premature
185418|NCT02014493|Electromyography
185419|NCT02014493|Diaphragm
185420|NCT02014480|Long-acting beta-agonist
185421|NCT02014480|Chronic Obstructive Pulmonary Disease
185422|NCT02014480|Umeclidinium
185423|NCT02014480|Long-acting muscarinic antagonist
185424|NCT02014480|Vilanterol
185425|NCT02014454|Retinopathy of prematurity
185426|NCT02014454|Propranolol
185427|NCT02014454|Eye drops
185428|NCT02014454|Newborns
185429|NCT02014454|Retinal angiogenesis
185430|NCT02014454|Retinal neovascularization
185431|NCT02014415|Alpha-1
185432|NCT02014415|AAT Deficiency
185433|NCT02014415|AATD
185434|NCT02014415|Liver
185435|NCT02014415|Fibrosis
185436|NCT02014415|Liver Transplant
185437|NCT02014415|Cirrhosis
185438|NCT02014402|Hemostasis
185439|NCT02014402|Vascular open surgery
185440|NCT02014402|Hepatic open surgery
185441|NCT02014402|Soft tissue open surgery
185442|NCT02014402|Spinal open surgery
185443|NCT02014402|during vascular, hepatic, soft tissue, and spinal open surgical procedures.
185444|NCT02014389|Retinal Dystrophies
185445|NCT02014389|Retinitis Pigmentosa
185446|NCT02014389|Glaucoma
185447|NCT02014389|Visual Field
185448|NCT02014376|Epidermolysis Bullosa
185449|NCT02014376|Simplex
185450|NCT02014376|Recessive Dystrophic
185451|NCT02014376|Junctional non-Herlitz
185452|NCT02014337|Mifepristone
185453|NCT02014337|Eribulin Mesylate
185454|NCT02014337|Breast Cancer
185455|NCT02014337|Ovarian Cancer
185456|NCT02014337|Sarcoma
185457|NCT02014337|Non-small cell lung cancer
185458|NCT02014337|Carcinoma, transitional cell
185459|NCT02014337|Prostate cancer
185460|NCT02014337|Prostatic neoplasms
185461|NCT02014311|Multidetector Computed Tomography
185462|NCT02014311|Myocardial Perfusion Imaging
185463|NCT02014311|Coronary Stenosis
185464|NCT02014311|Coronary Artery Disease
185465|NCT02014311|Angina Pectoris
185466|NCT02014298|Burns
185467|NCT02014298|Non-ablative fractional laser
185468|NCT02014298|scar texture
185469|NCT02014298|histology
185470|NCT02014298|laser treatment
185471|NCT02014298|erbium:glass laser
185472|NCT02014298|meshed skin-grafts
185473|NCT02014298|photothermolysis
185474|NCT02014298|skin
185475|NCT02014285|Acute Respiratory Failure
185476|NCT02014285|Critical Illness
185477|NCT02014285|Mechanical Ventilation
185478|NCT02014285|Muscle Architecture
185479|NCT02014285|Muscle Ultrasound
185480|NCT02014272|Bioequivalence
185481|NCT02014272|RIN 150
185482|NCT02014272|Healthy volunteers
185483|NCT02014246|Movement Disorders
185484|NCT02014246|Polymorphisms
185485|NCT02014246|DNA
185486|NCT02014246|Lymphoblast Cell Lines
185487|NCT02014233|Randomized clinical trial
185488|NCT02014233|Humans
185489|NCT02014233|Omega-3 fatty acids
185490|NCT02014233|Essential fatty acid
185491|NCT02014233|Neuromuscular function
185492|NCT02014233|Wingate
185493|NCT02014233|Maximum voluntary contraction
185494|NCT02014233|Electromyography
185495|NCT02014233|Seal oil
185496|NCT02014233|Cycling time trial
185497|NCT02014233|Placebo controlled
185498|NCT02014194|Attentional Bias
185499|NCT02014194|Attentional Bias modification treatment
185500|NCT02014181|cystic fibrosis
185501|NCT02014181|isoprostanes
185502|NCT02014181|8-oxo-dGuo
185503|NCT02014181|oxidative stress
185504|NCT02014181|inflammation
185505|NCT02014181|flaxseed
185506|NCT02014181|enterodiol
185507|NCT02014181|enterolactone
185508|NCT02014155|Chronic Obstructive Pulmonary Disease,
185509|NCT02014103|bioequivalence
185510|NCT02014103|tacrolimus
185511|NCT02014103|transplant
185512|NCT02014103|CYP3A5 expressors/non expressors
185513|NCT02014090|ECP
185514|NCT02014090|Endurance exercise
185515|NCT02014090|myocardial perfusion
185516|NCT02014077|VATS( Video-Assisted Thoracoscopy )
185517|NCT02014077|Thoracostomy Tube
185518|NCT02014077|Empyema
185519|NCT02014077|Thoracotomy
185520|NCT02014064|Methamphetamine, Atomoxetine, Clinical Pharmacology
185521|NCT02014038|Ultrarunners
185522|NCT02014038|ultramarathon runners
185523|NCT02014038|ULTRA
185524|NCT02014038|Physical activity
185525|NCT02014038|Health Risks
185526|NCT02014038|sedentary
185527|NCT02014038|moderately active
185528|NCT02014025|Laparoscope hepatectomy
185529|NCT02014025|Open hepatectomy
185530|NCT02014025|large PHC
185531|NCT02014025|safety and sensibility
185532|NCT02013986|salivary cortisol
185533|NCT02013986|circadian rhythm
185534|NCT02013986|children
185535|NCT02013986|etomidate
185536|NCT02013973|Anti mullerian hormone
185537|NCT02013973|In vitro fertilization
185538|NCT02013973|Optimal treatment
185539|NCT02013973|Randomized controlled trial
185540|NCT02013947|Exercise, moderate altitude, hypoxia, metabolic syndrome
185541|NCT02013921|Physical activity
185542|NCT02013921|Cancer
185543|NCT02013908|acupuncture
185544|NCT02013908|emergency department
185545|NCT02013908|acute pain
185546|NCT02013908|ankle sprain
185547|NCT02013908|neck pain
185548|NCT02013908|primary headache
185549|NCT02013895|liver
185550|NCT02013895|surgery
185551|NCT02013895|liver function
185552|NCT02013895|GSA
185553|NCT02013895|ICG
185554|NCT02013882|low flow anesthesia
185555|NCT02013882|wash-in
185556|NCT02013882|desflurane
185557|NCT02013869|fresh gas flow
185558|NCT02013869|quality of anaesthesia
185559|NCT02013869|minimal alveolar concentration
185560|NCT02013856|Blood pressure
185561|NCT02013856|Flavanols
185562|NCT02013856|Cardiovascular disease
185563|NCT02013843|Pediatric obesity
185564|NCT02013843|Community-based treatment
185565|NCT02013843|dyslipidemia
185566|NCT02013843|hypertension
185567|NCT02013843|diabetes
185568|NCT02013778|outside of transplant criteria
185569|NCT02013752|Delivery tears
185570|NCT02013752|Birth injuries
185571|NCT02013752|Perineal protection device
185572|NCT02013713|Cardiology
185573|NCT02013713|Family Hypercholesterolemia
185574|NCT02013700|IPF
185575|NCT02013700|Pulmonary fibrosis
185576|NCT02013674|Cardiovascular, Chronic Ischemic Left Ventricular Dysfunction
185577|NCT02013661|periodontal debridement
185578|NCT02013661|sutures
185579|NCT02013661|tissue reaction
185580|NCT02013648|AML
185581|NCT02013648|Dasatinib
185582|NCT02013648|Core Binding Factor (CBF)
185583|NCT02013635|cerebral venous thrombosis
185584|NCT02013635|thrombin generation
185585|NCT02013635|d-dimers
185586|NCT02013635|clinical evolution
185587|NCT02013622|schizophrenia
185588|NCT02013622|Mental Disorders
185589|NCT02013622|Psychotic Disorders
185590|NCT02013622|social avoidance
185591|NCT02013622|emotional withdrawal
185592|NCT02013622|passive/apathetic
185593|NCT02013622|social withdrawal
185594|NCT02013622|antipsychotic
185595|NCT02013609|schizophrenia
185596|NCT02013609|Major depressive disorder
185597|NCT02013609|Anxiety Symptoms
185598|NCT02013609|School, Work environment
185599|NCT02013609|Mental Disorders
185600|NCT02013609|Psychotic Disorders
185601|NCT02013609|antipsychotic
185602|NCT02013596|hepatic dysfunction
185603|NCT02013596|renal dysfunction
185604|NCT02013596|pneumoperitoneum
185605|NCT02013596|Transcutaneous electric stimulation
185606|NCT02013583|Glucose Transporter Type I Deficiency
185607|NCT02013583|Glucose Transporter Type 1 Deficiency
185608|NCT02013583|G1D
185609|NCT02013583|Glut1 Deficiency
185610|NCT02013570|postoperative pain; dexmedetomidine; adenotonsillectomy
185611|NCT02013557|Gestational Diabetes
185612|NCT02013557|Postpartum screening
185613|NCT02013557|Text-messages
185614|NCT02013557|75-g oral glucose tolerance test
185615|NCT02013544|Vulvovaginal atrophy (VVA)
185616|NCT02013544|Vaginal atrophy
185617|NCT02013544|Atrophic vaginitis
185618|NCT02013544|prasterone
185619|NCT02013544|DHEA
185620|NCT02013531|schizophrenia
185621|NCT02013531|Major depressive disorder
185622|NCT02013531|Anxiety Symptoms
185623|NCT02013531|Mental Disorders
185624|NCT02013531|Psychotic Disorders
185625|NCT02013531|emotional withdrawal
185626|NCT02013531|antipsychotic
185627|NCT02013518|Alzheimers' disease
185628|NCT02013518|Cognitive behavioral therapy
185629|NCT02013518|Depression
185630|NCT02013518|Self-efficacy
185631|NCT02013518|Quality of Life
185632|NCT02013505|Colonoscopy
185633|NCT02013492|Beta-Blocker
185634|NCT02013492|metastatic melanoma
185635|NCT02013492|hepatocellular carcinoma
185636|NCT02013466|Bioavailability
185637|NCT02013466|Amino Acids
185638|NCT02013466|Elderly
185639|NCT02013466|Supplement
185640|NCT02013427|chronic
185641|NCT02013427|back
185642|NCT02013427|pain
185643|NCT02013427|brain
185644|NCT02013427|MRI
185645|NCT02013401|mother-infant dyadic regulation
185646|NCT02013401|stress
185647|NCT02013401|psychophysiology
185648|NCT02013401|emotion regulation
185649|NCT02013388|N91115
185650|NCT02013388|GSNORi
185651|NCT02013388|SNO
185652|NCT02013388|Cavosonstat
185653|NCT02013336|pediatric
185654|NCT02013336|MM-398
185655|NCT02013336|cyclophosphamide
185656|NCT02013336|irinotecan
185657|NCT02013323|Septiline, chronic periodontitis, Immunomodulator, microbiology
185658|NCT02013297|Pediatrics
185659|NCT02013297|SBRT
185660|NCT02013297|Brain metastasis
185661|NCT02013297|Pulmonary metastasis
185662|NCT02013297|Spinal metastasis
185663|NCT02013297|Pulmonary primary tumor
185664|NCT02013297|Spinal primary tumor
185665|NCT02013297|Relapsed ependymoma
185666|NCT02013297|Relapsed irradiated tumors
185667|NCT02013297|Local control rate
185668|NCT02013297|Safety
185669|NCT02013297|Overall survival
185670|NCT02013297|Progression Free Survival
185671|NCT02013258|Prader Willi syndrome
185672|NCT02013258|Oxytocin
185673|NCT02013232|Risperidone;
185674|NCT02013232|Aripiprazole;
185675|NCT02013232|Hyperprolactinemia;
185676|NCT02013232|dose effects
185677|NCT02013193|drug-coated balloon
185678|NCT02013193|drug-eluting balloon
185679|NCT02013193|peripheral artery disease
185680|NCT02013193|claudication
185681|NCT02013180|Prostate cancer, PSA, zinc, zinc/PSA
185682|NCT02013167|Relapsed; Refractory; B-precursor; Acute Lymphoblastic Leukemia; Philadelphia Negative; ALL; Blinatumomab; Leukemia; Standard of Care; SOC
185683|NCT02013141|Gram positive bacteria
185684|NCT02013141|Telavancin
185685|NCT02013141|VIBATIV
185686|NCT02013141|Pediatric
185687|NCT02013141|Pharmacokinetics
185688|NCT02013115|infant
185689|NCT02013115|respiratory distress syndrome
185690|NCT02013089|genomic sequencing, Integrated genomic network analysis
185691|NCT02013076|Asthma; Children; Cohort study; Corticosteroids
185692|NCT02013063|Single Pulmonary Nodule
185693|NCT02013063|SPN
185694|NCT02013063|Lung cancer
185695|NCT02013063|Diagnostic
185696|NCT02013063|Computed Tomography
185697|NCT02013063|CT scan
185698|NCT02013063|FDG-PET scan
185699|NCT02013063|Dynamic CT scan
185700|NCT02013063|DCE-CT scan
185701|NCT02013063|Dynamic contrast enhanced CT scan
185702|NCT02013063|soft tissue solitary dominant
185703|NCT02013063|≥ 8mm and ≤30mm
185704|NCT02013037|cardiac transplantation
185705|NCT02013037|immunosuppression
185706|NCT02013037|acute cellular rejection
185707|NCT02013037|antibody mediated rejection
185708|NCT02013037|sensitization
185709|NCT02013037|antibody production in cardiac patients
185710|NCT02013037|panel reactive antibodies
185711|NCT02013037|desensitization strategies in heart transplant patients
185712|NCT02013037|complement activation
185713|NCT02013037|complement c3d and c4d deposition
185714|NCT02013037|terminal complement inhibition
185715|NCT02013037|complement C5 binding
185716|NCT02013037|Eculizumab
185717|NCT02013037|monoclonal antibody
185718|NCT02013037|donor specific antibodies
185719|NCT02012985|hyperoxaluria
185720|NCT02012985|oxalate
185721|NCT02012985|PH
185722|NCT02012972|Antiretroviral therapy
185723|NCT02012972|HIV/AIDS
185724|NCT02012972|Non-communicable diseases
185725|NCT02012972|South Africa
185726|NCT02012959|Hyponatremia
185727|NCT02012959|Euvolemic
185728|NCT02012959|Hypervolemic
185729|NCT02012959|Serum sodium
185730|NCT02012959|Dilutional hyponatremia
185731|NCT02012959|Electrolyte abnormality
185732|NCT02012959|Electrolyte imbalance
185733|NCT02012959|Metabolic disease
185734|NCT02012933|3,4DAP, LEMS, CM
185735|NCT02012920|castration-resistant prostate cancer
185736|NCT02012920|CYP17
185737|NCT02012920|P450c17a
185738|NCT02012920|lyase
185739|NCT02012920|Prostate Cancer
185740|NCT02012894|Obesity
185741|NCT02012894|Gastroesophageal reflux
185742|NCT02012894|sleeve gastrectomy
185743|NCT02012894|pH-monitoring
185744|NCT02012894|manometry
185745|NCT02012868|obstructive sleep apnoea
185746|NCT02012868|weight loss
185747|NCT02012868|bariatric surgery
185748|NCT02012842|Metabolic Syndrome
185749|NCT02012842|Periodontal Disease
185750|NCT02012842|Periodontal therapy
185751|NCT02012842|inflammatory markers
185752|NCT02012842|C reactive protein
185753|NCT02012842|serum fibrinogen
185754|NCT02012842|glycated hemoglobin
185755|NCT02012829|cancer, CRC screening, communication
185756|NCT02012816|Uncircumcised men
185757|NCT02012816|Voluntary Medical Male circumcision
185758|NCT02012816|Peer-referral incentive
185759|NCT02012803|Achilles tendon rupture
185760|NCT02012803|treatment, elongation
185761|NCT02012803|operative treatment of achilles tendon rupture
185762|NCT02012803|conservative treatment of achilles tendon rupture
185763|NCT02012790|Migraine disorders
185764|NCT02012777|sickle cell disease
185765|NCT02012777|propanolol
185766|NCT02012777|red blood cell adhesion
185767|NCT02012764|Anti-CCP antibody
185768|NCT02012764|Inflammatory arthritis
185769|NCT02012764|Rheumatoid arthritis
185770|NCT02012764|Musculoskeletal symptom
185771|NCT02012751|Computer-assisted diagnosis
185772|NCT02012751|General practice
185773|NCT02012751|Dermatoscopy
185774|NCT02012751|Melanoma
185775|NCT02012751|Nevus
185776|NCT02012725|Healthy
185777|NCT02012725|Myocardial fibrosis
185778|NCT02012725|Chronic kidney disease
185779|NCT02012712|Personal health record
185780|NCT02012712|medication management
185781|NCT02012712|patient safety
185782|NCT02012699|Pancreatic Cancer
185783|NCT02012699|Thyroid Cancer
185784|NCT02012699|Esophageal cancer
185785|NCT02012699|Thymus cancer
185786|NCT02012699|Pancreatic tumor
185787|NCT02012699|Esophageal tumor
185788|NCT02012699|Thymus tumor
185789|NCT02012699|Thyroid Tumor
185790|NCT02012699|Thyroid Nodule
185791|NCT02012699|Lung Tumor
185792|NCT02012686|transcutaneous electric nerve stimulation
185793|NCT02012686|thyroidectomy
185794|NCT02012686|neck pain
185795|NCT02012686|pain management
185796|NCT02012673|COPD
185797|NCT02012673|Emphysema
185798|NCT02012673|Bronchoscopy
185799|NCT02012673|Lung Volume Reduction
185800|NCT02012647|parkinson
185801|NCT02012647|PD
185802|NCT02012647|parkinson disease
185803|NCT02012647|parkinson's
185804|NCT02012647|parkinson's disease
185805|NCT02012647|parkinsons
185806|NCT02012647|parkinsons disease
185807|NCT02012647|TMS
185808|NCT02012647|DBS
185809|NCT02012647|transcranial magnetic stimulation
185810|NCT02012647|deep brain stimulation
185811|NCT02012634|Breast Cancer
185812|NCT02012634|Capecitabine
185813|NCT02012634|Triple Negative Breast CancerTNBC（TNBC）
185814|NCT02012621|HIV/AIDS
185815|NCT02012621|Adherence
185816|NCT02012621|Tenofovir
185817|NCT02012621|Dried Blood Spots
185818|NCT02012608|breast
185819|NCT02012569|skin grafting
185820|NCT02012569|elective treatment
185821|NCT02012543|constipation, agar
185822|NCT02012530|Articular cartilage
185823|NCT02012530|Hyaluronic Acid (HA)
185824|NCT02012530|Platelet rich plasma (PRP)
185825|NCT02012517|surgical site infection
185826|NCT02012517|breast reconstruction
185827|NCT02012517|drains
185828|NCT02012517|prophylaxis
185829|NCT02012491|Spontaneous abortion
185830|NCT02012491|Early Pregnancy Failure
185831|NCT02012491|Mifepristone
185832|NCT02012491|Misoprostol
185833|NCT02012465|Steroid induced hyperglycemia
185834|NCT02012465|Glucocorticoid induced hyperglycemia
185835|NCT02012452|posttraumatic stress disorder
185836|NCT02012452|tobacco dependence
185837|NCT02012452|cognitive behavioral therapy
185838|NCT02012439|multiple sclerosis
185839|NCT02012439|chronic pain
185840|NCT02012439|treatment
185841|NCT02012439|nonpharmacological
185842|NCT02012439|mindfulness
185843|NCT02012439|cognitive therapy
185844|NCT02012413|knee
185845|NCT02012413|chondromalacia
185846|NCT02012413|patella
185847|NCT02012413|pulsed signal therapy
185848|NCT02012413|PST
185849|NCT02012400|Asthma
185850|NCT02012400|Exercise
185851|NCT02012400|Asthma control
185852|NCT02012400|Physical fitness
185853|NCT02012400|Quality of life
185854|NCT02012387|Cholinergic urticaria
185855|NCT02012387|Omalizumab
185856|NCT02012374|aphasia
185857|NCT02012374|anomia
185858|NCT02012374|speech therapy
185859|NCT02012374|rehabilitation
185860|NCT02012374|neuroplasticity
185861|NCT02012374|fMRI
185862|NCT02012374|quality of life
185863|NCT02012361|Ischemic preconditioning
185864|NCT02012361|Human limb ischemia
185865|NCT02012361|Total knee arthroplasty
185866|NCT02012361|Supplemental inspired helium
185867|NCT02012348|bacteria survival, surfactants
185868|NCT02012322|Aging
185869|NCT02012322|Coenzyme Q10
185870|NCT02012322|Q10
185871|NCT02012322|Quality of Life
185872|NCT02012322|Oxidative Stress
185873|NCT02012322|Mitochondrial Function
185874|NCT02012322|Cell Energetics
185875|NCT02012322|Fatigue
185876|NCT02012322|Ubiquinone
185877|NCT02012309|HIV
185878|NCT02012309|Streptococcus pneumoniae infection
185879|NCT02012309|Streptococcus pneumoniae colonization
185880|NCT02012309|Pneumococcal vaccines
185881|NCT02012309|Prevnar
185882|NCT02012309|Pneumovax
185883|NCT02012309|Nasopharyngeal microbiome
185884|NCT02012283|spices and vegetables
185885|NCT02012270|Aortic Aneurysm
185886|NCT02012270|Hernia
185887|NCT02012270|Abdominal Wound Closure Techniques
185888|NCT02012257|anterior middle superior alveolar nerve
185889|NCT02012257|electric pulp tester
185890|NCT02012257|local anesthesia
185891|NCT02012244|analgesia; colorectal surgery; immunity; local anesthetics; opioids
185892|NCT02012231|melanoma
185893|NCT02012231|anaplastic thyroid cancer
185894|NCT02012231|advanced papillary thyroid cancer
185895|NCT02012231|colorectal cancer
185896|NCT02012231|non-small cell lung cancer
185897|NCT02012231|cholangiocarcinoma
185898|NCT02012231|histiocytosis
185899|NCT02012231|hairy cell leukemia
185900|NCT02012218|Major Depressive Disorder, Depression
185901|NCT02012205|wet cupping - back pain - NSLBP - Saudi
185902|NCT02012192|High-grade serous
185903|NCT02012192|high-grade endometrioid
185904|NCT02012192|undifferentiated
185905|NCT02012179|Diet
185906|NCT02012179|Dietary sodium reduction
185907|NCT02012179|Salt restriction
185908|NCT02012179|Nutrition
185909|NCT02012166|Diabetes Mellitus
185910|NCT02012166|Diabetes Mellitus, Type 2
185911|NCT02012166|Glucose Metabolism Disorders
185912|NCT02012166|Metabolic Diseases
185913|NCT02012166|Endocrine System Diseases
185914|NCT02012166|Therapeutic Uses
185915|NCT02012166|Pharmacologic Actions
185916|NCT02012166|Molecular Mechanisms of Pharmacological Action
185917|NCT02012166|Physiological Effects of Drugs
185918|NCT02012153|Mesenchymal stromal cells
185919|NCT02012153|Kidney transplantation
185920|NCT02012153|Tolerance
185921|NCT02012114|Cystinosis, compliance, cysteamine, neurological assessments
185922|NCT02012101|COPD
185923|NCT02012101|dyspnea
185924|NCT02012101|exercise
185925|NCT02012101|Noninvasive Ventilation
185926|NCT02012088|Follicular lymphoma, large B-cell lymphoma
185927|NCT02012062|Nasopharyngeal carcinoma
185928|NCT02012062|Neoadjuvant chemotherapy
185929|NCT02012062|Concurrent chemotherapy
185930|NCT02012062|Nimotuzumab
185931|NCT02012049|Healthy
185932|NCT02012049|Risperdal OD
185933|NCT02012049|Risperdal Quicklet
185934|NCT02012049|Korea
185935|NCT02012023|Low anterior resection
185936|NCT02012023|Anastomotic leakage
185937|NCT02012023|Defunctioning stoma
185938|NCT02012023|Controllable tube ileostomy
185939|NCT02012023|Loop ileostomy
185940|NCT02012010|hysteroscopy, water intoxication, hyponatremia
185941|NCT02011971|epilepsy
185942|NCT02011971|cognition
185943|NCT02011971|memory
185944|NCT02011958|Visceral Leishmaniasis
185945|NCT02011958|HIV positive patients
185946|NCT02011958|Phase III trial
185947|NCT02011958|Randomised
185948|NCT02011958|Liposomal amphotericin B
185949|NCT02011958|Ambisome
185950|NCT02011958|Miltefosine
185951|NCT02011958|Pentamidine
185952|NCT02011958|Efficacy
185953|NCT02011958|Safety
185954|NCT02011906|antioxidant enzymes
185955|NCT02011906|omega 3
185956|NCT02011906|vitamin E
185957|NCT02011906|CAD
185958|NCT02011906|Sirtuins
185959|NCT02011906|FOXOs
185960|NCT02011880|breast cancer
185961|NCT02011880|bone metastasis
185962|NCT02011880|traditional Chinese medicine(TCM)
185963|NCT02011867|Inner Ear Malformations
185964|NCT02011867|Gusher
185965|NCT02011867|Cochlear Implantation
185966|NCT02011854|acupuncture，rehabilitation,Shoulder-hand Syndrome
185967|NCT02011841|liver cirrhosis
185968|NCT02011841|ascites
185969|NCT02011841|spontaneous bacterial peritonitis
185970|NCT02011841|recurrence
185971|NCT02011828|Hemodialysis, paricalcitol
185972|NCT02011815|Breast neoplasms
185973|NCT02011815|Circadian rhythm
185974|NCT02011815|sleep
185975|NCT02011815|survival
185976|NCT02011815|distress
185977|NCT02011815|anxiety
185978|NCT02011815|depression
185979|NCT02011815|quality of life
185980|NCT02011815|actigraph
185981|NCT02011815|fatigue
185982|NCT02011802|Sorbact TM
185983|NCT02011802|Alginates
185984|NCT02011802|Dressing
185985|NCT02011802|Wound healing
185986|NCT02011789|hypercholesterolemia
185987|NCT02011789|inflammation
185988|NCT02011789|citrus limonoids
185989|NCT02011776|Corticosteroids Dry Eye Sjögren syndrome inflammation treatment
185990|NCT02011763|Hepatitis A
185991|NCT02011763|hepatitis A virus
185992|NCT02011763|Avaxim® 80U Pediatric
185993|NCT02011750|schizophrenia
185994|NCT02011750|toxoplasmosis
185995|NCT02011737|Medical Expulsive therapy
185996|NCT02011698|Groin hernia
185997|NCT02011698|lichtenstein herniorrhaphy
185998|NCT02011672|dairy
185999|NCT02011672|glucose
186000|NCT02011672|inflammation
186001|NCT02011659|Ramosetron, postoperative nausea and vomiting, laparoscopy
186002|NCT02011646|diet
186003|NCT02011646|body weight
186004|NCT02011646|eating
186005|NCT02011646|eating disorder
186006|NCT02011646|exercise
186007|NCT02011581|Overweight
186008|NCT02011568|Therapeutic Hypothermia
186009|NCT02011568|Out of hospital cardiac arrest
186010|NCT02011568|Mild hypothermia
186011|NCT02011568|Moderate hypothermia
186012|NCT02011542|GWI
186013|NCT02011542|IBS
186014|NCT02011542|Irritable Bowel Syndrome
186015|NCT02011542|Gulf War Illness
186016|NCT02011516|Marijuana
186017|NCT02011516|Addiction
186018|NCT02011516|fMRI
186019|NCT02011516|Baclofen
186020|NCT02011516|Treatment
186021|NCT02011477|Neural mobilization
186022|NCT02011477|Physical therapy
186023|NCT02011477|Asymptomatic subjects
186024|NCT02011451|Multiple Sclerosis
186025|NCT02011451|Green Tea
186026|NCT02011451|ECGC
186027|NCT02011451|Theaphenon
186028|NCT02011451|Randomized placebo controlled trial
186029|NCT02011451|NAA
186030|NCT02011451|Spectroscopy
186031|NCT02011451|Brain Atrophy
186032|NCT02011451|SIENA
186033|NCT02011438|Social Anxiety
186034|NCT02011438|Prevention
186035|NCT02011438|Peer Relations
186036|NCT02011438|Depression
186037|NCT02011438|Adolescent
186038|NCT02011438|High School
186039|NCT02011438|Interpersonal
186040|NCT02011438|Peer Victimization
186041|NCT02011425|obstructive sleep apnea
186042|NCT02011425|oral appliance
186043|NCT02011425|therapy
186044|NCT02011425|masseter muscle activity
186045|NCT02011425|randomized controlled trial
186046|NCT02011425|mandibular advancement device
186047|NCT02011425|mandibular advancement appliance
186048|NCT02011425|arousals
186049|NCT02011412|Trauma
186050|NCT02011412|Scoring Systems
186051|NCT02011412|Intermountain Risk Score
186052|NCT02011399|brain
186053|NCT02011399|computer
186054|NCT02011399|interfaces
186055|NCT02011399|mobility impairments
186056|NCT02011373|prolapse, laparoscopic sacrocolpopexy, IFABONDTM glue
186057|NCT02011360|Prader Willi syndrome
186058|NCT02011360|childhood obesity
186059|NCT02011360|ghrelin
186060|NCT02011360|appetite regulation
186061|NCT02011321|subarachnoid hemorrhage
186062|NCT02011321|aneurysm
186063|NCT02011321|vasospasm
186064|NCT02011321|clevidipine
186065|NCT02011321|transcranial dopplers
186066|NCT02011295|OLT
186067|NCT02011295|Surgical Intervention
186068|NCT02011295|BMAC
186069|NCT02011282|ICU,
186070|NCT02011282|MYOPATHY,
186071|NCT02011282|NEUROPATHY,
186072|NCT02011282|PNEUMONIA
186073|NCT02011269|TSO
186074|NCT02011269|Ova
186075|NCT02011269|Psoriasis
186076|NCT02011269|plaque psoriasis
186077|NCT02011269|plaque-type
186078|NCT02011269|Coronado
186079|NCT02011269|Moderate to severe plaque psoriasis
186080|NCT02011256|Transient Ischemic Attack
186081|NCT02011256|Atrial Fibrillation
186082|NCT02011256|NOTICE
186083|NCT02011256|Implantable loop-recorder
186084|NCT02011256|Holter-monitoring
186085|NCT02011243|deficit
186086|NCT02011243|internal rotation
186087|NCT02011243|gleno humeral articulation
186088|NCT02011243|hand ball
186089|NCT02011230|Dehydration
186090|NCT02011230|Hoist
186091|NCT02011230|pain control
186092|NCT02011230|The intervention is to provide a commercially available isotonic hydration solution (Hoist®) to the patients.
186093|NCT02011230|Patients will drink this solution post procedure as needed.
186094|NCT02011230|Patients in the control group will use their discretion to drink any solution they feel suitable
186095|NCT02011217|Rye
186096|NCT02011217|Dietary Fibre
186097|NCT02011217|Bread
186098|NCT02011217|Crisp bread
186099|NCT02011217|Appetite
186100|NCT02011217|Satiety
186101|NCT02011217|Hunger
186102|NCT02011217|Desire to eat
186103|NCT02011217|Metabolism
186104|NCT02011217|Glucose
186105|NCT02011217|Insulin
186106|NCT02011217|Gut hormones
186107|NCT02011217|Gastric emptying rate
186108|NCT02011191|Biotin
186109|NCT02011191|Restless
186110|NCT02011191|Kidney
186111|NCT02011191|Dialysis
186112|NCT02011191|Renal
186113|NCT02011165|Macular hole
186114|NCT02011165|Vitrectomy
186115|NCT02011165|Gas tamponade
186241|NCT02010606|Glioma stem-like cells
186116|NCT02011165|Vitreomacular traction in danger of macular hole formation
186117|NCT02011165|Epiretinal membrane in danger of macular hole formation
186118|NCT02011113|Pomalidomide,
186119|NCT02011113|CC-4047,
186120|NCT02011113|Dexamethasone,
186121|NCT02011113|Relapsed and refractory multiple myeloma,
186122|NCT02011113|phase 2
186123|NCT02011061|Multidetector Computed Tomography
186124|NCT02011061|Coronary Stenosis
186125|NCT02011061|Coronary Artery Disease
186126|NCT02011061|Angina Pectoris
186127|NCT02011035|Oral health
186128|NCT02011035|Mouth health
186129|NCT02011035|Halitosis
186130|NCT02011035|Oral bacteria
186131|NCT02011035|Sore throat
186132|NCT02011035|Colds
186133|NCT02011022|Methotrexate,
186134|NCT02011022|Pharmacokinetic
186135|NCT02011022|Acute lymphoblastic leukemia
186136|NCT02011022|Model
186137|NCT02010970|phase I
186138|NCT02010970|healthy volunteers
186139|NCT02010970|AZD3293
186140|NCT02010970|itraconazole
186141|NCT02010970|diltiazem
186142|NCT02010970|medazolam
186143|NCT02010970|drug interactions
186144|NCT02010970|Pharmacokinetics
186145|NCT02010957|123I Iodometomidate imaging
186146|NCT02010957|18F FDG positron emission tomography
186147|NCT02010957|Adrenal tumour
186148|NCT02010944|Solifenacin
186149|NCT02010944|Mirabegron
186150|NCT02010944|Fixed-dose combination (FDC)
186151|NCT02010944|Single Entity Tablet (SET)
186152|NCT02010944|Pharmacokinetics
186153|NCT02010944|Bioavailability
186154|NCT02010918|Knee Osteoarthritis;
186155|NCT02010918|Glucosamine;
186156|NCT02010918|Chondroitin.
186157|NCT02010905|Losartan
186158|NCT02010879|patent ductus arterioses
186159|NCT02010879|ductal closure
186160|NCT02010879|thrombocyte
186161|NCT02010866|internship and residency
186162|NCT02010866|physicians
186163|NCT02010866|prevention
186164|NCT02010866|counseling
186165|NCT02010866|suicide
186166|NCT02010866|depression
186167|NCT02010866|burnout
186168|NCT02010853|Transient Global amnesia
186169|NCT02010853|fMRI
186170|NCT02010853|resting state
186171|NCT02010840|Depressive symptoms, marital relationship, quality of life
186172|NCT02010827|Diabetes mellitus
186173|NCT02010827|Glucagon
186174|NCT02010827|Endogenous glucose production
186175|NCT02010827|Incretin hormones
186176|NCT02010814|PCOS
186177|NCT02010814|Inflammation
186178|NCT02010814|Body Composition
186179|NCT02010801|hepatocellular carcinoma
186180|NCT02010801|irreversible electroporation
186181|NCT02010801|liver cancer
186182|NCT02010762|Crohn's disease
186183|NCT02010762|Vitamin D
186184|NCT02010762|Postoperative
186185|NCT02010762|Recurrence
186186|NCT02010762|Inflammatory bowel disease
186187|NCT02010762|Gastroenteritis
186188|NCT02010762|Gastrointestinal Diseases
186189|NCT02010762|Digestive System Diseases
186190|NCT02010762|Colonic Diseases
186191|NCT02010762|Intestinal Diseases
186192|NCT02010762|Pathologic Processes
186193|NCT02010736|Cerebral palsy
186194|NCT02010736|Gait
186195|NCT02010736|Weight Bearing
186196|NCT02010736|Rehabilitation
186197|NCT02010723|varicosis
186198|NCT02010723|foam sclerotherapy
186199|NCT02010723|surgery
186200|NCT02010710|continuous electronic fetal monitoring
186201|NCT02010710|labour
186202|NCT02010710|pregnancy
186203|NCT02010710|fetal distress
186204|NCT02010697|smoking cessation
186205|NCT02010697|nonsmokers
186206|NCT02010697|proxy
186207|NCT02010697|mail intervention
186208|NCT02010697|self-help
186209|NCT02010697|behavioral intervention
186210|NCT02010684|Diabetes
186211|NCT02010684|Depression
186212|NCT02010684|Self care
186213|NCT02010684|Empowerment
186214|NCT02010684|Behavioral intervention
186215|NCT02010684|Cognitive behavioral therapy
186216|NCT02010684|Diabetes Mellitus, Type 2
186217|NCT02010671|Pregnancy
186218|NCT02010671|Cesarean Section
186219|NCT02010671|Survey
186220|NCT02010671|Delivery
186221|NCT02010645|Leukemia
186222|NCT02010645|Advanced Myelodysplastic Syndrome
186223|NCT02010645|MDS
186224|NCT02010645|Intermediate-2 Myelodysplastic Syndrome
186225|NCT02010645|High-Risk Myelodysplastic Syndrome
186226|NCT02010645|Chronic myelomonocytic leukemia
186227|NCT02010645|CMML
186228|NCT02010645|Eltrombopag
186229|NCT02010645|Promacta
186230|NCT02010645|Decitabine
186231|NCT02010645|Dacogen
186232|NCT02010632|Clopidogrel
186233|NCT02010632|Platelet inhibition
186234|NCT02010632|Platelet aggregation
186235|NCT02010606|Newly diagnosed glioblastoma
186236|NCT02010606|Recurrent glioblastoma
186237|NCT02010606|Dendritic cell vaccine
186238|NCT02010606|Immunotherapy
186239|NCT02010606|Cancer stem cells
186240|NCT02010606|Glioma stem cells
186242|NCT02010606|Cancer stem-like cells
186243|NCT02010606|Neurosphere
186244|NCT02010606|Therapeutic Uses
186245|NCT02010606|Antineoplastic Agents
186246|NCT02010606|Neoplasms
186247|NCT02010606|Immunologic Factors
186248|NCT02010606|Interferon Inducers
186249|NCT02010606|Physiological Effects of Drugs
186250|NCT02010606|Pharmacologic Actions
186251|NCT02010567|rectal cancer
186252|NCT02010567|colorectal cancer
186253|NCT02010567|locally advanced rectal cancer
186254|NCT02010567|locally advanced rectal cancer (resectable)
186255|NCT02010567|locally advanced rectal cancer (non-resectable)
186256|NCT02010567|chemoradiotherapy
186257|NCT02010567|nanopharmaceuticle
186258|NCT02010567|CLX101
186259|NCT02010567|camptothecin
186260|NCT02010567|capecitabine
186261|NCT02010554|Multiple Sclerosis
186262|NCT02010554|Disease modifying medication
186263|NCT02010554|Relapsing-Remitting MS
186264|NCT02010554|Motivational Interviewing
186265|NCT02010554|Telephone Counseling
186266|NCT02010541|type 1 diabetes among young children, sensor, insulin pump, education, psychological support
186267|NCT02010528|Diabetes related distress, children, T1D, family hardiness, psychological well-being
186268|NCT02010515|sudden cardiac death
186269|NCT02010515|risk stratification
186270|NCT02010515|t-wave alternans
186271|NCT02010515|Holter electrocardiography
186272|NCT02010515|heart rate turbulence
186273|NCT02010502|Beet root
186274|NCT02010502|exercise performance
186275|NCT02010502|cyclists
186276|NCT02010489|Bariatric Surgery
186277|NCT02010489|Exercise
186278|NCT02010489|Physical Fitness
186279|NCT02010476|Alzheimer's disease, CSF biomarkers, Insulin resistance
186280|NCT02010463|reward processing
186281|NCT02010463|impulse control
186282|NCT02010463|obese
186283|NCT02010463|clinically obese
186284|NCT02010450|Sudden Infant Death Syndrome
186285|NCT02010450|SIDS
186286|NCT02010450|safe sleep
186287|NCT02010450|safe sleep message
186288|NCT02010437|Superficial Venous Insufficiency
186289|NCT02010424|reduced fertility
186290|NCT02010398|Resistance training/methods
186291|NCT02010398|contralateral strength training
186292|NCT02010398|ipsilateral strength training
186293|NCT02010398|Isokinetic contraction
186294|NCT02010398|Adaptation, Physiological/physiology
186295|NCT02010398|Electromyography/methods
186296|NCT02010398|Transcranial Magnetic Stimulation/methods
186297|NCT02010398|Evoked Potentials, Motor
186298|NCT02010385|RYGB
186299|NCT02010385|Bariatric surgery
186300|NCT02010385|Taste
186301|NCT02010385|Reward
186302|NCT02010385|Food behaviour
186303|NCT02010385|Gut hormones
186304|NCT02010372|Immunization Registry
186305|NCT02010372|Human Papillomavirus
186306|NCT02010346|Early orthodontic treatment
186307|NCT02010346|Class II treatment
186308|NCT02010346|Orthodontic treatment outcome
186309|NCT02010320|population model
186310|NCT02010320|pharmacokinetic
186311|NCT02010320|tacrolimus
186312|NCT02010320|therapeutic drug monitoring
186313|NCT02010320|individualized dosing
186314|NCT02010294|Invasive GAS infection
186315|NCT02010294|emm genotypes
186316|NCT02010294|Bacterial virulence factors
186317|NCT02010294|Mendelian susceptibility to infections
186318|NCT02010281|rTMS
186319|NCT02010281|peripheral neuropathic pain
186320|NCT02010281|randomized controlled trial
186321|NCT02010268|Faecal calprotectin
186322|NCT02010268|Feces
186323|NCT02010268|Preterm neonates
186324|NCT02010268|Enterocolitis
186325|NCT02010268|Enteropathy
186326|NCT02010268|Necrotizing
186327|NCT02010242|Type 2 diabetes
186328|NCT02010242|Proteinuria
186329|NCT02010242|Albuminuria
186330|NCT02010229|Placenta accreta
186331|NCT02010229|previous caesarean
186332|NCT02010229|placenta praevia
186333|NCT02010229|severe obstetric haemorrhage
186334|NCT02010229|population-based study
186335|NCT02010203|TURBT
186336|NCT02010203|Bladder
186337|NCT02010203|Cancer
186338|NCT02010203|GP96
186339|NCT02010203|Vaccine
186340|NCT02010203|Immunotherapy
186341|NCT02010203|Heat Biologics
186342|NCT02010203|BCG
186343|NCT02010203|Bacillus Calmette-Guerin
186344|NCT02010203|Bacillus Calmette-Guérin
186345|NCT02010190|Pediatric malignancies
186346|NCT02010190|Cancer survivors
186347|NCT02010190|Coronary artery risk
186348|NCT02010190|Vascular function
186349|NCT02010190|Cardiovascular risk in survivors of pediatric cancer
186350|NCT02010164|Reproductive aging
186351|NCT02010164|Mitochondria
186352|NCT02010151|Out of Hospital Cardiac Arrest
186353|NCT02010151|Cardiopulmonary Resuscitation
186354|NCT02010151|dispatch
186355|NCT02010151|emergency medicine
186356|NCT02010138|Internal Limiting Membrane
186357|NCT02010138|Metamorphopsia
186358|NCT02010125|Anterior Cruciate Ligament (ACL)
186359|NCT02010125|Magnetic Resonance Imaging (MRI)
186360|NCT02010125|Osteoarthritis (OA)
186361|NCT02010125|Bio-specimens
186362|NCT02010125|Acute ACL Injury
186363|NCT02010125|Arthritis Foundation (AF)
186364|NCT02010112|H.Pylori
186365|NCT02010086|Intervention
186366|NCT02010086|Autism
186367|NCT02010086|Treatment sensitivity
186368|NCT02010086|School aged
186369|NCT02010086|Cognitive behavioral therapy
186370|NCT02010086|Social Skills Intervention
186371|NCT02010073|Lung
186372|NCT02010073|ARDS
186373|NCT02010073|acute
186374|NCT02010073|respiratory
186375|NCT02010073|syndrome
186376|NCT02010073|prognosis
186377|NCT02010073|outcome research
186378|NCT02010073|respiratory infection
186379|NCT02010073|sepsis
186380|NCT02010073|organ failure
186381|NCT02010073|hypoxaemia
186382|NCT02010060|Exercise training
186383|NCT02010060|Non-exercise physical activity
186384|NCT02010060|pedometers
186385|NCT02010047|Anaplastic lymphoma kinase gene
186386|NCT02010047|Polymerase chain reaction
186387|NCT02010047|Immunohistochemistry
186388|NCT02010047|Fluorescence in situ hybridization
186389|NCT02010034|TPN
186390|NCT02010034|Liver Function
186391|NCT02010034|parenteral nutritional fat emulsions
186392|NCT02010021|breast cancer
186393|NCT02010021|postmenopausal
186394|NCT02010021|letrozole
186395|NCT02010021|RAD001
186396|NCT02010021|Everolimus
186397|NCT02010008|breast cancer
186398|NCT02010008|cancer disparities
186399|NCT02010008|Latino women
186400|NCT02010008|Hispanic women
186401|NCT02010008|mammography
186402|NCT02010008|multi-level intervention
186403|NCT02009995|Diabetes Mellitus
186404|NCT02009995|Type 2 Diabetes Mellitus
186405|NCT02009995|Resistance Training
186406|NCT02009995|Resistance Exercise
186407|NCT02009995|Resistance Band
186408|NCT02009995|Thera-band
186409|NCT02009995|elastic band
186410|NCT02009995|exercise band
186411|NCT02009982|Fainting
186412|NCT02009982|Ablation
186413|NCT02009982|Cardiology
186414|NCT02009982|Cardiac Electrophysiology
186415|NCT02009969|Psychosis
186416|NCT02009969|Adverse effects
186417|NCT02009969|Symptom Severity
186418|NCT02009969|Magnetic Resonance Imaging
186419|NCT02009943|critical illness
186420|NCT02009943|iron supplementation
186421|NCT02009943|functional iron deficiency
186422|NCT02009943|ICU anemia
186423|NCT02009943|red blood cell transfusion
186424|NCT02009930|Enlisted military members
186425|NCT02009930|CAC
186426|NCT02009930|Coronary Artery Calcium
186427|NCT02009930|Cardiovascular
186428|NCT02009917|Indicator Amino Acid Oxidation
186429|NCT02009917|Non essential Amino acids
186430|NCT02009917|Protein
186431|NCT02009917|Amino acid
186432|NCT02009904|PKU
186433|NCT02009904|Phenylketonuria
186434|NCT02009904|Phenylalanine
186435|NCT02009904|Children
186436|NCT02009904|Stable isotopes
186437|NCT02009904|Sapropterin dihydrochloride responsiveness
186438|NCT02009891|predictive model
186439|NCT02009891|in vitro fertilization
186440|NCT02009891|elective single embryo transfer
186441|NCT02009878|SIADH
186442|NCT02009865|Hypertriglyceridemia
186443|NCT02009865|Dyslipidemia
186444|NCT02009865|Eicosapentaenoic acid
186445|NCT02009865|EPA
186446|NCT02009865|Docosahexaenoic acid
186447|NCT02009865|DHA
186448|NCT02009852|microRNA-29b
186449|NCT02009852|Oral squamous cell carcinoma
186450|NCT02009852|migration
186451|NCT02009852|prognosis
186452|NCT02009839|anxiety
186453|NCT02009839|frequency of speech
186454|NCT02009839|selective mutism
186455|NCT02009826|Schizophrenia
186456|NCT02009826|Psychosis
186457|NCT02009826|Neuroinflammation
186458|NCT02009826|Microglial activation
186459|NCT02009813|Insulin resistance
186460|NCT02009813|Inflammation
186461|NCT02009813|Hypoxia
186462|NCT02009787|hypercholesterolemia; vitamin D; adjuvant therapy
186463|NCT02009774|Colonoscopy
186464|NCT02009774|Adenoma detection rate
186465|NCT02009774|Narrow band imaging
186466|NCT02009774|Optical biopsy
186467|NCT02009774|Accuracy
186468|NCT02009735|Enterovirus 71 and Influenza Virus
186469|NCT02009722|Cesarean Delivery
186470|NCT02009722|Intrathecal Morphine
186471|NCT02009722|Intrathecal Hydromorphone
186472|NCT02009722|Obstetrical Analgesia
186473|NCT02009722|Spinal Anesthesia
186474|NCT02009709|keratoconus
186475|NCT02009709|collagen crosslinking
186476|NCT02009709|crosslinking
186477|NCT02009709|ectasia
186478|NCT02009644|Abdominal Aortic Aneurysm
186479|NCT02009644|AAA
186480|NCT02009644|Aneurysm
186481|NCT02009631|Solid Tumors
186482|NCT02009631|Ovarian Cancer
186483|NCT02009631|Colon Cancer
186484|NCT02009631|Lung Cancer
186485|NCT02009631|Breast Cancer
186486|NCT02009631|Gastric Cancer
186487|NCT02009618|IBS
186488|NCT02009618|Rifaximin
186489|NCT02009605|icotinib, SCC
186490|NCT02009592|Hepatosteatosis
186491|NCT02009592|Steatohepatitis
186492|NCT02009592|Rifaximin
186493|NCT02009592|Inflammatory cytokines
186494|NCT02009579|Uterine Cervical Cancer
186495|NCT02009579|Paclitaxel
186496|NCT02009579|Carboplatin
186497|NCT02009579|Nintedanib
186498|NCT02009553|Anxiety
186499|NCT02009553|Urodynamics
186500|NCT02009514|Hemodialysis
186501|NCT02009514|Continuous glucose monitoring
186502|NCT02009514|Hypoglycemia
186503|NCT02009514|Hyperglycemia
186504|NCT02009501|Infected wounds
186505|NCT02009501|NPWTi
186506|NCT02009501|VAC Instill
186507|NCT02009501|Biofilm
186508|NCT02009488|Diabetes Mellitus, Type 2
186509|NCT02009488|Metformin
186510|NCT02009488|Canagliflozin
186511|NCT02009488|INVOKANA®
186512|NCT02009488|Insulin sensitivity
186513|NCT02009488|DPP-4 inhibitor
186514|NCT02009488|dipeptidyl peptidase-4
186515|NCT02009475|Rehabilitation
186516|NCT02009475|Exercise Training
186517|NCT02009475|Interval training
186518|NCT02009462|HIV
186519|NCT02009462|Facial lipoatrophy
186520|NCT02009449|Phase 1/Phase 1b
186521|NCT02009449|Oncology
186522|NCT02009449|Cancer
186523|NCT02009449|Solid Tumors
186524|NCT02009423|Gastro-Intestinal Stromal Tumour, GIST, localized primary tumor, complete surgery, adjuvant therapy.
186525|NCT02009410|Exocrine Pancreatic Insufficiency
186526|NCT02009358|mental health promotion
186527|NCT02009358|depression
186528|NCT02009358|migrant workers
186529|NCT02009358|China
186530|NCT02009345|Familial hypercholesterolemia,
186531|NCT02009345|High LDL-cholesterol
186532|NCT02009345|Registry
186533|NCT02009345|Coronary artery disease
186534|NCT02009319|endobronchial ultrasound
186535|NCT02009319|EBUS - TBNA
186536|NCT02009319|elastography
186537|NCT02009319|strain ratio
186538|NCT02009319|lung cancer staging
186539|NCT02009306|Palliative
186540|NCT02009306|Symptom control
186541|NCT02009306|Hospice
186542|NCT02009306|Opioid
186543|NCT02009306|Benzodiazepine
186544|NCT02009293|idiopathic pulmonary fibrosis
186545|NCT02009293|cough
186546|NCT02009293|quality of life
186547|NCT02009280|Propofol
186548|NCT02009280|Lung transplantation
186549|NCT02009280|Extracorporeal membrane oxygenation
186550|NCT02009280|Acute kidney injury
186551|NCT02009241|Lymphangioleiomyomatosis
186552|NCT02009241|Rehabilitation
186553|NCT02009241|Exercise
186554|NCT02009228|Single-port laparoscopy
186555|NCT02009228|Abdominal pain
186556|NCT02009228|Ovarian spillage
186557|NCT02009228|Endobag rupture
186558|NCT02009228|Ovarian reserve
186559|NCT02009215|Uganda
186560|NCT02009215|intermittent preventive treatment
186561|NCT02009215|dihydroartemisinin-piperaquine
186562|NCT02009215|schoolchildren
186563|NCT02009215|malaria
186564|NCT02009202|Colon preparation
186565|NCT02009202|Child
186566|NCT02009189|home parenteral nutrition
186567|NCT02009189|central venous catheter
186568|NCT02009176|Hepatocellular Carcinoma
186569|NCT02009176|Laparoscopic
186570|NCT02009176|Aon-anatomical hepatectomy
186571|NCT02009176|Anatomical hepatectomy
186572|NCT02009176|Micrometastases
186573|NCT02009137|small breast
186574|NCT02009137|augmentation
186575|NCT02009137|breast volume
186576|NCT02009137|External Soft Tissue Expansion System(ESTES)
186577|NCT02009124|spinal cord injury
186578|NCT02009124|stem cell therapy
186579|NCT02009124|bone marrow
186580|NCT02009124|mononuclear cells
186581|NCT02009124|autologous
186582|NCT02009111|Transition to parenthood
186583|NCT02009111|Relationship intervention
186584|NCT02009098|Randomized Controlled Trial
186585|NCT02009098|Caesarean Section
186586|NCT02009098|preoperative
186587|NCT02009098|intraoperative
186588|NCT02009098|prophylactic antibiotics
186589|NCT02009098|antibiotics
186590|NCT02009098|timing
186591|NCT02009098|surgical site infections
186592|NCT02009098|endometritis
186593|NCT02009098|wound infections
186594|NCT02009098|urinary tract infections
186595|NCT02009098|infectious morbidity
186596|NCT02009098|neonatal antibiotics exposure
186597|NCT02009098|Antibiotic Prophylaxis
186598|NCT02009072|Pterygium surgery
186599|NCT02009072|Sutureless glue free conjunctival autograft
186600|NCT02009072|Amniotic membrane graft.
186601|NCT02009059|hypothermia
186602|NCT02009059|Temperature
186603|NCT02009059|epitympanic
186604|NCT02009059|pre-hospital
186605|NCT02009046|Adolescent
186606|NCT02009046|Sex education
186607|NCT02009046|Sexuality education
186608|NCT02009046|Sexually transmitted diseases
186609|NCT02009046|Pregnancy
186610|NCT02009046|Sexual behavior
186611|NCT02009046|Sexuality
186612|NCT02009046|Relationship rights
186613|NCT02009046|Gender norms
186614|NCT02009046|Human rights
186615|NCT02009046|Intervention studies
186616|NCT02009046|Parent intervention
186617|NCT02009046|Peer intervention
186618|NCT02009007|cerebral oximeter
186619|NCT02009007|one lung ventilation
186620|NCT02009007|dopamine
186621|NCT02009007|phenylephrine
186622|NCT02008994|metastatic breast cancer
186623|NCT02008994|breast cancer
186624|NCT02008994|genomics
186625|NCT02008994|personalized medicine
186626|NCT02008994|precision oncology
186627|NCT02008994|breast cancer treatment
186628|NCT02008994|metastatic breast cancer treatment
186629|NCT02008994|genetic testing and breast cancer treatment
186630|NCT02008994|breast cancer trial
186631|NCT02008994|metastatic breast cancer trial
186632|NCT02008955|lysine, indicator amino acid oxidation, elderly females
186633|NCT02008929|NKCELL
186634|NCT02008916|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, secukinumab, self-injection
186635|NCT02008890|palmoplantar, pustular, psoriasis
186636|NCT02008877|Malignant Peripheral Nerve Sheath Tumors
186637|NCT02008877|MPNST
186638|NCT02008877|Sarcoma
186639|NCT02008877|Ganetespib
186640|NCT02008877|Sirolimus
186641|NCT02008877|mTOR inhibitor
186642|NCT02008877|Heat shock protein
186643|NCT02008877|Hsp90
186644|NCT02008864|End stage renal diseases
186645|NCT02008864|Hemodialysis
186646|NCT02008864|Uremic pruritus
186647|NCT02008864|Iranian traditional medicine
186648|NCT02008864|Cassia angustifolia
186649|NCT02008851|Chronic kidney disease
186650|NCT02008851|Type 2 Diabetes
186651|NCT02008851|Neo-kidney augment
186652|NCT02008851|Regenerative medicine
186653|NCT02008825|ViSiGi
186654|NCT02008825|Calibration tube
186655|NCT02008825|Sleeve gastrectomy
186656|NCT02008812|Adenovirus
186657|NCT02008799|Stem cell, infertility, Azoospermia
186658|NCT02008786|Coronary Artery Dissection, Spontaneous
186659|NCT02008786|Angina
186660|NCT02008773|schizophrenia
186661|NCT02008773|schizoaffective
186662|NCT02008773|schizophreniform
186663|NCT02008773|inflammatory markers
186664|NCT02008773|HSV1
186665|NCT02008773|cognition
186666|NCT02008773|early psychosis
186667|NCT02008773|valacyclovir
186668|NCT02008760|pain
186669|NCT02008760|quality of life
186670|NCT02008760|ADL
186671|NCT02008760|DOLO test
186672|NCT02008760|compliance
186673|NCT02008760|D3
186674|NCT02008747|Atrial fibrillation
186675|NCT02008747|Neuropathic pain
186676|NCT02008747|Posterolateral thoracotomy
186677|NCT02008747|Lung resection
186678|NCT02008721|Multiple System Atrophy
186679|NCT02008721|epigallocatechin gallate
186680|NCT02008708|Health
186681|NCT02008708|Microfinance
186682|NCT02008695|Health
186683|NCT02008695|Youth
186684|NCT02008695|Microfinance
186685|NCT02008669|Multiple Sclerosis, Fatigue, Nutritional Status, Disability.
186686|NCT02008656|CAPECITABINE (ORAL)
186687|NCT02008656|FLUOROURACIL
186688|NCT02008656|LEUCOVORIN
186689|NCT02008656|OXALIPLATIN
186690|NCT02008656|Total mesorectal excision
186691|NCT02008656|Chemoradiation therapy
186692|NCT02008656|Total neoadjuvant therapy
186693|NCT02008656|13-213
186694|NCT02008643|Health related quality of life, food allergy, children, chronic diseases
186695|NCT02008617|Anterior cruciate ligament reconstruction
186696|NCT02008604|ischemia
186697|NCT02008604|stroke
186698|NCT02008604|transient ischemic attack (TIA)
186699|NCT02008604|microbiome
186700|NCT02008604|microbiota
186701|NCT02008604|gut
186702|NCT02008591|Neuraxial Technique
186703|NCT02008591|Epidural Technique
186704|NCT02008591|Dural Puncture Epidural Technique
186705|NCT02008591|Combined Spinal Epidural Technique
186706|NCT02008591|Labor Analgesia
186707|NCT02008591|Obstetric
186708|NCT02008578|Antiviral
186709|NCT02008578|Adjunctive Therapy
186710|NCT02008578|Antibody
186711|NCT02008565|Fecal incontinence
186712|NCT02008565|Loperamide
186713|NCT02008565|anal exercises
186714|NCT02008565|biofeedback
186715|NCT02008552|Genetic factor
186716|NCT02008552|Valvulopathy
186717|NCT02008552|Mediator
186718|NCT02008526|Text Messaging
186719|NCT02008526|mHealth
186720|NCT02008526|Methamphetamine
186721|NCT02008526|HIV
186722|NCT02008526|AIDS
186723|NCT02008513|AFFITOPE® AD02
186724|NCT02008513|Alzheimer Disease
186725|NCT02008513|Dementia
186726|NCT02008513|Brain Disease
186727|NCT02008513|Nervous System Diseases
186728|NCT02008513|Tauopathies
186729|NCT02008513|Neurodegenerative Diseases
186730|NCT02008513|Mental Disorders
186731|NCT02008500|Dentinal Hypersensitivity
186732|NCT02008500|Gingival Recession
186733|NCT02008500|Visual Analogue Score
186734|NCT02008487|wound
186735|NCT02008487|palliative care
186736|NCT02008487|hospice
186737|NCT02008487|pressure ulcers
186738|NCT02008435|Group-delivered Diabetes Prevention Program
186739|NCT02008435|Obesity
186740|NCT02008435|Overweight
186741|NCT02008435|Lifestyle change
186742|NCT02008435|Healthy eating
186743|NCT02008435|Weight loss
186744|NCT02008435|Exercise
186745|NCT02008435|Cognitive-behavioral intervention
186746|NCT02008435|Implementation intentions
186747|NCT02008435|Mental imagery
186748|NCT02008435|Mental practice
186749|NCT02008435|If-then plans
186750|NCT02008409|Minimally Invasive Surgery
186751|NCT02008409|EndoLift Liver Retractor
186752|NCT02008396|MDMA
186753|NCT02008396|autism
186754|NCT02008396|social anxiety
186755|NCT02008383|Colorectal cancer
186756|NCT02008383|Panitumumab
186757|NCT02008383|Cabozantinib
186758|NCT02008370|minimally invasive cardiac surgery
186759|NCT02008370|Exparel
186760|NCT02008357|Cognition
186761|NCT02008357|Prevention
186762|NCT02008344|influenza
186763|NCT02008344|flu
186764|NCT02008344|fever
186765|NCT02008344|cough
186766|NCT02008344|body aches
186767|NCT02008344|headache
186768|NCT02008344|nasal congestion
186769|NCT02008344|body pains
186770|NCT02008344|sore throat
186771|NCT02008344|fatigue
186772|NCT02008344|T-705
186773|NCT02008344|favipiravir
186774|NCT02008344|favor
186775|NCT02008344|flu symptoms
186776|NCT02008331|chronic kidney disease
186777|NCT02008331|p-cresol
186778|NCT02008331|synbiotic
186779|NCT02008292|smoking
186780|NCT02008292|schizophrenia
186781|NCT02008292|acetylcholine
186782|NCT02008279|Healthy
186783|NCT02008279|CNTO 3157
186784|NCT02008279|Pharmacokinetics
186785|NCT02008253|INTRASTROMAL CORNEAL RING
186786|NCT02008253|ASTIGMATISM
186787|NCT02008240|Infertility
186788|NCT02008240|Hydrosalpinx
186789|NCT02008240|IVF-ET
186790|NCT02008240|Salpingectomy
186791|NCT02008214|Pentoxifylline
186792|NCT02008214|Sustained virologic response
186793|NCT02008214|Hepatic fibrosis
186794|NCT02008201|dose-response study
186795|NCT02008188|Type 1 Diabetes Mellitus
186796|NCT02008188|Artificial Pancreas
186797|NCT02008188|Closed Loop Control
186798|NCT02008188|Diabetes Assistant (DiAs)
186799|NCT02008188|Continuous Glucose Monitor (CGM)
186800|NCT02008188|Insulin Pump
186801|NCT02008188|Metabolic Diseases
186802|NCT02008188|Endocrine System Diseases
186803|NCT02008188|Autoimmune Diseases
186804|NCT02008175|paediatric, keratoconus, collagen cross linking
186805|NCT02008162|Emphysema, COPD, bronchoreversibility, ventilatory obstruction, lung volume reduction surgery, LVRS
186806|NCT02008149|Osteoporosis
186807|NCT02008136|myofascial pain
186808|NCT02008136|muscle spasm
186809|NCT02008136|botulinum toxin
186810|NCT02008136|cervicalgia
186811|NCT02008136|lumbago
186812|NCT02008136|low back pain
186813|NCT02008123|Clopidogrel
186814|NCT02008123|Clopidogrel Resistance
186815|NCT02008123|Primidone
186816|NCT02008123|Secondary Stroke Prevention
186817|NCT02008110|Heart failure
186818|NCT02008110|Biomarker guided-therapy
186819|NCT02008110|Carbohydrate antigen 125
186820|NCT02008110|Clinical outcomes.
186821|NCT02008097|Ultrasound
186822|NCT02008097|Ultrasonography
186823|NCT02008097|Liver transplantation
186824|NCT02008097|Arterial Occlusive Diseases
186825|NCT02008097|Hypertension
186826|NCT02008097|Pregnancy, High Risk
186827|NCT02008097|Pregnancy
186828|NCT02008084|hypertriglyceridemia
186829|NCT02008084|mixed hyperlipidemia
186830|NCT02008058|Metastatic Castrate-Resistant Prostate Cancer
186831|NCT02008058|LCCC 1231
186832|NCT02008058|Lineberger Comprehensive Cancer Center
186833|NCT02008058|UNC Lineberger
186834|NCT02008058|Prostate Cancer
186835|NCT02008058|Pain
186836|NCT02008045|MRI
186837|NCT02008045|Imaging
186838|NCT02008045|Neurocognitive
186839|NCT02008045|White matter injury
186840|NCT02008032|Mammography
186841|NCT02008032|Breast
186842|NCT02008032|Implants
186843|NCT02008019|Chondrosarcoma
186844|NCT02008019|Neoadjuvant therapy
186845|NCT02008019|Phase II
186846|NCT02008019|Everolimus
186847|NCT02008019|Success Rate
186848|NCT02008019|Progression Free Survival
186849|NCT02008019|Overall Survival
186850|NCT02008019|Safety
186851|NCT02008019|Quality of Life
186852|NCT02008019|Molecular study (ancillary study)
186853|NCT02008006|Follicular Lymphoma
186854|NCT02008006|Chemosensitive relapse
186855|NCT02008006|High Dose Chemotherapy
186856|NCT02008006|Bendamustine
186857|NCT02008006|BeEAM
186858|NCT02008006|Autologous Stem Cell Transplantation
186859|NCT02008006|Safety
186860|NCT02008006|Event Free Survival
186861|NCT02008006|Overall Response Rate
186862|NCT02008006|Progression Free Survival
186863|NCT02008006|Overall Survival
186864|NCT02008006|Phase II
186865|NCT02008006|World Health Organization (WHO) 1 grade
186866|NCT02008006|WHO 2 grade
186867|NCT02008006|WHO 3a grade
186868|NCT02007993|Halitosis,
186869|NCT02007993|Photodynamic Therapy,
186870|NCT02007993|Adolescent
186871|NCT02007980|urological problems
186872|NCT02007980|indwelling urologic stent
186873|NCT02007980|kidney stone disease
186874|NCT02007980|urinary system obstruction
186875|NCT02007980|hydronephrosis
186876|NCT02007980|ureteral damage
186877|NCT02007954|HCC
186878|NCT02007915|Adolescent
186879|NCT02007915|Avascular Necrosis
186880|NCT02007915|Bisphosphonates
186881|NCT02007915|Pamidronate
186882|NCT02007902|Preterm baby
186883|NCT02007902|Total plasma protein
186884|NCT02007902|Albumin
186885|NCT02007902|Hemodynamic disturbances
186886|NCT02007902|Perfusion
186887|NCT02007902|Near Infra Red Spectroscopy (NIRS)
186888|NCT02007902|Ultrasound
186889|NCT02007876|Mobility
186890|NCT02007876|Activity
186891|NCT02007876|Training
186892|NCT02007876|Abdominal
186893|NCT02007876|Surgery
186894|NCT02007876|Adult
186895|NCT02007863|Leukemia
186896|NCT02007863|Myelodysplasia
186897|NCT02007863|Acute lymphocytic leukemia
186898|NCT02007863|ALL
186899|NCT02007863|Acute myelogenous leukemia
186900|NCT02007863|AML
186901|NCT02007863|Pediatric
186902|NCT02007850|continuous femoral nerve block
186903|NCT02007850|knee arthroplasty
186904|NCT02007850|quadriceps muscle strength
186905|NCT02007837|pregnancy induced hypertension
186906|NCT02007837|gestational hypertension
186907|NCT02007837|pre-eclampsia
186908|NCT02007837|preeclampsia
186909|NCT02007837|hypertensive disorders in pregnancy
186910|NCT02007824|pressure ulcer
186911|NCT02007824|chronic wound
186912|NCT02007824|tissue necrosis
186913|NCT02007824|slough
186914|NCT02007824|ultra sound
186915|NCT02007798|dexmedetomidine
186916|NCT02007798|supratentorial tumors
186917|NCT02007785|Cognitive Orientation to daily Occupational Performance
186918|NCT02007785|CO-OP
186919|NCT02007772|COPD, nHF, BiPAP
186920|NCT02007759|Dysphagia
186921|NCT02007759|neuromuscular electrical stimulation
186922|NCT02007759|NMES
186923|NCT02007759|Neonates
186924|NCT02007759|Vitalstim
186925|NCT02007746|sickle cell disease
186926|NCT02007746|hemochromatosis
186927|NCT02007746|liver fibrosis
186928|NCT02007746|liver cirrhosis
186929|NCT02007746|FibroScan
186930|NCT02007746|Ferriscan
186931|NCT02007746|liver iron
186932|NCT02007733|Diarrhea
186933|NCT02007733|Dehydration
186934|NCT02007733|Children
186935|NCT02007733|Resuscitation
186936|NCT02007733|Clinical Prediction Rule
186937|NCT02007733|Low Income Country
186938|NCT02007733|Bangladesh
186939|NCT02007720|Serelaxin,
186940|NCT02007720|WHF,
186941|NCT02007720|Likert Scale,
186942|NCT02007720|RELAX-AHF-ASIA,
186943|NCT02007720|RLX030,
186944|NCT02007720|AHF,
186945|NCT02007720|acute heart failure
186946|NCT02007707|Asian American
186947|NCT02007707|Vietnamese American
186948|NCT02007707|Smoking cessation
186949|NCT02007707|Community Health Worker
186950|NCT02007707|Lay Health Worker Outreach
186951|NCT02007707|Family Intervention
186952|NCT02007694|Phobic Disorders (Fear of Flying and acrophobia)
186953|NCT02007694|Virtual Reality Exposure Therapy
186954|NCT02007694|Fear extinction
186955|NCT02007694|propranolol
186956|NCT02007694|Yohimbine
186957|NCT02007681|Sedentary Behavior; Breaks; Workplace; Energy Expenditure; Physical activity; doubly labeled water
186958|NCT02007668|low back pain
186959|NCT02007668|kinesio taping
186960|NCT02007655|Cardiovascular
186961|NCT02007616|Cognitive aging
186962|NCT02007616|Video games training
186963|NCT02007616|Attention
186964|NCT02007616|Memory
186965|NCT02007616|Wellbeing
186966|NCT02007616|Speed of processing
186967|NCT02007616|Executive functions
186968|NCT02007603|chronic hemodialysis
186969|NCT02007603|ampicillin
186970|NCT02007603|sulbactam
186971|NCT02007603|amoxicillin
186972|NCT02007603|clavulanic acid
186973|NCT02007603|pharmacokinetics
186974|NCT02007577|insulin resistant
186975|NCT02007564|Palliative care dyads
186976|NCT02007564|Volunteers
186977|NCT02007564|Community-based
186978|NCT02007564|Mixed methods
186979|NCT02007551|Social Isolation
186980|NCT02007551|Nutrition Assessments
186981|NCT02007551|Food Habits
186982|NCT02007551|Meals
186983|NCT02007551|Self Efficacy
186984|NCT02007551|Quality of Life
186985|NCT02007551|Peer Group
186986|NCT02007538|Lung Cancer
186987|NCT02007538|Bronchoscopy
186988|NCT02007538|Fine Need Aspiration
186989|NCT02007538|Cytochemical Assays
186990|NCT02007512|advanced breast cancer
186991|NCT02007512|enzalutamide
186992|NCT02007512|MDV3100
186993|NCT02007512|Estrogen receptor positive (ER +)
186994|NCT02007512|Progesterone receptor positive (PgR +)
186995|NCT02007512|HER-2 normal
186996|NCT02007499|Prehospital emergency care
186997|NCT02007499|Out of hospital cardiac arrest
186998|NCT02007499|Cardiopulmonary resuscitation
186999|NCT02007499|CPR
187000|NCT02007499|Heart arrest
187001|NCT02007499|Outcome
187002|NCT02007499|Bystander
187003|NCT02007486|Heart Failure
187004|NCT02007486|Exercise
187005|NCT02007486|Dyspnea
187006|NCT02007486|Diaphragm electromyogram
187007|NCT02007486|Respiratory mechanics
187008|NCT02007473|Haemovigilance
187009|NCT02007473|Plasma
187010|NCT02007473|Pathogen reduction
187011|NCT02007473|Methylene Blue
187012|NCT02007447|autism, oxytocin, autism spectrum disorder, social skills.
187013|NCT02007421|Human Papillomavirus,
187014|NCT02007421|Anal High Grade Squamous intraepithelial lesions,
187015|NCT02007421|Homosexual Men
187016|NCT02007421|High resolution anoscopy,
187017|NCT02007421|Cancer Screening
187018|NCT02007421|HIV
187019|NCT02007408|abortion
187020|NCT02007408|analgesia
187021|NCT02007408|paracervical block
187022|NCT02007408|lidocaine spray
187023|NCT02007343|Enterobacteriaceae
187024|NCT02007343|Pseudomonas
187025|NCT02007343|Acinetobacter
187026|NCT02007343|Stenotrophomonas
187027|NCT02007343|Mortality
187028|NCT02007343|Morbidity
187029|NCT02007343|Cost of Illness
187030|NCT02007343|Causality
187031|NCT02007343|Multicenter Study
187032|NCT02007343|Cohort Studies
187033|NCT02007343|Case-Control Studies
187034|NCT02007343|Prospective Studies
187035|NCT02007343|Follow-up Studies
187036|NCT02007330|systemic lidocaine
187037|NCT02007330|postoperative pain
187038|NCT02007330|recovery, pediatric
187039|NCT02007330|inguinal hernia
187040|NCT02007330|laparoscopy
187041|NCT02007317|BCC
187042|NCT02007291|Alzheimer, MMSE, response, colinesterase inhibitors (ChEI)
187043|NCT02007278|diabetes
187044|NCT02007278|hypoglycemia
187045|NCT02007278|glycemic variability
187046|NCT02007278|vildagliptin
187047|NCT02007278|glimepiride
187048|NCT02007252|Abdominal Aortic Aneurysm
187049|NCT02007252|AAA
187050|NCT02007252|IL-1b
187051|NCT02007252|Abdominal ultrasound
187052|NCT02007239|tocilizumab
187053|NCT02007239|hemophagocytic lymphohistiocytosis (HLH)
187054|NCT02007239|cytokine
187055|NCT02007239|cytokine release syndrome
187056|NCT02007226|Coronary Heart Disease
187057|NCT02007226|spinal cord injury
187058|NCT02007226|risk factor
187059|NCT02007226|postprandial lipemia
187060|NCT02007213|Neuromuscular Disease
187061|NCT02007213|Motor Function
187062|NCT02007213|Proxy Reported Outcome
187063|NCT02007213|Young Children
187064|NCT02007187|Unstable Angina Pectoris
187065|NCT02007187|Randomized Controlled Trial
187066|NCT02007187|Traditional Chinese Medicine
187067|NCT02007174|recurrent pterygium
187068|NCT02007174|bevacizumab
187069|NCT02007174|triple dose
187070|NCT02007148|gastric adenocarcinoma,
187071|NCT02007148|capecitabine,
187072|NCT02007148|second line treatment,
187073|NCT02007148|recurrent or metastatic disease,
187074|NCT02007148|overall survival,
187075|NCT02007148|tumor response,
187076|NCT02007148|quality of life
187077|NCT02007122|HD
187078|NCT02007122|CVVH
187079|NCT02007122|renal replacement therapy
187080|NCT02007122|ceftaroline
187081|NCT02007122|pharmacokinetics
187082|NCT02007096|Transabdominal plane block
187083|NCT02007096|ventral hernia
187084|NCT02007096|umbilical hernia
187085|NCT02007096|incisional hernia
187086|NCT02007096|hernia repair
187087|NCT02007083|Lumbar Spinal stenosis
187088|NCT02007083|Surgical treatment of LSS.
187089|NCT02007070|PD1
187090|NCT02007070|PD-1
187091|NCT02007070|PDL1
187092|NCT02007070|PD-L1
187093|NCT02007057|Suprascapular nerve block
187094|NCT02007057|Interscalene nerve block
187095|NCT02007044|Leukemia
187096|NCT02007044|Chronic lymphocytic leukemia
187097|NCT02007044|CLL
187098|NCT02007044|Relapsed
187099|NCT02007044|Ibrutinib
187100|NCT02007044|PCI-32765
187101|NCT02007044|Rituximab
187102|NCT02007044|Rituxan
187103|NCT02007031|Hypertension
187104|NCT02007031|Cold temperature
187105|NCT02007031|Blood pressure
187106|NCT02007031|Electrocardiography
187107|NCT02007018|Surgical Site Infections
187108|NCT02007018|Colorectal Resection
187109|NCT02007018|Negative Pressure Wound Therapy
187110|NCT02007005|superficial bladder cancer
187111|NCT02007005|mistletoe extract
187112|NCT02007005|maximum tolerated dose
187113|NCT02007005|marker tumor
187114|NCT02007005|remission
187115|NCT02007005|recurrence rate
187116|NCT02006979|cardiotoxicity
187117|NCT02006979|Chemotherapy, Adjuvant
187118|NCT02006979|Breast Neoplasms
187119|NCT02006979|Exercise
187120|NCT02006979|Cardiotoxins
187121|NCT02006979|Echocardiography
187122|NCT02006979|Speckle tracking
187123|NCT02006979|Biological Markers
187124|NCT02006979|Electrocardiography
187125|NCT02006966|Systemic lidocaine
187126|NCT02006966|postoperative pain
187127|NCT02006966|Video-assisted thoracic surgery
187128|NCT02006966|VATS
187129|NCT02006953|gastrostomy
187130|NCT02006953|enteral
187131|NCT02006940|alveoflex
187132|NCT02006940|probe-based confocal laser endomicroscopy
187133|NCT02006940|pCLE
187134|NCT02006940|alveoscopy
187135|NCT02006940|morphology
187136|NCT02006940|high resolution computed tomography
187137|NCT02006927|Prostate Cancer
187138|NCT02006914|Insulin resistance
187139|NCT02006914|HIV disease
187140|NCT02006914|chromium picolinate
187141|NCT02006901|surgical procedures, operative
187142|NCT02006901|lumbar vertebrae
187143|NCT02006901|decompression, surgical
187144|NCT02006901|microdecompression
187145|NCT02006901|laminectomy
187146|NCT02006901|registries
187147|NCT02006888|Inflammation
187148|NCT02006888|cataract surgery
187149|NCT02006875|repetitive transcranial magnetic stimulation
187150|NCT02006875|postural
187151|NCT02006875|balance
187152|NCT02006875|mobility
187153|NCT02006875|leg
187154|NCT02006875|stroke
187155|NCT02006862|olanzapine
187156|NCT02006862|olanzapine treatment efficacy
187157|NCT02006849|AfricanAmericans
187158|NCT02006849|Hypertension
187159|NCT02006849|Proteinuria
187160|NCT02006849|ApoL1 gene
187161|NCT02006836|glycemic index
187162|NCT02006836|glycemic response
187163|NCT02006836|diabetes
187164|NCT02006836|pomelo
187165|NCT02006823|Chronic Hepatitis C
187166|NCT02006810|Endothelium biomarkers
187167|NCT02006810|Atherosclerotic disease
187168|NCT02006810|Endothelial function
187169|NCT02006810|Nutritional stimuli
187170|NCT02006797|reconciliation
187171|NCT02006797|discharge
187172|NCT02006797|pharmacist
187173|NCT02006797|drug related problems
187174|NCT02006771|Meal
187175|NCT02006771|Postprandial oxidative stress
187176|NCT02006719|Adhesive Capsulitis
187177|NCT02006719|Frozen Shoulder
187178|NCT02006719|Shoulder Range of Motion limitation
187179|NCT02006719|Shoulder Pain
187180|NCT02006693|XEN
187181|NCT02006693|Primary Open Angle Glaucoma
187182|NCT02006693|Filtration Device
187183|NCT02006693|Ab interno
187184|NCT02006680|Central Precocious Puberty
187185|NCT02006680|Suppression
187186|NCT02006680|Alpha Subunit
187187|NCT02006680|Leuprolide Stimulation Test
187188|NCT02006628|GWP42003
187189|NCT02006628|Cannabinoids
187190|NCT02006628|Schizophrenia
187191|NCT02006602|Candesartan cilexetil
187192|NCT02006602|Healthy adult human subjects
187193|NCT02006602|Bioequivalence
187194|NCT02006589|Bioequivalence
187195|NCT02006589|Candesartan cilexetil
187196|NCT02006589|Healthy adult human subjects
187197|NCT02006576|Emphysema
187198|NCT02006576|Prostaglandin E
187199|NCT02006576|Bronchoalveolar lavage
187200|NCT02006563|Brain Tumor
187201|NCT02006563|Glioblastoma multiforme
187202|NCT02006563|GBM
187203|NCT02006563|Metabolic Tumor Volume
187204|NCT02006563|MTV
187205|NCT02006563|Clinical Tumor Volume
187206|NCT02006563|CTV
187207|NCT02006550|Wnt
187208|NCT02006550|Notch
187209|NCT02006550|Hedgehog
187210|NCT02006550|Tumor Sample
187211|NCT02006537|soluble epoxide hydrolase inhibitor
187212|NCT02006537|Entero-Test
187213|NCT02006537|pharmacokinetics
187214|NCT02006537|COPD
187215|NCT02006537|safety
187216|NCT02006524|Silent atrial fibrillation
187217|NCT02006524|primary care
187218|NCT02006524|screening
187219|NCT02006524|influenza vaccination
187220|NCT02006511|incisional negative pressure wound therapy
187221|NCT02006511|groin incision
187222|NCT02006511|incisional VAC
187223|NCT02006511|Prevena
187224|NCT02006511|groin wound
187225|NCT02006498|non-alcoholic fatty liver disease
187226|NCT02006498|sillymarin
187227|NCT02006498|randomised trial
187228|NCT02006498|non-alcoholic steatohepatitis
187229|NCT02006472|Huntington's Disease
187230|NCT02006472|Pridopidine
187231|NCT02006472|Pride-HD
187232|NCT02006459|Gastrointestinal-mediated glucose disposal
187233|NCT02006459|Total pancreatectomy
187234|NCT02006459|Incretin hormones
187235|NCT02006459|Glucagon
187236|NCT02006446|Male infertility
187237|NCT02006446|sperm head vacuoles
187238|NCT02006446|sperm morphology
187239|NCT02006446|aneuploidy
187240|NCT02006446|DNA fragmentation
187241|NCT02006446|abnormal chromatin condensation
187242|NCT02006446|telomere abnormalities
187243|NCT02006394|Inflammation
187244|NCT02006394|Monocytes
187245|NCT02006381|healthy boys
187246|NCT02006381|plasma oxytocin
187247|NCT02006381|pediatric
187248|NCT02006368|Volunteers
187249|NCT02006368|Blood Platelets
187250|NCT02006368|Platelet Transfusion
187251|NCT02006342|Diabetes Mellitus
187252|NCT02006342|Diabetic Ketoacidosis
187253|NCT02006342|Insulin Glargine
187254|NCT02006342|Anion gap
187255|NCT02006342|Metabolic acidosis
187256|NCT02006303|Benign Prostate Hyperplasia
187257|NCT02006303|Green light
187258|NCT02006303|Photoselective vaporization of the prostate
187259|NCT02006303|Prostatic artery embolization
187260|NCT02006303|Outcome
187261|NCT02006277|healthy volunteers
187262|NCT02006277|taste
187263|NCT02006277|bioavailability
187264|NCT02006238|Hot flash
187265|NCT02006238|Farabloc
187266|NCT02006238|menopausal women
187267|NCT02006225|autologous
187268|NCT02006225|stem cell
187269|NCT02006225|transplantation
187270|NCT02006199|obsessive-compulsive disorder
187271|NCT02006199|mindfulness
187272|NCT02006199|meditation
187273|NCT02006186|Bicycling
187274|NCT02006173|Hya-Dermis mixed with lidocaine on reducing pain
187275|NCT02006134|Vasculitis
187276|NCT02006134|Primary CNS Vasculitis
187277|NCT02006134|Systemic vasculitis
187278|NCT02006134|Churg-Strauss Syndrome
187279|NCT02006134|Polyarteritis Nodosa
187280|NCT02006134|Wegener Granulomatosis
187281|NCT02006134|Pediatric vasculitis
187282|NCT02006134|Childhood vasculitis
187283|NCT02006134|Granulomatosis with polyangiitis
187284|NCT02006134|Microscopic Polyangiitis
187285|NCT02006134|Takayasu Arteritis
187286|NCT02006134|Autoimmune
187287|NCT02006134|ANCA-associated vasculitis
187288|NCT02006121|Parkinson's disease
187289|NCT02006121|motor fluctuations
187290|NCT02006121|not well controlled
187291|NCT02006121|medical treatment
187292|NCT02006108|kidney
187293|NCT02006108|transplant
187294|NCT02006108|rejection
187295|NCT02006108|Feraheme
187296|NCT02006108|ferumoxytol
187297|NCT02006095|carotid artery stenting
187298|NCT02006095|carotid endarterectomy
187299|NCT02006095|magnetic resonance imaging (MRI)
187300|NCT02006095|neuropsychological testing
187301|NCT02006095|microemboli
187302|NCT02006082|Telemedicine video-consultation (TVC)
187303|NCT02006082|Re-admission to hospital
187304|NCT02006082|Time to re-admission
187305|NCT02006082|Length if hospital stay
187306|NCT02006082|Patient satisfaction
187307|NCT02006082|Chronic obstructive pulmonary disease (COPD)
187308|NCT02006069|CRT, non responders, MultiPoint Pacing (MPP)
187309|NCT02006030|Unresectable Hepatocellular Carcinoma
187310|NCT02006030|Liver Cancer
187311|NCT02006030|ADI
187312|NCT02006030|ADI-PEG 20
187313|NCT02006004|AML
187314|NCT02005991|PF-05212377
187315|NCT02005991|phase 1
187316|NCT02005991|open-label
187317|NCT02005991|5-HT2a receptor occupancy
187318|NCT02005991|positron emission tomography
187319|NCT02005991|healthy subjects
187320|NCT02005991|brain
187321|NCT02005991|cortex
187322|NCT02005991|alzheimers disease
187323|NCT02005965|Rectal Cancer
187324|NCT02005965|Low Rectal Cancer
187325|NCT02005965|MERCURY
187326|NCT02005965|Cancer
187327|NCT02005965|CRM
187328|NCT02005965|Circumferential Margin
187329|NCT02005965|Quality of Life
187330|NCT02005965|MRI
187331|NCT02005965|Radiology
187332|NCT02005965|Abdominoperineal Excision
187333|NCT02005965|Anterior Resection
187334|NCT02005965|Surgery
187335|NCT02005965|Pathology
187336|NCT02005939|Pomegranate
187337|NCT02005939|Blood pressure
187338|NCT02005939|Insulin sensitivity
187339|NCT02005939|Cortisol
187340|NCT02005939|Quality of life
187341|NCT02005939|Body composition
187342|NCT02005926|Breast cancer
187343|NCT02005926|Sentinel lymph node biopsy
187344|NCT02005926|Ultrasonography
187345|NCT02005926|Fine needle aspiration
187346|NCT02005900|DHA
187347|NCT02005900|Omega 3
187348|NCT02005900|Polyunsaturated Fatty Acids
187349|NCT02005900|Dyslipidemia induced by HAART
187350|NCT02005900|Lipid metabolic alterations
187351|NCT02005900|HIV
187352|NCT02005887|Premenopausal patients
187353|NCT02005887|ER-positive
187354|NCT02005887|PgR+ (>50%)
187355|NCT02005887|HER2-negative or not amplified
187356|NCT02005861|osteochondral lesion
187357|NCT02005861|talus
187358|NCT02005861|ankle
187359|NCT02005861|cartilage repair
187360|NCT02005848|Type-1 Diabetes
187361|NCT02005848|T1D
187362|NCT02005848|Diabetes Mellitus
187363|NCT02005835|HIV
187364|NCT02005835|Option B+
187365|NCT02005835|Prevention of Mother to Child Transmission
187366|NCT02005822|Cytomegalovirus
187367|NCT02005822|Congenital infection
187368|NCT02005822|Sensorineural hearing loss
187369|NCT02005822|Valganciclovir
187370|NCT02005809|Endoscopic submucosal dissection
187371|NCT02005809|gastric neoplasm
187372|NCT02005809|second look endoscopy
187373|NCT02005783|incidence of grade 3/4 neutropenia
187374|NCT02005783|incidence of febrile neutropenia
187375|NCT02005783|time to neutropenia recovery
187376|NCT02005783|safety
187377|NCT02005757|rheumatoid arthritis
187378|NCT02005757|RA
187379|NCT02005757|Mizoribine
187380|NCT02005757|DAS28
187381|NCT02005757|European League Against Rheumatism
187382|NCT02005744|CKD-501
187383|NCT02005731|Low Intensity Shockwave
187384|NCT02005731|Extracorporeal shockwave therapy
187385|NCT02005731|Erectile dysfunction
187386|NCT02005692|pressure ulcers
187387|NCT02005692|bed sores
187388|NCT02005692|patient turn protocol
187389|NCT02005692|patient movement
187390|NCT02005692|patient monitoring
187391|NCT02005679|Prelingual Deafness
187392|NCT02005679|Retention Disorders, Cognitive
187393|NCT02005679|Sign language
187394|NCT02005679|Mini-Mental State
187395|NCT02005666|Acne Vulgaris
187396|NCT02005666|DUAC
187397|NCT02005666|CADILA
187398|NCT02005666|CLIANTHA
187399|NCT02005653|Lymphatic filariasis
187400|NCT02005653|W. bancrofti
187401|NCT02005653|DEC
187402|NCT02005653|Albendazole
187403|NCT02005653|Doxycycline
187404|NCT02005627|grass pollen allergy
187405|NCT02005627|hayfever
187406|NCT02005627|atopy
187407|NCT02005627|allergic rhinitis
187408|NCT02005627|sublingual immunotherapy tablets
187409|NCT02005614|Rational dose selection
187410|NCT02005614|gamma knife radiosurgery
187411|NCT02005588|amino acid chelated iron
187412|NCT02005588|iron salt
187413|NCT02005588|iron deficiency anemia
187414|NCT02005536|Poliomyelitis
187415|NCT02005536|Poliovirus
187416|NCT02005536|Polio
187417|NCT02005536|IMOVAX POLIO®
187418|NCT02005536|Inactivated polio vaccine
187419|NCT02004535|Hearing loss
187420|NCT02004535|Asymmetric hearing loss
187421|NCT02004535|Cochlear implantation
187422|NCT02004522|Phase 3
187423|NCT02004522|CLL/SLL
187424|NCT02004522|Pi3K
187425|NCT02004509|atrial fibrillation
187426|NCT02004509|stroke
187427|NCT02004509|pacemaker
187428|NCT02004509|anticoagulant
187429|NCT02004483|percutaneous coronary intervention
187430|NCT02004483|ischemia
187431|NCT02004483|strain
187432|NCT02004483|coronary stenosis
187433|NCT02004470|post laparoscopic shoulder pain
187434|NCT02004470|active suction
187435|NCT02004470|lavage and suction
187436|NCT02004470|right shoulder pain
187437|NCT02004470|post operative shoulder pain
187438|NCT02004457|HIV
187439|NCT02004457|Primary care
187440|NCT02004457|Engagement
187441|NCT02004457|Acceptance
187442|NCT02004457|Disclosure
187443|NCT02004457|Stigma
187444|NCT02004444|JC Virus
187445|NCT02004444|Natalizumab
187446|NCT02004431|Chronic post surgical pain
187447|NCT02004431|Orthopaedic
187448|NCT02004431|Anxiety
187449|NCT02004431|depression
187450|NCT02004418|C-Choline PET scans
187451|NCT02004418|external beam radiotherapy
187452|NCT02004405|autonomic nervous system
187453|NCT02004405|fibromyalgia
187454|NCT02004405|autonomic dysfunction
187455|NCT02004405|strengthening
187456|NCT02004405|flexibility
187457|NCT02004405|exercise
187458|NCT02004405|heart rate variability
187459|NCT02004392|Alzheimer's disease
187460|NCT02004392|Cognition
187461|NCT02004392|Alpha-7 nAChR
187462|NCT02004379|HCV
187463|NCT02004379|Hepatitis C
187464|NCT02004379|telaprevir
187465|NCT02004379|boceprevir
187466|NCT02004379|clinical practice
187467|NCT02004366|Diabetes
187468|NCT02004366|Linagliptin
187469|NCT02004366|hospital hyperglycemia
187470|NCT02004366|inpatient diabetes
187471|NCT02004353|Cochlear® Hearing Implants
187472|NCT02004340|pediatric epilepsy
187473|NCT02004340|transcutaneous vagus nerve stimulation
187474|NCT02004314|Chloroquine
187475|NCT02004314|T cell immune activation
187476|NCT02004314|CD4 recovery
187477|NCT02004314|HIV
187478|NCT02004301|Formulation behaviour
187479|NCT02004301|Drug absorption profile
187480|NCT02004288|Probiotics
187481|NCT02004288|Anorexia nervosa
187482|NCT02004288|Constipation
187483|NCT02004288|Body weight
187484|NCT02005510|cervical cancer
187485|NCT02005510|screening
187486|NCT02005510|human papillomavirus
187487|NCT02005510|cervical intraepithelial neoplasia
187488|NCT02005497|Cancer prevention and control
187489|NCT02005497|Health promotion
187490|NCT02005497|Workplace
187491|NCT02005497|Dissemination
187492|NCT02005497|Implementation
187493|NCT02005458|Neutropenia
187494|NCT02005458|Febrile neutropenia
187495|NCT02005458|PEG-rhG-CSF
187496|NCT02005458|Myelosuppressive chemotherapy
187497|NCT02005445|Obstructive sleep apnea
187498|NCT02005445|Coronary heart disease
187499|NCT02005445|Cardiac rehabilitation
187500|NCT02005445|Cardiopulmonary exercise testing
187501|NCT02005432|Diabetis
187502|NCT02005432|Retinal Neovascularization
187503|NCT02005432|laser treatment
187504|NCT02005419|Pancreatic Cancer
187505|NCT02005419|Pancreatic Adenocarcinoma
187506|NCT02005419|Metformin
187507|NCT02005419|Gemcitabine
187508|NCT02005419|Adjuvant Therapy
187509|NCT02005406|Wei JET
187510|NCT02005393|FICE
187511|NCT02005393|NBI
187512|NCT02005380|Alzheimer's Disease Rehabilitation
187513|NCT02005367|substance use treatment
187514|NCT02005367|person-centered treatment
187515|NCT02005367|residential treatment outcomes
187516|NCT02005367|dual diagnosis
187517|NCT02005367|recovery model
187518|NCT02005367|psychosocial treatment
187519|NCT02005354|Pain
187520|NCT02005354|Bone marrow aspiration
187521|NCT02005354|trephine biopsy
187522|NCT02005341|Lumbar
187523|NCT02005341|fusion
187524|NCT02005328|Xerostomia
187525|NCT02005328|hyposialia
187526|NCT02005328|hyposalivation
187527|NCT02005328|saliva substitute
187528|NCT02005328|Salivary Gland
187529|NCT02005328|Mouth Diseases
187530|NCT02005328|Dry mouth
187531|NCT02005315|Pancreatic Cancer
187532|NCT02005315|Stage IV Pancreatic Cancer
187533|NCT02005302|chronic kidney disease
187534|NCT02005302|mineral and bone disease
187535|NCT02005302|Malnutrition
187536|NCT02005302|Vitamin D
187537|NCT02005302|low protein diet
187538|NCT02005289|CLL
187539|NCT02005289|SLL
187540|NCT02005289|PLL
187541|NCT02005289|Chronic Lymphocytic Leukemia
187542|NCT02005289|Small Lymphocytic Lymphoma
187543|NCT02005289|Prolymphocytic Leukemia
187544|NCT02005289|MOR00208
187545|NCT02005289|MOR208
187546|NCT02005276|Sedentary
187547|NCT02005276|Behavioral Economic Intervention
187548|NCT02005276|Team Studies
187549|NCT02005276|Financial Incentives
187550|NCT02005276|Workplace Wellness
187551|NCT02005276|Team Incentives
187552|NCT02005263|Hysteroscopy
187553|NCT02005250|osteoporosis
187554|NCT02005250|hyperthyroidism
187555|NCT02005250|hypothyroidism
187556|NCT02005237|Exercise
187557|NCT02005237|Cognition
187558|NCT02005237|Neuroimaging
187559|NCT02005237|Rehabilitation
187560|NCT02005237|Connectivity
187561|NCT02005224|Insulin sensitivity
187562|NCT02005224|Lipid profile
187563|NCT02005224|Body composition
187564|NCT02005224|Weight
187565|NCT02005211|AZD3293
187566|NCT02005211|Healthy volunteers
187567|NCT02005211|Young volunteers
187568|NCT02005211|Elderly volunteers
187569|NCT02005211|Japanese volunteers
187570|NCT02005211|Phase 1
187571|NCT02005211|Single and multiple ascending dose study
187572|NCT02005172|arrhythmia, palpitations, lightheadedness
187573|NCT02005159|Enterobacteria
187574|NCT02005159|Bacteremia
187575|NCT02005159|Minimum inhibitory concentration
187576|NCT02005159|Susceptible
187577|NCT02005159|Prognosis
187578|NCT02005146|Hepatitis B
187579|NCT02005146|Nucleoside/nucleotide
187580|NCT02005146|HBsAg loss
187581|NCT02005133|Wet age-related macular degeneration
187582|NCT02005068|Osteoarticular infections
187583|NCT02005068|Osteomyelitis
187584|NCT02005068|Joint infections
187585|NCT02005068|MRSA (Methicillin- Resistant Staphylococcus Aureus)
187586|NCT02005068|MSSA (Methicillin- Susceptible Staphylococcus Aureus)
187587|NCT02005055|Brachytherapy
187588|NCT02005055|Radiotherapy
187589|NCT02005055|Scar treatment
187590|NCT02005042|Physical activity
187591|NCT02005042|Ecological Momentary Assessment
187592|NCT02005042|Ecological Momentary Intervention
187593|NCT02005042|Accelerometer
187594|NCT02005042|Smartphone
187595|NCT02005029|Parkinson's Disease
187596|NCT02005029|Levodopa
187597|NCT02005029|motor fluctuations
187598|NCT02005029|gastroparesis
187599|NCT02005016|Aphasia
187600|NCT02005016|Language Therapy
187601|NCT02005016|Acquired Language Disorders
187602|NCT02005016|Semantics
187603|NCT02005016|Stroke
187604|NCT02004990|Children, Plaque
187605|NCT02004951|Superficial femoral artery
187606|NCT02004951|paclitaxel
187607|NCT02004951|stent
187608|NCT02004951|self expandable
187609|NCT02004951|restenosis
187610|NCT02004951|endovascular
187611|NCT02004951|above-the-knee intermediate length
187612|NCT02004938|measurements
187613|NCT02004938|jugular
187614|NCT02004938|ultrasound
187615|NCT02004938|pediatric
187616|NCT02004938|respiratory
187617|NCT02004938|diameter
187618|NCT02004925|pneumoperitoneum
187619|NCT02004925|free peritoneal air
187620|NCT02004925|ultrasonography
187621|NCT02004912|maternal
187622|NCT02004912|neonatal
187623|NCT02004912|child
187624|NCT02004912|health services
187625|NCT02004912|health care
187626|NCT02004912|Karnataka
187627|NCT02004912|India
187628|NCT02004899|Labor epidural analgesia
187629|NCT02004899|Fentanyl
187630|NCT02004899|Bupivacaine
187631|NCT02004899|Onset
187632|NCT02004886|Diabetes Mellitus
187633|NCT02004886|Diabetes Mellitus, Type 2
187634|NCT02004886|Glucose Metabolism Disorders
187635|NCT02004886|Metabolic Diseases
187636|NCT02004886|Endocrine System Diseases
187637|NCT02004886|Therapeutic Uses
187638|NCT02004886|Pharmacologic Actions
187639|NCT02004886|Molecular Mechanisms of Pharmacological Action
187640|NCT02004886|Physiological Effects of Drugs
187641|NCT02004886|Metformin
187642|NCT02004873|pacemaker
187643|NCT02004873|leadless
187644|NCT02004873|single chamber
187645|NCT02004860|local immunosuppressive
187646|NCT02004860|Maintenance therapy
187647|NCT02004795|Boron Neutron Capture Therapy
187648|NCT02004795|Image-guided intensity modulation radiotherapy
187649|NCT02004769|Metastatic gastric or gastro-esophageal junction cancer
187650|NCT02004769|Trastuzumab
187651|NCT02004769|HER2-positive
187652|NCT02004769|Capecitabine
187653|NCT02004769|Docetaxel
187654|NCT02004769|First-line therapy
187655|NCT02004756|pediatric
187656|NCT02004756|fontan
187657|NCT02004756|congenital heart disease
187658|NCT02004756|cardiac and musculoskeletal funion
187659|NCT02004756|cardiac and/or musculoskeletal metabolism
187660|NCT02004756|exercise training intervention
187661|NCT02004743|Early Intervention
187662|NCT02004743|Prevention
187663|NCT02004743|Risk Factors
187664|NCT02004743|Exposure Therapy
187665|NCT02004743|Psychoeducation
187666|NCT02004717|advanced solid tumor
187667|NCT02004717|Phase 1
187668|NCT02004717|Oncology
187669|NCT02004652|Prucalopride
187670|NCT02004652|Gastrointestinal Diseases
187671|NCT02004652|Postoperative ileus
187672|NCT02004652|Randomised trial
187673|NCT02004639|IMRT or HT with chemotherapy
187674|NCT02004626|Collagenase
187675|NCT02004626|Phase III
187676|NCT02004626|National
187677|NCT02004626|Noninferiority
187678|NCT02004626|Double-blind
187679|NCT02004626|Multicenter
187680|NCT02004626|Prospective.
187681|NCT02004587|Hepatic impairment
187682|NCT02004587|Pharmacokinetics
187683|NCT02004587|Pharmacodynamics
187684|NCT02004587|Gemigliptin
187685|NCT02004561|bariatric_surgery
187686|NCT02004561|pediatric obesity
187687|NCT02004561|diabetes
187688|NCT02004262|cancer
187689|NCT02004262|cancer vaccine
187690|NCT02004262|Listeria monocytogenes
187691|NCT02004262|Listeria-based vaccine
187692|NCT02004262|GVAX
187693|NCT02004262|cyclophosphamide
187694|NCT02004262|Cytoxan
187695|NCT02004262|immunotherapy
187696|NCT02004262|mesothelin
187697|NCT02004236|tRNS
187698|NCT02004236|QEEG
187699|NCT02004236|ERP
187700|NCT02004236|ASD
187701|NCT02004236|Autism
187702|NCT02004236|verbal fluency
187703|NCT02004236|empathy
187704|NCT02004236|noninvasive brain stimulation
187705|NCT02004236|tDCS
187706|NCT02004223|Prostate Cancer
187707|NCT02004223|Dose escalation
187708|NCT02004223|Stereotactic
187709|NCT02004223|SBRT
187710|NCT02004223|Hypofractionation
187711|NCT02004210|transarterial chemoembolization
187712|NCT02004210|transarterial radioembolization
187713|NCT02004210|advanced hepatocellular carcinoma
187714|NCT02004184|Pemetrexed
187715|NCT02004184|drug therapy
187716|NCT02004171|electronic cigarette
187717|NCT02004171|nicotine inhaler
187718|NCT02004171|smoking cessation
187719|NCT02004158|Acute coronary syndrome
187720|NCT02004158|Health behavior
187721|NCT02004158|Mental health
187722|NCT02004145|MDD
187723|NCT02004145|Positive Psychology
187724|NCT02004145|Suicidality
187725|NCT02004080|TBI
187726|NCT02004080|ICU
187727|NCT02004080|Comparative Effectiveness Research
187728|NCT02004067|Evaporative
187729|NCT02004067|Aqueous deficient
187730|NCT02004067|Dry eye disease
187731|NCT02004054|multiple sclerosis
187732|NCT02004054|diameter pupil
187733|NCT02004041|pruritus
187734|NCT02004041|atopic dermatitis
187735|NCT02004041|VLY-686
187736|NCT02004028|Mesothelioma
187737|NCT02004028|adenoma
187738|NCT02004028|Neoplasms, Mesothelial
187739|NCT02004028|Focal Adhesion Kinase Inhibitor
187740|NCT02004015|Analytical
187741|NCT02004015|Diagnostic
187742|NCT02004015|Anesthesia
187743|NCT02004015|Analgesia
187744|NCT02003976|knee osteoarthritis
187745|NCT02003976|high tibial osteotomy
187746|NCT02003976|gait analysis
187747|NCT02003976|muscular strength
187748|NCT02003976|body composition
187749|NCT02003976|magnetic resonance imaging
187750|NCT02003976|biological markers
187751|NCT02003963|Physical Activity
187752|NCT02003963|Sedentary Behavior
187753|NCT02003963|Video Games
187754|NCT02003963|Exergames
187755|NCT02003911|Asthma
187756|NCT02003911|Acute asthma exacerbation
187757|NCT02003911|Pediatric
187758|NCT02003911|Azithromycin
187759|NCT02003911|Macrolide
187760|NCT02003911|Length of Stay
187761|NCT02003911|Hospital Medicine
187762|NCT02003898|Diabetes
187763|NCT02003898|Insulin pump
187764|NCT02003898|Threshold Suspend
187765|NCT02003885|Desflurane, mitral annular velocity, tissue Doppler imaging
187766|NCT02003859|IBD
187767|NCT02003859|Pediatrics
187768|NCT02003859|pCLE
187769|NCT02003833|Poly-L-lactic acid
187770|NCT02003833|Sculptra Aesthetic
187771|NCT02003833|Skin Quality
187772|NCT02003833|Wrinkles
187773|NCT02003833|Filler
187774|NCT02003820|Autism
187775|NCT02003820|Dental Caries
187776|NCT02003820|Prevention
187777|NCT02003820|Oral Hygiene
187778|NCT02003794|acute ischemic stroke
187779|NCT02003794|intravenous fluid
187780|NCT02003794|้hydration
187781|NCT02003781|cardiovascular disease
187782|NCT02003781|metabolic disease
187783|NCT02003781|high risk
187784|NCT02003781|prospective cohort
187785|NCT02003768|pneumoperitoneum
187786|NCT02003768|optic nerve sheath diameter
187787|NCT02003768|laparoscopy
187788|NCT02003768|Patients
187789|NCT02003768|general anesthesia
187790|NCT02003768|diameter
187791|NCT02003755|Cerebral palsy
187792|NCT02003755|Continuous passive motion
187793|NCT02003755|Hypertonia
187794|NCT02003742|LUTS
187795|NCT02003742|BPH
187796|NCT02003729|obstructive sleep apnea
187797|NCT02003729|Portable Monitor
187798|NCT02003729|AHI
187799|NCT02003729|ESS
187800|NCT02003729|Cost effectiveness
187801|NCT02003703|Vaccine
187802|NCT02003703|Primary Prevention
187803|NCT02003703|Immunogenicity
187804|NCT02003690|Bipolar disorder
187805|NCT02003690|Adolescent suicidal behavior
187806|NCT02003690|Psychotherapy
187807|NCT02003664|Cocaine
187808|NCT02003664|Treatment
187809|NCT02003664|fMRI
187810|NCT02003664|Outcomes
187811|NCT02003651|Common cold
187812|NCT02003625|Non-Hodgkin's lymphoma
187813|NCT02003625|Hodgkin's lymphoma
187814|NCT02003625|Multiple myeloma
187815|NCT02003625|Hematopoietic stem cells
187816|NCT02003599|Radiodermatitis
187817|NCT02003599|Breast neoplasms
187818|NCT02003599|Laser Therapy, Low- Level
187819|NCT02003586|subjects
187820|NCT02003560|breast cancer
187821|NCT02003560|breast conserving therapy
187822|NCT02003560|accelerated partial breast irradiation
187823|NCT02003560|3D conformal radiotherapy
187824|NCT02003560|intensity modulated radiotherapy
187825|NCT02003521|Lung Flute
187826|NCT02003508|Prevalence
187827|NCT02003508|HPV
187828|NCT02003508|Human papillomavirus
187829|NCT02003508|Vaccination
187830|NCT02003495|Immunogenicity, Safety, Meningococcal Conjugate Vaccine
187831|NCT02003482|Head and Neck Cancer
187832|NCT02003482|Head and Neck Squamous Cell Carcinoma
187833|NCT02003482|Intensity modulated radiation therapy
187834|NCT02003482|IMRT
187835|NCT02003482|Anatomic Changes
187836|NCT02003482|Postoperative
187837|NCT02003482|Unresectable
187838|NCT02003469|hypertension
187839|NCT02003469|kidney disease
187840|NCT02003469|cardiovascular disease
187841|NCT02003456|positron emission tomography
187842|NCT02003456|rubidium
187843|NCT02003456|myocardial perfusion imaging
187844|NCT02003456|viability
187845|NCT02003456|FDG
187846|NCT02003443|Acupressure
187847|NCT02003443|Older Adults
187848|NCT02003443|Knee pain
187849|NCT02003443|Pain Treatment
187850|NCT02003430|gynecologic malignancy
187851|NCT02003430|non-ovarian gynecological cancer
187852|NCT02003430|cervical cancer
187853|NCT02003430|vaginal cancer
187854|NCT02003430|vulvar cancer
187855|NCT02003430|endometrial cancer
187856|NCT02003417|Prostate cancer
187857|NCT02003417|External beam radiation treatment
187858|NCT02003417|Androgen deprivation therapy
187859|NCT02003417|Definitive treatment
187860|NCT02003417|Cardiovascular risk factors
187861|NCT02003417|Quality of life
187862|NCT02003404|ostomy appliance
187863|NCT02003391|Open Angle Glaucoma
187864|NCT02003391|Ocular Hypertension
187865|NCT02003391|Intraocular Pressure
187866|NCT02003378|Chronotropic incompetence
187867|NCT02003365|osteoarthritis
187868|NCT02003365|knee
187869|NCT02003365|steroids
187870|NCT02003365|FX006
187871|NCT02003365|triamcinolone acetonide
187872|NCT02003365|synovial fluid
187873|NCT02003352|TBI
187874|NCT02003352|PTSD
187875|NCT02003352|Functional Neurology
187876|NCT02003352|Vestibular Rehabilitation
187877|NCT02003352|Dynamic Computerized Posturography
187878|NCT02003352|Saccadometry
187879|NCT02003313|safety, immunogenicity, Meningococcal Polysaccharide Vaccine
187880|NCT02003300|Oxygen uptake
187881|NCT02003300|Anesthetic gas uptake
187882|NCT02003287|Deglutition Disorders
187883|NCT02003287|Intensive Care Units, Neonatal
187884|NCT02003274|Mixed Meal Test
187885|NCT02003274|Insulin Pump
187886|NCT02003274|Continuous Glucose Monitoring
187887|NCT02003274|Metabolic Control Analysis
187888|NCT02003274|Closed Loop Control
187889|NCT02003274|Artificial Pancreas
187890|NCT02003248|Parkinson's disease
187891|NCT02003248|ultrasound
187892|NCT02003248|dyskinesia
187893|NCT02003248|magnetic resonance
187894|NCT02003235|Amblyopia
187895|NCT02003196|Brain injury
187896|NCT02003196|virus
187897|NCT02003196|immunosuppression
187898|NCT02003196|mechanical ventilation
187899|NCT02003183|CTE
187900|NCT02003183|TBI
187901|NCT02003183|Cognitive Impairment
187902|NCT02003183|Brain Imaging
187903|NCT02003183|PET
187904|NCT02003170|Autism
187905|NCT02003170|Autism Spectrum Disorder (ASD)
187906|NCT02003170|Pervasive Developmental Disorder (PDD)
187907|NCT02003170|Developmental delays
187908|NCT02003170|Genetic disorder
187909|NCT02003170|Mitochondrial disorder
187910|NCT02003157|hypnosis embryo transfer IVF ICSI
187911|NCT02003144|Long-term safety study
187912|NCT02003144|Extension trial
187913|NCT02003144|Eculizumab
187914|NCT02003144|Neuromyelitis Optica Spectrum Disorder
187915|NCT02003144|Devic's disease
187916|NCT02003144|Transverse Myelitis
187917|NCT02003144|Optic Neuritis
187918|NCT02003144|Relapse
187919|NCT02003144|NMO-IgG
187920|NCT02003144|CNS Autoimmune Disorders
187921|NCT02003144|Demyelinating Disorders
187922|NCT02003131|osteoarthritis
187923|NCT02003131|umbilical cord
187924|NCT02003131|mesenchymal
187925|NCT02003131|stem cells
187926|NCT02003131|trophic factors
187927|NCT02003092|solid tumor
187928|NCT02003092|Rexahn
187929|NCT02003092|Phase 1
187930|NCT02003066|Fluid Therapy
187931|NCT02003066|Head and Neck Neoplasms
187932|NCT02003066|Surgical Flaps
187933|NCT02003053|Critically ill
187934|NCT02003053|intubated
187935|NCT02003053|safety
187936|NCT02003053|feasibility
187937|NCT02003053|inspiratory muscle training
187938|NCT02003014|Drug Therapy
187939|NCT02002975|Drug Therapy
187940|NCT02002949|Hemodialysis
187941|NCT02002910|iFR
187942|NCT02002910|FFR
187943|NCT02002910|Medical Economy
187944|NCT02002910|physiological assessment
187945|NCT02002910|SYNTAX score
187946|NCT02002897|Localized scleroderma UVA1 fractional carbon dioxide laser
187947|NCT02002884|Upper limb spasticity
187948|NCT02002884|lower limb spasticity
187949|NCT02002884|combined upper and lower limb spasticity
187950|NCT02002858|smoking
187951|NCT02002858|cessation
187952|NCT02002858|anxiety
187953|NCT02002858|anxious
187954|NCT02002858|depression
187955|NCT02002858|depressed
187956|NCT02002858|smoker
187957|NCT02002858|stress
187958|NCT02002845|Tongue base resection, partial glossectomy
187959|NCT02002819|Alzheimer's disease
187960|NCT02002819|AD
187961|NCT02002819|Early-onset AD
187962|NCT02002819|EOAD
187963|NCT02002819|Early-onset Alzheimer's
187964|NCT02002819|Early-onset Alzheimer's disease
187965|NCT02002806|Pancreatic cancer
187966|NCT02002806|Pain
187967|NCT02002793|pancreatitis
187968|NCT02002793|early stage
187969|NCT02002793|mini-invasive abdominal drainage
187970|NCT02002780|pediatrics
187971|NCT02002780|stress
187972|NCT02002780|cardiac surgery
187973|NCT02002754|eosinophilic bronchitis
187974|NCT02002754|cough variant asthma
187975|NCT02002754|bronchodilator
187976|NCT02002741|patent ductus arteriosus
187977|NCT02002741|PDA
187978|NCT02002741|Preterm
187979|NCT02002741|Infant
187980|NCT02002741|Electrocardiography
187981|NCT02002741|Paracetamol
187982|NCT02002741|Acamol
187983|NCT02002741|ibuprofen
187984|NCT02002741|Placebo
187985|NCT02002715|eosinophilic bronchitis
187986|NCT02002715|inhaled corticosteroids
187987|NCT02002715|therapeutic effect
187988|NCT02002702|Acute heart failure (AHF),
187989|NCT02002702|Japanese,
187990|NCT02002702|Safety and tolerability, Pharmacokinetics,
187991|NCT02002702|Renal Impairment
187992|NCT02002689|Solid tumor malignancy,
187993|NCT02002689|hematologic malignancy,
187994|NCT02002689|mutation, translocations,
187995|NCT02002689|signature,
187996|NCT02002689|PTCH1,
187997|NCT02002689|SMO,
187998|NCT02002689|LDE225,
187999|NCT02002689|endometrial cancer,
188000|NCT02002689|colon cancer,
188001|NCT02002689|bladder,
188002|NCT02002689|NSCLC
188003|NCT02002676|rest energy expenditure,critical ill, outcome
188004|NCT02002650|Indomethacin, pancreatitis, ERCP
188005|NCT02002611|Lobeglitazone
188006|NCT02002611|Warfarin
188007|NCT02002611|Type 2 Diabetes Mellitus
188008|NCT02002611|Drug-Drug interaction
188009|NCT02002611|Phase 1
188010|NCT02002598|Newly diagnosed
188011|NCT02002598|multiple myeloma
188012|NCT02002598|myeloma
188013|NCT02002598|bendamustine
188014|NCT02002598|treanda
188015|NCT02002598|carfilzomib
188016|NCT02002598|dexamethasone
188017|NCT02002598|phase I
188018|NCT02002598|phase II
188019|NCT02002598|dose escalation
188020|NCT02002598|transplant
188021|NCT02002598|non-transplant, plasma cells
188022|NCT02002585|Renal protection
188023|NCT02002585|Renal sympathetic denervation
188024|NCT02002572|Facial Mimic Muscle
188025|NCT02002572|MRI
188026|NCT02002572|Segmentation
188027|NCT02002572|Three dimensional assessment
188028|NCT02002572|Motion capture
188029|NCT02002572|Movement analysis
188030|NCT02002572|Digital Image Correlation
188031|NCT02002546|Heart Attack
188032|NCT02002546|Myocardial Infarction
188033|NCT02002546|Angina
188034|NCT02002546|Chest Pain
188035|NCT02002520|Acute pain
188036|NCT02002520|Epigenetic
188037|NCT02002520|Dental pain
188038|NCT02002468|Risk Communication
188039|NCT02002468|Follow-up
188040|NCT02002468|Organisation of screening
188041|NCT02002455|FACBC
188042|NCT02002455|PET/CT
188043|NCT02002455|PET/MRI
188044|NCT02002455|Radical prostatectomy
188045|NCT02002455|Radiotherapy
188046|NCT02002442|Mouthwash
188047|NCT02002442|Chlorhexidine
188048|NCT02002442|cetylpyridinium chloride
188049|NCT02002442|Saline
188050|NCT02002442|Implants
188051|NCT02002442|Saliva Collection
188052|NCT02002429|Facet joint
188053|NCT02002429|Medial branch block
188054|NCT02002429|Radiofrequency denervation
188055|NCT02002429|Zygapophysial joint
188056|NCT02002429|Low back pain
188057|NCT02002416|C-met expression, gastric cancer, overall survival
188058|NCT02002403|Edema
188059|NCT02002403|Macular Edema
188060|NCT02002403|Retinal Diseases
188061|NCT02002403|Eye Diseases
188062|NCT02002403|Danazol
188063|NCT02002403|Estrogen Antagonists
188064|NCT02002403|Estrogen Receptor Modulators
188065|NCT02002403|Hormone Antagonists
188066|NCT02002403|Hormones, Hormone Substitutes, and Hormone Antagonists
188067|NCT02002403|Physiological Effects of Drugs
188068|NCT02002403|Pharmacologic Actions
188069|NCT02002390|Stroke,Fingolimod(FTY 720), treatment
188070|NCT02002377|Age Related Macular Degeneration, wet
188071|NCT02002377|aflibercept
188072|NCT02002364|tracheal intubation
188073|NCT02002338|pterygium surgery
188074|NCT02002338|refractive changes
188075|NCT02002338|surgical technique
188076|NCT02002312|Advanced Renal Cell Carcinoma
188077|NCT02002312|Clear Cell Renal Cell Carcinoma (ccRCC)
188078|NCT02002312|Lutetium-177
188079|NCT02002312|Lu-177
188080|NCT02002312|girentuximab
188081|NCT02002312|cG250
188082|NCT02002312|Monoclonal Antibody
188083|NCT02002299|colorectal cancer
188084|NCT02002299|surface
188085|NCT02002299|invasive front
188086|NCT02002299|tumor budding
188087|NCT02002286|HIV-infected immunological non-responders
188088|NCT02002286|Tripterygium Wilfordii Hook F
188089|NCT02002286|Immune activation
188090|NCT02002247|antioxidants
188091|NCT02002247|selenium
188092|NCT02002247|heart disease
188093|NCT02002247|cardiac surgery
188094|NCT02002247|perioperative
188095|NCT02002234|Hemicraniectomy, stroke, decompressive surgery, HeMMI
188096|NCT02002221|Diabetes Mellitus (DM) ,
188097|NCT02002221|diabetes,
188098|NCT02002221|noninsulin-dependent diabetes mellitus (NIDDM),
188099|NCT02002221|adult-onset diabetes,
188100|NCT02002221|high blood sugar,
188101|NCT02002221|T2DM
188102|NCT02002195|metastatic gastric cancer,
188103|NCT02002195|elderly,
188104|NCT02002195|folinic acid,
188105|NCT02002195|fluorouracil,
188106|NCT02002195|oxaliplatin,
188107|NCT02002195|capecitabine,
188108|NCT02002195|overall survival,
188109|NCT02002195|progression free survival
188110|NCT02002182|HPV
188111|NCT02002182|0ropharynx
188112|NCT02002182|squamous cell carcinoma
188113|NCT02002182|head and neck cancer
188114|NCT02002182|transoral robotic surgery
188115|NCT02002169|Catheter Related Bacteremia
188116|NCT02002143|Diabetes
188117|NCT02002143|Older People
188118|NCT02002143|Seniors
188119|NCT02002143|Group Appointments
188120|NCT02002143|Group Medical Visits
188121|NCT02002143|Shared Appointments
188122|NCT02002143|Quality of Life
188123|NCT02002143|Physical Activity
188124|NCT02002143|Health care Utilization
188125|NCT02002143|Depression
188126|NCT02002143|Anxiety
188127|NCT02002130|Diabetes
188128|NCT02002104|Expanded polytetrafluoroethylene( ePTFE)
188129|NCT02002091|Type2 diabetes mellitus
188130|NCT02002091|Microangiopathy
188131|NCT02002091|Chronic Kidney disease
188132|NCT02002091|Cardiovascular disease
188133|NCT02002078|caustic
188134|NCT02002078|corticosteroid therapy
188135|NCT02002078|stricture
188136|NCT02002078|children
188137|NCT02002065|hepatitis A
188138|NCT02002065|inactivated hepatitis A vaccine
188139|NCT02002065|attenuated alive hepatitis A vaccine
188140|NCT02002065|immune persistence
188141|NCT02002052|non-small cell lung cancer, radiotherapy, chemotherapy, pneumonitis, functional lung avoidance
188142|NCT02002039|Perinatal asphyxia
188143|NCT02002039|erythropoietin
188144|NCT02002026|placenta previa, uterine artery ligation
188145|NCT02002013|Adult
188146|NCT02002013|ICU patient
188147|NCT02002013|Fluid resuscitation
188148|NCT02002013|observational study
188149|NCT02002000|Vitamin D deficiency
188150|NCT02002000|Musculoskeletal pain
188151|NCT02002000|Vitamin D supplementation
188152|NCT02001974|HER 2 negative
188153|NCT02001974|metastatic breast cancer
188154|NCT02001974|Cancer Stem Cells
188155|NCT02001961|Fibrosis
188156|NCT02001961|collagen metabolism
188157|NCT02001961|paediatric, dilated cardiomyopathy
188158|NCT02001961|biomarkers
188159|NCT02001961|T1 mapping
188160|NCT02001961|MRI
188161|NCT02001948|Spinal anaesthesia
188162|NCT02001948|morphine
188163|NCT02001948|postoperative analgesia
188164|NCT02001948|vomiting
188165|NCT02001935|COPD
188166|NCT02001935|theophylline
188167|NCT02001935|CYP1A2
188168|NCT02001935|CYP2E1
188169|NCT02001922|COPD
188170|NCT02001922|Pulmonary disease, chronic obstructive
188171|NCT02001922|Integrated care
188172|NCT02001922|Outcome and process assessment
188173|NCT02001922|Quality indicators, Health care
188174|NCT02001922|Self-management,
188175|NCT02001922|Patient empowerment
188176|NCT02001922|Quantitative and qualitative methods
188177|NCT02001909|Regorafenib
188178|NCT02001909|Neomycin
188179|NCT02001909|Cancer
188180|NCT02001909|Pharmacokinetics
188181|NCT02001909|Safety
188182|NCT02001896|NSCLC
188183|NCT02001896|EGFR-TKI
188184|NCT02001883|Coronary artery disease, nutraceuticals, statins
188185|NCT02001870|Infertility
188186|NCT02001870|female age
188187|NCT02001870|intra-uterine insemination
188188|NCT02001870|in vitro fecundation
188189|NCT02001870|assisted reproductive technology center
188190|NCT02001857|patients,
188191|NCT02001857|undergoing
188192|NCT02001857|pelvic
188193|NCT02001857|lymph
188194|NCT02001857|node
188195|NCT02001857|dissection.
188196|NCT02001831|Sarcopenia
188197|NCT02001831|Frailty
188198|NCT02001831|Aging
188199|NCT02001831|Skeletal muscle
188200|NCT02001831|Nutrition
188201|NCT02001792|sedation
188202|NCT02001792|endoscopy
188203|NCT02001792|patient positioning
188204|NCT02001792|hypoxemia
188205|NCT02001779|Malignant biliary obstruction
188206|NCT02001779|Obstruction/stricture
188207|NCT02001779|Stent
188208|NCT02001779|Brachytherapy
188209|NCT02001779|Bile duct
188210|NCT02001766|High intensity exercise
188211|NCT02001766|Glycemic control
188212|NCT02001766|Exercise
188213|NCT02001740|shoulder
188214|NCT02001701|vitreomacular adhesion
188215|NCT02001701|vitreomacular traction
188216|NCT02001701|macular hole
188217|NCT02001701|epiretinal membrane
188218|NCT02001701|intravitreal gas
188219|NCT02001701|sulfahexafluoride gas
188220|NCT02001701|perfluoropropane gas
188221|NCT02001701|ocriplasmin
188222|NCT02001701|vitrectomy
188223|NCT02001675|Neuromuscular electrical stimulation (NMES)
188224|NCT02001662|Minor arthroscopic knee surgery including ACL-reconstruction (hamstrins graft)
188225|NCT02001662|High pain responders
188226|NCT02001662|Adductore Canal Block
188227|NCT02001662|Analgesics
188228|NCT02001662|Ultrasound guided nerve block
188229|NCT02001649|suicide
188230|NCT02001649|adolescent
188231|NCT02001649|genetic
188232|NCT02001649|SNP
188233|NCT02001636|Bariatric surgery
188234|NCT02001636|Protein malnutrition
188235|NCT02001636|Protein supplementation
188236|NCT02001636|Body composition
188237|NCT02001636|Body fat mass
188238|NCT02001636|Protein intake
188239|NCT02001623|ovary cancer
188240|NCT02001623|cervix cancer
188241|NCT02001623|endometrium cancer
188242|NCT02001623|bladder cancer
188243|NCT02001623|prostate cancer (CRPC)
188244|NCT02001623|esophagus cancer
188245|NCT02001623|lung cancer(NSCLC)
188246|NCT02001623|Squamous cell carcinoma of the head and neck (SCCHN)
188247|NCT02001610|microbiota
188248|NCT02001610|probiotics
188249|NCT02001610|fecal markers
188250|NCT02001597|surgery
188251|NCT02001597|robotic
188252|NCT02001597|ultrasound
188253|NCT02001597|guidance
188254|NCT02001597|endorectal
188255|NCT02001571|Prostate Cancer
188256|NCT02001571|Abiraterone acetate
188257|NCT02001571|Pharmacokinetics
188258|NCT02001558|Spinal cord injuries
188259|NCT02001558|Pressure ulcer
188260|NCT02001545|acute coronary syndrome, antithrombotic management patterns,quality of life, acute clinical management strategies
188261|NCT02001532|Diabetes Mellitus, Type 2
188262|NCT02001532|Diabetes Complications
188263|NCT02001532|Diabetic Angiopathies
188264|NCT02001532|Diabetic Nephropathies
188265|NCT02001532|Myocardial Infarction
188266|NCT02001532|Stroke
188267|NCT02001532|Vascular Stiffness
188268|NCT02001532|Pulse Wave Analysis
188269|NCT02001506|breast cancer
188270|NCT02001506|neoadjuvant
188271|NCT02001506|different number of chemotherapy cycles
188272|NCT02001441|Physical Activity, Aging, Memory, Cognitive Impairment, MRI, Neuroscience
188273|NCT02001428|malaria
188274|NCT02001428|vivax
188275|NCT02001428|falciparum
188276|NCT02001428|infants
188277|NCT02001415|Progressive Myopia
188278|NCT02001415|Contact Lenses
188279|NCT02001415|Spectacles
188280|NCT02001402|climacteric symptoms ; nurse ;
188281|NCT02001402|intervention;follow-up
188282|NCT02001389|Enzyme occupancy
188283|NCT02001389|Positron emission tomography (PET)
188284|NCT02001389|Phosphodiesterase 10 inhibitor
188285|NCT02001363|Reperfusion injury
188286|NCT02001363|Liraglutide
188287|NCT02001337|pancreatic cancer
188288|NCT02001337|new-onset diabetic
188289|NCT02001337|diabetes
188290|NCT02001324|quality of life, heavy menstrual bleeding, electronic data collection
188291|NCT02001311|chlorhexidine gel
188292|NCT02001311|orthodontic brackets
188293|NCT02001311|orthodontic patients
188294|NCT02001311|bacterial count
188295|NCT02001311|friction
188296|NCT02001298|remifentanil
188297|NCT02001298|nitroprusside
188298|NCT02001298|hypotension
188299|NCT02001285|remifentanil
188300|NCT02001272|Elderly
188301|NCT02001272|Vulnerable
188302|NCT02001272|Ovarian cancer
188303|NCT02001272|Chemotherapy
188304|NCT02001259|post-operative pain control
188305|NCT02001259|total knee arthroplasty
188306|NCT02001259|epidural steroid injection
188307|NCT02001246|mindfulness
188308|NCT02001246|cognitive behavior therapy
188309|NCT02001246|awareness
188310|NCT02001246|anger
188311|NCT02001246|aggression
188312|NCT02001233|EV71 vaccine
188313|NCT02001233|EV71-associated HFMD
188314|NCT02001233|efficacy
188315|NCT02001233|safety
188316|NCT02001233|immune persistence
188317|NCT02001220|screening
188318|NCT02001220|invasive ventilation
188319|NCT02001220|mechanical ventilation
188320|NCT02001220|weaning
188321|NCT02001220|spontaneous breathing trials
188322|NCT02001194|Sedentary
188323|NCT02001194|Behavioral Economic Intervention
188324|NCT02001194|Team Studies
188325|NCT02001194|Financial Incentives
188326|NCT02001194|Workplace Wellness
188327|NCT02001194|Team Incentives
188328|NCT02001181|Atopic Dermatitis
188329|NCT02001181|Atopic Eczema
188330|NCT02001181|Eczema
188331|NCT02001181|topical treatment
188332|NCT02001181|skin diseases
188333|NCT02001181|tofacitinib
188334|NCT02001181|CP-690
188335|NCT02001181|550
188336|NCT02001181|Janus Kinase inhibitor
188337|NCT02001155|Water drinking test
188338|NCT02001155|trabeculectomy
188339|NCT02001155|tube shunt
188340|NCT02001142|Insulin Sensitivity
188341|NCT02001142|Exercise
188342|NCT02001142|Metabolism
188343|NCT02001129|Eye care adherence
188344|NCT02001129|health care utilization
188345|NCT02001116|Quality of care
188346|NCT02001116|Hospital
188347|NCT02001116|Children
188348|NCT02001116|WHO guideline
188349|NCT02001103|adjuvant therapy
188350|NCT02001103|cognitive deficits
188351|NCT02001103|first episode schizophrenia
188352|NCT02001103|glutamate hypothesis
188353|NCT02001103|memantine
188354|NCT02001103|negative symptoms
188355|NCT02001090|Cardiac Surgical Procedures
188356|NCT02001090|Heart-Lung Machine
188357|NCT02001090|Coronary Artery Bypass
188358|NCT02001090|Brachial Artery
188359|NCT02001090|Vasodilation
188360|NCT02001090|Regional Blood Flow
188361|NCT02001090|Ultrasonography
188362|NCT02001064|interventions
188363|NCT02001064|technology
188364|NCT02001064|adherence
188365|NCT02001064|ARV
188366|NCT02001051|Unilateral Adrenal Neoplasm
188367|NCT02001051|Cushing Syndrome
188368|NCT02001051|Adrenal Incidentalomas
188369|NCT02001025|coronary vessels
188370|NCT02001025|coronary stenosis
188371|NCT02001025|percutaneous transluminal angioplasty
188372|NCT02001025|stents
188373|NCT02001025|drug-eluting stents
188374|NCT02001025|bioresorbable scaffolds
188375|NCT02001025|optical coherence tomography
188376|NCT02001012|uncomplicated
188377|NCT02001012|plasmodium
188378|NCT02001012|knowlesi
188379|NCT02001012|malaria
188380|NCT02001012|infection
188381|NCT02000999|Bile duct stricture
188382|NCT02000999|Cholangiocarcinoma
188383|NCT02000999|Pancreatic cancer
188384|NCT02000999|Chronic pancreatitis
188385|NCT02000986|Hodgkin's Lymphoma
188386|NCT02000986|Brain and Nervous System
188387|NCT02000986|Non-Hodgkin's Lymphoma
188388|NCT02000986|Leukemia, not otherwise specified
188389|NCT02000960|Glut1 DS
188390|NCT02000947|anti-CTLA-4
188391|NCT02000947|anti-PD-L1
188392|NCT02000947|immunotherapy
188393|NCT02000947|IMTC
188394|NCT02000934|TAK-659
188395|NCT02000934|Solid Tumors
188396|NCT02000934|CLL
188397|NCT02000934|DLBCL
188398|NCT02000921|Cigarette Smoking
188399|NCT02000921|Very Low Nicotine Content cigarettes (VLNC)
188400|NCT02000921|Dual Tobacco Use
188401|NCT02000908|gynecological cancer
188402|NCT02000908|ovarian cancer
188403|NCT02000908|primary peritoneal cancer
188404|NCT02000908|cervical caner
188405|NCT02000908|peripheral neuropathy
188406|NCT02000882|Breast Cancer
188407|NCT02000882|Triple Negative Breast Cancer
188408|NCT02000882|Brain Metastases
188409|NCT02000882|Capecitabine
188410|NCT02000882|Metastatic Breast Cancer
188411|NCT02000843|perforation
188412|NCT02000843|tympanoplasty
188413|NCT02000843|conchal cavum approach
188414|NCT02000843|perichondrium/ cartilage
188415|NCT02000843|scar
188416|NCT02000830|stannsoporfin
188417|NCT02000817|Beta Cell
188418|NCT02000817|Monoclonal Antibody
188419|NCT02000817|Otelixizumab
188420|NCT02000817|Cytokine Release Syndrome
188421|NCT02000817|Epstein-Barr Virus
188422|NCT02000817|Diabetes Mellitus
188423|NCT02000804|Darapladib, Safety, Pharmacokinetics, Pharmacodynamics, Healthy Chinese Subjects
188424|NCT02000791|cLMA
188425|NCT02000791|laryngoscopy
188426|NCT02000791|fiberoptic
188427|NCT02000778|Occult Ovarian Carcinoma
188428|NCT02000765|mass balance
188429|NCT02000765|[14C]-GSK2140944
188430|NCT02000765|radiolabel
188431|NCT02000765|oral
188432|NCT02000765|healthy volunteer
188433|NCT02000765|ADME
188434|NCT02000765|IV
188435|NCT02000765|antibiotic
188436|NCT02000752|Labor
188437|NCT02000752|Acupuncture
188438|NCT02000752|Placental expulsion time
188439|NCT02000752|Postpartum hemorrhage
188440|NCT02000739|Breast cancer
188441|NCT02000739|melanoma
188442|NCT02000739|GI cancer
188443|NCT02000739|ovarian cancer
188444|NCT02000739|lung cancer
188445|NCT02000739|metastatic cancer
188446|NCT02000739|brain cancer
188447|NCT02000739|head and neck cancer
188448|NCT02000700|Diabetes Mellitus, Type 2
188449|NCT02000700|Canagliflozin
188450|NCT02000700|JNJ-28431754
188451|NCT02000700|Pharmacokinetics
188452|NCT02000700|Pharmacodynamics
188453|NCT02000700|Children
188454|NCT02000700|Adolescents
188455|NCT02000674|tracheal intubation
188456|NCT02000674|pre hospital emergency
188457|NCT02000661|Fractional Flow Reserve (FFR)
188458|NCT02000661|FFR guided coronary interventions
188459|NCT02000661|Percutaneous Coronary Intervention
188460|NCT02000648|Allergic Rhinitis
188461|NCT02000648|Non-allergic Rhinitis
188462|NCT02000648|Chronic urticaria
188463|NCT02000622|Breast Cancer
188464|NCT02000622|Metastatic
188465|NCT02000622|Olaparib
188466|NCT02000622|BRCA
188467|NCT02000622|PARP inhibitor
188468|NCT02000622|HER2
188469|NCT02000622|chemotherapy
188470|NCT02000609|pharmacodynamics COPD
188471|NCT02000596|HER2 overexpressed
188472|NCT02000596|Metastatic Breast Cancer
188473|NCT02000596|Elderly
188474|NCT02000583|Alzheimer's Disease
188475|NCT02000583|AD
188476|NCT02000583|Aerobic Exercise
188477|NCT02000583|Exercise
188478|NCT02000570|sitting position
188479|NCT02000570|PPV
188480|NCT02000570|SVV
188481|NCT02000570|PVI
188482|NCT02000570|fluid challenge
188483|NCT02000570|preload indicators
188484|NCT02000557|Photographic analysis
188485|NCT02000557|Cephalometric analysis
188486|NCT02000557|Standardized photographs
188487|NCT02000557|Angular measurements
188488|NCT02000557|Linear measurements
188489|NCT02000557|Malocclusion
188490|NCT02000557|Facial Profile
188491|NCT02000544|Extracorporeal Circulation
188492|NCT02000544|Cardiopulmonary Bypass
188493|NCT02000544|Cardiac surgery
188494|NCT02000531|Non-small-cell lung cancer (NSCLC)
188495|NCT02000518|emergency radiotherapy
188496|NCT02000518|MSCC
188497|NCT02000518|spine
188498|NCT02000518|neurological outcome
188499|NCT02000466|Women
188500|NCT02000466|Pregnancy exposure
188501|NCT02000466|FluLaval Quadrivalent
188502|NCT02000466|Pregnancy outcome
188503|NCT02000466|Pregnancy Registry
188504|NCT02000453|Quality of Life
188505|NCT02000453|Infection
188506|NCT02000453|GSK2586184
188507|NCT02000453|ulcerative colitis
188508|NCT02000440|GW856553
188509|NCT02000440|Focal segmental glomerulosclerosis (FSGS)
188510|NCT02000440|p38 mitogen-activated protein kinase (MAPK) inhibitor
188511|NCT02000440|losmapimod
188512|NCT02000440|nephrotic syndrome
188513|NCT02000427|Relapsed; Refractory; Philadelphia Positive; B-precursor; Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;
188514|NCT02000414|intraperitoneal
188515|NCT02000414|peritoneal dialysis
188516|NCT02000414|daptomycin
188517|NCT02000414|pharmacokinetics
188518|NCT02000414|peritonitis
188519|NCT02000375|metastatic breastcancer
188520|NCT02000375|ER/PgR-negative/AR-positive
188521|NCT02000375|ER and/or PgR-positive/AR-positive
188522|NCT02000375|Androgen Receptor positve
188523|NCT02000362|Crohn's Disease
188524|NCT02000362|Stem cell
188525|NCT02000362|Cell therapy
188526|NCT02000362|Auto-immune disease
188527|NCT02000362|furestem
188528|NCT02000362|CD
188529|NCT02000362|inflammatory bowel disease
188530|NCT02000362|MSCs
188531|NCT02000362|Mesenchymal Stem Cells
188532|NCT02000362|hUCB-MSC
188533|NCT02000362|UCB-MSC
188534|NCT02000362|Umbilical cord Blood
188535|NCT02000349|infertility
188536|NCT02000349|next generation sequencing
188537|NCT02000336|radiographic damage
188538|NCT02000336|rheumatoid arthritis
188539|NCT02000323|pancreatitis
188540|NCT02000323|enteral nutrition
188541|NCT02000310|Gaucher disease
188542|NCT02000310|Fabry disease
188543|NCT02000310|Pompe disease
188544|NCT02000310|Niemann-Pick disease
188545|NCT02000297|Osteoarthritis
188546|NCT02000297|Knee
188547|NCT02000297|High tibial osteotomy
188548|NCT02000297|Calcium phosphate
188549|NCT02000297|Calcium sulfate
188550|NCT02000284|Autism Spectrum Disorder
188551|NCT02000284|ASD
188552|NCT02000284|Autism
188553|NCT02000284|Pervasive developmental disorder - Not Otherwise Specified
188554|NCT02000284|PDD-NOS
188555|NCT02000284|Asperger's Syndrome
188556|NCT02000284|Mitochondrial Disease
188557|NCT02000284|Developmental Delay
188558|NCT02000284|Typical Development
188559|NCT02000258|Anterior cruciate ligament reconstruction
188560|NCT02000258|Double-bundle
188561|NCT02000258|MRI
188562|NCT02000258|Graft location
188563|NCT02000245|bronchoscopy
188564|NCT02000245|anxiety
188565|NCT02000245|touch
188566|NCT02000245|sympathy
188567|NCT02000232|gout
188568|NCT02000232|colchicine
188569|NCT02000219|hyperoxaluria
188570|NCT02000219|oxalate
188571|NCT02000219|PH
188572|NCT02000219|dialysis
188573|NCT02000206|Ketamine
188574|NCT02000206|Alfentanil
188575|NCT02000206|Propofol
188576|NCT02000206|Oxygen saturation
188577|NCT02000206|Percutaneous carbon dioxide
188578|NCT02000206|Bronchoscopy
188579|NCT02000167|Electron Transport Chain
188580|NCT02000167|Mitochondrial Disease
188581|NCT02000167|Chromosomal Deletion
188582|NCT02000128|Peritoneal Dialysis
188583|NCT02000128|fluid overload
188584|NCT02000128|bioimpedance analysis
188585|NCT02000128|Randomized Controlled Trial
188586|NCT02000089|familial pancreas cancer
188587|NCT02000089|PJS
188588|NCT02000089|BRCA2
188589|NCT02000089|PALB2
188590|NCT02000089|FAMMM
188591|NCT02000089|p16
188592|NCT02000089|BRCA1
188593|NCT02000089|HNPCC
188594|NCT02000089|Lynch Syndrome
188595|NCT02000089|hereditary pancreatitis
188596|NCT02000089|PRSS
188597|NCT02000089|CTRC
188598|NCT02000089|ATM
188599|NCT02000076|Sleep
188600|NCT02000076|resting state
188601|NCT02000076|functional connectivity
188602|NCT02000076|emotional contagion
188603|NCT02000076|empathy
188604|NCT02000076|emotional regulation
188605|NCT02000063|Hepatitis C
188606|NCT02000063|acute
188607|NCT02000063|early chronic
188608|NCT02000050|resectable rectal cancer
188609|NCT02000050|up-front chemotherapy
188610|NCT02000050|neo-adjuvant short course radiotherapy
188611|NCT02000050|short course radiotherapy
188612|NCT02000011|patients
188613|NCT02000011|aged 70 years old
188614|NCT02000011|thoracic,
188615|NCT02000011|digestive or
188616|NCT02000011|urological
188617|NCT02000011|resectable
188618|NCT01999985|Epidermal Growth Factor Receptor (EGFR)
188619|NCT01999985|Tyrosine kinase inhibitors
188620|NCT01999985|Neoplasms
188621|NCT01999985|Lung Diseases
188622|NCT01999985|Respiratory Tract Diseases
188623|NCT01999985|Pleural Diseases
188624|NCT01999985|Pleural Neoplasms
188625|NCT01999985|Lung Neoplasms
188626|NCT01999985|Pleural Effusion
188627|NCT01999985|Pleural Effusion, Malignant
188628|NCT01999985|Respiratory Tract Neoplasms
188629|NCT01999985|Thoracic Neoplasms
188630|NCT01999985|Neoplasms by Site
188631|NCT01999985|EGFR mutation
188632|NCT01999985|Afatinib
188633|NCT01999985|Dasatinib
188634|NCT01999985|Carcinoma, Bronchogenic
188635|NCT01999985|Gene Mutation
188636|NCT01999985|T790M mutation.
188637|NCT01999985|Non-small cell lung cancer
188638|NCT01999972|Carcinoma
188639|NCT01999972|Renal Cell
188640|NCT01999959|Unexplained Infertility, Pertubation, Gonadotrophin, Ovulation Induction, Intrauterine Insemination
188641|NCT01999946|Heroin Dependence
188642|NCT01999946|Opioid-Related Disorders
188643|NCT01999933|Cervical cancer
188644|NCT01999933|postoperative risk factor
188645|NCT01999933|treatment
188646|NCT01999920|Adult separation anxiety disorder
188647|NCT01999920|ASAD
188648|NCT01999907|asthma
188649|NCT01999907|virus diseases
188650|NCT01999907|pediatric
188651|NCT01999907|RCT
188652|NCT01999907|steroid
188653|NCT01999894|Namenda
188654|NCT01999894|Autism
188655|NCT01999894|Memantine
188656|NCT01999894|Pediatric
188657|NCT01999894|Forest Laboratories
188658|NCT01999868|psoriasis vulgaris
188659|NCT01999868|ustekinumab
188660|NCT01999868|abatacept
188661|NCT01999842|Adults
188662|NCT01999842|Adjuvant
188663|NCT01999842|H7N9
188664|NCT01999842|Influenza
188665|NCT01999842|Safety
188666|NCT01999842|Immunogenicity
188667|NCT01999816|pressure ulcer
188668|NCT01999816|lifestyle redesign
188669|NCT01999816|spinal cord injury
188670|NCT01999790|upper lid
188671|NCT01999790|exophthalmos
188672|NCT01999790|grave's orbitopathy
188673|NCT01999777|Epilepsy
188674|NCT01999777|seizure clusters
188675|NCT01999777|acute repetitive seizures
188676|NCT01999777|rescue treatment
188677|NCT01999751|Magnetic Resonance Imaging
188678|NCT01999751|Pacemaker, Artificial
188679|NCT01999751|Defibrillators, Implantable
188680|NCT01999725|Normal Volunteers, Safety, Pharmacokinetics
188681|NCT01999712|heart failure
188682|NCT01999712|left ventricular assist device
188683|NCT01999712|right ventricular failure
188684|NCT01999699|Heplisav
188685|NCT01999686|Polycystic ovarium syndrome
188686|NCT01999686|DLBS3233
188687|NCT01999686|metformin
188688|NCT01999686|insulin resistance
188689|NCT01999686|Female
188690|NCT01999673|SUNRISE
188691|NCT01999673|PPHM 1202
188692|NCT01999673|Bavituximab
188693|NCT01999673|Peregrine
188694|NCT01999660|Prostatic Neoplasms
188695|NCT01999660|Radiotherapy
188696|NCT01999660|rectal toxicity
188697|NCT01999647|Lower Extremity
188698|NCT01999647|Sciatic Nerve
188699|NCT01999647|Anesthetics, Local
188700|NCT01999647|Ropivacaine
188701|NCT01999647|Ultrasonography
188702|NCT01999634|rectum
188703|NCT01999634|microdialysis
188704|NCT01999634|anastomotic leaks
188705|NCT01999621|organ failure
188706|NCT01999621|intensive care
188707|NCT01999621|palliative care
188708|NCT01999621|patient's wishes
188709|NCT01999608|Infertility
188710|NCT01999595|transcutaneous electrical nerve stimulation
188711|NCT01999595|pad size
188712|NCT01999595|pulse frequency
188713|NCT01999595|blunt pressure pain
188714|NCT01999595|healthy humans.
188715|NCT01999582|Anemia
188716|NCT01999582|End Stage Kidney Disease
188717|NCT01999582|Chronic Kidney Disease
188718|NCT01999582|Dialysis
188719|NCT01999582|Erythrpoietin Stimulating Agent (ESA)
188720|NCT01999543|Blood glucose
188721|NCT01999530|prazosin
188722|NCT01999530|dopamine
188723|NCT01999530|healthy
188724|NCT01999530|Positron Emission Tomography
188725|NCT01999530|PHNO
188726|NCT01999530|scan
188727|NCT01999530|effect
188728|NCT01999504|Glucagon-like peptide-1
188729|NCT01999504|Glucose-dependent Insulinotropic Peptide
188730|NCT01999504|Peptide YY
188731|NCT01999504|Glucagon
188732|NCT01999504|Satiety
188733|NCT01999504|Meal
188734|NCT01999504|palaeolithic
188735|NCT01999491|Advanced Cancers
188736|NCT01999491|Lymphoma
188737|NCT01999491|Advanced Solid Tumors
188738|NCT01999491|NC-4016
188739|NCT01999465|Brachial plexus injury
188740|NCT01999465|Brachial plexus palsy
188741|NCT01999465|Neonate
188742|NCT01999452|Paleolithic diet
188743|NCT01999426|Physical Therapy Modalities
188744|NCT01999426|Pediatrics
188745|NCT01999426|Critical Care
188746|NCT01999426|Respiration, Artificial
188747|NCT01999413|AML
188748|NCT01999413|high-risk cytogenetics
188749|NCT01999413|younger patients
188750|NCT01999413|Induction treatment
188751|NCT01999413|OMEGAVEN
188752|NCT01999387|food
188753|NCT01999387|consumption
188754|NCT01999309|Schizophrenia spectrum disorders
188755|NCT01999283|Cervical pain
188756|NCT01999283|yoga
188757|NCT01999283|pilates
188758|NCT01999283|exercise
188759|NCT01999257|Genetic Counseling
188760|NCT01999257|Technology
188761|NCT01999257|Ashkenazi Jewish
188762|NCT01999257|Carrier screening
188763|NCT01999244|Overweight
188764|NCT01999244|Obesity
188765|NCT01999244|Weight Loss
188766|NCT01999244|Self-monitoring
188767|NCT01999244|Food Records
188768|NCT01999244|Self-weighing
188769|NCT01999244|Technology
188770|NCT01999231|Safety
188771|NCT01999231|Tolerability
188772|NCT01999231|ESAT6
188773|NCT01999231|CFP10
188774|NCT01999231|skin test
188775|NCT01999231|diagnostic test
188776|NCT01999205|workplace
188777|NCT01999205|intervention
188778|NCT01999205|physical activity
188779|NCT01999205|sedentary behavior
188780|NCT01999205|evaluation
188781|NCT01999192|inadequate response to MTX
188782|NCT01999192|Methotrexate
188783|NCT01999192|rheumatoid Arthritis
188784|NCT01999192|Phase 2b
188785|NCT01999179|catheter related thrombosis
188786|NCT01999179|upper extremity deep venous thrombosis
188787|NCT01999179|central venous catheters
188788|NCT01999179|cancer
188789|NCT01999179|Catheters
188790|NCT01999153|skin graft
188791|NCT01999153|donor site
188792|NCT01999114|Healthy subjects
188793|NCT01999114|Opioid
188794|NCT01999114|Transdermal
188795|NCT01999114|ECG
188796|NCT01999088|Fatty Acids, Omega-3
188797|NCT01999088|Rosemary extract
188798|NCT01999088|Functional meat
188799|NCT01999088|Cardiovascular disease
188800|NCT01999075|Duchenne Muscular Dystrophy
188801|NCT01999075|Pulmonary complications
188802|NCT01999075|Lung volume recruitment,
188803|NCT01999075|Breath-stacking,
188804|NCT01999075|Cough efficacy,
188805|NCT01999075|Maximal insufflation capacity
188806|NCT01999062|Breast RT
188807|NCT01999062|Breast radiation therapy
188808|NCT01999036|cardiac arrest, CPR, resuscitation
188809|NCT01999010|psychiatry
188810|NCT01999010|mental health
188811|NCT01999010|major depressive disorder
188812|NCT01999010|self-management
188813|NCT01999010|data visualization
188814|NCT01999010|mood diaries
188815|NCT01999010|electronic diaries
188816|NCT01999010|cell phones
188817|NCT01999010|software
188818|NCT01999010|mental health telemetry
188819|NCT01999010|ecological momentary assessment
188820|NCT01998997|Delirium
188821|NCT01998997|Hospitalized elderly
188822|NCT01998971|Multiple myeloma
188823|NCT01998971|Daratumumab
188824|NCT01998971|JNJ-54767414
188825|NCT01998971|Velcade-dexamethasone
188826|NCT01998971|Velcade-melphalan-prednisone
188827|NCT01998971|Velcade-thalidomide-dexamethasone
188828|NCT01998971|Pomalidomide-dexamethasone
188829|NCT01998971|Carfilzomib-dexamethasone
188830|NCT01998971|Carfilzomib-lenalidomide-dexamethasone
188831|NCT01998971|Anti-CD38 Monoclonal Antibody
188832|NCT01998971|Immunomodulatory drug
188833|NCT01998971|IMiD
188834|NCT01998958|Treatment resistant depressive disorder
188835|NCT01998958|Intranasal esketamine
188836|NCT01998958|Efficacy
188837|NCT01998958|SYNAPSE
188838|NCT01998958|JNJ-54135419
188839|NCT01998945|Exposure therapy
188840|NCT01998945|Cognitive behavioral therapy
188841|NCT01998945|Relaxation Training
188842|NCT01998945|Older Adults
188843|NCT01998945|Fall Injury
188844|NCT01998945|Anxiety
188845|NCT01998945|Posttraumatic Stress
188846|NCT01998932|Venous Ulcer
188847|NCT01998932|Leg Ulcer
188848|NCT01998932|Metabonomics
188849|NCT01998932|Ulcer Fluid
188850|NCT01998854|Menorrhagia
188851|NCT01998854|Leiomyoma
188852|NCT01998854|Uterine Fibroids
188853|NCT01998828|Polycythemia
188854|NCT01998828|Polycythemia Vera
188855|NCT01998828|Essential Thrombocythemia
188856|NCT01998828|Thrombocytosis
188857|NCT01998828|Myeloproliferative Disorders
188858|NCT01998828|Bone Marrow Diseases
188859|NCT01998828|Hematologic Diseases
188860|NCT01998828|Blood Coagulation Disorders
188861|NCT01998828|Blood Platelet Disorders
188862|NCT01998828|Hemorrhagic Disorders
188863|NCT01998789|Liver Transplantation
188864|NCT01998789|Everolimus
188865|NCT01998789|Immunosuppression
188866|NCT01998776|ulcer
188867|NCT01998763|Vitamin D3 supplementation
188868|NCT01998763|metabolite profile
188869|NCT01998763|SNPs
188870|NCT01998763|bone-turnover marker
188871|NCT01998750|obesity
188872|NCT01998750|genetics
188873|NCT01998750|early-onset
188874|NCT01998750|childhood
188875|NCT01998737|Osteoporosis, diagnostics, ultrasound
188876|NCT01998724|Chronic bronchitis
188877|NCT01998724|Emphysema
188878|NCT01998724|Pulmonary
188879|NCT01998724|COPD
188880|NCT01998711|Alzheimer's disease
188881|NCT01998711|Mild cognitive impairment
188882|NCT01998711|Memory intervention
188883|NCT01998711|Strategy use
188884|NCT01998711|Memory group
188885|NCT01998698|cataract
188886|NCT01998698|phacoemulsification
188887|NCT01998698|monovision
188888|NCT01998698|multifocal lens
188889|NCT01998685|Prostatectomy
188890|NCT01998685|Coagulation Factor
188891|NCT01998685|Balanced Anesthesia
188892|NCT01998685|Intravenous Anesthesia,
188893|NCT01998646|ASP4058
188894|NCT01998646|healthy subjects
188895|NCT01998633|Hemophagocytic lymphohistiocytosis
188896|NCT01998633|Chronic Active EBV
188897|NCT01998633|Chronic Granulomatous Disease
188898|NCT01998633|Hyperimmunoglobulin M Syndrome (Hyper IGM)
188899|NCT01998633|Leukocyte Adhesion Deficiency
188900|NCT01998633|IPEX
188901|NCT01998633|Hematopoietic Stem Cell Transplant (HSCT)
188902|NCT01998633|Non-Myeloablative Transplant (NST)
188903|NCT01998633|Reduced-Intensity Conditioning (RIC)
188904|NCT01998620|Hepatitis B
188905|NCT01998620|Cholestasis
188906|NCT01998607|Solid tumours
188907|NCT01998607|Bone Metastasis
188908|NCT01998594|Thumb arthritis
188909|NCT01998594|CMC arthritis
188910|NCT01998594|Arthroplasty
188911|NCT01998568|Intraocular pressure
188912|NCT01998568|Corneal edema
188913|NCT01998568|Tonometer
188914|NCT01998568|Dynamic contour tonometer
188915|NCT01998568|Tonopen
188916|NCT01998568|iCare
188917|NCT01998568|Goldmann applanation
188918|NCT01998542|Head and neck cancers
188919|NCT01998542|tumor vaccine
188920|NCT01998542|immunotherapy
188921|NCT01998542|personalized anti-cancer vaccine
188922|NCT01998529|Lung Cancer
188923|NCT01998529|Unilateral Pleural Malignancy
188924|NCT01998529|Metastatic active pleural malignancy
188925|NCT01998529|Lung tumors
188926|NCT01998529|Sarcomas
188927|NCT01998529|Cytoreductive Surgery
188928|NCT01998529|Hyperthermic Intrathoracic Pleural Chemotherapy
188929|NCT01998529|HITC
188930|NCT01998529|Cisplatin
188931|NCT01998529|Platinol-AQ
188932|NCT01998529|Platinol
188933|NCT01998529|CDDP
188934|NCT01998529|Amifostine
188935|NCT01998529|Ethyol
188936|NCT01998529|Ethiofos
188937|NCT01998529|Gammaphos
188938|NCT01998516|Emotional Intelligence
188939|NCT01998503|AL amyloidosis
188940|NCT01998503|bortezomib
188941|NCT01998503|autologous stem cell transplantation
188942|NCT01998477|Influenza
188943|NCT01998477|Vaccine
188944|NCT01998477|Flu
188945|NCT01998477|Children
188946|NCT01998477|Adolescents
188947|NCT01998464|Retinal Vasculitis
188948|NCT01998464|Optical coherence tomography
188949|NCT01998464|OCT
188950|NCT01998464|Imaging
188951|NCT01998451|double sphincter in gallbladder
188952|NCT01998451|recurrence rate of gallstones
188953|NCT01998438|tranexamic acid
188954|NCT01998438|cardiac surgery
188955|NCT01998438|cardiopulmonary bypass
188956|NCT01998425|circulating fibrocytes
188957|NCT01998425|fibrocyte
188958|NCT01998425|NSCLC
188959|NCT01998425|treatment response
188960|NCT01998425|survival
188961|NCT01998425|stage
188962|NCT01998399|CAP
188963|NCT01998399|Pneumonia
188964|NCT01998399|Intensive Care Unit
188965|NCT01998399|Mechanical Ventilation
188966|NCT01998386|Tooth Whitening
188967|NCT01998386|Adolescent
188968|NCT01998386|Clinical Trial
188969|NCT01998373|Patient training
188970|NCT01998373|Rheumatoid arthritis
188971|NCT01998373|Quality of life
188972|NCT01998360|Circumcision
188973|NCT01998360|Voluntary medical male circumcision
188974|NCT01998360|Minimally-invasive
188975|NCT01998360|HIV prevention
188976|NCT01998334|Systemic Inflammatory Response Syndrome
188977|NCT01998334|Continuous Blood Purification
188978|NCT01998321|PSI: Patient Specific Instrument
188979|NCT01998321|TKA: Total Knee Arthroplasty
188980|NCT01998321|Articular Deformity
188981|NCT01998321|Varus
188982|NCT01998295|Clearance time
188983|NCT01998295|Recurrence time
188984|NCT01998295|Artemether/lumefantrine
188985|NCT01998295|P. falciparum
188986|NCT01998295|Uncomplicated malaria
188987|NCT01998295|Children
188988|NCT01998282|Focus of study is to assess filter/stove use and efficacy in reducing exposure to waterborne and airborne pathogens.
188989|NCT01998256|AV optimization
188990|NCT01998256|Interatrial conduction delay
188991|NCT01998243|morbid obesity
188992|NCT01998243|bioenterics intragastric balloon
188993|NCT01998243|bariatric surgery
188994|NCT01998230|esophageal cancer
188995|NCT01998230|esophagectomy
188996|NCT01998230|oral feeding
188997|NCT01998217|extracorporeal shock wave lithotripsy
188998|NCT01998217|remifentanil
188999|NCT01998217|flurbiprofen
189000|NCT01998217|pancreatic stone
189001|NCT01998204|Parkinson's disease
189002|NCT01998204|propofol
189003|NCT01998204|deep brain stimulator
189004|NCT01998191|mortality
189005|NCT01998191|adverse events
189006|NCT01998165|Anesthesia
189007|NCT01998165|Remifentanil
189008|NCT01998165|Ultiva
189009|NCT01998113|gestational diabetes mellitus
189010|NCT01998113|glyburide
189011|NCT01998113|metformin
189012|NCT01998113|oral agents
189013|NCT01998113|insulin
189014|NCT01998113|outcomes
189015|NCT01998100|PTSD
189016|NCT01998100|Anxiety
189017|NCT01998100|Behavior Therapy
189018|NCT01998100|Prolonged Exposure
189019|NCT01998100|Exercise
189020|NCT01998100|Wellness
189021|NCT01998100|Post-traumatic
189022|NCT01998100|Stress
189023|NCT01998087|Exclusive breastfeeding
189024|NCT01998087|Breastfeeding
189025|NCT01998087|Proactive breastfeeding support
189026|NCT01998087|Telephone breastfeeding support
189027|NCT01998087|Infant feeding attitudes
189028|NCT01998087|Breastfeeding self-efficacy
189029|NCT01998087|Breastfeeding difficulties
189030|NCT01998074|Cow's Milk protein Allergy
189031|NCT01998048|surgical treatment
189032|NCT01998048|Bankart
189033|NCT01998048|Latarjet
189034|NCT01998048|redislocation
189035|NCT01998035|Lymphoid Malignancies
189036|NCT01998035|Lymphoma
189037|NCT01998035|Hodgkin Lymphoma
189038|NCT01998035|Non-hodgkin Lymphoma
189039|NCT01998035|Follicular Lymphoma
189040|NCT01998035|Diffuse Large B-Cell Lymphoma
189041|NCT01998035|Anaplastic Large Cell Lymphoma
189042|NCT01998035|Chronic Lymphocytic Leukemia
189043|NCT01998035|Small Lymphocytic Lymphoma
189044|NCT01998035|Mantle Cell Lymphoma
189045|NCT01998035|Marginal Zone Lymphoma
189046|NCT01998035|Burkitt Lymphoma
189047|NCT01998035|Waldenstrom Macroglobulinemia
189048|NCT01998035|Peripheral T-cell Lymphoma
189049|NCT01998035|Cutaneous T-cell Lymphoma
189050|NCT01998022|hypertension
189051|NCT01998022|knowledge
189052|NCT01998022|blood pressure control
189053|NCT01998009|colorectal cancer
189054|NCT01998009|mass screening
189055|NCT01998009|fecal occult blood
189056|NCT01997996|Pelvic Organ Prolapse
189057|NCT01997996|PROLIFT+M
189058|NCT01997996|Vita sexualis
189059|NCT01997983|interstitial cystitis
189060|NCT01997983|PBS/IC
189061|NCT01997983|IC
189062|NCT01997983|Botox
189063|NCT01997983|Botulinum toxin
189064|NCT01997983|TC-3 Gel
189065|NCT01997983|TCGel
189066|NCT01997983|TheraCoat
189067|NCT01997970|NEAT
189068|NCT01997970|Treadmill desk
189069|NCT01997957|Hepatocellular Carcinoma
189070|NCT01997957|Transarterial Chemoembolization
189071|NCT01997957|Hepatic Arterial Infusion Chemotherapy
189072|NCT01997957|Efficacy
189073|NCT01997931|bispectral index
189074|NCT01997931|sedation
189075|NCT01997931|intensive care
189076|NCT01997931|mechanical ventilation
189077|NCT01997918|Secondary allogeneic HSCT
189078|NCT01997918|Haploidentical HSCT
189079|NCT01997905|Left Atrial Appendage
189080|NCT01997905|LAA
189081|NCT01997905|Atrial Fibrillation
189082|NCT01997905|AFib
189083|NCT01997905|AF
189084|NCT01997905|IRB approved
189085|NCT01997905|clinical
189086|NCT01997905|Stroke
189087|NCT01997905|TIA
189088|NCT01997905|contraindication to oral anticoagulation therapy
189089|NCT01997905|Arrhythmias, Cardiac
189090|NCT01997905|OAC
189091|NCT01997905|trial
189092|NCT01997905|study
189093|NCT01997905|LAA occlusion
189094|NCT01997905|occluded
189095|NCT01997905|prevent
189096|NCT01997892|CKD
189097|NCT01997892|Darbepoetin Alfa
189098|NCT01997892|Dialysis
189099|NCT01997892|Hemodialysis
189100|NCT01997892|Anemia
189101|NCT01997892|Peg epoetin beta
189102|NCT01997866|Obstructive Sleep Apnea
189103|NCT01997866|Sleep Apnea
189104|NCT01997866|Congestive Heart Failure
189105|NCT01997866|Heart Failure
189106|NCT01997853|Omega 3 fatty acids
189107|NCT01997853|C Reactive Protein
189108|NCT01997853|Host Modulation
189109|NCT01997853|Chronic Periodontitis
189110|NCT01997840|Multiple Myeloma
189111|NCT01997840|Neoplasms, Plasma Cell
189112|NCT01997840|Neoplasms by Histologic Type
189113|NCT01997840|Neoplasms
189114|NCT01997840|Blood Protein Disorders
189115|NCT01997840|Hematologic Diseases
189116|NCT01997840|Dexamethasone
189117|NCT01997840|Dexamethasone acetate
189118|NCT01997840|Pomalidomide
189119|NCT01997814|Herbal medicine,
189120|NCT01997814|Host modulation therapy,
189121|NCT01997814|Periodontitis,
189122|NCT01997814|Meta-analysis,
189123|NCT01997814|Scaling and root planing.
189124|NCT01997801|Thyroidectomy
189125|NCT01997801|Endoscopy
189126|NCT01997801|Ketamine
189127|NCT01997801|Acute Pain
189128|NCT01997801|Chronic Pain
189129|NCT01997801|Postoperative period
189130|NCT01997788|Injection, Spinal
189131|NCT01997788|Morphine
189132|NCT01997788|Analgesia
189133|NCT01997788|Patient-Controlled
189134|NCT01997788|Pain
189135|NCT01997788|Postoperative
189136|NCT01997788|Combined Modality Therapy
189137|NCT01997788|Nephrectomy
189138|NCT01997775|IL-6
189139|NCT01997775|Metformin
189140|NCT01997775|Non-small cell lung cancer
189141|NCT01997775|Lung adenocarcinoma
189142|NCT01997762|resveratrol,
189143|NCT01997762|gestational diabetes,
189144|NCT01997762|beta cell function
189145|NCT01997762|history
189146|NCT01997749|stroke, ketogenic diet, ketosis, ischemia, brain, ketones, hyperglycemia, neuroprotection
189147|NCT01997736|Paroxysmal Atrial Fibrillation
189148|NCT01997736|Catheter Ablation
189149|NCT01997736|Ablation Techniques
189150|NCT01997723|OSA, portable monitoring, home diagnosis
189151|NCT01997684|Colorectal Cancer
189152|NCT01997684|Colonic Obstruction
189153|NCT01997671|Primary Care
189154|NCT01997671|Lipid-lowering therapy
189155|NCT01997671|Prescription
189156|NCT01997671|Adequacy
189157|NCT01997671|Primary prevention
189158|NCT01997671|Cardiovascular diseases
189159|NCT01997671|Electronic Medical records
189160|NCT01997671|Clinical Practice Guideline
189161|NCT01997658|Glucocorticoids
189162|NCT01997658|Total complication rate
189163|NCT01997658|Hepatectomy.
189164|NCT01997645|Anal fistula
189165|NCT01997645|Rectal fistula
189166|NCT01997645|Intersphincteric fistula
189167|NCT01997645|Perianal fistula
189168|NCT01997632|Poliomyelitis
189169|NCT01997632|Vaccine
189170|NCT01997619|biological mesh
189171|NCT01997619|contaminated hernia
189172|NCT01997619|abdominal wall reconstruction
189173|NCT01997593|analgesia
189174|NCT01997593|pediatric
189175|NCT01997593|pain
189176|NCT01997593|laparoscopy
189177|NCT01997593|ropivacaine
189178|NCT01997580|depression
189179|NCT01997580|treatment
189180|NCT01997580|electrophysiology
189181|NCT01997580|biomarker
189182|NCT01997567|Hip Arthroscopy
189183|NCT01997567|Regional Anesthesia
189184|NCT01997567|Peripheral Nerve block
189185|NCT01997554|TSH Testing
189186|NCT01997554|sub-clinical hypothyroidism
189187|NCT01997515|QOR-40
189188|NCT01997515|Pain
189189|NCT01997515|Hypoxia
189190|NCT01997515|Gastric Surgery
189191|NCT01997515|Obesity
189192|NCT01997515|Ketamine
189193|NCT01997502|Hemoglobin
189194|NCT01997502|Non-invasive
189195|NCT01997489|Eye
189196|NCT01997489|Fabry
189197|NCT01997489|vessels
189198|NCT01997476|Combined Endoscopic Ultrasound Morphologic Evaluation.
189199|NCT01997450|Q/LAIV/FluMist® Quadrivalent Vaccine, Inactivated Influenza Vaccine (IIV), Effectiveness, Influenza
189200|NCT01997437|Tissue-engineered tracheal transplantation
189201|NCT01997411|Diabetes Mellitus
189202|NCT01997411|Glucagon
189203|NCT01997398|Deep brain stimulation surgery under general anesthesia
189204|NCT01997398|Deep brain stimulation target accuracy
189205|NCT01997398|Deep brain stimulation for Parkinsons's disease
189206|NCT01997398|Deep brain stimulation functional outcomes
189207|NCT01997398|Deep brain stimulation quality of life outcomes
189208|NCT01997385|adapted APD
189209|NCT01997385|dwell time
189210|NCT01997385|fill volume
189211|NCT01997372|ATG
189212|NCT01997372|SAA
189213|NCT01997372|immunosuppressive treatment
189214|NCT01997372|cyclosporine
189215|NCT01997359|ART initiation
189216|NCT01997359|HIV
189217|NCT01997359|AIDS
189218|NCT01997359|Ethiopia
189219|NCT01997346|ART initiation
189220|NCT01997346|Ethiopia
189221|NCT01997346|Clinic observation
189222|NCT01997346|VCT observation
189223|NCT01997333|Metastatic Breast Cancer
189224|NCT01997333|Locally advanced breast cancer
189225|NCT01997333|Breast cancer
189226|NCT01997333|Triple negative
189227|NCT01997333|Estrogen
189228|NCT01997333|Progesterone
189229|NCT01997333|HER2 receptors
189230|NCT01997333|Targeted treatment for breast cancer
189231|NCT01997333|Antibody-drug-conjugate
189232|NCT01997333|Breast Neoplasms
189233|NCT01997333|CDX-011
189234|NCT01997333|gpNMB
189235|NCT01997333|METRIC
189236|NCT01997333|Glembatumumab vedotin
189237|NCT01997333|Triple Negative Breast Cancer
189238|NCT01997333|TNBC
189239|NCT01997320|Sarcopenia
189240|NCT01997320|Frailty
189241|NCT01997320|Strength
189242|NCT01997320|Protein supplementation
189243|NCT01997320|Ageing
189244|NCT01997307|acute coronary syndrome, coronary arteriography, menopause
189245|NCT01997294|sequential therapy
189246|NCT01997294|atorvastatin
189247|NCT01997294|acute myocardial infarction
189248|NCT01997281|dietary fiber
189249|NCT01997281|diabetes mellitus
189250|NCT01997281|gut hormone
189251|NCT01997268|Dyslipidemia
189252|NCT01997268|Hyperlipidemia
189253|NCT01997268|Omega-3 Fatty Acids
189254|NCT01997268|Metabolic Diseases
189255|NCT01997268|TG ≥500 mg/dL and ≤ 2,000 mg/dL
189256|NCT01997255|Everolimus
189257|NCT01997255|Epilepsy
189258|NCT01997255|Sturge Weber Syndrome
189259|NCT01997255|Port wine stain
189260|NCT01997255|Glaucoma
189261|NCT01997242|CORONARY STENT
189262|NCT01997242|CARDIAC SURGERY
189263|NCT01997242|NON CARDIAC SURGEY
189264|NCT01997229|Myasthenia Gravis
189265|NCT01997229|Eculizumab
189266|NCT01997229|safety
189267|NCT01997229|efficacy
189268|NCT01997216|contact lenses
189269|NCT01997216|multifocal
189270|NCT01997203|hepatitis C infection
189271|NCT01997203|vitamin D
189272|NCT01997190|Immunotherapy
189273|NCT01997190|Gene therapy
189274|NCT01997190|Tumor vaccine
189275|NCT01997177|simulation
189276|NCT01997177|training
189277|NCT01997177|colonoscopy
189278|NCT01997177|standard setting
189279|NCT01997138|pain, inflammation, surgery
189280|NCT01997112|Blood pressure
189281|NCT01997112|Hypertension
189282|NCT01997112|Paracetamol
189283|NCT01997112|Acetaminophen
189284|NCT01997099|Drug Library
189285|NCT01997099|Ambulatory Infusion Pump
189286|NCT01997099|Medication Safety Software
189287|NCT01997099|CADD®-Solis VIP
189288|NCT01997099|Pump Programming
189289|NCT01997099|Home Infusion Workflow
189290|NCT01997073|Respiratory enthalpy
189291|NCT01997073|One Lung Ventilation
189292|NCT01997060|Lifestyle intervention
189293|NCT01997060|Body weight
189294|NCT01997060|Body composition
189295|NCT01997060|Weight loss maintenance
189296|NCT01997060|Physical activity
189297|NCT01997047|Pneumonia
189298|NCT01997047|bronchiolitis
189299|NCT01997047|asthma
189300|NCT01997047|children
189301|NCT01997047|tachypnea
189302|NCT01997047|developing countries
189303|NCT01997047|diagnostic criteria
189304|NCT01997034|Weight loss maintenance
189305|NCT01997034|Body composition
189306|NCT01997034|Physical activity
189307|NCT01997034|Lifestyle intervention
189308|NCT01997021|Sedentary behavior
189309|NCT01997021|physical activity
189310|NCT01997021|older adults
189311|NCT01996982|Induced therapeutic hypothermia
189312|NCT01996969|metastatic colorectal cancer
189313|NCT01996969|refractory
189314|NCT01996969|regorafenib
189315|NCT01996969|biomarker
189316|NCT01996969|gene sequencing
189317|NCT01996956|stroke volume variation,
189318|NCT01996956|cardiac output,
189319|NCT01996956|fluid responsiveness,
189320|NCT01996956|noninvasive cardiac output monitor
189321|NCT01996943|Atrial Fibrillation
189322|NCT01996943|Alcohol
189323|NCT01996943|Electrophysiologic properties of the atria
189324|NCT01996943|Randomized Clinical Study
189325|NCT01996917|wound closure
189326|NCT01996917|prineo
189327|NCT01996917|scar
189328|NCT01996904|subscapularis tear
189329|NCT01996904|arthroscopic tendon repair
189330|NCT01996904|arthroscopic tendon debridement
189331|NCT01996904|ASES
189332|NCT01996891|Asthma
189333|NCT01996891|Nutrition
189334|NCT01996891|Anti-inflammatory diet
189335|NCT01996878|Parkinson's disease
189336|NCT01996878|Genetic Polymorphism
189337|NCT01996865|Lymphoma, Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma, Lenalidomide treatment, rituximab treatment, Non Hodgkins Lymphoma
189338|NCT01996852|Erectile dysfunction
189339|NCT01996852|ED
189340|NCT01996852|Prostate
189341|NCT01996852|Prostatectomy
189342|NCT01996826|Corneal Neovascularization
189343|NCT01996826|Cornea Blood Vessels
189344|NCT01996826|Corneal Graft Failure
189345|NCT01996826|High-Risk Penetrating Keratoplasty
189346|NCT01996826|Corneal Transplant
189347|NCT01996813|arthroscopy
189348|NCT01996813|shoulder
189349|NCT01996813|obesity
189350|NCT01996813|beach chair
189351|NCT01996813|compression hose
189352|NCT01996787|visibility tinted silicone hydrogel contact lenses for daily wear
189353|NCT01996735|Endothelial function
189354|NCT01996735|Adenosine receptor stimulation
189355|NCT01996709|Silicone hydrogel contact lenses
189356|NCT01996709|Multi-purpose solution
189357|NCT01996709|Lid Papillae
189358|NCT01996709|Palpebral Roughness
189359|NCT01996696|metformin
189360|NCT01996696|metabolic syndrome
189361|NCT01996696|weight gain
189362|NCT01996683|B-thalassemia
189363|NCT01996683|ferritin
189364|NCT01996657|mechanical valves replacement
189365|NCT01996657|INR
189366|NCT01996657|D-dimer
189367|NCT01996657|thromboembolic events
189368|NCT01996644|Anorexia, Bulimia, Eating disorder, Anxiety, Exposure Therapy
189369|NCT01996618|Premature Ventricular Beats
189370|NCT01996618|Premature Heart Beats
189371|NCT01996618|Ranolazine
189372|NCT01996592|chronic pain
189373|NCT01996592|cesarean section pain
189374|NCT01996579|Critically Ill
189375|NCT01996579|Intensive care
189376|NCT01996579|Nasogastric tube
189377|NCT01996579|Orogastric tube
189378|NCT01996579|mechanically ventilated
189379|NCT01996579|nosocomially acquired infections
189380|NCT01996579|length of stay
189381|NCT01996579|lactoferrin
189382|NCT01996579|placebo controlled
189383|NCT01996579|antibiotic free days
189384|NCT01996566|taste
189385|NCT01996566|non-esterified fatty acids
189386|NCT01996566|threshold
189387|NCT01996566|sensitivity
189388|NCT01996566|human
189389|NCT01996553|blood flow, regional
189390|NCT01996553|complications
189391|NCT01996553|disease, arterial obstructive
189392|NCT01996553|cardiac catheterization
189393|NCT01996553|radial artery
189394|NCT01996540|gastric neoplasm
189395|NCT01996540|pancreatic neoplasm
189396|NCT01996540|advanced
189397|NCT01996540|palliative care
189398|NCT01996514|Children
189399|NCT01996514|Food advertisement
189400|NCT01996514|Obesity
189401|NCT01996514|Television viewing
189402|NCT01996514|Food intake
189403|NCT01996449|Hypertension
189404|NCT01996449|blood pressure
189405|NCT01996449|Aldosterone
189406|NCT01996449|Eplerenone
189407|NCT01996449|Amlodipine
189408|NCT01996449|Primary aldosteronism
189409|NCT01996449|Exercise pressor reflex
189410|NCT01996449|handgrip exercise
189411|NCT01996449|passive arm cycling
189412|NCT01996449|active arm cycling
189413|NCT01996436|cerebral vasospasm
189414|NCT01996436|aneurysmal subarachnoid hemorrhage
189415|NCT01996436|intra arterial drug treatment for cerebral vasospasm
189416|NCT01996436|nicardipine milrinone nitroglycerin verapamil
189417|NCT01996423|Atopic dermatitis
189418|NCT01996423|vitamin D
189419|NCT01996410|Breast Cancer
189420|NCT01996410|Acupuncture
189421|NCT01996410|Taxol
189422|NCT01996410|Cytoxan
189423|NCT01996410|Adriamycin
189424|NCT01996410|Taxotere
189425|NCT01996410|Carboplatin
189426|NCT01996410|Perjeta
189427|NCT01996410|Chemotherapy
189428|NCT01996410|Chemotherapy-induced nausea, vomiting
189429|NCT01996410|Chemotherapy-induced peripheral neuropathy
189430|NCT01996410|Adriamycin (60 mg/m2), Cytoxan (600 mg/m2), Taxol (175 mg/m2)
189431|NCT01996410|Adriamycin (60 mg/m2), Cytoxan (600 mg/m2), Taxol (80 g/m2)
189432|NCT01996410|Taxotere (75mg/m2), Cytoxan (600 mg/m2)
189433|NCT01996410|Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose)
189434|NCT01996397|Heart failure
189435|NCT01996397|Bundle branch block
189436|NCT01996397|CRT response
189437|NCT01996384|Vulvodynia
189438|NCT01996384|Provoked, localized vulvodynia
189439|NCT01996384|vulvar vestibulitis
189440|NCT01996384|provoked vestibulodynia
189441|NCT01996384|vulvovaginal pain
189442|NCT01996384|vulvar pain
189443|NCT01996384|vaginal pain
189444|NCT01996384|chronic pain
189445|NCT01996384|lidocaine
189446|NCT01996384|numbing agent
189447|NCT01996384|anesthetic cream
189448|NCT01996384|acupuncture
189449|NCT01996384|electroacupuncture
189450|NCT01996384|electrical stimulated acupuncture
189451|NCT01996384|manual acupuncture
189452|NCT01996384|classical acupuncture
189453|NCT01996384|non-classical acupuncture
189454|NCT01996384|Traditional Chinese Medicine
189455|NCT01996384|TCM
189456|NCT01996384|Chinese medicine
189457|NCT01996384|Acupuncture and Oriental Medicine
189458|NCT01996384|AOM
189459|NCT01996384|treatment
189460|NCT01996384|feasibility
189461|NCT01996384|pilot study
189462|NCT01996384|Patient Reported Outcomes Measure Information System
189463|NCT01996384|Tampon Test
189464|NCT01996384|cotton swab test
189465|NCT01996384|pain diary
189466|NCT01996384|Research Electronic Data Capture
189467|NCT01996384|REDCap
189468|NCT01996358|Succinylcholine
189469|NCT01996358|Rocuronium
189470|NCT01996358|Rigid Bronchoscopy
189471|NCT01996345|Placenta Previa
189472|NCT01996345|Vaginal Pessary
189473|NCT01996345|Premature Birth
189474|NCT01996319|Chronic obstructive pulmonary disease
189475|NCT01996319|COPD
189476|NCT01996306|AXEPT
189477|NCT01996306|Fluorouracil
189478|NCT01996306|CPT-11
189479|NCT01996306|XELIRI
189480|NCT01996306|Bevacizumab
189481|NCT01996306|FOLFIRI
189482|NCT01996306|Capecitabine
189483|NCT01996306|2nd-line metastatic colorectal cancer
189484|NCT01996293|pregnant
189485|NCT01996293|bipolar
189486|NCT01996293|lamotrigine
189487|NCT01996293|lamictal
189488|NCT01996293|women
189489|NCT01996293|female
189490|NCT01996267|neoadjuvant
189491|NCT01996267|breast cancer
189492|NCT01996267|HER2 positive
189493|NCT01996254|electrical stimulation
189494|NCT01996254|neurostimulation
189495|NCT01996254|neuromodulation
189496|NCT01996254|post-amputation pain
189497|NCT01996254|phantom limb pain
189498|NCT01996254|residual limb pain
189499|NCT01996254|neuropathic pain
189500|NCT01996254|amputee pain
189501|NCT01996241|adolescent girls
189502|NCT01996241|female sex work
189503|NCT01996241|age at marriage
189504|NCT01996241|retention in school
189505|NCT01996241|sexual debut
189506|NCT01996241|India
189507|NCT01996241|Karnataka
189508|NCT01996228|Type 1 diabetes
189509|NCT01996228|autoimmune
189510|NCT01996228|cord blood stem cell
189511|NCT01996228|stem cell educator
189512|NCT01996228|immune modulation
189513|NCT01996228|children
189514|NCT01996228|Control autoimmunity
189515|NCT01996228|stimulate the regeneration of islet beta cells
189516|NCT01996202|Melanoma
189517|NCT01996176|Sedentary Lifestyle
189518|NCT01996176|Sedentary work
189519|NCT01996176|Office workers
189520|NCT01996176|Work
189521|NCT01996176|Workplace intervention
189522|NCT01996176|Sitting time
189523|NCT01996150|atopic dermatitis
189524|NCT01996150|eczema
189525|NCT01996150|bleach bath
189526|NCT01996150|itch
189527|NCT01996150|skin barrier
189528|NCT01996150|staphylococcus aureus
189529|NCT01996137|Stroke
189530|NCT01996137|Treadmill
189531|NCT01996137|Gait Speed
189532|NCT01996124|COPD
189533|NCT01996124|Pulmonary Hyperinflation
189534|NCT01996124|Ultra Long Acting Beta 2 Agonists
189535|NCT01996124|Cor Pulmonale
189536|NCT01996124|Cardiac performance
189537|NCT01996111|plantar fasciitis
189538|NCT01996085|arterial hypertension
189539|NCT01996085|hemodynamics
189540|NCT01996085|impedance cardiography
189541|NCT01996085|hypotensive therapy
189542|NCT01996072|Primary hyperparathyroidism
189543|NCT01996072|Parathyroid
189544|NCT01996059|nutritional status
189545|NCT01996059|functional jejunal interposition
189546|NCT01996059|Roux-en-Y
189547|NCT01996059|gastrectomy
189548|NCT01996033|uncontrolled hypertension
189549|NCT01996033|Renal Denervation
189550|NCT01996007|Pneumococcus
189551|NCT01996007|Carriage
189552|NCT01996007|Children
189553|NCT01996007|Parents
189554|NCT01996007|Immunogenicity
189555|NCT01996007|PCV13
189556|NCT01995981|Sarcoma, Soft Tissue
189557|NCT01995981|Pazopanib
189558|NCT01995981|Positron-Emission Tomography
189559|NCT01995981|Pharmacokinetics
189560|NCT01995981|Biomarker
189561|NCT01995968|Stillbirth
189562|NCT01995968|Fetal growth restriction
189563|NCT01995968|Small for gestational age
189564|NCT01995968|Antenatal detection
189565|NCT01995968|Prenatal Care
189566|NCT01995968|Mass Screening
189567|NCT01995955|Coronary Microvascular Dysfunction
189568|NCT01995955|coronary artery disease
189569|NCT01995955|index of myocardial resistance
189570|NCT01995942|Rectal Cancer
189571|NCT01995942|EMVI
189572|NCT01995942|Extramural Venous Invasion
189573|NCT01995942|Microarray
189574|NCT01995942|Biomarker
189575|NCT01995942|mrEMVI
189576|NCT01995942|Tumour Regression Grade
189577|NCT01995942|Cancer
189578|NCT01995942|Circumferential Resection Margin
189579|NCT01995942|CRM
189580|NCT01995942|MRI
189581|NCT01995942|Radiology
189582|NCT01995942|Surgery
189583|NCT01995942|Pathology
189584|NCT01995929|neurogenic dysphagia
189585|NCT01995929|transnasal endoscopy
189586|NCT01995929|functional endoscopy
189587|NCT01995890|nepafenac eye drops
189588|NCT01995890|intraocular pressure
189589|NCT01995864|Schizophrenia and Disorders with Psychotic Features
189590|NCT01995864|Community Psychiatry
189591|NCT01995851|Influenza
189592|NCT01995851|Vaccine
189593|NCT01995838|Chronic Insomnia
189594|NCT01995838|Adults
189595|NCT01995838|Elderly
189596|NCT01995825|bioequivalence
189597|NCT01995825|lamotrigine
189598|NCT01995825|epilepsy
189599|NCT01995799|Myocardial Infarction (and related inflammation)
189600|NCT01995786|Fluid Therapy
189601|NCT01995786|Cost-Benefit Analysis
189602|NCT01995786|Hemodynamics
189603|NCT01995786|Cost Control
189604|NCT01995773|Healthy women
189605|NCT01995773|Quality of life
189606|NCT01995773|Glucose metabolism
189607|NCT01995773|Adrenal reactivity
189608|NCT01995773|Physical activity
189609|NCT01995773|Body Composition
189610|NCT01995760|vancomycin
189611|NCT01995760|therapeutic response monitoring
189612|NCT01995760|AUC/MIC
189613|NCT01995747|IgE
189614|NCT01995747|Atopic Dermatitis
189615|NCT01995747|antibody
189616|NCT01995747|allergy
189617|NCT01995734|Acromegaly, Pituitary diseases
189618|NCT01995721|recurrent respiratory papillomatosis
189619|NCT01995721|human papillomavirus
189620|NCT01995721|vaccine
189621|NCT01995721|treatment
189622|NCT01995721|immunology
189623|NCT01995721|relapse
189624|NCT01995708|CT7
189625|NCT01995708|MAGE-A3
189626|NCT01995708|WT1 mRNA-electroporated Autologous Langerhans
189627|NCT01995708|vaccine
189628|NCT01995708|Autologous Stem Cell Transplantation
189629|NCT01995708|13-009
189630|NCT01995682|Independent living
189631|NCT01995682|walk with or without walking aids
189632|NCT01995669|Lymphoma
189633|NCT01995669|Relapsed Indolent Non-Hodgkin's Lymphoma
189634|NCT01995669|non-Hodgkin's lymphoma
189635|NCT01995669|NHL
189636|NCT01995669|Relapsed/refractory indolent lymphoma
189637|NCT01995669|Small lymphocytic lymphoma
189638|NCT01995669|SLL
189639|NCT01995669|Follicular lymphoma
189640|NCT01995669|Marginal zone lymphoma
189641|NCT01995669|Lenalidomide
189642|NCT01995669|CC-5013
189643|NCT01995669|Revlimid
189644|NCT01995669|Obinutuzumab
189645|NCT01995669|GA101
189646|NCT01995643|Grape seed extract
189647|NCT01995643|Polyphenols
189648|NCT01995643|Insulin
189649|NCT01995643|Oxidative stress Marker
189650|NCT01995643|Inflammatory marker
189651|NCT01995643|Healthy human
189652|NCT01995617|vaccine
189653|NCT01995617|Streptococcus pneumoniae
189654|NCT01995617|Strep pneumo
189655|NCT01995591|colon cancer
189656|NCT01995591|sentinel lymph node
189657|NCT01995591|Indocyanine Green
189658|NCT01995578|5'-Azacitidine
189659|NCT01995578|Stem cell transplant
189660|NCT01995578|13-192
189661|NCT01995552|Post myocardial infarction patients with low EF.
189662|NCT01995539|Type 2
189663|NCT01995500|CAD
189664|NCT01995500|PCI
189665|NCT01995500|ACS
189666|NCT01995500|non ACS
189667|NCT01995500|BioNIR
189668|NCT01995500|DES
189669|NCT01995487|more comers
189670|NCT01995487|DES
189671|NCT01995487|BioNIR
189672|NCT01995487|ACS
189673|NCT01995487|non ACS
189674|NCT01995487|complex lesions
189675|NCT01995474|EUS
189676|NCT01995474|pancreatic cancer
189677|NCT01995474|cytology
189678|NCT01995474|fine needle aspiration
189679|NCT01995448|The acute phase of Sepsis
189680|NCT01995448|multiparameter 8-color flow cytometry
189681|NCT01995422|Major depressive disorder
189682|NCT01995422|Follow-up study
189683|NCT01995422|Ecological momentary assessment
189684|NCT01995422|Physical activity
189685|NCT01995422|Depression
189686|NCT01995422|Self-esteem
189687|NCT01995422|Anxiety
189688|NCT01995422|Rumination
189689|NCT01995422|Quality of life
189690|NCT01995396|rectal cancer,
189691|NCT01995396|fecal incontinence,
189692|NCT01995396|severe co-morbidity,
189693|NCT01995396|Hartmann´s procedure,
189694|NCT01995396|abdominoperineal excision with intersphincteric dissection,
189695|NCT01995396|postoperative complications,
189696|NCT01995396|pelvic abscess,
189697|NCT01995396|perineal infections
189698|NCT01995370|Noncardioembolic cerebral infarction
189699|NCT01995370|Dual antiplatelet therapy (DAPT)
189700|NCT01995370|Cilostazol
189701|NCT01995370|Aspirin
189702|NCT01995370|Clopidogrel
189703|NCT01995331|aplastic anemia;
189704|NCT01995331|cyclophosphamide;
189705|NCT01995331|immunosuppressive therapy;
189706|NCT01995331|cyclosporine A
189707|NCT01995318|Kinesiotaping
189708|NCT01995305|fanconi anemia
189709|NCT01995305|hematopoiesis maintainance
189710|NCT01995292|awake fiberoptic intubation
189711|NCT01995292|spray as you go technique
189712|NCT01995292|anesthesia
189713|NCT01995292|Enk Fiberoptic Atomizer Set
189714|NCT01995279|low back pain
189715|NCT01995279|French Auriculotherapy
189716|NCT01995279|postural control
189717|NCT01995279|balance
189718|NCT01995279|posture
189719|NCT01995240|pancreatic cancer
189720|NCT01995240|MRI
189721|NCT01995240|reproducibility
189722|NCT01995240|optimalization
189723|NCT01995227|liver cancer
189724|NCT01995227|HCC
189725|NCT01995227|tumor vaccine
189726|NCT01995227|immunotherapy
189727|NCT01995227|personalized anti-cancer vaccine
189728|NCT01995214|Postoperative delirium
189729|NCT01995214|Geriatric
189730|NCT01995214|General anesthesia
189731|NCT01995214|Propofol
189732|NCT01995214|Sevoflurane
189733|NCT01995175|Respiratory Syncytial virus
189734|NCT01995175|New born
189735|NCT01995175|Lower Respiratory Tract Infection
189736|NCT01995149|Familial Hypercholesterolemia
189737|NCT01995149|Familial Combined Hypercholesterolemia
189738|NCT01995149|Weight loss; Lipids; Phytosterols
189739|NCT01995149|Obesity
189740|NCT01995149|Overweight.
189741|NCT01995149|Lipids
189742|NCT01995136|Glaucoma
189743|NCT01995136|Ocular hypertension
189744|NCT01995123|Tobacco dependence
189745|NCT01995123|PTSD
189746|NCT01995123|Behavioral Activation Therapy
189747|NCT01995097|smoking cessation
189748|NCT01995097|smoking reduction
189749|NCT01995097|scheduled gradual reduction
189750|NCT01995097|pregnancy
189751|NCT01995097|text message intervention
189752|NCT01995084|hypoxia
189753|NCT01995084|HX4
189754|NCT01995084|PET
189755|NCT01995084|cancer
189756|NCT01995071|Chronic Hepatitis C
189757|NCT01995071|Cirrhosis
189758|NCT01995071|Child Pugh A
189759|NCT01995071|Hepatitis C virus
189760|NCT01995071|Compensated Cirrhosis
189761|NCT01995071|Hepatitis C Genotype 1
189762|NCT01995071|Hepatitis C
189763|NCT01995071|Interferon-Free
189764|NCT01995071|Cirrhotic
189765|NCT01995058|CRPC
189766|NCT01995058|castration resistant prostate cancer
189767|NCT01995058|prostate cancer
189768|NCT01995045|Retina
189769|NCT01995045|Vitreoretinal
189770|NCT01995045|Surgery
189771|NCT01995032|Duchenne's muscular dystrophy
189772|NCT01995032|DMD
189773|NCT01995019|Arthralgia
189774|NCT01995019|Temporomandibular joint
189775|NCT01995019|corticosteroids
189776|NCT01995019|injection
189777|NCT01995019|intra-articular
189778|NCT01995006|Effect
189779|NCT01995006|metamizole
189780|NCT01995006|salt-depleted
189781|NCT01995006|subjects
189782|NCT01994993|Antibiotics
189783|NCT01994993|ampicillin
189784|NCT01994993|metronidazole
189785|NCT01994993|clindamycin
189786|NCT01994993|piperacillin-tazobactam
189787|NCT01994993|Safety
189788|NCT01994993|Infants
189789|NCT01994993|Intra abdominal infections
189790|NCT01994967|Phase III
189791|NCT01994967|Noninferiority
189792|NCT01994967|Controlled
189793|NCT01994967|Double-blind
189794|NCT01994967|Randomized
189795|NCT01994967|Spinal
189796|NCT01994967|Anesthetic
189797|NCT01994967|Lower limb
189798|NCT01994954|newborn intensive care unit
189799|NCT01994954|NICU
189800|NCT01994954|supplemental oxygen
189801|NCT01994941|Acute Coronary Syndrome
189802|NCT01994941|Platelet Reactivity
189803|NCT01994941|P2Y12 Receptor Blocker
189804|NCT01994941|CYP2C19 Genotyping
189805|NCT01994915|exacerbation
189806|NCT01994915|functionality
189807|NCT01994915|occupational therapy
189808|NCT01994915|chronic obstructive pulmonary disease
189809|NCT01994889|amyloidosis
189810|NCT01994889|amyloid
189811|NCT01994889|transthyretin
189812|NCT01994889|TTR
189813|NCT01994837|AML
189814|NCT01994837|Acute Myelogenous Leukemia
189815|NCT01994837|Acute Myeloid Leukemia
189816|NCT01994837|GDC-0199
189817|NCT01994837|ABT-199
189818|NCT01994837|Myeloid Leukemia
189819|NCT01994811|cancer
189820|NCT01994811|cardiovascular disease
189821|NCT01994811|diabetes
189822|NCT01994785|Sedation
189823|NCT01994785|Endoscopy
189824|NCT01994785|Capnography
189825|NCT01994772|Therapeutic hypothermia
189826|NCT01994772|Targeted controlled temperature
189827|NCT01994772|Cardiac arrest
189828|NCT01994772|Non shockable rhythm
189829|NCT01994772|successful resuscitation
189830|NCT01994759|Plantar fasciitis
189831|NCT01994759|Treatment
189832|NCT01994759|Training
189833|NCT01994759|Glucocorticosteroid injection
189834|NCT01994746|Diabetes Mellitus
189835|NCT01994746|Hypoglycemia
189836|NCT01994746|Glucagon
189837|NCT01994733|end-stage renal disease
189838|NCT01994733|hemodialysis
189839|NCT01994733|mineral metabolism
189840|NCT01994733|serum phosphate
189841|NCT01994733|phosphate binders
189842|NCT01994720|Acute ischaemic stroke.
189843|NCT01994720|Transient ischaemic attack.
189844|NCT01994707|Remote ischemic preconditioning
189845|NCT01994707|Coronary artery bypass graft surgery
189846|NCT01994707|Troponin T
189847|NCT01994707|Apoptosis
189848|NCT01994707|Experimental
189849|NCT01994707|Cardioprotection
189850|NCT01994668|lorazepam
189851|NCT01994668|intravenous
189852|NCT01994668|pharmacolinetics
189853|NCT01994668|healthy
189854|NCT01994668|Japanese
189855|NCT01994655|climacteric symptoms
189856|NCT01994655|menopause
189857|NCT01994655|nurses
189858|NCT01994629|meningococcal disease
189859|NCT01994629|children
189860|NCT01994629|vaccination
189861|NCT01994616|Keloid, hypertrophic scar
189862|NCT01994603|Prevention
189863|NCT01994603|HIV
189864|NCT01994603|AIDS
189865|NCT01994603|Fetal Alcohol Syndrome (FAS)
189866|NCT01994603|Alcohol Related Neurodevelopmental Disorder (ARND)
189867|NCT01994590|Prostate Cancer
189868|NCT01994590|Metastatic Castrate-Resistant Prostate Cancer
189869|NCT01994590|mCRPC
189870|NCT01994590|Dovitinib
189871|NCT01994590|TKI258
189872|NCT01994590|Abiraterone Acetate
189873|NCT01994590|Zytiga
189874|NCT01994590|Prednisone
189875|NCT01994577|Emergency Department
189876|NCT01994577|Cardiac troponin
189877|NCT01994577|Myocardial infarction
189878|NCT01994564|OAG
189879|NCT01994538|Urinary Tract Infections
189880|NCT01994538|Urinary antiinfective agents
189881|NCT01994512|Spinal stenosis
189882|NCT01994512|Decompression
189883|NCT01994512|Fusion
189884|NCT01994512|Olisthesis
189885|NCT01994486|HCV Genotype 1
189886|NCT01994486|Hepatitis C Virus Genotype 1
189887|NCT01994486|HCV
189888|NCT01994486|TVR
189889|NCT01994473|Schizophrenia
189890|NCT01994460|Tuberculosis
189891|NCT01994447|Informed Consent
189892|NCT01994447|Instructional Films and Video
189893|NCT01994447|Consent Comprehension
189894|NCT01994447|Multimedia Consent
189895|NCT01994447|Parent
189896|NCT01994434|Deep branch of the ulnar nerve
189897|NCT01994434|Distal ulnar nerve compression
189898|NCT01994421|Facilitating kinesiotape
189899|NCT01994421|Inhibiting kinesiotape
189900|NCT01994421|Classical tape
189901|NCT01994421|No tape
189902|NCT01994408|physician inertia
189903|NCT01994408|hypertension
189904|NCT01994408|telemedicine
189905|NCT01994408|mobile technology
189906|NCT01994395|Stroke
189907|NCT01994395|Gait
189908|NCT01994395|Stride Management Assist
189909|NCT01994395|Mild-moderate Stroke, post 30 days or longer
189910|NCT01994382|Leukemia
189911|NCT01994382|Lymphocytic
189912|NCT01994382|Chronic
189913|NCT01994382|B Cell
189914|NCT01994369|Breast Cancer
189915|NCT01994356|Contraceptive counseling
189916|NCT01994356|Physician self disclosure
189917|NCT01994356|Satisfaction
189918|NCT01994356|Intrauterine contraceptive use
189919|NCT01994343|Chronic pelvic pain, women, pain, posture.
189920|NCT01994330|acquired von Willebrand disease
189921|NCT01994330|severe aortic stenosis
189922|NCT01994330|Heye´s syndrome
189923|NCT01994330|desmopressin
189924|NCT01994330|von Willebrand multimers
189925|NCT01994304|Safe Childbirth Checklist
189926|NCT01994304|Intrapartum mortality, Quality of Institutional delivery care
189927|NCT01994304|Maternal & newborn care practices
189928|NCT01994291|Chemokine Antagonist
189929|NCT01994291|Diabetic Macular Edema
189930|NCT01994291|Diabetes
189931|NCT01994291|Diabetes Mellitus
189932|NCT01994291|Macular Edema
189933|NCT01994291|Diabetic Retinopathy
189934|NCT01994291|Anti-VEGF
189935|NCT01994265|Atrial fibrillation
189936|NCT01994265|Cognition
189937|NCT01994265|Cognitive impairment
189938|NCT01994265|Anticoagulation
189939|NCT01994265|Dabigatran
189940|NCT01994265|Warfarin
189941|NCT01994265|Efficacy
189942|NCT01994252|defibrillator
189943|NCT01994252|cardiac resynchronization
189944|NCT01994239|Prostate-Specific Antigen
189945|NCT01994239|LHRH antagonist
189946|NCT01994239|Radiotherapy
189947|NCT01994213|Famitinib
189948|NCT01994213|Gastroenteropancreatic Neuroendocrine Tumor
189949|NCT01994213|GEPNET
189950|NCT01994200|Thyroid cancer
189951|NCT01994200|New diagnosis
189952|NCT01994200|Dedicated Nurse
189953|NCT01994200|Interdisciplinary team
189954|NCT01994200|Randomized Controlled Trial
189955|NCT01994200|Intervention
189956|NCT01994200|Supportive care
189957|NCT01994187|Carotid stenosis
189958|NCT01994187|Angioplasty
189959|NCT01994187|Carotid endarterectomy
189960|NCT01994187|Stroke
189961|NCT01994174|vascular
189962|NCT01994174|retina
189963|NCT01994174|Anti-VEGF
189964|NCT01994174|Aqueous humor dynamics
189965|NCT01994161|ischemic stroke
189966|NCT01994161|intracranial stenting
189967|NCT01994161|vascular risk factor management
189968|NCT01994148|Trauma
189969|NCT01994148|Gastrointestinal injury
189970|NCT01994148|Laparoscopy
189971|NCT01994109|Sialorrhea
189972|NCT01994109|Parkinson's disease
189973|NCT01994109|Amyotrophic lateral sclerosis (ALS)
189974|NCT01994109|stroke
189975|NCT01994109|neuroleptics
189976|NCT01994057|Non-small cell lung cancer (NSCLC);
189977|NCT01994057|EGFR-TKI;
189978|NCT01994057|Pharmacogenetics;
189979|NCT01994057|Precision medicine
189980|NCT01994057|somatic mutations ,germline mutations;
189981|NCT01994044|Whiplash, surgery, multimodal rehabilitation, independent examiners
189982|NCT01994031|paclitaxel liposome injection
189983|NCT01994031|paclitaxel
189984|NCT01994018|Vitamin D
189985|NCT01994018|Interferon Beta
189986|NCT01994018|Glatiramer Acetate
189987|NCT01994018|Relapse rates
189988|NCT01993992|Anesthesia
189989|NCT01993979|Adjuvant chemotherapy
189990|NCT01993979|Surveillance
189991|NCT01993979|Nephro-ureterectomy
189992|NCT01993966|Urothelial carcinoma (UC),
189993|NCT01993966|(-)-epigallocatechin-3-gallate(EGCG),
189994|NCT01993966|chemotherapy,
189995|NCT01993966|cytotoxicity,
189996|NCT01993966|drug resistance,
189997|NCT01993966|xenograft.
189998|NCT01993953|Muscle strength
189999|NCT01993953|Body composition
190000|NCT01993953|Body weight
190001|NCT01993953|Resistance training
190002|NCT01993953|Personal training
190003|NCT01993953|BodyPump
190004|NCT01993940|Opioid-induced Constipation
190005|NCT01993927|Drug Therapy
190006|NCT01993901|lung SBRT, ESAS, anxiety
190007|NCT01993888|Hepatobiliary Surgery
190008|NCT01993849|Anxiety
190009|NCT01993849|Impulse control
190010|NCT01993849|Depression
190011|NCT01993849|ADHD
190012|NCT01993849|Fingernail Biting
190013|NCT01993849|N-Acetylcysteine
190014|NCT01993849|NAC
190015|NCT01993836|isoflurane
190016|NCT01993836|propofol
190017|NCT01993836|total intravenous anesthesia
190018|NCT01993836|inhaled anesthetic
190019|NCT01993836|volatile anesthetic
190020|NCT01993836|anesthesia
190021|NCT01993836|delirium
190022|NCT01993836|Post Operative Cognitive Dysfunction
190023|NCT01993836|Alzheimer's Disease
190024|NCT01993836|Mild Cognitive Impairment
190025|NCT01993810|Non small cell lung cancer
190026|NCT01993810|NSCLC
190027|NCT01993810|proton radiotherapy
190028|NCT01993797|Bronchiolitis
190029|NCT01993758|tourniquet pressure
190030|NCT01993758|total knee arthroplasty
190031|NCT01993745|ECMO
190032|NCT01993745|APACH II score
190033|NCT01993732|Cancer
190034|NCT01993732|Cryopreservation
190035|NCT01993732|Ovarian Function
190036|NCT01993732|In Vitro
190037|NCT01993719|Metastatic
190038|NCT01993719|Melanoma
190039|NCT01993719|Adoptive Cell Therapy
190040|NCT01993706|Broadly HIV-1 Neutralizing Activity
190041|NCT01993706|Healthy Adults
190042|NCT01993706|Placebo
190043|NCT01993706|HIV Prevention
190044|NCT01993706|Monoclonal Antibodies
190045|NCT01993706|Antibodies
190046|NCT01993693|knee
190047|NCT01993693|pain
190048|NCT01993693|osteoarthritis
190049|NCT01993693|ultrasound
190050|NCT01993654|Pigmented Lesions
190051|NCT01993654|PAM
190052|NCT01993654|Ocular lesion
190053|NCT01993641|Myelodysplastic Syndrome
190054|NCT01993641|MDS
190055|NCT01993641|pracinostat
190056|NCT01993641|Hypomethylating Agent
190057|NCT01993641|HMA
190058|NCT01993641|azacitadine
190059|NCT01993641|Vidaza
190060|NCT01993641|decitabine
190061|NCT01993641|dacogen
190062|NCT01993615|FAI
190063|NCT01993615|femoroacetabular impingement
190064|NCT01993615|hip pain
190065|NCT01993615|hip arthroscopy
190066|NCT01993615|physical therapy
190067|NCT01993602|general surgery
190068|NCT01993602|postoperative care
190069|NCT01993602|breathing exercises
190070|NCT01993602|respiratory muscle
190071|NCT01993602|postoperative complications
190072|NCT01993602|lung volume measurements
190073|NCT01993602|pulmonary ventilations
190074|NCT01993602|thoracic wall
190075|NCT01993589|Curettage; analgesia; paracetamol; lidocaine; Dexketoprofen trometamol; pethidine; diclofenac.
190076|NCT01993563|Stroke
190077|NCT01993563|Rehabilitation
190078|NCT01993563|Motor Imagery
190079|NCT01993563|Upper Extremity
190080|NCT01993563|Mirror Therapy
190081|NCT01993550|lung cancer
190082|NCT01993550|family caregiving
190083|NCT01993550|behavioral intervention
190084|NCT01993550|counseling
190085|NCT01993550|symptom management
190086|NCT01993498|cancer toxicities
190087|NCT01993498|cohort
190088|NCT01993498|breast cancer
190089|NCT01993485|transaortic valve replacement (TAVI)
190090|NCT01993485|endothelial function
190091|NCT01993485|circulating microparticles
190092|NCT01993459|Quality of Recovery
190093|NCT01993394|human centrifuge, oxygen, imaging, stroke volume, lung
190094|NCT01993381|chemotherapy-induced nausea and vomiting
190095|NCT01993368|wisdom teeth extraction
190096|NCT01993355|non-specific chronic low back pain,
190097|NCT01993355|health-related quality of life,
190098|NCT01993355|physioterapy,
190099|NCT01993355|sophrology,
190100|NCT01993355|cognitive-behavioral therapy,
190101|NCT01993355|motivational interviewing
190102|NCT01993342|adipocytokines
190103|NCT01993342|osteoarthritis
190104|NCT01993342|inflammation
190105|NCT01993342|ultrasonography
190106|NCT01993316|neurofeedback
190107|NCT01993316|EEG
190108|NCT01993316|transcranial magnetic stimulation
190109|NCT01993303|Myocardial Perfusion Imaging
190110|NCT01993303|PET
190111|NCT01993303|Rb-82
190112|NCT01993264|Heart disease
190113|NCT01993264|Echocardiogram
190114|NCT01993264|Ultrasound
190115|NCT01993264|Heart defect
190116|NCT01993264|Heart Dysfunction
190117|NCT01993264|Pediatric Cardiologists
190118|NCT01993264|Prenatal
190119|NCT01993251|sleep,melatonin,autism,children
190120|NCT01993225|Low Testosterone
190121|NCT01993212|Low Testosterone
190122|NCT01993186|Glucose Transporter Type 1 Deficiency Syndrome Glut1
190123|NCT01993173|Diphtheria
190124|NCT01993173|Tetanus
190125|NCT01993173|Pertussis
190126|NCT01993173|ADACEL®
190127|NCT01993173|Tdap vaccine
190128|NCT01993160|Fluorocholine (FCH)
190129|NCT01993160|Positron emission tomography (PET)
190130|NCT01993160|Magnetic resonance imaging (MRI)
190131|NCT01993147|Methylphenidate
190132|NCT01993147|Placebo
190133|NCT01993147|functional Magnetic Resonance Imaging (fMRI)
190134|NCT01993147|Attention Control
190135|NCT01993134|Postoperative infection
190136|NCT01993134|Antibiotic prophylaxis
190137|NCT01993134|Cefazolin
190138|NCT01993121|diabetes
190139|NCT01993121|exercise
190140|NCT01993121|heart
190141|NCT01993121|cardiovascular
190142|NCT01993108|Methylphenidate
190143|NCT01993108|Naltrexone
190144|NCT01993108|Placebo
190145|NCT01993108|Neuroimaging
190146|NCT01993108|Prefrontal Control Circuits
190147|NCT01993108|Attention Control
190148|NCT01993108|Motor Control
190149|NCT01993108|Appetitive Control
190150|NCT01993095|Multiple Sclerosis
190151|NCT01993095|Quality of Life
190152|NCT01993095|Functional Fitness
190153|NCT01993082|Caregivers
190154|NCT01993082|Telomerase
190155|NCT01993082|Telomere Length
190156|NCT01993082|Psychological Stress
190157|NCT01993082|Cardiovascular Risk
190158|NCT01993082|Exercise
190159|NCT01993056|injury incidence, male veteran soccer, 11+, Functional Movement Screen, FMS, warm-up
190160|NCT01993043|ROP
190161|NCT01993043|Bevacizumab
190162|NCT01993043|Laser
190163|NCT01993043|Development
190164|NCT01993017|Acute Coronary Syndrome
190165|NCT01993017|Depressive Symptoms
190166|NCT01992991|transcranial stimulation
190167|NCT01992991|Intracranial hemorrhage
190168|NCT01992991|Home training
190169|NCT01992991|Occupational Therapy
190170|NCT01992991|Jebsen Taylor Hand Function Test
190171|NCT01992978|radiofrequency-assisted（RF）
190172|NCT01992978|hepatectomy
190173|NCT01992978|postoperative liver injury
190174|NCT01992965|continuous glucose monitoring；
190175|NCT01992965|critically ill;
190176|NCT01992939|pulse
190177|NCT01992939|heat
190178|NCT01992939|blood circulation
190179|NCT01992926|health literacy
190180|NCT01992926|health numeracy
190181|NCT01992913|Schizophrenia
190182|NCT01992913|Cognitive Behavioral Therapy
190183|NCT01992913|Cognition
190184|NCT01992913|Vocational Rehabilitation
190185|NCT01992913|Supported Employment
190186|NCT01992913|Schizoaffective Disorder
190187|NCT01992900|Plasmodium falciparum Malaria
190188|NCT01992900|Eurartesim
190189|NCT01992900|ACT
190190|NCT01992887|HIV/AIDS
190191|NCT01992887|Retention
190192|NCT01992887|ART (anti-retroviral therapy) ineligible
190193|NCT01992874|Neoplasms
190194|NCT01992874|Pimasertib
190195|NCT01992874|Cancer
190196|NCT01992822|rTMS
190197|NCT01992822|fibromyalgia
190198|NCT01992822|experimental pain
190199|NCT01992809|Nonalcoholic fatty liver
190200|NCT01992809|omega 3
190201|NCT01992796|irbesartan, angiotensin, sepsis
190202|NCT01992783|Resistant Starch
190203|NCT01992783|Antioxidant Status
190204|NCT01992783|Insulin Resistance
190205|NCT01992783|Overweight
190206|NCT01992783|Obesity
190207|NCT01992770|behavioural medicine
190208|NCT01992770|pain
190209|NCT01992770|physical therapy
190210|NCT01992770|physical exercise
190211|NCT01992770|primary care
190212|NCT01992757|functional fibrinogen assay
190213|NCT01992757|cardiac surgery
190214|NCT01992744|pregnancy
190215|NCT01992744|brain-derived neurotrophic factor
190216|NCT01992744|birth outcomes
190217|NCT01992731|Age (38-42 years)
190218|NCT01992731|pregnancy rates
190219|NCT01992731|3 IUI cycles
190220|NCT01992731|1 IVF/ICSI cycle
190221|NCT01992705|pancreatic cancer
190222|NCT01992692|Parkinson's disease
190223|NCT01992692|remifentanil
190224|NCT01992692|deep brain stimulator
190225|NCT01992692|cardiovascular response
190226|NCT01992666|Systemic lupus erythematosus
190227|NCT01992666|genetic
190228|NCT01992666|immunological
190229|NCT01992666|pediatric
190230|NCT01992666|mutation
190231|NCT01992666|lupus
190232|NCT01992627|High Intensity Laser Therapy
190233|NCT01992627|elbow epicondylosis
190234|NCT01992614|Single Ascending Dose
190235|NCT01992614|healthy subjects
190236|NCT01992614|Hypercholesterolemia
190237|NCT01992614|Hyperlipidemias
190238|NCT01992614|Dyslipidemias
190239|NCT01992614|Lipid Metabolism Disorders
190240|NCT01992614|Metabolic Diseases
190241|NCT01992601|Drug interaction
190242|NCT01992601|Rosuvastatin
190243|NCT01992601|Telmisartan
190244|NCT01992601|Pharmacokinetic
190245|NCT01992601|(Pharmacokinetics and Drug Interaction)
190246|NCT01992575|Retinal vein occlusion
190247|NCT01992575|OCT
190248|NCT01992575|Optical coherence tomography
190249|NCT01992575|Imaging
190250|NCT01992536|Meningococcal
190251|NCT01992536|Booster
190252|NCT01992536|MenABCWY
190253|NCT01992536|Menveo
190254|NCT01992536|Vaccine Adolescents
190255|NCT01992536|Immune Response
190256|NCT01992536|N. Meningitidis
190257|NCT01992523|Ticagrelor
190258|NCT01992523|antiplatelet
190259|NCT01992523|Acute Coronary Syndrome
190260|NCT01992497|Cesarean section, probiotic, formula fed, gut microbiota
190261|NCT01992484|platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin
190262|NCT01992471|BRCA1 testing
190263|NCT01992471|BRCA2 testing
190264|NCT01992471|13-215
190265|NCT01992458|implantable cardioverter defibrillator
190266|NCT01992458|death
190267|NCT01992458|shock
190268|NCT01992458|mortality
190269|NCT01992458|complication
190270|NCT01992458|sudden death
190271|NCT01992445|suicide
190272|NCT01992445|suicidal intent
190273|NCT01992445|thought markers
190274|NCT01992432|Brain magnetic resonance imaging
190275|NCT01992432|chemotherapy toxicity
190276|NCT01992432|older woman
190277|NCT01992432|breast cancer
190278|NCT01992419|Out-of-hospital Cardiac arrest
190279|NCT01992419|telephone dispatch assisted resuscitation
190280|NCT01992419|cardiac arrest phone detection
190281|NCT01992393|Epilepsy
190282|NCT01992393|Schizophrenia
190283|NCT01992393|Schizoaffective Disorder
190284|NCT01992393|Bipolar Disorder
190285|NCT01992393|Depression
190286|NCT01992393|Intervention
190287|NCT01992393|Treatment
190288|NCT01992393|Adherence
190289|NCT01992341|sarcomas
190290|NCT01992341|carcinomas
190291|NCT01992328|Immunoglobulin G Deficiency
190292|NCT01992315|Scar
190293|NCT01992315|Soft tissue defect
190294|NCT01992302|Rapid cycling
190295|NCT01992289|XLHED
190296|NCT01992289|HED
190297|NCT01992289|Hypohidrotic ectodermal dysplasia
190298|NCT01992289|Christ-Siemens-Touraine Syndrome
190299|NCT01992276|Influenza
190300|NCT01992276|Virus
190301|NCT01992276|Monoclonal Antibody
190302|NCT01992276|Immunization
190303|NCT01992276|Treatment
190304|NCT01992263|tuberculosis
190305|NCT01992263|vitamin D
190306|NCT01992263|immunity
190307|NCT01992250|Cryoablation
190308|NCT01992237|ALI,
190309|NCT01992237|ARDS,
190310|NCT01992237|ECMO,
190311|NCT01992237|energy expenditure,
190312|NCT01992237|mechanical ventilation,
190313|NCT01992237|Extracorporeal Membrane Oxygenation
190314|NCT01992237|Nutrition Assessment
190315|NCT01992237|Pulmonary Ventilation
190316|NCT01992224|severe acute pancreatitis
190317|NCT01992224|mechanical ventilation
190318|NCT01992198|antibiothearpy strategy
190319|NCT01992198|cefoperazone
190320|NCT01992198|metronidazole
190321|NCT01992198|meropenem
190322|NCT01992159|Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
190323|NCT01992146|central sensitization
190324|NCT01992146|endogenous opioids
190325|NCT01992146|humans
190326|NCT01992146|latent sensitization
190327|NCT01992146|naloxone
190328|NCT01992146|open groin hernia repair
190329|NCT01992146|pain
190330|NCT01992146|randomized controlled trial
190331|NCT01992146|secondary hyperalgesia
190332|NCT01992146|target-controlled infusion
190333|NCT01992133|Former gestational Diabetes
190334|NCT01992133|Vitamin D deficiency
190335|NCT01992133|insulin resistance
190336|NCT01992133|beta cell function
190337|NCT01992120|Simulation
190338|NCT01992120|Sepsis
190339|NCT01992120|High-fidelity
190340|NCT01992120|Severe Sepsis
190341|NCT01992120|Septic Shock
190342|NCT01992120|Education
190343|NCT01992107|Influenza
190344|NCT01992107|Influenza vaccine
190345|NCT01992107|Novartis
190346|NCT01992107|children
190347|NCT01992094|Influenza
190348|NCT01992094|Influenza vaccine
190349|NCT01992094|Novartis
190350|NCT01992094|Adults
190351|NCT01992081|COPD, Physical Activity, Telecoaching, PROactive
190352|NCT01992068|lung cancer
190353|NCT01992055|Executive dysfunction
190354|NCT01992055|Neuropsychological rehabilitation
190355|NCT01992055|Goal Management Training
190356|NCT01992029|ALS
190357|NCT01992029|miRNA
190358|NCT01992029|biomarker
190359|NCT01992029|monocentric observational study
190360|NCT01992016|Prostate cancer
190361|NCT01992016|F18 FDG-PET
190362|NCT01992016|Imaging
190363|NCT01992016|Ranolazine
190364|NCT01992016|Bone metastases
190365|NCT01992016|Soft tissue metastases
190366|NCT01991964|stridor
190367|NCT01991964|laryngomalacia
190368|NCT01991964|ultrasound
190369|NCT01991938|PI3K Inhibitor
190370|NCT01991938|mTOR Inhibitor
190371|NCT01991938|Dual PI3K/mTOR Inhibitor
190372|NCT01991938|CSC
190373|NCT01991938|Cancer Stem Cells
190374|NCT01991912|irrigation endoscopic decompression
190375|NCT01991912|minimally invasive surgery
190376|NCT01991912|spinal stenosis
190377|NCT01991899|Measles, mumps and rubella vaccine
190378|NCT01991899|Tetraviral vaccine
190379|NCT01991899|Immunogenicity, Reactogenicity and Safety
190380|NCT01991899|Consistency of production
190381|NCT01991886|nasal High Flow
190382|NCT01991886|premature baby
190383|NCT01991886|CPAP (Continuous positive airways pressure)
190384|NCT01991873|metastatic colorectal cancer
190385|NCT01991873|maintenance therapy
190386|NCT01991873|Panitumumab
190387|NCT01991873|Vectibix®
190388|NCT01991847|colon
190389|NCT01991847|cancer
190390|NCT01991847|prevention
190391|NCT01991847|exercise
190392|NCT01991847|physical
190393|NCT01991847|activity
190394|NCT01991834|laparoscopy
190395|NCT01991834|surgical wound infection
190396|NCT01991834|antibiotic prophylaxis
190397|NCT01991834|gynecologic surgical procedures
190398|NCT01991795|Diabetes
190399|NCT01991795|Coronary artery disease
190400|NCT01991795|Outcome
190401|NCT01991795|Prevention
190402|NCT01991795|Antiplatelet
190403|NCT01991782|Telemedicine
190404|NCT01991782|Fracture
190405|NCT01991782|Orthopaedics
190406|NCT01991769|exercise
190407|NCT01991769|endothelium
190408|NCT01991769|postprandial period
190409|NCT01991756|Abdominal Aortic Aneurysms
190410|NCT01991756|AAA
190411|NCT01991743|Version
190412|NCT01991743|Pregnancy
190413|NCT01991743|Vaginal Delivery
190414|NCT01991743|Pain Control
190415|NCT01991743|Combined Spinal Epidural
190416|NCT01991717|Victus
190417|NCT01991717|lensfragmentation
190418|NCT01991717|femtosecond laser assisted
190419|NCT01991717|capsulotomy,
190420|NCT01991717|manual, continuous curvilinear capsulorhexis (CCC)
190421|NCT01991717|effective phaco time, phaco
190422|NCT01991704|incubation
190423|NCT01991704|Craving
190424|NCT01991704|alcohol dependence
190425|NCT01991691|Antineoplastic Agents
190426|NCT01991665|Intrapartum Ultrasound
190427|NCT01991665|Vacuum
190428|NCT01991665|Occiput position
190429|NCT01991652|Wilms tumour
190430|NCT01991652|Childhood cancer
190431|NCT01991652|Africa
190432|NCT01991639|frailty
190433|NCT01991639|community-dwelling
190434|NCT01991639|malnutrition
190435|NCT01991639|physical activity
190436|NCT01991639|nutritional intervention
190437|NCT01991600|iron absorption
190438|NCT01991600|bioavailability
190439|NCT01991600|anaemia
190440|NCT01991600|iron deficiency
190441|NCT01991600|ferrous sulphate
190442|NCT01991587|Influenza
190443|NCT01991587|Human
190444|NCT01991587|RNA Virus Infections
190445|NCT01991587|Immunologic
190446|NCT01991587|Immunogenic Factors
190447|NCT01991587|Physiological Effects of Drugs
190448|NCT01991587|Virus diseases
190449|NCT01991587|Orthomyxoviridae Infections
190450|NCT01991587|Infection
190451|NCT01991574|urinary phosphate
190452|NCT01991574|iron hydroxide
190453|NCT01991574|hypophosphatemia
190454|NCT01991574|phosphate binder
190455|NCT01991574|ferric hydroxide adipate
190456|NCT01991561|Influenza, Human
190457|NCT01991561|RNA Virus Infections
190458|NCT01991561|Respiratory Tract Diseases
190459|NCT01991561|Respiratory Tract Infections
190460|NCT01991561|Aluminum Hydroxide
190461|NCT01991561|Adjuvants, Immunologic
190462|NCT01991561|Immunogenic Factors
190463|NCT01991561|GLA-SE
190464|NCT01991561|Physiological Effects of Drugs
190465|NCT01991561|Virus Diseases
190466|NCT01991561|Orthomyxoviridae Infections
190467|NCT01991561|Infection
190468|NCT01991548|Insulin pump
190469|NCT01991470|Insulin requiring diabetes
190470|NCT01991470|Children
190471|NCT01991470|Sensor
190472|NCT01991470|Accuracy
190473|NCT01991457|ALL
190474|NCT01991418|non-small cell lung cancer
190475|NCT01991418|thioredoxin reductase
190476|NCT01991418|carcina embryonic antigen
190477|NCT01991405|Mild Cognitive Impairment
190478|NCT01991405|Working Memory Training
190479|NCT01991405|Neuropsychological function in MCI
190480|NCT01991392|Pancreaticoduodenectomy
190481|NCT01991392|nasogastric tube
190482|NCT01991379|MEK162
190483|NCT01991379|Imatinib
190484|NCT01991379|13-162
190485|NCT01991366|Major adverse microvascular integrity
190486|NCT01991366|all cause mortality
190487|NCT01991366|Q Wave MI
190488|NCT01991353|Knee
190489|NCT01991353|meniscus
190490|NCT01991353|platelet rich plasma
190491|NCT01991301|graft-versus-host disease
190492|NCT01991301|stem cell transplantation
190493|NCT01991301|matched unrelated donors
190494|NCT01991301|proteosmoe inhibitor
190495|NCT01991301|carfilzumib
190496|NCT01991288|Total Knee Replacement
190497|NCT01991288|Bupivacaine
190498|NCT01991288|Levobupivacaine
190499|NCT01991288|Saphenous Nerve Block
190500|NCT01991288|Local Infiltration Analgesia
190501|NCT01991275|Prostatic Neoplasms
190502|NCT01991275|Laparoscopy
190503|NCT01991275|Injections, Spinal
190504|NCT01991275|Morphine
190505|NCT01991249|pediatric acute leukemia
190506|NCT01991249|Targeted high throughput sequencing
190507|NCT01991249|messenger RNA
190508|NCT01991197|Psoriasis
190509|NCT01991197|Type 2 Diabetes
190510|NCT01991197|Dipeptidyl peptidase-4 inhibition
190511|NCT01991197|Sitagliptin
190512|NCT01991197|Gliclazide
190513|NCT01991197|Psoriasis area and severity index
190514|NCT01991171|kinesio taping
190515|NCT01991171|Muscle activation
190516|NCT01991171|Muscle inhibition
190517|NCT01991158|GAD-M regimen
190518|NCT01991158|first line chemotherapy
190519|NCT01991158|NK/T-cell Lymphoma
190520|NCT01991145|Cerebral Palsy
190521|NCT01991145|Umbilical Cord Blood
190522|NCT01991145|Erythropoietin
190523|NCT01991145|Rehabilitation
190524|NCT01991132|Dry Eyes
190525|NCT01991132|Meibomian glands
190526|NCT01991132|Algorithm
190527|NCT01991132|MediView software
190528|NCT01991119|Atrial fibrillation
190529|NCT01991119|Propafenone
190530|NCT01991119|Dronedarone
190531|NCT01991106|Exercise
190532|NCT01991106|Myocardial function
190533|NCT01991106|Vascular function
190534|NCT01991106|Cardiovascular disease/prevention & control
190535|NCT01991106|Paediatric obesity
190536|NCT01991106|Visceral adipose tissue
190537|NCT01991093|light transmittance aggregometry (LTA),multiple electrode aggregometry, clopidogrel-resistance
190538|NCT01991080|biofeedback
190539|NCT01991080|relaxation
190540|NCT01991080|Wheat germ juice
190541|NCT01991067|Marrow transplant recipients
190542|NCT01991054|Diabetes mellitus
190543|NCT01991054|HgA1C
190544|NCT01991054|25(OH) vitamin D
190545|NCT01991054|HgA1C levels above 7.5%
190546|NCT01991041|Lennox-Gastaut Syndrome
190547|NCT01991002|14/21 diet
190548|NCT01991002|BMI
190549|NCT01991002|biochemical blood markers
190550|NCT01991002|quality of life
190551|NCT01990989|clopidogrel
190552|NCT01990989|pharmacogenomics
190553|NCT01990989|CYP2C19
190554|NCT01990989|platelet aggregation
190555|NCT01990989|score system
190556|NCT01990989|ischemic cardiovascular outcomes
190557|NCT01990989|hemorrhage complications
190558|NCT01990976|Muscular Dystrophy
190559|NCT01990976|Facioscapulohumeral
190560|NCT01990976|Physical training
190561|NCT01990976|Magnetic Resonance Imaging
190562|NCT01990976|Muscle Biopsy
190563|NCT01990963|Brain trauma;
190564|NCT01990963|MALUNA;
190565|NCT01990963|densitometric data
190566|NCT01990963|CT
190567|NCT01990950|Aneurysm
190568|NCT01990950|Aortic Aneurysm
190569|NCT01990950|Iliac Aneurysm
190570|NCT01990950|Aortic Aneurysm, Abdominal
190571|NCT01990950|Vascular Diseases
190572|NCT01990950|Cardiovascular Diseases
190573|NCT01990950|Aortic Diseases
190574|NCT01990937|oral midazolam
190575|NCT01990937|sedation
190576|NCT01990937|premedication
190577|NCT01990937|upper gastrointestinal endoscopy
190578|NCT01990937|EGD
190579|NCT01990924|fluoroscopy
190580|NCT01990924|radiation
190581|NCT01990924|transradial
190582|NCT01990924|diagnostic
190583|NCT01990924|angiography
190584|NCT01990924|cardiac
190585|NCT01990924|coronary
190586|NCT01990924|angioplasty
190587|NCT01990911|hypertension
190588|NCT01990911|hypertensive heart disease
190589|NCT01990911|atrial fibrillation
190590|NCT01990911|autonomic imbalance
190591|NCT01990872|Vitamin D status
190592|NCT01990872|25-hydroxyvitamin D
190593|NCT01990872|Vitamin D3
190594|NCT01990872|RCT
190595|NCT01990872|Calcium intake
190596|NCT01990872|Dietary requirement
190597|NCT01990846|antiviral, influenza
190598|NCT01990820|Pediatric Chronic Rhinosinusitis
190599|NCT01990807|high risk
190600|NCT01990807|Philadelphia Chromosome absent
190601|NCT01990807|Childhood acute lymphoblastic leukemia
190602|NCT01990794|Cobalt
190603|NCT01990794|Dietary Supplements
190604|NCT01990794|Hematological
190605|NCT01990794|Thyroid
190606|NCT01990781|Lidocaine, Dexamethasone, Postoperative sore throat
190607|NCT01990768|tranexamic acid
190608|NCT01990768|traumatic brain injury
190609|NCT01990768|intracranial hemorrhage
190610|NCT01990768|prehospital
190611|NCT01990768|neurologic outcome
190612|NCT01990768|glasgow outcome scale extended
190613|NCT01990768|disability rating scale
190614|NCT01990716|Adult
190615|NCT01990716|Colonoscopy
190616|NCT01990703|Contraception
190617|NCT01990703|Birth Control
190618|NCT01990703|Levonorgestrel IUD
190619|NCT01990703|Mirena IUD
190620|NCT01990690|oligohydramnios,antioxidant,oxidative stress and pregnancy outcomes
190621|NCT01990677|Central Serous Chorioretinopathy
190622|NCT01990677|csr
190623|NCT01990677|cscr
190624|NCT01990677|eplerenone
190625|NCT01990677|vision
190626|NCT01990677|choroid
190627|NCT01990677|retina
190628|NCT01990677|acute
190629|NCT01990677|chronic
190630|NCT01990638|coronary artery bypass graft
190631|NCT01990638|Diabetes mellitus, type 2
190632|NCT01990625|Maternal Near Miss Morbidity
190633|NCT01990625|Maternal Mortality
190634|NCT01990625|Neonatal Mortality
190635|NCT01990625|Gestational Age Dating
190636|NCT01990625|Pregnancy Complications
190637|NCT01990625|Ultrasound
190638|NCT01990625|Stillbirth
190639|NCT01990599|nasopharyngeal tube
190640|NCT01990599|airway management
190641|NCT01990599|thermal coagulation of the Gasserian ganglion
190642|NCT01990573|spinal surgery
190643|NCT01990573|Methadone
190644|NCT01990560|mild hypercortisolism
190645|NCT01990560|Subclinical Cushing's Syndrome
190646|NCT01990560|Preclinical Cushing's Syndrome
190647|NCT01990547|Virtual Reality Exposure Therapy
190648|NCT01990547|functional Magnetic Resonance Imaging
190649|NCT01990547|Traumatic Event
190650|NCT01990547|Trauma Survivor
190651|NCT01990547|Combat-related PTSD
190652|NCT01990547|mTBI
190653|NCT01990547|mild TBI
190654|NCT01990547|PTSD
190655|NCT01990547|Veteran
190656|NCT01990534|Lymphoma
190657|NCT01990534|Hodgkin
190658|NCT01990534|Relapsed
190659|NCT01990534|Refractory
190660|NCT01990534|Antigens, CD30
190661|NCT01990534|Antibody-Drug Conjugate
190662|NCT01990534|Antibodies, Monoclonal
190663|NCT01990534|Monomethyl auristatin E
190664|NCT01990534|Drug Therapy
190665|NCT01990534|Immunotherapy
190666|NCT01990534|Hematologic Diseases
190667|NCT01990534|Additional Relevant MeSH terms:
190668|NCT01990534|Lymphoma, Large B-Cell, Diffuse
190669|NCT01990534|Lymphoma, Hodgkin
190670|NCT01990534|Neoplasms by Histologic Type
190671|NCT01990534|Neoplasms
190672|NCT01990534|Lymphoproliferative Disorders
190673|NCT01990534|Lymphatic Diseases
190674|NCT01990534|Immunoproliferative Disorders
190675|NCT01990534|Immune System Diseases
190676|NCT01990534|Lymphoma, B-Cell
190677|NCT01990534|Lymphoma, T-Cell
190678|NCT01990534|Immunologic Factors
190679|NCT01990534|Physiological Effects of Drugs
190680|NCT01990534|Pharmacologic Actions
190681|NCT01990508|sugar-sweetened beverages
190682|NCT01990508|traffic-light labels
190683|NCT01990508|financial incentives
190684|NCT01990508|low-income community
190685|NCT01990508|obesity prevention
190686|NCT01990495|Renal failure
190687|NCT01990495|Exercise testing
190688|NCT01990495|Exercise training
190689|NCT01990495|Protein signaling
190690|NCT01990495|Skeletal muscle
190691|NCT01990469|Type 2 Diabetes Mellitus
190692|NCT01990456|Extracorporeal Membrane Oxygenation
190693|NCT01990456|Ventilator-Induced Lung Injury
190694|NCT01990456|Ventilators, Mechanical
190695|NCT01990456|Pulmonary Heart Disease
190696|NCT01990456|Ultrasonography
190697|NCT01990443|Reslizumab
190698|NCT01990443|monoclonal antibody
190699|NCT01990417|Muscle Stretching Exercises
190700|NCT01990417|Joint range of motion
190701|NCT01990417|Resistance Training
190702|NCT01990417|Physical Therapy
190703|NCT01990404|Premixed nitrous oxide and oxygen
190704|NCT01990404|Severe acute pain
190705|NCT01990404|Prehospital setting
190706|NCT01990365|Vertebral fracture, low back pain, gips, mobility
190707|NCT01990313|Parkinson's Disease
190708|NCT01990313|DBS
190709|NCT01990313|Deep Brain Stimulation
190710|NCT01990313|Subthalamic Nucleus
190711|NCT01990300|Drug Therapy
190712|NCT01990287|Low Back Pain
190713|NCT01990287|Failed Back surgery Syndrome
190714|NCT01990287|Post-Laminectomy Syndrome
190715|NCT01990287|Spinal Cord Stimulation
190716|NCT01990287|Peripheral Nerve field Stimulation
190717|NCT01990287|Pain
190718|NCT01990274|Tuberculosis
190719|NCT01990274|Diagnosis
190720|NCT01990274|GeneXpert MTB/RIF
190721|NCT01990274|Point-of-treatment
190722|NCT01990274|Mobile unit
190723|NCT01990235|Advance care planning
190724|NCT01990235|Aging
190725|NCT01990235|Health communication
190726|NCT01990235|Health literacy
190727|NCT01990235|Medical decision making
190728|NCT01990235|primary care
190729|NCT01990235|vulnerable population
190730|NCT01990235|chronic illness
190731|NCT01990222|ADHD
190732|NCT01990209|triple-negative breast cancer
190733|NCT01990209|orteronel
190734|NCT01990209|TAK-700
190735|NCT01990209|metastatic breast cancer
190736|NCT01990196|prostate cancer
190737|NCT01990196|hormone therapy
190738|NCT01990196|radical prostatectomy
190739|NCT01990183|preterm infants
190740|NCT01990183|early intervention
190741|NCT01990183|enrichment
190742|NCT01990183|cognitive, motor, visual development
190743|NCT01990183|tele-rehabilitation
190744|NCT01990131|computerized intervention
190745|NCT01990131|cognitive bias modification
190746|NCT01990131|anxiety
190747|NCT01990131|suicide
190748|NCT01990118|Renal transplant
190749|NCT01990118|Renal allograft rejection
190750|NCT01990118|Cyclosporine
190751|NCT01990118|Gengraf
190752|NCT01990105|atrial fibrillation
190753|NCT01990105|anticoagulation
190754|NCT01990105|antiarrhythmic medication
190755|NCT01990105|CHA2DS2VASc score
190756|NCT01990105|HAS-BLED score
190757|NCT01990105|CHADS2 score
190758|NCT01990092|Metanx
190759|NCT01990092|B vitamins
190760|NCT01990092|neuropathy
190761|NCT01990092|nutrition
190762|NCT01990079|PTSD
190763|NCT01990079|smoking
190764|NCT01990066|Quality of Life
190765|NCT01990066|Physical Function
190766|NCT01990040|Short Bowel Syndrome
190767|NCT01990040|SBS
190768|NCT01990040|teduglutide
190769|NCT01990040|Gattex
190770|NCT01990027|kidney stone
190771|NCT01990001|contraception, adherence, medication reminder
190772|NCT01989988|Type 2 Diabetes Mellitus (T2DM)
190773|NCT01989988|Obesity
190774|NCT01989988|Laparoscopic gastric bypass
190775|NCT01989988|Duodenum exclusion
190776|NCT01989975|Sensor-Augmented Pump Therapy
190777|NCT01989975|Connected Care
190778|NCT01989962|Aboriginal Health
190779|NCT01989962|Diabetes Mellitus Type 2
190780|NCT01989962|Cultural Competency
190781|NCT01989962|Continuing Medical Education
190782|NCT01989923|Smoking cessation
190783|NCT01989923|Traditional nicotine replacement therapy
190784|NCT01989923|Electronic nicotine delivery devices
190785|NCT01989923|electronic cigarettes
190786|NCT01989923|cervical dysplasia
190787|NCT01989910|Efavirenz
190788|NCT01989910|Raltegravir
190789|NCT01989910|Combination antiretroviral therapy
190790|NCT01989897|diluent
190791|NCT01989897|rhinitis
190792|NCT01989897|allergic
190793|NCT01989871|preterm
190794|NCT01989871|oral feeding
190795|NCT01989871|outcome
190796|NCT01989858|localized gastric adenocarcinoma, operable considered.
190797|NCT01989832|cohort
190798|NCT01989832|pharmaco-economic
190799|NCT01989832|kidney
190800|NCT01989832|transplantation
190801|NCT01989832|quality of life
190802|NCT01989806|Spinal cord injury
190803|NCT01989806|robotic
190804|NCT01989806|locomotion
190805|NCT01989793|sarcopenia
190806|NCT01989793|frailty
190807|NCT01989793|losartan
190808|NCT01989767|sickness absence
190809|NCT01989767|rehabilitation
190810|NCT01989767|mental disorders
190811|NCT01989767|screening
190812|NCT01989754|Albuminuria
190813|NCT01989754|Canagliflozin
190814|NCT01989754|Cardiovascular outcomes
190815|NCT01989754|Type 2 Diabetes Mellitus
190816|NCT01989754|T2DM
190817|NCT01989754|JNJ-28431754
190818|NCT01989754|Antihyperglycemic Agent
190819|NCT01989741|sleep restriction, decision making, wakefullness
190820|NCT01989728|sickness absence, return to work, psychiatric examination, feedback, psychological distress, quality of life, attrition analysis, multiple imputation
190821|NCT01989689|PSORIASIS
190822|NCT01989676|Phase 3
190823|NCT01989676|trastuzumab
190824|NCT01989676|Breast Neoplasms
190825|NCT01989663|Healthy Women
190826|NCT01989624|Pancreatic adenocarcinoma
190827|NCT01989624|diagnosis
190828|NCT01989624|treatment
190829|NCT01989572|locally advanced or stage IV melanoma
190830|NCT01989572|GM-CSF
190831|NCT01989572|peptide vaccine
190832|NCT01989546|DNA Damage
190833|NCT01989546|Advanced Solid Tumors
190834|NCT01989546|BRCA Mutations
190835|NCT01989546|PARP Inhibitor
190836|NCT01989546|Pharmacodynamics
190837|NCT01989533|HIV Vaccine
190838|NCT01989533|Adenovirus
190839|NCT01989520|Relative bioavailability, Healthy volunteers, Neutrophils
190840|NCT01989507|tobacco smoking
190841|NCT01989507|smoking cessation
190842|NCT01989507|nicotine dependence
190843|NCT01989507|tobacco use disorder
190844|NCT01989494|anesthesiologists
190845|NCT01989494|physical activity
190846|NCT01989494|pedometer
190847|NCT01989494|wellness
190848|NCT01989494|exercise
190849|NCT01989468|Psoriatic arthritis
190850|NCT01989468|AIN457
190851|NCT01989468|PsA
190852|NCT01989468|ACR
190853|NCT01989468|CASPAR
190854|NCT01989468|PASDAS
190855|NCT01989468|secukinumab
190856|NCT01989468|autoinjector
190857|NCT01989455|Healthy
190858|NCT01989455|Deferiprone
190859|NCT01989455|DFP
190860|NCT01989455|L1
190861|NCT01989442|cpap failure
190862|NCT01989442|bronchopulmonary dysplasia
190863|NCT01989442|nasal trauma
190864|NCT01989442|ventilation duration
190865|NCT01989442|non-invasive ventilation
190866|NCT01989429|psoriasis
190867|NCT01989429|Vitamin D3
190868|NCT01989429|topical
190869|NCT01989429|ointments
190870|NCT01989416|colonization
190871|NCT01989338|hallux valgus
190872|NCT01989338|pain
190873|NCT01989338|functional status
190874|NCT01989338|quality of life
190875|NCT01989312|ultrasound
190876|NCT01989312|peripheral nerves
190877|NCT01989312|anesthetics
190878|NCT01989312|local
190879|NCT01989299|Heart failure with preserved ejection fraction (HFpEF)
190880|NCT01989299|ILR
190881|NCT01989299|ventricular tachyarrhythmias
190882|NCT01989299|Safety
190883|NCT01989286|Plagiocephaly
190884|NCT01989286|Posture
190885|NCT01989286|Spine
190886|NCT01989260|Endometriosis
190887|NCT01989247|Depression
190888|NCT01989247|Anxiety
190889|NCT01989247|Randomized Controlled Trial
190890|NCT01989247|Self Care
190891|NCT01989247|Intervention Studies
190892|NCT01989247|Health Education
190893|NCT01989208|Heart Failure
190894|NCT01989208|Congestive Heart Failure
190895|NCT01989208|Oxidative Stress
190896|NCT01989208|Hydrogen Sulfide
190897|NCT01989195|ISCHEMIC OR CORONARY HEART DISEASE
190898|NCT01989195|MYOCARDIAL INFARCTION
190899|NCT01989195|MAGNETIC RESONANCE IMAGING
190900|NCT01989195|DELAYED GADOLINIUM ENHANCEMENT MRI
190901|NCT01989195|MANGANESE-ENHANCED MRI
190902|NCT01989195|INFARCT VOLUME/SIZE
190903|NCT01989195|ALL CAUSE MORTALITY
190904|NCT01989195|VENTRICULAR ARRHYTHMIAS
190905|NCT01989182|Endobronchial Valves
190906|NCT01989182|Intrabronchial Valves
190907|NCT01989182|Bronchial Valve
190908|NCT01989182|Chronic Obstructive Pulmonary Disease
190909|NCT01989182|COPD
190910|NCT01989182|Pulmonary Disease, Chronic Obstructive
190911|NCT01989182|Bronchoscopic Lung Volume Reduction
190912|NCT01989182|BLVR
190913|NCT01989182|TLVR
190914|NCT01989182|Emphysema
190915|NCT01989182|Pulmonary Emphysema
190916|NCT01989182|Pathologic Process
190917|NCT01989182|Lung Diseases
190918|NCT01989182|Respiratory Tract Disease
190919|NCT01989182|China
190920|NCT01989156|Smoking
190921|NCT01989156|Candidate modified risk tobacco product
190922|NCT01989156|Menthol conventional cigarettes
190923|NCT01989156|Reduced exposure
190924|NCT01989156|HPHCs
190925|NCT01989156|Ambulatory
190926|NCT01989143|Phase 1
190927|NCT01989143|Randomized
190928|NCT01989143|Double-blind
190929|NCT01989143|Placebo-controlled
190930|NCT01989143|Dose escalating
190931|NCT01989143|Single and Multiple doses
190932|NCT01989143|Safety
190933|NCT01989143|Tolerability
190934|NCT01989143|PK/PD
190935|NCT01989143|PF-06480605
190936|NCT01989130|antimicrobial stewardship
190937|NCT01989130|Cepheid Xpert CT/NG
190938|NCT01989130|chlamydia
190939|NCT01989130|gonorrhea
190940|NCT01989130|emergency department
190941|NCT01989130|Diagnostic Techniques, Obstetrical and Gynecological
190942|NCT01989130|Diagnostic Techniques, Urological
190943|NCT01989104|Indirect calorimetry
190944|NCT01989091|kidney dialysis
190945|NCT01989091|hemodialysis
190946|NCT01989091|locking solution
190947|NCT01989091|antimicrobial
190948|NCT01989091|thrombolytic
190949|NCT01989078|Kidney disorder
190950|NCT01989078|Blood disorder
190951|NCT01989078|Pediatrics
190952|NCT01989065|Child obesity
190953|NCT01989065|childhood obesity
190954|NCT01989065|obesity treatment
190955|NCT01989065|text messaging
190956|NCT01989065|Lifestyle
190957|NCT01989052|Carboxyamidotriazole Orotate
190958|NCT01989052|CTO
190959|NCT01989052|Lomustine
190960|NCT01989052|N-(2-chloroethyl)-N'-cyclo-hexyl-N-nitrosourea (CCNU)
190961|NCT01989052|CeeNU
190962|NCT01989052|Malignant Glioma
190963|NCT01989052|Pro00047969
190964|NCT01989052|Desjardins
190965|NCT01989052|Duke
190966|NCT01989052|The Preston Robert Tisch Brain Tumor Center
190967|NCT01989026|BCG
190968|NCT01989026|non-specific effects
190969|NCT01989026|neonatal mortality
190970|NCT01989026|vaccines
190971|NCT01989013|Parkinson's disease
190972|NCT01989013|Craniosacral therapy
190973|NCT01989013|cranial osteopathy
190974|NCT01989000|Pancreatic cancer
190975|NCT01989000|Hypoxia
190976|NCT01989000|Vasculature
190977|NCT01989000|Stroma
190978|NCT01988987|Gestational diabetes
190979|NCT01988987|Postpartum glucose testing
190980|NCT01988987|Impaired glucose metabolism
190981|NCT01988987|Diabetes mellitus
190982|NCT01988961|Colitis, Ulcerative
190983|NCT01988961|Golimumab
190984|NCT01988961|CNTO148
190985|NCT01988961|SIMPONI
191111|NCT01988480|Sinus graft
190986|NCT01988961|Length-109 Probe Set Panel
190987|NCT01988948|Human papilloma virus
190988|NCT01988948|Young women
190989|NCT01988948|I-Share
190990|NCT01988922|ketamine polymorphisms
190991|NCT01988909|Cutaneous leishmaniasis
190992|NCT01988909|Paromomycin + Gentamicin Topical Cream
190993|NCT01988909|Safety
190994|NCT01988909|Efficacy
190995|NCT01988883|Postural Tachycardia Syndrome
190996|NCT01988883|Tachycardia
190997|NCT01988883|Orthostatic Intolerance
190998|NCT01988883|Autonomic Nervous System Diseases
190999|NCT01988883|Primary Dysautonomias
191000|NCT01988883|Nervous System Diseases
191001|NCT01988883|Cardiovascular Diseases
191002|NCT01988883|Modafinil
191003|NCT01988883|Propranolol
191004|NCT01988883|Neurobehavioral Manifestations
191005|NCT01988883|Neurologic Manifestations
191006|NCT01988883|Cognitive Symptoms
191007|NCT01988883|Neuropsychological Tests
191008|NCT01988857|Vietnam
191009|NCT01988857|Children
191010|NCT01988857|Reactogenicity
191011|NCT01988857|BoostrixTM
191012|NCT01988857|Safety
191013|NCT01988857|dTpa
191014|NCT01988857|Booster
191015|NCT01988857|Healthy
191016|NCT01988844|functionality
191017|NCT01988844|Cerebral palsy
191018|NCT01988844|Handwriting
191019|NCT01988831|Malignant melanoma
191020|NCT01988831|betablocker
191021|NCT01988831|propranolol
191022|NCT01988831|interventional
191023|NCT01988831|prospective
191024|NCT01988831|adjuvant
191025|NCT01988831|recurrence
191026|NCT01988818|wound dressing
191027|NCT01988818|silicone
191028|NCT01988818|standard wound dressing
191029|NCT01988766|Thrombosis
191030|NCT01988766|Central Venosis Catheter
191031|NCT01988766|Renal Disease
191032|NCT01988766|Vascular Access
191033|NCT01988753|Serum Biomarkers
191034|NCT01988753|Sheer-wave Elastography
191035|NCT01988753|Ultrasound imaging
191036|NCT01988753|Viral hepatitis
191037|NCT01988753|Liver Fibrosis
191038|NCT01988753|Liver disease
191039|NCT01988753|Hepatitis B
191040|NCT01988753|Hepatitis C
191041|NCT01988740|Ischemia-modified albumin
191042|NCT01988740|Recurrent pregnancy loss
191043|NCT01988740|Abnormal placenta
191044|NCT01987895|Post-antibiotic diarrhea
191045|NCT01987895|Clostridium difficile infection
191046|NCT01987882|Outcomes research, treatment effectiveness, quality of life
191047|NCT01987869|hiperemesis gravidarum,vomiting,serotonin levels,ketonuria
191048|NCT01987856|aCGH
191049|NCT01987856|chromosome
191050|NCT01987856|blastocyst
191051|NCT01987856|trophectoderm
191052|NCT01987856|vitrification
191053|NCT01987856|natural cycle
191054|NCT01987856|pregnancy
191055|NCT01987856|live birth
191056|NCT01988714|Targeted cognitive training (TCT) plus evidence-based SE
191057|NCT01988714|Computer games (CG) plus evidence-based SE
191058|NCT01988701|GVHD
191059|NCT01988701|chronic Graft versus Host Disease
191060|NCT01988688|deep brain stimulation
191061|NCT01988662|nAMD, VEGF, VEGF agent, BCVA, CRT, Ranibizumab, Lucentis, Aflibercept, Eylea
191062|NCT01988649|Pain
191063|NCT01988649|Oxytocin
191064|NCT01988636|Randomized
191065|NCT01988636|Double Blinded
191066|NCT01988636|Mali
191067|NCT01988636|Malaria
191068|NCT01988636|Transmission
191069|NCT01988623|Intellectual Disabilities
191070|NCT01988623|Speech Delay
191071|NCT01988623|Language Disorder
191072|NCT01988610|cognition
191073|NCT01988610|prediabetes
191074|NCT01988610|mood
191075|NCT01988597|Dry Eyes
191076|NCT01988597|Quality of life
191077|NCT01988597|Utility assessment
191078|NCT01988584|Cerebral Palsy
191079|NCT01988584|Brain Injury
191080|NCT01988584|Stem Cells
191081|NCT01988584|Mononuclear Cells
191082|NCT01988584|Bone Morrow
191083|NCT01988584|Umbilical Cord Blood
191084|NCT01988571|Stage I breast cancer
191085|NCT01988571|Stage II breast cancer
191086|NCT01988571|Stage III breast cancer
191087|NCT01988558|Recurrent Tonsillitis
191088|NCT01988558|Streptococcus A
191089|NCT01988545|GLP-1
191090|NCT01988545|blood flow
191091|NCT01988545|cardiac out put
191092|NCT01988545|stroke volume
191093|NCT01988545|beat to beat
191094|NCT01988545|effect of GLP-1 on cardiac parameters and blood flow
191095|NCT01988506|IL2,
191096|NCT01988506|Interleukin 2,
191097|NCT01988506|IL-2,
191098|NCT01988506|Proleukin®, RhIL-2
191099|NCT01988506|Auto-immune disease
191100|NCT01988506|Inflammatory disease
191101|NCT01988506|Inflammation
191102|NCT01988506|Regulatory T cells,
191103|NCT01988506|Treg
191104|NCT01988506|Immunoregulation
191105|NCT01988506|Immune tolerance
191106|NCT01988493|Carcinoma, Hepatocellular
191107|NCT01988493|MSC2156119J
191108|NCT01988493|Sorafenib
191109|NCT01988493|Recommended Phase 2 dose
191110|NCT01988480|Guided surgery
191112|NCT01988467|nasal breathing, oral breathing, secondhand smoking,
191113|NCT01988441|autophagy
191114|NCT01988441|children
191115|NCT01988441|polymorphism
191116|NCT01988428|sepsis
191117|NCT01988428|severe sepsis
191118|NCT01988428|septic shock
191119|NCT01988402|gout
191120|NCT01988402|allopurinol
191121|NCT01988363|greater occipital nerve
191122|NCT01988363|occipital neuralgia
191123|NCT01988363|cervicogenic headache
191124|NCT01988350|pancreatic insufficiency
191125|NCT01988350|pancreatic elastase
191126|NCT01988350|fecal elastase
191127|NCT01988350|smoking
191128|NCT01988350|tobacco
191129|NCT01988311|Psilocybin
191130|NCT01988311|Hallucinogens
191131|NCT01988311|Pharmacologic Actions
191132|NCT01988311|Central Nervous System Agents
191133|NCT01988311|Therapeutic Uses
191134|NCT01988311|Psychotropic Drugs
191135|NCT01988285|Esophagitis
191136|NCT01988285|Eosinophilic Esophagitis
191137|NCT01988285|Esophageal Diseases
191138|NCT01988285|Gastrointestinal Diseases
191139|NCT01988285|Digestive System Diseases
191140|NCT01988272|SPECT/CT
191141|NCT01988272|Dosimetry
191142|NCT01988272|Radiation absorbed dose
191143|NCT01988272|Non-Hodgkin's Lymphoma
191144|NCT01988272|I-131 tositumomab radioimmunotherapy
191145|NCT01988246|Diabetes
191146|NCT01988246|Diabetic Retinopathy
191147|NCT01988233|Physical activity
191148|NCT01988233|Dance
191149|NCT01988233|Latinos
191150|NCT01988233|Aging
191151|NCT01988233|Older adults
191152|NCT01988233|Health disparities
191153|NCT01988220|stroke
191154|NCT01988220|sensory deficit
191155|NCT01988220|sensory retraining
191156|NCT01988220|perceptual learning
191157|NCT01988220|lower extremity
191158|NCT01988207|Muscle Tension Dysphonia
191159|NCT01988207|Voice
191160|NCT01988207|Hyperfunction
191161|NCT01988194|acupuncture
191162|NCT01988194|postoperative pain
191163|NCT01988194|nausea
191164|NCT01988194|vomiting
191165|NCT01988194|anxiety
191166|NCT01988194|depression
191167|NCT01988194|hospitalization
191168|NCT01988194|inpatient
191169|NCT01988181|Intradialytic Hypotension
191170|NCT01988181|Renal Dialysis
191171|NCT01988181|Blood Volume Determination
191172|NCT01988181|Clinical Trials, Randomized
191173|NCT01988181|Crossover Studies
191174|NCT01988168|Suture Techniques
191175|NCT01988168|Sutures
191176|NCT01988168|Surgical Staplers
191177|NCT01988142|Spinal Cord Injury
191178|NCT01988142|Passive motion
191179|NCT01988142|Fatigue index
191180|NCT01988142|Hypertonia
191181|NCT01988129|sleep
191182|NCT01988129|firefighter
191183|NCT01988129|fire
191184|NCT01988129|apnea
191185|NCT01988129|insomnia
191186|NCT01988129|shift
191187|NCT01988129|narcolepsy
191188|NCT01988129|restless leg
191189|NCT01988129|rls
191190|NCT01988129|fatigue
191191|NCT01988129|actigraph
191192|NCT01988129|actigraphy
191193|NCT01988129|actiwatch
191194|NCT01988129|safety
191195|NCT01988129|sleepiness
191196|NCT01988129|sleepy
191197|NCT01988129|work
191198|NCT01988129|hours
191199|NCT01988129|Federal Emergency Management Agency
191200|NCT01988129|drowsy
191201|NCT01988116|Chronic kidney disease
191202|NCT01988116|Anemia of chronic disease
191203|NCT01988116|Iron Metabolism
191204|NCT01988116|Iron Homeostasis
191205|NCT01988116|Vitamin D
191206|NCT01988116|Calcitriol
191207|NCT01988116|hemojuvelin
191208|NCT01988116|hepcidin
191209|NCT01988116|anemia
191210|NCT01988116|ferroportin
191211|NCT01988103|Psoriasis; Psoriatic Arthritis
191212|NCT01988090|Breast Cancer
191213|NCT01988090|Hormone Receptor Positive
191214|NCT01988090|Vitamin D
191215|NCT01988064|pulse rate
191216|NCT01988064|patient education
191217|NCT01988064|training
191218|NCT01988038|Polycystic Kidney Disease
191219|NCT01988038|Autosomal Dominant Polycystic Kidney Disease
191220|NCT01988038|Disease Progression
191221|NCT01987986|cellulite
191222|NCT01987986|dimple
191223|NCT01987986|orange peel
191224|NCT01987986|cottage cheese
191225|NCT01987986|mattress texture
191226|NCT01987947|MEMP1972A
191227|NCT01987934|Squamous Cell Carcinoma of the Head and Neck
191228|NCT01987934|Methyl Green Pyronin Staining
191229|NCT01987934|AgNORs
191230|NCT01987934|Morphometry
191231|NCT01987921|Acute kidney injury
191232|NCT01987921|Pediatrics
191233|NCT01987921|Critical Care
191234|NCT01987908|Pain
191235|NCT01987908|Biomarkers
191236|NCT01987908|6 minute walk test
191237|NCT01987908|5-HMF
191238|NCT01987908|Pharmacokinetics
191239|NCT01987908|Analgesic use
191240|NCT01987908|Sickle cell disease
191241|NCT01987908|Aes-103
191242|NCT01987908|SpO2
191243|NCT01987908|Anemia
191244|NCT01987908|Hemoglobin
191245|NCT01987843|Psoriasis
191246|NCT01987843|Plaque Psoriasis
191247|NCT01987830|Recurrent glioblastoma
191248|NCT01987817|Characterized Peanut Allergen
191249|NCT01987817|Peanut
191250|NCT01987817|OIT
191251|NCT01987817|Oral Desensitization
191252|NCT01987817|Peanut Allergen
191253|NCT01987817|Allergy
191254|NCT01987817|Peanut Allergy
191255|NCT01987817|Peanut-Allergic Children
191256|NCT01987817|Children
191257|NCT01987817|Peanut-Allergic Adults
191258|NCT01987778|Hot flashes
191259|NCT01987778|Menopause
191260|NCT01987778|HRQoL
191261|NCT01987778|Resistance training
191262|NCT01987778|Physical activity
191263|NCT01987778|Adipose tissue
191264|NCT01987739|Almorexant
191265|NCT01987739|Zolpidem
191266|NCT01987726|Solid Tumor Malignancies
191267|NCT01987700|Abdominal Hernia Repair
191268|NCT01987700|Dermal Allograft
191269|NCT01987700|Mesh
191270|NCT01987700|Component Separation
191271|NCT01987661|COPD
191272|NCT01987661|NIV
191273|NCT01987661|Airtrapping
191274|NCT01987661|Ventimotion2
191275|NCT01987648|Craniotomy
191276|NCT01987648|Postoperative complications
191277|NCT01987648|Perioperative care
191278|NCT01987648|Postoperative intracerebral hemorrhage
191279|NCT01987648|Postoperative seizure
191280|NCT01987635|Mitral valve disease
191281|NCT01987635|primarily regurgitation
191282|NCT01987635|necessitating surgical repair
191283|NCT01987622|lumbar spinal stenosis
191284|NCT01987622|claudication
191285|NCT01987622|low back pain
191286|NCT01987622|radiculopathy
191287|NCT01987622|acupuncture
191288|NCT01987622|Korean medicine
191289|NCT01987622|randomized controlled trial
191290|NCT01987609|Psoriasis
191291|NCT01987609|Dendritic cells
191292|NCT01987609|Hyaluronidase
191293|NCT01987609|Hylenex
191294|NCT01987570|Xanthine oxidase
191295|NCT01987570|Magnetic resonance
191296|NCT01987570|Oxidative stress
191297|NCT01987570|Inflammation
191298|NCT01987557|treadmill
191299|NCT01987557|parkinson's
191300|NCT01987557|proprioception
191301|NCT01987557|cadence
191302|NCT01987557|step length
191303|NCT01987557|intrinsic feedback
191304|NCT01987544|COPD
191305|NCT01987544|telemonitoring
191306|NCT01987544|training
191307|NCT01987544|ergometer
191308|NCT01987544|telemedicine
191309|NCT01987531|after open cardiac chamber cardiac surgery
191310|NCT01987466|Neutrophil Gelatinase-associated Lipocalin(NGAL)
191311|NCT01987466|Acute renal failure
191312|NCT01987466|Cardiac arrest
191313|NCT01987466|Hypothermia
191314|NCT01987453|genotype 1
191315|NCT01987427|Overweight
191316|NCT01987427|Obese
191317|NCT01987427|Weight Management
191318|NCT01987414|Stroke
191319|NCT01987414|Cardiovascular Accident
191320|NCT01987414|Task-oriented approach
191321|NCT01987414|Orthosis
191322|NCT01987414|occupational therapy
191323|NCT01987401|pulmonary
191324|NCT01987401|lung
191325|NCT01987401|military and environmental exposures
191326|NCT01987401|epidemiologic
191327|NCT01987401|observational
191328|NCT01987401|interview or questionnaire
191329|NCT01987401|deployment related
191330|NCT01987401|Enduring Freedom
191331|NCT01987401|Iraqi Freedom
191332|NCT01987375|HNSCC
191333|NCT01987375|Imaging
191334|NCT01987349|Influenza vaccines
191335|NCT01987336|Standard Foley Catheter
191336|NCT01987323|glaucoma
191337|NCT01987323|raised intraocular pressure
191338|NCT01987310|non alcoholic fatty liver disease
191339|NCT01987310|endothelial function
191340|NCT01987310|liver steatosis
191341|NCT01987310|liver fibrosis
191342|NCT01987310|statin treatment
191343|NCT01987297|arsenic
191344|NCT01987297|acute promyelocytic leukemia
191345|NCT01987297|outcome
191346|NCT01987271|exercise tolerance
191347|NCT01987271|exercise test
191348|NCT01987271|noninvasive ventilation
191349|NCT01987258|Glycemic control
191350|NCT01987258|excess post-exercise oxygen consumption
191351|NCT01987219|familial dysautonomia
191352|NCT01987206|artificial pancreas
191353|NCT01987193|Proton radiation
191354|NCT01987193|tumor blood flow
191355|NCT01987180|self-efficacy
191356|NCT01987167|acute optic neuritis
191357|NCT01987115|Trigger Finger
191358|NCT01987115|Physiotherapy
191359|NCT01987115|Fascial Manipulation
191360|NCT01987102|Methotrexate
191361|NCT01987102|rescue treatment
191362|NCT01987089|Insomnia
191363|NCT01987089|Sleep initiation and maintenance disorder
191364|NCT01987089|Alcoholism
191365|NCT01987089|Cognitive behavioral therapy for insomnia
191366|NCT01987076|DRESS
191367|NCT01987076|Systemic steroid
191368|NCT01987076|Topical steroid
191369|NCT01987076|Treatment
191370|NCT01987063|Twin delivery
191371|NCT01987063|Planned vaginal delivery
191372|NCT01987063|Planned cesarean delivery
191373|NCT01987063|Total breech extraction
191374|NCT01987063|Internal cephalic version
191375|NCT01987063|External cephalic version
191376|NCT01987037|autism spectrum disorder
191377|NCT01987037|neuropsychomotor assessment
191378|NCT01987037|NP-MOT
191379|NCT01987037|motor skills
191380|NCT01987037|gross motor
191381|NCT01987011|Avian influenza
191382|NCT01986998|Multiple sclerosis relapse
191383|NCT01986998|oral methylprednisolone
191384|NCT01986998|EDSS
191385|NCT01986998|gadolinium
191386|NCT01986972|Toothbrushing
191387|NCT01986972|Dental plaque
191388|NCT01986972|Dentifrice
191389|NCT01986972|Oral hygiene
191390|NCT01986959|Periodontal Dressings
191391|NCT01986959|Surgical crown lengthening
191392|NCT01986959|Periodontal surgery
191393|NCT01986920|SK
191394|NCT01986907|wet AMD
191395|NCT01986907|macular degeneration
191396|NCT01986907|ranibizumab
191397|NCT01986907|mono-bilateral
191398|NCT01986907|poor visual acuity
191399|NCT01986907|retinal disease
191400|NCT01986907|eye disease
191401|NCT01986907|Angiogenesis Inhibitors
191402|NCT01986907|Angiogenesis Modulating Agents
191403|NCT01986894|TQT
191404|NCT01986894|Pharmacokinetic
191405|NCT01986894|Healthy
191406|NCT01986868|Coronary Magnetic Resonance Angiography
191407|NCT01986868|CMRA
191408|NCT01986868|MRI with contrast
191409|NCT01986868|MultiHance
191410|NCT01986868|Optimark
191411|NCT01986868|Gadolinium-based contrast
191412|NCT01986868|MRA
191413|NCT01986868|MR angiography
191414|NCT01986842|Muscle protein synthesis
191415|NCT01986842|Digestion and absorption kinetics
191416|NCT01986842|Leucine
191417|NCT01986842|Whey protein
191418|NCT01986816|Obesity
191419|NCT01986816|Bariatric surgery
191420|NCT01986816|Laparoscopic gastric bypass
191421|NCT01986816|Quality of life
191422|NCT01986816|QALY
191423|NCT01986803|ST-elevation Myocardial Infarction (STEMI)
191424|NCT01986803|Primary Percutaneous Coronary Intervention within 24 hrs
191425|NCT01986803|Healing score
191426|NCT01986803|OFDI
191427|NCT01986790|Health insurance
191428|NCT01986790|Health services accessibility
191429|NCT01986790|Decision making
191430|NCT01986790|Health literacy
191431|NCT01986777|cognitive complains
191432|NCT01986777|RRSO
191433|NCT01986777|oophorectomy
191434|NCT01986777|memory
191435|NCT01986777|cognition
191436|NCT01986777|early menopause
191437|NCT01986764|oophorectomy
191438|NCT01986764|RRSO
191439|NCT01986764|menopause
191440|NCT01986764|early menopause
191441|NCT01986764|cognition
191442|NCT01986764|memory
191443|NCT01986764|brain-imaging
191444|NCT01986751|nerve
191445|NCT01986751|block
191446|NCT01986751|motor blockade
191447|NCT01986751|lower extremity pain
191448|NCT01986751|nerve block
191449|NCT01986725|vulvar neoplasia
191450|NCT01986725|vulvar cancer
191451|NCT01986725|vulvar intraepithelial neoplasia
191452|NCT01986725|self management
191453|NCT01986725|symptom management
191454|NCT01986699|polypectomy
191455|NCT01986699|laparoscopic
191456|NCT01986673|Pharmacokinetic Characterization
191457|NCT01986660|Pharmacokinetic Study
191458|NCT01986647|exercise
191459|NCT01986647|older adults
191460|NCT01986647|mobility disability
191461|NCT01986634|Laser Resurfacing
191462|NCT01986634|Rhytids
191463|NCT01986634|Perioral
191464|NCT01986608|Lacosamide
191465|NCT01986608|Vimpat
191466|NCT01986608|Bioequivalence
191467|NCT01986608|Bioavailability
191468|NCT01986608|Japanese
191469|NCT01986595|Neuroblastoma
191470|NCT01986595|anaplastic lymphoma kinase
191471|NCT01986595|cancer genetics
191472|NCT01986595|target therapy
191473|NCT01986595|RNA and genomic DNA extraction
191474|NCT01986595|complementary DNA(cDNA) preparation
191475|NCT01986595|Array-comparative genomic hybridization
191476|NCT01986595|Multiplex ligation-dependent probe amplification (MLPA)
191477|NCT01986595|Sequencing of cDNA prepared from NB
191478|NCT01986595|Pyrosequencing
191479|NCT01986595|Quantitative real-time polymerase chain reaction(RT-PCR)
191480|NCT01986595|Immunohistochemistry
191481|NCT01986582|Allergic Rhinitis
191482|NCT01986582|Congestion
191483|NCT01986582|Mucoadhesive Treatment
191484|NCT01986582|Nasal Decongestant
191485|NCT01986569|Fluoroestradiol (FES)
191486|NCT01986569|PET/CT scan
191487|NCT01986569|Estrogen Receptor
191488|NCT01986569|Recurrent breast cancer
191489|NCT01986569|Stage IV breast cancer
191490|NCT01986543|Pharmacokinetic
191491|NCT01986530|irisin
191492|NCT01986530|adiponectin
191493|NCT01986530|leptin
191494|NCT01986530|lean body mass
191495|NCT01986530|fat mass
191496|NCT01986517|Feedback
191497|NCT01986517|Therapeutic competencies
191498|NCT01986517|Training
191499|NCT01986504|Infection
191500|NCT01986504|Cohort
191501|NCT01986504|Prospective
191502|NCT01986504|Epidemiology
191503|NCT01986504|Outcome
191504|NCT01986491|Healthy
191505|NCT01986491|JNJ-39393406
191506|NCT01986491|Relative Bioavailability
191507|NCT01986491|Solid Formulation
191508|NCT01986465|lateral epicondylitis
191509|NCT01986465|treatment
191510|NCT01986465|steroid
191511|NCT01986465|immobilization
191512|NCT01986452|OSA
191513|NCT01986452|Apoplexy
191514|NCT01986452|CPAP
191515|NCT01986452|adherence
191516|NCT01986452|telemonitoring
191517|NCT01986426|Transdermal accessible tumours
191518|NCT01986413|COPD
191519|NCT01986413|chronic hypercapnic respiratory failure
191520|NCT01986413|NIV
191521|NCT01986413|respiratory events
191522|NCT01986413|IVAPS
191523|NCT01986400|Adolescent
191524|NCT01986400|Skype
191525|NCT01986400|Peer Mentorship
191526|NCT01986400|Internet Self-Management
191527|NCT01986387|adolescent
191528|NCT01986387|Skype
191529|NCT01986387|peer mentorship
191530|NCT01986387|internet self-management
191531|NCT01986374|IVF , embryo implantation, HCG
191532|NCT01986361|Pharyngitis
191533|NCT01986361|Sore Throat
191534|NCT01986361|acute upper respiratory tract infection (URTI)
191535|NCT01986348|GBM
191536|NCT01986348|Glioblastoma
191537|NCT01986348|selinexor
191538|NCT01986348|KPT-330
191539|NCT01986348|Karyopharm
191540|NCT01986348|brain tumor
191541|NCT01986348|brain cancer
191542|NCT01986348|Glioma
191543|NCT01986348|Astrocytoma
191544|NCT01986348|Oligodendrogliomas
191545|NCT01986348|Oligo-astrocytomas
191546|NCT01986335|Combined pentavalent DTP/HB/Hib vaccine
191547|NCT01986335|Infants
191548|NCT01986335|Primary vaccination
191549|NCT01986322|DTP/HB/Hib vaccine
191550|NCT01986322|Immunogenicity
191551|NCT01986322|Infants
191552|NCT01986322|Safety
191553|NCT01986309|Postoperative
191554|NCT01986309|Nausea
191555|NCT01986309|Vomiting
191556|NCT01986309|Pain
191557|NCT01986309|Surgery
191558|NCT01986283|Abuse potential
191559|NCT01986283|PF-00345439
191560|NCT01986283|drug abuse
191561|NCT01986244|Osteoarthritis
191562|NCT01986244|Arthritis
191563|NCT01986244|Joint Diseases
191564|NCT01986231|diabetes
191565|NCT01986231|insulin
191566|NCT01986231|glucagon
191567|NCT01986231|glycogen
191568|NCT01986231|MRS
191569|NCT01986205|Concussion, mild
191570|NCT01986205|Traumatic brain injury
191571|NCT01986205|Hyperbaric oxygenation
191572|NCT01986205|Post-concussion symptoms
191573|NCT01986205|Headache
191574|NCT01986192|anticoagulation
191575|NCT01986192|pharmacomechanical thrombolysis
191576|NCT01986192|aspiration thrombectomy
191577|NCT01986153|Fatty acid, essential
191578|NCT01986153|Immune system
191579|NCT01986153|Home parenteral nutrition
191580|NCT01986140|Breast Cancer
191581|NCT01986140|Alopecia
191582|NCT01986140|Scalp
191583|NCT01986140|Cooling
191584|NCT01986127|Crohn disease
191585|NCT01986075|Cocaine Dependence Treatment
191586|NCT01986075|Computer-assisted therapy
191587|NCT01986075|Pharmacotherapy
191588|NCT01986062|ADHD
191589|NCT01986062|AR11
191590|NCT01986062|classroom design
191591|NCT01986062|amphetamine sulfate
191592|NCT01986023|Stroke
191593|NCT01986023|Medication Adherence
191594|NCT01986023|SMS
191595|NCT01986023|Randomised
191596|NCT01985997|FluMist, Quadrivalent, Vaccine
191597|NCT01985984|Head and neck cancer
191598|NCT01985906|Aorta
191599|NCT01985906|Aneurysm
191600|NCT01985906|Stents
191601|NCT01985906|Collateral Circulation
191602|NCT01985893|Metastatic
191603|NCT01985893|breast
191604|NCT01985893|cancer
191605|NCT01985880|Biomarkers
191606|NCT01985854|Desflurane
191607|NCT01985854|Propofol
191608|NCT01985854|Total intravenous anesthesia
191609|NCT01985854|Neurosurgery
191610|NCT01985841|Early breast cancer
191611|NCT01985841|Primary operable breast cancer
191612|NCT01985841|HER2- negative
191613|NCT01985841|bevacizumab
191614|NCT01985828|Prostate neoplasm
191615|NCT01985828|Prostate Cancer
191616|NCT01985815|obsessive-compulsive disorder
191617|NCT01985815|Deep Brain Stimulation
191618|NCT01985815|Psychosurgery
191619|NCT01985789|airway hyperresponsiveness
191620|NCT01985776|Exercise
191621|NCT01985776|Electric Stimulation
191622|NCT01985763|Genistein
191623|NCT01985763|soy supplements
191624|NCT01985763|phytoestrogens
191625|NCT01985763|colon cancer
191626|NCT01985763|rectal cancer
191627|NCT01985763|colorectal cancer
191628|NCT01985763|metastatic
191629|NCT01985763|stage IV
191630|NCT01985763|FOLFOX
191631|NCT01985763|FOLFOX-Avastin
191632|NCT01985763|Chemotherapy
191633|NCT01985750|dyspnea
191634|NCT01985750|fmri
191635|NCT01985750|d-cycloserine
191636|NCT01985737|Neonatal Intensive Care Units (NICUs)
191637|NCT01985737|NICUs
191638|NCT01985737|Neonates
191639|NCT01985737|CLABSI
191640|NCT01985737|Microbiome
191641|NCT01985737|DNA signature
191642|NCT01985737|Catheter infections
191643|NCT01985724|Early breast cancer
191644|NCT01985724|Axillary node positive
191645|NCT01985724|HER-2 negative
191646|NCT01985724|Adjuvant chemotherapy
191647|NCT01985724|Dose dense
191648|NCT01985724|Docetaxel
191649|NCT01985724|FEC
191650|NCT01985711|Motivational Interviewing
191651|NCT01985711|Cognitive Behavioral Therapy
191652|NCT01985711|Transtheoretical Model of behavior change
191653|NCT01985711|Questionnaires
191654|NCT01985711|Telemedicine/*methods
191655|NCT01985711|Comorbidity
191656|NCT01985711|Diabetes
191657|NCT01985711|Glucose/metabolism
191658|NCT01985711|Hemoglobin A, Glycosylated
191659|NCT01985711|Blood Pressure
191660|NCT01985711|Cholesterol, LDL/blood
191661|NCT01985711|Quality of life
191662|NCT01985711|Depressive Disorder/psychology/*therapy
191663|NCT01985711|Randomized Controlled Trials
191664|NCT01985698|Low rectal cancer
191665|NCT01985698|Robotic
191666|NCT01985698|Laparoscopic
191667|NCT01985698|Abdominoperineal resection
191668|NCT01985685|VO2, critically ill, oxygen consumption
191669|NCT01985672|Infertility
191670|NCT01985659|Lymph Node Excision
191671|NCT01985659|Thoracic Surgical Procedures
191672|NCT01985659|Thoracic Surgery, Video-Assisted
191673|NCT01985659|Thoracotomy
191674|NCT01985646|Hirschsprung disease
191675|NCT01985646|conservative treatment
191676|NCT01985646|surgery treatment
191677|NCT01985646|infants
191678|NCT01985633|Osteoarthritis
191679|NCT01985633|stem cells
191680|NCT01985633|Platelet gel
191681|NCT01985633|Functional outcome
191682|NCT01985620|Vaccination
191683|NCT01985620|RSV
191684|NCT01985620|Influenza
191685|NCT01985620|Prematurity
191686|NCT01985594|preterm labor
191687|NCT01985581|Attention Deficit Hyperactivity Disorder
191688|NCT01985581|Intuniv extended release
191689|NCT01985581|Executive Function
191690|NCT01985581|Quality of Life
191691|NCT01985568|Obesity
191692|NCT01985568|weight-loss
191693|NCT01985568|Physical activity
191694|NCT01985555|Phase I
191695|NCT01985555|Safety
191696|NCT01985555|Pharmacokinetics
191697|NCT01985516|Pain
191698|NCT01985516|Urethra
191699|NCT01985516|Catheter
191700|NCT01985503|positron emission tomography
191701|NCT01985503|magnetic resonance imaging
191702|NCT01985503|brown adipose tissue
191703|NCT01985503|obesity
191704|NCT01985503|cardiovascular disease
191705|NCT01985503|subclinical atherosclerosis
191706|NCT01985490|epiretinal membrane
191707|NCT01985490|foveal avascular zone
191708|NCT01985490|internal limiting membrane
191709|NCT01985477|Myeloma
191710|NCT01985477|Multiple myeloma
191711|NCT01985477|MM
191712|NCT01985477|Relapsed/Refractory Multiple Myeloma
191713|NCT01985477|RR MM
191714|NCT01985477|Lenalidomide
191715|NCT01985477|CC-5013
191716|NCT01985477|Revlimid
191717|NCT01985477|Dexamethasone
191718|NCT01985477|Decadron
191719|NCT01985477|All-Trans Retinoic Acid
191720|NCT01985477|ATRA
191721|NCT01985477|Tretinoin (Oral)
191722|NCT01985477|Vesanoid
191723|NCT01985464|rheumatoid arthritis
191724|NCT01985464|umbilical cord
191725|NCT01985464|mesenchymal
191726|NCT01985464|stem cells
191727|NCT01985451|Lymphoma
191728|NCT01985438|Head and Neck Neoplasms
191729|NCT01985438|Nutritional Support
191730|NCT01985438|Randomized Controlled Trial
191731|NCT01985438|Percutaneous Endoscopic Gastrostomy tube
191732|NCT01985438|Nasogastric tube
191733|NCT01985438|Radiation Effects
191734|NCT01985438|Pakistan
191735|NCT01985412|Rejection
191736|NCT01985412|Transplant
191737|NCT01985412|Cardiac
191738|NCT01985412|Pulmonary
191739|NCT01985412|Heart
191740|NCT01985412|Lung
191741|NCT01985412|Cell-Free DNA
191742|NCT01985412|cfDNA
191743|NCT01985412|Cell
191744|NCT01985412|Free
191745|NCT01985412|DNA
191746|NCT01985412|Biopsy
191747|NCT01985412|Non-Invasive
191748|NCT01985399|HIV
191749|NCT01985399|AIDS
191750|NCT01985399|Aging
191751|NCT01985386|Iron absorption
191752|NCT01985386|Slow release iron
191753|NCT01985386|Gastric delivery system
191754|NCT01985386|Iron deficiency
191755|NCT01985373|intravenous immunoglobulin
191756|NCT01985373|pharmacokinetics
191757|NCT01985373|10% IVIG
191758|NCT01985334|Moderate COPD, glycopyrronium bromide, indacaterol maleate and glycopyrronium bromide FDC, NVA237, QVA149
191759|NCT01985321|herpes labialis
191760|NCT01985321|cold sore
191761|NCT01985269|High risk
191762|NCT01985269|ART naive
191763|NCT01985243|Dietary diversity
191764|NCT01985243|Infant and young child
191765|NCT01985243|Adolescents
191766|NCT01985243|Anemia
191767|NCT01985243|Rural health
191768|NCT01985204|iodine
191769|NCT01985204|thyroid hormones
191770|NCT01985204|obesity
191771|NCT01985204|TSH
191772|NCT01985204|dyslipidemia
191773|NCT01985204|insulin resistance
191774|NCT01985139|Obesity, food pleasure, behavioral tasks, endocannabinoids
191775|NCT01985126|Multiple myeloma
191776|NCT01985126|Daratumumab
191777|NCT01985126|Proteasome inhibitor
191778|NCT01985126|Immunomodulatory drug
191779|NCT01985126|IMiD
191780|NCT01985113|thioredoxin reductase
191781|NCT01985113|non-small cell lung cancer
191782|NCT01985074|case management, disease management, emergency
191783|NCT01985074|department
191784|NCT01985061|Myelodysplasic syndrome
191785|NCT01985061|Acute Myeloid leukemia
191786|NCT01985035|Obstructive sleep apnea
191787|NCT01985035|obesity
191788|NCT01985035|diet
191789|NCT01985035|energy expenditure
191790|NCT01985022|autism
191791|NCT01985022|autism spectrum disorders
191792|NCT01985022|pervasive developmental disorders
191793|NCT01985022|toddlers
191794|NCT01985022|intervention
191795|NCT01984983|Venezuelan equine encephalitis virus
191796|NCT01984983|DNA vaccine
191797|NCT01984983|electroporation
191798|NCT01984983|intradermal
191799|NCT01984983|intramuscular
191800|NCT01984970|McGrath Videolaryngoscope
191801|NCT01984970|double-lumen tube intubation
191802|NCT01984970|Thoracic surgery
191803|NCT01984957|ALS
191804|NCT01984957|Motor neuron diseases
191805|NCT01984957|Transcriptome
191806|NCT01984944|circadian rhythm
191807|NCT01984931|post operative nausea and vomiting
191808|NCT01984931|Trimebutine Maleate
191809|NCT01984905|18 FDG PET-scan
191810|NCT01984905|angioscan
191811|NCT01984905|aortic dissection
191812|NCT01984892|Autologous Vaccination
191813|NCT01984892|Intratumoral Injections
191814|NCT01984892|Intramuscular Injections
191815|NCT01984892|Advanced Accessible Solid Tumors
191816|NCT01984892|Poly-ICLC
191817|NCT01984892|Phase II Clinical Trial
191818|NCT01984892|Safety
191819|NCT01984892|Efficacy
191820|NCT01984892|Autovaccination
191821|NCT01984892|In Situ
191822|NCT01984892|Host Targeted Strategy
191823|NCT01984892|Overall Survival
191824|NCT01984892|Immunotherapy
191825|NCT01984892|Adjuvant
191826|NCT01984866|CPR: Complete Pathological Response
191827|NCT01984853|ACS
191828|NCT01984853|repository
191829|NCT01984853|Observational
191830|NCT01984827|Hyperglycaemia
191831|NCT01984827|Moxifloxacin
191832|NCT01984827|QTc prolongation
191833|NCT01984827|C-peptide
191834|NCT01984827|Dead in bed syndrome
191835|NCT01984801|Gel
191836|NCT01984801|Topical Administration
191837|NCT01984801|Acne
191838|NCT01984801|SCD1
191839|NCT01984788|Oral Prophylaxis
191840|NCT01984775|safety
191841|NCT01984775|dermal
191842|NCT01984775|GSK2894512
191843|NCT01984775|Cumulative irritation
191844|NCT01984736|Pharmacokinetic
191845|NCT01984736|Safety
191846|NCT01984723|Pharmacokinetic
191847|NCT01984723|Safety
191848|NCT01984710|Treatment Resistant Depression
191849|NCT01984710|Deep Brain Stimulation
191850|NCT01984710|Psychiatry
191851|NCT01984710|Neuro Surgery
191852|NCT01984684|Bacterial skin infection
191853|NCT01984684|infection
191854|NCT01984684|skin
191855|NCT01984684|delafloxacin
191856|NCT01984684|vancomycin
191857|NCT01984684|aztreonam
191858|NCT01984684|MRSA bacteria
191859|NCT01984684|bacterial infection
191860|NCT01984684|Anti-Infective Agents
191861|NCT01984658|pancreatic cancer
191862|NCT01984645|Emergency Visit
191863|NCT01984645|Secure Health messaging
191864|NCT01984645|Inpatient
191865|NCT01984593|Yoga
191866|NCT01984593|Hypertension
191867|NCT01984593|Quality of Life
191868|NCT01984593|Primary Health Care
191869|NCT01984593|Stress
191870|NCT01984593|Anxiety
191871|NCT01984593|Depression
191872|NCT01984580|Barrett's esophagus
191873|NCT01984580|Esophagus
191874|NCT01984580|Adenocarcinoma
191875|NCT01984567|Oxyphytosterols
191876|NCT01984567|Oxidative stress
191877|NCT01984567|Vitamin E
191878|NCT01984567|Lipoic acid
191879|NCT01984541|Pollen
191880|NCT01984528|Immunotherapy
191881|NCT01984528|Skin prick test
191882|NCT01984528|Standardization
191883|NCT01984528|Alternaria alternata
191884|NCT01984515|Post-traumatic Stress Disorder
191885|NCT01984515|Evidence-Based Psychotherapy
191886|NCT01984515|Treatment Engagement
191887|NCT01984515|Cognitive Behavioral Therapy
191888|NCT01984515|Implementation Science
191889|NCT01984502|Larynx Cancer
191890|NCT01984489|SHR117887, Metformin,combination,PhaseII
191891|NCT01984476|spinal cord injury
191892|NCT01984476|autonomic dysreflexia
191893|NCT01984476|baroreceptor integrity
191894|NCT01984476|sympathetic integrity
191895|NCT01984476|vagal integrity
191896|NCT01984476|autonomic integrity
191897|NCT01984476|arterial stiffness
191898|NCT01984476|cognitive function
191899|NCT01984476|traumatic brain injury
191900|NCT01984476|cerebral blood flow
191901|NCT01984476|white matter hyperintensities
191902|NCT01984476|cerebral vascular resistance index
191903|NCT01984463|Postoperative pain
191904|NCT01984463|Shoulder pain
191905|NCT01984463|Thoracotomy
191906|NCT01984450|Articular cartilage
191907|NCT01984450|Autologous collagen
191908|NCT01984450|BMAC
191909|NCT01984437|Vascular disease
191910|NCT01984437|Minimally invasive treatment
191911|NCT01984437|Endovascular treatment
191912|NCT01984437|Magellan
191913|NCT01984437|Robotic
191914|NCT01984424|High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
191915|NCT01984346|Atrial Fibrillation
191916|NCT01984346|Convergent Procedure
191917|NCT01984346|Combined Epicardial/ Endocardial Ablation
191918|NCT01984346|Hybrid Procedure
191919|NCT01984346|Radiofrequency Ablation
191920|NCT01984346|Arrhythmia
191921|NCT01984346|RF Ablation
191922|NCT01984333|trichotillomania
191923|NCT01984333|response inhibition
191924|NCT01984333|cognitive retraining
191925|NCT01984320|OHSS
191926|NCT01984320|ICSI
191927|NCT01984320|Coasting
191928|NCT01984320|Cabergoline
191929|NCT01984307|Acute coronary syndrome
191930|NCT01984307|Myocardial infarction
191931|NCT01984307|retrospective
191932|NCT01984307|cohort study
191933|NCT01984307|Healthcare resources utilization
191934|NCT01984294|HCV genotype 1
191935|NCT01984294|HCV
191936|NCT01984294|Sustained Virologic Response
191937|NCT01984294|Direct-Acting Antiviral
191938|NCT01984294|Combination Therapy
191939|NCT01984294|GS-7977
191940|NCT01984294|GS-5885
191941|NCT01984294|Ribavirin
191942|NCT01984294|Open Label
191943|NCT01984294|Sofosbuvir
191944|NCT01984294|Treatment-Naive
191945|NCT01984294|Protease Inhibitors
191946|NCT01984294|PI
191947|NCT01984294|Treatment experienced
191948|NCT01984294|Cirrhotic
191949|NCT01984281|Physical Activity
191950|NCT01984281|Pedometers
191951|NCT01984281|Quality of Life
191952|NCT01984268|Rheumatoid arthritis
191953|NCT01984268|ACTHAR
191954|NCT01984268|Methotrexate
191955|NCT01984268|Inadequate response
191956|NCT01984203|Shoulder
191957|NCT01984203|Impingement
191958|NCT01984203|Rotator Cuff Syndrome
191959|NCT01984203|Subacromial Impingement Syndrome
191960|NCT01984203|Exercise
191961|NCT01984203|Physiotherapy
191962|NCT01984190|venous thromboembolism
191963|NCT01984190|deep vein thrombosis
191964|NCT01984190|pulmonary emboli
191965|NCT01984190|hip arthroplasty
191966|NCT01984190|knee arthroplasty
191967|NCT01984190|efficacy
191968|NCT01984190|mobile compression device
191969|NCT01984190|mechanical device
191970|NCT01984190|prophylaxis.
191971|NCT01984177|Cocaine
191972|NCT01984177|Substance-Related Disorders
191973|NCT01984177|Drug Addiction
191974|NCT01984177|Substance Addiction
191975|NCT01984177|Dopamine
191976|NCT01984177|Receptors, Dopamine D2
191977|NCT01984177|Receptors, Dopamine D3
191978|NCT01984177|Stress, Psychological
191979|NCT01984177|Corticorelin
191980|NCT01984177|Neuroendocrine System
191981|NCT01984177|Cortisol
191982|NCT01984177|Adrenocorticotropic Hormone
191983|NCT01984177|Positron-Emission Tomography
191984|NCT01984177|11C-PHNO
191985|NCT01984164|cerebrovascular function
191986|NCT01983410|BRCA Mutation Carriers
191987|NCT01983410|PDAC carriers
191988|NCT01983410|BRCAmut carriers
191989|NCT01983410|Registry
191990|NCT01983410|13-217
191991|NCT01983397|aged, 80 and over
191992|NCT01983397|Exercise
191993|NCT01983397|Cognition
191994|NCT01983397|Balance
191995|NCT01983397|Randomized controlled trial
191996|NCT01983384|Delirium
191997|NCT01983384|Cognition
191998|NCT01983384|Surgery
191999|NCT01983384|Anesthesia
192000|NCT01983384|Aging
192001|NCT01983358|PARP-1 inhibitor
192002|NCT01983345|Myelomeningocele
192003|NCT01983345|Arnold Chiari malformation
192004|NCT01983345|Spina bifida
192005|NCT01983332|MDACC
192006|NCT01983332|MOHO
192007|NCT01984138|estrogen receptor positive breast cancer
192008|NCT01984138|breast cancer
192009|NCT01984125|Adolescent Immunization Rates
192010|NCT01984125|Provider prompts
192011|NCT01984112|Humerus
192012|NCT01984112|fracture
192013|NCT01984112|nail
192014|NCT01984112|plate
192015|NCT01984112|tuberosity
192016|NCT01984099|Postmolar Gestational Trophoblastic Disease, Hydatidiform Mole
192017|NCT01984086|COPD
192018|NCT01984086|Asthma
192019|NCT01984086|Respiratory
192020|NCT01984073|Atherogenic dyslipidemia phenotype
192021|NCT01984060|Aging
192022|NCT01984060|Physical Activity
192023|NCT01984060|Physical Function
192024|NCT01984060|HIV
192025|NCT01984060|Frailty
192026|NCT01984060|Autonomous Motivation
192027|NCT01984060|Depression
192028|NCT01984047|CCL20
192029|NCT01984047|safety
192030|NCT01984047|single dose escalation
192031|NCT01984047|GSK3050002
192032|NCT01984047|Phase 1
192033|NCT01984047|CCR6 receptor
192034|NCT01984034|Educational outreach
192035|NCT01984034|Academic detailing
192036|NCT01984034|Guideline adherence
192037|NCT01984034|Family Practice
192038|NCT01984034|Drug utilization
192039|NCT01984034|Program evaluation
192040|NCT01984034|Cost effectiveness
192041|NCT01984021|Physical Therapy Modalities
192042|NCT01984021|Neck pain
192043|NCT01984021|Acupuncture
192044|NCT01983995|Breast Cancer
192045|NCT01983995|Aromatase Inhibitors
192046|NCT01983995|Actigraphy
192047|NCT01983995|Pain
192048|NCT01983995|Fatigue
192049|NCT01983995|Sleep quality
192050|NCT01983982|Breast Cancer
192051|NCT01983982|Chemotherapy
192052|NCT01983982|Chronic Pain
192053|NCT01983982|Survivorship
192054|NCT01983969|Advanced Cancers
192055|NCT01983969|Lymphoma
192056|NCT01983969|Recurrent Hodgkin's
192057|NCT01983969|non-Hodgkin's lymphoma
192058|NCT01983969|Stem cell transplant
192059|NCT01983969|Azacitidine
192060|NCT01983969|5-azacytidine
192061|NCT01983969|5-aza
192062|NCT01983969|Vidaza
192063|NCT01983969|5-AZC
192064|NCT01983969|AZA-CR
192065|NCT01983969|Ladakamycin
192066|NCT01983969|NSC-102816
192067|NCT01983969|Azacytidine
192068|NCT01983969|Vorinostat
192069|NCT01983969|SAHA
192070|NCT01983969|Suberoylanilide Hydroxamic Acid
192071|NCT01983969|MSK-390
192072|NCT01983969|Zolinza
192073|NCT01983969|Gemcitabine
192074|NCT01983969|Gemcitabine Hydrochloride
192075|NCT01983969|Gemzar
192076|NCT01983969|Busulfan
192077|NCT01983969|Busulfex
192078|NCT01983969|Myleran
192079|NCT01983969|Melphalan
192080|NCT01983969|Alkeran
192081|NCT01983969|Dexamethasone
192082|NCT01983969|Decadron
192083|NCT01983969|Caphosol
192084|NCT01983969|Glutamine
192085|NCT01983969|Enterex
192086|NCT01983969|Glutapak-10
192087|NCT01983969|NutreStore
192088|NCT01983969|Resource
192089|NCT01983969|GlutaSolve
192090|NCT01983969|Sympt-X G.I.
192091|NCT01983969|Sympt-X
192092|NCT01983969|Pyridoxine
192093|NCT01983969|Rituximab
192094|NCT01983969|Rituxan
192095|NCT01983956|early palliative care
192096|NCT01983956|patient empowerment
192097|NCT01983956|cancer
192098|NCT01983956|assessment
192099|NCT01983956|end of life
192100|NCT01983930|Memory impairment
192101|NCT01983930|Meditation
192102|NCT01983930|Yoga
192103|NCT01983930|memory training
192104|NCT01983930|Mild cognitive impairment
192105|NCT01983930|MCI
192106|NCT01983930|geriatric
192107|NCT01983930|fMRI
192108|NCT01983917|diabetes
192109|NCT01983917|mobile application
192110|NCT01983917|diabetic retinopathy
192111|NCT01983904|Major depressive disorder (MDD)
192112|NCT01983904|Bi-polar disorder (BP)
192113|NCT01983891|food shelf
192114|NCT01983891|nutrition education
192115|NCT01983891|cooking course
192116|NCT01983852|End of Life Care
192117|NCT01983852|Paediatric
192118|NCT01983852|Experiences
192119|NCT01983852|Needs
192120|NCT01983852|Current Practices
192121|NCT01983839|Moxifloxacin
192122|NCT01983839|Pneumonia
192123|NCT01983839|Pharmacokinetics
192124|NCT01983826|nitrates
192125|NCT01983826|blood flow
192126|NCT01983826|vascular function
192127|NCT01983826|exercise
192128|NCT01983813|Diabetes
192129|NCT01983813|High Blood Pressure
192130|NCT01983813|High Cholesterol
192131|NCT01983813|Heart Irregularity
192132|NCT01983813|Stroke
192133|NCT01983800|Mechanical Ventilation
192134|NCT01983800|Volatile Sedation
192135|NCT01983800|Intravenous Sedation
192136|NCT01983800|Delirium
192137|NCT01983787|Cystic Fibrosis
192138|NCT01983787|Continuous infusion
192139|NCT01983787|Pharmacokinetics
192140|NCT01983774|CF
192141|NCT01983748|Uveal Melanoma, Monosomy 3
192142|NCT01983735|TELMINUVO Tab.
192143|NCT01983735|CKD-828
192144|NCT01983735|Hypertension
192145|NCT01983735|Stage 2 Hypertension
192146|NCT01983735|S-Amlodipine
192147|NCT01983735|Telmisartan
192148|NCT01983696|low oxygen tension
192149|NCT01983696|embryo quality
192150|NCT01983683|Clostridium difficile infection
192151|NCT01983683|Post-antibiotic diarrhea
192152|NCT01983670|Pre-movement facilitation
192153|NCT01983670|Fast goal directed movement
192154|NCT01983670|Triphasic EMG pattern
192155|NCT01983670|Temporal electrical stimulation,
192156|NCT01983670|Spinocerebellar Ataxia
192157|NCT01983657|Pulmonary
192158|NCT01983657|Pulmonary Alveolar Proteinosis
192159|NCT01983657|PAP
192160|NCT01983644|acute ischemic stroke,endovascular recanalization
192161|NCT01983644|mechanical thrombectomy
192162|NCT01983631|Whole body vibration
192163|NCT01983631|Reciprocal inhibition
192164|NCT01983631|Spinocerebellar ataxia
192165|NCT01983631|voluntary activation level
192166|NCT01983618|Cerebral ischemia
192167|NCT01983618|Beachchair position
192168|NCT01983618|Interscalene nerve block
192169|NCT01983592|Homeopathy
192170|NCT01983592|Fatigue
192171|NCT01983592|Chemotherapy
192172|NCT01983592|Cancer
192173|NCT01983553|Dengue Virus
192174|NCT01983553|Dengue Fever
192175|NCT01983553|Dengue Hemorrhagic Fever
192176|NCT01983553|CYD Dengue Vaccine
192177|NCT01983540|Diphtheria
192178|NCT01983540|Tetanus
192179|NCT01983540|Whooping Cough
192180|NCT01983540|Hepatitis B
192181|NCT01983540|Poliomyelitis
192182|NCT01983540|Pediatric combined vaccine
192183|NCT01983527|Arthrographic distention
192184|NCT01983527|Hydrodilatation
192185|NCT01983527|Intra-articular corticosteroid injection
192186|NCT01983514|oxytocin
192187|NCT01983514|fMRI
192188|NCT01983514|social cognition
192189|NCT01983514|heart rate variability
192190|NCT01983514|pupillometry
192191|NCT01983514|eye tracking
192192|NCT01983501|ONT-380
192193|NCT01983501|T-DM1
192194|NCT01983501|Kadcyla
192195|NCT01983501|HER2 positive breast cancer
192196|NCT01983501|Breast cancer
192197|NCT01983501|ARRY-380
192198|NCT01983501|Tucatinib
192199|NCT01983488|Uveitis
192200|NCT01983488|Vision Loss
192201|NCT01983475|Spinal Cord Injury
192202|NCT01983475|Denosumab
192203|NCT01983475|Osteoporosis
192204|NCT01983475|Dual Energy X-ray Absorptiometry
192205|NCT01983462|Prehypertension
192206|NCT01983462|Hypertension
192207|NCT01983462|Obese
192208|NCT01983462|Sympathetic Nervous System
192209|NCT01983462|renin-angiotensin system
192210|NCT01983462|Endothelial function
192211|NCT01983449|Adventitia
192212|NCT01983449|Peripheral Artery Disease
192213|NCT01983449|Restenosis
192214|NCT01983449|Inflammation
192215|NCT01983449|Anti-Inflammatory
192216|NCT01983449|Dexamethasone
192217|NCT01983436|Maxillofacial Orthognathic Surgery
192218|NCT01983436|Manual lymphatic drainage
192219|NCT01983423|Endometrial Biopsy
192220|NCT01983423|Endometrial Sampling
192221|NCT01983423|In Vitro Fertilization
192222|NCT01983423|Pregnancy
192223|NCT01983423|Implantation
192224|NCT01983306|Constipation
192225|NCT01983306|Opioid
192226|NCT01983306|GC C Agonist
192227|NCT01983306|Pain
192228|NCT01983293|Non-left bundle branch block
192229|NCT01983293|QLV
192230|NCT01983293|LV lead pacing location
192231|NCT01983293|CRT-D
192232|NCT01983280|polysomnography
192233|NCT01983280|sleep
192234|NCT01983280|healing touch
192235|NCT01983280|pediatric burn
192236|NCT01983254|coping
192237|NCT01983254|acute respiratory failure
192238|NCT01983254|critical illness
192239|NCT01983254|depression
192240|NCT01983254|anxiety
192241|NCT01983254|post-traumatic stress
192242|NCT01983254|intensive care unit
192243|NCT01983241|Pulmonary Emphysema
192244|NCT01983241|Alpha-1 Antitrypsin Deficiency
192245|NCT01983241|AATD
192246|NCT01983241|Alpha-1 PI Deficiency
192247|NCT01983241|Alpha-1 Protienase Inhibitor
192248|NCT01983228|Musculoskeletal Pain
192249|NCT01983228|Walking
192250|NCT01983228|African American
192251|NCT01983228|Telephone Coaching
192252|NCT01983228|Pedometer
192253|NCT01983215|groin incisions
192254|NCT01983202|PCOS
192255|NCT01983202|Pregnancy
192256|NCT01983202|Obstetric
192257|NCT01983189|TMS
192258|NCT01983189|transcranial magnetic stimulation
192259|NCT01983189|rTMS
192260|NCT01983189|recurrent transcranial magnetic stimulation
192261|NCT01983189|fMRI
192262|NCT01983189|functional magnetic resonance imaging.
192263|NCT01983176|Parotid tumor
192264|NCT01983176|Partial superficial parotidectomy
192265|NCT01983176|Facial palsy
192266|NCT01983150|Population Health
192267|NCT01983150|Smoking cessation
192268|NCT01983150|Young adults
192269|NCT01983150|Cancer prevention
192270|NCT01983150|Tobacco control strategies
192271|NCT01983150|Behaviour modification
192272|NCT01983150|Social Media
192273|NCT01983150|Smartphone technology
192274|NCT01983137|Chronic pain
192275|NCT01983137|Severe pain
192276|NCT01983137|oxycodon
192277|NCT01983137|naloxon
192278|NCT01983137|opioid-induced constipation
192279|NCT01983137|opioid
192280|NCT01983137|quality of life
192281|NCT01983137|laxative
192282|NCT01983137|analgesic rescue medication
192283|NCT01983124|Advanced Melanoma
192284|NCT01983098|Colorectal cancer
192285|NCT01983098|Metastatic
192286|NCT01983098|Circulating tumor DNA
192287|NCT01983098|Biomaker
192288|NCT01983085|Nitric Oxide Dressing
192289|NCT01983085|Nitric oxide
192290|NCT01983085|Superficial partial thickness wound
192291|NCT01983085|Burns
192292|NCT01983085|Skin graft donor sites
192293|NCT01983085|Improved healing
192294|NCT01983085|Vasodilation
192295|NCT01983085|Angiogenesis
192296|NCT01983085|Anti-microbial
192297|NCT01983072|colonization of the gastrointestinal tract with bacteria
192298|NCT01983007|Diabetes Mellitus.
192299|NCT01982994|Physical Activity Education
192300|NCT01982994|Caregivers
192301|NCT01982981|perception
192302|NCT01982981|wellbeing
192303|NCT01982981|plain water
192304|NCT01982968|Idiopathic pulmonary fibrosis
192305|NCT01982968|IPF
192306|NCT01982968|Gastroesophageal reflux
192307|NCT01982968|GER
192308|NCT01982968|GERD
192309|NCT01982955|MSC2156119J
192310|NCT01982955|Gefitinib
192311|NCT01982955|Pemetrexed
192312|NCT01982955|Cisplatin
192313|NCT01982955|MET positive
192314|NCT01982955|Tepotinib
192315|NCT01982916|Allergic Rhinitis
192316|NCT01982916|Perennial Allergic Rhinitis
192317|NCT01982916|Non-seasonal Allergic Rhinitis
192318|NCT01982916|PAR
192319|NCT01982903|kidney transplantation
192320|NCT01982903|connective tissue growth factor
192321|NCT01982903|fibrosis
192322|NCT01982890|Telomere length
192323|NCT01982890|Longitudinal observation
192324|NCT01982877|decision making
192325|NCT01982877|values elicitation
192326|NCT01982877|patient centered care
192327|NCT01982877|Four Supports
192328|NCT01982877|Family Support
192329|NCT01982864|Aminoglycosides
192330|NCT01982864|hemodialysis
192331|NCT01982864|clinical pharmacokinetics
192332|NCT01982864|pharmacokinetic modelling
192333|NCT01982864|Bayesian estimation
192334|NCT01982864|Necessity
192335|NCT01982864|of the treatment
192336|NCT01982864|gentamicin
192337|NCT01982851|pain
192338|NCT01982851|epidural
192339|NCT01982851|combined spinal epidural
192340|NCT01982838|pain
192341|NCT01982838|epidural
192342|NCT01982838|combined spinal epidural
192343|NCT01982825|Tobacco use cessation
192344|NCT01982825|Cigarette smoking
192345|NCT01982799|Endodontic treatment, analgesics, anesthesia, post-operative pain
192346|NCT01982773|Virtual Hope Box
192347|NCT01982760|Rhinoplasty
192348|NCT01982760|Ecchymosis
192349|NCT01982760|Edema
192350|NCT01982747|Cardiac Safety
192351|NCT01982747|General Safety
192352|NCT01982747|Pharmacokinetics
192353|NCT01982734|bioavailability
192354|NCT01982734|curcumin
192355|NCT01982734|pharmacokinetic
192356|NCT01982734|curcuma longa
192357|NCT01982734|age differences
192358|NCT01982734|sex differences
192359|NCT01982708|Evaluation
192360|NCT01982695|Duchenne muscular Dystrophy (DMD)
192361|NCT01982695|Cardiomyopathy
192362|NCT01982695|Losartan
192363|NCT01982695|Lisinopril
192364|NCT01982669|Salty taste
192365|NCT01982669|Urinary sodium excretion
192366|NCT01982669|Spicy hedonic
192367|NCT01982669|Blood pressure
192368|NCT01982617|Transtheoretical Model
192369|NCT01982617|Stages of Change
192370|NCT01982617|Nicotine Dependence
192371|NCT01982617|Severe Mental Illness
192372|NCT01982578|Treatment
192373|NCT01982578|Genistein
192374|NCT01982578|Alzheimer's disease
192375|NCT01982578|Cerebrospinal fluid
192376|NCT01982578|Amyloid beta
192377|NCT01982565|Nitric oxide
192378|NCT01982565|Nitric oxide dressing
192379|NCT01982565|NOx
192380|NCT01982565|NOx dressing
192381|NCT01982565|Diabetic
192382|NCT01982565|Foot
192383|NCT01982565|Ulcers
192384|NCT01982565|Chronic
192385|NCT01982552|Plaque psoriasis
192386|NCT01982552|calcipotriene
192387|NCT01982552|betamethasone dipropionate
192388|NCT01982552|topical
192389|NCT01982539|pain
192390|NCT01982539|NSAID
192391|NCT01982539|moderate pain
192392|NCT01982539|mild pain
192393|NCT01982539|acute pain
192394|NCT01982539|mild acute pain
192395|NCT01982539|moderate acute pain
192396|NCT01982539|mild or moderate acute pain
192397|NCT01982526|Ovarian reserve
192398|NCT01982526|Antimullerian hormone
192399|NCT01982513|Cardiopulmonary Resuscitation
192400|NCT01982513|Pregnancy
192401|NCT01982513|Ultrasound
192402|NCT01982513|Inferior Vena Cava
192403|NCT01982500|Ovarian Cancer
192404|NCT01982500|Chemotherapy
192405|NCT01982500|Anti-angiogenic agent
192406|NCT01982500|Bevacizumab
192407|NCT01982500|Front Line
192408|NCT01982474|allergic rhinitis
192409|NCT01982448|TRIPLE NEGATIVE BREAST CANCER WITHOUT GERMLINE BRCA MUTATIONS
192410|NCT01982448|CISPLATIN
192411|NCT01982448|PACLITAXEL
192412|NCT01982435|Diabetes
192413|NCT01982435|Macular Edema
192414|NCT01982422|Attention Deficit and Hyperactivity Disorder
192415|NCT01982422|Nutrition
192416|NCT01982422|Diet
192417|NCT01982422|Developmental Origins of Disease
192418|NCT01982396|HIV
192419|NCT01982396|paediatric
192420|NCT01982396|Abacavir
192421|NCT01982396|lamivudine
192422|NCT01982383|CSC
192423|NCT01982383|Edema
192424|NCT01982383|Retinopathy
192425|NCT01982344|mini-exchange-room
192426|NCT01982344|physical activity
192427|NCT01982344|quality of life
192428|NCT01982344|peritoneal dialysis
192429|NCT01982331|H2N2
192430|NCT01982331|vaccine
192431|NCT01982318|Venous Leg Ulcer
192432|NCT01982318|Leg Ulcer
192433|NCT01982318|Venous Hypertension
192434|NCT01982318|Venous Reflux
192435|NCT01982318|Deep Venous System
192436|NCT01982318|Chronic leg ulceration
192437|NCT01982318|Calf perforator
192438|NCT01982292|Chronic Heart Failure, CHF, Heart Failure, HF, Immunogenicity, Anti-bodies, Hypersensitivity, Serelaxin, RELAX-REPEAT
192439|NCT01982279|Caloric compensation
192440|NCT01982279|Eating in the absence of hunger
192441|NCT01982279|Preschool children
192442|NCT01982279|Maternal feeding practices
192443|NCT01982279|Maternal eating behavior
192444|NCT01982279|one year
192445|NCT01982279|children
192446|NCT01982253|Drug therapy
192447|NCT01982240|CIC
192448|NCT01982240|Constipation
192449|NCT01982240|Chronic Constipation
192450|NCT01982240|Synergy
192451|NCT01982240|Plecanatide
192452|NCT01982227|colorectal cancer metastatic
192453|NCT01982227|indocyanine green
192454|NCT01982214|osteopenia
192455|NCT01982214|whole body vibration
192456|NCT01982214|women
192457|NCT01982214|bone microarchitecture
192458|NCT01982214|bone density
192459|NCT01982188|single incision sling
192460|NCT01982188|cough stress test
192461|NCT01982188|MiniArc
192462|NCT01982188|UDI-6
192463|NCT01982188|UIQ-7
192464|NCT01982188|Sandvick Severity Index (SSI)
192465|NCT01982175|Alemtuzumab
192466|NCT01982175|B-cell chronic lymphocytic leukemia
192467|NCT01982175|CD52
192468|NCT01982162|Sputum
192469|NCT01982162|Clinical cohorts
192470|NCT01982162|Smokers
192471|NCT01982162|Asthma
192472|NCT01982162|Biopsies
192473|NCT01982162|Severe asthma
192474|NCT01982162|Collaborative research
192475|NCT01982162|Phenotyping
192476|NCT01982162|Lipidomics
192477|NCT01982162|Transcriptomics
192478|NCT01982162|Proteomics
192479|NCT01982162|Paediatric cohort
192480|NCT01982162|Systems Biology
192481|NCT01982149|Chronic Obstructive Pulmonary Disease
192482|NCT01982149|COPD
192483|NCT01982149|Smokers
192484|NCT01982149|Nonsmokers
192485|NCT01982110|smoking cessation
192486|NCT01982110|mindfulness
192487|NCT01982110|behavioral intervention
192488|NCT01982097|Non-interventional
192489|NCT01982097|Nexavar
192490|NCT01982097|Sorafenib
192491|NCT01982097|Carcinoma, renal cell
192492|NCT01982097|Neoadjuvant
192493|NCT01982097|Nephrectomy
192494|NCT01982097|Russian Federation
192495|NCT01982084|Group B streptococcus
192496|NCT01982084|Immunisation
192497|NCT01982084|Pregnancy
192498|NCT01982084|Attitudes
192499|NCT01982071|Open-label design
192500|NCT01982071|candidiasis
192501|NCT01982071|candidemia
192502|NCT01982071|Micafungin
192503|NCT01982045|Bone graft
192504|NCT01982045|Ceramic
192505|NCT01982045|Spinal fusion
192506|NCT01982045|RCT
192507|NCT01982045|Thoracolumbar region
192508|NCT01982032|Periprosthetic aortic valve regurgitation
192509|NCT01982032|3D transesophageal echocardiography
192510|NCT01982032|Cardiac MRI
192511|NCT01982019|26RFa
192512|NCT01982019|sleeve gastrectomy
192513|NCT01982019|diabetes
192514|NCT01982019|obesity
192515|NCT01982006|cataract surgery
192516|NCT01982006|femtosecond laser cataract surgery
192517|NCT01982006|phacoemulsification
192518|NCT01982006|Cost-Benefit Analysis
192519|NCT01982006|Cost Effectiveness
192520|NCT01982006|Hospital Costs
192521|NCT01981980|Carbon dioxide
192522|NCT01981980|Carboxytherapy
192523|NCT01981980|Radiofrequency
192524|NCT01981967|Japanese encephalitis
192525|NCT01981967|IMOJEV®
192526|NCT01981967|Japanese encephalitis chimeric virus vaccine
192527|NCT01981954|Solifenacin succinate suspension
192528|NCT01981954|Efficacy
192529|NCT01981954|Safety
192530|NCT01981941|Gabapentin
192531|NCT01981941|Restless legs syndrome (RLS)
192532|NCT01981928|Phase 1
192533|NCT01981928|Healthy Subjects
192534|NCT01981928|Safety
192535|NCT01981928|Tolerability
192536|NCT01981928|Pharmacokinetics
192537|NCT01981928|Single Ascending Oral Dose
192538|NCT01981928|Food Effect
192539|NCT01981915|Cough augmentation
192540|NCT01981915|Peak cough flow
192541|NCT01981915|hyperinsufflation
192542|NCT01981902|Dehydration
192543|NCT01981889|steroid, inflammatory bowel diseases
192544|NCT01981876|Dysplasia
192545|NCT01981876|Esophageal Squamous Cell Carcinoma
192546|NCT01981863|cardiac surgery
192547|NCT01981863|cardiopulmonary bypass
192548|NCT01981863|fibrinolysis
192549|NCT01981863|thromboelastography
192550|NCT01981863|D-Dimers
192551|NCT01981863|antifibrinolytic agents
192552|NCT01981850|fibrosis
192553|NCT01981837|RNAi therapeutic
192554|NCT01981824|prediction IUGR FL/MTC
192555|NCT01981811|OPC-14597 Digital
192556|NCT01981811|Aripiprazole
192557|NCT01981811|Medical Information Device #1 System (MIND1)
192558|NCT01981811|Treatment Adherence
192559|NCT01981811|Ingestible Event Marker
192560|NCT01981798|outpatient intervention program
192561|NCT01981798|behavioral therapy approach
192562|NCT01981798|unspecific back pain
192563|NCT01981798|unspecific neck pain
192564|NCT01981798|chronic pain
192565|NCT01981798|physiotherapy
192566|NCT01981798|occupational therapy
192567|NCT01981798|psychosocial aspects
192568|NCT01981798|fear avoidance beliefs
192569|NCT01981798|health-related quality of life
192570|NCT01981785|Primary immune deficiencies
192571|NCT01981785|Autoimmune diseases
192572|NCT01981785|Inflammatory diseases
192573|NCT01981785|Common variable immune deficiencies
192574|NCT01981785|Primary Immunodeficiencies
192575|NCT01981785|Immunoglobulin
192576|NCT01981785|IgG
192577|NCT01981785|IVIG
192578|NCT01981785|Recurrent Infections
192579|NCT01981759|Schizophrenia
192580|NCT01981759|Delusions
192581|NCT01981759|D-Cycloserine
192582|NCT01981759|CBT
192583|NCT01981746|adductor canal block
192584|NCT01981746|healthy volunteers
192585|NCT01981746|US-guided peripheral nerve block
192586|NCT01981746|lower limb
192587|NCT01981733|Deep Vein Thrombosis
192588|NCT01981707|castration-resistant prostate cancer
192589|NCT01981707|abiraterone acetate
192590|NCT01981707|enzalutamide
192591|NCT01981707|choline pet
192592|NCT01981694|Phase 1
192593|NCT01981694|Randomized
192594|NCT01981694|Double Blind
192595|NCT01981694|Placebo-Controlled
192596|NCT01981694|Single-Dose Escalation
192597|NCT01981694|Safety
192598|NCT01981694|Tolerability
192599|NCT01981694|PK
192600|NCT01981694|PD
192601|NCT01981694|PF-06649751
192602|NCT01981681|Phase 1
192603|NCT01981681|Randomized
192604|NCT01981681|Placebo-Controlled
192605|NCT01981681|Multiple Dose Escalation
192606|NCT01981681|Tolerability
192607|NCT01981681|Safety
192608|NCT01981681|PK
192609|NCT01981681|Topical
192610|NCT01981681|Healthy
192611|NCT01981681|PF-06263276
192612|NCT01981655|Sodium Lactate
192613|NCT01981655|Acute
192614|NCT01981655|Heart
192615|NCT01981655|Failure
192616|NCT01981655|Perfusion
192617|NCT01981629|Shock
192618|NCT01981629|USCOM
192619|NCT01981629|Cardiac Ultrasound
192620|NCT01981629|Emergency Department
192621|NCT01981616|Drug therapy
192622|NCT01981603|Navigators
192623|NCT01981603|Kidney Transplant
192624|NCT01981603|Hemodialysis
192625|NCT01981590|breathing, heart failure, sleep apnea
192626|NCT01981577|Parkinson Disease
192627|NCT01981577|Subthalamic Nucleus
192628|NCT01981577|Ultrahigh field Magnetic Resonance imaging
192629|NCT01981577|Functional connectivity
192630|NCT01981577|Structural connectivity
192631|NCT01981564|Pediatric
192632|NCT01981564|Emergency department visit
192633|NCT01981551|Desmoid Tumor
192634|NCT01981551|Aggressive Fibromatosis
192635|NCT01981551|Gamma-secretase Inhibitor
192636|NCT01981551|Notch Pathway
192637|NCT01981538|Web-Based Survey
192638|NCT01981538|Cancer Caregivers
192639|NCT01981525|TP53 Mutation
192640|NCT01981525|Autosomal Dominant Hereditary Disorder
192641|NCT01981525|Chemoprevention
192642|NCT01981499|PF-05180999
192643|NCT01981499|safety
192644|NCT01981499|tolerability
192645|NCT01981499|pharmacokinetics
192646|NCT01981499|histamine
192647|NCT01981499|wheal
192648|NCT01981499|flare
192649|NCT01981499|migraine
192650|NCT01981499|PDE2
192651|NCT01981486|PF-05180999
192652|NCT01981486|safety
192653|NCT01981486|tolerability
192654|NCT01981486|pharmacokinetics
192655|NCT01981486|migraine
192656|NCT01981486|PDE2
192657|NCT01981486|cAMP
192658|NCT01981486|cGMP
192659|NCT01981486|cantharidin
192660|NCT01981486|blister
192661|NCT01981486|CYP3A induction
192662|NCT01981473|rheumatoid arthritis
192663|NCT01981473|etanercept
192664|NCT01981473|adalimumab
192665|NCT01981473|infliximab
192666|NCT01981473|anti-drug antibody
192667|NCT01981473|immunogenicity
192668|NCT01981473|drug concentration
192669|NCT01981447|epilepsy
192670|NCT01981421|Liver fibrosis
192671|NCT01981421|Elastography
192672|NCT01981421|MR Elastography
192673|NCT01981421|Quantitative imaging
192674|NCT01981395|fenobam
192675|NCT01981395|heat
192676|NCT01981395|capsaicin
192677|NCT01981395|hyperalgesia
192678|NCT01981395|allodynia
192679|NCT01981395|mood
192680|NCT01981395|cognitive function
192681|NCT01981382|low back pain
192682|NCT01981382|pain sensitivity
192683|NCT01981382|genes
192684|NCT01981382|gene expression,
192685|NCT01981382|quantitative sensory testing
192686|NCT01981369|Dexmedetomidine sedation
192687|NCT01981369|Regional Anesthesia
192688|NCT01981369|Infraclavicular block
192689|NCT01981356|Psychotic Disorders
192690|NCT01981356|Acceptance and Commitment Therapy
192691|NCT01981356|Inpatient psychiatry
192692|NCT01981356|Schizophrenia
192693|NCT01981356|Acute psychiatric disorder
192694|NCT01981343|Gallbladder motility
192695|NCT01981343|A-F Betafood
192696|NCT01981343|Betaine
192697|NCT01981343|Ejection fraction
192698|NCT01981343|Ejection rate
192699|NCT01981343|Ultrasound
192700|NCT01981330|vocal fold scarring
192701|NCT01981330|mesenchymal stem cells
192702|NCT01981317|Obsessive Compulsive Disorder
192703|NCT01981317|Cognitive Behavioral Therapy
192704|NCT01981317|Stepped Care CBT
192705|NCT01981317|Exposure and Response Prevention
192706|NCT01981317|Psychotherapy
192707|NCT01981317|Counseling
192708|NCT01981304|Coronary artery disease
192709|NCT01981304|Percutaneous coronary intervention
192710|NCT01981291|Lower Extremity
192711|NCT01981291|Sciatic Nerve
192712|NCT01981291|Anesthesia, Regional
192713|NCT01981291|Anesthetics, Local
192714|NCT01981291|Mepivacaine
192715|NCT01981291|Ultrasonography
192716|NCT01981278|Healthy
192717|NCT01981278|Tapentadol
192718|NCT01981278|Bioequivalence
192719|NCT01981278|Fasted
192720|NCT01981252|Ulthera® System
192721|NCT01981252|Ultherapy™ Treatment
192722|NCT01981252|Ulthera, Inc.
192723|NCT01981252|Micro-focused Ultrasound with Visualization (MFU-V)
192724|NCT01981239|voice analysis aspiration prediction
192725|NCT01981213|Acetaminophen
192726|NCT01981213|Suicide
192727|NCT01981213|Attempts
192728|NCT01981213|Early Predictors of Hepatic Injury
192729|NCT01981213|Childhood Suicidal Behaviour
192730|NCT01981200|COPD acute exacerbation
192731|NCT01981200|Physiotherapy
192732|NCT01981200|Resistance training
192733|NCT01981200|Muscle strength
192734|NCT01981200|Handheld dynamometer
192735|NCT01981161|progressive multifocal leucoencephalopathy
192736|NCT01981161|JC virus
192737|NCT01981161|Zoster infection
192738|NCT01981135|Controlled Human exposure study
192739|NCT01981135|Air Pollution
192740|NCT01981135|Temperature
192741|NCT01981135|Lung Function
192742|NCT01981135|Cardiovascular
192743|NCT01981096|juvenile fibromyalgia
192744|NCT01981096|pain in children
192745|NCT01981096|musculoskeletal pain
192746|NCT01981096|cognitive behavioral therapy
192747|NCT01981096|coping skills training
192748|NCT01981083|Protein-Energy Malnutrition
192749|NCT01981083|Chronic Kidney Disease
192750|NCT01981083|Malnutrition-Inflammation Score
192751|NCT01981083|Subjective Global Assessment
192752|NCT01981083|Hemodialysis
192753|NCT01981083|Egg albumin
192754|NCT01981070|parent support
192755|NCT01981070|mindfulness
192756|NCT01981070|intellectual disability
192757|NCT01981070|developmental disability
192758|NCT01981070|empowerment
192759|NCT01981070|psychological acceptance
192760|NCT01981070|parental stress
192761|NCT01981070|parental depression
192762|NCT01981057|parenteral nutrition
192763|NCT01981057|Numeta
192764|NCT01981057|prescription software Cato Pan
192765|NCT01981018|Mental imagery, CBT, anxiety, mood instability
192766|NCT01980992|Food Allergy
192767|NCT01980992|Wheat Allergy
192768|NCT01980992|Oral Immunotherapy
192898|NCT01980264|BD, AK
192769|NCT01980979|congenital heart disease,pulmonary hypertension,prostacyclin
192770|NCT01980927|Migraine
192771|NCT01980927|National Upper Cervical Chiropractic Association atlas correction
192772|NCT01980914|hypoglycemia
192773|NCT01980914|type 2 diabetes
192774|NCT01980914|insulin glargine
192775|NCT01980914|cardiac function
192776|NCT01980914|myocardial ischemia
192777|NCT01980914|cardiac rhythm
192778|NCT01980914|autonomic cardiovascular function
192779|NCT01980901|AAA
192780|NCT01980849|Nadroparin
192781|NCT01980849|venous thromboembolism prophylaxis
192782|NCT01980836|Rheumatoid arthritis
192783|NCT01980836|Tocilizumab
192784|NCT01980836|Seasonal influenza vaccine
192785|NCT01980823|Breast Cancer
192786|NCT01980823|Metformin
192787|NCT01980823|Atorvastatin
192788|NCT01980823|Ki-67
192789|NCT01980797|Bicuspid aortic valve disease
192790|NCT01980797|Thoracic aortic disease
192791|NCT01980797|Genetics
192792|NCT01980797|Echocardiography
192793|NCT01980797|Cardiac CT
192794|NCT01980797|Cardiac MRI
192795|NCT01980784|Spinal Cord Injury
192796|NCT01980771|HIV
192797|NCT01980771|prevention
192798|NCT01980771|men
192799|NCT01980771|African American
192800|NCT01980758|obesity, pediatric obesity, bariatric, bariatric surgery
192801|NCT01980745|autoimmune hepatitis
192802|NCT01980745|recurrence
192803|NCT01980745|treatment withdrawal
192804|NCT01980745|chloroquine
192805|NCT01980745|maintenance of remission
192806|NCT01980706|Baclofen
192807|NCT01980706|Alcohol Dependence
192808|NCT01980667|lurbinectedin
192809|NCT01980667|PM01183
192810|NCT01980667|tumors
192811|NCT01980667|cancer
192812|NCT01980667|Pharma Mar
192813|NCT01980654|Pharmacyclics
192814|NCT01980654|PCYC
192815|NCT01980654|Lymphoma
192816|NCT01980654|Follicular Lymphoma
192817|NCT01980654|FL
192818|NCT01980654|Rituximab
192819|NCT01980654|Ibrutinib
192820|NCT01980654|Rituxan
192821|NCT01980654|Non-Hodgkin's Lymphoma
192822|NCT01980654|NHL
192823|NCT01980654|B-cell Lymphoma
192824|NCT01980641|Stroke
192825|NCT01980641|ADL
192826|NCT01980641|mHealth
192827|NCT01980641|App
192828|NCT01980641|Adherence
192829|NCT01980641|Home
192830|NCT01980641|Environment
192831|NCT01980641|Tool
192832|NCT01980641|Advice
192833|NCT01980641|Smartphone
192834|NCT01980628|MZL
192835|NCT01980628|NHL
192836|NCT01980628|SMZL
192837|NCT01980628|NMZL
192838|NCT01980628|MALT
192839|NCT01980602|Intermittent claudication
192840|NCT01980602|endothelial function
192841|NCT01980602|cardiopulmonary testing
192842|NCT01980602|inflammation
192843|NCT01980602|muscle architecture
192844|NCT01980589|multiple myeloma
192845|NCT01980576|Pain
192846|NCT01980576|Sensitization
192847|NCT01980576|Spondylitis
192848|NCT01980485|smoker
192849|NCT01980459|Hypomagnesemia, Cellular Mg, Inflammation, Diabetes Mellitus
192850|NCT01980446|Coma
192851|NCT01980446|Cardiac arrest
192852|NCT01980446|Neurophysiology
192853|NCT01980446|Auditory evoked potential
192854|NCT01980433|Wilson disease
192855|NCT01980433|Dystonia
192856|NCT01980433|Movement Disorders
192857|NCT01980433|Handwriting
192858|NCT01980433|Repetitive Transcranial Magnetic Stimulation
192859|NCT01980420|Sleeve gastrectomy
192860|NCT01980420|Oesogastric junction - GEJ
192861|NCT01980420|Dynamic MRI Imaging
192862|NCT01980407|S-1
192863|NCT01980407|Oxaliplatin
192864|NCT01980407|Leucovorin
192865|NCT01980407|Gastric Cancer
192866|NCT01980394|esophagus
192867|NCT01980394|gastro-esophegeal junction
192868|NCT01980394|cancer
192869|NCT01980394|tumor seeding
192870|NCT01980394|free viable tumor cells
192871|NCT01980394|surgery
192872|NCT01980394|intraluminal tumor cells
192873|NCT01980394|stump washout
192874|NCT01980355|cancer
192875|NCT01980355|surgery
192876|NCT01980355|oncology
192877|NCT01980355|major
192878|NCT01980355|surgical oncology
192879|NCT01980355|tranexamic acid
192880|NCT01980342|Long acting reversible contraception
192881|NCT01980342|HIV
192882|NCT01980329|CYP3A5
192883|NCT01980329|maraviroc
192884|NCT01980329|polymorphism
192885|NCT01980316|Argatroban
192886|NCT01980316|Extracranial vertebral Artery Stenting
192887|NCT01980316|restenosis
192888|NCT01980303|Healthy
192889|NCT01980303|Japanese
192890|NCT01980303|Caucasian
192891|NCT01980303|Anesthetics
192892|NCT01980303|Intranasal
192893|NCT01980303|Esketamine
192894|NCT01980303|Pharmacokinetics
192895|NCT01980290|HCV genotype 1
192896|NCT01980290|Liver Fibrosis
192897|NCT01980290|ex-People who INject Drugs (ex-PWIDs)
192899|NCT01980251|Delirium, electroencephalography, CSD
192900|NCT01980238|LAR
192901|NCT01980238|anastomotic leakage
192902|NCT01980238|Cannula ileostomy
192903|NCT01980238|loop ileostomy
192904|NCT01980225|vitrification, blastocyst, artificial shrinkage, collapse
192905|NCT01980212|non-small cell lung cancer
192906|NCT01980212|thioredoxin reductase
192907|NCT01980199|visceral leishmaniasis
192908|NCT01980199|fexinidazole
192909|NCT01980199|adults
192910|NCT01980199|proof of concept
192911|NCT01980199|efficacy
192912|NCT01980199|safety
192913|NCT01980199|pharmacokinetic
192914|NCT01980199|pharmacodynamic
192915|NCT01980186|transcranial ultrasound
192916|NCT01980186|autism
192917|NCT01980186|cortical dysplasia
192918|NCT01980186|extra-axial fluid
192919|NCT01980173|Bakri balloon
192920|NCT01980147|Severe Mental Illness
192921|NCT01980134|adenomatous colorectal lesions
192922|NCT01980134|colorectal polyps
192923|NCT01980134|polyps
192924|NCT01980121|Respiratory Aspiration
192925|NCT01980121|Pregnancy
192926|NCT01980121|Ultrasound
192927|NCT01980121|Gastric Contents
192928|NCT01980108|Pregnancy
192929|NCT01980108|Respiratory Aspiration
192930|NCT01980108|Gastric Contents
192931|NCT01980108|Ultrasound
192932|NCT01980095|Helicobacter pylori
192933|NCT01980095|H. pylori
192934|NCT01980095|Dyspepsia
192935|NCT01980082|head and neck surgery
192936|NCT01980082|surgical wound infection
192937|NCT01980082|antibiotic prophylaxis
192938|NCT01980069|Sugammadex
192939|NCT01980069|Neostigmine
192940|NCT01980069|Surgery
192941|NCT01980056|INT-2 or high-risk MDS
192942|NCT01980017|Diabetes Type 2 Mellitus
192943|NCT01980017|Ottawa Model for Smoking Cessation
192944|NCT01980017|Diabetes Education Programs
192945|NCT01979965|Mitral Regurgitation
192946|NCT01979965|cardiac resynchronization therapy
192947|NCT01979965|ranolazine
192948|NCT01979965|maximal medical therapy
192949|NCT01979965|ischemic cardiomyopathy
192950|NCT01979913|Primary Open Angle Glaucoma
192951|NCT01979913|Ocular Hypertension
192952|NCT01979913|Tafluprost
192953|NCT01979913|Saflutan
192954|NCT01979913|Intraocular pressure
192955|NCT01979913|Preservative free
192956|NCT01979913|Single dose unit
192957|NCT01979900|TB Infection
192958|NCT01979900|Lesion Degree
192959|NCT01979900|Bacteriology Indicators
192960|NCT01979900|Cavity
192961|NCT01979900|Humoral Immunity
192962|NCT01979900|Cellular Immunologic Response
192963|NCT01979861|Endometrial ablation with vapor
192964|NCT01979848|continence outcomes
192965|NCT01979848|sexual function
192966|NCT01979848|Robotic Assisted Radical Prostatectomy
192967|NCT01979848|thermal imaging
192968|NCT01979848|localized hypothermia
192969|NCT01979835|intrauterine device, contraception
192970|NCT01979822|medication pump, complications, safety observation
192971|NCT01979809|Dietary change
192972|NCT01979809|Young adult
192973|NCT01979809|Prevention
192974|NCT01979809|Web-based intervention
192975|NCT01979809|eCoaching
192976|NCT01979796|Addiction, Schizophrenia, Electronic cigarettes
192977|NCT01979770|Adolescent
192978|NCT01979770|Nutritional status
192979|NCT01979770|Body composition
192980|NCT01979770|Biochemical status
192981|NCT01979744|Intravenous ultrasound,
192982|NCT01979744|third generation drug-eluting stent
192983|NCT01979731|Occupational health
192984|NCT01979731|Ergonomics
192985|NCT01979731|Environments
192986|NCT01979731|Prevention and Control
192987|NCT01979692|CLM
192988|NCT01979692|The study will
192989|NCT01979692|focus on using
192990|NCT01979692|CLM to
192991|NCT01979692|distinguish between
192992|NCT01979692|viable and
192993|NCT01979692|necrotic tissue
192994|NCT01979692|at TTNB in real time
192995|NCT01979666|Knee AVN, Nitrates
192996|NCT01979640|bronchial cuff
192997|NCT01979640|double lumen tube
192998|NCT01979640|blood tight seal
192999|NCT01979627|transulnar approach
193000|NCT01979627|transradial approach
193001|NCT01979627|angiography
193002|NCT01979627|angioplasty
193003|NCT01979614|coronary artery disease
193004|NCT01979601|hypercholesterolemia,
193005|NCT01979601|LGT209,
193006|NCT01979601|PCSK9,
193007|NCT01979601|LDL-C
193008|NCT01979575|Nexfin
193009|NCT01979575|Flotrac
193010|NCT01979575|Esophageal
193011|NCT01979575|Cardiac output
193012|NCT01979562|Overuse injury
193013|NCT01979562|Femur
193014|NCT01979562|Tibia
193015|NCT01979562|Running
193016|NCT01979562|Prevention
193017|NCT01979549|Adverse events
193018|NCT01979549|Upper gastrointestinal endoscopy
193019|NCT01979549|Sedation
193020|NCT01979484|bioavailability
193021|NCT01979471|Cardiovascular risk reduction
193022|NCT01979471|Diabetes
193023|NCT01979471|Chronic Kidney Disease
193024|NCT01979471|Atherosclerotic vascular disease
193025|NCT01979471|Community Pharmacist
193026|NCT01979471|Randomized controlled trial
193027|NCT01979471|[eGFR <60 ml/min/1.73m2 and/or (ACR >= 30 mg/mmol or two consecutive ACR tests which are >= 3 mg/mmol)]
193028|NCT01979458|Colonoscopy
193029|NCT01979445|CAD
193030|NCT01979432|Alzheimer, cognitive diseases, Ankle-to-brachial index
193031|NCT01979419|mild cognitive impairment
193032|NCT01979419|Alzheimer's disease
193033|NCT01979419|subcortical Vascular Dementia
193034|NCT01979419|amyloid
193035|NCT01979419|plaques
193036|NCT01979419|neuroimaging
193037|NCT01979419|biomarkers
193038|NCT01979419|cognition disorder
193039|NCT01979419|early detection
193040|NCT01979419|pre-dementia
193041|NCT01979419|dementia
193042|NCT01979419|vascular MCI
193043|NCT01979406|Anthrax vaccine
193044|NCT01979393|Locally advanced
193045|NCT01979393|stage III
193046|NCT01979393|stage IV
193047|NCT01979393|residual disease after primary surgery
193048|NCT01979393|newly diagnosed HGUS
193049|NCT01979393|Metastatic
193050|NCT01979380|KD101
193051|NCT01979380|Anti-obesity Agents
193052|NCT01979354|spinal morphine
193053|NCT01979354|VATs lobectomy
193054|NCT01979341|dual trigger
193055|NCT01979341|hCG
193056|NCT01979341|GnRH agonist
193057|NCT01979341|ICSI
193058|NCT01979341|pregnancy
193059|NCT01979341|OHSS
193060|NCT01979328|Deep Vein Thrombosis
193061|NCT01979302|Geriatric Depression
193062|NCT01979302|Depression Care Management
193063|NCT01979302|home healthcare
193064|NCT01979302|nurse training intervention
193065|NCT01979289|Executive Dysfunction
193066|NCT01979289|Cognitive Remediation
193067|NCT01979289|Geriatric
193068|NCT01979289|Depression
193069|NCT01979250|endothelial keratoplasty
193070|NCT01979250|Descemet's stripping automated endothelial keratoplasty
193071|NCT01979250|lamellar keratoplasty
193072|NCT01979224|educational intervention, Asthma control, asthma knowledge
193073|NCT01979211|head and neck cancer
193074|NCT01979198|burst fracture, kyphotic angle, surgical outcome
193075|NCT01979172|LASIK
193076|NCT01979172|Intraocular lens
193077|NCT01979172|Biometry
193078|NCT01979172|IOL master
193079|NCT01979159|aphasia
193080|NCT01979159|apraxia of speech
193081|NCT01979159|outcomes
193082|NCT01979146|Cancer
193083|NCT01979120|Sleep-disordered breathing
193084|NCT01979120|Chronic heart failure
193085|NCT01979120|Implantable cardioverter-defibrillator
193086|NCT01979120|Apnea-Hypopnea-Index
193087|NCT01979120|Portable Polygraphy Monitoring
193088|NCT01979120|Polysomnography
193089|NCT01979107|Health behavior
193090|NCT01979107|Chronic disease
193091|NCT01979107|Proactive action
193092|NCT01979107|General practitioner
193093|NCT01979107|Preventive health check
193094|NCT01979107|Social inequality in health
193095|NCT01979107|Randomised controlled trial
193096|NCT01979055|asthma
193097|NCT01979055|older adults
193098|NCT01979055|elderly
193099|NCT01979055|behavior
193100|NCT01979042|renal colic
193101|NCT01979042|acute renal failure
193102|NCT01979042|Neutrophil gelatinase associated lipocalin
193103|NCT01978977|mBC
193104|NCT01978977|HER2 negative
193105|NCT01978977|Chemotherapy
193106|NCT01978977|Anti-angiogenic agent
193107|NCT01978977|Bevacizumab
193108|NCT01978977|1st Line
193109|NCT01978964|ONT-10
193110|NCT01978964|MUC1
193111|NCT01978964|Vaccine
193112|NCT01978964|Phase 1b
193113|NCT01978964|Solid tumors
193114|NCT01978964|Maintenance therapy
193115|NCT01978951|Chronic Kidney Disease
193116|NCT01978951|Integrated Chronic Kidney Disease Care
193117|NCT01978951|Village Health Volunteers
193118|NCT01978925|Pharmaceutical care
193119|NCT01978925|Medication Adherence
193120|NCT01978925|Blood Pressure
193121|NCT01978925|Diabetes
193122|NCT01978925|Emergency
193123|NCT01978886|Diabetes Mellitus
193124|NCT01978886|frozen shoulder
193125|NCT01978886|adhesive capsulitis
193126|NCT01978860|CABG Coronary artery bypass grafting
193127|NCT01978860|CTO Chronic Total Occlusion
193128|NCT01978860|PCI Percutaneous coronary intervention
193129|NCT01978860|MACE Major adverse cardiovascular event(s)
193130|NCT01978860|MI Myocardial infarction
193131|NCT01978834|Osteoporosis, diagnosis, ultrasound
193132|NCT01978821|Cerebral Palsy
193133|NCT01978821|autologous bone marrow mononuclear cells
193134|NCT01978821|stem cell therapy
193135|NCT01978795|concussion
193136|NCT01978795|high school
193137|NCT01978795|web-based training
193138|NCT01978795|school-based health care
193139|NCT01978782|raltegravir
193140|NCT01978782|citalopram
193141|NCT01978782|pharmacokinetics
193142|NCT01978782|drug-drug interaction
193143|NCT01978756|Outpatient clinic
193144|NCT01978756|Breast cancer
193145|NCT01978756|Late toxicity
193146|NCT01978743|HIV
193147|NCT01978743|HIV-associated neurocognitive disorder
193148|NCT01978743|neurotoxicity
193149|NCT01978730|vascular dementia
193150|NCT01978730|cognition
193151|NCT01978730|stroke
193152|NCT01978717|Anesthesia
193153|NCT01978717|T-helper
193154|NCT01978717|MDSCs
193155|NCT01978717|Colorectal cancer
193156|NCT01978717|Fast track
193157|NCT01978691|Obesity
193158|NCT01978691|Blood glucose
193159|NCT01978691|Waist circumference
193160|NCT01978691|Lipid metabolism
193161|NCT01978691|Probiotics
193162|NCT01978691|Prebiotics
193163|NCT01978691|Dietary supplements
193164|NCT01978691|Endotoxemia
193165|NCT01978665|COPD exercise inflammation prednisone
193166|NCT01978626|Insomnia
193167|NCT01978626|Comorbid insomnia
193168|NCT01978626|Cognitive Behavioral Therapy
193169|NCT01978600|Open-Angle Glaucoma
193170|NCT01978600|Ocular Hypertension
193171|NCT01978600|Simbrinza™
193172|NCT01978600|Intraocular Pressure
193173|NCT01978587|End-stage Renal Disease
193174|NCT01978587|Hemodialysis
193175|NCT01978587|Pharmacokinetics
193176|NCT01978574|Cognitive reserve
193177|NCT01978574|intellectual enrichment
193178|NCT01978548|Alzheimer Disease
193179|NCT01978548|Prodromal Alzheimer Disease
193180|NCT01978548|Safety
193181|NCT01978548|Tolerability
193182|NCT01978548|Pharmacokinetic
193183|NCT01978548|Proof of Mechanism
193184|NCT01978548|JNJ-54861911
193185|NCT01978535|POTS
193186|NCT01978522|Randomised trial
193187|NCT01978522|postal questionnaires
193188|NCT01978522|return rates
193189|NCT01978509|Colonoscopy
193190|NCT01978483|Humans
193191|NCT01978483|Adult
193192|NCT01978483|skin
193193|NCT01978483|metabolism
193194|NCT01978483|radiation effects
193195|NCT01978483|Ultraviolet Rays
193196|NCT01978483|RANKL
193197|NCT01978483|RANK Ligand
193198|NCT01978483|denosumab
193199|NCT01978483|diphenylcyclopropenone
193200|NCT01978483|diphencyprone
193201|NCT01978483|immunology
193202|NCT01978483|immunosuppression
193203|NCT01978483|Antibodies, Monoclonal
193204|NCT01978483|Dermatitis, Allergic Contact
193205|NCT01978483|Hypersensitivity, Delayed
193206|NCT01978470|epilepsy
193207|NCT01978470|drug resistent epilepsy
193208|NCT01978470|partial onset seizures
193209|NCT01978470|trigeminal nerve stimulation
193210|NCT01978470|neuromodulation
193211|NCT01978444|D2 lymphadenectomy
193212|NCT01978444|Complete Mesogastrium Excision
193213|NCT01978418|Lung fluid
193214|NCT01978418|Postnatal adaptation
193215|NCT01978418|Salbutamol
193216|NCT01978418|Albuterol
193217|NCT01978418|Epithelial Sodium Channel
193218|NCT01978405|Type 2 diabetes
193219|NCT01978405|Nephropathy
193220|NCT01978405|Contrast medium
193221|NCT01978405|Alpha lipoic acid
193222|NCT01978392|disability
193223|NCT01978392|self-management
193224|NCT01978392|chronic illness
193225|NCT01978392|chronic pain
193226|NCT01978392|occupation
193227|NCT01978392|> 6 months
193228|NCT01978379|General Anesthesia
193229|NCT01978379|Nociception Level
193230|NCT01978366|Duchenne muscular dystrophy
193231|NCT01978366|halofuginone hydrobromide
193232|NCT01978366|anti-fibrotic
193233|NCT01978366|anti-inflammatory
193234|NCT01978366|muscle regeneration
193235|NCT01978366|protein synthesis inhibitor
193236|NCT01978353|Mild cognitive impairment
193237|NCT01978353|Dementia
193238|NCT01978353|Alzheimer's disease
193239|NCT01978353|Memory Training
193240|NCT01978353|Cognitive Training
193241|NCT01978353|Cognitive Rehabilitation
193242|NCT01978353|Neuropsychological Rehabilitation
193243|NCT01978327|Alzheimer's disease
193244|NCT01978327|GSK2647544
193245|NCT01978327|drug-drug interaction
193246|NCT01978327|healthy subjects
193247|NCT01978327|Lp-PLA2
193248|NCT01978327|simvastatin
193249|NCT01978314|Chronic Kidney Disease
193250|NCT01978314|Acute Kidney Injury
193251|NCT01978314|AKI
193252|NCT01978314|CKD
193253|NCT01978314|Plasma Volume
193254|NCT01978314|GFR
193255|NCT01978314|Glomerular Filtration Rate
193256|NCT01978314|Blood volume
193257|NCT01978314|mGFR
193258|NCT01978314|measured GFR
193259|NCT01978314|kidney biomarker
193260|NCT01978314|renal disease
193261|NCT01978314|renal biomarker
193262|NCT01978314|Renal function
193263|NCT01978314|kidney function
193264|NCT01978314|organ function
193265|NCT01978314|kidney monitor
193266|NCT01978314|kidney device
193267|NCT01978301|collagen synthesis
193268|NCT01978301|heavy water
193269|NCT01978301|collagen degradation
193270|NCT01978301|fibrosis
193271|NCT01978301|Keloid
193394|NCT01977859|Metabolism
193272|NCT01978301|triamcinolone acetonide (TAC)
193273|NCT01978301|deuterium
193274|NCT01978301|patient
193275|NCT01978275|total knee arthroplasty
193276|NCT01978275|lumbar plexus block
193277|NCT01978275|stimulating catheters
193278|NCT01978275|peripheral nerve blocks
193279|NCT01978262|influenza vaccine
193280|NCT01978262|cytokines
193281|NCT01978262|hormones
193282|NCT01978262|progesterone
193283|NCT01978249|Colorectal cancer
193284|NCT01978249|Primary tumor resection
193285|NCT01978249|Chemotherapy
193286|NCT01978249|Overall survival
193287|NCT01978249|Quality of life
193288|NCT01978236|BRAF V600E mutation
193289|NCT01978236|brain metastases
193290|NCT01978236|BRAF V600K mutation
193291|NCT01978236|Metastatic melanoma
193292|NCT01978236|BRAF inhibitor
193293|NCT01978236|brain neoplasms
193294|NCT01978236|GSK2118436
193295|NCT01978223|Rotarix™
193296|NCT01978223|Case-control
193297|NCT01978223|Venezuela
193298|NCT01978223|Vaccine effectiveness
193299|NCT01978223|Rotavirus Severe Gastroenteritis
193300|NCT01978223|Children
193301|NCT01978223|Hospitalised
193302|NCT01978210|autism
193303|NCT01978210|enuresis
193304|NCT01978210|toilet-training
193305|NCT01978184|Pancreatic Cancer, resectable adenocarcinoma of the pancreas
193306|NCT01978171|breast neoplasms
193307|NCT01978171|everolimus
193308|NCT01978171|interstitial lung disease
193309|NCT01978171|pneumonitis
193310|NCT01978158|Oxygen
193311|NCT01978158|Hypoxia
193312|NCT01978158|Hyperoxia
193313|NCT01978158|Inflammation
193314|NCT01978158|Innate immunity
193315|NCT01978145|efficacy
193316|NCT01978145|tolerability
193317|NCT01978145|capsule-based inhaler
193318|NCT01978145|quality of life
193319|NCT01978145|safety
193320|NCT01978145|multi-dose inhaler
193321|NCT01978145|fluticasone propionate/salmeterol (FSC) 250/50 mcg
193322|NCT01978145|Chronic obstructive pulmonary disease
193323|NCT01978132|primary hyperaldosteronism
193324|NCT01978132|primary hypertension
193325|NCT01978132|forearm ischemia-reperfusion
193326|NCT01978132|(reduction) in brachial artery FMD
193327|NCT01978132|endothelial ischemia-reperfusion injury
193328|NCT01978119|Multi-Dose Inhaler
193329|NCT01978119|safety
193330|NCT01978119|Asthma
193331|NCT01978119|efficacy
193332|NCT01978119|pharmacodynamics
193333|NCT01978119|fluticasone propionate/salmeterol (FSC) 250/50 mcg
193334|NCT01978119|tolerability
193335|NCT01978119|Capsule-Based Inhaler
193336|NCT01978106|toric calculator
193337|NCT01978106|toric intraocular lens power
193338|NCT01978106|Acrysof
193339|NCT01978106|Tecnis
193340|NCT01978106|iTrace
193341|NCT01978093|Conjugate
193342|NCT01978093|Immunogenicity
193343|NCT01978093|Hib-MenCY-TT vaccine
193344|NCT01978093|Haemophilus type b
193345|NCT01978093|Safety
193346|NCT01978093|Reactogenicity
193347|NCT01978067|Uterine Scar From Previous Cesarean Delivery
193348|NCT01978067|previous caesarean scar deficiency
193349|NCT01978067|transvaginal resection
193350|NCT01978067|quality of life
193351|NCT01978067|sexual activity
193352|NCT01978054|Information Dissemination
193353|NCT01978054|Information Sharing
193354|NCT01978054|Innovation Diffusion
193355|NCT01978054|Public Health Practice
193356|NCT01978054|Evidence-Based Public Health
193357|NCT01978054|Chronic Disease Prevention
193358|NCT01978054|Cancer Prevention and Control
193359|NCT01978041|pharmacokinetics, saliva, plasma, fluoride, dental fluorosis, dental caries
193360|NCT01978028|heart failure
193361|NCT01978015|primary open angle glaucoma
193362|NCT01978015|timolol
193363|NCT01978015|prostaglandin analogues
193364|NCT01977976|Endometrial injury
193365|NCT01977976|Pipelle
193366|NCT01977976|Implantation
193367|NCT01977976|Ongoing pregnancy rate
193368|NCT01977976|IVF
193369|NCT01977950|Undernutrition, Nutritional risk, NRS2002, nutritional care practices, hospital, elderly patients, nursing students
193370|NCT01977937|gabapentin
193371|NCT01977937|Analgesic Drugs
193372|NCT01977937|Analgesics, Nonopioid
193373|NCT01977924|sleep apnea
193374|NCT01977924|polyphenols
193375|NCT01977924|endothelial function
193376|NCT01977911|Airway reconstruction
193377|NCT01977911|Regenerative medicine
193378|NCT01977898|Postdural puncture headache
193379|NCT01977898|Intrathecal morphine
193380|NCT01977898|Intrathecal catheter
193381|NCT01977898|Headache
193382|NCT01977898|Labor and delivery
193383|NCT01977898|Unintentional dural puncture
193384|NCT01977885|epigenetics
193385|NCT01977885|obesity
193386|NCT01977885|overweight
193387|NCT01977885|high protein diet
193388|NCT01977885|exercise
193389|NCT01977885|post menopausal women
193390|NCT01977872|Arthritis
193391|NCT01977872|Physical Activity
193392|NCT01977872|Diet
193393|NCT01977859|B-type Natriuretic Peptide
193395|NCT01977859|Insulin infusion
193396|NCT01977846|genetic testing
193397|NCT01977846|ABCA4
193398|NCT01977846|Stargardt
193399|NCT01977846|retina
193400|NCT01977846|retinal degeneration
193401|NCT01977833|BTdiet
193402|NCT01977833|Dtdiet
193403|NCT01977833|High Calorie Breakfast diet (BTdiet)
193404|NCT01977833|High Calorie Dinner diet (DTdiet)
193405|NCT01977820|Phenylketonuria
193406|NCT01977820|Sapropterin
193407|NCT01977820|Placebo
193408|NCT01977820|Cognitive Abilities
193409|NCT01977820|Kuvan®
193410|NCT01977807|Myopia
193411|NCT01977807|Hyperopia
193412|NCT01977807|Presbyopia
193413|NCT01977807|Supracor
193414|NCT01977807|Zyoptix
193415|NCT01977807|Proscan
193416|NCT01977807|LASIK
193417|NCT01977794|Bisoprolol
193418|NCT01977794|Amlodipine
193419|NCT01977794|Fixed dose combination (FDC)
193420|NCT01977794|Systolic Blood Pressure (SBP)
193421|NCT01977794|Diastolic Blood Pressure (DBP)
193422|NCT01977781|GVHD
193423|NCT01977781|Ocular GVHD
193424|NCT01977781|Tacrolimus
193425|NCT01977781|Methylprednisolone
193426|NCT01977768|M. vaccae
193427|NCT01977768|TB
193428|NCT01977768|MDR-TB
193429|NCT01977768|V7-immunitor
193430|NCT01977729|anxiety
193431|NCT01977716|Peritonitis
193432|NCT01977716|loss of residual renal function
193433|NCT01977716|technique survival
193434|NCT01977703|Heart Failure
193435|NCT01977703|Advanced Heart Failure
193436|NCT01977703|LVAD
193437|NCT01977703|Left Ventricular Assist Device
193438|NCT01977703|Heart-Assist Devices
193439|NCT01977664|oocyte maturation failure
193440|NCT01977664|Maturation induction in vitro
193441|NCT01977651|enzalutamide
193442|NCT01977651|Xtandi
193443|NCT01977651|seizure
193444|NCT01977651|Central Nervous System
193445|NCT01977651|MDV3100
193446|NCT01977651|metastatic castration-resistant prostate cancer (mCRPC)
193447|NCT01977638|Advanced solid tumours
193448|NCT01977638|Lymphoma
193449|NCT01977638|Myeloma
193450|NCT01977625|Menopause
193451|NCT01977625|fMRI
193452|NCT01977625|Vyvanse
193453|NCT01977612|Wound infection
193454|NCT01977612|Wound separation
193455|NCT01977612|Skin staples
193456|NCT01977612|Subcuticular suture
193457|NCT01977599|Text message reminders
193458|NCT01977599|Short Message Service (SMS) Reminders
193459|NCT01977599|Social Health Inequalities
193460|NCT01977599|Breast Screening
193461|NCT01977599|Screening
193462|NCT01977599|Public Health Intervention
193463|NCT01977599|Missed Appointments
193464|NCT01977599|Non-attendance
193465|NCT01977586|Clear cell renal cell carcinoma
193466|NCT01977586|Stage IV renal cell carcinoma
193467|NCT01977586|Anti-angiogenic therapy
193468|NCT01977586|Response assessment
193469|NCT01977586|Magnetic resonance imaging
193470|NCT01977573|Prolyl hydroxylase inhibitor
193471|NCT01977573|pharmacokinetics
193472|NCT01977573|GSK1278863
193473|NCT01977573|Anemia
193474|NCT01977573|hemoglobin
193475|NCT01977573|erythropoiesis stimulating agents
193476|NCT01977573|Chronic kidney disease
193477|NCT01977560|Type 2 diabetes
193478|NCT01977560|Exercise
193479|NCT01977560|High protein
193480|NCT01977547|Red blood cell transfusions
193481|NCT01977547|Red blood cell storage age
193482|NCT01977547|Pediatrics
193483|NCT01977547|Critical Care
193484|NCT01977534|Bioabsorbable
193485|NCT01977534|Coronary Stent
193486|NCT01977534|Everolimus
193487|NCT01977534|drug eluting stents
193488|NCT01977534|stents
193489|NCT01977534|angioplasty
193490|NCT01977534|coronary artery disease
193491|NCT01977534|total coronary occlusion
193492|NCT01977534|coronary artery restenosis
193493|NCT01977534|stent thrombosis
193494|NCT01977534|vascular disease
193495|NCT01977534|myocardial ischemia
193496|NCT01977534|coronary artery stenosis
193497|NCT01977534|CAD
193498|NCT01977534|CAOD
193499|NCT01977508|Vascular access grafts
193500|NCT01977508|Haemodialysis
193501|NCT01977495|Diabetes
193502|NCT01977495|Enrollment methods
193503|NCT01977495|Behavioral Economic Intervention
193504|NCT01977495|Opt-in Enrollment
193505|NCT01977495|Opt-out Enrollment
193506|NCT01977495|lottery
193507|NCT01977495|financial incentives
193508|NCT01977482|hemoglobin
193509|NCT01977482|recombinant human erythropoietin
193510|NCT01977482|Chronic kidney disease
193511|NCT01977482|hemodialysis
193512|NCT01977482|pharmacokinetics
193513|NCT01977482|erythropoiesis stimulating agents
193514|NCT01977482|Anemia
193515|NCT01977482|GSK1278863
193516|NCT01977469|Chronic Obstructive Pulmonary Disease
193517|NCT01977469|Activities of Daily Living
193518|NCT01977469|Mortality
193519|NCT01977469|Strength Training
193520|NCT01977456|acute ischemic stroke
193521|NCT01977456|stroke
193522|NCT01977456|rt-PA, thrombolytic
193523|NCT01977456|t-PA
193524|NCT01977456|recombinant tissue plasminogen activator
193525|NCT01977456|Activase
193526|NCT01977456|eptifibatide
193527|NCT01977456|Integrilin
193528|NCT01977456|fibrinolytic agents
193529|NCT01977456|clot dissolving
193530|NCT01977456|blood clot
193531|NCT01977430|Residual renal function
193532|NCT01977430|Combined thiazide-furosemide therapy
193533|NCT01977430|Haemodialysis
193534|NCT01977417|Endothelial Function
193535|NCT01977417|Arterial Stiffness
193536|NCT01977417|Inflammation
193537|NCT01977417|Muscle Sympathetic Nervous System
193538|NCT01977417|Prediabetes
193539|NCT01977417|Autonomic function
193540|NCT01977404|Congestive heart failure
193541|NCT01977404|Energy expenditure
193542|NCT01977404|Body composition
193543|NCT01977404|Caloric intake
193544|NCT01977365|Cluster Randomized Trial,
193545|NCT01977365|Nutrition counseling,
193546|NCT01977365|Caretaker's knowledge
193547|NCT01977365|Child growth,
193548|NCT01977365|Prevention,
193549|NCT01977365|Acute malnutrition
193550|NCT01977352|Exparel
193551|NCT01977352|Liposomal Bupivacaine
193552|NCT01977352|Arthroscopic Shoulder Surgery
193553|NCT01977339|Femoral Nerve Block
193554|NCT01977339|Liposomal Bupivacaine
193555|NCT01977326|task sharing
193556|NCT01977326|task shifting
193557|NCT01977326|prenatal depression
193558|NCT01977326|counselling
193559|NCT01977326|lay health workers
193560|NCT01977287|Multiple Sclerosis
193561|NCT01977287|Functional Electrical Stimulation
193562|NCT01977287|Ankle Foot Orthosis
193563|NCT01977287|Walking performance
193564|NCT01977287|gait analysis
193565|NCT01977287|fatigue
193566|NCT01977287|activity monitoring
193567|NCT01977274|ovarian, endometrium, cervix cancer
193568|NCT01977235|Irinotecan; Cisplatin; Small-cell lung cancer; UGT1A1
193569|NCT01977209|NSCLC; Gossypol; APE1; Chemotherapy
193570|NCT01977196|DTB/HB/Hib vaccine
193571|NCT01977196|Infants
193572|NCT01977196|Phase I
193573|NCT01977183|gastrointestinal
193574|NCT01977183|microbiome
193575|NCT01977183|prebiotic
193576|NCT01977183|starch
193577|NCT01977170|Adults
193578|NCT01977170|Hib vaccines
193579|NCT01977170|Immunogenicity
193580|NCT01977170|Safety
193581|NCT01977157|Impedance cardiography
193582|NCT01977157|bioimpedance
193583|NCT01977157|spectroscopy
193584|NCT01977157|extracellular resistance
193585|NCT01977157|body composition
193586|NCT01977157|hemodynamics
193587|NCT01977157|alcohol
193588|NCT01977144|Single Embryo Transfer
193589|NCT01977144|Double Embryo Transfer
193590|NCT01977144|CCS (Comprehensive Chromosome Screening)
193591|NCT01977144|Aneuploidy
193592|NCT01977144|Low Responders
193593|NCT01977118|Streptokinase
193594|NCT01977118|Percutaneous catheter drainage
193595|NCT01977118|Pancreatic necrosis
193596|NCT01977118|peripancreatic necrosis
193597|NCT01977105|Infants
193598|NCT01977105|Mothers
193599|NCT01977105|Social media
193600|NCT01977105|Obesity prevention
193601|NCT01977092|sober living houses
193602|NCT01977092|HIV
193603|NCT01977092|alcohol and drugs
193604|NCT01977079|pregnancy
193605|NCT01977079|premature birth
193606|NCT01977079|procalcitonin
193607|NCT01977066|pancreatic cancer
193608|NCT01977066|exercise training
193609|NCT01977066|quality of life
193610|NCT01977066|physical functioning
193611|NCT01977053|breast cancer
193612|NCT01977053|colon cancer
193613|NCT01977053|rectal cancer
193614|NCT01977053|adjuvant chemotherapy
193615|NCT01977053|phone calls
193616|NCT01977053|emotional states
193617|NCT01977053|quality of life
193618|NCT01977040|Vasa Previa
193619|NCT01977027|Rehabilitation
193620|NCT01977027|Fingers
193621|NCT01977027|Grasp
193622|NCT01977027|Strength
193623|NCT01977027|Hand Function
193624|NCT01977027|Motor Function
193625|NCT01977027|Post Stroke
193626|NCT01977027|Brain Infraction
193627|NCT01977027|Biomechanis
193628|NCT01977027|Neuronal Plasticity
193629|NCT01977027|Weight-Bearing
193630|NCT01977001|Primary headache
193631|NCT01977001|Headache
193632|NCT01977001|MigraineBox
193633|NCT01976975|Depression
193634|NCT01976975|Major Depressive Disorder
193635|NCT01976975|Bipolar Disorder
193636|NCT01976975|Mania
193637|NCT01976975|Hypomania
193638|NCT01976975|EEG
193639|NCT01976975|MRI
193640|NCT01976975|Reward
193641|NCT01976962|Prostatic neoplasms
193642|NCT01976962|Radiotherapy
193643|NCT01976962|Dose fractionation
193644|NCT01976962|Magnetic resonance imaging
193645|NCT01976949|Cancer, social-networking intervention, cancer-related distress, internet health services, intervention delivery
193646|NCT01976936|Stroke
193647|NCT01976936|Rhabdomyolysis
193648|NCT01976936|Jaundice
193649|NCT01976923|Intravitreal Bevacizumab
193650|NCT01976923|Tractional Retinal Detachment
193651|NCT01976923|Proliferative Diabetic Retinopathy
193652|NCT01976923|Small gauge pars plana vitrectomy
193653|NCT01976923|Intraoperative bleeding
193654|NCT01976923|Post-operative vitreous hemorrhage
193655|NCT01976923|Visual acuity
193656|NCT01976910|Glioblastoma multiforme
193657|NCT01976910|Advanced cancers
193658|NCT01976910|Brain Neoplasms, Malignant, Primary
193659|NCT01976910|Brain Tumor, Recurrent
193660|NCT01976910|Advanced cancer
193661|NCT01976897|heel - mattress pressure interface
193662|NCT01976897|flexion
193663|NCT01976897|knee angular position
193664|NCT01976884|sepsis
193665|NCT01976884|immunosuppression
193666|NCT01976884|PD-L1
193667|NCT01976871|Restless Legs Syndrome
193668|NCT01976871|Ekbom Syndrome
193669|NCT01976871|Willis-Ekbom Disease
193670|NCT01976871|Rotigotine
193671|NCT01976871|Neupro
193672|NCT01976871|Dopamine Agonist
193673|NCT01976858|PEX168, diabetes, phase I
193674|NCT01976845|propofol
193675|NCT01976845|midazolam
193676|NCT01976845|sedative
193677|NCT01976845|anxiolytic
193678|NCT01976845|amnesic
193679|NCT01976845|recall
193680|NCT01976845|Memory
193681|NCT01976845|Perioperative outcomes
193682|NCT01976806|Docosahexaenoic acid
193683|NCT01976806|DHA
193684|NCT01976806|Periodontitis
193685|NCT01976806|Gingivitis
193686|NCT01976806|Omega-3 fatty acid
193687|NCT01976806|Fish oil
193688|NCT01976793|Recurrent depressive disorder
193689|NCT01976793|Depression
193690|NCT01976793|Depressive episode
193691|NCT01976793|Atypical antipsychotics
193692|NCT01976780|Malaria
193693|NCT01976780|P. falciparum mono infection
193694|NCT01976780|Early Treatment Failure
193695|NCT01976780|Late Treatment Failure
193696|NCT01976767|Sputum
193697|NCT01976767|Clinical cohorts
193698|NCT01976767|Smokers
193699|NCT01976767|Asthma
193700|NCT01976767|Biopsies
193701|NCT01976767|Severe asthma
193702|NCT01976767|Collaborative research
193703|NCT01976767|Phenotyping
193704|NCT01976767|Lipidomics
193705|NCT01976767|Transcriptomics
193706|NCT01976767|Proteomics
193707|NCT01976767|Paediatric cohort
193708|NCT01976767|Systems Biology
193709|NCT01976741|Phase I
193710|NCT01976741|Dose escalation
193711|NCT01976741|refractory, locally advanced or metastatic solid tumor
193712|NCT01976741|Bladder cancer
193713|NCT01976741|squamous non-small cell lung cancer
193714|NCT01976741|pan-FGFR inhibitor
193715|NCT01976741|lung adenocarcinoma
193716|NCT01976741|head and neck cancer
193717|NCT01976715|HIV
193718|NCT01976715|Treatment Failure
193719|NCT01976715|Drug Resistance
193720|NCT01976702|HIV risk behaviors
193721|NCT01976702|Pregnant drug abusers
193722|NCT01976689|Glucose Regulation
193723|NCT01976689|Left Ventricular Hypertrophy
193724|NCT01976689|New-onset Diabetes
193725|NCT01976689|Renal Transplantation
193726|NCT01976598|chronic
193727|NCT01976598|back
193728|NCT01976598|leg
193729|NCT01976598|pain
193730|NCT01976598|sub-sensory
193731|NCT01976598|stimulation
193732|NCT01976598|Neuromodulation
193733|NCT01976598|Yearwood
193734|NCT01976585|Intratumoral injections
193735|NCT01976585|rhuFlt3L
193736|NCT01976585|Flt3L
193737|NCT01976585|CDX-301
193738|NCT01976585|Vaccine
193739|NCT01976585|Poly-ICLC
193740|NCT01976585|iNHL
193741|NCT01976585|TLR3
193742|NCT01976585|Low-Grade B-cell Lymphoma
193743|NCT01976585|Follicular
193744|NCT01976585|Marginal Zone
193745|NCT01976585|SLL
193746|NCT01976585|Small lymphocytic
193747|NCT01976572|CKD Stage V
193748|NCT01976572|dialysis
193749|NCT01976559|ICP
193750|NCT01976559|Intracranial pressure
193751|NCT01976559|Hydrocephalus
193752|NCT01976559|Idiopathic normal pressure hydrocephalus
193753|NCT01976559|CSF
193754|NCT01976559|Cerebrospinal fluid
193755|NCT01976559|Noninvasive ICP
193756|NCT01976520|Cancer vaccine
193757|NCT01976520|Chronic lymphocytic leukemia
193758|NCT01976520|CLL
193759|NCT01976520|Autologous vaccine
193760|NCT01976520|B cell leukemia
193761|NCT01976494|Patient controlled analgesia equipment
193762|NCT01976494|efficacy
193763|NCT01976494|safety
193764|NCT01976494|Accufuser Omnibus®
193765|NCT01976494|Upper abdominal surgery
193766|NCT01976494|laparotomy
193767|NCT01976455|obesity
193768|NCT01976455|carbon13
193769|NCT01976455|over-eating
193770|NCT01976455|metabolic chamber
193771|NCT01976455|room calorimeter
193772|NCT01976442|Leukemia
193773|NCT01976442|Transfusion
193774|NCT01976429|barotrauma
193775|NCT01976429|barotitis
193776|NCT01976429|middle ear
193777|NCT01976429|flying
193778|NCT01976429|diving
193779|NCT01976429|Eustachian tube
193780|NCT01976416|Hydroxyurea
193781|NCT01976390|Kidney
193782|NCT01976390|Kidney transplant
193783|NCT01976390|Renal failure
193784|NCT01976390|End Stage Renal Disease
193785|NCT01976390|kidney transplant recipient
193786|NCT01976364|Tofacitinib
193787|NCT01976364|Psoriatic Arthritis
193788|NCT01976364|Xeljanz
193789|NCT01976364|CP-690550
193790|NCT01976364|Jak-inhibitor
193791|NCT01976364|oral treatment
193792|NCT01976364|psoriasis
193793|NCT01976364|OPAL BALANCE
193794|NCT01976364|moderate
193795|NCT01976364|sever
193796|NCT01976364|pruritus
193797|NCT01976364|itch
193798|NCT01976364|DLQI
193799|NCT01976351|Barrett's esophagus
193800|NCT01976351|image-enhanced endoscopy
193801|NCT01976338|BRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab
193802|NCT01976325|decision aid
193803|NCT01976325|imported malaria
193804|NCT01976325|malaria prevention and control
193805|NCT01976325|malaria chemoprophylaxis
193806|NCT01976325|mefloquine
193807|NCT01976325|lariam
193808|NCT01976325|atovaquone-proguanil
193809|NCT01976325|malarone
193810|NCT01976325|doxycycline
193811|NCT01976325|vibramycin
193812|NCT01976312|CRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab
193813|NCT01976221|Comprehensive referrals
193814|NCT01976221|Appropriate referring
193815|NCT01976221|Priority setting
193816|NCT01976221|Waiting time in hospital
193817|NCT01976208|Omalizumab
193818|NCT01976208|IgE
193819|NCT01976208|Asthma
193820|NCT01976195|Thalidomide
193821|NCT01976195|Dexamethasone
193822|NCT01976195|ITP
193823|NCT01976182|large granular lymphocytes leukemia
193824|NCT01976182|immunosuppressive drugs
193825|NCT01976182|methotrexate
193826|NCT01976182|cyclophosphamide
193827|NCT01976182|efficiency
193828|NCT01976182|phase II randomized controlled trial
193829|NCT01976169|Breast Cancer
193830|NCT01976169|Advanced Breast Cancer
193831|NCT01976104|Thrombocytopenia
193832|NCT01976104|Chronic Liver Disease
193833|NCT01976091|limb girdle muscular dystrophy
193834|NCT01976091|LGMD2D
193835|NCT01976091|alpha-sarcoglycan
193836|NCT01976091|gene transfer
193837|NCT01976091|adeno-associated virus
193838|NCT01976078|Voriconazole
193839|NCT01976078|Pharmacokinetics
193840|NCT01976078|Ontogeny
193841|NCT01976078|Modeling
193842|NCT01976078|Bayesian
193843|NCT01976065|Necrotic tooth pulp
193844|NCT01976065|Immature permanent teeth
193845|NCT01976065|Regeneration
193846|NCT01976052|Biomarkers
193847|NCT01976052|Genomics
193848|NCT01976039|motorcyclist
193849|NCT01976039|nasal mucociliary clearance
193850|NCT01976039|physical therapy
193851|NCT01976026|Flow Diversion
193852|NCT01976026|Aneurysm
193853|NCT01976026|Intracranial
193854|NCT01976026|Cerebral
193855|NCT01976026|Vertebral
193856|NCT01976026|blood blister-like
193857|NCT01976026|ruptured aneurysm
193858|NCT01976026|Pipeline Flow Diversion
193859|NCT01976026|Pipeline Flow Diverter
193860|NCT01976026|Best-Standard Treatment
193861|NCT01976013|PT
193862|NCT01976013|INR
193863|NCT01976013|intraventricular haemorrhage
193864|NCT01976013|pulmonary haemorrhage
193865|NCT01976013|ELBW infants
193866|NCT01975987|Intubation
193867|NCT01975987|Bonfils fiberscope
193868|NCT01975974|vascular
193869|NCT01975974|access
193870|NCT01975974|ultrasound
193871|NCT01975948|Mental Health
193872|NCT01975948|Education and Practice Support Program
193873|NCT01975948|Depression
193874|NCT01975948|Primary Care
193875|NCT01975948|Skill-based training
193876|NCT01975935|diabetes mellitus type 2
193877|NCT01975935|non-alcoholic fatt liver disease
193878|NCT01975935|obesity
193879|NCT01975922|language impairment
193880|NCT01975922|language disorder
193881|NCT01975922|language delay
193882|NCT01975922|late talkers
193883|NCT01975922|late talking
193884|NCT01975909|Spinocerebellar Ataxia
193885|NCT01975909|SCA
193886|NCT01975909|Ataxia
193887|NCT01975909|Transcranial Magnetic Stimulation
193888|NCT01975909|TMS
193889|NCT01975883|Blood Glucose
193890|NCT01975883|Postoperative Complications
193891|NCT01975883|Spine
193892|NCT01975883|Orthopedic surgery
193893|NCT01975870|Sedentary behavior, smartphone, application
193894|NCT01975857|mild traumatic brain injury
193895|NCT01975857|sleep
193896|NCT01975857|mind body intervention
193897|NCT01975857|mind body bridging
193898|NCT01975844|Anemia
193899|NCT01975844|End Stage Renal Disease
193900|NCT01975831|Non Triple Negative Breast Cancer
193901|NCT01975818|Anemia of CKD on dialysis
193902|NCT01975805|cesarean delivery
193903|NCT01975805|chlorhexidine
193904|NCT01975805|iodine
193905|NCT01975805|skin disinfectant
193906|NCT01975792|PPROM
193907|NCT01975792|Pregnant
193908|NCT01975792|Preterm
193909|NCT01975792|Premature, labor
193910|NCT01975766|Carcinoma, squamous cell of head and neck
193911|NCT01975766|Head and neck cancer
193912|NCT01975766|ketogenic diet
193913|NCT01975766|radiotherapy
193914|NCT01975766|cisplatin
193915|NCT01975753|pain
193916|NCT01975727|PONV
193917|NCT01975727|Dexamethasone
193918|NCT01975727|Treatment
193919|NCT01975714|Glaucoma
193920|NCT01975714|Ocular hypertension
193921|NCT01975714|Preservative-free prostaglandins
193922|NCT01975701|BGJ398,
193923|NCT01975701|recurrent glioblastoma'
193924|NCT01975701|recurrent GBM,
193925|NCT01975701|FGFR,
193926|NCT01975662|MRSA
193927|NCT01975662|bacteremia
193928|NCT01975662|vancomycin
193929|NCT01975662|daptomycin
193930|NCT01975649|postmenopausal
193931|NCT01975649|hypoactive
193932|NCT01975649|sexual disorder
193933|NCT01975649|androgen
193934|NCT01975636|Metabolism and Elimination
193935|NCT01975623|Video assisted thoracoscopic surgery (VATS)
193936|NCT01975610|Arthritis, Rheumatoid, Autoimmune, Inflammatory, Synovial, Bruton's tyrosine kinase (Btk), CC-292, Joint Disease
193937|NCT01975571|residual hearing
193938|NCT01975571|hybrid
193939|NCT01975571|hearing preservation
193940|NCT01975545|Down syndrome
193941|NCT01975545|Caries
193942|NCT01975545|Dental varnish
193943|NCT01975519|TRC105
193944|NCT01975519|CD105
193945|NCT01975519|Endoglin
193946|NCT01975519|Angiogenesis Inhibitor
193947|NCT01975519|STS
193948|NCT01975519|Soft Tissue Sarcoma
193949|NCT01975519|TKI
193950|NCT01975519|Tyrosine Kinase Inhibitor
193951|NCT01975519|Pazopanib
193952|NCT01975519|Votrient
193953|NCT01975519|Advanced Soft Tissue Sarcoma
193954|NCT01975519|Angiosarcoma
193955|NCT01975506|Head Start
193956|NCT01975506|Occupational Therapy
193957|NCT01975493|Infectious Diseases
193958|NCT01975493|Paediatrics
193959|NCT01975493|Neonatology
193960|NCT01975493|Pharmacokinetics
193961|NCT01975493|Antimicrobials
193962|NCT01975467|midshaft clavicle fracture
193963|NCT01975467|intramedullary nail
193964|NCT01975467|sling
193965|NCT01975454|Metastatic colorectal cancer
193966|NCT01975454|Chemotherapy
193967|NCT01975454|Traditional Chinese Medicine (TCM)
193968|NCT01975454|Teng-Long-Bu-Zhong-Tang
193969|NCT01975441|Diethycarbamazine
193970|NCT01975441|Albendazole
193971|NCT01975441|Ivermectin
193972|NCT01975441|Lymphatic filariasis
193973|NCT01975415|Meditation
193974|NCT01975415|Sensors
193975|NCT01975415|Digital medicine
193976|NCT01975402|Congestive Heart Failure
193977|NCT01975389|myocardial infarction
193978|NCT01975389|stroke
193979|NCT01975389|hyperlipidemia
193980|NCT01975376|myocardial infarction
193981|NCT01975376|stroke
193982|NCT01975376|hyperlipidemia
193983|NCT01975363|Breast Cancer
193984|NCT01975350|Colistimethate sodium inhalation
193985|NCT01975324|Ampyra
193986|NCT01975324|NAION
193987|NCT01975324|Dalfampridine
193988|NCT01975298|RRMS
193989|NCT01975285|Pain management
193990|NCT01975285|Postoperative opioid requirements
193991|NCT01975285|Perioperative outcomes
193992|NCT01975285|Dexamethasone
193993|NCT01975285|Anesthetic adjuvant
193994|NCT01975285|Analgesic adjuvant
193995|NCT01975272|postoperative
193996|NCT01975272|anemia
193997|NCT01975272|gynaecologic
193998|NCT01975272|surgery
193999|NCT01975233|Endovascular
194000|NCT01975233|Brain Aneurysm
194001|NCT01975181|cardiovascular disease risk factors
194002|NCT01975181|cardiovascular disease prevention
194003|NCT01975168|laser acupuncture
194004|NCT01975168|obesity
194005|NCT01975155|Celiac disease
194006|NCT01975155|Gluten free diet nutrient content
194007|NCT01975155|mycotoxins
194008|NCT01975155|Gluten free diet
194009|NCT01975142|Metastatic breast cancer
194010|NCT01975142|Primary tumor HER2 negative
194011|NCT01975142|CTC HER2 positive
194012|NCT01975077|patients with mCRC who failed 2nd therapy or more
194013|NCT01975064|Breast neoplasms
194014|NCT01975064|Colonic neoplasms
194015|NCT01975064|Rectal neoplasms
194016|NCT01975051|Kala- azar
194017|NCT01975051|PKDL
194018|NCT01975051|Treatment
194019|NCT01975051|Pathogenesis
194020|NCT01975051|Bangladesh
194021|NCT01975038|Melanin Index
194022|NCT01975038|Fitzpatrick Skin Phototype
194023|NCT01975038|Spectrophotometry
194024|NCT01975038|Skin Diseases
194025|NCT01975025|Renal Dialysis
194026|NCT01974999|Kidney
194027|NCT01974999|Transplant
194028|NCT01974999|Rejection
194029|NCT01974986|dehydration
194030|NCT01974986|exercise
194031|NCT01974986|rehydration
194032|NCT01974986|sodium
194033|NCT01974986|water
194034|NCT01974986|carbohydrate
194035|NCT01974973|autism spectrum disorders
194036|NCT01974973|stem cells
194037|NCT01974947|Metabolic syndrome
194038|NCT01974947|Epigenetic
194039|NCT01974947|Male infertility
194040|NCT01974947|Sperm parameters
194041|NCT01974947|Biomarkers
194042|NCT01974921|Asthma
194043|NCT01974921|Bronchial Thermoplasty
194044|NCT01974921|Bronchial smooth muscle
194045|NCT01974908|Ventricular Tachycardia
194046|NCT01974895|Children
194047|NCT01974895|Immunogenicity
194048|NCT01974895|Fluzone®
194049|NCT01974895|6 to 35 months of age
194050|NCT01974895|Seasonal influenza
194051|NCT01974895|Safety
194052|NCT01974882|abdominal surgery
194053|NCT01974882|cryotherapy
194054|NCT01974882|pain score
194055|NCT01974882|narcotic utilization
194056|NCT01974869|Surgery,Crohn's disease,Ulcerative colitis
194057|NCT01974830|alpha-1
194058|NCT01974830|anti-trypsin
194059|NCT01974830|pulmonary function
194060|NCT01974830|augmentation therayp
194061|NCT01974830|home care
194062|NCT01974817|pneumococcal vaccine
194063|NCT01974817|end stage renal disease
194064|NCT01974817|dialysis
194065|NCT01974804|MRI
194066|NCT01974804|Brain metastases
194067|NCT01974804|13-094
194068|NCT01974765|Enzalutamide
194069|NCT01974765|Androgen Receptor Positive (AR+)
194070|NCT01974765|13-119
194071|NCT01974752|uveal melanoma
194072|NCT01974739|intensive care
194073|NCT01974739|diuretics
194074|NCT01974726|ear
194075|NCT01974726|middle ear
194076|NCT01974726|Eustachian tube
194077|NCT01974726|Eustachian tube dysfunction
194078|NCT01974726|Eustachian tube function
194079|NCT01974713|CKD progression
194080|NCT01974713|Inflammation
194081|NCT01974713|FGF23
194082|NCT01974713|Genetic biomarkers
194083|NCT01974687|Hepatitis C virus
194084|NCT01974687|HCV
194085|NCT01974674|diabetes
194086|NCT01974674|transplantation
194087|NCT01974648|Laryngeal Mask Airway Supreme
194088|NCT01974648|propofol
194089|NCT01974648|remifentanil
194090|NCT01974648|effective dose of intravenous propofol
194091|NCT01974648|ED50
194092|NCT01974635|Spinal Cord Injury
194093|NCT01974635|Robotic therapy
194094|NCT01974635|Rehabilitation
194095|NCT01974635|Sensation
194096|NCT01974635|Movement
194097|NCT01974635|Proprioception
194098|NCT01974635|Stroke
194099|NCT01974635|Acquired Brain Injury
194100|NCT01974609|pain relief
194101|NCT01974609|narcotic pain relief
194102|NCT01974609|non-narcotic pain relief
194103|NCT01974609|post-operative pain relief
194104|NCT01974609|carpal tunnel
194105|NCT01974596|Dental implants
194106|NCT01974596|Probiotics
194107|NCT01974596|Lactobacillus reuteri
194108|NCT01974596|Periimplant mucositis
194109|NCT01974596|Cytokines
194110|NCT01974596|Bacterial load
194111|NCT01974583|the split-thickness skin graft （STSG） donor site
194112|NCT01974583|regraft
194113|NCT01974583|wound healing
194114|NCT01974570|Prehypertension
194115|NCT01974570|Hypertension
194116|NCT01974570|Shrimp protein hydrolysate
194117|NCT01974570|Marine protein hydrolysate
194118|NCT01974570|Ambulatory blood pressure
194119|NCT01974570|Blood pressure
194120|NCT01974557|Cardiac physiology
194121|NCT01974557|ageing
194122|NCT01974557|gender differences
194123|NCT01974557|diastole
194124|NCT01974557|fluid challenge
194125|NCT01974544|diabetes complications
194126|NCT01974544|metabolic surgery
194127|NCT01974544|Intensive medicines
194128|NCT01974518|Pemphigus
194129|NCT01974518|Rituximab
194130|NCT01974518|Rituximab and IV cyclophosphamide combination
194131|NCT01974518|B cell re-population characteristics following Rituximab
194132|NCT01974492|saphenous vein graft
194133|NCT01974492|composite graft
194134|NCT01974492|coronary artery bypass grafting
194135|NCT01974492|graft remodeling
194136|NCT01974479|Redirected Natural Killer Cells
194137|NCT01974479|Haploidentical Cell Therapy
194138|NCT01974466|pancreatitis
194139|NCT01974466|resuscitation goal
194140|NCT01974453|Radiation dose, transradial approach, percutaneous coronary interventions, coronary angiography
194141|NCT01974440|Lymphoma
194142|NCT01974440|Follicular lymphoma
194143|NCT01974440|Marginal zone lymphoma
194144|NCT01974440|Indolent Non-Hodgkin lymphoma
194145|NCT01974440|PCI-32765
194146|NCT01974440|Ibrutinib
194147|NCT01974440|Bendamustine
194148|NCT01974440|Rituximab
194149|NCT01974440|Cyclophosphamide
194150|NCT01974440|Doxorubicin
194151|NCT01974440|Vincristine
194152|NCT01974440|Prednisone
194153|NCT01974440|R-CHOP
194154|NCT01974427|Magnetic Resonance Imaging (MRI)
194155|NCT01974427|Functional Imaging
194156|NCT01974427|BOLD Effect
194157|NCT01974427|EEG
194158|NCT01974427|MEG
194159|NCT01974414|oral lichen planus
194160|NCT01974414|cedar honey
194161|NCT01974414|atrophic
194162|NCT01974414|erosive
194163|NCT01974414|pain
194164|NCT01974414|treatment
194165|NCT01974414|clinical trial
194166|NCT01974401|oral irrigator
194167|NCT01974401|leukemia
194168|NCT01974401|blood dyscrasia
194169|NCT01974401|Oral Health Index Simplified (OHI-S)
194170|NCT01974401|supra gingival irrigator
194171|NCT01974388|Bariatric surgery, sleeve gastrectomy, gastric leak
194172|NCT01974375|Living donor
194173|NCT01974375|Liver transplant
194174|NCT01974375|antifungal prevention
194175|NCT01974362|Monolithic Zirconia
194176|NCT01974362|Zirconia-Feldspathic zirconia
194177|NCT01974362|Dental Implants
194178|NCT01974362|Fracture
194179|NCT01974362|Chipping
194180|NCT01974349|Phase I, healthy, pharmacokinetics, food effect.
194181|NCT01974310|Macular Holes
194182|NCT01974310|Non face down positioning
194183|NCT01974310|Face down positioning
194184|NCT01974297|Hyperlipidemia
194185|NCT01974297|Atorvastatin
194186|NCT01974297|Fenofibric acid
194187|NCT01974297|combination
194188|NCT01974297|monotherapy
194189|NCT01974245|Cholecalciferol
194190|NCT01974245|Kidney diseases
194191|NCT01974232|Immune Thrombocytopenia (ITP), Thrombopoietin (TPO) agents, children, romiplostim and eltrombopag
194192|NCT01974219|HIV
194193|NCT01974219|COPD
194194|NCT01974219|Chronic Obstructive Pulmonary Disease
194195|NCT01974219|Smoking
194196|NCT01974206|ASP0113
194197|NCT01974206|Cytomegalovirus (CMV)
194198|NCT01974206|Kidney Transplantation
194199|NCT01974180|Smoking
194200|NCT01974180|COPD
194201|NCT01974180|Chronic Obstructive Pulmonary Disease
194202|NCT01974180|Healthy Smoker
194203|NCT01974180|Non-smoker
194204|NCT01974167|glucocorticoid-induced osteoporosis
194205|NCT01974154|COPD
194206|NCT01974154|Smoking
194207|NCT01974154|Non-smoker
194208|NCT01974128|MI
194209|NCT01974115|Cellulite
194210|NCT01974115|Extracorporeal shock wave therapy
194211|NCT01974115|ESWT
194212|NCT01974115|Radial shock wave therapy
194213|NCT01974115|RSWT
194214|NCT01974089|Dysphagia
194215|NCT01974089|Modified diet
194216|NCT01974089|Community acquired pneumonia
194217|NCT01974089|Mortality
194218|NCT01974089|Rehospitalization
194219|NCT01974063|Smoking
194220|NCT01974063|Smoking Cessation
194221|NCT01974063|Healthy Smoker
194222|NCT01974063|Shisha Smoker
194223|NCT01974063|Non-smoker
194224|NCT01974050|Influenza vaccination
194225|NCT01974024|Dexamethasone
194226|NCT01974024|Hiccup
194227|NCT01974024|Chemotherapy
194228|NCT01974024|Methylprednisolone
194229|NCT01973998|COPD
194230|NCT01973998|Emphysema
194231|NCT01973998|Roflumilast
194232|NCT01973998|readmission
194233|NCT01973985|Pleural Effusion
194234|NCT01973972|Diabetes
194235|NCT01973972|Obesity
194236|NCT01973972|Complex Care
194237|NCT01973972|Primary Care
194238|NCT01973972|Chronic Disease
194239|NCT01973946|Cancer
194240|NCT01973933|Metformin
194241|NCT01973933|Pyrimethamine
194242|NCT01973933|Drug interaction
194243|NCT01973920|Diabetes Mellitus
194244|NCT01973920|Oral Insulin
194245|NCT01973907|Sepsis
194246|NCT01973907|Septic Shock
194247|NCT01973907|Fluid Therapy
194248|NCT01973907|Pediatrics
194249|NCT01973907|Resuscitation
194250|NCT01973907|Emergency Medicine
194251|NCT01973907|Critical Care
194252|NCT01973894|PBPK
194253|NCT01973894|Midazolam
194254|NCT01973894|Pharmacokinetics
194255|NCT01973894|Critically ill patients
194256|NCT01973868|Regorafenib
194257|NCT01973868|Cetuximab
194258|NCT01973868|Solid tumors
194259|NCT01973868|Cancer
194260|NCT01973868|Safety
194261|NCT01973868|Tolerability
194262|NCT01973868|Pharmacokinetics
194263|NCT01973842|GnRH agonist
194264|NCT01973842|OHSS
194265|NCT01973842|Triggering final oocyte maturation
194266|NCT01973829|CERTAIN, Checklist, ICU, Outcome, Adults
194267|NCT01973816|deep endometriosis;
194268|NCT01973816|rectal endometriosis;
194269|NCT01973816|rectal shaving;
194270|NCT01973816|colorectal resection;
194271|NCT01973816|bowel endometriosis
194272|NCT01973803|Carpometacarpal joint
194273|NCT01973803|Osteoarthritis of CMC-1 joint
194274|NCT01973790|Z-338
194275|NCT01973790|Functional Dyspepsia
194276|NCT01973790|Postprandial Distress Syndrome
194277|NCT01973777|intrauterine device, contraception
194278|NCT01973764|Intraoperative ultrasound
194279|NCT01973764|Ventricular System
194280|NCT01973764|Puncture
194281|NCT01973764|Ventricular catheter
194282|NCT01973764|Ventriculostomy
194283|NCT01973764|Hydrocephalus
194284|NCT01973764|Excessive accumulation of cerebrospinal fluids within the cranium. Often associated with dilatation of cerebral ventricles
194285|NCT01973764|Intracranial Hypertension
194286|NCT01973764|increased pressure within the cranial vault. This may result from several conditions, including hydrocephalus, brain edema.
194287|NCT01973738|raloxifene
194288|NCT01973738|bazedoxifene
194289|NCT01973738|bone mineral density
194290|NCT01973738|bone turnover markers
194291|NCT01973738|bone quality
194292|NCT01973699|shoulder arthroscopy, epinephrine, visualization
194293|NCT01973673|prostate cancer
194294|NCT01973673|ADT
194295|NCT01973673|bone health
194296|NCT01973660|Human Epidermal Growth Factor Receptor 2
194297|NCT01973660|HER2
194298|NCT01973660|HER2 positive
194299|NCT01973660|PAM50
194300|NCT01973660|lapatinib
194301|NCT01973660|trastuzumab
194302|NCT01973660|dual HER2 blockade
194303|NCT01973660|neoadjuvant
194304|NCT01973647|insomnia
194305|NCT01973647|cognitive behavioral therapy
194306|NCT01973647|COPD
194307|NCT01973647|fatigue
194308|NCT01973634|Radiotherapy
194309|NCT01973608|Melanoma
194310|NCT01973608|MSB0010445
194311|NCT01973608|Dose limiting toxicity
194312|NCT01973608|Stereotactic body radiation therapy
194313|NCT01973595|almonds
194314|NCT01973595|inflammation
194315|NCT01973595|immunity
194316|NCT01973595|gut microbiota
194317|NCT01973595|stress
194318|NCT01973595|diet quality
194319|NCT01973582|Hepatitis B
194320|NCT01973582|epidemiology
194321|NCT01973582|youth
194322|NCT01973582|vaccine
194323|NCT01973569|Rheumatoid Arthritis
194324|NCT01973569|Denosumab
194325|NCT01973569|RANKL
194326|NCT01973569|RANK
194327|NCT01973569|AMG 162
194328|NCT01973569|joint damage
194329|NCT01973543|PD
194330|NCT01973543|Parkinson's disease
194331|NCT01973543|Aromatic Amino Acid Decarboxylase
194332|NCT01973543|AADC
194333|NCT01973543|AAV2-AADC
194334|NCT01973543|AAV2
194335|NCT01973543|Viral Vector
194336|NCT01973543|Gene Therapy
194337|NCT01973543|Gene Transfer
194338|NCT01973543|MRI
194339|NCT01973543|PET
194340|NCT01973543|VY-AADC01
194341|NCT01973530|femoral nerve block
194342|NCT01973530|adductor canal block
194343|NCT01973530|steroid
194344|NCT01973530|total knee replacement
194345|NCT01973517|Multiple sclerosis
194346|NCT01973517|MRI
194347|NCT01973517|USPIO
194348|NCT01973517|Ferumoxytol
194349|NCT01973517|Feraheme
194350|NCT01973504|Trauma
194351|NCT01973504|Hemorrhagic shock
194352|NCT01973504|Hemorrhage
194353|NCT01973504|Lactic acidosis
194354|NCT01973504|Oxygen therapeutics
194355|NCT01973504|Oxygen carriers
194356|NCT01973504|Ischemic rescue therapy
194357|NCT01973504|Hemoglobin solutions
194358|NCT01973504|PEGylated hemoglobin
194359|NCT01973491|ATX-MS-1467 (MSC2358825A)
194360|NCT01973491|Relapsing Multiple Sclerosis
194361|NCT01973491|Magnetic resonance imaging (MRI)
194362|NCT01973491|M2736
194363|NCT01973478|Major depressive disorder
194364|NCT01973478|Recurrent depressive disorder
194365|NCT01973478|Bipolar disorder
194366|NCT01973478|Deep brain stimulation
194367|NCT01973478|Accumbens
194368|NCT01973465|C-Diff
194369|NCT01973465|Diarrhea
194370|NCT01973452|Dexmedetomidine
194371|NCT01973452|Opioid
194372|NCT01973452|Thoracic Surgery
194373|NCT01973439|HIV
194374|NCT01973439|Abacavir
194375|NCT01973439|Lamivudine
194376|NCT01973439|Pharmacokinetics
194377|NCT01973426|Robot
194378|NCT01973426|Thumb
194379|NCT01973426|Orthosis
194380|NCT01973426|Hemiplegia
194381|NCT01973426|Hemiplegic Stroke
194382|NCT01973426|Hemiplegic Cerebral Palsy
194383|NCT01973426|Stroke
194384|NCT01973426|Cerebral Palsy
194385|NCT01973426|Grasp assistance
194386|NCT01973413|Artificial Pancreas Project
194387|NCT01973413|Diabetes Mellitus, Type 1
194388|NCT01973413|Insulin pump therapy
194389|NCT01973413|Continuous Glucose Monitors (CGM)
194390|NCT01973413|Juvenile-Onset Diabetes
194391|NCT01973413|Autoimmune Diabetes
194392|NCT01973413|Closed-to-Range
194393|NCT01973413|Diabetes Assistant (DiAs)
194394|NCT01973387|Chronic lymphocytic leukemia
194395|NCT01973387|Small lymphocytic lymphoma
194396|NCT01973387|Relapsed or refractory chronic lymphocytic leukemia
194397|NCT01973387|Relapsed or refractory small lymphocytic lymphoma
194398|NCT01973387|Ibrutinib
194399|NCT01973387|PCI-32765
194400|NCT01973387|Bruton's tyrosine kinase inhibitor
194401|NCT01973387|Rituximab
194402|NCT01973387|Asia Pacific region participants
194403|NCT01973361|Wounds
194404|NCT01973361|Lower extremity
194405|NCT01973361|Diabetes
194406|NCT01973361|Arterial Insufficiency
194407|NCT01973361|Debridement
194408|NCT01973361|Low frequency ultrasound
194409|NCT01973361|Contact ultrasound
194410|NCT01973361|Wound clinic
194411|NCT01973361|Wound bed preparation
194412|NCT01973361|Wound infection
194413|NCT01973361|Chronic wound inflammation
194414|NCT01973348|amblyopia
194415|NCT01973335|acetazolamide
194416|NCT01973335|bumetanide
194417|NCT01973335|cardio-renal syndrome
194418|NCT01973335|diuretics
194419|NCT01973335|heart failure
194420|NCT01973335|natriuresis
194421|NCT01973335|spironolactone
194422|NCT01973322|Malignant melanoma stage III or IV
194423|NCT01973322|pretreated melanoma
194424|NCT01973322|vaccination
194425|NCT01973322|autologous dendritic cells
194426|NCT01973322|autologous tumor lysate or homogenate
194427|NCT01973322|immunomodulating radiotherapy
194428|NCT01973309|Locally Recurrent
194429|NCT01973309|Metastatic Breast Cancer
194430|NCT01973296|Health Literacy
194431|NCT01973296|Care Transition Intervention
194432|NCT01973296|Emergency Department Population
194433|NCT01973296|Access to Care
194434|NCT01973218|Meningitis, adolescents, Meningococcal B
194435|NCT01973205|Migraine
194436|NCT01973205|acetaminophen
194437|NCT01973205|aspirin
194438|NCT01973166|Tattoo Removal
194439|NCT01973166|Q-switched laser
194440|NCT01973166|Nd:YAG laser
194441|NCT01973166|Nanosecond laser
194442|NCT01973166|Picosecond laser
194443|NCT01973166|Laser therapy
194444|NCT01973166|Tattoo
194445|NCT01973166|pulsed-laser
194446|NCT01973166|laser treatment
194447|NCT01973166|remove tattoo
194448|NCT01973166|tattoo clearing
194449|NCT01973166|tattoo lightening
194450|NCT01973166|tattoo lighten
194451|NCT01973153|Obesity prevention
194452|NCT01973153|Weight management
194453|NCT01973153|Motivational Interviewing
194454|NCT01973140|Tolvaptan
194455|NCT01973140|Aquaretic Efficacy
194456|NCT01973127|alcohol
194457|NCT01973127|addiction
194458|NCT01973127|TMS
194459|NCT01973127|craving
194460|NCT01973127|use
194461|NCT01973127|rTMS
194462|NCT01973127|EEG
194463|NCT01973127|LPP
194464|NCT01973127|p300
194465|NCT01973127|ERN
194466|NCT01973127|SST
194467|NCT01973127|CCT
194468|NCT01973127|AAAT
194469|NCT01973114|Menière's disease
194470|NCT01973114|Vertigo
194471|NCT01973114|Hearing loss
194472|NCT01973114|Tinnitus
194473|NCT01973101|Advanced carcinomas of uterine cervix
194474|NCT01973101|Chemoradiation
194475|NCT01973101|Chemo-induction
194476|NCT01973101|Cisplatin
194477|NCT01973101|Gemcitabine
194478|NCT01973075|Premature Ovarian Insufficiency (POI)
194479|NCT01973036|foley catheter
194480|NCT01973036|foley bulb
194481|NCT01973036|oxytocin
194482|NCT01973023|botulinum toxin injection
194483|NCT01973023|stroke
194484|NCT01973023|3D motion analysis
194485|NCT01973023|gait pattern
194486|NCT01973010|massage
194487|NCT01973010|low back pain
194488|NCT01972984|Estrogen receptor positive
194489|NCT01972971|warfarin
194490|NCT01972971|pharmacist
194491|NCT01972971|anticoagulation
194492|NCT01972945|vaginoscopy
194493|NCT01972945|hysteroscopy
194494|NCT01972945|office hysteroscopy
194495|NCT01972945|outpatient hysteroscopy
194496|NCT01972932|Bio-K+®
194497|NCT01972932|Placebo
194498|NCT01972932|AAD
194499|NCT01972932|CDI
194500|NCT01972932|hospitalized subjects
194501|NCT01972906|moxibustion
194502|NCT01972906|primary dysmenorrhea
194503|NCT01972893|Selective GLP-1 agonist
194504|NCT01972880|Open-label design
194505|NCT01972880|Bioequivalence
194506|NCT01972880|ASP1941
194507|NCT01972867|Focal
194508|NCT01972867|Prostate
194509|NCT01972867|Cancer
194510|NCT01972867|Irreversible
194511|NCT01972867|Electroporation
194512|NCT01972867|NanoKnife
194513|NCT01972854|keratoconus
194514|NCT01972854|cross-linking
194515|NCT01972854|KXL
194516|NCT01972841|Combination Therapy
194517|NCT01972841|Mirabegron
194518|NCT01972841|Overactive Bladder
194519|NCT01972841|Urgency
194520|NCT01972841|Urinary Incontinence
194521|NCT01972841|Nocturia
194522|NCT01972841|Solifenacin Succinate
194523|NCT01972828|Septic shock
194524|NCT01972828|Randomized controlled trial
194525|NCT01972828|Preload dependence
194526|NCT01972828|Pulmonary thermodilution
194527|NCT01972802|HEAD AND NECK
194528|NCT01972789|Subfoveal choroidal neovascularization (CNV); wet age-related macular degeneration(AMD); inject and extend; retinal fluid
194529|NCT01972776|COPD, inflammation, small airways, LCI, PFTs, lung heterogeneity
194530|NCT01972750|glioblastoma
194531|NCT01972750|recurrence
194532|NCT01972737|Vaccine
194533|NCT01972737|Colon cancer
194534|NCT01972737|safety
194535|NCT01972737|tolerability
194536|NCT01972737|antibody responses
194537|NCT01972737|T cell responses
194538|NCT01972724|Drug therapy
194539|NCT01972711|Schizophrenia
194540|NCT01972698|Focused Cardiac Ultrasound
194541|NCT01972698|Lung Ultrasound
194542|NCT01972698|Simulation
194543|NCT01972698|Education
194544|NCT01972698|Web-based learning
194545|NCT01972685|ILD, transbronchial, cryoprobe, VATS
194546|NCT01972659|sugammadex
194547|NCT01972659|rocuronium
194548|NCT01972659|magnesium
194549|NCT01972659|female
194550|NCT01972646|Cellulitis, treatment failure, skin and soft tissue infections, risk factors.
194551|NCT01972633|endovenous treatment
194552|NCT01972633|Laser, Vnus Closure Fast
194553|NCT01972633|Varicosis
194554|NCT01972633|great saphenous vein
194555|NCT01972633|small saphenous vein
194556|NCT01972633|Venous Insufficiency
194557|NCT01972620|gallstones
194558|NCT01972620|cholelithiasis
194559|NCT01972620|cholecystectomy, laparoscopic
194560|NCT01972620|pain
194561|NCT01972607|Migraine, aerobic exercise, prevention
194562|NCT01972581|neurocognitive visual reaction training
194563|NCT01972581|baseball
194564|NCT01972568|Atacicept 75 and 150 mg
194565|NCT01972568|Placebo
194566|NCT01972542|Postprandial period
194567|NCT01972542|triglyceride
194568|NCT01972542|Diabetes mellitus, type 2
194569|NCT01972542|Prediabetic state
194570|NCT01972529|Thrombocytopenia
194571|NCT01972529|Chronic Liver Disease
194572|NCT01972516|Platinum-Sensitive
194573|NCT01972516|Ovarian Cancer
194574|NCT01972516|Fallopian Tube Cancer
194575|NCT01972516|Primary Peritoneal Cancer
194576|NCT01972516|High-grade Serous
194577|NCT01972503|Colorectal Neoplasms
194578|NCT01972503|Liver
194579|NCT01972503|Neoplasm Metastasis
194580|NCT01972503|Tegafur
194581|NCT01972503|oxaliplatin
194582|NCT01972490|colorectal neoplasms
194583|NCT01972490|liver metastasis
194584|NCT01972490|chemotherapy
194585|NCT01972490|avastin
194586|NCT01972477|DLBS1449
194587|NCT01972477|diabetes mellitus
194588|NCT01972477|HDL-cholesterol
194589|NCT01972464|Progesterone
194590|NCT01972464|Placebo
194591|NCT01972464|Postpartum
194592|NCT01972464|Tobacco
194593|NCT01972464|Pregnancy
194594|NCT01972438|Graft Versus Host Disease
194595|NCT01972438|Hematopoietic Stem Cell Transplant
194596|NCT01972412|nursing care
194597|NCT01972412|diabetes mellitus
194598|NCT01972412|phone support
194599|NCT01972412|chronic care model
194600|NCT01972373|VEGF
194601|NCT01972373|Fluorescence
194602|NCT01972373|Endoscopy
194603|NCT01972373|Rectal cancer
194604|NCT01972360|SPECT
194605|NCT01972360|CMR
194606|NCT01972360|High risk for ischemic cardiovascular events
194607|NCT01972347|Melanoma
194608|NCT01972347|Cutaneous melanoma
194609|NCT01972347|Malignant melanoma
194610|NCT01972347|Stage III B / C melanoma
194611|NCT01972347|Neoadjuvant treatment
194612|NCT01972347|Pyrexia
194613|NCT01972347|Biomarkers
194614|NCT01972347|Dabrafenib
194615|NCT01972347|Trametinib
194616|NCT01972334|clostridium difficile
194617|NCT01972334|children
194618|NCT01972334|fecal transplant
194619|NCT01972321|Community health worker
194620|NCT01972321|Motivation
194621|NCT01972321|Performance
194622|NCT01972321|Quality of care
194623|NCT01972321|Africa
194624|NCT01972308|asthma
194625|NCT01972308|patient advocate
194626|NCT01972308|health disparity
194627|NCT01972308|patient-provder communication
194628|NCT01972282|Atrial fibrillation
194629|NCT01972282|Stroke
194630|NCT01972282|Thrombus
194631|NCT01972282|Thromboembolism
194632|NCT01972282|Left atrial appendage
194633|NCT01972269|Epidural
194634|NCT01972269|Labor Analgesia
194635|NCT01972269|Bupivacaine
194636|NCT01972269|Minimum effective volume
194637|NCT01972243|risk of recurrent
194638|NCT01972217|Olaparib
194639|NCT01972217|castration-resistant, metastatic prostate cancer
194640|NCT01972217|Prior Docetaxel Chemotherapy
194641|NCT01972191|Toric marking, Corneal horizontal marking
194642|NCT01972165|Carpal tunnel syndrome
194643|NCT01972152|Hypoglycemia
194644|NCT01972152|Glucagon
194645|NCT01972139|Uncontrolled hypertension
194646|NCT01972139|blood pressure
194647|NCT01972139|renal denervation
194648|NCT01972139|HTN-4
194649|NCT01972139|SYMPLICITY
194650|NCT01972113|Vitamin K
194651|NCT01972113|Vitamin K2
194652|NCT01972113|Menaquinone-7
194653|NCT01972113|Osteocalcin
194654|NCT01972113|Children
194655|NCT01972113|Obesity
194656|NCT01972113|Insulin resistance
194657|NCT01972113|Insulin sensitivity
194658|NCT01972113|Beta-cell function
194659|NCT01972113|Prediabetes
194660|NCT01972113|Matrix Gla protein
194661|NCT01972113|Arterial stiffness
194662|NCT01972113|Endothelial function
194663|NCT01972100|Low-level laser therapy
194664|NCT01972100|Muscle fatigue resistance
194665|NCT01972074|Autism spectrum disorder
194666|NCT01972074|Treatment
194667|NCT01972074|Adolescents
194668|NCT01972074|Memantine
194669|NCT01972074|functional Magnetic Resonance Imaging
194670|NCT01972074|MRS
194671|NCT01972074|Neuroimaging
194672|NCT01972048|breast cancer
194673|NCT01972048|breast cancer screening
194674|NCT01972048|mammogram
194675|NCT01972035|EBV
194676|NCT01972035|CMV
194677|NCT01972035|Kidney transplant
194678|NCT01972035|valganciclovir
194679|NCT01972035|valacyclovir
194680|NCT01972022|Drug Eluting Stents
194681|NCT01972022|Bioabsorbale Polymer Coating
194682|NCT01972022|Neoatherosclerosis
194683|NCT01972022|Stent Coverage
194684|NCT01972022|Stent Failure
194685|NCT01971996|Near infrared Spectroscopy
194686|NCT01971983|Low back pain
194687|NCT01971983|Spinal manipulation
194688|NCT01971983|Osteopathy
194689|NCT01971983|Muscle energy technique
194690|NCT01971983|Muscle thickness
194691|NCT01971970|Inflammatory bowel disease
194692|NCT01971970|Pediatric
194693|NCT01971970|Adult
194694|NCT01971970|Biomarker
194695|NCT01971970|Anti-TNF response
194696|NCT01971970|Infliximab
194697|NCT01971970|Adalimumab
194698|NCT01971957|ichthyosis
194699|NCT01971957|spasticity
194700|NCT01971957|spastic diplegia
194701|NCT01971957|intellectual disability
194702|NCT01971944|Beta Blocker
194703|NCT01971944|Inotrope
194704|NCT01971918|spondyloarthritis
194705|NCT01971918|monoclonal antibodies anti-TNF
194706|NCT01971918|secondary treatment failure
194707|NCT01971892|Abdominal surgery;
194708|NCT01971892|Postoperative complication;
194709|NCT01971892|Acute respiratory failure;
194710|NCT01971892|Hypoxemia;
194711|NCT01971892|Intubation;
194712|NCT01971892|Non-invasive ventilation
194713|NCT01971879|Remote ischemic preconditioning
194714|NCT01971879|Obliterating Arteriopathy of the Lower Limbs
194715|NCT01971866|Proton radiation
194716|NCT01971866|AlignRT
194717|NCT01971853|Analgesia
194718|NCT01971840|Physical activity
194719|NCT01971840|Physical fitness
194720|NCT01971840|Obesity
194721|NCT01971840|Adiposity
194722|NCT01971840|Adiposity rebound period
194723|NCT01971840|Children
194724|NCT01971840|Blood pressure
194725|NCT01971840|Randomized controlled trials
194726|NCT01971840|Barriers and facilitators of the environment
194727|NCT01971827|Physical activity
194728|NCT01971827|Obesity
194729|NCT01971827|Adiposity rebound period
194730|NCT01971827|Children with ADHD
194731|NCT01971827|Children without ADHD
194732|NCT01971827|Academic performance
194733|NCT01971827|Motor skills
194734|NCT01971827|Health related-quality of life
194735|NCT01971827|Sleep
194736|NCT01971801|urinary incontinence
194737|NCT01971801|bowel incontinence
194738|NCT01971801|vitamin D
194739|NCT01971801|overactive bladder
194740|NCT01971801|lower urinary tract symptoms
194741|NCT01971801|quality of life
194742|NCT01971775|Ultrasonically Activated Shear
194743|NCT01971775|Conventional Monopolar Electrocautery
194744|NCT01971775|Gastric Cancer
194745|NCT01971762|multiresistant bacteremia
194746|NCT01971762|bacteremia management
194747|NCT01971762|blood culture
194748|NCT01971749|Coronary stent procedure (CSP
194749|NCT01971749|Coronary-artery bypass grafting (CABG)
194750|NCT01971736|1064nm YAG laser
194751|NCT01971736|laxity
194752|NCT01971736|rhytides
194753|NCT01971736|asian
194754|NCT01971723|Testosterone
194755|NCT01971723|Estrogen
194756|NCT01971723|Insulin
194757|NCT01971723|Blood Lipid
194758|NCT01971723|Glucose
194759|NCT01971723|Creatine Kinase
194760|NCT01971723|Strength
194761|NCT01971723|Power Athlete
194762|NCT01971710|HIV
194763|NCT01971710|AIDS
194764|NCT01971710|PMTCT
194765|NCT01971684|ITP
194766|NCT01971684|idiopathic thrombocytopenic purpura
194767|NCT01971684|bleeding score
194768|NCT01971684|platelet count
194769|NCT01971684|health-related quality of life
194770|NCT01971684|HRQL
194771|NCT01971684|Purpura
194772|NCT01971684|Purpura, Thrombocytopenic
194773|NCT01971684|Purpura, Thrombocytopenic, Idiopathic
194774|NCT01971684|Blood Coagulation Disorders
194775|NCT01971684|Hematologic Diseases
194776|NCT01971684|Hemorrhage
194777|NCT01971684|Skin Manifestations
194778|NCT01971684|Thrombocytopenia
194779|NCT01971684|Blood Platelet Disorders
194780|NCT01971684|Immune System Diseases
194781|NCT01971684|Hemorrhagic Disorders
194782|NCT01971684|Autoimmune Diseases
194783|NCT01971684|Therapeutic Uses
194784|NCT01971658|Multiple myeloma
194785|NCT01971658|Newly Diagnosed
194786|NCT01971645|Dexamethasone
194787|NCT01971645|Ropivacaine
194788|NCT01971645|Knee arthroscopy
194789|NCT01971645|Femoral nerve blocks
194790|NCT01971645|Peripheral nerve blocks
194791|NCT01971645|Adjuvant
194792|NCT01971645|Pediatrics
194793|NCT01971606|Statin, coronary artery bypass grafting, off-pump surgery, acute coronary syndrome
194794|NCT01971567|Insomnia
194795|NCT01971567|Electroencephalic
194796|NCT01971567|Biofeedback
194797|NCT01971567|Neural oscillations
194798|NCT01971567|Auto calibration
194799|NCT01971567|Relaxation
194800|NCT01971541|mindfulness
194801|NCT01971541|behavior therapies, cognitive
194802|NCT01971541|posttraumatic stress disorder
194803|NCT01971541|group therapy
194804|NCT01971528|Muscle strength, fatigue, electromyography (EMG), central fatigue, strength straining
194805|NCT01971515|MSC2363318A
194806|NCT01971515|Maximum tolerated dose
194807|NCT01971515|Dose limiting toxicities
194808|NCT01971515|Recommended phase 2 dose
194809|NCT01971515|M2698
194810|NCT01971515|Metastatic Breast Cancer
194811|NCT01971515|HER2+ Metastatic Breast Cancer
194812|NCT01971515|ER+ and/or PgR+ and HER2-
194813|NCT01971515|Tamoxifen
194814|NCT01971450|Non-interventional
194815|NCT01971450|Ventavis
194816|NCT01971450|Iloprost
194817|NCT01971450|Pulmonary hypertension
194818|NCT01971450|Compliance
194819|NCT01971450|Russian Federation
194820|NCT01971437|Overactive Bladder
194821|NCT01971437|OAB
194822|NCT01971437|Cystoscopy
194823|NCT01971437|Cystodistension
194824|NCT01971437|UTI
194825|NCT01971437|Cytokines
194826|NCT01971424|magnesium
194827|NCT01971424|SPPB
194828|NCT01971424|strength
194829|NCT01971424|physical performance
194830|NCT01971424|24 hour magnesuria
194831|NCT01971411|Hyperparathyroidism
194832|NCT01971411|Hypoparathyroidism
194833|NCT01971411|Calcium
194834|NCT01971411|Vitamin D
194835|NCT01971411|Bone mineral density
194836|NCT01971411|African American
194837|NCT01971411|Female
194838|NCT01971411|Elderly
194839|NCT01971398|Fetal Alcohol Spectrum Disorders (FASD)
194840|NCT01971398|Prevention
194841|NCT01971398|Alcohol-Exposed Pregnancy
194842|NCT01971398|Knowledge
194843|NCT01971398|Attitudes
194844|NCT01971359|Stroke, Intracerebral Hemorrhage, ICH
194845|NCT01971346|Psoriasis
194846|NCT01971346|ENBREL
194847|NCT01971346|etanercept
194848|NCT01971346|anti-TNF
194849|NCT01971333|pulse pressure variation
194850|NCT01971333|stroke volume variation
194851|NCT01971333|plethysmographic variation index
194852|NCT01971333|fluid responsiveness
194853|NCT01971294|Urinary symptoms
194854|NCT01971294|Systemic sclerosis
194855|NCT01971294|Severity index
194856|NCT01971294|Urinary tract infection
194857|NCT01971294|mortality
194858|NCT01971294|Quality of life
194859|NCT01971281|Pancreatic adenocarcinoma
194860|NCT01971281|Pancreas tumor
194861|NCT01971281|Treatment
194862|NCT01971281|Minimal toxicity
194863|NCT01971281|TTFields
194864|NCT01971281|Tumor Treating Fields
194865|NCT01971281|Novocure
194866|NCT01971268|T3 dental implants
194867|NCT01971268|Marginal bone loss
194868|NCT01971268|Survival rate
194869|NCT01971255|Influenza A
194870|NCT01971255|HAI
194871|NCT01971255|H1N1
194872|NCT01971255|Challenge Study
194873|NCT01971255|Correlates of Protection
194874|NCT01971242|Parkinson's
194875|NCT01971242|Parkinson's Disease
194876|NCT01971242|Exenatide
194877|NCT01971242|Bydureon
194878|NCT01971216|Breastfeeding, relaxation, anxiety, infant growth
194879|NCT01971203|seroquel XR
194880|NCT01971203|quetiapine XR
194881|NCT01971203|major depression
194882|NCT01971203|generalized anxiety disorder
194883|NCT01971203|CBT
194884|NCT01971203|co-morbid MDD
194885|NCT01971164|anemia
194886|NCT01971164|chronic kidney disease
194887|NCT01971164|hemodialysis
194888|NCT01971151|Chronic
194889|NCT01971151|Back pain
194890|NCT01971151|Low back
194891|NCT01971125|Diabetes Mellitus, Type 2
194892|NCT01971125|Heart Diseases
194893|NCT01971125|Left Ventricular Dysfunction
194894|NCT01971112|Multi-vitamins
194895|NCT01971112|Minerals
194896|NCT01971112|Respiratory infections
194897|NCT01971112|DTH
194898|NCT01971112|CRP
194899|NCT01971112|Cathelicidin
194900|NCT01971099|sexual function
194901|NCT01971099|hypoactive
194902|NCT01971099|desire
194903|NCT01971099|androgens
194904|NCT01971073|schizophrenic patients
194905|NCT01971073|tDCS
194906|NCT01971073|Executive functions
194907|NCT01971073|Dorsolateral prefrontal cortex
194908|NCT01971060|uterine fibroids
194909|NCT01971060|barbed suture
194910|NCT01971060|infertility
194911|NCT01971060|adhesions
194912|NCT01971047|Diabetes
194913|NCT01971047|Surgery
194914|NCT01971047|anesthesiology
194915|NCT01971047|endocrinology
194916|NCT01970995|Candidate modified risk tobacco product
194917|NCT01970995|Conventional cigarettes
194918|NCT01970995|Reduced exposure
194919|NCT01970995|HPHCs
194920|NCT01970995|Ambulatory
194921|NCT01970982|Candidate modified risk tobacco product
194922|NCT01970982|Conventional cigarette
194923|NCT01970982|Reduced exposure
194924|NCT01970982|HPHCs
194925|NCT01970982|Confinement
194926|NCT01970969|Atrial Fibrillation
194927|NCT01970969|Cardiac monitoring
194928|NCT01970969|Genomics
194929|NCT01970943|migraine, headache, episodic, chronic, pain
194930|NCT01970930|Tissue banking
194931|NCT01970917|tear film thickness
194932|NCT01970917|optical coherence tomography
194933|NCT01970917|topical lubricants
194934|NCT01970917|tear film thickness in healthy subjects
194935|NCT01970904|Chronic hepatitis C
194936|NCT01970904|DEB025
194937|NCT01970904|Alisporivir
194938|NCT01970904|ribavirin therapy
194939|NCT01970904|genotype 2/3 treatment naive patients
194940|NCT01970891|Freezing of Gait
194941|NCT01970891|Gait
194942|NCT01970891|Comfort
194943|NCT01970891|Pain tolerance
194944|NCT01970891|Pain
194945|NCT01970891|Sensory threshold
194946|NCT01970891|Motor threshold
194947|NCT01970891|Pain threshold
194948|NCT01970865|Phase 1
194949|NCT01970865|Phase 2
194950|NCT01970865|safety
194951|NCT01970865|pharmacokinetic
194952|NCT01970865|pharmacodynamic
194953|NCT01970865|efficacy
194954|NCT01970852|Inpatient
194955|NCT01970852|PHR Portal
194956|NCT01970852|Information Technology
194957|NCT01970839|Tourniquet
194958|NCT01970839|Endoneural
194959|NCT01970839|Ischemia
194960|NCT01970826|aseptic sterilized field
194961|NCT01970826|clean sterilized field
194962|NCT01970826|dental implants
194963|NCT01970826|Surgery
194964|NCT01970813|Parkinson's disease
194965|NCT01970813|Idiopathic Parkinson's disease
194966|NCT01970813|acupuncture
194967|NCT01970813|bee venom acupuncture
194968|NCT01970800|IGF-1
194969|NCT01970800|Short Stature
194970|NCT01970800|GH
194971|NCT01970748|Variceal bleeding
194972|NCT01970748|Portal hypertension
194973|NCT01970748|Hepatocellular carcinoma
194974|NCT01970748|Endoscopic variceal ligation
194975|NCT01970748|Non-selective beta-blocker
194976|NCT01970709|Adverse Drug Reactions
194977|NCT01970709|Emergency Department Visits
194978|NCT01970709|Hospitalizations
194979|NCT01970709|Pharmacogenomic
194980|NCT01970696|ovarian
194981|NCT01970696|testicular
194982|NCT01970696|stromal
194983|NCT01970696|Sertoli
194984|NCT01970696|Leydig
194985|NCT01970696|gynandroblastoma
194986|NCT01970696|juvenile granulosa cell tumor
194987|NCT01970696|DICER1
194988|NCT01970657|Venous Stasis Ulcer
194989|NCT01970657|VLU
194990|NCT01970644|Neoplasm metastasis
194991|NCT01970644|Brain neoplasms
194992|NCT01970644|Radiosurgery
194993|NCT01970644|Cognition disorders
194994|NCT01970644|Cranial irradiation
194995|NCT01970631|Osteoarthritis
194996|NCT01970631|Total Knee Replacement
194997|NCT01970631|total Knee Arthroplasty
194998|NCT01970631|Post-operative recovery TKR
194999|NCT01970631|Physical Activity
195000|NCT01970631|Motivational Interviewing
195001|NCT01970631|Financial Incentives
195002|NCT01970592|exercise
195003|NCT01970592|rehabilitation
195004|NCT01970592|walking
195005|NCT01970566|Intense Exercise/Moderate Calorie Restriction
195006|NCT01970566|Topiramate-Phentermine
195007|NCT01970553|lurbinectedin
195008|NCT01970553|PM01183
195009|NCT01970553|tumors
195010|NCT01970553|cancer
195011|NCT01970553|Pharma Mar
195012|NCT01970540|lurbinectedin
195013|NCT01970540|PM01183
195014|NCT01970540|tumors
195015|NCT01970540|cancer
195016|NCT01970540|Pharma Mar
195017|NCT01970501|atrial fibrillation
195018|NCT01970501|atrial flutter
195019|NCT01970501|heart failure
195020|NCT01970501|reduced left ventricle ejection fraction
195021|NCT01970501|electrical cardioversion
195022|NCT01970501|GENETIC-AF
195023|NCT01970501|Medtronic
195024|NCT01970501|bucindolol
195025|NCT01970501|pharmacogenetic
195026|NCT01970501|ARCA
195027|NCT01970501|Toprol
195028|NCT01970501|Toprol-XL
195029|NCT01970501|Metoprolol
195030|NCT01970501|Metoprolol succinate
195031|NCT01970488|Plaque Psoriasis
195032|NCT01970475|Arthritis
195033|NCT01970475|Rheumatoid
195034|NCT01970436|Prenatal care
195035|NCT01970436|Pregnancy
195036|NCT01970436|Obstetrics
195037|NCT01970436|Telemedicine
195038|NCT01970423|Patients with pacemaker or ICD therapy
195039|NCT01970410|teriflunomide
195040|NCT01970410|natalizumab
195041|NCT01970410|relapsing multiple sclerosis
195042|NCT01970384|transcranial direct current stimulation
195043|NCT01970384|stroke-related dysphagia
195044|NCT01970384|cortical plasticity
195045|NCT01970371|Gram-negative
195046|NCT01970371|bacterial infection
195047|NCT01970371|antibacterial
195048|NCT01970371|antimicrobial
195049|NCT01970371|CRE
195050|NCT01970371|CPE
195051|NCT01970371|BSI
195052|NCT01970371|pneumonia
195053|NCT01970371|HABP
195054|NCT01970371|VABP
195055|NCT01970371|AP
195056|NCT01970371|cUTI
195057|NCT01970371|UTI
195058|NCT01970358|melanoma
195059|NCT01970358|melanoma vaccine
195060|NCT01970358|adjuvant therapy
195061|NCT01970345|Autism Spectrum Disorder
195062|NCT01970345|IGF-1
195063|NCT01970332|Peripheral Arterial Disease
195064|NCT01970332|Peripheral Vascular Disease
195065|NCT01970332|Claudication
195066|NCT01970332|Myopathy
195067|NCT01970332|Oxidative stress
195068|NCT01970332|Mitochondrial dysfunction
195069|NCT01970332|Biomechanics
195070|NCT01970332|Inflammation
195071|NCT01970306|Esophageal Reinforcement
195072|NCT01970306|ACell MatriStem
195073|NCT01970306|13-178
195074|NCT01970293|Alcohol use
195075|NCT01970293|STI
195076|NCT01970293|Incarcerated women
195077|NCT01970293|AA
195078|NCT01970254|hepatitis B virus infection
195079|NCT01970254|HBV
195080|NCT01970254|Cancer Patients
195081|NCT01970254|chemotherapy
195082|NCT01970254|HBV screening strategy
195083|NCT01970254|HBV care
195084|NCT01970254|chronic HBV
195085|NCT01970254|concomitant HBV infection
195086|NCT01970254|viral infections
195087|NCT01970241|corticosteroid
195088|NCT01970241|diabetes
195089|NCT01970241|insulin
195090|NCT01970202|obesity
195091|NCT01970202|overweight
195092|NCT01970202|sleeve gastrectomy
195093|NCT01970189|Immune Thrombocytopenia
195094|NCT01970189|Primary Immune Thrombocytopenia
195095|NCT01970189|Purpura, Thrombocytopenic, Idiopathic
195096|NCT01970189|Autoimmune Thrombocytopenia
195097|NCT01970189|Thrombocytopenia
195098|NCT01970163|Diabetic foot ulcer
195099|NCT01970163|Venous stasis ulcer
195100|NCT01970163|Wound of the lower extremity
195101|NCT01970163|Skin substitute
195102|NCT01970163|Acellular Dermal Matrix
195103|NCT01970150|rTMS
195104|NCT01970150|Alzheimer Disease
195105|NCT01970150|Memory
195106|NCT01970150|attention
195107|NCT01970150|EEG
195108|NCT01969734|Emphysema
195109|NCT01969734|Moderate COPD
195110|NCT01969734|Hyperinflation
195111|NCT01969734|Endobronchial valves
195112|NCT01969695|non-Hodgkin's lymphoma
195113|NCT01969695|ABT-199
195114|NCT01969695|Safety
195115|NCT01969695|Refractory
195116|NCT01969695|GDC-0199
195117|NCT01969695|Relapsed
195118|NCT01969695|Cancer
195119|NCT01969682|non-Hodgkin's lymphoma
195120|NCT01969682|GDC-0199
195121|NCT01969682|Safety
195122|NCT01969682|Relapsed
195123|NCT01969682|Refractory
195124|NCT01969682|ABT-199
195125|NCT01969682|Pharmacokinetics
195126|NCT01969682|Cancer
195127|NCT01970137|Spinocerebellar degeneration (SCD)
195128|NCT01970137|Thyrotropin-Releasing Hormone (TRH)
195129|NCT01970137|Spinocerebellar Ataxia (SCA)
195130|NCT01970124|Spinocerebellar degeneration (SCD)
195131|NCT01970124|Thyrotropin-Releasing Hormone (TRH)
195132|NCT01970124|Spinocerebellar Ataxia (SCA)
195133|NCT01970111|Spinocerebellar degeneration (SCD)
195134|NCT01970111|Thyrotropin-Releasing Hormone (TRH)
195135|NCT01970111|Spinocerebellar Ataxia (SCA)
195136|NCT01970111|Cortical Cerebellar Atrophy (CCA)
195137|NCT01970098|Spinocerebellar degeneration (SCD)
195138|NCT01970098|Thyrotropin-Releasing Hormone (TRH)
195139|NCT01970098|Spinocerebellar Ataxia (SCA)
195140|NCT01970098|Cortical Cerebellar Atrophy (CCA)
195141|NCT01970072|Remimazolam Tosylate
195142|NCT01970072|Phase Ⅰ study
195143|NCT01970072|Health
195144|NCT01970059|Hypertension
195145|NCT01970046|SP2086
195146|NCT01970046|Phase III
195147|NCT01970046|combination therapy
195148|NCT01970033|SP2086
195149|NCT01970033|Phase III
195150|NCT01970033|Monotherapy
195151|NCT01970020|Healthy
195152|NCT01970020|JNJ-38518168
195153|NCT01970020|14C-JNJ-38518168
195154|NCT01970020|Absorption
195155|NCT01970020|Metabolism
195156|NCT01970020|Excretion
195157|NCT01970007|venous
195158|NCT01970007|outflow obstruction
195159|NCT01970007|iliofemoral vein
195160|NCT01969994|Epicatechin
195161|NCT01969994|Flavanols
195162|NCT01969994|Procyanidins
195163|NCT01969994|Polyphenols
195164|NCT01969994|Phytonutrients
195165|NCT01969994|AMDE
195166|NCT01969994|Antioxidants
195167|NCT01969981|Peripheral Inserted Central Catheter
195168|NCT01969955|nanoparticle albumin-bound paclitaxel
195169|NCT01969955|Squamous Cell Carcinoma of Lung
195170|NCT01969942|Ewings sarcoma
195171|NCT01969916|Cardiac CT imaging
195172|NCT01969916|Myocardial ischemia
195173|NCT01969916|Myocardial perfusion
195174|NCT01969916|Vasodilator stress testing
195175|NCT01969916|Regadenoson
195176|NCT01969903|brachial plexus block
195177|NCT01969903|lidocaine
195178|NCT01969903|dexmedetomidine
195179|NCT01969903|bradycardia
195180|NCT01969903|hypotension
195181|NCT01969877|Head and neck cancer
195182|NCT01969877|Cetuximab
195183|NCT01969877|Cisplatin
195184|NCT01969877|Radiotherapy
195185|NCT01969877|Quality of life
195186|NCT01969877|Human papilloma virus
195187|NCT01969877|Health economy
195188|NCT01969877|Biomarker investigations
195189|NCT01969864|Randomized Controlled Trial
195190|NCT01969864|Healthcare Disparities
195191|NCT01969851|Lacosamide
195192|NCT01969851|Vimpat
195193|NCT01969851|Epilepsy
195194|NCT01969851|Children
195195|NCT01969825|Infertility
195196|NCT01969825|Intrauterine insemination
195197|NCT01969825|Male factor infertility
195198|NCT01969825|Massage
195199|NCT01969825|Total motile sperm count
195200|NCT01969812|Infertility
195201|NCT01969812|Intrauterine Insemination
195202|NCT01969812|Slow-release Insemination
195203|NCT01969812|Evie
195204|NCT01969799|Gram-negative pneumonia
195205|NCT01969799|Aerosol antibiotics
195206|NCT01969799|Mechanical ventilation
195207|NCT01969799|Amikacin
195208|NCT01969799|Fosfomycin
195209|NCT01969799|Pneumonia, Bacterial
195210|NCT01969799|Pneumonia
195211|NCT01969799|Bacterial Infections
195212|NCT01969799|Lung Diseases
195213|NCT01969799|Respiratory Tract Diseases
195214|NCT01969799|Respiratory Tract Infections
195215|NCT01969799|Anti-Bacterial Agents
195216|NCT01969799|Anti-Infective Agents
195217|NCT01969799|Therapeutic Uses
195218|NCT01969799|Pharmacologic Actions
195219|NCT01969773|Botulinum Toxin A (BoNT-A)
195220|NCT01969773|Interstitial Cystitis
195221|NCT01969669|non-Hodgkin's lymphoma
195222|NCT01969669|GDC-0199
195223|NCT01969669|Safety
195224|NCT01969669|Relapsed
195225|NCT01969669|Refractory
195226|NCT01969669|ABT-199
195227|NCT01969669|Pharmacokinetics
195228|NCT01969669|Cancer
195229|NCT01969643|Breast cancer
195230|NCT01969643|Monomethyl auristatin E
195231|NCT01969643|Antibody-drug conjugate
195232|NCT01969643|Drug therapy
195233|NCT01969643|Metastatic
195234|NCT01969643|LIV-1 protein, human
195235|NCT01969643|Trastuzumab
195236|NCT01969630|femoropopliteal lesions
195237|NCT01969604|Rheumatoid Arthritis
195238|NCT01969604|Sedentary Behaviour
195239|NCT01969604|Motivational Counselling
195240|NCT01969604|Short Text Message Service
195241|NCT01969604|Fatigue
195242|NCT01969604|Pain
195243|NCT01969604|Self-efficacy
195244|NCT01969604|ActivPAL
195245|NCT01969591|Fast track surgery, Laparoscopic surgery, colorectal cancer
195246|NCT01969578|salivary duct cancer
195247|NCT01969578|adenocarcinoma, NOS
195248|NCT01969578|androgen deprivation
195249|NCT01969578|androgen receptor
195250|NCT01969552|TSH, thyroid hormones, thyroid tresting, levothyroxine
195251|NCT01969526|Frail elderly
195252|NCT01969513|Vestibular Diseases
195253|NCT01969513|Vertigo
195254|NCT01969513|Primary care
195255|NCT01969513|Epley maneuver
195256|NCT01969500|Schizophrenia
195257|NCT01969500|Schizoaffective Disorder
195258|NCT01969500|Self Management of Schizophrenia
195259|NCT01969500|SOS
195260|NCT01969500|SMI
195261|NCT01969500|Psychosis
195262|NCT01969500|Social Dysfunction
195263|NCT01969500|Medication Adherence
195264|NCT01969500|Mobile Application
195265|NCT01969500|EHealth
195266|NCT01969500|E-Health
195267|NCT01969500|Health Technology
195268|NCT01969500|mHealth
195269|NCT01969500|m-Health
195270|NCT01969474|Tinnitus Cannabis
195271|NCT01969461|HIV positive
195272|NCT01969461|Adolescents
195273|NCT01969461|Adolescent Trials Network
195274|NCT01969461|Comparative Effectiveness Trial
195275|NCT01969461|Implementation
195276|NCT01969461|Adherence Intervention
195277|NCT01969461|Alcohol Intervention
195278|NCT01969448|Nipple-areola skin sparing mastectomy
195279|NCT01969448|Immediate reconstruction
195280|NCT01969448|Prophylactic Mastectomy
195281|NCT01969448|Breast-Q
195282|NCT01969448|Breast Cancer
195283|NCT01969448|Ductal Carcinoma in Situ - Category
195284|NCT01969409|Lung
195285|NCT01969409|Fibrosis
195286|NCT01969396|Biopsy
195287|NCT01969396|Endometrial biopsy
195288|NCT01969396|Endometrial sampling
195289|NCT01969396|sonohysterography
195290|NCT01969383|healthy
195291|NCT01969370|Cancer
195292|NCT01969370|Cardiovascular disease
195293|NCT01969370|Neurodegenerative disease
195294|NCT01969370|Neurodevelopmental disease
195295|NCT01969370|Dysmorphology
195296|NCT01969370|Hearing loss
195297|NCT01969370|Other conditions, including ophthalmic conditions
195298|NCT01969357|Sp2086
195299|NCT01969357|Phase II
195300|NCT01969357|monotherapy
195301|NCT01969331|Gastritis
195302|NCT01969331|Helicobacter pylori
195303|NCT01969318|SP2086
195304|NCT01969318|Phase II
195305|NCT01969318|combination therapy
195306|NCT01969305|Kazakhstan
195307|NCT01969305|Central Asia
195308|NCT01969305|HIV prevention
195309|NCT01969305|Adolescents
195310|NCT01969305|Sexual risk behaviors
195311|NCT01969305|Drug abuse prevention
195312|NCT01969305|Multi-media intervention
195313|NCT01969305|Drug use
195314|NCT01969292|colonoscopy
195315|NCT01969292|quality assurance
195316|NCT01969279|Osteoporosis
195317|NCT01969279|Bisphosphonate
195318|NCT01969279|Atypical femoral fracture
195319|NCT01969279|Side effect
195320|NCT01969266|Healthy volunteer
195321|NCT01969266|PCI-32765
195322|NCT01969266|PCI 45227
195323|NCT01969266|JNJ-54179060
195324|NCT01969266|Pharmacokinetic
195325|NCT01969253|Breast Cancer, Axillary Lymph Node Dissection, Lymphedema
195326|NCT01969240|Chest Pain
195327|NCT01969240|Decision Aid
195328|NCT01969240|Acute Coronary Syndrome
195329|NCT01969240|Cardiac
195330|NCT01969240|Emergency Department
195331|NCT01969240|Cardiac Testing
195332|NCT01969240|Healthcare Utilization
195333|NCT01969240|Patient Centered Outcomes
195334|NCT01969240|Shared Decision Making
195335|NCT01969240|Unnecessary hospital admissions
195336|NCT01969201|In vitro fertilization (IVF)
195337|NCT01969201|Assisted reproduction technologies (ART)
195338|NCT01969201|GnRH-antagonist
195339|NCT01969201|Follicle stimulating hormone (FSH)
195340|NCT01969188|spondyloarthritis
195341|NCT01969188|ankylosing spondylitis
195342|NCT01969188|psoriatic arthritis
195343|NCT01969149|Stress Hyperglycemia
195344|NCT01969149|Perioperative glycemic control
195345|NCT01969149|Cardiac surgery
195346|NCT01969149|Coronary artery bypass surgery
195347|NCT01969136|Alzheimer's disease
195348|NCT01969136|Cognition
195349|NCT01969136|Alpha-7 nAChR
195350|NCT01969123|Alzheimer's disease
195351|NCT01969123|Cognition
195352|NCT01969123|Alpha-7 nAChR
195353|NCT01969110|Immunonutrition
195354|NCT01969097|Stroke
195355|NCT01969097|Hemiparesis
195356|NCT01969097|tDCS
195357|NCT01969097|Motor cortex
195358|NCT01969084|Type II Diabetes Mellitus
195359|NCT01969084|Diabetes
195360|NCT01969084|Metabolism
195361|NCT01969084|Linagliptin
195362|NCT01969084|Tradjenta
195363|NCT01969084|Glucose
195364|NCT01969071|levosimendan
195365|NCT01969071|mitral valve surgery
195366|NCT01969071|cardiopulmonary bypass
195367|NCT01969071|serum creatinine
195368|NCT01969071|estimated glomerular filtration rate
195369|NCT01969071|ejection fraction
195370|NCT01969045|felxible bronchoscopy
195371|NCT01969045|anaesthetics
195372|NCT01969045|transcutaneous pCO2
195373|NCT01969045|capillary pCO2
195374|NCT01969006|inguinal hernia, postoperative pain, localanesthesia, nerve blockage
195375|NCT01968993|Degenerative Disc Disease
195376|NCT01968980|High Risk of cardiovascular events
195377|NCT01968980|Heterozygous familial hypercholesterolemia
195378|NCT01968967|mixed dyslipidemia
195379|NCT01968967|high risk of cardiovascular events
195380|NCT01968967|multiple cardiovascular disease risk factors
195381|NCT01968954|mixed dyslipidemia
195382|NCT01968954|high risk of cardiovascular events
195383|NCT01968941|stereotactic body radiotherapy
195384|NCT01968941|conventional radiotherapy
195385|NCT01968941|inoperable patients
195386|NCT01968941|local control
195387|NCT01968941|cancer recurrence
195388|NCT01968941|toxicity
195389|NCT01968941|survival
195390|NCT01968928|Bladder urothelial carcinoma (UC)
195391|NCT01968928|pyruvate kinase
195392|NCT01968928|drug resistance
195393|NCT01968928|shikonin
195394|NCT01968915|LCL161, Paclitaxel, Japanese patient, Neoplasms
195395|NCT01968902|spasticity
195396|NCT01968902|lower limb
195397|NCT01968902|multiple sclerosis
195398|NCT01968902|toxin
195399|NCT01968889|Critical illness neuromyopathy
195400|NCT01968889|Diaphragm dysfunction
195401|NCT01968889|Mechanical ventilation
195402|NCT01968889|Weaning
195403|NCT01968889|Ultrasound
195404|NCT01968850|osteoporosis
195405|NCT01968850|HIV
195406|NCT01968850|bone Mineral Density
195407|NCT01968850|alendronate
195408|NCT01968850|vitamin D
195409|NCT01968824|pain
195410|NCT01968798|ACES
195411|NCT01968798|ASPREE Cancer Endpoints Study
195412|NCT01968798|Cancer
195413|NCT01968798|Aspirin
195414|NCT01968798|Tumor
195415|NCT01968772|Fibromyalgia
195416|NCT01968772|Fibromyalgia Syndrome
195417|NCT01968772|Magnesium Chloride
195418|NCT01968772|Transdermal Magnesium Chloride
195419|NCT01968759|Chronic kidney disease
195420|NCT01968759|Sevelamer carbonate
195421|NCT01968759|Proteinuria
195422|NCT01968759|Phosphate binders
195423|NCT01968746|Sepsis
195424|NCT01968746|Shock
195425|NCT01968733|Pneumonia
195426|NCT01968733|CABP
195427|NCT01968733|CAP
195428|NCT01968733|Macrolide
195429|NCT01968707|surgical prep
195430|NCT01968707|CHG
195431|NCT01968707|IPA
195432|NCT01968694|endometriosis
195433|NCT01968694|chronic pain
195434|NCT01968694|intravenous lidocaine
195435|NCT01968668|BAY94-8862
195436|NCT01968668|MR antagonist
195437|NCT01968668|Diabetic nephropathy
195438|NCT01968668|Japanese patients
195439|NCT01968655|Factor VIII Inhibitory Auto-antibodies
195440|NCT01968642|Transthoracic echocardiograms
195441|NCT01968642|Appropriate Use Criteria
195442|NCT01968642|Medical Education
195443|NCT01968629|Hepatocellular Carcinoma
195444|NCT01968590|Vitamin D
195445|NCT01968590|Cholecalciferol
195446|NCT01968590|Bone density
195447|NCT01968577|Coronary angioplasty
195448|NCT01968577|Myocardial infarction
195449|NCT01968551|HIV-1
195450|NCT01968551|HIV
195451|NCT01968551|Treatment-Experienced
195452|NCT01968525|anemia
195453|NCT01968525|non-hypoxic apnoea
195454|NCT01968525|tracheal intubation
195455|NCT01968525|anesthesia
195456|NCT01968512|Attention Deficit Hyperactivity Disorder (ADHD);
195457|NCT01968512|Transcranial Direct Current Stimulation (tDCS);
195458|NCT01968512|Control Inhibitory;
195459|NCT01968512|Quantitative electroencephalography;
195460|NCT01968512|Functional Brain Network;
195461|NCT01968512|Go/No Go test.
195462|NCT01968499|coronary stent implantation; clopidogrel low response
195463|NCT01968473|Parkinson's disease
195464|NCT01968473|Freezing of Gait
195465|NCT01968473|Neuromuscular Electrical Stimulation
195466|NCT01968473|Comfort
195467|NCT01968473|Pain tolerance
195468|NCT01968473|Pain
195469|NCT01968473|Sensory threshold
195470|NCT01968473|Motor threshold
195471|NCT01968473|Pain threshold
195472|NCT01968460|Parkinson's Disease, Rasagiline, Pramipexole
195473|NCT01968434|cough
195474|NCT01968434|common cold
195475|NCT01968434|antitussive agents
195476|NCT01968434|mucosal protection
195477|NCT01968434|medical device
195478|NCT01968421|OM-85, bronchiectasis, placebo, acute exacerbation
195479|NCT01968408|nosocomial diarrhea
195480|NCT01968408|Lactobacillus reuteri DSM 17938
195481|NCT01968408|rotavirus diarrhea
195482|NCT01968408|probiotics
195483|NCT01968382|IMM 124-E
195484|NCT01968382|Bovine Colostrum
195485|NCT01968382|Alcoholic
195486|NCT01968382|Hepatitis
195487|NCT01968382|LPS
195488|NCT01968382|Hyper-immune
195489|NCT01968369|flow mediated vasodilatation
195490|NCT01968369|tomato
195491|NCT01968369|arterial stiffness
195492|NCT01968369|lycopene
195493|NCT01968356|surgical skin prep
195494|NCT01968356|CHG
195495|NCT01968356|IPA
195496|NCT01968317|Endometrial Atypical Hyperplasia
195497|NCT01968317|Endometrial Adenocarcinoma
195498|NCT01968317|Conservative Medication
195499|NCT01968304|Iron Status, Cancer
195500|NCT01968291|Health Literacy
195501|NCT01968291|Teach-back
195502|NCT01968291|Emergency
195503|NCT01968265|Type 2 Diabetes Mellitus
195504|NCT01968265|T2DM
195505|NCT01968252|Speckle-tracking echocardiography
195506|NCT01968252|Transthoracic echocardiography
195507|NCT01968252|Transesophageal echocardiography
195508|NCT01968239|BRVO
195509|NCT01968239|Macular edema
195510|NCT01968239|Ranibizumab
195511|NCT01968239|re-treatment
195512|NCT01968226|carotid artery disease
195513|NCT01968226|carotid stenosis
195514|NCT01968226|carotid endarterectomy
195515|NCT01968226|RDG-K5
195516|NCT01968226|PET imaging
195517|NCT01968213|ARIEL3
195518|NCT01968213|ARIEL 3
195519|NCT01968213|platinum sensitive
195520|NCT01968213|PARP Inhibitor
195521|NCT01968213|rucaparib
195522|NCT01968213|homologous recombination
195523|NCT01968213|homologous recombination deficiency
195524|NCT01968213|CO-338
195525|NCT01968213|PF 01367338
195526|NCT01968213|AG 14699
195527|NCT01968213|platinum sensitive ovarian cancer
195528|NCT01968213|platinum sensitive fallopian tube cancer
195529|NCT01968213|platinum sensitive primary peritoneal cancer
195530|NCT01968213|platinum sensitive peritoneal cancer
195531|NCT01968213|gynecological cancer
195532|NCT01968213|Clovis
195533|NCT01968213|Clovis Oncology
195534|NCT01968200|cancer
195535|NCT01968200|chemotherapy
195536|NCT01968200|anthracyclines
195537|NCT01968174|astigmatism
195538|NCT01968174|lid surgery
195539|NCT01968174|older than 40 years
195540|NCT01968174|can sign an acceptance form
195541|NCT01968174|uper lid surgery
195542|NCT01968148|glucose
195543|NCT01968148|cardiac arrest
195544|NCT01968148|resuscitation
195545|NCT01968148|insulin
195546|NCT01968148|GLP-1
195547|NCT01968122|symptomatic Intracranial artery stenosis
195548|NCT01968122|conventional treatment
195549|NCT01968122|stenting
195550|NCT01968122|stroke prevention
195551|NCT01968122|medical treatment
195552|NCT01968122|endovascular treatment
195553|NCT01968096|Reflex
195554|NCT01968096|Post activation
195555|NCT01968096|Spinal cord injury
195556|NCT01968096|Pre-synaptic inhibition
195557|NCT01968096|Machine driven passive strech
195558|NCT01968044|renal impairment
195559|NCT01968031|Parkinson's disease
195560|NCT01968031|Moderate to Severe Parkinson's Disease
195561|NCT01968018|Cancer
195562|NCT01968018|Chronic Cancer Pain
195563|NCT01968018|Tramadol HCI
195564|NCT01968018|Acetaminophen
195565|NCT01968018|Analgesics
195566|NCT01968018|Pain assessment
195567|NCT01967992|diabetes
195568|NCT01967992|obesity
195569|NCT01967992|mindful eating
195570|NCT01967992|positive affect
195571|NCT01967992|low carbohydrate
195572|NCT01967992|ketogenic
195573|NCT01967992|diet
195574|NCT01967940|HIV-1
195575|NCT01967940|HIV
195576|NCT01967940|Treatment-Experienced
195577|NCT01967927|carcinoma
195578|NCT01967927|cancer
195579|NCT01967927|head
195580|NCT01967927|neck
195581|NCT01967927|otolaryngology
195582|NCT01967901|Diabetic nephropathies
195583|NCT01967901|Nursing
195584|NCT01967901|Multidisciplinary
195585|NCT01967901|Self-care
195586|NCT01967901|Quality of Life
195587|NCT01967888|Pancreatic islet auto-transplantation
195588|NCT01967875|Gastric Cancer
195589|NCT01967875|ERCC1
195590|NCT01967875|Platinum
195591|NCT01967875|Chemotherapy
195592|NCT01967849|obesity
195593|NCT01967849|type 2 diabetes
195594|NCT01967836|Invasive Line
195595|NCT01967836|IV Dressing protection
195596|NCT01967836|Hygiene
195597|NCT01967836|Oncology
195598|NCT01967836|Ambulatory Care
195599|NCT01967823|Metastatic Cancer
195600|NCT01967823|Gene Therapy
195601|NCT01967823|Immunotherapy
195602|NCT01967823|Tumor Regression
195603|NCT01967810|glioma
195604|NCT01967810|glioblastoma
195605|NCT01967810|brain cancer
195606|NCT01967810|brain tumor
195607|NCT01967810|recurrent
195608|NCT01967797|Obesity
195609|NCT01967784|Influenza
195610|NCT01967784|Quadrivalent Inactivated Influenza Vaccine
195611|NCT01967771|healthy volunteers
195612|NCT01967771|drug interaction
195613|NCT01967771|carbamazepine
195614|NCT01967771|Dolutegravir
195615|NCT01967771|pharmacokinetics
195616|NCT01967758|Astrocytic Tumors
195617|NCT01967758|Glioblastoma Multiforme
195618|NCT01967758|Anaplastic Astrocytoma
195619|NCT01967758|Brain Tumor
195620|NCT01967758|Brain Cancer
195621|NCT01967758|Immunotherapy
195622|NCT01967745|open appendectomy
195623|NCT01967745|laparoscopic appendectomy
195624|NCT01967745|appendicitis
195625|NCT01967732|Smoking
195626|NCT01967732|Nicotine absorption
195627|NCT01967732|Modified risk tobacco product
195628|NCT01967732|Conventional cigarette
195629|NCT01967732|Nicotine replacement therapy
195630|NCT01967732|Nicotine nasal spray
195631|NCT01967719|Smoking
195632|NCT01967719|Nicotine absorption
195633|NCT01967719|Candidate modified risk tobacco product
195634|NCT01967719|Conventional cigarette
195635|NCT01967719|Nicotine replacement therapy: nasal spray
195636|NCT01967706|Smoking
195637|NCT01967706|Nicotine absorption
195638|NCT01967706|Modified risk tobacco product
195639|NCT01967706|Conventional cigarette
195640|NCT01967706|Nicotine replacement therapy
195641|NCT01967706|Nicotine gum
195642|NCT01967693|Laryngeal contact granuloma
195643|NCT01967693|Treatment type
195644|NCT01967693|Outcome
195645|NCT01967641|opioid dependence
195646|NCT01967641|opioid abuse
195647|NCT01967641|suboxone
195648|NCT01967641|prescription pain medications
195649|NCT01967628|Vitamin D
195650|NCT01967628|Respiratory infection
195651|NCT01967628|Innate immunity
195652|NCT01967615|PCI,
195653|NCT01967615|CTO,
195654|NCT01967615|bifurcation,
195655|NCT01967615|clopidogrel,
195656|NCT01967615|prasugrel,
195657|NCT01967615|ticagrelor
195658|NCT01967602|Acute respiratory distress syndrome (ARDS)
195785|NCT01967082|Smoking prevention
195659|NCT01967602|Extracorporeal membrane oxygenation (ECMO)
195660|NCT01967602|biomarker
195661|NCT01967576|Mutation in SDHB gene
195662|NCT01967576|Mutation in SDHV gene
195663|NCT01967576|Mutation in VHL gene
195664|NCT01967576|Pharmacogenomics analyses
195665|NCT01967576|Germline DNA examination
195666|NCT01967563|Energy Expenditure
195667|NCT01967563|Obesity
195668|NCT01967563|Carbohydrate
195669|NCT01967563|Fat
195670|NCT01967563|Ketones
195671|NCT01967550|Symptomatic knee OA Kellgren-Lawrence grade 1-3
195672|NCT01967537|NET
195673|NCT01967537|MEN1
195674|NCT01967537|Von Hippel Lindau (VHL)
195675|NCT01967537|Surgical Resection
195676|NCT01967537|Somatostatin Receptor Status
195677|NCT01967524|Myofascial pain
195678|NCT01967524|Perineal pain
195679|NCT01967524|Chronic pelvic pain
195680|NCT01967524|Botulinum toxin type A
195681|NCT01967524|Ropivacaïne
195682|NCT01967511|Cross-sectional study
195683|NCT01967511|Fibromuscular dysplasia
195684|NCT01967511|Fibroblast
195685|NCT01967511|FMD
195686|NCT01967498|chronic otitis media with effusion
195687|NCT01967498|conductive hearing loss
195688|NCT01967485|Attention Deficit Hyperactivity Disorder
195689|NCT01967485|Medication adherence
195690|NCT01967485|Disease management
195691|NCT01967485|Text message
195692|NCT01967485|ADHD
195693|NCT01967485|Children
195694|NCT01967485|Reminder systems
195695|NCT01967485|Text Messaging
195696|NCT01967485|Telemedicine
195697|NCT01967433|Fentanyl
195698|NCT01967433|Midazolam
195699|NCT01967433|Sedation
195700|NCT01967433|Patient tolerance
195701|NCT01967433|Duration of colonoscopy
195702|NCT01967420|Cognitive remediation
195703|NCT01967420|Social cognition training
195704|NCT01967420|First episode psychosis
195705|NCT01967420|Schizophrenia
195706|NCT01967407|kidney tumor
195707|NCT01967407|renal cell cancer
195708|NCT01967407|RCC
195709|NCT01967407|irreversible electroporation
195710|NCT01967407|IRE
195711|NCT01967407|partial kidney resection
195712|NCT01967407|percutaneous
195713|NCT01967407|ablation
195714|NCT01967407|IRENE
195715|NCT01967394|Health Care Quality
195716|NCT01967394|Access
195717|NCT01967394|Evaluation
195718|NCT01967368|Influenza vaccine
195719|NCT01967368|intradermal
195720|NCT01967368|intramuscular
195721|NCT01967368|efficacy
195722|NCT01967368|safety
195723|NCT01967355|preeclampsia
195724|NCT01967355|lipid apheresis
195725|NCT01967355|apheresis
195726|NCT01967342|chronic pain
195727|NCT01967342|pain
195728|NCT01967342|chronic pain syndrome
195729|NCT01967342|widespread chronic pain
195730|NCT01967342|back pain
195731|NCT01967342|literacy
195732|NCT01967342|health literacy
195733|NCT01967342|group therapy
195734|NCT01967342|psychosocial treatment
195735|NCT01967342|cognitive-behavioral therapy
195736|NCT01967342|pain education
195737|NCT01967342|health disparities
195738|NCT01967342|patient-centered outcomes
195739|NCT01967303|Restless legs syndrome
195740|NCT01967303|Stroke
195741|NCT01967303|Transient ischemic attack
195742|NCT01967303|Cerebrovascular risk factors
195743|NCT01967290|stroke
195744|NCT01967290|motor deficits
195745|NCT01967290|motor rehabilitation
195746|NCT01967290|neurorehabilitation
195747|NCT01967290|medical devices
195748|NCT01967290|wearable devices
195749|NCT01967290|e-health systems
195750|NCT01967264|Drug therapy
195751|NCT01967251|Prostatic Hyperplasia
195752|NCT01967251|Phosphodiesterase 5 inhibitors
195753|NCT01967251|Erectile DysfunctionDrug Therapy
195754|NCT01967238|immune response
195755|NCT01967225|Methicillin Resistant Staphylococcus Aureus,
195756|NCT01967225|Skin and soft tissue infection,
195757|NCT01967225|Bacteremia,
195758|NCT01967225|Tedizolid
195759|NCT01967212|stroke
195760|NCT01967212|swallowing training
195761|NCT01967212|game-based
195762|NCT01967212|biofeedback
195763|NCT01967199|drug-eluting stent
195764|NCT01967199|drug-coated Balloon
195765|NCT01967199|recurrent In-Stent restenosis
195766|NCT01967186|Type 1 diabetes
195767|NCT01967186|islets
195768|NCT01967186|transplantation
195769|NCT01967186|nephropathy
195770|NCT01967186|intramuscular
195771|NCT01967173|Asthma
195772|NCT01967173|Fluticasone
195773|NCT01967173|Salmeterol
195774|NCT01967147|Dry eye
195775|NCT01967147|Lipid deficiency
195776|NCT01967147|Tear film break-up time
195777|NCT01967134|HIV Negative
195778|NCT01967121|Compex, ice
195779|NCT01967095|Erlotinib
195780|NCT01967095|12-278
195781|NCT01967095|CNS involvement
195782|NCT01967082|Cancer Prevention
195783|NCT01967082|Tobacco Control Program for Youth
195784|NCT01967082|Smoking cessation
195786|NCT01967082|Smokers
195787|NCT01967082|Non smokers
195788|NCT01967082|Students
195789|NCT01967082|University of Houston
195790|NCT01967082|Survey
195791|NCT01967082|Questionnaire
195792|NCT01967082|Telephone survey
195793|NCT01967082|Smart phone application
195794|NCT01967056|Muscle strength
195795|NCT01967056|respiratory failure
195796|NCT01967056|extubation failure
195797|NCT01967056|intensive care unit
195798|NCT01967056|outcome prediction
195799|NCT01967030|gestational diabetes mellitus
195800|NCT01967030|breastfeeding
195801|NCT01967030|obesity
195802|NCT01967030|diabetes
195803|NCT01967030|lactation
195804|NCT01967017|Intrauterine device
195805|NCT01967017|Paracervical block
195806|NCT01966991|Down syndrome
195807|NCT01966991|prenatal screening
195808|NCT01966991|trisomy 21
195809|NCT01966991|patient satisfaction
195810|NCT01966978|Diabetes Mellitus, Type 2
195811|NCT01966978|Insulin
195812|NCT01966978|Insulin, Long-Acting
195813|NCT01966978|Insulin, Short Acting
195814|NCT01966978|Detemir
195815|NCT01966978|Liraglutide
195816|NCT01966978|GLP-1
195817|NCT01966978|Glucagon Like Peptide
195818|NCT01966978|Metformin
195819|NCT01966978|Uncontrolled Diabetes
195820|NCT01966978|Elevated A1c
195821|NCT01966978|Incretins
195822|NCT01966965|PIOLIN®, PEDICULOSIS, EFFICACY, SAFETY, PHYTOMEDICINE,
195823|NCT01966965|ARRUDA, RUTA
195824|NCT01966952|Hypertension
195825|NCT01966939|craniotomy
195826|NCT01966939|craniectomy
195827|NCT01966939|temporalis
195828|NCT01966939|TMJ
195829|NCT01966939|mastication
195830|NCT01966939|QoL
195831|NCT01966926|self monitoring
195832|NCT01966926|self weighing
195833|NCT01966926|weight tracking
195834|NCT01966926|psychosocial outcomes
195835|NCT01966926|feasibility
195836|NCT01966913|Germ Cell Tumors
195837|NCT01966913|Bevacizumab
195838|NCT01966913|salvage therapy
195839|NCT01966900|Human immunodeficiency disease
195840|NCT01966900|HIV
195841|NCT01966900|Vaccine
195842|NCT01966900|CN54gp140
195843|NCT01966900|Glucopyranosyl lipid adjuvant
195844|NCT01966900|GLA
195845|NCT01966900|GLA-AF
195846|NCT01966887|Heart failure
195847|NCT01966887|Gene therapy
195848|NCT01966887|Serca2a
195849|NCT01966887|Cardiomyopathy
195850|NCT01966874|Medical abortion
195851|NCT01966874|Mifepristone
195852|NCT01966874|Misoprostol
195853|NCT01966874|Zacafemyl
195854|NCT01966874|Mexico
195855|NCT01966861|mechanical ventilation
195856|NCT01966861|weaning
195857|NCT01966861|acute respiratory failure
195858|NCT01966861|weaning failure
195859|NCT01966861|lung ultrasound
195860|NCT01966848|Knee
195861|NCT01966848|osteoarthritis
195862|NCT01966848|arthroplasty
195863|NCT01966848|tka
195864|NCT01966848|rsa
195865|NCT01966835|sleep quality
195866|NCT01966835|sleep disturbances
195867|NCT01966835|high intensity aerobic interval training
195868|NCT01966835|rheumatoid arthritis
195869|NCT01966835|fatigue
195870|NCT01966835|pain
195871|NCT01966835|polysomnography
195872|NCT01966835|watt max
195873|NCT01966822|Osteoporosis
195874|NCT01966822|Bone mineral density
195875|NCT01966822|Dual-energy X-ray absorptiometry
195876|NCT01966822|HIV infection
195877|NCT01966822|Dolutegravir
195878|NCT01966822|Integrase inhibitor
195879|NCT01966809|Brain Tumor
195880|NCT01966809|Photodynamic Therapy
195881|NCT01966809|Photochemotherapy
195882|NCT01966809|Astrocytoma
195883|NCT01966809|Pilocytic Astrocytoma
195884|NCT01966809|Low grade Astrocytoma
195885|NCT01966809|Anaplastic Astrocytoma
195886|NCT01966809|Glioblastoma
195887|NCT01966809|GBM
195888|NCT01966809|Chordoma
195889|NCT01966809|Germinoma
195890|NCT01966809|Germ Cell Tumor
195891|NCT01966809|Non-germinoma
195892|NCT01966809|CNS Lymphoma
195893|NCT01966809|Craniopharyngioma
195894|NCT01966809|Mixed Glioma
195895|NCT01966809|Optic Nerve Glioma
195896|NCT01966809|Meningioma
195897|NCT01966809|Oligodendroglioma
195898|NCT01966809|Pituitary Tumors
195899|NCT01966809|Desmoplastic Neuroepithelial Tumor
195900|NCT01966809|DNET
195901|NCT01966809|glioblastoma multiforme
195902|NCT01966809|glioma
195903|NCT01966809|glioblastoma survivors
195904|NCT01966809|what is glioblastoma
195905|NCT01966809|gbm cancer
195906|NCT01966809|oligoastrocytoma
195907|NCT01966809|gbm tumor
195908|NCT01966809|anaplastic oligodendroglioma
195909|NCT01966809|High-Grade Glioma
195910|NCT01966809|high grade glioma
195911|NCT01966809|glioblastomas
195912|NCT01966809|glioblastoma cancer
195913|NCT01966809|anaplastic oligoastrocytoma
195914|NCT01966809|astrocytoma glioma
195915|NCT01966809|glioblastoma clinical trials
195916|NCT01966809|photodynamic therapy for cancer
195917|NCT01966809|glioblastoma multiforme clinical trials
195918|NCT01966809|astrocytoma glioblastoma
195919|NCT01966809|gbm grade 4
195920|NCT01966809|clinical trials for glioblastoma
195921|NCT01966809|photodynamic therapy cancer
195922|NCT01966809|clinical trials glioblastoma
195923|NCT01966809|glioblastoma clinical trials 2015
195924|NCT01966809|glioblastoma clinical trials 2014 not open in 2014
195925|NCT01966809|glioblastoma trials
195926|NCT01966809|gbm clinical trials
195927|NCT01966809|glioblastoma immunotherapy
195928|NCT01966809|malignant gliomas
195929|NCT01966809|anaplastic astrocytomas
195930|NCT01966809|immunotherapy for glioblastoma
195931|NCT01966809|immunotherapy glioblastoma
195932|NCT01966809|High Grade Glioblastoma Multiforme
195933|NCT01966809|clinical trial glioblastoma
195934|NCT01966809|glioblastoma clinical trial
195935|NCT01966809|glioblastoma trial
195936|NCT01966809|brain tumors
195937|NCT01966809|recurrent brain tumors
195938|NCT01966809|glioma grade 3
195939|NCT01966809|grade 3 brain tumor
195940|NCT01966809|grade 4 brain tumor
195941|NCT01966796|healthcare associated pneumonia
195942|NCT01966796|drug-resistant bacteria
195943|NCT01966796|pneumonia severity index
195944|NCT01966757|Neuronal Ceroid Lipofuscinosis
195945|NCT01966757|NCL
195946|NCT01966757|Batten's Disease
195947|NCT01966757|Children's Sleep Habits Questionnaire
195948|NCT01966757|Restless Leg Syndrome
195949|NCT01966731|Africa
195950|NCT01966718|Rheumatoid arthritis
195951|NCT01966718|Joint pain
195952|NCT01966718|Repository corticotropin injection
195953|NCT01966705|severe health anxiety
195954|NCT01966705|somatic symptom disorder
195955|NCT01966705|illness anxiety disorder
195956|NCT01966705|cognitive behavior therapy
195957|NCT01966705|bibliotherapy
195958|NCT01966705|internet
195959|NCT01966705|exposure
195960|NCT01966692|Bioequivalence
195961|NCT01966692|Fluticasone Propionate
195962|NCT01966666|Alzheimer's disease
195963|NCT01966666|mild to moderate
195964|NCT01966653|nitrofurantoin
195965|NCT01966653|fosfomycin
195966|NCT01966653|urinary tract infection
195967|NCT01966653|clinical efficacy
195968|NCT01966653|bacteriologic response
195969|NCT01966640|diagnosis of allergy
195970|NCT01966640|Basophil Activation Test
195971|NCT01966627|non alcoholic fatty liver
195972|NCT01966627|childhood obesity
195973|NCT01966627|genetic variants
195974|NCT01966614|Benign prostatic hyperplasia
195975|NCT01966614|BPH
195976|NCT01966614|Enlarged prostate
195977|NCT01966614|Lower urinary tract symptoms (LUTS)
195978|NCT01966588|Antipsychotic agents
195979|NCT01966588|Adverse effects
195980|NCT01966588|Genomics
195981|NCT01966588|Transcriptome
195982|NCT01966575|Polycystic ovary syndrome
195983|NCT01966575|Progestin
195984|NCT01966575|Endometrial shedding
195985|NCT01966575|Ovulation induction cycles
195986|NCT01966575|Clomiphene citrate
195987|NCT01966575|Clinical pregnancy rate
195988|NCT01966549|Pulmonary Disease, Chronic Obstructive
195989|NCT01966549|Moderate to Severe Chronic Obstructive Pulmonary Disease
195990|NCT01966549|CNTO 6785
195991|NCT01966549|Placebo
195992|NCT01966510|cord blood transplant
195993|NCT01966510|advanced lymphoid malignancies
195994|NCT01966497|AML
195995|NCT01966484|Succinylcholine
195996|NCT01966484|Mivacurium
195997|NCT01966484|Rigid Bronchoscopy
195998|NCT01966484|Intubating conditions
195999|NCT01966484|Short Procedure
196000|NCT01966445|GSK2849330
196001|NCT01966445|Oncology
196002|NCT01966445|First Time in Human
196003|NCT01966445|HER3
196004|NCT01966432|Substance abuse
196005|NCT01966432|Alcohol use
196006|NCT01966432|Tobacco use
196007|NCT01966432|Brief intervention
196008|NCT01966432|Referral to treatment
196009|NCT01966419|hepatic encephalopathy
196010|NCT01966419|hyperammonemia
196011|NCT01966419|cirrhosis
196012|NCT01966419|ornithine phenylacetate
196013|NCT01966419|OCR-002
196014|NCT01966406|Pancreaticoduodenectomy
196015|NCT01966406|nasogastric tube
196016|NCT01966393|Type 1 diabetes
196017|NCT01966393|Hypoglycemia
196018|NCT01966393|Insulin
196019|NCT01966393|Glucagon
196020|NCT01966393|Closed-loop strategy
196021|NCT01966393|Artificial pancreas
196022|NCT01966367|Unrelated donor transplant
196023|NCT01966367|Haploidentical donor transplant
196024|NCT01966367|Peripheral blood stem cell transplantation
196025|NCT01966367|CD34+ selection
196026|NCT01966367|Non-malignant disease
196027|NCT01966367|Bone marrow failure syndrome
196028|NCT01966367|Severe Aplastic Anemia
196029|NCT01966367|Severe Congenital Neutropenia
196030|NCT01966367|Amegakaryocytic Thrombocytopenia
196031|NCT01966367|Diamond-Blackfan Anemia
196032|NCT01966367|Schwachman Diamond Syndrome
196033|NCT01966367|Primary Immunodeficiency Syndrome
196034|NCT01966367|Acquired Immunodeficiency Syndrome
196035|NCT01966367|Histiocytic Syndrome
196036|NCT01966367|Familial Hemophagocytic Lymphocytosis
196037|NCT01966367|Lymphohistiocytosis
196038|NCT01966367|Macrophage Activation Syndrome
196039|NCT01966367|Langerhans Cell Histiocytosis (LCH)
196040|NCT01966367|Hemoglobinopathies
196041|NCT01966367|Sickle Cell Disease
196042|NCT01966367|Sickle Cell-beta-thalassemia
196043|NCT01966354|adult
196044|NCT01966354|catheterization, central venous
196045|NCT01966354|ultrasonography, interventional
196046|NCT01966354|evidence-based medicine
196047|NCT01966354|cost-benefit analysis
196048|NCT01966302|Pulmonary Arterial Hypertension
196049|NCT01966302|prostacyclin
196050|NCT01966302|oral
196051|NCT01966289|Colorectal Neoplasms
196052|NCT01966289|Intestinal Neoplasms
196053|NCT01966289|Gastrointestinal Neoplasms
196054|NCT01966289|Digestive System Neoplasms
196055|NCT01966289|Neoplasms by Site
196056|NCT01966289|Neoplasms
196057|NCT01966289|Digestive System Diseases
196058|NCT01966289|Gastrointestinal Diseases
196059|NCT01966289|Colonic Diseases
196060|NCT01966289|Intestinal Diseases
196061|NCT01966289|Rectal Diseases
196062|NCT01966276|Chronic Fatigue Syndrome (CFS)
196063|NCT01966276|Myalgic Encephalomyelitis (ME)
196064|NCT01966276|central nervous system (CNS)
196065|NCT01966276|fatigue
196066|NCT01966276|alertness
196067|NCT01966276|brain fog
196068|NCT01966276|mitochondria
196069|NCT01966276|methylphenidate
196070|NCT01966276|Ritalin
196071|NCT01966276|stimulant
196072|NCT01966276|multivitamin
196073|NCT01966276|multimineral
196074|NCT01966276|micronutrients
196075|NCT01966276|supplements
196076|NCT01966263|total knee arthroplasty
196077|NCT01966263|femoral nerve block
196078|NCT01966263|local infiltration analgesia
196079|NCT01966263|fast track
196080|NCT01966198|pulse plethysmography, autonomic nervous system, heart rate variability, baro-reflex
196081|NCT01966185|virtual simulation
196082|NCT01966185|temporal bone
196083|NCT01966185|surgical training
196084|NCT01966185|medical education
196085|NCT01966185|self-directed learning
196086|NCT01966185|final product assessment
196087|NCT01966185|cognitive load
196088|NCT01966185|reaction time
196089|NCT01966185|skills training
196090|NCT01966185|simulator metrics
196091|NCT01966172|NSAID, gabapentin, multimodal, morphine, dexamethasone, cardiac surgery, postoperative pain, analgesia.
196092|NCT01966133|HCC
196093|NCT01966133|Randomised controlled trial
196094|NCT01966133|TACE
196095|NCT01966133|Resection
196096|NCT01966120|Photodynamic Therapy
196097|NCT01966120|Field-directed Treatment
196098|NCT01966068|Asthma
196099|NCT01966068|Pediatrics
196100|NCT01966068|Health Technology
196101|NCT01966068|Meaningful Use Stage-3
196102|NCT01966068|Web Portal
196103|NCT01966042|Refractory angina
196104|NCT01966042|Cell Therapy
196105|NCT01966042|Bone Marrow
196106|NCT01966042|Mononuclear Cells
196107|NCT01966016|LV- Left Ventricular
196108|NCT01966016|CRT- Cardiac resynchronization therapy
196109|NCT01966016|MSCRT- Multisite Cardiac resynchronization therapy (P-pacemaker; D-defibrillator)
196110|NCT01966016|BBB -bundle branch block
196111|NCT01965990|Enteral nutrition
196112|NCT01965990|very low-calorie diet
196113|NCT01965990|severe obesity
196114|NCT01965990|weight loss
196115|NCT01965990|ketosis
196116|NCT01965964|Dysphagia, Swallowing functions, Questionnaire in German
196117|NCT01965925|Cognition
196118|NCT01965925|Sleep problems
196119|NCT01965925|Bipolar Disorder
196120|NCT01965912|Phenylketonuria
196121|NCT01965912|Kuvan
196122|NCT01965912|Sapropterin dihydrochloride
196123|NCT01965886|osteoarthritis
196124|NCT01965886|knee
196125|NCT01965886|arthroplasty
196126|NCT01965886|replacement
196127|NCT01965873|Pancreatitis, Acute necrotizing
196128|NCT01965873|Enteral nutrition
196129|NCT01965873|Fasting
196130|NCT01965873|Complications
196131|NCT01965873|Mortality
196132|NCT01965834|Multiple Myeloma
196133|NCT01965834|Fenofibrate
196134|NCT01965821|tracheal cuff pressure
196135|NCT01965821|continuous control
196136|NCT01965821|microaspiration
196137|NCT01965795|Brain-derived neurotrophic factor
196138|NCT01965795|Cognitive function
196139|NCT01965795|Dietary supplement
196140|NCT01965795|Coffee plant extract
196141|NCT01965769|Very low birth weight infants
196142|NCT01965769|premature
196143|NCT01965769|nutrition
196144|NCT01965769|gastric residual
196145|NCT01965756|Alzheimer's Disease
196146|NCT01965756|Vascular Dementia
196147|NCT01965756|Dementia
196148|NCT01965756|Memory Impairment
196149|NCT01965743|intrauterine contraception (IUC)
196150|NCT01965743|social networks
196151|NCT01965743|social influence
196152|NCT01965743|diffusion of innovation
196153|NCT01965743|intrauterine device (IUD)
196154|NCT01965743|LARC
196155|NCT01965730|dilated ascending aorta
196156|NCT01965717|endoleak
196157|NCT01965717|MMP- 9
196158|NCT01965717|biomarker
196159|NCT01965704|Narcotic addiction during pregnancy
196160|NCT01965704|Neonatal abstinence syndrome
196161|NCT01965704|NAS
196162|NCT01965691|Phenylketonuria
196163|NCT01965691|PKU
196164|NCT01965691|Phenylalanine metabolism
196165|NCT01965691|Protein requirements
196166|NCT01965691|Indicator Amino acid Oxidation
196167|NCT01965691|Stable isotopes
196168|NCT01965678|Osteopathic manipulative treatment
196169|NCT01965678|muscle-skeletal disorder
196170|NCT01965678|quality of life
196171|NCT01965665|Diabetes
196172|NCT01965665|Surgical Intervention
196173|NCT01965665|Honey
196174|NCT01965652|Opioid Induced Constipation
196175|NCT01965639|Diabetes Mellitus Type 2
196176|NCT01965639|Standard of care
196177|NCT01965639|Quality of life
196178|NCT01965639|Disease management
196179|NCT01965626|Oseltamivir
196180|NCT01965626|Dexamethasone
196181|NCT01965626|ITP
196182|NCT01965613|Pyoderma Gangrenosum
196183|NCT01965600|Endotoxin challenge
196184|NCT01965587|novasure
196185|NCT01965587|Mirena IUS
196186|NCT01965587|menorrhagia
196187|NCT01965587|pelvic pain
196188|NCT01965587|ashermanns
196189|NCT01965574|ARDS - FLUID LOADING - PRELOAD DEPENDENCE
196190|NCT01965548|spleen
196191|NCT01965548|injury
196192|NCT01965548|patient transfer
196193|NCT01965548|splenectomy
196194|NCT01965548|embolization, theurapeutic
196195|NCT01965535|Hepatitis C
196196|NCT01965535|HCV
196197|NCT01965535|Cirrhosis
196198|NCT01965522|Breast cancer
196199|NCT01965522|melatonin
196200|NCT01965522|vitamin d
196201|NCT01965522|ki67
196202|NCT01965509|PEX168
196203|NCT01965509|Phase I/II
196204|NCT01965509|add on to metformin
196205|NCT01965496|PEX168
196206|NCT01965496|Phase I
196207|NCT01965496|titration
196208|NCT01965483|radiotherapy
196209|NCT01965483|adjuvant
196210|NCT01965483|weekly hypofractionation
196211|NCT01965457|obstructive sleep apnea
196212|NCT01965457|pediatric
196213|NCT01965457|adenoid hypertrophy
196214|NCT01965444|Sub-epidermal moisture
196215|NCT01965444|Pressure Ulcers
196216|NCT01965405|HIV
196217|NCT01965405|AIDS
196218|NCT01965405|Nicotine Dependence
196219|NCT01965405|Smoking
196220|NCT01965405|Smoking cessation
196221|NCT01965405|Contingency Management
196222|NCT01965379|Dialysis
196223|NCT01965379|Phosphorus
196224|NCT01965379|Diet
196225|NCT01965366|Dexamethasone
196226|NCT01965366|Virtual Reality
196227|NCT01965366|Military
196228|NCT01965366|PTSD
196229|NCT01965353|Relapsed Multiple Myeloma
196230|NCT01965353|Relapse-Refractory Multiple Myeloma
196231|NCT01965340|patients
196232|NCT01965327|Friedreich ataxia
196233|NCT01965327|Interferon gamma-1b
196234|NCT01965327|FRDA
196235|NCT01965314|ultrasound guided regional anaesthesia
196236|NCT01965314|upper limb surgery
196237|NCT01965314|ultrasound guided axillary brachial plexus blockade
196238|NCT01965275|Advanced non-small cell lung cancer
196239|NCT01965275|High-dose
196240|NCT01965275|Pulsatile
196241|NCT01965275|EGFR-TKIs
196242|NCT01965249|Laparotomy
196243|NCT01965249|short stitch
196244|NCT01965249|long stitch
196245|NCT01965249|MonoMax
196246|NCT01965236|hypertension, sodium intake, left ventricular function
196247|NCT01965223|Oligometastatic
196248|NCT01965223|Neoplasia
196249|NCT01965223|Radiosurgery
196250|NCT01965223|Stereotactic Ablative Body Radiotherapy
196251|NCT01965223|SABR
196252|NCT01965223|Metastases to the Lung
196253|NCT01965223|Non Haematological
196254|NCT01965210|Rye
196255|NCT01965210|Fermentable dietary fibre
196256|NCT01965210|Inulin
196257|NCT01965210|Plant protein
196258|NCT01965210|Gluten
196259|NCT01965210|Porridge
196260|NCT01965210|Bread
196261|NCT01965210|Appetite
196262|NCT01965210|Satiety
196263|NCT01965210|Hunger
196264|NCT01965210|Desire to eat
196265|NCT01965210|Metabolism
196266|NCT01965210|Glucose
196267|NCT01965210|Insulin
196268|NCT01965210|Gut hormones
196269|NCT01965210|Metabolomics
196270|NCT01965210|Gastric emptying rate
196271|NCT01965210|Breath hydrogen and methane excretion
196272|NCT01965184|child
196273|NCT01965184|cognitive behavioral therapy
196274|NCT01965184|CBT
196275|NCT01965184|aggression
196276|NCT01965184|disruptive behavior
196277|NCT01965184|treatment
196278|NCT01965184|frustrative non-reward
196279|NCT01965171|hematologic malignancy
196280|NCT01965171|iron overload
196409|NCT01964573|Pharmacokinetics
196281|NCT01965171|magnetic resonance imaging
196282|NCT01965171|childhood cancer survivors
196283|NCT01965158|Opioid-induced Constipation
196284|NCT01965132|Rheumatiod Arhthritis
196285|NCT01965132|Ankylosing spondylitis
196286|NCT01965132|Psoriatic arthritis
196287|NCT01965132|Biologic agents
196288|NCT01965132|Cohort studies
196289|NCT01965106|Glaucoma, Angle-Closure
196290|NCT01965106|Glaucoma, Closed-Angle
196291|NCT01965106|Primary angle closure
196292|NCT01965106|Acute angle closure
196293|NCT01965106|Acute angle-closure glaucoma
196294|NCT01965093|perioperative
196295|NCT01965093|desaturation
196296|NCT01965093|growth development
196297|NCT01965093|intelligence outcome
196298|NCT01965080|Endometrial cancer
196299|NCT01965054|Intrahepatic cholestasis of pregnancy
196300|NCT01965054|fish oil
196301|NCT01965054|omega-3
196302|NCT01965054|Docosahexaenoic acid,
196303|NCT01965054|eicosapentaenoic acid
196304|NCT01965041|AVA Study
196305|NCT01965028|tinnitus
196306|NCT01965028|transcranial random noise stimulation
196307|NCT01965028|tRNS
196308|NCT01965028|auditory cortex
196309|NCT01965028|non-invasive brain stimulation
196310|NCT01965015|Heart Failure (HF)
196311|NCT01965015|Left Atrial Pressure
196312|NCT01964989|Influenza
196313|NCT01964989|children
196314|NCT01964911|Martorell ulcer
196315|NCT01964911|Hypertensive leg ulcer
196316|NCT01964911|Pain
196317|NCT01964911|Continuous nerve block
196318|NCT01964911|Ropivacaïne
196319|NCT01964911|Local anesthesic
196320|NCT01964898|Smoking
196321|NCT01964898|Mood Management
196322|NCT01964898|Depression
196323|NCT01964898|Behavioral Activation
196324|NCT01964898|Acute Coronary Syndrome
196325|NCT01964898|Myocardial Infarction
196326|NCT01964872|Healthy volunteers
196327|NCT01964872|JNJ-38877618
196328|NCT01964872|Pharmacokinetic
196329|NCT01964872|Safety
196330|NCT01964872|Single-ascending dose
196331|NCT01964872|Multiple-ascending dose
196332|NCT01964859|healthy skin
196333|NCT01964859|wounds and injuries
196334|NCT01964859|prosthetics
196335|NCT01964859|amputations
196336|NCT01964859|dermal fibroblasts
196337|NCT01964846|inflammation
196338|NCT01964846|high fat meal
196339|NCT01964846|resveratrol
196340|NCT01964846|curcumin
196341|NCT01964846|gene expression
196342|NCT01964833|clinical trial
196343|NCT01964833|DMT2
196344|NCT01964833|periodontitis
196345|NCT01964833|PDT
196346|NCT01964807|Cardiovascular
196347|NCT01964807|tobacco
196348|NCT01964807|cigarettes
196349|NCT01964807|secondhand cigarette smoke
196350|NCT01964807|SHS
196351|NCT01964807|smokeless tobacco
196352|NCT01964807|chewing tobacco
196353|NCT01964807|snus
196354|NCT01964807|electronic cigarettes
196355|NCT01964807|vapor
196356|NCT01964807|particles
196357|NCT01964807|oxidative stress
196358|NCT01964807|flow-mediated dilation
196359|NCT01964807|FMD
196360|NCT01964794|Warfarin
196361|NCT01964781|Administration, topical
196362|NCT01964781|tranexamic acid
196363|NCT01964781|adrenaline
196364|NCT01964781|bupivacaine
196365|NCT01964781|surgery
196366|NCT01964755|EBV+
196367|NCT01964755|NHL
196368|NCT01964755|HL
196369|NCT01964755|Non Hodgkin's Lymphoma
196370|NCT01964755|Hodgkin's Lymphoma
196371|NCT01964755|Epstein Barr Virus
196372|NCT01964755|Epstein Barr Virus Associated Non Hodgkin's Lymphoma
196373|NCT01964755|Epstein Barr Virus Associated Hodgkin's Lymphoma
196374|NCT01964755|Post-Transplant Lymphoproliferative Disease
196375|NCT01964729|rTMS
196376|NCT01964729|Pain threshold
196377|NCT01964729|Neuromodulation
196378|NCT01964729|Myofascial
196379|NCT01964716|Prevenar 13
196380|NCT01964716|13vPnC
196381|NCT01964716|Healthy Subjects
196382|NCT01964690|Lactate
196383|NCT01964690|Sepsis
196384|NCT01964690|Capillary lactate
196385|NCT01964690|Venous lactate
196386|NCT01964690|Quick test
196387|NCT01964677|Magnetic Resonance Imaging (MRI)
196388|NCT01964677|High Intensity Focused Ultrasound (HIFU)
196389|NCT01964664|Mindfulness
196390|NCT01964664|Meditation
196391|NCT01964664|acute lateral sclerosis
196392|NCT01964664|Cerebral Palsy
196393|NCT01964664|Cerebral Ataxia
196394|NCT01964664|Locked-in Syndrome
196395|NCT01964651|Healthy
196396|NCT01964651|JNJ-42165279
196397|NCT01964651|Pharmacokinetics
196398|NCT01964651|Elderly
196399|NCT01964651|Young
196400|NCT01964638|Prostate Cancer
196401|NCT01964638|Prostate Biopsy
196402|NCT01964638|Targeted Biopsy
196403|NCT01964625|Chronic GvHD
196404|NCT01964599|Fiber
196405|NCT01964599|Gastrointestinal
196406|NCT01964586|Septoplasty, Dexmedetomidine, Surgical Conditions
196407|NCT01964573|Parkinson's Disease
196408|NCT01964573|Rotigotine
196410|NCT01964573|Healthy subjects
196411|NCT01964560|Lacosamide
196412|NCT01964560|Vimpat
196413|NCT01964560|UCB
196414|NCT01964560|Epilepsy
196415|NCT01964560|Partial Onset Seizures
196416|NCT01964560|Pediatric
196417|NCT01964547|Cognition
196418|NCT01964547|Mood
196419|NCT01964534|Metastatic
196420|NCT01964534|Pancreatic
196421|NCT01964534|Cancer
196422|NCT01964534|Pancreas
196423|NCT01964534|GERCOR
196424|NCT01964534|Gemcitabine
196425|NCT01964534|LV5FU2
196426|NCT01964534|ABI-007
196427|NCT01964534|PACLITAXEL ALBUMIN-BOUND PARTICLES
196428|NCT01964482|Hospitalization
196429|NCT01964482|Older
196430|NCT01964482|Medical patient
196431|NCT01964482|Strength training
196432|NCT01964456|Bodily self-consciousness
196433|NCT01964456|intersubjective body
196434|NCT01964456|Anorexia Nervosa
196435|NCT01964456|Joint perception task
196436|NCT01964456|Interoceptive awareness
196437|NCT01964443|Plaque Psoriasis
196438|NCT01964443|Alexithymia
196439|NCT01964443|Quality of life
196440|NCT01964430|Resectable pancreatic cancer
196441|NCT01964430|resected
196442|NCT01964430|resectable PDA
196443|NCT01964430|adenocarcinoma
196444|NCT01964430|surgically resected
196445|NCT01964430|adjuvant
196446|NCT01964430|Abraxane
196447|NCT01964430|nab-paclitaxel
196448|NCT01964430|ABI-007
196449|NCT01964430|gemcitabine
196450|NCT01964430|Gemzar
196451|NCT01964430|Phase 3
196452|NCT01964417|BOWEL PREPARATION
196453|NCT01964417|PEG
196454|NCT01964417|Low-volume PEG Plus Ascorbic Acid
196455|NCT01964404|Dronabinol
196456|NCT01964404|Schizophrenia
196457|NCT01964404|Dual Diagnosis
196458|NCT01964404|Substance Abuse
196459|NCT01964404|Cannabis Use Disorder
196460|NCT01964378|cancer-related pain
196461|NCT01964378|neuropathic related cancer pain
196462|NCT01964378|morphine
196463|NCT01964378|cebranopadol (GRT6005)
196464|NCT01964378|Numerical Rating Scale
196465|NCT01964326|atorvastatin
196466|NCT01964326|Hypercholesterolemia
196467|NCT01964313|Acute coronary syndrome
196468|NCT01964313|treatment strategy
196469|NCT01964313|genetics
196470|NCT01964274|Nursing Delirium Screening Scale,
196471|NCT01964274|Acetylcholinesterase Activity
196472|NCT01964261|Neural
196473|NCT01964261|Prosthetic
196474|NCT01964261|Brain machine interface
196475|NCT01964261|brain computer interface
196476|NCT01964261|brain control
196477|NCT01964261|paralysis
196478|NCT01964261|tetraplegia
196479|NCT01964261|quadriplegia
196480|NCT01964261|spinal cord injury
196481|NCT01964261|stimulation
196482|NCT01964261|sensory feedback
196483|NCT01964248|Blood gas analysis
196484|NCT01964248|Arterial puncture
196485|NCT01964248|Local anesthesia
196486|NCT01964248|Eutectic mixture
196487|NCT01964248|Lidocaïne/prilocaïne cream (5%)
196488|NCT01964248|Placebo
196489|NCT01964248|Pain Intensity Scale
196490|NCT01964248|Numerical Rating Scale
196491|NCT01964235|INC280, advanced hepatocellular carcinoma, c-MET pathway dysregulation.
196492|NCT01964222|Cancer
196493|NCT01964222|Clinical trials
196494|NCT01964222|Informed consent
196495|NCT01964222|Health literacy
196496|NCT01964209|ADHD
196497|NCT01964209|Validation
196498|NCT01964209|Quality Improvement
196499|NCT01964209|Vanderbilt
196500|NCT01964209|Conners 3rd Edition
196501|NCT01964209|ADHD Measures
196502|NCT01964209|ADHD Adolescent
196503|NCT01964209|ADHD Questionnaire
196504|NCT01964209|ICISS
196505|NCT01964209|Integrated Clinical Information Sharing System
196506|NCT01964196|Renal anemia
196507|NCT01964196|Chronic Renal Failure
196508|NCT01964196|ASP1517
196509|NCT01964183|Open-label design
196510|NCT01964183|Pharmacokinetics
196511|NCT01964183|Drug-Drug Interaction
196512|NCT01964183|Mirabegron
196513|NCT01964170|ASP3550
196514|NCT01964170|Prostate cancer
196515|NCT01964157|non-small cell lung cancer (NSCLC)
196516|NCT01964144|thyroid cancer, dovitinib
196517|NCT01964131|Bioequivalence
196518|NCT01964131|pharmacodynamics
196519|NCT01964131|pharmacokinetics
196520|NCT01964131|safety
196521|NCT01964131|tolerability
196522|NCT01964131|D961H
196523|NCT01964131|Japanese
196524|NCT01964118|intermittent fasting
196525|NCT01964118|obesity
196526|NCT01964118|calorie restriction
196527|NCT01964105|Hypomastia
196528|NCT01964105|Augmentation
196529|NCT01964105|Breast
196530|NCT01964105|3D
196531|NCT01964105|Breast Q
196532|NCT01964092|Disability
196533|NCT01964092|Individual placement and support
196534|NCT01964092|Mental health
196535|NCT01964092|Quality of life
196536|NCT01964092|Randomized controlled trial
196537|NCT01964092|Rehabilitation
196538|NCT01964092|Return to work
196539|NCT01964092|Supported employment
196540|NCT01964066|therapeutic ERCP
196541|NCT01964066|prevention of post-ERCP pancreatitis
196542|NCT01964066|thoracic epidural analgesia
196543|NCT01964053|Self-management adherence
196544|NCT01964053|post acute care
196545|NCT01964053|critical access hospitals
196546|NCT01964053|patient activation
196547|NCT01964053|hospital readmission
196548|NCT01964040|femoral nerve block
196549|NCT01964040|peri-neural dexmedetomidine
196550|NCT01964027|second line chemoregime
196551|NCT01964027|gastric cancer
196552|NCT01964014|once
196553|NCT01963988|Bladder Pain Syndrome
196554|NCT01963988|Transurethral Resection of Ulcer
196555|NCT01963988|Transurethral Coagulation of Ulcer
196556|NCT01963962|Emergency contraception
196557|NCT01963962|Levonorgestrel IUD
196558|NCT01963962|Copper IUD
196559|NCT01963962|Oral Levonorgestrel
196560|NCT01963936|Infant newborn
196561|NCT01963936|Laryngeal mask airway
196562|NCT01963936|Positive pressure ventilation
196563|NCT01963936|Resuscitation
196564|NCT01963923|Pulmonary Rehabilitation
196565|NCT01963923|Lung Cancer Resection
196566|NCT01963923|Video-assisted thoracic surgery
196567|NCT01963923|Exercise tolerance
196568|NCT01963923|Quality of life
196569|NCT01963910|Mannitol
196570|NCT01963910|TRPV1 receptor
196571|NCT01963910|Pain
196572|NCT01963910|Burning pain
196573|NCT01963910|neuropathy
196574|NCT01963910|neuropathic pain
196575|NCT01963897|Genotype/phenotype correlations
196576|NCT01963897|Growth
196577|NCT01963897|Bone health
196578|NCT01963897|Puberty
196579|NCT01963897|Quality of life
196580|NCT01963884|Extraction Sockets
196581|NCT01963884|Ridge dimensions
196582|NCT01963884|Dental Alveolar Anatomy
196583|NCT01963884|Dental Implants
196584|NCT01963884|Bone Physiology
196585|NCT01963871|chronic low back pain
196586|NCT01963871|low back pain
196587|NCT01963871|yoga
196588|NCT01963832|stroke
196589|NCT01963832|Fluoxetine (FLX)
196590|NCT01963832|eCIMT
196591|NCT01963832|Central Nervous System
196592|NCT01963793|Pruritus
196593|NCT01963780|lung transplantation
196594|NCT01963780|lung preservation
196595|NCT01963780|breathing lung transplant
196596|NCT01963767|memory
196597|NCT01963767|cognition
196598|NCT01963767|dietary supplements
196599|NCT01963754|Articaine 1:100.000
196600|NCT01963754|Dental Implants
196601|NCT01963754|Posterior mandible
196602|NCT01963754|Loco-regional Anesthesia
196603|NCT01963754|Subperiosteal Anesthesia
196604|NCT01963741|Leukotriene D4
196605|NCT01963741|allergic rhinitis
196606|NCT01963741|nasal airway resistance
196607|NCT01963741|nasal provocation test
196608|NCT01963741|nasal hyperreactivity
196609|NCT01963741|airway inflammation
196610|NCT01963741|asthma
196611|NCT01963728|post-transplant
196612|NCT01963728|diabetes mellitus
196613|NCT01963728|renal transplant
196614|NCT01963728|kidney transplant
196615|NCT01963728|lung transplant
196616|NCT01963728|heart transplant
196617|NCT01963728|insulin
196618|NCT01963715|IMGN289
196619|NCT01963715|Antibody Drug Conjugate
196620|NCT01963715|antibody
196621|NCT01963715|EGFR
196622|NCT01963715|NSCLC
196623|NCT01963715|SCCHN
196624|NCT01963715|Head and neck
196625|NCT01963715|Squamous cell carcinoma
196626|NCT01963715|Solid tumor
196627|NCT01963715|Immunogen
196628|NCT01963715|Lung
196629|NCT01963715|Phase 1
196630|NCT01963702|predictive factor
196631|NCT01963702|response
196632|NCT01963702|gastric neoplasm
196633|NCT01963702|oxaliplatin
196634|NCT01963702|docetaxol
196635|NCT01963702|capecitabine
196636|NCT01963689|Anxiety
196637|NCT01963689|Self-Esteem
196638|NCT01963676|schizophrenia
196639|NCT01963676|auditory hallucinations
196640|NCT01963676|transcranial stimulation
196641|NCT01963676|tDCS
196642|NCT01963676|tACS
196643|NCT01963663|YKL-40
196644|NCT01963663|Chronic low grade inflammation
196645|NCT01963663|type 2 diabetes mellitus
196646|NCT01963663|metformin
196647|NCT01963663|pioglitazone
196648|NCT01963637|obesity, sleeve gastrectomy, gastric bypass, gastric tomodensitometry, gastric pouch size, weight regain
196649|NCT01963624|Breast
196650|NCT01963624|Screening
196651|NCT01963624|Ultrasound
196652|NCT01963624|Elastography
196653|NCT01963624|Doppler ultrasonography
196654|NCT01963611|Multiple Sclerosis
196655|NCT01963611|Relapsing Remitting
196656|NCT01963611|Plovamer acetate
196657|NCT01963611|Copaxone
196658|NCT01963585|C reactive protein
196659|NCT01963585|Airway hyperreactivity
196660|NCT01963585|Body mass index
196661|NCT01963572|Breast cancer
196662|NCT01963572|Care model
196663|NCT01963572|Physical Therapy
196664|NCT01963546|diabetic
196665|NCT01963546|laparoscopic gastric bypass surgery
196666|NCT01963546|stress response
196667|NCT01963546|anesthesia
196668|NCT01963546|dexmedetomidine
196669|NCT01963533|lung cancer
196670|NCT01963533|telomere length
196671|NCT01963533|comorbidity
196672|NCT01963533|Eastern Cooperation Oncology Group (ECOG)
196673|NCT01963533|chemotherapy
196674|NCT01963520|Hip prosthesis infection
196675|NCT01963520|Reinfection
196676|NCT01963520|Excision-synovectomy
196677|NCT01963520|One stage/two stage revision
196678|NCT01963520|Antibiotherapy
196679|NCT01963494|Physical activity
196680|NCT01963494|Health-behavior-change
196681|NCT01963494|Dyadic Planning
196682|NCT01963494|Individual Planning
196683|NCT01963481|hormonal therapy
196684|NCT01963481|immunotherapy
196685|NCT01963468|Hearing Loss
196686|NCT01963468|Cochlear Implant
196687|NCT01963468|Deaf
196688|NCT01963468|Hearing Impairment
196689|NCT01963468|Hard of Hearing
196690|NCT01963455|transplantation autologous stress urinary incontinence
196691|NCT01963455|muscle derived cells
196692|NCT01963429|hepatocellular
196693|NCT01963429|Proton
196694|NCT01963429|RFA
196695|NCT01963403|etonogestrel implant
196696|NCT01963403|birth control
196697|NCT01963403|irregular bleeding
196698|NCT01963403|heavy bleeding
196699|NCT01963390|Hypogonadism
196700|NCT01963390|Testosterone Deficiency
196701|NCT01963377|bronchoscopy
196702|NCT01963377|O2-supplementation
196703|NCT01963364|fructans
196704|NCT01963364|inulin
196705|NCT01963364|oligofructose
196706|NCT01963364|colonic fermentation
196707|NCT01963364|microbiota
196708|NCT01963364|whoe gut transit
196709|NCT01963351|NSCLC
196710|NCT01963351|Non-squamous
196711|NCT01963286|ICD
196712|NCT01963286|CRT-D
196713|NCT01963286|Sudden cardiac death
196714|NCT01963286|Device settings
196715|NCT01963286|Optimized programming strategy
196716|NCT01963221|elderly
196717|NCT01963221|aorta
196718|NCT01963221|inflammation
196719|NCT01963221|arterial stiffness
196720|NCT01963221|PET/CT Imaging
196721|NCT01963221|hypertension
196722|NCT01963221|MRI
196723|NCT01963208|partial onset seizures
196724|NCT01963208|complex partial seizures
196725|NCT01963208|simple partial seizures
196726|NCT01963208|anticonvulsant
196727|NCT01963208|ganaxolone
196728|NCT01963208|neurosteroid
196729|NCT01963208|Marinus
196730|NCT01963208|epilepsy
196731|NCT01963195|Adverse Reaction to Drug
196732|NCT01963195|Self Efficacy
196733|NCT01963169|Bone Health
196734|NCT01963169|Online intervention
196735|NCT01963169|Dissemination
196736|NCT01963169|Theory-based intervention
196737|NCT01963156|Prescription synchronization
196738|NCT01963156|Cardiovascular disease
196739|NCT01963156|Medication adherence
196740|NCT01963156|Randomized controlled trial
196741|NCT01963156|Chronic disease
196742|NCT01963156|Pharmacy benefit design
196743|NCT01963156|Quality improvement
196744|NCT01963130|Vildagliptin
196745|NCT01963130|Portal Vein Pressure
196746|NCT01963130|Hepatosteatosis
196747|NCT01963104|hearing test, audiology, healthcare utilization,
196748|NCT01963104|patient education, hearing screening
196749|NCT01963065|Children's environmental health
196750|NCT01963065|preterm birth
196751|NCT01963065|newborns
196752|NCT01963065|bisphenol A
196753|NCT01963065|BPA
196754|NCT01963065|phthalates
196755|NCT01963065|metals exposure
196756|NCT01963065|very low birth weight
196757|NCT01963065|NICU
196758|NCT01963052|Metastatic Urothelial Cancer
196759|NCT01963052|Pharmacokinetics of AGS15E
196760|NCT01963052|AGS15E
196761|NCT01963052|ASG-15ME
196762|NCT01963052|AGS15E-13-1
196763|NCT01963026|spinal cord injury
196764|NCT01963026|upper extremity
196765|NCT01963026|skill performance
196766|NCT01963026|motor learning
196767|NCT01963013|Non-returning catheter valve
196768|NCT01963013|Catheter associated urinary tract infection
196769|NCT01963013|Critically ill patients
196770|NCT01963013|Prevention
196771|NCT01963000|Community Acquired Pneumonia
196772|NCT01963000|Emergency Department
196773|NCT01963000|Standardized Care
196774|NCT01963000|Reduced Mortality
196775|NCT01963000|CRB-65 Risk Classes
196776|NCT01963000|Antibiotic Therapy
196777|NCT01962974|Arthritis, Rheumatoid
196778|NCT01962961|HIV
196779|NCT01962961|Endothelial function
196780|NCT01962961|Oxidative stress
196781|NCT01962961|Cardiovascular disease
196782|NCT01962961|N-acetylcysteine
196783|NCT01962935|Healthy volunteer
196784|NCT01962935|Multiple ascending dose
196785|NCT01962909|Pancreatic Resection
196786|NCT01962883|Post Concussion Syndrome
196787|NCT01962883|Vestibular disturbance
196788|NCT01962883|Balance
196789|NCT01962883|Dizziness
196790|NCT01962883|Dizziness handicap inventory
196791|NCT01962883|Balance Error Scoring System
196792|NCT01962857|Physical activity
196793|NCT01962857|Exercise
196794|NCT01962857|Insulin resistance
196795|NCT01962857|High intensity interval training
196796|NCT01962857|Fat oxidation
196797|NCT01962857|Fitness
196798|NCT01962857|Lipids
196799|NCT01962857|Blood pressure
196800|NCT01962844|chronic coronary artery disease
196801|NCT01962844|coconut oil extra virgin
196802|NCT01962844|index of diet quality
196803|NCT01962844|nutritional treatment
196804|NCT01962831|obesity
196805|NCT01962831|labor, induced
196806|NCT01962831|pregnancy
196807|NCT01962831|cervical ripening
196808|NCT01962831|dinoprostone
196809|NCT01962818|Respiratory Distress Syndrome In Premature Infants
196810|NCT01962818|Bronchopulmonary Dysplasia
196811|NCT01962818|Ventilator-Induced Lung Injury
196812|NCT01962818|Functional Residual Capacity
196813|NCT01962818|Electric impedance tomography
196814|NCT01962792|PCI-32765
196815|NCT01962792|Multiple Myeloma
196816|NCT01962792|Relapsed Refractory Multiple Myeloma
196817|NCT01962792|Bruton's Tyrosine Kinase
196818|NCT01962792|Carfilzomib
196819|NCT01962792|Dexamethasone
196820|NCT01962792|Ibrutinib
196821|NCT01962779|Sleep Disordered Breathing
196822|NCT01962779|Cognitively normal elderly
196823|NCT01962779|Alzheimer's disease
196824|NCT01962779|Prevention
196825|NCT01962779|Continuous positive airway pressure (CPAP)
196826|NCT01962753|Affective symptoms as prodromal stage of Alzheimer
196827|NCT01962727|scapular dyskinesis, kinematics, muscular activities
196828|NCT01962714|Behavior therapies, cognitive
196829|NCT01962714|Mindfulness
196830|NCT01962714|Emotion
196831|NCT01962714|Group therapy
196832|NCT01962701|C-section
196833|NCT01962688|Heart Failure
196834|NCT01962688|Handheld ultrasound
196835|NCT01962688|Inferior Vena Cava
196836|NCT01962675|tDCS
196837|NCT01962675|motor training
196838|NCT01962675|SCI
196839|NCT01962662|stroke
196840|NCT01962662|transcranial magnetic stimulation
196841|NCT01962662|EMG biofeedback
196842|NCT01962662|motor function
196843|NCT01962662|neural plasticity
196844|NCT01962662|force
196845|NCT01962636|Umbilical Cord Transplant
196846|NCT01962636|Acute Myeloid Leukemia (AML)
196847|NCT01962636|Acute Lymphocytic Leukemia (ALL)
196848|NCT01962636|Chronic Myelogenous Leukemia
196849|NCT01962636|Plasma Cell Leukemia
196850|NCT01962636|Myelofibrosis
196851|NCT01962636|Myelodysplasia
196852|NCT01962636|Chronic Lymphocytic Leukemia
196853|NCT01962636|Small Lymphocytic Lymphoma
196854|NCT01962636|Marginal Zone B-Cell Lymphoma
196855|NCT01962636|Follicular Lymphoma
196856|NCT01962636|Lymphoplasmacytic Lymphoma
196857|NCT01962636|Mantle-Cell Lymphoma
196858|NCT01962636|Prolymphocytic Leukemia
196859|NCT01962636|Large Cell Non-Hodgkin Lymphoma
196860|NCT01962636|Lymphoblastic Lymphoma
196861|NCT01962636|Burkitt's Lymphoma
196862|NCT01962636|Non-Hodgkin Lymphoma
196863|NCT01962636|Multiple Myeloma
196864|NCT01962623|Severe Mood Dysregulation
196865|NCT01962623|Mood Disorders
196866|NCT01962623|Irritability
196867|NCT01962623|Disruptive Mood Dysregulation Disorder
196868|NCT01962623|Interpersonal Psychotherapy
196869|NCT01962610|Pain care
196870|NCT01962610|emergency
196871|NCT01962610|clinical decision support
196872|NCT01962610|abdominal pain
196873|NCT01962597|hemodialysis
196874|NCT01962597|aerobic exercise
196875|NCT01962597|resistance training
196876|NCT01962597|walking speed
196877|NCT01962597|randomized controlled trial
196878|NCT01962571|Optic neuritis
196879|NCT01962571|Multiple Sclerosis
196880|NCT01962571|Clinically isolated syndrome
196881|NCT01962571|Erythropoietin
196882|NCT01962558|Tinnitus
196883|NCT01962558|Medical Device
196884|NCT01962558|Randomized
196885|NCT01962558|Vagus Nerve Stimulation
196886|NCT01962545|Atrial Fibrillation
196887|NCT01962545|Percutaneous coronary intervention
196888|NCT01962545|Stent
196889|NCT01962545|Anticoagulant therapy
196890|NCT01962545|Antiplatelet therapy
196891|NCT01962545|Warfarin
196892|NCT01962545|NOAC
196893|NCT01962545|Aspirin
196894|NCT01962545|Clopidogrel
196895|NCT01962532|Neoplasms
196896|NCT01962532|Lymphoma
196897|NCT01962532|Advanced or refractory solid tumors
196898|NCT01962532|Advanced or refractory lymphoma
196899|NCT01962532|Gastric adenocarcinoma
196900|NCT01962532|Gastroesophageal junctions
196901|NCT01962532|JNJ-42756493
196902|NCT01962532|Pharmacokinetics
196903|NCT01962532|Japanese
196904|NCT01962532|Asian
196905|NCT01962532|Pharmacodynamics
196906|NCT01962519|gastrectomy
196907|NCT01962519|gastric cancer
196908|NCT01962519|oral feeding
196909|NCT01962519|complications
196910|NCT01962506|Chest pain
196911|NCT01962506|Copeptin
196912|NCT01962506|High-sensitivity cardiac troponin
196913|NCT01962506|Non-ST-Elevation (NSTE) - ACS
196914|NCT01962467|Allergic rhinitis
196915|NCT01962467|healthy volunteers
196916|NCT01962467|fluticasone furoate
196917|NCT01962467|levocabastine
196918|NCT01962467|fixed dose combination
196919|NCT01962467|pharmacokinetics
196920|NCT01962454|D2O
196921|NCT01962454|Microbiopsy
196922|NCT01962454|dynamic proteomics
196923|NCT01962454|muscle mass
196924|NCT01962454|testosterone
196925|NCT01962454|Duke University
196926|NCT01962454|skeletal muscle
196927|NCT01962441|7977
196928|NCT01962441|GS-7977
196929|NCT01962441|PSI-7977
196930|NCT01962441|Sofosbuvir (SOF)
196931|NCT01962441|Pegylated Interferon (PEG)
196932|NCT01962441|Ribavirin (RBV)
196933|NCT01962428|ticagrelor
196934|NCT01962428|loading dose
196935|NCT01962428|non-ST-segment elevation acute coronary syndromes
196936|NCT01962428|percutaneous coronary intervention
196937|NCT01962428|the antiplatelet effects
196938|NCT01962428|bleeding events
196939|NCT01962428|major adverse cardiac events
196940|NCT01962415|Severe Combined Immune Deficiency (SCID) with NK cell activity
196941|NCT01962415|Omenn Syndrome
196942|NCT01962415|Bare Lymphocyte Syndrome (BLS)
196943|NCT01962415|Combined Immune Deficiency (CID) syndromes
196944|NCT01962415|Combined Variable Immune Deficiency (CVID) syndrome
196945|NCT01962415|Wiskott-Aldrich Syndrome
196946|NCT01962415|Leukocyte adhesion deficiency
196947|NCT01962415|Chronic granulomatous disease (CGD)
196948|NCT01962415|X-linked Hyper IgM (XHIM) syndrome
196949|NCT01962415|IPEX syndrome
196950|NCT01962415|Chediak -Higashi Syndrome
196951|NCT01962415|Autoimmune Lymphoproliferative Syndrome (ALPS)
196952|NCT01962415|Hemophagocytic Lymphohistiocytosis (HLH) syndromes
196953|NCT01962415|Lymphocyte Signaling defects
196954|NCT01962415|Other primary immune defects where HSCT may be beneficial
196955|NCT01962415|Dyskeratosis Congenita (DC)
196956|NCT01962415|Congenital Amegakaryocytic Thrombocytopenia (CAMT)
196957|NCT01962415|Osteopetrosis
196958|NCT01962415|Mucopolysaccharidoses
196959|NCT01962415|Hurler syndrome (MPS I)
196960|NCT01962415|Hunter syndrome (MPS II)
196961|NCT01962415|Sanfilippo syndrome (MPS II)
196962|NCT01962415|Leukodystrophies
196963|NCT01962415|Krabbe Disease, also known as globoid cell leukodystrophy
196964|NCT01962415|Metachromatic leukodystrophy (MLD)
196965|NCT01962415|X-linked adrenoleukodystrophy (ALD)
196966|NCT01962415|Other inherited metabolic disorders
196967|NCT01962415|alpha mannosidosis
196968|NCT01962415|Other inheritable metabolic diseases where HSCT may be beneficial.
196969|NCT01962415|Thalassemia major
196970|NCT01962415|Sickle cell disease (SCD)
196971|NCT01962415|Diamond Blackfan Anemia (DBA)
196972|NCT01962415|other congenital transfusion dependent anemias
196973|NCT01962415|Gaucher Disease
196974|NCT01962389|ISR, Laser, SFA, PAD
196975|NCT01962376|Capecitabine
196976|NCT01962376|Oxaliplatin
196977|NCT01962376|Bevacizumab
196978|NCT01962376|Potentially Resectable Gastric Cancer Liver Metastasis
196979|NCT01962363|Friedreich's ataxia point mutation
196980|NCT01962350|Deep Brain Transcranial Magnetic Stimulation;
196981|NCT01962350|H1-Coil deep brain rTMS;
196982|NCT01962350|H1-Coil;
196983|NCT01962350|Bipolar Depression;
196984|NCT01962350|Cognition.
196985|NCT01962324|Quality of Life
196986|NCT01962324|Radiotherapy
196987|NCT01962324|Radiotherapy, dose-escalation
196988|NCT01962311|ALS
196989|NCT01962311|Spinal Cerebrospinal Fluid
196990|NCT01962311|Urine
196991|NCT01962311|SERUM
196992|NCT01962311|Diagnosis
196993|NCT01962285|neuronal inertia
196994|NCT01962285|loss of consciousness
196995|NCT01962285|propofol pharmacodynamics
196996|NCT01962285|Bispectral index
196997|NCT01962285|anesthesia, general/pharmacology
196998|NCT01962272|cancer
196999|NCT01962272|radiotherapy
197000|NCT01962272|chemotherapy
197001|NCT01962272|nutrition
197002|NCT01962272|dietary counseling
197003|NCT01962272|quality of life
197004|NCT01962246|Capecitabine
197005|NCT01962246|Oxaliplatin
197006|NCT01962246|Preoperative Concurrent Chemoradiotherapy
197007|NCT01962246|Gastroesophageal Junction Adenocarcinoma
197008|NCT01962220|HIV/AIDS
197009|NCT01962220|PMTCT
197010|NCT01962220|Pregnant Women
197011|NCT01962220|Kenya
197012|NCT01962220|Maternal Health
197013|NCT01962207|10 years Meningitec
197014|NCT01962207|Safety
197015|NCT01962207|booster response
197016|NCT01962207|Adolescents
197017|NCT01962207|Adults
197018|NCT01962207|Immunogenicity
197019|NCT01962207|Mencevax ACWY
197020|NCT01962181|EEG Attention Deficit / Hyperactivity Disorder (ADHD) Ritalin machine learning
197021|NCT01962168|Biliary Tract Neoplasms
197022|NCT01962168|Neoplasms
197023|NCT01962168|Gastrointestinal Diseases
197146|NCT01961453|Hypertension
197024|NCT01962168|Digestive System Diseases
197025|NCT01962168|Biliary Tract
197026|NCT01962168|Stents
197027|NCT01962155|Fibrosis
197028|NCT01962155|Liver Cirrhosis
197029|NCT01962155|non-invasive
197030|NCT01962155|biopsy
197031|NCT01962155|hepatitis B virus
197032|NCT01962103|Neuroblastoma, Rhabdomyosarcoma, Soft Tissue; Pediatric Oncology, Abraxane, albumin-bound paclitaxel, nab-paclitaxel, ABI-007, taxane, solid tumors
197033|NCT01962090|Neck Pain
197034|NCT01962090|Thoracic spine thrust manipulation
197035|NCT01962090|Osteopathic Manipulation
197036|NCT01962090|Dentistry
197037|NCT01962090|Range of Motion
197038|NCT01962077|pulpotomy
197039|NCT01962077|MTA
197040|NCT01962077|primary teeth
197041|NCT01962077|formocresol
197042|NCT01962038|Mild Cognitive Impairment
197043|NCT01962038|Aging
197044|NCT01962025|Renal failure
197045|NCT01962025|Hemodialysis
197046|NCT01962025|Canulation technique
197047|NCT01962025|Training time
197048|NCT01962025|Cost
197049|NCT01962025|Patient discomfort with cannulation technique
197050|NCT01962012|Orthodontic
197051|NCT01962012|Orthodontic Treatment
197052|NCT01962012|Accelerated Tooth Movement
197053|NCT01962012|Malocclusion
197054|NCT01962012|Device
197055|NCT01962012|AcceleDent Aura
197056|NCT01962012|Clear Aligners
197057|NCT01961999|Acute kidney injury
197058|NCT01961999|Cardiac surgery
197059|NCT01961999|Renal replacement therapy
197060|NCT01961986|Rotator Cuff
197061|NCT01961986|Rotator Cuff Sparing
197062|NCT01961986|Shoulder Replacement
197063|NCT01961986|Total Shoulder Replacement
197064|NCT01961986|Total Shoulder Arthroplasty
197065|NCT01961986|Arthritis
197066|NCT01961973|Articular cartilage
197067|NCT01961973|Chondrocytes
197068|NCT01961973|BMAC
197069|NCT01961960|ASP7374
197070|NCT01961960|Prevention of seasonal influenza
197071|NCT01961947|ASP7374
197072|NCT01961947|Approved egg-derived vaccine
197073|NCT01961947|Prevention of seasonal influenza
197074|NCT01961934|glioblastoma
197075|NCT01961934|high grade brain tumors
197076|NCT01961934|recurrent
197077|NCT01961934|pseudo-progression
197078|NCT01961934|radionecrosis
197079|NCT01961934|carbon acetate
197080|NCT01961934|C11 aceate
197081|NCT01961934|PET
197082|NCT01961934|positron emission tomography
197083|NCT01961921|RNAi therapeutic
197084|NCT01961895|Continuous lumbar plexus (LP) block analgesia
197085|NCT01961882|OCV-501
197086|NCT01961882|Acute Myeloid Leukemia
197087|NCT01961882|Antigen specific cancer immunotherapeutic
197088|NCT01961869|black raspberry
197089|NCT01961869|chemoprevention
197090|NCT01961869|oral delivery
197091|NCT01961856|platelet reactivity
197092|NCT01961856|ticagrelor loading dose
197093|NCT01961856|clopidogrel loading dose
197094|NCT01961843|Castration Resistant
197095|NCT01961817|Retromolar
197096|NCT01961817|Difficult Intubation
197097|NCT01961791|gastric cancer, staging system, prognosis
197098|NCT01961765|Relapsed acute myeloid leukemia
197099|NCT01961765|Refractory acute myeloid leukemia
197100|NCT01961752|bupivacaine,
197101|NCT01961752|triamcinolone acetonide,
197102|NCT01961752|endoscopic
197103|NCT01961752|submucosal
197104|NCT01961752|dissection
197105|NCT01961752|Patients
197106|NCT01961739|Hemorrhoids
197107|NCT01961739|Lidocaine
197108|NCT01961713|circulating tumor cells
197109|NCT01961713|CTC-Chip
197110|NCT01961661|intestinal inflammation
197111|NCT01961661|intestinal microflora
197112|NCT01961661|children
197113|NCT01961648|Apnea
197114|NCT01961648|Sleep Apnea Disorder
197115|NCT01961648|Respiratory chemical drive
197116|NCT01961648|CO2
197117|NCT01961635|Dental Implants
197118|NCT01961635|Zirconia Abutments
197119|NCT01961635|Titanium abutments
197120|NCT01961635|Acrylic abutments
197121|NCT01961635|Gingival Healing
197122|NCT01961635|Inflammation
197123|NCT01961635|Bone loss
197124|NCT01961622|Type 1 diabetes
197125|NCT01961622|Closed loop insulin delivery
197126|NCT01961622|Continuous subcutaneous glucose monitoring
197127|NCT01961622|Continuous subcutaneous insulin infusion
197128|NCT01961609|Chronic plaque psoriasis
197129|NCT01961596|Cooling ice spray
197130|NCT01961596|Time to stability
197131|NCT01961596|Jump
197132|NCT01961570|Early stage hand osteoarthritis
197133|NCT01961570|Carpometacarpal osteoarthritis
197134|NCT01961557|EEG
197135|NCT01961557|Cerebral Palsy
197136|NCT01961557|Knee
197137|NCT01961544|Breast Cancer
197138|NCT01961544|Metastatic
197139|NCT01961531|DCIS
197140|NCT01961531|IDC
197141|NCT01961531|Invasive breast carcinoma
197142|NCT01961479|Premenstrual syndrome (PMS)
197143|NCT01961479|Premenstrual Dysphoric Disorder (PMDD)
197144|NCT01961479|Internet-based Therapy
197145|NCT01961479|Cognitive Behavioural Therapy (CBT)
197147|NCT01961453|Isosorbide Mononitrate
197148|NCT01961453|Myocardial fibrosis
197149|NCT01961427|dietary nitrate
197150|NCT01961427|beetroot juice
197151|NCT01961427|exercise performance
197152|NCT01961427|oxygen consumption
197153|NCT01961414|Exudative
197154|NCT01961414|AMD
197155|NCT01961414|Macular
197156|NCT01961414|Degeneration
197157|NCT01961414|Aflibercept
197158|NCT01961414|Eylea
197159|NCT01961414|Intravitreal
197160|NCT01961401|exercise
197161|NCT01961401|exercise therapy
197162|NCT01961401|insulin resistance
197163|NCT01961388|Type 2 Diabetes
197164|NCT01961362|Pulmonary fibrosis
197165|NCT01961362|Interstitial lung disease
197166|NCT01961362|Connective tissue disease
197167|NCT01961362|Chronic hypersensitivity pneumonitis
197168|NCT01961362|Idiopathic pulmonary fibrosis
197169|NCT01961362|Pulmonary fibrosis of any cause
197170|NCT01961362|Primary supporters/caregivers
197171|NCT01961349|sedation, propofol, gastrointestinal endoscopy
197172|NCT01961336|IVF, poor responder, testosterone
197173|NCT01961323|Hypertension
197174|NCT01961323|high blood pressure
197175|NCT01961323|stress echocardiogram
197176|NCT01961323|nebivolol
197177|NCT01961323|left ventricular diastolic dysfunction
197178|NCT01961310|bacterial translocation
197179|NCT01961310|intestinal microbiota
197180|NCT01961297|dystonia
197181|NCT01961297|tremor
197182|NCT01961297|treatment
197183|NCT01961297|sodium oxybate
197184|NCT01961297|brain activity
197185|NCT01961271|Norspan
197186|NCT01961271|buprenorphine
197187|NCT01961271|transdermal
197188|NCT01961271|patch
197189|NCT01961271|chronic pain
197190|NCT01961271|non-malignant
197191|NCT01961271|osteoarthritis
197192|NCT01961271|rheumatoid arthritis
197193|NCT01961271|lower back pain
197194|NCT01961271|joint pain
197195|NCT01961271|muscle pain
197196|NCT01961271|opioid
197197|NCT01961271|analgesic
197198|NCT01961271|painkiller
197199|NCT01961271|Mundipharma
197200|NCT01961258|Severe Asthma, Community, comorbidities, patient compliance,PFT, anti-IgE therapy
197201|NCT01961232|Pulmonary Hypertension
197202|NCT01961232|biomarker
197203|NCT01961232|cardiac
197204|NCT01961232|circulation
197205|NCT01961232|heart disease
197206|NCT01961232|lung disease
197207|NCT01961193|critically ill patients
197208|NCT01961193|punctal plug
197209|NCT01961193|corneal injuries
197210|NCT01961180|Quality of Life
197211|NCT01961180|Adrenal hyper activity
197212|NCT01961180|Glucose metabolism
197213|NCT01961154|Asthma
197214|NCT01961154|medication reduction
197215|NCT01961154|asthma exacerbation
197216|NCT01961141|Ultrasound Doppler
197217|NCT01961141|Pulmonary diseases
197218|NCT01961141|Cardiopulmonary conditions
197219|NCT01961128|High risk
197220|NCT01961102|postmenopausal bleeding
197221|NCT01961102|postmenopausal hyperplasia
197222|NCT01961102|endometrial cancer
197223|NCT01961102|atypical hyperplasia
197224|NCT01961102|curettage
197225|NCT01961102|intraoperative rapid section
197226|NCT01961050|alcohol
197227|NCT01961050|pregnancy
197228|NCT01961050|fetal exposure
197229|NCT01961050|prevention
197230|NCT01961050|FAS
197231|NCT01961050|Alcohol-Related Neurodevelopmental Disorder (ARND)
197232|NCT01961037|Accidental Falls
197233|NCT01961037|Tai Chi
197234|NCT01961037|Older Adults
197235|NCT01961037|Balance
197236|NCT01961037|Moving for Better Balance
197237|NCT01961037|Church
197238|NCT01961037|Congregational Intervention
197239|NCT01961037|Rural
197240|NCT01961037|West Virginia
197241|NCT01961024|VLDL-TG kinetics
197242|NCT01961024|Postprandial state
197243|NCT01961024|Obesity
197244|NCT01961011|nerve compression, carpal tunnel, clinical decision making
197245|NCT01960998|radical prostatectomy
197246|NCT01960998|urinary incontinence
197247|NCT01960998|prostate cancer
197248|NCT01960998|telehealth
197249|NCT01960998|pelvic floor muscle training
197250|NCT01960985|Balance, Postural
197251|NCT01960985|Parkinson´s Disease
197252|NCT01960985|H&Y 1-3
197253|NCT01960985|Exrecice
197254|NCT01960985|Postural adjustments
197255|NCT01960985|antecipatory postural
197256|NCT01960985|compensatory postural adjustments
197257|NCT01960972|Blood pressure
197258|NCT01960972|Hypertension
197259|NCT01960972|Stepped wedge trial design
197260|NCT01960946|Hypertension
197261|NCT01960946|Galectin 3
197262|NCT01960946|Fibrosis
197263|NCT01960946|Vascular Stiffness
197264|NCT01960946|Echocardiography
197265|NCT01960933|STEMI
197266|NCT01960933|MVD
197267|NCT01960933|Full revascularization
197268|NCT01960933|Culprit lesion revascularization only
197269|NCT01960933|Primary PCI
197270|NCT01960920|Air Pollution
197271|NCT01960920|Heart Failure
197272|NCT01960920|Endothelium
197273|NCT01960920|Autonomic Dysfunction
197274|NCT01960920|Cardiopulmonary Exercise Test
197275|NCT01960907|COPD
197276|NCT01960907|CHF
197277|NCT01960907|SDB
197278|NCT01960881|Prostate cancer
197279|NCT01960855|anti-inflammatory agents
197280|NCT01960855|Joint Diseases
197281|NCT01960855|Arthritis
197282|NCT01960855|Musculoskeletal Disease
197283|NCT01960855|antirheumatic agents
197284|NCT01960842|levodopa
197285|NCT01960842|Advanced Parkinson's Disease
197286|NCT01960842|carbidopa
197287|NCT01960842|levodopa-carbidopa intestinal gel
197288|NCT01960842|Safety and Efficacy
197289|NCT01960829|melanoma
197290|NCT01960829|TOR Serine-Threonine Kinases
197291|NCT01960816|nasal obstruction
197292|NCT01960803|Stage I Breast Carcinoma
197293|NCT01960790|Humira®
197294|NCT01960790|Behcet's Disease
197295|NCT01960790|Adalimumab
197296|NCT01960777|Hernia, Inguinal
197297|NCT01960777|Laparoscopy
197298|NCT01960777|Onstep
197299|NCT01960764|Autologous microbiome transplant
197300|NCT01960764|Bacteria transplant
197301|NCT01960764|Treatment for atopic dermatitis
197302|NCT01960738|Diving
197303|NCT01960738|Water
197304|NCT01960738|Recreation
197305|NCT01960738|Precursor
197306|NCT01960725|Gastroenteritis
197307|NCT01960725|Diarrhea
197308|NCT01960725|Rotavirus
197309|NCT01960725|Vaccine
197310|NCT01960725|Dehydration
197311|NCT01960699|Prognosis
197312|NCT01960699|Neurological outcome
197313|NCT01960699|Resuscitation
197314|NCT01960699|Biomarker
197315|NCT01960673|supraglottic airway,igel-LMA, ambu-LMA, changing position, head and neck position, oropharyngeal leak pressure,degree of rotation
197316|NCT01960660|Fish Oil
197317|NCT01960660|EPA
197318|NCT01960660|DHA
197319|NCT01960660|Omega-Score
197320|NCT01960660|Lipemic Index
197321|NCT01960660|ethyl esters
197322|NCT01960660|triglycerides
197323|NCT01960660|phospholipids
197324|NCT01960595|PCA,Nerve block,Hullax Valgus
197325|NCT01960582|Housing adaptation
197326|NCT01960582|Independence
197327|NCT01960582|Costs
197328|NCT01960569|Thrombexx
197329|NCT01960569|Topical r-Hirudin
197330|NCT01960569|Efficacy
197331|NCT01960569|haematoma
197332|NCT01960556|simulation
197333|NCT01960543|Intrathecal anesthesia
197334|NCT01960543|Levobupivacaine
197335|NCT01960543|Bupivacaine
197336|NCT01960543|Hip fracture
197337|NCT01960517|Urinary
197338|NCT01960517|Incontinence
197339|NCT01960517|Catheter
197340|NCT01960504|DREAMS
197341|NCT01960504|Drug Eluting Absorbable Metal Scaffold
197342|NCT01960504|Scaffold
197343|NCT01960504|Coronary Artery Disease
197344|NCT01960504|Myocardial Ischemia
197345|NCT01960504|Atherosclerosis
197346|NCT01960465|CPAP treatment
197347|NCT01960465|hypertension
197348|NCT01960452|Insomnia
197349|NCT01960452|Primary insomnia
197350|NCT01960452|High density EEG
197351|NCT01960452|Polysomnography
197352|NCT01960452|Healthy sleeping controls
197353|NCT01960439|disease activity
197354|NCT01960439|central reader
197355|NCT01960439|endoscopic indices
197356|NCT01960426|Harvey Bradshaw score
197357|NCT01960426|Partial Mayo Clinical Score
197358|NCT01960426|Infliximab
197359|NCT01960426|Adalimumab
197360|NCT01960400|Complex regional pain syndrome type 1 (CRPS)
197361|NCT01960400|Transcranial direct current stimulation (tDCS)
197362|NCT01960400|Graded motor imagery (GMI)
197363|NCT01960400|Magnetic resonance imaging (MRI)
197364|NCT01960400|Functional magnetic resonance imaging (fMRI)
197365|NCT01960387|AML
197366|NCT01960387|clofarabine
197367|NCT01960387|cytarabine
197368|NCT01960387|persistent AML
197369|NCT01960387|induction therapy
197370|NCT01960374|RAS or RAF oncogenes, Inhibition of MEK pathway, inhibition cancer cell proliferation promising anti-cancer therapeutic strategy.
197371|NCT01960348|RNAi therapeutic
197372|NCT01960348|FAP
197373|NCT01960348|Familial Amyloid Polyneuropathy
197374|NCT01960348|TTR
197375|NCT01960348|Transthyretin
197376|NCT01960348|Amyloidosis
197377|NCT01960335|whey protein intake
197378|NCT01960335|obesity
197379|NCT01960335|visceral fat
197380|NCT01960335|resistance exercise training
197381|NCT01960335|sprint interval training
197382|NCT01960335|endurance exercise training
197383|NCT01960335|yoga training
197384|NCT01960335|healthy eating
197385|NCT01960335|healthy lifestyle strategies
197386|NCT01960335|leptin
197387|NCT01960335|hunger
197388|NCT01960322|adherence
197389|NCT01960322|nonadherence
197390|NCT01960322|compliance
197391|NCT01960322|noncompliance
197392|NCT01960322|liver transplantation
197393|NCT01960296|clopidogrel
197394|NCT01960296|general surgery
197517|NCT01959594|healthy volunteers
197395|NCT01960270|relapse after an initial clinical response
197396|NCT01960257|tuberculosis
197397|NCT01960257|tuberculosis treatment
197398|NCT01960257|wirelessly observed therapy
197399|NCT01960257|proteus digital health
197400|NCT01960257|digital health feedback system
197401|NCT01960244|familial
197402|NCT01960244|hypercholesterolemia
197403|NCT01960244|FH
197404|NCT01960218|acute decompensated heart failure
197405|NCT01960218|gas exchange
197406|NCT01960218|cardiopulmonary
197407|NCT01960218|dyspnea
197408|NCT01960218|cardiopulmonary analyzer
197409|NCT01960218|heart disease
197410|NCT01960218|cardiovascular disease
197411|NCT01960218|cardiopulmonary exercise
197412|NCT01960205|Saxagliptin, prediabetes, glucose intolerance,obesity
197413|NCT01960192|primary CNS lymphoma;chemotherapy;
197414|NCT01960192|RR;PFS;OS
197415|NCT01960153|Heart failure
197416|NCT01960153|Pulmonary hypertension
197417|NCT01960153|tadalafil
197418|NCT01960153|Phosphodiesterase Type 5 Inhibition
197419|NCT01960114|Acetaminophen
197420|NCT01960114|Paracetamol Analgesics
197421|NCT01960114|Analgesics
197422|NCT01960114|Non-Narcotic Pain
197423|NCT01960114|Postoperative Pain
197424|NCT01960114|Antipyretics Dental Surgery
197425|NCT01960114|Third molar extraction
197426|NCT01960101|xerostomia
197427|NCT01960101|Saliva
197428|NCT01960101|iatrogenic oral dryness
197429|NCT01960101|antidepressants
197430|NCT01960101|mouth dryness
197431|NCT01960101|milk product
197432|NCT01960088|Adolescent vaccines
197433|NCT01960088|HPV vaccine
197434|NCT01960088|Pharmacies
197435|NCT01960075|status epilepticus, refractory, benzodiazepine, fosphenytoin, levetiracetam, valproic acid
197436|NCT01960062|diabetes
197437|NCT01960062|web-based
197438|NCT01960062|software
197439|NCT01960062|device
197440|NCT01960049|Postoperative pain
197441|NCT01960049|Liver resection
197442|NCT01960049|Medial Open Transversus Abdominis Plane catheter
197443|NCT01960036|Substance Use Disorders
197444|NCT01960036|Complementary Therapies
197445|NCT01960036|Women
197446|NCT01960036|Mind-Body Therapies
197447|NCT01960036|Behavior and Behavior Mechanisms
197448|NCT01960023|Colorectal cancer
197449|NCT01960023|KRAS
197450|NCT01960023|BRAF
197451|NCT01960023|NRAS
197452|NCT01960023|PIK3CA
197453|NCT01960023|NSABP
197454|NCT01959958|Nocturnal enuresis
197455|NCT01959958|Barriers to treatment
197456|NCT01959945|Prevention
197457|NCT01959932|Smoking
197458|NCT01959932|Candidate Modified Risk Tobacco Product
197459|NCT01959932|Conventional cigarettes
197460|NCT01959932|Reduced exposure
197461|NCT01959932|Confinement
197462|NCT01959906|Esophagectomy
197463|NCT01959880|Breast Augmentation
197464|NCT01959880|Breast Reconstruction
197465|NCT01959880|Breast Revision
197466|NCT01959880|Silicone Gel
197467|NCT01959880|Contour Profile Gel
197468|NCT01959880|Siltex
197469|NCT01959880|CPG Styles
197470|NCT01959867|mastectomy
197471|NCT01959867|breast reconstruction
197472|NCT01959867|bovine
197473|NCT01959867|ADM
197474|NCT01959867|breast cancer
197475|NCT01959867|breast implants
197476|NCT01959867|breast expanders
197477|NCT01959867|radiation therapy
197478|NCT01959828|pulmonary hypertension
197479|NCT01959828|cardiac surgery
197480|NCT01959828|Glenn surgery
197481|NCT01959828|fontan surgery
197482|NCT01959828|left ventricular assist device
197483|NCT01959828|LVAD
197484|NCT01959802|Macular pseudohole
197485|NCT01959802|Cone outer segment tips line
197486|NCT01959789|Randomized Controlled Clinical Trial
197487|NCT01959789|Tooth Bleaching
197488|NCT01959776|cone outer segment tips line, foveal displacement
197489|NCT01959763|Metabolic syndrome
197490|NCT01959763|obesity
197491|NCT01959763|overweight
197492|NCT01959763|weight loss intervention
197493|NCT01959763|cognitive behavioral therapy
197494|NCT01959763|ICT intervention
197495|NCT01959763|cardiovascular disease
197496|NCT01959763|persuasive systems design
197497|NCT01959737|reactivity of HPA axis
197498|NCT01959724|Macular detachment
197499|NCT01959724|Macular retinoschisis
197500|NCT01959724|Vitrectomy
197501|NCT01959711|Lateral transperitoneal laparoscopic adrenalectomy
197502|NCT01959711|Posterior retroperitoneoscopic adrenalectomy
197503|NCT01959646|Immune Function
197504|NCT01959646|Aged Garlic Extract
197505|NCT01959646|Supplementation
197506|NCT01959646|Inflammation
197507|NCT01959620|PTSD
197508|NCT01959607|Smoking
197509|NCT01959607|Nicotine absorption
197510|NCT01959607|Modified risk tobacco product
197511|NCT01959607|Conventional cigarettes
197512|NCT01959607|Nicotine Replacement Therapy gum (NRT gum)
197513|NCT01959594|multiple doses
197514|NCT01959594|pharmacokinetics
197515|NCT01959594|safety
197516|NCT01959594|tolerability
197518|NCT01959594|steady state
197519|NCT01959594|cognitive impairment associated with schizophrenia
197520|NCT01959581|Wilmington Robotic Exoskeleton
197521|NCT01959581|Reaching
197522|NCT01959581|Upper extremity function
197523|NCT01959581|Preterm Infants
197524|NCT01959581|Brain injury
197525|NCT01959581|Pediatrics
197526|NCT01959581|Early Intervention
197527|NCT01959581|Arthrogryposis
197528|NCT01959568|Retinal Detachment
197529|NCT01959568|Double Tamponade
197530|NCT01959568|Perfluorocarbon liquids
197531|NCT01959568|Vitrectomy
197532|NCT01959542|Prostate Cancer
197533|NCT01959516|COPD, early morning symptoms
197534|NCT01959503|Aorta
197535|NCT01959503|Aortic
197536|NCT01959503|Reconstruction
197537|NCT01959503|CABG
197538|NCT01959503|Bypass
197539|NCT01959464|Assisted reproductive technology
197540|NCT01959464|Infertility
197541|NCT01959464|Progesterone
197542|NCT01959464|Vaginal gel
197543|NCT01959464|Luteal-phase support
197544|NCT01959451|Prasugrel
197545|NCT01959451|Clopidogrel
197546|NCT01959438|Phase I study for safety
197547|NCT01959438|Later Phase II study for responses
197548|NCT01959425|Anticoagulation
197549|NCT01959425|Oral
197550|NCT01959425|Paroxysmal atrial fibrillation
197551|NCT01959425|Patients post successful cardiac ablation
197552|NCT01959425|Symptomatic high-burden paroxysmal AF
197553|NCT01959425|3 months post procedure
197554|NCT01959425|Remain free from AF recurrence
197555|NCT01959412|wheezing, short of breath, laba, inhaler
197556|NCT01959399|ASP015K
197557|NCT01959399|healthy subjects
197558|NCT01959360|Arthroplasty, Total Hip Replacement, Hip
197559|NCT01959360|Surgical Procedures, Operative
197560|NCT01959360|Surgical Procedures, Minimally Invasive
197561|NCT01959347|urinary incontinence
197562|NCT01959347|midurethral sling
197563|NCT01959347|pelvic floor therapy
197564|NCT01959334|Diabetes Mellitus
197565|NCT01959334|Hypoglycemia
197566|NCT01959334|Glucagon
197567|NCT01959334|Anti-glucagon Antibody
197568|NCT01959334|Immunogenicity
197569|NCT01959308|Adherence
197570|NCT01959308|Compliance
197571|NCT01959308|Immunosuppressive Therapy
197572|NCT01959308|Liver Transplant
197573|NCT01959308|Liver Recipients
197574|NCT01959308|Adult
197575|NCT01959308|Adolescent
197576|NCT01959282|Colitis, Ulcerative
197577|NCT01959282|JNJ-54781532
197578|NCT01959282|Moderate
197579|NCT01959282|Severe
197580|NCT01959282|Active
197581|NCT01959256|Stroke
197582|NCT01959256|Visual Field Defect
197583|NCT01959256|Visual perceptual learning
197584|NCT01959256|Brain connectivity
197585|NCT01959243|Ocular redness
197586|NCT01959230|Ocular redness
197587|NCT01959217|HIV
197588|NCT01959217|Substance Abuse
197589|NCT01959217|Prospective Memory
197590|NCT01959204|pharmacokinetics
197591|NCT01959204|safety
197592|NCT01959191|Platelet activity, CABG, off-pump surgery
197593|NCT01959165|Ulcerative Colitis, Japanese, subcutaneously
197594|NCT01959152|Cochlear Implant
197595|NCT01959152|HiRes™ 90K Advantage implant
197596|NCT01959152|Cochlear Implantation
197597|NCT01959152|HiFocus™ Mid-Scala electrode
197598|NCT01959152|Listening Benefits
197599|NCT01959152|Adults
197600|NCT01959152|Cochlear Implant Benefit
197601|NCT01959152|HiRes Fidelity 120™
197602|NCT01959152|Electrical Stimulation
197603|NCT01959126|Telomerase
197604|NCT01959126|Telomere length
197605|NCT01959126|Psychological Sress
197606|NCT01959126|Mindfulness
197607|NCT01959113|Microbiome
197608|NCT01959113|Bacteria transplant
197609|NCT01959113|Atopic dermatitis treatments
197610|NCT01959100|hematopoietic stem cell transplantation
197611|NCT01959100|pulmonary non-infectious complications
197612|NCT01959100|bronchiolitis obliterans syndrome
197613|NCT01959087|Single port surgery
197614|NCT01959087|Colonic surgery
197615|NCT01959087|Postoperative morbidity
197616|NCT01959087|Postoperative outcomes
197617|NCT01959061|Advanced colorectal cancer of liver metastatic
197618|NCT01959048|Clostridium difficile associated disease
197619|NCT01959048|fecal microbiota transplantation
197620|NCT01959022|Posttramatic Stress Disorder
197621|NCT01959022|Post-traumatic Stress Disorder
197622|NCT01959022|PTSD
197623|NCT01959022|Doxazosin
197624|NCT01959022|Nightmares
197625|NCT01959022|Sleep Disturbance
197626|NCT01959009|newborn, lung disease, mechanical ventilation, lung recruitment, high frequency ventilation
197627|NCT01958983|dementia
197628|NCT01958983|drumming
197629|NCT01958983|emotion
197630|NCT01958983|cognition
197631|NCT01958983|functional MRI
197632|NCT01958970|End Stage Renal Disease
197633|NCT01958970|ESRD
197634|NCT01958970|Maintenance Hemodialysis
197635|NCT01958970|Hemodialysis
197636|NCT01958970|Dialysis
197637|NCT01958970|MHD
197638|NCT01958970|Protein Energy Wasting
197639|NCT01958970|PEW
197640|NCT01958957|ischemic stroke
197641|NCT01958957|safety
197642|NCT01958957|Ginkgolides Meglumine Injection
197643|NCT01958944|CF
197644|NCT01958944|Cystic Fibrosis
197645|NCT01958944|NO
197646|NCT01958944|nitric oxide
197647|NCT01958944|inhalation
197648|NCT01958918|neovascular AMD
197649|NCT01958918|ranibizumab
197650|NCT01958918|aflibercept
197651|NCT01958918|BCVA
197652|NCT01958918|SD OCT
197653|NCT01958892|BPH
197654|NCT01958879|internal derangement,arthrocentesis,corticosteroid
197655|NCT01958866|Fever
197656|NCT01958866|Body temperature
197657|NCT01958853|Pain
197658|NCT01958840|Behavioral
197659|NCT01958840|Activation
197660|NCT01958840|Treatment
197661|NCT01958827|Dose Escalation
197662|NCT01958827|Crohn's Disease
197663|NCT01958801|Supraclavicular brachial plexus block
197664|NCT01958801|Interscalene brachial plexus block
197665|NCT01958801|Arthroscopic shoulder surgery
197666|NCT01958788|Cognitive-behavioral treatment
197667|NCT01958788|Generalized anxiety disorder
197668|NCT01958788|Worry
197669|NCT01958788|Behavioral experiments
197670|NCT01958788|Safety behaviors
197671|NCT01958788|Anxiety
197672|NCT01958775|Lipoproteins, apoB, GLP-2
197673|NCT01958762|Screening
197674|NCT01958762|Cancer
197675|NCT01958762|Tobacco
197676|NCT01958762|General Practitioner
197677|NCT01958762|Precancerous Lesion
197678|NCT01958762|Dysplasia
197679|NCT01958762|Tobacco vendor
197680|NCT01958723|Problem Specific Template
197681|NCT01958723|Physician Documentation
197682|NCT01958723|Electronic Medical Record Documentation
197683|NCT01958710|Catheterization, Bronchial
197684|NCT01958710|Pneumonectomy
197685|NCT01958710|Lobectomy
197686|NCT01958710|Thoracoplasty
197687|NCT01958697|Nutritional Disorders
197688|NCT01958697|Feeding Behavior
197689|NCT01958684|Bleeding pattern
197690|NCT01958684|LNG-IUS
197691|NCT01958684|Cu-IUD
197692|NCT01958684|postabortion
197693|NCT01958645|Phase 1, healthy male subjects, safety and tolerability, pharmacodynamic, pharmacokinetic
197694|NCT01958619|open label
197695|NCT01958619|healthy volunteers
197696|NCT01958619|pharmacokinetic
197697|NCT01958619|parallel group
197698|NCT01958606|Stroke
197699|NCT01958606|Rehabilitation
197700|NCT01958606|Exercise
197701|NCT01958606|Intensity
197702|NCT01958606|Gait
197703|NCT01958593|PTSD
197704|NCT01958593|Posttraumatic stress disorder
197705|NCT01958593|MDMA
197706|NCT01958593|psychotherapy
197707|NCT01958567|Scleritis
197708|NCT01958567|Episcleritis
197709|NCT01958567|Optical coherence Tomography
197710|NCT01958541|Sleep
197711|NCT01958541|Insomnia
197712|NCT01958541|Suicidal Symptoms
197713|NCT01958541|Suicidal Ideation
197714|NCT01958541|Military Veteran
197715|NCT01958541|Service Member
197716|NCT01958541|Depression
197717|NCT01958515|Radiation Therapy
197718|NCT01958515|Chemotherapy
197719|NCT01958515|Chemoradiation Therapy
197720|NCT01958502|nonunion
197721|NCT01958502|mesenchymal stem cell
197722|NCT01958502|scaffold
197723|NCT01958502|BMP2
197724|NCT01958502|long bone
197725|NCT01958476|Neonatal Abstinence Syndrome
197726|NCT01958476|Opioids
197727|NCT01958463|Clostridium Difficile Infection
197728|NCT01958463|Fecal Microbiota Transplantation
197729|NCT01958450|acne scar
197730|NCT01958450|Laser therapy
197731|NCT01958450|wound healing
197732|NCT01958437|Aging
197733|NCT01958437|Alzheimer's Disease/Dementia
197734|NCT01958437|Cognitive Disorders
197735|NCT01958437|Imaging
197736|NCT01958437|Magnetic Resonance Imaging (MRI)
197737|NCT01958437|Neurology
197738|NCT01958437|Physical Medicine & Rehabilitation
197739|NCT01958437|transcranial direct current stimulation
197740|NCT01958424|metabolic syndrome
197741|NCT01958424|in vitro fertilization
197742|NCT01958424|c reactive protein
197743|NCT01958424|over-weight women
197744|NCT01958424|ovarian stimulation
197745|NCT01958398|Randomized Controlled Trial
197746|NCT01958398|Alcohol
197747|NCT01958398|Internet
197748|NCT01958398|Mobile phone
197749|NCT01958398|Screening
197750|NCT01958398|Brief intervention
197751|NCT01958385|Total Body Weight Loss
197752|NCT01958359|Randomized Controlled Trial
197753|NCT01958359|Alcohol
197754|NCT01958359|Telephone
197755|NCT01958359|Mobile phone
197756|NCT01958359|Screening
197757|NCT01958359|Brief intervention
197758|NCT01958359|IVR-based conversation menu with exercises and vignettes
197759|NCT01958333|Health-Related Physical Fitness
197760|NCT01958333|Aerobic Endurance
197761|NCT01958333|Muscular Endurance
197762|NCT01958333|Flexibility
197763|NCT01958320|patent ductus arteriosus
197764|NCT01958320|patent ductus arteriosus ligation
197765|NCT01958320|necrotizing enterocolitis
197766|NCT01958320|spontaneous intestinal perforation
197767|NCT01958255|tobacco quit rates
197768|NCT01958242|Cardiopulmonary bypass
197769|NCT01958242|pediatric
197770|NCT01958242|blood products
197771|NCT01958242|conservation
197772|NCT01958216|TICE-human-stable isotopes
197773|NCT01958190|Liver transplantation long term renal function
197774|NCT01958190|tacrolimus sirolimus
197775|NCT01958177|stem cell
197776|NCT01958177|cerebellar ataxia
197777|NCT01958177|BMMNC
197778|NCT01958151|colonoscopy
197779|NCT01958151|deep sedation
197780|NCT01958151|anxiety
197781|NCT01958138|Laryngeal Mask Airway
197782|NCT01958138|Propofol
197783|NCT01958138|Isoflurane
197784|NCT01958138|Pediatric patients
197785|NCT01958138|Emergence
197786|NCT01958125|vagus nerve stimulation
197787|NCT01958125|vagal nerve stimulation
197788|NCT01958125|nVNS
197789|NCT01958125|VNS
197790|NCT01958125|cluster headache
197791|NCT01958125|non invasive
197792|NCT01958125|gammacore
197793|NCT01958112|Cervical Cancer
197794|NCT01958112|Cervical
197795|NCT01958112|Cervix
197796|NCT01958099|Injury Prevention
197797|NCT01958086|Neural
197798|NCT01958086|Prosthetic
197799|NCT01958086|brain machine interface
197800|NCT01958086|brain computer interface
197801|NCT01958086|brain control
197802|NCT01958086|paralysis
197803|NCT01958086|tetraplegia
197804|NCT01958086|quadriplegia
197805|NCT01958086|spinal cord injury
197806|NCT01958073|Recurrent Urinary Tract Infection
197807|NCT01958073|Postmenopausal
197808|NCT01958073|Vaginal Estrogen
197809|NCT01958047|Phase I
197810|NCT01958047|ASP3652
197811|NCT01958047|Single dose
197812|NCT01958047|Dietary intake
197813|NCT01958021|HR-positive
197814|NCT01958021|HER2-negative
197815|NCT01958021|Advanced breast cancer
197816|NCT01958021|LEE011
197817|NCT01958021|Letrozole
197818|NCT01958021|CDK
197819|NCT01958021|CDK4
197820|NCT01958021|CDK6
197821|NCT01958021|CDK4/6
197822|NCT01958021|Phase III
197823|NCT01958021|ER-positive
197824|NCT01958021|PR-positive
197825|NCT01958021|Postmenopausal
197826|NCT01957943|Omega 3 lipid emulsions
197827|NCT01957943|Liver transplantation
197828|NCT01957943|Ischemia reperfusion injury
197829|NCT01957943|graft function
197830|NCT01957930|HbA1c
197831|NCT01957930|Iontophoresis
197832|NCT01957930|Intensified insulin treatment
197833|NCT01957930|Ischemic foot ulcer
197834|NCT01957930|Type 1 diabetes
197835|NCT01957917|HIV
197836|NCT01957917|Food Insecurity
197837|NCT01957917|Antiretroviral Therapy
197838|NCT01957904|ArterX, surgical sealant
197839|NCT01957891|Hypoxia
197840|NCT01957891|Multiple wavelengths
197841|NCT01957865|HIV/AIDS
197842|NCT01957865|adherence
197843|NCT01957865|real time monitoring
197844|NCT01957865|SMS
197845|NCT01957865|mHealth
197846|NCT01957865|social support
197847|NCT01957826|mesenchymal
197848|NCT01957826|stem cells
197849|NCT01957826|transendocardial injection
197850|NCT01957826|dilated idiopathic cardiomyopathy
197851|NCT01957826|idiopathic cardiomyopathy
197852|NCT01957813|APHIA AIDS, Population and Health Integrated Assistance
197853|NCT01957813|DIC Drop-in center
197854|NCT01957813|DMPA depot medroxyprogesterone acetate
197855|NCT01957813|DRH Division of Reproductive Health
197856|NCT01957813|FAIR Family AIDS Initiative Response
197857|NCT01957813|FHOK Family Health Options Kenya
197858|NCT01957813|FP Family planning
197859|NCT01957813|FGD Focus group discussion
197860|NCT01957813|FSW Female sex worker
197861|NCT01957813|GSKenya Gold Star Kenya
197862|NCT01957813|HTC HIV testing and counseling
197863|NCT01957813|HIV Human Immunodeficiency Virus
197864|NCT01957813|KNASP Kenya National AIDS Strategic Plan
197865|NCT01957813|MARPS Most at-risk populations
197866|NCT01957813|MoPHS Ministry of Public Health and Sanitation
197867|NCT01957813|MMS Ministry of Medical Services
197868|NCT01957813|NASCOP National AIDS and STI Control Program
197869|NCT01957813|RH Reproductive health
197870|NCT01957813|SRH Sexual and reproductive health
197871|NCT01957813|STI Sexually transmitted infection
197872|NCT01957813|USAID United States Agency for International Development
197873|NCT01957800|weight loss
197874|NCT01957800|healthy diet
197875|NCT01957800|website
197876|NCT01957800|action planning
197877|NCT01957800|phone
197878|NCT01957800|social
197879|NCT01957787|Metastatic lung tumors
197880|NCT01957787|Pulmonary metastatic disease
197881|NCT01957748|Retention
197882|NCT01957748|Care
197883|NCT01957748|Engagement
197884|NCT01957735|metastatic cancer
197885|NCT01957735|solid tumor
197886|NCT01957735|unresectable tumor
197887|NCT01957735|brain cancer
197888|NCT01957735|lymphoma
197889|NCT01957696|Diabetes mellitus
197890|NCT01957696|Pancreas transplantation
197891|NCT01957696|Rejection
197892|NCT01957696|Surgical complications
197893|NCT01957696|Allograft biopsies
197894|NCT01957696|Immunological analyses
197895|NCT01957696|Pancreas graft survival
197896|NCT01957683|intracranial aneurysm
197897|NCT01957683|bifurcation
197898|NCT01957683|wide-neck
197899|NCT01957683|saccular
197900|NCT01957683|endovascular treatment
197901|NCT01957683|coil embolization
197902|NCT01957683|stent
197903|NCT01957683|bare platinum
197904|NCT01957670|Keratoconjunctivitis Sicca
197905|NCT01957670|Dry Eye Syndromes
197906|NCT01957631|Plantar Fasciitis
197907|NCT01957631|Steroid
197908|NCT01957631|Platelet rich plasma
197909|NCT01957631|Injection
197910|NCT01957631|Ultrasound
197911|NCT01957605|prone position
197912|NCT01957605|hemodynamic variation
197913|NCT01957605|mean systemic pressure
197914|NCT01957579|Phase I
197915|NCT01957579|advanced
197916|NCT01957579|B cell malignancies
197917|NCT01957579|dose escalation
197918|NCT01957579|CD19
197919|NCT01957579|Japanese
197920|NCT01957566|propofol sedation
197921|NCT01957566|children
197922|NCT01957566|procedure sedation
197923|NCT01957540|ticagrelor
197924|NCT01957540|prasugrel
197925|NCT01957540|endothelial function
197926|NCT01957527|ticagrelor
197927|NCT01957527|endothelial function
197928|NCT01957527|peripheral arterial tonometry
197929|NCT01957501|Major Depressive Disorder
197930|NCT01957501|Bipolar Disorder
197931|NCT01957501|Adolescents
197932|NCT01957501|Biomarker
197933|NCT01957436|prostate
197934|NCT01957436|cancer
197935|NCT01957436|metastatic hormone-naive
197936|NCT01957436|radiotherapy
197937|NCT01957436|abiraterone acetate
197938|NCT01957423|Crohn's disease
197939|NCT01957423|whey protein
197940|NCT01957423|soy protein
197941|NCT01957423|nutritional status
197942|NCT01957423|activity of disease
197943|NCT01957410|Major Depressive Disorder
197944|NCT01957410|Ketamine
197945|NCT01957410|Evoked potentials
197946|NCT01957410|Somatosensory evoked potentials
197947|NCT01957410|Motor evoked potentials
197948|NCT01957410|Cortical plasticity
197949|NCT01957371|PTSD
197950|NCT01957371|Yoga
197951|NCT01957371|Complementary and Alternative Medicine (CAM)
197952|NCT01957371|Chronic Pain
197953|NCT01957345|constitutional functional disorders of platelets
197954|NCT01957345|platelet signalling defects
197955|NCT01957332|molecular imaging
197956|NCT01957332|HER2-PET
197957|NCT01957332|89Zr-trastuzumab
197958|NCT01957332|FES-PET
197959|NCT01957332|metastatic breast cancer
197960|NCT01957332|clinical utility
197961|NCT01957306|hot flashes, night sweats
197962|NCT01957280|HER3
197963|NCT01957267|Glaucoma
197964|NCT01957267|Optical Coherence Tomography
197965|NCT01957267|Intraocular pressure
197966|NCT01957267|Optic nervehead
197967|NCT01957267|Nerve fiber layer
197968|NCT01957202|levocabastine fixed dose combination, Rhinitis, Allergic, Perennial and Seasonal, Allergic Rhinitis, fluticasone furoate
197969|NCT01957189|pharmacokinetics, Chinese
197970|NCT01957189|Avodart, Duodart, dutasteride, tamsulosin, drug-drug interaction,
197971|NCT01957176|myelodysplastic syndromes
197972|NCT01957176|thrombocytopenia
197973|NCT01957176|acute myeloid leukemia
197974|NCT01957176|, idiopathic thrombocytopenic purpura
197975|NCT01957176|Eltrombopag
197976|NCT01957176|pediatrics
197977|NCT01957163|dry powder inhaler
197978|NCT01957163|fluticasone furoate/vilanterol
197979|NCT01957163|umeclidinium bromide
197980|NCT01957163|safety
197981|NCT01957163|long acting beta2- receptor agonist
197982|NCT01957163|long acting muscarininc receptor antagonist
197983|NCT01957163|efficacy
197984|NCT01957163|COPD
197985|NCT01957163|inhaled corticosteroid
197986|NCT01957137|Urinary
197987|NCT01957137|Urge
197988|NCT01957137|Incontinence
197989|NCT01957098|L-arabinose
197990|NCT01957098|D-xylose
197991|NCT01957098|sucrose
197992|NCT01957098|glucose
197993|NCT01957098|insulin
197994|NCT01957098|C-peptide
197995|NCT01957098|GLP-1
197996|NCT01957085|Hepatitis C
197997|NCT01957072|Cystic fibrosis
197998|NCT01957072|Nutrition
197999|NCT01957072|Weight
198000|NCT01957072|BMI
198001|NCT01957072|Behaviour change
198002|NCT01957059|DMD
198003|NCT01957059|Duchenne muscular dystrophy
198004|NCT01957059|Duchenne
198005|NCT01957059|BMN053
198006|NCT01957059|BioMarin
198007|NCT01957046|Opioid induced constipation
198008|NCT01957046|Laxatives
198009|NCT01957033|whiplash
198010|NCT01957033|neck pain
198011|NCT01957033|manual therapy
198012|NCT01957033|exercise
198013|NCT01957033|dosage
198014|NCT01957007|Phase 1
198015|NCT01957007|dose escalation
198016|NCT01957007|histologically confirmed
198017|NCT01957007|malignancy metastatic
198018|NCT01956994|Whey Protein
198019|NCT01956994|Arterial Stiffness
198020|NCT01956994|Neurovascular Coupling
198021|NCT01956994|Cerebrovascular Reactivity
198022|NCT01956994|Hemodynamics
198023|NCT01956994|Blood Flow
198024|NCT01956994|Pulsatility
198025|NCT01956981|controlled hypotension, dexmedetomidine, magnesium sulfate.
198026|NCT01956968|Shoulder pain, Scapular dyskinesia, Physical examination
198027|NCT01956942|GLAUCOMA
198028|NCT01956942|MICROPULSE
198029|NCT01956942|LASER
198030|NCT01956942|TRABECULOPLASTY
198031|NCT01956942|OPEN ANGLE
198032|NCT01956942|INTRAOCULAR PRESSURE
198033|NCT01956929|Insulin Resistance
198034|NCT01956929|Prediabetic State
198035|NCT01956929|Metformin
198036|NCT01956916|Pulmonary exacerbation
198037|NCT01956916|Inflammation
198038|NCT01956916|Intestinal microbiota
198039|NCT01956903|mesenchymal stem cell transplantation
198040|NCT01956890|Breast neoplasms
198041|NCT01956890|PET
198042|NCT01956890|MRI
198043|NCT01956864|Vitamin D
198044|NCT01956851|insulin, kisspeptin, GLP 1
198045|NCT01956838|food intake
198046|NCT01956838|tastants
198047|NCT01956838|obesity
198048|NCT01956825|non alcoholic fatty liver disease
198049|NCT01956825|LCARNITINE amino acid
198050|NCT01956825|magnesium
198051|NCT01956825|fat content
198052|NCT01956812|clivatuzumab tetraxetan
198053|NCT01956812|90Y-clivatuzumab tetraxetan
198054|NCT01956812|IMMU-107
198055|NCT01956799|MDS
198056|NCT01956799|PMF
198057|NCT01956799|CMML
198058|NCT01956799|AA
198059|NCT01956786|Amlodipine
198060|NCT01956786|Folic Acid
198061|NCT01956786|Homocysteine
198062|NCT01956786|Blood Pressure
198063|NCT01956773|family health history
198064|NCT01956773|prevention
198065|NCT01956773|genetic risk
198066|NCT01956773|clinical decision support
198067|NCT01956760|Insomnia
198068|NCT01956734|glioblastoma
198069|NCT01956734|first recurrence
198070|NCT01956734|temozolomide
198071|NCT01956721|Heart Failure , Skeletal muscle,Calcium,Ryanodine Receptor, Mitochondria, Exercise training, Muscle biopsy, Healthy volunteers
198072|NCT01956669|VEGF
198073|NCT01956669|Pazopanib
198074|NCT01956669|Sarcoma
198075|NCT01956669|GW786034
198076|NCT01956669|Refractory Solid Tumors
198077|NCT01956656|lotus leaf, mouthwash, gingivitis
198078|NCT01956643|sham feeding
198079|NCT01956643|postoperative ileus
198080|NCT01956643|liver transplantation
198081|NCT01956591|Treatment efficacy
198082|NCT01956591|Long-term effects
198083|NCT01956591|Tachyphylaxis
198084|NCT01956591|Undesirable effects
198085|NCT01956591|Side effects
198086|NCT01956591|Self-assessment
198087|NCT01956591|Hyperhidrosis
198088|NCT01956591|Quality of life
198089|NCT01956565|Pulmonary Disease, Chronic Obstructive
198090|NCT01956565|Rehabilitation
198091|NCT01956565|Physiotherapy
198092|NCT01956565|Patient Compliance
198093|NCT01956565|Inspiratory Muscle Training
198094|NCT01956565|Respiratory Muscle Training
198095|NCT01956552|Metastatic breast cancer
198096|NCT01956552|Tumor biopsy
198097|NCT01956552|Phenotype and genotype characterization
198098|NCT01956526|Heart Failure with Preserved Ejection Fraction (HFpEF)
198099|NCT01956526|Diastolic Heart Failure (DHF)
198100|NCT01956526|Diastolic Dysfunction (DD)
198101|NCT01956513|ADC
198102|NCT01956513|breast cancer
198103|NCT01956513|complete pathological response
198104|NCT01956500|glucosamine
198105|NCT01956500|inflammation
198106|NCT01956500|quality of life
198107|NCT01956500|physical function
198108|NCT01956487|Bioequivalence
198109|NCT01956487|RYTHMOL SR®
198110|NCT01956487|Atrial fibrillation
198111|NCT01956487|Propafenone
198112|NCT01956487|Pharmavokinetics
198113|NCT01956474|keratoconus
198114|NCT01956474|cross-linking
198115|NCT01956474|Post-LASIK ectasia
198116|NCT01956474|Pellucid marginal degeneration
198117|NCT01956474|Forme fruste pellucid marginal degeneration
198118|NCT01956474|FFKC
198119|NCT01956474|Radial Keratotomy
198120|NCT01956474|Terrien's Marginal Degeneration
198121|NCT01956461|osteoporosis
198122|NCT01956461|BMD
198123|NCT01956461|teriparatide
198124|NCT01956461|nursing home
198125|NCT01956448|Percutaneous coronary intervention
198126|NCT01956448|DES
198127|NCT01956448|Angina pectoris
198128|NCT01956448|Stent
198129|NCT01956409|breast neoplasms
198130|NCT01956409|18F-FCH PET
198131|NCT01956409|MRI
198132|NCT01956396|male circumcision
198133|NCT01956396|HIV
198134|NCT01956396|Zimbabwe
198135|NCT01956383|male circumcision
198136|NCT01956383|HIV
198137|NCT01956383|Zimbabwe
198138|NCT01956370|Male Circumcision
198139|NCT01956370|HIV Prevention
198140|NCT01956370|Medical Device
198141|NCT01956357|aquatic exercises;
198142|NCT01956357|deep water running;
198143|NCT01956357|diabetes;
198144|NCT01956357|blood glucose;
198145|NCT01956357|inflammation.
198146|NCT01956344|Hoarding Disorder
198147|NCT01956344|Clutter
198148|NCT01956344|CBT
198149|NCT01956344|Cognitive behavior therapy
198150|NCT01956344|fMRI
198151|NCT01956344|Obsessive compulsive disorder (OCD)
198152|NCT01956344|Healthy control
198153|NCT01956331|NSC lung Cancer,Elderly patients,post operative,
198154|NCT01956318|Chronic venous insufficiency
198155|NCT01956318|Varicose vein
198156|NCT01956318|Crenobalneotherapy
198157|NCT01956318|Balneotherapy
198158|NCT01956318|Spa therapy
198159|NCT01956279|Pregnenolone
198160|NCT01956279|Gulf War Veteran
198161|NCT01956279|Fatigue
198162|NCT01956279|Musculoskeletal Pain
198163|NCT01956279|Cognitive Decline
198164|NCT01956279|Placebo Control
198165|NCT01956266|Prosody
198166|NCT01956266|Communication
198167|NCT01956266|Dysarthria
198168|NCT01956253|Bladder Cancer
198169|NCT01956253|Neratinib
198170|NCT01956253|13-2526
198171|NCT01956240|shoulder
198172|NCT01956240|pectoralis minor
198173|NCT01956240|stretching
198174|NCT01956240|scapular kinematics
198175|NCT01956214|hemodialysis
198176|NCT01956214|exercise
198177|NCT01956214|electrical stimulation
198178|NCT01956175|electrical pharyngeal stimulation
198179|NCT01956175|stroke-related dysphagia
198180|NCT01956175|tracheostomy
198181|NCT01956175|decannulation
198182|NCT01956149|gastric cancer
198183|NCT01956149|second-line treatment
198184|NCT01956149|Cabazitaxel
198185|NCT01956149|response
198186|NCT01956045|Intensive Care Units
198187|NCT01956045|Judgment
198188|NCT01956045|Disability Evaluation
198189|NCT01956045|Autonomy
198190|NCT01956032|LCIG
198191|NCT01956032|Parkinson's disease
198192|NCT01956032|levodopa carbidopa intestinal gel
198193|NCT01956032|Telemedicine
198194|NCT01955993|Obesity, adolescence,pharmacokinetics,fentanyl
198195|NCT01955980|CRS
198196|NCT01955980|without polyposis
198197|NCT01955967|Effect
198198|NCT01955967|Lidocaine
198199|NCT01955954|carbon dioxide monitoring
198200|NCT01955954|panic disorder
198201|NCT01955954|biofeedback
198202|NCT01955954|breathing training
198203|NCT01955954|Primary diagnosis
198204|NCT01955941|Uveal melanoma
198205|NCT01955941|brachytherapy
198206|NCT01955941|radiation
198207|NCT01955941|ciliary body
198208|NCT01955941|choroid
198209|NCT01955941|I-125 plaque brachytherapy
198210|NCT01955915|choroid
198211|NCT01955915|tumor
198212|NCT01955915|OCT
198213|NCT01955915|malignant melanoma
198214|NCT01955902|Opioid dependence
198215|NCT01955902|Buprenorphine
198216|NCT01955902|Adherence
198217|NCT01955902|Substance use
198218|NCT01955902|Suboxone
198219|NCT01955889|Exercise
198220|NCT01955889|Rehabilitation
198221|NCT01955889|Telemedicine
198222|NCT01955876|Fosrenol
198223|NCT01955876|hyperphosphatemia
198224|NCT01955876|chronic kidney disease not on dialysis
198225|NCT01955863|Prostatic Neoplasms
198226|NCT01955863|Prostatectomy, Retropubic
198227|NCT01955863|Patient Discharge
198228|NCT01955824|bronchoscopy
198229|NCT01955824|lignocaine
198230|NCT01955824|cough
198231|NCT01955811|platelet transfusion
198232|NCT01955811|Fibrinogen
198233|NCT01955811|blood coagulation
198234|NCT01955811|Thrombocytopenia
198235|NCT01955811|in-vitro experiments
198236|NCT01955811|FGTW
198237|NCT01955811|Fit2012
198238|NCT01955811|factor I
198239|NCT01955811|Fibrin
198240|NCT01955798|Laparoscopy
198241|NCT01955798|Gyneacological
198242|NCT01955798|Entry techniques
198243|NCT01955785|Traumatic brain injury
198244|NCT01955785|Intracranial pressure
198245|NCT01955785|Ventilation
198246|NCT01955785|Respiratory therapy
198247|NCT01955772|Haematopoietic stem cell transplantation
198248|NCT01955772|Malignant hemopathy
198249|NCT01955772|Artificial nutrition
198250|NCT01955694|BAY94-8862
198251|NCT01955694|MR antagonist
198252|NCT01955694|Heart failure
198253|NCT01955694|Japanese patients
198254|NCT01955681|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor retrement.
198255|NCT01955668|11q-deleted relapsed/refractory chronic lymphocytic leukaemia
198256|NCT01955668|Prolymphocytic leukaemia
198257|NCT01955668|B cell lymphomas
198258|NCT01955655|Baclofen
198259|NCT01955655|cerebral palsy
198260|NCT01955655|colic
198261|NCT01955655|crying infant
198262|NCT01955655|recurrent crying spells
198263|NCT01955655|spasticity
198264|NCT01955655|therapy
198265|NCT01955642|Clopidogrel
198266|NCT01955642|Brain Ischemia
198267|NCT01955642|Ischemic attack
198268|NCT01955642|Biological response to clopidogrel
198269|NCT01955616|Parkinson's disease, chronic constipation
198270|NCT01955590|Metacognitive therapy
198271|NCT01955590|Eye Movement Desensitization Reprocessing (EMDR)
198272|NCT01955590|Cognitive therapy
198273|NCT01955577|Vitamin D deficiency
198274|NCT01955577|Ring fixator
198275|NCT01955577|Tibial fracture
198276|NCT01955525|Acute coronary syndrome
198277|NCT01955525|health related quality of life
198278|NCT01955525|mortality
198279|NCT01955486|flight simulation
198280|NCT01955486|middle ear
198281|NCT01955486|Eustachian tube function
198282|NCT01955473|Solid tumors
198283|NCT01955473|Sym004
198284|NCT01955473|Phase 1
198285|NCT01955460|Melanoma
198286|NCT01955460|Metastatic
198287|NCT01955460|T-cells
198288|NCT01955460|Autologous tumor infiltrating lymphocytes
198289|NCT01955460|TIL
198290|NCT01955460|DNRII
198291|NCT01955460|NGFR
198292|NCT01955460|Cyclophosphamide
198293|NCT01955460|Cytoxan
198294|NCT01955460|Neosar
198295|NCT01955460|Mesna
198296|NCT01955460|Mesnex
198297|NCT01955460|Fludarabine
198298|NCT01955460|Fludarabine phosphate
198299|NCT01955460|Fludara
198300|NCT01955460|Interleukin-2
198301|NCT01955460|IL-2
198302|NCT01955460|Aldesleukin
198303|NCT01955460|Proleukin
198304|NCT01955447|Blood glucose
198305|NCT01955421|NSCLC
198306|NCT01955421|stage IIIB
198307|NCT01955421|stage IV)
198308|NCT01955421|confirmed by histology or cytology methods
198309|NCT01955421|Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation
198310|NCT01955408|overactive bladder
198311|NCT01955408|bladder cancer
198312|NCT01955408|Synergo
198313|NCT01955408|urodynamic study
198314|NCT01955395|Relaxation Response Resiliency Program (3RP)
198315|NCT01955395|monoclonal gammopathy of undetermined significance
198316|NCT01955395|smoldering multiple myeloma
198317|NCT01955382|Parasite Clearance Rate
198318|NCT01955382|Parasite Half Life
198319|NCT01955382|Actidose Aqua
198320|NCT01955382|Severe Malaria
198321|NCT01955369|incidence
198322|NCT01955369|phenotype
198323|NCT01955369|mortality
198324|NCT01955356|Scratching
198325|NCT01955356|Endometrial biopsy
198326|NCT01955356|Ongoing embryo implantation
198327|NCT01955356|Assisted reproductive techniques
198328|NCT01955343|Immune response
198329|NCT01955343|Cancer
198330|NCT01955330|CABG, Hybrid, Robotic surgery
198331|NCT01955317|Neonate
198332|NCT01955317|Bangladesh
198333|NCT01955317|Health behavior
198334|NCT01955317|Handwashing
198335|NCT01955317|Developing countries
198336|NCT01955317|Infectious disease
198337|NCT01955291|Virtual Reality, Motor Learning, Rehabilitation, Upper Limb
198338|NCT01955278|Laparoscopic colorectal surgery
198339|NCT01955278|Parastomal hernia
198340|NCT01955278|Prophylactic
198341|NCT01955278|Mesh
198342|NCT01955265|Positive youth development
198343|NCT01955265|Sports / physical activity
198344|NCT01955252|Endemic treponematoses
198345|NCT01955252|Azithromycin
198346|NCT01955252|Mass drug administration
198347|NCT01955252|Eradication
198348|NCT01955239|Head and Neck Cancer
198349|NCT01955239|Radiotherapy
198350|NCT01955239|IMRT
198351|NCT01955239|Stem cell
198352|NCT01955239|Parotid gland
198353|NCT01955213|constipation, methylnaltrexone, opoid
198354|NCT01955200|Stent implantation
198355|NCT01955200|Clopidogrel low response
198356|NCT01955200|Ticagrelor
198357|NCT01955200|Cilostazol
198358|NCT01955200|Clopidogrel
198359|NCT01955187|SEQUENTIAL THERAPY
198360|NCT01955187|PRIMARY MEMBRANOUS NEPHROPATHY
198361|NCT01955187|TACROLIMUS
198362|NCT01955187|RITUXIMAB
198363|NCT01955174|Botulinum toxin
198364|NCT01955174|Esophageal motility disorder
198365|NCT01955174|Distal esophageal spasm
198366|NCT01955148|PTB
198367|NCT01955148|sPTB
198368|NCT01955148|cervical cerclage
198369|NCT01955148|LEEP
198370|NCT01955148|PROM
198371|NCT01955148|short cervix
198372|NCT01955135|Prematurity, Retinopathy, propofol, ketamine, sedation
198373|NCT01955122|polyp/adenoma miss rate
198374|NCT01955122|colonoscopy add-on device
198375|NCT01955122|enhanced screening
198376|NCT01955109|Food allergy
198377|NCT01955109|Immediate hypersensitivity
198378|NCT01955109|Whole peanut extract
198379|NCT01955109|Allergenic product
198380|NCT01955109|Specific Immunotherapy
198381|NCT01955109|Epicutaneous Immunotherapy (EPIT)
198382|NCT01955096|fast-track surgery, laparoscopic gastrectomy
198383|NCT01955083|Obstructive sleep apnea
198384|NCT01955083|snoring
198385|NCT01955083|radiofrequency
198386|NCT01955083|pillar implant
198387|NCT01955083|snore sound analysis
198388|NCT01955070|Informed consent
198389|NCT01955070|Ethics
198390|NCT01955044|neonatal prematurity
198391|NCT01955044|infant, extremely low birth weight
198392|NCT01955044|fatty acids, polyunsaturated
198393|NCT01955031|Telemedicine
198394|NCT01955031|Telemonitoring
198395|NCT01955031|Education
198396|NCT01955031|Nutrition
198397|NCT01955031|Food behaviour
198398|NCT01955031|Weight
198399|NCT01955031|Physical activity
198400|NCT01955031|Glycaemia
198401|NCT01955031|Self-monitoring blood glucose
198402|NCT01955018|computed tomography
198403|NCT01955018|radiation
198404|NCT01955018|screening
198405|NCT01955018|asbestos
198406|NCT01955018|workers
198407|NCT01955018|cancer
198408|NCT01955005|Health Records, Personal
198409|NCT01955005|Delivery of healthcare
198410|NCT01955005|Consumer Participation
198411|NCT01955005|Internet
198412|NCT01954992|glufosfamide
198413|NCT01954992|5-FU
198414|NCT01954992|metastatic pancreatic adenocarcinoma
198415|NCT01954979|Graft versus Host Disease
198416|NCT01954979|ABATACEPT
198417|NCT01954966|Nicotine
198418|NCT01954966|Smoking
198419|NCT01954953|Retinitis Pigmentosa Syndromic
198420|NCT01954953|Congenital Deafness
198421|NCT01954953|Usher Syndrome Retinitis Pigmentosa and Deafness
198422|NCT01954953|Progressive Hearing Loss
198423|NCT01954953|Retinitis Pigmentosa
198424|NCT01954940|Whole body vibration therapy, muscle strength testing, bone health, ambulatory, endurance.
198425|NCT01954927|Pain control
198426|NCT01954914|Plerixafor
198427|NCT01954914|donor
198428|NCT01954914|allogeneic peripheral stam cell donation
198429|NCT01954914|PBSC
198430|NCT01954914|poor donors
198431|NCT01954875|neurodegenerative diseases
198432|NCT01954875|amyotrophic lateral sclerosis
198433|NCT01954875|multiple sclerosis
198434|NCT01954875|Parkinson's Disease
198435|NCT01954862|Water-aided colonoscopy
198436|NCT01954862|Water Immersion colonoscopy
198437|NCT01954862|Water Exchange colonoscopy
198438|NCT01954862|Carbon-dioxide colonoscopy
198439|NCT01954862|Painless unsedated colonoscopy
198440|NCT01954862|Adenoma detection rate
198441|NCT01954862|Mean Adenomas per Procedure
198442|NCT01954849|gingivitis
198443|NCT01954849|inflammation
198444|NCT01954849|plaque
198445|NCT01954849|orthodontics
198446|NCT01954836|short-term fasting
198447|NCT01954836|adjuvant chemotherapy
198448|NCT01954836|toxicity
198449|NCT01954836|side-effects
198450|NCT01954836|ovarial carinoma
198451|NCT01954836|breast cancer
198452|NCT01954823|Multiple sclerosis, Patient-reported outcomes, patient diary
198453|NCT01954810|JECV
198454|NCT01954810|IMOJEV
198455|NCT01954810|Booster response
198456|NCT01954810|Children
198457|NCT01954810|antibody response
198458|NCT01954810|Duration
198459|NCT01954797|Physical fitness
198460|NCT01954797|relaxation
198461|NCT01954797|stroke
198462|NCT01954797|cerebral ischemia
198463|NCT01954797|cerebral perfusion
198464|NCT01954797|biomarkers
198465|NCT01954797|MRI
198466|NCT01954758|Window of implantation
198467|NCT01954758|Personalized embryo transfer
198468|NCT01954758|Fresh embryo transfer
198469|NCT01954758|Delayed embryo transfer
198470|NCT01954758|Elective deferred embryo transfer
198471|NCT01954758|Endometrial receptivity array
198472|NCT01954758|Endometrial receptivity analysis
198473|NCT01954758|Endometrial receptivity test
198474|NCT01954745|Bile Duct Cancer
198475|NCT01954745|intrahepatic cholangiocarcinoma
198476|NCT01954745|extrahepatic cholangiocarcinoma
198477|NCT01954745|Cabozantinib
198478|NCT01954719|Cervix Uteri, Cesarean Section, Infection, Dilatation
198479|NCT01954693|Tuberous Sclerosis
198480|NCT01954693|Everolimus
198481|NCT01954693|Neurocognitive functioning
198482|NCT01954680|bipolar disorder
198483|NCT01954680|child
198484|NCT01954680|adolescent
198485|NCT01954667|Gastroesophageal Reflux Disease; Anthropometric Measures; Leptin
198486|NCT01954641|breast cancer
198487|NCT01954641|lung cancer
198488|NCT01954641|cancer treatments
198489|NCT01954641|racial inequity
198490|NCT01954641|health systems change
198491|NCT01954641|transparency
198492|NCT01954641|accountability
198493|NCT01954628|Exacerbation of COPD
198494|NCT01954628|Unstable COPD
198495|NCT01954615|ACT-281959
198496|NCT01954615|ACT-246475
198497|NCT01954602|Biliary cannulation
198498|NCT01954602|Endoscopic retrograde cholangiopancreatography
198499|NCT01954602|Touch guide-wire techniques
198500|NCT01954602|No touch guide-wire techniques
198501|NCT01954589|ACT-462206
198502|NCT01954589|Selective dual orexin receptor antagonist
198503|NCT01954563|Tuberculosis
198504|NCT01954563|Vaccine
198505|NCT01954563|Immunogenicity
198506|NCT01954550|Exercise
198507|NCT01954550|Dementia
198508|NCT01954550|Cognition
198509|NCT01954550|Brain Volume
198510|NCT01954550|Aging
198511|NCT01954537|Exertional heat illness
198512|NCT01954537|Hydration Status
198513|NCT01954537|Preseason football
198514|NCT01954537|heat stroke
198515|NCT01954511|Stomatognathic diseases;
198516|NCT01954511|Temporomandibular Joint Dysfunction Syndrome
198517|NCT01954498|Randomized controlled trial
198518|NCT01954498|Spermatozoa
198519|NCT01954498|Sperm
198520|NCT01954498|Male Infertility
198521|NCT01954498|Walnuts
198522|NCT01954498|Nutrition
198523|NCT01954498|Male Reproduction
198524|NCT01954485|LaserLok, connective tissue, adhesion
198525|NCT01954472|Portfolio diet
198526|NCT01954472|dietary modification
198527|NCT01954472|hypercholesterolemia
198528|NCT01954472|diabetes
198529|NCT01954472|Exercise
198530|NCT01954472|CVD risk
198531|NCT01954472|glycemic index
198532|NCT01954472|inflammatory biomarkers
198533|NCT01954472|monounsaturated fat
198534|NCT01954472|saturated fat
198535|NCT01954472|nuts
198536|NCT01954472|plant sterols
198537|NCT01954472|vegetable protein
198538|NCT01954472|viscous fiber
198539|NCT01954472|soy
198540|NCT01954459|Type 1 diabetes
198541|NCT01954459|Continuous glucose sensor
198542|NCT01954459|Insupatch
198543|NCT01954433|Cost-effectiveness analyses
198544|NCT01954433|Cost-utility analyses
198545|NCT01954433|Upper extremity
198546|NCT01954433|Orthopedic
198547|NCT01954433|Shoulder arthroplasty
198548|NCT01954433|Rotator cuff tear repair
198549|NCT01954433|Resection interposition suspension arthroplasty
198550|NCT01954420|Pain
198551|NCT01954420|Fatigue
198552|NCT01954420|Sleep
198553|NCT01954420|Cancer
198554|NCT01954420|Relaxation
198555|NCT01954420|Distraction
198556|NCT01954420|Symptoms
198557|NCT01954407|smoking-related messages
198558|NCT01954407|anti-smoking messages
198559|NCT01954407|smoking-related beliefs
198560|NCT01954407|anti-smoking intentions
198561|NCT01954355|advanced solid tumor
198562|NCT01954355|ovarian cancer
198563|NCT01954355|LDE225
198564|NCT01954355|Paclitaxel
198565|NCT01954355|Hedgehog inhibitor
198566|NCT01954342|Pregnancy
198567|NCT01954342|Postpartum
198568|NCT01954329|Biomarkers
198569|NCT01954329|TIA
198570|NCT01954329|Diagnosis
198571|NCT01954316|advanced cancer
198572|NCT01954316|CFI-400945 fumarate
198573|NCT01954316|polo-like kinase 4
198574|NCT01954316|PLK4
198575|NCT01954316|tablet
198576|NCT01954316|dose escalation
198577|NCT01954316|genetic testing
198578|NCT01954290|Stroke
198579|NCT01954290|Brain Edema
198580|NCT01954290|Brain Herniation
198581|NCT01954290|Conivaptan
198582|NCT01954277|Chronic Tension-Type Headache
198583|NCT01954277|Electroacupuncture
198584|NCT01954277|Headache Impact
198585|NCT01954277|BDNF
198586|NCT01954277|TNF
198587|NCT01954264|Saharan Western Africa
198588|NCT01954264|Epidemiology
198589|NCT01954264|Post-Approval Programme study
198590|NCT01954264|Malaria
198591|NCT01954264|Burden of Disease Study
198592|NCT01954251|FLU-D-QIV
198593|NCT01954251|Adults
198594|NCT01954251|Safety
198595|NCT01954251|Immunogenicity
198596|NCT01954251|co-administration
198597|NCT01954251|Herpes zoster
198598|NCT01954238|Anti-coagulant
198599|NCT01954238|Coagulation factor Xa inhibitor
198600|NCT01954225|Fistula in ano
198601|NCT01954225|Bhagandara
198602|NCT01954225|Udumbara sutra
198603|NCT01954212|Oral health
198604|NCT01954199|Sciatica
198605|NCT01954199|Nerve pain
198606|NCT01954199|Low back pain
198607|NCT01954186|Oxytocin
198608|NCT01954186|Active Management of Third Stage of Labour
198609|NCT01954134|Tumor Suppressor Protein p53,
198610|NCT01954134|Iodine Radioisotopes
198611|NCT01954121|Levetiracetam
198612|NCT01954121|Keppra
198613|NCT01954121|Monotherapy
198614|NCT01954121|China
198615|NCT01954121|Epilepsy
198616|NCT01954121|Partial-onset Seizures
198617|NCT01954108|tendinopathy
198618|NCT01954108|hyaluronan
198619|NCT01954108|tendon
198620|NCT01954108|hyaluronic acid
198621|NCT01954108|extracorporeal shock wave
198622|NCT01954095|17-OHPC, Prometrium, Cerclage, Pre-term birth, Short cervix
198623|NCT01954082|Retinopathy
198624|NCT01954082|Prematurity
198625|NCT01954082|Infant, Newborn, Diseases
198626|NCT01954056|NICHD Neonatal Research Network
198627|NCT01954056|Mechanical ventilation
198628|NCT01954056|Intubation
198629|NCT01954056|Neurodevelopmental impairment
198630|NCT01954043|melanoma
198631|NCT01954043|dabrafenib
198632|NCT01954043|BRAF V600
198633|NCT01954043|rabeprazole
198634|NCT01954043|rifampin
198635|NCT01954030|Carboxyamidotriazole Orotate
198636|NCT01954030|CTO
198637|NCT01954030|Bevacizumab
198638|NCT01954030|Avastin
198639|NCT01954030|Malignant Glioma
198640|NCT01954030|Pro00044274
198641|NCT01954030|Desjardins
198642|NCT01954030|Duke
198643|NCT01954030|The Preston Robert Tisch Brain Tumor Center
198644|NCT01953978|Pain
198645|NCT01953978|Analgesia
198646|NCT01953978|Postoperative
198647|NCT01953978|Dexamethasone
198648|NCT01953978|Spine surgery
198649|NCT01953926|Neratinib
198650|NCT01953926|Fulvestrant
198651|NCT01953926|Breast
198652|NCT01953926|Gastroesophageal
198653|NCT01953926|Endometrial Ovarian Cancer
198654|NCT01953926|Biliary Tract
198655|NCT01953926|Solid tumors
198656|NCT01953926|HER2
198657|NCT01953926|Paclitaxel
198658|NCT01953926|Bladder/Urinary Tract
198659|NCT01953900|Sarcoma
198660|NCT01953900|T-Cells
198661|NCT01953900|varicella zoster virus (VZV)
198662|NCT01953900|GD2
198663|NCT01953887|Phase I
198664|NCT01953887|Final formulation EC905
198665|NCT01953887|Solifenacin succinate
198666|NCT01953887|Tamsulosin HCl
198667|NCT01953887|Marketed drugs
198668|NCT01953874|heart failure
198669|NCT01953874|congestive heart failure
198670|NCT01953874|acute decompensated heart failure
198671|NCT01953874|chronic heart failure
198672|NCT01953874|left-sided heart failure
198673|NCT01953874|heart failure decompensation
198674|NCT01953874|sleep apnea
198675|NCT01953874|sleep disordered breathing
198676|NCT01953874|central sleep apnea
198677|NCT01953874|obstructive sleep apnea
198678|NCT01953874|cheyne-stokes respiration
198679|NCT01953861|Phase I
198680|NCT01953861|Combination tablet EC905
198681|NCT01953861|Omnic OCAS®
198682|NCT01953861|Vesicare®
198683|NCT01953861|Food effect
198684|NCT01953861|Vesomni
198685|NCT01953861|VesiFlow
198686|NCT01953861|Urizia
198687|NCT01953848|Phase I
198688|NCT01953848|Combination tablet EC905
198689|NCT01953848|Steady-state
198690|NCT01953848|Vesomni
198691|NCT01953848|VesiFlow
198692|NCT01953848|Urizia
198693|NCT01953835|Pharmacokinetics
198694|NCT01953835|GSK2586184
198695|NCT01953835|Simvastatin
198696|NCT01953835|Rosuvastatin
198697|NCT01953835|Poloxamer
198698|NCT01953822|Observational
198699|NCT01953822|Cohort
198700|NCT01953822|Autoimmune disease
198701|NCT01953822|Cervarix®
198702|NCT01953822|Women aged 9 to 25 years
198703|NCT01953822|United Kingdom
198704|NCT01953809|oral
198705|NCT01953809|oral contraceptive
198706|NCT01953809|pharmacokinetics
198707|NCT01953809|drug interaction
198708|NCT01953809|pharmacodynamics
198709|NCT01953809|GSK1322322
198710|NCT01953809|antibiotic
198711|NCT01953809|safety
198712|NCT01953796|Polycystic Ovarian Syndrome stair step traditional protocol
198713|NCT01953770|Acute lymphoblastic leukemia, children, adolescents, L-asparaginase, methotrexate
198714|NCT01953757|diabetic neuropathy, diet, vegan, vegetarian
198715|NCT01953744|Fluconazole; Meglumine antimoniate;L.Braziliensis;
198716|NCT01953744|L.Guyanensis
198717|NCT01953731|palbociclib
198718|NCT01953731|PD-0332991
198719|NCT01953731|rifampin
198720|NCT01953731|drug-drug interaction study
198721|NCT01953705|omega 3 fatty acids
198722|NCT01953705|cognitive decline
198723|NCT01953705|MRI
198724|NCT01953705|endothelial function
198725|NCT01953705|white matter
198726|NCT01953705|executive function
198727|NCT01953705|prevention
198728|NCT01953705|DTI
198729|NCT01953705|ASL
198730|NCT01953692|PD1
198731|NCT01953692|PD-1
198732|NCT01953692|PDL1
198733|NCT01953692|PD-L1
198734|NCT01953666|word prediction software, text input speed, copm, occupational therapist, rehabilitation, spinal cord injury
198735|NCT01953614|quantitative encephalography
198736|NCT01953614|brain computer interface
198737|NCT01953614|chiropractic
198738|NCT01953614|sacro-occipital technique
198739|NCT01953575|Mucosal Impedance
198740|NCT01953575|Eosinophilic Esophagitis
198741|NCT01953575|EoE
198742|NCT01953562|infants
198743|NCT01953562|NICU
198744|NCT01953562|intubated
198745|NCT01953562|ventilator
198746|NCT01953549|physical activity, relaxation, activities of daily living, motor functions, cognitive functions
198747|NCT01953523|erectile dysfunction
198748|NCT01953523|peyronies
198749|NCT01953523|interstitial cystitis
198750|NCT01953523|cardiomyopathy
198751|NCT01953523|emphysema
198752|NCT01953523|copd
198753|NCT01953523|arthritis
198754|NCT01953523|multiple sclerosis
198755|NCT01953523|parkinson's
198756|NCT01953510|Pneumococcal vaccines
198757|NCT01953510|10-valent pneumococcal vaccine
198758|NCT01953510|13-valent pneumococcal vaccine
198759|NCT01953510|Immunization Schedule
198760|NCT01953510|Public Health
198761|NCT01953458|Hepatitis B and C
198762|NCT01953458|ANRS HEPATHER French Cohort
198763|NCT01953432|Cocaine-Related Disorders
198764|NCT01953432|Cocaine
198765|NCT01953432|Doxazosin
198766|NCT01953432|Cardiovascular Agents
198767|NCT01953432|Antihypertensive Agents
198768|NCT01953432|Adrenergic alpha-1 Receptor Antagonists
198769|NCT01953432|Adrenergic alpha-Antagonists
198770|NCT01953432|Adrenergic Antagonists
198771|NCT01953432|Molecular Mechanisms of Pharmacological Action
198772|NCT01953432|Neurotransmitter Agents
198773|NCT01953432|Therapeutic Uses
198774|NCT01953432|Pharmacologic Actions
198775|NCT01953432|Substance-Related Disorders
198776|NCT01953406|hepatocellular carcinoma
198777|NCT01953406|lung metastasis
198778|NCT01953406|5-fluorouracil/mitomycin
198779|NCT01953380|Intervention Studies
198780|NCT01953380|Eczema
198781|NCT01953380|Randomized Controlled Trial
198782|NCT01953380|Knowledge
198783|NCT01953380|Quality of Life
198784|NCT01953367|Bioequivalence
198785|NCT01953367|AUC
198786|NCT01953367|Cmax
198787|NCT01953354|Ulcerative colitis (UC)
198788|NCT01953354|Inflammatory Bowel Disease (IBD)
198789|NCT01953354|Trichuris suis ova (TSO)
198790|NCT01953341|Migraine
198791|NCT01953328|Japanese, high cholesterol, LDL-C, High Cardiovascular Risk
198792|NCT01953315|urinary incontinence, muscle progenitor cells, MPCs
198793|NCT01953302|ventral hernia
198794|NCT01953302|infection
198795|NCT01953302|hematoma
198796|NCT01953302|seroma
198797|NCT01953302|recurrence
198798|NCT01953302|mesh technique
198799|NCT01953289|Appendicitis
198800|NCT01953289|Free fluid
198801|NCT01953276|Acute Coronary Syndrome
198802|NCT01953276|Chest pain
198803|NCT01953276|Electrocardiograms
198804|NCT01953276|Risk Stratification
198805|NCT01953276|Emergency Department
198806|NCT01953263|urinary incontinence, muscle fibers
198807|NCT01953250|Deep infiltrating endometriosis
198808|NCT01953250|Laparoscopic sigmoid resection
198809|NCT01953250|laparoscopic rectum resection
198810|NCT01953250|Colorectal surgery
198811|NCT01953237|Schizophrenia
198812|NCT01953237|antipsychotic medication adherence
198813|NCT01953237|mobile phones
198814|NCT01953224|Physical activity
198815|NCT01953224|Video game
198816|NCT01953224|Mobile
198817|NCT01953224|Technology
198818|NCT01953224|Obesity
198819|NCT01953198|hypoxia hypobaric
198820|NCT01953185|elderly
198821|NCT01953185|subjects
198822|NCT01953146|PCOS
198823|NCT01953107|Anemia
198824|NCT01953107|Ovarian cancer
198825|NCT01953107|Uterine cancer
198826|NCT01953107|Cervical cancer
198827|NCT01953107|Oral iron
198828|NCT01953094|Cervical
198829|NCT01953081|Enteral feeding
198830|NCT01953068|POCD
198831|NCT01953068|Executive Reaction Time Test
198832|NCT01953068|Aortic valve surgery
198833|NCT01953068|Cognitive functions
198834|NCT01953068|Transcatheter Aortic Valve Implantation
198835|NCT01953055|stereotactic ablative radiotherapy
198836|NCT01953055|androgen deprivation therapy
198837|NCT01953042|Obsessive-Compulsive Disorder
198838|NCT01953042|Health Education
198839|NCT01953016|ADA-SCID
198840|NCT01953016|Adenosine Deaminase Deficiency
198841|NCT01953016|Wiskott Aldrich Syndrome
198842|NCT01953016|Severe Combined Immune Deficiency
198843|NCT01953016|Primary Immunodeficiency
198844|NCT01952990|Pharmacokinetic
198845|NCT01952964|exit site infection
198846|NCT01952964|skin allergy
198847|NCT01952964|physical damage
198848|NCT01952951|rectal neoplasms
198849|NCT01952951|radiotherapy
198850|NCT01952951|Antineoplastic Agents
198851|NCT01952938|knee revision surgery,
198852|NCT01952938|rotating hinge prosthesis
198853|NCT01952899|Intensive Care Unit
198854|NCT01952899|Delirium
198855|NCT01952899|Implementation
198856|NCT01952899|Guideline
198857|NCT01952886|malignant glioma
198858|NCT01952886|antiemetic
198859|NCT01952886|ondansetron
198860|NCT01952886|granisetron
198861|NCT01952886|Preston Robert Tisch Brain Tumor Center
198862|NCT01952886|Pro00041233
198863|NCT01952886|Duke
198864|NCT01952873|stents
198865|NCT01952873|angioplasty, balloon, coronary
198866|NCT01952873|coronary artery stenosis
198867|NCT01952873|optical coherence tomography
198868|NCT01952860|Lung Cancer
198869|NCT01952860|Non-small cell lung cancer
198870|NCT01952860|NSCLC
198871|NCT01952860|Caregiving partner
198872|NCT01952860|Hatha Yoga
198873|NCT01952860|Radiation therapy
198874|NCT01952860|XRT
198875|NCT01952860|Questionnaires
198876|NCT01952860|Surveys
198877|NCT01952847|Advanced Cancers
198878|NCT01952847|Mucositis
198879|NCT01952847|Esophagitis
198880|NCT01952847|mTOR Inhibitor-based Regimen
198881|NCT01952847|Radiation to the Esophagus
198882|NCT01952847|Thoracic malignancies
198883|NCT01952847|Placebo
198884|NCT01952847|Glutamine
198885|NCT01952847|Enterex
198886|NCT01952847|Glutapak-10
198887|NCT01952847|NutreStore
198888|NCT01952847|Resource
198889|NCT01952847|GlutaSolve
198890|NCT01952847|Sympt-X G.I.
198891|NCT01952847|Sympt-X
198892|NCT01952847|Questionnaires
198893|NCT01952847|Surveys
198894|NCT01952834|coronary artery disease
198895|NCT01952834|probiotic
198896|NCT01952834|endothelial function
198897|NCT01952834|brachial artery
198898|NCT01952834|ntric oxide
198899|NCT01952821|Head and Neck Cancer
198900|NCT01952821|Physical function
198901|NCT01952821|Cancer Related Fatigue
198902|NCT01952821|Gait Speed
198903|NCT01952821|6MWT
198904|NCT01952821|10-Meter Walk Test
198905|NCT01952821|30-Second Chair Stand
198906|NCT01952821|Linear Analog Scale of Function
198907|NCT01952821|Modified Brief Fatigue Inventory
198908|NCT01952769|anti PD1,diffuse pontine glioma
198909|NCT01952756|cilostazol
198910|NCT01952756|endothelial progenitor cells
198911|NCT01952756|vasculogenesis
198912|NCT01952756|angiogenesis
198913|NCT01952756|peripheral arterial disease
198914|NCT01952756|biomarkers
198915|NCT01952743|Atrial Fibrillation
198916|NCT01952743|Hypertension
198917|NCT01952743|Renal Denervation
198918|NCT01952730|Stage IV
198919|NCT01952730|Hepatic Lesions
198920|NCT01952691|hallux valgus
198921|NCT01952691|pain
198922|NCT01952691|conservative
198923|NCT01952691|treatment
198924|NCT01952678|DaTscan
198925|NCT01952678|Parkinson's Disease
198926|NCT01952652|Naproxen-codeine
198927|NCT01952652|preemptive analgesia
198928|NCT01952652|day case surgery
198929|NCT01952626|intrathecal
198930|NCT01952626|morphine
198931|NCT01952626|ondansetron
198932|NCT01952626|palonosetron
198933|NCT01952626|pruritus
198934|NCT01952613|Foot drop
198935|NCT01952613|Functional Electrical Stimulation
198936|NCT01952600|Chronic Kidney Disease
198937|NCT01952600|Hemodialysis
198938|NCT01952600|Peritoneal Dialysis
198939|NCT01952574|migraine, headache, prevention, prophylaxis
198940|NCT01952561|pharmacokinetics
198941|NCT01952561|vaginal ring
198942|NCT01952522|Resistance training
198943|NCT01952522|Walking
198944|NCT01952522|Weight bearing
198945|NCT01952496|Cerebral Palsy
198946|NCT01952496|Non ambulatory
198947|NCT01952496|Neuromuscular disability
198948|NCT01952496|Children
198949|NCT01952483|Multiple Sclerosis (MS)
198950|NCT01952470|Lung transplantation
198951|NCT01952470|Respiratory Tract Infections
198952|NCT01952470|Respiratory Therapy
198953|NCT01952470|Isotonic Solutions
198954|NCT01952470|Sodium Chloride
198955|NCT01952470|Postoperative complications
198956|NCT01952470|Postoperative care
198957|NCT01952470|dornase alpha
198958|NCT01952431|Total Lung Capacity
198959|NCT01952392|Effectiveness study
198960|NCT01952392|Acute coronary Syndrome
198961|NCT01952392|Real-life
198962|NCT01952392|France
198963|NCT01952379|Melasma
198964|NCT01952379|Lymphocytes
198965|NCT01952379|Macrophages
198966|NCT01952379|Mast cells
198967|NCT01952379|Interleukin 17
198968|NCT01952379|COX-2
198969|NCT01952379|Inflammation
198970|NCT01952366|Aged
198971|NCT01952366|Depression
198972|NCT01952366|Cognition
198973|NCT01952366|Longitudinal study
198974|NCT01952353|Hepatocellular Carcinoma; Transarterial Chemoembolization; Hepatic Resection; Portal Vein Tumor Thrombosis
198975|NCT01952301|Autologous; Collagen Matrix; Keratinized Tissue
198976|NCT01952262|ultrasound
198977|NCT01952262|diaphragm
198978|NCT01952262|intensive care
198979|NCT01952262|critical care
198980|NCT01952249|Ovarian
198981|NCT01952249|Primary Peritoneal
198982|NCT01952249|Fallopian Tube Cancer
198983|NCT01952236|Smoking
198984|NCT01952236|Quit
198985|NCT01952236|Tobacco
198986|NCT01952236|Abstinence
198987|NCT01952236|Adult
198988|NCT01952236|Text Messaging
198989|NCT01952236|Web-based
198990|NCT01952236|Mobile phone
198991|NCT01952236|smartphone
198992|NCT01952236|internet
198993|NCT01952236|web
198994|NCT01952223|adenocarcinome
198995|NCT01952223|prostate
198996|NCT01952223|relapse
198997|NCT01952223|Radiotherapy
198998|NCT01952223|Androgen Deprivation Therapy
198999|NCT01952223|Cabazitaxel
199000|NCT01952197|Passive Leg Raise
199001|NCT01952197|Cardiac arrest
199002|NCT01952197|Survival after CPR
199003|NCT01952184|vitrification
199004|NCT01952184|oocyte
199005|NCT01952184|donor
199006|NCT01952184|open
199007|NCT01952184|closed
199008|NCT01952171|Genomics
199009|NCT01952171|Congenital Malformations
199010|NCT01952171|Birth Defects
199011|NCT01952171|Heart Disease
199012|NCT01952158|Multidrug-Resistant Organisms
199013|NCT01952158|Hospital Infection
199014|NCT01952158|Colonization
199015|NCT01952158|Healthcare Personnel
199016|NCT01952132|Schizophrenia
199017|NCT01952119|hypertension
199018|NCT01952106|venepuncture
199019|NCT01952106|distraction
199020|NCT01952106|distress
199021|NCT01952093|Early intervention
199022|NCT01952093|Mother-child interaction
199023|NCT01952093|Neurodevelopment
199024|NCT01952093|Parenting
199025|NCT01952093|Prematurity
199026|NCT01952093|School age
199027|NCT01952080|Short Bowel Syndrome
199028|NCT01952080|SBS
199029|NCT01952080|Pediatric SBS
199030|NCT01952067|Hip Prosthesis
199031|NCT01952067|surgery
199032|NCT01952067|cements
199033|NCT01952067|Radiostereometric Analysis
199034|NCT01952054|Breast cancer
199035|NCT01952054|Breast carcinoma
199036|NCT01952054|Bone metastasis
199037|NCT01952054|Cancer that has spread to the bone
199038|NCT01952054|Denosumab
199039|NCT01952054|AMG 162
199040|NCT01952054|Prolia
199041|NCT01952054|Hormonal agent
199042|NCT01952041|Schizophrenia
199043|NCT01952041|Schizoaffective Disorder
199044|NCT01952041|Mobile Application
199045|NCT01952041|Relapse Signature
199046|NCT01952041|Relapse
199047|NCT01952041|SMI
199048|NCT01952041|EHealth
199049|NCT01952041|E-Health
199050|NCT01952041|Health Technology
199051|NCT01952041|mHealth
199052|NCT01952041|m-Health
199053|NCT01952028|MDC1A
199054|NCT01952028|Congenital Muscular Dystrophy
199055|NCT01952028|Merosin Deficient
199056|NCT01952028|LAMA2
199057|NCT01952028|brain white matter abnormalities
199058|NCT01952028|Seizure
199059|NCT01952015|generalized pustular psoriasis
199060|NCT01952002|Blood Pressure
199061|NCT01952002|heart rate
199062|NCT01952002|electrocardiogram
199063|NCT01952002|Cardiac arrhythmias
199064|NCT01952002|respiratory exercise
199065|NCT01951989|Gaucher disease
199066|NCT01951989|Imiglucerase
199067|NCT01951989|Pharmacokinetics
199068|NCT01951976|breast
199069|NCT01951976|carcinoma
199070|NCT01951976|stage 0-III breast cancer
199071|NCT01951976|post-menopausal
199072|NCT01951976|aromatase inhibitor (AI)
199073|NCT01951976|joint pain
199074|NCT01951976|AI-associated joint pain
199075|NCT01951963|pain management
199076|NCT01951963|ketamine
199077|NCT01951963|morphine
199078|NCT01951963|pediatrics
199079|NCT01951963|emergency medicine
199080|NCT01951937|Cognitive Test
199081|NCT01951937|Omega-3 Fatty acids
199082|NCT01951924|Multifocal Motor Neuropathy
199083|NCT01951911|Pain Management
199084|NCT01951911|Ketamine
199085|NCT01951911|Palliative care
199086|NCT01951898|asthma
199087|NCT01951898|regulatory T cells
199088|NCT01951898|leukotriene antagonist
199089|NCT01951872|caffeine dependence
199090|NCT01951872|caffeine withdrawal
199091|NCT01951872|caffeine use disorder
199092|NCT01951833|Lung clearance index (LCI)
199093|NCT01951807|Psychosocial Effects of Cancer and Treatment
199094|NCT01951807|Coping
199095|NCT01951794|HIV infected
199096|NCT01951794|HIV exposed
199097|NCT01951794|HIV-free
199098|NCT01951781|marker CD64
199099|NCT01951781|blood sample
199100|NCT01951781|nosocomial infection
199101|NCT01951781|preterm newborn
199102|NCT01951755|Inoperable NSCLC
199103|NCT01951755|TKIs
199104|NCT01951742|wrinkles
199105|NCT01951729|Blood sugar
199106|NCT01951729|GIP
199107|NCT01951729|Xenin-25
199108|NCT01951729|Cholinergic Signaling
199109|NCT01951729|Atropine
199110|NCT01951729|Insulin
199111|NCT01951729|Glucagon
199112|NCT01951729|Pancreatic polypeptide
199113|NCT01951716|Vagotomy
199114|NCT01951716|Vagus Nerve
199115|NCT01951716|Xenin-25
199116|NCT01951716|GIP
199117|NCT01951716|Insulin Secretion
199118|NCT01951716|Glucagon Secretion
199119|NCT01951716|Gastric Emptying
199120|NCT01951690|Focal Adhesion Kinase inhibitor
199121|NCT01951690|FAK inhibitor
199122|NCT01951690|Cancer Stem Cells
199123|NCT01951690|CSC
199124|NCT01951690|KRAS mutation
199125|NCT01951677|hepatitis B virus
199126|NCT01951677|vaccine
199127|NCT01951677|adjuvant
199128|NCT01951677|prophylaxis
199129|NCT01951651|Diabetes
199130|NCT01951638|Worsening Heart Failure
199131|NCT01951638|Heart Failure with Preserved Ejection Fraction
199132|NCT01951625|Worsening Heart Failure
199133|NCT01951625|Heart Failure with Reduced Ejection Fraction
199134|NCT01951612|cognitive impairment
199135|NCT01951612|ischemic white matter disease
199136|NCT01951612|small vessel disease
199137|NCT01951612|transient ischemic attack
199138|NCT01951612|mild stroke
199139|NCT01951612|stroke risk
199140|NCT01951599|Phase I, healthy, bioavailability, pharmacokinetics, safety, tolerability.
199141|NCT01951573|contact lenses
199142|NCT01951573|multifocal
199143|NCT01951573|daily disposable
199144|NCT01951573|silicone hydrogel
199145|NCT01951573|presbyopia
199146|NCT01951547|HbA1c
199147|NCT01951547|hs-CRP
199148|NCT01951547|non-surgical periodontal therapy
199149|NCT01951547|oral health education
199150|NCT01951547|probing pocket depth
199151|NCT01951547|plaque index
199152|NCT01951547|gingival bleeding index.
199153|NCT01951534|breast reconstruction
199154|NCT01951521|Rectal cancer
199155|NCT01951521|Locally advanced rectal cancer
199156|NCT01951521|Radiotherapy
199157|NCT01951521|Boost
199158|NCT01951521|Dose-escalation
199159|NCT01951521|Pathological complete response
199160|NCT01951521|Response
199161|NCT01951508|Methylphenidate
199162|NCT01951508|Modafinil
199163|NCT01951508|MDMA
199164|NCT01951508|fMRI
199165|NCT01951508|emotion-processing
199166|NCT01951508|social cognition
199167|NCT01951456|Smoking cessation
199168|NCT01951456|resistance training
199169|NCT01951443|ginseng
199170|NCT01951443|clinical trial
199171|NCT01951443|vascular
199172|NCT01951443|ginsenosides
199173|NCT01951443|blood pressure
199174|NCT01951430|Adult patients
199175|NCT01951430|Infective events
199176|NCT01951430|Antibiotic
199177|NCT01951430|Antifungal
199178|NCT01951430|Myelodysplastic syndrome
199179|NCT01951404|Left Ventricular Hypertrophy
199180|NCT01951404|Allopurinol
199181|NCT01951404|End Stage Renal Disease
199182|NCT01951404|Haemodialysis
199183|NCT01951404|Renal Replacement Therapy
199184|NCT01951404|MRI
199185|NCT01951391|study
199186|NCT01951391|subjects
199187|NCT01951378|Asthma
199188|NCT01951378|Asthma exacerbation
199189|NCT01951365|Schwannoma
199190|NCT01951365|Growth
199191|NCT01951365|intradural
199192|NCT01951365|natural history
199193|NCT01951352|study
199194|NCT01951352|meant
199195|NCT01951352|individuals
199196|NCT01951339|diabetes
199197|NCT01951339|type 2 diabetes
199198|NCT01951339|exercise
199199|NCT01951339|echo
199200|NCT01951339|heart
199201|NCT01951339|sitagliptin
199202|NCT01951339|glimepiride
199203|NCT01951339|cardiovascular
199204|NCT01951326|Crohn's Disease
199205|NCT01951326|moderate to severe
199206|NCT01951326|remission
199207|NCT01951326|MAP
199208|NCT01951326|antibiotic
199209|NCT01951313|Meal tolerance test focusing on carotenoids absorption
199210|NCT01951261|Telemonitoring
199211|NCT01951261|COPD
199212|NCT01951261|Home care
199213|NCT01951248|chronic kidney disease
199214|NCT01951248|obstructive sleep apnea
199215|NCT01951248|24-h blood pressure
199216|NCT01951248|central blood pressure
199217|NCT01951248|peripheral blood pressure
199218|NCT01951222|Asthma, COPD, broncodilator, airway, lung, inhalation, antimuscarinic
199219|NCT01951209|Human
199220|NCT01951209|Hepatitis C
199221|NCT01951209|Cirrhosis
199222|NCT01951209|B-cell
199223|NCT01951209|Rifaximin
199224|NCT01951196|Chronic kidney disease
199225|NCT01951196|24 hour blood pressure
199226|NCT01951196|central blood pressure
199227|NCT01951196|peripheral blood pressure
199228|NCT01951196|obstructive sleep apnea
199229|NCT01951144|Phase 1
199230|NCT01951144|Single Dose
199231|NCT01951144|Pharmacokinetics
199232|NCT01951144|Safety
199233|NCT01951144|Toleration
199234|NCT01951144|Pharmacodynamics
199235|NCT01951118|Smell
199236|NCT01951118|Olfaction Disorders
199237|NCT01951118|Atropine
199238|NCT01951118|Donepezil
199239|NCT01951118|Cholinesterase Inhibitors
199240|NCT01951118|Cognition Disorders
199241|NCT01951105|Subacute
199242|NCT01951105|Back
199243|NCT01951105|Pain
199244|NCT01951105|Brain
199245|NCT01951105|MRI
199246|NCT01951092|HIV
199247|NCT01951092|adherence
199248|NCT01951092|retention
199249|NCT01951092|texting
199250|NCT01951079|Digoxin
199251|NCT01951079|Intra-amniotic injection
199252|NCT01951079|feticide
199253|NCT01951079|second trimester abortion
199254|NCT01951053|Healthy
199255|NCT01951053|Safety
199256|NCT01951053|Tolerability
199257|NCT01951053|Pharmacokinetics
199258|NCT01951053|Pharmacodynamics
199259|NCT01951053|JNJ-40411813
199260|NCT01951053|Positive allosteric modulator
199261|NCT01951040|Oxytocin, breastfeeding
199262|NCT01951027|Safety
199263|NCT01951027|Pharmacokinetics
199264|NCT01951027|Pharmacodynamics
199265|NCT01951027|DLT
199266|NCT01951027|Immunogenecity
199267|NCT01951014|Adolescence
199268|NCT01951014|Pregnancy
199269|NCT01951014|Telemedicine
199270|NCT01951001|Acute Coronary Syndrome, Asians, platelet, prasugrel
199271|NCT01950936|Infection
199272|NCT01950936|Antibiotics
199273|NCT01950936|COLD
199274|NCT01950910|Amyotrophic lateral sclerosis
199275|NCT01950910|motor neuron disease
199276|NCT01950910|biological markers
199277|NCT01950910|biomarkers
199278|NCT01950897|muscular dystrophies
199279|NCT01950897|muscular dystrophy
199280|NCT01950884|•Non-alcoholic Steatohepatitis (NASH)
199281|NCT01950871|HistoScanning
199282|NCT01950871|TRUS
199283|NCT01950871|Prostate cancer
199284|NCT01950871|Biopsy guidance
199285|NCT01950845|anesthesiology, Closed-Loop system, automated fluid management, cardiac output optimization, high risk surgical patient, major abdominal surgery
199286|NCT01950832|Structure of Retina
199287|NCT01950832|Macular Thickness
199288|NCT01950832|Retinal Nerve Fiber Layer
199289|NCT01950832|Choroidal Thickness
199290|NCT01950832|PCOS
199291|NCT01950832|Optical Coherence Tomography
199292|NCT01950819|kidney failure
199293|NCT01950819|dialysis
199294|NCT01950819|renal failure
199295|NCT01950819|transplantation
199296|NCT01950793|Hyaluronic acid, trigger finger
199297|NCT01950780|Alopecia Areata
199298|NCT01950780|Ruxolitinib
199299|NCT01950728|volunteers
199300|NCT01950728|18 to 65 years
199301|NCT01950728|Females
199302|NCT01950715|Irritable Bowel Syndrome
199303|NCT01950715|Sacral Nerve Stimulation
199304|NCT01950715|Gastro-colic response
199305|NCT01950715|Multimodal Stimulation
199306|NCT01950663|Diagnostic Equipment
199307|NCT01950663|Validation Studies
199308|NCT01950624|Patient Registry
199309|NCT01950624|Down Syndrome
199310|NCT01950611|acute promyelocytic leukemia
199311|NCT01950611|arsenic trioxide
199312|NCT01950611|proteasome inhibition
199313|NCT01950611|bortezomib
199314|NCT01950598|Boston Keratoprosthesis type I surgery, frozen corneal graft
199315|NCT01950585|Hydroxyurea
199316|NCT01950585|Pulmonary Hypertension
199317|NCT01950585|Idiopathic Pulmonary Arterial Hypertension
199318|NCT01950585|Familial Pulmonary Arterial Hypertension
199319|NCT01950585|CD34 + Cells
199320|NCT01950572|Samples
199321|NCT01950572|Biobank
199322|NCT01950572|Pleural Mesothelioma
199323|NCT01950572|Peritoneal Mesothelioma
199324|NCT01950559|soy allergy
199325|NCT01950559|food allergy
199326|NCT01950559|pediatric
199327|NCT01950559|adult
199328|NCT01950546|silver nanoparticles
199329|NCT01950546|antimicrobial activity
199330|NCT01950546|toxicity
199331|NCT01950546|biofilm
199332|NCT01950546|cariostatic agents
199333|NCT01950533|Peanut allergy
199334|NCT01950533|Milk allergy
199335|NCT01950533|Egg allergy
199336|NCT01950533|Pediatric
199337|NCT01950533|Adult
199338|NCT01950533|Food allergy
199339|NCT01950520|Adipose Tissue
199340|NCT01950520|Adult
199341|NCT01950520|Body Composition
199342|NCT01950520|Brown Adipose Tissue
199343|NCT01950520|Non-Shivering Thermogenesis
199344|NCT01950507|Fluconazole
199345|NCT01950507|Graft Versus Host Disease
199346|NCT01950507|Voriconazole
199347|NCT01950507|Azoles
199348|NCT01950494|hand dermatitis
199349|NCT01950494|health care workers
199350|NCT01950494|hand sanitizer
199351|NCT01950481|LDK378
199352|NCT01950481|pharmacokinetics
199353|NCT01950481|hepatic impairment
199354|NCT01950468|Parkinson's Disease
199355|NCT01950455|Parkinson's Disease
199356|NCT01950442|malignant strictures
199357|NCT01950442|esophageal staging
199358|NCT01950429|Microbiome
199359|NCT01950429|Sickle Cell Disease
199360|NCT01950429|Bone Marrow Transplant
199361|NCT01950416|ST elevation myocardial infarction
199362|NCT01950416|Fibrinolysis
199363|NCT01950416|Ticagrelor
199364|NCT01950416|Clopidogrel
199365|NCT01950416|Platelet reactivity
199366|NCT01950377|Dopamine Transporter
199367|NCT01950377|D2 Dopamine Receptor Subtype
199368|NCT01950377|Dopamine
199369|NCT01950377|Dopamine Genes
199370|NCT01950377|Dopaminergic Mechanisms
199371|NCT01950364|Lymphoma
199372|NCT01950364|Hodgkin
199373|NCT01950364|Anaplastic Large-cell
199374|NCT01950364|Relapsed
199375|NCT01950364|Refractory
199376|NCT01950364|Antigens, CD30
199377|NCT01950364|Antibody-Drug Conjugate
199378|NCT01950364|Antibodies, Monoclonal
199379|NCT01950364|Lymphoma, Non-Hodgkin
199380|NCT01950364|Lymphoma, Large-Cell, Anaplastic
199381|NCT01950364|Monomethyl auristatin E
199382|NCT01950364|Drug Therapy
199383|NCT01950364|Immunotherapy
199384|NCT01950364|Hematologic Diseases
199385|NCT01950351|Prostate Cancer
199386|NCT01950351|Localized prostate cancer
199387|NCT01950351|Adenocarcinoma of the prostate
199388|NCT01950351|Proton therapy
199389|NCT01950351|Radiation therapy
199390|NCT01950351|XRT
199391|NCT01950351|Gray
199392|NCT01950351|Gy
199393|NCT01950351|Questionnaire
199394|NCT01950351|Survey
199395|NCT01950325|HIV-1 Viral Load
199396|NCT01950325|CD4 Count
199397|NCT01950325|Antiviral
199398|NCT01950325|HIV-1 Infection
199399|NCT01950325|Broadly Neutralizing Antibody
199400|NCT01950312|Autoimmune Inner Ear Disease
199401|NCT01950312|Inner Ear Disease
199402|NCT01950312|Meniere's Disease
199403|NCT01950312|Sudden Sensorineural Hearing Loss
199404|NCT01950286|T-cell Acute Lymphoblastic Leukemia
199405|NCT01950286|chemotherapy
199406|NCT01950286|allogeneic stem cell transplantation
199407|NCT01950260|Graves' disease
199408|NCT01950260|Radioactive iodine
199409|NCT01950260|Hypothyroidism
199410|NCT01950221|Double-blind Trial
199411|NCT01950221|Placebo-controlled
199412|NCT01950221|Pomegranate
199413|NCT01950221|Memory
199414|NCT01950221|Memory Impairment
199415|NCT01950221|Cognition
199416|NCT01950221|Ages 50-75
199417|NCT01950208|Assessment
199418|NCT01950195|Melanoma
199419|NCT01950195|Metastases
199420|NCT01950195|Brain
199421|NCT01950195|Spine
199422|NCT01950195|SRS(Stereotactic Radiosurgery))
199423|NCT01950195|Ipilimumab
199424|NCT01950182|Luminal B2 subtype
199425|NCT01950182|First line treatment
199426|NCT01950169|Hip fracture
199427|NCT01950169|Nutritional supplement
199428|NCT01950169|Bisphosphonates
199429|NCT01950169|Bone mineral density
199430|NCT01950169|Body composition
199431|NCT01950143|prostate cancer prevention
199432|NCT01950143|diet
199433|NCT01950143|global gene expression
199434|NCT01950143|metabolic changes
199435|NCT01950130|IABP
199436|NCT01950130|IABC
199437|NCT01950130|coronary artery disease
199438|NCT01950130|prophylactic
199439|NCT01950130|cardiac assist
199440|NCT01950117|nonpedunculated
199441|NCT01950117|neoplastic
199442|NCT01950117|colorectal
199443|NCT01950117|polyps
199444|NCT01950104|Embryo biopsy
199445|NCT01950104|Blastocyst stage
199446|NCT01950104|Day 3
199447|NCT01950104|Preimplantation genetic screening
199448|NCT01950091|low back pain
199449|NCT01950091|internet
199450|NCT01950091|app
199451|NCT01950091|prevention
199452|NCT01950091|treatment
199453|NCT01950078|gene polymorphism
199454|NCT01950078|pain perception
199455|NCT01950078|postoperative pain
199456|NCT01950052|VLCD
199457|NCT01950052|Low calorie diet
199458|NCT01950052|very low calorie diet
199459|NCT01950052|pre-operative diet
199460|NCT01950052|liver shrinking diet
199461|NCT01950052|bariatric surgery
199462|NCT01950052|gastric bypass
199463|NCT01950039|Obesity
199464|NCT01950039|Glucose Intolerance
199465|NCT01950026|skin temperature
199466|NCT01950026|ethnic groups
199467|NCT01950026|cryotherapy
199468|NCT01950013|Presbycusis
199469|NCT01950013|Aging
199470|NCT01950013|hearing aids
199471|NCT01950013|hearing training
199472|NCT01950000|Pain. Analgesia. Prevention
199473|NCT01949974|Palliative Chemotherapy
199474|NCT01949974|Integral Attention Program
199475|NCT01949974|Advanced cancer
199476|NCT01949974|Randomized Clinical Trial
199477|NCT01949961|intervention
199478|NCT01949961|sonothrombolysis
199479|NCT01949961|Ultrasound treatment
199480|NCT01949948|treatment, intervention, thrombolysis
199481|NCT01949935|Mupirocin
199482|NCT01949935|Surgical Site Infections
199483|NCT01949935|Coronary Artery Bypass Grafting
199484|NCT01949922|regenerative medicine
199485|NCT01949922|fecal incontinence
199486|NCT01949922|muscle fiber injection
199487|NCT01949909|plasmodium falciparum
199488|NCT01949909|long synthetic peptide
199489|NCT01949909|antibody
199490|NCT01949909|T cell
199491|NCT01949909|cytokine
199492|NCT01949909|vaccine
199493|NCT01949909|safety
199494|NCT01949909|phase 1
199495|NCT01949896|Pro inflammatory cytokine
199496|NCT01949896|Necrotizing enterocolitis
199497|NCT01949896|Packed red blood cell transfusion
199498|NCT01949883|Phase 1
199499|NCT01949883|Oncology
199500|NCT01949883|BET Inhibitor
199501|NCT01949857|Hepatitis A
199502|NCT01949857|Vaccine
199503|NCT01949857|Safety
199504|NCT01949857|efficacy
199505|NCT01949844|MRI
199506|NCT01949844|Magnetic Resonance Imaging
199507|NCT01949844|myocardial perfusion
199508|NCT01949844|myocardial perfusion imaging
199509|NCT01949844|Novel MRI Techniques
199510|NCT01949831|functional assessment
199511|NCT01949831|acute care
199512|NCT01949831|older medical patients
199513|NCT01949753|Obsessive-compulsive disorder (OCD)
199514|NCT01949753|Exposure therapy
199515|NCT01949753|Extinction learning
199516|NCT01949753|Pregnenolone
199517|NCT01949727|AECOPD
199518|NCT01949727|COPD
199519|NCT01949727|Emphysema
199520|NCT01949727|Chronic bronchitis
199521|NCT01949675|Cholera
199522|NCT01949675|Shanchol™
199523|NCT01949675|Cholera Vaccine
199524|NCT01949662|Advanced Cancers
199525|NCT01949662|Locally advanced cancer
199526|NCT01949662|Metastatic cancer
199527|NCT01949662|Recurrent cancer
199528|NCT01949662|Incurable cancer
199529|NCT01949662|Delirium
199530|NCT01949662|Agitation
199531|NCT01949662|Lorazepam
199532|NCT01949662|Haloperidol
199533|NCT01949662|Placebo
199534|NCT01949662|Questionnaires
199535|NCT01949662|Surveys
199536|NCT01949662|Acute palliative care unit
199537|NCT01949649|body image
199538|NCT01949649|body dissatisfaction
199539|NCT01949623|RP
199540|NCT01949610|Healthy Participants
199541|NCT01949610|JNJ26489112
199542|NCT01949610|14C-JNJ26489112
199543|NCT01949610|Absorption
199544|NCT01949610|Metabolism
199545|NCT01949610|Excretion
199546|NCT01949571|Mirtazapine.
199547|NCT01949571|Addiction.
199548|NCT01949571|Cocaine.
199549|NCT01949571|Cocaine-craving.
199550|NCT01949571|Cocaine-withdrawal
199551|NCT01949558|diet
199552|NCT01949558|lifestyle
199553|NCT01949519|prostate cancer
199554|NCT01949519|lycopene
199555|NCT01949519|docetaxel
199556|NCT01949519|metastatic
199557|NCT01949519|castration resistant
199558|NCT01949506|Lung metastases
199559|NCT01949506|Radiation Therapy
199560|NCT01949506|Stereotactic Body Radiation Therapy
199561|NCT01949493|carpal tunnel syndrome
199562|NCT01949493|traction
199563|NCT01949493|mechanical traction
199564|NCT01949493|Phystrac
199565|NCT01949480|Peripheral nerve block
199566|NCT01949480|Ultrasound guidance
199567|NCT01949480|Postoperative pain management post status thoracotomy
199568|NCT01949480|Postoperative pain management post status VATS
199569|NCT01949467|ferroportin disease
199570|NCT01949467|dysmetabolic hepatosiderosis
199571|NCT01949467|genetic hemochromatosis
199572|NCT01949467|hyperferritinemia
199573|NCT01949467|hepcidin
199574|NCT01949467|iron fumarate
199575|NCT01949467|physiopathological study
199576|NCT01949467|diagnosis
199577|NCT01949467|HFE gene
199578|NCT01949467|TRF2 gene
199579|NCT01949467|iron parameters
199580|NCT01949467|divalent cations
199581|NCT01949454|trachoma
199582|NCT01949454|trichiasis
199583|NCT01949454|trachomatous trichiasis
199584|NCT01949454|bilamellar tarsal rotation
199585|NCT01949454|fluorometholone
199586|NCT01949454|placebo controlled
199587|NCT01949441|HDM Allergy
199588|NCT01949441|Rhinoconjunctivitis
199589|NCT01949441|Immunotherapy
199590|NCT01949441|ToleroMune HDM
199591|NCT01949428|HDM Allergy
199592|NCT01949428|Rhinoconjunctivitis
199593|NCT01949415|House Dust Mite
199594|NCT01949415|Rhinoconjunctivitis
199595|NCT01949415|ToleroMune
199596|NCT01949376|breast cancer
199597|NCT01949376|invasive ductal carcinoma
199598|NCT01949376|cognitive impairment
199599|NCT01949376|adjuvant therapy
199600|NCT01949376|hormone therapy
199601|NCT01949376|hormonal therapy
199602|NCT01949376|chemotherapy
199603|NCT01949376|chemo brain
199604|NCT01949376|MRI
199605|NCT01949363|Gonococcal Infections, Cefixime, Neisseria gonorrhoeae, Azithromycin, antibiotic, cephalosporin
199606|NCT01949324|MacTel
199607|NCT01949298|immediate loading of dental implant
199608|NCT01949298|implant supported over denture
199609|NCT01949285|Spinal cord injury
199610|NCT01949285|Paralysis
199611|NCT01949285|Rehabilitation
199612|NCT01949285|Assessment
199613|NCT01949285|Theranostics
199614|NCT01949272|ARDS
199615|NCT01949259|Retrospective
199616|NCT01949259|Lung cancer
199617|NCT01949246|Biomarkers
199618|NCT01949220|Inherited
199619|NCT01949220|Von Willebrand disease
199620|NCT01949220|Von Willebrand factor
199621|NCT01949220|Deficiency
199622|NCT01949220|safety
199623|NCT01949207|Incompetent perforating veins
199624|NCT01949207|EVLA
199625|NCT01949207|Phlebectomies
199626|NCT01949207|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
199627|NCT01949194|liver metastases
199628|NCT01949181|Metals
199629|NCT01949181|Metalloids
199630|NCT01949181|Blood
199631|NCT01949181|Hair
199632|NCT01949181|Lung
199633|NCT01949181|Lung cancer
199634|NCT01949181|Chronic obstructive pulmonary disease
199635|NCT01949155|otitis media
199636|NCT01949155|otorrhea
199637|NCT01949155|middle ear effusion
199638|NCT01949155|tympanostomy tubes
199639|NCT01949142|otitis media
199640|NCT01949142|otorrhea
199641|NCT01949142|middle ear effusion
199642|NCT01949142|tympanostomy tubes
199643|NCT01949129|stem cell transplantation
199644|NCT01949129|children and adolescents
199645|NCT01949129|high risk acute lymphoblastic leukaemia
199646|NCT01949103|Gram-positive
199647|NCT01949090|H7N1
199648|NCT01949090|AS03 adjuvant
199649|NCT01949090|Safety
199650|NCT01949090|Immunogenicity
199651|NCT01949090|Influenza
199652|NCT01949090|Adults
199653|NCT01949090|Elderly adults
199654|NCT01949077|Hepatitis
199655|NCT01949077|Hepatitis C
199656|NCT01949077|Observational study
199657|NCT01949077|Biomarkers of treatment response
199658|NCT01949051|Allergic rhinitis
199659|NCT01949051|levocabastine
199660|NCT01949051|allergen challenge
199661|NCT01949038|Pain
199662|NCT01949038|Discomfort
199663|NCT01949038|Anxiety
199664|NCT01949038|Satisfaction
199665|NCT01949038|Compliance
199666|NCT01949012|Midazolam
199667|NCT01949012|Endtidal carbon dioxide
199668|NCT01949012|Desaturation
199669|NCT01948999|electroconvulsive therapy
199670|NCT01948999|treatment-refractory schizophrenia
199671|NCT01948973|Irritable Bowel Syndrome
199672|NCT01948973|Sacral Nerve Stimulation
199673|NCT01948973|Symptoms
199674|NCT01948973|Quality of Life
199675|NCT01948973|Bowel habits
199676|NCT01948960|Breast Neoplasms
199677|NCT01948960|everolimus
199678|NCT01948960|pharmacokinetics
199679|NCT01948960|elderly patients
199680|NCT01948960|obese patients
199681|NCT01948934|Skin
199682|NCT01948934|Injury
199683|NCT01948934|Membrane amniotic
199684|NCT01948934|Wound
199685|NCT01948921|EGD
199686|NCT01948921|tolerance
199687|NCT01948921|discomfort
199688|NCT01948908|Sedation
199689|NCT01948908|Laceration repair
199690|NCT01948908|Children
199691|NCT01948908|Intranasal
199692|NCT01948908|Midazolam
199693|NCT01948895|Desvenlafaxine
199694|NCT01948895|Open-label
199695|NCT01948895|Flexible-dose
199696|NCT01948895|Dysthymic disorder
199697|NCT01948895|Anxiety disorders
199698|NCT01948895|Generalized anxiety disorder
199699|NCT01948895|Social anxiety disorder
199700|NCT01948895|Post-traumatic stress disorder
199701|NCT01948882|Birth control
199702|NCT01948869|Phoenix
199703|NCT01948869|Mild atopic dermatitis
199704|NCT01948869|efficacy
199705|NCT01948869|safety
199706|NCT01948856|Recurrent common cold
199707|NCT01948856|laryngitis
199708|NCT01948856|pharyngitis/tonsillitis
199709|NCT01948856|acute rhinitis
199710|NCT01948856|acute rhinosinusitis
199711|NCT01948856|acute otitis media
199712|NCT01948843|HER2 Negative Metastatic Breast Cancer
199713|NCT01948830|Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen
199714|NCT01948817|Thalassemia
199715|NCT01948791|Alzheimer's disease
199716|NCT01948791|ENA713
199717|NCT01948791|Chinese patients
199718|NCT01948791|INSTINCT
199719|NCT01948765|xenon anesthesia
199720|NCT01948765|Off-pump coronary artery bypass graft surgery
199721|NCT01948752|Nutrition policy
199722|NCT01948752|food labelling
199723|NCT01948752|diet
199724|NCT01948752|obesity
199725|NCT01948752|health behavior
199726|NCT01948739|Brain machine interface
199727|NCT01948739|Rehabilitation robotics
199728|NCT01948739|Stroke
199729|NCT01948739|Hemiparesis
199730|NCT01948726|Breast cancer
199731|NCT01948726|Hypofractionation
199732|NCT01948726|Simultaneous integrated boost
199733|NCT01948726|Toxicity
199734|NCT01948700|Motivational Interviewing
199735|NCT01948700|Problem Drinking
199736|NCT01948700|Adolescents
199737|NCT01948700|Minority Health
199738|NCT01948687|real time elastography
199739|NCT01948687|hepatitis
199740|NCT01948648|plant sterols
199741|NCT01948648|cholesterol
199742|NCT01948648|colesevelam
199743|NCT01948648|phytosterolemia
199744|NCT01948648|fish oil
199745|NCT01948635|tracheal cuff shape
199746|NCT01948635|microaspiration
199747|NCT01948635|pepsin
199748|NCT01948635|ventilator-associated pneumonia
199749|NCT01948622|Anxiety
199750|NCT01948622|Third molar surgery
199751|NCT01948622|Blood pressure
199752|NCT01948622|Heart rate
199753|NCT01948622|Oxygen saturation
199754|NCT01948596|pregnant women
199755|NCT01948596|depression
199756|NCT01948596|depressive symptoms
199757|NCT01948596|omega-3 fatty acids
199758|NCT01948583|vaginal dryness
199759|NCT01948583|hyaluronic acid
199760|NCT01948583|menopause
199761|NCT01948570|acne,comedones, oily skin
199762|NCT01948557|Breastfeeding
199763|NCT01948557|Infants
199764|NCT01948557|Mother to child transmission of HIV
199765|NCT01948557|Survival
199766|NCT01948544|COPD
199767|NCT01948544|LTOT
199768|NCT01948544|Long-Term Oxygen Therapy
199769|NCT01948544|Portable Oxygen Concentrator
199770|NCT01948544|Quality of Life
199771|NCT01948544|Six Minute Walk Distance Test
199772|NCT01948531|Antiage
199773|NCT01948518|Pulmonary hypertension
199774|NCT01948518|Parenchymal Lung Disease
199775|NCT01948518|Diffusion Capacity
199776|NCT01948505|Craniotomy
199777|NCT01948466|Nutrition
199778|NCT01948466|Commercials
199779|NCT01948466|Elementary
199780|NCT01948466|Lunchroom
199781|NCT01948466|Fruits
199782|NCT01948466|Vegetables
199783|NCT01948453|CAD
199784|NCT01948453|CIMT
199785|NCT01948453|FMD
199786|NCT01948440|Substance abuse, early recovery, relapse prevention
199787|NCT01948427|UCD
199788|NCT01948427|BUPHENYL
199789|NCT01948427|RAVICTI
199790|NCT01948427|Urea
199791|NCT01948427|Urea cycle disorder
199792|NCT01948427|Glycerol phenylbutyrate
199793|NCT01948427|Benzoate
199794|NCT01948427|Sodium phenylbutyrate
199795|NCT01948427|Ornithine transcarbamylase (OTC)
199796|NCT01948427|Argininosuccinate synthetase (ASS)
199797|NCT01948427|Argininosuccinate lyase (ASL)
199798|NCT01948427|Carbamyl phosphate synthetase (CPS)
199799|NCT01948427|Arginine
199800|NCT01948427|Citrulline
199801|NCT01948427|Ammonia
199802|NCT01948414|Obesity
199803|NCT01948414|Hyperalimentation
199804|NCT01948414|Event-Related Potential
199805|NCT01948414|P300
199806|NCT01948388|Rheumatoid arthritis
199807|NCT01948375|subject blinding
199808|NCT01948375|placebo needle
199809|NCT01948336|Contrast-induced nephropathy, Dexmedetomidine, Endothelin-1
199810|NCT01948323|Pregnancy
199811|NCT01948323|Maternal health
199812|NCT01948323|Newborn health
199813|NCT01948323|Information technology
199814|NCT01948323|Health education
199815|NCT01948323|Cellphone
199816|NCT01948323|Touch screen technology
199817|NCT01948323|Pregnancy outcome
199818|NCT01948323|Low-Middle income
199819|NCT01948323|Nurse-led
199820|NCT01948323|Nutrition
199821|NCT01948323|Exercise
199822|NCT01948284|cecal intubation time
199823|NCT01948284|water exchange
199824|NCT01948284|pain
199825|NCT01948271|Psoriasis
199826|NCT01948271|Trichuris suis ova
199827|NCT01948271|T-lymphocytes
199828|NCT01948258|Pregnancy
199829|NCT01948245|Catheter Related Blood Stream Infection
199830|NCT01948245|Long-term intestinal Failure
199831|NCT01948245|Taurolidine
199832|NCT01948245|Catheter lock solution
199833|NCT01948245|Antimicrobial agent
199834|NCT01948245|Home Parenteral Nutrition
199835|NCT01948245|Anti-infective agents
199836|NCT01948206|Sudden Cardiac Death
199837|NCT01948206|Implantable Cardioverter-Defibrillator
199838|NCT01948206|Cardiomyopathy
199839|NCT01948206|Prolonged Paced QRS Duration
199840|NCT01948193|Diphtheria
199841|NCT01948193|Tetanus
199842|NCT01948193|Whooping Cough
199843|NCT01948193|Hepatitis B
199844|NCT01948193|Poliomyelitis
199845|NCT01948193|DTaP IPV-Hep B-PRP~T combined vaccine (Hexaxim™)
199846|NCT01948167|Depression
199847|NCT01948167|Prevention
199848|NCT01948167|Adolescents
199849|NCT01948154|Cerebral Palsy
199850|NCT01948154|Early Intervention
199851|NCT01948154|Speech Function
199852|NCT01948154|Quality of Life
199853|NCT01948128|Breast
199854|NCT01948115|Breech presentation
199855|NCT01948115|equimolar mixture of oxygen and nitrous oxide
199856|NCT01948115|external cephalic version
199857|NCT01948102|Amyotrophic Lateral Sclerosis
199858|NCT01948102|motor neuron disease
199859|NCT01948102|biological markers
199860|NCT01948102|biomarkers
199861|NCT01948089|Chronic Stroke
199862|NCT01948089|near transfer
199863|NCT01948089|far transfer
199864|NCT01948089|working memory
199865|NCT01948089|fluid intelligence
199866|NCT01948089|cognitive training
199867|NCT01948089|dual n-back
199868|NCT01948076|splenomegaly
199869|NCT01948076|pleural effusion
199870|NCT01948037|hydrotherapy
199871|NCT01948037|randomized controlled trial
199872|NCT01948037|lower extremity arterial disease
199873|NCT01948037|diabetes
199874|NCT01947998|Rivaroxaban,
199875|NCT01947998|Pulmonary Embolism,
199876|NCT01947998|Venous Thrombosis,
199877|NCT01947998|Venous Thromboembolism,
199878|NCT01947998|Acute Coronary Syndrome,
199879|NCT01947998|Intracranial Hemorrhages,
199880|NCT01947998|Gastrointestinal Hemorrhage,
199881|NCT01947998|Warfarin
199882|NCT01947985|Rivaroxaban
199883|NCT01947985|Stroke Prevention in Atrial Fibrillation,
199884|NCT01947985|Anticoagulants
199885|NCT01947985|Hematologic Agents
199886|NCT01947985|Therapeutic Uses
199887|NCT01947985|Observational
199888|NCT01947985|Venous Thromboembolism
199889|NCT01947985|Secondary Prevention of Acute Coronary Syndrome
199890|NCT01947985|Intracranial Hemorrhages
199891|NCT01947985|Gastrointestinal Hemorrhage
199892|NCT01947972|preterm neonate
199893|NCT01947972|tailored fortification
199894|NCT01947972|nutrition
199895|NCT01947972|maternal breast milk composition
199896|NCT01947959|Rivaroxaban
199897|NCT01947959|Stroke Prevention in Atrial Fibrillation,
199898|NCT01947959|Anticoagulants
199899|NCT01947959|Hematologic Agents
199900|NCT01947959|Therapeutic Uses
199901|NCT01947959|Observational
199902|NCT01947959|Venous Thromboembolism
199903|NCT01947959|Secondary Prevention of Acute Coronary Syndrome
199904|NCT01947959|Intracranial Hemorrhages
199905|NCT01947959|Gastrointestinal Hemorrhage,
199906|NCT01947946|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
199907|NCT01947920|Healthy
199908|NCT01947920|Pain
199909|NCT01947920|Tramadol hydrochloride
199910|NCT01947920|Tramadol HCl
199911|NCT01947920|Analgesic
199912|NCT01947920|QT prolongation
199913|NCT01947920|RWJ-26898-002
199914|NCT01947907|Human Growth Hormone
199915|NCT01947907|rhGH
199916|NCT01947907|hGH
199917|NCT01947907|GHD
199918|NCT01947881|Diabetic Macular Edema
199919|NCT01947881|anti-VEGF
199920|NCT01947881|Treatment Response
199921|NCT01947842|Smartphone
199922|NCT01947842|adherence
199923|NCT01947842|contraceptives
199924|NCT01947842|college
199925|NCT01947842|females
199926|NCT01947829|hemodialysis
199927|NCT01947829|dialysis dose
199928|NCT01947816|Ulcerative Colitis
199929|NCT01947803|Schizophrenia
199930|NCT01947803|Paliperidone
199931|NCT01947803|Safety
199932|NCT01947803|Effectiveness
199933|NCT01947803|Chinese
199934|NCT01947790|Type 2 diabetes
199935|NCT01947790|left ventricular mass
199936|NCT01947790|pioglitazone
199937|NCT01947777|Phase 1
199938|NCT01947777|Healthy subjects
199939|NCT01947777|DDI
199940|NCT01947777|CYP3A
199941|NCT01947764|HIV
199942|NCT01947764|Disclosure
199943|NCT01947764|Pediatrics
199944|NCT01947751|Catheter related infection
199945|NCT01947751|Central venous catheter
199946|NCT01947751|CVC infection
199947|NCT01947738|Healthy
199948|NCT01947738|Subjects
199949|NCT01947738|Safety
199950|NCT01947738|Tolerability
199951|NCT01947738|VBY891
199952|NCT01947738|Maximum
199953|NCT01947738|Pharmacodynamic
199954|NCT01947738|Pharmacokinetic
199955|NCT01947725|Posttraumatic Stress Disorders
199956|NCT01947725|PTSD
199957|NCT01947725|Smoking Cessation
199958|NCT01947725|Smoking
199959|NCT01947725|Behavior Therapy
199960|NCT01947712|Peripheral arterial disease
199961|NCT01947712|Oxidative stress
199962|NCT01947712|Cocoa
199963|NCT01947712|polyphenols
199964|NCT01947712|NADPH oxidase
199965|NCT01947686|osteoarthritis, patellofemoral
199966|NCT01947647|behavior therapy
199967|NCT01947647|Randomized Controlled Trials
199968|NCT01947647|Depressive Disorder
199969|NCT01947647|Anxiety Disorders
199970|NCT01947647|comorbidity
199971|NCT01947621|Broken heart syndrome, stress cardiomyopathy
199972|NCT01947595|diabetes mellitus type 2
199973|NCT01947595|impaired glucose tolerance
199974|NCT01947595|lifestyle intervention
199975|NCT01947595|body fat distribution
199976|NCT01947595|prevention
199977|NCT01947582|multiple sclerosis
199978|NCT01947582|gait
199979|NCT01947582|ankle foot orthosis (AFO)
199980|NCT01947556|diabetes
199981|NCT01947556|insulin administration
199982|NCT01947556|hyperglycaemia
199983|NCT01947556|insulin aspart
199984|NCT01947478|Drug-Eluting Angioplasty Balloon
199985|NCT01947478|Drug Coated Angioplasty Balloon
199986|NCT01947478|Peripheral Artery Disease
199987|NCT01947478|Experimental
199988|NCT01947478|Percutaneous Transluminal Angioplasty (PTA)
199989|NCT01947452|Youth violence reduction
199990|NCT01947452|Youth crime reduction
199991|NCT01947452|School engagement
199992|NCT01947452|Employment
199993|NCT01947452|Social-emotional learning
199994|NCT01947439|multivessel stenting
199995|NCT01947426|DHA, term neonates, mother milk
199996|NCT01947413|repetitive transcranial magnetic stimulation
199997|NCT01947413|BoNTA
199998|NCT01947413|stroke
199999|NCT01947413|optimal treatment protocol
200000|NCT01947413|randomized controlled trial
200001|NCT01947413|motor control
200002|NCT01947413|clinical predictors
200003|NCT01947400|Physician and Patient Communication
200004|NCT01947400|Acknowledge Introduce Duration Explanation Thank
200005|NCT01947400|Hospital Consumer Assessment of Health Plans Survey
200006|NCT01947374|Cartilage
200007|NCT01947374|Articular
200008|NCT01947335|Coronary
200009|NCT01947335|Angioplasty
200010|NCT01947335|Percutaneous coronary intervention
200011|NCT01947335|Stent
200012|NCT01947335|Contrast
200013|NCT01947335|Acute Renal failure
200014|NCT01947335|Intravascular ultrasound
200015|NCT01947335|Prevention
200016|NCT01947322|Natural killer cell
200017|NCT01947322|Haploidentical
200018|NCT01947322|Acute myeloid leukemia
200019|NCT01947322|Chemotherapy
200020|NCT01947309|Revlimid, lenalidomide, multiple myeloma, PFS, Response Rates
200021|NCT01947296|Oral antineoplastic agent
200022|NCT01947296|Adverse Effects
200023|NCT01947296|Cancer Networks
200024|NCT01947296|Continuity of care
200025|NCT01947296|Coordination of patient's care
200026|NCT01947283|Patient-Provider Relationship
200027|NCT01947283|Shared Decision Making
200028|NCT01947283|Therapeutic Alliance
200029|NCT01947283|Mental Health
200030|NCT01947283|Minority Health
200031|NCT01947283|Patient Activation
200032|NCT01947283|Communication
200033|NCT01947270|Potentially inappropriate medications
200034|NCT01947270|Elderly
200035|NCT01947270|Prevention
200036|NCT01947270|Multidisciplinary program
200037|NCT01947270|Checklist
200038|NCT01947270|Stepped wedge design
200039|NCT01947270|AGED, 75 AND OVER
200040|NCT01947244|Doulas
200041|NCT01947244|Parenting
200042|NCT01947244|Breast Feeding
200043|NCT01947244|Pregnancy in Adolescence
200044|NCT01947244|Child Development
200045|NCT01947231|neck pain
200046|NCT01947231|chronic
200047|NCT01947231|Global Postural Re-education
200048|NCT01947231|manual therapy
200049|NCT01947231|physical therapy
200050|NCT01947205|Curettage
200051|NCT01947205|analgesia
200052|NCT01947205|paracervical block
200053|NCT01947205|paracetamol
200054|NCT01947205|lidocaine
200055|NCT01947205|Dexketoprofen trometamol
200056|NCT01947192|Chlorhexidine
200057|NCT01947192|Matrix metalloproteinases (MMP) inhibitor
200058|NCT01947192|Adhesive system
200059|NCT01947192|Controlled clinical trial
200060|NCT01947192|Dental restoration
200061|NCT01947192|Noncarious cervical lesions
200062|NCT01947192|Dental restoration failure
200063|NCT01947166|Whipple
200064|NCT01947140|Lymphoid Malignancies
200065|NCT01947140|Multiple Myeloma
200066|NCT01947140|Lymphoma
200067|NCT01947140|Hodgkin Lymphoma
200068|NCT01947140|Non-hodgkin Lymphoma
200069|NCT01947140|Follicular Lymphoma
200070|NCT01947140|Diffuse Large B-Cell Lymphoma
200071|NCT01947140|Anaplastic Large Cell Lymphoma
200072|NCT01947140|Chronic Lymphocytic Leukemia
200073|NCT01947140|Small Lymphocytic Lymphoma
200074|NCT01947140|Mantle Cell Lymphoma
200075|NCT01947140|Marginal Zone Lymphoma
200076|NCT01947140|Burkitt Lymphoma
200077|NCT01947140|Waldenstrom Macroglobulinemia
200078|NCT01947140|Peripheral T-cell Lymphoma
200079|NCT01947140|Cutaneous T-cell Lymphoma
200080|NCT01947127|Lactate
200081|NCT01947127|Sepsis
200082|NCT01947127|Septic shock
200083|NCT01947127|Disease progression
200084|NCT01947127|Prognosis
200085|NCT01947114|General anesthesia,
200086|NCT01947114|Children,
200087|NCT01947114|Rigid Bronchoscopy,
200088|NCT01947114|Remifentanil,
200089|NCT01947114|Propofol,
200090|NCT01947114|Ketamine.
200091|NCT01947101|Stool transplant
200092|NCT01947101|Ulcerative Colitis
200093|NCT01947101|Fecal transplant
200094|NCT01947101|Inflammatory Bowel Disease
200095|NCT01947088|Epilepsy, seizure disorder
200096|NCT01947075|Fever
200097|NCT01947075|Tanzania
200098|NCT01947075|Pneumonia
200099|NCT01947075|HIV
200100|NCT01947075|Diabetes
200101|NCT01947075|Indoor Air Pollution
200102|NCT01947062|NSCLC
200103|NCT01947062|Metronomic chemotherapy
200104|NCT01947062|Metronomic cyclophosphamide
200105|NCT01947049|Influenza
200106|NCT01947049|diagnostic testing
200107|NCT01947049|antiviral treatment
200108|NCT01947049|rapid influenza testing
200109|NCT01947036|autoimmune disease
200110|NCT01947036|immune-mediated disease
200111|NCT01947036|T and B cells immunophenotype
200112|NCT01947036|IL23 signaling
200113|NCT01947036|genetic risk variants
200114|NCT01947010|antibodies
200115|NCT01946984|diclofenac, ERCP and pancreatitis
200116|NCT01946958|Triple P
200117|NCT01946945|infertility
200118|NCT01946945|recurrent pregnancy loss
200119|NCT01946945|miscarriage
200120|NCT01946945|Next Generation Sequencing
200121|NCT01946932|Induced hypothermia
200122|NCT01946932|Mild induced hypothermia
200123|NCT01946932|Resuscitation
200124|NCT01946932|Therapeutic hypothermia
200125|NCT01946932|Neurological function
200126|NCT01946932|Cardiovascular diseases
200127|NCT01946932|Rehabilitation
200128|NCT01946932|Quality of life
200129|NCT01946932|Cognition
200130|NCT01946919|Cinepazide
200131|NCT01946919|Adverse Drug Reaction
200132|NCT01946919|Safety
200133|NCT01946919|Real World Study
200134|NCT01946893|meditation
200135|NCT01946893|education
200136|NCT01946893|stress, psychological
200137|NCT01946893|aged
200138|NCT01946880|Systemic Lupus Erythematosus
200139|NCT01946880|Mycophenolate Mofetil (MMF)
200140|NCT01946867|Oral cavity Cancer
200141|NCT01946867|Oropharynx Cancer
200142|NCT01946854|Gastrointestinal
200143|NCT01946854|Metastatic Well-differentiated Mucinous Appendiceal Adenocarcinomas with Pseudomyxoma Peritonea
200144|NCT01946854|Appendiceal cancer
200145|NCT01946854|Surgically unresectable
200146|NCT01946854|Chemotherapy
200147|NCT01946854|Observation
200148|NCT01946854|Questionnaires
200149|NCT01946841|Chronic kidney disease
200150|NCT01946841|Hemodialysis
200151|NCT01946841|Severe malnutrition
200152|NCT01946841|Enteral nutrition
200153|NCT01946828|Field Induced Mydriasis
200154|NCT01946828|FIM
200155|NCT01946828|ATI
200156|NCT01946802|Heart arrest
200157|NCT01946802|Cardiopulmonary resuscitation
200158|NCT01946802|Hypothermia induced
200159|NCT01946802|Seizures
200160|NCT01946802|Electroencephalography
200161|NCT01946789|cancer
200162|NCT01946789|IL-15
200163|NCT01946789|melanoma
200164|NCT01946789|metastatic
200165|NCT01946789|unresectable
200166|NCT01946789|solid tumors
200167|NCT01946789|renal cell
200168|NCT01946789|non-small cell lung
200169|NCT01946789|squamous cell head and neck
200170|NCT01946737|Coronary
200171|NCT01946737|Artery
200172|NCT01946737|Disease
200173|NCT01946737|Diagnostic
200174|NCT01946737|Performance
200175|NCT01946737|Angiography
200176|NCT01946711|CRS
200177|NCT01946711|polyposis
200178|NCT01946672|gynaecological malignancy
200179|NCT01946672|pelvic lymphadenectomy
200180|NCT01946672|lymphedema
200181|NCT01946672|sentinel node
200182|NCT01946672|reverse mapping
200183|NCT01946659|Tailored Telephone Intervention
200184|NCT01946620|Chronic Obstructive Pulmonary Disease
200185|NCT01946620|Exacerbations
200186|NCT01946620|FEV1 ≤ 50%
200187|NCT01946607|Neuroticism
200188|NCT01946607|Emotion processing
200189|NCT01946607|Eye gaze movements
200190|NCT01946607|Heart Rate Variability
200191|NCT01946594|fever
200192|NCT01946594|antipyretics
200193|NCT01946594|acetaminophen
200194|NCT01946594|influenza vaccine
200195|NCT01946594|influenza, human
200196|NCT01946594|body temperature changes
200197|NCT01946594|Orthomyxoviridae Infections
200198|NCT01946594|RNA virus infections
200199|NCT01946594|Virus Diseases
200200|NCT01946594|Respiratory Tract Infections
200201|NCT01946594|Respiratory Tract Diseases
200202|NCT01946555|Breakthrough cancer pain
200203|NCT01946555|Neuropathic pain
200204|NCT01946555|Major opioid
200205|NCT01946555|Analgesics
200206|NCT01946542|exercise
200207|NCT01946542|heart failure
200208|NCT01946542|fatigue
200209|NCT01946542|physical endurance
200210|NCT01946542|functional food
200211|NCT01946516|viral screening
200212|NCT01946503|Short Gut
200213|NCT01946503|Short Bowel Syndrome
200214|NCT01946503|Intestinal Failure
200215|NCT01946503|Home parenteral nutrition
200216|NCT01946503|Feeding Behavior
200217|NCT01946503|Enteral Nutrition
200218|NCT01946503|Parent-Child Relations
200219|NCT01946503|Parenteral Nutrition
200220|NCT01946503|Digestive System Diseases
200221|NCT01946477|Multiple Myeloma, MM, cancer, oncology, hematology, plasma, neoplasm, plasmacytoma
200222|NCT01946464|edentulous
200223|NCT01946464|bearded
200224|NCT01946464|patients
200225|NCT01946464|requiring
200226|NCT01946464|general anesthesia
200227|NCT01946464|Mallampati Class II or IV
200228|NCT01946451|idiopathic epiretinal membranes
200229|NCT01946451|secondary epiretinal membranes
200230|NCT01946438|Influenza
200231|NCT01946438|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
200232|NCT01946438|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),
200233|NCT01946438|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
200234|NCT01946425|Influenza
200235|NCT01946425|Influenza virus vaccine
200236|NCT01946425|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
200237|NCT01946412|Cystic Fibrosis
200238|NCT01946373|Melanoma
200239|NCT01946373|Dendritic cell vaccination
200240|NCT01946373|Lymphodepletion
200241|NCT01946373|Adoptive cell transfer
200242|NCT01946373|T cells
200243|NCT01946373|Tumor infiltrating lymphocytes
200244|NCT01946373|Fludarabine
200245|NCT01946373|IL-2
200246|NCT01946373|Interleukin-2
200247|NCT01946373|Cyclophosphamide
200248|NCT01946373|Phase I study
200249|NCT01946373|Monocytes
200250|NCT01946373|Autologous
200251|NCT01946373|NY-ESO-1
200252|NCT01946347|Insulin Resistance
200253|NCT01946347|Hyperglycemia
200254|NCT01946347|Endothelial function
200255|NCT01946347|Oxidative stress
200256|NCT01946308|sleep
200257|NCT01946308|sleep efficiency
200258|NCT01946308|active sleep
200259|NCT01946308|quiet sleep
200260|NCT01946308|arousals
200261|NCT01946308|premature infant
200262|NCT01946308|conformational positioning
200263|NCT01946308|mattress
200264|NCT01946308|feeding difficulty
200265|NCT01946308|neonatal intensive care unit
200266|NCT01946308|sleep state
200267|NCT01946308|behavioral observation
200268|NCT01946308|stress behavior
200269|NCT01946308|self-regulatory behavior
200270|NCT01946308|surgery
200271|NCT01946308|gastrointestinal
200272|NCT01946282|neoplasm
200273|NCT01946282|colorectal
200274|NCT01946282|cancer
200275|NCT01946282|uninsured
200276|NCT01946282|FIT
200277|NCT01946282|Fecal Immunochemical Test
200278|NCT01946204|Prostate neoplasms
200279|NCT01946204|Prostate cancer
200280|NCT01946204|Castration-resistant prostate cancer
200281|NCT01946204|Non-metastatic castration-resistant prostate cancer
200282|NCT01946204|ARN-509
200283|NCT01946204|Apalutamide
200284|NCT01946191|Weight maintenance
200285|NCT01946191|Electronic health record
200286|NCT01946191|Primary care
200287|NCT01946178|Uterine Fibroids
200288|NCT01946178|Leiomyomas
200289|NCT01946178|High-Intensity Focused Ultrasound Ablation
200290|NCT01946178|Ultrasonography
200291|NCT01946165|Prostate Cancer
200292|NCT01946165|High risk prostate cancer
200293|NCT01946165|Abiraterone acetate
200294|NCT01946165|Zytiga
200295|NCT01946165|Prednisone
200296|NCT01946165|Enzalutamide
200297|NCT01946165|MDV3100
200298|NCT01946165|XTANDI
200299|NCT01946165|Androgen ablation
200300|NCT01946165|LHRHa
200301|NCT01946165|Hormonal therapy
200302|NCT01946152|Myeloma
200303|NCT01946152|Relapsed/Refractory Multiple Myeloma
200304|NCT01946152|MM
200305|NCT01946152|Pomalidomide
200306|NCT01946152|CC-4047
200307|NCT01946152|Dexamethasone
200308|NCT01946152|Decadron
200309|NCT01946152|C-CSF
200310|NCT01946152|Filgrastim
200311|NCT01946152|Neupogen
200312|NCT01946152|Granulocyte colony stimulating factor
200313|NCT01946100|multifocal
200314|NCT01946100|genetic
200315|NCT01946100|bronchoalveolar carcinoma
200316|NCT01946100|adenocarcinoma in situ
200317|NCT01946100|ground glass opacity
200318|NCT01946100|next generation sequencing
200319|NCT01946087|Remote ischemic preconditioning
200320|NCT01946087|cardiac surgery
200321|NCT01946087|left ventricular hypertrophy
200322|NCT01946087|reperfusion injury salvage kinase
200323|NCT01946074|advanced solid tumor
200324|NCT01946074|cancer
200325|NCT01946074|neoplasm
200326|NCT01946074|colorectal cancer
200327|NCT01946061|Oxaliplatin, S-1, Gastric cancer, Adjuvant chemotherapy
200328|NCT01946022|infertility
200329|NCT01946022|ovulation induction
200330|NCT01946022|luteal phase
200331|NCT01946022|granulosa cells function
200332|NCT01946022|GnRH agonist and antagonist
200333|NCT01946022|HMG
200334|NCT01946022|FSHr
200335|NCT01945996|Hispanic Americans
200336|NCT01945996|Cellular Phone
200337|NCT01945996|Behavior
200338|NCT01945983|Septic shock
200339|NCT01945983|Severe sepsis
200340|NCT01945983|Norepinephrine
200341|NCT01945970|Vascular function
200342|NCT01945970|Flow mediated dilation
200343|NCT01945970|Tea
200344|NCT01945957|autism
200345|NCT01945957|brain
200346|NCT01945957|functional magnetic resonance imaging
200347|NCT01945957|oxytocin
200348|NCT01945944|pediatric
200349|NCT01945944|mucolytic
200350|NCT01945944|respiratory failure
200351|NCT01945944|atelectasis
200352|NCT01945944|hypertonic saline
200353|NCT01945931|Maternal health
200354|NCT01945931|perinatal health
200355|NCT01945931|mHealth
200356|NCT01945931|smartphone
200357|NCT01945931|mobile phone
200358|NCT01945931|Ethiopia
200359|NCT01945918|Diabetes Mellitus, Type 2
200360|NCT01945918|Diabetes Mellitus
200361|NCT01945918|Primary Health Care
200362|NCT01945918|Self care
200363|NCT01945905|Tuberculosis
200364|NCT01945905|Adherence, medication
200365|NCT01945905|Patient compliance
200366|NCT01945892|macular edema, irvine gass syndrome, ozurdex
200367|NCT01945879|pancreatic cancer
200368|NCT01945879|heparin
200369|NCT01945879|thromboembolic events
200370|NCT01945879|bleedings
200371|NCT01945866|Diabetic Macular Edema
200372|NCT01945866|Anti-vascular endothelial growth factor
200373|NCT01945866|Dexamethasone Intravitreal implant
200374|NCT01945866|Ranibizumab intravitreal injection
200375|NCT01945801|Sleep apnea
200376|NCT01945801|Treatment
200377|NCT01945801|Sodium-Restricted Diet
200378|NCT01945801|Diuretic
200379|NCT01945801|Lasilactone
200380|NCT01945775|Breast cancer
200381|NCT01945775|BRCA mutation
200382|NCT01945775|PARP inhibitor
200383|NCT01945775|BRCA 1
200384|NCT01945775|BRCA 2
200385|NCT01945762|RET Mutation
200386|NCT01945762|DIagnostics
200387|NCT01945762|Medullary Thyroid Cancer
200388|NCT01945762|MTC
200389|NCT01945736|Opiate withdrawal in children
200390|NCT01945723|Endoscopy
200391|NCT01945723|Gastrointestinal tract
200392|NCT01945723|Bacterial markers
200393|NCT01945723|volunteers
200394|NCT01945710|Tumors
200395|NCT01945697|DNA methylation, biomarkers, oral cancer
200396|NCT01945645|Prevention
200397|NCT01945645|Screening
200398|NCT01945645|Type 2 diabetes
200399|NCT01945645|Action Competence
200400|NCT01945645|Family practice
200401|NCT01945645|Health Services Research
200402|NCT01945619|CMV
200403|NCT01945619|Adenovirus
200404|NCT01945619|EBV
200405|NCT01945619|Stem cell transplant
200406|NCT01945619|cytotoxic T-lymphocytes
200407|NCT01945580|POP
200408|NCT01945580|Transvaginal
200409|NCT01945580|Native Tissue Repair
200410|NCT01945580|Repair Augmented with Mesh
200411|NCT01945580|Biologic Graft
200412|NCT01945580|Pelvic Organ Prolapse
200413|NCT01945567|Parkinson's disease
200414|NCT01945567|Essential tremor
200415|NCT01945567|Tremor
200416|NCT01945567|Deep brain stimulation
200417|NCT01945567|Posterior subthalamic area
200418|NCT01945567|Zona incerta
200419|NCT01945554|infiltrative therapy
200420|NCT01945554|cervical disc herniation
200421|NCT01945554|lumbar disc herniation
200422|NCT01945541|Intraoperative Fluid Administration
200423|NCT01945541|Body Composition Measurement
200424|NCT01945528|Platelet Rich Plasma
200425|NCT01945528|tendinopathy
200426|NCT01945528|epicondylitis
200427|NCT01945528|ultrasound
200428|NCT01945528|injection therapy
200429|NCT01945528|needle tenotomy
200430|NCT01945515|Stroke
200431|NCT01945515|transcranial direct current stimulation
200432|NCT01945515|robotic rehabilitation
200433|NCT01945515|gait
200434|NCT01945476|midazolam
200435|NCT01945476|premedication
200436|NCT01945476|functional recovery
200437|NCT01945476|breast cancer
200438|NCT01945424|Quadrivalent Influenza Vaccine
200439|NCT01945424|Pregnancy Registry
200440|NCT01945424|Influenza
200441|NCT01945411|Airway Management
200442|NCT01945411|Ventilation
200443|NCT01945398|Pulmonary Rehabilitation
200444|NCT01945398|Inspiratory Muscle Training
200445|NCT01945398|Inspiratory Muscle Strength
200446|NCT01945398|Vascular Resistance
200447|NCT01945398|Exercise
200448|NCT01945398|Chronic Obstructive Pulmonary Disease
200449|NCT01945385|Abortion
200450|NCT01945385|LARC
200451|NCT01945385|Contraception
200452|NCT01945385|IUD
200453|NCT01945385|Contraceptive implant
200454|NCT01945385|behavioral change
200455|NCT01945385|video intervention
200456|NCT01945359|Relapsing Multiple Sclerosis
200457|NCT01945359|Dimethyl Fumarate
200458|NCT01945359|Natalizumab
200459|NCT01945346|PRX167700
200460|NCT01945346|Osteoarthritis
200461|NCT01945333|Cognitive remediation
200462|NCT01945333|Schizophrenia
200463|NCT01945333|Schizoaffective disorder
200464|NCT01945320|hemodialysis
200465|NCT01945320|wasting and malnutrition
200466|NCT01945320|nutrition status
200467|NCT01945320|bioelectrical impedance analysis
200468|NCT01945320|body composition
200469|NCT01945307|Complement
200470|NCT01945307|Serum Bactericidal Assay
200471|NCT01945268|vascular, influenza, vaccine, heart failure
200472|NCT01945255|Calcification
200473|NCT01945255|aortic pulse wave velocity
200474|NCT01945255|peripheral artery occlusion disease
200475|NCT01945255|hemodialysis
200476|NCT01945255|metabolic syndrome
200477|NCT01945242|Drug Therapy
200478|NCT01945216|Drug therapy
200479|NCT01945203|Calcification
200480|NCT01945203|aortic pulse wave velocity
200481|NCT01945203|peripheral artery occlusion disease
200482|NCT01945203|peritoneal dialysis
200483|NCT01945203|metabolic syndrome
200484|NCT01945177|endoscopy
200485|NCT01945177|gastric intestinal metaplasia
200486|NCT01945177|gastric cancer
200487|NCT01945164|XL999
200488|NCT01945164|Advanced Malignancy
200489|NCT01945151|spastic hemiparesis
200490|NCT01945138|Total Pancreatectomy
200491|NCT01945138|Islet Auto-Transplantation
200492|NCT01945138|Closed Loop Insulin Pump
200493|NCT01945099|diabetes, insulin,post prandial, closed loop, artificial pancreas, hyperglycemia
200494|NCT01945086|Dermatitis, Atopic
200495|NCT01945086|Eczema
200496|NCT01945086|Ustekinumab
200497|NCT01945086|CNTO1275
200498|NCT01945086|STELARA
200499|NCT01945073|Educational intervention
200500|NCT01945073|Formal Counselling
200501|NCT01945073|Knowledge
200502|NCT01945073|Illness Perception
200503|NCT01945060|Artificial Pancreas Project
200504|NCT01945060|Diabetes Assistant (DiAs) Medical Platform System
200505|NCT01945060|Artificial Pancreas Platform
200506|NCT01945060|Insulin Pump
200507|NCT01945060|Continuous Glucose Monitor
200508|NCT01945060|Closed-Loop Control
200509|NCT01945060|heart rate Control to Range System (hrCTR)
200510|NCT01945047|depression
200511|NCT01945047|treatment
200512|NCT01945047|ketamine
200513|NCT01945047|ottawa
200514|NCT01945047|treatment-resistant
200515|NCT01945047|infusion
200516|NCT01945034|topical ibuprofen
200517|NCT01945034|ankle sprain
200518|NCT01945021|Non small cell lung cancer
200519|NCT01945021|NSCLC
200520|NCT01945021|ROS1
200521|NCT01945021|ROS1 positive
200522|NCT01945021|ROS1 proto oncogene
200523|NCT01945021|c ros tyrosine kinases
200524|NCT01945021|ROS1 positive NSCLC
200525|NCT01945021|ROS1 lung cancer
200526|NCT01945021|ALK negative
200527|NCT01945021|Lung Carcinoma
200528|NCT01945021|Neoplasm
200529|NCT01945021|Crizotinib
200530|NCT01945021|Xalkori
200531|NCT01945021|Previously treated or untreated
200532|NCT01945021|North East Asian
200533|NCT01945008|HCV
200534|NCT01945008|observational study
200535|NCT01945008|HCV direct-acting antiviral agents
200536|NCT01944982|Immunotherapy
200537|NCT01944982|NKAEs
200538|NCT01944982|Expanded haploidentical natural killer cells
200539|NCT01944982|Activated natural killer cells
200540|NCT01944956|Maturation
200541|NCT01944956|preterm infants
200542|NCT01944956|sucking and swallowing
200543|NCT01944943|refractory/relapsed
200544|NCT01944943|diffuse large B-cell lymphoma
200545|NCT01944943|"indolent non-hodgkin lymphoma"
200546|NCT01944943|Primary central nervous system lymphoma
200547|NCT01944943|chronic lymphocytic leukemia
200548|NCT01944917|Electromagnetic field
200549|NCT01944917|VAS score
200550|NCT01944917|Heart Rate Variability
200551|NCT01944904|XOS
200552|NCT01944904|pre-diabetic
200553|NCT01944904|abnormal glucose levels
200554|NCT01944891|Adolescent girls
200555|NCT01944891|Mozambique
200556|NCT01944891|Diet
200557|NCT01944891|Anthropometrics
200558|NCT01944891|Serum biomarkers
200559|NCT01944878|Peptic ulcer
200560|NCT01944878|Liver cirrhosis
200561|NCT01944878|Portal hypertension
200562|NCT01944865|Aerobic Interval Training
200563|NCT01944865|Supramaximal Training
200564|NCT01944852|icodextrin
200565|NCT01944852|double dose
200566|NCT01944852|elderly incident CAPD patients
200567|NCT01944852|DIDo study
200568|NCT01944839|Wet AMD
200569|NCT01944839|choroidal neovascularization
200570|NCT01944839|Fovista®
200571|NCT01944839|E10030
200572|NCT01944839|Lucentis®
200573|NCT01944826|Dyspnea
200574|NCT01944826|Angina pectoris
200575|NCT01944813|Advance Care planning
200576|NCT01944813|End-of-life Discussions
200577|NCT01944813|Questionaires
200578|NCT01944813|Palliative Care
200579|NCT01944800|Ticagrelor
200580|NCT01944800|Prasugrel
200581|NCT01944800|Acute coronary syndrome
200582|NCT01944800|Percutaneous coronary intervention
200583|NCT01944774|Moxifloxacin
200584|NCT01944761|pediatrics
200585|NCT01944761|Brain Tumor
200586|NCT01944761|Neuro-radiation
200587|NCT01944761|Exercise
200588|NCT01944709|melanoma
200589|NCT01944709|dendritic cells
200590|NCT01944709|peptide
200591|NCT01944709|Melan-A
200592|NCT01944696|hyperbilirubinemia
200593|NCT01944696|prematurity
200594|NCT01944696|extremely low birth weight (ELBW)
200595|NCT01944696|phototherapy
200596|NCT01944696|cycled phototherapy
200597|NCT01944696|intermittent phototherapy
200598|NCT01944657|Major Depressive Disorder Clinical Outcomes
200599|NCT01944657|Transcranial Magnetic Stimulation
200600|NCT01944657|Standard Medication Monotherapy
200601|NCT01944657|Exploratory Field Study
200602|NCT01944605|Endotoxin
200603|NCT01944605|Cytokine
200604|NCT01944605|Metabolism
200605|NCT01944592|Gynaecology Teaching Associate
200606|NCT01944592|Pelvic examination
200607|NCT01944592|Students
200608|NCT01944553|Spine
200609|NCT01944553|Accurancy
200610|NCT01944553|Robotic
200611|NCT01944553|Screw placement
200612|NCT01944553|Degenerative
200613|NCT01944514|Action potential duration restitution
200614|NCT01944514|Ventricular arrhythmia
200615|NCT01944514|Sudden cardiac death
200616|NCT01944514|Peri-infarct zone
200617|NCT01944514|Electrocardiogram
200618|NCT01944501|tinnitus
200619|NCT01944501|hearing loss
200620|NCT01944501|Transcranial magnetic stimulation
200621|NCT01944501|Transcranial direct current stimulation
200622|NCT01944488|Precocious puberty
200623|NCT01944488|GnRH-test
200624|NCT01944475|Precocious puberty
200625|NCT01944475|Premature thelarche
200626|NCT01944475|Tanner-stage
200627|NCT01944475|GnRH-test
200628|NCT01944462|pneumococcal vaccine
200629|NCT01944462|pharmacist vaccination
200630|NCT01944462|Pneumovax 23
200631|NCT01944462|pneumococcal vaccine polyvalent
200632|NCT01944449|Type 2 diabetes (T2D)
200633|NCT01944449|Whey Protein Concentrate (WPC)
200634|NCT01944436|Pharmacogenomics
200635|NCT01944436|Dementia with Lewy bodies
200636|NCT01944436|Adverse events
200637|NCT01944436|Polymorphisms
200638|NCT01944436|Acetylcholinesterase
200639|NCT01944436|Parkinson's Disease Dementia
200640|NCT01944436|Cognitive enhancers
200641|NCT01944436|Clinical efficacy
200642|NCT01944436|Cytochrome P450
200643|NCT01944436|Butyrylcholinesterase
200644|NCT01944410|PRP
200645|NCT01944410|TBC
200646|NCT01944410|Treatment
200647|NCT01944397|Atrial fibrillation
200648|NCT01944397|Heart failure
200649|NCT01944397|Stroke
200650|NCT01944397|Myocardial infarction
200651|NCT01944371|Latent reservoir
200652|NCT01944358|Syphilis; human immunodeficiency virus; penicillin
200653|NCT01944332|gamete treatment
200654|NCT01944332|ICSI
200655|NCT01944332|IVF
200656|NCT01944332|infertility
200657|NCT01944332|oocyte activation
200658|NCT01944319|Infection; Meropenem; Pharmacokinetics; Pharmacodynamics
200659|NCT01944306|Pharmacokinetics
200660|NCT01944306|Pharmacology, Clinical
200661|NCT01944306|Drug Efficacy
200662|NCT01944306|Drug Failure
200663|NCT01944306|Contraceptive Agents
200664|NCT01944293|Ketamine
200665|NCT01944293|Midazolam
200666|NCT01944293|Bipolar Disorder
200667|NCT01944293|Major Depressive Episode
200668|NCT01944293|Suicidal Ideation
200669|NCT01944293|Suicide
200670|NCT01944293|Depression
200671|NCT01944293|Treatment
200672|NCT01944293|Ketamine Treatment
200673|NCT01944254|Cardiac surgical procedures
200674|NCT01944254|Pulmonary Artery Catheterizations
200675|NCT01944254|Cardiac output
200676|NCT01944254|Swan Ganz Catheterization
200677|NCT01944241|cervical surgery
200678|NCT01944241|LLETZ
200679|NCT01944241|LEEP
200680|NCT01944241|Cone biopsy
200681|NCT01944241|Fertility
200682|NCT01944228|inflammation
200683|NCT01944228|vagus nerve stimulation
200684|NCT01944228|chronic heart failure
200685|NCT01944228|Systemic Inflammatory Response Syndrome
200686|NCT01944228|sepsis
200687|NCT01944228|auto-immune diseases
200688|NCT01944215|Normal subjects
200689|NCT01944215|Female
200690|NCT01944215|Molecular Breast Imaging
200691|NCT01944215|Fasting
200692|NCT01944215|Exercise
200693|NCT01944215|Tracer Uptake
200694|NCT01944215|Tc-99m Sestamibi
200695|NCT01944215|Prandial status
200696|NCT01944215|metabolic status
200697|NCT01944215|negative mammogram
200698|NCT01944215|Caffeine
200699|NCT01944215|External Warming
200700|NCT01944202|Echocardiography
200701|NCT01944202|Appropriate Use Criteria
200702|NCT01944202|Educational Intervention
200703|NCT01944189|lumefantrine pharmacokinetics & bioavailability
200704|NCT01944176|COPD
200705|NCT01944176|Statins
200706|NCT01944176|Cytokines
200707|NCT01944163|Low back pain
200708|NCT01944163|Impact analysis
200709|NCT01944163|Cluster randomized trial
200710|NCT01944163|Referral rule
200711|NCT01944163|Axial spondyloarthritis
200712|NCT01944150|Hypnosis
200713|NCT01944150|chronic pain
200714|NCT01944150|transcutaneous electrical nerve stimulation
200715|NCT01944150|nociceptive pain
200716|NCT01944150|neuropathic pain
200717|NCT01944150|complementary therapies
200718|NCT01944137|colonic neoplasms
200719|NCT01944137|Lung neoplasms
200720|NCT01944137|patient-centered nursing
200721|NCT01944137|breast neoplasms
200722|NCT01944124|Mobile health
200723|NCT01944124|Metabolic syndrome
200724|NCT01944124|Exercise prescription
200725|NCT01944124|Exercise intervention
200726|NCT01944124|Disease prevention
200727|NCT01944124|Rural health
200728|NCT01944111|Gastric plication
200729|NCT01944085|children
200730|NCT01944085|supracondylar fracture
200731|NCT01944085|pin removal
200732|NCT01944085|analgesia
200733|NCT01944085|pain score
200734|NCT01944072|Chronic Obstructive Pulmonary Disease
200735|NCT01944072|COPD
200736|NCT01944072|Pulmonary rehabilitation
200737|NCT01944072|Aerobic exercise
200738|NCT01944072|CEDOC
200739|NCT01944072|FCM
200740|NCT01944072|UNL
200741|NCT01944072|NOVA MEDICAL SCHOOL
200742|NCT01944046|autism, ASD, autistic, Asperger's, PDD-NOS, oxytocin
200743|NCT01944033|β2-agonist
200744|NCT01944033|Ipratropium Bromide
200745|NCT01944033|Chronic Obstructive Pulmonary Disease Exacerbation
200746|NCT01944033|Emergency departement
200747|NCT01944020|Sleep Apnea, Obstructive
200748|NCT01944020|Energy Balance
200749|NCT01944020|Food Intake
200750|NCT01944020|Energy Expenditure
200751|NCT01944020|Sleep
200752|NCT01944020|Obesity
200753|NCT01944007|CLP
200754|NCT01943994|Psilocybin
200755|NCT01943994|Smoking cessation
200756|NCT01943955|dizziness
200757|NCT01943955|vertigo
200758|NCT01943955|unsteadiness
200759|NCT01943955|unbalance
200760|NCT01943955|falls
200761|NCT01943942|Mexico
200762|NCT01943942|Montelukast
200763|NCT01943942|Pharmacokinetics
200764|NCT01943942|Bioequivalence
200765|NCT01943929|Nasal septum
200766|NCT01943929|Headache
200767|NCT01943929|Mucosa contact point headache
200768|NCT01943916|breast imaging diagnosis
200769|NCT01943916|breast ultrasound
200770|NCT01943916|Imagio
200771|NCT01943916|Seno Medical Instruments, Inc.
200772|NCT01943916|Seno
200773|NCT01943916|opto-acoustics
200774|NCT01943916|OA
200775|NCT01943916|angiogenesis
200776|NCT01943916|blood map
200777|NCT01943890|Hypertonic saline
200778|NCT01943890|Lung physiotherapy
200779|NCT01943864|pharmacokinetics
200780|NCT01943864|second line monotherapy
200781|NCT01943864|GSK1120212 (trametinib)
200782|NCT01943864|MEK inhibitor
200783|NCT01943864|locally advanced or metastatic biliary tract cancers
200784|NCT01943851|leukemia
200785|NCT01943851|Acute myeloid leukemia
200786|NCT01943851|BET inhibitor
200787|NCT01943851|lymphoma
200788|NCT01943851|Myelodysplastic syndromes
200789|NCT01943851|Oncology
200790|NCT01943851|multiple myeloma
200791|NCT01943851|GSK525762
200792|NCT01943825|Dengue
200793|NCT01943825|Dengue fever
200794|NCT01943825|CYD dengue vaccine
200795|NCT01943825|IXIARO JE vaccine
200796|NCT01943825|Flavivirus
200797|NCT01943799|Hepatitis B (HBV)
200798|NCT01943799|Oral antiviral (OAV)
200799|NCT01943799|GS-4774
200800|NCT01943786|Wild type KRAS
200801|NCT01943773|delirium
200802|NCT01943773|surgery
200803|NCT01943773|operation
200804|NCT01943773|geriatric
200805|NCT01943773|complication
200806|NCT01943760|Tramadol
200807|NCT01943760|Children
200808|NCT01943760|Hernioplasty
200809|NCT01943760|Wound infiltration
200810|NCT01943747|sepsis
200811|NCT01943747|severe sepsis
200812|NCT01943747|septic shock
200813|NCT01943747|infection
200814|NCT01943747|organ dysfunction
200815|NCT01943747|quality improvement
200816|NCT01943734|Information
200817|NCT01943734|Lifestyle
200818|NCT01943734|Occupational Health
200819|NCT01943695|Breast Cancer
200820|NCT01943695|Exercise
200821|NCT01943695|Chemotherapy
200822|NCT01943695|15-178
200823|NCT01943682|Relapsed acute myeloid leukemia
200824|NCT01943682|non-therapy related acute myeloid leukemia
200825|NCT01943682|Refractory acute myeloid leukemia
200826|NCT01943682|Untreated acute myeloid leukemia
200827|NCT01943682|Lymphoma
200828|NCT01943682|Leukemia
200829|NCT01943669|Spinal Cord Injury
200830|NCT01943656|Spinal Cord Injury
200831|NCT01943643|angiography, bifurcation, stenting, CT
200832|NCT01943630|HPV condyloma acuminata
200833|NCT01943617|Liver Cirrhosis
200834|NCT01943617|Hepatitis B
200835|NCT01943617|Compensation
200836|NCT01943617|Efficacy
200837|NCT01943604|Neuropsychology
200838|NCT01943604|Breakfast eating patters
200839|NCT01943604|Glucose
200840|NCT01943604|Child Psychology
200841|NCT01943591|treatment trial
200842|NCT01943591|cerebral aneurysm
200843|NCT01943591|randomized
200844|NCT01943591|coils
200845|NCT01943591|endovascular
200846|NCT01943591|Aneurysm
200847|NCT01943591|Intracranial Aneurysm
200848|NCT01943591|Vascular Diseases
200849|NCT01943591|Cardiovascular Diseases
200850|NCT01943591|Intracranial Arterial Diseases
200851|NCT01943591|Cerebrovascular Disorders
200852|NCT01943591|Brain Diseases
200853|NCT01943591|Central Nervous System Diseases
200854|NCT01943591|Nervous System Diseases
200855|NCT01943565|Pregnancy
200856|NCT01943565|Healthy
200857|NCT01943565|Intrathecal
200858|NCT01943565|Opioids
200859|NCT01943565|Spinal
200860|NCT01943565|Anesthesia
200861|NCT01943565|Pain
200862|NCT01943565|Cesarean
200863|NCT01943565|Delivery
200864|NCT01943565|Human
200865|NCT01943526|Ireland
200866|NCT01943526|Natalizumab
200867|NCT01943513|Muscle Disuse Atrophy
200868|NCT01943500|Breast cancer
200869|NCT01943500|Prostate cancer
200870|NCT01943500|Colorectal cancer
200871|NCT01943500|Circulating tumor cell (CTC)
200872|NCT01943487|Phase I
200873|NCT01943487|Verapamil
200874|NCT01943487|Tamsulosin OCAS
200875|NCT01943487|Solifenacin
200876|NCT01943487|Pharmacokinetics
200877|NCT01943487|EC905
200878|NCT01943474|IV Catheter comparison
200879|NCT01943474|AccuCath versus Conventional IV Catheters
200880|NCT01943474|IV Catheter Study
200881|NCT01943474|IV Catheter User Preference Comparison
200882|NCT01943474|First Attempt Success Rate for IV Catheters
200883|NCT01943474|AccuCath Device Performance
200884|NCT01943474|Complication Rates for IV Catheters
200885|NCT01943474|Average Dwell Time for IV Catheters
200886|NCT01943474|Patient Satisfaction with IV Catheters
200887|NCT01943474|Clinician Satisfaction with AccuCath Device Performance
200888|NCT01943461|Solid Tumors
200889|NCT01943461|MSB0010718C
200890|NCT01943461|anti PD-L1
200891|NCT01943461|avelumab
200892|NCT01943461|Phase 1
200893|NCT01943448|Macula Lutea Hemorrhage
200894|NCT01943448|High Myopia
200895|NCT01943448|Optical Coherence Tomography
200896|NCT01943435|Spinal Stenosis
200897|NCT01943435|Spinal manipulation
200898|NCT01943435|Exercise
200899|NCT01943435|Epidural injection
200900|NCT01943422|advanced
200901|NCT01943422|melanoma
200902|NCT01943422|Vemurafenib
200903|NCT01943422|High-dose Interferon alfa-2b
200904|NCT01943409|Parenteral nutrition
200905|NCT01943409|lipid emulsion
200906|NCT01943409|Intralipid
200907|NCT01943409|ClinOleic
200908|NCT01943409|Inflammation
200909|NCT01943409|Infection
200910|NCT01943409|Bloodstream Infection
200911|NCT01943409|length of stay
200912|NCT01943409|mortality
200913|NCT01943396|age-related macular degeneration
200914|NCT01943396|AMD
200915|NCT01943396|rheohemapheresis
200916|NCT01943396|plasma filtration
200917|NCT01943396|electroretinography
200918|NCT01943396|ERG
200919|NCT01943396|multifocal ERG
200920|NCT01943396|double plasma filtration
200921|NCT01943383|Hypertension
200922|NCT01943370|endoscopic sinus surgery
200923|NCT01943370|post-operative irrigation
200924|NCT01943370|pain
200925|NCT01943370|debridement
200926|NCT01943357|diabetes
200927|NCT01943357|patient education
200928|NCT01943357|self management
200929|NCT01943357|health improvement
200930|NCT01943344|vascular large hole closure
200931|NCT01943344|arteriotomy closure
200932|NCT01943344|Large hole vascular closure device
200933|NCT01943344|vascular closure device
200934|NCT01943344|percutaneous vascular closure device
200935|NCT01943318|Liver Cirrhosis
200936|NCT01943318|Hepatocellular carcinoma
200937|NCT01943305|Yellow Fever
200938|NCT01943305|vaccination
200939|NCT01943305|Japanese encephalitis
200940|NCT01943305|antibodies
200941|NCT01943292|Focal Adhesion Kinase inhibitor
200942|NCT01943292|FAK inhibitor
200943|NCT01943292|Cancer Stem Cells
200944|NCT01943292|CSC
200945|NCT01943279|medical abortion
200946|NCT01943279|telephone follow-up
200947|NCT01943279|ultrasound
200948|NCT01943279|serum hCG
200949|NCT01943279|methotrexate
200950|NCT01943279|misoprostol
200951|NCT01943253|Early gastric cancer,
200952|NCT01943253|endoscopic submucosal dissection (ESD)
200953|NCT01943253|water-jet assisted ESD
200954|NCT01943227|humidity
200955|NCT01943227|enthalpy
200956|NCT01943227|mechanical ventilation
200957|NCT01943214|Diabetes Mellitus
200958|NCT01943214|Body constitution
200959|NCT01943175|schizophrenia
200960|NCT01943175|stem cells
200961|NCT01943175|neurons
200962|NCT01943175|genetic hish risk for schizophrenia
200963|NCT01943136|impetigo
200964|NCT01943136|papaya extract ointment
200965|NCT01943123|probiotics,
200966|NCT01943123|streptococcus mutans,
200967|NCT01943123|lactobacilli,
200968|NCT01943123|plaque index,
200969|NCT01943123|gingival index
200970|NCT01943110|Intradermal injections
200971|NCT01943110|Vaccine delivery devices
200972|NCT01943071|dementia
200973|NCT01943071|day care centre programs
200974|NCT01943071|patients
200975|NCT01943071|family carers
200976|NCT01943071|cost-consequence analysis
200977|NCT01943006|Mucopolysaccaride polysulfate (MPS)
200978|NCT01943006|MPS
200979|NCT01943006|Heparinoide
200980|NCT01943006|Infusionphlebitis
200981|NCT01943006|Prevention
200982|NCT01943006|Superficial thrombophlebitis
200983|NCT01943006|Treatment
200984|NCT01942993|melanoma
200985|NCT01942993|unresectable
200986|NCT01942993|mutation
200987|NCT01942993|BRAF protein
200988|NCT01942980|Breast cancer
200989|NCT01942980|one brain metastasis
200990|NCT01942967|Neonate
200991|NCT01942967|Hemodynamic
200992|NCT01942967|Tissue oxygenation
200993|NCT01942967|Non invasive ventilation
200994|NCT01942954|Alcohol Dependence
200995|NCT01942954|Cognitive Therapy
200996|NCT01942954|Executive Function
200997|NCT01942954|Mobile Health
200998|NCT01942954|Recovery of Function
200999|NCT01942954|Rehabilitation
201000|NCT01942889|COPD
201001|NCT01942889|exercise training
201002|NCT01942889|pulmonary rehabilitation
201003|NCT01942889|antioxidant
201004|NCT01942889|muscle
201005|NCT01942876|Drugs
201006|NCT01942876|at risk
201007|NCT01942876|community health center patients
201008|NCT01942837|Enzalutamid
201009|NCT01942837|Prostate Cancer
201010|NCT01942811|DRUG PREVENTION
201011|NCT01942811|BINATIONAL
201012|NCT01942811|CASUAL USE OF ILLICIT DRUGS
201013|NCT01942811|BRIEF INTERVENTION
201014|NCT01942811|SBIRT
201015|NCT01942798|Rehabilitation
201016|NCT01942798|Lower Limb Amputation
201017|NCT01942798|Prosthetic
201018|NCT01942798|Walking
201019|NCT01942798|unilateral transtibial amputation
201020|NCT01942798|unilateral transfemoral amputation
201021|NCT01942798|older adults
201022|NCT01942798|cognitive computer games
201023|NCT01942798|home-based training
201024|NCT01942798|Nintendo Wii
201025|NCT01942798|virtual reality
201026|NCT01942772|powered ankle-foot orthosis
201027|NCT01942772|mechanical structure
201028|NCT01942772|optimization
201029|NCT01942772|dorsiflexion
201030|NCT01942772|plantar flexion
201031|NCT01942772|gait
201032|NCT01942772|servomotor
201033|NCT01942772|ankle rehabilitation
201034|NCT01942759|Breast Neoplasms
201035|NCT01942759|Positron-Emission Tomography
201036|NCT01942759|Diffusion Magnetic Resonance Imaging
201037|NCT01942746|blueberry
201038|NCT01942746|anthocyanin
201039|NCT01942746|dark vision
201040|NCT01942746|photo bleaching
201041|NCT01942746|Visual Perception
201042|NCT01942746|Photic Stimulation
201043|NCT01942707|Abdominoplasty,Seroma,Bariatric surgery
201044|NCT01942694|Prediabetes
201045|NCT01942694|Vitamin D
201046|NCT01942681|female
201047|NCT01942681|mixed urinary incontinence
201048|NCT01942668|Vasomotor symptoms
201049|NCT01942668|Hot flashes
201050|NCT01942668|Endometrial protection
201051|NCT01942655|HIV
201052|NCT01942655|Chronic inflammatory bowel disease
201053|NCT01942655|Reservoirs
201054|NCT01942655|IL-17
201055|NCT01942655|IL-23
201056|NCT01942655|Intestinal biopsies
201057|NCT01942642|cataract surgery, meibomian gland dysfunction, meibum expressibility, meibography
201058|NCT01942629|prognostic markers,Pancreatic ductal adenocarcinoma
201059|NCT01942616|IPV
201060|NCT01942603|Minimal (SN) tumor burden
201061|NCT01942603|Stage III
201062|NCT01942603|Patients
201063|NCT01942603|Lymphnode Dissections
201064|NCT01942590|Pompe disease
201065|NCT01942577|NoSting
201066|NCT01942577|Skin protectants
201067|NCT01942577|Emollients
201068|NCT01942577|Skin microbiome
201069|NCT01942564|traumatic brain injury
201070|NCT01942564|photophobia
201071|NCT01942564|photosensitivity
201072|NCT01942564|pupil
201073|NCT01942538|rTMS
201074|NCT01942538|fibromyalgia
201075|NCT01942538|sham
201076|NCT01942538|maintenance session
201077|NCT01942538|pain
201078|NCT01942525|IUGR
201079|NCT01942525|aEEG
201080|NCT01942525|preterm infants
201081|NCT01942525|neurodevelopmental outcome
201082|NCT01942512|Intracranial Aneurysm - Endovascular treatment -
201083|NCT01942512|Coiling - Stenting - Flow diversion - Flow disruption -
201084|NCT01942512|Recanalization - Risk factors
201085|NCT01942499|COPD, exercise, community
201086|NCT01942486|migraine
201087|NCT01942486|photophobia
201088|NCT01942486|light sensitivity
201089|NCT01942486|melanopsin cells
201090|NCT01942486|intrinsically photosensitive retinal ganglion cells
201091|NCT01942460|Iron
201092|NCT01942460|Anemia
201093|NCT01942460|Chronic Kidney Disease
201094|NCT01942460|Peritoneal Dialysis
201095|NCT01942460|Inflammation
201096|NCT01942460|Oxidative stress
201097|NCT01942447|Fecal microbiota transplantation
201098|NCT01942447|microbiota
201099|NCT01942447|clostridium difficile
201100|NCT01942447|clostridium difficile infection
201101|NCT01942447|Efficacy of FMT
201102|NCT01942434|Fatty acids
201103|NCT01942434|Breast milk nutrients
201104|NCT01942434|Cognitive development
201105|NCT01942434|Electrophysiology
201106|NCT01942434|Long-term assessment
201107|NCT01942421|Limbal deficiency
201108|NCT01942421|Cultivated limbal transplantation
201109|NCT01942421|Ex vivo limbal transplantation
201110|NCT01942421|Cultivated autologous mucosal epithelial transplantation
201111|NCT01942408|Atrial fibrillation
201112|NCT01942408|Pulmonary vein isolation
201113|NCT01942408|Pulmonary vein reconnection
201114|NCT01942395|Diet
201115|NCT01942395|Sodium
201116|NCT01942395|Hypertension
201117|NCT01942395|Potassium
201118|NCT01942395|Antioxidants
201119|NCT01942395|Congestive Heart Failure
201120|NCT01942395|Heart failure with normal ejection fraction
201121|NCT01942395|Heart failure with preserved ejection fraction
201122|NCT01942382|Schizophrenia
201123|NCT01942382|JNS010
201124|NCT01942382|Paliperidone Palmitate
201125|NCT01942382|Clinical Pharmacology
201126|NCT01942369|Endometriosis
201127|NCT01942304|Sinus Floor Augmentation
201128|NCT01942304|Maxillary Sinus
201129|NCT01942304|Bone Substitutes
201130|NCT01942304|Bone Regeneration
201131|NCT01942291|Niacin
201132|NCT01942291|Endothelial function
201133|NCT01942291|Laropiprant
201134|NCT01942291|HDL
201135|NCT01942278|Healthcare
201136|NCT01942278|Patients
201137|NCT01942265|Influenza, Immunogenicity, Monovalent, A/H7N9, Vaccine, AS03, Adjuvant
201138|NCT01942252|Secondhand smoking, pain, postoperative complications
201139|NCT01942239|hypoglycemia
201140|NCT01942239|very low birth weight neonate
201141|NCT01942239|continuous glucose monitoring
201142|NCT01942226|Dry eye syndrome
201143|NCT01942213|Macular
201144|NCT01942213|Degeneration
201145|NCT01942213|Age related
201146|NCT01942213|Neovascular
201147|NCT01942200|carcinoma
201148|NCT01942200|colon cancer
201149|NCT01942200|colorectal cancer
201150|NCT01942200|ambulant chemotherapy
201151|NCT01942200|treatment cycles
201152|NCT01942200|Oxaliplatin
201153|NCT01942200|Oxaliplatin onkovis
201154|NCT01942200|Quantity of Oxaliplatin
201155|NCT01942200|Packaging Sizes
201156|NCT01942174|Antipneumococcal vaccination
201157|NCT01942174|Methotrexate treatment
201158|NCT01942161|Schyzophrenia, pediatric patients
201159|NCT01942148|Schizophrenia, Pediatric patients
201160|NCT01942135|Palbociclib (PD-0332991)
201161|NCT01942135|Fulvestrant
201162|NCT01942135|Goserelin
201163|NCT01942135|Hormone receptor-+
201164|NCT01942135|HER2-negative
201165|NCT01942135|Prior Endocrine treatment
201166|NCT01942135|any menopausal status
201167|NCT01942135|PALOMA-3
201168|NCT01942122|DLBS1442
201169|NCT01942122|Endometriosis
201170|NCT01942122|Pain
201171|NCT01942122|Visual Analogue Scale
201172|NCT01942122|Endometriosis Health Profile (EHP-30TM)
201173|NCT01942109|heart failure
201174|NCT01942109|diuretics
201175|NCT01942109|furosemide
201176|NCT01942109|torasemide
201177|NCT01942070|Cardiovascular Disease
201178|NCT01942070|Myocardial Infarction
201179|NCT01942070|Bioresorbable vascular scaffold
201180|NCT01942070|Durable polymer everolimus-eluting stent
201181|NCT01942070|Primary angioplasty
201182|NCT01942070|Stent
201183|NCT01942044|Shear stress
201184|NCT01942044|Optical coherence tomography
201185|NCT01942044|Drug-eluting stents
201186|NCT01942031|Ischemic stroke
201187|NCT01942031|Hemorrhagic stroke
201188|NCT01942031|TIA
201189|NCT01942031|Atrial fibrillation
201190|NCT01942031|prevention
201191|NCT01942031|primary care
201192|NCT01942018|esophagogastric junction outflow obstruction
201193|NCT01942018|EGOO
201194|NCT01942018|Per oral endoscopic myotomy
201195|NCT01942018|POEM
201196|NCT01942018|Gastroesophageal reflux disease
201197|NCT01942018|GERD
201198|NCT01941992|head and neck
201199|NCT01941992|Squamous Cell Carcinoma
201200|NCT01941992|oral mucositis
201201|NCT01941992|Chemo-radiotherapy
201202|NCT01941966|Anal canal cancer;capecitabine; mitomycin; radiotherapy.
201203|NCT01941953|Metformin
201204|NCT01941953|Metastatic Colorectal Cancer
201205|NCT01941953|Fluorouracil
201206|NCT01941927|Melanoma
201207|NCT01941927|Wild-type
201208|NCT01941927|BRAF
201209|NCT01941914|Calcium electroporation
201210|NCT01941914|calcium
201211|NCT01941914|electroporation
201212|NCT01941914|electrotransfer
201213|NCT01941914|keloid
201214|NCT01941901|Cutaneous metastases
201215|NCT01941875|controlled ovarian hyperstimulation
201216|NCT01941875|gonadotropins
201217|NCT01941875|intrauterine insemination
201218|NCT01941875|infertility
201219|NCT01941875|luteal progesterone
201220|NCT01941862|computerized intervention
201221|NCT01941862|cognitive bias modification
201222|NCT01941862|anxiety
201223|NCT01941862|mood
201224|NCT01941862|perceived burdensomeness
201225|NCT01941862|thwarted belongingness
201226|NCT01941862|suicide
201227|NCT01941862|post-traumatic stress disorder
201228|NCT01941849|Phaeochromocytoma
201229|NCT01941849|Paraganglioma
201230|NCT01941849|Neuroendocrine Tumour
201231|NCT01941849|Vandetanib
201232|NCT01941849|131I-mIBG
201233|NCT01941849|Radionucleotide Therapy
201234|NCT01941849|Vascular Endothelial Growth Factor (VEGF)
201235|NCT01941849|Epidermal Growth Factor Receptor (EGFR)
201236|NCT01941849|RET
201237|NCT01941849|Tyrosine Kinase
201238|NCT01941836|Statin intolerant
201239|NCT01941836|Statin tolerant
201240|NCT01941836|LDL
201241|NCT01941836|Cholesterol
201242|NCT01941823|acute renal failure
201243|NCT01941823|CRRT
201244|NCT01941823|continuous dialysis
201245|NCT01941823|carnitine
201246|NCT01941823|cardiac strain
201247|NCT01941771|Breast cancer
201248|NCT01941771|Metronomic chemotherapy
201249|NCT01941771|Vinorelbine
201250|NCT01941771|Navelbine
201251|NCT01941771|Capecitabine
201252|NCT01941771|Xeloda
201253|NCT01941771|Antineoplastic Agents
201254|NCT01941719|Diabetes Mellitus
201255|NCT01941719|Diabetic Foot
201256|NCT01941719|Diabetic Peripheral Neuropathy
201257|NCT01941719|Diabetic Foot Education
201258|NCT01941706|Epilepsy
201259|NCT01941706|Seizure
201260|NCT01941706|Cognitive Behavioral Therapy
201261|NCT01941706|Mindfulness
201262|NCT01941706|Depression
201263|NCT01941706|Depressive symptoms
201264|NCT01941706|prevention
201265|NCT01941706|Coping skills
201266|NCT01941706|Quality of life
201267|NCT01941706|Telehealth
201268|NCT01941706|Phone intervention
201269|NCT01941706|Internet-based intervention
201270|NCT01941693|alcohol
201271|NCT01941693|anxiety
201272|NCT01941693|depression
201273|NCT01941693|comorbidity
201274|NCT01941693|CBT
201275|NCT01941667|Congenital Heart Disease
201276|NCT01941667|Neonates and infants
201277|NCT01941667|Telehealth
201278|NCT01941667|Virtual Home Visits
201279|NCT01941628|Cesarean section
201280|NCT01941628|General anesthesia
201281|NCT01941628|neuromuscular blockade
201282|NCT01941628|Surgical conditions
201283|NCT01941602|surgery
201284|NCT01941602|enoxaparin
201285|NCT01941602|venous thromboembolism
201286|NCT01941602|perioperative care
201287|NCT01941576|Heart defects, Congenital
201288|NCT01941576|rhBNP
201289|NCT01941576|heart failure
201290|NCT01941550|untreated, high risk prostate cancer
201291|NCT01941537|Atopic Dermatitis
201292|NCT01941524|Brain oxygenation
201293|NCT01941524|NIRS
201294|NCT01941524|aEEG
201295|NCT01941524|surfactant
201296|NCT01941511|QTc
201297|NCT01941511|African-American
201298|NCT01941511|GMI-1070
201299|NCT01941511|QT/QTc interval prolongation
201300|NCT01941498|nearsighted
201301|NCT01941498|farsighted
201302|NCT01941498|astigmatism
201303|NCT01941498|LASIK
201304|NCT01941498|refractive surgery
201305|NCT01941498|WaveLight
201306|NCT01941485|nearsighted
201307|NCT01941485|astigmatism
201308|NCT01941485|LASIK
201309|NCT01941485|refractive surgery
201310|NCT01941485|WaveLight
201311|NCT01941459|CK-MB
201312|NCT01941459|troponin-T
201313|NCT01941433|rheumatoid arthritis
201314|NCT01941433|self-management
201315|NCT01941433|online
201316|NCT01941433|patient passport
201317|NCT01941420|CK-MB
201318|NCT01941420|troponin-T
201319|NCT01941420|Cytokines under ischemia
201320|NCT01941394|GVHD
201321|NCT01941394|Relapse
201322|NCT01941394|Overall Survival
201323|NCT01941381|Otitis Media
201324|NCT01941381|Tympanometry
201325|NCT01941368|Performance
201326|NCT01941368|Aerobic Exercise
201327|NCT01941342|Obstructive Jaundice
201328|NCT01941342|Preoperative Biliary Drainage
201329|NCT01941342|Pancreatoduodenectomy
201330|NCT01941329|Diabetes
201331|NCT01941329|Proliferative Retinopathy
201332|NCT01941329|Ranibizumab
201333|NCT01941329|Panretinal Photocoagulation
201334|NCT01941316|Carfilzomib
201335|NCT01941316|Irinotecan
201336|NCT01941316|Small Cell Lung Cancer
201337|NCT01941316|Non Small Cell Lung Cancer
201338|NCT01941316|Ovarian Cancer
201339|NCT01941316|Gastric Cancer
201340|NCT01941316|Esophageal Cancer
201341|NCT01941316|Cervical Cancer
201342|NCT01941303|Non-small cell lung cancer
201343|NCT01941290|International
201344|NCT01941290|Multicenter
201345|NCT01941290|Observational registry
201346|NCT01941290|Orsiro Drug Eluting Stents (DES)
201347|NCT01941290|Stenting
201348|NCT01941290|Treatment of Coronary Artery Disease
201349|NCT01941290|Coronary Revascularization
201350|NCT01941290|Percutaneous Coronary Intervention (PCI)
201351|NCT01941290|Diabetes Mellitus Type 1
201352|NCT01941290|Diabetes Mellitus Type 2
201353|NCT01941290|STEMI
201354|NCT01941290|NSTEMI
201355|NCT01941290|Ischemia
201356|NCT01941290|Angina
201357|NCT01941290|Subgroups
201358|NCT01941290|Acute Myocardial Infarction
201359|NCT01941290|Small Vessels
201360|NCT01941290|Chronic Total Occlusion
201361|NCT01941264|malaria
201362|NCT01941264|placenta
201363|NCT01941264|pregnancy
201364|NCT01941264|plasmodium falciparum
201365|NCT01941264|screening and treatment
201366|NCT01941264|rapid diagnostic test
201367|NCT01941264|coartem
201368|NCT01941264|artemether-lumefantrine
201369|NCT01941264|community health worker
201370|NCT01941251|Transcranial Magnetic Stimulation
201371|NCT01941251|Repetitive Transcranial Magnetic Stimulation
201372|NCT01941251|Schizophrenia
201373|NCT01941251|Schizoaffective Disorder
201374|NCT01941251|Treatment
201375|NCT01941251|Negative Symptoms
201376|NCT01941251|Positive Symptoms
201377|NCT01941251|TMS
201378|NCT01941251|rTMS
201379|NCT01941238|Ramadan
201380|NCT01941238|Fasting
201381|NCT01941238|Diabetes
201382|NCT01941238|Type1
201383|NCT01941238|Insulin
201384|NCT01941238|Pump
201385|NCT01941225|Chronic obstructive pulmonary disease
201386|NCT01941225|Pulmonary vasculature
201387|NCT01941225|Inhaled iloprost
201388|NCT01941225|Inhaled prostacyclin
201389|NCT01941225|Dynamic hyperinflation
201390|NCT01941225|Oxidative stress
201391|NCT01941225|Cardiopulmonary exercise testing
201392|NCT01941225|B-type natriuretic peptide
201393|NCT01941212|Music therapy
201394|NCT01941212|pain
201395|NCT01941212|gynecological surgeries
201396|NCT01941186|Children
201397|NCT01941186|Developmental Delays
201398|NCT01941186|Early Intervention (EI)
201399|NCT01941186|Patient Decision Aid (PDA)
201400|NCT01941147|Acute Stroke
201401|NCT01941147|Brain Ischemia
201402|NCT01941147|Extremely Low Frequency Magnetic Fields
201403|NCT01941121|HIV Screening
201404|NCT01941121|Linkage to PrEP
201405|NCT01941121|Linkage to Care
201406|NCT01941121|CCTG
201407|NCT01941121|593
201408|NCT01941108|AIDS
201409|NCT01941108|peer navigation
201410|NCT01941108|ecological momentary assessment
201411|NCT01941108|eMOCHA
201412|NCT01941108|Baltimore
201413|NCT01941108|IDU
201414|NCT01941030|Peripheral Artery Disease
201415|NCT01941030|Critical Limb Ischemia
201416|NCT01941030|Orbital Atherectomy
201417|NCT01941030|Balloon Angioplasty
201418|NCT01941030|Intravascular Ultrasound (IVUS)
201419|NCT01941030|Fractional Flow Reserve (FFR)
201420|NCT01941030|Quality of Life
201421|NCT01941004|multiple sclerosis (MS)
201422|NCT01941004|relapsing remitting multiple sclerosis (RRMS)
201423|NCT01941004|fingolimod
201424|NCT01940978|Methamphetamine
201425|NCT01940978|Methylphenidate
201426|NCT01940978|ADHD
201427|NCT01940939|schizophrenia
201428|NCT01940926|rheumatoid arthritis
201429|NCT01940926|angiogenesis
201430|NCT01940926|68Ga-PRGD2
201431|NCT01940926|18F-FDG
201432|NCT01940926|positron emission tomography/computed tomography
201433|NCT01940900|Wet AMD
201434|NCT01940900|choroidal neovascularization
201435|NCT01940900|Fovista®
201436|NCT01940900|E10030
201437|NCT01940900|Lucentis®
201438|NCT01940887|Wet AMD
201439|NCT01940887|choroidal neovascularization
201440|NCT01940887|Fovista®
201441|NCT01940887|E10030
201442|NCT01940887|Avastin®
201443|NCT01940887|Eylea®
201444|NCT01940874|Cerebral Oximetry.
201445|NCT01940874|Aortic valve stenosis.
201446|NCT01940874|Aortic valve regurgitation.
201447|NCT01940874|Coronary artery disease.
201448|NCT01940848|Iberogast
201449|NCT01940848|efficacy
201450|NCT01940848|safety
201451|NCT01940796|Brentuximab Vedotin
201452|NCT01940796|GVHD
201453|NCT01940796|Refractory Chronic Graft vs Host Disease
201454|NCT01940770|Diabetes Mellitus(DM)
201455|NCT01940770|Bydureon
201456|NCT01940770|Exenatide
201457|NCT01940757|Necator americanus
201458|NCT01940757|Hookworm Infection
201459|NCT01940757|Experimental challenge infection
201460|NCT01940744|Low back pain
201461|NCT01940744|Non-specific Low back pain
201462|NCT01940718|Priapism
201463|NCT01940718|Sickle cell disease
201464|NCT01940718|Testosterone
201465|NCT01940718|Androgen deficiency
201466|NCT01940705|hearing aids
201467|NCT01940705|counseling
201468|NCT01940705|outcomes assessment (health care)
201469|NCT01940705|rehabilitation
201470|NCT01940666|Hyperandrogenism/
201471|NCT01940666|FAI/
201472|NCT01940666|Metabolic syndrome/
201473|NCT01940666|Adipocytokines/
201474|NCT01940666|Insulin resistance.
201475|NCT01940640|neonates, DHA
201476|NCT01940627|Ubiquinol, exercise
201477|NCT01940614|Copeptin
201478|NCT01940614|differential diagnosis of polyuria polydipsia syndrome
201479|NCT01940614|diabetes insipidus
201480|NCT01940614|compulsive water drinking
201481|NCT01940614|water deprivation test
201482|NCT01940601|solid tumors
201483|NCT01940601|balugrastim
201484|NCT01940575|Tissue restorative biomaterial
201485|NCT01940575|Hyaluronic acid
201486|NCT01940575|Restylane®
201487|NCT01940575|Wrinkle Severity Rating Scale (WSRS)
201488|NCT01940575|Global Aesthetic Improvement Scale (GAIS)
201489|NCT01940575|Nasolabial fold(NLF)
201490|NCT01940562|cord blood transplantation
201491|NCT01940562|platelets
201492|NCT01940562|eltrombopag
201493|NCT01940549|PTSD
201494|NCT01940549|tDCS
201495|NCT01940549|Trauma
201496|NCT01940536|Hip Fracture
201497|NCT01940536|Blood Transfusion
201498|NCT01940536|Blood Loss
201499|NCT01940536|Tranexamic Acid
201500|NCT01940523|total knee arthroplasty
201501|NCT01940523|total knee replacement
201502|NCT01940523|tranexamic acid
201503|NCT01940523|osteoarthritis
201504|NCT01940523|degenerative joint disease
201505|NCT01940471|Hepatitis
201506|NCT01940471|Tenofovir
201507|NCT01940471|Viread
201508|NCT01940432|simple stress urinary incontinence
201509|NCT01940419|Reduction of blood loss
201510|NCT01940419|Surgical complication
201511|NCT01940419|Hysterectomy
201512|NCT01940419|Antifibrinolytic Agents
201513|NCT01940419|Randomized Controlled Trials
201514|NCT01940406|Essential Tremor
201515|NCT01940406|Parkinson Disease
201516|NCT01940406|Electrical Stimulation
201517|NCT01940406|Tremor
201518|NCT01940393|urticaria
201519|NCT01940393|bilastine
201520|NCT01940393|fexofenadine
201521|NCT01940393|cetirizine
201522|NCT01940393|ebastine
201523|NCT01940393|desloratadine
201524|NCT01940367|Overactive Bladder
201525|NCT01940367|TENS
201526|NCT01940367|PTNS
201527|NCT01940367|Electrical Nerve Stimulation
201528|NCT01940367|Urge Urinary Incontinence
201529|NCT01940354|IV Catheter comparison
201530|NCT01940354|AccuCath versus Conventional IV Catheters
201531|NCT01940354|IV Catheter Study
201532|NCT01940354|IV Catheter User Preference Comparison
201533|NCT01940354|First Attempt Success Rate for IV Catheters
201534|NCT01940354|AccuCath Device Performance
201535|NCT01940354|Patient Satisfaction with IV Catheters
201536|NCT01940354|Clinician Satisfaction with AccuCath Device Performance
201537|NCT01940341|Hepatitis
201538|NCT01940341|Tenofovir
201539|NCT01940341|Viread
201540|NCT01940328|Ultrasound Doppler
201541|NCT01940328|Congestive heart failure
201542|NCT01940328|Pulmonary Edema
201543|NCT01940315|Defender Study
201544|NCT01940315|experimental vaccine
201545|NCT01940315|inhalational intoxication
201546|NCT01940302|Malnutrition; Metabolic disorders
201547|NCT01940289|algometry
201548|NCT01940289|pain
201549|NCT01940289|VAS
201550|NCT01940276|Prostate cancer
201551|NCT01940276|metastatic
201552|NCT01940276|castrate resistant
201553|NCT01940276|abiraterone acetate
201554|NCT01940276|prednisone
201555|NCT01940276|metastatic prostate cancer
201556|NCT01940263|oxidative stress
201557|NCT01940263|dyslipidemia
201558|NCT01940263|inflammation
201559|NCT01940263|apoptosis
201560|NCT01940250|Hand, foot and mouth disease
201561|NCT01940250|Autonomic nervous system dysregulation
201562|NCT01940250|Magnesium sulphate
201563|NCT01940237|Depression
201564|NCT01940237|Psychotherapy
201565|NCT01940237|Cancer
201566|NCT01940237|Pancreatic Cancer
201567|NCT01940237|Lung Cancer
201568|NCT01940237|Colon Cancer
201569|NCT01940237|Prostate Cancer
201570|NCT01940224|Pregabalin
201571|NCT01940224|Laparoscopic colorectal surgery
201572|NCT01940224|Postoperative pain
201573|NCT01940224|Opioid consumption
201574|NCT01940198|Atazanavir
201575|NCT01940198|long-term
201576|NCT01940198|primary care setting
201577|NCT01940198|sydney
201578|NCT01940159|Schizophrenia
201579|NCT01940159|Schizoaffective disorders
201580|NCT01940120|Mitral Valve Insufficiency
201581|NCT01940120|Mitral Valve Regurgitation
201582|NCT01940120|Mitral Valve Incompetence
201583|NCT01940120|Mitral Regurgitation
201584|NCT01940120|Mitral Insufficiency
201585|NCT01940120|Mitral Valve
201586|NCT01940120|MR
201587|NCT01940120|Mitral Valve Prolapse
201588|NCT01940120|Edge to Edge (E2E)
201589|NCT01940120|Alfieri Technique
201590|NCT01940120|MitraClip
201591|NCT01940120|Functional MR
201592|NCT01940120|Degenerative MR
201593|NCT01940120|Echocardiogram
201594|NCT01940120|CAD - Coronary Artery Disease
201595|NCT01940120|Heart Failure
201596|NCT01940120|Heart Attack
201597|NCT01940120|EVEREST
201598|NCT01940120|EVEREST I
201599|NCT01940120|EVEREST II
201600|NCT01940120|REALISM
201601|NCT01940107|breast cancer,
201602|NCT01940107|radiotherapy,
201603|NCT01940107|physical therapy,
201604|NCT01940107|upper limb
201605|NCT01940094|Granulomatosis with polyangiitis
201606|NCT01940094|Wegener's granulomatosis
201607|NCT01940094|WG
201608|NCT01940094|GPA
201609|NCT01940094|ANCA-Associated Vasculitis
201610|NCT01940094|AAV
201611|NCT01940094|Vasculitis
201612|NCT01940094|Prednisone
201613|NCT01940094|Glucocorticoid
201614|NCT01940094|Taper
201615|NCT01940081|Cardiomyopathy, Dilated
201616|NCT01940081|Tachycardia, Ventricular
201617|NCT01940081|Ventricular Fibrillation
201618|NCT01940081|Arrhythmias, Cardiac/etiology
201619|NCT01940081|Arrhythmias, Cardiac/physiopathology
201620|NCT01940081|Magnetic Resonance Imaging
201621|NCT01940081|3-Iodobenzylguanidine/diagnostic use
201622|NCT01940081|Sympathetic Nervous System/radionuclide imaging
201623|NCT01940081|Electrophysiologic Techniques, Cardiac
201624|NCT01940081|Biopsy
201625|NCT01940081|Genetic Testing
201626|NCT01940081|Echocardiography
201627|NCT01940081|Electrocardiography, Ambulatory
201628|NCT01940081|Exercise Test
201629|NCT01940068|Hypersensitivity
201630|NCT01940068|Milk Hypersensitivity
201631|NCT01940068|Immune System Diseases
201632|NCT01940068|Food Hypersensitivity
201633|NCT01940055|Balance
201634|NCT01940055|Gait
201635|NCT01940055|Instrumented Treadmill
201636|NCT01940055|Recumbent cycle
201637|NCT01940055|Cognitive games
201638|NCT01940029|vancomycin, neurosurgery, critical ill, pharmacokinetics
201639|NCT01940016|Feasibility study
201640|NCT01940016|Interactive voice response system (IVR)
201641|NCT01940016|health coach
201642|NCT01940016|no evidence of disease
201643|NCT01940003|Diabetes, Gestational
201644|NCT01940003|Pregnancy Outcome
201645|NCT01940003|Exercise
201646|NCT01940003|glycemic control
201647|NCT01939990|Chronic Obstructive Pulmonary Disease
201648|NCT01939977|Hyperparathyroidism
201649|NCT01939977|Hyperparathyroidism Secondary
201650|NCT01939977|Paricalcitol
201651|NCT01939977|Calcifediol
201652|NCT01939977|Parathyroid hormone
201653|NCT01939977|Renal transplantation
201654|NCT01939964|Wrinkles
201655|NCT01939964|Activation Mist
201656|NCT01939951|Asthma
201657|NCT01939951|Persistent
201658|NCT01939925|patient education
201659|NCT01939925|Health Knowledge, Attitudes, Practice
201660|NCT01939925|comprehension
201661|NCT01939925|consumer health information
201662|NCT01939899|MLN9708
201663|NCT01939899|Lymphoma
201664|NCT01939899|IXAZOMIB
201665|NCT01939886|Malaria treatment efficacy
201666|NCT01939886|Malaria transmission
201667|NCT01939873|Kristeller maneuver; Second stage of labor;
201668|NCT01939873|Perineal laceration; Obstetrical outcome;
201669|NCT01939873|Neonatal outcome
201670|NCT01939847|Metastatic breast cancer
201671|NCT01939847|Breast cancer
201672|NCT01939847|Molecular profiling
201673|NCT01939847|Personalized medicine
201674|NCT01939834|Type 1 Diabetes Mellitus
201675|NCT01939834|Artificial Pancreas
201676|NCT01939834|Diabetes Assistant (DiAs)
201677|NCT01939834|Continuous Glucose Monitor
201678|NCT01939821|Fecal incontinence
201679|NCT01939821|attitudes
201680|NCT01939821|knowledge
201681|NCT01939821|quality of care
201682|NCT01939795|cardiac resynchronization therapy (CRT)
201683|NCT01939782|Metabolic CLock Genes (MCG)
201684|NCT01939782|Type 2 Diabetes (T2D)
201685|NCT01939769|fMRI
201686|NCT01939769|Catecholamines
201687|NCT01939769|Stress
201688|NCT01939769|Exercise
201689|NCT01939769|Memory
201690|NCT01939756|High risk non-muscle invasive urothelial bladder cancer
201691|NCT01939756|Intravesical BCG
201692|NCT01939756|Local toxicity
201693|NCT01939756|Natural baobab oil
201694|NCT01939730|Lymphoma
201695|NCT01939730|Follicular B-Cell Lymphoma
201696|NCT01939730|Rituximab
201697|NCT01939730|Rituxan
201698|NCT01939730|GM-CSF
201699|NCT01939730|Sargramostim
201700|NCT01939730|Leukine
201701|NCT01939717|Parkinson's disease
201702|NCT01939717|Irish set dancing
201703|NCT01939665|Locally advanced pancreatic carcinoma
201704|NCT01939665|LAPC
201705|NCT01939665|Irreversible electroporation
201706|NCT01939665|NanoKnife
201707|NCT01939665|IRE
201708|NCT01939665|Safety
201709|NCT01939665|Efficacy
201710|NCT01939665|Non-thermal ablation
201711|NCT01939665|Percutaneous ablation
201712|NCT01939665|Low Energy Direct Current
201713|NCT01939652|minilaparotomy
201714|NCT01939652|AAA
201715|NCT01939652|fluid regime
201716|NCT01939639|Oxytocin
201717|NCT01939639|fMRI
201718|NCT01939626|embryo
201719|NCT01939626|culture
201720|NCT01939613|fluid resuscitation
201721|NCT01939613|burn
201722|NCT01939613|colloid,
201723|NCT01939613|multiple organ dysfunction
201724|NCT01939613|intra-abdominal pressure
201725|NCT01939600|Resistant starch
201726|NCT01939600|Ileostomy
201727|NCT01939600|In vivo
201728|NCT01939600|Carbohydrate digestibility
201729|NCT01939587|Adenosine A1 receptor antagonist
201730|NCT01939587|Asthma
201731|NCT01939587|adenosine receptor modulator
201732|NCT01939587|COPD
201733|NCT01939574|Glioblastoma
201734|NCT01939574|Potential Image Biomarkers
201735|NCT01939574|PFS
201736|NCT01939574|Bevacizumab
201737|NCT01939574|Conventional Therapy
201738|NCT01939561|Myotonia
201739|NCT01939561|Lamotrigine
201740|NCT01939561|RCT
201741|NCT01939561|treatment
201742|NCT01939548|PF-02545920
201743|NCT01939548|schizophrenia
201744|NCT01939548|outpatient
201745|NCT01939548|safety
201746|NCT01939548|efficacy
201747|NCT01939548|suboptimal response
201748|NCT01939535|Endometriosis
201749|NCT01939535|Magnetic resonance imaging
201750|NCT01939522|diabetes
201751|NCT01939522|pneumococcal
201752|NCT01939496|Diabetes Mellitus, Type 2
201753|NCT01939496|Hypertension
201754|NCT01939496|Canagliflozin
201755|NCT01939496|JNJ 28431754
201756|NCT01939496|Sodium-Glucose Transporter 2
201757|NCT01939496|Blood Glucose
201758|NCT01939496|Type 2 Diabetes Mellitus
201759|NCT01939483|Irinotecan hydrochloride
201760|NCT01939483|Irinotecan
201761|NCT01939483|CAMPTOSAR
201762|NCT01939470|osteoporosis
201763|NCT01939470|bone
201764|NCT01939470|inflammation
201765|NCT01939470|diabetes
201766|NCT01939470|vitamin D
201767|NCT01939444|Antidotes
201768|NCT01939444|naloxone
201769|NCT01939444|administration, intravenous
201770|NCT01939444|administration, intranasal
201771|NCT01939444|pharmacology
201772|NCT01939431|Podoconiosis
201773|NCT01939431|Gene Expression
201774|NCT01939431|Genomics
201775|NCT01939431|Pathogenesis
201776|NCT01939418|metastatic breast cancer
201777|NCT01939418|triple negative breast cancer
201778|NCT01939418|gemcitabine
201779|NCT01939418|RAD001
201780|NCT01939405|Obesity
201781|NCT01939405|Overweight
201782|NCT01939405|Physical Activity
201783|NCT01939405|Built Environment
201784|NCT01939405|counseling
201785|NCT01939392|Resistant hypertension
201786|NCT01939392|Uncontrolled hypertension
201787|NCT01939392|Renal artery ablation
201788|NCT01939379|Total knee arthroplasty
201789|NCT01939379|nerve block
201790|NCT01939379|Pain control after surgery
201791|NCT01939366|Painful Diabetic Peripheral Neuropathy
201792|NCT01939353|Adult ADHD
201793|NCT01939327|diffuse large B cell
201794|NCT01939327|non-Hodgkin lymphoma
201795|NCT01939314|Headache
201796|NCT01939314|Migraine
201797|NCT01939301|Pulmonary embolism clot
201798|NCT01939262|Arthritis
201799|NCT01939262|Pain
201800|NCT01939262|Function
201801|NCT01939262|Diet
201802|NCT01939262|Vegan
201803|NCT01939262|Vegetarian
201804|NCT01939262|Restriction
201805|NCT01939236|chronic heart failure
201806|NCT01939236|traditional Chinese medicine
201807|NCT01939236|syndrome differentiation
201808|NCT01939223|Stage IV colorectal cancer / Liver Metastasis
201809|NCT01939197|Cirrhotic
201810|NCT01939197|HCV Genotype 4
201811|NCT01939197|Hepatitis C Genotype 1
201812|NCT01939197|HCV Genotype 1
201813|NCT01939197|Compensated Cirrhosis
201814|NCT01939197|Hepatitis C Genotype 4
201815|NCT01939197|Interferon-Free
201816|NCT01939197|HIV-1
201817|NCT01939197|HCV / HIV coinfection
201818|NCT01939197|Hepatitis C
201819|NCT01939171|Thymoglobulin
201820|NCT01939171|Cadaver donor
201821|NCT01939171|Kidney injury brain death related
201822|NCT01939158|Co-administration
201823|NCT01939158|Safety
201824|NCT01939158|Persistence
201825|NCT01939158|Immunogenicity
201826|NCT01939158|Prevenar 13
201827|NCT01939158|Meningococcal vaccine
201828|NCT01939158|Toddlers
201829|NCT01939158|5 years
201830|NCT01939145|hospital admission
201831|NCT01939132|Psoriatic Arthritis
201832|NCT01939132|ACTH
201833|NCT01939132|Acthar
201834|NCT01939119|retinal vascular occlusion
201835|NCT01939119|drinking habits
201836|NCT01939119|body hydration
201837|NCT01939119|body-fluid balance
201838|NCT01939106|Stoma
201839|NCT01939106|Ileostomy
201840|NCT01939106|pouch
201841|NCT01939106|Drainable Pouch for collection of stool
201842|NCT01939093|Quetiapine
201843|NCT01939093|Haloperidol
201844|NCT01939093|Methamphetamine
201845|NCT01939093|Psychosis
201846|NCT01939080|moderate risk
201847|NCT01939080|high risk
201848|NCT01939067|respiratory distress
201849|NCT01939067|Heated Humidified High Flow Nasal Cannula (HHHFNC)
201850|NCT01939067|HHHFNC
201851|NCT01939067|noninvasive nasal continuous positive airway pressure (NCPAP)
201852|NCT01939067|NCPAP
201853|NCT01939041|Subacute Stroke
201854|NCT01939041|Unilateral Robot-Assisted Training
201855|NCT01939041|Bilateral Robot-Assisted Training
201856|NCT01939041|Motor control
201857|NCT01939041|Physiological Response
201858|NCT01939015|3D miniplate
201859|NCT01939015|angle mandibular fracture
201860|NCT01939015|champy technique
201861|NCT01939015|internal rigid fixation
201862|NCT01939002|flu-like symptoms
201863|NCT01938989|cataract
201864|NCT01938989|intraocular lens
201865|NCT01938989|IOL
201866|NCT01938989|blue light filter
201867|NCT01938976|Asthma
201868|NCT01938976|Tobacco
201869|NCT01938976|Waterpipe
201870|NCT01938976|Cigarettes
201871|NCT01938976|Adolescents
201872|NCT01938976|Peer education
201873|NCT01938976|Jordan
201874|NCT01938963|Depression
201875|NCT01938963|Hypertension
201876|NCT01938963|Older Adults
201877|NCT01938911|Trier social stress test
201878|NCT01938911|Oxytocin
201879|NCT01938911|Hypertension
201880|NCT01938898|Randomized trial
201881|NCT01938898|Invitation letter
201882|NCT01938898|Recruitment
201883|NCT01938898|Retention
201884|NCT01938872|critical limb ischemia
201885|NCT01938872|drug-eluting balloon
201886|NCT01938872|restenosis
201887|NCT01938859|bipolar disorder
201888|NCT01938859|lithium
201889|NCT01938859|quetiapine
201890|NCT01938859|Medicine, Chinese Traditional
201891|NCT01938859|efficacy
201892|NCT01938859|safety
201893|NCT01938859|Recurrence
201894|NCT01938820|Hepatitis B
201895|NCT01938820|Liver Cirrhosis
201896|NCT01938820|Regression
201897|NCT01938820|Efficacy
201898|NCT01938807|type 1 diabetes
201899|NCT01938807|parents
201900|NCT01938807|mobile application
201901|NCT01938807|diabetes management
201902|NCT01938781|Hepatitis B
201903|NCT01938781|Liver fibrosis
201904|NCT01938781|Regression
201905|NCT01938781|Efficacy
201906|NCT01938768|Multiple trauma
201907|NCT01938768|Polytrauma
201908|NCT01938768|Hyperfibrinolysis
201909|NCT01938768|Tranexamic acid
201910|NCT01938768|Thrombelastometry
201911|NCT01938742|A/H7N9,Adjuvant,Immunogenicity,Influenza,MF59,Monovalent,Vaccine
201912|NCT01938729|HEPATIC ARTERIAL INFUSION
201913|NCT01938729|FLOXURIDINE
201914|NCT01938729|DEXAMETHASONE
201915|NCT01938729|GEMCITABINE
201916|NCT01938729|Pump
201917|NCT01938729|13-148
201918|NCT01938716|Pancreatic Cancer
201919|NCT01938716|Adenocarcinoma of the Pancreas
201920|NCT01938716|Intratumoral gemcitabine levels
201921|NCT01938716|Pancreatic surgery
201922|NCT01938716|Pharmacokinetic testing
201923|NCT01938716|PK
201924|NCT01938716|Gemcitabine
201925|NCT01938716|Gemcitabine Hydrochloride
201926|NCT01938716|Gemzar
201927|NCT01938690|stroke, transcranial magnetic stimulation, rehabilitation
201928|NCT01938677|Vestibular schwannoma
201929|NCT01938677|Gamma knife radiosurgery
201930|NCT01938677|Hearing preservation
201931|NCT01938664|cocaine
201932|NCT01938664|dependence
201933|NCT01938664|pharmacotherapy
201934|NCT01938638|Advanced malignancies
201935|NCT01938638|TNBC
201936|NCT01938638|DLBCL
201937|NCT01938638|Gastric cancer
201938|NCT01938625|Hepatitis C, Chronic
201939|NCT01938625|Recurrent Chronic Hepatitis C
201940|NCT01938625|Pharmacokinetics
201941|NCT01938625|Simeprevir
201942|NCT01938625|Daclatasvir
201943|NCT01938625|Ribavirin
201944|NCT01938625|Orthotopic Liver Transplantation
201945|NCT01938625|TMC435
201946|NCT01938625|BMS-790052
201947|NCT01938625|RBV
201948|NCT01938612|MEDI4736
201949|NCT01938612|Advanced solid tumors
201950|NCT01938612|squamous cell carcinoma of the head and Neck
201951|NCT01938612|biliary tract cancer
201952|NCT01938612|squamous cell carcinoma of esophagus cancer
201953|NCT01938612|B7-H1
201954|NCT01938612|PD-L1
201955|NCT01938599|Plaque Psoriasis
201956|NCT01938586|Scar
201957|NCT01938586|Appearance
201958|NCT01938547|perioperative
201959|NCT01938547|blood pressure
201960|NCT01938547|pediatrics
201961|NCT01938547|pediatric surgery
201962|NCT01938521|Red Grape Cells powder (RGC)
201963|NCT01938521|Placebo (PLA)
201964|NCT01938508|dermatitis
201965|NCT01938508|Minocycline
201966|NCT01938508|bioavailability
201967|NCT01938495|ALS
201968|NCT01938495|DPS
201969|NCT01938495|Diaphragm Pacing
201970|NCT01938482|Gel
201971|NCT01938482|Acne
201972|NCT01938482|SCD1
201973|NCT01938482|Topical Administration
201974|NCT01938469|Bariatric
201975|NCT01938469|Gastric Bypass
201976|NCT01938469|Gastric Banding,
201977|NCT01938469|Incretins
201978|NCT01938469|glucagon-like peptide-1(GLP-1)
201979|NCT01938469|gastric inhibitory peptide (GIP)
201980|NCT01938456|Non-small cell lung cancer
201981|NCT01938456|GSK1120212 (trametinib)
201982|NCT01938456|Japanese
201983|NCT01938456|Phase Ib
201984|NCT01938456|combination therapy
201985|NCT01938456|docetaxel
201986|NCT01938456|MEK inhibitor
201987|NCT01938443|pharmacodynamics
201988|NCT01938443|MEK inhibitor
201989|NCT01938443|Focal adhesion kinase inhibitor
201990|NCT01938443|cancer
201991|NCT01938443|pharmacokinetic
201992|NCT01938443|mesothelioma
201993|NCT01938443|Phase 1
201994|NCT01938417|tobramycin
201995|NCT01938417|bone graft substitute
201996|NCT01938417|pharmacokinetics
201997|NCT01938417|renal failure
201998|NCT01938404|Plasma exchange
201999|NCT01938404|Thrombotic Thrombocytopenic Purpura
202000|NCT01938404|TTP
202001|NCT01938391|Peripheral Artery Disease
202002|NCT01938391|PAD
202003|NCT01938391|Claudication
202004|NCT01938391|Peripheral Vascular Disease
202005|NCT01938391|PVD
202006|NCT01938391|Orbital Atherectomy
202007|NCT01938391|Balloon Angioplasty
202008|NCT01938391|Intravascular Ultrasound (IVUS)
202009|NCT01938378|Octaplas
202010|NCT01938352|Influenza
202011|NCT01938352|Virus
202012|NCT01938352|Monoclonal Antibody
202013|NCT01938352|Immunization
202014|NCT01938352|Treatment
202015|NCT01938339|prostate cancer
202016|NCT01938339|MRI
202017|NCT01938339|PET
202018|NCT01938326|Stomach neoplasm
202019|NCT01938326|TLDG
202020|NCT01938326|SIDG
202021|NCT01938326|single-port
202022|NCT01938326|inflammatory response
202023|NCT01938313|gastric cancer
202024|NCT01938313|ERAS (early recovery after surgery)
202025|NCT01938313|fast track
202026|NCT01938313|laparoscopic gastrectomy
202027|NCT01938274|Hip
202028|NCT01938274|Knee
202029|NCT01938274|Osteoarthritis
202030|NCT01938274|Arthroplasty
202031|NCT01938274|Physical Activity
202032|NCT01938274|Expectations
202033|NCT01938274|Leisure Activity
202034|NCT01938248|Pacemaker, Artificial
202035|NCT01938248|Defibrillators, Implantable
202036|NCT01938248|Atrial Fibrillation
202037|NCT01938248|Stroke Risk
202038|NCT01938235|Myocardial infarction
202039|NCT01938235|Percutaneous coronary intervention
202040|NCT01938235|Reperfusion injury
202041|NCT01938235|Exenatide
202042|NCT01938235|Magnetic resonance imaging
202043|NCT01938222|abdominal wall closure
202044|NCT01938222|short stitch technique
202045|NCT01938196|Chronic Constipation
202046|NCT01938196|Constipation
202047|NCT01938196|Functional gastrointestinal disorders
202048|NCT01938183|chronic periodontitis
202049|NCT01938183|metronidazole
202050|NCT01938157|High Risk of Breast Cancer
202051|NCT01938157|Diffusion Magnetic Resonance Imaging
202052|NCT01938144|Common cold
202053|NCT01938144|efficacy
202054|NCT01938144|symptoms
202055|NCT01938144|Wisconsin Upper Respiratory Symptom Survey - 21
202056|NCT01938144|ibuprofen
202057|NCT01938144|phenylephrine
202058|NCT01938144|pseudoephedrine
202059|NCT01938131|knee, osteoarthritis, muscle vibration
202060|NCT01938118|Infant diet
202061|NCT01938118|Family diet
202062|NCT01938118|Responsive feeding
202063|NCT01938118|Infant temperament
202064|NCT01938118|Physical activity
202065|NCT01938118|Television
202066|NCT01938105|Cervical cancer
202067|NCT01938105|Nimotuzumab
202068|NCT01938105|Intensity-modulated radiation therapy
202069|NCT01938105|Concurrent chemoradiotherapy
202070|NCT01938092|High-tone pelvic floor dysfunction
202071|NCT01938092|Spasm
202072|NCT01938092|Pelvic pain
202073|NCT01938092|Diazepam
202074|NCT01938092|Female
202075|NCT01938092|Randomized trial
202076|NCT01938079|ECMO
202077|NCT01938079|Ketamine
202078|NCT01938079|Opiates
202079|NCT01938079|Lung failure
202080|NCT01938079|Extracorporeal membrane oxygenation
202081|NCT01938079|Mechanical ventilation
202082|NCT01938079|Sedation
202083|NCT01938066|procellera
202084|NCT01938053|STI, STD
202085|NCT01938040|laparoscopic cholecystectomy
202086|NCT01938027|Rectal Neoplasms
202087|NCT01938027|Colorectal Neoplasms
202088|NCT01938027|transanal surgery
202089|NCT01938014|MPS I
202090|NCT01938014|MPS II
202091|NCT01938014|MPS III
202092|NCT01938014|MPS VI
202093|NCT01938014|Krabbe disease
202094|NCT01938014|globoid cell leukodystrophy
202095|NCT01938014|galactosylceramide lipidosis
202096|NCT01938014|mucopolysaccharidoses
202097|NCT01938014|mucopolysaccharidosis
202098|NCT01938014|Rare Diseases Clinical Research Network
202099|NCT01938014|Lysosomal Disease Network
202100|NCT01938014|enzyme replacement therapy
202101|NCT01938014|hematopoietic stem cell transplant
202102|NCT01938014|telephone-based surveillance
202103|NCT01938014|Hurler syndrome
202104|NCT01938014|Hunter syndrome
202105|NCT01938014|Scheie syndrome
202106|NCT01938014|Hurler-Scheie syndrome
202107|NCT01938014|Sanfilippo syndrome
202108|NCT01938014|Maroteaux-Lamy syndrome
202109|NCT01938001|Non-Hodgkins Follicular lymphoma, Non-Hodgkins Marginal zone lymphoma, treatment for follicular lymphoma, treatment for Marginal zone lymphoma
202110|NCT01937988|Doula
202111|NCT01937988|Abortion
202112|NCT01937988|Pain
202113|NCT01937988|support
202114|NCT01937949|Aortic aneurysm
202115|NCT01937936|caregiver stress
202116|NCT01937936|depression
202117|NCT01937936|quality of life
202118|NCT01937936|cognitive behavioral therapy
202119|NCT01937910|neuroplastic change
202120|NCT01937910|myelin
202121|NCT01937897|Unilateral Massage
202122|NCT01937897|Depression
202123|NCT01937858|HbA1c
202124|NCT01937858|glycated hemoglobin
202125|NCT01937858|correlation
202126|NCT01937858|diabetes
202127|NCT01937858|renal failure
202128|NCT01937819|BOWEL PREPARATION
202129|NCT01937819|SMARTPHONE APPLICATION
202130|NCT01937806|Chronic hepatitis B
202131|NCT01937793|radiation
202132|NCT01937793|speech-language pathology
202133|NCT01937754|Prehypertension
202134|NCT01937754|Nitric Oxide
202135|NCT01937754|Blood Pressure
202136|NCT01937754|Functional Capacity
202137|NCT01937754|Quality of Life
202138|NCT01937728|Hepatitis C
202139|NCT01937728|Genotype 1
202140|NCT01937728|Peg interferon
202141|NCT01937728|alfa 1a
202142|NCT01937728|Ribavirin
202143|NCT01937689|Breast cancer
202144|NCT01937689|advanced
202145|NCT01937689|Pyrotinib
202146|NCT01937689|Phase I
202147|NCT01937689|HER2 positive advanced breast cancer
202148|NCT01937663|Chronic Constipation
202149|NCT01937663|Constipation
202150|NCT01937663|Functional gastrointestinal disorders
202151|NCT01937650|Radiotherapy, metronidazole, cervical cancer, Mulago
202152|NCT01937637|Cognitive Behavioral Intervention for Breathlessness
202153|NCT01937624|Diagnostic ultrasound
202154|NCT01937611|dexmedetomidine
202155|NCT01937611|intramuscular premedication
202156|NCT01937611|bradycardiac
202157|NCT01937598|Incretin, DPP-4 inhibitor
202158|NCT01937585|prostate cancer
202159|NCT01937585|partner
202160|NCT01937585|communication messages
202161|NCT01937585|monitoring style
202162|NCT01937585|AA men
202163|NCT01937572|Total knee arthroplasty (TKA)
202164|NCT01937572|Computer aided systems
202165|NCT01937559|tranexaminic acid (TXA)
202166|NCT01937546|Anal Canal/injuries
202167|NCT01937546|Delivery, Obstetric/methods
202168|NCT01937546|Labour Stage, Second
202169|NCT01937546|Lacerations/prevention & control
202170|NCT01937546|Obstetric Labour Complications/prevention & control
202171|NCT01937546|perineum/injuries
202172|NCT01937533|Magnetic Resonance Imaging
202173|NCT01937520|acupuncture
202174|NCT01937520|inflammation
202175|NCT01937520|thyroid
202176|NCT01937520|parathyroid
202177|NCT01937494|asthma
202178|NCT01937494|bronchial hyperresponsiveness
202179|NCT01937494|histamine challenge test
202180|NCT01937494|spirometry
202181|NCT01937481|Child, Preschool
202182|NCT01937481|Parents
202183|NCT01937481|Family
202184|NCT01937481|Obesity
202185|NCT01937481|Overweight
202186|NCT01937481|Diet
202187|NCT01937481|Overnutrition
202188|NCT01937481|Motor Activity
202189|NCT01937481|Child Care
202190|NCT01937481|Schools
202191|NCT01937468|Chronic GVHD
202192|NCT01937468|Chronic graft versus host disease
202193|NCT01937468|Allogeneic stem cell transplant
202194|NCT01937455|HIV
202195|NCT01937455|AIDS
202196|NCT01937455|HIV vaccine
202197|NCT01937455|HIV prevention
202198|NCT01937455|AAV
202199|NCT01937455|PG9
202200|NCT01937442|Multiple myeloma
202201|NCT01937442|Pharmacokinetics
202202|NCT01937442|Thalidomide
202203|NCT01937429|Colonoscopy - Chromoendoscopy - Indigo Carmin® - Adenoma detection - Tepid water
202204|NCT01937403|Physical Therapy
202205|NCT01937403|Return to sport
202206|NCT01937351|Atherectomy
202207|NCT01937351|Optical Coherence Tomography
202208|NCT01937351|Lumivascular
202209|NCT01937338|Healthy volunteers, Phase 1
202210|NCT01937325|Eligible CF patients with G551D gene mutation
202211|NCT01937312|glaucoma
202212|NCT01937312|prostaglandin analogue
202213|NCT01937312|brinzolamide
202214|NCT01937312|brimonidine
202215|NCT01937299|glaucoma
202216|NCT01937299|prostaglandin analogue
202217|NCT01937299|brinzolamide
202218|NCT01937299|brimonidine
202219|NCT01937286|LDLT,HCC, Microvascular invasion
202220|NCT01937273|Nutritional status, malnutrition, chemo-radiotherapy
202221|NCT01937247|Operative Time
202222|NCT01937247|Operating Rooms
202223|NCT01937247|Efficiency
202224|NCT01937221|mild cognitive impairment
202225|NCT01937221|mild to moderate cognitive impairment
202226|NCT01937208|Esophageal Carcinoma
202227|NCT01937208|chemoradiation
202228|NCT01937208|radiation dose
202229|NCT01937195|IV Catheter comparison
202230|NCT01937195|AccuCath versus Conventional IV Catheters
202231|NCT01937195|IV Catheter Study
202232|NCT01937195|IV Catheter User Preference Comparison
202233|NCT01937195|First Attempt Success Rate for IV Catheters
202234|NCT01937195|AccuCath Device Performance
202235|NCT01937195|Complication Rates for IV Catheters
202236|NCT01937195|Average Dwell Time for IV Catheters
202237|NCT01937195|Patient Satisfaction with IV Catheters
202238|NCT01937195|Clinician Satisfaction with AccuCath Device Performance
202239|NCT01937182|Stroke
202240|NCT01937182|SSRI (Selective Serotonin Reuptake Inhibitors)
202241|NCT01937182|Serotonin
202242|NCT01937182|5-HT
202243|NCT01937182|Neuroprotection
202244|NCT01937182|MRI (Magnetic Resonance Imaging)
202245|NCT01937182|Platelet
202246|NCT01937182|CT (computerized tomography)
202247|NCT01937182|Post Stroke Depression
202248|NCT01937143|parent education
202249|NCT01937143|immunization
202250|NCT01937143|vaccination
202251|NCT01937143|infant
202252|NCT01937143|pain management
202253|NCT01937130|Liver Failure
202254|NCT01937130|Cirrhosis
202255|NCT01937130|Alcoholic Hepatitis
202256|NCT01937117|Breast cancer
202257|NCT01937117|Preoperative treatment
202258|NCT01937117|Neoadjuvant treatment
202259|NCT01937104|Intracranial pressure
202260|NCT01937104|Laparoscopy
202261|NCT01937104|Optic nerve sheath diameter
202262|NCT01937104|Position
202263|NCT01937091|HIV
202264|NCT01937091|clinical trials
202265|NCT01937013|Frontotemporal Dementia
202266|NCT01937013|emotion
202267|NCT01937013|oxytocin
202268|NCT01937013|fMRI
202269|NCT01936181|Rheumatoid Arthritis
202270|NCT01936181|Infliximab
202271|NCT01936181|Biosimilar
202272|NCT01936168|GSV
202273|NCT01936168|Primary Varicose Veins
202274|NCT01936168|Great Saphenous Vein
202275|NCT01936168|Treatment
202276|NCT01936155|Joint Mobility
202277|NCT01936155|Skin Tissue Oxygenation
202278|NCT01936155|Neuromuscular Electrical Stimulation
202279|NCT01936155|Goniometry
202280|NCT01936155|Transcutaneous Oxygen Measurements (tcpO2)
202281|NCT01936155|Water Displacement
202282|NCT01936142|Resynchroniztion therapy
202283|NCT01936142|Kidney
202284|NCT01936142|Contrast media
202285|NCT01936142|Prevention
202286|NCT01936116|Sonohysterography
202287|NCT01936116|catheter placement
202288|NCT01936116|pain magnitude
202289|NCT01936116|vasovagal reaction
202290|NCT01936103|Acute anterior myocardial infarction
202291|NCT01936103|Percutaneous coronary stent implantation
202292|NCT01936103|Intensive statin therapy
202293|NCT01936103|Left ventricular function
202294|NCT01936077|Infertility, IVF, ovarian stimulation, rec LH, GnRH antagonist
202295|NCT01936064|Breast Cancer
202296|NCT01936064|Jobelyn
202297|NCT01936064|Sorghum bicolor
202298|NCT01936038|CPAP
202299|NCT01936038|Upper Airway Toning
202300|NCT01936038|Obstructive Sleep Apnoea
202301|NCT01936025|Diabetes mellitus
202302|NCT01936012|Lisinopril
202303|NCT01936012|Bioequivalence
202304|NCT01936012|Bioavailability
202305|NCT01936012|Pharmacokinetic
202306|NCT01936012|Angiotensin-converting enzyme inhibitor
202307|NCT01935999|Colostomy
202308|NCT01935999|peristomal skin
202309|NCT01935999|stoma
202310|NCT01935999|pouch
202311|NCT01936961|Cancer
202312|NCT01936948|Large colon polyps
202313|NCT01936948|Polyp resection
202314|NCT01936948|Colon cancer screening
202315|NCT01936948|Colonoscopy
202316|NCT01936948|Endoscopic mucosal resection
202317|NCT01936935|Insulin sensitivity
202318|NCT01936922|Fall accidents
202319|NCT01936922|Gait
202320|NCT01936922|Balance
202321|NCT01936922|Fear of falling
202322|NCT01936922|Virtual reality
202323|NCT01936896|Acute myocardial infarction
202324|NCT01936896|Heart Failure
202325|NCT01936896|Inflammation
202326|NCT01936883|prostatic neoplasm
202327|NCT01936883|brachytherapy
202328|NCT01936883|quality of life
202329|NCT01936883|high dose rate
202330|NCT01936883|low dose rate
202331|NCT01936870|Toviaz
202332|NCT01936870|Fesoterodine
202333|NCT01936870|Post marketing surveillance
202334|NCT01936870|Japanese
202335|NCT01936870|Overactive Bladder
202336|NCT01936870|OAB
202337|NCT01936870|Good post marketing practice
202338|NCT01936870|Regulatory Post Marketing Commitment Plan
202339|NCT01936792|Concussion
202340|NCT01936792|Mild Traumatic Brain Injury
202341|NCT01936792|Traumatic Brain Injury
202342|NCT01936779|plasma triglycerides
202343|NCT01936779|dietary fat
202344|NCT01936779|liver fat metabolism
202345|NCT01936779|human
202346|NCT01936766|malaria, falciparum
202347|NCT01936766|sepsis
202348|NCT01936766|fluid therapy
202349|NCT01936766|thermodilution
202350|NCT01936766|extravascular lung water
202351|NCT01936766|acute kidney injury
202352|NCT01936753|PMTCT
202353|NCT01936753|HIV
202354|NCT01936753|Mentor Mothers
202355|NCT01936753|Nigeria
202356|NCT01936753|Retention
202357|NCT01936753|Adherence
202358|NCT01936740|Efficacy and Safety
202359|NCT01936727|efficiency and safety
202360|NCT01936714|Efficacy and Safety
202361|NCT01936675|Coronary Artery Disease
202362|NCT01936675|Myocardial Infarction
202363|NCT01936675|Genomic Risk Communication
202364|NCT01936675|Risk Stratification
202365|NCT01936662|Airway management comparison
202366|NCT01936649|Nuclear imaging
202367|NCT01936649|Radiopharmaceutical
202368|NCT01936649|Iobenguane
202369|NCT01936649|I-123
202370|NCT01936649|reproducibility
202371|NCT01936649|Quantitative measurements
202372|NCT01936649|myocardial uptake
202373|NCT01936649|SPECT imaging
202374|NCT01936649|planar imaging
202375|NCT01936649|AdreView™
202376|NCT01936636|Breakthrough cancer pain
202377|NCT01936636|diary
202378|NCT01936636|quality of life
202379|NCT01936636|Abstral
202380|NCT01936636|BTcP
202381|NCT01936623|brief intervention
202382|NCT01936623|computerized brief intervention
202383|NCT01936610|Lecture
202384|NCT01936610|Role-playing
202385|NCT01936610|Knowledge
202386|NCT01936610|Attitude
202387|NCT01936610|Decision making
202388|NCT01936610|Type of delivery
202389|NCT01936597|external cardiac massage, medical hotline,
202390|NCT01936545|Liver transplantation, reactive oxygen species, antioxidant
202391|NCT01936532|multiple myeloma
202392|NCT01936519|Everolimus
202393|NCT01936519|Zortress
202394|NCT01936519|Renal Function
202395|NCT01936519|Tacrolimus
202396|NCT01936519|Cyclosporine
202397|NCT01936519|Myfortic
202398|NCT01936519|Mycophenolic Acid
202399|NCT01936519|Liver Transplantation
202400|NCT01936506|Cognitive training
202401|NCT01936506|Depression
202402|NCT01936493|Uterine leiomyomas (fibroids or myomas)
202403|NCT01936493|Uterine fibroids
202404|NCT01936493|Fibroids
202405|NCT01936493|Uterine leiomyomas
202406|NCT01936467|Pancreatic solid lesions
202407|NCT01936467|Pancreatic mass
202408|NCT01936467|Pancreatic cancer
202409|NCT01936467|Endoscopic Ultrasound
202410|NCT01936467|EUS
202411|NCT01936467|Fine needle aspiration
202412|NCT01936467|FNA
202413|NCT01936467|EUS-FNA
202414|NCT01936441|Menopause
202415|NCT01936441|Vasomotor
202416|NCT01936441|Symptoms
202417|NCT01936441|Sleep
202418|NCT01936441|Cognitive Behavioral Therapy
202419|NCT01936415|Knee prosthesis
202420|NCT01936402|Cardiopulmonary Resuscitation
202421|NCT01936376|kidney safety
202422|NCT01936376|biomarkers
202423|NCT01936376|serum creatinine
202424|NCT01936376|BUN
202425|NCT01936376|cystic fibrosis
202426|NCT01936376|head and neck cancer
202427|NCT01936376|renal injury
202428|NCT01936376|drug induced acute kidney injury
202429|NCT01936376|aminoglycoside
202430|NCT01936376|cisplatin
202431|NCT01936376|nephrotoxicity
202432|NCT01936376|biomarker qualification
202433|NCT01936363|Ovarian Cancer
202434|NCT01936363|Pimasertib
202435|NCT01936363|Placebo
202436|NCT01936363|SAR245409
202437|NCT01936350|Heart failure
202438|NCT01936324|acne vulgaris
202439|NCT01936311|Health Behavior
202440|NCT01936311|Behavior change
202441|NCT01936311|self-management goal
202442|NCT01936311|health goal
202443|NCT01936298|Hand Edema
202444|NCT01936298|Exercise Therapy
202445|NCT01936233|Hepatocellular Carcinoma
202446|NCT01936233|Aspirin
202447|NCT01936233|antiviral treatment
202448|NCT01936233|recurrence free survival
202449|NCT01936233|radical therapy
202450|NCT01936220|Schizophrenia
202451|NCT01936220|First-psychotic episode
202452|NCT01936220|Initial phase
202453|NCT01936220|Relapse prevention
202454|NCT01936220|Specialized treatment
202455|NCT01936220|Parent groups
202456|NCT01936220|Social functioning
202457|NCT01936207|acute
202458|NCT01936207|respiratory
202459|NCT01936207|syndrome
202460|NCT01936207|prognosis
202461|NCT01936207|outcome research
202462|NCT01936207|respiratory infection
202463|NCT01936207|sepsis
202464|NCT01936207|organ failure
202465|NCT01935908|Subarachnoid Hemorrhage
202466|NCT01935908|Seizures
202467|NCT01935908|Prophylaxis
202468|NCT01935908|Levetiracetam
202469|NCT01935895|blood pressure reduction
202470|NCT01935895|vascular reactivity
202471|NCT01935895|combined exercise session
202472|NCT01935856|patients
202473|NCT01935856|receiving
202474|NCT01935856|hemodialysis
202475|NCT01935856|Secondary
202476|NCT01935843|CART-HER-2
202477|NCT01935843|HER-2 positive
202478|NCT01935843|Advanced
202479|NCT01935843|Refactory
202480|NCT01935843|Solid tumors
202481|NCT01935830|PET Imaging
202482|NCT01935830|Efavirenz
202483|NCT01935830|Ritonavior [11C] LAAM
202484|NCT01935830|Healthy volunteers
202485|NCT01935804|pioglitazone
202486|NCT01935804|metformin
202487|NCT01935804|hyperglycemic agents
202488|NCT01935804|physiological effects of drugs
202489|NCT01935804|bone health
202490|NCT01935765|Type 1 diabetes, sleep apnea, polysomnography,
202491|NCT01935765|autonomic neuropathy, intima media thickness
202492|NCT01935752|fibromuscular
202493|NCT01935752|dysplasia
202494|NCT01935752|endothelium
202495|NCT01935752|microparticles
202496|NCT01935752|microRNA
202497|NCT01935726|Pulmonary fibrosis
202498|NCT01935726|Interstitial lung disease
202499|NCT01935726|Connective tissue disease
202500|NCT01935726|Chronic hypersensitivity pneumonitis
202626|NCT01935180|adenoma resection
202501|NCT01935726|Idiopathic pulmonary fibrosis
202502|NCT01935700|hepatocellular carcinoma
202503|NCT01935700|colchicine
202504|NCT01935687|Instrumented Wheel
202505|NCT01935687|Manual Wheelchair
202506|NCT01935687|Spinal Cord Injury (SCI)
202507|NCT01935687|Manual wheelchair Users
202508|NCT01935687|Aged between 18-70 years
202509|NCT01935674|Hypercholesterolaemia
202510|NCT01935674|HIV
202511|NCT01935674|Rosuvastatin
202512|NCT01935674|Protease inhibitor switching
202513|NCT01935661|Blood transfusion
202514|NCT01935661|Hemosiderosis
202515|NCT01935661|ERP
202516|NCT01935648|Knee arthroplasty
202517|NCT01935635|CHB
202518|NCT01935635|Antiviral
202519|NCT01935635|Dentritic cells
202520|NCT01935635|Immune Therapy
202521|NCT01935622|heart failure
202522|NCT01935622|non-ischemic cardiomyopathy
202523|NCT01935609|traumatic brain injury
202524|NCT01935609|acquired brain injury
202525|NCT01935596|Anesthesia
202526|NCT01935596|Randomized study
202527|NCT01935596|Lower limbs surgery
202528|NCT01935583|traumatic brain injury
202529|NCT01935570|Bioavailability of magnesium
202530|NCT01935570|Digestive and general tolerance
202531|NCT01935557|Continuous heparin infusion
202532|NCT01935557|Intermittent heparin infusion
202533|NCT01935557|during catheter ablation
202534|NCT01935544|Botulinum Toxin
202535|NCT01935544|Ultrasound-guidance
202536|NCT01935544|Stroke
202537|NCT01935544|Spasticity
202538|NCT01935544|Ultrasonography
202539|NCT01935544|Hemiplegia
202540|NCT01935531|actinic keratoses
202541|NCT01935531|tumor metabolism
202542|NCT01935531|glycolysis
202543|NCT01935531|diclofenac
202544|NCT01935531|warburg effect
202545|NCT01935505|smoking cessation
202546|NCT01935505|intervention model
202547|NCT01935505|Chinese
202548|NCT01935505|quitting rate
202549|NCT01935492|metastatic breast cancer
202550|NCT01935492|HER2/neu negative
202551|NCT01935492|paclitaxel
202552|NCT01935492|bevacizumab
202553|NCT01935492|liposomal doxorubicine
202554|NCT01935492|capecitabine
202555|NCT01935479|AK159, teriparatide acetate
202556|NCT01935466|Pioglitazone
202557|NCT01935466|Bladder cancer
202558|NCT01935466|Type 2 Diabetes
202559|NCT01935440|HIV, drug use
202560|NCT01935427|Pulse Oximeter
202561|NCT01935427|Stroke Volume
202562|NCT01935427|Hemorrhagic shock
202563|NCT01935427|Compensatory Reserve Index
202564|NCT01935401|Bulimia Nervosa
202565|NCT01935401|Bulimia
202566|NCT01935401|Response Inhibition
202567|NCT01935401|fNIR
202568|NCT01935401|Neuroimaging
202569|NCT01935388|Mechanical ventilation
202570|NCT01935388|chronic obstructive pulmonary disease
202571|NCT01935388|asthma
202572|NCT01935388|common canister
202573|NCT01935388|MDI
202574|NCT01935388|ventilator associated pneumonia
202575|NCT01935375|Postpartum Depression
202576|NCT01935375|Nurse Midwife
202577|NCT01935375|Interpersonal Psychotherapy
202578|NCT01935362|Flavanones
202579|NCT01935362|Bioavailability
202580|NCT01935362|Blood vessel health
202581|NCT01935362|Blood glucose
202582|NCT01935349|Diabetes mellitus (DM)
202583|NCT01935349|hypertension (HT)
202584|NCT01935349|Hong Kong
202585|NCT01935336|Lung Cancer
202586|NCT01935336|Malignancy
202587|NCT01935336|Predictive biomarkers
202588|NCT01935323|high intensity interval training
202589|NCT01935323|aerobic exercise
202590|NCT01935323|insulin sensitivity
202591|NCT01935323|obesity
202592|NCT01935323|cardiovascular fitness
202593|NCT01935310|Photoaging
202594|NCT01935310|imiquimod
202595|NCT01935310|wrinkles
202596|NCT01935310|elastosis
202597|NCT01935271|immunosenescence
202598|NCT01935271|sarcopenia
202599|NCT01935258|Medically unexplained symptoms
202600|NCT01935258|Somatization
202601|NCT01935258|Psychosomatic therapy
202602|NCT01935245|Coronary artery bypass grafting
202603|NCT01935245|Extracorporeal circulation
202604|NCT01935245|Minimal extracorporeal circulation
202605|NCT01935245|Coagulopathy
202606|NCT01935245|Thrombocytopathy
202607|NCT01935245|Platelet dysfunction
202608|NCT01935232|Osteoporosis, diagnostics, ultrasound
202609|NCT01935219|mild cognitive impairment
202610|NCT01935219|seniors
202611|NCT01935219|cognitive training
202612|NCT01935219|driving
202613|NCT01935219|driving simulation
202614|NCT01935219|intervention
202615|NCT01935219|goal management training
202616|NCT01935219|process speed training
202617|NCT01935206|secondary hyperalgesia
202618|NCT01935206|allodynia
202619|NCT01935206|mechanical pain threshold
202620|NCT01935206|naloxone
202621|NCT01935206|endogenous opioids
202622|NCT01935206|pain
202623|NCT01935193|platelets aggregation
202624|NCT01935193|asa resistance
202625|NCT01935180|colon polyps
202627|NCT01935180|colon cancer screening
202628|NCT01935180|colonoscopy
202629|NCT01935180|polyp detection
202630|NCT01935167|Microalbuminuria
202631|NCT01935154|NSCLC
202632|NCT01935154|Vaccine
202633|NCT01935141|Pulmonary Embolus
202634|NCT01935141|Radio Contrast Material
202635|NCT01935141|Computed Tomography
202636|NCT01935128|Renal Transplant
202637|NCT01935128|Immunosuppression
202638|NCT01935128|Steroid Avoidance
202639|NCT01935128|Calcineurin Avoidance
202640|NCT01935128|Mammalian Target of Rapamycin (mTOR)
202641|NCT01935128|Kidney
202642|NCT01935115|Depression
202643|NCT01935115|MDD
202644|NCT01935115|Treatment Resistant Depression
202645|NCT01935115|Electroconvulsive Therapy
202646|NCT01935115|ECT
202647|NCT01935115|Ketamine
202648|NCT01935115|Propofol
202649|NCT01935115|NMDA
202650|NCT01935102|metastatic breast cancer
202651|NCT01935102|bevacizumab
202652|NCT01935102|single nucleotide polymorphism
202653|NCT01935102|VEGF-A
202654|NCT01935102|VEGFR-2
202655|NCT01935102|IL-8
202656|NCT01935089|HIV-1
202657|NCT01935089|Interferon alpha
202658|NCT01935089|Integrated DNA
202659|NCT01935089|Latent reservoir
202660|NCT01935076|Maternal obesity
202661|NCT01935076|Macrosomic
202662|NCT01935076|miRNA
202663|NCT01935076|Fetal overgrowth
202664|NCT01935063|Vulvodynia
202665|NCT01935063|Provoked vestibulodynia
202666|NCT01935063|Vulvar pain
202667|NCT01935063|Dyspareunia
202668|NCT01935063|Couples therapy
202669|NCT01935063|Lidocaine
202670|NCT01935063|Cognitive behavioral couple therapy
202671|NCT01935063|Cognitive behavioral therapy
202672|NCT01935063|Pain
202673|NCT01935063|Pain during sexual intercourse
202674|NCT01935050|Depression
202675|NCT01935050|Parkinson's disease
202676|NCT01935050|Cognitive-Behavioral Treatment
202677|NCT01935024|Alzheimer's disease
202678|NCT01935024|dementia
202679|NCT01935024|aerobic exercise
202680|NCT01934998|SCA6, parkinsonism, Datscan
202681|NCT01934985|Single-Photon Emission-Computed Tomography
202682|NCT01934985|Myocardial Perfusion Imaging
202683|NCT01934985|Ischemia
202684|NCT01934985|Stress test
202685|NCT01934985|Coronary Artery Disease (CAD)
202686|NCT01934985|Coronary Flow Reserve (CFR)
202687|NCT01934985|Coronary Angiography
202688|NCT01934972|Bipolar disorder
202689|NCT01934946|hip fracture
202690|NCT01934933|ossification
202691|NCT01934933|etanercept
202692|NCT01934894|HER2-positive breast cancer
202693|NCT01934894|intracranial metastases
202694|NCT01934894|lapatinib
202695|NCT01934894|cabazitaxel
202696|NCT01934868|low back pain
202697|NCT01934868|sciatica
202698|NCT01934868|spinal stenosis
202699|NCT01934868|epidural injections
202700|NCT01934868|prolotherapy
202701|NCT01934868|sacroiliac pain or dysfunction.
202702|NCT01934855|cancer
202703|NCT01934855|radiotherapy
202704|NCT01934855|4D-MRI
202705|NCT01934855|4D-CT
202706|NCT01934855|MRI
202707|NCT01934816|Incretins, KATP channels, intradermal injection
202708|NCT01934803|Alcohol Use
202709|NCT01934803|Microbial Translocation
202710|NCT01934803|Inflammation
202711|NCT01934803|Altered Coagulation
202712|NCT01934803|Russia
202713|NCT01934803|Zinc
202714|NCT01934803|AMI
202715|NCT01934803|VACS index
202716|NCT01934803|Reynolds risk score
202717|NCT01934777|NAFLD
202718|NCT01934777|NASH
202719|NCT01934777|fibrosis
202720|NCT01934738|Multiple dose
202721|NCT01934738|safety
202722|NCT01934738|tolerability
202723|NCT01934738|PK
202724|NCT01934725|Ischemic Stroke
202725|NCT01934725|Brain Infarction
202726|NCT01934725|Patent Foramen Ovale
202727|NCT01934725|Stroke in the Young
202728|NCT01934725|Myocardial Infarction
202729|NCT01934725|Cerebral Venous Thrombosis
202730|NCT01934725|Pulmonary Embolism
202731|NCT01934725|Deep Vein Thrombosis
202732|NCT01934725|Subarachnoid Hemorrhage
202733|NCT01934725|Prognosis
202734|NCT01934725|Databases, Genetic
202735|NCT01934699|Coronary stenosis
202736|NCT01934699|Angina pectoris
202737|NCT01934699|Left ventricular wall motion abnormalities
202738|NCT01934699|2D-Strain
202739|NCT01934660|Cardiovascular Disease
202740|NCT01934660|Diabetes Mellitus
202741|NCT01934660|Inflammation
202742|NCT01934634|Pancreatic Cancer
202743|NCT01934634|Stage IV Pancreatic Cancer
202744|NCT01934634|Stage IV metastatic pancreatic ductal adenocarcinoma
202745|NCT01934621|Stroke
202746|NCT01934621|Rehabilitation
202747|NCT01934621|Cognition
202748|NCT01934621|Disability
202749|NCT01934595|Critically ill
202750|NCT01934595|Protein
202751|NCT01934595|Supplement
202752|NCT01934595|ICU
202753|NCT01934595|Protein synthesis
202754|NCT01934530|implant complications
202755|NCT01934530|esthetics
202756|NCT01934530|soft tissue grafting
202757|NCT01934504|clinical tolerance
202758|NCT01934504|biomarker(s) identification
202759|NCT01934491|Cognitive training
202760|NCT01934491|Depression
202761|NCT01934478|Breast
202762|NCT01934478|Cancer
202763|NCT01934478|Human Epidermal Growth Factor 2 (Her2)
202764|NCT01934478|irradiation
202765|NCT01934465|NSCLC
202766|NCT01934465|Chemotherapy
202767|NCT01934465|Anti-angiogenic agent
202768|NCT01934465|Bevacizumab
202769|NCT01934465|1st Line
202770|NCT01934452|complete remission
202771|NCT01934439|Stroke
202772|NCT01934439|Rehabilitation
202773|NCT01934439|Dyssynergia
202774|NCT01934439|Robotics
202775|NCT01934439|AMES
202776|NCT01934439|Cerebrovascular Accident
202777|NCT01934426|Admission High Risk Elderly
202778|NCT01934413|Palliative Care
202779|NCT01934413|Technology
202780|NCT01934413|Rural
202781|NCT01934413|Transitional Care
202782|NCT01934400|Osteoporosis
202783|NCT01934400|fall prevention
202784|NCT01934400|high risk population
202785|NCT01934387|World Health Organization Fracture Risk Assessment Tool
202786|NCT01934387|Osteoporosis
202787|NCT01934387|Aged
202788|NCT01934387|Prevention
202789|NCT01934387|Fracture
202790|NCT01934387|FRAX
202791|NCT01934374|task-oriented training, long-term effects, plasticity
202792|NCT01934361|BKM120,
202793|NCT01934361|Recurrent glioblastoma multiforme,
202794|NCT01934361|rGBM,
202795|NCT01934361|buparlisib
202796|NCT01934335|breast cancer, TKI, tyrosine kinase inhibitor, vandetanib, Ki-67
202797|NCT01934322|frequent users of the emergency department
202798|NCT01934322|vulnerable populations
202799|NCT01934322|case management
202800|NCT01934322|cost savings intervention
202801|NCT01934322|quality of life
202802|NCT01934322|number of emergency department visits
202803|NCT01934309|tuberculosis
202804|NCT01934309|isoniazid preventative therapy
202805|NCT01934309|clinical decision support
202806|NCT01934309|HIV
202807|NCT01934309|Kenya
202808|NCT01934309|eHealth
202809|NCT01934296|deep brain stimulation
202810|NCT01934296|cortical recording
202811|NCT01934296|neuroprosthesis
202812|NCT01934231|Acute bacterial rhinosinusitis
202813|NCT01934231|Amoxicilin
202814|NCT01934231|Infection
202815|NCT01934231|Potassium clavulanate
202816|NCT01934218|Knee
202817|NCT01934218|Osteoarthritis
202818|NCT01934218|Intra-articular injection
202819|NCT01934205|GSK2140944
202820|NCT01934205|pharmacokinetics
202821|NCT01934205|bronchoalveolar lavage
202822|NCT01934205|pulmonary
202823|NCT01934205|antimicrobial
202824|NCT01934205|healthy volunteer
202825|NCT01934192|tolerability
202826|NCT01934192|camicinal
202827|NCT01934192|single dose
202828|NCT01934192|acetaminophen
202829|NCT01934192|gastric emptying
202830|NCT01934192|critically ill
202831|NCT01934192|GSK962040
202832|NCT01934192|pharmacokinetics
202833|NCT01934192|pharmacodynamics
202834|NCT01934192|gut motility
202835|NCT01934153|hyperhidrosis
202836|NCT01934153|topical
202837|NCT01934153|[14C] radiolabel
202838|NCT01934153|palm
202839|NCT01934153|GSK573719
202840|NCT01934153|axilla
202841|NCT01934153|Umeclidinium
202842|NCT01934140|Healthy
202843|NCT01934140|Adults
202844|NCT01934140|Safety
202845|NCT01934140|Neisseria meningitidis
202846|NCT01934140|Booster response
202847|NCT01934140|Immunogenicity
202848|NCT01934140|Adolescents
202849|NCT01934140|Serogroups A, C, W-135, and Y
202850|NCT01934140|long-term antibody persistence
202851|NCT01934127|Immunogenicity
202852|NCT01934127|H7N1
202853|NCT01934127|Influenza
202854|NCT01934127|Safety
202855|NCT01934127|AS03 adjuvant
202856|NCT01934127|Adults
202857|NCT01934088|Inflammatory Bowel disease
202858|NCT01934088|IBD
202859|NCT01934088|Sedation
202860|NCT01934088|NAPS
202861|NCT01934088|Propofol
202862|NCT01934088|Midazolam
202863|NCT01934088|Satisfaction
202864|NCT01934088|Feasibility
202865|NCT01934075|Obstetric fistula
202866|NCT01934075|Mental health
202867|NCT01934075|Tanzania
202868|NCT01934036|Weight loss
202869|NCT01934036|Nutritional supplement
202870|NCT01934036|Waist
202871|NCT01934036|Body composition
202872|NCT01934036|Skinfolds
202873|NCT01934023|plasticity, schizophrenia, varenicline, non smokers,
202874|NCT01933997|pharmacokinetics
202875|NCT01933997|metadoxine
202876|NCT01933984|Bronchodilator agents,
202877|NCT01933984|chronic obstructive pulmonary disease,
202878|NCT01933984|endotracheal intubation,
202879|NCT01933984|mechanical ventilator
202880|NCT01933958|Regorafenib
202881|NCT01933958|Gastrointestinal stromal tumors
202882|NCT01933932|Mitogen-Activated Protein Kinase Kinase inhibitor; Non Small Cell Lung Cancer; metastatic; second line treatment for Non Small Cell Lung Cancer; KRAS mutation
202883|NCT01933919|Obsessive Compulsive Disorder
202884|NCT01933919|Adolescent Subjects
202885|NCT01933919|Pediatric Subjects
202886|NCT01933906|CML
202887|NCT01933906|Chronic myeloid leukemia
202888|NCT01933906|Chronic myeloid leukaemia
202889|NCT01933906|PEG-Proline-Interferon-alpha 2b
202890|NCT01933906|Interferon
202891|NCT01933906|P1101
202892|NCT01933906|Imatinib
202893|NCT01933893|Pipelle, luteal, follicular, implantation
202894|NCT01933880|Attention Deficit Hyperactivity Disorder
202895|NCT01933880|Methylphenidate Hydrochloride
202896|NCT01933880|CONCERTA
202897|NCT01933867|water
202898|NCT01933867|colonoscopy
202899|NCT01933867|Crohn´s disease
202900|NCT01933867|ulcerative colitis
202901|NCT01933854|Urinary incontinence
202902|NCT01933854|riverside
202903|NCT01933854|women
202904|NCT01933854|Amapa
202905|NCT01933841|Post operative residual curaization
202906|NCT01933841|Neuromuscular blocking drugs
202907|NCT01933828|Lung cancer
202908|NCT01933828|surgery video-assisted
202909|NCT01933828|robot
202910|NCT01933828|surgical treatment
202911|NCT01933815|Glioblastoma multiforme
202912|NCT01933815|Glioblastoma
202913|NCT01933815|Radiotherapy
202914|NCT01933815|Temozolomide
202915|NCT01933815|TPI 287
202916|NCT01933815|Taxoid
202917|NCT01933815|Avastin
202918|NCT01933815|Bevacizumab
202919|NCT01933802|mesenchymal stem cells
202920|NCT01933802|neural progenitors
202921|NCT01933802|autologous
202922|NCT01933802|bone marrow
202923|NCT01933802|multiple sclerosis
202924|NCT01933789|Palliative Care
202925|NCT01933789|End-of-Life Issues
202926|NCT01933789|Patient/Clinician Communication
202927|NCT01933789|Patient/Family Communication
202928|NCT01933789|Concordance
202929|NCT01933789|Treatment Preferences
202930|NCT01933789|Anxiety
202931|NCT01933789|Depressive Symptoms
202932|NCT01933789|Talking with Your Doctor
202933|NCT01933789|Coping with Serious Illness
202934|NCT01933789|Outpatient Collaboration
202935|NCT01933776|Diphtheria
202936|NCT01933776|Tetanus
202937|NCT01933776|Pertussis
202938|NCT01933776|ADACEL®
202939|NCT01933776|Tdap vaccine
202940|NCT01933750|Presbyopia
202941|NCT01933750|Reading Glasses
202942|NCT01933750|Near Vision
202943|NCT01933737|postural balance;
202944|NCT01933737|elderly;
202945|NCT01933737|proprioception;
202946|NCT01933737|prevention;
202947|NCT01933737|fall
202948|NCT01933724|granulomatosis with polyangiitis
202949|NCT01933724|GPA
202950|NCT01933724|Wegeners'
202951|NCT01933724|WG
202952|NCT01933724|vasculitis
202953|NCT01933724|taper
202954|NCT01933724|prednisone
202955|NCT01933724|glucocorticoid
202956|NCT01933724|ANCA-associated vasculitis
202957|NCT01933724|AAV
202958|NCT01933724|Wegener Granulomatosis
202959|NCT01933724|Systemic Vasculitis
202960|NCT01933724|Lung diseases, interstitial
202961|NCT01933724|Lung diseases
202962|NCT01933724|Respiratory Tract Diseases
202963|NCT01933724|Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
202964|NCT01933724|Vascular Diseases
202965|NCT01933724|Cardiovascular Diseases
202966|NCT01933724|Glucocorticoids
202967|NCT01933724|Hormones
202968|NCT01933724|Hormones, Hormone Substitutes, and Hormone Antagonists
202969|NCT01933724|Physiological Effects of Drugs
202970|NCT01933724|Pharmacologic Actions
202971|NCT01933724|Antineoplastic Agents, Hormonal
202972|NCT01933724|Antineoplastic Agents
202973|NCT01933724|Therapeutic Uses
202974|NCT01933724|Anti-Inflammatory Agents
202975|NCT01933711|CD20+ aggressive lymphoma
202976|NCT01933711|mantle cell lymphoma
202977|NCT01933711|rituximab
202978|NCT01933711|maintenance
202979|NCT01933698|Bioequivalence
202980|NCT01933698|Amoxicillin
202981|NCT01933698|Human
202982|NCT01933672|Phase 1b
202983|NCT01933672|type 2 diabetes
202984|NCT01933672|metformin background
202985|NCT01933672|PF-04937319
202986|NCT01933659|Helicobacter pylori
202987|NCT01933659|deep see water
202988|NCT01933646|Group B streptococcus
202989|NCT01933646|Incidence
202990|NCT01933646|Case fatality rate
202991|NCT01933646|Serotype distribution
202992|NCT01933633|Pregnancy
202993|NCT01933633|Fertility
202994|NCT01933633|exercise
202995|NCT01933633|Fertilization in vitro
202996|NCT01933620|Microbiome
202997|NCT01933620|Nosocomial Infection
202998|NCT01933620|Multidrug Resistance
202999|NCT01933542|Chlorzoxazone
203000|NCT01933542|Postoperative pain
203001|NCT01933542|Spine surgery
203002|NCT01933542|Opioid consumption
203003|NCT01933529|diabetes
203004|NCT01933529|glucose tolerance
203005|NCT01933529|insulin secretion
203006|NCT01933529|insulin sensitivity
203007|NCT01933529|erythropoietin
203008|NCT01933529|inflammation
203009|NCT01933529|cytokines
203010|NCT01933516|GP2013
203011|NCT01933516|Japanese
203012|NCT01933516|indolent B-cell non-Hodgkin's lymphoma
203013|NCT01933516|biosimilar
203014|NCT01933516|CD20
203015|NCT01933516|GP13-101
203016|NCT01933503|MAD
203017|NCT01933503|SAD
203018|NCT01933503|Obeticholic Acid (OCA)
203019|NCT01933490|hyperinsulinemic hypoglycemia
203020|NCT01933477|Maternal Health
203021|NCT01933477|Child Health
203022|NCT01933477|HIV infection
203023|NCT01933477|Antenatal care
203024|NCT01933477|Postpartum care
203025|NCT01933477|Prevention of mother to child transmission (PMTCT)
203026|NCT01933477|Breast feeding
203027|NCT01933477|Antiretrovirals
203028|NCT01933464|Rosacea
203029|NCT01933464|Cromolyn sodium
203030|NCT01933451|fluid therapy
203031|NCT01933451|Intraoperative care
203032|NCT01933451|Patient Outcome Assessment
203033|NCT01933451|pulse pressure variation
203034|NCT01933451|restrictive fluid therapy
203035|NCT01933451|goal-directed fluid therapy
203036|NCT01933451|esophagectomy
203037|NCT01933438|birth related brachial plexus injury
203038|NCT01933438|brachial plexus
203039|NCT01933438|splint
203040|NCT01933425|surgical conditions
203041|NCT01933425|laparoscopy
203042|NCT01933412|Dialysis
203043|NCT01933412|Hepatitis B
203044|NCT01933399|Low back pain
203045|NCT01933399|Back brace
203046|NCT01933399|Lumbar orthoses
203047|NCT01933399|Lumbosacral orthoses
203048|NCT01933399|Low back pain treatment
203049|NCT01933386|Single Sided Deafness
203050|NCT01933386|SSD
203051|NCT01933386|Unilateral hearing loss
203052|NCT01933373|Randomized
203053|NCT01933373|Toupet
203054|NCT01933373|Dor
203055|NCT01933373|Achalasia
203056|NCT01933360|Misoprostol
203057|NCT01933360|First trimester pregnancy
203058|NCT01933360|Surgical abortion
203059|NCT01933360|Cervical priming
203060|NCT01933334|pirfenidone
203061|NCT01933334|SSc-ILD
203062|NCT01933334|scleroderma
203063|NCT01933334|systemic sclerosis
203064|NCT01933334|interstitial lung disease
203065|NCT01933321|ALS, stem cells
203066|NCT01933308|Pulmonary Rehabilitation
203067|NCT01933308|Comparison of exercise training protocol
203068|NCT01933308|Exercise tolerance
203069|NCT01933308|Functional and quality of life status
203070|NCT01933308|Cognitive and psychological status
203071|NCT01933308|Compliance to exercise recommendations
203072|NCT01933308|Long term adherence to exercise recommendations
203073|NCT01933295|treatment
203074|NCT01933282|MESA, chemotherapy,NK/T cell lymphoma
203075|NCT01933256|Type 2 Diabetes Mellitus
203076|NCT01933256|HIP2B
203077|NCT01933256|Placebo
203078|NCT01933256|islet β cell
203079|NCT01933243|Anxiety
203080|NCT01933243|Anorexia nervosa
203081|NCT01933243|Adolescents
203082|NCT01933243|Fish oil
203083|NCT01933217|TBI
203084|NCT01933217|traumatic brain injury
203085|NCT01933217|ADHD
203086|NCT01933217|methylphenidate
203087|NCT01933217|Concerta
203088|NCT01933217|attention problems
203089|NCT01933204|perimenopause
203090|NCT01933204|hot flash
203091|NCT01933204|palpitation
203092|NCT01933191|Dental Anxiety, Physical Activity, Dental Phobia
203093|NCT01933191|Cortisol, Amylase
203094|NCT01933178|Dry eyes
203095|NCT01933178|Cirrus AS-OCT
203096|NCT01933178|Excess folds of the conjunctiva
203097|NCT01933165|Dry Eyes
203098|NCT01933165|LipiView
203099|NCT01933165|Lipid thickness
203100|NCT01933152|wAMD
203101|NCT01933152|anti-VEGF
203102|NCT01933139|Informed consent
203103|NCT01933139|preoperative counseling
203104|NCT01933139|hysterectomy
203105|NCT01933113|Obesity
203106|NCT01933113|Deep Brain Stimulation
203107|NCT01933113|LHA
203108|NCT01933100|Functional constipation
203109|NCT01933100|Brown rice based-meal
203110|NCT01933100|Polished rice based-meal
203111|NCT01933100|Wheat based-meal
203112|NCT01933087|Hand hygiene,
203113|NCT01933087|Randonmised Controlled Trials,
203114|NCT01933087|Hospital
203115|NCT01933074|Urinary Urgency
203116|NCT01933061|Skin cancer, Melanoma
203117|NCT01933048|influenza
203118|NCT01933035|ITP
203119|NCT01933035|Thrombocytopenia
203120|NCT01933035|mean platelet mass
203121|NCT01933035|mean platelet component
203122|NCT01933022|Metastatic prostate cancer
203123|NCT01933022|Exploratory
203124|NCT01933022|Biomarkers
203125|NCT01933022|Eligard
203126|NCT01932996|Smoking Cessation
203127|NCT01932996|Smoking Cessation Products
203128|NCT01932996|Tobacco Use Cessation Products
203129|NCT01932983|Neuromuscular blockade
203130|NCT01932983|TOF test
203131|NCT01932983|Quantitative TOF method
203132|NCT01932983|Visual interpretation of TOF
203133|NCT01932970|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
203134|NCT01932957|Laparoscopy
203135|NCT01932957|Ruptured ectopic pregnancy
203136|NCT01932931|Vitamin D
203137|NCT01932931|Major depression
203138|NCT01932931|SSRIs
203139|NCT01932931|Osteoporosis
203140|NCT01932918|reactive oxygen species
203141|NCT01932918|ischemia reperfusion injury
203142|NCT01932905|deep repetitive transcranial magnetic stimulation
203143|NCT01932905|chronic pain
203144|NCT01932905|assessment
203145|NCT01932905|neuropathic pain
203146|NCT01932905|central pain
203147|NCT01932905|treatment
203148|NCT01932892|transhumeral
203149|NCT01932866|pre-diabetes
203150|NCT01932866|diabetes risk score
203151|NCT01932866|motivation
203152|NCT01932866|Air Force
203153|NCT01932866|Military
203154|NCT01932866|Lifestyle change
203155|NCT01932840|attitudes and understanding of plant sterol claims
203156|NCT01932840|general Canadian population
203157|NCT01932827|Attitudes and understanding of oat fibre claims
203158|NCT01932827|Food labels
203159|NCT01932827|General Canadian population
203160|NCT01932814|Aminoglycosides
203161|NCT01932814|Acute kidney injury
203162|NCT01932814|Severe sepsis
203163|NCT01932814|Critically ill patient
203164|NCT01932801|harm reduction, naltrexone, alcohol dependence, homelessness
203165|NCT01932788|pregnancy
203166|NCT01932788|Vitamin D status
203167|NCT01932736|middle ear
203168|NCT01932736|Eustachian tube
203169|NCT01932736|fMRI
203170|NCT01932723|Stabilization exercises, Pain, Disability, Menstruation
203171|NCT01932710|Leukemia
203172|NCT01932710|Acute myelogenous leukemia
203173|NCT01932710|AML
203174|NCT01932710|High-risk myelodysplastic leukemia
203175|NCT01932710|MDS
203176|NCT01932710|Infection risk
203177|NCT01932710|White Blood Cell transfusion
203178|NCT01932710|Prophylactic therapy
203179|NCT01932671|Cardiovascular diseases
203180|NCT01932671|Atherosclerosis
203181|NCT01932671|Multidetector Computed Tomography
203182|NCT01932671|Diabetes Mellitus, Type 2
203183|NCT01932658|autologous
203184|NCT01932658|Lymphoablation
203185|NCT01932658|hematopoietic
203186|NCT01932658|immune system
203187|NCT01932645|prostatitis
203188|NCT01932645|pelvic pain
203189|NCT01932645|urinary symptoms
203190|NCT01932645|sexual dysfunction
203191|NCT01932632|Polypharmacy
203192|NCT01932632|De-prescribing
203193|NCT01932632|Frailty
203194|NCT01932593|multiple sclerosis
203195|NCT01932593|bone marrow
203196|NCT01932593|stem cell therapy
203197|NCT01932580|gastric
203198|NCT01932580|esophageal
203199|NCT01932580|adenocarcinoma
203200|NCT01932554|Sickle Cell Pain Crisis
203201|NCT01932554|Abciximab
203202|NCT01932554|Integrins
203203|NCT01932554|Cell Adhesion Molecules
203204|NCT01932541|Bipolar Disorder
203205|NCT01932541|Mania
203206|NCT01932541|Bipolar I
203207|NCT01932541|Bipolar II
203208|NCT01932541|Bipolar Spectrum Disorder
203209|NCT01932541|Pediatric
203210|NCT01932528|Absorption
203211|NCT01932528|Metabolism
203212|NCT01932528|Excretion
203213|NCT01932502|epilepsy
203214|NCT01932502|Onfi
203215|NCT01932502|clonazepam
203216|NCT01932463|Tremor
203217|NCT01932463|Essential Tremor
203218|NCT01932463|Medication-refractory Essential Tremor
203219|NCT01932450|hypertension
203220|NCT01932450|radiofrequency ablation
203221|NCT01932450|autosomal dominant polycystic kidney disease
203222|NCT01932424|Children
203223|NCT01932398|Alpha
203224|NCT01932398|Lateralization
203225|NCT01932398|Attention
203226|NCT01932398|ADHD
203227|NCT01932398|Oscillation
203228|NCT01932385|Sorafenib
203229|NCT01932385|Hepatocellular carcinoma
203230|NCT01932385|Best supportive care
203231|NCT01932385|Survival
203232|NCT01932372|Rheumatoid Arthritis
203233|NCT01932372|Good Post Marketing Study Practice
203234|NCT01932372|Tofacitinib
203235|NCT01932372|Xeljanz
203236|NCT01932372|Regulatory Post Marketing Commitment Plan
203237|NCT01932359|Scar outcome
203238|NCT01932359|Mohs surgery
203239|NCT01932359|face
203240|NCT01932346|near infra-red spectroscopy, coronary artery bypass grafting
203241|NCT01932333|Healthy
203242|NCT01932333|Safety
203243|NCT01932333|Tolerability
203244|NCT01932333|Pharmacokinetics
203245|NCT01932333|Pharmacodynamics
203246|NCT01932333|JNJ-40411813
203247|NCT01932333|Positive allosteric modulator
203248|NCT01932320|Healthy
203249|NCT01932320|Relative Bioavailability
203250|NCT01932320|Food effect
203251|NCT01932320|JNJ-40411813
203252|NCT01932320|Positive allosteric modulator
203253|NCT01932320|Solid Dosage Formulation of JNJ-40411813
203254|NCT01932320|Ketoconazole
203255|NCT01932307|Surgeon neck health
203256|NCT01932294|Advanced Heart Failure
203257|NCT01932294|Refractory Heart Failure
203258|NCT01932294|Mechanical Circulatory Support Device
203259|NCT01932294|Ventricular Assist Device
203260|NCT01932294|Medamacs
203261|NCT01932281|muscle power
203262|NCT01932281|muscle fatigue
203263|NCT01932281|SierraSil
203264|NCT01932255|microvascular decompression surgery
203265|NCT01932255|cerebrospinal fluid leakage
203266|NCT01932255|postoperative complications
203267|NCT01932229|Advanced NSCLC
203268|NCT01932229|EGFR mutation
203269|NCT01932229|TKIs
203270|NCT01932229|Tyrosine Kinase Inhibitors
203271|NCT01932216|robotic single-site cholecystectomy
203272|NCT01932216|laparoscopic cholecystectomy
203273|NCT01932216|cosmesis
203274|NCT01932216|quality of life
203275|NCT01932203|Cerebral small vessel disease
203276|NCT01932203|Leukoaraiosis
203277|NCT01932203|Magnetic Resonance Imaging
203278|NCT01932203|Diffusion Tensor Imaging
203279|NCT01932190|Acute Kidney Injury
203280|NCT01932190|Critical Care
203281|NCT01932190|Renal Replacement Therapy
203282|NCT01932190|Treatment Outcome
203283|NCT01932177|Everolimus ; Sorafenib ; Phase 1 trial ; Solid tumor
203284|NCT01932164|Cleft lip and palate
203285|NCT01932164|Deciduous dental pulp stem cells
203286|NCT01932164|mesenchymal stem cells
203287|NCT01932164|tissue engineering
203288|NCT01932164|bone tissue engineering
203289|NCT01932164|bioengineering
203290|NCT01932151|type-1 HRS
203291|NCT01932151|active bacterial infections
203292|NCT01932151|terlipressin and albumin
203293|NCT01932151|kidney function
203294|NCT01932138|Community-based intervention
203295|NCT01932138|Community health workers
203296|NCT01932138|Antenatal care
203297|NCT01932138|HIV
203298|NCT01932138|PMTCT
203299|NCT01932138|HIV vertical transmission
203300|NCT01932138|Public-sector health systems
203301|NCT01932112|Pulmonary Vein Isolation
203302|NCT01932112|Adenosin effect
203303|NCT01932112|Atrial fibrillation ablation
203304|NCT01932099|pathological constriction; restricted outflow, stenosis
203305|NCT01932086|male
203306|NCT01932086|Glucose
203307|NCT01932086|Triglyceride
203308|NCT01932086|Glycemic index
203309|NCT01932086|White rice
203310|NCT01932086|Brown rice
203311|NCT01932086|Black rice
203312|NCT01932086|Bread
203313|NCT01932073|Radiation
203314|NCT01932073|dermatitis
203315|NCT01932073|radiodermatitis
203316|NCT01932073|radiotherapy induced
203317|NCT01932073|skin reactions
203318|NCT01932073|low level laser therapy
203319|NCT01932073|breast cancer
203320|NCT01932060|Oxytocin
203321|NCT01932060|blood loss
203322|NCT01932060|Cesarean delivery
203323|NCT01932034|Vancomycin
203324|NCT01932034|Pharmacokinetics
203325|NCT01932034|Pharmacodynamics
203326|NCT01932034|Decision support
203327|NCT01932021|necrotitis angiodermatitis
203328|NCT01932021|autologous fat transplantation
203329|NCT01932021|mesenchymal stem cells
203330|NCT01932008|Coronary artery bypass grafting
203331|NCT01932008|Chronic kidney disease
203332|NCT01932008|Body composition
203333|NCT01932008|Physical activity
203334|NCT01932008|Physical function
203335|NCT01931982|diabetes, GLP-1, Victoza, CFR, microvascular dysfunction
203336|NCT01931969|Vein catheterization; Ultrasound; Landmark; Complication
203337|NCT01931956|Mitral Valve Insufficiency
203338|NCT01931956|Mitral Valve Regurgitation
203339|NCT01931956|Mitral Valve Incompetence
203340|NCT01931956|Mitral Regurgitation
203341|NCT01931956|Mitral Insufficiency
203342|NCT01931956|Mitral Valve
203343|NCT01931956|MR
203344|NCT01931956|Mitral Valve Prolapse
203345|NCT01931956|E2E - Edge to Edge
203346|NCT01931956|Alfieri Technique
203347|NCT01931956|MitraClip
203348|NCT01931956|Functional MR
203349|NCT01931956|Degenerative MR
203350|NCT01931956|Echocardiogram
203351|NCT01931956|CAD - Coronary Artery Disease
203352|NCT01931956|Heart Failure
203353|NCT01931956|Heart Attack
203354|NCT01931956|EVEREST
203355|NCT01931956|EVEREST I
203356|NCT01931956|EVEREST II
203357|NCT01931956|REALISM
203358|NCT01931930|Gastrointestinal discomfort
203359|NCT01931930|Perilla frutescens
203360|NCT01931930|bloating
203361|NCT01931930|abdominal discomfort
203362|NCT01931930|human study
203363|NCT01931930|healthy subjects
203364|NCT01931917|Prevention
203365|NCT01931917|Parenting
203366|NCT01931917|Infants
203367|NCT01931917|Family programs
203368|NCT01931917|Early intervention
203369|NCT01931904|IOP
203370|NCT01931904|Glaucoma
203371|NCT01931904|Trabeculectomy
203616|NCT01930643|mechanical ventilation
203372|NCT01931891|preeclampsia, ADAMTS , wharton jelly, extracellüler matrix, placenta
203373|NCT01931878|Restless Legs Syndrome
203374|NCT01931878|Leg pain
203375|NCT01931878|Sleep
203376|NCT01931878|Dysesthesias
203377|NCT01931878|incobotulinumtoxin
203378|NCT01931865|cancer pain, radiation therapy, surgery, incobotulinum toxin
203379|NCT01931852|Acute Coronary Syndrome
203380|NCT01931852|Chest pain
203381|NCT01931852|Cardiac MRI
203382|NCT01931852|Risk Stratification
203383|NCT01931852|Emergency Department
203384|NCT01931852|Elevated Troponin
203385|NCT01931852|Troponin
203386|NCT01931852|Non-ST Elevation Myocardial Infarction
203387|NCT01931826|Schistosomiasis
203388|NCT01931826|Surgical treatment
203389|NCT01931826|Endoscopic treatment
203390|NCT01931774|acne vulgaris cognitive functions
203391|NCT01931761|Pharmacokinetics, mass balance, AZD6244
203392|NCT01931735|menisci
203393|NCT01931735|tibial
203394|NCT01931722|branched chain amino acid requirement
203395|NCT01931722|older men
203396|NCT01931722|strength training
203397|NCT01931722|sarcopenia
203398|NCT01931696|Efficacy
203399|NCT01931696|Acupuncture
203400|NCT01931696|Asthma
203401|NCT01931683|LMA removal
203402|NCT01931683|remifentanil
203403|NCT01931683|propofol
203404|NCT01931670|Dysmenorrhea (DYS)
203405|NCT01931670|Elagolix
203406|NCT01931670|Gonadotropin-Releasing Hormone Antagonist
203407|NCT01931670|Non-Menstrual Pelvic Pain (NMPP)
203408|NCT01931670|Endometriosis Associated Pain
203409|NCT01931657|LNG-IUS
203410|NCT01931657|Mirena
203411|NCT01931657|Contraception
203412|NCT01931657|Bleeding
203413|NCT01931657|Hormonal effects in the breast
203414|NCT01931644|Graft-versus-Host Disease (GVHD)
203415|NCT01931644|Amyotrophic Lateral Sclerosis (ALS)
203416|NCT01931644|Cancer
203417|NCT01931644|Diabetes
203418|NCT01931644|Melanoma
203419|NCT01931644|Hepatitis B
203420|NCT01931644|Lupus
203421|NCT01931644|Multiple Sclerosis
203422|NCT01931644|Asthma
203423|NCT01931644|Crohn's Disease
203424|NCT01931644|Ulcerative Colitis
203425|NCT01931644|Kidney Disease
203426|NCT01931644|Alzheimer's Disease
203427|NCT01931644|Parkinson's Disease
203428|NCT01931644|Huntington's Disease
203429|NCT01931644|Rheumatoid Arthritis
203430|NCT01931644|Sjogren's Syndrome
203431|NCT01931644|Leukemia
203432|NCT01931644|Lymphoma
203433|NCT01931644|Myeloma
203434|NCT01931644|CIDP
203435|NCT01931644|COPD
203436|NCT01931644|Idiopathic Thrombocytopenia Purpura
203437|NCT01931644|Cystic Fibrosis
203438|NCT01931644|Primary Biliary Cirrhosis
203439|NCT01931631|Diabetes Mellitus, Type 2
203440|NCT01931631|Diet, Vegetarian
203441|NCT01931631|Diet, Fat-Restricted
203442|NCT01931631|Glycemic Index
203443|NCT01931618|alcohol
203444|NCT01931618|online intervention
203445|NCT01931618|hazardous drinking
203446|NCT01931618|harmful drinking
203447|NCT01931618|early intervention
203448|NCT01931618|behavior change intervention
203449|NCT01931592|ESBL
203450|NCT01931592|neutropenia
203451|NCT01931592|eradication
203452|NCT01931592|bloodstream infection
203453|NCT01931592|immunosuppression
203454|NCT01931579|confocal endo-microscopy, lung nodule, respiratory neoplasms
203455|NCT01931566|Drug therapy
203456|NCT01931540|Obesity
203457|NCT01931540|Epigenesis, Genetic
203458|NCT01931540|Exercise Therapy
203459|NCT01931527|Obesity
203460|NCT01931527|Metabolic syndrome
203461|NCT01931527|Hyperuricemia
203462|NCT01931462|Cancer of the Kidney
203463|NCT01931462|Renal Cancer
203464|NCT01931462|Renal Neoplasms
203465|NCT01931462|Neoplasms, Kidney
203466|NCT01931449|Pancreatoduodenectomy
203467|NCT01931449|Digestive Tract Reconstruction
203468|NCT01931449|Pancreas
203469|NCT01931436|Menopause, pharmacokinetic
203470|NCT01931397|Dried blood spots
203471|NCT01931397|kidney transplant
203472|NCT01931397|Children
203473|NCT01931384|Luteal phase support
203474|NCT01931384|Human chorionic gonadotrophin
203475|NCT01931384|frozen-thawed embryo transfer cycle
203476|NCT01931371|fistula in ano
203477|NCT01931371|anal fistula
203478|NCT01931371|recurrence
203479|NCT01931371|costs
203480|NCT01931345|Rapid HIV testing
203481|NCT01931345|MSM
203482|NCT01931345|Motivational Interviewing
203483|NCT01931345|HIV prevention
203484|NCT01931345|HIV/AIDS
203485|NCT01931345|At-risk anal intercourse
203486|NCT01931345|Randomized trial
203487|NCT01931332|Arthroplasty
203488|NCT01931332|Analgesia
203489|NCT01931319|baclofen withdrawal
203490|NCT01931319|interruption
203491|NCT01931319|spasticity
203492|NCT01931319|pharmacokinetics
203493|NCT01931319|tolerability
203494|NCT01931319|intravenous
203740|NCT01929018|Rehabilitation
203495|NCT01931293|atrophic glossitis, burning mouth syndrome, gastric parietal cell antibody, thyroglobulin antibody, thyroid microsomal antibody, HLA-DR, HLA-DQ
203496|NCT01931280|Gestational diabetes
203497|NCT01931241|atherosclerosis
203498|NCT01931241|atherosclerotic heart disease
203499|NCT01931241|hypercholesteremia
203500|NCT01931241|atherosclerotic plaque
203501|NCT01931241|hyperlipidemia
203502|NCT01931228|Intensive care unit
203503|NCT01931228|acute respiratory insufficiency
203504|NCT01931228|Respiratory failure
203505|NCT01931228|Mechanical Insufflation-Exsufflation
203506|NCT01931150|Topical Dapsone 5% Gel
203507|NCT01931150|Moisturizer
203508|NCT01931150|rash
203509|NCT01931150|13-012
203510|NCT01931124|maximal oxygen uptake, activity levels, elderly
203511|NCT01931111|physical activity
203512|NCT01931111|maximal oxygen uptake
203513|NCT01931098|Brain Tumors
203514|NCT01931072|Exercise
203515|NCT01931072|High-intensity interval training
203516|NCT01931072|Moderate training
203517|NCT01931072|Healthy elderly
203518|NCT01931072|Skeletal muscle
203519|NCT01931072|DNA-methylation
203520|NCT01931072|Gene expression
203521|NCT01931072|subjects
203522|NCT01931059|Imaging
203523|NCT01931059|Risperidone
203524|NCT01931059|Placebo
203525|NCT01931059|antipsychotic
203526|NCT01931046|prostate cancer
203527|NCT01931046|adenocarcinoma of the prostate
203528|NCT01931033|Autism Spectrum Disorders
203529|NCT01931033|Pervasive Developmental Disorders
203530|NCT01931033|ASD
203531|NCT01931033|PDD
203532|NCT01931033|Oxytocin
203533|NCT01931033|Syntocinon
203534|NCT01931033|treatment
203535|NCT01931020|Pain
203536|NCT01931020|Preterm
203537|NCT01931020|Neonates
203538|NCT01931020|24% Sucrose
203539|NCT01931020|25% Dextrose
203540|NCT01931007|osteoarthritis
203541|NCT01930994|LNG: Levonorgestrel
203542|NCT01930994|MSI: Marie Stopes International
203543|NCT01930994|MSK: Marie Stopes Kenya
203544|NCT01930994|PK: Pharmacokinetic
203545|NCT01930981|quality of life
203546|NCT01930981|toxicities
203547|NCT01930981|hematopoietic stem cell transplantation
203548|NCT01930968|uveal melanoma, ocular melanoma
203549|NCT01930955|Non-antibiotic prescribing
203550|NCT01930955|acute upper respiratory tract infection
203551|NCT01930955|white cell count
203552|NCT01930955|vomiting
203553|NCT01930942|rectal carcinoma
203554|NCT01930942|preoperative concurrent chemoradiotherapy
203555|NCT01930929|Bariatric surgery
203556|NCT01930929|Complications
203557|NCT01930929|Drugs
203558|NCT01930916|Prothrombin Time/instrumentation
203559|NCT01930916|Prothrombin Time/utilization
203560|NCT01930916|Blood Coagulation Disorders/blood
203561|NCT01930916|Blood Coagulation Disorders/complications
203562|NCT01930916|Blood Coagulation Disorders/diagnosis
203563|NCT01930916|Prospective Studies
203564|NCT01930916|Adult
203565|NCT01930916|Reproducibility of Results
203566|NCT01930916|Point-of-Care Systems/utilization
203567|NCT01930916|Aged
203568|NCT01930916|Elderly
203569|NCT01930903|PRO-Kinetic Energy BMS + Pantera Lux DEB combination
203570|NCT01930877|quality of recovery
203571|NCT01930877|spine surgery
203572|NCT01930877|intravenous lidocaine
203573|NCT01930864|metformin
203574|NCT01930864|colorectal cancer
203575|NCT01930864|chemotherapy
203576|NCT01930851|Bariatric surgery
203577|NCT01930851|Quality of life
203578|NCT01930851|Complications
203579|NCT01930838|Bariatric surgery
203580|NCT01930838|Complications
203581|NCT01930838|Osteoporosis
203582|NCT01930838|Neuropathy
203583|NCT01930838|Vitamine deficiency
203584|NCT01930812|18F-NaF PET/CT
203585|NCT01930812|Bone imaging
203586|NCT01930773|clopidogrel
203587|NCT01930773|prasugrel
203588|NCT01930773|platelet function testing
203589|NCT01930773|genotyping
203590|NCT01930773|peri-procedural MI
203591|NCT01930760|pediatric
203592|NCT01930760|Childhood Obesity
203593|NCT01930760|motivational interviewing
203594|NCT01930760|pediatric primary care physicians
203595|NCT01930747|pneumoperitoneum
203596|NCT01930747|laparoscopy
203597|NCT01930734|Heart Failure
203598|NCT01930734|Dobutamine
203599|NCT01930708|BG-12
203600|NCT01930695|DX functionality
203601|NCT01930695|Atrial fibrillation
203602|NCT01930695|CRT-D indication
203603|NCT01930682|Myocardial Infarction
203604|NCT01930682|Catheterization
203605|NCT01930682|Fibrinolysis
203606|NCT01930669|Heart Rate Variability
203607|NCT01930669|Multiple Organ Dysfunction Syndrome
203608|NCT01930669|Critically Ill
203609|NCT01930656|osteoporisis
203610|NCT01930656|fracture
203611|NCT01930656|risk
203612|NCT01930656|cost effectiveness
203613|NCT01930656|FRAX
203614|NCT01930656|mobile device
203615|NCT01930643|Electric muscle stimulation
203617|NCT01930643|chronic respiratory failure
203618|NCT01930630|extraesophageal saline injection (ESI);
203619|NCT01930630|esophageal squamous cell carcinoma (ESCC);
203620|NCT01930630|esophageal cancer;
203621|NCT01930630|endoscopic ultrasonography (EUS)
203622|NCT01930617|surgery
203623|NCT01930617|trephining
203624|NCT01930617|drainage
203625|NCT01930617|therapeutic irrigation
203626|NCT01930617|subdural space
203627|NCT01930617|postoperative complications
203628|NCT01930617|mortality
203629|NCT01930604|Palmar hyperhidrosis.
203630|NCT01930604|Plantar hyperhidrosis.
203631|NCT01930604|Inguinal (groins and buttocks) hyperhidrosis.
203632|NCT01930604|Craniofacial hyperhidrosis.
203633|NCT01930604|Truncal hyperhidrosis.
203634|NCT01930591|fibrinolytic therapy
203635|NCT01930591|stenting
203636|NCT01930591|platelet activity
203637|NCT01930578|bioimpedance analysis
203638|NCT01930578|spectroscopy
203639|NCT01930578|electrolyte sodium bromide
203640|NCT01930578|extracellular water
203641|NCT01930565|acne
203642|NCT01930565|therapeutics
203643|NCT01930565|clinical trial
203644|NCT01930565|natural compound
203645|NCT01930565|Lactobacillus fermented Chamaecypris obtuse
203646|NCT01930565|tea tree oil
203647|NCT01930526|COPD
203648|NCT01930526|Exercise
203649|NCT01930526|Cycling
203650|NCT01930526|Single leg
203651|NCT01930526|Pulmonary Rehabilitation
203652|NCT01930513|Obesity
203653|NCT01930513|Obstructive Sleep Apnea
203654|NCT01930513|Exercise
203655|NCT01930513|Walking tests
203656|NCT01930513|Cardiopulmonary exercise tests
203657|NCT01930513|Physical activity
203658|NCT01930487|Primary open angle glaucoma
203659|NCT01930487|intraocular pressure
203660|NCT01930487|ocular perfusion pressure
203661|NCT01930487|retrobulbar blood flow
203662|NCT01930487|retinal capillary blood flow
203663|NCT01930487|choroidal blood flow
203664|NCT01930474|lung cancer, plasma DNA, free DNA, EGFR, ALK
203665|NCT01930448|Bariatric
203666|NCT01930448|Gastric Bypass
203667|NCT01930448|Gastric Banding,
203668|NCT01930448|Type 2 Diabetes
203669|NCT01930448|Incretins
203670|NCT01930448|GLP-1
203671|NCT01930448|GIP
203672|NCT01930448|Insulin secretion
203673|NCT01930448|insulin sensitivity
203674|NCT01930435|Quality of Life
203675|NCT01930422|Direct transcranial electrical stimulation (tDCS)
203676|NCT01930422|Sham procedure
203677|NCT01930422|Tobacco consumption
203678|NCT01930422|Craving
203679|NCT01930409|Femoral Fractures
203680|NCT01930409|Hip Fractures
203681|NCT01930409|Frail older adults
203682|NCT01930409|Quality of Life
203683|NCT01930409|Feasibility Studies
203684|NCT01930396|Hemodialysis
203685|NCT01930396|Anticoagulation
203686|NCT01930396|Tinzaparin
203687|NCT01930396|Unfractionated Heparin
203688|NCT01930396|Randomized Controlled Trial
203689|NCT01930383|biomarkers
203690|NCT01930370|pediatrics
203691|NCT01930370|phosphate and postassium revmoval
203692|NCT01930370|dialysate bicarbonate modeling
203693|NCT01930357|Rabies
203694|NCT01930357|Purified Vero Rabies Vaccine - Serum Free (VRVg)
203695|NCT01930357|Imovax® rabies
203696|NCT01930357|Human Diploid Cell Vaccine
203697|NCT01930344|stereopsis
203698|NCT01930344|3D laparoscopy
203699|NCT01930344|OCHRA
203700|NCT01930331|Uncomplicated Plasmodium falciparum Malaria
203701|NCT01930305|Heating transfusion
203702|NCT01930279|T cell markers
203703|NCT01930227|hypotension
203704|NCT01930227|spinal anesthesia
203705|NCT01930227|cesarean
203706|NCT01930175|Pemphigus vulgaris
203707|NCT01930175|pemphigus
203708|NCT01930175|blistering disease
203709|NCT01930162|single umbilical cord blood transplantation, non-myeloablative conditioning
203710|NCT01930149|Cholesterol screening
203711|NCT01930149|High cholesterol
203712|NCT01930149|Cardiovascular disease
203713|NCT01930149|Statin treatment
203714|NCT01930136|Calorie restriction
203715|NCT01930136|Type 2 diabetes
203716|NCT01930136|Obesity
203717|NCT01930136|Diabetic nephropathy prevention
203718|NCT01930123|Fructose
203719|NCT01930123|NASH
203720|NCT01930123|advanced fibrosis
203721|NCT01930123|biomarker
203722|NCT01930123|magnetic resonance
203723|NCT01930110|Type 1 diabetes
203724|NCT01930110|Hypoglycemia
203725|NCT01930110|Insulin
203726|NCT01930110|Glucagon
203727|NCT01930110|Closed-loop system
203728|NCT01930110|Artificial pancreas
203729|NCT01930097|Type 1 diabetes
203730|NCT01930097|Hypoglycemia
203731|NCT01930097|Insulin
203732|NCT01930097|Glucagon
203733|NCT01930097|Closed-loop system
203734|NCT01930097|Artificial pancreas
203735|NCT01930097|Carbohydrate counting
203736|NCT01930084|HIV
203737|NCT01930084|linkage
203738|NCT01930084|retention
203739|NCT01929018|Amputation
203741|NCT01929018|Exercise
203742|NCT01929018|Movement
203743|NCT01929005|Comprehensive care
203744|NCT01929005|Medicare
203745|NCT01929005|Cost-sharing
203746|NCT01929005|Quality of care
203747|NCT01928992|Mammography
203748|NCT01928992|3D
203749|NCT01928992|Breast Cancer Detection
203750|NCT01928979|LA/LAA Thrombus
203751|NCT01928979|Atrial Fibrillation
203752|NCT01928979|Observation
203753|NCT01928966|dietary fat
203754|NCT01928966|fat intake
203755|NCT01928966|blood pressure
203756|NCT01928966|women
203757|NCT01928966|phytoestrogen
203758|NCT01928966|pumpkin seeds
203759|NCT01928966|cardiovascular disease
203760|NCT01928966|heart disease
203761|NCT01928966|secoisolariciresinol
203762|NCT01928966|monounsaturated fat
203763|NCT01928966|polyunsaturated fat
203764|NCT01928966|feeding study
203765|NCT01928953|opioid induced constipation in patients without cancer and with cancer
203766|NCT01928940|Advanced solid tumors
203767|NCT01928940|BRAF
203768|NCT01928940|Melanoma
203769|NCT01930032|Clostridium difficile infection
203770|NCT01930019|etomidate,
203771|NCT01930019|thiopental,
203772|NCT01930019|serum cortisol concentration,
203773|NCT01930006|c-Met
203774|NCT01930006|VEGFR
203775|NCT01930006|Ron
203776|NCT01930006|Cancer
203777|NCT01930006|Tumor
203778|NCT01930006|Safety
203779|NCT01930006|Phase 1
203780|NCT01929993|Conization
203781|NCT01929993|Cervical Intraepithelial Neoplasia
203782|NCT01929993|Cervix Dysplasia
203783|NCT01929993|Therapy
203784|NCT01929993|Electrosurgery
203785|NCT01929980|HSCT
203786|NCT01929980|cytopenia
203787|NCT01929980|immune suppression
203788|NCT01929980|proteasome inhibitor
203789|NCT01929967|Heterotaxy syndrome
203790|NCT01929967|Asplenia
203791|NCT01929967|Polysplenia
203792|NCT01929889|schizophrenia
203793|NCT01929889|schizoaffective disorder
203794|NCT01929889|iloperidone
203795|NCT01929889|Fanapt
203796|NCT01929889|social cognition
203797|NCT01929889|cognition
203798|NCT01929863|Metformin
203799|NCT01929863|Diabetes
203800|NCT01929837|Tinnitus
203801|NCT01929837|Transcranial magnetic stimulation
203802|NCT01929824|dysphagia, trouble swallowing, chest pain
203803|NCT01929798|artificial pancreas
203804|NCT01929785|post tranplant heart allograft
203805|NCT01929759|HIV
203806|NCT01929759|neurocognitive symptoms
203807|NCT01929759|efavirenz
203808|NCT01929759|elvitegravir
203809|NCT01929759|neurometabolites
203810|NCT01929733|Patent Ductus Arteriosus
203811|NCT01929720|cancer
203812|NCT01929720|cancer survivors
203813|NCT01929720|worry
203814|NCT01929720|insomnia
203815|NCT01929720|symptoms
203816|NCT01929720|fatigue
203817|NCT01929720|depression
203818|NCT01929720|anxiety
203819|NCT01929681|Low Field Magnetic Stimulation
203820|NCT01929681|bipolar
203821|NCT01929681|depression
203822|NCT01929681|alternative treatment
203823|NCT01929668|ulcerative colitis
203824|NCT01929668|bowel preparation
203825|NCT01929655|Phase II
203826|NCT01929655|symptomatic castration-resistant prostate cancer
203827|NCT01929655|bone metastases
203828|NCT01929642|Tuberous Sclerosis Complex (TSC)
203829|NCT01929642|self-injury
203830|NCT01929642|Autism
203831|NCT01929629|Phase 1
203832|NCT01929629|Healthy Volunteers
203833|NCT01929629|First Time in Man
203834|NCT01929629|Pharmacokinetics
203835|NCT01929616|adenocarcinoma, colorectal,regorafenib
203836|NCT01929603|oncology, cancer, tumour, anticancer drug, pharmacokinetics, olaparib, rifampicin, neoplasm, CYP P450 inducer
203837|NCT01929590|Colonoscopy
203838|NCT01929590|Preparation
203839|NCT01929590|Polyp
203840|NCT01929590|Polyethylene glycol
203841|NCT01929577|ASP015K
203842|NCT01929577|healthy subjects
203843|NCT01929564|cardiovascular disease
203844|NCT01929564|risk factor
203845|NCT01929564|broccoli
203846|NCT01929564|GST
203847|NCT01929564|blood pressure
203848|NCT01929564|Total cholesterol
203849|NCT01929551|glycemic index
203850|NCT01929538|Chronic pancreatitis
203851|NCT01929538|Biliary stricture
203852|NCT01929538|Endoscopic treatment
203853|NCT01929538|cSEMS
203854|NCT01929499|Colon cancer
203855|NCT01929499|Cytokine-induced killer cells
203856|NCT01929499|Adjuvant immunotherapy
203857|NCT01929499|Adjuvant chemotherapy
203858|NCT01929473|Pertussis infection
203859|NCT01929473|Risk factors
203860|NCT01929447|sleep disorders
203861|NCT01929447|sleep apnea
203862|NCT01929447|ambulatory device
203863|NCT01929447|WatchPAT
203864|NCT01929434|cerebral palsy
203865|NCT01929434|cell transplantation
203866|NCT01929434|rehabilitation
203867|NCT01929421|colorectal cancer
203868|NCT01929421|gemcitabine
203869|NCT01929421|S-1
203870|NCT01929395|Breast Cancer
203871|NCT01929395|Breast Conserving Surgery
203872|NCT01929395|Breast diagnostics
203873|NCT01929395|Breast imaging
203874|NCT01929382|dose titration
203875|NCT01929382|FLS
203876|NCT01929382|flu like symptoms
203877|NCT01929382|Actimmune
203878|NCT01929369|ESRD
203879|NCT01929369|CKD
203880|NCT01929369|AV GRAFTS
203881|NCT01929369|THROMBOSED AV GRAFTS
203882|NCT01929356|lung function tests
203883|NCT01929356|chest physiotherapy
203884|NCT01929343|cocaine
203885|NCT01929343|addiction
203886|NCT01929343|lidocaine
203887|NCT01929343|memory
203888|NCT01929343|drug abuse
203889|NCT01929330|Bioequivalence
203890|NCT01929330|Healthy Male Volunteers
203891|NCT01929330|Androgenetic Alopecia
203892|NCT01929330|Dutasteride
203893|NCT01929330|Safety
203894|NCT01929330|Tolerability
203895|NCT01929317|Ropinirole
203896|NCT01929317|Parkinson's disease
203897|NCT01929291|Korea
203898|NCT01929291|Post-marketing surveillance
203899|NCT01929291|Boostrix
203900|NCT01929291|Prescribing information
203901|NCT01929291|Safety
203902|NCT01929265|INFL
203903|NCT01929265|Indolent non-follicular
203904|NCT01929265|untreated INFL
203905|NCT01929252|dexmedetomidine
203906|NCT01929252|wound infiltration
203907|NCT01929252|postoperative analgesia
203908|NCT01929187|Onychomycosis, BioEqual carrier system, amorolfine.
203909|NCT01929174|Congenital heart disease
203910|NCT01929174|Myocardial fibrosis
203911|NCT01929174|Diastolic dysfunction
203912|NCT01929161|positive emotions
203913|NCT01929161|meditation
203914|NCT01929161|oxytocin
203915|NCT01929148|risk-reducing salpingectomy
203916|NCT01929148|prophylactic bilateral salpingectomy
203917|NCT01929148|ovarian cancer prevention
203918|NCT01929148|ovarian reserve
203919|NCT01929135|Periodontal Disease
203920|NCT01929135|Chronic Periodontitis
203921|NCT01929135|Atorvastatin
203922|NCT01929135|Statins
203923|NCT01929135|Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors
203924|NCT01929135|Dentifrice
203925|NCT01929122|Prevention & control
203926|NCT01929122|Diet
203927|NCT01929122|Functional food
203928|NCT01929122|Nutrition Assessment
203929|NCT01929122|Oryza sativa
203930|NCT01929122|Rice Bran
203931|NCT01929122|Phaseolus vulgaris L.
203932|NCT01929122|Legumes
203933|NCT01929122|Microbiome
203934|NCT01929122|Metabolomics
203935|NCT01929122|Prebiotics
203936|NCT01929083|Torsades de pointes
203937|NCT01929083|Progesterone
203938|NCT01929083|Clinical trial
203939|NCT01929083|Risk reduction
203940|NCT01929083|Electrocardiography
203941|NCT01929070|HCP1007
203942|NCT01929070|Rosuvastatin
203943|NCT01929070|Omega-3
203944|NCT01928888|Acute heartburn episodes
203945|NCT01928849|Amputation
203946|NCT01928849|Post-amputation Pain
203947|NCT01928849|Neuropathic pain
203948|NCT01928849|Valproic Acid
203949|NCT01928849|Anesthesia, Conduction
203950|NCT01928849|Neuralgia, stump
203951|NCT01928836|Carcinoma, Non-Small-Cell Lung
203952|NCT01928836|Small Cell Lung Carcinoma
203953|NCT01928836|Biological Markers
203954|NCT01928836|ROC Curve
203955|NCT01928836|Delayed Diagnosis
203956|NCT01928823|agoraphobia
203957|NCT01928823|panic disorder
203958|NCT01928823|D-Cycloserine
203959|NCT01928823|DCS
203960|NCT01928823|exposure
203961|NCT01928823|cognitive behavioral therapy
203962|NCT01928823|CBT
203963|NCT01928823|augmentation
203964|NCT01928810|Panic Disorder
203965|NCT01928810|Agoraphobia
203966|NCT01928810|Physical Activity
203967|NCT01928797|cardiac output pregnancy spinal anesthesia
203968|NCT01928784|Low back pain
203969|NCT01928784|extracorporeal shock wave therapy
203970|NCT01928784|Trigger Points
203971|NCT01928771|Asthma,
203972|NCT01928771|Bronchial Diseases,
203973|NCT01928771|Respiratory Tract Diseases,
203974|NCT01928771|Lung Diseases,
203975|NCT01928771|Obstructive Lung Diseases
203976|NCT01928758|Smoking
203977|NCT01928758|Nicotine
203978|NCT01928745|Stewart approach
203979|NCT01928745|sepsis
203980|NCT01928745|SIRS
203981|NCT01928745|cardiothoracic surgery
203982|NCT01928745|CABG
203983|NCT01928719|Smoking
203984|NCT01928719|Nicotine
203985|NCT01928706|edentulism
203986|NCT01928706|denture liner
203987|NCT01928706|prosthodontics
203988|NCT01928706|OHIP EDENT
203989|NCT01928693|infectious corneal ulcers
203990|NCT01928680|Triple Negative Breast Cancer, Cisplatin, Capecitabine
203991|NCT01928654|Edema
203992|NCT01928654|Diabetic
203993|NCT01928654|Laser
203994|NCT01928654|Treatment
203995|NCT01928602|Crossover
203996|NCT01928602|Chronic stroke
203997|NCT01928602|Stroke
203998|NCT01928602|Rehabilitation
203999|NCT01928602|Language Therapy
204000|NCT01928602|Aphasia
204001|NCT01928602|Aphasia Therapy
204002|NCT01928602|Computerised Therapy
204003|NCT01928602|Computerised Rehabilitation
204004|NCT01928602|Tablet
204005|NCT01928602|Apps
204006|NCT01928602|Aphasia Rehabilitation
204007|NCT01928602|Rehabilitation on Portable Tablets
204008|NCT01928589|Cyclophosphamide
204009|NCT01928589|Doxorubicin
204010|NCT01928589|Docetaxel
204011|NCT01928589|Carboplatin
204012|NCT01928589|Herceptin
204013|NCT01928589|Partial Breast Irradiation
204014|NCT01928589|Concurrent Chemotherapy
204015|NCT01928550|Diabetes
204016|NCT01928550|OCT
204017|NCT01928550|PDR
204018|NCT01928537|International Working Group
204019|NCT01928537|azacitidine
204020|NCT01928537|decitabine
204021|NCT01928524|Gastric cancer
204022|NCT01928524|Cancer of the esophagus
204023|NCT01928524|Oxaliplatin
204024|NCT01928524|Docetaxel
204025|NCT01928524|S1
204026|NCT01928511|Hepatitis B virus
204027|NCT01928511|HBeAg positive
204028|NCT01928511|HBeAg negative
204029|NCT01928511|antiviral therapy
204030|NCT01928511|nucleoside analogues
204031|NCT01928498|arteriovenous fistulae
204032|NCT01928498|arteriovenous graft
204033|NCT01928498|restenosis
204034|NCT01928498|angioplasty
204035|NCT01928498|drug eluting balloon
204036|NCT01928472|Influenza, H7N9, Vaccine
204037|NCT01928459|BGJ398
204038|NCT01928459|BYL719
204039|NCT01928459|advanced solid tumor
204040|NCT01928459|metastatic breast cancer
204041|NCT01928459|PK3CA
204042|NCT01928459|FGFR
204043|NCT01928459|fibroblast growth factor receptor
204044|NCT01928446|Lithium
204045|NCT01928446|Placebos
204046|NCT01928446|Double-blind methods
204047|NCT01928446|Clinical Trials, Randomized
204048|NCT01928446|Veterans
204049|NCT01928433|Urinary Tract Infection
204050|NCT01928433|Pyelonephritis
204051|NCT01928420|Alzheimer Disease
204052|NCT01928420|Alzheimer Type Senile Dementia
204053|NCT01928420|Alzheimer's Disease
204054|NCT01928420|clinical trial
204055|NCT01928420|dementia
204056|NCT01928420|diabetes
204057|NCT01928420|dietary supplements
204058|NCT01928420|Senile Dementia, Alzheimer
204059|NCT01928420|Therapeutics
204060|NCT01928420|Brain Diseases
204061|NCT01928420|Central Nervous System Diseases
204062|NCT01928420|Nervous System Diseases
204063|NCT01928420|Neurodegenerative Diseases
204064|NCT01928420|Delirium, Dementia, Amnestic, Cognitive
204065|NCT01928420|Disorders
204066|NCT01928420|Mental Disorders
204067|NCT01928407|naives, CD4 < 200 cell/mm3, Atazanavir, Darunavir
204068|NCT01928368|Mild asthma
204069|NCT01928368|Atopic asthma
204070|NCT01928368|Healthy volunteers
204071|NCT01928368|First-in-human
204072|NCT01928316|Healthy
204073|NCT01928316|Bioequivalence
204074|NCT01928316|Mizolastine
204075|NCT01928316|Domestic
204076|NCT01928316|Imported
204077|NCT01928303|opioids
204078|NCT01928303|chronic pain
204079|NCT01928303|oxycodone
204080|NCT01928303|oxymorphone
204081|NCT01928303|patients using opioid pain medication
204082|NCT01928277|Symptom assessment agreement
204083|NCT01928277|Work of breathing
204084|NCT01928264|Mental disorders
204085|NCT01928264|Physical activity
204086|NCT01928264|Disability pension
204087|NCT01928264|Disability pension due to mental illness
204088|NCT01928264|Ability to work
204089|NCT01928264|Mental toughness
204090|NCT01928238|NIV
204091|NCT01928238|NAVA
204092|NCT01928238|noninvasive neurally adjusted ventilatory
204093|NCT01928238|noninvasive pressure support ventilation
204094|NCT01928225|HSIL
204095|NCT01928225|CIN
204096|NCT01928225|HPV
204097|NCT01928225|HPV vaccination
204098|NCT01928225|gardasil
204099|NCT01928225|HIV
204100|NCT01928225|cervical dysplasia
204101|NCT01928225|LEEP
204102|NCT01928225|cervical cancer
204103|NCT01928212|retinal nerve fiber layer thickness
204104|NCT01928212|optical coherence tomography
204105|NCT01928212|Parkinson disease
204106|NCT01928199|diabetes
204107|NCT01928199|transplant
204108|NCT01928199|kidney
204109|NCT01928173|Sleep Initiation and Maintenance Disorders
204110|NCT01928173|Cognitive Therapy
204111|NCT01928160|Non-small cell lung cancer, EGFR mutation, erlotinib acquired resistance
204112|NCT01928147|NS5B polymerase inhibitor
204113|NCT01928147|Phase 1
204114|NCT01928147|Genotype 1
204115|NCT01928134|Vitamin K2
204116|NCT01928134|Vitamin D3
204117|NCT01928134|Bioavailability of calcium
204118|NCT01928134|volunteers
204119|NCT01928134|Men
204120|NCT01928134|non-pregnant women
204121|NCT01928134|twenty years of age
204122|NCT01928121|nurse
204123|NCT01928121|expert program
204124|NCT01928121|primary care
204125|NCT01928121|implementation
204126|NCT01928121|interdisciplinary
204127|NCT01928121|effectiveness
204128|NCT01928121|disease management system
204129|NCT01928095|atherosclerosis
204130|NCT01928095|carotid endartherectomy
204131|NCT01928082|Hypercalciuria, Familial Idiopathic
204132|NCT01928082|Hypercalciuria
204133|NCT01928082|Osteopenia
204134|NCT01928082|Osteoporosis
204135|NCT01928082|Postmenopausal women
204136|NCT01928004|edentulous
204137|NCT01928004|complete denture
204138|NCT01927991|tinnitus
204139|NCT01927991|cognitive behavioural therapy
204140|NCT01927991|internet treatment
204141|NCT01927978|Esophageal cancer
204142|NCT01927978|18F-FDG PET
204143|NCT01927978|staging
204144|NCT01927978|therapy planning
204145|NCT01927978|therapy response monitoring
204146|NCT01927978|prognosis
204147|NCT01927965|gastrointestinal tract
204148|NCT01927965|GI tract
204149|NCT01927965|advanced gastrointestinal tumors
204150|NCT01927965|gastrointestinal tumors
204151|NCT01927965|GI tumors
204152|NCT01927965|biliary
204153|NCT01927965|gallbladder,
204154|NCT01927965|colorectal,
204155|NCT01927965|gastric,
204156|NCT01927965|hepatocellular
204157|NCT01927965|esophageal
204158|NCT01927965|pancreatic
204159|NCT01927952|hammertoe
204160|NCT01927939|Breast cancer; bone metastases; 18F-FDG PET; 99mTc bone scintigraphy; therapy response monitoring; prognosis
204161|NCT01927926|Energy intake
204162|NCT01927926|appetite
204163|NCT01927926|satiety
204164|NCT01927926|gut hormones
204165|NCT01927900|Human milk oligosaccharides
204166|NCT01927900|Microbiota
204167|NCT01927900|Prebiotics
204168|NCT01927887|Papillary Carcinoma of Thyroid Metastatic to Regional Lymph Node
204169|NCT01927887|Follicular thyroid cancer lymph node metastasis
204170|NCT01927887|Metastatic medullary thyroid cancer
204171|NCT01927874|infiltration
204172|NCT01927874|hemorrhoidectomy
204173|NCT01927874|Postoperative pain
204174|NCT01927822|termination of pregnancy, abortion
204175|NCT01927809|Hereditary Diseases
204176|NCT01927809|Colon
204177|NCT01927783|Cardiovascular Disease
204178|NCT01927783|Obesity
204179|NCT01927770|Whole Genome Sequencing
204180|NCT01927770|Informed Choice
204181|NCT01927757|rheumatoid arthritis
204182|NCT01927757|etanercept
204183|NCT01927757|arthritis
204184|NCT01927757|adalimumab failure to respond
204185|NCT01927757|loss of response to adalimumab
204186|NCT01927757|ACR20
204187|NCT01927757|methotrexate
204188|NCT01927757|Swollen joints
204189|NCT01927757|tender joints
204190|NCT01927744|Head and Neck Cancer
204191|NCT01927744|Squamous cell carcinoma of the head and neck
204192|NCT01927744|SCCHN
204193|NCT01927744|Oral cavity squamous cell carcinomas
204194|NCT01927744|Docetaxel
204195|NCT01927744|Taxotere
204196|NCT01927744|Erlotinib
204197|NCT01927744|Erlotinib Hydrochloride
204198|NCT01927744|OSI-774
204199|NCT01927744|CP358774
204200|NCT01927744|Tarceva
204201|NCT01927744|Questionnaire
204202|NCT01927744|Survey
204203|NCT01927744|Phone call
204204|NCT01927731|Blood And Marrow Transplantation
204205|NCT01927731|Cord blood transplantation
204206|NCT01927731|CBT
204207|NCT01927731|Platelet count
204208|NCT01927731|Haploidentical donor stem cell transplant
204209|NCT01927731|Eltrombopag
204210|NCT01927731|Promacta
204211|NCT01927718|Blood And Marrow Transplantation
204212|NCT01927718|Myeloma
204213|NCT01927718|Multiple myeloma
204214|NCT01927718|MM
204215|NCT01927718|Autologous stem cell transplantation
204216|NCT01927718|ASCT
204217|NCT01927718|Thalidomide
204218|NCT01927718|Thalomid
204219|NCT01927718|Lenalidomide
204220|NCT01927718|CC-5013
204221|NCT01927718|Revlimid
204222|NCT01927718|Questionnaires
204223|NCT01927718|Surveys
204224|NCT01927705|Atopic dermatitis
204225|NCT01927705|Stem cell
204226|NCT01927705|Cell therapy
204227|NCT01927705|skin disease
204228|NCT01927705|furestem
204229|NCT01927705|AD
204230|NCT01927705|hUCB-MSC
204231|NCT01927705|UCB-MSC
204232|NCT01927705|Umbilical cord Blood
204233|NCT01927692|MG
204234|NCT01927666|glucoraphanin
204235|NCT01927666|broccoli
204236|NCT01927666|gut microbiota
204237|NCT01927653|Amnestic mild cognitive impairment
204238|NCT01927653|Dysexecutive mild cognitive impairment
204239|NCT01927653|Diffusion MRI
204240|NCT01927640|Cocaine
204241|NCT01927640|Dexmedetomidine
204242|NCT01927640|Myocardial Contrast Echocardiography
204243|NCT01927627|Prostate cancer
204244|NCT01927627|adenocarcinoma of the prostate
204245|NCT01927627|Enzalutamide
204246|NCT01927614|Cardiac Allograft Vasculopathy
204247|NCT01927614|Cardiac MRI
204248|NCT01927614|Cardiac CT
204249|NCT01927614|Observational study
204250|NCT01927601|TAVR
204251|NCT01927601|aortic disease
204252|NCT01927588|Certican
204253|NCT01927588|Renal Transplant
204254|NCT01927588|Cytomegalovirus Infection
204255|NCT01927575|TOMOSYNTHESIS
204256|NCT01927549|cardiogenic shock
204257|NCT01927549|infarction
204258|NCT01927549|multivessel coronary artery disease
204259|NCT01927549|angioplasty
204260|NCT01927523|Youth violence
204261|NCT01927523|Crime
204262|NCT01927523|Educational achievement
204263|NCT01927510|Early mobilization, rehabilitation, intensive care
204264|NCT01927497|Rectal cancer
204265|NCT01927497|Extralevator abdominoperineal resection
204266|NCT01927497|Biological Mesh
204267|NCT01927497|Primary closure
204268|NCT01927484|methotrexate,
204269|NCT01927484|osteoarthritis,
204270|NCT01927484|pain,
204271|NCT01927484|function,
204272|NCT01927484|synovitis
204273|NCT01927471|Menstrual cycles
204274|NCT01927471|Ultrasound
204275|NCT01927471|Ovary
204276|NCT01927471|Polycystic Ovary Syndrome (PCOS)
204277|NCT01927471|Physical activity
204278|NCT01927471|Diet
204279|NCT01927432|Polycystic Ovary Syndrome (PCOS)
204280|NCT01927432|Nutrition
204281|NCT01927432|Metabolism
204282|NCT01927432|Antral follicle growth
204283|NCT01927432|Menstrual Cyclicity
204284|NCT01927406|Thyroid Eye Disease
204285|NCT01927406|Graves' Disease
204286|NCT01927406|Prostaglandin Analogues
204287|NCT01927380|autonomic nervous system modulation
204288|NCT01927380|heart rate variability
204289|NCT01927380|prostatectomy
204290|NCT01927380|steep trendelenburg
204291|NCT01927380|pneumoperitoneum
204292|NCT01927367|Clinical Decision Support System
204293|NCT01927367|Primary Health Care
204294|NCT01927367|Clinical Practice Guidelines
204295|NCT01927354|Head-and-Neck squamous cell carcinoma (HNSCC)
204296|NCT01927354|epithelial-mesenchymal transition (EMT)
204297|NCT01927354|microRNA29
204298|NCT01927354|Twist1
204299|NCT01927341|MEK162,
204300|NCT01927341|panitumumab,
204301|NCT01927341|mutant RAS,
204302|NCT01927341|wild-type RAS,
204303|NCT01927341|metastatic colorectal cancer,
204304|NCT01927341|adult mCRC patient
204305|NCT01927328|Adenocarcinoma
204306|NCT01927328|Anemia
204307|NCT01927328|Palliative therapy
204308|NCT01927328|Palliative care
204309|NCT01927328|Palliative treatments
204310|NCT01927328|Chemotherapy
204311|NCT01927328|Esophageal Cancer
204312|NCT01927328|Gastric Cancer
204313|NCT01927315|Stem cells
204314|NCT01927315|Regeneration
204315|NCT01927315|Angiogenesis
204316|NCT01927315|Prevention
204317|NCT01927302|Aphasia
204318|NCT01927302|Dysgraphia
204319|NCT01927302|Anomia
204320|NCT01927302|Agrammatism
204321|NCT01927302|Stroke
204322|NCT01927302|Language Recovery
204323|NCT01927302|Treatment
204324|NCT01927302|Biomarkers of Recovery
204325|NCT01927289|Ultrasound
204326|NCT01927289|supraclavicular block
204327|NCT01927289|distal forearm block
204328|NCT01927289|Grip Strength
204329|NCT01927289|Satisfaction
204330|NCT01927276|Schizophrenia
204331|NCT01927276|Gluten
204332|NCT01927250|cohort study
204333|NCT01927250|diet program
204334|NCT01927250|art therapy
204335|NCT01927250|laying-on-of-hands
204336|NCT01927250|quality of life
204337|NCT01927237|pulmonary artery pressure
204338|NCT01927237|ARDS
204339|NCT01927237|alveolar hypoventilation
204340|NCT01927237|hypercapnic acidosis
204341|NCT01927237|permissive hypercapnia
204342|NCT01927237|myocardial strain
204343|NCT01927211|cesarean section incisions
204344|NCT01927211|silver
204345|NCT01927211|C-section
204346|NCT01927211|wound infection
204347|NCT01927211|scar appearance
204348|NCT01927211|pain
204349|NCT01927185|central venous access
204350|NCT01927185|ultrasonography
204351|NCT01927185|subclavian vein
204352|NCT01927185|pneumothorax
204353|NCT01927185|vessel view
204354|NCT01927159|Tuberculosis
204355|NCT01927159|TB
204356|NCT01927159|Pulmonary
204357|NCT01927159|Vaccine
204358|NCT01927159|Adjuvant
204359|NCT01927146|Lauren classification
204360|NCT01927146|HER2 status
204361|NCT01927146|Resectable gastric cancer
204362|NCT01927133|Fibrosis, HBV, HCV, ALD, NAFLD
204363|NCT01927120|GVHD
204364|NCT01927120|Allogeneic
204365|NCT01927120|Hematopoietic Cell Transplant
204366|NCT01927107|probiotics
204367|NCT01927107|obesity
204368|NCT01927107|oxidative stress
204369|NCT01927094|probiotics, diarrhea
204370|NCT01927055|NOH
204371|NCT01927055|OH
204372|NCT01927055|PD
204373|NCT01927055|MSA
204374|NCT01927055|PAF
204375|NCT01927055|DBH
204376|NCT01927042|Eating Disorders
204377|NCT01927042|Carers
204378|NCT01927029|twin pregnancy
204379|NCT01927029|progesterone
204380|NCT01927029|preterm delivery
204381|NCT01927029|>14 years
204382|NCT01927029|Abscense of cerclage,
204383|NCT01927029|TTTS, hemorrage,
204384|NCT01927029|history of thrombosis.
204385|NCT01927029|cervix >15mm
204386|NCT01927016|Esophageal Neoplasm
204387|NCT01927016|Esophagus
204388|NCT01927016|Surgery
204389|NCT01927016|Outcome assessment
204390|NCT01927003|defect,
204391|NCT01927003|dorsal branch of the digital artery,
204392|NCT01927003|dorsal digital flap,
204393|NCT01927003|dorsal metacarpal artery flap.
204394|NCT01926964|Adjuvant treatment recommendation
204395|NCT01926964|Early breast cancer
204396|NCT01926964|Oncotype DX
204397|NCT01926964|Genetic profiling
204398|NCT01926951|hypertension
204399|NCT01926925|Type 2 diabetes, Endothelium, children/adolescents
204400|NCT01926912|Schizophrenia
204401|NCT01926912|Paliperidone Palmitate
204402|NCT01926912|Hospital setting
204403|NCT01926912|Schizophrenic Disorders
204404|NCT01926860|Prevenar13
204405|NCT01926860|pneumococcal conjugate vaccine
204406|NCT01926860|Epaxal
204407|NCT01926860|hepatitis A vaccine
204408|NCT01926847|Digital ischemia
204409|NCT01926847|Raynaud's phenomenon
204410|NCT01926834|promoting angiogenesis in multiple targets
204411|NCT01926834|herbal medicine
204412|NCT01926834|traditional chinese medicine
204413|NCT01926834|random clinical trial
204414|NCT01926795|toddler's fracture
204415|NCT01926795|tibial fracture
204416|NCT01926795|children
204417|NCT01926769|Colorectal cancer
204418|NCT01926769|Metformin
204419|NCT01926769|FOLFOX6
204420|NCT01926769|FOFIRI
204421|NCT01926769|5FU
204422|NCT01926769|irinotecan
204423|NCT01926769|oxaliplatin
204424|NCT01926756|bacteriuria
204425|NCT01926756|straight catheterization
204426|NCT01926756|urinary tract infections
204427|NCT01926756|iatrogenic
204428|NCT01926743|near infrared
204429|NCT01926743|fluorescence imaging
204430|NCT01926743|indocyanine green
204431|NCT01926743|gastrectomy
204432|NCT01926717|Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy
204433|NCT01926691|dementia
204434|NCT01926691|poststroke cognitive impairment
204435|NCT01926691|inflammation
204436|NCT01926691|stress
204437|NCT01926678|swedish massage
204438|NCT01926678|fatigue
204439|NCT01926678|light touch
204440|NCT01926678|inflammation
204441|NCT01926665|Blood And Marrow Transplantation
204442|NCT01926665|Mantle cell lymphoma
204443|NCT01926665|MCL
204444|NCT01926665|T-cell lymphoma
204445|NCT01926665|TCL
204446|NCT01926665|Diffuse large b-cell lymphoma
204447|NCT01926665|DLBCL
204448|NCT01926665|Autologous stem cell transplantation
204449|NCT01926665|ASCT
204450|NCT01926665|Carfilzomib
204451|NCT01926665|CFZ
204452|NCT01926665|Dexamethasone
204453|NCT01926665|Decadron
204454|NCT01926639|Follicular lymphoma
204455|NCT01926639|Rituximab
204456|NCT01926639|Autologous dendritic cells
204457|NCT01926639|Cancer vaccine
204458|NCT01926626|Nicotine addiction
204459|NCT01926626|Smoking Cessation
204460|NCT01926626|Quit Smoking
204461|NCT01926626|moclobemide
204462|NCT01926626|Nicotine Patch
204463|NCT01926613|Schizophrenia
204464|NCT01926613|Chronic Mental Disorder
204465|NCT01926613|Employment
204466|NCT01926613|Cognitive remediation
204467|NCT01926613|Vocational rehabilitation
204468|NCT01926600|gastric ulcer
204469|NCT01926600|duodenal ulcer
204470|NCT01926600|re-bleeding rate
204471|NCT01926600|intragastric pH
204472|NCT01926600|proton pump inhibitor
204473|NCT01926587|rigosertib
204474|NCT01926587|ON 01910.Na
204475|NCT01926587|azacitidine
204476|NCT01926587|Vidaza
204477|NCT01926574|absenteeism
204478|NCT01926574|rehabilitation
204479|NCT01926574|return to work
204480|NCT01926561|Hypotensive bradycardic event
204481|NCT01926561|Interscalene brachial plexus block
204482|NCT01926561|Sitting position
204483|NCT01926561|Shoulder arthroscopic surgery
204484|NCT01926548|Pharmacokinetics
204485|NCT01926548|Safety
204486|NCT01926535|amniotic membrane
204487|NCT01926535|contact lens
204488|NCT01926535|bullous keratopathy
204489|NCT01926522|Exercise Therapy
204490|NCT01926483|Stage IIIA-N2 NSCLC
204491|NCT01926470|epidural injections, intravascular injection
204492|NCT01926457|First trimester treatment of prediabetes
204493|NCT01926457|First trimester treatment of gestational diabetes
204494|NCT01926457|Umbilical cord C-Peptide
204495|NCT01926457|Neonatal fat mass
204496|NCT01926457|Gestational weight gain
204497|NCT01926457|Infant obesity
204498|NCT01926444|colonoscopy
204499|NCT01926444|sedation-free
204500|NCT01926444|colorectal cancer
204501|NCT01926444|CRC screening
204502|NCT01926444|prevention
204503|NCT01926444|analgesia
204504|NCT01926444|colonic
204505|NCT01926444|kappa
204506|NCT01926444|opioid agonist
204507|NCT01926444|pain management
204508|NCT01926444|oral
204509|NCT01926444|hydrogen sulfide
204510|NCT01926444|peripheral
204511|NCT01926418|HIV
204512|NCT01926418|Condoms
204513|NCT01926418|Men who have sex with men
204514|NCT01926418|implementation intentions
204515|NCT01926418|executive function
204516|NCT01926405|hypersomnia
204517|NCT01926405|narcolepsy
204518|NCT01926405|amylase
204519|NCT01926405|salivary sampling
204520|NCT01926379|Ethiopia
204521|NCT01926379|TB
204522|NCT01926379|tuberculosis
204523|NCT01926379|HIV
204524|NCT01926379|IPT
204525|NCT01926379|isoniazid
204526|NCT01926379|adherence
204527|NCT01926379|combination intervention package
204528|NCT01926379|retention
204529|NCT01926353|Vesicoureteral Reflux (VUR)
204530|NCT01926353|Complicated Urinary Tract Infection
204531|NCT01926353|Vantris
204532|NCT01926353|Polyacrylate Polyalcohol Copolymer
204533|NCT01926327|PRP PRGF Osteoarthritis
204534|NCT01926301|sepsis
204535|NCT01926301|cerebrovascular autoregulation
204536|NCT01926301|delirium
204537|NCT01926275|COPD
204538|NCT01926275|Noninvasive Positive Pressure Ventilation
204539|NCT01926275|Respiratory Muscle Training
204540|NCT01926262|Pain, Neck, Exercise, Pilots, Crewmembers,
204541|NCT01926249|Alzheimer's disease
204542|NCT01926249|Mild Cognitive Impairment
204543|NCT01926210|Poor ovarian response
204544|NCT01926210|in vitro fertilization
204545|NCT01926210|mild ovarian stimulation
204546|NCT01926210|controlled ovarian stimulation
204547|NCT01926184|HIV/AIDS
204548|NCT01926184|Treatment as Prevention
204549|NCT01926184|Methamphetamine
204550|NCT01926184|Cocaine
204551|NCT01926184|HIV viral Load
204552|NCT01926158|Denosumab
204553|NCT01926158|Osteoporosis
204554|NCT01926158|Hip replacement
204555|NCT01926158|Osteoarthritis
204556|NCT01926158|Radiostereometric analysis (RSA)
204557|NCT01926158|Dual energy X-ray absorptiometry (DXA)
204558|NCT01926132|ascorbic acid
204559|NCT01926132|fatigue
204560|NCT01926132|mitochondrial DNA
204561|NCT01926132|patient for more than 6 months
204562|NCT01926106|Nasal Intermittent Positive-Pressure Ventilation
204563|NCT01926106|Nasal Continuous Positive Airway Pressure
204564|NCT01926106|twin
204565|NCT01926106|respiratory distress syndrome
204566|NCT01926093|Acute Respiratory Distress Syndrome (ARDS)
204567|NCT01926080|Depression
204568|NCT01926080|Spirituality
204569|NCT01926080|Neonatal death
204570|NCT01926080|Bereavement
204571|NCT01926080|Randomized controlled trial
204572|NCT01926067|Accelerometer
204573|NCT01926067|Cardiopulmonary by pass
204574|NCT01926041|community
204575|NCT01926041|preventive medicine
204576|NCT01926041|prediabetes
204577|NCT01926041|smoking cessation
204578|NCT01926028|recurrent vulvovaginal candidiasis
204579|NCT01926028|candida
204580|NCT01926028|NDV3
204581|NCT01926028|vaginal thrush
204582|NCT01926028|chronic yeast infection
204583|NCT01925976|obesity
204584|NCT01925976|dietetic intervention
204585|NCT01925976|eating behaviors
204586|NCT01925976|children
204587|NCT01925976|healthy eating
204588|NCT01925976|energy dense foods
204589|NCT01925963|Normal
204590|NCT01925963|Traumatic brain injury
204591|NCT01925963|Neuroimaging
204592|NCT01925963|Hyperbaric oxygen
204593|NCT01925963|Neurobehavioral symptom inventory
204594|NCT01925950|BDP
204595|NCT01925950|orBec
204596|NCT01925950|GVHD
204597|NCT01925950|beclomethasone dipropionate
204598|NCT01925950|bone marrow transplant
204599|NCT01925950|hematopoietic cell transplant
204600|NCT01925950|HCT
204601|NCT01925950|stem cell transplant
204602|NCT01925950|marrow transplant
204603|NCT01925950|SCT
204604|NCT01925950|beclomethasone 17,21-dipropionate
204605|NCT01925937|Coenzyme Q10
204606|NCT01925937|Atorvastatin
204607|NCT01925937|clinical trial
204608|NCT01925937|congestive heart failure
204609|NCT01925924|Dental cements
204610|NCT01925924|Orthodontic adhesives
204611|NCT01925924|Glass ionomer cement
204612|NCT01925924|Tooth demineralization
204613|NCT01925911|Phase 1
204614|NCT01925911|Healthy subjects
204615|NCT01925911|DDI
204616|NCT01925911|CYP3A
204617|NCT01925898|Laceration
204618|NCT01925898|Sedation
204619|NCT01925898|Pediatrics
204620|NCT01925885|Atrial Arrhythmia
204621|NCT01925872|ischemic cerebrovascular disease
204622|NCT01925872|Percutaneous transluminal angioplasty and stenting
204623|NCT01925872|Clopidogrel resistance
204624|NCT01925859|Pharmacokinetic analysis
204625|NCT01925859|EryDex
204626|NCT01925846|Pseudomonas aeruginosa
204627|NCT01925846|type three secretory system
204628|NCT01925846|contact lens associated microbial keratitis
204629|NCT01925820|Hepatitis B,Entecavir,Pegylated IFN
204630|NCT01925807|Adolescent
204631|NCT01925807|Suicidal Ideation
204632|NCT01925807|Emergency Department
204633|NCT01925807|Crisis
204634|NCT01925807|Attachment
204635|NCT01925807|Coping
204636|NCT01925794|Stent, Coronary Arteries for Early healing
204637|NCT01925781|Smoking Cessation
204638|NCT01925781|Nicotine Addiction
204639|NCT01925781|e-Cigarette
204640|NCT01925781|electronic nicotine delivery device
204641|NCT01925781|electronic cigarette
204642|NCT01925781|nicotine replacement therapy
204643|NCT01925768|Apremilast, Psoriatic Arthritis, PDE4 inhibitor
204644|NCT01925755|Non-interventional
204645|NCT01925755|Rivaroxaban
204646|NCT01925755|Prevention in prior stroke or TIA
204647|NCT01925755|Russian Federation
204648|NCT01925742|Fetal aneuploidy
204649|NCT01925729|middle ear
204650|NCT01925729|allergy
204651|NCT01925729|nose
204652|NCT01925716|cholesterol,LDL
204653|NCT01925716|vegetable oils
204654|NCT01925716|heart diseases
204655|NCT01925690|Multiple Sclerosis
204656|NCT01925690|Disease modifying medication
204657|NCT01925690|Relapsing-Remitting MS
204658|NCT01925690|Motivational Interviewing
204659|NCT01925690|Telephone Counseling
204660|NCT01925677|Transplant
204661|NCT01925677|donor
204662|NCT01925677|nephrectomy
204663|NCT01925677|robotic
204664|NCT01925677|laparoscopy
204665|NCT01925677|single-port
204666|NCT01925664|Doulas
204667|NCT01925664|Parenting
204668|NCT01925664|Breastfeeding
204669|NCT01925664|Pregnancy in Adolescence
204670|NCT01925651|Post Mastectomy Radiotherapy
204671|NCT01925651|Breast Cancer
204672|NCT01925651|Bolus
204673|NCT01925651|Radiodermatitis
204674|NCT01925638|Healthy Volunteers
204675|NCT01925638|Refametinib
204676|NCT01925638|Ketoconazole
204677|NCT01925638|Pharmacokinetics
204678|NCT01925612|Antibodies, Monoclonal
204679|NCT01925612|Antibody-Drug Conjugate
204680|NCT01925612|Antigens, CD30
204681|NCT01925612|Drug Therapy
204682|NCT01925612|Hematologic Diseases
204683|NCT01925612|Lymphoma, B-cell
204684|NCT01925612|Lymphoma, Large B-cell, Diffuse
204685|NCT01925612|Monomethyl auristatin E
204686|NCT01925599|Nevus
204687|NCT01925599|Choroidal Melanoma
204688|NCT01925599|BAP1 mutation
204689|NCT01925573|RECURRENT GLIOBLASTOMA
204690|NCT01925573|Brain Tumor
204691|NCT01925534|Optiflow
204692|NCT01925534|Humidified high-flow oxygen therapy
204693|NCT01925534|Noninvasive ventilation
204694|NCT01925534|Acute respiratory failure
204695|NCT01925534|Standard oxygen therapy
204696|NCT01925521|Intestinal Infection
204697|NCT01925495|otitis media
204698|NCT01925495|middle ear
204699|NCT01925495|feedback pathways
204700|NCT01925495|middle-ear pressure
204701|NCT01925482|middle ear
204702|NCT01925482|otitis
204703|NCT01925482|gas exchange
204704|NCT01925469|Hysterosalpingogram
204705|NCT01925469|HSG
204706|NCT01925469|Pain relief
204707|NCT01925469|Analgesia
204708|NCT01925469|Benzocaine
204709|NCT01925456|urge urinary incontinence
204710|NCT01925443|diabetes mellitus non-insulin-dependent
204711|NCT01925443|low level laser therapy
204712|NCT01925430|Observational
204713|NCT01925430|Sleep
204714|NCT01925430|Algorithm
204715|NCT01925417|Clostridium difficile
204716|NCT01925417|C diff
204717|NCT01925417|Microbiota Restoration Therapy
204718|NCT01925417|MRT
204719|NCT01925417|microbiota suspension
204720|NCT01925417|CDI
204721|NCT01925417|CDAD
204722|NCT01925417|Fecal transplant
204723|NCT01925417|Fecal Microbiota Transplant
204724|NCT01925417|FMT
204725|NCT01925417|Diarrhea
204726|NCT01925417|Fecal bacteriotherapy
204727|NCT01925404|Physical activity
204728|NCT01925404|parks
204729|NCT01925404|programming
204730|NCT01925404|public health
204731|NCT01925391|Pediatric glaucoma
204732|NCT01925391|Intraocular pressure
204733|NCT01925391|pediatric glaucoma diagnosis
204734|NCT01925391|Volatiles and intraocular pressure
204735|NCT01925391|nitrous oxide
204736|NCT01925391|Tetracaine
204737|NCT01925378|Cervical Dysplasia
204738|NCT01925352|ischemic heart disease
204739|NCT01925352|adenovirus
204740|NCT01925352|hepatocyte growth factor
204741|NCT01925313|Safety
204742|NCT01925313|Pharmacokinetics
204743|NCT01925300|Pharmacokinetics
204744|NCT01925300|Pharmacodynamics
204745|NCT01925300|Safety
204746|NCT01925300|Tolerability
204747|NCT01925287|bioavailability
204748|NCT01925287|curcumin
204749|NCT01925287|curcuma longa
204750|NCT01925287|healthy humans
204751|NCT01925287|safety
204752|NCT01925287|sex differences
204753|NCT01925274|metastatic colorectal cancer
204754|NCT01925274|colorectal cancer
204755|NCT01925274|KRAS
204756|NCT01925274|colon cancer
204757|NCT01925274|mCRC
204758|NCT01925274|CRC
204759|NCT01925274|PF-05212384
204760|NCT01925274|KRAS wild type colorectal cancer
204761|NCT01925274|irinotecan
204762|NCT01925274|cetuximab
204763|NCT01925274|NRAS
204764|NCT01925261|knee osteoarthritis
204765|NCT01925261|bilateral
204766|NCT01925261|osteoarthritis
204767|NCT01925248|Whey protein
204768|NCT01925248|protein supplement
204769|NCT01925248|Diabetes
204770|NCT01925248|Type 2 DM
204771|NCT01925248|Hyperglycemia
204772|NCT01925248|Insulin secretagogue
204773|NCT01925235|remote ischemic preconditioning
204774|NCT01925235|acute kidney injury
204775|NCT01925235|TAVI
204776|NCT01925235|RenPRO trial
204777|NCT01925235|parameters
204778|NCT01925209|sporadic inclusion body myositis,
204779|NCT01925209|myositis,
204780|NCT01925209|muscle wasting,
204781|NCT01925209|controlled clinical trial,
204782|NCT01925209|randomized,
204783|NCT01925209|body mass,
204784|NCT01925209|muscle function,
204785|NCT01925209|strength,
204786|NCT01925209|performance,
204787|NCT01925209|physical function
204788|NCT01925196|Motor Neuron Disease
204789|NCT01925196|Frontotemporal Dementia
204790|NCT01925196|Cognitive Testing
204791|NCT01925196|Magnetic Resonance Imaging (MRI)
204792|NCT01925196|Transcranial Magnetic Stimulation (TMS)
204793|NCT01925183|Boceprevir
204794|NCT01925183|HIV/HCV-coinfection
204795|NCT01925183|HIV/HCV coinfection
204796|NCT01925183|HIV/HCV
204797|NCT01925183|Response-guided therapy
204798|NCT01925170|Dense breast tissue
204799|NCT01925170|Breast Cancer Screening
204800|NCT01925170|Molecular Breast Imaging
204801|NCT01925170|Breast Cancer
204802|NCT01925170|Breast
204803|NCT01925105|Polypharmacy
204804|NCT01925092|Cushing's disease
204805|NCT01925092|Mifepristone
204806|NCT01925092|Cushing's syndrome
204807|NCT01925092|Pharmacokinetic-pharmacodynamic
204808|NCT01925092|Child/pediatric population
204809|NCT01925092|Safety-efficacy
204810|NCT01925079|acute coronary syndrome
204811|NCT01925079|statins
204812|NCT01925079|LDL-C
204813|NCT01925079|intensive education
204814|NCT01925027|Nano+ DES
204815|NCT01925027|OCT
204816|NCT01925027|Neointimal hyperplasia
204817|NCT01925027|DAPT
204818|NCT01925027|3 month
204819|NCT01925014|Appendectomy
204820|NCT01925014|Appendicitis
204821|NCT01925014|False Positive Reactions
204822|NCT01925014|Humans
204823|NCT01925014|Radiation Dosage
204824|NCT01925014|Tomography, X-Ray Computed
204825|NCT01925014|Young Adult
204826|NCT01925001|Sickle cell anemia
204827|NCT01925001|Sickle cell disease
204828|NCT01925001|Sickling crisis
204829|NCT01925001|Vaso-occlusive crisis
204830|NCT01925001|Carboxyhemoglobin
204831|NCT01925001|Oxygen therapeutic
204832|NCT01925001|Ischemic rescue therapy
204833|NCT01925001|Hemoglobin solution
204834|NCT01925001|Pegylated hemoglobin
204835|NCT01924988|BPH, benign prostatic hyperplasia
204836|NCT01924962|chronic occlusion of coronary artery
204837|NCT01924962|left ventricular function
204838|NCT01924962|revascularisation
204839|NCT01924949|7977
204840|NCT01924949|5885
204841|NCT01924949|GS-7977
204842|NCT01924949|GS-5885
204843|NCT01924949|SOF
204844|NCT01924949|LDV
204845|NCT01924949|Sofosbuvir
204846|NCT01924949|Ledipasvir
204847|NCT01924949|FDC
204848|NCT01924923|uveal melanoma
204849|NCT01924923|biopsy
204850|NCT01924923|enucleation
204851|NCT01924923|ocular cancer
204852|NCT01924910|Healthy, by self report
204853|NCT01924897|CPET test
204854|NCT01924897|Exercise training
204855|NCT01924897|Prehabilitation
204856|NCT01924897|Exercise Test
204857|NCT01924884|Vacuum-Assisted Closure
204858|NCT01924884|Topical Negative-Pressure Therapy
204859|NCT01924884|Negative-Pressure Dressings
204860|NCT01924858|PET, healthy subjects
204861|NCT01924858|Lp-PLA2
204862|NCT01924858|positron emission tomography
204863|NCT01924858|Alzheimer's disease
204864|NCT01924858|brain exposure
204865|NCT01924858|GSK2647544
204866|NCT01924819|Gastric cancer
204867|NCT01924819|Stomach cancer
204868|NCT01924819|Chemoradiotherapy
204869|NCT01924819|Surgery
204870|NCT01924819|Chemotherapy
204871|NCT01924819|Neoadjuvant
204872|NCT01924806|debridement
204873|NCT01924806|post-debridement
204874|NCT01924806|infection
204875|NCT01924806|prevention
204876|NCT01924806|wound
204877|NCT01924806|wound tissue
204878|NCT01924806|wound management
204879|NCT01924806|WoundWand
204880|NCT01924806|wound size reduction
204881|NCT01924806|wound bed debridement
204882|NCT01924806|WoundWand Debridement Device
204883|NCT01924806|chronic wound
204884|NCT01924806|delayed healing
204885|NCT01924806|cellular senescence
204886|NCT01924806|acute wound
204887|NCT01924806|diabetic foot ulcer
204888|NCT01924806|venous leg ulcers
204889|NCT01924806|radiofrequency debridement
204890|NCT01924806|necrotic tissue
204891|NCT01924806|wound healing
204892|NCT01924806|skin
204893|NCT01924780|Dose-Response Relationship, Immunologic
204894|NCT01924754|HPV
204895|NCT01924754|Gardasil
204896|NCT01924754|seroconversion
204897|NCT01924741|Liver neoplasms
204898|NCT01924741|Liver regeneration
204899|NCT01924715|somatoform disorder
204900|NCT01924715|psychotherapy
204901|NCT01924715|depression
204902|NCT01924715|anxiety
204903|NCT01924715|personality disorder
204904|NCT01924689|Phase 1
204905|NCT01924689|Metastatic Disease
204906|NCT01924689|Solid Tumor
204907|NCT01924689|Malignancy
204908|NCT01924689|Metastases
204909|NCT01924689|Clinical Trial
204910|NCT01924689|Hypoxia
204911|NCT01924689|Necrosis
204912|NCT01924689|Intratumoral
204913|NCT01924689|Locally advanced cancer
204914|NCT01924689|Immunotherapy
204915|NCT01924689|Sarcoma
204916|NCT01924689|Chordoma
204917|NCT01924689|Bacteriolytic
204918|NCT01924676|food effect
204919|NCT01924676|pharmacokinetics
204920|NCT01924676|bioavailability
204921|NCT01924676|oxycodone
204922|NCT01924676|management of moderate to severe pain
204923|NCT01924663|Heart Failure
204924|NCT01924663|Acute Kidney Injury
204925|NCT01924663|Myocardial Dysfunction
204926|NCT01924663|Pediatric Critical Care
204927|NCT01924663|Pediatric Intensive Care Units
204928|NCT01924663|Respiratory Virus
204929|NCT01924611|Dental caries
204930|NCT01924611|Atraumatic Restorative Technique
204931|NCT01924598|Anorexia Nervosa
204932|NCT01924598|Treatment Development
204933|NCT01924598|Capacity
204934|NCT01924598|Neuroimaging
204935|NCT01924598|Magnetoencephalography
204936|NCT01924598|functional MRI
204937|NCT01924598|Reward processing
204938|NCT01924598|Habit formation
204939|NCT01924585|Colorectal
204940|NCT01924585|Surgery
204941|NCT01924585|Frailty
204942|NCT01924585|Elderly
204943|NCT01924585|Quality of Life
204944|NCT01924572|umbilical cord clamping
204945|NCT01924572|Placental residual blood volume
204946|NCT01924572|hematocrit
204947|NCT01924572|hemoglobin
204948|NCT01924572|bilirubin
204949|NCT01924559|Airway
204950|NCT01924546|cognition
204951|NCT01924546|hydration
204952|NCT01924546|schoolchildren
204953|NCT01924520|Antipsychotic
204954|NCT01924520|FK949E
204955|NCT01924520|Quetiapine
204956|NCT01924507|Sleep medicine
204957|NCT01924507|Sleep apnea
204958|NCT01924507|Acute myocardial infarction
204959|NCT01924507|Heart failure
204960|NCT01924507|CPAP
204961|NCT01924494|telemedicine, tele-endoscopy
204962|NCT01924481|Caffeine
204963|NCT01924481|Flavonoids
204964|NCT01924481|MRI
204965|NCT01924481|Brain blood flow
204966|NCT01924481|Cognition
204967|NCT01924481|Perfusion
204968|NCT01924481|Resting functional magnetic resonance imaging (fMRI)
204969|NCT01924468|Cognitive Control
204970|NCT01924468|fMRI
204971|NCT01924468|Genetics
204972|NCT01924468|Dopamine
204973|NCT01924455|HIV
204974|NCT01924455|HBV
204975|NCT01924442|Coronary Artery Disease
204976|NCT01924442|Off-Pump
204977|NCT01924442|Myocardial Ischemia
204978|NCT01924442|Heart Disease
204979|NCT01924429|Attention Deficit Hyperactivity Disorder
204980|NCT01924429|ADHD
204981|NCT01924429|fMRI
204982|NCT01924429|Imaging
204983|NCT01924429|Vyvanse
204984|NCT01924429|Stimulant Medication
204985|NCT01924429|Treatment
204986|NCT01924429|Clinical Trial
204987|NCT01924429|Adult
204988|NCT01924403|TKA
204989|NCT01924403|Wound Closure
204990|NCT01924403|Wound Perfusion
204991|NCT01924390|Tooth extraction
204992|NCT01924377|AF
204993|NCT01924364|Craniomaxillofacial (CMF) Battle-injured (BI)
204994|NCT01924364|Facial Trauma
204995|NCT01924364|Fat Grafts
204996|NCT01924364|Autogenous Fat Transfers (AFT)
204997|NCT01924364|Wounded warriors
204998|NCT01924351|Breast Cancer with Brain Metastasis
204999|NCT01924351|HER2-positive
205000|NCT01924351|HER-2 therapy
205001|NCT01924338|Patient
205002|NCT01924338|localisation
205003|NCT01924338|in cranial
205004|NCT01924338|radiation
205005|NCT01924338|therapy
205006|NCT01924338|thickness of
205007|NCT01924325|apixaban
205008|NCT01924325|clopidogrel
205009|NCT01924325|aspirin
205010|NCT01924325|new oral anticoagulant
205011|NCT01924325|TIA
205012|NCT01924325|acute minor ischemic stroke
205013|NCT01924312|stroke, dementia, hypertension, diabetes, hyperlipidemia, smoking, obesity
205014|NCT01924286|HIV
205015|NCT01924286|Tuberculosis
205016|NCT01924286|Immune reconstitution inflammatory syndrome
205017|NCT01924286|Highly active antiretroviral therapy
205018|NCT01924286|Glucocorticoids
205019|NCT01924286|Prednisone
205020|NCT01924286|Preventive therapy
205021|NCT01924273|Port Wine Stain Birthmarks
205022|NCT01924234|Remifentanil
205023|NCT01924234|Pharyngeal dysfunction
205024|NCT01924234|Subjective swallowing difficulties
205025|NCT01924234|Pulmonary aspiration
205026|NCT01924208|Timothy
205027|NCT01924208|Influenza
205028|NCT01924208|Interferon
205029|NCT01924208|T cell
205030|NCT01924208|Tonsil
205031|NCT01924195|lung
205032|NCT01924195|Anlotinib
205033|NCT01924195|AL3818
205034|NCT01924195|NSCLC
205035|NCT01924195|Cancer
205036|NCT01924182|chronic pain
205037|NCT01924182|inadequate pain relief
205038|NCT01924182|intolerable side effects
205039|NCT01924169|Hematologic Disorder
205040|NCT01924169|Chronic Lymphocytic Leukemia
205041|NCT01924169|CLL
205042|NCT01924169|Hypogammaglobulinemia
205043|NCT01924169|Impaired Response to Vaccinations
205044|NCT01924169|Immunoglobulins
205045|NCT01924169|Immune system's function
205046|NCT01924169|Lenalidomide
205047|NCT01924169|CC-5013
205048|NCT01924169|Revlimid
205049|NCT01924169|Flu vaccine
205050|NCT01924169|TIV
205051|NCT01924169|Pneumonia vaccine
205052|NCT01924143|ADHD
205053|NCT01924143|Fibromyalgia
205054|NCT01924117|cervical intraepithelial neoplasia, HPV, Cancer
205055|NCT01924104|IVF failure, implantation rate, heparin & aspirin
205056|NCT01924078|breast cancer
205057|NCT01924078|metronomic chemotherapy
205058|NCT01924078|aromatase inhibitors
205059|NCT01924065|Atrial fibrillation, conversion, stroke
205060|NCT01924039|Psychosis
205061|NCT01924039|Substance Use
205062|NCT01924039|Motivational Enhancement Therapy
205063|NCT01924026|Phenylketonuria
205064|NCT01924026|Mild Hyperphenylalaninemia
205065|NCT01924026|PKU
205066|NCT01924026|MHP
205067|NCT01924013|Pregnancy
205068|NCT01924013|Infant Growth
205069|NCT01924013|Vitamin D
205070|NCT01924013|Bangladesh
205071|NCT01923987|Short course radiotherapy
205072|NCT01923987|Modified FOLFOX6
205073|NCT01923987|Delayed surgery
205074|NCT01923987|Rectal cancer
205075|NCT01923987|Synchronous metastasis
205076|NCT01923987|Liver metastasis
205077|NCT01923987|Lung metastasis
205078|NCT01923961|Maintenance hemodialysis or hemodiafiltration
205079|NCT01923961|>18 years
205080|NCT01923961|Stable condition
205081|NCT01923948|Hepatocellular carcinoma
205082|NCT01923948|Hepatectomy
205083|NCT01923948|randomized controlled trials(RCTs)
205084|NCT01923948|Postoperative Pain
205085|NCT01923935|Multiple myeloma, busulfan, melphalan,transplantation
205086|NCT01923922|glioblastoma multiforme
205087|NCT01923922|CT Perfusion
205088|NCT01923922|Survival
205089|NCT01923909|Knee
205090|NCT01923909|Osteoarthritis
205091|NCT01923909|Bahrain
205092|NCT01923909|PRP
205093|NCT01923909|Steroid
205094|NCT01923909|WOMAC
205095|NCT01923909|Oxford Knee Score
205096|NCT01923909|Platelet-rich plasma
205097|NCT01923896|food refusal
205098|NCT01923896|behavioral intervention
205099|NCT01923896|D-cycloserine
205100|NCT01923844|Newborn
205101|NCT01923844|perfusion index
205102|NCT01923844|pulsatility index
205103|NCT01923844|respiratory distress syndrome
205104|NCT01923844|surfactant
205105|NCT01923844|transcutaneous carbon monoxide
205106|NCT01923831|Magnesium, Post operative sore throat, Prone position, Tracheal intubation
205107|NCT01923818|rivaroxaban
205108|NCT01923818|aspirin
205109|NCT01923818|new oral anticoagulant
205110|NCT01923818|TIA
205111|NCT01923818|acute minor ischemic stroke
205112|NCT01923792|House Dust Mite Allergy
205113|NCT01923792|Rhinoconjunctivitis
205114|NCT01923792|Environmental Exposure Unit
205115|NCT01923792|Immunotherapy
205116|NCT01923792|ToleroMune HDM
205117|NCT01923779|Grass allergy
205118|NCT01923779|Rhinoconjunctivitis
205119|NCT01923779|Environmental Exposure Unit
205120|NCT01923779|Immunotherapy
205121|NCT01923779|ToleroMune Grass
205122|NCT01923766|Transplantation
205123|NCT01923753|Cystic Fibrosis
205124|NCT01923753|Neural respiratory drive
205125|NCT01923753|Airway clearance technique
205126|NCT01923753|Expectoration
205127|NCT01923753|Positive expiratory pressure device
205128|NCT01923740|Absorb™ BVS
205129|NCT01923740|Angioplasty
205130|NCT01923740|Bioabsorbable
205131|NCT01923740|BVS
205132|NCT01923740|Bioresorbable
205133|NCT01923740|Coronary Artery Disease
205134|NCT01923740|Coronary Artery Endothelial Responsiveness
205135|NCT01923740|Coronary artery restenosis
205136|NCT01923740|Coronary artery stenosis
205137|NCT01923740|Coronary scaffold
205138|NCT01923740|Coronary Stent
205139|NCT01923740|Drug eluting stents
205140|NCT01923740|Everolimus
205141|NCT01923740|Myocardial ischemia
205142|NCT01923740|Stent thrombosis
205143|NCT01923740|Stents
205144|NCT01923727|[89Zr]Df-IAB2M
205145|NCT01923727|Prostate
205146|NCT01923727|PET Scan
205147|NCT01923714|Glaucoma
205148|NCT01923701|At Risk Mental State
205149|NCT01923701|Attenuated Psychosis Syndrome
205150|NCT01923701|Prodrom
205151|NCT01923701|Paranoia
205152|NCT01923701|Psychosis
205153|NCT01923701|Cognitive Behavioral Therapy
205154|NCT01923701|Group
205155|NCT01923701|Family
205156|NCT01923701|ARMS
205157|NCT01923688|Prediction Prevention Severe Hypoglycemia RealTime Alert
205158|NCT01923675|myopia
205159|NCT01923675|nearsightedness
205160|NCT01923675|axial elongation of the eye
205161|NCT01923675|refractive error
205162|NCT01923662|Paraplegia
205163|NCT01923662|Tetraplegia
205164|NCT01923662|Spinal Cord Injury
205165|NCT01923662|FES
205166|NCT01923649|postoperative dumping
205167|NCT01923649|somatostatin analogues
205168|NCT01923649|somatulin
205169|NCT01923649|lanreotide
205170|NCT01923649|dumping syndrome
205171|NCT01923636|Cytomegalovirus, congenital, handicap
205172|NCT01923610|Low risk HIV infection
205173|NCT01923610|HIV Seronegativity
205174|NCT01923610|HIV Preventive Vaccine
205175|NCT01923597|Proteinuria
205176|NCT01923597|Oxidative stress
205177|NCT01923597|Epigallocatechin gallate
205178|NCT01923545|PEG-G-CSF
205179|NCT01923493|neck pain
205180|NCT01923493|tuina
205181|NCT01923467|smoking
205182|NCT01923467|nicotine replacement
205183|NCT01923467|internet
205184|NCT01923454|paracentesis
205185|NCT01923454|primary acute angle closure
205186|NCT01923454|iridotomy
205187|NCT01923454|filtration
205188|NCT01923454|glaucoma
205189|NCT01923415|Lupus Erythematosus, Subacute, Cutaneous
205190|NCT01923415|Lupus Erythematosus, Systemic
205191|NCT01923415|Lupus Erythematosus, Discoid
205192|NCT01923415|Active Cutaneous Lupus Erythematosus
205193|NCT01923415|Systemic Cutaneous Lupus Erythematosus
205194|NCT01923415|Skin Biopsy
205195|NCT01923415|Lesions
205196|NCT01923402|Biomarkers
205197|NCT01923402|Metabolic Profiling
205198|NCT01923402|Metabolomics
205199|NCT01923402|Tobacco
205200|NCT01923402|Smokeless Tobacco
205201|NCT01923402|Moist Snuff
205202|NCT01923389|T2DM
205203|NCT01923389|obesity
205204|NCT01923389|safety
205205|NCT01923389|multiple dose
205206|NCT01923389|intravenous
205207|NCT01923376|hepatic encephalopathy
205208|NCT01923376|hepatic coma
205209|NCT01923376|HE
205210|NCT01923376|PSE
205211|NCT01923376|lactulose
205212|NCT01923376|golytely
205213|NCT01923376|cirrhosis
205214|NCT01923376|Hepatic Insufficiency
205215|NCT01923376|Liver Cirrhosis
205216|NCT01923376|Fibrosis
205217|NCT01923376|Brain Damage, Chronic
205218|NCT01923376|Delirium
205219|NCT01923376|Encephalitis
205220|NCT01923376|Neurotoxicity Syndromes
205221|NCT01923376|Liver Failure
205222|NCT01923376|Liver Diseases
205223|NCT01923376|Digestive System Diseases
205224|NCT01923376|Brain Diseases, Metabolic
205225|NCT01923376|Brain Diseases
205226|NCT01923376|Central Nervous System Diseases
205227|NCT01923376|Nervous System Diseases
205228|NCT01923376|Metabolic Diseases
205229|NCT01923376|Pathologic Processes
205230|NCT01923376|Confusion
205231|NCT01923376|Neurobehavioral Manifestations
205232|NCT01923376|Neurologic Manifestations
205233|NCT01923376|Signs and Symptoms
205234|NCT01923376|Delirium, Dementia, Amnestic, Cognitive Disorders
205235|NCT01923376|Mental Disorders
205236|NCT01923376|Central Nervous System Viral Diseases
205237|NCT01923376|Virus Diseases
205238|NCT01923376|Central Nervous System Infections
205239|NCT01923376|Poisoning
205240|NCT01923376|Substance-Related Disorders
205241|NCT01923376|Citric Acid
205242|NCT01923363|pharmacokinetics
205243|NCT01923363|obesity
205244|NCT01923363|piperacillin-tazobactam combination product
205245|NCT01923363|pharmacodynamics
205246|NCT01923363|piperacillin/tazobactam
205247|NCT01923350|Weight reduction
205248|NCT01923350|Behavioral intervention
205249|NCT01923350|Gestational diabetes mellitus
205250|NCT01923350|Type 2 diabetes
205251|NCT01923350|Diabetes testing
205252|NCT01923337|Colorectal cancer
205253|NCT01923311|Pediatrics
205254|NCT01923311|Adolescents
205255|NCT01923311|HIV
205256|NCT01923311|HIV-1
205257|NCT01923311|Treatment-experienced
205258|NCT01923246|Alcohol consumption
205259|NCT01923246|Brief intervention
205260|NCT01923246|Automated techniques
205261|NCT01923233|liver cancer
205262|NCT01923233|HCC
205263|NCT01923233|tumor vaccine
205264|NCT01923233|immunotherapy
205265|NCT01923220|Breast Cancer
205266|NCT01923220|Radiation Therapy
205267|NCT01923220|Radiation Dermatitis
205268|NCT01923168|Breast Cancer, Pathological Complete Response, neoadjuvant, hormone receptor-positive
205269|NCT01923142|Vitiligo
205270|NCT01923142|Outer-Root-Sheath
205271|NCT01923142|Melanocytes
205272|NCT01923142|Hair Follicles
205273|NCT01923129|indwelling catheter
205274|NCT01923129|foley
205275|NCT01923129|duration
205276|NCT01923116|Anal intraepithelial neoplasia
205277|NCT01923116|HIV
205278|NCT01923116|HPV
205279|NCT01923116|Vaccination
205280|NCT01923116|Treatment
205281|NCT01923077|acute myocardial infarction
205282|NCT01923077|Statin
205283|NCT01923077|speckle tracking echocardiography
205284|NCT01923077|Strain
205285|NCT01923077|MSCT
205286|NCT01923077|plaque
205287|NCT01923077|vulnerable plaque
205288|NCT01923051|chronic obstructive pulmonary disease
205289|NCT01923051|COPD
205290|NCT01923051|national database
205291|NCT01923051|observational
205292|NCT01923038|atelectasis
205293|NCT01923038|laparoscopic surgery
205294|NCT01923038|anesthesia
205295|NCT01923038|mechanical ventilation
205296|NCT01923038|Prevent
205297|NCT01923038|shape of the airway
205298|NCT01923038|pressure-time curve
205299|NCT01922986|stroke
205300|NCT01922986|rehabilitation
205301|NCT01922986|hemiplegia
205302|NCT01922986|repetitive transcranial magnetic stimulation
205303|NCT01922973|ghrelin
205304|NCT01922973|growth hormone
205305|NCT01922973|aging
205306|NCT01922973|normal volunteers
205307|NCT01922960|trauma
205308|NCT01922960|multiple organ dysfunction syndrome
205309|NCT01922908|Ischemic
205310|NCT01922908|Stroke
205311|NCT01922908|Stem Cells
205312|NCT01922908|MSC
205313|NCT01922908|Allogeneic
205314|NCT01922908|Bone Marrow
205315|NCT01922895|Alcoholic Hepatitis
205316|NCT01922895|MELD < 20
205317|NCT01922895|Probiotic
205318|NCT01922895|Nutritional Supplement
205319|NCT01922895|Lactobacillus Rhamnosus GG
205320|NCT01922882|HIV
205321|NCT01922882|Maternal disclosure
205322|NCT01922882|Health promotion
205323|NCT01922882|Maternal mental health
205324|NCT01922882|Child behavior
205325|NCT01922869|Absorption
205326|NCT01922869|Metabolism
205327|NCT01922869|Excretion
205328|NCT01922869|Flavonoids
205329|NCT01922869|Polyphenols
205330|NCT01922869|Genes
205331|NCT01922869|Gut-microflora
205332|NCT01922843|Hemodialysis
205333|NCT01922830|Sleeve Gastrectomy
205334|NCT01922830|NAFLD
205335|NCT01922830|gut microbiot
205336|NCT01922830|Bariatric surgery
205337|NCT01922791|Nutrition
205338|NCT01922791|Probiotics
205339|NCT01922791|Fish oil
205340|NCT01922765|Helicobacter
205341|NCT01922765|Eradication
205342|NCT01922752|CEP-37440
205343|NCT01922752|Advanced solid tumors
205344|NCT01922752|Metastatic solid tumors
205345|NCT01922739|low back pain
205346|NCT01922739|hydrocodone bitartrate
205347|NCT01922739|opioids
205348|NCT01922713|biofortification
205349|NCT01922713|vitamin A
205350|NCT01922713|maize
205351|NCT01922713|beta-carotene
205352|NCT01922713|breastmilk
205353|NCT01922713|Zambia
205354|NCT01922700|Pepper spray
205355|NCT01922700|bronchospasm
205356|NCT01922700|lacrimation
205357|NCT01922648|RSV
205358|NCT01922648|Immune response
205359|NCT01922648|Paediatric
205360|NCT01922635|Primary lymphedema quality of life, genetic research
205361|NCT01922622|minimum effective dose of local anaesthetic
205362|NCT01922622|spinal catheter
205363|NCT01922622|fractured neck of femur
205364|NCT01922622|a step up, step down methodology
205365|NCT01922609|Carotid stenting
205366|NCT01922609|Proximal protection system
205367|NCT01922609|Transcranial Doppler ultrasound
205368|NCT01922609|Cerebrovascular reserve
205369|NCT01922596|Total Knee Arthroplasty
205370|NCT01922596|Adductor Canal Blockade
205371|NCT01922596|Us-guided nerve blockade
205372|NCT01922583|NSCLC, EGFR mutation
205373|NCT01922570|Enteral nutrition
205374|NCT01922570|Supplemental parenteral nutrition
205375|NCT01922570|Critical illness
205376|NCT01922570|ICU patients
205377|NCT01922570|diarrhea
205378|NCT01922544|heart failure
205379|NCT01922544|cardiac resynchronization therapy
205380|NCT01922544|coronary sinus lead
205381|NCT01922531|mTBI
205382|NCT01922531|Mild Traumatic Brain Injury
205383|NCT01922531|Axonal Injury
205384|NCT01922518|atrioventricular block, cardiomyopathy
205385|NCT01922492|autologous islet transplantation
205386|NCT01922492|partial pancreatectomy
205387|NCT01922492|pancreatogenic diabetes
205388|NCT01922479|Heart Failure
205389|NCT01922479|Anemia
205390|NCT01922479|Iron Deficiency
205391|NCT01922479|Ferric Carboxymaltose
205392|NCT01922479|Asian
205393|NCT01922466|chronic neck pain
205394|NCT01922466|combined treatment between conventional and complementary alternative medical treatment
205395|NCT01922466|bee venom acupuncture
205396|NCT01922466|NSAIDs
205397|NCT01922453|breech presentation
205398|NCT01922453|vertex presentation
205399|NCT01922440|Registry
205400|NCT01922440|Chronic Hypoparathyroidism
205401|NCT01922440|Observational study
205402|NCT01922440|Natural History
205403|NCT01922440|Chronic HPTH
205404|NCT01922414|Staghorn stones
205405|NCT01922414|Percutaneous nephrolithotomy
205406|NCT01922414|Laser
205407|NCT01922414|Randomized trial
205408|NCT01922414|Lithotripsy
205409|NCT01922388|Parkinson disease
205410|NCT01922388|deep brain stimulation
205411|NCT01922388|subthalamic nucleus
205412|NCT01922388|motor complication
205413|NCT01922388|quality of life
205414|NCT01922362|STSG
205415|NCT01922362|wound healing
205416|NCT01922336|Pharmacokinetics
205417|NCT01922323|Living liver donor
205418|NCT01922297|Delinquency
205419|NCT01922297|HIV Associated Risk Behavior
205420|NCT01922297|Juveniles
205421|NCT01922297|Family based treatment
205422|NCT01922297|Multidimensional Family Therapy
205423|NCT01922284|HIV
205424|NCT01922284|Vaccine
205425|NCT01922284|Immunisation
205426|NCT01922284|DNA
205427|NCT01922284|Adverse events
205428|NCT01922284|MVA-C
205429|NCT01922284|GLA-AF
205430|NCT01922284|Antibody
205431|NCT01922271|COPD
205432|NCT01922258|OPC-34712
205433|NCT01922258|brexpiprazole
205434|NCT01922258|Dementia
205435|NCT01922258|Alzheimer's Disease
205436|NCT01922258|Cognitive Disorders
205437|NCT01922258|Memory
205438|NCT01922258|Agitation
205439|NCT01922245|aphasia
205440|NCT01922245|therapy
205441|NCT01922245|stroke
205442|NCT01922245|language
205443|NCT01922245|naming
205444|NCT01922245|quality of life
205445|NCT01922245|tDCS
205446|NCT01922245|treatment
205447|NCT01922219|depression
205448|NCT01922219|cognitive therapy
205449|NCT01922219|cognitive behavioral therapy
205450|NCT01922219|CBT
205451|NCT01922219|psychotherapy
205452|NCT01922219|MDD
205453|NCT01922219|major depressive disorder
205454|NCT01922219|MRI
205455|NCT01922219|fMRI
205456|NCT01922206|HIV
205457|NCT01922206|Maternal Disclosure
205458|NCT01922180|Chest Computed Tomography
205459|NCT01922167|Aging
205460|NCT01922167|Frailty
205461|NCT01922167|Leucine
205462|NCT01922167|Resistance Exercise
205463|NCT01922154|Angiogenesis inhibitors
205464|NCT01922154|Neovascular
205465|NCT01922154|Intraocular pressure
205466|NCT01922154|Retinal Vein Occlusion
205467|NCT01922154|Vascular Endothelial Growth Factor
205468|NCT01922141|High blood pressure, stage 1 and 2 hypertension
205469|NCT01922128|Non-exudative, dry AMD
205470|NCT01922115|COGNITIVE FUNCTION
205471|NCT01922115|OVERACTIVE BLADDER
205472|NCT01922115|[C23.888.942.343.780]
205473|NCT01922102|Pathologic myopia (PM), choroidal neovascularization (CNV), ranibizumab, verteporfin PDT, Brilliance
205474|NCT01922089|Heart failure, reduced ejection fraction, LCZ696, titration, safety, tolerability
205475|NCT01922063|disc herniation surgery
205476|NCT01922063|physiotherapy, exercise therapy
205477|NCT01922063|randomized
205478|NCT01922063|long term
205479|NCT01922063|follow up
205480|NCT01921972|AD, Dementia
205481|NCT01921946|Fimasartan
205482|NCT01921933|End-stage renal disease
205483|NCT01921933|ESRD
205484|NCT01921933|AVF
205485|NCT01921933|Fistulas
205486|NCT01921920|Omeprazole, Prilosec, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence
205487|NCT01921907|Actinic keratosis
205488|NCT01921907|topical
205489|NCT01921907|dermatology
205490|NCT01921907|treatment
205491|NCT01921907|clinical study
205492|NCT01921907|double blinded
205493|NCT01921894|asthma
205494|NCT01921894|vitamin D
205495|NCT01921881|Glucose tolerance
205496|NCT01921829|Cardiorenal failure
205497|NCT01921829|Cardiorenal syndrome
205498|NCT01921829|Diuretic resistance
205499|NCT01921829|Volume overload
205500|NCT01921829|Edema
205501|NCT01921829|Health-related quality of life
205502|NCT01921829|Outcomes
205503|NCT01921829|Treatment protocol
205504|NCT01921790|Avastin+ GemAOD
205505|NCT01921790|first line chemotherapy
205506|NCT01921790|NK/T-cell Lymphoma
205507|NCT01921777|Muscle
205508|NCT01921777|exercise
205509|NCT01921777|soreness
205510|NCT01921777|Damage
205511|NCT01921777|Traumeel
205512|NCT01921777|homeopathy
205513|NCT01921751|SMAD4
205514|NCT01921751|IMRT
205515|NCT01921751|gemcitabine
205516|NCT01921751|FOLFIRINOX
205517|NCT01921751|high-dose radiotherapy
205518|NCT01921738|Chronic Periodontitis, Azithromycin, SRP
205519|NCT01921725|wound healing
205520|NCT01921725|carbon
205521|NCT01921712|COPD
205522|NCT01921712|Chronic Obstructive Pulmonary Disease
205523|NCT01921699|macrophages
205524|NCT01921699|adenocarcinoma
205525|NCT01921699|chemoresistance
205526|NCT01921686|Eosinophil
205527|NCT01921686|Reflux
205528|NCT01921686|Esophagus
205529|NCT01921686|Food allergy
205530|NCT01921686|Trouble Swallowing
205531|NCT01921686|Pediatrics
205532|NCT01921686|Healthy Volunteers
205533|NCT01921673|Gastric cancer
205534|NCT01921673|Phase I/II
205535|NCT01921673|Second-line chemotherapy
205536|NCT01921673|Dovitinib
205537|NCT01921673|Docetaxel
205538|NCT01921673|Refractory to first-line chemotherapy
205539|NCT01920620|obesity, inpatient, intervention, weight loss
205540|NCT01920607|Fecal Incontinence.
205541|NCT01920607|Anal Incontinence.
205542|NCT01920607|Functional Bowel Disorders.
205543|NCT01920607|SNS.
205544|NCT01920607|Artificial Sphincters.
205545|NCT01920607|Magnetic Anal Sphincter.
205546|NCT01920594|GSK1278863
205547|NCT01920594|Thoracic Aortic Aneurysm Repair
205548|NCT01920581|CEIP
205549|NCT01920581|pharmacodependance
205550|NCT01920581|addictovigilance
205551|NCT01920581|benzodiazepines and benzodiazepines related drugs
205552|NCT01920581|elderly
205553|NCT01920568|GSK2371746
205554|NCT01920568|Denosumab
205555|NCT01920568|China
205556|NCT01920568|skeletal-related events
205557|NCT01920568|bone metastases
205558|NCT01920568|bridging study
205559|NCT01920568|solid tumors
205560|NCT01920555|Depression
205561|NCT01920555|Treatment Resistant Depression
205562|NCT01920555|Ketamine
205563|NCT01920555|Antidepressant
205564|NCT01920555|MDD
205565|NCT01920555|Major Depression
205566|NCT01920529|asthma, aerobic exercise, child, cytokines
205567|NCT01920516|Isolated limb infusion
205568|NCT01920516|Melphalan
205569|NCT01920516|Limb Melanoma
205570|NCT01920516|Tumor response
205571|NCT01921647|safety/tolerability and pharmacokinetics/pharmacodynamics
205572|NCT01921621|proficiency based progression
205573|NCT01921621|surgical skill
205574|NCT01921621|metric validation
205575|NCT01921621|formative feedback
205576|NCT01921621|simulator model
205577|NCT01921608|Male Circumcision
205578|NCT01921608|HIV Prevention
205579|NCT01921608|HIV Infections
205580|NCT01921595|balanced salt colloid, coagulation profiles, spinal cord tumor
205581|NCT01921543|Deep Brain Stimulation
205582|NCT01921543|Major Depressive Disorder
205583|NCT01921543|Psychosurgery
205584|NCT01921543|Electrical stimulation
205585|NCT01921530|Posterolateral Fusion
205586|NCT01921530|Interbody Fusion
205587|NCT01921530|Lumbar
205588|NCT01921530|Spinal Stenosis
205589|NCT01921530|Degenerative Spondylolisthesis
205590|NCT01921517|Biomechanics
205591|NCT01921517|Osteogenesis
205592|NCT01921504|Functional Dyspepsia
205593|NCT01921504|Acupuncture
205594|NCT01921504|Genotype
205595|NCT01921504|Ghrelin
205596|NCT01921465|outpatient care
205597|NCT01921465|videoconferencing
205598|NCT01921465|elective cesarean section
205599|NCT01921452|Hypothyroidism
205600|NCT01921452|Third generation TSH kit
205601|NCT01921452|Quantitative POC TSH kit
205602|NCT01921452|Qualitative POC TSH kit
205603|NCT01921439|smoking
205604|NCT01921439|quit smoking
205605|NCT01921439|smoking cessation
205606|NCT01921439|smoking study
205607|NCT01921439|secondhand smoke
205608|NCT01921439|smokers
205609|NCT01921426|Squamous Cell Carcinoma of the Head and Neck
205610|NCT01921426|Oral Cavity
205611|NCT01921426|Oropharynx
205612|NCT01921426|Radiation
205613|NCT01921426|Chemotherapy
205614|NCT01921426|Cisplatin
205615|NCT01921426|Oral Mucositis
205616|NCT01921426|Superoxide Dismutase
205617|NCT01921413|Plasmodium falciparum
205618|NCT01921413|Clinical Malaria
205619|NCT01921413|Fever
205620|NCT01921413|Schistosoma hematobium
205621|NCT01921413|Rheumatoid arthritis
205622|NCT01921400|Hepatitis C (HCV)
205623|NCT01921400|Infection Transmission, Maternal-Fetal
205624|NCT01921400|Placenta
205625|NCT01921400|Trophoblast
205626|NCT01921374|Duchenne;
205627|NCT01921374|mothers caregivers;
205628|NCT01921374|sleep;
205629|NCT01921374|hormonal profile;
205630|NCT01921374|cardiac profile;
205631|NCT01921374|biochemical profile;
205632|NCT01921374|inflammatory profile.
205633|NCT01921361|Shivering
205634|NCT01921361|Dexmedetomidine
205635|NCT01921361|Spinal anesthesia
205636|NCT01921348|Hay Fever
205637|NCT01921348|Hayfever
205638|NCT01921348|Pollen Allergy
205639|NCT01921348|Pollinosis
205640|NCT01921348|Seasonal Allergic Rhinitis
205641|NCT01921335|ARRY-380
205642|NCT01921335|Trastuzumab
205643|NCT01921335|Advanced HER2-positive breast cancer
205644|NCT01921309|osteoarthritis
205645|NCT01921309|avascular necrosis
205646|NCT01921309|rheumatoid arthritis
205647|NCT01921309|correction of functional deformity
205648|NCT01921309|dysplasia of the hip
205649|NCT01921296|Breast cancer
205650|NCT01921296|Aromatase inhibitor
205651|NCT01921283|propofol, endoscopy, bispectral index
205652|NCT01921270|Oromandibular Dystonia
205653|NCT01921270|Oral Dystonia
205654|NCT01921270|Tardive Dystonia
205655|NCT01921270|botulinum toxin
205656|NCT01921270|abobotulinumtoxinA
205657|NCT01921257|Cat Allergy
205658|NCT01921257|Rhinoconjunctivitis
205659|NCT01921244|Autistic Disorder
205660|NCT01921244|Decision Making
205661|NCT01921244|Medication Therapy Management
205662|NCT01921218|Kidney transplant
205663|NCT01921205|Lacosamide
205664|NCT01921205|Vimpat
205665|NCT01921205|UCB
205666|NCT01921205|Epilepsy
205667|NCT01921205|Partial Onset Seizures
205668|NCT01921205|Pediatric
205669|NCT01921179|Post Traumatic Stress Disorder,
205670|NCT01921179|Mild Traumatic Brain Injury
205671|NCT01921179|Concussion
205672|NCT01921179|Cognitive Rehabilitation
205673|NCT01921166|infertility
205674|NCT01921166|diminished ovarian reserve
205675|NCT01921166|fertilization in vitro
205676|NCT01921166|ovulation inducion
205677|NCT01921166|vitrification
205678|NCT01921140|Oncology, cancer, tumour, neoplasm, anticancer drug, food, area under the curve, pharmacokinetics, olaparib, neoplasm, metabolites, QT interval effects
205679|NCT01921127|COPD, Comparative effectiveness, Symbicort
205680|NCT01921101|nutrition
205681|NCT01921101|enteral feeding
205682|NCT01921101|parenteral feeding
205683|NCT01921101|hospital malnutrition
205684|NCT01921088|fMRI
205685|NCT01921088|Neurofeedback
205686|NCT01921088|Blood pressure
205687|NCT01921088|Psychophysiology
205688|NCT01921075|physiology, normal function
205689|NCT01921062|Distal radius fracture
205690|NCT01921062|Motor imagery
205691|NCT01921062|Immobilisation
205692|NCT01921062|Effectivity
205693|NCT01921023|Blood Gas analysis
205694|NCT01920997|Healthy
205695|NCT01920997|normal menstrual cycles
205696|NCT01920971|chronic low back pain
205697|NCT01920971|infrared energy
205698|NCT01920971|effects
205699|NCT01920932|Pediatric cancer
205700|NCT01920932|Hodgkin lymphoma
205701|NCT01920932|Targeted therapy
205702|NCT01920932|Frontline therapy
205703|NCT01920932|Brentuximab vedotin
205704|NCT01920932|Quality of Life
205705|NCT01920932|OEPA/COPDac
205706|NCT01920906|Psoriasis
205707|NCT01920906|Korean
205708|NCT01920906|Healthy Volunteers
205709|NCT01920880|Anterior cutaneous nerve entrapment syndrome
205710|NCT01920880|ACNES
205711|NCT01920880|chronic abdominal wall pain
205712|NCT01920880|CAWP
205713|NCT01920867|Stem Cells
205714|NCT01920867|Bone Marrow Derived Stem Cells
205715|NCT01920867|BMSC
205716|NCT01920867|BMC (Bone Marrow Cell)
205717|NCT01920867|Mesenchymal Stem Cells
205718|NCT01920867|MSC
205719|NCT01920867|Eye Disease
205720|NCT01920867|Eye Stem Cells
205721|NCT01920867|Ophthalmology
205722|NCT01920867|Ophthalmic Disease
205723|NCT01920867|Retina
205724|NCT01920867|Retinal Disease
205725|NCT01920867|Macular Degeneration
205726|NCT01920867|Age Related Macular Degeneration
205727|NCT01920867|Myopic Macular Degeneration
205728|NCT01920867|Geographic Atrophy
205729|NCT01920867|Dry Macular Degeneration
205730|NCT01920867|Wet Macular Degeneration
205731|NCT01920867|Retinal Atrophy
205732|NCT01920867|Retinal Dystrophy
205733|NCT01920867|Hereditary Retinal Dystrophy
205734|NCT01920867|Retinitis Pigmentosa
205735|NCT01920867|Stargardt Disease
205736|NCT01920867|Cone Dystrophy
205737|NCT01920867|Cone Rod Dystrophy
205738|NCT01920867|Maculopathy
205739|NCT01920867|Optic Nerve Disease
205740|NCT01920867|Optic Nerve Atrophy
205741|NCT01920867|Optic Atrophy
205742|NCT01920867|Ischemic Optic Neuropathy
205743|NCT01920867|Optic Nerve Damage
205744|NCT01920867|Optic Nerve Compression
205745|NCT01920867|Compressive Optic Neuropathy
205746|NCT01920867|Devics Syndrome
205747|NCT01920854|Soluble Ferric Pyrophosphate, Pharmacokinetics, Iron, Hemodialysis
205748|NCT01920841|lipolytic
205749|NCT01920841|herbal extracts
205750|NCT01920841|thigh girth
205751|NCT01920841|thigh smoothness
205752|NCT01920789|Non-small call lung cancer
205753|NCT01920789|Medically inoperable
205754|NCT01920789|Stage one
205755|NCT01920789|Radiotherapy
205756|NCT01920789|SBRT
205757|NCT01920789|Hypofractionation
205758|NCT01920789|Conventional fractionation
205759|NCT01920776|critical ultrasound
205760|NCT01920763|Intracerebral hemorrhage
205761|NCT01920763|Surgical evacuation
205762|NCT01920763|Minimally-invasive surgery
205763|NCT01920750|Leprosy, skin test, MLSA-LAM, MLCwA, diagnosis, Protocol 98-202
205764|NCT01920737|ALL
205765|NCT01920737|Bone Marrow
205766|NCT01920737|Ph Negative
205767|NCT01920737|Daunorubicin
205768|NCT01920737|Vincristine
205769|NCT01920737|Prednisone
205770|NCT01920737|PEG-Asparaginase
205771|NCT01920737|Methotrexate
205772|NCT01920737|16-MP (6-Mercaptopurine)
205773|NCT01920737|Cyclophosphamide
205774|NCT01920737|Cytarabine
205775|NCT01920737|Leucovorin
205776|NCT01920737|Dexamethasone
205777|NCT01920737|12-266
205778|NCT01920724|Preschool children
205779|NCT01920724|Body composition
205780|NCT01920711|Heart failure, preserved ejection fraction, diastolic heart failure
205781|NCT01920698|Heart Valve Diseases
205782|NCT01920698|Heart failure
205783|NCT01920698|Heart diseases
205784|NCT01920698|Mitral valve insufficiency
205785|NCT01920685|Paranoia
205786|NCT01920685|CBT
205787|NCT01920685|Reasoning
205788|NCT01920685|Anxiety
205789|NCT01920659|High Intensity Training
205790|NCT01920659|Insulin sensitivity
205791|NCT01920659|Fitness
205792|NCT01920503|cholangiocarcinoma
205793|NCT01920503|transarterial chemoembolization
205794|NCT01920503|doxorubicin
205795|NCT01920503|tumor response
205796|NCT01920477|Pemphigus
205797|NCT01920477|(MAB)
205798|NCT01920477|autoimmune disorder
205799|NCT01920477|human CD20 antigen
205800|NCT01920477|subcutaneous
205801|NCT01920477|Pemphigus vulgaris
205802|NCT01920477|Phase 3
205803|NCT01920477|monoclonal antibody
205804|NCT01920477|ofatumumab
205805|NCT01920477|PV
205806|NCT01920477|rare disease
205807|NCT01920451|sleep
205808|NCT01920451|insomnia
205809|NCT01920451|posttraumatic stress disorder
205810|NCT01920451|hypertension
205811|NCT01920451|cardiovascular disease
205812|NCT01920438|Percutaneous endoscopic gastrostomy,
205813|NCT01920438|Radiologically inserted gastrostomy,
205814|NCT01920438|Complications
205815|NCT01920425|Parkinson's disease
205816|NCT01920425|dyskinesia
205817|NCT01920425|fluctuations
205818|NCT01920425|tremor
205819|NCT01920425|bradykinesia
205820|NCT01920425|levodopa
205821|NCT01920412|Atrial fibrillation
205822|NCT01920412|Thrombosis
205823|NCT01920412|Ischemic stroke
205824|NCT01920412|Left atrial appendage occluder
205825|NCT01920412|Intervention method
205826|NCT01920399|CAZ-AVI China phase I PK study
205827|NCT01920386|Acute Toothache
205828|NCT01920386|Wontran
205829|NCT01920386|Wontran SR Tab.
205830|NCT01920386|Tramadol Hydrochloride/Acetaminophen
205831|NCT01920373|degenerative joint disease
205832|NCT01920373|temporomandibular joint
205833|NCT01920360|KNEE OSTEOARTHRITIS
205834|NCT01920360|BALNEOTHERAPY
205835|NCT01920360|SULPHUROUS WATERS
205836|NCT01920360|WOMAC
205837|NCT01920360|LEQUESNE
205838|NCT01920360|HEALTH ASSESSMENT QUESTIONNAIRE
205839|NCT01920360|SHORT FORM - 36
205840|NCT01920360|VAS
205841|NCT01920347|hypoxic encephalopathy
205842|NCT01920347|cardiac arrest
205843|NCT01920347|outcome
205844|NCT01920347|pupillary reflex
205845|NCT01920334|coronary disease
205846|NCT01920334|heart diseases
205847|NCT01920334|enzymes
205848|NCT01920334|sleep
205849|NCT01920334|troponin
205850|NCT01920334|zolpidem
205851|NCT01920321|COPD
205852|NCT01920321|Bronchoscopic LVR
205853|NCT01920321|Emphysema
205854|NCT01920321|Hot injury
205855|NCT01920269|non-muscle invasive bladder cancer
205856|NCT01920269|intravesical chemotherapy
205857|NCT01920269|mitomycin
205858|NCT01920269|passive diffusion
205859|NCT01920269|electromotive drug administration
205860|NCT01920256|Insulin therapy
205861|NCT01920256|Type 2 diabetes
205862|NCT01920243|Telemedicine
205863|NCT01920243|self-management
205864|NCT01920243|Medical psychology
205865|NCT01920243|Health psychology
205866|NCT01920243|Rehabilitation
205867|NCT01920243|Education, Health
205868|NCT01920230|Burnout
205869|NCT01920230|Stress
205870|NCT01920230|Mindfulness
205871|NCT01920230|Acceptance-commitment therapy (ACT)
205872|NCT01920230|Intervention
205873|NCT01920230|Effectiveness
205874|NCT01920230|Working conditions
205875|NCT01920230|Work engagement
205876|NCT01920230|Psychological well-being
205877|NCT01920230|Life situation
205878|NCT01920217|sepsis
205879|NCT01920217|SNP
205880|NCT01920217|mortality
205881|NCT01920204|Mastocytosis
205882|NCT01920204|ISM
205883|NCT01920204|SSM
205884|NCT01920191|Glioblastoma
205885|NCT01920165|respiratory tract infections
205886|NCT01920165|upper respiratory tract infections
205887|NCT01920165|lower respiratory tract infections
205888|NCT01920165|hospitalisation
205889|NCT01920165|child
205890|NCT01920165|children
205891|NCT01920165|minors
205892|NCT01920165|infants
205893|NCT01920165|second-hand smoke
205894|NCT01920165|tobacco smoke pollution
205895|NCT01920165|smoke-free
205896|NCT01920165|smoke-free policy
205897|NCT01920165|smoke-free legislation
205898|NCT01920165|public places
205899|NCT01920152|Hip, Chondropenia, Osteoarthritis.
205900|NCT01920126|sodium bicarbonate, renal function, infective endocarditis, open heart surgery
205901|NCT01920113|Endoscopic submucosal dissection
205902|NCT01920113|propofol
205903|NCT01920113|remifentanil
205904|NCT01920113|dexmedetomidine
205905|NCT01920113|efficacy
205906|NCT01920113|safeness
205907|NCT01920100|Health Care Costs
205908|NCT01920100|Genetic Polymorphism
205909|NCT01920087|Atypical Facial Pain
205910|NCT01920087|Persistent Idiopathic Facial Pain
205911|NCT01920087|Atypical Trigeminal Neuralgia
205912|NCT01920087|Orofacial Pain
205913|NCT01920087|Orofacial neuropathic pain
205914|NCT01920087|Fothergill Disease
205915|NCT01920087|Tic Douloureux
205916|NCT01920087|Prosopalgia
205917|NCT01920074|Anal Fissure
205918|NCT01920074|Nitroglycerin
205919|NCT01920074|Pediatrics
205920|NCT01920074|RECTIV®
205921|NCT01920074|Pediatric Research Equity Act
205922|NCT01920061|Advanced cancer
205923|NCT01920061|solid tumors
205924|NCT01920061|PI3K
205925|NCT01920061|mTOR
205926|NCT01920061|PI3K/mTOR
205927|NCT01920061|metastatic
205928|NCT01920048|Heart Failure
205929|NCT01920048|Ventricular Dysfunction
205930|NCT01920048|Ischemic Cardiomyopathy
205931|NCT01920048|Ischemic Heart Disease
205932|NCT01920048|Revascularization
205933|NCT01920048|Percutaneous Coronary Intervention
205934|NCT01920048|Randomized Control Trial
205935|NCT01920048|Implantable Cardioverter Defibrillator
205936|NCT01920035|Incontinence post RARP
205937|NCT01920035|Surgery induced incontinence
205938|NCT01920035|Incontinence after prostatectomy
205939|NCT01920035|Neuropathy-induced incontinence
205940|NCT01920022|medical abortion
205941|NCT01920022|postabortion contraception
205942|NCT01920022|LARC
205943|NCT01920022|Nexplanon
205944|NCT01920022|subdermal contraceptive implant
205945|NCT01920009|pharmacy care
205946|NCT01920009|adherence
205947|NCT01920009|coronary heart disease
205948|NCT01919996|Ocular safety
205949|NCT01919996|azithromycin
205950|NCT01919996|pharyngitis
205951|NCT01919996|tonsillitis
205952|NCT01919983|cardiac
205953|NCT01919983|innervation
205954|NCT01919983|inflammation
205955|NCT01919983|sudden
205956|NCT01919983|death
205957|NCT01919970|Autism
205958|NCT01919970|Asperger's Syndrome
205959|NCT01919970|Pervasive Developmental Disorder Not Otherwise Specified
205960|NCT01919970|Treatment
205961|NCT01919970|Cognitive-behavioral therapy
205962|NCT01919970|Anxiety
205963|NCT01919970|Children
205964|NCT01919970|Therapy
205965|NCT01919970|Generalized Anxiety Disorder
205966|NCT01919970|Social Phobia
205967|NCT01919970|Separation Anxiety Disorder
205968|NCT01919970|Obsessive-compulsive Disorder
205969|NCT01919970|Specific Phobia
205970|NCT01919957|epilepsy
205971|NCT01919957|surgery
205972|NCT01919957|functional MRI
205973|NCT01919957|memory outcome
205974|NCT01919944|itch
205975|NCT01919931|Candida albicans
205976|NCT01919931|Candidiasis
205977|NCT01919931|Biofilm
205978|NCT01919931|Flow cytometry
205979|NCT01919931|Mannose Binding Lectin
205980|NCT01919905|Mozzarella cheese fortification
205981|NCT01919905|Bioavailability of Vitamin D
205982|NCT01919892|predictors of response
205983|NCT01919892|bipolar disorder
205984|NCT01919892|depression
205985|NCT01919892|lithium treatment
205986|NCT01919892|biomarkers
205987|NCT01919879|Chemotherapy refractory
205988|NCT01919879|wtKRAS metastatic colorectal cancer
205989|NCT01919879|cross over
205990|NCT01919853|Cancer
205991|NCT01919853|Fatigue
205992|NCT01919853|Mindfulness
205993|NCT01919853|Meditation
205994|NCT01919853|Neoplasms
205995|NCT01919853|Signs and symptoms
205996|NCT01919840|hemostatic disorders
205997|NCT01919840|ardiac surgery
205998|NCT01919840|cardiopulmonary bypass
205999|NCT01919827|Idiopathic pulmonary fibrosis
206000|NCT01919827|Stem cells
206001|NCT01919827|Mesenchymal stem cells
206002|NCT01919801|ACE-I
206003|NCT01919801|Firazyr
206004|NCT01919801|icatibant
206005|NCT01919788|Diabetes Mellitus Type I
206006|NCT01919788|Hypoglycemia
206007|NCT01919788|Counter-regulatory mechanisms
206008|NCT01919762|Bacteremia
206009|NCT01919762|Sepsis
206010|NCT01919762|Acinetobacter baumannii
206011|NCT01919762|Staphylococcus aureus
206012|NCT01919762|Klebsiella pneumonia
206013|NCT01919762|Pseudomonas aeruginosa
206014|NCT01919762|Enterococcus faecalis
206015|NCT01919762|Magnetic Relaxation Detection
206016|NCT01919762|Nuclear Magnetic Resonance Detection
206017|NCT01919762|Blood culture
206018|NCT01919749|breast cancer metastatic
206019|NCT01919749|molecular profiling
206020|NCT01919749|sequencing
206021|NCT01919749|profiling
206022|NCT01919749|breast cancer
206023|NCT01919736|knee OA
206024|NCT01919723|PCI
206025|NCT01919723|Ticagrelor
206026|NCT01919723|Eptifibatide
206027|NCT01919710|Neutropenia
206028|NCT01919710|chemotherapy
206029|NCT01919710|rHSA/GCSF
206030|NCT01919697|Plecantaide
206031|NCT01919697|Chronic Idiopathic Constipation
206032|NCT01919697|Chronic
206033|NCT01919697|Idiopathic
206034|NCT01919697|Constipation
206035|NCT01919697|Synergy
206036|NCT01919697|CIC
206037|NCT01919697|CIC study
206038|NCT01919697|CIC OLE
206039|NCT01919697|CIC OLE study
206040|NCT01919697|OLE
206041|NCT01919697|OLE CIC
206042|NCT01919697|OLE CIC3
206043|NCT01919697|Open label
206044|NCT01919697|Open label study
206045|NCT01919697|Long term
206046|NCT01919697|Long term study
206047|NCT01919697|Extension
206048|NCT01919697|Extension study
206049|NCT01919684|Glucagon receptor antagonist
206050|NCT01919671|Ischemic Stroke
206051|NCT01919671|Tongxinluo capsule
206052|NCT01919658|nerve blocks in Anterior cruciate ligament surgery
206053|NCT01919645|Rheumatoid Arthritis
206054|NCT01919645|Sleep Disorders
206055|NCT01919645|Polysomnography
206056|NCT01919645|Sleep Stages
206057|NCT01919645|Physical Exercise
206058|NCT01919632|lifestyle
206059|NCT01919632|physical activity
206060|NCT01919632|endothelial function
206061|NCT01919632|cardiovascular
206062|NCT01919632|occupational
206063|NCT01919632|prevention
206064|NCT01919619|Blood And Marrow Transplantation
206065|NCT01919619|Leukemia
206066|NCT01919619|Lymphoma
206067|NCT01919619|Allogeneic stem cell transplant
206068|NCT01919619|Autologous stem cell transplant
206069|NCT01919619|SCT
206070|NCT01919619|Lenalidomide CC-5013
206071|NCT01919619|Revlimid
206072|NCT01919619|Ipilimumab
206073|NCT01919619|Yervoy
206074|NCT01919619|BMS-734016
206075|NCT01919619|MDX010
206076|NCT01919606|hysterectomy
206077|NCT01919606|analgesia
206078|NCT01919593|Blood culture
206079|NCT01919593|Contamination
206080|NCT01919593|Chlorhexidine gluconate
206081|NCT01919593|Povidone iodine
206082|NCT01919580|Gα12
206083|NCT01919580|Oral cancer
206084|NCT01919567|SOX-9
206085|NCT01919567|Oral cancer
206086|NCT01919567|arecoline
206087|NCT01919554|House Dust Mite Allergic Rhinitis
206088|NCT01919554|Phase I
206089|NCT01919554|House Dust Mite Allergen Extract
206090|NCT01919541|Colorectal Surgery
206091|NCT01919528|ultrasonography
206092|NCT01919528|catheterization
206093|NCT01919528|central line
206094|NCT01919528|mechanical ventilation
206095|NCT01919528|intensive care
206096|NCT01919528|axillary vein
206097|NCT01919515|pediatric
206098|NCT01919515|primary molars
206099|NCT01919515|stainless steel crowns
206100|NCT01919489|Incretins
206101|NCT01919489|Liraglutide
206102|NCT01919489|Glargine
206103|NCT01919489|Randomized controlled trial
206104|NCT01919489|basal insulin
206105|NCT01919489|hospital discharge
206106|NCT01919489|inpatient diabetes
206107|NCT01919476|Postprandial
206108|NCT01919476|Insulin resistance
206109|NCT01919476|Lipids
206110|NCT01919476|Satiety
206111|NCT01919476|Almonds
206112|NCT01919463|Colonoscopy
206113|NCT01919463|Lower Gastrointestinal Tract
206114|NCT01919463|Magnetic Endoscopic Imaging
206115|NCT01919463|Abdominal Compression
206116|NCT01919450|PET
206117|NCT01919450|Lexiscan
206118|NCT01919450|Regadenoson
206119|NCT01919450|Rubidium
206120|NCT01919450|Blood Flow Reserve
206121|NCT01919450|Myocardial Perfusion
206122|NCT01919450|Quantitated Myocardial Perfusion
206123|NCT01919411|Chronic rhinosinusitis
206124|NCT01919411|Sinus surgery
206125|NCT01919411|Antibiotics
206126|NCT01919385|Type 1 diabetes
206127|NCT01919385|Insulin Pump
206128|NCT01919359|ablative laser
206129|NCT01919359|soft tissue filler
206130|NCT01919346|Kidney Transplantation
206131|NCT01919346|Delayed Graft Function
206132|NCT01919320|SynCardia
206133|NCT01919320|Total Artificial Heart
206134|NCT01919320|TAH-t
206135|NCT01919307|Seizures
206136|NCT01919307|Convulsions
206137|NCT01919307|Anticonvulsants
206138|NCT01919307|Epilepsy
206139|NCT01919307|Neurologic
206140|NCT01919294|nonalcoholic fatty liver disease
206141|NCT01919294|nonalcoholic steatohepatitis
206142|NCT01919294|hypogonadism
206143|NCT01919294|testosterone replacement therapy
206144|NCT01919281|exercise
206145|NCT01919281|resistance training
206146|NCT01919281|insulin resistance
206147|NCT01919281|high intensity interval training
206148|NCT01919268|Pilates-based exercises
206149|NCT01919268|Electrotherapy
206150|NCT01919268|Interferencial current
206151|NCT01919255|Colonoscopy
206152|NCT01919255|Bowel preparation
206153|NCT01919255|Picolight
206154|NCT01919255|Clicolon
206155|NCT01919255|Coolprep
206156|NCT01919229|HR-positive
206157|NCT01919229|HER2-negative
206158|NCT01919229|Breast cancer
206159|NCT01919229|LEE011
206160|NCT01919229|Letrozole
206161|NCT01919229|CDK
206162|NCT01919229|CDK4
206163|NCT01919229|CDK6
206164|NCT01919229|CDK4/6
206165|NCT01919229|Pharmacodynamics
206166|NCT01919229|Pre-surgical
206167|NCT01919229|Postmenopausal
206168|NCT01919177|Heart Failure
206169|NCT01919177|Arterial hemodynamics
206170|NCT01919177|Exercise capacity
206171|NCT01919177|Mitochondrial oxidative capacity
206172|NCT01919164|Osteoarthritis of knee
206173|NCT01919164|AS902330
206174|NCT01919164|Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)
206175|NCT01919164|Sprifermin
206176|NCT01919164|Placebo
206177|NCT01919151|survival
206178|NCT01919125|Chronic hepatitis C
206179|NCT01919125|Hepatitis C virus
206180|NCT01919125|HCV
206181|NCT01919112|Brain stimulation
206182|NCT01919099|Transplantation Costs
206183|NCT01919099|Risk Factors
206184|NCT01919099|Transplant Infections
206185|NCT01919086|Bortezomib
206186|NCT01919086|Dexamethasone
206187|NCT01919086|Lenalidomide
206188|NCT01919086|13-064
206189|NCT01919073|Attention Deficit, ADD, ADHD, ODD, Oppositional Behavior, Disruptive Behavior, Behavior Modification, Parent Management Training, Pre-School
206190|NCT01919047|overactive bladder
206191|NCT01919047|mirabegron
206192|NCT01919047|occurrence of adverse events
206193|NCT01919047|Overactive Bladder Symptom Score
206194|NCT01919034|Interleukin-20, Thrombomodulin, Huntington disease, patient control analgesic
206195|NCT01919008|FK949E
206196|NCT01919008|Pharmacokinetics
206197|NCT01919008|Major Depressive Disorder
206198|NCT01918995|CVT3146
206199|NCT01918995|Regadenoson
206200|NCT01918982|Aortic aneurysm
206201|NCT01918982|circulating endothelial progenitor cells
206202|NCT01918969|Endothelial progenitor cells
206203|NCT01918969|Healthy blood donors
206204|NCT01918956|immunotherapy
206205|NCT01918956|birch pollen
206206|NCT01918956|seasonal allergy
206207|NCT01918956|up-dosing
206208|NCT01918943|Spine
206209|NCT01918943|Aspen device
206210|NCT01918943|PLIF
206211|NCT01918943|Low back pain
206212|NCT01918930|Melanoma
206213|NCT01918930|Accessible tumors
206214|NCT01918930|B7-H3 positive tumors
206215|NCT01918917|Arthroscopic knee surgery
206216|NCT01918917|Dexmedetomidine
206217|NCT01918917|Analgesia
206218|NCT01918904|calcinosis
206219|NCT01918904|sodium thiosulfate
206220|NCT01918904|topical treatment
206221|NCT01918904|connective tissue disease
206222|NCT01918891|stroke
206223|NCT01918891|transient ischemic attack
206224|NCT01918891|High blood pressure
206225|NCT01918891|Hypertension
206226|NCT01918878|age-related macular degeneration
206227|NCT01918878|intravitreal injections
206228|NCT01918878|Aflibercept
206229|NCT01918878|EYLEA
206230|NCT01918865|Type 2 Diabetes Mellitus
206231|NCT01918865|T2DM
206232|NCT01918852|Hand-foot syndrome
206233|NCT01918852|Toxicity
206234|NCT01918852|Fluoropyrimidine
206235|NCT01918852|Capecitabine
206236|NCT01918852|Teysuno
206237|NCT01918852|S1
206238|NCT01918839|Investigational Device (VINCI Plus)
206239|NCT01918839|Correction of nasolabial fold
206240|NCT01918839|Wrinkle improvement
206241|NCT01918839|Wrinkle correction
206242|NCT01918800|fatigue
206243|NCT01918800|quality of life
206244|NCT01918800|rehabilitation
206245|NCT01918800|self management
206246|NCT01918800|energy effectiveness
206247|NCT01918774|Unemployment
206248|NCT01918774|Cognitive Behavioral Therapy
206249|NCT01918774|Mental Disorders
206250|NCT01918761|NSCLC
206251|NCT01918761|Stage IV
206252|NCT01918761|Pemetrexed
206253|NCT01918761|Dacomitinib
206254|NCT01918735|Safety
206255|NCT01918735|Tolerability
206256|NCT01918735|Assessment of potential adverse events
206381|NCT01918176|Rabeprazole
206257|NCT01918735|Assessment of potential laboratory abnormalities
206258|NCT01918722|Activating blood stagnation and expelling blood stasis
206259|NCT01918722|Hematoma enlargement
206260|NCT01918722|herbal medicine
206261|NCT01918722|traditional chinese medicine
206262|NCT01918722|random clinical trial
206263|NCT01918696|suicide
206264|NCT01918696|anger
206265|NCT01918696|interpretation modification
206266|NCT01918696|computerized treatment
206267|NCT01918670|atrial fibrillation; catheter ablation; relapse; stroke; death
206268|NCT01918657|Interventional
206269|NCT01918657|Randomized
206270|NCT01918657|Double blind
206271|NCT01918657|Placebo controlled
206272|NCT01918657|Pediatric
206273|NCT01918618|levosimendan
206274|NCT01918618|renal effects
206275|NCT01918618|cardiac surgery
206276|NCT01918618|left heart insufficiency
206277|NCT01918605|prostate cancer
206278|NCT01918605|brachytherapy
206279|NCT01918605|spacer
206280|NCT01918605|side effect
206281|NCT01918592|bladder cancer
206282|NCT01918592|neoadjuvant chemotherapy
206283|NCT01918592|radical cystectomy
206284|NCT01918592|lymphadenectomy
206285|NCT01918592|biomarker
206286|NCT01918553|AMD
206287|NCT01918553|epidemiology
206288|NCT01918553|risk factors
206289|NCT01918553|cohort study
206290|NCT01918540|Radiostereometry
206291|NCT01918540|Total Hip Arthroplasty
206292|NCT01918540|Stem design
206293|NCT01918527|Locally advanced colon cancer
206294|NCT01918527|Neoadjuvant chemotherapy
206295|NCT01918514|Magnesium sulfate
206296|NCT01918514|epidural
206297|NCT01918514|interscalene
206298|NCT01918514|NMDA receptor
206299|NCT01918501|multiple sclerosis
206300|NCT01918501|Remyelination
206301|NCT01918501|Mitochondria
206302|NCT01918501|fatty acids
206303|NCT01918488|Diabetic Nephropathies
206304|NCT01918488|Hypertension
206305|NCT01918488|Proteinuria
206306|NCT01918488|Albuminuria
206307|NCT01918488|Epithelial Sodium Channels
206308|NCT01918488|Epithelial Sodium Channel Blockers
206309|NCT01918488|Amiloride
206310|NCT01918475|randomized controlled trial
206311|NCT01918475|placebo controlled trial
206312|NCT01918475|cross over trial
206313|NCT01918462|Alcoholic hepatitis
206314|NCT01918462|IL-22
206315|NCT01918462|Kupffer cells
206316|NCT01918449|OSA
206317|NCT01918449|CPAP treatment
206318|NCT01918449|primary care
206319|NCT01918449|efficacy
206320|NCT01918436|Attention Deficit Hyperactivity Disorder
206321|NCT01918436|Neurocognitive training for preschool children with ADHD
206322|NCT01918436|Play intervention for children with ADHD
206323|NCT01918423|Childhood adiposity
206324|NCT01918423|Metabolic risk factors
206325|NCT01918423|Bone mineralization
206326|NCT01918410|contact lens
206327|NCT01918410|alginic
206328|NCT01918410|dry eyes
206329|NCT01918384|Duchenne muscular dystrophy
206330|NCT01918384|NPC-14
206331|NCT01918384|Arbekacin
206332|NCT01918384|nonsense
206333|NCT01918384|readthrough
206334|NCT01918345|Diabetes
206335|NCT01918345|Diabetes Mellitus
206336|NCT01918345|Diabetes Mellitus, Type 2
206337|NCT01918345|Diabetes, gestational
206338|NCT01918345|Prevention & control
206339|NCT01918345|Postpartum Period
206340|NCT01918345|Mothers
206341|NCT01918345|Diet
206342|NCT01918345|Diabetic Diet
206343|NCT01918345|Exercise
206344|NCT01918345|Life Style
206345|NCT01918345|Motivation
206346|NCT01918345|Health Behavior
206347|NCT01918345|Insulin-Secreting Cells
206348|NCT01918345|Randomized Controlled Trial
206349|NCT01918345|Clinical Trial
206350|NCT01918345|Pilot Projects
206351|NCT01918345|Feasibility Studies
206352|NCT01918306|Triple Negative Breast Cancer
206353|NCT01918306|Estrogen receptor negative breast cancer
206354|NCT01918306|Metastatic breast cancer
206355|NCT01918306|Stage IV breast cancer
206356|NCT01918306|HER2 negative breast cancer
206357|NCT01918293|ASTHMA
206358|NCT01918293|SMARTPHONE APPLICATION
206359|NCT01918280|Klinefelter Syndrome
206360|NCT01918280|Azoospermia
206361|NCT01918280|Seminal analyses
206362|NCT01918280|Testicular biopsy
206363|NCT01918241|Pegylation
206364|NCT01918241|G-CSF
206365|NCT01918241|Efficacy
206366|NCT01918241|Satety
206367|NCT01918202|Enzyme occupancy
206368|NCT01918202|PET
206369|NCT01918202|Phosphodiesterase 10 inhibitor
206370|NCT01918189|back pain
206371|NCT01918189|low back pain
206372|NCT01918189|chronic pain
206373|NCT01918189|cognitive behavior therapy
206374|NCT01918189|behavior therapy
206375|NCT01918176|Palbociclib
206376|NCT01918176|PD-0332991
206377|NCT01918176|Proton Pump Inhibitor
206378|NCT01918176|DDI
206379|NCT01918176|Healthy Volunteers
206380|NCT01918176|Pharmacokinetics
206382|NCT01918163|pomegranate pills, male infertility, pregnancy rate, semen analysis, ROS, oxidative stress
206383|NCT01918124|disease free survival, overall survival
206384|NCT01918111|Renal denervation, Exercise diastolic function, Atherosclerosis, New methods
206385|NCT01918072|Women's Health
206386|NCT01918072|Hospitals, Veterans
206387|NCT01918072|Education
206388|NCT01918072|Remote consultation
206389|NCT01918072|Videoconferencing
206390|NCT01918059|Trauma
206391|NCT01918059|Eyelid
206392|NCT01918059|Laceration
206393|NCT01918059|Tissue adhesive
206394|NCT01918059|suture
206395|NCT01918059|cosmetic
206396|NCT01918059|octyl-2-cyanoacrylate
206397|NCT01918046|biomarker
206398|NCT01918046|MIOX
206399|NCT01918033|Rhinitis
206400|NCT01918033|Allergic Rhinitis
206401|NCT01918033|Nose Diseases
206402|NCT01918033|Respiratory Tract Diseases
206403|NCT01918033|Immune System Diseases
206404|NCT01918033|Cholinergic Antagonists
206405|NCT01918033|Cholinergic Agents
206406|NCT01918033|Neurotransmitter Agents
206407|NCT01918033|Histamine H1 Antagonists, Non-Sedating
206408|NCT01918033|Histamine H1 Antagonists
206409|NCT01918033|Histamine Antagonists
206410|NCT01918033|Histamine Agents
206411|NCT01918020|Fruit
206412|NCT01918020|Vegetables
206413|NCT01918020|Motor Activity
206414|NCT01918007|Apnea
206415|NCT01918007|Sleep Apnea Syndromes
206416|NCT01918007|Snoring
206417|NCT01918007|Sleep Apnea, Obstructive
206418|NCT01918007|Respiration Disorders
206419|NCT01918007|Respiratory Tract Diseases
206420|NCT01918007|Signs and Symptoms, Respiratory Signs and Symptoms
206421|NCT01918007|Sleep Disorders, Intrinsic
206422|NCT01918007|Dyssomnias
206423|NCT01918007|Sleep Disorders
206424|NCT01918007|Respiratory Sounds
206425|NCT01917981|Intermittent cardiac monitoring
206426|NCT01917981|Implantable device
206427|NCT01917968|POP
206428|NCT01917968|Transvaginal
206429|NCT01917968|Native Tissue Repair
206430|NCT01917968|Repair Augmented with Mesh
206431|NCT01917968|Pelvic Organ Prolapse
206432|NCT01917955|MRI
206433|NCT01917942|Radiotherapy
206434|NCT01917942|Humidification
206435|NCT01917942|Mucositis
206436|NCT01917929|[E04.555.110.110.110]
206437|NCT01917903|walking
206438|NCT01917903|Parkinson's disease
206439|NCT01917903|traumatic brain injury
206440|NCT01917903|multiple sclerosis
206441|NCT01917903|physical therapy
206442|NCT01917903|falls
206443|NCT01917903|memory
206444|NCT01917903|attention
206445|NCT01917903|multitasking
206446|NCT01917903|exercise
206447|NCT01917890|curcumin
206448|NCT01917890|radioprotective
206449|NCT01917890|radiosensitizer
206450|NCT01917877|Becacizumab
206451|NCT01917877|pulmonary fibrosis
206452|NCT01917877|irradiation
206453|NCT01917877|chemotherapy
206454|NCT01917864|Autism
206455|NCT01917864|Autism Spectrum Disorders
206456|NCT01917864|Prosody
206457|NCT01917864|Speech treatment
206458|NCT01917851|Accurate
206459|NCT01917851|Hb
206460|NCT01917851|noninvasive measurement
206461|NCT01917838|Mental Health Services
206462|NCT01917825|radicular pain
206463|NCT01917812|physical activity
206464|NCT01917812|exercise
206465|NCT01917812|mHealth
206466|NCT01917812|smartphone
206467|NCT01917812|activity tracker
206468|NCT01917812|pedometer
206469|NCT01917812|text messaging
206470|NCT01917812|SMS
206471|NCT01917799|Aspirin
206472|NCT01917799|Heparin
206473|NCT01917799|pregnancy
206474|NCT01917799|miscarriage
206475|NCT01917760|Gamma-aminobutyric acid
206476|NCT01917760|Pharmacokinetics
206477|NCT01917760|Pharmacodynamics
206478|NCT01917760|Insulin
206479|NCT01917760|C-peptide
206480|NCT01917760|Glucagon
206481|NCT01917747|Infant hearing screening
206482|NCT01917747|Patient Navigator
206483|NCT01917734|severe acute malnutrition
206484|NCT01917734|severe wasting
206485|NCT01917734|facility-based care
206486|NCT01917734|community-based care
206487|NCT01917734|Madhya Pradesh
206488|NCT01917734|India
206489|NCT01917721|Kawasaki disease
206490|NCT01917721|doxycycline
206491|NCT01917721|coronary artery aneurysm
206492|NCT01917708|non malignant conditions
206493|NCT01917708|blood and marrow transplant
206494|NCT01917695|Bulky cervical cancers
206495|NCT01917695|Neoadjuvant Chemotherapy
206496|NCT01917695|Neoadjuvant Chemoradiotherapy
206497|NCT01917682|robotic-assisted PCI
206498|NCT01917682|coronary intervention
206499|NCT01917682|CorPath PRECISION Registry
206500|NCT01917682|PCI
206501|NCT01917682|angioplasty
206502|NCT01917643|COPD, Comparative Effectiveness, Symbicort
206503|NCT01917630|Celiac disease
206504|NCT01917630|Gluten-free diet
206505|NCT01917630|Coeliac disease
206506|NCT01917630|Celiac sprue
206507|NCT01917604|open versus closed surgical technique
206508|NCT01917604|impacted maxillary canine
206509|NCT01917604|orthodontic disimpaction
206510|NCT01917591|Bandages
206511|NCT01917591|Biological Dressings
206512|NCT01917591|Chronic Disease
206513|NCT01917591|Collagen
206514|NCT01917591|Epithelium
206515|NCT01917591|Extracellular Matrix
206516|NCT01917591|Extra Cellular Matrix
206517|NCT01917591|Fibroblasts
206518|NCT01917591|Granulation Tissue
206519|NCT01917591|Leg Ulcer
206520|NCT01917591|Middle Aged
206521|NCT01917591|Prospective Studies
206522|NCT01917591|Soft Tissue Injuries
206523|NCT01917591|Treatment Outcome
206524|NCT01917591|Varicose Ulcer
206525|NCT01917591|Wound Healing
206526|NCT01917591|Wounds and Injuries
206527|NCT01917591|biopsy
206528|NCT01917591|autoimmunity
206529|NCT01917578|Breast Cancer
206530|NCT01917578|shrinkage modes
206531|NCT01917578|three-dimensional reconstruction
206532|NCT01917578|neoadjuvant chemotherapy
206533|NCT01917578|Magnetic Resonance Imaging
206534|NCT01917565|airway management
206535|NCT01917565|laryngoscope
206536|NCT01917565|Airtraq
206537|NCT01917565|Macintosh laryngoscope
206538|NCT01917565|fiberoptic bronchoscope
206539|NCT01917565|intubation
206540|NCT01917552|Gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, adjuvant, capecitabine, gastric cancer, stage 1b
206541|NCT01917526|Oxygen
206542|NCT01917526|PACU
206543|NCT01917526|Hypoxemia
206544|NCT01917513|Adenoma
206545|NCT01917513|Polyps
206546|NCT01917513|CRC
206547|NCT01917513|Colonoscopy
206548|NCT01917513|Detection Yield
206549|NCT01917500|Continues non-invasive Blood pressure measurement
206550|NCT01917500|Continues non-invasive Cardiac Output measurement
206551|NCT01917474|low-lipid diet
206552|NCT01917474|normal lipid intake
206553|NCT01917474|saturated fats reduction
206554|NCT01917474|headache attacks
206555|NCT01917448|postoperative pain
206556|NCT01917448|spinal morphine
206557|NCT01917448|video-assisted thoracoscopic surgery
206558|NCT01917435|fiberoptic bronchoscopy,
206559|NCT01917435|Video-stylet,
206560|NCT01917435|Nasotracheal Intubation
206561|NCT01917409|Conventional Laryngoscopy ,
206562|NCT01917409|Video-stylet ,
206563|NCT01917409|Nasotracheal Intubation
206564|NCT01917396|caesarean, bowel, gass
206565|NCT01917383|glaucoma
206566|NCT01917383|primary open angle glaucoma
206567|NCT01917383|ocular hypertension
206568|NCT01917383|adenosine agonist
206569|NCT01917383|eye drop
206570|NCT01917383|trabodenoson
206571|NCT01917383|trabecular meshwork
206572|NCT01917370|intrahepatic cholangiocarcinoma
206573|NCT01917370|icc
206574|NCT01917370|vegf signal pathway
206575|NCT01917357|Vaccination
206576|NCT01917357|Immunisation
206577|NCT01917357|Virus
206578|NCT01917357|Diphtheria
206579|NCT01917357|Pertussis
206580|NCT01917357|Tetanus
206581|NCT01917357|Hepatitis B
206582|NCT01917357|Haemophilus Influenzae
206583|NCT01917357|Immunity
206584|NCT01917344|Phenylketonuria
206585|NCT01917344|MRI
206586|NCT01917344|Neuropsychological functioning
206587|NCT01917344|Neurological functioning
206588|NCT01917344|EEG
206589|NCT01917331|spirometry
206590|NCT01917331|severe COPD
206591|NCT01917331|lung disease
206592|NCT01917331|fixed combination
206593|NCT01917318|Post traumatic stress disorder
206594|NCT01917318|Treatment of post traumatic stress disorder
206595|NCT01917318|Symptoms of arousal in post traumatic stress disorder
206596|NCT01917318|Iloperidone in post traumatic stress disorder
206597|NCT01917305|Bacteria
206598|NCT01917305|bone level
206599|NCT01917305|bone loss
206600|NCT01917305|dental implants
206601|NCT01917305|implant design
206602|NCT01917305|platform-shifting
206603|NCT01917305|platform-matching
206604|NCT01917292|Periodontitis
206605|NCT01917292|Prehypertension
206606|NCT01917292|Periodontal Intervention
206607|NCT01917279|Metastatic Breast Cancer
206608|NCT01917279|Antineoplastic Agents
206609|NCT01917279|Therapeutic Uses
206610|NCT01917279|Antimetabolites
206611|NCT01917279|Tubulin Modulators
206612|NCT01917279|Maintenance chemotherapy
206613|NCT01917279|Metronomic chemotherapy
206614|NCT01917279|Capecitabine
206615|NCT01917279|Docetaxel
206616|NCT01917253|infiltration, phlebitis, occlusion, thrombosis
206617|NCT01917240|Monophasic
206618|NCT01917240|Sequential
206619|NCT01917240|Media
206620|NCT01917201|Coronary Artery Disease
206621|NCT01917201|Drug Eluting Stents
206622|NCT01917201|Intravascular Ultrasound
206623|NCT01917201|Optical Coherence Tomography
206624|NCT01917201|Intravascular Visualization
206625|NCT01917175|HIV
206626|NCT01917175|Cohort
206627|NCT01917175|Early HIV infection
206628|NCT01917175|Côte d'Ivoire
206629|NCT01917175|Disease progression
206630|NCT01917162|contact lenses
206631|NCT01917162|daily disposable contact lenses
206632|NCT01917162|silicone hydrogel
206633|NCT01917162|contact lens comfort
206634|NCT01917162|near-sighted
206635|NCT01917149|Dilated cardiomyopathy
206636|NCT01917149|High dose ACEI/ARB
206637|NCT01917136|pulmonary hypertension
206638|NCT01917136|right ventricular function
206639|NCT01917136|11C acetate
206640|NCT01917136|FDG
206641|NCT01917136|ranolazine
206642|NCT01917123|L-Citrulline malate,Coronary Heart Disease, Brachial Index
206643|NCT01917084|Passive range of motion
206644|NCT01917084|Single ventricle
206645|NCT01917084|Infants
206646|NCT01917084|Congenital heart disease
206647|NCT01917058|Alopecia Areata
206648|NCT01917058|Abatacept
206649|NCT01917045|sufentanil
206650|NCT01917045|morphine
206651|NCT01917045|postoperative pain control
206652|NCT01917045|body fat percentage
206653|NCT01917045|gynecology laparoscopic surgery
206654|NCT01917045|lipid solubility
206655|NCT01917032|Trace Elements
206656|NCT01917032|Preschool
206657|NCT01917032|Malnutrition
206658|NCT01917032|Fortified Food
206659|NCT01917019|Japan
206660|NCT01916980|Dermatitis
206661|NCT01916980|Dermatitis, Atopic
206662|NCT01916980|Skin Diseases
206663|NCT01916980|Skin Diseases, Genetic
206664|NCT01916980|Genetic Diseases, Inborn
206665|NCT01916980|Skin Diseases, Eczematous
206666|NCT01916980|Hypersensitivity, Immediate
206667|NCT01916980|Hypersensitivity
206668|NCT01916980|Immune System Diseases
206669|NCT01916967|Urticaria
206670|NCT01916967|Skin Diseases, Vascular
206671|NCT01916967|Skin Diseases
206672|NCT01916967|Hypersensitivity, Immediate
206673|NCT01916967|Hypersensitivity
206674|NCT01916967|Immune System Diseases
206675|NCT01916967|Cholinergic Antagonists
206676|NCT01916967|Cholinergic Agents
206677|NCT01916967|Neurotransmitter Agents
206678|NCT01916967|Histamine H1 Antagonists, Non-Sedating
206679|NCT01916967|Histamine H1 Antagonists
206680|NCT01916967|Histamine Antagonists
206681|NCT01916967|Histamine Agents
206682|NCT01916954|Malaria
206683|NCT01916954|Pregnancy
206684|NCT01916954|Plasmodium falciparum
206685|NCT01916928|Circulating cell free fetal DNA
206686|NCT01916928|Intrauterine fetal demise
206687|NCT01916928|Miscarriage
206688|NCT01916902|Optical Coherence Tomography
206689|NCT01916902|Ticagrelor
206690|NCT01916889|Delirium
206691|NCT01916876|medical in-patients
206692|NCT01916876|follow-up care
206693|NCT01916876|developing country
206694|NCT01916837|Breast cancer
206695|NCT01916837|Feasibility
206696|NCT01916837|Genomic grade index
206697|NCT01916824|depression
206698|NCT01916824|melancholia
206699|NCT01916824|treatment
206700|NCT01916811|Low Back Pain
206701|NCT01916811|Load quantitative MRI
206702|NCT01916798|Infertility
206703|NCT01916798|intralipid
206704|NCT01916798|invitro fertilization
206705|NCT01916798|repeated implantation failure
206706|NCT01916798|repeated miscarriage
206707|NCT01916772|cherubism
206708|NCT01916772|bone tumors
206709|NCT01916759|immunization
206710|NCT01916746|Caesarean Scar Pregnancy
206711|NCT01916746|Transvaginal Resection
206712|NCT01916746|treatment
206713|NCT01916707|trauma
206714|NCT01916707|enoxaparin
206715|NCT01916707|weight based
206716|NCT01916707|prophylaxis
206717|NCT01916694|Gestational diabetes mellitus
206718|NCT01916694|m Health
206719|NCT01916694|Smartphone
206720|NCT01916694|Blood glucose monitoring
206721|NCT01916681|Induction
206722|NCT01916681|Labor
206723|NCT01916681|Cervical foley
206724|NCT01916681|Misoprostol
206725|NCT01916681|Pitocin
206726|NCT01916681|Oxytocin
206727|NCT01916681|Cytotec
206728|NCT01916681|Delivery
206729|NCT01916681|IOL
206730|NCT01916655|Obstructive Sleep Apnea
206731|NCT01916655|Adherence
206732|NCT01916655|Chronic Disease
206733|NCT01916655|Telemedicine
206734|NCT01916655|Continuous Positive Airway Pressure
206735|NCT01916655|Mobile Health
206736|NCT01916642|iv lidocaine
206737|NCT01916642|inducing dose
206738|NCT01916642|etomidate
206739|NCT01916642|dose response
206740|NCT01916616|paradoxical vocal fold motion
206741|NCT01916616|cognitive-behavioral therapy
206742|NCT01916590|Post-operative pain
206743|NCT01916590|Anterior Cruciate Ligament repair
206744|NCT01916577|Stem Cell Mobilization
206745|NCT01916577|Stem Cells
206746|NCT01916577|Transplantation
206747|NCT01916577|Autologous
206748|NCT01916564|Bowel preparation
206749|NCT01916564|Morning colonoscopy
206750|NCT01916564|Split-dose
206751|NCT01916564|Same-morning whole-dose
206752|NCT01916564|Reduced-volume PEG-ELS
206753|NCT01916538|anorexia nervosa
206754|NCT01916538|genetics
206755|NCT01916538|gene
206756|NCT01916538|eating disorder
206757|NCT01916525|Acute coronary syndrome
206758|NCT01916525|Cost-effectiveness
206759|NCT01916525|Cardiac rehabilitation
206760|NCT01916525|Exercise
206761|NCT01916525|Physical activity
206762|NCT01916525|Home monitoring
206763|NCT01916512|CETP, HDL, LDL, apoB-100, apoB-48, remnants
206764|NCT01916499|Child, adolescent
206765|NCT01916499|Coronary artery disease
206766|NCT01916499|Magnetic resonance imaging
206767|NCT01916473|Epidural analgesia
206768|NCT01916473|continuous wound infusion
206769|NCT01916473|ropivacaine
206770|NCT01916473|total abdominal hysterectomy
206771|NCT01916460|Gastroparesis
206772|NCT01916460|Endoscopic ultrasound
206773|NCT01916460|Interstitial cell of Cajal
206774|NCT01916447|Angiogenesis Inhibitor
206775|NCT01916447|Monoclonal Antibody
206776|NCT01916447|Vascular Endothelial Growth Factor A (VEGF-A)
206777|NCT01916434|Farmed fish
206778|NCT01916434|Dietary intervention
206779|NCT01916434|Long-term intervention
206780|NCT01916434|Omega-3 index
206781|NCT01916434|Cardiovascular risk markers
206782|NCT01916434|Coagulation and endothelial activation
206783|NCT01916434|Bleeding time
206784|NCT01916434|Inflammation
206785|NCT01916434|Oxidative stress
206786|NCT01916434|Gut health
206787|NCT01916434|Micronutrient availability
206788|NCT01916421|Pancreatic adenocarcinoma
206789|NCT01916421|lymphadenopathy
206790|NCT01916421|Endoscopic ultrasound
206791|NCT01916408|Exercise
206792|NCT01916408|Inflammation
206793|NCT01916408|Upper Respiratory Tract Illness
206794|NCT01916408|Oral Proteolytic and Hydrolytic Enzymes
206795|NCT01916408|Flavinoids
206796|NCT01916395|Migraine
206797|NCT01916382|Alkaptonuria, nitisinone,Ochronosis, Homogentisic acid
206798|NCT01916369|Peripheral Arterial Disease
206799|NCT01916369|Fontaine Stage II, III or IV
206800|NCT01916369|Vascular disease
206801|NCT01916369|Cardiovascular diseases
206802|NCT01916369|Neural stem cell
206803|NCT01916356|Infertility
206804|NCT01916356|Education
206805|NCT01916356|Risk Factors
206806|NCT01916356|Fertility knowledge
206807|NCT01916356|Fertility myths
206808|NCT01916343|Laparoscopy
206809|NCT01916343|Surgical skills
206810|NCT01916343|Team training
206811|NCT01916343|Obstetrics and Gynecology
206812|NCT01916343|Curriculum
206813|NCT01916304|Drug Therapy
206814|NCT01916252|Multiple Myeloma
206815|NCT01916252|MEL200
206816|NCT01916252|BUMEL
206817|NCT01916239|Pomegranate
206818|NCT01916239|Urolithins
206819|NCT01916239|Colorectal cancer
206820|NCT01916239|Colon cancer
206821|NCT01916239|Metabolite
206822|NCT01916239|Gene expression
206823|NCT01916239|microRNA
206824|NCT01916239|Nutraceutical
206825|NCT01916239|Food supplement
206826|NCT01916239|Polyphenol
206827|NCT01916239|Gut microbiota
206828|NCT01916226|cetirizine
206829|NCT01916226|seasonal allergic rhinitis
206830|NCT01916226|Quality of Life
206831|NCT01916226|fluticasone propionate nasal spray
206832|NCT01916161|Crohn's disease
206833|NCT01916161|ulcerative colitis
206834|NCT01916161|anxiety
206835|NCT01916161|patient knowledge
206836|NCT01916161|information sources
206837|NCT01916148|Hypoglycemia
206838|NCT01916148|Hyperinsulinism
206839|NCT01916135|[18F]-SKI-249380
206840|NCT01916135|PET Imaging
206841|NCT01916135|CT Imaging
206842|NCT01916135|12-182
206843|NCT01916122|Fluorestradiol (FES)
206844|NCT01916122|PET/CT scan
206845|NCT01916122|Estrogen Receptor
206846|NCT01916122|13-071
206847|NCT01916109|Gemcitabine
206848|NCT01916109|Carboplatin
206849|NCT01916109|Panitumumab
206850|NCT01916109|(GCaP)
206851|NCT01916109|radical cystectomy
206852|NCT01916109|10-103
206853|NCT01916070|syncope
206854|NCT01916070|near syncope
206855|NCT01916070|prognosis
206856|NCT01916070|emergency department
206857|NCT01916057|Positron-Emission Tomography Scan
206858|NCT01916057|Fluorodeoxyglucose F18
206859|NCT01916057|Magnetic Resonance Imaging
206860|NCT01916057|Enzyme-Linked Immunospot Assay
206861|NCT01916057|Immune Reconstitution Inflammatory Syndrome
206862|NCT01916057|Real-Time Polymerase Chain Reaction
206863|NCT01916057|beta-1,3-D-glucan
206864|NCT01916057|Candida spp.
206865|NCT01916057|Genetic Susceptibility
206866|NCT01916057|Genotype
206867|NCT01916044|caesarean,
206868|NCT01916044|trial of labor,
206869|NCT01916044|ultrasound
206870|NCT01916018|Congenital hypothyroidism
206871|NCT01916018|Thyroid dysgenesis
206872|NCT01916018|Genetics
206873|NCT01916018|Associated malformations
206874|NCT01916018|Psychomotor delay
206875|NCT01916018|Mental retardation
206876|NCT01915979|plasma rich in growth factors, tendinopathy, traumatology
206877|NCT01915979|,rotator cuff, effectiveness, plasma rich in platelets
206878|NCT01915953|Accurte Hb noninvasive measurement
206879|NCT01915940|Glaucoma
206880|NCT01915940|Primary Open-Angle Glaucoma
206881|NCT01915940|Ocular Hypertension
206882|NCT01915888|Clinical
206883|NCT01915888|Children
206884|NCT01915888|Rotavirus
206885|NCT01915888|Cost
206886|NCT01915888|Rotarix vaccination
206887|NCT01915875|Cystic fibrosis-pain-sophrology
206888|NCT01915862|Acute ischemic stroke
206889|NCT01915862|Blood pressure variability
206890|NCT01915862|Ambulatory arterial stiffness index
206891|NCT01915862|Ambulatory blood pressure monitoring
206892|NCT01915862|Outcome
206893|NCT01915836|11-043
206894|NCT01915836|MSKCC Tobacco Cessation Program
206895|NCT01915810|Tobacco Use Cessation
206896|NCT01915810|Smoking Cessation with Physical Activity
206897|NCT01915810|SCwPA
206898|NCT01915810|Cancer Prevention
206899|NCT01915810|African American cigarette smoker
206900|NCT01915810|Questionnaires
206901|NCT01915810|Surveys
206902|NCT01915810|Phone Counseling
206903|NCT01915810|Breath Test
206904|NCT01915810|Walking Program
206905|NCT01915810|Nicotine Patch
206906|NCT01915810|Audio Recorded Focus Group
206907|NCT01915797|Pediatric patients, tumor, developmental abnormalities
206908|NCT01915745|Osteoporosis
206909|NCT01915745|Bone densitometry
206910|NCT01915745|Fracture
206911|NCT01915745|Anti-osteoporotic treatment
206912|NCT01915745|Short message service
206913|NCT01915706|Glaucoma drainage device
206914|NCT01915706|Baerveldt 350
206915|NCT01915706|Ripcord
206916|NCT01915706|Complications
206917|NCT01915693|Radiotherapy
206918|NCT01915693|stent
206919|NCT01915693|quality of life
206920|NCT01915654|Cardiac surgery
206921|NCT01915654|Transfusion
206922|NCT01915641|walking capacity
206923|NCT01915641|COPD
206924|NCT01915641|OSA
206925|NCT01915641|CPAP
206926|NCT01915628|MACE
206927|NCT01915628|Safety
206928|NCT01915628|Efficacy
206929|NCT01915628|On label
206930|NCT01915628|Myocardial Infarction
206931|NCT01915628|Cardiac death
206932|NCT01915628|TVR
206933|NCT01915628|stent thrombosis
206934|NCT01915615|Hypertrophic cardiomyopathy
206935|NCT01915615|Cardiac magnetic resonance imaging
206936|NCT01915615|CMR
206937|NCT01915615|Genetics
206938|NCT01915615|Biomarkers
206939|NCT01915615|Late gadolinium enhancement
206940|NCT01915615|T1 mapping
206941|NCT01915602|Hepatocellular Carcinoma
206942|NCT01915602|Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor
206943|NCT01915602|Sorafenib
206944|NCT01915602|Objective tumor response rate (ORR)
206945|NCT01915602|modified RECIST criteria
206946|NCT01915589|Hepatocellular Carcinoma
206947|NCT01915589|Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor
206948|NCT01915589|Objective tumor response rate (ORR)
206949|NCT01915589|modified RECIST criteria
206950|NCT01915563|Mechanical ventilation
206951|NCT01915563|Weaning
206952|NCT01915563|Extubation failure
206953|NCT01915550|Diabetes mellitus
206954|NCT01915550|Pregnancy
206955|NCT01915550|Insulin
206956|NCT01915550|Metformin
206957|NCT01915537|poor prognosis
206958|NCT01915537|severe RA
206959|NCT01915537|infliximab
206960|NCT01915511|Idiopathic pulmonary fibrosis
206961|NCT01915511|Pulmonary fibrosis
206962|NCT01915511|IPF
206963|NCT01915511|Registry
206964|NCT01915511|1199.174
206965|NCT01915498|acute myeloid leukemia
206966|NCT01915498|AML
206967|NCT01915498|myelodysplastic syndrome
206968|NCT01915498|MDS
206969|NCT01915498|hematologic malignancies
206970|NCT01915498|IDH2
206971|NCT01915498|Phase I
206972|NCT01915498|Phase II
206973|NCT01915498|AG-221
206974|NCT01915498|relapse AML
206975|NCT01915498|refractory AML
206976|NCT01915472|Metastatic Colorectal Cancer
206977|NCT01915472|Colorectal Cancer
206978|NCT01915472|Rectal Cancer
206979|NCT01915472|previously treated
206980|NCT01915459|Stroke
206981|NCT01915459|Spasticity
206982|NCT01915446|EVAR
206983|NCT01915446|endovascular aortic repair
206984|NCT01915446|acute kidney failure
206985|NCT01915446|mesenteric ischemia
206986|NCT01915433|Secondary Progressive Multiple Sclerosis
206987|NCT01915433|Primary Progressive Multiple Sclerosis
206988|NCT01915433|Relapsing progressive multiple sclerosis
206989|NCT01915433|relapsing remitting multiple sclerosis
206990|NCT01915433|Fatigue
206991|NCT01915433|Quality of life
206992|NCT01915433|Paleo
206993|NCT01915433|Nutrition
206994|NCT01915433|Ketogenic
206995|NCT01915420|Drug eluting stent
206996|NCT01915420|Bioabsorbable
206997|NCT01915420|Bioresorbable
206998|NCT01915420|Coronary Stent
206999|NCT01915420|Scaffold
207000|NCT01915420|Stents
207001|NCT01915420|Angioplasty
207002|NCT01915420|Coronary Artery Disease
207003|NCT01915420|Stentthrombosis
207004|NCT01915420|Rotational atherectomy
207005|NCT01915394|Respiratory Syncytial Virus Infections
207006|NCT01915394|Epidemics
207007|NCT01915394|Neonatal Intensive Care Unit
207008|NCT01915394|Newborn infants
207009|NCT01915381|Intellectual disability
207010|NCT01915381|mHealth
207011|NCT01915381|App
207012|NCT01915381|Physical activity
207013|NCT01915381|Adherence
207014|NCT01915368|Exercise
207015|NCT01915368|Rehabilitation
207016|NCT01915368|Dose
207017|NCT01915368|Randomized controlled trial
207018|NCT01915368|Stroke
207019|NCT01915355|onychomycosis
207020|NCT01915355|nail
207021|NCT01915355|fungus
207022|NCT01915342|Monosynaptic reflex
207023|NCT01915342|H-reflex
207024|NCT01915329|CRPS
207025|NCT01915329|repetitive sensory stimulation
207026|NCT01915329|cortical reorganization
207027|NCT01915329|2-point-discrimination
207028|NCT01915303|Cushing's disease, pituitary tumors, pasireotide, cabergoline, combination treatment, UFC, hormone disorder, cortisol, adrenocorticotropic hormone
207029|NCT01915290|physical activity
207030|NCT01915290|maximal oxygen uptake
207031|NCT01915277|Pediatric corrective cardiac surgery
207032|NCT01915264|Diabetes Mellitus
207033|NCT01915264|Type 2 Diabetes
207034|NCT01915264|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination
207035|NCT01915251|Vulvovaginal Candidiasis
207036|NCT01915251|Amoxicilin
207037|NCT01915251|Microbiome
207038|NCT01915238|Age-Related Macular Degeneration (AMD)
207039|NCT01915238|AMD
207040|NCT01915225|Tissue Procurement
207041|NCT01915225|Surgery
207042|NCT01915225|Metastasectomy
207043|NCT01915212|Vaccination
207044|NCT01915212|Replication-Defective
207045|NCT01915212|Genital Herpes
207046|NCT01915212|Safety
207047|NCT01915212|Immune Responses
207048|NCT01915186|DHEA
207049|NCT01915186|Poor ovarian reserve
207050|NCT01915186|Normal ovarian reserve
207051|NCT01915186|In vitro fertilization treatment
207052|NCT01915186|Ovarian response
207053|NCT01915186|Pregnancy outcomes
207054|NCT01915173|Gastroesophageal reflux disease (GERD)
207055|NCT01915173|Heartburn
207056|NCT01915173|Dyspepsia
207057|NCT01915147|oxycodone naloxone combination
207058|NCT01915147|severe chronic pain
207059|NCT01915147|non-malignant pain
207060|NCT01915147|Non-malignant pain that requires around-the-clock opioid therapy
207061|NCT01915134|nasopharyngeal carcinoma
207062|NCT01915134|Recombinant Human Endostatin
207063|NCT01915134|chemotherapy
207064|NCT01915134|gemcitabine and cisplatin
207065|NCT01915121|Bladder Cancer
207066|NCT01915121|Intervention
207067|NCT01915121|Education
207068|NCT01915121|Randomized Controlled Trials
207069|NCT01915095|spinal cord injury
207070|NCT01915095|neural control
207071|NCT01915095|motor function
207072|NCT01915095|hand movement
207073|NCT01915082|Lung Function
207074|NCT01915082|Allograft Outcome
207075|NCT01915069|contraception
207076|NCT01915069|Cilostazol
207077|NCT01915069|phosphodiesterase inhibitors
207078|NCT01915069|To assess the ability of Cilostazol to act as a contraceptive agent
207079|NCT01915056|Comprehensive Geriatric Assessment (CGA)
207080|NCT01915056|GA-driven interventions
207081|NCT01915056|Toxicity
207082|NCT01915056|Outcomes
207083|NCT01915056|providing information
207084|NCT01915056|older cancer patients
207085|NCT01915056|first-line chemotherapy
207086|NCT01915056|second-line chemotherapy
207087|NCT01915043|lymphedema, prevention, ehealth, cancer
207088|NCT01915030|Muscle
207089|NCT01915030|Physical performance
207090|NCT01915030|Protein
207091|NCT01915030|Diet
207092|NCT01915030|Caloric restriction
207093|NCT01915017|Cognitive Adaptation Training
207094|NCT01915017|Cognitive Behavior Therapy for Psychosis
207095|NCT01915017|Schizophrenia
207096|NCT01915004|Pediatric Urology
207097|NCT01915004|Urotherapy
207098|NCT01915004|Nonneurogenic Lower Urinary Tract Dysfunction
207099|NCT01915004|Dysfunctional Elimination Syndrome
207100|NCT01915004|Randomized Controlled Trial
207101|NCT01914991|proximal interphalangeal joint
207102|NCT01914991|Orthoses
207103|NCT01914965|Huntington's disease
207104|NCT01914965|Apathy
207105|NCT01914965|Bupropion
207106|NCT01914952|CaHMB
207107|NCT01914952|HMB free acid
207108|NCT01914952|HMB
207109|NCT01914939|autism spectrum disorder
207110|NCT01914939|social skills deficits
207111|NCT01914939|cognitive behavioral therapy
207112|NCT01914939|oxytocin
207113|NCT01914939|young adult
207114|NCT01914926|metoprolol
207115|NCT01914926|diltiazem
207116|NCT01914926|heart rate
207117|NCT01914913|retinitis pigmentosa
207118|NCT01914913|Bone marrow
207119|NCT01914913|stem cell
207120|NCT01914913|BMMNC
207121|NCT01914900|oral cavity cancer
207122|NCT01914900|induction chemotherapy
207123|NCT01914900|TP53
207124|NCT01914900|beta tubulin II
207125|NCT01914887|Ulcerative Colitis
207126|NCT01914887|Inflammatory Bowel Disease
207127|NCT01914887|Mesenchymal stem cells
207128|NCT01914874|Community Sample
207129|NCT01914835|cocaine dependence
207130|NCT01914835|neuropsychological rehabilitation
207131|NCT01914835|executive functions
207132|NCT01914822|Ritalin
207133|NCT01914822|methylphenidate hydrochloride
207134|NCT01914822|experimental pain
207135|NCT01914796|Phase 1
207136|NCT01914796|Randomized
207137|NCT01914796|Double Blind
207138|NCT01914796|Placebo-Controlled
207139|NCT01914796|Single-Dose Escalation
207140|NCT01914796|Safety
207141|NCT01914796|Tolerability
207142|NCT01914796|PK
207143|NCT01914796|PD
207144|NCT01914796|PF-06412562
207145|NCT01914783|air pollution
207146|NCT01914783|ozone
207147|NCT01914783|fine particle
207148|NCT01914783|cytokine
207149|NCT01914783|chemokine
207150|NCT01914783|oxidative stress
207151|NCT01914783|inflammation
207152|NCT01914783|heart rate variability
207153|NCT01914783|autonomic nervous system
207154|NCT01914783|sympathetic nerve activity
207155|NCT01914783|plasma catecholamine
207156|NCT01914770|pooled analyses
207157|NCT01914770|quality of life
207158|NCT01914770|SELENA SLEDAI
207159|NCT01914770|SLE
207160|NCT01914770|steroid use
207161|NCT01914770|responder rate
207162|NCT01914770|flares
207163|NCT01914770|belimumab
207164|NCT01914770|BILAG
207165|NCT01914757|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
207166|NCT01914744|NHL
207167|NCT01914744|HBV
207168|NCT01914744|entecavir
207169|NCT01914744|lamivudine
207170|NCT01914731|Fecal Microbiota Transplant
207171|NCT01914731|Clostridium difficile
207172|NCT01914731|Diarrhea
207173|NCT01914718|DLBCL
207174|NCT01914718|DA-EPOCH-R
207175|NCT01914705|Landmark
207176|NCT01914705|Ultrasound
207177|NCT01914705|central venous catheter
207178|NCT01914679|Fibromyalgia
207179|NCT01914679|Pain
207180|NCT01914679|Brain
207181|NCT01914679|Stimulation
207182|NCT01914679|Device
207183|NCT01914679|Treatment
207184|NCT01914666|Chronic Low Back Pain
207185|NCT01914666|CLBP
207186|NCT01914640|Waist circumference, Metabolic Syndrome, Cardiovascular risk
207187|NCT01914627|Psoriasis capitis
207188|NCT01914627|Scaling
207189|NCT01914627|Salicylic acid
207190|NCT01914627|Dimethicone
207191|NCT01914627|Plaque removal
207192|NCT01914614|Breast Cancer
207193|NCT01914614|Working Women
207194|NCT01914601|Laryngoscope
207195|NCT01914601|Macintosh
207196|NCT01914601|King Vision
207197|NCT01914601|tracheal intubation
207198|NCT01914601|cervical spines
207199|NCT01913938|Hemophagocytosis, adults, rhG-CSF
207200|NCT01913899|phantom limb pain
207201|NCT01913899|mirror therapy
207202|NCT01913899|amputees
207203|NCT01913899|phantom limb
207204|NCT01913899|occupational therapy
207205|NCT01913886|Cardiovascular Diseases
207206|NCT01913886|Myocardial Ischemia
207207|NCT01913886|Coronary Artery Disease
207208|NCT01913886|Heart Diseases
207209|NCT01913886|Coronary Disease
207210|NCT01913886|Ventricular Dysfunction
207211|NCT01913886|Arteriosclerosis
207212|NCT01913873|High-sensitivity Cardiac Troponin
207213|NCT01913873|Creatinin Kinase MB
207214|NCT01913873|Cardiac Surgery
207215|NCT01913873|Myocardial injury
207216|NCT01913873|Myocardial infarction
207217|NCT01913873|Concentration change
207218|NCT01913860|UTI
207219|NCT01913860|antibiotics
207220|NCT01913860|prescribing
207221|NCT01913860|primary care
207222|NCT01913834|Parathyroid hormone 1-34
207223|NCT01913808|Postoperative anemia
207224|NCT01913808|Total knee arthroplasty
207225|NCT01913808|Iron therapy
207226|NCT01914536|POMPE
207227|NCT01914536|Glycogenosis type II
207228|NCT01914536|Acid maltase deficiency
207229|NCT01914523|Laryngoscope
207230|NCT01914523|Macintosh
207231|NCT01914523|Glidescope
207232|NCT01914523|King Vision
207233|NCT01914523|AirTraq
207234|NCT01914523|tracheal intubation
207235|NCT01914510|ovarian
207236|NCT01914510|cancer
207237|NCT01914510|clear cell
207238|NCT01914510|ENMD-2076
207239|NCT01914510|oral
207240|NCT01914510|capsule
207241|NCT01914484|tyrosine kinase inhibitor resistance
207242|NCT01914484|chronic myeloid leukemia
207243|NCT01914484|acute lymphoblastic leukemia
207244|NCT01914484|nilotinib
207245|NCT01914484|ruxolitinib
207246|NCT01914458|Lung cancer
207247|NCT01914458|Low-dose computed tomography scan
207248|NCT01914419|Postpartum hemorrhage
207249|NCT01914419|Oxytocin
207250|NCT01914419|Prevention
207251|NCT01914419|Third stage of labor
207252|NCT01914419|Hemoglobin
207253|NCT01914419|Intravenous
207254|NCT01914419|Intramuscular
207255|NCT01914419|Bolus
207256|NCT01914406|Heart transplant recipients
207257|NCT01914406|Exercise capacity
207258|NCT01914406|endothelial function
207259|NCT01914406|Quality of life
207260|NCT01914393|Schizophrenia
207261|NCT01914393|Autism
207262|NCT01914393|Lurasidone
207263|NCT01914393|Latuda
207264|NCT01914380|Wet age-related macular degeneration
207265|NCT01914380|Anti-VEGF-Therapy
207266|NCT01914380|Observational study
207267|NCT01914354|T cells
207268|NCT01914354|Human Alloimmune Reactivity
207269|NCT01914354|immunosuppression
207270|NCT01914341|Infant
207271|NCT01914341|Newborn
207272|NCT01914341|Music
207273|NCT01914328|Postoperative Pulmonary Complications
207274|NCT01914328|PORC
207275|NCT01914328|Surgical Related Outcome
207276|NCT01914328|Surgical Related Mortality
207277|NCT01914328|Postoperative ICU length of stay
207278|NCT01914315|Rehabilitation
207279|NCT01914315|Heart failure
207280|NCT01914315|HFPEF
207281|NCT01914315|Exercise training
207282|NCT01914289|Intrahepatic Cholangiocarcinoma
207283|NCT01914289|Prognosis
207284|NCT01914289|Resection
207285|NCT01914289|Radiotherapy
207286|NCT01914263|Cord blood-Derived cytokine induced killer cells,
207287|NCT01914263|Radical resection
207288|NCT01914250|Frenotomy
207289|NCT01914250|Pain
207290|NCT01914237|Single-Branched Stent Graft System
207291|NCT01914237|Aortic Dissection
207292|NCT01914237|Endovascular Repair
207293|NCT01914224|Prehypertension
207294|NCT01914224|Hypertension
207295|NCT01914224|Sodium
207296|NCT01914224|Potassium
207297|NCT01914224|renin
207298|NCT01914224|aldosterone
207299|NCT01914198|sleep study
207300|NCT01914198|NCH
207301|NCT01914185|Childhood
207302|NCT01914185|Physical activity
207303|NCT01914185|Nutrition
207304|NCT01914185|Health Promotion
207305|NCT01914172|rare disease
207306|NCT01914172|community-based participatory research
207307|NCT01914172|health promotion
207308|NCT01914172|quantitative research
207309|NCT01914172|qualitative research
207310|NCT01914172|focus group
207311|NCT01914146|Diabetes
207312|NCT01914146|Insulin
207313|NCT01914146|Orthostatic Hypotension
207314|NCT01914146|Falls
207315|NCT01914146|Syncope
207316|NCT01914133|Acarbose
207317|NCT01914133|PPH (Post Prandial Hypotension)
207318|NCT01914133|Falls
207319|NCT01914133|Syncope
207320|NCT01914133|Elderly
207321|NCT01914120|lung cancer
207322|NCT01914120|quality of life
207323|NCT01914120|FACT-L
207324|NCT01914107|malignancy
207325|NCT01914107|solid tumor
207326|NCT01914107|cancer pain
207327|NCT01914094|Preoperative care
207328|NCT01914094|Exercise therapy
207329|NCT01914094|Cardiac surgery
207330|NCT01914081|Non-ischemic cardiomyopathy
207331|NCT01914081|Resveratrol
207332|NCT01914068|Neoadjuvant chemoradiotherapy (NACRT)
207333|NCT01914068|Rectal cancer
207334|NCT01914068|Physical fitness
207335|NCT01914068|Exercise programme
207336|NCT01914068|Surgery
207337|NCT01914068|Stage III/IV
207338|NCT01914068|Locally advanced operable
207339|NCT01914068|patients
207340|NCT01914042|Opioid induced hyperalgesia
207341|NCT01914042|Neuropathic pain
207342|NCT01914042|Opioids
207343|NCT01914042|Sciatica
207344|NCT01914042|Serotonin-norepinephrine reuptake inhibitor (SNRI)
207345|NCT01913990|Nausea
207346|NCT01913990|Vomiting
207347|NCT01913782|Chronic low back pain, CLBC, fMRI
207348|NCT01913769|post-RT
207349|NCT01913769|myocardial perfusion images
207350|NCT01913743|fMRI
207351|NCT01913743|cognitive strategies
207352|NCT01913743|obesity
207353|NCT01913743|weight loss
207354|NCT01913743|mindsets
207355|NCT01913730|Multiple Myeloma
207356|NCT01913730|Refractory
207357|NCT01913730|Relapsed
207358|NCT01913717|Prostate cancer
207359|NCT01913717|Radiotherapy
207360|NCT01913717|hypofractionated radiotherapy
207361|NCT01913704|venous leg ulcer
207362|NCT01913704|mixed aetiology leg ulcers
207363|NCT01913691|Neuroendocrine Skin Cancer
207364|NCT01913691|Merkel Cell Polyomavirus
207365|NCT01913691|Immunotherapy
207366|NCT01913652|dedifferentiated liposarcoma
207367|NCT01913652|cabazitaxel
207368|NCT01913652|ifosfamide
207369|NCT01913639|BAY 73-4506 (REGORAFENIB)
207370|NCT01913639|FLUOROURACIL
207371|NCT01913639|LEUCOVORIN
207372|NCT01913639|OXALIPLATIN
207373|NCT01913626|subjective memory complains
207374|NCT01913600|TARGET LESION REVASCULARIZATION (TLR)
207375|NCT01913600|TARGET VESSEL REVASCULARIZATION (TVR)
207376|NCT01913600|Coronary Artery Disease
207377|NCT01913600|MYOCARDIAL INFARCTION (MI)
207378|NCT01913600|PERCUTANEOUS CORONARY INTERVENTION (PCI)
207379|NCT01913600|STENT THROMBOSIS
207380|NCT01913600|TARGET LESION FAILURE (TLF)
207381|NCT01913561|Electrocardiogram
207382|NCT01913561|gel electrodes
207383|NCT01913561|textile electrodes
207384|NCT01913535|Depression
207385|NCT01913535|Treatment Resistant Depression
207386|NCT01913535|Antidepressant
207387|NCT01913535|Major Depression
207388|NCT01913535|MDD
207389|NCT01913509|hemiplegic shoulder pain
207390|NCT01913509|poststroke fatigue
207391|NCT01913509|functional electrical stimulation
207392|NCT01913509|stroke rehabilitation
207393|NCT01913496|web application
207394|NCT01913496|nutrition knowledge
207395|NCT01913496|physical activity
207396|NCT01913470|NAFLD
207397|NCT01913470|Non-alcoholic Fatty Liver Disease
207398|NCT01913470|Obesity
207399|NCT01913470|Pediatrics
207400|NCT01913470|Children
207401|NCT01913470|Losartan
207402|NCT01913470|Cozaar
207403|NCT01913457|Ultrasound Doppler
207404|NCT01913457|Lungs
207405|NCT01913457|Pulmonary artery hypertension
207406|NCT01913444|Recombinant Antithrombin
207407|NCT01913444|ATryn
207408|NCT01913444|Pharmacokinetics
207409|NCT01913444|ECMO
207410|NCT01913444|Neonates
207411|NCT01913418|Traditional Chinese Medicine
207412|NCT01913418|Suan-Zao-Ren Tang
207413|NCT01913418|Methadone
207414|NCT01913418|Opiate dependence
207415|NCT01913418|Sleep
207416|NCT01913379|Phase 1
207417|NCT01913379|MDV3100
207418|NCT01913379|Gemfibrozil
207419|NCT01913379|Itraconazole
207420|NCT01913379|Xtandi
207421|NCT01913379|enzalutamide
207422|NCT01913340|erythropoietin
207423|NCT01913340|therapeutic hypothermia
207424|NCT01913327|cognition
207425|NCT01913327|executive function
207426|NCT01913327|prefrontal cortex
207427|NCT01913327|locus coeruleus
207428|NCT01913288|neonatal care, preterm, maternal sounds, auditory stimulation
207429|NCT01913275|cholecystojejunostomy
207430|NCT01913275|whipple's pancreaticoduodenectomy
207431|NCT01913275|endoscopic stenting
207432|NCT01913275|hyperbilirubinemia
207433|NCT01913262|depression
207434|NCT01913262|phq9
207435|NCT01913262|phq-9
207436|NCT01913262|standard treatment
207437|NCT01913249|Anorectal fistula
207438|NCT01913249|LIFT
207439|NCT01913249|Seton
207440|NCT01913236|Tailored implementation interventions
207441|NCT01913236|Primary care
207442|NCT01913236|Depression in the elderly
207443|NCT01913223|Endoscopic submucosal dissection
207444|NCT01913223|jet injector
207445|NCT01913223|saline solution
207446|NCT01913223|safety
207447|NCT01913223|effectiveness
207448|NCT01913197|Prostate Brachytherapy
207449|NCT01913119|extranodal NKTcell lymphoma
207450|NCT01913093|Childhood leukemia survivors
207451|NCT01913093|Acute lymphoblastic leukemia
207452|NCT01913093|Leukemia
207453|NCT01913093|Late effects
207454|NCT01913093|Folate
207455|NCT01913093|Blood folate
207456|NCT01913093|Neurotoxicity
207457|NCT01913093|Methotrexate
207458|NCT01913093|Pharmacogenetics
207459|NCT01913093|Cognitive
207460|NCT01913093|Cognitive late effects
207461|NCT01913093|N-PhenoGENICS
207462|NCT01913080|health management
207463|NCT01913067|brain metastasis
207464|NCT01913067|breast cancer
207465|NCT01913067|HER2 negative
207466|NCT01913067|NSCLC
207467|NCT01913054|Etomidate
207468|NCT01913054|Propofol
207469|NCT01913054|Painless gastroscopy
207470|NCT01913041|perioperative hypothermia
207471|NCT01913041|Epidemiology
207472|NCT01913041|Tympanic temperature
207473|NCT01913028|safety, tolerability, pharmacokinetics,immunogenicity, MEDI9929, Japanese
207474|NCT01912989|motivational interviewing
207475|NCT01912989|obesity
207476|NCT01912989|parent
207477|NCT01912976|Bowen's disease
207478|NCT01912976|Er:YAG
207479|NCT01912976|AFL-assisted
207480|NCT01912976|MAL-PDT
207481|NCT01912963|HER-2 Positive Breast Cancer
207482|NCT01912950|intense pulsed light
207483|NCT01912950|IPL
207484|NCT01912950|healthy volunteer
207485|NCT01912950|light-based hair removal
207486|NCT01912950|hair removal
207487|NCT01912950|epilation
207488|NCT01912950|laser hair removal
207489|NCT01912950|permanent hair reduction
207490|NCT01912937|Paclitaxel
207491|NCT01912937|Percutaneous Transluminal Angioplasty
207492|NCT01912937|Balloon Catheter
207493|NCT01912937|Pharmacokinetic
207494|NCT01912937|Peripheral Artery Disease
207495|NCT01912937|PAD
207496|NCT01912924|chronic pain from failed knee surgery
207497|NCT01912846|End-of-life care
207498|NCT01912846|Preference of end-of-life care
207499|NCT01912846|RCT
207500|NCT01912846|Terminally ill cancer patients
207501|NCT01912833|postpartum depression
207502|NCT01912807|Postoperative vomiting
207503|NCT01912807|Children
207504|NCT01912794|Cerebrovascular Accident
207505|NCT01912794|Rehabilitation
207506|NCT01912794|Sensory System
207507|NCT01912781|contact lenses
207508|NCT01912781|contact lens solution
207509|NCT01912781|gas permeable contact lenses
207510|NCT01912768|contact lenses
207511|NCT01912768|contact lens solution
207512|NCT01912768|soft contact lenses
207513|NCT01912755|Pulpitis
207514|NCT01912755|Hot tooth
207515|NCT01912755|Articaine
207516|NCT01912755|Lidocaine
207517|NCT01912755|Local anesthetics
207518|NCT01912742|Weight loss
207519|NCT01912742|Speed of weight loss
207520|NCT01912742|Metabolic compensation
207521|NCT01912742|Diet therapy
207522|NCT01912729|Depression prevention
207523|NCT01912729|Technology Assisted
207524|NCT01912729|Adolescents
207525|NCT01912729|Peer networked
207526|NCT01912716|pancreatitis
207527|NCT01912716|ERCP
207528|NCT01912677|hypertension in pregnancy
207529|NCT01912677|preeclampsia
207530|NCT01912677|anti-hypertension
207531|NCT01912677|labetalol
207532|NCT01912677|nifedipine
207533|NCT01912677|methyldopa
207534|NCT01912664|Depression
207535|NCT01912664|Web-based Intervention
207536|NCT01912651|facial skin wound
207537|NCT01912651|facial wound
207538|NCT01912651|skin wound
207539|NCT01912651|facial defect
207540|NCT01912651|reconstructive skin graft
207541|NCT01912638|Trabeculectomy
207542|NCT01912638|Glaucoma
207543|NCT01912638|Steroids
207544|NCT01912638|Ologen
207545|NCT01912638|Viscoelastic
207546|NCT01912612|Breast cancer
207547|NCT01912612|Pain sensitivity
207548|NCT01912599|Glaucoma
207549|NCT01912599|Intraocular Pressure
207550|NCT01912599|Blood Pressure
207551|NCT01912586|erectile dysfunction
207552|NCT01912586|laparoscopic surgery
207553|NCT01912586|rectal cancer
207554|NCT01912586|sildenafil
207555|NCT01912586|vacuum erection device
207556|NCT01912573|heroin
207557|NCT01912573|prescription pain killers
207558|NCT01912573|narcotics
207559|NCT01912534|Sarcomere Mutations
207560|NCT01912521|HIV
207561|NCT01912521|Stigma
207562|NCT01912521|Social support
207563|NCT01912521|Social network
207564|NCT01912521|Kenya
207565|NCT01912508|cervical length
207566|NCT01912508|cervical curvature
207567|NCT01912469|Muscle
207568|NCT01912469|exercise
207569|NCT01912469|soreness
207570|NCT01912469|Damage
207571|NCT01912469|Traumeel
207572|NCT01912456|Hereditary Angioedema
207573|NCT01912430|Integrated Care Coaching
207574|NCT01912430|Chronic Care Coaching
207575|NCT01912430|Care Coaching
207576|NCT01912417|HEMODIALYSIS
207577|NCT01912417|Kidney Failure, Chronic
207578|NCT01912417|AEROBIC EXERCISE
207579|NCT01912404|alcoholic hepatitis
207580|NCT01912391|Depression
207581|NCT01912391|Anxiety
207582|NCT01912391|Headaches
207583|NCT01912391|Migraines
207584|NCT01912391|Irritable Bowel Syndrome IBS
207585|NCT01912391|Neurodermatitis
207586|NCT01912391|Fibromyalgia
207587|NCT01912391|Premenstrual Syndrome PMS
207588|NCT01912391|Temporomandibular Joint Dysfunction TMJ
207589|NCT01912365|Fracture
207590|NCT01912365|Supracondylar
207591|NCT01912365|Pediatric
207592|NCT01912365|Orthopedic
207593|NCT01912352|ADHD
207594|NCT01912352|ADRA2A
207595|NCT01912352|Methylphenidate
207596|NCT01912352|Response
207597|NCT01912339|Hyperlasia
207598|NCT01912339|Retention
207599|NCT01912339|Prostate
207600|NCT01912326|pacemaker
207601|NCT01912326|atrial fibrillation
207602|NCT01912313|IBS patients
207603|NCT01912313|healthy subjects
207604|NCT01912287|Generalized Anxiety Disorder
207605|NCT01912287|GAD
207606|NCT01912287|Yoga
207607|NCT01912287|CBT
207608|NCT01912274|AML
207609|NCT01912274|open label
207610|NCT01912274|nonrandomized
207611|NCT01912274|single arm
207612|NCT01912274|elderly patients
207613|NCT01912274|HMA
207614|NCT01912274|newly diagnosed
207615|NCT01912261|Coronary artery bypass gafting
207616|NCT01912261|Anemia
207617|NCT01912261|Postoperative fatigue
207618|NCT01912261|Functional Capacity
207619|NCT01912261|Iron
207620|NCT01912261|Adherence
207621|NCT01912248|acute rise of systolic and diastolic bloodpressure
207622|NCT01912235|Arginine synthesis
207623|NCT01912235|15N2 arginine, 1-13C Glutamine, 2-15N Glutamine, 15N Proline
207624|NCT01912209|employees
207625|NCT01912209|metabolic syndrome
207626|NCT01912209|obesity
207627|NCT01912209|sub-clinical cardiovascular disease
207628|NCT01912209|weight loss
207629|NCT01912209|diet
207630|NCT01912196|Depressive Disorder
207631|NCT01912183|pediatric obesity
207632|NCT01912183|e-learning
207633|NCT01912183|personal health record
207634|NCT01912183|personal electronic device
207635|NCT01912183|pilot
207636|NCT01912170|omega-3 fatty acid
207637|NCT01912170|gestational diabetes
207638|NCT01912170|insulin sensitivity
207639|NCT01912131|13-120
207640|NCT01912118|Nociception
207641|NCT01912118|General anesthesia
207642|NCT01912105|endotracheal tube
207643|NCT01912105|ct scan
207644|NCT01912105|cleaning device
207645|NCT01912105|biofilm
207646|NCT01912105|mechanical ventilation
207647|NCT01912053|Intra-hepatic Cholangiocarcinoma treatment
207648|NCT01912040|Safety profile
207649|NCT01912040|locally produced 123 Iodine MIBG
207650|NCT01912014|stroke
207651|NCT01912014|psychosocial
207652|NCT01912014|intervention
207653|NCT01912014|quality of life
207654|NCT01912001|end stage renal disease
207655|NCT01912001|kidney failure
207656|NCT01912001|home dialysis
207657|NCT01912001|hemodialysis
207658|NCT01912001|peritoneal dialysis
207659|NCT01912001|gaps in care
207660|NCT01912001|co-morbidity
207661|NCT01912001|transitions of care settings
207662|NCT01911988|Peripheral immune cells
207663|NCT01911988|Colorectal Cancers
207664|NCT01911988|Stage II/ Stage III
207665|NCT01911988|Recurrence
207666|NCT01911988|Metastasis
207667|NCT01911975|Small Fiber Neuropathy
207668|NCT01911975|Painful Neuropathy
207669|NCT01911975|NAV1.7 Voltage-Gated Sodium Channel
207670|NCT01911975|SCN9A
207671|NCT01911949|femoral nerve block
207672|NCT01911949|ultrasound guided
207673|NCT01911949|total hip arthroplasty
207674|NCT01911936|CLJM716,
207675|NCT01911936|Japanese patients,
207676|NCT01911936|Neoplasms
207677|NCT01911910|primary prevention
207678|NCT01911910|Cardiovascular disease
207679|NCT01911910|Cardiovascular magnetic resonance (CMR)
207680|NCT01911910|Electronic coaching (e-coaching)
207681|NCT01911897|Hypertension
207682|NCT01911884|Rokitansky syndrome
207683|NCT01911884|surgical or vaginal dilatation of vaginal aplasia
207684|NCT01911884|quality of global and sexual life
207685|NCT01911871|Thalassemia
207686|NCT01911871|sickle cell disease
207687|NCT01911871|myelodysplasia
207688|NCT01911871|transfusion
207689|NCT01911871|chelation
207690|NCT01911845|HCV Genotype 1
207691|NCT01911845|Hepatitis Genotype 1
207692|NCT01911845|Interferon Free
207693|NCT01911845|methadone
207694|NCT01911845|HCV
207695|NCT01911845|Buprenorphine
207696|NCT01911845|Hepatitis C
207697|NCT01911845|Viekira Pak
207698|NCT01911845|paritaprevir
207699|NCT01911845|Viekira
207700|NCT01911845|ombitasvir
207701|NCT01911845|dasabuvir
207702|NCT01911832|Cancer of the esophagogastric junction
207703|NCT01911832|Reconstruction of gastric tube
207704|NCT01911832|Quality of life
207705|NCT01911832|Width
207706|NCT01911832|Regurgitation
207707|NCT01911819|Histomorphometric Analysis
207708|NCT01911819|New bone Formation
207709|NCT01911819|Sinus Augmentation
207710|NCT01911819|Bone Graft Materials
207711|NCT01911806|Back care pillow
207712|NCT01911806|chronic non-specific low back pain
207713|NCT01911806|randomized controlled trial
207714|NCT01911793|stoma
207715|NCT01911793|ileus
207716|NCT01911793|postoperative
207717|NCT01911793|stoma tube
207718|NCT01911741|Phase I
207719|NCT01911741|Enzalutamide
207720|NCT01911741|Relative bioavailability of MDV3100
207721|NCT01911741|Immediate release oral formulation
207722|NCT01911741|Xtandi
207723|NCT01911728|Phase 1
207724|NCT01911728|Enzalutamide
207725|NCT01911728|MDV3100
207726|NCT01911728|Drug-Drug Interaction
207727|NCT01911728|Xtandi
207728|NCT01911715|Phase 1
207729|NCT01911715|Mass Balance
207730|NCT01911715|MDV3100
207731|NCT01911715|Xtandi
207732|NCT01911715|Enzalutamide
207733|NCT01911715|Metabolism
207734|NCT01911715|Excretion
207735|NCT01911689|pancreatitis
207736|NCT01911689|MRI
207737|NCT01911689|APACHEⅡ
207738|NCT01911689|T2*
207739|NCT01911689|T2 star
207740|NCT01911650|Achilles
207741|NCT01911650|tendinopathy
207742|NCT01911637|Healthy
207743|NCT01911637|Subjects
207744|NCT01911637|Safety
207745|NCT01911637|Tolerability
207746|NCT01911637|VBY-036
207747|NCT01911637|Maximum
207748|NCT01911637|Pharmacodynamic
207749|NCT01911637|Pharmacokinetic
207750|NCT01911585|Posttraumatic Stress Disorder
207751|NCT01911585|PTSD
207752|NCT01911585|Prolonged Exposure Therapy
207753|NCT01911585|Cognitive Behavioral Therapy
207754|NCT01911572|Streptococcus species
207755|NCT01911572|Streptococcus pyogenes
207756|NCT01911572|Streptococcus agalactiae
207757|NCT01911572|Necrotising fasciitis
207758|NCT01911572|Sepsis
207759|NCT01911559|Standing-frame
207760|NCT01911559|Chronic constipation
207761|NCT01911559|Cerebral palsy
207762|NCT01911559|Quadriplegia
207763|NCT01911559|Severe diplegia
207764|NCT01911494|cluster randomized controlled trial
207765|NCT01911494|pre-eclampsia
207766|NCT01911494|eclampsia
207767|NCT01911494|maternal mortality
207768|NCT01911468|PCOS
207769|NCT01911468|obesity
207770|NCT01911468|GLP-1 receptor agonist
207771|NCT01911468|liraglutide
207772|NCT01911468|metformin
207773|NCT01911455|Fragile X Syndrome
207774|NCT01911442|Autism, Lurasidone, Latuda
207775|NCT01911429|schizophrenia
207776|NCT01911429|Lurasidone
207777|NCT01911429|Latuda
207778|NCT01911403|Femoral Artery puncture
207779|NCT01911390|High cholesterol.
207780|NCT01911364|Frequent exacerbators
207781|NCT01911351|nitrous oxide
207782|NCT01911351|pediatric pain and anxiety
207783|NCT01911338|Spinal Manipulation
207784|NCT01911338|Teaching
207785|NCT01911338|Thoracic Vertebrae
207786|NCT01911338|Feedback
207787|NCT01911325|Squamous non-small cell lung cancer
207788|NCT01911325|NSCLC
207789|NCT01911325|Docetaxel
207790|NCT01911325|Buparlisib
207791|NCT01911325|BKM120
207792|NCT01911325|Metastatic
207793|NCT01911325|Stage IIIb
207794|NCT01911325|Stage IV
207795|NCT01911325|PI3K inhibitor
207796|NCT01911299|Choline
207797|NCT01911299|Glycerophosphocholine
207798|NCT01911299|Choline alphoscerate
207799|NCT01911299|Fetal alcohol spectrum disorders
207800|NCT01911299|Fetal alcohol syndrome
207801|NCT01911299|Partial fetal alcohol syndrome
207802|NCT01911299|Alcohol-related neurodevelopmental disorder
207803|NCT01911299|Prenatal alcohol exposure
207804|NCT01911299|Fetal Alcohol Effects
207805|NCT01911299|Pregnancy Complications
207806|NCT01911299|Alcohol-Induced Disorders
207807|NCT01911299|Alcohol-Related Disorders
207808|NCT01911299|Central Nervous System Agents
207809|NCT01911299|Therapeutic Uses
207810|NCT01911273|Hepatocellular carcinoma
207811|NCT01911273|monoclonal antibody
207812|NCT01911273|ALK-1
207813|NCT01911273|best supportive care
207814|NCT01911260|Zinc
207815|NCT01911260|Growth
207816|NCT01911260|Child
207817|NCT01911260|Dietary Supplements
207818|NCT01911260|Randomized Controlled Trial
207819|NCT01911221|Meningococcal disease,
207820|NCT01911221|Adults
207821|NCT01911208|Minority
207822|NCT01911208|Recruitment
207823|NCT01911195|General anesthesia
207824|NCT01911195|cognition
207825|NCT01911195|consciousness
207826|NCT01911182|apnea of prematurity
207827|NCT01911182|control of breathing
207828|NCT01911182|newborn
207829|NCT01911182|CO2 inhalation
207830|NCT01911169|atherosclerosis
207831|NCT01911169|systemic lupus erythematosus
207832|NCT01911169|flow mediated dilation
207833|NCT01911169|interferon gene signature
207834|NCT01911156|Chronic Hepatitis B
207835|NCT01911130|outcomes measures
207836|NCT01911130|strength measurement
207837|NCT01911130|disease progression
207838|NCT01911104|muscle
207839|NCT01911104|mitochondrial function
207840|NCT01911104|exercise resistance
207841|NCT01911104|human
207842|NCT01911104|myotubes
207843|NCT01911104|epigenetics
207844|NCT01911091|skeletal muscle
207845|NCT01911091|adipose tissue
207846|NCT01911091|metabolism
207847|NCT01911091|oxidation
207848|NCT01911091|mitochondrial capacity
207849|NCT01911078|Metabolic syndrome
207850|NCT01911078|Renal denervation
207851|NCT01911078|Renal artery
207852|NCT01911078|Muscle sympathetic nerve activity
207853|NCT01911065|Herpes zoster
207854|NCT01911065|chicken pox
207855|NCT01911065|immune response
207856|NCT01911065|Zostavax
207857|NCT01911052|Bowel preparation
207858|NCT01911039|GVHD
207859|NCT01911039|cGVHD
207860|NCT01911026|Bowel preparation
207861|NCT01911013|degenerative cervical disease
207862|NCT01911013|anterior cervical discectomy and fusion
207863|NCT01911013|plate and cage
207864|NCT01911013|cage alone
207865|NCT01910987|Multiple Myeloma
207866|NCT01910987|bortezomib
207867|NCT01910987|Velcade
207868|NCT01910987|First or Second Relapse
207869|NCT01910987|retreatment
207870|NCT01910987|Prolonged therapy
207871|NCT01910974|oesophagus
207872|NCT01910974|stomach
207873|NCT01910974|intestine
207874|NCT01910974|rectum
207875|NCT01910948|omega-3 gastric cancer perioperation
207876|NCT01910935|Physical activity
207877|NCT01910935|Hypertension
207878|NCT01910935|Scheme reference
207879|NCT01910935|Primary care
207880|NCT01910922|vegetable acceptance
207881|NCT01910922|vegetable intake
207882|NCT01910922|vegetable liking
207883|NCT01910922|learning mechanisms
207884|NCT01910922|repeated exposure to flavor
207885|NCT01910922|flavor learning
207886|NCT01910922|replace salt with spice
207887|NCT01910909|Hepatocellular carcinoma
207888|NCT01910909|unresectable
207889|NCT01910909|small size
207890|NCT01910909|Stereotactic body radiotherapy
207891|NCT01910883|Safety
207892|NCT01910883|Tolerability
207893|NCT01910883|Pharmacokinetic
207894|NCT01910870|Early-relapse
207895|NCT01910844|triple negative breast cancer
207896|NCT01910844|late-relapse
207897|NCT01910831|bruising, reduction, older age, aging
207898|NCT01910818|radiation
207899|NCT01910818|dermatitis
207900|NCT01910818|laser
207901|NCT01910818|fractional
207902|NCT01910818|CO2
207903|NCT01910818|chronic
207904|NCT01910818|fibrosis
207905|NCT01910818|scar
207906|NCT01910805|Gestational diabetes
207907|NCT01910805|Diabetes mellitus
207908|NCT01910805|diabetes in pregnancy
207909|NCT01910805|diabetes risk
207910|NCT01910805|diabetes risk awareness
207911|NCT01910805|African-American
207912|NCT01910805|Women
207913|NCT01910779|Atrial Fibrillation
207914|NCT01910779|Cardioversion
207915|NCT01910779|Biphasic Shock
207916|NCT01910766|pcos
207917|NCT01910766|coenzymeQ10
207918|NCT01910766|clomiphene citrate
207919|NCT01910753|Head and neck cancer,
207920|NCT01910753|physical activity,
207921|NCT01910753|nutrition therapeutic education
207922|NCT01910740|Randomized Controlled Trial
207923|NCT01910740|Exercise Movement Techniques
207924|NCT01910740|Frail Elderly
207925|NCT01910740|Gait
207926|NCT01910727|American Indian
207927|NCT01910727|Diabetes
207928|NCT01910727|Pre-diabetes
207929|NCT01910727|Family health Coach
207930|NCT01910714|HIV/AIDS
207931|NCT01910714|Prevention
207932|NCT01910714|American Indian
207933|NCT01910714|Substance use
207934|NCT01910714|CBPR
207935|NCT01910701|Home visiting interventions
207936|NCT01910701|American Indian
207937|NCT01910701|Community based participatory research
207938|NCT01910688|RGB Salvage, RFA
207939|NCT01910662|Suction Skin Blister
207940|NCT01910662|Induration
207941|NCT01910662|Tuberculin Purified Protein Derivative
207942|NCT01910662|Erythema
207943|NCT01910662|Biopsy
207944|NCT01910662|Keyhole Limpet Hemocyanin
207945|NCT01910662|Delayed Type Hypersensitivity
207946|NCT01910649|drisapersen
207947|NCT01910636|HCV genotype 2 (GT-2)
207948|NCT01910623|Quality of life
207949|NCT01910623|Health related quality of life outcomes
207950|NCT01910623|Long-term
207951|NCT01910623|Aida 0493
207952|NCT01910623|AIDA 2000
207953|NCT01910610|wild-type RAS metastatic colorectal cancer
207954|NCT01910584|quality of life
207955|NCT01910584|sexual activity
207956|NCT01910584|Novasure endometrial ablation
207957|NCT01910584|menorrhagia
207958|NCT01910558|Alpha-cyclodextrin
207959|NCT01910558|Dietary fiber
207960|NCT01910558|Fecal fat
207961|NCT01910558|Saturated fat
207962|NCT01910519|influenza A (H5N1) virus
207963|NCT01910519|H5N1 influenza
207964|NCT01910519|influenza A/H5/N1
207965|NCT01910519|monovalent H5N1 influenza vaccine
207966|NCT01910519|systems biology
207967|NCT01910519|AS03 adjuvant
207968|NCT01910519|unadjuvanted
207969|NCT01910493|mhealth
207970|NCT01910493|mobile health
207971|NCT01910493|SMS
207972|NCT01910493|SMS reminders
207973|NCT01910493|ART retention in care
207974|NCT01910493|PMTCT
207975|NCT01910493|PMTCT cascade
207976|NCT01910493|retention in care
207977|NCT01910454|Stroke
207978|NCT01910454|Occupational Therapy
207979|NCT01910454|Cognition
207980|NCT01910441|Type 2 Diabetes Mellitus, Glycemic variability
207981|NCT01910428|L-asparaginase encapsulated in RBCs, leukemia, lymphoma
207982|NCT01910402|antiretroviral therapy naïve
207983|NCT01910402|women
207984|NCT01910402|once daily
207985|NCT01910402|HIV infection
207986|NCT01910402|atazanavir
207987|NCT01910402|tenofovir/emtricitabine
207988|NCT01910402|dolutegravir/abacavir/lamivudine fixed dose combination
207989|NCT01910402|integrase inhibitor
207990|NCT01910402|ritonavir
207991|NCT01910389|Heart failure
207992|NCT01910389|Pulmonary hypertension
207993|NCT01910389|tadalafil
207994|NCT01910389|Phosphodiesterase Type 5 Inhibition
207995|NCT01910363|poststroke spasticity
207996|NCT01910363|lower limb
207997|NCT01910363|botulinum toxin
207998|NCT01910363|A2
207999|NCT01910350|Breast & cervical cancer prevention & screening
208000|NCT01910337|ASA I patients
208001|NCT01910324|Juvenile Offenders
208002|NCT01910324|HIV/STD Prevention
208003|NCT01910324|Adolescent Substance Abuse
208004|NCT01910324|Multidimensional Family Therapy
208005|NCT01910298|Breast reconstruction
208006|NCT01910298|Breast implant
208007|NCT01910298|Breast cancer
208008|NCT01910298|Mastectomy
208009|NCT01910285|Anesthetic induction
208010|NCT01910285|Intubation conditions
208011|NCT01910285|Tooth extraction
208012|NCT01910285|Propofol
208013|NCT01910285|Sufentanil
208014|NCT01910285|Remifentanil
208015|NCT01910272|Radiation attenuation
208016|NCT01910272|Fluoroscopy
208017|NCT01910272|Invasive cardiac procedures
208018|NCT01910272|Cardiac Catheterization
208019|NCT01910259|Secondary Progressive Multiple Sclerosis
208020|NCT01910259|Neuroprotective
208021|NCT01910259|Repurposed drugs
208022|NCT01910259|Brain atrophy
208023|NCT01910259|Percentage Brain Volume Change
208024|NCT01910259|Magnetic Resonance Imaging
208025|NCT01910259|Optical Coherence Tomography
208026|NCT01910259|Cerebrospinal fluid
208027|NCT01910259|Ibudilast
208028|NCT01910259|Amiloride
208029|NCT01910259|Riluzole
208030|NCT01910259|Double blind
208031|NCT01910259|Placebo
208032|NCT01910246|Metformin
208033|NCT01910246|Insulin Resistance
208034|NCT01910246|Cardiac Function
208035|NCT01910233|dyspnea
208036|NCT01910233|registry
208037|NCT01910233|baseline characteristics
208038|NCT01910233|mortality
208039|NCT01910233|risk assessment
208040|NCT01910233|emergency department
208041|NCT01910142|bone metabolism
208042|NCT01910129|vagus nerve stimulation
208043|NCT01910129|vagal nerve stimulation
208044|NCT01910129|nVNS
208045|NCT01910129|VNS
208046|NCT01910129|epilepsy
208047|NCT01910129|non invasive
208048|NCT01910129|gammacore
208049|NCT01910116|osteoarthritis
208050|NCT01910116|hand
208051|NCT01910116|Shinbaro
208052|NCT01910116|GCSB-5
208053|NCT01910103|Breast Neoplasms/radiography
208054|NCT01910103|Mammography/methods
208055|NCT01910103|Mass Screening
208056|NCT01910103|Tomography, X-Ray Computed/methods
208057|NCT01910103|Predictive Value of Tests
208058|NCT01910103|False Positive Reactions
208059|NCT01910090|fasting condition
208060|NCT01910077|tacrolimus
208061|NCT01910077|tacrobell capsule
208062|NCT01910077|prograf capsule
208063|NCT01910077|bioequivalence
208064|NCT01910064|Acne Vulgaris
208065|NCT01910025|Argininosuccinate Synthetase
208066|NCT01910025|Arginine
208067|NCT01910025|Arginine deiminase
208068|NCT01910012|Argininosuccinate Synthetase
208069|NCT01910012|Arginine
208070|NCT01910012|Arginine deiminase
208071|NCT01909999|Dental Implants
208072|NCT01909999|Osseointegration
208073|NCT01909999|Immediate Dental Implant Loading
208074|NCT01909999|Bone formation
208075|NCT01909986|ONO-4053
208076|NCT01909986|Healthy adult male subjects
208077|NCT01909986|pharmacokinetics
208078|NCT01909986|metabolism
208079|NCT01909986|excretion
208080|NCT01909986|mass balance
208081|NCT01909973|Depression
208082|NCT01909973|Antidepressant Medication
208083|NCT01909973|Adherence
208084|NCT01909973|Mobile Smartphone Intervention
208085|NCT01909973|Telemedicine
208086|NCT01909973|Primary Care
208087|NCT01909960|Normal pressure hydrocephalus
208088|NCT01909960|Flow MRI
208089|NCT01909960|Dementia
208090|NCT01909960|Cerebrospinal fluid
208091|NCT01909960|Shunt
208092|NCT01909947|Respiratory rate variability
208093|NCT01909947|Heart rate variability
208094|NCT01909947|Extubation readiness
208095|NCT01909947|Extubation failure
208096|NCT01909947|Clinical predictors
208097|NCT01909934|Lymphoma
208098|NCT01909934|Anaplastic Large-cell
208099|NCT01909934|Relapsed
208100|NCT01909934|Refractory
208101|NCT01909934|Antigens, CD30
208102|NCT01909934|Antibody-Drug Conjugate
208103|NCT01909934|Antibodies, Monoclonal
208104|NCT01909934|Lymphoma, Non-Hodgkin
208105|NCT01909934|Lymphoma, Large-Cell, Anaplastic
208106|NCT01909934|monomethyl auristatin E
208107|NCT01909934|Drug Therapy
208108|NCT01909934|Immunotherapy
208109|NCT01909934|Hematologic Diseases
208110|NCT01909908|Wounds and injuries
208111|NCT01909908|Ulcer
208112|NCT01909908|Diabetic angiopathies
208113|NCT01909908|Diabetic foot
208114|NCT01909908|Venous insufficiency
208115|NCT01909908|Extracellular matrix
208116|NCT01909882|Family member's massage therapy
208117|NCT01909882|Vital signs
208118|NCT01909882|Glasgow coma scale
208119|NCT01909882|Intensive care unit
208120|NCT01909882|Randomized controlled Clinical Trial
208121|NCT01909882|Iran
208122|NCT01909869|MACE
208123|NCT01909869|TVR
208124|NCT01909869|MI
208125|NCT01909869|TLF
208126|NCT01909869|Death
208127|NCT01909830|Colorectal Cancer Metastatic
208128|NCT01909830|pretreated
208129|NCT01909804|Hepatitis
208130|NCT01909804|Genotype 1
208131|NCT01909804|Genotype 3
208132|NCT01909804|Treatment experienced
208133|NCT01909791|Diabetic Macular Edema
208134|NCT01909791|anti-vascular endothelial growth factor
208135|NCT01909765|Circumcision
208136|NCT01909765|postoperative pain
208137|NCT01909752|Lung cancer
208138|NCT01909752|DRibble Vaccine
208139|NCT01909752|Imiquimod
208140|NCT01909752|GM-CSF
208141|NCT01909752|HPV vaccine (Ceravix)
208142|NCT01909752|Cyclophosphamide
208143|NCT01909739|AKI, atrovastatin, Valvular heart surgery
208144|NCT01909726|Hospital Design
208145|NCT01909726|Technology
208146|NCT01909726|Anxiety
208147|NCT01909713|acne, pediatric
208148|NCT01909700|Single Incision, Mesh, Complications
208149|NCT01909687|blood glucose monitoring systems
208150|NCT01909687|ISO 15197
208151|NCT01909687|system accuracy
208152|NCT01909661|allergy
208153|NCT01909661|Cow's milk protein
208154|NCT01909661|Tolerance
208155|NCT01909661|Efficacy
208156|NCT01909661|Infants' growth
208157|NCT01909622|Vitamin D
208158|NCT01909622|Milk fortification
208159|NCT01909622|Children
208160|NCT01909622|Colombia
208161|NCT01909609|male
208162|NCT01909583|congenital
208163|NCT01909583|surgery
208164|NCT01909583|peri-operative
208165|NCT01909583|counselling
208166|NCT01909557|Acetyl-L-carnitine
208167|NCT01909557|Interferons
208168|NCT01909557|Ribavirin
208169|NCT01909557|Hepatitis C
208170|NCT01909557|Fatigue
208171|NCT01909544|Pulmonary Disease, Chronic Obstructive
208172|NCT01909544|Muscle fatigue
208173|NCT01909544|Energy metabolism
208174|NCT01909544|Muscle oxygenation
208175|NCT01909531|Deep Brain Stimulation
208176|NCT01909531|Parkinsons Disease
208177|NCT01909531|Essential Tremor
208178|NCT01909531|Asleep DBS
208179|NCT01909518|Esophageal Squamous Intraepithelial Neoplasia
208180|NCT01909518|surface maturation scoring
208181|NCT01909518|probe-based confocal laser endomicroscopy
208182|NCT01909518|virtual chromoendoscopy
208183|NCT01909492|Multiple Sclerosis
208184|NCT01909492|MS
208185|NCT01909492|Relaxin
208186|NCT01909466|OPC-14597
208187|NCT01909466|Aripiprazole
208188|NCT01909466|Schizophrenia
208189|NCT01909453|Melanoma
208190|NCT01909453|Cutaneous melanoma
208191|NCT01909453|Skin disease
208192|NCT01909453|Skin cancer
208193|NCT01909453|Skin Neoplasms
208194|NCT01909453|Neoplasm Metastasis
208195|NCT01909453|BRAF mutant
208196|NCT01909453|BRAF V600E
208197|NCT01909453|BRAF V600K
208198|NCT01909453|Cancer
208199|NCT01909453|LGX818
208200|NCT01909453|MEK162
208201|NCT01909453|vemurafenib
208202|NCT01909453|combination
208203|NCT01909453|BRAF inhibitor
208204|NCT01909453|resistance
208205|NCT01909453|The combination of a selective BRAF- and a MEK1/2-inhibitor
208206|NCT01909453|Prior immunotherapy
208207|NCT01909453|MEK inhibitor
208208|NCT01909453|Phase III
208209|NCT01909453|Combo 300, Combo 450
208210|NCT01909427|Active rheumatoid arthritis despite methotrexate therapy
208211|NCT01909427|CNTO 6785
208212|NCT01909427|Methotrexate
208213|NCT01909401|Liver Transplantation
208214|NCT01909388|Cancer
208215|NCT01909388|Prostate Cancer
208216|NCT01909388|Brachytherapy
208217|NCT01909388|Dose escalation
208218|NCT01909388|High Dose Rate
208219|NCT01909388|MRI-TRUS fusion
208220|NCT01909388|Detection of DILs by MRI
208221|NCT01909362|advanced metastatic colorectal cancer
208222|NCT01909362|mCRC
208223|NCT01909362|Colorectal Cancer
208224|NCT01909362|Colorectal Carcinoma
208225|NCT01909362|Colorectal Tumors
208226|NCT01909362|Genetic mutation testing
208227|NCT01909362|Tumor tissue sampling
208228|NCT01909349|medical rehabilitation
208229|NCT01909349|aftercare
208230|NCT01909349|multiple health behavior change
208231|NCT01909349|diet
208232|NCT01909349|physical activity
208233|NCT01909349|computer
208234|NCT01909349|international study
208235|NCT01909349|ETHNOPSYCHOLOGY
208236|NCT01909349|HABIT
208237|NCT01909349|HEALTH
208238|NCT01909349|eHealth
208239|NCT01909349|eLearning
208240|NCT01909310|anesthesia, cardiac arrest, resuscitation, ventilation
208241|NCT01909297|airway management
208242|NCT01909271|Stroke
208243|NCT01909271|Community Health Education
208244|NCT01909271|Minority Health
208245|NCT01909271|healthcare disparities
208246|NCT01909245|Islet cells
208247|NCT01909245|hypoglycemia
208248|NCT01909245|hypoglycemia unawareness
208249|NCT01909245|islet after kidney transplantation
208250|NCT01909245|islet transplant
208251|NCT01909245|insulin independence
208252|NCT01909245|insulin dependence
208253|NCT01909232|Depression
208254|NCT01909232|Depressive Disorder
208255|NCT01909232|Major depression
208256|NCT01909232|Major depressive disorder
208257|NCT01909232|MDD
208381|NCT01908647|mTBI
208258|NCT01909232|Treatment resistant depression
208259|NCT01909232|Treatment intolerant depression
208260|NCT01909232|TRMD
208261|NCT01909232|TIMD
208262|NCT01909232|Transcranial Magnetic Stimulation
208263|NCT01909232|TMS
208264|NCT01909219|preparation, cleansing, colon
208265|NCT01909167|Pregnancy
208266|NCT01909167|symptoms of depression
208267|NCT01909167|anxiety
208268|NCT01909167|online CBT therapy
208269|NCT01909167|treatment as usual
208270|NCT01909167|maternal bonding
208271|NCT01909167|postnatal period
208272|NCT01909154|neurophysiological parameters improvement
208273|NCT01909154|spinal cord injury
208274|NCT01909154|biology therapy
208275|NCT01909141|letrozole
208276|NCT01909141|clomiphene citrate
208277|NCT01909141|pioglitazone
208278|NCT01909141|metformin
208279|NCT01909141|ovulation induction
208280|NCT01909141|PCOS
208281|NCT01909128|children, fermented milk fermented rice, gastrointestinal infections, respiratory infections
208282|NCT01909102|Acceptance and Commitment Therapy
208283|NCT01909102|Cardiac rehabilitation
208284|NCT01909050|celiac disease
208285|NCT01909050|refractory celiac disease
208286|NCT01909050|gluten sensitivity
208287|NCT01909037|osteoarthritis
208288|NCT01909037|curcumin
208289|NCT01909037|biomarker
208290|NCT01909037|pain
208291|NCT01909024|Randomised controlled trial
208292|NCT01909024|Endovenous laser treatment
208293|NCT01909024|Transjugular coil embolisation
208294|NCT01908998|Y-Balance test
208295|NCT01908985|glaucoma
208296|NCT01908985|high intensity focused ultrasound
208297|NCT01908985|aqueous humor
208298|NCT01908985|fluorophotometry
208299|NCT01908972|Hemangioma
208300|NCT01908972|Propranolol
208301|NCT01908972|prednisolone
208302|NCT01908972|steroid
208303|NCT01908959|Hispanic Women
208304|NCT01908959|Postpartum
208305|NCT01908959|Overweight Hispanic Women
208306|NCT01908959|Low-income
208307|NCT01908959|Physical Activity
208308|NCT01908959|Walking
208309|NCT01908946|Polio
208310|NCT01908933|Advanced Emphysema
208311|NCT01908933|Heterogeneous Lower Lobe Predominant Emphysema
208312|NCT01908933|Heterogeneous Upper and Lower Lobe Predominant
208313|NCT01908907|Premature Infants
208314|NCT01908907|DHA(docosahexaenoic acid)
208315|NCT01908907|DHA deficit
208316|NCT01908881|Child Development
208317|NCT01908881|Mother-Child relations
208318|NCT01908881|Primary Health Care
208319|NCT01908881|Public Policy
208320|NCT01908855|somatoform symptoms
208321|NCT01908855|somatic symptoms
208322|NCT01908855|somatoform disorder
208323|NCT01908855|somatic symptom disorder
208324|NCT01908855|cognitive-behavioral therapy
208325|NCT01908855|emotion regulation training
208326|NCT01908842|Opioid
208327|NCT01908842|Dependence
208328|NCT01908842|agonist
208329|NCT01908842|buprenorphine
208330|NCT01908842|naloxone
208331|NCT01908842|BUP/NAL
208332|NCT01908829|Overactive Bladder (OAB)
208333|NCT01908829|Urinary incontinence
208334|NCT01908829|Urgency incontinence
208335|NCT01908829|Frequency
208336|NCT01908829|Urgency
208337|NCT01908829|Micturition
208338|NCT01908829|YM178
208339|NCT01908829|Mirabegron
208340|NCT01908829|Solifenacin
208341|NCT01908829|Betmiga
208342|NCT01908829|Myrbetriq
208343|NCT01908829|Betanis
208344|NCT01908829|Vesicare
208345|NCT01908829|Vesitrim
208346|NCT01908829|Vesikur
208347|NCT01908829|YM905
208348|NCT01908803|AOMT
208349|NCT01908803|tympanostomy tubes
208350|NCT01908803|Otorrhea
208351|NCT01908803|anti-infective
208352|NCT01908790|venous oximeter
208353|NCT01908790|non-invasive monitor
208354|NCT01908790|heart failure (HF)
208355|NCT01908764|ear tubes
208356|NCT01908764|tympanostomy tubes
208357|NCT01908764|Otitis Media at the time of Tympanostomy Tube surgery
208358|NCT01908764|OMTT
208359|NCT01908738|Endometrial biopsy
208360|NCT01908738|paracervical block
208361|NCT01908738|Lidocaine spray
208362|NCT01908738|women
208363|NCT01908738|abnormal uterine bleeding
208364|NCT01908686|ASD
208365|NCT01908673|heart rate variability biofeedback
208366|NCT01908673|automatic self transcedental meditation
208367|NCT01908660|HIV
208368|NCT01908660|hepatitis C virus
208369|NCT01908660|hepatitis B virus
208370|NCT01908660|antiretroviral drugs
208371|NCT01908660|nucleos(t)ide reverse transcriptase inhibitors
208372|NCT01908660|non-nucleos(t)ide reverse transcriptase inhibitors
208373|NCT01908660|protease inhibitors
208374|NCT01908660|integrase inhibitors
208375|NCT01908660|entry inhibitors
208376|NCT01908660|transaminase elevations
208377|NCT01908660|alanine aminotransferase
208378|NCT01908660|aspartate aminotransferase
208379|NCT01908660|bilirubin elevations
208380|NCT01908660|hepatic fibrosis
208382|NCT01908647|PTSD
208383|NCT01908634|Bioavailability
208384|NCT01908634|Strawberry polyphenols
208385|NCT01908634|Fruit Beverage Matrix
208386|NCT01908621|multiple myeloma
208387|NCT01908621|mobilization
208388|NCT01908621|G-CSF
208389|NCT01908621|filgrastim
208390|NCT01908621|cytosine arabinoside
208391|NCT01908621|autologous stem cell transplantation
208392|NCT01908569|MACS, time-lapse, embryo, spermatozoid, sperm
208393|NCT01908543|Iron deficiency
208394|NCT01908543|Nosebleeds
208395|NCT01908530|Diabetes,Continuous Glucose Monitoring,Microprobes
208396|NCT01908517|HPV Vaccine Adherence
208397|NCT01908517|Electronic Reminders
208398|NCT01908491|patient controlled analgesia
208399|NCT01908491|wound catheter infusion
208400|NCT01908491|postoperative pain control
208401|NCT01908491|pectus excavatum
208402|NCT01908491|pain score
208403|NCT01908478|locally advanced
208404|NCT01908478|unresectable
208405|NCT01908478|pancreatic
208406|NCT01908478|pancreas
208407|NCT01908478|pancreatic adenocarcinoma
208408|NCT01908452|Schizophrenia
208409|NCT01908452|pyridoxal kinase activity
208410|NCT01908452|plasma pyridoxal level
208411|NCT01908439|muscle electrical activity
208412|NCT01908439|whole-body vibration
208413|NCT01908439|latency
208414|NCT01908426|cabozantinib
208415|NCT01908426|XL184
208416|NCT01908426|liver cancer
208417|NCT01908426|hepatocellular carcinoma
208418|NCT01908426|tyrosine kinase inhibitor
208419|NCT01908426|MET
208420|NCT01908426|vascular endothelial growth factor receptor 2 (VEGFR2)
208421|NCT01908413|Advanced Solid Tumors
208422|NCT01908413|Lymphoma
208423|NCT01908413|Open-Label
208424|NCT01908413|Dose-Escalation
208425|NCT01908413|IAP
208426|NCT01908400|Mental retardation , stem cell,BMMNC
208427|NCT01908387|Oral azacitidine
208428|NCT01908387|CC-486
208429|NCT01908387|Hematological neoplasms
208430|NCT01908387|Phase 1
208431|NCT01908374|Active-placebo controlled double blind cross over
208432|NCT01908361|comparative efficacy research
208433|NCT01908361|combination therapy
208434|NCT01908361|neurorehabilitation
208435|NCT01908361|robotic rehabilitation
208436|NCT01908361|restraint therapy
208437|NCT01908335|interferon
208438|NCT01908335|ribavirin
208439|NCT01908335|virological response
208440|NCT01908322|Hepatocellular carcinoma
208441|NCT01908322|Intermediate stage
208442|NCT01908322|Observational study
208443|NCT01908309|acute kidney injury
208444|NCT01908309|contrast media
208445|NCT01908309|cystatin-C
208446|NCT01908296|FK949E
208447|NCT01908296|fluvoxamine
208448|NCT01908296|Antipsychotic
208449|NCT01908296|Quetiapine
208450|NCT01908244|Preterm infants, music, Neonatal Intensive Care Unit (NICU)
208451|NCT01908231|Pulmonary embolism, plasma lactate, right ventricular dysfunction
208452|NCT01908218|ULBT, diffficult laryngoscopy, Predictive Value of Tests
208453|NCT01908205|Autism
208454|NCT01908205|Social
208455|NCT01908205|Functioning
208456|NCT01908205|Cognition
208457|NCT01908205|Repetitive Behaviors
208458|NCT01908205|Anxiety
208459|NCT01908205|Quality of Life
208460|NCT01908192|Sodium Benzoate
208461|NCT01908192|Schizophrenia
208462|NCT01908192|Adolescent
208463|NCT01908192|Antipsychotic
208464|NCT01908192|Anti-psychotic
208465|NCT01908192|NMDA
208466|NCT01908192|NaBen
208467|NCT01908192|pediatric
208468|NCT01908179|Sterotactic Radiosurgery
208469|NCT01908153|Picture food type
208470|NCT01908153|Taste type
208471|NCT01908127|film modelling
208472|NCT01908127|dental anxiety
208473|NCT01908127|cooperative behaviour
208474|NCT01908127|children
208475|NCT01908114|Polio disease
208476|NCT01908114|Intervention Package
208477|NCT01908114|Polio sero prevalence and sero conversion
208478|NCT01908114|Polio high risk areas of Pakistan
208479|NCT01908088|Epidermolysis Bullosa mitten hand deformity autologous cultured fibroblast
208480|NCT01908088|amniotic membrane
208481|NCT01908075|Primary care
208482|NCT01908075|Asthma management
208483|NCT01908075|Real-world
208484|NCT01908075|Observational
208485|NCT01908075|Fostair
208486|NCT01908075|Seretide
208487|NCT01908062|Substance related disorders
208488|NCT01908062|HIV
208489|NCT01908062|naltrexone
208490|NCT01908049|Probiotic
208491|NCT01908049|HIV
208492|NCT01908049|Microbial translocation
208493|NCT01908049|inflammation
208494|NCT01908049|microbiota composition
208495|NCT01908036|Chronic fatigue syndrome
208496|NCT01908036|CFS
208497|NCT01908036|myalgic encephalomyelitis
208498|NCT01908036|M.E.
208499|NCT01908036|activity monitor
208500|NCT01908023|exercise therapy
208501|NCT01908023|oxygen consumption
208502|NCT01908010|Alzheimer's disease
208627|NCT01907230|Rheumatoid arthritis
208503|NCT01907997|Systemic lidocaine, Intravenous lidocaine infusion, postoperative pain, quality of recovery, Robot-assisted thyroidectomy, thyroid cancer
208504|NCT01907984|premedication
208505|NCT01907984|diclofenac
208506|NCT01907984|postoperative headache
208507|NCT01907984|Visual Analog Scale
208508|NCT01907958|Microalbuminuria
208509|NCT01907958|Hypertensive
208510|NCT01907958|Diabetics
208511|NCT01907958|urine albumin
208512|NCT01907945|Household water treatment
208513|NCT01907945|Waterborne illness
208514|NCT01907945|ceramic filters
208515|NCT01907945|social network
208516|NCT01907932|splenomegaly
208517|NCT01907932|ultrasound
208518|NCT01907932|VScan
208519|NCT01907919|Pulp capping, Diode laser 808 nm, Tertiary dentin, RM-GIC
208520|NCT01907906|Pathogen reduction technology
208521|NCT01907880|breast
208522|NCT01907880|bone
208523|NCT01907880|pain
208524|NCT01907841|Investigate IPC on EIMD
208525|NCT01907789|Ovarian Carcinoma
208526|NCT01907789|Ovary
208527|NCT01907789|BRCA Mutation Carriers
208528|NCT01907789|BRCA1 or BRCA2 mutation
208529|NCT01907789|High risk for developing ovarian cancer
208530|NCT01907789|Ovarian cancer screening
208531|NCT01907789|Risk-reducing salpingo-oophorectomy
208532|NCT01907789|RRSO
208533|NCT01907789|Prophylactic salpingectomy with delayed oophorectomy
208534|NCT01907789|PSDO
208535|NCT01907789|Questionnaire
208536|NCT01907789|Quality of life
208537|NCT01907789|QOL
208538|NCT01907789|Survey
208539|NCT01907789|Transvaginal ultrasound
208540|NCT01907789|Phone call
208541|NCT01907763|asthma
208542|NCT01907763|SOTB07
208543|NCT01907750|biliary fistula
208544|NCT01907750|biliary stricture
208545|NCT01907750|biliary drainage tube
208546|NCT01907724|Chronic hepatitis C
208547|NCT01907724|Hepatitis C virus
208548|NCT01907724|HCV
208549|NCT01907711|Acupuncture.
208550|NCT01907711|Fatigue syndrome chronic.
208551|NCT01907711|Sleep disturbances.
208552|NCT01907711|Pain.
208553|NCT01907711|Cognitive impairment.
208554|NCT01907698|vaginal intercourse
208555|NCT01907698|labour
208556|NCT01907698|term pregnancy
208557|NCT01907672|Malaria
208558|NCT01907672|Rapid Diagnostic Tests for Malaria
208559|NCT01907672|Chemical Shops
208560|NCT01907672|Drug Shops
208561|NCT01907672|Diagnostics
208562|NCT01907672|Testing for Malaria
208563|NCT01907659|Respiratory
208564|NCT01907659|Viruses
208565|NCT01907659|Bacterial
208566|NCT01907659|Antibiotics
208567|NCT01907659|Procalcitonin
208568|NCT01907646|bladder training, radical hysterectomy,gynaecologic cancer
208569|NCT01907633|Death, Sudden, Cardiac
208570|NCT01907633|Risk of Sudden Cardiac Death
208571|NCT01907633|Domperidone
208572|NCT01907633|Proton Pump Inhibitors (PPI)
208573|NCT01907633|Metoclopramide
208574|NCT01907633|Observational Study
208575|NCT01907607|Advanced Gastrointestinal Stromal Tumor Refractory to Imatinib and Sunitinib
208576|NCT01907607|PD-0332991
208577|NCT01907607|Orally
208578|NCT01907607|Efficacy and safety
208579|NCT01907607|Adult patients
208580|NCT01907607|Refractory
208581|NCT01907607|Imatinib
208582|NCT01907607|Sunitinib
208583|NCT01907490|Topical treatment of Head Lice Infestation
208584|NCT01907464|Anorexia nervosa
208585|NCT01907464|Bone mineral density
208586|NCT01907464|Teenagers or young women
208587|NCT01907464|Bone remodelling markers
208588|NCT01907438|BRCA
208589|NCT01907438|estrogen
208590|NCT01907438|epithelial breast cells
208591|NCT01907438|genome profile
208592|NCT01907412|First time parents
208593|NCT01907412|Coparenting
208594|NCT01907412|Family Foundations
208595|NCT01907399|obese patients
208596|NCT01907399|obese patients with type 2 diabetes
208597|NCT01907399|healthy volunteers
208598|NCT01907386|Endoleaks
208599|NCT01907386|Non-invasive vascular elastography
208600|NCT01907373|olmesartan
208601|NCT01907373|probenecid
208602|NCT01907373|pharmacokinetics
208603|NCT01907373|tolerability
208604|NCT01907347|intensive care unit (ICU)
208605|NCT01907347|body composition
208606|NCT01907347|phase angle
208607|NCT01907347|mortality
208608|NCT01907347|nosocomial infection
208609|NCT01907347|bioimpedance analysis
208610|NCT01907347|nutrition
208611|NCT01907334|oscillometry
208612|NCT01907334|asthma
208613|NCT01907334|methacholine
208614|NCT01907321|stroke
208615|NCT01907321|dysphagia
208616|NCT01907321|dystussia
208617|NCT01907321|cough
208618|NCT01907321|maximum expiratory pressure
208619|NCT01907308|Bladder cancer
208620|NCT01907308|Urothelial cancer
208621|NCT01907308|Urothelial carcinoma
208622|NCT01907295|idiopathic
208623|NCT01907295|heritable
208624|NCT01907295|anorexigen
208625|NCT01907282|Schizophrenia
208626|NCT01907282|psychosis
208628|NCT01907230|Inactive HBV carrier
208629|NCT01907230|Resolved Hepatitis B
208630|NCT01907230|HBV reactivation
208631|NCT01907230|Anti-tumor necrotic factor-alfa
208632|NCT01907217|Electroconvulsive therapy
208633|NCT01907217|ECT
208634|NCT01907217|electrode placement
208635|NCT01907217|effectiveness
208636|NCT01907217|cognition
208637|NCT01907217|autobiographical memory
208638|NCT01907191|Hip Arthroscopy
208639|NCT01907191|Liposomal Bupivacaine
208640|NCT01907191|Bupivacaine
208641|NCT01907178|total knee arthroplasty
208642|NCT01907152|malnutrition
208643|NCT01907152|undernourishment
208644|NCT01907152|loss of muscle mass
208645|NCT01907139|comparative efficacy research
208646|NCT01907139|combination therapy
208647|NCT01907139|neurorehabilitation
208648|NCT01907139|robot-assisted therapy
208649|NCT01907139|constraint-induced therapy
208650|NCT01907126|HIV
208651|NCT01907126|Sexually transmitted infections
208652|NCT01907126|Sexual abuse
208653|NCT01907126|Physical abuse
208654|NCT01907126|Women
208655|NCT01907126|Prison
208656|NCT01907087|Late infantile Neuronal Ceroid Lipofuscinosis Type 2
208657|NCT01907087|LINCL
208658|NCT01907087|NCL2
208659|NCT01907087|CLN2
208660|NCT01907087|Jansky-Bielschowsky disease
208661|NCT01907074|liver function tests
208662|NCT01907074|end stage liver disease
208663|NCT01907074|cirrhosis
208664|NCT01907074|living liver donor
208665|NCT01907061|acute renal failure
208666|NCT01907061|post liver transplant
208667|NCT01907048|Survey
208668|NCT01907048|Effectiveness of risk minimization measures
208669|NCT01907048|Rivaroxaban
208670|NCT01907048|Anticoagulants
208671|NCT01907022|repetitive transcranial magnetic stimulation
208672|NCT01907022|chronic tinnitus
208673|NCT01907022|relaxation
208674|NCT01906944|trigger point injection
208675|NCT01906944|transversus abdominis plane
208676|NCT01906944|abdominal wall pain
208677|NCT01906931|Interstitial lung disease
208678|NCT01906931|Oxygen therapy
208679|NCT01906931|Walk
208680|NCT01906918|ischemia
208681|NCT01906918|reperfusion
208682|NCT01906918|myocardial ischemia
208683|NCT01906918|myocardial reperfusion
208684|NCT01906866|Sleep disturbance
208685|NCT01906866|Circadian
208686|NCT01906866|Prolong release melatonin
208687|NCT01906866|Autism Spectrum Disorder
208688|NCT01906866|Smith-Magenis Syndrome
208689|NCT01906866|Angelman Syndrome
208690|NCT01906866|tuberous sclerosis
208691|NCT01906853|BCG
208692|NCT01906853|Bacille Calmette Guérin
208693|NCT01906853|Allergy
208694|NCT01906853|Immunity
208695|NCT01906853|Immune response
208696|NCT01906853|Vaccine
208697|NCT01906853|Infants
208698|NCT01906853|Children
208699|NCT01906853|Infection
208700|NCT01906840|Chronic renal failure
208701|NCT01906840|Hemodialysis
208702|NCT01906840|Oxidative stress
208703|NCT01906840|Turmeric
208704|NCT01906827|cholestasis
208705|NCT01906827|pregnancy
208706|NCT01906827|p wave dispersion
208707|NCT01906827|arrhythmia
208708|NCT01906801|Osteoarthritis
208709|NCT01906801|Glucosamine sulfate
208710|NCT01906801|Diacerein
208711|NCT01906801|Randomized controlled trial
208712|NCT01906775|ICD
208713|NCT01906775|ventricular tachyarrhythmia
208714|NCT01906775|shock
208715|NCT01906775|sub-threshold pacing
208716|NCT01906762|Morphine, Acetaminophen, Renal colic, Emergency treatment
208717|NCT01906749|Acute coronary syndrome
208718|NCT01906749|Colchicine
208719|NCT01906710|Adverse Drug Events
208720|NCT01906710|Drug related problems
208721|NCT01906710|Medication Reconciliation
208722|NCT01906710|Medication review
208723|NCT01906710|discharge counseling
208724|NCT01906710|Hospital Pharmacy based
208725|NCT01906710|integrated medicines management
208726|NCT01906710|patient safety
208727|NCT01906684|Acthar Gel
208728|NCT01906684|MS relapse
208729|NCT01906684|7T MRI imaging
208730|NCT01906684|Quality of Life
208731|NCT01906671|6-mercaptopurine
208732|NCT01906671|Drug formulation
208733|NCT01906658|H.P. Acthar Gel
208734|NCT01906658|Acthar
208735|NCT01906658|amyotrophic lateral sclerosis
208736|NCT01906658|ALS
208737|NCT01906645|Patient Readmission
208738|NCT01906645|Continuity of Patient Care
208739|NCT01906619|Febrile Seizure
208740|NCT01906619|Respiratory physiology
208741|NCT01906619|Respiratory drive
208742|NCT01906619|Respiratory alkalosis
208743|NCT01906606|child nutritional status
208744|NCT01906606|child development
208745|NCT01906606|maternal depression
208746|NCT01906593|safety
208747|NCT01906593|influenza vaccine
208748|NCT01906593|post-marketing
208749|NCT01906580|HBV
208750|NCT01906580|entecavir
208751|NCT01906580|peginterferon
208752|NCT01906567|cadmium
208753|NCT01906567|lead
208754|NCT01906567|mercury
208755|NCT01906567|preeclampsia
208756|NCT01906567|pregnancy
208757|NCT01906541|X-CGD
208758|NCT01906541|chronic granulomatous disease
208759|NCT01906541|gene-therapy
208760|NCT01906528|Nondepolarizing neuromuscular blocking drug
208761|NCT01906528|Mivacurium
208762|NCT01906528|Sensitivity
208763|NCT01906528|Sex
208764|NCT01906515|Anemia
208765|NCT01906515|Blood transfusion
208766|NCT01906515|non invasive hemoglobin monitoring
208767|NCT01906515|patient safety
208768|NCT01906489|anemia
208769|NCT01906489|chronic kidney disease
208770|NCT01906489|CKD
208771|NCT01906489|chronic renal insufficiency
208772|NCT01906489|renal impairment
208773|NCT01906489|erythropoietin
208774|NCT01906489|kidney
208775|NCT01906489|oral anemia treatment
208776|NCT01906489|hemoglobin
208777|NCT01906489|hypoxia-inducible factor
208778|NCT01906489|HIF
208779|NCT01906489|hypoxia-inducible factor prolyl-hydroxylase inhibitor
208780|NCT01906489|HIF-PHI
208781|NCT01906489|efficacy
208782|NCT01906489|safety
208783|NCT01906489|pharmacokinetics
208784|NCT01906476|Depression
208785|NCT01906476|Telephone Cognitive Behavior Therapy
208786|NCT01906476|Internet Cognitive Behavioral Therapy
208787|NCT01906437|Cardiac fibrosis and Lymphoma
208788|NCT01906424|spinal cord injury
208789|NCT01906424|quadriplegia
208790|NCT01906424|tetraplegia
208791|NCT01906424|stimulation
208792|NCT01906398|Refractory epilepsy
208793|NCT01906398|ketogenic diet
208794|NCT01906398|efficacy
208795|NCT01906385|Glioblastoma
208796|NCT01906385|Astrocytoma
208797|NCT01906385|Brain Tumor
208798|NCT01906385|Radiotherapy
208799|NCT01906372|dermatomyositis
208800|NCT01906372|polymyositis
208801|NCT01906359|Interesterified fat
208802|NCT01906359|Stereospecific number 2
208803|NCT01906359|Gut hormones
208804|NCT01906359|GIP
208805|NCT01906359|Insulin sensitivity
208806|NCT01906359|Postprandial lipaemia
208807|NCT01906359|Haemostatic markers
208808|NCT01906333|Exercise
208809|NCT01906333|Ectopic fat accumulation
208810|NCT01906320|anorexia nervosa
208811|NCT01906320|restricting type
208812|NCT01906320|muscle strength
208813|NCT01906320|exercise
208814|NCT01906320|body composition
208815|NCT01906320|physical activity
208816|NCT01906307|hepatorenal syndrome
208817|NCT01906294|Type 2 Diabetes Mellitus
208818|NCT01906281|adipocytokines
208819|NCT01906281|osteoarthritis
208820|NCT01906281|cardiovascular risk
208821|NCT01906268|Generalized Anxiety Disorder
208822|NCT01906268|Social Anxiety Disorder
208823|NCT01906268|Panic Disorder
208824|NCT01906268|Antidepressants Resistant
208825|NCT01906268|Attentional Bias Modification Treatment (ABMT)
208826|NCT01906268|Attentional Retraining
208827|NCT01906268|Adjuvant Therapy
208828|NCT01906255|HIV-1
208829|NCT01906255|Truvada
208830|NCT01906255|FTC/TDF
208831|NCT01906255|Pre-exposure prophylaxy
208832|NCT01906255|PrEP
208833|NCT01906255|Adherence
208834|NCT01906255|Resistance
208835|NCT01906216|Hepatocellular carcinoma
208836|NCT01906216|sorafenib
208837|NCT01906216|transarterial chemoembolization
208838|NCT01906203|Ultramarathon
208839|NCT01906203|bioelectrical impedance
208840|NCT01906203|Phase-Angle
208841|NCT01906190|influenza vaccine
208842|NCT01906190|immune response
208843|NCT01906190|persistence
208844|NCT01906164|RSV
208845|NCT01906125|Bioequivalence
208846|NCT01906125|Cmax
208847|NCT01906125|AUC
208848|NCT01906073|fentanyl
208849|NCT01906073|administration, intranasal
208850|NCT01906073|morphine
208851|NCT01906073|patient satisfaction
208852|NCT01906073|patient preference
208853|NCT01906047|Non-cystic fibrosis bronchiectasis
208854|NCT01906021|Thermomap
208855|NCT01906021|Hepatic Lesions
208856|NCT01906021|Radiofrequency Ablation
208857|NCT01906021|Microwave
208858|NCT01906021|Non-Invasive Technique
208859|NCT01906008|Colorectal cancer
208860|NCT01906008|CRC
208861|NCT01906008|Acute peripheral neuropathy
208862|NCT01906008|Numbness
208863|NCT01906008|Pain
208864|NCT01906008|Loss of motor function
208865|NCT01906008|Minocycline
208866|NCT01906008|Dynacin
208867|NCT01906008|Minocin
208868|NCT01906008|Minocin PAC
208869|NCT01906008|Myrac
208870|NCT01906008|Solodyn
208871|NCT01906008|Placebo
208872|NCT01906008|Questionnaires
208873|NCT01906008|Surveys
208874|NCT01906008|Sensory tests
208875|NCT01905995|deep brain sitimulation
208876|NCT01905995|local field potentials
208877|NCT01905969|Gastric caner, adjuvant chemotherapy
208878|NCT01905917|Stroke
208879|NCT01905904|electroconvulsive therapy
208880|NCT01905904|seizures
208881|NCT01905904|sevoflurane
208882|NCT01905891|Non melanoma skin cancer
208883|NCT01905891|Field of cancerization
208884|NCT01905891|Skin carcinogenesis
208885|NCT01905865|Uncertainty
208886|NCT01905865|Undiagnosed Disease
208887|NCT01905865|Coping
208888|NCT01905852|Transcatheter Aortic Valve Replacement
208889|NCT01905852|Ejection Fraction
208890|NCT01905852|Fractional Flow Reserve
208891|NCT01905852|Myocardial Fibrosis
208892|NCT01905839|Rigidity
208893|NCT01905839|Assessment
208894|NCT01905839|Parkinson's Disease
208895|NCT01905839|Physiological Measures
208896|NCT01905826|Hematopoiesis
208897|NCT01905826|Immunodeficiency
208898|NCT01905826|Myelodysplasia/Leukemia
208899|NCT01905826|Lymphedema
208900|NCT01905826|Pulmonary Alveolar Proteinosis
208901|NCT01905800|Vertigo and dizziness.
208902|NCT01905800|semicircular canals
208903|NCT01905774|Renal Function
208904|NCT01905761|obesity
208905|NCT01905748|Coagulation
208906|NCT01905735|RA
208907|NCT01905722|MRI
208908|NCT01905722|metabolism
208909|NCT01905722|healthy
208910|NCT01905722|7 Tesla
208911|NCT01905709|C diff
208912|NCT01905709|CDI
208913|NCT01905709|clostridium difficile associated diarrhea
208914|NCT01905670|Cardiac Resynchronization Therapy
208915|NCT01905670|cardiac pacing
208916|NCT01905670|electrical stimulation
208917|NCT01905670|bi-ventricular pacing
208918|NCT01905657|PD1
208919|NCT01905657|PD-1
208920|NCT01905657|PDL1
208921|NCT01905657|PD-L1
208922|NCT01905644|Vaginal delivery
208923|NCT01905644|Perineal lesions
208924|NCT01905644|Anal sphincter rupture
208925|NCT01905644|Ultrasound
208926|NCT01905618|Medical Education
208927|NCT01905618|Tobacco Dependence Treatment
208928|NCT01905618|Physician Delivered Intervention
208929|NCT01905592|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
208930|NCT01905592|BRCA1 Gene Mutation
208931|NCT01905592|BRCA2 Gene Mutation
208932|NCT01905592|Parp Inhibitor
208933|NCT01905592|BRCA
208934|NCT01905579|flaremetry
208935|NCT01905579|aqueous proteins
208936|NCT01905579|clinical grading
208937|NCT01905579|Compare flaremetry readings with the protein content of the aqueous
208938|NCT01905579|Compare flaremetry readings with clinical grading of flare
208939|NCT01905566|Plaque, Atherosclerotic
208940|NCT01905566|clopidogrel
208941|NCT01905566|ticagrelor
208942|NCT01905566|Fluorodeoxyglucose F18
208943|NCT01905566|Positron-Emission Tomography and Computed Tomography
208944|NCT01905527|Multiple Sclerosis
208945|NCT01905527|Relapsing-Remitting
208946|NCT01905527|Rebif
208947|NCT01905527|Quintiles Geographic Area Group
208948|NCT01905527|Standard Subgroup
208949|NCT01905527|Custom Subgroup
208950|NCT01905527|RxCrossroads Geographic Area Group
208951|NCT01905501|Balanced anesthesia
208952|NCT01905501|Inhalation anesthesia
208953|NCT01905501|Reperfusion injury
208954|NCT01905501|Microsurgical Free flap
208955|NCT01905475|STEMI
208956|NCT01905475|AMI
208957|NCT01905475|repair
208958|NCT01905462|Cervarix
208959|NCT01905462|Spontaneous abortion
208960|NCT01905462|Vaccine
208961|NCT01905462|Human Papillomavirus
208962|NCT01905436|Filariasis
208963|NCT01905436|Onchocerciasis
208964|NCT01905436|Albendazole
208965|NCT01905436|Ivermectin
208966|NCT01905436|STH Soil Transmitted Helminth infections
208967|NCT01905436|MDA Mass Drug Administration
208968|NCT01905423|Filariasis
208969|NCT01905423|Albendazole
208970|NCT01905423|Diethylcarbamazine
208971|NCT01905423|STH Soil Transmitted Helminths
208972|NCT01905423|MDA Mass Drug Administration
208973|NCT01905384|pancreatic cancer
208974|NCT01905384|cholangiocarcinoma
208975|NCT01905384|metastatic malignancy
208976|NCT01905384|jaundice
208977|NCT01905371|amphetamine
208978|NCT01905371|stroke recovery
208979|NCT01905319|juvenile idiopathic arthritis
208980|NCT01905319|incidence rate
208981|NCT01905306|dental implants
208982|NCT01905306|immediate loading
208983|NCT01905306|full-arch
208984|NCT01905306|computer guided implant surgery
208985|NCT01905280|allograft
208986|NCT01905280|acellular dermal matrix
208987|NCT01905280|alveolar ridge
208988|NCT01905267|mindfulness
208989|NCT01905267|relapse prevention
208990|NCT01905267|recovery
208991|NCT01905267|depression
208992|NCT01905267|adolescents
208993|NCT01905254|Transient elastography
208994|NCT01905254|mini-laparoscopy
208995|NCT01905254|liver biopsy
208996|NCT01905254|liver cirrhosis
208997|NCT01905254|autoimmune hepatitis
208998|NCT01905228|Metastatic Advance Solid Neoplasms
208999|NCT01905228|Unresectable Advance Solid Neoplasms
209000|NCT01905215|Respiratory Syncytial Virus
209001|NCT01905215|Reactogenicity
209002|NCT01905215|Immunogenicity
209003|NCT01905215|Vaccination
209004|NCT01905215|Safety
209005|NCT01905202|Proton Pump Inhibitor
209006|NCT01905202|Safety
209007|NCT01905202|Tolerability
209008|NCT01905202|pH control
209009|NCT01905202|Bile Acid
209010|NCT01905189|pulmonary arterial hypertension
209011|NCT01905189|cardiac resynchronization therapy
209012|NCT01905176|Heart Failure
209013|NCT01905176|Randomized Control Trial
209014|NCT01905176|Disease management
209015|NCT01905176|Self-care
209016|NCT01905176|Nursing
209017|NCT01905176|Patient education as topic
209018|NCT01905163|Laparoscopy, interval debulking surgery
209019|NCT01905150|pancreatic Cancer
209020|NCT01905150|G-FLIP, Gemcitabine 5FU Leucovorin Irinotecan Oxaliplatin
209021|NCT01905150|G-FLIP-DM (G-FLIP + Low doses Docetaxel and Mitomycin C)
209022|NCT01905150|Vitamin C (ascorbic acid)
209023|NCT01905137|Myofascial pelvic pain
209024|NCT01905124|Uveitis
209025|NCT01905124|Intermediate uveitis
209026|NCT01905124|Posterior uveitis
209027|NCT01905098|Detoxification
209028|NCT01905098|Sauna
209029|NCT01905098|Hyperthermia
209030|NCT01905072|Obesity
209031|NCT01905072|Breastfeeding
209032|NCT01905072|Educational Intervention
209033|NCT01905059|HIV infection
209034|NCT01905059|second line ART
209035|NCT01905059|maintenance strategies
209036|NCT01905059|Protease inhibitors
209037|NCT01905059|mono or bi-therapy
209038|NCT01905033|Sepsis
209039|NCT01905033|Pneumonia
209040|NCT01905033|Peritonitis
209041|NCT01905033|Biomarkers
209042|NCT01905033|Transcriptomics
209043|NCT01905033|Pathogen detection
209044|NCT01905020|Type 1 diabetes
209045|NCT01905020|Hypoglycemia
209046|NCT01905020|Insulin
209047|NCT01905020|Glucagon
209048|NCT01905020|Closed-loop system
209049|NCT01905020|Artificial pancreas
209050|NCT01905007|Implantable cardioverter defibrillator
209051|NCT01905007|Defibrillation threshold testing
209052|NCT01904994|HIV (Human Immunodeficiency Virus)
209053|NCT01904994|ART (antiretroviral therapy)
209054|NCT01904994|financial incentive
209055|NCT01904994|linkage
209056|NCT01904994|retention
209057|NCT01904994|SMS (Short Message Service) appointment reminder
209058|NCT01904994|accelerated ART
209059|NCT01904994|CD4+ count
209060|NCT01904903|Breast Cancer HER2 Positive
209061|NCT01904903|Cardiac Safety
209062|NCT01904890|Asian Americans
209063|NCT01904890|colorectal cancer screening
209064|NCT01904890|cancer prevention
209065|NCT01904890|Filipinos Americans
209066|NCT01904890|Hmong Americans
209067|NCT01904890|Korean Americans
209068|NCT01904890|Randomized Controlled Trials
209069|NCT01904877|HIV testing
209070|NCT01904877|linkage
209071|NCT01904877|care
209072|NCT01904864|randomized controlled trial
209073|NCT01904864|iron medication
209074|NCT01904864|Anemia
209075|NCT01904864|Hematologic Disease
209076|NCT01904864|Anemia, Iron deficiency
209077|NCT01904864|anemia, nutritional
209078|NCT01904864|ferrous sulfate
209079|NCT01904864|NovaFerrum®
209080|NCT01904851|Peripheral Arterial Disease
209081|NCT01904851|Stents
209082|NCT01904851|Registry
209083|NCT01904851|Angioplasty
209084|NCT01904851|Endovascular Procedures
209085|NCT01904786|Hypoxic Ischemic Encephalopathy
209086|NCT01904786|Newborn
209087|NCT01904786|Outcomes
209088|NCT01904786|Melatonin
209089|NCT01904773|Combined Multiple Motor and Vocal Tic Disorder; Tourette Disorder; Gilles de la Tourette Syndrome; Tourette Disease
209090|NCT01904760|agitation
209091|NCT01904760|delirium
209092|NCT01904760|dexmedetomidine
209093|NCT01904760|head and neck surgery
209094|NCT01904760|microvascular free tissue transfer
209095|NCT01904760|flap
209096|NCT01904747|Food
209097|NCT01904747|Bioavailability
209098|NCT01904747|Fasted
209099|NCT01904747|Fed
209100|NCT01904734|testosterone
209101|NCT01904734|hypogonadism
209102|NCT01904734|pituitary
209103|NCT01904708|Phenylketonuria
209104|NCT01904708|PKU
209105|NCT01904708|Exercise
209106|NCT01904708|Muscle Protein Synthesis
209107|NCT01904708|Plasma Phenylalanine concentration
209108|NCT01904695|resistant hypertension
209109|NCT01904695|causal inference
209110|NCT01904695|a chorot study
209111|NCT01904695|recipe of removing both phlegm and blood stasis
209112|NCT01904682|Erythrocyte transfusion
209113|NCT01904682|Erythropoiesis-stimulating agent
209114|NCT01904682|International Prognostic Scoring System
209115|NCT01904669|Fertility
209116|NCT01904669|Infertility
209117|NCT01904669|Pregnancy
209118|NCT01904669|Conception
209119|NCT01904669|Behavioral
209120|NCT01904669|Lifestyle
209121|NCT01904669|Preconception Care
209122|NCT01904669|Women's Health
209123|NCT01904669|Abortion, Spontaneous
209124|NCT01904669|Cohort Studies
209125|NCT01904669|Epidemiology
209126|NCT01904669|Internet
209127|NCT01904656|Colorectal Cancer Screening
209128|NCT01904656|Ohio Appalachia
209129|NCT01904630|gene sequencing
209130|NCT01904630|familial
209131|NCT01904630|risk factors
209132|NCT01904617|Length of labor
209133|NCT01904617|second stage of labor
209134|NCT01904617|intravenous hydration of labor
209135|NCT01904617|intravenous glucose
209136|NCT01904604|Peanut Allergy
209137|NCT01904604|Food Allergy
209138|NCT01904604|Viaskin peanut patch
209139|NCT01904604|Allergen Immunotherapy
209140|NCT01904604|Epicutaneous Immunotherapy
209141|NCT01904604|Whole peanut extract
209142|NCT01904604|Allergenic product
209143|NCT01904604|Immediate hypersensitivity
209144|NCT01904591|Spinal Cord Injury
209145|NCT01904591|Antioxidants
209146|NCT01904591|tractography
209147|NCT01904591|ASIA assessment
209148|NCT01904578|Menopause
209149|NCT01904578|Sleep quality
209150|NCT01904578|Acupressure
209151|NCT01904565|Hyperthermia,
209152|NCT01904565|Proton beam therapy
209153|NCT01904565|Soft Tissue Sarcoma
209154|NCT01904565|Radiotherapy
209155|NCT01904565|Phase I/II trial
209156|NCT01904552|Apical periodontitis
209157|NCT01904552|Dentaport ZX
209158|NCT01904552|electronic apex locators
209159|NCT01904552|i-Root
209160|NCT01904552|Raypex 5
209161|NCT01904552|working length
209162|NCT01904526|Guanfacine
209163|NCT01904526|PK/PD
209164|NCT01904526|Smokers
209165|NCT01904513|Metals
209166|NCT01904513|Pesticides
209167|NCT01904513|Toxicity
209168|NCT01904500|Cesarean delivery
209169|NCT01904474|obesity
209170|NCT01904474|overweight
209171|NCT01904474|technology
209172|NCT01904474|internet
209173|NCT01904474|intervention
209174|NCT01904474|adolescents
209175|NCT01904461|tonsillectomy
209176|NCT01904461|children
209177|NCT01904461|vacuum
209178|NCT01904461|medical device
209179|NCT01904461|pain
209180|NCT01904461|hemorrhage
209181|NCT01904461|post-surgical complications
209182|NCT01904448|pediatric
209183|NCT01904448|profound hearing loss
209184|NCT01904448|auditory brainstem implant
209185|NCT01904448|cochlear implant
209186|NCT01904448|developmental or acquired cochlear nerve deficiency (CND)
209187|NCT01904448|cochlear aplasia (Michel)
209188|NCT01904448|post-meningitis cochlear ossification
209189|NCT01904448|cochlear malformation
209190|NCT01904448|CND
209191|NCT01904422|Diabetes mellitus.
209192|NCT01904422|Periodontitis
209193|NCT01904422|Periodontal treatment.
209194|NCT01904357|Cefazolin, Pediatric
209195|NCT01904344|Sleep
209196|NCT01904344|Sleep- related breathing disorders
209197|NCT01904344|Respiratory pathology
209198|NCT01904331|Cardiotoxicity
209199|NCT01904331|long-term effects
209200|NCT01904331|chemotherapy
209201|NCT01904331|radiotherapy
209202|NCT01904318|male
209203|NCT01904318|Phase I
209204|NCT01904318|A dose block-randomized
209205|NCT01904318|Double-blinded
209206|NCT01904318|Placebo controlled
209207|NCT01904318|Single Dose
209208|NCT01904318|dose Escalation
209209|NCT01904318|IDP-73152 mesylate
209210|NCT01904318|Food Effect
209211|NCT01904318|Pharmacokinetics
209212|NCT01904318|health male volunteer
209213|NCT01904318|PDF inhibitor
209214|NCT01904305|Pneumonia
209215|NCT01904253|Second line Small Cell Lung Cancer, (SCLC), Refractory or Sensitive to First line Platinum based chemotherapy
209216|NCT01904240|Parkinson's disease
209217|NCT01904240|GI tract
209218|NCT01904240|Lipopolysaccharide binding protein
209219|NCT01904227|Borderline Personality Disorder
209220|NCT01904227|Dialectical Behavior Therapy
209221|NCT01904214|renal impairement
209222|NCT01904214|pharmacokinetics
209223|NCT01904201|Immune function
209224|NCT01904201|Interferon-gamma release assays
209225|NCT01904201|Active HIV cell Reservoirs
209226|NCT01904188|microbial identification
209227|NCT01904188|antibiotic resistance
209228|NCT01904188|GeneZ
209229|NCT01904188|sepsis
209230|NCT01904188|Systemic Inflammatory Response Syndrome
209231|NCT01904175|Stem cell transplantation, non-myeloablative
209232|NCT01904149|Moderate to severe acute pain
209233|NCT01904149|Postoperative pain
209234|NCT01904149|Abdominal hysterectomy
209235|NCT01904149|Analgesics
209236|NCT01904149|Dexketoprofen
209237|NCT01904149|Tramadol
209238|NCT01904136|Leukemia
209239|NCT01904136|Myeloproliferative Diseases
209240|NCT01904136|Blood And Marrow Transplantation
209241|NCT01904136|High Risk Myeloid Malignancies
209242|NCT01904136|Acute myeloid leukemia
209243|NCT01904136|AML
209244|NCT01904136|Myelodysplastic syndrome
209245|NCT01904136|MDS
209246|NCT01904136|Chronic myeloid leukemia
209247|NCT01904136|CML
209248|NCT01904136|Haploidentical Stem-cell Transplantation
209249|NCT01904136|HaploSCT
209250|NCT01904136|Expanded natural killer cells
209251|NCT01904136|NK
209252|NCT01904136|Melphalan
209253|NCT01904136|Alkeran
209254|NCT01904136|Mesna
209255|NCT01904136|Mesnex
209256|NCT01904136|Cyclophosphamide
209257|NCT01904136|Cytoxan
209258|NCT01904136|Neosar
209259|NCT01904136|Tacrolimus
209260|NCT01904136|Prograf
209261|NCT01904136|Mycophenolate mofetil
209262|NCT01904136|MMF
209263|NCT01904136|CellCept
209264|NCT01904136|G-CSF
209265|NCT01904136|Filgrastim
209266|NCT01904136|Neupogen
209267|NCT01904136|Fludarabine
209268|NCT01904136|Fludarabine phosphate
209269|NCT01904136|Fludara
209270|NCT01904123|Brain cancer
209271|NCT01904123|Central nervous system neoplasms
209272|NCT01904123|CNS
209273|NCT01904123|Melanoma
209274|NCT01904123|Glioblastoma Multiforme
209275|NCT01904123|GBM
209276|NCT01904123|Solid tumors
209277|NCT01904123|Metastatic to the brain
209278|NCT01904123|WP1066
209279|NCT01904123|Recurrent malignant glioma
209280|NCT01904123|Glioblastoma
209281|NCT01904123|Anaplastic glioma
209282|NCT01904123|Advanced Brain Tumor Imaging
209283|NCT01904123|ABTI
209284|NCT01904110|Risedronate,cholecalciferol,BMD,montly,weekly,compliance
209285|NCT01904097|Fibromyalgia
209286|NCT01904097|Transcranial Direct Current Stimulation
209287|NCT01904097|tDCS
209288|NCT01904097|Pregabalin
209289|NCT01904097|Functional Neuroimaging
209290|NCT01904097|Near Infrared Spectroscopy
209291|NCT01904097|NIRS
209292|NCT01904097|Chronic Pain
209293|NCT01904097|Transcranial Magnetic Stimulation
209294|NCT01904097|TMS
209295|NCT01904084|Distal radius fracture
209296|NCT01904071|Hip Fracture
209297|NCT01904071|Ultrasound
209298|NCT01904071|Nerve Block
209299|NCT01904058|PBC
209300|NCT01904032|Vitamin D
209301|NCT01904032|Diabetes
209302|NCT01904032|Self-Management
209303|NCT01904032|Depression
209304|NCT01904032|Women
209305|NCT01904019|arthroplasty
209306|NCT01904019|trapezio-metacarpial
209307|NCT01904006|Embryo, group,low oxygen tension, assisted reproduction
209308|NCT01903980|Epipericardial Fat Necrosis
209309|NCT01903980|Fat Necrosis
209310|NCT01903980|Chest Pain
209311|NCT01903980|Pericardial Necrosis
209312|NCT01903980|Pleuritic pain
209313|NCT01903967|Pituitary
209314|NCT01903967|CGH array
209315|NCT01903967|Tumor
209316|NCT01903941|exercise
209317|NCT01903928|cytomegalovirus
209318|NCT01903928|DNA vaccine
209319|NCT01903928|transplantation
209320|NCT01903928|HCT
209321|NCT01903902|Coronary artery disease
209322|NCT01903902|Balloon angioplasty
209323|NCT01903902|Drug-eluting balloon
209324|NCT01903889|AE adverse event
209325|NCT01903889|AIDS acquired immunodeficiency syndrome
209326|NCT01903889|ALT (SGPT) alanine aminotransferase
209327|NCT01903889|ART antiretroviral therapy
209328|NCT01903889|AST (SGOT) aspartate aminotransferase
209329|NCT01903889|DCF data collection forms
209330|NCT01903889|DMC Data Monitoring Committee
209331|NCT01903889|FDA (U.S.) Food and Drug Administration
209332|NCT01903889|GCP Good Clinical Practice guidelines
209333|NCT01903889|HB sAg Hepatitis B surface antigen
209334|NCT01903889|ICH International Conference of Harmonization
209335|NCT01903889|IND Investigational New Drug Application
209336|NCT01903889|IRB Institutional Review Board
209337|NCT01903889|IU International units
209338|NCT01903889|mg milligram(s)
209339|NCT01903889|mm3 cubic millimeter(s)
209340|NCT01903889|PCR polymerase chain reaction
209341|NCT01903889|SAE serious adverse event
209342|NCT01903889|µg microgram
209343|NCT01903889|ULN upper limit of the normal range
209344|NCT01903889|WB Western Blot
209345|NCT01903889|ANC Antenatal care
209346|NCT01903889|ARV Antiretroviral
209347|NCT01903889|C&T Care and treatment
209348|NCT01903889|CPR Contraceptive prevalence rate
209349|NCT01903889|DHS Demographic and Health Survey
209350|NCT01903889|EGPAF Elizabeth Glaser Pediatric AIDS Foundation
209351|NCT01903889|FP Family planning
209352|NCT01903889|HIV Human immunodeficiency virus
209353|NCT01903889|HTC HIV testing and counseling
209354|NCT01903889|IUCD Intrauterine contraceptive device
209355|NCT01903889|MCH Maternal/child health
209356|NCT01903889|PDA Personal digital assistant
209357|NCT01903889|PEPFAR President's Emergency Plan for AIDS Relief
209358|NCT01903889|PHSC Protection of Human Subjects Committee
209359|NCT01903889|PMTCT Prevention of maternal to child transmission
209360|NCT01903889|STAR-SW Strengthening TB and HIV/AIDS Response in the South Western Region of Uganda
209361|NCT01903889|STI Sexually transmitted infection
209362|NCT01903889|TM Technical monitor
209363|NCT01903889|USAID United States Agency for International Development
209364|NCT01903889|WHO World Health Organization
209365|NCT01903863|FFP
209366|NCT01903863|fresh frozen plasma
209367|NCT01903863|ECMO
209492|NCT01903174|Breast Tissue Expander
209368|NCT01903863|extracorporeal membrane oxygenation
209369|NCT01903863|anticoagulation
209370|NCT01903863|transfusion
209371|NCT01903850|Benign central airway obstruction
209372|NCT01903850|Malignant central airway obstruction
209373|NCT01903850|Spray cryotherapy
209374|NCT01903850|Endoluminal tumors
209375|NCT01903850|Airway granulation tissue
209376|NCT01903837|Schizophrenia
209377|NCT01903837|Olanzapine
209378|NCT01903837|Samidorphan
209379|NCT01903837|Alkermes
209380|NCT01903824|Irdabisant
209381|NCT01903824|cognitive impairment
209382|NCT01903811|carfilzomib
209383|NCT01903811|relapsed
209384|NCT01903811|refractory
209385|NCT01903811|multiple myeloma
209386|NCT01903785|exercise-induced bronchoconstriction (EIB)
209387|NCT01903785|inhaled salbutamol
209388|NCT01903785|performance enhancing
209389|NCT01903785|cycling
209390|NCT01903733|Subjects
209391|NCT01903733|Chronic Myeloid Leukemia
209392|NCT01903733|CML
209393|NCT01903733|Bosutinib
209394|NCT01903733|Extension
209395|NCT01903707|Schizophrenia
209396|NCT01903707|Psychosis
209397|NCT01903707|Cognitive deficits
209398|NCT01903681|Sleep problems, autism spectrum disorder, prolonged-release melatonin, Circadin, endogenous saliva melatonin
209399|NCT01903681|Smith-Magenis syndrome, Angelman syndrome, Tuberous Sclerosis
209400|NCT01903603|cerebral palsy
209401|NCT01903603|multi-modal brain techniques
209402|NCT01903603|MRI
209403|NCT01903603|Kinematic
209404|NCT01903603|motor control
209405|NCT01903590|TVT,TOT,Randomized
209406|NCT01903577|Ergonomics
209407|NCT01903577|Robotic Surgery
209408|NCT01903577|Laparoscopic Surgery
209409|NCT01903564|fetus
209410|NCT01903564|fetal arrhythmia
209411|NCT01903564|fetal heart rate
209412|NCT01903564|long QT syndrome
209413|NCT01903551|post-operative pain
209414|NCT01903551|loco-regional analgesia
209415|NCT01903551|minimally invasive surgery
209416|NCT01903512|TMJ arthrocentesis
209417|NCT01903512|internal derangement
209418|NCT01903512|conservative treatment
209419|NCT01903486|Trouble swallowing
209420|NCT01903486|dysphagia
209421|NCT01903486|disorder of the esophagus
209422|NCT01903473|Allogeneic hematopoietic cell transplantation
209423|NCT01903473|GVHD
209424|NCT01903473|Regulatory T cells
209425|NCT01903473|Steroid refractory
209426|NCT01903473|Rapamycin
209427|NCT01903473|Immune recovery
209428|NCT01903473|Infusion
209429|NCT01903473|HLA-identical sibling
209430|NCT01903473|HLA-matched unrelated donor
209431|NCT01903447|Internalizing psychopathologies
209432|NCT01903447|Depression
209433|NCT01903447|Anxiety
209434|NCT01903447|MRI
209435|NCT01903447|medication treatment
209436|NCT01903447|psychotherapy
209437|NCT01903447|brain function
209438|NCT01903421|Elderly surgical patients
209439|NCT01903421|Alzheimer's disease
209440|NCT01903421|Dementia
209441|NCT01903421|Elderly
209442|NCT01903421|Surgery
209443|NCT01903395|Colorectal Neoplasms/*drug therapy/*secondary
209444|NCT01903395|Health Services Accessibility
209445|NCT01903395|Humans
209446|NCT01903395|Supportive Care Needs
209447|NCT01903395|Psychooncology
209448|NCT01903395|Primary Health Care/*methods
209449|NCT01903395|Treatment Outcome
209450|NCT01903395|Socioeconomic Factors
209451|NCT01903395|Quality Assurance, Health Care
209452|NCT01903395|Adult
209453|NCT01903395|Aged
209454|NCT01903395|Aged, 80 and over
209455|NCT01903369|Shear wave
209456|NCT01903369|Elastography
209457|NCT01903369|Repeatability and Reproducibility
209458|NCT01903343|Shear wave
209459|NCT01903343|Elastography
209460|NCT01903343|Repeatability and Reproducibility
209461|NCT01903330|ERC1671
209462|NCT01903330|GM-CSF
209463|NCT01903330|Cyclophosphamide
209464|NCT01903330|Bevacizumab
209465|NCT01903304|Olive oil
209466|NCT01903304|DTH
209467|NCT01903304|elderly
209468|NCT01903278|interferon
209469|NCT01903278|ribavirin
209470|NCT01903278|sustained virological response
209471|NCT01903265|pain
209472|NCT01903265|sleep
209473|NCT01903252|UC
209474|NCT01903226|spinal cord injury
209475|NCT01903226|physical capacity
209476|NCT01903226|energy expenditure
209477|NCT01903226|training
209478|NCT01903213|Peritoneal dialysis
209479|NCT01903213|Bixalomer
209480|NCT01903213|Chronic renal failure patients with Hyperphosphatemia
209481|NCT01903213|Kiklin®
209482|NCT01903200|Antipsychotic
209483|NCT01903200|FK949E
209484|NCT01903200|Quetiapine
209485|NCT01903200|Elderly
209486|NCT01903187|hypertension
209487|NCT01903187|resistant hypertension
209488|NCT01903187|renal denervation
209489|NCT01903174|Breast Cancer
209490|NCT01903174|Breast Reconstruction
209491|NCT01903174|Breast Tissue Expansion
209493|NCT01903174|Two Stage Breast Reconstruction
209494|NCT01903161|delayed remote ischemic preconditioning
209495|NCT01903161|troponin
209496|NCT01903161|valve replacement surgery
209497|NCT01903148|ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
209498|NCT01903135|Obesity Hypoventilation Syndrome
209499|NCT01903135|Prevalence
209500|NCT01903135|Bicarbonate
209501|NCT01903096|Panic disorder
209502|NCT01903096|Generalized anxiety disorder
209503|NCT01903096|Social phobia
209504|NCT01903096|Specific phobia
209505|NCT01903096|Major depressive disorder
209506|NCT01903096|Dysthymia
209507|NCT01903096|Somatizations disorder
209508|NCT01903096|Pain disorder
209509|NCT01903083|Pancreas
209510|NCT01903083|Pancreatic cancer
209511|NCT01903083|Immunotherapy
209512|NCT01903083|Chemotherapy
209513|NCT01903083|Radiation
209514|NCT01903083|Surgery
209515|NCT01903083|Pancreaticoduodenectomy
209516|NCT01903057|Mass Drug Administration
209517|NCT01903057|Neglected Tropical Diseases
209518|NCT01903057|Preventive Chemotherapy and Transmission Control
209519|NCT01903057|Preventive Chemotherapy
209520|NCT01903044|Lowe extremity ischemia
209521|NCT01903044|Bone marrow
209522|NCT01903044|Neoangiogenesis
209523|NCT01903005|Opioid, Dependence, agonist, Buprenorphine, Naloxone
209524|NCT01902966|Cervical Cancer
209525|NCT01902966|Propranolol
209526|NCT01902966|Betachron
209527|NCT01902966|Inderal
209528|NCT01902966|Beta blocker
209529|NCT01902966|Questionnaires
209530|NCT01902966|Surveys
209531|NCT01902966|Symptom inventory
209532|NCT01902966|Anxiety and depression survey
209533|NCT01902966|Pain inventory
209534|NCT01902966|Quality of life survey
209535|NCT01902966|Relaxation audio recording
209536|NCT01902966|MP3 player
209537|NCT01902966|Diary
209538|NCT01902953|Sentinel lymph nodes
209539|NCT01902953|colon cancer
209540|NCT01902953|rectal cancer
209541|NCT01902953|immunohistochemistry
209542|NCT01902927|Exercise tolerance
209543|NCT01902927|Dyspnea
209544|NCT01902927|Affective distraction
209545|NCT01902914|hearing aids
209546|NCT01902914|hearing disability
209547|NCT01902914|community
209548|NCT01902914|hearing aids service
209549|NCT01902901|Whole Genome Sequencing
209550|NCT01902901|Carrier status
209551|NCT01902901|Genetics
209552|NCT01902888|popliteal artery
209553|NCT01902888|aneurysm
209554|NCT01902888|popliteal artery aneurysm
209555|NCT01902888|asymptomatic aneurysm
209556|NCT01902888|mural thrombus
209557|NCT01902888|Viabahn
209558|NCT01902888|Gore
209559|NCT01902888|Endoprosthesis
209560|NCT01902862|Lymphoma, follicular
209561|NCT01902862|Bortezomib
209562|NCT01902862|Rituximab
209563|NCT01902849|intravenous anesthesia
209564|NCT01902849|inhalational anesthesia
209565|NCT01902849|interleukins
209566|NCT01902849|colorectal surgery
209567|NCT01902836|Dialyzable Leukocyte Extracts
209568|NCT01902836|Transferon
209569|NCT01902836|atopic dermatitis
209570|NCT01902823|Nurse Navigator
209571|NCT01902823|Satisfaction with Care
209572|NCT01902823|Quality of Life
209573|NCT01902823|Symptom Distress
209574|NCT01902797|Refugee camps
209575|NCT01902797|Household residence
209576|NCT01902797|Treated bednets
209577|NCT01902797|PCR
209578|NCT01902784|Intensive Care Unit patients and families
209579|NCT01902784|Surrogate decision making
209580|NCT01902784|Life Sustaining Treatments (LST)
209581|NCT01902771|Dendritic Cell Vaccine
209582|NCT01902771|DCV
209583|NCT01902771|Pediatric
209584|NCT01902771|Brain Tumor
209585|NCT01902771|In Situ
209586|NCT01902771|Lysate
209587|NCT01902771|Tumor Lysate
209588|NCT01902771|Glioblastoma Multiforme
209589|NCT01902771|GBM
209590|NCT01902771|Pheresis
209591|NCT01902771|Leukapheresis
209592|NCT01902771|High Grade Glioma
209593|NCT01902771|HGG
209594|NCT01902758|exercise performance
209595|NCT01902693|HIV
209596|NCT01902693|Chemotherapy
209597|NCT01902693|Cohort
209598|NCT01902693|Cancer
209599|NCT01902693|HAART
209600|NCT01902693|Malignancy
209601|NCT01902680|Prostate cancer, permanent implant brachytherapy, image fusion, focal therapy, active surveillance
209602|NCT01902667|Retroperitoneal Sarcoma
209603|NCT01902667|Magnetic Resonance Imaging
209604|NCT01902654|Osteoarthritis
209605|NCT01902654|cardiovascular disease
209606|NCT01902641|succinylcholine
209607|NCT01902641|rocuronium
209608|NCT01902641|sugammadex
209609|NCT01902641|Intubating Conditions
209610|NCT01902641|short Procedures
209611|NCT01902563|osteopathic manipulative treatment
209612|NCT01902563|newborns
209613|NCT01902563|preterm infants
209614|NCT01902563|procedures
209615|NCT01902550|Healthy
209616|NCT01902550|JNJ-54452840
209746|NCT01902004|Comorbidity
209617|NCT01902550|Metoprolol Tartrate Immediate-Release
209618|NCT01902550|Placebo
209619|NCT01902550|Male
209620|NCT01902537|Constipation
209621|NCT01902537|Prucalopride
209622|NCT01902524|Chronic Pain
209623|NCT01902524|Fentanyl-TTS
209624|NCT01902524|Fentanyl Patch
209625|NCT01902524|Transdermal
209626|NCT01902524|Non-cancer Pain
209627|NCT01902498|aspirin
209628|NCT01902485|Contraception
209629|NCT01902485|Medical Abortion
209630|NCT01902485|Implant
209631|NCT01902485|Injectable
209632|NCT01902485|Quickstart
209633|NCT01902472|HIV-1
209634|NCT01902472|Truvada
209635|NCT01902472|FTC/TDF
209636|NCT01902472|Pre-exposure prophylaxy
209637|NCT01902472|PrEP
209638|NCT01902472|Resistance
209639|NCT01902459|Hemostasis
209640|NCT01902446|Chlorhexidine
209641|NCT01902446|Randomized Controlled Trial
209642|NCT01902446|Emergency Medical Services
209643|NCT01902446|Intubation, Endotracheal
209644|NCT01902407|Pcrit
209645|NCT01902407|Critical closing pressure
209646|NCT01902407|Down syndrome
209647|NCT01902407|Obstructive Sleep Apnea
209648|NCT01902407|Sleep MRI
209649|NCT01902394|digestive health and natural defenses
209650|NCT01902368|Gluten free diet
209651|NCT01902355|Central Venous Catheterization
209652|NCT01902329|Acute Myeloid Leukemia
209653|NCT01902329|Antibody-Drug Conjugate
209654|NCT01902329|CD33 Antigen
209655|NCT01902329|Immunotherapy
209656|NCT01902329|Drug Therapy
209657|NCT01902329|Acute Myelogenous Leukemia
209658|NCT01902329|Acute Promyelocytic Leukemia
209659|NCT01902329|APL
209660|NCT01902316|Type 2 Diabetes Mellitus
209661|NCT01902316|peptide biomarker
209662|NCT01902316|early diagnosis
209663|NCT01902316|label free
209664|NCT01902303|Herpes Labialis
209665|NCT01902303|Herpes Simplex
209666|NCT01902303|Herpes
209667|NCT01902303|Ultra Violet (UV) Induced
209668|NCT01902290|Inadequately controlled asthma, brodalumab, AMG 827
209669|NCT01902277|Delirium
209670|NCT01902277|Intensive Care Unit
209671|NCT01902277|Critical illness
209672|NCT01902264|Levomefolate calcium
209673|NCT01902264|Contraceptives, oral, combined
209674|NCT01902264|Neural tube defects
209675|NCT01902251|Phase 1
209676|NCT01902251|Prostate cancer
209677|NCT01902251|Bioavailability
209678|NCT01902251|Food effect
209679|NCT01902251|Pharmacokinetics
209680|NCT01902251|Xtandi
209681|NCT01902251|Enzalutamide
209682|NCT01902251|MDV3100
209683|NCT01902238|neuroendocrine tumor
209684|NCT01902238|ethanol
209685|NCT01902238|endoscopic ultrasonography
209686|NCT01902225|Lymphoma
209687|NCT01902225|T-Cell
209688|NCT01902225|Cutaneous
209689|NCT01902225|Doxil
209690|NCT01902225|romidepsin
209691|NCT01902225|skin
209692|NCT01902186|HIV
209693|NCT01902186|osteopenia
209694|NCT01902186|t-score
209695|NCT01902186|DEXA
209696|NCT01902186|tenofovir
209697|NCT01902186|raltegravir
209698|NCT01902147|abdominal
209699|NCT01902147|thoracic
209700|NCT01902147|arthroplasty
209701|NCT01902134|Moderate to severe acute pain
209702|NCT01902134|Postoperative pain
209703|NCT01902134|Hip arthroplasty
209704|NCT01902134|Analgesics
209705|NCT01902134|Dexketoprofen
209706|NCT01902134|Tramadol
209707|NCT01902108|clonidine
209708|NCT01902108|bupivacaine
209709|NCT01902108|post-operative pain
209710|NCT01902108|arthrodesis
209711|NCT01902108|discectomy
209712|NCT01902108|local infiltration
209713|NCT01902095|tooth pastes
209714|NCT01902095|tooth powders
209715|NCT01902095|Stain Index
209716|NCT01902082|ARDS
209717|NCT01902082|mesenchymal stem cells
209718|NCT01902082|Safety
209719|NCT01902082|Cytokines
209720|NCT01902069|sweet and fat preference
209721|NCT01902056|allograft
209722|NCT01902056|acellular dermal matrix
209723|NCT01902056|Alloderm
209724|NCT01902043|diabetes mellitus
209725|NCT01902043|cohort study
209726|NCT01902043|quality of care
209727|NCT01902043|quality indicators, Health care
209728|NCT01902043|quality of Health Care
209729|NCT01902043|outcome and process assessment
209730|NCT01902043|health services research
209731|NCT01902043|chronic diseases prevention and management
209732|NCT01902017|Joint
209733|NCT01902017|Contracture
209734|NCT01902017|Elbow
209735|NCT01902017|Fracture
209736|NCT01902017|Dislocation
209737|NCT01902004|Major Depression
209738|NCT01902004|Geriatric Major Depression
209739|NCT01902004|Executive Cognitive Dysfunction
209740|NCT01902004|Mild Cognitive Impairment
209741|NCT01902004|Older Adults
209742|NCT01902004|Geriatric
209743|NCT01902004|Executive Cognitive Impairment
209744|NCT01902004|Quality of Life
209745|NCT01902004|Disability
209747|NCT01902004|Medical Burden
209748|NCT01902004|Safety
209749|NCT01902004|Candidate Genes
209750|NCT01901991|Nonpalpable breast lesions
209751|NCT01901991|Breast Cancer and carcinoma in situ
209752|NCT01901991|Radioactive seed localization
209753|NCT01901991|Wire-guided localization
209754|NCT01901991|Randomized study
209755|NCT01901978|Obesity
209756|NCT01901978|Insulin Resistance
209757|NCT01901978|Weight loss
209758|NCT01901978|Women
209759|NCT01901952|Self management diabetes intervention
209760|NCT01901939|exercise
209761|NCT01901939|elderly
209762|NCT01901939|activities of daily living
209763|NCT01901939|disability
209764|NCT01901913|Type 1 Diabetes
209765|NCT01901913|Artificial pancreas
209766|NCT01901913|Closed loop
209767|NCT01901900|moderate to severe RA
209768|NCT01901900|anti-TNF inadequate responders
209769|NCT01901887|Adults
209770|NCT01901887|Suicidality
209771|NCT01901861|GLP-1, GIP, DPP-4 inhibition, iset function
209772|NCT01901848|Smoking Cessation
209773|NCT01901848|Stress Disorders, Post-Traumatic
209774|NCT01901848|Psychotherapy
209775|NCT01901822|acellular dermal matrix
209776|NCT01901809|Heart failure, diastolic
209777|NCT01901809|HFpEF
209778|NCT01901809|Diuretics
209779|NCT01901809|Dopamine
209780|NCT01901796|Anxiety
209781|NCT01901796|Depression
209782|NCT01901796|CBT
209783|NCT01901783|allograft
209784|NCT01901783|regeneration
209785|NCT01901783|alveolar ridge
209786|NCT01901770|HPV
209787|NCT01901770|Ohio Appalachia
209788|NCT01901770|HPV vaccine
209789|NCT01901770|No evidence of disease
209790|NCT01901744|Contrast Sensitivity , Pediatric Cataract Surgery,
209791|NCT01901731|transjugular coil embolisation
209792|NCT01901731|endovenous treatment of varicose veins
209793|NCT01901731|pelvic venous reflux
209794|NCT01901731|recurrent varicose veins
209795|NCT01901718|Breakthrough Pain
209796|NCT01901718|Subsys
209797|NCT01901718|Fentanyl
209798|NCT01901718|Opioid
209799|NCT01901718|Persistent Pain
209800|NCT01901705|Psoriasis
209801|NCT01901705|Indigo Naturalis
209802|NCT01901705|chinese medicine
209803|NCT01901679|Obesity
209804|NCT01901679|Post-menopausal
209805|NCT01901666|growth hormone, Chronic Myelogenous Leukemia, Imatinib,serum IGF-1
209806|NCT01901653|Small cell lung cancer
209807|NCT01901627|Spondylitis, Ankylosing
209808|NCT01901627|adalimumab
209809|NCT01901627|Prospective Studies
209810|NCT01901614|Keratoconus
209811|NCT01901614|Corneal Opacity
209812|NCT01901614|Keratoplasty
209813|NCT01901601|KERATOPLASTY
209814|NCT01901601|STROMAL OPACITIES
209815|NCT01901588|strabismus
209816|NCT01901588|pediatric
209817|NCT01901588|emergence delirium
209818|NCT01901588|precedex/dexmedetomidine
209819|NCT01901575|idiopathic ventricular tachycardia
209820|NCT01901562|ductoscopy
209821|NCT01901562|nipple discharge
209822|NCT01901562|breast
209823|NCT01901562|papilloma
209824|NCT01901536|First time parents
209825|NCT01901536|Coparenting
209826|NCT01901536|Family Foundations
209827|NCT01901523|Discrepancy
209828|NCT01901523|Committee on Publication Ethics
209829|NCT01901523|Correction
209830|NCT01901523|Erratum
209831|NCT01901523|Retraction
209832|NCT01901510|polyp
209833|NCT01901497|non invasive ventilation
209834|NCT01901497|single limb circuit ventilator
209835|NCT01901497|bilevel
209836|NCT01901497|nebulization
209837|NCT01901497|nebulizer
209838|NCT01901497|vibrating mesh nebulizer
209839|NCT01901497|amikacin
209840|NCT01901484|Schistosoma mansoni
209841|NCT01901484|morbidity
209842|NCT01901484|chemotherapy
209843|NCT01901471|Cyclosporine, cardiogenic shock, SOFA score,
209844|NCT01901458|apheresis
209845|NCT01901458|peripheral blood progenitor cells
209846|NCT01901458|peripheral blood stem cells
209847|NCT01901445|Quality of life
209848|NCT01901445|Constipation
209849|NCT01901445|Focus groups
209850|NCT01901445|Health education
209851|NCT01901445|Problem-based learning
209852|NCT01901432|chronic myeloproliferative neoplasms
209853|NCT01901432|Polycythemia Vera
209854|NCT01901432|Essential Thrombocythemia
209855|NCT01901432|Primary Myelofibrosis
209856|NCT01901432|Post-Polycythemia Vera Myelofibrosis
209857|NCT01901432|Post-Essential Thrombocythemia Myelofibrosis
209858|NCT01901432|Givinostat
209859|NCT01901419|nitroglycerin
209860|NCT01901419|cardiopulmonary bypass
209861|NCT01901419|cardiac surgery
209862|NCT01901406|epiretinal membrane, stereopsis, aniseikonia
209863|NCT01901393|Post Operative Pain,
209864|NCT01901393|Pail relief
209865|NCT01901367|Adiponectin, Glucose, Insulin, Leptin
209866|NCT01901354|Acute lung injury (ALI)
209867|NCT01901354|Adult respiratory distress syndrome (ARDS)
209868|NCT01901354|Low-tidal-volume strategy
209869|NCT01901354|ARDSNet
209870|NCT01901354|airway pressure release ventilation (APRV)
209871|NCT01901354|biomarkers of lung injury
209872|NCT01901341|Opioid
209873|NCT01901341|Constipation
209874|NCT01901341|Chronic
209875|NCT01901341|Pain
209876|NCT01901328|Opioid
209877|NCT01901328|Constipation
209878|NCT01901328|Chronic
209879|NCT01901328|Pain
209880|NCT01901315|telepsychiatry
209881|NCT01901315|telemental health
209882|NCT01901315|teleassistance
209883|NCT01901315|health care delivery
209884|NCT01901315|depression
209885|NCT01901315|Telemedicine
209886|NCT01901315|Remote Consultation
209887|NCT01901315|Videoconferencing
209888|NCT01901315|Community Mental Health Services
209889|NCT01901302|Opioid
209890|NCT01901302|Constipation
209891|NCT01901302|Chronic
209892|NCT01901302|Pain
209893|NCT01901289|Peripheral Vascular Disease
209894|NCT01901289|Femoral Artery
209895|NCT01901289|Popliteal Artery
209896|NCT01901289|Drug-Eluting Stent
209897|NCT01901276|Proton Pump Inhibitors
209898|NCT01901276|Microbiome
209899|NCT01901276|Clostridium difficile
209900|NCT01901263|Cognitive and behavioral units
209901|NCT01901263|Alzheimer Disease
209902|NCT01901263|Dementia
209903|NCT01901250|Dental Caries
209904|NCT01901250|Xylitol
209905|NCT01901250|Prevention
209906|NCT01901237|Cancer
209907|NCT01901237|Adolescent and Young Adult
209908|NCT01901237|Exercise
209909|NCT01901237|Physical Activity
209910|NCT01901237|Quality of Life
209911|NCT01901237|End-of-Life
209912|NCT01901237|Palliative
209913|NCT01901237|Terminal
209914|NCT01901237|Yoga
209915|NCT01901237|Alternative Therapies
209916|NCT01901237|Fitness
209917|NCT01901237|Fatigue
209918|NCT01901211|Cerebral palsy
209919|NCT01901211|Interactive computer play
209920|NCT01901211|Multi-player gaming
209921|NCT01901211|Exercise
209922|NCT01901146|Human Epidermal Growth Factor Receptor 2 (HER2)
209923|NCT01901146|Positive Early Breast Cancer
209924|NCT01901133|Phase 1
209925|NCT01901133|MDV3100
209926|NCT01901133|Hepatic Impairment
209927|NCT01901133|Kidney Diseases
209928|NCT01901133|Xtandi
209929|NCT01901133|enzalutamide
209930|NCT01901120|Betanis®
209931|NCT01901120|mirabegron
209932|NCT01901120|Overactive Bladder
209933|NCT01901107|Hemodialysis
209934|NCT01901107|CKD (chronic kidney disease)
209935|NCT01901107|ASP1585
209936|NCT01901107|Hyperphosphatemia
209937|NCT01901081|Implantable Myoelectric Sensor
209938|NCT01901081|IMES
209939|NCT01901081|transradial
209940|NCT01901081|amputation
209941|NCT01901081|myoelectric
209942|NCT01901081|prosthesis
209943|NCT01901081|prosthetic control
209944|NCT01901068|Laparotomy
209945|NCT01901068|Surgical Procedures, Elective
209946|NCT01901068|Sutures
209947|NCT01901068|Abdominal Wound Closure Techniques
209948|NCT01901055|sleep apnea
209949|NCT01901055|diabetes
209950|NCT01901042|Quality of life
209951|NCT01901042|Symbiotic
209952|NCT01901042|Proctitis/Radiotherapy
209953|NCT01901029|Male Reproductive Health
209954|NCT01901029|Floating Population
209955|NCT01901029|Sexual Behavior
209956|NCT01901029|Erectile Dysfunction
209957|NCT01901029|Premature Ejaculation
209958|NCT01901016|HIV
209959|NCT01901016|depressive symptoms
209960|NCT01901016|quality of life
209961|NCT01901016|relaxation
209962|NCT01901016|viral load
209963|NCT01901016|CD4+ T cell count
209964|NCT01900990|Noninvasive Positive Pressure Ventilation
209965|NCT01900990|Invasive Positive Pressure Ventilation
209966|NCT01900990|tracheotomy
209967|NCT01900977|Universal Test and Treat (UTT)
209968|NCT01900977|Combination Prevention
209969|NCT01900964|Regeneration
209970|NCT01900964|Bone regeneration
209971|NCT01900964|Grafting, Bone
209972|NCT01900964|Allograft
209973|NCT01900964|Xenograft
209974|NCT01900951|Small cell lung cancer
209975|NCT01900951|temozolomide
209976|NCT01900951|Maintenance chemotherapy
209977|NCT01900938|Cholangiopancreatography
209978|NCT01900938|Endoscopic Retrograde
209979|NCT01900925|Low back pain, non-specific low back pain
209980|NCT01900912|sanitation
209981|NCT01900912|diarrhea prevalence
209982|NCT01900912|health
209983|NCT01900912|social networks
209984|NCT01900912|cooperation
209985|NCT01900899|Healthy
209986|NCT01900899|Immunogenicity
209987|NCT01900899|Children
209988|NCT01900899|Neisseria meningitidis
209989|NCT01900899|Long-term antibody persistence
209990|NCT01900899|Safety
209991|NCT01900899|Serogroups A, C, W-135, and Y
209992|NCT01900886|prison, disorder, hepatitis c
209993|NCT01900873|Inspiratory Muscle Training
209994|NCT01900873|COPD
209995|NCT01900873|Inspiratory Muscle Function
209996|NCT01900873|Dyspnea
209997|NCT01900860|Vitamin D
209998|NCT01900860|Bone quality
209999|NCT01900860|Bone density
210000|NCT01900860|calcium metabolism
210001|NCT01900860|High resolution peripheral quantitative computed tomography
210002|NCT01900860|Dual X-ray absorptiometry
210003|NCT01900860|Quality of life
210004|NCT01900847|Ketamine
210005|NCT01900847|Acute Pain
210006|NCT01900795|Postsurgical pain
210007|NCT01900743|Sarcoma
210008|NCT01900743|Metastatic
210009|NCT01900743|Regorafenib
210010|NCT01900730|Breast cancer
210011|NCT01900730|Metastatic
210012|NCT01900730|Indwelling pleural catheter
210013|NCT01900730|Valproic acid
210014|NCT01900730|VPA
210015|NCT01900730|Depakene
210016|NCT01900730|Placebo
210017|NCT01900730|Pill diary
210018|NCT01900730|Drainage diary
210019|NCT01900730|Questionnaires
210020|NCT01900730|Surveys
210021|NCT01900691|Esophageal Fistula
210022|NCT01900691|Esophageal Neoplasms
210023|NCT01900691|Esophageal Perforation
210024|NCT01900691|Esophageal Stenosis
210025|NCT01900691|Stents
210026|NCT01900639|aspirin
210027|NCT01900639|circadian rhythm
210028|NCT01900639|platelet reactivity
210029|NCT01900639|platelet activation
210030|NCT01900639|time dependent
210031|NCT01900613|child obesity
210032|NCT01900613|Mexican-American
210033|NCT01900613|Nutrition education
210034|NCT01900613|Intervention
210035|NCT01900587|Healthy
210036|NCT01900587|Bio-equivalence
210037|NCT01900587|Tapentadol extended release
210038|NCT01900587|Tamper-resistant formulation
210039|NCT01900574|Colitis, Ulcerative
210040|NCT01900574|Ulcerative Colitis
210041|NCT01900574|Moderately to Severely Active Ulcerative Colitis
210042|NCT01900574|Golimumab
210043|NCT01900574|Simponi
210044|NCT01900574|Human anti-TNFα Antibody
210045|NCT01900574|Pediatric participants
210046|NCT01900574|Safety and Pharmacokinetics
210047|NCT01900561|prostate cancer
210048|NCT01900561|survivorship
210049|NCT01900561|intervention
210050|NCT01900561|telemedicine
210051|NCT01900548|Osteopenia
210052|NCT01900548|Sarcopenia
210053|NCT01900548|Osteoporosis
210054|NCT01900548|Physical function
210055|NCT01900548|Body composition
210056|NCT01900548|Muscle protein
210057|NCT01900548|Leucine
210058|NCT01900548|Ketogenic amino acids
210059|NCT01900548|Resistance Training
210060|NCT01900548|Whey protein
210061|NCT01900548|Soy protein
210062|NCT01900548|Bone turnover
210063|NCT01900535|chlorhexidine
210064|NCT01900535|gingivitis
210065|NCT01900535|periodontitis
210066|NCT01900522|Drug therapy
210067|NCT01900509|Childhood leukemia
210068|NCT01900509|Childhood lymphoma
210069|NCT01900509|Bendamustine
210070|NCT01900496|cHL
210071|NCT01900496|Hodgkin lymphoma
210072|NCT01900496|Lymphoma
210073|NCT01900496|relapsed Lymphoma
210074|NCT01900496|SGN-35
210075|NCT01900496|Brentuximab Vedotin
210076|NCT01900496|Rituxan
210077|NCT01900496|Rituximab
210078|NCT01900470|Multiple chronic conditions
210079|NCT01900444|Japanese encephalitis
210080|NCT01900444|Japanese encephalitis chimeric virus vaccine
210081|NCT01900444|IMOJEV®
210082|NCT01900418|breast cancer
210083|NCT01900418|aromatase inhibitors
210084|NCT01900418|physical activity
210085|NCT01900418|joint pain
210086|NCT01900405|Dexmedetomidine
210087|NCT01900405|Administration, Intranasal
210088|NCT01900405|Children
210089|NCT01900405|Computerized Tomography
210090|NCT01900379|Obstructive sleep apneas syndrome
210091|NCT01900379|Continuous positive airway pressure treatment
210092|NCT01900379|Heart failure
210093|NCT01900379|Coronary reperfusion surgery
210094|NCT01900366|Obesity
210095|NCT01900366|Healthy Volunteers
210096|NCT01900340|GLP-1
210097|NCT01900340|satiation peptides
210098|NCT01900340|food intake
210099|NCT01900327|pancreatic cancer
210100|NCT01900327|surgery
210101|NCT01900327|chemoradiation
210102|NCT01900327|neoadjuvant treatment
210103|NCT01900327|overall survival
210104|NCT01900314|Major Depression
210105|NCT01900314|Major Depressive Disorder
210106|NCT01900314|TMS
210107|NCT01900314|rTMS
210108|NCT01900301|exposure
210109|NCT01900301|scopolamine
210110|NCT01900301|extinction learning
210111|NCT01900301|social anxiety
210112|NCT01900288|short bowel disorder
210113|NCT01900288|short bowel syndrome
210114|NCT01900288|home parenteral nutrition
210115|NCT01900288|HPN
210116|NCT01900288|total parenteral nutrition
210117|NCT01900288|TPN
210118|NCT01900288|telehealth
210119|NCT01900288|telemedicine
210120|NCT01900275|Sepsis
210121|NCT01900275|Trauma
210122|NCT01900275|Shock
210123|NCT01900275|Acute kidney injury
210124|NCT01900275|Heparanase
210125|NCT01900262|Biomechanics
210126|NCT01900262|Ankle Strength
210127|NCT01900262|Postural Control
210128|NCT01900262|Running Mechanics
210129|NCT01900236|Patients newly initiating outpatient HIV medical care
210130|NCT01900210|Criminal justice
210131|NCT01900210|substance abuse treatment
210132|NCT01900210|HIV risk behaviors
210133|NCT01900158|Phase I, Phase II, Dose Escalation, Safety, Tolerability,
210134|NCT01900158|Efficacy, Amphinex induced Photochemical Internalisation, PCI, Amphinex, Gemcitabine, Cisplatin,
210135|NCT01900158|Inoperable Cholangiocarcinomas, CCA, Cholangiocarcinoma, bile duct cancer, photodynamic therapy
210136|NCT01900132|Electrophysiology
210137|NCT01900132|Neuromuscular Disease
210138|NCT01900119|Oral Microbiome
210139|NCT01900119|Next Generation Sequencing
210140|NCT01900106|late presenter
210141|NCT01900106|naïve
210142|NCT01900106|advanced HIV disease
210143|NCT01900080|HIV
210144|NCT01900080|AIDS
210145|NCT01900080|Antiretroviral therapy
210146|NCT01900080|Retention in care
210147|NCT01900080|Adherence
210148|NCT01900080|Cost-effectiveness
210149|NCT01900054|TAU-284
210150|NCT01900054|Bepotastine besilate
210151|NCT01900054|Histamine H1 receptor antagonists
210152|NCT01900054|children
210153|NCT01900028|oncology,
210154|NCT01900028|cancer,
210155|NCT01900028|tumour,
210156|NCT01900028|anticancer drug,
210157|NCT01900028|pharmacokinetics,
210158|NCT01900028|olaparib,itraconazole,
210159|NCT01900028|neoplasm,
210160|NCT01900028|QT interval
210161|NCT01900002|Liver Cancer
210162|NCT01900002|Advanced Hepatocellular Carcinoma
210163|NCT01900002|HCC
210164|NCT01900002|Sorafenib
210165|NCT01900002|Nexavar
210166|NCT01900002|BAY 43-9006
210167|NCT01900002|Yttrium-90
210168|NCT01900002|Microspheres
210169|NCT01900002|Phone calls
210170|NCT01899989|Stereotactic Body Radiation Therapy (SBRT)
210171|NCT01899989|Chemotherapy
210172|NCT01899989|13-113
210173|NCT01899976|covered biliary stent
210174|NCT01899976|X-Suit NIR Covered Biliary Stent
210175|NCT01899976|malignant strictures in biliary tree
210176|NCT01899963|wet Age Related Macular Degeneration
210177|NCT01899963|Diabetic Macular Edema
210178|NCT01899963|Telemedicine
210179|NCT01899963|Teleophthalmology
210180|NCT01899963|Time to Treatment
210181|NCT01899950|Niemann-Pick disease type C
210182|NCT01899950|Lysosomal disease
210183|NCT01899937|Endothelial dysfunction
210184|NCT01899937|Flow mediated dilation
210185|NCT01899937|Brachial artery flow mediated dilation
210186|NCT01899937|FMD
210187|NCT01899898|Refractory epilepsy
210188|NCT01899898|Dietary therapy
210189|NCT01899898|Non-Pharmacological therapy
210190|NCT01899898|Simplified Modified Atkins Diet
210191|NCT01899885|Emergency laparotomy
210192|NCT01899885|Emergency laparoscopy
210193|NCT01899872|Type 1 Diabetes Mellitus
210194|NCT01899872|Endothelial progenitor cell
210195|NCT01899872|Endothelial function
210196|NCT01899872|Exercise
210197|NCT01899859|Non-Alcoholic Steatohepatitis (NASH)
210198|NCT01899846|Makena
210199|NCT01899846|Pharmacokinetics
210200|NCT01899846|Prior preterm delivery
210201|NCT01899846|Hydroxyprogesterone Caproate
210202|NCT01899846|17P
210203|NCT01899833|Coronary Artery Disease
210204|NCT01899833|CAD
210205|NCT01899781|Lacerations
210206|NCT01899781|Tendons
210207|NCT01899781|Antobiotic
210208|NCT01899768|efficacy
210209|NCT01899768|hypertussive challenge
210210|NCT01899768|voltage gated sodium channels (VGSC)
210211|NCT01899768|anaesthesia
210212|NCT01899768|Safety and tolerability
210213|NCT01899768|capsaicin challenge
210214|NCT01899768|cough
210215|NCT01899768|citric acid challenge
210216|NCT01899768|pharmacokinetics
210217|NCT01899755|monoclonal antibody
210218|NCT01899755|healthy volunteer
210219|NCT01899755|TNF alpha
210220|NCT01899729|plaque psoriasis
210221|NCT01899729|autoimmune disease
210222|NCT01899729|Toll like receptor
210223|NCT01899716|Severe Depression
210224|NCT01899716|Quality of life
210225|NCT01899716|Exercise
210226|NCT01899716|BDNF
210227|NCT01899716|TBARS
210228|NCT01899703|Intestinal bile acid transport inhibitor
210229|NCT01899703|Pruritus
210230|NCT01899703|Primary biliary cirrhosis
210231|NCT01899703|Ursodeoxycholic acid
210232|NCT01899703|GSK2330672
210233|NCT01899703|Pharmacokinetics
210234|NCT01899690|breast reconstruction
210235|NCT01899690|cancer
210236|NCT01899690|expander
210237|NCT01899690|antibiotics
210238|NCT01899690|infection
210239|NCT01899690|surgical site infection
210240|NCT01899690|surgery
210241|NCT01899690|oncology
210242|NCT01899690|plastic surgery
210243|NCT01899677|Symbiotic,cytokines, necrotising enterocolitis
210244|NCT01899664|peripheral nerves
210245|NCT01899664|quadriplegia
210246|NCT01899664|nerve transfer
210247|NCT01899664|surgical procedures, operative
210248|NCT01899664|hand
210249|NCT01899664|upper extremity
210250|NCT01899664|quality of life
210251|NCT01899651|EEG
210252|NCT01899651|Brain
210253|NCT01899651|Infants
210254|NCT01899651|Preterm
210255|NCT01899651|Hemorrhage
210256|NCT01899651|Bleeding
210257|NCT01899625|Obesity
210258|NCT01899625|weight loss
210259|NCT01899625|young adults
210260|NCT01899612|menopause
210261|NCT01899612|vaginal atrophy
210262|NCT01899612|cytokine
210263|NCT01899612|IL-1beta
210264|NCT01899612|IL-6
210265|NCT01899612|IL-8
210266|NCT01899612|TNF-alpha
210267|NCT01899586|Aging
210268|NCT01899586|Functional Capacity
210269|NCT01899586|Exercise Independence
210270|NCT01899586|Peripheral Adaptations
210271|NCT01899586|Vascular
210272|NCT01899573|Heart failure
210273|NCT01899573|mitral regurgitation
210274|NCT01899573|mitral valve
210275|NCT01899560|Acute respiratory distress syndrome (ARDS)
210276|NCT01899560|positive end expiratory pressure (PEEP)
210277|NCT01899560|Staircase recruitment maneuver (SRM)
210278|NCT01899560|Lung elastance
210279|NCT01899560|chest wall elastance
210280|NCT01899534|Pregnancy
210281|NCT01899534|Mental Health
210282|NCT01899534|Screening
210283|NCT01899534|Computer
210284|NCT01899534|Feasibility
210285|NCT01899521|alcoholism
210286|NCT01899521|lung health
210287|NCT01899521|pulmonary
210288|NCT01899521|macrophage
210289|NCT01899521|zinc
210290|NCT01899521|SAMe
210291|NCT01899521|S-adenosylmethionine
210292|NCT01899521|alveolar
210293|NCT01899495|blood pressure
210294|NCT01899495|hypertension
210295|NCT01899495|salt sensitivity
210296|NCT01899482|Venous Insufficiency
210297|NCT01899482|Physical Therapy Techniques
210298|NCT01899482|Manual Lymphatic Drainage
210299|NCT01899443|total hip replacement
210300|NCT01899443|total knee replacement
210301|NCT01899443|patient outcomes
210302|NCT01899443|health services research
210303|NCT01899430|PCOS
210304|NCT01899430|obesity
210305|NCT01899430|GLP-1 receptor agonist
210306|NCT01899430|liraglutide
210307|NCT01899430|metformin
210308|NCT01899417|osteoarthritis
210309|NCT01899417|knee replacement
210310|NCT01899417|patient-specific
210311|NCT01899417|economics
210312|NCT01899404|Cervical Cancer
210313|NCT01899404|PET Scan for cervix
210314|NCT01899404|MRI for cervix
210315|NCT01899391|Prostate cancer
210316|NCT01899378|probiotics
210317|NCT01899365|anti-pneumococcal vaccination
210318|NCT01899365|information
210319|NCT01899365|emergency department
210320|NCT01899339|submassive pulmonary embolism
210321|NCT01899339|Ultrasonic energy
210322|NCT01899339|Ekosonic Endovascular Device
210323|NCT01899339|RV:LV function after Pulmonary Embolism
210324|NCT01899313|methamphetamine dependence
210325|NCT01899313|texting
210326|NCT01899313|short message service
210327|NCT01899313|addiction
210328|NCT01899313|amphetamine
210329|NCT01899313|outpatient
210330|NCT01899300|Refractory Benign Esophageal Strictures caused by Caustic Ingestion
210331|NCT01899287|workers education
210332|NCT01899287|occupational
210333|NCT01899209|Obstructed Defecation
210334|NCT01899209|Rectal rectocele
210335|NCT01899209|Intussusception
210336|NCT01899209|STARR
210337|NCT01899209|Ventral Rectopexy
210338|NCT01899196|Cardiac surgery
210339|NCT01899183|Chronic cough
210340|NCT01899183|Esophagus
210341|NCT01899183|Gastro-esophageal reflux disease
210342|NCT01899183|Esophageal surgery
210343|NCT01899183|Minimally invasive surgery
210344|NCT01899183|Extra-esophageal reflux symptoms.
210345|NCT01899170|deep brain stimulation
210346|NCT01899170|multi-coil transcranial magnetic stimulation
210347|NCT01899170|PET-imaging
210348|NCT01899170|personalized treatment
210349|NCT01899157|Nutritional status
210350|NCT01899157|Nutritional situation
210351|NCT01899144|Albuterol Spiromax
210352|NCT01899144|ProAir HFA
210353|NCT01899144|albuterol sulfate
210354|NCT01899131|dental implants
210355|NCT01899131|crestal bone
210356|NCT01899131|gingival margin
210357|NCT01899118|locally advanced rectal cancer
210358|NCT01899118|Neoadjuvant chemoradiotherapy
210359|NCT01899118|Nimotuzumab
210360|NCT01899092|Genotype 1
210361|NCT01899092|Chronic Hepatitis C
210362|NCT01899092|CHC
210363|NCT01899092|HCV
210364|NCT01899092|Hepatitis
210365|NCT01899092|RNAi
210366|NCT01899092|shRNA
210367|NCT01899092|ddRNAi
210368|NCT01899092|AAV8
210369|NCT01899092|AAV
210370|NCT01899092|Adeno-associated virus
210371|NCT01899092|Adeno-associated viral vectors
210372|NCT01899079|Breast Cancer
210373|NCT01899079|Prosigna
210374|NCT01899079|FFPE
210375|NCT01899079|node negative
210376|NCT01899079|estrogen receptor positive
210377|NCT01899079|HER2 negative
210378|NCT01899066|Efficacy
210379|NCT01899053|Solid tumors
210380|NCT01899053|MLN0128
210381|NCT01899053|MLN1117
210382|NCT01899040|neuromodulation
210383|NCT01899040|migraine headache
210384|NCT01899027|Arterial hypertension
210385|NCT01899027|Radiofrequency ablation
210386|NCT01899027|Renal function
210387|NCT01899014|Atherosclerosis
210388|NCT01899014|18F-choline
210389|NCT01899014|PET-CT
210390|NCT01899014|MRI
210391|NCT01899014|Ultrasound
210392|NCT01899001|Polycystic Ovary Syndrome
210393|NCT01899001|PCOS
210394|NCT01899001|Depression
210395|NCT01899001|Anxiety
210396|NCT01899001|Weight loss
210397|NCT01899001|Exercise
210398|NCT01899001|Nutrition
210399|NCT01899001|Therapy
210400|NCT01899001|Mood symptoms
210401|NCT01899001|Stress
210402|NCT01898975|Neurosurgical patients
210403|NCT01898975|Fluid loading
210404|NCT01898975|Fluid responsiveness
210405|NCT01898975|NICOM
210406|NCT01898975|Stroke volume variation
210407|NCT01898975|Pulse pressure variation
210408|NCT01898975|Total peripheral resistance
210409|NCT01898975|Gray zone approach
210410|NCT01898962|Oligometastases
210411|NCT01898962|Metastatic cancer
210412|NCT01898962|Stereotactic radiosurgery
210413|NCT01898949|Diet-induced thermogenesis
210414|NCT01898949|Cold-induced thermogenesis
210415|NCT01898949|Brown adipose tissue
210416|NCT01898949|Brown fat
210417|NCT01898923|WH-1,Diabetic Foot,Ulcer
210418|NCT01898845|Neoplasms
210419|NCT01898832|Cholestasis, pregnant, interleukin 17
210420|NCT01898819|DEXMEDETOMIDINE
210421|NCT01898819|intraocular pressure
210422|NCT01898806|Alopecia Areata
210423|NCT01898806|Kenalog
210424|NCT01898806|Triamcinolone
210425|NCT01898767|mild
210426|NCT01898767|asthma
210427|NCT01898767|allergic
210428|NCT01898754|Transmitted Drug Resistance
210429|NCT01898741|Pancreatic cancer
210430|NCT01898741|Radiotherapy
210431|NCT01898741|SBRT
210432|NCT01898715|Adrenocortical carcinoma
210433|NCT01898715|Adrenal cancer
210434|NCT01898715|ACC
210435|NCT01898676|Extended-release divalproex sodium
210436|NCT01898676|Depakote ER
210437|NCT01898650|craniosynostosis
210438|NCT01898650|sagittal synostosis
210439|NCT01898650|metopic synostosis
210440|NCT01898650|coronal synostosis
210441|NCT01898650|lambdoid synostosis
210442|NCT01898637|pulmonary embolism
210443|NCT01898637|pulse oximetry
210444|NCT01898637|change in oxygen saturation
210445|NCT01898637|hypoxemia
210446|NCT01898637|emergency department
210447|NCT01898637|deep inspiration
210448|NCT01898637|vital capacity
210449|NCT01898637|clinical diagnosis
210450|NCT01898624|mirabegron
210451|NCT01898624|Overactive Bladder
210452|NCT01898624|Betanis®
210453|NCT01898624|glaucoma
210454|NCT01898611|Frailty
210455|NCT01898611|Sarcopenia
210456|NCT01898611|Weight Loss
210457|NCT01898611|Exercise
210458|NCT01898611|Aging
210459|NCT01898611|Ghrelin
210460|NCT01898611|Elderly
210461|NCT01898572|Newly Diagnosed Type II Diabetes Mellitus
210462|NCT01898572|Carotid Intimae-media Thickness
210463|NCT01898572|Carotid Plaque
210464|NCT01898572|Cardiovascular Disease
210465|NCT01898559|little cigars
210466|NCT01898559|cigarettes
210467|NCT01898559|smoking
210468|NCT01898546|Ischemic postconditioning
210469|NCT01898546|Myocardial Infarction
210470|NCT01898546|Microvascular Obstruction
210471|NCT01898520|Spasticity
210472|NCT01898507|low nicotine
210473|NCT01898507|cigarettes
210474|NCT01898507|NMR
210475|NCT01898481|Health care decision making
210476|NCT01898468|Neuropathic pain symptoms
210477|NCT01898468|Intracostal Closure Technique
210478|NCT01898468|Pericostal Suture Closure Technique
210479|NCT01898468|Post surgical pain
210480|NCT01898468|Post thoracotomy pain
210481|NCT01898455|Migraine
210482|NCT01898455|Cluster headache
210483|NCT01898455|headache
210484|NCT01898442|platelet function
210485|NCT01898442|ticagrelor
210486|NCT01898442|STEMI
210487|NCT01898429|Treatment Resistant Depression
210488|NCT01898429|Treatment Refractory Depression
210489|NCT01898429|Treatment Resistant Bipolar Disorder
210490|NCT01898429|Treatment Refractory Bipolar Disorder
210491|NCT01898429|Deep brain stimulation
210492|NCT01898429|DBS
210493|NCT01898390|Parkinson's Disease
210494|NCT01898390|Allo-Transplantation
210495|NCT01898390|Fetal Ventral Mesencephalic Tissue
210496|NCT01898377|Children
210497|NCT01898377|Chronic graft-versus-host disease
210498|NCT01898351|Alternative sources of plant proteins
210499|NCT01898351|High protein diets
210500|NCT01898351|Satiety
210501|NCT01898351|Postprandial effects
210502|NCT01898351|Bioactive phytochemicals
210503|NCT01898351|Phytochemicals bioactivity and metabolism
210504|NCT01898351|Macronutrients metabolism
210505|NCT01898351|Health effects of plant proteins vs. meat proteins
210506|NCT01898351|Partial meat proteins replacement with plant proteins
210507|NCT01898351|Satiety of meals rich in plant proteins
210508|NCT01898351|Postprandial effects of meals rich in plant proteins
210509|NCT01898351|Plant phytochemicals and macronutrients bioavailability and metabolism
210510|NCT01898338|MRSA
210511|NCT01898338|bacteremia
210512|NCT01898338|therapy
210513|NCT01898325|Fibrosis
210514|NCT01898325|Gaucher disease
210515|NCT01898299|Schizophrenia
210516|NCT01898286|C peptide
210517|NCT01898286|beta cell function
210518|NCT01898286|immune modulation of type 1 diabetes
210519|NCT01898286|immune intervention in type 1 diabetes
210520|NCT01898273|Glioma
210521|NCT01898273|Glioblastoma Multiforme
210522|NCT01898273|PET
210523|NCT01898273|Imaging
210524|NCT01898273|Radiopharmaceutical
210525|NCT01898273|Diagnostic
210526|NCT01898260|contact lenses
210527|NCT01898260|daily disposable contact lenses
210528|NCT01898260|silicone hydrogel
210529|NCT01898260|contact lens comfort
210530|NCT01898260|near-sighted
210531|NCT01898247|Thoracentesis
210532|NCT01898247|Simulation Based Mastery Learning
210533|NCT01898247|Medical Education
210534|NCT01898247|Length of Stay
210535|NCT01898247|Cost of Care
210536|NCT01898234|Hemodynamics
210537|NCT01898234|intradialytic hypotension
210538|NCT01898234|subjective tolerance
210539|NCT01898234|dialysis membranes
210540|NCT01898234|high flux
210541|NCT01898234|low flux
210542|NCT01898234|hemodialysis
210543|NCT01898208|Bacteremia
210544|NCT01898208|Fungemia
210545|NCT01898208|Bloodstream infection
210546|NCT01898208|susceptibility
210547|NCT01898208|MRSA
210548|NCT01898208|VRE
210549|NCT01898143|Whole body vibration, cardiorespiratory response
210550|NCT01898117|Triple negative
210551|NCT01898117|Metastatic
210552|NCT01898104|rectal
210553|NCT01898104|low risk
210554|NCT01898104|moderate risk
210555|NCT01898091|Oral
210556|NCT01898091|Mucositis
210557|NCT01898091|Stomatitis
210558|NCT01898091|Radiotherapy
210559|NCT01898078|MLN8237
210560|NCT01898078|alisertib
210561|NCT01898078|food effects
210562|NCT01898065|Hypoxia
210563|NCT01898065|radiotherapy
210564|NCT01898065|PET with 18-F-MISO
210565|NCT01898065|MRI
210566|NCT01898052|pain control
210567|NCT01898052|periarticular injection
210568|NCT01898052|Total knee arthroplasty
210569|NCT01898052|levobupivacaine
210570|NCT01898052|multimodal drug injection
210571|NCT01898039|malignant melanoma
210572|NCT01898039|vaccine
210573|NCT01898039|cell line
210574|NCT01898039|high risk
210575|NCT01898039|residual disease
210576|NCT01898026|PGX
210577|NCT01898026|fibre
210578|NCT01898026|postprandial glycemia
210579|NCT01898013|pain
210580|NCT01898013|pregnenolone
210581|NCT01898013|Veterans
210582|NCT01898013|clinical trial
210583|NCT01898013|neurosteroid
210584|NCT01898013|allopregnanolone
210585|NCT01898013|low back
210586|NCT01898013|placebo controlled
210587|NCT01898013|randomized
210588|NCT01898013|musculoskeletal
210589|NCT01898000|Gingivitis
210590|NCT01898000|Herbal medicine
210591|NCT01898000|Plaque control
210592|NCT01897987|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
210593|NCT01897987|Bronchopulmonary dysplasia
210594|NCT01897987|Premature infants
210595|NCT01897935|Uveitis
210596|NCT01897896|Chorea
210597|NCT01897896|Huntington Disease
210598|NCT01897870|continuity of care
210599|NCT01897870|medicines management
210600|NCT01897870|home visit
210601|NCT01897870|drug-related problems
210602|NCT01897857|diabetes mellitus(DM)
210603|NCT01897857|radial artery cannulation
210604|NCT01897857|artery blood flow
210605|NCT01897857|complication
210606|NCT01897857|End stage renal disease undergoing kidney transplantation
210607|NCT01897844|volunteers
210608|NCT01897831|Piperacillin Sodium and sulbactam sodium
210609|NCT01897831|Phase IV clinical studies
210610|NCT01897831|Respiratory and urinary tract infections
210611|NCT01897805|Coronary artery disease
210612|NCT01897766|Genotropin
210613|NCT01897766|Somatropin
210614|NCT01897766|Long Term Follow-Up
210615|NCT01897766|Special Investigation
210616|NCT01897766|Small for Gestational Age
210617|NCT01897766|SGA
210618|NCT01897753|SGA
210619|NCT01897753|Growth hormone
210620|NCT01897740|sildenafil
210621|NCT01897740|pulmonary arterial hypertension
210622|NCT01897740|PAH
210623|NCT01897727|sleep apnea
210624|NCT01897727|hypertension
210625|NCT01897727|aldosterone
210626|NCT01897727|hyperaldosteronism
210627|NCT01897727|spironolactone
210628|NCT01897727|blood pressure
210629|NCT01897727|resistant
210630|NCT01897701|H7N9
210631|NCT01897688|Diabetes
210632|NCT01897688|Islet
210633|NCT01897688|Pancreas
210634|NCT01897688|Hypoglycemia
210635|NCT01897688|T1D
210636|NCT01897688|Transplant
210637|NCT01897675|Cutaneous Abscess
210638|NCT01897675|Emergency Department
210639|NCT01897662|overweight
210640|NCT01897662|satiety
210641|NCT01897662|functional food
210642|NCT01897662|food intake
210643|NCT01897662|digestive tolerance
210644|NCT01897649|functional food
210645|NCT01897649|digestive tolerance
210646|NCT01897649|microbiota
210647|NCT01897649|bifidogenic effect
210648|NCT01897636|endoscopic ultrasound-guided fine-needle injection
210649|NCT01897636|dendritic cell
210650|NCT01897636|vaccination
210651|NCT01897610|Immuncell-LC, advanced hepatocellular carcinoma
210652|NCT01897584|laparoscopy, Trendelenburg Position, ventilation
210653|NCT01897545|Arterial hypertension
210654|NCT01897545|Atrial Fibrillation
210655|NCT01897545|Percutaneous renal denervation
210656|NCT01897519|High risk surgery
210657|NCT01897519|Acute Kidney Injury
210658|NCT01897506|Food insecurity
210659|NCT01897506|Health literacy
210660|NCT01897506|Quality of life
210661|NCT01897402|Central Nervous System Infections
210662|NCT01897402|Meningitis
210663|NCT01897402|toxoid
210664|NCT01897402|Meningococcal vaccine
210665|NCT01897402|conjugate vaccines
210666|NCT01897389|Healthy volunteers
210667|NCT01897389|Bioavailability
210668|NCT01897389|Abiraterone acetate
210669|NCT01897389|ZYTIGA
210670|NCT01897376|wound
210671|NCT01897376|infection
210672|NCT01897376|cesarean delivery
210673|NCT01897376|obesity
210674|NCT01897363|Prader Willi Syndrome
210675|NCT01897363|Hypoglycemia
210676|NCT01897363|Fasting study
210677|NCT01897350|STEMI
210678|NCT01897350|Myocardial edema
210679|NCT01897350|Cardiovascular magnetic resonance
210680|NCT01897324|Poor Ovarian Response
210681|NCT01897324|Poor Responders
210682|NCT01897324|IVF/ICSI
210683|NCT01897324|Growth Hormone
210684|NCT01897311|cesarean section
210685|NCT01897311|pain
210686|NCT01897311|transcutaneous electrical nerve stimulation
210687|NCT01897311|postpartum period
210688|NCT01897298|chronic obstructive pulmonary disease (COPD)
210689|NCT01897298|urban training
210690|NCT01897298|physical activity
210691|NCT01897298|active aging
210692|NCT01897285|Performance and safety of the AQUACEL® foam adhesive dressing
210693|NCT01897272|carpal tunnel syndrome
210694|NCT01897272|splinting
210695|NCT01897272|nerve decompression
210696|NCT01897259|tennis elbow
210697|NCT01897259|lateral epicondylitis
210698|NCT01897246|distal radius malunion
210699|NCT01897246|extra-articular
210700|NCT01897220|Noncardiac surgery;
210701|NCT01897220|Perioperative ischemic complications;
210702|NCT01897220|Perioperative bleeding complications;
210703|NCT01897220|Antithrombotic therapy;
210704|NCT01897220|Coronary artery disease;
210705|NCT01897220|Stent thrombosis;
210706|NCT01897220|Perioperative infarction.
210707|NCT01897207|prostate cancer
210708|NCT01897207|dendritic cells
210709|NCT01897207|vaccination
210710|NCT01897181|Central auditory processing
210711|NCT01897181|Bilateral sensorineural hearing loss
210712|NCT01897181|Hearing aids
210713|NCT01897155|analgesia, postoperative;
210714|NCT01897155|analgesics opioid;
210715|NCT01897155|hyperalgesia;
210716|NCT01897155|remifentanil;
210717|NCT01897155|hypertension.
210718|NCT01897103|Peripheral Artery Disease
210719|NCT01897103|Endarterectomy (Carotid)
210720|NCT01897103|Aortic Aneurysm, Abdominal
210721|NCT01897103|Aortic Aneurysm, Thoracic
210722|NCT01897103|Amputation
210723|NCT01897103|Platelet Activity
210724|NCT01897103|Thrombin
210725|NCT01897103|Transcriptomics
210726|NCT01897090|Elimination Diet
210727|NCT01897090|Crohn's disease
210728|NCT01897077|Food Allergy
210729|NCT01897077|Peanut
210730|NCT01897077|Sublingual Immunotherapy
210731|NCT01897064|Schizophrenia
210732|NCT01897064|Cognition
210733|NCT01897064|Aerobic Exercise
210734|NCT01897051|Liver cirrhosis
210735|NCT01897051|Portal hypertension
210736|NCT01897051|Hepatic Venous Pressure Gradient
210737|NCT01897051|Rifaximin
210738|NCT01897025|Stroke
210739|NCT01897025|Noninvasive brain stimulation
210740|NCT01897025|Brain-computer interface
210741|NCT01897025|Motor imagery
210742|NCT01897025|Rehabilitation
210743|NCT01896986|Special risk patients
210744|NCT01896986|Immunosuppressive biologic treatments
210745|NCT01896986|PRD (Paediatric Rheumatological Disease)
210746|NCT01896986|IBD (Inflammatory Bowel Disease)
210747|NCT01896973|Benign Prostatic Hyperplasia
210748|NCT01896973|BPH
210749|NCT01896973|LUTS
210750|NCT01896973|Vortx Rx
210751|NCT01896973|Histotripsy
210752|NCT01896960|Post spinal hypotension
210753|NCT01896960|Cesarian Section
210754|NCT01896960|ET50
210755|NCT01896960|Bupivacaine
210756|NCT01896960|Fentanyl
210757|NCT01896934|Depression
210758|NCT01896934|Antidepressants
210759|NCT01896934|Elderly
210760|NCT01896934|Geriatrics
210761|NCT01896921|HIV
210762|NCT01896908|diastolic dysfunction
210763|NCT01896908|Sodium restriction
210764|NCT01896908|Randomized clinical trial
210765|NCT01896882|Diet, Sodium-Restricted
210766|NCT01896882|Food and Nutrition Education
210767|NCT01896882|Renal Dialyisis
210768|NCT01896869|Pancreatic Cancer
210769|NCT01896869|Vaccine
210770|NCT01896869|Immunotherapy
210771|NCT01896869|Ipilimumab
210772|NCT01896869|CTLA-4
210773|NCT01896869|antibody
210774|NCT01896869|FOLFIRINOX
210775|NCT01896856|SGI-110
210776|NCT01896856|irinotecan
210777|NCT01896856|regorafenib
210778|NCT01896856|methylation
210779|NCT01896856|colorectal
210780|NCT01896856|metastatic
210781|NCT01896856|TAS-102
210782|NCT01896856|lonsurf
210783|NCT01896843|Positron Emission Tomography (PET)
210784|NCT01896843|Metabotropic Glutamate Receptors
210785|NCT01896830|Clostridium difficile infection
210786|NCT01896830|Clostridium difficile Toxoid Vaccine
210787|NCT01896739|Healthy infants with over than 37 weeks gestation periods.
210788|NCT01896739|over than 2.5Kg at at birth weight.
210789|NCT01896713|Prostate Cancer
210790|NCT01896713|MRI
210791|NCT01896713|TRUSBx
210792|NCT01896700|Multiple sclerosis
210793|NCT01896700|postural balance
210794|NCT01896700|walking
210795|NCT01896687|nonspecific low back pain
210796|NCT01896687|chronic low back pain
210797|NCT01896674|Computed tomography
210798|NCT01896661|Sleep apnea
210799|NCT01896661|Hypertension
210800|NCT01896661|Treatment
210801|NCT01896661|Diuretics
210802|NCT01896661|Chlorthalidone
210803|NCT01896661|Amlodipine
210804|NCT01896635|Ulcerative Colitis
210805|NCT01896635|Inflammatory Bowel Disease
210806|NCT01896635|Fecal Transplantation
210807|NCT01896635|Fecal Microbiota Transplantation
210808|NCT01896622|Dabigatran Etexilate
210809|NCT01896622|Ritonavir
210810|NCT01896622|Cobicistat
210811|NCT01896622|P-Glycoprotein
210812|NCT01896609|Chronic hepatitis c
210813|NCT01896609|Egyptian population
210814|NCT01896609|Reiferon Retard
210815|NCT01896609|Ribavirin
210816|NCT01896609|Nitazoxanide
210817|NCT01896609|Bon one
210818|NCT01896596|vaccines
210819|NCT01896596|immunogenicity
210820|NCT01896596|adverse reactions
210821|NCT01896570|atrial fibrillation
210822|NCT01896570|catheter ablation
210823|NCT01896570|subsequent atrial tachycardia
210824|NCT01896570|mechanisms
210825|NCT01896557|clopidogrel
210826|NCT01896557|omeprazole
210827|NCT01896557|ranitidin
210828|NCT01896557|interaction
210829|NCT01896557|aggregability
210830|NCT01896544|cholecalciferol
210831|NCT01896544|vitamin D
210832|NCT01896544|sepsis
210833|NCT01896544|infection
210834|NCT01896518|second hand smoke exposure; children
210835|NCT01896505|bone
210836|NCT01896505|soft-tissue
210837|NCT01896505|sarcoma
210838|NCT01896505|KPT-330
210839|NCT01896505|food
210840|NCT01896505|effects
210841|NCT01896505|Selinexor
210842|NCT01896492|PCOS,
210843|NCT01896492|NAC,
210844|NCT01896492|OVULATION INDUCTION,
210845|NCT01896492|CLOMOPHEN CITRATE
210846|NCT01896479|thyroid cancer
210847|NCT01896479|medullary thyroid cancer
210848|NCT01896466|Fall Risk
210849|NCT01896466|Gait
210850|NCT01896466|Dynamic Balance
210851|NCT01896466|Static Balance
210852|NCT01896466|Neuromodulation
210853|NCT01896440|Pediatric
210854|NCT01896440|Ondansetron
210855|NCT01896440|Cardiac repolarization
210856|NCT01896440|QTc interval
210857|NCT01896427|Third Molar
210858|NCT01896427|Edema
210859|NCT01896427|pain
210860|NCT01896427|trismus
210861|NCT01896414|Metabolic Syndrome
210862|NCT01896414|Omega 3 Fish Oil
210863|NCT01896401|large bore endovascular catheterization procedures
210864|NCT01896401|Vascular Closure Device
210865|NCT01896388|PTSD/ifenprodil
210866|NCT01896375|Gutkha
210867|NCT01896375|Pan masala ban
210868|NCT01896375|Legislation
210869|NCT01896375|Smokeless tobacco
210870|NCT01896349|Psychotherapy, Treatment Resistant Depression, depression
210871|NCT01896271|kidney cancer
210872|NCT01896271|metastatic cancer
210873|NCT01896245|hoarseness
210874|NCT01896245|sore throat
210875|NCT01896245|intubating conditions
210876|NCT01896245|vocal cord injuries
210877|NCT01896245|sevoflurane
210878|NCT01896232|Secondary Hyperparathyroidism, renal, kidney, kidneys, dialysis, hemodialysis, chronic kidney disease, CKD, SHPT
210879|NCT01896219|Medical device
210880|NCT01896219|CT
210881|NCT01896219|Needle
210882|NCT01896219|Navigation
210883|NCT01896219|IMACTIS-CT®
210884|NCT01896219|Thoraco-abdominal level
210885|NCT01896219|anesthesia needles
210886|NCT01896180|POAG
210887|NCT01896180|OHT
210888|NCT01896180|OHTN
210889|NCT01896180|IOP
210890|NCT01896167|Headache
210891|NCT01896167|Migraine
210892|NCT01896167|Aura
210893|NCT01896167|Cerebral hemodynamics
210894|NCT01896154|dietary fibers, influenza vaccination, HI titres
210895|NCT01895101|blood loss
210896|NCT01895101|tranexamix acid
210897|NCT01895101|cardiac surgery
210898|NCT01895088|presbyopia
210899|NCT01895075|Budesonide
210900|NCT01895075|Inhalation
210901|NCT01895075|Premature infants
210902|NCT01895062|colonoscopy
210903|NCT01895062|oxygen desaturation
210904|NCT01895049|Tacrolimus
210905|NCT01895049|Everolimus
210906|NCT01895049|Cytomegalovirus
210907|NCT01895049|Thymoglobulin
210908|NCT01895049|Deceased donors
210909|NCT01895049|Expanded criteria
210910|NCT01895036|maintained on 2 mg or less of buprenorphine, in which discontinuation of agonist treatment is clinically feasible but difficult
210911|NCT01895010|prevention and treatment
210912|NCT01895010|improvement of the patient's appetite
210913|NCT01895010|TACE
210914|NCT01894997|Deep Vein Thrombosis
210915|NCT01894997|Neuromuscular Electrical Stimulation
210916|NCT01894997|Intermittent Pneumatic Compression
210917|NCT01894997|Doppler Ultrasound
210918|NCT01894984|Schizophrenia
210919|NCT01894984|Risperidone
210920|NCT01894984|Risperdal Consta
210921|NCT01894984|Oral antipsychotic
210922|NCT01894958|Fragile X disorder
210923|NCT01894958|Autism
210924|NCT01894932|Psychotherapy, Group
210925|NCT01894919|Meningococcal B disease,
210926|NCT01894919|Antibody persistence
210927|NCT01894906|Soluble Ferric Pyrophosphate,
210928|NCT01894906|Pharmacokinetics,
210929|NCT01894906|Iron, Mass Transfer,
210930|NCT01894906|Hemodialysis
210931|NCT01894906|chronic therapy;
210932|NCT01896128|stroke
210933|NCT01896128|CVA
210934|NCT01896128|cerebrovascular accident
210935|NCT01896128|hemiparesis
210936|NCT01896128|impairment
210937|NCT01896128|motor recovery
210938|NCT01896128|neuroplasticity
210939|NCT01896128|nuvigil
210940|NCT01896128|armodafinil
210941|NCT01896115|Stimulation, implantable pulse generator, deep brain stimulation
210942|NCT01896102|Adrenoleukodystrophy
210943|NCT01896102|X-linked adrenoleukodystrophy
210944|NCT01896102|Gene therapy
210945|NCT01896102|Hematopoietic stem cell
210946|NCT01896076|caudal space
210947|NCT01896076|children
210948|NCT01896076|ultrasound evaluation
210949|NCT01896063|Electroacupuncture, Sedation
210950|NCT01896050|Joint pain
210951|NCT01896050|Grip strength
210952|NCT01896050|Hormone receptor positive breast cancer
210953|NCT01896037|Spinal cord injury
210954|NCT01896037|Tetraplegia
210955|NCT01896037|Quadraplegia
210956|NCT01896037|Cholesterol
210957|NCT01896037|HDL-c
210958|NCT01896037|LDL-c
210959|NCT01896037|Omega-3 fatty acids
210960|NCT01895998|sickle cell disease
210961|NCT01895998|pulmonary hypertension
210962|NCT01895998|airway hyperreactivity
210963|NCT01895998|acute chest syndrome
210964|NCT01895959|knee osteoarthritis (OA)
210965|NCT01895959|hyaluronic acid injection
210966|NCT01895946|Advanced solid malignancy, AZD5363,
210967|NCT01895946|food effect,
210968|NCT01895946|formulation comparison
210969|NCT01895933|Investigational device (chitosan gel)
210970|NCT01895933|Wound healing
210971|NCT01895933|Endoscopic sinus surgery
210972|NCT01895933|SurgiShield
210973|NCT01895920|HIV
210974|NCT01895920|Biofilm
210975|NCT01895920|Transmission
210976|NCT01895907|Special Olympics
210977|NCT01895907|occupational therapy
210978|NCT01895907|SCOPE
210979|NCT01895907|life participation improvement
210980|NCT01895894|Mycophenolate mofetil
210981|NCT01895894|Immunosuppressive Agents
210982|NCT01895894|Nephrosis
210983|NCT01895881|Intracranial Aneurysm
210984|NCT01895881|Estradiol
210985|NCT01895868|Ultrasound training
210986|NCT01895868|Ultrasound simulation
210987|NCT01895868|Ultrasound assessment
210988|NCT01895868|Technology-enhanced learning
210989|NCT01895868|virtual reality simulation
210990|NCT01895842|Leukemia
210991|NCT01895842|Myelodysplastic syndrome
210992|NCT01895842|MDS
210993|NCT01895842|Low or intermediate-1 risk
210994|NCT01895842|Maximum tolerated dose
210995|NCT01895842|MTD
210996|NCT01895842|Ruxolitinib
210997|NCT01895842|Jakafi
210998|NCT01895842|INCB018424
210999|NCT01895842|INC424
211000|NCT01895829|Head and Neck Cancer
211001|NCT01895829|Squamous cell carcinomas of the head and neck
211002|NCT01895829|HNSCC
211003|NCT01895829|Magnetic resonance imaging
211004|NCT01895829|MRI
211005|NCT01895829|Ferumoxytol
211006|NCT01895829|Ultra-small superparamagnetic iron oxide nanoparticle
211007|NCT01895829|USPIO
211008|NCT01895829|Contrast agent
211009|NCT01895829|Dynamic contrast imaging
211010|NCT01895829|DCI
211011|NCT01895816|male infertility,oligo spermia
211012|NCT01895803|smoking woman
211013|NCT01895790|Pancreatic Cancer
211014|NCT01895790|Pancreatic Duct
211015|NCT01895790|Stent
211016|NCT01895790|Pancreatic Duct Stent
211017|NCT01895790|Cancer
211018|NCT01895790|Pain
211019|NCT01895790|Obstructive Pain
211020|NCT01895790|Palliative
211021|NCT01895764|ankylosing spondylitis
211022|NCT01895751|Non-ST elevation myocardial infarction (NSTEMI)
211023|NCT01895751|Non-ST elevation acute coronary syndrome (NSTE-ACS)
211024|NCT01895751|Unstable Angina
211025|NCT01895751|Medical therapy
211026|NCT01895751|Coronary angiogram
211027|NCT01895751|Percutaneous coronary intervention
211028|NCT01895751|Coronary artery bypass surgery
211029|NCT01895751|Coronary revascularization
211030|NCT01895751|Health economics
211031|NCT01895738|Trauma
211032|NCT01895738|Injuries
211033|NCT01895738|Violence
211034|NCT01895738|Adolescent
211035|NCT01895738|WrapAround care
211036|NCT01895712|International
211037|NCT01895712|Multicenter
211038|NCT01895712|Observational registry
211039|NCT01895712|Orsiro Drug Eluting Stents (DES)
211040|NCT01895712|Stenting
211041|NCT01895712|Treatment of Coronary Artery Disease
211042|NCT01895712|Coronary revascularization
211043|NCT01895712|Percutaneous Coronary Intervention (PCI)
211044|NCT01895712|Diabetes Mellitus Type 1
211045|NCT01895712|Diabetes Mellitus Type 2
211046|NCT01895712|STEMI
211047|NCT01895712|NSTEMI
211048|NCT01895712|Ischemia
211049|NCT01895712|Angina
211050|NCT01895712|Subgroups
211051|NCT01895712|Acute Myocardial Infarction
211052|NCT01895712|Small vessels
211053|NCT01895712|Chronic Total Occlusion
211054|NCT01895699|Contrast agent
211055|NCT01895699|endothelium
211056|NCT01895699|Free radical
211057|NCT01895699|Alpha lipoic acid
211058|NCT01895686|open angle glaucoma
211059|NCT01895686|narrow angles
211060|NCT01895686|angle closure glaucoma
211061|NCT01895686|gonioscopy
211062|NCT01895686|anterior segment OCT
211063|NCT01895673|FDG-PET
211064|NCT01895673|Radiofrequency Ablation
211065|NCT01895673|Magnetic Resonance Imaging
211066|NCT01895660|P-CIMT
211067|NCT01895660|Pediatric Constraint Induced Movement Therapy
211068|NCT01895660|Hemiparesis
211069|NCT01895660|Cerebral Palsy
211070|NCT01895660|Children
211071|NCT01895647|electric muscle stimulation
211072|NCT01895647|respiratory failure
211073|NCT01895647|sepsis
211074|NCT01895647|interleukin 6
211075|NCT01895647|interleukin 15
211076|NCT01895634|Ischemia
211077|NCT01895634|Stroke
211078|NCT01895634|Ischemic Stroke
211079|NCT01895634|Thrombectomy
211080|NCT01895634|Brain clot
211081|NCT01895634|Cerebrovascular disease
211082|NCT01895634|Recanalization
211083|NCT01895634|Revascularization
211084|NCT01895634|Clot Retriever
211085|NCT01895634|Neurovascular Intervention
211086|NCT01895634|Interventional Neuroradiology
211087|NCT01895634|neurovascular clinical trial
211088|NCT01895608|aged or aged 80 and over
211089|NCT01895608|gait disorder
211090|NCT01895608|attention
211091|NCT01895595|obesity
211092|NCT01895595|stress
211093|NCT01895595|intuitive eating
211094|NCT01895595|guided imagery
211095|NCT01895595|latinos
211096|NCT01895595|adolescents
211097|NCT01895595|insulin resistance
211098|NCT01895582|Ageing
211099|NCT01895582|Tuberculosis
211100|NCT01895582|Interferon gamma releasing tests
211101|NCT01895556|Malawi
211102|NCT01895556|Risk Compensation
211103|NCT01895556|Male Circumcision
211104|NCT01895556|Demand
211105|NCT01895530|Probiotics
211106|NCT01895530|colorectal cancer
211107|NCT01895530|postoperative infection
211108|NCT01895530|immune function
211109|NCT01895530|bacterial translocation
211110|NCT01895530|gastrointestinal surgery
211111|NCT01895504|Colonoscopy
211112|NCT01895504|Colorectal cancer
211113|NCT01895504|Adenoma
211114|NCT01895478|asthma
211115|NCT01895478|pediatrics
211116|NCT01895478|control
211117|NCT01895478|medication adherence
211118|NCT01895465|urine collection, contamination
211119|NCT01895452|Schizophrenia
211120|NCT01895439|Bone marrow derived Mesenchymal Stem Cells
211121|NCT01895439|Multiple Sclerosis
211122|NCT01895439|Oligodendrocytes
211123|NCT01895439|Neuroimmunology
211124|NCT01895439|Autoimmune disease
211125|NCT01895413|Cartilage injury
211126|NCT01895413|Osteoarthritis
211127|NCT01895413|Mesenchymal stem cells
211128|NCT01895400|Renexin for Recurrent Vestibulopathy
211129|NCT01895374|Laser therapy
211130|NCT01895374|Biological dressing
211131|NCT01895374|Amniotic membrane
211132|NCT01895374|Hydrocolloid bandages
211133|NCT01895374|wound healing
211134|NCT01895361|SelG1
211135|NCT01895361|P-selectin
211136|NCT01895361|monoclonal antibody
211137|NCT01895361|sickle cell disease
211138|NCT01895361|sickle cell anemia
211139|NCT01895361|sickle cell
211140|NCT01895361|pain crisis
211141|NCT01895361|pain crises
211142|NCT01895361|vasoocclusion
211143|NCT01895361|vaso-occlusion
211144|NCT01895361|priapism
211145|NCT01895361|hepatic sequestration
211146|NCT01895361|splenic sequestration
211147|NCT01895361|chest syndrome
211148|NCT01895322|Tolvaptan
211149|NCT01895322|dialysis
211150|NCT01895309|Rheumatoid Arthritis
211151|NCT01895309|Etanercept
211152|NCT01895309|Biosimilar
211153|NCT01895296|dumping syndrome
211154|NCT01895296|OGTT
211155|NCT01895296|hypoglycemia
211156|NCT01895283|Aerobic training
211157|NCT01895283|VO2max
211158|NCT01895283|Bethlem myopathy
211159|NCT01895270|opioid dependence
211160|NCT01895270|buprenorphine
211161|NCT01895270|isradipine
211162|NCT01895270|opioid withdrawal
211163|NCT01895270|opioid detoxification
211164|NCT01895257|TTP1
211165|NCT01895257|TTP2
211166|NCT01895257|PFS
211167|NCT01895257|Safety
211168|NCT01895257|R0 resection rate
211169|NCT01895257|Quality of life
211170|NCT01895257|Overall Survival
211171|NCT01895244|scleroderma
211172|NCT01895244|autologous stem cell transplantation
211173|NCT01895244|thiotepa
211174|NCT01895244|cluster of differentiation (CD) 34 selection
211175|NCT01895192|sperm morphology
211176|NCT01895192|vacuoles
211177|NCT01895192|fertile
211178|NCT01895192|Motile Sperm Organellar Morphology Examination
211179|NCT01895192|high magnification
211180|NCT01895192|reference values
211181|NCT01895179|Time-restricted feeding
211182|NCT01895179|Intermittent fasting
211183|NCT01895179|Prediabetes
211184|NCT01895179|Insulin resistance
211185|NCT01895179|Glucose tolerance
211186|NCT01895179|Insulin sensitivity
211187|NCT01895179|Circadian rhythms
211188|NCT01895179|Diurnal
211189|NCT01895166|Endobronchial ultrasonography with a guide sheath
211190|NCT01895166|Peripheral pulmonary lesions
211191|NCT01895166|Transbronchial biopsy
211192|NCT01895153|bladder pain syndrome
211193|NCT01895153|pentosan polysulfate
211194|NCT01895153|hydrodistension
211195|NCT01895140|Treatment-resistant hypertension
211196|NCT01895140|Renal denervation
211197|NCT01895140|Ambulatory blood pressure
211198|NCT01895127|Kidney Transplant
211199|NCT01895127|Renal Transplant
211200|NCT01895127|Rejection
211201|NCT01895127|Antibody mediated
211202|NCT01895127|Humoral
211203|NCT01895127|Eculizumab
211204|NCT01895114|Renal function
211205|NCT01895114|cirrhotic patients
211206|NCT01895114|transplant evaluation
211207|NCT01894867|LIVER CIRRHOSIS
211208|NCT01894867|MAGNESIUM
211209|NCT01894867|MINIMAL ENCEPHALOPATHY
211210|NCT01894867|MUSCLE WEAKNESS
211211|NCT01894854|Radiostereometry
211212|NCT01894854|Total Hip Arthroplasty
211213|NCT01894854|Stem design
211214|NCT01894841|depression
211215|NCT01894841|prevention
211216|NCT01894841|Veterans health
211217|NCT01894828|Nutritional support
211218|NCT01894828|Gastrointestinal cancer
211219|NCT01894828|Malnutrition
211220|NCT01894815|major depressive disorder
211221|NCT01894815|major depression
211222|NCT01894815|depressive disorder
211223|NCT01894815|major depressive episode
211224|NCT01894802|Tetraplegia
211225|NCT01894802|Quadriplegia
211226|NCT01894802|Spinal cord injury
211227|NCT01894802|Brainstem or spinal stroke
211228|NCT01894802|Neuroprosthetic
211229|NCT01894802|Brain-machine interface
211230|NCT01894802|Brain-computer interface
211231|NCT01894802|Neural activity
211232|NCT01894802|Sensory stimulation
211233|NCT01894802|Microstimulation
211234|NCT01894789|myocardial blood flow
211235|NCT01894789|myocardial perfusion imaging
211236|NCT01894789|myocardial blood flow reserve
211237|NCT01894789|positron emission tomography
211238|NCT01894789|adenosine
211239|NCT01894789|ticagrelor
211240|NCT01894789|clopidogrel
211241|NCT01894776|healthy volunteers
211242|NCT01894763|esophagus
211243|NCT01894763|cancer
211244|NCT01894750|Heart Failure
211245|NCT01894750|Self-Care
211246|NCT01894685|Colorectal
211247|NCT01894685|Adenoma
211248|NCT01894685|Recurrence
211249|NCT01894685|Mesalazine
211250|NCT01894685|Chemoprevention
211251|NCT01894672|LGX818
211252|NCT01894672|BRAF Inhibitor
211253|NCT01894672|Stage IV melanoma
211254|NCT01894672|unresectable stage III melanoma
211255|NCT01894672|BRAFV600 mutation
211256|NCT01894672|13-053
211257|NCT01894633|Prophylactic Cranial Irradiation
211258|NCT01894633|Metastasis
211259|NCT01894633|Cloroquine
211260|NCT01894620|Alzheimer's
211261|NCT01894620|rTMS
211262|NCT01894620|sleep quality
211263|NCT01894620|dementia
211264|NCT01894620|memory
211265|NCT01894607|Kidney Cancer
211266|NCT01894607|Renal Mass
211267|NCT01894607|Open partial nephrectomy
211268|NCT01894607|Ultrasound-guided surgery
211269|NCT01894607|DEFINITY
211270|NCT01894607|Contrast agent
211271|NCT01894607|Phone call
211272|NCT01894594|Sickle cell disease
211273|NCT01894594|Chronic kidney disease
211274|NCT01894594|Bicarbonate therapy
211275|NCT01894555|Platelet Transcriptome
211276|NCT01894555|Coronary Artery Disease
211277|NCT01894555|Myocardial Ischemia
211278|NCT01894555|Coronary Disease
211279|NCT01894555|Heart Diseases
211280|NCT01894555|Cardiovascular Diseases
211281|NCT01894555|Arteriosclerosis
211282|NCT01894555|Arterial Occlusive Diseases
211283|NCT01894555|Vascular Diseases
211284|NCT01894555|Aspirin
211285|NCT01894529|ischemic stroke
211286|NCT01894529|immune biomarkers
211287|NCT01894529|stroke-associated infection
211288|NCT01894529|functional outcome
211289|NCT01894529|prediction
211290|NCT01894490|Gastrointestinal surgery, complications, length of hospital stay, mortality
211291|NCT01894464|truancy
211292|NCT01894464|attendance
211293|NCT01894464|education
211294|NCT01894464|primary school
211295|NCT01894464|elementary school
211296|NCT01894451|Inflammatory Breast Carcinoma
211297|NCT01894451|89Zr-bevacizumab
211298|NCT01894438|NAFLD
211299|NCT01894438|NASH
211300|NCT01894438|Mediterranean diet
211301|NCT01894438|Mediterranean lifestyle
211302|NCT01894425|Medically assisted procreation
211303|NCT01894425|Assisted reproductive technology
211304|NCT01894425|Human papilloma virus
211305|NCT01894399|HM61713
211306|NCT01894399|pharmacokinetics
211307|NCT01894399|Phase I
211308|NCT01894399|healthy
211309|NCT01894399|olmutinib
211310|NCT01894386|GW642444 (Vilanterol)
211311|NCT01894386|GSK573719 (Umeclidinium)
211312|NCT01894386|GW685698 (Fluticasone Furoate)
211313|NCT01894386|pharmacokinetics
211314|NCT01894386|Healthy subjects
211315|NCT01894360|Pharmacokinetics
211316|NCT01894360|Phase 1
211317|NCT01894360|Healthy Subjects
211318|NCT01894360|Comparability
211319|NCT01894360|Belimumab
211320|NCT01894347|Colistin, MDR, inhalative therapy
211321|NCT01894334|Aortic dissection
211322|NCT01894334|acute lung injury
211323|NCT01894334|injury mechanism
211324|NCT01894334|early intervention
211325|NCT01894321|Acute cholecystitis
211326|NCT01894321|Elderly
211327|NCT01894321|Critically ill patients
211328|NCT01894321|Surgical high risk
211329|NCT01894321|Percutaneous cholecystostomy
211330|NCT01894321|Cholecystectomy
211331|NCT01894308|Male Hormone Replacement
211332|NCT01894308|Multiple Dose
211333|NCT01894308|Single Period
211334|NCT01894308|Phase II
211335|NCT01894308|Dose Ranging
211336|NCT01894308|Adult Male Subjects
211337|NCT01894308|Testosterone Replacement
211338|NCT01894295|Vitamin D analogues
211339|NCT01894295|Resting Metabolic rate
211340|NCT01894295|obesity
211341|NCT01894282|Chronic Lower Back Pain
211342|NCT01894282|Manual Therapy
211343|NCT01894282|Cognitive Behavioral Therapy
211344|NCT01894256|oncology,
211345|NCT01894256|cancer,
211346|NCT01894256|neoplasm,
211347|NCT01894256|anticancer drug,
211348|NCT01894256|pharmacokinetics,
211349|NCT01894256|area under curve,
211350|NCT01894256|olaparib,
211351|NCT01894256|solid tumour,
211352|NCT01894256|mild renal impairment,
211353|NCT01894256|moderate renal impairment
211354|NCT01894243|oncology,
211355|NCT01894243|cancer,
211356|NCT01894243|neoplasm,
211357|NCT01894243|anticancer drug,
211358|NCT01894243|pharmacokinetics,
211359|NCT01894243|area under curve,
211360|NCT01894243|olaparib,
211361|NCT01894243|solid tumour,
211362|NCT01894243|mild hepatic impairment,
211363|NCT01894243|moderate hepatic impairment
211364|NCT01894230|high cholesterol
211365|NCT01894230|genetic testing
211366|NCT01894230|medication adherence
211367|NCT01894230|statins
211368|NCT01894230|Adverse Effects
211369|NCT01894230|pharmacogenetics
211370|NCT01894217|high cholesterol
211371|NCT01894217|genetic testing
211372|NCT01894217|medication adherence
211373|NCT01894217|statins
211374|NCT01894217|Adverse Effects
211375|NCT01894217|Pharmacogenetic
211376|NCT01894204|HTTPE
211377|NCT01894204|Idiopathic Pulmonary embolism
211378|NCT01894191|adenoma detection rate
211379|NCT01894191|colonoscopy
211380|NCT01894191|water exchange
211381|NCT01894165|molybdenum cofactor deficiency (MoCD)
211382|NCT01894165|deficiency of activity of molybdenum-dependent enzymes
211383|NCT01894152|XIENCE PRIME EECSS
211384|NCT01894152|XIENCE V EECSS
211385|NCT01894152|XIENCE PRIME
211386|NCT01894152|SPIRIT PRIME
211387|NCT01894152|XIENCE PRIME SV (Small Vessel)
211388|NCT01894152|XIENCE PRIME LL (Long Lesion)
211389|NCT01894152|Coronary Artery Disease
211390|NCT01894152|Coronary Heart Disease
211391|NCT01894152|Cardiovascular Disease
211392|NCT01894152|Myocardial Infarction
211393|NCT01894152|Stent Thrombosis
211394|NCT01894139|Gestational weight gain
211395|NCT01894139|Obese women
211396|NCT01894139|Fetal programming
211397|NCT01894139|Metabolic disorders
211398|NCT01894139|Development of obesity
211399|NCT01894139|Development og overweight
211400|NCT01894139|Complications during pregnancy and birth
211401|NCT01894113|interstitial lung disease
211402|NCT01894113|transbronchial biopsy
211403|NCT01894113|cryobiopsy
211404|NCT01894074|Subfertility
211405|NCT01894074|Anovulatory
211406|NCT01894074|Obese
211407|NCT01894074|Women
211408|NCT01894061|adult giant cell glioblastoma
211409|NCT01894061|adult glioblastoma
211410|NCT01894061|adult gliosarcoma
211411|NCT01894061|recurrent adult brain tumor
211412|NCT01894061|Bevacizumab-naive
211413|NCT01894061|NovoTTF-100A
211414|NCT01894048|asthma control
211415|NCT01894048|small airways
211416|NCT01894048|extra-fine particle inhaled corticosteroids
211417|NCT01894035|Pulmonary Hypertension
211418|NCT01894035|Ventavis
211419|NCT01894035|Patient compliance
211420|NCT01894022|Inoperable chronic thromboembolic pulmonary hypertension, endothelin receptor antagonist
211421|NCT01894009|Osteopathic manipulation
211422|NCT01894009|Exercise therapy
211423|NCT01894009|Pregnancy pelvic girdle pain
211424|NCT01893996|rheumatoid
211425|NCT01893996|arthritis
211426|NCT01893996|cardiovascular
211427|NCT01893996|adalimumab
211428|NCT01893996|tnf
211429|NCT01893996|biologic
211430|NCT01893983|Mental Health
211431|NCT01893983|Veterans Health
211432|NCT01893983|Rural
211433|NCT01893983|Motivational Interviewing
211434|NCT01893957|breast cancer
211435|NCT01893957|physical therapy
211436|NCT01893957|electrical stimulation
211437|NCT01893957|tactile sensitivity
211438|NCT01893957|flow blood
211439|NCT01893944|Breast cancer
211440|NCT01893944|vibratory therapy
211441|NCT01893944|virtual reality
211442|NCT01893931|Geriatrics
211443|NCT01893931|Emergency Medicine
211444|NCT01893931|Care Transitions
211445|NCT01893918|Smoking
211446|NCT01893918|Dyspnea
211447|NCT01893892|Basal Cell Carcinoma
211448|NCT01893892|Gorlin syndrome
211449|NCT01893892|Erivedge
211450|NCT01893892|Basal Cell Nevus Syndrome
211451|NCT01893853|dehydration
211452|NCT01893853|fluid balance
211453|NCT01893853|exercise
211454|NCT01893853|heat
211455|NCT01893853|body weight
211456|NCT01893853|performance
211457|NCT01893827|Naltrexone
211458|NCT01893827|Extended-release naltrexone
211459|NCT01893827|Oral naltrexone
211460|NCT01893827|Vivitrol
211461|NCT01893827|XR-NTX
211462|NCT01893827|alcohol dependence
211463|NCT01893827|primary care
211464|NCT01893827|Medical Management
211465|NCT01893801|pancreatic cancer
211466|NCT01893801|pancreatic adenocarcinoma
211467|NCT01893801|Stage IV pancreatic cancer
211468|NCT01893801|pancreas
211469|NCT01893801|pancreatic
211470|NCT01893788|hypertension
211471|NCT01893788|left ventricular hypertrophy
211472|NCT01893788|renin angiotensin system
211473|NCT01893788|aldosterone
211474|NCT01893788|aliskiren
211475|NCT01893788|eplerenone
211476|NCT01893788|P3NP
211477|NCT01893775|Anti CD 122
211478|NCT01893775|Monoclonal Antibody Therapy
211479|NCT01893775|Autoimmune Inflammatory Enteropathy
211480|NCT01893762|neutrophil
211481|NCT01893762|exercise
211482|NCT01893762|URTI
211483|NCT01893762|Innate
211484|NCT01893762|Immune
211485|NCT01893749|depression
211486|NCT01893749|prevention
211487|NCT01893749|teen
211488|NCT01893749|at risk
211489|NCT01893749|internet
211490|NCT01893736|Breastfeeding
211491|NCT01893736|professional support
211492|NCT01893736|postnatal
211493|NCT01893736|interventions
211494|NCT01893736|exclusive breastfeeding
211495|NCT01893736|randomized controlled trial
211496|NCT01893723|autonomous nervous system monitoring
211497|NCT01893723|analgesia nociception balance
211498|NCT01893723|remifentanil
211499|NCT01893723|analgesia nociception index
211500|NCT01893723|hemodynamic reactivity
211501|NCT01893710|peritoneal dialysis
211502|NCT01893710|parietal peritoneum
211503|NCT01893710|omentum
211504|NCT01893710|children
211505|NCT01893684|protein
211506|NCT01893684|physical function
211507|NCT01893684|muscle quality
211508|NCT01893684|fatigue
211509|NCT01893684|weight loss
211510|NCT01893671|LASIK
211511|NCT01893671|corneal power
211512|NCT01893671|astigmatism
211513|NCT01893671|HOA
211514|NCT01893671|Optical Coherence Tomography
211515|NCT01893658|Interstitial Nephritis
211516|NCT01893658|Nephritis
211517|NCT01893658|Tubulointerstitial
211518|NCT01893658|Renal disease
211519|NCT01893658|Kidney
211520|NCT01893645|Pronto-7
211521|NCT01893645|SpHb
211522|NCT01893645|Obstetric patients
211523|NCT01893632|Benzodiazepines
211524|NCT01893632|clonazepam
211525|NCT01893632|alprazolam
211526|NCT01893632|Klonopin
211527|NCT01893632|Xanax
211528|NCT01893632|diazepam
211529|NCT01893632|Valium
211530|NCT01893632|lorazepam
211531|NCT01893632|Ativan
211532|NCT01893619|Chronic fatigue syndrome
211533|NCT01893619|Karnofsky score
211534|NCT01893619|supplements
211535|NCT01893606|diarrhea
211536|NCT01893606|abdominal pain
211537|NCT01893593|Cardiovascular risk
211538|NCT01893593|lifestyle change
211539|NCT01893593|blood pressure
211540|NCT01893593|body mass index
211541|NCT01893593|tobacco
211542|NCT01893580|Cancer
211543|NCT01893580|Rehabilitation
211544|NCT01893580|Exercise
211545|NCT01893580|Lung cancer
211546|NCT01893580|NSCLC
211547|NCT01893541|CIRRHOTIC
211548|NCT01893541|VARICEAL BLEEDING
211549|NCT01893541|PRIMARY PROPHYLAXIS
211550|NCT01893489|positron emission tomography
211551|NCT01893489|macrophage
211552|NCT01893489|neomannosyl human serum albumin
211553|NCT01893476|chronic obstructive pulmonary disease
211554|NCT01893476|implementation
211555|NCT01893463|hemorrhage control
211556|NCT01893463|wound closure
211557|NCT01893450|Graves ophthalmopathy
211558|NCT01893450|Exophthalmos
211559|NCT01893450|Proptosis
211560|NCT01893450|Quality of life
211561|NCT01893424|Biological Availability
211562|NCT01893424|Pharmacokinetics
211563|NCT01893385|vitamin D
211564|NCT01893385|supplementation
211565|NCT01893385|immunocompetente cells, immune system
211566|NCT01893385|influenza vaccine
211567|NCT01893385|elderly
211568|NCT01893372|Leukemia
211569|NCT01893372|Myelodysplastic syndrome
211570|NCT01893372|MDS
211571|NCT01893372|Overall response rate
211572|NCT01893372|ORR
211573|NCT01893372|Eltrombopag
211574|NCT01893372|Promacta
211575|NCT01893372|Hypomethylating Agent
211576|NCT01893359|hyperopia
211577|NCT01893359|hyperopic astigmatism
211578|NCT01893359|cross-linking
211579|NCT01893346|Ceftazidime, Avibactam, Anti-Infectives
211580|NCT01893333|cervical cancer
211581|NCT01893333|nerve sparing radical hysterectomy
211582|NCT01893320|Leukemia
211583|NCT01893320|Acute Myeloid Leukemia
211584|NCT01893320|AML
211585|NCT01893320|High-risk Myelodysplastic Syndrome
211586|NCT01893320|MDS
211587|NCT01893320|Chronic Myelomonocytic Leukemia
211588|NCT01893320|CMM
211589|NCT01893320|Maximum tolerated dose
211590|NCT01893320|MTD
211591|NCT01893320|Vosaroxin
211592|NCT01893320|Decitabine
211593|NCT01893320|Dacogen
211594|NCT01893307|Head And Neck Cancer
211595|NCT01893307|Oropharyngeal Cancer
211596|NCT01893307|Squamous cell carcinoma of the oropharynx
211597|NCT01893307|Acute and late toxicity
211598|NCT01893307|Intensity modulated photon therapy
211599|NCT01893307|IMRT
211600|NCT01893307|Intensity modulated proton therapy
211601|NCT01893307|IMPT
211602|NCT01893307|Modified barium swallow
211603|NCT01893307|MBS
211604|NCT01893307|Questionnaires
211605|NCT01893307|Surveys
211606|NCT01893229|Bipolar disorder
211607|NCT01893229|Comparative Effectiveness Research
211608|NCT01893229|Therapeutics
211609|NCT01893229|Patient Dropouts
211610|NCT01893216|anxiety
211611|NCT01893216|depression
211612|NCT01893216|sexual dysfunction
211613|NCT01893216|infertility
211614|NCT01893190|Ruptured saccular aneurysm
211615|NCT01893190|nimodipine
211616|NCT01893190|safety
211617|NCT01893190|tolerability
211618|NCT01893190|Subarachnoid hemorrhage
211619|NCT01893177|Influenza
211620|NCT01893177|Virus
211621|NCT01893177|Vaccination
211622|NCT01893177|Inflexal V
211623|NCT01893164|cubital tunnel syndrome
211624|NCT01893164|simple decompression
211625|NCT01893164|anterior subcutaneous transposition of ulnar nerve
211626|NCT01893164|anterior intramuscular transposition of ulnar nerve
211627|NCT01893164|severity scale
211628|NCT01893151|Iguratimod
211629|NCT01893151|MRI
211630|NCT01893151|Rheumatoid Arthritis
211631|NCT01893138|Urinary Incontinence, Stress
211632|NCT01893138|Tissue Therapy (Cell Therapy)
211633|NCT01893138|Transplantation, Autologous
211634|NCT01893060|Prematurity
211635|NCT01893060|Central line care
211636|NCT01893060|Umbilical line colonization
211637|NCT01893060|Colonization
211638|NCT01893060|Newborn Intensive Care Unit
211639|NCT01893060|Neonatal Intensive Care Unit
211640|NCT01893047|breast milk production
211641|NCT01893034|Femoroacetabular Impingement
211642|NCT01893034|Arthroscopy
211643|NCT01893034|Physiotherapy
211644|NCT01893034|Randomised Controlled Trial
211645|NCT01893008|Esophageal cancer
211646|NCT01893008|Surgery
211647|NCT01892995|suicide
211648|NCT01892995|ketamine
211649|NCT01892995|low-dose ketamine
211650|NCT01892995|suicidal ideations
211651|NCT01892995|emergency department
211652|NCT01892982|Maternal Depression
211653|NCT01892982|Preterm Birth
211654|NCT01892982|Preterm Outcomes
211655|NCT01892982|Child Development
211656|NCT01892917|International
211657|NCT01892917|Multicenter
211658|NCT01892917|Observational registry
211659|NCT01892917|Orsiro Drug Eluting Stent (DES)
211660|NCT01892917|Stenting
211661|NCT01892917|Treatment of Coronary Artery Disease
211662|NCT01892917|Coronary revascularization
211663|NCT01892917|Percutaneous Coronary Intervention
211664|NCT01892917|STEMI
211665|NCT01892917|NSTEMI
211666|NCT01892917|Ischemia
211667|NCT01892917|Subgroups
211668|NCT01892917|Acute Myocardial Infarction
211669|NCT01892917|Diabetes
211670|NCT01892917|Small Vessels
211671|NCT01892917|Chronic Total Occlusion (CTO)
211672|NCT01892904|YAZ
211673|NCT01892904|Flexible regimen
211674|NCT01892904|Drospirenone
211675|NCT01892904|Ethinylestradiol Betadex
211676|NCT01892904|Dysmenorrhea
211677|NCT01892904|Japanese patients
211678|NCT01892891|Healthy
211679|NCT01892891|Subjects
211680|NCT01892891|Safety
211681|NCT01892891|Tolerability
211682|NCT01892891|VBY036
211683|NCT01892891|maximum
211684|NCT01892891|pharmacodynamic
211685|NCT01892891|pharmacokinetic
211686|NCT01892865|Operating room utilization
211687|NCT01892852|Acupuncture
211688|NCT01892852|Traditional Korean Medicine
211689|NCT01892826|FET
211690|NCT01892826|Blastocyst
211691|NCT01892826|natural cycle
211692|NCT01892826|hCG
211693|NCT01892826|Spontaneous LH pic
211694|NCT01892813|Nicotine dependence
211695|NCT01892813|Smoking cessation
211696|NCT01892813|Telehealth
211697|NCT01892813|Alcohol use
211698|NCT01892813|Depression
211699|NCT01892813|Body weight
211700|NCT01892800|Lung Cancer
211701|NCT01892800|Ventricular function, Right
211702|NCT01892787|Asthma
211703|NCT01892787|Small airways
211704|NCT01892787|Extra fine particle long-acting beta agonists
211705|NCT01892774|LSPAF
211706|NCT01892774|asymptomatic
211707|NCT01892774|exercise tolerance
211708|NCT01892761|mycophenolate mofetil
211709|NCT01892761|mycophenolic acid
211710|NCT01892761|MPA
211711|NCT01892761|MMF
211712|NCT01892761|Pharmacokinetics
211713|NCT01892761|renal transplantation
211714|NCT01892748|Lupus
211715|NCT01892748|Juvenile
211716|NCT01892748|Cholecalciferol
211717|NCT01892748|Disease activity
211718|NCT01892748|Bone Mass
211719|NCT01892748|Fatigue
211720|NCT01892748|Safety
211721|NCT01892722|pediatric
211722|NCT01892722|multiple sclerosis
211723|NCT01892709|acute
211724|NCT01892709|pain
211725|NCT01892709|emergency department
211726|NCT01892709|hydromorphone
211727|NCT01892709|in ER
211728|NCT01892696|inspiratory flow pattern
211729|NCT01892696|mechanical ventilation
211730|NCT01892696|cardiac preload
211731|NCT01892696|arterial pulse pressure variation
211732|NCT01892696|inferior vena cava collapsibility
211733|NCT01892683|propofol
211734|NCT01892683|exhaled
211735|NCT01892683|monitoring
211736|NCT01892683|anesthesia
211737|NCT01892670|Blood
211738|NCT01892670|Whole blood
211739|NCT01892670|Cold-storage
211740|NCT01892670|Filtration
211741|NCT01892670|Transfusion
211742|NCT01892670|Platelet-function
211743|NCT01892657|Cetaphil Daily Facial Moisturizer with SPF 50+
211744|NCT01892657|Hypoallergenicity
211745|NCT01892657|Skin Irritation
211746|NCT01892644|Hemochromatosis
211747|NCT01892644|Myelodysplastic syndromes
211748|NCT01892644|Iron overload
211749|NCT01892644|Deferasirox
211750|NCT01892644|Chelation therapy
211751|NCT01892644|Venesection
211752|NCT01892644|Phlebotomy
211753|NCT01892644|Ferritin
211754|NCT01892644|Transfusional siderosis
211755|NCT01892631|Text messaging
211756|NCT01892605|Mozart K.448
211757|NCT01892605|first unprovoked seizure
211758|NCT01892605|epileptiform discharges
211759|NCT01892605|music therapy
211760|NCT01892605|children
211761|NCT01892592|Hypertension
211762|NCT01892592|African American
211763|NCT01892592|Health Disparities
211764|NCT01892592|Stroke
211765|NCT01892592|Cardiovascular Disease
211766|NCT01892579|Agitation
211767|NCT01892579|Dementia
211768|NCT01892579|Alzheimer's Disease
211769|NCT01892579|Neuropsychiatric Behaviors
211770|NCT01892566|HIV
211771|NCT01892566|mobile health
211772|NCT01892566|spirometry
211773|NCT01892553|Dyspnea
211774|NCT01892553|Transcranial direct current stimulation (tDCS)
211775|NCT01892553|Perception
211776|NCT01892527|Colorectal Cancer Metastatic
211777|NCT01892527|wild type KRAS
211778|NCT01892527|C-met overexpression
211779|NCT01892527|Tivantinib
211780|NCT01892527|Cetuximab
211781|NCT01892514|osteonecrosis
211782|NCT01892514|bone marrow concentrate
211783|NCT01892514|demineralized bone matrix
211784|NCT01892514|homologous lyophilized bone chips
211785|NCT01892514|autologous platelet rich fibrin
211786|NCT01892514|mesenchymal stromal cells
211787|NCT01892501|Mediastinal lymphadenopathy
211788|NCT01892501|PET CT to 18FDG
211789|NCT01892501|EUS
211790|NCT01892488|COPD
211791|NCT01892488|AE-COPD
211792|NCT01892488|Chronic obstructive pulmonary disease
211793|NCT01892488|acute exacerbations of Chronic obstructive pulmonary disease
211794|NCT01892475|Physical Activity
211795|NCT01892475|Incentives
211796|NCT01892475|Mental Accounting
211797|NCT01892475|Older adults
211798|NCT01892436|Extension study, psoriatic arthritis, pre-filled syringe
211799|NCT01892397|intracranial supratentorial meningioma
211800|NCT01892397|Atypical and Anaplastic Meningioma
211801|NCT01892397|Optune (NovoTTF-100A)
211802|NCT01892397|13-067
211803|NCT01892371|Leukemia
211804|NCT01892371|Acute Myeloid Leukemia
211805|NCT01892371|AML
211806|NCT01892371|Myelodysplastic Syndrome
211807|NCT01892371|MDS
211808|NCT01892371|Quizartinib
211809|NCT01892371|AC220
211810|NCT01892371|ASP2689
211811|NCT01892371|Cytarabine
211812|NCT01892371|Ara-C
211813|NCT01892371|Cytosar
211814|NCT01892371|DepoCyt
211815|NCT01892371|Cytosine arabinosine hydrochloride
211816|NCT01892371|AZA
211817|NCT01892371|Vidaza
211818|NCT01892371|Azacitidine
211819|NCT01892371|5-Azacytidine
211820|NCT01892371|5-AZA
211821|NCT01892371|5-AZC
211822|NCT01892371|AZA-CR
211823|NCT01892371|Ladakamycin
211824|NCT01892371|NSC-102816
211825|NCT01892371|Azacytidine
211826|NCT01892371|Maximum tolerated dose
211827|NCT01892371|MTD
211828|NCT01892371|Overall response
211829|NCT01892371|Complete remission
211830|NCT01892371|CR
211831|NCT01892371|Complete remission with incomplete blood count recovery
211832|NCT01892371|Cri
211833|NCT01892371|Partial remission
211834|NCT01892371|PR
211835|NCT01892371|Hematologic improvement
211836|NCT01892371|HI
211837|NCT01892358|injection drug use
211838|NCT01892345|Neuromyelitis Optica
211839|NCT01892345|Neuromyelitis Optica Spectrum Disorder
211840|NCT01892345|Devic's disease, Transverse Myelitis
211841|NCT01892345|Optic Neuritis
211842|NCT01892345|relapse
211843|NCT01892345|eculizumab
211844|NCT01892345|soliris
211845|NCT01892345|NMO-IgG
211846|NCT01892345|CNS Autoimmune Disorders
211847|NCT01892345|Demyelinating Disorders
211848|NCT01892293|Multiple Myeloma
211849|NCT01892293|Autologous stem cell transplantation
211850|NCT01892293|Received initial treatment previously
211851|NCT01892267|PEGJ
211852|NCT01892267|PEG-J
211853|NCT01892267|Percutaneous Endoscopic Gastrostomy
211854|NCT01892267|Feeding tube
211855|NCT01892267|Gastroparesis
211856|NCT01892267|Acute pancreatitis
211857|NCT01892267|Stroke
211858|NCT01892267|Respiratory failure
211859|NCT01892267|GERD
211860|NCT01892267|Balloon
211861|NCT01892267|Self-propelled
211862|NCT01892254|incretin effect
211863|NCT01892254|PCOS
211864|NCT01892254|insulin resistance
211865|NCT01892254|OGTT
211866|NCT01892254|IIGI
211867|NCT01892241|Chronic hepatitis B,Spontaneous Decline of HBV DNA,Peginterferon a-2a, entecavir
211868|NCT01892228|antiretroviral therapy
211869|NCT01892228|education
211870|NCT01892228|mortality
211871|NCT01892215|Uterine incision.
211872|NCT01892215|Blunt transversal expansion.
211873|NCT01892215|Blunt cephalad-caudad expansion.
211874|NCT01892189|Drug therapy
211875|NCT01892176|coenzyme Q10, Parkinson disease, oxidative damage
211876|NCT01892163|Diabetic macular edema, Ozurdex
211877|NCT01892137|Actinic Keratosis
211878|NCT01892137|Histopathology
211879|NCT01892137|Reflectance Confocal Microscopy
211880|NCT01892137|Local Skin Reaction
211881|NCT01892124|Motivational Interviewing
211882|NCT01892124|Cognitive Therapy
211883|NCT01892124|Community-Based Participatory Research
211884|NCT01892124|Indians, North American
211885|NCT01892111|SET
211886|NCT01892111|infertility
211887|NCT01892111|IVF/ICSI
211888|NCT01892111|pregnancy
211889|NCT01892098|Zinc
211890|NCT01892098|Bone
211891|NCT01892098|Adolescents
211892|NCT01892098|Growth
211893|NCT01892085|Breast milk
211894|NCT01892085|lactogenesis stage two
211895|NCT01892085|premature infant
211896|NCT01892085|insufficient milk supply
211897|NCT01892085|breast milk expression
211898|NCT01892072|hepatocellular carcinoma
211899|NCT01892072|HCC
211900|NCT01892072|VEGF signaling pathway
211901|NCT01892059|renal tumour
211902|NCT01892059|partial nephrectomy
211903|NCT01892059|laparoscope
211904|NCT01892059|segmental renal artery clamping
211905|NCT01892046|Small Cell Lung Cancer
211906|NCT01892046|Non Small Cell Lung Cancer
211907|NCT01892046|Hsp90
211908|NCT01892033|Posttraumatic Stress Disorder
211909|NCT01892033|PTSD
211910|NCT01892033|Aerobic Exercise
211911|NCT01892033|Women
211912|NCT01892033|Veteran
211913|NCT01892007|Hearing loss
211914|NCT01892007|Hearing aid
211915|NCT01892007|Speech intelligibility
211916|NCT01892007|Speech perception
211917|NCT01892007|Cognitive training
211918|NCT01892007|Working memory
211919|NCT01892007|Working memory training
211920|NCT01891994|Cytokine
211921|NCT01891994|Hematopoiesis
211922|NCT01891994|Autoimmunity
211923|NCT01891994|Thrombocytopenia
211924|NCT01891994|Neutropenia
211925|NCT01891981|Leukemia
211926|NCT01891981|Acute Lymphoblastic Leukemia
211927|NCT01891981|ALL
211928|NCT01891981|Relapsed and/or refractory
211929|NCT01891981|Moxetumomab Pasudotox
211930|NCT01891981|Maximum tolerated dose
211931|NCT01891981|MTD
211932|NCT01891968|Leukemia
211933|NCT01891968|Myelodysplastic syndrome
211934|NCT01891968|MDS
211935|NCT01891968|Low or intermediate-1
211936|NCT01891968|Bortezomib
211937|NCT01891968|Velcade
211938|NCT01891968|LDP-341
211939|NCT01891968|MLN341
211940|NCT01891968|PS-341
211941|NCT01891955|Diabetes mellitus type 2
211942|NCT01891955|Cereals
211943|NCT01891955|Dairy
211944|NCT01891955|Dietary carbohydrates
211945|NCT01891955|Dietary fiber
211946|NCT01891955|Food
211947|NCT01891955|Metabolic syndrome
211948|NCT01891955|Satiety
211949|NCT01891942|Normal
211950|NCT01891942|subjects
211951|NCT01891929|Schizophrenia
211952|NCT01891929|Cognitive Remediation
211953|NCT01891929|Working abilities and social functioning
211954|NCT01891877|Sickle Cell Trait
211955|NCT01891877|Football
211956|NCT01891877|Sickling
211957|NCT01891877|Heat Illness
211958|NCT01891877|SCT
211959|NCT01891851|Healthy
211960|NCT01891851|Hepatitis C
211961|NCT01891851|TMC435350
211962|NCT01891851|Ritonavir
211963|NCT01891851|Pharmacokinetics
211964|NCT01891838|surgery
211965|NCT01891838|transsphenoidal surgery
211966|NCT01891838|pituitary adenoma
211967|NCT01891838|mechanical ventilation
211968|NCT01891838|bleeding
211969|NCT01891825|Atrial fibrillation
211970|NCT01891825|Persistent atrial fibrillation
211971|NCT01891825|Atrial fibrillation ablation
211972|NCT01891812|Sickle cell disease
211973|NCT01891812|Vaso-occlusive crisis
211974|NCT01891812|Nitrous oxide
211975|NCT01891812|Emergency department
211976|NCT01891799|HIV/AIDS
211977|NCT01891799|PMTCT
211978|NCT01891799|Option B+
211979|NCT01891799|Swaziland
211980|NCT01891773|Asthma
211981|NCT01891773|Inhaled Corticosteroids
211982|NCT01891773|School Nurses
211983|NCT01891747|gliomas
211984|NCT01891734|Veterans
211985|NCT01891734|Health Services
211986|NCT01891734|Mental Health
211987|NCT01891734|Technology
211988|NCT01891734|Primary Health Care
211989|NCT01891734|Psychotherapy
211990|NCT01891721|cognitive training
211991|NCT01891721|schizophrenia
211992|NCT01891721|mismatch negativity
211993|NCT01891721|cognition
211994|NCT01891721|functional capacity
211995|NCT01891721|EEG
211996|NCT01891682|Methionine Metabolism
211997|NCT01891682|Parenteral Nutrition
211998|NCT01891682|Pediatric
211999|NCT01891682|Pediatrics
212000|NCT01891682|Sepsis
212001|NCT01891682|Observational Study
212002|NCT01891669|ADC 5T4
212003|NCT01891669|PF-06263507
212004|NCT01891669|solid tumors
212005|NCT01891669|lung cancer
212006|NCT01891669|breast cancer
212007|NCT01891669|ovarian cancer
212008|NCT01891669|cancer
212009|NCT01891669|tumors
212010|NCT01891669|neoplasm metastasis
212011|NCT01891656|Motivational Interviewing
212012|NCT01891656|Internet
212013|NCT01891656|Treatment
212014|NCT01891656|Substance-Related Disorders
212015|NCT01891656|Criminal Justice
212016|NCT01891630|African American
212017|NCT01891630|Asthma
212018|NCT01891617|exercise
212019|NCT01891617|high carbohydrate and high fat diets
212020|NCT01891617|insulin
212021|NCT01891617|gut peptides
212022|NCT01891617|appetite
212023|NCT01891617|metabolism
212024|NCT01891617|glucose
212025|NCT01891591|Obesity
212026|NCT01891591|Gastric bypass
212027|NCT01891591|Energy balance
212028|NCT01891591|Nutritional status
212029|NCT01891591|Protein balance
212030|NCT01891552|Colon Cancer, Liver Metastasis, DEBIRI, cetuximab, efficacy
212031|NCT01891539|Hepatocellular carcinoma, doxorubicin, chemoembolization
212032|NCT01891526|Metabolisation of 9-cis-retinoic acid
212033|NCT01891526|hepatic patients
212034|NCT01891526|investigation of urine and blood samples
212035|NCT01891513|Physical activity
212036|NCT01891513|Hypertension
212037|NCT01891513|Physical function
212038|NCT01891513|Aging
212039|NCT01891500|Persistent Fetal Circulation Syndrome
212040|NCT01891500|Infant, Newborn
212041|NCT01891500|Nitric Oxide
212042|NCT01891500|Oxidative Stress
212043|NCT01891500|Endothelin 1
212044|NCT01891500|Vascular Endothelial Growth Factor
212045|NCT01891487|Eyebrow
212046|NCT01891487|Hypotrichosis
212047|NCT01891487|Thinning
212048|NCT01891487|Bimatoprost
212049|NCT01891461|total knee arthroplasty
212050|NCT01891461|post-operative bleeding
212051|NCT01891461|floseal
212052|NCT01891435|antipyretics
212053|NCT01891435|oral paracetamol
212054|NCT01891435|intravenous paracetamol
212055|NCT01891435|intramuscular diclofenac
212056|NCT01891435|emergency department
212057|NCT01891422|Glycoprotein Storage Disease
212058|NCT01891422|Lysosomal Storage Disease
212059|NCT01891422|mannosidase deficiency disorders
212060|NCT01891422|Neuraminidase deficiency with beta-galactosidase deficiency
212061|NCT01891422|mucolipidoses
212062|NCT01891422|Oligosaccharidoses
212063|NCT01891422|Lysosomal Disease
212064|NCT01891422|Metabolic Disease, Inborn
212065|NCT01891422|aspartylglucosaminuria
212066|NCT01891422|fucosidosis
212067|NCT01891422|galactosialidosis
212068|NCT01891422|alpha mannosidosis
212069|NCT01891422|beta mannosidosis
212070|NCT01891422|mucolipidosis II
212071|NCT01891422|mucolipidosis III
212072|NCT01891422|Schindler disease
212073|NCT01891422|sialidosis
212074|NCT01891409|HIV prevention
212075|NCT01891409|Male Circumcision
212076|NCT01891409|Children
212077|NCT01891409|Childhood
212078|NCT01891409|Shang Ring
212079|NCT01891396|Knee osteoarthritis
212080|NCT01891396|Hyaluronic acid
212081|NCT01891396|HA Injection
212082|NCT01891396|Steroid Injection
212083|NCT01891396|Knee injection
212084|NCT01891383|Dementia
212085|NCT01891383|Traumatic brain injury (TBI)
212086|NCT01891383|Mild cognitive impairment (MCI)
212087|NCT01891383|Chronic traumatic encephalopathy (CTE)
212088|NCT01891383|Remote effects of TBI
212089|NCT01891383|Post-traumatic stress disorder (PTSD_
212090|NCT01891357|Unilateral primary invasive carcinoma of the breast
212091|NCT01891344|ovarian cancer
212092|NCT01891344|fallopian tube cancer
212093|NCT01891344|primary peritoneal cancer
212094|NCT01891344|peritoneal cancer
212095|NCT01891344|platinum sensitive
212096|NCT01891344|relapsed disease
212097|NCT01891344|PARP Inhibitor
212098|NCT01891344|rucaparib
212099|NCT01891344|homologous recombination
212100|NCT01891344|homologous recombination deficiency
212101|NCT01891344|genomic scarring
212102|NCT01891344|loss of heterozygosity
212103|NCT01891344|CO-338
212104|NCT01891344|PF 01367338
212105|NCT01891344|AG 14699
212106|NCT01891344|platinum sensitive ovarian cancer
212107|NCT01891344|platinum sensitive fallopian tube cancer
212108|NCT01891344|platinum sensitive primary peritoneal cancer
212109|NCT01891344|platinum sensitive peritoneal cancer
212110|NCT01891344|gynecological cancer
212111|NCT01891344|Clovis
212112|NCT01891344|Clovis Oncology
212113|NCT01891344|ARIEL2
212114|NCT01891344|ARIEL 2
212115|NCT01891344|ARIEL3
212116|NCT01891344|ARIEL 3
212117|NCT01891279|short bowel syndrome
212118|NCT01891279|Elemental formula
212119|NCT01891279|partially hydrolyzed formula
212120|NCT01891279|Enteral feeding
212121|NCT01891279|TPN dependency
212122|NCT01891279|Intestinal adaptation
212123|NCT01891279|TPN cholestasis
212124|NCT01891253|cardiac output
212125|NCT01891253|mechanical ventilation
212126|NCT01891253|inert gas rebreathing
212127|NCT01891253|pulse contour analysis
212128|NCT01891240|Diagnostic
212129|NCT01891240|Pre-eclampsia
212130|NCT01891240|Pregnancy outcome
212131|NCT01891240|Mass screening
212132|NCT01891240|Diagnostic Techniques and Procedures
212133|NCT01891227|Bendamustine
212134|NCT01891227|Capecitabine
212135|NCT01891227|Pretreated
212136|NCT01891227|Her2 negative
212137|NCT01891227|Advanced breast cancer
212138|NCT01891227|Metastatic breast cancer
212139|NCT01891227|Anthracycline pretreatment
212140|NCT01891227|Taxane pretreatment
212141|NCT01891214|Inflammatory bowel diseases
212142|NCT01891214|Inflammatory Bowel Disease Questionnaire (IBDQ)
212143|NCT01891201|Bonding
212144|NCT01891201|Oxytocin
212145|NCT01891201|Breastfeeding
212146|NCT01891201|Newborn
212147|NCT01891201|Delivery
212148|NCT01891188|hepatic blood,
212149|NCT01891188|cardiac cath,
212150|NCT01891188|hepatic oxygenation,
212151|NCT01891188|pediatrics
212152|NCT01891175|Caesarean
212153|NCT01891175|hypotension
212154|NCT01891175|Spinal Anaesthesia
212155|NCT01891175|intermittent pneumatic compression
212156|NCT01891175|lower extremities
212157|NCT01891162|quality of life, incontinence urinary, socioeconomic
212158|NCT01891136|Peanut allergy
212159|NCT01891123|Non-small Cell Lung Cancer
212160|NCT01891123|Breast cancer
212161|NCT01891123|plasma drug concentration
212162|NCT01891123|Nasopharygeal carcinoma
212163|NCT01891110|electric stimulation
212164|NCT01891110|tilt-table
212165|NCT01891097|Insomnia
212166|NCT01891097|Acupuncture
212167|NCT01891097|Electroacupuncture
212168|NCT01891097|Aricular acupuncture
212169|NCT01891097|Randomized Clinical Trial
212170|NCT01891097|Traditional Chinese Medicine
212171|NCT01891084|Influenza
212172|NCT01891084|Antipyretics
212173|NCT01891084|Fever
212174|NCT01891071|Multiple sclerosis
212175|NCT01891071|Lung volume recruitment
212176|NCT01891071|Pulmonary function impairment
212177|NCT01891071|Cough impairment
212178|NCT01891045|Psychotherapy
212179|NCT01891045|Drug addiction
212180|NCT01891045|Drop-out
212181|NCT01891045|OQ-45.2
212182|NCT01891045|Clinical trial
212183|NCT01891045|Randomized Controlled Trail
212184|NCT01891032|acute kidney injury, partial nephrectomy, biomarker
212185|NCT01891006|Randomized Controlled Trial
212186|NCT01891006|Economical Evaluation
212187|NCT01891006|Caesarean Section
212188|NCT01891006|Cesarean Section
212189|NCT01891006|Postoperative Wound Treatment
212190|NCT01891006|Surgical Site Infections
212191|NCT01891006|Wound Infections
212192|NCT01891006|Infectious Morbidity
212193|NCT01891006|Negative Pressure Wound Therapy
212194|NCT01890980|WT-1-vaccine Montanide
212195|NCT01890980|GM-CSF
212196|NCT01890980|Wilms Tumor-1 vaccine
212197|NCT01890980|immunotherapy
212198|NCT01890980|Montanide
212199|NCT01890980|Sargramostim
212200|NCT01890980|Granulocyte Macrophage Colony Stimulating Factor
212201|NCT01890980|Malignant Pleural Mesothelioma
212202|NCT01890980|MPM
212203|NCT01890980|soluble mesothelin related protein
212204|NCT01890980|SMRP
212205|NCT01890967|low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia
212206|NCT01890954|Type 1 Diabetes Mellitus (T1DM)
212207|NCT01890954|Closed Loop Control (CLC)
212208|NCT01890954|Diabetes Assistant (DiAs)
212209|NCT01890954|Continuous Glucose Monitor (CGM)
212210|NCT01890941|Dry eye syndromes
212211|NCT01890941|Corneal diseases
212212|NCT01890941|Conjunctival diseases
212213|NCT01890928|Gluconeogenesis
212214|NCT01890928|Glycogenolysis
212215|NCT01890928|Pyruvate cycling
212216|NCT01890928|Glucose production rates
212217|NCT01890928|Mitochondria
212218|NCT01890928|Acylcarnitines
212219|NCT01890915|Spinal cord injury
212220|NCT01890915|Body temperature
212221|NCT01890915|Executive function
212222|NCT01890915|Sweat
212223|NCT01890889|Total Cholesterol
212224|NCT01890889|LDL
212225|NCT01890876|glucose tolerance, hypoxia, myokines, exercise
212226|NCT01890863|asthma
212227|NCT01890863|fluticasone propionate/salmeterol
212228|NCT01890863|PK equivalence
212229|NCT01890863|COPD
212230|NCT01890863|pharmacokinetics
212231|NCT01890863|fluticasone propionate/salmeterol in a capsule-based inhaler
212232|NCT01890863|fluticasone propionate/salmeterol in a multi-dose dry powder inhaler
212233|NCT01890863|Respiratory
212234|NCT01890850|Risk factors
212235|NCT01890850|U.S. commercially insured population
212236|NCT01890850|Pertussis/whooping cough infection
212237|NCT01890850|Retrospective database study
212238|NCT01890837|Rectal Compliance
212239|NCT01890837|Rectal Sensation
212240|NCT01890837|Rectal Tone
212241|NCT01890824|Breast Cancer
212242|NCT01890824|Fat metabolism
212243|NCT01890824|Fat digestion
212244|NCT01890824|physical activity
212245|NCT01890824|muscle function
212246|NCT01890811|CKD
212247|NCT01890811|Hemodialysis
212248|NCT01890811|Protein Digestion
212249|NCT01890811|Fat Digestion
212250|NCT01890811|Gut Function
212251|NCT01890811|Glucose Absorption
212252|NCT01890811|Muscle Function
212253|NCT01890798|Duchenne Muscular Dystrophy
212254|NCT01890798|GSK2402968
212255|NCT01890798|drisapersen
212256|NCT01890772|Hepatitis C Genotype 1
212257|NCT01890772|Vitamin D
212258|NCT01890772|treatment-naive
212259|NCT01890759|Meningitis
212260|NCT01890759|Meningococcal Infection
212261|NCT01890759|Menactra®
212262|NCT01890746|de novo AML
212263|NCT01890746|Eltrombopag
212264|NCT01890746|leukemia
212265|NCT01890746|sAML/MDS
212266|NCT01890746|acute myeloid leukemia
212267|NCT01890746|secondary acute myeloid
212268|NCT01890746|thrombocytopenia
212269|NCT01890733|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff,
212270|NCT01890720|Randomized Controlled Trial
212271|NCT01890720|Economical Evaluation
212272|NCT01890720|Caesarean Section
212273|NCT01890720|postoperative wound treatment
212274|NCT01890720|surgical site infections
212275|NCT01890720|wound infections
212276|NCT01890720|infectious morbidity
212277|NCT01890720|Negative Pressure Wound Therapy
212278|NCT01890720|Incisional Negative Pressure Wound Therapy
212279|NCT01890720|Obesity
212280|NCT01890707|Gynecology
212281|NCT01890707|Pain
212282|NCT01890707|Anesthesia
212283|NCT01890707|Quality of Recovery 40
212284|NCT01890694|Hyponatremia
212285|NCT01890694|Dilutional Hyponatremia
212286|NCT01890694|Euvolemic Hyponatremia
212287|NCT01890694|Hypervolemic Hyponatremia
212288|NCT01890694|Fluid Restriction
212289|NCT01890694|Tolvaptan
212290|NCT01890681|childhood obesity
212291|NCT01890681|child care
212292|NCT01890681|infant
212293|NCT01890681|toddler
212294|NCT01890668|Breastfeeding behaviour
212295|NCT01890668|OMT (Osteopathic Manipulative Treatment)
212296|NCT01890668|suboptimal infant breastfeeding behaviour
212297|NCT01890668|healthy newborns
212298|NCT01890655|relapsing-remitting multiple sclerosis
212299|NCT01890655|RRMS
212300|NCT01890642|Pain
212301|NCT01890642|Children
212302|NCT01890642|Venipuncture
212303|NCT01890642|J tip
212304|NCT01890642|Lidocaine
212305|NCT01890642|video observation
212306|NCT01890629|diabetes mellitus
212307|NCT01890603|Care coordination, primary care
212308|NCT01890603|nurse care management
212309|NCT01890603|practice facilitation
212310|NCT01890590|Renal Cell Carcinoma
212311|NCT01890590|Cyberknife
212312|NCT01890577|Chronic kidney disease
212313|NCT01890577|Dialysis
212314|NCT01890577|Erythropoiesis stimulating agent
212315|NCT01890577|South Africa
212316|NCT01890551|Adoloescent, patellofemoral, instability,biomechanics, magnetic resonance imaging
212317|NCT01890538|vertigo
212318|NCT01890538|dimenhydrinate
212319|NCT01890538|piracetam
212320|NCT01890525|radiation
212321|NCT01890499|tolerability
212322|NCT01890499|diet after operation
212323|NCT01890447|Cocooning
212324|NCT01890447|Web-based questionnaire
212325|NCT01890447|Italy
212326|NCT01890447|Pertussis
212327|NCT01890447|Spain
212328|NCT01890447|Survey
212329|NCT01890434|Myocardial Perfusion Imaging
212330|NCT01890421|Myocardial Perfusion Imaging
212331|NCT01890408|Laparotomy
212332|NCT01890408|Hepatic resection
212333|NCT01890408|continuous wound catheter analgesia
212334|NCT01890408|morphine
212335|NCT01890408|post operative recovery
212336|NCT01890395|mitochondrial DAMPS
212337|NCT01890382|resistance exercise
212338|NCT01890382|protein
212339|NCT01890382|creatine
212340|NCT01890382|leucine
212341|NCT01890382|aging
212342|NCT01890369|Old Age
212343|NCT01890369|Sarcopenia
212344|NCT01890369|Amino Acid
212345|NCT01890369|Muscle
212346|NCT01890356|Depression
212347|NCT01890356|Treatment
212348|NCT01890356|Transcranial electrical stimulation
212349|NCT01890356|Maintenance
212350|NCT01890330|Canola Oil
212351|NCT01890330|Metabolic Syndrome
212352|NCT01890330|Serum LDL cholesterol
212353|NCT01890317|Cardiogenic shock
212354|NCT01890317|acute myocardial infarction
212355|NCT01890317|mild hypothermia
212356|NCT01890304|Traumatic Brain Injury
212357|NCT01890304|TBI
212358|NCT01890304|Concussion
212359|NCT01890304|Sports related injury
212360|NCT01890291|Immuncell-LC, Hepatocellular carcinoma
212361|NCT01890278|Brain Cancer
212362|NCT01890278|Metastatic Brain Cancer
212363|NCT01890278|IMRT
212364|NCT01890265|Idiopathic Pulmonary Fibrosis, IPF, Idiopathic Interstitial Pneumonia, Interstitial Lung Disease, Lung Fibrosis
212365|NCT01890213|alphavirus
212366|NCT01890213|colon cancer
212367|NCT01890213|immune response
212368|NCT01890213|CEA
212369|NCT01890200|add-on treatment
212370|NCT01890200|botanical drug
212371|NCT01890200|HCV genotype 1
212372|NCT01890200|TCM-700C
212373|NCT01890161|asthma
212374|NCT01890148|Asthma
212375|NCT01890135|randomized
212376|NCT01890135|double blind
212377|NCT01890135|blood flow
212378|NCT01890135|muscle perfusion
212379|NCT01890135|safety
212380|NCT01890122|Drug therapy
212381|NCT01890109|Vasomotor symptoms; Hot Flashes
212382|NCT01890096|HDR
212383|NCT01890096|monotherapy
212384|NCT01890096|low
212385|NCT01890096|intermediate
212386|NCT01890096|prostate cancer
212387|NCT01890083|Hepatitis C
212388|NCT01890083|Interferon-alpha
212389|NCT01890083|Depression
212390|NCT01890083|Major Depressive Disorder
212391|NCT01890083|Exercise
212392|NCT01890083|Physical Activity
212393|NCT01890070|mediterranean diet, nutrigenomics, body composition, inflammation, oxidative stress
212394|NCT01890044|VTE
212395|NCT01890044|DVT
212396|NCT01890044|Venous Thromboembolism
212397|NCT01890044|Deep Vein Thrombosis
212398|NCT01890044|Pulmonary embolus
212399|NCT01890044|Trauma
212400|NCT01890031|cardiovascular disease
212401|NCT01890031|cholesterol
212402|NCT01890018|Acute Myocardial Infarction (AMI)
212403|NCT01890018|taking a statin medication
212404|NCT01890018|also have a medication adherence ratio (MPR)
212405|NCT01890005|Preeclampsia
212406|NCT01890005|Low dose aspirin
212407|NCT01890005|Fetal growth restriction
212408|NCT01890005|Neonatal death
212409|NCT01890005|Stillbirth
212410|NCT01890005|Abruptio placenta
212411|NCT01889992|Heart transplantation
212412|NCT01889992|Cardiac allograft remodeling
212413|NCT01889992|Immunosuppression
212414|NCT01889992|Cardiac MRI
212415|NCT01889992|M-TOR inhibitor
212416|NCT01889979|Pain during labour
212417|NCT01889979|Duration of labour
212418|NCT01889979|Apgar score
212419|NCT01889979|Umbilical cord pH
212420|NCT01889966|vasoreactivity testing
212421|NCT01889966|Sildenafil
212422|NCT01889966|precapillary pulmonary hypertension
212423|NCT01889966|connective tissue disease
212424|NCT01889966|mean pressure in the pulmonary artery 25 mmHg or more
212425|NCT01889966|mean pulmonary capillary wedge pressure below 16 mmHg
212426|NCT01889953|EUS-Guided Biliary Drainage
212427|NCT01889953|Endoscopic retrograde cholangiopancreatography
212428|NCT01889953|Malignant Biliary Obstruction
212429|NCT01889940|Acute Spinal Cord Injury
212430|NCT01889940|Patient Satisfaction
212431|NCT01889940|Psychological Distress
212432|NCT01889940|Rehabilitation
212433|NCT01889940|Training Professionals
212434|NCT01889940|Burnout
212435|NCT01889940|Job Content
212436|NCT01889927|exercise
212437|NCT01889927|physiotherapy
212438|NCT01889927|lung function
212439|NCT01889927|quality of life
212440|NCT01889901|Physical Activity
212441|NCT01889901|Epilepsy
212442|NCT01889901|Seizures
212443|NCT01889901|Quality of Life
212444|NCT01889888|Male urethral stricture
212445|NCT01889888|ADRC
212446|NCT01889888|Adipose-derived regenerative cells
212447|NCT01889888|Fat tissue
212448|NCT01889888|Stem cells
212449|NCT01889862|PKU
212450|NCT01889862|PEG-PAL
212451|NCT01889862|Prism
212452|NCT01889862|BioMarin
212453|NCT01889862|rAvPAL-PEG
212454|NCT01889862|Pegvalaise
212455|NCT01889836|meningococcal conjugate vaccine serogroup C
212456|NCT01889836|Prevention
212457|NCT01889823|Oxygen
212458|NCT01889823|Hypoxia
212459|NCT01889823|Hyperoxia
212460|NCT01889823|Inflammation
212461|NCT01889823|Innate immunity
212462|NCT01889810|Vitamin D, Pre-diabetes, Insulin Resistance
212463|NCT01889797|Untreated Non-Hodgkin's Lymphoma
212464|NCT01889797|Low Tumor Burden Non-Hodgkin's Lymphoma
212465|NCT01889797|NHL
212466|NCT01889797|Indolent
212467|NCT01889797|Rituximab
212468|NCT01889797|Rituxan
212469|NCT01889797|GA101
212470|NCT01889797|Obinutuzumab
212471|NCT01889784|diabetes mellitus, type 2
212472|NCT01889784|phototherapy
212473|NCT01889784|physical exercise
212474|NCT01889784|oxygen consumption
212475|NCT01889784|arterial blood pressure
212476|NCT01889784|heart rate
212477|NCT01889784|baroreflex sensitivity
212478|NCT01889784|cardiovascular autonomic control
212479|NCT01889758|bioequivalence
212480|NCT01889758|tacrolimus
212481|NCT01889758|kidney
212482|NCT01889758|liver
212483|NCT01889758|transplant
212484|NCT01889719|HIV Prevention
212485|NCT01889706|Type 1 diabetes mellitus,
212486|NCT01889706|metformin,
212487|NCT01889706|insulin resistance,
212488|NCT01889706|obesity
212489|NCT01889693|positron emission tomography
212490|NCT01889693|macrophage
212491|NCT01889693|neomannosyl human serum albumin
212492|NCT01889680|colorectal cancer
212493|NCT01889680|metastatic colorectal cancer
212494|NCT01889680|ziv-aflibercept
212495|NCT01889680|NSABP
212496|NCT01889667|Oral Insulin
212497|NCT01889667|Diabetes Mellitus Type 2
212498|NCT01889667|Safety
212499|NCT01889667|Pharmacodynamics
212500|NCT01889667|Pharmacokinetics
212501|NCT01889628|Glycaemic response
212502|NCT01889628|Glycaemic Index
212503|NCT01889628|Nutritional formula
212504|NCT01889628|Asia
212505|NCT01889628|Ethnic differences
212506|NCT01889628|Chinese
212507|NCT01889628|Malay
212508|NCT01889628|Indian
212509|NCT01889615|Ovarian cancer
212510|NCT01889615|PET/CT
212511|NCT01889615|glucose 6 phosphatase
212512|NCT01889602|Healthy volunteers
212513|NCT01889602|Topiramate
212514|NCT01889602|Neurocognition
212515|NCT01889602|Drug-induced cognitive deficits
212516|NCT01889576|glucose
212517|NCT01889563|chronic obstructive pulmonary disease
212518|NCT01889563|heart rate variability
212519|NCT01889563|physical training
212520|NCT01889550|Screening
212521|NCT01889550|Downs syndrome
212522|NCT01889550|Informed choice
212523|NCT01889550|eHealth
212524|NCT01889537|Virtual Reality Ketamine
212525|NCT01889511|Text Messaging
212526|NCT01889511|Medication Adherence
212527|NCT01889511|Oral Agents
212528|NCT01889498|Acetazolamide, intracranial/cerebrospinal fluid pressure, paraplegia, thoracoabdominal aortic surgery
212529|NCT01889485|Aortic Aneurysm, Abdominal
212530|NCT01889485|Carotid Stenosis
212531|NCT01889485|Peripheral Arterial Disease
212532|NCT01889485|Health Services Accessibility
212533|NCT01889472|CPAP compliance
212534|NCT01889472|leaks
212535|NCT01889472|Respiratory disturbances index
212536|NCT01889472|quality of life
212537|NCT01889446|Propionic acid
212538|NCT01889446|Food preservatives
212539|NCT01889433|Hepatitis C
212540|NCT01889433|Cepeginterferon alfa
212541|NCT01889433|Peginterferon
212542|NCT01889433|Treatment
212543|NCT01889420|myeloma
212544|NCT01889420|relapse
212545|NCT01889420|refractory
212546|NCT01889420|relapsed
212547|NCT01889420|pomalidomide
212548|NCT01889420|pomalyst
212549|NCT01889420|everolimus
212550|NCT01889420|afinitor
212551|NCT01889420|dexamethasone
212552|NCT01889407|Acute Myeloid Leukemia
212553|NCT01889394|pilonidal sinus
212554|NCT01889394|excision
212555|NCT01889394|primary wound closure
212556|NCT01889394|limberg flap
212557|NCT01889368|Insulin resistance
212558|NCT01889368|Central adiposity
212559|NCT01889368|Elevated blood pressure
212560|NCT01889368|Vascular reactivity
212561|NCT01889368|Elevated triglycerides
212562|NCT01889368|Low high-density lipoprotein (HDL)
212563|NCT01889355|diabetes
212564|NCT01889355|glucose
212565|NCT01889355|glucometer
212566|NCT01889342|MCT
212567|NCT01889342|Metacognitive therapy
212568|NCT01889342|Anxiety disorders
212569|NCT01889342|Transdiagnostic
212570|NCT01889316|Fetal monitoring
212571|NCT01889316|ECG
212572|NCT01889303|concurrent chemoradiotherapy
212573|NCT01889303|FOLFOX6
212574|NCT01889303|chemotherapy
212575|NCT01889303|docetaxel
212576|NCT01889303|cisplatin
212577|NCT01889303|gastric cancer
212578|NCT01889290|methylnaltrexone
212579|NCT01889290|opioid-antagonist
212580|NCT01889290|Obstipation
212581|NCT01889290|pharmacokinetics
212582|NCT01889277|Diabetic Nephropathy
212583|NCT01889264|Methionine Metabolism
212584|NCT01889264|Enteral Nutrition
212585|NCT01889264|Pediatric
212586|NCT01889264|Pediatrics
212587|NCT01889264|Sepsis
212588|NCT01889264|Observational Study
212589|NCT01889251|Vitreomacular Adhesion
212590|NCT01889251|Vitreomacular Traction
212591|NCT01889251|Vitreomacular Traction Syndrome
212592|NCT01889251|Vitrectomy
212593|NCT01889251|Central Visual Field Defect
212594|NCT01889251|Blind Spot
212595|NCT01889251|Intravitreal Injection
212596|NCT01889251|Macula
212597|NCT01889251|Retina
212598|NCT01889251|Decreased Visual Acuity
212599|NCT01889251|Visual Complaint
212600|NCT01889251|SD-OCT
212601|NCT01889251|Macular Hole
212602|NCT01889238|breast cancer
212603|NCT01889238|triple negative
212604|NCT01889238|androgen receptor positive
212605|NCT01889199|polycystic ovary syndrome
212606|NCT01889199|hirsutism
212607|NCT01889199|anovulation
212608|NCT01889199|oligomenorrhea
212609|NCT01889199|amenorrhea
212610|NCT01889199|hyperandrogenism
212611|NCT01889199|antiandrogen effect
212612|NCT01889186|Chronic Lymphocytic Leukemia
212613|NCT01889186|17 p Deletion
212614|NCT01889160|Healthy volunteers, Phase 1
212615|NCT01889147|Peak plasma concentration
212616|NCT01889147|safety and efficacy
212617|NCT01889147|therapeutic agent
212618|NCT01889147|LPS-mediated diseases
212619|NCT01889147|Pharmacokinetics of administered hRESCAP
212620|NCT01889147|Determine half-time
212621|NCT01889134|primary hyperparathyroidism
212622|NCT01889134|RANKL
212623|NCT01889134|osteoprotegerin
212624|NCT01889134|bone mineral density
212625|NCT01889134|alendronate
212626|NCT01889134|parathyroidectomy
212627|NCT01889108|Premature
212628|NCT01889108|Development
212629|NCT01889108|Motor
212630|NCT01889108|Cognitive
212631|NCT01889108|Parent
212632|NCT01889082|Obesity
212633|NCT01889082|weight loss
212634|NCT01889082|young adults
212635|NCT01889056|Erythropoietin
212636|NCT01889056|Cognition
212637|NCT01889056|Exercise
212638|NCT01889043|Amyotrophic Lateral Sclerosis
212639|NCT01889043|Noninvasive Ventilation
212640|NCT01889043|Polysomnography
212641|NCT01889030|Cardiovascular primary prevention
212642|NCT01889030|Cardiovascular risk strtification
212643|NCT01889017|generic immunosuppressive
212644|NCT01889004|Cerebral blood flow
212645|NCT01889004|Consciousness
212646|NCT01889004|Dexmedetomidine
212647|NCT01889004|EEG
212648|NCT01889004|Event related potentials
212649|NCT01889004|Functional magnetic resonance imaging
212650|NCT01889004|General anesthesia
212651|NCT01889004|Positron emission tomography
212652|NCT01889004|Propofol
212653|NCT01888991|Glucose
212654|NCT01888991|Exercise
212655|NCT01888991|Metabolic flexibility
212656|NCT01888991|Substrate Oxidation
212657|NCT01888991|Food intake
212658|NCT01888978|Pancreas
212659|NCT01888978|cancer
212660|NCT01888978|metastatic
212661|NCT01888978|chemotherapy
212662|NCT01888965|Maintenance therapy
212663|NCT01888965|Adjuvant Therapy
212664|NCT01888939|Executive Function
212665|NCT01888939|Child
212666|NCT01888939|Obesity
212667|NCT01888939|Exercise
212668|NCT01888939|Insulin Sensitivity
212669|NCT01888926|rPAS
212670|NCT01888926|Dystonia
212671|NCT01888913|Body Weight
212672|NCT01888913|Virtual Reality Technology
212673|NCT01888900|Hepatitis C
212674|NCT01888900|Non-Responders
212675|NCT01888900|Direct Acting Antivirals
212676|NCT01888900|Interferon Free
212677|NCT01888900|Cirrhosis
212678|NCT01888874|Methotrexate insufficient responders
212679|NCT01888861|length of stay in ICU
212680|NCT01888861|ventilator free days
212681|NCT01888848|Postural Balance
212682|NCT01888848|Walking
212683|NCT01888848|Gait
212684|NCT01888848|Cognition
212685|NCT01888848|Learning
212686|NCT01888848|Memory
212687|NCT01888848|Blueberry
212688|NCT01888848|Antioxidants
212689|NCT01888848|Anti-Inflammatory Agents
212690|NCT01888848|Brain
212691|NCT01888835|HIV
212692|NCT01888835|sexual behavior
212693|NCT01888822|Laparoscopic cholecystectomy
212694|NCT01888822|Prophylactic antibiotics
212695|NCT01888809|teen parents
212696|NCT01888809|early childhood development
212697|NCT01888809|home visitation
212698|NCT01888809|evidence-based treatment
212699|NCT01888796|T2DM
212700|NCT01888796|diastolic dysfunction
212701|NCT01888783|CRPS Type I
212702|NCT01888783|tactile acuity
212703|NCT01888783|2-point-discrimination
212704|NCT01888783|Grating Orientation Task
212705|NCT01888783|sensory signs
212706|NCT01888757|Bioequivalence
212707|NCT01888757|Lamotrigine Extended Release
212708|NCT01888757|crossover
212709|NCT01888744|Intracytoplasmic sperm injection (ICSI)
212710|NCT01888744|PGD
212711|NCT01888744|GnrH agonist
212712|NCT01888744|GnRH antagonist
212713|NCT01888731|Bioequivalence
212714|NCT01888731|Lamotrigine Extended Release
212715|NCT01888731|crossover
212716|NCT01888705|COPD
212717|NCT01888705|Complexity
212718|NCT01888705|Entropy Sampling
212719|NCT01888705|Variability
212720|NCT01888705|Respiratory Mechanics
212721|NCT01888705|FOT
212722|NCT01888692|PET/CT
212723|NCT01888692|Radiotherapy
212724|NCT01888692|Lung Cancer
212725|NCT01888679|Airway
212726|NCT01888679|Endotracheal intubation
212727|NCT01888679|selective intubation
212728|NCT01888653|PTSD
212729|NCT01888653|Attention Bias to threat
212730|NCT01888653|Attention Bias Modification Treatment
212731|NCT01888640|TENS
212732|NCT01888640|Fibromyalgia
212733|NCT01888640|Accelerometer
212734|NCT01888627|Schizophrenia
212735|NCT01888627|Bipolar disorder
212736|NCT01888627|Assertive community treatment
212737|NCT01888627|Integrated care
212738|NCT01888627|Severe and persistent mental disorder
212739|NCT01888614|carbon mono oxide
212740|NCT01888614|sickle cell
212741|NCT01888614|hemolysis
212742|NCT01888588|Uncomplicated peptic ulcer
212743|NCT01888588|Low dose aspirin (ASA)
212744|NCT01888588|Acid-suppressing drugs
212745|NCT01888588|Epidemiology
212746|NCT01888575|Discontinuation of low dose ASA,
212747|NCT01888575|Secondary cardiovascular prevention,
212748|NCT01888575|Acid-suppressing drugs,
212749|NCT01888575|Gastrointestinal risk,
212750|NCT01888575|Epidemiology
212751|NCT01888549|Chronic cough, proton pump inhibitor, GERD, nonacid reflux,
212752|NCT01888497|Sleeplessness
212753|NCT01888484|PID
212754|NCT01888471|serotype specific
212755|NCT01888471|anti-capsular antibodies
212756|NCT01888471|Group B Streptococcus
212757|NCT01888471|Feasibility
212758|NCT01888458|Adult
212759|NCT01888458|allo-Stem Cell Transplantation
212760|NCT01888458|Cord Blood
212761|NCT01888445|Renal anemia
212762|NCT01888445|Chronic Renal Failure
212763|NCT01888445|ASP1517
212764|NCT01888432|liver transplantation
212765|NCT01888432|everolimus
212766|NCT01888432|tacrolimus
212767|NCT01888432|reduced calcineuron inhibitor
212768|NCT01888432|renal function
212769|NCT01888432|living donor
212770|NCT01888432|RAD001H2307
212771|NCT01888432|RAD001H
212772|NCT01888419|Post Breast Therapy Pain Syndrome
212773|NCT01888419|Lipotransplantation
212774|NCT01888419|Breast Cancer
212775|NCT01888419|Pain
212776|NCT01888406|Obesity
212777|NCT01888406|Weight gain prevention
212778|NCT01888406|Eating disorder
212779|NCT01888406|Binge eating
212780|NCT01888393|pharmacokinetics, hepatic impairment
212781|NCT01888380|Autopsy
212782|NCT01888380|Minimally invasive
212783|NCT01888380|Foetuses
212784|NCT01888380|Newborns
212785|NCT01888380|Children
212786|NCT01888380|Adolescents
212787|NCT01888354|MS
212788|NCT01888354|Multiple Sclerosis
212789|NCT01888315|Hypertension
212790|NCT01888315|Heart Failure
212791|NCT01888315|Sympathetic activity
212792|NCT01888276|Words generation, compulsive gamblers
212793|NCT01888263|Bioequivalence
212794|NCT01888263|Lamotrigine Extended Release
212795|NCT01888263|crossover
212796|NCT01888250|Bioequivalence
212797|NCT01888250|Lamotrigine Extended Release
212798|NCT01888250|crossover
212799|NCT01888237|Dyspepsia
212800|NCT01888237|Helicobacter pylori
212801|NCT01888237|Clarithromycin resistance
212802|NCT01888237|Other Specified Disorders of Function of Stomach
212803|NCT01888198|ablation
212804|NCT01888198|quality of Life (QOL)
212805|NCT01888198|kidney
212806|NCT01888198|registry
212807|NCT01888198|Ablation of Renal Masses Outcomes Registry (ARMOR)
212808|NCT01888198|13-116
212809|NCT01888185|Parkinson's
212810|NCT01888185|PD
212811|NCT01888185|nigrostriatal
212812|NCT01888185|substantia nigra
212813|NCT01888185|MRI
212814|NCT01888185|DTI
212815|NCT01888185|FA
212816|NCT01888185|R2*
212817|NCT01888185|Parkinson's Disease Biomarkers Program
212818|NCT01888185|PDBP
212819|NCT01888185|ferritin
212820|NCT01888185|transferrin
212821|NCT01888185|Fe
212822|NCT01888185|iron protein
212823|NCT01888185|PSP
212824|NCT01888185|MSA
212825|NCT01888146|Pain management
212826|NCT01888146|Opioid use
212827|NCT01888146|Pragmatic
212828|NCT01888146|Collaborative care
212829|NCT01888146|Primary care
212830|NCT01888107|Schizophrenia
212831|NCT01888107|Schizoaffective Disorder
212832|NCT01888107|Antipsychotics
212833|NCT01888107|Risperidone
212834|NCT01888107|Long-acting injectable
212835|NCT01888094|Central venous catheter
212836|NCT01888094|Complications
212837|NCT01888094|Ultrasound
212838|NCT01888094|Subclavian vein cannulation
212839|NCT01888094|Critical care
212840|NCT01888094|Echocardiography
212841|NCT01888094|Chest radiographyiography
212842|NCT01888055|Healthy older adults Cortical Plasticity
212843|NCT01888055|Transcranial Direct Current Stimulation
212844|NCT01888029|mild cognitive impairment
212845|NCT01888029|Transcranial Direct Current Stimulation
212846|NCT01888029|Cortical Plasticity
212847|NCT01888003|anemia
212848|NCT01887977|Orthognathic surgery
212849|NCT01887977|Speech production
212850|NCT01887977|MRI
212851|NCT01887964|Diabetes
212852|NCT01887964|Obesity
212853|NCT01887964|Cardiovascular disease
212854|NCT01887964|Metabolic syndrome
212855|NCT01887925|breast neoplasms
212856|NCT01887925|sleep
212857|NCT01887925|anxiety
212858|NCT01887925|depression
212859|NCT01887925|life quality
212860|NCT01887912|Clostridium difficile Toxoid Vaccine
212861|NCT01887912|Clostridium difficile infection
212862|NCT01887912|Cdiffense
212863|NCT01887899|cortical plasticity
212864|NCT01887899|transcranial direct current stimulation
212865|NCT01887873|open angle glaucoma
212866|NCT01887873|cataract
212867|NCT01887860|Cetaphil Daily Facial Moisturizer SPF 50
212868|NCT01887847|nicotine
212869|NCT01887847|pharmacokinetics
212870|NCT01887834|bloating
212871|NCT01887834|constipation
212872|NCT01887834|diarrhea
212873|NCT01887834|gas
212874|NCT01887834|mucous
212875|NCT01887834|cramping
212876|NCT01887808|Determine
212877|NCT01887808|Hypoallergenicity
212878|NCT01887808|Cetaphil DermaControl Oil Control Moisturizer SPF 30
212879|NCT01887795|Informed Consent;
212880|NCT01887795|Ethical Principles;
212881|NCT01887795|Data collection
212882|NCT01887782|depression
212883|NCT01887782|magnetic
212884|NCT01887782|brain stimulation
212885|NCT01887782|treatment-resistant
212886|NCT01887769|Lung cancer
212887|NCT01887769|Body composition analysis
212888|NCT01887769|Ct-Scan
212889|NCT01887769|Muscle mass
212890|NCT01887769|Cachexia
212891|NCT01887756|telerehabilitation stroke virtual reatlity
212892|NCT01887743|GERD
212893|NCT01887743|Obesity
212894|NCT01887743|Pediatric
212895|NCT01887743|Pantoprazole
212896|NCT01887743|CYP2C19
212897|NCT01887743|Pharmacokinetic
212898|NCT01887730|Hand Hygiene
212899|NCT01887730|Communicable Diseases
212900|NCT01887730|Prevention
212901|NCT01887717|hepatocellular carcinoma
212902|NCT01887717|portal vein thrombosis
212903|NCT01887691|Diabetes
212904|NCT01887691|Prediabetic
212905|NCT01887691|Prediabetes
212906|NCT01887691|Glucose intolerance
212907|NCT01887691|Sleep quality
212908|NCT01887691|Continuous glucose monitoring
212909|NCT01887691|Diabetes risk
212910|NCT01887691|eszopiclone
212911|NCT01887665|substance use disorders
212912|NCT01887665|substance abuse
212913|NCT01887665|substance abuse treatment
212914|NCT01887665|contingency management
212915|NCT01887652|In Vitro Fertilization
212916|NCT01887652|ovulation induction
212917|NCT01887652|anti-mullerian hormone
212918|NCT01887639|Non-psychotic unipolar major depression
212919|NCT01887639|Resistant depression
212920|NCT01887626|Phase 1, pharmacokinetic, safety, Ticagrelor
212921|NCT01887613|Gabapentin
212922|NCT01887600|anemia
212923|NCT01887600|chronic kidney disease (CKD)
212924|NCT01887600|Hemoglobin (Hb)
212925|NCT01887600|non-dialysis
212926|NCT01887548|Crohn's disease
212927|NCT01887548|inflammatory bowel disease
212928|NCT01887548|quality of life
212929|NCT01887548|personality
212930|NCT01887548|neuroticism
212931|NCT01887535|Healthy
212932|NCT01887535|Elderly
212933|NCT01887535|Safety
212934|NCT01887535|Tolerability
212935|NCT01887535|Pharmacokinetic
212936|NCT01887535|Alzheimer's Disease
212937|NCT01887535|JNJ-54861911
212938|NCT01887522|Children
212939|NCT01887522|Adolescents
212940|NCT01887522|Young Adults
212941|NCT01887509|Rectal cancer
212942|NCT01887509|Tumor margin
212943|NCT01887509|Confocal endomicroscopy
212944|NCT01887509|Virtual biopsy
212945|NCT01887509|Fluorescein
212946|NCT01887496|Varicella
212947|NCT01887496|Turkey
212948|NCT01887496|hospitalization
212949|NCT01887496|varicella vaccine
212950|NCT01887483|IBS
212951|NCT01887483|bowel function
212952|NCT01887483|probiotic
212953|NCT01887470|Bowel Evacuation
212954|NCT01887470|Colonoscopy Preparation
212955|NCT01887457|voriconazole
212956|NCT01887457|VFEND
212957|NCT01887457|individualised
212958|NCT01887457|personalised
212959|NCT01887444|Pediatric Gastroenterology
212960|NCT01887444|Probiotics
212961|NCT01887444|Lactobacillus reuteri
212962|NCT01887431|Diabetes Mellitus, Type 1
212963|NCT01887431|Adult
212964|NCT01887431|Insulin Infusion Systems
212965|NCT01887431|Telecare
212966|NCT01887418|Hypogonadism
212967|NCT01887418|Testosterone enanthate
212968|NCT01887405|Adrenaline
212969|NCT01887405|Auto-injector
212970|NCT01887405|Jext
212971|NCT01887405|Epipen
212972|NCT01887392|Long-term Care
212973|NCT01887392|Knowledge Translation
212974|NCT01887379|Gastroretentive drug formulation
212975|NCT01887379|Furosemide
212976|NCT01887379|Magnetic Marker Monitoring
212977|NCT01887379|Magnetic marker
212978|NCT01887379|Oedema
212979|NCT01887366|Cocaine addiction
212980|NCT01887366|TV-1380
212981|NCT01887366|Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)
212982|NCT01887353|atrial fibrillation
212983|NCT01887353|heart failure
212984|NCT01887353|ranolazine
212985|NCT01887353|cardioversion
212986|NCT01887353|persistent AF
212987|NCT01887353|paroxysmal AF
212988|NCT01887327|G6PD deficiency
212989|NCT01887327|ABO incompatibility
212990|NCT01887327|Coombs positive ABO/RH incompatibility
212991|NCT01887327|intensive phototherapy in neonates
212992|NCT01887327|Hyperbilirubinemia
212993|NCT01887327|Neonatal Jaundice
212994|NCT01887314|Cancer
212995|NCT01887314|Cisplatin
212996|NCT01887314|Nausea
212997|NCT01887314|Ginger
212998|NCT01887314|Zingiber officinale
212999|NCT01887314|5HT3
213000|NCT01887314|Dexamethasone
213001|NCT01887314|Neurokinin-1 (NK-1)
213002|NCT01887314|Interleukin-6 (IL-6)
213003|NCT01887314|Tumor necrosis factor-alpha (TNF-alpha)
213004|NCT01887314|Insulin like growth factor-1 (IGF-1)
213005|NCT01887314|Placebo
213006|NCT01887314|FLIE
213007|NCT01887314|BFI
213008|NCT01887275|Chronic hepatitis B
213009|NCT01887275|Medical Ozone
213010|NCT01887275|Interferon-α
213011|NCT01887275|Efficacy
213012|NCT01887262|fluid
213013|NCT01887262|edema
213014|NCT01887223|Encapsulated blebs
213015|NCT01887223|trabeculectomy failure
213016|NCT01887223|glaucoma
213017|NCT01887210|HIV
213018|NCT01887210|youth
213019|NCT01887210|medical adherence
213020|NCT01887197|cystic fibrosis
213021|NCT01887197|mucociliary clearance
213022|NCT01887197|airway surface liquid
213023|NCT01887197|nuclear medicine
213024|NCT01887197|mannitol
213025|NCT01887171|Liver transplantation
213026|NCT01887171|Early allograft dysfunction
213027|NCT01887171|Ischemic reperfusion injury
213028|NCT01887171|Portal and arterial ex vivo HTK flush
213029|NCT01887145|Carpal tunnel syndrome
213030|NCT01887145|Surgery
213031|NCT01887145|Outcomes
213032|NCT01887132|Sleep Architecture
213033|NCT01887132|Autism
213034|NCT01887132|Language Development
213035|NCT01887093|coronary artery disease
213036|NCT01887093|walking
213037|NCT01887093|lipids
213038|NCT01887093|inflammatory markers
213039|NCT01887093|time of day
213040|NCT01887080|Cardiovascular rehabilitation home-based
213041|NCT01887080|Acute myocardial infarction
213042|NCT01887080|Obesity
213043|NCT01887080|Microcurrent
213044|NCT01887067|Hypertension
213045|NCT01887067|Diabetes Mellitus
213046|NCT01887041|Advanced, metastasising pancreatic head carcinoma
213047|NCT01887041|Jaundice
213048|NCT01887041|Biliodigestive anastomosis
213049|NCT01887041|Endoscopically inserted biliary tract drainage
213050|NCT01887041|Quality of Life
213051|NCT01887028|Carbon deoxide pneumoperitoneum
213052|NCT01887028|Intraperitoneal pressure
213053|NCT01887028|Peritoneum
213054|NCT01887028|Gene expression
213055|NCT01887028|Post-operative recovery
213056|NCT01887028|Laparoscopic Humidification System
213057|NCT01887015|Postoperative pulmonary complications
213058|NCT01887015|Oxygen therapy
213059|NCT01887015|Nasal high flow oxygen therapy
213060|NCT01887015|Nasal high flow cannula
213061|NCT01887002|Irritable Bowel Syndrome
213062|NCT01887002|IBS
213063|NCT01887002|ONO-2952
213064|NCT01886989|diabetes
213065|NCT01886989|cocoa polyphenols
213066|NCT01886989|postprandial glycemia
213067|NCT01886989|postprandial lipemia
213068|NCT01886976|multiple myeloma
213069|NCT01886950|CKD stage 5
213070|NCT01886950|Bone histomorphometry
213071|NCT01886950|Renal transplantation
213072|NCT01886924|Tobacco
213073|NCT01886924|Nicotine
213074|NCT01886924|Dependence
213075|NCT01886924|Quitline
213076|NCT01886911|prosocial behavior
213077|NCT01886911|prosocial
213078|NCT01886911|attention training
213079|NCT01886911|attention
213080|NCT01886911|empathy
213081|NCT01886911|emotion recognition
213082|NCT01886885|Mindfulness
213083|NCT01886885|Meditation
213084|NCT01886885|Chronic Pain
213085|NCT01886833|Rotavirus
213086|NCT01886833|Diarrhoea
213087|NCT01886833|Dmmunisation
213088|NCT01886833|Seroconversion
213089|NCT01886833|Breastmilk
213090|NCT01886833|HIV
213091|NCT01886833|Zinc
213092|NCT01886833|Vitamin A
213093|NCT01886833|Failure
213094|NCT01886820|Dementia
213095|NCT01886820|Alzheimer's Disease
213096|NCT01886820|Terminally Ill
213097|NCT01886794|pelvic floor dysfunction
213098|NCT01886794|pelvic organ prolapse
213099|NCT01886794|vaginal estrogen effects
213100|NCT01886781|only constipation and diarrhea predominant
213101|NCT01886781|no mixed or alternating types
213102|NCT01886768|Nasal anesthesia
213103|NCT01886768|endoscopes
213104|NCT01886768|transnasal endoscopy
213105|NCT01886755|Acute gastroenteritis
213106|NCT01886755|Probiotics
213107|NCT01886755|Lactobacillus reuteri
213108|NCT01886755|Zinc supplementation
213109|NCT01886755|Infants
213110|NCT01886755|Age 6 months to 36 months
213111|NCT01886742|Perioperative antibiotic prophylaxis
213112|NCT01886742|Morbidly Obese
213113|NCT01886729|transcranial direct current stimulation
213114|NCT01886729|time shift
213115|NCT01886716|Alcohol Abuse
213116|NCT01886716|Alcohol Dependence
213117|NCT01886716|Alcohol Drinking
213118|NCT01886716|Social Anxiety
213119|NCT01886716|Social Phobia
213120|NCT01886716|Anxiety Disorders
213121|NCT01886703|Physical activity
213122|NCT01886703|Exercise
213123|NCT01886703|Quality of Life
213124|NCT01886703|Radiation Therapy
213125|NCT01886703|Breast Cancer
213126|NCT01886703|Head and Neck Cancer
213127|NCT01886677|prostate cancer
213128|NCT01886677|intervention
213129|NCT01886677|diet
213130|NCT01886677|physical activity
213131|NCT01886677|exercise
213132|NCT01886677|weight loss
213133|NCT01886677|biomarkers
213134|NCT01886677|cancer progression
213135|NCT01886651|acute lymphoblastic leukemia
213136|NCT01886651|child
213137|NCT01886651|6-mercaptopurine
213138|NCT01886651|methotrexate
213139|NCT01886638|Platelets
213140|NCT01886638|HIV
213141|NCT01886638|Cardiovascular disease
213142|NCT01886638|Acute myocardial infarction
213143|NCT01886638|Abacavir
213144|NCT01886638|Antiretrovirals
213145|NCT01886612|Deep Vein Thrombosis
213146|NCT01886612|Neuromuscular Electrical Stimulation
213147|NCT01886612|Intermittent Pneumatic Compression
213148|NCT01886612|Doppler Ultrasound
213149|NCT01886586|Mild Cognitive Impairment
213150|NCT01886586|memory impairment
213151|NCT01886586|problem-solving therapy
213152|NCT01886586|depression prevention
213153|NCT01886586|caregiver stress
213154|NCT01886586|exercise
213155|NCT01886534|Heart failure
213156|NCT01886534|Heart diseases
213157|NCT01886534|Cardiovascular diseases
213158|NCT01886534|Health information technology
213159|NCT01886534|Disease management
213160|NCT01886534|Patient care management
213161|NCT01886534|Self care
213162|NCT01886534|Informal caregiver
213163|NCT01886534|Care partner
213164|NCT01886534|Peer support
213165|NCT01886534|Transitional care
213166|NCT01886534|Patient education
213167|NCT01886534|Teach-back
213168|NCT01886534|Clinical decision aid
213169|NCT01886443|Liver
213170|NCT01886443|Transplantation
213171|NCT01886443|Ischemia-reperfusion
213172|NCT01886443|Safety
213173|NCT01886404|HIV
213174|NCT01886404|efavirenz
213175|NCT01886404|Sustiva
213176|NCT01886404|pharmacokinetics
213177|NCT01886404|Pharmacogenomics
213178|NCT01886391|Heart Failure
213179|NCT01886391|Dyspnea
213180|NCT01886391|Diaphragmatic breathing retraining
213181|NCT01886391|Fatigue
213182|NCT01886391|Health-related Outcomes
213183|NCT01886378|FAOD
213184|NCT01886378|VLCAD
213185|NCT01886378|CPT II
213186|NCT01886378|CPT2
213187|NCT01886378|CPT 2
213188|NCT01886378|LCHAD
213189|NCT01886378|UX007
213190|NCT01886378|Triheptanoin
213191|NCT01886378|TFP
213192|NCT01886378|C7
213193|NCT01886365|Computer based glycemic control, insulin, blood glucose
213194|NCT01886352|laparoscopic
213195|NCT01886352|pain
213196|NCT01886326|Obesity
213197|NCT01886326|energy balance
213198|NCT01886326|variety
213199|NCT01886326|nut intake
213200|NCT01886313|Herpes Zoster
213201|NCT01886313|Postherpetic Neuralgia
213202|NCT01886313|Shingles
213203|NCT01886313|Civamide
213204|NCT01886313|Zucapsaicin
213205|NCT01886313|Neuropeptides
213206|NCT01886313|TRPV-1
213207|NCT01886287|endocrine system
213208|NCT01886287|neuroendocrine tumors
213209|NCT01886287|neuroendocrine cancer
213210|NCT01886287|metastatic
213211|NCT01886287|neuroendocrine
213212|NCT01886287|gastrointestinal (GI)
213213|NCT01886287|high-dose octreotide
213214|NCT01886287|flushing
213215|NCT01886287|diarrhea
213216|NCT01886287|quality of life in patients
213217|NCT01886287|disease-related symptoms
213218|NCT01886274|EEG
213219|NCT01886274|migraine
213220|NCT01886274|pain
213221|NCT01886274|phosphene
213222|NCT01886274|tDCs
213223|NCT01886274|TMS
213224|NCT01886261|validation
213225|NCT01886261|physical activity
213226|NCT01886261|place-based interventions
213227|NCT01886261|construct validity
213228|NCT01886261|divergent validity
213229|NCT01886261|usability
213230|NCT01886261|gps
213231|NCT01886261|PALMS
213232|NCT01886248|hepatic veno-occlusive disease after hematopoietic stem cell transplantation
213233|NCT01886222|Traumatic brain injury
213234|NCT01886196|elderly
213235|NCT01886196|women
213236|NCT01886196|exercise
213237|NCT01886196|pQCT
213238|NCT01886196|ibuprofen
213239|NCT01886183|Postural Balance
213240|NCT01886183|Virtual Reality Exposure Therapy
213241|NCT01886183|Gait
213242|NCT01886183|Stroke
213243|NCT01886170|Adults with self-reported diagnosis of diabetes recruited from waiting rooms at outpatient primary care sites at the University of Pennsylvania
213244|NCT01886157|trigger finger
213245|NCT01886157|orthotic intervention
213246|NCT01886144|OA
213247|NCT01886144|arthritis
213248|NCT01886144|knee OA
213249|NCT01886131|Parkinson disease
213250|NCT01886131|REM behaviour disorder
213251|NCT01886131|Subthalamic nucleus
213252|NCT01886131|Local field potential
213253|NCT01886131|Motor control
213254|NCT01886118|In vitro fertilization
213255|NCT01886118|Autologous Endometrial Co-Culture
213256|NCT01886105|Osteosarcoma
213257|NCT01886105|Osteogenic Sarcoma
213258|NCT01886105|Sarcoma
213259|NCT01886105|Bone Cancer
213260|NCT01886092|tinnitus
213261|NCT01886027|IBS
213262|NCT01886027|Relaxation
213263|NCT01886027|Emotional exposure
213264|NCT01886027|Emotional Processing
213265|NCT01886014|pain
213266|NCT01886014|pain modulation
213267|NCT01886014|placebo analgesia
213268|NCT01886001|Newborn Intensive Care Unit
213269|NCT01886001|Neonatal Intensive Care Unit
213270|NCT01886001|Colonization
213271|NCT01886001|Line Colonization
213272|NCT01886001|Umbilical line
213273|NCT01886001|Umbilical Cord Care
213274|NCT01885988|Erectile dysfunction
213275|NCT01885975|Apical Ballooning syndrome
213276|NCT01885975|Personality
213277|NCT01885962|pressure ulcer prevention
213278|NCT01885962|spinal cord injury
213279|NCT01885962|internet delivered pressure ulcer intervention
213280|NCT01885949|Metastatic
213281|NCT01885936|LOPD
213282|NCT01885936|Pompe Disease
213283|NCT01885923|schizophrenia; relapse prevention; information technology
213284|NCT01885897|Acute myelogenous leukemia (AML)
213285|NCT01885897|Acute lymphoblastic leukemia (ALL)
213286|NCT01885897|Myelodysplastic syndromes (MDS)
213287|NCT01885897|Lymphoma
213288|NCT01885897|Myeloma
213289|NCT01885897|Chronic Lymphocytic Leukemia (CLL)
213290|NCT01885897|Chronic myelogenous leukemia (CML)
213291|NCT01885884|Supportive Care
213292|NCT01885884|Palliative Care
213293|NCT01885884|Pancreatic Cancer
213294|NCT01885884|Embedded, coordinated model of supportive care within oncology care
213295|NCT01885884|Patient and Caregiver support
213296|NCT01885871|Sun
213297|NCT01885871|Age
213298|NCT01885871|Spot
213299|NCT01885858|health services research
213300|NCT01885858|family planning
213301|NCT01885858|ethnicity
213302|NCT01885858|healthcare disparities
213303|NCT01885845|postpartum blood loss measurement
213304|NCT01885845|BRASSS-V drape
213305|NCT01885832|autologous adipose stem cells
213306|NCT01885832|stromal vascular fraction
213307|NCT01885832|osteoarthritis
213308|NCT01885819|Adipose stromal vascular fraction
213309|NCT01885819|Rheumatoid arthritis
213310|NCT01885819|adult stem cells
213311|NCT01885806|Apathy; Alzheimer's disease; Cognition; Burden of Care
213312|NCT01885780|Astigmatism, arcuate incisions, astigmatic keratotomy
213313|NCT01885767|Neurofibromatosis
213314|NCT01885767|NF
213315|NCT01885767|Neurofibromatosis 1
213316|NCT01885767|NF1
213317|NCT01885767|Neurofibromatosis 2
213318|NCT01885767|NF2
213319|NCT01885767|Schwannomatosis
213320|NCT01885754|Biopsy
213321|NCT01885754|Maximal incremental cardiopulmonary test
213322|NCT01885754|Muscle strength test
213323|NCT01885754|magnetic stimulation
213324|NCT01885702|Dendritic cell vaccination
213325|NCT01885702|MSI-high colorectal cancer (CRC)
213326|NCT01885702|Vaccines
213327|NCT01885702|Immunotherapy
213328|NCT01885702|CRC
213329|NCT01885702|Germline MMR-gene mutation without disease criteria of CRC
213330|NCT01885663|Umbilical cord blood
213331|NCT01885663|Acquired brain injury
213332|NCT01885650|Non invasive ventilation
213333|NCT01885650|Chest physiotherapy
213334|NCT01885650|Airway clearance
213335|NCT01885637|Palliative
213336|NCT01885637|Palliation
213337|NCT01885637|Cancer
213338|NCT01885637|Care
213339|NCT01885637|SPC
213340|NCT01885637|Caregivers
213341|NCT01885637|Home Care Services, Hospital-Based
213342|NCT01885637|Psychological
213343|NCT01885637|From Oncological Treatment to Palliative Care at Home
213344|NCT01885637|Place of death
213345|NCT01885624|TAB08
213346|NCT01885624|healthy volunteers
213347|NCT01885611|Leprosy
213348|NCT01885572|breast reconstruction
213349|NCT01885572|mastectomy
213350|NCT01885572|mesh
213351|NCT01885572|breast cancer
213352|NCT01885559|polycystic kidney disease
213353|NCT01885559|polycystic
213354|NCT01885559|kidney
213355|NCT01885559|disease
213356|NCT01885559|adpkd
213357|NCT01885559|halt
213358|NCT01885559|pkd
213359|NCT01885559|blood pressure
213360|NCT01885559|bp
213361|NCT01885559|hypertension
213362|NCT01885559|renal
213363|NCT01885559|renin-angiotensin-aldosterone-system
213364|NCT01885559|RAAS
213365|NCT01885546|diabetes
213366|NCT01885546|glucose
213367|NCT01885546|glucometer
213368|NCT01885533|Graves' disease
213369|NCT01885533|radioiodine
213370|NCT01885533|thyroid
213371|NCT01885533|hypothyroidism
213372|NCT01885533|Graves' orbitopathy
213373|NCT01885520|low back pain
213374|NCT01885481|dexamethasone
213375|NCT01885481|betamethasone
213376|NCT01885481|epidural steroid injection
213377|NCT01885481|comparative effectiveness research
213378|NCT01885468|Hydrocephalus shunt
213379|NCT01885468|proGAV
213380|NCT01885455|non-small cell lung cancer (NSCLC)
213381|NCT01885442|mechanical ventilation
213382|NCT01885442|cycle ergometry
213383|NCT01885442|intensive care unit
213384|NCT01885442|rehabilitation
213385|NCT01885429|Protein Turnover
213386|NCT01885429|Resistance Exercise
213387|NCT01885429|Whey Protein
213388|NCT01885429|Leucine
213389|NCT01885403|Acute Cardiogenic Pulmonary Edema,
213390|NCT01885403|Acute Decompensated Heart Failure,
213391|NCT01885403|BiLevel Positive Airway Pressure,
213392|NCT01885403|Continuous Positive Airway Pressure
213393|NCT01885390|Hypertension
213394|NCT01885390|High blood pressure
213395|NCT01885390|Resistant blood pressure
213396|NCT01885390|Uncontrolled blood pressure
213397|NCT01885377|Subacromial pain
213398|NCT01885377|Impingement
213399|NCT01885377|Exercises
213400|NCT01885377|Physical therapy
213401|NCT01885377|Primary care
213402|NCT01885364|esmolol
213403|NCT01885364|pain
213404|NCT01885364|propofol
213405|NCT01885364|remifentanil
213406|NCT01885351|Colorectal Cancer Screening
213407|NCT01885351|Ambulatory Care
213408|NCT01885351|Patient-Centered Care
213409|NCT01885351|Intervention Studies
213410|NCT01885351|Longitudinal Studies
213411|NCT01885338|Schizophrenia
213412|NCT01885338|Cognition
213413|NCT01885338|Neurocognition
213414|NCT01885338|N-Acetylcysteine
213415|NCT01885338|NAC
213416|NCT01885338|EEG
213417|NCT01885325|Physical Activity
213418|NCT01885325|Sedentary Behavior
213419|NCT01885325|Preschool Children
213420|NCT01885312|Drinking
213421|NCT01885312|Heavy Drinking
213422|NCT01885312|Technology
213423|NCT01885312|Mobile Phone
213424|NCT01885312|Text Message
213425|NCT01885312|Problem Drinking
213426|NCT01885312|Alcohol Problems
213427|NCT01885312|Alcoholism
213428|NCT01885312|Moderation-Oriented Treatment
213429|NCT01885312|Controlled Drinking
213430|NCT01885312|Reduced Drinking
213431|NCT01885299|Radiosurgery
213432|NCT01885299|CyberKnife
213433|NCT01885299|Benign tumors
213434|NCT01885299|Malignant tumors
213435|NCT01885299|Cranial tumors
213436|NCT01885299|Extracranial tumors
213437|NCT01885299|Lung
213438|NCT01885299|Liver
213439|NCT01885299|Pancreas
213440|NCT01885299|Prostate
213441|NCT01885299|Stereotactic radiosurgery
213442|NCT01885299|Stereotactic body radiotherapy
213443|NCT01885286|circumcision
213444|NCT01885286|HIV prevention
213445|NCT01885273|pressurized irrigation
213446|NCT01885273|wound cleansing method
213447|NCT01885273|irrigation
213448|NCT01885273|swabbing
213449|NCT01885273|appropriate pressure for irrigation
213450|NCT01885260|Type 2 Diabetes Mellitus
213451|NCT01885260|T2DM
213452|NCT01885234|Glycated hemoglobin
213453|NCT01885234|HOMA
213454|NCT01885234|Pregnancy
213455|NCT01885234|aerobic exercise
213456|NCT01885221|smokeless tobacco cessation
213457|NCT01885221|social support
213458|NCT01885221|partner support
213459|NCT01885195|RAS, RAF, MEK, NF1, MEK162, signature, papillary thyroid, small intestine, bladder, esophagus, lung cancer, NSCLC, acute myelogenous leukemia, AML
213460|NCT01885169|Cystic fibrosis
213461|NCT01885169|Influenza
213462|NCT01885169|Vaccine
213463|NCT01885143|Mammography
213464|NCT01885117|Influenza,
213465|NCT01885117|Adults,
213466|NCT01885117|Elderly,
213467|NCT01885117|Immunology,
213468|NCT01885117|Safety
213469|NCT01885052|Smoking Cessation Clinical Trial
213470|NCT01885052|Text Messaging Program
213471|NCT01885052|Smoking Cessation Aid
213472|NCT01885039|Cancer
213473|NCT01885039|Breast Cancer
213474|NCT01885039|Molecular Subtypes
213475|NCT01885039|Asian Breast Cancer
213476|NCT01885026|Randomized Controlled Trial
213477|NCT01885026|Alcohol
213478|NCT01885026|Drugs
213479|NCT01885026|Internet
213480|NCT01885026|Screening
213481|NCT01885026|Brief intervention
213482|NCT01885013|HER2 negative
213483|NCT01885013|metastatic breast cancer
213484|NCT01885013|non endocrine responsive disease
213485|NCT01884974|Myeloproliferative disease
213486|NCT01884974|Pulmonary Hypertension
213487|NCT01884948|at least 1 segment
213488|NCT01884948|multiple wedge resections (≥3)
213489|NCT01884935|Pediatric
213490|NCT01884922|Children
213491|NCT01884922|adolescents
213492|NCT01884922|young adults
213493|NCT01884870|Asymptomatic
213494|NCT01884870|ureteral
213495|NCT01884870|calculi
213496|NCT01884870|renal function
213497|NCT01884870|treatment
213498|NCT01884831|damage to the skin, the skin equivalent, cell therapy
213499|NCT01884818|Thoracic spine, pain, manipulation
213500|NCT01884805|Adaptive Optics Visual Simulator
213501|NCT01884805|Wavefront aberrometer
213502|NCT01884805|Optical Aberrations
213503|NCT01884805|Hyperopia
213504|NCT01884792|prediabetes
213505|NCT01884792|physical inactivity
213506|NCT01884792|sedentary
213507|NCT01884792|standing
213508|NCT01884779|HIV
213509|NCT01884779|Histoplasmosis
213510|NCT01884779|Histoplasma capsulatum var.capsulatum
213511|NCT01884779|ELISA test
213512|NCT01884753|lower urinary tract symptoms
213513|NCT01884753|overactive bladder syndrome
213514|NCT01884753|antimuscarinic drug
213515|NCT01884753|three-dimensional power Doppler ultrasound
213516|NCT01884753|sexual dysfunction
213517|NCT01884740|GBM
213518|NCT01884740|AA
213519|NCT01884740|FA
213520|NCT01884740|PXA
213521|NCT01884740|AOA
213522|NCT01884740|High grade glioma
213523|NCT01884727|Obesity
213524|NCT01884727|Overweight
213525|NCT01884727|Over nutrition
213526|NCT01884727|nutrition disorders
213527|NCT01884727|energy expenditure
213528|NCT01884727|metabolic rate
213529|NCT01884714|diabetes
213530|NCT01884714|obesity
213531|NCT01884714|metabolism
213532|NCT01884714|clinical study
213533|NCT01884701|Chronic Total Occlusion CTO
213534|NCT01884688|Asymptomatic Multiple Myeloma
213535|NCT01884688|Auto-ENK Cell Therapy
213536|NCT01884688|Natural Killer Cells
213537|NCT01884675|Endothelin Receptor Antagonist
213538|NCT01884675|Inoperable Chronic Thromboembolic Pulmonary Hypertension
213539|NCT01884662|spinal cord injury
213540|NCT01884662|neuropathic pain
213541|NCT01884649|Acute phase reactant, fetuin A, Hashimoto thyroiditis
213542|NCT01884636|Isavuconazole
213543|NCT01884636|Pharmacokinetics
213544|NCT01884636|Healthy Subjects
213545|NCT01884636|BAL8557
213546|NCT01884636|BAL4815
213547|NCT01884636|methotrexate
213548|NCT01884597|PEARL2
213549|NCT01884597|PCV
213550|NCT01884597|Polypoidal Choroidal Vasculopathy
213551|NCT01884571|Immunosuppression
213552|NCT01884571|ALS
213553|NCT01884558|Isavuconazole
213554|NCT01884558|Pharmacokinetics
213555|NCT01884558|Healthy Subjects
213556|NCT01884558|BAL8557
213557|NCT01884558|BAL4815
213558|NCT01884558|metformin
213559|NCT01884545|heart disease
213560|NCT01884545|type 2 diabetes
213561|NCT01884545|genetic testing
213562|NCT01884545|health coaching
213563|NCT01884545|risk assessment
213564|NCT01884532|Adverse Local Tissue Reaction
213565|NCT01884532|Metal Ions
213566|NCT01884532|Serum
213567|NCT01884532|Whole Blood
213568|NCT01884532|Metal-on-Metal
213569|NCT01884532|Total Hip Arthroplasty
213570|NCT01884532|ASR-XL Metal-on-Metal
213571|NCT01884532|Revised ASR-XL Metal-on-Metal
213572|NCT01884519|Elderly
213573|NCT01884519|Influenza
213574|NCT01884519|Safety
213575|NCT01884519|Adults
213576|NCT01884519|Immunogenicity
213577|NCT01884493|Parkinson's Disease
213578|NCT01884493|Freezing of Gait
213579|NCT01884493|movement-related cortical potential
213580|NCT01884493|repetitive transcranial magnetic stimulation
213581|NCT01884480|Advagraf, pharmacogenetics, Cyp3A5
213582|NCT01884467|Urinary Tract Infections
213583|NCT01884467|Gentamicin
213584|NCT01884454|sleep
213585|NCT01884454|obstructive sleep apnea
213586|NCT01884454|reproduction
213587|NCT01884454|sperm
213588|NCT01884454|hormones
213589|NCT01884454|men
213590|NCT01884441|Hodgkin
213591|NCT01884441|Lymphoma
213592|NCT01884441|refractory
213593|NCT01884441|relapsed
213594|NCT01884428|Hodgkin
213595|NCT01884428|Lymphoma
213596|NCT01884389|HIV
213597|NCT01884389|Chronic disease
213598|NCT01884389|Early palliative care
213599|NCT01884389|Patient navigation
213600|NCT01884376|nerve biopsy
213601|NCT01884376|nerve regeneration
213602|NCT01884376|neuroma pain
213603|NCT01884376|loss of sensation
213604|NCT01884363|Endothelial function
213605|NCT01884363|walnuts
213606|NCT01884363|clinical trial
213607|NCT01884363|Nutrition
213608|NCT01884363|cardiovascular disease
213609|NCT01884324|Gastroschisis
213610|NCT01884324|Cesarean delivery
213611|NCT01884324|Neonatal outcomes
213612|NCT01884311|Primary Immune Deficiency Disorders
213613|NCT01884311|Common Variable Immunodeficiency
213614|NCT01884311|X-linked agammaglobulinaemia
213615|NCT01884311|Hyper-IgM Syndrome
213616|NCT01884311|Subcutaneous
213617|NCT01884311|Immunoglobulins
213618|NCT01884298|remifentanil
213619|NCT01884298|isolated systolic hypertension
213620|NCT01884298|morbidity
213621|NCT01884298|epidural combined general anesthesia
213622|NCT01884285|Advanced Castrate-resistant Prostate Cancer(CRPC)
213623|NCT01884285|Squamous Non-Small Cell Lung Cancer(sqNSCLC)
213624|NCT01884285|Triple Negative Breast Cancer(TNBC)
213625|NCT01884285|PTEN-deficient/mutated Advanced Solid Malignancies
213626|NCT01884285|PIK3CB mutated/amplified advanced solid malignancies
213627|NCT01884259|local advanced squamous cell carcinoma
213628|NCT01884259|Larynx
213629|NCT01884259|Hypopharynx
213630|NCT01884259|Oropharynx
213631|NCT01884259|Cavum oris
213632|NCT01884259|docetaxel
213633|NCT01884259|cisplatin
213634|NCT01884259|5-fluorouracil
213635|NCT01884259|Cetuximab
213636|NCT01884246|lifestyle change
213637|NCT01884246|behavior change
213638|NCT01884246|obesity
213639|NCT01884246|hypertension
213640|NCT01884246|hyperlipidemia
213641|NCT01884246|physical inactivity
213642|NCT01884246|depression
213643|NCT01884233|HIV
213644|NCT01884233|Opioid Abuse
213645|NCT01884233|Mobile technology
213646|NCT01884220|Wolman Disease
213647|NCT01884220|Cholesteryl Ester Storage Disease
213648|NCT01884220|Enzyme deficiency
213649|NCT01884220|Natural History
213650|NCT01884220|Medical Records Review
213651|NCT01884194|retinoblastoma
213652|NCT01884194|pineoblastoma
213653|NCT01884181|Huntington Disease, diffusion MRI, diagnosis, fast imaging
213654|NCT01884129|Circulating tumor cells
213655|NCT01884129|Head and neck cancer
213656|NCT01884129|Squamous cell carcinoma
213657|NCT01884129|Survival
213658|NCT01884129|Prognosis
213659|NCT01884116|Capsaicin
213660|NCT01884116|myofascial pain syndrome
213661|NCT01884116|non-steroidal anti-inflammatory agents
213662|NCT01884116|transcutaneous electric nerve stimulation
213663|NCT01884103|TBI
213664|NCT01884103|Trauma
213665|NCT01884103|Traumatic Brain Injury
213666|NCT01884090|Empowerment
213667|NCT01884090|Youth
213668|NCT01884090|Violence
213669|NCT01884090|Community
213670|NCT01884090|Prevention
213671|NCT01884077|patient outcomes two years after shoulder replacement
213672|NCT01884077|seventy years of age and older
213673|NCT01884064|focal hand dystonia
213674|NCT01884064|rehabilitation
213675|NCT01884064|rTMS
213676|NCT01884064|writer's cramp
213677|NCT01884064|clinical
213678|NCT01884051|Pulmonary arterial hypertension
213679|NCT01884038|Liver Transplant
213680|NCT01884038|Prostacyclin
213681|NCT01884038|Treprostinil sodium
213682|NCT01884038|Remodulin
213683|NCT01884038|Reperfusion Injury
213684|NCT01884038|Primary Nonfunction
213685|NCT01884025|patient centered care
213686|NCT01884025|physical activity
213687|NCT01884025|behavioral activation
213688|NCT01884025|self efficacy
213689|NCT01884025|serious mental illness
213690|NCT01883986|palliative care
213691|NCT01883973|PD
213692|NCT01883973|DBS
213693|NCT01883960|cerebral palsy
213694|NCT01883960|cerebral vascular accident
213695|NCT01883960|multi-modal brain techniques
213696|NCT01883960|MRI
213697|NCT01883960|motor control
213698|NCT01883947|Stroke
213699|NCT01883947|Massage
213700|NCT01883947|General Health
213701|NCT01883947|Independence
213702|NCT01883934|In Vitro Fertilization (IVF)
213703|NCT01883934|Embryo donation
213704|NCT01883921|Primary Immunodeficiency
213705|NCT01883921|Immunodeficiencies
213706|NCT01883921|Primary Immunodeficiency Diseases
213707|NCT01883921|PIDD
213708|NCT01883921|CVID
213709|NCT01883921|PI
213710|NCT01883921|Common Variable Immunodeficiency
213711|NCT01883921|Hypogammaglobulinemia
213712|NCT01883921|Acquired Hypogammaglobulinemia
213713|NCT01883921|Immunology
213714|NCT01883921|Autoimmune Deficiency
213715|NCT01883921|Intravenous Immunoglobulin
213716|NCT01883921|Subcutaneous Immunoglobulin
213717|NCT01883921|IVIg
213718|NCT01883921|SCIg
213719|NCT01883921|Immune Globulin
213720|NCT01883921|Outcomes Research
213721|NCT01883921|Immunodeficiency
213722|NCT01883908|Acupuncture therapy
213723|NCT01883908|Mucositis
213724|NCT01883908|oropharyngeal cancer
213725|NCT01883895|Pain
213726|NCT01883895|exercise-induced hypoalgesia
213727|NCT01883882|chronic non-cancer pain
213728|NCT01883882|opioid taper
213729|NCT01883882|chronic pain self-management
213730|NCT01883882|motivational interviewing
213731|NCT01883869|Platelet inhibition
213732|NCT01883869|Platelet-leukocyte aggregates
213733|NCT01883869|Platelet-neutrophil aggregates
213734|NCT01883869|CAP
213735|NCT01883869|HAP
213736|NCT01883869|ALI
213737|NCT01883869|Blood Platelets
213738|NCT01883856|Refractory Glaucoma
213739|NCT01883856|Intractable Glaucoma
213740|NCT01883856|Primary Open Angle Glaucoma
213741|NCT01883856|Neovascular Glaucoma
213742|NCT01883843|Chronic Stroke
213743|NCT01883843|tDCS
213744|NCT01883843|transcranial direct current stimulation
213745|NCT01883843|task oriented circuit training
213746|NCT01883843|TOCT
213747|NCT01883843|gait training
213748|NCT01883830|traumatic brain injury (TBI)
213749|NCT01883830|balance disorders
213750|NCT01883830|attention deficits
213751|NCT01883830|x-box
213752|NCT01883830|gaming
213753|NCT01883830|virtual reality
213754|NCT01883817|ADHD
213755|NCT01883804|Diabetes
213756|NCT01883804|Diabetes Mellitus
213757|NCT01883804|Type 1 Diabetes
213758|NCT01883791|substance abuse prevention and treatment
213759|NCT01883791|comorbidity
213760|NCT01883791|SBIRT
213761|NCT01883778|Attitudes of health personnel
213762|NCT01883778|Attitudes of patients
213763|NCT01883778|Medical compliance
213764|NCT01883778|Cost awareness
213765|NCT01883778|Cost analysis
213766|NCT01883778|Patient knowledge
213767|NCT01883778|Physician knowledge
213768|NCT01883778|Medical economics
213769|NCT01883778|Policy
213770|NCT01883778|Questionnaires
213771|NCT01883778|Health literacy
213772|NCT01883765|ADHD, Neurofeedback, CBT
213773|NCT01883752|Goal-directed fluid therapy
213774|NCT01883739|Parental anxiety
213775|NCT01883739|Children's safety
213776|NCT01883739|Family Centered Care
213777|NCT01883739|Bedside Transfer Rounds
213778|NCT01883739|Pediatric Cardiac Intensive Care
213779|NCT01883726|Unilateral complete cleft lip, Nasoalveolar molding
213780|NCT01883713|anemia
213781|NCT01883713|CPB
213782|NCT01883713|methemoglobin
213783|NCT01883713|hypoxia
213784|NCT01883700|Healthy
213785|NCT01883700|Glycemic Index
213786|NCT01883700|Glycemic Load
213787|NCT01883700|Blood Glucose
213788|NCT01883700|Arterial Stiffness
213789|NCT01883674|Sarcopenia
213790|NCT01883674|Physical capacity
213791|NCT01883674|Muscle force
213792|NCT01883674|Muscle quality
213793|NCT01883674|Milk proteins
213794|NCT01883674|Essential amino acids
213795|NCT01883674|Proteins
213796|NCT01883674|Resistance training
213797|NCT01883674|Exercise
213798|NCT01883661|stem cell
213799|NCT01883661|Multiple Sclerosis
213800|NCT01883661|BMMNC
213801|NCT01883648|Mild to Moderate Alzheimer's disease
213802|NCT01883622|diabetes
213803|NCT01883622|pregnancy
213804|NCT01883622|glucose variability
213805|NCT01883622|continuous glucose monitoring (CGM)
213806|NCT01883622|gestational diabetes mellitus (GDM)
213807|NCT01883609|Plasmodium Falciparum
213808|NCT01883609|Malaria
213809|NCT01883609|Vaccine
213810|NCT01883609|Plasmodium
213811|NCT01883609|Falciparum
213812|NCT01883583|Ultrasound
213813|NCT01883583|Perfusion Imaging
213814|NCT01883583|Elasticity Imaging Techniques
213815|NCT01883583|Kidney Transplantation
213816|NCT01883583|Graft Rejection
213817|NCT01883583|Chronic allograft nephropathy
213818|NCT01883570|visual search strategy, training, chest x-ray
213819|NCT01883544|Safety
213820|NCT01883544|Tolerability
213821|NCT01883544|Pharmacokinetics
213822|NCT01883544|Pharmacodynamics
213823|NCT01883544|ALXN1007
213824|NCT01883544|Healthy Male and Female Subjects
213825|NCT01883531|improving lung function
213826|NCT01883531|paediatric and adolescent
213827|NCT01883531|FEV1
213828|NCT01883518|Fibrosarcoma
213829|NCT01883518|Neurofibrosarcoma
213830|NCT01883518|Histiocytoma
213831|NCT01883518|Histiocytoma, Malignant Fibrous
213832|NCT01883518|Chondrosarcoma
213833|NCT01883518|Synovial Sarcoma
213834|NCT01883518|Leiomyosarcoma
213835|NCT01883518|Liposarcoma
213836|NCT01883518|Myosarcoma
213837|NCT01883518|Rhabdomyosarcoma
213838|NCT01883518|Sarcoma, Alveolar Soft Part
213839|NCT01883518|NY-ESO-1
213840|NCT01883518|MAGE
213841|NCT01883518|MAGE A3
213842|NCT01883518|Vaccine
213843|NCT01883518|Immunotherapy
213844|NCT01883505|Motor fluctuations
213845|NCT01883505|levodopa pharmacokinetics
213846|NCT01883505|levodopa and carbidopa solution
213847|NCT01883505|continuous subcutaneous delivery
213848|NCT01883505|Patch-pump
213849|NCT01883492|Only Female
213850|NCT01883492|Age between 20 - 75 at the time of operation
213851|NCT01883466|Air Pollution
213852|NCT01883466|Biodiesel exhaust
213853|NCT01883466|Diesel exhaust
213854|NCT01883466|Vascular function
213855|NCT01883466|Fibrinolysis
213856|NCT01883466|Acute endothelial responses
213857|NCT01883440|Duration
213858|NCT01883427|Days with URTI symptoms
213859|NCT01883414|Ulthera, Ultherapy, Surgical scar, scar,
213860|NCT01883401|Strawberries
213861|NCT01883401|Heart health
213862|NCT01883401|Anthocyanins
213863|NCT01883388|Lung Cancer
213864|NCT01883388|blood sample
213865|NCT01883375|Palliative Care
213866|NCT01883375|Family
213867|NCT01883375|adaptation, psychological
213868|NCT01883362|acute myeloid leukemia
213869|NCT01883362|AML
213870|NCT01883362|FLT3-ITD
213871|NCT01883362|midostaurin
213872|NCT01883362|PKC412
213873|NCT01883362|allogeneic hematopoeitic stem cell tranplant
213874|NCT01883362|SCT
213875|NCT01883362|HSCT
213876|NCT01883362|CR1
213877|NCT01883336|Incidental pancreatic cysts
213878|NCT01883323|Measurable
213879|NCT01883323|Unresectable
213880|NCT01883323|Stage III
213881|NCT01883323|Stage IV
213882|NCT01883323|Metastatic
213883|NCT01883323|Melanoma
213884|NCT01883323|Tumor-Infiltrating Lymphocytes
213885|NCT01883323|Low-Dose Interleukin-2
213886|NCT01883323|Cyclophosphamide
213887|NCT01883323|Fludarabine
213888|NCT01883310|Multiple Sclerosis
213889|NCT01883310|transcranial direct current stimulation
213890|NCT01883310|TOCT
213891|NCT01883310|task-oriented circuit training
213892|NCT01883310|locomotor function
213893|NCT01883310|mobility
213894|NCT01883310|balance
213895|NCT01883297|Measurable
213896|NCT01883297|Recurrent
213897|NCT01883297|Platinum resistant
213898|NCT01883297|Tumor-Infiltrating Lymphocytes
213899|NCT01883297|Low-Dose Interleukin-2
213900|NCT01883297|Autologous dendritic cells
213901|NCT01883297|Anti-CD3 monoclonal antibody
213902|NCT01883297|High grade serous ovarian, fallopian tube, or primary peritoneal cancer
213903|NCT01883297|Cyclophosphamide
213904|NCT01883284|Cystic Fibrosis
213905|NCT01883284|nasal epithelia
213906|NCT01883284|mucins
213907|NCT01883245|Orofacial chronic pain
213908|NCT01883245|tDCS
213909|NCT01883245|Transcranial direct current stimulation
213910|NCT01883245|Brain stimulation
213911|NCT01883219|Philadelphia chromosome
213912|NCT01883219|Acute lymphoblastic leukemia
213913|NCT01883219|Allogeneic hematopoietic cell transplantation
213914|NCT01883219|Minimal residual disease
213915|NCT01883219|Tyrosine kinase inhibitor
213916|NCT01883206|Cytomegalovirus
213917|NCT01883193|preconception maternal nutrition
213918|NCT01883193|LBW
213919|NCT01883193|Length-for-age
213920|NCT01883193|maternal nutrition supplement
213921|NCT01883193|multi-micronutrient fortified lipid-based supplement
213922|NCT01883193|infant growth
213923|NCT01883193|low-resource settings
213924|NCT01883180|haploidentical hematopoietic Stem Cell Transplantation
213925|NCT01883180|Antithymocyte globulin
213926|NCT01883180|viral infection
213927|NCT01883128|Biochemical Failure
213928|NCT01883128|Radiotherapy
213929|NCT01883128|Radiorecurrent Prostate Cancer
213930|NCT01883128|MRI Prostate
213931|NCT01883128|Whole Body MRI
213932|NCT01883128|Bone Scan
213933|NCT01883128|Choline PET
213934|NCT01883128|Focal Salvage Treatment
213935|NCT01883128|HIFU
213936|NCT01883128|Cryotherapy
213937|NCT01883115|Telescopic extraperitoneal dissection
213938|NCT01883115|Single incision laparosocpic surgery
213939|NCT01883115|Inguinal hernia
213940|NCT01883115|Triport system
213941|NCT01883076|Hypoplastic Left Heart Syndrome
213942|NCT01883076|HLHS
213943|NCT01883076|Congenital Heart Disease
213944|NCT01883076|Umbilical cord blood
213945|NCT01883076|UCB
213946|NCT01883076|Cord blood
213947|NCT01883076|Stem cells
213948|NCT01883076|Regenerative therapy
213949|NCT01883076|Stage II Glenn
213950|NCT01883076|Glenn Surgery
213951|NCT01883050|Coronary artery disease
213952|NCT01883050|Percutaneous Intervention
213953|NCT01883050|Stent
213954|NCT01883050|Balloon angioplasty
213955|NCT01883050|Angiogram
213956|NCT01883050|Coronary angiogram
213957|NCT01883037|Cystic Fibrosis
213958|NCT01883037|Cystic Fibrosis related diabetes
213959|NCT01883037|Oral glucose tolerance test
213960|NCT01883024|Real time continuous glucose monitoring, decision support software, smartphone application.
213961|NCT01883011|Piracetam
213962|NCT01883011|Stroke
213963|NCT01883011|Aphasia
213964|NCT01883011|Acute
213965|NCT01883011|Cerebral
213966|NCT01883011|Ischemic
213967|NCT01883011|Nootropil
213968|NCT01882998|HIV and pregnancy
213969|NCT01882998|HIV and breastfeeding
213970|NCT01882998|Mother-to-child transmission of HIV
213971|NCT01882998|Africa
213972|NCT01882998|Uganda
213973|NCT01882985|docetaxel
213974|NCT01882985|lycopene
213975|NCT01882985|prostate cancer
213976|NCT01882933|Gastric adenocarcinoma
213977|NCT01882933|HIPEC
213978|NCT01882933|Oxaliplatin
213979|NCT01882933|Signet ring cell
213980|NCT01882920|Cytoreductive surgery
213981|NCT01882920|hyperthermic intraperitoneal chemotherapy
213982|NCT01882920|Goal directed fluid therapy
213983|NCT01882907|vildagliptin
213984|NCT01882907|metformin
213985|NCT01882894|Plantar fasciitis, orthotic, functional outcome
213986|NCT01882842|Infertility
213987|NCT01882842|Endometrium
213988|NCT01882842|Live birth
213989|NCT01882829|depression
213990|NCT01882829|major depressive disorder
213991|NCT01882829|treatment resistant
213992|NCT01882829|Nuedexta
213993|NCT01882829|dextromethorphan
213994|NCT01882829|antidepressant
213995|NCT01882829|glutamate
213996|NCT01882829|NMDA receptor
213997|NCT01882816|non-anaplastic
213998|NCT01882816|non-medullary
213999|NCT01882816|radiation
214000|NCT01882816|IMRT
214001|NCT01882816|Doxorubicin
214002|NCT01882816|13-070
214003|NCT01882803|PI3K Inhibitor
214004|NCT01882790|coronary artery spasm
214005|NCT01882790|hypertension
214006|NCT01882790|Pathophysiology
214007|NCT01882790|atrioventricular block
214008|NCT01882790|blood pressure
214009|NCT01882790|autonomic nervous function
214010|NCT01882751|kinematics
214011|NCT01882751|knee joint
214012|NCT01882738|Cervical length
214013|NCT01882738|BMI
214014|NCT01882699|Insomnia
214015|NCT01882686|Pain
214016|NCT01882686|Back Pain
214017|NCT01882686|Low Back Pain
214018|NCT01882686|Chronic Low Back Pain
214019|NCT01882686|Cognitive Functional Therapy
214020|NCT01882686|Intervention
214021|NCT01882686|Subclassification
214022|NCT01882686|Multidimensional
214023|NCT01882673|Tobacco
214024|NCT01882673|nicotine
214025|NCT01882673|dependence
214026|NCT01882673|quitline
214027|NCT01882647|psoriasis
214028|NCT01882647|lotion
214029|NCT01882647|investigator's global assessment
214030|NCT01882621|NSCLC
214031|NCT01882621|Monosialoganglioside(GM1)
214032|NCT01882621|neurotoxicity
214033|NCT01882608|psychiatry
214034|NCT01882608|mental health
214035|NCT01882608|mood disorders
214036|NCT01882608|mood diaries
214037|NCT01882608|electronic diaries
214038|NCT01882608|cell phones
214039|NCT01882608|software
214040|NCT01882608|mental health telemetry
214041|NCT01882608|ecological momentary assessment
214042|NCT01882595|Nebulization aerosol nebulizer tracheostomy
214043|NCT01882556|Early treatment of spasticity.
214044|NCT01882556|Post stroke spasticity.
214045|NCT01882543|Interstitial cystitis
214046|NCT01882543|Bladder pain syndrome
214047|NCT01882543|IC/BPS
214048|NCT01882543|AQX-1125
214049|NCT01882543|SHIP1
214050|NCT01882530|Post operative analgesia ;
214051|NCT01882530|Paracetamol ;
214052|NCT01882530|Ketoprofen ;
214053|NCT01882530|Nefopam ;
214054|NCT01882530|Morphine
214055|NCT01882504|Pyoderma Gangrenosum
214056|NCT01882504|Classic Pyoderma Gangrenosum
214057|NCT01882504|Atypical Pyoderma Gangrenosum
214058|NCT01882504|Peristomal Pyoderma Gangrenosum
214059|NCT01882491|Erosive Osteoarthritis
214060|NCT01882491|Osteoarthritis
214061|NCT01882491|Osteoarthritis of the Hand
214062|NCT01882478|Barrett's esophagus
214063|NCT01882478|Early esophageal adenocarcinoma
214064|NCT01882478|Radio Frequency Ablation
214065|NCT01882478|Cryotherapy
214066|NCT01882452|Memory specificity training
214067|NCT01882452|Autobiographical memory
214068|NCT01882452|Major depressive disorder
214069|NCT01882439|psoriatic arthritis
214070|NCT01882439|tofacitinib
214071|NCT01882439|ACR20
214072|NCT01882439|HAQ-DI
214073|NCT01882439|TNF inhibitor failure
214074|NCT01882426|CONSTRUCT
214075|NCT01882426|Cluster randomization controlled trial
214076|NCT01882426|Gastroenterology practices in North America
214077|NCT01882400|Osteoporosis
214078|NCT01882400|Severe muscular dystrophy
214079|NCT01882400|Cystic fibrosis
214080|NCT01882387|Allogeneic Peripheral Blood Stem Cell Transplantation
214081|NCT01882387|Graft-vs-Host Disease
214082|NCT01882387|Neutrophil Engraftment
214083|NCT01882387|Platelet Engraftment
214084|NCT01882387|Immune Reconstitution
214085|NCT01882387|Mucositis
214086|NCT01882374|Double Umbilical Cord Blood Transplantation
214087|NCT01882374|Acute Graft versus Host Disease
214088|NCT01882374|Neutrophil Engraftment
214089|NCT01882374|Platelet Recovery
214090|NCT01882374|Immune Reconstitution
214091|NCT01882374|Mucositis
214092|NCT01882361|opioid addiction
214093|NCT01882361|opioid treatment
214094|NCT01882361|naloxone
214095|NCT01882348|tobacco control, tobacco treatment, pediatrics, parents
214096|NCT01882335|Human capital formation
214097|NCT01882322|FK506
214098|NCT01882322|tacrolimus
214099|NCT01882322|immunosuppressant
214100|NCT01882283|serum lipids
214101|NCT01882283|cholesterol
214102|NCT01882283|serum cholesterol
214103|NCT01882283|black tea
214104|NCT01882283|flavonoids
214105|NCT01882283|crossover trial
214106|NCT01882283|randomized control trial
214107|NCT01882283|diet controlled
214108|NCT01882270|pericoronitis
214109|NCT01882270|periodontal
214110|NCT01882257|obstructive sleep apnea
214111|NCT01882257|sleep-disordered breathing
214112|NCT01882257|hypercapnia
214113|NCT01882257|spinal cord injury
214114|NCT01882244|traumatic brain injury
214115|NCT01882244|cognition
214116|NCT01882244|rehabilitation
214117|NCT01882244|attentional regulation
214118|NCT01882244|working memory
214119|NCT01882231|Osteosarcoma
214120|NCT01882231|Ewing sarcoma
214121|NCT01882231|Paget's disease
214122|NCT01882231|bone cancer
214123|NCT01882231|childhood cancers
214124|NCT01882231|DCE MRI
214125|NCT01882231|DW MRI
214126|NCT01882231|CEST MRI
214127|NCT01882231|MT MRI
214128|NCT01882218|Liver cancer
214129|NCT01882205|Ulcerative colitis
214130|NCT01882205|DALM
214131|NCT01882205|chromoendoscopy
214132|NCT01882205|dysplasia
214133|NCT01882205|virtual chromoendoscopy
214134|NCT01882205|FICE
214135|NCT01882205|NBI
214136|NCT01882205|I-scan
214137|NCT01882192|family
214138|NCT01882192|physical activity
214139|NCT01882192|planning
214140|NCT01882179|Reperfusion injury
214141|NCT01882179|myocardial infarct size
214142|NCT01882179|MRI
214143|NCT01882179|spironolactone
214144|NCT01882166|Fertilization in Vitro
214145|NCT01882166|Sperm Injections, Intracytoplasmic
214146|NCT01882166|Follicle Stimulating Hormone
214147|NCT01882166|Embryonic Development
214148|NCT01882140|burns
214149|NCT01882140|wound healing
214150|NCT01882140|magnetic field therapy
214151|NCT01882127|Purpura
214152|NCT01882127|Idiopathic Thrombocytopenic Purpura
214153|NCT01882101|Fecal incontinence
214154|NCT01882101|posterior tibial nerve stimulation
214155|NCT01882101|biofeedback
214156|NCT01882101|quality of life
214157|NCT01882075|Anesthesia
214158|NCT01882075|Fluid administration
214159|NCT01882075|Closed-loop
214160|NCT01882023|EDNOS
214161|NCT01882023|adolescents
214162|NCT01882010|Parkinson's disease
214163|NCT01882010|motor function
214164|NCT01882010|immune activation
214165|NCT01882010|T cells
214166|NCT01882010|CD4
214167|NCT01882010|GMCSF
214168|NCT01882010|leukine
214169|NCT01882010|sargramostim
214170|NCT01882010|magnetoencephalography
214171|NCT01881997|Procedure
214172|NCT01881997|Abscess
214173|NCT01881997|Emergency Department
214174|NCT01881997|Opioid
214175|NCT01881997|Fentanyl
214176|NCT01881984|Medium-chain acyl-CoA dehydrogenase deficiency
214177|NCT01881984|MCAD deficiency
214178|NCT01881984|MCADD
214179|NCT01881984|ACADM deficiency
214180|NCT01881984|MCADH deficiency
214181|NCT01881984|985A>G mutation
214182|NCT01881984|K304E mutation
214183|NCT01881984|Ravicti
214184|NCT01881984|glycerol phenylbutyrate
214185|NCT01881971|HIV
214186|NCT01881971|lung
214187|NCT01881971|lipids
214188|NCT01881971|no lipid lowering medication
214189|NCT01881971|normal liver and kidney function
214190|NCT01881971|on stable ART regimen
214191|NCT01881971|not pregnant
214192|NCT01881945|Swallowing
214193|NCT01881945|Hyperventilation
214194|NCT01881932|acupuncture therapy
214195|NCT01881932|sham acupuncture therapy
214196|NCT01881932|chemotherapy-induced peripheral neuropathy (CIPN)
214197|NCT01881919|Functional Food
214198|NCT01881906|aerobic exercise
214199|NCT01881906|Lung cancer
214200|NCT01881906|psyco-social
214201|NCT01881893|Quality of life
214202|NCT01881893|Psychosocial Support Systems
214203|NCT01881893|Randomized Controls as Topic
214204|NCT01881893|Cognitive Therapy
214205|NCT01881893|Feasibility Studies
214206|NCT01881880|Tomosynthesis
214207|NCT01881880|Mammography
214208|NCT01881880|Breast cancer
214209|NCT01881841|Alcohol abuse
214210|NCT01881841|Substance use
214211|NCT01881841|Tobacco use disorder
214212|NCT01881841|Motivational Enhancement Therapy
214213|NCT01881841|Adolescents
214214|NCT01881815|Chronic wounds with different etiologies
214215|NCT01881815|Diabetic foot ulcers
214216|NCT01881815|venous leg ulcers
214217|NCT01881815|pressure sores
214218|NCT01881815|acute wounds
214219|NCT01881802|Opioid drug Abuse
214220|NCT01881802|Morphine
214221|NCT01881802|Immune Function
214222|NCT01881789|multiple myeloma
214223|NCT01881789|proteasome inhibitor
214224|NCT01881789|oprozomib
214225|NCT01881789|orpozomib tablets
214226|NCT01881776|Single injection interscalene brachial plexus block
214227|NCT01881776|Continuous interscalene brachial plexus block
214228|NCT01881776|General anesthesia
214229|NCT01881776|Postoperative pain
214230|NCT01881776|Recovery profile
214231|NCT01881763|Electroconvulsive Therapy
214232|NCT01881763|Ketamine
214233|NCT01881763|anesthesia
214234|NCT01881763|depression
214235|NCT01881763|unipolar
214236|NCT01881763|bipolar
214237|NCT01881750|Autism PRT
214238|NCT01881737|autism
214239|NCT01881711|hydrocephalus
214240|NCT01881711|CSF shunt
214241|NCT01881711|shunt malfunction
214242|NCT01881711|shunt obstruction
214243|NCT01881711|ShuntCheck
214244|NCT01881711|ShuntCheck-Micro-Pumper
214245|NCT01881698|pregnancy
214246|NCT01881698|platelet function
214247|NCT01881698|monitoring
214248|NCT01881698|multiple electrode aggregometry
214249|NCT01881672|Aspiration pneumonia
214250|NCT01881672|Coma
214251|NCT01881672|Mechanical ventilation
214252|NCT01881659|cervical cancer
214253|NCT01881659|cancer prevention
214254|NCT01881659|cervical screening
214255|NCT01881659|HPV testing
214256|NCT01881659|triage techniques
214257|NCT01881646|Neuroinflammation
214258|NCT01881646|Postoperative cognitive dysfunction
214259|NCT01881633|gaucher disease, imiglucerase, ISU302
214260|NCT01881620|PET scan
214261|NCT01881620|CT scan
214262|NCT01881620|Diagnostic performance
214263|NCT01881607|tobacco smoke pollution
214264|NCT01881607|Tobacco use
214265|NCT01881594|ileostomy closure,postoperative ileus,stimulation ileostomy
214266|NCT01881581|Therapeutic
214267|NCT01881581|Vaccine
214268|NCT01881581|HIV
214269|NCT01881581|MVA
214270|NCT01881581|DNA
214271|NCT01881568|Total Knee Arthroplasty, TKA, blood loss
214272|NCT01881555|fractional flow reserve
214273|NCT01881555|multivessel coronary artery disease
214274|NCT01881555|angiography
214275|NCT01881542|preeclampsia
214276|NCT01881542|proteinuria
214277|NCT01881542|urine collection
214278|NCT01881529|limited scleroderma
214279|NCT01881529|diffuse scleroderma
214280|NCT01881529|Sclerosis
214281|NCT01881529|Progressive
214282|NCT01881529|Limited
214283|NCT01881503|life-threatening anemia
214284|NCT01881503|blood alternative
214285|NCT01881503|HBOC
214286|NCT01881490|Crohn's Disease
214287|NCT01881490|MRE
214288|NCT01881490|Pelvic MRI
214289|NCT01881490|P-MRI
214290|NCT01881490|colonoscopy
214291|NCT01881490|gastroscopy
214292|NCT01881477|immobilization
214293|NCT01881477|physical therapy
214294|NCT01881477|intensive care
214295|NCT01881477|bed rest
214296|NCT01881477|movement
214297|NCT01881451|Tumour hypoxia
214298|NCT01881451|Clear Cell Ovarian Cancer
214299|NCT01881451|Recurrent
214300|NCT01881451|Metastatic
214301|NCT01881438|Retinal Detachment
214302|NCT01881438|Fluoroquinolones
214303|NCT01881438|Ciprofloxacin
214304|NCT01881438|Levofloxacin
214305|NCT01881438|Gatifloxacin
214306|NCT01881438|Gemifloxacin
214307|NCT01881438|Moxifloxacin
214308|NCT01881438|Norfloxacin
214309|NCT01881438|Ofloxacin
214310|NCT01881438|Beta-Lactam
214311|NCT01881425|POAG
214312|NCT01881412|Asthma
214313|NCT01881412|Children
214314|NCT01881412|Inhaled Corticosteroids
214315|NCT01881412|Emergency Department
214316|NCT01881399|Cholelithiasis
214317|NCT01881399|Gallbladder polyps
214318|NCT01881399|Fluorescence
214319|NCT01881399|Indocyanine green (ICG)
214320|NCT01881399|Intraoperative cholangiography (IOC)
214321|NCT01881399|da Vinci surgical system
214322|NCT01881386|Magnetic Resonance Spectroscopy
214323|NCT01881386|Lactate
214324|NCT01881373|Obesity
214325|NCT01881373|Child
214326|NCT01881373|Food
214327|NCT01881373|Physical Activity
214328|NCT01881373|Pacific
214329|NCT01881360|fibromyalgia
214330|NCT01881360|celiac-type symptoms
214331|NCT01881360|gluten-free diet
214332|NCT01881360|hypocaloric diet
214333|NCT01881347|endothelium
214334|NCT01881347|mitochondria
214335|NCT01881347|reactive oxygen species
214336|NCT01881347|vascular biology
214337|NCT01881347|arterial stiffness
214338|NCT01881347|nitric oxide
214339|NCT01881334|Haploidentical Donor
214340|NCT01881334|T-cell depleted Stem Cells
214341|NCT01881334|Allogeneic Transplant
214342|NCT01881334|Umbilical Cord Blood Donor
214343|NCT01881334|High Risk Malignancies
214344|NCT01881334|Metabolic Disorders
214345|NCT01881334|Immune Deficiency
214346|NCT01881334|Acute Lymphoblastic Leukemia
214347|NCT01881334|Acute Myelogenous Leukemia
214348|NCT01881334|Myelodysplastic Syndrome
214349|NCT01881334|ALL
214350|NCT01881334|AML
214351|NCT01881334|MDS
214352|NCT01881334|CGD
214353|NCT01881334|SCID
214354|NCT01881334|Adrenoleukodystrophy
214355|NCT01881334|Metachromaticleukodystrophy
214356|NCT01881334|Krabbe
214357|NCT01881334|PMD
214358|NCT01881334|Hunter's
214359|NCT01881334|Hurler's
214360|NCT01881334|Severe Aplastic Anemia
214361|NCT01881334|Lymphoma
214362|NCT01881334|Sickle Cell Disease
214363|NCT01881334|Thalassemia
214364|NCT01881321|Contraception
214365|NCT01881321|Counseling
214366|NCT01881295|Potassium
214367|NCT01881295|Potato
214368|NCT01881295|French Fries
214369|NCT01881295|Bioavailability
214370|NCT01881295|Blood Pressure
214371|NCT01881282|Hemorrhoids
214372|NCT01881282|Carraghenates
214373|NCT01881282|Mayinglong Musk
214374|NCT01881282|Titanoreine
214375|NCT01881256|Preterm birth
214376|NCT01881256|Parenteral and enteral nutrition
214377|NCT01881256|Body composition in preterm infants
214378|NCT01881243|Cardiac Arrest, Hyperoxia, Ischemia-reperfusion Injury, Reactive Oxygen Species, Oxidative Stress, Neuropsychological Tests
214379|NCT01881230|Breast Cancer
214380|NCT01881230|Cancer of the Breast
214381|NCT01881230|Metastatic Breast Cancer
214382|NCT01881230|Metastatic Triple Negative Breast Cancer
214383|NCT01881230|Triple Negative Breast Cancer
214384|NCT01881230|Triple Negative Metastatic Breast Cancer
214385|NCT01881230|Basal-like breast cancer
214386|NCT01881230|Hormone receptor negative breast cancer
214387|NCT01881230|Estrogen receptor negative breast cancer
214388|NCT01881230|Progesterone negative receptor breast cancer
214389|NCT01881230|HER2 Negative Breast Cancer
214390|NCT01881230|Abraxane
214391|NCT01881230|nab-Paclitaxel
214392|NCT01881230|ABI-007
214393|NCT01881230|gemcitabine
214394|NCT01881230|Gemzar
214395|NCT01881230|carboplatin
214396|NCT01881230|Paraplatin
214397|NCT01881230|Paraplatin AQ
214398|NCT01881230|Phase 2
214399|NCT01881230|Phase 3
214400|NCT01881217|Phase I
214401|NCT01881217|Dose escalation
214402|NCT01881217|Advanced, refractory solid tumors
214403|NCT01881217|FGFR2
214404|NCT01881204|Hesperidin
214405|NCT01881204|Osteoporosis
214406|NCT01881204|Bone Loss
214407|NCT01881191|multiple sclerosis
214408|NCT01881191|relapsing remitting
214409|NCT01881191|MRI
214410|NCT01881191|teriflunomide
214411|NCT01881191|aubagio
214412|NCT01881191|gray matter atrophy
214413|NCT01881191|gray matter pathology
214414|NCT01881178|CRP
214415|NCT01881178|Nopalea
214416|NCT01881178|Fruit
214417|NCT01881178|Juice
214418|NCT01881152|Stroke
214419|NCT01881152|Community education
214420|NCT01881152|Awareness
214421|NCT01881152|Prehospital delay
214422|NCT01881139|Exercise
214423|NCT01881139|Lipid
214424|NCT01881139|Left ventricular
214425|NCT01881139|heart function
214426|NCT01881100|resin infiltration
214427|NCT01881100|randomized clinical trial
214428|NCT01881100|fluoride varnish
214429|NCT01881100|caries lesion
214430|NCT01881100|deciduous teeth
214431|NCT01881087|Knee Arthroscopy
214432|NCT01881087|Levobupivacaine
214433|NCT01881087|Spinal Anesthesia
214434|NCT01881087|Motor Block
214435|NCT01881074|Type II Diabetes
214436|NCT01881074|Periodontal Disease
214437|NCT01881074|Periodontitis
214438|NCT01881074|Gum Disease
214439|NCT01881074|Gingivitis
214440|NCT01881074|Triclosan
214441|NCT01881074|Inflammatory Markers
214442|NCT01881074|Immune Response
214443|NCT01881061|Sonography
214444|NCT01881061|ICU
214445|NCT01881061|PEEP
214446|NCT01881048|Breast cancer
214447|NCT01881048|Omega-3 Fatty Acid
214448|NCT01881048|Celecoxib
214449|NCT01881048|Celebrex
214450|NCT01881048|Surgery
214451|NCT01881035|Hypertension
214452|NCT01881035|End stage renal disease
214453|NCT01881022|Breast Cancer
214454|NCT01881022|Couples
214455|NCT01881022|Sexual Dysfunction
214456|NCT01881022|Psychosexual Intervention
214457|NCT01881022|Sex Therapy
214458|NCT01881022|Online Support
214459|NCT01881022|e-health
214460|NCT01881009|Diabetes
214461|NCT01881009|Insulin
214462|NCT01881009|Closed loop
214463|NCT01881009|Nocturnal glucose control
214464|NCT01880996|Ovarian Cancer
214465|NCT01880996|Gynecological Malignancies
214466|NCT01880996|Chemotherapy
214467|NCT01880996|Tai-chi
214468|NCT01880996|Qigong
214469|NCT01880996|Fatigue
214470|NCT01880996|Quality of life
214471|NCT01880996|Sleep disturbance
214472|NCT01880983|EPP
214473|NCT01880983|Bloomer
214474|NCT01880983|Porphyria
214475|NCT01880957|bipolar disorder
214476|NCT01880957|bipolar depression
214477|NCT01880957|serotonin transporter
214478|NCT01880957|serotonin receptors
214479|NCT01880957|binding potential
214480|NCT01880957|brain imaging
214481|NCT01880957|unipolar depression
214482|NCT01880944|spine
214483|NCT01880944|trauma
214484|NCT01880944|MRI
214485|NCT01880944|contrast
214486|NCT01880918|Compression Anastomosis
214487|NCT01880905|the length of uterine ovarian ligament
214488|NCT01880879|coronary artery disease
214489|NCT01880879|PCI
214490|NCT01880879|stent
214491|NCT01880866|PAH
214492|NCT01880853|breast cancer
214493|NCT01880853|screening
214494|NCT01880853|mammography
214495|NCT01880853|ultrasound
214496|NCT01880827|GIP
214497|NCT01880827|GLP-1
214498|NCT01880827|type 2 diabetes
214499|NCT01880827|obesity
214500|NCT01880827|splanchnic blood flow
214501|NCT01880827|incretin hormones
214502|NCT01880814|Depression, child, cognitive behavioral treatment, parent training, personalized treatment
214503|NCT01880801|ITP
214504|NCT01880788|Age Related Macular Degeneration
214505|NCT01880788|Choroidal Neovascularization
214506|NCT01880788|Central Serous Chorioretinopathy
214507|NCT01880762|PET MR development and validation
214508|NCT01880723|exhaled breath condensate
214509|NCT01880723|diffusion capacity of the lungs for carbon monoxide and nitric oxide
214510|NCT01880723|albuterol
214511|NCT01880723|peripheral oxygen saturation
214512|NCT01880723|ion regulation
214513|NCT01880710|long term follow-up
214514|NCT01880710|urinary incontinence
214515|NCT01880710|pelvic organ prolapse
214516|NCT01880710|total versus subtotal hysterectomy
214517|NCT01880697|Influenza
214518|NCT01880697|adults
214519|NCT01880697|elderly
214520|NCT01880697|immunology
214521|NCT01880697|safety
214522|NCT01880684|Thermodilution
214523|NCT01880684|Blood Volume
214524|NCT01880684|Cardiac Output
214525|NCT01880684|Leg
214526|NCT01880684|Capnography
214527|NCT01880684|Blood Pressure
214528|NCT01880658|Maintenance therapy
214529|NCT01880658|Capecitabine
214530|NCT01880658|Adjuvant chemotherapy
214531|NCT01880658|Post-operation
214532|NCT01880645|Breast Cancer
214533|NCT01880645|Invasive breast cancer
214534|NCT01880645|Axillary lymph node metastases
214535|NCT01880645|Ultrasound
214536|NCT01880645|Fine needle aspiration
214537|NCT01880645|FNA
214538|NCT01880645|Lymph node surgery
214539|NCT01880645|Partial mastectomy
214540|NCT01880645|Total mastectomy
214541|NCT01880632|XELOX
214542|NCT01880632|perioperative treatment
214543|NCT01880632|locally advanced gastric adenocarcinoma
214544|NCT01880632|D2 resection
214545|NCT01880619|Double J
214546|NCT01880619|Ureteral stents
214547|NCT01880619|Symptoms
214548|NCT01880619|Alpha blockers
214549|NCT01880619|Anticholinergic
214550|NCT01880593|Ketamine
214551|NCT01880593|glutamate
214552|NCT01880593|N-methyl-D-aspartate
214553|NCT01880593|depression
214554|NCT01880593|major depressive disorder
214555|NCT01880593|treatment resistant
214556|NCT01880593|antidepressant
214557|NCT01880593|lithium
214558|NCT01880567|Lymphoma
214559|NCT01880567|Relapsed/Refractory Mantle Cell Lymphoma
214560|NCT01880567|R/R MCL
214561|NCT01880567|Ibrutinib
214562|NCT01880567|PCI-32765
214563|NCT01880567|Rituximab
214564|NCT01880567|Rituxan
214565|NCT01880567|Newly-Diagnosed Untreated Mantle Cell Lymphoma
214566|NCT01880567|MCL
214567|NCT01880554|Liver metastases
214568|NCT01880554|Colorectal primary cancer
214569|NCT01880554|Contrast-enhanced ultrasound
214570|NCT01880554|Sonovue®
214571|NCT01880541|Patients with breast cancer and breast surgery requiring
214572|NCT01880515|Lung cancer
214573|NCT01880515|BIBW 2992
214574|NCT01880515|Skin Rash
214575|NCT01880515|Tetracycline
214576|NCT01880502|Healthy, Volunteers
214577|NCT01880489|transgender women
214578|NCT01880489|sexual risk
214579|NCT01880489|substance use
214580|NCT01880489|HIV prevention
214581|NCT01880489|behavioral intervention
214582|NCT01880476|Diabetes Mellitus, Type 2
214583|NCT01880476|Comorbidity
214584|NCT01880476|Aged
214585|NCT01880476|Health Services
214586|NCT01880463|Dry eye disease
214587|NCT01880463|incidence
214588|NCT01880463|progression
214589|NCT01880411|PEK fusion protein Healthbanks
214590|NCT01880398|FIstula in ano; Bhagandar
214591|NCT01880385|bevacizumab
214592|NCT01880385|inflammatory breast cancer
214593|NCT01880385|non metastatic
214594|NCT01880385|Avastin
214595|NCT01880372|Diabetes
214596|NCT01880372|Diabetic Retinopathy
214597|NCT01880372|Retinopathy
214598|NCT01880372|Free radical
214599|NCT01880372|Retinal diseases
214600|NCT01880372|Antioxidants
214601|NCT01880372|Protective agents
214602|NCT01880372|Thioctic acid
214603|NCT01880346|Cystic Fibrosis
214604|NCT01880346|Vitamin D
214605|NCT01880346|absorption
214606|NCT01880346|vitamin Deficiency
214607|NCT01880346|fat soluble
214608|NCT01880333|Refractory epilepsy
214609|NCT01880333|dietary therapy
214610|NCT01880333|non-pharmacological therapy
214611|NCT01880333|Modified Atkin Diet
214612|NCT01880307|Crohn's disease
214613|NCT01880307|pediatric
214614|NCT01880307|infliximab
214615|NCT01880307|top-down
214616|NCT01880307|ITSKids
214617|NCT01880294|Constipation
214618|NCT01880294|Chronic constipation
214619|NCT01880294|Asia-Pacific
214620|NCT01880294|Gastroentrology
214621|NCT01880294|Asian participants
214622|NCT01880281|G protein-coupled receptor 99 (GPR99)
214623|NCT01880281|2-oxoglutarate receptor 1 (OXGR1)
214624|NCT01880281|alpha-ketoglutarate
214625|NCT01880281|urine
214626|NCT01880281|pH
214627|NCT01880281|acidosis
214628|NCT01880281|alkalosis
214629|NCT01880281|Healthy volunteers
214630|NCT01880255|Repetitive Transcranial Magnetic Stimulation
214631|NCT01880255|Schizophrenia
214632|NCT01880255|Cognition
214633|NCT01880255|Working Memory
214634|NCT01880242|International
214635|NCT01880242|Multicenter
214636|NCT01880242|Observational registry
214637|NCT01880242|Orsiro Drug Eluting Stent (DES)
214638|NCT01880242|Stenting
214639|NCT01880242|Treatment of Coronary Artery Disease
214640|NCT01880242|Coronary revascularization
214641|NCT01880242|Percutaneous Coronary Intervention (PCI)
214642|NCT01880242|STEMI
214643|NCT01880242|NSTEMI
214644|NCT01880242|Ischemia
214645|NCT01880242|Angina
214646|NCT01880242|Subgroups
214647|NCT01880242|Acute Myocardial Infarction
214648|NCT01880242|Diabetes
214649|NCT01880242|Small Vessels
214650|NCT01880242|Chronic Total Occlusion (CTO)
214651|NCT01880216|Deep vein thrombosis
214652|NCT01880216|DVT
214653|NCT01880216|Treatment
214654|NCT01880216|Low molecular weight heparin
214655|NCT01880216|Bemiparin
214656|NCT01880216|Enoxaparin
214657|NCT01880203|thyroid
214658|NCT01880203|elastography SWE
214659|NCT01880203|indeterminate cytology
214660|NCT01880164|Scoliosis
214661|NCT01880164|Kyphosis
214662|NCT01880164|Sagittal plane deformity
214663|NCT01880151|Alzheimer's disease
214664|NCT01880151|Dementia
214665|NCT01880151|Prodromal
214666|NCT01880151|EEG
214667|NCT01880151|ERP
214668|NCT01880151|Biomarkers
214669|NCT01880138|Animated cartoon, Emergence agitation
214670|NCT01880125|Tramadol
214671|NCT01880125|Acetaminophen
214672|NCT01880125|Pharmacokinetics
214673|NCT01880125|Sustained release
214674|NCT01880125|Immediate release
214675|NCT01880112|Infection
214676|NCT01880112|Cesarean delivery
214677|NCT01880112|Antibiotic prophylaxis
214678|NCT01880112|Cefazolin dosing
214679|NCT01880099|addiction
214680|NCT01880099|smoking
214681|NCT01880099|tobacco
214682|NCT01880099|cigarettes
214683|NCT01880086|Chronic pain
214684|NCT01880086|Low testosterone
214685|NCT01880086|Hypogonadism
214686|NCT01880086|Opioid analgesics
214687|NCT01880086|Narcotics
214688|NCT01880086|Opioid-induced androgen deficiency
214689|NCT01880086|OPIAD
214690|NCT01880086|Male infertility
214691|NCT01880086|Clomiphene citrate
214692|NCT01880086|Selective Estrogen Receptor Modulators
214693|NCT01880086|Testosterone replacement therapy
214694|NCT01880060|Worksite
214695|NCT01880060|weight loss
214696|NCT01880060|obesity
214697|NCT01880047|Immune Thrombocytopenia
214698|NCT01880047|ITP
214699|NCT01880047|Eltrombopag
214700|NCT01880047|Promacta
214701|NCT01880008|positron emission tomography
214702|NCT01880008|magnetic resonance imaging
214703|NCT01880008|diffusion magnetic resonance imaging
214704|NCT01880008|radionuclide imaging
214705|NCT01880008|disease management
214706|NCT01880008|radiation therapy
214707|NCT01879982|Bipolar disorder
214708|NCT01879982|subtypes
214709|NCT01879969|computer-assisted orthognathic surgery; facial asymmetry
214710|NCT01879956|Executive Functions
214711|NCT01879956|Schizophrenia
214712|NCT01879956|Occupational Therapy
214713|NCT01879943|Colorectal cancer
214714|NCT01879943|Follow up
214715|NCT01879943|Colonoscopy
214716|NCT01879943|Videocapsule
214717|NCT01879930|randomized
214718|NCT01879930|placebo-controlled
214719|NCT01879930|double-blind study
214720|NCT01879930|doxycycline
214721|NCT01879917|c-peptide
214722|NCT01879917|insulin
214723|NCT01879917|hypoglycemia
214724|NCT01879917|Newly onset
214725|NCT01879917|Diabetes
214726|NCT01879917|Type 1
214727|NCT01879917|Beta cell
214728|NCT01879917|Autoimmune
214729|NCT01879917|Glucagon
214730|NCT01879917|Meal test
214731|NCT01879904|Colorectal Neoplasms
214732|NCT01879891|Exercise Intensity
214733|NCT01879891|Metabolism
214734|NCT01879891|Insulin
214735|NCT01879878|pancreatic adenocarcinoma
214736|NCT01879878|broccoli sprouts
214737|NCT01879878|sulforaphane
214738|NCT01879878|palliative chemotherapy
214739|NCT01879878|cancer stem cells
214740|NCT01879865|PKPD
214741|NCT01879865|Dexmedetomidine
214742|NCT01879865|Auditory Stimulation
214743|NCT01879865|Cardiac Output
214744|NCT01879852|Quadriceps strength
214745|NCT01879852|Knee
214746|NCT01879852|Rehabilitation
214747|NCT01879826|Aculaser
214748|NCT01879826|Microlight ML830
214749|NCT01879826|Kidney biopsy
214750|NCT01879826|Pain
214751|NCT01879826|Anxiety
214752|NCT01879826|Sedation
214753|NCT01879813|Memory
214754|NCT01879813|Attention
214755|NCT01879787|Stroke
214756|NCT01879787|transcranial direct current stimulation
214757|NCT01879787|constraint-induced movement therapy
214758|NCT01879787|mental practice
214759|NCT01879774|Hyponatremia
214760|NCT01879761|Immunosuppressed
214761|NCT01879761|Sepsis
214762|NCT01879761|Staphylococcus Aureus
214763|NCT01879761|Bacteremia
214764|NCT01879761|HLA-DR
214765|NCT01879748|Parkinson's disease
214766|NCT01879748|Azilect
214767|NCT01879748|rasagiline mesylate
214768|NCT01879722|Drug therapy
214769|NCT01879709|schizophrenia
214770|NCT01879709|Cognition
214771|NCT01879709|Independent living skills
214772|NCT01879683|Hunner's lesion
214773|NCT01879644|ADHD
214774|NCT01879644|Neurofeedback
214775|NCT01879644|Self-Management
214776|NCT01879644|Parental Psychoeducation
214777|NCT01879644|Social Support
214778|NCT01879631|radial keratotomy; keratoconus; optical rehabilitation
214779|NCT01879618|Fragmin
214780|NCT01879618|dalteparin
214781|NCT01879618|hemodialysis
214782|NCT01879618|anticoagulation
214783|NCT01879618|Renal Failure
214784|NCT01879605|Spinal surgery
214785|NCT01879605|Bowel preparation
214786|NCT01879605|Ileus
214787|NCT01879605|Constipation
214788|NCT01879605|Well-being
214789|NCT01879592|Sickle cell disease
214790|NCT01879592|Asthma
214791|NCT01879592|Metabolomics
214792|NCT01879592|Gene expression
214793|NCT01879579|Insulin
214794|NCT01879579|Telemedicine
214795|NCT01879553|Influenza,
214796|NCT01879553|Adults,
214797|NCT01879553|Elderly,
214798|NCT01879553|Immunology,
214799|NCT01879553|Safety
214800|NCT01879540|Influenza,
214801|NCT01879540|Elderly,
214802|NCT01879540|Immunology,
214803|NCT01879540|Safety
214804|NCT01879514|IgA nephropathy
214805|NCT01879514|Therapy of Chinese medicine
214806|NCT01879501|Low vision
214807|NCT01879501|Self management
214808|NCT01879501|Randomized controlled trial
214809|NCT01879501|Quality of life
214810|NCT01879501|Self efficacy
214811|NCT01879501|Effectiveness
214812|NCT01879501|Chronic eye diseases management
214813|NCT01879488|Aerosol
214814|NCT01879488|Lung deposition
214815|NCT01879488|Mechanical ventilation
214816|NCT01879462|chronic hepatitis C (CHC)
214817|NCT01879462|Hepatitis C virus (HCV)
214818|NCT01879462|NS5B
214819|NCT01879462|pharmacokinetics
214820|NCT01879462|GSK2878175
214821|NCT01879462|safety
214822|NCT01879462|FTIH
214823|NCT01879462|healthy subjects
214824|NCT01879449|Spasticity
214825|NCT01879449|Veterans
214826|NCT01879449|Prevalence
214827|NCT01879436|Pregnancy, Placenta, Cancer
214828|NCT01879410|GSK573719
214829|NCT01879410|lung function
214830|NCT01879410|salmeterol (SAL)
214831|NCT01879410|umeclidinium bromide (UMEC)
214832|NCT01879410|GW642444
214833|NCT01879410|Chronic obstructive pulmonary disease
214834|NCT01879410|Novel Dry Powder Inhaler (NDPI)
214835|NCT01879410|fluticasone propionate (FP)
214836|NCT01879410|vilanterol (VI)
214837|NCT01879397|atherosclerosis
214838|NCT01879397|arteriosclerosis
214839|NCT01879397|carotid stenosis
214840|NCT01879397|carotid endarterectomy
214841|NCT01879397|Stroke
214842|NCT01879384|microdialysis
214843|NCT01879384|bone free flap
214844|NCT01879384|head and neck
214845|NCT01879384|monitoring free flap
214846|NCT01879384|reconstructive surgery
214847|NCT01879358|Drug-eluting stent
214848|NCT01879358|Safety
214849|NCT01879358|Efficacy
214850|NCT01879345|Anticonvulsant
214851|NCT01879332|Anticonvulsant
214852|NCT01879319|LDL-C, triglycerides, high cholesterol
214853|NCT01879293|Metformin
214854|NCT01879293|Left ventricular mass
214855|NCT01879293|Endothelial dysfunction
214856|NCT01879293|cardiac magnetic resonance
214857|NCT01879293|aortic pulse wave
214858|NCT01879280|pterional craniotomy
214859|NCT01879280|osteoplastic craniotomy
214860|NCT01879280|temporalis
214861|NCT01879280|minimally-invasive
214862|NCT01879254|obsessive compulsive disorder (OCD)
214863|NCT01879254|deep brain stimulation (DBS)
214864|NCT01879254|psychosurgery
214865|NCT01879254|long-term follow-up
214866|NCT01879241|amyotrophic lateral sclerosis
214867|NCT01879241|survival time
214868|NCT01879241|ALS functioning Rating Scale
214869|NCT01879241|quality of life
214870|NCT01879241|survival
214871|NCT01879228|Cystic Fibrosis
214872|NCT01879228|Diabetes
214873|NCT01879228|Pancreatic Insufficiency
214874|NCT01879202|multiple sclerosis
214875|NCT01879202|fatigue
214876|NCT01879202|fatigue severity scale
214877|NCT01879202|fatigue impact scale
214878|NCT01879202|quality of life
214879|NCT01879163|Vaccine
214880|NCT01879163|Immunogenicity
214881|NCT01879137|Copeptin
214882|NCT01879137|Arginin stimulation test
214883|NCT01879111|Depressive episode
214884|NCT01879111|Chronic ischaemic heart disease
214885|NCT01879111|Hypertension
214886|NCT01879098|probiotics
214887|NCT01879098|inflammation
214888|NCT01879098|bile
214889|NCT01879098|hunger
214890|NCT01879098|satiety
214891|NCT01879085|advanced
214892|NCT01879085|metastatic
214893|NCT01879085|unresectable
214894|NCT01879085|soft
214895|NCT01879085|tissue
214896|NCT01879085|sarcomas
214897|NCT01879072|Biomarkers
214898|NCT01879072|Hematopoietic stem cell transplant
214899|NCT01879059|insulin resistance
214900|NCT01879059|exercise
214901|NCT01879059|continuous glucose monitoring
214902|NCT01879059|blood flow
214903|NCT01879059|endothelial function
214904|NCT01879046|Mesenchymal stem cells
214905|NCT01879046|articular cartilage
214906|NCT01879046|tissue engineering
214907|NCT01879046|immunomodulation
214908|NCT01879046|osteo-arthritis
214909|NCT01879033|Obesity
214910|NCT01879033|endothelial function
214911|NCT01879033|Rh-PAT
214912|NCT01879033|adipocytokines
214913|NCT01879020|MT-8995
214914|NCT01879020|Dyslipidemia
214915|NCT01879020|Cholesteryl ester transfer proteins
214916|NCT01878994|Overweight
214917|NCT01878994|Obesity
214918|NCT01878994|Children
214919|NCT01878994|Behaviour
214920|NCT01878994|Physical Activity
214921|NCT01878994|Nutrition
214922|NCT01878981|Catheter Ablation versus Drug Therapy in AF in China
214923|NCT01878955|Antimullarian hormone(AMH)
214924|NCT01878955|Polycystic Ovary
214925|NCT01878955|Multicystic Ovary
214926|NCT01878942|LSD
214927|NCT01878942|Pharmacology
214928|NCT01878942|Pharmacokinetics
214929|NCT01878942|Pharmacodynamics
214930|NCT01878942|Mechanism of action
214931|NCT01878942|Psychedelic
214932|NCT01878942|Serotonin
214933|NCT01878942|Prepulse inhibition
214934|NCT01878942|LSD-induced neuroendocrine effects
214935|NCT01878942|Long-term psychological effects
214936|NCT01878929|pollen
214937|NCT01878929|allergen immunotherapy
214938|NCT01878929|subcutaneous allergen immunotherapy
214939|NCT01878929|SCIT
214940|NCT01878916|the incidence of thrombosis,
214941|NCT01878916|the effect of Hcy on thrombosis formation,
214942|NCT01878916|the relation between Hcy and plasma vitamin levels,
214943|NCT01878916|to compare these results with the control group
214944|NCT01878890|Solid tumors (other than pancreas)
214945|NCT01878877|Chronic pain
214946|NCT01878877|neuropathic pain
214947|NCT01878864|Pain, Discomfort, Periodontitis, Scaling and Root Planning, Visual Analogue Scale, McGills Pain Questionnaire
214948|NCT01878825|Immunogenicity
214949|NCT01878825|Trivalent
214950|NCT01878825|Safety
214951|NCT01878825|Adults
214952|NCT01878825|Elderly
214953|NCT01878825|Influenza
214954|NCT01878812|Immunogenicity
214955|NCT01878812|Influenza
214956|NCT01878812|Adults
214957|NCT01878812|Safety
214958|NCT01878812|Elderly
214959|NCT01878799|Direct Acting Antiviral
214960|NCT01878799|Treatment Naive
214961|NCT01878799|Interferon Sparing
214962|NCT01878799|Ribavirin Sparing
214963|NCT01878786|kidney failure
214964|NCT01878773|Prostate Cancer
214965|NCT01878773|MRI scan
214966|NCT01878773|External beam radiotherapy
214967|NCT01878760|APRICOT
214968|NCT01878760|Anaesthesia
214969|NCT01878760|Children
214970|NCT01878760|kids
214971|NCT01878760|Paediatric Anaesthesia
214972|NCT01878760|Observational Trial
214973|NCT01878760|epidemiology
214974|NCT01878760|severe critical events in
214975|NCT01878760|European Society of Anaesthesiology
214976|NCT01878760|Europe
214977|NCT01878747|Pediatric
214978|NCT01878747|Pain
214979|NCT01878747|Postoperative
214980|NCT01878747|General Anesthesia
214981|NCT01878747|Anesthesia Recovery Period
214982|NCT01878747|Infant Behavior
214983|NCT01878747|Adolescent Behavior
214984|NCT01878747|Patient Satisfaction
214985|NCT01878721|PET/CT
214986|NCT01878721|infection
214987|NCT01878721|vasculitis
214988|NCT01878708|T-Cell Lymphoma
214989|NCT01878708|Relapsed T-Cell Lymphoma
214990|NCT01878708|Refractory T-Cell Lymphoma
214991|NCT01878708|Oncaspar®
214992|NCT01878708|PEG-L-asparaginase and dexamethasone
214993|NCT01878695|Integrative Medicine
214994|NCT01878695|Breast Cancer
214995|NCT01878695|Stage 0
214996|NCT01878695|Stage 1
214997|NCT01878669|n-acetyl cysteine
214998|NCT01878669|percutaneous coronary intervention
214999|NCT01878643|aerosolized antibiotic
215000|NCT01878643|ventilator-associated pneumonia
215001|NCT01878643|bacterial resistance
215002|NCT01878643|ventilator -associated tracheobronchitis
215003|NCT01878643|clinical pulmonary infection score
215004|NCT01878630|Chronic Heart Failure
215005|NCT01878630|CHF
215006|NCT01878617|SJMB12
215007|NCT01878617|Brain Cancer
215008|NCT01878617|Brain Tumors in Children
215009|NCT01878617|Cisplatin
215010|NCT01878617|Cyclophosphamide
215011|NCT01878617|Embryonal Tumors of CNS
215012|NCT01878617|GDC-0449
215013|NCT01878617|Gemcitabine
215014|NCT01878617|Hedgehog Pathway Inhibitor
215015|NCT01878617|Infratentorial
215016|NCT01878617|Mass in Brain
215017|NCT01878617|Medulloblastoma
215018|NCT01878617|Medulloblastoma Brain Tumor
215019|NCT01878617|Medulloblastoma Tumor
215020|NCT01878617|Molecular
215021|NCT01878617|Neuroectodermal Tumor, Primitive
215022|NCT01878617|Newly Diagnosed Childhood Medulloblastoma
215023|NCT01878617|Non-SHH Non-WNT
215024|NCT01878617|Pediatric Brain Tumor
215025|NCT01878617|Pemetrexed
215026|NCT01878617|Posterior Fossa Tumor
215027|NCT01878617|Proton Beam Therapy
215028|NCT01878617|Radiation Therapy
215029|NCT01878617|Rare Brain Tumor
215030|NCT01878617|Risk
215031|NCT01878617|SHH
215032|NCT01878617|Sonic Hedgehog Pathway
215033|NCT01878617|St Jude Medullo
215034|NCT01878617|St. Jude Brain Tumor Studies
215035|NCT01878617|St. Jude Medullo
215036|NCT01878617|St. Jude Studies
215037|NCT01878617|St. Jude Treatment
215038|NCT01878617|Treatment for Brain Tumors in Children
215039|NCT01878617|Untreated Childhood Medulloblastoma
215040|NCT01878617|Vincristine
215041|NCT01878617|Vismodegib
215042|NCT01878617|WNT
215043|NCT01878591|labour
215044|NCT01878591|dystocia
215045|NCT01878591|operative delivery
215046|NCT01878591|vacuum
215047|NCT01878591|ultrasound
215048|NCT01878578|Anticonvulsant, BIA 2-093
215049|NCT01878565|HBIg
215050|NCT01878565|GM-CSF
215051|NCT01878565|HBV vaccine
215052|NCT01878565|immune regulatory therapy
215053|NCT01878526|gastroesophageal reflux disease
215054|NCT01878526|heart burn
215055|NCT01878526|regurgitation
215056|NCT01878526|systemic sclerosis
215057|NCT01878526|scleroderma
215058|NCT01878526|proton pump inhibitor
215059|NCT01878526|alginic acid
215060|NCT01878526|omeprazole
215061|NCT01878526|prokinetic
215062|NCT01878500|Bladder exstrophy epispadias complex
215063|NCT01878500|Pelvic floor musculature
215064|NCT01878500|Intraoperative stereotactic imaging
215065|NCT01878487|Acute MI
215066|NCT01878487|Primary percutaneous coronary intervention
215067|NCT01878487|thrombus aspiration, IVUS
215068|NCT01878474|MT-8995
215069|NCT01878474|Dyslipidemia
215070|NCT01878474|Cholesteryl ester transfer proteins
215071|NCT01878435|Short Message System
215072|NCT01878435|SMS reminder
215073|NCT01878435|mobile phone
215074|NCT01878435|cell phone
215075|NCT01878435|vaccination
215076|NCT01878435|immunization
215077|NCT01878435|mHealth
215078|NCT01878409|Sexuality
215079|NCT01878409|Parkinson Disease
215080|NCT01878409|BISF
215081|NCT01878409|IIEF
215082|NCT01878409|FSFI
215083|NCT01878396|Circulating Melanoma cells in metastatic melanoma
215084|NCT01878383|(HSV)
215085|NCT01878357|MST
215086|NCT01878357|Malaria
215087|NCT01878357|Indonesia
215088|NCT01878357|Transmission
215089|NCT01878305|hepatic encephalopathy
215090|NCT01878305|brain waves
215091|NCT01878305|electroencephalogram
215092|NCT01878305|transcranial Doppler ultrasonography
215093|NCT01878305|physiological monitoring
215094|NCT01878305|intensive care
215095|NCT01878266|Diffuse Intrinsic Pontine Glioma (DIPG)
215096|NCT01878266|Hypofractionated Radiotherapy
215097|NCT01878266|Radiotherapy
215098|NCT01878266|Median survival
215099|NCT01878240|Vascular surgery
215100|NCT01878240|Abdominal Aortic aneurysm
215101|NCT01878240|endovascular
215102|NCT01878214|Health communication
215103|NCT01878214|Smoking cessation
215104|NCT01878214|Health behavior
215105|NCT01878214|Construction industry
215106|NCT01878214|Audience segmentation
215107|NCT01878201|Fimasartan
215108|NCT01878201|24 hours ABP monitoring(ABPM)
215109|NCT01878201|antihypertension
215110|NCT01878175|Arthroplasty, Replacement, Hip
215111|NCT01878175|Veterans
215112|NCT01878175|Exercise
215113|NCT01878162|Prevention
215114|NCT01878162|Wellness
215115|NCT01878162|Occupation
215116|NCT01878162|Work
215117|NCT01878162|Law Enforcement
215118|NCT01878162|Exercise
215119|NCT01878123|Arthritis
215120|NCT01878123|Rheumatoid Arthritis
215121|NCT01878123|Joint Diseases
215122|NCT01878123|Musculoskeletal Diseases
215123|NCT01878123|Rheumatic Diseases
215124|NCT01878123|Connective Tissue Diseases
215125|NCT01878123|Autoimmune Diseases
215126|NCT01878123|Immune System Diseases
215127|NCT01878123|Antirheumatic agents
215128|NCT01878110|Trichotillomania
215129|NCT01878110|Hair pulling
215130|NCT01878110|Behavior therapy
215131|NCT01878084|Tissue regeneration
215132|NCT01878084|sol gel bioglass
215133|NCT01878084|alveolar ridge preservation
215134|NCT01878084|children
215135|NCT01878084|Egyptian
215136|NCT01878084|class II orthodontic cases
215137|NCT01878058|Prostate cancer
215138|NCT01878058|Brachytherapy
215139|NCT01878058|Seed implant
215140|NCT01878045|American Indians
215141|NCT01878045|Diabetic Nephropathy
215142|NCT01878045|Kidney Biopsy
215143|NCT01878045|Type 2 Diabetes Mellitus
215144|NCT01878045|Retinopathy
215145|NCT01878032|Retinal Disease
215146|NCT01878032|Inherited Retinal Degeneration
215147|NCT01878019|Pain
215148|NCT01878019|Placebo
215149|NCT01878019|Opiate Antagonist
215150|NCT01878006|Opiate Receptor
215151|NCT01878006|Genotype
215152|NCT01878006|PET Imaging
215153|NCT01877993|coronary artery spasm
215154|NCT01877993|pathophysiology
215155|NCT01877993|atrioventricular block
215156|NCT01877993|blood pressure
215157|NCT01877993|autonomic nervous function
215158|NCT01877954|hydrofluoroalkane beclomethasone
215159|NCT01877954|fluticasone
215160|NCT01877954|paediatrics
215161|NCT01877954|real-life
215162|NCT01877954|observational
215163|NCT01877954|primary care
215164|NCT01877941|cardiac output
215165|NCT01877941|pulse oximetry
215166|NCT01877941|hemodynamics
215167|NCT01877928|Obstructive sleep apnea, CPAP, Boussignac
215168|NCT01877915|Heart Failure
215169|NCT01877915|Coronary Artery Disease
215170|NCT01877915|Stroke
215171|NCT01877915|Myocardial Infarction
215172|NCT01877915|Anticoagulation
215173|NCT01877889|Healthy
215174|NCT01877889|Canagliflozin
215175|NCT01877889|INVOKANA
215176|NCT01877889|Dapagliflozin
215177|NCT01877889|FORXIGA
215178|NCT01877889|Pharmacodynamics
215179|NCT01877863|intradialytic exercise
215180|NCT01877863|hemodialysis
215181|NCT01877837|Stem cell transplant
215182|NCT01877837|Sickle cell
215183|NCT01877837|Stem cell transplantation
215184|NCT01877837|Related
215185|NCT01877837|Unrelated
215186|NCT01877824|Surgery
215187|NCT01877824|Training
215188|NCT01877811|Lung Cancer
215189|NCT01877811|RET Inhibitor
215190|NCT01877811|Solid Tumors
215191|NCT01877811|RET mutations or rearrangements
215192|NCT01877811|BRAF mutations or rearrangements
215193|NCT01877811|Squamous NSCLC
215194|NCT01877811|KRAS mutation
215195|NCT01877811|Other Lung adenocarcinomas
215196|NCT01877772|cuff repair
215197|NCT01877772|arthroscopic
215198|NCT01877772|Trephination
215199|NCT01877772|Bone
215200|NCT01877772|cuff tear
215201|NCT01877759|Stem cell ,liver cirrhosis
215202|NCT01877746|ICM
215203|NCT01877746|myocarditis
215204|NCT01877746|cardiomyopathy
215205|NCT01877746|endomyocardial biopsy
215206|NCT01877746|immunosuppression
215207|NCT01877733|Resistance training
215208|NCT01877720|Preterm infant less than 32 weeks of gestation age
215209|NCT01877720|intubated more than 48 hours after birth
215210|NCT01877720|postextubation
215211|NCT01877694|pink eye
215212|NCT01877668|psoriatic arthritis
215213|NCT01877668|radiographic changes
215214|NCT01877668|active comparator
215215|NCT01877668|tofacitinib
215216|NCT01877655|ASP0113
215217|NCT01877655|Cytomegalovirus (CMV)
215218|NCT01877655|Hematopoietic Cell Transplant (HCT)
215219|NCT01877642|ADASUVE
215220|NCT01877642|inhaled loxapine
215221|NCT01877642|drug drug interaction
215222|NCT01877642|lorazepam
215223|NCT01877642|acute treatment of agitation
215224|NCT01877629|ACT-129968
215225|NCT01877629|Pharmacokinetics
215226|NCT01877629|Safety
215227|NCT01877629|Tolerability
215228|NCT01877616|sleep disorders
215229|NCT01877616|insomnia
215230|NCT01877616|hypersomnia
215231|NCT01877616|sleep-disordered breathing
215232|NCT01877616|cardiovascular health
215233|NCT01877616|stroke
215234|NCT01877616|ischemic heart disease
215235|NCT01877616|Atahualpa
215236|NCT01877551|HIV
215237|NCT01877551|Protease inhibitor
215238|NCT01877551|insulin resistance
215239|NCT01877551|Tauroursodeoxycholic acid
215240|NCT01877525|colorectal polyps
215241|NCT01877525|resect and discard
215242|NCT01877525|endoscopic prediction
215243|NCT01877525|histological diagnosis
215244|NCT01877525|narrow band imaging
215245|NCT01877499|Hemodiafiltration
215246|NCT01877499|Convection volume
215247|NCT01877499|Filtration fraction
215248|NCT01877499|Blood flow
215249|NCT01877499|Treatment time
215250|NCT01877486|atrial fibrillation
215251|NCT01877486|cryoballoon ablation
215252|NCT01877486|persistent AF
215253|NCT01877486|paroxysmal AF
215254|NCT01877486|dofetilide
215255|NCT01877473|atrial fibrillation
215256|NCT01877473|persistent AF
215257|NCT01877473|catheter ablation
215258|NCT01877473|duration of 7 days to one year
215259|NCT01877473|with symptoms and failure of at least one antiarrhythmic drug
215260|NCT01877460|sodium alginate
215261|NCT01877460|chocolate milk
215262|NCT01877460|satiety
215263|NCT01877460|energy intake
215264|NCT01877460|glycemia
215265|NCT01877460|insulinemia
215266|NCT01877447|tDCS
215267|NCT01877447|Brain stimulation
215268|NCT01877447|depressive disorder
215269|NCT01877434|Reversed shoulder arthroplasty
215270|NCT01877434|Treatment
215271|NCT01877434|TESS
215272|NCT01877421|Reducing plaque
215273|NCT01877421|Reducing gingivitis
215274|NCT01877421|safety
215275|NCT01877421|proof of concept
215276|NCT01877421|antiplaque chewing gum
215277|NCT01877408|disposable circumcision device
215278|NCT01877408|Tissue adhesive
215279|NCT01877408|Open surgical circumcision
215280|NCT01877408|Minimally-invasive circumcision
215281|NCT01877395|Rabies
215282|NCT01877395|Purified Vero Rabies Vaccine - Serum Free
215283|NCT01877395|Human Diploid Cell Vaccine
215284|NCT01877395|Imovax® Rabies
215285|NCT01877356|ambulatory surgery
215286|NCT01877356|spinal anesthesia
215287|NCT01877356|micturition
215288|NCT01877356|bladder retention
215289|NCT01877356|unilateral block
215290|NCT01877356|prilocaine hyperbaric
215291|NCT01877356|prilocaine plain
215292|NCT01877356|local anaesthetic dose
215293|NCT01877343|cardiac functional health classification
215294|NCT01877343|Congenital heart failure
215295|NCT01877343|chronic heart failure
215296|NCT01877330|shoulder arthroscopy
215297|NCT01877330|ultrasound guided nerve block
215298|NCT01877330|interscalene nerve block
215299|NCT01877317|Audiology
215300|NCT01877317|hearing loss
215301|NCT01877317|hearing healthcare
215302|NCT01877317|mobile app
215303|NCT01877317|hearing aid fitting
215304|NCT01877317|audiometry
215305|NCT01877317|audiogram
215306|NCT01877291|smoking, nasal lavage, exhaled breath condensate, mucociliary transport
215307|NCT01877278|Osteoarthritis
215308|NCT01877278|Pulsed electromagnetic fields
215309|NCT01877278|Device
215310|NCT01877278|Pain
215311|NCT01877278|Pressure algometry
215312|NCT01877252|critical limb ischemia
215313|NCT01877252|endovascular treatment
215314|NCT01877252|open surgical repair
215315|NCT01877252|diabetic foot
215316|NCT01877226|Healthy
215317|NCT01877226|Tapentadol
215318|NCT01877213|coaching
215319|NCT01877213|therapeutic education
215320|NCT01877213|hospital admission
215321|NCT01877213|quality improvement strategies
215322|NCT01877213|management program
215323|NCT01877213|nurse follow up
215324|NCT01877213|discharge planning
215325|NCT01877213|rehospitalization
215326|NCT01877187|Primary liver cancer
215327|NCT01877187|Metastatic liver cancer
215328|NCT01877174|Internal Carotid Stenosis
215329|NCT01877174|Reverse Flow
215330|NCT01877174|Carotid stenting
215331|NCT01877174|MICHI(TM) NPS+f
215332|NCT01877148|Parkinson, rehabilitation, tDCS
215333|NCT01877135|anal carcinoma
215334|NCT01877135|AIN3
215335|NCT01877135|cohort study
215336|NCT01877109|Lymphoma
215337|NCT01877109|Prognosis
215338|NCT01877109|Biomarker
215339|NCT01877109|Quality of life
215340|NCT01877096|Motivational Interviewing
215341|NCT01877096|Screening Colonoscopy
215342|NCT01877096|Cancer Prevention
215343|NCT01877083|KIF5B-RET-Positive Adenocarcinoma
215344|NCT01877083|Lung Cancer
215345|NCT01877083|NSCLC
215346|NCT01877083|Non-Small Cell Lung Cancer
215347|NCT01877070|assessments
215348|NCT01877070|13-076
215349|NCT01877057|Pea protein
215350|NCT01877057|Satiety hormone
215351|NCT01877057|Ussing Chamber
215352|NCT01877044|Prebiotics
215353|NCT01877044|Intestinal permeability
215354|NCT01877044|Gut barrier function
215355|NCT01877044|Immunity
215356|NCT01877031|central line
215357|NCT01877031|ultrasound guided central line insertion
215358|NCT01877031|virtual reality
215359|NCT01877031|augmented reality
215360|NCT01877018|Comparative Effectiveness Research
215361|NCT01877018|Reminder Systems
215362|NCT01877018|Patient Participation
215363|NCT01877018|Primary Health Care
215364|NCT01877018|Early Detection of Cancer
215365|NCT01877018|Colorectal Neoplasms
215366|NCT01877005|Multicenter, single arm and opened label phase II study
215367|NCT01876992|diabetes
215368|NCT01876992|pediatrics
215369|NCT01876992|obesity
215370|NCT01876992|healthy volunteers
215371|NCT01876992|metformin
215372|NCT01876992|nutrition
215373|NCT01876992|healthy controls
215374|NCT01876992|bmi
215375|NCT01876966|HIV
215376|NCT01876966|pharmacokinetic interaction
215377|NCT01876966|healthy HIV-negative person
215378|NCT01876940|supraglottic airway
215379|NCT01876940|children
215380|NCT01876940|tracheal intubation
215381|NCT01876940|fiberoptic bronchoscopy
215382|NCT01876927|Locally
215383|NCT01876927|Advanced
215384|NCT01876927|Resectable
215385|NCT01876927|Gastric Cancer
215386|NCT01876914|Diabetes
215387|NCT01876914|Edema
215388|NCT01876914|DME
215389|NCT01876914|OCT
215390|NCT01876901|Rectal cancer
215391|NCT01876901|Coloanal anastomosis
215392|NCT01876901|Phase 2 clinical trial
215393|NCT01876888|patient satisfaction
215394|NCT01876888|physical therapy
215395|NCT01876888|MedRisk instrument
215396|NCT01876875|psoriasis
215397|NCT01876875|obesity
215398|NCT01876862|HIV-1
215399|NCT01876862|chronic infection
215400|NCT01876862|cure
215401|NCT01876862|remission
215402|NCT01876849|diabetes
215403|NCT01876849|exenatide
215404|NCT01876849|Byetta
215405|NCT01876849|Amylin
215406|NCT01876849|Lilly
215407|NCT01876836|i-gel
215408|NCT01876836|C-LMA
215409|NCT01876836|gastroeosephageal reflux
215410|NCT01876836|sore troat
215411|NCT01876823|Memory Decline
215412|NCT01876823|Depression
215413|NCT01876823|Elderly
215414|NCT01876823|Antidepressants
215415|NCT01876823|Treatment
215416|NCT01876823|memantine
215417|NCT01876810|Gemfibrozil
215418|NCT01876810|Nicotine Dependence
215419|NCT01876810|Smoking
215420|NCT01876810|Cigarettes
215421|NCT01876784|vandetanib, AZD 6474, Differentiated Thyroid Cancer
215422|NCT01876771|177lutetium-DOTA(O)Tyr3)octreotate
215423|NCT01876758|ECT
215424|NCT01876758|Memory Training
215425|NCT01876758|Cognitive Remediation
215426|NCT01876758|Electroconvulsive Therapy
215427|NCT01876758|Treatment Resistant Depression
215428|NCT01876758|Depression
215429|NCT01876758|Geriatric Depression
215430|NCT01876758|Memory Loss
215431|NCT01876758|Cognitive Training
215432|NCT01876732|hemodialysis
215433|NCT01876732|viatmin B12 deficiency
215434|NCT01876732|Epogen
215435|NCT01876719|ADHD
215436|NCT01876719|AR08
215437|NCT01876719|adrenergic receptor agonists
215438|NCT01876719|randomized, placebo-controlled clinical trial
215439|NCT01876706|UroLift System
215440|NCT01876680|chronic
215441|NCT01876680|neck
215442|NCT01876680|shoulder
215443|NCT01876680|exercise
215444|NCT01876654|Total Knee Replacement
215445|NCT01876654|Patient specific instrumentation
215446|NCT01876641|Metastatic melanoma
215447|NCT01876641|melanoma
215448|NCT01876641|BRAF-mutated Metastatic Melanoma
215449|NCT01876641|V600EBRAF-mutated metastatic melanoma
215450|NCT01876641|Decitabine
215451|NCT01876641|Vemurafenib
215452|NCT01876628|Clindamycin
215453|NCT01876628|Cellulitis
215454|NCT01876628|Flucloxacillin
215455|NCT01876628|Group A streptococcus
215456|NCT01876628|Staphylococcus aureus
215457|NCT01876615|safety/tolerability and pharmacokinetics/pharmacodynamics
215458|NCT01876602|adolescents
215459|NCT01876602|exercise
215460|NCT01876602|fitness
215461|NCT01876602|school-based
215462|NCT01876589|Coronary Artery Disease (CAD)
215463|NCT01876589|Invasive coronary angiography (ICA)
215464|NCT01876589|Positron Emission Tomography (PET)
215465|NCT01876576|colonoscopy
215466|NCT01876563|thioredoxin
215467|NCT01876563|TBP-2
215468|NCT01876563|thioredoxin reductase
215469|NCT01876563|vitamin D
215470|NCT01876563|DIABETES
215471|NCT01876550|Mupirocin Calcium Cream 2%
215472|NCT01876550|Bactroban® Cream
215473|NCT01876550|Secondarily infected traumatic skin lesions
215474|NCT01876524|Substance Use Disorder
215475|NCT01876524|Attention Deficit Disorder With Hyperactivity
215476|NCT01876524|Schizophrenia
215477|NCT01876524|Bipolar disorder
215478|NCT01876524|Personality disorder
215479|NCT01876511|MSI
215480|NCT01876511|MSS
215481|NCT01876511|MLH 1
215482|NCT01876511|MSH 2
215483|NCT01876511|MSH 6
215484|NCT01876511|PMS2
215485|NCT01876511|BRAF pV600E
215486|NCT01876511|TGFBR2
215487|NCT01876485|Diabetes Mellitus
215488|NCT01876485|health literacy
215489|NCT01876485|patient activation
215490|NCT01876485|goals of care
215491|NCT01876394|Healthy
215492|NCT01876394|Arterial Stiffness
215493|NCT01876394|Blood Pressure
215494|NCT01876394|Blood Glucose
215495|NCT01876394|Vascular Function
215496|NCT01876368|hypertension,
215497|NCT01876368|LCZ696,
215498|NCT01876368|olmesartan
215499|NCT01876355|Delirium, clonidine, ICU, sedation
215500|NCT01876342|sports hernia
215501|NCT01876342|sportsman's hernia
215502|NCT01876342|chronic groin pain
215503|NCT01876342|open minimal repair
215504|NCT01876342|totally extraperitoneal endoscopic technique
215505|NCT01876329|Rheumatoid Arthritis
215506|NCT01876329|Vitamin B12 deficiency
215507|NCT01876329|Autoimmune Thyroid Disease
215508|NCT01876329|Autoantibodies
215509|NCT01876316|Moxifloxacin
215510|NCT01876316|QT interval prolongation
215511|NCT01876316|Korean
215512|NCT01876316|Japanese
215513|NCT01876290|Anesthesiology
215514|NCT01876290|Complications
215515|NCT01876290|Closed-loop
215516|NCT01876277|Cancer
215517|NCT01876277|Body image
215518|NCT01876277|Adolescent
215519|NCT01876264|Colorectal surgery
215520|NCT01876264|Colonoscopy
215521|NCT01876264|Randomized controlled trial
215522|NCT01876251|Breast cancer metastatic
215523|NCT01876251|docetaxel
215524|NCT01876251|PF-03084014
215525|NCT01876238|Breast Cancer
215526|NCT01876238|Patient-Doctor Communication
215527|NCT01876238|Supportive Care
215528|NCT01876225|cervical biopsy
215529|NCT01876225|forced cough
215530|NCT01876225|pain
215531|NCT01876225|VAS scale
215532|NCT01876212|melanoma
215533|NCT01876212|metastatic
215534|NCT01876212|vaccine
215535|NCT01876212|BRAF
215536|NCT01876199|HIV-1
215537|NCT01876199|acute
215538|NCT01876199|diagnosis
215539|NCT01876199|pharmacies
215540|NCT01876199|healthcare facilities
215541|NCT01876186|antimuscarinic treatment
215542|NCT01876186|urodynamic studies
215543|NCT01876186|nerve growth factor
215544|NCT01876173|Sudden cardiac death
215545|NCT01876173|implantable cardioverter defibrillator
215546|NCT01876173|decision aid
215547|NCT01876147|Low vision
215548|NCT01876147|Vision testing
215549|NCT01876147|Retinitis Pigmentosa
215550|NCT01876147|AMD
215551|NCT01876147|Visual acuity
215552|NCT01876147|Poor vision
215553|NCT01876147|Quantification
215554|NCT01876134|Cardiac surgery
215555|NCT01876134|Acute kidney injury
215556|NCT01876134|Cyr-61
215557|NCT01876134|Pulse wave analysis
215558|NCT01876121|NSAIDs
215559|NCT01876121|Acute pain
215560|NCT01876108|Steatohepatitis
215561|NCT01876108|Helicobacter pylori
215562|NCT01876108|Alanine aminotransferase
215563|NCT01876108|Aspartate aminotransferase
215564|NCT01876108|Fatty Liver
215565|NCT01876108|Liver Diseases
215566|NCT01876108|Digestive System Diseases
215567|NCT01876082|Desmoids tumors
215568|NCT01876082|Pazopanib
215569|NCT01876082|Phase 2 clinical trial
215570|NCT01876082|Cross over
215571|NCT01876056|Psychosis
215572|NCT01876056|Culture
215573|NCT01876056|CBT
215574|NCT01876030|Functional electrical stimulation (FES)
215575|NCT01876030|Sub acute stroke
215576|NCT01876030|Gait analysis
215577|NCT01876017|CRF
215578|NCT01876017|STEM CELL
215579|NCT01876017|CKD
215580|NCT01876004|ectopic pregnancy
215581|NCT01876004|methotrexate
215582|NCT01876004|human chorionic gonadotropin beta subunit
215583|NCT01876004|expectant management
215584|NCT01875978|Phytosterols
215585|NCT01875978|Endothelial progenitor cells
215586|NCT01875952|Latent tuberculosis infection
215587|NCT01875952|Human immunodeficiency virus (HIV)
215588|NCT01875952|Treatment
215589|NCT01875952|Isoniazid
215590|NCT01875939|healthy volunteers
215591|NCT01875913|Curiosity
215592|NCT01875913|Intention
215593|NCT01875913|Follow Through
215594|NCT01875900|neonatal resuscitation
215595|NCT01875900|video-assisted learning
215596|NCT01875900|self-directed training
215597|NCT01875900|simulation
215598|NCT01875900|simulation-based training
215599|NCT01875900|simulation-based medical education
215600|NCT01875900|objective structured clinical examination
215601|NCT01875874|liver failure
215602|NCT01875874|acute liver failure
215603|NCT01875874|fulminant hepatic failure
215604|NCT01875874|primary graft non-function
215605|NCT01875874|surgically-induced liver failure
215606|NCT01875874|ELAD
215607|NCT01875874|ALF
215608|NCT01875874|FHF
215609|NCT01875874|PNF
215610|NCT01875861|Antipsychotic Agents
215611|NCT01875861|Metabolic Syndrome
215612|NCT01875861|Quality Improvement
215613|NCT01875848|pain management
215614|NCT01875835|Acute myocardiac infarction
215615|NCT01875835|Bare-metal stent
215616|NCT01875835|Everolimus-eluting stent
215617|NCT01875835|Optical coherence tomography
215618|NCT01875822|Curcumin
215619|NCT01875822|Epigenetics
215620|NCT01875822|Schizophrenia
215621|NCT01875822|Nitric Oxide synthetase
215622|NCT01875822|cognition
215623|NCT01875822|negative symptoms
215624|NCT01875809|RDN
215625|NCT01875809|renal denervation
215626|NCT01875809|catecholamine
215627|NCT01875809|spill-over
215628|NCT01875809|blood pressure
215629|NCT01875809|electrophysiology
215630|NCT01875809|ablation
215631|NCT01875796|cannabis
215632|NCT01875796|marijuana
215633|NCT01875796|anxiety
215634|NCT01875796|transdiagnostic
215635|NCT01875796|dual diagnosis
215636|NCT01875796|cannabis abuse
215637|NCT01875796|cannabis dependence
215638|NCT01875796|cannabis use disorder
215639|NCT01875783|diabetes
215640|NCT01875783|diabetic macular edema
215641|NCT01875783|diabetic retinopathy
215642|NCT01875783|optical coherence tomography
215643|NCT01875770|Retinal Vein Occlusion
215644|NCT01875757|Vitamin D
215645|NCT01875757|Acute bronchitis
215646|NCT01875757|Upper respiratory tract infection
215647|NCT01875757|Recurrent bronchitis
215648|NCT01875757|Acute bronchiolitis
215649|NCT01875757|Infants
215650|NCT01875744|constipation
215651|NCT01875744|children
215652|NCT01875744|polyethylene glycol
215653|NCT01875731|Pneumonia
215654|NCT01875731|Acute respiratory infection
215655|NCT01875731|Decision-support techniques
215656|NCT01875692|Metagenomic
215657|NCT01875692|Ventilator-Associated Pneumonia (VAP)
215658|NCT01875679|Surgical education
215659|NCT01875679|Deliberate practice
215660|NCT01875679|Debriefing
215661|NCT01875679|Behaviour modelling
215662|NCT01875666|breast cancer
215663|NCT01875666|Kinome
215664|NCT01875666|HER two positive
215665|NCT01875653|metastatic melanoma
215666|NCT01875653|dendritic cells
215667|NCT01875653|immunotherapy
215668|NCT01875653|Granulocyte-Macrophage Colony Stimulating Factor
215669|NCT01875653|overall survival
215670|NCT01875653|autologous
215671|NCT01875653|peripheral blood mononuclear cells
215672|NCT01875653|treatment
215673|NCT01875653|phase 3
215674|NCT01875653|tumor cells
215675|NCT01875640|disorder of sex development
215676|NCT01875640|intersex
215677|NCT01875640|46,XX congenital adrenal hyperplasia
215678|NCT01875640|hypospadias
215679|NCT01875640|decision support tool
215680|NCT01874769|RDEB
215681|NCT01874769|COL7A1
215682|NCT01874769|Collagen VII
215683|NCT01874756|schizophrenia
215684|NCT01874756|Estrogen receptor agonist
215685|NCT01874756|cognitive impairment
215686|NCT01874756|negative symptoms
215687|NCT01874743|HIV,
215688|NCT01874743|Rosuvastatine,
215689|NCT01874743|Antiretroviral therapy
215690|NCT01874730|colorectal surgery
215691|NCT01874730|fluid therapy
215692|NCT01874717|Conscious sedation
215693|NCT01874717|Dental anxiety
215694|NCT01874717|Oral midazolam
215695|NCT01874717|Intravenous midazolam
215696|NCT01874717|Behaviour
215697|NCT01874704|Stress, occupation, biomarkers, emergency, physicians
215698|NCT01874691|acute myocardial infarction
215699|NCT01874691|China
215700|NCT01874691|Registry
215701|NCT01874665|Gastrointestinal Neoplasms
215702|NCT01874665|Gastrointestinal stromal tumor
215703|NCT01874665|mesenchymal tumor
215704|NCT01874639|Hepatectomy
215705|NCT01874639|blood loss
215706|NCT01874639|hemostasis
215707|NCT01874639|coagulation
215708|NCT01874639|Liver surgery (benign or malign)
215709|NCT01874639|Resection of 2 or more segments
215710|NCT01874626|acute ankle sprain
215711|NCT01874626|Grade I or Grade II
215712|NCT01874613|Craniofacial bone reconstruction
215713|NCT01874613|Fibre-reinforced composite
215714|NCT01874613|Bioactive glass
215715|NCT01874613|Craniotomy
215716|NCT01874613|Skull bone defect
215717|NCT01874587|Adaptative radiotherapy
215718|NCT01874587|oropharynx carcinoma
215719|NCT01874587|xerostomia
215720|NCT01875601|NK Cells
215721|NCT01875601|Cytokine
215722|NCT01875601|Lymphodepleting Chemotherapy
215723|NCT01875601|Immunotherapy
215724|NCT01875601|Pediatric
215725|NCT01875588|Healthy Controls
215726|NCT01875588|HIV-positive
215727|NCT01875588|Neurophyschological Testing
215728|NCT01875588|PET/CT Scan
215729|NCT01875588|Lumbar Drain/Puncture
215730|NCT01875575|glucagon-like peptide-1
215731|NCT01875575|peptide tyrosine tyrosine
215732|NCT01875575|ghrelin
215733|NCT01875575|stomach
215734|NCT01875575|small intestine
215735|NCT01875575|gastric emptying
215736|NCT01875562|Neck pain
215737|NCT01875562|Cervical radiculopathy
215738|NCT01875562|Qishe Pill
215739|NCT01875562|Traditional Chinese Medicine
215740|NCT01875536|transcranial magnetic stimulation
215741|NCT01875536|spasticity
215742|NCT01875536|physiotherapy
215743|NCT01875536|Rehabilitation
215744|NCT01875523|Renal disease
215745|NCT01875523|renal impairment
215746|NCT01875523|End stage renal disease
215747|NCT01875523|Healthy volunteer
215748|NCT01875523|Pharmacokinetics
215749|NCT01875497|athletes, polyphenols, nutrition, oxidative stress
215750|NCT01875484|miR-126
215751|NCT01875484|Left Ventricular Remodeling
215752|NCT01875484|Myocardial Infarction
215753|NCT01875484|primary percutaneous coronary intervention
215754|NCT01875484|left ventricular end diastolic volume
215755|NCT01875484|left ventricular ejection fraction
215756|NCT01875484|major adverse cardiovascular events
215757|NCT01875458|Aclasta
215758|NCT01875458|Actonel
215759|NCT01875458|alendronate
215760|NCT01875458|alendronate/cholecalciferol
215761|NCT01875458|Aredia
215762|NCT01875458|Atelvia
215763|NCT01875458|Boniva
215764|NCT01875458|Didronel
215765|NCT01875458|etidronate
215766|NCT01875458|Fosamax
215767|NCT01875458|Fosamax Plus D
215768|NCT01875458|ibandronate
215769|NCT01875458|pamidronate
215770|NCT01875458|Reclast
215771|NCT01875458|risedronate
215772|NCT01875458|Skelid
215773|NCT01875458|tiludronate
215774|NCT01875458|zoledronic acid
215775|NCT01875458|Zometa
215776|NCT01875458|Bisphosphonate
215777|NCT01875458|Atypical Femur Fracture (AFF)
215778|NCT01875458|Osteoporosis
215779|NCT01875458|Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ)
215780|NCT01875445|Inositol
215781|NCT01875445|Trichotillomania
215782|NCT01875445|Hair Pulling
215783|NCT01875445|Impulse Control Disorder
215784|NCT01875393|Prostatic Disease
215785|NCT01875393|Genital Neoplasm,male
215786|NCT01875393|Urogenital neoplasm
215787|NCT01875393|Genital disease,male
215788|NCT01875393|Male urogenital disease
215789|NCT01875393|Neoplasms
215790|NCT01875393|Neoplasms by site
215791|NCT01875393|Prostatic neoplasm
215792|NCT01875393|Carcinoma
215793|NCT01875380|metastatic colorectal cancer
215794|NCT01875380|frail and unfit patient
215795|NCT01875380|regorafenib
215796|NCT01875367|Subcutaneous trastuzumab
215797|NCT01875367|Intravenous trastuzumab
215798|NCT01875367|HER2 positive
215799|NCT01875367|Advanced Breast Cancer
215800|NCT01875341|type 2 diabetes
215801|NCT01875341|diabetic nephropathy
215802|NCT01875341|hypertension
215803|NCT01875341|sleep apnea
215804|NCT01875341|sympathetic hyperactivity
215805|NCT01875328|stroke
215806|NCT01875328|blood pressure
215807|NCT01875328|telemedicine
215808|NCT01875302|COPD PRO Instraments equivalency
215809|NCT01875276|Rhinitis
215810|NCT01875276|Antihistamine
215811|NCT01875276|Nasal Steroid Therapy
215812|NCT01875263|catheter-related bacteremia, SAMS
215813|NCT01875263|catheter related bacteremia
215814|NCT01875263|susceptible
215815|NCT01875263|aureus meticillin
215816|NCT01875250|Gene Transfer
215817|NCT01875250|Androgen Receptor Antagonist
215818|NCT01875250|PSA
215819|NCT01875250|Immune Response
215820|NCT01875250|Immunotherapy
215821|NCT01875237|Leukemia
215822|NCT01875237|Myeloma
215823|NCT01875237|Myeloproliferative Diseases
215824|NCT01875237|Myelodysplastic syndrome
215825|NCT01875237|MDS
215826|NCT01875237|Lymphoma
215827|NCT01875237|Hodgkin disease
215828|NCT01875237|Multiple myeloma
215829|NCT01875237|MM
215830|NCT01875237|Transplant donor
215831|NCT01875237|T-cells
215832|NCT01875237|G-versus-host disease
215833|NCT01875237|GvHD
215834|NCT01875237|G-CSF
215835|NCT01875237|Filgrastim
215836|NCT01875237|Neupogen
215837|NCT01875237|Fludarabine
215838|NCT01875237|Fludarabine phosphate
215839|NCT01875237|Fludara
215840|NCT01875237|Melphalan
215841|NCT01875237|Alkeran
215842|NCT01875237|Alemtuzumab
215843|NCT01875237|CAMPATH-1H
215844|NCT01875237|Campath
215845|NCT01875237|Tacrolimus
215846|NCT01875237|Prograf
215847|NCT01875237|Mini-methotrexate
215848|NCT01875237|AP 1903
215849|NCT01875237|Methylprednisolone
215850|NCT01875237|Depo-Medrol
215851|NCT01875237|Medrol
215852|NCT01875237|Solu-Medrol
215853|NCT01875237|Stem cell infusion
215854|NCT01875237|Donor lymphocyte infusion
215855|NCT01875237|DLI
215856|NCT01875237|Questionnaire
215857|NCT01875237|Survey
215858|NCT01875224|kidney transplant
215859|NCT01875224|diabetes after transplant
215860|NCT01875224|belatacept
215861|NCT01875198|Splenectomy;
215862|NCT01875198|Spleen-preserving
215863|NCT01875185|acute coronary syndrome
215864|NCT01875185|clotting
215865|NCT01875185|hormones
215866|NCT01875185|women
215867|NCT01875172|bupropion SR
215868|NCT01875172|randomized controlled trial
215869|NCT01875172|pregnancy
215870|NCT01875159|Prematurity
215871|NCT01875159|Apnea of prematurity
215872|NCT01875159|Intermittent hypoxia
215873|NCT01875133|airway disease
215874|NCT01875133|bronchitis
215875|NCT01875133|emphysema
215876|NCT01875133|lung
215877|NCT01875120|Anxiety
215878|NCT01875120|Somatoform Disorders
215879|NCT01875068|referrals
215880|NCT01875068|nurse practitioners
215881|NCT01875068|physician assistants
215882|NCT01875068|consultative general internal medicine
215883|NCT01875055|Cerebral
215884|NCT01875055|desaturation
215885|NCT01875029|Low back pain
215886|NCT01875029|chronic pain
215887|NCT01875029|tDCS
215888|NCT01875029|transcranial direct current stimulation
215889|NCT01875016|Cryo ablation
215890|NCT01875016|Cardiomyopathy
215891|NCT01874977|rheumatoid arthritis
215892|NCT01874977|fatigue
215893|NCT01874977|physical activity
215894|NCT01874964|HIV Prevention
215895|NCT01874964|Opioid-Related Disorders
215896|NCT01874964|Medication Assisted Treatment
215897|NCT01874964|Methadone
215898|NCT01874951|Depression
215899|NCT01874951|Recurrence
215900|NCT01874951|Relapse
215901|NCT01874951|Antidepressants
215902|NCT01874951|Naltrexone
215903|NCT01874951|Drug augmentation
215904|NCT01874886|Magnetic resonance imaging
215905|NCT01874886|Diffusion tensor imaging
215906|NCT01874886|Hippocampus
215907|NCT01874886|Cannabis
215908|NCT01874886|Geriatrics
215909|NCT01874886|Neuropsychology
215910|NCT01874886|Apolipoprotein E
215911|NCT01874847|melatonin
215912|NCT01874847|placebo
215913|NCT01874847|post-concussion syndrome
215914|NCT01874847|mild traumatic brain injury
215915|NCT01874847|concussion
215916|NCT01874847|treatment
215917|NCT01874847|outcome
215918|NCT01874847|children
215919|NCT01874847|functional magnetic resonance imaging
215920|NCT01874847|transcranial magnetic stimulation
215921|NCT01874847|sleep
215922|NCT01874834|ozone
215923|NCT01874834|diesel
215924|NCT01874834|lung function
215925|NCT01874834|cardiac electrophysiology
215926|NCT01874834|mediators of inflammation and clotting
215927|NCT01874821|Frozen Shoulder
215928|NCT01874821|Adhesive Capsulitis
215929|NCT01874821|ROM
215930|NCT01874821|Dynasplint
215931|NCT01874808|movement preparation
215932|NCT01874808|gait
215933|NCT01874808|gait initiation
215934|NCT01874808|postural control
215935|NCT01874808|neuroimaging
215936|NCT01874795|Autonomic Nervous System
215937|NCT01874795|Neuromodulation
215938|NCT01874795|Exercise
215939|NCT01874795|Pulmonary oxygen kinetics
215940|NCT01874795|Oxygen uptake
215941|NCT01874782|spinal cord injury
215942|NCT01874782|cardiovascular
215943|NCT01874782|orthostatic hypotension
215944|NCT01874782|transcranial electrical stimulation
215945|NCT01874782|electrotherapy
215946|NCT01874574|Knee Osteoarthritis
215947|NCT01874574|Corticosteroid
215948|NCT01874574|Hyaluronic acid
215949|NCT01874574|Intra-articular injection
215950|NCT01874561|Custirsen sodium
215951|NCT01874561|TV1011
215952|NCT01874561|OGX-011
215953|NCT01874561|Thorough QT study
215954|NCT01874561|cancer
215955|NCT01874548|Autophagy
215956|NCT01874548|Cancer metabolism
215957|NCT01874548|Cervical cancer
215958|NCT01874548|Diffusion weighted imaging
215959|NCT01874548|Human papillomavirus
215960|NCT01874548|Magnetic resonance spectroscopy.
215961|NCT01874522|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
215962|NCT01874405|Iron overload
215963|NCT01874405|thalassaemia
215964|NCT01874405|deferasirox
215965|NCT01874405|magnetic resonance
215966|NCT01874405|endocrine function
215967|NCT01874379|Joint Replacement
215968|NCT01874379|Hip Replacement
215969|NCT01874379|Knee Replacement
215970|NCT01874379|Complementary Medicine Intervention
215971|NCT01874353|BRCA
215972|NCT01874353|Ovarian cancer
215973|NCT01874353|Chemotherapy
215974|NCT01874353|PARP Inhibitor
215975|NCT01874353|Platinum sensitive
215976|NCT01874340|Multiple Sclerosis
215977|NCT01874340|Relapsing Multiple Sclerosis
215978|NCT01874340|AIN457
215979|NCT01874340|Secukinumab
215980|NCT01874340|Magnetic Resonance Imaging
215981|NCT01874340|Relapsing Remitting Multiple Sclerosis
215982|NCT01874340|Autoimmune Diseases
215983|NCT01874340|Nervous System Diseases
215984|NCT01874340|Immune System Diseases
215985|NCT01874340|Demyelinating Diseases
215986|NCT01874314|tuberculosis, SQ109, QTc, moxifloxacin, crossover, placebo, pharmacokinetic, randomized, single-center
215987|NCT01874288|NHL
215988|NCT01874288|Immunocytokine
215989|NCT01874288|Lymphoma
215990|NCT01874288|Non-Hodgkin
215991|NCT01874288|B-cell
215992|NCT01874288|IL (interleukin)
215993|NCT01874249|Hepatic fibrosis
215994|NCT01874249|Steatosis
215995|NCT01874249|Noninvasive markers.
215996|NCT01874236|SI joint pain, SI joint dysfunction, degenerative sacroiliitis, sacroiliac joint disruption
215997|NCT01874223|Interstitial Lung Disease (ILD)
215998|NCT01874223|Idiopathic Pulmonary Fibrosis (IPF)
215999|NCT01874197|Thoracoabdominal Aortic Aneurysm
216000|NCT01874197|Branched vessels
216001|NCT01874158|Trichomonas vaginalis
216002|NCT01874145|Multiple Sclerosis
216132|NCT01873625|mesenchymal stem cells
216003|NCT01874145|Relapsing-Remitting Multiple Sclerosis
216004|NCT01874145|Glatiramer Acetate
216005|NCT01874145|Glatiramer
216006|NCT01874132|Exercise
216007|NCT01874132|Blood pressure
216008|NCT01874132|Lipids
216009|NCT01874132|Body composition
216010|NCT01874132|Fitness
216011|NCT01874132|Bone density
216012|NCT01874132|Quality of life
216013|NCT01874119|melanoma
216014|NCT01874119|renal cell carcinoma
216015|NCT01874119|interleukin-2
216016|NCT01874106|Hemodialysis
216017|NCT01874106|Diet
216018|NCT01874106|Inflammation
216019|NCT01874106|Malnutrition
216020|NCT01874054|Antibody-Drug Conjugate
216021|NCT01874054|Antibodies, Monoclonal
216022|NCT01874054|Hodgkin Disease
216023|NCT01874054|Hematologic Diseases
216024|NCT01874054|Drug Therapy
216025|NCT01874054|Immunotherapy
216026|NCT01874054|Antigens, CD30
216027|NCT01874054|Lymphoma
216028|NCT01874054|monomethylauristatin E
216029|NCT01874041|Physical Therapy Modalities
216030|NCT01874041|Facial Pain
216031|NCT01874041|Orthodontic Appliances
216032|NCT01874028|Trientine
216033|NCT01874028|Pharmacokinetics
216034|NCT01874015|Crohn's disease
216035|NCT01874015|mesenchymal stem cell
216036|NCT01874015|fistula
216037|NCT01874002|Stents
216038|NCT01874002|Stent
216039|NCT01874002|Drug eluting
216040|NCT01874002|Drug eluting stent
216041|NCT01874002|Drug eluting stents
216042|NCT01874002|Endothelial progenitor cell
216043|NCT01874002|Endothelial progenitor cell capturing
216044|NCT01874002|Sirolimus
216045|NCT01874002|Sirolimus eluting
216046|NCT01874002|Percutaneous Coronary Intervention
216047|NCT01874002|PCI
216048|NCT01874002|Registry
216049|NCT01874002|Registries
216050|NCT01874002|Multi center
216051|NCT01874002|Multi centre
216052|NCT01873989|Chronic pain
216053|NCT01873989|Opioid addiction
216054|NCT01873989|Symptomatic hypogonadism
216055|NCT01873989|Testosterone replacement
216056|NCT01873989|Opioid agonist maintenance
216057|NCT01873989|Methadone
216058|NCT01873989|Buprenorphine
216059|NCT01873937|Lasertherapy
216060|NCT01873937|Ledtherapy
216061|NCT01873937|TMJs
216062|NCT01873937|pain relief
216063|NCT01873937|oral aperture
216064|NCT01873924|Batten disease
216065|NCT01873924|NCL
216066|NCT01873924|Neuronal Ceroid Lipofuscinosis
216067|NCT01873911|MPS IIIA
216068|NCT01873911|MPS IIIB
216069|NCT01873911|Sanfilippo syndrome type A
216070|NCT01873911|Sanfilippo syndrome type B
216071|NCT01873911|Hurler syndrome
216072|NCT01873911|cognitive decline
216073|NCT01873911|MPS IH
216074|NCT01873885|PB1046, VIP, Essential Hypertension, Vasomera
216075|NCT01873859|Lactic acidosis
216076|NCT01873859|Contrast media
216077|NCT01873859|Angiography
216078|NCT01873859|Diabetic
216079|NCT01873859|Metformin
216080|NCT01873820|Vitamin C
216081|NCT01873820|calcium ascorbate
216082|NCT01873820|ascorbic acid
216083|NCT01873807|Idarubicin
216084|NCT01873807|Etoposide
216085|NCT01873807|HSCT
216086|NCT01873807|Acute Lymphoblastic Leukemia
216087|NCT01873794|Fatigue
216088|NCT01873794|Sleep
216089|NCT01873794|Quality of life
216090|NCT01873794|Cancer
216091|NCT01873794|Light
216092|NCT01873768|Tranexamic acid
216093|NCT01873768|6-Aminocaproic Acid
216094|NCT01873768|Arthroplasty
216095|NCT01873768|Osteoarthritis
216096|NCT01873768|Arthritis
216097|NCT01873768|Joint Diseases
216098|NCT01873768|Musculoskeletal Diseases
216099|NCT01873768|Rheumatic Diseases
216100|NCT01873768|Antifibrinolytic Agents
216101|NCT01873768|Fibrin Modulating Agents
216102|NCT01873768|Pharmacologic Actions
216103|NCT01873768|Coagulants
216104|NCT01873768|Therapeutic Uses
216105|NCT01873755|asthma
216106|NCT01873755|children
216107|NCT01873755|physical activity
216108|NCT01873755|school
216109|NCT01873742|Psychotherapy feedback
216110|NCT01873729|ADHD
216111|NCT01873729|Naltrexone
216112|NCT01873729|Adults
216113|NCT01873716|Atherosclerosis
216114|NCT01873716|Molecular Imaging
216115|NCT01873716|Vascular Biology
216116|NCT01873716|Inflammation
216117|NCT01873716|Fluorescence
216118|NCT01873703|MDS
216119|NCT01873703|High risk myelodysplastic syndrome
216120|NCT01873703|Intermediate-2 Myelodysplastic syndrome
216121|NCT01873703|Untreated
216122|NCT01873690|Antibiotics
216123|NCT01873690|Shock Wave Lithotripsy
216124|NCT01873690|Urinary Tract Infection
216125|NCT01873664|fMRI
216126|NCT01873664|Jaw tapping
216127|NCT01873664|Memory disorder
216128|NCT01873664|Mild cognitive impairment
216129|NCT01873664|MCI
216130|NCT01873664|Working memory
216131|NCT01873638|5-year outcome after cholecystectomy
216133|NCT01873625|osteoarthritis
216134|NCT01873625|arthritis rheumatoid
216135|NCT01873612|Dexmedetomidine
216136|NCT01873612|Propofol
216137|NCT01873612|Hypoxic ventilatory response
216138|NCT01873612|Hypercapnic ventilatory response
216139|NCT01873573|radiation-induced stricture
216140|NCT01873573|anastomotic stricture
216141|NCT01873573|esophagogastroduodenoscopy (EGD)
216142|NCT01873573|dilation
216143|NCT01873573|steroid injection
216144|NCT01873573|triamcinolone
216145|NCT01873573|difficulty swallowing
216146|NCT01873560|fractional flow reserve
216147|NCT01873560|drug eluting stent
216148|NCT01873560|coronary atherosclerosis
216149|NCT01873547|spinal cord injury
216150|NCT01873547|cell transplantation
216151|NCT01873547|rehabilitation
216152|NCT01873534|Anemia
216153|NCT01873521|Positive Pressure Ventilation
216154|NCT01873521|Neurally Adjusted Ventilatory Assist
216155|NCT01873521|Patient/ventilator Asynchrony
216156|NCT01873521|Pediatric patient
216157|NCT01873521|Infant
216158|NCT01873469|glioblastoma multiforme
216159|NCT01873469|radiotherapy
216160|NCT01873430|Melatonin
216161|NCT01873430|Sunburn
216162|NCT01873430|Erythema
216163|NCT01873430|Sunlight
216164|NCT01873430|Ultraviolet rays
216165|NCT01873391|Diagnostic hysteroscopy
216166|NCT01873391|Pain
216167|NCT01873391|VAS
216168|NCT01873391|Multivariate analysis
216169|NCT01873391|Normal saline
216170|NCT01873391|Carbon dioxide
216171|NCT01873378|Uterine myoma
216172|NCT01873378|GnRHa
216173|NCT01873378|Hysteroscopy
216174|NCT01873378|Cold loop
216175|NCT01873365|Quality of life
216176|NCT01873365|Herpes zoster
216177|NCT01873365|Postherpetic neuralgia
216178|NCT01873365|Japan
216179|NCT01873365|Physician-practice
216180|NCT01873365|Adults
216181|NCT01873365|Health economics
216182|NCT01873339|Drug interaction, healthy volunteer, SB-480848, Lp-PLA2, darapladib, atherosclerosis, midazolam
216183|NCT01873326|newly diagnosed GCT
216184|NCT01873326|Intermediate
216185|NCT01873326|Poor-Risk
216186|NCT01873326|BLEOMYCIN
216187|NCT01873326|CISPLATIN
216188|NCT01873326|ETOPOSIDE (VP-16)
216189|NCT01873326|IFOSFAMIDE
216190|NCT01873326|TAXOL (PACLITAXEL)
216191|NCT01873326|13-074
216192|NCT01873300|Achalasia
216193|NCT01873300|Dysphagia
216194|NCT01873300|Endoscopic
216195|NCT01873300|Myotomy
216196|NCT01873300|Heller
216197|NCT01873300|NOTES
216198|NCT01873300|POEM
216199|NCT01873287|Concussions
216200|NCT01873287|Persistent post-concussion symptoms
216201|NCT01873287|PCS
216202|NCT01873287|Clinical Prediction Rule
216203|NCT01873261|Neurally Adjusted Ventilatory Assist
216204|NCT01873261|Pediatric Acute Respiratory Failure
216205|NCT01873261|non-invasive ventilation
216206|NCT01873248|Neuroendocrine Carcinoma
216207|NCT01873222|Coronary Artery Disease
216208|NCT01873222|Percutaneous Coronary Intervention
216209|NCT01873222|Optical Frequency Domain Imaging
216210|NCT01873222|Intravascular Ultrasound
216211|NCT01873183|echocardiography
216212|NCT01873183|morbid obesity
216213|NCT01873183|bariatric surgery
216214|NCT01873183|venous return
216215|NCT01873183|mean arterial blood pressure
216216|NCT01873170|immune cells
216217|NCT01873170|contraception
216218|NCT01873170|intrauterine device
216219|NCT01873170|IUD
216220|NCT01873170|copper
216221|NCT01873170|microflora
216222|NCT01873170|DMPA
216223|NCT01873170|etonogestrel
216224|NCT01873170|subdermal implant
216225|NCT01873157|Kidney transplantation
216226|NCT01873157|Antibody formation
216227|NCT01873157|Graft rejection
216228|NCT01873157|Proteasome inhibitors
216229|NCT01873157|Randomized controlled trial
216230|NCT01873144|Bronchiolitis
216231|NCT01873144|Hypertonic saline solution
216232|NCT01873144|High-flow oxygen therapy
216233|NCT01873144|Respiratory distress
216234|NCT01873144|Comfort
216235|NCT01873131|hemangioma
216236|NCT01873131|infantile hemangioma
216237|NCT01873131|pulsed dye laser
216238|NCT01873131|PDL
216239|NCT01873131|topical beta blocker
216240|NCT01873131|timolol maleate
216241|NCT01873131|timolol
216242|NCT01873118|hospital discharge
216243|NCT01873118|discharge readiness
216244|NCT01873118|readmission
216245|NCT01873118|Emergency Department visits
216246|NCT01873118|Nurse assessment
216247|NCT01873092|Oximetry
216248|NCT01873092|Physical Activity
216249|NCT01873079|ERCP
216250|NCT01873079|sphincterotomy
216251|NCT01873079|proton pump inhibitor
216252|NCT01873066|Type 1 diabetes
216253|NCT01873066|Closed-loop glucose control
216254|NCT01873066|Artificial Pancreas
216255|NCT01873066|Continuous subcutaneous insulin infusion
216256|NCT01873066|Continuous glucose monitoring
216257|NCT01873053|Osteoarthritis, Knee
216258|NCT01873053|WIN-34B
216259|NCT01873040|Social Media
216260|NCT01873040|Vaccine
216261|NCT01873040|Immunization
216262|NCT01873027|Coronary Artery Disease
216263|NCT01873027|Percutaneous Coronary Intervention
216264|NCT01873027|Optical Frequency Domain Imaging
216265|NCT01873027|Intravascular Ultrasound
216266|NCT01873001|Healthy volunteers
216267|NCT01873001|Drug-drug Interaction
216268|NCT01873001|Pharmacokinetics
216269|NCT01873001|Abiraterone
216270|NCT01873001|JNJ-589485
216271|NCT01873001|Abiraterone acetate
216272|NCT01873001|JNJ-212082
216273|NCT01873001|Pioglitazone HCl
216274|NCT01872988|antiviral therapy
216275|NCT01872988|intermediate stage
216276|NCT01872988|hepatitis B virus
216277|NCT01872962|Nasopharyngeal carcinoma
216278|NCT01872962|Induction chemotherapy
216279|NCT01872962|Concurrent chemoradiotherapy
216280|NCT01872962|Clinical trial
216281|NCT01872949|Heart Failure
216282|NCT01872949|NYHA Class III
216283|NCT01872949|NYHA Class IV
216284|NCT01872923|Amphinex
216285|NCT01872923|PCI
216286|NCT01872923|Bleomycin
216287|NCT01872923|Cutaneous malignancies
216288|NCT01872923|Sub-cutaneous malignancies
216289|NCT01872923|Safety
216290|NCT01872923|Phase I
216291|NCT01872923|Photochemical Internalisation
216292|NCT01872923|Squamous Cell Carcinoma
216293|NCT01872923|Head and Neck cancer
216294|NCT01872923|Breast Cancer
216295|NCT01872923|HNSCC
216296|NCT01872923|SCCHN
216297|NCT01872923|Advanced or metastatic cancer
216298|NCT01872923|Dose finding
216299|NCT01872910|Wisdom tooth extraction
216300|NCT01872897|Gastroesophageal Reflux Disease
216301|NCT01872897|GERD
216302|NCT01872897|Acid reflux
216303|NCT01872897|Compound Sodium Alginate Double Action Chewable Tablet
216304|NCT01872897|Gaviscon Double Action Tablets
216305|NCT01872884|Stroke
216306|NCT01872884|Ischemic stroke
216307|NCT01872884|Acute stroke
216308|NCT01872884|Embolectomy
216309|NCT01872884|Endovascular therapy
216310|NCT01872884|Intra-arterial therapy
216311|NCT01872884|Sedation
216312|NCT01872884|Anesthesia
216313|NCT01872845|Statin
216314|NCT01872845|CIMT
216315|NCT01872845|BES
216316|NCT01872793|bioelectrical impedance vector analysis
216317|NCT01872793|nutritional assessment
216318|NCT01872793|nutritional status
216319|NCT01872793|mortality
216320|NCT01872793|complications
216321|NCT01872780|CYP2C8
216322|NCT01872780|genetic polymorphism
216323|NCT01872780|rosiglitazone
216324|NCT01872780|Korean
216325|NCT01872767|Acute on Chronic Liver Failure (ACLF),Cirrhosis,
216326|NCT01872767|Institute of Liver & Biliary Sciences (ILBS)
216327|NCT01872754|Bronchial fibroscopy
216328|NCT01872754|Remifentanil
216329|NCT01872754|Propofol
216330|NCT01872754|Sedation
216331|NCT01872754|Target Controlled Infusion
216332|NCT01872741|craniotomy,
216333|NCT01872741|intracerebral aneurysms,
216334|NCT01872741|atrophy,
216335|NCT01872741|temporal muscle,
216336|NCT01872741|outcome
216337|NCT01872728|facial block
216338|NCT01872728|levobupivacaine
216339|NCT01872728|regional anesthesia
216340|NCT01872728|rhinoplasty
216341|NCT01872728|outpatient
216342|NCT01872715|Papulopustular Rosacea
216343|NCT01872715|Oracea
216344|NCT01872715|anti inflammatory doxycycline
216345|NCT01872702|Malaria elimination
216346|NCT01872702|Chemotherapy
216347|NCT01872702|Epidemiology
216348|NCT01872702|South East Asia
216349|NCT01872702|Artemisinin resistance
216350|NCT01872702|Dihydroartemisinin piperaquine
216351|NCT01872702|Primaquine
216352|NCT01872676|Thermography
216353|NCT01872676|Skin Temperature
216354|NCT01872676|Manipulation, Spinal
216355|NCT01872676|Physical Therapy Modalities
216356|NCT01872663|Morbid obesity
216357|NCT01872663|Bariatric surgery
216358|NCT01872663|Pulmonary atelectasis
216359|NCT01872663|Spirometry
216360|NCT01872663|Continuos Positive Airway Pressure
216361|NCT01872663|Physical therapy speciality
216362|NCT01872650|postoperative adhesions
216363|NCT01872650|adhesion prevention
216364|NCT01872650|colorectal surgery
216365|NCT01872650|temporary ostomy
216366|NCT01872611|Diabetes Type I
216367|NCT01872611|Diabetes Type II
216368|NCT01872611|Non-proliferative diabetic retinopathy
216369|NCT01872611|Macular edema
216370|NCT01872611|Cataract
216371|NCT01872598|Alzheimer
216372|NCT01872598|dementia
216373|NCT01872598|cognitive disease
216374|NCT01872598|memory loss
216375|NCT01872598|cerebrovascular disease
216376|NCT01872585|Parenting
216377|NCT01872585|Mental Illness
216378|NCT01872585|Maternal sensitivity
216379|NCT01872585|Parent-child relationship
216380|NCT01872533|obesity
216381|NCT01872533|hypoxia
216382|NCT01872533|insulin sensitivity
216383|NCT01872533|altitude
216384|NCT01872520|the Injection of DanShenDuoFenSuanYan
216385|NCT01872520|Magnesium Lithospermate B
216386|NCT01872520|Safety
216387|NCT01872520|Real World Study
216388|NCT01872507|cerebral palsy
216389|NCT01872507|autonomic nerveus system
216390|NCT01872507|heart rate variability
216391|NCT01872494|Local analgesia system
216392|NCT01872494|Ropivacaine
216393|NCT01872494|Analgesic efficacy after operation
216394|NCT01872494|Postoperative
216395|NCT01872481|Phantom limb pain syndrome
216396|NCT01872481|Neuropathic pain
216397|NCT01872481|Antipersonnel landmines
216398|NCT01872481|Transcranial Magnetic Stimulation
216399|NCT01872468|Glomerular filtration Rate.
216400|NCT01872468|Primary Health Care.
216401|NCT01872468|Cluster Clinical Trial.
216402|NCT01872429|subtotal parathyroidectomy
216403|NCT01872429|calcium
216404|NCT01872429|phosphorus
216405|NCT01872429|parathyroid hormone
216406|NCT01872429|hyperparathyroidism
216407|NCT01872416|Refractory and relapsed small cell lung cancer
216408|NCT01872416|Liposomal Doxorubicin
216409|NCT01872416|ifosfamide
216410|NCT01872403|Squamous Cell Carcinoma of the lung
216411|NCT01872390|Lesotho
216412|NCT01872390|TB
216413|NCT01872390|tuberculosis
216414|NCT01872390|HIV
216415|NCT01872390|antiretroviral therapy
216416|NCT01872390|ART
216417|NCT01872390|adherence
216418|NCT01872390|combination intervention package
216419|NCT01872390|retention
216420|NCT01872377|pancreas
216421|NCT01872377|pancreatic
216422|NCT01872377|unresectable
216423|NCT01872377|CyberKnife
216424|NCT01872377|SBRT
216425|NCT01872364|Hernia repair
216426|NCT01872364|Hydrocelectomy
216427|NCT01872364|Global Health
216428|NCT01872364|Global Disease Burden
216429|NCT01872364|Surgical Mission
216430|NCT01872364|Dominican Republic
216431|NCT01872364|Cost-minimization
216432|NCT01872364|Procedural cost
216433|NCT01872364|Material cost
216434|NCT01872364|Item utilization
216435|NCT01872364|Excision of benign cutaneous mass
216436|NCT01872364|Minor procedure
216437|NCT01872351|chronic fatigue syndrome
216438|NCT01872351|mitochondrial disorder
216439|NCT01872351|conditioning exercise
216440|NCT01872351|nutraceutical supplements
216441|NCT01872351|high protein diet
216442|NCT01872338|suicide prevention
216443|NCT01872338|cognitive behavioral therapy
216444|NCT01872338|mindfulness meditation
216445|NCT01872338|Veterans
216446|NCT01872338|safety planning
216447|NCT01872325|cardiac arrest
216448|NCT01872325|bystander cardiopulmonary resuscitation CPR
216449|NCT01872325|dispatch-assisted CPR instructions
216450|NCT01872325|agonal breathing
216451|NCT01872312|BPF(Bronchopleural fistulae)
216452|NCT01872286|Capsule Endoscopy
216453|NCT01872273|Metabolic Syndrome
216454|NCT01872273|Obese
216455|NCT01872273|Overweight
216456|NCT01872273|Hypertension
216457|NCT01872273|Hyperlipidemia
216458|NCT01872273|Glucose Intolerant
216459|NCT01872273|High blood sugar
216460|NCT01872273|Exercise in obesity
216461|NCT01872273|Platelets
216462|NCT01872260|Hormone-receptor positive
216463|NCT01872234|Heart Failure
216464|NCT01872234|Cardiac Resynchronization Therapy
216465|NCT01872234|Mild systolic dysfunction
216466|NCT01872234|Left Bundle Branch Block
216467|NCT01872221|Glioblastoma
216468|NCT01872221|Spectroscopy
216469|NCT01872221|MRI
216470|NCT01872221|Glioma stem cells
216471|NCT01872221|Surgery
216472|NCT01872221|Radioresistance
216473|NCT01872208|PAD
216474|NCT01872208|Atherosclerosis
216475|NCT01872208|Peripheral circulation
216476|NCT01872208|Blood Vessel Prosthesis
216477|NCT01872208|Tissue-Engineered Vascular Graft
216478|NCT01872208|Vascular Prosthesis Implantation
216479|NCT01872208|Femoro-Popliteal Bypass
216480|NCT01872195|Checklist
216481|NCT01872195|In-Hospital Mortality
216482|NCT01872195|In-Hospital Morbidity
216483|NCT01872156|Smoking
216484|NCT01872156|Primary care
216485|NCT01872130|Moh's Surgery
216486|NCT01872130|mosaicing algorithm
216487|NCT01872130|intraoperative imaging
216488|NCT01872130|12-239
216489|NCT01872104|rectal cancer
216490|NCT01872104|rectal adenocarcinoma
216491|NCT01872104|photodynamic therapy
216492|NCT01872104|chemothrapy
216493|NCT01872078|Pharmacokinetics, Pharmacodynamics, endocrinopathies, PCOS, female, hormone, LH
216494|NCT01872039|Nicardipine
216495|NCT01872039|Hypertension
216496|NCT01872039|Calcium blocker
216497|NCT01872026|Plasma concentration
216498|NCT01872026|Pharmacokinetics
216499|NCT01872026|Pharmacodynamics
216500|NCT01872026|ASP7991
216501|NCT01872013|Plasma concentration
216502|NCT01872013|Urinary concentration
216503|NCT01872013|ASP7991
216504|NCT01872000|Intraocular lens
216505|NCT01872000|Phacoemulsification
216506|NCT01871987|FK949E
216507|NCT01871987|Antipsychotic
216508|NCT01871987|Quetiapine
216509|NCT01871974|FK949E
216510|NCT01871974|Antipsychotic
216511|NCT01871974|Quetiapine
216512|NCT01871909|Physical trauma
216513|NCT01871896|Surgical Endoscopy
216514|NCT01871896|Morbid Obesity
216515|NCT01871896|Weight Loss
216516|NCT01871896|Bariatrics
216517|NCT01871896|Surgical Revision
216518|NCT01871883|Sensitive skin
216519|NCT01871883|Transient potential receptor vanilloid 1
216520|NCT01871883|TRPV1
216521|NCT01871883|Transepidermal water loss
216522|NCT01871883|Skin Phototype
216523|NCT01871883|Lactic acid test
216524|NCT01871883|Skin irritancy tests
216525|NCT01871818|Multiple sclerosis
216526|NCT01871818|Rehabilitation
216527|NCT01871818|Chronic evolutive disease
216528|NCT01871818|Physiotherapy
216529|NCT01871818|Resistance training
216530|NCT01871818|Endurance training
216531|NCT01871792|Contrast-induced nephropathy
216532|NCT01871792|Prevention
216533|NCT01871792|Statin
216534|NCT01871792|Pitavastatin
216535|NCT01871766|Rhabdomyosarcoma
216536|NCT01871766|Radiation therapy
216537|NCT01871766|Proton beam
216538|NCT01871740|Folic acid
216539|NCT01871740|Renal function decline
216540|NCT01871740|Hypertension
216541|NCT01871740|Hyperhomocysteinemia
216542|NCT01871740|Chronic kidney disease
216543|NCT01871740|MTHFR C677T genotype
216544|NCT01871740|Randomized controlled trial
216545|NCT01871727|Persistent or Recurrent Cutaneous T-Cell Lymphoma
216546|NCT01871727|E7777
216547|NCT01871714|XLHED
216548|NCT01871714|HED
216549|NCT01871714|Hypohidrotic Ectodermal Dysplasia
216550|NCT01871714|X Linked Hypohidrotic Ectodermal Dysplasia
216551|NCT01871701|Corrected QT interval prolongation
216552|NCT01871701|Psychotropic drugs
216553|NCT01871688|pelvic floor dysfunction
216554|NCT01871688|neuromodulation
216555|NCT01871688|rehabilitation
216556|NCT01871675|Lymphoma
216557|NCT01871675|Chronic Lymphocytic Leukemia
216558|NCT01871675|Non-Hodgkin Lymphoma
216559|NCT01871675|T-cell Lymphoma
216560|NCT01871675|Rituxan
216561|NCT01871675|Bendamustine
216562|NCT01871675|Hematologic Malignancy
216563|NCT01871675|Relapsed
216564|NCT01871675|Refractory
216565|NCT01871662|HCV
216566|NCT01871662|Hepatitis C
216567|NCT01871649|psoriatic arthritis
216568|NCT01871649|golimumab
216569|NCT01871649|methotrexate
216570|NCT01871649|minimal disease activity
216571|NCT01871649|safety
216572|NCT01871649|withdrawal
216573|NCT01871636|endoscopy
216574|NCT01871636|WESD
216575|NCT01871636|EMR
216576|NCT01871623|Cleft lip and palate
216577|NCT01871623|Cone-Beam Computed Tomography
216578|NCT01871623|Le Fort I Osteotomy
216579|NCT01871623|Segmental Osteotomy
216580|NCT01871623|Stability
216581|NCT01871610|Traumatic brain injury
216582|NCT01871610|mild TBI
216583|NCT01871610|Alzheimer's disease
216584|NCT01871610|[18F]AV-45 PET amyloid binding imaging
216585|NCT01871597|Lung cancer
216586|NCT01871597|VATS procedure
216587|NCT01871597|Pulmonary Artery Sealing
216588|NCT01871584|A colon hydrotherapy system
216589|NCT01871584|Hydrocolonic preparation
216590|NCT01871584|Preparation for colonoscopy
216591|NCT01871558|type 2 diabetes
216592|NCT01871558|basal insulin
216593|NCT01871558|vildagliptin
216594|NCT01871545|hepatocellular carcinoma
216595|NCT01871545|HCC
216596|NCT01871545|liver cancer
216597|NCT01871545|liver disease
216598|NCT01871545|magnetic resonance imaging
216599|NCT01871545|MRI
216600|NCT01871532|Monofollicular Development
216601|NCT01871532|Gonal-f®
216602|NCT01871532|Recombinant Follicle Stimulating Hormone
216603|NCT01871532|Ovarian hyperstimulation syndrome (OHSS)
216604|NCT01871519|vertebral body compression fracture
216605|NCT01871480|NSCLC
216606|NCT01871480|CIK
216607|NCT01871480|Gefitinib
216608|NCT01871480|Adenocarcinoma
216609|NCT01871402|psoriasis
216610|NCT01871402|lotion
216611|NCT01871402|investigator's global assessment
216612|NCT01871376|PCV
216613|NCT01871363|Preoperative Chemoradiotherapy
216614|NCT01871363|Bevacizumab
216615|NCT01871363|Locally Advanced Rectal Cancer
216616|NCT01871350|Cancer
216617|NCT01871350|Chemotherapy
216618|NCT01871350|Chemo related toxicity
216619|NCT01871350|Protein digestion
216620|NCT01871350|Fat digestion
216621|NCT01871350|Gut function
216622|NCT01871350|Glucose absorption
216623|NCT01871350|Muscle function
216624|NCT01871337|Multiple Sclerosis
216625|NCT01871337|urinary incontinence
216626|NCT01871311|metastatic Kras wildtype
216627|NCT01871311|squamous cell carcinoma
216628|NCT01871311|cetuximab
216629|NCT01871311|nilotinib
216630|NCT01871298|internet and mobile technology use
216631|NCT01871298|history of drug use
216632|NCT01871298|injection drug user (IDU) syringe customers
216633|NCT01871285|ATC, Opioid, withdrawal, switch
216634|NCT01871259|Sedation, sleep apnea, propofol
216635|NCT01871233|anti-epileptic drug
216636|NCT01871233|Extended Access Program
216637|NCT01871233|partial onset seizures
216638|NCT01871233|Perampanel
216639|NCT01871220|Implant Abutments
216640|NCT01871220|Oral Mucosa Changes
216641|NCT01871220|Implant Esthetics
216642|NCT01871207|Erythropoietin (EPO)
216643|NCT01871207|Diabetes
216644|NCT01871207|Diabetic Retinopathy
216645|NCT01871207|Vascular Endothelial Growth Factor (VEGF)
216646|NCT01871207|Erythropoiesis Stimulating Agents (ESA)
216647|NCT01871142|5 Hydroxymethyl 2 Furfural
216648|NCT01871142|AES103
216649|NCT01871142|Exercise
216650|NCT01871129|Dexmedetomidine
216651|NCT01871129|Postoperative Period
216652|NCT01871129|Airway extubation
216653|NCT01871129|Systolic Pressure
216654|NCT01871116|breast cancer
216655|NCT01871116|early stage
216656|NCT01871116|weight loss
216657|NCT01871103|Soft tissue defect
216658|NCT01871103|dorsal branch of the digital artery
216659|NCT01871103|dorsal branch of the digital nerve
216660|NCT01871103|dorsal homodigital island flap
216661|NCT01871090|Remote Monitoring
216662|NCT01871090|Remote Care
216663|NCT01871090|Cardiac Resynchronization Therapy
216664|NCT01871090|Pacemaker
216665|NCT01871090|Implantable Cardioverter Defibrillator
216666|NCT01871064|Laparotomy
216667|NCT01871064|laparoscopic surgery
216668|NCT01871064|general anesthesia
216669|NCT01871064|Neuromuscular Block
216670|NCT01871038|vaccine effectiveness
216671|NCT01871038|rotavirus
216672|NCT01871038|acute gastroenteritis
216673|NCT01871025|Chronic obstructive pulmonary disease
216674|NCT01871012|Nerve Block
216675|NCT01871012|Intraoperative Care
216676|NCT01871012|Postoperative Recovery and Complications
216677|NCT01871012|Stress and Inflammation
216678|NCT01870986|Healthy Volunteers
216679|NCT01870986|Phase 1
216680|NCT01870986|PK
216681|NCT01870986|adalimumab
216682|NCT01870986|Single-dose
216683|NCT01870986|Immunology
216684|NCT01870986|Bioequivalence
216685|NCT01870986|Biosimilarity
216686|NCT01870986|Similarity.
216687|NCT01870973|postoperative pain
216688|NCT01870973|root canal treatment
216689|NCT01870947|Stage I endometrial adenocarcinoma
216690|NCT01870947|Obesity
216691|NCT01870947|Exercise and Physical Fitness
216692|NCT01870947|Diet
216693|NCT01870947|Cancer
216694|NCT01870934|Telemedicine
216695|NCT01870934|Diabetes
216696|NCT01870934|Foot Ulcers
216697|NCT01870895|YM060
216698|NCT01870895|Ramosetron
216699|NCT01870895|Diarrhea-predominant Irritable Bowel Syndrome
216700|NCT01870882|Opioid-Related Disorders
216701|NCT01870882|Cocaine-Related Disorders
216702|NCT01870882|Substance-Related Disorders
216703|NCT01870882|Mental Disorders
216704|NCT01870882|Cocaine
216705|NCT01870882|Methadone
216706|NCT01870882|Therapeutic Uses
216707|NCT01870856|Ocular discomfort
216708|NCT01870856|Contact lenses
216709|NCT01870856|Myopia
216710|NCT01870843|Depressive Disorder, Major
216711|NCT01870843|Depressive Disorder
216712|NCT01870843|Depression
216713|NCT01870843|Anxiety
216714|NCT01870843|Escitalopram
216715|NCT01870843|Quality of life
216716|NCT01870843|Social functionality
216717|NCT01870817|Randomized
216718|NCT01870817|Jejunostomy
216719|NCT01870817|Enteral
216720|NCT01870817|Nutrition
216721|NCT01870817|Esophagectomy
216722|NCT01870817|Gastrectomy
216723|NCT01870804|Statins
216724|NCT01870804|Contrast-Induced Acute Kidney Injury
216725|NCT01870804|Periprocedural Myocardial Damage
216726|NCT01870791|Esophageal adenocarcinoma
216727|NCT01870791|Gastric adenocarcinoma
216728|NCT01870778|acute heart failure,
216729|NCT01870778|AHF,
216730|NCT01870778|multi-center,
216731|NCT01870778|randomized,
216732|NCT01870778|double-blind
216733|NCT01870739|LCZ696,
216734|NCT01870739|Hypertension,
216735|NCT01870739|Aortic stiffness,
216736|NCT01870739|Central blood pressure,
216737|NCT01870739|Cardiovascular MRI
216738|NCT01870713|gastric bypass surgery
216739|NCT01870713|proteomics
216740|NCT01870687|vitex agnus castus
216741|NCT01870687|clinical trial
216742|NCT01870687|cyclic mastodynia
216743|NCT01870687|PMS
216744|NCT01870687|prospective
216745|NCT01870674|safety
216746|NCT01870674|tolerability
216747|NCT01870674|pharmacokinetics
216748|NCT01870674|pharmacodynamics
216749|NCT01870661|Intravenous placement
216750|NCT01870661|Ultrasound
216751|NCT01870648|Low-middle income country
216752|NCT01870648|Dehydration
216753|NCT01870648|Intravenous Rehydration
216754|NCT01870648|Pakistan
216755|NCT01870635|Low-middle income country
216756|NCT01870635|Dehydration
216757|NCT01870635|Intravenous Rehydration
216758|NCT01870635|Pakistan
216759|NCT01870622|Newborn,
216760|NCT01870622|Infant,
216761|NCT01870622|Endotracheal Intubation,
216762|NCT01870622|Carbon dioxide detector,
216763|NCT01870622|Flow waves
216764|NCT01870583|Cesarean delivery
216765|NCT01870583|Surgical site infection
216766|NCT01870583|Pregnancy
216767|NCT01870583|Postpartum
216768|NCT01870570|Glycaemia
216769|NCT01870570|Insulinemia
216770|NCT01870557|Diabetes Mellitus
216771|NCT01870557|Bone
216772|NCT01870557|Bone Status
216773|NCT01870557|Glycemic Markers
216774|NCT01870557|Osteoporosis
216775|NCT01870557|Osteopenia
216776|NCT01870544|gastric bypass
216777|NCT01870544|microbiota
216778|NCT01870544|probiotic
216779|NCT01870531|Transient Ischemic Attack
216780|NCT01870518|Parkinson's disease
216781|NCT01870518|Dementia
216782|NCT01870505|BYL719
216783|NCT01870505|Letrozole
216784|NCT01870505|Exemestane
216785|NCT01870505|13-027
216786|NCT01870492|IV-tPA
216787|NCT01870492|Activase
216788|NCT01870492|endovascular therapy
216789|NCT01870479|Malignant Lymphoma
216790|NCT01870479|Chemotherapy
216791|NCT01870479|Music therapy
216792|NCT01870453|Alzheimer Disease
216793|NCT01870453|Dementia
216794|NCT01870453|Postoperative Care
216795|NCT01870453|Cognitive Reserve
216796|NCT01870440|Uveitis
216797|NCT01870440|Macular Edema
216798|NCT01870427|Macular Edema
216799|NCT01870427|Central Retinal Vein Occlusion
216800|NCT01870427|CRVO
216801|NCT01870427|Aflibercept
216802|NCT01870427|VEGF Trap-Eye
216803|NCT01870427|Eylea
216804|NCT01870427|Ranibizumab
216805|NCT01870427|Bevacizumab
216806|NCT01870375|Mucopolysaccharidosis
216807|NCT01870375|Longitudinal
216808|NCT01870375|Brain
216809|NCT01870375|Cognition
216810|NCT01870375|Quality-of-Life
216811|NCT01870375|Hurler syndrome
216812|NCT01870375|Hunter syndrome
216813|NCT01870375|Hurler-Scheie syndrome
216814|NCT01870375|Scheie syndrome
216815|NCT01870375|Maroteaux-Lamy syndrome
216816|NCT01870375|MPS I
216817|NCT01870375|MPS II
216818|NCT01870375|MPS VI
216819|NCT01870375|Mucopolysaccharidosis type I
216820|NCT01870375|Mucopolysaccharidosis type II
216821|NCT01870375|Mucopolysaccharidosis type VI
216822|NCT01870375|MPS IV
216823|NCT01870375|MPS VII
216824|NCT01870375|Mucopolysaccharidosis type IV
216825|NCT01870375|Mucopolysaccharidosis type VII
216826|NCT01870375|Morquio syndrome
216827|NCT01870375|Sly syndrome
216828|NCT01870349|cytokines
216829|NCT01870349|dental implants
216830|NCT01870349|peri-implantitis
216831|NCT01870310|Heart failure
216832|NCT01870310|Renal denervation
216833|NCT01870271|PTSD
216834|NCT01870271|childhood sexual abuse
216835|NCT01870271|physical abuse
216836|NCT01870271|developmentally adapted cognitive processing therapy
216837|NCT01870258|Myocardial infarction
216838|NCT01870258|artificial neural networks
216839|NCT01870258|Electrocardiography
216840|NCT01870232|Greater palatine nerve Block
216841|NCT01870232|Inferior Alveolar nerve block
216842|NCT01870232|dental anesthesia
216843|NCT01870232|Ultrasonography
216844|NCT01870219|sevoflurane
216845|NCT01870219|ketamine
216846|NCT01870219|QT interval
216847|NCT01870206|Immunogenicity
216848|NCT01870206|Safety
216849|NCT01870206|Efficacy
216850|NCT01870206|Poliomyelitis
216851|NCT01870206|Newborn
216852|NCT01870193|Glutathione deficiency in aging
216853|NCT01870193|Impaired mitochondrial fatty-acid oxidation in aging
216854|NCT01870180|Meibomian Glad Dysfunction
216855|NCT01870180|EyeBag
216856|NCT01870180|Hot Compress
216857|NCT01870180|Dry Eyes
216858|NCT01870167|PEG
216859|NCT01870167|Percutaneous Endoscopic Gastrostomy
216860|NCT01870167|antibiotic prophylaxis
216861|NCT01870154|Burnout syndrome
216862|NCT01870154|Job stressors
216863|NCT01870154|Primary Health Care
216864|NCT01870154|Health professional
216865|NCT01870141|Glucose Control
216866|NCT01870141|Depression
216867|NCT01870141|Self-Efficacy
216868|NCT01870128|Rheumatoid arthritis
216869|NCT01870128|Steroid
216870|NCT01870115|Melatonin
216871|NCT01870115|Strontium Citrate
216872|NCT01870115|Osteoporosis
216873|NCT01870115|Osteopenia
216874|NCT01870089|Non invasive ventilation
216875|NCT01870089|Computer-driven system
216876|NCT01870089|Acute respiratory failure
216877|NCT01870063|5 minute bleeding test
216878|NCT01870063|swamb
216879|NCT01870063|fibtem
216880|NCT01870063|extem
216881|NCT01870050|lichen simplex chronicus
216882|NCT01870050|prurigo
216883|NCT01870037|OAB, gene therapy
216884|NCT01870024|status epilepticus
216885|NCT01870024|epilepsy
216886|NCT01870024|seizures
216887|NCT01870024|convulsive seizures
216888|NCT01870024|convulsions
216889|NCT01870024|benzodiazepines
216890|NCT01870024|anticonvulsants
216891|NCT01870011|Propofol, renal protection, kidney transplantation
216892|NCT01869998|Vortex
216893|NCT01869998|Thrombus
216894|NCT01869998|Contrast echocardiography
216895|NCT01869998|Prediction and prevention of apical thrombus formation in acute myocardial infarction patient by using Vortex parameters.
216896|NCT01869985|HCP1104
216897|NCT01869985|Eperisone Hydrochloride
216898|NCT01869985|Aceclofenac
216899|NCT01869972|PKU
216900|NCT01869972|phenylketonuria
216901|NCT01869972|hyperphenylalaninemia
216902|NCT01869972|Kuvan
216903|NCT01869972|sapropterin
216904|NCT01869946|Hip arthroplasty
216905|NCT01869933|Proliferative, Diabetic, Retinopathy
216906|NCT01869920|breastfeeding
216907|NCT01869920|education
216908|NCT01869920|intervention
216909|NCT01869894|Malignant biliary obstruction
216910|NCT01869894|metal stent
216911|NCT01869894|patency
216912|NCT01869855|chronic subdural hematoma
216913|NCT01869855|traumatic brain injury
216914|NCT01869855|burr hole trepanation
216915|NCT01869855|drainage after evacuation of chronic subdural hematoma
216916|NCT01869855|intracranial bleed
216917|NCT01869842|Resolute zotarolumus-eluting stent
216918|NCT01869842|optical coherence tomography
216919|NCT01869829|Candida
216920|NCT01869829|Pediatric
216921|NCT01869829|Antifungal
216922|NCT01869738|heart attack
216923|NCT01869725|Neuroendocrine Tumor
216924|NCT01869725|Ga-DOTATOC PET
216925|NCT01869725|Imaging
216926|NCT01869712|cupping therapy
216927|NCT01869712|acupuncture
216928|NCT01869712|partially randomized
216929|NCT01869712|patient preference
216930|NCT01869712|fibromyalgia
216931|NCT01869712|criteria formulated by American College Rheumatology 2002
216932|NCT01869699|Fever
216933|NCT01869699|Acetaminophen
216934|NCT01869699|Critical Care
216935|NCT01869699|ICU
216936|NCT01869699|Febrile
216937|NCT01869673|Difficult mask ventilation
216938|NCT01869673|extubation
216939|NCT01869673|nasal surgery
216940|NCT01869660|First hospitalization
216941|NCT01869647|kidney stones
216942|NCT01869634|HIV
216943|NCT01869634|cardiovascular risk
216944|NCT01869634|systemic immune activation
216945|NCT01869608|postpartum screening
216946|NCT01869608|type 2 diabetes
216947|NCT01869595|2000 MSM and TG sites in Bangkok,Lampang,Ubonratchathani
216948|NCT01869582|Fetal hypoxia
216949|NCT01869582|Birth asphyxia
216950|NCT01869582|Neonatal resuscitation
216951|NCT01869569|Radiation
216952|NCT01869569|Neuropathic Pain
216953|NCT01869569|Pregabalin
216954|NCT01869556|pregnancy
216955|NCT01869556|postpartum hemorrhage
216956|NCT01869556|Cesarean delivery
216957|NCT01869556|failure to progress in labor
216958|NCT01869504|Ballooned intercostal drain
216959|NCT01869504|Pleural effusion
216960|NCT01869491|Gastroesophageal Reflux Disease
216961|NCT01869491|GERD
216962|NCT01869491|Dyspepsia
216963|NCT01869491|Indigestion
216964|NCT01869491|Heartburn
216965|NCT01869491|Acid reflux
216966|NCT01869491|Compound Sodium Alginate Double Action Chewable Tablets
216967|NCT01869491|Gaviscon Double Action Tablets
216968|NCT01869452|education
216969|NCT01869452|risk factors
216970|NCT01869452|quality of life
216971|NCT01869452|coronary disease
216972|NCT01869452|telephone follow up
216973|NCT01869452|dedicated nurse
216974|NCT01869439|Pressure Ulcers
216975|NCT01869439|Bed Sores
216976|NCT01869439|Measuring
216977|NCT01869439|Visual Images
216978|NCT01869439|Thermal Images
216979|NCT01869439|External Wounds
216980|NCT01869439|Area
216981|NCT01869439|Length
216982|NCT01869439|Width
216983|NCT01869439|Gradiency
216984|NCT01869426|colics
216985|NCT01869413|urothelial cell carcinoma
216986|NCT01869413|transition cell carcinoma
216987|NCT01869413|bladder cancer
216988|NCT01869413|radical cystectomy
216989|NCT01869413|cystectomy
216990|NCT01869413|bladder removal
216991|NCT01869413|tranexamic acid
216992|NCT01869413|cyklokapron
216993|NCT01869374|Depression
216994|NCT01869374|Brain Stimulation
216995|NCT01869374|Seizure therapy
216996|NCT01869374|Convulsive Therapy
216997|NCT01869361|preterm labor
216998|NCT01869361|tocolysis
216999|NCT01869361|indomethacin
217000|NCT01869348|Physical activity
217001|NCT01869348|Activity monitor
217002|NCT01869348|Technology
217003|NCT01869348|Obesity
217004|NCT01869348|Aging muscle
217005|NCT01869335|breast cancer
217006|NCT01869335|MRI
217007|NCT01869335|mammography
217008|NCT01869335|microcalcifications
217009|NCT01869335|Local staging of breast microcalcifications
217010|NCT01869335|Evaluation of ex vivo MRI for breast malignancies detected by MRI only
217011|NCT01869322|Humerus
217012|NCT01869322|Fracture
217013|NCT01869322|Sling
217014|NCT01869322|Splint
217015|NCT01869322|Coaptation
217016|NCT01869309|Coronary artery disease
217017|NCT01869309|anti-platelet medications
217018|NCT01869309|Platelet-aggregation Inhibitors
217019|NCT01869296|unsedated
217020|NCT01869296|water immersion colonoscopy
217021|NCT01869296|endoscope water pump flow rates
217022|NCT01869283|Physical Therapy Modalities
217023|NCT01869283|Myofascial Pain Syndromes
217024|NCT01869283|Skeletal Muscle
217025|NCT01869270|hexosaminidase deficiency
217026|NCT01869270|Tay-Sachs disease
217027|NCT01869270|Sandhoff disease
217028|NCT01869270|late-onset Tay-Sachs disease
217029|NCT01869270|adult-onset Tay-Sachs disease
217030|NCT01869270|late onset Tay Sachs disease
217031|NCT01869270|adult onset Tay Sachs disease
217032|NCT01869270|retrospective
217033|NCT01869270|hexosaminidase A activity
217034|NCT01869270|GM2-ganglioside
217035|NCT01869270|gangliosidoses
217036|NCT01869270|natural history
217037|NCT01869270|hexosaminidase
217038|NCT01869257|triclosan
217039|NCT01869257|colorectal
217040|NCT01869257|surgery
217041|NCT01869257|surgical site infection
217042|NCT01869218|Cancer
217043|NCT01869218|Advanced
217044|NCT01869218|Solid
217045|NCT01869218|Hematological
217046|NCT01869218|Malignancy
217047|NCT01869218|Tissue
217048|NCT01869218|Bank
217049|NCT01869205|COPD
217050|NCT01869205|Emphysema
217051|NCT01869205|Bronchoscopic lung volume reduction
217052|NCT01869205|Endobronchial valve
217053|NCT01869192|Malignant
217054|NCT01869192|Neoplasm
217055|NCT01869192|Cancer
217056|NCT01869192|Female
217057|NCT01869192|Breast
217058|NCT01869192|Stage II
217059|NCT01869192|Stage III
217060|NCT01869179|Well being
217061|NCT01869179|Low income
217062|NCT01869179|Choir singing
217063|NCT01869179|Spanish speaking
217064|NCT01869179|Community based
217065|NCT01869179|Seniors
217066|NCT01869179|60+ aged adults
217067|NCT01869166|chemotherapy and/or EGFR-antibody/kinase inhibitor therapy refractory solid tumors
217068|NCT01869153|Growth, weight
217069|NCT01869127|hookworm
217070|NCT01869127|necator americanus
217071|NCT01869127|ancyclostoma duodenale
217072|NCT01869127|shoes
217073|NCT01869127|anaemia
217074|NCT01869127|children
217075|NCT01869101|Prediabetes
217076|NCT01869101|Diabetes prevention
217077|NCT01869088|TACE
217078|NCT01869088|Carcinoma,Hepatocellular
217079|NCT01869088|Liver Neoplasms
217080|NCT01869088|overall survival
217081|NCT01869088|Recombinant Human Adenovirus Type 5 Injection
217082|NCT01869075|Quality Improvement
217083|NCT01869075|Patient Safety
217084|NCT01869075|Knowledge Translation
217085|NCT01869062|CRT
217086|NCT01869049|Immune Thrombocytopenia
217087|NCT01869049|macrophage
217088|NCT01869049|spleen tissue
217089|NCT01869036|Caudal
217090|NCT01869036|anesthesia
217091|NCT01869036|morphine
217092|NCT01869036|children
217093|NCT01869023|Advanced Malignant Pleural Mesothelioma
217094|NCT01869023|Gemcitabine and cisplatin
217095|NCT01869023|Gemcitabine continuous infusion
217096|NCT01869010|HIV infection
217097|NCT01869010|Antiretroviral treatment
217098|NCT01869010|Renal disease
217099|NCT01869010|Renal tubular damage
217100|NCT01869010|Free-water clearance
217101|NCT01868997|Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated
217102|NCT01868997|Ophthalmopathy
217103|NCT01868958|Magnetic resonance imaging (MRI)
217104|NCT01868958|Diffusion tensor imaging
217105|NCT01868958|Spine
217106|NCT01868945|Vitamin D3
217107|NCT01868945|Calcifediol 25
217108|NCT01868945|Frail
217109|NCT01868945|Dose-response
217110|NCT01868932|wheeze
217111|NCT01868932|early childhood
217112|NCT01868932|asthma
217113|NCT01868932|bronchiolitis
217114|NCT01868932|infection triggered
217115|NCT01868919|"Pilot Projects[Mesh]"
217116|NCT01868919|"Parenting[Mesh]"
217117|NCT01868919|"Child Behaviour[Mesh]"
217118|NCT01868919|"Mental Health[Mesh]"
217119|NCT01868919|"Family Practice[Mesh]"
217120|NCT01868906|Anaplastic Astrocytoma
217121|NCT01868906|Brain Tumors
217122|NCT01868906|Cancer Imaging
217123|NCT01868906|Fluoromisonidazole
217124|NCT01868906|FMISO PET
217125|NCT01868906|Glioblastoma
217126|NCT01868906|High Grade Glioma
217127|NCT01868906|Hypoxia Modification
217128|NCT01868906|Positron Emission Tomography
217129|NCT01868906|Radiation-Sensitizing Agents
217130|NCT01868906|Spinal Cord Stimulation
217131|NCT01868906|Tumor Hypoxia Measurement
217132|NCT01868854|Tip catheter
217133|NCT01868854|Peritoneal Dialysis
217134|NCT01868854|Risk Factot
217135|NCT01868854|Mecanical Function
217136|NCT01868841|123I-mIBG
217137|NCT01868841|AdreView
217138|NCT01868841|SPECT
217139|NCT01868841|Heart to Mediastinal Ratio
217140|NCT01868828|Multiple Myeloma
217141|NCT01868828|Combination Therapy
217142|NCT01868802|Ketamine
217143|NCT01868802|Depression
217144|NCT01868802|Depressive Disorder
217145|NCT01868789|Adult-acquired flatfoot disorder (AAFD)
217146|NCT01868789|flexible flatfoot
217147|NCT01868789|computed tomography (CT)
217148|NCT01868763|telemedicine
217149|NCT01868763|coaching
217150|NCT01868763|lifestyle change
217151|NCT01868763|weight loss
217152|NCT01868737|Human Immunodeficiency Virus
217153|NCT01868737|Necrotizing Enterocolitis
217154|NCT01868737|Premature infant
217155|NCT01868737|Probiotic
217156|NCT01868737|Very Low Birth Weight
217157|NCT01868724|Kidney Renal
217158|NCT01868711|Major Depressive Disorder
217159|NCT01868711|Cognitive Behavior Therapy
217160|NCT01868711|Psychological Mindedness
217161|NCT01868698|Physical Therapy Modalities
217162|NCT01868698|Electric Stimulation Therapy
217163|NCT01868698|Hyperthermia, Induced
217164|NCT01868698|Diabetes Mellitus
217165|NCT01868685|Muscle, anabolism, cachexia, respiratory failure, diaphragm
217166|NCT01868672|Secondhand smoke exposure
217167|NCT01868672|Smoke-free homes
217168|NCT01868672|Smoke-free home bans
217169|NCT01868646|Combined Treatment of Patients With Type II Diabetes Mellitus
217170|NCT01868633|Cesarean delivery
217171|NCT01868633|Analgesia
217172|NCT01868633|Pain
217173|NCT01868633|Dexamethasone
217174|NCT01868633|intrathecal morphine
217175|NCT01868633|spinal anesthesia
217176|NCT01868620|Progressive keratoconus
217177|NCT01868620|standard CXL
217178|NCT01868620|iontophoretic CXL
217179|NCT01868620|keratometry
217180|NCT01868607|Respiratory resistance
217181|NCT01868607|Respiratory reactance
217182|NCT01868607|Adult lung function
217183|NCT01868607|Forced oscillation technique
217184|NCT01868607|subjects
217185|NCT01868594|Combined treatment of patients with type I diabetes mellitus
217186|NCT01868490|Cholangiocarcinoma
217187|NCT01868490|Cytokine induced killer cells
217188|NCT01868490|CIK
217189|NCT01868490|Treg
217190|NCT01868490|Th17
217191|NCT01868477|myelodysplastic syndrome
217192|NCT01868477|MDS
217193|NCT01868477|myelodysplasia
217194|NCT01868477|blood disorder
217195|NCT01868477|cytopenias
217196|NCT01868477|low blood counts
217197|NCT01868477|progressive bone marrow failure
217198|NCT01868464|tuberculosis, TB, Mycobacterium tuberculosis, Tice BCG, challenge, parent protocol
217199|NCT01868451|DACARBAZINE
217200|NCT01868451|DOXORUBICIN/ADRIAMYCIN
217201|NCT01868451|SGN-35 (BRENTUXIMAB VEDOTIN)
217202|NCT01868451|VINBLASTINE
217203|NCT01868451|Involved-site radiation therapy (ISRT)
217204|NCT01868451|Early stage
217205|NCT01868451|13-034
217206|NCT01868438|Pyronaridine artesunate tablet
217207|NCT01868438|Pyronaridine artesunate granules
217208|NCT01868438|Pyramax tablet
217209|NCT01868438|Pyramax granules
217210|NCT01868438|Bioavailability
217211|NCT01868412|Wound healing
217212|NCT01868412|Wound infection
217213|NCT01868412|Resin salve
217214|NCT01868412|Medical honey
217215|NCT01868399|dengue virus
217216|NCT01868386|Radiotherapy, hypofractionated
217217|NCT01868386|Salvage therapy
217218|NCT01868386|Radiotherapy, adjuvant
217219|NCT01868373|commensal microbiota bacteroides colitis pseudomembranous
217220|NCT01868360|cornea
217221|NCT01868360|transplant
217222|NCT01868360|graft
217223|NCT01868360|neovascularization
217224|NCT01868347|obese patients
217225|NCT01868347|specific elastance
217226|NCT01868347|Trendelenburg Position
217227|NCT01868347|Pneumoperitoneum
217228|NCT01868347|robotic surgery
217229|NCT01868347|Prostatectomy
217230|NCT01868334|influenza vaccine
217231|NCT01868334|PPSV
217232|NCT01868334|Tdap
217233|NCT01868334|vaccination
217234|NCT01868334|adult
217235|NCT01868321|Mechanical ventilation
217236|NCT01868321|Acute respiratory failure
217237|NCT01868321|Acute respiratory distress syndrome
217238|NCT01868282|anterior cruciate ligament repair, Obturator nerve block, Hamstrings graft, Ropivacaine,
217239|NCT01868282|Postoperative pain
217240|NCT01868256|myocardial infarction
217241|NCT01868256|primary percutaneous intervention
217242|NCT01868256|prognosis
217243|NCT01868256|early discharge
217244|NCT01868243|Atrial Fibrillation
217245|NCT01868243|Bioprosthesis
217246|NCT01868243|Stroke
217247|NCT01868243|Dabigatran
217248|NCT01868243|Warfarin
217249|NCT01868204|Obesity
217250|NCT01868204|Binge eating disorder
217251|NCT01868204|Pharmacogenetic
217252|NCT01868204|Food craving
217253|NCT01868204|Brain areas
217254|NCT01868204|Topiramate
217255|NCT01868191|Diabetes
217256|NCT01868191|Neuropathy
217257|NCT01868178|awareness
217258|NCT01868165|Cognitive decline
217259|NCT01868165|High blood pressure
217260|NCT01868165|Hypertension
217261|NCT01868165|Ageing
217262|NCT01868165|Dementia
217263|NCT01868165|Antihypertensives
217264|NCT01868152|sufentanil
217265|NCT01868152|individual variation
217266|NCT01868152|pain threshold
217267|NCT01868152|narcotrend index
217268|NCT01868139|Cryotherapy
217269|NCT01868139|Esophageal cancer
217270|NCT01868139|Esophageal carcinoma
217271|NCT01868139|Liquid nitrogen
217272|NCT01868139|Esophageal adenocarcinoma
217273|NCT01868139|Esophageal squamous cell carcinoma
217274|NCT01868139|Endoscopy
217275|NCT01868139|Ablation
217276|NCT01868126|Santen
217277|NCT01868126|Eye
217278|NCT01868126|Glaucoma
217279|NCT01868126|Ocular hypertension
217280|NCT01868113|Children U-5
217281|NCT01868113|ALRI
217282|NCT01868113|Inhaled Corticosteroids
217283|NCT01868100|Cancer
217284|NCT01868100|quality of life
217285|NCT01868100|palliative care
217286|NCT01868100|supportive care
217287|NCT01868100|Financial distress
217288|NCT01868087|nutritional supplement
217289|NCT01868087|immune system
217290|NCT01868087|RC surgery
217291|NCT01868074|pregnancy, arch height, collapsed arch
217292|NCT01868048|Spasticity
217293|NCT01868048|Multiple Sclerosis
217294|NCT01868035|radioimmunotherapy
217295|NCT01868035|Iodine 131 Tositumomab
217296|NCT01868022|FGFR1
217297|NCT01868022|FP1039
217298|NCT01868022|GSK3052230
217299|NCT01868022|docetaxel
217300|NCT01868022|FGFR
217301|NCT01868022|carboplatin
217302|NCT01868022|HGS1036
217303|NCT01868022|squamous non-small cell lung cancer
217304|NCT01868022|paclitaxel
217305|NCT01868009|fluticasone furoate
217306|NCT01868009|COPD
217307|NCT01868009|ELLIPTA
217308|NCT01868009|fluticasone propionate
217309|NCT01868009|DISKUS
217310|NCT01868009|Novel Dry Powder Inhaler (NDPI)
217311|NCT01868009|device preference
217312|NCT01868009|salmeterol
217313|NCT01868009|vilanterol
217314|NCT01867996|Retosiban, Efavirenz, Induction
217315|NCT01867983|Tobacco cessation
217316|NCT01867983|Weight gain prevention
217317|NCT01867970|remote sensing technology
217318|NCT01867970|physical activity
217319|NCT01867970|self-management support
217320|NCT01867970|primary care nursing
217321|NCT01867957|anthrax
217322|NCT01867957|vaccine
217323|NCT01867957|bioterrorism
217324|NCT01867957|efficacy
217325|NCT01867957|safety
217326|NCT01867944|Chronic constipation
217327|NCT01867944|Hemorrhoids
217328|NCT01867944|Acupressure
217329|NCT01867905|Severe sepsis
217330|NCT01867905|Septic shock
217331|NCT01867905|Bacteremia
217332|NCT01867905|Antibiotics
217333|NCT01867905|Blood culture positivity
217334|NCT01867892|Locally Advanced Pancreatic Cancer
217335|NCT01867879|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
217336|NCT01867866|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
217337|NCT01867801|PCI
217338|NCT01867801|Coronary disease
217339|NCT01867801|Ischemia
217340|NCT01867775|Alzheimer's disease
217341|NCT01867775|Sleep disorders
217342|NCT01867775|Mirtazapine
217343|NCT01867775|Treatment
217344|NCT01867775|Intervention
217345|NCT01867775|insomnia
217346|NCT01867762|Chronic Obstructive Pulmonary Disease
217347|NCT01867762|JNJ 49095397
217348|NCT01867762|RV568
217349|NCT01867762|Forced expiratory volume in one second
217350|NCT01867762|FEV1
217351|NCT01867749|Major Depressive Disorder (MDD)
217352|NCT01867749|Miscarriage
217353|NCT01867749|Stillbirth
217354|NCT01867749|Neonatal death
217355|NCT01867749|Interpersonal psychotherapy
217356|NCT01867749|Group Therapy
217357|NCT01867749|Coping with Depression (CWD)
217358|NCT01867736|Stenosis
217359|NCT01867736|Occlusions
217360|NCT01867736|Infrapopliteal arteries
217361|NCT01867736|Below the knee arteries
217362|NCT01867736|PTA
217363|NCT01867736|POBA
217364|NCT01867736|DRB
217365|NCT01867723|Cancer internet support program
217366|NCT01867710|Mineralocorticoid Excess ; Chemotherapy-Naïve; Metastatic Castration-Resistant Prostate Cancer; Abiraterone Acetate; Zytiga; Prednisone; dexamethasone
217367|NCT01867684|Stroke
217368|NCT01867684|Acquired brain injury
217369|NCT01867671|Allergy, Peanut
217370|NCT01867671|Peanut allergy
217371|NCT01867671|Hypersensitivity
217372|NCT01867671|Immunotherapy
217373|NCT01867671|Desensitization, Immunologic
217374|NCT01867658|Pleural Air Leak
217375|NCT01867658|Pulmonary resection
217376|NCT01867658|Video Assisted
217377|NCT01867658|Robotic Assisted
217378|NCT01867645|Critical illness
217379|NCT01867645|Critical illness polyneuropathy and/or myopathy
217380|NCT01867645|Intravenous immunoglobulins
217381|NCT01867645|Multiple organ failure
217382|NCT01867645|SIRS
217383|NCT01867645|Sepsis
217384|NCT01867632|Furlow Palatoplasty
217385|NCT01867632|Acellular Dermal Matrix
217386|NCT01867619|Brain Neoplasms
217387|NCT01867619|Melanoma
217388|NCT01867619|Metastatic Melanoma
217389|NCT01867619|Brain Metastasis
217390|NCT01867619|Temozolomide
217391|NCT01867619|Temodar
217392|NCT01867619|Thalidomide
217393|NCT01867619|Thalomid
217394|NCT01867619|Lomustine
217395|NCT01867619|CCNU
217396|NCT01867619|CeeNU
217397|NCT01867593|Newly diagnosed
217398|NCT01867567|cesarean
217399|NCT01867567|bandage removal
217400|NCT01867567|infection
217401|NCT01867567|disruption
217402|NCT01867567|satisfaction
217403|NCT01867567|patient satisfaction
217404|NCT01867554|Intellectual disability
217405|NCT01867554|Autism spectrum disorders
217406|NCT01867554|gene
217407|NCT01867554|Next generation sequencing
217408|NCT01867541|cataract surgery
217409|NCT01867541|intraocular lens power calculation
217410|NCT01867541|effective lens position
217411|NCT01867541|improving the refractive outcome after cataract surgery
217412|NCT01867541|predicting the IOL position
217413|NCT01867515|Hearing
217414|NCT01867515|Hearing Loss, sensorineural
217415|NCT01867515|Speech Perception
217416|NCT01867463|Antigen
217417|NCT01867463|Ookinetes
217418|NCT01867463|Mosquito
217419|NCT01867463|Membrane
217420|NCT01867463|Assay
217421|NCT01867450|Biomarkers
217422|NCT01867450|Deisel Exhaust
217423|NCT01867450|Occupational Exposure
217424|NCT01867450|Cross-Sectional Study
217425|NCT01867437|24 Hour Energy Expenditure
217426|NCT01867437|Resting Energy Expenditure
217427|NCT01867437|Obesity
217428|NCT01867437|Healthy Volunteers
217429|NCT01867424|Testosterone Membrane Transporter
217430|NCT01867424|OATP1B3
217431|NCT01867424|Castration Resistant Prostate Cancer
217432|NCT01867424|Prostatectomy
217433|NCT01867424|Gadolinium-Based Contrast Agent
217434|NCT01867411|Smoking Cessation
217435|NCT01867411|Biomarkers
217436|NCT01867411|fMRI
217437|NCT01867411|e-Cigarettes
217438|NCT01867398|Conduct Disorder
217439|NCT01867398|Antipsychotic
217440|NCT01867398|Treatment Study
217441|NCT01867398|Functional Magnetic Resonance Imaging (fMRI)
217442|NCT01867398|Adolescents
217443|NCT01867385|Fatigue
217444|NCT01867385|Chronic Hepatitis
217445|NCT01867385|Chronic Hepatitis B
217446|NCT01867385|Chronic Hepatitis C
217447|NCT01867385|Hepatitis
217448|NCT01867372|Alzheimer's Disease
217449|NCT01867359|Alzheimer Disease
217450|NCT01867359|Molecular
217451|NCT01867359|Molecular Genetics
217452|NCT01867359|DNA
217453|NCT01867346|Cognition
217454|NCT01867346|Aging
217455|NCT01867346|Cognitive Decline
217456|NCT01867346|Dementia
217457|NCT01867346|Alzheimer's Disease
217458|NCT01867333|Immunotherapy
217459|NCT01867333|Gene Transfer
217460|NCT01867333|Androgen Receptor Antagonist
217461|NCT01867333|PSA
217462|NCT01867333|Immune Response
217463|NCT01867320|HTLV-1
217464|NCT01867320|HTLV-1 Associated Myelopathy
217465|NCT01867281|aspirin
217466|NCT01867281|asthma
217467|NCT01867281|Aspirin desensitization
217468|NCT01867281|Aspirin induced asthma
217469|NCT01867281|Immune System Diseases
217470|NCT01867281|Respiratory Hypersensitivity
217471|NCT01867268|Acetazolamide administration
217472|NCT01867268|prone positioning
217473|NCT01867268|Cerebrospinal fluid leakage
217474|NCT01867268|Cerebrospinal fluid collection
217475|NCT01867268|wound dehiscence
217476|NCT01867255|venlafaxine
217477|NCT01867255|Effexor
217478|NCT01867255|antidepressive agent
217479|NCT01867242|cigarette
217480|NCT01867242|snus
217481|NCT01867242|smoking
217482|NCT01867242|tobacco
217483|NCT01867229|pre-menauposal
217484|NCT01867229|neo-adjuvant or adjuvant chemotherapy
217485|NCT01867229|no metastases
217486|NCT01867190|CLI
217487|NCT01867177|HIV
217488|NCT01867177|health care utilization
217489|NCT01867177|HIV testing
217490|NCT01867177|access to care
217491|NCT01867164|Vaginitis
217492|NCT01867164|Infectious vaginosis
217493|NCT01867164|Terconazole
217494|NCT01867164|Clindamycin
217495|NCT01867164|Fluocinolone
217496|NCT01867164|Metronidazole
217497|NCT01867164|Nystatin
217498|NCT01867151|Burning Mouth Syndrome
217499|NCT01867151|Gluten
217500|NCT01867151|Gluten Free Diet
217501|NCT01867138|Coagulase negative staphylococcus
217502|NCT01867138|nosocomial neonatal sepsis
217503|NCT01867138|cefazolin
217504|NCT01867138|vancomycin
217505|NCT01867138|newborn
217506|NCT01867086|ovarian cancer
217507|NCT01867060|Cardiac monitoring
217508|NCT01867060|Biomarkers
217509|NCT01867060|Transthoracic echocardiography
217510|NCT01867034|non ST segment myocardial infarction
217511|NCT01867021|Trivalent inactivated subunit influenza vaccines
217512|NCT01867021|50 years and above
217513|NCT01867021|healthy subjects
217514|NCT01865968|inactivated HAV vaccine; live attenuated HAV vaccine; immunogenicity; safety
217515|NCT01865955|Ultrasound
217516|NCT01865955|Spinal anesthesia
217517|NCT01865955|Cesarean section
217518|NCT01865942|spinal metastases
217519|NCT01865942|spine surgery
217520|NCT01865942|metastatic spinal cord compression
217521|NCT01865942|EQ-5D
217522|NCT01865942|HRQOL
217523|NCT01865903|NSCLC
217524|NCT01865903|sarcopenia
217525|NCT01865903|cachexia
217526|NCT01865890|Plavix or clopidogrel resistance
217527|NCT01865877|Parkinson's disease
217528|NCT01865877|Motor
217529|NCT01865877|Non-motor
217530|NCT01865877|Progression
217531|NCT01865877|Complications
217532|NCT01865864|CPAP
217533|NCT01865864|diurnal blood pressure
217534|NCT01865864|obstructive sleep apnea
217535|NCT01865864|24 hour blood pressure monitor
217536|NCT01865851|Inspired oxygen
217537|NCT01865851|end-tidal oxygen
217538|NCT01865851|end-tidal carbon dioxide
217539|NCT01865851|respiratory rate
217540|NCT01865851|preoxygenation
217541|NCT01865851|classic face mask
217542|NCT01865851|NuMask
217543|NCT01865838|Total thyroidectomy
217544|NCT01865838|Seprafilm
217545|NCT01865838|Swallowing difficulty post thyroidectomy
217546|NCT01865825|Erosive Esophagitis
217547|NCT01865825|Gastroesophageal reflux disease
217548|NCT01865799|FTC/TDF
217549|NCT01865799|PrEP
217550|NCT01865799|Truvada
217551|NCT01865799|Drug utilization
217552|NCT01866995|Ginseng
217553|NCT01866995|Prostatostasis
217554|NCT01866995|Erectile Dysfunction
217555|NCT01866982|umbilical cord milking
217556|NCT01866982|delayed cord clamping
217557|NCT01866943|Blood Loss
217558|NCT01866943|Tranexamic Acid
217559|NCT01866943|Total Hip Arthroplasty
217560|NCT01866943|Post Op
217561|NCT01866943|Post Operative
217562|NCT01866943|Prevent Post Operative Blood Loss
217563|NCT01866917|Transversis Abdominis Plane Block
217564|NCT01866917|obese
217565|NCT01866917|robotic surgery
217566|NCT01866917|laparoscopic surgery
217567|NCT01866904|Coronary artery disease, Myocardial infarction
217568|NCT01866891|hemodialysis
217569|NCT01866891|microcirculation
217570|NCT01866891|physical perdialytic activity
217571|NCT01866891|cycling
217572|NCT01866878|transcutaneous electrical nerve stimulation, sensitivity, multiple sclerosis,Reeducation through labor tactile discrimination
217573|NCT01866865|BRCA1
217574|NCT01866865|BRCA2
217575|NCT01866852|Longitudinal Study
217576|NCT01866839|Acute Lymphoblastic Leukemia (ALL)
217577|NCT01866839|Acute Myelogenous Leukemia (AML)
217578|NCT01866839|Chronic Lymphocytic Leukemia (CLL)
217579|NCT01866839|Chronic Myelogenous Leukemia (CML)
217580|NCT01866839|Myelodyplastic Syndrome (MDS)
217581|NCT01866826|HIV
217582|NCT01866826|Eradication Strategies
217583|NCT01866826|Immune Activation
217584|NCT01866813|breast cancer
217585|NCT01866813|cancer survivors
217586|NCT01866800|TAVI
217587|NCT01866800|TAVR
217588|NCT01866800|CIN
217589|NCT01866800|AKI
217590|NCT01866787|Postoperative orthostatic intolerance
217591|NCT01866787|Surgical inflammatory response
217592|NCT01866722|nicotine dependence
217593|NCT01866722|smoking cessation
217594|NCT01866722|lapse
217595|NCT01866722|relapse
217596|NCT01866722|tobacco
217597|NCT01866722|quit attempts
217598|NCT01866722|abstinence
217599|NCT01866722|motivation
217600|NCT01866722|reduction
217601|NCT01866696|Computer assisted implant surgery,
217602|NCT01866696|Immediate loading,
217603|NCT01866696|CAD/CAM
217604|NCT01866683|Yoga
217605|NCT01866683|Electroencephalography
217606|NCT01866683|Heart rate variability
217607|NCT01866683|Breathing Exercises
217608|NCT01866683|Quality of life
217609|NCT01866670|spiritual distress
217610|NCT01866670|nursing
217611|NCT01866670|breast neoplasms
217612|NCT01866657|cerebral oximetry
217613|NCT01866657|randomized controlled pilot study
217614|NCT01866657|thoracic surgery
217615|NCT01866657|single lung ventilation
217616|NCT01866644|Liver transplantation, n-acetylcysteine
217617|NCT01866618|Natural
217618|NCT01866618|IVF Cycle
217619|NCT01866605|anxiety
217620|NCT01866605|midazolam
217621|NCT01866605|forced-air warming
217622|NCT01866592|Psoriasis
217623|NCT01866592|Cardiovascular Disease
217624|NCT01866592|Vascular Inflammation
217625|NCT01866592|Lipid Biomarkers
217626|NCT01866592|Metabolic biomarkers
217627|NCT01866592|FDG-PET/CT
217628|NCT01866579|Retinal Nerve Fiber Layer Thickness, Optical Coherence Tomography, Ethambutol optic neuropathy
217629|NCT01866553|CML
217630|NCT01866553|suboptimal molecular response
217631|NCT01866553|nilotinib
217632|NCT01866553|pegylated interferon α2b
217633|NCT01866540|influenza, LAIV, immune response
217634|NCT01866527|Developmental dysplasia of the hip,
217635|NCT01866527|DDH,
217636|NCT01866527|avascular necrosis,
217637|NCT01866527|late detected cases
217638|NCT01866514|EZ-IO
217639|NCT01866514|IO
217640|NCT01866514|Intraosseous Vascular Access
217641|NCT01866501|Intraosseous Vascular Access
217642|NCT01866501|IO Access
217643|NCT01866501|IO Vascular Access
217644|NCT01866501|EZ-IO
217645|NCT01866488|Labor induction
217646|NCT01866488|Misoprostol
217647|NCT01866488|Cytotec
217648|NCT01866488|Cook Obstetric Double Balloon Catheter
217649|NCT01866475|IO access
217650|NCT01866475|Intraosseous vascular access
217651|NCT01866475|EZ-IO
217652|NCT01866436|Cognitive skills
217653|NCT01866436|Multimedia
217654|NCT01866436|Education
217655|NCT01866436|Colorectal surgery
217656|NCT01866397|cidofovir
217657|NCT01866397|cvvh
217658|NCT01866397|renal replacement therapy
217659|NCT01866397|HCMV
217660|NCT01866397|Pharmacokinetics of cidofovir during CVVH
217661|NCT01866397|continuous venovenous hemofiltration
217662|NCT01866371|Retina
217663|NCT01866371|imaging
217664|NCT01866371|retinal degeneration
217665|NCT01866345|orthodontics
217666|NCT01866345|Tooth Movement
217667|NCT01866345|Bone Remodeling
217668|NCT01866345|Mandible
217669|NCT01866345|Osteotomy
217670|NCT01866332|back pain
217671|NCT01866332|tape
217672|NCT01866332|chronic
217673|NCT01866319|PD-1
217674|NCT01866319|PD1
217675|NCT01866319|PD-L1
217676|NCT01866319|PDL1
217677|NCT01866293|Cabozantinib (XL184)
217678|NCT01866293|12-240
217679|NCT01866280|Sleep
217680|NCT01866280|Sleep duration
217681|NCT01866280|Meals
217682|NCT01866280|Food intake
217683|NCT01866280|Obesity
217684|NCT01866267|Human Immunodeficiency Virus
217685|NCT01866267|AIDS
217686|NCT01866254|Hydromorphone
217687|NCT01866254|Morphine
217688|NCT01866254|cesarean delivery
217689|NCT01866254|pain management
217690|NCT01866254|respiratory depression
217691|NCT01866228|Consultation Recording
217692|NCT01866228|Brain Tumor
217693|NCT01866228|Neuroendocrine Cancer
217694|NCT01866228|Quality of Life
217695|NCT01866228|Patient Satisfaction
217696|NCT01866215|gluconeogenesis
217697|NCT01866215|de novo lipogenesis
217698|NCT01866215|intramyocellular lipids
217699|NCT01866215|muscle glycogen
217700|NCT01866215|fructose
217701|NCT01866189|ischemic stroke
217702|NCT01866189|hypoxic tissues
217703|NCT01866189|F-MISO uptake
217704|NCT01866189|Magnetic Resonance Imaging
217705|NCT01866189|F-MISO Positon Emission Tomography
217706|NCT01866137|Copeptin
217707|NCT01866137|psychological stress
217708|NCT01866137|The Trier Social Stress Test (TSST)
217709|NCT01866124|acute malnutrition
217710|NCT01866124|multiannual and seasonal cash transfers
217711|NCT01866124|safety nets
217712|NCT01866124|Burkina Faso
217713|NCT01866098|antipsychotic
217714|NCT01866098|severe mental illness
217715|NCT01866098|weight loss
217716|NCT01866085|stress urinary incontinence
217717|NCT01866085|post prostatectomy
217718|NCT01866072|ACLF
217719|NCT01866072|AVH
217720|NCT01866072|Fibroscan
217721|NCT01866072|Transient elastography
217722|NCT01866059|root caries
217723|NCT01866059|GIC
217724|NCT01866059|RMGIC
217725|NCT01866059|Biodentine
217726|NCT01866059|Calcium silicate
217727|NCT01866046|battered women
217728|NCT01866046|HIV risk
217729|NCT01866046|STI risk
217730|NCT01866033|Healthy volunteer
217731|NCT01866033|PCI-32765
217732|NCT01866033|PCI 45227
217733|NCT01866033|13C6 PCI-32765
217734|NCT01866033|Pharmacokinetic
217735|NCT01866033|Bioavailability
217736|NCT01866020|aspergillosis
217737|NCT01866020|fungal infection
217738|NCT01866020|ICU
217739|NCT01866007|Healthy
217740|NCT01866007|Guselkumab
217741|NCT01866007|CNTO1959
217742|NCT01866007|Pharmacokinetics
217743|NCT01866007|UltraSafe Passive Delivery System (PFS-U)
217744|NCT01866007|Prefilled syringe facilitated injection device (PFS FID)
217745|NCT01865994|Cardiac Output
217746|NCT01865994|esCCO
217747|NCT01865994|TEE
217748|NCT01865994|Pediatric cardiac surgery
217749|NCT01865981|iPS cells
217750|NCT01865981|cardiomyocytes
217751|NCT01865981|Brugada
217752|NCT01865981|Ventricular Fibrillation
217753|NCT01865981|electrophysiology
217754|NCT01865786|FTC/TDF
217755|NCT01865786|Truvada
217756|NCT01865786|PrEP
217757|NCT01865786|Antiretroviral Pregnancy Registry
217758|NCT01865760|Glucagon like peptide 1
217759|NCT01865760|Insulin secretion
217760|NCT01865760|Hypoglycemia
217761|NCT01865747|renal cell cancer
217762|NCT01865747|kidney
217763|NCT01865747|vascular endothelial growth factor receptor 2 (VEGFR2)
217764|NCT01865747|tyrosine kinase inhibitor
217765|NCT01865747|hepatocyte growth factor receptor protein (MET)
217766|NCT01865747|von Hippel-Lindau gene
217767|NCT01865734|Fasciitis, Plantar
217768|NCT01865734|Heel Pain
217769|NCT01865734|Physical Therapy
217770|NCT01865734|Podiatry
217771|NCT01865734|Musculoskeletal Manipulations
217772|NCT01865734|Exercise Therapy
217773|NCT01865721|Bowel cancer screening
217774|NCT01865721|Analgesia
217775|NCT01865721|Entonox
217776|NCT01865721|Pain
217777|NCT01865721|Side effects
217778|NCT01865721|Colonoscopy
217779|NCT01865708|Ethanol Lock
217780|NCT01865708|Alcohol lock
217781|NCT01865708|Urinary catheter
217782|NCT01865708|Safety
217783|NCT01865695|pancreatic exocrine insufficiency
217784|NCT01865695|faecal elastase
217785|NCT01865695|diarrhoea
217786|NCT01865695|coeliac
217787|NCT01865695|creon
217788|NCT01865695|gastrointestinal
217789|NCT01865682|Ankle
217790|NCT01865682|Knee
217791|NCT01865682|Orthosis
217792|NCT01865682|Kinematics
217793|NCT01865682|Kinetics
217794|NCT01865669|Uterine contraction
217795|NCT01865669|Dose response
217796|NCT01865669|Oxytocin
217797|NCT01865656|provider skill and self-efficacy
217798|NCT01865656|Appropriate and timely referral for obstetric emergencies
217799|NCT01865656|Intervention feasibility and acceptability
217800|NCT01865643|Laryngoscopy
217801|NCT01865643|Intubation
217802|NCT01865643|Glidescope
217803|NCT01865630|Prophylactic treatment with Etanercept in aSAH.
217804|NCT01865630|Safety of Etanercept in the prevention of DCI in aSAH.
217805|NCT01865591|hypertension
217806|NCT01865591|uncontrolled hypertension
217807|NCT01865591|resistant hypertension
217808|NCT01865565|gastrointestinal stromal tumor
217809|NCT01865565|GIST
217810|NCT01865565|neoadjuvant
217811|NCT01865565|imatinib
217812|NCT01865552|Pharmacokinetics
217813|NCT01865539|Chronic lower back pain
217814|NCT01865539|Custom foot orthotics
217815|NCT01865539|Veterans
217816|NCT01865526|Chronic kidney disease
217817|NCT01865526|Low protein diet
217818|NCT01865526|CKD stage 3b-5
217819|NCT01865513|Anaesthesia
217820|NCT01865513|Anaesthesiology
217821|NCT01865513|muscle Relaxants
217822|NCT01865513|POPULAR
217823|NCT01865513|postoperative pulmonary complications
217824|NCT01865513|Respiratory failure
217825|NCT01865513|Suspected pulmonary infection
217826|NCT01865513|Pulmonary infiltrates
217827|NCT01865513|Pleural effusion
217828|NCT01865513|Atelectasis
217829|NCT01865513|Pneumothorax
217830|NCT01865513|Bronchospasm
217831|NCT01865513|Aspiration pneumonitis
217832|NCT01865513|Cardiopulmonary oedema
217833|NCT01865513|European Society of Anaesthesiology
217834|NCT01865513|neuromuscular blockade
217835|NCT01865513|europe
217836|NCT01865500|COPD exacerbation
217837|NCT01865500|Nebulized budesonide
217838|NCT01865500|Parenteral steroid
217839|NCT01865487|BCG Vaccinated
217840|NCT01865487|HIV Negative
217841|NCT01865474|DLBS1033, Type 2 DM, fibrinolytic, hypercoagulation
217842|NCT01865461|Magnetic Resonance Imaging
217843|NCT01865448|Docosahexaenoic Acids
217844|NCT01865448|Fatty Acids, Omega-3
217845|NCT01865448|Obesity
217846|NCT01865448|Inflammation
217847|NCT01865409|Newborn
217848|NCT01865409|Prematures
217849|NCT01865409|Feeding difficulty
217850|NCT01865409|Kangaroo Care
217851|NCT01865409|Heart rate variability
217852|NCT01865266|ventilator-associated pneumonia
217853|NCT01865266|mechanical ventilation
217854|NCT01865266|ulinastatin for injection
217855|NCT01865266|bronchoalveolar lavage fluid
217856|NCT01865266|inflammatory factors
217857|NCT01865253|renal denervation
217858|NCT01865253|blood pressure
217859|NCT01865253|cardiovascular risk
217860|NCT01865253|target organ damage
217861|NCT01865253|sympathetic activity
217862|NCT01865253|chronic kidney disease
217863|NCT01865253|non-compliance
217864|NCT01865240|renal denervation
217865|NCT01865240|blood pressure
217866|NCT01865240|cardiovascular risk
217867|NCT01865240|target organ damage
217868|NCT01865240|sympathetic activity
217869|NCT01865227|Obesity
217870|NCT01865227|Bariatric surgery
217871|NCT01865227|Binge Eating Disorder
217872|NCT01865227|Psychological Health
217873|NCT01865227|Counselling
217874|NCT01865201|Radiotherapy
217875|NCT01865201|Radiation-induced brain necrosis
217876|NCT01865201|Edaravone
217877|NCT01865201|Effectiveness
217878|NCT01865201|Safety
217879|NCT01865188|LCZ696,
217880|NCT01865188|amlodipine,
217881|NCT01865188|hypertension,
217882|NCT01865188|ABPM
217883|NCT01865162|Glioblastoma multiforme, ketogenic diet, neoplasm
217884|NCT01865149|Child
217885|NCT01865149|Optic nerve sheath diameter
217886|NCT01865149|Hydrocephalus
217887|NCT01865149|Intracranial hypertension
217888|NCT01865123|post-traumatic stress disorder
217889|NCT01865123|transcendental meditation
217890|NCT01865123|cognitive behavioral therapy
217891|NCT01865123|prolonged exposure
217892|NCT01865110|Mantle Cell Lymphoma
217893|NCT01865110|RCHOP
217894|NCT01865110|RHAD
217895|NCT01865110|rituximab
217896|NCT01865110|lenalidomide
217897|NCT01865097|Imagery
217898|NCT01865097|Pain
217899|NCT01865097|Depression
217900|NCT01865097|Non-Motor
217901|NCT01865071|ileostomy
217902|NCT01865071|rectal resection
217903|NCT01865071|proctectomy
217904|NCT01865071|stoma closure
217905|NCT01865071|rectal cancer
217906|NCT01864993|non celiac gluten sensitivity
217907|NCT01864993|gluten
217908|NCT01864993|irritable bowel syndrome
217909|NCT01864993|functional disorders
217910|NCT01864967|carbon dioxide infusion
217911|NCT01864967|dilatation of peripheral blood vessels
217912|NCT01864967|capillaries
217913|NCT01864967|macrophags
217914|NCT01864967|fibroblasts
217915|NCT01864967|Improvement granulation tissue in chronic wounds
217916|NCT01864954|Smoking
217917|NCT01864954|Postpartum
217918|NCT01864954|Pregnancy
217919|NCT01864954|Quit
217920|NCT01864954|Tobacco
217921|NCT01864954|Abstinence
217922|NCT01864954|Relapse
217923|NCT01864954|Relapse prevention
217924|NCT01864941|Multiple Sclerosis
217925|NCT01864941|MS
217926|NCT01864941|CCSVI
217927|NCT01864941|Zamboni
217928|NCT01864941|catheter venography
217929|NCT01864941|balloon angioplasty
217930|NCT01864928|Acute Ischemic stroke
217931|NCT01864928|ePRISM
217932|NCT01864915|colon capsule
217933|NCT01864915|bowel preparation
217934|NCT01864915|booster
217935|NCT01864915|prucalopride
217936|NCT01864915|picosalax
217937|NCT01864902|CD33 positive acute myeloid leukemia (AML)
217938|NCT01864850|HNSCC
217939|NCT01864850|Elderly
217940|NCT01864850|Geriatry
217941|NCT01864837|tongue coating thickness
217942|NCT01864837|tongue diagnosis system
217943|NCT01864837|tongue coating percentage
217944|NCT01864837|availability
217945|NCT01864837|diagnostic device
217946|NCT01864824|air pollution
217947|NCT01864824|particulate matter 2.5 (PM2.5)
217948|NCT01864824|methyl donor
217949|NCT01864824|DNA methylation
217950|NCT01864824|mRNA
217951|NCT01864824|epigenetics
217952|NCT01864824|controlled human exposures
217953|NCT01864824|cardiovascular responses
217954|NCT01864811|infants
217955|NCT01864811|unilateral cerebral pares
217956|NCT01864811|hand function
217957|NCT01864811|early intervention
217958|NCT01864811|constraint induced movement therapy
217959|NCT01864798|Young
217960|NCT01864798|Breast Neoplasms
217961|NCT01864798|Denosumab
217962|NCT01864798|RANKL
217963|NCT01864785|Operative treatment
217964|NCT01864785|internal fixation
217965|NCT01864785|posterior spinal fusion
217966|NCT01864772|HNSCC
217967|NCT01864772|Metastatic
217968|NCT01864772|Recurrent
217969|NCT01864772|Elderly
217970|NCT01864772|Geriatry
217971|NCT01864759|melanoma
217972|NCT01864759|oncolytic
217973|NCT01864759|adenovirus
217974|NCT01864759|virotherapy
217975|NCT01864759|locally advanced
217976|NCT01864759|metastatic
217977|NCT01864733|Chronic heart failure
217978|NCT01864733|Undernutrition
217979|NCT01864733|Rehabilitation
217980|NCT01864733|Physical exercise
217981|NCT01864733|Nutrition
217982|NCT01864733|n-3 fatty acids
217983|NCT01864733|Androgen
217984|NCT01864733|Testosterone
217985|NCT01864720|stepped care model
217986|NCT01864720|insomnia
217987|NCT01864720|cancer
217988|NCT01864720|cognitive-behavioural therapy
217989|NCT01864720|self-help treatment
217990|NCT01864720|Internet
217991|NCT01864720|non-inferiority design
217992|NCT01864720|cost-effectiveness
217993|NCT01864707|multiple sclerosis, fatigue
217994|NCT01864694|behavioral research
217995|NCT01864694|diet
217996|NCT01864694|health information systems
217997|NCT01864681|NSCLC
217998|NCT01864681|TKIs
217999|NCT01864681|Metformin
218000|NCT01864681|PFS
218001|NCT01864681|overall survival
218002|NCT01864681|IL-6
218003|NCT01864668|Acute respiratory distress syndrome
218004|NCT01864668|lung strain
218005|NCT01864668|small tidal volume
218006|NCT01864616|Vitamin D
218007|NCT01864616|Crohn disease
218008|NCT01864616|Disease activity
218009|NCT01864616|Inflammation
218010|NCT01864616|prevention
218011|NCT01864603|HIV treatment and prevention
218012|NCT01864603|Tuberculosis
218013|NCT01864603|Community health campaign
218014|NCT01864603|PrEP
218015|NCT01864590|Open Abdomen
218016|NCT01864590|Negative Pressure Wound Therapy
218017|NCT01864590|Temporary Abdominal Closure
218018|NCT01864590|Mesh
218019|NCT01864590|Abdominal reconstruction
218020|NCT01864564|Gestational diabetes
218021|NCT01864564|Screening
218022|NCT01864564|Obesity
218023|NCT01864564|Anhydroglucitol
218024|NCT01864538|TH-302
218025|NCT01864538|Advanced Melanoma
218026|NCT01864538|Metastatic
218027|NCT01864538|Biomarker
218028|NCT01864538|Mucosal Melanoma
218029|NCT01864538|Evofosfamide
218030|NCT01864525|voice
218031|NCT01864525|tremor
218032|NCT01864525|essential tremor
218033|NCT01864525|essential voice tremor
218034|NCT01864525|voice treatment
218035|NCT01864525|octanoic acid
218036|NCT01864525|octanol
218037|NCT01864525|voice disorder
218038|NCT01864525|dysphonia
218039|NCT01864512|Immune Thrombocytopenia
218040|NCT01864512|eltrombopag
218041|NCT01864512|immune regulation
218042|NCT01864473|Fistula , Bhagandar
218043|NCT01864460|autonomic
218044|NCT01864460|neuropathy
218045|NCT01864460|balance
218046|NCT01864460|exercise
218047|NCT01864447|VTE
218048|NCT01864447|Exercise
218049|NCT01864447|Diet
218050|NCT01864447|Weight loss
218051|NCT01864447|DVT
218052|NCT01864447|PE
218053|NCT01864434|Knee Prosthesis
218054|NCT01864434|Total Knee Arthroplasty
218055|NCT01864434|Cruciate Retaining
218056|NCT01864434|Posterior Cruciate Retaining
218057|NCT01864421|Infant, Newborn
218058|NCT01864421|Delivery, Obstetric
218059|NCT01864421|Umbilical Cord
218060|NCT01864408|Patient counseling
218061|NCT01864408|Patient satisfaction
218062|NCT01864408|Pelvic organ prolapse
218063|NCT01864395|cardiovascular surgery
218064|NCT01864395|cardiac surgery
218065|NCT01864395|cardiopulmonary bypass
218066|NCT01864395|IV fluids
218067|NCT01864395|blood pressure
218068|NCT01864395|heart-lung machine
218069|NCT01864395|hemofilter
218070|NCT01864395|online MUF
218071|NCT01864395|offline MUF
218072|NCT01864395|modified ultrafiltration
218073|NCT01864395|multiple-pass hemofiltration
218074|NCT01864395|centrifugation method
218075|NCT01864395|blood transfusion
218076|NCT01864395|plasma proteins
218077|NCT01864395|post-cardiopulmonary bypass
218078|NCT01864395|hemoglobin
218079|NCT01864395|clotting factors
218080|NCT01864395|systemic blood pressure
218081|NCT01864395|cardiac index
218082|NCT01864395|cytokines
218083|NCT01864395|post-operative bleeding
218084|NCT01864395|protamine administration
218085|NCT01864395|patient size
218086|NCT01864395|allogeneic transfusion
218087|NCT01864395|total protein
218088|NCT01864395|albumin
218089|NCT01864395|vasoactive inotrope score
218090|NCT01864395|fluid balance
218091|NCT01864395|chest tube loss
218092|NCT01864395|length of stay
218093|NCT01864395|ventilation time
218094|NCT01864395|markers of inflammation
218095|NCT01864382|Trunk performance
218096|NCT01864382|exercise,
218097|NCT01864382|"core stability,"
218098|NCT01864382|sitting balance
218099|NCT01864369|Heart Failure
218100|NCT01864369|e-counseling
218101|NCT01864369|quality of life
218102|NCT01864369|self-care
218103|NCT01864356|IVF failure
218104|NCT01864356|Repeated IVF failure
218105|NCT01864356|Implantation failure
218106|NCT01864356|Repeated implantation failure
218107|NCT01864356|IVF
218108|NCT01864356|NT100
218109|NCT01864343|Myocardial Infarction
218110|NCT01864343|Myocardial Reperfusion Injury
218111|NCT01864343|Reperfusion Injury
218112|NCT01864343|Anterior Wall Myocardial Infarction
218113|NCT01864343|Inferior Wall Myocardial Infarction
218114|NCT01864343|Myocardial Ischemia
218115|NCT01864330|topical lubricants
218116|NCT01864330|optical coherence tomography
218117|NCT01864330|tear break up time
218118|NCT01864330|Schirmer I test
218119|NCT01864317|7-Tesla Magnetic Resonance Imaging
218120|NCT01864317|Intraocular Pressure
218121|NCT01864317|Retinal Nerve Fiber Thickness
218122|NCT01864317|Visual Field Test
218123|NCT01864304|Williams Syndrome
218124|NCT01864291|Auditory Brainstem Implant
218125|NCT01864291|ABI
218126|NCT01864291|Nucleus 24
218127|NCT01864291|Deafness
218128|NCT01864291|Hearing loss
218129|NCT01864291|Non-tumor
218130|NCT01864291|Non-NF2
218131|NCT01864291|Pediatric
218132|NCT01864291|ABI541
218133|NCT01864265|Rheumatoid arthritis
218134|NCT01864265|functional MRI
218135|NCT01864265|Prediction of Response
218136|NCT01864265|Certolizumab Pegol
218137|NCT01864265|RF and/or ACPA positive
218138|NCT01864239|Adherence
218139|NCT01864187|Pharmacokinetics
218140|NCT01864187|Dexmedetomidine
218141|NCT01864187|Obesity
218142|NCT01864122|nutrient biomarkers
218143|NCT01864122|food frequency questionnaire
218144|NCT01864122|predictors of CVD
218145|NCT01864122|fatty acids
218146|NCT01864122|phylloquinone
218147|NCT01864122|dihydrophylloquinone
218148|NCT01864109|CYCLOPHOSPHAMIDE (CYTOXAN)
218149|NCT01864109|DOXORUBICIN/ADRIAMYCIN
218150|NCT01864109|ETOPOSIDE (VP-16)
218151|NCT01864109|IFOSFAMIDE
218152|NCT01864109|IRINOTECAN (CPT-11) CAMPTOSAR
218153|NCT01864109|TEMOZOLOMIDE
218154|NCT01864109|VINCRISTINE
218155|NCT01864109|13-068
218156|NCT01864096|localized
218157|NCT01864096|prostate
218158|NCT01864096|cancer
218159|NCT01864096|metformin
218160|NCT01864096|active surveillance
218161|NCT01864083|FACBC PET/PEM
218162|NCT01864083|MR
218163|NCT01864083|11-177
218164|NCT01864070|Liver cancer
218165|NCT01864070|Neuroendocrine tumors
218166|NCT01864070|NET
218167|NCT01864070|Liver dominant disease
218168|NCT01864070|TheraSphere
218169|NCT01864070|Yttrium-90
218170|NCT01864070|Y-90
218171|NCT01864070|Everolimus
218172|NCT01864070|Afinitor
218173|NCT01864070|Zortress
218174|NCT01864070|RAD001
218175|NCT01864070|Microspheres
218176|NCT01864057|thiamine deficiency
218177|NCT01864031|Alcohol
218178|NCT01864031|Drinking
218179|NCT01864031|Abstainers
218180|NCT01864031|Former drinkers
218181|NCT01864031|Ex-drinkers
218182|NCT01864031|Aetiology
218183|NCT01864031|Initial presentation
218184|NCT01864031|Chronic Stable Angina
218185|NCT01864031|Unstable Angina
218186|NCT01864031|Coronary Heart Disease Not Otherwise Specified
218187|NCT01864031|Acute Myocardial Infarction
218188|NCT01864031|Heart Failure
218189|NCT01864031|ST elevation Myocardial Infarction (STEMI)
218190|NCT01864031|non-ST elevation Myocardial Infarction (nSTEMI)
218191|NCT01864031|Myocardial Infarction Not Otherwise Specified (MI NOS)
218192|NCT01864031|Ventricular Arrhythmias
218193|NCT01864031|Cardiac Arrest
218194|NCT01864031|Abdominal Aortic Aneurysm
218195|NCT01864031|Peripheral Arterial Disease
218196|NCT01864031|Ischaemic Stroke
218197|NCT01864031|Subarachnoid Haemorrhagic Stroke
218198|NCT01864031|Intracerebral haemorrhagic Stroke
218199|NCT01864031|Stroke Not Otherwise Specified
218200|NCT01864031|Sudden Cardiac Death
218201|NCT01864031|Unheralded Coronary Death
218202|NCT01864031|Mortality
218203|NCT01864031|Coronary Heart Disease (CHD)
218204|NCT01864031|Cardiovascular Disease (CVD)
218205|NCT01864031|Fatal Cardiovascular Disease (fatal CVD)
218206|NCT01864005|Non-ST or ST Elevation Acute Coronary Syndromes, Ticagrelor, Clopidogrel, Antiplatelet Effect
218207|NCT01863992|home ventilation
218208|NCT01863979|Atrial Fibrillation
218209|NCT01863979|Thromboembolism
218210|NCT01863966|Achalasia
218211|NCT01863966|Hot water drinking therapy
218212|NCT01863966|Pneumatic dilation
218213|NCT01863914|ESRD
218214|NCT01863914|Diabetes mellitus
218215|NCT01863914|Endothelial progenitor cells
218216|NCT01863914|Hemodialysis
218217|NCT01863914|rosuvastatin
218218|NCT01863875|Cochlear Implant
218219|NCT01863875|Hearing loss
218220|NCT01863875|Language Development
218221|NCT01863875|Quality of life
218222|NCT01863862|Rectal cancer
218223|NCT01863862|Chemoradiation
218224|NCT01863862|Complete pathological response
218225|NCT01863849|uncontrolled,
218226|NCT01863849|open,
218227|NCT01863849|multi-centre
218228|NCT01863849|immunogenicity and tolerability
218229|NCT01863849|two groups according to age (18-59 years and ≥60 years)
218230|NCT01863836|Radial endobronchial ultrasound
218231|NCT01863836|Peripheral lung lesion
218232|NCT01863836|Fluoroscopy
218233|NCT01863836|Lung cancer
218234|NCT01863823|Symptomatic patients
218235|NCT01863823|asymptomatic individuals
218236|NCT01863823|clinical trial
218237|NCT01863810|Diabetic Neuropathy
218238|NCT01863810|Neuropathic Pain
218239|NCT01863810|Pregabalin
218240|NCT01863784|Hepatic Impairment
218241|NCT01863784|Mild and moderate hepatic impairment
218242|NCT01863784|Normal hepatic function
218243|NCT01863784|Pharmacokinetics
218244|NCT01863784|JNJ-38518168
218245|NCT01863771|Ulcerative Colitis
218246|NCT01863771|Japanese
218247|NCT01863771|Subcutaneous
218248|NCT01863771|Golimumab
218249|NCT01863745|ggastrointestinal stromal tumors
218250|NCT01863745|gastrointestinal,
218251|NCT01863745|stromal,
218252|NCT01863745|tumors,
218253|NCT01863745|GIST,
218254|NCT01863745|AMN107,
218255|NCT01863745|nilotinib
218256|NCT01863732|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, PFS, pre-filled syringe, secukinumab, self-injection
218257|NCT01863719|Colistin, Pneumococcal Infections, Nosocomial Pneumonia, Multi Drug Resistant
218258|NCT01863706|Misoprostol
218259|NCT01863706|Oxytocin
218260|NCT01863706|Post Partum Hemorrhage (PPH)
218261|NCT01863706|Third stage of labour
218262|NCT01863680|Infertility
218263|NCT01863680|COL-1620
218264|NCT01863680|progesterone gel
218265|NCT01863680|Fertilization in Vitro
218266|NCT01863680|Embryo Transfer
218267|NCT01863654|Bioequivalence
218268|NCT01863654|Mexico
218269|NCT01863654|Asthma
218270|NCT01863654|Montelukast
218271|NCT01863654|Chewable
218272|NCT01863641|lupus nephritis
218273|NCT01863641|proteinuria
218274|NCT01863641|SLE
218275|NCT01863641|calcitriol
218276|NCT01863628|Prodromal Symptoms
218277|NCT01863628|bipolar disorder
218278|NCT01863628|Neuropsychological Tests
218279|NCT01863628|Magnetic Resonance Imaging
218280|NCT01863628|Treatment Outcome
218281|NCT01863628|aerobic exercise
218282|NCT01863628|psychotherapy
218283|NCT01863615|pharmacokinetics
218284|NCT01863615|Isotretinoin
218285|NCT01863615|bioequivalence
218286|NCT01863615|Mexico
218287|NCT01863576|Chagas disease
218288|NCT01863576|Chagas Cardiomyopathy
218289|NCT01863576|Trypanosoma cruzi
218290|NCT01863576|Omega-3
218291|NCT01863576|Cytokines
218292|NCT01863576|Lipid profile
218293|NCT01863576|Nutritional assessment
218294|NCT01863563|tonsillectomy
218295|NCT01863563|adenoidectomy
218296|NCT01863563|obstructive sleep apnea
218297|NCT01863524|Abdominal Aortic Aneurysm (AAA),
218298|NCT01863524|Echocardiography (TTE),
218299|NCT01863524|Acute Coronary Syndrome (ACS)
218300|NCT01863524|Patients over 65 years old
218301|NCT01863511|Treatment options for acute decompensated heart failure
218302|NCT01863511|Ultrafiltration
218303|NCT01863511|tolvaptan
218304|NCT01863498|pectus excavatum
218305|NCT01863498|pain control
218306|NCT01863485|advanced cancer
218307|NCT01863459|ADHD
218308|NCT01863459|ADD
218309|NCT01863459|Anxiety
218310|NCT01863459|Anxiety Disorders
218311|NCT01863459|Depression
218312|NCT01863459|Attention
218313|NCT01863459|Attention Deficit
218314|NCT01863446|Pregnancy
218315|NCT01863446|Melatonin
218316|NCT01863446|Contractions
218317|NCT01863446|Light
218318|NCT01863420|gastric cancer
218319|NCT01863420|rectal cancer
218320|NCT01863420|bone marrow toxicity
218321|NCT01863420|IMRT
218322|NCT01863420|hematologic toxicity
218323|NCT01863407|Ileus
218324|NCT01863407|Intestinal Obstruction
218325|NCT01863407|Intestinal Diseases
218326|NCT01863407|Gastrointestinal Diseases
218327|NCT01863407|Digestive System Diseases
218328|NCT01863394|Screening
218329|NCT01863394|Malnutrition
218330|NCT01863394|Community Management of Acute Malnutrition
218331|NCT01863381|Hydrocephalus
218332|NCT01863381|Idiopathic intracranial hypertension
218333|NCT01863381|Pseudotumor cerebri
218334|NCT01863381|ICP
218335|NCT01863381|Intracranial pressure
218336|NCT01863381|CSF pressure
218337|NCT01863381|VIIP
218338|NCT01863368|Dry eye syndrome
218339|NCT01863368|Systane Ultra
218340|NCT01863368|Optive
218341|NCT01863368|Ocular Surface Staining
218342|NCT01863368|OSDI
218343|NCT01863368|Eye drops
218344|NCT01863355|IntravenousPCA, fentanyl, postoperative pain, laparoscopic gastrectomy
218345|NCT01863342|central sensitization; osteoarthritis; epidural analgesia
218346|NCT01863329|Optic nerve sheath diameter
218347|NCT01863329|Hydrocephalus
218348|NCT01863329|Intracranial hypertension
218349|NCT01863316|LMA Supreme, i-gel, supraglottic airway
218350|NCT01863303|colorectal cancer
218351|NCT01863303|epidemiology
218352|NCT01863303|industry
218353|NCT01863303|genetic
218354|NCT01863290|prison
218355|NCT01863290|reentry
218356|NCT01863290|health care utilization
218357|NCT01863264|dysphagia
218358|NCT01863264|swallowing
218359|NCT01863264|infant
218360|NCT01863264|premature
218361|NCT01863264|neonate
218362|NCT01863264|thermal
218363|NCT01863264|cold
218364|NCT01863264|bolus
218365|NCT01863264|temperature
218366|NCT01863264|deglutition
218367|NCT01863264|NICU
218368|NCT01863264|bottle
218369|NCT01863264|nippling
218370|NCT01863251|Opiates
218371|NCT01863251|ATS
218372|NCT01863251|HIV Risks
218373|NCT01863238|Cystic Fibrosis
218374|NCT01863199|Wet AMD
218375|NCT01863199|AMD
218376|NCT01863199|Choroidal neovascularization
218377|NCT01863199|Neovascular membrane
218378|NCT01863186|lofexidine
218379|NCT01863186|opioid dependence
218380|NCT01863186|acute withdrawal syndrome
218381|NCT01863186|opioid withdrawal
218382|NCT01863173|Thalassemia cardiomyopathy
218383|NCT01863173|metoprolol succinate
218384|NCT01863173|echocardiography
218385|NCT01863173|six minute walk test
218386|NCT01863160|Safety
218387|NCT01863160|Tolerability
218388|NCT01863160|Pharmacokinetic profile
218389|NCT01863160|ZEP-3 Cream (0.1% and 1.0%)
218390|NCT01863160|administered topically
218391|NCT01863147|Type 2 diabetes
218392|NCT01863147|left ventricular mass
218393|NCT01863147|inhibitor of dipeptidyl peptidase-4
218394|NCT01863121|cirrhosis
218395|NCT01863121|CTPK
218396|NCT01863121|CTP
218397|NCT01863121|MELD
218398|NCT01863121|Severity Score
218399|NCT01863108|Melanoma
218400|NCT01863108|Immunotherapy
218401|NCT01863108|Dermatology
218402|NCT01863108|cancer vaccine
218403|NCT01863108|Plasmacytoid dendritic cell line
218404|NCT01863108|Advanced Medicinal Therapy Product
218405|NCT01863108|allogeneic
218406|NCT01863082|Resistant Hypertension
218407|NCT01863069|inhaled
218408|NCT01863069|interferon beta-1a
218409|NCT01863069|healthy subjects
218410|NCT01863056|Sedentary time
218411|NCT01863056|Non Exercise Activity
218412|NCT01863056|Sit Stand Workstation
218413|NCT01863043|Premature Infant
218414|NCT01863043|Nutrition
218415|NCT01863043|Enteral
218416|NCT01863030|Resorbable mesh
218417|NCT01863030|Phasix mesh
218418|NCT01863017|Obesity
218419|NCT01863017|Over weight
218420|NCT01862991|Induced Abortion
218421|NCT01862991|Mifepristone
218422|NCT01862991|Dilation and Evacuation
218423|NCT01862991|Cervical Preparation
218424|NCT01862991|Osmotic Dilators
218425|NCT01862978|Stroke
218426|NCT01862978|Heparin
218427|NCT01862978|Nadroparin
218428|NCT01862965|firstline
218429|NCT01862965|treatment
218430|NCT01862965|prednisone
218431|NCT01862965|everolimus
218432|NCT01862939|type 2 diabetes mellitus
218433|NCT01862926|connective tissue disease
218434|NCT01862926|interstitial lung disease
218435|NCT01862926|pulmonary fibrosis
218436|NCT01862926|rituximab
218437|NCT01862926|scleroderma
218438|NCT01862926|polymyositis
218439|NCT01862926|dermatomyositis
218440|NCT01862913|depression
218441|NCT01862913|adolescents
218442|NCT01862900|Breast Cancer
218443|NCT01862900|Metastatic
218444|NCT01862900|Lung metastases
218445|NCT01862900|Liver metastases
218446|NCT01862900|Stereotactic body radiation
218447|NCT01862900|anti-OX40 antibody
218448|NCT01862900|MEDI6469
218449|NCT01862900|Immunotherapy
218450|NCT01862861|Bioidentical Hormone Replacement Therapy
218451|NCT01862848|Topical Compounded Pain Creams and Pain Perception
218452|NCT01862822|Paediatrics
218453|NCT01862822|Urinary tract infection
218454|NCT01862822|Urine collection
218455|NCT01862809|Oral Microbiota
218456|NCT01862809|Cigarette Smoking
218457|NCT01862809|Tobacco- Related Cancer
218458|NCT01862796|Food Intake
218459|NCT01862796|Weight Loss
218460|NCT01862796|Compliance
218461|NCT01862783|Erythrocytes
218462|NCT01862783|Parasites
218463|NCT01862783|Plasmodium Falciparum
218464|NCT01862783|Placenta
218465|NCT01862783|Resistant
218466|NCT01862770|Lung Cancer
218467|NCT01862770|Smokers
218468|NCT01862770|Genetic Risk Communication
218469|NCT01862770|Smoking Cessation
218470|NCT01862757|Obesity
218471|NCT01862757|Insulin
218472|NCT01862757|Skeletal Muscle
218473|NCT01862757|Strength Testing
218474|NCT01862744|Parkinson's Disease
218475|NCT01862744|MRI
218476|NCT01862744|Cognitive
218477|NCT01862731|Muscle Force
218478|NCT01862731|Knee
218479|NCT01862731|Magnetic Resonance Imaging
218480|NCT01862731|Quadriceps
218481|NCT01862731|Ultrasound
218482|NCT01862718|Fusion
218483|NCT01862718|Tracking
218484|NCT01862718|Ablation
218485|NCT01862718|Hepatic Neoplasms
218486|NCT01862666|Barrett's Esophagus
218487|NCT01862666|Dysplasia
218488|NCT01862666|Intramucosal Adenocarcinoma
218489|NCT01862666|EMR
218490|NCT01862666|Endoscopy
218491|NCT01862653|Post Traumatic Stress Disorder
218492|NCT01862653|Sleep Disturbance
218493|NCT01862653|Acupuncture
218494|NCT01862640|OPC-34712
218495|NCT01862640|brexpiprazole
218496|NCT01862640|Dementia
218497|NCT01862640|Alzheimer's Disease
218498|NCT01862640|Cognitive Disorders
218499|NCT01862640|Memory
218500|NCT01862640|Agitation
218501|NCT01862627|Macular retinoschisis
218502|NCT01862627|Macular detachment
218503|NCT01862627|vitrectomy
218504|NCT01862614|Degree of pulpal anesthesia obtained.
218505|NCT01862614|Primary infiltration in the lower first molar.
218506|NCT01862614|Buffered local anesthetic.
218507|NCT01862588|septic shock
218508|NCT01862588|acute kidney injury
218509|NCT01862588|renal resistive index
218510|NCT01862562|Laparoscopic surgery
218511|NCT01862562|Colorectal cancer
218512|NCT01862562|Elderly patient
218513|NCT01862562|Randomized control study
218514|NCT01862536|Randomized trial
218515|NCT01862536|COPD
218516|NCT01862536|tadalafil
218517|NCT01862536|Phosphodiesterase inhibitor
218518|NCT01862536|Pulmonary hypertension
218519|NCT01862510|Celiac Disease
218520|NCT01862510|Hypothyroidism
218521|NCT01862510|Celiac Sprue
218522|NCT01862510|Malabsorption
218523|NCT01862497|Intradialytic Hypertension
218524|NCT01862497|Hemodialysis
218525|NCT01862497|Hypertension
218526|NCT01862497|Extracellular Volume
218527|NCT01862497|Endothelial Cell Dysfunction
218528|NCT01862497|Endothelin 1
218529|NCT01862497|Carvedilol
218530|NCT01862484|ADHD
218531|NCT01862484|Diet
218532|NCT01862484|Functional Magnetic Resonance Imaging
218533|NCT01862471|Deep Vein Thrombosis
218534|NCT01862471|Neuromuscular Electrical Stimulation
218535|NCT01862471|Intermittent Pneumatic Compression
218536|NCT01862471|Doppler Ultrasound
218537|NCT01862458|empyema
218538|NCT01862458|tPA
218539|NCT01862458|dornase
218540|NCT01862445|Chronic Lymphoid Leukemia, Chlorambucil, Rituximab
218541|NCT01862393|electrical stimulation
218542|NCT01862393|torque
218543|NCT01862380|Adrenocortical function
218544|NCT01862380|Adrenal hyperplasia, Congenital
218545|NCT01862380|21-hydroxylase
218546|NCT01862380|deficiency
218547|NCT01862380|cortisol
218548|NCT01862380|replacement therapy
218549|NCT01862380|Woman
218550|NCT01862380|Healthy people
218551|NCT01862354|Postoperative analgesia
218552|NCT01862354|Abdominoplasty
218553|NCT01862354|Continuous wound infusion
218554|NCT01862354|Transverse abdominal plan block
218555|NCT01862354|Local anesthetics : Ropivacaine
218556|NCT01862354|Regional anesthesia
218557|NCT01862341|Constipation
218558|NCT01862341|Bowel movement
218559|NCT01862341|Intestinal health
218560|NCT01862328|MLN4924
218561|NCT01862328|Solid Tumors
218562|NCT01862315|Hepatic Arterial Infusion (HAI)
218563|NCT01862315|Floxuridine (FUDR)
218564|NCT01862315|Dexamethasone (DEX)
218565|NCT01862315|Gemcitabine
218566|NCT01862315|Oxaliplatin
218567|NCT01862315|13-066
218568|NCT01862302|Prevention delirium
218569|NCT01862302|Cardiac surgery
218570|NCT01862289|difficult asthma
218571|NCT01862289|hyperventilation syndrome
218572|NCT01862289|prevalence
218573|NCT01862263|Diabetes,
218574|NCT01862263|Type 2 diabetes,
218575|NCT01862263|Diabetes mellitus,
218576|NCT01862263|insulin,
218577|NCT01862237|Type II diabetes
218578|NCT01862237|aortic valve stenosis
218579|NCT01862237|left ventricular remodeling
218580|NCT01862237|aortic valve replacement surgery
218581|NCT01862224|Active rheumatoid arthritis despite methotrexate therapy
218582|NCT01862224|JNJ-38518168
218583|NCT01862224|Synovial
218584|NCT01862211|alpha antitrypsin, hepatic disease, genetic, polymorphism
218585|NCT01862185|semiquantitative
218586|NCT01862185|procalcitonin
218587|NCT01862185|sepsis
218588|NCT01862185|antibiotics
218589|NCT01862185|mortality
218590|NCT01862172|Cortical focal atrophy
218591|NCT01862172|Stroke
218592|NCT01862172|Internal capsule
218593|NCT01862172|Corticospinal tract
218594|NCT01862172|Wallerian degeneration
218595|NCT01862172|Primary motor area.
218596|NCT01862159|bariatric surgery
218597|NCT01862159|postoperative complications
218598|NCT01862146|TCA
218599|NCT01862146|FMD
218600|NCT01862146|IMT
218601|NCT01862146|Smoking
218602|NCT01862133|Electronic Health Record
218603|NCT01862133|Health Information Technology
218604|NCT01862133|Patient Privacy
218605|NCT01862133|Personal Health Information
218606|NCT01862120|Recently diagnosed
218607|NCT01862120|Regulatory T Cells
218608|NCT01862120|Tolerance Induction
218609|NCT01862120|Paediatrics
218610|NCT01862120|Low dose
218611|NCT01862120|IL-2
218612|NCT01862107|Biomarkers
218613|NCT01862107|Immune Responses
218614|NCT01862107|Lumbar Puncture
218615|NCT01862107|Neurological Diseases
218616|NCT01862107|Novel Pathogens
218617|NCT01862068|Pronostic factors
218618|NCT01862068|Neutrophils
218619|NCT01862068|Granulomatosis with polyangiitis
218620|NCT01862068|Microscopic polyangiitis
218621|NCT01862068|ANCA associated vasculitis
218622|NCT01862068|Proteomics
218623|NCT01862055|Stress
218624|NCT01862055|Anxiety
218625|NCT01862055|Cesarean Section
218626|NCT01862055|Spinal anesthesia
218627|NCT01862055|Hypotension
218628|NCT01862042|Spinal Muscular Atrophy (SMA) type 1
218629|NCT01862042|Supportive care
218630|NCT01862042|Palliative care
218631|NCT01862029|Mitochondria in Diabetes
218632|NCT01862029|Obesity
218633|NCT01862029|Roflumilast
218634|NCT01862029|Phosphodiesterase-4
218635|NCT01862029|Pre-Diabetes
218636|NCT01862016|Acute respiratory distress syndrome
218637|NCT01862016|APRV ventilatory mode
218638|NCT01862016|Spontaneous breathing
218639|NCT01862016|Intensive Care Unit
218640|NCT01862003|Colorectal cancer
218641|NCT01862003|Metastatic Colorectal cancer
218642|NCT01862003|Recurrent Colorectal cancer
218643|NCT01862003|FOLFIRI
218644|NCT01862003|AZD8931
218645|NCT01862003|Chemotherapy
218646|NCT01862003|EGFR
218647|NCT01861990|Glioma
218648|NCT01861990|Glioblastoma
218649|NCT01861990|Pediatric
218650|NCT01861990|Child
218651|NCT01861990|Brain tumor
218652|NCT01861990|Astrocytoma
218653|NCT01861990|Medulloblastoma
218654|NCT01861990|PNET
218655|NCT01861977|Cognitive Therapy
218656|NCT01861977|Health Education
218657|NCT01861977|Secondary Prevention
218658|NCT01861977|Cardiovascular Disease
218659|NCT01861964|XOS
218660|NCT01861964|Xylooligosarcharide
218661|NCT01861964|Prebiotic
218662|NCT01861951|soft tissue sarcoma
218663|NCT01861951|firstline treatment
218664|NCT01861951|eldery patients
218665|NCT01861938|melanoma
218666|NCT01861938|vaccine
218667|NCT01861938|Resectable AJCC stage IV
218668|NCT01861938|AJCC stages IIb-c, III
218669|NCT01861938|Patients with low-burden
218670|NCT01861938|failed
218671|NCT01861938|respond
218672|NCT01861938|one treatment line
218673|NCT01861912|Carcinoma, Hepatocellular
218674|NCT01861912|Arsenic trioxide
218675|NCT01861899|Sacro-iliac Joint
218676|NCT01861886|Birth control
218677|NCT01861886|Permanent Contraception
218678|NCT01861873|liver function
218679|NCT01861873|galactose
218680|NCT01861873|18-F-deoxy-galactose
218681|NCT01861860|stenting using IVUS in long lEsion
218682|NCT01861834|Total parenteral nutrition
218683|NCT01861834|TPN
218684|NCT01861834|Intestinal Failure
218685|NCT01861834|Short Bowel Syndrome
218686|NCT01861834|Cholestasis
218687|NCT01861834|Intestinal failure associated liver disease
218688|NCT01861834|Parenteral nutrition associated liver disease
218689|NCT01861821|Epidural catheter
218690|NCT01861821|Epidural analgesia
218691|NCT01861821|Labor epidural analgesia
218692|NCT01861821|Analgesic efficacy
218693|NCT01861821|Multiport epidural catheter
218694|NCT01861821|Uniport epidural catheter
218695|NCT01861821|Flexible epidural catheter
218696|NCT01861808|Spinal Cord Injuries
218697|NCT01861808|Cerebrospinal Fluid
218698|NCT01861795|Drug therapy
218699|NCT01861769|Cognitive Processing Therapy
218700|NCT01861769|Consultation
218701|NCT01861756|Shared Decision Making
218702|NCT01861756|Decision Aids
218703|NCT01861743|Multi-modal Pain Management
218704|NCT01861743|Lumbar fusion
218705|NCT01861743|misTLIF
218706|NCT01861730|BCG Vaccinated
218707|NCT01861730|HIV Negative
218708|NCT01861717|excess growth hormone
218709|NCT01861717|excess GH
218710|NCT01861717|gigantism
218711|NCT01861717|pituitary tumor
218712|NCT01861717|pituitary adenoma
218713|NCT01861717|growth hormone tumor
218714|NCT01861717|GH secreting adenoma
218715|NCT01861717|Somatuline
218716|NCT01861717|lanreotide
218717|NCT01861704|Mild to moderate hearing loss
218718|NCT01861691|Transverse colon cancer
218719|NCT01861691|Descending colon cancer
218720|NCT01861691|Laparoscopic surgery
218721|NCT01861691|Randomized controlled trial
218722|NCT01861678|Rectal cancer
218723|NCT01861678|Anterior resection
218724|NCT01861678|High tie of inferior mesenteric artery
218725|NCT01861678|Low tie of inferior mesenteric artery
218726|NCT01861678|Randomized controlled trial
218727|NCT01861652|Restless legs syndrome, Ekbom syndrome, Restless legs
218728|NCT01861600|Stool composition
218729|NCT01861535|VIN
218730|NCT01861535|Imiquimod
218731|NCT01861535|Surgery
218732|NCT01861535|HPV
218733|NCT01861535|Patient satisfaction
218734|NCT01861522|TAU-284
218735|NCT01861522|Bepotastine besilate
218736|NCT01861522|Histamine H1 receptor antagonists
218737|NCT01861522|children
218738|NCT01861509|BP-C1
218739|NCT01861509|CDBPA
218740|NCT01861509|Metronomic chemotherapy
218741|NCT01861509|Platinum analogue
218742|NCT01861509|Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
218743|NCT01861509|Benzene polycarboxylic acids complex with cis-diammineplatinum(II)
218744|NCT01861509|Breast cancer
218745|NCT01861509|Cisplatin
218746|NCT01861509|Metastatic Breast Cancer
218747|NCT01861496|Cisplatin
218748|NCT01861496|Liposomal formulation
218749|NCT01861457|nasal sanitizer®
218750|NCT01861457|S. aureus
218751|NCT01861457|general bacteria
218752|NCT01861457|nasal carriage
218753|NCT01861457|decolonization
218754|NCT01861431|HIV, prevention, microfinance, sex work, Mongolia
218755|NCT01861418|chronic low back pain
218756|NCT01861418|low back pain
218757|NCT01861418|lumbopelvic manipulation
218758|NCT01861418|Chicago manipulation
218759|NCT01861418|EMG median frequency
218760|NCT01861418|electromyography
218761|NCT01861418|reliability
218762|NCT01861392|postural balance sensory motor trayning physical therapy modalities diabetes mellitus
218763|NCT01861366|Implementation
218764|NCT01861366|Guidelines
218765|NCT01861366|Nutrition
218766|NCT01861366|Nursing home
218767|NCT01861327|Carbon dioxide
218768|NCT01861327|aortic aneurysm
218769|NCT01861327|angioplasty
218770|NCT01861327|Critical lower limb ischemia
218771|NCT01861288|Inflammatory Bowel Disease
218772|NCT01861288|Fecal Calprotectin
218773|NCT01861288|Clinical IBD score (SCCAI, PUCAI, aPCDAI)
218774|NCT01861288|Endoscopic deep remission
218775|NCT01861288|Histopathologic deep remission
218776|NCT01861288|Immunological deep remission
218777|NCT01861288|Treatment algorithm
218778|NCT01861275|osa
218779|NCT01861275|cerebral palsy
218780|NCT01861275|thrombolysis in cerebral palsy
218781|NCT01861275|sleep registration
218782|NCT01861262|emergency
218783|NCT01861262|drug poisoning
218784|NCT01861262|StO2 measurement
218785|NCT01861262|blood pressure
218786|NCT01861262|hemodynamic failure
218787|NCT01861223|acquired resistance
218788|NCT01861223|gefitinib
218789|NCT01861223|erlotinib
218790|NCT01861210|Homosexuality, Male
218791|NCT01861197|Efficacy
218792|NCT01861197|Dovitinib
218793|NCT01861197|Squamous NSCLC
218794|NCT01861184|Lower respiratory tract infection
218795|NCT01861184|LRTI
218796|NCT01861184|Pneumococcal carriage
218797|NCT01861158|Parenting
218798|NCT01861158|Adolescence
218799|NCT01861158|Delinquency
218800|NCT01861158|Online intervention
218801|NCT01861158|Juvenile Justice
218802|NCT01861145|Intranasal steroids
218803|NCT01861132|Pregnancy, cesarean delivery, blood pressure, cardiac output
218804|NCT01861106|Allogeneic Donors
218805|NCT01861106|Peripheral Blood Stem Cell
218806|NCT01861106|Immunodeficiency
218807|NCT01861106|Myelodysplasia
218808|NCT01861106|Haploidentical
218809|NCT01861093|Unrelated Hematopoietic Stem Cell Transplantation
218810|NCT01861093|Cryopreserved Cord Blood Units
218811|NCT01861093|National Cord Blood Program
218812|NCT01861080|target organ damage
218813|NCT01861080|incident hypertension
218814|NCT01861080|cohort
218815|NCT01861054|Cancer Stem Cells
218816|NCT01861054|Novel targeted therapy
218817|NCT01861054|CXCR1/2 Inhibitors
218818|NCT01861041|low dose
218819|NCT01861041|different baricity
218820|NCT01861041|spinal anesthesia
218821|NCT01861028|total knee replacement
218822|NCT01861028|total knee arthroplasty
218823|NCT01861028|patient-specific
218824|NCT01861002|Relapse
218825|NCT01861002|Lymphoblastic
218826|NCT01861002|Leukemia
218827|NCT01861002|Azacytidine
218828|NCT01861002|Refractory
218829|NCT01861002|Myelogenous
218830|NCT01861002|Acute
218831|NCT01861002|Childhood
218832|NCT01861002|Pediatric
218833|NCT01861002|ALL
218834|NCT01861002|AML
218835|NCT01861002|Methylation
218836|NCT01861002|Epigenetic therapy
218837|NCT01860989|parasitemia
218838|NCT01860963|ASIL
218839|NCT01860963|Anal dysplasia
218840|NCT01860963|IBD
218841|NCT01860963|HPV DNA
218842|NCT01860950|Healthy Adults
218843|NCT01860950|Pain Perception
218844|NCT01860937|T cell Immunotherapy
218845|NCT01860937|CD19 Targeted Therapy
218846|NCT01860937|Chimeric Antigen Receptor (CAR) Modified T cells
218847|NCT01860937|Conditioning Chemotherapy
218848|NCT01860937|13-052
218849|NCT01860924|exercise
218850|NCT01860924|depression
218851|NCT01860924|smoking
218852|NCT01860898|lung
218853|NCT01860898|cancer
218854|NCT01860898|thoracic
218855|NCT01860898|chest
218856|NCT01860898|pulmonary
218857|NCT01860885|naloxone
218858|NCT01860885|children
218859|NCT01860885|opioid
218860|NCT01860885|respiratory depression
218861|NCT01860885|safety
218862|NCT01860872|Cystic Fibrosis
218863|NCT01860872|Pulmonary perfusion
218864|NCT01860872|Inflammatory markers
218865|NCT01860872|MRI
218866|NCT01860872|CT of chest
218867|NCT01860872|Lung Clearance Index
218868|NCT01860859|cesarean
218869|NCT01860859|ultrasound
218870|NCT01860859|hysterotomy
218871|NCT01860859|uterus
218872|NCT01860859|suture
218873|NCT01860846|Crohn's disease
218874|NCT01860833|Knee Osteoarthritis
218875|NCT01860820|IPC/TEDS
218876|NCT01860820|Geko device
218877|NCT01860807|methamphetamine
218878|NCT01860807|ibudilast
218879|NCT01860807|HIV
218880|NCT01860781|Schizophrenia
218881|NCT01860781|Injection
218882|NCT01860781|Switch
218883|NCT01860781|Paliperidone
218884|NCT01860781|refractory, chronic akathisia, poor complianc
218885|NCT01860768|Acute aortic dissection
218886|NCT01860768|Serum biomarkers
218887|NCT01860768|Early diagnosis
218888|NCT01860755|Sport-related concussion
218889|NCT01860755|Dizziness
218890|NCT01860755|Neck pain
218891|NCT01860755|Headaches
218892|NCT01860755|Physiotherapy
218893|NCT01860755|Treatment
218894|NCT01860742|Peptide Receptor Radionuclide Therapy (PRRT)
218895|NCT01860742|Neuroendocrine Tumors
218896|NCT01860742|Interferon alpha
218897|NCT01860716|Melatonin, liver transplant, oxidative stress
218898|NCT01860703|Ferriprox®
218899|NCT01860703|LI
218900|NCT01860703|DFP
218901|NCT01860703|Deferiprone
218902|NCT01860703|Healthy Volunteers
218903|NCT01860690|MTX
218904|NCT01860690|Ectopic pregnancy
218905|NCT01860690|medical treatment
218906|NCT01860677|PTSD
218907|NCT01860677|cranial stimulation
218908|NCT01860677|fMRI (BOLD)
218909|NCT01860677|spectroscopy
218910|NCT01860664|allergy
218911|NCT01860664|allergic
218912|NCT01860664|conjunctivitis
218913|NCT01860664|corticosteroid
218914|NCT01860664|hydrocortisone
218915|NCT01860664|ophthalmic
218916|NCT01860664|ointment
218917|NCT01860651|Inflammatory Bowel Disease
218918|NCT01860651|Ulcerative Colitis
218919|NCT01860651|Crohn´s Disease
218920|NCT01860651|Children
218921|NCT01860651|Adolescence
218922|NCT01860651|E-health web-monitoring
218923|NCT01860651|Adherence
218924|NCT01860651|Disease activity
218925|NCT01860651|Fecal Calprotectin
218926|NCT01860599|prediabetes
218927|NCT01860599|EPC's
218928|NCT01860599|vascular reactivity
218929|NCT01860586|pvr
218930|NCT01860586|rd
218931|NCT01860586|Proliferative Vitreoretinopathy
218932|NCT01860586|retinal detachment
218933|NCT01860586|detachment
218934|NCT01860573|Amino acids
218935|NCT01860573|Protein
218936|NCT01860560|OSA
218937|NCT01860560|Obstructive Sleep Apnea
218938|NCT01860560|High Flow Therapy
218939|NCT01860560|CPAP
218940|NCT01860560|HFT
218941|NCT01860560|Continuous Positive Airway Pressure
218942|NCT01860560|Mild OSA
218943|NCT01860560|Moderate OSA
218944|NCT01860534|pain
218945|NCT01860534|mydriasis
218946|NCT01860534|light
218947|NCT01860521|Termination of pregnancy
218948|NCT01860521|Second trimester
218949|NCT01860521|Programmed intermittent epidural bolus
218950|NCT01860521|Continuous epidural infusion
218951|NCT01860521|Epidural analgesia
218952|NCT01860521|Legally Induced Abortion
218953|NCT01860508|Progression free Survival
218954|NCT01860495|growth factors
218955|NCT01860495|periodontal pockets
218956|NCT01860482|Refractory Reflux Esophagitis
218957|NCT01860482|GERD
218958|NCT01860482|Phase 4
218959|NCT01860456|Chronic myeloid leukemia
218960|NCT01860456|Imatinib
218961|NCT01860456|Nilotinib
218962|NCT01860456|Polymorphism, Single Nucleotide
218963|NCT01860456|Pharmacokinetics
218964|NCT01860456|ATP-Binding Cassette Transporters
218965|NCT01860456|SLC Transporters
218966|NCT01860456|Treatment outcome
218967|NCT01860456|Toxicity
218968|NCT01860443|depression
218969|NCT01860443|adolescents
218970|NCT01860430|Locally Advanced
218971|NCT01860430|Head and Neck Cancer
218972|NCT01860430|Ipilimumab (YERVOY®)
218973|NCT01860417|Degenerative Disc Disease,
218974|NCT01860417|Intervertebral Disc Disease
218975|NCT01860417|Low Back Pain
218976|NCT01860417|Nucleus pulposus
218977|NCT01860417|Stem cell
218978|NCT01860417|Cellular therapy
218979|NCT01860417|Regenerative therapy
218980|NCT01860417|Mesenchymal stem cells
218981|NCT01860417|Bone marrow
218982|NCT01860417|Musculoskeletal Diseases
218983|NCT01860417|Mesenchymal Stromal Cells (allogenic)
218984|NCT01860404|Concussion
218985|NCT01860404|Branched chain amino acids
218986|NCT01860404|BCAA
218987|NCT01860404|HIT HEADS
218988|NCT01860391|Silver
218989|NCT01860391|Fluoride
218990|NCT01860391|Diammine Silver Fluoride
218991|NCT01860391|Saliva
218992|NCT01860378|Whooping Cough
218993|NCT01860378|Pertussis
218994|NCT01860378|Tdap vaccination
218995|NCT01860378|Randomized placebo controlled factorial trial
218996|NCT01860365|Quality of life
218997|NCT01860365|Integrative medicine
218998|NCT01860365|Supportive care
218999|NCT01860365|Cancer
219000|NCT01860365|Chemotherapy
219001|NCT01860352|Fish Oil
219002|NCT01860352|colon health
219003|NCT01860352|fatty acid metabolism
219004|NCT01860339|Huntington's Disease
219005|NCT01860339|HD
219006|NCT01860339|Huntington Disease
219007|NCT01860339|Juvenile Huntington's Disease
219008|NCT01860339|JHD
219009|NCT01860326|hepatic impairment
219010|NCT01860326|mild and moderate hepatic impairment
219011|NCT01860326|Alisporivir
219012|NCT01860313|effectiveness
219013|NCT01860313|distance learning
219014|NCT01860313|mental health
219015|NCT01860300|Tic Disorders
219016|NCT01860300|Tourette Syndrome
219017|NCT01860287|opioid
219018|NCT01860287|subjective
219019|NCT01860287|stress
219020|NCT01860287|buprenorphine
219021|NCT01860274|Mesh
219022|NCT01860274|Graft
219023|NCT01860274|Patency
219024|NCT01860261|HIV
219025|NCT01860261|AIDS
219026|NCT01860261|sedentary
219027|NCT01860261|fitness
219028|NCT01860261|aging
219029|NCT01860261|V02max
219030|NCT01860261|d-dimer
219031|NCT01860261|IL-6
219032|NCT01860261|CRP
219033|NCT01860261|ChiWalking
219034|NCT01860261|ChiRunning
219035|NCT01860261|aerobic exercise
219036|NCT01860261|strength training
219037|NCT01860248|vapocoolant effectiveness
219038|NCT01860248|arterial puncture
219039|NCT01860235|Local anesthesia
219040|NCT01860235|Pain measurement
219041|NCT01860235|Pain perception
219042|NCT01860235|Dental anesthesia
219043|NCT01860235|Root planing
219044|NCT01860222|Hepatocellular carcinoma
219045|NCT01860222|CSPH
219046|NCT01860222|Hepatectomy
219047|NCT01860222|percutaneous local ablative
219048|NCT01860222|therapy (PLAT)
219049|NCT01860222|randomized controlled trials(RCTs)
219050|NCT01860209|obstructive sleep apnea
219051|NCT01860209|overhydration
219052|NCT01860209|end stage renal disease
219053|NCT01860209|intermittent ambulatory hemodialysis
219054|NCT01860209|polysomnography
219055|NCT01860209|bioimpedance
219056|NCT01860209|leg fluid shift
219057|NCT01860209|neck circumference
219058|NCT01860183|kidney transplantation
219059|NCT01860183|chronic allograft dysfunction
219060|NCT01860183|mycophenolate mofetil
219061|NCT01860183|Chronic
219062|NCT01860170|Blood and Marrow Transplant (BMT)
219063|NCT01860170|MRD
219064|NCT01860170|MUD
219065|NCT01860170|GVHD
219066|NCT01860157|rTMS
219067|NCT01860157|depression
219068|NCT01860157|magnetic
219069|NCT01860144|bevacizumab
219070|NCT01860144|overall survival
219071|NCT01860144|adverse events
219072|NCT01860144|tumor resection rate
219073|NCT01860131|bariatrics, lifestyle and behavioral modification programs
219074|NCT01860079|Early discharge
219075|NCT01860079|STEMI
219076|NCT01860079|PPCI
219077|NCT01860066|COPD
219078|NCT01860014|Pulmonary hemorrhage
219079|NCT01860014|Mortality
219080|NCT01860014|Newborn
219081|NCT01860001|cancer
219082|NCT01860001|metabolic acidosis
219083|NCT01859988|Eczema
219084|NCT01859962|Liver diseases
219085|NCT01859962|Virus diseases
219086|NCT01859962|Ribavirin
219087|NCT01859962|protease inhibitor
219088|NCT01859962|NS5B polymerase inhibitor
219089|NCT01859962|NS5A inhibitor
219090|NCT01859949|Genotropin(somatropin)
219091|NCT01859949|SGA
219092|NCT01859949|Short Stature
219093|NCT01859949|Long-term
219094|NCT01859949|Safety
219095|NCT01859923|Tuberculosis
219096|NCT01859923|Tuberculosis, Multidrug-Resistant
219097|NCT01859923|Mycobacterium Infections
219098|NCT01859923|Actinomycetales Infections
219099|NCT01859923|Gram-Positive Infections
219100|NCT01859923|Bacterial Infections
219101|NCT01859923|Pediatric
219102|NCT01859884|Kidney transplantation
219103|NCT01859884|Increased risk donor kidneys
219104|NCT01859884|Kidney donation
219105|NCT01859884|Organ donation
219106|NCT01859884|Human Immunodeficiency Virus
219107|NCT01859884|Hepatitis B
219108|NCT01859884|Hepatitis C
219109|NCT01859884|Infectious disease
219110|NCT01859884|Disease transmission
219111|NCT01859884|Centers for Disease Control (CDC)
219112|NCT01859884|Web-based intervention
219113|NCT01859871|Living kidney donation
219114|NCT01859871|End-stage renal disease
219115|NCT01859871|Latinos
219116|NCT01859871|Undocumented Immigrants
219117|NCT01859871|Bilingual
219118|NCT01859871|Spanish
219119|NCT01859871|Website
219120|NCT01859871|Dialysis
219121|NCT01859871|Hispanics
219122|NCT01859871|Transplantation
219123|NCT01859858|mCRC (metastatic colorectal cancer)
219124|NCT01859858|CRC (colorectal cancer)
219125|NCT01859858|Advanced colorectal cancer
219126|NCT01859858|Metastatic colorectal cancer
219127|NCT01859858|Colon cancer
219128|NCT01859845|Melanoma
219129|NCT01859845|Opportunistic surveillance
219130|NCT01859845|Melanoma simulation model
219131|NCT01859845|Smartphone devices
219132|NCT01859832|renal transplant
219133|NCT01859832|kidney transplantation
219134|NCT01859832|immune status
219135|NCT01859832|immunosuppressive medications
219136|NCT01859819|Pediatric
219137|NCT01859819|Lymphoma (NOT primary mediastinal B-cell lymphoma)
219138|NCT01859819|B-Cell---Burkitt's like
219139|NCT01859819|Rituximab
219140|NCT01859819|Liposomal ARA-C
219141|NCT01859806|periampullary tumour
219142|NCT01859806|isolated Roux loop PJ
219143|NCT01859806|PG
219144|NCT01859793|dipeptidyl peptidase-4 inhibitor
219145|NCT01859793|endothelium, vascular
219146|NCT01859793|diabetes type 2
219147|NCT01859793|nitric oxide
219148|NCT01859793|inflammation
219149|NCT01859780|Poison control
219150|NCT01859780|Child resistant packaging
219151|NCT01859780|prescription vials
219152|NCT01859780|prescription blisters
219153|NCT01859780|drug packaging
219154|NCT01859767|Alzheimer's disease
219155|NCT01859767|SPECT
219156|NCT01859754|Primary Immune Deficiency Syndrome
219157|NCT01859754|Primary immunodeficiency Disease (PIDD)
219158|NCT01859754|PID
219159|NCT01859741|Newly diagnosed Stage IV Small Cell Lung Cancer
219160|NCT01859728|biliary cancer
219161|NCT01859728|irinotecan
219162|NCT01859728|cisplatin
219163|NCT01859728|gemcitabine
219164|NCT01859715|Drug Interactions
219165|NCT01859715|CYP2D6
219166|NCT01859715|opioid efficacy
219167|NCT01859715|pain
219168|NCT01859715|nausea
219169|NCT01859702|Aqueous Humor
219170|NCT01859702|Moxifloxacin
219171|NCT01859702|Vigadexa
219172|NCT01859663|Polycystic Ovary Syndrome (PCOS)
219173|NCT01859663|Diet
219174|NCT01859663|Exercise
219175|NCT01859663|Questionnaires
219176|NCT01859663|Health Beliefs
219177|NCT01859637|Filgrastim, immunogenicity, severe chronic neutropenia
219178|NCT01859624|LOPD
219179|NCT01859624|Pompe Disease
219180|NCT01859598|diabetes
219181|NCT01859598|basal insulin
219182|NCT01859598|effectiveness and safety
219183|NCT01859598|oral antidiabetic drugs
219184|NCT01859598|real world clinical practice
219185|NCT01859585|preemptive analgesia
219186|NCT01859585|lumbar fusion
219187|NCT01859585|Parecoxib
219188|NCT01859585|Ketorolac
219189|NCT01859572|Stroke
219190|NCT01859572|Cerebral Infarction
219191|NCT01859572|Brain Disorders
219192|NCT01859572|Central Nervous System Diseases
219193|NCT01859572|Nervous System Diseases
219194|NCT01859572|Vascular Diseases
219195|NCT01859572|Cardiovascular Diseases
219196|NCT01859572|Brain Infarction
219197|NCT01859572|Brain Ischaemia
219198|NCT01859559|ultrasound
219199|NCT01859559|peripheral intravenous access
219200|NCT01859559|operator experience
219201|NCT01859546|SMS
219202|NCT01859520|Spermatozoa
219203|NCT01859520|DNA fragmentation
219204|NCT01859520|Swim-up
219205|NCT01859520|Density gradient
219206|NCT01859507|Vaginismus
219207|NCT01859507|Botox
219208|NCT01859507|Sex
219209|NCT01859507|Clostridium
219210|NCT01859507|Botulinum
219211|NCT01859507|Neurotoxin
219212|NCT01859507|Perineal
219213|NCT01859507|Muscles
219214|NCT01859455|Hypercholesterolemia,
219215|NCT01859455|LDL cholesterol lowering,
219216|NCT01859455|proprotein convertase subtilisin/kexin type 9 (PCSK9),
219217|NCT01859455|LGT209,
219218|NCT01859455|drug safety,
219219|NCT01859455|pharmacokinetics,
219220|NCT01859455|pharmacodynamics
219221|NCT01859429|Cancer patients
219222|NCT01859429|Psycho-oncological Care Provision
219223|NCT01859429|Structured Screening
219224|NCT01859429|Stepped care
219225|NCT01859403|veteran
219226|NCT01859403|obesity
219227|NCT01859403|personalized genomics
219228|NCT01859390|Antioxidants
219229|NCT01859390|Vitamins
219230|NCT01859390|Inflammation
219231|NCT01859390|Oxidative stress
219232|NCT01859364|Tobacco
219233|NCT01859364|Smoking
219234|NCT01859364|Smoking Cessation
219235|NCT01859364|Outcome
219236|NCT01859364|Nicotine Dependence
219237|NCT01859325|HIV-MAG pDNA Prime
219238|NCT01859325|HIV Therapy
219239|NCT01859325|Therapeutic Vaccine
219240|NCT01859312|Glucocorticoids
219241|NCT01859312|Adrenal Insufficiency
219242|NCT01859312|Congenital Adrenal Hyperplasia (CAH)
219243|NCT01859312|Adrenal
219244|NCT01859299|Oral Tolerance
219245|NCT01859299|Uveitis
219246|NCT01859299|AMD
219247|NCT01859273|renal failure
219248|NCT01859273|medication adherence
219249|NCT01859273|hypertension
219250|NCT01859260|chronic kidney disease, acute kidney injury, obstructive sleep apnea
219251|NCT01859247|cervical dystonia
219252|NCT01859247|torticollis
219253|NCT01859247|rTMS
219254|NCT01859234|multiple myeloma
219255|NCT01859234|PET scan
219256|NCT01859221|Prostate cancer
219257|NCT01859221|Oligometastatic prostate cancer
219258|NCT01859221|Proton radiation
219259|NCT01859195|HIV/STI
219260|NCT01859195|Prevention
219261|NCT01859195|Microbicides, Topical
219262|NCT01859169|bili duct neoplasms
219263|NCT01859169|bile duct cancer
219264|NCT01859169|photodynamic therapy
219265|NCT01859169|biliary drainage
219266|NCT01859156|Carbon Monoxide
219267|NCT01859156|Carboxyhemoglobin
219268|NCT01859156|End-tidal carbon dioxide
219269|NCT01859156|Capnography
219270|NCT01859143|Trivalent
219271|NCT01859143|Influenza
219272|NCT01859143|FluMist Quadrivalent
219273|NCT01859143|Vaccine
219274|NCT01859143|Prevention
219275|NCT01859143|Healthy
219276|NCT01859117|Peripheral arterial disease
219277|NCT01859117|diabetic foot
219278|NCT01859091|Lipolysis
219279|NCT01859091|Cryolipolysis
219280|NCT01859091|Fat Reduction
219281|NCT01859065|Non-urgent ED visits
219282|NCT01859065|Neonates
219283|NCT01859065|Newborn care
219284|NCT01859052|migraine
219285|NCT01859052|obesity
219286|NCT01859052|low fat diet
219287|NCT01859052|low carbohydrate diet
219288|NCT01859039|Egg allergy
219289|NCT01859039|Anaphylaxis
219290|NCT01859039|Children
219291|NCT01859039|Influenza vaccine
219292|NCT01859026|Epidermal growth factor receptor (EGFR)
219293|NCT01859026|EGFR mutation
219294|NCT01859026|Kirsten rat sarcoma 2 viral oncogene homolog(KRAS)
219295|NCT01859026|KRAS mutation
219296|NCT01859026|Non-Small Cell Lung Cancer (NSCLC)
219297|NCT01859026|Advanced-stage IV
219298|NCT01859000|Adolescents
219299|NCT01859000|Hurricane Katrina
219300|NCT01859000|Family-based treatment
219301|NCT01859000|Multidimensional Family Therapy
219302|NCT01859000|Group CBT
219303|NCT01858974|multiplex PCR
219304|NCT01858974|MALDI-TOF
219305|NCT01858974|pneumonia
219306|NCT01858974|microbiological investigation
219307|NCT01858974|intensive care
219308|NCT01858948|Bipolar disorder
219309|NCT01858948|Second-generation antipsychotics
219310|NCT01858948|Obesity
219311|NCT01858948|Cardiometabolic risk
219312|NCT01858922|Hodgkin's Lymphoma
219313|NCT01858922|ABVE-PC
219314|NCT01858922|doxorubicin
219315|NCT01858922|bleomycin
219316|NCT01858922|vincristine
219317|NCT01858922|etoposide
219318|NCT01858922|prednisone
219319|NCT01858922|cyclophosphamide
219320|NCT01858922|DECA
219321|NCT01858922|decadron
219322|NCT01858922|cisplatin
219323|NCT01858922|cytarabine
219324|NCT01858922|Radiation
219325|NCT01858909|Sepsis
219326|NCT01858896|hypoglycemia
219327|NCT01858896|GLP-1
219328|NCT01858896|Type 2 diabetes
219329|NCT01858896|endothelial function
219330|NCT01858870|Lacosamide
219331|NCT01858870|Partial Crisis
219332|NCT01858857|geriatric psychiatry
219333|NCT01858857|pharmacovigilance
219334|NCT01858818|CAIS Computer Assisted Infusion System
219335|NCT01858818|real life drinking behavior
219336|NCT01858818|family history of alcoholism
219337|NCT01858818|conditioning
219338|NCT01858818|instrumental learning
219339|NCT01858818|habitization
219340|NCT01858805|esophagus carcinoma
219341|NCT01858805|surgery
219342|NCT01858805|circulating tumor cells
219343|NCT01858779|stroke
219344|NCT01858779|atrial fibrillation
219345|NCT01858779|secondary prevention of stroke
219346|NCT01858779|peripheral pulse measurement
219347|NCT01858766|Hepatitis
219348|NCT01858766|HCV Genotype 1
219349|NCT01858766|HCV Genotype 2
219350|NCT01858766|HCV Genotype 3
219351|NCT01858766|HCV Genotype 4
219352|NCT01858766|HCV Genotype 5
219353|NCT01858766|HCV Genotype 6
219354|NCT01858766|treatment naive
219355|NCT01858753|burn scars
219356|NCT01858753|restrictive
219357|NCT01858753|contractures
219358|NCT01858753|autologous fibroblasts
219359|NCT01858727|forced-air
219360|NCT01858727|hypothermia
219361|NCT01858727|TUR-P surgery
219362|NCT01858727|core temperatures
219363|NCT01858727|prewarming
219364|NCT01858727|general anaesthesia
219365|NCT01858714|obesity
219366|NCT01858714|overweight
219367|NCT01858714|weight loss
219368|NCT01858701|myopia
219369|NCT01858701|hyperopia
219370|NCT01858701|astigmatism
219371|NCT01858701|contact lenses
219372|NCT01858688|Prostate Cancer
219373|NCT01858688|MRI
219374|NCT01858688|Active surveillance in prostate cancer
219375|NCT01858675|ProADM
219376|NCT01858675|ProANP
219377|NCT01858675|proendothelin
219378|NCT01858675|proAVP
219379|NCT01858675|Cr 51
219380|NCT01858675|Volemia
219381|NCT01858675|fluid management
219382|NCT01858675|ICU patients
219383|NCT01858675|poly trauma patients
219384|NCT01858662|metastatic colorectal cancer
219385|NCT01858662|Liver
219386|NCT01858662|cetuximab
219387|NCT01858662|Pathological response
219388|NCT01858649|metastatic
219389|NCT01858649|colorectal
219390|NCT01858649|cancer
219391|NCT01858649|liver
219392|NCT01858649|Bevacizumab
219393|NCT01858649|Pathological response
219394|NCT01858623|Healthy Normotensive Participants
219395|NCT01858623|Fixed dose combination
219396|NCT01858623|Pharmacokinetics
219397|NCT01858623|Losartan
219398|NCT01858623|Hydrochlorothiazide
219399|NCT01858610|Fixed dose combination
219400|NCT01858610|Pharmacokinetics
219401|NCT01858610|Irbesartan
219402|NCT01858610|Hydrochlorothiazide
219403|NCT01858610|Pharmacodynamics
219404|NCT01858610|Normotensive Participants
219405|NCT01858597|GDM, FGF
219406|NCT01858584|GER
219407|NCT01858584|Alginate
219408|NCT01858584|Regurgitation
219409|NCT01858584|questionnaire
219410|NCT01858571|Childhood Cancer
219411|NCT01858532|Diabetes
219412|NCT01858532|Nephropathy
219413|NCT01858519|pancreatic enzyme replacement therapy
219414|NCT01858519|antibodies
219415|NCT01858519|porcine viruses
219416|NCT01858519|epidemiology
219417|NCT01858519|prospective
219418|NCT01858506|Type 2 diabetes mellitus
219419|NCT01858506|Lifestyle counselling
219420|NCT01858506|Lifestyle assessment
219421|NCT01858506|Randomized controlled trial
219422|NCT01858506|Diabetes education
219423|NCT01858493|Urinary incontinence
219424|NCT01858493|Falls
219425|NCT01858493|Quality of life
219426|NCT01858493|Stigma
219427|NCT01858493|Community-dwelling older women
219428|NCT01858493|Continence promotion
219429|NCT01858480|CHF
219430|NCT01858467|Airway, Cesarean
219431|NCT01858402|Pediatric spinal anesthesia, paracetamol, dipyrone
219432|NCT01858389|Non-small cell lung cancer
219433|NCT01858389|T790M mutation. dacomitinib
219434|NCT01858376|LDL cholesterol
219435|NCT01858376|anti-hyperlipidemic
219436|NCT01858376|hyperlipidemic
219437|NCT01858376|Capros
219438|NCT01858376|Natural Supplement
219439|NCT01858363|Peripheral arterial disease
219440|NCT01858363|claudication
219441|NCT01858363|drug-coated balloon
219442|NCT01858363|drug-eluting balloon
219443|NCT01858350|CAM
219444|NCT01858350|Sedation
219445|NCT01858350|MRI
219446|NCT01858350|Music Therapy
219447|NCT01858337|weaning
219448|NCT01858337|infants
219449|NCT01858337|vegetables
219450|NCT01858337|repeated-exposure
219451|NCT01858324|Preeclampsia
219452|NCT01858324|Hypertensive disorders of pregnancy
219453|NCT01858324|Patient education
219454|NCT01858324|Educationnal tools
219455|NCT01858324|Pamphlet
219456|NCT01858324|Video
219457|NCT01858324|Knowledge
219458|NCT01858324|Anxiety
219459|NCT01858324|Satisfaction
219460|NCT01858311|Stroke survivors
219461|NCT01858311|TIA survivors
219462|NCT01858311|Vitamin E
219463|NCT01858311|Carotech
219464|NCT01858311|Tocotrienol
219465|NCT01858298|Dental caries
219466|NCT01858298|Quality of Life
219467|NCT01858298|Pulpectomy
219468|NCT01858298|Tooth extraction
219469|NCT01858285|Epilepsy
219470|NCT01858285|Ohtahara
219471|NCT01858285|Dravet
219472|NCT01858285|MMPEI
219473|NCT01858285|EMEE
219474|NCT01858285|EIEE
219475|NCT01858246|Hearing Loss, Conductive
219476|NCT01858246|Bone Conduction
219477|NCT01858246|bone conduction thresholds better than 45 dBHL
219478|NCT01858233|Gestational diabetes
219479|NCT01858220|Gastroparesis
219480|NCT01858220|Small bowel video capsule
219481|NCT01858220|gastric retention
219482|NCT01858207|HCC
219483|NCT01858207|hepatocellular carcinoma
219484|NCT01858207|liver cancer
219485|NCT01858194|Tachycardia, Renal Sympathetic Denervation
219486|NCT01858194|Catheter Ablation
219487|NCT01858194|Cardioverter-Defibrillator
219488|NCT01858142|Pediatric anesthesia
219489|NCT01858142|Pre-operative anxiety
219490|NCT01858142|parental presence
219491|NCT01858142|children
219492|NCT01858142|elective surgical procedures
219493|NCT01858142|mask induction
219494|NCT01858129|TTN
219495|NCT01858103|Mucopolysaccharidosis IVA Type A
219496|NCT01858103|MPS IVA Type A
219497|NCT01858103|Mucopolysaccharidosis IVA
219498|NCT01858103|MPS IVA
219499|NCT01858103|Morquio A Syndrome
219500|NCT01858103|Lysosomal Storage Disorder
219501|NCT01858103|LSD
219502|NCT01858103|N-acetylgalactosamine-6-sulfatase
219503|NCT01858103|N-acetylgalactosamine-6-sulfate
219504|NCT01858090|spinal anesthesia
219505|NCT01858090|caesarean section
219506|NCT01858090|local anesthetics
219507|NCT01858090|levobupivacaine
219508|NCT01858090|sufentanil
219509|NCT01858090|fentanyl
219510|NCT01858090|above 18 years of age
219511|NCT01858090|pregnant women
219512|NCT01858090|multiparous
219513|NCT01858090|nulliparous
219514|NCT01858064|ADHD
219515|NCT01858064|OROS-MPH
219516|NCT01858064|Adults
219517|NCT01858064|Functional Magnetic Resonance Imaging
219518|NCT01858051|Vitamin D
219519|NCT01858051|Perioperative immune regulation
219520|NCT01858051|LL-37
219521|NCT01858051|Hospital-acquired infection
219522|NCT01858051|Surgical site infections
219523|NCT01858038|Scar
219524|NCT01858012|insulin resistance
219525|NCT01857999|Renin-aldosterone system
219526|NCT01857999|Hemodynamic
219527|NCT01857999|Low cardiac output
219528|NCT01857999|Vasodilation
219529|NCT01857999|Natriuretic peptide
219530|NCT01857986|Endotracheal intubation
219531|NCT01857986|Mechanical ventilation
219532|NCT01857986|Critical care
219533|NCT01857973|OCL
219534|NCT01857973|Type 1 Diabetes
219535|NCT01857973|Sensor
219536|NCT01857973|Artificial calibration error
219537|NCT01857960|Acne
219538|NCT01857960|Treatment
219539|NCT01857960|Cost
219540|NCT01857960|Behavior
219541|NCT01857947|AECOPD Mr ProADM Biomarkers ER Outcome
219542|NCT01857934|Anti-GD2 monoclonal antibody
219543|NCT01857934|hu14.18K322A
219544|NCT01857934|High-risk neuroblastoma
219545|NCT01857934|Phase II
219546|NCT01857934|Allogeneic NK cells
219547|NCT01857908|Adenocarcinoma
219548|NCT01857908|Abiraterone
219549|NCT01857908|Abiraterone Acetate
219550|NCT01857908|Zytiga
219551|NCT01857908|Correlative study
219552|NCT01857908|Castrate Resistant Prostate Cancer
219553|NCT01857908|Abiraterone Correlative study
219554|NCT01857895|Nausea
219555|NCT01857895|subcutaneous infusion
219556|NCT01857895|exenatide
219557|NCT01857882|breast cancer
219558|NCT01857882|breast reconstruction
219559|NCT01857882|shared decision making
219560|NCT01857882|decision support intervention
219561|NCT01857869|Efficacy
219562|NCT01857869|Sporozoite challenge model
219563|NCT01857869|Malaria
219564|NCT01857869|Immunogenicity
219565|NCT01857869|Malaria- naïve adults
219566|NCT01857869|Safety
219567|NCT01857856|Phospholamban
219568|NCT01857856|cardiomyopathy
219569|NCT01857856|Eplerenone
219570|NCT01857856|presymptomatic
219571|NCT01857830|Telomerase
219572|NCT01857830|Telomere Length
219573|NCT01857830|Psychological Stress
219574|NCT01857830|Amyloid beta proteins
219575|NCT01857830|Meditation
219576|NCT01857804|peri-implantitis
219577|NCT01857804|surgical therapy
219578|NCT01857804|systemic antibiotics
219579|NCT01857804|local antiseptics
219580|NCT01857778|Breastfeeding
219581|NCT01857778|Breast tissue
219582|NCT01857778|Breast pump
219583|NCT01857765|rehabilitation
219584|NCT01857765|reconstructive surgery
219585|NCT01857752|Retinoblastoma
219586|NCT01857726|hepatocellular carcinoma
219587|NCT01857726|portal vein invasion
219588|NCT01857726|transarterial chemoembolization
219589|NCT01857726|transarterial chemoinfusion
219590|NCT01857674|Laryngeal edema
219591|NCT01857674|Post-extubation
219592|NCT01857674|Acute respiratory distress
219593|NCT01857674|Ultrasonography
219594|NCT01857674|Intensive care unit
219595|NCT01857661|tinnitus
219596|NCT01857661|hearing loss
219597|NCT01857661|hearing devices
219598|NCT01857648|Physical Activity
219599|NCT01857648|Health Promotion
219600|NCT01857648|Primary Health Care
219601|NCT01857648|Intervention Studies
219602|NCT01857648|Public health Practice
219603|NCT01857635|Acute respiratory failure
219604|NCT01857635|Hypercapnia
219605|NCT01857635|Non invasive ventilation
219606|NCT01857635|Transcutaneous CO2 measurement
219607|NCT01857622|anticoagulant
219608|NCT01857622|DU-176b
219609|NCT01857622|edoxaban
219610|NCT01857622|factor Xa
219611|NCT01857622|oral
219612|NCT01857622|atrial fibrillation
219613|NCT01857622|severe renal impairment
219614|NCT01857609|Metformin
219615|NCT01857609|Proton pump inhibitor
219616|NCT01857609|Drug interaction
219617|NCT01857596|Female Sexual Dysfunction
219618|NCT01857596|Hypoactive Sexual Desire Disorder
219619|NCT01857596|Sexual Interest/Arousal Disorder
219620|NCT01857596|Lorexys
219621|NCT01857596|Premenopausal female health
219622|NCT01857583|anticoagulant
219623|NCT01857583|DU-176b
219624|NCT01857583|edoxaban
219625|NCT01857583|factor Xa
219626|NCT01857583|oral
219627|NCT01857583|orthopedic surgery of lower limbs
219628|NCT01857583|severe renal impairment
219629|NCT01857570|Radius fracture
219630|NCT01857570|Scaphoid fracture
219631|NCT01857570|Tomography, x-ray computed
219632|NCT01857557|Exercise
219633|NCT01857557|Fitness program
219634|NCT01857544|Retinal Vein Occlusion
219635|NCT01857544|Central Retinal Vein Occlusion
219636|NCT01857544|Macular Edema
219637|NCT01857531|Smoking Cessation
219638|NCT01857531|Quit Smoking
219639|NCT01857531|Ganaxolone
219640|NCT01857531|Nicotine Patch
219641|NCT01857505|Total Hip replacement
219642|NCT01857505|Fracture table
219643|NCT01857505|DePuySynthes
219644|NCT01857505|Direct anterior approach hip replacement
219645|NCT01857505|Posterior approach hip replacement
219646|NCT01857492|abdominal pain
219647|NCT01857492|pancreatitis
219648|NCT01857492|chronic abdominal pain
219649|NCT01857492|visceral pain
219650|NCT01857492|meditation
219651|NCT01857492|tDCS
219652|NCT01857492|noninvasive brain stimulation
219653|NCT01857492|EEG
219654|NCT01857492|Kirtan Kriya
219655|NCT01857479|ABPA
219656|NCT01857453|Adult Patients Medulloblatoma Standard risk group Chemotherapy Radiotherapy Quality of Life
219657|NCT01857440|Glaucoma
219658|NCT01857440|Pupil
219659|NCT01857440|Melanopsin
219660|NCT01857414|ST-elevation myocardial infarction
219661|NCT01857414|Remote Ischaemic Conditioning
219662|NCT01857414|Myocardial Reperfusion Injury
219663|NCT01857414|Cardiovascular mortality
219664|NCT01857388|school-based program, mental health, implementation
219665|NCT01857375|Diabetes - insulin administration
219666|NCT01857362|Orfadin
219667|NCT01857362|Nitisinone
219668|NCT01857362|Bioequivalence
219669|NCT01857349|Efficacy
219670|NCT01857349|surgical scrubs
219671|NCT01857349|Total Knee Arthroplasty
219672|NCT01857323|asthma
219673|NCT01857323|chronic obstructive pulmonary disease
219674|NCT01857323|COPD
219675|NCT01857323|Albuterol Spiromax®
219676|NCT01857310|Folic Acid
219677|NCT01857310|Zinc
219678|NCT01857310|Semen
219679|NCT01857310|In vitro fertilization
219680|NCT01857310|Assisted reproductive technology
219681|NCT01857310|Ovulation induction
219682|NCT01857310|Intrauterine insemination
219683|NCT01857310|Pregnancy
219684|NCT01857310|Live Birth
219685|NCT01857310|Abortion, spontaneous
219686|NCT01857284|Tauroursodeoxycholic Acid
219687|NCT01857284|Primary Biliary Cirrhosis
219688|NCT01857284|Safety
219689|NCT01857284|Efficacy
219690|NCT01857258|green tea
219691|NCT01857258|catechins
219692|NCT01857258|vascular endothelial function
219693|NCT01857258|postprandial hyperglycemia
219694|NCT01857258|oxidative stress
219695|NCT01857245|addiction
219696|NCT01857245|Adherence (attribute)
219697|NCT01857245|Adverse effects
219698|NCT01857245|Agonist
219699|NCT01857245|Antiviral Agents
219700|NCT01857245|arm
219701|NCT01857245|base
219702|NCT01857245|care delivery
219703|NCT01857245|Caring
219704|NCT01857245|Chronic Hepatitis C
219705|NCT01857245|Clinic
219706|NCT01857245|Clinical Trials
219707|NCT01857245|Complex
219708|NCT01857245|Computer Simulation
219709|NCT01857245|cost
219710|NCT01857245|cost effective
219711|NCT01857245|cost effectiveness
219712|NCT01857245|Data
219713|NCT01857245|Development
219714|NCT01857245|Directly Observed Therapy
219715|NCT01857245|Disease
219716|NCT01857245|Dose
219717|NCT01857245|Drug resistance
219718|NCT01857245|drug resistant virus
219719|NCT01857245|Educational aspects
219720|NCT01857245|Epidemic
219721|NCT01857245|experience
219722|NCT01857245|Frequencies (time pattern)
219723|NCT01857245|Fright
219724|NCT01857245|Genotype
219725|NCT01857245|Group Therapy
219726|NCT01857245|Health Care Costs
219727|NCT01857245|Health Personnel
219728|NCT01857245|Healthcare Systems
219729|NCT01857245|Hepatitis C
219730|NCT01857245|Hepatitis C Prevalence
219731|NCT01857245|Hepatitis C Transmission
219732|NCT01857245|Hepatitis C virus
219733|NCT01857245|HIV
219734|NCT01857245|Homelessness
219735|NCT01857245|improved
219736|NCT01857245|Incidence
219737|NCT01857245|Infection
219738|NCT01857245|Injecting drug user
219739|NCT01857245|Injection of therapeutic agent
219740|NCT01857245|Intensive Care
219741|NCT01857245|Interferons
219742|NCT01857245|Intervention
219743|NCT01857245|Knowledge
219744|NCT01857245|Life
219745|NCT01857245|Liver diseases
219746|NCT01857245|Liver Failure
219747|NCT01857245|liver transplantation
219748|NCT01857245|Living Costs
219749|NCT01857245|Mental disorders
219750|NCT01857245|Methadone
219751|NCT01857245|methadone clinic/center
219752|NCT01857245|Modeling
219753|NCT01857245|Mortality Vital Statistics
219754|NCT01857245|Motivation
219755|NCT01857245|multidisciplinary
219756|NCT01857245|Opiates
219757|NCT01857245|Oral
219758|NCT01857245|Outcome
219759|NCT01857245|Patients
219760|NCT01857245|Persons
219761|NCT01857245|Pharmaceutical Preparations
219762|NCT01857245|Physicians
219763|NCT01857245|pill (pharmacologic)
219764|NCT01857245|Play
219765|NCT01857245|Poverty
219766|NCT01857245|Primary Health Care
219767|NCT01857245|programs
219768|NCT01857245|Psychiatric therapeutic procedure
219769|NCT01857245|psychosocial
219770|NCT01857245|Publishing
219771|NCT01857245|Quality-Adjusted Life Years
219772|NCT01857245|Randomized
219773|NCT01857245|Randomized Controlled Trials
219774|NCT01857245|randomized trial
219775|NCT01857245|Recruitment Activity
219776|NCT01857245|Regimen
219777|NCT01857245|Resistance
219778|NCT01857245|Resistance development
219779|NCT01857245|response
219780|NCT01857245|Risk
219781|NCT01857245|risk perception
219782|NCT01857245|Role
219783|NCT01857245|Site
219784|NCT01857245|skills
219785|NCT01857245|Social support
219786|NCT01857245|standard care
219787|NCT01857245|substance abuse treatment
219788|NCT01857245|success
219789|NCT01857245|Time
219790|NCT01857245|Treatment outcome
219791|NCT01857245|Treatment Protocols
219792|NCT01857245|treatment site
219793|NCT01857245|Trust
219794|NCT01857245|United States
219795|NCT01857245|Viral
219796|NCT01857245|Virus
219797|NCT01857219|fMRI
219798|NCT01857206|Influenza
219799|NCT01857206|children and adolescents
219800|NCT01857206|trivalent vaccine
219801|NCT01857206|cell culture
219802|NCT01857206|embryonated chicken eggs
219803|NCT01857193|Open label; dose escalation; ER+; LEE011; CDK4/6; everolimus; advanced breast cancer; mTOR; HR positive; HER2 negative
219804|NCT01857167|omega-3 fatty acids
219805|NCT01857167|randomized controlled trial
219806|NCT01857154|Bone mineral density
219807|NCT01857154|Bone mineral content
219808|NCT01857154|Bone density
219809|NCT01857154|Bone health
219810|NCT01857154|Dual-energy x-ray absorptiometry
219811|NCT01857141|dexmedetomidine
219812|NCT01857141|heart rate variability
219813|NCT01857141|preemptive epidural
219814|NCT01857141|gastrectomy
219815|NCT01857115|Multiple myeloma
219816|NCT01857115|Diagnosis
219817|NCT01857115|Weekly
219818|NCT01857115|CCyd
219819|NCT01857089|Pressure Ulcer
219820|NCT01857089|prevention
219821|NCT01857076|Type 2 Diabetes mellitus
219822|NCT01857076|Grade I obesity
219823|NCT01857076|Inadequate glycemic control
219824|NCT01857011|Anemia, Iron-Deficiency
219825|NCT01857011|bariatric surgery
219826|NCT01857011|abdominoplasty
219827|NCT01857011|surgery, plastic
219828|NCT01857011|iron
219829|NCT01856998|Therapeutic Equivalence
219830|NCT01856998|Propofol
219831|NCT01856985|Medical abortion
219832|NCT01856985|Misoprostol
219833|NCT01856985|Mifepristone
219834|NCT01856972|Limited Dorsiflexion Range of Motion
219835|NCT01856972|Gastrocnemius tightness
219836|NCT01856972|Soleus tightness
219837|NCT01856959|magnesium sulfate
219838|NCT01856959|nebulized
219839|NCT01856959|lung function
219840|NCT01856933|GBM
219841|NCT01856933|Glioblastoma Multiforme
219842|NCT01856933|Gliosarcoma
219843|NCT01856920|Calcitonin
219844|NCT01856920|T-cells
219845|NCT01856920|Immune Response
219846|NCT01856920|HLA Patients
219847|NCT01856920|Vaccine
219848|NCT01856907|prediabetes
219849|NCT01856907|impaired fasting/impaired glucose tolerance
219850|NCT01856907|post gestational diabetes
219851|NCT01856907|diabetes prevention
219852|NCT01856894|polycystic ovary syndrome
219853|NCT01856894|Anti-Mullerian Hormone
219854|NCT01856894|obesity
219855|NCT01856881|Type 2 diabetes
219856|NCT01856868|BMD
219857|NCT01856868|Becker muscular dystrophy
219858|NCT01856868|epicatechin
219859|NCT01856868|clinical trial
219860|NCT01856868|neuromuscular disease
219861|NCT01856855|Prostate Cancer
219862|NCT01856855|Prostate Adenocarcinoma
219863|NCT01856855|Radiation
219864|NCT01856855|SBRT
219865|NCT01856855|Stereotactic Body Radiation Therapy
219866|NCT01856842|Pulmonary Arteriovenous Malformations
219867|NCT01856842|Hereditary Hemorrhagic Telangiectasia (HHT)
219868|NCT01856842|Embolization
219869|NCT01856842|reperfusion rates
219870|NCT01856777|Medical Abortion
219871|NCT01856777|Pregnancy Test
219872|NCT01856777|continuing pregnancy
219873|NCT01856764|Atopic dermatitis
219874|NCT01856751|Haemophilia
219875|NCT01856751|TGA
219876|NCT01856751|TEM
219877|NCT01856738|Parkinson's disease
219878|NCT01856738|Visual hallucinations
219879|NCT01856738|Rivastigmine
219880|NCT01856738|Cholinesterase inhibitor
219881|NCT01856738|Randomized controlled trial
219882|NCT01856738|Cost-effectiveness analysis
219883|NCT01856712|alcohol
219884|NCT01856712|veterans
219885|NCT01856699|supratentorial superficial siderosis
219886|NCT01856699|intracerebral hemorrhage
219887|NCT01856699|cerebral amyloid angiopathy
219888|NCT01856686|ADD
219889|NCT01856686|ADHD
219890|NCT01856686|Proteins
219891|NCT01856686|Dietary
219892|NCT01856686|Nutrition
219893|NCT01856686|QEEG
219894|NCT01856686|ERP
219895|NCT01856686|ICA
219896|NCT01856673|Mental Health
219897|NCT01856673|Displacement
219898|NCT01856673|Torture
219899|NCT01856673|Violence
219900|NCT01856673|Post-Traumatic Stress Disorder
219901|NCT01856673|Depression
219902|NCT01856673|Anxiety
219903|NCT01856673|Community-based intervention
219904|NCT01856673|Prevention trial
219905|NCT01856673|Disabled Persons
219906|NCT01856660|Obesity
219907|NCT01856660|Weight Loss
219908|NCT01856660|Body Weight Change
219909|NCT01856660|Taste
219910|NCT01856660|Taste Phenotype
219911|NCT01856660|Lifestyle Intervention
219912|NCT01856647|Psoriasis
219913|NCT01856647|Obesity
219914|NCT01856634|Tuberculosis
219915|NCT01856634|Tuberculosis, Multidrug-Resistant
219916|NCT01856634|Mycobacterium Infections
219917|NCT01856634|Actinomycetales Infections
219918|NCT01856634|Gram-Positive Infections
219919|NCT01856634|Bacterial Infections
219920|NCT01856634|Pediatric
219921|NCT01856582|Primary Immunodeficiency Disease(s)
219922|NCT01856582|Mixed Donor Chimerism
219923|NCT01856582|bone marrow failure syndromes
219924|NCT01856582|allogeneic hematopoietic stem cell transplant (HSCT)
219925|NCT01856582|children
219926|NCT01856556|safety
219927|NCT01856556|tolerability
219928|NCT01856556|pharmacokinetics
219929|NCT01856543|Breast cancer
219930|NCT01856543|Status post mastectomy
219931|NCT01856543|plan to receive PMRT
219932|NCT01856543|Topical
219933|NCT01856543|steroid cream
219934|NCT01856543|emollient skin care
219935|NCT01856543|Eucerin
219936|NCT01856543|Mometasone Furoate 0.1%
219937|NCT01856517|pressor response
219938|NCT01856517|chronotropic response
219939|NCT01856504|Heart Disease
219940|NCT01856504|Coronary Artery Disease
219941|NCT01856504|Coronary Arteriosclerosis
219942|NCT01856491|RELIANCE 4-FRONT
219943|NCT01856491|Implantable Cardioverter Defibrillator (ICD)
219944|NCT01856491|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
219945|NCT01856465|Bariatric surgery
219946|NCT01856465|NAFLD
219947|NCT01856465|Steatohepatitis
219948|NCT01856465|Simple Steatosis
219949|NCT01856465|Intestinal Microbiota
219950|NCT01856452|Sentinel lymph node
219951|NCT01856452|multimodal
219952|NCT01856452|breast cancer
219953|NCT01856439|ProSavin
219954|NCT01856439|Gene therapy
219955|NCT01856426|Hepatitis C infected subjects
219956|NCT01856413|Prevention
219957|NCT01856413|Hepatitis B virus re-infection
219958|NCT01856413|HBV-DNA negative
219959|NCT01856413|Liver transplantation
219960|NCT01856400|ventricular arrythmias
219961|NCT01856400|SERCA2a
219962|NCT01856400|Chronic Kidney Disease
219963|NCT01856400|microvolt T wave alternans
219964|NCT01856387|preeclampsia
219965|NCT01856387|eclampsia
219966|NCT01856387|prediction
219967|NCT01856387|neutrophil-to Lymphocyte ratio
219968|NCT01856361|Male infertility
219969|NCT01856361|Low sperm count
219970|NCT01856361|Poor sperm motility
219971|NCT01856361|Poor Sperm shape and morphology
219972|NCT01856335|Seizures
219973|NCT01856335|Epilepsy
219974|NCT01856322|Colorectal Cancer
219975|NCT01856322|Liver Metastasis
219976|NCT01856322|Sulindac
219977|NCT01856309|Rheumatoid Arthritis
219978|NCT01856309|Sirukumab
219979|NCT01856309|CNTO 136
219980|NCT01856309|CNTO136ARA3002
219981|NCT01856309|SIRROUND-D
219982|NCT01856309|CNTO136ARA3003
219983|NCT01856309|SIRROUND-T
219984|NCT01856309|SIRROUND-LTE
219985|NCT01856270|Traumatic brain injury
219986|NCT01856270|Post-traumatic headache
219987|NCT01856270|Drug therapy
219988|NCT01856257|Kidney Transplantation
219989|NCT01856257|Transplantation
219990|NCT01856257|NULOJIX
219991|NCT01856257|belatacept
219992|NCT01856257|chronic immunosuppression
219993|NCT01856244|Parkinson's Disease
219994|NCT01856244|treadmill training
219995|NCT01856244|gait
219996|NCT01856244|balance
219997|NCT01856244|mobility
219998|NCT01856231|COPD
219999|NCT01856231|Physical activity
220000|NCT01856218|Mucopolysaccharidosis type 7, MPS 7, Sly syndrome, enzyme replacement therapy, rare disease, lysosomal storage disease, metabolic disorder
220001|NCT01856205|Japanese Encephalitis, Randomized Controlled Trial, intravenous immunoglobulin, safety, efficacy, Nepal
220002|NCT01856179|Conversion of ALA and SDA
220003|NCT01856179|Metabolism of n-3 fatty acids
220004|NCT01856166|Nulliparous
220005|NCT01856166|Singleton
220006|NCT01856166|delivery
220007|NCT01856166|pregnancy
220008|NCT01856153|Bioavailability
220009|NCT01856153|Strawberry polyphenols
220010|NCT01856153|Time Influence
220011|NCT01856140|adipose derived mesenchymal stem cell
220012|NCT01856140|allogeneic stem cell
220013|NCT01856127|Sexual Dysfunction
220014|NCT01856127|Antidepressant
220015|NCT01856127|Major Depressant
220016|NCT01856127|SSRI
220017|NCT01856127|SNRI
220018|NCT01856127|Vilazodone
220019|NCT01856127|Sertraline
220020|NCT01856114|Advanced Cancers
220021|NCT01856114|Cancer with evidence of active disease
220022|NCT01856114|Exercise induced breakthrough dyspnea
220023|NCT01856114|Shortness of breath
220024|NCT01856114|Fentanyl Buccal Tablets
220025|NCT01856114|FBT
220026|NCT01856114|Placebo
220027|NCT01856114|Walk tests
220028|NCT01856114|Questionnaires
220029|NCT01856114|Surveys
220030|NCT01856101|TCC
220031|NCT01856101|Failure of platinum based chemotherapy
220032|NCT01856088|Coronary artery
220033|NCT01856088|Drug eluting stent
220034|NCT01856088|thrombosis
220035|NCT01856075|Atrial Fibrillation
220036|NCT01856075|Dronedarone
220037|NCT01856075|Cohort
220038|NCT01856075|Effectiveness
220039|NCT01856062|ovulation induction
220040|NCT01856062|dexamethasone
220041|NCT01856049|HLHS
220042|NCT01856049|Hypoplastic Left Heart Syndrome
220043|NCT01856049|UCB (umbilical cord blood)
220044|NCT01856049|Umbilical cord blood
220045|NCT01856049|Cord blood
220046|NCT01856049|Cardiac regeneration
220047|NCT01856036|Ductal Histology
220048|NCT01856036|Unifocal
220049|NCT01856036|Estrogen Receptor Positive
220050|NCT01856036|her2neu negative
220051|NCT01856023|melanoma
220052|NCT01856023|metastatic
220053|NCT01856023|skin cancer
220054|NCT01856023|Stage IV
220055|NCT01856023|interleukin-2
220056|NCT01856010|Dementia
220057|NCT01856010|Aggression
220058|NCT01856010|Agitation
220059|NCT01855984|ADHD
220060|NCT01855984|Children
220061|NCT01855984|Tocotrienol
220062|NCT01855958|Osteoarthritis
220063|NCT01855958|Electro acupuncture
220064|NCT01855958|Deep intramuscular stimulation
220065|NCT01855958|Transcranial Magnetic Stimulation
220066|NCT01855958|Pain pressure threshold
220067|NCT01855958|Conditioned pain modulation
220068|NCT01855958|Clinical trial
220069|NCT01855945|Influenza
220070|NCT01855919|Chronic Low Back Pain
220071|NCT01855919|CLBP
220072|NCT01855906|Total knee replacement
220073|NCT01855906|Gap balanced
220074|NCT01855906|Measured resection
220075|NCT01855893|Neck pain
220076|NCT01855880|psoriasis
220077|NCT01855880|dermatology
220078|NCT01855880|monoclonal antibody
220079|NCT01855867|HIV
220080|NCT01855867|PEP
220081|NCT01855867|nPEP
220082|NCT01855867|Prophylaxis
220083|NCT01855867|Post Exposure Prophylaxis
220084|NCT01855867|exposure to HIV
220085|NCT01855867|HIV prevention
220086|NCT01855841|ERCP
220087|NCT01855841|virgin papilla
220088|NCT01855841|risk of post-ERCP acute pancreatitis
220089|NCT01855802|Greece
220090|NCT01855802|Ophthalmology
220091|NCT01855802|Glaucoma
220092|NCT01855802|Generics
220093|NCT01855802|Perception
220094|NCT01855776|Physical Activity/Walking
220095|NCT01855776|Full-time employees
220096|NCT01855776|RCT
220097|NCT01855776|Incentives
220098|NCT01855776|Wireless pedometer
220099|NCT01855763|gestational diabetes
220100|NCT01855763|type 2 diabetes
220101|NCT01855763|pregnancy
220102|NCT01855763|metformin
220103|NCT01855763|insulin
220104|NCT01855750|Lymphoma
220105|NCT01855750|B-cell lymphoma
220106|NCT01855750|Non-germinal center B-cell subtype
220107|NCT01855750|Diffuse large B-cell lymphoma
220108|NCT01855750|Bruton's tyrosine kinase inhibitor
220109|NCT01855750|PCI-32765
220110|NCT01855750|JNJ-54179060
220111|NCT01855750|Ibrutinib
220112|NCT01855750|Rituximab
220113|NCT01855750|Cyclophosphamide
220114|NCT01855750|Doxorubicin
220115|NCT01855750|Vincristine
220116|NCT01855750|Prednisone
220117|NCT01855737|gene guided
220118|NCT01855737|warfarin dose
220119|NCT01855737|Chinese
220120|NCT01855711|Alosetron hydrochloride
220121|NCT01855711|Global Improvement Scale(GIS)
220122|NCT01855711|Diarrhea-predominant IBS
220123|NCT01855698|hematologic neoplasm, profhylaxis, arterial and venous thromboembolism
220124|NCT01855685|XCGD, lentivirus, cellular therapy
220125|NCT01855672|Migraine, occipital nerve, stimulation
220126|NCT01855659|Lung diseases,
220127|NCT01855659|Obstructive,
220128|NCT01855659|Peak Inspiratory Flow
220129|NCT01855659|[C08.381.495.389]
220130|NCT01855620|Contraception
220131|NCT01855620|Implant
220132|NCT01855620|Obesity
220133|NCT01855607|chemotherapy induced neuropathy
220134|NCT01855542|metabolic acidosis, plasmalyte solution, 0.9% normal saline
220135|NCT01855529|ropivacaine, pain, mastectomy
220136|NCT01855516|Antithrombotic prophylaxis
220137|NCT01855503|Metastatic
220138|NCT01855503|Breast Cancer
220139|NCT01855503|Metastatic Breast Cancer
220140|NCT01855503|Breast
220141|NCT01855503|Biopsy
220142|NCT01855503|Molecular
220143|NCT01855503|Genetic
220144|NCT01855464|pneumothorax
220145|NCT01855464|primary pneumothorax
220146|NCT01855464|lung collapse
220147|NCT01855451|Human Papilloma Virus
220148|NCT01855451|HPV
220149|NCT01855451|Oropharyngeal
220150|NCT01855451|Squamous Cell
220151|NCT01855451|Carcinoma
220152|NCT01855438|Live donor kidney transplantation
220153|NCT01855438|Living donation
220154|NCT01855438|Patient education
220155|NCT01855438|Kidney transplant candidates
220156|NCT01855412|PAD
220157|NCT01855412|LIBERTY
220158|NCT01855412|Observational
220159|NCT01855399|Peer Support
220160|NCT01855399|Self Management
220161|NCT01855399|Health Disparities
220162|NCT01855373|Blood Sugar
220163|NCT01855373|Endothelial Function
220164|NCT01855373|Blood Vessel Health
220165|NCT01855360|amyloid
220166|NCT01855360|amyloidosis
220167|NCT01855360|cardiac amyloidosis
220168|NCT01855360|senile amyloidosis
220169|NCT01855360|familial amyloidosis
220170|NCT01855360|transthyretin amyloidosis
220171|NCT01855347|Prematurity
220172|NCT01855347|Hypoxia
220173|NCT01855347|Necrotizing Enterocolitis
220174|NCT01855347|Near Infrared Spectroscopy
220175|NCT01855347|Abdominal tissue oxygenation
220176|NCT01855347|NICU
220177|NCT01855334|Dialysis
220178|NCT01855334|ESRD
220179|NCT01855334|Cardiovascular disease
220180|NCT01855334|spironolactone
220181|NCT01855334|L-arginine
220182|NCT01855334|myocardial perfusion
220183|NCT01855334|coronary flow reserve
220184|NCT01855334|diastolic function
220185|NCT01855321|uncontrolled diabetes
220186|NCT01855321|vitamin D deficiency
220187|NCT01855295|Dialysis
220188|NCT01855295|End Stage Renal Disease
220189|NCT01855295|Protein supplementation
220190|NCT01855295|Inflammation
220191|NCT01855295|Quality of Life
220192|NCT01855282|Diabetes Type II,
220193|NCT01855282|Overweight,
220194|NCT01855282|Obesity,
220195|NCT01855282|Behavioral Intervention,
220196|NCT01855282|Latino, farm worker
220197|NCT01855282|randomized controlled intervention
220198|NCT01855269|probiotic
220199|NCT01855269|infantile colic
220200|NCT01855256|hyperhidrosis
220201|NCT01855256|oxybutynin
220202|NCT01855243|Type 2 D M
220203|NCT01855243|sliding scale insulin
220204|NCT01855243|70/30 insulin
220205|NCT01855243|basals insulin
220206|NCT01855243|supplemental insulin
220207|NCT01855217|morbid
220208|NCT01855217|obesity
220209|NCT01855217|sugammadex
220210|NCT01855217|pharmacodynamics
220211|NCT01855204|Computed Tomography, Spiral
220212|NCT01855204|Urography
220213|NCT01855204|Radiation dosage
220214|NCT01855204|Contrast media
220215|NCT01855178|nocturnal
220216|NCT01855178|epilepsy
220217|NCT01855165|chronic heart failure
220218|NCT01855165|drug-drug interactions
220219|NCT01855165|pharmacist's intervention
220220|NCT01855152|Dementia
220221|NCT01855152|Care Homes
220222|NCT01855152|Quality of life
220223|NCT01855152|Antipsychotic medication
220224|NCT01855152|Behavioural symptoms
220225|NCT01855152|Cost effectiveness
220226|NCT01855152|Implementation
220227|NCT01855152|Person centred care
220228|NCT01855152|Social interaction
220229|NCT01855139|Non-valvular atrial fibrillation
220230|NCT01855139|Stroke
220231|NCT01855139|Systemic embolism
220232|NCT01855139|Oral anticoagulation
220233|NCT01855139|Real-life setting
220234|NCT01855139|Preventive measure
220235|NCT01855126|light
220236|NCT01855126|circadian rhythms
220237|NCT01855126|dim light melatonin onset
220238|NCT01855126|sleep
220239|NCT01855113|PAIN
220240|NCT01855113|ORTHODONTIC TREATMENT
220241|NCT01855113|INVISALIGN
220242|NCT01855100|Treatment of acute deep vein thrombosis
220243|NCT01855100|Prevention of recurrence
220244|NCT01855100|Oral anticoagulation
220245|NCT01855100|Real-life setting
220246|NCT01855074|Schizophrenia
220247|NCT01855074|Schizophreniform Disorder
220248|NCT01855074|Schizoaffective Disorder
220249|NCT01855074|Risperidone
220250|NCT01855074|Risperdal consta
220251|NCT01855061|Feasibility studies
220252|NCT01855061|Sequence analysis, DNA
220253|NCT01855061|Biological markers
220254|NCT01855061|Solid tumors
220255|NCT01855061|Neoplasm metastasis
220256|NCT01855061|Irinotecan
220257|NCT01855061|Pharmacokinetics SN-38
220258|NCT01855061|Carboxylesterase activity within metastasis
220259|NCT01855048|N-Rephasin® SAL200
220260|NCT01855048|endolysin
220261|NCT01855048|Placebo
220262|NCT01855035|ischemic stroke
220263|NCT01855035|ECG monitoring
220264|NCT01855035|atrial fibrillation (/flutter)
220265|NCT01855022|Motivational interviewing
220266|NCT01855022|Interactive voice response
220267|NCT01855022|Hospital readmission
220268|NCT01855009|Quality of Life
220269|NCT01855009|Body Weight and Measures
220270|NCT01855009|Malnutrition
220271|NCT01855009|Adolescent Nutrition Sciences
220272|NCT01855009|Sleep Initiation and Maintenance Disorder
220273|NCT01855009|Motor Activity
220274|NCT01855009|Drinking
220275|NCT01854983|fluorescence colposcopy
220276|NCT01854983|cervical cancer
220277|NCT01854957|Multiple sclerosis
220278|NCT01854957|Mesenchymal stem cells
220279|NCT01854931|Tai Ji Quan
220280|NCT01854931|fall prevention
220281|NCT01854931|community dissemination
220282|NCT01854918|High cholesterol
220283|NCT01854918|Raised cholesterol
220284|NCT01854918|Cholesterol
220285|NCT01854918|Elevated Cholesterol
220286|NCT01854892|low back pain
220287|NCT01854892|manipulation
220288|NCT01854892|laser therapy
220289|NCT01854892|osteopathic
220290|NCT01854892|chiropractic
220291|NCT01854892|mobilization
220292|NCT01854892|muscle energy
220293|NCT01854892|physical therapy
220294|NCT01854892|muscle
220295|NCT01854892|spine
220296|NCT01854892|adjustment
220297|NCT01854892|rehabilitation
220298|NCT01854866|Pleural Effusion
220299|NCT01854866|ascites
220300|NCT01854866|Malignant
220301|NCT01854853|unsafe sex
220302|NCT01854853|safer sex
220303|NCT01854853|HIV
220304|NCT01854853|STI
220305|NCT01854853|Pregnancy
220306|NCT01854840|hyaline membrane disease
220307|NCT01854840|placenta
220308|NCT01854840|betamethasone
220309|NCT01854827|Biliary atresia
220310|NCT01854827|Hepatic portoenterostomy
220311|NCT01854827|Intravenous immunoglobulin
220312|NCT01854801|IEI-EMF
220313|NCT01854801|WI-FI
220314|NCT01854801|DECT
220315|NCT01854801|Electro-sensitivity
220316|NCT01854801|Radiofrequency
220317|NCT01854801|EHS
220318|NCT01854801|Idiopathic
220319|NCT01854801|Environmental
220320|NCT01854801|Intolerance fields
220321|NCT01854801|Mobile phone
220322|NCT01854788|Airway clearance techniques
220323|NCT01854788|Mucus clearance
220324|NCT01854788|Chest physiotherapy
220325|NCT01854788|Autogenic drainage
220326|NCT01854788|Slow expiration with glottis opened in lateral posture(ELTGOL)
220327|NCT01854788|Temporary-positive expiratory pressure (T-PEP)
220328|NCT01854788|Non cystic fibrosis bronchiectasis
220329|NCT01854775|Adolescents
220330|NCT01854775|HIV-1
220331|NCT01854775|HIV
220332|NCT01854775|Treatment-naive
220333|NCT01854762|HIV
220334|NCT01854762|Treatment
220335|NCT01854762|Pregnancy
220336|NCT01854749|ESCC
220337|NCT01854736|Allergy
220338|NCT01854736|Phleum pratense
220339|NCT01854736|Rhinoconjunctivitis
220340|NCT01854736|asthma
220341|NCT01854736|positive SPT to Phleum pratense
220342|NCT01854723|Diabetes
220343|NCT01854723|Insulin glargine
220344|NCT01854723|NPH insulin
220345|NCT01854710|ADASUVE
220346|NCT01854710|inhaled loxapine
220347|NCT01854710|thorough QT/QTc study
220348|NCT01854697|Chronic Hepatitis C
220349|NCT01854697|Interferon Free
220350|NCT01854697|Hepatitis C Treatment Naive
220351|NCT01854697|Hepatitis C Virus
220352|NCT01854697|Hepatitis C Genotype 1
220353|NCT01854671|postpartum contraception
220354|NCT01854671|contraceptive counseling
220355|NCT01854632|influenza vaccine
220356|NCT01854632|trivalent live-attenuated influenza vaccine
220357|NCT01854632|efficacy
220358|NCT01854632|Africa
220359|NCT01854632|Senegal
220360|NCT01854619|chronic rhinosinusitis
220361|NCT01854619|sinusitis
220362|NCT01854619|photodisinfection
220363|NCT01854619|photodynamic therapy
220364|NCT01854619|antimicrobial photodynamic therapy
220365|NCT01854619|aPDT
220366|NCT01854619|PDT
220367|NCT01854619|paranasal sinus diseases
220368|NCT01854619|respiratory tract infections
220369|NCT01854619|respiratory tract diseases
220370|NCT01854606|Diffuse Large B-Cell Lymphoma, DBCL, AEB071, Everolimus
220371|NCT01854580|Comparative effectiveness research
220372|NCT01854580|health economic evaluation
220373|NCT01854567|Cord Blood
220374|NCT01854567|Stem Cells
220375|NCT01854567|MPC
220376|NCT01854567|Mesoblast
220377|NCT01854567|Expanded
220378|NCT01854567|AML
220379|NCT01854567|ALL
220380|NCT01854567|NHL
220381|NCT01854567|Leukemia
220382|NCT01854567|Lymphoma
220383|NCT01854554|Brain cancer
220384|NCT01854554|Glioblastoma
220385|NCT01854554|Glioblastoma Multiforme
220386|NCT01854554|GBM
220387|NCT01854554|Intensity Modulated Proton Radiotherapy
220388|NCT01854554|IMPT
220389|NCT01854554|Intensity Modulated Radiotherapy
220390|NCT01854554|IMRT
220391|NCT01854554|Radiotherapy
220392|NCT01854554|XRT
220393|NCT01854554|Cognitive tests
220394|NCT01854554|Thinking skills tests
220395|NCT01854554|Questionnaires
220396|NCT01854554|Surveys
220397|NCT01854554|Quality of life
220398|NCT01854554|QOL
220399|NCT01854541|Cancer
220400|NCT01854541|Radiotherapy
220401|NCT01854528|Partial responder
220402|NCT01854528|Interferon free
220403|NCT01854528|Treatment-experienced
220404|NCT01854528|Relapser
220405|NCT01854528|Hepatitis C Virus
220406|NCT01854528|Null responder
220407|NCT01854528|Hepatitis C Genotype 1
220408|NCT01854528|paritaprevir
220409|NCT01854528|ombitasvir
220410|NCT01854528|dasabuvir
220411|NCT01854528|ribavirin
220412|NCT01854528|Viekira PAK
220413|NCT01854528|Chronic hepatitis C
220414|NCT01854502|Young children
220415|NCT01854502|counseling
220416|NCT01854502|fluoride
220417|NCT01854502|xylitol
220418|NCT01854489|Buprenorphine
220419|NCT01854489|Rifampicin
220420|NCT01854489|Interactions
220421|NCT01854489|Pharmakokinetics
220422|NCT01854489|Pharmakodynamics
220423|NCT01854476|Hemodialysis
220424|NCT01854476|Bleeding
220425|NCT01854476|Hemostatic dressing
220426|NCT01854476|Tranexamic Acid
220427|NCT01854463|DIABETES MELLITUS
220428|NCT01854463|VITAMIN D
220429|NCT01854463|ARTERIAL STIFFNESS
220430|NCT01854463|FATTY LIVER
220431|NCT01854463|BONE TURNOVER
220432|NCT01854450|Occipitoposterior position
220433|NCT01854450|Maternal posturing
220434|NCT01854450|Labor
220435|NCT01854437|mg oxide
220436|NCT01854437|hyperphosphatemia
220437|NCT01854437|plasma phosphor level
220438|NCT01854424|Fibrocyte
220439|NCT01854424|Acute Respiratory Distress Syndrome
220440|NCT01854424|Serum Amyloid P
220441|NCT01854424|Fibrosis
220442|NCT01854424|Mortality
220443|NCT01854411|Analgesics
220444|NCT01854411|Ibuprofene
220445|NCT01854411|Ketoprofene
220446|NCT01854411|Breastmilk
220447|NCT01854411|Relative Infant Dose
220448|NCT01854411|Theoric Infant Dose
220449|NCT01854398|Obstructive sleep apnea
220450|NCT01854398|Continuous positive airway pressure
220451|NCT01854398|diastolic function
220452|NCT01854385|Post-traumatic headache
220453|NCT01854385|Traumatic brain injury
220454|NCT01854385|Sumatriptan
220455|NCT01854359|Multiple Sclerosis
220456|NCT01854359|Extension Trial
220457|NCT01854346|Autism spectrum disorder
220458|NCT01854346|Social skills training
220459|NCT01854346|Group training
220460|NCT01854346|Comorbidity
220461|NCT01854346|Intervention
220462|NCT01854346|Evidence-based
220463|NCT01854333|Diagnostics
220464|NCT01854333|ADOS
220465|NCT01854333|ADI-R
220466|NCT01854333|Psychometrics
220467|NCT01854333|Autism spectrum disorders
220468|NCT01854333|Autism
220469|NCT01854307|Difference of
220470|NCT01854307|measurements
220471|NCT01854307|before and after
220472|NCT01854294|ALS
220473|NCT01854294|motorneuron disease
220474|NCT01854294|Central Nervous System (CNS) disease
220475|NCT01854294|neurodegeneration
220476|NCT01854294|neuroprotective
220477|NCT01854294|mechanisms of action
220478|NCT01854294|pathways
220479|NCT01854294|biomarkers
220480|NCT01854294|Cerebral Spinal Fluid (CSF)
220481|NCT01854294|blood biomarkers
220482|NCT01854294|multi-factorial
220483|NCT01854294|multisystem
220484|NCT01854294|single target
220485|NCT01854294|pathogenic mechanisms
220486|NCT01854294|Protein Bands Selection by Function
220487|NCT01854294|in silico analysis
220488|NCT01854294|active site
220489|NCT01854294|protein
220490|NCT01854294|peptide
220491|NCT01854294|embryonic stage
220492|NCT01854294|endogenous
220493|NCT01854294|master regulators
220494|NCT01854294|fetal development
220495|NCT01854294|embryonic development
220496|NCT01854294|common pathways
220497|NCT01854294|Blood Brain Barrier (BBB)
220498|NCT01854294|anti-inflammatory
220499|NCT01854294|anti-apoptotic
220500|NCT01854294|anti-oxidative
220501|NCT01854294|regenerative
220502|NCT01854294|distress signals
220503|NCT01854294|neurotrophin
220504|NCT01854294|Motoneuronotrophic factor (MNTF)
220505|NCT01854294|ALS model
220506|NCT01854294|life span
220507|NCT01854294|disease onset
220508|NCT01854294|grip strength
220509|NCT01854294|protein expression
220510|NCT01854294|DNA microarray
220511|NCT01854294|differential expression
220512|NCT01854294|Phase 1 clinical trial
220513|NCT01854294|rare disease
220514|NCT01854294|common underlying pathogenic mechanisms
220515|NCT01854294|neurological deficits
220516|NCT01854294|gene mutation
220517|NCT01854294|misfolded proteins
220518|NCT01854294|inadvertent errors
220519|NCT01854294|modulation of genes
220520|NCT01854294|master regulator peptide drug
220521|NCT01854294|ALS related genes
220522|NCT01854294|mitochondria dysfunction
220523|NCT01854294|excitotoxicity
220524|NCT01854294|axonal transport
220525|NCT01854294|oxidative stress
220526|NCT01854294|protein aggregation
220527|NCT01854294|pathogenesis
220528|NCT01854294|target biomarkers
220529|NCT01854294|efficacy biomarkers
220530|NCT01854281|Patent foramen ovale
220531|NCT01854281|Catheter-based closure
220532|NCT01854281|Nitrogen bubbles
220533|NCT01854281|Decompression sickness
220534|NCT01854268|cough
220535|NCT01854255|Gastric
220536|NCT01854255|Cancer
220537|NCT01854255|Chemotherapy
220538|NCT01854255|Intraperitoneal
220539|NCT01854229|Morphine
220540|NCT01854229|Implantable Infusion Pumps
220541|NCT01854229|Intrathecal Pump
220542|NCT01854216|Rotigotine
220543|NCT01854216|Neupro
220544|NCT01854216|Japanese
220545|NCT01854216|Caucasian
220546|NCT01854216|Male
220547|NCT01854216|Female
220548|NCT01854216|Single dose
220549|NCT01854216|Pharmacokinetics
220550|NCT01854203|Cisplatin
220551|NCT01854203|neoadjuvant chemotherapy
220552|NCT01854203|intensity-modulated radiation therapy
220553|NCT01854203|concurrent chemoradiotherapy
220554|NCT01854190|Obstructive sleep apnea
220555|NCT01854190|Resistent hypertension
220556|NCT01854190|Endothelial function
220557|NCT01854190|Blood pressure
220558|NCT01854177|breathlessness; substance P; beta-endorphin
220559|NCT01854164|HGE, impaired fasting glucose, clinical trial
220560|NCT01854151|Medication errors
220561|NCT01854151|Medication dosing
220562|NCT01854138|primary knee arthroplasty
220563|NCT01854138|primary hip arthroplasty
220564|NCT01854138|negative pressure wound therapy
220565|NCT01854125|immun function
220566|NCT01854125|liver function
220567|NCT01854125|ascites
220568|NCT01854125|quality of life
220569|NCT01854125|Child-Pugh score
220570|NCT01854112|Helical tomotherapy
220571|NCT01854112|total skin electron therapy
220572|NCT01854112|TSEB
220573|NCT01854112|irradiation 5.
220574|NCT01854099|Brain Tumor
220575|NCT01854086|osteoporosis
220576|NCT01854086|postmenopausal
220577|NCT01854086|patient compliance
220578|NCT01854086|compliance
220579|NCT01854086|diphosphonates
220580|NCT01854086|bisphosphonates
220581|NCT01854060|Irritable bowel syndrome
220582|NCT01854060|Epidimiology
220583|NCT01854060|Deterioration in the severity of irritable bowel syndrome
220584|NCT01854034|Advanced disease
220585|NCT01854034|EGFR mutation
220586|NCT01854021|Anesthesia
220587|NCT01854021|general
220588|NCT01854021|Immunity
220589|NCT01854021|Tongue neoplasms
220590|NCT01854021|immune
220591|NCT01854021|general anesthesia
220592|NCT01854008|Exercise, Physical activity, Rehabilitation, COPD.
220593|NCT01853995|Fixed Lingual Mandibular Growth Modificator (FLMGM)
220594|NCT01853995|Class II division 1 malocclusion
220595|NCT01853995|Sagittal Occlusal Correction
220596|NCT01853995|Skeletal changes
220597|NCT01853995|Dental changes
220598|NCT01853956|Mexico
220599|NCT01853956|Bioequivalence
220600|NCT01853956|Alprazolam
220601|NCT01853956|Pharmacokinetics
220602|NCT01853943|Transradial approach
220603|NCT01853943|radial occlusion
220604|NCT01853943|hand grip
220605|NCT01853943|coronary angiography
220606|NCT01853930|reading rehabilitation
220607|NCT01853930|macular degeneration
220608|NCT01853930|eccentric viewing
220609|NCT01853904|Bronchoscopy
220610|NCT01853904|BAL
220611|NCT01853904|Suction
220612|NCT01853878|Non-Small Cell Lung Cancer
220613|NCT01853878|Immunotherapy
220614|NCT01853878|Antigen-Specific
220615|NCT01853865|Endometrial cancer
220616|NCT01853865|Follow-up examination
220617|NCT01853813|colorectal cancer
220618|NCT01853813|advanced disease
220619|NCT01853813|LDH
220620|NCT01853800|Relative bioavailability
220621|NCT01853800|Rivaroxaban
220622|NCT01853787|COPD
220623|NCT01853787|bronchial inflammation
220624|NCT01853787|NO concentration
220625|NCT01853787|small airways
220626|NCT01853787|LABA
220627|NCT01853787|Small Airways Stretching
220628|NCT01853787|Stretch and strain of small airways in COPD
220629|NCT01853787|Acute LABA effect on NO production
220630|NCT01853787|Pulmonary desufflation
220631|NCT01853774|Tailored navigation
220632|NCT01853774|Tailored messages
220633|NCT01853761|abdominal fat
220634|NCT01853761|metabolic syndrome
220635|NCT01853761|microcurrent
220636|NCT01853761|aerobic exercise
220637|NCT01853722|DCN01
220638|NCT01853722|Ocular Surgical Preparation
220639|NCT01853722|Prophylaxis against infection
220640|NCT01853722|Pre-operative prep
220641|NCT01853683|General Surgery
220642|NCT01853644|Cancer
220643|NCT01853644|Recurrent
220644|NCT01853644|Ovary
220645|NCT01853644|Fallopian Tube
220646|NCT01853644|Primary Peritioneal
220647|NCT01853644|Phase II
220648|NCT01853644|Platinum Resistant
220649|NCT01853631|chronic Lymphocytic Leukemia
220650|NCT01853631|refractory
220651|NCT01853631|recurrent
220652|NCT01853631|aggressive B-cell Lymphoma
220653|NCT01853631|CD19
220654|NCT01853631|Non-Hodgkin Lymphoma
220655|NCT01853631|CD28
220656|NCT01853631|CD137
220657|NCT01853631|4-1BB
220658|NCT01853631|acute lymphocytic leukemia
220659|NCT01853618|Liver Cancer
220660|NCT01853618|Monoclonal Antibody
220661|NCT01853618|CTLA-4
220662|NCT01853618|Ablative Therapy
220663|NCT01853592|Gadolinium Contrast
220664|NCT01853592|Cardiac MRI
220665|NCT01853592|MRA
220666|NCT01853592|MRI
220667|NCT01853592|MRI Safety
220668|NCT01853579|Randomized controlled trial
220669|NCT01853579|Subclinical hypothyroidism
220670|NCT01853579|Levothyroxine
220671|NCT01853579|Depression
220672|NCT01853566|Muscle Strength
220673|NCT01853566|Growth Hormone
220674|NCT01853566|men
220675|NCT01853540|Ciliary Beat Frequency (CBF)
220676|NCT01853540|Nasal Nitric Oxide (nNO)
220677|NCT01853540|Mucociliary Dysfunction
220678|NCT01853527|CT coronary angiography
220679|NCT01853527|Contrast stress echocardiography
220680|NCT01853527|Arterial stiffness
220681|NCT01853527|Quality of life
220682|NCT01853527|Biochemical and genetic markers
220683|NCT01853514|Low income
220684|NCT01853514|Fruit and vegetables
220685|NCT01853514|Conventional produce
220686|NCT01853514|Organic produce
220687|NCT01853514|Pesticide
220688|NCT01853514|Purchasing behavior
220689|NCT01853514|Message framing
220690|NCT01853501|POF
220691|NCT01853488|Osteoporosis
220692|NCT01853488|BMD
220693|NCT01853488|SCI
220694|NCT01853488|DXA
220695|NCT01853488|pQCT
220696|NCT01853475|pharmacokinetics
220697|NCT01853475|safety
220698|NCT01853475|tolerability
220699|NCT01853475|bioavailability
220700|NCT01853449|Fentanyl Citrate
220701|NCT01853449|Opioids
220702|NCT01853449|Exercise
220703|NCT01853436|Breast Cancer
220704|NCT01853436|Reconstructive Tissue Matrix
220705|NCT01853436|Acellular Dermal Matrices (ADM)
220706|NCT01853423|Rapamune
220707|NCT01853423|Topical
220708|NCT01853423|Pediatric
220709|NCT01853423|Safety
220710|NCT01853423|Efficiency
220711|NCT01853423|Angiofibroma
220712|NCT01853423|Skin Cream
220713|NCT01853410|coronary artery disease
220714|NCT01853410|coronary flow reserve
220715|NCT01853410|endothelial function
220716|NCT01853384|Venous leg ulcer
220717|NCT01853384|ulcer
220718|NCT01853384|venous stasis
220719|NCT01853384|compression
220720|NCT01853384|venous
220721|NCT01853384|venous stasis ulcer
220722|NCT01853384|vlu
220723|NCT01853384|wound
220724|NCT01853384|varicose veins
220725|NCT01853384|venous insufficiency
220726|NCT01853384|dvt
220727|NCT01853384|deep vein thrombosis
220728|NCT01853358|hematological malignancy
220729|NCT01853358|stem cell transplantation
220730|NCT01853345|Refractory
220731|NCT01853345|Recurrent
220732|NCT01853345|High Risk
220733|NCT01853332|Cardiovascular Disease
220734|NCT01853332|Diabetes
220735|NCT01853332|Adjustment
220736|NCT01853332|Adversity
220737|NCT01853332|Psychology
220738|NCT01853332|Midlife
220739|NCT01853332|Functioning
220740|NCT01853332|Socioeconomic
220741|NCT01853332|Psychosocial outcomes
220742|NCT01853319|Regorafenib
220743|NCT01853319|Metastatic colorectal cancer
220744|NCT01853306|High grade serous ovarian cancer
220745|NCT01853306|BRCA mutated breast cancer
220746|NCT01853306|BRCA mutated
220747|NCT01853306|Oncology
220748|NCT01853293|Alcohol Abuse
220749|NCT01853293|Alcohol Dependence
220750|NCT01853293|Heavy drinking days
220751|NCT01853293|Kudzu
220752|NCT01853280|ADHD
220753|NCT01853280|Attention Deficit Hyperactivity Disorder
220754|NCT01853280|Deplin
220755|NCT01853280|L-methylfolate
220756|NCT01853280|Natural Treatments
220757|NCT01853280|Medical Food
220758|NCT01853267|Colorectal
220759|NCT01853267|Surgery
220760|NCT01853267|Perianal
220761|NCT01853267|Abscess
220762|NCT01853241|small intestine
220763|NCT01853241|endoscopy, gastrointestinal
220764|NCT01853228|Acute myeloid leukemia
220765|NCT01853228|Relapsed or refractory acute myeloid leukemia
220766|NCT01853228|Children
220767|NCT01853228|Decitabine
220768|NCT01853228|DACOGEN
220769|NCT01853228|Cytarabine
220770|NCT01853215|sternal intraosseous infusion study
220771|NCT01853202|Cancer
220772|NCT01853202|Chemotherapy
220773|NCT01853202|Thrombosis
220774|NCT01853202|Prevention
220775|NCT01853202|Exercise
220776|NCT01853189|pediatrics
220777|NCT01853189|asthma
220778|NCT01853189|osteopathic manipulative treatment
220779|NCT01853176|Pain, Postoperative
220780|NCT01853176|Analgesia
220781|NCT01853176|Anesthesia, local
220782|NCT01853176|Abdominoplasty
220783|NCT01853163|Gadolinium
220784|NCT01853163|Contrast Agent
220785|NCT01853163|Long-term retention
220786|NCT01853137|Class II division 1 malocclusion
220787|NCT01853137|Dentofacial orthopedics
220788|NCT01853137|Fixed Lingual Mandibular Growth Modificator (FLMGM)
220789|NCT01853124|Diarrhea
220790|NCT01853098|loving-kindness meditation
220791|NCT01853098|mindfulness meditation
220792|NCT01853098|compassion
220793|NCT01853072|Diabetes Type I
220794|NCT01853072|Diabetes Type II
220795|NCT01853072|non-proliferative diabetic retinopathy
220796|NCT01853072|macular edema
220797|NCT01853072|Cataract
220798|NCT01853059|Anal cancer
220799|NCT01853059|Squamous cell cancer
220800|NCT01853059|Radiotherapy
220801|NCT01853059|Chemoradiotherapy
220802|NCT01853059|Conformational radiotherapy
220803|NCT01853059|Intensity modulated radiation therapy
220804|NCT01853059|IMRT
220805|NCT01853046|Regorafenib
220806|NCT01853046|pharmacokinetics
220807|NCT01853046|safety
220808|NCT01853046|severe renal impairment
220809|NCT01853046|Solid tumors
220810|NCT01853033|Tolerability
220811|NCT01853033|Immunogenicity
220812|NCT01853033|Safety
220813|NCT01853033|Rheumatoid Arthritis
220814|NCT01853033|Pharmacokinetics
220815|NCT01853020|Cannabinoids
220816|NCT01853020|Eyeblink Conditioning
220817|NCT01853020|EBC
220818|NCT01853007|End stage renal disease
220819|NCT01853007|Kidney transplantation
220820|NCT01853007|Transplant options (living and deceased donor)
220821|NCT01853007|Patient education
220822|NCT01853007|Communication skills training
220823|NCT01852981|Physical activity promotion
220824|NCT01852981|Intervention
220825|NCT01852981|Public Health
220826|NCT01852968|hypoglycemia
220827|NCT01852968|hypoglycemia unawareness
220828|NCT01852968|type 1 diabetes, hippocampus
220829|NCT01852968|glucose transport
220830|NCT01852968|cognitive dysfunction
220831|NCT01852955|Outpatient
220832|NCT01852955|Surgery
220833|NCT01852955|Breast
220834|NCT01852955|Pain
220835|NCT01852942|Infection
220836|NCT01852942|HIV 1
220837|NCT01852942|HIV
220838|NCT01852942|Losartan
220839|NCT01852942|Fibrosis
220840|NCT01852942|Immune Activation
220841|NCT01852942|Immune Reconstitution
220842|NCT01852929|Memory
220843|NCT01852916|RDS
220844|NCT01852903|vitamin C
220845|NCT01852903|calcium ascorbate
220846|NCT01852903|ascorbic acid
220847|NCT01852903|bioavailability
220848|NCT01852890|Ascorbate
220849|NCT01852890|Vitamin C
220850|NCT01852890|Radiation
220851|NCT01852890|Gemcitabine
220852|NCT01852890|Ascorbic Acid
220853|NCT01852877|HIV Diagnosis
220854|NCT01852877|Case Management
220855|NCT01852877|Telemedicine
220856|NCT01852877|Patient Compliance
220857|NCT01852877|Prisoners
220858|NCT01852864|Prostate cancer
220859|NCT01852864|testosterone
220860|NCT01852864|castration
220861|NCT01852864|degarelix
220862|NCT01852864|proliferation
220863|NCT01852838|lung cancer
220864|NCT01852838|volatile organic compounds
220865|NCT01852838|Warburg effect
220866|NCT01852838|early detection
220867|NCT01852799|Multiple myeloma
220868|NCT01852799|PAD
220869|NCT01852799|ASCT
220870|NCT01852799|Bone metabolites
220871|NCT01852799|Bone marker
220872|NCT01852786|Contraception
220873|NCT01852786|Hyperandrogenism
220874|NCT01852786|Female sexual function
220875|NCT01852773|blunt
220876|NCT01852773|injury
220877|NCT01852773|aorta
220878|NCT01852773|endovascular
220879|NCT01852760|endoscopic ultrasound
220880|NCT01852760|ulcerative colitis
220881|NCT01852760|inflammatory bowel disease
220882|NCT01852747|Spinal Deformity
220883|NCT01852747|Multilevel
220884|NCT01852747|Posterior
220885|NCT01852747|Lumbar
220886|NCT01852747|Fusion
220887|NCT01852747|Levoscoliosis
220888|NCT01852747|Dextroscoliosis
220889|NCT01852747|Graft
220890|NCT01852721|Cardiovascular diseases
220891|NCT01852721|Nutritional intervention program
220892|NCT01852721|Self-Determination Theory
220893|NCT01852721|Motivational interviewing
220894|NCT01852721|Gender differences
220895|NCT01852721|Women
220896|NCT01852721|Men
220897|NCT01852721|Motivation
220898|NCT01852721|Dietary intakes
220899|NCT01852721|Mediterranean diet
220900|NCT01852721|Eating behaviors
220901|NCT01852721|Lipid profile
220902|NCT01852708|22q
220903|NCT01852708|1p36
220904|NCT01852708|Angelman
220905|NCT01852708|Cri-du-chat
220906|NCT01852708|Prader-Willi
220907|NCT01852708|DiGeorge
220908|NCT01852708|Turner syndrome
220909|NCT01852708|Patau syndrome
220910|NCT01852708|Edwards syndrome
220911|NCT01852708|Down syndrome
220912|NCT01852695|Family integrated Care
220913|NCT01852695|Family centered care
220914|NCT01852695|NICU family centered care
220915|NCT01852695|NICU parent program
220916|NCT01852682|Peritoneal Dialysis
220917|NCT01852682|Hyperphosphatemia
220918|NCT01852656|Influenza, Human
220919|NCT01852656|Immunization
220920|NCT01852643|Rhinoplasty
220921|NCT01852643|Spreader graft technique
220922|NCT01852643|Lateral crural overlay technique
220923|NCT01852643|Rhinomanometry
220924|NCT01852617|Smoking Cessation
220925|NCT01852617|Pregnancy
220926|NCT01852617|Implementation
220927|NCT01852617|Knowledge translation
220928|NCT01852604|HCV
220929|NCT01852604|Hepatitis C
220930|NCT01852604|chronic hepatitis C
220931|NCT01852604|antiviral
220932|NCT01852591|autologous transplant
220933|NCT01852591|multiple myeloma
220934|NCT01852578|Metastatic NSCLC
220935|NCT01852578|2nd Line
220936|NCT01852578|Docetaxel-based treatment
220937|NCT01852578|Progressed
220938|NCT01852578|Refractory
220939|NCT01852565|CYP3A4
220940|NCT01852565|Lp-PLA2
220941|NCT01852565|Atherosclerosis
220942|NCT01852565|healthy volunteer
220943|NCT01852565|Drug interaction
220944|NCT01852552|Aortic stenosis
220945|NCT01852552|Transcatheter aortic valve implantation
220946|NCT01852552|Aortic valve replacement
220947|NCT01852552|Costs
220948|NCT01852552|Cognitive function
220949|NCT01852552|Quality of life
220950|NCT01852539|LMA insertion
220951|NCT01852539|dexmedetomidine
220952|NCT01852539|propofol
220953|NCT01852526|degenerative disc disease
220954|NCT01852526|spondylolisthesis
220955|NCT01852526|Lumbar spine
220956|NCT01852526|fusion
220957|NCT01852526|adjacent instability
220958|NCT01852487|Pumpkin seed oil
220959|NCT01852487|Hair growth
220960|NCT01852487|Men
220961|NCT01852474|motor learning
220962|NCT01852474|cortical plasticity
220963|NCT01852474|direct current stimulation
220964|NCT01852461|natural surfactants; perfusion index
220965|NCT01852435|diffuse large B-cell lymphoma
220966|NCT01852435|follicular lymphoma grade 3B
220967|NCT01852409|refractory malignant ascites
220968|NCT01852409|Bevacizumab
220969|NCT01852409|intraperitoneal
220970|NCT01852409|phase I
220971|NCT01852396|Infraclavicular block
220972|NCT01852396|Brachial Plexus
220973|NCT01852396|Retroclavicular Approach
220974|NCT01852396|Complications of retroclavicular approach
220975|NCT01852396|Success of retroclavicular approach
220976|NCT01852383|Duloxetine
220977|NCT01852383|Antidepressant
220978|NCT01852383|Depression
220979|NCT01852383|Dysthymic Disorder
220980|NCT01852383|Side Effects
220981|NCT01852383|Elderly
220982|NCT01852370|Lung transplantation
220983|NCT01852370|Bone Marrow Transplantation
220984|NCT01852370|Unrelated Donor
220985|NCT01852370|Cadaveric Donor
220986|NCT01852370|Deceased Donor
220987|NCT01852370|HLA-mismatch
220988|NCT01852370|BOLT
220989|NCT01852370|BMT
220990|NCT01852370|HSCT
220991|NCT01852344|Methylphenidate
220992|NCT01852344|Effortful Control
220993|NCT01852344|Attention Control
220994|NCT01852344|Cognitive functions
220995|NCT01852331|Schizophrenia
220996|NCT01852331|Schizophrenic Disorder
220997|NCT01852331|Hyperprolactinemia
220998|NCT01852331|Hyperprolactinaemia
220999|NCT01852331|Chinese herbal medicine
221000|NCT01852331|Traditional Chinese medicine
221001|NCT01852331|Peony-Glycyrrhiza Decoction
221002|NCT01852331|PGD
221003|NCT01852331|Glycyrrhiza Radix
221004|NCT01852331|Liquorice Root
221005|NCT01852331|Gancao
221006|NCT01852331|Paeoniae Alba Radix
221007|NCT01852331|White Peony Root
221008|NCT01852331|Baishao
221009|NCT01852318|uremic pruritus
221010|NCT01852318|pregabalin
221011|NCT01852318|gabapentin
221012|NCT01852318|fexofenadine
221013|NCT01852305|Obstructive sleep apnea
221014|NCT01852305|Continuous positive airway pressure (CPAP)
221015|NCT01852305|Oximetry
221016|NCT01852305|Bariatric Surgery
221017|NCT01852305|Anesthesia
221018|NCT01852305|Oxygen desaturation index (ODI)
221019|NCT01852292|platinum pre-treated recurrent or metastatic
221020|NCT01852292|Head and neck squamous cell carcinoma,
221021|NCT01852292|recurrent
221022|NCT01852292|metastatic
221023|NCT01852292|BKM120
221024|NCT01852253|Dental implants
221025|NCT01852253|Periodontal diseases
221026|NCT01852253|Peri-implantitis
221027|NCT01852253|Chlorhexidine
221028|NCT01852253|Microbiology
221029|NCT01852214|Diabetes mellitus
221030|NCT01852214|Coronary artery disease
221031|NCT01852214|prasugrel
221032|NCT01852214|ticagrelor
221033|NCT01852188|Intrapartum
221034|NCT01852188|Glove
221035|NCT01852188|Chorioamnionitis
221036|NCT01852175|Coronary artery disease
221037|NCT01852175|Dual antiplatelet therapy
221038|NCT01852175|prasugrel
221039|NCT01852175|ticagrelor
221040|NCT01852162|Coronary artery disease
221041|NCT01852162|antiplatelet therapy
221042|NCT01852162|anticoagulant therapy
221043|NCT01852149|Mitral Valve Regurgitation
221044|NCT01852149|Coaptation
221045|NCT01852149|Mitral Valve Repair
221046|NCT01852149|Plication
221047|NCT01852149|Leaflet
221048|NCT01852149|Annulus
221049|NCT01852149|Mitral Annuloplasty
221050|NCT01852136|pen needle
221051|NCT01852136|insulin
221052|NCT01852123|High-sensitivity troponin assay
221053|NCT01852123|Myocardial infarction
221054|NCT01852123|Unstable angina
221055|NCT01852123|Myocardial injury
221056|NCT01852123|Cluster randomized trial
221057|NCT01852097|Inflammatory Bowel Disease (IBD)
221058|NCT01852097|Crohn's disease
221059|NCT01852097|Ulcerative colitis
221060|NCT01852097|Cognitive Behavioural Therapy (CBT)
221061|NCT01852097|Medication adherence
221062|NCT01852071|gene therapy, hematopoietic stem cell, SCID, lentivirus
221063|NCT01852032|Breast Cancer
221064|NCT01852019|CAD
221065|NCT01851993|Ondansetron
221066|NCT01851993|Exercise
221067|NCT01851980|Furosemide
221068|NCT01851980|Exercise
221069|NCT01851980|Restrictive pulmonary disorder
221070|NCT01851967|Major depressive disorder
221071|NCT01851967|Cognitive behavioral therapy
221072|NCT01851967|Computerized CBT
221073|NCT01851967|Online CBT
221074|NCT01851915|Major depression
221075|NCT01851915|Interpersonal psychotherapy
221076|NCT01851915|Cognitive Behavioral Therapy
221077|NCT01851915|Alliance
221078|NCT01851915|Return to Work
221079|NCT01851902|Atrial Fibrillation
221080|NCT01851902|Atrial Flutter
221081|NCT01851902|Arrhythmia
221082|NCT01851863|functional dyspepsia
221083|NCT01851863|depression
221084|NCT01851863|compliance
221085|NCT01851850|PD
221086|NCT01851850|Off periods
221087|NCT01851850|quality of life
221088|NCT01851850|dyskinesia
221089|NCT01851850|end-off-dose motor fluctuations
221090|NCT01851811|OSA
221091|NCT01851798|OSA
221092|NCT01851798|Sleep disordered breathing
221093|NCT01851798|anesthesia
221094|NCT01851798|ambulatory orthopedic surgery
221095|NCT01851785|Knee Arthroplasty
221096|NCT01851785|Knee Osteoarthritis
221097|NCT01851785|Osteoarthritis
221098|NCT01851785|disparity
221099|NCT01851785|joint replacement
221100|NCT01851772|cervical
221101|NCT01851772|cancer
221102|NCT01851772|brachytherapy
221103|NCT01851772|electronic
221104|NCT01851772|device
221105|NCT01851772|applicator
221106|NCT01851772|toxicity
221107|NCT01851772|gynecologic
221108|NCT01851772|high-dose-rate (HDR)
221109|NCT01851772|x-ray
221110|NCT01851772|safety
221111|NCT01851772|external beam radiation therapy (EBRT)
221112|NCT01851746|recurrent ovarian cancer
221113|NCT01851746|lobaplatin
221114|NCT01851746|docetaxel
221115|NCT01851746|carboplatin
221116|NCT01851694|Cystic Fibrosis
221117|NCT01851694|Diabetes
221118|NCT01851694|Pancreatic insufficiency
221119|NCT01851681|dental implants
221120|NCT01851681|wound healing
221121|NCT01851681|amoxicillin
221122|NCT01851681|pain
221123|NCT01851668|vibration
221124|NCT01851668|noise
221125|NCT01851668|transfer
221126|NCT01851668|intraventricular hemorrhage
221127|NCT01851655|rehabilitation
221128|NCT01851655|plyometric
221129|NCT01851642|Macrophage
221130|NCT01851642|Alpha-1 Antitrypsin Deficiency
221131|NCT01851642|Cystic Fibrosis
221132|NCT01851629|Locomotor training
221133|NCT01851629|Walking recovery
221134|NCT01851629|Neuroplasticity
221135|NCT01851616|glucose, blood
221136|NCT01851603|Schizophrenia
221137|NCT01851590|Dermatophyte onychomycosis
221138|NCT01851590|Fungal nail infection
221139|NCT01851590|Resin Lacquer
221140|NCT01851590|Amorolfine
221141|NCT01851590|Terbinafine
221142|NCT01851577|Coparenting
221143|NCT01851577|Problem solving
221144|NCT01851577|Child development
221145|NCT01851577|Father involvement
221146|NCT01851564|Gastrointestinal Haemorrhage
221147|NCT01851564|Varices
221148|NCT01851564|Liver Cirrhosis
221149|NCT01851564|Stent
221150|NCT01851551|NHL
221151|NCT01851551|non-Hodgkin's lymphoma
221152|NCT01851551|diffuse large b-cell lymphoma
221153|NCT01851551|mantle cell lymphoma
221154|NCT01851538|Heart failure
221155|NCT01851538|Biomarkers
221156|NCT01851538|Echocardiography
221157|NCT01851525|Atrial fibrillation
221158|NCT01851525|Ablation
221159|NCT01851499|Neuropathic pain following spinal cord injury
221160|NCT01851473|Cocaine
221161|NCT01851473|Pharmacokinetics
221162|NCT01851473|Pharmacodynamics
221163|NCT01851473|Drug Interactions
221164|NCT01851473|Acetazolamide
221165|NCT01851460|Staphylococcus Infection
221166|NCT01851460|RFA
221167|NCT01851460|Hepatic
221168|NCT01851460|CGD
221169|NCT01851447|Muscle
221170|NCT01851447|Inflammatory Cytokines
221171|NCT01851447|Exercise
221172|NCT01851447|Biomarkers
221173|NCT01851447|Predictors of Outcome
221174|NCT01851434|OCT
221175|NCT01851434|Multiple Sclerosis
221176|NCT01851434|Optic Neuritis
221177|NCT01851434|Magnetic Resonance Imaging (MRI)
221178|NCT01851421|Body Fat
221179|NCT01851421|Adult
221180|NCT01851421|Obesity
221181|NCT01851421|Free Fatty Acids
221182|NCT01851421|Melanocortin-3 Receptor
221183|NCT01851408|Sorafenib
221184|NCT01851408|Temsirolimus
221185|NCT01851408|Stage IV
221186|NCT01851408|recurrent
221187|NCT01851408|unresectable
221188|NCT01851408|non-choroidal origin
221189|NCT01851408|CCI-779
221190|NCT01851408|BAY43-9006
221191|NCT01851408|metastatic melanoma
221192|NCT01851395|Palliative
221193|NCT01851395|Tumor Heterogeneity
221194|NCT01851395|Genomic and Proteomic Alterations
221195|NCT01851395|Deep Sequencing and Global Analysis
221196|NCT01851395|Clonal Evolution
221197|NCT01851382|ELISA
221198|NCT01851382|Spectrometry
221199|NCT01851382|Protein Biomarkers
221200|NCT01851382|Proteomic Analyses
221201|NCT01851369|Solid Tumors
221202|NCT01851369|Lymphomas
221203|NCT01851369|DNA Damage
221204|NCT01851369|Pharmacodynamics
221205|NCT01851369|Pharmacokinetics
221206|NCT01851356|PBR28
221207|NCT01851356|Depression
221208|NCT01851356|PET Imaging
221209|NCT01851356|Neuroinflammation
221210|NCT01851343|Stem Cell Infusion
221211|NCT01851343|Crohns
221212|NCT01851343|Ulcerative Colitis
221213|NCT01851343|Inflammation
221214|NCT01851343|Diarrhea
221215|NCT01851330|HCV genotype 1 (GT-1)
221216|NCT01851330|HCV
221217|NCT01851330|Sustained Virologic Response
221218|NCT01851330|Direct Acting Antiviral
221219|NCT01851330|Combination Therapy
221220|NCT01851330|GS-7977
221221|NCT01851330|GS-5885
221222|NCT01851330|Ribavirin
221223|NCT01851330|Open Label
221224|NCT01851330|Sofosbuvir
221225|NCT01851330|Additional relevant MeSH terms:
221226|NCT01851330|Hepatitis
221227|NCT01851330|Hepatitis, Chronic
221228|NCT01851330|Hepatitis C
221229|NCT01851330|Hepatitis C, Chronic
221230|NCT01851330|Liver Diseases
221231|NCT01851330|Digestive System Diseases
221232|NCT01851330|Hepatitis, Viral, Human
221233|NCT01851330|Virus Diseases
221234|NCT01851330|Enterovirus Infections
221235|NCT01851330|Picornaviridae Infections
221236|NCT01851330|RNA Virus Infections
221237|NCT01851330|Flaviviridae Infections
221238|NCT01851330|Antiviral Agents
221239|NCT01851330|Anti-Infective Agents
221240|NCT01851330|Therapeutic Uses
221241|NCT01851330|Pharmacologic Actions
221242|NCT01851330|Antimetabolites
221243|NCT01851330|Molecular Mechanisms of Pharmacological Action
221244|NCT01851304|beta-Glucans
221245|NCT01851304|Bitter
221246|NCT01851304|Bread
221247|NCT01851304|Coffee
221248|NCT01851304|Gentiana lutea
221249|NCT01851304|Melanoidins
221250|NCT01851304|Microencapsulation
221251|NCT01851278|injection
221252|NCT01851278|arthritis
221253|NCT01851278|corticosteroid
221254|NCT01851265|oncology, cancer, tumour, neoplasm, anticancer drug, food effect, area under the curve, pharmacokinetics, olaparib, solid tumour, metabolites, drug availability
221255|NCT01851239|Venous Thromboembolism Prophylaxis
221256|NCT01851239|ICU
221257|NCT01851213|genomics
221258|NCT01851213|cancer
221259|NCT01851213|registry
221260|NCT01851213|neoplasm metastasis
221261|NCT01851200|Testicular neoplasms
221262|NCT01851200|Germ Cell cancers
221263|NCT01851200|Embryonal Carcinoma
221264|NCT01851200|Metastatic
221265|NCT01851200|Brentuximab Vedotin
221266|NCT01851187|Psychological intervention,
221267|NCT01851187|prenatal period,
221268|NCT01851187|cesarean section rate,
221269|NCT01851187|stage of labor
221270|NCT01851148|osteopathic manipulative treatment
221271|NCT01851148|migraine
221272|NCT01851135|Quality of life
221273|NCT01851135|Neuropsychological disorders
221274|NCT01851135|Neurofibromatosis type 1
221275|NCT01851122|l-theanine
221276|NCT01851122|alertness
221277|NCT01851122|well-being
221278|NCT01851109|ovarian cancer
221279|NCT01851109|prevention
221280|NCT01851109|prophylactic surgery
221281|NCT01851109|risk
221282|NCT01851109|biomarkers
221283|NCT01851109|screening
221284|NCT01851109|symptoms
221285|NCT01851096|Hsp90
221286|NCT01851096|SNX-5422
221287|NCT01851096|Erlotinib
221288|NCT01851096|Lung adenocarcinoma
221289|NCT01851083|Traumatic Brain Injury
221290|NCT01851083|TBI
221291|NCT01851083|pediatric
221292|NCT01851083|acute
221293|NCT01851083|stem cells
221294|NCT01851057|Epilepsy
221295|NCT01851044|Platelet Rich Plasma
221296|NCT01851044|Whole Blood Injection
221297|NCT01851044|Lateral Epicondylitis
221298|NCT01851044|Tennis Elbow
221299|NCT01851031|medial or low condylar fractures
221300|NCT01851031|the minor parotid anterior approach
221301|NCT01851031|the retromandibular approach
221302|NCT01851018|Prostate cancer
221303|NCT01851018|brachytherapy
221304|NCT01851018|hypofractionated radiation therapy
221305|NCT01851018|hormonal therapy
221306|NCT01851005|Dexmedetomidine
221307|NCT01851005|Anesthesia
221308|NCT01851005|Recovery profile
221309|NCT01850992|Obstructive sleep apnea.
221310|NCT01850992|sleep
221311|NCT01850992|male hormones
221312|NCT01850979|CYCLOSPORINE/TACROLIMUS [VA Drug Interaction]
221313|NCT01850966|Arthritis, Rheumatoid, Iguratimod
221314|NCT01850953|Varenicline
221315|NCT01850953|Schizophrenia
221316|NCT01850953|smoking
221317|NCT01850953|Lapse
221318|NCT01850940|Cirrhotic Patients
221319|NCT01850940|Hyponatremia
221320|NCT01850940|tolvaptan
221321|NCT01850914|Normal pressure hydrocephalus
221322|NCT01850914|Vascular risk factors
221323|NCT01850901|Hypertension
221324|NCT01850901|Renal denervation
221325|NCT01850901|Sympathetic denervation
221326|NCT01850888|neuroblastoma
221327|NCT01850888|pheochromocytoma
221328|NCT01850875|Eye-Movement-Desensitization and Reprocessing
221329|NCT01850875|EMDR
221330|NCT01850875|Chronic back pain
221331|NCT01850875|CBP
221332|NCT01850875|treatment
221333|NCT01850836|Aphasia, Stroke, repetitive transcranial magnetic stimulation.
221334|NCT01850797|oral anticoagulants
221335|NCT01850797|ischemic stroke
221336|NCT01850797|blood thinner
221337|NCT01850797|intracranial hemorrhage
221338|NCT01850784|Congenital heart disease, Growth,Neurodevelopment
221339|NCT01850771|Lumbar Radiculopathy
221340|NCT01850771|Disc bulge
221341|NCT01850771|Disc herniation
221342|NCT01850771|Disc degeneration
221343|NCT01850758|ACL
221344|NCT01850758|Anterior Cruciate Ligament
221345|NCT01850758|ACL Tear
221346|NCT01850758|Anterior Cruciate Ligament Tear
221347|NCT01850758|Partial ACL Tear
221348|NCT01850745|Chronic hepatitis C virus infection (CHC)
221349|NCT01850719|Tibial meniscus
221350|NCT01850719|Arthroscopy
221351|NCT01850719|Meniscectomy
221352|NCT01850719|Conservative treatment
221353|NCT01850719|Physical therapy
221354|NCT01850719|Osteoarthritis knee joint
221355|NCT01850706|uNGF
221356|NCT01850706|urinary nerve growth factor
221357|NCT01850706|detrusor overactivity
221358|NCT01850706|InterStim
221359|NCT01850706|sacral neuromodulation
221360|NCT01850706|sacral nerve stimulation
221361|NCT01850706|quality of life
221362|NCT01850706|questionnaire
221363|NCT01850706|urodynamic detrusor overactivity
221364|NCT01850706|overactive bladder
221365|NCT01850693|coronary artery disease
221366|NCT01850693|stroke
221367|NCT01850693|coronary CT angiography
221368|NCT01850667|Hepatocellular carcinoma
221369|NCT01850667|Stereotactic body radiotherapy
221370|NCT01850667|Stereotactic ablative radiotherapy
221371|NCT01850654|colorectal cancer
221372|NCT01850654|colon cancer
221373|NCT01850654|rectal cancer
221374|NCT01850654|endometrial cancer
221375|NCT01850654|Lynch syndrome
221376|NCT01850654|Ohio colon cancer study
221377|NCT01850654|OSU colon study
221378|NCT01849679|Dysphagia
221379|NCT01849679|extubation
221380|NCT01849679|aspiration
221381|NCT01849653|vaginal swabs
221382|NCT01849653|diagnosis
221383|NCT01849640|Malaria
221384|NCT01849640|Drug resistance
221385|NCT01849640|DHA-piperaquine
221386|NCT01849640|Cambodia
221387|NCT01849640|Transmission Blocking
221388|NCT01849627|weight loss maintenance
221389|NCT01849588|Hepatitis C positive
221390|NCT01849575|Ultrasonography
221391|NCT01849575|Cardiovascular diseases
221392|NCT01849575|Prevention
221393|NCT01849575|Risk communication
221394|NCT01849575|Risk assessment
221395|NCT01849575|Behavioral change
221396|NCT01849562|Hepatitis C, Chronic
221397|NCT01849562|Genotype 1
221398|NCT01849562|Hepatitis C
221399|NCT01849562|Liver Diseases
221400|NCT01849562|Hepatitis, viral, human
221401|NCT01849562|ribavirin
221402|NCT01849562|antiviral agents
221403|NCT01849562|anti-infective agents
221404|NCT01849562|protease inhibitors
221405|NCT01849562|NS5a inhibitors
221406|NCT01849549|neuropsychological Study
221407|NCT01849549|brain Imaging
221408|NCT01849536|Open angle glaucoma
221409|NCT01849536|Corneal biomechanics
221410|NCT01849536|Intra ocular pressure
221411|NCT01849536|IOP
221412|NCT01849536|IOP fluctuation
221413|NCT01849536|Continuous IOP monitoring
221414|NCT01849536|SENSIMED Triggerfish®
221415|NCT01850641|Hemodialysis
221416|NCT01850641|Hyperphosphatemia
221417|NCT01850628|National Surgical Adjuvant Breast and Bowel Project (NSABP)
221418|NCT01850628|paclitaxel
221419|NCT01850628|trastuzumab
221420|NCT01850628|pertuzumab
221421|NCT01850628|HER2 positive (human epidermal growth factor receptor 2)
221422|NCT01850628|Proteomics
221423|NCT01850628|Neoadjuvant Therapy
221424|NCT01850628|Anthracycline therapy
221425|NCT01850628|Locally advanced
221426|NCT01850628|Operable
221427|NCT01850628|Biomarkers
221428|NCT01850602|Hemodialysis
221429|NCT01850602|Hyperphosphatemia
221430|NCT01850576|prevention
221431|NCT01850576|testing
221432|NCT01850576|counseling
221433|NCT01850576|linkage
221434|NCT01850563|Demonstrate coordination of HBO with SRS treatments is feasible.
221435|NCT01850563|Demonstrate outcomes for patients treated with combination of HBO and SRS are non-inferior .
221436|NCT01850550|Weight loss
221437|NCT01850537|DDD
221438|NCT01850537|PROW
221439|NCT01850537|FUSION
221440|NCT01850537|eSPIN
221441|NCT01850537|Cage
221442|NCT01850537|IBF
221443|NCT01850537|Discectomy
221444|NCT01850537|Lumbar Fusion
221445|NCT01850537|TLIF
221446|NCT01850537|MIS
221447|NCT01850524|Newly Diagnosed multiple myeloma
221448|NCT01850524|multiple myeloma
221449|NCT01850524|MLN9708
221450|NCT01850524|IXAZOMIB
221451|NCT01850524|Proteasome inhibitor
221452|NCT01850524|Tourmaline MM2
221453|NCT01850511|Nasal obstruction
221454|NCT01850511|Vibrissae
221455|NCT01850511|Nasal hair
221456|NCT01850498|Epilepsy
221457|NCT01850498|Seizure
221458|NCT01850498|Motor
221459|NCT01850498|Motion
221460|NCT01850498|Accelerometer
221461|NCT01850485|cardiac arrest
221462|NCT01850485|therapeutic hypothermia
221463|NCT01850485|microcirculation
221464|NCT01850472|Anhedonia
221465|NCT01850472|Depression
221466|NCT01850472|Stress
221467|NCT01850472|Cortisol
221468|NCT01850472|Inflammatory cytokines
221469|NCT01850472|Learning
221470|NCT01850472|Magnetic resonance imaging (MRI)
221471|NCT01850433|BDD
221472|NCT01850433|CBT
221473|NCT01850420|fibromyalgia
221474|NCT01850420|Myofascial
221475|NCT01850407|Lack of Preparation for Abused Children during Medical Examination
221476|NCT01850381|Parkinson Disease
221477|NCT01850381|Efficacy
221478|NCT01850381|Safety
221479|NCT01850381|Tolerability
221480|NCT01850381|Phase 2A
221481|NCT01850381|Pilot trial
221482|NCT01850381|human Motoneuronotrophic Factor
221483|NCT01850381|neuroprotective agent
221484|NCT01850381|neurodegenerative diseases
221485|NCT01850381|rate of clinical progression of PD
221486|NCT01850381|UPDRS
221487|NCT01850381|Proof of principle
221488|NCT01850368|Hepatocellular carcinoma
221489|NCT01850368|Stereotactic ablative radiotherapy
221490|NCT01850368|Stereotactic body radiotherapy
221491|NCT01850368|Portal vein tumor thrombus
221492|NCT01850355|Autism Spectrum Disorders
221493|NCT01850355|Anxiety
221494|NCT01850355|Children
221495|NCT01850355|Adolescents
221496|NCT01850355|Buspar
221497|NCT01850355|Buspirone
221498|NCT01850355|Pervasive Developmental Disorders
221499|NCT01850342|Male stress urinary incontinence
221500|NCT01850342|Cell-assisted lipotransfer
221501|NCT01850342|Adipose-derived regenerative cells
221502|NCT01850342|ADRC
221503|NCT01850342|Micrograft
221504|NCT01850342|Fat tissue
221505|NCT01850342|Stem cells
221506|NCT01850303|Elderly
221507|NCT01850303|lung cancer
221508|NCT01850303|switch
221509|NCT01850303|maintenance
221510|NCT01850303|Elderly patients (between 70 and 89 years)
221511|NCT01850303|NSCLC
221512|NCT01850290|TBI
221513|NCT01850277|Atrial fibrillation
221514|NCT01850277|Cardiac resynchronization therapy
221515|NCT01850277|Heart failure
221516|NCT01850277|Rhythm control strategy
221517|NCT01850264|cardiac resynchronization therapy; heart failure, congestive
221518|NCT01850251|Hip fractures
221519|NCT01850251|Ageing
221520|NCT01850251|Sarcopenia
221521|NCT01850251|Function
221522|NCT01850238|Alzheimer disease
221523|NCT01850238|tau protein
221524|NCT01850238|neurofibrillary degeneration
221525|NCT01850238|disease-modifying
221526|NCT01850212|Treatment Experienced
221527|NCT01850212|Male greater than or equal to 50 years
221528|NCT01850212|Female postmenopausal
221529|NCT01850199|Gestational diabetes
221530|NCT01850199|Telemedicine
221531|NCT01850199|Artificial Intelligence
221532|NCT01850160|Hypertension
221533|NCT01850160|High blood pressure
221534|NCT01850160|Drug therapy combination
221535|NCT01850160|Valsartan
221536|NCT01850160|Chlorthalidone
221537|NCT01850160|Safety
221538|NCT01850160|Efficacy
221539|NCT01850147|sunitinib
221540|NCT01850147|chemotherapy
221541|NCT01850147|non-small cell lung cancer
221542|NCT01850147|NSCLC
221543|NCT01850121|Ankylosing Spondylitis
221544|NCT01850121|infiximab
221545|NCT01850121|single armed trial
221546|NCT01850095|acne
221547|NCT01850095|adult
221548|NCT01850095|women
221549|NCT01850095|TLR
221550|NCT01850095|CD1d
221551|NCT01850095|androgens
221552|NCT01850082|Coronary artery disease
221553|NCT01850082|CABG
221554|NCT01850082|Coronary revascularization
221555|NCT01850082|Endoscopic vein harvest
221556|NCT01850082|Saphenous vein graft
221557|NCT01850082|Graft failure
221558|NCT01850069|Intracranial hypertension
221559|NCT01850069|intracranial elastance
221560|NCT01850056|drug eluting balloon catheter
221561|NCT01850017|Opiate consumption
221562|NCT01850017|Visual Analogue Scale
221563|NCT01849991|Crying
221564|NCT01849991|Fussiness
221565|NCT01849991|Gas
221566|NCT01849991|Hydrogen Breath
221567|NCT01849991|Fecal Calprotectin
221568|NCT01849978|breast cancer
221569|NCT01849978|survivor
221570|NCT01849978|exercise
221571|NCT01849978|physical activity
221572|NCT01849978|strenuous exercise
221573|NCT01849978|moderate exercise
221574|NCT01849978|enjoyable exercise
221575|NCT01849978|enjoy exercise
221576|NCT01849978|breast cancer survivor
221577|NCT01849965|diabetic foot ulcers
221578|NCT01849965|Wagner Grade 1 or 2 ulcers
221579|NCT01849952|glioblastoma
221580|NCT01849952|miRNA
221581|NCT01849952|GBM
221582|NCT01849952|astrocytoma
221583|NCT01849939|Allogeneic transplantation of hematopoietic stem cells transplantation
221584|NCT01849939|Chronic Lymphocytic Leukemia
221585|NCT01849939|Donor Lymphocyte Injection
221586|NCT01849939|Preemptive immunointervention
221587|NCT01849913|neck pain
221588|NCT01849913|hydrocortisone
221589|NCT01849913|stress
221590|NCT01849913|electromyography
221591|NCT01849913|adolescent
221592|NCT01849913|low-level laser therapy
221593|NCT01849900|Menstrual cycle
221594|NCT01849900|Ovulation time
221595|NCT01849900|pregnancy recognition
221596|NCT01849900|Community-based participatory research
221597|NCT01849900|Unintended pregnancy
221598|NCT01849861|Cardiopulmonary Capacity
221599|NCT01849861|Ranges of TSH
221600|NCT01849861|Elderly Population
221601|NCT01849835|rate of positive detection
221602|NCT01849822|neural
221603|NCT01849822|prosthetic
221604|NCT01849822|brain machine interface
221605|NCT01849822|brain computer interface
221606|NCT01849822|brain control
221607|NCT01849822|paralysis
221608|NCT01849822|tetraplegia
221609|NCT01849822|quadriplegia
221610|NCT01849822|spinal cord injury
221611|NCT01849796|tDCS
221612|NCT01849796|Neuropathic
221613|NCT01849796|Facial
221614|NCT01849796|Pain
221615|NCT01849796|Neuralgia
221616|NCT01849796|deafferentation
221617|NCT01849796|Trigeminal
221618|NCT01849770|SALS
221619|NCT01849770|Mexiletine
221620|NCT01849770|Safety
221621|NCT01849757|Cardiopulmonary bypass
221622|NCT01849757|prime
221623|NCT01849757|crystalloid
221624|NCT01849757|albumin
221625|NCT01849757|HES 130/0.4
221626|NCT01849744|Focal Adhesion Kinase inhibitor
221627|NCT01849744|FAK inhibitor
221628|NCT01849744|Cancer Stem Cells
221629|NCT01849744|CSC
221630|NCT01849731|Diabetes Mellitus type 2;
221631|NCT01849731|Primary Care, healthcare inequalities;
221632|NCT01849731|Diabetes self-management,
221633|NCT01849731|Quality of diabetes care
221634|NCT01849705|Obesity
221635|NCT01849705|MC4R
221636|NCT01849705|Blood pressure
221637|NCT01849705|Blood glucose
221638|NCT01849692|Exudative Age-Related Macular Degeneration
221639|NCT01849692|Wet AMD
221640|NCT01849692|Choroidal neovascularization (CNV)
221641|NCT01849692|Vascular endothelial growth factor (VEGF)
221642|NCT01849523|Neuroendocrine tumor
221643|NCT01849523|Website
221644|NCT01849523|Information
221645|NCT01849523|Psychosocial support
221646|NCT01849510|spinal metastases
221647|NCT01849510|vertebral body
221648|NCT01849510|stereotaxis
221649|NCT01849510|image-guided radiotherapy
221650|NCT01849510|hypofractionated
221651|NCT01849510|dose intensified
221652|NCT01849510|dose elevation
221653|NCT01849497|LDL-C, triglycerides, high cholesterol
221654|NCT01849484|meningioma
221655|NCT01849484|skull base meningioma
221656|NCT01849484|pituitary adenoma
221657|NCT01849484|brain metastases
221658|NCT01849484|small cell lung carcinoma
221659|NCT01849471|socioeconomic aspects
221660|NCT01849471|costs of therapy
221661|NCT01849471|follow-up costs
221662|NCT01849471|primary radiation
221663|NCT01849471|percutaneous
221664|NCT01849471|interstitial
221665|NCT01849393|Adolescents
221666|NCT01849393|Medication Compliance
221667|NCT01849393|Rewards-Based Incentive Programs
221668|NCT01849380|Local Advanced Breast Neoplasms
221669|NCT01849380|Neoadjuvant Chemotherapy
221670|NCT01849380|S-1
221671|NCT01849341|COPD
221672|NCT01849302|Appetite
221673|NCT01849302|Satiety hormones
221674|NCT01849302|Dietary Protein
221675|NCT01849237|Mesenchymal Stromal Cells
221676|NCT01849237|Septic Shock
221677|NCT01849237|Neutropenia
221678|NCT01849237|Procalcitonin
221679|NCT01849237|Interleukin-6
221680|NCT01849237|Interleukin-10
221681|NCT01849237|C-reactive protein
221682|NCT01849237|Survival
221683|NCT01849237|Organ dysfunction
221684|NCT01849224|Lower extremity edema
221685|NCT01849224|Lower leg lymphedema
221686|NCT01849224|Lower leg edema
221687|NCT01849224|Lymphedema
221688|NCT01849224|Pelvic lymphadenectomy
221689|NCT01849224|Exercise
221690|NCT01849211|ventilation
221691|NCT01849211|face mask
221692|NCT01849211|NMBA
221693|NCT01849198|accelerometry
221694|NCT01849198|neuromuscular block
221695|NCT01849198|m. trapezius
221696|NCT01849185|Hypercholesterolemia
221697|NCT01849159|Mesenchymal stem cells
221698|NCT01849159|Hypoxia
221699|NCT01849159|Emphysema
221700|NCT01849133|Breast cancer
221701|NCT01849133|conservative surgery
221702|NCT01849133|intraoperative radiation therapy
221703|NCT01849133|mobile linear accelerator
221704|NCT01849120|near infrared spectroscopy (NIRS)
221705|NCT01849120|EQUANOX Advance 8004CB probes
221706|NCT01849120|cerebral vascular circulation
221707|NCT01849120|peripheral perfusion
221708|NCT01849107|Radiation-induced small bowel toxicity
221709|NCT01849107|Plasma citrulline
221710|NCT01849081|Non-alcoholic fatty liver disease
221711|NCT01849081|Obstructive sleep apnea
221712|NCT01849029|Post traumatic Stress Disorders
221713|NCT01849029|PTSD
221714|NCT01849029|HIV risk
221715|NCT01849029|sexual risk
221716|NCT01849029|substance use
221717|NCT01849029|alcohol misuse
221718|NCT01849029|Substance Abuse
221719|NCT01849029|Substance Addiction
221720|NCT01849029|Substance Dependence
221721|NCT01849029|Substance Use Disorders
221722|NCT01849029|Alcohol-Related Disorders
221723|NCT01849029|Binge Drinking
221724|NCT01849029|Sexual Partners
221725|NCT01849029|Sexual Behavior
221726|NCT01849029|Unsafe Sex
221727|NCT01849016|Sickle Cell Disease
221728|NCT01849016|Sickle Cell Anemia
221729|NCT01849016|Pain
221730|NCT01849016|N-Acetylcysteine
221731|NCT01849016|Acetylcysteine
221732|NCT01849016|Oxidative stress
221733|NCT01849003|Long QT Syndrome
221734|NCT01849003|LQTS
221735|NCT01849003|Long QT-3 Syndrome
221736|NCT01849003|LQT-3
221737|NCT01849003|prolonged QT interval
221738|NCT01849003|GS-6615
221739|NCT01849003|late sodium current inhibitor
221740|NCT01848990|Type 1 Diabetes Mellitus
221741|NCT01848990|Sub Cutaneous Insulin Infusion
221742|NCT01848990|Rapid Acting Analog Insulin
221743|NCT01848990|Hylenex
221744|NCT01848990|Halozyme
221745|NCT01848990|Phase 4
221746|NCT01848977|Measures
221747|NCT01848977|near-Infrared spectroscopy
221748|NCT01848977|ischemia
221749|NCT01848977|reperfusion
221750|NCT01848964|amputation
221751|NCT01848964|prosthesis
221752|NCT01848964|stump
221753|NCT01848964|socket
221754|NCT01848964|pressure
221755|NCT01848964|gait
221756|NCT01848964|posture
221757|NCT01848938|female
221758|NCT01848938|stress urinary incontinence
221759|NCT01848938|treatment
221760|NCT01848938|pelvic floor muscle training
221761|NCT01848938|smartphone
221762|NCT01848938|internet
221763|NCT01848938|life style
221764|NCT01848938|eHealth
221765|NCT01848925|SANGUINATE
221766|NCT01848899|Coronary angiography
221767|NCT01848899|Percutaneous coronary intervention
221768|NCT01848899|Contrast media
221769|NCT01848899|Platelet activity
221770|NCT01848899|Thrombin generation
221771|NCT01848899|Fibrinolysis
221772|NCT01848886|ERAH
221773|NCT01848886|Endoscopic Radial Artery Harvest
221774|NCT01848886|Y-graft
221775|NCT01848886|Radial Artery Harvest
221776|NCT01848886|Total Arterial Revascularisation
221777|NCT01848886|CABG
221778|NCT01848886|Radial Artery Conduit
221779|NCT01848873|Hyperhomocysteinemia
221780|NCT01848873|Amlodipine-folic acid tablets
221781|NCT01848873|Hypertension
221782|NCT01848873|MTHFR C677T
221783|NCT01848860|Pneumothorax
221784|NCT01848860|thoracoscopy
221785|NCT01848860|mesh
221786|NCT01848860|pleurodesis
221787|NCT01848860|treatment
221788|NCT01848847|Hysteroscopy
221789|NCT01848847|Bladder
221790|NCT01848847|Pain
221791|NCT01848847|Feasibility
221792|NCT01848847|Duration
221793|NCT01848821|OASIS ultra
221794|NCT01848821|faster healing time
221795|NCT01848821|better healing quality
221796|NCT01848821|standard of care
221797|NCT01848795|Type 2 Diabetes
221798|NCT01848795|Obesity
221799|NCT01848795|gastrointestinal hormones
221800|NCT01848795|intestinal bypass
221801|NCT01848795|endoscopy
221802|NCT01848782|abstract
221803|NCT01848782|meta-analysis
221804|NCT01848782|systematic review
221805|NCT01848782|interpretation
221806|NCT01848782|results
221807|NCT01848782|quality
221808|NCT01848782|bias
221809|NCT01848782|spin
221810|NCT01848782|limits
221811|NCT01848782|limitation
221812|NCT01848782|risk of bias
221813|NCT01848769|Asthma
221814|NCT01848769|ICS+LABA
221815|NCT01848769|Children
221816|NCT01848769|Inhalation
221817|NCT01848769|pMDI
221818|NCT01848756|SNX-5422
221819|NCT01848756|HER2 positive cancer
221820|NCT01848743|tenofovir, lamivudine, hepatitis B, acute exacerbation
221821|NCT01848704|spin
221822|NCT01848704|interpretation
221823|NCT01848704|bias
221824|NCT01848652|cerebral lymphoma B cell refractory
221825|NCT01848652|Myocet
221826|NCT01848652|efficacy
221827|NCT01848652|safety
221828|NCT01848639|chronic kidney disease
221829|NCT01848639|end-stage renal disease
221830|NCT01848639|hemodialysis (ESRD)
221831|NCT01848639|cardiovascular morbimortality
221832|NCT01848639|aldosterone antagonist
221833|NCT01848639|spironolactone
221834|NCT01848600|limitation
221835|NCT01848600|quality
221836|NCT01848600|bias
221837|NCT01848600|meta-analysis
221838|NCT01848600|interpretation
221839|NCT01848600|abstract
221840|NCT01848587|Pregnancy
221841|NCT01848587|Acupuncture
221842|NCT01848587|Pelvic and low back pain
221843|NCT01848587|Impairment
221844|NCT01848587|Economic evaluation
221845|NCT01848574|Understanding
221846|NCT01848574|Patients
221847|NCT01848574|Emergency
221848|NCT01848574|Information
221849|NCT01848561|Inflammatory Bowel Diseases
221850|NCT01848561|Gastroenteritis
221851|NCT01848561|Adalimumab
221852|NCT01848561|Ulcerative Colitis
221853|NCT01848561|Registry
221854|NCT01848561|Gastrointestinal Diseases
221855|NCT01848561|Colitis
221856|NCT01848535|intestinal microbiota composition
221857|NCT01848535|intestinal microbiota activity
221858|NCT01848535|gastro-intestinal complains
221859|NCT01848522|qualitative study
221860|NCT01848522|rehabilitation
221861|NCT01848522|physical therapy
221862|NCT01848522|patient education
221863|NCT01848522|health care
221864|NCT01848522|administration
221865|NCT01848522|patient satisfaction
221866|NCT01848522|handicap
221867|NCT01848509|CPAP
221868|NCT01848509|adherence
221869|NCT01848509|SAOS
221870|NCT01848509|telemedicine
221871|NCT01848483|Early Palliative Care
221872|NCT01848483|Motivational Interviewing
221873|NCT01848483|Persons Living With Human immunodeficiency virus(HIV)
221874|NCT01848483|Acquired Immunodeficiency Syndrome (AIDS)
221875|NCT01848457|Osteosarcoma
221876|NCT01848457|Cancer
221877|NCT01848457|Nephrotoxicity
221878|NCT01848457|Ototoxicity
221879|NCT01848457|Cisplatin
221880|NCT01848457|High-dose methotrexate
221881|NCT01848457|Biomarkers
221882|NCT01848457|Patient reported outcomes
221883|NCT01848444|Public Health
221884|NCT01848444|Epidemiology
221885|NCT01848444|Pharmacy Toxicology
221886|NCT01848444|Perinatal period
221887|NCT01848418|ICF
221888|NCT01848418|Core sets
221889|NCT01848418|Systemic sclerosis
221890|NCT01848418|Function
221891|NCT01848418|Evaluation
221892|NCT01848392|Cystic fibrosis
221893|NCT01848392|Adults
221894|NCT01848392|Physical activity
221895|NCT01848366|Frequency
221896|NCT01848366|urgency
221897|NCT01848366|incontinence
221898|NCT01848340|mass balance
221899|NCT01848340|GSK1265744
221900|NCT01848340|supratherapeutic
221901|NCT01848340|integrase inhibitor
221902|NCT01848340|healthy volunteer
221903|NCT01848327|Cognition
221904|NCT01848327|Neuropsychology
221905|NCT01848327|Multiple Sclerosis
221906|NCT01848301|Optical Coherence Tomography
221907|NCT01848301|OCT
221908|NCT01848301|Coronary Allograft Vasculopathy
221909|NCT01848301|Donor Specific Antibodies
221910|NCT01848301|Acetylcholine
221911|NCT01848301|Coronary endothelial function
221912|NCT01848301|Brachial Artery Flow Mediated Dilation
221913|NCT01848301|Heart transplantation
221914|NCT01848288|Cataract
221915|NCT01848288|Phacoemulsification
221916|NCT01848288|Cumulative Dissipated Energy (CDE)
221917|NCT01848262|ECALMIST
221918|NCT01848262|InSurE
221919|NCT01848262|CPAP
221920|NCT01848262|Ventilation
221921|NCT01848262|Vascular Catheter
221922|NCT01848249|deceased donors
221923|NCT01848249|kidney donor
221924|NCT01848249|transplant recipients
221925|NCT01848249|kidney transplant
221926|NCT01848249|delayed graft function
221927|NCT01848249|biomarkers
221928|NCT01848249|end stage renal disease
221929|NCT01848249|graft failure
221930|NCT01848223|quality of life
221931|NCT01848223|QoL
221932|NCT01848223|late menopause
221933|NCT01848210|Drug therapy
221934|NCT01848184|PARIETEX Composite Ventral Patch
221935|NCT01848184|PCO VP OR PCOVP
221936|NCT01848184|Primary ventral hernia repair
221937|NCT01848184|Panacea
221938|NCT01848171|Hypothyroidism
221939|NCT01848171|Lipid
221940|NCT01848171|Atherosclerosis
221941|NCT01848171|Oxidative Stress
221942|NCT01848171|Chronic Inflammation
221943|NCT01848171|Endothelial Function
221944|NCT01848171|Adipocytokine
221945|NCT01848171|L-thyroxine
221946|NCT01848158|acupuncture
221947|NCT01848158|pediatric
221948|NCT01848158|critical care
221949|NCT01848158|mechanical ventilation
221950|NCT01848158|sedation
221951|NCT01848158|comfort
221952|NCT01848145|Chronic Lymphocytic Leukemia
221953|NCT01848145|Ofatumumab
221954|NCT01848145|Rapid Infusion
221955|NCT01848132|Lymphoma
221956|NCT01848132|Large B-Cell
221957|NCT01848119|Gabapentin
221958|NCT01848119|Cesarean section
221959|NCT01848106|Percutaneous Coronary Intervention
221960|NCT01848106|Coronary Artery Disease
221961|NCT01848106|Acute Coronary Syndrome
221962|NCT01848106|Regado
221963|NCT01848106|Reg 1
221964|NCT01848106|bivalirudin
221965|NCT01848093|lung
221966|NCT01848093|airway
221967|NCT01848093|pulmonary exacerbation
221968|NCT01848093|mucus
221969|NCT01848080|Telemedicine
221970|NCT01848080|Telerehabilitation
221971|NCT01848080|Acute Stroke
221972|NCT01848080|Tai Chi
221973|NCT01848080|Tai Ji
221974|NCT01848080|Rehabilitation
221975|NCT01848080|Home care services
221976|NCT01848080|Single blind method
221977|NCT01848080|Randomized controlled trial
221978|NCT01848054|opioid dependence, buprenorphine/naloxone, sublingual
221979|NCT01848041|Blepharoptosis
221980|NCT01848041|Ptosis
221981|NCT01848028|Patient registry
221982|NCT01848028|Germany
221983|NCT01848028|Psoriasis
221984|NCT01848028|psoriatic-arthritis
221985|NCT01848028|Efalizumab
221986|NCT01848028|Psonet
221987|NCT01848028|Effectiveness
221988|NCT01848028|Safety
221989|NCT01848015|CTCs before and after gastrectomy
221990|NCT01847976|breast
221991|NCT01847976|bone pain
221992|NCT01847963|Urolithiasis
221993|NCT01847963|Kalladaippu Kudineer
221994|NCT01847963|Siddha
221995|NCT01847963|Sindhuvallathy
221996|NCT01847963|Kidney stones
221997|NCT01847911|self instructed resuscitation training
221998|NCT01847898|Osteoporosis
221999|NCT01847898|Vertebral Body
222000|NCT01847898|Compression Fracture
222001|NCT01847898|Kyphoplasty
222002|NCT01847885|electrical stimulation
222003|NCT01847885|neurostimulation
222004|NCT01847885|neuromodulation
222005|NCT01847885|post-stroke shoulder pain
222006|NCT01847885|hemiplegic shoulder pain
222007|NCT01847872|Inactivated Poliovirus Vaccine
222008|NCT01847872|Randomised Control Phase IV Study
222009|NCT01847872|Gambia
222010|NCT01847872|IPV
222011|NCT01847872|Safety and Immunogenicity
222012|NCT01847872|Non-interference study
222013|NCT01847872|IM Jet injector
222014|NCT01847872|ID Jet Injector
222015|NCT01847859|Cardiothoracic surgery
222016|NCT01847859|Post-operative
222017|NCT01847859|Nurses
222018|NCT01847859|Cardiac
222019|NCT01847859|Echocardiography
222020|NCT01847859|Pocket-size
222021|NCT01847859|Hand-held
222022|NCT01847820|ROM
222023|NCT01847820|PROM
222024|NCT01847820|PPROM (preterm premature rupture of membranes)
222025|NCT01847807|5-10 gram astragalus per day
222026|NCT01847781|Opsonophagocytic antibodies
222027|NCT01847781|Cellular immunity
222028|NCT01847781|Vaccine immunity
222029|NCT01847781|Antimicrobial peptides
222030|NCT01847768|asthma
222031|NCT01847768|rhinovirus
222032|NCT01847768|remodeling mediators
222033|NCT01847768|human rhinovirus infection
222034|NCT01847729|Opiate dependence
222035|NCT01847729|Opiate substitution treatment
222036|NCT01847729|co-addictions
222037|NCT01847729|Patients addicted to opiates
222038|NCT01847729|methadone
222039|NCT01847729|buprenorhine
222040|NCT01847729|morphine
222041|NCT01847729|OST in place
222042|NCT01847729|pathological gambling
222043|NCT01847729|pharmacokinetic
222044|NCT01847729|pharmacogenetic
222045|NCT01847729|polymorphism
222046|NCT01847729|cytochrome P450 2D6
222047|NCT01847729|Therapeutic Drug Monitoring
222048|NCT01847716|Muscle weakness
222049|NCT01847716|Pulmonary arterial hypertension
222050|NCT01847716|Transforming growth factor beta
222051|NCT01847716|Growth and differentiation factor 15
222052|NCT01847690|Addison Disease
222053|NCT01847677|ovarian cancer
222054|NCT01847677|neoadyuvant
222055|NCT01847677|bevacizumab
222056|NCT01847651|hepatic encephalopathy
222057|NCT01847651|minimal hepatic encephalopathy
222058|NCT01847651|cirrhosis
222059|NCT01847651|lateral vastus
222060|NCT01847651|muscle biopsy
222061|NCT01847651|L ornithine L aspartate
222062|NCT01847651|functional magnetic resonance imaging
222063|NCT01847651|magnetic resonance spectroscopy
222064|NCT01847651|cognitive testing
222065|NCT01847651|Paper and pencil Hepatic Encephalopathy score (PHES)
222066|NCT01847651|Cogstate
222067|NCT01847651|urine metabonomics
222068|NCT01847651|plasma metabonomics
222069|NCT01847651|muscle metabonomics
222070|NCT01847638|Retinal edema
222071|NCT01847638|Cataract
222072|NCT01847638|inflammation
222073|NCT01847612|per operative cholangiography
222074|NCT01847612|liver resection
222075|NCT01847612|biliary fistula
222076|NCT01847599|educational intervention
222077|NCT01847599|adherence
222078|NCT01847599|capecitabine
222079|NCT01847599|lapatinib
222080|NCT01847586|Alzheimer's Disease
222081|NCT01847586|Brain stimulation
222082|NCT01847586|transcranial magnetic stimulation
222083|NCT01847573|halofuginone hydrobromide
222084|NCT01847573|anti-fibrotic
222085|NCT01847573|anti-inflammatory
222086|NCT01847573|muscle regeneration
222087|NCT01847573|protein synthesis inhibitor
222088|NCT01847495|Stage IV Colorectal Carcinoma
222089|NCT01847495|Liver metastasis
222090|NCT01847495|Cyberknife
222091|NCT01847495|Stereotactic Body Radiotherapy
222092|NCT01847495|SBRT
222093|NCT01847495|Irinotecan HCl
222094|NCT01847495|CPT-11
222095|NCT01847482|Cardiac arrest
222096|NCT01847482|Return of Spontaneous Circulation (ROSC)
222097|NCT01847482|IntraVascular Temperature Management (IVTM)
222098|NCT01847482|Therapeutic Hypothermia
222099|NCT01847482|Japan
222100|NCT01847469|Alcohol Dependence
222101|NCT01847469|Post-Traumatic Stress Disorder (PTSD)
222102|NCT01847469|Zonisamide
222103|NCT01847469|Cognitive Processing Therapy (CPT)
222104|NCT01847456|whole body insulin sensitivity
222105|NCT01847456|insulin action in the brain
222106|NCT01847443|nicotine
222107|NCT01847443|nicotine replacement therapy
222108|NCT01847443|nicotine gum
222109|NCT01847430|Healthy
222110|NCT01847430|Hepatitis B
222111|NCT01847430|Adolescents
222112|NCT01847430|Engerix™-B Kinder
222113|NCT01847417|Acetylsalicylic acid
222114|NCT01847417|Pantoprazole
222115|NCT01847417|Fixed dose combination
222116|NCT01847404|Fixed dose combination
222117|NCT01847404|Acetylsalicylic acid
222118|NCT01847404|Pantoprazole
222119|NCT01847391|Ischemic Heart Disease
222120|NCT01847391|Heart Disease
222121|NCT01847378|ventricular tachycardia
222122|NCT01847378|catheter ablation
222123|NCT01847378|chagas disease
222124|NCT01847378|epicardial mapping
222125|NCT01847378|magnetic resonance imaging
222126|NCT01847365|Retinitis Pigmentosa
222127|NCT01847365|Transcorneal electrical stimulation
222128|NCT01847365|Okustim
222129|NCT01847352|Hypoxia
222130|NCT01847352|Pulmonary hypertension
222131|NCT01847352|Iron deficiency
222132|NCT01847352|Hypoxic pulmonary vasoconstriction
222133|NCT01847300|alcohol abuse
222134|NCT01847300|tobacco dependence
222135|NCT01847300|substance abuse
222136|NCT01847300|SBIRT
222137|NCT01847287|Multiple sclerosis
222138|NCT01847287|Tysabri
222139|NCT01847287|MRI
222140|NCT01847287|Natalizumab
222141|NCT01847274|ovarian cancer
222142|NCT01847274|platinum sensitive
222143|NCT01847274|gBRCAmut
222144|NCT01847274|BRCA
222145|NCT01847274|high-grade serous histology
222146|NCT01847274|PARP inhibitor
222147|NCT01847261|soy
222148|NCT01847261|whey
222149|NCT01847261|muscle
222150|NCT01847261|older
222151|NCT01847261|mTOR
222152|NCT01847261|sarcopenia
222153|NCT01847248|sepsis
222154|NCT01847248|biomarker
222155|NCT01847248|HSPA12B
222156|NCT01847235|Temozolomide
222157|NCT01847209|lung nodule
222158|NCT01847209|lung cancer
222159|NCT01847209|lung mass
222160|NCT01847196|Pulmonary Embolism
222161|NCT01847196|PE
222162|NCT01847196|DVT
222163|NCT01847196|Deep Vein Thrombosis
222164|NCT01847196|VTE
222165|NCT01847196|Venous Thromboembolism
222166|NCT01847196|prophylaxis
222167|NCT01847196|thromboprophylaxis
222168|NCT01847196|contraindications to thromboprophylaxis
222169|NCT01847196|prophylactic
222170|NCT01847196|prevention
222171|NCT01847196|Inferior vena cava filter
222172|NCT01847196|IVC filter
222173|NCT01847196|filter
222174|NCT01847196|prevention of pulmonary embolism
222175|NCT01847196|trauma
222176|NCT01847196|critically-ill
222177|NCT01847183|heavy drinking
222178|NCT01847183|prevention
222179|NCT01847183|high school
222180|NCT01847183|adolescence
222181|NCT01847157|recovery of function
222182|NCT01847157|stroke
222183|NCT01847157|Upper extremity
222184|NCT01847157|Motor
222185|NCT01847157|transcranial direct current stimulation
222186|NCT01847131|Rhinitis
222187|NCT01847131|Oxymetazoline
222188|NCT01847092|albuminuria
222189|NCT01847066|wrinkles
222190|NCT01847066|acne scars
222191|NCT01847066|pigmentation
222192|NCT01847053|Cinnamon
222193|NCT01847053|Bioavailability
222194|NCT01847053|Glucose
222195|NCT01847053|Proanthocyanidins
222196|NCT01847040|Traumatic Brain Injury
222197|NCT01847040|Epidemiology
222198|NCT01847040|Concussion
222199|NCT01847040|Outcomes
222200|NCT01847040|PTSD
222201|NCT01847040|Prospective
222202|NCT01847040|Longitudinal
222203|NCT01847040|Military
222204|NCT01847040|Symptoms
222205|NCT01847040|Validation
222206|NCT01847040|Screening
222207|NCT01847040|Mild Traumatic Brain Injury
222208|NCT01847027|Healthy
222209|NCT01847027|Stem cells
222210|NCT01847027|Aging
222211|NCT01847027|Increase stem cell replacement
222212|NCT01847027|decreased stem cell proliferation
222213|NCT01847014|Pulmonary Arterial Hypertension (PAH)
222214|NCT01847014|psychometric instrument
222215|NCT01847014|PAH-SYMPACT
222216|NCT01847001|Breast Cancer
222217|NCT01847001|Neoadjuvant
222218|NCT01847001|Experimental
222219|NCT01847001|Biomarker
222220|NCT01847001|Breast imaging
222221|NCT01846988|Obstructive Sleep Apnea
222222|NCT01846988|Pediatric Obstructive Sleep Apnea
222223|NCT01846988|Auto PAP
222224|NCT01846988|Auto-adjustable Positive Airway Pressure
222225|NCT01846988|APAP
222226|NCT01846988|CPAP
222227|NCT01846975|Abatacept
222228|NCT01846975|Low disease activity
222229|NCT01846975|Intravenous
222230|NCT01846975|Subcutaneous
222231|NCT01846975|Rheumatoid arthritis
222232|NCT01846962|Eosinophilic esophagitis (EoE)
222233|NCT01846962|budesonide
222234|NCT01846962|fluticasione
222235|NCT01846962|six-foods elimination diet
222236|NCT01846936|one lung ventilation
222237|NCT01846936|efficacy
222238|NCT01846936|bronchial blocker
222239|NCT01846910|Cessation
222240|NCT01846845|Amputee
222241|NCT01846832|Hepatitis C, Chronic
222242|NCT01846832|Infection
222243|NCT01846832|Triple therapy
222244|NCT01846832|TMC435
222245|NCT01846832|simeprevir
222246|NCT01846832|Pegylated interferon alfa-2a (PegIFNα-2a)
222247|NCT01846832|ribavirin (RBV)
222248|NCT01846832|PEGASYS
222249|NCT01846832|COPEGUS
222250|NCT01846806|Hepatic Encephalopathy
222251|NCT01846793|Benign prostatic hyperplasia
222252|NCT01846793|BPH
222253|NCT01846793|Enlarged prostate
222254|NCT01846793|Lower urinary tract symptoms
222255|NCT01846793|LUTS
222256|NCT01846793|LUTS secondary to BPH
222257|NCT01846793|LUTS/BPH
222258|NCT01846793|Benign prostatic obstruction (BPO)
222259|NCT01846793|BPO
222260|NCT01846793|Bladder outlet obstruction
222261|NCT01846793|BOO
222262|NCT01846767|13CO2
222263|NCT01846767|Breath test
222264|NCT01846767|Glucose oxidation
222265|NCT01846767|Diabetes mellitus
222266|NCT01846754|Hemodialysis
222267|NCT01846754|Fatigue
222268|NCT01846754|Muscle strength
222269|NCT01846754|Metabolomics
222270|NCT01846741|Automatic Magnet Mode (AMM)
222271|NCT01846741|Vagus Nerve Stimulation (VNS)
222272|NCT01846715|Kidney disease
222273|NCT01846715|Renal insufficiency
222274|NCT01846715|CKD
222275|NCT01846715|Autologous cell therapy
222276|NCT01846676|Hearing loss, rehabilitation programs, adherence to hearing aids.
222277|NCT01846663|Hepatic Encephalopathy
222278|NCT01846663|Liver Failure
222279|NCT01846663|Hepatic Insufficiency
222280|NCT01846663|Liver Diseases
222281|NCT01846663|Brain Diseases
222282|NCT01846663|Rifaximin
222283|NCT01846663|Cirrhosis
222284|NCT01846611|Ovarian neoplasms
222285|NCT01846611|Peritoneal neoplasms
222286|NCT01846611|Fallopian tube neoplasms
222662|NCT01844765|chronic phase
222287|NCT01846611|Advanced-relapsed epithelial ovarian cancer
222288|NCT01846611|Advanced-relapsed primary peritoneal cancer
222289|NCT01846611|Advanced-relapsed fallopian tube cancer
222290|NCT01846611|Trabectedin
222291|NCT01846611|Yondelis
222292|NCT01846611|Doxil
222293|NCT01846611|Caelyx
222294|NCT01846611|Platinum sensitive
222295|NCT01846611|Tthird-line
222296|NCT01846611|BRCA
222297|NCT01846611|Patient related outcome
222298|NCT01846572|Stroke
222299|NCT01846572|Clopidogrel
222300|NCT01846572|Aggregometry
222301|NCT01846572|Antiplatelet therapy
222302|NCT01846572|Platelet function tests
222303|NCT01846559|Immune system processes
222304|NCT01846546|Traumatic brain injury;
222305|NCT01846546|Endostatin/collagen XVIII;
222306|NCT01846546|Cerebrospinal fluid;
222307|NCT01846546|Prognosis
222308|NCT01846507|Heavy Menstrual Bleeding
222309|NCT01846507|HMB
222310|NCT01846507|Lysteda
222311|NCT01846481|Cocaine
222312|NCT01846455|Hepatic
222313|NCT01846455|Hepatitis C Virus
222314|NCT01846455|Suboxone
222315|NCT01846455|Buprenorphine
222316|NCT01846455|Naloxone
222317|NCT01846442|Vulvar/vaginal atrophy
222318|NCT01846442|Atrophic Vaginitis
222319|NCT01846442|Dehydroepiandrosterone
222320|NCT01846442|DHEA
222321|NCT01846442|Prasterone
222322|NCT01846442|Vaginorm
222323|NCT01846442|Menopause
222324|NCT01846429|cancer
222325|NCT01846429|pain fibers
222326|NCT01846429|acid levels
222327|NCT01846429|tumor related pain
222328|NCT01846429|cancer related pain
222329|NCT01846429|sodium bicarbonate
222330|NCT01846429|pain reliever
222331|NCT01846429|metastatic
222332|NCT01846429|unresectable
222333|NCT01846429|solid malignancy
222334|NCT01846429|hematologic malignancy
222335|NCT01846429|multiple myeloma
222336|NCT01846429|lymphoma
222337|NCT01846377|video game
222338|NCT01846377|diet
222339|NCT01846377|physical activity
222340|NCT01846377|sedentary behavior
222341|NCT01846377|obesity
222342|NCT01846377|diabetes
222343|NCT01846364|Thyroid
222344|NCT01846364|DIM
222345|NCT01846351|choroidal neovascularization
222346|NCT01846351|epiretinal membrane
222347|NCT01846351|anti-VEGF
222348|NCT01846338|acne, EGCG, green tea
222349|NCT01846299|Vision Impairment
222350|NCT01846286|Neuropathic Pain
222351|NCT01846286|Squamous cell cancer of the head and neck
222352|NCT01846286|acute pain
222353|NCT01846286|pain management
222354|NCT01846286|genome-wide analyses
222355|NCT01846286|Squamous cell carcinoma of the head and neck
222356|NCT01846286|chronic pain
222357|NCT01846286|neuropathic
222358|NCT01846286|locoregional squamous cell carcinoma of the head and neck
222359|NCT01846247|stroke
222360|NCT01846234|Multiple Sclerosis
222361|NCT01846234|Salt
222362|NCT01846221|Analgesia
222363|NCT01846221|Epidural
222364|NCT01846221|Pregnancy
222365|NCT01846221|Labor
222366|NCT01846221|Clonidine
222367|NCT01846221|Fentanyl
222368|NCT01846221|Bupivacaine
222369|NCT01846221|Childbirth
222370|NCT01846208|Egg Allergy
222371|NCT01846208|Egg Oral Immunotherapy
222372|NCT01846208|Food Allergy
222373|NCT01846195|blood loss
222374|NCT01846182|Gulf War Illness
222375|NCT01846182|Pregabalin
222376|NCT01846182|Duloxetine
222377|NCT01846182|Gulf War Veterans
222378|NCT01846182|Cymbalta
222379|NCT01846182|Lyrica
222380|NCT01846169|food insecurity
222381|NCT01846169|older adults
222382|NCT01846169|nutrition
222383|NCT01846169|food deliveries
222384|NCT01846156|convulsion rate
222385|NCT01846130|Bed rest,
222386|NCT01846117|lignans
222387|NCT01846117|oxidative stress
222388|NCT01846117|inflammation
222389|NCT01846117|aging
222390|NCT01846117|muscle weakness
222391|NCT01846117|pain
222392|NCT01846052|achromatopsia, CNGB3
222393|NCT01846013|Sit-Stand Workstations
222394|NCT01846013|Increase Workplace Physical Activity
222395|NCT01846000|temporomandibular joint
222396|NCT01846000|temporomandibular disorder
222397|NCT01846000|electromyography
222398|NCT01846000|low-level laser therapy
222399|NCT01845987|Palmoplantaris Pustulosis
222400|NCT01845987|CNTO 1959
222401|NCT01845987|Psoriasis
222402|NCT01845987|Anti-IL 23 Monoclonal Antibody
222403|NCT01845974|Radiofrequency Catheter Ablation
222404|NCT01845974|Atrial Fibrillation
222405|NCT01845948|parents
222406|NCT01845948|school transition
222407|NCT01845948|parental-child relationship
222408|NCT01845935|Cryoablation
222409|NCT01845935|Venous vascular malformation
222410|NCT01845935|MRI
222411|NCT01845935|safety
222412|NCT01845935|pain
222413|NCT01845922|Refeeding Syndrome
222414|NCT01845922|low sodium
222415|NCT01845922|slowly absorbed carbohydrates
222416|NCT01845922|hypopotassemia
222417|NCT01845922|hypophosphatemia
222418|NCT01845909|Sudden cardiac death
222419|NCT01845909|Young adults
222420|NCT01845909|Cardiac Disease
222421|NCT01845909|Arrhythmia
222422|NCT01845909|Sports
222423|NCT01845896|high intensity interval training
222424|NCT01845896|combined training
222425|NCT01845896|insulin resistance
222426|NCT01845896|muscle contractile properties
222427|NCT01845857|Long term health problems
222428|NCT01845857|chronic disease
222429|NCT01845831|Diabetes
222430|NCT01845831|DPP4 inhibitors
222431|NCT01845831|Sitagliptin
222432|NCT01845831|Glargine
222433|NCT01845831|RCT
222434|NCT01845831|basal insulin
222435|NCT01845831|hospital hyperglycemia
222436|NCT01845831|inpatient diabetes
222437|NCT01845818|work productivity
222438|NCT01845818|multicenter study
222439|NCT01845792|Metastatic Castrate Resistant Prostate Cancer
222440|NCT01845766|sepsis, septic shock, rehabilitation, exercise
222441|NCT01845740|systemic lupus erythematoses
222442|NCT01845740|lupus
222443|NCT01845740|SLE
222444|NCT01845727|Cutaneous leishmaniasis
222445|NCT01845727|Topical treatment
222446|NCT01845727|Colombia
222447|NCT01845714|Keratoconus
222448|NCT01845714|Corneal cross Linking
222449|NCT01845714|Topo guided PRK
222450|NCT01845714|Quality of Life
222451|NCT01845701|malaria, cure rate, efficacy, safety
222452|NCT01845688|Idiopathic Membranous Nephropathy
222453|NCT01845688|Traditional Chinese Medicine
222454|NCT01845688|Randomized Control Trial
222455|NCT01845675|temozolomide
222456|NCT01845675|endostatin
222457|NCT01845675|advanced
222458|NCT01845675|well-differentiated
222459|NCT01845675|pancreatic neuroendocrine tumor
222460|NCT01845662|splenectomy
222461|NCT01845662|embolization
222462|NCT01845662|observation
222463|NCT01845662|blood transfusion
222464|NCT01845649|Vulvovaginal Atrophy
222465|NCT01845649|Dyspareunia
222466|NCT01845649|Postmenopausal
222467|NCT01845636|Olfaction
222468|NCT01845636|Donepezil
222469|NCT01845636|Alzheimer's Disease
222470|NCT01845636|Mild Cognitive Impairment
222471|NCT01845636|Memory
222472|NCT01845623|Asthma
222473|NCT01845623|Indacaterol
222474|NCT01845623|QAB149
222475|NCT01845584|IVIG in Neuromyelitis Optica spectrum disorder
222476|NCT01845584|Patients with Neuromyelitis Optica spectrum disorder
222477|NCT01845558|Muscle soreness
222478|NCT01845558|Exercise induced muscle damage
222479|NCT01845558|Inflammation
222480|NCT01845558|Proteolytic enzymes
222481|NCT01845558|Muscle strength Dynamometer
222482|NCT01845545|microfinance
222483|NCT01845545|under five mortality
222484|NCT01845545|underweight
222485|NCT01845545|malnutrition
222486|NCT01845506|wireless pressure sensor
222487|NCT01845506|Elderly
222488|NCT01845493|asthma
222489|NCT01845493|Asthmatics
222490|NCT01845493|allergic
222491|NCT01845493|allergies
222492|NCT01845480|health promotion
222493|NCT01845480|obesity prevention
222494|NCT01845480|Childhood obesity
222495|NCT01845480|home-based
222496|NCT01845480|Lifestyle intervention
222497|NCT01845480|Body composition
222498|NCT01845480|quality of life
222499|NCT01845480|physical activity
222500|NCT01845480|nutrition
222501|NCT01845467|Secretin MRCP, diagnosis, Autoimmune pancreatitis
222502|NCT01845454|Barrett's Esophagus
222503|NCT01845454|Spray cryotherapy
222504|NCT01845441|Dexmedetomidine
222505|NCT01845441|Endovascular procedure
222506|NCT01845441|Stroke
222507|NCT01845441|Vasospasm, intracranial
222508|NCT01845441|Conscious sedation
222509|NCT01845428|nephrotic
222510|NCT01845428|hyperlipidemia
222511|NCT01845428|oxLDL
222512|NCT01845428|kidney
222513|NCT01845402|Kidney Failure, Chronic
222514|NCT01845402|Adolescent
222515|NCT01845402|Heart Defects, Congenital
222516|NCT01845389|Anesthesia
222517|NCT01845389|Regional
222518|NCT01845389|Epidural
222519|NCT01845389|Continuous spinal
222520|NCT01845389|Wiley Catheter
222521|NCT01845389|Geriatric
222522|NCT01845389|TURP
222523|NCT01845376|Inflammatory Markers after Inguinal Hernia Repair
222524|NCT01845376|Anesthetic technique for hernia repair
222525|NCT01845363|Obesity
222526|NCT01845363|Bariatric surgery
222527|NCT01845363|Cefazolin
222528|NCT01845363|antimicrobial prophylaxis
222529|NCT01845363|administration and dosage
222530|NCT01845324|Pregnancy
222531|NCT01845324|Diabetes Mellitus
222532|NCT01845285|transcatheter valve replacement
222533|NCT01845285|aortic valve disease
222534|NCT01845285|aortic stenosis
222535|NCT01845285|Aortic regurgitation,catheter
222536|NCT01845285|Effective orifice area
222537|NCT01845246|Colistin
222538|NCT01845246|Polymyxins
222539|NCT01845246|Therapeutic drug monitoring
222540|NCT01845246|Multi-drug resistant Gram negative bacterial infections
222541|NCT01845220|Broccoli sprouts
222542|NCT01845220|alcohol sensitivity
222543|NCT01845220|sulforaphane
222544|NCT01845220|alcohol metabolism
222545|NCT01845220|in the Asian Community
222546|NCT01845207|Aortic stenosis
222547|NCT01845207|Aortic valve replacement
222548|NCT01845207|Transcatheter aortic valve implantation
222549|NCT01845207|Outcomes
222550|NCT01845207|Frailty
222551|NCT01845207|Elderly
222552|NCT01845194|pharmacokinetic
222553|NCT01845194|heritability
222554|NCT01845194|drug membrane transport
222555|NCT01845194|drug biotransformation
222556|NCT01845181|Adenosine A1 receptor antagonist
222557|NCT01845181|Asthma
222558|NCT01845181|adenosine receptor modulator
222559|NCT01845181|COPD
222560|NCT01845168|Bleeding peptic ulcer
222561|NCT01845168|NSAID and Aspirin
222562|NCT01845168|Computer-alert
222563|NCT01845168|General practitioner
222564|NCT01845155|Tinnitus
222565|NCT01845155|music therapy
222566|NCT01845155|directive counselling
222567|NCT01845155|acoustic stimulation
222568|NCT01845155|group comparison
222569|NCT01845155|subjective evaluation
222570|NCT01845155|pitch
222571|NCT01845142|vitamin D
222572|NCT01845142|vitamin D deficiency
222573|NCT01845142|immune cells
222574|NCT01845142|pharmacokinetic
222575|NCT01845142|< 50 nmol/L 25(OH)D serum concentration
222576|NCT01845116|PNALD
222577|NCT01845116|Cholestasis
222578|NCT01845116|Omegaven®
222579|NCT01845116|Short Bowel Syndrome
222580|NCT01845103|ANGINA
222581|NCT01845103|Thoracoscopic
222582|NCT01845064|type 2 diabetes
222583|NCT01845064|diabetes mellitus
222584|NCT01845064|type 2 diabetes mellitus
222585|NCT01845064|HbA1c
222586|NCT01845064|blood glucose
222587|NCT01845064|glucose control
222588|NCT01845064|DiaMedica
222589|NCT01845064|DM-199
222590|NCT01845064|DM199
222591|NCT01845064|recombinant human tissue kallikrein-1
222592|NCT01845064|tissue kallikrein-1
222593|NCT01845051|Migraine
222594|NCT01845051|allergic rhinitis
222595|NCT01845051|Specific Immunoglobulin E (IgE)
222596|NCT01845051|nasal symptoms
222597|NCT01845051|signs of allergy.
222598|NCT01845025|Asthma, formoterol fumarate, Foradil, inhaled corticosteroid, fluticasone propionate, safety
222599|NCT01845025|Asthma
222600|NCT01845025|formoterol fumarate
222601|NCT01845025|Foradil
222602|NCT01845025|inhaled corticosteroid
222603|NCT01845025|fluticasone propionate
222604|NCT01845025|safety
222605|NCT01845012|Short daily hemodialysis
222606|NCT01845012|Low dialysate flow
222607|NCT01845012|End stage renal disease
222608|NCT01844999|Prostate cancer
222609|NCT01844999|Decision
222610|NCT01844986|BRCA
222611|NCT01844986|Ovarian Cancer
222612|NCT01844986|Chemotherapy
222613|NCT01844986|PARP inhibitor
222614|NCT01844986|First Line
222615|NCT01844986|FIGO Stage III
222616|NCT01844986|FIGO Stage IV
222617|NCT01844960|Single Incision Surgery
222618|NCT01844960|SILS
222619|NCT01844960|Laparoscopic Gastric Band
222620|NCT01844960|Morbid Obesity
222621|NCT01844960|Bariatric Surgery
222622|NCT01844934|Knee Arthroplasty
222623|NCT01844934|Knee Replacement
222624|NCT01844934|Prehabilitation
222625|NCT01844882|The effects
222626|NCT01844882|dietary
222627|NCT01844882|fiber
222628|NCT01844882|kidney function
222629|NCT01844882|CKD patients
222630|NCT01844869|omacetaxine
222631|NCT01844869|omacetaxine mepesuccinate
222632|NCT01844869|pharmacokinetics
222633|NCT01844869|hematologic malignancies
222634|NCT01844869|advanced solid tumors
222635|NCT01844843|Drug eluting stents
222636|NCT01844843|coronary artery disease
222637|NCT01844843|Percutaneous Coronary Intervention
222638|NCT01844843|Tomography, Optical Coherence
222639|NCT01844830|operative
222640|NCT01844830|dental procedure
222641|NCT01844817|untreated
222642|NCT01844817|metastatic
222643|NCT01844817|OGX-427
222644|NCT01844804|Bioequivalence
222645|NCT01844804|Biosimilarity
222646|NCT01844804|Similarity
222647|NCT01844804|PK
222648|NCT01844804|Phase 1
222649|NCT01844804|Infliximab
222650|NCT01844804|Healthy Volunteers
222651|NCT01844804|Single-dose
222652|NCT01844804|Immunology
222653|NCT01844791|Non-small cell lung cancer
222654|NCT01844791|OCZ103-OS
222655|NCT01844791|Pentamidine bis(2-hydroxyethanesulfonate)
222656|NCT01844791|platinum-gemcitabine based doublet first line therapy
222657|NCT01844778|Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI,
222658|NCT01844778|colistimethate
222659|NCT01844778|Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI, colistimethate
222660|NCT01844765|Tasigna
222661|NCT01844765|nilotinib treatment
222663|NCT01844765|Ph+ CML
222664|NCT01844765|accelerated phase
222665|NCT01844765|newly diagnosed Ph+ CML
222666|NCT01844765|pediatric
222667|NCT01844765|24 month treatment
222668|NCT01844752|acne
222669|NCT01844739|Propionibacterium acnes
222670|NCT01844739|acne
222671|NCT01844726|healthy individuals
222672|NCT01844726|schizophrenia
222673|NCT01844726|schizoaffective disorder
222674|NCT01844726|learning
222675|NCT01844726|memory
222676|NCT01844726|cognitive enhancement
222677|NCT01844726|fMRI
222678|NCT01844713|Kidney transplant
222679|NCT01844713|Renal transplant
222680|NCT01844713|Sun protection
222681|NCT01844713|Skin cancer
222682|NCT01844700|MC4R genotype
222683|NCT01844700|antipsychotic induced weight gain
222684|NCT01844700|pediatric population
222685|NCT01844687|reinforcement, good drug effect, high, mood, cannabidiol
222686|NCT01844661|Mesenchymal stem cells
222687|NCT01844661|Oncolytic adenovirus
222688|NCT01844648|Parkinson's disease
222689|NCT01844648|Sialorrhea
222690|NCT01844648|Tropicamide
222691|NCT01844648|Non-motor symptoms
222692|NCT01844648|Thin strip delivery
222693|NCT01844622|Digestive System Diseases Disease
222694|NCT01844609|Comprehension
222695|NCT01844609|Verbal Learning
222696|NCT01844609|Writing
222697|NCT01844609|Testing
222698|NCT01844596|linkage to care
222699|NCT01844596|hypertension management
222700|NCT01844596|behavioral science
222701|NCT01844596|cardiovascular health
222702|NCT01844596|global health
222703|NCT01844596|multi-disciplinary implementation research approach
222704|NCT01844596|linking and retaining
222705|NCT01844596|community health workers
222706|NCT01844596|CHWs
222707|NCT01844596|behavioral communication strategy
222708|NCT01844596|smartphone-based tool
222709|NCT01844596|electronic health record
222710|NCT01844596|retention to care
222711|NCT01844557|Head And Neck Cancer
222712|NCT01844557|Nasopharyngeal cancer
222713|NCT01844557|Oropharyngeal cancer
222714|NCT01844557|Hypopharyngeal cancer
222715|NCT01844557|Laryngeal cancer
222716|NCT01844557|Primary cancer with cervical metastases
222717|NCT01844557|Swallowing exercises
222718|NCT01844557|Videotape
222719|NCT01844557|Videocamera
222720|NCT01844557|M.D. Anderson Symptom Inventory
222721|NCT01844557|Questionnaires
222722|NCT01844557|Surveys
222723|NCT01844544|drug related problems
222724|NCT01844544|clinical pharmacist
222725|NCT01844544|femoral neck fractures
222726|NCT01844544|orthopedic patients
222727|NCT01844492|decision making for incapacitated patients
222728|NCT01844492|intensive care
222729|NCT01844492|surrogate decision making
222730|NCT01844492|patient centered care
222731|NCT01844492|Palliative Care
222732|NCT01844492|End of Life
222733|NCT01844492|Quality of Communication
222734|NCT01844479|diabetic foot ulcer
222735|NCT01844479|diabetic foot
222736|NCT01844466|course of motor and visual rehabilitation
222737|NCT01844466|improvement of deficits
222738|NCT01844466|stroke patients
222739|NCT01844453|Subfertility
222740|NCT01844453|Recurrent Implantation Failure
222741|NCT01844440|GERD
222742|NCT01844440|tLESR
222743|NCT01844440|impedance
222744|NCT01844440|manometry
222745|NCT01844427|ADHD
222746|NCT01844427|Executive function deficits
222747|NCT01844427|Psychiatry
222748|NCT01844427|Psychopharmacology
222749|NCT01844427|Namenda
222750|NCT01844414|Homeless Men
222751|NCT01844414|Parolees
222752|NCT01844414|Hepatitis B
222753|NCT01844414|Hepatitis C
222754|NCT01844414|HIV
222755|NCT01844414|Community Drug Treatment
222756|NCT01844414|Recidivism
222757|NCT01844401|persistent asthma
222758|NCT01844401|Albuterol Spiromax®
222759|NCT01844401|ProAir® HFA
222760|NCT01844401|Pediatric Patients
222761|NCT01844401|Phase 1
222762|NCT01844375|oral carbohydrate loading
222763|NCT01844375|walking capacity
222764|NCT01844362|uterus
222765|NCT01844362|transplantation
222766|NCT01844362|infertility
222767|NCT01844349|North Africa
222768|NCT01844349|Urban women
222769|NCT01844349|Double burden of malnutrition
222770|NCT01844349|Iron depletion
222771|NCT01844349|Overweight/obesity
222772|NCT01844349|Metabolic syndrome
222773|NCT01844349|Abdominal obesity
222774|NCT01844349|Excess body fat
222775|NCT01844284|Absorb™ BVS
222776|NCT01844284|Angioplasty
222777|NCT01844284|Bioabsorbable
222778|NCT01844284|Bioreabsorbable
222779|NCT01844284|BVS
222780|NCT01844284|Coronary Artery Disease
222781|NCT01844284|Coronary Artery Endothelial Responsiveness
222782|NCT01844284|Coronary artery restenosis
222783|NCT01844284|Coronary artery stenosis
222784|NCT01844284|Coronary scaffold
222785|NCT01844284|Coronary Stent
222786|NCT01844284|Drug eluting stents
222787|NCT01844284|Everolimus
222788|NCT01844284|Myocardial ischemia
222789|NCT01844284|Stent thrombosis
222790|NCT01844284|Stents
222791|NCT01844271|LLLT
222792|NCT01844271|muscle fatigue and recovery
222793|NCT01844271|phototherapy parameter
222794|NCT01844258|pediatric cataract
222795|NCT01844258|lens regeneration
222796|NCT01844258|endogenous lens epithelial stem cells
222797|NCT01844258|visual axis opacification
222798|NCT01844258|visual function
222799|NCT01844245|Cholangiocarcinoma
222800|NCT01844245|Ampullary carcinoma
222801|NCT01844245|Endoscopic retrograde cholangiopancreatography
222802|NCT01844245|Radiofrequency ablation
222803|NCT01844232|Multiple sclerosis
222804|NCT01844232|spasticity
222805|NCT01844232|arbaclofen
222806|NCT01844219|aortic surgery
222807|NCT01844219|acute kidney injury
222808|NCT01844219|gray zone approach
222809|NCT01844206|Post-cesarean analgesia
222810|NCT01844206|Second dose of epidural morphine after surgery
222811|NCT01844206|Post-operative analgesia
222812|NCT01844206|Self-administered epidural morphine
222813|NCT01844206|Pain management after cesarean
222814|NCT01844180|Irritable Bowel Syndrome
222815|NCT01844180|IBS
222816|NCT01844180|ONO-2952
222817|NCT01844167|noxipoint
222818|NCT01844167|physical therapy
222819|NCT01844167|cervical pain
222820|NCT01844167|trigger point
222821|NCT01844167|neck pain
222822|NCT01844167|TENS
222823|NCT01844167|transcutaneous electrical nerve stimulation
222824|NCT01844141|phenol
222825|NCT01844141|ingrown toenail
222826|NCT01844141|chemical matricectomy
222827|NCT01844128|MMA, AFC, Ovarian reserve
222828|NCT01844115|Generalized Anxiety Disorder, GAD
222829|NCT01844102|HIV Prevention, PrePex, voluntary medical circumcision, non-surgical,
222830|NCT01844102|medical device, wound healing, Zambia
222831|NCT01844089|Postpartum hemorrhage
222832|NCT01844089|Bakri Postpartum Balloon
222833|NCT01844076|advanced stage colorectal adenocarcinoma
222834|NCT01844050|Chinese herbal medicine
222835|NCT01844050|diabetes symptoms
222836|NCT01844011|fetal movement
222837|NCT01844011|pregnancy
222838|NCT01843998|Early stage
222839|NCT01843998|Stage 1A
222840|NCT01843998|Cutaneous T-cell Lymphoma
222841|NCT01843998|CTCL
222842|NCT01843985|Stage IV cancer
222843|NCT01843985|Survival
222844|NCT01843959|adenovirus-36
222845|NCT01843959|Emirati population
222846|NCT01843920|eye
222847|NCT01843920|pneumatic retinopexy
222848|NCT01843920|topical
222849|NCT01843894|sever dry eye,keratoconjunctivitis sicca
222850|NCT01843881|Gastric Bypass
222851|NCT01843881|bariatric surgery
222852|NCT01843881|carbohydrate metabolism
222853|NCT01843868|Lymphoma
222854|NCT01843868|Non-Hodgkin
222855|NCT01843868|Emesis
222856|NCT01843868|Chemotherapy
222857|NCT01843868|Nausea
222858|NCT01843868|Vomiting
222859|NCT01843868|Aprepitant
222860|NCT01843855|Gastric Bypass
222861|NCT01843855|bariatric surgery
222862|NCT01843855|glucose metabolism
222863|NCT01843829|Oesophageal cancer
222864|NCT01843816|Tragus-to-wall distance
222865|NCT01843816|obesity
222866|NCT01843816|body shape
222867|NCT01843816|height
222868|NCT01843816|weight
222869|NCT01843803|patient centered care
222870|NCT01843803|collaborative decision making
222871|NCT01843803|cost impact
222872|NCT01843777|hearing loss
222873|NCT01843777|hearing aids
222874|NCT01843777|motivational interviewing
222875|NCT01843777|counseling
222876|NCT01843777|rehabilitation
222877|NCT01843764|RDT
222878|NCT01843764|malaria
222879|NCT01843764|treatment follow up
222880|NCT01843764|diagnosis
222881|NCT01843725|breast cancer
222882|NCT01843725|digestive cancer
222883|NCT01843712|Caloric compensation
222884|NCT01843712|Eating in the absence of hunger
222885|NCT01843712|Children
222886|NCT01843712|Parental feeding practices
222887|NCT01843686|Acute 2nd and 3rd Degree Burns
222888|NCT01843686|Autologous Platelet Rich Plasma (PRP)
222889|NCT01843686|Skin Grafting
222890|NCT01843686|Magellan® System
222891|NCT01843686|Wounds
222892|NCT01843673|Lip, Oral Cavity and Pharynx
222893|NCT01843673|Larynx
222894|NCT01843660|Low back pain
222895|NCT01843660|Shoulder pain
222896|NCT01843660|Neck pain
222897|NCT01843660|Tramadol hydrochloride
222898|NCT01843660|Paracetamol
222899|NCT01843621|Dengue, Vaccine, Thailand
222900|NCT01843608|Physical treatment
222901|NCT01843608|Exercise prescription to breast cancer survival
222902|NCT01843608|Side cancer effect treatment
222903|NCT01843582|Keyword: blind spot
222904|NCT01843569|In Vitro Maturation
222905|NCT01843569|IVM
222906|NCT01843569|Natural cycle IVF
222907|NCT01843569|PCOS
222908|NCT01843543|Functional MRI (fMRI)
223157|NCT01842243|MRI
222909|NCT01843543|Resting state functional connectivity MRI (rs-fcMRI)
222910|NCT01843543|Diffusion Tensor Imaging (DTI)
222911|NCT01843517|Pain
222912|NCT01843517|Facilitation
222913|NCT01843517|Inhibition
222914|NCT01843517|Oxytocin
222915|NCT01843517|Postpartum
222916|NCT01843504|platelet rich plasma
222917|NCT01843504|PRP
222918|NCT01843504|plasma
222919|NCT01843504|plasma injection
222920|NCT01843504|patellar tendinopathy
222921|NCT01843504|patella tendon
222922|NCT01843504|patella
222923|NCT01843504|ultrasound
222924|NCT01843504|shear wave ultrasound
222925|NCT01843504|tendinosis
222926|NCT01843504|tendinopathy
222927|NCT01843504|tendinitis
222928|NCT01843504|jumper's knee
222929|NCT01843478|women
222930|NCT01843478|human immunodeficiency virus
222931|NCT01843478|cervical cancer screening
222932|NCT01843478|Pap testing
222933|NCT01843478|human papillomavirus
222934|NCT01843465|atrial fibrillation
222935|NCT01843465|balloon cryoablation
222936|NCT01843465|pulmonary veins
222937|NCT01843439|Acute exacerbation
222938|NCT01843439|Quality of life
222939|NCT01843439|Magnesium deficiency
222940|NCT01843439|Multidisciplinary intervention
222941|NCT01843426|Comorbidity
222942|NCT01843413|unspecified adult solid tumor, protocol specific
222943|NCT01843400|Regorafenib
222944|NCT01843400|Colorectal Neoplasms
222945|NCT01843387|Diabetic nephropathy
222946|NCT01843387|Chronic kidney disease
222947|NCT01843387|Metabolic disease
222948|NCT01843387|Diabetes mellitus, type 2
222949|NCT01843374|tremelimumab
222950|NCT01843374|pleural, peritoneal
222951|NCT01843374|malignant mesothelioma
222952|NCT01843374|CTLA-4
222953|NCT01843361|Stroke
222954|NCT01843361|Clopidogrel
222955|NCT01843361|Aggregometry
222956|NCT01843361|Antiplatelet therapy
222957|NCT01843361|Platelet function tests
222958|NCT01843335|Cardiovascular Diagnostic Technique
222959|NCT01843335|Ultrasound
222960|NCT01843322|Image guided therapy
222961|NCT01843322|Endovascular procedures
222962|NCT01843322|Angiography
222963|NCT01843322|Vascular surgical procedures
222964|NCT01843296|Spinal Anesthesia
222965|NCT01843296|Bupivacaine
222966|NCT01843296|Fentanyl
222967|NCT01843296|Magnesium sulfate
222968|NCT01843296|Postoperative Pain
222969|NCT01843283|Mild Cognitive Impairment
222970|NCT01843283|Family Caregivers
222971|NCT01843283|Intervention studies
222972|NCT01843270|general anesthesia
222973|NCT01843270|body weight
222974|NCT01843270|laryngeal mask airway size
222975|NCT01843257|Alcohol intake after bariatric surgery
222976|NCT01843257|Alcohol and bariatric surgery
222977|NCT01843244|plethysmography
222978|NCT01843231|g-Cath EZ Suture Anchor Delivery Catheter
222979|NCT01843231|Weight Loss Intervention
222980|NCT01843218|Localized rectal cancer in a male patient
222981|NCT01843179|Newly diagnosed
222982|NCT01843179|Complete Remission
222983|NCT01843166|Pessary
222984|NCT01843166|Patient Satisfaction
222985|NCT01843166|Estrogen Cream
222986|NCT01843153|pain score
222987|NCT01843140|cancer
222988|NCT01843140|fertility preservation
222989|NCT01843140|infertility
222990|NCT01843140|pregnancy
222991|NCT01843114|Retinal blood flow
222992|NCT01843114|Retinal vessel diameter
222993|NCT01843114|Fourier Domain Optical Coherence Tomography
222994|NCT01843114|Retinal blood velocities
222995|NCT01843101|Optical Coherence Tomography
222996|NCT01843101|Cornea
222997|NCT01843101|Imaging
222998|NCT01843088|Pain
222999|NCT01843088|exercise
223000|NCT01843088|muscle
223001|NCT01843062|Selumetinib, Differentiated Thyroid Cancer , AZD6244
223002|NCT01843036|Child Abuse
223003|NCT01843036|Child Neglect
223004|NCT01843036|Child Emergency Medical Care Presentations
223005|NCT01843036|Child Well-Care Compliance
223006|NCT01843036|Mother Well-Care Compliance
223007|NCT01843036|Mother Emergency Medical Care Presentations
223008|NCT01843036|Mother Mental Health
223009|NCT01843036|Family Connections to Community Resources
223010|NCT01843036|Parent-Child Relationship Quality
223011|NCT01843023|opioid dependence
223012|NCT01843010|NSAIDs
223013|NCT01843010|Hyperalgesia
223014|NCT01843010|Postlaparoscopic shoulder pain
223015|NCT01842997|Flu
223016|NCT01842997|non-adjuvanted H1N1 vaccine
223017|NCT01842997|Safety
223018|NCT01842997|pregnant women
223019|NCT01842984|Loneliness
223020|NCT01842984|Social isolation
223021|NCT01842984|Depression
223022|NCT01842984|Older adults
223023|NCT01842984|Social competence
223024|NCT01842984|Social integration
223025|NCT01842971|two stage hepatectomy
223026|NCT01842971|liver metastasis
223027|NCT01842971|colorectal cancer
223028|NCT01842958|Dental Implant
223029|NCT01842945|Procrastination
223030|NCT01842945|internet based cognitive behavior therapy
223031|NCT01842945|randomized controlled trial
223032|NCT01842932|Colonoscopy
223033|NCT01842932|Anticholinergics
223034|NCT01842906|positive end expiratory pressure
223035|NCT01842906|acute mountain sickness
223036|NCT01842906|prevention
223037|NCT01842906|high altitude
223038|NCT01842893|fentanyl
223039|NCT01842893|breakthrough pain
223040|NCT01842893|opioid treated cancer patients
223041|NCT01842880|MicroRNAs
223042|NCT01842880|Chagas disease
223043|NCT01842880|Biomarkers
223044|NCT01842867|Syndecan-4
223045|NCT01842867|Chagas disease
223046|NCT01842867|Biomarkers
223047|NCT01842854|Galectin-3
223048|NCT01842854|Chagas disease
223049|NCT01842854|Biomarkers
223050|NCT01842789|Acessa
223051|NCT01842789|Fibroids
223052|NCT01842789|Halt
223053|NCT01842789|Targeting Animation
223054|NCT01842789|Image Overlay
223055|NCT01842789|Radiofrequency Ablation
223056|NCT01842789|RFA
223057|NCT01842763|Chronic daily headache
223058|NCT01842763|treated by occipital nerves stimulation
223059|NCT01842763|peripheral neuromodulation
223060|NCT01842763|occipital nerves
223061|NCT01842763|network
223062|NCT01842763|database
223063|NCT01842737|Low Back Pain
223064|NCT01842737|Chiropractic
223065|NCT01842737|Spinal Manipulation
223066|NCT01842737|Massage
223067|NCT01842698|Thoracotomy surgery
223068|NCT01842698|Anesthesia
223069|NCT01842698|Ultrasound-guided PVB
223070|NCT01842698|Post-operative pain
223071|NCT01842685|Overactive Bladder
223072|NCT01842685|Bladder Distention
223073|NCT01842672|pediatric non-hodgkins lymphoma
223074|NCT01842672|pediatric acute leukemia
223075|NCT01842672|clofarabine
223076|NCT01842672|mitoxantrone
223077|NCT01842659|MI
223078|NCT01842659|amniocentesis
223079|NCT01842659|cord blood
223080|NCT01842659|placenta
223081|NCT01842659|Silver Russell Syndrome
223082|NCT01842659|Beckwith Wiedemann Syndrome
223083|NCT01842646|Leukemia
223084|NCT01842646|Myeloid Malignancies
223085|NCT01842620|Metformin
223086|NCT01842620|Bioequivalence
223087|NCT01842607|eosinophils
223088|NCT01842607|mepolizumab
223089|NCT01842607|SB-240563
223090|NCT01842607|safety
223091|NCT01842607|extension study
223092|NCT01842607|Severe refractory asthma
223093|NCT01842594|Sarcoma, Hydroxychloroquine, Sirolimus, PET
223094|NCT01842581|Liver Failure
223095|NCT01842581|Hepatic Insufficiency
223096|NCT01842581|Liver Diseases
223097|NCT01842581|Brain Diseases
223098|NCT01842581|Rifaximin
223099|NCT01842581|Cirrhosis
223100|NCT01842568|Cardiac surgery
223101|NCT01842568|Troponin
223102|NCT01842568|Vascular events
223103|NCT01842568|Myocardial injury
223104|NCT01842568|Observational cohort study
223105|NCT01842568|Public health
223106|NCT01842555|PDT
223107|NCT01842555|Photodynamic therapy
223108|NCT01842542|Postpartum Depression, NeuroStar TMS Therapy, TMS
223109|NCT01842503|alcohol dependence
223110|NCT01842503|cue reactivity
223111|NCT01842503|alcohol self administration
223112|NCT01842490|Biomarker
223113|NCT01842490|Carotid enhanced ultrasound
223114|NCT01842490|Intraplaque neovascularization
223115|NCT01842438|Sexual Dysfunctions, Psychological
223116|NCT01842425|Liver volume
223117|NCT01842425|Gastric bypass
223118|NCT01842425|Magnetic resonance imaging
223119|NCT01842412|Mitochondria, Muscle
223120|NCT01842412|Exercise
223121|NCT01842399|Vascular Stiffness
223122|NCT01842399|Aging
223123|NCT01842399|Resveratrol
223124|NCT01842399|Aerobic Capacity
223125|NCT01842399|Inflammation
223126|NCT01842386|Anti-CD20
223127|NCT01842386|Anticytokine Autoanitbody-Associated Disease
223128|NCT01842386|Rituximab
223129|NCT01842373|topical anesthetics
223130|NCT01842373|laser resurfacing
223131|NCT01842360|Vaccine
223132|NCT01842360|Chronic obstructive pulmonary disease (COPD)
223133|NCT01842334|Nicotine Dependence
223134|NCT01842334|Smoking Cessation
223135|NCT01842334|D-cycloserine
223136|NCT01842321|locally advanced
223137|NCT01842321|metastatic
223138|NCT01842321|Breast Cancer
223139|NCT01842321|Molecular Apocrine
223140|NCT01842321|HER2-negative
223141|NCT01842321|Abiraterone acetate
223142|NCT01842295|Obesity
223143|NCT01842295|Bariatric surgery
223144|NCT01842295|Sperm quality
223145|NCT01842295|Fertility
223146|NCT01842282|diabetes mellitus type 2
223147|NCT01842282|non alcoholic fatty liver disease
223148|NCT01842282|obesity
223149|NCT01842282|amlexanox
223150|NCT01842269|Mycophenolate Mofetil
223151|NCT01842269|MMF
223152|NCT01842256|Telminouveau
223153|NCT01842256|Atorvastatin
223154|NCT01842256|Pharmacokinetic
223155|NCT01842256|Healthy volunteers
223156|NCT01842243|Ventricular dysfunction
223158|NCT01842243|Echocardiography
223159|NCT01842243|Pacemakers
223160|NCT01842230|Telminuvo
223161|NCT01842230|Telmisartan
223162|NCT01842230|S-amlodipine
223163|NCT01842230|Atorvastatin
223164|NCT01842230|pharmacokinetics
223165|NCT01842230|Healthy volunteers
223166|NCT01842217|18F-FES PET
223167|NCT01842217|Nuclear Medicine
223168|NCT01842217|Premenopausal
223169|NCT01842217|Postmenopausal
223170|NCT01842217|Estrogen receptor
223171|NCT01842217|Anxiety
223172|NCT01842217|Depression
223173|NCT01842217|Cognition
223174|NCT01842204|inguinal hernia
223175|NCT01842191|R-R MS
223176|NCT01842165|Peptide Receptor Radionuclide Therapy (PRRT)
223177|NCT01842165|Neuroendocrine Tumors
223178|NCT01842126|Sciatica
223179|NCT01842100|Induced abortion
223180|NCT01842100|Postaboral pelvic inflammatory disease
223181|NCT01842100|Sexually transmitted infections
223182|NCT01842100|Universal antibiotic prophylaxis
223183|NCT01842100|Screen-and-treat approach
223184|NCT01842087|Chronic Kidney Disease
223185|NCT01842087|Fiber
223186|NCT01842087|BUN
223187|NCT01842087|Serum Creatinine
223188|NCT01842087|Uremic Symptoms
223189|NCT01842087|Quality of Life
223190|NCT01842074|bortezomib
223191|NCT01842074|desensitization
223192|NCT01842074|living kidney transplantation
223193|NCT01842061|active living
223194|NCT01842061|retirement
223195|NCT01842048|External-beam radiotherapy
223196|NCT01842048|Hyperthermia
223197|NCT01842035|Implantable cardiac defibrillator
223198|NCT01842035|regadenoson
223199|NCT01842035|sudden cardiac death
223200|NCT01842035|heart rate response
223201|NCT01842022|Glycemic load
223202|NCT01842022|memory
223203|NCT01842022|mood
223204|NCT01842009|transcranial stimulation
223205|NCT01842009|direct current
223206|NCT01841983|Total worker health
223207|NCT01841983|Sleep
223208|NCT01841983|MSDs
223209|NCT01841983|Diet
223210|NCT01841983|Physical Activity
223211|NCT01841957|Bilateral Cataract
223212|NCT01841957|Simultaneous Cataract Surgery
223213|NCT01841957|ISBCS
223214|NCT01841944|Fatty Acids, Omega-3
223215|NCT01841944|Aged
223216|NCT01841944|Myocardial Infarction
223217|NCT01841931|Opioids
223218|NCT01841931|Dependence
223219|NCT01841931|Buprenorphine
223220|NCT01841931|Pain
223221|NCT01841905|Alzheimer's Disease
223222|NCT01841905|Family History
223223|NCT01841905|Memory Concerns
223224|NCT01841866|post operative sore throat
223225|NCT01841866|laryngeal mask airway
223226|NCT01841866|children
223227|NCT01841853|Elderly
223228|NCT01841853|Health promotion
223229|NCT01841853|Randomized controlled study
223230|NCT01841853|Immigrant
223231|NCT01841853|Vulnerable population
223232|NCT01841853|ADL
223233|NCT01841853|KASAM
223234|NCT01841853|Implementation
223235|NCT01841840|Stroke
223236|NCT01841840|Hemiparetic
223237|NCT01841840|Passive Vibration
223238|NCT01841840|Arterial Stiffness
223239|NCT01841840|Pulse Wave Velocity
223240|NCT01841840|Wave Reflection
223241|NCT01841840|Body Composition
223242|NCT01841840|Autonomic Function
223243|NCT01841814|Lymphoma
223244|NCT01841814|Osteoporosis
223245|NCT01841814|Chemotherapy
223246|NCT01841814|Patient with
223247|NCT01841775|Hepatitis C, Chronic
223248|NCT01841775|Genotype 2/3
223249|NCT01841775|Interferon α 2b
223250|NCT01841775|Ribavirin
223251|NCT01841775|Pharmacovigilance
223252|NCT01841762|PAH-SYMPACT
223253|NCT01841762|Pulmonary Arterial Hypertension
223254|NCT01841762|psychometric instrument
223255|NCT01841749|Breast cancer
223256|NCT01841710|Bitter Taste
223257|NCT01841710|Pediatric Medications
223258|NCT01841697|Diabetes Mellitus
223259|NCT01841697|Diabetes Mellitus, Type 2
223260|NCT01841697|Glucose Metabolism Disorders
223261|NCT01841697|Metabolic Diseases
223262|NCT01841697|Endocrine System Diseases
223263|NCT01841697|Glimepiride
223264|NCT01841697|Metformin
223265|NCT01841697|Hypoglycemic Agents
223266|NCT01841697|Physiological Effects of Drugs
223267|NCT01841697|Pharmacologic Actions
223268|NCT01841684|HoFH
223269|NCT01841671|Polio
223270|NCT01841671|IPV
223271|NCT01841671|bOPV
223272|NCT01841671|mOPV
223273|NCT01841671|vaccination
223274|NCT01841658|Folate Status
223275|NCT01841658|Folate Biomarkers
223276|NCT01841645|CLA-enriched butter
223277|NCT01841645|CLA metabolism
223278|NCT01841645|inflammation
223279|NCT01841632|Liver transplantation
223280|NCT01841632|Allogeneic liver transplantation
223281|NCT01841632|Solid organ transplantation
223282|NCT01841619|skin, lupus, intravenous immunoglobulin, ivig
223283|NCT01841606|Spinal anesthesia
223284|NCT01841606|Elective cesarean deliveries
223285|NCT01841606|Ondansetron
223286|NCT01841580|Tear proteins profiles
223287|NCT01841580|Longitudinal
223288|NCT01841580|Ocular surface damage
223289|NCT01841580|Trabeculectomy
223290|NCT01841567|hip
223291|NCT01841567|knee
223292|NCT01841554|Mitral Valve
223293|NCT01841554|Annuloplasty
223294|NCT01841541|Tuberculosis
223295|NCT01841541|Informal providers
223296|NCT01841541|Informal carers
223297|NCT01841541|Barriers to health system
223298|NCT01841528|Polycystic Ovary Syndrome
223299|NCT01841528|Infertility
223300|NCT01841528|In-vitro fertilization
223301|NCT01841528|fresh embryo transfer
223302|NCT01841528|frozen-thawed embryo transfer
223303|NCT01841502|telaprevir
223304|NCT01841502|paroxetine
223305|NCT01841502|interaction
223306|NCT01841502|pharmacokinetics
223307|NCT01841489|Chronic Lymphocytic Leukemia
223308|NCT01841489|CLL
223309|NCT01841476|Peripheral blood
223310|NCT01841476|HSC
223311|NCT01841476|Mobilization
223312|NCT01841476|CXCR4
223313|NCT01841476|volunteers
223314|NCT01841463|Malignant Melanoma
223315|NCT01841450|Primary open-angle glaucoma (POAG)
223316|NCT01841450|Trabecular meshwork
223317|NCT01841450|iStent
223318|NCT01841437|Primary open-angle glaucoma (POAG)
223319|NCT01841437|Trabecular meshwork
223320|NCT01841437|iStent
223321|NCT01841424|dietary counseling
223322|NCT01841424|food diary
223323|NCT01841424|obesity
223324|NCT01841424|pregnancy
223325|NCT01841424|weight gain
223326|NCT01841411|bacterial vaginosis, recurrence, N-Acetyl cysteine
223327|NCT01841398|Cardiovascular
223328|NCT01841398|Prevention
223329|NCT01841398|Ethnicity
223330|NCT01841398|Culture
223331|NCT01841398|Internet
223332|NCT01841398|Text Message
223333|NCT01841385|Exercise
223334|NCT01841385|spirometry
223335|NCT01841385|muscle strength
223336|NCT01841385|physical therapy modalities
223337|NCT01841372|Obesity
223338|NCT01841372|Overweight
223339|NCT01841372|Weight Maintenance
223340|NCT01841359|Hypoglycemia
223341|NCT01841359|Gastric bypass surgery
223342|NCT01841346|Outcome after PCI
223343|NCT01841346|Middle Eastern Patients
223344|NCT01841333|Lymphoblastic leukemia in remission
223345|NCT01841333|Myeloid leukemia in remission
223346|NCT01841333|Recurrent lymphoblastic leukemia
223347|NCT01841333|Recurrent myeloid leukemia
223348|NCT01841281|Asthma
223349|NCT01841281|Severe Asthma
223350|NCT01841268|premature, preterm, premie, skin
223351|NCT01841255|Preoxygenation
223352|NCT01841255|Device
223353|NCT01841255|Tolerability
223354|NCT01841255|Efficacy
223355|NCT01841242|Infection
223356|NCT01841242|Cardiac Resynchronization Device
223357|NCT01841242|Heart Failure
223358|NCT01841216|Gluteus Maximus
223359|NCT01841216|Gluteus Medius
223360|NCT01841216|TFL
223361|NCT01841216|EMG
223362|NCT01841216|Perceived Exertion
223363|NCT01841216|Thera-Band
223364|NCT01841203|Diagnosis
223365|NCT01841203|Rapid tests
223366|NCT01841203|non-treponemal serology
223367|NCT01841203|eradication
223368|NCT01841190|Prognosis
223369|NCT01841190|Sepsis
223370|NCT01841190|Septic shock
223371|NCT01841190|Procalcitonin
223372|NCT01841190|SOFA
223373|NCT01841177|Congenital Heart Disease
223374|NCT01841177|Pediatrics
223375|NCT01841177|Milrinone
223376|NCT01841177|Cardiopulmonary Bypass
223377|NCT01841177|Therapeutic Drug Monitoring
223378|NCT01841164|Leukotriene responsiveness
223379|NCT01841164|LTE4
223380|NCT01841164|asthma
223381|NCT01841164|airway hyperresponsiveness
223382|NCT01841164|bronchoprovocation
223383|NCT01841164|anti-asthmatic agents
223384|NCT01841164|human
223385|NCT01841151|AD/HD in Children and Adolescents
223386|NCT01841138|colonoscopy
223387|NCT01841138|bowel preparation
223388|NCT01841138|electrolytes
223389|NCT01841138|osmolality
223390|NCT01841138|water
223391|NCT01841125|Alzheimer's Disease
223392|NCT01841125|depressive disorder
223393|NCT01841073|Prediabetes
223394|NCT01841073|Fermentable carbohydrate
223395|NCT01841073|Appetite
223396|NCT01841073|Glucose homeostasis
223397|NCT01841073|Weight management
223398|NCT01841060|Malignant Non-small Cell Neoplasm of Lung
223399|NCT01841047|Retroperitoneal liposarcoma operable
223400|NCT01841034|Male
223401|NCT01841021|Peripheral T-Cell Lymphoma (PTCL)
223402|NCT01841021|Relapsed
223403|NCT01841021|Refractory
223404|NCT01841021|CD30 Receptor
223405|NCT01841021|Large B-Cell Lymphoma
223406|NCT01841008|[C17.800.621]
223407|NCT01840995|stellate ganglion block
223408|NCT01840982|Mixed grains
223409|NCT01840982|Glycemic index
223410|NCT01840982|Giant embryonic brown rice
223411|NCT01840982|Giant embryonic rice
223412|NCT01840982|diabetes
223413|NCT01840969|off-pump coronary artery bypass surgery
223414|NCT01840969|common carotid artery
223415|NCT01840969|speckle tracking analysis
223416|NCT01840969|peak strain
223417|NCT01840956|End-stage Renal Disease
223418|NCT01840956|Hemodialysis
223419|NCT01840956|Chronic Renal Insufficiency
223420|NCT01840956|Renal Dialysis
223421|NCT01840956|Hemodiafiltration
223422|NCT01840956|Blood Vessel Prosthesis
223423|NCT01840956|Tissue-Engineered Vascular Graft
223424|NCT01840956|Vascular Prosthesis Implantation
223425|NCT01840956|Kidney Diseases
223426|NCT01840956|Kidney Failure, Chronic
223427|NCT01840956|Renal Insufficiency
223428|NCT01840956|Urologic Diseases
223429|NCT01840943|Epithelial ovarian cancer
223430|NCT01840943|Recurrent epithelial ovarian carcinoma
223431|NCT01840943|Carcinoma
223432|NCT01840943|Malignancy
223433|NCT01840943|Ovarian carcinoma
223434|NCT01840943|CAELYX
223435|NCT01840943|Topotecan hydrochloride
223436|NCT01840943|Topotecan
223437|NCT01840943|Platinum-based regimen chemotherapy
223438|NCT01840943|Chinese patients
223439|NCT01840930|Cohort
223440|NCT01840930|Cerebral Palsy
223441|NCT01840930|Children
223442|NCT01840930|Pain
223443|NCT01840930|Orthopedic complications
223444|NCT01840930|Epidemiology
223445|NCT01840865|young healthy subjects
223446|NCT01840865|brain stimulation
223447|NCT01840865|tSOS
223448|NCT01840865|tDCS
223449|NCT01840865|sleep
223450|NCT01840865|daytime sleep
223451|NCT01840865|nap
223452|NCT01840865|memory
223453|NCT01840865|memory consolidation
223454|NCT01840839|aging
223455|NCT01840839|cognitive decline
223456|NCT01840839|brain stimulation
223457|NCT01840839|tSOS
223458|NCT01840839|tDCS
223459|NCT01840839|sleep
223460|NCT01840839|nap
223461|NCT01840839|daytime sleep
223462|NCT01840839|memory
223463|NCT01840839|memory consolidation
223464|NCT01840826|Rehospitalization
223465|NCT01840826|Reutilization
223466|NCT01840826|Depressive Symptoms
223467|NCT01840826|Pharmacotherapy
223468|NCT01840826|Cognitive Therapy
223469|NCT01840826|Self-help
223470|NCT01840826|Complementary Therapies
223471|NCT01840813|Intraumbilical misoprostol
223472|NCT01840813|Retained placenta
223473|NCT01840813|Active management of third stage of labour
223474|NCT01840800|Postoperative pain
223475|NCT01840800|anterior cruciate ligament reconstruction
223476|NCT01840800|ultrasound guided nerve blocks
223477|NCT01840800|opioid consumption
223478|NCT01840761|delayed vasospasm,
223479|NCT01840761|medicine,
223480|NCT01840761|standardization
223481|NCT01840735|CF
223482|NCT01840735|Cystic Fibrosis
223483|NCT01840735|PK
223484|NCT01840722|HIV
223485|NCT01840722|HCV
223486|NCT01840722|Substance abuse
223487|NCT01840722|women
223488|NCT01840709|Systemic lupus erythematosus
223489|NCT01840709|Psychotherapy
223490|NCT01840683|Age-Related Macular Degeneration (AMD)
223491|NCT01840683|Age Related Eye Disease Study (AREDS)
223492|NCT01840683|Best-Corrected Visual Acuity (BCVA)
223493|NCT01840683|Early Treatment Diabetic Retinopathy Study (ETDRS)
223494|NCT01840683|Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation (HELP)
223495|NCT01840683|Visual Function Questionnaire (VFQ)
223496|NCT01840670|Inferior Vena Cava
223497|NCT01840670|Central Venous Pressure
223498|NCT01840670|Abdominal Pressure
223499|NCT01840657|CMDIR (Congenital Muscle Disease International Registry)
223500|NCT01840657|X-linked myotubular myopathy
223501|NCT01840657|centronuclear myopathy
223502|NCT01840657|myotubularin
223503|NCT01840657|MTM1 gene
223504|NCT01840657|mutation
223505|NCT01840657|survival
223506|NCT01840657|adverse event
223507|NCT01840657|disease complication
223508|NCT01840657|hospital admission
223509|NCT01840657|emergency room visit
223510|NCT01840657|motor function
223511|NCT01840657|respiratory function
223512|NCT01840657|natural history study
223513|NCT01840631|Obesity
223514|NCT01840631|Nutritional counseling
223515|NCT01840631|Physical activity
223516|NCT01840631|Food diary
223517|NCT01840618|insulin function
223518|NCT01840618|sleep apnea
223519|NCT01840618|girls
223520|NCT01840618|PCOS
223521|NCT01840618|insulin action
223522|NCT01840592|Liver
223523|NCT01840592|Sorafenib
223524|NCT01840592|Doxorubicin
223525|NCT01840592|12-259
223526|NCT01840566|Relapsed
223527|NCT01840566|Refractory
223528|NCT01840566|Autologous Stem Cell Transplantation
223529|NCT01840566|HIGH DOSE CHEMOTHERAPY
223530|NCT01840566|19-28z T cells/kg
223531|NCT01840566|12-117
223532|NCT01840540|renal artery stenosis
223533|NCT01840540|renovascular hypertension
223534|NCT01840540|ischemic nephropathy
223535|NCT01840540|chronic kidney disease
223536|NCT01840527|Biomarker
223537|NCT01840527|BRAF
223538|NCT01840527|blood-based
223539|NCT01840514|recipient
223540|NCT01840501|Healthy
223541|NCT01840501|JNJ-42721458
223542|NCT01840501|Male
223543|NCT01840501|Safety
223544|NCT01840501|Tolerability
223545|NCT01840501|Pharmacokinetics
223546|NCT01840501|Pharmacodynamics
223547|NCT01840501|Immunogenicity
223548|NCT01840436|MUCIPLIQ
223549|NCT01840436|Matrix therapy
223550|NCT01840436|RGTA
223551|NCT01840436|Oral mucositis
223552|NCT01840423|First in man study
223553|NCT01840423|Volunteer study
223554|NCT01840410|Vision Impairment
223555|NCT01840410|Abnormal growth of blood vessels
223556|NCT01840397|S-100B
223557|NCT01840397|NSE
223558|NCT01840384|Healthy infants
223559|NCT01840384|Anemia, iron-deficiency
223560|NCT01840371|ERCP
223561|NCT01840371|Sedation
223562|NCT01840371|Fentanyl
223563|NCT01840371|Propofol
223564|NCT01840358|Hypoglycemias
223565|NCT01840358|Insulin pump
223566|NCT01840358|Children
223567|NCT01840345|uncontrolled
223568|NCT01840345|neuropathic pain
223569|NCT01840332|thyroid cancer
223570|NCT01840280|carcinoma
223571|NCT01840280|colorectal cancer
223572|NCT01840280|ambulant chemotherapy
223573|NCT01840280|treatment cycles
223574|NCT01840280|Irinotecan
223575|NCT01840280|Irinotecan onkovis
223576|NCT01840280|Quantity of Irinotecan
223577|NCT01840280|Packaging Sizes
223578|NCT01840267|pneumoperitoneum
223579|NCT01840267|pediatric laparoscopy
223580|NCT01840267|optic nerve sheath diameter
223581|NCT01840267|intracranial pressure
223582|NCT01840254|PONV
223583|NCT01840254|IV PCA
223584|NCT01840254|dexmedetomidine
223585|NCT01840254|Female
223586|NCT01840254|non-smoking
223587|NCT01840254|lumbar spine surgery
223588|NCT01840241|sodium bicarbonate
223589|NCT01840241|acute kidney injury
223590|NCT01840241|OPCAB
223591|NCT01840228|Preterm
223592|NCT01840228|Progesterone
223593|NCT01840189|Addison disease
223594|NCT01840189|Type 1 diabetes
223595|NCT01840189|treatment
223596|NCT01840176|McCall culdoplasty
223597|NCT01840176|Total laparoscopic hysterectomy
223598|NCT01840176|Vaginal vault prolapse
223599|NCT01840176|Sexual function
223600|NCT01840124|Fibroids
223601|NCT01840124|Radiofrequency ablation
223602|NCT01840111|smoking environment
223603|NCT01840111|cue-exposure
223604|NCT01840111|cigarettes
223605|NCT01840111|nicotine
223606|NCT01840111|fMRI
223607|NCT01840085|Diabetic foot ulcer
223608|NCT01840085|plantar neuropathic ulcer
223609|NCT01840085|plantar neuroischemic ulcer
223610|NCT01840085|Wagner Grade 1 or Grade 2 DFU
223611|NCT01840072|Ischemic stroke
223612|NCT01840072|Hypertension
223613|NCT01840072|Antihypertensive Agents
223614|NCT01840072|Randomized Controlled Trial
223615|NCT01840059|Cardiac Failure
223616|NCT01840059|Autonomic Denervation
223617|NCT01840020|bariatric surgery
223618|NCT01840020|alcohol drinking
223619|NCT01840020|alcoholism
223620|NCT01840020|ethanol
223621|NCT01840020|metabolism
223622|NCT01839994|prostate cancer,
223623|NCT01839994|high-dose-rate brachytherapy boost,
223624|NCT01839994|stereotactic body radiotherapy boost,
223625|NCT01839994|conformal radiotherapy,
223626|NCT01839994|randomized trial
223627|NCT01839942|Hernia, Ventral
223628|NCT01839929|tacrolimus
223629|NCT01839929|immunosuppressant
223630|NCT01839929|FK506
223631|NCT01839903|Smoking
223632|NCT01839903|Tobacco
223633|NCT01839903|Emergency Department
223634|NCT01839890|Paclitaxel
223635|NCT01839890|stent
223636|NCT01839890|Acute infarction
223637|NCT01839890|Systolic time elevation
223638|NCT01839877|Metastatic colorectal Cancer
223639|NCT01839864|Promotoras
223640|NCT01839864|Hispanic Adults
223641|NCT01839864|metabolic syndrome
223642|NCT01839864|rural
223643|NCT01839864|patient attitudes
223644|NCT01839864|provider cultural competency
223645|NCT01839864|patient activation measure
223646|NCT01839851|Hair cortisol
223647|NCT01839851|asthma
223648|NCT01839851|allergic rhinitis
223649|NCT01839851|inhaled corticosteroids
223650|NCT01839851|intranasal glucocorticoids
223651|NCT01839838|Women
223652|NCT01839838|age 50 and above
223653|NCT01839838|with
223654|NCT01839838|that has been
223655|NCT01839838|surgically excised
223656|NCT01839825|elderly
223657|NCT01839825|fall
223658|NCT01839825|acute illness
223659|NCT01839825|care giver
223660|NCT01839812|Cardiopulmonary bypass
223661|NCT01839812|Cortisol
223662|NCT01839812|Dexamethasone
223663|NCT01839799|Patients
223664|NCT01839799|with
223665|NCT01839799|resected
223666|NCT01839786|Pulmonary Hypertension
223667|NCT01839786|Doppler
223668|NCT01839786|Valsalva
223669|NCT01839773|Stomach Neoplasms
223670|NCT01839773|Cancer of Stomach
223671|NCT01839773|Gastric Cancer
223672|NCT01839773|Gastric Neoplasms
223673|NCT01839773|Neoplasms, Gastric
223674|NCT01839773|Neoplasms, Stomach
223675|NCT01839773|Stomach Cancer
223676|NCT01839773|paclitaxel
223677|NCT01839773|Taxol
223678|NCT01839760|Influenza
223679|NCT01839760|Virus
223680|NCT01839760|Viral shedding
223681|NCT01839760|Epidemiology
223682|NCT01839747|Pediatric
223683|NCT01839734|CD4+
223684|NCT01839721|Probiotics
223685|NCT01839721|radiation-induced enteritis
223686|NCT01839721|radiation-induced diarrhea
223687|NCT01839721|radiation, diarrhea, enteritis
223688|NCT01839721|diet
223689|NCT01839721|nutrition
223690|NCT01839708|Intervention
223691|NCT01839695|Thoracic Aneurysm
223692|NCT01839695|Endovascular Aortic Repair
223693|NCT01839695|TEVAR
223694|NCT01839682|StabiliT
223695|NCT01839682|Kyphoplasty
223696|NCT01839682|Vertebral
223697|NCT01839682|Compression
223698|NCT01839682|Fracture
223699|NCT01839682|Osteoporosis
223700|NCT01839669|conservative therapy
223701|NCT01839669|Foot-Function-Index
223702|NCT01839669|functional movement changes
223703|NCT01839669|non-surgical treatment
223704|NCT01839669|pes planovalgus
223705|NCT01839669|posterior tibial tendon dysfunction
223706|NCT01839656|Spinal Muscular Atrophy
223707|NCT01839656|SMA
223708|NCT01839656|SMN
223709|NCT01839656|SMNRx
223710|NCT01839656|ISIS-SMNRx
223711|NCT01839656|ISIS 396443
223712|NCT01839656|IONIS-SMNRx
223713|NCT01839643|pharmacokinetic
223714|NCT01839630|Sorafenib
223715|NCT01839630|Hepatocellular cancer
223716|NCT01839630|TACE combination
223717|NCT01839630|Treatment pattern
223718|NCT01839630|Safety
223719|NCT01839630|Effectiveness
223720|NCT01839617|parenteral nutrition
223721|NCT01839617|early nutrition
223722|NCT01839617|abdominal surgery
223723|NCT01839617|cancer
223724|NCT01839604|Child-Pugh A to B7,
223725|NCT01839604|Advanced/Metastatic Hepatocellular Carcinoma,
223726|NCT01839604|AZD9150,
223727|NCT01839604|Antisense Oligonucleotide Inhibitor of STAT3
223728|NCT01839578|cytokines
223729|NCT01839578|blood purification
223730|NCT01839578|super high flux hemodialysis
223731|NCT01839565|Adverse events
223732|NCT01839565|Osteosynthesis
223733|NCT01839565|Quality of life
223734|NCT01839552|Fentanyl Citrate Nasal Spray (FCNS)
223735|NCT01839552|Lazanda
223736|NCT01839552|Breakthrough pain in cancer patients
223737|NCT01839539|colorectal cancer
223738|NCT01839539|DC-CIK
223739|NCT01839539|CRC
223740|NCT01839526|Fabry disease
223741|NCT01839513|Analgesia/nociception index
223742|NCT01839513|Desflurane
223743|NCT01839513|Remifentanil
223744|NCT01839513|Orthopedic surgery
223745|NCT01839513|Ear-nose-throat surgery
223746|NCT01839513|Hemodynamic reactivity
223747|NCT01839487|pancreatic ductal carcinoma(PDA)
223748|NCT01839487|Pancreatic ductal carcinoma
223749|NCT01839487|PEGPH20
223750|NCT01839487|Gemcitabine
223751|NCT01839487|Nab-paclitaxel
223752|NCT01839474|Continuous Positive Airway Pressure
223753|NCT01839474|Controlled trial
223754|NCT01839474|Pneumonia
223755|NCT01839474|Children
223756|NCT01839461|Pharmacogenetics
223757|NCT01839461|postoperative
223758|NCT01839461|pediatric
223759|NCT01839461|opioid
223760|NCT01839461|perioperative
223761|NCT01839461|respiratory depression
223762|NCT01839461|chronic pain
223763|NCT01839448|post partum diabetes
223764|NCT01839448|impaired fasting glucose
223765|NCT01839435|appendectomy
223766|NCT01839435|acute appendicitis
223767|NCT01839435|outpatient
223768|NCT01839409|Circadian Rhythm
223769|NCT01839409|Exercise
223770|NCT01839409|Reflex, Vestibular Ocular
223771|NCT01839409|Postural Balance
223772|NCT01839396|Intrepid, Vercise, PD, DBS, Boston Scientific
223773|NCT01839370|Pramlintide
223774|NCT01839370|Closed Loop
223775|NCT01839370|Continuous Glucose Monitor (CGM)
223776|NCT01839370|Diabetes Assistant (DiAs)
223777|NCT01839357|Rivaroxaban
223778|NCT01839357|Oral anticoagulant
223779|NCT01839357|Nonvalvular atrial fibrillation
223780|NCT01839357|Left atrial thrombus
223781|NCT01839357|Transesophageal echocardiography
223782|NCT01839357|Thrombus resolution
223783|NCT01839357|Stroke
223784|NCT01839357|Thromboembolism
223785|NCT01839344|hyperglycemia
223786|NCT01839344|Diabetes Mellitus, Type 2
223787|NCT01839344|endothelial dysfunction
223788|NCT01839344|quercetin
223789|NCT01839344|Acarbose
223790|NCT01839344|glucose tolerance
223791|NCT01839344|maltose
223792|NCT01839331|osteoarthritis
223793|NCT01839331|osteoarthrisis of the knee
223794|NCT01839318|Soft contact lenses
223795|NCT01839318|Daily disposable contact lenses
223796|NCT01839318|Tear Film Break Up Time
223797|NCT01839318|Contact lens wettability
223798|NCT01839305|Kinematics
223799|NCT01839305|Fibromyalgia
223800|NCT01839305|Physical Therapy
223801|NCT01839305|3D Kinematics
223802|NCT01839305|Heart Rate Frequency
223803|NCT01839305|Hydrotherapy
223804|NCT01839292|gastric outlet obstruction
223805|NCT01839292|palliative treatment
223806|NCT01839292|stent
223807|NCT01839266|acute PTE, prognostic factors
223808|NCT01839253|antihypertensive agents
223809|NCT01839253|hemodynamic
223810|NCT01839253|anesthetics reduction
223811|NCT01839253|orthognathic surgery
223812|NCT01839227|Post-operative cognitive dysfunction
223813|NCT01839227|regional cerebral oxygen saturation
223814|NCT01839227|elderly
223815|NCT01839201|anesthesia
223816|NCT01839201|modification of dreaming
223817|NCT01839201|suggestions
223818|NCT01839162|Transradial approach
223819|NCT01839162|shield drape
223820|NCT01839162|radiation
223821|NCT01839162|PTCA
223822|NCT01839149|Refractory Chronic Migraine
223823|NCT01839149|Medically Intractable Chronic Migraine
223824|NCT01839149|Oxytocin
223825|NCT01839149|Intranasal oxytocin
223826|NCT01839136|Assisted Reproductive Techniques
223827|NCT01839136|Health Services Accessibility
223828|NCT01839136|Ovulation Induction
223829|NCT01839136|Embryo Transfer
223830|NCT01839123|Amputee
223831|NCT01839110|pulmonary hypertension
223832|NCT01839110|right ventricular function
223833|NCT01839110|ranolazine
223834|NCT01839097|PTCL
223835|NCT01839097|Maximum Tolerated Dose
223836|NCT01839097|Belinostat
223837|NCT01839084|Xenon
223838|NCT01839084|Isoflurane
223839|NCT01839084|Anesthetics, Inhalation
223840|NCT01839084|Nephroprotection
223841|NCT01839084|Partial nephrectomy
223842|NCT01839084|Xenon versus Isoflurane anesthesia
223843|NCT01839058|Non Cardiac Chest Pain
223844|NCT01839045|Woman
223845|NCT01839045|Breast Cancer
223846|NCT01839045|Cancer
223847|NCT01839045|Mammogram
223848|NCT01839045|Ultrasound
223849|NCT01839045|Imaging
223850|NCT01839045|Biomarkers
223851|NCT01839045|ACR BI RAD Category 3
223852|NCT01839045|ACR BI RAD Category 4
223853|NCT01839019|Healthy volunteers
223854|NCT01839006|hydronephrosis
223855|NCT01839006|ultrasonography
223856|NCT01839006|Kidney Function Test
223857|NCT01839006|Patients with unilateral UPJO and patients with preop HN in USG and supranormal renal function in DTPA renography
223858|NCT01838993|anesthetics,
223859|NCT01838993|local,
223860|NCT01838993|lidocaine;
223861|NCT01838993|nebulizers and vaporizers;
223862|NCT01838993|complications,
223863|NCT01838993|intubation,
223864|NCT01838993|intratracheal.
223865|NCT01838980|Colonoscopy Cleaning
223866|NCT01838967|cilnidipin and valsartn
223867|NCT01838967|pharmacokinetic drug drug interaction
223868|NCT01838967|oral administration
223869|NCT01838967|healthy male subjects
223870|NCT01838954|hand osteoarthritis
223871|NCT01838954|short-wave diathermy
223872|NCT01838941|Peroxisome Biogenesis Disorder
223873|NCT01838941|PBD
223874|NCT01838941|neonatal adrenoleukodystrophy
223875|NCT01838941|infantile Refsum disease
223876|NCT01838941|PEX1 mutation
223877|NCT01838941|Betaine
223878|NCT01838928|Axillary brachial plexus block
223879|NCT01838928|Ultrasound
223880|NCT01838928|Minimum effective concentration
223881|NCT01838928|Bupivacaine
223882|NCT01838928|ultrasound-guided axillary brachial plexus block
223883|NCT01838915|HIV
223884|NCT01838915|immunoactivation
223885|NCT01838915|bacterial translocation
223886|NCT01838915|prebiotics
223887|NCT01838915|glutamine
223888|NCT01838915|microbiota
223889|NCT01838902|Malaria
223890|NCT01838902|Falciparum
223891|NCT01838902|Direct membrane feeding
223892|NCT01838902|QT-NASBA
223893|NCT01838902|Asexual parasite
223894|NCT01838902|Asymptomatic carrier
223895|NCT01838902|Gametocytocidal, Gametocyte
223896|NCT01838902|Transmission blocking
223897|NCT01838902|Sexual stage
223898|NCT01838902|Primaquine
223899|NCT01838902|Dihydroartemisinin
223900|NCT01838902|Piperaquine
223901|NCT01838902|Gambia
223902|NCT01838902|Africa
223903|NCT01838889|Culturally adapted
223904|NCT01838889|Group psychological intervention
223905|NCT01838889|British South Asian women
223906|NCT01838889|CBT
223907|NCT01838876|Major Depressive Disorder
223908|NCT01838876|MDD
223909|NCT01838876|Depression
223910|NCT01838863|coagulopathy
223911|NCT01838863|hemorrhagic shock
223912|NCT01838863|plasma
223913|NCT01838863|blood product transfusion
223914|NCT01838824|Processing Speed
223915|NCT01838824|Intervention
223916|NCT01838824|Multiple Sclerosis
223917|NCT01838824|Cognition
223918|NCT01838811|Processing Speed
223919|NCT01838811|Intervention
223920|NCT01838811|Traumatic Brain Injury
223921|NCT01838811|Cognition
223922|NCT01838798|cognitive disorders
223923|NCT01838798|quality of life
223924|NCT01838798|Intensive care
223925|NCT01838785|18F-DTBZ AV-133 imaging
223926|NCT01838772|HCV and HIV co-infection
223927|NCT01838759|Bioimpedance spectroscopy
223928|NCT01838759|Hypervolemia
223929|NCT01838759|Hypovolemia
223930|NCT01838746|Percutaneous coronary intervention
223931|NCT01838746|Coronary artery bypass grafting
223932|NCT01838746|Coronary artery bypass surgery
223933|NCT01838746|Survival
223934|NCT01838746|Acute coronary syndrome
223935|NCT01838746|ST segment elevation myocardial infarction
223936|NCT01838746|Non-ST segment elevation myocardial infarction
223937|NCT01838746|Younge patient
223938|NCT01838720|renal cell carcinoma
223939|NCT01838720|ischemia
223940|NCT01838720|radio frequency ablation
223941|NCT01838707|postoperative
223942|NCT01838707|spine surgery
223943|NCT01838655|Albinism
223944|NCT01838655|Nitisinone
223945|NCT01838655|Melanin
223946|NCT01838655|Vision Loss
223947|NCT01838642|Monoclonal Antibody
223948|NCT01838642|AP24534
223949|NCT01838642|RET Mutation Positive
223950|NCT01838642|RET Mutation Negative
223951|NCT01838642|RET Inhibitor
223952|NCT01838616|Severe chronic low back pain
223953|NCT01838616|Neuropathic pain
223954|NCT01838616|Constipation
223955|NCT01838590|Liver Diseases
223956|NCT01838590|Digestive System Diseases
223957|NCT01838590|Hepatitis, Viral, Human
223958|NCT01838590|Virus Diseases
223959|NCT01838590|Enterovirus Infections
223960|NCT01838590|Picornaviridae Infections
223961|NCT01838590|RNA Virus Infections
223962|NCT01838590|Flaviviridae Infections
223963|NCT01838590|Antiviral Agents
223964|NCT01838590|Anti-Infective Agents
223965|NCT01838590|Therapeutic Uses
223966|NCT01838590|Pharmacologic Actions
223967|NCT01838590|Antimetabolites
223968|NCT01838590|Molecular Mechanisms of Pharmacological Action
223969|NCT01838590|HCV genotype 4 (GT-4)
223970|NCT01838590|HCV
223971|NCT01838590|Sustained Virologic Response
223972|NCT01838590|Direct Acting Antiviral
223973|NCT01838590|Combination Therapy
223974|NCT01838590|GS-7977
223975|NCT01838590|Ribavirin
223976|NCT01838590|Open Label
223977|NCT01838590|Sofosbuvir
223978|NCT01838590|Additional relevant MeSH terms:
223979|NCT01838590|Hepatitis
223980|NCT01838590|Hepatitis, Chronic
223981|NCT01838590|Hepatitis C
223982|NCT01838590|Hepatitis C, Chronic
223983|NCT01838564|Pediatric Advanced Cancer
223984|NCT01838564|Children
223985|NCT01838564|Quality of Life
223986|NCT01838564|Health Information technology
223987|NCT01838564|Patient reported outcomes
223988|NCT01838525|sepsis
223989|NCT01838525|alpha-1-acid glycoprotein (AGP)
223990|NCT01838525|diagnosis
223991|NCT01838525|prognosis
223992|NCT01838525|SIRS
223993|NCT01838486|Interstitial cystitis
223994|NCT01838486|painful bladder syndrome
223995|NCT01838486|bladder hydrodistention
223996|NCT01838486|hyperthermia
223997|NCT01838473|smokeless tobacco
223998|NCT01838473|Nicotine
223999|NCT01838473|Cadmium
224000|NCT01838473|lead
224001|NCT01838473|Tobacco Specific Nitrosamines
224002|NCT01838447|Vitamin D
224003|NCT01838447|Congenital Heart Disease
224004|NCT01838447|Cardiac Surgery
224005|NCT01838447|Pediatrics
224006|NCT01838447|Phase II Clinical Trial
224007|NCT01838408|screening colonoscopy
224008|NCT01838408|surveillance colonoscopy
224009|NCT01838408|colonoscopy
224010|NCT01838395|AML
224011|NCT01838395|Acute Myeloid Leukemia
224012|NCT01838395|Relapsed Acute Myeloid Leukemia
224013|NCT01838395|Refractory Acute Myeloid Leukemia
224014|NCT01838382|pain
224015|NCT01838382|total laparoscopic hysterectomy
224016|NCT01838356|Depression
224017|NCT01838356|Vascular depression
224018|NCT01838356|Intracranial atherosclerosis
224019|NCT01838356|Coronary artery disease
224020|NCT01838356|Coronary artery bypass graft
224021|NCT01838356|Cognitive impairment
224022|NCT01838330|Kidney Disease
224023|NCT01838330|Fiber
224024|NCT01838330|Dietary Intervention
224025|NCT01838304|propofol sedation endoscopy
224026|NCT01838291|Ferriprox
224027|NCT01838291|Deferiprone
224028|NCT01838291|DFP
224029|NCT01838291|L1
224030|NCT01838278|Vojta therapy
224031|NCT01838278|Exercise Movement Technique
224032|NCT01838278|Early intervention
224033|NCT01838252|Ectropion
224034|NCT01838252|Hyaluronic Acid
224035|NCT01838252|Keratoconjunctivitis Sicca
224036|NCT01838252|Lower eyelid retraction
224037|NCT01838239|Fish oil
224038|NCT01838239|Omega-3 fatty acids
224039|NCT01838226|Chronic Disease
224040|NCT01838226|Prevention
224041|NCT01838226|cardiovascular disease
224042|NCT01838213|Urinary tract infection
224043|NCT01838213|ESBL
224044|NCT01838213|treatment
224045|NCT01838213|carriage
224046|NCT01838213|risk factors
224047|NCT01838213|water contamination
224048|NCT01838200|BCG
224049|NCT01838200|Bacillus Calmette-Guérin
224050|NCT01838200|Ipilimumab
224051|NCT01838200|YERVOY
224052|NCT01838200|Advanced Metastatic Melanoma
224053|NCT01838200|Metastatic Melanoma
224054|NCT01838174|Optic Neuritis
224055|NCT01838161|adolescents
224056|NCT01838161|immunizations
224057|NCT01838148|coronary artery disease
224058|NCT01838148|angina, stable
224059|NCT01838148|exercise test
224060|NCT01838148|biological Markers
224061|NCT01838148|SPECT
224062|NCT01838135|wheelchair
224063|NCT01838135|manual wheelchair
224064|NCT01838135|rehabilitation
224065|NCT01838135|self-efficacy
224066|NCT01838135|older adults
224067|NCT01838135|feasibility
224068|NCT01838135|intervention
224069|NCT01838135|training
224070|NCT01838122|PCOS
224071|NCT01838122|HbA1C
224072|NCT01838122|Insulin resistance
224073|NCT01838122|OGTT
224074|NCT01838122|HOMA-IR
224075|NCT01838122|HOMA-B-cell
224076|NCT01838070|Hepatitis A
224077|NCT01838070|Hepatitis A vaccine
224078|NCT01838070|AVAXIM 160U
224079|NCT01838031|antenatal thyroid screening
224080|NCT01838031|subclinical hypothyroidism
224081|NCT01838031|thyroid function
224082|NCT01838031|thyroid antibody
224083|NCT01838031|pregnancy outcome
224084|NCT01838031|childhood cognitive function
224085|NCT01838018|PKAN
224086|NCT01838018|brain iron
224087|NCT01838018|NBIA
224088|NCT01838018|neurodegeneration with brain iron accumulation
224089|NCT01838018|Hallervorden Spatz Syndrome
224090|NCT01838005|Contingency management
224091|NCT01838005|conditional cash transfer
224092|NCT01838005|PMTCT
224093|NCT01838005|Retention
224094|NCT01838005|HIV
224095|NCT01837979|prenatal testing for fetal aneuploidy
224096|NCT01837979|dried blood spots
224097|NCT01837979|cell-free fetal DNA
224098|NCT01837979|detection rate
224099|NCT01837979|cost-effectiveness
224100|NCT01837966|re-operative anxiety
224101|NCT01837966|breast surgery
224102|NCT01837966|lavender oil
224103|NCT01837966|aromatherapy
224104|NCT01837927|Efficacy, NVA237, Tiotropium, Chronic Obstructive Pulmonary Disease, COPD
224105|NCT01837901|transcorneal electrostimulation
224106|NCT01837888|wheelchair
224107|NCT01837888|manual wheelchair
224108|NCT01837888|rehabilitation
224109|NCT01837888|self-efficacy
224110|NCT01837888|older adults
224111|NCT01837888|feasibility
224112|NCT01837888|intervention
224113|NCT01837888|training
224114|NCT01837888|Wheelchair mobility
224115|NCT01837875|Intervention
224116|NCT01837875|Quality of life
224117|NCT01837875|African American
224118|NCT01837875|Stress
224119|NCT01837862|pilomyxoid astrocytoma
224120|NCT01837862|Pilocytic Astrocytoma
224121|NCT01837862|Glioma
224122|NCT01837862|Optic Nerve Glioma
224123|NCT01837862|mebendazole
224124|NCT01837862|Pleomorphic Xanthoastrocytoma
224125|NCT01837862|glioblastoma multiforme
224126|NCT01837862|anaplastic astrocytoma
224127|NCT01837862|gliosarcoma
224128|NCT01837862|diffuse intrinsic pontine glioma
224129|NCT01837862|DIPG
224130|NCT01837862|low-grade glioma
224131|NCT01837862|high-grade glioma
224132|NCT01837862|brainstem glioma
224133|NCT01837862|pediatric
224134|NCT01837849|heart failure
224135|NCT01837849|rhBNP
224136|NCT01837849|Dobutamine
224137|NCT01837836|Health education
224138|NCT01837836|water handling practices
224139|NCT01837836|Bacteriological quality of water
224140|NCT01837823|Coronary artery disease
224141|NCT01837823|Lipid
224142|NCT01837823|Regression
224143|NCT01837823|Plaque
224144|NCT01837810|Post tonsillectomy hemorrhage
224145|NCT01837810|post operative hemorrhage
224146|NCT01837810|complications
224147|NCT01837810|tonsillectomy
224148|NCT01837758|Platelet function
224149|NCT01837758|hemofiltration
224150|NCT01837758|Multiplate
224151|NCT01837732|Chronic pain
224152|NCT01837732|elderly
224153|NCT01837732|relational touch
224154|NCT01837706|Empathy
224155|NCT01837706|Communication
224156|NCT01837706|Physician litigation
224157|NCT01837693|cervical cancer screening
224158|NCT01837693|CIN
224159|NCT01837693|cervical cancer
224160|NCT01837693|biomarkers
224161|NCT01837693|sensitivity and specificity
224162|NCT01837680|Insulin, Long-Acting
224163|NCT01837654|Detrusor Overactivity
224164|NCT01837654|Plantarflexion
224165|NCT01837654|Urgency
224166|NCT01837628|Urodynamic
224167|NCT01837628|Paraffin oil
224168|NCT01837628|Lidocaine gel
224169|NCT01837628|Pain
224170|NCT01837615|Ulcerative Colitis
224171|NCT01837615|Ulcerative Proctitis
224172|NCT01837615|Low Level Light Therapy
224173|NCT01837615|Safety
224174|NCT01837615|Efficacy
224175|NCT01837602|refractory to at least one standard therapy
224176|NCT01837602|newly diagnosed
224177|NCT01837602|with operable triple negative breast cancer
224178|NCT01837589|Cystic fibrosis-DXA-QCT-Osteopenia- Osteoporosis
224179|NCT01837576|Psoriasis Vulgaris
224180|NCT01837576|Calcipotriol
224181|NCT01837576|Betamethasone Dipropionate
224182|NCT01837550|audiologic rehabilitation
224183|NCT01837550|hearing loss
224184|NCT01837550|patient education
224185|NCT01837550|patient participation
224186|NCT01837550|structured rehabilitation
224187|NCT01837550|counseling
224188|NCT01837550|Internet
224189|NCT01837524|Dietary advice
224190|NCT01837524|Nutritional knowledge
224191|NCT01837524|Self-efficacy
224192|NCT01837524|Nutrition
224193|NCT01837511|Tumor antigens
224194|NCT01837511|Asiatic patients
224195|NCT01837511|Reverse Transciptase-Polymerase chain reaction (RT-PCR)
224196|NCT01837511|Non-small cell lung cancer (NSCLC)
224197|NCT01837498|residual neuromuscular blockade, sugammadex, neostigmine, thoracic surgery
224198|NCT01837485|Irritable bowel syndrome
224199|NCT01837485|Functional gastrointestinal disorders
224200|NCT01837485|Gut flora
224201|NCT01837485|Probiotics
224202|NCT01837472|Irritable bowel syndrome
224203|NCT01837472|Functional gastrointestinal disorders
224204|NCT01837472|Gut flora
224205|NCT01837472|Probiotics
224206|NCT01837459|Obstructive Sleep Apnea
224207|NCT01837459|Sleep Disordered Breathing
224208|NCT01837459|Vascular function
224209|NCT01837459|Arterial stiffness
224210|NCT01837459|Polysomnography
224211|NCT01837459|Cytokines
224212|NCT01837446|mucositis
224213|NCT01837446|topical morphine
224214|NCT01837446|pain
224215|NCT01837446|head and neck carcinoma
224216|NCT01837433|Efficacy
224217|NCT01837433|safety
224218|NCT01837433|short
224219|NCT01837433|term
224220|NCT01837433|subacute thyroiditis
224221|NCT01837407|Soft tissue loss
224222|NCT01837407|nerve defect
224223|NCT01837407|dorsal branch of the proper digital nerve
224224|NCT01837407|heterodigital arterialized nerve pedicle flap
224225|NCT01837407|Composite Flap
224226|NCT01837407|nerve flap
224227|NCT01837407|nerve transfer
224228|NCT01837394|Nerve block
224229|NCT01837394|Ultrasound
224230|NCT01837394|postoperative pain
224231|NCT01837394|Saphenous nerve
224232|NCT01837394|Obturator nerve
224233|NCT01837329|Non-Squamous
224234|NCT01837329|NSCLC
224235|NCT01837329|Adenocarcinoma
224236|NCT01837329|Lung Cancer
224237|NCT01837329|Tetrathiomolybdate
224238|NCT01837329|Copper
224239|NCT01837329|Carboplatin
224240|NCT01837329|Pemetrexed Platinum
224241|NCT01837329|Newly Diagnosed
224242|NCT01837329|Chemo-naive
224243|NCT01837316|pharmacodynamics
224244|NCT01837316|FF/VI
224245|NCT01837316|asthma
224246|NCT01837316|duration of action
224247|NCT01837303|Cervical dysplasia
224248|NCT01837303|Cervical cancer
224249|NCT01837290|Renal failure,
224250|NCT01837290|hip fracture,
224251|NCT01837290|spinal anesthesia,
224252|NCT01837290|dexmedetomidine
224253|NCT01837290|patient
224254|NCT01837264|Magellan MAR01
224255|NCT01837264|Autologous Platelet Rich Plasma
224256|NCT01837264|Compartment Syndrome
224257|NCT01837264|Battlefield Trauma
224258|NCT01837264|Fasciotomy
224259|NCT01837251|Ovarian Carcinoma
224260|NCT01837251|Bevacizumab
224261|NCT01837251|Gemcitabine
224262|NCT01837251|PLD
224263|NCT01837251|pegylated liposomal doxorubicin
224264|NCT01837251|Carboplatin
224265|NCT01837251|best therapeutic index
224266|NCT01837251|progression-free survival
224267|NCT01837238|hemodialysis
224268|NCT01837238|physical function
224269|NCT01837225|Fluorescence Imaging
224270|NCT01837225|Breast Tumor Margins
224271|NCT01837225|Real-time Assessment
224272|NCT01837199|Periodontal disease
224273|NCT01837199|Scaling and root planing
224274|NCT01837199|Metronidazole
224275|NCT01837199|Amoxicillin
224276|NCT01837199|Generalized chronic periodontitis
224277|NCT01837199|Periodontal treatment
224278|NCT01837186|Surgery
224279|NCT01837186|NSCLC
224280|NCT01837173|Adenocarcinoma
224281|NCT01837173|Squamous Cell Carcinoma
224282|NCT01837173|Neoadjuvant treatment
224283|NCT01837173|Esophagectomy
224284|NCT01837160|Angiogenesis
224285|NCT01837160|Fibrosis
224286|NCT01837160|Aortic Stenosis
224287|NCT01837160|Imaging
224288|NCT01837160|CT-PET
224289|NCT01837160|PET-CT
224290|NCT01837160|Cardiac MRI
224291|NCT01837147|primary prevention
224292|NCT01837147|sedentary
224293|NCT01837147|overweight
224294|NCT01837147|obesity
224295|NCT01837147|breast cancer
224296|NCT01837147|post-menopausal
224297|NCT01837147|women
224298|NCT01837134|telemedicine
224299|NCT01837134|overweight
224300|NCT01837134|obesity
224301|NCT01837121|not-attended rate
224302|NCT01837121|re-visit
224303|NCT01837121|vision
224304|NCT01837121|knowledge
224305|NCT01837121|satisfaction
224306|NCT01837108|healthy
224307|NCT01837095|Overall survival
224308|NCT01837095|Progression free survival
224309|NCT01837082|Heart Failure
224310|NCT01837082|Iron Deficiency
224311|NCT01837082|Anemia
224312|NCT01837082|Ferric Carboxymaltose
224313|NCT01837069|Hypertension
224314|NCT01837069|Diabetes
224315|NCT01837069|Coronary Artery Disease
224316|NCT01837069|Peripheral Vascular Disease
224317|NCT01837056|Toxoplasma gondii
224318|NCT01837056|Toxocara canis
224319|NCT01837043|Delayed Graft Function
224320|NCT01837043|Renal Transplantation
224321|NCT01837043|Kidney Transplant
224322|NCT01837017|Falls,
224323|NCT01837017|Balance,
224324|NCT01837017|Gait,
224325|NCT01837017|Older adults
224326|NCT01837004|adherence
224327|NCT01837004|cognition
224328|NCT01837004|exercise
224329|NCT01837004|aging
224330|NCT01836991|gastric cancer
224331|NCT01836991|surgery
224332|NCT01836991|surgery safety
224333|NCT01836991|effect
224334|NCT01836965|Aspergers
224335|NCT01836965|Social Skills
224336|NCT01836965|Adolescents
224337|NCT01836965|High-functioning Autism
224338|NCT01836939|psoriasis, oral therapy
224339|NCT01836939|ova
224340|NCT01836939|Trichuris suis ova
224341|NCT01836939|TSO
224342|NCT01836939|CNDO 201 Trichuris suis ova
224343|NCT01836926|sphincter sparing procedures
224344|NCT01836926|intersphincteric resection
224345|NCT01836926|rectal cancer
224346|NCT01836926|low rectal cancer
224347|NCT01836926|sphincter preserving procedures
224348|NCT01836926|Abdominoperineal resection
224349|NCT01836926|laparoscopic resection of rectal cancer
224350|NCT01836926|laparoscopic versus open colorectal resection
224351|NCT01836926|laparoscopic versus open rectal surgery
224352|NCT01836926|neoadjuvant chemo-radiotherapy for rectal cancer
224353|NCT01836913|PET/CT
224354|NCT01836913|Esophageal cancer
224355|NCT01836913|Radiotherapy
224356|NCT01836900|OTSC
224357|NCT01836900|Upper gastrointestinal bleeding
224358|NCT01836887|Polyphenol
224359|NCT01836887|Fruit
224360|NCT01836887|Metabolic
224361|NCT01836887|Healthy
224362|NCT01836874|Migraine
224363|NCT01836874|Indian
224364|NCT01836874|Topiramate
224365|NCT01836861|Phase I
224366|NCT01836861|healthy male volunteers
224367|NCT01836861|ADME
224368|NCT01836861|Bioavailability
224369|NCT01836861|PI3K inhibitor
224370|NCT01836861|Absorption
224371|NCT01836861|Distribution
224372|NCT01836861|Metabolism
224373|NCT01836861|Excretion
224374|NCT01836861|safety
224375|NCT01836848|subarachnoid hemorrhage
224376|NCT01836848|near-infrared-spectroscopy
224377|NCT01836848|indocyanine green
224378|NCT01836848|secondary ischemia
224379|NCT01836835|Hyperemesis gravidarum
224380|NCT01836835|Pregnancy
224381|NCT01836835|Nausea
224382|NCT01836835|Nutritional status
224383|NCT01836835|Questionnaire
224384|NCT01836835|Case-control
224385|NCT01836822|mediastinal lymph node enlargement
224386|NCT01836822|sarcoidosis
224387|NCT01836822|bronchoscopy
224388|NCT01836822|EBUS guided transbronchial needle aspiration (EBUS-TBNA)
224389|NCT01836822|transbronchial needle aspiration (EBUS-TBNA)
224390|NCT01836822|EBUS guided transbronchial forceps biopsy EBUS-TBFB)
224391|NCT01836809|Total Artificial Heart
224392|NCT01836809|Left Ventricular Assist Device
224393|NCT01836809|Natriuretic peptides
224394|NCT01836809|Heart Failure
224395|NCT01836809|Cardiorenal Syndrome
224396|NCT01836783|Allograft
224397|NCT01836783|Amnion Allograft
224398|NCT01836770|Transforaminal Epidural Steroid Injections
224399|NCT01836757|osteoarthritis
224400|NCT01836757|CAM treatments
224401|NCT01836757|MSM
224402|NCT01836731|weight-for age
224403|NCT01836731|height-for-age
224404|NCT01836731|water sanitation facilities
224405|NCT01836731|hygiene behavior
224406|NCT01836718|Hepatitis C Virus
224407|NCT01836718|Liver Transplantation
224408|NCT01836718|Antiviral Therapy
224409|NCT01836718|HCV
224410|NCT01836679|Chidamide,lung cancer
224411|NCT01836653|Bevacizumab
224412|NCT01836653|Cetuximab
224413|NCT01836653|KRAS wild type colorectal cancer
224414|NCT01836653|RAS wild type colorectal cancer
224415|NCT01836653|liver metastasis
224416|NCT01836627|Congenital Muscular Dystrophy
224417|NCT01836627|Collagen VI Deficiency
224418|NCT01836627|Hyperinsufflation
224419|NCT01836627|Cough Assist
224420|NCT01836627|LAMA2- Muscular Dystrophy
224421|NCT01836601|safety
224422|NCT01836601|patient experience
224423|NCT01836601|family-centered rounds
224424|NCT01836575|Advanced NSCLC
224425|NCT01836575|PS2
224426|NCT01836575|Pemetrexed
224427|NCT01836575|First line
224428|NCT01836575|non squamous
224429|NCT01836562|Autism stem cell MNCs
224430|NCT01836536|High grade glioma
224431|NCT01836536|Bevacizumab
224432|NCT01836536|Chemotherapy
224433|NCT01836536|Myeloid Cells
224434|NCT01836536|Treg
224435|NCT01836510|Heart Failure
224436|NCT01836510|Remote Monitoring
224437|NCT01836510|Lung Edema
224438|NCT01836510|Patient Monitoring
224439|NCT01836510|Prediction
224440|NCT01836484|Surgically staged endometrial carcinoma
224441|NCT01836484|Surgically staged cervical carcinoma
224442|NCT01836458|Malaria, KAE609
224443|NCT01836432|Pancreatic Cancer
224444|NCT01836432|Immunotherapy
224445|NCT01836432|Vaccine Therapy
224446|NCT01836419|classic laryngeal mask airway
224447|NCT01836419|elderly patients
224448|NCT01836406|ketorolac
224449|NCT01836406|remote ischemic preconditioning
224450|NCT01836406|partial nephrectomy
224451|NCT01836393|Plai
224452|NCT01836393|Efficacy
224453|NCT01836393|OA knee
224454|NCT01836393|The efficacy study of Plai cream for OA knee
224455|NCT01836367|Actinic Keratosis
224456|NCT01836367|Face
224457|NCT01836367|Scalp
224458|NCT01836367|Ingenol Mebutate
224459|NCT01836354|stroke
224460|NCT01836354|interactive educational intervention
224461|NCT01836354|acute ischemic stroke
224462|NCT01836354|transient ischemic attack
224463|NCT01836341|Afatinib
224464|NCT01836341|Cisplatin
224465|NCT01836341|Carboplatin
224466|NCT01836341|Pemetrexed
224467|NCT01836341|Radiation therapy
224468|NCT01836341|EGFR mutation
224469|NCT01836341|12-279
224470|NCT01836328|Methadone
224471|NCT01836328|Pain
224472|NCT01836328|Neoplasms
224473|NCT01836328|Ratio
224474|NCT01836237|Surgical site infection rate
224475|NCT01836237|Wound protector use
224476|NCT01836237|Whipple
224477|NCT01836211|Chest pain
224478|NCT01836211|Acute coronary syndrome
224479|NCT01836211|Cardiac biomarkers
224480|NCT01836211|Computed coronary tomography angiography
224481|NCT01836211|Emergency department
224482|NCT01836172|The treatment of diabetic complication
224483|NCT01836159|Stroke Rehabilitation
224484|NCT01836159|iPad
224485|NCT01836159|Fine Motor Function
224486|NCT01836159|Ischemic Stroke
224487|NCT01836159|Visual Neglect
224488|NCT01836120|second-line chemotherapy
224489|NCT01836120|Raltitrexed
224490|NCT01836107|Clinical notes
224491|NCT01836107|Communication between physicians
224492|NCT01836107|Quality
224493|NCT01836107|Cross-cultural adaptation
224494|NCT01836094|Methylene Blue
224495|NCT01836094|Memory
224496|NCT01836094|Mental Fatigue
224497|NCT01836094|Brain metabolism
224498|NCT01836094|fMRI
224499|NCT01836094|psychomotor vigilance task (PVT)
224500|NCT01836094|delayed match-to-sample memory task
224501|NCT01836094|PVT
224502|NCT01836094|DMS
224503|NCT01836081|fluid responsiveness
224504|NCT01836081|carotid artery peak velocity variation
224505|NCT01836081|coronary disease
224506|NCT01836068|HIV positive
224507|NCT01836068|HIV-1
224508|NCT01836068|Bone Marrow Transplant
224509|NCT01836068|Allogeneic BMT
224510|NCT01836068|BMT
224511|NCT01836055|Multiple Sclerosis
224512|NCT01836055|White Matter Lesions
224513|NCT01836055|Contrast Agent
224514|NCT01836055|Magnetic Resonance Imaging
224515|NCT01836042|Primary open-angle glaucoma (POAG)
224516|NCT01836042|Trabecular meshwork
224517|NCT01836042|iStent
224518|NCT01836029|SCCHN
224519|NCT01836029|HNSCC
224520|NCT01836016|Pulmonary Disease, Chronic Obstructive
224521|NCT01836016|Comparative effectiveness research
224522|NCT01836016|Medicine, Chinese Traditional
224523|NCT01836016|Humans
224524|NCT01836016|Treatment Outcome
224525|NCT01836003|Pregnancy
224526|NCT01836003|Prevention of Mother to Child Transmission
224527|NCT01836003|Short Message Service (SMS)
224528|NCT01836003|HIV infection
224529|NCT01836003|CD4 testing
224530|NCT01836003|Antiretroviral therapy
224531|NCT01835990|venous thromboembolism
224532|NCT01835990|trauma
224533|NCT01835990|mechanical methods of prophylaxis
224534|NCT01835977|Focal therapy
224535|NCT01835977|Irreversible electroporation
224536|NCT01835977|Unilateral prostate cancer
224537|NCT01835964|Glucose Variability (GV)
224538|NCT01835964|Continuous Glucose Monitor (CGM)
224539|NCT01835951|Simulation
224540|NCT01835951|Debriefing
224541|NCT01835951|Anaesthesia Crisis Management
224542|NCT01835951|Cardiac Arrest
224543|NCT01835951|Pregnancy
224544|NCT01835938|Hepatitis C Virus infection
224545|NCT01835938|entry inhibitor
224546|NCT01835938|kinase inhibitor
224547|NCT01835925|adenocarcinoma of rectum
224548|NCT01835925|rectal cancer
224549|NCT01835925|stage II
224550|NCT01835925|stage III
224551|NCT01835912|performance
224552|NCT01835912|speed
224553|NCT01835912|exertion
224554|NCT01835860|BPH
224555|NCT01835834|zirconia crown
224556|NCT01835821|zirconia
224557|NCT01835821|crown
224558|NCT01835821|IPS e.max CAD
224559|NCT01835808|Fractional flow reserve
224560|NCT01835795|Myofascial Pain Syndromes
224561|NCT01835795|Myofascial Trigger Point
224562|NCT01835795|Low Back Pain
224563|NCT01835795|Lumbago
224564|NCT01835795|Shock Waves, High-Energy
224565|NCT01835795|High-Energy Shock Waves
224566|NCT01835795|Interdisciplinary Health Team
224567|NCT01835795|Multidisciplinary Pain Centers
224568|NCT01835782|ALS
224569|NCT01835782|L-Serine
224570|NCT01835782|BMAA
224571|NCT01835717|Preclinical phase of Alzheimer's disease
224572|NCT01835717|Asymptomatic phase of Alzheimer's disease
224573|NCT01835717|Cognitive normal
224574|NCT01835717|Exogenous factors
224575|NCT01835717|Endogenous factors
224576|NCT01835717|Episodic memory test
224577|NCT01835717|Executive function test
224578|NCT01835717|Memory binding test validation into Spanish
224579|NCT01835717|Memory binding test validation into Catalan
224580|NCT01835691|Chronic Kidney Disease
224581|NCT01835691|Vitamin D
224582|NCT01835691|Vitamin D2
224583|NCT01835691|Vitamin D3
224584|NCT01835652|Exercise
224585|NCT01835652|Parkinson's Disease
224586|NCT01835652|Positron Emission Tomography
224587|NCT01835652|fMRI
224588|NCT01835639|Glomerular Disease
224589|NCT01835639|Vitamin D
224590|NCT01835639|Steroid-resistant nephrotic syndrome
224591|NCT01835639|Minimal change disease
224592|NCT01835639|Focal segmental glomerulosclerosis (FSGS)
224593|NCT01835639|Membranous Nephropathy
224594|NCT01835639|Membranoprolfierative Glomerulonephritis
224595|NCT01835639|immunoglobulin A (IgA) Nephropathy
224596|NCT01835639|FSGS
224597|NCT01835639|IgA Nephropathy
224598|NCT01835626|Locally advanced basal cell carcinoma
224599|NCT01835626|Skin cancer
224600|NCT01835626|Radiation therapy
224601|NCT01835626|Vismodegib
224602|NCT01835626|Head and neck cancer
224603|NCT01835626|Cutaneous malignancy
224604|NCT01835613|Rheumatoid Arthritis
224605|NCT01835613|Early RA
224606|NCT01835613|RA
224607|NCT01835613|IL-6
224608|NCT01835613|IL-6R
224609|NCT01835613|Inhibitor
224610|NCT01835613|Inhibition
224611|NCT01835613|Tocilizumab
224612|NCT01835613|Biomarkers
224613|NCT01835613|DMARDs
224614|NCT01835613|Biological
224615|NCT01835613|DAS
224616|NCT01835613|SDAI
224617|NCT01835613|AR/BIOM
224618|NCT01835613|OEG
224619|NCT01835587|Acute myeloid leukemia,
224620|NCT01835587|myelodysplastic syndromes,
224621|NCT01835587|CC-486, oral Azacitidine,
224622|NCT01835587|transplantation,
224623|NCT01835587|allogeneic,
224624|NCT01835587|HSCT.
224625|NCT01835574|Amphetamine-type substance use
224626|NCT01835561|Hepatic, Liver disease; Pharmacokinetic; Healthy
224627|NCT01835509|Childhood Cancer Survivors
224628|NCT01835496|sickle cell disease
224629|NCT01835496|iron overload
224630|NCT01835496|pharmacokinetics
224631|NCT01835496|Ferriprox
224632|NCT01835496|deferiprone
224633|NCT01835457|Endotoxemia
224634|NCT01835457|Autonomic Nervous System
224635|NCT01835457|Inflammation
224636|NCT01835457|Meditation
224637|NCT01835457|Concentration
224638|NCT01835457|Iceman
224639|NCT01835457|LPS
224640|NCT01835457|Cortisol
224641|NCT01835457|Catecholamines
224642|NCT01835444|Physician Assistant
224643|NCT01835444|Substitution
224644|NCT01835444|Hospital ward care
224645|NCT01835444|Secondary health care
224646|NCT01835418|managed with bedtime administration of lisinopril versus amlodipine
224647|NCT01835392|Remote ischemic preconditioning
224648|NCT01835392|Heart defects, congenital
224649|NCT01835392|cardiac surgery
224650|NCT01835392|Neurodevelopmental outcomes
224651|NCT01835379|Diabetes
224652|NCT01835379|Diabetic Foot Ulcer
224653|NCT01835379|Diabetic Foot Wound
224654|NCT01835379|Non-healing foot wound
224655|NCT01835379|Oasis
224656|NCT01835379|Diabetic neuropathy
224657|NCT01835353|prasugrel
224658|NCT01835353|ST elevation myocardial infarction
224659|NCT01835327|intraoperative, post-operative recovery
224660|NCT01835327|thoracic surgery
224661|NCT01835327|cerebral oximetry
224662|NCT01835262|pain
224663|NCT01835262|Ketamine
224664|NCT01835262|Emergency Medicine
224665|NCT01835262|morphine
224666|NCT01835249|Hypertension
224667|NCT01835249|Nighttime blood pressure
224668|NCT01835236|Breast cancer
224669|NCT01835236|HER2-positive
224670|NCT01835236|Metastases
224671|NCT01835197|Phase 1
224672|NCT01835197|Randomized
224673|NCT01835197|Double Blind
224674|NCT01835197|Placebo-Controlled
224675|NCT01835197|Single- & Multiple Dose Escalation
224676|NCT01835197|Safety
224677|NCT01835197|Tolerability
224678|NCT01835197|PK
224679|NCT01835197|PD
224680|NCT01835197|Pf-04965842
224681|NCT01835132|Scleritis
224682|NCT01835132|IL-1
224683|NCT01835119|gynecological malignancies
224684|NCT01835119|postoperative
224685|NCT01835119|bowel activity
224686|NCT01835119|gum chewing
224687|NCT01835106|Postoperative Care
224688|NCT01835080|Obstructive Sleep Apnea, OSA, Pulmonary Arterial Hypertension, PAH, sleep study, polysomnogram, Respiratory Disturbance Index, RDI
224689|NCT01835067|Macular degeneration
224690|NCT01835067|Submacular haemorrhage
224691|NCT01835054|Mitral regurgitation
224692|NCT01835054|Mitral valve prolapse
224693|NCT01835054|Echocardiography, Doppler
224694|NCT01835054|Stress echocardiography
224695|NCT01835054|Cardiopulmonary exercice testing
224696|NCT01835054|Magnetic Resonance Imaging
224697|NCT01835054|Cardiac neurohormones
224698|NCT01835054|Visceral obesity
224699|NCT01835054|Cardiometabolic risk
224700|NCT01835054|Risk stratification
224701|NCT01835028|Aortic Stenosis
224702|NCT01835028|Low Flow
224703|NCT01835028|Low Gradient
224704|NCT01835028|Left Ventricle
224705|NCT01835028|Echocardiography, Doppler
224706|NCT01835015|First in human
224707|NCT01835015|Safety
224708|NCT01835015|Tolerability
224709|NCT01835015|Serum PK
224710|NCT01835015|Intravitreal (IVT)
224711|NCT01835015|Age-related macular degeneration
224712|NCT01835015|AMD
224713|NCT01835015|Geographic Atrophy
224714|NCT01835015|Choroidal neovascularization
224715|NCT01835002|transcorneal electrostimulation
224716|NCT01834976|cardiac biomarker
224717|NCT01834976|congenital heart disease
224718|NCT01834976|surgery
224719|NCT01834937|ExAblate
224720|NCT01834937|MRgFUS
224721|NCT01834937|Bone Metastases
224722|NCT01834937|Pain Palliation
224723|NCT01834924|Health literacy
224724|NCT01834924|Patient education
224725|NCT01834911|Huntington disease
224726|NCT01834911|HD
224727|NCT01834911|tetrabenazine
224728|NCT01834911|Stroop
224729|NCT01834898|postoperative
224730|NCT01834898|analgesia
224731|NCT01834898|adverse effects
224732|NCT01834898|opioid
224733|NCT01834898|oxycodone
224734|NCT01834885|COPD
224735|NCT01834859|weight reduction programs
224736|NCT01834859|diet
224737|NCT01834859|Caloric restriction
224738|NCT01834859|weight loss
224739|NCT01834859|weight gain
224740|NCT01834846|comparative study
224741|NCT01834846|Cardiac Surgical Procedures
224742|NCT01834833|Acute heart failure; rehospitalisation; education; follow-up
224743|NCT01834820|Bronchiolitis
224744|NCT01834820|Epinephrine
224745|NCT01834820|Dexamethasone
224746|NCT01834820|Hospitalization
224747|NCT01834820|Hypertonic Saline
224748|NCT01834794|Tobacco Use
224749|NCT01834781|multiple chemical sensitivity, re5 therapy, pulsed electromagnetic fields
224750|NCT01834742|Moviprep
224751|NCT01834742|PEG3350
224752|NCT01834742|Laxative
224753|NCT01834742|Stool Output
224754|NCT01834690|Liver transplantation/epidemiology
224755|NCT01834690|Liver transplantation/pharmacology
224756|NCT01834690|Health status/drug effects
224757|NCT01834690|Agents, immunosuppressive agents
224758|NCT01834677|Depression
224759|NCT01834677|Neurocognition
224760|NCT01834677|Electroconvulsive Therapy (ECT)
224761|NCT01834677|Parkinson's Disease
224762|NCT01834664|Ataxic Infantile Cerebral Palsy stem cell therapy
224763|NCT01834651|liver metastasis
224764|NCT01834651|lung metastasis
224765|NCT01834651|metastatic castrate-resistant
224766|NCT01834651|prostate cancer
224767|NCT01834638|schizophrenia
224768|NCT01834612|blood loss, hemorrhage, hemorrhagic shcok
224769|NCT01834599|placental oxygenation
224770|NCT01834599|obstetric anesthesia
224771|NCT01834599|NIRS
224772|NCT01834599|cerebral oximetry
224773|NCT01834599|cerebral oximeter
224774|NCT01834573|inflammatory bowel disease
224775|NCT01834573|IBD
224776|NCT01834573|quality of life
224777|NCT01834573|Inflammatory Bowel Disease Questionnaire
224778|NCT01834560|deep brain stimulation
224779|NCT01834560|subgenual cortex (CG25)
224780|NCT01834547|chess, cognition
224781|NCT01834521|Breast cancer
224782|NCT01834521|psychosocial
224783|NCT01834521|website
224784|NCT01834521|empowerment
224785|NCT01834508|Experienced Treatment
224786|NCT01834495|Peripheral artery disease
224787|NCT01834495|atherosclerosis
224788|NCT01834495|stent
224789|NCT01834482|seizures
224790|NCT01834482|epilepsy
224791|NCT01834482|adult
224792|NCT01834482|intractable
224793|NCT01834482|medically refractory
224794|NCT01834482|Atkins
224795|NCT01834482|ketogenic
224796|NCT01834482|diet
224797|NCT01834469|Ovarian,metastasis
224798|NCT01834456|Medically Complex Children
224799|NCT01834456|Family Experience in Healthcare
224800|NCT01834456|Patient Centered Care
224801|NCT01834456|Family Centered Care
224802|NCT01834456|Case Management
224803|NCT01834456|Care Management
224804|NCT01834456|Care Coordination
224805|NCT01834456|Care Plan
224806|NCT01834456|Extensivist
224807|NCT01834456|Medical Home
224808|NCT01834456|Children with Special Health Care Needs
224809|NCT01834456|Coordinated Care
224810|NCT01834456|Quality in Healthcare
224811|NCT01834456|Satisfaction in Healthcare
224812|NCT01834456|Cost
224813|NCT01834456|Utilization
224814|NCT01834456|Impact on Family
224815|NCT01834456|Quality of Life
224816|NCT01834456|Palliative Care
224817|NCT01834456|Complex Chronic Conditions
224818|NCT01834456|Life-limiting illness
224819|NCT01834456|Integrative Care
224820|NCT01834456|Primary Care
224821|NCT01834456|Comprehensive Care
224822|NCT01834456|Behavioral Care
224823|NCT01834443|spatial neglect
224824|NCT01834443|galvanic vestibular stimulation as therapy
224825|NCT01834417|Pressure ulcer, spinal cord injury, on-board device
224826|NCT01834404|Obesity
224827|NCT01834404|BMI
224828|NCT01834404|Incretin
224829|NCT01834404|Satiety
224830|NCT01834404|Phentermine
224831|NCT01834404|Topiramate
224832|NCT01834378|diabetes
224833|NCT01834378|insulin resistance
224834|NCT01834378|exercise
224835|NCT01834365|Hypertension
224836|NCT01834352|Walnut hypersensitivity
224837|NCT01834352|Tree nut hypersensitivity
224838|NCT01834339|vestibuloplasty
224839|NCT01834326|dental implants
224840|NCT01834326|deficient keratinized oral mucosa
224841|NCT01834313|Willingness-to-pay
224842|NCT01834313|Patient-centredness
224843|NCT01834313|Health insurers
224844|NCT01834313|Fertility care
224845|NCT01834300|Hepatic insulin sensitivity
224846|NCT01834300|Muscle insulin sensitivity
224847|NCT01834300|B cell function
224848|NCT01834300|VLDL1 TG metabolism
224849|NCT01834300|VLDL2 TG metabolism
224850|NCT01834287|Physical Activity
224851|NCT01834287|Latinas
224852|NCT01834287|Web-based
224853|NCT01834287|Spanish-language
224854|NCT01834274|Drug Therapy
224855|NCT01834261|oxytocin
224856|NCT01834261|trust
224857|NCT01834261|kinship
224858|NCT01834261|kin selection
224859|NCT01834235|Pancreatic neoplasms
224860|NCT01834235|Pancreatic cancer
224861|NCT01834235|Pancreatic cancer, adult
224862|NCT01834235|Adenoma of the pancreas
224863|NCT01834235|Carcinoma of the pancreas
224864|NCT01834209|Prostate neoplasms
224865|NCT01834209|Prostate cancer
224866|NCT01834209|Metastatic prostate cancer
224867|NCT01834209|Metatatic castration resistant prostate cancer
224868|NCT01834209|Abiraterone acetate
224869|NCT01834209|Prednisone
224870|NCT01834209|Prednisolone
224871|NCT01834209|Early access program
224872|NCT01834196|retinal vascular disease
224873|NCT01834196|Swept-Source Ocular Coherence Tomography
224874|NCT01834196|SSOCT
224875|NCT01834183|Metastatic
224876|NCT01834170|Pancreatic cancer
224877|NCT01834170|Pancreatic adenocarcinoma
224878|NCT01834170|Endoscopic ultrasound
224879|NCT01834144|Type 1 Diabetes
224880|NCT01834144|Hypoglycaemia
224881|NCT01834144|Glycaemic variability
224882|NCT01834144|Vigorous Intensity Physical Activity
224883|NCT01834144|Continuous Glucose Monitoring
224884|NCT01834131|hypertension
224885|NCT01834131|community health worker
224886|NCT01834131|home health education
224887|NCT01834131|medication adherence
224888|NCT01834131|mobile health
224889|NCT01834131|physician education
224890|NCT01834131|home blood pressure monitoring
224891|NCT01834131|implementation
224892|NCT01834105|Postmenopausal osteoporosis; Kidney Yin deficiency syndrome; Liuwei dihuang pill; CLCF1; JAK - STAT signal pathway
224893|NCT01834092|Abdominal Aortic Aneurism
224894|NCT01834092|Endothelia
224895|NCT01834092|Glycocalyx
224896|NCT01834092|Reperfusion
224897|NCT01834092|Plasma
224898|NCT01834079|Optic Atrophy,Stem cell therapy
224899|NCT01834066|muscular Dystrophy stem cell
224900|NCT01834053|Huntington Disease,stem cell therapy
224901|NCT01834040|Duchenne Muscular Dystrophy
224902|NCT01834040|Muscular Dystrophy
224903|NCT01834040|Myopathy
224904|NCT01834027|music
224905|NCT01834027|stress
224906|NCT01834027|anxiety
224907|NCT01834027|post-surgical
224908|NCT01834027|pain
224909|NCT01834014|Liver only metastasis from KRAS Exon 2 wild type
224910|NCT01834014|Liver only metastasis from RAS wild type
224911|NCT01834001|MRI
224912|NCT01834001|Prostate Cancer
224913|NCT01834001|MRI-Guided Biopsy
224914|NCT01834001|Radiation
224915|NCT01834001|Biochemical Failure
224916|NCT01833988|bionic pancreas
224917|NCT01833988|artificial pancreas
224918|NCT01833988|insulin
224919|NCT01833988|glucagon
224920|NCT01833988|continuous glucose monitoring (CGM)
224921|NCT01833988|outpatient
224922|NCT01833988|insulin pump
224923|NCT01833988|pediatrics
224924|NCT01833988|children
224925|NCT01833988|camp
224926|NCT01833988|summer camp
224927|NCT01833975|Spinal Cord Injury stem cell
224928|NCT01833962|Lumbar fusion rates
224929|NCT01833962|Actifuse synthetic bone graft
224930|NCT01833962|Baxter Healthcare
224931|NCT01833962|Other synthetic bone graft
224932|NCT01833949|polycystic ovary syndrome,laparoscopic ovarian drilling
224933|NCT01833936|Achilles
224934|NCT01833923|Advanced cancer
224935|NCT01833910|Cardiopulmonary Resuscitation
224936|NCT01833910|Education
224937|NCT01833897|Bipolar Disorder
224938|NCT01833884|Hodgkin Lymphoma, Adult
224939|NCT01833884|Cytokines
224940|NCT01833884|TARC
224941|NCT01833884|IL-6
224942|NCT01833884|IL1-RA
224943|NCT01833884|sCD30
224944|NCT01833884|TNFR1
224945|NCT01833845|HCV
224946|NCT01833845|Hepatitis C
224947|NCT01833845|Hep-C
224948|NCT01833832|Synergy for Cisplatin and Hyperthermia
224949|NCT01833832|Rare Tumor
224950|NCT01833832|Poor Prognosis
224951|NCT01833819|Laparoscopic cholecystectomy,
224952|NCT01833819|Total intravenous anesthesia,
224953|NCT01833819|Propofol,
224954|NCT01833819|Dexmedetomidine,
224955|NCT01833819|Lidocaine,
224956|NCT01833819|Remifentanil,
224957|NCT01833819|Postoperative analgesic consumption,
224958|NCT01833819|Postoperative nausea and vomiting
224959|NCT01833793|Mirena
224960|NCT01833793|Contraception
224961|NCT01833793|Amenorrhea
224962|NCT01833780|carriage status
224963|NCT01833780|Culture
224964|NCT01833780|PCR
224965|NCT01833754|Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment
224966|NCT01833715|Pain, Postoperative
224967|NCT01833715|Analgesics, Opioid
224968|NCT01833715|Methadone
224969|NCT01833715|Morphine
224970|NCT01833702|Sickle cell
224971|NCT01833702|Pain
224972|NCT01833689|glucose response
224973|NCT01833689|glycaemic index
224974|NCT01833676|sevoflurane
224975|NCT01833676|desflurane
224976|NCT01833676|protective airway reflexes
224977|NCT01833676|elderly
224978|NCT01833663|Overactive Bladder
224979|NCT01833663|Solifenacin Succinate Tablets
224980|NCT01833663|Estrogen
224981|NCT01833650|thyroid cancer
224982|NCT01833650|radioiodine treatment
224983|NCT01833650|xerostomia
224984|NCT01833650|sialadenitis
224985|NCT01833637|Advanced Care Planning
224986|NCT01833637|Palliative Care
224987|NCT01833637|Women
224988|NCT01833598|Chronic tendinopathy
224989|NCT01833598|platelet rich plasma
224990|NCT01833598|tendonitis
224991|NCT01833598|percutaneous tendon tenotomy
224992|NCT01833598|pain
224993|NCT01833598|shoulder
224994|NCT01833598|knee
224995|NCT01833598|ankle
224996|NCT01833598|foot
224997|NCT01833585|critical limb ischemia
224998|NCT01833585|atherosclerosis
224999|NCT01833585|ischemic ulcer
225000|NCT01833585|rest pain
225001|NCT01833585|gangrene
225002|NCT01833572|epidermal growth factor receptor
225003|NCT01833572|EGFR mutation
225004|NCT01833572|Tyrosine kinase inhibitor
225005|NCT01833572|gefitinib
225006|NCT01833572|neo-adjuvant therapy
225007|NCT01833546|Solid tumor
225008|NCT01833546|Pancreatic cancer
225009|NCT01833546|TH-302
225010|NCT01833546|gemcitabine
225011|NCT01833546|Evofosfamide
225012|NCT01833533|Chronic Hepatitis C
225013|NCT01833533|Hepatitis C Virus
225014|NCT01833533|Hepatitis C Genotype 1a
225015|NCT01833533|Hepatitis C
225016|NCT01833533|Treatment-Naïve
225017|NCT01833533|Interferon-Free
225018|NCT01833533|Paritaprevir
225019|NCT01833533|Ombitasvir
225020|NCT01833533|Dasabuvir
225021|NCT01833533|Ribavirin
225022|NCT01833533|Viekira PAK
225023|NCT01833520|Sarcoma
225024|NCT01833520|Osteosarcoma
225025|NCT01833520|recurrent or metastatic
225026|NCT01833520|Ra-223 dichloride
225027|NCT01833520|Radium-223 chloride
225028|NCT01833520|Alpharadin
225029|NCT01833507|increased activity
225030|NCT01833507|weight loss
225031|NCT01833507|obesity
225032|NCT01833494|Hemodialysis
225033|NCT01833494|Hyperphosphatemia
225034|NCT01833481|Surgical approach
225035|NCT01833481|Direct-anterior
225036|NCT01833481|Anterior-lateral
225037|NCT01833481|Posterior-lateral
225038|NCT01833481|Hip implant
225039|NCT01833481|Total Hip Arthroplasty
225040|NCT01833481|Total Hip replacement
225041|NCT01833481|Hip replacement
225042|NCT01833481|Hip prosthesis
225043|NCT01833468|ankylosing spondylitis
225044|NCT01833468|Psoriatic arthritis
225045|NCT01833468|Foot
225046|NCT01833468|FAOS
225047|NCT01833468|SpA-TRI
225048|NCT01833442|OCD
225049|NCT01833442|YBOCS
225050|NCT01833429|Resistant hypertension
225051|NCT01833429|White-coat phenomenon
225052|NCT01833429|Heart rate variability
225053|NCT01833429|autonomic activity
225054|NCT01833416|CMV infection
225055|NCT01833416|CMV disease
225056|NCT01833416|Natural history
225057|NCT01833416|Kidney transplant
225058|NCT01833403|bariatric surgery, l
225059|NCT01833403|iver insulin resistance,
225060|NCT01833390|Hyperpolarized Xenon
225061|NCT01833390|HXe
225062|NCT01833390|MagniXene
225063|NCT01833377|obesity
225064|NCT01833377|overweight
225065|NCT01833377|BMI
225066|NCT01833364|Parkinson's Disease
225067|NCT01833364|Deep Brain Stimulation
225068|NCT01833364|Peripheral Nerve Graft
225069|NCT01833351|Phase I
225070|NCT01833351|safety and pharmacokinetics,
225071|NCT01833351|intravenous ascorbate,
225072|NCT01833351|IV Vitamin C,
225073|NCT01833351|Oncology
225074|NCT01833338|Non ST elevation myocardial infarction
225075|NCT01833338|optical coherence tomography
225076|NCT01833338|intravascular ultrasound
225077|NCT01833338|multi-slice computed tomography
225078|NCT01833325|Age-Related Macular Degeneration
225079|NCT01833325|Macular Degeneration
225080|NCT01833325|Proton radiation
225081|NCT01833325|Choroidal Neovascular Membranes
225082|NCT01833312|acute ischemic stroke
225083|NCT01833312|hypothermia
225084|NCT01833299|TACE
225085|NCT01833299|Sorafenib
225086|NCT01833299|overall survival
225087|NCT01833299|time to progression
225088|NCT01833286|hepatocellular carcinoma
225089|NCT01833286|repeat hepatectomy
225090|NCT01833286|radiofrequency ablation
225091|NCT01833286|transcatheter arterial chemoembolization
225092|NCT01833247|epilepsy
225093|NCT01833247|lactic acid
225094|NCT01833247|saliva
225095|NCT01833247|postictal
225096|NCT01833234|epilepsy
225097|NCT01833234|quality of life
225098|NCT01833234|seizure severity
225099|NCT01833234|antiepileptic drug side effects
225100|NCT01833234|questionnaire
225101|NCT01833234|patient reported outcomes
225102|NCT01833221|facial palsy
225103|NCT01833221|lengthening temporalis myoplasty
225104|NCT01833221|neurotization of facial muscles
225105|NCT01833195|molecular diagnostics
225106|NCT01833195|heart transplantation
225107|NCT01833195|risk factors
225108|NCT01833195|prognosis
225109|NCT01833182|falls in community dwelling older adults
225110|NCT01833182|falls and ADL performance
225111|NCT01833182|tailored home intervention
225112|NCT01833169|Solid tumor
225113|NCT01833169|malignancy
225114|NCT01833169|hematologi malignancy
225115|NCT01833169|PI3K pathway activation
225116|NCT01833169|BKM120
225117|NCT01833169|signature
225118|NCT01833169|AML, acute myelogenous leukemia
225119|NCT01833169|cervical, ovarian
225120|NCT01833169|hepatobiliary
225121|NCT01833169|buparlisib
225122|NCT01833156|local edema
225123|NCT01833156|dielectric constant values
225124|NCT01833156|validation study
225125|NCT01833143|KRAS-Mutant
225126|NCT01833143|Bortezomib
225127|NCT01833143|KRAS G12D
225128|NCT01833143|12-222
225129|NCT01833117|Dry eye
225130|NCT01833117|Tear film
225131|NCT01833117|Tear break-up time
225132|NCT01833117|Ocular surface
225133|NCT01833117|Eye drops
225134|NCT01833104|Healthy subjects
225135|NCT01833039|Mantle Cell Lymphoma
225136|NCT01833039|Ibrutinib
225137|NCT01833026|pulmonary disease
225138|NCT01833026|chronic obstructive airflow
225139|NCT01833026|spirometry
225140|NCT01833026|primary healthcare
225141|NCT01833026|guideline-based therapy
225142|NCT01833013|Endometriosis
225143|NCT01833013|Cohort study
225144|NCT01833013|fertility
225145|NCT01833013|pregnancy
225146|NCT01833013|assisted reproductive technics
225147|NCT01833013|laparoscopy
225148|NCT01833000|rectal bleeding
225149|NCT01833000|necrotizing enterolitis
225150|NCT01833000|splanchnic oxygenation
225151|NCT01833000|mesenteric doppler
225152|NCT01832987|co-trimoxazole
225153|NCT01832987|sulfamethoxazole
225154|NCT01832987|tuberculosis
225155|NCT01832987|pharmacokinetics
225156|NCT01832974|Adrenal Gland Cancer
225157|NCT01832974|Treatment Refractory Malignancies
225158|NCT01832974|Metastatic Cancer
225159|NCT01832961|COPD
225160|NCT01832961|physiotherapy care
225161|NCT01832961|lung function testing
225162|NCT01832961|inflammation
225163|NCT01832935|Glargin
225164|NCT01832935|NPH
225165|NCT01832935|Cost-effectiveness
225166|NCT01832922|bendamustine
225167|NCT01832922|rituximab
225168|NCT01832922|Chronic Lymphocytic Leukemia
225169|NCT01832922|comorbidities
225170|NCT01832922|renal insufficiency
225171|NCT01832909|metabolizable energy
225172|NCT01832909|walnuts
225173|NCT01832909|Atwater factors
225174|NCT01832909|energy value
225175|NCT01832896|Hereditary Angioedema
225176|NCT01832896|Children
225177|NCT01832896|Adolescents
225178|NCT01832896|Ecallantide
225179|NCT01832857|metastatic
225180|NCT01832857|advanced
225181|NCT01832857|solid tumor
225182|NCT01832857|cancer
225183|NCT01832857|colon cancer
225184|NCT01832857|hepatocellular carcinoma
225185|NCT01832857|breast cancer
225186|NCT01832857|lung cancer
225187|NCT01832857|gastric cancer
225188|NCT01832857|esophageal cancer
225189|NCT01832844|Scan control
225190|NCT01832844|Epidural infiltration
225191|NCT01832844|visual analogue scale (VAS)
225192|NCT01832818|Total Disc Replacement
225193|NCT01832805|depression
225194|NCT01832779|Achalasia
225195|NCT01832766|schizophrenia
225196|NCT01832766|dronabinol
225197|NCT01832766|P50
225198|NCT01832766|cannabis
225199|NCT01832766|memory
225200|NCT01832766|symptoms
225201|NCT01832753|Down syndrome
225202|NCT01832753|subclinical hypothyroidism
225203|NCT01832753|thyroid
225204|NCT01832753|levothyroxine
225205|NCT01832740|young healthy subjects
225206|NCT01832740|brain stimulation
225207|NCT01832740|tSOS
225208|NCT01832740|tDCS
225209|NCT01832740|sleep
225210|NCT01832740|memory
225211|NCT01832740|memory consolidation
225212|NCT01832727|multiple myeloma
225213|NCT01832727|oprozomib
225214|NCT01832727|OPZ
225215|NCT01832727|ONX 0912
225216|NCT01832727|Onyx
225217|NCT01832727|proteasome inhibitor
225218|NCT01832727|oprozomib tablets
225219|NCT01832714|Concussion
225220|NCT01832714|mTBI
225221|NCT01832714|military
225222|NCT01832714|MACE
225223|NCT01832714|NKI
225224|NCT01832714|NOTC
225225|NCT01832714|VNG
225226|NCT01832714|VOG
225227|NCT01832714|Neuro Kinetics
225228|NCT01832714|oculomotor
225229|NCT01832714|vestibular
225230|NCT01832714|reaction time
225231|NCT01832714|I-Portal
225232|NCT01832714|eye tracking
225233|NCT01832714|Dizziness Handicap Inventory
225234|NCT01832688|iron and folic acid supplements
225235|NCT01832688|anemia
225236|NCT01832688|gestational weight gain
225237|NCT01832675|Endoscopy
225238|NCT01832675|Anesthetics, Local
225239|NCT01832675|Bupivacaine
225240|NCT01832675|Lidocaine
225241|NCT01832649|Exercise
225242|NCT01832649|Cocaine dependence
225243|NCT01832636|L-Alanyl-L-Glutamine
225244|NCT01832636|Environmental enteric dysfunction
225245|NCT01832636|Tropical enteropathy
225246|NCT01832623|Vitamin D
225247|NCT01832623|bone
225248|NCT01832623|cardiovascular status
225249|NCT01832623|nutritional status
225250|NCT01832584|Red Grapes
225251|NCT01832584|polyphenols
225252|NCT01832584|cyclists
225253|NCT01832584|resveratrol
225254|NCT01832584|aerobic fitness
225255|NCT01832584|trained
225256|NCT01832571|HIV
225257|NCT01832571|PrEP
225258|NCT01832571|Female Sex Workers
225259|NCT01832571|Kenya
225260|NCT01832545|Aquatic exercise
225261|NCT01832545|Knee Osteoarthritis
225262|NCT01832545|Exercise
225263|NCT01832545|Pain
225264|NCT01832545|Obesity.
225265|NCT01832532|Sleep Apnea
225266|NCT01832532|Sleep Disordered Breathing
225267|NCT01832532|liraglutide
225268|NCT01832532|glucagon-like peptide-1 agonist
225269|NCT01832532|Orexin
225270|NCT01832532|leptin,
225271|NCT01832519|Cystic Fibrosis
225272|NCT01832519|CF
225273|NCT01832519|MRI
225274|NCT01832519|vascularization
225275|NCT01832519|perfusion
225276|NCT01832506|Solid Tumors
225277|NCT01832506|MSC2156119J
225278|NCT01832506|c-Met inhibitor
225279|NCT01832506|Japanese
225280|NCT01832506|Phase 1
225281|NCT01832480|Trichomonas vaginalis
225282|NCT01832480|metronidazole
225283|NCT01832467|cetuximab-based chemotherapy
225284|NCT01832467|previously treated
225285|NCT01832454|cerebral palsy stem cells [MNCS]
225286|NCT01832441|Diabetes Mellitus stem cells [MNCS ]
225287|NCT01832415|First line treatment
225288|NCT01832415|Ovarian cancer
225289|NCT01832415|Avastin
225290|NCT01832415|fallopian tube or primary peritoneal
225291|NCT01832402|Advanced Cancers
225292|NCT01832402|Exercise-Induced Breakthrough Dyspnea
225293|NCT01832402|Shortness of breath
225294|NCT01832402|Fentanyl pectin nasal spray
225295|NCT01832402|Placebo nasal spray
225296|NCT01832402|Walk test
225297|NCT01832402|Questionnaires
225298|NCT01832402|Surveys
225299|NCT01832402|Mental ability tests
225300|NCT01832389|Subarachnoid Haemorrhage (SAH)
225301|NCT01832389|vasospasm
225302|NCT01832389|delayed cerebral ischaemia (DCI)
225303|NCT01832389|goal directed therapy (GDT)
225304|NCT01832389|Pulse Contour Cardiac Output (PiCCO)
225305|NCT01832376|Calcific tendinitis
225306|NCT01832376|Shoulder
225307|NCT01832376|Needle lavage
225308|NCT01832376|Ultrasound-guided
225309|NCT01832363|Severe asthma
225310|NCT01832363|Bronchial thermoplasty
225311|NCT01832363|MagniXene
225312|NCT01832363|Hyperpolarized Xenon
225313|NCT01832363|HXe
225314|NCT01832363|HyXe
225315|NCT01832324|Food Allergy
225316|NCT01832324|Eosinophilic Esophagitis
225317|NCT01832324|Food Protein Induced Enterocolitis
225318|NCT01832324|iNKT Cells
225319|NCT01832324|T cells
225320|NCT01832311|type 2 diabetes mellitus
225321|NCT01832311|cataract
225322|NCT01832311|cytokines
225323|NCT01832311|chemokines
225324|NCT01832311|aqueous humor
225325|NCT01832298|Tolerability
225326|NCT01832298|Pharmacokinetics
225327|NCT01832285|fluvoxamine
225328|NCT01832285|cognition
225329|NCT01832285|schizophrenia
225330|NCT01832285|protein expression
225331|NCT01832272|Osteoarthritis
225332|NCT01832272|Knee
225333|NCT01832272|Total knee arthroplasty
225334|NCT01832272|Tourniquet
225335|NCT01832272|Early release
225336|NCT01832272|Reinflation
225337|NCT01832246|endoscopy
225338|NCT01832246|endosonography
225339|NCT01832246|stomach cancer
225340|NCT01832246|tumor staging
225341|NCT01832220|Genomics
225342|NCT01832220|Microbiome
225343|NCT01832220|Microflora
225344|NCT01832220|Virome
225345|NCT01832220|Alpha-1
225346|NCT01832194|Scrotal pain
225347|NCT01832194|Botox
225348|NCT01832181|Diabetes
225349|NCT01832181|MiTy
225350|NCT01832181|Metformin in Women
225351|NCT01832181|Type 2 Diabetes Pregnancy
225352|NCT01832155|Yoga
225353|NCT01832155|Knee osteoarthritis
225354|NCT01832155|Symptom management
225355|NCT01832155|Older women
225356|NCT01832155|Pain
225357|NCT01832155|Stiffness
225358|NCT01832155|Physical function)
225359|NCT01832155|Physical function of the lower extremities
225360|NCT01832155|Quality of sleep
225361|NCT01832155|Quality of life
225362|NCT01832116|Pancreatic cancer
225363|NCT01832116|Ovarian cancer
225364|NCT01832077|sensibility
225365|NCT01832077|specificity
225366|NCT01832077|positive predictive value
225367|NCT01832077|negative predictive value
225368|NCT01832077|Cost-effectiveness
225369|NCT01832064|chronic disease
225370|NCT01832064|patient education
225371|NCT01832064|self management
225372|NCT01832051|HER2-PET
225373|NCT01832051|89Zr-trastuzumab
225374|NCT01832051|metastatic breast cancer
225375|NCT01832051|clinical dilemma
225376|NCT01832038|Lacosamide
225377|NCT01832038|Epilepsy
225378|NCT01832038|Partial-onset Seizures
225379|NCT01832025|intraoperative
225380|NCT01832025|postoperative
225381|NCT01832025|complications
225382|NCT01832025|discomfort
225383|NCT01832025|external
225384|NCT01832025|internal
225385|NCT01832025|maxillary
225386|NCT01832025|elevation
225387|NCT01832025|implant
225388|NCT01832025|reconstruction
225389|NCT01832025|bone
225390|NCT01832025|sinus
225391|NCT01832012|Eliciting which type of refresher provides the greatest improvement in BLS CPR skills.
225392|NCT01831999|Web-based
225393|NCT01831999|HIV Assessment
225394|NCT01831999|Outreach
225395|NCT01831999|Retention
225396|NCT01831999|Substance Abuse Treatment
225397|NCT01831986|Schizophrenia
225398|NCT01831986|Schizoaffective disorder
225399|NCT01831986|Pregnenolone
225400|NCT01831986|L-Theanine
225401|NCT01831986|Augmentation
225402|NCT01831960|Intrepid
225403|NCT01831960|cortexolone
225404|NCT01831960|cortexolone 17α-propionate
225405|NCT01831960|anti-androgen
225406|NCT01831947|age-related macular degeneration
225407|NCT01831947|Ranibizumab
225408|NCT01831934|Mitochondrial Disorder; Immune Response; Influenza Vaccine
225409|NCT01831921|pre diabetes
225410|NCT01831921|obesity
225411|NCT01831921|weight loss
225412|NCT01831921|lifestyle
225413|NCT01831921|prevention
225414|NCT01831908|cardiovascular health, stroke, ischemic heart disease
225415|NCT01831895|Hypertension
225416|NCT01831895|Carotid Sinus
225417|NCT01831869|Subclinical hypothyroidism
225418|NCT01831869|L-thyroxine
225419|NCT01831869|Lipid
225420|NCT01831869|endothelial function
225421|NCT01831869|inflammatory factor
225422|NCT01831869|adipocytokine
225423|NCT01831856|Cardiovascular diseases
225424|NCT01831856|Chronic Heart Failure
225425|NCT01831843|core body temperature
225426|NCT01831843|humidity
225427|NCT01831843|circuit temperature
225428|NCT01831830|traumatic brain injury
225429|NCT01831830|occupational therapy
225430|NCT01831830|family
225431|NCT01831804|diabetic foot ulcer
225432|NCT01831804|pharmacodynamics
225433|NCT01831804|pharmacokinetics
225434|NCT01831804|ischemic
225435|NCT01831791|male pattern hair loss
225436|NCT01831791|safety
225437|NCT01831791|Dutasteride
225438|NCT01831791|efficacy
225439|NCT01831791|hair growth
225440|NCT01831791|Androgenetic alopecia
225441|NCT01831791|hair restoration
225442|NCT01831778|mammography
225443|NCT01831778|screening
225444|NCT01831752|Diabetes
225445|NCT01831752|Type 1
225446|NCT01831752|Continuous glucose monitor
225447|NCT01831739|Genomics
225448|NCT01831739|Microbiome
225449|NCT01831739|Microflora
225450|NCT01831739|Virome
225451|NCT01831726|Solid tumor malignancy
225452|NCT01831726|hematologic malignancy
225453|NCT01831726|mutation
225454|NCT01831726|translocations
225455|NCT01831726|FGFR
225456|NCT01831726|PDGFR
225457|NCT01831726|VEGF
225458|NCT01831726|cKIT
225459|NCT01831726|FLT3
225460|NCT01831726|CSR1
225461|NCT01831726|Trk
225462|NCT01831726|RET
225463|NCT01831726|TKI258
225464|NCT01831726|dovitinib
225465|NCT01831726|signature
225466|NCT01831726|AML
225467|NCT01831726|acute myelogenous leukemia
225468|NCT01831726|GIST
225469|NCT01831726|gastrointestinal stromal tumor
225470|NCT01831726|Head and Neck cancer
225471|NCT01831726|Melanoma
225472|NCT01831726|NSCLC
225473|NCT01831726|non-small cell lung carcinoma
225474|NCT01831726|lung cancer
225475|NCT01831726|ovarian cancer
225476|NCT01831726|thyroid cancer
225477|NCT01831726|amplification
225478|NCT01831648|IGF1
225479|NCT01831648|standards
225480|NCT01831648|Assays
225481|NCT01831648|Z-score
225482|NCT01831648|Healthy volunteers
225483|NCT01831648|Population
225484|NCT01831622|Decision-Making
225485|NCT01831622|functional MRI
225486|NCT01831622|pharmacological MRI
225487|NCT01831622|Reinforcement Learning
225488|NCT01831622|Methylphenidate
225489|NCT01831609|Gastrointestinal
225490|NCT01831609|Genitourinary
225491|NCT01831609|Rare Cancer
225492|NCT01831583|sleep apnea
225493|NCT01831570|Hand osteoarthritis
225494|NCT01831570|predictive factors
225495|NCT01831570|erosive hand OA
225496|NCT01831544|Heart Failure
225497|NCT01831518|Heart Failure
225498|NCT01831518|Cardiac Resynchronization Therapy
225499|NCT01831518|ECG Imaging
225500|NCT01831518|Body Surface Mapping
225501|NCT01831505|personalized medicine
225502|NCT01831505|in vivo drug sensitivity
225503|NCT01831505|chemotherapy
225504|NCT01831505|lymphoma
225505|NCT01831505|microinjection
225506|NCT01831492|performance
225507|NCT01831492|acidosis
225508|NCT01831492|oxidative stress
225509|NCT01831492|inflammation
225510|NCT01831492|oxygen uptake
225511|NCT01831479|Pharmacokinetics, drug-drug interaction
225512|NCT01831466|plaque psoriasis
225513|NCT01831466|vulgaris
225514|NCT01831466|topical treatment
225515|NCT01831466|skin diseases
225516|NCT01831466|papulosquamous
225517|NCT01831466|Tofacitinib
225518|NCT01831466|CP-690550
225519|NCT01831466|Xeljanz
225520|NCT01831466|psoriasis
225521|NCT01831466|moderate
225522|NCT01831466|severe
225523|NCT01831466|itch
225524|NCT01831466|nail psoriasis
225525|NCT01831453|omega-3
225526|NCT01831453|recurrent aphthous stomatitis
225527|NCT01831453|quality of life
225528|NCT01831440|depression
225529|NCT01831440|remission
225530|NCT01831440|Pharmacotherapy
225531|NCT01831440|psychotherapy
225532|NCT01831440|neuroimaging
225533|NCT01831440|psychology
225534|NCT01831427|ulcerative colitis
225535|NCT01831427|moderate
225536|NCT01831427|severe
225537|NCT01831414|Lung function
225538|NCT01831414|Water immersion
225539|NCT01831414|Balneotherapy
225540|NCT01831401|Acetabular component inclination
225541|NCT01831388|Dyspnea
225542|NCT01831388|Breath Training Exercise
225543|NCT01831388|12-261
225544|NCT01831336|International
225545|NCT01831336|Multicenter
225546|NCT01831336|Observational registry
225547|NCT01831336|Orsiro Drug Eluting Stent (DES)
225548|NCT01831336|Stenting
225549|NCT01831336|Treatment of Coronary Artery Disease
225550|NCT01831336|Coronary revascularization
225551|NCT01831336|Percutaneous Coronary Intervention
225552|NCT01831336|STEMI
225553|NCT01831336|NSTEMI
225554|NCT01831336|Ischemia
225555|NCT01831336|Angina
225556|NCT01831336|Subgroups
225557|NCT01831336|Acute Myocardial Infarction
225558|NCT01831336|Diabetes
225559|NCT01831336|Small Vessels
225560|NCT01831336|Chronic Total Occlusion (CTO)
225561|NCT01831310|Colorectal cancer
225562|NCT01831310|nutrition
225563|NCT01831310|neutrophil phagocytosis
225564|NCT01831310|neutrophil adhesivity
225565|NCT01831310|glutamine
225566|NCT01831310|omega 3 fatty acids
225567|NCT01831271|Exercise, Physical
225568|NCT01831271|Physical Activity
225569|NCT01831271|Outcome Measures
225570|NCT01831219|osteoarthritis
225571|NCT01831219|arthroplasty
225572|NCT01831219|hip arthroplasty
225573|NCT01831206|corneal ulcer
225574|NCT01831206|keratitis
225575|NCT01831180|hair
225576|NCT01831180|scalp
225577|NCT01831180|blood flow
225578|NCT01831180|Caucasian
225579|NCT01831180|Histamine stimulation
225580|NCT01831180|Wake Forest
225581|NCT01831167|dynamic light application
225582|NCT01831167|sustained attention
225583|NCT01831167|divided attention
225584|NCT01831167|nursing
225585|NCT01831154|Glycemic control
225586|NCT01831141|Congenital Solitary Kidney
225587|NCT01831141|Glomerular filtration rate
225588|NCT01831141|Chronic kidney damage
225589|NCT01831141|Hypertension
225590|NCT01831141|Proteinuria
225591|NCT01831128|Congestive Heart Failure
225592|NCT01831128|Central Sleep Apnea
225593|NCT01831128|Sleep-Disordered Breathing
225594|NCT01831115|heart failure
225595|NCT01831115|BNP
225596|NCT01831115|acute dyspnoea
225597|NCT01831102|insulin resistance
225598|NCT01831102|ethnic disparities
225599|NCT01831102|adiponectin
225600|NCT01831076|Breast cancer
225601|NCT01831076|estrogen receptor-positive breast cancer
225602|NCT01831076|progesterone receptor-positive breast cancer
225603|NCT01831076|Postmenopausal
225604|NCT01831076|Exemestane
225605|NCT01831076|Tamoxifen
225606|NCT01831063|Seizure
225607|NCT01831063|Caregivers
225608|NCT01831063|Family Centered Care
225609|NCT01831063|Learning modality
225610|NCT01831050|Poliovirus
225611|NCT01831050|Inactivated poliovirus vaccine
225612|NCT01831050|Trivalent oral polio vaccine
225613|NCT01831050|Bivalent oral polio vaccine
225614|NCT01831050|Stool shedding index
225615|NCT01831050|Polio eradication
225616|NCT01831037|Hepatocellular carcinoma
225617|NCT01831037|Regressed cirrhosis
225618|NCT01831037|Hepatitis C
225619|NCT01831037|Hepatitis B
225620|NCT01831037|Noninvasive markers of fibrosis
225621|NCT01831037|FibroTest
225622|NCT01831037|FibroSure
225623|NCT01831037|FibroScan
225624|NCT01831037|Transient elastography
225625|NCT01831024|Cold cap
225626|NCT01831024|Scalp cooling
225627|NCT01831024|Chemotherapy induced alopecia
225628|NCT01831024|Breast cancer
225629|NCT01831011|randomized trial
225630|NCT01831011|acute ischemic stroke
225631|NCT01831011|mildronate
225632|NCT01830998|Dementia
225633|NCT01830998|Olfactory
225634|NCT01830959|Sarcoidosis, fibrosis, bronchiectasis
225635|NCT01830946|Protein
225636|NCT01830946|Metabolism
225637|NCT01830946|Nighttime eating
225638|NCT01830946|Exercise Training
225639|NCT01830933|Breast cancer concern, breast cancer risk perception, breast cancer risk
225640|NCT01830920|Acute Kidney Injury
225641|NCT01830920|AKI
225642|NCT01830920|Cardiac surgery
225643|NCT01830907|Malnutrition
225644|NCT01830907|Gastric cancer
225645|NCT01830907|preoperative nutrition
225646|NCT01830881|pain
225647|NCT01830881|anxiety
225648|NCT01830881|surgical abortion
225649|NCT01830881|midazolam
225650|NCT01830881|benzodiazepine
225651|NCT01830868|ZNS
225652|NCT01830868|AED
225653|NCT01830868|Partial Onset Seizures
225654|NCT01830868|Retention Rate
225655|NCT01830868|Seizure Control
225656|NCT01830868|Antiepileptic
225657|NCT01830868|Secondary generalization
225658|NCT01830868|Seizure freedom rates
225659|NCT01830842|Nicotine
225660|NCT01830842|Smoking
225661|NCT01830842|Cigarettes
225662|NCT01830842|Reinforcement Learning
225663|NCT01830842|fMRI
225664|NCT01830829|BPH
225665|NCT01830829|CPPS
225666|NCT01830816|Relapsed
225667|NCT01830816|Refractory
225668|NCT01830816|Multiple Myeloma
225669|NCT01830816|Advanced solid tumors
225670|NCT01830803|howRU
225671|NCT01830803|howRwe
225672|NCT01830803|reliability
225673|NCT01830803|quality of life
225674|NCT01830803|quality of care
225675|NCT01830803|patient satisfaction
225805|NCT01830114|hazardous alcohol use
225676|NCT01830751|self treatment technique
225677|NCT01830751|chronic
225678|NCT01830751|non specific
225679|NCT01830751|LBP
225680|NCT01830751|control trunk flexion
225681|NCT01830751|diurnal
225682|NCT01830738|laparoscopy
225683|NCT01830738|hysterectomy
225684|NCT01830738|single-port trocar
225685|NCT01830738|surgical technique
225686|NCT01830738|trocar
225687|NCT01830725|Xanthine Oxidase
225688|NCT01830725|Gout
225689|NCT01830725|Hyperuricemia
225690|NCT01830725|SNP
225691|NCT01830725|Single Nucleotide Polymorphisms
225692|NCT01830699|Rilonacept
225693|NCT01830699|Subacromial Bursitis treatment
225694|NCT01830699|Corticosteroid Injection
225695|NCT01830686|Sugarcane bagasse, glucose tolerance, insulin resistance
225696|NCT01830673|T-regulatory cells
225697|NCT01830673|TH1, TH2 cells
225698|NCT01830673|specific IgE
225699|NCT01830673|specific IgG
225700|NCT01830673|specific IgG4
225701|NCT01830673|IL2
225702|NCT01830673|IL5
225703|NCT01830673|IL10
225704|NCT01830673|IL12/23
225705|NCT01830673|Y-IFN
225706|NCT01830673|TNF-a
225707|NCT01830634|Community-dwelling elderly
225708|NCT01830634|Rehabilitation
225709|NCT01830634|Theraband
225710|NCT01830634|Strengthening and stretching exercise
225711|NCT01830582|MRI
225712|NCT01830582|rectum
225713|NCT01830582|13-019
225714|NCT01830569|Decision Support Systems, Clinical
225715|NCT01830569|Evidence-Based practice
225716|NCT01830569|Family Practice
225717|NCT01830543|Atrial Fibrillation
225718|NCT01830543|Irregular heart beat
225719|NCT01830543|rivaroxaban
225720|NCT01830543|aspirin
225721|NCT01830543|clopidogrel
225722|NCT01830543|prasugrel
225723|NCT01830543|ticagrelor
225724|NCT01830543|vitamin K antagonist
225725|NCT01830530|arterial hypertension
225726|NCT01830530|high altitude
225727|NCT01830530|hypobaric hypoxia
225728|NCT01830530|combination treatment
225729|NCT01830530|angiotensin receptor blocker
225730|NCT01830530|calcium antagonist
225731|NCT01830504|thyroid cancers
225732|NCT01830504|refractory
225733|NCT01830504|PI3K inhibitor
225734|NCT01830465|Non Hodgkin's Follicular Lymphoma
225735|NCT01830465|relapsed
225736|NCT01830465|progressed
225737|NCT01830452|Chronic pain
225738|NCT01830452|Progrip Mesh
225739|NCT01830452|Self gripping mesh
225740|NCT01830452|Lichtenstein
225741|NCT01830439|tuberculosis
225742|NCT01830439|PK
225743|NCT01830439|PA-824
225744|NCT01830439|food effect
225745|NCT01830439|pretomanid
225746|NCT01830439|CL-009
225747|NCT01830413|stent, systematic Intracranial artery stenosis
225748|NCT01830400|ESL
225749|NCT01830400|Partial onset seizures
225750|NCT01830400|Retention Rate
225751|NCT01830400|Seizure Control
225752|NCT01830400|Antiepileptic
225753|NCT01830400|Secondary Generalisation
225754|NCT01830387|Polymetric Clips (Hem-o-Lok)
225755|NCT01830387|Laparoscopic Appendectomy
225756|NCT01830387|Endoscopic Staplers
225757|NCT01830374|Bulimia nervosa
225758|NCT01830374|Eating disorder
225759|NCT01830374|Weight suppression
225760|NCT01830374|Dieting
225761|NCT01830361|AML
225762|NCT01830361|Acute Myeloid Leukemia
225763|NCT01830361|c-KIT
225764|NCT01830361|FLT3-ITD
225765|NCT01830361|t(8;21)
225766|NCT01830361|chemotherapy
225767|NCT01830361|midostaurin
225768|NCT01830348|diabetic foot ulcers
225769|NCT01830348|Wagner Grade 1 or 2 foot ulcers
225770|NCT01830322|metastatic
225771|NCT01830322|pancreatic
225772|NCT01830322|adenocarcinoma
225773|NCT01830322|cancer
225774|NCT01830309|Food-Effect
225775|NCT01830309|Pharmacokinetics
225776|NCT01830309|Pharmacodynamics
225777|NCT01830296|Postthoracotomy pain,
225778|NCT01830296|patient controlled analgesia,
225779|NCT01830296|remifentanil and
225780|NCT01830296|morphine.
225781|NCT01830270|medical oncology
225782|NCT01830270|chemotherapy optimization
225783|NCT01830270|dose density
225784|NCT01830244|chemotherapy
225785|NCT01830244|nab paclitaxel
225786|NCT01830244|neoadjuvant therapy
225787|NCT01830244|breast cancer
225788|NCT01830244|pathologic complete response
225789|NCT01830231|TCCU
225790|NCT01830231|Vinflunine
225791|NCT01830231|Cabazitaxel
225792|NCT01830231|Metastatic
225793|NCT01830231|Locally advance
225794|NCT01830192|endometrial cancer
225795|NCT01830192|score
225796|NCT01830192|nomogram
225797|NCT01830192|ultrasound
225798|NCT01830192|HE4
225799|NCT01830153|Soft tissue sarcomas
225800|NCT01830153|Bone sarcomas
225801|NCT01830153|RAD001
225802|NCT01830153|Refractory to conventional chemotherapy
225803|NCT01830114|alcohol abuse
225804|NCT01830114|drug abuse
225806|NCT01830114|hazardous drug use
225807|NCT01830101|recurrent glioblastoma
225808|NCT01830101|re-irradiation
225809|NCT01830101|continuous low-dose temozolomide
225810|NCT01830036|cardiological treatment
225811|NCT01830036|sleep Apnea
225812|NCT01830023|cardiac ultrasound
225813|NCT01830023|vitality
225814|NCT01830023|data
225815|NCT01830023|patients
225816|NCT01830023|examined
225817|NCT01829984|Injection Teaching
225818|NCT01829984|13-057
225819|NCT01829971|microRNA
225820|NCT01829971|Advanced cancer
225821|NCT01829958|Geriatric
225822|NCT01829958|Toxicity
225823|NCT01829958|rituximab
225824|NCT01829958|prednisone
225825|NCT01829958|Comprehensive Geriatric Assessment (CGA)
225826|NCT01829958|13-028
225827|NCT01829932|Diet
225828|NCT01829919|Menopause
225829|NCT01829919|Hot flashes
225830|NCT01829919|Vasomotor symptoms
225831|NCT01829919|Climacteric symptoms
225832|NCT01829919|perimenopause
225833|NCT01829919|Mesafem
225834|NCT01829919|Brisdelle
225835|NCT01829919|Low-Dose Mesylate salt of Paroxetine (LDMP)
225836|NCT01829906|weight loss
225837|NCT01829906|bariatric surgery
225838|NCT01829906|gastric bypass
225839|NCT01829906|health education
225840|NCT01829906|nutrition therapy
225841|NCT01829906|diet
225842|NCT01829906|exercise
225843|NCT01829906|cognitive therapy
225844|NCT01829893|Benign Prostatic Hyperplasia (BPH)
225845|NCT01829893|pharmacokinetics
225846|NCT01829893|bioequivalence
225847|NCT01829893|finasteirde
225848|NCT01829893|tamsulosin
225849|NCT01829880|Chronic heart failure
225850|NCT01829880|Bisoprolol
225851|NCT01829880|Ramipril
225852|NCT01829880|Pharmacokinetic
225853|NCT01829880|Cachexia
225854|NCT01829880|Body composition
225855|NCT01829880|Renal function
225856|NCT01829880|Iohexol
225857|NCT01829841|MRCC
225858|NCT01829841|Metastatic Renal Cell Cancer
225859|NCT01829841|Famitinib
225860|NCT01829841|Sunitinib
225861|NCT01829828|Pain
225862|NCT01829828|Cancer pain
225863|NCT01829828|Self-reported pain scoring tool
225864|NCT01829828|Opioid analgesics
225865|NCT01829815|Child
225866|NCT01829815|Parents
225867|NCT01829815|Parenting
225868|NCT01829815|Child Development
225869|NCT01829815|Parent Child Relations
225870|NCT01829815|Malaria
225871|NCT01829815|Primary Prevention
225872|NCT01829815|Punishment
225873|NCT01829815|Education
225874|NCT01829802|HIV
225875|NCT01829802|Raltegravir
225876|NCT01829802|Boosted atazanavir
225877|NCT01829789|Adolescents
225878|NCT01829789|Teens
225879|NCT01829789|Parents
225880|NCT01829789|Parenting
225881|NCT01829789|Substance Abuse
225882|NCT01829789|Treatment Efficacy
225883|NCT01829776|Accidental falls
225884|NCT01829776|Multiple Sclerosis
225885|NCT01829776|Education
225886|NCT01829776|Exercise
225887|NCT01829776|Postural balance
225888|NCT01829750|Univentricular heart
225889|NCT01829737|Asymptomatic Parasitemia
225890|NCT01829737|RBC Polymorphism
225891|NCT01829737|Acquired Immunity
225892|NCT01829724|Functional Brain Imaging
225893|NCT01829724|Cerebral Palsy
225894|NCT01829724|Motion Analysis
225895|NCT01829724|Macro- EMG
225896|NCT01829711|Moxetumomab Paudotox
225897|NCT01829711|CAT-8015
225898|NCT01829711|anti-CD22 recombination immunotoxin
225899|NCT01829711|Biologic Therapy
225900|NCT01829711|Recombinant Immunotoxin
225901|NCT01829711|Monoclonal Antibody
225902|NCT01829711|Pseudomonas Exotoxin
225903|NCT01829711|Targeted Therapy
225904|NCT01829698|tudca PBC Cholestasis tauroursodeoxycholic acid taurolite
225905|NCT01829672|Early diagnosis of pulmonary arterial hypertension
225906|NCT01829672|dynamic dual-energy computed tomography
225907|NCT01829646|DWI
225908|NCT01829646|DCE MRI
225909|NCT01829646|ADC
225910|NCT01829646|FDG PET
225911|NCT01829646|Hypoxia
225912|NCT01829646|Prognostic and predictive model
225913|NCT01829620|suicide
225914|NCT01829620|suicide intervention
225915|NCT01829620|suicide prevention
225916|NCT01829620|military
225917|NCT01829620|military suicide
225918|NCT01829620|caring letters
225919|NCT01829620|caring contacts
225920|NCT01829620|text messages
225921|NCT01829594|Case Management
225922|NCT01829594|Frail Elderly
225923|NCT01829594|Health Services Administration
225924|NCT01829594|Delivery of Health Care
225925|NCT01829594|Accidental Falls
225926|NCT01829594|Health Status
225927|NCT01829594|Health Care Economics
225928|NCT01829542|flow-mediated dilation
225929|NCT01829542|blueberry polyphenols
225930|NCT01829542|dose-dependency
225931|NCT01829529|Antibiotic prophylaxis
225932|NCT01829503|Phase II
225933|NCT01829503|decitabine
225934|NCT01829503|cytarabine
225935|NCT01829503|older patients
225936|NCT01829503|newly diagnosed
225937|NCT01829503|AML
225938|NCT01829503|Newly Diagnosed AML
225939|NCT01829490|Vaccine
225940|NCT01829490|Immunogenicity
225941|NCT01829477|Drug Therapy
225942|NCT01829464|Drug Therapy
225943|NCT01829438|exercise tolerance
225944|NCT01829438|6MWT
225945|NCT01829425|Hypnosis
225946|NCT01829425|Mind-Body Therapy
225947|NCT01829425|Anticholinergics
225948|NCT01829425|fMRI
225949|NCT01829425|Functional Neuroimaging
225950|NCT01829425|Gyrus Cinguli
225951|NCT01829425|Female Urogenital Diseases
225952|NCT01829399|Tourniquet pain
225953|NCT01829399|Subcutaneous axillary local anesthetic
225954|NCT01829399|ability to tolerate tourniquet discomfort.
225955|NCT01829373|lung cancer
225956|NCT01829347|liver failure
225957|NCT01829347|acute alcoholic hepatitis
225958|NCT01829347|patients failing steroid therapy
225959|NCT01829347|alcoholic hepatitis
225960|NCT01829347|steroid failure
225961|NCT01829347|Lille criteria
225962|NCT01829347|ELAD
225963|NCT01829334|dental caries
225964|NCT01829308|implementation
225965|NCT01829308|SBIRT
225966|NCT01829308|alcohol screening
225967|NCT01829308|drug screening
225968|NCT01829308|Brief Intervention
225969|NCT01829308|Referral to Treatment
225970|NCT01829308|adolescents
225971|NCT01829308|Federally Qualified Health Centers
225972|NCT01829295|antimetabolite, noninfectious
225973|NCT01829282|Implementation
225974|NCT01829282|HIV
225975|NCT01829282|serodiscordant couples
225976|NCT01829282|African American
225977|NCT01829282|Cultural congruency
225978|NCT01829243|Milnacipran
225979|NCT01829243|Fibromyalgia
225980|NCT01829243|Neurocognition
225981|NCT01829178|cisplatin
225982|NCT01829178|nephrotoxicity
225983|NCT01829178|antioxidant
225984|NCT01829178|urine neutrophil gelatinase-associated lipocalin (NGAL)
225985|NCT01829152|heart failure
225986|NCT01829139|Common bile duct stone
225987|NCT01829139|Gallbladder in situ
225988|NCT01829139|Choleretics
225989|NCT01829113|Recurrent Lung Cancer
225990|NCT01829113|Stage IV Lung Cancer
225991|NCT01829113|OGX-427
225992|NCT01829113|Sarah Cannon Research Institute
225993|NCT01829113|SCRI
225994|NCT01829113|OncoGenex
225995|NCT01829113|NSCLC
225996|NCT01829113|Non Small Cell Lung Cancer
225997|NCT01829100|Adolescent
225998|NCT01829100|Transdiagnostic therapy
225999|NCT01829100|Behavioral activation
226000|NCT01829100|Exposure therapy
226001|NCT01829100|Depressive Disorder
226002|NCT01829100|Anxiety Disorders
226003|NCT01829074|Laryngopharyngeal Reflux
226004|NCT01829074|Hoarseness
226005|NCT01829074|Throat Clearing
226006|NCT01829074|Globus Sensation
226007|NCT01829061|Type I Diabetes
226008|NCT01829061|Type II Diabetes
226009|NCT01829061|HbA1C
226010|NCT01829048|PF-02545920
226011|NCT01829048|safety
226012|NCT01829048|schizophrenia
226013|NCT01829035|TACE
226014|NCT01829035|Sorafenib
226015|NCT01829022|Myoma
226016|NCT01829022|Uterine myomectomy
226017|NCT01829009|Sarcopenia
226018|NCT01829009|Elderly
226019|NCT01829009|Women
226020|NCT01829009|Resistance
226021|NCT01829009|Exercise
226022|NCT01828996|Chronic pelvic pain syndrome
226023|NCT01828996|Chronic prostatitis
226024|NCT01828996|Shock wave therapy
226025|NCT01828996|Prostate
226026|NCT01828996|Pelvic floor
226027|NCT01828996|Pain
226028|NCT01828983|Telephone
226029|NCT01828983|Support groups
226030|NCT01828983|Social support
226031|NCT01828983|Depression
226032|NCT01828970|Diabetes Mellitus
226033|NCT01828970|Hemodialysis
226034|NCT01828970|Continuous glucose monitoring
226035|NCT01828970|Insulin analogues
226036|NCT01828957|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
226037|NCT01828957|Bronchopulmonary dysplasia
226038|NCT01828957|Premature infants
226039|NCT01828944|Vitamin D
226040|NCT01828944|bone loss
226041|NCT01828918|early diagnosis
226042|NCT01828918|prediction
226043|NCT01828918|prognosis
226044|NCT01828905|tibia fracture
226045|NCT01828905|bone graft
226046|NCT01828905|iliac crest
226047|NCT01828905|bone graft substitute
226048|NCT01828905|Cerament
226049|NCT01828905|void filler
226050|NCT01828905|quality of life
226051|NCT01828905|pain
226052|NCT01828905|costs of care
226053|NCT01828892|Autologous platelet rich fibrin glue
226054|NCT01828892|Enterocutaneous fistulas
226055|NCT01828892|Single low output GI fistulas
226056|NCT01828879|Dermatitis, Atopic
226057|NCT01828879|Tacrolimus
226058|NCT01828866|EMDR
226059|NCT01828866|Alcohol
226060|NCT01828866|Relapse
226061|NCT01828866|Craving
226062|NCT01828853|Membrane sweeping
226063|NCT01828853|Membrane stripping
226064|NCT01828853|Maternal outcomes
226065|NCT01828853|Neonatal outcomes
226066|NCT01828840|morphine
226067|NCT01828840|fentanyl
226068|NCT01828840|methadone
226069|NCT01828840|epidural
226070|NCT01828840|intravenous
226071|NCT01828840|pain
226072|NCT01828840|analgesia
226073|NCT01828827|tuberculosis
226074|NCT01828827|PK
226075|NCT01828827|PA-824
226076|NCT01828827|food effect,
226077|NCT01828827|bioavailability
226078|NCT01828827|pretomanid
226079|NCT01828827|CL-003
226080|NCT01828814|pediatrics
226081|NCT01828814|Ready-to-use Supplementary Food
226082|NCT01828814|corn soy blend
226083|NCT01828814|cash transfer
226084|NCT01828814|prevention of malnutrition
226085|NCT01828814|Niger
226086|NCT01828801|Adverse Local Tissue Reaction
226087|NCT01828801|Metal Ions
226088|NCT01828801|Serum
226089|NCT01828801|Whole Blood
226090|NCT01828801|Metal-on-Metal
226091|NCT01828801|Total Hip Arthroplasty
226092|NCT01828788|Sternotomy
226093|NCT01828788|Anesthesia
226094|NCT01828788|Post-operative pain
226095|NCT01828762|DC
226096|NCT01828762|Immunotherapy
226097|NCT01828762|TC
226098|NCT01828749|blunt abdominal trauma
226099|NCT01828749|CT
226100|NCT01828749|radiation exposure, pediatric
226101|NCT01828736|Urothelial carcinoma
226102|NCT01828736|Trastuzumab
226103|NCT01828736|Treatment
226104|NCT01828723|Autologous Adult Stem Cell
226105|NCT01828723|Adipose Derived Stem Cell
226106|NCT01828723|Stromal Vascular Fraction
226107|NCT01828723|SVF
226108|NCT01828723|Antria
226109|NCT01828723|Shah Rahimian
226110|NCT01828723|Leonard Maliver
226111|NCT01828723|David Bizousky
226112|NCT01828723|Rahul Gore
226113|NCT01828723|Lee Quist
226114|NCT01828723|Dudley McNitt
226115|NCT01828710|Myo-inositol
226116|NCT01828710|oligoasthenoteratospermia
226117|NCT01828710|semen parameters
226118|NCT01828710|IVF
226119|NCT01828697|Low-molecular-weight heparin
226120|NCT01828697|Pregnancy
226121|NCT01828697|Venous thrombosis
226122|NCT01828684|Migraine with Aura
226123|NCT01828684|Migraine without Aura
226124|NCT01828684|Photophobia
226125|NCT01828684|Chronic Daily Headache
226126|NCT01828671|Soy
226127|NCT01828671|Corn
226128|NCT01828671|Flour
226129|NCT01828671|Tortilla
226130|NCT01828671|Glycemic
226131|NCT01828671|Glucose,
226132|NCT01828671|glycemic index
226133|NCT01828658|hemodialysis
226134|NCT01828658|fluid management
226135|NCT01828658|bioimpedance
226136|NCT01828658|mortality
226137|NCT01828658|arterial stiffness
226138|NCT01828645|gastric emptying
226139|NCT01828645|whey protein
226140|NCT01828645|carbohydrate
226141|NCT01828645|fasting
226142|NCT01828632|Obesity, Morbid; Hypoxemia; Postoperative complications; Bariatric surgery; Respiratory physical therapy; Preoperative care.
226143|NCT01828619|Hematopoietic Stem Cell Transplantation
226144|NCT01828619|Busulfan
226145|NCT01828619|Fludarabine
226146|NCT01828606|leg lymphedema
226147|NCT01828606|volume measurement
226148|NCT01828606|compression therapy
226149|NCT01828606|interface pressure
226150|NCT01828606|static stiffness index (SSI)
226151|NCT01828606|volume change
226152|NCT01828580|laparoscopic Cholecystectomy
226153|NCT01828580|Gallbladder removal
226154|NCT01828580|laparoscope holder
226155|NCT01828567|veterans
226156|NCT01828567|health risk assessment
226157|NCT01828567|primary prevention
226158|NCT01828567|shared decision making
226159|NCT01828567|Healthy Living Assessment
226160|NCT01828554|Capecitabine pharmacokinetics PK
226161|NCT01828554|Elevated Body Mass Index (BMI)
226162|NCT01828554|Advanced Solid Tumors
226163|NCT01828541|Burn injuries
226164|NCT01828528|Nonalcoholic fatty liver disease
226165|NCT01828528|Nonalcoholic steatohepatitis
226166|NCT01828528|Obesity
226167|NCT01828528|Bariatric surgery
226168|NCT01828528|Weight loss
226169|NCT01828502|Cotinine
226170|NCT01828502|Secondhand Smoke Exposure (SHSE)
226171|NCT01828502|Secondhand Smoke (SHS)
226172|NCT01828476|prostate cancer
226173|NCT01828476|hormone-resistant prostate cancer
226174|NCT01828476|recurrent prostate cancer
226175|NCT01828476|stage IV prostate cancer
226176|NCT01828424|acute pain
226177|NCT01828411|Cardiac surgery
226178|NCT01828411|Echocardiography
226179|NCT01828411|Cerebral perfusion
226180|NCT01828411|Intraoperative period
226181|NCT01828385|Physiological Effects of Drugs
226182|NCT01828385|Rocuronium
226183|NCT01828385|Sugammadex sodium
226184|NCT01828385|Magnesium
226185|NCT01828385|Molecular Mechanisms of Pharmacological Action
226186|NCT01828385|Neuromuscular block, antagonism
226187|NCT01828385|Pharmacologic Actions
226188|NCT01828372|concomitant diseases
226189|NCT01828372|multiple drug consumption
226190|NCT01828372|therapeutic drug monitoring
226191|NCT01828372|TDM
226192|NCT01828372|drug monitoring
226193|NCT01828372|drug level
226194|NCT01828372|quantification
226195|NCT01828372|drug
226196|NCT01828372|drug concentration
226197|NCT01828372|concentration
226198|NCT01828372|therapeutic range
226199|NCT01828372|therapeutic index
226200|NCT01828346|TL32711
226201|NCT01828346|Birinapant
226202|NCT01828346|5-Azacitidine
226203|NCT01828346|Myelodysplastic syndrome
226204|NCT01828346|MDS
226205|NCT01828346|Relapsed
226206|NCT01828346|Refractory
226207|NCT01828346|Failed
226208|NCT01828346|open-label
226209|NCT01828346|non-Randomized
226210|NCT01828346|dose-escalation
226211|NCT01828346|dose-expansion
226212|NCT01828333|Malaria
226213|NCT01828333|Severe
226214|NCT01828333|Artesunate
226215|NCT01828333|Quinine
226216|NCT01828333|Democratic Republic of Congo
226217|NCT01828320|Risk: Emotional, Cognitive, Behavioral, Social, Physical
226218|NCT01828294|MG
226219|NCT01828268|HIV
226220|NCT01828268|Metabolomics Fingerprinting
226221|NCT01828242|HbA1C
226222|NCT01828229|Inactivity
226223|NCT01828229|Obesity
226224|NCT01828229|Type 2 diabetes
226225|NCT01828229|glucose metabolism
226226|NCT01828229|Lipid metabolism
226227|NCT01828229|Cognitive function
226228|NCT01828203|minocycline
226229|NCT01828203|randomized control trial
226230|NCT01828203|phase 3
226231|NCT01828203|spinal cord injury
226232|NCT01828190|crohn's disease
226233|NCT01828190|perianal fistulas
226234|NCT01828190|TNF alpha blockers
226235|NCT01828190|hyperbaric oxygen therapy
226236|NCT01828177|PreCision
226237|NCT01828177|PDI-320
226238|NCT01828177|Foam
226239|NCT01828164|Orthodontics
226240|NCT01828164|Braces
226241|NCT01828164|Tooth
226242|NCT01828151|Pressure ulcer
226243|NCT01828151|Noninvasive ventilation
226244|NCT01828138|Proteinuria
226245|NCT01828138|Pregnancy
226246|NCT01828138|Hypertension
226247|NCT01828138|Plasmin
226248|NCT01828138|Plasminogen
226249|NCT01828138|Aldosterone
226250|NCT01828138|Angiotensin
226251|NCT01828138|Renin
226252|NCT01828138|sodium chloride
226253|NCT01828138|epithelial sodium channel
226254|NCT01828138|Placenta
226255|NCT01828125|Type 1 diabetes
226256|NCT01828125|Hypoglycemia
226257|NCT01828125|Glucagon
226258|NCT01828125|Hypoglycaemic hyperinsulinemic clamp
226259|NCT01828112|Non-Small Cell Lung Cancer, ALK, LDK378
226260|NCT01828099|Non-Small Cell Lung Cancer, ALK, LDK378
226261|NCT01828086|Psoriasis, chronic plaque-type psoriasis, IL17, monoclonal antibody
226262|NCT01828034|Gemcitabine
226263|NCT01828034|Cisplatin
226264|NCT01828034|MEK162
226265|NCT01828034|13-004
226266|NCT01828021|HER2 2+
226267|NCT01828021|FISH non-amplified
226268|NCT01828021|Relapsed
226269|NCT01828021|Refractory
226270|NCT01828021|Advanced
226271|NCT01828021|Margetuximab
226272|NCT01828021|MGAH22
226273|NCT01828008|Mabthera
226274|NCT01828008|cytokine induced killer cell
226275|NCT01827995|Low sensitivity urinary hCG
226276|NCT01827995|follow up
226277|NCT01827995|medical abortion
226278|NCT01827995|rural India
226279|NCT01827995|RCT
226280|NCT01827982|Healthy
226281|NCT01827982|Safety
226282|NCT01827982|Tolerability
226283|NCT01827982|Pharmacokinetic
226284|NCT01827982|Alzheimer's Disease
226285|NCT01827982|JNJ-54861911
226286|NCT01827969|Women
226287|NCT01827969|breast tumor
226288|NCT01827969|planned mastectomy
226289|NCT01827956|Upper aero-digestive tract tumours
226290|NCT01827956|FCGR3A and FCGR2A receptor polymorphism
226291|NCT01827956|Cetuximab efficacy
226292|NCT01827943|Relapsed bladder cancer
226293|NCT01827930|chronic myeloid leukemia in chronic phase
226294|NCT01827904|ExAblate Transcranial MRgFUS
226295|NCT01827891|acute kidney injury
226296|NCT01827891|percutaneous coronary intervention
226297|NCT01827891|remote ischemic preconditioning
226298|NCT01827839|Zoster
226299|NCT01827839|Immunogenicity
226300|NCT01827839|Safety
226301|NCT01827839|Adults
226302|NCT01827826|Intervention
226303|NCT01827826|Telephone
226304|NCT01827826|Diabetes
226305|NCT01827826|Prevention
226306|NCT01827813|prostate-specific antigen
226307|NCT01827813|digital rectal examination
226308|NCT01827813|transrectal ultrasonography
226309|NCT01827813|needle biopsy
226310|NCT01827813|prostate cancer
226311|NCT01827800|weight loss
226312|NCT01827800|primary care
226313|NCT01827800|eHealth
226314|NCT01827774|Pelvic organ prolapse
226315|NCT01827774|Graft repair
226316|NCT01827761|chemotherapy teaching
226317|NCT01827761|questionnaire
226318|NCT01827748|Autorefractor
226319|NCT01827735|Interleukin 2
226320|NCT01827735|Type 1 diabetes
226321|NCT01827735|T regulatory cells
226322|NCT01827735|Adaptive trial
226323|NCT01827722|Macular edema
226324|NCT01827722|Central retinal vein occlusion
226325|NCT01827722|CRVO
226326|NCT01827722|Retinal vein occlusion
226327|NCT01827722|RVO
226328|NCT01827722|Ozurdex
226329|NCT01827722|Dexamethasone intravitreal implant
226330|NCT01827722|Lucentis
226331|NCT01827722|Ranibizumab
226332|NCT01827709|DWI
226333|NCT01827709|ADC
226334|NCT01827709|DCE-MRI
226335|NCT01827709|FDG-PET
226336|NCT01827709|SUV
226337|NCT01827709|Hypoxia
226338|NCT01827709|Head and neck squamous cell carcinoma
226339|NCT01827696|Muscle
226340|NCT01827696|Soreness
226341|NCT01827696|Muscle function
226342|NCT01827696|Damage
226343|NCT01827696|Ginseng
226344|NCT01827683|hyperbaric oxygen
226345|NCT01827683|fibromyalgia
226346|NCT01827683|chronic pain syndrome
226347|NCT01827657|plasma
226348|NCT01827657|tolerability
226349|NCT01827657|safety
226350|NCT01827657|matched control
226351|NCT01827657|GSK2336805
226352|NCT01827657|hepatic impairment
226353|NCT01827657|pharmacokinetics
226354|NCT01827644|AKT inhibitor
226355|NCT01827644|formulation
226356|NCT01827644|food effect
226357|NCT01827644|bioavailability
226358|NCT01827644|GSK2110183
226359|NCT01827631|healthy
226360|NCT01827631|GSK1605786
226361|NCT01827631|CCR9 receptor antagonist
226362|NCT01827631|Chinese subjects
226363|NCT01827631|pharmacokinetics
226364|NCT01827618|bladder
226365|NCT01827618|Cancer
226366|NCT01827618|Cystectomy
226367|NCT01827618|Rapamycin
226368|NCT01827605|Relapsed follicular Lymphoma
226369|NCT01827605|RIT
226370|NCT01827605|Zevalin
226371|NCT01827579|Transplant
226372|NCT01827579|CD25/71 allodepleted donor T cells
226373|NCT01827579|Infection
226374|NCT01827579|Acute Myeloid Leukaemia
226375|NCT01827579|Acute Lymphoblastic Leukaemia
226376|NCT01827579|Adult
226377|NCT01827579|Diffuse Large B-Cell Lymphoma
226378|NCT01827579|Mantle Cell Lymphoma
226379|NCT01827566|Celiac Disease
226380|NCT01827566|Gluten Sensitivity
226381|NCT01827566|Gluten
226382|NCT01827566|Double-blind challenge, placebo-controlled challenge
226383|NCT01827566|Gluten free flour
226384|NCT01827553|pancreatic cancer
226385|NCT01827553|chemoradiotherapy
226386|NCT01827553|chemotherapy
226387|NCT01827553|FOLFIRINOX
226388|NCT01827553|gemcitabine
226389|NCT01827540|HIV/AIDS
226390|NCT01827540|Cenicriviroc (CVC)
226391|NCT01827540|Dolutegravir (DTG)
226392|NCT01827540|Midazolam
226393|NCT01827540|Healthy Subjects
226394|NCT01827527|Adenosine Triphosphate
226395|NCT01827527|Validation
226396|NCT01827527|Magnetic Resonance Spectroscopy
226397|NCT01827527|Optical Spectroscopy
226398|NCT01827514|cancer, erythropoetin
226399|NCT01827501|postoperative delirium
226400|NCT01827501|hemodynamic management
226401|NCT01827501|goal directed therapy
226402|NCT01827475|musculoskeletal pain
226403|NCT01827475|acetaminophen
226404|NCT01827475|ibuprofen
226405|NCT01827462|influenza vaccine
226406|NCT01827462|immune response
226407|NCT01827462|immunosenescence
226408|NCT01827462|biomarkers
226409|NCT01827449|rewarming
226410|NCT01827449|core cooling
226411|NCT01827449|afterdrop
226412|NCT01827449|hospital treatment
226413|NCT01827449|hypothermia
226414|NCT01827436|pediatric stroke
226415|NCT01827436|hemiplegia
226416|NCT01827436|physical therapy
226417|NCT01827436|gait training
226418|NCT01827436|transcranial magnetic stimulation
226419|NCT01827436|gait asymmetry
226420|NCT01827423|squamous cell carcinoma antigen
226421|NCT01827423|sinonasal inverted papilloma
226422|NCT01827423|clinical marker
226423|NCT01827423|hidden reccurence
226424|NCT01827423|surgery
226425|NCT01827397|Safety of this HIV vaccine
226426|NCT01827371|Smallpox, vaccine, IMVAMUNE, Stratis, parent protocol
226427|NCT01827358|antibacterial agent,children,colonisation,critically ill,infants,mupirocin,prevention,Staphylococcus aureus
226428|NCT01827345|Vitamin D
226429|NCT01827345|Falls
226430|NCT01827345|Balance
226431|NCT01827345|Physical Function
226432|NCT01827332|marijuana
226433|NCT01827332|substance abuse
226434|NCT01827332|drug abuse
226435|NCT01827332|marijuana dependence
226436|NCT01827332|drug addiction
226437|NCT01827319|Angina
226438|NCT01827319|Transmyocardial revascularization
226439|NCT01827280|endothelial function
226440|NCT01827280|microvascular function
226441|NCT01827280|incretins
226442|NCT01827280|diabetes mellitus
226443|NCT01827280|postprandial lipemia
226444|NCT01827267|Lung cancer
226445|NCT01827267|Puma
226446|NCT01827267|neratinib
226447|NCT01827254|sutent rechallenge
226448|NCT01827241|Gastroenterology
226449|NCT01827241|Colonoscopy
226450|NCT01827241|Screening
226451|NCT01827241|Surveillance
226452|NCT01827241|Symptom evaluation
226453|NCT01827241|Chart review
226454|NCT01827241|Data review
226455|NCT01827241|Examination findings
226456|NCT01827241|Resection techniques
226457|NCT01827241|Pathology reports
226458|NCT01827228|HIV
226459|NCT01827228|transmission prevention
226460|NCT01827228|social network and venue
226461|NCT01827228|community intervention
226462|NCT01827228|treatment as prevention
226463|NCT01827228|recent infection
226464|NCT01827228|phylogenetics
226465|NCT01827228|infection chains
226466|NCT01827215|Preconception Care
226467|NCT01827215|Racial Disparities
226468|NCT01827215|Health Information Technology
226469|NCT01827202|renin-angiotensin-system
226470|NCT01827202|RAS blockade
226471|NCT01827189|primary care, Medicare costs, hospitalizations
226472|NCT01827176|Characteristic
226473|NCT01827176|Recurrent Acute Rhinosinusitis
226474|NCT01827176|Children
226475|NCT01827163|Paclitaxel
226476|NCT01827163|Trastuzumab
226477|NCT01827163|Lapatinib
226478|NCT01827163|HER2
226479|NCT01827163|13-002
226480|NCT01827137|WT1 Analog Peptide Vaccine
226481|NCT01827137|12-288
226482|NCT01827124|CARBETOCIN AND OXYTOCIN AND SECOND TRIMESTER INTERRUPTION
226483|NCT01827111|Melanoma
226484|NCT01827111|Metastatic Melanoma
226485|NCT01827111|Advanced stage IV melanoma
226486|NCT01827111|Unresectable stage III mucosal melanoma
226487|NCT01827111|Cutaneous melanoma
226488|NCT01827111|Progression-free survival
226489|NCT01827111|(PFS)
226490|NCT01827111|ABI-007
226491|NCT01827111|Nab-paclitaxel
226492|NCT01827111|Paclitaxel
226493|NCT01827111|Abraxane
226494|NCT01827111|Ipilimumab
226495|NCT01827111|Yervoy
226496|NCT01827111|BMS-734016
226497|NCT01827111|MDX010
226498|NCT01827098|Immature teeth
226499|NCT01827098|Calcium Hydroxide
226500|NCT01827098|Blood clot
226501|NCT01827098|Revascularization
226502|NCT01827098|Revitalization
226503|NCT01827072|IVIG in Multifocal Motor Neuropathy
226504|NCT01827072|Patients with Multifocal Motor Neuropathy
226505|NCT01827046|intracerebral hemorrhage
226506|NCT01827046|ICH
226507|NCT01827046|brain hemorrhage
226508|NCT01827046|minimally invasive surgery
226509|NCT01827046|rt-PA
226510|NCT01827007|norepinephrine infusion
226511|NCT01827007|under 48 hours in ICU
226512|NCT01826968|Lung recruitment, cesarean, lung compliance, atelectasis
226513|NCT01826955|pneumoperitoneum, cognitive function
226514|NCT01826942|Scar prevention
226515|NCT01826942|CO2 fractional laser
226516|NCT01826929|Health Services Research
226517|NCT01826929|Cardiovascular Diseases
226518|NCT01826929|Primary Care
226519|NCT01826929|Secondary Prevention.
226520|NCT01826903|Depression
226521|NCT01826903|Cognitive Behavior Therapy
226522|NCT01826903|Child Development
226523|NCT01826890|Ventilator Weaning
226524|NCT01826890|Mechanical Ventilation
226525|NCT01826890|Critical Care
226526|NCT01826890|Neurally Adjusted Ventilatory Assist
226527|NCT01826890|Diaphragm
226528|NCT01826851|Pain management
226529|NCT01826851|Anesthetic, local
226530|NCT01826851|Nerve blockade
226531|NCT01826851|Coronary Artery Bypass Surgery
226532|NCT01826851|Analgesics, opioid
226533|NCT01826851|Postoperative complications
226534|NCT01826851|Bupivacaine
226535|NCT01826838|Prostate Cancer
226536|NCT01826825|aging
226537|NCT01826825|cognition
226538|NCT01826825|surgery
226539|NCT01826799|sleep
226540|NCT01826799|noise
226541|NCT01826799|ICU
226542|NCT01826799|delirium
226543|NCT01826799|RCSQ
226544|NCT01826786|Healthy
226545|NCT01826786|Anxiety Disorders
226546|NCT01826786|Anxiety Modulation
226547|NCT01826786|Male
226548|NCT01826773|CardioPET
226549|NCT01826773|Coronary Artery Disease
226550|NCT01826773|Myocardial Perfusion Imaging
226551|NCT01826773|Coronary Angiography
226552|NCT01826773|Myocardial Fatty Acid Utilization
226553|NCT01826747|intrauterine insemination
226554|NCT01826747|luteal phase
226555|NCT01826747|gonadotrophins
226556|NCT01826734|dacryolith
226557|NCT01826734|dacryocystorhinostomy
226558|NCT01826734|composition
226559|NCT01826734|chemical analysis
226560|NCT01826734|infrared spectrometry
226561|NCT01826734|scanning electron microscopy
226562|NCT01826734|elemental analysis
226563|NCT01826721|Solid organ transplantation
226564|NCT01826721|Immunosuppression
226565|NCT01826721|Education
226566|NCT01826721|E-learning
226567|NCT01826721|Medication knowledge
226568|NCT01826721|Patient satisfaction
226569|NCT01826721|Medication adherence
226570|NCT01826708|Chromosomal translocations
226571|NCT01826708|psychomotor delay
226572|NCT01826695|Fibromyalgia, neurodynamic, dexterity
226573|NCT01826682|COPD, physiotherapy, exacerbation
226574|NCT01826656|intramembranous bone healing
226575|NCT01826656|post-menopausal osteoporosis
226576|NCT01826656|tooth extraction
226577|NCT01826630|CLn Body Wash
226578|NCT01826630|CLn BodyWash
226579|NCT01826617|Prostate Disease Nomogram
226580|NCT01826617|Asian Men
226581|NCT01826604|cesarean section
226582|NCT01826604|Pregnant
226583|NCT01826565|success
226584|NCT01826552|Orsiro hybrid stent
226585|NCT01826552|Drug-eluting stent
226586|NCT01826552|Zotarolimus-eluting stent
226587|NCT01826552|Coronary heart disease
226588|NCT01826552|Cobalt chromium
226589|NCT01826539|Dorsal digital nerve
226590|NCT01826539|dorsal branch of the digital nerve
226591|NCT01826539|dorsal branch of the digital artery
226592|NCT01826539|dorsal digital island flap
226593|NCT01826539|finger pulp defect.
226594|NCT01826513|Obstructive sleep apnea
226595|NCT01826513|Efficacy
226596|NCT01826513|Subjective feedback
226597|NCT01826513|Preference
226598|NCT01826500|embryo transfer
226599|NCT01826500|IVF cycle
226600|NCT01826500|endometriosis
226601|NCT01826487|Duchenne muscular dystrophy
226602|NCT01826487|Dystrophinopathy
226603|NCT01826487|Nonsense mutation
226604|NCT01826487|Premature stop codon
226605|NCT01826487|Becker muscular dystrophy
226606|NCT01826487|DMD/BMD
226607|NCT01826487|PTC124
226608|NCT01826487|Ataluren
226609|NCT01826474|Duchenne muscular dystrophy
226610|NCT01826474|DMD
226611|NCT01826474|Prosensa
226612|NCT01826474|Duchenne
226613|NCT01826461|atopic dermatitis
226614|NCT01826461|eczema
226615|NCT01826461|PDI-192
226616|NCT01826461|Precision
226617|NCT01826422|Muscular Dystrophy
226618|NCT01826422|Duchenne Muscular Dystrophy
226619|NCT01826422|Becker Muscular Dystrophy
226620|NCT01826422|Omega 3
226621|NCT01826422|Eicosapentaenoic fatty acid
226622|NCT01826422|Docosahexaenoic fatty acid
226623|NCT01826383|Infant
226624|NCT01826383|Immunization
226625|NCT01826357|metabolic syndrome
226626|NCT01826357|cluster analysis
226627|NCT01826357|PCOS
226628|NCT01826318|Stress
226629|NCT01826318|coping
226630|NCT01826318|simulation
226631|NCT01826292|Post anesthesia care unit length of stay
226632|NCT01826279|Obesity
226633|NCT01826279|Gastric bypass surgery
226634|NCT01826279|Resveratrol
226635|NCT01826279|Insulin sensitivity
226636|NCT01826279|Lipid turnover
226637|NCT01826279|VLDL-triglyceride uptake
226638|NCT01826279|Liver
226639|NCT01826266|PER977
226640|NCT01826266|Activated partial thromboplastin time
226641|NCT01826266|Assessment
226642|NCT01826266|D-dimer
226643|NCT01826266|Enrollment
226644|NCT01826266|Investigational drug
226645|NCT01826266|Investigational treatment
226646|NCT01826266|Period
226647|NCT01826266|Premature subject withdrawal
226648|NCT01826266|Prothrombin time
226649|NCT01826266|Randomization number
226650|NCT01826266|Study discontinuation
226651|NCT01826266|Study drug
226652|NCT01826266|Subject number
226653|NCT01826266|Study treatment
226654|NCT01826266|Thromboelastography-reaction time
226655|NCT01826253|Hypovolemia
226656|NCT01826253|Fluid challenge
226657|NCT01826253|Fluid expansion
226658|NCT01826253|Oxygene delivery
226659|NCT01826253|Cardiac output
226660|NCT01826227|PET (Positron Emission Tomography)
226661|NCT01826227|18F-FDG
226662|NCT01826227|Cytoreductive Surgery
226663|NCT01826227|13-017
226664|NCT01826214|acute myeloid leukemia
226665|NCT01826214|AML
226666|NCT01826214|acute lymphoblastic leukemia
226667|NCT01826214|ALL
226668|NCT01826214|leukemia
226669|NCT01826214|acute
226670|NCT01826214|LDE225
226671|NCT01826214|adult patients
226672|NCT01826214|relapsed/refractory
226673|NCT01826201|psoriasis
226674|NCT01826188|Crohn's disease
226675|NCT01826188|IBD Cannabis
226676|NCT01826188|THC
226677|NCT01826188|CBD
226678|NCT01826175|Optical Coherence Tomography
226679|NCT01826175|ticagrelor
226680|NCT01826175|clopidogrel
226681|NCT01826123|Coagulopathy
226682|NCT01826123|Hemorrhage
226683|NCT01826123|Cardiac surgery
226684|NCT01826123|Point-of-Care testing
226685|NCT01826123|POC
226686|NCT01826123|ROTEM
226687|NCT01826123|multiplate
226688|NCT01826123|Multiple electrode aggregometry (MEA)
226689|NCT01826097|Cytology
226690|NCT01826097|Whole body massage vibration
226691|NCT01826071|Osgood-Schlatter syndrome (OSS)
226692|NCT01826071|Sinding-Larsen and Johansson syndrome (SLJ)
226693|NCT01826071|Sever's disease
226694|NCT01826071|apophysitis
226695|NCT01826058|Stereotactic body radiation therapy
226696|NCT01826058|Radiosurgery
226697|NCT01826045|Treatment of Cervical Intraepithelial Neoplasia(CIN1)
226698|NCT01826006|Myocardial Infarction
226699|NCT01826006|No-reflow
226700|NCT01826006|Primary PCI
226701|NCT01826006|Coronary no-reflow phenomenon
226702|NCT01826006|Primary percoutaneous coronary intervention (primary PCI)
226703|NCT01825993|Peridural catheter
226704|NCT01825993|Morphine PCA
226705|NCT01825993|Transabdominal Block
226706|NCT01825993|laparoscopic sigmoidectomy
226707|NCT01825954|Fibromyalgia
226708|NCT01825954|Pain
226709|NCT01825954|Brain
226710|NCT01825954|Stimulation
226711|NCT01825954|Device
226712|NCT01825941|migraine
226713|NCT01825941|headache
226714|NCT01825941|metoclopramide
226715|NCT01825941|diphenhydramine
226716|NCT01825928|Methamphetamine
226717|NCT01825928|paliperidone
226718|NCT01825915|Laparoscopic
226719|NCT01825915|Hysterectomy
226720|NCT01825915|Total
226721|NCT01825915|Subtotal
226722|NCT01825915|Recovery
226723|NCT01825915|Outcomes
226724|NCT01825915|Surgery
226725|NCT01825863|Laparoscopy
226726|NCT01825863|Adult
226727|NCT01825863|Nerve block
226728|NCT01825863|Ultrasonography
226729|NCT01825837|bipolar I disorder
226730|NCT01825837|Eslicarbazepine acetate
226731|NCT01825837|BIA 2-093
226732|NCT01825824|Hepatocellular carcinoma
226733|NCT01825824|Stereotactic ablative radiotherapy
226734|NCT01825824|Stereotactic body radiotherapy
226735|NCT01825811|Cell mediated gene therapy
226736|NCT01825811|Osteoarthritis
226737|NCT01825811|Fibrin-glue
226738|NCT01825811|Degenerative Arthritis
226739|NCT01825798|Metformin
226740|NCT01825798|Overweight
226741|NCT01825798|Atypical Antipsychotic
226742|NCT01825798|Medication
226743|NCT01825798|Randomized Clinical Trial
226744|NCT01825798|Children
226745|NCT01825772|Cross-Sectional Studies
226746|NCT01825772|Prevalence
226747|NCT01825772|Peri-Implantitis
226748|NCT01825733|palonosetron, ramosetron, PONV, opioid
226749|NCT01825720|GIK, valvular heart surgery, lactate
226750|NCT01825694|Substance Abuse
226751|NCT01825694|Traumatic Stress
226752|NCT01825681|positive affect
226753|NCT01825681|caregivers
226754|NCT01825681|caregiving
226755|NCT01825681|stress
226756|NCT01825681|mood
226757|NCT01825681|dementia
226758|NCT01825681|Alzheimer's
226759|NCT01825681|FTD
226760|NCT01825681|Lewy
226761|NCT01825681|mindfulness
226762|NCT01825681|help
226763|NCT01825642|Prostate cancer
226764|NCT01825642|sexual function
226765|NCT01825642|seminal vesicle sparing
226766|NCT01825642|nerve-sparing
226767|NCT01825642|radical prostatectomy
226768|NCT01825629|Pain
226769|NCT01825629|Temporomandibular joint
226770|NCT01825629|Manual therapy
226771|NCT01825629|Physical therapy
226772|NCT01825629|Fibromyalgia Syndrome
226773|NCT01825616|Strength
226774|NCT01825616|Anaerobic power
226775|NCT01825616|Muscle soreness
226776|NCT01825616|Immune function
226777|NCT01825590|hemodialysis
226778|NCT01825590|dialysate and serum sodium
226779|NCT01825577|Alzheimer Dementia
226780|NCT01825577|Gait
226781|NCT01825564|G-tube
226782|NCT01825564|Feeding tube
226783|NCT01825564|Feeding tube placement verification
226784|NCT01825564|Enteral feeding
226785|NCT01825551|Amyotrophic Lateral Sclerosis
226786|NCT01825551|Granulocyte Colony Stimulating Factor
226787|NCT01825538|Chronic obstructive pulmonary disease
226788|NCT01825538|Pulmonary fibrosis
226789|NCT01825538|Advanced care planning
226790|NCT01825512|chronic iron overload
226791|NCT01825512|hereditary haemoglobinopathy
226792|NCT01825512|beta thalassaemia major
226793|NCT01825512|chelating agents
226794|NCT01825512|deferiprone
226795|NCT01825512|deferasirox
226796|NCT01825512|children
226797|NCT01825512|paediatrics
226798|NCT01825499|Birth weight
226799|NCT01825499|Gestational age
226800|NCT01825499|Very low birth weight
226801|NCT01825486|Balance
226802|NCT01825486|Gait characteristics
226803|NCT01825473|neonate
226804|NCT01825473|apnea
226805|NCT01825473|preterm
226806|NCT01825473|reflux
226807|NCT01825473|gastroesophageal reflux
226808|NCT01825473|impedance
226809|NCT01825473|erythromycin
226810|NCT01825473|desaturation
226811|NCT01825473|bradycardia
226812|NCT01825473|hypoxia
226813|NCT01825460|Cervical spine
226814|NCT01825460|Neck pain
226815|NCT01825460|Manual therapy
226816|NCT01825460|Controlled clinical trial
226817|NCT01825447|abuse potential
226818|NCT01825447|abuse liability
226819|NCT01825447|drug liking
226820|NCT01825447|oxycodone
226821|NCT01825447|naltrexone
226822|NCT01825447|intravenous
226823|NCT01825447|pharmacodynamic
226824|NCT01825434|chronic constipation
226825|NCT01825434|Lactobacillus acidophilus NCFM
226826|NCT01825434|Bifidobacterium lactis HN019
226827|NCT01825421|Infant
226828|NCT01825421|Infection
226829|NCT01825421|Newborn
226830|NCT01825421|Antibiotics
226831|NCT01825421|Neutrophil CD64
226832|NCT01825421|Blood Culture
226833|NCT01825369|congenital heart disease
226834|NCT01825369|ventricular septal defect
226835|NCT01825369|atrioventricular septal defect
226836|NCT01825369|increased pulmonary blood flow
226837|NCT01825369|nitric oxide
226838|NCT01825343|fall
226839|NCT01825343|burn
226840|NCT01825343|road traffic crash
226841|NCT01825330|Alzheimer's Disease
226842|NCT01825330|Alzheimer's
226843|NCT01825330|TMS
226844|NCT01825330|Cognitive Training
226845|NCT01825330|NeuroAD
226846|NCT01825317|Alzheimer's disease
226847|NCT01825317|TMS
226848|NCT01825317|NeuroAd
226849|NCT01825317|cognitive training
226850|NCT01825317|ADAS-Cog
226851|NCT01825304|mechanical ventilation
226852|NCT01825304|Intra-abdominal hypertension
226853|NCT01825304|positive end-expiratory pressure
226854|NCT01825291|sleep apnea
226855|NCT01825291|co-morbidities of sleep apnea
226856|NCT01825291|CPAP treatment
226857|NCT01825278|respiratory rate
226858|NCT01825278|tidal volume
226859|NCT01825278|minute ventilation
226860|NCT01825278|obese patients
226861|NCT01825278|obstructive sleep apnea
226862|NCT01825265|Neoplasm Metastasis
226863|NCT01825265|Breast Cancer
226864|NCT01825265|Docetaxel
226865|NCT01825265|RAD001
226866|NCT01825265|Taxotere
226867|NCT01825252|HIV
226868|NCT01825252|sexually transmitted diseases
226869|NCT01825239|ischemic cardiomyopathy
226870|NCT01825239|cardiomyopathy
226871|NCT01825239|left ventricular lead
226872|NCT01825239|cardiac electrophysiologic studies
226873|NCT01825213|Liver disease
226874|NCT01825213|Multi Spectral CT
226875|NCT01825200|Influenza
226876|NCT01825148|Diabetes
226877|NCT01825135|muscle strength
226878|NCT01825135|muscle function
226879|NCT01825135|functional status
226880|NCT01825109|Rotavirus
226881|NCT01825109|Immunogenicity
226882|NCT01825109|vaccine, Bangladesh
226883|NCT01825096|cerebral metabolism
226884|NCT01825096|functional magnetic resonance imaging
226885|NCT01825096|near infrared spectroscopy
226886|NCT01825083|Hypercarbia
226887|NCT01825083|TOSCA monitor
226888|NCT01825083|Ketamine
226889|NCT01825083|Fentanyl
226890|NCT01825083|Intraoperative monitoring
226891|NCT01825070|Montmorency tart cherries
226892|NCT01825070|Inflammation
226893|NCT01825070|Uric acid
226894|NCT01825057|implementation study
226895|NCT01825057|motivational interviewing
226896|NCT01825057|substance use
226897|NCT01825044|Traumatic Brain Injury
226898|NCT01825044|TBI
226899|NCT01825044|ciclosporin
226900|NCT01825044|pharmacokinetic
226901|NCT01825044|safety
226902|NCT01825044|microdialysis
226903|NCT01825044|mitochondrial protection
226904|NCT01825031|HIV
226905|NCT01825018|HIV
226906|NCT01825018|AIDS
226907|NCT01825018|treatment adherence
226908|NCT01825005|cervical cancer
226909|NCT01824966|Esophagectomy
226910|NCT01824966|Signet Ring Cells
226911|NCT01824953|Gastric atrophy
226912|NCT01824953|Helicobacter pylori
226913|NCT01824953|Pepsinogen
226914|NCT01824953|Gastric cancer
226915|NCT01824953|Gastric adenoma
226916|NCT01824940|Cluster randomized trial
226917|NCT01824940|Nutrition
226918|NCT01824940|Water Sanitation Hygiene
226919|NCT01824940|Environmental enteropathy
226920|NCT01824914|videolaryngoscope
226921|NCT01824914|tracheal intubation
226922|NCT01824914|Cormack-Lehane grade
226923|NCT01824914|airway evaluation
226924|NCT01824914|sedation
226925|NCT01824914|anesthesia
226926|NCT01824901|AZD4547
226927|NCT01824901|recurrent non-small cell lung cancer
226928|NCT01824888|JUC
226929|NCT01824888|hand rub
226930|NCT01824888|European standard
226931|NCT01824862|clinically significant macular edema
226932|NCT01824862|foveal thickness
226933|NCT01824862|foveal sensitivity
226934|NCT01824862|perimetry
226935|NCT01824862|diabetic retinopathy
226936|NCT01824849|Vocal cords
226937|NCT01824849|Vocal cord paralysis
226938|NCT01824849|Arytenoid cartilage
226939|NCT01824823|afatinib
226940|NCT01824823|head and neck squamous cell carcinoma
226941|NCT01824810|Intramuscular Stimulation
226942|NCT01824810|myoActivation
226943|NCT01824810|Neural Prolotherapy
226944|NCT01824810|Whiplash-Associated Disorders
226945|NCT01824810|myofascial pain
226946|NCT01824797|Bone mineral density
226947|NCT01824797|sleeve gastrectomy
226948|NCT01824797|roux-en-y
226949|NCT01824797|postmenopausal females
226950|NCT01824797|bone loss
226951|NCT01823809|Coronary Artery Disease
226952|NCT01823809|Computed Tomography
226953|NCT01823809|Cardiac Magnetic Resonance
226954|NCT01823809|Fractional Flow Reserve
226955|NCT01823796|Fibromyalgia
226956|NCT01823796|balance
226957|NCT01823796|falls
226958|NCT01823783|Duchenne muscular distrophy
226959|NCT01823783|Endomysial Fibrosis
226960|NCT01823783|Muscular Inflammatory Response
226961|NCT01823783|Calcium Homeostasis Dysfunction
226962|NCT01823783|Muscle biopsy
226963|NCT01823770|Restless Legs Syndrome (RLS)
226964|NCT01823770|Rotigotine
226965|NCT01823770|HTA
226966|NCT01823770|Cardiovascular diseases
226967|NCT01823770|Periodic Limb Movements in Sleep (PLMS)
226968|NCT01823770|dopaminergic agonist
226969|NCT01823770|Sympathetic overactivity
226970|NCT01823770|blood pressure
226971|NCT01823757|elderly
226972|NCT01823757|potential inappropriate medications
226973|NCT01823757|pharmaceutical care
226974|NCT01823757|quality of life
226975|NCT01823757|medical expenditure
226976|NCT01823744|micronutrient
226977|NCT01823744|genomic
226978|NCT01823744|SAM/SAH ratio
226979|NCT01823731|PCI,SOTOC, Ovarian cancer
226980|NCT01823692|Radius Fracture
226981|NCT01823692|Sensitivity
226982|NCT01823692|Reduction
226983|NCT01823692|Adequacy
226984|NCT01823666|Dementia
226985|NCT01823666|Alzheimer's disease
226986|NCT01823666|mild cognitive impairment
226987|NCT01823640|HRV
226988|NCT01823640|Pharmacodynamics / kinetics
226989|NCT01823640|Resistance
226990|NCT01823627|COPD
226991|NCT01823627|Psychiatric inpatient
226992|NCT01823627|Smoking
226993|NCT01823614|HIV infection
226994|NCT01823614|tropism determination
226995|NCT01823614|genotypic methodic
226996|NCT01823614|R5-tropic variant
226997|NCT01823614|X4-tropic variant
226998|NCT01823601|Well-Being
226999|NCT01823601|Life Management Program
227000|NCT01823601|Breathing
227001|NCT01823601|Meditation
227002|NCT01823601|Cognitive-Behavioral Training
227003|NCT01824784|Normal Eyes
227004|NCT01824771|Continuous veno-venoous haemofiltration
227005|NCT01824771|Plasma lactate
227006|NCT01824771|Critical illness
227007|NCT01824771|Acute kidney injurytissue perfusion
227008|NCT01824771|Multiple organ dysfunction syndrome
227009|NCT01824758|esmolol, injection pain, lidocaine, rocuronium
227010|NCT01824706|cranial prosthesis
227011|NCT01824680|Obesity
227012|NCT01824680|Appetite regulation
227013|NCT01824680|Hormones
227014|NCT01824680|Adolescents
227015|NCT01824680|Exercise
227016|NCT01824654|Aortic Aneurysm, Abdominal
227017|NCT01824654|Imaging, Three-Dimensional
227018|NCT01824654|Tomography Scanners, X-Ray Computed
227019|NCT01824654|Angiography, Digital Subtraction
227020|NCT01824654|Endovascular Procedures
227021|NCT01824654|Radiography, Interventional
227022|NCT01824641|Acute myocardial infarction
227023|NCT01824641|Manual thrombus aspiration
227024|NCT01824641|Coronary physiology
227025|NCT01824615|Sunitinib
227026|NCT01824615|recurrent ovarian cancer
227027|NCT01824615|clear cell carcinoma
227028|NCT01824602|BIPOLAR I DISORDER, Eslicarbazepine acetate
227029|NCT01824589|traumatic brain injury
227030|NCT01824589|TBI
227031|NCT01824589|ITPR
227032|NCT01824589|intrathoracic pressure regulator
227033|NCT01824589|hepatic encephalopathy
227034|NCT01824589|pseudotumorcerebri
227035|NCT01824589|obstructive hydrocephalus
227036|NCT01824589|intracranial hemorrhage
227037|NCT01824576|ITPR
227038|NCT01824576|CPP
227039|NCT01824576|TBI
227040|NCT01824576|traumatic brain injury
227041|NCT01824576|cerebral perfusion pressure
227042|NCT01824576|intrathoracic pressure regulator
227043|NCT01824537|Human papillomavirus (HPV)
227044|NCT01824537|Vaccination
227045|NCT01824537|Cervical cancer prevention
227046|NCT01824537|Herd immunity
227047|NCT01824524|Pain
227048|NCT01824524|Hydromorphone
227049|NCT01824524|OROS
227050|NCT01824511|smoking
227051|NCT01824511|nicotine
227052|NCT01824511|tobacco
227053|NCT01824511|anhedonia
227054|NCT01824511|reward
227055|NCT01824511|withdrawal
227056|NCT01824498|omega-3 fatty acids
227057|NCT01824498|sex hormones
227058|NCT01824498|urinary sex hormone metabolites
227059|NCT01824485|Osteoarthritis
227060|NCT01824485|Knee
227061|NCT01824485|Viscosupplementation
227062|NCT01824485|Clinical Trial
227063|NCT01824459|Diffuse-type gastric cancer
227064|NCT01824459|Advance Gastric Cancer
227065|NCT01824459|Recurrent Gastric Cancer
227194|NCT01823484|hemofilter
227066|NCT01824459|Gastroesophageal Junction Adenocarcinoma
227067|NCT01824459|SOX, S-1+Oxaliplatin
227068|NCT01824459|OS,
227069|NCT01824459|ORR,
227070|NCT01824459|TTP,
227071|NCT01824459|TTF,
227072|NCT01824459|safety
227073|NCT01824433|venlafaxine
227074|NCT01824433|fluoxetine
227075|NCT01824433|postmenopause
227076|NCT01824433|major depressive disorder
227077|NCT01824420|Refractory overactive bladder syndrome
227078|NCT01824420|Antimuscarinic agent
227079|NCT01824407|foot
227080|NCT01824407|ulcers
227081|NCT01824407|diabetes
227082|NCT01824407|wound
227083|NCT01824407|healing
227084|NCT01824394|nMARQ
227085|NCT01824394|Atrial Fibrillation
227086|NCT01824394|Drug Refractory
227087|NCT01824394|Radio Frequency
227088|NCT01824381|extensive wounds
227089|NCT01824381|amniotic membrane
227090|NCT01824381|healing
227091|NCT01824381|patients
227092|NCT01824381|phase granulation
227093|NCT01824329|Bladder Cancer
227094|NCT01824329|Transitional cell carcinoma of the bladder
227095|NCT01824264|Type 2 Diabetes mellitus, SGLT inhibitors, dose-response
227096|NCT01824251|IVIG in Chronic Inflammatory Demyelinating Polyneuropathy
227097|NCT01824251|Patients with Chronic Inflammatory Demyelinating Polyneuropathy
227098|NCT01824225|aflibercept
227099|NCT01824225|intravitreal injection
227100|NCT01824212|Ventricular fibrillation
227101|NCT01824212|Cardiac arrest
227102|NCT01824212|Mobile technology
227103|NCT01824199|Esophagitis
227104|NCT01824173|muscle
227105|NCT01824173|mitochondria
227106|NCT01824173|amino acids
227107|NCT01824173|exercise
227108|NCT01824147|ASS-Nonresponse
227109|NCT01824147|cardiac
227110|NCT01824147|surgery
227111|NCT01824121|Progressive Supranuclear palsy
227112|NCT01824121|stem cell therapy
227113|NCT01824108|Lumbar disc herniation
227114|NCT01824108|Wallis interspinous implants
227115|NCT01824108|lumbar discectomy
227116|NCT01824108|interspinous dynamic stability system
227117|NCT01824082|phantom pain
227118|NCT01824082|traumatic limb amputation
227119|NCT01824082|amputees
227120|NCT01824069|Critical Ischemia
227121|NCT01824069|Amputation
227122|NCT01824056|18F-FDG
227123|NCT01824043|diabetic retinopathy
227124|NCT01824043|vitreous hemorrhage
227125|NCT01824043|intravitreal ranibizumab
227126|NCT01824030|FFR, OCT, Seattle Angina Questionnaire
227127|NCT01824017|Type 2 diabetes
227128|NCT01824017|metabolic syndrome
227129|NCT01824017|oxidative stress
227130|NCT01824017|GSH
227131|NCT01824004|Gastric cancer
227132|NCT01824004|Adjuvant
227133|NCT01824004|Chemoradiotherapy
227134|NCT01824004|S-1
227135|NCT01824004|Cisplatin
227136|NCT01823991|polyphenolics
227137|NCT01823991|anthocyanins
227138|NCT01823991|n-3 fatty acids
227139|NCT01823978|metastatic
227140|NCT01823978|castration resistant prostate cancer
227141|NCT01823978|Therapeutic Vaccine
227142|NCT01823978|Dendritic cell
227143|NCT01823978|BPX-201
227144|NCT01823978|BPX201
227145|NCT01823978|AP1903
227146|NCT01823952|HAMS
227147|NCT01823952|ORS
227148|NCT01823952|Cholera
227149|NCT01823952|Diarrhea
227150|NCT01823939|Cholera
227151|NCT01823939|V. Cholerae O1
227152|NCT01823939|iOWH032
227153|NCT01823939|diarrhoea
227154|NCT01823939|pharmacokinetic
227155|NCT01823939|Bangladesh
227156|NCT01823926|vibrating mesh nebulizers
227157|NCT01823926|noninvasive ventilation
227158|NCT01823926|residual volume
227159|NCT01823926|pulmonary scintigraphy
227160|NCT01823926|radioaerosol
227161|NCT01823926|nebulization.
227162|NCT01823913|Pharmacokinetics
227163|NCT01823900|Pharmacokinetics
227164|NCT01823887|Heart Failure
227165|NCT01823887|Vagus Nerve
227166|NCT01823887|VNS
227167|NCT01823874|Virtual reality analgesia
227168|NCT01823874|pain control
227169|NCT01823848|constipation
227170|NCT01823848|enema
227171|NCT01823822|Anorexia nervosa
227172|NCT01823822|Protein supplements
227173|NCT01823822|IGF-I
227174|NCT01823575|malignant ureteral obstruction
227175|NCT01823575|silicone-covered metallic ureteral stent
227176|NCT01823575|double-J stent
227177|NCT01823562|Lyophilized Black Raspberry
227178|NCT01823562|Prostate Cancer
227179|NCT01823562|Surgery
227180|NCT01823549|CAM
227181|NCT01823549|Alternative Medicine
227182|NCT01823536|Meningitis
227183|NCT01823510|Antiplatelet
227184|NCT01823510|Ticagrelor
227185|NCT01823510|Clopidogrel
227186|NCT01823510|Thrombosis
227187|NCT01823510|Diabetes
227188|NCT01823510|Coronary Artery Disease
227189|NCT01823497|Neonatal Intensive Care Unit
227190|NCT01823497|neonate
227191|NCT01823497|pain
227192|NCT01823497|morphine
227193|NCT01823497|Parent/Nurse Controlled Analgesia
227195|NCT01823484|coagulation
227196|NCT01823484|CRRT
227197|NCT01823484|critically ill
227198|NCT01823471|HNPCC
227199|NCT01823471|Hereditary non-polyposis colon carcinoma
227200|NCT01823471|Lynch syndrome
227201|NCT01823471|i-scan
227202|NCT01823471|virtual chromo-endoscopy
227203|NCT01823471|chromo-endoscopy
227204|NCT01823471|high definition endoscopy
227205|NCT01823471|polyp detection
227206|NCT01823471|adenoma detection
227207|NCT01823471|adenoma miss rate
227208|NCT01823458|behavioral economics
227209|NCT01823458|incentives
227210|NCT01823458|health behavior
227211|NCT01823458|exercise
227212|NCT01823445|Xylitol
227213|NCT01823445|Dental caries
227214|NCT01823393|balloon aortic valvuloplasty indication
227215|NCT01823393|heparin
227216|NCT01823393|hemorrhagic
227217|NCT01823393|ischemic
227218|NCT01823380|Amyotrophic lateral sclerosis
227219|NCT01823380|Vitamin D
227220|NCT01823380|Blood Levels
227221|NCT01823367|type 2 diabetes mellitus prevention
227222|NCT01823367|gestational diabetes mellitus
227223|NCT01823367|pre-diabetes
227224|NCT01823367|lifestyle interventions
227225|NCT01823367|pediatric primary prevention of type 2 diabetes
227226|NCT01823354|Restless Legs Syndrome
227227|NCT01823354|Polysomnography
227228|NCT01823354|Executive cognition
227229|NCT01823341|Type 1 Diabetes
227230|NCT01823341|Hypoglycemia
227231|NCT01823341|Continuous Glucose Monitoring
227232|NCT01823341|Pump Suspension
227233|NCT01823328|Intubation
227234|NCT01823328|Airway
227235|NCT01823328|Emergent intubation
227236|NCT01823328|Rapid sequence intubation
227237|NCT01823328|Rapid sequence induction
227238|NCT01823328|RSI
227239|NCT01823328|Ketamine
227240|NCT01823328|Etomidate
227241|NCT01823328|Sepsis
227242|NCT01823328|Sedative
227243|NCT01823328|Sedation
227244|NCT01823302|Children with picky-eating behaviors
227245|NCT01823302|Children aged 2.5 - 5 years
227246|NCT01823302|reported by caregivers
227247|NCT01823302|with weight-for-height z-scores ≤ 25th percentile at enrollment
227248|NCT01823289|Invasive Pulmonary Fungal Infection
227249|NCT01823289|Itraconazole
227250|NCT01823250|Hispanic
227251|NCT01823250|adolescent
227252|NCT01823250|drug abuse treatment
227253|NCT01823250|evidence-based
227254|NCT01823250|family therapy
227255|NCT01823250|adaptive family treatment
227256|NCT01823250|Culturally Informed Family-Based Treatment for Adolescents
227257|NCT01823237|Dystonia
227258|NCT01823237|Transcranial Magnetic Stimulation
227259|NCT01823237|Rehabilitation
227260|NCT01823237|Plasticity
227261|NCT01823211|ICD (Implantable cardioverter-defibrillator)
227262|NCT01823211|Heart rate variability
227263|NCT01823211|MTWA (Microvolt T-alternans)
227264|NCT01823211|Magnetic resonance imaging (MRI)
227265|NCT01823198|Leukemia
227266|NCT01823198|Acute myeloid leukemia
227267|NCT01823198|AML
227268|NCT01823198|Myelodysplastic syndromes
227269|NCT01823198|MDS
227270|NCT01823198|Blood And Marrow Transplantation
227271|NCT01823198|Myeloproliferative Diseases
227272|NCT01823198|High Risk Myeloid Malignancies
227273|NCT01823198|Allogeneic stem cell transplant
227274|NCT01823198|Natural Killer Cells
227275|NCT01823198|NK
227276|NCT01823198|Immune cells
227277|NCT01823198|Stem cell transplant
227278|NCT01823198|Busulfan
227279|NCT01823198|Busulfex
227280|NCT01823198|Myleran
227281|NCT01823198|Interleukin-2
227282|NCT01823198|IL-2
227283|NCT01823198|Aldesleukin
227284|NCT01823198|Proleukin
227285|NCT01823198|Thymoglobulin
227286|NCT01823198|Antithymocyte globulin
227287|NCT01823198|ATG
227288|NCT01823198|G-CSF
227289|NCT01823198|Filgrastim
227290|NCT01823198|Neupogen
227291|NCT01823198|Tacrolimus
227292|NCT01823198|Prograf
227293|NCT01823198|Methotrexate
227294|NCT01823185|Clopidogrel
227295|NCT01823185|Ticagrelor
227296|NCT01823185|Prasugrel
227297|NCT01823185|Platelet aggregation inhibitor
227298|NCT01823185|Dammam University
227299|NCT01823185|King Fahd Hospital
227300|NCT01823185|Purinergic P2 receptor Antagonists
227301|NCT01823172|breast cancer
227302|NCT01823172|melanoma
227303|NCT01823172|sentinel lymph node biopsy
227304|NCT01823172|lymphadenectomy
227305|NCT01823159|retigabine
227306|NCT01823159|cortical excitability
227307|NCT01823159|Transcranial Magnetic Stimulation
227308|NCT01823146|oxytocin
227309|NCT01823146|socioemotional functioning
227310|NCT01823146|trust
227311|NCT01823146|amygdala
227312|NCT01823146|aging
227313|NCT01823120|Self harm
227314|NCT01823120|Emergency Department
227315|NCT01823120|Repetition
227316|NCT01823120|Supportive Text messages
227317|NCT01823120|Interactive
227318|NCT01823107|Meso BioMatrix
227319|NCT01823107|Breast
227320|NCT01823107|Breast Cancer
227321|NCT01823107|Mastectomy
227322|NCT01823107|Biologic Mesh
227323|NCT01823107|Breast Reconstruction
227324|NCT01823094|lung cancer
227325|NCT01823094|computed tomography
227326|NCT01823094|blood flow
227327|NCT01823068|Lung cancer
227328|NCT01823068|RET fusion
227329|NCT01823068|Vandetanib
227330|NCT01823042|Crohn's Disease
227331|NCT01823042|maintain remission
227332|NCT01823042|postoperative recurrence
227333|NCT01823042|surgery
227334|NCT01823042|living quality
227335|NCT01823029|Crohn's Disease
227336|NCT01823029|intravenous iron
227337|NCT01823029|iron deficiency anaemia
227338|NCT01823029|Oxidative Stress
227339|NCT01823029|inflammation
227340|NCT01823016|Uncontrolled, persistent asthma
227341|NCT01823003|Carcinoma, Non-Small-Cell Lung
227342|NCT01823003|Neoplasm Metastasis
227343|NCT01823003|Radiosurgery
227344|NCT01822990|Anti-beta2-glycoprotein antibodies
227345|NCT01822990|Peripheral arterial disease
227346|NCT01822990|Inflammation
227347|NCT01822990|Nitric oxide
227348|NCT01822990|Endothelial dysfunction
227349|NCT01822977|gut microbiota
227350|NCT01822977|proton pump inhibitor
227351|NCT01822977|Clostridium difficile infection
227352|NCT01822977|Fecal microbiome
227353|NCT01822977|single episode of CDI
227354|NCT01822951|DAT Study
227355|NCT01822925|Diabetes
227356|NCT01822925|Pain
227357|NCT01822925|Neuropathy
227358|NCT01822912|Skilled Nursing Facility
227359|NCT01822912|Heart Failure
227360|NCT01822912|Transitional Care
227361|NCT01822899|Novel Dry Powder Inhaler (NDPI)
227362|NCT01822899|umeclidinium bromide (UMEC)
227363|NCT01822899|GSK573719
227364|NCT01822899|lung function
227365|NCT01822899|GW642444
227366|NCT01822899|salmeterol (SAL)
227367|NCT01822899|fluticasone propionate (FP)
227368|NCT01822899|vilanterol (VI)
227369|NCT01822899|Chronic obstructive pulmonary disease
227370|NCT01822886|T-cell lymphoma
227371|NCT01822886|Romidepsin
227372|NCT01822860|Hypertension
227373|NCT01822860|Endothelial dysfunction
227374|NCT01822847|adrenal
227375|NCT01822847|steroids
227376|NCT01822847|cortisol
227377|NCT01822847|stress
227378|NCT01822821|Males or females
227379|NCT01822821|18 years of age or older.
227380|NCT01822821|Non-emergency
227381|NCT01822821|cardiac surgery
227382|NCT01822821|midline sternotomy.
227383|NCT01822808|acute heart failure
227384|NCT01822808|left ventricular dysfunction
227385|NCT01822808|hydralazine
227386|NCT01822808|isosorbide dinitrate
227387|NCT01822795|Chronic obstructive pulmonary disease
227388|NCT01822795|Endoscopic lung volume reduction
227389|NCT01822782|Perineal tear
227390|NCT01822782|Perineal lesion
227391|NCT01822782|Vaginal flora
227392|NCT01822782|Birth
227393|NCT01822769|congenital heart disease
227394|NCT01822769|adult congenital heart disease
227395|NCT01822769|cardiac rehabilitation
227396|NCT01822769|cardiopulmonary rehabilitation
227397|NCT01822769|exercise
227398|NCT01822769|cardiopulmonary exercise testing
227399|NCT01822769|peak vO2
227400|NCT01822769|quality of life
227401|NCT01822743|Osteopathy
227402|NCT01822743|Sleep Apnea Syndromes
227403|NCT01822743|Obstructive Sleep Apnea
227404|NCT01822743|Pcrit
227405|NCT01822743|Polysomnography
227406|NCT01822730|Methamphetamine-Associated Psychosis
227407|NCT01822730|Aripiprazole
227408|NCT01822730|Risperidone
227409|NCT01822717|Diabetes
227410|NCT01822717|Visual Impairment
227411|NCT01822717|Blindness
227412|NCT01822717|Foot Care
227413|NCT01822717|Self-Management
227414|NCT01822704|Stroke
227415|NCT01822704|Exercise
227416|NCT01822704|Rehabilitation
227417|NCT01822704|Vibration
227418|NCT01822691|myelodysplastic syndromes (MDS)
227419|NCT01822691|neoplastic stem cell disorders
227420|NCT01822691|refractory cytopenias
227421|NCT01822691|dysplastic morphological features
227422|NCT01822691|acute myeloid leukemia (AML)
227423|NCT01822652|Neuroblastoma
227424|NCT01822652|Solid tumor
227425|NCT01822652|Neuroblastoma-specific immunotherapy targeting GD2
227426|NCT01822652|CAR T cells
227427|NCT01822652|Gene Therapy
227428|NCT01822652|Relapsed
227429|NCT01822652|Refractory
227430|NCT01822639|Hypertension
227431|NCT01822639|enalapril maleate
227432|NCT01822639|healthy volunteers
227433|NCT01822639|amlodipine
227434|NCT01822639|pharmacokinetics
227435|NCT01822626|overweight
227436|NCT01822626|obesity
227437|NCT01822626|children
227438|NCT01822626|BMI
227439|NCT01822626|counseling
227440|NCT01822626|pediatrician
227441|NCT01822613|esophageal cancer
227442|NCT01822600|hypoalbuminemia
227443|NCT01822600|peptic ulcer
227444|NCT01822600|rebleeding
227445|NCT01822600|hospitalization
227446|NCT01822587|Drug Abuse
227447|NCT01822587|Cocaine
227448|NCT01822587|Addiction
227449|NCT01822561|Central Serous Chorioretinopathy
227450|NCT01822561|Eplerenone
227451|NCT01822561|Optical Coherence Tomography
227452|NCT01822561|Enhanced Depth Imaging
227453|NCT01822561|Subretinal Fluid
227454|NCT01822548|EPC
227455|NCT01822548|diabetes
227456|NCT01822548|DPP IV inhibitors
227457|NCT01822535|Quadriplegia
227458|NCT01822535|Spinal Cord Injuries
227459|NCT01822535|Body Temperature Regulation
227460|NCT01822535|Mild Cognitive Impairment
227461|NCT01822483|Renal transplantation
227462|NCT01822483|mycophenolic acid
227463|NCT01822483|mycophenolate mofetil
227464|NCT01822483|mycophenolate sodium
227465|NCT01822483|area under the curve
227466|NCT01822470|functional dyspepsia
227467|NCT01822470|post prandial distress syndrome
227468|NCT01822470|small bowel bacteria overgrowth
227469|NCT01822470|epigastric pain syndrome
227470|NCT01822470|diarrhea
227471|NCT01822470|bloating
227472|NCT01822470|post prandial fullness
227473|NCT01822470|weight loss
227474|NCT01822444|Colorectal Cancer
227475|NCT01822444|Advanced Colorectal Cancer
227476|NCT01822444|Metastatic Colorectal Cancer
227477|NCT01822444|Locally Advanced Colorectal Cancer
227478|NCT01822444|Colon Cancer
227479|NCT01822444|Rectal Cancer
227480|NCT01822418|Schizophrenia
227481|NCT01822418|Depression
227482|NCT01822418|Cognition
227483|NCT01822418|Agomelatine
227484|NCT01822418|Antidepressant
227485|NCT01822392|Online treatment
227486|NCT01822392|Treatment of conduct problems
227487|NCT01822392|Parent training
227488|NCT01822366|Children
227489|NCT01822366|Adolescents
227490|NCT01822366|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
227491|NCT01822366|Low- and Middle-Income Countries (LAMIC)
227492|NCT01822366|Randomized Controlled Trial (RCT)
227493|NCT01822366|Evidence-Based Practice (EBP)
227494|NCT01822366|Childhood Traumatic Grief (CTG)
227495|NCT01822366|Post-Traumatic Stress Disorder (PTSD)
227496|NCT01822366|Kenya
227497|NCT01822366|Tanzania
227498|NCT01822366|East Africa
227499|NCT01822366|Mental Health
227500|NCT01822353|food allergy
227501|NCT01822353|milk allergy
227502|NCT01822353|egg allergy
227503|NCT01822353|nut allergy
227504|NCT01822340|AGHD
227505|NCT01822314|breast
227506|NCT01822314|cancer
227507|NCT01822314|unilateral
227508|NCT01822314|non metastatic
227509|NCT01822314|HER2 negative
227510|NCT01822301|Craniomaxillofacial (CMF) Battle-injured (BI)
227511|NCT01822301|Facial Trauma
227512|NCT01822301|Fat Grafts
227513|NCT01822301|Autogenous Fat Transfers (AFT)
227514|NCT01822301|Wounded warriors
227515|NCT01822288|Menopause
227516|NCT01822288|Tibolone
227517|NCT01822288|Estradiol
227518|NCT01822288|Hormone therapy
227519|NCT01822275|GBM
227520|NCT01822262|Cholecystolithotomy with gallbladder reservation
227521|NCT01822262|cholecystolithiasis
227522|NCT01822249|Rett syndrome
227523|NCT01822249|EPI-743
227524|NCT01822249|Edison
227525|NCT01822236|low back pain
227526|NCT01822236|Manual Therapy
227527|NCT01822236|Randomized Controlled Trial
227528|NCT01822236|Quality of life
227529|NCT01822223|Dental Implants
227530|NCT01822223|Implant abutments
227531|NCT01822210|Botulinum Toxins
227532|NCT01822210|Injections
227533|NCT01822210|Stomach
227534|NCT01822210|Tomography, X-Ray Computed
227535|NCT01822197|Phototherapy
227536|NCT01822184|Neurodevelopmental Status
227537|NCT01822184|Pediatric Hunter syndrome patients
227538|NCT01822184|Central Nervous System (CNS) involvement
227539|NCT01822184|Observational study
227540|NCT01822184|Cognitive impairment
227541|NCT01822171|Heart Failure
227542|NCT01822171|Medication Therapy Management
227543|NCT01822158|Vaginal Delivery
227544|NCT01822158|Debrief
227545|NCT01822158|Medical Team Communication
227546|NCT01822158|Obstetrical Safety
227547|NCT01822145|implantable-cardioverter-defibrillator
227548|NCT01822145|ventricular tachycardia
227549|NCT01822145|ventricular fibrillation
227550|NCT01822145|sudden cardiac arrest
227551|NCT01822080|Endometriosis
227552|NCT01822080|Efficacy
227553|NCT01822080|Safety
227554|NCT01822080|Dienogest
227555|NCT01822041|healthy volunteers
227556|NCT01822041|mass balance study
227557|NCT01822041|Pharmacokinetics
227558|NCT01822028|diarrhea
227559|NCT01822002|Vertigo
227560|NCT01822002|Nystagmus
227561|NCT01822002|BPPV = benign paroxysmal positional vertigo
227562|NCT01822002|Treatment outcome
227563|NCT01821963|Infection
227564|NCT01821963|Hepatitis C Genotype 1 Infection
227565|NCT01821963|Hepatitis C virus
227566|NCT01821963|HCV
227567|NCT01821963|Hepatocellular Carcinoma
227568|NCT01821963|HCC
227569|NCT01821963|Liver Transplantation
227570|NCT01821963|Pegylated Interferon Alfa 2a
227571|NCT01821963|PegIFN alfa-2a
227572|NCT01821963|Ribavirin
227573|NCT01821963|RBV
227574|NCT01821963|Telaprevir
227575|NCT01821963|Incivek
227576|NCT01821963|Antiviral drugs
227577|NCT01821950|Mental health
227578|NCT01821950|Substance use
227579|NCT01821950|Substance use initiation
227580|NCT01821950|Education
227581|NCT01821950|Mind Body Therapies
227582|NCT01821950|Yoga
227583|NCT01821950|Meditation
227584|NCT01821950|Adolescent
227585|NCT01821950|Adolescence
227586|NCT01821950|Child
227587|NCT01821950|Children
227588|NCT01821950|Middle School
227589|NCT01821898|Eosinophil
227590|NCT01821898|Reflux
227591|NCT01821898|Esophagus
227592|NCT01821898|Food allergy
227593|NCT01821898|Trouble Swallowing
227594|NCT01821898|Pediatrics
227595|NCT01821885|Spirometry
227596|NCT01821885|screening
227597|NCT01821885|smoking cessation
227598|NCT01821885|tobacco
227599|NCT01821885|COPD
227600|NCT01821872|paracetamol
227601|NCT01821872|acetaminophen
227602|NCT01821872|AM404
227603|NCT01821872|CSF
227604|NCT01821872|pharmacokinetics
227605|NCT01821833|omega-3
227606|NCT01821833|fatty acids
227607|NCT01821833|paclitaxel
227608|NCT01821833|acute pain syndrome
227609|NCT01821833|peripheral neuropathy
227610|NCT01821833|chemotherapy induced neuropathy
227611|NCT01821820|Inflammation
227612|NCT01821820|Oxidative stress
227613|NCT01821820|Immune dysfunction
227614|NCT01821820|Metabolites
227615|NCT01821807|spinal anesthesia
227616|NCT01821807|spinal needle
227617|NCT01821807|cesarean section
227618|NCT01821807|headache
227619|NCT01821807|backache
227620|NCT01821781|Immune deficiency
227621|NCT01821781|Immune disorders
227622|NCT01821781|Immune dysregulatory
227623|NCT01821781|Reduced Intensity
227624|NCT01821781|Alemtuzumab
227625|NCT01821781|Campath
227626|NCT01821742|Shock
227627|NCT01821742|Fluid bolus
227628|NCT01821742|Cardiac output
227629|NCT01821742|Children in intensive care
227630|NCT01821729|Locally Advanced
227631|NCT01821690|Traumatic Brain Injury
227632|NCT01821690|Buspirone
227633|NCT01821690|Behavior
227634|NCT01821690|Irritability
227635|NCT01821690|Aggression
227636|NCT01821664|Prosthetic vascular graft infection
227637|NCT01821664|negative pressure wound therapy
227638|NCT01821664|microbiology
227639|NCT01821664|antimicrobial therapy
227640|NCT01821651|TAVI
227641|NCT01821651|MitraClip
227642|NCT01821651|image modality
227643|NCT01821651|echocardiography
227644|NCT01821651|angiography
227645|NCT01821638|Heart failure
227646|NCT01821638|Cognition
227647|NCT01821638|Brain
227648|NCT01821638|Older adults
227649|NCT01821625|Thrombocytopenia
227650|NCT01821625|HCV
227651|NCT01821625|Hepatitis
227652|NCT01821625|Platelets
227653|NCT01821625|Eltrombopag
227654|NCT01821625|Liver Disease
227655|NCT01821625|Antiviral Treatment
227656|NCT01821599|Anterior Cruciate Ligament
227657|NCT01821599|Knee
227658|NCT01821599|Rehabilitation
227659|NCT01821586|Diarrhoea;
227660|NCT01821586|Severe malnutrition;
227661|NCT01821586|Benefiber;
227662|NCT01821586|ReSoMal;
227663|NCT01821586|modified ORS
227664|NCT01821573|botulinum toxin injection,3D motion analysis, muscular lengthening,muscle strength
227665|NCT01821560|Nicotine Addiction
227666|NCT01821560|fMRI
227667|NCT01821560|Baclofen
227668|NCT01821508|Gastroplasty, Diabetes Mellitus Type II, Obesity
227669|NCT01821495|NPC,DC-CIK
227670|NCT01821482|Hepatocellular carcinoma, DC-CIK
227671|NCT01821469|bipolar disorders
227672|NCT01821469|euthymic
227673|NCT01821469|psychotherapy
227674|NCT01821469|Functional magnetic resonance imaging
227675|NCT01821456|hematological malignancies
227676|NCT01821456|cancer
227677|NCT01821456|chemotherapy
227678|NCT01821456|anti-infectives
227679|NCT01821456|treatment
227680|NCT01821456|outcome
227681|NCT01821443|1 to 10 measurable brain metastases
227682|NCT01821430|Chronic Pain
227683|NCT01821430|Narcotic Abuse
227684|NCT01821430|Opioid related disorders
227685|NCT01821430|Opiate substitution treatment
227686|NCT01821430|Buprenorphrine
227687|NCT01821430|Pregabalin
227688|NCT01821430|Methadone
227689|NCT01821417|dental implants
227690|NCT01821417|screw-vent dental implants
227691|NCT01821404|Apoptosis
227692|NCT01821404|Atorvastatin
227693|NCT01821404|Inflammation
227694|NCT01821404|Pre-surgical trial
227695|NCT01821404|Proliferation
227696|NCT01821404|Prostate cancer
227697|NCT01821391|actinic keratoses
227698|NCT01821391|photodynamic therapy
227699|NCT01821391|natural daylight
227700|NCT01821378|Schizophrenia
227701|NCT01821378|Lurasidone
227702|NCT01821378|Latuda
227703|NCT01821365|COPD,PETCO2,PaCO2
227704|NCT01821326|capsule endoscopy
227705|NCT01821326|obscure gastrointestinal bleeding
227706|NCT01821326|rebleeding
227707|NCT01821326|risk factors
227708|NCT01821313|Childhood obesity
227709|NCT01821313|Inflammation
227710|NCT01821313|Endothelial function
227711|NCT01821313|Exercise
227712|NCT01821300|Down syndrome
227713|NCT01821300|Philadelphia
227714|NCT01821300|The Children's Hospital of Philadelphia
227715|NCT01821300|Body composition
227716|NCT01821300|Obesity
227717|NCT01821300|Cardiovascular
227718|NCT01820442|lofexidine
227719|NCT01820442|buprenorphine
227720|NCT01820442|interaction
227721|NCT01820442|pharmacodynamic
227722|NCT01820442|ECG
227723|NCT01820442|QTc
227724|NCT01820429|Platelet aggregation
227725|NCT01820429|Aspirin
227726|NCT01820416|Hearing Loss, Bilateral
227727|NCT01820416|Hearing Loss, Sensorineural
227728|NCT01820390|Deep Brain Stimulation (DBS)
227729|NCT01820390|Parkinson's Disease
227730|NCT01820390|Essential Tremor
227731|NCT01820377|Peer-mentoring
227732|NCT01820377|Obesity
227733|NCT01820377|Type 2 Diabetes
227734|NCT01820377|Physical Activity
227735|NCT01820377|After-school program
227736|NCT01820364|open-label study
227737|NCT01820364|BRAF inhibitor
227738|NCT01820364|LGX818
227739|NCT01820364|MEK1620
227740|NCT01820364|MAPK1/2 inhibitor
227741|NCT01820364|Pi3K inhibitor
227742|NCT01820364|FGFR
227743|NCT01820364|c-Met
227744|NCT01820364|CDK4/6
227745|NCT01820364|metastatic melanoma
227746|NCT01820364|BRAF
227747|NCT01820364|V600
227748|NCT01820338|Children, Obesity, Intervention
227749|NCT01820325|Squamous non-small cell lung cancer
227750|NCT01820325|NSCLC
227751|NCT01820325|stage IV
227752|NCT01820325|BKM120
227753|NCT01820286|Bipolar disorder
227754|NCT01820286|Depression
227755|NCT01820286|Positive psychology
227756|NCT01820273|Type 2 diabetes
227757|NCT01820273|Bariatric surgery
227758|NCT01820273|incretines
227759|NCT01820273|GLP-1
227760|NCT01820273|GIP
227761|NCT01820273|gastric bypass
227762|NCT01820273|foregut
227763|NCT01820273|hindgut
227764|NCT01820247|Crohn's Disease
227765|NCT01820247|enteral nutrition
227766|NCT01820247|Tripterygium Glycosides
227767|NCT01820247|induction remission
227768|NCT01821222|Maternal health
227769|NCT01821222|Neonatal health
227770|NCT01821222|mHealth
227771|NCT01821222|Mobile phones
227772|NCT01821222|Access to health services
227773|NCT01821222|Health behavior
227774|NCT01821209|prostate cancer, robotic surgery, urethral sling,
227775|NCT01821196|Tumor Markers, Biological
227776|NCT01821196|PGP9.5 protein, human
227777|NCT01821196|adenocarcinoma
227778|NCT01821170|ADHD
227779|NCT01821170|children
227780|NCT01821170|cognitive remediation
227781|NCT01821170|virtual reality
227782|NCT01821157|crown lengthening
227783|NCT01821157|gingivoplasty
227784|NCT01821157|surgical procedures
227785|NCT01821157|gingivectomy
227786|NCT01821157|esthetic surgery
227787|NCT01821144|dietary salt
227788|NCT01821144|24 hour urinary sodium
227789|NCT01821144|blood pressure
227790|NCT01821131|flax
227791|NCT01821131|muffin
227792|NCT01821131|cholesterol
227793|NCT01821131|lignan
227794|NCT01821131|ALA
227795|NCT01821118|Cerebral amyloid angiopathy (CAA)
227796|NCT01821118|cerebrovascular reactivity
227797|NCT01821118|functional MRI
227798|NCT01821118|randomized
227799|NCT01821118|double blind
227800|NCT01821118|safety
227801|NCT01821118|efficacy
227802|NCT01821105|computed tomography
227803|NCT01821105|CT scan
227804|NCT01821105|positron emission tomography
227805|NCT01821105|PET
227806|NCT01821105|Metastatic Colorectal Cancer
227807|NCT01821092|osseointegrated Implant, bone level
227808|NCT01821079|Single dose
227809|NCT01821079|Relative Bioavailability
227810|NCT01821079|Food effect
227811|NCT01821079|Healthy subjects
227812|NCT01821079|Diabetes Mellitus Type 2
227813|NCT01821066|PD-0332991
227814|NCT01821066|palbociclib
227815|NCT01821066|tamoxifen
227816|NCT01821066|drug-drug interaction (DDI) study
227817|NCT01821053|Preeclampsia
227818|NCT01821053|Pregestational Type 1 diabetes
227819|NCT01821053|diabetes mellitus
227820|NCT01821053|proteinuria
227821|NCT01821053|plasminogen
227822|NCT01821053|plasmin
227823|NCT01821053|renin
227824|NCT01821053|aldosterone
227825|NCT01821053|angiotensin
227826|NCT01821053|epithelial sodium channel
227827|NCT01821053|ENaC
227828|NCT01821040|Polymyalgia rheumatica
227829|NCT01821040|PMR
227830|NCT01821040|Modified release prednisone
227831|NCT01821027|Healthy
227832|NCT01821027|Canagliflozin (JNJ-28431754)
227833|NCT01821027|Pharmacokinetics
227834|NCT01821027|Pharmacodynamics
227835|NCT01821027|Simvastatin (ZOCOR)
227836|NCT01821014|Diagnostic concordance
227837|NCT01821014|Treatment concordance
227838|NCT01821014|patient satisfaction
227839|NCT01821014|physician satisfaction
227840|NCT01821014|Medical Outreach Clinics
227841|NCT01821014|Medical Brigades
227842|NCT01821014|Medical Missions
227843|NCT01821014|Telemedicine
227844|NCT01821014|Videoconference
227845|NCT01821014|diagnoses
227846|NCT01821014|treatments
227847|NCT01821014|Satellite Internet
227848|NCT01821014|VSAT
227849|NCT01821014|cross cultural telemedicine
227850|NCT01821001|Adenomyosis
227851|NCT01821001|Dysmenorrhea
227852|NCT01821001|Abnormal Uterine bleeding
227853|NCT01821001|Heavy Menstrual Bleeding
227854|NCT01821001|Menorrhagia
227855|NCT01820975|Muscle protein synthesis
227856|NCT01820975|Dietary protein
227857|NCT01820962|hematological patients
227858|NCT01820962|central venous catheters
227859|NCT01820962|catheter related thrombosis
227860|NCT01820962|catheter related infections
227861|NCT01820962|concentrated citrate
227862|NCT01820949|patient blood management
227863|NCT01820949|patients safety
227864|NCT01820936|Healthy volunteers
227865|NCT01820936|PCI-32765
227866|NCT01820936|PCI-45227
227867|NCT01820936|Pharmacokinetics
227868|NCT01820871|T2DM
227869|NCT01820871|smartphone application
227870|NCT01820871|serum fasting glucose
227871|NCT01820871|HbA1c
227872|NCT01820845|Plethysmographic Variability Index
227873|NCT01820845|Esophageal Doppler
227874|NCT01820845|Scoliosis
227875|NCT01820845|Children
227876|NCT01820845|Age < 18 years
227877|NCT01820845|Scheduled for Scoliosis Surgery
227878|NCT01820832|mild proteinuria
227879|NCT01820832|calcitriol
227880|NCT01820832|renal function
227881|NCT01820832|blood pressure
227882|NCT01820819|Inpatient
227883|NCT01820819|Liver cirrhosis
227884|NCT01820819|Liver Cirrhosis, Alcoholic
227885|NCT01820819|Physician's Practice Patterns
227886|NCT01820819|Liver Transplantation
227887|NCT01820819|Delivery of Health Care
227888|NCT01820819|Resource Allocation
227889|NCT01820793|antibiotic resistance
227890|NCT01820793|E.coli
227891|NCT01820793|cefoxitin
227892|NCT01820793|pyelonephritis
227893|NCT01820780|Heart failure
227894|NCT01820780|Disease management program
227895|NCT01820767|Chronic Kidney Disease
227896|NCT01820767|Vd-stadium.
227897|NCT01820767|Inflammatory patterns
227898|NCT01820767|Paricalcitol
227899|NCT01820767|Atorvastatin
227900|NCT01820754|Non Small Cell Lung Cancer
227901|NCT01820754|Lung Cancer
227902|NCT01820754|Non Small Cell
227903|NCT01820702|bone metabolism
227904|NCT01820702|acid base balance
227905|NCT01820702|bed rest
227906|NCT01820663|stroke
227907|NCT01820663|ketones
227908|NCT01820663|ketogenic diet
227909|NCT01820663|impairment
227910|NCT01820663|disability
227911|NCT01820650|osteoarthritis
227912|NCT01820650|knee replacement
227913|NCT01820650|patient-specific
227914|NCT01820637|atherosclerosis
227915|NCT01820637|SFA
227916|NCT01820637|PPA
227917|NCT01820637|lower extremities
227918|NCT01820637|stenting
227919|NCT01820637|paclitaxel
227920|NCT01820585|fibromyalgia
227921|NCT01820585|Eslicarbazepine acetate (BIA 2-093)
227922|NCT01820585|ESL
227923|NCT01820559|migraine; ESL; eslicarbazepine acetate
227924|NCT01820533|Smoking
227925|NCT01820533|Cellular phones
227926|NCT01820533|Low income population
227927|NCT01820507|Post-extubation respiratory failure
227928|NCT01820507|Endotracheal intubation
227929|NCT01820507|Mechanical ventilation
227930|NCT01820494|growth
227931|NCT01820494|infants
227932|NCT01820481|Asthma
227933|NCT01820481|Bronchial Diseases
227934|NCT01820481|Respiratory Tract Diseases
227935|NCT01820481|Lung Diseases, Obstructive
227936|NCT01820481|Lung Diseases
227937|NCT01820455|MRSA decolonization
227938|NCT01820455|MRSA subtyping
227939|NCT01820455|MRSA infection rates
227940|NCT01820234|Skin cancer
227941|NCT01820234|Teledermatology
227942|NCT01820234|Screening
227943|NCT01820234|Store-and-forward
227944|NCT01820221|cesarean delivery
227945|NCT01820221|wound complications
227946|NCT01820221|skin closure methods
227947|NCT01820195|Contrast Nephropathy
227948|NCT01820195|N-Acetyl Cystein
227949|NCT01820195|Prophylaxy
228073|NCT01819571|diastolic dysfunction
227950|NCT01820117|long-term health outcomes
227951|NCT01820078|Chronic
227952|NCT01820078|Kidney
227953|NCT01820078|Disease
227954|NCT01820078|Proteinuria
227955|NCT01820078|Albuminuria
227956|NCT01820078|Paricalcitol
227957|NCT01820052|Fibromyalgia
227958|NCT01820039|e-health intervention
227959|NCT01820039|infertility
227960|NCT01820039|primary care
227961|NCT01820039|referral rate
227962|NCT01820026|healthcare infection cirrhosis antibiotic
227963|NCT01820013|Pelvic Girdle pain
227964|NCT01820013|Symphysis Pubis Dysfunction
227965|NCT01820013|Sacroiliac Joint
227966|NCT01820013|Sacroiliitis
227967|NCT01820013|Physiotherapy
227968|NCT01820013|Physical Therapy
227969|NCT01820013|Orthotic Devices
227970|NCT01819987|Overweight
227971|NCT01819987|mother
227972|NCT01819987|childhood obesity prevention
227973|NCT01819987|Chinese American
227974|NCT01819948|Breast cancer
227975|NCT01819948|Stage 0-IIIA
227976|NCT01819948|No evidence of disease
227977|NCT01819935|MRSA. pneumonia
227978|NCT01819935|outcomes
227979|NCT01819922|Cardiopulmonary exercise testing
227980|NCT01819922|metabolic parameters
227981|NCT01819922|Diabetes Mellitus Type 2
227982|NCT01819909|Rotator cuff repair
227983|NCT01819909|Shoulder
227984|NCT01819909|Surgery
227985|NCT01819909|Rehabilitation
227986|NCT01819909|Pulleys
227987|NCT01819909|Jackins
227988|NCT01819870|Carvedilol
227989|NCT01819870|Dilatrend SR capsule
227990|NCT01819870|Dilatrend Tablet
227991|NCT01819870|Pharmacokinetics
227992|NCT01819870|Healthy male subjects
227993|NCT01819844|Closed-loop blood glucose control
227994|NCT01819844|Continuous glucose monitoring
227995|NCT01819844|Bionic pancreas
227996|NCT01819844|Artificial pancreas
227997|NCT01819831|extremity soft tissue sarcoma
227998|NCT01819831|proton radiation
227999|NCT01819831|preoperative radiation
228000|NCT01819818|Schizophrenia
228001|NCT01819818|Paliperidone palmitate
228002|NCT01819818|Invega
228003|NCT01819818|Sustenna
228004|NCT01819818|Korea
228005|NCT01819805|Chronic pain
228006|NCT01819805|Chronic non-malignant pain
228007|NCT01819805|Non-malignant
228008|NCT01819805|Pain
228009|NCT01819805|Extended release tablet
228010|NCT01819805|Tramadol hydrochloride
228011|NCT01819805|Tramadol HCl
228012|NCT01819805|Acetaminophen
228013|NCT01819805|Ultracet ER
228014|NCT01819792|Acute Myeloid Leukemia
228015|NCT01819766|Cancer
228016|NCT01819766|Colorectal Cancer
228017|NCT01819766|Neoplasm
228018|NCT01819766|Colorectal Neoplasm
228019|NCT01819766|Intestinal Neoplasms
228020|NCT01819766|Gastrointestinal Neoplasms
228021|NCT01819766|Digestive System Neoplasms
228022|NCT01819766|Neoplasms by Site
228023|NCT01819766|Neoplasms
228024|NCT01819766|Digestive System Diseases
228025|NCT01819766|Gastrointestinal Diseases
228026|NCT01819766|Colonic Diseases
228027|NCT01819766|Intestinal Diseases
228028|NCT01819766|Inflammatory Bowel Disease
228029|NCT01819766|Primary Sclerosing Cholangitis
228030|NCT01819753|percutaneous nephrolithotomy
228031|NCT01819753|urinary Stones
228032|NCT01819753|99m-Technetium-Dimercaptosuccinic Acid
228033|NCT01819727|PKU
228034|NCT01819727|PEG-PAL
228035|NCT01819727|BioMarin
228036|NCT01819727|rAv-PAL PEG
228037|NCT01819727|BMN 165
228038|NCT01819727|open label
228039|NCT01819727|Prism301
228040|NCT01819727|Pegvaliase
228041|NCT01819714|Snoezelen
228042|NCT01819714|Multi-sensorial care session
228043|NCT01819714|Alzheimer's-type neurodegenerative disease
228044|NCT01819714|Dementia
228045|NCT01819688|laparoscopic liver resection
228046|NCT01819688|cytokine release
228047|NCT01819675|Neuronal plasticity
228048|NCT01819675|Neurotransmitter agents
228049|NCT01819675|Receptors, neurotransmitter
228050|NCT01819675|Transcranial magnetic stimulation
228051|NCT01819675|Stroke
228052|NCT01819675|gamma-Aminobutyric Acid
228053|NCT01819662|Pacemaker, heart failure, hospitalisation
228054|NCT01819649|selenium
228055|NCT01819649|selenium supplementation
228056|NCT01819649|randomised controlled trial
228057|NCT01819649|prevention
228058|NCT01819636|Blood triglyceride
228059|NCT01819636|Bicarbonated mineral wate
228060|NCT01819636|Post-prandial triglyceridemia
228061|NCT01819636|lipid metabolism
228062|NCT01819636|Cardiovascular risk
228063|NCT01819623|Mild Cognitive Impairment
228064|NCT01819623|Cognitive training
228065|NCT01819610|Postoperative pain management
228066|NCT01819597|Intracranial Arterial Stenosis
228067|NCT01819597|Atherosclerosis
228068|NCT01819597|Stroke
228069|NCT01819597|EDAS
228070|NCT01819597|Angiogenesis
228071|NCT01819571|pulse pressure variation
228072|NCT01819571|fluid responsiveness
228074|NCT01819558|acute myeloid leukemia
228075|NCT01819558|chronic myeloid leukemia
228076|NCT01819558|myelodysplastic syndrome
228077|NCT01819558|allograft
228078|NCT01819558|WT1 expression
228079|NCT01819545|Alzheimer's disease
228080|NCT01819545|diagnosis
228081|NCT01819545|MicRNA
228082|NCT01819545|mRNA
228083|NCT01819532|neonate
228084|NCT01819532|umbilical cord
228085|NCT01819532|cord milking
228086|NCT01819532|prematurity
228087|NCT01819519|Intervention studies
228088|NCT01819519|Pregnancy
228089|NCT01819519|Cytomegalovirus Infections
228090|NCT01819506|rehabilitation
228091|NCT01819506|occupational therapy
228092|NCT01819506|upper extremity
228093|NCT01819493|Diabetes Prevention
228094|NCT01819493|Lifestyle Intervention
228095|NCT01819493|African American Families
228096|NCT01819480|Surgery
228097|NCT01819480|Robotic
228098|NCT01819480|Carcinoma
228099|NCT01819480|squamous cell of head and neck
228100|NCT01819454|chronic rhinosinusitis
228101|NCT01819454|extraesophageal reflux
228102|NCT01819454|Restech system
228103|NCT01819454|antireflux therapy
228104|NCT01819441|cerebral small Vessel diseases, blood pressure,CCB, ACEI
228105|NCT01819428|EGFR mutation
228106|NCT01819428|Lung Adenocarcinoma
228107|NCT01819428|Firstline therapy
228108|NCT01819428|Second generation of tyrosine kinase
228109|NCT01819415|wet AMD
228110|NCT01819415|Omega-3
228111|NCT01819415|VEGF
228112|NCT01819415|Lipidomics
228113|NCT01819415|DHA
228114|NCT01819415|EPA
228115|NCT01819402|visceral fat metabolism; FDG-PET/CT; pioglitazone; glimepiride; adiponectin
228116|NCT01819389|Chronic myeloid leukemia
228117|NCT01819389|suboptimal response
228118|NCT01819389|imatinib
228119|NCT01819389|nilotinib
228120|NCT01819376|Obesity
228121|NCT01819376|Overweight
228122|NCT01819376|Adolescents
228123|NCT01819376|Teenagers
228124|NCT01819376|Facebook
228125|NCT01819376|Social Networks
228126|NCT01819363|Pleural effusion
228127|NCT01819363|Pleural elastance
228128|NCT01819363|Pleurodesis
228129|NCT01819363|Quality of life
228130|NCT01819363|Computed Tomography
228131|NCT01819350|Dental caries
228132|NCT01819350|Sucrose
228133|NCT01819350|Oral administration
228134|NCT01819350|Ion Concentration of Hydrogen
228135|NCT01819350|Pediatric medicines
228136|NCT01819324|breast cancer survivors
228137|NCT01819324|lifestyle intervention
228138|NCT01819324|health behaviors
228139|NCT01819285|Malignant Neoplasm of Prostate
228140|NCT01819285|Tumor-node-metastasis (TNM) Staging Regional Lymph Nodes (N0-2)
228141|NCT01819285|Not suitable for local treatment with curative intent
228142|NCT01819259|Nonsmoker
228143|NCT01819259|ADHD
228144|NCT01819259|Nicotine
228145|NCT01819259|Nicotine Nasal Spray
228146|NCT01819259|Nicotine Reinforcement
228147|NCT01819181|TAVI
228148|NCT01819181|women
228149|NCT01819181|aortic stenosis
228150|NCT01819181|VARC2
228151|NCT01819155|influenza
228152|NCT01819155|influenza vaccine
228153|NCT01819155|immunogenicity
228154|NCT01819155|Africa
228155|NCT01819155|Senegal
228156|NCT01819142|non healing wound
228157|NCT01819142|pressure ulcer
228158|NCT01819116|Tissue Oxygen Saturation
228159|NCT01819116|Management of the DNC Organ Donor
228160|NCT01819103|Mortality
228161|NCT01819103|Acute Myocardial Infarction
228162|NCT01819103|Drug Adherence
228163|NCT01819103|Drug Compliance
228164|NCT01819103|Health-related quality of life
228165|NCT01819090|Neuromuscular disorder
228166|NCT01819090|Mechanical ventilation
228167|NCT01819090|Speech
228168|NCT01819090|Respiratory failure
228169|NCT01819077|Cervical cancer
228170|NCT01819077|TMMR
228171|NCT01819077|therapeutic lymphadenectomy
228172|NCT01819077|register study
228173|NCT01819064|Atropine
228174|NCT01819064|bradycardia
228175|NCT01819064|tachycardia
228176|NCT01819025|Depression
228177|NCT01819025|Behavioral activation
228178|NCT01819025|Smartphone application
228179|NCT01819025|Face-to-face
228180|NCT01819025|Blended therapy
228181|NCT01819012|Isoflurane
228182|NCT01819012|mitral valve annular velocity
228183|NCT01819012|tissue Doppler imaging
228184|NCT01819012|Monitoring
228185|NCT01819012|echocardiography
228186|NCT01818999|METASTATIC BREAST CANCER
228187|NCT01818973|Rectal Cancer
228188|NCT01818973|Bevacizumab
228189|NCT01818973|capecitabine
228190|NCT01818973|oxaliplatin
228191|NCT01818973|preoporative IMRT
228192|NCT01818960|Stent, Myocardial Infarction, Coronary Intervention
228193|NCT01818947|Lung cancer
228194|NCT01818947|epidermal growth factor receptor mutation
228195|NCT01818947|gefitinib
228196|NCT01818947|Iressa
228197|NCT01818934|hip dysplasia
228198|NCT01818934|screening
228199|NCT01818921|Beloranib
228200|NCT01818921|ZGN-440
228201|NCT01818921|ZGN-440 for injectable suspension
228202|NCT01818921|ZGN-433
228203|NCT01818908|non-Hodgkin's lymphoma
228204|NCT01818908|hemophagocytic lymphohistiocytosis
228205|NCT01818908|DA-EPOCH
228206|NCT01818908|rituximab
228207|NCT01818895|Mechanical ventilation
228208|NCT01818895|End of life
228209|NCT01818895|Extubation
228210|NCT01818895|Terminal weaning
228211|NCT01818895|Complicated grief
228212|NCT01818882|Vscan
228213|NCT01818882|portable ultrasound
228214|NCT01818882|emergency care
228215|NCT01818882|emergency room
228216|NCT01818869|Safety,
228217|NCT01818869|tolerability,
228218|NCT01818869|Phase I,
228219|NCT01818869|pharmacokinetic,
228220|NCT01818869|pharmacodynamic,
228221|NCT01818869|inhaled
228222|NCT01818856|Chronic hepatitis C
228223|NCT01818856|HIV-infection
228224|NCT01818856|Drug interaction
228225|NCT01818843|Carbon monoxide
228226|NCT01818843|safety
228227|NCT01818843|Adverse Reaction
228228|NCT01818843|newborn
228229|NCT01818817|Ultrasound-guided paravertebral block
228230|NCT01818817|regional anesthesia
228231|NCT01818817|breast surgery
228232|NCT01818765|Cardiac resynchronisation therapy
228233|NCT01818765|Endocardial
228234|NCT01818765|Pacing
228235|NCT01818739|Endometrial Cancer
228236|NCT01818739|Robotic-Assisted Staging
228237|NCT01818726|Aplastic anemia, deferasirox, renal function
228238|NCT01818713|2B3-101, liposomal doxorubicin, leptomeningeal metastases
228239|NCT01818661|apraxia of speech
228240|NCT01818661|non-fluent aphasia
228241|NCT01818661|aphasia
228242|NCT01818622|Bipolar disorder
228243|NCT01818622|Mania
228244|NCT01818622|Blue-blockers
228245|NCT01818622|Virtual darkness therapy
228246|NCT01818622|Actigraphy
228247|NCT01818622|Randomized controlled trial
228248|NCT01818609|sarcopenia
228249|NCT01818609|muscle
228250|NCT01818609|reduced activity
228251|NCT01818609|insulin sensitivity
228252|NCT01818609|protein
228253|NCT01818609|step reduction
228254|NCT01818609|muscle protein synthesis
228255|NCT01818609|whey protein
228256|NCT01818609|leg strength
228257|NCT01818609|whole body protein
228258|NCT01818596|HIV
228259|NCT01818596|HIV-1 Infected
228260|NCT01818596|Treatment Experienced
228261|NCT01818596|Treatment Naive
228262|NCT01818583|Atrial fibrillation
228263|NCT01818583|Atrial flutter
228264|NCT01818583|Potassium
228265|NCT01818583|Cardioversion
228266|NCT01818570|Gastroesophageal Reflux
228267|NCT01818557|glucose monitoring
228268|NCT01818557|gestational diabetes
228269|NCT01818544|Elastase Inhibition
228270|NCT01818531|Partial knee replacement
228271|NCT01818518|Preterm delivery
228272|NCT01818518|Premature delivery
228273|NCT01818518|Premature birth
228274|NCT01818505|antiphospholipid syndrome
228275|NCT01818505|gouty arthritis
228276|NCT01818505|Hyperuricemia
228277|NCT01818505|metabolic syndrome
228278|NCT01818505|osteoarthritis
228279|NCT01818505|cardiovascular co-morbidities
228280|NCT01818453|Mood Disorders
228281|NCT01818453|Depression
228282|NCT01818453|Genetics
228283|NCT01818453|Treatment response
228284|NCT01818453|Treatment study
228285|NCT01818440|Surgical Navigation
228286|NCT01818440|Liver
228287|NCT01818440|Cancer
228288|NCT01818440|Image-guided Therapy
228289|NCT01818427|hemmorhagic shock, plasma, air medical transport, randomized, multicenter
228290|NCT01818414|Misoprostol administration & dosage
228291|NCT01818414|Abortion techniques
228292|NCT01818414|Abortion Induced methods
228293|NCT01818414|Dilatation and Curettage
228294|NCT01818401|Ancillary tailored
228295|NCT01818401|medico-economic study,
228296|NCT01818401|total knee replacement
228297|NCT01818401|primary or secondary osteoarthritis
228298|NCT01818362|Influenza
228299|NCT01818362|T cells
228300|NCT01818349|stroke
228301|NCT01818349|exercise
228302|NCT01818349|muscle strength
228303|NCT01818349|gait
228304|NCT01818349|rehabilitation
228305|NCT01818336|penicillin allergy
228306|NCT01818323|Chimeric antigen receptor
228307|NCT01818323|Immunotherapy
228308|NCT01818323|Head and Neck Cancer
228309|NCT01818323|Phase I trial
228310|NCT01818323|Maximum tolerated dose
228311|NCT01818310|ischemia
228312|NCT01818310|diabetes mellitus
228313|NCT01818310|bone marrow aspirate concentrate (BMAC)
228314|NCT01818284|Blood And Marrow Transplantation
228315|NCT01818284|Normal allogeneic donors
228316|NCT01818284|Stem cell mobilization
228317|NCT01818284|peripheral blood progenitor cells
228318|NCT01818284|PBPC
228319|NCT01818284|Allogeneic hematopoietic stem cell transplantation
228320|NCT01818284|HSCT
228321|NCT01818284|Donating blood stem cells
228322|NCT01818284|C-CSF
228323|NCT01818284|Neupogen
228324|NCT01818284|Filgrastim
228325|NCT01818284|Plerixafor
228326|NCT01818284|Mobozil
228327|NCT01818284|Apheresis
228328|NCT01818271|community-stroke-rehabilitation,
228329|NCT01818271|group-exercise,
228330|NCT01818271|balance-mobility-exercise,
228331|NCT01818271|instrumented treadmill
228332|NCT01818258|HIV
228333|NCT01818258|Children
228334|NCT01818258|HAART
228335|NCT01818258|Malnourished
228336|NCT01818219|Electrical activity of the diaphragm
228337|NCT01818219|Neuro regulation of breathing
228338|NCT01818219|Abnormal respiratory mechanics
228339|NCT01818219|Assisted mechanical ventilation
228340|NCT01818219|Pressure support
228341|NCT01818219|Neurally adjusted ventilatory assist
228342|NCT01818206|Cystic Fibrosis
228343|NCT01818206|Bacteriophages
228344|NCT01818206|Pseudomonas aeruginosa
228345|NCT01818206|Sputum
228346|NCT01818193|Pulmonary transplant
228347|NCT01818167|Hidradenitis Suppurativa
228348|NCT01818167|HS
228349|NCT01818167|Acne Inversa
228350|NCT01818167|Velpeau's disease
228351|NCT01818167|Verneuil's disease
228352|NCT01818154|phototherapy
228353|NCT01818154|light emitting diode
228354|NCT01818154|minimal erythema dose
228355|NCT01818154|narrowband UVB
228356|NCT01818115|POAG
228357|NCT01818115|PXG
228358|NCT01818115|IOL Surgery
228359|NCT01818115|CE Surgery
228360|NCT01818024|healthy volunteer
228361|NCT01818024|TNFR1
228362|NCT01818024|domain antibody
228363|NCT01818024|Lung injury
228364|NCT01818011|Japanese, GSK1322322, pharmacokinetics, relative bioavailability, single dose, repeat dose, healthy subjects, dose-escalation, antimicrobial, over granulation,
228365|NCT01817985|Hepatitis C (HCV) Infection
228366|NCT01817985|Moderate Hepatic Impairment
228367|NCT01817985|Severe Hepatic Impairment
228368|NCT01817972|Crohn's Disease
228369|NCT01817972|Crohn's colitis
228370|NCT01817972|Crohn's ileocolitis
228371|NCT01817959|Pancreatic islet transplantation
228372|NCT01817959|Diabetes Mellitus Type 1
228373|NCT01817959|Islet transplantation graft survival & function
228374|NCT01817946|Congenital Myopathy
228375|NCT01817946|Centronuclear Myopathy
228376|NCT01817946|Myotubular Myopathy
228377|NCT01817946|Myotubularin
228378|NCT01817946|MTM1 Gene
228379|NCT01817946|Genetic testing
228380|NCT01817946|Sequencing
228381|NCT01817946|Deletion/Duplication Mutation
228382|NCT01817946|CGH array
228383|NCT01817907|Apnea- Hypopnea index
228384|NCT01817907|Arousal Threshold
228385|NCT01817894|Unwanted facial hair growth
228386|NCT01817868|Hemophilia
228387|NCT01817868|Turkey
228388|NCT01817868|Observational
228389|NCT01817868|Adult
228390|NCT01817855|Phase 1,
228391|NCT01817855|Safety,
228392|NCT01817855|Tolerability,
228393|NCT01817855|Healthy,
228394|NCT01817855|COPD patients
228395|NCT01817842|mHealth
228396|NCT01817842|EMA
228397|NCT01817842|Ecological Momentary Assessment
228398|NCT01817842|Personal Informatics
228399|NCT01817842|Tobacco Quitline
228400|NCT01817803|Heart failure
228401|NCT01817803|diuretics
228402|NCT01817803|kidney
228403|NCT01817803|glomerular filtration rate
228404|NCT01817777|Socioeconomic category
228405|NCT01817777|Medication compliance
228406|NCT01817777|Metformin
228407|NCT01817777|small pack
228408|NCT01817764|umeclidinium bromide (UMEC)
228409|NCT01817764|vilanterol (VI)
228410|NCT01817764|salmeterol (SAL)
228411|NCT01817764|fluticasone propionate (FP)
228412|NCT01817764|Novel Dry Powder Inhaler (NDPI)
228413|NCT01817764|Chronic obstructive pulmonary disease
228414|NCT01817764|GW642444
228415|NCT01817764|GSK573719
228416|NCT01817764|lung function
228417|NCT01817751|central nervous system
228418|NCT01817751|Brain and Nervous System
228419|NCT01817738|Metastatic
228420|NCT01817738|Castrate-refractory
228421|NCT01817725|Therapeutic vaccine
228422|NCT01817725|HBsAg clearance
228423|NCT01817725|Immune clearance
228424|NCT01817725|HBsAg clearance induced by vaccination
228425|NCT01817725|s seroconversion in carriers after vaccination
228426|NCT01817712|Posttraumatic neuroses
228427|NCT01817712|posttraumatic stress disorder
228428|NCT01817712|PTSD
228429|NCT01817712|Supported employment
228430|NCT01817712|IPS
228431|NCT01817712|CWT
228432|NCT01817712|TWP
228433|NCT01817712|Individual placement and support
228434|NCT01817712|Compensated work therapy
228435|NCT01817712|Transitional work program
228436|NCT01817699|Cholecalciferol
228437|NCT01817699|Methoxy polyethylene glycol-epoetin beta
228438|NCT01817699|Hematinics
228439|NCT01817699|Bone Diseases, Metabolic
228440|NCT01817699|Neoplasms
228441|NCT01817699|Cardiovascular Diseases
228442|NCT01817699|Graft Rejection
228443|NCT01817660|popliteal artery aneurysm
228444|NCT01817660|endovascular repair
228445|NCT01817660|open surgical repair
228446|NCT01817660|comparative study
228447|NCT01817647|AL
228448|NCT01817647|Enhanced recovery after surgery (ERAS)
228449|NCT01817647|reduce postoperative complications
228450|NCT01817647|increased risk of delayed diagnosis and treatment of AL
228451|NCT01817647|diagnose anastomotic leak
228452|NCT01817634|Malnutrition.
228453|NCT01817621|Body Image Disturbance
228454|NCT01817621|Medication Adherence
228455|NCT01817621|Sexual Risk Behavior
228456|NCT01817621|HIV
228457|NCT01817621|MSM
228458|NCT01817608|sf-36
228459|NCT01817608|Katz
228460|NCT01817595|Type 2 Diabetes
228461|NCT01817595|Internet Blood Glucose Monitoring
228462|NCT01817595|iphone
228463|NCT01817595|meter
228464|NCT01817582|Dry Eye Disease
228465|NCT01817569|Diabetes Mellitus (DM)
228466|NCT01817569|Byetta
228467|NCT01817569|Exenatide
228468|NCT01817543|venous leg ulcers
228469|NCT01817543|non healing wounds
228470|NCT01817530|Uterine Fibroids
228471|NCT01817530|Leiomyomata
228472|NCT01817530|Elagolix
228473|NCT01817530|Menorrhagia
228474|NCT01817530|Elagolix sodium
228475|NCT01817530|Heavy Uterine Bleeding
228476|NCT01817530|ABT-620
228477|NCT01817504|Renal failure,
228478|NCT01817504|Transplantectomy
228479|NCT01817504|Immunosuppression
228480|NCT01817504|Sensitization
228481|NCT01817491|Vegan Diet
228482|NCT01817491|Hypercholesterolemia
228483|NCT01817491|American Heart Association Diet
228484|NCT01817491|Cardiovascular Risk
228485|NCT01817491|Obesity
228486|NCT01817478|conjunctival flora
228487|NCT01817439|oral Amiodarone
228488|NCT01817439|IV Amiodarone
228489|NCT01817439|phlebitis
228490|NCT01817439|thrombophlebitis
228491|NCT01817439|adverse events
228492|NCT01817413|Calcium hydroxide
228493|NCT01817413|Pulp regeneration
228494|NCT01817413|Regenerative endodontics
228495|NCT01817413|Pulp revitalisation
228496|NCT01817413|Triple antibiotic paste
228497|NCT01817413|Root canal therapy
228498|NCT01817413|Root end closure
228499|NCT01817413|Tooth root
228500|NCT01817413|Tooth apex
228501|NCT01817413|Dental trauma
228502|NCT01817413|Non-vital
228503|NCT01817413|Immature
228504|NCT01817413|Incisor
228505|NCT01817413|Periapical periodontitis
228506|NCT01817413|Dental pulp
228507|NCT01817374|Breast Cancer
228508|NCT01817374|Definity
228509|NCT01817374|Ultrasound
228510|NCT01817361|oral health
228511|NCT01817348|Adhesive capsulitis
228512|NCT01817348|Frozen shoulder
228513|NCT01817348|Shoulder pain
228514|NCT01817348|Intra-articular injection
228515|NCT01817348|Lidocaine injection
228516|NCT01817348|Physiotherapy
228517|NCT01817348|Manipulation
228518|NCT01817348|Stretch exercise
228519|NCT01817322|kidney transplantation
228520|NCT01817309|renal failure
228521|NCT01817309|survival
228522|NCT01817309|peritoneal failure
228523|NCT01817296|Klinefelter
228524|NCT01817296|Fertility
228525|NCT01817283|HIV-infected immunological non-responders
228526|NCT01817283|Triptolide
228527|NCT01817283|immune activation
228528|NCT01817283|inflammation
228529|NCT01817283|CD4 T cell
228530|NCT01817257|Cancer
228531|NCT01817257|Thrombosis
228532|NCT01817257|Venous thromboembolism
228533|NCT01817257|Deep vein thrombosis
228534|NCT01817257|Pulmonary embolus
228535|NCT01817244|care management
228536|NCT01817244|depression
228537|NCT01817244|elderly
228538|NCT01817244|Korea
228539|NCT01817231|breast cancer
228540|NCT01817231|vitamin D
228541|NCT01817231|25 OH vitamin D
228542|NCT01817218|PRP
228543|NCT01817218|chronic vascular ulcer
228544|NCT01817218|primary care
228545|NCT01817192|Non-Squamous
228546|NCT01817192|Adjuvant Chemotherapy
228547|NCT01817179|hemiplegia, cerebral palsy, neuroprosthesis, children
228548|NCT01817166|cholecalciferol
228549|NCT01817166|vitamin D
228550|NCT01817166|immune disease
228551|NCT01817166|clinically isolated syndrome
228552|NCT01817140|oral cancer
228553|NCT01817140|mandibular invasion
228554|NCT01817140|SWIFT MRI
228555|NCT01817114|Remote Ischemic Conditioning
228556|NCT01817114|PCI
228557|NCT01817114|STEMI
228558|NCT01817114|LAD
228559|NCT01817088|Deep Brain Stimulation (DBS)
228560|NCT01817088|Parkinson disease
228561|NCT01817088|Stereotaxis Technique
228562|NCT01817088|Subthalamic nucleus
228563|NCT01817062|Capillary leakage
228564|NCT01817062|Acute Abdomen
228565|NCT01817062|Low birth weight
228566|NCT01817049|prevention
228567|NCT01817049|sport injury
228568|NCT01817049|soccer
228569|NCT01817049|youth
228570|NCT01817049|neuromuscular training
228571|NCT01817049|intervention
228572|NCT01817049|behaviour
228573|NCT01817036|vitamin D
228574|NCT01817036|deficiency
228575|NCT01817036|dose response
228576|NCT01817023|Nasopharyngeal carcinoma
228577|NCT01817023|current chemotherapy
228578|NCT01817023|intensity-modulated radiotherapy
228579|NCT01817023|low-risk
228580|NCT01817010|Total Hip Arthroplasty
228581|NCT01817010|Muscle Strength
228582|NCT01817010|Hip Osteoarthritis
228583|NCT01816997|Statins
228584|NCT01816997|Glucose homeostasis
228585|NCT01816997|Diabetes
228586|NCT01816997|Impaired fasting glucose
228587|NCT01816958|thalamocortical dysrhythmia
228588|NCT01816958|transcranial magnetic stimulation (TMS)
228589|NCT01816958|transcranial Electrical Stimulation (tES)
228590|NCT01816958|(N-methyl-D-aspartate) NMDA-R antagonist
228591|NCT01816958|ketamine infusion
228592|NCT01816958|neuromodulation
228593|NCT01816958|synergistic effect
228594|NCT01816958|remission
228595|NCT01816945|Depression
228596|NCT01816945|Stress
228597|NCT01816945|Social support
228598|NCT01816945|Social capital
228599|NCT01816945|Maternal
228600|NCT01816893|Hypoglycemia
228601|NCT01816893|Autonomic Nervous System
228602|NCT01816867|hernia
228603|NCT01816867|Treatment
228604|NCT01816867|laparoscopic
228605|NCT01816867|open technique
228606|NCT01816854|SFA,
228607|NCT01816854|stent,
228608|NCT01816854|endovascular
228609|NCT01816854|Patient outcome
228610|NCT01816841|Direct Visual Fluorescense
228611|NCT01816841|Oral Examination
228612|NCT01816841|oral cancer
228613|NCT01816828|HIV, MSM, unprotected anal intercourse, sexual health
228614|NCT01816815|PK/PD
228615|NCT01816815|BAY1002670
228616|NCT01816802|In vitro fertilization
228617|NCT01816802|Assisted reproductive therapy
228618|NCT01816802|Time-lapse image recording
228619|NCT01816802|Image analysis software
228620|NCT01816789|Starting dose
228621|NCT01816789|rFSH
228622|NCT01816789|controlled
228623|NCT01816789|ovarian
228624|NCT01816789|stimulation
228625|NCT01816789|IVF/ICSI
228626|NCT01816789|cycles
228627|NCT01816763|Health Care Quality, Access, and Evaluation
228628|NCT01816763|Primary Health Care
228629|NCT01816763|Medical Informatics
228630|NCT01816750|CT coronary angiography
228631|NCT01816750|Coronary disease
228632|NCT01816750|Gemstone Spectral Imaging
228633|NCT01816750|Diagnostic value
228634|NCT01816750|Adaptive statistical iterative reconstruction
228635|NCT01816750|iterative reconstruction
228636|NCT01816750|Feasibility of coronary and myocardial assessment
228637|NCT01816750|novel Cardiac CT GSI protocol
228638|NCT01816724|NOCTURIA
228639|NCT01816724|SYMPTOMATIC QUESTIONNAIRE
228640|NCT01816724|N-QOL
228641|NCT01816711|Frail elderly
228642|NCT01816711|Hip fracture
228643|NCT01816711|Vitamin D
228644|NCT01816711|Geriatrics
228645|NCT01816698|Hypertension
228646|NCT01816698|Taurine
228647|NCT01816698|Metabolism
228648|NCT01816672|Wagner 1
228649|NCT01816672|Wagner 2
228650|NCT01816672|Non healing diabetic foot wound
228651|NCT01816659|Colorectal Carcinoma
228652|NCT01816659|Endoscopically Non- Resectable Adenomas
228653|NCT01816659|Colonic lesion
228654|NCT01816659|Biomarker
228655|NCT01816659|Metformin-ER
228656|NCT01816659|Metformin
228657|NCT01816659|Extended release
228658|NCT01816659|Colonoscopy
228659|NCT01816659|Colon cancer surgery
228660|NCT01816646|Blood And Marrow Transplantation
228661|NCT01816646|Hemorrhagic Cystitis
228662|NCT01816646|Bleeding from bladder
228663|NCT01816646|Foley catheter
228664|NCT01816646|Probenecid
228665|NCT01816646|Cidofovir
228666|NCT01816646|Vistide
228667|NCT01816633|non healing wound
228668|NCT01816620|POEMS Syndrome
228669|NCT01816620|lenalidomide
228670|NCT01816620|newly diagnosed
228671|NCT01816620|plasma cell disorder
228672|NCT01816620|Dexamethasone
228673|NCT01816607|Magnetic Resonance Imaging
228674|NCT01816607|Magnetic Resonance Imaging, Functional
228675|NCT01816594|HER2, breast cancer, neoadjuvant, PI3K inhibitor, first line chemotherapy, trastuzumab, GBG, SOLTI, BIG
228676|NCT01816568|appendicitis, laparoscopy, single incision
228677|NCT01816542|patch-testing
228678|NCT01816542|personal-care
228679|NCT01816542|cosmetic
228680|NCT01816542|dermatitis
228681|NCT01816542|allergy
228682|NCT01816542|sensitive skin
228683|NCT01816516|childhood obesity
228684|NCT01816516|low-income
228685|NCT01816516|maternal responsiveness
228686|NCT01816516|infant feeding
228687|NCT01816516|infant feeding practices
228688|NCT01816516|infant feeding style
228689|NCT01816516|primary prevention
228690|NCT01816503|Pain
228691|NCT01816503|Cancer pain
228692|NCT01816503|Fentanyl
228693|NCT01816503|Fentanyl matrix
228694|NCT01816503|Opioid analgesic
228695|NCT01816464|Influenza
228696|NCT01816464|Vaccination
228697|NCT01816451|aerobic capacity
228698|NCT01816451|cardiorespiratory training
228699|NCT01816451|blood lactate concentration
228700|NCT01816451|heart rate
228701|NCT01816438|abnormal histological colorectal lesions
228702|NCT01816425|Dental Prosthesis
228703|NCT01816425|Dental Prosthesis Design
228704|NCT01816412|Arms
228705|NCT01816412|Experimental
228706|NCT01816412|Drug Coated Angioplasty Balloon
228707|NCT01816412|Active Comparator
228708|NCT01816412|Standard angioplasty balloon
228709|NCT01816386|acupuncture
228710|NCT01816386|anaesthetic recovery
228711|NCT01816386|perioperative care
228712|NCT01816386|Age 18+
228713|NCT01816386|ASA-score ≤ 2
228714|NCT01816386|Surgery: Uterus
228715|NCT01816386|Surgery: Adnex
228716|NCT01816386|Surgery: Ovaries
228717|NCT01816373|Chest wall; Chest, funnel; pectus excavatum; congenital abnormality
228718|NCT01816360|Womens health
228719|NCT01816360|Menopause
228720|NCT01816360|Complementary therapies
228721|NCT01816360|Aromatherapy
228722|NCT01816360|Essential oils
228723|NCT01816360|Yogatherapy
228724|NCT01816360|Psychoneuroendocrineimmunology
228725|NCT01816334|sciatica
228726|NCT01816334|Anti-Inflammatory Agents, Non-Steroidal
228727|NCT01816334|Glucocorticoids
228728|NCT01816308|AF
228729|NCT01816308|MCI
228730|NCT01816282|TKR
228731|NCT01816282|Blood loss
228732|NCT01816282|Fibrin Sealant
228733|NCT01816269|Helicobacter pylori
228734|NCT01816269|Dental scaling
228735|NCT01816269|Eradication
228736|NCT01816269|Reinfection
228737|NCT01816269|Helicobacter status
228738|NCT01816243|Chronic Pain
228739|NCT01816243|Chronic Non-Malignant Pain
228740|NCT01816243|TTS-fentanyl
228741|NCT01816243|Durogesic
228742|NCT01816217|Difficult intubation
228743|NCT01816217|Complications
228744|NCT01816217|Intensive care units
228745|NCT01816217|Videolaryngoscope
228746|NCT01816217|Laryngoscopy
228747|NCT01816204|anxiety treatment
228748|NCT01816204|anxiety online treatment
228749|NCT01816204|anxiety electronic treatment
228750|NCT01816204|anxiety therapist assisted
228751|NCT01816178|Autism spectrum Disorders
228752|NCT01816178|Voice Output Communication
228753|NCT01816165|diabetes
228754|NCT01816165|insulin
228755|NCT01816165|blood vessel
228756|NCT01816165|type 1
228757|NCT01816152|light treatment
228758|NCT01816152|circadian rhythms
228759|NCT01816152|sleep
228760|NCT01816152|agitation
228761|NCT01816152|depression
228762|NCT01816139|vaginal dryness
228763|NCT01816139|vaginal atrophy
228764|NCT01816139|estrogen
228765|NCT01816113|PvDBP
228766|NCT01816113|Malaria
228767|NCT01816113|Plasmodium vivax
228768|NCT01816100|multiple sclerosis
228769|NCT01816100|exercise
228770|NCT01816100|MEG
228771|NCT01816100|DTI
228772|NCT01816100|Brain changes
228773|NCT01816074|Mothers
228774|NCT01816074|ADHD
228775|NCT01816074|Treatment
228776|NCT01816074|Child
228777|NCT01816061|Veterans Health
228778|NCT01816061|Social Adjustment
228779|NCT01816061|Traumatic Brain Injury (TBI)
228780|NCT01816061|Post-Traumatic Stress Disorder (PTSD)
228781|NCT01816061|Independent Living
228782|NCT01816061|Goals
228783|NCT01816061|Education
228784|NCT01816048|prostate, prostate cancer
228785|NCT01816022|CMPN
228786|NCT01816022|Fracture
228787|NCT01816022|Osteoporosis
228788|NCT01816022|Biochemical Bone Markers
228789|NCT01816009|infection
228790|NCT01816009|antibiotic
228791|NCT01816009|prosthesis
228792|NCT01815996|Pregnancy
228793|NCT01815996|pulmonary embolism
228794|NCT01815996|myocardial infarction
228795|NCT01815996|autoimmune disease
228796|NCT01815996|healthy controls
228797|NCT01815983|Laryngoscopy
228798|NCT01815983|Tracheal Intubation
228799|NCT01815983|Video Laryngoscopy
228800|NCT01815970|dyspnea
228801|NCT01815970|exercise
228802|NCT01815970|neuromechanical uncoupling
228803|NCT01815970|COPD
228804|NCT01815970|pulmonary rehabilitation
228805|NCT01815957|coronary microcirculation
228806|NCT01815957|coronary artery disease
228807|NCT01815957|myocardial disease
228808|NCT01815957|ischemia
228809|NCT01815944|onset time
228810|NCT01815944|ultrasound-guided supraclavicular block
228811|NCT01815944|ropivacaine
228812|NCT01815944|normal saline
228813|NCT01815944|dextrose 5%
228814|NCT01815918|Orthopedic Procedures
228815|NCT01815918|Prostheses and Implants
228816|NCT01815918|Joint Prosthesis
228817|NCT01815918|Knee Prosthesis
228818|NCT01815918|Arthroplasty, Replacement, Knee
228819|NCT01815918|Thromboembolism
228820|NCT01815918|Inflammation
228821|NCT01815918|B-Cell Differentiation Factor-2
228822|NCT01815918|Differentiation Factor-2, B-Cell
228823|NCT01815918|B-Cell Stimulatory Factor-2
228824|NCT01815918|BSF-2
228825|NCT01815918|IFN-beta 2
228826|NCT01815918|MGI-2
228827|NCT01815918|Interleukin-6 (IL-6)
228828|NCT01815918|Steroids
228829|NCT01815918|Pregnenediones
228830|NCT01815918|Hydrocortisone
228831|NCT01815918|Physiological Effects of Drugs
228832|NCT01815918|Therapeutic Uses
228833|NCT01815892|Hemodialysis
228834|NCT01815892|Response to Furosemide
228835|NCT01815879|metastatic colorectal cancer
228836|NCT01815879|liver metastases
228837|NCT01815879|90Y resin microsphere radioembolization
228838|NCT01815879|retrospective data analysis
228839|NCT01815866|Positive Nontuberculous Mycobacteria
228840|NCT01815853|pre-operative,
228841|NCT01815853|chemoradiotherapy,
228842|NCT01815853|chemotherapy,
228843|NCT01815853|treatment
228844|NCT01815853|outcome
228845|NCT01815814|spasticity
228846|NCT01815814|cerebral palsy
228847|NCT01815814|hemiplegia
228848|NCT01815814|hemiparesis
228849|NCT01815814|diplegia
228850|NCT01815814|paraplegia
228851|NCT01815814|quadriplegia
228852|NCT01815814|quadriparesis
228853|NCT01815775|Normal pressure hydrocephalus
228854|NCT01815775|flow MRI
228855|NCT01815775|dementia
228856|NCT01815775|cerebrospinal fluid
228857|NCT01815775|shunt
228858|NCT01815762|bioimpedance
228859|NCT01815762|overhydration
228860|NCT01815762|hemodialysis
228861|NCT01815762|arterial stiffness
228862|NCT01815762|mortality
228863|NCT01815736|HIV
228864|NCT01815736|HIV 1 Infected
228865|NCT01815736|Virologically-Suppressed
228866|NCT01815723|Psoriasis
228867|NCT01815723|Dimethyl fumarate
228868|NCT01815723|Fumaderm®
228869|NCT01815710|Clinical Pathways
228870|NCT01815710|Knowledge translation
228871|NCT01815710|Evaluation
228872|NCT01815697|Men
228873|NCT01815684|Phase I
228874|NCT01815684|ASP3652
228875|NCT01815684|Dose escalation
228876|NCT01815684|Maximum Tolerated Dose (MTD)
228877|NCT01815671|colonoscopy
228878|NCT01815671|technique
228879|NCT01815671|tilt
228880|NCT01815671|insertion
228881|NCT01815671|safety
228882|NCT01815671|efficacy
228883|NCT01815645|Cocaine related disorders
228884|NCT01815645|Contingency Management
228885|NCT01815645|psychosocial treatment
228886|NCT01815632|multiple sclerosis
228887|NCT01815632|progressive MS
228888|NCT01815632|stem cell
228889|NCT01815632|cell therapy
228890|NCT01815632|neurodegeneration
228891|NCT01815632|CNS repair
228892|NCT01815606|Pancreas
228893|NCT01815606|cancer
228894|NCT01815606|EUS-FNA
228895|NCT01815606|19Gauge
228896|NCT01815606|25Gauge
228897|NCT01815606|35mm mass
228898|NCT01815580|HIV
228899|NCT01815580|Treatment as Prevention
228900|NCT01815580|Seek, Test, Treat, Retain Strategies
228901|NCT01815567|Hypertension
228902|NCT01815567|Retinal Disorder
228903|NCT01815567|Cognitive impairment
228904|NCT01815554|Tetraplegia
228905|NCT01815554|Spinal Cord Injury
228906|NCT01815554|Ventilator
228907|NCT01815554|Diaphragmatic Pacing System
228908|NCT01815541|subcutaneous teicoplanin
228909|NCT01815541|osteoarticular
228910|NCT01815541|infections
228911|NCT01815541|tolerance
228912|NCT01815541|teicoplanin
228913|NCT01815528|recurrent epithelial ovarian cancer
228914|NCT01815515|Metastatic Prostate Cancer
228915|NCT01815502|Single ventricle
228916|NCT01815502|Fontan
228917|NCT01815502|Sildenafil
228918|NCT01815502|Pressure-Volume Loops
228919|NCT01815489|Necrotizing Pancreatitis
228920|NCT01815489|Pancreatitis
228921|NCT01815489|Infection
228922|NCT01815489|Bacteria
228923|NCT01815489|Microbiology
228924|NCT01815476|DCIS
228925|NCT01815476|Early Stage Invasive breast cancer
228926|NCT01815476|Prone breast radiotherapy
228927|NCT01815463|stool
228928|NCT01815463|monoclonal antibody
228929|NCT01815463|Adnab-9
228930|NCT01815463|FOBT
228931|NCT01815463|FIT
228932|NCT01815463|iFOBT
228933|NCT01815463|colonoscopy
228934|NCT01815463|barium enema
228935|NCT01815463|flexible sigmoidoscopy
228936|NCT01815424|Tofacitinib
228937|NCT01815424|CP-690
228938|NCT01815424|550
228939|NCT01815424|Xeljanz
228940|NCT01815424|Jak-Inhibitor
228941|NCT01815424|Oral Treatment
228942|NCT01815424|Psoriasis vulgaris
228943|NCT01815424|Pruritus
228944|NCT01815424|Itch
228945|NCT01815424|DLQI
228946|NCT01815424|moderate
228947|NCT01815424|severe
228948|NCT01815424|chronic
228949|NCT01815424|plaque psoriasis
228950|NCT01815411|Rheumatoid arthritis
228951|NCT01815411|symptom score
228952|NCT01815411|fatigue
228953|NCT01815411|life quality
228954|NCT01815411|cytokines
228955|NCT01815411|mRNA expression
228956|NCT01815411|Quality of Life
228957|NCT01815411|Signs and Symptoms
228958|NCT01815411|Indication for Modification of Patient Physical Status
228959|NCT01815385|Term gestation
228960|NCT01815385|Environmental exposure
228961|NCT01815385|Benzo(a)pyrene
228962|NCT01815385|Polycyclic aromatic hydrocarbons
228963|NCT01815385|Adiposity
228964|NCT01815385|Cytosine methylation
228965|NCT01815372|nerve blocks
228966|NCT01815372|ultrasound-guided
228967|NCT01815372|leg surgery
228968|NCT01815359|ICARuS
228969|NCT01815359|Intraperitoneal Chemotherapy
228970|NCT01815359|hyperthermic intraperitoneal chemotherapy
228971|NCT01815359|Optimal Surgical Debulking
228972|NCT01815359|Leucovorin
228973|NCT01815359|Floxuridine (FUDR)
228974|NCT01815359|Mitomycin
228975|NCT01815359|12-289
228976|NCT01815346|Breast Cancer
228977|NCT01815346|Breast cancer survivors
228978|NCT01815346|Chronic, taxane-based chemotherapy-induced peripheral neuropathy
228979|NCT01815346|CIPN
228980|NCT01815346|Acupuncture treatments
228981|NCT01815346|Quality of life
228982|NCT01815346|Hand function
228983|NCT01815346|Balance
228984|NCT01815346|Questionnaires
228985|NCT01815346|Surveys
228986|NCT01815333|Cancer of Lymph Node
228987|NCT01815333|Magnetic resonance imaging
228988|NCT01815333|MRI
228989|NCT01815333|Ultrasuperparamagnetic nanoparticle iron oxide
228990|NCT01815333|USPIO
228991|NCT01815333|Feraheme
228992|NCT01815333|Ferumoxytole
228993|NCT01815320|Renal Transplant
228994|NCT01815320|Contrast-enhanced ultrasound
228995|NCT01815320|Acute allograft rejection
228996|NCT01815294|Ovarian cancer
228997|NCT01815294|Breast cancer
228998|NCT01815294|Solid malignancy
228999|NCT01815294|Advanced or refractory solid malignancy
229000|NCT01815294|Metastatic cancer
229001|NCT01815294|DOXIL/CAELYX
229002|NCT01815294|Doxorubicin HCL
229003|NCT01815294|Bioequivalence
229004|NCT01815268|Randomized Controlled Trial
229005|NCT01815268|Influenza
229006|NCT01815268|Influenza vaccine
229007|NCT01815268|Flu Vaccine
229008|NCT01815268|Fluzone
229009|NCT01815268|HD Fluzone
229010|NCT01815268|Nursing Home
229011|NCT01815268|Hospitalization
229012|NCT01815268|Mortality
229013|NCT01815268|Health Care worker vaccination
229014|NCT01815268|ADL decline
229015|NCT01815268|Effectiveness
229016|NCT01815268|Elderly
229017|NCT01815268|Morbidity
229018|NCT01815268|Nursing Home resident
229019|NCT01815268|Frail
229020|NCT01815268|Institutionalized
229021|NCT01815268|Epidemiology
229022|NCT01815268|CDC
229023|NCT01815268|US
229024|NCT01815268|city
229025|NCT01815255|TDF-based regimen
229026|NCT01815255|HIV-infected children
229027|NCT01815255|Thai
229028|NCT01815255|generic
229029|NCT01815255|safety and efficacy
229030|NCT01815255|renal status
229031|NCT01815255|To assess effect of TDF on renal problem in HIV-infected children receiving TDF-based once daily regimen
229032|NCT01815255|To compare the effectiveness and clinical usefulness of different tools of adherence
229033|NCT01815229|endotracheal
229034|NCT01815229|intubation
229035|NCT01815216|Bariatric surgery
229036|NCT01815216|Cognition
229037|NCT01815216|Satiety hormones
229038|NCT01815216|Brain networks
229039|NCT01815216|Inhibitory control
229040|NCT01815216|Food intake
229041|NCT01815203|Caffeine effects
229042|NCT01815203|Inhibitory control
229043|NCT01815190|immune complex vasculitis
229044|NCT01815190|cutaneous vasculitis
229045|NCT01815190|IgA vasculitis
229046|NCT01815190|IgA nephropathy
229047|NCT01815138|OHSS, GnRH agonist trigger, low dose hCG, PCOS, IVF
229048|NCT01815125|Mild traumatic brain injury
229049|NCT01815125|Brain concussion
229050|NCT01815125|Post-concussion syndrome
229051|NCT01815125|Emergency department
229052|NCT01815125|Ondansetron
229053|NCT01815112|Neurodegenerative disease
229054|NCT01815112|Elderly
229055|NCT01815112|Dementia
229056|NCT01815112|FDG-PET
229057|NCT01815112|MRI
229058|NCT01815112|Neuroimaging
229059|NCT01815086|Radioimmunoimaging
229060|NCT01815086|AL Amyloidosis
229061|NCT01815086|PET/CT
229062|NCT01815047|Vitamin D
229063|NCT01815047|Pregnancy
229064|NCT01815047|Inflammation
229065|NCT01815047|Infection
229066|NCT01815047|Placenta
229067|NCT01815047|Cytokine
229068|NCT01815047|Microbiome
229069|NCT01815008|Platelet aggregation
229070|NCT01815008|Clopidogrel
229071|NCT01815008|Platelet transcriptome
229072|NCT01814995|behavioural
229073|NCT01814995|diabetes prevention
229074|NCT01814995|overweight
229075|NCT01814995|physical activity
229076|NCT01814995|gestational diabetes
229077|NCT01814982|Traumatic brain injury
229078|NCT01814982|JNJ-17299425
229079|NCT01814982|Intracranial pressure
229080|NCT01814982|Intravascular bolus injection
229081|NCT01814969|Rectal neoplasm
229082|NCT01814969|Preoperative hyperfractionated radiotherapy
229083|NCT01814969|Preoperative hyperfractionated radiochemotherapy
229084|NCT01814943|Uncomplicated peptic ulcer
229085|NCT01814943|Acid-suppressing drugs
229086|NCT01814943|Epidemiology
229087|NCT01814891|vitamin A
229088|NCT01814891|maize
229089|NCT01814891|total body reserves
229090|NCT01814891|Condition is vitamin A status.
229091|NCT01814891|Focus: change in vitamin A status with maize feeding.
229092|NCT01814891|Focus: feeding orange maize to children for 90 days.
229093|NCT01814891|Focus: total body reserves of vitamin A.
229094|NCT01814878|Pain, Postoperative
229095|NCT01814878|Tramadol Hydrochloride
229096|NCT01814878|Acetaminophen
229097|NCT01814878|Ultracet
229098|NCT01814865|Post-menopausal
229099|NCT01814865|ER+
229100|NCT01814865|Stage I-IIIA
229101|NCT01814865|Operable
229102|NCT01814865|Breast Cancer
229103|NCT01814852|Low Intensity Shockwave
229104|NCT01814852|Extracorporeal shockwave therapy
229105|NCT01814852|Erectile dysfunction
229106|NCT01814839|RNAi therapeutic
229107|NCT01814826|MLN4924
229108|NCT01814826|Acute
229109|NCT01814826|Myelogenous
229110|NCT01814826|Leukemia
229111|NCT01814800|PIDD, PID, humoral immunity, antibody deficiency
229112|NCT01814787|Type 2 Diabetes
229113|NCT01814787|Pediatrics
229114|NCT01814787|Computerized Decision Support System
229115|NCT01814748|Diabetes Mellitus
229116|NCT01814748|Diabetes Mellitus, Type 2
229117|NCT01814748|Glucose Metabolism Disorders
229118|NCT01814748|Metabolic Diseases
229119|NCT01814748|Endocrine System Diseases
229120|NCT01814748|Metformin
229121|NCT01814748|Hypoglycemic Agents
229122|NCT01814748|Pharmacologic Actions
229123|NCT01814748|Therapeutic Uses
229124|NCT01814722|HIV Infections
229125|NCT01814722|Anti-HIV Agents
229126|NCT01814722|Anti-Retroviral Agents
229127|NCT01814722|Nucleoside Reverse Transcriptase Inhibitors
229128|NCT01814722|Non-nucleoside Reverse Transcriptase Inhibitor
229129|NCT01814722|Protease inhibitors
229130|NCT01814696|Heart Failure
229131|NCT01814696|Congestive Heart Failure
229132|NCT01814696|Medication Adherence
229133|NCT01814696|Medication Compliance
229134|NCT01814696|Telemedicine
229135|NCT01814696|Telehealth
229136|NCT01814683|Vivax malaria
229137|NCT01814683|Primaquine
229138|NCT01814683|Placebo
229139|NCT01814683|Recurrence
229140|NCT01814657|Infertility
229141|NCT01814605|Sciatic Nerve Block
229142|NCT01814605|Subgluteal space
229143|NCT01814605|Infragluteal space
229144|NCT01814592|coronally positioned flap
229145|NCT01814592|connective tissue
229146|NCT01814592|gingival margin
229147|NCT01814592|gingival recession/ treatment
229148|NCT01814592|gingival recession/ surgery
229149|NCT01814592|subepithelial connective tissue graft
229150|NCT01814592|randomized controlled clinical trial
229151|NCT01814592|surgical flaps
229152|NCT01814592|Treatment outcome
229153|NCT01814579|vaginal
229154|NCT01814579|cuff
229155|NCT01814579|robotic
229156|NCT01814579|hysterectomy
229157|NCT01814579|vloc
229158|NCT01814579|v-loc
229159|NCT01814579|vicryl
229160|NCT01814579|unidirectional
229161|NCT01814579|barbed
229162|NCT01814579|suture
229163|NCT01814527|Fish oil
229164|NCT01814527|Omega 3 Fatty acids
229165|NCT01814527|Docosahexaenoic acid
229166|NCT01814527|Mild Concussion
229167|NCT01814527|Brain Concussion
229168|NCT01814527|Cerebral Concussion
229169|NCT01814514|hypertensive
229170|NCT01814514|phase
229171|NCT01814514|success rate
229172|NCT01814514|AGV
229173|NCT01814501|Metastatic colon cancer
229174|NCT01814488|Active acute leukemia
229175|NCT01814488|PIF
229176|NCT01814488|Allogeneic transplant
229177|NCT01814488|Acute Myeloid Leukemia
229178|NCT01814488|Acute Lymphoblastic Leukemia
229179|NCT01814488|Marrow Unrelated Donor
229180|NCT01814488|Cord Blood
229181|NCT01814488|Family Haploidentical donor
229182|NCT01814475|myelofibrosis
229183|NCT01814475|unfavourable prognostic factors
229184|NCT01814475|Allogeneic stem cell transplantation
229185|NCT01814475|Progression Free Survival
229186|NCT01814475|thrombocythemia vera
229187|NCT01814475|polycythemia vera
229188|NCT01814475|Reduced-intensity conditioning
229189|NCT01814462|Obstructive Sleep Apnea
229190|NCT01814462|Pulse wave analysis
229191|NCT01814449|Breast cancer
229192|NCT01814449|Hypoxia
229193|NCT01814449|Hypoxia related gene
229194|NCT01814449|Endocrine therapy
229195|NCT01814449|Treatment resistance
229196|NCT01814423|Plasmodium falciparum
229197|NCT01814423|malaria
229198|NCT01814423|chloroquine
229199|NCT01814423|pharmacokinetic
229200|NCT01814423|children
229201|NCT01814410|Intravenous Ethanol
229202|NCT01814410|Intravenous Nicotine
229203|NCT01814410|Interactive effects
229204|NCT01814410|cognition
229205|NCT01814410|subjective effects
229206|NCT01814410|healthy subjects
229207|NCT01814397|Aromatase inhibitor
229208|NCT01814397|Pain threshold
229209|NCT01814384|Ancillary tailored
229210|NCT01814384|medico-economic study,
229211|NCT01814384|total knee replacement
229212|NCT01814384|primary or secondary osteoarthritis
229213|NCT01814371|Abscesses
229214|NCT01814371|Furunculosis
229215|NCT01814371|Staphylococcus aureus colonization
229216|NCT01814371|Staphylococcal Skin Infection
229217|NCT01814371|MRSA
229218|NCT01814345|Her2 testing (Human Epidermal Growth Factor Receptor 2)
229219|NCT01814332|Stress disorders, Post-traumatic
229220|NCT01814332|Sleep
229221|NCT01814319|heart failure
229222|NCT01814319|ejection fraction equal or less than 40%
229223|NCT01814306|LMA Supreme,LMA Proseal,airway management,prone position
229224|NCT01814293|Pediatric
229225|NCT01814293|Upper Respiratory infection
229226|NCT01814293|Over the Counter Drugs
229227|NCT01814293|Drugs, Non-Prescription
229228|NCT01814293|Vaporizer
229229|NCT01814280|Medication errors
229230|NCT01814280|Medication review
229231|NCT01814280|Risk stratification
229232|NCT01814280|Patient safety
229233|NCT01814267|innovative care
229234|NCT01814267|telemedicine
229235|NCT01814267|cost effectiveness
229236|NCT01814267|diabetes
229237|NCT01814241|Peanut allergy
229238|NCT01814215|Obesity
229239|NCT01814215|Prevention and Control
229240|NCT01814215|Diet
229241|NCT01814215|Motor Activity
229242|NCT01814215|Intervention Studies
229243|NCT01814215|Child, Preschool
229244|NCT01814215|Child Care
229245|NCT01814215|Food Habits
229246|NCT01814215|Feeding Behavior
229247|NCT01814215|Child Behavior
229248|NCT01814163|First line treatment
229249|NCT01814163|Non small cell lung cancer, non squamous
229250|NCT01814150|Docetaxel
229251|NCT01814150|Alpha 1 Acid Glycoprotein
229252|NCT01814150|Outcome
229253|NCT01814111|Hypertension
229254|NCT01814111|Atrial Fibrillation
229255|NCT01814111|Arrhythmias, Cardiac
229256|NCT01814111|Heart Diseases
229257|NCT01814111|Cardiovascular Diseases
229258|NCT01814098|Depressive Disorder, Major
229259|NCT01814098|Escitalopram
229260|NCT01814098|Lexapro
229261|NCT01814085|Major Depressive Disorder
229262|NCT01814085|Escitalopram
229263|NCT01814085|Lexapro
229264|NCT01814059|Sirolimus
229265|NCT01814059|Eosinophilic Esophagitis
229266|NCT01814059|Eosinophilic Gastroenteritis
229267|NCT01814059|T -Cells
229268|NCT01814059|Food Allergy
229269|NCT01814046|Metastatic
229270|NCT01814046|Ocular Melonoma
229271|NCT01814046|Autologous Tumor-Infiltrating Lymphocytes
229272|NCT01814046|Uveal Melanoma
229273|NCT01814046|Adoptive Cell Therapy
229274|NCT01814033|LRU
229275|NCT01814033|Total Knee Arthroplasty
229276|NCT01814033|Total Knee Replacement
229277|NCT01814033|Acute Rehabilitation Total Knee
229278|NCT01814033|Total Knee Range of Motion
229279|NCT01814033|Total Knee Acute care Outcomes
229280|NCT01814020|DSO
229281|NCT01814007|Lipolysis
229282|NCT01814007|Cryolipolysis
229283|NCT01814007|Fat Reduction
229284|NCT01813994|Statin; Gastric inflammation; Gastric cancer
229285|NCT01813968|Ischemic postconditioning
229286|NCT01813968|Adult cardiac surgery
229287|NCT01813968|Aortic valve surgery
229288|NCT01813968|Swan-Ganz
229289|NCT01813968|Cardiac index
229290|NCT01813955|phosphodiesterase inhibitor
229291|NCT01813955|Psychophysiology
229292|NCT01813955|Cognition
229293|NCT01813955|Schizophrenia
229294|NCT01813955|Papaverine
229295|NCT01813942|clinical narrative report
229296|NCT01813942|time series data
229297|NCT01813942|missing value
229298|NCT01813929|Diabetes
229299|NCT01813929|Insulin
229300|NCT01813929|Metformin
229301|NCT01813929|Vascular
229302|NCT01813929|Vessels
229303|NCT01813929|Type 1
229304|NCT01813916|Osteoarthritis
229305|NCT01813916|synovial fluid
229306|NCT01813916|hyaluronic acid
229307|NCT01813890|Bunionectomy
229308|NCT01813890|Acute pain
229309|NCT01813890|Post-operative pain
229310|NCT01813890|Tapentadol IR
229311|NCT01813890|Analgesia
229312|NCT01813890|Hallux valgus
229313|NCT01813864|treatment planning
229314|NCT01813864|resource guide
229315|NCT01813864|service matching
229316|NCT01813864|Service matching for substance abuse clients
229317|NCT01813864|CASPAR resource guide
229318|NCT01813864|Improved treatment planning
229319|NCT01813851|Dialysis, Exercise, Protein Energy Wasting, Nutrition and Physical Fitness
229320|NCT01813825|Mammosite
229321|NCT01813799|Diabetic Neuropathies
229322|NCT01813734|RET gene mutation
229323|NCT01813721|NHL
229324|NCT01813721|Breast Cancer
229325|NCT01813721|Lung Cancer
229326|NCT01813708|Type 2 Diabetes
229327|NCT01813708|Intensive Life-Style
229328|NCT01813708|Collaborative Education
229329|NCT01813708|Clinical Trial
229330|NCT01813708|Metabolic Control
229331|NCT01813695|Preemptive genetic testing
229332|NCT01813695|Pain
229333|NCT01813695|Pediatrics
229334|NCT01813695|Orthopedics
229335|NCT01813695|Pectus excavatum
229336|NCT01813695|Scoliosis
229337|NCT01813682|preterm infant
229338|NCT01813682|anemia
229339|NCT01813682|iron fortified TPN
229340|NCT01813669|Childhood anxiety
229341|NCT01813669|Pediatric Pain
229342|NCT01813669|Yoga
229343|NCT01813669|Cognitive behavioral therapy
229344|NCT01813656|Methamphetamine-Associated Psychosis
229345|NCT01813656|Aripiprazole
229346|NCT01813643|Methamphetamine-Associated Psychosis
229347|NCT01813643|Aripiprazole
229348|NCT01813643|Risperidone
229349|NCT01813630|Turner's Syndrome
229350|NCT01813630|Short Stature
229351|NCT01813630|Dwarfism
229352|NCT01813617|Polymyositis
229353|NCT01813617|Dermatomyositis
229354|NCT01813617|Muscle endurance
229355|NCT01813617|Muscle stength
229356|NCT01813617|Outcome
229357|NCT01813604|Polio
229358|NCT01813604|Inactivated polio vaccine
229359|NCT01813604|oral polio vaccine
229360|NCT01813604|vaccine trial
229361|NCT01813591|Chronic Migraine
229362|NCT01813591|Headache
229363|NCT01813591|Refractory Chronic Migraine
229364|NCT01813578|Systemic sclerosis
229365|NCT01813578|Exercise
229366|NCT01813578|Physical capacity
229367|NCT01813578|Aerobic capacity
229368|NCT01813578|Muscle function
229369|NCT01813578|Fatigue
229370|NCT01813552|HCV
229371|NCT01813552|Hepatitis C
229372|NCT01813552|antiviral drugs
229373|NCT01813552|liver
229374|NCT01813539|malignancy
229375|NCT01813513|HCV
229376|NCT01813513|Hepatitis C Virus
229377|NCT01813513|Hepatitis C
229378|NCT01813513|antiviral drugs
229379|NCT01813513|liver
229380|NCT01813474|Cancer
229381|NCT01813474|Tumour
229382|NCT01813474|Solid Malignancies
229383|NCT01813461|BAL8557
229384|NCT01813461|14C-labeled isavuconazole
229385|NCT01813461|14C-labeled prodrug isavuconazonium sulfate (BAL8557)/([cyano-14C]ASP9766 sulfate)
229386|NCT01813448|Fidaxomicin
229387|NCT01813448|OPT-80
229388|NCT01813448|Healthy Subjects
229389|NCT01813435|CAD
229390|NCT01813435|ACS
229391|NCT01813435|All comers
229392|NCT01813435|DAPT
229393|NCT01813435|PCI
229394|NCT01813422|Cholesterol
229395|NCT01813422|High Cholesterol
229396|NCT01813422|Elevated Cholesterol
229397|NCT01813422|Raised Cholesterol
229398|NCT01813396|shoulder
229399|NCT01813396|muscle stiffness
229400|NCT01813396|shoulder physical activity
229401|NCT01813396|range of motion
229402|NCT01813396|joint mobility
229403|NCT01813383|Celiac disease
229404|NCT01813383|HLA-DQ2.2
229405|NCT01813383|HLA-DQ2.5
229406|NCT01813383|HLA-DR7-DQ2
229407|NCT01813383|HLA-DR3-DQ2
229408|NCT01813370|TAX 3503
229409|NCT01813370|MSKCC IRB#07-101
229410|NCT01813370|12-225
229411|NCT01813357|HIV
229412|NCT01813357|Cardiovascular disease
229413|NCT01813357|Inflammation
229414|NCT01813357|Statin
229415|NCT01813344|Adult lymphoblastic lymphoma
229416|NCT01813344|Hyper-CVAD
229417|NCT01813344|first-line treatment
229418|NCT01813305|Diabetic Foot Ulcer
229419|NCT01813305|Diabetes Mellitus
229420|NCT01813305|Debridement
229421|NCT01813305|Standard of Care
229422|NCT01813305|wounds
229423|NCT01813292|male patients
229424|NCT01813292|treated by TRUVADA® or VIREAD® for more than 60 months
229425|NCT01813253|epidermal growth factor receptor
229426|NCT01813253|second line
229427|NCT01813214|melanoma
229428|NCT01813214|vemurafenib
229429|NCT01813214|cobitmetinib
229430|NCT01813201|Testosterone
229431|NCT01813201|Anabolic deterioration
229432|NCT01813188|Fractures
229433|NCT01813188|Bone
229434|NCT01813188|Stem Cells
229435|NCT01813149|Complex Regional Pain Syndrome (CRPS)
229436|NCT01813136|radioiodine refractory Differentiated Thyroid Carcinoma
229437|NCT01813136|pazopanib
229438|NCT01813136|intermittent administration
229439|NCT01813136|time to treatment failure
229440|NCT01813136|TUTHYREF
229441|NCT01813123|gender-specific
229442|NCT01813123|web-based
229443|NCT01813123|drug abuse
229444|NCT01813123|prevention
229445|NCT01813110|inflammation
229446|NCT01813110|omega-3
229447|NCT01813110|fish oil
229448|NCT01813097|To detective the effect of the treatment of combination iodine 125 seed implants and LHRH agonists for the patients with locally advanced prostate cancer.
229449|NCT01813071|Enterobacteriaceae Infections
229450|NCT01813071|Gram-Negative Bacterial Infections
229451|NCT01813071|Bacterial Infections
229452|NCT01813071|Gastroenteritis
229453|NCT01813071|Gastrointestinal Diseases
229454|NCT01813071|Digestive System Diseases
229455|NCT01813071|Intestinal Diseases
229456|NCT01813071|Shigellosis
229457|NCT01813058|Tranexamic acid, Blood loss
229458|NCT01813045|Angiogenesis
229459|NCT01813045|Fibrosis
229460|NCT01813045|Myocardial Infarction
229461|NCT01813045|Imaging
229462|NCT01813045|CT-PET
229463|NCT01813045|PET-CT
229464|NCT01813045|Cardiac MRI
229465|NCT01813032|firefighters
229466|NCT01813032|police officers
229467|NCT01813032|emergency service professionals
229468|NCT01813032|myocardial infarction
229469|NCT01813032|endothelial function
229470|NCT01813032|thrombosis
229471|NCT01813019|Obsessive compulsive disorder (OCD), obsessive fears, obsessions,
229472|NCT01813019|compulsions, OCD SSRI resistant
229473|NCT01812993|Ischemic stroke, sleep apnea, non-invasive ventilatory treatment
229474|NCT01812980|Influenza
229475|NCT01812980|Human Immunodeficiency Virus
229476|NCT01812954|moderate-to-severe psoriasis
229477|NCT01812954|cost utility analysis
229478|NCT01812954|cost effectiveness analysis
229479|NCT01812954|systemic treatment
229480|NCT01812941|burns
229481|NCT01812941|trauma
229482|NCT01812928|Flexible Cystoscopy
229483|NCT01812928|Pain control
229484|NCT01812928|Diclofenac
229485|NCT01812928|Non steroidal anti inflammatory drug
229486|NCT01812915|Cuff pressure
229487|NCT01812915|Cylindrical cuff
229488|NCT01812915|Endotracheal tube
229489|NCT01812915|Nitrous oxide
229490|NCT01812915|Tapered cuff
229491|NCT01812902|Prostate cancer
229492|NCT01812902|Prostate specific antigen
229493|NCT01812902|lymphadenectomy
229494|NCT01812902|Limited lymphadenectomy
229495|NCT01812902|Extended lymphadenectomy
229496|NCT01812902|Immunohistochemistry
229497|NCT01812889|bacterial vaginosis, vulvovaginal candidiasis, TOL-463, intravaginal therapy, vaginitis, women, cross-over
229498|NCT01812863|Pain Management
229499|NCT01812863|Child
229500|NCT01812863|Surgery
229501|NCT01812850|Temporomandibular joint
229502|NCT01812850|Orofacial muscular complex
229503|NCT01812850|Bruxism
229504|NCT01812850|Clenching
229505|NCT01812850|Orthodontic treatment
229506|NCT01812850|Invisalign®
229507|NCT01812837|actinic keratosis
229508|NCT01812837|microneedles
229509|NCT01812837|photodynamic therapy
229510|NCT01812837|levulan
229511|NCT01812837|Aminolevulinic acid
229512|NCT01812824|Preconception Health
229513|NCT01812824|Health Information Technology
229514|NCT01812824|Reproductive Life Plan
229515|NCT01812824|Healthcare Disparities
229516|NCT01812824|Low birth-weight
229517|NCT01812824|Preterm Delivery
229518|NCT01812811|pulse wave analysis
229519|NCT01812811|pulse wave velocity
229520|NCT01812811|Arteriograph24
229521|NCT01812811|Ambulatory
229522|NCT01812811|diabetes
229523|NCT01812811|reproducibility
229524|NCT01812811|diurnal variation
229525|NCT01812798|Peanut allergy
229526|NCT01812798|Threshold
229527|NCT01812798|Modelling
229528|NCT01812798|Risk assessment
229529|NCT01812785|Fever
229530|NCT01812785|Children
229531|NCT01812785|Non-malaria fevers
229532|NCT01812785|Diagnosis
229533|NCT01812772|urinary stents
229534|NCT01812772|ureteroscopy
229535|NCT01812759|Pain
229536|NCT01812759|Breakthrough cancer pain
229537|NCT01812759|Emergency Department
229538|NCT01812759|ED
229539|NCT01812759|Fentanyl nasal spray
229540|NCT01812759|Lazanda
229541|NCT01812759|Placebo nasal spray
229542|NCT01812759|Hydromorphone PCA
229543|NCT01812759|Dilaudid
229544|NCT01812694|Pregnancy
229545|NCT01812694|Weight Control
229546|NCT01812694|Weight Gain
229547|NCT01812681|vitamin D, Respiratory distress syndrome, sepsis, preterm
229548|NCT01812655|pain
229549|NCT01812655|anxiety
229550|NCT01812655|children
229551|NCT01812655|adolescents
229552|NCT01812655|burn
229553|NCT01812655|virtual reality
229554|NCT01812655|distraction
229555|NCT01812642|Schizophrenia
229556|NCT01812642|JNJ-37822681
229557|NCT01812642|Placebo
229558|NCT01812616|Cancer
229559|NCT01812616|Safety
229560|NCT01812603|Cancer
229561|NCT01812603|Safety
229562|NCT01812564|Platelet rich plasma
229563|NCT01812564|Interventional
229564|NCT01812564|Randomized
229565|NCT01812564|Double-blind
229566|NCT01812551|cystic fibrosis
229567|NCT01812551|children
229568|NCT01812551|adolescents
229569|NCT01812551|low bone mass
229570|NCT01812551|osteoporosis
229571|NCT01812551|alendronate
229572|NCT01812551|fractures
229573|NCT01812525|Bronchiolitis
229574|NCT01812525|Moderate to Severe
229575|NCT01812525|Hypertonic saline
229576|NCT01812525|NaCl 3% inhalations
229577|NCT01812525|Standard therapy
229578|NCT01812525|Wang score
229579|NCT01812525|in-patients
229580|NCT01812512|Heart Failure
229581|NCT01812512|Communication
229582|NCT01812512|Telemedicine
229583|NCT01812512|Veterans
229584|NCT01812512|Nurse-patient relations
229585|NCT01812499|blood transfusion
229586|NCT01812499|adverse event
229587|NCT01812499|incident reporting
229588|NCT01812473|protein binding
229589|NCT01812473|voriconazole
229590|NCT01812473|pediatrics
229591|NCT01812473|hematology
229592|NCT01812473|intensive care
229593|NCT01812473|albumin
229594|NCT01812473|alpha-1-acid-glycoprotein
229595|NCT01812460|COPD
229596|NCT01812460|muscle strength
229597|NCT01812460|resistance training
229598|NCT01812460|Physiotherapi
229599|NCT01812460|m. quadriceps
229600|NCT01812460|Acute exacerbation
229601|NCT01812447|Endobronchial Valves
229602|NCT01812447|Intrabronchial Valves
229603|NCT01812447|Bronchial Valve
229604|NCT01812447|Chronic Obstructive Pulmonary Disease
229605|NCT01812447|COPD
229606|NCT01812447|Pulmonary Disease, Chronic Obstructive
229607|NCT01812447|Bronchoscopic Lung Volume Reduction
229608|NCT01812447|BLVR
229609|NCT01812447|TLVR
229610|NCT01812447|Emphysema
229611|NCT01812447|Pulmonary Emphysema
229612|NCT01812447|Pathologic Process
229613|NCT01812447|Lung Diseases
229614|NCT01812447|Respiratory Tract Disease
229615|NCT01812395|thyroidectomy
229616|NCT01812395|ultrasonic dissector
229617|NCT01812395|harmonic focus device
229618|NCT01812395|superior laryngeal nerve
229619|NCT01812382|Penetration
229620|NCT01812382|Antibiotic
229621|NCT01812382|Microdialysis
229622|NCT01812382|Formulation Pharmacokinetics
229623|NCT01812382|Feasibility
229624|NCT01812356|Atrial fibrillation
229625|NCT01812356|maze operation
229626|NCT01812356|cryoablation
229627|NCT01812343|Ankle Brachial Index
229628|NCT01812343|Maximal Exercise Test
229629|NCT01812330|ACS
229630|NCT01812330|CR
229631|NCT01812330|PCI
229632|NCT01812330|Platelet funtion
229633|NCT01812330|Ticagrelor
229634|NCT01812317|firefighters
229635|NCT01812317|fire-simulation training
229636|NCT01812317|myocardial infarction
229637|NCT01812317|endothelial function
229638|NCT01812317|thrombosis
229639|NCT01812291|Major Depression
229640|NCT01812291|Minor Depression
229641|NCT01812291|Sub-Threshold Depression
229642|NCT01812291|Affective Condition
229643|NCT01812291|Mood Disorder
229644|NCT01812291|Light Affective Disorder
229645|NCT01812291|Subclinical Depressive Symptoms
229646|NCT01812291|Diabetes Mellitus
229647|NCT01812291|Diabetes-Related Distress
229648|NCT01812291|Self-Care Behaviour
229649|NCT01812291|Glycaemic Control
229650|NCT01812291|Inflammatory Markers
229651|NCT01812252|myelodysplastic syndrome
229652|NCT01812252|chronic myelomonocytic leukemia
229653|NCT01812252|bone marrow transplant
229654|NCT01812252|hypomethylating agent
229655|NCT01812252|induction chemotherapy
229656|NCT01812239|premature birth
229657|NCT01812239|twins
229658|NCT01812239|short cervix
229659|NCT01812213|Mild Cognitive Impairment
229660|NCT01812187|Alcohol
229661|NCT01812187|Alcohol Abuse
229662|NCT01812187|Alcohol Dependence
229663|NCT01812187|Veterans
229664|NCT01812174|heart valve
229665|NCT01812161|Electro-acupuncture
229666|NCT01812161|HCG stimulation test
229667|NCT01812161|Menstrual frequency
229668|NCT01812161|polycystic ovary syndrome
229669|NCT01812161|Randomized
229670|NCT01812161|controlled
229671|NCT01812161|trial
229672|NCT01812148|Peritoneal Mesotheliomas
229673|NCT01812148|hyperthermic intra-peritoneal chemotherapy (HIPEC)
229674|NCT01812148|Oxaliplatin
229675|NCT01812148|Cytoreductive surgery
229676|NCT01812148|Oxaliplatin HIPEC
229677|NCT01812109|Acute Scrotum
229678|NCT01812109|Testicular Torsion
229679|NCT01812096|multiple myeloma
229680|NCT01812096|bortezomib
229681|NCT01812096|Subcutaneous
229682|NCT01812083|Periodontitis; adverse pregnancy outcomes; IL-1 polymorphism
229683|NCT01812070|smoking cessation
229684|NCT01812070|quit smoking
229685|NCT01812057|Anesthesia
229686|NCT01812057|Cesarean Section
229687|NCT01812057|Pain, Postoperative
229688|NCT01812057|Postoperative Nausea and Vomiting
229689|NCT01812057|Dexamethasone
229690|NCT01812057|Injections, Spinal
229691|NCT01812057|morphine
229692|NCT01812031|PET/CT
229693|NCT01812031|18F-fluoro-2-deoxyglucose
229694|NCT01812031|lung neoplasms
229695|NCT01812031|respiratory motion
229696|NCT01812018|Soft Tissue Sarcoma
229697|NCT01812018|Pulmonary metastases
229698|NCT01812005|MLN8237
229699|NCT01812005|B-cell Non Hodgkin Lymphoma
229700|NCT01812005|Rituximab
229701|NCT01811979|eye examination, oral sucrose, premature infant pain scale
229702|NCT01811966|preoperative volume substitution
229703|NCT01811966|hypovolemia
229704|NCT01811966|preoperative fasting
229705|NCT01811940|cocaine dependence
229706|NCT01811940|adderall
229707|NCT01811940|topiramate
229708|NCT01811914|focused TTE
229709|NCT01811914|intraoperative TTE
229710|NCT01811914|transthoracic echocardiography
229711|NCT01811914|high risk non-cardiac surgery
229712|NCT01811914|hemodynamic instabilities
229713|NCT01811901|inhospital delays, door-to-needle time, thrombolysis, acute ischemic stroke, SITS, SITS-WATCH, stroke registry
229714|NCT01811875|Haemophilia A
229715|NCT01811862|Acupuncture
229716|NCT01811862|Hematopoietic stem cell transplantation (HSCT)
229717|NCT01811862|13-038
229718|NCT01811849|diabetes
229719|NCT01811823|Tuberculosis
229720|NCT01811823|HIV infection
229721|NCT01811823|Immune responses to Influenza vaccination
229722|NCT01811810|Men under the age of 75 with histologically confirmed high risk
229723|NCT01811797|Erectile Dysfunction
229724|NCT01811797|Extracorporeal shockwave
229725|NCT01811797|Low intensity shockwaves
229726|NCT01811784|Nipah virus infection
229727|NCT01811784|date palm sap
229728|NCT01811784|community intervention
229729|NCT01811784|capacity building
229730|NCT01811784|disease prevention
229731|NCT01811784|Bangladesh
229732|NCT01811784|Healthy Community people
229733|NCT01811784|Sap harvesters
229734|NCT01811784|Date palm three owners
229735|NCT01811784|Date palm sap consumers
229736|NCT01811758|Culturally Specific Cognitive Behavioral Therapy
229737|NCT01811758|Standard Cognitive Behavioral Therapy
229738|NCT01811745|Aged
229739|NCT01811745|Cognition
229740|NCT01811745|Exercise
229741|NCT01811745|Falls
229742|NCT01811745|Gait
229743|NCT01811745|Physical function
229744|NCT01811745|Dual-task
229745|NCT01811745|Music
229746|NCT01811745|Postural Balance
229747|NCT01811745|Randomized controlled trial
229748|NCT01811732|Bacterial skin infection
229749|NCT01811732|skin infection
229750|NCT01811732|infection
229751|NCT01811732|skin
229752|NCT01811732|delafloxacin
229753|NCT01811732|vancomycin
229754|NCT01811732|aztreonam
229755|NCT01811732|MRSA bacteria
229756|NCT01811732|bacterial infection
229757|NCT01811732|Anti-Infective Agents
229758|NCT01811732|Anti-Bacterial Agents
229759|NCT01811719|Intimate Partner Physical Violence
229760|NCT01811719|Intimate Partner Emotional Abuse
229761|NCT01811719|Intimate Partner Controlling Behaivor
229762|NCT01811719|Pregnancy Outcomes
229763|NCT01811719|Quality of Parental Care Giving
229764|NCT01811719|Maternal Life Course
229765|NCT01811693|Stroke
229766|NCT01811693|Intracerebral Hemorrhage
229767|NCT01811693|Prehospital
229768|NCT01811693|Antihypertensive
229769|NCT01811680|Stroke
229770|NCT01811680|Hemiplegia
229771|NCT01811680|Variable automated treadmill treadmill
229772|NCT01811667|Vascular Abnormalities
229773|NCT01811654|Patellofemoral
229774|NCT01811654|Hyaluronan
229775|NCT01811654|Intra-articular
229776|NCT01811654|Hyaluronic acid
229777|NCT01811641|season of conception
229778|NCT01811641|maternal nutritional status
229779|NCT01811641|infant DNA methylation
229780|NCT01811628|Cancer Prevention
229781|NCT01811628|Tobacco Use Cessation
229782|NCT01811628|Smokers
229783|NCT01811628|Recent quitters
229784|NCT01811628|Latino
229785|NCT01811628|Hispanic
229786|NCT01811628|Information
229787|NCT01811628|Interview
229788|NCT01811628|Questionnaire
229789|NCT01811628|Survey
229790|NCT01811628|Audio-recorded
229791|NCT01811602|Training
229792|NCT01811602|Physiotherapy
229793|NCT01811602|Pelvic floor muscles
229794|NCT01811589|ventricular catheter, hydrocephalus, shunt, brain disease
229795|NCT01811576|Growth hormone deficiency
229796|NCT01811576|Insulin-like growth factor I (IGF-I)
229797|NCT01811576|TV-1106
229798|NCT01811563|Total Knee Replacement
229799|NCT01811563|Lower Quarter Y-Balance Test
229800|NCT01811563|Functional Outcomes
229801|NCT01811563|Patient Reported Outcomes
229802|NCT01811537|Artificial Chordae
229803|NCT01811537|Mitral Valve Repair
229804|NCT01811524|Brain tumor
229805|NCT01811524|Glioma
229806|NCT01811524|Meningioma
229807|NCT01811524|Diagnosis
229808|NCT01811524|Prognosis
229809|NCT01811524|Heredity
229810|NCT01811472|Multi-center,
229811|NCT01811472|randomized,
229812|NCT01811472|double-blind,
229813|NCT01811472|NAFLD,
229814|NCT01811472|elevated triglycerides
229815|NCT01811459|Delirium
229816|NCT01811459|ICU
229817|NCT01811459|Burn patients
229818|NCT01811459|Antipsychotics
229819|NCT01811459|Haloperidol
229820|NCT01811459|Quetiapine
229821|NCT01811433|Postoperative Period
229822|NCT01811433|Anesthesia Recovery Period
229823|NCT01811433|Postoperative Complications
229824|NCT01811433|Pulse Oximetry
229825|NCT01811420|dental caries
229826|NCT01811420|caries removal
229827|NCT01811420|chemomechanical caries removal
229828|NCT01811394|sacral chordoma
229829|NCT01811394|chordoma
229830|NCT01811394|carbon ion therapy
229831|NCT01811394|proton therapy
229832|NCT01811394|hypofractionation
229833|NCT01811381|Alzheimer
229834|NCT01811381|Prevention
229835|NCT01811381|mild cognitive impairment
229836|NCT01811381|physical exercise
229837|NCT01811381|synergism
229838|NCT01811381|curcumin
229839|NCT01811381|dietary supplement
229840|NCT01811381|anti-inflammatory
229841|NCT01811381|anti-tau
229842|NCT01811381|subjective memory complaints without MCI
229843|NCT01811355|Muscle cramps
229844|NCT01811355|Cramp
229845|NCT01811355|ALS
229846|NCT01811355|Amyotrophic Lateral Sclerosis
229847|NCT01811355|Lou Gehrig's disease
229848|NCT01811355|Motor Neuron Disease
229849|NCT01811355|MND
229850|NCT01811342|Hemoglobin
229851|NCT01811342|Patient Monitoring
229852|NCT01811277|palliative chemotherapy
229853|NCT01811277|ORR
229854|NCT01811277|PFS
229855|NCT01811277|OS
229856|NCT01811277|safety
229857|NCT01811277|advanced Biliary Tract Carcinoma
229858|NCT01811264|Metastatic
229859|NCT01811264|Quality of life
229860|NCT01811264|Decision making
229861|NCT01811251|Co-analgesia
229862|NCT01811251|Dexamethasone
229863|NCT01811251|Pregabalin
229864|NCT01811251|Lumbar slipped disc surgery
229865|NCT01811251|Post-operative pain
229866|NCT01811238|spinal disorders
229867|NCT01811225|Women
229868|NCT01811225|Pregnancy
229869|NCT01811225|Smoking
229870|NCT01811199|Thyroid cancer
229871|NCT01811199|Breast cancer
229872|NCT01811199|Dexamethasone
229873|NCT01811199|Emesis
229874|NCT01811186|moderate to severe non-malignant chronic pain
229875|NCT01811173|multimorbidity
229876|NCT01811173|primary care
229877|NCT01811173|physician - nurse team
229878|NCT01811173|proactive monitoring
229879|NCT01811173|support for self-care
229880|NCT01811173|primary caregiver
229881|NCT01811160|Melatonin
229882|NCT01811160|Second generation antipsychotic
229883|NCT01811160|bipolar disorder
229884|NCT01811160|schizophrenia
229885|NCT01811160|Metabolic
229886|NCT01811147|Bipolar
229887|NCT01811147|Depression
229888|NCT01811147|Mania
229889|NCT01811147|Hypomania
229890|NCT01811147|fMRI
229891|NCT01811147|antidepressant
229892|NCT01811134|endovascular procedure; flow diverter stent
229893|NCT01811121|Glioblastoma
229894|NCT01811121|5ALA
229895|NCT01811121|fluorescence
229896|NCT01811121|resection
229897|NCT01811108|mCRC
229898|NCT01811108|KRAS mutation
229899|NCT01811108|Chemotherapy
229900|NCT01811108|Anti-angiogenic agent
229901|NCT01811108|Bevacizumab
229902|NCT01811108|1st Line
229903|NCT01811095|Robotics
229904|NCT01811095|Computer-assisted surgery
229905|NCT01811095|Computer simulation
229906|NCT01811095|Gynecology
229907|NCT01811095|General surgery
229908|NCT01811069|Obese patients
229909|NCT01811069|Upper airway patency
229910|NCT01811056|medical abortion
229911|NCT01811056|mifepristone
229912|NCT01811043|breast biopsy
229913|NCT01811043|anxiety
229914|NCT01810978|congenital heart disease, probiotic, prebiotic
229915|NCT01810965|Hemochromatosis type 1
229916|NCT01810952|glucocorticoids
229917|NCT01810952|hyperglycemia
229918|NCT01810952|diabetes mellitus
229919|NCT01810939|Chronic Kidney Disease
229920|NCT01810939|Treatment of Hyperkalemia
229921|NCT01810939|Hyperkalemia
229922|NCT01810926|indication for HSCT
229923|NCT01810926|matched related donor
229924|NCT01810926|MRD
229925|NCT01810926|Matched Unrelated Donor
229926|NCT01810926|MUD
229927|NCT01810900|anti-adhesive effect and safety, laparoscopic myomectomy
229928|NCT01810887|Healthy
229929|NCT01810887|Darunavir
229930|NCT01810887|JNS011
229931|NCT01810887|Ritonavir
229932|NCT01810874|extraperitoneal
229933|NCT01810874|transperitoneal
229934|NCT01810874|laparoscopic aortic lymphadenectomy
229935|NCT01810874|endometrial ovarian cancer
229936|NCT01810874|ovarian cancer
229937|NCT01810874|surgical staging
229938|NCT01810861|serotype distribution
229939|NCT01810861|streptococcus pneumoniae
229940|NCT01810861|pneumonia
229941|NCT01810848|Knee Osteoarthritis
229942|NCT01810848|Osteoarthritis
229943|NCT01810848|Synvisc
229944|NCT01810848|Hylan G-F 20
229945|NCT01810848|Exercise
229946|NCT01810848|Cardiovascular risk
229947|NCT01810848|Knee pain
229948|NCT01810848|Pain
229949|NCT01810835|HBV mother-to-child transmission
229950|NCT01810835|women with HBV DNA > 105 I.U./mL
229951|NCT01810835|France
229952|NCT01810822|oxidative stress
229953|NCT01810822|genetic susceptibility
229954|NCT01810822|GPX4
229955|NCT01810822|NOX2
229956|NCT01810809|Osteoarthritis
229957|NCT01810809|Hip
229958|NCT01810809|Viscosupplementation
229959|NCT01810809|Clinical Trial
229960|NCT01810770|Radium-223 Dichloride
229961|NCT01810770|Prostatic Neoplasms
229962|NCT01810770|Bone Metastasis
229963|NCT01810731|influenza vaccine immunogenicity
229964|NCT01810731|HIV
229965|NCT01810731|pregnancy
229966|NCT01810731|influenza vaccine safety
229967|NCT01810718|cGVHD
229968|NCT01810718|steroid therapy
229969|NCT01810718|Nilotinib
229970|NCT01810718|cGVHD steroid refractory
229971|NCT01810718|intolerant to steroid therapy
229972|NCT01810718|Tasigna
229973|NCT01810718|MTD
229974|NCT01810705|myeloid
229975|NCT01810705|leukemia
229976|NCT01810679|aortic valve replacement
229977|NCT01810679|aortic stenosis
229978|NCT01810679|aortic steno-insufficiency
229979|NCT01810679|Perceval
229980|NCT01810679|Sutureless aortic heart valve
229981|NCT01810653|Macrogol
229982|NCT01810640|Liver biopsy
229983|NCT01810640|organ donation
229984|NCT01810640|donor management
229985|NCT01810627|Prostate
229986|NCT01810627|Cancer
229987|NCT01810614|ADPKD
229988|NCT01810614|PKD
229989|NCT01810614|Kidney Disease
229990|NCT01810614|ADPKD diet
229991|NCT01810601|Embryo transfer, transabdominal ultrasound, IVF, ICSI
229992|NCT01810588|Allogeneic transplant
229993|NCT01810588|Hematologic Malignancies
229994|NCT01810588|Acute Leukemia
229995|NCT01810588|Myeloproliferative disorders
229996|NCT01810588|Lymphoma
229997|NCT01810588|Myeloma
229998|NCT01810562|Stroke
229999|NCT01810562|Tactile
230000|NCT01810562|Sensibility
230001|NCT01810562|Stimulation
230002|NCT01810562|Extremities
230003|NCT01810562|Arm
230004|NCT01810562|Leg
230005|NCT01810549|Fatigue
230006|NCT01810536|Cystic fibrosis
230007|NCT01810536|oxygen
230008|NCT01810536|respiratory failure
230009|NCT01810523|Acute
230010|NCT01810523|lower
230011|NCT01810523|extremity
230012|NCT01810523|not requiring
230013|NCT01810523|diagnostic
230014|NCT01810523|imaging
230015|NCT01810510|respiration, artificial
230016|NCT01810497|External ear
230017|NCT01810497|Ear abnormalities
230018|NCT01810497|External ear cartilages
230019|NCT01810484|Ulthera® System
230020|NCT01810484|Ultherapy® Treatment
230021|NCT01810484|Ulthera, Inc.
230022|NCT01810484|Ultrasound treatment for skin
230023|NCT01810458|Liver
230024|NCT01810458|Fibrosis
230025|NCT01810458|Alpha-1
230026|NCT01810458|AAT
230027|NCT01810458|AATD
230028|NCT01810445|Bladder Cancer
230029|NCT01810445|Laser
230030|NCT01810445|Optical
230031|NCT01810419|splenomegaly
230032|NCT01810419|ultrasound
230033|NCT01810419|Vscan
230034|NCT01810367|PFS
230035|NCT01810354|Cefazolin
230036|NCT01810354|Tissue concentration
230037|NCT01810354|infection
230038|NCT01810354|cesarean section
230039|NCT01810354|obese
230040|NCT01810341|Autism
230041|NCT01810341|Autism Spectrum Disorders
230042|NCT01810341|RNA
230043|NCT01810341|Gene expression
230044|NCT01810341|Developmental Delay
230045|NCT01810341|Metabolites
230046|NCT01810341|DNA
230047|NCT01810302|Vasospasm
230048|NCT01810302|Subarachnoid hemorrhage
230049|NCT01810302|Aneurysmal subarachnoid hemorrhage
230050|NCT01810302|Nicardipine
230051|NCT01810302|Intrathecal
230052|NCT01810302|SAH
230053|NCT01810302|aSAH
230054|NCT01810289|HIV, ART, CD4
230055|NCT01810276|traumatic head injury
230056|NCT01810276|intracranial hemorrhage
230057|NCT01810276|platelets
230058|NCT01810276|anti-platelet therapy
230059|NCT01810276|plavix
230060|NCT01810276|asprin
230061|NCT01810263|stroke
230062|NCT01810263|malnutrition
230063|NCT01810263|high protein
230064|NCT01810211|Shoulder
230065|NCT01810211|Surgery
230066|NCT01810211|Posterior Shoulder Tightness
230067|NCT01810211|Flexibility
230068|NCT01810211|Range of Motion
230069|NCT01810198|Coronary Artery Disease
230070|NCT01810198|Cardiac CT
230071|NCT01810198|Catheterization
230072|NCT01810185|Inflammatory Bowel Disease
230073|NCT01810185|Crohn's disease
230074|NCT01810185|Ulcerative colitis
230075|NCT01810185|Naltrexone
230076|NCT01810185|Low Dose Naltrexone
230077|NCT01810185|Inflammatory Bowel Disease Questionnaire
230078|NCT01810172|lobectomy
230079|NCT01810172|segmentectomy
230080|NCT01810172|pneumothorax
230081|NCT01810172|pleural
230082|NCT01810172|digital
230083|NCT01810172|air leak
230084|NCT01810159|substance use disorders
230085|NCT01810159|implementation science
230086|NCT01810159|collaborative care
230087|NCT01810159|opiate disorders
230088|NCT01810159|alcohol disorders
230089|NCT01810146|Patients eligible for bariatric surgery (BMI>40kg/m2)
230090|NCT01810133|Comorbidity
230091|NCT01810120|Hematologic
230092|NCT01810120|Malignant
230093|NCT01810120|Non-Malignant
230094|NCT01810120|Allogeneic
230095|NCT01810120|Transplant
230096|NCT01810120|Non-Hodgkin Lymphoma
230097|NCT01810120|Pediatric
230098|NCT01810120|Acute lymphoblastic leukemia
230099|NCT01810120|Acute Myeloid leukemia
230100|NCT01810120|Myelodysplastic Syndromes
230101|NCT01810120|T cells receptor alfa beta
230102|NCT01810094|thoracolumbar fracture
230103|NCT01810094|fixation
230104|NCT01810094|fixateur interne
230105|NCT01810094|minimal invasive
230106|NCT01810094|percutaneous
230107|NCT01810081|Cholelithiasis
230108|NCT01810081|Gastric H.Pylori infection
230109|NCT01810081|H.Pylori infection
230110|NCT01810081|Gastric mucosa
230111|NCT01810068|BPH- Erectile function- Transurethral- Laser
230112|NCT01810042|age-related macular degeneration
230113|NCT01810042|choroidal neovascularization
230114|NCT01810042|ranibizumab
230115|NCT01810042|indocyanine angiography
230116|NCT01810029|transcendental meditation
230117|NCT01810029|cardiac rehabilitation
230118|NCT01810016|NY-ESO-1
230119|NCT01810016|Metastatic Melanoma
230120|NCT01810016|Ipilimumab
230121|NCT01810016|Phase I
230122|NCT01810016|Adjuvant
230123|NCT01810016|Immunologic
230124|NCT01810016|Vaccination
230125|NCT01810016|Immunotherapy
230126|NCT01810016|Neoplasm
230127|NCT01810003|Cardiovascular disease
230128|NCT01810003|Inflammation
230129|NCT01810003|EPA/DHA supplementation
230130|NCT01809990|cognitive behavior therapy
230131|NCT01809990|pediatric obsessive-compulsive disorder
230132|NCT01809990|internet-delivered cognitive behavior therapy
230133|NCT01809977|Keratoconus
230134|NCT01809977|remove
230135|NCT01809977|cornea
230136|NCT01809977|visual acuity
230137|NCT01809938|Gastrointestinal tract emptying
230138|NCT01809938|Pre-operative fasting
230139|NCT01809938|Ultrasound
230140|NCT01809938|Paracetamol Absorption
230141|NCT01809912|solid tumor
230142|NCT01809899|Trauma
230143|NCT01809899|Abuse
230144|NCT01809899|Domestic Violence
230145|NCT01809899|Rape
230146|NCT01809899|Assault
230147|NCT01809899|MRI
230148|NCT01809886|Neuromuscular relaxants
230149|NCT01809886|short-term pediatric surgery
230150|NCT01809886|reverses neuromuscular blockade
230151|NCT01809873|Malaria
230152|NCT01809873|Diagnostics
230153|NCT01809873|Health Services
230154|NCT01809860|isavuconazole
230155|NCT01809860|sirolimus
230156|NCT01809860|BAL8557
230157|NCT01809860|Healthy Volunteers
230158|NCT01809847|CLL
230159|NCT01809847|Chronic Lymphatic Leukemia
230160|NCT01809847|Leukemia
230161|NCT01809847|HLA
230162|NCT01809847|Histocompatibility
230163|NCT01809847|HCT
230164|NCT01809847|hematopoietic stem cell transplantation
230165|NCT01809847|Ofatumumab
230166|NCT01809847|CD20
230167|NCT01809821|Hypertension
230168|NCT01809821|Sleep Disorders
230169|NCT01809821|Insomnia
230170|NCT01809821|Cardiovascular Diseases
230171|NCT01809821|Internet treatment
230172|NCT01809808|Acromegaly
230173|NCT01809808|Pituitary tumor
230174|NCT01809795|Obesity
230175|NCT01809795|Exercise
230176|NCT01809795|Blueberry Plant
230177|NCT01809743|Coronary artery disease
230178|NCT01809743|Regadenoson
230179|NCT01809743|Adenosine
230180|NCT01809743|Maximal hyperemia
230181|NCT01809743|Fractional flow reserve
230182|NCT01809743|FFR
230183|NCT01809691|Prostate cancer
230184|NCT01809691|TAK-700
230185|NCT01809691|Bicalutamide
230186|NCT01809691|S1216
230187|NCT01809691|androgen therapy
230188|NCT01809691|Phase III
230189|NCT01809678|Smoking
230190|NCT01809678|Tobacco
230191|NCT01809678|Yoga
230192|NCT01809665|ICD therapy
230193|NCT01809665|CRT-P therapy
230194|NCT01809665|MRI
230195|NCT01809652|Pacemaker
230196|NCT01809652|Defibrillator
230197|NCT01809652|Remote Consultation
230198|NCT01809639|Concussion
230199|NCT01809613|Parkinson disease
230200|NCT01809613|Deep Brain Stimulation
230201|NCT01809613|Functional Magnetic Resonance Imaging
230202|NCT01809574|Interstitial lung disease
230203|NCT01809574|Idiopathic pulmonary fibrosis
230204|NCT01809574|Connective tissue disease
230205|NCT01809561|endometriosis
230206|NCT01809561|telomere
230207|NCT01809561|telomerase
230208|NCT01809548|complementary feeding
230209|NCT01809548|premature infant
230210|NCT01809548|body composition
230211|NCT01809548|atopy
230212|NCT01809548|neurodevelopmental outcome
230213|NCT01809548|obesity
230214|NCT01809535|endoscopic variceal ligation
230215|NCT01809535|post-EVL ulcer
230216|NCT01809535|variceal bleeding
230217|NCT01809522|Robotic-assisted radical prostatectomy
230218|NCT01809522|Urinary continence
230219|NCT01809522|Posterior reconstruction of the rhabdosphincter
230220|NCT01809522|Posterior musculofascial plate reconstruction
230221|NCT01809509|CYTOKINES , IL11 IL6 IMLANTATION RATE IVF.
230222|NCT01809496|hearing loss
230223|NCT01809496|hearing aids
230224|NCT01809496|spouses
230225|NCT01809496|rehabilitation
230226|NCT01809483|mechanical corneal erosion
230227|NCT01809483|bandage contact lens
230228|NCT01809483|pressure patching
230229|NCT01809483|erosion area
230230|NCT01809483|pain scale
230231|NCT01809470|Blood pressure
230232|NCT01809470|Appetite
230233|NCT01809470|Heart rate
230234|NCT01809470|Salivary cortisol
230235|NCT01809457|educational poster, knowledge, dental trauma,
230236|NCT01809431|gestational diabetes
230237|NCT01809431|women
230238|NCT01809431|infants
230239|NCT01809431|blood glucose
230240|NCT01809431|weight
230241|NCT01809431|adiposity
230242|NCT01809431|health behaviors
230243|NCT01809431|self-efficacy
230244|NCT01808378|Bilateral limbic associated keratopathy
230245|NCT01808378|Expanded Adipose Derived Stem Cells
230246|NCT01808365|Philippines
230247|NCT01808365|carriage
230248|NCT01808365|Neisseria meningitidis
230249|NCT01808365|meningococcus
230250|NCT01808352|AE adverse event
230251|NCT01808352|AIDS acquired immunodeficiency syndrome
230252|NCT01808352|ALT (SGPT) alanine aminotransferase
230253|NCT01808352|ART antiretroviral therapy
230254|NCT01808352|AST (SGOT) aspartate aminotransferase
230255|NCT01808352|DCF data collection forms
230256|NCT01808352|DMC Data Monitoring Committee
230257|NCT01808352|FDA (U.S.) Food and Drug Administration
230258|NCT01808352|GCP Good Clinical Practice guidelines
230259|NCT01808352|HB sAg Hepatitis B surface antigen
230260|NCT01808352|ICH International Conference of Harmonisation
230261|NCT01808352|IND Investigational New Drug Application
230262|NCT01808352|IRB Institutional Review Board
230263|NCT01808352|IU International units
230264|NCT01808352|mg milligram(s)
230265|NCT01808352|mm3 cubic millimeter(s)
230266|NCT01808352|PCR polymerase chain reaction
230267|NCT01808352|SAE serious adverse event
230268|NCT01808352|µg microgram
230269|NCT01808352|ULN upper limit of the normal range
230270|NCT01808352|WB Western Blot
230271|NCT01808339|Fluticasone Furoate, FF Inhalation Powder, morning dosing, evening dosing, efficacy, FEV1
230272|NCT01809392|Decitabine
230273|NCT01809392|hematopoietic stem cell transplant
230274|NCT01809392|Wilms' tumor 1
230275|NCT01809392|cytolytic T lymphocyte
230276|NCT01809392|Regulatory T cell
230277|NCT01809379|ovarian cancer, recurrent, chemotherapy, intraperitoneal
230278|NCT01809366|seminal plasma/uterine receptivity
230279|NCT01809353|Healthy
230280|NCT01809353|Japanese
230281|NCT01809353|Caucasian
230282|NCT01809353|Male
230283|NCT01809353|Pharmacokinetic
230284|NCT01809353|JNJ-54452840
230285|NCT01809340|Depressive Disorder
230286|NCT01809340|Major Depressive Disorder
230287|NCT01809340|Depression
230288|NCT01809340|Bipolar Disorder Type II
230289|NCT01809340|Anti-depressant
230290|NCT01809340|Ketamine
230291|NCT01809340|Minocycline
230292|NCT01809327|Diabetes Mellitus, Type 2
230293|NCT01809327|Diabetes Mellitus
230294|NCT01809327|Canagliflozin (JNJ-28431754)
230295|NCT01809327|Metformin
230296|NCT01809301|Bioavailability
230297|NCT01809288|Women
230298|NCT01809288|Diet
230299|NCT01809288|Obesity
230300|NCT01809288|African
230301|NCT01809288|African Americans
230302|NCT01809275|Crohn's Disease
230303|NCT01809275|Inflammatory Bowel Disease
230304|NCT01809275|CDAI
230305|NCT01809249|Living donor liver transplantation
230306|NCT01809249|Donar safety
230307|NCT01809210|MEK1/2 inhibitor,
230308|NCT01809210|Non Small Cell Lung Cancer,
230309|NCT01809210|metastatic,
230310|NCT01809210|first line treatment for Non Small Cell Lung Cancer
230311|NCT01809197|Refractive error
230312|NCT01809197|Myopia
230313|NCT01809197|Hyperopia
230314|NCT01809197|Astigmatism
230315|NCT01809197|Presbyopia
230316|NCT01809197|Contact lenses
230317|NCT01809197|Contact lens solution
230318|NCT01809197|Comfort
230319|NCT01809145|sarcoidosis
230320|NCT01809145|occupational exposure
230321|NCT01809145|MELISA
230322|NCT01809132|Hepatitis, alcoholic
230323|NCT01809132|pentoxifylline
230324|NCT01809132|zinc
230325|NCT01809132|anakinra
230326|NCT01809132|glucocorticoids
230327|NCT01809132|MELD score
230328|NCT01809132|Intestinal mucosa
230329|NCT01809119|Kidney Neoplasms, Minimally invasive surgery, Renal cell carcinoma
230330|NCT01809106|cancer pain
230331|NCT01809106|major opioid
230332|NCT01809106|analgesics
230333|NCT01809093|PEDF
230334|NCT01809093|TSP1
230335|NCT01809093|Thrombospondin
230336|NCT01809093|pigment epithelium derived factor
230337|NCT01809093|Wills Eye Institute
230338|NCT01809093|Pars plana vitrectomy
230339|NCT01809093|Vitreous levels
230340|NCT01809093|Mid Atlantic Retina
230341|NCT01809093|Blood draw
230342|NCT01809093|Blood test
230343|NCT01809067|stress
230344|NCT01809067|anxiety
230345|NCT01809067|MRI
230346|NCT01809067|aromatherapy
230347|NCT01809054|Hip, Knee, Arthroplasty, venous thromboembolic events, blood loss
230348|NCT01809028|cell block, number of passes
230349|NCT01809015|Oral Anticoagulation
230350|NCT01809015|Regular Medical Care
230351|NCT01809015|Coagulation Service
230352|NCT01809015|Vitamin-K Antagonists
230353|NCT01809015|Quality of therapy
230354|NCT01809015|Atrial fibrillation
230355|NCT01809015|Venous thromboembolism
230356|NCT01809015|Bypass surgery
230357|NCT01809015|Prosthetic heart valve
230358|NCT01808989|peripheral artery disease
230359|NCT01808989|tcpo2
230360|NCT01808989|treadmill walking test
230361|NCT01808989|intermittent claudication
230362|NCT01808963|Enthalpy
230363|NCT01808963|Physiologic Monitors
230364|NCT01808963|Critical Care Medicine
230365|NCT01808924|aging
230366|NCT01808924|insulin resistance
230367|NCT01808924|diabetes
230368|NCT01808924|sarcopenia in aging
230369|NCT01808924|muscle mitochondria
230370|NCT01808924|intramyocellular lipids
230371|NCT01808911|Acquired haemophilia
230372|NCT01808911|Comparative and randomized study
230373|NCT01808911|Cyclophosphamide
230374|NCT01808911|Rituximab
230375|NCT01808898|Ablation
230376|NCT01808898|Outpatient
230377|NCT01808885|safety
230378|NCT01808885|multiple sclerosis
230379|NCT01808885|olesoxime
230380|NCT01808885|double-blind
230381|NCT01808885|randomized
230382|NCT01808859|Total Knee Arthroplasty
230383|NCT01808859|Thigh Tourniquet
230384|NCT01808846|Obesity
230385|NCT01808846|Insulin Resistance
230386|NCT01808846|functional magnetic resonance imaging
230387|NCT01808846|glucose
230388|NCT01808846|fructose
230389|NCT01808846|hypothalamus
230390|NCT01808846|neuronal circuits
230391|NCT01808846|feeding behavior
230392|NCT01808833|Frailty
230393|NCT01808833|Geriatric oncology
230394|NCT01808820|Malignant Glioma
230395|NCT01808820|Glioblastoma Multiforme
230396|NCT01808820|Anaplastic Astrocytoma
230397|NCT01808820|High Grade Glioma
230398|NCT01808820|HGG
230399|NCT01808820|Dendritic Cell Vaccine
230400|NCT01808820|DC Vaccine
230401|NCT01808820|Leukapheresis
230402|NCT01808807|cesarean section rate
230403|NCT01808807|the cesarean section rate audit
230404|NCT01808794|membranes
230405|NCT01808794|Mucograft
230406|NCT01808794|Dynamatrixw
230407|NCT01808794|ridge
230408|NCT01808794|preservation
230409|NCT01808794|bone
230410|NCT01808794|allograft
230411|NCT01808794|extraction
230412|NCT01808794|site
230413|NCT01808794|healing
230414|NCT01808781|Power
230415|NCT01808781|muscle strength
230416|NCT01808781|total knee replacement
230417|NCT01808781|physical activity behavior
230418|NCT01808755|recurrent urinary tract infections
230419|NCT01808755|D Mannose
230420|NCT01808755|cystitis
230421|NCT01808755|antibiotic treatment
230422|NCT01808729|fibromuscular dysplasia
230423|NCT01808729|coronary artery disease
230424|NCT01808716|low-level laser therapy
230425|NCT01808716|muscle damage
230426|NCT01808703|Periodontitis
230427|NCT01808703|Periodontal pocket
230428|NCT01808703|Periodontal diseases
230429|NCT01808690|Adolescent
230430|NCT01808690|Youth
230431|NCT01808690|Diabetes
230432|NCT01808690|Insulin Resistance
230433|NCT01808690|Cardiovascular
230434|NCT01808690|Metformin
230435|NCT01808677|Non-Small Cell Lung Cancer
230436|NCT01808677|NSCLC
230437|NCT01808677|Thoracic reirradiation
230438|NCT01808677|Proton beam therapy
230439|NCT01808677|PBT
230440|NCT01808677|Intensity modulated radiation therapy
230441|NCT01808677|IMRT
230442|NCT01808677|Registry
230443|NCT01808677|Data
230444|NCT01808638|Adenocarcinoma
230445|NCT01808638|Pancreas
230446|NCT01808638|Gemcitabine
230447|NCT01808638|Atu027
230448|NCT01808625|BRAIN MALIGNANCIES , RADIATION THERAPY
230449|NCT01808586|Neck
230450|NCT01808586|chronic pain
230451|NCT01808586|facet injection
230452|NCT01808521|Purpura, Thrombotic Thrombocytopenic
230453|NCT01808521|TTP
230454|NCT01808508|Down syndrome
230455|NCT01808508|Obstructive sleep apnea syndrome
230456|NCT01808508|Continuous positive airway pressure
230457|NCT01808508|sham or placebo CPAP
230458|NCT01808495|Human corneal fibroblasts
230459|NCT01808495|Fibulin-1
230460|NCT01808495|Nuclear accumulation
230461|NCT01808482|monoclonal antibody
230462|NCT01808482|Multiple Sclerosis
230463|NCT01808482|Interleukin-7 Receptor
230464|NCT01808456|kidney transplant
230465|NCT01808456|heart transplant
230466|NCT01808456|lung transplant
230467|NCT01808456|influenza vaccine
230468|NCT01808443|cryotherapy
230469|NCT01808443|laser
230470|NCT01808443|cutaneous warts
230471|NCT01808430|NSCLC
230472|NCT01808404|Acceptance and Commitment Therapy
230473|NCT01808404|Mindfulness
230474|NCT01808404|Guided Self-Help
230475|NCT01808404|College
230476|NCT01808391|Coronary artery disease
230477|NCT01808391|Heart disease
230478|NCT01808391|Myocardial ischemia
230479|NCT01808391|Cardiovascular disease
230480|NCT01808391|Arteriosclerosis
230481|NCT01808391|Vascular disease
230482|NCT01808287|Transcatheter Aortic Valve Replacement
230483|NCT01808287|Aortic Stenosis
230484|NCT01808274|Transcatheter Aortic Valve Replacement
230485|NCT01808274|Aortic Stenosis
230486|NCT01808261|Ischemic Stroke
230487|NCT01808248|HCV genotype 2 (GT-2)
230488|NCT01808248|HCV genotype 3 (GT-3)
230489|NCT01808248|HCV
230490|NCT01808248|Sustained Virologic Response
230491|NCT01808248|Direct Acting Antiviral
230492|NCT01808248|Combination Therapy
230493|NCT01808248|Treatment-Naïve
230494|NCT01808248|GS-7977
230495|NCT01808248|Ribavirin
230496|NCT01808248|RBV
230497|NCT01808248|Peginterferon Alfa 2a
230498|NCT01808248|PEG
230499|NCT01808248|Additional relevant MeSH terms:
230500|NCT01808248|Hepatitis
230501|NCT01808248|Hepatitis A
230502|NCT01808248|Hepatitis, Chronic
230503|NCT01808248|Hepatitis C
230504|NCT01808248|Hepatitis C, Chronic
230505|NCT01808248|Liver Diseases
230506|NCT01808248|Digestive System Diseases
230507|NCT01808248|Hepatitis, Viral, Human
230508|NCT01808248|Virus Diseases
230509|NCT01808248|Enterovirus Infections
230510|NCT01808248|Picornaviridae Infections
230511|NCT01808248|RNA Virus Infections
230512|NCT01808248|Flaviviridae Infections
230513|NCT01808248|Peginterferon alfa-2a
230514|NCT01808248|Interferon-alpha
230515|NCT01808248|Antiviral Agents
230516|NCT01808248|Anti-Infective Agents
230517|NCT01808248|Therapeutic Uses
230518|NCT01808248|Pharmacologic Actions
230519|NCT01808248|Antimetabolites
230520|NCT01808248|Molecular Mechanisms of Pharmacological Action
230521|NCT01808248|Immunologic Factors
230522|NCT01808248|Physiological Effects of Drugs
230523|NCT01808196|Eosinophilic Esophagitis
230524|NCT01808196|Connective Tissue Disorders
230525|NCT01808196|Drug trial
230526|NCT01808183|supracondylar
230527|NCT01808183|pediatric
230528|NCT01808183|humerus
230529|NCT01808183|NIRS
230530|NCT01808183|near Infrared spectroscopy
230531|NCT01808183|compartment perfusion
230532|NCT01808170|Laparoscopy
230533|NCT01808170|AMH
230534|NCT01808170|AFC
230535|NCT01808170|Endometrioma
230536|NCT01808170|ovarian reserve
230537|NCT01808170|Ovarian cystectomy
230538|NCT01808170|ovarian cyst deroofing
230539|NCT01808157|atopic dermatitis
230540|NCT01808157|pruritus
230541|NCT01808144|Gout
230542|NCT01808131|Gout
230543|NCT01808118|Musculoskeletal Diseases
230544|NCT01808118|Joint Diseases
230545|NCT01808118|Adalimumab
230546|NCT01808118|Spondylarthropathy
230547|NCT01808118|Arthritis
230548|NCT01808118|Anti-Inflammatory Agents
230549|NCT01808118|Spondyloarthritis
230550|NCT01808118|Spinal Diseases
230551|NCT01808118|Antirheumatic Agents
230552|NCT01808118|Ankylosing Spondyloarthritis
230553|NCT01808118|Spondylitis
230554|NCT01808092|Ceftazidime,
230555|NCT01808092|Meropenem,
230556|NCT01808092|Anti-Bacterial Agents,
230557|NCT01808092|Anti-Infective Agents,
230558|NCT01808092|Therapeutic Uses,
230559|NCT01808092|Pharmacologic Actions,
230560|NCT01808092|Physiological Effects of Drugs
230561|NCT01808040|breast cancer
230562|NCT01808040|ER positive
230563|NCT01808040|PR positive
230564|NCT01808040|post menopausal
230565|NCT01808027|quality of life drug adherence drug compliance mortality
230566|NCT01808014|nefopam, spinal surgery, postoperative pain control
230567|NCT01807988|Relapse, Recurrence, Depression, Internet, Sick-leave
230568|NCT01807962|Injections, Subcutaneous
230569|NCT01807962|Cortisone
230570|NCT01807962|Anesthetics, Local
230571|NCT01807936|Esophageal Neoplasms
230572|NCT01807936|lymphadenectomy
230573|NCT01807910|Obesity
230574|NCT01807910|NAFLD
230575|NCT01807910|NASH
230576|NCT01807910|Steatosis
230577|NCT01807897|Heart Failure
230578|NCT01807897|Sleep Apnea
230579|NCT01807897|Ventricular Ejection Fraction
230580|NCT01807897|Exercise Test
230581|NCT01807884|Microaspiration
230582|NCT01807884|Ventilator acquired Pneumonia
230583|NCT01807884|Amylase
230584|NCT01807884|Mechanical ventilation
230585|NCT01807884|Suction
230586|NCT01807871|nicotine dependence
230587|NCT01807871|smoking cessation
230588|NCT01807871|lapse
230589|NCT01807871|relapse
230590|NCT01807871|tobacco
230591|NCT01807871|nicotine patch
230592|NCT01807871|nicotine replacement therapy
230593|NCT01807871|NRT
230594|NCT01807858|Necrotizing enterocolitis
230595|NCT01807858|Sepsis
230596|NCT01807858|Length of hospital stay
230597|NCT01807858|Mortality
230598|NCT01807845|Casein micelles
230599|NCT01807845|vitamin D3 (cholecalciferol)
230600|NCT01807845|Bioavailability
230601|NCT01807845|Nanoencapsulation
230602|NCT01807845|Nutrition
230603|NCT01807832|chronic cough
230604|NCT01807832|cough reflex hypersensitivity
230605|NCT01807832|capsaicin
230606|NCT01807819|Heart Failure
230607|NCT01807819|Myocardial Strain
230608|NCT01807819|Functional Capacity
230609|NCT01807806|veterans, military, families
230610|NCT01807793|Stroke
230611|NCT01807793|TIA
230612|NCT01807793|African American
230613|NCT01807754|automated ultrasound imaging (AUS)
230614|NCT01807754|digital breast tomosynthesis (DBT)
230615|NCT01807754|photoacoustic imaging (PAT)
230616|NCT01807741|Bipolar Disorder
230617|NCT01807741|Depression
230618|NCT01807728|Quality of life
230619|NCT01807728|Participation
230620|NCT01807728|Training
230621|NCT01807715|first trimester
230622|NCT01807715|surgical abortion
230623|NCT01807715|contraception
230624|NCT01807702|dichloroacetate
230625|NCT01807702|pyruvate
230626|NCT01807702|lactate
230627|NCT01807702|pyruvate dehydrogenase
230628|NCT01807689|Dry mouth
230629|NCT01807689|Dry eyes
230630|NCT01807689|Saliva
230631|NCT01807689|Salivary gland biopsy
230632|NCT01807663|neuromuscular disease
230633|NCT01807650|Split-Thickness Skin Graft Donor Site
230634|NCT01807650|Split-thickness skin graft
230635|NCT01807650|STSG
230636|NCT01807650|Wound healing
230637|NCT01807650|Skin grafting
230638|NCT01807650|Superficial wound
230639|NCT01807650|Partial-thickness wound
230640|NCT01807650|Time to wound closure
230641|NCT01807624|Pharmacokinetic
230642|NCT01807611|Haploidentical donor transplantation
230643|NCT01807611|NK cell
230644|NCT01807585|GSV
230645|NCT01807559|Single Sided Deafness
230646|NCT01807559|Conductive Hearing Loss
230647|NCT01807559|Unilateral Hearing Loss
230648|NCT01807559|SSD
230649|NCT01807546|Head and neck cancer
230650|NCT01807546|Platinum-resistant
230651|NCT01807546|Squamous cell carcinoma
230652|NCT01807533|Environment
230653|NCT01807533|Gene
230654|NCT01807533|Intervention
230655|NCT01807533|Neurodevelopment
230656|NCT01807533|Pathways
230657|NCT01807533|Preterm infants
230658|NCT01807520|Moderate nail psoriasis
230659|NCT01807520|Severe nail psoriasis
230660|NCT01807520|psoriasis
230661|NCT01807520|Secukinumab
230662|NCT01807507|Veins
230663|NCT01807507|Vascular Access
230664|NCT01807481|Mircera
230665|NCT01807481|PD
230666|NCT01807481|Maitenance
230667|NCT01807468|haploidentical stem cell transplantation
230668|NCT01807468|natural killer cell therapy
230669|NCT01807468|pediatric solid tumor
230670|NCT01807442|Acute Coronary Syndrome
230671|NCT01807442|Positive Psychology
230672|NCT01807442|Adherence to Health Behaviors
230673|NCT01807429|Ketamine,
230674|NCT01807429|Midazolam,
230675|NCT01807429|Morphine,
230676|NCT01807429|visual analogue score
230677|NCT01807416|Osseointegrated Implant, Bone level
230678|NCT01807403|Obsessive-Compulsive Disorder
230679|NCT01807403|Deep brain stimulation
230680|NCT01807403|Subthalamic nucleus
230681|NCT01807403|Caudate nucleus
230682|NCT01807403|Nucleus accumbens
230683|NCT01807390|Minimally invasive surgery
230684|NCT01807390|Patient perspectives
230685|NCT01807390|Lung cancer
230686|NCT01807390|Esophageal cancer
230687|NCT01807390|Pain
230688|NCT01807364|Congenital adrenal hyperplasia (CAH)
230689|NCT01807364|Cardiovascular risk
230690|NCT01807364|Microvascular dysfunction
230691|NCT01807351|Diabetes Mellitus
230692|NCT01807351|Hypertension
230693|NCT01807351|Impaired Fasting Glucose
230694|NCT01807351|Primary Health Care
230695|NCT01807351|Chinese
230696|NCT01807312|colonoscopy
230697|NCT01807299|Physical Training
230827|NCT01806701|neuroimaging
230698|NCT01807299|ADHD-Attention deficit hyperactivity disorder
230699|NCT01807299|Omega 3
230700|NCT01807286|Myeloma
230701|NCT01807286|Untreated Systemic AL Amyloidosis
230702|NCT01807286|Amyloid light-chain (AL) amyloidosis
230703|NCT01807286|Pomalidomide
230704|NCT01807286|Melphalan
230705|NCT01807286|Alkeran
230706|NCT01807286|Dexamethasone
230707|NCT01807286|Decadron
230708|NCT01807286|Questionnaires
230709|NCT01807286|Surveys
230710|NCT01807273|hemiplegic
230711|NCT01807273|time up and go test
230712|NCT01807273|motion analysis
230713|NCT01807273|center of mass
230714|NCT01807247|Strengthening muscle
230715|NCT01807247|Central nervous system diseases
230716|NCT01807247|Gait
230717|NCT01807221|Heart Decompensation
230718|NCT01807208|Acute myocardial infarction
230719|NCT01807208|patient education
230720|NCT01807208|prevention
230721|NCT01807195|contrast
230722|NCT01807195|Intensive care unit
230723|NCT01807195|Acute kidney injury
230724|NCT01807169|colon
230725|NCT01807169|endoscopy
230726|NCT01807169|resection
230727|NCT01807169|clopidogrel
230728|NCT01807156|Tivozanib
230729|NCT01807156|Advanced hepatocellular cancer
230730|NCT01807156|Angiogenesis
230731|NCT01807130|Heart Failure
230732|NCT01807130|Medical Therapy
230733|NCT01807130|ICD
230734|NCT01807130|CRT
230735|NCT01807104|Anterior Approach
230736|NCT01807104|Posterior Approach
230737|NCT01807078|Coronary artery disease
230738|NCT01807039|hip fracture
230739|NCT01807039|proximal femur
230740|NCT01807039|pertrochanteric fracture
230741|NCT01807039|subtrochanteric fracture
230742|NCT01807039|subcapital fracture
230743|NCT01807039|safety issue
230744|NCT01807039|anesthesia
230745|NCT01807013|cirrhosis
230746|NCT01807013|liver
230747|NCT01807013|elastometry
230748|NCT01807013|ultrasound
230749|NCT01807013|laparoscopy
230750|NCT01807013|diagnosis
230751|NCT01806987|school readiness
230752|NCT01806987|literacy
230753|NCT01806987|social emotional skills
230754|NCT01806987|self regulation
230755|NCT01806987|caregiver involvement
230756|NCT01806987|socioeconomic disadvantage
230757|NCT01806974|Periodontitis
230758|NCT01806974|rheumatoid arthritis
230759|NCT01806974|anti-interleukin 6
230760|NCT01806974|immunotherapy
230761|NCT01806974|inflammation
230762|NCT01806974|bacteria
230763|NCT01806974|periodontal sulci
230764|NCT01806974|periodontal pockets
230765|NCT01806935|associated
230766|NCT01806935|aged population
230767|NCT01806922|Yoga
230768|NCT01806922|Stroke
230769|NCT01806922|Standing balance
230770|NCT01806922|Depression
230771|NCT01806909|Flu Vaccine
230772|NCT01806909|Healthy Volunteer
230773|NCT01806883|Hemiparesis,
230774|NCT01806883|Rehabilitation,
230775|NCT01806883|WII,
230776|NCT01806883|Upper limb,
230777|NCT01806883|Movement strategies.
230778|NCT01806870|HIV
230779|NCT01806870|ART
230780|NCT01806857|Amyotrophic lateral sclerosis
230781|NCT01806857|ALS
230782|NCT01806857|Nuedexta
230783|NCT01806857|Bulbar function
230784|NCT01806857|motor neurons
230785|NCT01806844|Cardiac arrest
230786|NCT01806844|Cerebral oxygenation
230787|NCT01806844|Pre-hospital
230788|NCT01806805|Movement disorder
230789|NCT01806805|Myoclonus dystonia
230790|NCT01806805|DYT 11
230791|NCT01806805|Antiepileptic drugs
230792|NCT01806805|Zonisamide
230793|NCT01806805|Clinical Trial
230794|NCT01806805|Double-mind method
230795|NCT01806792|Osteoporosis
230796|NCT01806779|Nicotine addiction
230797|NCT01806779|Cigarette smoking
230798|NCT01806779|Smoking cessation
230799|NCT01806779|Zyban
230800|NCT01806779|Chantix
230801|NCT01806779|Nicotine patches
230802|NCT01806779|varenicline
230803|NCT01806779|bupropion
230804|NCT01806766|cementless total hip arthroplasty
230805|NCT01806766|ceramic on ceramic bearing
230806|NCT01806766|ceramic on highly cross linked polyethylene
230807|NCT01806766|young patient
230808|NCT01806753|Endoscopic submucosal dissection
230809|NCT01806753|Sedation
230810|NCT01806753|Propofol
230811|NCT01806753|Midazolam
230812|NCT01806740|DCE-MRI
230813|NCT01806740|Sorafenib response
230814|NCT01806727|Diabetes
230815|NCT01806727|Diabetes Self Management
230816|NCT01806727|LIFT Diabetes
230817|NCT01806727|Weight Loss
230818|NCT01806727|Diet
230819|NCT01806727|Physical Activity
230820|NCT01806727|Overweight
230821|NCT01806727|Obese
230822|NCT01806714|HPV vaccination
230823|NCT01806714|Adolescent well care
230824|NCT01806714|Adolescent HPV immunization
230825|NCT01806714|HPV
230826|NCT01806701|fMRI
230828|NCT01806701|PTSD
230829|NCT01806701|adolescent
230830|NCT01806701|trauma
230831|NCT01806701|brain
230832|NCT01806688|satiety
230833|NCT01806688|appetite
230834|NCT01806688|snack
230835|NCT01806662|Atopic Dermatitis
230836|NCT01806662|Eczema
230837|NCT01806649|esophageal cancer
230838|NCT01806649|second line therapy
230839|NCT01806649|BKM120
230840|NCT01806636|Coil
230841|NCT01806636|RePneu
230842|NCT01806636|PneumRx
230843|NCT01806636|LVRC
230844|NCT01806610|Randomized
230845|NCT01806610|Placebo-controlled trial
230846|NCT01806610|BPS804
230847|NCT01806610|Safety, tolerability, and PK
230848|NCT01806610|Patients with late-stage chronic kidney disease.
230849|NCT01806597|Moderate palmoplantar psoriasis
230850|NCT01806597|Severe palmoplantar psoriasis
230851|NCT01806597|psoriasis
230852|NCT01806597|Secukinumab
230853|NCT01806584|Vascular Injury
230854|NCT01806584|Arteriovenous Graft Surgery
230855|NCT01806584|Hemodialysis Access
230856|NCT01806558|Breast cancer
230857|NCT01806558|molecular breast imaging
230858|NCT01806558|breast
230859|NCT01806558|breast lesion
230860|NCT01806545|Arteriovenous Fistula Surgery
230861|NCT01806545|Vascular Injury
230862|NCT01806545|Hemodialysis Access
230863|NCT01806532|computed tomography and positron emission tomography
230864|NCT01806532|respiration, artificial
230865|NCT01806532|respiratory distress syndrome, adult
230866|NCT01806519|neck pain
230867|NCT01806519|motor control
230868|NCT01806519|intervention
230869|NCT01806519|forward head posture
230870|NCT01806506|Bariatric surgery
230871|NCT01806506|Gastric bypass
230872|NCT01806506|Sleeve gastrectomy
230873|NCT01806506|Weight loss
230874|NCT01806506|Lipoproteins
230875|NCT01806506|Insulin resistance
230876|NCT01806506|Incretins
230877|NCT01806506|Quality of life
230878|NCT01806493|body composition
230879|NCT01806493|obesity
230880|NCT01806480|Breastfeeding, Preterm Infant, Neonatal Care, Support, Mothers.
230881|NCT01806415|Fenobam,
230882|NCT01806415|Pharmacokinetics
230883|NCT01806415|side effects
230884|NCT01806389|Breast milk
230885|NCT01806389|Breastfeeding
230886|NCT01806389|Lactation
230887|NCT01806389|Buprenorphine
230888|NCT01806389|Opioid
230889|NCT01806363|Pharmacokinetics
230890|NCT01806363|Safety
230891|NCT01806363|Male
230892|NCT01806350|Pelvic floor muscle training; incontinence; quality of life
230893|NCT01806337|peripheral T cell lymphoma
230894|NCT01806337|alemtuzumab
230895|NCT01806337|consolidation
230896|NCT01806311|Pharmacokinetics
230897|NCT01806311|Safety
230898|NCT01806311|Male
230899|NCT01806298|Adult Growth hormone deficiency
230900|NCT01806298|Saizen®
230901|NCT01806298|Recombinant human growth hormone (r-hGH)
230902|NCT01806298|Somatropin
230903|NCT01806285|Respiratory Virus
230904|NCT01806272|rhGM-CSF
230905|NCT01806272|Oral Mucositis
230906|NCT01806272|Primary Nasopharyngeal Cancers
230907|NCT01806272|Chemoradiotherapy
230908|NCT01806246|rehabilitation
230909|NCT01806246|adolescent
230910|NCT01806246|heart rate variability biofeedback
230911|NCT01806246|psychoeducation
230912|NCT01806220|Gastroesophageal Reflux Disease (GERD)
230913|NCT01806220|Chronic Laryngitis
230914|NCT01806220|Epidermal Growth factor receptor
230915|NCT01806168|Post-traumatic stress disorder
230916|NCT01806168|Repetitive transcranial magnetic stimulation
230917|NCT01806168|Civilians
230918|NCT01806168|Neurostimulation
230919|NCT01806168|Dorsolateral prefrontal cortex
230920|NCT01806155|craniotomy
230921|NCT01806155|headache
230922|NCT01806155|postoperative
230923|NCT01806116|myelodysplastic syndrome
230924|NCT01806116|higher-risk
230925|NCT01806116|acute myeloid leukemia
230926|NCT01806116|relapsed /refractory
230927|NCT01806116|decitabine
230928|NCT01806116|hematopoietic cell transplantation
230929|NCT01806116|bridge therapy
230930|NCT01806103|antimicrobial stewardship program
230931|NCT01806103|inappropriate prescribing of antibiotics
230932|NCT01806103|physician prescribing
230933|NCT01806103|antibiotic prescribing for respiratory tract infections
230934|NCT01806103|respiratory tract infections
230935|NCT01806077|Cardiovascular Diseases
230936|NCT01806077|Vascular Diseases
230937|NCT01806077|Coronary Artery Disease
230938|NCT01806077|Coronary Disease
230939|NCT01806077|Arteriosclerosis
230940|NCT01806077|Platelet Aggregation Inhibitors
230941|NCT01806064|TRC105
230942|NCT01806064|CD105
230943|NCT01806064|RCC
230944|NCT01806064|Renal Cell Carcinoma
230945|NCT01806064|Axitinib
230946|NCT01806064|INLYTA
230947|NCT01806064|Advanced Renal Cell Carcinoma
230948|NCT01806038|Adverse events
230949|NCT01806038|Drug interactions
230950|NCT01806038|Healthcare utilization
230951|NCT01806038|Discharge medication counseling
230952|NCT01806025|Cystic Fibrosis
230953|NCT01806025|Haptoglobin
230954|NCT01806012|Supracervical Hysterectomy
230955|NCT01806012|Leiomyomas
230956|NCT01806012|Adenomyosis
230957|NCT01805999|Ispaghula
230958|NCT01805999|Gastrointestinal physiology
230959|NCT01805999|Gastrointestinal response to sugars
230960|NCT01805999|MRI
230961|NCT01805999|gastrointestinal
230962|NCT01805999|stomach
230963|NCT01805999|small bowel
230964|NCT01805999|colon
230965|NCT01805986|Multiple Sclerosis, other neurological conditions
230966|NCT01805934|Helicobacter pylori, rescue, quadruple therapy，dual therapy
230967|NCT01805921|Respiratory Syncytial Virus
230968|NCT01805921|RSV
230969|NCT01805921|Vaccine
230970|NCT01805908|metastatic
230971|NCT01805908|breast cancer
230972|NCT01805908|herceptin
230973|NCT01805908|imaging
230974|NCT01805908|tumour response
230975|NCT01805908|adenocarcinoma
230976|NCT01805908|SPECT-CT
230977|NCT01805908|pertuzumab
230978|NCT01805908|trastuzumab
230979|NCT01805908|locally advanced
230980|NCT01805895|Stroke
230981|NCT01805895|Acute Intracerebral Hemorrhage
230982|NCT01805895|Intracerebral Hemorrhage
230983|NCT01805895|Hemorrhagic stroke
230984|NCT01805895|Hemorrhage
230985|NCT01805895|Minocycline
230986|NCT01805882|Interferon Sparing
230987|NCT01805882|Directly Acting Antiviral
230988|NCT01805882|Ribavarin Sparing
230989|NCT01805869|Third Molar
230990|NCT01805869|Specimen Acquisition
230991|NCT01805856|antimicrobial prophylaxis
230992|NCT01805856|AMP
230993|NCT01805856|surgical site infection
230994|NCT01805856|SSI
230995|NCT01805856|thyroid
230996|NCT01805856|thyroidectomy
230997|NCT01805856|parathyroid
230998|NCT01805856|surgery
230999|NCT01805843|Pulmonary hypertension
231000|NCT01805843|chronic myeloid leukemia
231001|NCT01805843|dasatinib
231002|NCT01805843|nilotinib
231003|NCT01805830|Type2DM / DPP-IV inhibitors
231004|NCT01805817|lipid profile
231005|NCT01805817|bleeding scores
231006|NCT01805817|menstrual pattern
231007|NCT01805817|beneficial
231008|NCT01805817|side effects
231009|NCT01805817|changes in a year period
231010|NCT01805804|dual chamber pacing, left ventricle remodeling, valsartan
231011|NCT01805791|Ulcerative Colitis,
231012|NCT01805791|UC
231013|NCT01805791|Patients
231014|NCT01805791|active
231015|NCT01805791|mild
231016|NCT01805791|moderate
231017|NCT01805765|menopausal syndrome
231018|NCT01805765|climacteric syndrome
231019|NCT01805765|Hot flashes
231020|NCT01805765|Sweat
231021|NCT01805752|Prevention of mother to child HIV transmission
231022|NCT01805752|HIV/AIDS
231023|NCT01805739|transcatheter aortic valve implantation
231024|NCT01805739|CT
231025|NCT01805739|MRI
231026|NCT01805739|angiography
231027|NCT01805739|echocardiography
231028|NCT01805739|rotational C-arm CT
231029|NCT01805726|bronchoscopy
231030|NCT01805726|sedation
231031|NCT01805726|pulmonary function
231032|NCT01805726|tolerance
231033|NCT01805726|xylocain
231034|NCT01805726|dexmedetomidine
231035|NCT01805726|alfentanil
231036|NCT01805713|Biomarkers
231037|NCT01805700|type 1
231038|NCT01805700|diabetes
231039|NCT01805700|caffeine-enhanced energy drink
231040|NCT01805700|cardiac output
231041|NCT01805700|glucose
231042|NCT01805700|cognitive performance
231043|NCT01805674|menopause
231044|NCT01805674|quality of life
231045|NCT01805674|soy isoflavones
231046|NCT01805674|magnolia extract
231047|NCT01805661|early ambulation
231048|NCT01805661|knee arthroplasty
231049|NCT01805648|ITP
231050|NCT01805648|rhTPO
231051|NCT01805635|Children
231052|NCT01805635|Asthma
231053|NCT01805635|Allergic rhinitis
231054|NCT01805635|Atopic dermatitis
231055|NCT01805635|Urticaria
231056|NCT01805635|Healthy
231057|NCT01805622|community-based participatory research
231058|NCT01805622|colorectal cancer screening
231059|NCT01805609|practice nurse
231060|NCT01805609|clinical Nurse
231061|NCT01805609|inpatient staff
231062|NCT01805609|inpatient social worker
231063|NCT01805609|didactic training sessions
231064|NCT01805609|13-030
231065|NCT01805596|coronary artery disease
231066|NCT01805596|endothelial function
231067|NCT01805596|antiplatelet agent
231068|NCT01805570|platelet inhibitor
231069|NCT01805570|ST-segment Elevation
231070|NCT01805570|Myocardial Infarction
231071|NCT01805570|stent
231072|NCT01805570|prasugrel
231073|NCT01805570|ticagrelor
231074|NCT01805557|Diffuse Large B-cell Lymphoma (DLBCL)
231075|NCT01805557|Bortezomib
231076|NCT01805544|SF36 questionnaire
231077|NCT01805544|Anti Clot Treatment Scale
231078|NCT01805544|Satisfaction
231079|NCT01805544|Quality of Life
231080|NCT01805544|Rivaroxaban
231081|NCT01805544|Prevention & control
231082|NCT01805544|Pulmonary embolism
231083|NCT01805531|SF36 questionnaire
231084|NCT01805531|Anti Clot Treatment Scale
231085|NCT01805531|Satisfaction
231086|NCT01805531|Quality of Life
231087|NCT01805531|Rivaroxaban
231088|NCT01805531|Stroke prevention
231089|NCT01805518|CNSVS
231090|NCT01805518|Tower of London
231091|NCT01805518|Letter-Number Test
231092|NCT01805518|Trail Making Test
231093|NCT01805518|Vital signs
231094|NCT01805518|Mood
231095|NCT01805518|Suicidal ideation
231096|NCT01805518|ECG
231097|NCT01805518|Physical exam
231098|NCT01805518|Blood
231099|NCT01805518|Urine (Including pregnancy and drug screen)
231100|NCT01805518|Cytokines
231101|NCT01805518|Side effects
231102|NCT01805518|Brief Psychiatric Rating Scale
231103|NCT01805518|Positive and Negative Symptom Scale
231104|NCT01805505|Female infertility
231105|NCT01805505|Oocyte donation
231106|NCT01805505|Embryo transfer
231107|NCT01805505|Transvaginal ultrasonography
231108|NCT01805505|Transabdominal ultrasonography
231109|NCT01805492|Heart diseases
231110|NCT01805492|Cardiovascular diseases
231111|NCT01805492|Lifestyle modification
231112|NCT01805492|Diet
231113|NCT01805492|Exercise
231114|NCT01805479|exercise
231115|NCT01805479|depression
231116|NCT01805479|traumatic brain injury
231117|NCT01805466|Extracorporeal Vacuum Assisted Device Optimised (EVADO)
231118|NCT01805453|Glioblastoma
231119|NCT01805453|Angiotensin-II inhibitors
231120|NCT01805453|Losartan
231121|NCT01805453|steroids
231122|NCT01805453|Radiotherapy
231123|NCT01805453|Edema
231124|NCT01805453|Randomized trial
231125|NCT01805440|Adolescent
231126|NCT01805440|Bipolar Disorder
231127|NCT01805440|Bipolar Depression
231128|NCT01805440|Manic Depression
231129|NCT01805440|Neuroimaging
231130|NCT01805440|Magnetic Resonance Spectroscopy
231131|NCT01805440|Uridine
231132|NCT01805440|Pyrimidines
231133|NCT01805427|trough concentration
231134|NCT01805427|weight
231135|NCT01805427|HIV
231136|NCT01805427|virological failure
231137|NCT01805414|inpatient diabetes
231138|NCT01805414|inpatient diabetes nutrition
231139|NCT01805401|Decision-making
231140|NCT01805401|Impulse control
231141|NCT01805401|Transcranial direct current stimulation
231142|NCT01805401|Brain stimulation
231143|NCT01805401|Neuromodulation
231144|NCT01805401|tDCS
231145|NCT01805401|Iowa Gambling Task
231146|NCT01805401|Stroop Word-Color Task
231147|NCT01805388|Dental Pulp Regeneration
231148|NCT01805375|Phase I, Cancer, CD19 positive, B-Cell lymphoma, chronic lymphocytic leukaemia
231149|NCT01805375|Waldenström Macroglobulinaemia
231150|NCT01805336|Relapsing-Remitting MS
231151|NCT01805336|cognitive impairment
231152|NCT01805336|virtual reality
231153|NCT01805310|Pelvic organ prolapse
231154|NCT01805310|Prolapse
231155|NCT01805310|Cathartics
231156|NCT01805310|Mechanical bowel preparation
231157|NCT01805297|Proliferative Diabetic Retinopathy
231158|NCT01805284|pneumonia
231159|NCT01805271|ER-positive HER2-negative
231160|NCT01805258|India
231161|NCT01805258|Nevirapine
231162|NCT01805258|Rifampicin
231163|NCT01805258|Efavirenz
231164|NCT01805258|HIV
231165|NCT01805258|TB
231166|NCT01805232|severe
231167|NCT01805232|Falciaparum
231168|NCT01805232|Malaria
231169|NCT01805206|Prematurity
231170|NCT01805206|Necrotizing Enterocolitis
231171|NCT01805206|Biomarkers
231172|NCT01805206|Intestinal Fatty Acid Binding Protein
231173|NCT01805206|Feeding
231174|NCT01805193|Coronary heart disease
231175|NCT01805193|computed tomography myocardial perfusion
231176|NCT01805193|positron emission tomography
231177|NCT01805193|oxygen 15 labelled water
231178|NCT01805193|myocardial perfusion
231179|NCT01805193|myocardial blood flow
231180|NCT01805167|Subject with cochlear implant
231181|NCT01805141|Cervix Uteri
231182|NCT01805128|Schizophrenia
231183|NCT01805128|Autistic Disorder
231184|NCT01805128|social cognition
231185|NCT01805115|hysteroscopy
231186|NCT01805115|misoprostol
231187|NCT01805102|In vitro fertilization
231188|NCT01805102|implantation
231189|NCT01805102|miscarriage
231190|NCT01805102|live birth
231191|NCT01805063|firefighters
231192|NCT01805063|myocardial infarction
231193|NCT01805063|endothelial function
231194|NCT01805063|thrombosis
231195|NCT01805063|fire suppression
231196|NCT01805063|non-fire emergency duty
231197|NCT01805063|sedentary shift
231198|NCT01805050|HAGL
231199|NCT01805050|Shoulder instability
231200|NCT01804998|laparoscopic sentinel lymph node biopsy
231201|NCT01804998|phase 3
231202|NCT01804998|early gastric cancer
231203|NCT01804972|Patient information
231204|NCT01804972|Vascular disease
231205|NCT01804972|Abdominal aortic aneurysm
231206|NCT01804972|Varicose veins
231207|NCT01804972|Web based information
231208|NCT01804933|profound muscle relaxation
231209|NCT01804933|muscle trauma
231210|NCT01804933|postoperative analgesic demand
231211|NCT01804933|postoperative pulmonary function
231212|NCT01804907|HAART adherence
231213|NCT01804907|HIV
231214|NCT01804907|Fatigue
231215|NCT01804907|treatment
231216|NCT01804868|case vignette
231217|NCT01804868|nurse
231218|NCT01804868|critical assessment
231219|NCT01804868|randomized controlled trial
231220|NCT01804855|Obesity; mobile health; telemedicine; family-based treatment
231221|NCT01804829|HCV Liver Transplant Immunoglobulin PCR SVR
231222|NCT01804816|Chronic Heart Failure
231223|NCT01804816|Heart Failure
231224|NCT01804803|glycated hemoglobin
231225|NCT01804803|hyperglycemia
231226|NCT01804803|hypoglycemia
231227|NCT01804803|insulin
231228|NCT01804803|self-monitoring of blood glucose
231229|NCT01804803|telemedicine
231230|NCT01804790|rectum
231231|NCT01804790|cancer
231232|NCT01804790|locally advanced
231233|NCT01804777|ENaC
231234|NCT01804777|Amiloride
231235|NCT01804777|Hydrochlorothiazide(HCTZ)
231236|NCT01804777|Hypertension
231237|NCT01804777|Type II Diabetes
231238|NCT01804777|Natriuresis
231239|NCT01804777|Proteinuria
231240|NCT01804764|Severe Sepsis
231241|NCT01804764|Septic Shock
231242|NCT01804764|Sepsis Six bundle
231243|NCT01804738|Ethnic differences
231244|NCT01804738|Inter-individual variability
231245|NCT01804738|Glycemic response
231246|NCT01804738|Insulin response
231247|NCT01804738|Mastication
231248|NCT01804738|Salivary alpha-amylase
231249|NCT01804738|Gastric emptying
231250|NCT01804738|Metagenome
231251|NCT01804725|bike seats
231252|NCT01804725|Erectile dysfunction
231253|NCT01804725|Perineum
231254|NCT01804725|Impotence
231255|NCT01804712|Prostate
231256|NCT01804712|Cancer
231257|NCT01804712|Castration-resistant
231258|NCT01804712|Rituximab
231259|NCT01804712|neoadjuvant
231260|NCT01804712|Rituxan
231261|NCT01804699|ARVC, Cardiomyopathy
231262|NCT01804686|Chronic lymphocytic leukemia
231263|NCT01804686|Small lymphocytic lymphoma
231264|NCT01804686|Mantle cell lymphoma
231265|NCT01804686|Follicular lymphoma
231266|NCT01804686|Diffuse large B-cell lymphoma
231267|NCT01804686|PCI-32765
231268|NCT01804686|Ibrutinib
231269|NCT01804686|Bruton's tyrosine kinase inhibitor
231270|NCT01804686|IMBRUVICA
231271|NCT01804686|JNJ-54179060
231272|NCT01804673|Postoperative Pain
231273|NCT01804673|Fentanyl Hydrochloride
231274|NCT01804673|IONSYS
231275|NCT01804660|Multiple Sclerosis (MS)
231276|NCT01804660|Multiple Sclerosis associated RetroVirus (MSRV)
231277|NCT01804660|MSRV envelop protein (MSRV-Env)
231278|NCT01804647|Multiple sclerosis (MS)
231279|NCT01804647|Relapsing-Remitting MS
231280|NCT01804647|Primary progressive MS
231281|NCT01804647|Secondary progressive MS
231282|NCT01804647|Clinically Isolated Syndrome (CIS)
231283|NCT01804647|Multiple Sclerosis associated RetroVirus (MSRV)
231284|NCT01804647|MSRV envelop protein (MSRV-Env)
231285|NCT01804634|Solid Tumors
231286|NCT01804634|Neuroblastoma
231287|NCT01804634|Osteosarcoma
231288|NCT01804634|Ewing Sarcoma
231289|NCT01804634|Rhabdomyosarcoma
231290|NCT01804634|Hepatoblastoma
231291|NCT01804634|Melanoma
231292|NCT01804634|Desmoplastic Round Cell Tumor
231293|NCT01804634|brain tumors
231294|NCT01804621|Exercise
231295|NCT01804621|Nutrition
231296|NCT01804621|Mammography
231297|NCT01804621|Colorectal screening
231298|NCT01804595|Worksite intervention
231299|NCT01804595|Sun protection intervention
231300|NCT01804595|Operating Engineers
231301|NCT01804582|Family navigator
231302|NCT01804582|Patient Centered Outcomes
231303|NCT01804582|Pediatric Antipsychotic treatment
231304|NCT01804556|muscle cramps, trigger points, sleep disturbance
231305|NCT01804530|solid tumors
231306|NCT01804530|activating NTRK point or fusion mutations
231307|NCT01804530|Tenosynovial giant cell tumor
231308|NCT01804530|TGCT
231309|NCT01804517|migraine
231310|NCT01804504|Metabolic syndrome
231311|NCT01804504|Eating out of home
231312|NCT01804504|Nutrition education
231313|NCT01804465|castration resistant
231314|NCT01804465|prostate
231315|NCT01804465|cancer
231316|NCT01804465|ipilimumab
231317|NCT01804465|provenge
231318|NCT01804465|SipT
231319|NCT01804452|Progressive Supranuclear Palsy
231320|NCT01804452|Corticobasal Degeneration
231321|NCT01804452|Biomarker
231322|NCT01804452|Neuroimaging
231323|NCT01804452|MRI
231324|NCT01804452|Tau
231325|NCT01804452|Oculomotor
231326|NCT01804439|Heart diseases
231327|NCT01804439|Cardiovascular diseases
231328|NCT01804439|Coronary heart disease not otherwise specified
231329|NCT01804439|Cerebrovascular disorders
231330|NCT01804439|Brain diseases
231331|NCT01804439|Central nervous system diseases
231332|NCT01804439|Nervous system diseases
231333|NCT01804439|Atherosclerosis
231334|NCT01804439|Arteriosclerosis
231335|NCT01804439|Pathologic processes
231336|NCT01804439|Acute myocardial infarction
231337|NCT01804439|Myocardial infarction
231338|NCT01804439|Myocardial ischemia
231339|NCT01804439|Infarction
231340|NCT01804439|Necrosis
231341|NCT01804439|Unstable angina
231342|NCT01804439|Chronic stable angina
231343|NCT01804439|Stable angina
231344|NCT01804439|Angina pectoris
231345|NCT01804439|Chest pain
231346|NCT01804439|Pain
231347|NCT01804439|Signs and symptoms
231348|NCT01804439|Ischemia
231349|NCT01804439|Ischemic stroke
231350|NCT01804439|Hemorrhagic stroke
231351|NCT01804439|Stroke
231352|NCT01804439|Subarachnoid hemorrhage
231353|NCT01804439|Transient ischemic attack
231354|NCT01804439|Abdominal aortic aneurysm
231355|NCT01804439|Aneurysm
231356|NCT01804439|Aortic aneurysm
231357|NCT01804439|Aortic aneurysm, abdominal
231358|NCT01804439|Aortic diseases
231359|NCT01804439|Peripheral arterial diseases
231360|NCT01804439|Peripheral vascular diseases
231361|NCT01804439|Vascular diseases
231362|NCT01804439|Peripheral occlusive diseases
231363|NCT01804439|Sudden coronary death
231364|NCT01804439|Ventricular arrhythmia
231365|NCT01804439|Sudden cardiac death
231366|NCT01804439|Cardiac arrest
231367|NCT01804439|Heart failure
231368|NCT01804426|PTSD
231369|NCT01804426|Post Traumatic Stress Disorder
231370|NCT01804426|Cortisol
231371|NCT01804426|Alpha-Amylase
231372|NCT01804426|bio-Markers
231373|NCT01804413|Pegvisomant
231374|NCT01804413|Growth hormone
231375|NCT01804413|Cortisol
231376|NCT01804413|Glucagon
231377|NCT01804413|Insulin
231378|NCT01804387|Chronic Hepatitis B
231379|NCT01804387|Telbivudine
231380|NCT01804387|Adefovir
231381|NCT01804387|Lamivudine resistance
231382|NCT01804374|osteosarcoma
231383|NCT01804374|sorafenib
231384|NCT01804374|everolimus
231385|NCT01804374|sarcoma
231386|NCT01804361|Dry Eye Syndromes
231387|NCT01804348|PROM
231388|NCT01804335|Lymphoma
231389|NCT01804335|Early Stage Cutaneous T-Cell Lymphoma
231390|NCT01804335|CTCL
231391|NCT01804335|CD5789 0.01% cream
231392|NCT01804322|epilepsy
231393|NCT01804322|chronic comorbidities
231394|NCT01804322|educational strategies
231395|NCT01804322|drug interactions
231396|NCT01804322|drug adverse effects
231397|NCT01804309|axyllary lymph node
231398|NCT01804309|sentinel lymph node
231399|NCT01804309|lymphatic drainage
231400|NCT01804309|early breast cancer
231401|NCT01804309|axillary lymph node dissection
231402|NCT01804296|Teen
231403|NCT01804296|Adolescent
231404|NCT01804296|Depression
231405|NCT01804296|Transcranial Magnetic Stimulation
231406|NCT01804296|TMS
231407|NCT01804270|Teen
231408|NCT01804270|Adolescent
231409|NCT01804270|Depression
231410|NCT01804270|Transcranial Magnetic Stimulation
231411|NCT01804270|TMS
231412|NCT01804257|Adherence
231413|NCT01804257|Bipolar disorder
231414|NCT01804257|Cellular phone
231415|NCT01804257|Cloud computing
231416|NCT01804257|Computers
231417|NCT01804257|Computers, handheld
231418|NCT01804257|Digital health
231419|NCT01804257|Digital health feedback system
231420|NCT01804257|Ingestion Sensor
231421|NCT01804257|Medication adherence
231422|NCT01804257|Medication non-adherence
231423|NCT01804257|Medication nonadherence
231424|NCT01804257|Mobile phone
231425|NCT01804257|Mobile health
231426|NCT01804257|Patient adherence
231427|NCT01804257|Patient non-adherence
231428|NCT01804257|Patient nonadherence
231429|NCT01804257|Schizophrenia
231430|NCT01804257|Telehealth
231431|NCT01804257|Telemedicine
231432|NCT01804257|Telenursing
231433|NCT01804257|Wearable sensor
231434|NCT01804244|Healthy
231435|NCT01804244|Pharmacokinetics
231436|NCT01804244|Japanese
231437|NCT01804231|Prostate Cancer
231438|NCT01804231|PET
231439|NCT01804231|MRI
231440|NCT01804231|Hybrid
231441|NCT01804231|Recurrence
231442|NCT01804231|Fluorocholine
231443|NCT01804205|magnesium sulfate
231444|NCT01804205|rocuronium
231445|NCT01804205|neuromuscular block
231446|NCT01804205|onset time
231447|NCT01804205|elderly
231448|NCT01804192|Acu-TENS
231449|NCT01804192|MAP
231450|NCT01804192|HR
231451|NCT01804192|HRV
231452|NCT01804179|colon
231453|NCT01804179|rectum
231454|NCT01804179|cancer
231455|NCT01804179|screening
231456|NCT01804179|questionnaire
231457|NCT01804179|testing
231458|NCT01804179|educational materials
231459|NCT01804166|Lymphoma, T-Cell, Peripheral, Infliximab, Golimumab, Remicade, Simponi, Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease
231460|NCT01804153|Feminine stress urinary incontinence
231461|NCT01804153|Autologous expanded stem cells
231462|NCT01804127|DLBCL
231463|NCT01804127|R-CHOP
231464|NCT01804127|PET/CT
231465|NCT01804088|Peripheral artery disease
231466|NCT01804088|Iliac arteries
231467|NCT01804088|Balloon-expandable stent
231468|NCT01804075|NAS
231469|NCT01804075|NICU
231470|NCT01804075|EMMC
231471|NCT01804049|metformin
231472|NCT01804049|muscle
231473|NCT01804049|insulin resistance
231474|NCT01804049|sarcopenia
231475|NCT01804049|older adults
231476|NCT01804049|impaired fasting glucose
231477|NCT01803997|Child
231478|NCT01803997|Nutrition
231479|NCT01803997|resonance Raman spectroscopy
231480|NCT01803997|Fruit & Vegetable
231481|NCT01803997|Children Cooking
231482|NCT01803984|Migraine
231483|NCT01803984|Brain structure
231484|NCT01803984|MRI
231485|NCT01803971|cardiac arrest
231486|NCT01803971|peripheral venous access
231487|NCT01803971|intraosseous access
231488|NCT01803945|Parkinson's disease
231489|NCT01803945|cognitive impairment
231490|NCT01803945|movement disorder
231491|NCT01803932|intimate partner violence
231492|NCT01803932|gender
231493|NCT01803932|primary prevention intervention
231494|NCT01803932|conflict
231495|NCT01803932|Cote d'Ivoire
231496|NCT01803932|Ivory Coast
231497|NCT01803919|Spinal cord injuries
231498|NCT01803919|Urinary tract infection
231499|NCT01803919|Urinary catheters
231500|NCT01803919|Protocol
231501|NCT01803919|Randomized clinical trial
231502|NCT01803906|mitochondrial disorder
231503|NCT01803906|mitochondria
231504|NCT01803906|oxidative phosphorylation
231505|NCT01803906|oxidative phosphorylation disorders
231506|NCT01803906|respiratory chain disorders
231507|NCT01803906|mitochondrial disease
231508|NCT01803906|melas
231509|NCT01803906|kearns sayer
231510|NCT01803906|NARP
231511|NCT01803906|MNGIE
231512|NCT01803906|LHON
231513|NCT01803906|Mitochondrial depletion syndrome
231514|NCT01803906|Leigh's disease
231515|NCT01803893|In vitro fertilization
231516|NCT01803893|implantation
231517|NCT01803893|miscarriage
231518|NCT01803893|live birth
231519|NCT01803880|Articular cartilage
231520|NCT01803880|Cartilage lesion
231521|NCT01803880|Cartilage defect
231522|NCT01803880|Radiofrequency
231523|NCT01803880|Debridement
231524|NCT01803880|Cartilage
231525|NCT01803880|Coblation
231526|NCT01803880|Knee
231527|NCT01803880|Meniscus
231528|NCT01803880|Meniscectomy
231529|NCT01803880|MR imaging
231530|NCT01803880|Mechanical debridement
231531|NCT01803880|Mechanical shaver
231532|NCT01803880|Torn meniscus
231533|NCT01803880|Arthroscopic knee surgery
231534|NCT01803880|Damaged cartilage
231535|NCT01803867|MS
231536|NCT01803867|Multiple Sclerosis
231537|NCT01803841|Coronary artery disease
231538|NCT01803828|Diabetic Cardiomyopathy
231539|NCT01803828|Genders
231540|NCT01803828|Phosphodiesterase 5A inhibitors
231541|NCT01803828|miRNAs
231542|NCT01803828|Chemokines
231543|NCT01803815|obstructive sleep apnea
231544|NCT01803815|hypertension
231545|NCT01803815|antihypertensive drugs
231546|NCT01803802|childhood sexual abuse
231547|NCT01803802|depression
231548|NCT01803802|PTSD
231549|NCT01803802|sexual function
231550|NCT01803802|women
231551|NCT01803789|Metacarpal V Fractures
231552|NCT01803789|Single Kirschner Wires
231553|NCT01803789|Double Kirschner Wires
231554|NCT01803776|child
231555|NCT01803776|physical activity
231556|NCT01803776|sedentary activity
231557|NCT01803776|nutrition
231558|NCT01803776|diet
231559|NCT01803776|body composition
231560|NCT01803776|overweight
231561|NCT01803776|obesity
231562|NCT01803776|glucose metabolism disorders
231563|NCT01803776|lipid metabolism disorders
231564|NCT01803776|physical fitness
231565|NCT01803776|cardiovascular system
231566|NCT01803776|musculoskeletal system
231567|NCT01803776|bone mineral density
231568|NCT01803776|oral health
231569|NCT01803776|quality of life
231570|NCT01803776|wellbeing
231571|NCT01803776|gene-lifestyle interaction
231572|NCT01803776|health economics
231573|NCT01803763|Omalizumab
231574|NCT01803763|Xolair
231575|NCT01803763|Urticaria
231576|NCT01803763|basophils
231577|NCT01803763|chronic Urticaria
231578|NCT01803763|Fc Receptor
231579|NCT01803750|Primary Care Providers
231580|NCT01803750|Latino Populations
231581|NCT01803750|Disseminate Cancer Prevention
231582|NCT01803750|semi-structured interviews
231583|NCT01803750|13-031
231584|NCT01803737|Weight Loss
231585|NCT01803737|Physical Activity
231586|NCT01803737|Dietary Intake
231587|NCT01803737|Weight Loss Self-Efficacy
231588|NCT01803737|Motivation
231589|NCT01803724|Irritable Bowel Syndrome
231590|NCT01803724|Small Intestinal Bacterial Overgrowth
231591|NCT01803724|Lactulose breath test
231592|NCT01803724|Glucose breath test
231593|NCT01803724|Rifaximin
231594|NCT01803711|Omega 3 fatty acid
231595|NCT01803711|Fish oil
231596|NCT01803711|Depression
231597|NCT01803711|cancer
231598|NCT01803711|diabetes
231599|NCT01803711|high blood pressure
231600|NCT01803711|cardiovascular
231601|NCT01803698|Pregnancy
231602|NCT01803698|Gestational weight gain
231603|NCT01803698|Primary care
231604|NCT01803698|Guidelines
231605|NCT01803685|Intracranial Arteriovenous Malformations
231606|NCT01803685|Surgical removal
231607|NCT01803685|Endovascular embolism
231608|NCT01803685|Stereotaxic radiosurgery
231609|NCT01803685|Outcomes
231610|NCT01803672|Adventure-Based training
231611|NCT01803672|Health education
231612|NCT01803672|childhood cancer
231613|NCT01803672|physical activity
231614|NCT01803659|b-carotene
231615|NCT01803659|breastmilk
231616|NCT01803659|vitamin A
231617|NCT01803568|Myokine
231618|NCT01803568|Insulin sensitivity
231619|NCT01803568|Exercise
231620|NCT01803568|Skeletal muscle
231621|NCT01803555|Budesonide/Formoterol SPIROMAX®
231622|NCT01803555|SYMBICORT® TURBOHALER®
231623|NCT01803555|Asthma
231624|NCT01803542|Non-small Cell Lung Cancer
231625|NCT01803542|Stereotactic radiation for Lung Cancer
231626|NCT01803542|Cone beam CT for Lung Cancer
231627|NCT01803542|PET/CT for Lung Cancer
231628|NCT01803529|thorax
231629|NCT01803529|Intercostal Muscles
231630|NCT01803529|massage
231631|NCT01803529|heat-pack
231632|NCT01803529|hot temperature
231633|NCT01803516|Quality of Life
231634|NCT01803516|Assessments
231635|NCT01803516|Radiation
231636|NCT01803516|Telangiectasias
231637|NCT01803516|13-013
231638|NCT01803464|Botox
231639|NCT01803464|Muscle strength
231640|NCT01803451|gastric bypass
231641|NCT01803451|glucose metabolism
231642|NCT01803451|hypoglycemia
231643|NCT01803438|paroxysmal Atrial Fibrillation
231644|NCT01803438|Cryoablation
231645|NCT01803438|Pulmonary Vein Isolation
231646|NCT01803425|Post-marketing surveillance
231647|NCT01803425|Prescribing Information (PI)
231648|NCT01803425|Healthy infants and children
231649|NCT01803425|Streptococcus pneumoniae
231650|NCT01803425|Synflorix™
231651|NCT01803425|Sri Lanka
231652|NCT01803412|GSK2402968
231653|NCT01803412|open-label extension
231654|NCT01803412|safety
231655|NCT01803412|drisapersen
231656|NCT01803412|Duchenne Muscular Dystrophy
231657|NCT01803412|tolerability
231658|NCT01803412|Quality of Life
231659|NCT01803399|cardiac repolarization
231660|NCT01803399|oral
231661|NCT01803399|QTc
231662|NCT01803399|GSK1322322
231663|NCT01803399|antibiotic
231664|NCT01803399|12-lead ECG
231665|NCT01803399|placebo
231666|NCT01803399|IV
231667|NCT01803399|moxifloxacin
231668|NCT01803386|ALS
231669|NCT01803386|EIM
231670|NCT01803373|Healthy
231671|NCT01803373|Biological Availability
231672|NCT01803373|Bioavailability
231673|NCT01803373|TMC207
231674|NCT01803373|Bedaquiline
231675|NCT01803373|R207910
231676|NCT01803347|phase III
231677|NCT01803347|Adipose derived stem cells
231678|NCT01803347|Anal fistula
231679|NCT01803347|Cell therapy
231680|NCT01803347|Stem cell therapy
231681|NCT01803334|surgical incision
231682|NCT01803334|laparoscopy
231683|NCT01803334|pain
231684|NCT01803321|SJIA
231685|NCT01803308|Hepatitis C Infection
231686|NCT01803308|Treatment Naïve, Chronic
231687|NCT01803308|First In Human
231688|NCT01803308|Single Ascending Dose
231689|NCT01803308|Multiple Ascending Dose
231690|NCT01803295|Non Muscle Invasive Bladder Cancer
231691|NCT01803295|Intravesical instillation
231692|NCT01803295|Mitomycin C
231693|NCT01803295|Hydrogel Reverse thermal gelation
231694|NCT01803295|Drug retention
231695|NCT01803295|Urinary Bladder Neoplasms
231696|NCT01803295|Urologic Neoplasms
231697|NCT01803295|Urinary Bladder Diseases
231698|NCT01803295|Urologic Diseases
231699|NCT01803295|Mitomycin
231700|NCT01803282|Solid Tumor
231701|NCT01803282|NSCLC
231702|NCT01803282|Pancreatic
231703|NCT01803282|Esophagogastric
231704|NCT01803282|Colorectal
231705|NCT01803282|Breast
231706|NCT01803230|children
231707|NCT01803204|Anxiety
231708|NCT01803204|Orthognathic surgery
231709|NCT01803204|Patient educational as topic
231710|NCT01803204|Patient educational handout
231711|NCT01803204|Pamphlets
231712|NCT01803191|Transrectal ultrasound-guided prostate biopsy
231713|NCT01803191|Bacteriuria
231714|NCT01803191|Antibiotic prophylaxis
231715|NCT01803191|Prostate-Specific antigen
231716|NCT01803178|vascular function
231717|NCT01803178|plant sterols
231718|NCT01803178|blood lipids
231719|NCT01803165|emesis,post operative.
231720|NCT01803165|cognitive dysfunction, post operative.
231721|NCT01803165|wound infection, post operative.
231722|NCT01803165|pain, post operative.
231723|NCT01803165|Anesthesia, Conduction/methods
231724|NCT01803165|Anesthesiology/methods
231725|NCT01803165|Arteriovenous Shunt, Surgical/adverse effects
231726|NCT01803165|Regional Blood Flow/drug effects
231727|NCT01803165|Risk Factors
231728|NCT01803165|Thrombosis
231729|NCT01803165|Treatment Outcome
231730|NCT01803165|Vascular Surgical Procedures/methods
231731|NCT01803165|Vasodilation/drug effects
231732|NCT01803152|Metastatic Sarcoma
231733|NCT01803152|Relapsed Sarcoma
231734|NCT01803152|Dendritic Cell
231735|NCT01803152|Myeloid Derived Suppressor Cells
231736|NCT01803152|MDSC
231737|NCT01803152|MDSC Inhibition
231738|NCT01803139|Breast cancer radiotherapy IMRT
231739|NCT01803126|atherosclerosis
231740|NCT01803113|Pregnancy
231741|NCT01803113|hCG
231742|NCT01803100|Bacterial Colonization
231743|NCT01803087|adolescents
231744|NCT01803087|adults
231745|NCT01803061|Head and neck cancer
231746|NCT01803061|Quality of life
231747|NCT01803061|Symptom-burden
231748|NCT01803061|Late effects
231749|NCT01803048|Traumatic Brain Injury
231750|NCT01803048|Diffusion Weighted Imaging
231751|NCT01803048|Resting State Functional Connectivity
231752|NCT01803048|Cognition
231753|NCT01803035|Impetigo
231754|NCT01803035|LTX-109
231755|NCT01803035|Topical
231756|NCT01803035|Antibiotic
231757|NCT01803035|Placebo
231758|NCT01803035|Lytic
231759|NCT01803035|Peptide
231760|NCT01803035|Gram Positive
231761|NCT01803022|Venous Thromboembolism
231762|NCT01803022|Cancer
231763|NCT01803022|Low Molecular Weight Heparin
231764|NCT01802983|Aged
231765|NCT01802983|Multiple organ failure
231766|NCT01802983|Extubation
231767|NCT01802983|Prognosis
231768|NCT01802983|MODS
231769|NCT01802983|invasive mechanical ventilation
231770|NCT01802970|Anakinra
231771|NCT01802970|Nab Paclitaxel
231772|NCT01802970|Capecitabine
231773|NCT01802970|Eribulin
231774|NCT01802970|Vinorelbin
231775|NCT01802931|GSK239512
231776|NCT01802931|H3 receptor antagonist
231777|NCT01802931|drug-drug interaction
231778|NCT01802931|pharmacokinetics
231779|NCT01802931|ketoconazole
231780|NCT01802918|single dose
231781|NCT01802918|HIV
231782|NCT01802918|maturation inhibitor
231783|NCT01802918|GSK2838232
231784|NCT01802918|FTIH
231785|NCT01802918|healthy subjects
231786|NCT01802905|neoplasm
231787|NCT01802905|metastatic cancer
231788|NCT01802905|cancer genome
231789|NCT01802905|genomic analysis
231790|NCT01802905|adults
231791|NCT01802892|ronacaleret
231792|NCT01802892|parathyroid hormone (PTH)
231793|NCT01802892|CD34+cells
231794|NCT01802892|calcium sensing receptor antagonist
231795|NCT01802892|hematopoietic stem cells
231796|NCT01802892|stem cell mobilization
231797|NCT01802892|plerixafor
231798|NCT01802892|healthy human volunteer, phase Ib
231799|NCT01802879|Hematologic Neoplasms, LBH589,
231800|NCT01802879|Panobinostat,
231801|NCT01802866|Geographic atrophy
231802|NCT01802866|GA
231803|NCT01802866|Dry AMD
231804|NCT01802827|airway colonization
231805|NCT01802827|tracheobronchitis
231806|NCT01802827|pneumonia
231807|NCT01802814|ALL
231808|NCT01802788|Aortic Stenosis
231809|NCT01802788|Heart Valve Prosthesis
231810|NCT01802788|Trans Catheter Aortic Valve Replacement
231811|NCT01802788|TAVR
231812|NCT01802788|Trans Catheter Aortic Valve Implant
231813|NCT01802788|TAVI
231814|NCT01802749|second line
231815|NCT01802749|platinum sensitive
231816|NCT01802749|first line bevacizumab
231817|NCT01802749|biologic factors
231818|NCT01802749|clinical factors
231819|NCT01802736|Alcohol HIV intervention counselling
231820|NCT01802736|Alcohol Use in HIV infected Persons
231821|NCT01802697|volunteers
231822|NCT01802684|unresectable
231823|NCT01802684|metastatic
231824|NCT01802684|colorectal
231825|NCT01802684|cancer
231826|NCT01802684|OPTIMOX
231827|NCT01802684|aflibercept
231828|NCT01802671|Low back pain
231829|NCT01802671|Cognitive behavioural treatment
231830|NCT01802671|internet
231831|NCT01802671|disability
231832|NCT01802658|Bone marrow demineralization lesions,: efficacy and tolerability, zoledronic acid
231833|NCT01802645|neoadjuvant
231834|NCT01802645|cetuximab
231835|NCT01802645|irinotecan
231836|NCT01802645|bevacizumab
231837|NCT01802645|oxaliplatin
231838|NCT01802645|5-FU
231839|NCT01802645|Resection
231840|NCT01802645|colorectal liver metastases
231841|NCT01802645|liver resection
231842|NCT01802645|Chemotherapy
231843|NCT01802645|k-ras
231844|NCT01802645|non-resectable
231845|NCT01802632|Oncology,
231846|NCT01802632|Non Small Cell Lung Cancer,
231847|NCT01802632|Metastatic,
231848|NCT01802632|EGFR sensitivity mutation,
231849|NCT01802632|T790M resistance mutation
231850|NCT01802606|surgery
231851|NCT01802606|administration
231852|NCT01802606|infection
231853|NCT01802593|Pediatric
231854|NCT01802593|Crohn's disease
231855|NCT01802593|Infliximab
231856|NCT01802593|Thiopurine
231857|NCT01802554|Behavioral Activation
231858|NCT01802554|Caregiver
231859|NCT01802554|Dementia
231860|NCT01802554|Cardiovascular Disease
231861|NCT01802554|Alzheimer's Disease
231862|NCT01802554|Coagulation
231863|NCT01802541|diacylglycerol oil
231864|NCT01802541|insulin sensitivity
231865|NCT01802541|type 2 diabetes
231866|NCT01802541|cardiovascular disease
231867|NCT01802541|risk factors
231868|NCT01802528|obturator externus
231869|NCT01802515|addiction
231870|NCT01802515|cocaine
231871|NCT01802515|methadone
231872|NCT01802515|opiates
231873|NCT01802515|atomoxetine
231874|NCT01802502|tuberculous meningitis
231875|NCT01802502|rifampicin
231876|NCT01802502|bioequivalence
231877|NCT01802502|oral administration
231878|NCT01802502|intravenous administration
231879|NCT01802489|Optic neuritis
231880|NCT01802489|Multiple sclerosis
231881|NCT01802489|Retinal nerve fibre layer
231882|NCT01802489|Axonal loss
231883|NCT01802489|Neuroprotection
231884|NCT01802489|MRI
231885|NCT01802489|Optical coherence tomography
231886|NCT01802489|Amiloride
231887|NCT01802489|Acid Sensing Ion Channels
231888|NCT01802476|PD-0332991
231889|NCT01802476|Absolute Bioavailability Study
231890|NCT01802424|Open trial
231891|NCT01802424|Indicative prevention
231892|NCT01802424|Youth anxiety
231893|NCT01802424|Cognitive behavioral therapy
231894|NCT01802411|liposome bupivacaine
231895|NCT01802411|posterolateral thoracotomy
231896|NCT01802411|intercostal nerve block
231897|NCT01802411|postoperative pain
231898|NCT01802398|Risk Stratification
231899|NCT01802398|Syncope
231900|NCT01802398|Geriatric
231901|NCT01802385|cryptococcal meningitis
231902|NCT01802385|cryptococcus
231903|NCT01802385|meningitis
231904|NCT01802385|yeast
231905|NCT01802385|fungus
231906|NCT01802372|Hypertension
231907|NCT01802372|High Blood Pressure
231908|NCT01802372|Cardiovascular Diseases
231909|NCT01802372|Health Insurance Coverage
231910|NCT01802372|Low income countries
231911|NCT01802372|Ghana
231912|NCT01802372|Low resource settings
231913|NCT01802372|Comparative Effectiveness
231914|NCT01802372|Global Health
231915|NCT01802359|Erectile dysfunction
231916|NCT01802359|Mirodenafil
231917|NCT01802359|Bravonto
231918|NCT01802307|Focal therapy
231919|NCT01802307|Brachytherapy
231920|NCT01802307|Active surveillance
231921|NCT01802307|low risk cancer
231922|NCT01802294|Randomized Controlled Trials as Topic
231923|NCT01802294|Child
231924|NCT01802294|Parents
231925|NCT01802268|sirolimus
231926|NCT01802268|tacrolimus
231927|NCT01802268|early conversion
231928|NCT01802255|Inhalatory sedation
231929|NCT01802255|Sevoflurane
231930|NCT01802255|AnaConDa
231931|NCT01802255|Nephrotoxicity
231932|NCT01802255|Hepatotoxicity
231933|NCT01802255|Midazolam
231934|NCT01802255|Propofol
231935|NCT01802242|Prostate Cancer
231936|NCT01802242|Prostate tumour
231937|NCT01802242|Prostate radiotherapy
231938|NCT01802242|prostate cancer treatment
231939|NCT01802216|chronic kidney disease progression
231940|NCT01802216|periodontal disease
231941|NCT01802216|intensive periodontal disease treatment
231942|NCT01802203|Barrett esophagus
231943|NCT01802203|Esophageal dysplasia
231944|NCT01802203|Upper gastrointestinal squamous dysplasia
231945|NCT01802203|Esophageal cancer
231946|NCT01802203|Endobronchial cancer
231947|NCT01802203|Central airway cancer
231948|NCT01802203|Central airway precancerous disease
231949|NCT01802203|Central airway granulation tissue
231950|NCT01802203|Central airway papillomatosis
231951|NCT01802203|Central airway sarcoidosis
231952|NCT01802203|Central airway tuberculosis
231953|NCT01802203|Tracheal stenosis
231954|NCT01802203|Bronchial stenosis
231955|NCT01802190|Genetic deafness
231956|NCT01802190|SLC17A8 et POU4F3 genes
231957|NCT01802177|Alopecia areata
231958|NCT01802177|Excimer
231959|NCT01802177|UVB
231960|NCT01802151|probiotics
231961|NCT01802151|microbiota
231962|NCT01802151|survival
231963|NCT01802151|gastrointestinal
231964|NCT01802151|wellness
231965|NCT01802138|refractory/relapsed neuroblastoma patients
231966|NCT01802112|Colonic transit
231967|NCT01802112|Dietary Fiber
231968|NCT01802112|Radiopaque marker
231969|NCT01802099|mechanical ventilation
231970|NCT01802099|early enteral nutrition
231971|NCT01802099|intensive care unit
231972|NCT01802099|early parenteral nutrition
231973|NCT01802099|critical care medicine
231974|NCT01802099|nosocomial infection
231975|NCT01802099|mortality
231976|NCT01802099|shock
231977|NCT01802099|vasoactive drug
231978|NCT01802086|Children
231979|NCT01802086|Pain
231980|NCT01802086|Vaccination
231981|NCT01802086|Emla
231982|NCT01802086|Pneumococcal
231983|NCT01802086|Painscale
231984|NCT01802073|Inflammation of the bile ducts
231985|NCT01802073|biliary scarring
231986|NCT01802073|obstruction
231987|NCT01802060|Persona
231988|NCT01802060|E3G
231989|NCT01802060|LH
231990|NCT01802060|ovulation
231991|NCT01802047|Mothers of Preterms
231992|NCT01802047|Breastfeeding Mothers of Preterm infants
231993|NCT01802047|mother milk feeding
231994|NCT01802021|chinese medicine
231995|NCT01802021|non-small cell lung cancer
231996|NCT01802021|immunosuppression
231997|NCT01802008|Polyp/adenoma detection rate
231998|NCT01802008|Polyp/adenoma miss rate
231999|NCT01802008|Colonoscopy withdrawal time
232000|NCT01801982|PPHN; development progress after PPHN; developmental progress after sildenafil.
232001|NCT01801969|Brain injuries
232002|NCT01801969|Rehabilitation services
232003|NCT01801969|Return to Work
232004|NCT01801969|Quality of life
232005|NCT01801956|Maximum oxygen uptake
232006|NCT01801956|Physical activity
232007|NCT01801956|Physical inactivity
232008|NCT01801956|Motivational interview
232009|NCT01801956|Cardiorespiratory fitness
232010|NCT01801956|Primary care
232011|NCT01801956|Community care
232012|NCT01801930|OCV-C02
232013|NCT01801930|Colorectal Cancer
232014|NCT01801930|Antigen specific cancer immunotherapeutic
232015|NCT01801917|Polymyositis, Myositis, PM
232016|NCT01801904|cetuximab-refractory
232017|NCT01801891|Venous ulceration
232018|NCT01801891|Leg ulcers
232019|NCT01801891|Venous haemodynamics
232020|NCT01801891|Surface neuromuscular electrical stimulation
232021|NCT01801891|SNMES
232022|NCT01801878|breast cancer
232023|NCT01801878|loss of elasticity in irradiated breast skin
232024|NCT01801878|Other Reconstructive Surgery
232025|NCT01801865|NICU
232026|NCT01801865|MRI
232027|NCT01801865|Neonatal
232028|NCT01801865|Cincinnati
232029|NCT01801813|Neuro-surgery
232030|NCT01801813|Post-operative complications
232031|NCT01801813|Neuro-ICU resources
232032|NCT01801800|Aneurysmal subarachnoid haemorrhage
232033|NCT01801774|post-operative inflammation
232034|NCT01801774|steroid
232035|NCT01801774|intraocular pressure
232036|NCT01801748|wheat allergy
232037|NCT01801748|wheat outgrowing
232038|NCT01801748|wheat hypersensitivity
232039|NCT01801748|omega-5-gliadin
232040|NCT01801748|natural history of wheat hypersensitivity
232041|NCT01801709|Brain Gene Therapy
232042|NCT01801709|Adeno Associated vector
232043|NCT01801709|Lysosomal sotage diseases
232044|NCT01801709|Leukodystrophies
232045|NCT01801696|Massage
232046|NCT01801696|effectiveness
232047|NCT01801696|autism
232048|NCT01801696|parent stress
232049|NCT01801683|EBM
232050|NCT01801683|general practice
232051|NCT01801670|itch
232052|NCT01801670|pruritus
232053|NCT01801670|skin
232054|NCT01801670|vorinostat
232055|NCT01801670|cutaneous T-cell lymphoma
232056|NCT01801670|mycosis fungoides
232057|NCT01801657|bronchiectasis
232058|NCT01801657|exacerbation
232059|NCT01801657|virus
232060|NCT01801644|bladder cancer
232061|NCT01801644|neoadjuvant chemotherapy
232062|NCT01801644|gem/cis
232063|NCT01801631|Type 2 diabetes
232064|NCT01801631|Acute Coronary Event (ACE)
232065|NCT01801631|Distress
232066|NCT01801631|Self-efficacy
232067|NCT01801631|Quality of Life
232068|NCT01801631|Depression
232069|NCT01801631|Primary care
232070|NCT01801631|Illness representations
232071|NCT01801618|HIV
232072|NCT01801618|PI based 2nd line ARV treatment
232073|NCT01801618|Virological failure
232074|NCT01801618|Drug resistance
232075|NCT01801618|Cambodia
232076|NCT01801618|Adherence
232077|NCT01801605|IBS - rectal hypersensitivity - rectal barostat - rTMS.
232078|NCT01801592|OBSTRUCTIVE SLEEP APNOEA
232079|NCT01801592|INTERMITTENT CLAUDICATION
232080|NCT01801592|Respiratory disease
232081|NCT01801592|Peripheral artery disease
232082|NCT01801579|Ankle Brachial Index
232083|NCT01801579|Maximal exercise
232084|NCT01801566|Mandibular Prosthesis Implantation
232085|NCT01801566|Prostheses and Implants
232086|NCT01801566|Denture, Complete, Lower
232087|NCT01801553|spinal manipulation
232088|NCT01801553|low back pain
232089|NCT01801553|manual therapy
232090|NCT01801553|clinical predictive rule
232091|NCT01801527|Telehealth
232092|NCT01801527|Fatigue
232093|NCT01801527|Breast cancer
232094|NCT01801527|Exercise
232095|NCT01801527|Quality of life
232096|NCT01801527|Telerehabilitation
232097|NCT01801475|Pharmacokinetics of ondansetron in women
232098|NCT01801475|Pharmacokinetics of ondansetron in neonates
232099|NCT01801475|Term pregnancy
232100|NCT01801475|Cesarean section
232101|NCT01801462|Medical education
232102|NCT01801462|Simulation
232103|NCT01801462|Ultrasound training
232104|NCT01801462|Patient safety
232105|NCT01801449|DIRA
232106|NCT01801449|Clinical Trial
232107|NCT01801449|IL-1
232108|NCT01801449|Autoinflammatory Syndrome
232109|NCT01801449|Rilonacept
232110|NCT01801436|Multiple Myeloma
232111|NCT01801436|Bortezomib
232112|NCT01801436|Velcade
232113|NCT01801423|transcranial Doppler
232114|NCT01801423|stroke
232115|NCT01801423|sickle cell anemia
232116|NCT01801423|Nigeria
232117|NCT01801423|hydroxyurea
232118|NCT01801423|low income country
232119|NCT01801410|pre-eclampsia
232120|NCT01801410|labor induction
232121|NCT01801410|misoprostol
232122|NCT01801410|Foley catheter
232123|NCT01801384|pregnancy
232124|NCT01801384|cigarette smoking
232125|NCT01801384|incentives
232126|NCT01801384|smoking cessation
232127|NCT01801384|birth outcomes
232128|NCT01801371|Glioma
232129|NCT01801371|Diagnostic imaging
232130|NCT01801371|Integrin receptor
232131|NCT01801371|68Ga-BNOTA-PRGD2
232132|NCT01801371|PET/CT
232133|NCT01801358|Melanoma,
232134|NCT01801358|melanoma of the eye,
232135|NCT01801358|uveal,
232136|NCT01801358|MEK162,
232137|NCT01801358|AEB071
232138|NCT01801345|Human Performance
232139|NCT01801345|Clinical Performance
232140|NCT01801319|major depressive disorder (MDD)
232141|NCT01801319|deep brain stimulation (DBS)
232142|NCT01801319|subcallosal cingulate gyrus
232143|NCT01801319|Therapy-Resistant Depression
232144|NCT01801319|Electrical Stimulation of the Brain
232145|NCT01801319|Brain Stimulation, Deep
232146|NCT01801293|RSV infection
232147|NCT01801280|immunosuppressive medication
232148|NCT01801280|mycophenolic acid
232149|NCT01801280|interaction
232150|NCT01801280|proton pump inhibitor
232151|NCT01801280|pantoprazole
232152|NCT01801280|renal transplant patients
232153|NCT01801280|pharmacokinetics
232154|NCT01801280|pharmacodynamics
232155|NCT01801280|bioavailability
232156|NCT01801267|Hydrocephalus
232157|NCT01801267|Pediatric
232158|NCT01801267|Ventricular shunt
232159|NCT01801267|Ventriculoperitoneal shunt
232160|NCT01801267|Third ventriculostomy
232161|NCT01801267|Randomized controlled trial
232162|NCT01801254|Obesity
232163|NCT01801254|Type II diabetes
232164|NCT01801254|Cardiovascular disease
232165|NCT01801254|Health behavior promotion
232166|NCT01801254|Neuroeconomics
232167|NCT01801254|EEG biofeedback
232168|NCT01801254|Low-resolution electromagnetic tomography (LORETA)
232169|NCT01801254|EEG
232170|NCT01801176|proved by biopsy
232171|NCT01801150|Diabetes
232172|NCT01801150|Apnea- hypopnea Syndrome
232173|NCT01801150|Glycemic control
232174|NCT01801150|Prevalence
232175|NCT01801150|SAHS
232176|NCT01801150|life quality
232177|NCT01801124|analgesia
232178|NCT01801124|hernia repair
232179|NCT01801098|TAVI
232180|NCT01801098|complete AV-block
232181|NCT01801098|HV-interval
232182|NCT01801098|permanent pacemaker
232183|NCT01801085|Time-and-Motion
232184|NCT01801085|Neoplasm
232185|NCT01801085|Colorectal Cancer
232186|NCT01801059|colon cancer
232187|NCT01801059|Colorectal Cancer Screening
232188|NCT01801033|Trioodothyronine (T3)
232189|NCT01801033|Thyroid Hormone Action
232190|NCT01801033|Deiodinases
232191|NCT01801033|Hypothyroid
232192|NCT01801033|Propylthiouracil (PTU)
232193|NCT01801020|temperature
232194|NCT01800994|convenience
232195|NCT01800981|Functionality
232196|NCT01800981|extremities
232197|NCT01800981|ROM
232198|NCT01800981|Upper and lower Extremity for burned patients
232199|NCT01800955|physical therapy
232200|NCT01800955|diathermy
232201|NCT01800955|knee
232202|NCT01800955|osteoarthritis
232203|NCT01800955|pain
232204|NCT01800955|physical function
232205|NCT01800942|prevention
232206|NCT01800942|bacterial infection
232207|NCT01800942|neonates
232208|NCT01800942|women in labour
232209|NCT01800942|Azithromycin
232210|NCT01800916|ileostomy
232211|NCT01800916|Subjects
232212|NCT01800890|stoma ileostomy
232213|NCT01800877|hypotension
232214|NCT01800877|vasopressors
232215|NCT01800877|titration
232216|NCT01800877|tissue perfusion
232217|NCT01800877|organ failure
232218|NCT01800851|Kidney transplantation
232219|NCT01800851|Energy expenditure
232220|NCT01800851|Weight gain
232221|NCT01800851|Insulin resistance
232222|NCT01800825|Pregnancy
232223|NCT01800825|Prematurity
232224|NCT01800825|Preterm birth
232225|NCT01800825|bacterial vaginosis
232226|NCT01800799|Urinary tract infection
232227|NCT01800799|Urothelium
232228|NCT01800799|Inflammation
232229|NCT01800799|Apoptosis
232230|NCT01800773|PTSD
232231|NCT01800773|exposure treatment
232232|NCT01800773|clinical trial
232233|NCT01800773|trauma
232234|NCT01800760|healthy
232235|NCT01800760|obese
232236|NCT01800760|women
232237|NCT01800747|Delayed antibiotic treatment
232238|NCT01800747|Acute respiratory infections
232239|NCT01800747|Pediatrics
232240|NCT01800747|Satisfaction
232241|NCT01800734|Mixed meal test
232242|NCT01800734|Insulin pump
232243|NCT01800734|Continuous glucose monitoring
232244|NCT01800734|Metabolic control analysis
232245|NCT01800734|Closed loop control
232246|NCT01800734|Artificial pancreas
232247|NCT01800721|HIV
232248|NCT01800721|testing
232249|NCT01800721|Social Network
232250|NCT01800721|African American
232251|NCT01800721|MSM
232252|NCT01800721|Men who have sex with men
232253|NCT01800695|GBM
232254|NCT01800682|Healthy
232255|NCT01800682|Tramodol
232256|NCT01800682|Ultram
232257|NCT01800669|Computer based clinical decision support
232258|NCT01800669|medical legal partnership
232259|NCT01800669|child
232260|NCT01800669|pediatrics
232261|NCT01800643|Busulfan
232262|NCT01800643|plasmatic dosage
232263|NCT01800643|Stem Cell Transplantation
232264|NCT01800578|Cerebral State Index Monitor
232265|NCT01800565|precocious puberty
232266|NCT01800565|urinary LH
232267|NCT01800565|GnRH stimulation test
232268|NCT01800565|gonadotropins
232269|NCT01800552|Infiltration
232270|NCT01800552|Extravasation
232271|NCT01800552|Leaking
232272|NCT01800552|PIV Infiltration
232273|NCT01800552|IV Infiltration
232274|NCT01800552|Ultrasound Detection of Infiltration
232275|NCT01800552|Ultrasound Imaging
232276|NCT01800539|Autism
232277|NCT01800539|Early Intervention
232278|NCT01800539|Minority
232279|NCT01800526|Sickle Cell Disease
232280|NCT01800526|Sickle Cell Anemia
232281|NCT01800513|Implantation Failure
232282|NCT01800513|In-vitro Fertilization
232283|NCT01800513|Infertility
232284|NCT01800513|Endometrial Biopsy
232285|NCT01800487|Drug-induced liver injury
232286|NCT01800487|Tuberculosis
232287|NCT01800487|Silymarin
232288|NCT01800461|Participation
232289|NCT01800461|Occupational Therapy
232290|NCT01800461|Valued Activities
232291|NCT01800448|Respiratory monitoring
232292|NCT01800448|cardiac monitoring
232293|NCT01800448|skin conductance monitoring
232294|NCT01800448|variability
232295|NCT01800409|Tetraplegia
232296|NCT01800396|Bacterial infection
232297|NCT01800396|Dairy
232298|NCT01800396|Diarrhea
232299|NCT01800396|Diet
232300|NCT01800396|E.Coli
232301|NCT01800396|Gastroenteritis
232302|NCT01800396|Milk
232303|NCT01800396|Stool consistency
232304|NCT01800383|posttraumatic stress disorder
232305|NCT01800383|fear conditioning
232306|NCT01800383|proton magnetic resonance spectroscopy
232307|NCT01800383|GABA
232308|NCT01800370|Healthy
232309|NCT01800370|Male
232310|NCT01800357|randomized trial
232311|NCT01800357|acute ischemic stroke
232312|NCT01800357|mildronate
232313|NCT01800344|Airway Cuff
232314|NCT01800344|LMA
232315|NCT01800344|Ultra
232316|NCT01800344|Cuff Pressure
232317|NCT01800344|Ventilation
232318|NCT01800344|Anesthesia
232319|NCT01800344|Intubation
232320|NCT01800318|NESAP
232321|NCT01800318|sucrose
232322|NCT01800318|pain
232323|NCT01800318|infants
232324|NCT01800305|PK & PD study
232325|NCT01800305|rhEPO
232326|NCT01800305|Pegylated rhEPO
232327|NCT01800305|male healthy subject
232328|NCT01800292|Pulmonary Artery Hypertension
232329|NCT01800292|pulmonary capillary wedge pressure
232330|NCT01800292|sildenafil
232331|NCT01800292|echocardiography
232332|NCT01800292|left ventricular longitudinal wall strain
232333|NCT01800292|strain rate pre and post medical therapy
232334|NCT01800292|speckle tracking
232335|NCT01800279|Fibromyalgia Syndrome, Temporomandibular Joint, Pain.
232336|NCT01800266|Supervision
232337|NCT01800266|Implementation
232338|NCT01800266|Community Based Mental Health Services
232339|NCT01800266|Trauma Focused Cognitive Behavioral Therapy
232340|NCT01800266|Skill Building and Behavioral Rehearsal
232341|NCT01800266|Symptom and Fidelity Monitoring
232342|NCT01800266|Children
232343|NCT01800266|Adolescents
232344|NCT01800214|neurodengeneration
232345|NCT01800214|neuroimaging
232346|NCT01800201|Initial occurrence Acute Myocardial Infarction (AMI)
232347|NCT01800188|Dialysis
232348|NCT01800188|Incretin hormones
232349|NCT01800149|Tooth extraction
232350|NCT01800149|Ridge Preservation
232351|NCT01800149|Ridge Augmentation
232352|NCT01800149|Guided Bone Regeneration
232353|NCT01800136|pain
232354|NCT01800136|neuropathic
232355|NCT01800136|cortical stimulation
232356|NCT01800136|motor cortex
232357|NCT01800136|plasticity
232358|NCT01800136|rTMS
232359|NCT01800136|tDCS
232360|NCT01800123|Intoxication, overdose, poisoning, EtCO2, emergency medicine
232361|NCT01800097|stroke
232362|NCT01800097|fatigue
232363|NCT01800097|modafinil
232364|NCT01800084|ASIR
232365|NCT01800084|image acquisition
232366|NCT01800084|FBP
232367|NCT01800071|Nasopharyngeal cancer
232368|NCT01800071|Epstein Barr Virus Infections
232369|NCT01800071|Vaccination
232370|NCT01800045|Narcolepsy
232371|NCT01800045|Cataplexy
232372|NCT01800045|Sleep disorder
232373|NCT01800045|Excessive daytime sleepiness
232374|NCT01800006|Atrial Fibrillation
232375|NCT01800006|Observation
232376|NCT01800006|Stroke
232377|NCT01800006|Embolism
232378|NCT01799993|Gram-negative pneumonia
232379|NCT01799993|Intubation
232380|NCT01799993|Mechanical ventilation
232381|NCT01799993|Amikacin
232382|NCT01799980|Lung cancer
232383|NCT01799980|Cervical mediastinoscopy
232384|NCT01799980|Endobronchial ultrasound
232385|NCT01799980|Staging
232386|NCT01799967|gastro-esophageal junction
232387|NCT01799967|minimally invasive
232388|NCT01799967|Achalasia
232389|NCT01799967|Paraesophageal hernia
232390|NCT01799967|GERD
232391|NCT01799967|Epiphrenic diverticula
232392|NCT01799967|Zenker's diverticulum
232393|NCT01799967|All minimally invasive surgeries of the gastro-esophageal junction
232394|NCT01799902|Observational
232395|NCT01799902|Non-Interventional Prospective
232396|NCT01799902|Phase IV Treatment
232397|NCT01799902|Overactive Bladder Syndrome
232398|NCT01799902|Solifenacin
232399|NCT01799889|GS-US-339-0102
232400|NCT01799889|SYK inhibitor
232401|NCT01799889|GS-9973
232402|NCT01799889|entospletinib
232403|NCT01799889|CLL
232404|NCT01799889|leukemia
232405|NCT01799889|lymphoma
232406|NCT01799889|MCL
232407|NCT01799889|DLBCL
232408|NCT01799889|iNHL
232409|NCT01799889|FL
232410|NCT01799889|MZL
232411|NCT01799889|LPL
232412|NCT01799889|SLL
232413|NCT01799889|WM
232414|NCT01799889|Waldenström's macroglobulinemia
232415|NCT01799876|knee
232416|NCT01799876|cartilage
232417|NCT01799876|microfracture
232418|NCT01799876|cell therapy
232419|NCT01799863|Conjunctivitis, Viral
232420|NCT01799863|Ketorolac
232421|NCT01799863|Artificial tears
232422|NCT01799850|muscle
232423|NCT01799850|glucose transporters
232424|NCT01799850|GLUT4
232425|NCT01799850|GLUT5
232426|NCT01799850|Actos
232427|NCT01799837|PTSD
232428|NCT01799811|allograft
232429|NCT01799811|limb salvage
232430|NCT01799811|patency
232431|NCT01799811|Cryopreserved
232432|NCT01799811|open bypass
232433|NCT01799798|Osteogenesis imperfecta
232434|NCT01799798|COL1A1/A2
232435|NCT01799798|Denosumab
232436|NCT01799798|Bisphosphonates
232437|NCT01799798|Children
232438|NCT01799798|Areal bone mineral density
232439|NCT01799759|Body Mass Percentile
232440|NCT01799759|Authoritative parenting
232441|NCT01799759|Online interventions
232442|NCT01799759|Prevention
232443|NCT01799733|Premenstrual Dysphoric Disorder
232444|NCT01799733|Women
232445|NCT01799733|Depression
232446|NCT01799733|Light therapy
232447|NCT01799733|Wake therapy
232448|NCT01799733|Phase
232449|NCT01799733|Chronobiology
232450|NCT01799720|blood cholesterol
232451|NCT01799720|blood lipid profile
232452|NCT01799720|triglycerides
232453|NCT01799720|commercial pills
232454|NCT01799720|fish oil
232455|NCT01799720|lipid peroxidation
232456|NCT01799720|Circulating lipidic profile
232457|NCT01799707|vision
232458|NCT01799707|restoration
232459|NCT01799707|visual field
232460|NCT01799694|Urinary incontinence
232461|NCT01799694|Autologous expanded stem cells
232462|NCT01799694|Radical prostate cancer surgery
232463|NCT01799681|randomised controlled trial, postural balance, rehabilitation, exercise therapy, accidental falls
232464|NCT01799668|Psychotherapy
232465|NCT01799668|Preferences
232466|NCT01799642|dyspnea
232467|NCT01799642|exercise
232468|NCT01799642|cystic fibrosis
232469|NCT01799642|neuromechanical dissociation
232470|NCT01799629|Glycerin suppositories
232471|NCT01799629|Feeding intolerance
232472|NCT01799629|preterm infants
232473|NCT01799629|prophylactic use
232474|NCT01799629|elimination of meconium
232475|NCT01799616|MODIC changes
232476|NCT01799616|Chronic low back pain
232477|NCT01799616|Pamidronate
232478|NCT01799616|Magnetic resonance imaging
232479|NCT01799616|Vertebrae
232480|NCT01799616|Intervertebral disc
232481|NCT01799603|Healthy
232482|NCT01799603|TMC435
232483|NCT01799603|G008
232484|NCT01799590|Migraine
232485|NCT01799590|Topiramate
232486|NCT01799577|laparoscopy, accuracy, duration
232487|NCT01799564|Geographic atrophy
232488|NCT01799564|Age-related macular degeneration
232489|NCT01799564|Fundus autofluorescence
232490|NCT01799551|Depression
232491|NCT01799551|Culture
232492|NCT01799551|CBT
232493|NCT01799551|Adaptation
232494|NCT01799538|Albuterol
232495|NCT01799538|Bronchodilator
232496|NCT01799538|Nebulizer
232497|NCT01799538|Metered Dose Inhaler
232498|NCT01799525|Aneurysm
232499|NCT01799525|subarachnoid hemorrhage
232500|NCT01799525|vasospasm
232501|NCT01799525|cerebral ischemia
232502|NCT01799525|stroke
232503|NCT01799512|medical ICU patients
232504|NCT01799512|APACHE-II score ≥20
232505|NCT01799499|Non Muscle Invasive Bladder Cancer
232506|NCT01799499|Intravesical instillation
232507|NCT01799499|Mitomycin C
232508|NCT01799499|Hydrogel
232509|NCT01799499|Reverse thermal gelation
232510|NCT01799499|Drug retention
232511|NCT01799499|Urinary Bladder Neoplasms
232512|NCT01799499|Carcinoma
232513|NCT01799499|Urologic Neoplasms
232514|NCT01799499|Urogenital Neoplasms
232515|NCT01799499|Neoplasms by Site
232516|NCT01799499|Neoplasms
232517|NCT01799499|Urinary Bladder Diseases
232518|NCT01799499|Urologic Diseases
232519|NCT01799499|Neoplasms, Glandular and Epithelial
232520|NCT01799499|Neoplasms by Histologic Type Mitomycins
232521|NCT01799499|Mitomycin
232522|NCT01799499|Antibiotics, Antineoplastic
232523|NCT01799499|Antineoplastic Agents
232524|NCT01799499|Therapeutic Uses
232525|NCT01799499|Pharmacologic Actions
232526|NCT01799499|Nucleic Acid Synthesis Inhibitors
232527|NCT01799499|Enzyme Inhibitors
232528|NCT01799499|Molecular Mechanisms of Pharmacological Action
232529|NCT01799499|Alkylating Agents
232530|NCT01799486|Telbivudine
232531|NCT01799486|renoprotective efficacy
232532|NCT01799486|liver cirrhosis
232533|NCT01799473|Tyvaso
232534|NCT01799473|PAH
232535|NCT01799460|single-nucleotide-polymorphism
232536|NCT01799460|Traditional Chinese Medicine
232537|NCT01799460|the Comprehensive Treatment Regimen
232538|NCT01799447|Early intervention
232539|NCT01799447|Intervention study
232540|NCT01799447|Infant mother relations
232541|NCT01799447|First time mothers
232542|NCT01799447|Parental program
232543|NCT01799447|Marte Meo method
232544|NCT01799447|Video guidances
232545|NCT01799369|Surgical Apgar Score
232546|NCT01799356|Treatment, moksifloksasin
232547|NCT01799343|Prenatal care
232548|NCT01799343|Blood flow velocity
232549|NCT01799343|Hydrotherapy
232550|NCT01799343|Fetalplacental circulation
232551|NCT01799343|Uteroplacental circulation
232552|NCT01799330|COPD
232553|NCT01799330|Rehabilitation
232554|NCT01799330|Exercise
232555|NCT01799330|TCEMS
232556|NCT01799304|Locomotion
232557|NCT01799304|cerebral palsy
232558|NCT01799304|Postural; Defect
232559|NCT01799291|Decision Making
232560|NCT01799291|Pediatric Bipolar Disorder
232561|NCT01799291|Assessment
232562|NCT01799291|Intervention
232563|NCT01799278|Metastatic prostate carcinoma
232564|NCT01799265|obstructive sleep apnea
232565|NCT01799265|OSA
232566|NCT01799265|AutoPAP
232567|NCT01799265|PAP
232568|NCT01799265|sleep disordered breathing
232569|NCT01799265|CPAP
232570|NCT01799265|Apnea hypopnea index
232571|NCT01799265|AHI
232572|NCT01799252|medical abortion
232573|NCT01799252|doxycycline
232574|NCT01799252|antibiotics
232575|NCT01799252|adherence
232576|NCT01799252|nausea
232577|NCT01799239|stoma ileostomy
232578|NCT01799213|Knee Osteoarthritis
232579|NCT01799213|NSAID
232580|NCT01799213|Cognitive Behavioral Therapy
232581|NCT01799200|Collegiate Athletes
232582|NCT01799200|Hip Pathomorphology
232583|NCT01799200|Age-Matched Controls
232584|NCT01799200|Femoroacetabular Impingement
232585|NCT01799200|Dysplasia
232586|NCT01799187|Immature Permanent Teeth
232587|NCT01799161|NSCLC
232588|NCT01799161|Lung Cancer
232589|NCT01799161|gp96
232590|NCT01799161|gp96 Vaccine
232591|NCT01799161|AD100-gp96Ig-HLA A1
232592|NCT01799148|Acute coronary syndrome
232593|NCT01799148|Air pollution.
232594|NCT01799148|Inflammation.
232595|NCT01799148|Oxidative Stress.
232596|NCT01799148|Prognosis
232597|NCT01799109|magnesium sulfate
232598|NCT01799109|nebulization
232599|NCT01799109|lung function
232600|NCT01799083|Advanced solid tumors
232601|NCT01799083|B cell lymphoma
232602|NCT01799070|Prediction
232603|NCT01799070|Transcranial Doppler
232604|NCT01799057|Peripheral Arterial Disease
232605|NCT01799057|Intermittent Claudication
232606|NCT01799057|Peripheral Vascular Diseases
232607|NCT01799057|Vascular Diseases
232608|NCT01799057|Cardiovascular Diseases
232609|NCT01799057|Arterial Occlusive Diseases
232610|NCT01799057|Atherosclerosis
232611|NCT01799057|Insulin Resistance
232612|NCT01799057|Glucose Metabolism
232613|NCT01799057|Blood Glucose
232614|NCT01799057|Metformin
232615|NCT01799057|Biguanides
232616|NCT01799057|Hypoglycemic Agents
232617|NCT01799057|Endothelium, Vascular
232618|NCT01799057|Hemorheology
232619|NCT01799057|Blood Circulation
232620|NCT01799057|Regional Blood Flow
232621|NCT01799057|Microcirculation
232622|NCT01799057|Exercise
232623|NCT01799057|Physical Fitness
232624|NCT01799057|Exercise Test
232625|NCT01799057|Sedentary Lifestyle
232626|NCT01799057|Quality of Life
232627|NCT01799057|Plethysmography
232628|NCT01799044|Irreversible electroporation
232629|NCT01799044|IRE
232630|NCT01799044|Electroporation
232631|NCT01799044|Colorectal liver metastases
232632|NCT01799044|CRLM
232633|NCT01799044|Safety
232634|NCT01799044|Feasibility
232635|NCT01799044|Efficacy
232636|NCT01799044|Single-center
232637|NCT01799044|Low Energy Direct Current
232638|NCT01799044|Ablate-and-resect
232639|NCT01799044|Nonthermal ablation
232640|NCT01799044|Ablation
232641|NCT01799018|Xanthine Oxidase
232642|NCT01799018|Cerebrospinal fluid
232643|NCT01799005|flavanols
232644|NCT01799005|diet
232645|NCT01799005|endothelial function
232646|NCT01799005|blood pressure
232647|NCT01799005|FLAVIOLA
232648|NCT01798992|ejection fraction
232649|NCT01798992|beta-blocker
232650|NCT01798992|carvedilol
232651|NCT01798992|metoprolol
232652|NCT01798992|myocardial gene expression
232653|NCT01798992|human heart
232654|NCT01798992|ventricular remodeling
232655|NCT01798992|wall stress
232656|NCT01798992|adrenergic signaling
232657|NCT01798992|myosin heavy chain
232658|NCT01798953|Ulcerative Colitis
232659|NCT01798953|Primary Sclerosing Cholangitis
232660|NCT01798953|Ileal pouch-anal anastomosis
232661|NCT01798953|Ileorectal anastomosis
232662|NCT01798953|Surgical outcome
232663|NCT01798953|Functional outcome
232664|NCT01798953|Failure
232665|NCT01798927|Parkinson's disease
232666|NCT01798927|ankle foot orthosis (AFO)
232667|NCT01798927|gait
232668|NCT01798901|Acute Myeloid Leukemia
232669|NCT01798901|AML
232670|NCT01798901|AR-42
232671|NCT01798901|Decitabine
232672|NCT01798888|Deep Brain Stimulation
232673|NCT01798888|Alcohol Dependence
232674|NCT01798875|pcos
232675|NCT01798875|metformin
232676|NCT01798875|oral contraception
232677|NCT01798875|cyproterone acetate
232678|NCT01798862|Failed IVF cycles
232679|NCT01798862|IVF outcome parameters
232680|NCT01798862|endometrial injury
232681|NCT01798862|hysteroscopy
232682|NCT01798862|pipelle sampling
232683|NCT01798862|Repeated implantation failures
232684|NCT01798836|IVF/ICSI cycles, poor responders, ultrashort flare protocol, antagonist protocol
232685|NCT01798823|children
232686|NCT01798823|asthma
232687|NCT01798810|Surgical Site Infection Risk Prediction
232688|NCT01798810|Bacterial species type and antibacterial sensitivities
232689|NCT01798810|Resource Utilization and Cost
232690|NCT01798797|Heart Failure
232691|NCT01798797|HFRS
232692|NCT01798797|OptiVol
232693|NCT01798797|ICD
232694|NCT01798797|CRT-D
232695|NCT01798771|primary brain tumor
232696|NCT01798771|malignant glioma
232697|NCT01798771|intraoperative MRI
232698|NCT01798771|5-ALA
232699|NCT01798745|Heart failure
232700|NCT01798745|JNJ-54452840
232701|NCT01798745|Anti-beta-1 adrenergic receptor auto antibodies
232702|NCT01798745|Beta-1 adrenergic receptor
232703|NCT01798745|Antibodies
232704|NCT01798745|Auto antibodies
232705|NCT01798745|Systolic function
232706|NCT01798719|NAFLD
232707|NCT01798719|Clinical Trial
232708|NCT01798719|Mediterranean Diet
232709|NCT01798719|Low Glycemic Index
232710|NCT01798693|Shoulder
232711|NCT01798693|Supplement
232712|NCT01798693|Amino Acids
232713|NCT01798693|Collagen
232714|NCT01798693|Standard of Care
232715|NCT01798641|Hydrocephalus
232716|NCT01798641|Cross-over
232717|NCT01798628|Healthy volunteers
232718|NCT01798628|Abiraterone acetate
232719|NCT01798628|Pharmacokinetics
232720|NCT01798602|H1N1
232721|NCT01798602|Rosuvastatin
232722|NCT01798589|ethylenediamine dihydrochloride
232723|NCT01798563|Parkinson
232724|NCT01798563|Parkinson Disease
232725|NCT01798550|Enoxaparin dosing
232726|NCT01798550|Obesity
232727|NCT01798524|Transplant
232728|NCT01798524|Kidney
232729|NCT01798524|England
232730|NCT01798511|enteral nutrition
232731|NCT01798511|acute pancreatitis
232732|NCT01798511|oral food intolerance
232733|NCT01798472|displaced femoral neck fractures
232734|NCT01798472|treatment
232735|NCT01798472|uncemented arthroplasty
232736|NCT01798472|cemented arthroplasty
232737|NCT01798459|Attention Deficit Hyperactivity Disorder
232738|NCT01798459|Methylphenidate
232739|NCT01798459|Placebo
232740|NCT01798459|State anxiety
232741|NCT01798446|Renal cell carcinoma
232742|NCT01798446|Nonclear cell
232743|NCT01798446|Temsirolimus resistance
232744|NCT01798433|Angioplasty
232745|NCT01798433|Transluminal
232746|NCT01798433|Percutaneous Coronary
232747|NCT01798420|COPD
232748|NCT01798420|Diabetes
232749|NCT01798420|steroids
232750|NCT01798420|Hemoglobin A1C DIFFERENCE
232751|NCT01798407|Deep Brain Stimulation
232752|NCT01798407|Major Depressive Disorder
232753|NCT01798407|Depression
232754|NCT01798407|Lateral Habenula
232755|NCT01798394|pregnant
232756|NCT01798394|smoker
232757|NCT01798394|cigarette
232758|NCT01798394|tobacco
232759|NCT01798355|Dental Fear
232760|NCT01798355|Dental Phobia
232761|NCT01798355|Cognitive Behavior Therapy
232762|NCT01798355|Specific Phobia
232763|NCT01798355|Children and Adolescents anxiety
232764|NCT01798355|Self Efficacy
232765|NCT01798342|preoperative care
232766|NCT01798342|maltodextrine
232767|NCT01798342|glutamine
232768|NCT01798342|gastric residual volume
232769|NCT01798342|MRI
232770|NCT01798329|Minimal Hepatic Encephalopathy
232771|NCT01798329|Pre-hepatic Portal Hypertension
232772|NCT01798329|portal vein thrombosis
232773|NCT01798316|IV Acetaminophen
232774|NCT01798316|Laparoscopic cholecystectomy
232775|NCT01798316|Postoperative nausea
232776|NCT01798316|Postoperative vomiting
232777|NCT01798277|Keywords provided by Newmarket Electrophysiology Research Group Inc:
232778|NCT01798277|Ventricular tachycardia
232779|NCT01798277|Ventricular tachyarrhythmia
232780|NCT01798277|Ablation
232781|NCT01798277|Coronary artery disease
232782|NCT01798277|Ischemic heart disease
232783|NCT01798277|Amiodarone
232784|NCT01798277|Sotalol
232785|NCT01798277|Anti-Arrhythmia Agents
232786|NCT01798277|Therapeutic Uses
232787|NCT01798277|Pharmacologic Actions
232788|NCT01798277|Additional relevant MeSH terms:
232789|NCT01798277|Atrial Fibrillation
232790|NCT01798277|Arrhythmias, Cardiac
232791|NCT01798277|Heart Diseases
232792|NCT01798277|Cardiovascular Diseases
232793|NCT01798277|Pathologic Processes
232794|NCT01798277|Catheter Ablation, Radiofrequency
232795|NCT01798251|Elderly Gastric Cancer
232796|NCT01798251|Capecitabine Maintenance
232797|NCT01798238|Type 2 Diabetes Mellitus / Dipeptidyl peptidase-IV inhibitors
232798|NCT01798225|Periodontal Disease
232799|NCT01798225|Type 2 Diabetes Mellitus
232800|NCT01798225|Gullah African Americans
232801|NCT01798212|GERD
232802|NCT01798199|Alzheimer
232803|NCT01798199|virtual reality system
232804|NCT01798199|Alzheimer's disease related conditions
232805|NCT01798173|Hepatocellular carcinoma
232806|NCT01798173|Cirrhosis
232807|NCT01798173|Environmental risk factors
232808|NCT01798173|Nutrition
232809|NCT01798173|Metabolic syndrome
232810|NCT01798147|Cholangiocellular Carcinoma
232811|NCT01798147|TACE
232812|NCT01798147|SIRT
232813|NCT01798134|To show safety
232814|NCT01798134|and efficacy
232815|NCT01798134|investigational product
232816|NCT01798121|PPD
232817|NCT01798121|Tuberculosis
232818|NCT01798108|Advanced skeletal metastases
232819|NCT01798108|Radium-223
232820|NCT01798108|Radium-223 dichloride
232821|NCT01798108|Alpharadin
232822|NCT01798095|TB, Aplisol
232823|NCT01798056|≥18 years of age
232824|NCT01798056|Chemotherapy
232825|NCT01798056|Solid tumours
232826|NCT01798056|Immunogenicity
232827|NCT01798056|Herpes Zoster
232828|NCT01798056|Safety
232829|NCT01798056|Shingles
232830|NCT01798030|Vitamin D
232831|NCT01798030|Diabetes
232832|NCT01798030|Osteoporosis
232833|NCT01798030|Cardiovascular Risk
232834|NCT01798017|menstrual regulation
232835|NCT01798017|mifepristone
232836|NCT01798017|misoprostol
232837|NCT01797991|Hypersensitivity, drug
232838|NCT01797978|Sepsis
232839|NCT01797978|Septic shock
232840|NCT01797978|Methylene blue
232841|NCT01797952|lactobacillus CD 2
232842|NCT01797952|oral mucositis
232843|NCT01797952|hematopoietic stem cell transplantation
232844|NCT01797939|Erosive reflux disease (ERD)
232845|NCT01797939|Non-erosive reflux disease (NERD)
232846|NCT01797939|Functional heartburn (FH)
232847|NCT01797926|pharmacokinetics
232848|NCT01797926|Hypertension
232849|NCT01797926|losartan
232850|NCT01797926|healthy volunteers
232851|NCT01797926|amlodipine
232852|NCT01797900|adjuvants
232853|NCT01797900|inductive
232854|NCT01797900|concurrent
232855|NCT01797900|chemoradiotherapy
232856|NCT01797900|high-risk
232857|NCT01797900|locally advanced
232858|NCT01797900|NPC
232859|NCT01797887|Burnout-Syndrome
232860|NCT01797887|Ayurveda
232861|NCT01797887|Ayurvedic
232862|NCT01797887|Traditional Indian Medicine
232863|NCT01797887|CAM
232864|NCT01797887|Whole Medical System
232865|NCT01797887|Diet and Lifestyle Counseling
232866|NCT01797874|pazopanib maintenance
232867|NCT01797874|efficacy
232868|NCT01797874|SCLC
232869|NCT01797861|chronic central serous chorioretinopathy
232870|NCT01797861|photodynamic therapy
232871|NCT01797861|micropulse laser
232872|NCT01797835|adolescents
232873|NCT01797835|intervention
232874|NCT01797835|motivational interviewing
232875|NCT01797835|alcohol and drug use
232876|NCT01797783|Myopia
232877|NCT01797783|Presbyopia
232878|NCT01797783|Refractive error
232879|NCT01797783|Contact lenses
232880|NCT01797783|Multifocal
232881|NCT01797770|mechanical bowel preparation
232882|NCT01797770|Colon Cancer
232883|NCT01797757|EPA
232884|NCT01797757|LC-PUFA
232885|NCT01797757|Orlistat
232886|NCT01797757|Obesity
232887|NCT01797744|Stroke
232888|NCT01797744|Dizziness
232889|NCT01797744|Vestibular rehabiliation
232890|NCT01797744|Balance
232891|NCT01797731|Orthalign
232892|NCT01797731|KneeAlign
232893|NCT01797731|Total Knee Replacement
232894|NCT01797731|Total Knee Arthroplasty
232895|NCT01797731|Degenerative joint disease
232896|NCT01797731|Osteoarthritis
232897|NCT01797731|Unilateral
232898|NCT01797718|Puberty
232899|NCT01797718|Constitutional
232900|NCT01797718|Delay
232901|NCT01797718|Letrozole
232902|NCT01797718|Testosterone
232903|NCT01797692|prostate cancer cured
232904|NCT01797692|aged patients
232905|NCT01797679|Osteoarthritis,Articular Cartilage, Relaxometry, Morphometry, MRI, T2 mapping, T1 rho
232906|NCT01797640|Tibia Fractures
232907|NCT01797640|Medial Fractures
232908|NCT01797640|Posterior Malleolar Fractures
232909|NCT01797627|Pediatric Hydrocephalus
232910|NCT01797627|Ventricular Size
232911|NCT01797627|Neuropsychological Outcomes
232912|NCT01797627|Quality of Life
232913|NCT01797614|intra-abdominal pressure
232914|NCT01797614|spontaneous breathing trail
232915|NCT01797614|weaning
232916|NCT01797588|Total Knee Arthroplasty
232917|NCT01797588|Pain
232918|NCT01797588|Periarticular infiltration
232919|NCT01797588|Adductor canal block
232920|NCT01797588|Postoperative
232921|NCT01797575|Bipolar Disorder
232922|NCT01797575|Mood Disorder
232923|NCT01797575|Bipolar Depression
232924|NCT01797575|Mood Swings
232925|NCT01797562|Contact dermatitis
232926|NCT01797562|Eczema
232927|NCT01797549|Traumatic brain injury
232928|NCT01797549|functional near infrared spectroscopy
232929|NCT01797523|Endometrial cancer
232930|NCT01797523|Advanced or Recurrent Endometrial Carcinoma
232931|NCT01797523|Metformin
232932|NCT01797523|Letrozole
232933|NCT01797523|Femara
232934|NCT01797523|Everolimus
232935|NCT01797523|Afinitor
232936|NCT01797523|Zortress
232937|NCT01797523|RAD001
232938|NCT01797497|Parents
232939|NCT01797497|Primary Care Providers
232940|NCT01797497|Specialists
232941|NCT01797497|Children with Special Healthcare Needs
232942|NCT01797497|Referral
232943|NCT01797497|Health Outcomes
232944|NCT01797497|Self-Efficacy
232945|NCT01797497|Communication
232946|NCT01797484|ischemia
232947|NCT01797484|myocardium
232948|NCT01797484|Ranolazine
232949|NCT01797484|dyskinesia
232950|NCT01797484|speckle tracking echocardiography
232951|NCT01797471|Non-Small Cell Lung Cancer
232952|NCT01797471|NSCLC
232953|NCT01797471|Lung Cancer
232954|NCT01797458|class II carious primary molar
232955|NCT01797458|Opening-up cavities
232956|NCT01797458|Hall Technique
232957|NCT01797458|Conventional restorations
232958|NCT01797445|HIV
232959|NCT01797445|Treatment Naive
232960|NCT01797445|HIV 1 Infected
232961|NCT01797445|Women
232962|NCT01797445|Female
232963|NCT01797419|Respiratory
232964|NCT01797419|Syncytial
232965|NCT01797419|Virus
232966|NCT01797419|RSV
232967|NCT01797380|Depression
232968|NCT01797380|HIV
232969|NCT01797367|HIV
232970|NCT01797367|COPD
232971|NCT01797367|FEV1
232972|NCT01797367|respiratory function
232973|NCT01797354|patients at the end of treatment
232974|NCT01797341|Renal Transplantation
232975|NCT01797341|Kidney transplantation
232976|NCT01797341|Pancreas Transplantation
232977|NCT01797341|Tacrolimus
232978|NCT01797341|Advagraf
232979|NCT01797341|Prograf
232980|NCT01797341|Drug Adherence
232981|NCT01797328|brown adipose tissue, human
232982|NCT01797302|Obesity
232983|NCT01797302|Vitamin D Deficiency
232984|NCT01797302|Vascular Function
232985|NCT01797302|Insulin resistance
232986|NCT01797302|metabolic syndrome
232987|NCT01797289|syncope
232988|NCT01797289|pulmonary embolism
232989|NCT01797276|Dichloroacetate (DCA)
232990|NCT01797276|Congenital Lactic Acidosis (CLA)
232991|NCT01797276|acidosis
232992|NCT01797276|orphan disease
232993|NCT01797263|fibromyalgia
232994|NCT01797263|yoga
232995|NCT01797263|exercise
232996|NCT01797263|pain
232997|NCT01797237|surgery
232998|NCT01797237|fixation
232999|NCT01797237|intramedullary nail
233000|NCT01797224|Autoimmune disease
233001|NCT01797224|certolizumab pegol
233002|NCT01797224|Cimzia
233003|NCT01797224|pregnancy
233004|NCT01797224|birth defect
233005|NCT01797224|birth outcome
233006|NCT01797224|TNF
233007|NCT01797224|Tumor necrosis factor
233008|NCT01797211|Mediterranean diet; FMD; obesity; cardiovascular risk.
233009|NCT01797198|Phase I
233010|NCT01797198|ASP3652
233011|NCT01797198|Gemfibrozil
233012|NCT01797198|Repaglinide
233013|NCT01797198|Pharmacokinetics
233014|NCT01797185|baclofen, spasticity
233015|NCT01797172|nucleoplasty
233016|NCT01797172|pulsed radio frequency
233017|NCT01797172|herniated disc
233018|NCT01797172|cervical
233019|NCT01797172|percutaneous disc decompression
233020|NCT01797172|cervical radiculopathy
233021|NCT01797159|Prophylactic Cranial Irradiation
233022|NCT01797159|PCI
233023|NCT01797159|Hippocampal-sparing irradiation
233024|NCT01797120|Post-Menopausal Patients
233025|NCT01797120|Hormone-Receptor Positive
233026|NCT01797120|Resistant to Aromatase Inhibitor Therapy
233027|NCT01797120|Fulvestrant
233028|NCT01797120|Faslodex
233029|NCT01797120|mTOR Inhibitor
233030|NCT01797120|Everolimus
233031|NCT01797120|RAD001
233032|NCT01797120|Afinitor
233033|NCT01797107|Meibomian gland dysfunction
233034|NCT01797068|HEALTHCARE UTILIZATION
233035|NCT01797068|ED UTILIZATION
233036|NCT01797068|PRIMARY CARE UTILIZATION
233037|NCT01797068|PATIENT NAVIGATION
233038|NCT01797068|UNDERSERVED POPULATIONS
233039|NCT01797068|HEALTH DISPARITIES
233040|NCT01797055|transferrin
233041|NCT01797055|anemia
233042|NCT01797055|iron overload
233043|NCT01797042|Fructose
233044|NCT01797042|High fructose corn syrup
233045|NCT01797042|Energy regulation
233046|NCT01797042|Ectopic fat
233047|NCT01797042|Understanding
233048|NCT01797042|potential
233049|NCT01797016|Myocardial Infarction
233050|NCT01797016|flow cytometry
233051|NCT01797016|Blood Cell Count
233052|NCT01797016|Platelet Activation
233053|NCT01797003|osteoarthritis
233054|NCT01797003|osteotomy
233055|NCT01797003|closing
233056|NCT01797003|opening
233057|NCT01797003|wedge
233058|NCT01797003|kne
233059|NCT01797003|tibia
233060|NCT01796990|physical activity
233061|NCT01796990|psychological well-being
233062|NCT01796990|acceptance and commitment therapy
233063|NCT01796990|adults
233064|NCT01796977|Nipple-sparing Mastectomy
233065|NCT01796977|NSM
233066|NCT01796977|Nipple Sparing Mastectomy
233067|NCT01796964|Age-Related Macular Degeneration
233068|NCT01796964|Wet
233069|NCT01796964|Exudative
233070|NCT01796964|AMD
233071|NCT01796964|Intravitreal injection
233072|NCT01796964|Retina
233073|NCT01796938|Lacosamide
233074|NCT01796938|Vimpat
233075|NCT01796938|Single Dose
233076|NCT01796938|Pharmacokinetics
233077|NCT01796938|Renal Impairment
233078|NCT01796925|Apnea
233079|NCT01796925|Respiration Disorders
233080|NCT01796925|Signs and Symptoms
233081|NCT01796925|Signs and Symptoms, Respiratory
233082|NCT01796925|Sleep Apnea Syndromes
233083|NCT01796925|Sleep Apnea, Obstructive
233084|NCT01796925|Respiratory Tract Diseases
233085|NCT01796925|Sleep Disorders, Intrinsic
233086|NCT01796925|Sleep Disorders
233087|NCT01796925|Nervous System Diseases
233088|NCT01796899|Healthy Volunteers
233089|NCT01796899|Brivaracetam
233090|NCT01796873|Female
233091|NCT01796873|Hispanic
233092|NCT01796873|Percutaneous Coronary Intervention
233093|NCT01796860|Gait
233094|NCT01796860|AFO
233095|NCT01796860|MS
233096|NCT01796847|ICU
233097|NCT01796847|Hyperglycemia
233098|NCT01796847|Length of stay
233099|NCT01796834|Mindfulness-Based Stress Reduction
233100|NCT01796834|Diabetes Management
233101|NCT01796834|Stress Reduction
233102|NCT01796834|Diabetes Testing
233103|NCT01796821|Condyloma acuminata
233104|NCT01796821|Genital warts
233105|NCT01796821|Condylomata acuminata
233106|NCT01796821|Venereal warts
233107|NCT01796808|pedal
233108|NCT01796808|atrophy
233109|NCT01796808|fat grafting
233110|NCT01796808|adipose tissue
233111|NCT01796795|common wart
233112|NCT01796795|verruca vulgaris
233113|NCT01796769|Obstructive Sleep Apnea Syndrome
233114|NCT01796769|Telemedicine
233115|NCT01796769|Patient Compliance
233116|NCT01796756|Handover
233117|NCT01796756|Handoff
233118|NCT01796756|Signout
233119|NCT01796756|Quality Improvement
233120|NCT01796756|General Internal Medicine
233121|NCT01796743|MRI
233122|NCT01796743|Double Inversion radial fast Spin Echo T2 mapping
233123|NCT01796743|Heart failure risk stratification
233124|NCT01796743|30 day post hospitalization outcome
233125|NCT01796730|efficacy
233126|NCT01796730|safety
233127|NCT01796730|Bambuterol tablets
233128|NCT01796730|COPD
233129|NCT01796717|Piperacillin/tazobactam
233130|NCT01796717|MIC
233131|NCT01796704|functional capacity
233132|NCT01796704|NYHA class
233133|NCT01796691|Clopidogrel
233134|NCT01796691|aspirin
233135|NCT01796691|low response
233136|NCT01796691|platelet aggregation
233137|NCT01796691|Acute Coronary Syndrome
233138|NCT01796691|Coronary Stent Implantation
233139|NCT01796678|sickle cell disease
233140|NCT01796678|vaso-occlusive pain episodes
233141|NCT01796678|arginine
233142|NCT01796678|nitric oxide
233143|NCT01796652|Acute interstitial pancreatitis
233144|NCT01796652|Home therapy
233145|NCT01796600|distal limbs fracture, acute trauma, imaging, cone beam computed tomography,
233146|NCT01796574|status epilepticus
233147|NCT01796574|seizure
233148|NCT01796574|epilepsy
233149|NCT01796574|ketogenic diet
233150|NCT01796574|modified Atkins diet
233151|NCT01796548|Detrusor function, overactive
233152|NCT01796548|Urinary incontinence
233153|NCT01796548|Oxybutynin
233154|NCT01796548|Lyrinel
233155|NCT01796509|Quality of life,
233156|NCT01796509|Sequela disorders,
233157|NCT01796509|Socio-professional impact,
233158|NCT01796509|Anxiety, depression,
233159|NCT01796509|Post traumatic stress disorder,
233160|NCT01796509|ICU acquired paresis.
233161|NCT01796496|Low back pain.
233162|NCT01796496|Manipulative therapy techniques.
233163|NCT01796496|Randomized controlled trial.
233164|NCT01796496|Chronic pain.
233165|NCT01796483|Parkinson disease
233166|NCT01796483|STN-DBS
233167|NCT01796483|Impulsivity
233168|NCT01796483|Akinesia
233169|NCT01796483|Noradrenergic
233170|NCT01796483|system
233171|NCT01796470|GS-US-339-0103
233172|NCT01796470|SYK inhibitor
233173|NCT01796470|PI3K inhibitor
233174|NCT01796470|GS-9973
233175|NCT01796470|GS 9973
233176|NCT01796470|GS-1101
233177|NCT01796470|GS 1101
233178|NCT01796470|Cal-101
233179|NCT01796470|Cal 101
233180|NCT01796470|idelalisib
233181|NCT01796470|leukemia
233182|NCT01796470|lymphoma
233183|NCT01796470|CLL
233184|NCT01796470|MCL
233185|NCT01796470|DLBCL
233186|NCT01796470|iNHL
233187|NCT01796470|FL
233188|NCT01796470|MZL
233189|NCT01796470|LPL
233190|NCT01796470|SLL
233191|NCT01796470|WM
233192|NCT01796470|Waldenström's macroglobulinemia
233193|NCT01796457|Hepatitis B
233194|NCT01796457|Immunology
233195|NCT01796457|HBV
233196|NCT01796457|Immune tolerant
233197|NCT01796457|Immune active
233198|NCT01796444|Breast Cancer
233199|NCT01796444|Sentinel Lymph Node Biopsy
233200|NCT01796444|Axillary Lymph Node Dissection
233201|NCT01796392|emphysema
233202|NCT01796392|endobronchial valve
233203|NCT01796392|treatments
233204|NCT01796392|pulmonary rehabilitation
233205|NCT01796392|lung volume reduction
233206|NCT01796353|heart disease
233207|NCT01796353|sexual dysfunction
233208|NCT01796353|exercise test
233209|NCT01796353|comprehensive rehabilitation
233210|NCT01796353|complex intervention
233211|NCT01796340|cue exposure
233212|NCT01796340|childhood
233213|NCT01796340|overeating
233214|NCT01796340|overweight
233215|NCT01796340|obese
233216|NCT01796340|treatment
233217|NCT01796327|dacomitinib
233218|NCT01796327|PF-00299804
233219|NCT01796327|pharmacokinetics
233220|NCT01796327|bioavailability
233221|NCT01796314|Therapeutic educational programme for Alzheimer's disease patients and their caregiver
233222|NCT01796314|Alzheimer's disease, mild to moderately severe stages
233223|NCT01796314|Community dwelling patients with family caregiver
233224|NCT01796314|Alzheimer's disease patient's quality of life
233225|NCT01796301|Postmenopausal Osteoporosis
233226|NCT01796288|NSCLC
233227|NCT01796288|oligometastatic
233228|NCT01796288|second-line
233229|NCT01796288|Radiotherapy
233230|NCT01796288|Erlotinib
233231|NCT01796262|ADHD
233232|NCT01796262|DHA
233233|NCT01796262|neuropsychological task
233234|NCT01796262|fNIRS
233235|NCT01796262|Docosahexaenoic Acid
233236|NCT01796262|n-3 polyunsaturated fatty acid
233237|NCT01796262|cognition
233238|NCT01796262|behavior
233239|NCT01796249|Analgesia Nociception Index
233240|NCT01796249|ANI
233241|NCT01796236|Bone anchored hearing aid
233242|NCT01796236|Bone anchored implant
233243|NCT01796236|Abbreviated Profile of Hearing Aid Benefit (APHAB)
233244|NCT01796236|Health Utility Index (HUI)
233245|NCT01796236|Holgers Index
233246|NCT01796236|Implant stability
233247|NCT01796223|Community mental health services
233248|NCT01796223|Psychotherapy
233249|NCT01796223|Physician-Patient Relations
233250|NCT01796223|Norway
233251|NCT01796210|Analgesia/nociception index
233252|NCT01796210|Bispectral index
233253|NCT01796210|Propofol
233254|NCT01796210|Remifentanil
233255|NCT01796210|Suspension laryngoscopy
233256|NCT01796210|Endoscopy
233257|NCT01796210|Ear-nose-throat
233258|NCT01796184|Inflammation
233259|NCT01796184|Glycation
233260|NCT01796184|Continuous glucose monitoring
233261|NCT01796184|Adult population
233262|NCT01796171|Radioimmunotherapy
233263|NCT01796171|Lu-177
233264|NCT01796171|Phase I study
233265|NCT01796171|Phase II study
233266|NCT01796171|Betalutin
233267|NCT01796158|adolescents
233268|NCT01796158|alcohol abuse
233269|NCT01796158|drug abuse
233270|NCT01796158|substance use
233271|NCT01796132|Depression
233272|NCT01796132|Lactation
233273|NCT01796132|Breastfeeding
233274|NCT01796132|Pharmacokinetics
233275|NCT01796132|Antidepressant
233276|NCT01796119|Dental implants, Ridge splitting, Ridge expansion
233277|NCT01796106|caries infiltration
233278|NCT01796106|caries progression
233279|NCT01796106|Icon
233280|NCT01796093|Digoxin
233281|NCT01796093|Ivabradine
233282|NCT01796093|Cardiac failure
233283|NCT01796093|Economics
233284|NCT01796067|Motivational intervention
233285|NCT01796067|Positive Parenting Intervention
233286|NCT01796067|Obesity
233287|NCT01796067|Physical Activity
233288|NCT01796067|Diet
233289|NCT01796067|African American
233290|NCT01796067|Adolescent
233291|NCT01796054|Perceived stress
233292|NCT01796054|Burnout
233293|NCT01796054|Mindfulness
233294|NCT01796054|Intent to leave nursing
233295|NCT01796028|Prostate Cancer
233296|NCT01796015|paediatrics
233297|NCT01796015|optic nerve sheath diameter
233298|NCT01796015|ultrasound
233299|NCT01796002|PTCL
233300|NCT01795989|Coil
233301|NCT01795989|MRI
233302|NCT01795989|safety
233303|NCT01795989|efficacy
233304|NCT01795989|musculoskeletal imaging
233305|NCT01795989|Cincinnati
233306|NCT01795989|Safety and efficacy of a new elbow coil on pediatric patients and healthy participants
233307|NCT01795976|Oesophageal cancer
233308|NCT01795963|intimate partner violence
233309|NCT01795950|cell therapy
233310|NCT01795950|Pulmonary arterial hypertension
233311|NCT01795898|Osteoarthritis
233312|NCT01795898|Low back pain
233313|NCT01795898|Fentanyl transdermal patch
233314|NCT01795898|Durogesic-D-Trans
233315|NCT01795885|Pregnancy in Adolescence
233316|NCT01795885|Contraception
233317|NCT01795859|Huntington disease
233318|NCT01795859|Chorea
233319|NCT01795859|Tetrabenazine
233320|NCT01795846|allergen specific immunotherapy, house dust mite (Der p), monosensitization, polysensitization, allergic rhinitis, asthma,
233321|NCT01795833|Prediabetes
233322|NCT01795833|Prediabetic State
233323|NCT01795820|ticagrelor
233324|NCT01795820|clopidogrel
233325|NCT01795820|platelet aggregation
233326|NCT01795781|Anticoagulant measurement
233327|NCT01795781|Anticoagulant reversal
233328|NCT01795781|Dabigatran
233329|NCT01795781|Rivaroxaban
233330|NCT01795768|Non randomised
233331|NCT01795768|Open label
233332|NCT01795768|Multicentre
233333|NCT01795768|Phase II biomarker study
233334|NCT01795755|Horse Assisted Therapy (HAT)
233335|NCT01795755|Equine Assisted Psychotherapy (EAP)
233336|NCT01795755|clinical trial
233337|NCT01795755|Randomised Controlled Trial (RCT)
233338|NCT01795755|psychotherapy
233339|NCT01795742|Asthma
233340|NCT01795742|Nebulizers
233341|NCT01795742|Salbutamol
233342|NCT01795742|Developing Countries
233343|NCT01795729|Heart transplant
233344|NCT01795729|Coronary artery disease
233345|NCT01795729|Allograft vascular disease
233346|NCT01795729|Coronary stent
233347|NCT01795729|Optimal medical therapy
233348|NCT01795729|Prognosis
233349|NCT01795703|Prostate Cancer
233350|NCT01795703|Abiraterone Acetate
233351|NCT01795703|JNJ-212082
233352|NCT01795690|Anemia
233353|NCT01795690|Cancer
233354|NCT01795690|Hemoglobin
233355|NCT01795690|Quality of Life
233356|NCT01795690|FACT-An
233357|NCT01795690|FACT-GP
233358|NCT01795690|Erythropoiesis-Stimulating Agents (ESA)
233359|NCT01795690|Epoetin
233360|NCT01795690|Ferric Carboxymaltose
233361|NCT01795690|Blood Transfusions
233362|NCT01795677|JAK2 inhibitor RUXOLITINIB
233363|NCT01795677|Primary or secondary myelofibrosis
233364|NCT01795664|Asthma
233365|NCT01795664|Salmeterol xinafoate and Fluticasone propionate
233366|NCT01795664|Seretide Evohaler
233367|NCT01795664|Functional Respiratory Imaging
233368|NCT01795664|Computational Fluid Dynamic
233369|NCT01795651|teaching
233370|NCT01795651|knowledge translation
233371|NCT01795651|ICU
233372|NCT01795651|postgraduate
233373|NCT01795651|lecture
233374|NCT01795638|anthropometrics
233375|NCT01795638|weight
233376|NCT01795638|nutrition
233377|NCT01795586|breast - female
233378|NCT01795586|advanced breast cancer
233379|NCT01795586|histologically confirmed
233380|NCT01795586|cytologically confirmed
233381|NCT01795586|metastatic
233382|NCT01795586|locally advanced
233383|NCT01795586|unresectable
233384|NCT01795573|GVHD
233385|NCT01795573|AML
233386|NCT01795573|ALL
233387|NCT01795573|MDS
233388|NCT01795573|CLL
233389|NCT01795573|NHL
233390|NCT01795573|HL
233391|NCT01795573|MM
233392|NCT01795560|Periappendicular abscess
233393|NCT01795560|Ultrasound
233394|NCT01795521|NSCLC, SBRT, PET, Medically Inoperable
233395|NCT01795508|Parent training
233396|NCT01795508|Child behavior
233397|NCT01795508|Randomized Controlled Trials
233398|NCT01795495|Spinal Fusion
233399|NCT01795495|Scoliosis
233400|NCT01795495|Methadone
233401|NCT01795495|Magnesium
233402|NCT01795495|Adolescents
233403|NCT01795495|Back Surgery
233404|NCT01795482|perioperative hypothermia
233405|NCT01795482|prewarming
233406|NCT01795482|preoperative warming
233407|NCT01795482|general anaesthesia
233408|NCT01795482|epidural anaesthesia
233409|NCT01795482|temperature measurement
233410|NCT01795469|POTS
233411|NCT01795469|Orthostatic
233412|NCT01795469|Adolescent
233413|NCT01795456|Takayasu's arteritis
233414|NCT01795456|Giant Cell arteritis
233415|NCT01795456|Arteritis
233416|NCT01795456|Vasculitis
233417|NCT01795456|Aortitis
233418|NCT01795456|Disease Activity
233419|NCT01795456|Carotidynia
233420|NCT01795456|Neovascularization
233421|NCT01795456|Carotid Intima Media Thickness
233422|NCT01795443|vibration
233423|NCT01795443|proprioception
233424|NCT01795417|wrinkles
233425|NCT01795417|rhytids
233426|NCT01795417|periorbital
233427|NCT01795404|IBSR
233428|NCT01795404|Cancer Survivors
233429|NCT01795404|Katie Byron
233430|NCT01795404|Quality of Life
233431|NCT01795404|Stress
233432|NCT01795404|Stress reduction
233433|NCT01795391|Prevention
233434|NCT01795391|Dressings
233435|NCT01795391|Catheters
233436|NCT01795378|acute myelogenous leukemia
233437|NCT01795378|acute lymphoblastic leukemia
233438|NCT01795378|donor natural killer cells
233439|NCT01795378|HLA-haploidentical hematopoietic cell transplantation
233440|NCT01795352|EGFR,
233441|NCT01795352|lung cancer,
233442|NCT01795352|mutated
233443|NCT01795339|AZD3293
233444|NCT01795339|Healthy volunteers
233445|NCT01795339|Elderly volunteers
233446|NCT01795339|Alzheimer's Disease patients
233447|NCT01795339|AD patients
233448|NCT01795339|Phase 1
233449|NCT01795339|Multiple Ascending Dose Study
233450|NCT01795326|Effectiveness of risk minimization
233451|NCT01795326|Metabolic monitoring
233452|NCT01795326|Seroquel®
233453|NCT01795326|Seroquel® XR/quetiapine fumarate
233454|NCT01795287|tibial fracture
233455|NCT01795287|intramedullary nailing
233456|NCT01795287|spinal anesthesia
233457|NCT01795287|patient safety
233458|NCT01795261|HIV
233459|NCT01795248|gestational diabetes mellitus
233460|NCT01795248|incretin
233461|NCT01795248|glucose homeostasis
233462|NCT01795248|GLP-1
233463|NCT01795248|type 2 diabetes mellitus
233464|NCT01795248|liraglutide
233465|NCT01795248|Victoza
233466|NCT01795235|men
233467|NCT01795222|conscious sedation
233468|NCT01795222|stress psychological
233469|NCT01795222|dental care for children
233470|NCT01795222|child behavior
233471|NCT01795222|saliva
233472|NCT01795209|Branch retinal vein occlusion
233473|NCT01795209|Macular edema
233474|NCT01795209|Ranibizumab
233475|NCT01795196|pediatric extubation failure
233476|NCT01795196|weaning
233477|NCT01795196|integrated pulmonary index
233478|NCT01795196|mechanical ventilation
233479|NCT01795196|extubation readiness
233480|NCT01795196|respiratory monitoring tool
233481|NCT01795196|Endotracheal Extubation
233482|NCT01795196|Pediatric Intensive Care Unit
233483|NCT01795196|Rapid Shallow Breathing Index
233484|NCT01795196|Physiologic Deadspace
233485|NCT01795170|Pyridoxine Dependant Epilepsy
233486|NCT01795170|Antiquitin Deficiency
233487|NCT01795170|Lysine Restricted Diet
233488|NCT01795157|decision support systems, clinical
233489|NCT01795157|decision making, computer assisted
233490|NCT01795157|evidence based practice
233491|NCT01795157|practice guidelines as topic
233492|NCT01795131|Nutritional anemia
233493|NCT01795131|Vitamin B12
233494|NCT01795131|flu vaccine
233495|NCT01795131|immunity
233496|NCT01794078|Acute Mountain Sickness
233497|NCT01794078|High altitude induced fatigue
233498|NCT01794026|diffusion weighted
233499|NCT01794026|magnetic resonance imaging
233500|NCT01794026|surgery
233501|NCT01794026|histopathology
233502|NCT01795092|Cellulitis
233503|NCT01795092|Outpatient Medicine
233504|NCT01795079|transcranial stimulation
233505|NCT01795079|direct current
233506|NCT01795053|ADHD preschoolers
233507|NCT01795053|playtraining
233508|NCT01795053|child-focused intervention
233509|NCT01795040|omega-3/omega-6 fatty acids
233510|NCT01795040|Pre-school children with ADHD symptoms
233511|NCT01795040|randomized controlled trial
233512|NCT01795027|gastric cancer
233513|NCT01795027|chemotherapy
233514|NCT01795027|D2 resection
233515|NCT01795027|S-1
233516|NCT01795001|pathophysiology
233517|NCT01794988|Acute Pain
233518|NCT01794988|Low Back Pain
233519|NCT01794988|Back Pain
233520|NCT01794988|Functional Magnetic Resonance Imaging (fMRI)
233521|NCT01794988|Cognitive Behavioral Therapy
233522|NCT01794988|Pain Education
233523|NCT01794975|PET
233524|NCT01794975|striatum
233525|NCT01794975|receptor occupancy
233526|NCT01794975|noradrenaline
233527|NCT01794975|alpha2c
233528|NCT01794962|Classification
233529|NCT01794962|LBP
233530|NCT01794962|Cognitive functional therapy
233531|NCT01794962|Manual Therapy
233532|NCT01794949|Angioplasty
233533|NCT01794949|Atherosclerosis
233534|NCT01794949|Wound Healing
233535|NCT01794936|Prostate cancer
233536|NCT01794936|Nerve Sparing Prostatectomy
233537|NCT01794936|VTI Probe
233538|NCT01794923|Delayed onset muscle soreness
233539|NCT01794923|ibuprofen
233540|NCT01794923|topical
233541|NCT01794910|Pregnancy
233542|NCT01794910|Pelvic Floor
233543|NCT01794910|Muscle strength
233544|NCT01794910|Exercise therapy
233545|NCT01794910|natural childbirth
233546|NCT01794910|cesarean section
233547|NCT01794910|physiotherapy
233548|NCT01794884|Glutamine
233549|NCT01794884|Cardiosurgery
233550|NCT01794884|Cardiopulmonary bypass
233551|NCT01794884|Cardiac function
233552|NCT01794884|Recovery
233553|NCT01794845|SCCHN
233554|NCT01794845|Head and Neck Cancer
233555|NCT01794845|Squamous Cell Carcinoma
233556|NCT01794845|Recurrent
233557|NCT01794832|HRQoL
233558|NCT01794832|Aortic stenosis
233559|NCT01794832|Aortic valve surgery
233560|NCT01794819|antibiotics
233561|NCT01794819|primary care
233562|NCT01794819|radiology/radiography
233563|NCT01794819|respiratory tract infections
233564|NCT01794793|SOM230,
233565|NCT01794793|roll-over study
233566|NCT01794793|pasireotide LAR
233567|NCT01794793|Cushing's disease
233568|NCT01794793|Acromegaly
233569|NCT01794793|neuroendocrine tumorsNETs
233570|NCT01794793|pituitary tumors
233571|NCT01794793|Ectopic ACTH secreting
233572|NCT01794793|EAS
233573|NCT01794793|Dumping Syndrome
233574|NCT01794793|metastatic prostate cancer, metastatic melanoma
233575|NCT01794793|bRAF
233576|NCT01794793|nRAS
233577|NCT01794767|peripheral venous catheter, children.
233578|NCT01794754|Hand osteoarthritis
233579|NCT01794754|CMC1-joint
233580|NCT01794754|surgery
233581|NCT01794754|occupational therapy
233582|NCT01794754|hand exercises
233583|NCT01794754|assistive devices
233584|NCT01794754|orthoses
233585|NCT01794728|Pain Management
233586|NCT01794715|Heart failure
233587|NCT01794715|Nurse led
233588|NCT01794715|Outpatient clinic
233589|NCT01794715|Echocardiography
233590|NCT01794715|Pocket-size
233591|NCT01794715|Ultrasound
233592|NCT01794702|Leukemia
233593|NCT01794702|Acute Leukemia
233594|NCT01794702|Acute myelogenous leukemia
233595|NCT01794702|AML
233596|NCT01794702|Acute lymphoblastic leukemia
233597|NCT01794702|ALL
233598|NCT01794702|Maximum Tolerated Dose
233599|NCT01794702|MTD
233600|NCT01794702|Response Rate
233601|NCT01794702|Decitabine
233602|NCT01794702|Dacogen
233603|NCT01794702|Idarubicin
233604|NCT01794702|Idamycin
233605|NCT01794702|Cytarabine
233606|NCT01794702|Ara-C
233607|NCT01794702|Cytosar
233608|NCT01794702|DepoCyt
233609|NCT01794702|Cytosine Arabinosine Hydrochloride
233610|NCT01794676|Pancreatic cancer
233611|NCT01794676|Thymic cancer
233612|NCT01794676|Parathyroid disease
233613|NCT01794676|MEN1 syndrome
233614|NCT01794676|Genomic DNA
233615|NCT01794676|MEN1 gene sequence
233616|NCT01794663|Early kidney graft dysfunction
233617|NCT01794663|renal transplantation
233618|NCT01794650|T1DM, Exercise, Hypoglycaemia
233619|NCT01794637|End stage liver disease
233620|NCT01794637|Peripheral microcirculatory dysfunction
233621|NCT01794637|Liver transplantation
233622|NCT01794637|Near infrared spectroscopy
233623|NCT01794624|TMD
233624|NCT01794624|TMJD
233625|NCT01794624|Temporomandibular Joint Disorders
233626|NCT01794624|Sleep Continuity Disturbance
233627|NCT01794624|Pain Catastrophizing
233628|NCT01794624|Cognitive Therapy
233629|NCT01794624|Behavioral Therapy
233630|NCT01794598|Heart failure
233631|NCT01794598|depression
233632|NCT01794598|depression care education
233633|NCT01794585|traumatic brain injury
233634|NCT01794585|balance deficits
233635|NCT01794585|virtual reality
233636|NCT01794585|home-based therapy
233637|NCT01794572|Multiple Myeloma
233638|NCT01794572|Relapse
233639|NCT01794572|Complete Remission
233640|NCT01794572|Very Good Partial Remission
233641|NCT01794546|pediatric obesity
233642|NCT01794546|telehealth
233643|NCT01794533|Irreversible Pulpitis
233644|NCT01794533|Infiltration injection
233645|NCT01794533|Fentanyl
233646|NCT01794533|Lidocaine
233647|NCT01794520|relapsed/refractory multiple myeloma
233648|NCT01794520|multiple myeloma
233649|NCT01794520|refractory multiple myeloma
233650|NCT01794520|relapsed multiple myeloma
233651|NCT01794507|refractory multiple myeloma
233652|NCT01794507|relapsed/refractory multiple myeloma
233653|NCT01794507|relapsed multiple myeloma
233654|NCT01794507|multiple myeloma
233655|NCT01794494|Peripheal arterial disease
233656|NCT01794494|Critical limb ischemia
233657|NCT01794494|Bypass surgery
233658|NCT01794494|Subintimal angioplasty
233659|NCT01794494|Health related cost
233660|NCT01794468|Dermal blood flow
233661|NCT01794468|critically ill
233662|NCT01794455|Depression
233663|NCT01794455|Depressive Disorder
233664|NCT01794455|Geriatrics
233665|NCT01794455|Hypertension
233666|NCT01794429|Obesity
233667|NCT01794429|The Metabolic Syndrome/disturbances
233668|NCT01794429|Drug-induced adipositas
233669|NCT01794429|Schizophrenia
233670|NCT01794429|GLP-1 analogue
233671|NCT01794429|cerebral effects
233672|NCT01794403|Prostate Cancer
233673|NCT01794403|Prostate
233674|NCT01794403|Radiation Therapy
233675|NCT01794403|Hypofractionation Radiotherapy
233676|NCT01794403|Extended Hypofractionation Radiotherapy
233677|NCT01794403|Accelerated Hypofractionation Radiotherapy
233678|NCT01794403|AHRT
233679|NCT01794403|EHRT
233680|NCT01794390|COPD (Chronic Obstructive Pulmonary Disease)
233681|NCT01794390|Asthma
233682|NCT01794390|Pulmojet
233683|NCT01794390|Inhalers
233684|NCT01794390|Respiratory
233685|NCT01794390|Inhaler Technique
233686|NCT01794390|Critical Errors
233687|NCT01794377|Obesity
233688|NCT01794364|T2DM
233689|NCT01794364|Diabetes Mellitus Type 2
233690|NCT01794325|Occupational radiation exposure
233691|NCT01794325|Transradial approach
233692|NCT01794325|Transfemoral approach
233693|NCT01794299|Haploidentical stem cell transplantation
233694|NCT01794299|Graft-versus-host disease
233695|NCT01794299|Immune reconstitution
233696|NCT01794299|Alloreactive T-cells
233697|NCT01794299|Photodepletion
233698|NCT01794299|Photodynamic treatment
233699|NCT01794299|TH9402
233700|NCT01794299|Transplant-related mortality
233701|NCT01794299|Hematologic malignancy
233702|NCT01794273|Ephedrine
233703|NCT01794273|Phenylephrine
233704|NCT01794273|Vasopressor
233705|NCT01794273|Carotid surgery
233706|NCT01794273|Hypotension
233707|NCT01794273|Haemodynamics
233708|NCT01794273|Brain ischemia
233709|NCT01794273|Tissue perfusion
233710|NCT01794273|Stroke
233711|NCT01794273|anaesthesia;
233712|NCT01794260|Osteoarthritis
233713|NCT01794260|Moderate ot severe pain
233714|NCT01794260|ZINGIBER CASSUMUNAR ROXB
233715|NCT01794221|circumcision
233716|NCT01794221|2 octyl cyanoacrylate
233717|NCT01794221|phimosis
233718|NCT01794208|in-vitro fertilization
233719|NCT01794208|reproductive disorder
233720|NCT01794195|Parkinson's disease
233721|NCT01794195|Apathy
233722|NCT01794195|diffusion tensor imaging
233723|NCT01794195|tractography
233724|NCT01794156|Inference-based therapy
233725|NCT01794156|Cognitive behavior therapy
233726|NCT01794156|Obsessive compulsive disorder
233727|NCT01794156|Randomized clinical trial
233728|NCT01794143|Treatment of Type 2 diabetes
233729|NCT01794143|Comparative effectiveness research
233730|NCT01794143|Clinical trial
233731|NCT01794143|Patient-centered outcomes
233732|NCT01794117|Efficacy
233733|NCT01794117|Optimal Dosing
233734|NCT01794117|Safety
233735|NCT01794117|Pustular Skin Lesion
233736|NCT01794117|Neutrophilic Pustulosis
233737|NCT01794104|Topoisomerase Inhibitor
233738|NCT01794104|Advanced Malignancies
233739|NCT01794104|Pharmacodynamics
233740|NCT01794104|DNA Damage
233741|NCT01794104|Pharmacokinetics
233742|NCT01794091|Cardiac Magnetic Resonance Imaging
233743|NCT01794091|Diabetes
233744|NCT01794013|Parent training
233745|NCT01794013|DIR/ Floortime Approach
233746|NCT01794013|Children with developmental disabilities
233747|NCT01793987|blood loss between two groups
233748|NCT01793974|LADA
233749|NCT01793974|Latent Autoimmune Diabetes in Adults
233750|NCT01793974|Latent Autoimmune Diabetes
233751|NCT01793974|Latent Diabetes in Adults
233752|NCT01793935|Schizophrenia
233753|NCT01793935|Sensoril
233754|NCT01793935|Withania Somnifera extract
233755|NCT01793935|Total/ Positive / Negative Symptoms
233756|NCT01793935|Stress
233757|NCT01793935|Inflammation
233758|NCT01793935|Immunomodulation
233759|NCT01793909|Type 2 Diabetes
233760|NCT01793909|Exercise Impairment
233761|NCT01793909|Blood Flow
233762|NCT01793909|Muscle Oxygen Uptake
233763|NCT01793909|Exercise Training
233764|NCT01793896|Metabolic syndrome
233765|NCT01793896|Ageing
233766|NCT01793896|Mitochondrial density
233767|NCT01793896|Oxidative damage
233768|NCT01793896|Inflammatory mediators
233769|NCT01793896|AMPK
233770|NCT01793896|Adipogenesis
233771|NCT01793883|Influenza Laninamivir Octanoate
233772|NCT01793870|pharmacokinetic
233773|NCT01793870|carvedilol
233774|NCT01793870|Stable isotope technique
233775|NCT01793857|Primary caregiver
233776|NCT01793857|Survey
233777|NCT01793857|Acute Otitis Media
233778|NCT01793857|Ear infection
233779|NCT01793857|Panama
233780|NCT01793857|Healthcare seeking behaviour
233781|NCT01793844|diffuse large B cell lymphoma
233782|NCT01793844|DFS
233783|NCT01793844|OS
233784|NCT01793831|Crohn's diseases
233785|NCT01793831|Inflammatory bowel disease
233786|NCT01793831|Fecal transplantation
233787|NCT01793831|Fecal bacteriotherapy
233788|NCT01793831|Fecal microbiota transplantation
233789|NCT01793818|Vaccine
233790|NCT01793818|HIV-1
233791|NCT01793818|Tat
233792|NCT01793792|intracranial, saccular, aneurysms, stenting, coiling
233793|NCT01793740|sickle cell disease
233794|NCT01793740|pediatric
233795|NCT01793740|learning disability
233796|NCT01793740|cognitive impairment
233797|NCT01793740|memory
233798|NCT01793740|attention
233799|NCT01793740|Children with sickle cell disease
233800|NCT01793727|infants
233801|NCT01793727|general anesthesia
233802|NCT01793727|tracheal intubation
233803|NCT01793714|Magnetic Resonance Imaging
233804|NCT01793701|Cervical Cancer, Intensity-modulated radiotherapy
233805|NCT01793688|UNASYN-S
233806|NCT01793688|High Dose
233807|NCT01793662|Aortobifemoral bypass
233808|NCT01793662|Laparoscopic aortic surgery
233809|NCT01793662|Aortoiliac occlusive disease
233810|NCT01793662|TASC Type D Lesions
233811|NCT01793662|Open aortic surgery
233812|NCT01793649|Respiratory health
233813|NCT01793649|Cystic Fibrosis
233814|NCT01793649|Chronic Obstructive Pulmonary Disease
233815|NCT01793623|atrial fibrillation
233816|NCT01793623|genetics
233817|NCT01793623|cardiac arrhythmias
233818|NCT01793623|heart disease
233819|NCT01793610|MDMA
233820|NCT01793610|Posttraumatic stress disorder
233821|NCT01793610|sleep
233822|NCT01793610|Depression
233823|NCT01793610|Safety
233824|NCT01793597|ticagrelor
233825|NCT01793597|Coronary artery bypass surgery
233826|NCT01793597|platelet function
233827|NCT01793597|receptor binding
233828|NCT01793597|platelet reactivity
233829|NCT01793597|reversible binding
233830|NCT01793584|Comparative effectiveness
233831|NCT01793584|Surgical success
233832|NCT01793571|Abdominal Muscles/Ultrasonography
233833|NCT01793571|Adult
233834|NCT01793571|Ambulatory Surgical Procedures
233835|NCT01793571|Anesthetics, Local/Administration & Dosage
233836|NCT01793571|Levobupivacaine/Administration & Dosage
233837|NCT01793571|Levobupivacaine/Analogs & Derivatives
233838|NCT01793571|Hernia, Inguinal/Surgery
233839|NCT01793571|Humans
233840|NCT01793571|Nerve Block/Methods
233841|NCT01793571|Pain Measurement/Methods
233842|NCT01793571|Pain, Postoperative/Prevention & Control
233843|NCT01793571|Ultrasonography, Interventional
233844|NCT01793558|Thermoregulation Impairment
233845|NCT01793558|hypothermia
233846|NCT01793558|Postoperative shivering
233847|NCT01793558|cesarean section
233848|NCT01793558|newborn
233849|NCT01793545|Endometrial Cancer
233850|NCT01793545|Gynecological Cancers
233851|NCT01793545|Screening
233852|NCT01793532|PET Imaging
233853|NCT01793532|Epilepsy
233854|NCT01793532|Inflammation
233855|NCT01793532|Brain Imaging
233856|NCT01793519|Rheumatoid Arthritis
233857|NCT01793519|Autoimmune Diseases
233858|NCT01793519|Anti-TNF
233859|NCT01793506|immunodeficiency
233860|NCT01793493|Mild Cognitive Impairment
233861|NCT01793493|Cognitive Stimulation
233862|NCT01793493|Aging
233863|NCT01793493|Elderly
233864|NCT01793493|Randomized Controlled Trial
233865|NCT01793480|Methadone in cancer pain
233866|NCT01793428|adults admitted in vital emergency unit
233867|NCT01793389|gingival recession
233868|NCT01793389|fibrin
233869|NCT01793389|connective tissue
233870|NCT01793389|root coverage
233871|NCT01793389|microsurgery
233872|NCT01793389|case-control studies
233873|NCT01793363|Tracheotomy
233874|NCT01793363|Weaning from mechanical ventilation
233875|NCT01793363|Lung ultrasound score
233876|NCT01793350|Diabetes
233877|NCT01793350|Mellitus
233878|NCT01793350|Painful
233879|NCT01793350|Neuropathy
233880|NCT01793350|Peripheral
233881|NCT01793324|Effectiveness of risk minimization
233882|NCT01793324|Metabolic monitoring
233883|NCT01793324|Seroquel® or Seroquel® XR/quetiapine fumarate
233884|NCT01793311|intraocular pressure
233885|NCT01793311|caffeine
233886|NCT01793311|dosage
233887|NCT01793246|lung cancer
233888|NCT01793246|lung neoplasms
233889|NCT01793246|lung transplant
233890|NCT01793194|venous insufficiency
233891|NCT01793194|varicose veins
233892|NCT01793194|pregnancy
233893|NCT01793194|DVT
233894|NCT01793194|superficial thrombophlebitis
233895|NCT01793181|Vitamin d deficiency
233896|NCT01793181|Central retinal vein occlusion
233897|NCT01793168|Rare Diseases
233898|NCT01793168|Neglected Diseases
233899|NCT01793168|Orphan Diseases
233900|NCT01793168|Rare Disease Research
233901|NCT01793168|Registries
233902|NCT01793168|WAGR Syndrome
233903|NCT01793168|Ataxia
233904|NCT01793168|Cornelia de Lange Syndrome
233905|NCT01793168|Stickler Syndrome
233906|NCT01793168|Ataxia Telangiectasia
233907|NCT01793168|Kawasaki Disease
233908|NCT01793168|Batten Disease
233909|NCT01793168|Mucolipidosis IV
233910|NCT01793168|Klippel-Feil
233911|NCT01793155|Lung cancer surgery
233912|NCT01793155|Inspiratory muscle training
233913|NCT01793155|Postoperative pulmonary complications
233914|NCT01793155|Functional outcomes
233915|NCT01793155|Health related quality of life
233916|NCT01793142|Osteoporosis
233917|NCT01793142|postmenopausal
233918|NCT01793142|SERM
233919|NCT01793129|NICHD Neonatal Research Network
233920|NCT01793129|Hypoxic-ischemic encephalopathy (HIE)
233921|NCT01793129|Hypothermia
233922|NCT01793129|Neonatal depression
233923|NCT01793129|Perinatal asphyxia
233924|NCT01793116|NICHD Neonatal Research Network
233925|NCT01793116|Moderately Preterm
233926|NCT01793090|Cobalamin C defect
233927|NCT01793090|methylmalonic aciduria with homocystinuria
233928|NCT01793090|Visual function
233929|NCT01793090|VEP
233930|NCT01793090|ERG
233931|NCT01793090|antioxidant drugs
233932|NCT01793077|Prostate Cancer
233933|NCT01793077|Phase 4
233934|NCT01793077|Data collection
233935|NCT01793077|Observational
233936|NCT01793077|Depo-Eligard
233937|NCT01793077|Prospective
233938|NCT01793077|Non-interventional
233939|NCT01793077|Treatment
233940|NCT01793064|Pedometer,
233941|NCT01793064|adaptive,
233942|NCT01793064|exercise,
233943|NCT01793064|reinforcement,
233944|NCT01793064|goal setting,
233945|NCT01793064|technology,
233946|NCT01793064|email,
233947|NCT01793064|weight loss
233948|NCT01793064|mHealth
233949|NCT01793064|eHealth
233950|NCT01793051|Myeloma
233951|NCT01793051|Multiple Myeloma
233952|NCT01793051|MM
233953|NCT01793051|Symptom Burden
233954|NCT01793051|Symptom reduction
233955|NCT01793051|Maintenance therapy with lenalidomide
233956|NCT01793051|Minocycline
233957|NCT01793051|Dynacin
233958|NCT01793051|Minocin
233959|NCT01793051|Minocin PAC
233960|NCT01793051|Myrac
233961|NCT01793051|Solodyn
233962|NCT01793051|Placebo
233963|NCT01793051|Sugar pill
233964|NCT01793051|MD Anderson Symptom Inventory
233965|NCT01793051|MDASI
233966|NCT01793051|Questionnaires
233967|NCT01793051|Surveys
233968|NCT01793038|PCOS
233969|NCT01793038|clomiphene citrate resistant PCOS
233970|NCT01793038|Aromatase inhibitors
233971|NCT01793025|leukemia
233972|NCT01793025|myeloid
233973|NCT01793025|acute
233974|NCT01793025|acute myeloid leukemia
233975|NCT01793025|allogeneic
233976|NCT01793025|transient chimerism
233977|NCT01793025|cell therapy
233978|NCT01793025|immunotherapy
233979|NCT01793012|therapeutic drug monitoring
233980|NCT01793012|antibiotics
233981|NCT01793012|inflammation parameters
233982|NCT01793012|critically ill patients
233983|NCT01793012|septicaemia
233984|NCT01793012|intensive care unit
233985|NCT01792986|Diabetes
233986|NCT01792986|Fasting
233987|NCT01792986|Pre-diabetes
233988|NCT01792986|Hemoglobin A1C
233989|NCT01792973|HIV
233990|NCT01792973|HPV
233991|NCT01792973|Women
233992|NCT01792973|Thailand
233993|NCT01792973|Antiretrovirals
233994|NCT01792973|Cervical cancer
233995|NCT01792921|Age 7-10 years old
233996|NCT01792921|regular education system
233997|NCT01792921|no moderate or severe neurological and/or psychiatric disorders
233998|NCT01792908|ankle lateral ligament
233999|NCT01792908|athletic tape
234000|NCT01792908|position sense
234001|NCT01792908|Proprioception
234002|NCT01792895|Posterior Neck Pain
234003|NCT01792895|Cervical spine pain
234004|NCT01792895|Manual therapy
234005|NCT01792856|coaching
234006|NCT01792856|early psychosis
234007|NCT01792856|schizophrenia
234008|NCT01792830|Coronary Artery Bypass Graft surgery
234009|NCT01792817|Cluster Headache
234010|NCT01792817|GammaCore
234011|NCT01792817|vagal nerve stimulation
234012|NCT01792817|nVNS
234013|NCT01792817|VNS
234014|NCT01792817|non invasive
234015|NCT01792817|vagus nerve stimulation
234016|NCT01792804|Staphylococcus aureus
234017|NCT01792804|Bloodstream infection
234018|NCT01792804|Oral switch
234019|NCT01792778|IV Catheters
234020|NCT01792778|Blood control
234021|NCT01792765|urolithiasis
234022|NCT01792765|radiation free
234023|NCT01792765|ultrasound guidance
234024|NCT01792765|ureteroscopy
234025|NCT01792752|HIV/AIDS
234026|NCT01792752|Drug Users
234027|NCT01792752|Puerto Rico
234028|NCT01792739|Probiotics
234029|NCT01792739|Diarrhea
234030|NCT01792739|Intentive care units
234031|NCT01792726|breast cancer
234032|NCT01792726|radiotherapy
234033|NCT01792726|TARGIT
234034|NCT01792726|Intrabeam
234035|NCT01792713|Skin alterations
234036|NCT01792713|Atopic Dermatitis
234037|NCT01792687|Metastatic castrate resistant prostate cancer (CRPC)
234038|NCT01792674|Education
234039|NCT01792674|Patient simulation
234040|NCT01792674|In situ simulation
234041|NCT01792674|Stress
234042|NCT01792661|Chronic Kidney Disease
234043|NCT01792661|Electronic Health Record
234044|NCT01792661|Personal Health Record
234045|NCT01792661|Chronic Kidney Disease registry
234046|NCT01792661|Glomerular Filtration Rate
234047|NCT01792661|Patient Navigator
234048|NCT01792648|Almond
234049|NCT01792648|Carbohydrate
234050|NCT01792648|Diet
234051|NCT01792648|Cholesterol
234052|NCT01792635|Type 2 Diabetes Mellitus
234053|NCT01792635|Pharmacodynamics
234054|NCT01792635|Safety & Tolerability
234055|NCT01792622|Instrument Development
234056|NCT01792622|Patient Reported Outcomes
234057|NCT01792622|Pulmonary Arterial Hypertension.
234058|NCT01792609|Scoliosis
234059|NCT01792609|Cobb Angle
234060|NCT01792609|Screw Density
234061|NCT01792609|Outcomes Measures
234062|NCT01792583|pregnancy
234063|NCT01792570|HIV-1
234064|NCT01792570|darunavir
234065|NCT01792570|rilpivirine
234066|NCT01792570|strategic study
234067|NCT01792557|Pilonidal sinus
234068|NCT01792557|Crystallized phenol
234069|NCT01792557|Limberg Flap
234070|NCT01792557|Modified Limberg Flap
234071|NCT01792557|Karydakis
234072|NCT01792557|Recurrence
234073|NCT01792557|Complications
234074|NCT01792557|Recovery duration
234075|NCT01792557|Time to return to work
234076|NCT01792531|children
234077|NCT01792531|obesity
234078|NCT01792531|treatment
234079|NCT01792531|family
234080|NCT01792492|Thyroid Neoplasms
234081|NCT01792492|Optical Devices
234082|NCT01792492|Spectrum Analysis
234083|NCT01792492|Thyroid diseases
234084|NCT01792479|NSCLC
234085|NCT01792479|lung cancer
234086|NCT01792466|difficult biliary cannulation
234087|NCT01792453|Gastrointestinal physiology
234088|NCT01792453|MRI
234089|NCT01792453|Small bowel water volumes
234090|NCT01792453|Gastric volumes
234091|NCT01792401|Critical illness
234092|NCT01792401|Dietary supplements
234093|NCT01792401|Gastrointestinal tract/physio-pathology
234094|NCT01792388|Crohn's Disease
234095|NCT01792388|Vitamin D
234096|NCT01792388|Intestinal Permeability
234097|NCT01792388|Tara Raftery
234098|NCT01792375|Cervical ripening
234099|NCT01792375|Dinoprostone
234100|NCT01792375|Labor induction
234101|NCT01792375|Membrane sweeping
234102|NCT01792375|Nulliparous women
234103|NCT01792375|Trial
234104|NCT01792362|Anti-mullerian hormone (AMH) level, poly cystic ovarian syndrome obese infertility weight loss diet
234105|NCT01792336|Repetitive TMS (rTMS)
234106|NCT01792336|Transcranial Magnetic Stimulation (TMS)
234107|NCT01792336|Motor Cortex
234108|NCT01792336|Focal Hand Dystonia
234109|NCT01792336|Facilitation
234110|NCT01792323|insulin pump therapy
234111|NCT01792323|insulin bolus
234112|NCT01792323|rapid acting insulin
234113|NCT01792323|insulin lispro
234114|NCT01792323|pharmacodynamics
234115|NCT01792323|pharmacokinetics
234116|NCT01792323|glucose clamp
234117|NCT01792310|Glioma
234118|NCT01792310|Solid Tumours
234119|NCT01792310|Minerval
234120|NCT01792297|Sarcopenia
234121|NCT01792297|Osteoporosis
234122|NCT01792297|Cognition
234123|NCT01792297|Inflammation
234124|NCT01792271|COPD
234125|NCT01792271|Chronic Bronchitis
234126|NCT01792271|Hypertonic Saline
234127|NCT01792258|Percutaneous tracheostomy
234128|NCT01792258|Intensive Care Unit
234129|NCT01792258|Ineffective Airway Clearance
234130|NCT01792258|Weaning failure
234131|NCT01792245|narrow band UVB; PUVA; psoriasis; eczema; hand
234132|NCT01792232|Diesel exhaust
234133|NCT01792232|Air pollution
234134|NCT01792232|Airway responsiveness
234135|NCT01792232|Allergies
234136|NCT01792219|interprofessional learning
234137|NCT01792219|interprofessional collaboration
234138|NCT01792219|residents
234139|NCT01792219|nursing homes
234140|NCT01792206|Stage 3 chronic kidney disease (CKD)
234141|NCT01792206|Stage 4 chronic kidney disease (CKD)
234142|NCT01792206|CKD
234143|NCT01792180|Gait speed
234144|NCT01792180|Mobility
234145|NCT01792180|Falls
234146|NCT01792180|Fall risk
234147|NCT01792180|Self-management
234148|NCT01792180|Mental wellbeing
234149|NCT01792180|Elderly
234150|NCT01792115|Fatty Liver
234151|NCT01792115|Alpha-Tocopherol
234152|NCT01792115|Vitamin E
234153|NCT01792115|Non-Alcoholic Steatohepatitis
234154|NCT01792102|Multiple Myeloma
234155|NCT01792102|Carfilzomib
234156|NCT01792102|Krypolis
234157|NCT01792102|60 minute infusion
234158|NCT01792089|de novo lipogenesis
234159|NCT01792089|fructose
234160|NCT01792089|roux-en-Y gastric bypass
234161|NCT01792089|post-prandial triglycerides
234162|NCT01792050|IDO
234163|NCT01792050|IDO Inhibitor
234164|NCT01792050|Metastatic Breast Cancer
234165|NCT01792011|Elective living donor liver transplantation
234166|NCT01791985|Breast Cancer
234167|NCT01791985|AZD4547
234168|NCT01791985|Safety Run-In
234169|NCT01791985|FGFR1
234170|NCT01791985|ER positive breast cancer
234171|NCT01791985|Single arm phase IIa study
234172|NCT01791972|Exercise-Induced Bronchoconstriction (EIB)
234173|NCT01791972|Spiromax®
234174|NCT01791972|Albuterol sulfate
234175|NCT01791946|lazy eye
234176|NCT01791946|cross eye
234177|NCT01791946|cross eyed
234178|NCT01791933|LBP
234179|NCT01791933|Neck pain
234180|NCT01791933|Integrative package
234181|NCT01791933|CAM
234182|NCT01791868|Generalized convulsive status epilepticus
234183|NCT01791868|Sodium valproate
234184|NCT01791868|Refractory status epilepticus
234185|NCT01791868|Mortality
234186|NCT01791868|Epilepsy
234187|NCT01791868|Intensive Care Unit
234188|NCT01791868|Neurological sequela
234189|NCT01791868|Quality of life
234190|NCT01791868|Adult
234191|NCT01791855|Subjects with Renal Impairment
234192|NCT01791855|healthy
234193|NCT01791842|fibrous dysplasia of bone
234194|NCT01791842|tocilizumab
234195|NCT01791842|McCune-Albright syndrome
234196|NCT01791829|Luminal A
234197|NCT01791829|Ipsilateral Breast Tumour Recurrence
234198|NCT01791816|Vasovagal Syncope
234199|NCT01791816|Postural Tachycardia Syndrome
234200|NCT01791816|Orthostatic Intolerance
234201|NCT01791816|Nitric Oxide (NO)
234202|NCT01791816|Orthostatic Stress
234203|NCT01791816|L-Ng-monomethyl Arginine (L-NMMA)
234204|NCT01791816|Phenylephrine
234205|NCT01791816|Sodium Nitroprusside
234206|NCT01791803|Smoking cessation
234207|NCT01791803|Tobacco abstinence
234208|NCT01791803|hypnotherapy
234209|NCT01791803|Nicotine replacement therapy
234210|NCT01791790|old Subjects
234211|NCT01791790|Controls
234212|NCT01791790|brain stimulation
234213|NCT01791790|tSOS
234214|NCT01791790|tDCS
234215|NCT01791790|sleep
234216|NCT01791790|memory
234217|NCT01791790|memory consolidation
234218|NCT01791777|fidelity
234219|NCT01791777|implementation science
234220|NCT01791777|competence
234221|NCT01791777|training
234222|NCT01791777|coaching
234223|NCT01791738|Total Hip Arthroplasty (THA)
234224|NCT01791738|Patient-Specific Instruments
234225|NCT01791738|Acetabular Cup Placement
234226|NCT01791738|Accuracy
234227|NCT01791699|atrial fibrillation
234228|NCT01791699|paroxysmal
234229|NCT01791699|persistent
234230|NCT01791699|ablation
234231|NCT01791699|pulmonary vein isolation
234232|NCT01791699|recurrence
234233|NCT01791686|Dense Deposit Disease
234234|NCT01791686|DDD
234235|NCT01791673|Glaucoma
234236|NCT01791673|Cyclocoagulation
234237|NCT01791673|HIFU - High Intensity Focused Ultrasound
234238|NCT01791673|Ciliary Body
234239|NCT01791647|Polycystic ovary syndrome
234240|NCT01791647|myoinositol
234241|NCT01791647|metformin
234242|NCT01791647|glucose-insulinemic metabolism
234243|NCT01791647|menstrual pattern
234244|NCT01791647|insulin-lowering therapies
234245|NCT01791621|Irritable Bowel Syndrome
234246|NCT01791621|Elimination diet
234247|NCT01791621|Food allergies
234248|NCT01791608|Child, Preschool
234249|NCT01791608|Dietary Zinc
234250|NCT01791608|Zinc sulfate
234251|NCT01791608|zinc-glycine chelate
234252|NCT01791595|Phase I
234253|NCT01791595|Cancer
234254|NCT01791595|Solid Tumours
234255|NCT01791595|Prostate Cancer
234256|NCT01791595|Gastric Cancer
234257|NCT01791595|Diffuse Large B Cell Lymphoma
234258|NCT01791595|Monocarboxylate Transporter 1 Inhibitor
234259|NCT01791595|lactate
234260|NCT01791556|HIV
234261|NCT01791556|AIDS
234262|NCT01791556|Kenya
234263|NCT01791556|viral load
234264|NCT01791556|Antiretroviral therapy
234265|NCT01791556|randomized clinical trial
234266|NCT01791556|ART monitoring
234267|NCT01791556|treatment failure
234268|NCT01791556|HIV resistance
234269|NCT01791543|ventricular tachycardia
234270|NCT01791543|ablation
234271|NCT01791543|ventricular arrhythmia
234272|NCT01791530|VAT
234273|NCT01791530|VAP
234274|NCT01791530|Transition from VAT to VAP
234275|NCT01791504|Abdominoplasty
234276|NCT01791478|-Metastatic breast cancer, PI3K inhibitor, Endocrine therapy
234277|NCT01791465|HIV
234278|NCT01791465|Diabetes
234279|NCT01791400|Metoclopramide
234280|NCT01791400|Sumatriptan
234281|NCT01791400|migraine
234282|NCT01791400|headache
234283|NCT01791387|Renal cell
234284|NCT01791387|Kidney
234285|NCT01791387|Cancer
234286|NCT01791387|Metastatic carcinoma
234287|NCT01791374|Advanced Solid Tumors
234288|NCT01791374|Advanced or Metastatic Gastric Cancer
234289|NCT01791374|Advanced or Metastatic GEJ
234290|NCT01791374|Gastric Cancer
234291|NCT01791361|Metastatic colorectal cancer
234292|NCT01791335|Glottis
234293|NCT01791335|Respiratory Muscles
234294|NCT01791335|Upper airway
234295|NCT01791335|Noninvasive ventilation
234296|NCT01791309|Vemurafenib
234297|NCT01791309|Panitumumab
234298|NCT01791309|V600E BRAF mutation
234299|NCT01791309|colon
234300|NCT01791309|12-221
234301|NCT01791296|sedation
234302|NCT01791296|sleep
234303|NCT01791296|delirium
234304|NCT01791296|critical illness
234305|NCT01791296|sub-syndromal delirium
234306|NCT01791296|intensive care
234307|NCT01791283|Left ventricular stroke volume
234308|NCT01791283|Arterial waveform analysis
234309|NCT01791283|Esofageal doppler
234310|NCT01791283|Ultrasound
234311|NCT01791283|Cardiac magnetic Imaging
234312|NCT01791283|Limits of agreement
234313|NCT01791270|Obstructive Sleep Apnea
234314|NCT01791270|Hypertension
234315|NCT01791270|β1 Subunit of Maxi-k+Channel
234316|NCT01791270|Cardiovascular Risk
234317|NCT01791257|delayed
234318|NCT01791257|cerebral
234319|NCT01791257|ischemia
234320|NCT01791257|microrna
234321|NCT01791257|cerebrospinal fluid
234322|NCT01791257|subarachnoid
234323|NCT01791257|hemorrhage
234324|NCT01791244|Multiple Sclerosis
234325|NCT01791244|Relapsing-Remitting
234326|NCT01791244|Rebif
234327|NCT01791244|RebiSmart
234328|NCT01791244|Patient support program
234329|NCT01791231|Healthy
234330|NCT01791231|Male
234331|NCT01791231|Canagliflozin (JNJ-28431754)
234332|NCT01791231|Radiolabeled 14C-canagliflozin
234333|NCT01791231|Absorption
234334|NCT01791231|Metabolism
234335|NCT01791231|Excretion
234336|NCT01791231|Radioactivity
234337|NCT01791218|Pulmonary vein isolation
234338|NCT01791218|Paroxysmal atrial fibrillation
234339|NCT01791218|Quality of life
234340|NCT01791192|Uveitis, Fingolimod, Phase II, Visual Acuity, Vitreous Haze, OCT
234341|NCT01791114|Insulin sensitivity
234342|NCT01791114|Diabetes Prevention
234343|NCT01791114|Obesity
234344|NCT01791114|Brown adipose tissue
234345|NCT01791101|Thrombocytopenia
234346|NCT01791101|Eltrombopag
234347|NCT01791075|DSAEK
234348|NCT01791075|Tan Endoglide
234349|NCT01791075|Endosaver/Endoserter
234350|NCT01791062|cartilage tissue engineering
234351|NCT01791062|hyaluronan
234352|NCT01791062|hyaluronic acid
234353|NCT01791049|Gram-positive
234354|NCT01791049|Infections
234355|NCT01791049|Bacterial infections
234356|NCT01791036|Adductor canal block
234357|NCT01791036|Femoral Nerve Block
234358|NCT01791023|Depression
234359|NCT01791023|Physical exercise
234360|NCT01791023|Stress
234361|NCT01791010|Breathing exercises
234362|NCT01791010|Aged
234363|NCT01790997|DLBS1033
234364|NCT01790997|Lumbrokinase
234365|NCT01790997|Acute ischemic stroke
234366|NCT01790997|Bleeding profile
234367|NCT01790997|Clinical outcome
234368|NCT01790997|Aspirin
234369|NCT01790997|Clopidogrel
234370|NCT01790984|Dietary extrinsic sugars, atherogenic lipoprotein phenotype, lipoprotein kinetics, fatty liver
234371|NCT01790971|Obstructive sleep apnea
234372|NCT01790971|Spinal morphine
234373|NCT01790932|Metastatic
234374|NCT01790932|Triple Negative
234375|NCT01790919|Depression, Adults
234376|NCT01790906|Chronic Heart Failure
234377|NCT01790906|Renal Sympathetic Denervation
234378|NCT01790893|Histoplasmosis
234379|NCT01790880|Aphasia
234380|NCT01790880|Stroke
234381|NCT01790880|Speech Rehabilitation
234382|NCT01789840|BPH
234383|NCT01789840|Prostate
234384|NCT01789840|Prostatic Hyperplasia
234385|NCT01789840|enlarged prostate
234386|NCT01789840|LUTS
234387|NCT01789840|urinary retention
234388|NCT01789814|Percutaneous Coronary Intervention
234389|NCT01789814|Platelet Aggregation Inhibitors
234390|NCT01789814|bivalirudin
234391|NCT01789762|Platelet transfusions
234392|NCT01789762|Pathogen reduction
234393|NCT01789762|Haemorrhagic episodes
234394|NCT01789736|Glaucoma
234395|NCT01789736|Ocular hypertension
234396|NCT01789736|AR-12286
234397|NCT01789736|Travoprost
234398|NCT01789710|smoking
234399|NCT01789710|homelessness
234400|NCT01789710|contingency management
234401|NCT01789684|cluster
234402|NCT01789684|genetic counseling
234403|NCT01789684|breast cancer
234404|NCT01789684|HBOC
234405|NCT01789684|provider intervention
234406|NCT01789671|Childhood Obesity
234407|NCT01789658|Oral Mucositis
234408|NCT01789658|Children
234409|NCT01789658|Cryotherapy
234410|NCT01789658|Hematopoietic Stem Cell Transplantation
234411|NCT01789645|Carpal tunnel
234412|NCT01789645|Physical therapy
234413|NCT01789645|Surgery
234414|NCT01789645|Efficacy
234415|NCT01790854|prasugrel
234416|NCT01790854|antiplatelet
234417|NCT01790854|Acute Coronary Syndrome
234418|NCT01790815|Acute Malnutrition
234419|NCT01790815|Mid Upper Arm Circumference
234420|NCT01790815|Screening
234421|NCT01790802|laser treatment, high risk, early AMD
234422|NCT01790776|urethrography
234423|NCT01790763|Burn
234424|NCT01790763|Second-degree
234425|NCT01790750|PDA
234426|NCT01790750|Echo
234427|NCT01790750|PES
234428|NCT01790750|Handheld echo system
234429|NCT01790737|myeloma, stem cell mobilization, autologous stem cell transplantation
234430|NCT01790737|induction treatment, maintenance treatment
234431|NCT01790711|Gut bacteria
234432|NCT01790711|Bacteria
234433|NCT01790711|Fecal transplant
234434|NCT01790711|Bacteriotherapy
234435|NCT01790698|Necrotizing fasciitis
234436|NCT01790698|Streptococcus pyogenes
234437|NCT01790698|Staphylococcus aureus
234438|NCT01790698|Immunopathogenesis
234439|NCT01790672|Antioxidants
234440|NCT01790672|Central Nervous System Agents
234441|NCT01790672|Wine
234442|NCT01790659|leishmaniasis
234443|NCT01790659|cutaneous leishmaniasis
234444|NCT01790659|Leishmania panamensis
234445|NCT01790659|L panamensis
234446|NCT01790659|Paromomycin
234447|NCT01790659|Paromomycin/Gentamicin
234448|NCT01790633|rapid test
234449|NCT01790633|screening
234450|NCT01790633|ELISA
234451|NCT01790633|hepatitis B virus
234452|NCT01790633|hepatitis C virus
234453|NCT01790633|human immunodeficiency virus
234454|NCT01790633|access to care
234455|NCT01790620|Severe sepsis
234456|NCT01790620|Septic shock
234457|NCT01790620|Acute renal failure
234458|NCT01790620|Acute kidney injury
234459|NCT01790620|Continuous renal replacement therapies CRRT
234460|NCT01790607|Adult healthy subjects will be matched with individual subjects by age (± 5 years, gender, and BMI (± 15%)
234461|NCT01790594|transplantation
234462|NCT01790594|kidney
234463|NCT01790594|pancreas
234464|NCT01790594|immunosuppression
234465|NCT01790594|calcineurin inhibitor (CNI)
234466|NCT01790581|Chronic Ankle Instability
234467|NCT01790555|Postsurgical
234468|NCT01790555|Pain
234469|NCT01790555|THC
234470|NCT01790555|Sensitization
234471|NCT01790542|Iron
234472|NCT01790542|Intestinal inflammation
234473|NCT01790542|ROS
234474|NCT01790516|Head and neck cancer
234475|NCT01790516|genetic testing
234476|NCT01790516|cisplatin
234477|NCT01790516|erbitux
234478|NCT01790516|radiation therapy
234479|NCT01790503|glioblastoma
234480|NCT01790503|GBM
234481|NCT01790477|Tonsillectomy
234482|NCT01790477|Acupuncture
234483|NCT01790464|Glossopharyngeal nerve block
234484|NCT01790464|Airway anesthesia
234485|NCT01790464|Awake intubation
234486|NCT01790451|focal therapy
234487|NCT01790451|irreversible electroporation
234488|NCT01790451|prostate cancer
234489|NCT01790412|pregnancy, exercise, gestational diabetes
234490|NCT01790399|SENTINEL NODE
234491|NCT01790386|hemostasis
234492|NCT01790386|thromboelastography
234493|NCT01790386|coagulation
234494|NCT01790386|TEG
234495|NCT01790373|Suubi
234496|NCT01790373|Adolescents
234497|NCT01790373|Poverty
234498|NCT01790373|Economic empowerment interventions
234499|NCT01790373|Adherence to HIV antiretroviral therapy
234500|NCT01790373|Wisepill
234501|NCT01790373|HIV/AIDS infected Children
234502|NCT01790373|Medical event monitoring system
234503|NCT01790373|Uganda
234504|NCT01790360|MSM
234505|NCT01790360|HIV
234506|NCT01790360|Substance Abuse
234507|NCT01790360|Sexual Behavior
234508|NCT01790347|Exercise
234509|NCT01790347|Aerobic
234510|NCT01790347|Resistance training
234511|NCT01790347|Pregnancy
234512|NCT01790347|Maternal weight gain
234513|NCT01790347|IOM recommendations
234514|NCT01790295|Myelofibrosis
234515|NCT01790295|Stem cell transplant
234516|NCT01790295|Ruxolitinib
234517|NCT01790282|luteal support
234518|NCT01790282|high responder
234519|NCT01790282|ICSI
234520|NCT01790282|ivf
234521|NCT01790282|cycle outcome
234522|NCT01790269|Relapsing-Remitting Multiple Sclerosis
234523|NCT01790269|NK cells
234524|NCT01790269|Fingolimod
234525|NCT01790204|mutant p53
234526|NCT01790204|watercress
234527|NCT01790204|Phenethyl isothyocyanate
234528|NCT01790204|oral cells of smokers
234529|NCT01790191|Children
234530|NCT01790191|Eating behaviour
234531|NCT01790191|Intake
234532|NCT01790191|Liking
234533|NCT01790191|Conditioned liking
234534|NCT01790191|Flavour
234535|NCT01790191|Nutrient
234536|NCT01790191|Vegetable
234537|NCT01790165|Onychomycosis
234538|NCT01790165|Open Label
234539|NCT01790165|PK
234540|NCT01790126|Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
234541|NCT01790074|cervicogenic headache
234542|NCT01790074|trigger point
234543|NCT01790074|sternocleidomastoid
234544|NCT01790074|manual therapy
234545|NCT01790061|Gut bacteria
234546|NCT01790061|Gut flora
234547|NCT01790061|Bacteriotherapy
234548|NCT01790061|Fecal Microbiota Transplantation
234549|NCT01790061|Inflammatory bowel disease
234550|NCT01790061|Ulcerative colitis
234551|NCT01790048|MAM
234552|NCT01790009|ADME
234553|NCT01790009|Flavanols
234554|NCT01790009|Age
234555|NCT01790009|Pharmacokinetics
234556|NCT01789996|6 minute walk test
234557|NCT01789996|idiopathic pulmonary fibrosis
234558|NCT01789996|pulmonary arterial hypertension
234559|NCT01789996|interstitial lung disease
234560|NCT01789983|Physical Activity
234561|NCT01789983|Chemotherapy
234562|NCT01789983|Elderly
234563|NCT01789983|Geriatric
234564|NCT01789983|Walking
234565|NCT01789983|Geriatric Assessment
234566|NCT01789983|Geriatric Oncology
234567|NCT01789970|chronic low back pain
234568|NCT01789970|hydrocodone bitartrate
234569|NCT01789970|opioids
234570|NCT01789944|Childhood Obesity
234571|NCT01789918|Hypertension
234572|NCT01789918|Blood pressure
234573|NCT01789918|Renal denervation
234574|NCT01789905|Tygacil
234575|NCT01789905|Tigecycline
234576|NCT01789905|Post marketing surveillance
234577|NCT01789905|Japanese
234578|NCT01789905|Infection
234579|NCT01789879|Levonorgestrel
234580|NCT01789879|Efavirenz
234581|NCT01789879|Nevirapine
234582|NCT01789879|Pharmacokinetics
234583|NCT01789866|DHA
234584|NCT01789866|lutein
234585|NCT01789866|cognitive development
234586|NCT01789866|fMRI
234587|NCT01789853|stroke, rehabilitation, gait training
234588|NCT01789606|Self-selection and actual use/compliance trial.
234715|NCT01789138|Antiretroviral Therapy
234589|NCT01789580|Experimental study, moderators, online gambling,
234590|NCT01789580|problem gambling prevention
234591|NCT01789554|Out of hospital cardiac arrest
234592|NCT01789554|Cardiopulmonary resuscitation
234593|NCT01789554|Bystander CPR
234594|NCT01789554|Mobile phone positioning system
234595|NCT01789528|Phase I,
234596|NCT01789528|open label,
234597|NCT01789528|CAZ-AVI,
234598|NCT01789528|CXL,
234599|NCT01789528|healthy volunteers,
234600|NCT01789528|intestinal flora.
234601|NCT01789502|self-expandable metal stent; plastic stent
234602|NCT01789476|pain
234603|NCT01789476|acute pain
234604|NCT01789476|kappa agonis
234605|NCT01789476|opioid analgesia
234606|NCT01789476|bunionectomy
234607|NCT01789476|peripheral nervous system agents
234608|NCT01789476|physiological effects of drugs
234609|NCT01789476|surgery
234610|NCT01789476|post-operative
234611|NCT01789476|post-operative complications
234612|NCT01789450|sensitivity
234613|NCT01789450|section of periareolar dermis
234614|NCT01789450|breast reduction
234615|NCT01789437|retinal vein occlusion
234616|NCT01789437|systemic hypertension
234617|NCT01789437|arteriolar diameter
234618|NCT01789385|Deep brain stimulation
234619|NCT01789385|Parkinson
234620|NCT01789372|paroxysmal atrial fibrillation
234621|NCT01789372|yoga
234622|NCT01789372|quality of life
234623|NCT01789372|blood pressure
234624|NCT01789372|heart rate
234625|NCT01789372|heart rate variability
234626|NCT01789359|anthocyanin
234627|NCT01789359|bioavailability
234628|NCT01789359|urine
234629|NCT01789359|long-term
234630|NCT01789346|Scar
234631|NCT01789346|Scars
234632|NCT01789346|Surgical Scar
234633|NCT01789346|Surgical Scars
234634|NCT01789346|Cicatrix
234635|NCT01789346|Hypertrophic Cicatrix
234636|NCT01789346|Keloid
234637|NCT01789346|Hypertrophic Scar
234638|NCT01789346|Surgical Incision
234639|NCT01789346|Scarring
234640|NCT01789346|Abdominoplasty
234641|NCT01789346|Tummy Tuck
234642|NCT01789346|Augmentation Mammoplasty
234643|NCT01789346|Breast Augmentation
234644|NCT01789346|Thyroidectomy
234645|NCT01789333|Keratoconus
234646|NCT01789333|Ectasia
234647|NCT01789333|UVA light
234648|NCT01789333|riboflavin
234649|NCT01789333|post-LASIK
234650|NCT01789333|irregular astigmatism
234651|NCT01789320|uveitis
234652|NCT01789320|intermediate uveitis
234653|NCT01789320|posterior uveitis
234654|NCT01789320|panuveitis
234655|NCT01789320|noninfectious uveitis
234656|NCT01789320|microneedle
234657|NCT01789320|suprachoroidal space
234658|NCT01789320|SCS
234659|NCT01789320|inflammation
234660|NCT01789320|ocular inflammatory conditions
234661|NCT01789320|triamcinolone acetonide
234662|NCT01789320|TA
234663|NCT01789320|Triesence
234664|NCT01789320|injection
234665|NCT01789320|IVT
234666|NCT01789320|intravitreal
234667|NCT01789320|corticosteroid
234668|NCT01789320|sympathetic ophthalmia
234669|NCT01789320|temporal arteritis
234670|NCT01789320|vitreous haze
234671|NCT01789294|lymphoid nodular hyperplasia
234672|NCT01789294|food allergy
234673|NCT01789281|Neoplasms, Carcinoid tumor, Neuroendocrine tumor
234674|NCT01789268|acute,adaptive cellular immune phenotypes,infants,Lymphocyte,premature,respiratory viral infections
234675|NCT01789229|Breast cancer
234676|NCT01789229|Ovarian cancer
234677|NCT01789229|Endometrium carcinoma
234678|NCT01789229|Cervix carcinoma,
234679|NCT01789229|Mamma carcinoma,
234680|NCT01789229|Prostata carcinoma
234681|NCT01789229|Colon carcinoma
234682|NCT01789229|Rectal carcinoma
234683|NCT01789229|Bronchus carcinoma
234684|NCT01789229|NSCLC (non small cell lung cancer) & SCLC (small cell lung cancer)
234685|NCT01789229|Prostate carcinoma
234686|NCT01789216|Pilon fractures
234687|NCT01789216|Calcaneus fractures
234688|NCT01789216|Acute pain
234689|NCT01789216|Chronic pain
234690|NCT01789216|Isolated
234691|NCT01789216|unilateral
234692|NCT01789216|Grade I
234693|NCT01789216|Grade II
234694|NCT01789216|open
234695|NCT01789216|closed
234696|NCT01789203|BK infection
234697|NCT01789203|BK viremia
234698|NCT01789203|BK nephropathy
234699|NCT01789203|polyomavirus
234700|NCT01789203|fluoroquinolone
234701|NCT01789203|ciprofloxacin
234702|NCT01789190|Honeymoon
234703|NCT01789190|Type 1 diabetes
234704|NCT01789177|Spirometry
234705|NCT01789177|Postoperative Care
234706|NCT01789164|TBI
234707|NCT01789164|fNIRS
234708|NCT01789164|hypercapnea
234709|NCT01789164|Cerebrovascular reactivity
234710|NCT01789151|arthritis
234711|NCT01789151|nuclear imaging
234712|NCT01789151|rheumatoid
234713|NCT01789151|ankylosing spondylitis
234714|NCT01789151|glucosamine
234716|NCT01789138|Adherence
234717|NCT01789138|Intervention
234718|NCT01789125|anxiety
234719|NCT01789125|stress
234720|NCT01789125|smoking
234721|NCT01789125|cessation
234722|NCT01789099|Lung cancer
234723|NCT01789099|Peptide vaccine
234724|NCT01789073|Postoperative
234725|NCT01789073|Complications
234726|NCT01789073|Elective
234727|NCT01789073|Surgery
234728|NCT01789073|GI surgery
234729|NCT01789073|Immunonutrition
234730|NCT01789073|Immune-enhancing
234731|NCT01789073|Immune-modulating
234732|NCT01789073|Nutrition
234733|NCT01789073|Pancreatic cancer
234734|NCT01789073|Postoperative complications and length of hospital stay after major gastrointestinal (GI) elective surgery.
234735|NCT01789047|Parkinson's disease
234736|NCT01789047|dyskinesia
234737|NCT01789047|Indonesia
234738|NCT01789047|amantadine
234739|NCT01789021|blood glucose monitoring systems
234740|NCT01789021|ISO 15197
234741|NCT01789021|system accuracy
234742|NCT01789008|Transient elastography
234743|NCT01789008|Alcoholic liver disease
234744|NCT01789008|liver fibrosis
234745|NCT01788982|Thyroid Cancer
234746|NCT01788982|Medullary thyroid cancer (MTC)
234747|NCT01788982|Differentiated thyroid cancer (DTC)
234748|NCT01788969|Gait training
234749|NCT01788969|Lexapro
234750|NCT01788969|Tizanidine
234751|NCT01788956|venous oximeter
234752|NCT01788956|CO-Oximeter
234753|NCT01788956|ICU Patients
234754|NCT01788956|Sepsis
234755|NCT01788956|non-invasive device
234756|NCT01788943|positron emission tomography
234757|NCT01788943|nicotine receptor
234758|NCT01788917|n-3 LC-PUFA, vegetarians, fatty acids, blood lipids
234759|NCT01788904|Acute mesenteric ischemia
234760|NCT01788904|Percutaneous endovascular revascularization
234761|NCT01788904|Intestinal plasma fatty acid binding protein (i-FABP)
234762|NCT01788904|Bowel necrosis
234763|NCT01788891|longitudinal observational cohort study
234764|NCT01788891|multicenter
234765|NCT01788891|pediatrics
234766|NCT01788891|Asian
234767|NCT01788891|treatment failure
234768|NCT01788891|renal status
234769|NCT01788891|toxicities
234770|NCT01788891|therapeutic drug monitoring (TDM)
234771|NCT01788891|drug levels in blood and hair
234772|NCT01788878|socio-professional future
234773|NCT01788865|covered Metal stent
234774|NCT01788865|ureteral obstruction
234775|NCT01788852|HPV
234776|NCT01788852|HIV
234777|NCT01788852|cervical/anal dysplasia
234778|NCT01788852|intraepithelial neoplasia
234779|NCT01788852|E6/E7 biomarker
234780|NCT01788852|perinatally HIV-infected adolescents
234781|NCT01788852|behaviorally HIV-infected adolescents
234782|NCT01788852|anal and pap smear
234783|NCT01788839|Sexual and Reproductive Health
234784|NCT01788839|premenopausal
234785|NCT01788839|postmenopausal
234786|NCT01788839|12-249
234787|NCT01788839|Fertility
234788|NCT01788826|Ventral hernia
234789|NCT01788826|surgical meshes
234790|NCT01788826|polypropylenes
234791|NCT01788813|Repeat Dose Safety
234792|NCT01788813|Allergic Asthma
234793|NCT01788813|Effect on Allergen Reactivity
234794|NCT01788813|Allergic Rhinitis
234795|NCT01788813|TLR7 Agonist
234796|NCT01788813|Pharmacodynamics
234797|NCT01788800|Panic disorder
234798|NCT01788800|Physical activity
234799|NCT01788787|Cancer Prevention
234800|NCT01788787|Tobacco Use Cessation
234801|NCT01788787|Ask Advise Connect
234802|NCT01788787|AAC
234803|NCT01788787|Smoking Cessation Treatment
234804|NCT01788787|Texas Quitline
234805|NCT01788787|Saliva sample
234806|NCT01788787|Telephone Counseling
234807|NCT01788787|Nicotine replacement
234808|NCT01788787|Interviews
234809|NCT01788774|Pharmacokinetics
234810|NCT01788774|Safety
234811|NCT01788774|Risperidone ISM®
234812|NCT01788774|Intramuscular
234813|NCT01788774|Schizophrenia
234814|NCT01788761|Probiotics
234815|NCT01788761|Feeding Tolerance
234816|NCT01788761|Extremely Low Birthweight Infants
234817|NCT01788748|fractional
234818|NCT01788748|bipolar
234819|NCT01788748|radiofrequency
234820|NCT01788748|striae
234821|NCT01788748|infrared
234822|NCT01788748|combined
234823|NCT01788735|unexplained infertility
234824|NCT01788735|asthma
234825|NCT01788735|allergy
234826|NCT01788709|colonoscopy
234827|NCT01788709|preparation
234828|NCT01788696|Parkinsonism
234829|NCT01788696|Idiopathic Parkinson Disease
234830|NCT01788683|Rotator Cuff
234831|NCT01788683|Rotator Cuff Tear
234832|NCT01788683|Supraspinatus Tear
234833|NCT01788670|Antioxidants, Central Nervous System Agents
234834|NCT01788657|Depression
234835|NCT01788657|Internet
234836|NCT01788657|Cognitive Behavior Therapy
234837|NCT01788644|Child adiposity
234838|NCT01788644|Infancy
234839|NCT01788644|Motor activity
234840|NCT01788644|Feeding behavior
234841|NCT01788644|Sleep
234842|NCT01788644|Stress, Physiological
234843|NCT01788618|Cognitive functions
234844|NCT01788618|Quality of life
234845|NCT01788618|Cancer
234846|NCT01788605|hematologic malignancies
234847|NCT01788605|hematopoietic stem cell transplantation
234848|NCT01788605|ramosetron
234849|NCT01788605|emesis
234850|NCT01788592|coronary artery disease
234851|NCT01788592|drug eluting stent
234852|NCT01788579|Intimate Partner Violence (IPV)
234853|NCT01788579|Drug Abuse
234854|NCT01788579|Criminal Justice
234855|NCT01788553|remission
234856|NCT01788553|generalized anxiety disorder
234857|NCT01788540|Recurrent miscarriage
234858|NCT01788540|Implantation failure
234859|NCT01788540|Intralipid
234860|NCT01788540|ICSI / IVF failure
234861|NCT01788527|Diabetes
234862|NCT01788527|Type 1
234863|NCT01788527|CGM
234864|NCT01788527|Continuous Glucose Monitor
234865|NCT01788527|HGM
234866|NCT01788527|HbA1c
234867|NCT01788488|procalcitonin
234868|NCT01788488|antimicrobial stewardship
234869|NCT01788488|pneumonia
234870|NCT01788475|Diabetic Macular Edema
234871|NCT01788475|DME
234872|NCT01788475|Pars Plana Vitrectomy
234873|NCT01788462|Tesamorelin
234874|NCT01788462|Egrifta
234875|NCT01788462|HIV
234876|NCT01788462|Lipodystrophy
234877|NCT01788462|Sleep Apnea
234878|NCT01788449|Antibiotic Bacterial Resistance
234879|NCT01788436|Schizophrenia
234880|NCT01788436|Young healthy volunteers
234881|NCT01788436|Elderly healthy volunteers
234882|NCT01788436|Learning performance
234883|NCT01788423|presbycusis
234884|NCT01788423|hearing aids
234885|NCT01788410|Cryoablation
234886|NCT01788410|Nerves
234887|NCT01788410|Facet joint
234888|NCT01788410|Pain
234889|NCT01788410|Neuralgia
234890|NCT01788410|Neuropathy
234891|NCT01788410|Image-guided
234892|NCT01788397|physical disabilities
234893|NCT01788397|rehabilitation
234894|NCT01788384|acne
234895|NCT01788384|Clindamycin Phosphate/Benzoyl Peroxide
234896|NCT01788384|Acanya
234897|NCT01788384|Mild to severe acne vulgaris
234898|NCT01788358|Drug combination
234899|NCT01788358|Nifedipine GITS
234900|NCT01788358|Candesartan Cilexetil
234901|NCT01788358|Hypertension
234902|NCT01788358|Combination therapy
234903|NCT01788345|non-invasion ventilation
234904|NCT01788345|Boussignac
234905|NCT01788332|NSCLC
234906|NCT01788332|non-small cell
234907|NCT01788332|lung cancer
234908|NCT01788319|laser trabeculoplasty
234909|NCT01788319|glaucoma
234910|NCT01788306|Elevated risk
234911|NCT01788306|opioid overdose
234912|NCT01788293|Fluid management
234913|NCT01788293|Pleth Variability Index (PVI)
234914|NCT01788293|monitoring
234915|NCT01788293|high-risk surgery
234916|NCT01788267|Cystic Fibrosis
234917|NCT01788267|High-Resolution peripheral Quantitative Computed Tomography
234918|NCT01788267|Bone Mass Density
234919|NCT01788254|pharmacokinetic/genetic
234920|NCT01788254|Cyp450 polymorphisms
234921|NCT01788254|Noninvasive functional characterization of liver heart and kidneys using MRI
234922|NCT01788241|coronary artery disease
234923|NCT01788241|Atherosclerosis
234924|NCT01788241|Coronary Stenosis
234925|NCT01788241|Cardiovascular Diseases
234926|NCT01788241|Non-significant coronary artery disease
234927|NCT01788241|Mild Stenosis
234928|NCT01788241|Vascular Irregularities
234929|NCT01788241|Psychosocial factors
234930|NCT01788241|Personality
234931|NCT01788241|Type D personality
234932|NCT01788241|Hostility
234933|NCT01788241|Depression
234934|NCT01788241|Anxiety
234935|NCT01788241|Fatigue
234936|NCT01788241|Social Support
234937|NCT01788241|Socioeconomic Status
234938|NCT01788241|Patient Reported Outcomes
234939|NCT01788241|Patient Perceived Symptoms
234940|NCT01788241|Health Status
234941|NCT01788241|Quality of Life
234942|NCT01788241|Chest pain
234943|NCT01788241|Cardiac risk factors
234944|NCT01788241|Metabolic Syndrome
234945|NCT01788241|BMI
234946|NCT01788241|Obesity
234947|NCT01788241|Waist Circumference
234948|NCT01788241|Lifestyle
234949|NCT01788241|Smoking
234950|NCT01788241|Alcohol use
234951|NCT01788241|Activity
234952|NCT01788241|Hypertension
234953|NCT01788241|Diabetes
234954|NCT01788241|Familial Cardiovascular Disease
234955|NCT01788241|Coronary angiography
234956|NCT01788241|Computed Tomography
234957|NCT01788228|Vaccine
234958|NCT01788228|Occupational exposure
234959|NCT01788228|Influenza
234960|NCT01788228|H5N1
234961|NCT01788215|Polycystic Ovarian Syndrome
234962|NCT01788215|Irregular Menstrual Cycles
234963|NCT01788215|Androgen Excess in Women
234964|NCT01788202|cocaine and general anesthesia
234965|NCT01788189|Lymphoma
234966|NCT01788189|CD20
234967|NCT01788189|Relapse
234968|NCT01788189|Lenalidomide
234969|NCT01788176|Complex Regional Pain Syndromes
234970|NCT01788176|drug therapy
234971|NCT01788176|zoledronic acid
234972|NCT01788163|EGFR
234973|NCT01788163|aNSCLC
234974|NCT01788163|mutation status
234975|NCT01788163|diagnostic study
234976|NCT01788163|Russia
234977|NCT01788163|China
234978|NCT01788163|Asia
234979|NCT01788137|T-cell lymphoma,DFS,OS
234980|NCT01788124|Speculum
234981|NCT01788124|Metal
234982|NCT01788124|Plastic
234983|NCT01788124|Visual Analoge Scale
234984|NCT01788124|Discomfort
234985|NCT01788085|GERD
234986|NCT01788072|Autism Spectrum Disorders
234987|NCT01788072|Oxytocin
234988|NCT01788072|Adults
234989|NCT01788059|nonunion
234990|NCT01788059|mesenchymal stem cell
234991|NCT01788059|long bone
234992|NCT01788046|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
234993|NCT01788007|Actinic Keratosis
234994|NCT01788007|Imiquimod Topical Cream 3.75%
234995|NCT01788007|Zyclara® (imiquimod) Topical Cream 3.75%
234996|NCT01787968|Congenital transmission
234997|NCT01787968|Trypanosoma cruzi
234998|NCT01787968|Chagas disease
234999|NCT01787955|Pylorus preserving pancreaticoduodenectomy(PPPD), Delayed gastric emptying syndrome(DGE), Braun anastomosis
235000|NCT01787942|Lipid thickness
235001|NCT01787942|Blepharoplasty
235002|NCT01787942|Tear break up time
235003|NCT01787942|Corneal staining
235004|NCT01787916|type 1 diabetes
235005|NCT01787916|overweight
235006|NCT01787916|insulin
235007|NCT01787916|liraglutide
235008|NCT01787903|Type 1 diabetes mellitus
235009|NCT01787903|Hypoglycemia unawareness
235010|NCT01787903|Real-time continuous glucose monitoring
235011|NCT01787903|Glucose control
235012|NCT01787877|Cerebrovascular Accident, Inflammatory biomarkers
235013|NCT01787864|Barrett's Esophagus
235014|NCT01787864|Intestinal metaplasia
235015|NCT01787864|Intramucosal Adenocarcinoma
235016|NCT01787864|Gastric Cardia
235017|NCT01787864|High Cardia Dysplasia
235018|NCT01787864|Radiofrequency ablation (RFA)
235019|NCT01787851|Heart failure
235020|NCT01787851|Anaplerosis
235021|NCT01787851|Medium-chain fatty acid
235022|NCT01787838|Pneumococcal vaccination rates, ambulatory settings
235023|NCT01787799|Drug-eluting stents
235024|NCT01787786|Crohn's Disease
235025|NCT01787786|Ulcerative Colitis
235026|NCT01787786|Optimal Use of infliximab
235027|NCT01787773|Inferior Vena Cava Filter
235028|NCT01787773|Vena Cava Filters
235029|NCT01787747|Pharmacokinetics
235030|NCT01787747|Healthy Volunteers
235031|NCT01787747|dextromethorphan with quinidine
235032|NCT01787747|deuterated dextromethorphan
235033|NCT01787721|Gait
235034|NCT01787721|Ankle joint
235035|NCT01787721|Manipulation, Chiropractic
235036|NCT01787708|Vitiligo
235037|NCT01787708|red
235038|NCT01787708|laser
235039|NCT01787708|light
235040|NCT01787695|Vitiligo
235041|NCT01787695|UVA1
235042|NCT01787695|Phototherapy
235043|NCT01787682|CHF
235044|NCT01787682|Protein digestion
235045|NCT01787682|Fat digestion
235046|NCT01787682|Gut function
235047|NCT01787682|Glucose absorption
235048|NCT01787682|Muscle function
235049|NCT01787669|diabetic macular oedema
235050|NCT01787669|diabetic macular edema
235051|NCT01787669|diabetic retinopathy
235052|NCT01787669|dexamethasone
235053|NCT01787669|Ozurdex
235054|NCT01787669|Avastin
235055|NCT01787669|bevacizumab
235056|NCT01787669|DME
235057|NCT01787669|DMO
235058|NCT01787643|height-adjustable desk
235059|NCT01787643|office workers
235060|NCT01787643|sitting occupations
235061|NCT01787643|energy expenditure
235062|NCT01787643|BMI
235063|NCT01787643|Weight
235064|NCT01787643|Lower fat diet
235065|NCT01787630|Prostatic cancer
235066|NCT01787630|Radiotherapy
235067|NCT01787630|Hyaluronic acid
235068|NCT01787617|Exercise Training
235069|NCT01787617|Strength Training
235070|NCT01787617|African American Men
235071|NCT01787617|Insulin Resistance
235072|NCT01787604|Valve-sparing
235073|NCT01787604|Valve repair
235074|NCT01787591|Vitamin E
235075|NCT01787591|Metabolic syndrome
235076|NCT01787591|Liver disease
235077|NCT01787591|Non-alcoholic liver steatohepatitis
235078|NCT01787591|Fatty liver
235079|NCT01787591|Dairy consumption
235080|NCT01787578|X-linked adrenoleukodystrophy
235081|NCT01787578|adrenomyeloneuropathy
235082|NCT01787578|sobetirome
235083|NCT01787578|thyroid
235084|NCT01787578|thyromimetic
235085|NCT01787565|non-interventional
235086|NCT01787565|clinical
235087|NCT01787565|investigation
235088|NCT01787565|low
235089|NCT01787565|back
235090|NCT01787565|pain
235091|NCT01787565|painPREMIER
235092|NCT01787552|Dose escalation
235093|NCT01787552|Maximum Tolerated Dose
235094|NCT01787552|MTD
235095|NCT01787552|Safety Expansion
235096|NCT01787552|Safety
235097|NCT01787552|Efficacy
235098|NCT01787552|Myelofibrosis
235099|NCT01787552|Post-polycythemia vera myelofbrosis (Post PV-PMF)
235100|NCT01787552|Post essential thrombocythemia myelofibrosis (Post ET-MF)
235101|NCT01787552|Primary myelofibrosis (PMF)
235102|NCT01787552|Intermediate risk myelofibrosis
235103|NCT01787552|High risk myelofibrosis
235104|NCT01787552|Combination Treatment
235105|NCT01787552|Hedgehog Signaling Pathway
235106|NCT01787552|Smoothened inhibitor
235107|NCT01787552|JAK inhibitor
235108|NCT01787539|gastric cancer
235109|NCT01787539|perioperative chemotherapy
235110|NCT01787539|combined modality therapy
235111|NCT01787539|gastrectomy
235112|NCT01787526|iron depletion
235113|NCT01787526|donor safety
235114|NCT01787526|blood donation
235115|NCT01787526|transfusion medicine
235116|NCT01787526|iron deficiency
235117|NCT01787526|intravenous iron
235118|NCT01787526|fatigue
235119|NCT01787526|restless legs syndrome
235120|NCT01787526|anemia
235121|NCT01787500|Advanced Cancers
235122|NCT01787500|Advanced Solid Cancers
235123|NCT01787500|BRAF V600 Mutant Advanced Solid Malignancies
235124|NCT01787500|Metastatic
235125|NCT01787500|Unresectable
235126|NCT01787500|BRAF mutant, KRAS wild type colorectal cancer
235127|NCT01787500|BRAF mutant, KRAS wild type solid tumor cancers
235128|NCT01787500|Vemurafenib
235129|NCT01787500|PLX4032
235130|NCT01787500|RO5185426
235131|NCT01787500|Cetuximab
235132|NCT01787500|C225
235133|NCT01787500|Erbitux
235134|NCT01787500|IMC-C225
235135|NCT01787500|Irinotecan
235136|NCT01787500|CPT-11
235137|NCT01787500|Camptosar
235138|NCT01787487|Leukemia
235139|NCT01787487|Myelofibrosis
235140|NCT01787487|Myelodysplastic syndrome
235141|NCT01787487|Myeloproliferative neoplasm
235142|NCT01787487|Ruxolitinib
235143|NCT01787487|RUX
235144|NCT01787487|Jakafi
235145|NCT01787487|INCB018424
235146|NCT01787487|INC424
235147|NCT01787487|Azacitidine
235148|NCT01787487|AZA
235149|NCT01787487|5-Azacitidine
235150|NCT01787487|5-aza
235151|NCT01787487|Vidaza
235152|NCT01787487|5-AZC
235153|NCT01787487|AZA-CR
235154|NCT01787487|Ladakamycin
235155|NCT01787487|NSC-102816
235156|NCT01787474|Leukemia
235157|NCT01787474|Acute Myeloid Leukemia
235158|NCT01787474|Blood And Marrow Transplantation
235159|NCT01787474|Natural killer cells
235160|NCT01787474|NK
235161|NCT01787474|mbIL21-expanded haploidentical NK cells
235162|NCT01787474|G-CSF
235163|NCT01787474|Filgrastim
235164|NCT01787474|Neupogen
235165|NCT01787474|Fludarabine monophosphate
235166|NCT01787474|Fludarabine Phosphate
235167|NCT01787474|Fludara
235168|NCT01787474|Cytarabine
235169|NCT01787474|Ara-C
235170|NCT01787474|Cytosar
235171|NCT01787474|DepoCyt
235172|NCT01787474|Cytosine arabinosine hydrochloride
235173|NCT01787461|Trial assessing effects of an oral dietary supplement on overall facial appearance among healthy women with photodamaged skin.
235174|NCT01787448|repeat insult patch test
235175|NCT01787435|Asthma,
235176|NCT01787435|acid-suppressing drugs,
235177|NCT01787435|pregnancy,
235178|NCT01787435|epidemiology
235179|NCT01787422|Telemedicine
235180|NCT01787383|Actinic Keratosis
235181|NCT01787383|Ingenol mebutate gel
235182|NCT01787370|coronary artery disease, endothelial dysfunction
235183|NCT01787357|Healthy
235184|NCT01787357|Canagliflozin (JNJ-28431754)
235185|NCT01787357|Pharmacokinetics
235186|NCT01787357|Moxifloxacin
235187|NCT01787357|Electrocardiogram Parameters
235188|NCT01787357|QT/QTc Interval
235189|NCT01787357|Therapeutic dose
235190|NCT01787357|Supra-Therapeutic dose
235191|NCT01787344|Other Infantile Cerebral Palsy
235192|NCT01787331|biochemically relapsed
235193|NCT01787331|hormone sensitive
235194|NCT01787331|non-metastatic
235195|NCT01787331|prostate cancer
235196|NCT01787331|after prior definitive local therapy
235197|NCT01787331|PSA
235198|NCT01787331|Hedgehog-signaling pathway
235199|NCT01787305|microbiome
235200|NCT01787305|commensals
235201|NCT01787305|autoantibodies
235202|NCT01787305|autoreactive T cells
235203|NCT01787292|Exercise
235204|NCT01787292|Magnetic Resonance Imaging
235205|NCT01787292|Transcranial Magnetic Stimulation
235206|NCT01787292|Aging
235207|NCT01787214|glucose variability
235208|NCT01787214|glycemia
235209|NCT01787214|type-2 diabetes
235210|NCT01787175|Medication Therapy Management
235211|NCT01787175|Clinical Decision Support Systems
235212|NCT01787175|Medical Informatics
235213|NCT01787175|Patient Care Management
235340|NCT01786564|diabetes
235214|NCT01787175|United States Department of Veterans Affairs
235215|NCT01787162|Myeloproliferative disorders
235216|NCT01787162|pulmonary hypertension
235217|NCT01787162|pulmonary vascular diseases
235218|NCT01787149|ENIA11
235219|NCT01787149|DMARDs
235220|NCT01787149|RA
235221|NCT01787149|TNF
235222|NCT01787110|Acute coronary syndrome
235223|NCT01787110|Acute myocardial infarction
235224|NCT01787110|Non ST-segment Myocardial Infarction
235225|NCT01787110|ST-segment Myocardial Infarction
235226|NCT01787110|STEMI
235227|NCT01787110|NSTEMI
235228|NCT01787110|Oxygen
235229|NCT01787110|Unstable angina
235230|NCT01787110|Randomised trial
235231|NCT01787110|CMR
235232|NCT01787110|Mortality
235233|NCT01787110|RCRT
235234|NCT01787110|RRCT
235235|NCT01787084|Aortic Stenosis
235236|NCT01787084|TAVR
235237|NCT01787071|fluids
235238|NCT01787071|crtically ill patients
235239|NCT01787071|functional hemodynamics
235240|NCT01787071|cvp
235241|NCT01787058|WASH
235242|NCT01787058|schoolchildren
235243|NCT01787058|absenteeism
235244|NCT01787045|SEPSIS
235245|NCT01787006|non resectable
235246|NCT01787006|locally advanced
235247|NCT01787006|Cetuximab
235248|NCT01787006|radiation
235249|NCT01786967|overactive bladder
235250|NCT01786967|urge urinary incontinence
235251|NCT01786967|pharmacogenetics
235252|NCT01786954|vitreoretinal surgery
235253|NCT01786954|intraocular pressure
235254|NCT01786954|applanation
235255|NCT01786954|rebound
235256|NCT01786954|tonometry
235257|NCT01786941|Branched-chain Amino Acids
235258|NCT01786941|Insulin Sensitivity
235259|NCT01786941|Exercise
235260|NCT01786941|Leucine
235261|NCT01786928|chronic obstructive pulmonary disease
235262|NCT01786928|exacerbation
235263|NCT01786928|resistance training
235264|NCT01786928|muscle force
235265|NCT01786902|growth hormone
235266|NCT01786876|AME
235267|NCT01786876|Radiolabelled
235268|NCT01786850|Locally advanced Pancreatic Cancer
235269|NCT01786850|Noninvasive treatment
235270|NCT01786850|High Intensity focused ultrasound
235271|NCT01786850|Magnetic Resonance
235272|NCT01786837|constipation
235273|NCT01786837|gastric emptying
235274|NCT01786824|contrast induced nephropathy
235275|NCT01786824|hydration strategy
235276|NCT01786824|L-carnitine
235277|NCT01786798|Transvaginal sonography
235278|NCT01786798|Endometrial thickness
235279|NCT01786798|Endometrial pattern
235280|NCT01786798|Abnormal uterine bleeding
235281|NCT01786798|Endometrial hyperplasia
235282|NCT01786798|Endometrial cancer
235283|NCT01786772|arthroscopic partial meniscectomy
235284|NCT01786772|meniscus
235285|NCT01786772|quadriceps strength
235286|NCT01786772|quadriceps voluntary activation
235287|NCT01786772|cryotherapy
235288|NCT01786772|compression
235289|NCT01786772|vasopneumatic compression
235290|NCT01786772|intermittent pneumatic compression
235291|NCT01786759|lipids
235292|NCT01786759|preterm infants
235293|NCT01786759|parenteral nutrition
235294|NCT01786759|liver function
235295|NCT01786746|depression
235296|NCT01786746|cognitive behavioral therapy
235297|NCT01786746|culture
235298|NCT01786746|Chinese Americans
235299|NCT01786746|psychotherapy
235300|NCT01786733|Acute Inpatient Psychiatry
235301|NCT01786733|Continuity of Care
235302|NCT01786733|Behavioral Activation
235303|NCT01786733|Depression
235304|NCT01786720|COPD
235305|NCT01786720|Triple Therapy
235306|NCT01786720|ICS
235307|NCT01786720|LABA
235308|NCT01786720|LAMA
235309|NCT01786707|Type 2 Diabetes Mellitus
235310|NCT01786707|Hyperbaric oxygen therapy (HOT)
235311|NCT01786707|Autologous Bone Marrow-Derived Buffy Coat
235312|NCT01786707|Stem cells (SC)
235313|NCT01786694|rectum
235314|NCT01786694|microdialysis
235315|NCT01786694|quality of life
235316|NCT01786681|Morbid obesity
235317|NCT01786681|Bariatric Surgery
235318|NCT01786681|Pulmonary Atelectasis
235319|NCT01786681|Spirometry
235320|NCT01786681|Continuous Positive Airway Pressure
235321|NCT01786681|Physical Therapy Specialty
235322|NCT01786668|Ankylosing Spondylitis
235323|NCT01786668|Spondylitis
235324|NCT01786668|Ankylosing
235325|NCT01786668|Spondyloarthritis
235326|NCT01786668|Spondyloarthropathy
235327|NCT01786668|Oral preparation
235328|NCT01786655|local anesthetic
235329|NCT01786655|neosaxitoxin
235330|NCT01786655|neoSTX
235331|NCT01786655|bupivacaine
235332|NCT01786655|safety
235333|NCT01786655|phase 1
235334|NCT01786655|pharmacokinetic
235335|NCT01786577|Neuroimaging Biomarkers
235336|NCT01786577|Cognitive Decline in Elderly
235337|NCT01786577|Memory, Thinking problems for Older Adults
235338|NCT01786577|Executive Decline
235339|NCT01786577|Post-operative cognitive change
235341|NCT01786564|sleep
235342|NCT01786525|Live Donor Kidney Transplantation
235343|NCT01786525|LDKT
235344|NCT01786525|African American
235345|NCT01786525|Disparity
235346|NCT01786525|Education
235347|NCT01786525|Patient Support
235348|NCT01786512|Pharmacokinetics
235349|NCT01786512|Omecamtiv mecarbil
235350|NCT01786512|AMG 423
235351|NCT01786512|Double-blind
235352|NCT01786512|Randomized
235353|NCT01786512|Placebo-controlled
235354|NCT01786512|Oral forumlation
235355|NCT01786512|CK-1827452
235356|NCT01786512|Cardiac myosin activator
235357|NCT01786499|Burnout
235358|NCT01786499|Stress
235359|NCT01786499|Provider
235360|NCT01786499|Relaxation Response
235361|NCT01786434|colonoscopy
235362|NCT01786434|pain
235363|NCT01786421|Ethanol
235364|NCT01786421|Lipemia
235365|NCT01786421|Postprandial
235366|NCT01786421|Triglyceride
235367|NCT01786395|UF-021
235368|NCT01786395|unoprostone
235369|NCT01786395|rp
235370|NCT01786369|Schizophrenia
235371|NCT01786369|Psychotic Disorders
235372|NCT01786369|Bipolar Disorder
235373|NCT01786369|Antipsychotic Agents
235374|NCT01786369|Drug Monitoring
235375|NCT01786356|posterior capsule opacification
235376|NCT01786356|PCO
235377|NCT01786356|after cataract
235378|NCT01786356|intraocular lens
235379|NCT01786343|Leukemia
235380|NCT01786343|Acute myeloid leukemia
235381|NCT01786343|AML
235382|NCT01786343|Response rates
235383|NCT01786343|Decitabine
235384|NCT01786343|Dacogen
235385|NCT01786317|Fecal incontinence, ano-rectal manometry
235386|NCT01786304|Fecal incontinence, sacral nerve stimulation
235387|NCT01786291|obstructive sleep apnea
235388|NCT01786291|continuous positive airway pressure
235389|NCT01786291|cardiopulmonary exercise test
235390|NCT01786291|VE/VCO2
235391|NCT01786278|adenocarcinoma
235392|NCT01786278|esophago-gastric junction
235393|NCT01786278|dysphagia
235394|NCT01786278|brachytherapy
235395|NCT01786278|endoscopic stenting
235396|NCT01786265|Prostate Cancer
235397|NCT01786265|PSA Progression After Prostatectomy and/or Radiotherapy
235398|NCT01786265|Prostate specific antigen
235399|NCT01786265|PSA
235400|NCT01786265|Luteinizing-hormone-releasing hormone
235401|NCT01786265|LHRH
235402|NCT01786265|Finite maximal androgen ablation
235403|NCT01786265|Lupron
235404|NCT01786265|Leuprolide Acetate
235405|NCT01786265|Lupron Depot
235406|NCT01786265|Zoladex
235407|NCT01786265|Goserelin
235408|NCT01786265|Degarelix
235409|NCT01786265|Abiraterone Acetate
235410|NCT01786265|Zytiga
235411|NCT01786265|Prednisone
235412|NCT01786252|embryo
235413|NCT01786252|implantation
235414|NCT01786252|blastocyst
235415|NCT01786252|in vitro fertilization
235416|NCT01786252|human chorionic gonadotropin
235417|NCT01786239|Adolescence
235418|NCT01786239|Adult
235419|NCT01786239|Antipsychotic Agents
235420|NCT01786239|Female
235421|NCT01786239|Human
235422|NCT01786239|Male
235423|NCT01786239|Risperidone
235424|NCT01786239|Omega-3
235425|NCT01786239|Schizophrenia
235426|NCT01786239|Schizophreniform
235427|NCT01786239|Schizoaffective
235428|NCT01786239|Schizophrenia -- *drug therapy
235429|NCT01786226|leiomyoma, fibroid, mifepristone, antiprogestins
235430|NCT01786213|adenoma detection rate, colonoscopy, trainee, learning curve
235431|NCT01786200|colon
235432|NCT01786200|cancer
235433|NCT01786200|NSAID
235434|NCT01786200|inflammation
235435|NCT01786187|Lung Cancer
235436|NCT01786187|Symptoms
235437|NCT01786174|ALS
235438|NCT01786174|Gilenya
235439|NCT01786174|Fingolimod
235440|NCT01786148|HIV/AIDS
235441|NCT01786148|Adherence
235442|NCT01786148|Self-management
235443|NCT01786148|Antiretroviral therapy
235444|NCT01786135|Antibodies, Monoclonal
235445|NCT01786135|Antibody-Drug Conjugate
235446|NCT01786135|Antigens, CD19
235447|NCT01786135|B-Lineage Lymphoblastic Lymphoma
235448|NCT01786135|Burkitt Lymphoma
235449|NCT01786135|Diffuse Large B-Cell Lymphoma
235450|NCT01786135|Mantle Cell Lymphoma
235451|NCT01786135|B-Cell Lymphoma
235452|NCT01786135|Drug Therapy
235453|NCT01786135|Monomethylauristatin F
235454|NCT01786135|Follicular Lymphoma Grade 3
235455|NCT01786122|physical exercise
235456|NCT01786122|Health Related Quality of Life
235457|NCT01786122|Non-Small-Cell Lung Carcinoma
235458|NCT01786122|digestive system neoplasms
235459|NCT01786122|breast neoplasms
235460|NCT01786109|anandamide
235461|NCT01786109|cannabinoid
235462|NCT01786109|fatty acid amide hydrolase
235463|NCT01786109|gastric
235464|NCT01786109|motility
235465|NCT01786109|small bowel
235466|NCT01786109|sensory
235467|NCT01786109|motor
235468|NCT01786096|Burkitt Lymphoma
235469|NCT01786096|Antibodies, Monoclonal
235470|NCT01786096|Antibody-Drug Conjugate
235471|NCT01786096|B-Lineage Acute Lymphoblastic Leukemia
235472|NCT01786096|B-Lineage Lymphoblastic Lymphoma
235473|NCT01786096|Burkitt Leukemia
235474|NCT01786096|Monomethylauristatin F
235475|NCT01786096|Antigens, CD19
235476|NCT01786096|Drug Therapy
235477|NCT01786083|family caregivers
235478|NCT01786083|dependency
235479|NCT01786083|Problem Solving Technique
235480|NCT01786083|home based nursing
235481|NCT01786044|patient education
235482|NCT01786044|primary health care
235483|NCT01786018|Non Hodgkin lymphomas
235484|NCT01786018|Allogeneic Transplantation
235485|NCT01786018|Thiotepa
235486|NCT01786018|Busulfan
235487|NCT01786018|Fludarabin
235488|NCT01785992|Oestrogen receptor
235489|NCT01785992|Locally advanced
235490|NCT01785992|Metastatic
235491|NCT01785992|Breast cancer
235492|NCT01785992|Sulfatase inhibitor
235493|NCT01785966|Critical care
235494|NCT01785966|quality improvement
235495|NCT01785966|checklist
235496|NCT01785940|Interscalene Block
235497|NCT01785940|Perineural catheter
235498|NCT01785940|Ropivacaine
235499|NCT01785940|Postoperative pain
235500|NCT01785940|Home regional
235501|NCT01785927|Antituberculosis
235502|NCT01785927|Dry powder aerosols
235503|NCT01785927|Inhalation
235504|NCT01785901|asthma
235505|NCT01785901|control rate
235506|NCT01785901|budesonide/formoterol
235507|NCT01785901|Non-Interventional study
235508|NCT01785888|EGFR,
235509|NCT01785888|aNSCLC,
235510|NCT01785888|mutation status,
235511|NCT01785888|diagnostic study,
235512|NCT01785888|Europe,
235513|NCT01785888|Japan
235514|NCT01785875|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
235515|NCT01785862|sore throat pain
235516|NCT01785862|tonsillopharyngitis
235517|NCT01785862|upper respiratory tract infection
235518|NCT01785849|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
235519|NCT01785823|analgesia
235520|NCT01785823|fentanyl
235521|NCT01785823|total intravenous anesthesia
235522|NCT01785758|complications, renal;
235523|NCT01785758|kidney, failure;
235524|NCT01785758|neuromuscular block, antagonism;
235525|NCT01785758|neuromuscular block, rocuronium;
235526|NCT01785758|safety, drug
235527|NCT01785758|sugammadex
235528|NCT01785745|conservative treatment
235529|NCT01785745|shoulder
235530|NCT01785745|neurocognitive therapeutic exercise
235531|NCT01785745|traditional therapeutic exercise
235532|NCT01785745|pain
235533|NCT01785719|Weight Loss
235534|NCT01785719|Polycystic Ovary Syndrome (PCOS)
235535|NCT01785719|Ovarian Follicle Development
235536|NCT01785719|Metabolism
235537|NCT01785693|Nerve block
235538|NCT01785693|Femoropopliteal bypass
235539|NCT01785693|Postoperative analgesia
235540|NCT01785693|Peripheral circulation
235541|NCT01785693|Levobupivacaine
235542|NCT01785693|Clonidine
235543|NCT01785693|Pain
235544|NCT01785680|MAM
235545|NCT01785680|SAM
235546|NCT01785654|Reventilation collapse
235547|NCT01785654|Rate of reventilation collapse
235548|NCT01785654|Risk factor of reventilation collapse
235549|NCT01785654|Hemodynamic profile of reventilation collapse
235550|NCT01785654|Biologic approach of reventilation collapse
235551|NCT01785641|peritoneal dialysis
235552|NCT01785641|peritonitis
235553|NCT01785628|Parkinson's disease
235554|NCT01785628|dementia
235555|NCT01785628|NMDA
235556|NCT01785628|event related potential
235557|NCT01785628|Bereitschaftspotential
235558|NCT01785615|metabolic syndrome
235559|NCT01785615|atorvastatin
235560|NCT01785615|women
235561|NCT01785602|Atopic eczema
235562|NCT01785602|Skin Diseases
235563|NCT01785589|coronary artery disease
235564|NCT01785589|cardiac nuclear medicine
235565|NCT01785589|myocardial perfusion imaging
235566|NCT01785589|invasive coronary angiography
235567|NCT01785576|couples
235568|NCT01785576|head and neck cancer
235569|NCT01785576|oncology
235570|NCT01785576|spousal support
235571|NCT01785563|NAVA
235572|NCT01785563|NIV-NAVA
235573|NCT01785563|VLBW
235574|NCT01785563|electrical activity of the diaphragm
235575|NCT01785563|neural trigger, mechanical ventilation
235576|NCT01785563|respiratory distress syndrome
235577|NCT01785537|e-cigarette smoking
235578|NCT01785537|cigarette smoking
235579|NCT01785537|cardiovascular disease
235580|NCT01785537|hospitalization
235581|NCT01785537|chronic obstructive pulmonary diseases
235582|NCT01785537|observational study
235583|NCT01785537|efficacy
235584|NCT01785537|safety
235585|NCT01785524|Cardiovascular Diseases
235586|NCT01785524|Vascular Diseases
235587|NCT01785524|Arterial Occlusive Diseases
235588|NCT01785524|Diabetes
235589|NCT01785524|Exercise
235590|NCT01785524|Functional Capacity
235591|NCT01785511|hypertension
235592|NCT01785511|UV radiation
235593|NCT01785511|coronary flow reserve
235594|NCT01785511|nitric oxide
235595|NCT01785498|children
235596|NCT01785498|quality of life
235597|NCT01785498|physical activity
235598|NCT01785498|healthy lifestyle
235599|NCT01785485|Integrative medicine
235600|NCT01785485|primary care
235601|NCT01785485|cost-effectiveness
235602|NCT01785472|Essential hypertension
235603|NCT01785472|LCZ696
235604|NCT01785459|headache
235605|NCT01785459|migraine
235606|NCT01785459|bupivacaine
235607|NCT01785446|Dexmedetomidine
235608|NCT01785446|Cisatracurion infusion
235609|NCT01785446|Sufentanil
235610|NCT01785446|Recovery Index
235611|NCT01785446|Closed loop computer control system
235612|NCT01785433|COPD, pharmacokinetics, tiotropium
235613|NCT01785420|Pre-operative Trastuzumab Protocol
235614|NCT01785407|Iron bio availability
235615|NCT01785407|Hepcidin
235616|NCT01785407|Iron absorption
235617|NCT01785394|pollinosis
235618|NCT01785394|sublingual immunotherapy
235619|NCT01785394|exhaled breath temperature
235620|NCT01785381|Osteoporosis, hip fracture, fractures, Bone density
235621|NCT01785368|guidelines
235622|NCT01785368|referral guidelines
235623|NCT01785368|exam delays
235624|NCT01785368|exam relevance
235625|NCT01785355|periodontal disease
235626|NCT01785355|CKD
235627|NCT01785355|nutrition
235628|NCT01785355|inflammation
235629|NCT01785355|anemia response to ESA
235630|NCT01785355|quality of life
235631|NCT01785355|hemodialysis
235632|NCT01785316|Perfusion Cancer Chemotherapy, Regional
235633|NCT01785303|CBT
235634|NCT01785303|CPAP
235635|NCT01785303|Multidisciplinary Treatment
235636|NCT01785303|Combination treatment
235637|NCT01785290|Delirium
235638|NCT01785290|Survival
235639|NCT01785290|Side-effects
235640|NCT01785290|QoL
235641|NCT01785277|Spinal Cord Independence Measure
235642|NCT01785277|SCIM
235643|NCT01785277|Spinal cord injury
235644|NCT01785277|Traumatic spine injury
235645|NCT01785264|Achilles
235646|NCT01785264|Tendon
235647|NCT01785264|Rupture
235648|NCT01785264|Acute
235649|NCT01785264|Treatment
235650|NCT01785264|Outcome measure
235651|NCT01785251|Neuromuscular electrical stimulation
235652|NCT01785251|NMES
235653|NCT01785251|Deep vein thrombosis
235654|NCT01785251|DVT
235655|NCT01785251|total hip arthroplasty
235656|NCT01785251|lower limb hemodynamics
235657|NCT01785238|preterm infants
235658|NCT01785238|acute renal failure
235659|NCT01785238|nephronic reduction
235660|NCT01785199|apnea-hypopnea index
235661|NCT01785199|obstructive sleep apnea
235662|NCT01785199|body posture
235663|NCT01785199|ultra-wideband
235664|NCT01785186|TB
235665|NCT01785186|Tuberculosis
235666|NCT01785186|MAMS - Multiple-arm, multiple-stage
235667|NCT01785186|Pulmonary
235668|NCT01785186|SQ109
235669|NCT01785186|High dose rifampicin
235670|NCT01785186|moxifloxacin
235671|NCT01785173|Endoscopes
235672|NCT01785173|Esophago-gastro-duodenoscopy
235673|NCT01785173|Transnasal endoscopy
235674|NCT01785173|Nasal anesthesia
235675|NCT01785147|Tobacco addition
235676|NCT01785134|Obesity
235677|NCT01785134|Bariatric Surgery
235678|NCT01785134|Insulin Sensitivity
235679|NCT01785108|Diamyd
235680|NCT01785108|Diabetes
235681|NCT01785108|Juvenile Diabetes
235682|NCT01785108|Diabetes type 1
235683|NCT01785108|Autoimmune Diabetes
235684|NCT01785108|Insulin dependent Diabetes
235685|NCT01785108|Type 1 diabetes
235686|NCT01785108|Type 1 diabetes mellitus
235687|NCT01785108|rhGAD65
235688|NCT01785108|GAD
235689|NCT01785108|GAD65
235690|NCT01785108|GAD-alum
235691|NCT01785108|Diabetes Mellitus
235692|NCT01785108|Diabetes Mellitus, Type 1
235693|NCT01785108|Glucose Metabolism Disorders
235694|NCT01785108|Metabolic Diseases
235695|NCT01785108|Vitamin D
235696|NCT01785108|Ibuprofen
235697|NCT01785082|13-C-Methacetin
235698|NCT01785082|partial liver resection
235699|NCT01785082|liver function tests
235700|NCT01784250|Clonidine
235701|NCT01784250|Propranolol
235702|NCT01784250|Third molar
235703|NCT01784250|Anxiety
235704|NCT01784237|Endoscopes
235705|NCT01784237|Esophago-gastro-duodenoscopy
235706|NCT01784237|Transnasal endoscopy
235707|NCT01784237|Anterior meatoscopy
235708|NCT01784198|pregnancy
235709|NCT01784198|protein requirements
235710|NCT01784198|Indicator Amino acid oxidation
235711|NCT01784198|Stable isotopes
235712|NCT01784185|EBUS guided transbronchial needle aspiration (EBUS-TBNA)
235713|NCT01784185|virtual bronchoscopy (VB)
235714|NCT01784185|VB guided transbronchial needle aspiration VB-TBNA)
235715|NCT01784185|mediastinal sampling
235716|NCT01784185|transbronchial needle aspiration (TBNA)
235717|NCT01784172|efficacy
235718|NCT01784172|safety
235719|NCT01784172|electroacupuncture
235720|NCT01784172|simple female stress urinary incontinence
235721|NCT01785056|Systemic Sclerosis
235722|NCT01785056|Diffuse Scleroderma
235723|NCT01785056|SSc
235724|NCT01785043|DIABETES Mellitus Type 2
235725|NCT01785043|Difficult control
235726|NCT01785017|critical
235727|NCT01785017|asthma
235728|NCT01785017|children
235729|NCT01785004|Adiposity
235730|NCT01785004|Body composition
235731|NCT01785004|Vitamin D
235732|NCT01785004|Adipokines
235733|NCT01785004|Omega-3 fatty acid
235734|NCT01784991|Pain
235735|NCT01784991|Opioids
235736|NCT01784991|Hydromorphone
235737|NCT01784991|regimen
235738|NCT01784978|cancer
235739|NCT01784978|renal
235740|NCT01784978|metastatic
235741|NCT01784978|clear
235742|NCT01784978|cell
235743|NCT01784978|Sunitinib
235744|NCT01784978|Everolimus
235745|NCT01784978|Alternating
235746|NCT01784939|hereditary hemochromatosis C282Y homozygous
235747|NCT01784939|Iron Reabsorption Index (IRI)
235748|NCT01784939|Hepcidin / ferritin (H / F) ratio
235749|NCT01784926|cataract surgery
235750|NCT01784926|scleral suturing
235751|NCT01784926|Verisyse
235752|NCT01784926|Late in-the-bag IOL dislocation
235753|NCT01784913|Prostate
235754|NCT01784913|cancer
235755|NCT01784913|vaccine
235756|NCT01784874|Rabies
235757|NCT01784874|Human Diploid Cell Vaccine
235758|NCT01784874|Imovax® Rabies
235759|NCT01784848|high blood pressure
235760|NCT01784848|hypertension
235761|NCT01784848|bariatric surgery
235762|NCT01784848|Laparoscopic Roux-en-Y gastric bypass (LRYGB)
235763|NCT01784848|obesity
235764|NCT01784835|Osteopathic manipulative treatment
235765|NCT01784835|neonatology
235766|NCT01784835|neonatal care
235767|NCT01784835|prematurity
235768|NCT01784835|complementary and alternative medicine
235769|NCT01784835|length of stay
235770|NCT01784822|Ventral hernia
235771|NCT01784822|Graft repair
235772|NCT01784809|HIV
235773|NCT01784809|STIs
235774|NCT01784809|Condom Use
235775|NCT01784809|Criminal Justice
235776|NCT01784809|Drug Use
235777|NCT01784796|cardiovascular disease
235778|NCT01784796|women's health
235779|NCT01784796|psychological stress
235780|NCT01784796|Veterans
235781|NCT01784796|stroke
235782|NCT01784783|HIV transmission
235783|NCT01784783|PMTCT
235784|NCT01784783|Discordancy
235785|NCT01784783|Home-based testing
235786|NCT01784783|Couple counseling
235787|NCT01784783|Couple testing
235788|NCT01784783|Facility delivery
235789|NCT01784783|Exclusive breastfeeding
235790|NCT01784783|Family planning
235791|NCT01784783|Postpartum contraceptives
235792|NCT01784783|Linkage to care
235793|NCT01784783|ART initiation
235794|NCT01784770|Legionnaires' disease
235795|NCT01784770|Legionella pneumophila
235796|NCT01784770|Zithromax
235797|NCT01784770|Zithromac
235798|NCT01784770|Japanese
235799|NCT01784770|Regulatory Post Marketing Commitment Plan
235800|NCT01784744|Autism
235801|NCT01784744|ASD
235802|NCT01784744|Aspergers
235803|NCT01784744|Autism Spectrum Disorder
235804|NCT01784692|Immulina
235805|NCT01784692|Elderly
235806|NCT01784692|Immune
235807|NCT01784679|Hereditary Inclusion Body Myopathy
235808|NCT01784679|GNE Myopathy
235809|NCT01784679|Nonaka Disease
235810|NCT01784679|Quadriceps Sparing Myopathy
235811|NCT01784679|distal myopathy with rimmed vacuoles
235812|NCT01784679|ultragenyx
235813|NCT01784679|rare disease
235814|NCT01784666|Bipolar Disorder
235815|NCT01784666|Depression
235816|NCT01784666|Lithium
235817|NCT01784666|Valproate
235818|NCT01784666|Isradipine
235819|NCT01784653|Substance abuse
235820|NCT01784653|Drug abuse
235821|NCT01784653|Alcohol abuse
235822|NCT01784653|Tobacco
235823|NCT01784653|Adolescent
235824|NCT01784627|substance use
235825|NCT01784627|alcohol abuse
235826|NCT01784627|cannabis abuse
235827|NCT01784627|nicotine dependence
235828|NCT01784627|adolescents
235829|NCT01784601|Interscalene block
235830|NCT01784601|Hemidiaphragm palsy
235831|NCT01784575|Quality of care
235832|NCT01784575|Pediatric
235833|NCT01784575|Pregnancy
235834|NCT01784575|Low-income
235835|NCT01784575|Low literacy
235836|NCT01784562|Chronic thromboembolic pulmonary hypertension
235837|NCT01784549|NSCL
235838|NCT01784549|biomarkers
235839|NCT01784549|Customized Neoadjuvant Therapy
235840|NCT01784523|antiphospholipid autoantibodies
235841|NCT01784523|antiphospholipid positive
235842|NCT01784497|Health Related Quality of Life (HRQL)
235843|NCT01784497|Living Donor Liver Transplantation(LDLT)
235844|NCT01784471|Foot Symptoms
235845|NCT01784471|Diabetes
235846|NCT01784471|Peripheral Vascular Disease
235847|NCT01784471|Magic Foot shoe
235848|NCT01784458|severe sepsis
235849|NCT01784458|intra-abdominal hypertension
235850|NCT01784458|intra-abdominal pressure
235851|NCT01784445|Endoscopic Retrograde Cholangiopancreatography,
235852|NCT01784432|low-level laser therapy
235853|NCT01784432|muscle performance
235854|NCT01784432|strength training
235855|NCT01784432|gene expression
235856|NCT01784432|microarrays
235857|NCT01784419|Cystic fibrosis
235858|NCT01784419|Ivacaftor
235859|NCT01784419|Genotype
235860|NCT01784419|Phenotype
235861|NCT01784419|Sweat chloride
235862|NCT01784419|Pancreatic sufficient
235863|NCT01784406|Self-management intervention
235864|NCT01784406|Psychosocial care
235865|NCT01784406|Autonomy-supportive
235866|NCT01784406|Gynaecological cancer survivors
235867|NCT01784406|Guided self-Determination
235868|NCT01784367|Hypercapnia
235869|NCT01784367|noninvasive ventilation
235870|NCT01784367|acute respiratory failure
235871|NCT01784367|endotracheal intubation
235872|NCT01784367|invasive mechanical ventilation
235873|NCT01784341|Bipolar, Circadian, Melatonin
235874|NCT01784328|Peristeen Bowel Irrigation System
235875|NCT01784328|Cauda Equina Syndrome
235876|NCT01784328|Lower Motor Neuron Neurogenic Bowel
235877|NCT01784315|The presence of parasites in the blood
235878|NCT01784289|Interleukin 7
235879|NCT01784289|adipose tissue
235880|NCT01784276|Children
235881|NCT01784276|Autism Spectrum Disorders
235882|NCT01784276|Electronic Screen Media
235883|NCT01784276|Dental fear
235884|NCT01784263|Intervention
235885|NCT01784263|Autism
235886|NCT01784263|Treatment sensitivity
235887|NCT01784263|School aged
235888|NCT01784263|Cognitive behavioral therapy
235889|NCT01784133|rosacea
235890|NCT01784120|breast cancer
235891|NCT01784120|doxorubicin
235892|NCT01784120|genexol-PM
235893|NCT01784120|paclitaxel
235894|NCT01784107|SCLC
235895|NCT01784107|belotecan
235896|NCT01784107|Ifosfamide
235897|NCT01784081|palliative care
235898|NCT01784081|decision aid
235899|NCT01784068|Ph+ CML-CP
235900|NCT01784068|chronic phase
235901|NCT01784068|nilotinib treatment
235902|NCT01784068|2 years treatment
235903|NCT01784068|MR 4.5
235904|NCT01784068|Loss of MR 4
235905|NCT01784068|Loss of MMR
235906|NCT01784055|NeoChord
235907|NCT01784055|DS1000
235908|NCT01784055|Mitral Valve
235909|NCT01784055|Mitral Valve Regurgitation
235910|NCT01784055|MR
235911|NCT01784055|Mitral Valve Repair
235912|NCT01784055|Mitral Valve Prolapse
235913|NCT01784055|Artificial Chordae
235914|NCT01784042|breast cancer
235915|NCT01784042|omega-3 fatty acids
235916|NCT01784029|adolescents
235917|NCT01784029|minority
235918|NCT01783964|Elacytarabine
235919|NCT01783964|pharmacokinetic
235920|NCT01783964|Microdose
235921|NCT01783964|Mass Balance Recovery
235922|NCT01783951|Gastric cancer
235923|NCT01783951|S-1
235924|NCT01783951|DC-CIK
235925|NCT01783912|Smoking
235926|NCT01783912|Nicotine Dependence
235927|NCT01783912|Mental Disorders
235928|NCT01783886|Diabetic Macular Edema
235929|NCT01783886|DME
235930|NCT01783886|VEGF Trap-Eye
235931|NCT01783886|best-corrected visual acuity (BCVA)
235932|NCT01783860|Azithromycin
235933|NCT01783860|Doxycycline
235934|NCT01783860|Posterior Blepharitis
235935|NCT01783847|Erythropoietin
235936|NCT01783847|Traumatic Optic Neuropathy
235937|NCT01783847|Visual function
235938|NCT01783834|Pemetrexed
235939|NCT01783834|Gefitinib
235940|NCT01783834|iressa
235941|NCT01783834|alimta
235942|NCT01783821|Acute respiratory distress syndrome (ARDS)
235943|NCT01783808|COPD
235944|NCT01783808|Physical capacity
235945|NCT01783808|Physical activity
235946|NCT01783808|Inflammatory markers
235947|NCT01783808|Health related quality of life
235948|NCT01783795|Dent
235949|NCT01783795|Dents
235950|NCT01783795|Dent Disease
235951|NCT01783795|Dent genetic testing
235952|NCT01783795|CLCN5
235953|NCT01783795|OCRL1
235954|NCT01783795|Genetic testing for Dent Disease
235955|NCT01783795|Hereditary study for Dent Disease
235956|NCT01783782|Capsule Endoscopy
235957|NCT01783782|colon cleansing
235958|NCT01783782|children
235959|NCT01783782|age 2 -18 years
235960|NCT01783769|neurosurgery
235961|NCT01783769|operating room personnel
235962|NCT01783769|sterile procedures
235963|NCT01783769|infection
235964|NCT01783769|Conditions requiring surgery
235965|NCT01783743|Trichiasis
235966|NCT01783743|Trachoma
235967|NCT01783743|Mass treatment
235968|NCT01783730|Rheumatoid arthritis
235969|NCT01783704|hip fracture
235970|NCT01783704|randomized controlled trial
235971|NCT01783704|exercise
235972|NCT01783691|Sickle cell disease
235973|NCT01783652|Adolescent depression
235974|NCT01783652|internet intervention
235975|NCT01783639|Carotid
235976|NCT01783639|Carotid artery stenting
235977|NCT01783639|Stent
235978|NCT01783639|Embolic protection
235979|NCT01783639|Atherosclerotic Disease
235980|NCT01783600|Peripheral Arterial Disease
235981|NCT01783600|Infrapopliteal lesions
235982|NCT01783600|balloon catheter
235983|NCT01783574|Depression
235984|NCT01783574|Major Depressive Disorder (MDD)
235985|NCT01783561|caffeine
235986|NCT01783561|intubation
235987|NCT01783561|hemodynamic
235988|NCT01783548|allergic rhinitis
235989|NCT01783548|pediatric subjects
235990|NCT01783548|BDP nasal aerosol
235991|NCT01783535|intraocular retinoblastoma
235992|NCT01783509|GENETICALLY CONFIRMED limb girdle muscular dystrophy
235993|NCT01783483|CABG
235994|NCT01783483|Valve replacement
235995|NCT01783483|sternal closure
235996|NCT01783483|midline sternotomy
235997|NCT01783483|sternal plates
235998|NCT01783470|adipose tissue, brown
235999|NCT01783470|obesity
236000|NCT01783470|Adrenergic beta-3 Receptor Agonists
236001|NCT01783470|thermogenesis
236002|NCT01783470|metabolism
236003|NCT01783457|First psychotic episode
236004|NCT01783457|Individual psychoeducation
236005|NCT01783457|Telemedicine
236006|NCT01783457|BDNF
236007|NCT01783457|Oxidative stress
236008|NCT01783444|Estrogen receptor positive, locally advanced, metastatic breast cancer
236009|NCT01783418|mindfulness-based meditation
236010|NCT01783418|pediatric cancer
236011|NCT01783418|adolescence
236012|NCT01783418|quality of life
236013|NCT01783418|sleep
236014|NCT01783418|affect
236015|NCT01783418|health psychology
236016|NCT01783405|LDLR mutation
236017|NCT01783405|Statin
236018|NCT01783405|Cardiovascular disease
236019|NCT01783392|overactive bladder
236020|NCT01783392|transcutaneous posterior tibial nerve stimulation
236021|NCT01783392|placebo PTNS
236022|NCT01783379|invasive fungal infection
236023|NCT01783379|micafungin
236024|NCT01783379|intensive care
236025|NCT01783379|pharmacokinetics
236026|NCT01783366|nasogastric tube, tube exchange catheter
236027|NCT01783353|Recalcitrant cutaneous warts
236028|NCT01783353|verruca
236029|NCT01783340|Malaria
236030|NCT01783340|P falciparum
236031|NCT01783340|Chloroquine
236032|NCT01783340|Azithromycin
236033|NCT01783340|Immunization
236034|NCT01783327|Diabetes Mellitus, Type 1
236035|NCT01783327|Self care
236036|NCT01783327|Coping skills
236037|NCT01783327|Adolescent
236038|NCT01783327|Internet
236039|NCT01783327|Intervention Studies
236040|NCT01783327|Chronic Disease
236041|NCT01783314|hepatic fibrosis
236042|NCT01783314|Eovist
236043|NCT01783314|gadoxetate disodium
236044|NCT01783314|biomarker
236045|NCT01783314|liver biopsy
236046|NCT01783314|liver function
236047|NCT01783314|MRI
236048|NCT01783314|Hepatitis C
236049|NCT01783301|follicle stimulating hormone
236050|NCT01783301|ovarian stimulation
236051|NCT01783301|antimullerian hormone
236052|NCT01783301|antral follicle count
236053|NCT01783301|assisted reproductive technologies
236054|NCT01783288|Postural tachycardia syndrome
236055|NCT01783288|orthostatic intolerance
236056|NCT01783288|orthostatic tachycardia
236057|NCT01783288|POTS
236058|NCT01783275|Obesity
236059|NCT01783275|Type 2 diabetes
236060|NCT01783275|Liver
236061|NCT01783236|VATS
236062|NCT01783236|thoracic surgery
236063|NCT01783236|acetaminophen
236064|NCT01783236|ofirmev
236065|NCT01783236|lung surgery
236066|NCT01783236|thoracoscopic
236067|NCT01783236|intravenous acetaminophen
236068|NCT01783158|head and neck carcinoma
236069|NCT01783158|chromoendoscopy
236070|NCT01783158|Lugol's solution
236071|NCT01783158|esophageal carcinoma
236072|NCT01783158|synchronous tumors
236073|NCT01783158|deglutition
236074|NCT01783158|deglutition disorders
236075|NCT01783158|Newly diagnosed HNSCC
236076|NCT01783145|survivorship care
236077|NCT01783145|testicular cancer
236078|NCT01783145|shared care model
236079|NCT01783119|Ulcerative Colitis
236080|NCT01783119|Aloe Vera
236081|NCT01783106|Crohn's
236082|NCT01783106|antibiotics
236083|NCT01783106|hydroxychloroquine
236084|NCT01783106|ciprofloxacin
236085|NCT01783106|doxycycline
236086|NCT01783080|Chronic depression
236087|NCT01783080|Dysthymic disorder
236088|NCT01783080|Double Depression
236089|NCT01783080|Behavioral Activation therapy
236090|NCT01783080|Work impairment
236091|NCT01783080|Unemployment
236092|NCT01783067|Biofortification
236093|NCT01783067|Pearl millet
236094|NCT01783067|Iron absorption
236095|NCT01783067|Zinc absorption
236096|NCT01783054|NEOADJUVANT GEMCITABINE AND ABRAXANE CHEMOTHERAPY
236097|NCT01783054|SURGERY
236098|NCT01783054|RESECTABLE ADENOCARCINOMA OF THE PANCREAS
236099|NCT01783041|Prematurity
236100|NCT01783041|Carnitine supplementation
236101|NCT01783041|Neonatal Intensive Care
236102|NCT01783041|MRI
236103|NCT01783041|Amplitude-integrated EEG
236104|NCT01783041|NICU Network Neurobehavioral Scale
236105|NCT01783041|Bayley Scale of Infant Development III
236106|NCT01783028|asthma
236107|NCT01783015|Rheumatoid arthritis
236108|NCT01783015|etanercept
236109|NCT01783015|methotrexate
236110|NCT01783015|infliximab
236111|NCT01783015|adalimumab
236112|NCT01783015|anti-drug antibody
236113|NCT01782989|geographic atrophy
236114|NCT01782989|non-exudative age-related macular degeneration
236115|NCT01782989|macular degeneration
236116|NCT01782989|dry macular degeneration
236117|NCT01782989|dry AMD
236118|NCT01782976|Glioblastoma
236119|NCT01782976|GBM
236120|NCT01782976|Intracranial glioblastoma
236121|NCT01782976|Recurrent
236122|NCT01782976|MD Anderson Symptom Inventory for Brain Tumors
236123|NCT01782976|MDASI-BT
236124|NCT01782976|Questionnaire
236125|NCT01782976|Survey
236126|NCT01782963|Newly diagnosed
236127|NCT01782950|HIV
236128|NCT01782950|Tuberculosis
236129|NCT01782950|Antituberculosis drugs
236130|NCT01782911|Androgen
236131|NCT01782911|IVF
236132|NCT01782911|Resveratrol
236133|NCT01782911|PCOS.
236134|NCT01782898|Anesthesia
236135|NCT01782898|MEDOC neuro sensory analyzer
236136|NCT01782898|Pain
236137|NCT01782898|Quality of recovery
236138|NCT01782885|Osteoarthritis
236139|NCT01782885|Platelet-Rich Plasma
236140|NCT01782885|Intra-articular
236141|NCT01782885|Injection
236142|NCT01782807|Ovarian function
236143|NCT01782807|Hysterectomy
236144|NCT01782807|Salpingectomy
236145|NCT01782807|Anti mullerian hormone
236146|NCT01782794|Vaccination
236147|NCT01782794|Acceptability
236148|NCT01782794|General population
236149|NCT01782794|Hepatitis B
236150|NCT01782794|Vaccine coverage
236151|NCT01782781|Analgesia
236152|NCT01782781|Local infiltration analgesia
236153|NCT01782781|Pain, relief
236154|NCT01782781|Pain, Postoperative
236155|NCT01782781|Ropivacaine
236156|NCT01782781|Ketorolac
236157|NCT01782781|Epinephrine
236158|NCT01782781|Adrenergic Agonists
236159|NCT01782781|Sympathomimetics
236160|NCT01782781|Therapeutic Uses
236161|NCT01782781|Anti-Inflammatory Agents, Non-Steroidal
236162|NCT01782781|Analgesics, Non-Narcotic
236163|NCT01782781|Analgesics
236164|NCT01782781|Opioids
236165|NCT01782781|Morphine
236166|NCT01782781|Pain
236167|NCT01782781|Postoperative Complications
236168|NCT01782781|Physiological Effects of Drugs
236169|NCT01782781|Anesthetics, Local
236170|NCT01782781|Anesthetics
236171|NCT01782768|Neural respiratory drive in different level of NPPV
236172|NCT01782755|Probiotics
236173|NCT01782755|Ventilator Associated Pneumonia (VAP)
236174|NCT01782755|Infection
236175|NCT01782755|Antibiotic-Associated Diarrhea
236176|NCT01782755|C-Difficile
236177|NCT01782742|Mild to Moderate Alzheimer's Disease
236178|NCT01782729|Dermatitis, Atopic
236179|NCT01782729|Tacrolimus
236180|NCT01782716|Mortality
236181|NCT01782716|Length
236182|NCT01782716|hospitalization
236183|NCT01782716|cardiac surgery
236184|NCT01782716|patients
236185|NCT01782703|Atopic Dermatitis
236186|NCT01782703|Filaggrin
236187|NCT01782703|Biomarkers
236188|NCT01782703|Eczema
236189|NCT01782664|PASI
236190|NCT01782664|DLQI
236191|NCT01782664|GSK2586184
236192|NCT01782664|plaque-type psoriasis
236193|NCT01782664|PGA
236194|NCT01782664|inflammatory gene transcription
236195|NCT01782664|JAK-1 inhibitor
236196|NCT01782664|serum neopterin
236197|NCT01782664|skin biopsy
236198|NCT01782664|ACR response criteria
236199|NCT01782664|VAS itch score
236200|NCT01782651|HER2 positive
236201|NCT01782651|Breast Cancer
236202|NCT01782651|treatment patterns
236203|NCT01782638|Parkinson's disease
236204|NCT01782638|Deep brain stimulation
236205|NCT01782638|Gait
236206|NCT01782638|Freezing
236207|NCT01782638|Electrode placements
236208|NCT01782625|diving
236209|NCT01782625|cognitive impairment
236210|NCT01782625|nitrogen narcosis
236211|NCT01782625|narcosis
236212|NCT01782625|end tidal carbon dioxide
236213|NCT01782625|arterial carbon dioxide
236214|NCT01782625|immersion
236215|NCT01782612|Balanced Anesthesia
236216|NCT01782612|Nerve Block
236217|NCT01782612|Postoperative Recovery
236218|NCT01782612|Delirium
236219|NCT01782612|Postoperative Complications
236220|NCT01782612|Stress
236221|NCT01782612|Inflammation
236222|NCT01782586|kidney transplant
236223|NCT01782586|gene expression markers
236224|NCT01782586|renal allograft function
236225|NCT01782573|pre - disinfection scrubbing solution
236226|NCT01782573|surgical site culture
236227|NCT01782573|surgical site infection
236228|NCT01782573|liver tumors
236229|NCT01782573|hepatectomy
236230|NCT01782573|chlorhexidine gluconate
236231|NCT01782560|Laryngomalacia
236232|NCT01782560|Acid-reflux
236233|NCT01782547|diabetes mellitus
236234|NCT01782547|adolescents
236235|NCT01782521|Bracket failure rate
236236|NCT01782521|Orthodontic bonding
236237|NCT01782521|Primer
236238|NCT01782508|melanoma,adjuvant therapy,kit mutated melanoma
236239|NCT01782495|Hepatitis C Genotype 4
236240|NCT01782495|Chronic Hepatitis
236241|NCT01782495|Interferon-Free
236242|NCT01782495|Hepatitis C Virus
236243|NCT01782495|Renal Transplant
236244|NCT01782495|Liver Transplant
236245|NCT01782495|Hepatitis C Genotype 1
236246|NCT01782482|Color contact lenses
236247|NCT01782482|Refractive error
236248|NCT01782482|Myopia
236249|NCT01782469|Synovitis
236250|NCT01782469|Rheumatoid Arthritis
236251|NCT01782443|Progressive
236252|NCT01782443|Metastatic
236253|NCT01782430|Preoxygenation
236254|NCT01782430|Intubation
236255|NCT01782417|osteoarthritis
236256|NCT01782417|Hispanic
236257|NCT01782417|behavior
236258|NCT01782417|intervention
236259|NCT01782417|Spanish
236260|NCT01782391|mild cognitive impairment
236261|NCT01782391|dementia
236262|NCT01782391|MCI
236263|NCT01782391|brain stimulation
236264|NCT01782391|tSOS
236265|NCT01782391|tDCS
236266|NCT01782391|sleep
236267|NCT01782391|memory
236268|NCT01782391|memory consolidation
236269|NCT01782378|Persian Gulf Syndrome
236270|NCT01782378|Veterans Health
236271|NCT01782378|Executive Function
236272|NCT01782378|Memory
236273|NCT01782378|Attention
236274|NCT01782378|Cognition
236275|NCT01782378|Laser Therapy, Low-Level
236276|NCT01782378|Phototherapy
236277|NCT01782378|Light Therapy
236278|NCT01782378|Depression
236279|NCT01782365|mild cognitive impairment
236280|NCT01782365|dementia
236281|NCT01782365|MCI
236282|NCT01782365|brain stimulation
236283|NCT01782365|tSOS
236284|NCT01782365|tDCS
236285|NCT01782365|sleep
236286|NCT01782365|nap
236287|NCT01782365|daytime sleep
236288|NCT01782365|memory
236289|NCT01782365|memory consolidation
236290|NCT01782352|age-related macular degeneration
236291|NCT01782352|incidence
236292|NCT01782352|progression
236293|NCT01782326|COPD, QVA149, FLAME( EFfect of Indacaterol Glycopyronium Vs Fluticasone salmeterol on COPD Exacerbations)
236294|NCT01782287|Neoplasm Metastasis
236295|NCT01782287|Brain metastasis
236296|NCT01782287|Lung cancer
236297|NCT01782274|Neoplasm Metastasis
236298|NCT01782274|Brain metastasis
236299|NCT01782274|Breast cancer
236300|NCT01782261|autoimmune disease
236301|NCT01782261|diabetes type 1
236302|NCT01782261|incretin effect
236303|NCT01782222|Parkinson's Disease
236304|NCT01782222|Rotigotine
236305|NCT01782222|Apathy
236306|NCT01782222|Nonmotor
236307|NCT01782222|Motor
236308|NCT01782222|Neupro
236309|NCT01782209|BK virus viremia
236310|NCT01782209|renal transplant
236311|NCT01782209|other viral pathogens
236312|NCT01782183|sore throat
236313|NCT01782183|thermal camera photo
236314|NCT01782183|normal tonsils and pharynx
236315|NCT01782183|redness of tonsils and/or pharynx
236316|NCT01782183|exudates on tonsils
236317|NCT01782183|petechiae of the palate
236318|NCT01782170|Gingivitis
236319|NCT01782170|Biomarkers
236320|NCT01782170|Biological Markers of Inflammation
236321|NCT01782157|dementia
236322|NCT01782144|Obesity
236323|NCT01782144|Foot pain
236324|NCT01782105|weight gain
236325|NCT01782105|healthy lifestyle
236326|NCT01782105|gestational diabetes
236327|NCT01782105|adipokins
236328|NCT01782105|glycemic regulation
236329|NCT01782092|diabetes
236330|NCT01782079|Lactobacillus brevis
236331|NCT01782079|Oral health
236332|NCT01782079|Bacterial adhesion
236333|NCT01782040|Premenstrual syndrome
236334|NCT01782040|Physical distress
236335|NCT01782040|Behavioral changes
236336|NCT01782027|healthy controls
236337|NCT01782027|Tangier Disease
236338|NCT01782027|Adenosine triphosphate-binding cassette transporter 1 (ABCA1)
236339|NCT01782027|apoA-I
236340|NCT01782027|LCAT deficiency
236341|NCT01782027|Scavenger receptor BI (SRBI) deficiency
236342|NCT01782027|CETP deficiency
236343|NCT01782014|Screening colonoscopy
236344|NCT01782014|Water method
236345|NCT01782014|Carbon dioxide method
236346|NCT01782014|Air method
236347|NCT01782014|Water versus carbon dioxide versus air insufflation colonoscopy
236348|NCT01782014|Adenoma Detection Rate
236349|NCT01782014|Pain Scores in colonoscopy
236350|NCT01782001|Vitamin A
236351|NCT01782001|Zinc
236352|NCT01782001|Malaria
236353|NCT01782001|Morbidity
236354|NCT01782001|MRDR
236355|NCT01781988|lung cancer
236356|NCT01781988|gemcitabine
236357|NCT01781988|carboplatin
236358|NCT01781988|pemetrexed
236359|NCT01781949|HIV infection
236360|NCT01781949|Targeted screening
236361|NCT01781949|Nontargeted screening
236362|NCT01781949|Emergency department
236363|NCT01781949|Urgent care
236364|NCT01781949|Effectiveness
236365|NCT01781923|Cognitive remediation
236366|NCT01781923|Social Cognition
236367|NCT01781910|branched chain amino acids, exercise, delayed onset muscle soreness
236368|NCT01781897|acupuncture
236369|NCT01781897|electro-acupuncture
236370|NCT01781871|Pneumococcal vaccination
236371|NCT01781871|immunogenicity
236372|NCT01781871|solid organ transplant
236373|NCT01781858|Pulmonary embolism
236374|NCT01781858|Chronic thromboembolic pulmonary hypertension
236375|NCT01781858|Venous thromboembolism
236376|NCT01781793|dyspnea, exercise endurance, lung disease
236377|NCT01781780|Obesity
236378|NCT01781780|Weight Loss
236379|NCT01781780|Breakfast
236380|NCT01781767|UCP2
236381|NCT01781767|Thyroid function
236382|NCT01781767|Thyroid carcinoma
236383|NCT01781754|Glycemic control
236384|NCT01781754|Metabolic control
236385|NCT01781754|Oxidative stress
236386|NCT01781754|Diabetes
236387|NCT01781728|recurrent
236388|NCT01781728|unresectable
236389|NCT01781728|residual
236390|NCT01781728|stereotactic body radiation therapy (SBRT)
236391|NCT01781728|palliative management
236392|NCT01781715|STEMI, Multivessel Coronary Artery Disease, Primary PCI, multivessel stenting, zotarolimus-eluting stent
236393|NCT01781689|cortical activation
236394|NCT01781689|motor function
236395|NCT01781689|activity of daily living
236396|NCT01781650|Warm Water Infusion colonoscopy
236397|NCT01781650|Water Immersion colonoscopy
236398|NCT01781650|Water Exchange colonoscopy
236399|NCT01781650|Painless unsedated colonoscopy
236400|NCT01781650|Adenoma detection rate
236401|NCT01781650|Adenoma resection rate
236402|NCT01781637|Xolair
236403|NCT01781637|omalizumab
236404|NCT01781637|peanut
236405|NCT01781637|oral desensitization
236406|NCT01781611|lupus
236407|NCT01781611|dipyridamole
236408|NCT01781598|Total knee arthroplasty
236409|NCT01781598|Patient specific instruments
236410|NCT01781598|Patient matched cutting blocks
236411|NCT01781598|Alignment
236412|NCT01781598|Learning curve
236413|NCT01781598|VISIONAIRE
236414|NCT01781585|Sustained low-efficiency dialysis;
236415|NCT01781585|Continuous venovenous hemofiltration;
236416|NCT01781585|hemodynamic stability,
236417|NCT01781585|Intracranial pressure
236418|NCT01781546|drug eluting balloon
236419|NCT01781546|bare metal stent
236420|NCT01781546|coronary artery disease
236421|NCT01781546|acute coronary syndrome
236422|NCT01781546|percutaneous coronary intervention
236423|NCT01781546|DEB
236424|NCT01781546|BMS
236425|NCT01781520|Pancreatic Cancer
236426|NCT01781520|S1
236427|NCT01781520|DC-CIK
236428|NCT01781507|Asthma
236429|NCT01781507|Allergic rhinitis
236430|NCT01781507|Cetirizine
236431|NCT01781507|Impulse oscillometry
236432|NCT01781481|Psychosocial Stress and Adjustment
236433|NCT01781481|Pediatric Chronic Illness
236434|NCT01781481|Decision-support tool
236435|NCT01781481|Integrated Health Care
236436|NCT01781481|Case Complexity
236437|NCT01781442|Metastatic Renal Cell Carcinoma
236438|NCT01781416|cardiovascular risk
236439|NCT01781416|SCORE
236440|NCT01781416|cardiovascular primary prevention
236441|NCT01781416|risk factors
236442|NCT01781403|Temozolomide
236443|NCT01781403|capecitabine
236444|NCT01781403|rectal cancer
236445|NCT01781390|Acute Myocardial Infarction
236446|NCT01781390|STEMI
236447|NCT01781390|Heart Attack
236448|NCT01781390|AMI
236449|NCT01781390|Stem Cells
236450|NCT01781377|NAUSEA
236451|NCT01781377|VOMITING
236452|NCT01781377|CESAREAN SECTION
236453|NCT01781377|PREVENTION
236454|NCT01781377|PROPOFOL
236455|NCT01781364|Brain Oscillations
236456|NCT01781364|Cognitive Performance
236457|NCT01781325|musculoskeletal, physical therapy
236458|NCT01781299|Breast Cancer
236459|NCT01781299|Mastectomy
236460|NCT01781299|Immediate reconstruction
236461|NCT01781286|Obesity
236462|NCT01781286|Snacking
236463|NCT01781286|Appetite
236464|NCT01781286|Protein
236465|NCT01781286|Soy
236466|NCT01781286|Reward driven eating
236467|NCT01781286|Satiety
236468|NCT01781273|impaired driving
236469|NCT01781260|Prone position
236470|NCT01781260|Cardiac output
236471|NCT01781260|Liver Circulation
236472|NCT01781247|Stress Disorders, Post-Traumatic
236473|NCT01781247|Myocardial Infarction
236474|NCT01781247|Psychotherapy
236475|NCT01781247|Preventive Therapy
236476|NCT01781247|Randomized Controlled Trial
236477|NCT01781247|Cardiovascular Diseases
236478|NCT01781247|Psychological Stress
236479|NCT01781247|Biomarkers
236480|NCT01781195|Advagraf
236481|NCT01781195|MELD-score
236482|NCT01781195|Na-MELD-score
236483|NCT01781195|liver function
236484|NCT01781195|LiMAx-test
236485|NCT01781195|infection rate
236486|NCT01781195|HLA-DR status
236487|NCT01781195|immunostatus
236488|NCT01781169|Vitamin D,
236489|NCT01781169|Oral supplementation,
236490|NCT01781169|Obese males
236491|NCT01781156|phosphorus
236492|NCT01781156|hemodialysis
236493|NCT01781156|cardiac biomarkers
236494|NCT01781117|Benign prostatic obstruction (BPO)
236495|NCT01781117|Detrusor overactivity (DO)
236496|NCT01781117|Urinary nerve growth factor (NGF)
236497|NCT01781104|constipation gastric emptying gastrointestinal motility ghrelin
236498|NCT01781078|Single chamber pacing
236499|NCT01781078|Dual chamber pacing
236500|NCT01781078|MRI
236501|NCT01781078|MR scans
236502|NCT01781052|Iloprost Compliance
236503|NCT01781039|"hair cell"
236504|NCT01781039|"spiral ganglion"
236505|NCT01781039|"hearing aid"
236506|NCT01781039|"hearing loss"
236507|NCT01781026|B-raf V600E
236508|NCT01781026|V600K mutation
236509|NCT01781026|metastatic melanoma
236510|NCT01781013|Depression screening
236511|NCT01781013|Depression monitoring
236512|NCT01781013|Chronic illness
236513|NCT01781013|Behavioral health
236514|NCT01781013|Care management
236515|NCT01781013|Automatic telephone assessment
236516|NCT01781013|Clinical decision support
236517|NCT01781013|Suicide alert
236518|NCT01781000|Cognitive Training
236519|NCT01781000|Neuroplasticity
236520|NCT01781000|MEG
236521|NCT01781000|MATRICS
236522|NCT01780987|DVT
236523|NCT01780987|PE
236524|NCT01780987|VTE
236525|NCT01780974|Hypertension
236526|NCT01780974|Vascular Risk
236527|NCT01780974|Alzheimer's Risk
236528|NCT01780974|fish oil
236529|NCT01780974|Lipoic acid
236530|NCT01780961|Esophageal Cancer
236531|NCT01780961|ESBX
236532|NCT01780948|Drug Interaction
236533|NCT01780948|Pharmacokinetics
236534|NCT01780948|Everolimus
236535|NCT01780948|Atorvastatin
236536|NCT01780922|Inflammation
236537|NCT01780922|Oxidative Stress
236538|NCT01780922|Vaccinium macrocarpon
236539|NCT01780896|Topographical Memory
236540|NCT01780896|Non-Topographical Memory
236541|NCT01780896|Vestibular Function
236542|NCT01780896|Alzheimer's Disease
236543|NCT01780883|melatonin
236544|NCT01780883|childhood autism
236545|NCT01780883|6-Sulphatoxymelatonin
236546|NCT01780883|autistic disorder
236547|NCT01780883|dose-effect relation
236548|NCT01780870|Overweight
236549|NCT01780870|Obesity
236550|NCT01780870|Obese
236551|NCT01780870|Weight loss
236552|NCT01780857|palmoplantar pustulosis
236553|NCT01780857|psoriasis
236554|NCT01780844|Kidney Transplantation
236555|NCT01780844|de novo Kidney Transplantation
236556|NCT01780844|ASKP1240
236557|NCT01780818|Warm Water Infusion colonoscopy
236558|NCT01780818|Water Immersion colonoscopy
236559|NCT01780818|Water Exchange colonoscopy
236560|NCT01780818|Painless unsedated colonoscopy
236561|NCT01780818|Adenoma detection rate
236562|NCT01780818|Adenoma resection rate
236563|NCT01780792|multiple sclerosis
236564|NCT01780792|mobility
236565|NCT01780792|cognition
236566|NCT01780792|neuroplasticity
236567|NCT01780792|videogame play
236568|NCT01780779|Diffusion weighted MRI
236569|NCT01780779|Patient outcome assessment
236570|NCT01780779|Treatment response
236571|NCT01780779|Histopathology
236572|NCT01780766|Whole body MRI
236573|NCT01780766|Multiple myeloma
236574|NCT01780766|Diffusion Weighted MRI
236575|NCT01780766|Whole body scan
236576|NCT01780753|Primaquine
236577|NCT01780753|Vivax malaria
236578|NCT01780753|G6PD
236579|NCT01780740|Bypass Surgery, Coronary Artery
236580|NCT01780740|Atrial fibrillation
236581|NCT01780740|Ischaemia-reperfusion injury
236582|NCT01780740|Hydroxymethylglutaryl-CoA Reductase Inhibitors
236583|NCT01780740|Statins, HMG-CoA
236584|NCT01780727|echocardiography
236585|NCT01780727|hemodynamic management
236586|NCT01780714|smoking
236587|NCT01780714|cigarette
236588|NCT01780714|exposure
236589|NCT01780714|biomarker
236590|NCT01780714|human smoking topography (HST)
236591|NCT01780714|modified risk tobacco product (MRTP)
236592|NCT01780714|THS 2.1
236593|NCT01780701|prostate cancer aggressiveness
236594|NCT01780701|magnetic resonance imaging
236595|NCT01780701|fatty acid synthase
236596|NCT01780688|Modified risk tobacco product (MRTP)
236597|NCT01780688|Smoking
236598|NCT01780688|Nicotine profile
236599|NCT01780675|Prophylactic Cranial Irradiation
236600|NCT01780675|Hippocampal Avoidance Prophylactic Cranial Irradiation
236601|NCT01780649|IMSI
236602|NCT01780649|ICSI
236603|NCT01780649|ART Assisted reproductive technology
236604|NCT01780649|Spermatozoa
236605|NCT01780649|male infertility
236606|NCT01780649|vacuoles
236607|NCT01780636|Non relaxing puborectalis syndrome
236608|NCT01780636|Botulinum toxin A
236609|NCT01780636|Botox
236610|NCT01780636|Constipation
236611|NCT01780623|fatigue
236612|NCT01780623|sleep
236613|NCT01780623|quality of life
236614|NCT01780623|light
236615|NCT01780623|cancer
236616|NCT01780610|endometrium preparation protocols
236617|NCT01780610|frozen-thawed embryo transfer
236618|NCT01780610|irregular cycle
236619|NCT01780610|randomized controlled trial
236620|NCT01780597|Heart transplantation
236621|NCT01780597|Ev Vivo Perfusion
236622|NCT01780597|Cardiac function
236623|NCT01780584|congenital heart surgery, thyroid hormones
236624|NCT01780571|Obesity
236625|NCT01780571|general anaesthesia
236626|NCT01780571|preoxygenation
236627|NCT01780571|atelectasis
236628|NCT01780558|endometrium preparation protocols
236629|NCT01780558|frozen-thawed embryo transfer
236630|NCT01780558|natural cycles
236631|NCT01780558|hormone replacement therapy cycles
236632|NCT01780558|randomized controlled trial
236633|NCT01780545|OGX-427
236634|NCT01780545|Docetaxel
236635|NCT01780519|Alzheimer's disease (AD)
236636|NCT01780506|HIV
236637|NCT01780506|Treatment Naive
236638|NCT01780506|HIV 1 Infected
236639|NCT01780506|Female
236640|NCT01780506|Women
236641|NCT01780493|Nipple
236642|NCT01780493|Technique
236643|NCT01780493|Ureter
236644|NCT01780493|Vesicoureteral Reflux
236645|NCT01780480|Ischemic Stroke
236646|NCT01780480|Convalescence
236647|NCT01780480|Randomized Controlled Trial
236648|NCT01780480|Pilot Study
236649|NCT01780480|Traditional Chinese Medicine
236650|NCT01780467|Loss aversion
236651|NCT01780467|Dopamine
236652|NCT01780467|Parkinson's disease
236653|NCT01780454|End Stage Renal Disease
236654|NCT01780454|Renal Transplant
236655|NCT01780454|Bone Marrow Transplant
236656|NCT01780454|Tolerance
236657|NCT01780454|Chimerism
236658|NCT01780454|ESRD
236659|NCT01780441|Tuberous Sclerosis Complex
236660|NCT01780441|TSC
236661|NCT01780441|Autism
236662|NCT01780441|ASD
236663|NCT01780441|Biomarkers
236664|NCT01780441|Infants
236665|NCT01780428|Pain
236666|NCT01780428|Nausea
236667|NCT01780428|Vomiting
236668|NCT01780415|Blastocoele fluid
236669|NCT01780415|Human DNA
236670|NCT01780415|molecular diagnosis
236671|NCT01780402|feeding difficulty
236672|NCT01780402|eating difficulty
236673|NCT01780402|dementia
236674|NCT01780402|nursing home
236675|NCT01780402|careful hand feeding
236676|NCT01780389|Knee
236677|NCT01780389|Pain
236678|NCT01780389|Osteoarthritis
236679|NCT01780376|whole-body vibration
236680|NCT01780376|latency
236681|NCT01780376|reflex response
236682|NCT01780376|muscle
236683|NCT01780337|Oxytocin
236684|NCT01780337|Arrhythmia
236685|NCT01780298|COPD
236686|NCT01780298|Biomarkers
236687|NCT01780298|Cigarette Smoke
236688|NCT01780298|Lung Inflammation
236689|NCT01780298|FEV
236690|NCT01780298|Sputum
236691|NCT01780285|Hiatal hernia
236692|NCT01780285|Gastro-oesophageal reflux disease
236693|NCT01780285|Laparoscopic hiatal repair
236694|NCT01780285|Laparoscopic anti-reflux surgery
236695|NCT01780285|Partially absorbable lightweight mesh
236696|NCT01780285|Polytetrafluoroethylene
236697|NCT01780285|PTFE
236698|NCT01780285|Nitinol
236699|NCT01780285|Nitinol-framed lightweight PTFE mesh
236700|NCT01780259|Healthy
236701|NCT01780259|Esketamine
236702|NCT01780259|Pharmacokinetics
236703|NCT01780259|Intranasal
236704|NCT01780246|Spinal Muscular Atrophy
236705|NCT01780246|SMA
236706|NCT01780246|SMN
236707|NCT01780246|SMNRx
236708|NCT01780246|ISIS-SMNRx
236709|NCT01780246|ISIS 396443
236710|NCT01780220|abiraterone
236711|NCT01780220|biochemically-relapsing
236712|NCT01780220|prostate adenocarcinoma
236713|NCT01780181|lung cancer
236714|NCT01780181|traditional Chinese medicine
236715|NCT01780168|Inborn Error of Metabolism
236716|NCT01780168|Metabolism
236717|NCT01780168|UCD
236718|NCT01780168|Immunity
236719|NCT01780168|Nutrition
236720|NCT01780168|Mitochondrial Disease
236721|NCT01780155|Oxidative Stress
236722|NCT01780155|Hyperoxia
236723|NCT01780155|Brochopulmonary Dysplasia
236724|NCT01780155|Retinopathy of Prematurity
236725|NCT01780155|Very Low Birth Rate
236726|NCT01780142|Airflow Obstruction
236727|NCT01780142|Airflow Inflammation
236728|NCT01780142|Corticosteroid Resistance
236729|NCT01780142|Exacerbations
236730|NCT01780142|Quality of Life
236731|NCT01780116|schizophrenia
236732|NCT01780116|adherence therapy
236733|NCT01780116|medication
236734|NCT01780116|randomized controlled trial
236735|NCT01780116|cost-effectiveness
236736|NCT01780090|autism
236737|NCT01780090|prosody
236738|NCT01780090|speech
236739|NCT01780090|autism spectrum disorder
236740|NCT01780077|Scar
236741|NCT01780077|Scar prevention
236742|NCT01780077|Fibrosis
236743|NCT01780051|Diabetes Mellitus, Type 2
236744|NCT01780051|Pharmacokinetics
236745|NCT01780038|Cigarette Smoking
236746|NCT01780038|Nicotine Dependence
236747|NCT01780038|Smoking Abstinence
236748|NCT01780038|Health Literacy
236749|NCT01780038|Genetic Predisposition Testing
236750|NCT01780038|Heredity
236751|NCT01780025|Hearing
236752|NCT01780025|Thresholds
236753|NCT01780025|Coupling to the inner ear
236754|NCT01780012|osteoporosis
236755|NCT01780012|fragility fracture
236756|NCT01780012|secondary prevention
236757|NCT01779999|central venous catheters
236758|NCT01779999|thrombosis
236759|NCT01779999|secondary prevention
236760|NCT01779973|Skype
236761|NCT01779973|compliance
236762|NCT01779973|remote dosing
236763|NCT01779973|suboxone
236764|NCT01779973|opiate
236765|NCT01779973|opiates
236766|NCT01779973|heroin
236767|NCT01779973|oxycontin
236768|NCT01779973|Philadelphia
236769|NCT01779960|Pulmonary Disease, Chronic Obstructive
236770|NCT01779960|Motor activity
236771|NCT01779960|Climatologic station
236772|NCT01779908|Vitamin D supplementation
236773|NCT01779908|Insulin resistance
236774|NCT01779895|Dust mite
236775|NCT01779895|Perennial allergic rhinitis
236776|NCT01779869|PET MR myocardial perfusion imaging
236777|NCT01779856|End Stage Renal Disease, Hemodialysis, Arrhythmia, Reveal ICM
236778|NCT01779843|Newly diagnosed
236779|NCT01779804|foot , ankle, injury
236780|NCT01779791|Lymphoma
236781|NCT01779791|Refractory follicular lymphoma
236782|NCT01779791|Chemoimmunotherapy-resistant follicular lymphoma
236783|NCT01779791|PCI-32765
236784|NCT01779791|Ibrutinib
236785|NCT01779791|IMBRUVICA
236786|NCT01779765|IBS
236787|NCT01779765|Diarrhea
236788|NCT01779765|Constipation
236789|NCT01779765|Fibers
236790|NCT01779739|vaginal prolapse
236791|NCT01779739|sexual function
236792|NCT01779739|sexual dysfunction
236793|NCT01779739|prolapse surgery
236794|NCT01779726|Organization
236795|NCT01779726|of fast track
236796|NCT01779713|Aneurysmal subarachnoid hemorrhage
236797|NCT01779713|Vasospasm
236798|NCT01779713|Transcriptomic
236799|NCT01779713|Case-Control Study
236800|NCT01779700|psychosis
236801|NCT01779700|schizophrenia
236802|NCT01779700|cognition
236803|NCT01779700|fingolimod
236804|NCT01779687|pharmacokinetic
236805|NCT01779687|interaction
236806|NCT01779687|cholesterol
236807|NCT01779687|raltegravir
236808|NCT01779687|atorvastatin
236809|NCT01779661|Neurodevelopment, Infant-Aquatics, Prematurity
236810|NCT01779648|deep vein thrombosis
236811|NCT01779648|intermittent pneumatic compression
236812|NCT01779648|venous hemodynamics
236813|NCT01779635|Heparin-grafted membrane
236814|NCT01779635|Circuit lifespan
236815|NCT01779635|Continuous renal replacement therapy
236816|NCT01779635|Anticoagulation free
236817|NCT01779635|Bleeding risk
236818|NCT01779635|Acute kidney injury
236819|NCT01779635|Critical illness
236820|NCT01779622|mixed meal¨
236821|NCT01779622|insulin
236822|NCT01779622|glucagon
236823|NCT01779622|GIP
236824|NCT01779622|GLP-1
236825|NCT01779596|diabetes
236826|NCT01779596|endothelial function
236827|NCT01779596|exercise
236828|NCT01779596|blood flow
236829|NCT01779596|bosentan
236830|NCT01779583|Advanced gastric cancer
236831|NCT01779570|Influenza
236832|NCT01779570|Macrolide
236833|NCT01779570|Anti-inflammatory
236834|NCT01779557|CAPD
236835|NCT01779557|efficacy
236836|NCT01779557|safety
236837|NCT01779557|survival rate
236838|NCT01779544|rehabilitation,surgery,brief intervention, exercises
236839|NCT01779531|HER2-negative Luminal B breast cancer
236840|NCT01779518|HCV
236841|NCT01779518|Sustained Virologic Response
236842|NCT01779518|Direct Acting Antiviral
236843|NCT01779518|GS-7977
236844|NCT01779518|Pegylated interferon
236845|NCT01779518|Ribavirin
236846|NCT01779518|Open Label
236847|NCT01779518|Sofosbuvir
236848|NCT01779518|Liver transplant
236849|NCT01779518|Hepatitis
236850|NCT01779518|Hepatitis, Chronic
236851|NCT01779518|Hepatitis C
236852|NCT01779518|Hepatitis C, Chronic
236853|NCT01779518|Liver Diseases
236854|NCT01779518|Digestive System Diseases
236855|NCT01779518|Hepatitis, Viral, Human
236856|NCT01779518|Virus Diseases
236857|NCT01779518|Enterovirus Infections
236858|NCT01779518|Picornaviridae Infections
236859|NCT01779518|RNA Virus Infections
236860|NCT01779518|Flaviviridae Infections
236861|NCT01779518|Antiviral Agents
236862|NCT01779518|Anti-Infective Agents
236863|NCT01779518|Therapeutic Uses
236864|NCT01779518|Pharmacologic Actions
236865|NCT01779518|Antimetabolites
236866|NCT01779518|Molecular Mechanisms of Pharmacological Action
236867|NCT01779492|Oxycodone, controlled release formulation
236868|NCT01779479|German Breast Group
236869|NCT01779479|GBG Forschungs GmbH
236870|NCT01779479|GBG
236871|NCT01779479|GBG 74
236872|NCT01779479|Genevieve
236873|NCT01779479|Breast Cancer
236874|NCT01779479|Primary Breast Cancer
236875|NCT01779479|Cabazitaxel
236876|NCT01779479|Paclitaxel
236877|NCT01779479|neo-adjuvant
236878|NCT01779479|triple negative
236879|NCT01779479|luminal B
236880|NCT01779453|Atorvastatin
236881|NCT01779453|Drug-drug interaction
236882|NCT01779453|Combination therapy
236883|NCT01779440|Mental Illness
236884|NCT01779440|Tobacco Smoking
236885|NCT01779440|Young Adults
236886|NCT01779440|Treatment Engagement
236887|NCT01779440|Motivational Intervention
236888|NCT01779427|traumatic brain injury (TBI)
236889|NCT01779427|intracranial edema
236890|NCT01779427|brain edema
236891|NCT01779427|craniocerebral trauma
236892|NCT01779427|head injury
236893|NCT01779427|brain hemorrhage, traumatic
236894|NCT01779427|subdural hematoma
236895|NCT01779427|brain concussion
236896|NCT01779427|head injuries, closed
236897|NCT01779427|epidural hematoma
236898|NCT01779427|extra-axial hemorrhage
236899|NCT01779427|cortical contusion
236900|NCT01779427|wounds and injuries
236901|NCT01779427|disorders of environmental origin
236902|NCT01779427|trauma, nervous system
236903|NCT01779427|brain injuries
236904|NCT01779427|attention deficit hyperactivity disorder (ADHD)
236905|NCT01779427|attention
236906|NCT01779414|Suicide Ideation
236907|NCT01779401|PCI
236908|NCT01779401|platelet function monitoring
236909|NCT01779401|Thrombelastography
236910|NCT01779401|clopidogrel
236911|NCT01779401|cilostazol
236912|NCT01779401|in-stent thrombosis
236913|NCT01779388|Lung nodule
236914|NCT01779388|PET scanner
236915|NCT01779388|Bronchoscopy
236916|NCT01779388|Electromagnetic navigation
236917|NCT01779375|Children
236918|NCT01779375|Pediatric
236919|NCT01779349|benign prostatic hyperplasia (BPH)
236920|NCT01779349|acoustic vibration
236921|NCT01779336|Advanced Refractory Solid Tumors
236922|NCT01779323|SUI
236923|NCT01779323|stress urinary incontinence
236924|NCT01779323|male
236925|NCT01779323|transobturator sling
236926|NCT01779297|new integrative weaning indexes
236927|NCT01779297|mechanical ventilation
236928|NCT01779297|ICU
236929|NCT01779284|glaucoma
236930|NCT01779284|fixed combinations
236931|NCT01779284|24-hour monitoring
236932|NCT01779271|Pelubi
236933|NCT01779271|Pelubiprofen
236934|NCT01779271|Loxoprofen
236935|NCT01779271|Anti-pyretic
236936|NCT01779271|Fever
236937|NCT01779258|xerosis
236938|NCT01779258|dry skin
236939|NCT01779258|dermatitis
236940|NCT01779258|eczema
236941|NCT01779258|emollient
236942|NCT01779258|corticosteroid
236943|NCT01779258|flare
236944|NCT01779232|endometriosis
236945|NCT01779232|ivf
236946|NCT01779232|ovarian reserve
236947|NCT01779232|danazol
236948|NCT01779219|intraoperative magnetic resonance
236949|NCT01779219|stereotactic biopsy
236950|NCT01779219|brain tumor
236951|NCT01779219|frameless stereotaxy
236952|NCT01779219|image-guided neurosurgery
236953|NCT01779193|group B streptococcus
236954|NCT01779193|pregnancy
236955|NCT01779193|probiotics
236956|NCT01779180|Vitamin A supplementation
236957|NCT01779180|BCG vaccination
236958|NCT01779180|diphtheria-tetanus-pertussis vaccination
236959|NCT01779180|measles vaccination
236960|NCT01779180|atopy
236961|NCT01779167|WM
236962|NCT01779154|eosinophilic esophagitis
236963|NCT01779154|eosinophilic gastritis
236964|NCT01779154|eosinophilic enteritis
236965|NCT01779154|eosinophilic colitis
236966|NCT01779141|Type 1 Diabetes Mellitus - T1DM
236967|NCT01779141|Pregnancy
236968|NCT01779141|Insulin Pump
236969|NCT01779141|Glucose Sensor
236970|NCT01779141|Continuous Subcutaneous Insulin Infusion - CSII
236971|NCT01779141|Sensor Augmented Pump - SAP
236972|NCT01779141|Continuous Glucose Monitoring - CGM
236973|NCT01779115|Registry,Diabetes,Health Maintenance Organization
236974|NCT01779089|diabetic nephropathy
236975|NCT01779089|diabetic kidney disease
236976|NCT01779089|minocycline
236977|NCT01779089|proteinuria
236978|NCT01779089|albuminuria
236979|NCT01779063|lymphedema
236980|NCT01779063|self-care
236981|NCT01779063|breast cancer
236982|NCT01779024|Addiction
236983|NCT01779024|Alcohol
236984|NCT01779024|Alcohol Clamp
236985|NCT01778998|incision
236986|NCT01778998|pre-cut
236987|NCT01778998|wound architecture
236988|NCT01778998|OCT
236989|NCT01778985|Pelvic organ prolapse
236990|NCT01778985|Menopause
236991|NCT01778985|Estrogen
236992|NCT01778985|Premarin
236993|NCT01778972|Fall prevention
236994|NCT01778972|Home exercise
236995|NCT01778972|Strength training
236996|NCT01778972|Balance training
236997|NCT01778946|Nicotine
236998|NCT01778946|Down Syndrome
236999|NCT01778946|Mild Cognitive Impairment
237000|NCT01778946|Event Related Potential
237001|NCT01778946|Memory
237002|NCT01778946|Attention
237003|NCT01778946|Trisomy 21
237004|NCT01778946|Neuroprotection
237005|NCT01778946|Cognitive Enhancement
237006|NCT01778946|Alzheimer's Disease
237007|NCT01778946|Dementia
237008|NCT01778946|APOE
237009|NCT01778933|Renal cell carcinoma
237010|NCT01778933|Renal nodules
237011|NCT01778907|Pharmacogenetics
237012|NCT01778907|Depression
237013|NCT01778907|Depressive Disorder
237014|NCT01778907|Cytochrome P-450 CYP2D6
237015|NCT01778907|Antidepressive Agents, Tricyclic
237016|NCT01778907|Antidepressive Agents, Second-Generation
237017|NCT01778907|Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
237018|NCT01778907|Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant
237019|NCT01778907|Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant
237020|NCT01778907|Multicenter studies
237021|NCT01778894|Diastolic Dysfunction, Diastolic Heart Failure, Diastolic
237022|NCT01778894|Echocardiography
237023|NCT01778881|Bruxism
237024|NCT01778881|Physical therapy modalities
237025|NCT01778881|Massage
237026|NCT01778881|Muscle stretching exercises
237027|NCT01778881|Relaxation therapy
237028|NCT01778881|Imagination
237029|NCT01778855|stroke
237030|NCT01778855|hypothermia
237031|NCT01778855|thrombolysis
237032|NCT01778855|imaging
237033|NCT01778855|collateral circulation
237034|NCT01778855|recanalization
237035|NCT01778855|reperfusion
237036|NCT01778842|antiplatelet effect
237037|NCT01778842|prasugrel
237038|NCT01778842|clopidogrel
237039|NCT01778842|acute coronary syndrome
237040|NCT01778816|Achilles tendon, muscle volume, Achilles tendon length, force, ATRS, Hannover, AOFAS
237041|NCT01778777|rotator cuff tear arthropathy
237042|NCT01778777|inverse prosthesis
237043|NCT01778777|safety
237044|NCT01778777|universe reverse
237045|NCT01778751|Self-Management Support
237046|NCT01778751|Depression
237047|NCT01778751|Home Telehealth
237048|NCT01778725|Chorioamnionitis, S100B, Brain, Neuro-development
237049|NCT01778712|Multi-level intervention
237050|NCT01778712|Menopause
237051|NCT01778712|Body composition
237052|NCT01778712|Abdominal adipose tissue
237053|NCT01778712|Visceral adipose tissue
237054|NCT01778712|Perceived stress
237055|NCT01778712|Computed tomography
237056|NCT01778712|Dual energy X-ray absorptiometry
237057|NCT01778699|Lactobacillus brevis CD2
237058|NCT01778699|caries incidence
237059|NCT01778699|plaque-pH
237060|NCT01778686|Positron Emission Tomography
237061|NCT01778686|Serotonin
237062|NCT01778686|5-HT2A
237063|NCT01778686|Radioligand
237064|NCT01778660|Fecal Incontinence
237065|NCT01778660|Treatment options
237066|NCT01778660|Patient Satisfaction
237067|NCT01778647|ADHD
237068|NCT01778647|Omega- 3 Fatty acids
237069|NCT01778647|CGI
237070|NCT01778647|Conners rating scale
237071|NCT01778647|Stimulants
237072|NCT01778634|Ureaplasma parvum
237073|NCT01778634|Ureaplasma urealyticum
237074|NCT01778634|prematurity
237075|NCT01778634|bronchopulmonary dysplasia
237076|NCT01778634|azithromycin
237077|NCT01778621|Acupuncture
237078|NCT01778621|AMH
237079|NCT01778621|Infertility
237080|NCT01778621|PCOS
237081|NCT01778621|Pregnancy rate
237082|NCT01778608|Sedation
237083|NCT01778595|Microbiome
237084|NCT01778595|Feces
237085|NCT01778595|Cancer Screening
237086|NCT01778582|Emotion
237087|NCT01778582|Informed Consent
237088|NCT01778569|Psoriasis
237089|NCT01778569|Cardiovascular Risk Factors
237090|NCT01778569|Inflammation
237091|NCT01778569|Lipoproteins
237092|NCT01778569|Metabolic Dysfunction
237093|NCT01778556|Lipodystrophy
237094|NCT01778556|Leptin
237095|NCT01778556|Energy Expenditure
237096|NCT01778556|Diabetes
237097|NCT01778556|Hypertriglyceridemia
237098|NCT01778543|Coloboma
237099|NCT01778530|Glioblastoma
237100|NCT01778530|Anti-Angiogenesis
237101|NCT01778530|Radiotherapy
237102|NCT01778530|Malignant Glioma
237103|NCT01778530|Progression
237104|NCT01778517|Psychogenic Movement Disorders
237105|NCT01778504|Children and Adolescents
237106|NCT01778504|Natural History Study
237107|NCT01778504|Neurodevelopmental Disorders
237108|NCT01778504|Autism
237109|NCT01778504|Obsessive Compulsive Disorder
237110|NCT01778491|Phenotype-Genotype correlation
237111|NCT01778491|Phenotype
237112|NCT01778491|Phenotypes
237113|NCT01778491|Age Related Macular Degeneration
237114|NCT01778478|Anxiety
237115|NCT01778478|Depression
237116|NCT01778478|Adolescents and Adults
237117|NCT01778478|Cancer Diagnosis
237118|NCT01778465|Chronic Rhinosinusitis
237119|NCT01778465|Aspirin exacerbated respiratory disease
237120|NCT01778465|Asthma
237121|NCT01778465|Aspirin sensitivity
237122|NCT01778465|Salicylate
237123|NCT01778452|Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.
237124|NCT01778439|Phase 1
237125|NCT01778439|Dose escalation
237126|NCT01778439|relapsed or refractory
237127|NCT01778439|solid tumor
237128|NCT01778426|Chronic neuropathic pain syndrome
237129|NCT01778426|Spinal Cord Stimulation
237130|NCT01778426|Painstim devices
237131|NCT01778426|Efficacy
237132|NCT01778426|Safety
237133|NCT01778400|Ultrasound
237134|NCT01778400|Radiofrequency
237135|NCT01778400|Ethanol
237136|NCT01778400|Predominantly cystic thyroid nodule
237137|NCT01778400|Thyroid nodule
237138|NCT01778400|Thyroid
237139|NCT01778374|Emergency Medicine
237140|NCT01778374|Screening
237141|NCT01778374|Point of care testing
237142|NCT01778374|Video assisted counseling
237143|NCT01778361|Human immunodeficiency virus
237144|NCT01778361|low bone mineral density
237145|NCT01778361|osteopenia
237146|NCT01778361|osteoporosis
237147|NCT01778361|fracture
237148|NCT01778348|Type 1 diabetes
237149|NCT01778348|Closed-loop glucose control
237150|NCT01778348|Artificial Pancreas
237151|NCT01778348|Continuous subcutaneous insulin infusion
237152|NCT01778348|Continuous glucose monitoring
237153|NCT01778335|recanalization
237154|NCT01778335|endovascular
237155|NCT01778335|thrombectomy
237156|NCT01778309|aseptic inflammation
237157|NCT01778309|skeletal muscle function
237158|NCT01778309|exercise
237159|NCT01778296|Dorsal branch of the digital nerve;
237160|NCT01778296|dorsal digital artery;
237161|NCT01778296|dorsal digital island flap;
237162|NCT01778296|neurocutaneous island flap.
237163|NCT01778270|pleural effusion
237164|NCT01778270|pleural drainage
237165|NCT01778270|thorax impedance
237166|NCT01778270|respiration parameters
237167|NCT01778270|heart sounds analysis
237168|NCT01778257|Mate extracts
237169|NCT01778257|Obesity
237170|NCT01778257|abdominal fat
237171|NCT01778244|schizophrenia; dyslipidemia
237172|NCT01778231|Focus
237173|NCT01778231|uptake
237174|NCT01778231|Lutein
237175|NCT01778231|Zeaxanthin
237176|NCT01778231|individuals
237177|NCT01778218|Coronary Artery Disease
237178|NCT01778218|CAD
237179|NCT01778192|Bowel preparation
237180|NCT01778192|Polyethylene glycol
237181|NCT01778192|Sodium picosulphate
237182|NCT01778179|Lentigines
237183|NCT01778179|Cryotherapy
237184|NCT01778179|hyperpigmentation
237185|NCT01778166|Early enteral nutrition
237186|NCT01778166|Laparoscopic gastrointestinal surgery
237187|NCT01778166|Immuno-enhanced nutrition
237188|NCT01778153|Fitness training
237189|NCT01778153|Personal training
237190|NCT01778140|Clinical Decision Support Systems
237191|NCT01778140|Contrast-induced nephropathy
237192|NCT01778127|Cancer Survivor
237193|NCT01778127|Physical Activity
237194|NCT01778127|Health Outcomes
237195|NCT01778127|Rewards-Based Intervention
237196|NCT01778127|Cardiovascular Health
237197|NCT01778127|Musculoskeletal Health
237198|NCT01778127|Exercise
237199|NCT01778114|Vitamin D2
237200|NCT01778114|Vitamin D3
237201|NCT01778114|Vitamin D
237202|NCT01778114|Orange Juice
237203|NCT01778101|preterm infants
237204|NCT01778101|reflux
237205|NCT01778101|impedance
237206|NCT01778101|pH
237207|NCT01778101|monitoring
237208|NCT01778101|lansoprazole
237209|NCT01778075|Healthy
237210|NCT01778075|Ultracet extended release (ER)
237211|NCT01778075|Tramadol hydrochloride
237212|NCT01778075|Acetaminophen
237213|NCT01778075|Bioequivalence
237214|NCT01778036|Neck movement
237215|NCT01778036|motor control
237216|NCT01778036|disability
237217|NCT01778036|psychological variables
237218|NCT01778036|Head Movements
237219|NCT01778036|Physical therapy
237220|NCT01778036|Fear avoidance
237221|NCT01778036|Self Efficacy
237222|NCT01778036|Catastrophizing
237223|NCT01778036|Fly test
237224|NCT01778036|Postural sway
237225|NCT01778010|cocaine
237226|NCT01778010|modafinil
237227|NCT01778010|self-administration
237228|NCT01778010|DRD4
237229|NCT01777906|nasal polyps
237230|NCT01777906|nasal steriod sprays
237231|NCT01777893|Type-2 diabetes mellitus
237232|NCT01777893|Obesity
237233|NCT01777893|High protein diet
237234|NCT01777893|Low GI
237235|NCT01777893|Physical activity
237236|NCT01777815|NeoChord
237237|NCT01777815|DS1000
237238|NCT01777815|Mitral Valve
237239|NCT01777815|Mitral Valve Regurgitation
237240|NCT01777815|MR
237241|NCT01777815|Mitral Valve Repair
237242|NCT01777815|Mitral Valve Prolapse
237243|NCT01777815|Artificial Chordae
237244|NCT01777789|fMRI
237245|NCT01777789|Dementia
237246|NCT01777789|Alzheimer's disease
237247|NCT01777789|functional neuroimaging
237248|NCT01777789|Memory
237249|NCT01777776|Open-label dose escalation
237250|NCT01777776|BRAF inhibitor
237251|NCT01777776|LEE011
237252|NCT01777776|CDK4/6
237253|NCT01777776|LGX818
237254|NCT01777776|RAF kinase inhibitor
237255|NCT01777776|Metastatic melanoma
237256|NCT01777776|BRAF
237257|NCT01777776|V600
237258|NCT01777750|Myocardial Infarction
237259|NCT01777750|Myocardial Reperfusion Injury
237260|NCT01777750|Reperfusion Injury
237261|NCT01777750|Anterior Wall Myocardial Infarction
237262|NCT01777750|Inferior Wall Myocardial Infarction
237263|NCT01777750|Pathologic Processes
237264|NCT01777750|Myocardial Ischemia
237265|NCT01777737|Idiopathic Pulmonary Fibrosis
237266|NCT01777737|Trimethoprim-sulfamethoxazole
237267|NCT01777737|Pneumocystis jiroveci
237268|NCT01777711|mental contrasting
237269|NCT01777711|weight loss
237270|NCT01777711|obese couples
237271|NCT01777711|obesity
237272|NCT01777711|overweight
237273|NCT01777711|planning
237274|NCT01777711|health
237275|NCT01777711|diet
237276|NCT01777711|exercise
237277|NCT01777711|physical activity
237278|NCT01777711|goal
237279|NCT01777711|goal-setting
237280|NCT01777698|body composition
237281|NCT01777698|hepatocellular carcinoma
237282|NCT01777698|chemoembolization
237283|NCT01777685|Sulpiride
237284|NCT01777685|Therapeutic drug monitoring
237285|NCT01777685|Pharmacokinetics
237286|NCT01777659|exercise
237287|NCT01777659|neuromodulation
237288|NCT01777659|blood flow
237289|NCT01777659|exercise capacity
237290|NCT01777646|Mesenchymal Strmal Cells (MSC)
237291|NCT01777646|Amyotrophic Lateral Sclerosis (ALS)
237292|NCT01777646|Neuroprotection
237293|NCT01777646|Neurodegeneration
237294|NCT01777646|Stem cells
237295|NCT01777594|hepatocellular carcinoma
237296|NCT01777594|HCC
237297|NCT01777594|liver
237298|NCT01777594|liver cancer
237299|NCT01777594|sorafenib
237300|NCT01777581|sciatica radiculopathy lumbar disc lumbosacral disc
237301|NCT01777555|Parkinson's Disease
237302|NCT01777555|Motor fluctuations
237303|NCT01777555|levodopa
237304|NCT01777555|inhaled drugs
237305|NCT01777555|Off episodes
237306|NCT01777542|Rett syndrome
237307|NCT01777542|RTT
237308|NCT01777542|IGF-1
237309|NCT01777542|autism spectrum disorder
237310|NCT01777529|Measles
237311|NCT01777529|Mumps
237312|NCT01777529|Rubella
237313|NCT01777516|Platelet Aggregation
237314|NCT01777516|Cardiovascular Diseases
237315|NCT01777516|Salicylic Acid
237316|NCT01777503|acute coronary syndrome
237317|NCT01777503|elderly
237318|NCT01777503|percutaneous revascularization
237319|NCT01777503|antiaggregant drugs
237320|NCT01777490|Caregivers - Not professionals
237321|NCT01777490|Frail Elderly
237322|NCT01777490|Long-term Care
237323|NCT01777490|Quality of Life
237324|NCT01777451|Whole Body Imaging
237325|NCT01777451|Magnetic Resonance Imaging
237326|NCT01777451|Neurofibromatosis 1
237327|NCT01777451|Diffusion Magnetic Resonance Imaging
237328|NCT01777451|Peripheral Nerve Sheath Tumors, Malignant
237329|NCT01777412|NMO
237330|NCT01777412|NMOSD
237331|NCT01777412|NMO-IgG
237332|NCT01777412|Aquaporin-4
237333|NCT01777412|AQP4
237334|NCT01777412|anti-AQP4
237335|NCT01777386|scar
237336|NCT01777386|contracture
237337|NCT01777386|perforator flap
237338|NCT01777386|preexpanded perforator flap
237339|NCT01777386|perforator vessel
237340|NCT01777386|artery diameter
237341|NCT01777373|conducting airway, bronchiolization
237342|NCT01777360|severe
237343|NCT01777360|uncontrolled
237344|NCT01777347|Keywords provided by ASSISTANCE PUBLIQUE HOPITAUX DE PARIS:
237345|NCT01777347|Acute Viral bronchiolitis
237346|NCT01777347|Hypertonic saline
237347|NCT01777347|Hospitalization
237348|NCT01777347|Infants
237349|NCT01777347|Hospital admissions
237350|NCT01777347|Additional relevant MeSH terms:
237351|NCT01777347|Bronchiolitis
237352|NCT01777347|Bronchiolitis, Viral
237353|NCT01777347|Bronchial Diseases
237354|NCT01777347|Respiratory Tract Diseases
237355|NCT01777347|Lung Diseases, Obstructive
237356|NCT01777347|Respiratory Tract Infections
237357|NCT01777347|Virus Diseases
237358|NCT01777321|Herpes Zoster
237359|NCT01777321|Intramuscular
237360|NCT01777321|Subcutaneous
237361|NCT01777321|Safety
237362|NCT01777321|≥50 years of age
237363|NCT01777321|Adults
237364|NCT01777321|Immunogenicity
237365|NCT01777321|Elderly
237366|NCT01777308|Immunogenicity
237367|NCT01777308|Booster
237368|NCT01777308|Healthy
237369|NCT01777308|Vaccine response
237370|NCT01777308|Safety
237371|NCT01777308|Neisseria meningiditis
237372|NCT01777308|Antibody persistence
237373|NCT01777308|Meningococcal conjugate vaccine
237374|NCT01777295|Adults
237375|NCT01777295|Reactogenicity
237376|NCT01777295|Naive
237377|NCT01777295|Immune responses
237378|NCT01777295|Read-outs
237379|NCT01777295|Hepatitis B
237380|NCT01777295|Healthy
237381|NCT01777282|albiglutide
237382|NCT01777282|Japanese
237383|NCT01777282|glucagon-like peptide-1
237384|NCT01777282|GSK716155
237385|NCT01777256|systemic lupus erythematosus
237386|NCT01777256|adaptive design
237387|NCT01777256|clinical safety and efficacy
237388|NCT01777256|pharmacodynamics
237389|NCT01777243|pharmacokinetic
237390|NCT01777243|systemic amyloidosis
237391|NCT01777243|safety
237392|NCT01777243|dose escalation
237393|NCT01777243|Carboxy Pyrrolidine Hexanoyl Pyrrolidine Carboxylate (CPHPC)
237394|NCT01777243|biomarker
237395|NCT01777243|GSK2315698
237396|NCT01777243|GSK2398852
237397|NCT01777243|SAP
237398|NCT01777243|pharmacodynamic
237399|NCT01777243|co-administration
237400|NCT01777243|intravenous
237401|NCT01777217|Urination Disorder
237402|NCT01777217|Overactive Bladder
237403|NCT01777217|Prostate Cancer Radiation
237404|NCT01777217|Vesicare
237405|NCT01777204|Renal transplant, Gastrointestinal motility, Biomagnetism
237406|NCT01777178|bicarbonate
237407|NCT01777178|dialysis
237408|NCT01777165|GFR
237409|NCT01777165|Acute Kidney Injury
237410|NCT01777165|High Risk cardiac surgery
237411|NCT01777152|Antibodies, Monoclonal
237412|NCT01777152|Antibody-Drug Conjugate
237413|NCT01777152|Antigens, CD30
237414|NCT01777152|Drug Therapy
237415|NCT01777152|Hematologic Diseases
237416|NCT01777152|Lymphoma
237417|NCT01777152|Monomethyl auristatin E
237418|NCT01777152|Lymphoma, T-Cell
237419|NCT01777152|Lymphoma, Non-Hodgkin
237420|NCT01777152|Lymphoma, Large-Cell, Anaplastic
237421|NCT01777139|Retigabine
237422|NCT01777139|Drug-Resistant
237423|NCT01777139|Epilepsy
237424|NCT01777139|Partial-Onset Seizures
237425|NCT01777139|Safety and Tolerability
237426|NCT01777139|Immediate Release
237427|NCT01777139|Long-Term
237428|NCT01777139|Adjunctive Therapy
237429|NCT01777139|Asian Subjects
237430|NCT01777139|Efficacy
237431|NCT01777139|GW582892
237432|NCT01777126|cystectomy
237433|NCT01777126|parenteral nutrition
237434|NCT01777126|discharge
237435|NCT01777126|outcome
237436|NCT01777113|Chronic Stroke
237437|NCT01777113|Gait
237438|NCT01777113|Exercise
237439|NCT01777113|High intensity aerobic training
237440|NCT01777113|Strength training
237441|NCT01777113|Randomized controlled trial
237442|NCT01777100|Postoperative pain
237443|NCT01777100|Patient controlled analgesia
237444|NCT01777100|Hyperalgesia
237445|NCT01777100|Remifentanil
237446|NCT01777100|Sufentanil
237447|NCT01777100|Morphine
237448|NCT01777100|Abdominal surgery
237449|NCT01777100|Safety
237450|NCT01777087|Pain
237451|NCT01777087|Functional Magnetic Resonance Imaging
237452|NCT01777074|Vaccination
237453|NCT01777074|Acceptability
237454|NCT01777074|Hepatitis B
237455|NCT01777061|Prostate Cancer
237456|NCT01777061|Recurrent Prostate Cancer
237457|NCT01777061|PET Scan
237458|NCT01777061|FDG-PET
237459|NCT01777061|[11C]Acetate
237460|NCT01777061|C11-Acetate
237461|NCT01777035|mechanical ventilation
237462|NCT01777035|physical therapy
237463|NCT01777035|occupational therapy
237464|NCT01777035|ICU acquired weakness
237465|NCT01777035|critical illness myopathy
237466|NCT01777022|Education, Stillbirth, Prevention, Management
237467|NCT01777009|Total Knee Replacement
237468|NCT01777009|Patellar Eversion
237469|NCT01777009|Surgical Exposure
237470|NCT01777009|Outcomes
237471|NCT01777009|Quadriceps Strength
237472|NCT01777009|Straight Leg Raise
237473|NCT01777009|SF-36
237474|NCT01776996|Expanded access, HIV, maraviroc
237475|NCT01776970|Motor Neuron Disease
237476|NCT01776970|Amyotrophic lateral sclerosis
237477|NCT01776970|Cannabinoids
237478|NCT01776970|Sativex
237479|NCT01776970|Spasticity
237480|NCT01776957|Abortion rate
237481|NCT01776957|Intrauterine device
237482|NCT01776944|Resting energy expenditure
237483|NCT01776944|Handheld calorimeter
237484|NCT01776944|Obese and overweight
237485|NCT01776944|Pediatrics
237486|NCT01776931|Indicator Amino acid technique
237487|NCT01776931|Lysine requirements
237488|NCT01776931|Pregnancy
237489|NCT01776931|Dietary protein
237490|NCT01776918|POLG1 Mutation
237491|NCT01776918|Phenylketonuria
237492|NCT01776905|Melanoma
237493|NCT01776905|Cancer
237494|NCT01776892|Collagenase
237495|NCT01776892|Needle aponeurotomy
237496|NCT01776866|Coronary Angiography
237497|NCT01776866|Rotational Coronary Angiography
237498|NCT01776866|Contrast Media
237499|NCT01776866|Radiation
237500|NCT01776866|Quantitative Coronary Angiography
237501|NCT01776853|Irritable Bowel Syndrome
237502|NCT01776853|Fructose
237503|NCT01776853|Fructans
237504|NCT01776853|MRI
237505|NCT01776853|Fermentation
237506|NCT01776853|Breath Tests
237507|NCT01776853|Flatulence
237508|NCT01776853|Abdominal Pain
237509|NCT01776853|Diarrhoea
237510|NCT01776840|Mantle cell lymphoma
237511|NCT01776840|Ibrutinib
237512|NCT01776840|Bruton's tyrosine kinase inhibitor
237513|NCT01776840|Bendamustine hydrochloride
237514|NCT01776840|Rituximab
237515|NCT01776827|GERD
237516|NCT01776827|Hiatal Hernia
237517|NCT01776827|Paraesophageal Hernia
237518|NCT01776827|Biologic Mesh
237519|NCT01776814|Entecair
237520|NCT01776814|Tenofovir
237521|NCT01776801|intracranial baroreflex
237522|NCT01776762|Nutrition
237523|NCT01776762|Rehabilitation
237524|NCT01776762|Weightloss
237525|NCT01776749|low back pain
237526|NCT01776749|failed back surgery syndrome
237527|NCT01776749|spinal cord stimulation
237528|NCT01776749|subcutaneous stimulation
237529|NCT01776749|peripheral nerve field stimulation
237530|NCT01776736|Scoliosis
237531|NCT01776736|Posture correction
237532|NCT01776723|Chronic Myelomonocytic Leukemia
237533|NCT01776723|CMML
237534|NCT01776723|Leukemia
237535|NCT01776710|Intermittent claudication
237536|NCT01776710|Behavior therapy
237537|NCT01776710|Walking
237538|NCT01776710|Exercise
237539|NCT01776710|Patient education
237540|NCT01776710|Randomized controlled trial
237541|NCT01776658|Ocular pain
237542|NCT01776658|Dry Eye Syndrome
237543|NCT01776658|siRNA
237544|NCT01776658|RNAi
237545|NCT01776658|TRPV1
237546|NCT01776619|Safety
237547|NCT01776619|tolerability
237548|NCT01776619|PK
237549|NCT01776593|bladder capacity; bladder diary; bladder oversensitivity; lower urinary tract symptoms
237550|NCT01776580|Pelvic organ prolapse
237551|NCT01776580|lower urinary tract symptoms
237552|NCT01776580|sexual dysfunction
237553|NCT01776567|coronary artery disease
237554|NCT01776567|stents
237555|NCT01776567|optical imaging
237556|NCT01776554|Influenza, Pandemic, H5N1, Children
237557|NCT01776541|Influenza, Pandemic, H5N1, Adults
237558|NCT01776515|Low back pain
237559|NCT01776515|Wontran
237560|NCT01776515|Wontran SR Tab.
237561|NCT01776515|Tramadol Hydrochloride/Acetaminophen
237562|NCT01776489|Food allergy
237563|NCT01776489|Sphingosine-1-phosphate
237564|NCT01776489|Biomarker
237565|NCT01776489|Double-blind placebo-controlled food challenge
237566|NCT01776489|Anaphylaxis
237567|NCT01776476|glutamine dipeptide
237568|NCT01776476|randomized controlled trial
237569|NCT01776476|insulin resistance
237570|NCT01776476|critical illness
237571|NCT01776476|trauma
237572|NCT01776463|Z-360
237573|NCT01776463|Japanese
237574|NCT01776463|pK
237575|NCT01776450|Abdominal Aortic Aneurysm
237576|NCT01776424|Cardiovascular events
237577|NCT01776424|Rivaroxaban
237578|NCT01776424|Xarelto
237579|NCT01776424|anticoagulant
237580|NCT01776424|blood thinner
237581|NCT01776424|aspirin
237582|NCT01776424|ASA
237583|NCT01776424|CAD
237584|NCT01776424|coronary disease
237585|NCT01776424|artery disease
237586|NCT01776424|coronary artery bypass graft
237587|NCT01776424|stroke
237588|NCT01776424|heart attack
237589|NCT01776424|angina
237590|NCT01776424|arterial vascular disease
237591|NCT01776424|transient ischemic attack
237592|NCT01776424|TIA
237593|NCT01776424|heart disease
237594|NCT01776398|COPD
237595|NCT01776398|Chronic Obstructive Pulmonary Disease
237596|NCT01776398|Lung disease
237597|NCT01776398|Emphysema
237598|NCT01776398|Smoking
237599|NCT01776398|Healthy Smoker
237600|NCT01776398|Smoker
237601|NCT01776398|Non-smoker
237602|NCT01776385|[C08.785.640]
237603|NCT01776385|(C08.528.778)
237604|NCT01776385|[C19.642.713]
237605|NCT01776385|mesothelium
237606|NCT01776372|Drainage
237607|NCT01776372|Chest tubes
237608|NCT01776372|Randomized Controlled Trial
237609|NCT01776359|Muscle
237610|NCT01776359|Protein
237611|NCT01776359|Diet
237612|NCT01776359|Exercise
237613|NCT01776333|ICU
237614|NCT01776320|Erectile Dysfunction
237615|NCT01776320|Topical Alprostadil
237616|NCT01776307|BBI608
237617|NCT01776294|Prehypertension
237618|NCT01776294|Prevalence
237619|NCT01776294|Cardiovascular Risk Factors
237620|NCT01776281|effects
237621|NCT01776281|KMC
237622|NCT01776281|LBW
237623|NCT01776281|preterm
237624|NCT01776281|temperature
237625|NCT01776281|breastfeeding
237626|NCT01776281|secondary hospitals
237627|NCT01776268|antimicrobial proteins
237628|NCT01776255|Obesity
237629|NCT01776255|Overweight
237630|NCT01776255|Lifestyle
237631|NCT01776255|American Indian
237632|NCT01776242|low back pain
237633|NCT01776242|elderly
237634|NCT01776242|back pain
237635|NCT01776242|lumbar pain
237636|NCT01776242|over 65
237637|NCT01776229|nightmare
237638|NCT01776229|PTSD
237639|NCT01776229|trauma
237640|NCT01776229|children
237641|NCT01776229|cognitive behavior therapy
237642|NCT01776229|stress
237643|NCT01776229|sleep
237644|NCT01776216|Endothelial function
237645|NCT01776216|Dairy
237646|NCT01776177|Allergic asthma
237647|NCT01776177|Omalizumab therapy
237648|NCT01776177|IgE profile
237649|NCT01776164|Friedreich
237650|NCT01776164|ataxia
237651|NCT01776164|FRDA
237652|NCT01776164|FA
237653|NCT01776164|recessive
237654|NCT01776164|neurodegenerative
237655|NCT01776164|cerebellum
237656|NCT01776151|HIV
237657|NCT01776151|cardiovascular diseases
237658|NCT01776151|vascular stiffness
237659|NCT01776138|Elderly
237660|NCT01776138|Chemotherapy
237661|NCT01776138|Cystectomy
237662|NCT01776138|Radical Cystectomy
237663|NCT01776138|University of North Carolina
237664|NCT01776138|Cancer
237665|NCT01776138|Bladder Cancer
237666|NCT01776138|Bladder
237667|NCT01776125|Neurofibromatosis Type One
237668|NCT01776125|Scoliosis
237669|NCT01776112|schizophrenia
237670|NCT01776112|negative symptoms
237671|NCT01776112|cognitive deficits
237672|NCT01776112|synaptic plasticity
237673|NCT01776099|type 2 diabetes
237674|NCT01776099|nutrition
237675|NCT01776099|fibers
237676|NCT01776073|Transplantation
237677|NCT01776073|Healthcare Disparities
237678|NCT01776073|Quality Assurance
237679|NCT01776060|Primary Progressive Multiple Sclerosis
237680|NCT01776060|Multiple Sclerosis
237681|NCT01776060|biomarker
237682|NCT01776060|'omic
237683|NCT01776060|progression
237684|NCT01776034|Self Care
237685|NCT01776034|Exercise
237686|NCT01776034|Weight management
237687|NCT01776021|Urinary tract infection
237688|NCT01776021|Recurrent urinary tract infection
237689|NCT01776021|Cranberry
237690|NCT01776021|Prevention
237691|NCT01776021|E-coli
237692|NCT01775995|Chronic Pain
237693|NCT01775995|Low Back Pain
237694|NCT01775982|French language validation
237695|NCT01775982|The Confusion Assessment Method (CAM)
237696|NCT01775943|Epidermal growth factor receptor
237697|NCT01775943|Mutation
237698|NCT01775943|Lung cancer
237699|NCT01775943|Drug sensitivity
237700|NCT01775930|Kidney Cancer
237701|NCT01775930|Refractory Renal Cell Carcinoma
237702|NCT01775930|RCC
237703|NCT01775930|Clear cell kidney cancer with metastatic disease
237704|NCT01775930|Carfilzomib
237705|NCT01775891|pilsicainide
237706|NCT01775891|class IC antiarrhythmic drug
237707|NCT01775891|paroxysmal atrial fibrillation
237708|NCT01775891|catheter ablation
237709|NCT01775878|Diabetes
237710|NCT01775878|HbA1c
237711|NCT01775878|Fructosamine
237712|NCT01775878|Blood Pressure
237713|NCT01775878|Telemonitoring
237714|NCT01775865|aortic stiffness
237715|NCT01775865|endothelium-dependent dilation
237716|NCT01775865|vascular aging
237717|NCT01775865|oxidative stress
237718|NCT01775865|inflammation
237719|NCT01775865|nitric oxide
237720|NCT01775865|nuclear factor kappa B
237721|NCT01775852|Acceptance and Commitment Therapy (ACT)
237722|NCT01775852|Depression
237723|NCT01775852|Illness Management
237724|NCT01775852|Behavioral treatment
237725|NCT01775852|Impairment
237726|NCT01775826|physical activity
237727|NCT01775826|sedentary behavior
237728|NCT01775826|accelerometer
237729|NCT01775826|GPS
237730|NCT01775826|GIS
237731|NCT01775826|machine learning
237732|NCT01775813|Insulin resistance
237733|NCT01775813|Puberty
237734|NCT01775813|Obesity
237735|NCT01775813|Hypogonadism
237736|NCT01775813|Gonadal dysfunction
237737|NCT01775813|Metformin
237738|NCT01775787|smoking
237739|NCT01775774|Acute Respiratory Distress Syndrome
237740|NCT01775774|Acute Lung Injury
237741|NCT01775774|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
237742|NCT01775761|Thorough QTc evaluation of tafamidis compared to the effects of moxifloxacin and placebo in healthy volunteers.
237743|NCT01775735|headache
237744|NCT01775735|pain
237745|NCT01775735|chronic
237746|NCT01775709|middler ear infection
237747|NCT01775696|Alzheimer's disease
237748|NCT01775696|Pittsburgh binding Compound (PiB)
237749|NCT01775696|Positron Emission Tomography (PET)
237750|NCT01775696|Inflammation
237751|NCT01775696|Anti Abeta immune responses
237752|NCT01775696|Blood markers
237753|NCT01775696|MRI
237754|NCT01775683|homelessness
237755|NCT01775670|Arthrosis
237756|NCT01775657|pulmonary air leak
237757|NCT01775657|Thopaz
237758|NCT01775657|digital
237759|NCT01775657|analog
237760|NCT01775657|randomized
237761|NCT01775618|Hemophilia A
237762|NCT01775618|Factor VIII
237763|NCT01775618|Prophylaxis
237764|NCT01775618|Pediatric
237765|NCT01775605|Subject
237766|NCT01775592|P.f resistance
237767|NCT01775553|Relapsed Multiple Myeloma
237768|NCT01775553|Refractory Multiple Myeloma
237769|NCT01775553|High-Dose Carfilzomib
237770|NCT01775553|Standard Dose Carfilzomib
237771|NCT01775553|Carfilzomib
237772|NCT01775540|Dry eye
237773|NCT01775540|Artificial tears
237774|NCT01775540|Ocular surface inflammation
237775|NCT01775501|sorafenib
237776|NCT01775501|FOLFOX
237777|NCT01775488|Benign Prostatic Hyperplasia
237778|NCT01775488|BPH
237779|NCT01775488|LUTS
237780|NCT01775488|Vortx Rx
237781|NCT01775488|Histotripsy
237782|NCT01775462|Hypohidrotic Ectodermal Dysplasia
237783|NCT01775462|XLHED
237784|NCT01775449|Anticancer drug;
237785|NCT01775449|Oxaliplatin;
237786|NCT01775449|Digestive cancer system
237787|NCT01775449|Acute oxaliplatin-induced hypersensitivity
237788|NCT01775449|Hyperalgesia;
237789|NCT01775449|Allodynia;
237790|NCT01775449|Dysesthesia
237791|NCT01775449|Polyamines depleted diet
237792|NCT01775436|palliative care
237793|NCT01775436|HIV/AIDS
237794|NCT01775436|quality of life
237795|NCT01775436|adherence
237796|NCT01775436|spiritual
237797|NCT01775436|threat appraisal
237798|NCT01775436|treatment congruence
237799|NCT01775436|treatment preferences
237800|NCT01775436|dialysis
237801|NCT01775436|hospitalization
237802|NCT01775436|communication
237803|NCT01775436|family intervention
237804|NCT01775436|Family Centered Advance Care Planning
237805|NCT01775436|decision making
237806|NCT01775436|advance care planning
237807|NCT01775436|end of life
237808|NCT01775397|Clostridium
237809|NCT01775397|Difficile
237810|NCT01775397|Infections
237811|NCT01775397|Immunosuppression
237812|NCT01775397|Fidaxomicin
237813|NCT01775397|Vancomycin
237814|NCT01775397|Efficacy
237815|NCT01775397|Stem Cells
237816|NCT01775397|Transplantation
237817|NCT01775397|Adult
237818|NCT01775397|Dificid
237819|NCT01775384|Inflammation
237820|NCT01775384|Oxidative stress
237821|NCT01775384|Immune dysfunction
237822|NCT01775384|Metabolomics.
237823|NCT01775371|Pain
237824|NCT01775371|Emergency
237825|NCT01775371|Analgesia
237826|NCT01775371|ED patients
237827|NCT01775371|acute pain
237828|NCT01775371|IV opioid
237829|NCT01775345|Partial meniscectomy
237830|NCT01775345|Physiotherapy
237831|NCT01775345|Isokinetics
237832|NCT01775345|Cost-effectiveness
237833|NCT01775319|Zinc
237834|NCT01775293|Non-absorbable polypropylene mesh
237835|NCT01775293|WSRS
237836|NCT01775293|Rhytidectomy
237837|NCT01775254|Colon Cancer
237838|NCT01775254|FOLFOX
237839|NCT01775254|Laparoscopic Colectomy
237840|NCT01775254|Open Colectomy
237841|NCT01775254|Robotic Colectomy
237842|NCT01775254|Quality of Life
237843|NCT01775254|Sexual Function
237844|NCT01775254|Peripheral Neuropathy
237845|NCT01775254|Demands of Illness
237846|NCT01775254|Cancer Survivor
237847|NCT01775228|Depression, peer support, recovery, health services
237848|NCT01775215|Left Ventricular Function
237849|NCT01775215|Aortic Valve Replacement
237850|NCT01775215|Late Gadolinium Enhancement
237851|NCT01775215|Cardiac I123 MIBG
237852|NCT01775215|Longitudinal Strain
237853|NCT01775215|Brain Natriuretic Peptide
237854|NCT01775215|High Sensitivity Troponin I
237855|NCT01775189|Relative abuse potential study
237856|NCT01775189|Chronic pain
237857|NCT01775189|oxycodone
237858|NCT01775189|naltrexone
237859|NCT01775189|opioid-related disorders
237860|NCT01775189|drug abusers
237861|NCT01775176|PCOS, Weight, Insulin Sensitivity, Reproductive Function
237862|NCT01775163|Energy
237863|NCT01775163|Metabolism
237864|NCT01775163|Weight Loss
237865|NCT01775163|Exercise
237866|NCT01775150|mobile phone text messaging
237867|NCT01775150|maternality
237868|NCT01775150|infant
237869|NCT01775150|death rate
237870|NCT01775137|CF, Open-label, TIP, phase IV, extension study
237871|NCT01775111|strength training
237872|NCT01775111|protein supplementation
237873|NCT01775111|sarcopenia
237874|NCT01775098|Gout
237875|NCT01775098|uric acid
237876|NCT01775098|allopurinol
237877|NCT01775085|Interventions
237878|NCT01775085|Meaning-Centered Group (MCG)
237879|NCT01775085|Discussion Group (DG)
237880|NCT01775085|Modules
237881|NCT01775085|Sessions
237882|NCT01775085|12-291
237883|NCT01775072|tissue
237884|NCT01775072|blood
237885|NCT01775072|salvia
237886|NCT01775072|buccal swab
237887|NCT01775072|Genomic Profiling
237888|NCT01775072|Solid Tumors
237889|NCT01775072|hematologic cancer
237890|NCT01775072|Clinical Assay
237891|NCT01775072|Research Assay
237892|NCT01775072|12-245
237893|NCT01775046|Valiant
237894|NCT01775046|Captivia
237895|NCT01775046|Stent Graft
237896|NCT01775046|Thoracic
237897|NCT01775046|Aortic
237898|NCT01775033|Pediatrics
237899|NCT01775033|Emergency medical services
237900|NCT01775033|Emergency Treatment
237901|NCT01775033|Telemedicine
237902|NCT01775007|Lens
237903|NCT01775007|Cornea
237904|NCT01775007|Stiffness
237905|NCT01775007|Brillouin Shift
237906|NCT01775007|Young Modulus
237907|NCT01774994|volunteers
237908|NCT01774942|Diabetes Mellitus
237909|NCT01774942|C-Reactive Protein
237910|NCT01774942|Dental Implants, Single-Tooth
237911|NCT01774942|Dental Prosthesis, Implant-Supported
237912|NCT01774929|Osteoarthritis
237913|NCT01774929|Transdermal Therapeutic System (TTS)-fentanyl
237914|NCT01774929|Durogesic
237915|NCT01774903|Low Back Pain
237916|NCT01774903|TTS-fentanyl
237917|NCT01774903|Durogesic
237918|NCT01774877|xinfeng capsule;
237919|NCT01774877|rheumatoid arthritis (RA);
237920|NCT01774877|randomized;
237921|NCT01774877|double-blind;
237922|NCT01774851|HER-2 Gene Amplification
237923|NCT01774851|Esophagus Cancer
237924|NCT01774851|Gastroesophageal Junction Cancer
237925|NCT01774851|Stomach Cancer
237926|NCT01774851|Her2 Positive
237927|NCT01774851|Her2+
237928|NCT01774851|Esophageal Cancer
237929|NCT01774851|Metastatic
237930|NCT01774825|Irritable bowel syndrome
237931|NCT01774825|IBS
237932|NCT01774812|vitamin D
237933|NCT01774812|hemodialysis
237934|NCT01774812|sudden cardiac death
237935|NCT01774812|heart rate variability
237936|NCT01774812|cardiac autonomic tone
237937|NCT01774799|advanced dementia
237938|NCT01774799|advance care planning
237939|NCT01774799|nursing home
237940|NCT01774760|18F-EF5
237941|NCT01774760|PET/CT
237942|NCT01774760|Reproducibility
237943|NCT01774747|Pharmacokinetics
237944|NCT01774734|Chronic neck pain
237945|NCT01774734|Neck strength exerciser
237946|NCT01774734|Biofeedback
237947|NCT01774734|Physiotherapy
237948|NCT01774734|Strengthening exercise
237949|NCT01774734|Randomized trials
237950|NCT01774721|first-line
237951|NCT01774721|locally advanced or metastatic
237952|NCT01774721|non-small cell lung cancer
237953|NCT01774721|epidermal growth factor receptor
237954|NCT01774721|EGFR
237955|NCT01774721|Archer
237956|NCT01774721|mutation
237957|NCT01774721|dacomitinib
237958|NCT01774721|SFJ
237959|NCT01774721|PF-00299804
237960|NCT01774695|IBS
237961|NCT01774695|physical activity
237962|NCT01774695|exercise
237963|NCT01774682|obesity
237964|NCT01774682|surgery
237965|NCT01774669|ischemic stroke
237966|NCT01774669|hemorrhagic stroke
237967|NCT01774669|upper limb
237968|NCT01774669|virtual reality
237969|NCT01774669|physiotherapy
237970|NCT01774669|occupational therapy
237971|NCT01774656|HeartMate II, heart-assist device, left-ventricle assist device, reverse remodeling, recovery, pump explant
237972|NCT01774643|Pancreatic cancer
237973|NCT01774643|Liver metastases
237974|NCT01774643|Tumor tissue biopsy
237975|NCT01774643|Blood samples
237976|NCT01774643|Xenografts
237977|NCT01774643|Murine
237978|NCT01774643|Genomic profiling
237979|NCT01774643|Circulating biomarkers
237980|NCT01774630|Treatment, relapse, complete molecular response
237981|NCT01774617|portal hypertension
237982|NCT01774617|elastography
237983|NCT01774617|Hepatic venous pressure gradient measurement
237984|NCT01774604|Post ERCP acute pancreatitis
237985|NCT01774604|Post Fine Needle Aspiration (FNA) acute pancreatitis
237986|NCT01774604|Indomethacin
237987|NCT01774604|Rectal Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
237988|NCT01774591|Post Menopause
237989|NCT01774591|Female
237990|NCT01774591|Obese
237991|NCT01774578|Non-small Cell Lung Cancer
237992|NCT01774578|Vaccine Therapy
237993|NCT01774578|Immunotherapy
237994|NCT01774578|Second line therapy
237995|NCT01774578|Progressive
237996|NCT01774578|Relapsed
237997|NCT01774565|Diabetes
237998|NCT01774565|Insulin
237999|NCT01774565|Closed-Loop
238000|NCT01774565|Real-time CGM
238001|NCT01774565|Subcutaneous insulin pump
238002|NCT01774565|Hospital
238003|NCT01774539|Fracture
238004|NCT01774539|Physeal injury
238005|NCT01774539|Diffusion MRI
238006|NCT01774500|biomarkers
238007|NCT01774500|Emergency Department
238008|NCT01774500|Seizures
238009|NCT01774500|epilepsy
238010|NCT01774500|S100b
238011|NCT01774500|copeptin
238012|NCT01774487|Biliary Atresia
238013|NCT01774487|Pentoxifylline
238014|NCT01774487|Trental
238015|NCT01774487|Serum bilirubin
238016|NCT01774487|Conjugated bilirubin
238017|NCT01774487|Liver transplantation
238018|NCT01774487|Fibrosis
238019|NCT01774474|Prevention
238020|NCT01774448|Dementia
238021|NCT01774448|Spouse Caregiver
238022|NCT01774448|Depression
238023|NCT01774448|Mind Body Therapy
238024|NCT01774448|Cognitive Therapy
238025|NCT01774448|Quality of Life
238026|NCT01774448|Attention
238027|NCT01774448|Memory
238028|NCT01774435|Schizophrenia
238029|NCT01774435|Schizophrenic
238030|NCT01774435|Stable Schizophrenic
238031|NCT01774422|Hypercapnia
238032|NCT01774422|Respiratory Distress Syndrome
238033|NCT01774422|Extracorporeal CO2 remover
238034|NCT01774422|Noninvasive ventilation
238035|NCT01774409|all advanced malignant tumor
238036|NCT01774396|Hands Rejuvenation, fillers
238037|NCT01774383|Parkinson's disease
238038|NCT01774383|sub-thalamic nucleus
238039|NCT01774383|oscillation
238040|NCT01774383|local field potential
238041|NCT01774344|Regorafenib
238042|NCT01774344|BAY73-4506
238043|NCT01774318|sleep-wake-cycles
238044|NCT01774318|preterm infants
238045|NCT01774318|aEEG
238046|NCT01774318|conventional EEG
238047|NCT01774318|polysomnography
238048|NCT01774292|Impact of alkalized lidocaine on coughing at extubation
238049|NCT01774266|Gastric Cancer
238050|NCT01774266|DNA methylation
238051|NCT01774266|Reprimo
238052|NCT01774266|cell-free DNA
238053|NCT01774266|non-invasive
238054|NCT01774253|DIPG
238055|NCT01774240|Delirium
238056|NCT01774240|Cardiac surgery
238057|NCT01774240|DOS scale
238058|NCT01774227|Refractory glaucoma
238059|NCT01774227|Transcleral cyclophotocoagulation (TSCPC)
238060|NCT01774227|Dark iris
238061|NCT01774227|Pops-titration
238062|NCT01774227|Slow-coagulation
238063|NCT01774214|Resuscitation
238064|NCT01774214|Shock
238065|NCT01774214|Fluid Therapy
238066|NCT01774214|Pediatrics
238067|NCT01774201|Multiple sclerosis
238068|NCT01774201|Self-assessment
238069|NCT01774201|Physical endurance
238070|NCT01774201|Respiratory function
238071|NCT01774201|Fatigue
238072|NCT01774188|Enhanced Extracorporeal Counterpulsation
238073|NCT01774188|intraocular pressure
238074|NCT01774188|Pen type tonometer
238075|NCT01774175|Bowel preparation
238076|NCT01774175|PEG with ascorbic acid
238077|NCT01774175|Picosulfate
238078|NCT01774162|Endoscopic Ultrasound
238079|NCT01774162|Fine needle aspiration
238080|NCT01774162|Fine needle biopsy
238081|NCT01774162|ProCore
238082|NCT01774136|community health workers
238083|NCT01774136|HIV
238084|NCT01774136|PMTCT
238085|NCT01774136|antenatal
238086|NCT01774136|postnatal
238087|NCT01774136|breastfeeding
238088|NCT01774136|South Africa
238089|NCT01774110|stroke
238090|NCT01774110|gait
238091|NCT01774110|acute
238092|NCT01774097|Peripheral Artery Disease
238093|NCT01774097|Intermittent Claudication
238094|NCT01774097|Autologous Stem Cells
238095|NCT01774097|ALDH cells
238096|NCT01774097|Claudicants
238097|NCT01774097|PAD
238098|NCT01774097|Peak Walking Time
238099|NCT01774097|MRI
238100|NCT01774097|Vascular Flow
238101|NCT01774097|Anatomy
238102|NCT01774097|Perfusion
238103|NCT01774084|Insulin sensitivity
238104|NCT01774084|Beta cell function
238105|NCT01774084|Carbohydrate preload
238106|NCT01774084|Elective hip replacement
238107|NCT01774084|Double-blind randomized control study
238108|NCT01774071|89Zr-DFO-MSTP2109A
238109|NCT01774071|tracer
238110|NCT01774071|pet scan
238111|NCT01774071|12-178
238112|NCT01774058|blood flow volume
238113|NCT01774058|ilomedin
238114|NCT01774058|measurement
238115|NCT01774058|intraarterial
238116|NCT01774058|neuropathy
238117|NCT01774045|Major depressive disorder
238118|NCT01774045|Depression
238119|NCT01774019|Pancreatic
238120|NCT01774019|Periampullary Cancer
238121|NCT01774019|Preoperative Biliary Drainage
238122|NCT01774019|Resectable
238123|NCT01774006|In vitro fertilization
238124|NCT01774006|Embryo transfer
238125|NCT01774006|Embryo culture
238126|NCT01774006|individual culture
238127|NCT01774006|Group culture
238128|NCT01774006|embryo quality
238129|NCT01774006|Pregnancy rate
238130|NCT01774006|Implantation
238131|NCT01773993|Lyrica
238132|NCT01773993|pregabalin
238133|NCT01773993|Good post marketing practice
238134|NCT01773993|Post Marketing Surveillance
238135|NCT01773993|Regulatory Post Marketing Commitment Plan
238136|NCT01773993|Fibromyalgia
238137|NCT01773967|Lactobacillus rhamnosus GG
238138|NCT01773967|LGG
238139|NCT01773967|Probiotic
238140|NCT01773967|Gastroenteritis
238141|NCT01773967|acute gastroenteritis
238142|NCT01773967|child
238143|NCT01773967|pediatric
238144|NCT01773967|RCT
238145|NCT01773954|amd
238146|NCT01773954|age related macular degeneration
238147|NCT01773954|macular degeneration
238148|NCT01773954|neovascular
238149|NCT01773135|threatened preterm labor
238150|NCT01773135|ACTH
238151|NCT01773135|PTL
238152|NCT01773109|Male and female subjects 18 years of age and older
238153|NCT01773109|metastatic or recurrent NSCLC
238154|NCT01773109|who have failed 2nd line therapy (with up to two prior cytotoxic regimens and one prior exposure to an oral TKI).
238155|NCT01773096|opioid-induced
238156|NCT01773928|Active immunization against influenza disease
238157|NCT01773889|Epithelial Ovarian Cancer
238158|NCT01773889|FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV
238159|NCT01773889|Extraovarian Peritoneal Cancer
238160|NCT01773889|Fallopian Tube Carcinoma Failing
238161|NCT01773876|survival without proven invasive candidiasis
238162|NCT01773876|effectiveness
238163|NCT01773876|micafungin versus placebo
238164|NCT01773876|pharmacokinetic
238165|NCT01773876|pharmacodynamic
238166|NCT01773876|tolerance
238167|NCT01773863|Community-acquired pneumonia
238168|NCT01773863|Acute myocardial infarction
238169|NCT01773863|Platelet activation
238170|NCT01773863|Coagulation abnormalities,
238171|NCT01773863|Thrombosis
238172|NCT01773863|Isoprosantes
238173|NCT01773863|NADPH oxidase
238174|NCT01773863|Major adverse cardiac and cerebrovascular events
238175|NCT01773850|breast cancer
238176|NCT01773837|asthenia
238177|NCT01773837|advanced cancer
238178|NCT01773837|randomized controlled trial
238179|NCT01773824|antibiotic
238180|NCT01773824|prescription rate
238181|NCT01773811|Posttraumatic Stress Disorder (PTSD)
238182|NCT01773811|Narrative Writing
238183|NCT01773759|Immunizations
238184|NCT01773759|Child care
238185|NCT01773759|School health promotion
238186|NCT01773746|neonatal
238187|NCT01773746|resuscitation
238188|NCT01773746|room air
238189|NCT01773720|cardiac index
238190|NCT01773720|coronary artery bypass
238191|NCT01773720|uncalibrated pulse contour analysis
238192|NCT01773720|hemodynamic monitoring
238193|NCT01773707|prevention of type 1 diabetes
238194|NCT01773707|prevention of abnormal glucose tolerance
238195|NCT01773694|Post-operative management
238196|NCT01773694|Post-operative complications
238197|NCT01773694|Post-operative treatment
238198|NCT01773694|water
238199|NCT01773694|skin
238200|NCT01773694|Dermatologic Surgical Procedures
238201|NCT01773655|somatic
238202|NCT01773655|germline
238203|NCT01773655|mutations
238204|NCT01773655|BAP1 (BRCA associated protein-1)
238205|NCT01773655|12-235
238206|NCT01773642|pediatric HIV diagnosis disclosure
238207|NCT01773642|cognitive behavioral intervention
238208|NCT01773642|Uganda
238209|NCT01773629|Depression
238210|NCT01773629|Pregnancy
238211|NCT01773629|Postpartum
238212|NCT01773629|Perinatal
238213|NCT01773616|Systemic lupus erythematosus
238214|NCT01773616|Lupus
238215|NCT01773616|Nephritis
238216|NCT01773603|Time-lapse
238217|NCT01773603|morphokinetics
238218|NCT01773603|blastocyst transfer
238219|NCT01773603|eSET
238220|NCT01773577|EHR
238221|NCT01773577|VHR
238222|NCT01773577|Electronic Health Record
238223|NCT01773564|Dressings, Prevention,
238224|NCT01773538|quality of life
238225|NCT01773512|Intravascular ultrasound
238226|NCT01773512|Virtual histology
238227|NCT01773512|Optical coherence tomography
238228|NCT01773512|Coronary atherosclerosis
238229|NCT01773512|Statins
238230|NCT01773512|Retinal imaging
238231|NCT01773499|cellulitis
238232|NCT01773499|ultrasound
238233|NCT01773486|Obesity
238234|NCT01773486|Insulin Resistance
238235|NCT01773486|Endothelial dysfunction
238236|NCT01773486|Blood pressure
238237|NCT01773460|everolimus progress exemestane
238238|NCT01773460|treated with exemestane and everolimus
238239|NCT01773460|progress under this treatment
238240|NCT01773395|Advanced
238241|NCT01773369|cerebral palsy
238242|NCT01773369|physical therapy
238243|NCT01773369|rehabilitation
238244|NCT01773356|Obesity
238245|NCT01773356|Body Weight
238246|NCT01773356|Body Composition
238247|NCT01773356|Metabolism
238248|NCT01773356|Resting Energy Expenditure
238249|NCT01773343|skin texture, efficacy, adverse effects
238250|NCT01773330|high resolution manometry
238251|NCT01773330|provocative swallow
238252|NCT01773330|impedence
238253|NCT01773304|Obesity
238254|NCT01773304|Adults
238255|NCT01773304|Bone metabolism
238256|NCT01773304|Metabolic profile
238257|NCT01773304|Dairy protein
238258|NCT01773304|Meat protein
238259|NCT01773291|Acupuncture; laser acupuncture; traumatic brain injury
238260|NCT01773278|Antioxidant treatment
238261|NCT01773278|Oxysterols
238262|NCT01773278|Cholesterol deficiency
238263|NCT01773278|Accumulation of 7-dehydrocholesterol
238264|NCT01773278|electroretinogram (ERG)
238265|NCT01773278|Auditory Brainstem Response (ABR)
238266|NCT01773252|RLS
238267|NCT01773252|RTLS
238268|NCT01773252|PFO
238269|NCT01773252|ASD
238270|NCT01773252|shunt
238271|NCT01773252|cardiac
238272|NCT01773252|paradoxical thromboembolism
238273|NCT01773252|interventional cardiology
238274|NCT01773252|stroke
238275|NCT01773252|migraine
238276|NCT01773252|aura
238277|NCT01773252|obstructive sleep apnea
238278|NCT01773252|decompression illness
238279|NCT01773252|neurology
238280|NCT01773252|transesophageal echocardiography
238281|NCT01773252|TEE
238282|NCT01773252|transthoracic echocardiography
238283|NCT01773252|TTE
238284|NCT01773252|transcranial Doppler
238285|NCT01773252|ultrasound
238286|NCT01773252|TCD
238287|NCT01773252|power m Mode
238288|NCT01773252|indocyanine green dye
238289|NCT01773252|ICG
238290|NCT01773252|Valsalva
238291|NCT01773239|social cognition
238292|NCT01773239|cognitive deficits
238293|NCT01773239|prodromal schizophrenia
238294|NCT01773239|recent-onset schizophrenia
238295|NCT01773239|remediation
238296|NCT01773239|computer training
238297|NCT01773239|cognitive training exercises
238298|NCT01773226|Autologous Protein Solution
238299|NCT01773226|APS
238300|NCT01773226|Osteoarthritis
238301|NCT01773226|Injection
238302|NCT01773213|Lower urinary tract
238303|NCT01773213|Bladder
238304|NCT01773213|Neuropathic bladder
238305|NCT01773213|Overactive bladder
238306|NCT01773200|endothelial progenitor cells
238307|NCT01773200|aneurysmal subarachnoid hemorrhage
238308|NCT01773200|vasospasm
238309|NCT01773200|BNP
238310|NCT01773187|Myelofibrosis
238311|NCT01773187|Post-Polycythemia Vera Myelofibrosis
238312|NCT01773187|Post-Essential Thrombocythemia Myelofibrosis
238313|NCT01773187|Primary Myelofibrosis
238314|NCT01773187|Polycythemia
238315|NCT01773187|Polycythemia Vera
238316|NCT01773187|Thrombocythemia, Essential
238317|NCT01773187|Thrombocythemia
238318|NCT01773187|Myeloproliferative Disorders
238319|NCT01773187|Bone Marrow Disease
238320|NCT01773187|Hematologic Diseases
238321|NCT01773187|Blood Platelet Disorders
238322|NCT01773187|Hemorrhagic Disorders
238323|NCT01773187|Splenomegaly
238324|NCT01773187|Pacritinib
238325|NCT01773187|MPN-SAF
238326|NCT01773187|MPN-SAF TSS
238327|NCT01773187|Anemia
238328|NCT01773187|Myeloproliferative
238329|NCT01773187|Myeloproliferative Neoplasm
238330|NCT01773187|Spleen
238331|NCT01773187|Spleen volume
238332|NCT01773187|Thrombocytopenia
238333|NCT01773187|SB1518
238334|NCT01773161|Cerebral Palsy
238335|NCT01773161|Hip surgery
238336|NCT01773161|Quality of Life
238337|NCT01773083|Inhalation trauma
238338|NCT01773083|pulmonary coagulopathy
238339|NCT01773083|heparin nebulization
238340|NCT01773083|mechanical ventilation
238341|NCT01773070|Chronic Hepatitis C
238342|NCT01773070|Hepatitis C virus
238343|NCT01773070|Direct Acting Antiviral
238344|NCT01773070|Sustained Virologic Response
238345|NCT01773070|Hepatitis C
238346|NCT01773057|Computerized Decision Support System
238347|NCT01773057|Heart failure
238348|NCT01773057|Effects on quality of care
238349|NCT01773057|Process of care
238350|NCT01773057|Patient outcomes
238351|NCT01773031|Autoimmune pancreatitis
238352|NCT01773031|MR pancreatography
238353|NCT01773005|Anesthetics, Intravenous
238354|NCT01772992|HIV couples adherence linkage to care viral suppression
238355|NCT01772979|Trabectedin
238356|NCT01772979|BRCA1 and BRCA2
238357|NCT01772979|BRCAness
238358|NCT01772979|Ovarian cancer
238359|NCT01772966|neck
238360|NCT01772966|pain
238361|NCT01772966|chronic
238362|NCT01772966|manipulation
238363|NCT01772966|control
238364|NCT01772966|randomized trial
238365|NCT01772953|AML
238366|NCT01772953|MDS
238367|NCT01772953|Treosulfan
238368|NCT01772940|First-line therapy
238369|NCT01772940|Protease inhibitor
238370|NCT01772940|Non-Nucleoside Reverse transcriptase Inhibitor
238371|NCT01772940|Resource-limited setting
238372|NCT01772927|parenteral nutrition
238373|NCT01772927|Very low birth weight infants
238374|NCT01772927|preterm infants
238375|NCT01772927|biochemical tolerance
238376|NCT01772927|nutritional intake
238377|NCT01772914|Copeptin
238378|NCT01772914|eating
238379|NCT01772914|glucose tolerance test
238380|NCT01772914|mixed meal test
238381|NCT01772914|physiological
238382|NCT01772901|influenza
238383|NCT01772901|influenza vaccines
238384|NCT01772901|infectious disease
238385|NCT01772901|pregnancy
238386|NCT01772875|urinary catheter
238387|NCT01772875|UTI
238388|NCT01772875|bladder lavage
238389|NCT01772862|childhood
238390|NCT01772862|cancer
238391|NCT01772862|physical activity
238392|NCT01772862|quality of life
238393|NCT01772849|childhood
238394|NCT01772849|cancer
238395|NCT01772849|education
238396|NCT01772849|physical activity
238397|NCT01772849|quality of life
238398|NCT01772823|HIV, PrEP, FTC/TDF, Truvada
238399|NCT01772810|Paralysis due to spinal cord injury (SCI)
238400|NCT01772797|anaplastic lymphoma kinase, ALK-rearranged lung cancer, non-small cell lung cancer
238401|NCT01772784|subjects
238402|NCT01772771|Cancer
238403|NCT01772771|Molecular testing
238404|NCT01772771|Personalized Cancer Therapy Program
238405|NCT01772771|Bladder
238406|NCT01772771|Bone
238407|NCT01772771|Breast
238408|NCT01772771|Cytology
238409|NCT01772771|Endocrine
238410|NCT01772771|Gynecology
238411|NCT01772771|Endocrine - Neoplasia
238412|NCT01772771|genitourinary
238413|NCT01772771|Research Biorepository
238414|NCT01772771|Head and Neck
238415|NCT01772771|Aerodigestive Tract
238416|NCT01772771|Hematopathology
238417|NCT01772771|Human Cancer Genetics
238418|NCT01772771|Kidney
238419|NCT01772771|Leukemia
238420|NCT01772771|Lower Gastrointestinal
238421|NCT01772771|Lymphoma
238422|NCT01772771|Melanoma
238423|NCT01772771|Neurology
238424|NCT01772771|Brain
238425|NCT01772771|Non-Melanoma Skin
238426|NCT01772771|Pancreas
238427|NCT01772771|Pediatrics
238428|NCT01772771|Prostate
238429|NCT01772771|Breast Cancer Patients, Serum
238430|NCT01772771|Plasma
238431|NCT01772771|Soft Tissue Sarcoma
238432|NCT01772771|Thoracic
238433|NCT01772771|Lung
238434|NCT01772771|S.P.O.R.E.
238435|NCT01772771|Upper Gastrointestinal
238436|NCT01772745|single incision
238437|NCT01772745|cholecystectomy
238438|NCT01772745|laparoscopy
238439|NCT01772732|Simotinib
238440|NCT01772732|Non-small Cell Lung Cancer
238441|NCT01772719|refractory multiple myeloma
238442|NCT01772706|Head and neck cancer
238443|NCT01772706|Low level laser therapy
238444|NCT01772706|Mucositis induced by radiochemotherpy
238445|NCT01772693|ExAblate Transcranial MRgFUS
238446|NCT01772680|Thalassemia
238447|NCT01772680|Diabetes
238448|NCT01772680|Zinc
238449|NCT01772680|Iron-Overload
238450|NCT01772667|pulmonary fibrosis
238451|NCT01772667|interstitial lung disease
238452|NCT01772667|pulmonary rehabilitation
238453|NCT01772667|exercise capacity
238454|NCT01772667|physical activity
238455|NCT01772667|quality of life
238456|NCT01772654|Epilepsy
238457|NCT01772654|Arterial Spin Labeled MRI
238458|NCT01772654|Brain lesions
238459|NCT01772654|Cerebral blood flow
238460|NCT01772641|cigarette
238461|NCT01772641|smoking
238462|NCT01772641|cessation
238463|NCT01772641|varenicline
238464|NCT01772641|scheduled reduction
238465|NCT01772641|craving
238466|NCT01772628|Communication
238467|NCT01772628|Healthy sexual behaviour
238468|NCT01772628|Sexual and reproductive health
238469|NCT01772628|Adolescents
238470|NCT01772615|EcN, Nissle, Mutaflor, Ulcerative Colitis, antibiotics, Inflammatory Bowel Diseases
238471|NCT01772602|Amyotrophic Lateral Sclerosis
238472|NCT01772602|Lou Gehrig's Disease
238473|NCT01772602|Motor Neuron Disease
238474|NCT01772576|Reliance
238475|NCT01772576|Implantable Cardioverter Defibrillator (ICD)
238476|NCT01772576|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
238477|NCT01772550|CECT, catheter, contrast
238478|NCT01772537|thoracoabdominal
238479|NCT01772537|aneurysm
238480|NCT01772537|open
238481|NCT01772537|stent
238482|NCT01772537|cardiopulmonary
238483|NCT01772537|abdominal
238484|NCT01772537|bypass
238485|NCT01772524|Migraine Disorders
238486|NCT01772524|Phase 1
238487|NCT01772524|ALD403
238488|NCT01772511|questionnaire
238489|NCT01772511|prior therapy
238490|NCT01772511|prior study volunteer
238491|NCT01772511|prior study patient
238492|NCT01772511|cancer
238493|NCT01772511|oncology
238494|NCT01772498|depression
238495|NCT01772498|anxiety
238496|NCT01772498|sleep
238497|NCT01772498|pain
238498|NCT01772498|biofeedback
238499|NCT01772498|breathing
238500|NCT01772498|resonant
238501|NCT01772459|Scoliosis
238502|NCT01772459|Adolescents
238503|NCT01772459|Questionnaire
238504|NCT01772459|Reliability
238505|NCT01772446|diabetes
238506|NCT01772446|management
238507|NCT01772446|glycated hemoglobin
238508|NCT01772446|preventive activities
238509|NCT01772433|Low Back Pain
238510|NCT01772433|Topical Olive Oil
238511|NCT01772433|Phonophoresis
238512|NCT01772407|Colon Cancer Surgery
238513|NCT01772407|Laparoscopy
238514|NCT01772407|Open surgery
238515|NCT01772407|Costs
238516|NCT01772407|Mortality
238517|NCT01772407|Morbidity
238518|NCT01772407|Quality of life
238519|NCT01772394|Anorexia Nervosa
238520|NCT01772394|Cognitive remediation therapy
238521|NCT01772394|Randomized clinical trial
238522|NCT01772381|Dexamethasone, term, elective cesarean section
238523|NCT01772368|Asthma
238524|NCT01772368|dry powder inhaler
238525|NCT01772368|long-acting beta2-agonist
238526|NCT01772368|bronchodilation
238527|NCT01772368|bronchodilator
238528|NCT01772368|metered dose inhaler
238529|NCT01772368|inhaled corticosteroid
238530|NCT01772355|orbit; tumor; core biopsy
238531|NCT01772342|Sleep Fragmentation
238532|NCT01772342|Quality of Life
238533|NCT01772342|Air Filters
238534|NCT01772303|Pressure Ulcers, diabetic Ulcers, post operational wounds
238535|NCT01772277|Endoscopic dacryocystorhinostomy
238536|NCT01772277|Mitomycin C
238537|NCT01772251|Diabetes Mellitus
238538|NCT01772251|Oral Insulin
238539|NCT01772238|Mexico
238540|NCT01772238|Respiratory infections
238541|NCT01772238|Amoxicillin-Clavulanic Acid
238542|NCT01772238|Bioequivalence
238543|NCT01772225|Observational Retrospective
238544|NCT01772225|Health-related quality of life (HRQoL)
238545|NCT01772225|Patients
238546|NCT01772225|Stage IB-IIIA
238547|NCT01772225|Burden of Illness
238548|NCT01772225|Non-small Cell Lung Cancer (NSCLC)
238549|NCT01772212|Mexico
238550|NCT01772212|terbinafine
238551|NCT01772212|mycoses
238552|NCT01772212|pharmacokinetics
238553|NCT01772199|GSK239512
238554|NCT01772199|remyelination
238555|NCT01772199|magnetic resonance imaging
238556|NCT01772199|Relapsing Remitting Multiple Sclerosis
238557|NCT01772199|Histamine 3 Receptor Antagonist
238558|NCT01772199|magnetization transfer ratio
238559|NCT01772186|Freezing of gait
238560|NCT01772186|Parkinson's disease
238561|NCT01772186|Somatosensory stimulation
238562|NCT01772186|Fall prevention
238563|NCT01772173|diabetes
238564|NCT01772173|computer
238565|NCT01772173|retina
238566|NCT01772173|vessel
238567|NCT01772173|analysis
238568|NCT01772160|Adults
238569|NCT01772160|Italy
238570|NCT01772160|Herpes Zoster
238571|NCT01772160|Complications
238572|NCT01772160|Quality of life
238573|NCT01772160|Surveillance
238574|NCT01772160|Burden
238575|NCT01772160|Cost
238576|NCT01772160|Incidence
238577|NCT01772121|HBV, HCV, chronic, India, observational study, prevalence,
238578|NCT01772121|genotypes, SNPs, viral hepatitis
238579|NCT01772108|Heart Valve Diseases
238580|NCT01772095|Donepezil (Dementis)
238581|NCT01772095|Elderly
238582|NCT01772069|systemic lupus erythematosus, disease activity, sleep, quality of life
238583|NCT01772056|Dermatitis, Atopic
238584|NCT01772056|Randomized Controlled Trial
238585|NCT01772056|Child
238586|NCT01772056|Fluticasone
238587|NCT01772056|Preventive therapy
238588|NCT01772043|muscular dystrophy
238589|NCT01772043|tissue bank
238590|NCT01772030|Atrial Fibrillation
238591|NCT01772030|Cryoballoon Ablation
238592|NCT01772017|Obstructive Sleep Apnea
238593|NCT01772017|OSA
238594|NCT01772017|Snoring
238595|NCT01772017|Tongue Advancement Retainer Device
238596|NCT01772004|Solid Tumors
238597|NCT01772004|MSB0010718C
238598|NCT01772004|Phase 1
238599|NCT01772004|Pharmacokinetic
238600|NCT01772004|anti PD-L1
238601|NCT01772004|Non-small cell lung cancer (NSCLC)
238602|NCT01772004|Metastatic breast cancer (MBC)
238603|NCT01772004|Gastric and gastroesophageal junction (GEJ) cancer
238604|NCT01772004|Ovarian cancer
238605|NCT01772004|Colorectal cancer (CRC)
238606|NCT01772004|Castrate-resistant prostate cancer (CRPC)
238607|NCT01772004|Melanoma
238608|NCT01772004|Urothelial carcinoma
238609|NCT01772004|Bladder cancer
238610|NCT01772004|Head and neck squamous cell carcinoma (HNSCC)
238611|NCT01772004|Renal cell carcinoma (RCC)
238612|NCT01772004|Adrenocortical carcinoma (ACC)
238613|NCT01771991|fibrosis
238614|NCT01771991|radiation
238615|NCT01771991|neck
238616|NCT01771991|cancer
238617|NCT01771991|Sodermix
238618|NCT01771978|ischaemia-reperfusion injury
238619|NCT01771978|cardiac surgery
238620|NCT01771978|oxidative stress markers
238621|NCT01771978|troponin
238622|NCT01771978|diltiazem
238623|NCT01771978|acetylcystein
238624|NCT01771952|Patellofemoral Chondromalacia
238625|NCT01771952|Anterior Knee Pain
238626|NCT01771952|Patellofemoral Pain Syndrome
238627|NCT01771952|Synvisc-One
238628|NCT01771952|Hyaluronic Acid
238629|NCT01771939|Idiopathic epiretinal membranes
238630|NCT01771939|25-G surgery in idiopathic epiretinal membranes
238631|NCT01771926|resistant starch
238632|NCT01771926|lifestyle intervention
238633|NCT01771913|adipocytes
238634|NCT01771913|cell transplantations
238635|NCT01771913|mesenchymal stem cell
238636|NCT01771913|immunophenotyping
238637|NCT01771913|adipose tissue
238638|NCT01771913|breast reconstruction
238639|NCT01771913|mammaplasty
238640|NCT01771913|magnetic resonance imaging
238641|NCT01771913|fat necrosis
238642|NCT01771900|heart failure
238643|NCT01771900|exercise
238644|NCT01771900|adherence to exercise
238645|NCT01771887|Diabetic Type2
238646|NCT01771887|education
238647|NCT01771887|self-management behaviors
238648|NCT01771887|self-efficacy
238649|NCT01771887|HbA1c
238650|NCT01771874|MDMA
238651|NCT01771874|pharmacokinetics
238652|NCT01771874|pharmacodynamics
238653|NCT01771874|emotions
238654|NCT01771874|Mechanism of action of MDMA
238655|NCT01771874|Interaction study
238656|NCT01771874|Effect of MDMA and bupropion on emotions
238657|NCT01771848|Malaria
238658|NCT01771848|Plasmodium falciparum
238659|NCT01771835|diabetes mellitus
238660|NCT01771835|retinal venous pressure
238661|NCT01771835|endothelin-1
238662|NCT01771822|cumulative irritancy patch test (CIPT)
238663|NCT01771809|Anti-TNF Refractory
238664|NCT01771809|Immunosuppressant Refractory
238665|NCT01771809|Active Ulcerative Colitis
238666|NCT01771796|Exercise; lung cancer; aerobic training, resistance training; respiratory muscle training
238667|NCT01771783|RAS-Peptide Profile
238668|NCT01771783|Renin-Angiotensin-System
238669|NCT01771783|Angiotensin-Converting-Enzyme-Inhibitor
238670|NCT01771783|Angiotensin-Receptor-Antagonist
238671|NCT01771783|Renin-inhibitor
238672|NCT01771770|retinal venous pressure (RVP)
238673|NCT01771770|chronically reduced ambient pressure
238674|NCT01771770|oxygen partial pressure
238675|NCT01771770|mountain sickness
238676|NCT01771757|retinal venous pressure
238677|NCT01771757|reduced ambient pressure
238678|NCT01771757|oxygen partial pressure
238679|NCT01771757|short-term hypoxic changes
238680|NCT01771705|Transplantation
238681|NCT01771705|Kidney
238682|NCT01771705|calcineurin inhibitor
238683|NCT01771705|NFAT
238684|NCT01771705|tacrolimus
238685|NCT01771692|Orthodontics
238686|NCT01771679|Mesenchymal Stem Cells
238687|NCT01771679|Bone Marrow Cells
238688|NCT01771679|Allogeneic Transplantation
238689|NCT01771679|Skin Wrinkling
238690|NCT01771679|Solar Aging of Skin
238691|NCT01771679|Intravenous Administration
238692|NCT01771653|Hepatitis C infection
238693|NCT01771653|Hepatitis C Virus
238694|NCT01771653|HCV
238695|NCT01771640|ALS intrathecal injection bone marrow mesenchymal stem cell
238696|NCT01771614|Glucotoxicity
238697|NCT01771614|Exercise
238698|NCT01771614|Beta-cell function
238699|NCT01771601|Near-infrared spectroscopy, cerebral oxygenation, term newborn, reproducibility,
238700|NCT01771562|HIV-1
238701|NCT01771562|Child
238702|NCT01771562|Adolescent
238703|NCT01771562|Growth
238704|NCT01771562|Lipodystrophy
238705|NCT01771562|ARV treatment
238706|NCT01771562|Senegal
238707|NCT01771549|Adriamycin
238708|NCT01771549|Trastuzumab
238709|NCT01771549|Brain Natriuretic Peptide (BNP)
238710|NCT01771549|Troponin
238711|NCT01771523|thyroidectomy
238712|NCT01771523|drain use
238713|NCT01771497|Breast CT
238714|NCT01771484|tachycardia
238715|NCT01771484|pots
238716|NCT01771484|orthostatic intolerance
238717|NCT01771471|back pain
238718|NCT01771471|intervertebral disc
238719|NCT01771471|lumbar spine
238720|NCT01771458|Metastatic/Reccurent
238721|NCT01771458|Solid Tumor
238722|NCT01771458|Refractory
238723|NCT01771458|Molecular profile
238724|NCT01771458|Targeted treatment
238725|NCT01771445|IL-1
238726|NCT01771445|IL-6
238727|NCT01771445|Inflammation
238728|NCT01771419|loop-tip
238729|NCT01771419|ERCP
238730|NCT01771419|cannulation of CBD
238731|NCT01771393|arthroscanner
238732|NCT01771393|cone-beam computed tomodensitometry
238733|NCT01771354|Volunteers
238734|NCT01771354|Identify
238735|NCT01771354|Biomarkers
238736|NCT01771354|Vaccine Safety
238737|NCT01771341|NAVA
238738|NCT01771341|post operative
238739|NCT01771328|Adrenal Hyperplasia, Congenital
238740|NCT01771315|total knee arthroplasty
238741|NCT01771315|telephone follow-up
238742|NCT01771315|physical function
238743|NCT01771315|health related quality of life
238744|NCT01771315|self-efficacy
238745|NCT01771302|PRGF-Endoret
238746|NCT01771302|Bone graft
238747|NCT01771302|Maxillary sinus
238748|NCT01771302|Vertical bone augmentation
238749|NCT01771289|Lung Cancer
238750|NCT01771276|POSE
238751|NCT01771263|Anesthesia
238752|NCT01771263|Propofol
238753|NCT01771263|Remifentanil
238754|NCT01771263|NeuroSENSE
238755|NCT01771237|HIV infection
238756|NCT01771224|Palmitoleic acid ulcerative colitis
238757|NCT01771211|MCI
238758|NCT01771211|Word-retrieval
238759|NCT01771211|tDCS
238760|NCT01771211|fMRI
238761|NCT01771198|Chronic rhinosinusitis
238762|NCT01771198|Refractory to treatment
238763|NCT01771198|SIMVASTATIN
238764|NCT01771185|Diabetes
238765|NCT01771185|metabolic surgery
238766|NCT01771185|insulin resistance
238767|NCT01771159|Spinal cord injury
238768|NCT01771159|Urinary dysfunction
238769|NCT01771159|Bladder drainage
238770|NCT01771146|Non-metastatic Pancreas Cancer
238771|NCT01771146|Pancreatic Cancer
238772|NCT01771146|Cancer of Pancreas
238773|NCT01771146|Adenocarcinoma of Pancreas
238774|NCT01771146|Neoadjuvant
238775|NCT01771133|Obesity
238776|NCT01771133|Maternal Welfare
238777|NCT01771133|Child Welfare
238778|NCT01771133|Nutritional Sciences
238779|NCT01771133|Clinical Trial
238780|NCT01771133|Pregnancy
238781|NCT01771133|Physical activity
238782|NCT01771133|Fetal Development
238783|NCT01771133|Metabolic Diseases
238784|NCT01771133|Life style
238785|NCT01771133|Behavior and Behavior Mechanisms
238786|NCT01771133|LIFE-Moms
238787|NCT01771120|Asthma
238788|NCT01771120|Rhinitis
238789|NCT01771120|Control
238790|NCT01771120|Burden
238791|NCT01771081|Longitudinal Studies,
238792|NCT01771081|Observation
238793|NCT01771081|Epidemiology
238794|NCT01771055|Trauma
238795|NCT01771055|Hypovolemia
238796|NCT01771042|weight loss
238797|NCT01771042|metabolic syndrome
238798|NCT01771042|sympathetic nervous system
238799|NCT01771042|insulin resistance
238800|NCT01771042|glucose tolerance
238801|NCT01771029|Procalcitonin
238802|NCT01771029|Infection
238803|NCT01771029|Point-of-Care
238804|NCT01771016|Emergency contraception
238805|NCT01771016|Emergency hormonal contraception
238806|NCT01771016|Community pharmacies
238807|NCT01771016|Pharmaceutical care
238808|NCT01771016|Time to access
238809|NCT01771016|Written assessments
238810|NCT01771016|Switzerland
238811|NCT01771003|Partial nephrectomy
238812|NCT01771003|renal cell carcinoma
238813|NCT01771003|Renal Function
238814|NCT01771003|Remote ischemia preconditioning
238815|NCT01770990|depression
238816|NCT01770990|telephone-based psychotherapy
238817|NCT01770990|cognitive-behavioral psychotherapy
238818|NCT01770990|manualized psychotherapy
238819|NCT01770990|telephone counseling
238820|NCT01770990|telephone psychological treatment
238821|NCT01770990|telephone-administered therapy
238822|NCT01770990|low-intensity treatment
238823|NCT01770990|motivational mail
238824|NCT01770990|reminder
238825|NCT01770990|letter
238826|NCT01770977|Light-emitting diode therapy
238827|NCT01770977|Muscle performance
238828|NCT01770977|Aerobic performance
238829|NCT01770977|Lactate
238830|NCT01770977|Creatine kinase
238831|NCT01770938|Light-emitting diode therapy
238832|NCT01770938|Muscle performance
238833|NCT01770938|Gene expression
238834|NCT01770938|Functional performance
238835|NCT01770912|facial pain
238836|NCT01770912|temporomandibular joint
238837|NCT01770912|arthrocentesis
238838|NCT01770912|steroid
238839|NCT01770899|Montelukast
238840|NCT01770899|Singulair
238841|NCT01770899|status asthmaticus
238842|NCT01770886|Drug Safety
238843|NCT01770873|Youth
238844|NCT01770873|Violence
238845|NCT01770873|Assault-injured
238846|NCT01770873|Mentoring
238847|NCT01770873|Emergency Room
238848|NCT01770873|Urban
238849|NCT01770860|Adhesive Bandages
238850|NCT01770860|Dermabrasion Wounds
238851|NCT01770821|sip drink
238852|NCT01770821|protein
238853|NCT01770821|muscle strength
238854|NCT01770821|6 minutes walking test
238855|NCT01770808|Bloating
238856|NCT01770808|Flatulence
238857|NCT01770808|Stomach discomfort
238858|NCT01770795|non-small cell lung cancer
238859|NCT01770795|gemcitabine
238860|NCT01770795|genexol-PM
238861|NCT01770795|paclitaxel
238862|NCT01770782|Palatal Expansion Technique
238863|NCT01770782|Orthognathic Surgery
238864|NCT01770782|Three Dimensional images
238865|NCT01770769|Femoral Neck Fracture
238866|NCT01770769|undisplaced
238867|NCT01770769|minimally displaced
238868|NCT01770769|internal fixation
238869|NCT01770769|hemiarthroplasty
238870|NCT01770769|harris hip score
238871|NCT01770769|hospital cost
238872|NCT01770769|society cost
238873|NCT01770769|quality of life
238874|NCT01770769|Timed Up and go test
238875|NCT01770756|Hypertension
238876|NCT01770756|High blood pressure
238877|NCT01770756|Willpower
238878|NCT01770756|Self care
238879|NCT01770743|post-exposure prophylaxis
238880|NCT01770743|toxin neutralization assay
238881|NCT01770730|urine LAM strip test
238882|NCT01770730|diagnostics
238883|NCT01770730|tuberculosis
238884|NCT01770704|Bipolar disorder
238885|NCT01770704|Clinical management
238886|NCT01770704|Clinical outcomes
238887|NCT01770678|Children
238888|NCT01770678|Cerebral Palsy
238889|NCT01770678|Randomised
238890|NCT01770678|Constraint Induced Movement Therapy
238891|NCT01770652|Renal Impairment
238892|NCT01770652|Kidney Impairment
238893|NCT01770652|Kidney Disease
238894|NCT01770652|Ferriprox
238895|NCT01770652|Deferiprone
238896|NCT01770652|DFP (deferiprone)
238897|NCT01770652|L1
238898|NCT01770639|charcot foot
238899|NCT01770639|charcot neuroarthropathy
238900|NCT01770639|midfoot arthrodesis
238901|NCT01770639|midfoot fusion
238902|NCT01770613|Adult
238903|NCT01770613|Allogeneic
238904|NCT01770613|Stem
238905|NCT01770613|Cells
238906|NCT01770613|Myocardial
238907|NCT01770613|Infarction
238908|NCT01770600|Age 19 to 64
238909|NCT01770600|Medically stable
238910|NCT01770600|No current or history of psychosis
238911|NCT01770600|No alcohol or benzodiazepine withdrawal
238912|NCT01770587|Insomnia
238913|NCT01770587|Sleep
238914|NCT01770587|Behavioral Medicine
238915|NCT01770587|Suicide
238916|NCT01770587|Suicidal Ideation
238917|NCT01770574|calcaneal lengthening
238918|NCT01770574|calcium ceramics
238919|NCT01770574|noninferiority
238920|NCT01770574|radiostereometric analysis
238921|NCT01770535|Ovarian cancer, paclitaxel
238922|NCT01770522|Bodyweight
238923|NCT01770522|Physical Acivitiy
238924|NCT01770522|Diet
238925|NCT01770522|Bodymass index
238926|NCT01770522|Pregnancy
238927|NCT01770522|Postnatal
238928|NCT01770509|Chronic venous leg ulcers
238929|NCT01770509|Venous ulcer
238930|NCT01770509|Stasis ulcer
238931|NCT01770509|Varicose ulcer
238932|NCT01770496|immunization
238933|NCT01770496|vaccination
238934|NCT01770496|immunization information system
238935|NCT01770496|immunization registry
238936|NCT01770496|reminder / recall
238937|NCT01770483|Nitazoxanide,
238938|NCT01770483|Sustained viral response
238939|NCT01770483|Type 2 DIABETICS
238940|NCT01770470|serum phosphate
238941|NCT01770470|chitosan
238942|NCT01770470|kidney disease
238943|NCT01770470|salivary phosphate
238944|NCT01770457|ICU population
238945|NCT01770444|Acute coronary syndrome
238946|NCT01770444|Cardiac computed tomographic angiography
238947|NCT01770444|Radiation dose reduction
238948|NCT01770444|Medical radiation exposure
238949|NCT01770431|Huaier Granule;
238950|NCT01770431|After radical hepatectomy;
238951|NCT01770431|Prevention of Recurrence and Metastasis;
238952|NCT01770431|Safety.
238953|NCT01770418|Non Small Cell Lung Cancer
238954|NCT01770418|Cancer
238955|NCT01770418|Lung
238956|NCT01770418|Proton
238957|NCT01770418|Radiation
238958|NCT01770405|endomicroscopy
238959|NCT01770405|needle-based
238960|NCT01770405|pancreatic
238961|NCT01770405|cyst
238962|NCT01770405|mass
238963|NCT01770405|EUSFNA
238964|NCT01770379|Rheumatoid Arthritis, RA, IL-17 blocker, subcutaneous, self-injection, AIN457, AIN457F, secukinumab, anti-TNFα, pre-filled syringe
238965|NCT01770366|obesity
238966|NCT01770366|weight loss surgery
238967|NCT01770366|virtual support
238968|NCT01770366|wireless devices
238969|NCT01770366|Internet
238970|NCT01770353|solid tumors
238971|NCT01770353|Triple Negative Breast Cancer
238972|NCT01770353|Colorectal Cancer
238973|NCT01770353|MM-398
238974|NCT01770353|nanoliposomal irinotecan
238975|NCT01770353|Ferumoxytol
238976|NCT01770353|ER/PR positive Breast Cancer
238977|NCT01770353|Pancreatic Cancer
238978|NCT01770353|Ovarian Cancer
238979|NCT01770353|Gastric Cancer
238980|NCT01770353|Gastro-Esophageal Junction Adenocarcinoma
238981|NCT01770353|Head and Neck Cancer
238982|NCT01770353|TNBC
238983|NCT01770340|radical prostatectomy
238984|NCT01770340|erectile function
238985|NCT01770340|nerve grafting
238986|NCT01770340|allogenic
238987|NCT01770340|prostate cancer
238988|NCT01770340|Allogenic nerve graft
238989|NCT01770340|Time required for nerve grafting
238990|NCT01770314|Opioid Pain Medication
238991|NCT01770314|Medication Safety
238992|NCT01770314|Correct storage
238993|NCT01770314|Correct disposal
238994|NCT01770314|Correct Use
238995|NCT01770288|Anerobic exercise
238996|NCT01770288|Pain
238997|NCT01770288|Analgesia
238998|NCT01770288|Diffuse Noxious Inhibitory Control (DNIC)
238999|NCT01770288|psychological stress
239000|NCT01770275|esophagus
239001|NCT01770249|dysphagia
239002|NCT01770210|hypercholesterolemia
239003|NCT01770210|atorvastatin
239004|NCT01770210|cardiovascular events
239005|NCT01770197|China
239006|NCT01770197|Stroke
239007|NCT01770197|Thrombolytic therapy
239008|NCT01770184|Self-management
239009|NCT01770184|Rehabilitation
239010|NCT01770184|Occupational Therapy
239011|NCT01770171|endometrial cancer
239012|NCT01770171|recurrent endometrial cancer
239013|NCT01770171|bevacizumab
239014|NCT01770158|Acute myeloid leukemia (AML)
239015|NCT01770158|Histamine Dihydrochloride
239016|NCT01770158|Interleukin-2
239017|NCT01770145|Motor symptoms
239018|NCT01770145|Parkinson's Disease
239019|NCT01770145|Delayed Onset
239020|NCT01770145|Akinesia
239021|NCT01770145|Hypomobility
239022|NCT01770145|Unified Parkinson Disease Rating Scale (UPDRS) motor scores
239023|NCT01770145|Dopamine agonist
239024|NCT01770145|Apomorphine
239025|NCT01770145|Apokyn
239026|NCT01770145|Levodopa
239027|NCT01770119|Measles
239028|NCT01770119|Mumps
239029|NCT01770119|Rubella
239030|NCT01770119|Pediatric
239031|NCT01770119|Solid-organ transplant
239032|NCT01770119|serology
239033|NCT01770119|vaccine
239034|NCT01770106|Rheumatoid arthritis
239035|NCT01770106|Bone density
239036|NCT01770106|Bone microarchitecture
239037|NCT01770106|HR-pQCT
239038|NCT01770067|Cardiac Resynchronization Therapy Devices
239039|NCT01770054|metabolic syndrome
239040|NCT01770054|diabetes mellitus
239041|NCT01770028|Obesity
239042|NCT01770028|Pregnancy
239043|NCT01770028|Spouse
239044|NCT01770028|Weight loss
239045|NCT01770028|Behavioral
239046|NCT01770015|patient ventilated for at least five days
239047|NCT01769963|Advanced glycation end-products
239048|NCT01769963|chronic kidney disease
239049|NCT01769963|nutrition
239050|NCT01769963|inflammation
239051|NCT01769963|insulin resistance
239052|NCT01769963|endothelial function
239053|NCT01769950|Choline PET
239054|NCT01769950|Choline PET-CT
239055|NCT01769950|Positron emission tomography
239056|NCT01769950|Prostate cancer
239057|NCT01769937|Lupus
239058|NCT01769937|SLE
239059|NCT01769937|ACTH
239060|NCT01769937|Acthar
239061|NCT01769924|kidney donors
239062|NCT01769924|arterial stiffness
239063|NCT01769924|blood pressure
239064|NCT01769898|Bronchiectasis
239065|NCT01769898|Theophylline
239066|NCT01769898|Therapeutic Uses
239067|NCT01769898|HDAC
239068|NCT01769898|HAT
239069|NCT01769898|Random placebo study
239070|NCT01769898|ICS(inhaled corticosteroid)
239071|NCT01769898|corticosteroid
239072|NCT01769898|Inhaled corticosteroid
239073|NCT01769859|Bipolar Disorder
239074|NCT01769859|Major Depressive Disorder
239075|NCT01769859|Genetics
239076|NCT01769833|HBsAg
239077|NCT01769833|Chronic hepatitis B
239078|NCT01769833|PEGinterferon Alfa-2A
239079|NCT01769820|Heavy menstrual bleeding (HMB)
239080|NCT01769820|Dexamethasone
239081|NCT01769820|glucocorticoid
239082|NCT01769807|Sleep apnea
239083|NCT01769807|CPAP treatment
239084|NCT01769807|Plasma nitrate
239085|NCT01769807|Urinary norepinephrine
239086|NCT01769807|Blood pressure
239087|NCT01769794|Hand, Foot and Mouth Disease
239088|NCT01769794|Medicine, Chinese Traditional
239089|NCT01769794|Enterovirus
239090|NCT01769794|Fever
239091|NCT01769781|endometriosis recurrence
239092|NCT01769781|pelvic pain
239093|NCT01769781|aromatase inhibitor
239094|NCT01769768|Adults, Hh (Hedgehog) pathway inhibitor, LDE225, Warfarin, Bupropion, advanced solid tumor, drug-drug interaction, pharmacokinetic
239095|NCT01769755|Crohn's disease
239096|NCT01769755|Fistula
239097|NCT01769755|Diarrhea
239098|NCT01769755|Colon
239099|NCT01769755|Stem cells
239100|NCT01769742|Pneumonia
239101|NCT01769742|promotion of activity
239102|NCT01769729|integrated primary care
239103|NCT01769729|depression
239104|NCT01769729|chronic low back pain
239105|NCT01769716|Global developmental delay
239106|NCT01769716|Umbilical cord blood
239107|NCT01769716|Rehabilitation
239108|NCT01769690|PD
239109|NCT01769690|Parkinson's Disease
239110|NCT01769690|DBS
239111|NCT01769690|deep brain stimulation
239112|NCT01769677|Bioequivalence
239113|NCT01769677|Hydrocodone bitartrate extended-release tablets
239114|NCT01769664|Acne vulgaris
239115|NCT01769664|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
239116|NCT01769664|Duac® Topical Gel
239117|NCT01769651|drug user patients
239118|NCT01769651|addiction nurses
239119|NCT01769651|overdose risk
239120|NCT01769638|Orally disintegrating Film
239121|NCT01769638|Film Coated Tablet
239122|NCT01769638|Sildenafil
239123|NCT01769638|Pharmacokinetics
239124|NCT01769625|breast
239125|NCT01769625|high risk women
239126|NCT01769625|biomarkers
239127|NCT01769625|vitamin D
239128|NCT01769586|Sedation
239129|NCT01769586|Endoscopy
239130|NCT01769586|Diphenhydramine
239131|NCT01769586|Midazolam
239132|NCT01769573|normal
239133|NCT01769560|tailored intervention
239134|NCT01769560|college aged students
239135|NCT01769560|HPV
239136|NCT01769521|Glaucoma
239137|NCT01769521|IOP
239138|NCT01769521|Blood pressure
239139|NCT01769521|ECG
239140|NCT01769508|Esophagogastric Adenocarcinoma
239141|NCT01769508|5-Fluorouracil
239142|NCT01769508|Oxaliplatin
239143|NCT01769508|Lapatinib
239144|NCT01769508|Radiation Therapy
239145|NCT01769508|Surgery
239146|NCT01769495|Emergency department, Geriatrics, mortality, readmission rates.
239147|NCT01769482|microvascular angina
239148|NCT01769482|PDE-5 inhibitors
239149|NCT01769482|Heart disease
239150|NCT01769482|Ischemia
239151|NCT01769482|Cardiac MRI
239152|NCT01769469|Tenofovir
239153|NCT01769469|Emtricitabine
239154|NCT01769469|Truvada
239155|NCT01769469|Renal, endocrine, bone changes
239156|NCT01769469|HIV prevention
239157|NCT01769469|PrEP
239158|NCT01769456|HIV, PrEP, FTC/TDF, Truvada
239159|NCT01769443|desensitization therapy
239160|NCT01769443|bortezomib (VELCADE®)
239161|NCT01769443|plasmapheresis
239162|NCT01769430|influenza virus
239163|NCT01769430|aerosol transmission
239164|NCT01769430|contact transmission
239165|NCT01769430|large droplet transmission
239166|NCT01769430|airborne infection
239167|NCT01769391|NSCLC
239168|NCT01769365|Helicobacter pylori infection
239169|NCT01769352|cystoid macular edema
239170|NCT01769339|Vulvar Candidiasis
239171|NCT01769339|Miconazole
239172|NCT01769339|Hydrocortisone
239173|NCT01769339|Daktacort Feminine Care Cream
239174|NCT01769326|Stroke
239175|NCT01769313|Cataract
239176|NCT01769313|Laser-assisted
239177|NCT01769313|Femtosecond
239178|NCT01769300|Clinical decision support
239179|NCT01769300|Electronic health records
239180|NCT01769300|Electronic medical records
239181|NCT01769300|Attention deficit-hyperactivity disorder
239182|NCT01769300|Primary care Pediatric research network
239183|NCT01769287|Atrial fibrillation
239184|NCT01769287|Electrophysiological Assessment
239185|NCT01769287|12 months post-operatively
239186|NCT01769287|High Intensity Ultrasound
239187|NCT01769261|quality of health care
239188|NCT01769261|continuity of patient care
239189|NCT01769261|adverse effects
239190|NCT01769261|outcome and process assessment (health care)
239191|NCT01769248|EUS
239192|NCT01769248|FNA
239193|NCT01769248|FNB
239194|NCT01769235|Acne Vulgaris
239195|NCT01769235|Clindamycin Phosphate and Benzoyl Peroxide Gel
239196|NCT01769235|Acanya® Gel
239197|NCT01769196|Idiopathic
239198|NCT01769196|Pulmonary
239199|NCT01769196|Fibrosis
239200|NCT01769196|IPF
239201|NCT01769183|Proliferative Diabetic Retinopathy
239202|NCT01769170|CMV
239203|NCT01769170|Hematopoietic Stem Cell Transplant Recipients
239204|NCT01769170|CMV seropositive
239205|NCT01769144|wound healing
239206|NCT01769144|wound infection
239207|NCT01769144|pain
239208|NCT01769144|pruritus
239209|NCT01769144|cicatrix
239210|NCT01769144|dressings
239211|NCT01769144|acticoat absorbent
239212|NCT01769144|BCT
239213|NCT01769144|KoCarbonAg
239214|NCT01769131|cervix
239215|NCT01769131|Allis
239216|NCT01769131|Tenaculum
239217|NCT01769131|gynecology
239218|NCT01769118|Autonomic nervous system
239219|NCT01769105|Meibomian Gland Dysfunction
239220|NCT01769105|Lipiflow
239221|NCT01769092|Epilepsy
239222|NCT01769092|Seizure
239223|NCT01769092|Fish Oil
239224|NCT01769053|Acute Lung Injury
239225|NCT01769053|Adult Respiratory Distress Syndrome
239226|NCT01769053|Interactive Ventilatory Support
239227|NCT01769053|Positive-Pressure Respiration
239228|NCT01769053|Ventilator-Induced Lung Injury
239229|NCT01769040|Decompensated liver cirrhosis
239230|NCT01769040|Ascites
239231|NCT01769040|Haemodynamics
239232|NCT01769040|Small intestinal bacterial overgrowth
239233|NCT01769040|Pathophysiology
239234|NCT01769014|adherence
239235|NCT01769001|Fabry disease
239236|NCT01769001|Alpha galactosidase deficiency
239237|NCT01769001|Metabolic storage disease
239238|NCT01768975|Knee
239239|NCT01768975|Osteoarthritis
239240|NCT01768975|OA
239241|NCT01768975|Knee pain
239242|NCT01768975|Moderate pain
239243|NCT01768975|Severe pain
239244|NCT01768975|Inflammation
239245|NCT01768975|Safety
239246|NCT01768975|Efficacy
239247|NCT01768975|Randomized
239248|NCT01768975|Topical
239249|NCT01768975|Gel
239250|NCT01768975|Olatec
239251|NCT01768975|OLT1177
239252|NCT01768975|Joint Diseases
239253|NCT01768975|Musculoskeletal Diseases
239254|NCT01768975|Rheumatic Diseases
239255|NCT01768975|Arthritis
239256|NCT01768975|Therapeutic
239257|NCT01768975|Analgesic
239258|NCT01768962|Microbicides
239259|NCT01768962|Tenofovir
239260|NCT01768962|Reduced-glycerin
239261|NCT01768962|Vaginal use
239262|NCT01768962|Rectal use
239263|NCT01768962|Pharmacokinetics
239264|NCT01768949|Acute respiratory distress syndrome
239265|NCT01768949|Echocardiography
239266|NCT01768949|Recruitment maneuver
239267|NCT01768936|on-demand relaparotomy
239268|NCT01768936|PCT
239269|NCT01768936|procalcitonin
239270|NCT01768936|peritonitis
239271|NCT01768936|sepsis
239272|NCT01768936|focus index
239273|NCT01768923|Early Rheumatoid Arthritis
239274|NCT01768923|Arterial stiffness
239275|NCT01768923|SDAI remission group
239276|NCT01768923|Minimal disease activity remission group
239277|NCT01768910|lower urinary tract
239278|NCT01768910|bladder
239279|NCT01768910|supraspinal control
239280|NCT01768910|neuroimaging
239281|NCT01768910|functional magnetic resonance imaging
239282|NCT01768910|diffusion tensor imaging
239283|NCT01768910|functional connectivity
239284|NCT01768910|neurogenic lower urinary tract dysfunction
239285|NCT01768910|overactive bladder
239286|NCT01768910|multiple sclerosis
239287|NCT01768910|spinal cord injury
239288|NCT01768884|Infants
239289|NCT01768884|Bronchiolitis
239290|NCT01768884|NO
239291|NCT01768884|inhalation
239292|NCT01768858|Arthritis
239293|NCT01768858|Morbus Crohn
239294|NCT01768858|Adherence
239295|NCT01768858|Spondylitis
239296|NCT01768858|Ulcerative colitis
239297|NCT01768858|Monoclonals
239298|NCT01768858|Rheumatoid
239299|NCT01768858|Antibodies
239300|NCT01768858|Ankylosing
239301|NCT01768858|Plaque psoriasis
239302|NCT01768858|Psoriatic
239303|NCT01768858|Crohn´s disease
239304|NCT01768858|Antirheumatic Agents
239305|NCT01768845|Chronic myelogenous leukemia (CML)
239306|NCT01768845|Acute myelogenous leukemia (AML)
239307|NCT01768845|Myelodysplastic syndrome
239308|NCT01768845|Multiple myeloma
239309|NCT01768845|Hodgkin lymphoma
239310|NCT01768845|Non Hodgkin lymphoma
239311|NCT01768845|Chronic lymphocytic leukemia (CLL)
239312|NCT01768845|Acute lymphocytic leukemia (ALL)
239313|NCT01768845|Severe Aplastic Anemia
239314|NCT01768845|Cord Blood
239315|NCT01768845|Umbilical cord blood transplantation
239316|NCT01768845|UBC transplantation
239317|NCT01768832|Parkinson disease
239318|NCT01768832|walking
239319|NCT01768832|fMRI
239320|NCT01768832|exercise
239321|NCT01768832|dance
239322|NCT01768832|treadmill
239323|NCT01768819|aging
239324|NCT01768819|exercise
239325|NCT01768819|muscle strength
239326|NCT01768819|physical activity
239327|NCT01768806|Autism
239328|NCT01768806|Autism Spectrum Disorder
239329|NCT01768806|PLAY and Language for Autistic Youngsters
239330|NCT01768806|Intensive Early Intervention
239331|NCT01768806|Parent Training
239332|NCT01768793|Obesity
239333|NCT01768793|Pregnancy
239334|NCT01768793|Body Weight Changes
239335|NCT01768793|Diet Therapy
239336|NCT01768780|spinal anesthesia
239337|NCT01768780|peripheral nerve stimulator
239338|NCT01768780|sensory block level
239339|NCT01768754|Exercise testing
239340|NCT01768754|Functional status
239341|NCT01768754|Pulmonary rehabilitation
239342|NCT01768741|hepatocellular carcinoma
239343|NCT01768715|Alcoholic hepatitis
239344|NCT01768715|Liver transplantation
239345|NCT01768715|Survival
239346|NCT01768715|Alcoholism
239347|NCT01768702|Chronic Heart Failure of Ischemic Origin
239348|NCT01768689|adherence
239349|NCT01768689|chronic myeloid leukemia
239350|NCT01768689|tyrosine kinase inhibitors
239351|NCT01768676|healthy male
239352|NCT01768650|traumatic brain injury
239353|NCT01768650|chronic pain
239354|NCT01768650|headache
239355|NCT01768650|Veteran
239356|NCT01768637|Chronic kidney disease
239357|NCT01768637|Platelet function
239358|NCT01768637|aspirin
239359|NCT01768637|antiplatelet agent
239360|NCT01768624|chronic kidney disease
239361|NCT01768624|dialysis
239362|NCT01768624|pre dialysis education
239363|NCT01768624|transplantation
239364|NCT01768624|conservative care
239365|NCT01768598|Wrist Fracture
239366|NCT01768598|Adolescents
239367|NCT01768598|Risk Taking Behaviour
239368|NCT01768598|Bone Microstructure
239369|NCT01768546|Diabetes Prevention Program
239370|NCT01768546|obesity
239371|NCT01768546|activity
239372|NCT01768546|diabetes
239373|NCT01768533|pediatric
239374|NCT01768533|obesity
239375|NCT01768533|prevention
239376|NCT01768533|health behaviors
239377|NCT01768533|guidelines
239378|NCT01768481|Obesity
239379|NCT01768481|Dyslipidemia
239380|NCT01768481|Cholesterol
239381|NCT01768481|Intima media thickness
239382|NCT01768468|LAYLA
239383|NCT01768468|Non-inferiority
239384|NCT01768468|100mm pain VAS
239385|NCT01768442|Head and neck cancer
239386|NCT01768403|Hypercholesterolemia
239387|NCT01768403|Cardiovascular disease
239388|NCT01768403|Hypertension
239389|NCT01768403|Coronary Heart disease
239390|NCT01768403|Peripheral Arterial disease
239391|NCT01768390|caries
239392|NCT01768390|prevention
239393|NCT01768390|orthodontics
239394|NCT01768390|fixed appliances
239395|NCT01768390|adolescents
239396|NCT01768377|Awake intubation
239397|NCT01768377|Nerve block
239398|NCT01768377|Sedation
239399|NCT01768377|Physician satisfaction
239400|NCT01768351|anemia
239401|NCT01768351|chronic kidney disease
239402|NCT01768351|vitamin D
239403|NCT01768351|paricalcitol
239404|NCT01768351|hyperparathyroidism
239405|NCT01768325|ProCore Needle
239406|NCT01768299|abortion
239407|NCT01768299|medical abortion
239408|NCT01768299|mifepristone
239409|NCT01768299|misoprostol
239410|NCT01768286|HCV genotype 1 (GT-1)
239411|NCT01768286|HCV
239412|NCT01768286|Sustained Virologic Response
239413|NCT01768286|Direct Acting Antiviral
239414|NCT01768286|Combination Therapy
239415|NCT01768286|GS-7977
239416|NCT01768286|GS-5885
239417|NCT01768286|Ribavirin
239418|NCT01768286|Open Label
239419|NCT01768286|Sofosbuvir
239420|NCT01768286|Additional relevant MeSH terms:
239421|NCT01768286|Hepatitis
239422|NCT01768286|Hepatitis, Chronic
239423|NCT01768286|Hepatitis C
239424|NCT01768286|Hepatitis C, Chronic
239425|NCT01768286|Liver Diseases
239426|NCT01768286|Digestive System Diseases
239427|NCT01768286|Hepatitis, Viral, Human
239428|NCT01768286|Virus Diseases
239429|NCT01768286|Enterovirus Infections
239430|NCT01768286|Picornaviridae Infections
239431|NCT01768286|RNA Virus Infections
239432|NCT01768286|Flaviviridae Infections
239433|NCT01768286|Antiviral Agents
239434|NCT01768286|Anti-Infective Agents
239435|NCT01768286|Therapeutic Uses
239436|NCT01768286|Pharmacologic Actions
239437|NCT01768286|Antimetabolites
239438|NCT01768286|Molecular Mechanisms of Pharmacological Action
239439|NCT01768273|PA-824,
239440|NCT01768273|midazolam
239441|NCT01768273|drug-drug interaction
239442|NCT01768273|pharmacokinetics
239443|NCT01768273|pretomanid
239444|NCT01768273|CL-006
239445|NCT01768260|visual acuity
239446|NCT01768260|artery flow velocity
239447|NCT01768260|Enhanced External Counterpulsation
239448|NCT01768260|Ischemic
239449|NCT01768260|Optic Neuropathy
239450|NCT01768247|endometrium
239451|NCT01768247|thickness
239452|NCT01768247|pregnancy
239453|NCT01768247|HCG
239454|NCT01768247|frozen cycles
239455|NCT01768234|cognition
239456|NCT01768234|hydration
239457|NCT01768234|schoolchildren
239458|NCT01768221|Palliative Care
239459|NCT01768221|Caregiver Outlook
239460|NCT01768195|Lymphoma
239461|NCT01768195|Hepatitis B Virus
239462|NCT01768195|Therapeutic Uses
239463|NCT01768195|Antiviral Agents
239464|NCT01768195|rituximab
239465|NCT01768182|folic acid; folates; Vascular Reactivity; HIV
239466|NCT01768169|metabolic syndrome,
239467|NCT01768169|waist, blood pressure,
239468|NCT01768169|fasting plasma glucose,
239469|NCT01768169|HDL cholesterol,
239470|NCT01768169|triglycerides
239471|NCT01768156|ovarian cancer
239472|NCT01768156|biomarker
239473|NCT01768156|metastatic
239474|NCT01768143|Propofol
239475|NCT01768143|Sedation
239476|NCT01768143|Endoscopy
239477|NCT01768143|nonanesthesiologist
239478|NCT01768104|upper gastrointestinal submucosal tumors
239479|NCT01768104|SMTs
239480|NCT01768104|Gastrointestinal stromal tumors
239481|NCT01768104|GISTs
239482|NCT01768104|Leiomyoma
239483|NCT01768104|Endoscopic submucosal tunnel dissection
239484|NCT01768104|ESTD
239485|NCT01768104|Submucosal tunneling endoscopic resection
239486|NCT01768104|STER
239487|NCT01768104|Submucosal endoscopic tumor resection
239488|NCT01768104|SET
239489|NCT01768091|Esophageal achalasia
239490|NCT01768091|Peroral endoscopic myotomy
239491|NCT01768091|POEM
239492|NCT01768091|Pneumatic dilation
239493|NCT01768065|NEPAP
239494|NCT01768065|CPAP
239495|NCT01768065|alternative
239496|NCT01768065|OSAS
239497|NCT01768052|MDD, major depression, treatment-resistant
239498|NCT01768039|Multiple sclerosis
239499|NCT01768039|Vitamin D
239500|NCT01768039|EDSS
239501|NCT01768039|ARR
239502|NCT01768026|Dystrophic Epidermolysis Bullosa
239503|NCT01768026|Type VII Collagen
239504|NCT01768026|QOL Evaluation in Epidermolysis Bullosa
239505|NCT01768026|Instrument for Scoring Clinical Outcomes for Research of Epidermolysis Bullosa
239506|NCT01768026|Birmingham Epidermolysis Bullosa Severity Score
239507|NCT01768000|Psychosis
239508|NCT01768000|Psychosis NOS
239509|NCT01768000|Schizophrenia
239510|NCT01768000|Schizoaffective Disorder
239511|NCT01768000|Bipolar Disorder
239512|NCT01767987|Acute Coronary Syndrome
239513|NCT01767987|ACS
239514|NCT01767987|Percutaneous Coronary Intervention
239515|NCT01767987|PCI
239516|NCT01767987|Ranolazine
239517|NCT01767987|Coronary Angiogram
239518|NCT01767987|Cardioprotectant
239519|NCT01767974|Non-Small Cell lung cancer
239520|NCT01767948|Hepatic Impairment
239521|NCT01767948|PCI 32765
239522|NCT01767948|Metabolite PCI-45227
239523|NCT01767948|Pharmacokinetics
239524|NCT01767922|Super-Oxyd-Dismutase
239525|NCT01767922|SOD
239526|NCT01767922|melon juce
239527|NCT01767922|perceived stress
239528|NCT01767909|Intranasal insulin
239529|NCT01767909|Alzheimer's disease
239530|NCT01767909|Amnestic mild cognitive impairment
239531|NCT01767909|Dementia
239532|NCT01767909|Brain diseases
239533|NCT01767909|Memory problems
239534|NCT01767909|Mental disorders
239535|NCT01767909|Cognitive disorders
239536|NCT01767896|Influenza vaccine
239537|NCT01767883|Chronic Kidney Disease
239538|NCT01767883|CKD
239539|NCT01767883|TRANSLATE
239540|NCT01767883|Practice Facilitation
239541|NCT01767883|Practice-based research
239542|NCT01767883|CKD Guidelines
239543|NCT01767870|advanced colorectal adenoma
239544|NCT01767870|colonoscopy
239545|NCT01767870|sigmoidoscopy
239546|NCT01767870|fecal immunochemical test
239547|NCT01767857|Pivotal
239548|NCT01767857|Colorectal
239549|NCT01767857|Survival
239550|NCT01767857|Phase 3
239551|NCT01767844|Rheumatoid Arthritis
239552|NCT01767844|Arthritis
239553|NCT01767844|Rheumatology
239554|NCT01767844|Creatine
239555|NCT01767831|Type 1 Diabetes Mellitus (T1DM)
239556|NCT01767831|Continuous Glucose Monitor (CGM)
239557|NCT01767831|Simulation-based Education
239558|NCT01767818|Parkinson's Disease
239559|NCT01767792|Neurofibromatosis Type 2
239560|NCT01767792|Progressive Vestibular Schwannomas
239561|NCT01767779|Epilepsy
239562|NCT01767779|TSC
239563|NCT01767779|Tuberous Sclerosis Complex
239564|NCT01767779|Infants
239565|NCT01767779|Seizures
239566|NCT01767779|Biomarkers
239567|NCT01767779|EEG
239568|NCT01767753|Glaucoma
239569|NCT01767753|SLT
239570|NCT01767740|Rotator Cuff Tear
239571|NCT01767740|Supraspinatus Tear
239572|NCT01767727|surgical flap;
239573|NCT01767727|dorsal branch of the digital artery
239574|NCT01767714|hematopoietic stem cell transplantation
239575|NCT01767701|raltegravir
239576|NCT01767701|MS
239577|NCT01767701|RRMS
239578|NCT01767701|Charcot Project
239579|NCT01767688|Diabetes Mellitus
239580|NCT01767688|Diabetes Mellitus, Type 2
239581|NCT01767688|Glucose Metabolism Disorders
239582|NCT01767688|Metabolic Diseases
239583|NCT01767688|Endocrine System Diseases
239584|NCT01767675|Secondary Cytoreductive Surgery
239585|NCT01767675|Carboplatin
239586|NCT01767675|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
239587|NCT01767675|12-275
239588|NCT01767662|TCV
239589|NCT01767649|Pregnancy
239590|NCT01767649|Remodelling
239591|NCT01767649|Extracellular matrix
239592|NCT01767649|Biomarkers
239593|NCT01767597|rapid test
239594|NCT01767597|screening
239595|NCT01767597|ELISA
239596|NCT01767597|hepatitis B virus
239597|NCT01767597|access to care
239598|NCT01767584|Pharmacokinetics
239599|NCT01767584|Bioequivalence
239600|NCT01767584|Mexico
239601|NCT01767584|Cephalexin
239602|NCT01767571|Mexico
239603|NCT01767571|Respiratory infections
239604|NCT01767571|Bioequivalence
239605|NCT01767571|Cepphalexin
239606|NCT01767532|Cephalexin
239607|NCT01767532|Respiratory infections
239608|NCT01767532|Mexico
239609|NCT01767532|Bioequivalence
239610|NCT01767506|Trachoma
239611|NCT01767506|Azithromycin
239612|NCT01767506|Mass treatment
239613|NCT01767493|Multiple sclerosis
239614|NCT01767480|Intensive Robot Assisted Therapy
239615|NCT01767480|Subacute Stroke
239616|NCT01767480|Brain Reorganization
239617|NCT01767480|Sensory Motor
239618|NCT01767480|Physiological Marker
239619|NCT01767467|Immunogenicity
239620|NCT01767467|Safety
239621|NCT01767467|Herpes zoster
239622|NCT01767467|Vaccination
239623|NCT01767467|Haematologic malignancies
239624|NCT01767454|BRAF V600E
239625|NCT01767454|Melanoma
239626|NCT01767454|V600K
239627|NCT01767454|Trametinib
239628|NCT01767454|Dabrafenib
239629|NCT01767454|Ipilimumab
239630|NCT01767441|bariatric surgery
239631|NCT01767441|gastric bypass
239632|NCT01767441|gastric banding
239633|NCT01767441|sleeve gastrectomy
239634|NCT01767441|weight loss
239635|NCT01767441|Type 2 Diabetes mellitus
239636|NCT01767441|GLP1
239637|NCT01767441|obesity
239638|NCT01767441|mixed meal test
239639|NCT01767415|brain tumor
239640|NCT01767415|resection
239641|NCT01767415|indigo carmine dye
239642|NCT01767402|Safety
239643|NCT01767402|Pneumococcal Infections
239644|NCT01767402|Immunogenicity
239645|NCT01767402|PhtD vaccine
239646|NCT01767402|Healthy adults
239647|NCT01767402|Reactogenicity
239648|NCT01767389|utilization
239649|NCT01767389|acute pancreatitis
239650|NCT01767389|Exenatide
239651|NCT01767389|DPP-4 inhibitors
239652|NCT01767389|liraglutide
239653|NCT01767389|GLP-1 receptor agonist
239654|NCT01767389|adherence
239655|NCT01767376|Immunogenicity
239656|NCT01767376|Diphtheria
239657|NCT01767376|Neisseria meningitidis
239658|NCT01767376|Adolescents
239659|NCT01767376|pertussis
239660|NCT01767376|Reactogenicity
239661|NCT01767376|Tetanus
239662|NCT01767376|Healthy
239663|NCT01767376|Meningococcal vaccines
239664|NCT01767376|Safety
239665|NCT01767376|Young adults
239666|NCT01767363|5-alpha reductase inhibitor
239667|NCT01767363|benign prostatic hyperplasia treatment
239668|NCT01767363|Prostate cancer mortality
239669|NCT01767350|Pediatric transplantation
239670|NCT01767350|Pharmacogenetics
239671|NCT01767350|Pharmacokinetics
239672|NCT01767350|Calcineurin inhibitors
239673|NCT01767350|CYP3A
239674|NCT01767350|Pgp
239675|NCT01767337|microneedle-based delivery
239676|NCT01767337|hollow microneedle
239677|NCT01767337|intracutaneous
239678|NCT01767337|drug delivery
239679|NCT01767324|microneedle-based array
239680|NCT01767324|hollow microneedle
239681|NCT01767324|intracutaneous
239682|NCT01767324|drug delivery
239683|NCT01767324|vaccine delivery
239684|NCT01767311|Alzheimer's Disease
239685|NCT01767311|BAN2401
239686|NCT01767298|Fixed dose combination
239687|NCT01767298|Pharmacokinetics
239688|NCT01767298|Valsartan
239689|NCT01767298|Hydrochlorothiazide
239690|NCT01767285|Etonogestrel Implant
239691|NCT01767285|Implanon
239692|NCT01767285|Nexplanon
239693|NCT01767285|Long Acting Reversible Contraception
239694|NCT01767272|Fexofenadine
239695|NCT01767272|Pharmacokinetics
239696|NCT01767272|Bioavailability
239697|NCT01767272|Linearity
239698|NCT01767272|HPLC
239699|NCT01767272|Dose proportionality of fexofenadine in Egyptian volunteers
239700|NCT01767259|Fixed dose combination
239701|NCT01767259|Pharmacokinetics
239702|NCT01767259|Valsartan
239703|NCT01767259|Hydrochlorothiazide
239704|NCT01767233|Acute necrotizing pancreatitis
239705|NCT01767233|ERCP
239706|NCT01767233|Pancreatic stenting
239707|NCT01767220|ventricular tachycardia
239708|NCT01767220|endocardial ablation
239709|NCT01767220|epicardial ablation
239710|NCT01767181|Light therapy
239711|NCT01767181|physical exercise
239712|NCT01767181|night shift workers
239713|NCT01767181|genetic markers
239714|NCT01767181|PBMCs
239715|NCT01767142|Lipolysis
239716|NCT01767142|Cryolipolysis
239717|NCT01767142|Fat Reduction
239718|NCT01767129|levodopa
239719|NCT01767129|dyskinesia
239720|NCT01767129|parkinson's disease
239721|NCT01767129|AVP-923
239722|NCT01767129|dextromethorphan
239723|NCT01767129|quinidine
239724|NCT01767116|Interferon-Free
239725|NCT01767116|Hepatitis C Genotype 1b
239726|NCT01767116|Chronic Hepatitis C
239727|NCT01767116|Hepatitis C Virus
239728|NCT01767116|Hepatitis C
239729|NCT01767116|Treatment-Naive
239730|NCT01767116|Paritaprevir
239731|NCT01767116|Ombitasvir
239732|NCT01767116|Dasabuvir
239733|NCT01767116|Viekira PAK
239734|NCT01767116|Ribavirin
239735|NCT01767103|Hepatic Impairment
239736|NCT01767103|Liver Impairment
239737|NCT01767103|Liver Disease
239738|NCT01767103|Ferriprox®
239739|NCT01767103|LI
239740|NCT01767103|DFP
239741|NCT01767103|Deferiprone
239742|NCT01767090|Endometriosis
239743|NCT01767090|ASP1707
239744|NCT01767090|Pelvic pain
239745|NCT01767090|Double-blind
239746|NCT01767090|Placebo-controlled
239747|NCT01767090|Phase 2
239748|NCT01767077|Saturated fat
239749|NCT01767077|Dairy products
239750|NCT01767077|Milk fat globule membrane
239751|NCT01767077|Cholesterol
239752|NCT01767077|Butter
239753|NCT01767077|Cream
239754|NCT01767064|ARIs, antibiotics, public commitment, quality improvement
239755|NCT01767051|PCOS
239756|NCT01767051|Children
239757|NCT01767051|Cardiovascular
239758|NCT01767051|Follow-up
239759|NCT01767025|Influence
239760|NCT01767025|oxytocin
239761|NCT01767025|automatic imitation
239762|NCT01767025|behaviour
239763|NCT01767025|volunteers
239764|NCT01766999|pulse oximetry
239765|NCT01766999|tumescent anesthesia
239766|NCT01766960|Bile acids
239767|NCT01766960|Pharmacokinetics
239768|NCT01766947|Glaucoma
239769|NCT01766947|Deep sclerectomy
239770|NCT01766934|Peripheral blood progenitor cell mobilization
239771|NCT01766934|allogenic hematopoetic stem cell transplantation
239772|NCT01766934|recombinant human granulocyte colony stimulating factor
239773|NCT01766934|filgrastim
239774|NCT01766921|Influenza, Pandemic, H5N1, Elderly adults
239775|NCT01766908|Timing of Umbilical Cord clamping
239776|NCT01766908|Cord Clamp 20 seconds
239777|NCT01766908|Cord Clamp 40 seconds
239778|NCT01766908|Cord Clamp 60 seconds
239779|NCT01766895|uremia
239780|NCT01766895|HBV
239781|NCT01766895|HCV
239782|NCT01766895|seroclearance
239783|NCT01766882|Hemodialysis
239784|NCT01766882|Blood Pressure
239785|NCT01766882|Hydration Status
239786|NCT01766882|Low-sodium diet
239787|NCT01766869|Prostate Cancer
239788|NCT01766869|MRI/MRS
239789|NCT01766856|perforation
239790|NCT01766856|tympanoplasty
239791|NCT01766856|myringoplasty
239792|NCT01766856|Eustachian tube function
239793|NCT01766856|tympanostomy tube
239794|NCT01766817|IPF
239795|NCT01766804|Acute Lymphoblastic Leukemia
239796|NCT01766804|Bovine Colostrum
239797|NCT01766804|Inflammation
239798|NCT01766804|Infection
239799|NCT01766804|Toxicity
239800|NCT01766791|resistance exercise
239801|NCT01766791|muscle mass
239802|NCT01766791|abdominal fat
239803|NCT01766791|strength
239804|NCT01766791|Coronary Heart Disease (CHD)-risk
239805|NCT01766791|myocardial mass
239806|NCT01766778|type-2 diabetes mellitus, inadequately controlled Metformin
239807|NCT01766739|GL-ONC1
239808|NCT01766739|pleural effusion
239809|NCT01766739|12-169
239810|NCT01766726|HIV
239811|NCT01766726|Atherosclerosis
239812|NCT01766700|Obesity, weight loss, weight maintenance
239813|NCT01766687|Chronic Kidney Disease
239814|NCT01766687|estimated glomerular filtration rate
239815|NCT01766687|water intake
239816|NCT01766687|fluid intake
239817|NCT01766687|renal decline
239818|NCT01766674|Kyphosis
239819|NCT01766648|Distal
239820|NCT01766648|Femur
239821|NCT01766648|Locking
239822|NCT01766648|Screw
239823|NCT01766648|Fracture
239824|NCT01766648|Healing
239825|NCT01766622|Apoptosis
239826|NCT01766622|Pro-Apoptotic Effects
239827|NCT01766622|PET Imaging
239828|NCT01766622|TL32711
239829|NCT01766622|Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer
239830|NCT01766609|Vitiligo; Intralesional; Triamcinolone acetonide
239831|NCT01766596|Ophthalmology
239832|NCT01766596|Age-related ocular pathologies
239833|NCT01766583|Open label, 3 + 3 dose escalation study followed by an expansion phase.
239834|NCT01766570|insulin sensitivity,
239835|NCT01766570|glucose tolerance,
239836|NCT01766570|inflammatory markers,
239837|NCT01766570|lipid profile,
239838|NCT01766570|oxidative stress,
239839|NCT01766570|pancreatic β-cell function
239840|NCT01766557|Polycystic ovarian syndrome, sex hormones, ovarian function, women, fish protein, insulin sensitivity, glucose tolerance, β-cell function, inflammation
239841|NCT01766544|asthma
239842|NCT01766544|COPD
239843|NCT01766544|guidelines
239844|NCT01766544|knowledge transfer
239845|NCT01766544|medical education
239846|NCT01766544|care gaps
239847|NCT01766531|Bioelectrical impedance
239848|NCT01766531|Nutrition
239849|NCT01766531|Phase angle
239850|NCT01766531|ICU patients
239851|NCT01766518|liver transplantation
239852|NCT01766518|LT
239853|NCT01766518|Mycophenolate mofetil
239854|NCT01766518|MMF
239855|NCT01766505|hypertension, heart failure, candesartan, losartan
239856|NCT01766492|prostate cancer
239857|NCT01766492|CyberKnife
239858|NCT01766479|Colorectal cancer
239859|NCT01766479|colorectal neoplasia
239860|NCT01766479|CT colonography
239861|NCT01766479|advanced neoplasia
239862|NCT01766479|colonoscopy
239863|NCT01766479|family history
239864|NCT01766453|South Asian
239865|NCT01766453|Cardiovascular
239866|NCT01766453|Exercise
239867|NCT01766453|Obesity
239868|NCT01766453|Visceral Adipose Tissue
239869|NCT01766401|Generalized Anxiety Disorder
239870|NCT01766401|GAD
239871|NCT01766375|idarubicin
239872|NCT01766375|busulfan
239873|NCT01766375|cyclophosphamide
239874|NCT01766375|pretreatment
239875|NCT01766375|high-risk acute myeloid leukemia patient
239876|NCT01766349|Esophageal cancer
239877|NCT01766349|Respiratory muscle strength
239878|NCT01766349|Pulmonary function testing
239879|NCT01766349|Functional exercise capacity
239880|NCT01766336|Agitation
239881|NCT01766336|Aggression
239882|NCT01766336|AD patients
239883|NCT01766323|Morphine
239884|NCT01766323|Palliation
239885|NCT01766323|Cancer
239886|NCT01766323|Hospice
239887|NCT01766323|Sleepiness
239888|NCT01766323|Modafinil
239889|NCT01766310|Folic acid
239890|NCT01766310|Folate
239891|NCT01766310|Homocysteine
239892|NCT01766310|Obese
239893|NCT01766310|Children
239894|NCT01766297|Breast Cancer
239895|NCT01766297|Proton
239896|NCT01766297|Radiation
239897|NCT01766284|Human Papillomavirus
239898|NCT01766284|Optical Coherence Tomography
239899|NCT01766284|Imaging Systems
239900|NCT01766284|Cervical intraepithelial neoplasia
239901|NCT01766284|Cervical Cancer
239902|NCT01766284|Cervical Dysplasia
239903|NCT01766271|Coronary heart disease
239904|NCT01766271|cardiovascular disease
239905|NCT01766271|risk
239906|NCT01766258|Parkinson's Disease
239907|NCT01766258|Motor-fluctuation
239908|NCT01766258|Wearing-off
239909|NCT01766245|mm
239910|NCT01766206|conjugate vaccine
239911|NCT01766206|phase IV clinical trial
239912|NCT01766206|Neisseria meningitidis
239913|NCT01766193|Delivery, obstetric
239914|NCT01766193|Obstetric Surgical Procedures
239915|NCT01766193|Vacuum Extraction, Obstetrical
239916|NCT01766193|Cesarean Section
239917|NCT01766193|Obstetrical Forceps
239918|NCT01766193|Epidemiology
239919|NCT01766193|Norway
239920|NCT01766180|Memory
239921|NCT01766180|Fruitflow
239922|NCT01766180|Resveratrol (resVida)
239923|NCT01766180|Cerebral blood flow
239924|NCT01766180|Cardiopulmonary exercise test
239925|NCT01766180|Maximal VO2
239926|NCT01766167|Genotype 2
239927|NCT01766154|tirofiban
239928|NCT01766154|pharmacokinetic
239929|NCT01766154|renal insufficiency
239930|NCT01766154|Phase 1
239931|NCT01766154|pharmacodynamic
239932|NCT01766141|Spinal manipulation
239933|NCT01766141|Tumor necrosis factor
239934|NCT01766141|Interleukin 1
239935|NCT01766141|Interleukin 10
239936|NCT01766141|Inflammatory cytokines
239937|NCT01766128|Parkinson disease
239938|NCT01766128|Early stage
239939|NCT01766128|Zonisamide
239940|NCT01766128|UPDRS
239941|NCT01766115|HCV
239942|NCT01766115|needlestick
239943|NCT01766115|occupational
239944|NCT01766115|transmission
239945|NCT01766115|health care worker
239946|NCT01766115|telaprevir
239947|NCT01766102|Mammography
239948|NCT01766089|Caesarean delivery
239949|NCT01766089|severe pre-eclampsia
239950|NCT01766089|remifentanil
239951|NCT01766089|dexmedetomidine
239952|NCT01766089|cardiovascular response
239953|NCT01766076|immune activation
239954|NCT01766076|antiretroviral therapy
239955|NCT01766076|atorvastatin
239956|NCT01766076|immune exhaustion
239957|NCT01766076|adults
239958|NCT01766076|Africa
239959|NCT01766063|Multiple Sclerosis
239960|NCT01766063|Sleep
239961|NCT01766063|Quality of life
239962|NCT01766063|Observational study
239963|NCT01766037|obesity
239964|NCT01766037|obese
239965|NCT01766037|weight loss
239966|NCT01766024|interferon beta-1a
239967|NCT01766024|pharmacokinetics
239968|NCT01766024|pharmacodynamics
239969|NCT01766024|volunteers
239970|NCT01765998|Crohn's disease, endothelial progenitor cells, probiotic
239971|NCT01765985|palmoplantar
239972|NCT01765959|Insomnia
239973|NCT01765959|Auricular acupuncture
239974|NCT01765959|CBT
239975|NCT01765946|Insulin resistance
239976|NCT01765946|Prediabetes
239977|NCT01765946|Longevity genes
239978|NCT01765946|Inflammation
239979|NCT01765946|Metformin
239980|NCT01765933|1,3-dimethylamylamine
239981|NCT01765894|glucose homeostasis
239982|NCT01765894|endogenous glucose production
239983|NCT01765894|moderate exercise
239984|NCT01765894|type 2 diabetes
239985|NCT01765894|metformin
239986|NCT01765881|Induction of labor
239987|NCT01765881|cervical ripening
239988|NCT01765881|misoprostol,
239989|NCT01765881|prostaglandin
239990|NCT01765881|cost-effectiveness
239991|NCT01765868|Betrixaban
239992|NCT01765868|Healthy
239993|NCT01765868|Bioavailability
239994|NCT01765855|Betrixaban
239995|NCT01765855|Healthy
239996|NCT01765855|Mass Balance
239997|NCT01765842|Lupus Nephritis
239998|NCT01765842|remission
239999|NCT01765842|immunosuppressive treatment
240000|NCT01765829|Non Affective Psychosis
240001|NCT01765829|First episode
240002|NCT01765829|Discontinuation scheme
240003|NCT01765816|Exercise
240004|NCT01765816|Elderly
240005|NCT01765816|Blood volume
240006|NCT01765816|Hemoglobin
240007|NCT01765803|Mellaril
240008|NCT01765803|Thioridazine
240009|NCT01765803|CD34+
240010|NCT01765803|Stem cells
240011|NCT01765803|Progenitor cells
240012|NCT01765803|Peripheral blood
240013|NCT01765803|mobilization
240014|NCT01765803|circulation
240015|NCT01765777|Low back pain
240016|NCT01765777|Lower back pain
240017|NCT01765777|Chronic back pain
240018|NCT01765751|Cervical pain
240019|NCT01765751|Neck pain
240020|NCT01765751|Arm pain
240021|NCT01765738|PICC
240022|NCT01765725|Chronic Fatigue Syndrome
240023|NCT01765725|Coping
240024|NCT01765725|Patient education
240025|NCT01765712|PRP
240026|NCT01765712|BPTB
240027|NCT01765712|VAS
240028|NCT01765712|Anterior Knee Pain
240029|NCT01765673|Swallowing
240030|NCT01765673|Dysphagia
240031|NCT01765673|Stroke
240032|NCT01765673|Sensory stimulation
240033|NCT01765673|Home based therapy
240034|NCT01765660|Hematopoietic Stem Cell Transplantation
240035|NCT01765660|Mesenchymal Stem Cells
240036|NCT01765660|Chronic Graft-versus-host disease
240037|NCT01765647|Celiac disease
240038|NCT01765647|AGY
240039|NCT01765634|Hematopoietic Stem Cell Transplantation
240040|NCT01765634|Mesenchymal Stem Cells
240041|NCT01765634|Acute Graft-versus-host disease
240042|NCT01765621|health care expenditure
240043|NCT01765621|drug drug interactions
240044|NCT01765621|electronic decision support systems
240045|NCT01765621|pharmacogenetics
240046|NCT01765621|Potential Reduction
240047|NCT01765608|Zonisamide
240048|NCT01765608|Zonegran
240049|NCT01765608|Obstructive Sleep apnea
240050|NCT01765608|Apnea
240051|NCT01765608|Respiration Disorders
240052|NCT01765608|Sleep Disorders
240053|NCT01765608|Obesity
240054|NCT01765608|Anti-Obesity Agents
240055|NCT01765608|Carbonic Anhydrase
240056|NCT01765608|Carbonic Anhydrase Inhibitors
240057|NCT01765608|Enzyme Inhibitors
240058|NCT01765608|Sulfonamides
240059|NCT01765608|Therapeutic Uses
240060|NCT01765608|Pharmacologic Actions
240061|NCT01765595|health care expenditure
240062|NCT01765595|drug drug interactions
240063|NCT01765595|electronic decision support systems
240064|NCT01765595|Potential reduction
240065|NCT01765530|Medical Devices
240066|NCT01765530|Ventilator-Associated Pneumonia (VAP)
240067|NCT01765530|Ventilator-Associated Events (VAE)
240068|NCT01765530|Endotracheal Tube
240069|NCT01765530|Microbial Diversity
240070|NCT01765530|Anti-Resistance
240071|NCT01765530|Computed Tomography (CT)
240072|NCT01765517|Diabetes Mellitus
240073|NCT01765504|Cardiac surgery; near infrared spectroscopy
240074|NCT01765491|colonoscopy
240075|NCT01765491|bowel preparation
240076|NCT01765491|polyethylene glycol
240077|NCT01765478|Rheumatoid Arthritis
240078|NCT01765465|postcholecystectomy syndrome
240079|NCT01765465|laparoscopic cholecystectomy
240080|NCT01765465|Rowachol
240081|NCT01765439|bile acids
240082|NCT01765439|metabolism
240083|NCT01765439|probiotics
240084|NCT01765426|Prophylactic vaccination
240085|NCT01765413|To identify
240086|NCT01765413|biomarkers
240087|NCT01765413|of vaccine safety
240088|NCT01765413|Volunteers
240089|NCT01765400|Heart failure
240090|NCT01765400|Antiplatelet therapy
240091|NCT01765400|Platelet aggregation
240092|NCT01765400|Clopidogrel
240093|NCT01765400|Prasugrel
240094|NCT01765387|Spatherpy
240095|NCT01765387|Aerobic exercise
240096|NCT01765374|rituximab
240097|NCT01765374|sonography
240098|NCT01765374|clinical response
240099|NCT01765348|language impairment
240100|NCT01765348|language disorders
240101|NCT01765348|syntax treatment
240102|NCT01765348|narrative-based treatment
240103|NCT01765335|heart failure, BNP, NICaS system, readmition
240104|NCT01765309|Tissue expanders
240105|NCT01765309|Botulinum toxin
240106|NCT01765309|Botox
240107|NCT01765283|CN,
240108|NCT01765283|UCD
240109|NCT01765270|Diabetes
240110|NCT01765270|Diabetes Mellitus
240111|NCT01765270|Type 2 Diabetes
240112|NCT01765270|Cardiovascular Disease
240113|NCT01765270|Coronary Artery Bypass Surgery
240114|NCT01765257|Drug-naïve patients with Parkinson's disease
240115|NCT01765257|Apathy
240116|NCT01765257|Rasagiline
240117|NCT01765244|Corneal trophic ulcers
240118|NCT01765231|Lymphoma
240119|NCT01765231|Hepatitis B virus
240120|NCT01765231|Therapeutic Uses
240121|NCT01765231|Antiviral Agents
240122|NCT01765218|Hypoxic ischemic encephalopathy
240123|NCT01765218|HIE
240124|NCT01765218|Perinatal depression
240125|NCT01765218|Whole body cooling
240126|NCT01765218|Therapeutic hypothermia
240127|NCT01765205|congenital cardiovascular malformation
240128|NCT01765205|newborn
240129|NCT01765192|Drug therapy
240130|NCT01765179|testosterone
240131|NCT01765179|male hypogonadism
240132|NCT01765179|low testosterone
240133|NCT01765166|Social Skill Training
240134|NCT01765166|Social Interaction
240135|NCT01765166|Peer relations
240136|NCT01765153|physical therapy
240137|NCT01765153|rehabilitation
240138|NCT01765153|neuroplasticity
240139|NCT01765140|3,4 diaminopyridine (DAP)
240140|NCT01765101|knee osteoarthritis
240141|NCT01765101|therapeutic effect
240142|NCT01765101|insole
240143|NCT01765088|High-grade glioma
240144|NCT01765088|chemotherapy
240145|NCT01765088|Temozolomide
240146|NCT01765088|Interferon-alpha
240147|NCT01765075|Electrophysiological mapping
240148|NCT01765075|Multi-electrode catheter
240149|NCT01765062|Rapid maxillary expansion
240150|NCT01765062|Cross bite
240151|NCT01765062|Haas appliance
240152|NCT01765062|Lateral cephalograms
240153|NCT01765049|breast density change
240154|NCT01765049|endocrine therapy response
240155|NCT01765049|aromatase inhibitor
240156|NCT01765036|contrast-enhanced endoscopic ultrasound
240157|NCT01765036|pancreatic adenocarcinoma
240158|NCT01765010|Vitamin D
240159|NCT01765010|Serum sclerostin
240160|NCT01765010|Serum dickkopf1
240161|NCT01764984|total knee arthroplasty
240162|NCT01764984|trabecular metal
240163|NCT01764984|bone mineral density
240164|NCT01764971|Chronic ITP, Cerebral dysfunction
240165|NCT01764958|mother-infant interaction
240166|NCT01764958|general movements
240167|NCT01764958|preterm infants
240168|NCT01764893|Overactive Bladder
240169|NCT01764880|Heparanase inhibitor
240170|NCT01764880|Multiple myeloma
240171|NCT01764867|major depressive disorder
240172|NCT01764867|algorithm guided treatment
240173|NCT01764867|treatment as usual
240174|NCT01764867|escitalopram
240175|NCT01764867|mirtazapine
240176|NCT01764867|transcranial magnetic stimulation (rTMS)
240177|NCT01764867|modified electroconvulsive therapy (mECT)
240178|NCT01764867|remission
240179|NCT01764867|relapse
240180|NCT01764867|quality of life
240181|NCT01764854|Hemodialysis
240182|NCT01764841|Ciprofloxacin
240183|NCT01764841|Dry Powder for Inhalation
240184|NCT01764841|Exacerbation
240185|NCT01764841|Bronchiectasis
240186|NCT01764828|Phase I
240187|NCT01764828|Pharmacokinetics
240188|NCT01764828|Safety measurements
240189|NCT01764802|Psychosexual Intervention
240190|NCT01764802|Cancer
240191|NCT01764802|Gynecologic Cancer
240192|NCT01764802|Breast Cancer
240193|NCT01764789|psychological intervention
240194|NCT01764789|breast cancer
240195|NCT01764789|gynecologic cancer
240196|NCT01764776|LDE225
240197|NCT01764776|Pharmacokinetics
240198|NCT01764776|PK
240199|NCT01764776|Postmenopausal women
240200|NCT01764776|normal hepatic function
240201|NCT01764776|mild hepatic impairment
240202|NCT01764776|moderate hepatic impairment
240203|NCT01764776|severe hepatic impairment
240204|NCT01764750|Intrasite
240205|NCT01764750|Antibiotic
240206|NCT01764750|Vancomycin
240207|NCT01764750|Infection
240208|NCT01764750|Pharmacokinetics
240209|NCT01764737|VX15/2503
240210|NCT01764737|Semaphorin 4D
240211|NCT01764737|SEMA4D
240212|NCT01764737|CD100
240213|NCT01764737|safety
240214|NCT01764737|tolerability
240215|NCT01764737|pharmacokinetics
240216|NCT01764737|immunogenicity
240217|NCT01764737|multiple sclerosis
240218|NCT01764737|monoclonal antibody
240219|NCT01764724|Attitudes and understanding of sodium claims
240220|NCT01764724|General canadian population
240221|NCT01764711|POTS
240222|NCT01764698|anxiety disorders
240223|NCT01764698|substance use disorders
240224|NCT01764698|treatment effectiveness
240225|NCT01764698|cognitive behavioral therapy
240226|NCT01764672|Attention Deficit Hyperactivity Disorder
240227|NCT01764672|Healthy Adults
240228|NCT01764672|Methylphenidate
240229|NCT01764672|Functional connectivity
240230|NCT01764672|Functional Magnetic Resonance Imaging
240231|NCT01764659|4D-CT
240232|NCT01764659|Contrast Enhanced CT
240233|NCT01764659|Radiotherapy Simulation
240234|NCT01764646|Prostate cancer
240235|NCT01764646|Radiation therapy
240236|NCT01764633|High cholesterol
240237|NCT01764633|Treatment for high cholesterol
240238|NCT01764633|Lowering cholesterol
240239|NCT01764633|Lowering high cholesterol
240240|NCT01764633|Hypercholesterolemia
240241|NCT01764620|shoulder
240242|NCT01764620|muscle fatigue
240243|NCT01764620|kinematics
240244|NCT01764620|athletes
240245|NCT01764607|Squamous
240246|NCT01764607|Renal
240247|NCT01764607|Transplant
240248|NCT01764594|Lupus
240249|NCT01764594|SLE
240250|NCT01764581|immune monitoring
240251|NCT01764581|immune cell function ImmuKnow
240252|NCT01764581|randomized controlled trial
240253|NCT01764581|immunosuppression management
240254|NCT01764581|infection
240255|NCT01764581|rejection
240256|NCT01764581|liver transplantation
240257|NCT01764581|Cylex
240258|NCT01764568|Metacognitive training
240259|NCT01764568|Cognitive behavioral therapy
240260|NCT01764568|Clinical trial
240261|NCT01764568|Group intervention
240262|NCT01764568|Group therapy
240263|NCT01764568|Schizophrenia
240264|NCT01764568|Psychosis
240265|NCT01764568|Cognitive remediation
240266|NCT01764542|Ulcerative colitis
240267|NCT01764542|dysplasia
240268|NCT01764542|risk factor
240269|NCT01764542|surgery
240270|NCT01764516|zinc
240271|NCT01764516|selenium
240272|NCT01764516|serum
240273|NCT01764516|epilepsy
240274|NCT01764516|antioxidants
240275|NCT01764503|ampullary tumors
240276|NCT01764503|endoscopic treatment
240277|NCT01764490|Bloodstream infections caused by multidrug-resistant Enterobacteriaceae, extended-spectrum β-lactamase-producers, carbapenemase-producing organisms
240278|NCT01764464|post laminectomy pain syndrome, failed back surgery syndrome
240279|NCT01764451|Hispanic
240280|NCT01764425|P7435
240281|NCT01764425|Healthy,overweight and or obese subjects
240282|NCT01764425|Single ascending dose
240283|NCT01764425|Multiple ascending dose
240284|NCT01764425|Pharmacokinetics
240285|NCT01764412|Healthy women
240286|NCT01764412|Menstrual cycle
240287|NCT01764412|Hepcidin
240288|NCT01764412|Seric iron
240289|NCT01764399|cardiovascular risk factors
240290|NCT01764386|obesity, overweight
240291|NCT01764373|Pain
240292|NCT01764373|Fitness
240293|NCT01764373|Diabetes
240294|NCT01764373|Aerobic Exercise
240295|NCT01764334|Non-ST elevation myocardial infarction (NSTEMI)
240296|NCT01764334|Fractional flow reserve (FFR)
240297|NCT01764334|Coronary angiogram
240298|NCT01764334|Diagnosis
240299|NCT01764334|Coronary revascularization
240300|NCT01764334|Prognosis
240301|NCT01764334|Health economics
240302|NCT01764321|Certolizumab Pegol
240303|NCT01764321|Cimzia®
240304|NCT01764321|TNF inhibitor
240305|NCT01764321|DMARD
240306|NCT01764321|Rheumatoid Arthritis
240307|NCT01764308|acne; omega-3; isotretinoin; placebo
240308|NCT01764282|HIV
240309|NCT01764282|serodiscordant couples HIV sero-conversion
240310|NCT01764282|anti-retroviral therapy
240311|NCT01764282|intervention
240312|NCT01764256|rotavirus
240313|NCT01764256|vaccine
240314|NCT01764243|Alzheimer's Disease
240315|NCT01764243|Nicotinic Acetylcholine Receptor Agonist
240316|NCT01764243|Cognitive function
240317|NCT01764243|Dementia
240318|NCT01764243|Central Nervous System Agents
240319|NCT01764230|Hodgkin lymphoma
240320|NCT01764230|Hodgkin disease
240321|NCT01764217|Cervix Cancer
240322|NCT01764217|SUV
240323|NCT01764217|Radiotherapy
240324|NCT01764217|Outcome Prediction
240325|NCT01764217|Imaging
240326|NCT01764217|PET
240327|NCT01764178|Pitavastatin
240328|NCT01764178|Valsartan
240329|NCT01764165|COPD
240330|NCT01764165|Sleep
240331|NCT01764165|Supplemental oxygen
240332|NCT01764165|Breathing mechanics
240333|NCT01764165|nasal insufflation
240334|NCT01764152|Prevention,
240335|NCT01764152|influenza,
240336|NCT01764152|adults hospitalized,
240337|NCT01764152|vaccines,
240338|NCT01764152|Effectiveness
240339|NCT01764139|Minimal knee changes
240340|NCT01764126|Safety
240341|NCT01764126|immunogenicity
240342|NCT01764126|pneumococcal
240343|NCT01764126|protein
240344|NCT01764126|vaccine
240345|NCT01764113|Obesity
240346|NCT01764113|Adolescence
240347|NCT01764113|Mindful Eating
240348|NCT01764087|Stomach Neoplasms
240349|NCT01764087|Breast Neoplasms
240350|NCT01764087|Carcinoma
240351|NCT01764087|Neoplasms
240352|NCT01764087|Paclitaxel
240353|NCT01764087|Tubulin Modulators
240354|NCT01764087|Antimitotic Agents
240355|NCT01764087|Protein Kinase Inhibitors
240356|NCT01764087|Enzyme Inhibitors
240357|NCT01764087|Pharmacologic Actions
240358|NCT01764074|Bipolar Disorder
240359|NCT01764074|Sleep Intervention
240360|NCT01764074|Suicide
240361|NCT01764074|Cognitive Behavioral Therapy
240362|NCT01764074|Sleep Quality
240363|NCT01764061|Red Cells
240364|NCT01764061|Blood donors
240365|NCT01764048|pain management
240366|NCT01764048|cesarean section
240367|NCT01764035|Psychotherapy
240368|NCT01764035|Bipolar Disorder
240369|NCT01764035|Sleep Problems
240370|NCT01764035|Insomnia
240371|NCT01764035|Hypersomnia
240372|NCT01764035|Mindfulness
240373|NCT01764035|Meditation
240374|NCT01764035|Sleep Disturbance
240375|NCT01764022|breast cancer
240376|NCT01764022|trastuzumab
240377|NCT01764009|Advanced Melanoma
240378|NCT01764009|Metastatic Melanoma
240379|NCT01764009|Melanoma Stage III and IV
240380|NCT01763996|Drug therapy
240381|NCT01763983|Multiple Sclerosis
240382|NCT01763983|Stress, Psychological
240383|NCT01763983|Psychological Stress
240384|NCT01763983|Emotional Stress
240385|NCT01763983|Cognitive Deficits
240386|NCT01763983|Cognitive Dysfunction
240387|NCT01763970|Stereotactic
240388|NCT01763970|Radiotherapy
240389|NCT01763970|Hypofractionated
240390|NCT01763944|diet
240391|NCT01763944|prostate cancer
240392|NCT01763944|carbohydrate
240393|NCT01763944|lifestyle
240394|NCT01763931|Digoxin
240395|NCT01763918|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
240396|NCT01763905|High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
240397|NCT01763892|Pediatric
240398|NCT01763892|Traumatic Brain Injury
240399|NCT01763892|TBI
240400|NCT01763892|Apolipoprotein E
240401|NCT01763892|apo-E
240402|NCT01763892|Vasospasm
240403|NCT01763892|Genetics
240404|NCT01763892|Physiologic Mechanisms
240405|NCT01763892|Neurocognitive Outcomes
240406|NCT01763892|Endothelin 1
240407|NCT01763879|Thoracic surgery
240408|NCT01763879|one lung ventilation
240409|NCT01763879|pressure-controlled ventilation
240410|NCT01763879|volume-controlled ventilation
240411|NCT01763879|right ventricular function
240412|NCT01763866|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
240413|NCT01763853|Acute respiratory distress syndrome (ARDS)
240414|NCT01763853|Pulmonary edema
240415|NCT01763853|Alveolar fluid clearance
240416|NCT01763853|Alveolar epithelial dysfunction
240417|NCT01763853|Receptor for advanced glycation end-products (RAGE)
240418|NCT01763853|Fluid resuscitation therapy
240419|NCT01763853|Hypovolemia
240420|NCT01763853|Crystalloid
240421|NCT01763853|Hydroxyethyl Starch
240422|NCT01763853|Intensive care unit
240423|NCT01763840|Pediatric Abdominal Trauma Ultrasound Contrast
240424|NCT01763827|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
240425|NCT01763801|chemo port
240426|NCT01763801|intravenous electrocardiographic guidance
240427|NCT01763801|P maximal wave
240428|NCT01763801|P submaximal wave
240429|NCT01763801|catheter tip
240430|NCT01763775|weight
240431|NCT01763775|total body water
240432|NCT01763775|body fat
240433|NCT01763775|muscle mass
240434|NCT01763775|bone mass
240435|NCT01763762|Electrical pudendal nerve stimulation
240436|NCT01763762|Pelvic floor muscle training
240437|NCT01763762|Transvaginal electrical stimulation
240438|NCT01763762|Stress urinary incontinence
240439|NCT01763762|Comparative study
240440|NCT01763723|Intense pulsed light,
240441|NCT01763723|UV-exposure,
240442|NCT01763723|skin type,
240443|NCT01763723|safety,
240444|NCT01763723|pigment,
240445|NCT01763723|home-use
240446|NCT01763723|subjects
240447|NCT01763710|Breast cancer
240448|NCT01763710|Neurotoxicity
240449|NCT01763697|Taste acuity
240450|NCT01763697|Feeding behavior
240451|NCT01763697|opioid
240452|NCT01763697|Quantitative assessment
240453|NCT01763684|Osteoarthritis
240454|NCT01763684|Osteoarthritis, Knee
240455|NCT01763684|Osteonecrosis
240456|NCT01763684|Arthritis
240457|NCT01763684|Knee Arthritis
240458|NCT01763684|Knee Replacement
240459|NCT01763671|Lung cancer
240460|NCT01763671|Paclitaxel bevacizumab
240461|NCT01763658|ITP, antioxidant therapy, oxidant status
240462|NCT01763645|NSCLC
240463|NCT01763645|bevacizumab
240464|NCT01763645|pharmacokinetics
240465|NCT01763632|Hyperbilirubinemia
240466|NCT01763632|Neonatal
240467|NCT01763632|Transcutaneous Bilirubin
240468|NCT01763619|Cervical DDD
240469|NCT01763619|DDD
240470|NCT01763619|degenerative disc disease
240471|NCT01763619|C3-C7
240472|NCT01763606|Enoxaparin
240473|NCT01763606|Aspirin
240474|NCT01763606|stroke
240475|NCT01763606|12-264
240476|NCT01763593|Patients having cataract
240477|NCT01763580|Glomerulonephritis
240478|NCT01763580|Tacrolimus
240479|NCT01763580|Nephrotic syndrome
240480|NCT01763567|Medtronic
240481|NCT01763567|Diabetes
240482|NCT01763567|Hospital
240483|NCT01763567|Continuous Glucose Monitor
240484|NCT01763567|Intensive Care Unit
240485|NCT01763554|Lu-177
240486|NCT01763554|Lutetium-177
240487|NCT01763554|DOTA-TATE
240488|NCT01763554|Neuroendocrine tumors
240489|NCT01763554|radiopharmaceutical
240490|NCT01763541|Natriuretic Peptides
240491|NCT01763528|body weight
240492|NCT01763528|Low-density-lipoprotein-type
240493|NCT01763515|Joint Diseases
240494|NCT01763515|Arthritis
240495|NCT01763515|Osteoarthritis
240496|NCT01763502|Cognitive development
240497|NCT01763502|Anemia
240498|NCT01763502|Preschool
240499|NCT01763502|Food transfers
240500|NCT01763502|Cash transfers
240501|NCT01763502|Early childhood
240502|NCT01763502|Nutrition
240503|NCT01763489|randomized controlled trial
240504|NCT01763489|applicability
240505|NCT01763489|ASSIST tool
240506|NCT01763489|surgery
240507|NCT01763489|digestive cancer
240508|NCT01763476|long infrapopliteal artery lesions
240509|NCT01763476|drug-coated balloon angioplasty
240510|NCT01763476|atherectomy
240511|NCT01763463|pneumonia requiring hospitalization
240512|NCT01763463|COPD
240513|NCT01763463|long-acting bronchodilators (LABD)
240514|NCT01763463|Inhaled Corticosteroids (ICS)
240515|NCT01763450|Bevacizumab
240516|NCT01763450|conversion therapy
240517|NCT01763450|liver metastases
240518|NCT01763450|colorectal cancer
240519|NCT01763450|objective response rate
240520|NCT01763437|Chalazia
240521|NCT01763437|Chalazion
240522|NCT01763437|Meibomian gland dysfunction
240523|NCT01763437|Rosacea
240524|NCT01763437|Ocular rosacea
240525|NCT01763411|Cataract
240526|NCT01763411|Vision
240527|NCT01763411|Intraocular lens
240528|NCT01763411|Multifocal
240529|NCT01763411|Monofocal
240530|NCT01763385|Erlotinib
240531|NCT01763385|brain radiotherapy
240532|NCT01763385|NSCLC
240533|NCT01763385|brain metastases
240534|NCT01763372|Arthroscopic
240535|NCT01763372|Iliopsoas
240536|NCT01763372|MRI
240537|NCT01763359|acetabular fracture
240538|NCT01763359|pelvic fracture
240539|NCT01763359|hip adductor strength
240540|NCT01763359|obturator nerve palsy
240541|NCT01763359|modified Stoppa approach
240542|NCT01763346|type 2 diabetes
240543|NCT01763346|prediabetes
240544|NCT01763346|obesity
240545|NCT01763346|gastric banding
240546|NCT01763346|metformin
240547|NCT01763320|ischemic stroke
240548|NCT01763320|intracranial stenting
240549|NCT01763320|vascular risk factor management
240550|NCT01763307|EGFRI
240551|NCT01763307|COLON CANCER
240552|NCT01763307|SKIN TOXICITY
240553|NCT01763307|RECONVAL K1 cream
240554|NCT01763294|multifocal refractory epilepsy
240555|NCT01763294|tDCS
240556|NCT01763294|neurostimulation
240557|NCT01763294|seizures
240558|NCT01763268|Immunogenicity
240559|NCT01763268|Reactogenicity
240560|NCT01763268|Trivivac
240561|NCT01763268|Measles
240562|NCT01763268|Mump
240563|NCT01763268|Rubella
240564|NCT01763255|cerebral palsy CD133 cells intrathecal injection
240565|NCT01763242|CKD, Anaemia, Synchronization, Monthly dosing, Home Delivery
240566|NCT01763216|depressive symptoms
240567|NCT01763216|clinical depression
240568|NCT01763216|visual processing speed
240569|NCT01763216|anxiety
240570|NCT01763216|pain
240571|NCT01763216|health-related quality of life
240572|NCT01763203|Self-management
240573|NCT01763203|Chronic Care Model
240574|NCT01763203|Community health worker
240575|NCT01763177|nebulizer
240576|NCT01763177|oxygen
240577|NCT01763177|post-operative sore throat
240578|NCT01763164|Melanoma
240579|NCT01763164|Cutaneous melanoma
240580|NCT01763164|Skin disease
240581|NCT01763164|Skin cancer
240582|NCT01763164|Skin Neoplasms
240583|NCT01763164|Neoplasm Metastasis
240584|NCT01763151|cataract surgery, astigmatism, opposite clear corneal incision, toric IOL, IOL rotational stability
240585|NCT01763125|Breast cancer
240586|NCT01763125|Ovarian cancer
240587|NCT01763125|Endometrium carcinoma
240588|NCT01763125|Cervix carcinoma,
240589|NCT01763125|Mamma carcinoma,
240590|NCT01763125|Prostata carcinoma
240591|NCT01763125|Colon carcinoma
240592|NCT01763125|Rectal carcinoma
240593|NCT01763125|Bronchus carcinoma
240594|NCT01763125|NSCLC & SCLC (Non Small Cell Lung Cancer & Small Cell Lung Cancer))
240595|NCT01763125|Prostate carcinoma
240596|NCT01763112|Influence of training with whole body vibration device
240597|NCT01763099|Autologous Hematopoietic Stem Cell Transplantation
240598|NCT01763099|Mesenchymal Stem Cells
240599|NCT01763099|Cord Blood
240600|NCT01763099|Graft failure
240601|NCT01763086|Poor Graft Function
240602|NCT01763086|Mesenchymal Stem Cells
240603|NCT01763086|Allogeneic hematopoietic stem cell transplantation
240604|NCT01763086|Third-party Donors
240605|NCT01763060|ards
240606|NCT01763060|ecmo
240607|NCT01763060|h1n1
240608|NCT01763060|pandemics
240609|NCT01763021|Healthy participants
240610|NCT01763021|PCI-32765
240611|NCT01763021|Rifampin
240612|NCT01763021|PCI-45227
240613|NCT01763021|CYP3A4
240614|NCT01763008|Pneumonia, Bacterial
240615|NCT01763008|Nosocomial Infection
240616|NCT01763008|Intraabdominal Infections
240617|NCT01763008|Urinary Tract Infection
240618|NCT01763008|Ventilator-associated pneumonia
240619|NCT01763008|Doripenem
240620|NCT01763008|Doribax
240621|NCT01763008|Filipino
240622|NCT01762995|Dolutegravir, pharmacokinetics, calcium, iron, drug interaction, healthy volunteers
240623|NCT01762956|Pelvic floor
240624|NCT01762956|Physical Therapy
240625|NCT01762956|Prostate cancer
240626|NCT01762956|Radiotherapy
240627|NCT01762956|Nuclear magnetic resonance
240628|NCT01762904|Antiseptics
240629|NCT01762904|Administration cutaneously
240630|NCT01762904|Anti-infecting agents, local
240631|NCT01762891|Coumadin
240632|NCT01762891|celecoxib
240633|NCT01762891|rofecoxib
240634|NCT01762891|acetaminophen
240635|NCT01762891|antiphospholipid syndrome and INR
240636|NCT01762878|pharmacodynamics
240637|NCT01762878|pharmacokinetics
240638|NCT01762878|healthy volunteers
240639|NCT01762878|Pi3K-delta
240640|NCT01762878|GSK2269557
240641|NCT01762878|safety
240642|NCT01762878|dry powder inhaler
240643|NCT01762865|acute bronchitis, bacteria, virus, clinical symoptoms
240644|NCT01762852|Benlysta
240645|NCT01762852|efficacy
240646|NCT01762852|proteinuria
240647|NCT01762852|Idiopathic membranous nephropathy
240648|NCT01762852|GSK1550188
240649|NCT01762852|anti-phospholipase A2 receptor antibodies
240650|NCT01762852|safety
240651|NCT01762852|placebo
240652|NCT01762852|BLyS
240653|NCT01762852|belimumab
240654|NCT01762852|Lymphostat-B
240655|NCT01762852|membrane attack complex
240656|NCT01762826|Inositol
240657|NCT01762826|GDM
240658|NCT01762813|Colon cancer
240659|NCT01762813|rectal cancer
240660|NCT01762813|liver metastasis
240661|NCT01762813|survival
240662|NCT01762813|biomarker
240663|NCT01762813|molecular profile
240664|NCT01762774|COPD
240665|NCT01762774|forearm blood flow
240666|NCT01762774|soluble Epoxide Hydrolase inhibitor
240667|NCT01762761|eltrombopag
240668|NCT01762761|TPO-R agonist
240669|NCT01762761|Chronic ITP
240670|NCT01762748|Probiotic
240671|NCT01762748|liver
240672|NCT01762748|transplant
240673|NCT01762748|permeability
240674|NCT01762722|Spectroscopy, near infrared
240675|NCT01762722|Oximetry
240676|NCT01762722|Hypoxemia
240677|NCT01762722|Tissue oxygenation
240678|NCT01762709|Video-assisted thoracoscopic surgery
240679|NCT01762709|one lung ventilation
240680|NCT01762709|low tidal volume
240681|NCT01762709|acute lung injury
240682|NCT01762709|lung water content
240683|NCT01762696|marijuana
240684|NCT01762696|intervention
240685|NCT01762696|adolescent, young adult
240686|NCT01762696|primary care
240687|NCT01762696|mobile
240688|NCT01762683|pregnancy
240689|NCT01762683|obesity
240690|NCT01762683|differentiation
240691|NCT01762670|Bacterial Vaginosis
240692|NCT01762670|BV
240693|NCT01762657|Type 1 Diabetes
240694|NCT01762657|Insulin Independence
240695|NCT01762657|Beta Regeneration
240696|NCT01762657|Immune Tolerance Agent
240697|NCT01762657|Lanzoprazole
240698|NCT01762657|Cyclosporine
240699|NCT01762644|Type 1 Diabetes
240700|NCT01762644|Insulin Independence
240701|NCT01762644|Beta Regeneration
240702|NCT01762644|Immune Tolerance Agent
240703|NCT01762644|Omeprazole
240704|NCT01762644|Cyclosporine
240705|NCT01762618|Group Cognitive Behavior Therapy, Alzheimer's disease, Caregivers¡
240706|NCT01762579|Not-celiac wheat sensitivity
240707|NCT01762579|Gluten
240708|NCT01762579|esophagogastroduodenoscopy
240709|NCT01762579|Rectoscopy
240710|NCT01762566|Not-celiac gluten (wheat) sensitivity
240711|NCT01762566|Bioelectrical impedance analysis
240712|NCT01762566|Bloating
240713|NCT01762566|Swelling
240714|NCT01762540|Protein breakdown
240715|NCT01762540|Insulin resistance
240716|NCT01762540|Glucose intolerance
240717|NCT01762540|Lipolysis
240718|NCT01762527|Adaptive radiotherapy
240719|NCT01762527|Bladder cancer
240720|NCT01762514|Nasopharyngeal carcinoma
240721|NCT01762514|Amifostine
240722|NCT01762514|Myelosuppression
240723|NCT01762514|Xerostomia
240724|NCT01762514|Mucositis
240725|NCT01762501|Hypertension
240726|NCT01762488|Treatment Resistant Hypertension
240727|NCT01762488|Renal Denervation
240728|NCT01762475|Magnetic resonance imaging
240729|NCT01762475|Blood oxygen level dependent signal
240730|NCT01762475|Hypercapnia
240731|NCT01762475|Endothelial progenitor cells
240732|NCT01762449|Scleroderma
240733|NCT01762449|interstitial lung disease
240734|NCT01762410|Advanced refractory solid tumors
240735|NCT01762371|ACL
240736|NCT01762371|Knee
240737|NCT01762371|Ligament
240738|NCT01762371|Cruciate
240739|NCT01762371|Anterior
240740|NCT01762358|ACL
240741|NCT01762358|Ligament
240742|NCT01762358|Knee
240743|NCT01762345|Stress urinary incontinence
240744|NCT01762345|SUI
240745|NCT01762332|nociception
240746|NCT01762332|analgesia
240747|NCT01762332|intraoperative monitoring
240748|NCT01762293|CRC
240749|NCT01762293|Famitinib
240750|NCT01762293|Phase II
240751|NCT01762293|Colorectal Cancer
240752|NCT01762280|Famitinib
240753|NCT01762280|Advanced Solid tumor
240754|NCT01762280|Phase I
240755|NCT01762254|pain score
240756|NCT01762254|complication
240757|NCT01762241|Prostate cancer
240758|NCT01762241|Androgen deprivation therapy
240759|NCT01762241|Exercise
240760|NCT01762241|Xbox
240761|NCT01762228|Oropharyngeal dysphagia
240762|NCT01762228|Elderly
240763|NCT01762228|Transcutaneous electrical stimulation
240764|NCT01762228|TRPV1 agonist
240765|NCT01762215|Epilepsy
240766|NCT01762215|Seizure
240767|NCT01762215|Veteran
240768|NCT01762202|CLL
240769|NCT01762202|Fludarabine
240770|NCT01762202|Cyclophosphamide
240771|NCT01762202|Ofatumumab
240772|NCT01762189|Hyperbilirubinemia
240773|NCT01762189|Neonatal
240774|NCT01762189|Incidence
240775|NCT01762189|Risk factors
240776|NCT01762176|Early Rheumatoid Arthritis
240777|NCT01762176|Usual care
240778|NCT01762176|Intensive Care
240779|NCT01762176|Boolean criteria
240780|NCT01762163|Ischemic Stroke,adaptive design, randomized, double-blind
240781|NCT01762150|collected duct carcinoma
240782|NCT01762150|sorafenib
240783|NCT01762137|Aneurysm
240784|NCT01762137|Coiling
240785|NCT01762137|Flow Diversion
240786|NCT01762124|Pulmonary valve
240787|NCT01762124|Congenital heart disease
240788|NCT01762124|Transcatheter pulmonary valve
240789|NCT01762124|Percutaneous pulmonary valve
240790|NCT01762111|Anti-Mullerian Hormone
240791|NCT01762111|In-Vitro fertilization
240792|NCT01762098|In vitro fertilization
240793|NCT01762098|Hysteroscopy
240794|NCT01762098|Endometrial biopsy
240795|NCT01762085|neuropathic diabetic foot ulcer
240796|NCT01762085|nerve decompression surgery
240797|NCT01762072|homocysteine-vitamin B12-fish oil-ferritin
240798|NCT01762059|bionic pancreas
240799|NCT01762059|artificial pancreas
240800|NCT01762059|insulin
240801|NCT01762059|glucagon
240802|NCT01762059|continuous glucose monitoring
240803|NCT01762059|CGM
240804|NCT01762059|outpatient
240805|NCT01762059|insulin pump
240806|NCT01762046|Diabetes Mellitus, Type 2
240807|NCT01762046|Pharmacogenetics
240808|NCT01762046|Genetics
240809|NCT01762046|Obesity
240810|NCT01762033|Renal cell carcinoma
240811|NCT01762033|Renal cell cancer
240812|NCT01762033|ASONEP
240813|NCT01762033|Sonepcizumab
240814|NCT01762020|Women with Breast Cancer
240815|NCT01762020|Receiving Adjuvant Radiation Therapy
240816|NCT01762007|hypospadias, bladder outlet obstruction, ultrasonography
240817|NCT01761994|nafamostat mesilate
240818|NCT01761994|heparin
240819|NCT01761994|continuous renal replacement therapy
240820|NCT01761981|Haemorrhagic Hereditary Telangiectasia
240821|NCT01761981|Rendu Osler Weber Syndrome
240822|NCT01761981|Osler Weber Rendu Syndrome
240823|NCT01761981|HHT
240824|NCT01761968|chronic myeloproliferative neoplasms
240825|NCT01761968|Polycythemia Vera
240826|NCT01761968|Essential Thrombocythemia
240827|NCT01761968|Primary Myelofibrosis
240828|NCT01761968|Post-Polycythemia Vera Myelofibrosis
240829|NCT01761968|Post-Essential Thrombocythemia Myelofibrosis
240830|NCT01761968|Givinostat
240831|NCT01761955|body weight
240832|NCT01761955|lipids
240833|NCT01761955|glucose
240834|NCT01761955|insulin
240835|NCT01761942|omega-3 fatty acids
240836|NCT01761942|anorexia nervosa
240837|NCT01761942|efficacy
240838|NCT01761942|safety
240839|NCT01761929|oligometastatic
240840|NCT01761929|oligometastases
240841|NCT01761929|stereotactic body radiotherapy
240842|NCT01761929|radiation therapy
240843|NCT01761929|Oligometastasis
240844|NCT01761929|Stereotactic ablative body
240845|NCT01761929|radiotherapy
240846|NCT01761916|captopril, clonidine, pregnancy-induced hypertension,
240847|NCT01761890|Chronic Myeloid Leukemia
240848|NCT01761890|Early phase
240849|NCT01761890|CML
240850|NCT01761890|Dasatinib
240851|NCT01761877|breast cancer, nonsteroidal antiinflammatory drug , breast density, chemoprevention, aromatase inhibitors
240852|NCT01761851|Resting metabolic rate
240853|NCT01761851|nutrition status
240854|NCT01761851|dietary intake
240855|NCT01761838|spinal manipulative therapy
240856|NCT01761838|low back pain
240857|NCT01761838|experimental pain
240858|NCT01761838|spinal stiffness
240859|NCT01761838|lumbar multifidus
240860|NCT01761838|degeneration
240861|NCT01761812|Prostate cancer
240862|NCT01761812|MRI
240863|NCT01761812|Elastography
240864|NCT01761812|Gadofosveset
240865|NCT01761799|Influenza
240866|NCT01761799|Pertussis
240867|NCT01761799|Vaccination
240868|NCT01761786|Myocardial Infarction
240869|NCT01761786|Thrombosis
240870|NCT01761786|Acute Coronary Syndrome
240871|NCT01761786|Myocardial Ischemia
240872|NCT01761786|Heart Diseases
240873|NCT01761786|Cardiovascular Diseases
240874|NCT01761786|Vascular Diseases
240875|NCT01761786|Embolism and Thrombosis
240876|NCT01761786|Genetic Testing
240877|NCT01761786|Clopidogrel
240878|NCT01761786|Prasugrel
240879|NCT01761786|Ticagrelor
240880|NCT01761786|Platelet Aggregation Inhibitors
240881|NCT01761786|Purinergic P2Y Receptor Antagonists
240882|NCT01761747|Squamous Cell Carcinoma
240883|NCT01761734|Influenza vaccination
240884|NCT01761721|Endometrial cancer (MeSH)
240885|NCT01761721|Robotics (MeSH)
240886|NCT01761708|primary ventral hernia repair with mesh
240887|NCT01761708|umbilical hernia repair
240888|NCT01761708|epigastric hernia repair
240889|NCT01761708|C-Qur V-patch
240890|NCT01761708|Size tailored repair
240891|NCT01761708|preperitoneal repair
240892|NCT01761708|abdominal hernia
240893|NCT01761708|dual sided mesh
240894|NCT01761708|trocar-site hernia
240895|NCT01761656|stable angina
240896|NCT01761656|unstable angina
240897|NCT01761656|acute non-ST-segment elevation myocardial infarction
240898|NCT01761656|PCI
240899|NCT01761656|perioperative myocardial infarction
240900|NCT01761656|major adverse cardiac events
240901|NCT01761643|PrEP
240902|NCT01761643|Pre exposure Prophylaxis
240903|NCT01761643|Text Messaging
240904|NCT01761643|Truvada
240905|NCT01761643|iTab
240906|NCT01761643|CCTG
240907|NCT01761643|595
240908|NCT01761630|Asthma
240909|NCT01761630|Severe Asthma
240910|NCT01761630|SARP
240911|NCT01761617|Yoga
240912|NCT01761617|Chronic Low Back Pain
240913|NCT01761617|CAM
240914|NCT01761617|Complementary and Alternative Medicine
240915|NCT01761617|Minorities
240916|NCT01761591|CAD
240917|NCT01761591|PCI
240918|NCT01761591|BMS
240919|NCT01761591|Svelte
240920|NCT01761591|Acrobat
240921|NCT01761591|direct stenting
240922|NCT01761591|RCT
240923|NCT01761578|Bioresorbable
240924|NCT01761578|Coronary
240925|NCT01761578|Stent
240926|NCT01761578|Vascular Remodeling
240927|NCT01761578|Angioplasty
240928|NCT01761578|Coronary Artery Disease
240929|NCT01761552|in ASA 4 AND ASA 4E patients
240930|NCT01761539|pancreatitis
240931|NCT01761539|pancreatitis, alcoholic
240932|NCT01761526|Rotigotine
240933|NCT01761526|Neupro
240934|NCT01761526|Japanese
240935|NCT01761526|Caucasian
240936|NCT01761526|Male
240937|NCT01761526|Female
240938|NCT01761526|Single dose
240939|NCT01761526|Pharmacokinetics
240940|NCT01761500|Non-Hodgkin's lymphoma;
240941|NCT01761500|Childhood and adolescence;
240942|NCT01761500|Survival Rate
240943|NCT01761474|Carbon dioxide insufflation
240944|NCT01761474|Air insufflatioin
240945|NCT01761474|ERCP
240946|NCT01761474|Sedation
240947|NCT01761448|Coronary Artery Disease
240948|NCT01761448|Cardiac rehabilitation program
240949|NCT01761448|telemedical homely rehabilitation
240950|NCT01761448|guided exercise
240951|NCT01761448|ECG- vest
240952|NCT01761435|Influenza
240953|NCT01761435|Solid Organ Transplant Recipients
240954|NCT01761396|Anxiety
240955|NCT01761396|Fear
240956|NCT01761396|Worry
240957|NCT01761396|Therapy
240958|NCT01761396|Cognitive behavioral therapy
240959|NCT01761383|Chronic Schizophrenia
240960|NCT01761383|Nintendo Wii
240961|NCT01761383|Quality of Life
240962|NCT01761370|Non alcoholic Steatohepatitis
240963|NCT01761370|Intra-gastric balloon
240964|NCT01761357|Aortic valve stenosis
240965|NCT01761357|Quality of life
240966|NCT01761357|Burden co morbidities
240967|NCT01761357|Transcatheter aortic valve implantation
240968|NCT01761357|Geriatric assessment
240969|NCT01761331|infant, colic, crying, acupuncture, stooling, sleep
240970|NCT01761318|Diabetes mellitus type 2
240971|NCT01761318|Glucagon-Like Peptide 1
240972|NCT01761318|Magnetic Resonance Imaging
240973|NCT01761318|Magnetic Resonance Spectroscopy
240974|NCT01761318|Steatosis
240975|NCT01761305|Idiopathic scoliosis
240976|NCT01761305|Brace
240977|NCT01761305|Scoliosis specific exercise
240978|NCT01761305|Physical activity
240979|NCT01761279|Colonic polyps
240980|NCT01761266|Hepatocellular Carcinoma
240981|NCT01761266|Neoplasms
240982|NCT01761266|Cancer
240983|NCT01761253|comorbidity, multiple chronic conditions, Medicaid, prediction of cost
240984|NCT01761253|Predictive models, cost containment, managed care
240985|NCT01761227|Vascular dementia
240986|NCT01761227|Fufangdanshen Tablets
240987|NCT01761227|Randomized Controlled trial
240988|NCT01761227|Chinese Medicine
240989|NCT01761214|bacteriology, inflammation, bronchiectasis, exacerbation
240990|NCT01761201|Prophylaxis
240991|NCT01761201|Tuberculosis
240992|NCT01761201|Transplant recipients
240993|NCT01761201|Transplant waiting list
240994|NCT01761188|Persistent Atrial fibrillation;LA substrate;ablation;voltage mapping
240995|NCT01761149|remifentanil,
240996|NCT01761149|opioid,
240997|NCT01761149|hyperalgesia,
240998|NCT01761149|visual analogue score
240999|NCT01761149|thyroidectomy,
241000|NCT01761123|Prevention of Influenza
241001|NCT01761110|Opioid dependence
241002|NCT01761110|Injection drug use
241003|NCT01761110|Buprenorphine
241004|NCT01761110|Opioid agonist treatment
241005|NCT01761110|Access to care
241006|NCT01761110|HIV risk behaviors
241007|NCT01761110|Opioids
241008|NCT01761097|Adenoma, polyp, colonoscopy.
241009|NCT01761084|Osteoporosis
241010|NCT01761084|Spine fracture
241011|NCT01761084|Vertebral fracture
241012|NCT01761084|Exercise Interventions
241013|NCT01761084|Exercise
241014|NCT01761058|Asthma
241015|NCT01761058|Bronchial Diseases
241016|NCT01761058|Respiratory Tract Diseases
241017|NCT01761058|Lung Diseases, Obstructive
241018|NCT01761058|Lung Diseases
241019|NCT01761058|Respiratory Hypersensitivity
241020|NCT01761058|Hypersensitivity, Immediate
241021|NCT01761058|Hypersensitivity
241022|NCT01761058|Immune System Disease
241023|NCT01761045|Monosodium L-Glutamate (MSG)
241024|NCT01761045|Nucleic Acid (IMP)
241025|NCT01761045|Satiety
241026|NCT01761045|Gastrointestinal Sensation
241027|NCT01761045|Consommé Soups
241028|NCT01761045|Snack Intake
241029|NCT01761032|Tanning
241030|NCT01761032|neuroimaging
241031|NCT01761032|dopamine
241032|NCT01761032|MRI
241033|NCT01761032|SPECT
241034|NCT01761019|psoriasis
241035|NCT01761019|Taclonex
241036|NCT01761019|Acitretin
241037|NCT01761019|Methotrexate
241038|NCT01761006|COPD
241039|NCT01761006|Chronic Obstructive Pulmonary Disease
241040|NCT01761006|Exhaled Nitric Oxide
241041|NCT01761006|NIOX MINO
241042|NCT01761006|Acute COPD exacerbation
241043|NCT01760993|Not Required
241044|NCT01760980|Rate and extend of absorption of Exemestane
241045|NCT01760967|Dexmedetomidine
241046|NCT01760967|sepsis
241047|NCT01760967|mortality
241048|NCT01760967|duration of mechanical ventilation
241049|NCT01760967|organ failure
241050|NCT01760954|Gonadotropin-Releasing Hormone Antagonist
241051|NCT01760954|Non-Menstrual Pelvic Pain (NMPP)
241052|NCT01760954|Dysmenorrhea (DYS)
241053|NCT01760954|Endometriosis associated pain
241054|NCT01760954|Elagolix
241055|NCT01760941|Urology
241056|NCT01760941|Prostate
241057|NCT01760941|Breast
241058|NCT01760941|Lung
241059|NCT01760941|Chest
241060|NCT01760915|asthma
241061|NCT01760915|severe
241062|NCT01760902|Inflammation
241063|NCT01760876|Optical Coherence Tomography
241064|NCT01760876|Biofreedom Stent
241065|NCT01760863|Revision
241066|NCT01760863|Knee
241067|NCT01760863|Hip
241068|NCT01760863|Arthroplasty
241069|NCT01760863|Oral
241070|NCT01760863|Antibiotics
241071|NCT01760863|Infection
241072|NCT01760837|cow's milk allergy
241073|NCT01760837|baked milk
241074|NCT01760837|tolerance
241075|NCT01760837|infants and children
241076|NCT01760824|Sequential
241077|NCT01760824|Quadruple
241078|NCT01760824|First
241079|NCT01760824|Line
241080|NCT01760824|Helicobacter
241081|NCT01760824|pylori
241082|NCT01760824|infection
241083|NCT01760811|tongue
241084|NCT01760811|Squamous cell carcinoma
241085|NCT01760811|locally advanced
241086|NCT01760811|cetuximab
241087|NCT01760798|osteoporosis
241088|NCT01760798|Teriparatide
241089|NCT01760785|Veterans
241090|NCT01760785|Traumatic Brain Injury(TBI)
241091|NCT01760785|Alcoholism
241092|NCT01760772|heart disease
241093|NCT01760772|GLP-1
241094|NCT01760772|Exendin-9
241095|NCT01760772|postprandial lipids
241096|NCT01760759|HIV
241097|NCT01760759|Antiretroviral therapy adherence
241098|NCT01760746|Proliferative Diabetic Retinopathy
241099|NCT01760746|Vitrectomy
241100|NCT01760746|Inflammatory Cytokines
241101|NCT01760707|Diabetes mellitus
241102|NCT01760707|Peripheral neuropathy
241103|NCT01760707|Exercise
241104|NCT01760707|Balance performance
241105|NCT01760694|Pancreatic
241106|NCT01760694|Pancreas
241107|NCT01760694|Intraoperative Radiation Therapy
241108|NCT01760694|Chemotherapy
241109|NCT01760668|Sex chromosome
241110|NCT01760668|Turner Syndrome
241111|NCT01760668|Marfan syndrome
241112|NCT01760668|Bicuspid aortic valve
241113|NCT01760668|Aortic Aneurysm
241114|NCT01760668|Epigenetics
241115|NCT01760668|Transcriptome
241116|NCT01760668|non-coding RNA
241117|NCT01760668|Electron microscopy
241118|NCT01760668|Proteomics
241119|NCT01760642|metabolite profiles
241120|NCT01760642|pharmacokinetics
241121|NCT01760642|CYP3A
241122|NCT01760642|metabolomics
241123|NCT01760629|Encephalopathy, Newborn, Low and Middle-income countries, Hypothermia
241124|NCT01760616|Huaier Granule;
241125|NCT01760616|After non-radical hepatectomy;
241126|NCT01760616|Prevention of Disease Progression of Hepatocarcinoma;
241127|NCT01760616|Safety.
241128|NCT01760603|pelvic organ prolapse
241129|NCT01760590|neck pain
241130|NCT01760590|cervical pain
241131|NCT01760590|pain pressure thresholds
241132|NCT01760590|pain catastrophizing
241133|NCT01760577|osteoarthritis, botulinum toxin, hyaluronate
241134|NCT01760564|Niemann-Pick disease type C
241135|NCT01760564|miglustat
241136|NCT01760551|Fracture
241137|NCT01760551|Trauma
241138|NCT01760551|impairment
241139|NCT01760538|Cardiac transplant recipients
241140|NCT01760538|Heart rate variability
241141|NCT01760538|Exercise training
241142|NCT01760525|p53, solid tumor
241143|NCT01760512|Gastric bypass
241144|NCT01760512|Robot-assisted surgery
241145|NCT01760512|Conventional laparoscopy
241146|NCT01760512|Pain assessment
241147|NCT01760512|Health economics outcomes
241148|NCT01760499|skin
241149|NCT01760499|metastatic
241150|NCT01760473|opioid dependence
241151|NCT01760434|scoliosis
241152|NCT01760434|long-term outcomes
241153|NCT01760434|sagittal plane
241154|NCT01760434|quality of life
241155|NCT01760434|curve progression
241156|NCT01760434|pulmonary function
241157|NCT01760382|Acute myocardial infarction
241158|NCT01760382|ST elevation myocardial infarction
241159|NCT01760382|primary PCI
241160|NCT01760382|reperfusion therapy
241161|NCT01760382|angioplasty
241162|NCT01760382|stent
241163|NCT01760356|Liver transplantation
241164|NCT01760356|Calcineurin inhibitors
241165|NCT01760356|Pharmacodynamic biomarkers
241166|NCT01760356|Calcineurin pathway
241167|NCT01760356|Tacrolimus
241168|NCT01760356|interindividual variability
241169|NCT01760304|COPD
241170|NCT01760278|Time-lapse monitoring of embryos.
241171|NCT01760278|Embryoscope
241172|NCT01760278|IVF-ET/ICSI
241173|NCT01760278|Cetrorelix
241174|NCT01760278|Gonal-F
241175|NCT01760265|dysbetalipoproteinemia
241176|NCT01760265|artery calcium score
241177|NCT01760265|carotid intima media
241178|NCT01760265|ankle brachial index
241179|NCT01760265|dysbetalipoproteinemic patients
241180|NCT01760252|Pancreatic Cancer
241181|NCT01760239|Adolescent Hypertension
241182|NCT01760239|Adolescent Pre Hypertension
241183|NCT01760239|Adolescent Pre Hypertension and Obesity
241184|NCT01760226|DLBCL
241185|NCT01760226|Diffuse large B cell lymphoma
241186|NCT01760226|dose adjusted
241187|NCT01760226|EPOCH
241188|NCT01760226|Etoposide
241189|NCT01760226|Doxorubicin
241190|NCT01760226|Vincristine
241191|NCT01760226|Cyclophosphamide
241192|NCT01760226|Prednisone
241193|NCT01760226|Rituximab
241194|NCT01760200|Coronary angioplasty
241195|NCT01760200|Coronary stent
241196|NCT01760200|paclitaxel drug-eluting stent
241197|NCT01760200|drug eluting balloon
241198|NCT01760174|Transversus abdominis plane catheter
241199|NCT01760161|postoperative pain
241200|NCT01760161|opioid consumption
241201|NCT01760161|termanalgesia
241202|NCT01760161|plasmaropivacain level
241203|NCT01760148|Hepatitis C Virus
241204|NCT01760148|HCV
241205|NCT01760148|Interferon
241206|NCT01760148|Prediction
241207|NCT01760148|SVR
241208|NCT01760148|Sustained Virus Response
241209|NCT01760135|trauma
241210|NCT01760135|nutrition
241211|NCT01760135|hyperglycemia
241212|NCT01760122|peginterferon
241213|NCT01760122|HBeAg Positive
241214|NCT01760122|Chronic hepatitis B
241334|NCT01759576|Pharmacodynamics
241215|NCT01760109|Respiratory and urinary tract infections
241216|NCT01760109|Piperacillin Sodium and Sulbactam Sodium for Injection (2:1)
241217|NCT01760109|Phase IV
241218|NCT01760096|Paroxysmal Nocturnal Hemoglobinuria
241219|NCT01760096|Anemia
241220|NCT01760096|Hematologic Diseases
241221|NCT01760096|bone marrow failure
241222|NCT01760096|Immunologic Factors
241223|NCT01760096|Physiological Effects of Drugs
241224|NCT01760096|Levamisole
241225|NCT01760096|cyclosporine A
241226|NCT01760070|cancer
241227|NCT01760070|endoscopy
241228|NCT01760070|endoscopic submucosal dissection
241229|NCT01760044|tissue oxygenation
241230|NCT01760044|perfusion status
241231|NCT01760031|preconditioning
241232|NCT01760031|contrast-induced acute kidney injury
241233|NCT01760031|renal faliure
241234|NCT01760018|desflurane, total intravenous anesthesia, QoR-40
241235|NCT01760005|Alzheimer's
241236|NCT01760005|Alzheimer's Disease
241237|NCT01760005|Dementia
241238|NCT01760005|Mutation
241239|NCT01760005|Genetic Mutation
241240|NCT01760005|Dominantly Inherited Alzheimer's Disease
241241|NCT01760005|Dominantly Inherited Alzheimer's Network
241242|NCT01760005|Autosomal Dominant Alzheimer's Disease
241243|NCT01760005|Early Onset Alzheimer's Disease
241244|NCT01760005|DIAN
241245|NCT01760005|DIAN-TU
241246|NCT01760005|DIAN TU
241247|NCT01759992|Frail elderly
241248|NCT01759992|Muscle weakness
241249|NCT01759992|Institutionalization
241250|NCT01759992|Respiratory muscle training
241251|NCT01759979|Cholelithiasis, Common Bile Duct
241252|NCT01759979|Choledocholithiasis
241253|NCT01759966|Heart transplantation
241254|NCT01759966|Autonomic cardiovascular control
241255|NCT01759966|Acute rejection
241256|NCT01759966|Cardiac allograft vasculopathy
241257|NCT01759953|Diabetes Mellitus
241258|NCT01759953|Insulin
241259|NCT01759953|Video Games
241260|NCT01759953|Medical Education
241261|NCT01759953|Educational Technology
241262|NCT01759953|Continuing Medical Education
241263|NCT01759940|carotid
241264|NCT01759940|endarterectomy
241265|NCT01759940|cervical block
241266|NCT01759927|Physical activity counselor
241267|NCT01759927|Workplace intervention
241268|NCT01759927|Active and healthy lifestyle
241269|NCT01759901|hepatectomy
241270|NCT01759901|vascular inflow occlusion
241271|NCT01759862|kidney transplant
241272|NCT01759862|Aminophylline
241273|NCT01759862|pediatric
241274|NCT01759849|Asthma
241275|NCT01759849|β-chain signaling
241276|NCT01759849|allergen inhalation challenges
241277|NCT01759849|sputum
241278|NCT01759849|bone marrow aspirate
241279|NCT01759849|blood collection
241280|NCT01759849|-methacholine challenge
241281|NCT01759836|Prostatectomy
241282|NCT01759836|Statins
241283|NCT01759810|Glioblastoma, recurrent glioblastoma
241284|NCT01759797|ALS bone marrow mesenchymal stem cell intravenous injection
241285|NCT01759784|mesenchymal stem cell intraventricular injection ALS
241286|NCT01759771|Prostate Cancer
241287|NCT01759771|Vitamin D3
241288|NCT01759771|Active surveillance
241289|NCT01759758|boxer's fracture
241290|NCT01759758|metacarpal neck fracture
241291|NCT01759758|metacarpal fracture
241292|NCT01759732|Aplastic anemia
241293|NCT01759732|T cell dose
241294|NCT01759732|CD3 depletion
241295|NCT01759732|Haploidentical hematopoietic stem cell transplantation
241296|NCT01759719|platinum-chromium stents
241297|NCT01759719|concertina effect
241298|NCT01759719|stent deformation
241299|NCT01759719|everolimus eluting stents
241300|NCT01759719|stent lenght
241301|NCT01759693|Platelet activation
241302|NCT01759680|Risk of falls
241303|NCT01759680|Whole Body Vibration
241304|NCT01759680|Nursing Home
241305|NCT01759667|Diet-induced Thermogenesis;
241306|NCT01759667|Respiratory Quotient;
241307|NCT01759667|Roux-en-Y Gastric Bypass;
241308|NCT01759667|Energy Expenditure.
241309|NCT01759641|Dialysis
241310|NCT01759641|Monitoring
241311|NCT01759641|Cardiovascular stability
241312|NCT01759641|biosignals
241313|NCT01759628|Steatohepatitis,
241314|NCT01759628|Helicobacter pylori,
241315|NCT01759628|Insulin resistance,
241316|NCT01759628|Alanine aminotransferase,
241317|NCT01759628|Aspartate aminotransferase,
241318|NCT01759615|Preterm
241319|NCT01759615|SGA
241320|NCT01759615|AREDF
241321|NCT01759615|Early feeding
241322|NCT01759615|Late feeding
241323|NCT01759615|Feed intolerence
241324|NCT01759615|Necrotizing enterocolitis
241325|NCT01759602|Neuromyelitis optica
241326|NCT01759602|Devic's disease
241327|NCT01759602|NMO
241328|NCT01759602|Devic
241329|NCT01759589|electroconvulsive therapy,sevoflurane,propofol,remifentanil
241330|NCT01759576|Renal Insufficiency
241331|NCT01759576|Healthy
241332|NCT01759576|Canagliflozin (JNJ-28431754)
241333|NCT01759576|Pharmacokinetics
241335|NCT01759576|Dialysis
241336|NCT01759550|Gastric Procedures
241337|NCT01759550|Force Triad
241338|NCT01759550|LigaSure Advance Pistol Grip
241339|NCT01759550|LigaSure Blunt Tip
241340|NCT01759524|local anaesthesia
241341|NCT01759524|analgesia
241342|NCT01759524|bupivacaine
241343|NCT01759524|lidocaine
241344|NCT01759524|clonidine
241345|NCT01759524|sciatic nerve
241346|NCT01759524|saphenous nerve
241347|NCT01759511|Idiopathic
241348|NCT01759511|Pulmonary
241349|NCT01759511|Fibrosis
241350|NCT01759511|IPF
241351|NCT01759498|Inflammation
241352|NCT01759498|Pain intensity
241353|NCT01759498|Flexibility
241354|NCT01759498|RICE protocol
241355|NCT01759498|Swelling
241356|NCT01759485|Clozapine
241357|NCT01759485|Schizophrenia
241358|NCT01759485|Vitamin-D
241359|NCT01759485|Treatment-resistant
241360|NCT01759472|leukotriene
241361|NCT01759472|leukotriene receptor antagonist
241362|NCT01759420|Ondansetron
241363|NCT01759420|QT interval
241364|NCT01759420|QTc
241365|NCT01759420|QT prolongation
241366|NCT01759420|Drug induced QT prolongation
241367|NCT01759381|Spinal Deformity
241368|NCT01759381|Complex Spinal Surgery
241369|NCT01759381|Negative Pressure Wound Therapy
241370|NCT01759381|Post-Operative Infection
241371|NCT01759368|self-care, heart failure, telemonitoring, health care utilization
241372|NCT01759342|Cystic fibrosis; pulmonary exacerbation, exercise
241373|NCT01759329|overweight
241374|NCT01759329|body weight
241375|NCT01759329|coffee
241376|NCT01759290|Angioplasty
241377|NCT01759290|Bioabsorbable
241378|NCT01759290|Bioresorbable
241379|NCT01759290|BVS
241380|NCT01759290|Coronary Artery Endothelial Responsiveness
241381|NCT01759290|Coronary Scaffold
241382|NCT01759290|Coronary Stent
241383|NCT01759264|Fecal Calprotectin
241384|NCT01759264|Crohn's Disease
241385|NCT01759264|Adalimumab
241386|NCT01759251|Meniere Disease
241387|NCT01759251|Betahistine Dihydrochloride
241388|NCT01759251|Vertigo
241389|NCT01759238|colorectal cancer
241390|NCT01759238|metastases
241391|NCT01759238|non resectable
241392|NCT01759238|chemoradiation
241393|NCT01759225|Registry, Cardiovascular, CVD, Health Maintenance Organization
241394|NCT01759212|stem cell implantation
241395|NCT01759212|coronary artery disease
241396|NCT01759212|left ventricular assist device
241397|NCT01759199|COPD
241398|NCT01759199|ST6: The six minute Stepper Test
241399|NCT01759199|Conventional respiratory rehabilitation
241400|NCT01759199|Pulmonary rehabilitation
241401|NCT01759186|Asthma
241402|NCT01759186|Biomakers
241403|NCT01759186|Phenotype
241404|NCT01759173|Minor traumatic brain injury (TBI)
241405|NCT01759173|Concussion
241406|NCT01759160|Target control infusion
241407|NCT01759160|propofol
241408|NCT01759160|cardiac depression
241409|NCT01759160|induction of anesthesia
241410|NCT01759160|hemodynamics
241411|NCT01759134|Premature neonate
241412|NCT01759134|Post-discharge
241413|NCT01759134|Formula
241414|NCT01759121|severe non-proliferative diabetic retinopathy
241415|NCT01759121|subthreshold
241416|NCT01759121|panretinal photocoagulation
241417|NCT01759121|PASCAL
241418|NCT01759121|endpoint management
241419|NCT01759108|xerostomia
241420|NCT01759108|rebamipide
241421|NCT01759108|efficacy
241422|NCT01759108|safety
241423|NCT01759095|adherence
241424|NCT01759095|electronic monitoring
241425|NCT01759095|primary care
241426|NCT01759095|community pharmacy
241427|NCT01759095|multidrug blister pack
241428|NCT01759095|pill box
241429|NCT01759056|Ulcerative colitis
241430|NCT01759043|coronary artery disease
241431|NCT01759043|Myocardial Infarction
241432|NCT01759043|Radial Artery
241433|NCT01759043|Catheters
241434|NCT01759030|rheumatoid arthritis, DMARDs
241435|NCT01759030|rituximab
241436|NCT01759030|biosimilar
241437|NCT01759030|interchangeability
241438|NCT01759017|Crohn's disease
241439|NCT01759017|Inflammatory bowel disease
241440|NCT01759017|IBD
241441|NCT01759017|Infliximab
241442|NCT01759017|PET
241443|NCT01759017|PET/CT
241444|NCT01759004|lipoedema
241445|NCT01759004|obesity
241446|NCT01758978|bioequivalence, hydrocodone bitartrate extended-release tablets
241447|NCT01758952|Peri-operative stroke
241448|NCT01758952|incidence
241449|NCT01758952|risk factors
241450|NCT01758952|prospective
241451|NCT01758939|Peg Interferon,
241452|NCT01758939|Ribavirin,
241453|NCT01758939|HCV,
241454|NCT01758939|Genotype IV.
241455|NCT01758926|Inflammatory Bowel Disease
241456|NCT01758926|Confocal Laser Endomicroscopy
241457|NCT01758913|Bronchopulmonary dysplasia
241458|NCT01758913|patent ductus arteriosus
241459|NCT01758913|prostaglandin
241460|NCT01758913|Respiratory distress syndrome
241461|NCT01758900|Single-Balloon Enteroscopy
241462|NCT01758874|Critical limb ischemia
241463|NCT01758874|Phlebotomy
241464|NCT01758874|Amputation
241465|NCT01758874|Rutherford classification Grade 3, Category 5 or 6
241466|NCT01758874|Fontaine stage IV
241467|NCT01758861|Erythropoietin
241468|NCT01758861|acute kidney injury
241469|NCT01758861|valvular heart surgery
241470|NCT01758848|overactive bladder
241471|NCT01758848|pelvic floor muscles
241472|NCT01758848|deep abdominal muscles
241473|NCT01758835|ER-stress-test negative
241474|NCT01758835|unimalleolar
241475|NCT01758835|fibula
241476|NCT01758835|Weber-B fractures
241477|NCT01758822|meconium stained amniotic fluid
241478|NCT01758822|endotracheal suction
241479|NCT01758822|non vigorous neonates
241480|NCT01758809|Video Assisted Thoracic Surgery
241481|NCT01758809|Postoperative Pain
241482|NCT01758809|Intravenous Patient Controlled Analgesia
241483|NCT01758809|Bupivacaine
241484|NCT01758809|Major Pulmonary Resection
241485|NCT01758809|Post Pulmonary Resection
241486|NCT01758796|ER-stress positive
241487|NCT01758796|Unimalleolar fibula fracture
241488|NCT01758796|Operative vs non-operative treatment
241489|NCT01758770|osteoporosis
241490|NCT01758770|osteoarthritis
241491|NCT01758770|bone mineral density
241492|NCT01758770|computed xray tomography
241493|NCT01758770|liver steatosis
241494|NCT01758770|obesity
241495|NCT01758757|Proliferative diabetic retinopathy
241496|NCT01758757|Vitrectomy
241497|NCT01758744|COPD PH
241498|NCT01758744|COPD associated Pulmonary Hypertension
241499|NCT01758744|COPD and Pulmonary Hypertension
241500|NCT01758744|Disease
241501|NCT01758731|Stage IVA-B Squamous Cell Carcinomas
241502|NCT01758731|Head and Neck Cancer
241503|NCT01758731|Heavy drinking
241504|NCT01758731|Smoking
241505|NCT01758718|Down's syndrome
241506|NCT01758718|entropion
241507|NCT01758718|lid plasty
241508|NCT01758705|Psoriasis
241509|NCT01758705|Related to Health Quality of Life
241510|NCT01758705|Patient Reported Outcomes
241511|NCT01758705|Venezuelan Patients
241512|NCT01758692|spinal cord injury
241513|NCT01758692|autonomic integrity
241514|NCT01758692|autonomic dysreflexia
241515|NCT01758692|baroreceptor integrity
241516|NCT01758692|sympathetic integrity
241517|NCT01758692|vagal integrity
241518|NCT01758679|Iodine[131I] Metuximab Injection
241519|NCT01758653|CO poisoning
241520|NCT01758640|mechanical heart valve
241521|NCT01758640|pregnancy
241522|NCT01758640|warfarin
241523|NCT01758640|phenindione
241524|NCT01758627|Peritoneal dialysis,
241525|NCT01758627|chronic kidney disease,
241526|NCT01758627|refractory heart failure
241527|NCT01758614|carotid artery occlusion
241528|NCT01758614|middle cerebral artery occlusion
241529|NCT01758614|EC-IC bypass surgery
241530|NCT01758614|stroke
241531|NCT01758601|white fish
241532|NCT01758601|Metabolic syndrome
241533|NCT01758601|Cardiovascular risk
241534|NCT01758588|Primary myelofibrosis
241535|NCT01758588|PMF
241536|NCT01758575|Patients
241537|NCT01758549|pancreatitis
241538|NCT01758549|cholangiopancreatography, endoscopic retrograde
241539|NCT01758549|hyperamylasemia
241540|NCT01758536|ischemic stroke
241541|NCT01758536|neural function
241542|NCT01758536|life quality
241543|NCT01758523|neuroactive steroids
241544|NCT01758510|Amyotrophic Lateral Sclerosis
241545|NCT01758510|ALS
241546|NCT01758510|Neurodegenerative disease
241547|NCT01758510|Motor Neuron Disease
241548|NCT01758510|Central Nervous System Disease
241549|NCT01758510|Neuromuscular Disease
241550|NCT01758510|Bone marrow derived stem cell
241551|NCT01758510|stem cell therapy
241552|NCT01758510|intrathecal injection
241553|NCT01758497|Fascia Iliaca compartment block, Pain, Sensorial blockade
241554|NCT01758484|Hematopoietic cell transplantation
241555|NCT01758484|Supportive/palliative care
241556|NCT01758471|Type 2 Diabetes
241557|NCT01758471|gut microbiome
241558|NCT01758471|incretin
241559|NCT01758471|Sulfonylurea
241560|NCT01758471|α-glucosidase inhibitor
241561|NCT01758445|Breast
241562|NCT01758445|Cancer
241563|NCT01758445|Radiation
241564|NCT01758445|Proton
241565|NCT01758432|Healthy volunteers
241566|NCT01758419|post-RT
241567|NCT01758419|myocardial perfusion images
241568|NCT01758406|Cardiac stem ce heart failure cardiac function intracoronary transplantation
241569|NCT01758393|IgG4-related disease
241570|NCT01758393|IgG4-RD
241571|NCT01758380|Type 2 Diabetes Mellitus
241572|NCT01758380|Ramadan
241573|NCT01758380|Vildagliptin
241574|NCT01758380|Hypoglycemia
241575|NCT01758367|demethylating agent
241576|NCT01758367|immunogenicity
241577|NCT01758367|decitabine(DAC)
241578|NCT01758367|donor lymphocyte infusion(DLI)
241579|NCT01758367|AML
241580|NCT01758354|Pompe disease
241581|NCT01758354|alpha glucosidase deficiency
241582|NCT01758341|Malignant biliary obstruction
241583|NCT01758341|Endoscopic radiofrequency ablation
241584|NCT01758341|Therapeutic endoscopy
241585|NCT01758328|BUSULFAN
241586|NCT01758328|FLUDARABINE
241587|NCT01758328|G-CSF
241588|NCT01758328|MELPHALAN
241589|NCT01758328|RABBIT ATG WT1
241590|NCT01758328|PEPTIDE SPECIFIC T CELLS
241591|NCT01758328|12-175
241592|NCT01758315|Ambulatory
241593|NCT01758315|Outpatient
241594|NCT01758315|Malpractice
241595|NCT01758315|Quality Improvement
241596|NCT01758315|Patient Safety
241597|NCT01758302|taste test
241598|NCT01758302|food consumption
241599|NCT01758302|hunger
241600|NCT01758289|Venezuelan Patients
241601|NCT01758289|Depressive Symptoms
241602|NCT01758289|Health Related Quality of Life
241603|NCT01758276|smoking, pregnancy
241604|NCT01758263|Hypertension
241605|NCT01758263|Health Care Cost
241606|NCT01758263|Monthly health care cost
241607|NCT01758250|Autoimmune diseases with cutaneous involvement
241608|NCT01758250|Systemic sclerosis
241609|NCT01758250|Scleroderma
241610|NCT01758250|Morphea
241611|NCT01758250|Dermatomyositis
241612|NCT01758250|Cutaneous lupus
241613|NCT01758250|Vasculitis
241614|NCT01758250|Sickle Cell Disease
241615|NCT01758250|Graft versus Host Disease
241616|NCT01758237|Laser Peripheral Iridotomy
241617|NCT01758237|Visual Dysphotopsia
241618|NCT01758237|Visual Disturbances
241619|NCT01758237|Angle Closure Glaucoma
241620|NCT01758224|Multiple Sclerosis
241621|NCT01758224|Functional Magnetic Stimulation
241622|NCT01758224|Pulmonary Function
241623|NCT01758211|Intracranial Arteriovenous Malformations
241624|NCT01758211|Functional Magnetic Resonance Imaging
241625|NCT01758211|Neuronavigation
241626|NCT01758185|Inactivated split influenza vaccine
241627|NCT01758185|Immunogenicity
241628|NCT01758185|Safety
241629|NCT01758185|Consistence
241630|NCT01758172|pancreaticoduodenectomy
241631|NCT01758172|postoperative patient
241632|NCT01758172|colloid
241633|NCT01758172|albumin
241634|NCT01758172|hetastarch
241635|NCT01758146|Breast cancer
241636|NCT01758146|obesity
241637|NCT01758146|aromatase inhibitors
241638|NCT01758146|postmenopausal
241639|NCT01758120|IgA nephropathy
241640|NCT01758120|Cyclophosphamide
241641|NCT01758120|prednisone
241642|NCT01758094|hypogonadism
241643|NCT01758094|Retinol binding globulin 4
241644|NCT01758094|Testosterone treatment
241645|NCT01758068|Preterms
241646|NCT01758068|Coconut Oil application
241647|NCT01758068|Trans epidermal water loss
241648|NCT01758068|Weight gain
241649|NCT01758055|Mesenchymal stem cell, emphysema, lung function
241650|NCT01758042|Kidney
241651|NCT01758042|Chronic Kidney Disease
241652|NCT01758042|CKD
241653|NCT01758042|Bone Marrow
241654|NCT01758042|Bone Marrow Transplant
241655|NCT01758042|BMT
241656|NCT01758042|Leukemia
241657|NCT01758042|AML
241658|NCT01758042|ALL
241659|NCT01758042|CML
241660|NCT01758042|CLL
241661|NCT01758042|MM
241662|NCT01758042|NHL
241663|NCT01758042|MDS
241664|NCT01758029|quality of life
241665|NCT01758029|Testosterone Undecanoate
241666|NCT01758029|partner
241667|NCT01758029|questionnaire
241668|NCT01758003|Physical Activity
241669|NCT01758003|Sedentary Behaviour
241670|NCT01758003|Healthy Volunteer
241671|NCT01758003|Quality of Life
241672|NCT01758003|Exercise Capacity
241673|NCT01758003|Transtheoretical Model
241674|NCT01757990|dental caries
241675|NCT01757990|Stevioside
241676|NCT01757990|Rebaudioside
241677|NCT01757990|plaque pH
241678|NCT01757990|Streptococcus mutans
241679|NCT01757977|Vivasight DL
241680|NCT01757977|double lumen endotracheal tube
241681|NCT01757977|fiberoptic confirmation of tube position
241682|NCT01757964|Crohns Disease
241683|NCT01757964|Ulcerative Colitis
241684|NCT01757964|Inflammatory Bowel Disease
241685|NCT01757964|IBD
241686|NCT01757951|Ankle
241687|NCT01757951|Fracture
241688|NCT01757951|medial malleolus
241689|NCT01757951|Osteosynthesis
241690|NCT01757938|HIV
241691|NCT01757938|Prevention
241692|NCT01757938|Adult Male Circumcision
241693|NCT01757938|Uganda
241694|NCT01757938|Shang Ring
241695|NCT01757925|activity
241696|NCT01757925|gaming
241697|NCT01757925|obesity
241698|NCT01757925|Active Gaming
241699|NCT01757925|Control
241700|NCT01757912|mechanical ventilation
241701|NCT01757899|ALI
241702|NCT01757899|Acute Lung Injury
241703|NCT01757899|ARDS
241704|NCT01757899|Acute Respiratory Distress Syndrome
241705|NCT01757899|Pediatric Critical Care Medicine
241706|NCT01757899|Inflammatory Response
241707|NCT01757886|Myocardial infarction, Inflammation, Thrombus, Coronary angioplasty.
241708|NCT01757847|Binge-Eating Disorder
241709|NCT01757847|Obesity
241710|NCT01757847|emotional eating
241711|NCT01757834|Thyroid Nodule
241712|NCT01757834|Thyroid Neoplasm
241713|NCT01757834|Differential Diagnosis
241714|NCT01757834|Elastography
241715|NCT01757834|Elasticity Imaging Technique
241716|NCT01757834|Sonoelastography
241717|NCT01757821|Stroke
241718|NCT01757821|rTMS
241719|NCT01757821|TMS
241720|NCT01757808|PAH
241721|NCT01757808|Ranolazine
241722|NCT01757808|right ventricle
241723|NCT01757808|Safety
241724|NCT01757808|cardiopulmonary exercise testing
241725|NCT01757795|acute ischemic stroke
241726|NCT01757795|ischemic stroke
241727|NCT01757795|stroke
241728|NCT01757769|Lower urinary tract symptoms
241729|NCT01757769|benign prostatic hyperplasia
241730|NCT01757743|Heart Septal Defects, Atrial
241731|NCT01757743|Oedema formation
241732|NCT01757717|radiation therapy
241733|NCT01757717|HDR brachytherapy
241734|NCT01757717|Ir-192 high dose rate
241735|NCT01757717|12-260
241736|NCT01757704|Cardiac de-airing
241737|NCT01757704|Air emboli
241738|NCT01757704|Trans-cranial Echo-Doppler
241739|NCT01757704|Intraoperative Trans-esophageal Echocardiography
241740|NCT01757691|Acute demyelinating optic neuritis
241741|NCT01757691|Optic neuritis
241742|NCT01757665|Aortic valve replacement
241743|NCT01757665|Mitral valve replacement
241744|NCT01757626|Bone Marrow
241745|NCT01757626|Hu3F8
241746|NCT01757626|GM-CSF
241747|NCT01757626|12-230
241748|NCT01757587|Type 2 Diabetes
241749|NCT01757587|Galvus
241750|NCT01757587|basal insulin
241751|NCT01757587|HbA1c
241752|NCT01757574|CIDP- chronic inflammatory demyelinating neuropathy
241753|NCT01757574|demyelinating neuropathy
241754|NCT01757574|alemtuzumab
241755|NCT01757561|jugular bulb oxygen saturation
241756|NCT01757561|postoperative cognitive dysfunction
241757|NCT01757561|propofol
241758|NCT01757561|sevoflurane
241759|NCT01757548|varicocele; male infertile;varicocelectomy
241760|NCT01757535|Maintenance therapy
241761|NCT01757535|AML
241762|NCT01757535|Acute Myeloid Leukemia
241763|NCT01757535|oral Azacitidine
241764|NCT01757535|best supportive care
241765|NCT01757535|complete remission
241766|NCT01757509|Parkinson's disease
241767|NCT01757509|Set dancing
241768|NCT01757496|Bronchiolitis
241769|NCT01757496|Respiratory Syncytial Virus
241770|NCT01757496|Cough Assist
241771|NCT01757496|Physiotherapy
241772|NCT01757470|effectiveness of risk mitigation,
241773|NCT01757470|knowledge and understanding survey,
241774|NCT01757470|drug utilisation study,
241775|NCT01757470|post marketing commitments
241776|NCT01757457|inflammation
241777|NCT01757457|thrombosis
241778|NCT01757457|platelets
241779|NCT01757457|adhesion molecules
241780|NCT01757457|endothelium
241781|NCT01757418|Sickle Cell Disease
241782|NCT01757418|Pain
241783|NCT01757418|Immune Globulin
241784|NCT01757405|with Factor VIII (FVIII) or Factor IX (FIX) inhibitors
241785|NCT01757392|Treatment
241786|NCT01757392|common wart lesions
241787|NCT01757392|(verruca vulgaris)
241788|NCT01757379|Short chain fatty acids
241789|NCT01757379|Acetate
241790|NCT01757379|Propionate
241791|NCT01757379|Butyrate
241792|NCT01757379|Bioavailability
241793|NCT01757314|arterial lines
241794|NCT01757301|Pain
241795|NCT01757301|Depression
241796|NCT01757301|Anxiety
241797|NCT01757301|Musculoskeletal
241798|NCT01757301|Fibromyalgia
241799|NCT01757288|STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
241800|NCT01757275|peptic ulcer bleeding
241801|NCT01757275|prevention of rebleeding
241802|NCT01757275|successful endoscopic haemostatic therapy
241803|NCT01757262|Coronary Heart Disease
241804|NCT01757236|Antibiotic
241805|NCT01757236|linezolid
241806|NCT01757236|linezolid/rifampin
241807|NCT01757223|Diffuse Coronary Artery Disease (CAD)
241808|NCT01757210|Aprepitant
241809|NCT01757210|Pediatrics
241810|NCT01757210|Chemotherapy-induced nausea/vomiting
241811|NCT01757210|Survey
241812|NCT01757184|Enzyme Replacement Therapy (ERT)
241813|NCT01757184|Lysosomal Storage Disease
241814|NCT01757184|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
241815|NCT01757184|Acid cholesteryl ester hydrolase deficiency, type 2
241816|NCT01757184|Acid lipase disease
241817|NCT01757184|Cholesterol ester hydrolase deficiency
241818|NCT01757184|LAL Deficiency
241819|NCT01757184|LIPA Deficiency
241820|NCT01757184|Wolman disease
241821|NCT01757171|Gastric Cancer
241822|NCT01757158|lung cancer
241823|NCT01757158|lobectomy
241824|NCT01757158|local recurrence
241825|NCT01757145|Cord blood transplantation
241826|NCT01757145|Eltrombopag
241827|NCT01757145|Platelet engraftment
241828|NCT01757106|xenon anesthesia
241829|NCT01757106|sevoflurane anesthesia
241830|NCT01757106|off-pump coronary artery bypass graft surgery
241831|NCT01757093|INDIRECT CALORIMETRY
241832|NCT01757093|MECHANICAL VENTILATION
241833|NCT01757093|WEANING VENTILATOR
241834|NCT01757093|AUTOMATIC TUBE COMPENSATION
241835|NCT01757067|ablations
241836|NCT01757067|CHF
241837|NCT01757067|PVC
241838|NCT01757054|probiotic
241839|NCT01757054|LGG
241840|NCT01757054|BB-12
241841|NCT01757054|fecal recovery
241842|NCT01757054|healthy subjects
241843|NCT01757041|Streptococcus agalactiae
241844|NCT01757041|Maternal
241845|NCT01757041|Newborn
241846|NCT01757041|Africa
241847|NCT01757028|Maternal and newborn health
241848|NCT01757028|Africa
241849|NCT01757015|COPD
241850|NCT01757015|Chronic Obstructive Pulmonary Disease
241851|NCT01757015|Moderate to severe airflow limitation
241852|NCT01757015|GOLD spirometric classification 2 and 3
241853|NCT01757015|GOLD group B and D
241854|NCT01757015|NVA237
241855|NCT01757015|Salmeterol fluticasone propionate
241856|NCT01757002|Urban adolescents
241857|NCT01757002|Acute asthma
241858|NCT01757002|Asthma
241859|NCT01757002|Computer tailoring
241860|NCT01757002|Web-based intervention
241861|NCT01757002|Puff City
241862|NCT01756950|Influenza
241863|NCT01756950|Virus
241864|NCT01756950|Monoclonal
241865|NCT01756950|Antibody
241866|NCT01756950|Immunization
241867|NCT01756950|Treatment
241868|NCT01756937|osteoarthritis of the knee
241869|NCT01756924|prosthetic joint infection
241870|NCT01756924|hip arthroplasty
241871|NCT01756924|MRSA
241872|NCT01756924|knee arthroplasty
241873|NCT01756911|MFM
241874|NCT01756911|Multilayer Flow Modulator
241875|NCT01756911|Multilayer stent
241876|NCT01756911|Thoracoabdominal Aortic Aneurysm
241877|NCT01756898|Atopic Dermatitis
241878|NCT01756898|eczema
241879|NCT01756885|Smoking cessation
241880|NCT01756885|Nicotine dependence
241881|NCT01756885|Varenicline
241882|NCT01756885|Chantix
241883|NCT01756885|Cancer
241884|NCT01756872|infertility
241885|NCT01756872|Assisted reproductive technology
241886|NCT01756872|ovarian reserve
241887|NCT01756859|Portal hypertension
241888|NCT01756859|HVPG
241889|NCT01756859|MRI
241890|NCT01756846|HEART score
241891|NCT01756846|risk score
241892|NCT01756846|impact
241893|NCT01756846|chest pain
241894|NCT01756833|abdominal
241895|NCT01756833|aortic
241896|NCT01756833|aneurysm
241897|NCT01756820|Carpal Tunnel Syndrome
241898|NCT01756820|transverse ligament
241899|NCT01756820|carpal tunnel release
241900|NCT01756820|endoscopic
241901|NCT01756820|minimal invasive
241902|NCT01756820|mini-open
241903|NCT01756820|median nerve
241904|NCT01756807|Optical Coherence Tomography
241905|NCT01756807|Geneous Stent
241906|NCT01756807|Combo Stent
241907|NCT01756794|Alcoholic hepatitis
241908|NCT01756794|Liver transplantation
241909|NCT01756794|Alcohol relapse
241910|NCT01756794|Alcoholic cirrhosis
241911|NCT01756781|PD-0332991
241912|NCT01756781|Midazolam
241913|NCT01756781|Drug-Drug Interaction Study
241914|NCT01756781|Healthy Adult Volunteer
241915|NCT01756768|Phase 1
241916|NCT01756768|Mass Balance study
241917|NCT01756768|Radio-labeled dose
241918|NCT01756768|PD-0332991
241919|NCT01756755|Sepsis
241920|NCT01756742|Pleural Effusion
241921|NCT01756742|Respiratory physiotherapy
241922|NCT01756742|Length of stay
241923|NCT01756729|Brain tumor
241924|NCT01756729|Treatment
241925|NCT01756729|Minimal toxicity
241926|NCT01756729|GBM
241927|NCT01756729|Glioblastoma
241928|NCT01756729|Recurrent
241929|NCT01756729|TTFields
241930|NCT01756716|Diabetic Nephropathy
241931|NCT01756703|Diabetic Nephropathy
241932|NCT01756690|respiratory distress syndrome, adult
241933|NCT01756690|blood component transfusion
241934|NCT01756690|gastrointestinal hemorrhage
241935|NCT01756690|blood coagulation
241936|NCT01756651|Intranasal fentanyl
241937|NCT01756651|Cystoscopy
241938|NCT01756638|Prostate cancer
241939|NCT01756638|Abiraterone acetate
241940|NCT01756638|JNJ-212082
241941|NCT01756625|cetuximab
241942|NCT01756625|nicotine
241943|NCT01756625|magnesium
241944|NCT01756586|popliteal block
241945|NCT01756586|analgesia duration
241946|NCT01756573|block duration
241947|NCT01756573|analgesia
241948|NCT01756560|anterior cruciate ligament
241949|NCT01756560|block duration
241950|NCT01756547|Nephrocalcinosis
241951|NCT01756547|Extreme premature
241952|NCT01756521|QT,
241953|NCT01756521|QTc,
241954|NCT01756521|electrocardiogram,
241955|NCT01756521|moxifloxacin
241956|NCT01756508|eculizumab
241957|NCT01756508|kidney transplantation
241958|NCT01756508|reperfusion
241959|NCT01756508|rejection
241960|NCT01756508|infection
241961|NCT01756495|QTc,
241962|NCT01756495|GW856553 .
241963|NCT01756495|P38,
241964|NCT01756482|Respiratory
241965|NCT01756482|Syncytial
241966|NCT01756482|Virus
241967|NCT01756482|Infections
241968|NCT01756482|RSV
241969|NCT01756456|Keratitis
241970|NCT01756456|Corneal Ulcer
241971|NCT01756443|sciatic nerve block
241972|NCT01756443|ORIF lateral malleolus
241973|NCT01756443|sequential injection
241974|NCT01756443|premixed injection
241975|NCT01756443|local anaesthetics
241976|NCT01756430|Carvedilol SR
241977|NCT01756430|Carvedilol IR
241978|NCT01756430|Hypertension
241979|NCT01756430|Essential Hypertension
241980|NCT01756417|Healthy
241981|NCT01756417|Canagliflozin (JNJ-28431754)
241982|NCT01756417|Metformin
241983|NCT01756417|Pharmacokinetics
241984|NCT01756417|Pharmacodynamics
241985|NCT01756404|Healthy
241986|NCT01756404|Canagliflozin (JNJ-28431754)
241987|NCT01756404|Pharmacokinetics
241988|NCT01756404|Pharmacodynamics
241989|NCT01756404|Obesity
241990|NCT01756391|pediatric
241991|NCT01756391|childhood
241992|NCT01756391|allergy
241993|NCT01756378|Mobilization with movement,knee osteoarthritis,
241994|NCT01756352|FET
241995|NCT01756352|Fluoroethyl tyrosine
241996|NCT01756352|GBM
241997|NCT01756352|Response to treatment
241998|NCT01756352|Avastin
241999|NCT01756352|Brain Tumor
242000|NCT01756339|Pneumonia
242001|NCT01756339|CABP
242002|NCT01756339|CAP
242003|NCT01756339|Macrolide
242004|NCT01756326|Non-Union Fractures
242005|NCT01756326|Impaired Healing
242006|NCT01756326|Fractures
242007|NCT01756326|Orthopedics
242008|NCT01756326|Bone
242009|NCT01756326|Musculoskeletal Disorders
242010|NCT01756300|Essential Hypertension
242011|NCT01756300|Renal Denervation
242012|NCT01756300|Vascular Disease
242013|NCT01756300|Renal Catheter Ablation
242014|NCT01756300|Primary Hypertension
242015|NCT01756261|EYLEA
242016|NCT01756261|Age-Related Macular Degeneration
242017|NCT01756261|QOL
242018|NCT01756248|EYLEA
242019|NCT01756248|Age-Related Macular Degeneration
242020|NCT01756235|Post-marketing observational study (PMOS) Protocol
242021|NCT01756235|Rheumatoid Arthritis
242022|NCT01756235|Physical Activity
242023|NCT01756222|Bicuspid Aortic Valve Disease
242024|NCT01756222|Bicuspid Aortic Valve
242025|NCT01756222|BAV
242026|NCT01756196|Spinal injection; Steroid; Systemic reaction; Complication; Side effect; Diabetes mellitus; Hypertension; Risk factor
242027|NCT01756170|cervical cancer
242028|NCT01756170|radiotherapy
242029|NCT01756170|postoperative therapy
242030|NCT01756170|chemotherapy
242031|NCT01756157|Crossover
242032|NCT01756157|Prevention
242033|NCT01756157|Hereditary Angioedema
242034|NCT01756157|C1 esterase inhibitor
242035|NCT01756157|C1 inhibitor
242036|NCT01756157|Subcutaneous
242037|NCT01756157|Recombinant human hyaluronidase
242038|NCT01756092|Breast Cancer
242039|NCT01756092|Lumpectomy
242040|NCT01756092|Mastectomy, Segmental
242041|NCT01756066|Obesity
242042|NCT01756066|Weight loss program
242043|NCT01756066|incentives
242044|NCT01756053|Smoking
242045|NCT01756053|Tobacco
242046|NCT01756040|intestinal permeability
242047|NCT01756040|preterm infants
242048|NCT01756040|dual sugar test
242049|NCT01756027|Rosacea
242050|NCT01756027|Ulthera System
242051|NCT01756027|Ultherapy™ Treatment
242052|NCT01756027|Ulthera, Inc.
242053|NCT01756027|Ultrasound treatment for the skin
242054|NCT01755988|Telemedicine
242055|NCT01755988|Heart Failure
242056|NCT01755988|Self care
242057|NCT01755988|Quality of life
242058|NCT01755988|Mortality
242059|NCT01755988|Hospitalization
242060|NCT01755975|LENALIDOMIDE (CC-5013)
242061|NCT01755975|Romidepsin (Istodax)
242062|NCT01755975|12-170
242063|NCT01755962|diet
242064|NCT01755962|obese
242065|NCT01755962|overweight
242066|NCT01755962|exercise
242067|NCT01755962|resistance training
242068|NCT01755962|nutrition
242069|NCT01755962|glycemic load
242070|NCT01755962|body composition
242071|NCT01755962|weight training
242072|NCT01755962|lifestyle
242073|NCT01755949|atrial fibrillation
242074|NCT01755949|catheter ablation
242075|NCT01755949|colchicine
242076|NCT01755949|c reactive protein
242077|NCT01755949|CRP
242078|NCT01755936|Aortic Stenosis
242079|NCT01755936|Cardiac magnetic resonance imaging
242080|NCT01755936|Late Gadolinium enhancement
242081|NCT01755936|T1 mapping techniques
242082|NCT01755936|Replacement fibrosis
242083|NCT01755936|Diffuse interstitial fibrosis
242084|NCT01755923|non-small cell lung cancer
242085|NCT01755923|wild-type EGFR
242086|NCT01755923|gefitinib
242087|NCT01755923|docetaxel
242088|NCT01755923|second-line therapy
242089|NCT01755910|Breast Surgery
242090|NCT01755910|Thoracic Paravertebral Block
242091|NCT01755910|HRV
242092|NCT01755910|Autonomic Nervous System
242093|NCT01755884|Wheat allergy
242094|NCT01755884|Immunotherapy
242095|NCT01755884|Desensitization
242096|NCT01755884|Food allergy
242097|NCT01755884|T cells
242098|NCT01755858|elamipretide
242099|NCT01755845|cervical cancer
242100|NCT01755845|radiotherapy
242101|NCT01755845|postoperative therapy
242102|NCT01755845|chemotherapy
242103|NCT01755832|inflammatory rheumatic joint disease
242104|NCT01755832|text message
242105|NCT01755832|> 18 years
242106|NCT01755832|Norwegian speaking
242107|NCT01755806|Aortic annulus
242108|NCT01755806|Aortic calcification
242109|NCT01755806|Multislice computed tomography
242110|NCT01755806|Cardiac cycle
242111|NCT01755767|MET diagnostic-high
242112|NCT01755767|Unresectable
242113|NCT01755767|Hepatocellular
242114|NCT01755767|Carcinoma
242115|NCT01755767|c-Met inhibitor
242116|NCT01755728|Paracetamol
242117|NCT01755728|Acetaminophen
242118|NCT01755728|PDA
242119|NCT01755728|Preterm infants
242120|NCT01755715|Abortion
242121|NCT01755715|Contraception
242122|NCT01755715|Intrauterine Devices
242123|NCT01755715|Intrauterine Device Expulsion
242124|NCT01755702|caffeine
242125|NCT01755702|paracetamol
242126|NCT01755702|tension headache
242127|NCT01755689|pertussis
242128|NCT01755689|Meningococcal meningitis
242129|NCT01755689|Meningococcal infections
242130|NCT01755689|HPV
242131|NCT01755689|Neisseria meningitidis
242132|NCT01755689|Vaccines, conjugate
242133|NCT01755689|tetanus
242134|NCT01755689|diphtheria
242135|NCT01755689|Meningococcal vaccines
242136|NCT01755689|Immunogenicity
242137|NCT01755663|CT coronary
242138|NCT01755663|Coronary arterial disease
242139|NCT01755663|ivabradine
242140|NCT01755663|metoprolol
242141|NCT01755650|18F FPM
242142|NCT01755650|PET/CT
242143|NCT01755650|microdosing
242144|NCT01755624|Non-Small Cell Lung Cancer
242145|NCT01755624|NSCLC
242146|NCT01755624|Brain metastases
242147|NCT01755624|Treatment
242148|NCT01755624|Minimal toxicity
242149|NCT01755624|TTFields
242150|NCT01755624|TTF
242151|NCT01755624|Tumor Treating Fields
242152|NCT01755624|NovoCure
242153|NCT01755611|Minocycline
242154|NCT01755611|Mexico
242155|NCT01755611|Acne
242156|NCT01755611|bioequivalence
242157|NCT01755598|Positive Interferon-γ release assay
242158|NCT01755598|Efficacy
242159|NCT01755598|Adults
242160|NCT01755598|Tuberculosis vaccine
242161|NCT01755598|Endemic region
242162|NCT01755585|Radiation therapy
242163|NCT01755585|5-fluorouracil
242164|NCT01755585|Cisplatin
242165|NCT01755585|Pharmacokinetics
242166|NCT01755585|Matrix Metalloproteinase
242167|NCT01755572|Type 2 Diabetes
242168|NCT01755572|Hypertension
242169|NCT01755572|Liraglutide
242170|NCT01755572|GLP-1
242171|NCT01755559|malaria
242172|NCT01755559|artemisinin
242173|NCT01755559|artemisinin-based combination therapies
242174|NCT01755559|Plasmodium falciparum
242175|NCT01755559|efficacy
242176|NCT01755546|Chronic Pain
242177|NCT01755546|CLBP
242178|NCT01755546|Chronic Low Back Pain
242179|NCT01755546|Back Pain
242180|NCT01755546|Osteoarthritis
242181|NCT01755546|OA
242182|NCT01755546|Neuropathic Pain
242183|NCT01755546|Nerve pain
242184|NCT01755546|Painful neuropathy
242185|NCT01755533|adolescent substance use
242186|NCT01755533|rural substance use
242187|NCT01755533|middle school prevention
242188|NCT01755533|implementation processes
242189|NCT01755533|implementation quality
242190|NCT01755533|adaptation of prevention curricula
242191|NCT01755533|dissemination
242192|NCT01755520|CABG
242193|NCT01755520|CAD
242194|NCT01755520|antiplatelet drug
242195|NCT01755520|Ticagrelor
242196|NCT01755520|Aspirin
242197|NCT01755507|PSC
242198|NCT01755494|Type 2 diabetes, Saxagliptin, Metformin,Fixed dose combination tablet, Bioequivalence, pharmacokinetic, safety, tolerability
242199|NCT01755468|beta-cell function, type 2 diabetes, intermittent insulin
242200|NCT01755455|Cystic fibrosis
242201|NCT01755455|Iron
242202|NCT01755455|Hepcidin
242203|NCT01755455|Anemia
242204|NCT01755455|Erythropoiesis
242205|NCT01755442|Ambulatory blood pressure
242206|NCT01755442|Type 2 diabetes
242207|NCT01755416|Type 1 diabetes
242208|NCT01755416|closed loop
242209|NCT01755416|artificial pancreas
242210|NCT01755416|insulin
242211|NCT01755416|victoza
242212|NCT01755416|liraglutide
242213|NCT01755338|cerebrospinal fluid
242214|NCT01755338|inflammatory markers
242215|NCT01755338|heart surgery
242216|NCT01755338|neuronal damage
242217|NCT01755338|blood brain barrier
242218|NCT01755299|Energy drinks
242219|NCT01755299|Wakefulness
242220|NCT01755299|Caffeine
242221|NCT01755273|Pancreaticoduodenectomy
242222|NCT01755273|Diabetes
242223|NCT01755260|POPF
242224|NCT01755260|pancreaticoduodenectomy
242225|NCT01755260|enteral nutrition
242226|NCT01755260|parenteral nutrition
242227|NCT01755247|acne
242228|NCT01755234|Outpatient
242229|NCT01755234|Surgery
242230|NCT01755234|Anesthesia
242231|NCT01755221|Laryngopharyngeal reflux (LPR)
242232|NCT01755221|Extraesophageal reflux
242233|NCT01755221|Reflux laryngitis
242234|NCT01755221|Posterior laryngitis
242235|NCT01755221|Proton pump inhibitor (PPI) medication
242236|NCT01755221|Restech pH probe
242237|NCT01755195|Dual Inhibitor of MET and VEGFR
242238|NCT01755195|XL184
242239|NCT01755195|Metastatic Refractory
242240|NCT01755195|Soft Tissue Sarcoma
242241|NCT01755195|Rare Heterogeneous Tumor
242242|NCT01755182|locoregional treatment
242243|NCT01755182|liver metastases
242244|NCT01755182|transarterial embolization
242245|NCT01755182|upfront treatment
242246|NCT01755182|inoperable
242247|NCT01755182|octreotide
242248|NCT01755182|gastroenteropancreatic (GEP)primary
242249|NCT01755182|pulmonary primary
242250|NCT01755182|primary unknown origin
242251|NCT01755182|systemic therapy
242252|NCT01755169|Chronic pain
242253|NCT01755169|Child
242254|NCT01755169|Pediatric
242255|NCT01755169|Ketamine
242256|NCT01755130|Breast Cancer
242257|NCT01755130|LOUIS-3D
242258|NCT01755130|Breast Study
242259|NCT01755130|x-ray
242260|NCT01755130|Multimode Laser Optoacoustic Ultrasonic Tomography System
242261|NCT01755130|Mass palpable or nonpalpable
242262|NCT01755130|Breast lesions
242263|NCT01755130|Ductal carcinomas
242264|NCT01755130|Lobular carcinomas
242265|NCT01755130|Fibroadenomas
242266|NCT01755078|Phosphate binder
242267|NCT01755065|laparoscopic surgery
242268|NCT01755065|teenager
242269|NCT01755052|Acute Myocardial Infarction
242270|NCT01755052|Geriatrics
242271|NCT01755052|Cardiology
242272|NCT01755052|Aging
242273|NCT01755052|Heart Attack
242274|NCT01755052|Risk Factors
242275|NCT01755052|Quality of Care
242276|NCT01755052|Risk Models
242277|NCT01755026|Cesarean Delivery
242278|NCT01755026|Wound infection
242279|NCT01755026|Obesity
242280|NCT01755026|Prophylactic antibiotics
242281|NCT01755013|Cholangiocarcinoma
242282|NCT01755013|Biliary Stricture
242283|NCT01755013|Biliary obstruction
242284|NCT01755013|Bile Duct Cancer
242285|NCT01755013|PDT
242286|NCT01755013|Photodynamic Therapy
242287|NCT01755013|Plastic optic Diffuser
242288|NCT01755013|Laser
242289|NCT01754987|Vitamins
242290|NCT01754987|Malignant Tumor, Tumour
242291|NCT01754987|Integrative Medicine
242292|NCT01754987|Complementary Medicine
242293|NCT01754987|Alternative Medicine Antioxidants
242294|NCT01754987|Molecular Mechanisms of Pharmacological Action
242295|NCT01754987|Pharmacologic Actions
242296|NCT01754987|Protective Agents
242297|NCT01754987|Physiological Effects of Drugs
242298|NCT01754987|Micronutrients
242299|NCT01754987|Growth Substances
242300|NCT01754987|Antineoplastic Agents, Phytogenic
242301|NCT01754987|Antineoplastic Agents
242302|NCT01754987|Therapeutic Uses
242303|NCT01754987|Radiation-Sensitizing Agents
242304|NCT01754987|Liver Cancer
242305|NCT01754948|asthma
242306|NCT01754948|reactive airway disease
242307|NCT01754948|cough
242308|NCT01754948|air pollution
242309|NCT01754948|nano particles
242310|NCT01754922|exercise tolerance
242311|NCT01754922|Veterans
242312|NCT01754922|operation enduring freedom
242313|NCT01754922|operation Iraqi freedom
242314|NCT01754909|lung cancer
242315|NCT01754909|radiation pneumonitis
242316|NCT01754909|mitigation
242317|NCT01754909|enalapril
242318|NCT01754909|placebo
242319|NCT01754896|colorectal cancer
242320|NCT01754896|fecal immunochemical test
242321|NCT01754896|fecal occult blood test
242322|NCT01754896|screening
242323|NCT01754883|Posttraumatic Stess Disorder
242324|NCT01754883|Lithium
242325|NCT01754870|CLL
242326|NCT01754870|SLL
242327|NCT01754857|Lymphoid Leukemia
242328|NCT01754857|Bendamustine
242329|NCT01754857|Rituximab
242330|NCT01754857|Small Lymphocytic Lymphoma
242331|NCT01754844|Phase 1
242332|NCT01754844|Healthy Volunteers
242333|NCT01754844|Single Ascending Dose (SAD)
242334|NCT01754844|First Time in Man
242335|NCT01754844|Pharmacokinetics
242336|NCT01754844|Pharmacodynamics
242337|NCT01754831|children
242338|NCT01754831|fluoride varnish
242339|NCT01754818|Pharmacokinetics
242340|NCT01754818|volunteers
242341|NCT01754805|ASP015K
242342|NCT01754805|Rheumatoid Arthritis
242343|NCT01754779|calcium phosphate
242344|NCT01754779|urolithiasis
242345|NCT01754779|kidney stones
242346|NCT01754779|hypercalciuria
242347|NCT01754753|Mental well-being
242348|NCT01754753|Befriending
242349|NCT01754740|Xerostomia, Salivary flow, Burning Mouth Syndrome.
242350|NCT01754727|Ankylosing Spondylitis
242351|NCT01754727|Effectiveness of adalimumab (Humira)
242352|NCT01754727|Post-marketing observational study (PMOS) Protocol
242353|NCT01754714|Steatohepatitis
242354|NCT01754662|Type 2 diabetes
242355|NCT01754662|Cardiovascular risk
242356|NCT01754662|Endothelial function
242357|NCT01754662|Insulin resistance
242358|NCT01754662|Soy
242359|NCT01754662|Isoflavones
242360|NCT01754662|Cocoa
242361|NCT01754662|Diet
242362|NCT01754649|intrauterine device
242363|NCT01754649|insertion failure
242364|NCT01754636|Colorectal neoplasms
242365|NCT01754636|Elderly
242366|NCT01754636|Randomized clinical trials
242367|NCT01754636|Inclusion.
242368|NCT01754623|Pancreas
242369|NCT01754623|Pancreatic
242370|NCT01754623|Neoplasms
242371|NCT01754623|Stereotactic
242372|NCT01754623|Radiosurgery
242373|NCT01754623|Borderline
242374|NCT01754623|Resectable
242375|NCT01754623|Gastrointestinal
242376|NCT01754623|Gemcitabine
242377|NCT01754623|Capecitabine
242378|NCT01754623|Fluorouracil
242379|NCT01754623|Docetaxel
242380|NCT01754623|SBRT
242381|NCT01754623|GTX Chemotherapy
242382|NCT01754610|family trauma
242383|NCT01754610|multi-family therapy
242384|NCT01754610|Posttraumatic Stress Disorder
242385|NCT01754610|poverty
242386|NCT01754597|Patients with breast cancer requiring surgical management with general anesthesia
242387|NCT01754584|hyaluronan including concentrations
242388|NCT01754584|molecular weight
242389|NCT01754584|mucociliary differentiation
242390|NCT01754584|human respiratory epithelial cells
242391|NCT01754571|medication overuse headache
242392|NCT01754545|Infusions, Intravenous
242393|NCT01754545|Plasma
242394|NCT01754545|ADAMTS-13 protein, human
242395|NCT01754532|Schizophrenia
242396|NCT01754532|Schizo-Affective Disorder
242397|NCT01754532|Stress
242398|NCT01754532|Cortisol
242399|NCT01754532|PANSS
242400|NCT01754506|leg ulcers
242401|NCT01754506|wounds
242402|NCT01754506|fish oil
242403|NCT01754506|lipid mediators
242404|NCT01754506|chronic venous stasis ulcers
242405|NCT01754493|Major Depression
242406|NCT01754493|Irritable Bowel Syndrome
242407|NCT01754493|Somatization
242408|NCT01754493|Cymbalta
242409|NCT01754493|Duloxetine
242410|NCT01754480|Fibrin Sealant
242411|NCT01754480|Parenchymous tissue open surgery
242412|NCT01754480|Hepatic Resection
242413|NCT01754480|Oxidized cellulose pads
242414|NCT01754441|Spinal Muscular Atrophy
242415|NCT01754441|SMA
242416|NCT01754441|Motor Neuron Abnormalities
242417|NCT01754428|Respiratory
242418|NCT01754428|Syncytial
242419|NCT01754428|Virus
242420|NCT01754428|RSV
242421|NCT01754415|Aging
242422|NCT01754415|Chronic illness
242423|NCT01754415|Resistance circuit training
242424|NCT01754402|Multiple Myeloma
242425|NCT01754376|Metastatic
242426|NCT01754376|Unresectable
242427|NCT01754376|V600E mutation
242428|NCT01754363|Osteoarthritis
242429|NCT01754350|ketogenic diet
242430|NCT01754350|glioma
242431|NCT01754350|fasting
242432|NCT01754350|reirradiation
242433|NCT01754350|nutrition
242434|NCT01754337|Type 1 diabetes
242435|NCT01754337|Hypoglycemia
242436|NCT01754337|Insulin
242437|NCT01754337|Glucagon
242438|NCT01754337|Closed-loop system
242439|NCT01754337|Artificial pancreas
242440|NCT01754324|Neonatal Abstinence Syndrome
242441|NCT01754324|Pharmacokinetics
242442|NCT01754324|Methadone
242443|NCT01754324|Neonate
242444|NCT01754324|Newborn
242445|NCT01754311|HTLV-I
242446|NCT01754298|osteochondritis dissecans (OCD)
242447|NCT01754298|juvenile osteochondritis dissecans (JOCD)
242448|NCT01754298|knee osteochondritis dissecans
242449|NCT01754298|retro-articular drilling
242450|NCT01754298|trans-articular drilling
242451|NCT01754298|stable osteochondritis dissecans lesion
242452|NCT01754272|metastatic colorectal cancer
242453|NCT01754272|mCRC
242454|NCT01754272|Aflibercept
242455|NCT01754272|FOLFIRI
242456|NCT01754272|translational research
242457|NCT01754272|retrospective
242458|NCT01754272|noninterventional
242459|NCT01754272|biomarkers
242460|NCT01754272|angiogenesis
242461|NCT01754259|type 1 diabetes
242462|NCT01754259|type 2 diabetes
242463|NCT01754259|exertion angina
242464|NCT01754259|suspected CAD
242465|NCT01754259|known CAD
242466|NCT01754194|Gastric Sleeve
242467|NCT01754194|Gastric Bypass
242468|NCT01754194|Roux en Y
242469|NCT01754194|Morbid Obesity
242470|NCT01754194|Laparoscopy
242471|NCT01754181|Glycemic control algorithm
242472|NCT01754181|closed loop
242473|NCT01754181|artificial pancreas
242474|NCT01754168|Parkinson disease
242475|NCT01754168|Cognition
242476|NCT01754155|Vitamin E
242477|NCT01754155|Zimmer
242478|NCT01754155|RSA
242479|NCT01754155|Radiostereometric Analysis
242480|NCT01754129|Caregiver
242481|NCT01754129|Quality of Life
242482|NCT01754129|Parkinson's Disease
242483|NCT01754116|healthy subjects
242484|NCT01754116|GSK1265744 LAP
242485|NCT01754116|integrase inhibitor
242486|NCT01754116|HIV-1 infection
242487|NCT01754116|long acting retroviral
242488|NCT01754116|relative bioavailability
242489|NCT01754103|blind
242490|NCT01754103|tactile stimulation
242491|NCT01754103|cross-modality
242492|NCT01754103|visual qualia
242493|NCT01754103|resting state MRI
242494|NCT01754103|functional connectivity
242495|NCT01754103|neuroplasticity
242496|NCT01754090|alcohol
242497|NCT01754090|online intervention
242498|NCT01754090|hazardous drinking
242499|NCT01754090|harmful drinking
242500|NCT01754090|early intervention
242501|NCT01754090|behavior change intervention
242502|NCT01754077|Language
242503|NCT01754077|Behavior change
242504|NCT01754077|Intervention
242505|NCT01754077|Home visiting
242506|NCT01754077|Child language development
242507|NCT01754064|Bradycardia
242508|NCT01754064|Tachycardia
242509|NCT01754064|Arrhythimas
242510|NCT01754064|ICD
242511|NCT01754064|pacemaker
242512|NCT01754064|pacing lead
242513|NCT01754038|Patient Reported Outcomes
242514|NCT01754038|PRO
242515|NCT01754038|Registry
242516|NCT01754025|Gene Mutation
242517|NCT01754012|Nutrition
242518|NCT01754012|Dietary intervention
242519|NCT01754012|Aging
242520|NCT01754012|Inflammation
242521|NCT01754012|Elderly
242522|NCT01754012|Europe
242523|NCT01753999|World Trade Center (WTC)
242524|NCT01753999|nasal symptoms
242525|NCT01753999|nasal inflammation
242526|NCT01753999|CPAP
242527|NCT01753973|Metabolic syndrome
242528|NCT01753973|Renal transplantation
242529|NCT01753895|Healthy Volunteers
242530|NCT01753882|Gait training
242531|NCT01753882|Lexapro
242532|NCT01753882|Tizanidine
242533|NCT01753843|Preterm Birth
242534|NCT01753830|Double-blind
242535|NCT01753830|Randomized
242536|NCT01753830|Intraarticular injection
242537|NCT01753830|Hyaluronic acid
242538|NCT01753830|Placebo
242539|NCT01753830|Knee osteoarthritis
242540|NCT01753817|Coronary catheterization
242541|NCT01753817|Transradial patency
242542|NCT01753804|DMD
242543|NCT01753804|Myopathy
242544|NCT01753804|Natural History
242545|NCT01753804|Muscular dystrophy
242546|NCT01753804|Biomarkers
242547|NCT01753804|Muscle testing
242548|NCT01753778|Nerve Entrapment, Morton's neuroma, entrapment neuropathy
242549|NCT01753765|occipital neuralgia
242550|NCT01753726|stretching, diaphragm, spinal movement, thoracic movement
242551|NCT01753700|crossover
242552|NCT01753700|UHT milk
242553|NCT01753700|Pasteurised milk
242554|NCT01753700|supplement
242555|NCT01753687|break up time
242556|NCT01753687|tear film thickness
242557|NCT01753687|tear film osmolarity
242558|NCT01753687|objective scattering index
242559|NCT01753687|impression cytology
242560|NCT01753687|tear cytokines/chemokines
242561|NCT01753687|visual acuity
242562|NCT01753687|fluorescein staining
242563|NCT01753674|metabolic syndrome, insulin resistance, HDL cholesterol,
242564|NCT01753661|Hearing loss
242565|NCT01753661|Language
242566|NCT01753661|Behavior change
242567|NCT01753661|Early Intervention
242568|NCT01753661|Home visiting
242569|NCT01753648|retinal blood flow
242570|NCT01753648|retinal blood velocity
242571|NCT01753648|retinal oxygen saturation
242572|NCT01753648|retinal vessel diameter
242573|NCT01753648|ocular perfusion pressure
242574|NCT01753635|Baska mask
242575|NCT01753635|LMA
242576|NCT01753635|single use LMA device
242577|NCT01753635|laryngeal mask airway
242578|NCT01753635|supraglottic airway device
242579|NCT01753622|Overweight, obese, pregnant, depression, outcomes
242580|NCT01753609|Over weight
242581|NCT01753609|Obesity
242582|NCT01753596|topical lubricants
242583|NCT01753596|tear film thickness
242584|NCT01753596|break up time
242585|NCT01753596|ocular surface disease index
242586|NCT01753596|Schirmer I test
242587|NCT01753583|optical coherence tomography
242588|NCT01753583|corneal abrasion
242589|NCT01753583|corneal infiltrate
242590|NCT01753570|Feron
242591|NCT01753557|Pegasys
242592|NCT01753531|Ultra Influenza A and B
242593|NCT01753531|Influenza Type A
242594|NCT01753531|Influenza Type B
242595|NCT01753531|Flu
242596|NCT01753531|Sekisui Diagnostics
242597|NCT01753518|Subcuticular suture
242598|NCT01753518|Subcuticular staple
242599|NCT01753518|Skin closure
242600|NCT01753518|Incision closure
242601|NCT01753518|Wound
242602|NCT01753505|multidetector coronary CT angiography, renal transplantation
242603|NCT01753492|Intraocular pressure
242604|NCT01753492|glaucoma
242605|NCT01753492|trabeculectomy
242606|NCT01753492|Ologen
242607|NCT01753479|Pancreatic adenocarcinoma
242608|NCT01753453|Hematopoietic stem cell transplantation
242609|NCT01753453|Tumour cell mobilization
242610|NCT01753440|coronary artery disease
242611|NCT01753440|heart failure
242612|NCT01753440|stem cells implantation
242613|NCT01753427|COPD,
242614|NCT01753427|symptoms,
242615|NCT01753427|Non-Interventional study,
242616|NCT01753414|Lung Cancer
242617|NCT01753401|SLE
242618|NCT01753401|Lupus
242619|NCT01753375|Multiple Sclerosis
242620|NCT01753375|Relapsing rate
242621|NCT01753375|Expanded disability status scale
242622|NCT01753375|Vitamin D3
242623|NCT01753323|acute malaria, KAF156
242624|NCT01753245|Anti-TNF drugs efficacy
242625|NCT01753245|Moderate-to-severe psoriasis vulgaris
242626|NCT01753245|Gene polymorphism
242627|NCT01753232|DALI adsorber
242628|NCT01753232|MONET lipoprotein filter
242629|NCT01753193|Systemic Lupus Erythematosus
242630|NCT01753180|CTO
242631|NCT01753180|PCI
242632|NCT01753180|Angioplasty
242633|NCT01753154|Peritoneal Dialysis
242634|NCT01753154|Biocompatible dialysis solution
242635|NCT01753154|Hydration status
242636|NCT01753154|Residual renal function
242637|NCT01753154|Body composition monitor
242638|NCT01753154|Bioimpedance spectroscopy
242639|NCT01753154|Cancer antigen 125
242640|NCT01753141|Cognitive Behavioral Therapy
242641|NCT01753141|Smoking Cessation
242642|NCT01753115|post-exposure prophylaxis
242643|NCT01753115|toxin neutralization assay
242644|NCT01753102|Estradiol
242645|NCT01753102|Vulvar atrophy
242646|NCT01753102|vaginal atrophy
242647|NCT01753089|Metastatic
242648|NCT01753076|efficacy
242649|NCT01753076|Amyotrophic lateral sclerosis
242650|NCT01753076|ozanezumab
242651|NCT01753076|safety
242652|NCT01753063|Obesity
242653|NCT01753063|Children
242654|NCT01753063|Adolescents
242655|NCT01753063|Attrition
242656|NCT01753037|Hyperandrogenism
242657|NCT01753037|Inflammation
242658|NCT01753037|Insulin sensitivity
242659|NCT01753037|Body composition
242660|NCT01753024|exocrine pancreatic insufficiency
242661|NCT01753024|fecal elastase-1
242662|NCT01753024|amylase
242663|NCT01753024|lipase
242664|NCT01753024|critical illness
242665|NCT01753024|enteral nutrition
242666|NCT01753024|malnutrition
242667|NCT01753024|sepsis
242668|NCT01753024|diabetes
242669|NCT01753024|hyperlactacidemia
242670|NCT01753024|hemodialysis
242671|NCT01753024|mechanical ventilation
242672|NCT01753011|Stress urinary Incontinence
242673|NCT01753011|Transobturator sling
242674|NCT01753011|TOT
242675|NCT01752998|pain
242676|NCT01752998|depression
242677|NCT01752998|substance use
242678|NCT01752972|Arsenic
242679|NCT01752972|Keratosis
242680|NCT01752972|Linoleic acid
242681|NCT01752972|Palm
242682|NCT01752972|Spirulina
242683|NCT01752972|Vitamin E
242684|NCT01752972|Zinc
242685|NCT01752920|FGFR
242686|NCT01752920|ARQ 087
242687|NCT01752920|Targeted therapy
242688|NCT01752920|Molecular therapy
242689|NCT01752920|Tyrosine kinase inhibitor
242690|NCT01752920|TKI
242691|NCT01752920|Receptor tyrosine kinase
242692|NCT01752920|RTK
242693|NCT01752920|Biomarker
242694|NCT01752920|Phase 1
242695|NCT01752920|Phase I
242696|NCT01752920|Solid tumor
242697|NCT01752920|Liver Cancer
242698|NCT01752920|Hepatobiliary carcinoma
242699|NCT01752920|Biliary tract cancer
242700|NCT01752920|Cholangiocarcinoma
242701|NCT01752920|Intrahepatic cholangiocarcinoma
242702|NCT01752920|FGFR inhibitor
242703|NCT01752920|Targeted FGFR kinase inhibitor
242704|NCT01752920|Pan-FGFR inhibitor
242705|NCT01752920|Selective FGFR inhibitor
242706|NCT01752920|FGFR pathway
242707|NCT01752920|FGFR signaling
242708|NCT01752920|Fibroblast growth factor
242709|NCT01752920|FGFR1
242710|NCT01752920|FGFR2
242711|NCT01752920|FGFR3
242712|NCT01752920|FGFR4
242713|NCT01752920|FGF
242714|NCT01752920|FGF19
242715|NCT01752920|FGF21
242716|NCT01752920|FGF23
242717|NCT01752920|FGFR mutation
242718|NCT01752920|FGFR gene fusion
242719|NCT01752920|FGFR gene translocation
242720|NCT01752920|FGFR genetic aberration
242721|NCT01752920|FGFR2 fusion
242722|NCT01752920|FGFR2 translocation
242723|NCT01752920|Phase 1 Clinical Trial
242724|NCT01752920|Phase I Clinical Trial
242725|NCT01752920|Clinical oncology
242726|NCT01752920|Tumor
242727|NCT01752920|Tumour
242728|NCT01752907|Breast cancer
242729|NCT01752907|Chemotherapy
242730|NCT01752907|Pegfilgrastim
242731|NCT01752907|Neulasta
242732|NCT01752907|Bone Pain
242733|NCT01752907|Education
242734|NCT01752881|Influenza
242735|NCT01752881|Vaccine
242736|NCT01752881|Immunogenicity
242737|NCT01752855|Rheumatoid Arthritis
242738|NCT01752842|Diabetes
242739|NCT01752842|Diabetic Cardiomyopathy
242740|NCT01752842|Triglycerides
242741|NCT01752829|Obesity
242742|NCT01752829|gastric
242743|NCT01752829|banding
242744|NCT01752829|Weight
242745|NCT01752829|co-morbidities
242746|NCT01752829|dilatation
242747|NCT01752829|Excess weight loss
242748|NCT01752829|adjustable gastric banding
242749|NCT01752816|endurance training,
242750|NCT01752816|strength training,
242751|NCT01752816|aerobic capacity,
242752|NCT01752816|muscle strenght
242753|NCT01752816|physical capacity
242754|NCT01752790|Pediatric Crohn's disease
242755|NCT01752790|Biologics
242756|NCT01752790|Immunomodulators
242757|NCT01752790|Top-down
242758|NCT01752790|step-up
242759|NCT01752777|HIV/AIDS, HIV infectiousness, Medication adherence, Sexual risks reduction
242760|NCT01752751|Neck cancer
242761|NCT01752751|Head cancer
242762|NCT01752751|Lung cancer
242763|NCT01752725|supracervical hysterectomy
242764|NCT01752725|vessel sealing
242765|NCT01752725|bipolar electrocoagulation
242766|NCT01752712|Oxytocin
242767|NCT01752712|Social function
242768|NCT01752712|CBSST
242769|NCT01752699|neuropathic pain,
242770|NCT01752699|post-herpetic neuralgia,
242771|NCT01752699|methadone,
242772|NCT01752686|Triple negative breast cancer
242773|NCT01752686|adjuvant chemotherapy
242774|NCT01752673|randomized controlled study
242775|NCT01752660|Exercise therapy
242776|NCT01752660|Aerobic training
242777|NCT01752660|Endurance training
242778|NCT01752647|lung cancer
242779|NCT01752647|screening
242780|NCT01752647|low dose
242781|NCT01752647|computed tomography
242782|NCT01752634|Psoriatic arthritis, PsA, ACR, CASPAR, PASDAS
242783|NCT01752621|Acromegaly
242784|NCT01752621|mortality
242785|NCT01752621|morbidity
242786|NCT01752621|incidence
242787|NCT01752621|prevalence
242788|NCT01752608|Depression
242789|NCT01752608|Real-time
242790|NCT01752608|iPhone
242791|NCT01752608|CBT
242792|NCT01752608|Cognitive behavioral therapy
242793|NCT01752582|BuMA
242794|NCT01752582|EXCEL
242795|NCT01752582|OCT
242796|NCT01752582|stent
242797|NCT01752582|neointima formation
242798|NCT01752569|HIV
242799|NCT01752569|Kaposi's sarcoma
242800|NCT01752569|Anti-retroviral therapy
242801|NCT01752569|HAART
242802|NCT01752569|AIDS
242803|NCT01752556|Sleep apnea, Portable monitor,autoCPAP
242804|NCT01752543|Vasopressin
242805|NCT01752543|Exercise capacity
242806|NCT01752543|Conivaptan
242807|NCT01752530|ADHD
242808|NCT01752517|small cell lung cancer
242809|NCT01752517|chemotherapy
242810|NCT01752517|vinorelbine
242811|NCT01752517|ifosfamide
242812|NCT01752517|third-line treatment
242813|NCT01752504|HIV prevention
242814|NCT01752504|HIV positive communities
242815|NCT01752491|Ascorbate
242816|NCT01752491|Ascorbic acid
242817|NCT01752491|Vitamin C
242818|NCT01752491|Radiation
242819|NCT01752491|Temozolomide
242820|NCT01752478|ptosis
242821|NCT01752478|retina surgery
242822|NCT01752478|droopy eye lid
242823|NCT01752465|Health behaviour
242824|NCT01752465|Antipsychotic agents
242825|NCT01752465|Adverse effects
242826|NCT01752465|Goals
242827|NCT01752465|Life style
242828|NCT01752439|Chronic Migraine
242829|NCT01752439|Medication Overuse Headache
242830|NCT01752439|Refractory
242831|NCT01752439|transcranial direct current stimulation
242832|NCT01752426|Leukemia
242833|NCT01752426|Chronic Lymphocytic Leukemia
242834|NCT01752426|CLL
242835|NCT01752426|Small Lymphocytic Lymphoma
242836|NCT01752426|SLL
242837|NCT01752426|PCI-32765
242838|NCT01752426|Ibrutinib
242839|NCT01752426|Btk inhibitor
242840|NCT01752426|Heavy water
242841|NCT01752426|2H2O
242842|NCT01752413|Iron depletion
242843|NCT01752413|blood donors
242844|NCT01752413|iron replacement
242845|NCT01752400|Advanced
242846|NCT01752361|Gastrointestinal Motility
242847|NCT01752361|Inflammatory Bowel Disease
242848|NCT01752361|Transit time
242849|NCT01752348|sepsis
242850|NCT01752348|cytokine release
242851|NCT01752348|fever
242852|NCT01752335|Rheumatoid Arthritis, tocilizumab, cardiovascular risk factors
242853|NCT01752309|Early Rheumatoid arthritis
242854|NCT01752309|Rheumatoid arthritis
242855|NCT01752309|Ultrasound
242856|NCT01752309|Predictive
242857|NCT01752309|Prognosis
242858|NCT01752296|Morquio
242859|NCT01752296|Mucopolysaccharidosis IV
242860|NCT01752296|Psychological health
242861|NCT01752283|Videoassited
242862|NCT01752283|Thyroidectomy
242863|NCT01752283|Minimal invasive surgery
242864|NCT01752283|General anesthesia
242865|NCT01752283|Hypnosis
242866|NCT01752257|Melanoma
242867|NCT01752244|Obesity, vitamin D analogue, VDR, PPARg, PGC1a
242868|NCT01752218|Femto-second Laser
242869|NCT01752218|arcuate incision
242870|NCT01752218|corneal astigmatism
242871|NCT01752218|astigmatic keratotomy
242872|NCT01752218|Cataract
242873|NCT01752205|Esophageal Squamous Carcinoma
242874|NCT01752205|Erlotinib
242875|NCT01752205|Chemoradiotherapy
242876|NCT01752192|Rehabilitation
242877|NCT01752192|Telemedicine
242878|NCT01752192|Heart patients
242879|NCT01752192|Social media
242880|NCT01752192|Organisational aspects
242881|NCT01752179|Kinesio taping
242882|NCT01752179|Piriformis syndrome
242883|NCT01752179|Trigger point
242884|NCT01752166|Candida
242885|NCT01752166|Candidemia
242886|NCT01752166|Blood culture
242887|NCT01752166|Diagnostics
242888|NCT01752153|Focus
242889|NCT01752153|immunomodulatory effect
242890|NCT01752153|of silymarin
242891|NCT01752153|on cell mediated immunity
242892|NCT01752153|Beta-Thalassemia
242893|NCT01752153|major patients.
242894|NCT01752140|Prostate cancer
242895|NCT01752140|Prostate biopsy
242896|NCT01752140|Vienna nomogram
242897|NCT01752127|Drug-eluting stent
242898|NCT01752127|diabetes
242899|NCT01752127|small vessel disease
242900|NCT01752114|Precancerous conditions
242901|NCT01752114|Carcinoma
242902|NCT01752101|Precancerous Conditions
242903|NCT01752101|Carcinoma
242904|NCT01752088|apularis, MRI clinical, results
242905|NCT01752075|Multiple myeloma
242906|NCT01752062|Chronic Myeloid Leukemia
242907|NCT01752062|CML
242908|NCT01752062|Pregnancy
242909|NCT01752049|Hereditary Hemorrhagic Telangiectasia
242910|NCT01752049|Anti-angiogenic Therapy
242911|NCT01752049|vascular malformations
242912|NCT01752049|HHT
242913|NCT01752036|stereotactic radiotherapy
242914|NCT01752036|SRS
242915|NCT01751984|lipid-lowering drugs
242916|NCT01751984|statin intolerance
242917|NCT01751945|EmONC
242918|NCT01751945|Neonatal mortality
242919|NCT01751945|Perinatal mortality
242920|NCT01751919|CML
242921|NCT01751919|GIST
242922|NCT01751906|Absorb™ BVS
242923|NCT01751906|Angioplasty
242924|NCT01751906|Bioabsorbable
242925|NCT01751906|BVS
242926|NCT01751906|Bioresorbable
242927|NCT01751906|Coronary Artery Disease
242928|NCT01751906|Coronary Artery Endothelial Responsiveness
242929|NCT01751906|Coronary artery restenosis
242930|NCT01751906|Coronary artery stenosis
242931|NCT01751906|Coronary scaffold
242932|NCT01751906|Coronary Stent
242933|NCT01751906|Drug eluting stents
242934|NCT01751906|Everolimus
242935|NCT01751906|Myocardial ischemia
242936|NCT01751906|Stent thrombosis
242937|NCT01751906|Stents
242938|NCT01751893|Hand-foot syndrome
242939|NCT01751893|palmar-plantar erythrodysesthesia
242940|NCT01751893|capecitabine
242941|NCT01751893|pegylated liposomal doxorubicin
242942|NCT01751893|henna
242943|NCT01751880|Gastric cancer, minimally invasive gastrectomy, Physical activity intervention
242944|NCT01751867|Myelodysplastic Syndrome
242945|NCT01751867|Dacogen
242946|NCT01751867|Oncology
242947|NCT01751867|Decitabine
242948|NCT01751867|Bone marrow disorders
242949|NCT01751854|pharmacology
242950|NCT01751854|rehabilitation
242951|NCT01751854|locomotion
242952|NCT01751828|Depression
242953|NCT01751828|Major Depressive Disorder
242954|NCT01751802|Lesch Nyhan Disease
242955|NCT01751802|Self-Injury
242956|NCT01751789|illicit opioid drug use
242957|NCT01751789|health service utilization
242958|NCT01751737|prostate
242959|NCT01751737|cancer
242960|NCT01751737|biopsy
242961|NCT01751737|18F-choline
242962|NCT01751737|PET
242963|NCT01751737|MRI
242964|NCT01751724|Premature infants
242965|NCT01751724|Caffeine
242966|NCT01751724|Methylxanthines
242967|NCT01751724|Mechanical ventilation
242968|NCT01751724|Oxygen
242969|NCT01751724|Weaning
242970|NCT01751724|Bronchopulmonary dysplasia
242971|NCT01751698|Autism
242972|NCT01751698|Minimally Verbal
242973|NCT01751698|School Age
242974|NCT01751685|kyphosis
242975|NCT01751672|SBIRT
242976|NCT01751672|Substance Use
242977|NCT01751672|Screening
242978|NCT01751672|Brief Intervention
242979|NCT01751672|Primary Care
242980|NCT01751633|Burst fractures
242981|NCT01751633|Thoracic or Lumbar Vertebrae/injuries [MeSH]
242982|NCT01751633|Thoracic or Lumbar Vertebrae/surgery [MeSH]
242983|NCT01751633|Spinal Fusion/methods [MeSH]
242984|NCT01751633|Thoracolumbar fracture management
242985|NCT01751633|Quality of life
242986|NCT01751633|Functional outcome
242987|NCT01751607|AF, catheter ablation, non-PV triggers, SNP
242988|NCT01751581|Obesity
242989|NCT01751581|Resting Metabolic Rate
242990|NCT01751581|Sleep
242991|NCT01751581|Eating
242992|NCT01751555|HBV co-infection ART TDF
242993|NCT01751529|renal malignancy
242994|NCT01751529|Pilot Study
242995|NCT01751529|LCCC 1219
242996|NCT01751529|UNC Lineberger
242997|NCT01751529|kidney cancer
242998|NCT01751529|contrast-enhanced ultrasound
242999|NCT01751529|ultrasound
243000|NCT01751503|Foot drop deformity
243001|NCT01751503|gold standard treatment
243002|NCT01751503|Tibialis posterior tendon transfer
243003|NCT01751503|Interosseous route
243004|NCT01751503|Extramembranous or circumtibial route
243005|NCT01751490|shoulder
243006|NCT01751490|instability
243007|NCT01751490|atraumatic
243008|NCT01751477|Very Low Birth Weight Infants
243009|NCT01751477|Probiotics
243010|NCT01751477|Necrotizing Enterocolitis
243011|NCT01751464|youth
243012|NCT01751464|violence
243013|NCT01751464|injury
243014|NCT01751464|emergency department
243015|NCT01751464|intervention
243016|NCT01751451|ABIRATERONE ACETATE (CB 7630)
243017|NCT01751451|DEGARELIX
243018|NCT01751451|PREDNISONE
243019|NCT01751451|12-187
243020|NCT01751438|Prostate cancer
243021|NCT01751438|Prostate carcinoma
243022|NCT01751438|Metastatic
243023|NCT01751438|M1
243024|NCT01751438|Best Systemic Therapy
243025|NCT01751438|BST
243026|NCT01751438|Androgen deprivation therapy
243027|NCT01751438|Bilateral orchiectomy
243028|NCT01751438|Radiation
243029|NCT01751438|Radiation Therapy
243030|NCT01751438|External beam radiation therapy
243031|NCT01751438|External-beam radiotherapy
243032|NCT01751438|Xray therapy
243033|NCT01751438|XRT
243034|NCT01751438|Surgery
243035|NCT01751425|Leukemia
243036|NCT01751425|Chronic Myeloid Leukemia
243037|NCT01751425|CML
243038|NCT01751425|Minimal Residual Disease
243039|NCT01751425|Philadelphia chromosome
243040|NCT01751425|(Ph)-positive
243041|NCT01751425|BCR/ABL-positive
243042|NCT01751425|Ruxolitinib
243043|NCT01751425|Jakafi
243044|NCT01751425|INCB018424
243045|NCT01751425|INC424
243046|NCT01751425|TKI
243047|NCT01751425|Tyrosine kinase inhibitor
243048|NCT01751412|Hodgkin
243049|NCT01751412|Non-Hodgkin Lymphoma
243050|NCT01751412|Mediastinal
243051|NCT01751412|Adult Lymphoma
243052|NCT01751412|Pediatric Lymphoma
243053|NCT01751386|Addiction
243054|NCT01751386|Cue-Induced Craving
243055|NCT01751386|Craving
243056|NCT01751386|Anxiety
243057|NCT01751386|Alcohol Consumption
243058|NCT01751373|Botulinum Toxin
243059|NCT01751373|Rehabilitation
243060|NCT01751373|Electromyography
243061|NCT01751373|Electroencephalography
243062|NCT01751373|Transcranial Magnetic Stimulation
243063|NCT01751347|Local anesthetics
243064|NCT01751347|Elective hand surgeries
243065|NCT01751334|Arthroplasty
243066|NCT01751334|Replacement
243067|NCT01751334|Knee
243068|NCT01751334|Rotational Alignment
243069|NCT01751282|Stem Cells
243070|NCT01751282|chronic wounds
243071|NCT01751282|fibrin
243072|NCT01751282|Bone marrow-derived mesenchymal stem cells
243073|NCT01751256|Postcesarean Section
243074|NCT01751256|Postoperative Pain
243075|NCT01751256|Care, Postoperative
243076|NCT01751256|Anesthesia, Local
243077|NCT01751256|Breast Feeding
243078|NCT01751256|Morphine
243079|NCT01751256|Pain Measurement
243080|NCT01751256|levobupivacaine
243081|NCT01751230|pregnancy
243082|NCT01751230|weight loss
243083|NCT01751217|Substance Abuse
243084|NCT01751217|Adolescents
243085|NCT01751217|Families
243086|NCT01751217|Functional Family Therapy
243087|NCT01751217|Video
243088|NCT01751217|Teleconferencing
243089|NCT01751217|Telemedicine
243090|NCT01751165|≥ 50 years of age
243091|NCT01751165|Herpes zoster
243092|NCT01751165|Safety
243093|NCT01751165|Immunogenicity
243094|NCT01751165|Adults
243095|NCT01751139|Endemic regions
243096|NCT01751139|Brazil
243097|NCT01751139|Incidence
243098|NCT01751139|Surveillance
243099|NCT01751139|Dengue
243100|NCT01751126|vernal keratoconjunctivitis
243101|NCT01751126|ciclosporin
243102|NCT01751126|cyclosporine
243103|NCT01751087|abortion, induced
243104|NCT01751074|Drug interaction, rosuvastatin, healthy volunteer, Lp-PLA2, atherosclerosis, darapladib, pharmacokinetics.
243105|NCT01751061|prolonged mechanical ventilation
243106|NCT01751061|chronic critical illness
243107|NCT01751061|decision making
243108|NCT01751061|decision aid
243109|NCT01751061|decisional support
243110|NCT01751061|critical illness
243111|NCT01751061|intensive care unit
243112|NCT01751048|GLA-SE,LEISH-F3,leishmaniasis,MPL-SE,parent protocol,vaccine
243113|NCT01751022|heart failure
243114|NCT01751022|cardiac pacing
243115|NCT01751022|cardiac resynchronization therapy
243116|NCT01751022|left ventricular lead
243117|NCT01751009|vitamin A, complementary foods, malnutrition, children
243118|NCT01750983|Advanced Cancers
243119|NCT01750983|Advanced Malignancies
243120|NCT01750983|Metastatic cancers
243121|NCT01750983|Ipilimumab
243122|NCT01750983|Yervoy
243123|NCT01750983|BMS-734016
243124|NCT01750983|MDX010
243125|NCT01750983|Lenalidomide
243126|NCT01750983|CC-5013
243127|NCT01750983|Revlimid
243128|NCT01750944|Blood pressure site
243129|NCT01750944|Good health
243130|NCT01750944|Brachial blood pressure
243131|NCT01750944|Ankle
243132|NCT01750944|Toe
243133|NCT01750944|Walking test
243134|NCT01750944|Exercise
243135|NCT01750931|BE study of Meloxicam GSK 15mg
243136|NCT01750918|MEK inhibitor
243137|NCT01750918|anti-EGFR antibody
243138|NCT01750918|colorectal cancer
243139|NCT01750918|BRAF inhibitor
243140|NCT01750879|peanut
243141|NCT01750879|allergy
243142|NCT01750879|food
243143|NCT01750879|immunotherapy
243144|NCT01750879|tolerance
243145|NCT01750879|desensitization
243146|NCT01750866|Prostrate Cancer
243147|NCT01750866|Castrate-resistant metastatic prostate cancer
243148|NCT01750866|Cabazitaxel
243149|NCT01750827|platelet function
243150|NCT01750827|atherosclerosis,
243151|NCT01750827|SB-659032
243152|NCT01750801|clinical trial
243153|NCT01750801|mouthwash
243154|NCT01750801|propolis
243155|NCT01750801|plaque
243156|NCT01750801|gingivitis
243157|NCT01750801|compliance
243158|NCT01750788|Stroke
243159|NCT01750788|Embolism
243160|NCT01750788|Atrial Fibrillation
243161|NCT01750775|sinus bradycardia
243162|NCT01750775|ventricular premature contraction
243163|NCT01750749|Venous ulcer
243164|NCT01750749|Cell therapy
243165|NCT01750736|Augmented Exercise
243166|NCT01750736|Cervicalgia
243167|NCT01750736|Manual Therapy
243168|NCT01750736|Manipulation
243169|NCT01750736|Quantitative Sensory
243170|NCT01750723|Acetazolamide
243171|NCT01750723|Headache
243172|NCT01750723|Migraine
243173|NCT01750710|Charcot-Marie-Tooth disease type 1A neuropathy
243174|NCT01750710|Isokinetic
243175|NCT01750710|Electromyography
243176|NCT01750710|Walking
243177|NCT01750684|Acute
243178|NCT01750684|Traumatic
243179|NCT01750684|SCI
243180|NCT01750684|Spinal Cord Injury
243181|NCT01750671|ICU
243182|NCT01750671|Body composition
243183|NCT01750671|Nutrition
243184|NCT01750671|Survival
243185|NCT01750671|Morbidity
243186|NCT01750658|Biomarkers
243187|NCT01750658|Exacerbations
243188|NCT01750658|COPD
243189|NCT01750593|radiofrequency
243190|NCT01750593|thyroid
243191|NCT01750593|nodule
243192|NCT01750567|Relapsed Chronic Lymphocytic Leukemia
243193|NCT01750567|untreated CLL patients
243194|NCT01750567|genomic deletion 11q
243195|NCT01750554|SpHb; hemoglobin monitoring;bupivacaine digital nerve block
243196|NCT01750515|Acupuncture
243197|NCT01750515|Hepatitis C (HCV)
243198|NCT01750489|COPD
243199|NCT01750476|oral contraception
243200|NCT01750476|Depo-Provera
243201|NCT01750476|Mirena
243202|NCT01750463|Pediatric critically ill
243203|NCT01750463|Masimo
243204|NCT01750463|hemoglobin
243205|NCT01750463|monitoring
243206|NCT01750463|UNC
243207|NCT01750463|PICU
243208|NCT01750450|Pressure Volume Area
243209|NCT01750450|Pressure Flow Area
243210|NCT01750450|Myocardial Work
243211|NCT01750437|NERD
243212|NCT01750424|Scar
243213|NCT01750424|Fat Grafting
243214|NCT01750424|Adipose Grafting
243215|NCT01750424|3-D imaging
243216|NCT01750424|Manchester Scar Scale
243217|NCT01750411|Severe Asthma
243218|NCT01750411|SARP
243219|NCT01750398|Testosterone, Leuprolide, Goserelin
243220|NCT01750385|Esophageal Achalasia
243221|NCT01750385|antibiotic prophylaxis
243222|NCT01750385|blood culture
243223|NCT01750385|procalcitonin levels
243224|NCT01750372|Artificial limbs
243225|NCT01750372|Questionnaires
243226|NCT01750372|Mobility limitation
243227|NCT01750359|antioxidants
243228|NCT01750359|curcumin
243229|NCT01750359|depression
243230|NCT01750346|Blepharospasm
243231|NCT01750346|Treatment
243232|NCT01750346|Dystonia
243233|NCT01750346|Acetyl-Hexapeptide
243234|NCT01750307|Attention Deficit Hyperactivity Disorder (ADHD)
243235|NCT01750307|Essential fatty acids (EFAs)
243236|NCT01750307|Electroencephalography (EEG)
243237|NCT01750307|Event-related potential (ERP)
243238|NCT01750307|Omega 3
243239|NCT01750307|Randomised Control Trial
243240|NCT01750307|Fish oil
243241|NCT01750307|Supplementation
243242|NCT01750307|Reading
243243|NCT01750307|Spelling
243244|NCT01750307|Behaviour
243245|NCT01750307|Emotional lability
243246|NCT01750294|hypertension
243247|NCT01750294|kidney disease
243248|NCT01750281|Mitogen-Activated Protein Kinase Kinase inhibitor
243249|NCT01750281|Non Small Cell Lung Cancer
243250|NCT01750281|Metastatic
243251|NCT01750281|Second line treatment for Non Small Cell Lung Cancer
243252|NCT01750268|TBI
243253|NCT01750268|hazardous and harmful alcohol use
243254|NCT01750268|veterans
243255|NCT01750268|co-occurring disorders
243256|NCT01750268|pharmacotherapy
243257|NCT01750255|Pharmaceutical care
243258|NCT01750255|Pharmacotherapy follow-up
243259|NCT01750255|Bipolar disorder
243260|NCT01750255|Pharmacy services
243261|NCT01750203|Diabetic foot ulcers, venous leg ulcers, pressure sores, acute wounds
243262|NCT01750190|anemia
243263|NCT01750190|chronic kidney disease (CKD)
243264|NCT01750190|non-dialysis
243265|NCT01750190|Hemoglobin (Hb)
243266|NCT01750190|End-Stage Renal Disease
243267|NCT01750190|erythropoeitin
243268|NCT01750190|ASP1517
243269|NCT01750190|erythropoeisis stimulating-agent
243270|NCT01750190|AZD9941
243271|NCT01750164|Breast Cancer
243272|NCT01750125|Doppler
243273|NCT01750112|Pectus excavatum
243274|NCT01750112|funnel chest
243275|NCT01750112|sunken chest
243276|NCT01750099|Labor
243277|NCT01750099|analgesia
243278|NCT01750099|epidural
243279|NCT01750099|spinal
243280|NCT01750086|osteoporosis
243281|NCT01750086|postmenopausal
243282|NCT01750086|denosumab
243283|NCT01750086|teriparatide
243284|NCT01750086|alendronate
243285|NCT01750086|Forteo®
243286|NCT01750086|Prolia®
243287|NCT01750047|pain perception
243288|NCT01750047|postoperative pain
243289|NCT01750047|demography
243290|NCT01750047|smoking
243291|NCT01750047|alcohol
243292|NCT01750034|Burns
243293|NCT01750034|Wounds and injuries
243294|NCT01750034|Bandages
243295|NCT01750008|Symptomatic Uterine Fibroids
243296|NCT01750008|Menorrhagia
243297|NCT01750008|Heavy Bleeding
243298|NCT01750008|Myomas
243299|NCT01750008|Radiofrequency Ablation
243300|NCT01750008|RFA
243301|NCT01750008|Leiomyoma
243302|NCT01750008|Fibroids
243303|NCT01749995|Elderly cancer patients
243304|NCT01749995|Screening tool
243305|NCT01749995|Cognitive impairment
243306|NCT01749995|Freund Clock Drawing Test
243307|NCT01749982|arsenic
243308|NCT01749982|Bangladesh
243309|NCT01749982|choline
243310|NCT01749982|betaine
243311|NCT01749982|methylation
243312|NCT01749956|Rectal Cancer
243313|NCT01749956|Chemoradiation
243314|NCT01749956|Aflibercept
243315|NCT01749956|Surgery
243316|NCT01749930|Intraocular pressure
243317|NCT01749917|Parkinson.
243318|NCT01749917|Dexterity.
243319|NCT01749917|Balance.
243320|NCT01749917|Exercises.
243321|NCT01749904|Intraocular pressure
243322|NCT01749891|Age Related Wet Macular Degeneration
243323|NCT01748864|Volunteers
243324|NCT01748825|MK-1775
243325|NCT01748825|Refractory
243326|NCT01748825|Solid Tumors
243327|NCT01748825|Wee1 Inhibitor
243328|NCT01748825|Tyrosine Kinase
243329|NCT01748812|Tumor Induced Osteomalacia
243330|NCT01748812|Hypophosphatemic Rickets
243331|NCT01748799|Cannabis dependence
243332|NCT01748799|Sativex
243333|NCT01748786|Fibromyalgia
243334|NCT01748786|Mindfulness
243335|NCT01748786|On-line intervention
243336|NCT01748786|Chronic pain
243337|NCT01748760|Suicide Attempts
243338|NCT01748760|Suicidal Ideation
243339|NCT01748734|Depression
243340|NCT01748708|Magnetic seizure therapy
243341|NCT01748708|Electroconvulsive therapy
243342|NCT01748708|Treatment resistant depression
243343|NCT01748708|Treatment resistance
243344|NCT01748708|Randomized controlled trial
243345|NCT01748695|Neuropathic pain
243346|NCT01748695|Spinal cord injury
243347|NCT01748682|Very low calorie diet
243348|NCT01748682|liquid diet
243349|NCT01748682|visceral fat
243350|NCT01748682|liver fat.
243351|NCT01748669|Arsenic
243352|NCT01748669|Arsenicosis
243353|NCT01748669|Garlic oil
243354|NCT01748669|Keratosis
243355|NCT01748656|Noninvasive ventilation
243356|NCT01748656|Obesity Hypoventilation Syndrome
243357|NCT01748630|scoliosis, sedation, children, fentanyl consumption, pain
243358|NCT01749813|Carbohydrate Specific Diet
243359|NCT01749813|Crohn's Disease
243360|NCT01749813|Immunomodulators
243361|NCT01749800|TBI
243362|NCT01749800|Attention deficits
243363|NCT01749800|upper extremity weakness
243364|NCT01749787|arthritis
243365|NCT01749787|rheumatoid
243366|NCT01749787|methotrexate
243367|NCT01749787|leflunomide
243368|NCT01749774|Physical activity
243369|NCT01749774|Testicular cancer
243370|NCT01749774|Chemotherapy
243371|NCT01749774|Feasibility
243372|NCT01749761|IDH, intradialytic hypotension,
243373|NCT01749761|hypotension on hemodialysis,
243374|NCT01749761|hemodialysis,
243375|NCT01749761|Blood pressure guided biofeedback
243376|NCT01749748|Breast diseases
243377|NCT01749748|magnetic resonance spectroscopy
243378|NCT01749722|Colorectal Cancer
243379|NCT01749722|Polyp
243380|NCT01749722|Adenoma
243381|NCT01749722|Detection Rate
243382|NCT01749722|Colonoscopy
243383|NCT01749722|NaviAid™ G-Eye procedure
243384|NCT01749722|NaviAid™ G-Eye system
243385|NCT01749722|G-Eye procedure
243386|NCT01749722|G-Eye system
243387|NCT01749709|Stroke
243388|NCT01749709|Recovery
243389|NCT01749709|Music
243390|NCT01749696|Pelvic organ prolapse
243391|NCT01749696|Connective tissue
243392|NCT01749696|Elastin
243393|NCT01749696|Collagen
243394|NCT01749670|Autism Spectrum Disorder
243395|NCT01749670|Exosomal miRNA expression
243396|NCT01749657|biomechanics
243397|NCT01749657|outcomes
243398|NCT01749657|foot
243399|NCT01749657|orthotic device
243400|NCT01749644|Cystic Fibrosis, Chronic Pseudomonas Infection, Inhaled Tobramycin
243401|NCT01749631|Patients suspected to have difficult intubation
243402|NCT01749631|Intratracheal intubation
243403|NCT01749631|Difficult to intubate
243404|NCT01749618|Seronegative Inflammatory Arthritis
243405|NCT01749618|SpA
243406|NCT01749618|PsA
243407|NCT01749618|Randomized
243408|NCT01749618|Behavioural Change
243409|NCT01749592|hearing loss
243410|NCT01749592|cochlear implant
243411|NCT01749592|PET
243412|NCT01749592|EEG
243413|NCT01749592|MEG
243414|NCT01749579|propofol
243415|NCT01749579|midazolam
243416|NCT01749579|duration of recovery
243417|NCT01749579|emergency procedure
243418|NCT01749566|HIV/AIDS, preexposure prophylaxis, women's health
243419|NCT01749527|24-hour pad test
243420|NCT01749527|Activity
243421|NCT01749527|Stress urinary incontinence
243422|NCT01749514|Myelodysplastic Syndrome
243423|NCT01749488|Dietitian
243424|NCT01749488|Nutritional recommendations
243425|NCT01749488|ICU nutrition
243426|NCT01749462|chronic obstructive pulmonary disease,
243427|NCT01749462|COPD,
243428|NCT01749462|Oxis,
243429|NCT01749449|high protein
243430|NCT01749449|high carbohydrate
243431|NCT01749449|meal frequency
243432|NCT01749449|abdominal body fat
243433|NCT01749449|postprandial thermogenesis
243434|NCT01749436|Atelectasis
243435|NCT01749436|Pneumoperitoneum
243436|NCT01749436|Hypoxemia
243437|NCT01749371|Alpha-Tocopherol
243438|NCT01749371|Gamma-Tocopherol
243439|NCT01749371|Inflammation
243440|NCT01749371|Oxidative Stress
243441|NCT01749371|Malondialdehyde
243442|NCT01749371|Isoprostanes
243443|NCT01749371|Lung Dysfunction
243444|NCT01749371|Wound Healing
243445|NCT01749358|stroke
243446|NCT01749358|hemiparesis
243447|NCT01749358|physical therapy
243448|NCT01749358|occupational therapy
243449|NCT01749358|neurorehabilitation
243450|NCT01749358|patient focused
243451|NCT01749358|motor learning
243452|NCT01749358|motor control
243453|NCT01749358|skill acquisition
243454|NCT01749358|skill training
243455|NCT01749358|motor recovery
243456|NCT01749358|task oriented training
243457|NCT01749358|task specific training
243458|NCT01749358|arm function
243459|NCT01749358|hand function
243460|NCT01749358|upper extremity
243461|NCT01749358|arm therapy
243462|NCT01749358|physical rehabilitation
243463|NCT01749358|arm rehabilitation
243464|NCT01749358|motor function
243465|NCT01749332|blood draw
243466|NCT01749332|Perihepatic Phlebotomy
243467|NCT01749332|12-236
243468|NCT01749319|baclofen, withdrawal, interuption, spasticity, pharmacokinetics, tolerability, intravenous, oral
243469|NCT01749306|epidermolysis bullosa, chronic wound, wound healing, dermal repair, fibroblasts, Dermagraft
243470|NCT01749280|Abdominal Aortic Aneurysm
243471|NCT01749280|MRI
243472|NCT01749280|USPIO
243473|NCT01749267|dentin remineralization
243474|NCT01749267|caries regression
243475|NCT01749254|Culprit plaques
243476|NCT01749254|Vulnerable Plaques
243477|NCT01749254|PET
243478|NCT01749254|calcification
243479|NCT01749254|inflammation
243480|NCT01749228|Fed
243481|NCT01749215|pharmacotherapy
243482|NCT01749215|alcohol dependence
243483|NCT01749215|Veterans
243484|NCT01749202|Omega 3 fatty acids
243485|NCT01749202|Omega 3 Index
243486|NCT01749202|Stearidonic acid (SDA)
243487|NCT01749202|Red Blood Cells
243488|NCT01749202|Lipids
243489|NCT01749189|soy
243490|NCT01749189|whey
243491|NCT01749189|casein
243492|NCT01749189|muscle
243493|NCT01749189|strength
243494|NCT01749189|protein
243495|NCT01749176|High risk Latino patients with diabetes
243496|NCT01749137|Overweight
243497|NCT01749124|mental illness
243498|NCT01749124|depression
243499|NCT01749124|schizophrenia
243500|NCT01749124|bipolar disorder
243501|NCT01749124|IVR
243502|NCT01749124|automated
243503|NCT01749124|telephone
243504|NCT01749111|bone marrow transplantation
243505|NCT01749111|graft versus host disease
243506|NCT01749111|Acute myelogenous leukemia
243507|NCT01749111|Acute lymphoid leukemia
243508|NCT01749111|Myeloproliferative disease
243509|NCT01749111|Myelodysplastic syndrome
243510|NCT01749111|Chronic myeloid leukemia
243511|NCT01749111|chronic myelomonocytic leukemia
243512|NCT01749098|PF-04958242
243513|NCT01749098|ketamine
243514|NCT01749098|cognition
243515|NCT01749098|healthy volunteers
243516|NCT01749085|PF-04449913
243517|NCT01749085|Food Effect
243518|NCT01749085|Drug-drug interaction
243519|NCT01749085|CYP3A4 inhibitor
243520|NCT01749085|Pharmacokinetics
243521|NCT01749072|non small cell lung cancer
243522|NCT01749072|chemotherapy
243523|NCT01749072|gefitinib
243524|NCT01749072|vinorelbine
243525|NCT01749072|ifosfamide
243526|NCT01749046|Epileptic seizures, Partial seizures
243527|NCT01749033|Intubation
243528|NCT01749033|Airway
243529|NCT01749033|Laryngeal Mask Airway
243530|NCT01749020|Diabetes type II, Insulin sensitivity
243531|NCT01749007|Veterans
243532|NCT01749007|HIV
243533|NCT01749007|AIDS
243534|NCT01749007|Cognitive Functioning
243535|NCT01749007|Suicide
243536|NCT01748994|Obesity
243537|NCT01748994|Fat distribution
243538|NCT01748994|Adipogenesis
243539|NCT01748994|Adipocyte
243540|NCT01748994|Preadipocyte
243541|NCT01748994|Ectopic fat
243542|NCT01748981|Pulmonary function
243543|NCT01748981|Maximal oxygen uptake
243544|NCT01748981|Cardiorespiratory fitness
243545|NCT01748981|High-intensity training
243546|NCT01748981|Surgery
243547|NCT01748968|Veterans
243548|NCT01748968|Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)
243549|NCT01748968|Self-Directed Violence
243550|NCT01748955|Major Depressive Disorder
243551|NCT01748955|MDD
243552|NCT01748955|Reward
243553|NCT01748955|BOLD signal
243554|NCT01748955|Suicide
243555|NCT01748916|Papaya
243556|NCT01748916|Carrot
243557|NCT01748916|Tomato
243558|NCT01748916|Carotenoids
243559|NCT01748916|Lycopene
243560|NCT01748916|Beta-carotene
243561|NCT01748916|Beta-cryptoxanthin
243562|NCT01748903|intracranial aneurysm
243563|NCT01748903|cerebral aneurysm
243564|NCT01748903|packing density
243565|NCT01748903|Target Coils
243566|NCT01748903|aneurysm embolization
243567|NCT01748877|shingles,
243568|NCT01748877|neuropathic pain
243569|NCT01748877|post herpetic neuralgia
243570|NCT01748877|sleep
243571|NCT01748604|Lymphedema
243572|NCT01748604|Physical Therapies
243573|NCT01748604|Randomized controlled study
243574|NCT01748604|Decongestive lymphatic therapy
243575|NCT01748604|Manual lymph drainage
243576|NCT01748604|Intermittent pneumatic compression
243577|NCT01748604|Multilayer bandages
243578|NCT01748578|Healthy
243579|NCT01748578|Interleukin 1 Receptor Inhibitor
243580|NCT01748578|Dry Eye
243581|NCT01748565|biomarkers
243582|NCT01748565|oxidative stress
243583|NCT01748565|BPD
243584|NCT01748565|prematurity
243585|NCT01748526|Healthy
243586|NCT01748526|Canagliflozin (JNJ-28431754)
243587|NCT01748526|Pharmacokinetics
243588|NCT01748526|Pharmacodynamics
243589|NCT01748526|Indian
243590|NCT01748513|morbidly obese patients,
243591|NCT01748513|preoperative volume-challenge,
243592|NCT01748513|transthoracic echocardiography,
243593|NCT01748513|TTE,
243594|NCT01748513|rapid weight loss,
243595|NCT01748513|venous return,
243596|NCT01748513|bariatric surgery,
243597|NCT01748513|left ventricular outflow tract,
243598|NCT01748513|stroke volume,
243599|NCT01748513|diastolic function,
243600|NCT01748513|hypervolemia,
243601|NCT01748513|hypovolemia
243602|NCT01748500|metastatic
243603|NCT01748461|intervention study in elderly (65+)
243604|NCT01748461|cycle ergometer
243605|NCT01748461|physical activity
243606|NCT01748461|physical fitness
243607|NCT01748461|assisted living facility
243608|NCT01748448|Cutaneous malignant melanoma
243609|NCT01748448|Vitamin D
243610|NCT01748448|Cholecalciferol
243611|NCT01748435|Neuropathic pain
243612|NCT01748435|Lower limb amputation
243613|NCT01748435|Pre-emptive analgesia
243614|NCT01748422|Neuropathic pain
243615|NCT01748422|Arteriovenous fistulae
243616|NCT01748422|End stage renal disease
243617|NCT01748409|Autonomic failure, Parkinson's disease, electrophysiological assessment, neuropathological assessment
243618|NCT01748396|FGF-23
243619|NCT01748396|Calcitriol
243620|NCT01748396|Calcium carbonate
243621|NCT01748396|CKD Stage 3
243622|NCT01748383|Bone marrow cells
243623|NCT01748383|Acute myocardial infarction
243624|NCT01748383|Transplantation of autologous mononuclear
243625|NCT01748383|Transplantation of autologous CD133 + cells
243626|NCT01748370|vitamin D
243627|NCT01748370|hypogonadism
243628|NCT01748370|testosterone
243629|NCT01748370|intervention
243630|NCT01748357|Tuberculosis
243631|NCT01748357|Volatile organic compounds
243632|NCT01748357|exhaled breath
243633|NCT01748357|Siemens
243634|NCT01748331|Heart Failure
243635|NCT01748331|Hyponatremia
243636|NCT01748331|Fluid restriction
243637|NCT01748318|Community acquired MRSA
243638|NCT01748318|New Mexico Honey
243639|NCT01748305|GDM
243640|NCT01748305|A1GDM
243641|NCT01748305|A2GDM
243642|NCT01748292|Age related
243643|NCT01748292|Macular
243644|NCT01748292|sub retinal fluid
243645|NCT01748292|Age related Macular degeneration
243646|NCT01748279|COPD
243647|NCT01748279|Atorvastatin
243648|NCT01748279|statins
243649|NCT01748279|COPD treatment
243650|NCT01748279|microarrays
243651|NCT01748266|StO2
243652|NCT01748266|microcirculation
243653|NCT01748266|NIRS
243654|NCT01748227|self-management
243655|NCT01748227|peer support
243656|NCT01748227|social support
243657|NCT01748214|continuous positive airway pressure
243658|NCT01748214|high flow nasal cannula
243659|NCT01748214|hearing outcomes
243660|NCT01748214|noise exposure
243661|NCT01748214|preterm infants
243662|NCT01748201|Osteoarthritis
243663|NCT01748201|Hemarthrosis
243664|NCT01748201|Hemophilia A
243665|NCT01748201|Hemophilia B
243666|NCT01748201|Viscosupplementation
243667|NCT01748188|Subacromial syndrome
243668|NCT01748188|Dexketoprofen
243669|NCT01748188|Phonophoresis
243670|NCT01748188|Iontophoresis
243671|NCT01748188|Ultrasounds
243672|NCT01748188|VAS
243673|NCT01748188|DASH score
243674|NCT01748188|Constant score
243675|NCT01748175|Severe asthma
243676|NCT01748175|longitudinal study
243677|NCT01748175|phenotypes
243678|NCT01748162|croup
243679|NCT01748162|recurrent croup
243680|NCT01748162|barky cough
243681|NCT01748149|recurrent/refractory BRAFV600E-mutant gliomas
243682|NCT01748149|pediatrics
243683|NCT01748149|children
243684|NCT01748149|neo-adjuvant vemurafenib
243685|NCT01748123|Pragmatic
243686|NCT01748123|Comparative Effectiveness
243687|NCT01748110|quality of life
243688|NCT01748110|erectile function
243689|NCT01748097|infiltration
243690|NCT01748097|extravasation
243691|NCT01748097|sodium bicarbonate
243692|NCT01748097|capnography
243693|NCT01748097|end tidal carbon dioxide
243694|NCT01748097|chemotherapy
243695|NCT01748084|Systemic sclerosis
243696|NCT01748084|Arthritis
243697|NCT01748084|B-cell therapy, Anti-CD20 therapy
243698|NCT01748084|Quality of life
243699|NCT01748084|Scleroderma
243700|NCT01748084|Lung fibrosis
243701|NCT01748084|Randomised controled trial
243702|NCT01748071|fentanyl
243703|NCT01748071|sufentanil
243704|NCT01748071|individual variation
243705|NCT01748071|pain threshold
243706|NCT01748071|nacro-trend index
243707|NCT01748045|Inhaled Nitric Oxide
243708|NCT01748045|Bronchopulmonary Dysplasia
243709|NCT01748045|Late Prematurity
243710|NCT01748045|Chronic Respiratory Morbidity
243711|NCT01748032|depression
243712|NCT01748032|intervention studies
243713|NCT01748019|ST1968
243714|NCT01748019|Camptothecin
243715|NCT01748019|Solid tumors
243716|NCT01748019|Topoisomerase I
243717|NCT01747993|Urinary retention; urinary catheterization; alpha blocking agents; women; elder
243718|NCT01747980|Gaucher disease
243719|NCT01747980|human glucocerebrosidase
243720|NCT01747980|plant recombinant human glucocerebrosidase
243721|NCT01747967|Antibodies
243722|NCT01747967|Beta cells
243723|NCT01747967|C-peptide
243724|NCT01747967|GAD
243725|NCT01747967|Glucose
243726|NCT01747967|Glycemia
243727|NCT01747967|Insulin
243728|NCT01747967|Meal test
243729|NCT01747967|Pancreas
243730|NCT01747967|Proinsulin,
243731|NCT01747967|T lymphocytes
243732|NCT01747954|Respiratory Insufficiency
243733|NCT01747954|Physiotherapy Techniques
243734|NCT01747954|Respiratory Mechanics
243735|NCT01747928|usability study
243736|NCT01747915|Primary Generalized Tonic Clonic Seizures
243737|NCT01747915|Epilepsy
243738|NCT01747915|Safety
243739|NCT01747915|Efficacy
243740|NCT01747915|Tolerability
243741|NCT01747915|Pregabalin
243742|NCT01747915|Lyrica
243743|NCT01747915|Adjunctive treatment
243744|NCT01747915|Placebo Controlled
243745|NCT01747915|Blinded
243746|NCT01747889|chest tube
243747|NCT01747889|lung resection
243748|NCT01747889|patient satisfaction
243749|NCT01747889|mobility
243750|NCT01747876|Phase 1
243751|NCT01747876|pediatric
243752|NCT01747876|CDK4/6 inhibitor
243753|NCT01747876|dose escalation
243754|NCT01747876|malignant rhabdoid tumors
243755|NCT01747876|MRT
243756|NCT01747876|neuroblastoma
243757|NCT01747863|Hypoxic Ischemic encephalopathy
243758|NCT01747837|Renal sympathetic denervation
243759|NCT01747837|Renal catheter ablation
243760|NCT01747837|Ventricular tachycardia
243761|NCT01747824|agitation
243762|NCT01747824|excited delirium
243763|NCT01747824|pain
243764|NCT01747824|unexplained-in-custody-death
243765|NCT01747824|UICD
243766|NCT01747824|visual analog scale
243767|NCT01747824|VAS
243768|NCT01747824|altered mental status
243769|NCT01747824|AMS
243770|NCT01747811|Mild traumatic brain injury
243771|NCT01747811|Concussion
243772|NCT01747811|Sleep problems
243773|NCT01747811|brain imaging
243774|NCT01747811|functional magnetic resonance imaging (FMRI)
243775|NCT01747785|Heart failure
243776|NCT01747785|HFpEF
243777|NCT01747785|Dyspnea
243778|NCT01747785|Fatigue
243779|NCT01747785|Shortness of Breath
243780|NCT01747785|exercise
243781|NCT01747785|strain
243782|NCT01747785|myocardial deformation
243783|NCT01747785|cardiac rehabilitation
243784|NCT01747785|cardiac hemodynamics
243785|NCT01747772|Non-focal Liver Disease
243786|NCT01747772|Fibrosis
243787|NCT01747772|Shear Wave Sonoelastography
243788|NCT01747772|Metavir Liver Fibrosis Grading
243789|NCT01747759|• Knee osteoarthritis
243790|NCT01747759|Total knee arthroplasty
243791|NCT01747759|Selfcare
243792|NCT01747759|Booklet
243793|NCT01747759|Rehabilitation
243794|NCT01747746|Rivaroxaban
243795|NCT01747746|Warfarin
243796|NCT01747746|Anticoagulation
243797|NCT01747746|Stroke
243798|NCT01747746|Thrombo-embolism
243799|NCT01747746|Bleeding
243800|NCT01747746|Atrial Fibrillation
243801|NCT01747746|Cardioversion
243802|NCT01747733|Endoscopy
243803|NCT01747733|ERCP
243804|NCT01747733|PCS
243805|NCT01747733|Sedation
243806|NCT01747733|Bispectral index
243807|NCT01747720|breast cancer
243808|NCT01747720|mammographic breast density
243809|NCT01747720|vitamin D
243810|NCT01747720|prevention
243811|NCT01747720|randomized controlled trial
243812|NCT01747707|gastric cancer
243813|NCT01747707|gastroesophageal junction cancer
243814|NCT01747707|chemotherapy
243815|NCT01747707|docetaxel
243816|NCT01747707|cisplatin
243817|NCT01747707|S-1
243818|NCT01747694|COPD,Respiratory muscle training,Exercise tolerance
243819|NCT01747681|chondral defect
243820|NCT01747681|microfracture
243821|NCT01747681|arthroscopy
243822|NCT01747681|cartilage repair
243823|NCT01747681|outcome study
243824|NCT01747681|Lysholm score
243825|NCT01747668|Mother and Infant Pairs
243826|NCT01747655|Early Observational Advanced
243827|NCT01747655|Parkinson's Disease
243828|NCT01747642|Hepatocellular carcinoma
243829|NCT01747642|Oncoxin
243830|NCT01747642|Surafenib
243831|NCT01747629|Asthma
243832|NCT01747629|dry powder inhaler
243833|NCT01747629|short-acting beta2-agonist
243834|NCT01747629|SABA
243835|NCT01747629|bronchoconstriction
243836|NCT01747629|bronchodilation
243837|NCT01747629|bronchodilator
243838|NCT01747629|metered dose inhaler
243839|NCT01747629|Albuterol Spiromax®
243840|NCT01747616|Chitosan-N-Acetylcysteine
243841|NCT01747616|contact lenses
243842|NCT01747616|safety and tolerability
243843|NCT01747603|Late preterm infant
243844|NCT01747603|Complications
243845|NCT01747603|Hospital readmissions
243846|NCT01747603|Follow-up
243847|NCT01747603|Pilot study
243848|NCT01747577|Muscarine antagonist
243849|NCT01747577|Prostatectomy
243850|NCT01747577|Uroflowmetry
243851|NCT01747564|Pharmacokinetics
243852|NCT01747564|Mirabegron
243853|NCT01747564|Phase 1
243854|NCT01747564|YM178
243855|NCT01747551|Advanced
243856|NCT01747538|Uveitis
243857|NCT01747538|Non-infectious Uveitis
243858|NCT01747538|Intermediate Uveitis
243859|NCT01747538|Posterior Uveitis
243860|NCT01747538|Panuveitis
243861|NCT01747512|99mTc Pertechnetate
243862|NCT01747512|thyroidectomy
243863|NCT01747512|thyroid neoplasms
243864|NCT01747473|Subjects
243865|NCT01747460|Subjects
243866|NCT01746693|retinal vessel diameter
243867|NCT01746693|retinal oxygen saturation
243868|NCT01746693|high resolution functional and anatomical imaging
243869|NCT01746693|inner retinal function
243870|NCT01746693|flicker response
243871|NCT01746680|rheumatoid arthritis
243872|NCT01746680|RA
243873|NCT01746680|tacrolimus
243874|NCT01746680|Disease Activity Score 28
243875|NCT01746680|EULAR
243876|NCT01746667|Social Anxiety Disorder
243877|NCT01746667|Social Phobia
243878|NCT01746667|Virtual Reality
243879|NCT01746667|Exposure
243880|NCT01746654|S.aureus
243881|NCT01746654|Methicillin Resistant S.aureus (MRSA)
243882|NCT01746654|Nasal carrier status
243883|NCT01746654|Prophylaxis
243884|NCT01746641|Remifentanil
243885|NCT01746641|Propofol
243886|NCT01746641|Sedation
243887|NCT01746641|Endoscopy
243888|NCT01746641|Gastroenterology
243889|NCT01746641|Target controlled infusion effect site
243890|NCT01746628|type 0 myomata
243891|NCT01746628|type 1 myomata
243892|NCT01746628|type 2 myomata
243893|NCT01746628|bleeding
243894|NCT01746628|hemorrhage
243895|NCT01746628|hysteroscopy
243896|NCT01746628|FloSeal
243897|NCT01746615|branch retinal vein occlusion
243898|NCT01746615|dynamic vessel analyzer
243899|NCT01746615|fourier-domain OCT
243900|NCT01746615|retinal oxygen saturation
243901|NCT01747408|subarachnoid hemorrhage
243902|NCT01747395|Heart Failure
243903|NCT01747395|Exercise and Physical Fitness
243904|NCT01747382|Treatment-resistant Hypertension
243905|NCT01747382|Chronic Kidney Disease
243906|NCT01747382|Symplicity catheters
243907|NCT01747382|Renal denervation
243908|NCT01747369|surveillance study
243909|NCT01747369|prospective
243910|NCT01747369|observational
243911|NCT01747369|health center-based
243912|NCT01747369|pneumonia, bacterial
243913|NCT01747369|pneumonia, viral
243914|NCT01747369|meningitis, bacterial
243915|NCT01747369|Africa south of the Sahara
243916|NCT01747343|Incontinence
243917|NCT01747343|Enuresis
243918|NCT01747330|cystic fibrosis
243919|NCT01747317|FFR
243920|NCT01747317|fractional flow reserve
243921|NCT01747317|CT
243922|NCT01747317|Computed Tomography
243923|NCT01747304|Atypical Femur Fracture
243924|NCT01747304|DXA
243925|NCT01747278|Pneumocystis carinii pneumonia
243926|NCT01747278|prophylaxis
243927|NCT01747278|trimethoprim/sulfamethoxazole
243928|NCT01747239|Ovarian cancer
243929|NCT01747239|Platinum refractory
243930|NCT01747226|Oral malodor
243931|NCT01747226|Halitosis
243932|NCT01747226|Bad Breath
243933|NCT01747226|Mouth rinses
243934|NCT01747226|Mouthwashes
243935|NCT01747226|Amine fluoride/Stannous fluoride
243936|NCT01747226|Zinc ions
243937|NCT01747226|Chlorhexidine
243938|NCT01747213|Neurodegenerative
243939|NCT01747213|Cholinergic
243940|NCT01747213|Single Dose
243941|NCT01747213|Inhibitor
243942|NCT01747213|Tolerability
243943|NCT01747200|Repetitive TMS (rTMS)
243944|NCT01747187|Septic shock
243945|NCT01747187|Critical care
243946|NCT01747187|cardiac failure
243947|NCT01747174|STEMI
243948|NCT01747174|Microvascular Obstruction
243949|NCT01747174|No-reflow
243950|NCT01747174|Adenosine
243951|NCT01747174|Sodium Nitroprusside
243952|NCT01747148|Antisense
243953|NCT01747148|Influenza
243954|NCT01747148|IV Injection
243955|NCT01747148|RNA Based Therapeutic
243956|NCT01747148|RNA Interference
243957|NCT01747135|2-Hydroxypropyl-B-Cyclodextrin
243958|NCT01747135|Niemann-Pick Disease, Type C1
243959|NCT01747135|Neurodegeneration
243960|NCT01747122|epidurals
243961|NCT01747122|wound catheters
243962|NCT01747122|liver resection
243963|NCT01747122|liver surgery
243964|NCT01747109|Acute hypoxemic respiratory failure
243965|NCT01747109|Preoxygenation
243966|NCT01747109|Crash induction
243967|NCT01747096|Gastroenteropancreatic Neuroendocrine Tumors
243968|NCT01747096|immuno PET (iPET)
243969|NCT01747096|Gallium (68-Ga)
243970|NCT01747096|DOTANOC
243971|NCT01747070|Electro Acupuncture
243972|NCT01747070|Knee Osteoarthritis
243973|NCT01747070|Chronic pain
243974|NCT01747070|Cortical Excitability
243975|NCT01747044|Fibromyalgia
243976|NCT01747044|Diffuse Noxious Inhibitory Controls
243977|NCT01747044|Milnacipran
243978|NCT01747031|iFR
243979|NCT01747031|FFR
243980|NCT01747031|instantaneous wave-free ratio
243981|NCT01747031|fractional flow reserve
243982|NCT01747018|Platelet-Rich Plasma
243983|NCT01747018|Knee pain
243984|NCT01747018|osteoarthritis
243985|NCT01747018|degenerative chondropathy
243986|NCT01747018|Intraarticular injection
243987|NCT01747005|abdominal hysterectomy
243988|NCT01747005|enhanced recovery after surgery
243989|NCT01747005|inflammatory response
243990|NCT01747005|ERAS
243991|NCT01747005|combined spinal-epidural anesthesia
243992|NCT01746979|TH-302
243993|NCT01746979|Evofosfamide
243994|NCT01746979|Pancreatic Cancer
243995|NCT01746979|EMR200592-001
243996|NCT01746966|gleno-humeral joint synovitis
243997|NCT01746966|anterior shoulder US
243998|NCT01746966|rotator interval
243999|NCT01746940|Surgery
244000|NCT01746940|Surgeries
244001|NCT01746940|Nasal
244002|NCT01746940|Cavities
244003|NCT01746940|Diagnosis
244004|NCT01746940|Diagnostic
244005|NCT01746940|Nose
244006|NCT01746940|Rhinoplasty
244007|NCT01746940|Endoscopy
244008|NCT01746940|Bronchoscopy
244009|NCT01746927|cricoid pressure, glidescope
244010|NCT01746901|Relative abuse potential study; oxycodone; nalteone; Opioid-related disorders; drug abusers
244011|NCT01746901|Chronic pain
244012|NCT01746875|Angiogenesis inhibitors
244013|NCT01746875|Photochemotherapy
244014|NCT01746875|Vascular Endothelium Growth Factors
244015|NCT01746875|Aflibercept
244016|NCT01746862|Saizen®
244017|NCT01746862|Recombinant human growth hormone (r-hGH)
244018|NCT01746862|Idiopathic short stature
244019|NCT01746862|Height velocity
244020|NCT01746862|Bone age
244021|NCT01746849|LUPRON DEPOT
244022|NCT01746849|PALIFERMIN
244023|NCT01746849|12-077
244024|NCT01746836|Leukemia
244025|NCT01746836|Chronic Myeloid Leukemia
244026|NCT01746836|CML
244027|NCT01746836|Imatinib-resistant or intolerant
244028|NCT01746836|Imatinib failure
244029|NCT01746836|Ph-positive (by cytogenetics or FISH)
244030|NCT01746836|BCR-ABL-positive (by PCR) CML in chronic phase
244031|NCT01746836|Ponatinib
244032|NCT01746836|AP24534
244033|NCT01746823|Keratoconus
244034|NCT01746823|Proteomics
244035|NCT01746810|Metastatic
244036|NCT01746810|Lung Cancer
244037|NCT01746810|NSCLC
244038|NCT01746797|infertility
244039|NCT01746797|depression
244040|NCT01746797|IVF
244041|NCT01746797|IUI
244042|NCT01746797|fertility treatment
244043|NCT01746784|Cystic Fibrosis
244044|NCT01746784|F508del-CFTR
244045|NCT01746784|N6022
244046|NCT01746784|S-Nitrosoglutathione
244047|NCT01746771|HM781-36B, Paclitaxel, Trastuzumab
244048|NCT01746758|Reproductive health, mHealth, Cluster randomised trial
244049|NCT01746602|topical lubricants
244050|NCT01746602|tear film thickness
244051|NCT01746602|anti-glaucoma drugs
244052|NCT01746602|break up time
244053|NCT01746602|anti-glaucoma treatment
244054|NCT01746589|LASIK
244055|NCT01746576|volunteers
244056|NCT01746563|Proliferative Diabetic Retinopathy
244057|NCT01746563|Ranibizumab
244058|NCT01746563|Panretinal Photocoagulation
244059|NCT01746524|Arthroplasty
244060|NCT01746524|Replacement
244061|NCT01746524|Knee
244062|NCT01746511|glycerin suppositories
244063|NCT01746511|glycerin shaves
244064|NCT01746511|neonatal hyperbilirubinemia
244065|NCT01746511|idiopathic hyperbilirubinemia
244066|NCT01746511|jaundice
244067|NCT01746511|neonatal jaundice
244068|NCT01746511|prematurity
244069|NCT01746498|Alzheimer disease
244070|NCT01746498|Direct current stimulation
244071|NCT01746498|cognitive function
244072|NCT01746498|memory
244073|NCT01746485|Volunteers
244074|NCT01746459|Sustainability of Innovations
244075|NCT01746459|Knowledge Translation
244076|NCT01746459|Gerontology
244077|NCT01746459|Mobility
244078|NCT01746420|elbow
244079|NCT01746407|Emergency Department
244080|NCT01746407|Infection
244081|NCT01746407|Sepsis
244082|NCT01746394|obesity
244083|NCT01746394|pregnant women
244084|NCT01746394|nutrition assessment
244085|NCT01746394|health behavior
244086|NCT01746381|amyotrophic lateral sclerosis
244087|NCT01746381|non-invasive ventilation
244088|NCT01746381|home ventilation
244089|NCT01746381|IVAPS
244090|NCT01746381|neuromuscular diseases
244091|NCT01746368|advance directives
244092|NCT01746355|atypical facial pain
244093|NCT01746355|atypical odontalgia
244094|NCT01746355|repetitive transcranial magnetic stimulation
244095|NCT01746355|neuropathic pain
244096|NCT01746355|chronic pain
244097|NCT01746355|assessment
244098|NCT01746329|Obesity, insulin resistance, muscle perfusion
244099|NCT01746303|Working memory
244100|NCT01746303|Long-term memory
244101|NCT01746303|Neurocognition
244102|NCT01746303|Dietary supplementation
244103|NCT01746303|dementia
244104|NCT01746290|Cardiac Arrest, cardiopulmonary resuscitation, automated external defibrillators, smartphones
244105|NCT01746277|non small cell lung cancer
244106|NCT01746277|chemotherapy
244107|NCT01746277|epidermal growth factor receptor tyrosine kinase inhibitor
244108|NCT01746277|retreatment
244109|NCT01746264|Obesity
244110|NCT01746264|Endothelial dysfunction
244111|NCT01746264|Vitamin D deficiency
244112|NCT01746251|EGFR mutation
244113|NCT01746251|Resected
244114|NCT01746238|soft tissue
244115|NCT01746238|high grade
244116|NCT01746225|Metastatic
244117|NCT01746225|Breast
244118|NCT01746225|Cancer
244119|NCT01746225|HER2-negative Stage IV
244120|NCT01746225|No previous chemotherapy
244121|NCT01746212|Degenerative Disc Disease
244122|NCT01746212|InQu Bone Graft Extender and Substitute
244123|NCT01746212|Anterior Lumbar Interbody Fusion
244124|NCT01746212|Oswestry Disability Index
244125|NCT01746212|Visual Analog Scale
244126|NCT01746212|Stand-alone ALIF
244127|NCT01746212|Bone Marrow Aspirate Concentrate
244128|NCT01746212|Fusion rate
244129|NCT01746212|Disc Height
244130|NCT01746212|Mean Optical Density
244131|NCT01746212|Integrated Optical Density
244132|NCT01746173|T Cell lymphoma
244133|NCT01746160|dental implant
244134|NCT01746160|healing
244135|NCT01746160|implant stability
244136|NCT01746147|MDS
244137|NCT01746147|AML
244138|NCT01746147|allogeneic SCT
244139|NCT01746108|Pneumococcal infection
244140|NCT01746108|Synflorix
244141|NCT01746108|Children
244142|NCT01746108|Immunogenicity
244143|NCT01746108|Safety
244144|NCT01746095|Cystic Fibrosis
244145|NCT01746095|MRSA
244146|NCT01746095|Methicillin-resistant Staphylococcus aureus
244147|NCT01746095|Lung infection
244148|NCT01746095|AeroVanc
244149|NCT01746095|Vancomycin
244150|NCT01746082|influenza, H3N2, H3N2v, vaccine, unadjuvanted, Parent Protocol
244151|NCT01746069|smoking
244152|NCT01746069|smoke cessation
244153|NCT01746069|sms
244154|NCT01746069|quit smoke
244155|NCT01746056|Warts
244156|NCT01746056|Verruca
244157|NCT01746056|Heat patch
244158|NCT01746043|Esophageal cancer
244159|NCT01746043|Chemotherapy
244160|NCT01746043|Radiation therapy
244161|NCT01746043|XRT
244162|NCT01746043|Chemoradiation
244163|NCT01746043|CXRT
244164|NCT01746043|Symptom Burden
244165|NCT01746043|Armodafinil
244166|NCT01746043|Nuvigil
244167|NCT01746043|Minocycline
244168|NCT01746043|Dynacin
244169|NCT01746043|Minocin
244170|NCT01746043|Minocin PAC
244171|NCT01746043|Myrac
244172|NCT01746043|Solodyn
244173|NCT01746043|Placebo
244174|NCT01746043|Sugar pill
244175|NCT01746043|Questionnaires
244176|NCT01746043|Surveys
244177|NCT01745952|Epilepsies, Partial
244178|NCT01745952|Transcranial Magnetic Stimulation
244179|NCT01745939|Back pain
244180|NCT01745913|Leukemia
244181|NCT01745913|Lymphoma
244182|NCT01745900|Diabetes
244183|NCT01745900|Gestational Diabetes
244184|NCT01745900|Female
244185|NCT01745887|Dry Eye Syndrome
244186|NCT01745887|Interleukin 1 Receptor Inhibitor
244187|NCT01745874|Rectal cancer
244188|NCT01745874|Whole-body MRI
244189|NCT01745874|FDG-PET-CT
244190|NCT01745874|preoperative staging
244191|NCT01745848|Roflumilast
244192|NCT01745848|COPD
244193|NCT01745822|Hepatitis B
244194|NCT01745822|Hepatitis B sAg
244195|NCT01745822|Hepatitis B eAg
244196|NCT01745822|pregnancy
244197|NCT01745796|Pseudomonas Aeruginosa
244198|NCT01745796|Ventilated Acquired Pneumonia
244199|NCT01745796|Transmission modes
244200|NCT01745718|prostate cancer
244201|NCT01745718|targeted biopsies
244202|NCT01745718|cytological imprints
244203|NCT01745718|histology
244204|NCT01745705|Manipulation
244205|NCT01745705|Balance
244206|NCT01745705|Proprioception
244207|NCT01745679|Ceftriaxone
244208|NCT01745679|Adverse drug effects
244209|NCT01745679|Therapeutic monitoring
244210|NCT01745679|Meningitis
244211|NCT01745666|Long QT syndrome, stress tests
244212|NCT01745640|Multiple myeloma
244213|NCT01745640|dexamethasone
244214|NCT01745640|pomalidomide
244215|NCT01745640|response
244216|NCT01745640|safety
244217|NCT01745640|del 17p
244218|NCT01745640|t 4-14
244219|NCT01745614|Bioequivalence
244220|NCT01745614|Nimesulide
244221|NCT01745614|Pharmacokinetics
244222|NCT01745614|Mexico
244223|NCT01745588|CC-4047(Pomalidomide)Pomalyst
244224|NCT01745588|Clarithromycin
244225|NCT01745588|Biaxin
244226|NCT01745588|DEXAMETHASONE
244227|NCT01745588|(ClaPD)
244228|NCT01745588|Stem cell
244229|NCT01745588|12-138
244230|NCT01745575|Bioequivalence
244231|NCT01745575|Alprazolam
244232|NCT01745575|Anxiety disorders
244233|NCT01745575|Mexico
244234|NCT01745562|Alprazolam
244235|NCT01745562|Anxiety disorders
244236|NCT01745562|Bioequivalence
244237|NCT01745562|Mexico
244238|NCT01745549|diabetes
244239|NCT01745549|insulin therapy
244240|NCT01745549|needle
244241|NCT01745536|Oocyte vitrification
244242|NCT01745536|survival rate
244243|NCT01745536|egg banking
244244|NCT01745536|ovum donation
244245|NCT01745523|Oocyte vitrification
244246|NCT01745523|survival rate
244247|NCT01745523|egg banking
244248|NCT01745523|ovum donation
244249|NCT01745510|docosahexaenoic acid
244250|NCT01745510|n-3 fatty acids
244251|NCT01745510|necrotizing enterocolitis
244252|NCT01745510|preterm infants
244253|NCT01745497|Autism Spectrum Disorder
244254|NCT01745497|Insomnia
244255|NCT01745484|SPECT
244256|NCT01745484|Toxicity
244257|NCT01745484|Non-small-cell lung cancer
244258|NCT01745484|Definitive Radiotherapy
244259|NCT01745484|Radiation pneumonitis
244260|NCT01745484|Randomized study
244261|NCT01745471|Abdominal Adipose
244262|NCT01745471|Gluteal Adipose
244263|NCT01745471|Polycystic Ovary Syndrome
244264|NCT01745471|Obesity
244265|NCT01745471|Women
244266|NCT01745445|limited-stage small cell lung cancer
244267|NCT01745445|concurrent chemo-radiotherapy
244268|NCT01745432|ADBLOCK
244269|NCT01745432|Adhesion Barrier System
244270|NCT01745432|laparoscopic surgery
244271|NCT01745432|myomectomy
244272|NCT01745419|COPD
244273|NCT01745419|Exacerbation
244274|NCT01745419|Haptoglobin
244275|NCT01745393|Smoking Cessation
244276|NCT01745393|Secondhand Smoke
244277|NCT01745393|Passive Smoking
244278|NCT01745393|Cotinine
244279|NCT01745393|Nicotine Replacement Products
244280|NCT01745380|operative
244281|NCT01745380|dental procedure
244282|NCT01745367|Tivozanib hydrochloride
244283|NCT01745367|triple negative breast cancer
244284|NCT01745367|paclitaxel
244285|NCT01745367|pharmacokinetics
244286|NCT01745367|biomarkers
244287|NCT01745367|metastatic breast cancer
244288|NCT01745367|mBC
244289|NCT01745367|TNBC
244290|NCT01745328|recurrent urinary tract infection
244291|NCT01745328|antibiotics
244292|NCT01745328|traditional chinese medicine
244293|NCT01745315|total laparoscopic hysterectomy
244294|NCT01745315|LigaSure
244295|NCT01745315|EnSeal
244296|NCT01745315|Halo PKS Cutting forceps
244297|NCT01745315|electrothermal bipolar vessel sealer
244298|NCT01745315|advanced bipolar device
244299|NCT01745302|lung cancer
244300|NCT01745302|traditional Chinese medicine
244301|NCT01745302|EGFR-TKI
244302|NCT01745289|Breast Cancer
244303|NCT01745289|Survival
244304|NCT01745289|Recurrence
244305|NCT01745276|Pin fixation
244306|NCT01745276|Osteotomy
244307|NCT01745276|hemicallotasis
244308|NCT01745250|lip
244309|NCT01745250|fillers
244310|NCT01745250|Hyaluronic acid
244311|NCT01745237|Sarcoidosis
244312|NCT01745237|Cardiac Magnetic Resonance
244313|NCT01745198|homocysteinemia
244314|NCT01745198|dementia
244315|NCT01745198|depression
244316|NCT01745198|vitamin B12
244317|NCT01745198|folate
244318|NCT01745198|mild cognitive impairment
244319|NCT01745198|alzheimer's
244320|NCT01745198|homocysteine
244321|NCT01745185|Fabry Disease
244322|NCT01745185|immunity
244323|NCT01745185|antibody
244324|NCT01745159|tacrolimus
244325|NCT01745159|Protopic
244326|NCT01745159|pediatric
244327|NCT01745159|atopic dermatitis
244328|NCT01745159|China
244329|NCT01745146|traumatic brain injury
244330|NCT01745146|TBI
244331|NCT01745146|head injury
244332|NCT01745146|brain injury
244333|NCT01745146|Psych-educational treatment
244334|NCT01745146|Anger
244335|NCT01745146|irritability
244336|NCT01745146|anger management
244337|NCT01745133|Olux E foam
244338|NCT01745133|Sorilux foam
244339|NCT01745120|gene therapy
244340|NCT01745120|beta thalassemia
244341|NCT01745120|hemoglobin
244342|NCT01745120|anemia
244343|NCT01745120|CD34
244344|NCT01745107|T2-3N0M0 disease of esophageal neoplasm
244345|NCT01745107|postoperative radiotherapy
244346|NCT01745107|intensity modulated radiation therapy
244347|NCT01745107|survival
244348|NCT01745094|mirabegron
244349|NCT01745094|solifenacin
244350|NCT01745068|fragility fracture
244351|NCT01745068|osteoporosis
244352|NCT01745068|fall prevention
244353|NCT01745068|integrated program
244354|NCT01745068|interorganizational collaboration
244355|NCT01745068|Canada
244356|NCT01745068|controlled clinical trial
244357|NCT01745068|evaluation
244358|NCT01745055|Pharmacokinetics
244359|NCT01745055|oral JAK inhibitor
244360|NCT01745055|methotrexate (MTX)
244361|NCT01745055|rheumatoid arthritis (RA)
244362|NCT01745042|Postmenopausal Women
244363|NCT01745042|Body Composition
244364|NCT01745042|Metabolic Syndrome
244365|NCT01745042|Menopause Symptoms
244366|NCT01745029|Gastrointestinal Motility
244367|NCT01745029|Inflammatory Bowel Disease
244368|NCT01745029|Transit time
244369|NCT01745016|dietary supplement
244370|NCT01745016|carnosine
244371|NCT01745003|Fibromyalgia
244372|NCT01744990|Nuts
244373|NCT01744990|allergy
244374|NCT01744990|Oral food challenge
244375|NCT01744990|skin testing
244376|NCT01744990|basophil activation tests
244377|NCT01744990|specific IgE's
244378|NCT01744964|apomorphine
244379|NCT01744964|dopamine transporter gene
244380|NCT01744964|SLC6A3
244381|NCT01744964|cold pressor test
244382|NCT01744964|tolerance
244383|NCT01744964|experimental pain
244384|NCT01744964|dopamine agonist
244385|NCT01744951|Adoption
244386|NCT01744951|Foster care
244387|NCT01744951|Substance abuse
244388|NCT01744951|Older children
244389|NCT01744951|Mental health
244390|NCT01744938|Postoperative Complications,
244391|NCT01744938|mortality,
244392|NCT01744938|length of Stay,
244393|NCT01744938|economics
244394|NCT01744912|Lymphoma
244395|NCT01744912|monoclonal antibody
244396|NCT01744912|immunomodulatory agent
244397|NCT01744912|ublituximab
244398|NCT01744912|lenalidomide
244399|NCT01744899|Lumbosacral spine
244400|NCT01744899|Nerve roots
244401|NCT01744899|Sitting
244402|NCT01744899|H-reflex
244403|NCT01744886|One-Lung Ventilation
244404|NCT01744886|Thoracic Surgical Procedures
244405|NCT01744886|Cardiac Surgical Procedures
244406|NCT01744834|Reward-based learning
244407|NCT01744834|Pavlovian-to-instrumental transfer
244408|NCT01744834|Functional imaging
244409|NCT01744834|alcohol use disorder risk
244410|NCT01744821|High Risk
244411|NCT01744808|Healthy
244412|NCT01744808|Normal
244413|NCT01744795|cardiac output
244414|NCT01744795|thermodilution
244415|NCT01744795|esophageal doppler
244416|NCT01744795|trending ability
244417|NCT01744782|Nephropathic Cystinosis
244418|NCT01744782|Cysteamine
244419|NCT01744782|Delayed-release Cysteamine
244420|NCT01744782|CTNS Protein, Human
244421|NCT01744782|Orphan Disease
244422|NCT01744769|thyroid cancer
244423|NCT01744769|hypothyroidism
244424|NCT01744769|metabolic parameters
244425|NCT01744769|Hypothyroidism after levothyroxine withdrawal
244426|NCT01744756|Subconjunctival Bevacizumab
244427|NCT01744756|Recurrent pterygium
244428|NCT01744743|preconception
244429|NCT01744743|hypothyroidism
244430|NCT01744743|neurocognitive development
244431|NCT01744730|Bacterial infections
244432|NCT01744730|Obesity
244433|NCT01744730|pharmacokinetics
244434|NCT01744730|clindamycin
244435|NCT01744717|Pain
244436|NCT01744717|mechanical ventilation
244437|NCT01744717|uncommunicative
244438|NCT01744717|Adult ICU patients pain
244439|NCT01744704|Nerve Growth Factor
244440|NCT01744704|Ophthalmic Solutions
244441|NCT01744704|Eye Drops
244442|NCT01744704|rh-NGF
244443|NCT01744691|CLL
244444|NCT01744691|SLL
244445|NCT01744665|CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl
244446|NCT01744652|Advanced Cancers
244447|NCT01744652|Advanced Malignancies
244448|NCT01744652|Unresectable
244449|NCT01744652|Metastatic
244450|NCT01744652|Crizotinib
244451|NCT01744652|PF-02341066
244452|NCT01744652|Xalkori
244453|NCT01744652|Dasatinib
244454|NCT01744652|BMS-354825
244455|NCT01744652|Sprycel
244456|NCT01744639|Hepatocellular carcinoma
244457|NCT01744639|Radioablation
244458|NCT01744626|Chronic Lymphocytic Leukemia
244459|NCT01744626|Small Lymphocytic Lymphoma
244460|NCT01744613|Clopidogrel
244461|NCT01744613|platelet inhibition
244462|NCT01744613|antiplatelet therapy
244463|NCT01744613|peripheral arterial disease
244464|NCT01744613|endovascular treatment
244465|NCT01744613|angioplasty
244466|NCT01744613|stenting
244467|NCT01744600|Dementia
244468|NCT01744600|Music Therapy
244469|NCT01744587|EBV
244470|NCT01744587|EGCG
244471|NCT01744561|Exercise
244472|NCT01744561|Motivation
244473|NCT01744561|Feedback
244474|NCT01744561|web-based diary
244475|NCT01744561|pedometer
244476|NCT01744535|smartphone
244477|NCT01744535|smartphone app
244478|NCT01744535|smartphone application
244479|NCT01744535|obesity
244480|NCT01744535|overweight
244481|NCT01744535|self monitoring
244482|NCT01744496|Parkinson's Disease
244483|NCT01744496|Rotigotine
244484|NCT01744496|Chronic Pain
244485|NCT01744496|Nonmotor symptoms
244486|NCT01744483|pneumonia
244487|NCT01744483|endotracheal intubation
244488|NCT01744470|Renal
244489|NCT01744470|Transplantation
244490|NCT01744470|Tacrolimus
244491|NCT01744457|tear film osmolarity
244492|NCT01744457|objective scattering index
244493|NCT01744457|tear break up time
244494|NCT01744457|Schirmer I test
244495|NCT01744418|ESRD
244496|NCT01744418|HEMODIALYSIS
244497|NCT01744418|CHRONIC RENAL INSUFFICIENCY
244498|NCT01744418|Renal Dialysis
244499|NCT01744418|Hemodiafiltration
244500|NCT01744418|Blood Vessel Prosthesis
244501|NCT01744418|Tissue-Engineered Vascular Graft
244502|NCT01744418|Vascular Prosthesis Implantation
244503|NCT01744405|Chagas disease
244504|NCT01744405|lactation
244505|NCT01744405|breastmilk
244506|NCT01744405|postpartum period
244507|NCT01744405|infants
244508|NCT01744405|pediatric clinical pharmacology
244509|NCT01744405|developmental clinical pharmacology
244510|NCT01744405|parasitology
244511|NCT01744405|trypanosoma cruzi
244512|NCT01744405|nifurtimox
244513|NCT01744353|newly diagnosed
244514|NCT01744353|advanced pancreatic cancer
244515|NCT01744353|pancreatic cancer
244516|NCT01744353|metastatic pancreatic cancer
244517|NCT01744353|pancreas
244518|NCT01744340|Head and Neck
244519|NCT01744340|Colon
244520|NCT01744314|Elbow trauma,Heterotopic Ossification,Indomethacin, Prophylaxis
244521|NCT01744301|Seizure
244522|NCT01744301|Acid-suppressing drugs
244523|NCT01744301|Epidemiology
244524|NCT01744288|Phase 1 Safety ,
244525|NCT01744288|pharmacodynamic,
244526|NCT01744288|Ticagrelor,
244527|NCT01744288|Clopidogrel,
244528|NCT01744288|Platelets
244529|NCT01744275|Epilepsy
244530|NCT01744275|Omega 3 fatty acids
244531|NCT01744262|intraocular pressure, total intravenous anesthesia, laparoscopic prostatectomy
244532|NCT01744249|carcinoid tumor
244533|NCT01744249|axitinib
244534|NCT01744236|GLP-1 Receptor Agonists, DPP-4 inhibitors
244535|NCT01744223|iCaspase9
244536|NCT01744223|iCasp9
244537|NCT01744223|Inducible Caspase
244538|NCT01744223|AP1903
244539|NCT01744223|Dimerizer drug
244540|NCT01744223|T depleted
244541|NCT01744223|Suicide gene
244542|NCT01744223|CD-34 selection
244543|NCT01744223|haplotransplantation
244544|NCT01744223|Graft versus host disease
244545|NCT01744223|Allogenic transplantation
244546|NCT01744197|Pain control
244547|NCT01744197|Needle stick pain
244548|NCT01744197|Venipuncture pain
244549|NCT01744184|gastroscopy
244550|NCT01744184|diagnostic
244551|NCT01744184|entonox
244552|NCT01744158|cerebral palsy
244553|NCT01744158|spasticity
244554|NCT01744158|dystonia
244555|NCT01744158|hypertonia
244556|NCT01744158|register
244557|NCT01744158|motor function
244558|NCT01744132|eye care utilization
244559|NCT01744132|ophthalmology
244560|NCT01744132|educational intervention
244561|NCT01744132|public health screening
244562|NCT01744093|HIV
244563|NCT01744093|COPD
244564|NCT01744093|Chronic Obstructive Pulmonary Disease
244565|NCT01744093|Emphysema
244566|NCT01744080|Rotator cuff
244567|NCT01744067|Renal transplantation
244568|NCT01744067|Interventional study
244569|NCT01744067|Glomerular filtration rate
244570|NCT01744067|Renal function
244571|NCT01744067|Proteinuria
244572|NCT01744067|Cardiovascular risk markers
244573|NCT01744067|Blood pressure
244574|NCT01744067|Flow mediated vasodilation
244575|NCT01744067|Heart rate variability
244576|NCT01744067|Pulse wave velocity
244577|NCT01744067|Lipids
244578|NCT01744067|Blood glucose
244579|NCT01744067|Bone mineral density
244580|NCT01744067|Body composition
244581|NCT01744067|Fat distribution
244582|NCT01744067|Body mass index
244583|NCT01744067|Fatty acid composition
244584|NCT01744067|Tacrolimus pharmacokinetics
244585|NCT01744067|Omega-3 fatty acids
244586|NCT01744067|Marine n-3 fatty acids
244587|NCT01744067|Fatty acids
244588|NCT01744067|Gas chromatography
244589|NCT01744067|Interstitial fibrosis
244590|NCT01744067|Inflammation
244591|NCT01744041|depression
244592|NCT01744041|pregnancy
244593|NCT01744041|postpartum
244594|NCT01744041|psychotherapy
244595|NCT01744028|COPD, remote patient monitoring, Hub, exacerbations, EXACT
244596|NCT01744015|Low back pain
244597|NCT01744002|Shoulder, Impingement syndrome, Neck
244598|NCT01743976|neuropathic pain
244599|NCT01743976|diabetic neuropathy
244600|NCT01743976|neuropathic pain after back surgery
244601|NCT01743963|efficacy
244602|NCT01743963|glucocorticoid
244603|NCT01743950|Glioblastoma
244604|NCT01743950|anaplastic glioma
244605|NCT01743937|Ischemic preconditioning
244606|NCT01743937|Ticagrelor
244607|NCT01743937|Antiplatelet therapy
244608|NCT01743937|Acute coronary syndrome
244735|NCT01743430|mobility
244609|NCT01743924|Broccoli; Isothiocyanates; Pharmacokinetics; Sulforaphane; Myrosinase
244610|NCT01743911|Tadalafil
244611|NCT01743911|Resistant Hypertension
244612|NCT01743911|Left Ventricle Diastolic Dysfunction
244613|NCT01743911|Brain natriuretic peptide
244614|NCT01743885|Hemangioma
244615|NCT01743885|Beta-blocker
244616|NCT01743885|Acebutolol
244617|NCT01743885|Propranolol
244618|NCT01743885|Randomized controlled trial
244619|NCT01743885|Infants
244620|NCT01743872|Optical Coherence Tomography
244621|NCT01743872|Contrast
244622|NCT01743872|Dextran
244623|NCT01743872|Carbon Dioxide
244624|NCT01743872|Imaging
244625|NCT01743872|Catheter
244626|NCT01743872|Lower Extremity Artery
244627|NCT01743859|Myeloid
244628|NCT01743859|Leukemia
244629|NCT01743807|Relapsed
244630|NCT01743807|Minimal Residual Disease
244631|NCT01743807|MRD
244632|NCT01743807|Acute Lymphoblastic Leukemia
244633|NCT01743807|Acute Myelogenous Leukemia
244634|NCT01743807|ALL
244635|NCT01743807|AML
244636|NCT01743807|GNKG168
244637|NCT01743807|Pediatric
244638|NCT01743807|Childhood
244639|NCT01743781|comprehensive eye examination
244640|NCT01743781|acceptance
244641|NCT01743781|glaucoma
244642|NCT01743781|diabetic retinopathy
244643|NCT01743768|Antisense oligonucleotide
244644|NCT01743768|Asthma
244645|NCT01743768|Healthy subjects
244646|NCT01743768|Phase 1
244647|NCT01743768|Transcription factor GATA-3
244648|NCT01743768|Oral inhalation
244649|NCT01743755|Community-acquired pneumonia
244650|NCT01743755|Dexamethasone
244651|NCT01743755|Corticosteroid
244652|NCT01743742|Oral vitamin E and vitamin C
244653|NCT01743729|SAR 1118
244654|NCT01743716|Major Depressive Disorder
244655|NCT01743716|MDD
244656|NCT01743716|depression
244657|NCT01743716|adolescent
244658|NCT01743703|traumatic injuries
244659|NCT01743703|Whole-body MRI
244660|NCT01743703|Skeletal survey
244661|NCT01743703|Children
244662|NCT01743703|Diagnostic
244663|NCT01743690|Probiotic
244664|NCT01743690|Candida
244665|NCT01743690|Oral Lichen Planus
244666|NCT01743677|TQT study
244667|NCT01743677|CP-690,550
244668|NCT01743664|Posttraumatic Stress Disorders
244669|NCT01743664|Multiple Sclerosis
244670|NCT01743664|Eye Movement Desensitization Reprocessing
244671|NCT01743664|Psychotherapy
244672|NCT01743664|Anxiety
244673|NCT01743664|Depression
244674|NCT01743664|Quality of Life
244675|NCT01743651|spasticity
244676|NCT01743651|multiple sclerosis
244677|NCT01743651|arbaclofen
244678|NCT01743612|healthy subject
244679|NCT01743612|hand blood flow
244680|NCT01743612|laser speckle contrast imaging
244681|NCT01743586|Lung cancer
244682|NCT01743586|Chest physiotherapy
244683|NCT01743586|Respiratory muscle strength
244684|NCT01743586|Dyspnea, Functional capacity
244685|NCT01743586|Quality of life
244686|NCT01743560|Breast Neoplasms
244687|NCT01743560|Neoplasms
244688|NCT01743560|Breast diseases
244689|NCT01743560|Skin diseases
244690|NCT01743560|Exemestane
244691|NCT01743560|Antibiotics, Antineoplastic
244692|NCT01743560|Everolimus
244693|NCT01743560|Antineoplastic Agents
244694|NCT01743560|Therapeutic Uses
244695|NCT01743560|Pharmacologic Actions
244696|NCT01743560|Immunosuppressive Agents
244697|NCT01743560|Physiological Effects of Drugs
244698|NCT01743560|Aromatase Inhibitors
244699|NCT01743560|Enzyme Inhibitors
244700|NCT01743560|Molecular Mechanisms of Pharmacological Action
244701|NCT01743547|Women
244702|NCT01743547|Yoga
244703|NCT01743547|Ovarian Cancer
244704|NCT01743547|Lifestyle
244705|NCT01743521|Hepatitis C
244706|NCT01743521|Individualised therapy
244707|NCT01743521|Response-guided therapy
244708|NCT01743521|Telaprevir
244709|NCT01743521|PEG-IFN
244710|NCT01743521|Ribavirin
244711|NCT01743521|Hepatitis
244712|NCT01743508|incomplete abortion
244713|NCT01743508|misoprostol treatment
244714|NCT01743508|midwife
244715|NCT01743508|uganda
244716|NCT01743495|Medical Costs
244717|NCT01743495|improved IADLs
244718|NCT01743495|and/or ADL's
244719|NCT01743495|decreased nursing home admissions
244720|NCT01743482|Testicular Cancer
244721|NCT01743482|Germ Cell Tumors
244722|NCT01743482|Salvage Therapy
244723|NCT01743482|Pazopanib
244724|NCT01743456|Postoperative cognitive dysfunction
244725|NCT01743456|Coronary artery bypass graft surgery
244726|NCT01743456|Postoperative cognitive improvement
244727|NCT01743456|Postoperative delirium
244728|NCT01743443|Corneal sensitivity
244729|NCT01743443|Cross-linking
244730|NCT01743443|Keratoconus
244731|NCT01743430|telerehabilitation
244732|NCT01743430|stroke
244733|NCT01743430|Berg balance scale
244734|NCT01743430|stroke impact scale
244736|NCT01743417|Cognitive rehabilitation
244737|NCT01743417|malaria
244738|NCT01743417|neuropsychology
244739|NCT01743417|attention
244740|NCT01743417|working memory
244741|NCT01743404|atherosclerosis
244742|NCT01743404|inflammation
244743|NCT01743404|intima-media thickness
244744|NCT01743391|IVF treatment
244745|NCT01743391|Office-hysteroscopy
244746|NCT01743391|Endometrial biopsy
244747|NCT01743352|Large arteries
244748|NCT01743352|stiffness
244749|NCT01743352|intima media thickness
244750|NCT01743352|ultrasound imaging
244751|NCT01743339|Randomized Controlled Trial
244752|NCT01743339|Cognitive Therapy
244753|NCT01743339|Stress Disorders, Post-Traumatic
244754|NCT01743339|Depression
244755|NCT01743339|Sleep
244756|NCT01743326|Zygapophyseal Joint
244757|NCT01743313|glucose metabolism disorders
244758|NCT01743313|metabolic syndrome
244759|NCT01743313|joint replacement
244760|NCT01743313|osteoarthritis
244761|NCT01743300|sunitinib
244762|NCT01743300|pharmacokinetics
244763|NCT01743300|phenotyping
244764|NCT01743300|interaction
244765|NCT01743287|osteoarthritis of the knee
244766|NCT01743274|acute coronary syndromes
244767|NCT01743274|non-ST elevation myocardial infarction
244768|NCT01743274|angioplasty
244769|NCT01743274|fractional flow reserve
244770|NCT01743274|optical coherence tomography
244771|NCT01743261|severe brain injury
244772|NCT01743261|graded intensive rehabilitation
244773|NCT01743248|vestibular schwannoma
244774|NCT01743248|balance
244775|NCT01743248|psychological factors
244776|NCT01743235|HSDD
244777|NCT01743209|androgen antagonists
244778|NCT01743196|Folic acid
244779|NCT01743196|Folate
244780|NCT01743196|Pharmacokinetics
244781|NCT01743196|Women of Child Bearing Age
244782|NCT01743183|hypertension
244783|NCT01743170|Blood pressure control
244784|NCT01743170|Hypertension
244785|NCT01743170|Office blood pressure
244786|NCT01743170|Self-measured blood pressure
244787|NCT01743170|Telemonitoring
244788|NCT01743144|emergence agitation in children
244789|NCT01743144|sevoflurane
244790|NCT01743144|general anesthesia
244791|NCT01743144|magnesium sulphate
244792|NCT01743105|diaphragm movement
244793|NCT01743105|ultrasound
244794|NCT01743105|emergency room
244795|NCT01743092|Pathological gambling
244796|NCT01743092|treatment
244797|NCT01743092|online counselling
244798|NCT01743092|webinar
244799|NCT01743092|workbook
244800|NCT01743079|Telbivudine
244801|NCT01743079|Lamivudine
244802|NCT01743079|safety
244803|NCT01743079|efficacy
244804|NCT01743079|pregnancy
244805|NCT01743066|Arsenic
244806|NCT01743066|Arsenicosis
244807|NCT01743066|Buccal cells
244808|NCT01743066|Serum
244809|NCT01743066|Vitamin E
244810|NCT01743066|Cholesterol
244811|NCT01743040|Coronary Artery Disease
244812|NCT01743040|Nuclear Stress Test
244813|NCT01743040|CT Angiography
244814|NCT01743040|Angiography
244815|NCT01743027|Allergic conjunctivitis
244816|NCT01743027|Olopatadine HCl solution
244817|NCT01743027|Conjunctival Allergen Challenge
244818|NCT01743027|Itching eyes
244819|NCT01743027|Ocular allergies
244820|NCT01743027|PATADAY
244821|NCT01743027|PATANOL
244822|NCT01743014|diabetes
244823|NCT01743014|diabetic nephropathy
244824|NCT01743014|vascular inflammation
244825|NCT01743014|oxidative stress
244826|NCT01743014|endothelial dysfunction
244827|NCT01743014|Asymmetric dimethylarginine
244828|NCT01743014|High sensitivity CRP
244829|NCT01743014|albumine to creatinine ratio
244830|NCT01743014|isoprostane
244831|NCT01743014|clopidogrel
244832|NCT01743014|ramipril
244833|NCT01743014|carotid intima media thickness
244834|NCT01743001|exercise capacity
244835|NCT01743001|Eisenmenger Syndrome
244836|NCT01742988|PI3K
244837|NCT01742988|HDAC
244838|NCT01742988|Open-Label
244839|NCT01742988|Dose-Escalation
244840|NCT01742962|Prostatectomy
244841|NCT01742962|Prostate cancer
244842|NCT01742962|Orgasm
244843|NCT01742962|Urinary incontinence
244844|NCT01742962|Climacturia(orgasm related urinary incontinence)
244845|NCT01742962|Penis
244846|NCT01742962|Dysorgasmia (pain in relation to orgasm)
244847|NCT01742962|Pain
244848|NCT01742962|Anorgasmia
244849|NCT01742962|Penile shortening
244850|NCT01742962|Erectile dysfunction
244851|NCT01742923|hypertension
244852|NCT01742923|medication adherence
244853|NCT01742923|motivational interviewing
244854|NCT01742897|Osteoarthritis, Knee
244855|NCT01742897|Transdermal therapeutic system (TTS) fentanyl
244856|NCT01742897|Durogesic
244857|NCT01742884|Dry Eye Syndrome
244858|NCT01742871|Antivitamin K
244859|NCT01742871|Bleeding
244860|NCT01742871|Haemorrhage
244861|NCT01742871|Nutritional status
244862|NCT01742871|impedancemetry
244863|NCT01742845|Ultrasound-guided
244864|NCT01742845|regional anaesthesia
244865|NCT01742845|Cervical block
244866|NCT01742832|Vilazodone
244867|NCT01742832|Citalopram
244868|NCT01742832|Major Depressive Disorder
244869|NCT01742819|Glaucoma, Optical Coherence Tomography, Progression
244870|NCT01742806|Gastric cancer
244871|NCT01742806|Minimally invasive surgery
244872|NCT01742806|Distal gastrectomy
244873|NCT01742806|Bio-absorbable Felt
244874|NCT01742793|relapsed /refractory Hodgkin lymphoma
244875|NCT01742793|mature T-cell lymphoma
244876|NCT01742793|multiple myeloma
244877|NCT01742780|Intraosseous Vascular Access
244878|NCT01742780|IO Access
244879|NCT01742780|IO Vascular Access
244880|NCT01742780|EZ-IO
244881|NCT01742767|NSCLC; split dose Cisplatinum; Pemetrexed
244882|NCT01742741|Diabetes Mellitus, Type 1 (T1DM)
244883|NCT01742741|Continuous Glucose Monitor (CGM)
244884|NCT01742741|Artificial Pancreas (AP)
244885|NCT01742741|Insulin Pump
244886|NCT01742741|Closed Loop Control (CLC)
244887|NCT01742741|Open Loop treatment
244888|NCT01742741|Diabetes Assistant
244889|NCT01742741|DiAs
244890|NCT01742728|oxidative stress, antioxidant, periodontitis, serum immunoglobulin G
244891|NCT01742728|antibody titer
244892|NCT01742715|ARDS
244893|NCT01742715|Lung compliance
244894|NCT01742702|Blood pressure
244895|NCT01742702|Hypertension
244896|NCT01742702|Arterial stiffness
244897|NCT01742702|Cardiac output
244898|NCT01742702|Vascular resistance
244899|NCT01742702|Pulse wave reflection
244900|NCT01742702|Head-up tilt
244901|NCT01742689|Renal colic
244902|NCT01742689|Pain
244903|NCT01742689|Desmopressin
244904|NCT01742689|Urinary obstruction
244905|NCT01742689|Indomethacin
244906|NCT01742676|tacrolimus
244907|NCT01742676|kidney
244908|NCT01742663|Diclofenac Sodium Gel 3%
244909|NCT01742663|Solaraze® (diclofenac sodium) Gel 3%
244910|NCT01742663|Actinic Keratosis
244911|NCT01742650|ankle; fracture; syndesmosis;
244912|NCT01742637|Acne Vulgaris
244913|NCT01742637|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%
244914|NCT01742637|Epiduo®
244915|NCT01742624|immunosuppressant
244916|NCT01742624|new-onset diabetes after kidney transplantation
244917|NCT01742624|NODAT
244918|NCT01742611|CKD
244919|NCT01742611|Not on dialysis
244920|NCT01742611|ASP1585
244921|NCT01742611|Bixalomer
244922|NCT01742598|TAVI
244923|NCT01742598|TAVR
244924|NCT01742598|aortic stenosis
244925|NCT01742598|Transcatheter
244926|NCT01742598|valvular heart disease
244927|NCT01742598|aortic valve stenosis
244928|NCT01742598|aortic valve replacement
244929|NCT01742598|transcatheter aortic valve implantation
244930|NCT01742585|CKD
244931|NCT01742585|Not on dialysis
244932|NCT01742585|ASP1585
244933|NCT01742585|Bixalomer
244934|NCT01742572|weight loss
244935|NCT01742572|obesity
244936|NCT01742572|overweight
244937|NCT01742572|diet
244938|NCT01742559|Treatment
244939|NCT01742546|myofascial pain syndrome
244940|NCT01742546|therapeutic ultrasound
244941|NCT01742546|combine therapy
244942|NCT01742533|Hormone Replacement Therapy，
244943|NCT01742533|Premature Ovarian Failure，
244944|NCT01742533|Stem Cell Therapy
244945|NCT01742520|Preterm infant
244946|NCT01742520|pain
244947|NCT01742520|neurodevelopment
244948|NCT01742507|Stent, OCT
244949|NCT01742494|Esophageal Achalasia,
244950|NCT01742494|Peroral endoscopic myotomy,
244951|NCT01742494|Water-jet assisted
244952|NCT01742481|childhood cancer survivors
244953|NCT01742481|long-term follow-up care
244954|NCT01742481|health communication
244955|NCT01742481|ethnic/racial minorities
244956|NCT01742481|longterm survivors
244957|NCT01742468|n-3 LC-PUFA, DHA, rheumatoid arthritis
244958|NCT01742455|Peripheral artery disease
244959|NCT01742455|Arterial Occlusive Diseases
244960|NCT01742455|Vascular Diseases
244961|NCT01742455|Cardiovascular Diseases
244962|NCT01742455|Coronary Artery Disease
244963|NCT01742455|Myocardial Ischemia
244964|NCT01742455|Arteriosclerosis
244965|NCT01742455|Pathologic Processes
244966|NCT01742442|Cancer
244967|NCT01742442|elderly OR older
244968|NCT01742442|chemotherapy
244969|NCT01742442|geriatric assessment
244970|NCT01742429|Helicobacter pylori
244971|NCT01742429|second line treatment
244972|NCT01742416|Arterial Cannulation
244973|NCT01742416|Ultrasound
244974|NCT01742416|Palpation Method
244975|NCT01742416|Pediatrics
244976|NCT01742416|Cardiac Surgery
244977|NCT01742416|Craniotomies
244978|NCT01742416|Cranial Vault Surgery
244979|NCT01742416|Abdominal Procedures
244980|NCT01742403|Prostate
244981|NCT01742403|IGRT
244982|NCT01742403|VMAT
244983|NCT01742390|schizophrenia
244984|NCT01742390|risperidone
244985|NCT01742390|paliperidone
244986|NCT01742390|aripiprazole
244987|NCT01742377|GERD
244988|NCT01742377|Dyspepsia
244989|NCT01742377|Ambulatory 24-hour Esophageal pH Monitoring
244990|NCT01742377|Minimal change erosions
244991|NCT01742364|disposable syringe jet injector (DSJI)
244992|NCT01742364|DSJI
244993|NCT01742364|BCG
244994|NCT01742364|tuberculosis
244995|NCT01742364|intradermal delivery
244996|NCT01742364|South Africa
244997|NCT01742338|Chronic Obstructive Pulmonary Disease
244998|NCT01742338|COPD
244999|NCT01742338|Chronic bronchitis
245000|NCT01742338|emphysema
245001|NCT01742338|Corticosteroids
245002|NCT01742325|fatigue
245003|NCT01742325|walking
245004|NCT01742325|childhood cancer
245005|NCT01742325|sleep disturbance
245006|NCT01742312|neoadjuvant chemotherapy
245007|NCT01742312|oesophageal cancer
245008|NCT01742312|cardiorespiratory performance
245009|NCT01742299|Glivec/Gleevec
245010|NCT01742299|CML
245011|NCT01742299|GIST
245012|NCT01742299|Imatinib mesylate
245013|NCT01742286|pediatric, anaplastic lymphoma kinase, ALK-activated tumors, neuroblastoma, rhabdomyosarcoma, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor
245014|NCT01742260|Cranioplasty
245015|NCT01742260|Mesenchymal stromal cells
245016|NCT01742260|Bioceramic polymer
245017|NCT01742247|Moisturizer, laser
245018|NCT01742221|Safety and Tolerability, Cytokines, Acute Radiation Syndrome, Hematopoietic Syndrome, Radiation Countermeasure
245019|NCT01742195|Endobronchial ultrasound
245020|NCT01742195|Bronchoscopy
245021|NCT01742195|Patient satisfaction
245022|NCT01742182|Parkinson's Disease
245023|NCT01742182|Excessive Daytime Sleepiness
245024|NCT01742182|Circadian Rhythms
245025|NCT01742182|Light Therapy
245026|NCT01742169|Colorectal Cancer Screening
245027|NCT01742169|Fecal Occult Blood Testing
245028|NCT01742156|CAD
245029|NCT01742156|microangiopathy
245030|NCT01742156|patients
245031|NCT01742156|more likely
245032|NCT01742156|to have tortuosity
245033|NCT01742156|of conjunctival vessels
245034|NCT01742143|Quality of life
245035|NCT01742143|cancer
245036|NCT01742143|12-223
245037|NCT01742130|Contrast-induced nephropathy
245038|NCT01742130|Contrast media
245039|NCT01742130|Angiography
245040|NCT01742130|Coronary percutaneous intervention
245041|NCT01742117|percutaneous coronary intervention
245042|NCT01742117|angioplasty
245043|NCT01742104|glaucoma
245044|NCT01742104|primary open-angle glaucoma
245045|NCT01742104|observational study
245046|NCT01742104|quality of life
245047|NCT01742091|Postmenopausal females
245048|NCT01742091|Volunteers
245049|NCT01742078|Postmenopausal females
245050|NCT01742078|Volunteers
245051|NCT01742065|Colorectal Cancer Screening
245052|NCT01742065|Cancer Screening
245053|NCT01742065|Pragmatic Trial
245054|NCT01742052|relapsing-remitting multiple sclerosis
245055|NCT01742052|RRMS
245056|NCT01742026|High risk aspergillosis infection patients
245057|NCT01742013|Chronic Fatigue
245058|NCT01742013|CFS
245059|NCT01742013|ICF
245060|NCT01742013|human placenta
245061|NCT01742000|postmenopause
245062|NCT01742000|phytoestrogen
245063|NCT01742000|atherosclerosis
245064|NCT01742000|intima-media thickness
245065|NCT01741974|perimenopause
245066|NCT01741974|phytoestrogen
245067|NCT01741974|atherosclerosis
245068|NCT01741974|intima-media thickness
245069|NCT01741961|uncontrolled glaucoma
245070|NCT01741961|glaucoma drainage device
245071|NCT01741948|Provoked vestibulodynia
245072|NCT01741948|Hormonal contraceptives
245073|NCT01741922|Low dose
245074|NCT01741922|aspirin
245075|NCT01741922|ASA
245076|NCT01741922|Hypertension
245077|NCT01741922|blood pressure
245078|NCT01741909|azythromycin
245079|NCT01741909|community acquired pneumonia
245080|NCT01741909|intravenous
245081|NCT01741909|oral
245082|NCT01741883|Randomized Controlled Trial
245083|NCT01741883|Patients´ Expectations
245084|NCT01741883|Breast Cancer
245085|NCT01741883|Adjuvant Endocrine Treatment
245086|NCT01741883|Nocebo
245087|NCT01741870|Nutritional supplement
245088|NCT01741870|Nutritional status
245089|NCT01741870|Physical functional activity
245090|NCT01741870|Nursing home elderly
245091|NCT01741844|Acquired Immune Deficiency Syndrome
245092|NCT01741844|TMC125
245093|NCT01741844|Etravirine
245094|NCT01741844|Intelence
245095|NCT01741844|AIDS
245096|NCT01741831|Acquired Immune Deficiency Syndrome
245097|NCT01741831|AIDS
245098|NCT01741831|TMC114
245099|NCT01741831|Darunavir
245100|NCT01741831|Prezista
245101|NCT01741818|IVC
245102|NCT01741818|ultrasonography
245103|NCT01741818|IVC collapsibility index
245104|NCT01741818|IVC diameter
245105|NCT01741792|Relapsed DLBCL
245106|NCT01741792|Refractory DLBCL
245107|NCT01741792|adult DLBCL
245108|NCT01741792|Lymphoma
245109|NCT01741792|Non-Hodgkin Lymphoma
245110|NCT01741792|Lymphatic diseases
245111|NCT01741792|Lymphoproliferative disorders
245112|NCT01741792|bispecific antibody
245113|NCT01741792|anti-CD19
245114|NCT01741792|Immunotherapeutic treatment
245115|NCT01741792|Immunoproliferative disorders
245116|NCT01741779|whole body vibration training
245117|NCT01741779|hypocaloric diet
245118|NCT01741779|prehypertension
245119|NCT01741779|hypertension
245120|NCT01741779|obesity
245121|NCT01741779|arterial function
245122|NCT01741779|arterial stiffness
245123|NCT01741779|pulse wave velocity
245124|NCT01741779|autonomic function
245125|NCT01741779|endothelial function
245126|NCT01741779|adipocytokines
245127|NCT01741766|prehypertension
245128|NCT01741766|hypertension
245129|NCT01741766|obesity
245130|NCT01741766|stretching
245131|NCT01741766|arterial function
245132|NCT01741766|arterial stiffness
245133|NCT01741766|pulse wave velocity
245134|NCT01741766|autonomic function
245135|NCT01741766|endothelial function
245136|NCT01741753|Docetaxel Pretreated
245137|NCT01741753|Castrate Resistant
245138|NCT01741753|Metastatic
245139|NCT01741740|pain, hernia, chronic, discomfort, retrospective
245140|NCT01741675|Questionnaires
245141|NCT01741675|Quality of Life
245142|NCT01741675|Response rate
245143|NCT01741649|Surgical wound infection
245144|NCT01741649|Clorhexidine
245145|NCT01741649|Povidone
245146|NCT01741610|Anaesthesia Spinal
245147|NCT01741610|Ephedrine
245148|NCT01741610|Fluid Therapy
245149|NCT01741610|Hypotension
245150|NCT01741558|Myocardial Ischemia
245151|NCT01741558|Myocardial Infarction
245152|NCT01741558|Methotrexate
245153|NCT01741558|Inflammation
245154|NCT01741558|Anti-Inflammatory Agents
245155|NCT01741558|Inflammation Mediators
245156|NCT01741532|Pantothenate Kinase-associated Neurodegeneration
245157|NCT01741532|PKAN
245158|NCT01741532|NBIA
245159|NCT01741532|Deferiprone
245160|NCT01741532|Ferriprox
245161|NCT01741519|PK
245162|NCT01741519|PD
245163|NCT01741519|landiolol
245164|NCT01741519|esmolol
245165|NCT01741519|healthy volunteers phase I study
245166|NCT01741506|Lung cancer
245167|NCT01741506|Surgery
245168|NCT01741506|Thromboembolism
245169|NCT01741506|Bleeding
245170|NCT01741493|Rheumatoid Arthritis
245171|NCT01741493|Methotrexate
245172|NCT01741493|Tolerability
245173|NCT01741493|Pharmacokinetics
245174|NCT01741493|Safety
245175|NCT01741493|Tofacitinib
245176|NCT01741480|Outcomes
245177|NCT01741480|Early warning systems
245178|NCT01741480|ICU transfer
245179|NCT01741454|Tolterodine
245180|NCT01741454|Tamsulosin
245181|NCT01741454|Ureteral Obstruction
245182|NCT01741441|Duodenogastroesophageal reflux
245183|NCT01741441|Weakly acidic reflux
245184|NCT01741441|Gastric emptying
245185|NCT01741441|Laparoscopic fundoplication
245186|NCT01741428|CVD Risk score
245187|NCT01741428|Physical activity
245188|NCT01741428|Overweight
245189|NCT01741428|Cholesterol
245190|NCT01741428|LDL-Cholesterol
245191|NCT01741428|HDL-Cholesterol
245192|NCT01741428|Triglycerides
245193|NCT01741428|HbA1C
245194|NCT01741428|Quality of life
245195|NCT01741402|Control posture
245196|NCT01741402|Gait
245197|NCT01741402|Virtual Reality
245198|NCT01741402|Elderly
245199|NCT01741389|Circadian variation, hemostasis, melatonin, tetraplegia
245200|NCT01741363|iFOBT
245201|NCT01741363|one-day sample
245202|NCT01741363|two-day sample
245203|NCT01741363|Helicobacter pylori stool antigen
245204|NCT01741350|Methadone-maintenance
245205|NCT01741350|HIV
245206|NCT01741350|Risk behavior
245207|NCT01741350|Injection drug use
245208|NCT01741350|Condom use
245209|NCT01741350|Health care participation
245210|NCT01741350|Opioid replacement therapy
245211|NCT01741337|central sleep apneas syndrome
245212|NCT01741337|heart failure
245213|NCT01741337|all coronary reperfusions
245214|NCT01741337|adaptive servo-ventilation treatment
245215|NCT01741311|viral load
245216|NCT01741311|HIV
245217|NCT01741311|CD4
245218|NCT01741311|methadone maintenance
245219|NCT01741311|substance use
245220|NCT01741311|Antiretroviral therapy (ART)
245221|NCT01741298|Metabolic syndrome
245222|NCT01741285|Asthma
245223|NCT01741285|Adenosine
245224|NCT01741285|Small airways
245225|NCT01741285|Smokers
245226|NCT01741285|Ex-smokers
245227|NCT01741272|rotator cuff tear
245228|NCT01741272|arthroscopically assisted
245229|NCT01741272|health related quality of life(HRQL)
245230|NCT01741272|functional outcome
245231|NCT01741259|analgesia
245232|NCT01741259|meperidine
245233|NCT01741259|epidural
245234|NCT01741246|Episodic migraine
245235|NCT01741246|Chronic migraine
245236|NCT01741246|Magnetic resonance imaging
245237|NCT01741246|Positron emission tomography
245238|NCT01741233|SNPs
245239|NCT01741233|vitamin D
245240|NCT01741233|Vitamin D status
245241|NCT01741233|UVB irradiation
245242|NCT01741233|genetics
245243|NCT01741181|25(OH)Vitamin D
245244|NCT01741181|Diabetes mellitus
245245|NCT01741181|Endothelial Function
245246|NCT01741142|Major Depressive Disorder
245247|NCT01741129|Nasal CPAP
245248|NCT01741129|Nasal IMV
245249|NCT01741129|Surfactant
245250|NCT01741129|Preterm infants
245251|NCT01741116|castration-resistant prostate cancer
245252|NCT01741116|TKI258
245253|NCT01741116|FGF23
245254|NCT01741090|Autologous Mesenchymal stem cell
245255|NCT01741090|alcoholic liver cirrhosis
245256|NCT01741077|pregnancy
245257|NCT01741077|folic acid supplementation
245258|NCT01741077|reproduction
245259|NCT01741077|folate
245260|NCT01741064|Secondary Hyperparathyroidism
245261|NCT01741064|Renal Transplantation
245262|NCT01741064|Myocardial Infarction
245263|NCT01741064|Fracture
245264|NCT01741064|Graft Failure
245265|NCT01741051|Air pollution
245266|NCT01741051|Particulate matter
245267|NCT01741051|Mongolia
245268|NCT01741051|Pregnancy
245269|NCT01741051|Intrauterine growth restriction (IUGR)
245270|NCT01741051|Fetal growth
245271|NCT01741051|Birth weight
245272|NCT01741051|Gestational age
245273|NCT01741038|Cancer Vaccine
245274|NCT01741038|AlloStim®
245275|NCT01741038|Immunovative
245276|NCT01741038|Immunotherapy
245277|NCT01741038|Allogeneic Cell Therapy
245278|NCT01741038|Cryoablation
245279|NCT01741012|Lupus
245280|NCT01740986|Asthma
245281|NCT01740973|SILC
245282|NCT01740973|lap. cholecystectomy
245283|NCT01740973|trocar-site hernia
245284|NCT01740960|delta-9-tetrahydrocannabinol
245285|NCT01740960|THC
245286|NCT01740960|Cannabis
245287|NCT01740947|Selective decontamination of the digestive tract
245288|NCT01740947|anastomotic leakage
245289|NCT01740947|colorectal cancer
245290|NCT01740934|rosacea
245291|NCT01740934|anatabine
245292|NCT01740934|Anatabloc
245293|NCT01740934|dermatology
245294|NCT01740921|GLP-1 analogues
245295|NCT01740921|microvascular
245296|NCT01740921|inflammation
245297|NCT01740921|fat tissue
245298|NCT01740921|clot structure
245299|NCT01740908|hyperbaric oxygen
245300|NCT01740908|stem cell
245301|NCT01740882|incisional hernia
245302|NCT01740882|mesh fixation
245303|NCT01740882|absorbable tacks
245304|NCT01740869|autism
245305|NCT01740869|autism spectrum
245306|NCT01740869|stem cells
245307|NCT01740869|children
245308|NCT01740856|cardiac catheterization
245309|NCT01740856|safety
245310|NCT01740856|nursing care
245311|NCT01740856|rest
245312|NCT01740856|Patients
245313|NCT01740817|diabetes
245314|NCT01740817|obesity
245315|NCT01740817|inflammation
245316|NCT01740804|Circulating tumor cell
245317|NCT01740804|Non-small cell lung cancer
245318|NCT01740804|chemotherapy
245319|NCT01740791|Hepatitis C
245320|NCT01740791|HCV
245321|NCT01740791|Genotype 1
245322|NCT01740791|Genotype 2
245323|NCT01740791|Genotype 3
245324|NCT01740791|Genotype 4
245325|NCT01740791|Genotype 5
245326|NCT01740791|Genotype 6
245327|NCT01740791|Liver Disease
245328|NCT01740778|Diabetes
245329|NCT01740778|Medical Device
245330|NCT01740778|Lancing
245331|NCT01740752|anorexia nervosa
245332|NCT01740752|eating disorder
245333|NCT01740752|couples
245334|NCT01740752|relationships
245335|NCT01740752|couple therapy
245336|NCT01740739|Health Risk Appraisal
245337|NCT01740739|HCardiac Risk Factors
245338|NCT01740726|Depression
245339|NCT01740726|Behavioral Activation
245340|NCT01740726|Fluoxetine
245341|NCT01740726|Prozac
245342|NCT01740726|Treatment
245343|NCT01740726|Therapy
245344|NCT01740726|Psychotherapy
245345|NCT01740726|Antidepressant
245346|NCT01740726|Intervention
245347|NCT01740713|chronic iron overload
245348|NCT01740713|hereditary haemoglobinopathy
245349|NCT01740713|beta thalassaemia major
245350|NCT01740700|Abdominal aortic aneurysm
245351|NCT01740700|Endovascular
245352|NCT01740700|Fenestration
245353|NCT01740700|Juxtarenal
245354|NCT01740700|Off-the-shelf
245355|NCT01740700|Pararenal
245356|NCT01740687|Endometrial Ablation
245357|NCT01740687|Permanent Sterilization
245358|NCT01740687|Essure
245359|NCT01740687|NovaSure
245360|NCT01740687|Prevention of Pregnancy
245361|NCT01740674|internet data collection
245362|NCT01740674|longitudinal research
245363|NCT01740674|cohort retention
245364|NCT01740648|MEK Inhibitor
245365|NCT01740648|Trametinib
245366|NCT01740648|Rectal Cancers
245367|NCT01740648|KRAS
245368|NCT01740648|BRAF
245369|NCT01740648|NRAS Mutant
245370|NCT01740648|Fluorouracil
245371|NCT01740635|rehabilitation
245372|NCT01740635|wheelchair
245373|NCT01740635|manual wheelchair
245374|NCT01740635|wheelchair users
245375|NCT01740635|older adults
245376|NCT01740635|cognitive computer games
245377|NCT01740635|home-based training
245378|NCT01740635|community mobility
245379|NCT01740622|Injury
245380|NCT01740622|Injury Prevention
245381|NCT01740622|Cincinnati Home Injury Prevention
245382|NCT01740622|Injury Hazards
245383|NCT01740622|Modifiable Injury Hazards
245384|NCT01740609|Phase 1
245385|NCT01740609|RN168
245386|NCT01740609|Healthy Volunteers
245387|NCT01740596|NYHA III
245388|NCT01740596|NYHA IV
245389|NCT01740596|ACC Stage C
245390|NCT01740596|Heart Failure
245391|NCT01740596|Congestive Heart Failure
245392|NCT01740596|C-Pulse
245393|NCT01740596|Counterpulsation
245394|NCT01740596|Heart Assist
245395|NCT01740596|Sunshine Heart
245396|NCT01740596|Left Heart Failure
245397|NCT01740583|mitral valve, regurgitation, annuloplasty
245398|NCT01740570|Brain cancer
245399|NCT01740570|Malignant glioma
245400|NCT01740570|Glioblastoma multiforme
245401|NCT01740570|Gliosarcoma
245402|NCT01740570|Anaplastic astrocytoma
245403|NCT01740570|Anaplastic oligodendroglioma
245404|NCT01740570|Anaplastic oligoastrocytoma
245405|NCT01740570|Cabazitaxel
245406|NCT01740570|Jevtana
245407|NCT01740557|Melanoma
245408|NCT01740557|Metastatic Melanoma
245409|NCT01740557|Stage III in-transit, subcutaneous, or regional nodal disease
245410|NCT01740557|Cytoxan
245411|NCT01740557|Cyclophosphamide
245412|NCT01740557|Neosar
245413|NCT01740557|Mesna
245414|NCT01740557|Mesnex
245415|NCT01740557|Fludarabine
245416|NCT01740557|Fludarabine Phosphate
245417|NCT01740557|Fludara
245418|NCT01740557|IL-2
245419|NCT01740557|Interleukin-2
245420|NCT01740557|Aldesleukin
245421|NCT01740557|Proleukin
245422|NCT01740557|T-cells
245423|NCT01740557|Autologous tumor infiltrating lymphocytes
245424|NCT01740557|TIL
245425|NCT01740557|CXCR2
245426|NCT01740531|S303 treated RBCs
245427|NCT01740505|energy cost of walking
245428|NCT01740505|energy metabolism
245429|NCT01740505|aged
245430|NCT01740505|older adult
245431|NCT01740505|exercise
245432|NCT01740505|gait
245433|NCT01740505|walking
245434|NCT01740505|aerobic
245435|NCT01740505|motor skill
245436|NCT01740492|Ketamine
245437|NCT01740492|Acute pain
245438|NCT01740492|Pain control
245439|NCT01740492|Pain
245440|NCT01740479|STEMI
245441|NCT01740479|ticagrelor
245442|NCT01740479|multi-vessel disease
245443|NCT01740479|culprit lesion
245444|NCT01740466|Prevalence
245445|NCT01740466|Vision disorders
245446|NCT01740466|Eye diseases
245447|NCT01740466|Visual acuity
245448|NCT01740466|Primary health care
245449|NCT01740440|Healthy females
245450|NCT01740427|breast cancer
245451|NCT01740427|postmenopausal women
245452|NCT01740427|estrogen-receptor positive
245453|NCT01740427|HER2 negative
245454|NCT01740427|locoregionally recurrent
245455|NCT01740427|metastatic
245456|NCT01740427|Palbociclib (PD-0332991)
245457|NCT01740427|PALOMA-2
245458|NCT01740414|prescription opioid abuse
245459|NCT01740414|pain
245460|NCT01740414|opioid withdrawal
245461|NCT01740414|oxycodone
245462|NCT01740414|ibudilast
245463|NCT01740401|Melanoma
245464|NCT01740401|Advanced Malignant Melanoma
245465|NCT01740401|Anti CTLA4 Blockade
245466|NCT01740401|Progression Free Survival
245467|NCT01740401|Interventional Therapy
245468|NCT01740401|Phase II Clinical Trial
245469|NCT01740401|Immunotherapy
245470|NCT01740401|T Cell Activation
245471|NCT01740362|CP-690
245472|NCT01740362|550
245473|NCT01740362|pharmacokinetics
245474|NCT01740362|renal impairment
245475|NCT01740323|Breast Cancer
245476|NCT01740323|Chemotherapy
245477|NCT01740323|Radiotherapy
245478|NCT01740323|NF-kB
245479|NCT01740323|DNA Binding
245480|NCT01740323|Curcumin
245481|NCT01740310|pregnancy,
245482|NCT01740310|vaccine acceptance,
245483|NCT01740310|vaccination,
245484|NCT01740310|influenza,
245485|NCT01740310|pertussis,
245486|NCT01740310|Tdap,
245487|NCT01740310|minority,
245488|NCT01740310|African-American
245489|NCT01740297|melanoma, talimogene laherparepvec, ipilimumab, metastatic melanoma, melanoma, immunotherapy, unresectable melanoma, oncolytic immunotherapy,
245490|NCT01740271|breast cancer
245613|NCT01739816|Pharmaceutical care
245491|NCT01740271|non-metastatic carcinoma of the breast chemotherapy
245492|NCT01740271|adjuvant therapy
245493|NCT01740271|neoadjuvant
245494|NCT01740258|malignant glioma
245495|NCT01740258|Grade 4 malignant glioma
245496|NCT01740258|glioblastoma
245497|NCT01740258|gliosarcoma
245498|NCT01740258|adult brain tumor
245499|NCT01740245|Laser therapy
245500|NCT01740245|Cervical lesions
245501|NCT01740245|Polyhexamethylene biguanide
245502|NCT01740245|Chlorhexidine
245503|NCT01740219|Health promotion
245504|NCT01740219|Religion and medicine
245505|NCT01740219|Hispanic Americans
245506|NCT01740219|Randomized controlled trial
245507|NCT01740219|Program evaluation
245508|NCT01740219|Neoplasms/prevention & control
245509|NCT01740219|Mass screening
245510|NCT01740219|Female
245511|NCT01740219|Male
245512|NCT01740219|Preventive Health Services/methods
245513|NCT01740219|Adult
245514|NCT01740219|Organizations
245515|NCT01740193|Pain
245516|NCT01740193|Regional Anesthesia
245517|NCT01740193|ultrasound
245518|NCT01740193|transversus abdominis plane
245519|NCT01740193|herniorrhaphy
245520|NCT01740193|pediatrics
245521|NCT01740167|prodrome
245522|NCT01740167|mental illness
245523|NCT01740167|health promotion
245524|NCT01740167|lifestyle behavior
245525|NCT01740141|Pain
245526|NCT01740128|spinal cord injuries
245527|NCT01740128|paraplegia
245528|NCT01740128|postural balance
245529|NCT01740128|locomotor activity
245530|NCT01740128|exercise therapy
245531|NCT01740128|electromyography
245532|NCT01740128|transcranial magnetic stimulation, single pulse
245533|NCT01740115|HIV
245534|NCT01740115|Alcohol Use
245535|NCT01740115|Bone Disease
245536|NCT01740115|Bone Mineral Density
245537|NCT01740115|Bone Microarchitecture
245538|NCT01740115|Substance Dependence
245539|NCT01740102|Ischemic preconditioning
245540|NCT01740102|Coronary artery bypass
245541|NCT01740102|Preoperative care
245542|NCT01740102|Postoperative period
245543|NCT01740089|Hepatitis C
245544|NCT01740089|Cepeginterferon alfa
245545|NCT01740089|Peginterferon
245546|NCT01740089|Treatment
245547|NCT01740076|isoflavones, hypertension, soy, diet, nutrition, women, inflammation, hot flashes
245548|NCT01740037|Chronic care program
245549|NCT01740037|Nurse specialist
245550|NCT01740037|Atrial Fibrillation guideline
245551|NCT01740024|Immunotherapy
245552|NCT01740024|Subcutaneous immunotherapy
245553|NCT01740024|Skin Prick Test
245554|NCT01740024|Dose Response Prick Test
245555|NCT01739985|Postoperative
245556|NCT01739985|Vomiting
245557|NCT01739985|Children
245558|NCT01739985|Prophylaxis
245559|NCT01739985|Droperidol
245560|NCT01739985|Ondansetron
245561|NCT01739985|Dexamethasone
245562|NCT01739972|Desiccated thyroid extract and levothyroxine
245563|NCT01739959|Necrotizing fasciitis
245564|NCT01739959|Fournier's gangrene
245565|NCT01739959|Cellulitis
245566|NCT01739959|Serum Lactate
245567|NCT01739933|Delirium
245568|NCT01739933|Delirium/coma-free days
245569|NCT01739933|Long term cognitive impairment
245570|NCT01739933|Sedation
245571|NCT01739933|Intensive care
245572|NCT01739933|Mechanical Ventilation
245573|NCT01739933|Dexmedetomidine
245574|NCT01739933|Propofol
245575|NCT01739933|Coma-free days
245576|NCT01739933|Sepsis
245577|NCT01739933|Organ dysfunction
245578|NCT01739933|Acute Respiratory Distress
245579|NCT01739933|Markers of inflammation
245580|NCT01739920|Povidone-Iodine
245581|NCT01739920|Ophthalmic Solutions
245582|NCT01739920|Endophthalmitis
245583|NCT01739920|Preoperative procedures
245584|NCT01739907|Iron deficiency
245585|NCT01739907|Menstruating women
245586|NCT01739907|Vitamin D
245587|NCT01739907|Functional food
245588|NCT01739894|Advanced gastric cancer
245589|NCT01739894|unresectable gastric cancer
245590|NCT01739894|recurrent gastric cancer
245591|NCT01739894|with peritoneal metastasis
245592|NCT01739894|cancer cells on peritoneal cytology
245593|NCT01739881|Exhaled breath condensate (EBC) method
245594|NCT01739881|Volatile Organic Compounds (VOCs)
245595|NCT01739881|Endobronchial Ultrasound (EBUS)
245596|NCT01739881|Confocal Endoscopy
245597|NCT01739881|Exhaled alveolar gas
245598|NCT01739868|Pre-diabetes
245599|NCT01739868|Type 2 diabetes
245600|NCT01739868|Biomarkers
245601|NCT01739868|Diabetes risk score
245602|NCT01739842|Alcohol consumption
245603|NCT01739842|Kudzu extract
245604|NCT01739842|Cerebral blood flow
245605|NCT01739829|xenotransplantation
245606|NCT01739829|type 1 diabetes
245607|NCT01739829|porcine islets
245608|NCT01739816|Compliance
245609|NCT01739816|Adherence
245610|NCT01739816|Polypharmacy
245611|NCT01739816|Medicines use
245612|NCT01739816|Medication review
245614|NCT01739816|Primary care
245615|NCT01739816|Drug related problem
245616|NCT01739816|Patient safety
245617|NCT01739803|Immunosuppressant therapy adherence
245618|NCT01739803|Quality of life
245619|NCT01739803|Economic outcomes
245620|NCT01739790|COPD
245621|NCT01739790|Chronic Bronchitis
245622|NCT01739790|N-acetylcysteine
245623|NCT01739777|Heart Failure
245624|NCT01739777|Coronary Heart Disease
245625|NCT01739777|Adult Stem Cells
245626|NCT01739777|Umbilical Progenitor Cells
245627|NCT01739777|Umbilical Cord Stem Cells Allogenic
245628|NCT01739777|Left Ventricular Function
245629|NCT01739777|Intravenous Injection
245630|NCT01739751|COPD
245631|NCT01739751|Physical activity
245632|NCT01739751|Pedometers
245633|NCT01739751|steps
245634|NCT01739751|non pharmacological treatment
245635|NCT01739751|rehabilitation
245636|NCT01739751|exercise
245637|NCT01739738|peristalsis, kidney stones, hydronephrosis, ureteral stent
245638|NCT01739725|kidney stones, ureteral stent, pain,
245639|NCT01739712|Diabetes
245640|NCT01739712|Sleep problems
245641|NCT01739712|School
245642|NCT01739712|Neurobehavioral
245643|NCT01739699|craniotomy
245644|NCT01739699|brain surgery
245645|NCT01739699|acetaminophen
245646|NCT01739699|Tylenol
245647|NCT01739686|Quality of Life
245648|NCT01739686|Symptoms
245649|NCT01739686|Palliative care
245650|NCT01739686|Symptom management
245651|NCT01739686|Disease management
245652|NCT01739686|Health delivery
245653|NCT01739673|Infectious Keratitis
245654|NCT01739660|Chronic Kidney Disease Stage 5
245655|NCT01739660|Hemodialysis
245656|NCT01739660|pegloticase
245657|NCT01739647|AZD3293
245658|NCT01739647|Healthy volunteers
245659|NCT01739647|Elderly volunteers
245660|NCT01739647|Phase 1
245661|NCT01739647|Single Ascending Dose Study
245662|NCT01739634|Diarrhea
245663|NCT01739634|Medullary thyroid cancer
245664|NCT01739608|CRC
245665|NCT01739569|Diet treatment
245666|NCT01739569|Mental Health
245667|NCT01739569|Reaction time
245668|NCT01739569|State of moods
245669|NCT01739569|Working hours
245670|NCT01739569|Medical Hospital Staff
245671|NCT01739556|antiplatelet therapy
245672|NCT01739556|primary PCI
245673|NCT01739556|modification
245674|NCT01739517|Short bowel syndrome
245675|NCT01739517|Cholestasis
245676|NCT01739517|Omegaven
245677|NCT01739517|Parenteral nutrition-associated Liver Disease
245678|NCT01739504|Arthritis
245679|NCT01739504|Joint pain
245680|NCT01739504|Articular cartilage
245681|NCT01739504|Mesenchymal stem cells
245682|NCT01739504|Autologous
245683|NCT01739504|Adipose tissue
245684|NCT01739491|Chronic lymphocytic leukemia
245685|NCT01739491|Bendamustine hydrochloride
245686|NCT01739491|Leukemia
245687|NCT01739491|Filipino
245688|NCT01739465|Cholangiocarcinoma
245689|NCT01739465|Pathologic
245690|NCT01739465|Digestive System
245691|NCT01739465|Neoplasms
245692|NCT01739465|Neoplasms by Site
245693|NCT01739465|Digestive System Diseases
245694|NCT01739465|Bile Duct Diseases
245695|NCT01739465|Biliary Tract Diseases
245696|NCT01739465|Pathological Conditions
245697|NCT01739465|Constriction
245698|NCT01739465|Adenocarcinoma
245699|NCT01739465|Carcinoma
245700|NCT01739452|Low-risk MDS
245701|NCT01739452|myelodysplastic syndrome
245702|NCT01739452|retrospective
245703|NCT01739426|LigaSure V (TM)
245704|NCT01739400|Eisenmenger Syndrome
245705|NCT01739400|exercise capacity
245706|NCT01739387|Flutiform®
245707|NCT01739387|Asthma
245708|NCT01739387|COPD
245709|NCT01739374|pelvic floor reconstruction
245710|NCT01739374|mesh implants
245711|NCT01739335|Stress Disorders, Post-Traumatic
245712|NCT01739335|Mifepristone
245713|NCT01739335|Veterans
245714|NCT01739335|Clinical Trial
245715|NCT01739309|Non- Hodgkins Lymphoma
245716|NCT01739296|osteoarthritis
245717|NCT01739296|osteoarthritis, knee
245718|NCT01739296|foot orthoses
245719|NCT01739296|orthotic insoles
245720|NCT01739270|analgesia
245721|NCT01739270|regional anesthesia
245722|NCT01739270|surgery
245723|NCT01739270|duration of analgesia
245724|NCT01739270|dexamethasone added to levobupivacaine compared to levobupivacaine alone
245725|NCT01739244|Glaucoma
245726|NCT01739244|Open Angle Glaucoma
245727|NCT01739244|Ocular Hypertension
245728|NCT01739244|IOP
245729|NCT01739244|RNAi
245730|NCT01739244|siRNA
245731|NCT01739244|beta inhibitor
245732|NCT01739205|Type 2 diabetes and depression
245733|NCT01739179|Ventricular peritoneal Shunt
245734|NCT01739179|Shunt Complications
245735|NCT01739179|Shunt Failure
245736|NCT01739179|Hydrocephalus
245737|NCT01739166|Health Services Research
245738|NCT01739166|Quality Assurance
245739|NCT01739153|Dairy
245740|NCT01739153|Cheese
245741|NCT01739153|Blood lipid concentrations
245742|NCT01739153|Blood lipid sizes
245743|NCT01739153|Fecal fat
245744|NCT01739153|Fat digestibility
245745|NCT01739153|bile acids
245746|NCT01739127|Antipsychotic agents
245747|NCT01739127|Adverse effects
245748|NCT01739127|Magnetic Resonance Imaging
245749|NCT01739114|Lung aeration
245750|NCT01739114|Bronchopulmonary dysplasia
245751|NCT01739114|Positive Pressure Respiration
245752|NCT01739114|Sustained Inflation
245753|NCT01739114|Continuous Positive Airway Pressure
245754|NCT01739088|Congenital heart disease
245755|NCT01739088|pediatrics
245756|NCT01739088|ischemia-reperfusion injury
245757|NCT01739088|long term outcomes
245758|NCT01739062|PSA test
245759|NCT01739062|Prostate cancer
245760|NCT01739062|Genetic screening
245761|NCT01739036|Malaria
245762|NCT01739036|Vaccine
245763|NCT01739036|Plasmodium
245764|NCT01739036|Falciparum
245765|NCT01739023|paraplegia
245766|NCT01739023|cell therapy
245767|NCT01739023|Schwann cells
245768|NCT01739023|spinal cord injury
245769|NCT01738997|Benign
245770|NCT01738997|Esophageal strictures
245771|NCT01738997|Esophagus
245772|NCT01738997|Balloon Dilation
245773|NCT01738984|exercise
245774|NCT01738984|video
245775|NCT01738984|DVD
245776|NCT01738984|mother
245777|NCT01738984|infant
245778|NCT01738971|emergency contraception
245779|NCT01738971|community pharmacy
245780|NCT01738958|Probiotic bacteria
245781|NCT01738958|Caries dentalis
245782|NCT01738958|QLF
245783|NCT01738932|endometriosis
245784|NCT01738932|mannan-binding lectin
245785|NCT01738932|immunology
245786|NCT01738893|Gabapentin
245787|NCT01738893|Bioequivalence
245788|NCT01738893|Pharmacokinetics
245789|NCT01738893|Mexico
245790|NCT01738867|mu opioid receptors
245791|NCT01738867|Addiction
245792|NCT01738867|Pharmacogenetics
245793|NCT01738867|OPRM1
245794|NCT01738867|Pharmacodynamics
245795|NCT01738854|laryngeal mask airway supreme
245796|NCT01738854|airway sealing
245797|NCT01738854|intracuff pressure
245798|NCT01738841|Combined measles-mumps-rubella-varicella vaccine
245799|NCT01738841|Priorix-Tetra™
245800|NCT01738841|MMRV
245801|NCT01738841|children
245802|NCT01738841|Post-marketing surveillance
245803|NCT01738841|Philippines
245804|NCT01738815|bladder cancer
245805|NCT01738815|hematuria
245806|NCT01738815|sodium valproate
245807|NCT01738815|valproic acid
245808|NCT01738802|Type 2 Diabetes
245809|NCT01738802|carotid intima medial thickness
245810|NCT01738802|micronutrient
245811|NCT01738802|anti-oxidant
245812|NCT01738789|Adnexal masses
245813|NCT01738789|Magnetic resonance imaging
245814|NCT01738789|Ovarian tumor
245815|NCT01738776|hip fracture
245816|NCT01738776|risk factors
245817|NCT01738776|vitamin K1
245818|NCT01738776|vitamin D
245819|NCT01738776|bone turnover markers
245820|NCT01738776|osteocalcin
245821|NCT01738776|undercarboxylated osteocalcin
245822|NCT01738776|bone specific alkaline phosphatase (BALP)
245823|NCT01738776|insulin like growth factor 1 (IGF1)
245824|NCT01738776|parathyroid hormone (PTH)
245825|NCT01738763|Glucose
245826|NCT01738763|Insulin
245827|NCT01738763|3-O-methyl-D-chiro-inositol
245828|NCT01738750|surgical choice
245829|NCT01738750|cost of care
245830|NCT01738750|decision making
245831|NCT01738750|health care
245832|NCT01738750|health care cost
245833|NCT01738750|pediatric
245834|NCT01738750|children
245835|NCT01738750|appendicitis
245836|NCT01738750|patient satisfaction
245837|NCT01738711|Idiopathic pulmonary fibrosis
245838|NCT01738711|Cognitive behavioural therapy
245839|NCT01738711|Anxiety
245840|NCT01738711|Quality of life
245841|NCT01738685|Breast Cancer.
245842|NCT01738685|Adjuvant Endocrine therapy.
245843|NCT01738672|Nitrous oxide
245844|NCT01738672|labor and delivery
245845|NCT01738672|analgesia
245846|NCT01738659|sodium ,diuretics, PCWP
245847|NCT01738646|vorinostat
245848|NCT01738646|SAHA
245849|NCT01738646|bevacizumab
245850|NCT01738646|AVASTIN
245851|NCT01738646|malignant glioma
245852|NCT01738646|GBM
245853|NCT01738646|glioblastoma multiforme
245854|NCT01738646|brain tumor
245855|NCT01738633|Esophageal Cancer
245856|NCT01738633|Quality of Life
245857|NCT01738620|esophageal cancer
245858|NCT01738620|sleep disturbance
245859|NCT01738620|quality of life
245860|NCT01738607|fecal incontinence, dietary fiber
245861|NCT01738581|focal hand dystonia (FHD)
245862|NCT01738581|repetitive transcranial magnetic stimulation (rTMS)
245863|NCT01738581|sensorimotor retraining
245864|NCT01738568|High intensity aerobic training
245865|NCT01738555|amdoxovir
245866|NCT01738555|zidovudine
245867|NCT01738555|HIV
245868|NCT01738555|HAART
245869|NCT01738555|antiretroviral
245870|NCT01738542|Bosentan
245871|NCT01738542|Peripheral Arterial Disease
245872|NCT01738529|confocal laser endomicroscopy
245873|NCT01738529|Crohn´disease
245874|NCT01738503|Opioid Dependence, Buprenorphine, Depot, SUBUTEX, RBP-6000
245875|NCT01738490|Bone anchored hearing aid
245876|NCT01738490|Bone anchored implant
245877|NCT01738490|Implant stability
245878|NCT01738490|Wide diameter implant
245879|NCT01738490|Linear incision
245880|NCT01738490|Ponto
245881|NCT01738477|Booster
245882|NCT01738477|Tdap
245883|NCT01738477|Immunogenicity
245884|NCT01738477|Repeat dose
245885|NCT01738477|Safety
245886|NCT01738477|BoostrixTM
245887|NCT01738477|Persistence
245888|NCT01738464|Pelvic Pain
245889|NCT01738464|Interstitial Cystitis
245890|NCT01738464|Microbiome
245891|NCT01738464|Prostatitis
245892|NCT01738464|Chronic
245893|NCT01738464|Depression
245894|NCT01738451|Holter monitor
245895|NCT01738451|cancer
245896|NCT01738451|BRAF inhibitor
245897|NCT01738451|BRAF-mutation positive tumor
245898|NCT01738451|pharmacokinetics
245899|NCT01738451|QTc
245900|NCT01738451|ECG intervals and morphology
245901|NCT01738451|GSK2118436
245902|NCT01738451|safety
245903|NCT01738438|Metastatic
245904|NCT01738438|Triple Negative
245905|NCT01738438|Stage IV
245906|NCT01738425|GIC-1001
245907|NCT01738425|opioid agonist
245908|NCT01738425|sulfide
245909|NCT01738425|colonoscopy
245910|NCT01738425|gicare
245911|NCT01738425|Phase I
245912|NCT01738425|safety
245913|NCT01738425|tolerability
245914|NCT01738425|pharmacokinetics
245915|NCT01738425|healthy subjects
245916|NCT01738425|single ascending dose
245917|NCT01738425|multiple ascending dose
245918|NCT01738425|SAD
245919|NCT01738425|MAD
245920|NCT01738425|food effect
245921|NCT01738412|Stroke
245922|NCT01738399|Insulin resistance
245923|NCT01738399|Coffee
245924|NCT01738399|Glucose metabolism
245925|NCT01738386|Adaptation
245926|NCT01738386|Coping
245927|NCT01738386|Presenile Dementia
245928|NCT01738386|Caregiver Burden
245929|NCT01738373|autologous stem cell transplantation
245930|NCT01738373|lymphoma
245931|NCT01738373|multiple myeloma
245932|NCT01738360|Arsenic trioxide
245933|NCT01738360|Systemic Lupus
245934|NCT01738360|clinically
245935|NCT01738360|biologically active
245936|NCT01738334|Meditation
245937|NCT01738334|Cognition
245938|NCT01738334|Attention Deficit Disorder with Hyperactivity
245939|NCT01738308|Healing Touch
245940|NCT01738308|Pediatrics
245941|NCT01738308|surgery
245942|NCT01738308|stress
245943|NCT01738308|pain
245944|NCT01738308|Pediatric Stress
245945|NCT01738308|maladaptive behaviors
245946|NCT01738308|energy medicine
245947|NCT01738308|emergence delirium
245948|NCT01738308|emergence agitation
245949|NCT01738308|length of stay
245950|NCT01738308|ease of wake up
245951|NCT01738308|distress parents
245952|NCT01738308|distress pediatric patients
245953|NCT01738308|Pediatric Post-Traumatic Stress Disorder
245954|NCT01738295|acetylcholine
245955|NCT01738295|cholinergic system
245956|NCT01738295|visual perception
245957|NCT01738295|visual attention
245958|NCT01738295|multiple objects tracking
245959|NCT01738295|perceptual learning
245960|NCT01738295|vision training
245961|NCT01738282|baclofene
245962|NCT01738282|Alcohol dependence
245963|NCT01738282|Maintenance of abstinence
245964|NCT01738269|Ovarian cancer, HE4, normal range
245965|NCT01738256|Cognitive Behavior Therapy
245966|NCT01738256|Acceptance Commitment Therapy
245967|NCT01738256|Psychological Stress
245968|NCT01738256|Metabolic Syndrome
245969|NCT01738256|Overweight
245970|NCT01738256|Life Style
245971|NCT01738243|Thyroid
245972|NCT01738243|Thyroid Eye Disease
245973|NCT01738243|Thyroid Orbitopathy
245974|NCT01738243|Eyelid Retraction
245975|NCT01738243|Upper Eyelid Retraction
245976|NCT01738217|Intra-operative imaging
245977|NCT01738217|NIR Fluorescence
245978|NCT01738217|Liver surgery
245979|NCT01738217|Tumoral margins
245980|NCT01738204|endometriosis
245981|NCT01738204|dysmenorrhea
245982|NCT01738204|pelvic pain
245983|NCT01738204|women's health
245984|NCT01738204|adolescence
245985|NCT01738204|biorepository
245986|NCT01738204|observational
245987|NCT01738204|women
245988|NCT01738204|female
245989|NCT01738204|gynecology
245990|NCT01738204|fertility
245991|NCT01738204|infertility
245992|NCT01738191|Parkinson's disease
245993|NCT01738165|Prospective
245994|NCT01738165|Multi-Center
245995|NCT01738165|Pilot Study
245996|NCT01738165|Single Arm
245997|NCT01738165|Safety
245998|NCT01738165|Efficacy
245999|NCT01738152|HYALOGYN VAGINAL GEL
246000|NCT01738152|vaginal dryness
246001|NCT01738152|12-232
246002|NCT01738139|Advanced Cancers
246003|NCT01738139|Advanced Malignancies
246004|NCT01738139|Metastatic
246005|NCT01738139|Unresectable
246006|NCT01738139|Ipilimumab
246007|NCT01738139|Yervoy
246008|NCT01738139|BMS-734016
246009|NCT01738139|MDX010
246010|NCT01738139|Imatinib Mesylate
246011|NCT01738139|Imatinib
246012|NCT01738139|Gleevec
246013|NCT01738139|STI 571
246014|NCT01738139|NSC-716051
246015|NCT01738126|cerebellum
246016|NCT01738126|fMRI
246017|NCT01738126|DTI
246018|NCT01738126|pain
246019|NCT01738126|heat
246020|NCT01738126|noxious
246021|NCT01738126|aversion
246022|NCT01738126|unpleasantness
246023|NCT01738126|anger
246024|NCT01738126|aversive stimulus
246025|NCT01738126|motor
246026|NCT01738126|human
246027|NCT01738126|image analysis
246028|NCT01738126|perception
246029|NCT01738126|central nervous system
246030|NCT01738126|sensory
246031|NCT01738126|somatosensory cortex
246032|NCT01738126|trigeminal system
246033|NCT01738126|white matter
246034|NCT01738113|Ilizarov
246035|NCT01738113|distraction osteogenesis
246036|NCT01738113|Muscle architecture
246037|NCT01738113|muscle mechanics
246038|NCT01738113|Rehabilitation
246039|NCT01738087|patients
246040|NCT01738087|Adult
246041|NCT01738074|rotavirus
246042|NCT01738074|trivalent genetic reassortment vaccine
246043|NCT01738074|Phase three clinical trials
246044|NCT01738061|Older workers
246045|NCT01738061|Multidimensional intervention
246046|NCT01738061|Worksite health promotion
246047|NCT01738061|Taiwan
246048|NCT01738048|Pain
246049|NCT01738048|Neuropathic pain
246050|NCT01738048|Chronic pain
246051|NCT01738035|IgA nephropathy
246052|NCT01738022|Sleep apnea
246053|NCT01738022|Pathophysiology
246054|NCT01738009|Sleep Apnea
246055|NCT01738009|Pathophysiology
246056|NCT01737983|cystic fibrosis
246057|NCT01737983|probiotics
246058|NCT01737983|Lactobacillus reuteri
246059|NCT01737957|Proliferative Diabetic retinopathy
246060|NCT01737957|Pan-retinal photocoagulation
246061|NCT01737944|methotrexate injection, subcutaneous, autoinjector
246062|NCT01737931|SPM 962
246063|NCT01737931|rotigotine
246064|NCT01737931|application site reaction
246065|NCT01737918|urge urinary incontinence, cesa, vasa, TOT, solifenacin
246066|NCT01737905|Asthma
246067|NCT01737905|Safety
246068|NCT01737905|Efficacy
246069|NCT01737905|Epinephrine
246070|NCT01737905|Bronchodilator
246071|NCT01737905|Metered dose inhaler
246072|NCT01737892|Asthma
246073|NCT01737892|Pharmacokinetics
246074|NCT01737892|Epinephrine
246075|NCT01737892|Bronchodilator
246076|NCT01737892|Metered dose inhaler
246077|NCT01737879|Anemia, Chronic Kidney Disease, End Stage Renal Disease, erythropoiesis-stimulating agents, Hemodialysis, Hemoglobin
246078|NCT01737866|Heart, Failure, Renal, Insufficiency, Cardiac, Kidney, Hemodialysis, Impairment, omecamtiv mecarbil, cardiac myosin activator, CK-1827452
246079|NCT01737853|Primary Open-Angle Glaucoma
246080|NCT01737853|Ocular Hypertension
246081|NCT01737853|Ganfort
246082|NCT01737840|dyspepsia
246083|NCT01737840|pantoprazole
246084|NCT01737840|ranitidine
246085|NCT01737840|emergency department
246086|NCT01737827|INC280, advanced hepatocellular carcinoma, c-MET pathway dysregulation
246087|NCT01737814|sickle cell disease
246088|NCT01737814|vaso-occlusive crisis
246089|NCT01737801|Lung function
246090|NCT01737801|Physiotherapy
246091|NCT01737788|Cervical cerclage
246092|NCT01737788|Uterine Cervical Incompetence
246093|NCT01737775|diaphragmatic dysfunction
246094|NCT01737775|ultrasonography
246095|NCT01737775|respiratory distress
246096|NCT01737775|abdominal surgery
246097|NCT01737775|Age
246098|NCT01737775|gender
246099|NCT01737775|biometric
246100|NCT01737775|body mass index
246101|NCT01737775|ASA score
246102|NCT01737775|smoking status
246103|NCT01737775|history of respiratory disease
246104|NCT01737762|Venous leg ulcer
246105|NCT01737762|ulcer
246106|NCT01737762|Venous stasis
246107|NCT01737762|compression
246108|NCT01737762|venous
246109|NCT01737762|venous stasis ulcer
246110|NCT01737762|vlu
246111|NCT01737762|wound
246112|NCT01737762|varicose veins
246113|NCT01737762|venous insufficiency
246114|NCT01737762|dvt
246115|NCT01737762|deep vein thrombosis
246116|NCT01737749|Stroke
246117|NCT01737736|Stroke
246118|NCT01737723|Stroke
246119|NCT01737710|Influenza Vaccines
246120|NCT01737710|Dermatitis
246121|NCT01737710|Injections, Intradermal
246122|NCT01737710|Injections, Intramuscular
246123|NCT01737710|Skin Diseases
246124|NCT01737710|Skin Diseases, Eczematous
246125|NCT01737710|Hypersensitivity, Immediate
246126|NCT01737710|Hypersensitivity
246127|NCT01737710|Immune System Diseases
246128|NCT01737710|Genetic Diseases, Inborn
246129|NCT01737710|Skin Diseases, Genetic
246130|NCT01737671|Brain tumor
246131|NCT01737671|Malignant Fourth Ventricular Brain Tumors
246132|NCT01737671|Ependymoma involving brain
246133|NCT01737671|Ependymoma involving spine
246134|NCT01737671|Recurrent ependymoma involving brain and/or spine
246135|NCT01737671|Recurrent atypical teratoid/rhabdoid tumor involving brain
246136|NCT01737671|Recurrent atypical teratoid/rhabdoid tumor involving spine
246137|NCT01737671|AT/RT
246138|NCT01737671|Ommaya reservoir catheter
246139|NCT01737671|Methotrexate
246140|NCT01737671|Medulloblastoma
246141|NCT01737671|ATRT
246142|NCT01737671|Atypical teratoid rhabdoid tumor
246143|NCT01737671|Ependymoma
246144|NCT01737671|Pediatric brain tumor
246145|NCT01737671|Intraventricular chemotherapy
246146|NCT01737632|Adolescents
246147|NCT01737632|Residential Treatment
246148|NCT01737632|Outpatient Treatment
246149|NCT01737632|Substance Abuse
246150|NCT01737632|Delinquency
246151|NCT01737632|Family Therapy
246152|NCT01737632|Multidimensional Family therapy
246153|NCT01737619|Gynecologic cancer
246154|NCT01737619|Endometrial Cancer
246155|NCT01737619|Lymph Nodes Metastasis
246156|NCT01737619|Surgical Staging
246157|NCT01737619|False negative rate
246158|NCT01737619|Detection of positive lymph nodes
246159|NCT01737619|Histologically confirmed high grade endometrial cancer
246160|NCT01737619|Sentinel lymph node mapping
246161|NCT01737606|Cerebral pulsatility
246162|NCT01737606|Fast Cerebral Pulsatility Imaging or FCPI
246163|NCT01737606|MRI
246164|NCT01737606|Arteriel Spin Labelling
246165|NCT01737606|Cognitive tasks
246166|NCT01737606|Aging
246167|NCT01737593|acetaminophen
246168|NCT01737593|emergence agitation
246169|NCT01737593|children
246170|NCT01737593|sevoflurane
246171|NCT01737580|influenza, human
246172|NCT01737580|influenza vaccines
246173|NCT01737580|older adults
246174|NCT01737580|immune response
246175|NCT01737554|Central venous access device
246176|NCT01737554|Catheter resistance monitoring
246177|NCT01737541|Cerebrovascular Disorders
246178|NCT01737541|Cardiovascular Diseases
246179|NCT01737541|Intracerebral Hemorrhage
246180|NCT01737541|Serotonin Uptake Inhibitors
246181|NCT01737541|Therapeutic Uses
246182|NCT01737528|severe symptomatic native aortic valve stenosis
246183|NCT01737528|inoperable or high risk for open aortic valve replacement
246184|NCT01737476|age 18-65
246185|NCT01737463|Ampulla of Vater adenoma
246186|NCT01737450|Metastatic head and neck cancer
246187|NCT01737450|PI3K inhibitor
246188|NCT01737450|Recurrent head and meck cancer
246189|NCT01737450|Progressive head and neck cancer
246190|NCT01737450|BKM120
246191|NCT01737411|surgery, solifenacin, urge urinary incontinence
246192|NCT01737398|FAP
246193|NCT01737398|Familial Amyloid Polyneuropathy
246194|NCT01737398|TTR
246195|NCT01737398|Transthyretin
246196|NCT01737398|Amyloidosis
246197|NCT01737385|microcirculation
246198|NCT01737385|proximal humeral fractures
246199|NCT01737385|O2C
246200|NCT01737372|Multiple Sclerosis
246201|NCT01737372|Secondary Progressive Multiple Sclerosis
246202|NCT01737372|Clinically Isolated Syndrome
246203|NCT01737359|amdoxovir
246204|NCT01737359|zidovudine
246205|NCT01737359|tenofovir DF
246206|NCT01737359|HIV
246207|NCT01737359|HAART
246208|NCT01737359|antiretroviral
246209|NCT01737346|glioblastoma, recurrent, refractory, CCNU, procarbazine
246210|NCT01737320|gram negative bacteremia
246211|NCT01737320|Duration of antibiotic treatment
246212|NCT01737320|safety
246213|NCT01737320|efficacy
246214|NCT01737320|short-course
246215|NCT01737307|Fluoride Varnish
246216|NCT01737307|CPP-ACP paste
246217|NCT01737307|Dry mouth
246218|NCT01737307|Burning sensation
246219|NCT01737307|Chemotherapy
246220|NCT01737294|Phase IV
246221|NCT01737294|Peripheral Neuropathic Pain
246222|NCT01737294|QUTENZA
246223|NCT01737281|Smoking
246224|NCT01737281|Tobacco control
246225|NCT01737281|Counseling
246226|NCT01737281|mental health
246227|NCT01737268|patients
246228|NCT01737268|Major depressive episode
246229|NCT01737268|FK949E
246230|NCT01737255|Li-Fraumeni Syndrome
246231|NCT01737255|Whole Body Magnetic Resonance Imaging
246232|NCT01737255|TP53
246233|NCT01737255|Psychological Impact
246234|NCT01737242|Prostate cancer
246235|NCT01737242|PSA
246236|NCT01737216|Aged
246237|NCT01737216|patients
246238|NCT01737203|Viagra
246239|NCT01737203|ODT
246240|NCT01737203|bioquivalence
246241|NCT01737190|esophageal pressure
246242|NCT01737190|ARDSnet protocol
246243|NCT01737177|MCL
246244|NCT01737177|Mantle Cell Lymphoma
246245|NCT01737177|RELAPSED-REFRACTORY
246246|NCT01737164|Glucose
246247|NCT01737164|Lipid
246248|NCT01737164|Metabolism
246249|NCT01737164|Non Diabetic
246250|NCT01737164|Healthy
246251|NCT01737138|Resistant hypertension
246252|NCT01737138|All-cause mortality
246253|NCT01737138|Renal function
246254|NCT01737112|Lung Cancer
246255|NCT01737112|integrin αvβ3 receptor
246256|NCT01737112|99mTc-3PRGD2
246257|NCT01737112|SPECT/CT
246258|NCT01737112|efficacy and safety
246259|NCT01737099|omega-3
246260|NCT01737099|DHA
246261|NCT01737099|triglycerides
246262|NCT01737099|lipids
246263|NCT01737099|cardiovascular
246264|NCT01737099|hypertriglyceridemia
246265|NCT01737073|chronic pain
246266|NCT01737073|opioid
246267|NCT01737073|cognitive behavior therapy
246268|NCT01737060|Reversed prosthesis, Philos, Severe displaced
246269|NCT01737047|HIV
246270|NCT01737047|Ageing
246271|NCT01737034|partitioning of weight gain
246272|NCT01737034|refeeding
246273|NCT01737034|catch-up fat phenomenon
246274|NCT01737034|glycemic index
246275|NCT01737021|PICU
246276|NCT01737021|Critical illness
246277|NCT01737021|Outcomes
246278|NCT01737021|Mental health
246279|NCT01737021|Education
246280|NCT01737021|Randomized Controlled Trial (RCT)
246281|NCT01737021|Pilot
246282|NCT01737021|Feasibility
246283|NCT01737008|Head and neck
246284|NCT01737008|Squamous cell carcinoma
246285|NCT01737008|Phase 1
246286|NCT01737008|Dacomitinib
246287|NCT01737008|Radiation
246288|NCT01737008|Radiotherapy
246289|NCT01737008|Chemotherapy
246290|NCT01737008|Chemoradiation
246291|NCT01737008|Chemoradiotherapy
246292|NCT01737008|Cisplatin
246293|NCT01737008|Pharmacokinetics
246294|NCT01737008|Maximum tolerated dose
246295|NCT01737008|Safety
246296|NCT01737008|Human epidermal growth factor receptor
246297|NCT01737008|Previously Untreated
246298|NCT01737008|Local or Locally Advanced
246299|NCT01736995|Substance Abuse
246300|NCT01736995|Adolescents
246301|NCT01736995|Families
246302|NCT01736995|Functional Family Therapy
246303|NCT01736995|Cognitive Behavioral Therapy
246304|NCT01736995|Motivational Therapy
246305|NCT01736995|Contingency Management
246306|NCT01736982|Cigarette Smoking
246307|NCT01736982|Homeless
246308|NCT01736982|Contingency Management
246309|NCT01736982|Smoking Cessation
246310|NCT01736956|aortic stenosis
246311|NCT01736956|hypoplastic left heart syndrome
246312|NCT01736956|fetal aortic valvuloplasty
246313|NCT01736943|Bortezomib
246314|NCT01736943|Doxil
246315|NCT01736930|Type 1 Diabetes
246316|NCT01736930|Hypoglycemia
246317|NCT01736930|Continuous Glucose Monitoring
246318|NCT01736930|Pump Suspension
246319|NCT01736917|Fosaprepitant
246320|NCT01736917|5HT3 Receptor Antagonists
246321|NCT01736917|Dexamethasone
246322|NCT01736917|Germ Cell Tumors
246323|NCT01736917|Testis Cancer
246324|NCT01736917|Rescue Medications
246325|NCT01736904|advanced colorectal cancer
246326|NCT01736904|FOLFIRI
246327|NCT01736904|XELIRI
246328|NCT01736891|Motor fluctuations
246329|NCT01736891|Parkinson´s Disease
246330|NCT01736891|Rasagiline
246331|NCT01736878|Medullary Thyroid Carcinoma
246332|NCT01736878|Sorafenib
246333|NCT01736878|Efficacy
246334|NCT01736852|Premature Rupture of Membrane (Pregnancy)
246335|NCT01736852|PROM
246336|NCT01736852|Cervical Ripening
246337|NCT01736852|Induced Labor
246338|NCT01736826|plasma nucleosome concentration
246339|NCT01736826|plasma free DNA concentration
246340|NCT01736813|colorectal cancer
246341|NCT01736813|liver metastases
246342|NCT01736813|chemotherapy
246343|NCT01736813|chemokine
246344|NCT01736813|CCR5 inhibition
246345|NCT01736800|Temozolomide
246346|NCT01736800|Topotecan
246347|NCT01736800|Central Nervous System Metastases
246348|NCT01736800|Chemotherapy
246349|NCT01736800|Brain Metastases
246350|NCT01736800|Solid Tumors
246351|NCT01736787|Cauliflower Mushroom extract
246352|NCT01736787|immunity
246353|NCT01736774|Manual therapy
246354|NCT01736774|Exercise
246355|NCT01736748|obesity
246356|NCT01736748|physical activity
246357|NCT01736748|metabolism
246358|NCT01736748|environment
246359|NCT01736748|obese children, as defined by a body mass index > 95th percentile
246360|NCT01736748|for age and sex
246361|NCT01736722|Laser Induced Thermal Therapy
246362|NCT01736722|Metastatic cancer
246363|NCT01736722|Brain Tumor
246364|NCT01736722|Visualase
246365|NCT01736722|Treatment resistant
246366|NCT01736722|Magnetic Resonance Thermal Imaging
246367|NCT01736722|Magnetic Imaging
246368|NCT01736709|2012-2013 trivalent seasonal influenza vaccine
246369|NCT01736709|immunogenicity,
246370|NCT01736709|safety
246371|NCT01736696|Psoriasis
246372|NCT01736696|PASI
246373|NCT01736696|plaques
246374|NCT01736696|skin biopsy
246375|NCT01736696|immunomodulation
246376|NCT01736683|ACE-011
246377|NCT01736683|anemia
246378|NCT01736683|dose-ranging
246379|NCT01736683|intermediate-1 risk myelodysplastic syndromes
246380|NCT01736683|low risk myelodysplastic syndromes (MDS)
246381|NCT01736683|multicenter
246382|NCT01736683|open-label
246383|NCT01736683|parallel
246384|NCT01736683|phase 2
246385|NCT01736683|randomized
246386|NCT01736683|Sotatercept
246387|NCT01736683|Non-proliferative chronic myelomonocytic leukemia (CMML)
246388|NCT01736683|hemoglobin
246389|NCT01736683|transfusions
246390|NCT01736644|blood loss
246391|NCT01736644|bipolar sealer
246392|NCT01736644|aquamantys
246393|NCT01736644|total knee replacement
246394|NCT01736644|primary total knee arthroplasty
246395|NCT01736631|social phobia
246396|NCT01736631|bipolar disorder
246397|NCT01736631|cognitive behavioural therapy
246398|NCT01736618|subcutaneous implantable defibrillator, post approval study, sudden cardiac arrest, Cameron Health defibrillator
246399|NCT01736605|Massage
246400|NCT01736605|Meditation
246401|NCT01736605|Breast Cancer
246402|NCT01736605|Breast Surgery
246403|NCT01736605|Breast Reconstruction
246404|NCT01736566|Primary Care
246405|NCT01736566|Cardiology
246406|NCT01736566|Hypertrophic Cardiomyopathy
246407|NCT01736566|Dilated Cardiomyopathy
246408|NCT01736566|Whole Genome Sequencing
246409|NCT01736553|Spinal Muscular Atrophy (SMA) Biomarkers
246410|NCT01736553|Healthy controls
246411|NCT01736553|Infants
246412|NCT01736540|iron overload, liver iron concentration (LIC), cardiac siderosis, transfusional siderosis, magnetic resonance imaging (MRI)
246413|NCT01736514|xanthine oxidase inhibitor
246414|NCT01736514|Uric acid lowering drug
246415|NCT01736488|Hypertension
246416|NCT01736488|Antihypertensive efficacy
246417|NCT01736488|Neurohormonal markers
246418|NCT01736488|Blood Pressure Response
246419|NCT01736488|Exercise
246420|NCT01736462|Cornea
246421|NCT01736462|Endothelial cell density
246422|NCT01736449|pterygium
246423|NCT01736449|bevacizumab
246424|NCT01736449|recurrence of pterygium
246425|NCT01736436|MDS
246426|NCT01736436|Myelodysplastic syndrome
246427|NCT01736436|Low and intermediate risk
246428|NCT01736436|Transfusion-dependent patients
246429|NCT01736436|Transfusion
246430|NCT01736436|Anemia
246431|NCT01736423|YM060
246432|NCT01736423|Ramosetron
246433|NCT01736423|long term study
246434|NCT01736423|Diarrhea-predominant Irritable Bowel Syndrome
246435|NCT01736423|Female
246436|NCT01736397|CKD
246437|NCT01736397|Chronic Kidney Disease
246438|NCT01736397|Phosphorus
246439|NCT01736397|Iron Deficiency
246440|NCT01736397|Iron Deficiency Anemia
246441|NCT01736397|Elevated Phosphorus
246442|NCT01736371|Sevoflurane
246443|NCT01736371|Cisatracurium infusion consumption
246444|NCT01736371|Closed loop computer control system
246445|NCT01736371|Recovery Index
246446|NCT01736358|Sprix
246447|NCT01736358|Intranasal ketoralac
246448|NCT01736358|Ketoralac
246449|NCT01736358|Urolithiasis
246450|NCT01736358|Kidney stone
246451|NCT01736358|Uretal stone
246452|NCT01736358|Ureteroscopic removal of stones
246453|NCT01736358|URS
246454|NCT01736358|Pain management
246455|NCT01736358|Pain
246456|NCT01736332|Methamphetamine
246457|NCT01736332|Amphetamines
246458|NCT01736332|Opiates
246459|NCT01736332|Oral Opiates (poppy seeds)
246460|NCT01736332|Intranasal amphetamines
246461|NCT01736319|Artemisinin-based Combination Therapies
246462|NCT01736319|Recrudescence
246463|NCT01736319|DHA-PPQ
246464|NCT01736319|Parasite Clearance Rate
246465|NCT01736306|Breast Cancer
246466|NCT01736306|Breast Milk
246467|NCT01736306|Epigenetics
246468|NCT01736293|Retinal Degeneration
246469|NCT01736280|Symptoms
246470|NCT01736280|Immunogenetics
246471|NCT01736280|Digestive Disorders
246472|NCT01736280|Gastrointestinal
246473|NCT01736267|Auditory Brainstem Implant
246474|NCT01736267|ABI
246475|NCT01736267|Nucleus 24
246476|NCT01736267|Deafness
246477|NCT01736267|Hearing loss
246478|NCT01736267|Non-tumor
246479|NCT01736267|Non-NF2
246480|NCT01736267|ABI541
246481|NCT01736228|xenotransplantation
246482|NCT01736228|type 1 diabetes
246483|NCT01736228|porcine islets
246484|NCT01736215|Anemia - cancer related
246485|NCT01736215|Eprex (Erythropoietin alfa)
246486|NCT01736202|oral fat
246487|NCT01736202|insulin sensitivity
246488|NCT01736189|Rheumatoid arthritis
246489|NCT01736176|Safety and efficacy
246490|NCT01736176|Advanced Parkinson's disease
246491|NCT01736176|levodopa-carbidopa intestinal gel,
246492|NCT01736176|carbidopa
246493|NCT01736176|levodopa
246494|NCT01736176|Non-Motor Symptom Scale
246495|NCT01736150|Hemodialysis
246496|NCT01736137|Heart failure
246497|NCT01736137|Autonomic Nervous System
246498|NCT01736137|Heart rate
246499|NCT01736137|Quality of life
246500|NCT01736124|computerize cognitive training
246501|NCT01736124|dementia
246502|NCT01736124|cognitive decline
246503|NCT01736124|Diabetes Mellitus, Type 2
246504|NCT01736111|obesity
246505|NCT01736111|weight loss
246506|NCT01736111|text message
246507|NCT01736085|tobacco cessation
246508|NCT01736085|smoking cessation
246509|NCT01736085|nicotine
246510|NCT01736085|telephone counseling
246511|NCT01736085|self-help
246512|NCT01736085|smoking abstinence
246513|NCT01736085|tobacco use disorder
246514|NCT01736085|nicotine replacement therapy
246515|NCT01736085|voucher
246516|NCT01736072|Rectal Cancer
246517|NCT01736072|Colorectal Cancer
246518|NCT01736072|Laparoscopic Surgery
246519|NCT01736072|Robotic Surgery
246520|NCT01736072|Robotic Assisted Laparoscopic Surgery
246521|NCT01736059|Stem cells
246522|NCT01736059|intravitreal
246523|NCT01736059|bone marrow CD34+ cells
246524|NCT01736059|retinal disease
246525|NCT01736059|clinical trial
246526|NCT01736059|autologous
246527|NCT01736046|CT Enterography
246528|NCT01736046|Crohn's Disease
246529|NCT01736046|Inflammatory Bowel Disease
246530|NCT01736033|Lower Urinary Tracts Symptoms
246531|NCT01736033|5 alpha reductase inhibitor
246532|NCT01736033|Proscar
246533|NCT01736033|Finasteride
246534|NCT01736033|alpha blocker
246535|NCT01736033|Tamsulosin
246536|NCT01736033|Harnal D
246537|NCT01736007|alopecia areata child
246538|NCT01736007|scalp
246539|NCT01735994|Eating disorders
246540|NCT01735994|body image
246541|NCT01735994|female athletes
246542|NCT01735994|female athlete triad
246543|NCT01735994|eating disorder prevention
246544|NCT01735994|cluster randomization
246545|NCT01735994|risk factors
246546|NCT01735994|prevention
246547|NCT01735981|Huntington's Disease
246548|NCT01735981|gait
246549|NCT01735981|exercise
246550|NCT01735981|balance
246551|NCT01735981|video game
246552|NCT01735968|Imatinib mesylate
246553|NCT01735968|BYL719
246554|NCT01735968|GIST
246555|NCT01735955|Tasigna
246556|NCT01735955|CML
246557|NCT01735955|GIST
246558|NCT01735955|nilotinib
246559|NCT01735890|Safety
246560|NCT01735890|Pharmacokinetics
246561|NCT01735877|Hemispatial neglect, Stroke
246562|NCT01735864|Indigo naturalis extract in oil
246563|NCT01735851|Thoracic epidural analgesia
246564|NCT01735851|Paravertebral block
246565|NCT01735851|pain
246566|NCT01735851|postoperative
246567|NCT01735825|coronary artery disease
246568|NCT01735825|stent
246569|NCT01735825|restenosis
246570|NCT01735812|cryoablation
246571|NCT01735812|uterine fibroid
246572|NCT01735812|uterine myoma
246573|NCT01735812|who completed her family planning
246574|NCT01735812|but wishes to preserve her uterus
246575|NCT01735786|Endoscopic Hemostasis
246576|NCT01735786|EndoClot Absorbable Polysaccharide Hemostat
246577|NCT01735786|Colonic Polyps
246578|NCT01735773|hemodialysis
246579|NCT01735773|inflammation
246580|NCT01735773|iron
246581|NCT01735773|peritoneal dialysis
246582|NCT01735773|prohepcidin
246583|NCT01735773|uremia
246584|NCT01735760|airway management
246585|NCT01735760|cricothyroid membrane
246586|NCT01735747|Lymphoma
246587|NCT01735734|Skin disease
246588|NCT01735734|Capillary Malformation
246589|NCT01735734|Laser therapy
246590|NCT01735721|Sinus Floor Augmentation
246591|NCT01735721|Bone Transplantation
246592|NCT01735721|Bone Substitute
246593|NCT01735708|pain
246594|NCT01735708|depression
246595|NCT01735708|HIV
246596|NCT01735708|adherence
246597|NCT01735695|Meconium
246598|NCT01735695|concentration
246599|NCT01735695|level
246600|NCT01735682|older adults
246601|NCT01735682|exercise
246602|NCT01735682|balance
246603|NCT01735682|gait
246604|NCT01735682|fall
246605|NCT01735682|rehabilitation
246606|NCT01735682|vibration
246607|NCT01735682|muscle
246608|NCT01735669|Remifentanil
246609|NCT01735669|Breech presentation
246610|NCT01735669|Nitrous oxide
246611|NCT01735669|Pregnancy complications
246612|NCT01735669|Caesarean section
246613|NCT01735669|Fetal version
246614|NCT01735656|Coronary heart disease;
246615|NCT01735656|Percutaneous coronary intervention;
246616|NCT01735656|Bifurcation lesion;
246617|NCT01735656|Double kissing culotte technique;
246618|NCT01735656|clinical trial
246619|NCT01735643|type 2 diabetes mellitus
246620|NCT01735643|physical activity
246621|NCT01735643|lifestyle change
246622|NCT01735643|motivation
246623|NCT01735643|patient empowerment
246624|NCT01735630|Agitation
246625|NCT01735630|Aggression
246626|NCT01735630|patients
246627|NCT01735617|congenital adrenal hyperplasia
246628|NCT01735617|glucocorticoids
246629|NCT01735617|cortisol
246630|NCT01735617|adrenal
246631|NCT01735591|Liver cirrhosis
246632|NCT01735591|Liver transplantation
246633|NCT01735591|Probiotics
246634|NCT01735591|Mortality
246635|NCT01735591|Liver function
246636|NCT01735591|Infections
246637|NCT01735578|splanchnic oxygen saturations
246638|NCT01735565|NET formation
246639|NCT01735565|neutraphil extracellular traps
246640|NCT01735565|post-engraftment immune system
246641|NCT01735552|gut reperfusion injury
246642|NCT01735552|blood transfusions
246643|NCT01735552|premature infants
246644|NCT01735552|anemia
246645|NCT01735552|regional oxygen saturations
246646|NCT01735552|necrotizing enterocolitis
246647|NCT01735552|mesenteric oxygenation
246648|NCT01735539|old age
246649|NCT01735539|sarcopenia
246650|NCT01735539|essential amino acid
246651|NCT01735539|arginine
246652|NCT01735539|contrast enhanced ultrasound
246653|NCT01735539|muscle microcirculation
246654|NCT01735539|muscle protein synthesis
246655|NCT01735526|Allogeneic and autologous
246656|NCT01735526|hematopoietic stem-cell transplantation
246657|NCT01735526|Lung diffusing capacity
246658|NCT01735526|for nitric oxide
246659|NCT01735526|carbon monoxide
246660|NCT01735526|Lung tissue density
246661|NCT01735526|microvascular damage
246662|NCT01735513|transaortic TAVI or TAVR
246663|NCT01735513|embolic protection device
246664|NCT01735513|EmbolX
246665|NCT01735513|efficacy
246666|NCT01735513|during transaortic TAVI
246667|NCT01735513|reduce the incidence of new foci of restricted diffusion on diffusion-weighted MRI
246668|NCT01735500|Prei-procedural
246669|NCT01735500|Elevation
246670|NCT01735500|cardia Troponin T
246671|NCT01735500|in stable
246672|NCT01735500|unknown
246673|NCT01735474|manual therapy
246674|NCT01735474|respiratory disease
246675|NCT01735474|thoracic movement
246676|NCT01735448|smoking cessation
246677|NCT01735448|tobacco
246678|NCT01735448|addiction
246679|NCT01735448|Aboriginal
246680|NCT01735448|youth
246681|NCT01735448|Indigenous
246682|NCT01735448|pharmacological
246683|NCT01735448|focus group
246684|NCT01735448|interview
246685|NCT01735435|geriatric patients
246686|NCT01735435|nutritional support
246687|NCT01735422|Infertility
246688|NCT01735422|Ovulation induction
246689|NCT01735422|Recombinant human Luteinizing Hormone (r-hLH)
246690|NCT01735422|Urinary human Chorionic Gonadotrophin (u-hCG)
246691|NCT01735422|Recombinant human Follicle Stimulating Hormone (Gonal-f®)
246692|NCT01735409|Advanced Nasopharyngeal Carcinoma
246693|NCT01735409|Abraxane
246694|NCT01735409|Cisplatin
246695|NCT01735409|Dose
246696|NCT01735396|African American men
246697|NCT01735396|metastatic prostate cancer
246698|NCT01735396|castration resistant
246699|NCT01735357|Eicosapentaenoic acid
246700|NCT01735357|Docosahexaenoic acid
246701|NCT01735357|Cardiovascular risk
246702|NCT01735357|Platelet function
246703|NCT01735357|Endothelial function
246704|NCT01735357|Vascular function
246705|NCT01735357|young males
246706|NCT01735331|Vascular endothelial growth factor, Recurrent Pregnancy Loss
246707|NCT01735305|Coronary Artery Disease
246708|NCT01735305|antiplatelet therapy
246709|NCT01735292|Ventilation, timer
246710|NCT01735279|tobacco dependence
246711|NCT01735279|tobacco treatment
246712|NCT01735279|omega 3 series
246713|NCT01735279|polyunsaturated fatty acids
246714|NCT01735266|Colonoscopy
246715|NCT01735253|metabolic surgery
246716|NCT01735253|gastric bypass
246717|NCT01735253|duodenojejunal bypass
246718|NCT01735253|type 2 DM
246719|NCT01735240|Phase I,
246720|NCT01735240|healthy volunteers,
246721|NCT01735240|fixed-sequence,
246722|NCT01735240|open-label,
246723|NCT01735240|ketoconazole,
246724|NCT01735240|combination,
246725|NCT01735240|safety
246726|NCT01735227|pantoprazole
246727|NCT01735227|omeprazole
246728|NCT01735227|anti - platelet effect
246729|NCT01735188|Natural history study
246730|NCT01735175|Prevention of neutropenic complications in breast cancer patients
246731|NCT01735175|Pegfilgrastim,
246732|NCT01735175|G-CSF,
246733|NCT01735175|neutropenia,
246734|NCT01735175|breast cancer,
246735|NCT01735175|myelosuppressive chemotherapy,
246736|NCT01735175|supportive care
246737|NCT01735162|Renal angina
246738|NCT01735162|AKI
246739|NCT01735162|Pediatric Intensive Care
246740|NCT01735123|infant formula
246741|NCT01735123|diet
246742|NCT01735123|diabetes mellitus, type 1
246743|NCT01735123|autoimmunity
246744|NCT01735097|Arsenic
246745|NCT01735097|Keratosis
246746|NCT01735097|Nigella sativa
246747|NCT01735097|Palm
246748|NCT01735097|Vitamin E
246749|NCT01735084|randomized controlled trial
246750|NCT01735084|pneumococcal conjugate vaccines
246751|NCT01735084|booster dose
246752|NCT01735084|immunogenicity
246753|NCT01735084|nasopharyngeal carriage
246754|NCT01735084|Australian Indigenous
246755|NCT01735084|pediatric
246756|NCT01735071|ovarian cancer
246757|NCT01735071|bevacizumab
246758|NCT01735071|trabectedin
246759|NCT01735071|carboplatin
246760|NCT01735071|randomized trial
246761|NCT01735071|phase II
246762|NCT01735032|focal epilepsy
246763|NCT01735032|pre-surgical evaluation
246764|NCT01735032|multimodal imaging
246765|NCT01735032|SEEG
246766|NCT01735019|EC95, effective concentration in 95% of subjects
246767|NCT01735006|Human Papillomavirus 16
246768|NCT01735006|Human Papillomavirus 18
246769|NCT01735006|vaccine
246770|NCT01735006|Cervical Intraepithelial Neoplasia
246771|NCT01735006|cervical Cancer
246772|NCT01735006|Vaginal intraepithelial neoplasia
246773|NCT01735006|Vulvar intraepithelial neoplasia
246774|NCT01734980|Endobronchial Ultrasound
246775|NCT01734980|transbronchial needle aspiration
246776|NCT01734967|confocal laser endomicroscopy
246777|NCT01734967|Pancreatic Neoplasms
246778|NCT01734967|CHRONIC PANCREATITIS
246779|NCT01734967|Endoscopic ultrasound
246780|NCT01734954|Nerve block
246781|NCT01734954|Sciatic nerve
246782|NCT01734954|Ultrasonography
246783|NCT01734954|Orthopedics
246784|NCT01734954|Hallux Valgus
246785|NCT01734954|Amputation
246786|NCT01734954|Arthrodesis
246787|NCT01734954|Arthroscopy
246788|NCT01734954|Fracture fixation
246789|NCT01734954|Osteotomy
246790|NCT01734954|Tendon transfer
246791|NCT01734954|Tenodesis
246792|NCT01734954|Tenotomy
246793|NCT01734954|Orthopedic procedure
246794|NCT01734941|Autism
246795|NCT01734941|Trichuris Suis Ova
246796|NCT01734941|Behavior
246797|NCT01734941|Irritability
246798|NCT01734928|Multiple Myeloma
246799|NCT01734928|Pomalidomide
246800|NCT01734915|Advanced
246801|NCT01734915|EGFR mutation
246802|NCT01734889|nitisinone
246803|NCT01734889|Orfadin
246804|NCT01734889|suspension
246805|NCT01734889|taste
246806|NCT01734889|acceptability
246807|NCT01734876|Parkinson´s disease
246808|NCT01734876|Pain
246809|NCT01734876|Sleep
246810|NCT01734876|HPA axis function
246811|NCT01734876|Health Related Quality of Life
246812|NCT01734850|HIV-1
246813|NCT01734837|Laparoscopic appendectomy
246814|NCT01734837|appendical stump closure
246815|NCT01734824|bone marrow edema, denosumab, PTH 1-84
246816|NCT01734811|Vaccine
246817|NCT01734811|Bronchospasm
246818|NCT01734798|locally advanced bladder cancer
246819|NCT01734798|Postoperative radiotherapy
246820|NCT01734798|Adjuvant chemotherapy
246821|NCT01734798|Radical Cystectomy
246822|NCT01734759|medication palatability
246823|NCT01734759|medication taste
246824|NCT01734746|ovarian cancer
246825|NCT01734746|sentinel node
246826|NCT01734733|Parkinson's Disease
246827|NCT01734733|Xenotransplantation
246828|NCT01734733|choroid plexus
246829|NCT01734707|atherosclerosis
246830|NCT01734707|regression
246831|NCT01734707|Allicor
246832|NCT01734707|garlic
246833|NCT01734707|intima-media thickness
246834|NCT01734642|Medication errors, patients hospitalized, ADRs, adverse events
246835|NCT01734629|Coronary Disease
246836|NCT01734629|COPD
246837|NCT01734629|Spirometry
246838|NCT01734629|Coronary tomography
246839|NCT01734616|Microvascular
246840|NCT01734616|Muscle
246841|NCT01734616|Nutrition
246842|NCT01734616|Exercise
246843|NCT01734616|Ageing
246844|NCT01734603|Assessment
246845|NCT01734603|Rehabilitation
246846|NCT01734603|Walking Constant Test
246847|NCT01734603|Walking Graded test
246848|NCT01734603|Six minute Walking test
246849|NCT01734603|Walking Distance
246850|NCT01734590|Flour,
246851|NCT01734590|carbohydrate,
246852|NCT01734590|digestibility
246853|NCT01734590|subjects
246854|NCT01734577|Back pain
246855|NCT01734551|Prenatal opiate exposure
246856|NCT01734551|neonatal withdrawal
246857|NCT01734551|Pharmacologic treatment
246858|NCT01734525|candidemia
246859|NCT01734525|intensive care unit
246860|NCT01734525|1,3 beta-D-glucan
246861|NCT01734512|pediatric recurrent progressive low-grade gliomas
246862|NCT01734512|pediatric progressive low-grade gliomas
246863|NCT01734512|everolimus
246864|NCT01734512|mTOR inhibition
246865|NCT01734499|Breast cancer
246866|NCT01734499|Survivorship
246867|NCT01734499|Coping
246868|NCT01734499|Quality of Life
246869|NCT01734473|COPD
246870|NCT01734473|Protein synthesis
246871|NCT01734473|Protein breakdown
246872|NCT01734473|Muscle wasting
246873|NCT01734473|Leucine
246874|NCT01734473|Hydrolyzed
246875|NCT01734473|Casein protein
246876|NCT01734473|Carbohydrates
246877|NCT01734460|pregnancy, snoring, fetal growth
246878|NCT01734434|Health care access, Pregnant women
246879|NCT01734421|Smoking cessation
246880|NCT01734421|Primary health care
246881|NCT01734421|Young people
246882|NCT01734421|Cellular phone
246883|NCT01734408|immunogenicity
246884|NCT01734408|safety
246885|NCT01734408|inactivated EV71 vaccine
246886|NCT01734395|Alzheimer's disease
246887|NCT01734395|Caregiver's Burden in Alzheimer's disease
246888|NCT01734395|Galantamine
246889|NCT01734395|Razadyne
246890|NCT01734395|Reminyl
246891|NCT01734369|Dermatomyositis
246892|NCT01734369|Inclusion Body Myositis
246893|NCT01734369|Myositis
246894|NCT01734369|Polymyositis
246895|NCT01734369|Military
246896|NCT01734356|iPS
246897|NCT01734356|fibroblast
246898|NCT01734356|arrhythmias
246899|NCT01734356|valvulopathies
246900|NCT01734356|electrophysiology
246901|NCT01734356|genetics
246902|NCT01734343|posterior capsule opacification
246903|NCT01734343|PCO
246904|NCT01734343|after cataract
246905|NCT01734343|intraocular lens
246906|NCT01734330|behavior cognitive therapy
246907|NCT01734330|Smokers
246908|NCT01734330|randomized clinical trial
246909|NCT01734304|vaccination
246910|NCT01734304|postremission therapy
246911|NCT01734304|acute myeloid leukemia
246912|NCT01734304|dendritic cells
246913|NCT01734291|Family psychoeducation
246914|NCT01734291|Major depressive disorder
246915|NCT01734291|Family burden
246916|NCT01734174|transesophageal and transthoracic echocardiogram
246917|NCT01734174|thermodilution
246918|NCT01734174|left ventricular volume
246919|NCT01734174|ejection volume
246920|NCT01734161|cesarean section
246921|NCT01734161|nausea
246922|NCT01734161|vomiting
246923|NCT01734161|dexamethasone
246924|NCT01734161|postoperative nausea and vomiting
246925|NCT01734161|antiemetics
246926|NCT01734148|pediatric
246927|NCT01734148|sleep difficulties in children
246928|NCT01734148|Sleep Education
246929|NCT01734135|B type natriuretic peptide
246930|NCT01734135|heart failure
246931|NCT01734135|cardiac imaging
246932|NCT01734135|quality of care
246933|NCT01734122|Stereotactic Radiosurgery
246934|NCT01734122|Essential Tremor
246935|NCT01734122|Parkinsonian Tremor
246936|NCT01734122|Quality of Life
246937|NCT01734122|Severity of Tremor
246938|NCT01734109|Negative Pressure Wound Therapy
246939|NCT01734109|Irrigation Therapy
246940|NCT01734109|Pressure Ulcers
246941|NCT01734109|Sacral Ulcers
246942|NCT01734096|hypertension
246943|NCT01734096|obesity
246944|NCT01734096|white coat hypertension
246945|NCT01734083|rehabilitation
246946|NCT01734083|exercise
246947|NCT01734083|fall
246948|NCT01734083|muscle
246949|NCT01734083|vibration
246950|NCT01734083|mobility
246951|NCT01734083|cognition
246952|NCT01734070|anthocyanins
246953|NCT01734070|catechins
246954|NCT01734070|chlorogenic acid
246955|NCT01734070|flavanol glycosides
246956|NCT01734057|Recombinant Human Thrombopoietin
246957|NCT01734057|rhTPO
246958|NCT01734057|Rituximab
246959|NCT01734057|Dexamethasone
246960|NCT01734044|Recombinant Human Thrombopoietin
246961|NCT01734044|rhTPO
246962|NCT01734044|Dexamethasone
246963|NCT01733953|Cardiovascular Disease
246964|NCT01733953|Childhood ALL
246965|NCT01733953|Childhood NHL
246966|NCT01733927|HIV screening
246967|NCT01733927|Rapid test for HIV
246968|NCT01733914|shoulder pain
246969|NCT01733914|acupuncture
246970|NCT01733901|Coronary heart disease
246971|NCT01733901|PCI
246972|NCT01733901|Renal sympathetic denervation
246973|NCT01733901|Hypertension
246974|NCT01733901|Diabetes
246975|NCT01733888|caries
246976|NCT01733888|caries infiltration
246977|NCT01733888|fluorosis treatment
246978|NCT01733875|Safety
246979|NCT01733875|Pharmacokinetics
246980|NCT01733875|Food effect
246981|NCT01733875|Healthy subjects
246982|NCT01733862|Impact
246983|NCT01733862|Vaccination
246984|NCT01733862|Hospitalizations
246985|NCT01733862|Rotavirus gastroenteritis
246986|NCT01733862|Japan
246987|NCT01733849|Bulgaria
246988|NCT01733849|Primary care settings
246989|NCT01733849|Children
246990|NCT01733849|Latvia
246991|NCT01733849|Acute gastroenteritis
246992|NCT01733810|Esophagitis
246993|NCT01733810|Reflux esophagitis
246994|NCT01733810|Gastroesophageal reflux disease
246995|NCT01733810|Acid
246996|NCT01733810|Inflammation
246997|NCT01733810|Esophagus
246998|NCT01733810|Cytokines
246999|NCT01733810|Esophageal squamous cell
247000|NCT01733810|Reflux
247001|NCT01733810|Squamous epithelium
247002|NCT01733797|Trismus
247003|NCT01733797|Therabite
247004|NCT01733797|Wooden spatula
247005|NCT01733797|Head and Neck cancer
247006|NCT01733784|Sleep Apnea
247007|NCT01733784|Pathophysiology
247008|NCT01733771|complementary medicine
247009|NCT01733771|hospitalized
247010|NCT01733758|albiglutide
247011|NCT01733758|Japanese
247012|NCT01733758|GSK716155
247013|NCT01733758|Type 2 diabetes mellitus
247014|NCT01733758|glucagon-like peptide 1
247015|NCT01733745|dry eye
247016|NCT01733745|lipid deficiency
247017|NCT01733745|meibomian gland
247018|NCT01733732|Dry eye
247019|NCT01733732|Lipid deficiency
247020|NCT01733732|Inflammatory markers
247021|NCT01733706|No Nicotine Electronic Cigarette
247022|NCT01733706|Antismoke intervention
247023|NCT01733693|Buprenorphine
247024|NCT01733693|Methadone
247025|NCT01733693|Cognition
247026|NCT01733680|ADHD
247027|NCT01733680|executive function
247028|NCT01733680|emotional self-regulation
247029|NCT01733667|synechia
247030|NCT01733667|Fess
247031|NCT01733667|sinus surgery
247032|NCT01733654|depression
247033|NCT01733654|major depressive disorder
247034|NCT01733628|Hypertension
247035|NCT01733628|Bevacizumab Response Predictors
247036|NCT01733628|Metastatic Breast Cancer
247037|NCT01733628|Metastatic Colon Cancer
247038|NCT01733615|Mucopolysaccharidosis Type IVA
247039|NCT01733615|Mucopolysaccharidosis Type IV
247040|NCT01733615|MPS Type IVA
247041|NCT01733615|MPS Type IV
247042|NCT01733615|Morquio Syndrome
247043|NCT01733615|Morquio Syndrome Type A
247044|NCT01733615|Urine biomarkers
247045|NCT01733589|Recombinant human endostatin
247046|NCT01733589|Non-small-Cell Lung Cancer
247047|NCT01733589|chemoradiotherapy
247048|NCT01733563|sugar sweetened beverages
247049|NCT01733563|fructose
247050|NCT01733563|lipogenesis
247051|NCT01733563|beta-oxidation
247052|NCT01733550|Intraocular Pressure
247053|NCT01733550|Tonometry, Ocular
247054|NCT01733550|iCare
247055|NCT01733537|traffic accidents, motorcycle, injury, conspicuity
247056|NCT01733524|adolescence
247057|NCT01733524|self care
247058|NCT01733485|Asthma
247059|NCT01733485|Electrophilic Fatty Acids
247060|NCT01733485|Inflammation
247061|NCT01733472|anaesthetic techniques
247062|NCT01733472|subarachnoid
247063|NCT01733472|analgesia
247064|NCT01733459|PCOS, DLBS3233, metformin,oral anti-hyperglycemic agent
247065|NCT01733446|High frequency jet ventilation
247066|NCT01733407|inherited neuropathies
247067|NCT01733394|Epilepsy
247068|NCT01733394|Generic
247069|NCT01733381|Barefoot running, minimally shod running, non-invasive measures of autonomic nervous system (ANS) functioning and mood state.
247070|NCT01733368|CRT
247071|NCT01733368|Optimization
247072|NCT01733368|Responders
247073|NCT01733329|Buccal Misoprostol
247074|NCT01733329|Uterine Atony
247075|NCT01733329|Postpartum Hemorrhage
247076|NCT01733316|Nephropathic Cystinosis
247077|NCT01733316|Cysteamine
247078|NCT01733316|Delayed-Release Cysteamine
247079|NCT01733316|Orphan Disease
247080|NCT01733316|CTNS Protein, Human
247081|NCT01733290|Botulinum Toxin A (BoNT-A)
247082|NCT01733290|Dysfunctional voiding
247083|NCT01733277|Neuropathic pain
247084|NCT01733277|Knee osteoarthritis
247085|NCT01733277|MRI
247086|NCT01732185|Congenital lung malformation
247087|NCT01732185|Congenital Cystic Adenomatoid Malformation
247088|NCT01732185|Cystic lung disease
247089|NCT01732172|Urethritis
247090|NCT01732172|Prevalence of a chronic inflammatory male genital tract
247091|NCT01732159|Ambulatory surgery
247092|NCT01732159|Checklist
247093|NCT01732159|Cancellation
247094|NCT01732146|Hypoxic Ischemic Encephalopathy
247095|NCT01732146|Term neonate
247096|NCT01732146|Neuroprotection
247097|NCT01732146|erythropoietin
247098|NCT01732133|Hypotension
247099|NCT01732133|Cesarean delivery
247100|NCT01732120|off-clamp
247101|NCT01732120|partial nephrectomy
247102|NCT01732120|renal cancer treatment
247103|NCT01732120|renal ischemia
247104|NCT01732107|Dovitinib
247105|NCT01732107|FGFR3 Mutations
247106|NCT01732107|BCG-Refractory Urothelial Carcinoma
247107|NCT01732094|Poor ovarian response
247108|NCT01732094|Poor ovarian responders
247109|NCT01732094|Bologna criteria for poor ovarian response
247110|NCT01733238|PNT2258
247111|NCT01733238|Lymphoma
247112|NCT01733238|Non-Hodgkin's Lymphoma
247113|NCT01733238|NHL
247114|NCT01733212|Nausea
247115|NCT01733212|Vomiting
247116|NCT01733212|Cesaraen
247117|NCT01733212|Ginger
247118|NCT01733212|cesarean section
247119|NCT01733199|Parkinson's disease
247120|NCT01733199|Behavioural addictions
247121|NCT01733199|Pathological gambling
247122|NCT01733199|Dopamine agonist
247123|NCT01733199|Dopamine dysregulation syndrome
247124|NCT01733199|Pharmacokinetic
247125|NCT01733199|Pramipexole
247126|NCT01733186|human umbilical cord blood-derived mesenchymal stem cells
247127|NCT01733186|MSC
247128|NCT01733186|cartilage lesion
247129|NCT01733186|cartilage defect
247130|NCT01733186|degenerative arthritis
247131|NCT01733186|stem cell implantation
247132|NCT01733173|mass in posterior fossa
247133|NCT01733173|benign
247134|NCT01733173|malignant
247135|NCT01733173|surgical resection
247136|NCT01733173|MRI
247137|NCT01733173|fMRI
247138|NCT01733173|DTI
247139|NCT01733173|12-121
247140|NCT01733160|Atrial Fibrillation
247141|NCT01733160|Stroke
247142|NCT01733160|Anticoagulants
247143|NCT01733147|Barrett's esophagus
247144|NCT01733147|Obesity
247145|NCT01733147|Omega-3 fatty acid
247146|NCT01733134|acute heart failure
247147|NCT01733134|emergency department
247148|NCT01733134|copeptin
247149|NCT01733134|adh antagonists
247150|NCT01733108|Healthy
247151|NCT01733108|Canagliflozin (JNJ-28431754)
247152|NCT01733108|Pharmacokinetics
247153|NCT01733108|Pharmacodynamics
247154|NCT01733108|Glyburide (MICRONASE)
247155|NCT01733056|Dermatology
247156|NCT01733056|Influenza Vaccine
247157|NCT01733017|heart failure
247158|NCT01733017|nutrition therapy
247159|NCT01733017|symptoms
247160|NCT01733017|quality of life
247161|NCT01733017|lycopene
247162|NCT01733017|omega-3 fatty acids
247163|NCT01733004|Cancer
247164|NCT01733004|Hepatocellular Carcinoma
247165|NCT01733004|Oncology
247166|NCT01733004|Phase I
247167|NCT01733004|ErbB3
247168|NCT01733004|IGF-1R
247169|NCT01733004|Everolimus
247170|NCT01733004|Gemcitabine
247171|NCT01733004|Abraxane
247172|NCT01732991|Prostatic Hypertrophy, Benign
247173|NCT01732991|Greenlight laser
247174|NCT01732991|Prostatic photovaporization
247175|NCT01732991|Prostatic MRI
247176|NCT01732991|Prostatic contrast-enhanced ultrasound
247177|NCT01732991|Urinary irritative signs
247178|NCT01732991|Postoperative necrotic area
247179|NCT01732978|Crying record
247180|NCT01732978|Newborn
247181|NCT01732965|Vitiligo
247182|NCT01732965|Phototherapy
247183|NCT01732965|Photochemotherapy
247184|NCT01732952|the prevalence,lipid abnormalities,CV risks
247185|NCT01732926|iNHL
247186|NCT01732926|indolent NHL
247187|NCT01732926|follicular lymphoma
247188|NCT01732926|CAL-101
247189|NCT01732926|rituximab
247190|NCT01732926|bendamustine
247191|NCT01732926|small lymphocytic lymphoma
247192|NCT01732926|lymphoplasmacytoid lymphoma
247193|NCT01732926|Waldenstrom macroglobulinemia
247194|NCT01732926|LPL
247195|NCT01732926|WM
247196|NCT01732926|Marginal zone lymphoma
247197|NCT01732926|MZL
247198|NCT01732926|SLL
247199|NCT01732926|FL
247200|NCT01732926|GS-1101
247201|NCT01732926|PI3K inhibitor
247202|NCT01732926|idelalisib
247203|NCT01732913|iNHL
247204|NCT01732913|indolent NHL
247205|NCT01732913|follicular lymphoma
247206|NCT01732913|CAL-101
247207|NCT01732913|Rituximab
247208|NCT01732913|Small lymphocytic lymphoma
247209|NCT01732913|lymphoplasmacytoid lymphoma
247210|NCT01732913|Waldenstrom macroglobulinemia
247211|NCT01732913|LPL
247212|NCT01732913|WM
247213|NCT01732913|Marginal zone lymphoma
247214|NCT01732913|MZL
247215|NCT01732913|SLL
247216|NCT01732913|FL
247217|NCT01732913|GS-1101
247218|NCT01732913|idelalisib
247219|NCT01732900|In vitro fertilization
247220|NCT01732900|Assisted reproduction
247221|NCT01732900|pregnancy outcome
247222|NCT01732900|cumulus cells
247223|NCT01732887|cochlear implants
247224|NCT01732887|speech comprehension
247225|NCT01732887|cognitive training
247226|NCT01732887|cognitive fitness
247227|NCT01732887|intervention
247228|NCT01732887|memory
247229|NCT01732887|attention
247230|NCT01732887|rehabilitation
247231|NCT01732874|DHA
247232|NCT01732874|Preterm infant
247233|NCT01732874|Inflammation
247234|NCT01732874|Growth
247235|NCT01732874|Developement
247236|NCT01732861|Chronic Lymphocytic Leukemia
247237|NCT01732861|Small Lymphocytic Leukemia
247238|NCT01732848|Volunteers
247239|NCT01732835|Aortic Insufficiency (AI) Aortic Regurgitation (AR)
247240|NCT01732822|Peripheral artery disease Atherothrombotic events Atherosclerosis
247241|NCT01732809|wrinkles
247242|NCT01732809|botulinum toxin
247243|NCT01732783|Wild-type RAS
247244|NCT01732783|Metastatic Colorectal Cancer
247245|NCT01732783|Vectibix
247246|NCT01732744|biofilm, castor bean, sodium hypochlorite, alkaline peroxide
247247|NCT01732731|Cerebral palsy
247248|NCT01732731|treadmill training
247249|NCT01732718|sickle cell disease
247250|NCT01732718|endothelial function
247251|NCT01732718|albuminuria
247252|NCT01732718|atorvastatin
247253|NCT01732718|soluble fms-like tyrosine kinase-1
247254|NCT01732705|Type 2 diabetes
247255|NCT01732705|Insulin sensitivity
247256|NCT01732705|High intensity interval training
247257|NCT01732692|Bowel preparation, MOVIPREP®
247258|NCT01732679|stroke, rehabilitation, multidisciplinary, description
247259|NCT01732666|Opioid-induced hyperalgesia (OIH)
247260|NCT01732653|virtual reality,
247261|NCT01732653|falls,
247262|NCT01732653|elderly,
247263|NCT01732653|Parkinson's disease,
247264|NCT01732653|MCI
247265|NCT01732640|Squamous cell carcinoma of the head and neck
247266|NCT01732627|Meningitis
247267|NCT01732627|Meningococcal Meningitis
247268|NCT01732627|Menactra®
247269|NCT01732627|Menomune® A/C/Y/W-135
247270|NCT01732614|Diabetic Macular Edema
247271|NCT01732614|DME
247272|NCT01732614|Laser
247273|NCT01732614|Topcon
247274|NCT01732614|EndPoint Management
247275|NCT01732601|Suicide Attempt
247276|NCT01732601|Suicidal Ideation
247277|NCT01732601|NSSI
247278|NCT01732601|Substance Use
247279|NCT01732588|Bioavailability
247280|NCT01732575|everyday activities
247281|NCT01732575|rehabilitation
247282|NCT01732575|mental illness
247283|NCT01732575|occupational therapy
247284|NCT01732562|Primary Total Knee Arthroplasty
247285|NCT01732562|Patient Expectations
247286|NCT01732562|Patient Satisfaction
247287|NCT01732562|Patient Education
247288|NCT01732562|e-Learning
247289|NCT01732523|Carotid stenosis
247290|NCT01732523|Vasa Vasorum
247291|NCT01732523|Ultrasonography
247292|NCT01732497|Underarm Hair
247293|NCT01732497|Underarm Hair Reduction
247294|NCT01732497|Axillary Hair
247295|NCT01732497|Axillary Hair Reduction
247296|NCT01732497|Underarm Odor
247297|NCT01732497|Axillary Odor
247298|NCT01732471|EMR 700733_510, Genetic disorder, Phenylketonuria, phenylalanine, Kuvan, sapropterin dihydrochloride
247299|NCT01732419|Rehabilitation, exercise therapy, coronary artery disease
247300|NCT01732393|Quercetin
247301|NCT01732393|Chemotherapy
247302|NCT01732393|Mucositis
247303|NCT01732393|Hematologic Malignancies
247304|NCT01732367|Tenofovir
247305|NCT01732367|Lamivudine
247306|NCT01732367|Adefovir
247307|NCT01732367|Chronic Hepatitis B
247308|NCT01732354|Hepatitis B virus, Tenofovir
247309|NCT01732341|STEMI
247310|NCT01732341|BMS
247311|NCT01732341|Self-expanding stent
247312|NCT01732315|Adolescent vaccination
247313|NCT01732315|Immunization rates
247314|NCT01732315|Barriers to vaccination
247315|NCT01732315|Attitudes
247316|NCT01732315|Intentions
247317|NCT01732302|Drug Utilization Review
247318|NCT01732302|Aged
247319|NCT01732302|Aged, 80 and over
247320|NCT01732302|Primary Health Care
247321|NCT01732289|Age-related hearing loss
247322|NCT01732289|Gene
247323|NCT01732289|Single nucleotide polymorphism
247324|NCT01732289|environmental factors
247325|NCT01732276|Triple-negative breast cancer
247326|NCT01732276|Epidermal growth factor receptor
247327|NCT01732276|Gefitinib
247328|NCT01732250|Gram-Negative Bacterial Infections
247329|NCT01732250|Resistant Bacteria
247330|NCT01732250|Drug Resistance, Bacterial
247331|NCT01732250|Colistin
247332|NCT01732237|Healthy
247333|NCT01732237|JNJ-42396302
247334|NCT01732237|JNJ-42692507
247335|NCT01732237|JNJ-53773187
247336|NCT01732237|Pharmacokinetics
247337|NCT01732211|Phase 2
247338|NCT01732211|Randomized
247339|NCT01732211|Double Blind
247340|NCT01732211|Placebo Controlled
247341|NCT01732211|Parallel
247342|NCT01732211|20 Week Safety
247343|NCT01732211|Tolerability
247344|NCT01732211|and Efficacy Study
247345|NCT01732081|Hepatitis B
247346|NCT01732068|Poor ovarian response
247347|NCT01732068|Poor ovarian responders
247348|NCT01732068|Bologna criteria for poor ovarian response
247349|NCT01732055|Pregnancy
247350|NCT01732055|Antenatal
247351|NCT01732055|Major Depressive Disorder
247352|NCT01732055|Psychotherapy
247353|NCT01732055|Antidepressant Medication
247354|NCT01732055|Partners
247355|NCT01732055|Spouses
247356|NCT01732055|Interpersonal Psychotherapy
247357|NCT01732042|retinal venous pressure
247358|NCT01732029|pulse oximeter
247359|NCT01732029|oxygen saturation
247360|NCT01732029|heart rate
247361|NCT01732029|calibration
247362|NCT01732029|accuracy
247363|NCT01732016|pulse oximeter
247364|NCT01732016|oxygen saturation
247365|NCT01732016|heart rate
247366|NCT01732016|calibration
247367|NCT01732016|accuracy
247368|NCT01732003|Omega-3
247369|NCT01732003|Skeletal Muscle
247370|NCT01732003|Eicosapentaenoic acid
247371|NCT01732003|Docosahexaenoic acid
247372|NCT01732003|Exercise
247373|NCT01732003|Membrane Composition
247374|NCT01732003|Lipid Metabolism
247375|NCT01731990|Peripheral artery disease
247376|NCT01731990|Intermittent claudication
247377|NCT01731990|magnetic resonance imaging
247378|NCT01731977|Psychotherapy, Psychotic disorders, Caregiver
247379|NCT01731964|Macular Degeneration
247380|NCT01731964|Visual Impairment
247381|NCT01731964|Implantable Telescope
247382|NCT01731951|Myelofibrosis
247383|NCT01731951|Myelodysplastic Syndromes
247384|NCT01731951|Myeloproliferative Neoplasm
247385|NCT01731951|Imetelstat
247386|NCT01731951|GRN163L
247387|NCT01731938|Fibrin Sealant
247388|NCT01731938|Soft tissue open surgery
247389|NCT01731938|Oxidized cellulose pads
247390|NCT01731925|midgut carcinoid tumors
247391|NCT01731925|progressive
247392|NCT01731925|advanced
247393|NCT01731925|metastatic
247394|NCT01731899|major depression
247395|NCT01731899|fibromyalgia
247396|NCT01731899|agomelatine
247397|NCT01731899|Becks' Depression Inventory (BDI)
247398|NCT01731899|Pittsburgh's Sleep Quality Index (PSQI)
247399|NCT01731886|Stem cell transplant
247400|NCT01731886|plasma cell myeloma
247401|NCT01731886|multiple myeloma
247402|NCT01731873|postoperative
247403|NCT01731873|pediatric
247404|NCT01731873|pharmacogenetic
247405|NCT01731873|opioid
247406|NCT01731873|perioperative
247407|NCT01731873|respiratory depression
247408|NCT01731860|PET/CT
247409|NCT01731860|Philips
247410|NCT01731847|dysphagia,endoscopy, electrical stimulation,stroke
247411|NCT01731834|Pain
247412|NCT01731834|Stress
247413|NCT01731834|Physiotherapy
247414|NCT01731834|Children
247415|NCT01731821|Pancreaticoduodenectomy
247416|NCT01731821|Pancreaticojejunostomy
247417|NCT01731808|Nursing counseling
247418|NCT01731808|diabetic foot
247419|NCT01731795|acute respiratory distress syndrome, mechanical ventilation
247420|NCT01731782|colorectal surgery
247421|NCT01731769|Seroma Formation
247422|NCT01731769|Axillary Lymph Node Dissection
247423|NCT01731769|Breast cancer
247424|NCT01731769|Early Vacuum Assisted Closure
247425|NCT01731756|Palm
247426|NCT01731756|Arsenic
247427|NCT01731756|Keratosis
247428|NCT01731756|Salicylic acid
247429|NCT01731756|Azadirachta indica
247430|NCT01731756|Neem
247431|NCT01731730|Postsurgical pain
247432|NCT01731730|Total knee arthroplasty
247433|NCT01731730|Total knee replacement
247434|NCT01731717|depression
247435|NCT01731717|stepped care
247436|NCT01731717|evidence-based medicine
247437|NCT01731717|health services research
247438|NCT01731717|psychotherapy
247439|NCT01731717|complex intervention
247440|NCT01731717|guideline
247441|NCT01731704|5 or more brain metastases
247442|NCT01731704|proven diagnosis of a non-hematopoietic malignancy
247443|NCT01731704|non-small cell lung cancer or germ cell malignancy
247444|NCT01731665|Crohn's disease
247445|NCT01731665|ulcerative colitis
247446|NCT01731665|epidemiology
247447|NCT01731665|Korea
247448|NCT01731652|bladder cancer
247449|NCT01731652|carcinoma in situ
247450|NCT01731652|non muscle invasive bladder cancer
247451|NCT01731587|Non-small cell lung cancer (NSCLC)
247452|NCT01731587|exploratory study
247453|NCT01731587|L-BLP25
247454|NCT01731561|Granulomatosis with Polyangiitis
247455|NCT01731561|Microscopic polyangiitis
247456|NCT01731561|Renal limited forms
247457|NCT01731561|ANCA-associated vasculitis
247458|NCT01731561|Rituximab
247459|NCT01731535|osteoporosis, low trauma fracture, non-union fracture, delayed healing fracture, bisphosphonate
247460|NCT01731509|congenital diaphragmatic hernia
247461|NCT01731509|fetoscopy
247462|NCT01731509|fetal endoscopic tracheal occlusion
247463|NCT01731509|pulmonary hypoplasia
247464|NCT01731509|fetal surgery
247465|NCT01731509|fetal lung
247466|NCT01731496|Human Papillomavirus
247467|NCT01731483|virulence factors
247468|NCT01731457|ischemia, reperfusion, kidney, transplantation
247469|NCT01731444|blood loss
247470|NCT01731444|burn
247471|NCT01731444|hemostasis
247472|NCT01731431|Gestational Diabetes,
247473|NCT01731431|Insulin,
247474|NCT01731431|Glyburide,
247475|NCT01731431|Glycemia
247476|NCT01731418|Post Traumatic Stress Disorder
247477|NCT01731418|Depression
247478|NCT01731418|Intimate Partner violence
247479|NCT01731418|Narrative Exposure Therapy
247480|NCT01731405|Medication Guides
247481|NCT01731405|FDA
247482|NCT01731405|Prototype
247483|NCT01731405|Format
247484|NCT01731392|Diarrhea
247485|NCT01731392|Children
247486|NCT01731392|Lactobacilli
247487|NCT01731379|spectroscopy
247488|NCT01731379|nerve
247489|NCT01731379|muscle
247490|NCT01731379|fat
247491|NCT01731353|invasive fungal infection
247492|NCT01731353|Web-based registry
247493|NCT01731340|Calcium Supplements
247494|NCT01731340|Dairy Foods
247495|NCT01731340|Cardiovascular Diseases
247496|NCT01731340|Osteoporosis
247497|NCT01731340|Postmenopause
247498|NCT01731340|Vitamin D
247499|NCT01731340|Micronutrients
247500|NCT01731340|Primary Prevention
247501|NCT01731340|Bone Health
247502|NCT01731327|Phase 1
247503|NCT01731327|relative bioavailability
247504|NCT01731327|modified release
247505|NCT01731327|tofacitinib
247506|NCT01731327|CP-690
247507|NCT01731327|550
247508|NCT01731327|pharmacokinetic
247509|NCT01731301|Chronic hepatitis C
247510|NCT01731301|HCV
247511|NCT01731301|End stage renal disease
247512|NCT01731301|ESRD
247513|NCT01731301|Boceprevir
247514|NCT01731301|Ribavirin
247515|NCT01731301|Peg-interferon
247516|NCT01731301|Triple therapy
247517|NCT01731288|pregnancy
247518|NCT01731288|childbirth
247519|NCT01731288|pain
247520|NCT01731288|vulvodynia
247521|NCT01731288|provoked vestibulodynia
247522|NCT01731275|Healthy volunteers
247523|NCT01731275|immunogenicity
247524|NCT01731275|anti-E6011 antibody
247525|NCT01731262|Arthritis, Rheumatoid
247526|NCT01731262|Sonic hedgehog protein, human
247527|NCT01731262|Neovascularization, Pathologic
247528|NCT01731262|Synovitis
247529|NCT01731249|Sublingual immunotherapy
247530|NCT01731249|Birch pollen extract solution
247531|NCT01731249|Allergic rhinoconjunctivitis
247532|NCT01731236|Carnitine metabolism
247533|NCT01731236|gut flora
247534|NCT01731223|Insomnia
247535|NCT01731223|Primary health care
247536|NCT01731197|obesity, isolated soy protein, satiety, food intake
247537|NCT01731184|acute traumatic pain, pre-hospital setting, Midazolam
247538|NCT01731171|mania
247539|NCT01731171|manic episode
247540|NCT01731171|mixed episode
247541|NCT01731171|bipolar disorder
247542|NCT01731171|schizoaffective disorder
247543|NCT01731171|probiotics
247544|NCT01731171|probiotic supplement
247545|NCT01731171|relapse prevention
247546|NCT01731171|new mood episode
247547|NCT01731171|re-hospitalization
247548|NCT01731145|Tremor
247549|NCT01731145|SNUMAP
247550|NCT01731145|accelerometry
247551|NCT01731145|gyroscope
247552|NCT01731145|clinical rating scale
247553|NCT01731132|HRQoL
247554|NCT01731132|IUD
247555|NCT01731132|Contraception
247556|NCT01731132|SEC-QoL
247557|NCT01731119|Latuda,lurasidone,antipsychotics,autism, mood, psychosis
247558|NCT01731093|aged
247559|NCT01731093|health
247560|NCT01731093|brain
247561|NCT01731054|lupus nephritis
247562|NCT01731054|normal healthy volunteer
247563|NCT01731054|MRI
247564|NCT01731041|coronary disease, platelet function, platelet inhibitors
247565|NCT01731002|Glaucoma
247566|NCT01730989|menopause
247567|NCT01730989|Kupperman
247568|NCT01730989|hot flushes
247569|NCT01730989|isoflavones
247570|NCT01730989|magnolia
247571|NCT01730989|chaste tree
247572|NCT01730976|asthma, elderly, vitamin D
247573|NCT01730924|Atrial fibrillation
247574|NCT01730924|Contact force
247575|NCT01730924|Ablation
247576|NCT01730911|Bleeding
247577|NCT01730911|Cramping
247578|NCT01730911|Pregnancy with intrauterine device in place
247579|NCT01730911|Intrauterine device expulsion
247580|NCT01730911|Intrauterine device removal
247581|NCT01730859|Balance exercise
247582|NCT01730859|Ankle
247583|NCT01730859|Postural stability
247584|NCT01730859|Taping
247585|NCT01730859|Biodex
247586|NCT01730846|smoking lapse behavior
247587|NCT01730846|smoking cessation
247588|NCT01730846|doxazosin
247589|NCT01730846|medication effect on smoking lapse behavior
247590|NCT01730846|medication effect on smoking cessation
247591|NCT01730846|stress
247592|NCT01730794|Acute Respiratory Failure
247593|NCT01730794|Mechanical Ventilation
247594|NCT01730794|NAVA
247595|NCT01730794|Lung protective ventilation
247596|NCT01730794|invasive ventilation
247597|NCT01730794|noninvasive ventilation
247598|NCT01730781|Cannabis dependence
247599|NCT01730781|Brain Imaging
247600|NCT01730781|Schizophrenia
247601|NCT01730768|schizophrenia, chronic stable schizophrenia, cognition, memory, visual learning, CogState
247602|NCT01730755|Polycythemia
247603|NCT01730716|Human spinal cord derived neural stem cell transplantation
247604|NCT01730716|ALS
247605|NCT01730703|walking
247606|NCT01730703|incentives
247607|NCT01730703|elderly
247608|NCT01730690|Bacterial meningitis in adults
247609|NCT01730690|determinants of in-hospital mortality
247610|NCT01730677|Lapatinib
247611|NCT01730677|Vinorelbine
247612|NCT01730664|ertapenem
247613|NCT01730664|tuberculosis
247614|NCT01730664|pharmacokinetics
247615|NCT01730651|cervical cancer with metastatic lymphadenopathies
247616|NCT01730638|thyroid,
247617|NCT01730638|endocrine tumour
247618|NCT01730638|Nuclear medicine,
247619|NCT01730638|molecular imaging
247620|NCT01730638|ImmunoTEP
247621|NCT01730625|Attention bias modification treatment (ABMT)
247622|NCT01730625|Attention biases
247623|NCT01730625|Anxious children
247624|NCT01730625|Cognitive Behavioral Therapy (CBT)
247625|NCT01730612|ImmunoTEP
247626|NCT01730612|HER2 negative
247627|NCT01730612|Breast Cancer
247628|NCT01730586|Colorectal Cancer
247629|NCT01730586|Cancer of Gastrointestinal Tract
247630|NCT01730586|CIMP-high Colorectal Adenocarcinoma
247631|NCT01730586|Small Bowel Adenocarcinomas
247632|NCT01730586|Colorectal
247633|NCT01730586|Small bowel cancer
247634|NCT01730586|Abraxane
247635|NCT01730586|Nab-Paclitaxel
247636|NCT01730586|Paclitaxel (Protein-Bound)
247637|NCT01730586|ABI-007
247638|NCT01730573|interscalene
247639|NCT01730573|suprascapular
247640|NCT01730573|axillary
247641|NCT01730547|Mesenchymal stem cells
247642|NCT01730547|Multiple Sclerosis
247643|NCT01730547|Autoimmune diseases
247644|NCT01730534|Phase IIIb
247645|NCT01730534|T2DM
247646|NCT01730534|cardiovascular events
247647|NCT01730495|Chronic fatigue syndrome
247648|NCT01730495|CFS
247649|NCT01730495|Myalgic Encephalomyelitis (ME)
247650|NCT01730495|CFS/ME
247651|NCT01730495|Tumor necrosis factor-alpha
247652|NCT01730495|TNF-alpha
247653|NCT01730495|Etanercept
247654|NCT01730482|excretion
247655|NCT01730482|healthy volunteer
247656|NCT01730482|migalastat hydrochloride
247657|NCT01730482|AT1001
247658|NCT01730482|pharmacokinetics
247659|NCT01730482|Fabry disease
247660|NCT01730469|Pharmacokinetics
247661|NCT01730469|GR181413
247662|NCT01730469|Safety
247663|NCT01730469|AT1001
247664|NCT01730469|Migalastat hydrochloride
247665|NCT01730443|traumatic brain injury
247666|NCT01730430|non-AD dementias
247667|NCT01730430|healthy elderly controls
247668|NCT01730417|Phase 1
247669|NCT01730417|no carrier added metaiodobenzylguanidine
247670|NCT01730417|radiation dosimetry
247671|NCT01730378|Influenza vaccine
247672|NCT01730365|spectroscopy
247673|NCT01730365|tumour
247674|NCT01730365|biopsy
247675|NCT01730365|malignancy
247676|NCT01730352|immune thrombocytopenic purpura
247677|NCT01730352|chronic immune thrombocytopenic purpura
247678|NCT01730352|secondary immune thrombocytopenic purpura
247679|NCT01730352|Helicobacter pylori infection
247680|NCT01730352|Helicobacter pylori gastritis
247681|NCT01730352|children
247682|NCT01730352|adolescents
247683|NCT01730339|Skin scarring
247684|NCT01730339|cicatrix
247685|NCT01730339|breast scar
247686|NCT01730339|hypertrophic scar
247687|NCT01730326|Headache
247688|NCT01730326|paracetamol
247689|NCT01730326|dexketoprofen
247690|NCT01730326|emergency department
247691|NCT01730313|Nodding syndrome
247692|NCT01730287|Stepwise Excavation
247693|NCT01730287|Pulpal vitality
247694|NCT01730287|Deep caries lesions
247695|NCT01730287|Clinical symptoms
247696|NCT01730287|Radiographic evaluation
247697|NCT01730261|Traumatic Brain Injury
247698|NCT01730261|TBI
247699|NCT01730261|Executive Dysfunction
247700|NCT01730261|Emotional Regulation
247701|NCT01730261|Problem Solving
247702|NCT01730261|Self-regulation
247703|NCT01730261|Cognitive Rehabilitation
247704|NCT01730261|Metacognitive Strategies
247705|NCT01730261|Cognitive-behavioral therapy
247706|NCT01730261|Online Therapy
247707|NCT01730261|Group therapy
247708|NCT01730261|Group videoconference
247709|NCT01730261|Telehealth
247710|NCT01730261|Telerehabilitation
247711|NCT01730248|Myelofibrosis,
247712|NCT01730248|PMF,
247713|NCT01730248|PPV-MF,
247714|NCT01730248|PET-MF,
247715|NCT01730248|Primary Myelofibrosis,
247716|NCT01730248|Post-polycythemia vera myelofibrosis,
247717|NCT01730248|Post-essential thrombocythemia myelofibrosis
247718|NCT01730222|pancreatic adenocarcinoma
247719|NCT01730222|stage III disease
247720|NCT01730222|stage IV disease
247721|NCT01730222|chemotherapy
247722|NCT01730209|Tuberous Sclerosis Complex
247723|NCT01730209|TSC
247724|NCT01730209|Autism
247725|NCT01730209|Learning problems
247726|NCT01730209|Everolimus
247727|NCT01730209|RAD001
247728|NCT01730209|Treatment
247729|NCT01730209|Cognition
247730|NCT01730209|Intellectual disability
247731|NCT01730170|Epilepsy
247732|NCT01730170|Pregnancy
247733|NCT01730144|Nasal Spray Vaccine
247734|NCT01730144|Nasal Cells
247735|NCT01730131|Immune Reconstitution Syndrome
247736|NCT01730131|Human Immunodeficiency Virus
247737|NCT01730131|Multiple Sclerosis
247738|NCT01730118|Metastatic Solid Tumors
247739|NCT01730118|Human Epidermal Growth Factor Receptor 2 Expression (HER2/neu)
247740|NCT01730118|Trastuzumab Exposure
247741|NCT01730118|Dendritic Cell Vaccine
247742|NCT01730118|Breast Cancer
247743|NCT01730105|Adaptive Thermogenesis
247744|NCT01730105|Adipose Tissue
247745|NCT01730105|Body Composition
247746|NCT01730105|Body Weight Regulation
247747|NCT01730105|Brown Adipose Tissue
247748|NCT01730092|Vascular Inflammation
247749|NCT01730092|Microarray
247750|NCT01730092|Right Ventricular Function
247751|NCT01730092|Endothelial Dysfunction
247752|NCT01730092|Magnetic Resonance Imaging
247753|NCT01730079|Attention Deficit Hyperactivity Disorder
247754|NCT01730079|Autism
247755|NCT01730079|Near Infrared Spectroscopy
247756|NCT01730079|Brain Activity
247757|NCT01730066|Probiotics
247758|NCT01730066|Pathogenic enteric bacteria
247759|NCT01730066|Oropharyngeal flora
247760|NCT01730066|CRP
247761|NCT01730066|WBC
247762|NCT01729949|Nutrition
247763|NCT01729949|Polyphenols
247764|NCT01729949|Berries
247765|NCT01729949|Overweight
247766|NCT01729949|Lipid Panels
247767|NCT01729936|Sitting time
247768|NCT01729936|Overweight
247769|NCT01729936|Obese
247770|NCT01729936|Primary Health Care
247771|NCT01729910|overweight
247772|NCT01729910|obesity
247773|NCT01729910|rural
247774|NCT01729910|primary care
247775|NCT01729897|gastroscopy
247776|NCT01729897|sedation
247777|NCT01729897|etomidate
247778|NCT01729871|Atrial Fibrillation
247779|NCT01729871|Irregular heart beat
247780|NCT01729871|Catheter Ablation
247781|NCT01729871|Rivaroxaban
247782|NCT01729793|TNFalpha
247783|NCT01729793|IL6
247784|NCT01729793|postprandial
247785|NCT01729793|digestive
247786|NCT01729793|inflammation
247787|NCT01729793|IL1beta
247788|NCT01729793|CRP
247789|NCT01729793|CBC
247790|NCT01729793|ESR
247791|NCT01729780|EEG-NF
247792|NCT01729780|Neurofeedback
247793|NCT01729780|Prevention
247794|NCT01729780|ACS
247795|NCT01729741|Drain or no drain
247796|NCT01729741|Thyroid surgery
247797|NCT01729741|Randomized Trial
247798|NCT01729728|Tonsillectomy
247799|NCT01729728|Dental surgery
247800|NCT01729728|Ear surgery
247801|NCT01729728|Nose surgery
247802|NCT01729728|Throat surgery
247803|NCT01729715|Pediatric
247804|NCT01729715|Insomnia
247805|NCT01729702|1- Hypertrophic cardiomyopathy
247806|NCT01729702|2- BNP
247807|NCT01729702|3- NT-proBNP
247808|NCT01729702|4- Neurohormons
247809|NCT01729663|melanoma
247810|NCT01729663|irradiated-allogeneic cells
247811|NCT01729663|therapeutic vaccine
247812|NCT01729663|Interferon alpha 2-b
247813|NCT01729650|Psychotic Disorders,
247814|NCT01729650|Heart Diseases
247815|NCT01729637|Lung Transplantation
247816|NCT01729637|Respiratory Mechanics
247817|NCT01729637|Isolated lung perfusion
247818|NCT01729637|Ex-vivo lung perfusion
247819|NCT01729637|Lung mechanics
247820|NCT01729624|Wegener Granulomatosis
247821|NCT01729624|Microscopic Polyangiitis
247822|NCT01729624|Churg-Strauss Syndrome
247823|NCT01729624|Antibodies, Antineutrophil Cytoplasmic
247824|NCT01729611|Scleroderma
247825|NCT01729611|Cirrhosis
247826|NCT01729598|cognitively normal elderly population
247827|NCT01729598|safety and tolerability
247828|NCT01729585|cystic fibrosis
247829|NCT01729585|quality of life
247830|NCT01729572|schizophrenia
247831|NCT01729572|Schizoaffective Disorder
247832|NCT01729572|disease management
247833|NCT01729572|treatment
247834|NCT01729572|rehabilitation
247835|NCT01729572|pharmacotherapy
247836|NCT01729559|venous thromboembolic disease
247837|NCT01729559|deep vein thrombosis
247838|NCT01729559|pulmonary embolism
247839|NCT01729559|trauma
247840|NCT01729559|antithrombotic prophylaxis
247841|NCT01729546|SMBG (self-monitoring of blood glucose)
247842|NCT01729546|POCT
247843|NCT01729546|System Accuracy
247844|NCT01729533|ICSI
247845|NCT01729533|IMSI
247846|NCT01729533|Pregnancy
247847|NCT01729533|Sperm morphology
247848|NCT01729533|Unexplained infertility
247849|NCT01729520|Total knee arthroplasty
247850|NCT01729520|Total knee replacement
247851|NCT01729520|Strength training
247852|NCT01729520|Resistance training
247853|NCT01729520|Physical therapy modalities
247854|NCT01729520|Fatigue
247855|NCT01729507|Smoking cessation
247856|NCT01729507|Add on and smoking cessation
247857|NCT01729507|Therapy for tobacco dependence
247858|NCT01729507|Transcranial direct current stimulation
247859|NCT01729494|belatacept
247860|NCT01729494|rabbit antithymocyte globulin
247861|NCT01729494|alemtuzumab
247862|NCT01729494|corticosteroid withdrawal
247863|NCT01729468|Low Dose Acetylsalicylic Acid
247864|NCT01729468|Prevention
247865|NCT01729468|Pre-eclampsia
247866|NCT01729468|Intra-uterine Growth Restriction
247867|NCT01729468|Primiparous Women
247868|NCT01729468|Bilateral Uterine Artery Notches
247869|NCT01729468|First Quarter
247870|NCT01729455|Belimumab
247871|NCT01729455|Connective Tissue Diseases
247872|NCT01729455|Lupus
247873|NCT01729455|Additional relevant MeSH terms:
247874|NCT01729455|Lupus Erythematosus, Systemic
247875|NCT01729455|Autoimmune Diseases
247876|NCT01729455|SLE
247877|NCT01729455|Systemic Lupus Erythematosus
247878|NCT01729455|Autoimmune Disease
247879|NCT01729455|Antibodies
247880|NCT01729455|Immune System Diseases
247881|NCT01729429|Papillomavirus Vaccines
247882|NCT01729429|Intervention Studies
247883|NCT01729429|Health Services Research
247884|NCT01729429|Cancer of Cervix
247885|NCT01729416|colon
247886|NCT01729416|cancer
247887|NCT01729416|screening
247888|NCT01729416|water exchange
247889|NCT01729416|air
247890|NCT01729416|method
247891|NCT01729416|polyp
247892|NCT01729416|adenoma
247893|NCT01729416|detection
247894|NCT01729416|rate
247895|NCT01729416|sedation
247896|NCT01729416|time
247897|NCT01729416|procedure
247898|NCT01729390|Feeding behavior
247899|NCT01729364|elective CABG
247900|NCT01729364|renal impairment
247901|NCT01729364|GFR
247902|NCT01729364|renal blood flow
247903|NCT01729364|colloid
247904|NCT01729364|crystalloid
247905|NCT01729364|thermodilution technique
247906|NCT01729364|oxygen supply demand
247907|NCT01729351|Primary Care
247908|NCT01729351|Particle size
247909|NCT01729351|beclomethasone dipropionate
247910|NCT01729351|Asthma Management
247911|NCT01729351|Maintenance Therapy
247912|NCT01729351|Metered-Dose Inhaler
247913|NCT01729351|Smoking
247914|NCT01729325|Post-traumatic Stress disorder (PTSD)
247915|NCT01729325|Aggressive Behavior
247916|NCT01729325|Appetitive Aggression
247917|NCT01729325|Resilience
247918|NCT01729325|Preventive Narrative Exposure Therapy
247919|NCT01729299|ghrelin
247920|NCT01729299|glucose control
247921|NCT01729299|GLP-1
247922|NCT01729299|Exendin (9-39)
247923|NCT01729299|insulin
247924|NCT01729260|Glioblastoma
247925|NCT01729260|mebendazole
247926|NCT01729260|temozolomide
247927|NCT01729247|Asthma
247928|NCT01729234|age related Endothelial Dysfunction
247929|NCT01729221|Hepatocellular carcinoma
247930|NCT01729221|Hepatitis C virus
247931|NCT01729208|myopia progression
247932|NCT01729208|myopia control
247933|NCT01729195|bioabsorbable implant
247934|NCT01729195|bone screw
247935|NCT01729195|local antibiotic prophylaxis
247936|NCT01729195|syndesmosis injury
247937|NCT01729195|ankle fracture
247938|NCT01729195|ciprofloxacin
247939|NCT01729182|Low dose Aspirin(LDA)
247940|NCT01729182|Gastric ulcer or duodenal ulcer
247941|NCT01729182|Nexium
247942|NCT01729169|Sarcoidosis
247943|NCT01729169|Cardiac sarcoidosis
247944|NCT01729169|18-FDG PET
247945|NCT01729169|68Ga-DOTANOC PET
247946|NCT01729156|Type 2 diabetes
247947|NCT01729156|Hepatic fatty acid oxidation
247948|NCT01729156|Dyslipidemia
247949|NCT01729156|Metformin
247950|NCT01729143|black pepper
247951|NCT01729143|metabolic chamber
247952|NCT01729143|respiratory chamber
247953|NCT01729117|Type 2 diabetes
247954|NCT01729117|Obesity
247955|NCT01729117|Insulin
247956|NCT01729117|Hispanic
247957|NCT01729117|Low-income
247958|NCT01729117|Meal replacement
247959|NCT01729104|Lymphoma
247960|NCT01729104|Mantle cell lymphoma
247961|NCT01729104|MCL
247962|NCT01729104|Relapsed
247963|NCT01729104|Refractory
247964|NCT01729104|Carfilzomib
247965|NCT01729104|Rituximab
247966|NCT01729104|Rituxan
247967|NCT01729104|Lenalidomide
247968|NCT01729104|CC-5013
247969|NCT01729104|Revlimid
247970|NCT01729091|Myeloma
247971|NCT01729091|Multiple myeloma
247972|NCT01729091|MM
247973|NCT01729091|Umbilical cord blood
247974|NCT01729091|UCB
247975|NCT01729091|Natural killer cells
247976|NCT01729091|NK
247977|NCT01729091|Autologous stem cell transplant
247978|NCT01729091|Stem cell infusion
247979|NCT01729091|High dose chemotherapy
247980|NCT01729091|Lenalidomide
247981|NCT01729091|CC-5013
247982|NCT01729091|Revlimid
247983|NCT01729091|Melphalan
247984|NCT01729091|Alkeran
247985|NCT01729091|Interleukin-2
247986|NCT01729091|IL-2
247987|NCT01729091|Aldesleukin
247988|NCT01729091|Proleukin
247989|NCT01729091|G-CSF
247990|NCT01729091|Filgrastim
247991|NCT01729091|Neupogen
247992|NCT01729065|Spinal Accessory Nerve Palsy, Cranial Nerve XI, shoulder weakness, neck stiffness, head and neck cancer, neck dissection
247993|NCT01729052|Acupuncture
247994|NCT01729052|Children
247995|NCT01729052|Postoperative nausea and vomiting
247996|NCT01729052|Postoperative pain
247997|NCT01729052|Parental attitudes
247998|NCT01729052|Parental expectations
247999|NCT01729039|rehabilitation
248000|NCT01729039|aged
248001|NCT01729039|aged, 80 and over
248002|NCT01729039|vestibular diseases
248003|NCT01729026|Veterans
248004|NCT01729026|Posttraumatic Stress Disorder
248005|NCT01729026|dog adoption
248006|NCT01729026|companion animal
248007|NCT01729013|vitamin D
248008|NCT01729013|fat
248009|NCT01729013|biopsy
248010|NCT01729000|prematurity
248011|NCT01729000|infection control
248012|NCT01729000|necrotizing entercolitis
248013|NCT01728974|Obstructive Sleep Apnea
248014|NCT01728974|Pathophysiology
248015|NCT01728961|HIV 1
248016|NCT01728961|NVP
248017|NCT01728961|malaria
248018|NCT01728961|Children
248019|NCT01728961|Youth
248020|NCT01728961|nevirapine
248021|NCT01728961|Coartem Dispersible
248022|NCT01728961|Artemether
248023|NCT01728961|Lumefantrine
248024|NCT01728961|Pharmacokinetics
248025|NCT01728948|Sorafenib
248026|NCT01728948|renal cell carcinoma(RCC)
248027|NCT01728948|elderly
248028|NCT01728948|effectiveness
248029|NCT01728948|safety
248030|NCT01728935|HBV
248031|NCT01728935|Tenofovir
248032|NCT01728935|HBV DNA
248033|NCT01728935|HBsAg
248034|NCT01728935|Resistance
248035|NCT01728922|Clinically isolated syndrome
248036|NCT01728922|Multiple sclerosis
248037|NCT01728922|Vitamin D
248038|NCT01728922|Immune response
248039|NCT01728922|CD4 T cell subsets
248040|NCT01728922|Cytokine
248041|NCT01728909|Oxytocin
248042|NCT01728909|Syntocinon
248043|NCT01728909|Social Cognition
248044|NCT01728909|Social Approach Behaviors
248045|NCT01728896|Acute pancreatitis, nutrition
248046|NCT01728883|Diabetic Retinopathy
248047|NCT01728883|Diabetic Macular Edema
248048|NCT01728883|Macular Edema
248049|NCT01728883|Maculopathy
248050|NCT01728883|home monitoring
248051|NCT01728883|shape discrimination hyperacuity
248052|NCT01728883|Psychophysical Testing
248053|NCT01728870|Pediatric
248054|NCT01728870|Crohn's disease
248055|NCT01728870|Mild to moderate Crohn's Disease
248056|NCT01728870|Diet
248057|NCT01728870|Enteral Nutrition
248058|NCT01728857|Lipolysis
248059|NCT01728857|Cryolipolysis
248060|NCT01728857|Fat Reduction
248061|NCT01728831|Red Cell Transfusion
248062|NCT01728831|Cerebral tissue oxygenation
248063|NCT01728831|Traumatic brain injury
248064|NCT01728805|Cutaneous T-Cell Lymphoma (CTCL)
248065|NCT01728805|myocis fungoides (MF)
248066|NCT01728805|Sezary Syndrome (SS)
248067|NCT01728792|Prophylactic vaccination
248068|NCT01728766|Breast milk zinc transfer
248069|NCT01728766|Bangladeshi infants
248070|NCT01728766|appropriate-for-gestational-age
248071|NCT01728766|small-for-gestational-age
248072|NCT01728766|plasma zinc
248073|NCT01728740|Bioequivalence
248074|NCT01728740|Acarbose
248075|NCT01728740|Metformin
248076|NCT01728740|FDC
248077|NCT01728727|liver cirrhosis
248078|NCT01728727|end stage liver disease
248079|NCT01728727|umbilical cord
248080|NCT01728727|mesenchymal stem cells
248081|NCT01728727|HBV
248082|NCT01728714|Diabetes; compliance
248083|NCT01728701|Malaria
248084|NCT01728701|Plasmodium falciparum
248085|NCT01728701|PfSPZ Challenge
248086|NCT01728701|Chemoprophylaxis
248087|NCT01728701|PfSPZ-CVac
248088|NCT01728688|liver cirrhosis
248089|NCT01728688|stem cell
248090|NCT01728688|peripheral blood
248091|NCT01728688|autologous
248092|NCT01728688|HBV
248093|NCT01728688|end stage liver disease
248094|NCT01728675|Aging
248095|NCT01728675|Skeletal muscle
248096|NCT01728675|Biomarkers
248097|NCT01728675|Adaptation
248098|NCT01728662|emphysema
248099|NCT01728662|lung volume reduction therapy
248100|NCT01728649|Acute Ischemic Stroke
248101|NCT01728649|Mild Hypothermia
248102|NCT01728649|Stroke
248103|NCT01728649|Hypothermia
248104|NCT01728623|Thyroid cancer
248105|NCT01728610|irritable bowel syndrome
248106|NCT01728610|probiotic
248107|NCT01728610|pain
248108|NCT01728610|bloating
248109|NCT01728610|diarrhoea
248110|NCT01728610|constipation
248111|NCT01728597|no history of cardiovascular diseases
248112|NCT01728571|COPD
248113|NCT01728571|asthma
248114|NCT01728571|pulmonary function
248115|NCT01728571|pneumonia
248116|NCT01728558|Sedation
248117|NCT01728558|Delirium
248118|NCT01728558|Goal Directed
248119|NCT01728558|Dexmedetomidine
248120|NCT01728558|Mortality
248121|NCT01728558|Mechanical ventilation
248122|NCT01728558|Intensive care
248123|NCT01728558|Critically Ill
248124|NCT01728545|Cord blood registry
248125|NCT01728545|Umbilical Cord Blood
248126|NCT01728545|fetal blood
248127|NCT01728545|placenta
248128|NCT01728545|Placental Blood Stem Cell Transplantation
248129|NCT01728545|hematopoietic progenitor cells
248130|NCT01728545|Hematopoietic Stem Cell Transplantation
248131|NCT01728545|cord blood unit total nucleated cell
248132|NCT01728545|TNC
248133|NCT01728545|CD34-positive(+) cell
248134|NCT01728545|human leukocyte antigen
248135|NCT01728545|HLA
248136|NCT01728545|allogeneic transplantation
248137|NCT01728519|Allergy
248138|NCT01728519|Birch Pollen
248139|NCT01728519|Immunotherapy
248140|NCT01728506|breast cancer survivor
248141|NCT01728506|Weight loss
248142|NCT01728506|Exercise
248143|NCT01728493|Prevalence
248144|NCT01728493|Primary aldosteronism
248145|NCT01728493|Organ damage
248146|NCT01728493|Mineralocorticoid receptor antagonists
248147|NCT01728441|PAD
248148|NCT01728441|stenting
248149|NCT01728441|angioplasty
248150|NCT01728428|hemifacial spasm
248151|NCT01728428|observational study
248152|NCT01728428|clinical manifestation
248153|NCT01728428|treatment
248154|NCT01728428|Chinese
248155|NCT01728415|Exercise
248156|NCT01728415|Hemodialysis
248157|NCT01728415|Physical therapy
248158|NCT01728415|high-intensity
248159|NCT01728389|allogenic stem cell transplantation
248160|NCT01728389|peripheral blood stem cells
248161|NCT01728389|intrabone
248162|NCT01728389|intra-bone
248163|NCT01728389|leukemia
248164|NCT01728389|lymphoma
248165|NCT01728363|Staphylococcal
248166|NCT01728350|traumatic brain injury
248167|NCT01728350|volunteering
248168|NCT01728350|well being
248169|NCT01728350|cortisol
248170|NCT01728337|botulinum toxin,
248171|NCT01728337|wrinkles
248172|NCT01728298|House Dust Mite
248173|NCT01728298|allergy
248174|NCT01728298|rhinitis
248175|NCT01728298|asthma
248176|NCT01728285|specific allergen immunotherapy
248177|NCT01728285|sublingual immunotherapy
248178|NCT01728285|allergen tablets
248179|NCT01728285|compliance
248180|NCT01728285|electronic compliance device
248181|NCT01728272|metoprolol, atrial fibrillation
248182|NCT01728246|Osteoarthritis
248183|NCT01728246|Celecoxib
248184|NCT01728246|Tramadol
248185|NCT01728246|Paracetamol
248186|NCT01728233|Molecular Targeted Therapy
248187|NCT01728233|Neoadjuvant therapy
248188|NCT01728233|Dacomitinib
248189|NCT01728220|Inhaled nitric oxide (iNO)
248190|NCT01728220|Pulmonary hypertension (PH)
248191|NCT01728220|Chronic obstructive pulmonary disease (COPD)
248192|NCT01728220|Long term oxygen therapy (LTOT)
248193|NCT01728207|NHL
248194|NCT01728207|CLL
248195|NCT01728207|follicular lymphoma
248196|NCT01728207|mantle cell lymphoma
248197|NCT01728207|marginal zone lymphoma
248198|NCT01728207|chronic lymphocytic leukemia
248199|NCT01728207|small lymphocytic lymphoma
248200|NCT01728194|Depression
248201|NCT01728194|Depressive Disorder
248202|NCT01728194|Behavioral Symptoms
248203|NCT01728194|Mood Disorders
248204|NCT01728194|Mental Disorders
248205|NCT01728194|Escitalopram
248206|NCT01728194|Central Nervous System Agents
248207|NCT01728194|Therapeutic Uses
248208|NCT01728194|Pharmacologic Actions
248209|NCT01728194|Physiological Effects of Drugs
248210|NCT01728194|Muscarinic Antagonists
248211|NCT01728194|Antidepressive Agents
248212|NCT01728194|Psychotropic Drugs
248213|NCT01728194|Serotonin Uptake Inhibitors
248214|NCT01728194|Neurotransmitter Uptake Inhibitors
248215|NCT01728194|Serotonin Agents
248216|NCT01728194|Magnetic Resonance Imaging, Functional
248217|NCT01728194|fMRI
248218|NCT01728194|Magnetic Resonance Imaging
248219|NCT01728168|lupin
248220|NCT01728168|peanut
248221|NCT01728168|soy
248222|NCT01728168|pea
248223|NCT01728168|legumes
248224|NCT01728168|cross-reactivity
248225|NCT01728168|sensitization
248226|NCT01728168|atopy
248227|NCT01728155|NEUROBLASTOMA, LOW RISK, INTERMEDIATE RISK
248228|NCT01728142|DANA
248229|NCT01728142|ANAM
248230|NCT01728142|Concussion
248231|NCT01728142|mild traumatic brain injury
248232|NCT01728129|Concussion
248233|NCT01728129|Mild traumatic brain injury
248234|NCT01728129|DANA
248235|NCT01728129|MACE
248236|NCT01728116|glycemic control, type 2 diabetes, device, obese
248237|NCT01728090|handwashing
248238|NCT01728090|hand sanitizer
248239|NCT01728090|absenteeism
248240|NCT01728090|school age children
248241|NCT01728090|preschool children
248242|NCT01728077|Brivaracetam
248243|NCT01728077|Long-term Follow-up
248244|NCT01728077|Epilepsy
248245|NCT01728077|Partial Onset Seizures
248246|NCT01728077|Adjunctive treatment
248247|NCT01728064|Friedreich's
248248|NCT01728064|Ataxia
248249|NCT01728064|FRDA
248250|NCT01728064|FA
248251|NCT01728064|EPI-743
248252|NCT01728064|Edison
248253|NCT01728038|Bronchiolitis
248254|NCT01728038|Cough
248255|NCT01728038|Ear Infection
248256|NCT01728038|Respiratory Infection
248257|NCT01728038|Wheezing
248258|NCT01728025|Long QT syndrome
248259|NCT01728025|Ranolazine
248260|NCT01728012|Successful transplantation
248261|NCT01728012|Long-term observation
248262|NCT01727999|TPO response
248263|NCT01727999|ITP
248264|NCT01727999|immune thrombocytopenia
248265|NCT01727973|Graves' orbitopathy
248266|NCT01727973|Graves´ ophthalmopathy
248267|NCT01727973|Thyroid eye disease
248268|NCT01727973|Thyroid-associated ophthalmopathy
248269|NCT01727973|Doxycycline
248270|NCT01727973|EUGOGO
248271|NCT01727973|CAS
248272|NCT01727960|Education
248273|NCT01727960|Neck pain
248274|NCT01727960|Shoulder pain
248275|NCT01727960|Prevalence
248276|NCT01727960|Associated factors
248277|NCT01727960|Students
248278|NCT01727934|Antisense
248279|NCT01727934|miR-122 antagonist
248280|NCT01727934|host factor
248281|NCT01727934|Chronic hepatitis C
248282|NCT01727934|Hepatitis C
248283|NCT01727921|ProCore FNA biopsy
248284|NCT01727908|Familial Gastric Cancer Screening
248285|NCT01727895|Betaglucan, immune modulation, immunoparalysis, immune suppression
248286|NCT01727882|Paroled offenders
248287|NCT01727882|Interactive Voice Response
248288|NCT01727882|Stress
248289|NCT01727882|Mental symptoms
248290|NCT01727882|Alcohol consumption
248291|NCT01727882|Substance use
248292|NCT01727856|rehabilitation
248293|NCT01727856|physical therapy
248294|NCT01727856|telemedicine
248295|NCT01727843|fracture
248296|NCT01727843|hip
248297|NCT01727843|tranexamic acid
248298|NCT01727843|topical
248299|NCT01727817|Diabetes Mellitus, Type 1
248300|NCT01727817|Continuous Glucose Monitor
248301|NCT01727817|Artificial Pancreas
248302|NCT01727817|Insulin Pump
248303|NCT01727817|Closed Loop
248304|NCT01727817|Open Loop
248305|NCT01727817|Diabetes Assistant
248306|NCT01727817|DiAs
248307|NCT01727817|Cell Phone
248308|NCT01727791|pharmacokinetic
248309|NCT01727791|pregabalin
248310|NCT01727791|lactation
248311|NCT01727765|Asthma, inspiratory muscle training
248312|NCT01727739|Tibial tunnel widening
248313|NCT01727739|Interference screws
248314|NCT01727726|OPC-34712
248315|NCT01727726|brexpiprazole
248316|NCT01727726|Major Depressive Disorder
248317|NCT01727726|Adjunctive Treatment
248318|NCT01727713|Tourette Syndrome
248319|NCT01727713|Basal Ganglia Diseases
248320|NCT01727713|Brain Diseases
248321|NCT01727713|Central Nervous System Diseases
248322|NCT01727713|Tic Disorders
248323|NCT01727713|Tics
248324|NCT01727713|Movement Disorders
248325|NCT01727713|Mental Disorders
248326|NCT01727713|Aripiprazole
248327|NCT01727700|Tourette Syndrome
248328|NCT01727700|Basal Ganglia Diseases
248329|NCT01727700|Brain Diseases
248330|NCT01727700|Central Nervous System Diseases
248331|NCT01727700|Tic Disorders
248332|NCT01727700|Tics
248333|NCT01727700|Movement Disorders
248334|NCT01727700|Mental Disorders
248335|NCT01727700|Aripiprazole
248336|NCT01727687|To asses the training effects on traffic safety between normal and patients with Parkinson's disease
248337|NCT01727674|Depression
248338|NCT01727674|experiences of communication
248339|NCT01727661|diabetes mellitus
248340|NCT01727661|cardiopulmonary fitness
248341|NCT01727661|lung function
248342|NCT01727661|muscular oxygenation
248343|NCT01727648|Stroke rehabilitation
248344|NCT01727648|Comparative efficacy research
248345|NCT01727648|Combined therapy
248346|NCT01727648|Robot-Assisted Therapy
248347|NCT01727648|Constraint-Induced Therapy
248348|NCT01727648|Kinematic analysis
248349|NCT01727635|Breast cancer, survivors, partners, group therapy
248350|NCT01727609|Preterm
248351|NCT01727609|Very low birth weight
248352|NCT01727609|Feeding
248353|NCT01727609|Enteral
248354|NCT01727609|Milk
248355|NCT01727609|Sepsis
248356|NCT01727609|Necrotizing enterocolitis (NEC)
248357|NCT01727583|Healthy
248358|NCT01727570|Cancer
248359|NCT01727570|Colon
248360|NCT01727570|Rectum
248361|NCT01727570|Surgery
248362|NCT01727557|Hemodialysis and AV fistula
248363|NCT01727544|superior semicircular canal
248364|NCT01727544|non-vestibular dizziness
248365|NCT01727544|vestibular dizziness
248366|NCT01727531|chloroquine
248367|NCT01727531|WBRT
248368|NCT01727531|survival
248369|NCT01727531|brain metastasis
248370|NCT01727531|radiotherapy
248371|NCT01727531|SNPs
248372|NCT01727531|gene coding
248373|NCT01727531|immunoregulatory enzyme IDO2
248374|NCT01727518|natural history
248375|NCT01727518|lung function
248376|NCT01727518|general population
248377|NCT01727518|COPD
248378|NCT01727505|hypoxemia
248379|NCT01727505|desaturation
248380|NCT01727505|mechanical ventilation
248381|NCT01727505|preterm infants
248382|NCT01727505|volume guarantee ventilation
248383|NCT01727492|prevention
248384|NCT01727492|noise-induced tinnitus
248385|NCT01727492|noise-induced hearing loss
248386|NCT01727492|young population
248387|NCT01727479|Peak VO2 consumption
248388|NCT01727479|3km time trial
248389|NCT01727479|fatigue perception
248390|NCT01727479|lactate
248391|NCT01727479|time to complete
248392|NCT01727440|severe acne
248393|NCT01727440|severe acne vulgaris
248394|NCT01727440|acne
248395|NCT01727440|acne vulgaris
248396|NCT01727440|isotretinoin
248397|NCT01727440|Accutane
248398|NCT01727440|Sortret
248399|NCT01727440|Amnesteem
248400|NCT01727440|Claravis
248401|NCT01727440|Clarus
248402|NCT01727440|Decutan
248403|NCT01727440|Isotane
248404|NCT01727440|Izotek
248405|NCT01727440|Oratane
248406|NCT01727440|Isotret
248407|NCT01727440|Roaccutane
248408|NCT01727427|Unsuspected
248409|NCT01727427|pulmonary embolism
248410|NCT01727427|cancer
248411|NCT01727414|ADHD
248412|NCT01727414|Inattention
248413|NCT01727414|Methylphenidate
248414|NCT01727414|Pharmacogenetics
248415|NCT01727401|Fondaparinux
248416|NCT01727401|medical patient
248417|NCT01727401|vein thromboembolism
248418|NCT01727401|prophylaxis
248419|NCT01727401|thrombocytopenia
248420|NCT01727388|rectal examination
248421|NCT01727388|colorectal cancer
248422|NCT01727375|delirium, light, ICU, sleep
248423|NCT01727362|Breast Cancer
248424|NCT01727362|Acupuncture
248425|NCT01727362|Quality of Life
248426|NCT01727258|Tooth Sensitivity
248427|NCT01727232|ITP
248428|NCT01727232|Rituximab
248429|NCT01727232|Efficacy
248430|NCT01727232|Anti-CD20
248431|NCT01727232|Regimen
248432|NCT01727206|Erdheim-Chester disease
248433|NCT01727206|Tocilizumab
248434|NCT01727206|Treatment
248435|NCT01727206|Phase II
248436|NCT01727193|myasthenia gravis
248437|NCT01727193|leflunomide
248438|NCT01727167|cardiac disease
248439|NCT01727167|mitochondrial biogenesis
248440|NCT01727167|carbon monoxide
248441|NCT01727141|COPD, QVA149
248442|NCT01727128|Hepatic impairment
248443|NCT01727128|Clinical pharmacology study
248444|NCT01727128|Volunteer study
248445|NCT01727063|Chronic ischemic heart disease
248446|NCT01727063|Coronary artery disease
248447|NCT01727063|Angina pectoris
248448|NCT01727063|Myocardial ischemia
248449|NCT01727063|Cardiac surgery
248450|NCT01727037|Emphysema
248451|NCT01727037|Chronic obstructive pulmonary disease
248452|NCT01727037|COPD
248453|NCT01727037|Bulla
248454|NCT01727037|Interventional bronchoscopy
248455|NCT01727037|Lung volume reduction
248456|NCT01727024|Breezhaler
248457|NCT01727024|Respimat
248458|NCT01727024|Indacaterol
248459|NCT01727024|Tiotropium
248460|NCT01727011|Single fraction
248461|NCT01727011|Elderly
248462|NCT01727011|Breast Irradiation
248463|NCT01726959|methotrexate
248464|NCT01726946|Chronic Hepatitis C
248465|NCT01726946|HCV
248466|NCT01726946|CHC
248467|NCT01726933|psoriasis, systemic treatment
248468|NCT01726920|Migraine
248469|NCT01726920|Naratriptan
248470|NCT01726920|Naproxen
248471|NCT01726907|submandibular gland
248472|NCT01726907|robotic
248473|NCT01726907|endoscopic
248474|NCT01726907|face lift
248475|NCT01726907|hairline
248476|NCT01726894|Focal Therapy
248477|NCT01726881|chronic
248478|NCT01726881|Spinal Cord Injury patients
248479|NCT01726855|tendon repair
248480|NCT01726829|Type 1 Diabetes
248481|NCT01726829|Artificial Pancreas
248482|NCT01726829|Closed Loop
248483|NCT01726816|Diabetic nephropathy
248484|NCT01726816|Albumin creatinine ratio
248485|NCT01726816|Probucol
248486|NCT01726803|Low Back Pain
248487|NCT01726803|Primary Care
248488|NCT01726803|Physical Therapy
248489|NCT01726790|corneal endothelium
248490|NCT01726790|Bevacizumab
248491|NCT01726790|Intravitreal injection
248492|NCT01726790|Confoscan
248493|NCT01726777|Randomized controlled clinical trial
248494|NCT01726777|Diabetes
248495|NCT01726777|Vitamin D
248496|NCT01726777|Oral glucose tolerance
248497|NCT01726777|Blood glucose
248498|NCT01726777|Insulin resistance
248499|NCT01726751|Spinal cord stimulation
248500|NCT01726751|Irritable bowel syndrome
248501|NCT01726751|Abdominal pain
248502|NCT01726751|Diarrhea
248503|NCT01726738|Melanoma
248504|NCT01726738|Stage III
248505|NCT01726738|Stage IV
248506|NCT01726738|Unresectable
248507|NCT01726738|BRAF Mutant
248508|NCT01726738|Dabrafenib
248509|NCT01726738|Trametinib
248510|NCT01726738|Kinome
248511|NCT01726738|Resistance
248512|NCT01726738|Sequencing
248513|NCT01726738|Mutations
248514|NCT01726738|Kinases
248515|NCT01726738|Mechanism
248516|NCT01726725|hemifacial spasm
248517|NCT01726725|microvascular decompression surgery
248518|NCT01726725|desflurane
248519|NCT01726712|Patient Care Management
248520|NCT01726712|Primary Health Care
248521|NCT01726712|HIV
248522|NCT01726712|Patient Acceptance of Health Care
248523|NCT01726686|Total Knee Arthroplasty
248524|NCT01726673|Stroke
248525|NCT01726673|Cerebrovascular Accident
248526|NCT01726673|Cerebral Stroke
248527|NCT01726673|CVA
248528|NCT01726673|Robotic therapy
248529|NCT01726673|Upper extremity recovery
248530|NCT01726673|tDCS
248531|NCT01726673|Non-invasive brain stimulation
248532|NCT01726660|Stroke
248533|NCT01726660|Cerebrovascular Accident
248534|NCT01726660|Cerebral stroke
248535|NCT01726660|CVA
248536|NCT01726660|robotic therapy
248537|NCT01726660|upper extremity recovery
248538|NCT01726660|kinematic training
248539|NCT01726647|obese women
248540|NCT01726647|fat mass distribution
248541|NCT01726647|Metabolomic profiles
248542|NCT01726634|upper limb
248543|NCT01726634|functional test
248544|NCT01726634|elastic tape
248545|NCT01726595|critical care
248546|NCT01726595|severe sepsis
248547|NCT01726595|microvascular function
248548|NCT01726595|ultrasound
248549|NCT01726582|pancreas
248550|NCT01726582|adenocarcinoma
248551|NCT01726582|molecular profile
248552|NCT01726582|molecular profiling
248553|NCT01726582|pancreatic cancer
248554|NCT01726582|pancreas cancer
248555|NCT01726582|cancer
248556|NCT01726582|molecular target
248557|NCT01726582|pancreas head
248558|NCT01726582|pancreas neck
248559|NCT01726582|pancreas uncinate
248560|NCT01726582|pancreas body
248561|NCT01726582|pancreas tail
248562|NCT01726569|glaucoma
248563|NCT01726569|educational intervention
248564|NCT01726569|post-operative satisfaction
248565|NCT01726569|knowledges
248566|NCT01726556|Pleural effusion
248567|NCT01726556|Semirigid thoracoscopy
248568|NCT01726556|Rigid thoracoscopy
248569|NCT01726543|canaloplasty
248570|NCT01726543|non-penetrating deep sclerectomy
248571|NCT01726543|glaucoma
248572|NCT01726543|cataract
248573|NCT01726543|ophthalmology
248574|NCT01726543|glaucoma surgery
248575|NCT01726530|transdermal fentanyl patch, postoperative pain,
248576|NCT01726517|HCV genotype 1 (GT-1)
248577|NCT01726517|HCV
248578|NCT01726517|Sustained Virologic Response
248579|NCT01726517|Direct Acting Antiviral
248580|NCT01726517|Combination Therapy
248581|NCT01726517|GS-7977
248582|NCT01726517|GS-5885
248583|NCT01726517|Ribavirin
248584|NCT01726517|Open Label
248585|NCT01726517|Sofosbuvir
248586|NCT01726517|Treatment-Naïve
248587|NCT01726517|Protease Inhibitors
248588|NCT01726517|PI
248589|NCT01726504|chronic functional constipation
248590|NCT01726504|electro-acupuncture
248591|NCT01726504|multi-center randomized controlled trial
248592|NCT01726504|efficacy
248593|NCT01726504|safety
248594|NCT01726491|Insulin resistance
248595|NCT01726491|Exercise
248596|NCT01726491|Type 2 diabetes mellitus
248597|NCT01726491|Obesity
248598|NCT01726491|Epigenetic studies
248599|NCT01726478|Oxytocin
248600|NCT01726478|Uterine tone
248601|NCT01726478|Mulago Hospital
248602|NCT01726478|Dose
248603|NCT01726478|Side effects
248604|NCT01726465|N-Acetylcysteine
248605|NCT01726465|Methylprednisolone
248606|NCT01726465|Liver ischemia reperfusion injury
248607|NCT01726465|Pringle manoeuvre
248608|NCT01726465|Hepatic resection
248609|NCT01726426|Chronic arsenic poisoning
248610|NCT01726426|Palmer arsenical keratosis
248611|NCT01726413|Diabetic neuropathy
248612|NCT01726400|Hepatitis C
248613|NCT01726400|Interferon
248614|NCT01726400|Ribavirin
248615|NCT01726400|Hepcidin
248616|NCT01726400|Iron metabolism
248617|NCT01726361|Multidimension Treatment Foster Care
248618|NCT01726361|Adolescents
248619|NCT01726361|Disadvantaged families
248620|NCT01726361|Out-of-home placement
248621|NCT01726361|Conduct Disorder
248622|NCT01726361|Family program
248623|NCT01726361|Denmark
248624|NCT01726361|Youth
248625|NCT01726348|Human Immunodeficiency Virus-Type 1
248626|NCT01726348|HIV-1
248627|NCT01726348|TMC114
248628|NCT01726348|Darunavir
248629|NCT01726348|Ritonavir
248630|NCT01726348|Filipino
248631|NCT01726335|Schizophrenia
248632|NCT01726335|Risperidone
248633|NCT01726335|Risperdal consta
248634|NCT01726283|fruste keratoconus
248635|NCT01726283|ectasia
248636|NCT01726257|Infrarenal
248637|NCT01726257|Abdominal
248638|NCT01726257|Aortic
248639|NCT01726257|Aneurysm
248640|NCT01726257|AAA
248641|NCT01726257|Endologix
248642|NCT01726257|EVAS
248643|NCT01726257|EndoVascular
248644|NCT01726257|Sealing
248645|NCT01726257|System
248646|NCT01726231|Laparoscopic access
248647|NCT01726231|Abdominal wall lifting
248648|NCT01726231|Direct trocar insertion
248649|NCT01726231|Safety endoscopy
248650|NCT01726218|Stroke
248651|NCT01726218|Physical Medicine & Rehabilitation
248652|NCT01726218|Neurology
248653|NCT01726218|Neurophysiology
248654|NCT01726218|Neuroscience
248655|NCT01726218|Transcranial Magnetic Stimulation (TMS)
248656|NCT01726179|caries infiltration
248657|NCT01726179|caries arrest
248658|NCT01726179|dental anxiety
248659|NCT01726179|dental stress
248660|NCT01726166|Infant
248661|NCT01726166|contamination rates
248662|NCT01726166|urinary catheterization
248663|NCT01726166|suprapubic aspiration
248664|NCT01726153|Condom Use
248665|NCT01726153|HIV+ gay males
248666|NCT01726153|Intervention
248667|NCT01726153|Tailored
248668|NCT01726153|On-line
248669|NCT01726153|Internet
248670|NCT01726153|Web-based
248671|NCT01726140|intubation
248672|NCT01726140|respiratory failure
248673|NCT01726140|cardiac surgery
248674|NCT01726114|Diabetes
248675|NCT01726114|Diabetes Mellitus
248676|NCT01726114|continuous Glucose Monitor
248677|NCT01726088|Modafinil
248678|NCT01726088|p50
248679|NCT01726088|Attentional Bias
248680|NCT01726075|diabetic retinopathy
248681|NCT01726062|Motivational Incentives
248682|NCT01726062|Motivational Interviewing
248683|NCT01726062|Secondhand Smoke
248684|NCT01726062|Neonatal Intensive Care Unit
248685|NCT01726062|NICU
248686|NCT01726062|High respiratory risk infants
248687|NCT01726062|Low birth weight infants
248688|NCT01726062|Environmental Tobacco Smoke
248689|NCT01726062|Smoking
248690|NCT01726062|Contingency management
248691|NCT01726062|Infants
248692|NCT01726062|Children
248693|NCT01726049|HFpEF
248694|NCT01726049|PH
248695|NCT01726036|neonatal circumcision
248696|NCT01726036|neonatal surgical pain
248697|NCT01726036|Mogen
248698|NCT01726036|Gomco
248699|NCT01726023|Ceftazidime-avibactam,
248700|NCT01726023|Metronidazole,
248701|NCT01726023|Meropenem,
248702|NCT01726023|Anti-Bacterial Agents,
248703|NCT01726023|Anti-Infective Agents,
248704|NCT01726023|Therapeutic Uses,
248705|NCT01726023|Pharmacologic Actions,
248706|NCT01726023|Physiological Effects of Drugs
248707|NCT01725997|acromioclavicular joint dislocation
248708|NCT01725997|ac joint dislocation
248709|NCT01725997|acromioclavicular joint separation
248710|NCT01725997|hook plate
248711|NCT01725997|Rockwood
248712|NCT01725984|Male Incontinence
248713|NCT01725984|AdVance Male Sling
248714|NCT01725984|AdVance XP Male Sling
248715|NCT01725984|Male Sling
248716|NCT01725971|Silicosis
248717|NCT01725971|forced oscillations
248718|NCT01725971|respiratory mechanics
248719|NCT01725945|DASH
248720|NCT01725945|diet
248721|NCT01725945|asthma
248722|NCT01725945|adults
248723|NCT01725945|asthma control
248724|NCT01725932|culture, depression, cognitive therapy, behaviour therapy,
248725|NCT01725919|motor
248726|NCT01725919|stroke
248727|NCT01725919|hemiparesis
248728|NCT01725919|rehabilitation
248729|NCT01725919|constraint induced movement therapy
248730|NCT01725919|CI therapy
248731|NCT01725906|genotypic resistance guided therapy
248732|NCT01725893|Claw Toe
248733|NCT01725880|Spinal Cord Injury
248734|NCT01725880|HuCNS-SC cells
248735|NCT01725880|Human Neural Stem Cells
248736|NCT01725880|Neural Stem Cells
248737|NCT01725880|Stem Cells
248738|NCT01725867|temporomandibular joint disorder
248739|NCT01725867|myofascial pain
248740|NCT01725867|manual myofascial release
248741|NCT01725867|physical therapy
248742|NCT01725867|oral appliance
248743|NCT01725841|To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan
248744|NCT01725841|To determine the susceptibility of ertapenem and other antimicrobial agents against Enterobacteriaceae isolates with and without expression of ESBLs
248745|NCT01725841|To determine the molecular typing of the Enterobacteriaceae isolates with expression of ESBLs
248746|NCT01725841|To analyze the association between geographic area, hospital types against the antimicrobial susceptibility
248747|NCT01725828|cricothyroid membrane
248748|NCT01725828|Ultrasound
248749|NCT01725828|Difficult Airway Management
248750|NCT01725789|Acute isovolemic anemia after gastrectomy for gastric cancer
248751|NCT01725776|Pulmonary hypertension
248752|NCT01725776|Cardiac surgery
248753|NCT01725776|Cardiopulmonary Bypass (CPB)
248754|NCT01725750|Traumatic Brain Injury
248755|NCT01725750|TBI
248756|NCT01725750|Fatigue
248757|NCT01725750|Post-TBI Fatigue
248758|NCT01725750|PTBIF
248759|NCT01725750|Depressed Mood
248760|NCT01725750|Excessive Daytime Sleepiness
248761|NCT01725750|Circadian Rhythm
248762|NCT01725750|Anxiety
248763|NCT01725750|Cognitive Dysfunction
248764|NCT01725750|Intervention
248765|NCT01725750|Treatment
248766|NCT01725737|ADHD
248767|NCT01725737|GlyTI-M
248768|NCT01725724|Autologous blood transfusion
248769|NCT01725724|Allogeneic blood transfusion
248770|NCT01725724|Infection rate
248771|NCT01725685|healthy volunteers
248772|NCT01725685|Umeclidinium
248773|NCT01725685|tolerability
248774|NCT01725685|Safety
248775|NCT01725685|Fluticasone Furoate
248776|NCT01725685|Pharmacokinetics
248777|NCT01725672|healthy volunteers
248778|NCT01725672|Diabetes mellitus
248779|NCT01725672|glimepiride
248780|NCT01725672|pharmacokinetics
248781|NCT01725672|metformin
248782|NCT01725659|Stroke
248783|NCT01725659|electric stimulation
248784|NCT01725659|robotics
248785|NCT01725659|motor learning
248786|NCT01725646|Hypertriglyceridemia, omega-3-acid ethyl ester
248787|NCT01725633|Stretching
248788|NCT01725633|Nonlinear Aerobic Training
248789|NCT01725633|14-170
248790|NCT01725607|dexmedetomidine, thoracic epidural anesthesia
248791|NCT01725581|OSAT
248792|NCT01725581|Pelvic Examination
248793|NCT01725581|Validation
248794|NCT01725581|Reliability
248795|NCT01725542|HCV-HIV Co-Infection
248796|NCT01725542|Quadruple therapy
248797|NCT01725542|null responder to a standard Pegylated interferon/Ribavirin regimen
248798|NCT01725529|Hepatitis C, Chronic
248799|NCT01725529|TMC435
248800|NCT01725529|Ribavirin
248801|NCT01725529|peginterferon-alpha (PegIFNα-2a)
248802|NCT01725503|creatine synthesis
248803|NCT01725490|chemoprevention, metformin, familial adenomatous polyposis
248804|NCT01725464|thoracotomy
248805|NCT01725464|oxygen saturation
248806|NCT01725464|postoperative
248807|NCT01725438|Circulating Trophoblastic Cells
248808|NCT01725438|Non-Invasive Prenatal Diagnosis
248809|NCT01725438|Genetic analysis
248810|NCT01725438|Trisomy 21
248811|NCT01725438|Down's Syndrome
248812|NCT01725425|snack food (chips)
248813|NCT01725425|fruit (red grapes) consumed in each condition
248814|NCT01725425|mood
248815|NCT01725399|post-operative vomiting
248816|NCT01725373|left main, stent,angioplasty
248817|NCT01725360|asthma
248818|NCT01725360|airway hyperresponsiveness
248819|NCT01725347|nutrition assessment
248820|NCT01725347|children
248821|NCT01725347|preschool
248822|NCT01725347|eating behavior
248823|NCT01725347|Head Start
248824|NCT01725347|digital technology
248825|NCT01725334|Schizophrenia
248826|NCT01725334|Negative Symptoms
248827|NCT01725334|Treatment Resistance
248828|NCT01725334|Deep Brain Stimulation
248829|NCT01725334|Electrical Stimulation
248830|NCT01725334|Mental Disorders
248831|NCT01725334|Brain Diseases
248832|NCT01725334|Neurologic Manifestations
248833|NCT01725334|Signs and Symptoms
248834|NCT01725321|Colonoscopy
248835|NCT01725321|colonic adenoma
248836|NCT01725321|serrated polyps
248837|NCT01725308|FK949E
248838|NCT01725308|Major depressive episode
248839|NCT01725308|patients
248840|NCT01725295|fibromyalgia treatment
248841|NCT01725295|physical therapy
248842|NCT01725295|hydrotherapy
248843|NCT01725282|FK949E
248844|NCT01725282|patients
248845|NCT01725269|AIR001
248846|NCT01725269|sodium nitrite
248847|NCT01725269|PAH
248848|NCT01725269|Pulmonary Arterial Hypertension
248849|NCT01725269|inhaled sodium nitrite
248850|NCT01725256|AIR001
248851|NCT01725256|sodium nitrite
248852|NCT01725256|PAH
248853|NCT01725256|Pulmonary Arterial Hypertension
248854|NCT01725256|inhaled sodium nitrite
248855|NCT01725243|pregnancy
248856|NCT01725243|postpartum hemorrhage
248857|NCT01725243|Cesarean delivery
248858|NCT01725243|carbetocin
248859|NCT01725243|failure to progress in labor
248860|NCT01725230|Fostamatinib,
248861|NCT01725230|simvastatin,
248862|NCT01725230|rosuvastatin,
248863|NCT01725230|Phase I,
248864|NCT01725230|Healthy Subjects,
248865|NCT01725230|Pharmacokinetics
248866|NCT01725217|Meningitis
248867|NCT01725217|children
248868|NCT01725217|adolescents
248869|NCT01725217|adults
248870|NCT01725217|MenACWY
248871|NCT01725204|dasatinib
248872|NCT01725204|Protein Kinase Inhibitors
248873|NCT01725204|pegylated IFN-alpha 2B
248874|NCT01725204|Interferon-alpha
248875|NCT01725178|Mild Cognitive Impairment
248876|NCT01725178|Dementia
248877|NCT01725178|Memory disorders
248878|NCT01725178|Physical fitness
248879|NCT01725165|Lung cancer
248880|NCT01725165|Non-Small Cell Lung Cancer
248881|NCT01725165|NSCLC
248882|NCT01725165|Oligometastatic Disease
248883|NCT01725165|Chemotherapy
248884|NCT01725165|Surgical control
248885|NCT01725165|primary and metastatic sites of disease
248886|NCT01725165|Radiation therapy
248887|NCT01725165|external beam radiation
248888|NCT01725165|2D/conventional techniques
248889|NCT01725165|three-dimensional conformal therapy
248890|NCT01725165|intensity modulated radiation therapy
248891|NCT01725165|IMRT
248892|NCT01725165|stereotactic radiosurgery
248893|NCT01725165|SRS
248894|NCT01725165|proton beam therapy
248895|NCT01725165|PBT
248896|NCT01725152|fragile x syndrome
248897|NCT01725152|ganaxolone
248898|NCT01725152|anxiety
248899|NCT01725152|attention
248900|NCT01725152|pediatric
248901|NCT01725126|metformin
248902|NCT01725126|diabetes
248903|NCT01725126|obesity
248904|NCT01725126|liraglutide
248905|NCT01725100|MEK inhibitor
248906|NCT01725100|GSK1120212
248907|NCT01725100|trametinib
248908|NCT01725100|solid tumors
248909|NCT01725100|dissolution
248910|NCT01725100|DMSO content
248911|NCT01725100|relative bioavailability
248912|NCT01725100|pharmacokinetics
248913|NCT01725074|Coronary Heart Disease, multimorbidity, primary care, case management, loneliness, depression, social support
248914|NCT01725048|Major depressive disorder
248915|NCT01725048|Neoplasms
248916|NCT01725035|De Novo Lipogenesis
248917|NCT01725035|Fatty Liver
248918|NCT01725035|Hepatic Steatosis
248919|NCT01725035|Gene variants
248920|NCT01725022|stem cell transplant
248921|NCT01725022|bowel microbiota
248922|NCT01725022|home care
248923|NCT01725009|Healthy volunteers
248924|NCT01725009|Japanese
248925|NCT01725009|Caucasian
248926|NCT01724983|pain
248927|NCT01724983|mood
248928|NCT01724983|depression
248929|NCT01724983|respiration
248930|NCT01724970|anesthesia
248931|NCT01724970|postanesthetic recovery
248932|NCT01724970|ventilation
248933|NCT01724970|bariatric surgery
248934|NCT01724957|Fractional flow reserve,
248935|NCT01724957|coronary bifurcation stenosis,
248936|NCT01724957|intracoronary ECG,
248937|NCT01724957|coronary stent
248938|NCT01724957|Coronary bifurcation lesions
248939|NCT01724957|icECG
248940|NCT01724944|Interval debulking surgery
248941|NCT01724944|IDS
248942|NCT01724944|NACT
248943|NCT01724944|Neoadjuvant chemotherapy
248944|NCT01724944|Lymphadenectomy
248945|NCT01724944|Ovarian cancer
248946|NCT01724931|antifolate
248947|NCT01724931|antiinflammatory
248948|NCT01724931|autoimmune disease
248949|NCT01724931|hematological treatment
248950|NCT01724931|rheumatic disease
248951|NCT01724931|folic acid antagonist
248952|NCT01724931|enzyme inhibitor
248953|NCT01724918|IV lacosamide
248954|NCT01724918|focal epilepsy
248955|NCT01724918|EEG
248956|NCT01724918|EKG
248957|NCT01724905|Diet
248958|NCT01724905|Obesity
248959|NCT01724905|Chronic disease
248960|NCT01724879|philadelphia chromosome
248961|NCT01724879|BCR-ABL
248962|NCT01724879|ALL
248963|NCT01724879|acute lymphoblastic leukemia
248964|NCT01724879|dasatinib
248965|NCT01724879|Sprycel
248966|NCT01724853|Carpometacarpal
248967|NCT01724853|osteoarthritis
248968|NCT01724853|outcome measures
248969|NCT01724827|Dental caries
248970|NCT01724827|inlays
248971|NCT01724827|composite resins
248972|NCT01724827|IPS-Empress ceramic
248973|NCT01724827|bicuspid
248974|NCT01724827|FDI dental restorations evaluation criteria
248975|NCT01724801|EGFR mutant
248976|NCT01724775|complete mesocolic excision
248977|NCT01724775|colon cancer
248978|NCT01724775|efficacy
248979|NCT01724775|safety
248980|NCT01724762|Baths
248981|NCT01724762|Anxiety
248982|NCT01724762|Acute Coronary Syndrome
248983|NCT01724762|Education, Nursing
248984|NCT01724749|Atherosclerosis
248985|NCT01724749|Sodium-Fluoride
248986|NCT01724749|18F-Sodium Fluoride
248987|NCT01724749|18F-NaF
248988|NCT01724749|fluorodeoxyglucose
248989|NCT01724749|18F-FDG
248990|NCT01724749|FDG
248991|NCT01724749|Positron emission tomography
248992|NCT01724749|PET
248993|NCT01724736|microbiome
248994|NCT01724736|prebiotic
248995|NCT01724736|cobiotic
248996|NCT01724736|NM504
248997|NCT01724736|GI microbiome
248998|NCT01724723|hepatitis during anti-tuberculous treatment
248999|NCT01724723|tuberculosis
249000|NCT01724723|hepatitis B virus
249001|NCT01724723|viral load
249002|NCT01724723|entecavir
249003|NCT01724697|liver cirrhosis
249004|NCT01724697|end stage liver disease
249005|NCT01724697|HBV
249006|NCT01724697|autologous
249007|NCT01724697|stem cell
249008|NCT01724697|bone morrow
249009|NCT01724671|MRSA
249010|NCT01724671|Bacteremia
249011|NCT01724671|ABSSSI
249012|NCT01724671|Pneumonia
249013|NCT01724671|Vancomycin
249014|NCT01724671|Ceftaroline
249015|NCT01724658|female sexual function
249016|NCT01724658|postmenopause
249017|NCT01724658|testosterone
249018|NCT01724645|Korean Traditional diets
249019|NCT01724645|hypertension
249020|NCT01724645|diabetes
249021|NCT01724632|Overweight
249022|NCT01724632|Obesity
249023|NCT01724632|Weight Loss
249024|NCT01724606|Whole Brain Radiotherapy (WBRT)
249025|NCT01724606|Sorafenib (BAY 43-9006)
249026|NCT01724606|12-046
249027|NCT01724593|functional recovery, critical illness, pediatrics
249028|NCT01724567|Interval Training
249029|NCT01724567|Weight Loss
249030|NCT01724567|Secondary Prevention
249031|NCT01724567|Rehabilitation
249032|NCT01724567|Cardiovascular Risk Factors
249033|NCT01724528|Febuxostat, Tumor lysis syndrome, leukemia, lymphoma
249034|NCT01724515|insulin resistance
249035|NCT01724502|insulin resistance
249036|NCT01724463|Systemic Inflammatory Response Syndrome (SIRS)
249037|NCT01724463|Sepsis
249038|NCT01724463|Severe Sepsis
249039|NCT01724463|Septic Shock
249040|NCT01724463|Electronic Health Record
249041|NCT01724463|Health Screening
249042|NCT01724463|Goal Directed Therapy
249043|NCT01724463|Infant
249044|NCT01724463|Child
249045|NCT01724463|Pediatric
249046|NCT01724463|Adolescent
249047|NCT01724463|Critical Illness
249048|NCT01724463|Outcomes Research
249049|NCT01724463|Resource Utilization
249050|NCT01724450|Breast Cancer
249051|NCT01724450|Heart Failure
249052|NCT01724450|Cardiotoxicity
249053|NCT01724450|Biomarkers
249054|NCT01724411|Overweight and Obesity
249055|NCT01724411|Appetite
249056|NCT01724411|Gut hormones and obesity
249057|NCT01724411|Resistant Starch
249058|NCT01724411|Gut microbiota and obesity
249059|NCT01724411|SmartPill
249060|NCT01724398|mesenchymal stem cells
249061|NCT01724398|plasma exchange
249062|NCT01724398|liver failure
249063|NCT01724398|hepatitis B virus
249064|NCT01724385|bevacizumab,
249065|NCT01724385|proliferative diabetic retinopathy,
249066|NCT01724385|vitreous hemorrhage,
249067|NCT01724359|Schizophrenia
249068|NCT01724359|Paliperidone extended-release (ER)
249069|NCT01724359|Antipsychotic agents
249070|NCT01724346|CLL, SLL
249071|NCT01724333|EORTC QLQ-C30
249072|NCT01724333|Oral health
249073|NCT01724333|Quality of life
249074|NCT01724333|Questionnaires
249075|NCT01724333|Patient reported
249076|NCT01724333|outcomes
249077|NCT01724320|solid tumors
249078|NCT01724320|first-in-man
249079|NCT01724320|phase I
249080|NCT01724320|cancer
249081|NCT01724320|galectin
249082|NCT01724281|lateral ventricles
249083|NCT01724281|Asymetry
249084|NCT01724255|Caesarian section
249085|NCT01724255|Surgical Wound
249086|NCT01724242|Vaginal dryness
249087|NCT01724242|Breast Cancer
249088|NCT01724242|Urinary Incontinence
249089|NCT01724242|Quality of Life
249090|NCT01724242|Sexual Satisfaction
249091|NCT01724229|Incontinence-associated dermatitis
249092|NCT01724229|Skin care regimen for moisture-associated conditions
249093|NCT01724229|Perineal skin care
249094|NCT01724229|Fungal infection in perineal area
249095|NCT01724203|Probiotics for infants
249096|NCT01724203|Bacterial and viral infections in infants
249097|NCT01724190|Type 1 Diabetes
249098|NCT01724190|Vitamin D
249099|NCT01724190|Clinical Remission
249100|NCT01724177|Lenalidomide
249101|NCT01724177|ATL
249102|NCT01724177|ATLL
249103|NCT01724138|deferasirox
249104|NCT01724125|serious mental illness
249105|NCT01724099|Obesity
249106|NCT01724099|Herbal product
249107|NCT01724099|Korean Medicine
249108|NCT01724086|Chronic hepatitis C
249109|NCT01724086|Chronic hepatitis C-infected patients
249110|NCT01724086|TMC647055
249111|NCT01724086|TMC435
249112|NCT01724086|Ritonavir
249113|NCT01724086|Ribavirin
249114|NCT01724086|Genotype 1a
249115|NCT01724086|Genotype 1b
249116|NCT01724086|GSK2336805
249117|NCT01724073|food to food fortification strategy
249118|NCT01724073|leafy vegetable
249119|NCT01724073|iron
249120|NCT01724073|zinc
249121|NCT01724073|vitamin A
249122|NCT01724073|growth
249123|NCT01724047|Autism
249124|NCT01724047|School Based Intervention
249125|NCT01724034|Weaning
249126|NCT01724034|Mechanical Ventilation
249127|NCT01724034|Lung Ultrasound
249128|NCT01723995|nipple/injure
249129|NCT01723995|breastfeeding
249130|NCT01723995|pain
249131|NCT01723995|laser
249132|NCT01723956|Cervical Dysplasia
249133|NCT01723956|Cin 2
249134|NCT01723956|Cin 3
249135|NCT01723956|HIV positive women
249136|NCT01723956|South Africa
249137|NCT01723904|Rotigotine
249138|NCT01723904|Neupro
249139|NCT01723865|Heart failure
249140|NCT01723865|Remote Monitoring
249141|NCT01723865|ICD
249142|NCT01723865|Follow-up
249143|NCT01723852|Vitamin D
249144|NCT01723852|Infectious diseases
249145|NCT01723852|cognitive development
249146|NCT01723852|Bone mineral density
249147|NCT01723852|Immunoregulation
249148|NCT01723852|Allergy
249149|NCT01723852|Growth
249150|NCT01723839|CLL
249151|NCT01723839|FCR
249152|NCT01723839|Rituximab
249153|NCT01723839|Lenalidomide
249154|NCT01723839|Cyclophosphamide
249155|NCT01723813|Immunotherapy
249156|NCT01723813|Tumor-specific peptides
249157|NCT01723813|GM-CT-01
249158|NCT01723761|air pollution
249159|NCT01723761|pacemaker
249160|NCT01723761|ICD
249161|NCT01723761|remote monitoring
249162|NCT01723761|supraventricular arrhythmias
249163|NCT01723761|ventricular arrhythmias
249164|NCT01723748|Acromegaly
249165|NCT01723748|Somatostatin treatment
249166|NCT01723748|metabolic effect
249167|NCT01723722|Neonatal Abstinence Syndrome
249168|NCT01723722|Methadone
249169|NCT01723722|Diluted Deodorized Tincture of Opium
249170|NCT01723722|dDTO
249171|NCT01723722|Phenobarbital
249172|NCT01723709|multiple sclerosis
249173|NCT01723709|immune response
249174|NCT01723709|genetic
249175|NCT01723709|progression
249176|NCT01723709|relapse
249177|NCT01723709|biomarkers
249178|NCT01723709|disease
249179|NCT01723709|proteomics
249180|NCT01723709|genome
249181|NCT01723709|gene
249182|NCT01723696|In-utero smoke;
249183|NCT01723696|Pulmonary function testing;
249184|NCT01723696|Wheeze;
249185|NCT01723696|Vitamin C;
249186|NCT01723696|Forced expiratory flows
249187|NCT01723683|Preterm infants
249188|NCT01723683|RDS
249189|NCT01723683|Surfactant
249190|NCT01723683|MISTCPAP
249191|NCT01723683|CPAP
249192|NCT01723657|Leukemia
249193|NCT01723657|Myeloid
249194|NCT01723657|Acute
249195|NCT01723657|Young
249196|NCT01723657|CETLAM
249197|NCT01723644|antibiotherapy, community acquired pneumonia, procalcitonin guided guidelines, clinical reassessment
249198|NCT01723631|Multiple sclerosis
249199|NCT01723631|TRAP
249200|NCT01723631|TRAP-Myéline
249201|NCT01723605|insitu repair
249202|NCT01723605|intestinal motility
249203|NCT01723592|chemotherapy
249204|NCT01723592|vaginal flora
249205|NCT01723553|aphasia
249206|NCT01723553|logopenic
249207|NCT01723553|PCA
249208|NCT01723553|LPA
249209|NCT01723540|Cholecystectomy,minilaparotomy,laparascopy,ultrasonic dissection
249210|NCT01723527|Cocaine
249211|NCT01723527|Heroin
249212|NCT01723527|HIV
249213|NCT01723527|Contingency Management
249214|NCT01723527|Incentives
249215|NCT01723527|Criminal Justice
249216|NCT01723527|Methadone
249217|NCT01723527|Buprenorphine
249218|NCT01723527|Employment
249219|NCT01723527|Job Training
249220|NCT01723527|Wage Subsidies
249221|NCT01723514|Migraine
249222|NCT01723501|chlorhexidine
249223|NCT01723501|sepsis
249224|NCT01723501|neonatal
249225|NCT01723501|whole-body skin cleansing
249226|NCT01723488|AD
249227|NCT01723475|Phase I
249228|NCT01723475|Dose Escalation
249229|NCT01723475|Prostate cancer
249230|NCT01723475|Antibodies
249231|NCT01723475|Bispecific T-cell Engager (BiTE)
249232|NCT01723436|Decision fatigue
249233|NCT01723423|breast cancer
249234|NCT01723423|evidence based medicine
249235|NCT01723423|reconstruction
249236|NCT01723423|mastectomy
249237|NCT01723423|outcomes
249238|NCT01723423|quality of life
249239|NCT01723384|methamphetamine
249240|NCT01723384|alcohol
249241|NCT01723384|HIV
249242|NCT01723384|sexual behavior
249243|NCT01723371|Pulmonary Arterial Hypertension (PAH
249244|NCT01723371|Pediatrics
249245|NCT01723371|Right Heart Failure (RHF)
249246|NCT01723371|Carvedilol
249247|NCT01723371|Beta-blockers
249248|NCT01723358|pediatrics
249249|NCT01723358|dysphagia
249250|NCT01723345|elective percutaneous coronary intervention
249251|NCT01723345|omega 3 polyunsaturated fatty acids (PUFAs)
249252|NCT01723345|short-term MACE
249253|NCT01723345|long-term MACE
249254|NCT01723332|Transition from pediatric to adult clinical care
249255|NCT01723319|ADHD
249256|NCT01723319|TMS
249257|NCT01723319|brain stimulation
249258|NCT01723319|clinical improvement
249259|NCT01723306|T cells
249260|NCT01723306|gene transfer
249261|NCT01723306|immunotherapy
249262|NCT01723306|metastatic cancers
249263|NCT01723306|lung cancer
249264|NCT01723306|gastric cancer
249265|NCT01723306|colorectal cancer
249266|NCT01723306|solid tumors
249267|NCT01723293|Fetal heart rate, pregnancy, fetus, cardiovascular system
249268|NCT01723267|IVF
249269|NCT01723267|3D ultrasound
249270|NCT01723267|SonoAVC
249271|NCT01723267|patients in IVF treatment
249272|NCT01723254|Vaccines
249273|NCT01723254|Phase 1
249274|NCT01723254|Allergic Rhinitis
249275|NCT01723241|volunteers
249276|NCT01723228|Parkinson's Disease
249277|NCT01723228|Cognition
249278|NCT01723228|Rasagiline
249279|NCT01723215|Attention bias modification
249280|NCT01723215|resilience
249281|NCT01723215|combat
249282|NCT01723215|PTSD
249283|NCT01723215|Depression
249284|NCT01723215|Anxiety
249285|NCT01723202|BRAF
249286|NCT01723202|BRAFi
249287|NCT01723202|thyroid cancer
249288|NCT01723202|thyroid carcinoma
249289|NCT01723189|central apnoeas
249290|NCT01723189|stroke
249291|NCT01723176|goal-directed echocardiography
249292|NCT01723176|cardiopulmonary failure
249293|NCT01723176|critical care ultrasound
249294|NCT01723163|veteran
249295|NCT01723163|smoking cessation
249296|NCT01723150|Klebsiella pneumoniae
249297|NCT01723137|Pain
249298|NCT01723137|Pain measurement
249299|NCT01723137|Visual analog scale
249300|NCT01723137|Anxiety
249301|NCT01723137|Stress
249302|NCT01723137|Opioid
249303|NCT01723137|Emergency department
249304|NCT01723137|Demographics
249305|NCT01723124|Dense breast tissue
249306|NCT01723124|breast cancer screening
249307|NCT01723124|molecular breast imaging
249308|NCT01723124|breast cancer
249309|NCT01723124|breast
249310|NCT01723111|hepcidin
249311|NCT01723111|ESA
249312|NCT01723111|hemodialysis
249313|NCT01723111|peritoneal dialysis
249314|NCT01723111|iron metabolism
249315|NCT01723111|dialysis modality
249316|NCT01723098|Pregnancy, cardiovascular system, physical exercise
249317|NCT01723085|Anti-Mullerian hormone
249318|NCT01723085|Myomectomy
249319|NCT01723085|Laparotomy
249320|NCT01723072|Chronic spontanous urticaria, refractory CSU, Angioedema
249321|NCT01723046|Upper extremity
249322|NCT01723046|Rehabilitation
249323|NCT01723046|Robot assisted therapy
249324|NCT01723046|Robotics
249325|NCT01723046|Devices
249326|NCT01723046|Orthosis
249327|NCT01723046|clinical outcome
249328|NCT01723033|PTSD
249329|NCT01723033|OCD
249330|NCT01723020|Solid Tumors
249331|NCT01723020|Multiple Myeloma
249332|NCT01723007|Weight loss
249333|NCT01723007|cholesterol
249334|NCT01722968|Metastatic breast cancer
249335|NCT01722955|Prewarmed fluid
249336|NCT01722955|monitored anesthesia care
249337|NCT01722955|core body temperature
249338|NCT01722955|anesthetic satisfaction
249339|NCT01722942|Chagas cardiomyopathy
249340|NCT01722942|sudden cardiac death
249341|NCT01722942|primary prevention of death
249342|NCT01722942|amiodarone
249343|NCT01722942|implantable cardioverter defibrillator
249344|NCT01722903|colorectal cancer
249345|NCT01722903|liver metastases
249346|NCT01722903|lung metastases
249347|NCT01722890|HER2-positive breast cancer
249348|NCT01722890|durable complete response
249349|NCT01722890|cytogenetic characteristics
249350|NCT01722890|molecular characteristics
249351|NCT01722890|trastuzumab
249352|NCT01722877|Restenosis
249353|NCT01722877|aspiration
249354|NCT01722877|in-stent restenosis
249355|NCT01722877|atherectomy
249356|NCT01722877|superficial femoral artery
249357|NCT01722877|popliteal artery
249358|NCT01722851|Breast Cancer
249359|NCT01722851|miRNAs
249360|NCT01722851|Newly diagnosed
249361|NCT01722851|Recurrent
249362|NCT01722838|Black MSM
249363|NCT01722838|HIV Prevention
249364|NCT01722799|angioplasty
249365|NCT01722799|Percutaneous Transluminal Coronary Angioplasty
249366|NCT01722799|Drug elluting Balloon
249367|NCT01722799|Coronary Balloon
249368|NCT01722799|Dilatation
249369|NCT01722786|severe bleeding
249370|NCT01722786|dabigatran
249371|NCT01722786|rivaroxaban
249372|NCT01722786|apixaban
249373|NCT01722786|edoxaban
249374|NCT01722786|PCC
249375|NCT01722786|aPCC
249376|NCT01722786|rVIIa
249377|NCT01722786|hemodialysis
249378|NCT01722786|antidots
249379|NCT01722786|idarucizumab
249380|NCT01722773|COPD
249381|NCT01722760|Neonatal
249382|NCT01722760|Preterm
249383|NCT01722760|Bronchopulmonary Dysplasia
249384|NCT01722760|Nasal Continuous Positive airway Pressure (CPAP)
249385|NCT01722760|Oxygen
249386|NCT01722760|Vitamin A
249387|NCT01722760|Vitamin D
249388|NCT01722760|Nitrogen oxide (NO)
249389|NCT01722760|Reference material
249390|NCT01722734|Malaria
249391|NCT01722734|ACTs
249392|NCT01722708|Abnormal vaginal flora
249393|NCT01722708|clindamycin Vs metronidazole
249394|NCT01722708|High risk pregnancies for preterm labor
249395|NCT01722708|Preterm labor
249396|NCT01722708|Late abortion
249397|NCT01722708|bacterial vaginosis
249398|NCT01722682|Diabetes
249399|NCT01722669|quercetin
249400|NCT01722669|isoquercetin
249401|NCT01722669|pharmacokinetic
249402|NCT01722669|pharmacodynamic
249403|NCT01722656|PED
249404|NCT01722656|AMD
249405|NCT01722656|CNV
249406|NCT01722630|dopamine
249407|NCT01722630|laparoscopy
249408|NCT01722630|fluid management
249409|NCT01722578|Cirrhosis
249410|NCT01722578|Encephalopathy
249411|NCT01722578|L-ornithine L-aspartate
249412|NCT01722565|Parastomal hernias
249413|NCT01722565|Tolerance of lightweight meshes
249414|NCT01722565|laparoscopic abdominoperineal resection
249415|NCT01722552|HIV
249416|NCT01722552|AIDS
249417|NCT01722552|antiretroviral therapy
249418|NCT01722552|adherence
249419|NCT01722552|China
249420|NCT01722539|intermittent
249421|NCT01722539|preventive
249422|NCT01722539|treatment
249423|NCT01722539|malaria
249424|NCT01722539|soil transmitted helminths
249425|NCT01722539|schistosomiasis
249426|NCT01722539|schoolchildren
249427|NCT01722526|Human acid sphingomyelinase deficiency
249428|NCT01722513|Contrast Induced Nephropathy
249429|NCT01722500|International
249430|NCT01722500|Childhood
249431|NCT01722500|Obesity
249432|NCT01722500|ISCOLE
249433|NCT01722500|Pennington Biomedical Research Center
249434|NCT01722500|PBRC
249435|NCT01722500|longitudinal
249436|NCT01722500|multinational
249437|NCT01722487|CLL, SLL
249438|NCT01722474|Pulse Wave Analysis
249439|NCT01722474|Arterial Stiffness
249440|NCT01722461|Excessive underarm sweating
249441|NCT01722448|muscle
249442|NCT01722448|muscle dysfunction
249443|NCT01722448|choline
249444|NCT01722448|exercise
249445|NCT01722448|exertional rhabdomyolysis
249446|NCT01722448|rhabdomyolysis
249447|NCT01722435|opioid dependence
249448|NCT01722435|opiate substitution treatment
249449|NCT01722435|methadone
249450|NCT01722435|completion
249451|NCT01722435|termination
249452|NCT01722422|sepsis
249453|NCT01722422|shock
249454|NCT01722422|hyperoxia
249455|NCT01722422|hypertonic saline
249456|NCT01722409|dexmedetomidine, endovascular coil embolization
249457|NCT01722357|bariatric surgery
249458|NCT01722357|physical activity
249459|NCT01722357|morbid obesity
249460|NCT01722344|Severe mental illness
249461|NCT01722344|Vocational rehabilitation
249462|NCT01722344|Supported employment
249463|NCT01722344|Individual placement and support
249464|NCT01722344|Cognitive remediation
249465|NCT01722344|Social skill training
249466|NCT01722279|bariatric surgery
249467|NCT01722279|long-term outcomes
249468|NCT01722279|obesity
249469|NCT01722266|Liraglutide
249470|NCT01722266|Glucagon
249471|NCT01722266|Systolic blood pressure
249472|NCT01722266|Weight
249473|NCT01722266|Carbohydrate intake
249474|NCT01722266|Insulin dose
249475|NCT01722266|HbA1c
249476|NCT01722266|Post-prandial glucagon
249477|NCT01722253|electroacupuncture
249478|NCT01722253|acupuncture
249479|NCT01722253|pain management
249480|NCT01722214|Psoriasis
249481|NCT01722214|Vascular Inflammation
249482|NCT01722214|Coronary Atherosclerosis
249483|NCT01722214|Ascending aorta
249484|NCT01722214|Pet scan
249485|NCT01722214|MRI
249486|NCT01722188|Optim
249487|NCT01722188|Insulation
249488|NCT01722149|malignant pleural mesothelioma
249489|NCT01722149|re-directed T cells
249490|NCT01722149|FAP
249491|NCT01722149|fibroblast activation protein
249492|NCT01722149|CD8 positive T cells
249493|NCT01722149|pleural effusion
249494|NCT01722123|Decision fatigue
249495|NCT01722071|Oxytocin
249496|NCT01722071|Functional Magnetic Resonance Imaging
249497|NCT01722071|Social
249498|NCT01722071|Motivation
249499|NCT01722058|peptide
249500|NCT01722058|colon
249501|NCT01722058|flat lesions
249502|NCT01722045|AMD
249503|NCT01722032|childhood obesity, early childhood, nutrition
249504|NCT01722019|venous insufficiency
249505|NCT01722006|methamphetamine
249506|NCT01722006|subjective
249507|NCT01722006|conditioning
249508|NCT01722006|preference
249509|NCT01721993|oral zoledronic acid
249510|NCT01721967|chest pain
249511|NCT01721967|dyspnea
249512|NCT01721954|colon
249513|NCT01721954|rectum
249514|NCT01721954|metastatic colorectal cancer
249515|NCT01721954|liver metastases
249516|NCT01721941|hepatocellular carcinoma
249517|NCT01721941|HCC
249518|NCT01721941|liver cancer
249519|NCT01721941|hepatoma
249520|NCT01721941|TACE
249521|NCT01721941|transarterial chemoembolization
249522|NCT01721941|TH302
249523|NCT01721928|Acute kidney injury
249524|NCT01721928|Deep venous thrombosis
249525|NCT01721928|Dialysis
249526|NCT01721928|Prophylaxis
249527|NCT01721915|Polycystic Ovary Syndrome (PCOS)
249528|NCT01721915|glucose metabolism
249529|NCT01721915|Vitamin D deficiency
249530|NCT01721915|vitamin D supplementation
249531|NCT01721915|pharmakogenetics
249532|NCT01721915|women
249533|NCT01721863|Atrial Fibrillation
249534|NCT01721863|Exercise Training
249535|NCT01721863|Endothelial Function
249536|NCT01721863|Autonomic Nerve Modulation
249537|NCT01721863|Exercise Capacity
249538|NCT01721863|Quality of Life
249539|NCT01721850|infant nutrition, infantile colic
249540|NCT01721824|Supported employment
249541|NCT01721824|Individual Placement and Support
249542|NCT01721824|Workability
249543|NCT01721824|Return to work
249544|NCT01721798|AE adverse event
249545|NCT01721798|AIDS acquired immunodeficiency syndrome
249546|NCT01721798|ALT (SGPT) alanine aminotransferase
249547|NCT01721798|ART antiretroviral therapy
249548|NCT01721798|AST (SGOT) aspartate aminotransferase
249549|NCT01721798|DCF data collection forms
249550|NCT01721798|DMC Data Monitoring Committee
249551|NCT01721798|FDA (U.S.) Food and Drug Administration
249552|NCT01721798|GCP Good Clinical Practice guidelines
249553|NCT01721798|HB sAg Hepatitis B surface antigen
249554|NCT01721798|ICH International Conference of Harmonization
249555|NCT01721798|IND Investigational New Drug Application
249556|NCT01721798|IRB Institutional Review Board
249557|NCT01721798|IU International units
249558|NCT01721798|mg milligram(s)
249559|NCT01721798|mm3 cubic millimeter(s)
249560|NCT01721798|PCR polymerase chain reaction
249561|NCT01721798|SAE serious adverse event
249562|NCT01721798|µg microgram
249563|NCT01721798|ULN upper limit of the normal range
249564|NCT01721798|WB Western Blot
249565|NCT01721785|Nodal imaging
249566|NCT01721785|Restaging
249567|NCT01721733|EPI743
249568|NCT01721733|Leigh syndrome
249569|NCT01721733|respiratory chain disease
249570|NCT01721733|mitochondrial disorders
249571|NCT01721720|Attention Deficit Hyperactivity Disorder
249572|NCT01721720|Behavioral Phenotype
249573|NCT01721720|Brain Development
249574|NCT01721720|Complex Disease
249575|NCT01721720|Social Networks
249576|NCT01721707|glaucoma
249577|NCT01721707|ocular hypertension
249578|NCT01721707|latanoprost
249579|NCT01721707|brinzolamide
249580|NCT01721694|bacterial ocular inflammation
249581|NCT01721694|blepharitis
249582|NCT01721694|keratitis
249583|NCT01721694|conjunctivitis
249584|NCT01721655|Spironolactone
249585|NCT01721655|Preterm Infants
249586|NCT01721655|Chronic Lung Disease
249587|NCT01721655|Bronchopulmonary Dysplasia
249588|NCT01721655|Electrolyte Supplementation
249589|NCT01721642|access
249590|NCT01721642|closure
249591|NCT01721642|trans-apical
249592|NCT01721642|trans-catheter aortic valve implantation
249593|NCT01721642|TAVI
249594|NCT01721642|trans-catheter aortic valve repair
249595|NCT01721642|TAVR
249596|NCT01721629|Nasal cpap weaning
249597|NCT01721629|Premature infants
249598|NCT01721629|Respiratory distress syndrome
249599|NCT01721629|Randomized controlled trial
249600|NCT01721603|BRAFV600E melanoma patients
249601|NCT01721603|melanoma
249602|NCT01721603|stereotactic radiosurgery
249603|NCT01721603|BRAFV600E melanoma brain metastases
249604|NCT01721603|dabrafenib
249605|NCT01721603|SRS
249606|NCT01721590|high on-treatment platelet reactivity
249607|NCT01721590|Coronary Heart Disease
249608|NCT01721590|Tongxinluo
249609|NCT01721577|glioblastoma
249610|NCT01721577|gliosarcoma
249611|NCT01721577|anaplastic astrocytoma
249612|NCT01721577|anaplastic oligodendroglioma
249613|NCT01721577|anaplastic oligoastrocytoma
249614|NCT01721577|AXL1717
249615|NCT01721577|IGF-1 receptor inhibitor
249616|NCT01721577|picropodophyllin
249617|NCT01721551|Dialysis fatigue,
249618|NCT01721551|exercise intolerance,
249619|NCT01721551|muscle atrophy,
249620|NCT01721551|cachexia,
249621|NCT01721551|disability,
249622|NCT01721551|Sleep disorders
249623|NCT01721551|Depression
249624|NCT01721551|Mental Fatigue,
249625|NCT01721551|Cognitive function
249626|NCT01721551|Physical Fatigue
249627|NCT01721538|stroke
249628|NCT01721538|prevention
249629|NCT01721538|obesity
249630|NCT01721538|weight reduction
249631|NCT01721525|BIBW2992 (AFATINIB)
249632|NCT01721525|CARBOPLATIN
249633|NCT01721525|RIBAVIRIN-ICN (VIRAZOLE)
249634|NCT01721525|TAXOL (PACLITAXEL)
249635|NCT01721525|OROPHARYNX
249636|NCT01721525|HPV associated
249637|NCT01721525|12-150
249638|NCT01721512|Prospective observational study
249639|NCT01721512|Breast feeding
249640|NCT01721512|Infant formula
249641|NCT01721512|Infant
249642|NCT01721512|Indonesia
249643|NCT01721499|Stress
249644|NCT01721499|obesity
249645|NCT01721499|overeating
249646|NCT01721486|tonsillitis
249647|NCT01721486|recurrent tonsillitis
249648|NCT01721486|obstructed air passages
249649|NCT01721486|swallowing difficulties
249650|NCT01721473|Tobacco
249651|NCT01721473|Positron Emission Tomography
249652|NCT01721473|Marijuana
249653|NCT01721473|Caffeine
249654|NCT01721473|Menthol
249655|NCT01721460|SubThalamic Nucleus
249656|NCT01721460|Microelectrode recording
249657|NCT01721460|Deep Brain Stimulation Electrode implantation
249658|NCT01721447|Atrial fibrillation
249659|NCT01721447|stroke
249660|NCT01721447|TEE
249661|NCT01721447|Left atrial thrombus
249662|NCT01721434|levosimendan
249663|NCT01721434|diaphragm function
249664|NCT01721434|mechanically ventilated patients
249665|NCT01721434|neuro-mechanical efficiency
249666|NCT01721421|haemodialysis
249667|NCT01721421|Crossover
249668|NCT01721421|Treatment time
249669|NCT01721421|nutritional status
249670|NCT01721395|Cough
249671|NCT01721395|Nocturnal Cough
249672|NCT01721395|Agave
249673|NCT01721395|Sleep Quality
249674|NCT01721395|Childhood cough
249675|NCT01721382|cystic fibrosis
249676|NCT01721382|CF
249677|NCT01721382|CFRD
249678|NCT01721382|sitagliptin
249679|NCT01721382|incretins
249680|NCT01721382|GLP1
249681|NCT01721382|GIP
249682|NCT01721382|beta cell function
249683|NCT01721382|adolescents
249684|NCT01721330|ADHD
249685|NCT01721330|Attention Deficit Hyperactivity Disorder
249686|NCT01721330|Psychopharmacology
249687|NCT01721330|Psychiatry
249688|NCT01721330|Non-stimulant treatment
249689|NCT01721317|Ezogabine/Retigabine
249690|NCT01721317|Adjunctive Treatment
249691|NCT01721317|Safety
249692|NCT01721317|Efficacy
249693|NCT01721317|Epilepsy
249694|NCT01721317|Tolerability
249695|NCT01721317|Immediate Release
249696|NCT01721317|GW582892
249697|NCT01721317|Dose-Optimization
249698|NCT01721317|Partial-Onset Seizures
249699|NCT01721304|decision making
249700|NCT01721304|abnormal uterine bleeding
249701|NCT01721304|adaptive conjoint analysis
249702|NCT01721304|satisfaction
249703|NCT01721304|regret
249704|NCT01721291|CHRONIC OBSTRUCTIVE PULMONARY DISEASE
249705|NCT01721291|ASTHMA
249706|NCT01721291|SALBUTAMOL
249707|NCT01721291|ALBUTEROL
249708|NCT01721291|VENTOLIN
249709|NCT01721291|LUNG PHYSIOLOGY
249710|NCT01721291|LUNG DEPOSITION
249711|NCT01721291|INHALERS
249712|NCT01721291|DRUG THERAPY
249713|NCT01721265|HCV
249714|NCT01721265|Hepatitis C
249715|NCT01721265|IDX184
249716|NCT01721265|IDX719
249717|NCT01721252|non-small cell lung cancer
249718|NCT01721252|Erlotinib
249719|NCT01721252|TarcevaTM
249720|NCT01721252|proteomic signature
249721|NCT01721239|ICU
249722|NCT01721239|Follow-up consultations
249723|NCT01721239|Quality of life
249724|NCT01721239|Sense Of Coherence
249725|NCT01721239|RCT multicenter study
249726|NCT01721226|Linkage to HIV care following release from prison
249727|NCT01721226|Anti-retroviral therapy adherence after release from prison
249728|NCT01721226|HIV loads after release from prison
249729|NCT01721226|information technology and ART adherence
249730|NCT01721226|information technology and linkage to HIV care
249731|NCT01721213|Epilepsy
249732|NCT01721213|survey
249733|NCT01721213|retigabine
249734|NCT01721213|patient information leaflet
249735|NCT01721213|physician's guide
249736|NCT01721213|Trobalt™
249737|NCT01721200|Rheumatoid Arthritis
249738|NCT01721200|web based interactive learning tool
249739|NCT01721187|fMRI
249740|NCT01721187|Satiety
249741|NCT01721187|Willingness to Pay
249742|NCT01721187|Incentive Delay
249743|NCT01721187|Dietary Disinhibition
249744|NCT01721174|Pancreatic cancer
249745|NCT01721174|Cholangiocarcinoma
249746|NCT01721174|Endoscopic radiofrequency ablation
249747|NCT01721161|Optic Neuritis
249748|NCT01721135|moxifloxacin
249749|NCT01721135|GSK2190915
249750|NCT01721135|pharmacokinetics
249751|NCT01721135|QTc
249752|NCT01721109|Adolescents
249753|NCT01721109|HIV-1
249754|NCT01721109|HIV
249755|NCT01721109|Treatment Naive
249756|NCT01721096|Angioplasty
249757|NCT01721096|Drug eluting stents
249758|NCT01721096|Stents
249759|NCT01721096|Real world
249760|NCT01721083|intramuscular injection
249761|NCT01721083|bunch
249762|NCT01721083|z-track
249763|NCT01721070|Area under curve, time to maximum concentration
249764|NCT01721031|Catheter Related Bladder Discomfort
249765|NCT01721031|Dorsal Penile Nerve Block
249766|NCT01721018|Oncolytic virus
249767|NCT01721018|HSV1716
249768|NCT01721018|Mesothelioma
249769|NCT01721018|MPM
249770|NCT01721018|Woll
249771|NCT01721018|Sheffield
249772|NCT01721018|Weston Park
249773|NCT01721018|Virttu
249774|NCT01721018|Crusade
249775|NCT01721005|atrial fibrillation
249776|NCT01721005|thromboembolism
249777|NCT01721005|patient education
249778|NCT01720979|TBI
249779|NCT01720979|Traumatic Brain Injury
249780|NCT01720979|Children
249781|NCT01720979|Prognosis
249782|NCT01720979|Neurocognition
249783|NCT01720966|Adhesions
249784|NCT01720966|laparoscopy
249785|NCT01720966|laparotomy
249786|NCT01720966|liver resection
249787|NCT01720966|colorectal malignancy
249788|NCT01720953|Borderline Personality Disorder
249789|NCT01720953|Mentalization Based Therapy
249790|NCT01720953|DNA methylation
249791|NCT01720953|BDNF
249792|NCT01720953|Cortisol
249793|NCT01720953|Neuropsychology
249794|NCT01720927|Acute Pharyngitis, GABHS
249795|NCT01720888|Autologous
249796|NCT01720888|Bone Marrow
249797|NCT01720888|Mesenchymal Stem Cells
249798|NCT01720888|Ischemic Dilated Cardiomyopathy
249799|NCT01720862|migraine
249800|NCT01720862|episodic migraine
249801|NCT01720862|chronic migraine
249802|NCT01720862|obesity
249803|NCT01720862|non-obese
249804|NCT01720823|Obstructive Sleep Apnea syndrome
249805|NCT01720823|polysomnography
249806|NCT01720823|Home monitoring
249807|NCT01720797|Malocclusion
249808|NCT01720797|Accelerated tooth movement
249809|NCT01720797|Braces
249810|NCT01720797|Orthodontic treatment
249811|NCT01720797|Propel
249812|NCT01720771|bacteriotherapy
249813|NCT01720771|caries
249814|NCT01720771|preschool children
249815|NCT01720771|probiotics
249816|NCT01720745|EUS
249817|NCT01720745|FNA
249818|NCT01720745|Wet suction
249819|NCT01720745|Dry suction
249820|NCT01720745|Solid lesions
249821|NCT01720719|Non-alcoholic Fatty Liver Disease
249822|NCT01720719|Dyslipidemias
249823|NCT01720719|Diabetes Mellitus
249824|NCT01720719|atorvastatin
249825|NCT01720719|Vitamin E
249826|NCT01720706|Liver tumour
249827|NCT01720706|Kidney tumour
249828|NCT01720706|Hepatectomy
249829|NCT01720706|Nephrectomy
249830|NCT01720706|Metastatic Colon Cancer
249831|NCT01720706|Renal Cell Carcinoma
249832|NCT01720693|partial nephrectomy
249833|NCT01720693|hypoperfusion
249834|NCT01720693|renal function
249835|NCT01720680|COPD
249836|NCT01720680|Functional Imaging
249837|NCT01720680|Patient Reported Outcome (PRO)
249838|NCT01720680|Lung Function
249839|NCT01720680|AlphaCore
249840|NCT01720680|Computational Fluid Dynamics
249841|NCT01720667|Seizures
249842|NCT01720667|Neonates
249843|NCT01720667|Anticonvulsants
249844|NCT01720667|Treatment
249845|NCT01720667|Levetiracetam
249846|NCT01720667|Phenobarbital
249847|NCT01720654|Expedited Partner Therapy
249848|NCT01720654|MSM
249849|NCT01720654|Peru
249850|NCT01720654|Gonorrhea
249851|NCT01720654|Chlamydia
249852|NCT01720641|MSM
249853|NCT01720641|Transgender Women
249854|NCT01720641|Partner Notification
249855|NCT01720641|Syphilis
249856|NCT01720641|Peru
249857|NCT01720628|Angiogenin, Behçet's disease, bFGF, VEGF
249858|NCT01720615|EEG
249859|NCT01720615|AEP
249860|NCT01720615|Propofol
249861|NCT01720615|Sevoflurane
249862|NCT01720615|Remifentanil
249863|NCT01720615|General anesthesia
249864|NCT01720589|Obesity
249865|NCT01720589|Dietary fat
249866|NCT01720589|Energy expenditure
249867|NCT01720589|Food intake
249868|NCT01720563|Cancer-related fatigue
249869|NCT01720563|astragalus polysaccharides
249870|NCT01720563|concurrent chemoradiotherapy
249871|NCT01720563|squamous cell carcinoma of head and neck
249872|NCT01720550|Cancer-related fatigue
249873|NCT01720550|Palliative Treatment
249874|NCT01720550|Astragalus polysaccharides
249875|NCT01720537|High Cholesterol
249876|NCT01720537|Dyslipidemia
249877|NCT01720524|persistent pulmonary hypertension
249878|NCT01720524|newborn
249879|NCT01720524|neonates
249880|NCT01720524|iv sildenafil
249881|NCT01720524|hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
249882|NCT01720472|Aging
249883|NCT01720472|Healthy Aging
249884|NCT01720472|Physical Performance
249885|NCT01720472|Physical Functioning
249886|NCT01720472|Cognitive Functioning
249887|NCT01720472|Fitness
249888|NCT01720472|Physical Activity
249889|NCT01720433|laparoscopic pain prospective blinded trial
249890|NCT01720420|edentulous
249891|NCT01720420|maxilla
249892|NCT01720420|mandible
249893|NCT01720420|dental implant
249894|NCT01720420|bar
249895|NCT01720420|overdenture
249896|NCT01720420|Oral Health Impact Profile (OHIP)
249897|NCT01720420|survival rate
249898|NCT01720420|technical complications
249899|NCT01720420|marginal bone level
249900|NCT01720420|soft tissue
249901|NCT01720407|Dermatology/ Skin cancers/Lentigo maligna melanoma
249902|NCT01720381|monitoring
249903|NCT01720381|blood glucose
249904|NCT01720381|intensive care unit
249905|NCT01720368|IBD
249906|NCT01720368|Crohn's
249907|NCT01720342|Medtronic Enable® aortic bioprosthesis
249908|NCT01720342|Aortic valve stenosis
249909|NCT01720342|Aortic valve insufficiency
249910|NCT01720342|"Real world patients"
249911|NCT01720316|Glycine
249912|NCT01720316|Glycine decarboxylase
249913|NCT01720316|Psychosis
249914|NCT01720316|Mutation
249915|NCT01720277|Randomized Controlled Trial
249916|NCT01720277|Influenza
249917|NCT01720277|Influenza vaccine
249918|NCT01720277|Flu Vaccine
249919|NCT01720277|Fluzone
249920|NCT01720277|HD Fluzone
249921|NCT01720277|Nursing Homes
249922|NCT01720277|Hospitalization
249923|NCT01720277|Mortality
249924|NCT01720277|Health Care worker vaccination
249925|NCT01720277|ADL decline
249926|NCT01720277|Pilot
249927|NCT01720277|Effectiveness
249928|NCT01720251|allergic rhinitis
249929|NCT01720251|birch pollen
249930|NCT01720251|immunotherapy
249931|NCT01720238|Compensated Liver Cirrhosis
249932|NCT01720238|Early Antiviral Therapy
249933|NCT01720238|Cost Effectiveness
249934|NCT01720225|Leukemia
249935|NCT01720225|Myelodysplastic syndromes
249936|NCT01720225|MDS
249937|NCT01720225|Low and Intermediate-1 Risk Disease
249938|NCT01720225|Decitabine
249939|NCT01720225|DAC
249940|NCT01720225|Dacogen
249941|NCT01720225|Azacitidine
249942|NCT01720225|AZA
249943|NCT01720225|5-azacytidine
249944|NCT01720225|5-aza
249945|NCT01720225|Vidaza
249946|NCT01720225|5-AZC
249947|NCT01720225|AZA-CR
249948|NCT01720225|Ladakamycin
249949|NCT01720225|NSC-102816
249950|NCT01720212|YM178
249951|NCT01720212|Mirabegron
249952|NCT01720212|OCAS
249953|NCT01720212|Chinese Healthy Volunteers
249954|NCT01720212|PK
249955|NCT01720212|Safety
249956|NCT01720199|universal prevention
249957|NCT01720199|primary prevention
249958|NCT01720199|health promotion
249959|NCT01720199|wellbeing
249960|NCT01720199|smoking
249961|NCT01720199|alcohol
249962|NCT01720199|diet
249963|NCT01720199|physical activity
249964|NCT01720199|emotional and social skills
249965|NCT01720186|Lung Cancer
249966|NCT01720186|PET/CT
249967|NCT01720186|FDG
249968|NCT01720186|Respiratory synchronization
249969|NCT01720147|Fanconi Anemia
249970|NCT01720147|FA
249971|NCT01720147|Quercetin
249972|NCT01720043|multiple myeloma
249973|NCT01720030|Renal
249974|NCT01720030|Acute Kidney Injury
249975|NCT01720030|AKI
249976|NCT01720030|Levosimendan
249977|NCT01720030|Simdax
249978|NCT01720030|Renal perfusion
249979|NCT01720030|Mortality
249980|NCT01720030|Renal flow
249981|NCT01720017|Airtraq
249982|NCT01720017|laryngoscope
249983|NCT01720017|airway
249984|NCT01720017|difficult
249985|NCT01720017|training
249986|NCT01720017|manikin
249987|NCT01720004|human labour
249988|NCT01720004|hands-and-knees positioning
249989|NCT01720004|pilot trial
249990|NCT01719991|Primary care
249991|NCT01719991|Self-management
249992|NCT01719991|Self-support
249993|NCT01719991|Nurse case management
249994|NCT01719978|Local Anaesthetics
249995|NCT01719978|Mepivacaine
249996|NCT01719978|hyaluronoglucosaminidase
249997|NCT01719978|Hemodynamic
249998|NCT01719978|Electrocardiography and Dentistry.
249999|NCT01719965|Community Advisory Board
250000|NCT01719965|Focus Group Discussion
250001|NCT01719965|Interview
250002|NCT01719965|Community Engagement
250003|NCT01719965|Thailand
250004|NCT01719952|pregnancy
250005|NCT01719952|anaesthesia
250006|NCT01719952|caesarean section
250007|NCT01719926|Colorectal
250008|NCT01719926|Esophageal
250009|NCT01719926|Indomethacin
250010|NCT01719926|PIFA
250011|NCT01719900|Dietary intervention
250012|NCT01719900|Dietary fibre
250013|NCT01719900|Obesity
250014|NCT01719900|Metabolic syndrome
250015|NCT01719900|Weight loss
250016|NCT01719900|Glucose regulation
250017|NCT01719900|Pulse fibre
250018|NCT01719887|humerus
250019|NCT01719887|humeral
250020|NCT01719887|shaft
250021|NCT01719887|diaphysis
250022|NCT01719887|fracture
250023|NCT01719887|RCT
250024|NCT01719874|Influenza
250025|NCT01719874|monoclonal antibody
250026|NCT01719848|Physical examinations, Percentage of glottic opening(POGO)
250027|NCT01719835|T cell lymphoma
250028|NCT01719835|untreated
250029|NCT01719822|Treatment Outcome [E01.789.800]
250030|NCT01719822|Rehabilitation [N02.421.784]
250031|NCT01719822|Physical Fitness [I03.621]
250032|NCT01719822|Lung Diseases, Obstructive [C08.381.495]
250033|NCT01719822|Pulmonary Disease, Chronic Obstructive [C08.381.495.389]
250034|NCT01719822|Bronchitis, Chronic [C08.381.495.389.500]
250035|NCT01719809|Glaucoma
250036|NCT01719809|Eye Drop
250037|NCT01719809|Eye Drop Technique
250038|NCT01719809|Training
250039|NCT01719809|Instilling Eye Drops
250040|NCT01719783|influenza
250041|NCT01719783|vaccine
250042|NCT01719783|pandemic
250043|NCT01719770|cardiac arrest
250044|NCT01719770|therapeutic hypothermia
250045|NCT01719770|skeletal muscle paralysis
250046|NCT01719770|shivering
250047|NCT01719770|serum drug levels
250048|NCT01719770|basal metabolism
250049|NCT01719757|Targin, Cancer Pain
250050|NCT01719744|ENMD-2076
250051|NCT01719744|advanced
250052|NCT01719744|metastatic
250053|NCT01719744|soft tissue sarcoma
250054|NCT01719731|BPD
250055|NCT01719718|ventral hernia
250056|NCT01719705|caesarean delivery
250057|NCT01719705|spinal anesthesia
250058|NCT01719705|pregabalin
250059|NCT01719705|postoperative pain
250060|NCT01719705|morphine
250061|NCT01719679|school located vaccine program
250062|NCT01719666|MPFL
250063|NCT01719666|patella
250064|NCT01719666|dislocation
250065|NCT01719666|release
250066|NCT01719653|Colonoscopy
250067|NCT01719653|Bowel Preparation
250068|NCT01719653|MiraLAX
250069|NCT01719653|Gatorade
250070|NCT01719653|PEG-3350
250071|NCT01719653|MoviPrep
250072|NCT01719653|SUPREP
250073|NCT01719653|Chicago Bowel Preparation Scale
250074|NCT01719653|Boston Bowel Preparation Scale
250075|NCT01719640|mesenchymal stem cell
250076|NCT01719640|central nervous system
250077|NCT01719627|HIV, Maraviroc, PrEP, Ex vivo infection, rectal mucosa.
250078|NCT01719614|Healthy participants
250079|NCT01719614|Rilpivirine
250080|NCT01719614|Metformin
250081|NCT01719614|Pharmacokinetics
250082|NCT01719601|Moderate to severe acute non-cancer pain
250083|NCT01719601|Immediate release tapentadol hydrochloride
250084|NCT01719601|Tapentadol IR
250085|NCT01719601|Nucynta IR
250086|NCT01719588|Moderate to severe chronic non-cancer pain
250087|NCT01719588|Prolonged release tapentadol hydrochloride
250088|NCT01719588|Tapentadol PR
250089|NCT01719588|Extended release tapentadol hydrochloride
250090|NCT01719588|Nucynta PR
250091|NCT01719549|Gastric Cancer
250092|NCT01719549|Dovitinib
250093|NCT01719523|Tourette syndrome
250094|NCT01719523|Tics
250095|NCT01719523|Tic Disorders
250096|NCT01719510|Group B Streptococcus,
250097|NCT01719510|Vaginal screening
250098|NCT01719510|Per partum antibiotic prophylaxis
250099|NCT01719510|Meningitis
250100|NCT01719510|Neonatal infection
250101|NCT01719510|PCR
250102|NCT01719510|Streptococcus agalactiae.
250103|NCT01719445|Energy Intake
250104|NCT01719432|Filgrastim
250105|NCT01719432|Obese
250106|NCT01719432|Non-obese
250107|NCT01719432|Pharmacokinetics
250108|NCT01719406|Gestational diabetes
250109|NCT01719406|Exercise
250110|NCT01719406|Diet
250111|NCT01719406|Fruits
250112|NCT01719406|Vegetables
250113|NCT01719406|Whole grains
250114|NCT01719406|pregnancy weight
250115|NCT01719393|Asthma
250116|NCT01719393|Pulse spectrum analysis
250117|NCT01719393|lung function
250118|NCT01719393|exhaled nitric oxide
250119|NCT01719393|metabolites
250120|NCT01719393|exhaled breath condensate
250121|NCT01719380|Open-label dose escalation; BRAF inhibitor; LGX818; PI3K inhibitor; BYL719; EGFR; cetuximab; metastatic colorectal cancer; KRAS; BRAF; V600
250122|NCT01719367|Baseline (pre-atenolol)
250123|NCT01719367|Post-atenolol
250124|NCT01719354|Community Mental Health Centers
250125|NCT01719354|Norway
250126|NCT01719354|Aftercare
250127|NCT01719328|yoga,
250128|NCT01719328|exercise
250129|NCT01719328|affect
250130|NCT01719328|mind/body therapies
250131|NCT01719328|stress, psychological
250132|NCT01719302|Soft tissue sarcoma
250133|NCT01719302|gemcitabine
250134|NCT01719302|docetaxel
250135|NCT01719302|pazopanib
250136|NCT01719289|depression
250137|NCT01719289|problem solving
250138|NCT01719263|emphysema
250139|NCT01719263|InterVapor
250140|NCT01719263|treatments
250141|NCT01719263|pulmonary rehabilitation
250142|NCT01719263|lung volume reduction
250143|NCT01719263|endoscopic lung volume reduction
250144|NCT01719237|Onset
250145|NCT01719237|Duration
250146|NCT01719237|Upper Limb Block
250147|NCT01719237|Ultrasound guided supraclavicular block
250148|NCT01719237|Ropivacaine
250149|NCT01719237|Chloroprocaine
250150|NCT01719211|MVP, mitral valve
250151|NCT01719198|adenoma
250152|NCT01719198|calprotectin
250153|NCT01719159|Progressive multiple sclerosis
250154|NCT01719159|Monoclonal antibodies
250155|NCT01719159|Mabthera
250156|NCT01719159|Intrathecal treatment
250157|NCT01719146|Anemia
250158|NCT01719146|Chronic Kidney Disease
250159|NCT01719146|Erythropoiesis Stimulating Agents
250160|NCT01719146|Erythropoietin
250161|NCT01719146|Iron
250162|NCT01719146|Iron Deficiency
250163|NCT01719133|allergy
250164|NCT01719133|birch
250165|NCT01719120|Insomnia
250166|NCT01719120|Cognitive-Behavioral Therapy
250167|NCT01719120|Internet-Based
250168|NCT01719120|Self-Help
250169|NCT01719120|Randomized Controlled Trial
250170|NCT01719107|Functional abdominal pain
250171|NCT01719107|Probiotics
250172|NCT01719107|Lactobacilus reuteri
250173|NCT01719081|Sacroiliac Joint
250174|NCT01719081|Ultrasound
250175|NCT01719081|Fluoroscopy
250176|NCT01719081|Chronic Pain
250177|NCT01719068|Mesothelioma
250178|NCT01719068|Lung Cancer
250179|NCT01719068|Early Detection
250180|NCT01719055|stimulation
250181|NCT01719055|implantable
250182|NCT01719055|pulse generator
250183|NCT01719055|back pain
250184|NCT01719055|chronic pain
250185|NCT01719055|leg pain
250186|NCT01719029|continuous glucose monitoring
250187|NCT01719029|gestational diabetes
250188|NCT01719029|diet therapy
250189|NCT01719016|Reversible ischemia
250190|NCT01719016|microvascular dysfunction
250191|NCT01718977|Intervention
250192|NCT01718977|Body Weight Supported Treadmill Training
250193|NCT01718977|Arm Cycle Ergometry Training
250194|NCT01718977|Aortic Pulse Wave Velocity
250195|NCT01718951|spondyloarthropathy
250196|NCT01718951|ankylosing spondylitis
250197|NCT01718938|Gastroparesis
250198|NCT01718938|Diabetic
250199|NCT01718938|Idiopathic
250200|NCT01718938|Delayed gastric emptying
250201|NCT01718912|periodontal disease
250202|NCT01718912|bleeding on probing
250203|NCT01718912|periodontal pockets
250204|NCT01718912|disabled
250205|NCT01718886|Obesity
250206|NCT01718886|Weight loss
250207|NCT01718886|Weight control
250208|NCT01718886|Intragastric balloon
250209|NCT01718886|gastric balloon
250210|NCT01718873|metastatic
250211|NCT01718873|stage IV
250212|NCT01718860|PORC
250213|NCT01718860|neostigmine
250214|NCT01718847|EGFR Tyrosine Kinase Inhibitor
250215|NCT01718847|Aquired resistance to EGFR TKI
250216|NCT01718847|Pan-Her inhibitor
250217|NCT01718834|prophylactic vaccine
250218|NCT01718834|chronic HCV patients
250219|NCT01718834|healthy risk volunteers
250220|NCT01718808|Metastatic Colorectal Cancer
250221|NCT01718808|KRAS
250222|NCT01718808|BRAF
250223|NCT01718808|Wild-type Metastatic
250224|NCT01718808|Cetuximab
250225|NCT01718808|Capecitabine
250226|NCT01718808|Phase II Trial
250227|NCT01718808|Elderly Patients
250228|NCT01718795|Airway
250229|NCT01718795|Cardiac Arrest
250230|NCT01718795|CPR
250231|NCT01718795|Ventilation
250232|NCT01718782|laryngeal mask, leakage pressure, ventilation
250233|NCT01718769|Nutritional assessment
250234|NCT01718769|children
250235|NCT01718769|malnutrition
250236|NCT01718756|Orthopaedic
250237|NCT01718756|General anaesthesia
250238|NCT01718756|lornoxicam
250239|NCT01718756|patient controlled analgesia
250240|NCT01718756|morphine consumption
250241|NCT01718743|Myeloma
250242|NCT01718743|Multiple Myeloma
250243|NCT01718743|MM
250244|NCT01718743|Post Autologous Stem Cell Transplant
250245|NCT01718743|Lenalidomide
250246|NCT01718743|CC-5013
250247|NCT01718743|Revlimid
250248|NCT01718743|MLN9708
250249|NCT01718743|Questionnaire
250250|NCT01718743|Survey
250251|NCT01718730|TMS
250252|NCT01718730|Adolescent
250253|NCT01718730|Child
250254|NCT01718730|MDD
250255|NCT01718730|Major depressive disorder
250256|NCT01718730|Mild MDD
250257|NCT01718730|Mild depression
250258|NCT01718730|SSRI
250259|NCT01718730|Motor cortex
250260|NCT01718730|Cortical excitability
250261|NCT01718730|Cortical inhibition
250262|NCT01718730|Cortical silent period
250263|NCT01718730|Motor threshold
250264|NCT01718730|Intracortical facilitation
250265|NCT01718730|Intracortical inhibition
250266|NCT01718730|gamma-aminobutyric acid (GABA)
250267|NCT01718730|Glutamate
250268|NCT01718730|N-methyl-D-aspartate (NMDA)
250269|NCT01718730|Magnetic resonance spectroscopy
250270|NCT01718730|MRS
250271|NCT01718717|Thoracotomy
250272|NCT01718717|Thoracic epidural analgesia
250273|NCT01718717|Arrythmiogenesis
250274|NCT01718717|Atrial fibrillation
250275|NCT01718717|Sympathetic outflow
250276|NCT01718704|rehabilitation
250277|NCT01718704|erectile dysfunction
250278|NCT01718704|incontinence
250279|NCT01718678|Multiple sclerosis
250280|NCT01718678|Melatonin
250281|NCT01718678|Fatigue
250282|NCT01718678|Quality of life
250283|NCT01718652|Healthy
250284|NCT01718652|Canagliflozin (JNJ-28431754)
250285|NCT01718652|Pharmacokinetics
250286|NCT01718652|Cyclosporine
250287|NCT01718600|carotid artery stenting
250288|NCT01718600|neuropsychological testing
250289|NCT01718600|microembolization
250290|NCT01718600|MRI
250291|NCT01718587|umbilical cord mesenchyma stem cell
250292|NCT01718587|liver cirrhosis
250293|NCT01718587|antiviral therapy
250294|NCT01718574|self-help book
250295|NCT01718574|support service
250296|NCT01718561|Airway assessment
250297|NCT01718561|Intubation
250298|NCT01718561|Mask ventilation
250299|NCT01718535|Cyp2C19
250300|NCT01718535|Genotyping
250301|NCT01718535|Spartan
250302|NCT01718535|Comparison
250303|NCT01718535|Sequencing
250304|NCT01718496|dyspnea
250305|NCT01718496|COPD
250306|NCT01718496|exercise tolerance
250307|NCT01718496|opioids
250308|NCT01718496|morphine
250309|NCT01718496|single dose oral Morphine
250310|NCT01718470|Systolic blood pressure
250311|NCT01718470|Heart rate
250312|NCT01718470|Laryngeal mask
250313|NCT01718470|Endotracheal tube
250314|NCT01718470|craniotomy
250315|NCT01718457|Endobarrier
250316|NCT01718457|Diabetes
250317|NCT01718457|Obesity
250318|NCT01718457|Weight
250319|NCT01718457|BMI
250320|NCT01718457|Lipid profile
250321|NCT01718457|fatty liver
250322|NCT01718457|gut peptides
250323|NCT01718457|HbA1c
250324|NCT01718444|PCOS
250325|NCT01718444|Polycystic ovary syndrome
250326|NCT01718444|Infertility
250327|NCT01718444|Anovulation
250328|NCT01718444|Clomiphene citrate
250329|NCT01718444|Clomid
250330|NCT01718444|Progestin
250331|NCT01718444|Provera
250332|NCT01718444|Progesterone
250333|NCT01718444|Endometrial shedding
250334|NCT01718392|combined training
250335|NCT01718392|insulin resistance
250336|NCT01718379|Myelodysplasia
250337|NCT01718340|PCOS
250338|NCT01718340|Hyper insulinaemia
250339|NCT01718340|metformin
250340|NCT01718340|recurrent abortion
250341|NCT01718327|Cholangiocarcinoma
250342|NCT01718314|Hysteroscopy
250343|NCT01718314|Misoprostol
250344|NCT01718314|Lidocaine
250345|NCT01718314|Visual analogue score
250346|NCT01718301|HCV
250347|NCT01718301|HIV
250348|NCT01718301|Coinfection
250349|NCT01718288|PAD; iloprost; walking distance; cardiovascular events
250350|NCT01718275|Appendicitis
250351|NCT01718275|Pediatrics
250352|NCT01718275|Children
250353|NCT01718275|Non-operative
250354|NCT01718262|Ropivacaine Level
250355|NCT01718262|continuous peripheral nerve blocks.
250356|NCT01718249|Deep Brain Stimulation (DBS)
250357|NCT01718249|Post-coma
250358|NCT01718249|Consciousness
250359|NCT01718249|Vegetative state
250360|NCT01718249|Minimally conscious state
250361|NCT01718236|caesarean section
250362|NCT01718236|rocuronium
250363|NCT01718236|sugammadex
250364|NCT01718210|GM-CSF
250365|NCT01718210|recurrent implantation failure
250366|NCT01718210|pregnancy rate
250367|NCT01718210|IVF
250368|NCT01718197|Severe Asthma
250369|NCT01718197|Bronchoscopy
250370|NCT01718184|sulcoflex
250371|NCT01718184|toric
250372|NCT01718184|corneal implantation
250373|NCT01718171|Appendicitis
250374|NCT01718171|SIRS
250375|NCT01718171|C-reactive protein
250376|NCT01718132|Quality of the anaesthetic care in a PACU
250377|NCT01718132|reduction of postoperative pain
250378|NCT01718132|reduction of postoperative nausea and vomiting
250379|NCT01718132|quality markers
250380|NCT01718106|coronary artery disease
250381|NCT01718106|drug eluting stent
250382|NCT01718106|bioabsorbable polymer
250383|NCT01718106|percutaneous coronary intervention
250384|NCT01718106|restenosis
250385|NCT01718106|late thrombosis
250386|NCT01718093|Adolescents
250387|NCT01718080|Obese, Lean, Pubertal, Prepubertal, Glucose Metabolism, Children, Adolescents, Type 2 Diabetes Prevention
250388|NCT01718067|Chest physiotherapy
250389|NCT01718067|Rehabilitation
250390|NCT01718067|Chronic respiratory diseases
250391|NCT01718054|Vascular function
250392|NCT01718054|Ready to use supplementary foods
250393|NCT01718054|Chloroquine
250394|NCT01718054|Children
250395|NCT01718054|Growth
250396|NCT01718054|Nitric Oxide
250397|NCT01718041|Growth hormone
250398|NCT01718041|Growth hormone deficiency
250399|NCT01718041|Growth
250400|NCT01718041|Pediatric growth hormone deficiency
250401|NCT01718041|Long acting growth hormone
250402|NCT01718041|GHD
250403|NCT01718041|PGHD
250404|NCT01718041|VRS 317
250405|NCT01718041|Exten
250406|NCT01718041|Versartis
250407|NCT01718028|Systane BALANCE
250408|NCT01718028|Dry eye
250409|NCT01718028|lipid deficiency
250410|NCT01718028|NITFBUT
250411|NCT01718015|Vascular Endothelial Growth Factor
250412|NCT01718015|Brain-Derived Neurothropic Factor
250413|NCT01718015|Diabetes Mellitus
250414|NCT01718015|CD-163
250415|NCT01718015|Cerebrospinal fluid
250416|NCT01718015|Peripheral Nervous System Diseases
250417|NCT01718015|Mass spectrometry
250418|NCT01718002|Nursing
250419|NCT01718002|Simulation
250420|NCT01718002|Education
250421|NCT01717989|Dialysis
250422|NCT01717989|Prospective Payment System
250423|NCT01717989|Center for Medicare and Medicaide Services
250424|NCT01717989|End Stage Renal Disease
250425|NCT01717989|Concomitant Medications Dosage /Treatment patterns
250426|NCT01717976|emergency department use
250427|NCT01717976|Veterans
250428|NCT01717950|Human Hookworm
250429|NCT01717950|Necator americanus
250430|NCT01717950|Hookworm
250431|NCT01717950|Hookworm Disease
250432|NCT01717950|Iron-deficiency anemia
250433|NCT01717950|Soil-transmitted helminth infection
250434|NCT01717950|Neglected Tropical Disease
250435|NCT01717950|Na-APR-1
250436|NCT01717937|retinovascular disease
250437|NCT01717937|imaging
250438|NCT01717937|fluorescein angiography
250439|NCT01717937|FA
250440|NCT01717937|angiography
250441|NCT01717937|optical coherence tomography
250442|NCT01717937|OCT
250443|NCT01717937|phase variance
250444|NCT01717937|comparison
250445|NCT01717937|age-related macular degeneration
250446|NCT01717937|diabetic retinopathy
250447|NCT01717937|hypertensive retinopathy
250448|NCT01717937|retinal vein occlusion
250449|NCT01717937|retinal artery occlusion
250450|NCT01717924|Signet ring cell
250451|NCT01717924|gastric adenocarcinoma
250452|NCT01717924|peri-operative chemotherapy
250453|NCT01717924|surgery
250454|NCT01717911|Newly diagnosed type 2 diabetes
250455|NCT01717911|Insulin, metformin, sitagliptin
250456|NCT01717911|beta-cell function, glycemic control
250457|NCT01717898|Castrate-resistant prostate cancer
250458|NCT01717885|Pharmacokinetics
250459|NCT01717885|Antimalarial
250460|NCT01717885|HIV
250461|NCT01717885|Antiretrovirals
250462|NCT01717885|Childhood development
250463|NCT01717885|Pregnancy
250464|NCT01717872|glottis, laryngoscopy, laryngoscope blade
250465|NCT01717859|Rheumatoid Arthritis
250466|NCT01717846|Apoptosos
250467|NCT01717846|Rheumatoid Arthritis
250468|NCT01717846|T cells, B cells
250469|NCT01717846|DAS28
250470|NCT01717846|Clinical Disease activity Index
250471|NCT01717846|CDAI
250472|NCT01717833|ICU acquired weakness
250473|NCT01717833|Critical illness polyneuromyopathy
250474|NCT01717833|post ICU rehabilitation
250475|NCT01717833|neuromuscular electrical rehabilitation
250476|NCT01717833|handgrip
250477|NCT01717820|Obesity
250478|NCT01717820|Postmenopausal women
250479|NCT01717820|Body composition
250480|NCT01717820|Resveratrol
250481|NCT01717820|Inflammatory biomarkers
250482|NCT01717820|Bone formation
250483|NCT01717820|Adipose metabolism
250484|NCT01717807|epithelial growth factor receptors
250485|NCT01717807|lung cancer
250486|NCT01717807|advanced tumor of pancrease
250487|NCT01717807|erlotinib
250488|NCT01717807|C11-Erlotinib PET/CT
250489|NCT01717794|operative time
250490|NCT01717794|laparoscopy
250491|NCT01717794|total hysterectomy
250492|NCT01717794|pelvic lymphadenectomy
250493|NCT01717794|endometrial cancer
250494|NCT01717794|Thunderbeat
250495|NCT01717781|operative time
250496|NCT01717781|laparoscopy
250497|NCT01717781|radical hysterectomy
250498|NCT01717781|pelvic lymphadenectomy
250499|NCT01717781|cervical cancer
250500|NCT01717781|thunderbeat
250501|NCT01717768|hypogonadism
250502|NCT01717768|Gonadal Disorders
250503|NCT01717768|Endocrine System Diseases
250504|NCT01717768|Testosterone
250505|NCT01717768|Testosterone enanthate
250506|NCT01717768|Testosterone undecanoate
250507|NCT01717768|Testosterone 17 beta-cypionate
250508|NCT01717768|Methyltestosterone
250509|NCT01717768|Androgens
250510|NCT01717768|Hormones
250511|NCT01717768|Hormones, Hormone Substitutes, and Hormone Antagonists
250512|NCT01717768|Physiological Effects of Drugs
250513|NCT01717768|Pharmacologic Actions
250514|NCT01717768|Therapeutic Uses
250515|NCT01717768|Anabolic Agents
250516|NCT01717755|basilar
250517|NCT01717755|stroke
250518|NCT01717755|mechanical
250519|NCT01717755|thrombolysis
250520|NCT01717755|intra-arterial
250521|NCT01717742|Randomized controlled trial
250522|NCT01717742|Pleural Empyema
250523|NCT01717742|tPA
250524|NCT01717742|DNase
250525|NCT01717729|HCC, RFA, Iodine-125, Recurrence
250526|NCT01717716|boys
250527|NCT01717716|obesity
250528|NCT01717716|glucose
250529|NCT01717716|sucrose
250530|NCT01717716|high-fructose corn syrup-55
250531|NCT01717703|prevention
250532|NCT01717690|MRSA
250533|NCT01717690|chlorhexidine
250534|NCT01717664|Relapsing Remitting Multiple Sclerosis
250535|NCT01717664|MAP
250536|NCT01717664|antibiotic
250537|NCT01717664|Interferon beta 1-a
250538|NCT01717664|MS
250539|NCT01717664|MRI
250540|NCT01717664|EDSS
250541|NCT01717664|relapse rate
250542|NCT01717651|Atrophy
250543|NCT01717651|Muscle wasting
250544|NCT01717651|Sepsis
250545|NCT01717638|Meningococcal disease, vaccines, children, persistence
250546|NCT01717625|montelukast
250547|NCT01717625|BPD
250548|NCT01717625|singulair
250549|NCT01717625|prematurity
250550|NCT01717612|gastric varices, thrombin, histoacryl
250551|NCT01717599|Post ERCP pancreatitis
250552|NCT01717599|Diclofenac
250553|NCT01717599|NSAID
250554|NCT01717586|preeclampsia
250555|NCT01717586|pravastatin
250556|NCT01717586|Pravachol®
250557|NCT01717586|statin
250558|NCT01717586|high-risk pregnancy
250559|NCT01717586|safety
250560|NCT01717586|fetal morbidity and mortality
250561|NCT01717586|maternal morbidity and mortality
250562|NCT01717586|neonatal mortality
250563|NCT01717586|premature delivery
250564|NCT01717586|preemie
250565|NCT01717573|STEMI
250566|NCT01717573|No-reflow
250567|NCT01717573|Primary percutaneous intervention
250568|NCT01717573|Deferred stenting
250569|NCT01717560|chronic hepatitis C
250570|NCT01717560|illicit drug use
250571|NCT01717560|Substance-Related Disorders
250572|NCT01717560|multidisciplinary care
250573|NCT01717560|integrated care
250574|NCT01717560|mental health care
250575|NCT01717560|intensive case management
250576|NCT01717547|Veterans
250577|NCT01717547|Yoga
250578|NCT01717547|Stress
250579|NCT01717534|Diarrhea
250580|NCT01717534|Children
250581|NCT01717534|Heat-treated lactobacilli
250582|NCT01717521|hysterectomy
250583|NCT01717521|gynecological abdominal surgery
250584|NCT01717508|MDD
250585|NCT01717508|depression
250586|NCT01717508|major depressive disorder
250587|NCT01717508|adolescent
250588|NCT01717495|Pacemaker
250589|NCT01717495|Implantable-cardioverter defibrillator
250590|NCT01717495|Cardiac Pacing, Artificial/adverse effects
250591|NCT01717495|Venous thrombosis
250592|NCT01717495|Pulmonary embolism
250593|NCT01717495|Phlebography
250594|NCT01717495|Biological markers
250595|NCT01717495|Computed tomography angiography
250596|NCT01717482|Bronchoscopy
250597|NCT01717482|Metformin
250598|NCT01717469|Pacemaker
250599|NCT01717469|Pacemaker implantation
250600|NCT01717469|Coronary sinus
250601|NCT01717469|Ventricular dysfunction
250602|NCT01717469|Right ventricular pacing
250603|NCT01717469|Left ventricular pacing
250604|NCT01717456|Fecal incontinence
250605|NCT01717456|Frail elders
250606|NCT01717456|Home health care
250607|NCT01717456|Nurse
250608|NCT01717456|Patient education
250609|NCT01717443|Human Papillomavirus
250610|NCT01717443|Renal transplantation
250611|NCT01717430|Injections, epidural
250612|NCT01717430|Injections, intra-articular
250613|NCT01717430|Chronic pain
250614|NCT01717430|Neck pain
250615|NCT01717430|Back pain
250616|NCT01717430|Low back pain
250617|NCT01717430|Sciatica
250618|NCT01717430|Sacroiliac joint
250619|NCT01717430|Corticosteroids
250620|NCT01717430|Dexamethasone
250621|NCT01717430|Adrenocorticotropic hormone
250622|NCT01717430|Adrenal insufficiency
250623|NCT01717430|Hemoglobin A, glycosylated
250624|NCT01717417|impacted canine
250625|NCT01717417|miniscrew
250626|NCT01717417|cone beam
250627|NCT01717404|IBS
250628|NCT01717391|radiotherapy
250629|NCT01717391|Positron-Emission Tomography and Computed Tomography
250630|NCT01717391|chemotherapy
250631|NCT01717391|bone marrow
250632|NCT01717378|Patient Recruitment
250633|NCT01717378|Research Subject Recruitment
250634|NCT01717378|Research Subject Selection
250635|NCT01717378|Selection of Subjects
250636|NCT01717378|Health Surveys
250637|NCT01717378|Health Questionnaires
250638|NCT01717378|Health Interviews
250639|NCT01717365|SCOPE
250640|NCT01717352|Weight loss
250641|NCT01717274|Functional Endoscopic Sinus Surgery
250642|NCT01717274|Hot water irrigation
250643|NCT01717261|breast cancer
250644|NCT01717261|early breast cancer
250645|NCT01717261|partial breast irradiation
250646|NCT01717261|preoperative radiation
250647|NCT01717222|Lignocaine
250648|NCT01717222|Laparoscopic cholecystectomy
250649|NCT01717222|Pain relief
250650|NCT01717209|heart failure
250651|NCT01717209|hypertension, pulmonary
250652|NCT01717209|heart failure, right-sided
250653|NCT01717209|heart-assist devices
250654|NCT01717209|Heart Transplantation
250655|NCT01717196|sample adequacy
250656|NCT01717196|diagnostic accuracy
250657|NCT01717196|complications
250658|NCT01717183|Patient
250659|NCT01717170|Non-infectious Uveitis, Tocilizumab
250660|NCT01717157|Healthy
250661|NCT01717157|Fentanyl
250662|NCT01717157|Transdermal patch
250663|NCT01717157|DUROGESIC
250664|NCT01717144|therapeutic education
250665|NCT01717144|Parkinson's disease
250666|NCT01717144|quality of life
250667|NCT01717131|Invasive breast cancer
250668|NCT01717118|Evaluation
250669|NCT01717118|Immunogenicity
250670|NCT01717118|Levels
250671|NCT01717118|Women
250672|NCT01717118|HPV
250673|NCT01717118|Vaccine
250674|NCT01717118|Mexico
250675|NCT01717105|Non-small cell lung cancer (NSCLC)
250676|NCT01717105|Epidermal growth factor receptor (EGFR) positive mutation
250677|NCT01717066|Hepatocellular Carcinoma
250678|NCT01717066|ginsenoside Rg3
250679|NCT01717040|Bipolar Disorder
250680|NCT01717040|Insulin Resistance
250681|NCT01717027|pharmacokinetics
250682|NCT01717027|bioavailability
250683|NCT01717027|oxycodone
250684|NCT01717027|management of moderate to severe pain
250685|NCT01717014|rectal cancer
250686|NCT01717014|stapler
250687|NCT01717001|kinematics
250688|NCT01717001|knee joint
250689|NCT01716988|Micafungin
250690|NCT01716988|pharmacokinetics
250691|NCT01716988|invasive candidiasis
250692|NCT01716988|intensive care
250693|NCT01716975|Schizophrenia
250694|NCT01716975|Cognition
250695|NCT01716975|Cognition Impairment
250696|NCT01716975|Alpha-7 nAChR
250697|NCT01716962|Acute respiratory distress syndrome, Fluid responsiveness, Pulse pressure variation
250698|NCT01716962|Pleth variability index, Passive leg raising test
250699|NCT01716949|rectal cancer
250700|NCT01716949|recurrent rectal cancer
250701|NCT01716949|hyperthermia
250702|NCT01716949|radiation
250703|NCT01716949|chemoradiation
250704|NCT01716949|5-FU
250705|NCT01716949|capecitabine
250706|NCT01716949|oxaliplatin
250707|NCT01716936|Thoracic Insufficiency Syndrome
250708|NCT01716936|Early Onset Spinal Deformity
250709|NCT01716884|STEMI
250710|NCT01716884|reperfution
250711|NCT01716884|primary PCI
250712|NCT01716858|Schizophrenia
250713|NCT01716858|Sulforaphane
250714|NCT01716858|Psychosis
250715|NCT01716858|Cognition
250716|NCT01716858|Oxidative stress
250717|NCT01716858|Antioxidant
250718|NCT01716858|Anti-inflammatory
250719|NCT01716845|autism
250720|NCT01716845|autism spectrum disorders
250721|NCT01716845|RNA
250722|NCT01716845|gene expression
250723|NCT01716845|developmental delay
250724|NCT01716819|Heart failure, abdominal obesity, RAAS
250725|NCT01716806|Antibody-Drug Conjugate
250726|NCT01716806|Antibodies, Monoclonal
250727|NCT01716806|Hematologic Diseases
250728|NCT01716806|Hodgkin Disease
250729|NCT01716806|Antigens, CD30
250730|NCT01716806|Lymphoma
250731|NCT01716806|monomethylauristatin E
250732|NCT01716806|Drug Therapy
250733|NCT01716793|Primary AML
250734|NCT01716793|Risk-adapted treatment
250735|NCT01716793|Hematopoietic transplantation
250736|NCT01716793|CD34+ cell selection
250737|NCT01716767|Carpal tunnel syndrome
250738|NCT01716767|hand pain
250739|NCT01716767|wrist pain
250740|NCT01716767|arm pain
250741|NCT01716767|topical menthol
250742|NCT01716754|asthma
250743|NCT01716754|asthma control
250744|NCT01716754|allergy
250745|NCT01716754|atopic
250746|NCT01716754|IgE
250747|NCT01716754|double-blind
250748|NCT01716754|placebo
250749|NCT01716754|omalizumab
250750|NCT01716741|Gaucher disease
250751|NCT01716741|lysosomal storage disorder
250752|NCT01716741|metabolic disease
250753|NCT01716741|medical records review
250754|NCT01716728|Lysosomal Acid Lipase Deficiency
250755|NCT01716728|Cholesterol Ester Storage Disease
250756|NCT01716728|Wolman Disease
250757|NCT01716728|Lysosomal Storage Disorder
250758|NCT01716728|Metabolic Disease
250759|NCT01716728|Recessive Inheritance
250760|NCT01716702|Prostate Cancer
250761|NCT01716702|Psychosocial Intervention
250762|NCT01716702|Sexual Rehabilitation
250763|NCT01716702|Online Intervention
250764|NCT01716663|Symptomatic paroxysmal
250765|NCT01716663|Atrial fibrillation
250766|NCT01716663|Observational
250767|NCT01716663|Acute procedural outcomes
250768|NCT01716663|Ablation
250769|NCT01716650|ankle
250770|NCT01716650|saphenous nerve block
250771|NCT01716637|Alzheimer's Disease
250772|NCT01716637|Dementia
250773|NCT01716637|Cognitive decline
250774|NCT01716637|Cognitive disorder
250775|NCT01716637|Degenerative brain disease
250776|NCT01716637|Cognitive impairment
250777|NCT01716637|Memory loss
250778|NCT01716637|TNF-alpha
250779|NCT01716624|Pediatric
250780|NCT01716611|liver cirrhosis
250781|NCT01716611|hyponatemia
250782|NCT01716611|ascites
250783|NCT01716611|vaptans
250784|NCT01716611|antidiuretic hormon
250785|NCT01716611|arginine vasopressin
250786|NCT01716598|COPD
250787|NCT01716598|TLD Therapy
250788|NCT01716598|Targeted Lung Denervation Therapy
250789|NCT01716598|IPS
250790|NCT01716598|Innovative Pulmonary Solutions, Inc.
250791|NCT01716598|Holaira, Inc.
250792|NCT01716585|Hepatitis C Virus
250793|NCT01716585|Hepatitis C Genotype 1
250794|NCT01716585|Hepatitis C
250795|NCT01716585|Treatment-Naïve
250796|NCT01716585|Interferon-Free
250797|NCT01716585|Chronic Hepatitis C
250798|NCT01716585|Viekira Pak
250799|NCT01716585|ombitasvir
250800|NCT01716585|paritaprevir
250801|NCT01716585|dasabuvir
250802|NCT01716572|Upper gastrointestinal bleeding
250803|NCT01716572|Endoscopy
250804|NCT01716572|Erythromycin
250805|NCT01716572|Gastric lavage
250806|NCT01716546|Advanced cancer of the stomach
250807|NCT01716546|Chemotherapy - naive patients
250808|NCT01716546|DCF
250809|NCT01716533|Serological
250810|NCT01716533|Adults
250811|NCT01716533|Clostridium difficile
250812|NCT01716533|Adult CDI patients
250813|NCT01716520|long-acting muscarinic antagonist
250814|NCT01716520|long-acting beta-agonist
250815|NCT01716520|Chronic Obstructive Pulmonary Disease
250816|NCT01716520|vilanterol
250817|NCT01716520|umeclidinium
250818|NCT01716507|RRD
250819|NCT01716507|Rhegmatogenous
250820|NCT01716507|Retinal
250821|NCT01716507|Detachment
250822|NCT01716507|PPV
250823|NCT01716507|Pars Plana Vitrectomy
250824|NCT01716507|Gauge
250825|NCT01716494|asthma
250826|NCT01716481|Stroke
250827|NCT01716481|Mesenchymal stem cells
250828|NCT01716481|Stem cells
250829|NCT01716481|Neurogenesis
250830|NCT01716468|Ketogenic Diet, Advanced Cancer, Neoplasm
250831|NCT01716468|Low carbohydrate
250832|NCT01716442|rituximab
250833|NCT01716442|nephrotic
250834|NCT01716442|refractory
250835|NCT01716429|vegetarian
250836|NCT01716429|vegan
250837|NCT01716429|low calorie
250838|NCT01716429|weight Loss
250839|NCT01716429|infertility
250840|NCT01716429|PCOS
250841|NCT01716403|C hepatitis, telaprevir concentration, ribavirin oncentration, anemia
250842|NCT01716377|Neck Pain
250843|NCT01716377|Musculoskeletal pain
250844|NCT01716377|Venlafaxine
250845|NCT01716351|Randomized Clinical Control Trial
250846|NCT01716351|Complementary and Alternative Medicine
250847|NCT01716351|Yoga
250848|NCT01716351|Electrophysiology
250849|NCT01716351|Implantable Cardioverter Defibrillator
250850|NCT01716351|Psychosocial
250851|NCT01716351|Anxiety
250852|NCT01716351|Self-Compassion
250853|NCT01716351|Anti-Tachycardia Pacing Events
250854|NCT01716338|glyburide
250855|NCT01716338|glybenclamide
250856|NCT01716338|hypoglycemia
250857|NCT01716312|Safety Of Omalizumab In Patients With SLE
250858|NCT01716312|Systemic Lupus Erythematosus
250859|NCT01716299|HIV
250860|NCT01716299|Diagnostics
250861|NCT01716247|Mammography (CESM)
250862|NCT01716247|MRI
250863|NCT01716247|Breast screening
250864|NCT01716247|12-214
250865|NCT01716208|Fresh Frozen Plasma
250866|NCT01716208|Complement
250867|NCT01716208|Monoclonal Antibody
250868|NCT01716195|Human Papillomavirus
250869|NCT01716195|HPV
250870|NCT01716143|atrial fibrillation
250871|NCT01716143|catheter ablation
250872|NCT01716143|Mapping
250873|NCT01716130|Fluzone Intradermal vaccine
250874|NCT01716117|Large aneurysm
250875|NCT01716117|Giant aneurysm
250876|NCT01716117|Wide neck aneurysm
250877|NCT01716091|focus of study is postoperative enfectious morbidity and postoperative GİS functionally recovery
250878|NCT01716078|Brachial Plexus
250879|NCT01716078|Nerve Block
250880|NCT01716078|Nerve Conduction
250881|NCT01716065|Anesthesia, Circulating tumor cells
250882|NCT01716052|Mammogram
250883|NCT01716052|Ibuprofen
250884|NCT01716052|Pain management
250885|NCT01716039|Moderately to severely active Ulcerative Colitis
250886|NCT01716026|high myopia
250887|NCT01716026|choroidal neovascularization
250888|NCT01716000|vaginal gel
250889|NCT01716000|vaginal coating
250890|NCT01716000|sensory perceptions
250891|NCT01715987|Hepatitis B
250892|NCT01715987|Antiviral
250893|NCT01715987|Tubular dysfunction
250894|NCT01715987|Entecavir
250895|NCT01715987|Tenofovir
250896|NCT01715974|G-CSF, IVF failure,pregnancy
250897|NCT01715961|70 years old
250898|NCT01715961|DLBCL
250899|NCT01715961|Rituximab-CHOP
250900|NCT01715961|Sarcopenia
250901|NCT01715948|CROS hearing aid
250902|NCT01715948|Bone-anchored hearing device
250903|NCT01715935|Clear cells renal carcinoma
250904|NCT01715935|everolimus
250905|NCT01715935|neo-adjuvant treatment
250906|NCT01715922|Cryptococcal meningitis
250907|NCT01715922|HIV Infections
250908|NCT01715922|Oral treatment
250909|NCT01715922|High dose of fluconazole
250910|NCT01715922|Flucytosine
250911|NCT01715922|Burundi
250912|NCT01715922|Ivory Coast
250913|NCT01715896|Rheumatoid Arthritis
250914|NCT01715896|Golimumab
250915|NCT01715896|Mavrilimumab
250916|NCT01715883|Lung transplant
250917|NCT01715883|Pulmonary Graft Dysfunction
250918|NCT01715883|Sodium Nitrite
250919|NCT01715870|Age related macular degeneration
250920|NCT01715870|Food habits
250921|NCT01715870|Life style
250922|NCT01715870|Risk factors
250923|NCT01715870|questionnaire
250924|NCT01715857|Economics, Pharmaceutical
250925|NCT01715857|Physician's Practice Patterns
250926|NCT01715857|Chinese
250927|NCT01715857|Sevoflurane
250928|NCT01715844|L-citrulline
250929|NCT01715844|ADMA
250930|NCT01715844|Asthma
250931|NCT01715844|Obesity
250932|NCT01715805|MDD
250933|NCT01715805|Major Depressive Disorder
250934|NCT01715792|Solid organ transplant rejection
250935|NCT01715792|United Kingdom
250936|NCT01715792|Influenza
250937|NCT01715792|H1N1
250938|NCT01715792|Pandemrix™
250939|NCT01715779|Liver transplantation
250940|NCT01715779|ENABLE
250941|NCT01715779|observational
250942|NCT01715779|mortality
250943|NCT01715779|Thromboembolic Events
250944|NCT01715779|Hepatic decompensation
250945|NCT01715779|Long-Term follow-up
250946|NCT01715779|TEE
250947|NCT01715766|Proteomics study
250948|NCT01715766|biomarker study of pain
250949|NCT01715753|Function
250950|NCT01715753|Muscle mass
250951|NCT01715740|Chinese herbal medicine
250952|NCT01715740|Urticaria
250953|NCT01715740|Antipruritics
250954|NCT01715740|Phase III clinical trial
250955|NCT01715727|diffusion kurtosis imaging
250956|NCT01715727|parkinson disease
250957|NCT01715727|parkinsonism
250958|NCT01715727|diagnosis
250959|NCT01715727|differential diagnosis
250960|NCT01715714|Coronary Artery Disease
250961|NCT01715714|Statins
250962|NCT01715714|Coronary Artery Bypass Grafting
250963|NCT01715714|Cardiac Surgery
250964|NCT01715675|asthma
250965|NCT01715675|allergy
250966|NCT01715675|sitostanol
250967|NCT01715675|cytokines
250968|NCT01715675|Th1
250969|NCT01715675|Treg
250970|NCT01715675|antibodies
250971|NCT01715675|IgE
250972|NCT01715675|vaccination
250973|NCT01715662|rehabilitation
250974|NCT01715662|lower limb amputation
250975|NCT01715662|unilateral transtibial amputation
250976|NCT01715662|unilateral transfemoral amputation
250977|NCT01715662|older adults
250978|NCT01715662|cognitive computer games
250979|NCT01715662|home-based training
250980|NCT01715662|Nintendo Wii
250981|NCT01715662|virtual reality
250982|NCT01715649|Type 2 diabetes
250983|NCT01715649|self-management
250984|NCT01715649|remote patient monitoring
250985|NCT01715623|polymorphism
250986|NCT01715623|serum Ig
250987|NCT01715597|uterine leiomyoma
250988|NCT01715597|laparoscopic myomectomy
250989|NCT01715597|intraoperative blood loss
250990|NCT01715597|ascorbic acid
250991|NCT01715584|Hypertension
250992|NCT01715584|Sevoflurane
250993|NCT01715584|Inhaled Anesthetic
250994|NCT01715584|Angiotensin Converting Enzyme Inhibitor
250995|NCT01715584|Angiotensin II Receptor Blocking Agent
250996|NCT01715571|erectile dysfunction
250997|NCT01715571|vibratory stimulation
250998|NCT01715571|viberect
250999|NCT01715545|day-3 poor quality embryo
251000|NCT01715545|vitrification
251001|NCT01715545|clinical outcome
251002|NCT01715532|Huachansu
251003|NCT01715532|Na+/K+-ATPase α3
251004|NCT01715532|transcatheter arterial chemoembolization
251005|NCT01715532|randomized controlled trial
251006|NCT01715519|Vilazodone
251007|NCT01715519|PTSD
251008|NCT01715519|Depression
251009|NCT01715506|Dementia
251010|NCT01715506|Resident
251011|NCT01715506|Nursinghome
251012|NCT01715506|Use of restraint
251013|NCT01715506|Agitation
251014|NCT01715493|COPD
251015|NCT01715493|Asthma
251016|NCT01715493|Lysozyme Hydrochloride
251017|NCT01715480|broccoli sprout
251018|NCT01715480|sickle cell
251019|NCT01715480|NRF2
251020|NCT01715467|Dupuytren
251021|NCT01715467|Contracture
251022|NCT01715467|Auxilium
251023|NCT01715467|XIAFLEX
251024|NCT01715441|Metastatic colorectal cancer patients
251025|NCT01715441|KRAS mutation
251026|NCT01715441|Sorafenib
251027|NCT01715428|diabetes, cardiovascular risk
251028|NCT01715415|Hepatitis C
251029|NCT01715415|Treatment-Experienced
251030|NCT01715415|Null responder
251031|NCT01715415|Partial Responder
251032|NCT01715415|Chronic Hepatitis
251033|NCT01715415|Hepatitis C Genotype 1
251034|NCT01715415|Interferon-Free
251035|NCT01715415|Hepatitis C Virus
251036|NCT01715415|Relapser
251037|NCT01715415|Non responder
251038|NCT01715415|Viekira Pak
251039|NCT01715415|ombitasvir
251040|NCT01715415|ribavirin
251041|NCT01715415|ritonavir
251042|NCT01715415|paritaprevir
251043|NCT01715415|dasabuvir
251044|NCT01715402|liver tumor
251045|NCT01715402|carcinoma
251046|NCT01715402|cholangiocarcinoma
251047|NCT01715402|metastasis
251048|NCT01715389|Asthma
251049|NCT01715389|Goals
251050|NCT01715389|Shared Decision Making
251051|NCT01715389|Patient Portal
251052|NCT01715389|Electronic Medical Record
251053|NCT01715376|traditional chinese medicine
251054|NCT01715376|complementary therapies
251055|NCT01715376|traditional chinese medicine syndrome scale
251056|NCT01715350|Alzheimer's Disease
251057|NCT01715337|muscle fibre
251058|NCT01715337|capillary
251059|NCT01715337|rehabilitation
251060|NCT01715337|exercise training
251061|NCT01715324|In vitro fertilization
251062|NCT01715324|Antagonist protocol
251063|NCT01715324|Growth Hormone
251064|NCT01715311|COPD
251065|NCT01715311|Chronic obstructive pulmonary disease
251066|NCT01715311|indacaterol
251067|NCT01715311|tiotropium
251068|NCT01715298|Anticholinergic
251069|NCT01715298|Antimuscarinic
251070|NCT01715298|Chronic Obstructive Airway Disease
251071|NCT01715298|Chronic Obstructive Lung Disease
251072|NCT01715298|Chronic Obstructive Pulmonary Disease
251073|NCT01715298|COPD
251074|NCT01715298|LAMA
251075|NCT01715298|Lung Disease
251076|NCT01715298|Lung Diseases, Obstructive
251077|NCT01715298|Lung Function
251078|NCT01715298|Muscarinic receptor antagonist
251079|NCT01715298|Pulmonary Disease, Chronic Obstructive
251080|NCT01715298|Respiratory Tract Diseases
251081|NCT01715285|Prostate neoplasms
251082|NCT01715285|Prostate cancer
251083|NCT01715285|Metastatic prostate cancer
251084|NCT01715285|Abiraterone acetate
251085|NCT01715285|ZYTIGA
251086|NCT01715285|Prednisone
251087|NCT01715285|Androgen deprivation therapy
251088|NCT01715259|Renal insufficiency
251089|NCT01715259|Renal impairment
251090|NCT01715259|End-stage renal disease
251091|NCT01715259|Abiraterone acetate
251092|NCT01715259|Pharmacokinetics
251093|NCT01715246|healthy babbies
251094|NCT01715246|infant formula
251095|NCT01715246|growth
251096|NCT01715246|HMO
251097|NCT01715220|Nitroglycerin
251098|NCT01715220|Biliary Colic
251099|NCT01715220|Cholelithiasis
251100|NCT01715220|Abdominal Pain.
251101|NCT01715194|OSAS
251102|NCT01715194|CPAP
251103|NCT01715194|Adherence
251104|NCT01715194|Telemedicine
251105|NCT01715168|Doxil generic
251106|NCT01715168|Caelyx generic
251107|NCT01715168|generic treatment
251108|NCT01715168|ovarian cancer
251109|NCT01715168|ovary
251110|NCT01715168|progressed
251111|NCT01715168|recurred cancer
251112|NCT01715168|platinum based therapy
251113|NCT01715155|Metastatic Breast Cancer,
251114|NCT01715155|retrospective study,
251115|NCT01715155|disease progression,
251116|NCT01715155|clinical management
251117|NCT01715142|Pancreatic cancer
251118|NCT01715142|Nab-paclitaxel
251119|NCT01715142|Gemcitabine
251120|NCT01715142|Neoadjuvant chemotherapy
251121|NCT01715116|Cardiac arrhythmias
251122|NCT01715116|Implantable Cardioverter-Defibrillator
251123|NCT01715116|Patient Safety
251124|NCT01715116|Quality of life
251125|NCT01715103|HIV infection
251126|NCT01715103|mucosa
251127|NCT01715103|immunological parameters
251128|NCT01715103|genital sampling
251129|NCT01715103|healthy women volunteers
251130|NCT01715077|melanoma
251131|NCT01715077|stage IV
251132|NCT01715077|stage III
251133|NCT01715077|unresectable
251134|NCT01715064|Prostate Cancer
251135|NCT01715064|Exercise
251136|NCT01715064|Cortical Inhibition
251137|NCT01715064|Cortical Silent Period
251138|NCT01715064|Transcranial Magnetic Stimulation
251139|NCT01715051|cocaine
251140|NCT01715051|D-serine
251141|NCT01715051|Drug dependence
251142|NCT01715038|malnutrition
251143|NCT01715038|stunting
251144|NCT01715038|LNS
251145|NCT01715038|micronutrient powder
251146|NCT01715038|hemoglobin
251147|NCT01715025|measured
251148|NCT01715025|heavy menstrual bleeding
251149|NCT01715025|combined oral contraceptive
251150|NCT01715025|alkaline haematin method
251151|NCT01715012|Burn
251152|NCT01715012|Diabetes
251153|NCT01715012|Skin graft
251154|NCT01715012|Donor site
251155|NCT01714999|olecranon
251156|NCT01714999|prepatellar
251157|NCT01714999|bursa
251158|NCT01714999|trauma
251159|NCT01714999|laceration
251160|NCT01714999|bursectomy
251161|NCT01714999|bursa reconstruction
251162|NCT01714986|Diabetes mellitus
251163|NCT01714986|Depression
251164|NCT01714986|Anxiety
251165|NCT01714986|Alexithymia
251166|NCT01714986|Self Image
251167|NCT01714986|HbA1c
251168|NCT01714986|Psychoeducation
251169|NCT01714934|IDIOPATHIC PULMONARY FIBROSIS
251170|NCT01714934|MICROASPIRATION
251171|NCT01714908|NSCLC
251172|NCT01714908|EGFR mutation
251173|NCT01714908|unresectable
251174|NCT01714908|erlotinib
251175|NCT01714908|concurrent radiotherapy
251176|NCT01714895|Interstitial glucose dynamics
251177|NCT01714895|Accuracy of continuous glucose monitoring under hypoglycemia
251178|NCT01714895|Glucose clamp
251179|NCT01714882|Infertility
251180|NCT01714882|In Vitro Fertilization (IVF)
251181|NCT01714882|Stress Management
251182|NCT01714882|Stress Reduction
251183|NCT01714869|Swedish massage
251184|NCT01714869|massage
251185|NCT01714869|osteoarthritis
251186|NCT01714869|knee
251187|NCT01714843|ASP0456
251188|NCT01714843|constipation
251189|NCT01714843|irritable bowel syndrome (IBS)
251190|NCT01714843|linaclotide
251191|NCT01714791|Coronary Artery Bypass Graft
251192|NCT01714791|Osteopathic Medicine
251193|NCT01714791|Vital Capacity
251194|NCT01714791|Quality of Life
251195|NCT01714791|Cardiac rehabilitation
251196|NCT01714765|Metastatic Clear Cell Renal Cancer Dovitinib Everolimus Cohort Maximum administered dose maximum tolerated dose
251197|NCT01714752|Diagnosis
251198|NCT01714752|Left ventricular end diastolic pressure (LVEDP)
251199|NCT01714752|Exercise echocardiography
251200|NCT01714752|Left atrial remodeling
251201|NCT01714726|MEDI2070
251202|NCT01714726|inflammatory bowel disease
251203|NCT01714726|moderate to severe Crohn's disease
251204|NCT01714713|Schizophrenia
251205|NCT01714713|Cognition
251206|NCT01714713|Cognition Impairment
251207|NCT01714713|Alpha-7 nAChR
251208|NCT01714700|protein
251209|NCT01714700|resistance exercise ghrelin
251210|NCT01714700|overweight
251211|NCT01714674|cardiac troponin T
251212|NCT01714674|cTnT
251213|NCT01714674|exercise
251214|NCT01714674|dietary nitrate
251215|NCT01714661|Schizophrenia
251216|NCT01714661|Cognition
251217|NCT01714661|Cognition Impairment
251218|NCT01714661|Alpha-7 nAChR
251219|NCT01714648|OVULATION INDUCTION
251220|NCT01714635|cataract
251221|NCT01714635|IOL
251222|NCT01714635|intraocular lens
251223|NCT01714622|metabolic syndrome
251224|NCT01714622|insulin resistance
251225|NCT01714622|gastric cancer
251226|NCT01714609|portal hypertension
251227|NCT01714609|sorafenib
251228|NCT01714596|Oral Antibiotic
251229|NCT01714596|Intravenous Antibiotic
251230|NCT01714596|Wound infection
251231|NCT01714596|Randomized Controlled Trial
251232|NCT01714583|Mechanical ventilation
251233|NCT01714583|ARDS
251234|NCT01714583|acute lung injury
251235|NCT01714583|cardiac function
251236|NCT01714583|cardiac index
251237|NCT01714583|heart-lung interaction
251238|NCT01714531|Mild TBI
251239|NCT01714518|Interstitial Lung Disease
251240|NCT01714518|Diagnosis
251241|NCT01714518|Cryobiopsy
251242|NCT01714518|Video-assisted thoracic surgery
251243|NCT01714518|Lung biopsy
251244|NCT01714505|Diabetes Mellitus, Type 1
251245|NCT01714505|Continuous Glucose Monitor
251246|NCT01714505|Artificial Pancreas
251247|NCT01714505|Insulin Pump
251248|NCT01714505|Closed Loop control
251249|NCT01714505|Open Loop treatment
251250|NCT01714492|Total Knee Arthroplasty (TKA)
251251|NCT01714492|in vivo mechanics
251252|NCT01714492|kinematics
251253|NCT01714492|fluoroscopy
251254|NCT01714440|genomics of kidney transplantation
251255|NCT01714440|genetic variation
251256|NCT01714440|recipient genotypes
251257|NCT01714440|donor genotypes
251258|NCT01714414|HIV
251259|NCT01714414|Fozivudine
251260|NCT01714414|Zidovudine
251261|NCT01714414|FATI
251262|NCT01714388|remifentanil
251263|NCT01714388|heart rate
251264|NCT01714388|autonomic nervous system
251265|NCT01714388|heart rate variability
251266|NCT01714388|autonomic nervous activity
251267|NCT01714388|vagotonic effect
251268|NCT01714388|single dose
251269|NCT01714362|oculocardiac effect
251270|NCT01714362|bradycardia
251271|NCT01714362|HRV
251272|NCT01714349|Spinal cord injury
251273|NCT01714349|nerve transfer
251274|NCT01714349|tetraplegia
251275|NCT01714349|quadriplegia
251402|NCT01713881|Polyp
251276|NCT01714336|Arbeitsgemeinschaft für Osteosynthesefragen (AO) fracture
251277|NCT01714336|Orthopaedic Trauma Association (OTA) fracture
251278|NCT01714323|Cigarette smoking
251279|NCT01714323|Tobacco smoking
251280|NCT01714323|Tobacco use disorder
251281|NCT01714310|severe mood dysregulation
251282|NCT01714310|irritability
251283|NCT01714310|lisdexamfetamine
251284|NCT01714310|fluoxetine
251285|NCT01714310|newly recognized syndrome
251286|NCT01714297|cemented total hip arthroplasty
251287|NCT01714297|blood loss
251288|NCT01714297|wound discharge
251289|NCT01714297|thromboprophylaxis
251290|NCT01714297|biomarkers
251291|NCT01714284|psoriasis
251292|NCT01714258|cardiac output
251293|NCT01714258|fick method
251294|NCT01714258|thermodilution
251295|NCT01714245|Eczema
251296|NCT01714245|Atopic Dermatitis
251297|NCT01714245|Compromised Skin
251298|NCT01714245|Inflamed Skin
251299|NCT01714219|prostatic neoplasms
251300|NCT01714219|prostatectomy
251301|NCT01714219|robotics
251302|NCT01714219|urinary incontinence
251303|NCT01714206|Healthy
251304|NCT01714206|Canagliflozin (JNJ-28431754)
251305|NCT01714206|Pharmacokinetics
251306|NCT01714206|Digoxin (LANOXIN)
251307|NCT01714193|Healthy
251308|NCT01714193|Canagliflozin (JNJ-28431754)
251309|NCT01714193|Pharmacokinetics
251310|NCT01714193|Contraceptives, Oral
251311|NCT01714193|Ethinyl Estradiol
251312|NCT01714193|Levonorgestrel
251313|NCT01714193|LEVORA
251314|NCT01714180|Acyclovir
251315|NCT01714180|Pharmacokinetics
251316|NCT01714180|Obese
251317|NCT01714180|Non-obese
251318|NCT01714180|Weight
251319|NCT01714180|Distribution
251320|NCT01714180|Clearance
251321|NCT01714167|Chronic
251322|NCT01714167|Ischemic Stroke
251323|NCT01714167|Intracerebral Hemorrhage
251324|NCT01714167|Bone Marrow Mesenchymal Stem Cell
251325|NCT01714141|Technology based intervention
251326|NCT01714141|Emerging adults
251327|NCT01714141|African Americans
251328|NCT01714141|Asthma
251329|NCT01714141|Controller medications
251330|NCT01714141|Motivational intervention
251331|NCT01714128|NCI protocol #8762
251332|NCT01714128|Estrogen receptor positive breast cancer
251333|NCT01714128|recurrent breast cancer
251334|NCT01714128|stage IV breast cancer
251335|NCT01714102|Obesity
251336|NCT01714102|Insulin resistance
251337|NCT01714102|Metabolic syndrome
251338|NCT01714102|Pre-diabetes
251339|NCT01714089|Relapsing remitting multiple sclerosis
251340|NCT01714089|RR-MS
251341|NCT01714063|pediatric
251342|NCT01714063|asthma
251343|NCT01714063|metered dose inhaler
251344|NCT01714063|valved holding chamber
251345|NCT01714063|pMDI
251346|NCT01714063|VHC
251347|NCT01714050|seasonal affective disorder
251348|NCT01714050|winter depression
251349|NCT01714050|cognitive-behavioral therapy
251350|NCT01714050|light therapy
251351|NCT01714037|Safety
251352|NCT01714037|Efficacy
251353|NCT01714037|HSP90
251354|NCT01714037|Debio 0932
251355|NCT01714037|Standard of care treatment, NSCLC
251356|NCT01714024|Dental
251357|NCT01714024|Implant
251358|NCT01714024|UNC Dental School
251359|NCT01714024|Trabecular Metal
251360|NCT01714024|Titanium
251361|NCT01714024|Healthy Volunteers
251362|NCT01714024|Diabetic
251363|NCT01714024|Osteopenic
251364|NCT01714024|Bone Inductive Properties
251365|NCT01714024|Osseous Healing
251366|NCT01714024|GO Health
251367|NCT01714024|Offenbacher
251368|NCT01714024|Zimmer Dental, Inc.
251369|NCT01714011|Randomized
251370|NCT01714011|Controlled
251371|NCT01714011|Trial
251372|NCT01714011|Safety
251373|NCT01714011|Efficacy
251374|NCT01714011|Aripiprazole
251375|NCT01714011|Ziprasidone
251376|NCT01714011|Metabolic Syndrome
251377|NCT01713998|Ulthera® System
251378|NCT01713998|Ultherapy™ Treatment
251379|NCT01713998|Ulthera, Inc.
251380|NCT01713998|Ultrasound treatment for skin tightening
251381|NCT01713985|Ulthera® System
251382|NCT01713985|Ultherapy™ Treatment
251383|NCT01713985|Ulthera, Inc.
251384|NCT01713985|Ultrasound treatment for skin tightening
251385|NCT01713972|BRAFi
251386|NCT01713972|BRAF-mutated
251387|NCT01713959|Underarm sweating
251388|NCT01713946|TSC seizures,
251389|NCT01713946|TSC epilepsy,
251390|NCT01713946|mTOR inhibitor,
251391|NCT01713946|RAD001,
251392|NCT01713946|Everolimus
251393|NCT01713933|Ulthera® System
251394|NCT01713933|Ultherapy™ treatment
251395|NCT01713933|Ulthera, Inc.
251396|NCT01713907|Ultherapy™ treatment
251397|NCT01713907|Ulthera® System
251398|NCT01713907|Ulthera, Inc.
251399|NCT01713907|Ultrasound treatment for skin tightening
251400|NCT01713894|Counseling
251401|NCT01713894|Limits of viability
251403|NCT01713881|colonoscopy
251404|NCT01713881|surveillance
251405|NCT01713868|Breastfeeding
251406|NCT01713868|Safe Sleep
251407|NCT01713868|Messaging
251408|NCT01713868|Social Media
251409|NCT01713855|ITP
251410|NCT01713855|Rituximab
251411|NCT01713855|Vaccine
251412|NCT01713855|Immune Reconstitution
251413|NCT01713842|Tocilizumab
251414|NCT01713842|Polymyalgia Rheumatica
251415|NCT01713842|Glucocorticotherapy
251416|NCT01713842|PMR-AS
251417|NCT01713829|cranberry
251418|NCT01713829|gamma delta T cell
251419|NCT01713829|improvement in immune cell function in healthy humans
251420|NCT01713829|proliferation
251421|NCT01713816|Glutathione
251422|NCT01713816|Ascorbate
251423|NCT01713816|Alzheimer's disease
251424|NCT01713816|Aging
251425|NCT01713816|Magnetic Resonance Spectroscopy
251426|NCT01713790|physical functional performance
251427|NCT01713790|postural balance
251428|NCT01713790|reaction time
251429|NCT01713790|mobility
251430|NCT01713790|muscle strength
251431|NCT01713790|cognition
251432|NCT01713777|Seizures
251433|NCT01713764|diabetes
251434|NCT01713764|obesity
251435|NCT01713764|mindful eating
251436|NCT01713764|positive affect
251437|NCT01713764|low carbohydrate
251438|NCT01713764|diet
251439|NCT01713751|Surgical site infection
251440|NCT01713751|Cesarean section
251441|NCT01713738|ITP
251442|NCT01713738|rituximab
251443|NCT01713738|bleeding score
251444|NCT01713738|platelet count
251445|NCT01713738|health-related quality of life
251446|NCT01713738|HRQL
251447|NCT01713725|Chronic urticaria
251448|NCT01713725|Chronic spontaneous urticaria
251449|NCT01713725|Autoimmune and non autoimmune urticaria
251450|NCT01713725|UAS7
251451|NCT01713712|Pregnancy
251452|NCT01713712|Obesity
251453|NCT01713712|Nutrition therapy
251454|NCT01713699|CTC, cytology, meningeal carcinomatosis, leptomeningeal metastases
251455|NCT01713686|Ulthera® System
251456|NCT01713686|Ultherapy™ Treatment
251457|NCT01713686|Ulthera, Inc.
251458|NCT01713686|Micro-focused Ultrasound with Visualization (MFU-V)
251459|NCT01713673|Hyperhidrosis
251460|NCT01713673|Axillary sweating
251461|NCT01713673|Ulthera® System
251462|NCT01713673|Ultherapy™ Treatment
251463|NCT01713673|Ulthera, Inc.
251464|NCT01713660|Cataract surgery
251465|NCT01713660|Femtosecond laser
251466|NCT01713660|Corneal incisions
251467|NCT01713647|Bio-equivalence, crossover
251468|NCT01713634|Bone resorption
251469|NCT01713634|Diet
251470|NCT01713621|P. falciparum
251471|NCT01713621|malaria
251472|NCT01713608|malaria
251473|NCT01713608|dose escalation
251474|NCT01713608|safety
251475|NCT01713608|tolerability
251476|NCT01713608|maximum tolerated dose
251477|NCT01713595|Acute Lung Injury
251478|NCT01713595|Mechanical Ventilation
251479|NCT01713569|Ulthera® System
251480|NCT01713569|Ultherapy™ Treatment
251481|NCT01713569|Ulthera, Inc.
251482|NCT01713569|Ultrasound treatment for skin tightening
251483|NCT01713556|PTSD, Propranolol
251484|NCT01713543|falls
251485|NCT01713517|Mosquito Control
251486|NCT01713517|Insecticide Resistance
251487|NCT01713491|brain ischemia
251488|NCT01713491|thrombolytic therapy
251489|NCT01713491|Impaired cognition
251490|NCT01713491|dementia
251491|NCT01713478|hepatic cirrhosis
251492|NCT01713478|subclinical myocardial dysfunction
251493|NCT01713478|echocardiography
251494|NCT01713478|specific biomarkers
251495|NCT01713478|vascular assessment
251496|NCT01713465|Diabetes
251497|NCT01713465|Hypertension
251498|NCT01713465|Hypercholesterolemia
251499|NCT01713465|Obesity
251500|NCT01713452|Surgical Stomas
251501|NCT01713452|ileostomy
251502|NCT01713452|surgical site infection
251503|NCT01713439|Relapsed/Refractory Neuroblastoma
251504|NCT01713439|Retroviral vector injections
251505|NCT01713439|Allogeneic neuroblastoma cells
251506|NCT01713439|Lymphotactin
251507|NCT01713439|Interleukin-2 (IL-2)
251508|NCT01713426|Post herpetic neuralgia
251509|NCT01713426|Peripheral Neuropathic Pain
251510|NCT01713426|Qutenza
251511|NCT01713426|Pregabalin
251512|NCT01713426|NGX-4010
251513|NCT01713413|Oxymizer
251514|NCT01713413|endurance time
251515|NCT01713413|exercise test
251516|NCT01713413|nasal cannula
251517|NCT01713413|COPD
251518|NCT01713413|ILD
251519|NCT01713413|oxygenation
251520|NCT01713400|Acute Graft vs. Host Disease (aGVHD)
251521|NCT01713400|Graft vs. Host Disease (GVHD)
251522|NCT01713387|adjuvant chemotherapy
251523|NCT01713374|endothelial function
251524|NCT01713374|sympathetic nervous system
251525|NCT01713361|total knee arthroplasty
251526|NCT01713361|Prophylaxis
251527|NCT01713348|CGM
251528|NCT01713348|MDI
251529|NCT01713322|parent education
251530|NCT01713322|pain management
251531|NCT01713322|immunization
251532|NCT01713322|infant
251533|NCT01713309|Filgrastim
251534|NCT01713309|G-CSF
251535|NCT01713309|Heparin-binding protein
251536|NCT01713309|critically ill
251537|NCT01713309|acute respiratory failure
251538|NCT01713296|SCLC
251539|NCT01713296|2nd Line
251540|NCT01713296|Relapsed or Refractory
251541|NCT01713270|Hypertension
251542|NCT01713270|Atrial Fibrillation
251543|NCT01713270|Arrhythmias, Cardiac
251544|NCT01713270|Heart Diseases
251545|NCT01713257|Critically ill patients
251546|NCT01713244|Hepatocellular Carcinoma
251547|NCT01713244|Radiofrequency Ablation
251548|NCT01713244|Hepatectomy
251549|NCT01713244|Recurrence
251550|NCT01713231|osteogenesis imperfecta
251551|NCT01713231|high-dose vitamin D
251552|NCT01713231|bone density
251553|NCT01713231|muscle function
251554|NCT01713218|Pancreas
251555|NCT01713218|Cancer
251556|NCT01713218|Hedgehog inhibitor
251557|NCT01713218|Neoadjuvant chemotherapy
251558|NCT01713218|Dynamic imaging
251559|NCT01713205|trauma ; sepsis; Multiple Organ Dysfunction Syndrome; Prediction; risk
251560|NCT01713153|postpartum hemorrhage
251561|NCT01713153|prevention
251562|NCT01713153|misoprostol
251563|NCT01713153|Uniject
251564|NCT01713153|oxytocin
251565|NCT01713140|strength training
251566|NCT01713140|resistance training
251567|NCT01713140|fatigue
251568|NCT01713140|knee extension
251569|NCT01713140|total knee arthroplasty
251570|NCT01713140|total knee replacement
251571|NCT01713140|electromyography
251572|NCT01713140|physical therapy modalities
251573|NCT01713101|Gastrointestinal Hemorrhage
251574|NCT01713101|Peptic Ulcer Hemorrhage
251575|NCT01713101|Hematemesis
251576|NCT01713101|Melena
251577|NCT01713101|Tranexamic acid
251578|NCT01713088|multisystemic therapy, RCT, young offenders, U.K.
251579|NCT01713075|chronic obstructive pulmonary disease
251580|NCT01713075|Symbicort
251581|NCT01713075|long-term use
251582|NCT01713049|FLT PET
251583|NCT01713049|breast neoplasms
251584|NCT01713049|mammography
251585|NCT01713049|breast ultrasound
251586|NCT01713036|Mass balance, bioavailability, cancer, 14C
251587|NCT01713023|type 1 diabetes
251588|NCT01713023|fructose
251589|NCT01713023|glucose
251590|NCT01713023|TAS1R2
251591|NCT01713023|oxidative stress
251592|NCT01713010|Keywords provided by Atlantic Health System:
251593|NCT01713010|Rapid Shallow Breathing Index
251594|NCT01713010|Mechanical Ventilation
251595|NCT01713010|Additional relevant MeSH terms:
251596|NCT01713010|Respiration Disorders
251597|NCT01713010|Traumatic Brain Injury
251598|NCT01713010|Weaning Failure
251599|NCT01713010|Mechanical ventilation complication
251600|NCT01712997|Treatment of
251601|NCT01712984|Influenza
251602|NCT01712984|Fluzone® Intradermal vaccine
251603|NCT01712984|Influenza Virus Vaccine USP Quadrivalent
251604|NCT01712984|Influenza Virus Vaccine USP Trivalent Types A and B
251605|NCT01712971|surgery
251606|NCT01712971|pancreas
251607|NCT01712971|tumour
251608|NCT01712971|blood loss
251609|NCT01712958|CRC miRNA
251610|NCT01712945|Alemtuzumab
251611|NCT01712945|Palifermin
251612|NCT01712945|Reconstitution
251613|NCT01712945|Thymus
251614|NCT01712919|Locoregionally advanced nasopharyngeal carcinoma
251615|NCT01712919|cetuximab
251616|NCT01712919|chemoradiation
251617|NCT01712893|breast cancer
251618|NCT01712893|adjuvant therapy
251619|NCT01712893|Ovarian suppression
251620|NCT01712854|COPD
251621|NCT01712854|Chronic Obstructive Lung Disease
251622|NCT01712854|Long acting beta agonist
251623|NCT01712841|Dry AMD
251624|NCT01712841|Age-related macular degeneration
251625|NCT01712841|Optical coherenece tomography
251626|NCT01712841|Imaging
251627|NCT01712841|Blood flow
251628|NCT01712828|Lenalidomide,
251629|NCT01712828|Revlimid,
251630|NCT01712828|pharmacokinetics,
251631|NCT01712828|healthy male subjects
251632|NCT01712789|Multiple Myeloma
251633|NCT01712789|Relapsed Multiple Myeloma
251634|NCT01712789|Relapsed and refractory Multiple Myeloma
251635|NCT01712789|Pomalidomide
251636|NCT01712789|Dexamethasone
251637|NCT01712776|Vapocoolant
251638|NCT01712763|Endometriosis
251639|NCT01712763|long acting GnRH antagonist
251640|NCT01712763|Degarelix
251641|NCT01712763|Recurrence
251642|NCT01712763|Pelvic Pain
251643|NCT01712750|Regional tissue oximetry
251644|NCT01712750|Cardiopulmonary bypass
251645|NCT01712750|Cardiac surgical procedures
251646|NCT01712737|raisins, grapes, snacks, appetite, food intake
251647|NCT01712724|exercise therapy
251648|NCT01712724|rehabilitation
251649|NCT01712711|Steatohepatitis,
251650|NCT01712711|Helicobacter pylori,
251651|NCT01712711|Insulin resistance,
251652|NCT01712711|Alanine aminotransferase,
251653|NCT01712711|Aspartate aminotransferase,
251654|NCT01712698|trauma
251655|NCT01712698|spinal cord injury
251656|NCT01712698|cervical spine
251657|NCT01712685|Kidney Neoplasm
251658|NCT01712685|RCC
251659|NCT01712685|Biodistribution of 18F-VM4-037
251660|NCT01712685|CAIX Staining
251661|NCT01712685|Tumor Angiogenesis
251662|NCT01712672|Dental Plaque
251663|NCT01712672|Biofilm
251664|NCT01712672|Bacterial Interactions
251665|NCT01712672|Receptor Polysaccharide
251666|NCT01712672|Oral Streptococci
251667|NCT01712659|JAK 1/2
251668|NCT01712659|Human T-Cell Lymphotropic Virus 1
251669|NCT01712659|HTLV-1
251670|NCT01712659|Janus Kinase Inhibitor
251671|NCT01712646|Oxytocin
251672|NCT01712646|Childhood Onset Schizophrenia
251673|NCT01712646|Double Blind
251674|NCT01712633|fMRI
251675|NCT01712633|Brain Perfusion
251676|NCT01712620|Microarray
251677|NCT01712620|Magnetic Resonance Imaging
251678|NCT01712620|Mineralocorticoid Receptor Antagonist
251679|NCT01712620|Neurohormonal Axis
251680|NCT01712620|Vascular Inflammation
251681|NCT01712620|Pulmonary Hypertension
251682|NCT01712620|Cardiovascular Disease
251683|NCT01712620|Vascular Disease
251684|NCT01712607|laparoscopy
251685|NCT01712607|surgery
251686|NCT01712607|warm-up
251687|NCT01712607|preoperative
251688|NCT01712607|surgical skills
251689|NCT01712594|United Kingdom Overnight closed loop
251690|NCT01712581|normal myocardial T1, T2 and T2* values
251691|NCT01712555|Anophthalmic orbits
251692|NCT01712555|autologous fat
251693|NCT01712555|platelet rich plasma
251694|NCT01712555|orbital atrophy
251695|NCT01712555|anophthalmos
251696|NCT01712555|cannula
251697|NCT01712529|Systemic lupus erythematosus
251698|NCT01712529|endothelium
251699|NCT01712529|exercise
251700|NCT01712516|COPD, QVA149
251701|NCT01712503|Cataract
251702|NCT01712503|Astigmatism
251703|NCT01712503|Toric
251704|NCT01712503|Phacoemulsification
251705|NCT01712503|Intraocular lens
251706|NCT01712490|Hodgkin Lymphoma
251707|NCT01712490|Hodgkins Lymphoma
251708|NCT01712490|Antibody, Monoclonal
251709|NCT01712490|Antibody-Drug Conjugate
251710|NCT01712490|Antigens, CD-30
251711|NCT01712490|Immunotherapy
251712|NCT01712490|Lymphoma
251713|NCT01712490|Lymphoma, Classical
251714|NCT01712490|ECHELON-1
251715|NCT01712451|adiposity
251716|NCT01712438|Previously untreated patients
251717|NCT01712425|vaccine
251718|NCT01712425|recently HIV-1 infected individuals
251719|NCT01712373|Multiple sclerosis
251720|NCT01712373|Ginseng
251721|NCT01712373|Fatigue
251722|NCT01712373|Quality of life
251723|NCT01712360|Tinea Pedis
251724|NCT01712360|Tinea Cruris
251725|NCT01712360|Athlete foot
251726|NCT01712360|Jock itch
251727|NCT01712321|Social Anxiety Disorder
251728|NCT01712321|Social Anxiety
251729|NCT01712321|Social Phobia
251730|NCT01712321|SAD
251731|NCT01712308|Leukemia
251732|NCT01712308|Myeloproliferative Neoplasm
251733|NCT01712308|MPN
251734|NCT01712308|Associated Myelofibrosis
251735|NCT01712308|Anemia
251736|NCT01712308|Sotatercept
251737|NCT01712308|ACE-011
251738|NCT01712295|Warts
251739|NCT01712295|salicylic acid
251740|NCT01712295|ethyl pyruvate
251741|NCT01712282|Physical Activity
251742|NCT01712282|Accelerometer
251743|NCT01712256|CD4
251744|NCT01712256|Clinical trial
251745|NCT01712256|Human immunodeficiency virus-1 (HIV-1)
251746|NCT01712256|HIV
251747|NCT01712256|Immunomodulary
251748|NCT01712256|Infection
251749|NCT01712256|Phase II
251750|NCT01712256|Re-boost
251751|NCT01712256|Vaccine
251752|NCT01712256|Vacc-4x
251753|NCT01712230|hormone therapy
251754|NCT01712230|obesity
251755|NCT01712230|menopause
251756|NCT01712230|disease /disorder proneness /risk
251757|NCT01712230|insulin sensitivity /resistance
251758|NCT01712230|metabolic syndrome
251759|NCT01712230|women's health
251760|NCT01712217|Non-small cell lung cancer
251761|NCT01712204|Prophylaxis of Acute Gout Flares
251762|NCT01712204|Urate-Lowering Therapy
251763|NCT01712204|Hyperuricemia
251764|NCT01712204|Gouty arthritis
251765|NCT01712191|NUsurface
251766|NCT01712191|Meniscus
251767|NCT01712191|Knee
251768|NCT01712191|KOOS
251769|NCT01712178|Pharmacodynamic,Pharmacokinetic
251770|NCT01712165|Folic acid supplement
251771|NCT01712165|Neural tube defect-affected pregnancy
251772|NCT01712165|Homocysteine concentration
251773|NCT01712165|Plasma Folate concentration
251774|NCT01712165|Plasma vitamin B12 concentration
251775|NCT01712152|Duchenne muscular dystrophy
251776|NCT01712152|carrier
251777|NCT01712152|cardiac MRI
251778|NCT01712152|myocardial fibrosis
251779|NCT01712152|female
251780|NCT01712087|spasticity
251781|NCT01712087|muscle spasticity
251782|NCT01712087|muscle rigidity
251783|NCT01712087|motor neuron disease
251784|NCT01712087|hyperreflexia
251785|NCT01712074|Randomized
251786|NCT01712074|Double Blind
251787|NCT01712074|Safety and Efficacy
251788|NCT01712061|Diabetic nephropathy
251789|NCT01712061|type 2 diabetes
251790|NCT01712061|albuminuria
251791|NCT01712061|chemokine antagonist
251792|NCT01712035|Wet AMD
251793|NCT01712035|Age-related macular degeneration
251794|NCT01712035|Optical coherenece tomography
251795|NCT01712035|Imaging
251796|NCT01712035|Blood flow
251797|NCT01712009|Breast cancer
251798|NCT01712009|Chemotherapy
251799|NCT01712009|Neulasta
251800|NCT01712009|Pegfilgrastim
251801|NCT01712009|Naproxen
251802|NCT01712009|Loratadine
251803|NCT01712009|Non-steroidal antiinflammatory drug (NSAID)
251804|NCT01712009|Anti-histamine
251805|NCT01712009|Bone Pain
251806|NCT01711996|hydronephrosis
251807|NCT01711996|biopsy
251808|NCT01711996|biomarker
251809|NCT01711957|Complications
251810|NCT01711957|Mortality
251811|NCT01711957|Liver transplantation
251812|NCT01711957|Platelet count
251813|NCT01711957|Survival
251814|NCT01711944|childhood cancer
251815|NCT01711944|Internet communication
251816|NCT01711944|parents
251817|NCT01711944|caregivers
251818|NCT01711944|problem solving
251819|NCT01711931|percutaneous coronary intervention
251820|NCT01711931|bioresorbable vascular scaffold stents
251821|NCT01711931|everolimus
251822|NCT01711931|biolimus
251823|NCT01711918|gastroparesis
251824|NCT01711918|domperidone
251825|NCT01711918|nausea
251826|NCT01711918|vomiting
251827|NCT01711892|Prostatic Neoplasms
251828|NCT01711892|Prostate Cancer
251829|NCT01711892|Exercise
251830|NCT01711892|Soccer
251831|NCT01711892|Androgen Deprivation Therapy
251832|NCT01711892|Body Composition
251833|NCT01711892|Cardiovascular fitness
251834|NCT01711892|Bone Health
251835|NCT01711892|Health Related Quality of Life
251836|NCT01711866|Rotigotine
251837|NCT01711866|Neupro
251838|NCT01711866|Switch
251839|NCT01711866|Dopamine agonists
251840|NCT01711840|Bronchial asthma
251841|NCT01711840|Symbicort Turbuhaler
251842|NCT01711827|isavuconazole
251843|NCT01711827|prednisone
251844|NCT01711827|prednisolone
251845|NCT01711827|BAL8557
251846|NCT01711827|healthy volunteers
251847|NCT01711814|Rheumatoid Arthritis
251848|NCT01711814|ASP015K
251849|NCT01711788|Hematopoietic stem cells
251850|NCT01711788|Umbilical cord blood transplantation
251851|NCT01711788|Intrabone infusion
251852|NCT01711788|Platelet recovery
251853|NCT01711788|Neutrophil recovery
251854|NCT01711788|Pediatric patients
251855|NCT01711736|Immunogenicity
251856|NCT01711736|Children
251857|NCT01711736|Safety
251858|NCT01711736|Seasonal influenza
251859|NCT01711736|Fluarix
251860|NCT01711723|darapladib
251861|NCT01711723|Lp-PLA2- inhibitor
251862|NCT01711723|healthy volunteer
251863|NCT01711723|renal impairment
251864|NCT01711723|pharmacokinetics
251865|NCT01711710|Breast cancer
251866|NCT01711710|reconstruction
251867|NCT01711710|augmentation
251868|NCT01711710|cohesive silicone gel
251869|NCT01711710|breast implant
251870|NCT01711710|rupture
251871|NCT01711710|capsular contracture
251872|NCT01711684|Neoplasm Metastasis
251873|NCT01711684|Melanoma
251874|NCT01711645|Tetanus, Diptheria toxoids, Acellular, Pertussis, Tdap, Adacel®, postpartum, women
251875|NCT01711632|VEMURAFENIB
251876|NCT01711632|BRAF Inhibitor
251877|NCT01711632|12-200
251878|NCT01711632|Zelboraf™
251879|NCT01711606|Fragile-X Syndrome
251880|NCT01711606|registry
251881|NCT01711606|non-interventional trial
251882|NCT01711606|patient-related outcome study
251883|NCT01711606|drug utilization
251884|NCT01711606|effectiveness
251885|NCT01711606|treatment patterns
251886|NCT01711606|patient characteristics under real life conditions
251887|NCT01711606|quality of life
251888|NCT01711606|economics
251889|NCT01711593|Asthma
251890|NCT01711593|Allergic
251891|NCT01711593|Inflammation
251892|NCT01711593|Airway
251893|NCT01711593|Challenge
251894|NCT01711593|Chemokines
251895|NCT01711593|Tolerization
251896|NCT01711580|Recurrent glioma
251897|NCT01711580|Quality of life
251898|NCT01711580|Glioblastoma multiforme
251899|NCT01711580|Anaplastic glioma
251900|NCT01711580|Cognition
251901|NCT01711580|Re-irradiation
251902|NCT01711567|Chronic Hepatitis B
251903|NCT01711567|TENOFOVIR
251904|NCT01711567|ENTECAVIR
251905|NCT01711567|PARTIAL RESPONDER
251906|NCT01711502|metastatic breast cancer,
251907|NCT01711502|epidemiology,
251908|NCT01711502|retrospective cohort
251909|NCT01711489|isavuconazole
251910|NCT01711489|mycophenolate mofetil (MMF)
251911|NCT01711489|BAL8557
251912|NCT01711489|BAL4815
251913|NCT01711489|healthy volunteers
251914|NCT01711489|Mycophenolic acid (MPA)
251915|NCT01711489|Phenolic glucuronide of MPA (MPAG)
251916|NCT01711489|CellCept
251917|NCT01711476|PCOS
251918|NCT01711476|Bdiet
251919|NCT01711476|Ddiet
251920|NCT01711476|OGTT
251921|NCT01711463|Pharmacodynamics
251922|NCT01711463|Fluticasone furoate (FF)
251923|NCT01711463|novel dry powder device
251924|NCT01711463|Safety and tolerability
251925|NCT01711463|vilanterol(VI)
251926|NCT01711463|Healthy Chinese subjects
251927|NCT01711463|Pharmacokinetics
251928|NCT01711437|colonoscopy
251929|NCT01711437|colon cleansing
251930|NCT01711437|children
251931|NCT01711437|age 2 -18 years
251932|NCT01711411|HIV prevention
251933|NCT01711411|PrePex
251934|NCT01711411|voluntary medical male circumcision
251935|NCT01711411|non-surgical
251936|NCT01711411|medical device
251937|NCT01711411|wound healing
251938|NCT01711411|Kenya
251939|NCT01711398|solid tumor
251940|NCT01711398|peptide
251941|NCT01711385|Oral Health
251942|NCT01711385|Prediabetes
251943|NCT01711385|Diabetes
251944|NCT01711385|Periodontitis
251945|NCT01711385|Early Identification
251946|NCT01711385|Prevention
251947|NCT01711372|ADHD
251948|NCT01711320|Omeprazole
251949|NCT01711320|Metformin
251950|NCT01711307|Achilles
251951|NCT01711307|Rupture
251952|NCT01711294|Pancreatic Cystic Lesions
251953|NCT01711294|PCL
251954|NCT01711294|EUS-FNA
251955|NCT01711281|Heart Failure
251956|NCT01711281|Implantable Cardioverter-Defibrillator
251957|NCT01711281|Intracardiac Impedance Measurement
251958|NCT01711281|Cardiac Resynchronization Therapy
251959|NCT01711281|Home Monitoring
251960|NCT01711281|Reverse Remodeling
251961|NCT01711268|Sunitinib
251962|NCT01711268|Renal Cell Carcinoma
251963|NCT01711268|Therapeutic Drug Monitoring
251964|NCT01711268|Pharmacokinetic
251965|NCT01711268|Treatment toxicity
251966|NCT01711255|Multiple sclerosis
251967|NCT01711255|Coagulation
251968|NCT01711255|Alternative Medicine
251969|NCT01711255|Clotting
251970|NCT01711255|Complementary Medicine
251971|NCT01711255|Inflammation
251972|NCT01711242|gastric cancer
251973|NCT01711242|radiotherapy
251974|NCT01711242|postoperative therapy
251975|NCT01711242|chemotherapy
251976|NCT01711229|oral acetaminophen
251977|NCT01711229|IV acetaminophen
251978|NCT01711229|Ofirmev
251979|NCT01711229|equianalgesic
251980|NCT01711229|arthroscopic rotator cuff repair
251981|NCT01711216|Dydrogesterone
251982|NCT01711216|Irregular Menstrual Cycle
251983|NCT01711216|Progestins
251984|NCT01711203|Spondylolysis
251985|NCT01711203|Spondylolisthesis
251986|NCT01711203|Rehabilitation
251987|NCT01711203|Physical Therapy
251988|NCT01711203|Children
251989|NCT01711190|glaucoma
251990|NCT01711190|trabeculectomy
251991|NCT01711190|astigmatism
251992|NCT01711190|intraocular pressure
251993|NCT01711177|primary open angle glaucoma
251994|NCT01711177|retinal oximetry
251995|NCT01711164|HCV
251996|NCT01711164|T regulatory cells (Tregs)
251997|NCT01711164|FGL2
251998|NCT01711151|ILD
251999|NCT01711138|Physical Activity
252000|NCT01711138|Physical Fitness
252001|NCT01711138|Transportation
252002|NCT01711138|Environment Design
252003|NCT01711138|Child
252004|NCT01711138|Adolescent
252005|NCT01711086|asthma
252006|NCT01711086|dry powder inhaler
252007|NCT01711047|catheter ablation
252008|NCT01711047|atrial fibrillation
252009|NCT01711047|pulmonary vein isolation
252010|NCT01711047|linear ablation
252011|NCT01711047|CFAE ablation
252012|NCT01711034|Solid tumors
252013|NCT01711021|ADHD
252014|NCT01711008|Breakfast size
252015|NCT01711008|Exercise
252016|NCT01711008|Cognitive performance
252017|NCT01711008|Mood
252018|NCT01711008|Appetite
252019|NCT01711008|Active women
252020|NCT01710956|concurrent chemoradiation in patients with limited disease small cell lung cancer
252021|NCT01710943|Web-based CBT
252022|NCT01710943|PTSD
252023|NCT01710943|Alcohol Misuse
252024|NCT01710943|Substance Misuse
252025|NCT01710943|Integrated Primary Care
252026|NCT01710943|OEF/OIF Veterans
252027|NCT01710930|Allergic Broncho-Pulmonary Aspergillosis
252028|NCT01710917|Chronic pain
252029|NCT01710917|Severe pain
252030|NCT01710917|Oxycodon
252031|NCT01710917|Naloxon
252160|NCT01710228|Natalizumab
252032|NCT01710917|Opioid-induced constipation
252033|NCT01710917|Opioid
252034|NCT01710917|Quality of life
252035|NCT01710917|Laxative
252036|NCT01710917|Analgesic rescue medication
252037|NCT01710904|Chronic pain
252038|NCT01710904|Severe pain
252039|NCT01710904|Oxycodone
252040|NCT01710904|Naloxone
252041|NCT01710904|Opioid-induced constipation
252042|NCT01710904|Opioid
252043|NCT01710904|Quality of life
252044|NCT01710904|Laxative
252045|NCT01710904|Analgesic rescue medication
252046|NCT01710891|endotracheal intubation
252047|NCT01710891|direct laryngoscopy
252048|NCT01710891|video laryngoscopy
252049|NCT01710865|Caries prevention
252050|NCT01710865|pit and fissure sealants
252051|NCT01710852|Atrial Fibrillation
252052|NCT01710852|Paroxysmal Atrial Fibrillation
252053|NCT01710852|AF
252054|NCT01710839|CRVO
252055|NCT01710839|BRVO
252056|NCT01710839|HRVO
252057|NCT01710839|Macular edema
252058|NCT01710839|vein occlusion
252059|NCT01710813|pompe disease
252060|NCT01710813|alglucosidase alfa
252061|NCT01710813|anaphylaxis
252062|NCT01710813|severe cutaneous
252063|NCT01710813|systemic immune complex-mediated reactions
252064|NCT01710800|impedance
252065|NCT01710800|reflux
252066|NCT01710800|GERD
252067|NCT01710787|operative
252068|NCT01710787|dental procedure
252069|NCT01710774|Diabetic Foot
252070|NCT01710774|Diabetes Mellitus
252071|NCT01710774|Foot Ulcer
252072|NCT01710774|Wound Healing
252073|NCT01710774|Delivery of Health Care
252074|NCT01710774|Depression
252075|NCT01710774|sequela
252076|NCT01710774|Sick Leave
252077|NCT01710774|Quality of Life
252078|NCT01710774|Amputation
252079|NCT01710761|nitric oxide
252080|NCT01710761|cycling performance
252081|NCT01710761|lactate
252082|NCT01710761|VO2
252083|NCT01710748|Percutaneous coronary intervention
252084|NCT01710748|Drug eluting stent
252085|NCT01710748|Neointimal hyperplasia
252086|NCT01710748|Diabetes Mellitus
252087|NCT01710735|TP
252088|NCT01710735|Myofascial pain
252089|NCT01710709|Aripiprazole, Intramuscular (IM) Depot, Bipolar
252090|NCT01710683|Discectomy
252091|NCT01710683|1st postoperative day
252092|NCT01710683|Intensive exercise training
252093|NCT01710683|Randomized controlled trial
252094|NCT01710670|Brivaracetam
252095|NCT01710670|Ethanol
252096|NCT01710670|Pharmacodynamics
252097|NCT01710670|Pharmacokinetic
252098|NCT01710670|Interaction
252099|NCT01710657|Lacosamide
252100|NCT01710657|Epilepsy
252101|NCT01710657|Partial Onset Seizures
252102|NCT01710631|Sleep
252103|NCT01710618|Protein Expression of Sciatic Nerve
252104|NCT01710618|traumatized sciatic nerve
252105|NCT01710605|Circulating tumor cells
252106|NCT01710605|Breast Cancer
252107|NCT01710605|Hormone-receptors positive
252108|NCT01710579|Primary esophageal achalasia
252109|NCT01710579|endoscopic myotomy
252110|NCT01710579|high resolution manometry
252111|NCT01710566|Postpartum hemorrhage
252112|NCT01710566|prevention
252113|NCT01710566|oxytocin
252114|NCT01710566|misoprostol
252115|NCT01710566|Uniject
252116|NCT01710566|community
252117|NCT01710527|Healthy Volunteers
252118|NCT01710488|COPD exacerbation
252119|NCT01710488|fluoroquinolones,
252120|NCT01710449|Lung Transplant
252121|NCT01710423|Obesity
252122|NCT01710423|Nutrition
252123|NCT01710423|Home Food Preparation
252124|NCT01710423|Peer Mentoring
252125|NCT01710423|Early Head Start
252126|NCT01710423|Cooking
252127|NCT01710423|Diet
252128|NCT01710410|transcranial direct current stimulation
252129|NCT01710410|nicotine dependence
252130|NCT01710410|dorsolateral prefrontal cortex
252131|NCT01710410|nicotine replacement therapy
252132|NCT01710410|nicotine patch
252133|NCT01710410|addiction
252134|NCT01710410|smoking cessation
252135|NCT01710410|neuroplasticity
252136|NCT01710397|Antiretroviral therapy
252137|NCT01710397|South Africa
252138|NCT01710384|late preterm, betamethasone,
252139|NCT01710332|Persistent
252140|NCT01710332|Central
252141|NCT01710332|Serous
252142|NCT01710332|Chorioretinopathy
252143|NCT01710332|Regeneron
252144|NCT01710332|CSR
252145|NCT01710332|CSCR
252146|NCT01710319|Immunoregulation
252147|NCT01710319|Natural Killer Cells
252148|NCT01710306|Women
252149|NCT01710306|Veterans
252150|NCT01710306|PTSD
252151|NCT01710293|Electronic Health Records
252152|NCT01710293|Diagnostic Delay
252153|NCT01710293|Triggers
252154|NCT01710280|Lipemia
252155|NCT01710280|Vascular function
252156|NCT01710280|Blood pressure
252157|NCT01710254|MRI
252158|NCT01710254|Atrial Fibrillation
252159|NCT01710228|MS
252161|NCT01710228|copaxone
252162|NCT01710215|Colorectal Neoplasms
252163|NCT01710215|Colorectal Cancer
252164|NCT01710215|Colon Cancer
252165|NCT01710215|Mass Screening
252166|NCT01710215|Health Services Research
252167|NCT01710215|Comparative Effectiveness Research
252168|NCT01710202|Hydrocortisone
252169|NCT01710202|Cortisol
252170|NCT01710202|Testosterone
252171|NCT01710202|Stress
252172|NCT01710202|Serotonin
252173|NCT01710202|5-HTTLPR
252174|NCT01710202|Amygdala
252175|NCT01710202|Depression
252176|NCT01710189|Tick-Borne Encephalitis Virus
252177|NCT01710163|Lithium Carbonate
252178|NCT01710163|Lithium
252179|NCT01710163|Central Nervous System Agents
252180|NCT01710163|Therapeutic Uses
252181|NCT01710163|Pharmacologic Actions
252182|NCT01710163|Enzyme Inhibitors
252183|NCT01710163|Molecular Mechanisms of Pharmacological Action
252184|NCT01710163|Neurotransmitter Agents
252185|NCT01710163|Physiological Effects of Drugs
252186|NCT01710163|Antimanic Agents
252187|NCT01710163|Tranquilizing Agents
252188|NCT01710163|Central Nervous System Depressants
252189|NCT01710163|Psychotropic Drugs
252190|NCT01710163|Sensory System Agents
252191|NCT01710163|Antipsychotic Agents
252192|NCT01710163|Antidepressive Agents
252193|NCT01710150|typical aflutter (AFLT)
252194|NCT01710150|CTI ablation
252195|NCT01710150|Atrial Fibrillation (AF)
252196|NCT01710150|PVI
252197|NCT01710137|Smoking cessation
252198|NCT01710137|Nicotine dependence
252199|NCT01710137|Varenicline
252200|NCT01710137|Chantix
252201|NCT01710137|HIV
252202|NCT01710137|AIDS
252203|NCT01710124|grocery purchases
252204|NCT01710124|financial incentives
252205|NCT01710124|obesogenic home food environment
252206|NCT01710111|Human challenge model
252207|NCT01710111|Quarantine study
252208|NCT01710111|Influenza virus
252209|NCT01710111|Modes of transmission
252210|NCT01710111|Droplet spray
252211|NCT01710111|Droplet nuclei
252212|NCT01710111|Secondary attack rate
252213|NCT01710111|Face shield
252214|NCT01710111|Hand hygiene
252215|NCT01710111|Fomites
252216|NCT01710111|Environmental deposition
252217|NCT01710111|Environmental dispersion
252218|NCT01710098|testosterone
252219|NCT01710098|S3-Adherence
252220|NCT01710098|Quality of Life
252221|NCT01710085|Diffusion weighted MRI
252222|NCT01710085|Curative surgery
252223|NCT01710085|Recurrence
252224|NCT01710072|aneurysm, inflammation, MRI
252225|NCT01710059|Health Status Disparities
252226|NCT01710059|Minority Health
252227|NCT01710059|Pediatrics
252228|NCT01710059|Behavioral Intervention
252229|NCT01710059|Cellular Phone
252230|NCT01710059|Peer Group
252231|NCT01710046|plaque psoriasis
252232|NCT01710046|tofacitinib
252233|NCT01710046|biopsy
252234|NCT01710046|Janus Kinase
252235|NCT01710046|randomized placebo controlled clinical trial
252236|NCT01710046|psoriasis vulgaris
252237|NCT01710033|CP-690,550
252238|NCT01710033|kidney transplant
252239|NCT01710020|CP-690
252240|NCT01710020|550
252241|NCT01710020|pharmacokinetics
252242|NCT01710020|end-stage renal disease
252243|NCT01710007|HMG-CoA reductase inhibitors
252244|NCT01709994|cardiovascular events
252245|NCT01709994|chronic kidney disease
252246|NCT01709994|bleedings
252247|NCT01709994|progression
252248|NCT01709994|antiinflammatory effects
252249|NCT01709968|Nocturnal Leg Cramps
252250|NCT01709968|Quality of life
252251|NCT01709968|Quality of sleep
252252|NCT01709955|Obesity
252253|NCT01709955|Overweight
252254|NCT01709955|Glucomannan
252255|NCT01709942|GnRH antagonist
252256|NCT01709942|PCOS
252257|NCT01709942|OHSS
252258|NCT01709942|COH
252259|NCT01709942|IVF
252260|NCT01709916|Glaucoma
252261|NCT01709916|intra ocular pressure
252262|NCT01709916|diurnal fluctuations
252263|NCT01709903|chronic obstructive pulmonary disease
252264|NCT01709877|Multiport laparoscopy
252265|NCT01709877|Single Port Laparoscopy
252266|NCT01709877|Symptomatic Gallstones
252267|NCT01709864|Anticholinergic
252268|NCT01709864|Antimuscarinic
252269|NCT01709864|Chronic Obstructive Airway Disease
252270|NCT01709864|Chronic Obstructive Lung Disease
252271|NCT01709864|Chronic Obstructive Pulmonary Disease
252272|NCT01709864|COPD
252273|NCT01709864|LAMA
252274|NCT01709864|Lung Disease
252275|NCT01709864|Lung Diseases, Obstructive
252276|NCT01709864|Lung Function
252277|NCT01709864|Muscarinic receptor antagonist
252278|NCT01709864|Pulmonary Disease, Chronic Obstructive
252279|NCT01709864|Respiratory Tract Diseases
252280|NCT01709851|Type 1 diabetes
252281|NCT01709851|Intravascular continuous glucose monitoring
252282|NCT01709851|Subcutaneous continuous glucose monitoring
252283|NCT01709838|Non-transfusion dependent thalassemia, NTDT
252284|NCT01709825|probiotics
252285|NCT01709825|cold
252286|NCT01709825|flu
252287|NCT01709825|immune function
252288|NCT01709825|microbiota
252289|NCT01709799|Cognitive Training
252290|NCT01709799|Aging
252291|NCT01709799|Seniors
252292|NCT01709786|Hemorrhage
252293|NCT01709786|Hemoglobin
252294|NCT01709786|Non-invasive monitoring
252295|NCT01709786|Medical device accuracy
252296|NCT01709760|ENIA11
252297|NCT01709760|MTX
252298|NCT01709760|RA
252299|NCT01709760|TNF
252300|NCT01709747|Hydromorphone Hydrochloride
252301|NCT01709747|Hydromorphone
252302|NCT01709747|Pain
252303|NCT01709747|Chronic Pain
252304|NCT01709747|Implantable Pump
252305|NCT01709747|Pump
252306|NCT01709747|Intrathecal
252307|NCT01709734|prostate cancer CRPC
252308|NCT01709721|Hydromorphone
252309|NCT01709721|Hydromorphone Hydrochloride
252310|NCT01709721|Pain Management
252311|NCT01709721|Non-narcotic analgesics
252312|NCT01709708|Migraine
252313|NCT01709708|Headache
252314|NCT01709708|Chronic Migraine
252315|NCT01709708|Marcaine
252316|NCT01709708|Tx360
252317|NCT01709695|Intuniv
252318|NCT01709695|Attention Deficit Hyperactivity Disorder
252319|NCT01709695|fMRI
252320|NCT01709682|atrial fibrillation
252321|NCT01709682|arrhythmias
252322|NCT01709682|anti-arrhythmic agents
252323|NCT01709669|acute coronary syndrome
252324|NCT01709669|gratitude
252325|NCT01709669|health behavior
252326|NCT01709669|myocardial infarction
252327|NCT01709669|unstable angina
252328|NCT01709617|carbohydrate, glycogen, glucose
252329|NCT01709604|acute paraquat poisoning
252330|NCT01709604|hemoperfusion
252331|NCT01709604|continuous blood purification
252332|NCT01709591|intrapartum pain management, epidural
252333|NCT01709565|Sepsis
252334|NCT01709565|Lactic acid
252335|NCT01709565|Shock
252336|NCT01709565|Resuscitation
252337|NCT01709539|Cancer diagnosis center
252338|NCT01709539|Time to diagnosis
252339|NCT01709539|Survival
252340|NCT01709539|Health economics
252341|NCT01709539|Biomarkers
252342|NCT01709526|Psychosocial functioning
252343|NCT01709526|Cognitive performance of inpatients
252344|NCT01709526|Psychiatric diseases
252345|NCT01709487|HIPEC
252346|NCT01709487|ovarian carcinoma
252347|NCT01709487|Bordet
252348|NCT01709474|SLE
252349|NCT01709474|Vitamin D3
252350|NCT01709474|Vitamin D deficiency
252351|NCT01709474|IFN alpha expression
252352|NCT01708499|Ulthera® System
252353|NCT01708499|Ultherapy™ Treatment
252354|NCT01708499|Ulthera, Inc.
252355|NCT01708499|Ultrasound treatment for skin tightening
252356|NCT01708486|asthma
252357|NCT01708486|Dry Powder Inhalers
252358|NCT01708486|FSI-10 questionnaire
252359|NCT01708460|Ulthera® System
252360|NCT01708460|Ultherapy™ Treatment
252361|NCT01708460|Ulthera, Inc.
252362|NCT01708460|Ultrasound treatment for skin tightening
252363|NCT01708434|Skin laxity
252364|NCT01708434|Knees
252365|NCT01709448|Neoplasms, Squamous Cell
252366|NCT01709448|Papillomavirus Infections
252367|NCT01709448|HIV
252368|NCT01709422|Propofol
252369|NCT01709422|Midazolam
252370|NCT01709422|Meperidine
252371|NCT01709409|Prematurity
252372|NCT01709383|Aphasia
252373|NCT01709383|Stroke
252374|NCT01709383|Transcranial Direct Current Stimulation
252375|NCT01709383|Neuroplasticity
252376|NCT01709357|manual therapy
252377|NCT01709357|trigger point
252378|NCT01709357|range of motion
252379|NCT01709357|pain threshold
252380|NCT01709357|pain perception
252381|NCT01709292|Thyroid Cancer
252382|NCT01709292|ERK
252383|NCT01709292|Extracellular-signal-regulated kinase
252384|NCT01709292|Biomarkers
252385|NCT01709292|Papillary thyroid cancer
252386|NCT01709292|PTC
252387|NCT01709292|BRAF mutated
252388|NCT01709292|Vemurafenib
252389|NCT01709292|PLX4032
252390|NCT01709292|RO5185426
252391|NCT01709292|Zelboraf™
252392|NCT01709279|Ischemic heart failure
252393|NCT01709279|Myocardial regeneration
252394|NCT01709279|ADRC
252395|NCT01709253|hpofractionation study using proton beam therapy
252396|NCT01709240|Chitosan
252397|NCT01709240|Plasma
252398|NCT01709240|Incision Closure
252399|NCT01709227|Acute kidney injury
252400|NCT01709227|AKI
252401|NCT01709227|cardiopulmonary bypass
252402|NCT01709214|Osteoarthritis
252403|NCT01709214|Knee
252404|NCT01709214|Pain
252405|NCT01709214|Chronic
252406|NCT01709214|OA
252407|NCT01709214|Arthritis
252408|NCT01709201|Alcohol abuse
252409|NCT01709201|Drug abuse
252410|NCT01709201|Diabetes Mellitus
252411|NCT01709201|Persistent Asthma
252412|NCT01709201|Juvenile Arthritis
252413|NCT01709201|Ulcerative Colitis
252414|NCT01709188|Musical Dual Task Training
252415|NCT01709188|dementia
252416|NCT01709188|attention control
252417|NCT01709188|dual task cost
252418|NCT01709188|gait stability
252419|NCT01709175|Cancer
252420|NCT01709175|Breast Cancer
252421|NCT01709175|Gynecologic Cancer
252422|NCT01709175|Strength Training
252423|NCT01709175|Exercise
252424|NCT01709175|Physical Activity
252425|NCT01709175|Fatigue
252426|NCT01709175|Quality of Life
252427|NCT01709175|Strength
252428|NCT01709175|Fitness
252429|NCT01709175|Cancer Survivor
252430|NCT01709175|Survivor
252431|NCT01709123|Diabetes Mellitus, Juvenile Onset
252432|NCT01709123|Cardiovascular Diseases
252433|NCT01709123|Hyperglycemia
252434|NCT01709123|Hyperketonemia
252435|NCT01709110|Bone Loss
252436|NCT01709110|Vertebral fractures
252437|NCT01709097|Adherence
252438|NCT01709097|Compliance
252439|NCT01709097|Kidney Transplant Recipient
252440|NCT01709097|An electronic drug dispenser
252441|NCT01709097|The Portal
252442|NCT01709084|Human immunodeficiency virus-type 1 infection
252443|NCT01709084|HIV-1
252444|NCT01709084|Infectious diseases
252445|NCT01709084|Ribonucleic acid
252446|NCT01709084|RNA
252447|NCT01709084|Tenofovir disoproxil fumarate
252448|NCT01709084|Emtricitabine
252449|NCT01709084|Rilpivirine
252450|NCT01709084|Efavirenz
252451|NCT01709084|Edurant
252452|NCT01709084|TMC278
252453|NCT01709084|R278474
252454|NCT01709084|Fixed dose combination
252455|NCT01709071|Vaccination
252456|NCT01709071|Inactivated poliomyelitis vaccine
252457|NCT01709071|poliomyelitis
252458|NCT01709071|Sabin strains
252459|NCT01709058|Back Pain
252460|NCT01709058|Therapeutics
252461|NCT01709058|Aged
252462|NCT01709058|Injections, Intramuscular
252463|NCT01709058|Oxygen
252464|NCT01709058|Ozone
252465|NCT01709058|Geriatric Assessment
252466|NCT01709058|Trace Elements
252467|NCT01709058|Oxidative stress
252468|NCT01709045|Endarterectomy, Carotid
252469|NCT01709045|Carotid Arteries
252470|NCT01709032|Thalassemia
252471|NCT01709032|Chelation
252472|NCT01709032|Transfusion
252473|NCT01709032|Safety
252474|NCT01709006|Head and neck cancer
252475|NCT01708980|Arthroplasty, Replacement, Knee
252476|NCT01708980|Electromyography
252477|NCT01708980|Resistance training
252478|NCT01708980|Physical Therapy Modalities
252479|NCT01708967|transnasal endoscopy
252480|NCT01708967|pretreatment method
252481|NCT01708954|erlotinib
252482|NCT01708954|cabozantinib
252483|NCT01708954|non-small cell lung cancer
252484|NCT01708928|Ulthera® System
252485|NCT01708928|Ultherapy™ Treatment
252486|NCT01708928|Ulthera, Inc.
252487|NCT01708928|Ultrasound treatment for skin tightening
252488|NCT01708876|uncomplicated
252489|NCT01708876|plasmodium
252490|NCT01708876|knowlesi
252491|NCT01708876|malaria
252492|NCT01708876|infection
252493|NCT01708863|Hypoplastic Left Heart Syndrome
252494|NCT01708863|Stage II palliative surgery
252495|NCT01708863|Glenn procedure
252496|NCT01708863|Congenital heart defect
252497|NCT01708863|Congenital heart disease
252498|NCT01708863|Underdeveloped left ventricle
252499|NCT01708837|Postoperative Cognitive Dysfunction
252500|NCT01708837|Bispectral index
252501|NCT01708824|colorectal cancer
252502|NCT01708824|cancer survivor
252503|NCT01708824|western pattern diet
252504|NCT01708824|physical activity
252505|NCT01708824|behavioral intervention
252506|NCT01708824|acceptability
252507|NCT01708824|feasibility
252508|NCT01708824|randomized controlled trial
252509|NCT01708824|compliance
252510|NCT01708811|Contractility
252511|NCT01708811|human
252512|NCT01708811|myometrium
252513|NCT01708811|hyponatraemia
252514|NCT01708798|Diastolic heart failure
252515|NCT01708785|obesity
252516|NCT01708785|overweight
252517|NCT01708785|overweight children
252518|NCT01708785|overweight parents
252519|NCT01708785|overeating
252520|NCT01708785|eating in the absence of hunger
252521|NCT01708785|families with overweight child
252522|NCT01708785|body mass index
252523|NCT01708785|BMI
252524|NCT01708785|weight
252525|NCT01708785|childhood obesity
252526|NCT01708785|treatment
252527|NCT01708785|cue exposure treatment
252528|NCT01708785|cravings
252529|NCT01708785|habituation to food cues
252530|NCT01708785|psychophysiological response to food cues
252531|NCT01708785|intervention
252532|NCT01708785|experiments
252533|NCT01708785|family based treatment
252534|NCT01708785|behavioral treatment
252535|NCT01708772|TNF alpha
252536|NCT01708772|SOFA score
252537|NCT01708759|Serum Il-8
252538|NCT01708759|IL8 polymorphism
252539|NCT01708759|critically ill patients
252540|NCT01708733|HCV carrier
252541|NCT01708733|Chinese herbal medicine
252542|NCT01708733|Liver function
252543|NCT01708733|HCV RNA titer
252544|NCT01708720|Vaccination
252545|NCT01708720|Inactivated Poliomyelitis Vaccine
252546|NCT01708720|Polio
252547|NCT01708720|Sabin
252548|NCT01708681|Seafood
252549|NCT01708681|Meat
252550|NCT01708681|Egg
252551|NCT01708681|Milk
252552|NCT01708681|Postprandial lipid metabolism
252553|NCT01708681|Postprandial glucose metabolism
252554|NCT01708681|Triglycerides
252555|NCT01708681|Cholesterol
252556|NCT01708681|Postprandial incretins
252557|NCT01708681|Postprandial hormones
252558|NCT01708668|Fever
252559|NCT01708668|Patient controlled epidural analgesia
252560|NCT01708668|Labor analgesia
252561|NCT01708668|Epidural analgesia
252562|NCT01708668|Combined spinal-epidural analgesia
252563|NCT01708655|Cystic Fibrosis
252564|NCT01708655|Sweat Evaporimeter
252565|NCT01708629|psoriasis, brodalumab, AMG 827
252566|NCT01708603|psoriasis, brodalumab, AMG 827
252567|NCT01708590|psoriasis, brodalumab (AMG 827)
252568|NCT01708577|heart rate
252569|NCT01708577|sweating
252570|NCT01708577|respiration
252571|NCT01708577|acceleration of body movement
252572|NCT01708577|heart activity.
252573|NCT01708551|Hyperhidrosis
252574|NCT01708551|Axillary sweating
252575|NCT01708551|Ulthera® System
252576|NCT01708551|Ultherapy™ Treatment
252577|NCT01708551|Ulthera, Inc.
252578|NCT01708538|keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia
252579|NCT01708525|Ulthera® System
252580|NCT01708525|Ultherapy® Treatment
252581|NCT01708525|Ulthera, Inc.
252582|NCT01708525|Ultrasound treatment for skin tightening
252583|NCT01708512|Ulthera® System
252584|NCT01708512|Ultherapy™ Treatment
252585|NCT01708512|Ulthera, Inc.
252586|NCT01708512|Ultrasound treatment for skin tightening
252587|NCT01708408|biorepository
252588|NCT01708408|biobank
252589|NCT01708408|registry
252590|NCT01708408|community
252591|NCT01708408|biospecimens
252592|NCT01708408|volunteers
252593|NCT01708408|chronic disease
252594|NCT01708408|longitudinal
252595|NCT01708408|blood
252596|NCT01708408|electronic health records
252597|NCT01708408|follow-up
252598|NCT01708395|Ulcerative colitis
252599|NCT01708382|Ulthera® System
252600|NCT01708382|Ultherapy™ Treatment
252601|NCT01708382|Ulthera, Inc.
252602|NCT01708382|Ultrasound treatment for skin tightening
252603|NCT01708369|human carboxylesterase-1
252604|NCT01708369|human carboxylesterase-2
252605|NCT01708369|alcohol
252606|NCT01708369|pharmacokinetics
252607|NCT01708356|Air Pollution
252608|NCT01708356|Particulate Matter
252609|NCT01708356|Exercise
252610|NCT01708356|Respiratory Rate
252611|NCT01708356|Inflammation
252612|NCT01708356|Oxidative Stress
252613|NCT01708356|Plethysmography
252614|NCT01708343|Myofascial Pain Syndrome,
252615|NCT01708343|intramuscular stimulation,
252616|NCT01708343|acupuncture,
252617|NCT01708343|sleep quality,
252618|NCT01708343|pain threshold.
252619|NCT01708330|manual vacuum aspiration
252620|NCT01708330|missed abortion
252621|NCT01708330|incomplete abortion
252622|NCT01708330|nonviable pregnancy
252623|NCT01708330|topical lidocaine
252624|NCT01708317|ACASI
252625|NCT01708317|Gonorrhea
252626|NCT01708317|Chlamydia
252627|NCT01708317|Emergency Department
252628|NCT01708317|Youth
252629|NCT01708317|Adolescents
252630|NCT01708317|Computer
252631|NCT01708317|Questionnaire
252632|NCT01708304|Dementia
252633|NCT01708304|Alzheimer's Disease
252634|NCT01708304|Exercise
252635|NCT01708304|Caregiver
252636|NCT01708304|Behavior modification
252637|NCT01708291|youth
252638|NCT01708291|Stress
252639|NCT01708291|mindfulness
252640|NCT01708291|foster care
252641|NCT01708291|stress reduction
252642|NCT01708291|high risk teens
252643|NCT01708278|COPD
252644|NCT01708278|Emphysema
252645|NCT01708278|chronic bronchitis
252646|NCT01708278|Quercetin
252647|NCT01708278|flavonoids
252648|NCT01708265|Mitral Valve Insufficiency
252649|NCT01708265|Mitral Valve Regurgitation
252650|NCT01708265|Asymptomatic Mitral Valve Regurgitation
252651|NCT01708265|Asymptomatic Mitral Valve Insufficiency
252652|NCT01708265|Mitral Valve Repair
252653|NCT01708265|Watchful Waiting
252654|NCT01708252|Ulthera® System
252655|NCT01708252|Ultherapy™ Treatment
252656|NCT01708252|Ulthera, Inc.
252657|NCT01708252|Ultrasound treatment for skin tightening
252658|NCT01708239|Pregnancy
252659|NCT01708239|Deep vein thrombosis
252660|NCT01708239|Clinical probability
252661|NCT01708239|D-Dimer
252662|NCT01708239|Compression ultrasonography
252663|NCT01708226|OCD
252664|NCT01708226|obsessive compulsive disorder
252665|NCT01708226|children
252666|NCT01708213|soft tissue
252667|NCT01708213|augmentation
252668|NCT01708213|correction
252669|NCT01708213|wrinkles
252670|NCT01708200|Memory
252671|NCT01708200|Intervention
252672|NCT01708200|Computerized
252673|NCT01708200|Psychoeducational
252674|NCT01708200|Mental Illness
252675|NCT01708187|Peroneal tendon
252676|NCT01708174|medulloblastoma,
252677|NCT01708174|relapsed,
252678|NCT01708174|pediatric,
252679|NCT01708174|children,
252680|NCT01708174|adults,
252681|NCT01708174|Hh pathway inhibitor,
252682|NCT01708174|LDE225
252683|NCT01708161|PIK3CA mutation
252684|NCT01708161|advanced solid tumor
252685|NCT01708161|breast cancer
252686|NCT01708161|ovarian cancer
252687|NCT01708122|Intranasal fentanyl
252688|NCT01708122|Cystoscopy
252689|NCT01708070|asthma
252690|NCT01708070|depression
252691|NCT01708070|anxiety
252692|NCT01708057|COPD
252693|NCT01708057|Chronic obstructive pulmonary disease
252694|NCT01708044|Pramlintide,
252695|NCT01708044|insulin,
252696|NCT01708044|type 1 diabetes,
252697|NCT01708044|reduction in postprandial glucose,
252698|NCT01708044|pramlintide:insulin dose-ratio
252699|NCT01708018|Pregnancy
252700|NCT01708018|Stress, Psychological
252701|NCT01708018|Low Back Pain
252702|NCT01708018|Breech Presentation
252703|NCT01708018|Relaxation
252704|NCT01708018|Hydrotherapy
252705|NCT01708018|Acupressure
252706|NCT01708018|WATSU
252707|NCT01708005|Mild Cognitive Impairment
252708|NCT01708005|Vitamin D
252709|NCT01708005|Cholecalciferol
252710|NCT01708005|Lecitone®Se-Vitamin D3
252711|NCT01707979|Near infrared light
252712|NCT01707979|Diabetic neuropathy
252713|NCT01707979|Sensory neuropathy
252714|NCT01707979|Autonomic neuropathy
252715|NCT01707979|Vagus
252716|NCT01707979|Sudomotor function
252717|NCT01707979|Monofilament
252718|NCT01707979|Impedance
252719|NCT01707966|adenocarcinoma of the prostate
252720|NCT01707966|metastatic castration-resistant prostate cancer
252721|NCT01707966|maintenance therapy
252722|NCT01707966|orteronel
252723|NCT01707966|TAK-700
252724|NCT01707927|EOA
252725|NCT01707914|oxidative stress
252726|NCT01707914|dyslipidemia
252727|NCT01707914|inflammation
252728|NCT01707901|GERD
252729|NCT01707862|Intravenous leiomyomatosis
252730|NCT01707862|Surgery
252731|NCT01707862|Smooth muscle tumor
252732|NCT01707849|Hepatitis C
252733|NCT01707849|Liver Fibrosis
252734|NCT01707849|m-TOR inhibitors
252735|NCT01707810|Liver transplatation
252736|NCT01707797|dental caries
252737|NCT01707797|high risk
252738|NCT01707797|dental cavities
252739|NCT01707797|children dental care
252740|NCT01707784|Pregnancy
252741|NCT01707784|Stress
252742|NCT01707784|Anxiety
252743|NCT01707784|Cortisol
252744|NCT01707784|Copeptin
252745|NCT01707784|Gestational diabetes
252746|NCT01707758|pancreatic cancer
252747|NCT01707758|nanoparticle
252748|NCT01707758|proteases
252749|NCT01707758|cell survival
252750|NCT01707758|tumor progression
252751|NCT01707758|angiogenesis
252752|NCT01707758|tissue remodeling/invasion
252753|NCT01707732|Obesity
252754|NCT01707732|thromboprophylaxis
252755|NCT01707732|Enoxaparin
252756|NCT01707719|Alzheimer's disease
252757|NCT01707719|Oxidative stress
252758|NCT01707719|HPA axis
252759|NCT01707706|Insomnia
252760|NCT01707706|Depression
252761|NCT01707706|Electroacupuncture
252762|NCT01707706|Acupuncture
252763|NCT01707706|Randomized Clinical Trial
252764|NCT01707706|Traditional Chinese Medicine
252765|NCT01707693|physical activity
252766|NCT01707693|prevention
252767|NCT01707693|coronary heart disease
252768|NCT01707693|women
252769|NCT01707680|weaning
252770|NCT01707680|mechanical ventilation
252771|NCT01707680|dexmedetomidine
252772|NCT01707680|propofol
252773|NCT01707680|midazolam
252774|NCT01707654|defect;
252775|NCT01707654|dorsal branch of the proper digital nerve;
252776|NCT01707654|proper digital nerve;
252777|NCT01707654|finger sensory reconstruction.
252778|NCT01707628|NHL
252779|NCT01707628|influenza vaccination
252780|NCT01707628|rituximab
252781|NCT01707615|proanthocyanidin,atherosclerosis, carotid plaque
252782|NCT01707602|Intradermal
252783|NCT01707602|transcutaneous
252784|NCT01707602|influenza
252785|NCT01707602|routes of vaccination
252786|NCT01707602|T cell responses
252787|NCT01707602|humoral responses
252788|NCT01707602|skin
252789|NCT01707602|clinical trial
252790|NCT01707602|Novel application of influenza vaccine
252791|NCT01707602|Transcutaneous vaccination(hair follicular targeting)
252792|NCT01707602|Intradermal vaccination(micro-needle)
252793|NCT01707589|monitoring
252794|NCT01707589|heart rate
252795|NCT01707589|respiration rate
252796|NCT01707589|temperature
252797|NCT01707589|motion
252798|NCT01707589|noninvasive
252799|NCT01707589|physiologic parameters
252800|NCT01707589|NICU
252801|NCT01707576|Follow-Up Studies
252802|NCT01707576|Adolescent
252803|NCT01707576|Depressive Disorder, Major/diagnosis
252804|NCT01707576|Attempted/prevention & control
252805|NCT01707576|Self-report questionnaire
252806|NCT01707576|emmergency department
252807|NCT01707576|parental perception
252808|NCT01707576|Emergency
252809|NCT01707563|Marfan syndrome
252810|NCT01707563|Variability
252811|NCT01707563|Fibrillin 1
252812|NCT01707563|clinical expression
252813|NCT01707537|OCV
252814|NCT01707537|cholera
252815|NCT01707511|Arterial carbondioxide pressure
252816|NCT01707511|Colon surgery
252817|NCT01707511|End-tidal carbondioxide
252818|NCT01707511|Laparoscopic Trendelenburg
252819|NCT01707498|BCI
252820|NCT01707498|TETRAPLEGIA
252821|NCT01707498|COMMUNICATION
252822|NCT01707498|P300
252823|NCT01707498|ASSISTIVE TECHNOLOGIE
252824|NCT01707485|Antibiotics
252825|NCT01707472|Liver Fibrosis
252826|NCT01707472|Fibrosis
252827|NCT01707472|HIV
252828|NCT01707472|HCV
252829|NCT01707472|GS-6624
252830|NCT01707472|Hepatitis
252831|NCT01707472|Hepatitis C
252832|NCT01707459|platelet function
252833|NCT01707459|perioperative complications
252834|NCT01707459|major adverse cardiac events (MACE)
252835|NCT01707459|thromboelastography
252836|NCT01707459|polymorphism analysis
252837|NCT01707459|coronary stents
252838|NCT01707459|non-cardiac surgery
252839|NCT01707446|Cardiac surgery
252840|NCT01707446|Delirium
252841|NCT01707446|Cerebral Oximetry
252842|NCT01707433|spondyloepiphyseal dysplasia
252843|NCT01707433|multiple epiphyseal dysplasia
252844|NCT01707433|bilateral Legg Calve Perthes
252845|NCT01707433|bilateral proximal femoral epiphyseal dysplasia
252846|NCT01707433|GALNS
252847|NCT01707420|pediatric pain
252848|NCT01707420|post operative pain
252849|NCT01707420|opioids
252850|NCT01707420|emergence agitation
252851|NCT01707420|preoperative anxiety
252852|NCT01707420|pharmacogenomics
252853|NCT01707407|CC-4047
252854|NCT01707407|Pomalidomide
252855|NCT01707407|Ketoconazole
252856|NCT01707407|Fluvoxamine
252857|NCT01707407|Carbamazepine
252858|NCT01707407|DDI
252859|NCT01707407|safety
252860|NCT01707407|tolerability
252861|NCT01707407|pharmacokinetic
252862|NCT01707368|Psoriasis
252863|NCT01707368|Psoriasis vulgaris
252864|NCT01707368|Plaque Psoriasis
252865|NCT01707368|Daivobet® Gel
252866|NCT01707368|Germany
252867|NCT01707355|education, knowledge, poster, dental trauma
252868|NCT01707342|Healthy male participants
252869|NCT01707342|Absolute bioavailability
252870|NCT01707342|Bioavailability
252871|NCT01707342|Pharmacokinetics
252872|NCT01707342|Simeprevir
252873|NCT01707342|TMC435
252874|NCT01707342|[3H]-TMC435
252875|NCT01707342|Hepatitis C virus
252876|NCT01707342|HCV
252877|NCT01707316|Healthy
252878|NCT01707316|JNJ-28431754
252879|NCT01707316|Canagliflozin
252880|NCT01707316|Pharmacokinetics
252881|NCT01707316|Pharmacodynamics
252882|NCT01707303|ICU
252883|NCT01707303|Critical Care
252884|NCT01707303|Intensive Care
252885|NCT01707303|Critical Illness
252886|NCT01707303|Acute Respiratory Failure
252887|NCT01707303|Mechanical Ventilation
252888|NCT01707303|Physical Therapy
252889|NCT01707303|Strength
252890|NCT01707303|Functional Status
252891|NCT01707303|Short Physical Performance Battery
252892|NCT01707277|Heart failure with preserved ejection fraction
252893|NCT01707277|Inspiratory muscle training
252894|NCT01707277|Exercise capacity
252895|NCT01707264|AL amyloidosis
252896|NCT01707264|Primary amyloidosis
252897|NCT01707251|Obesity, Morbid
252898|NCT01707251|Bariatric Surgery
252899|NCT01707251|Laparoscopy
252900|NCT01707251|Intravenous Ibuprofen
252901|NCT01707251|Analgesia
252902|NCT01707251|Morphine
252903|NCT01707225|GI Bleeding
252904|NCT01707225|Gastrointestinal bleeding
252905|NCT01707225|LVAD
252906|NCT01707212|parent education
252907|NCT01707212|pain management
252908|NCT01707212|immunization
252909|NCT01707212|infant
252910|NCT01707199|P. falciparum
252911|NCT01707199|Sulphadoxine-pyrimethamine
252912|NCT01707199|Artesunate
252913|NCT01707199|Artemisinin Combination Therapy (ACT)
252914|NCT01707173|SIDS
252915|NCT01707121|morbidity
252916|NCT01707121|sick-leave
252917|NCT01707121|hospital stay
252918|NCT01707108|dental implants
252919|NCT01707108|bone loss
252920|NCT01707095|Electrosurgery
252921|NCT01707095|Radiofrequency energy
252922|NCT01707095|Monopolar instruments
252923|NCT01707095|Capacitive coupling
252924|NCT01707095|Thermal injury
252925|NCT01707095|Surgical complications
252926|NCT01707056|levothyroxine
252927|NCT01707056|synthroid
252928|NCT01707056|coffee
252929|NCT01707056|absorption
252930|NCT01707056|tea
252931|NCT01707056|thyroid carcinoma
252932|NCT01707043|plaque psoriasis
252933|NCT01707043|taclonex
252934|NCT01707043|crossover
252935|NCT01707030|clinical trial
252936|NCT01707030|veteran
252937|NCT01707030|substance use disorder
252938|NCT01706978|rotator cuff tear
252939|NCT01706952|Endoscopic sinus surgery
252940|NCT01706952|Bleeding
252941|NCT01706952|Topical Vasocontriction
252942|NCT01706952|Cocaine
252943|NCT01706952|Adrenaline
252944|NCT01706939|Reduced radiotherapy
252945|NCT01706939|Randomization, Phase III
252946|NCT01706939|Reduced radiation therapy
252947|NCT01706939|head and neck
252948|NCT01706939|oropharynx
252949|NCT01706939|unknown primary (cervical lymph nodes)
252950|NCT01706939|nasopharynx primary
252951|NCT01706939|HPV
252952|NCT01706939|p16
252953|NCT01706926|Rheumatoid Arthritis
252954|NCT01706926|Mavrilimumab
252955|NCT01706926|CAM-3001
252956|NCT01706887|Nedd4-2
252957|NCT01706887|blood pressure
252958|NCT01706887|polymorphism
252959|NCT01706887|salt intake
252960|NCT01706887|between 18 and 35 years old
252961|NCT01706887|BMI between 18 and 28 Kg per m2
252962|NCT01706887|no active disease
252963|NCT01706887|no alcool or drug abuse or smoke
252964|NCT01706874|Rheumatoid arthritis
252965|NCT01706874|P.gingivalis
252966|NCT01706874|Periodontal disease
252967|NCT01706874|Plaque control
252968|NCT01706874|Prophylaxis
252969|NCT01706874|Oral hygiene instruction
252970|NCT01706835|solid tumor
252971|NCT01706835|aldoxorubicin
252972|NCT01706835|phase 1
252973|NCT01706835|pharmacokinetic
252974|NCT01706835|INNO-206
252975|NCT01706796|Pain
252976|NCT01706744|Hospital Readmissions
252977|NCT01706744|Community Health Services
252978|NCT01706744|Preventive Health Services
252979|NCT01706744|Norway
252980|NCT01706731|Buddhist monks
252981|NCT01706731|CBT
252982|NCT01706731|elderly
252983|NCT01706731|depression
252984|NCT01706718|Beetroot
252985|NCT01706718|Blood pressure
252986|NCT01706718|Vascular function
252987|NCT01706705|Cervical Cancer
252988|NCT01706705|Radiation therapy
252989|NCT01706705|XRT
252990|NCT01706705|External beam therapy
252991|NCT01706705|Brachytherapy
252992|NCT01706705|Intracavitary brachytherapy
252993|NCT01706705|ICBT
252994|NCT01706705|MRI compatible intracavitary applicators
252995|NCT01706705|Computed tomography
252996|NCT01706705|CT
252997|NCT01706705|Magnetic resonance imaging
252998|NCT01706705|MRI
252999|NCT01706705|MRI compatible applicators
253000|NCT01706705|3D image guided treatment planning
253001|NCT01706705|2D treatment planning
253002|NCT01706692|Methotrexate
253003|NCT01706692|Acitretin
253004|NCT01706692|Cyclosporine A
253005|NCT01706692|Systemic PUVA
253006|NCT01706692|Infliximab
253007|NCT01706692|Adalimumab
253008|NCT01706692|Etanercept
253009|NCT01706692|Ustekinumab
253010|NCT01706692|Fumaric acids
253011|NCT01706692|Psoriasis
253012|NCT01706692|Psoriatic arthritis
253013|NCT01706692|Skin disease
253014|NCT01706679|Healthy volunteers
253015|NCT01706666|Maintenance
253016|NCT01706666|Consolidation
253017|NCT01706653|Polyphenol
253018|NCT01706653|Fruit
253019|NCT01706653|Metabolic
253020|NCT01706653|Healthy
253021|NCT01706627|cancer
253022|NCT01706627|melatonin
253023|NCT01706627|adjuvant therapy
253024|NCT01706627|quality of life
253025|NCT01706627|survival
253026|NCT01706627|adverse events
253027|NCT01706627|oxidative stress
253028|NCT01706588|diclofenac, postsurgical pain, oral surgery
253029|NCT01706562|Neutropenia
253030|NCT01706562|Hematologic malignancy
253031|NCT01706562|Itraconazole
253032|NCT01706562|Fungal infection
253033|NCT01706562|Antifungal agent
253034|NCT01706562|Neutropenic fever
253035|NCT01706549|Chronic pain
253036|NCT01706549|Hysterectomy
253037|NCT01706549|Quality of life
253038|NCT01706523|Autism Spectrum Disorders
253039|NCT01706523|Autism
253040|NCT01706523|Asperger
253041|NCT01706523|Pervasive Developmental Disorder - Not otherwise specified
253042|NCT01706510|Clopidogrel
253043|NCT01706510|Ticagrelor
253044|NCT01706510|Coronary Artery Disease
253045|NCT01706510|Myocardial Ischemia
253046|NCT01706510|Coronary Disease
253047|NCT01706510|Heart Diseases
253048|NCT01706510|Cardiovascular Diseases
253049|NCT01706510|Arteriosclerosis
253050|NCT01706510|Arterial Occlusive Diseases
253051|NCT01706510|Vascular Diseases
253052|NCT01706510|Platelet Aggregation Inhibitors
253053|NCT01706510|Hematologic Agents
253054|NCT01706510|Therapeutic Uses
253055|NCT01706510|Pharmacologic Actions
253056|NCT01706510|Purinergic P2Y Receptor Antagonists
253057|NCT01706510|Purinergic P2 Receptor Antagonists
253058|NCT01706510|Purinergic Antagonists
253059|NCT01706510|Purinergic Agents
253060|NCT01706510|Physiological Effects of Drugs
253061|NCT01706497|cerebral tissue oxygen saturation
253062|NCT01706497|congenital cardiac surgery
253063|NCT01706497|pediatric intensive care unit
253064|NCT01706497|Near Infra-Red Spectroscopy
253065|NCT01706497|early warning monitor
253066|NCT01706497|outcome prediction
253067|NCT01706484|randomized clinical trial
253068|NCT01706484|chronic rhinosinusitis
253069|NCT01706484|herbal extract BNO 1016
253070|NCT01706484|exacerbation
253071|NCT01706484|pharmacoeconomic
253072|NCT01706484|quality of life
253073|NCT01706471|verLowCNI
253074|NCT01706458|Vaccine
253075|NCT01706458|pTVG-HP
253076|NCT01706458|Prostate Cancer
253077|NCT01706458|Castrate Resistant
253078|NCT01706445|cystic fibrosis
253079|NCT01706445|exercise
253080|NCT01706445|children
253081|NCT01706445|cardiorespiratory fitness
253082|NCT01706445|muscle strength
253083|NCT01706445|pulmonary function
253084|NCT01706445|quality of life
253085|NCT01706419|vitamin A
253086|NCT01706419|iron
253087|NCT01706419|zinc
253088|NCT01706419|school children
253089|NCT01706419|fortified rice
253090|NCT01706419|morbidity
253091|NCT01706419|growth
253092|NCT01706406|female sexual arousal
253093|NCT01706406|female sexual desire
253094|NCT01706406|psychoeducational intervention
253095|NCT01706393|probiotics
253096|NCT01706393|intestinal microbiome
253097|NCT01706393|radiotherapy
253098|NCT01706380|Substance use disorders
253099|NCT01706380|Adolescents
253100|NCT01706380|Retention
253101|NCT01706380|Mobile telephone
253102|NCT01706380|Follow-up
253103|NCT01706380|Interactive voice response
253104|NCT01706367|Clostridium difficile
253105|NCT01706367|vaccine
253106|NCT01706354|end stage renal disease
253107|NCT01706354|vascular access
253108|NCT01706354|regional anaesthesia
253109|NCT01706341|cesarean section
253110|NCT01706341|intravenous fluid
253111|NCT01706341|a glucose-containing solution
253112|NCT01706341|fetal hypoglycemia
253113|NCT01706341|neonatal hypoglycemia
253114|NCT01706328|Vilanterol (VI)
253115|NCT01706328|Novel Dry Powder Inhaler (NDPI)
253116|NCT01706328|FEV1
253117|NCT01706328|Fluticasone Furoate (FF)
253118|NCT01706328|COPD
253119|NCT01706302|General Practice Research Database
253120|NCT01706302|Burden of Disease
253121|NCT01706302|Clinical Practice Research Datalink
253122|NCT01706302|Hospital Episode Statistics
253123|NCT01706302|Office of National Statistics
253124|NCT01706302|RSV
253125|NCT01706289|diabetes
253126|NCT01706289|cardiovascular autonomic neuropathy
253127|NCT01706289|VAP 1
253128|NCT01706237|Myopia
253129|NCT01706237|LASIK
253130|NCT01706224|Pertussis antibodies
253131|NCT01706224|Bordetella pertussis
253132|NCT01706224|sero-prevalence
253133|NCT01706224|Healthcare professionals (HCP)
253134|NCT01706224|Spain
253135|NCT01706211|non insulin dependent diabetes mellitus, rosiglitazone
253136|NCT01706198|respiratory
253137|NCT01706198|adult
253138|NCT01706198|asthma
253139|NCT01706185|Patients
253140|NCT01706185|Tumor antigens
253141|NCT01706185|Bladder cancer
253142|NCT01706172|TMD
253143|NCT01706172|temporomandibular
253144|NCT01706172|dextrose
253145|NCT01706172|prolotherapy
253146|NCT01706146|atrial fibrillation
253147|NCT01706146|reveal xt
253148|NCT01706146|oral anticoagulation
253149|NCT01706146|dabigatran
253150|NCT01706146|rivaroxaban
253151|NCT01706146|apixaban
253152|NCT01706133|Frailty, emergency services, elderly
253153|NCT01706120|prognostic factors
253154|NCT01706120|biologic factors
253155|NCT01706120|clinical factors
253156|NCT01706120|routine clinical practice
253157|NCT01706107|Quality of life
253158|NCT01706094|stroke
253159|NCT01706094|head position
253160|NCT01706081|acupuncture
253161|NCT01706068|acute ECG changes
253162|NCT01706068|acute illness of gallbladder
253163|NCT01706068|acute illness of biliary tract
253164|NCT01706055|Multiple Sclerosis (MS)
253165|NCT01706055|Interferon
253166|NCT01706003|Migraine
253167|NCT01706003|Headaches
253168|NCT01706003|Telemedicine
253169|NCT01705990|HIV
253170|NCT01705990|AIDS
253171|NCT01705990|HIV vaccine
253172|NCT01705990|HIV prevention
253173|NCT01705977|Antibodies
253174|NCT01705977|Lupus
253175|NCT01705977|SLE
253176|NCT01705977|Systemic Lupus Erythematosus
253177|NCT01705977|Autoimmune Disease
253178|NCT01705977|Belimumab
253179|NCT01705964|Status asthmaticus
253180|NCT01705964|Asthma exacerbation
253181|NCT01705964|Epinephrine
253182|NCT01705964|Adjunctive therapy
253183|NCT01705951|Smoking
253184|NCT01705951|Insulin resistance
253185|NCT01705951|Metabolic Syndrome
253186|NCT01705951|Endothelial Function
253187|NCT01705951|Smoking Cessation
253188|NCT01705951|Resistance Training
253189|NCT01705951|Nicotine Replacement
253190|NCT01705951|Exercise
253191|NCT01705951|Cardiovascular Disease
253192|NCT01705951|Arterial Stiffness
253193|NCT01705951|Body Composition
253194|NCT01705912|fall
253195|NCT01705912|prevention
253196|NCT01705899|Type 1 Diabetes
253197|NCT01705899|Islet transplant
253198|NCT01705899|Kidney transplant
253199|NCT01705886|Osteoarthritis
253200|NCT01705886|Joint Disease
253201|NCT01705886|Arthritis
253202|NCT01705886|Musculoskeletal Disease
253203|NCT01705873|HIV
253204|NCT01705873|cardiovascular
253205|NCT01705873|risk
253206|NCT01705873|mortality
253207|NCT01705860|Collagen, collagenase, scar
253208|NCT01705847|chronic lymphocytic leukemia (CLL)
253209|NCT01705847|non-Hodgkin lymphoma (NHL)
253210|NCT01705847|Hodgkin lymphoma (HL)
253211|NCT01705847|indolent non-Hodgkin lymphoma (iNHL)
253212|NCT01705847|diffuse large B-cell lymphoma-activated B-cell (DLBCL-ABC)
253213|NCT01705847|DLBCL-germinal center B-cell (GCB)
253214|NCT01705847|mantle cell lymphoma (MCL)
253215|NCT01705847|GS-9820
253216|NCT01705847|phosphatidylinositol 3-kinase (PI3K)
253217|NCT01705834|Arthritis
253218|NCT01705834|Stiffness
253219|NCT01705834|Range of movement
253220|NCT01705834|Goniometry
253221|NCT01705834|Digital
253222|NCT01705834|Dataglove
253223|NCT01705834|Outcome
253224|NCT01705821|Skull base
253225|NCT01705821|Pituitary
253226|NCT01705821|Robotics
253227|NCT01705821|Endonasal surgery
253228|NCT01705821|Sinus surgery
253229|NCT01705769|treatment
253230|NCT01705769|severe acute malnutrition
253231|NCT01705756|Colchicine
253232|NCT01705756|Anakinra
253233|NCT01705756|FMF
253234|NCT01705756|Colchicine resistance
253235|NCT01705743|anaesthesia
253236|NCT01705743|middle aged
253237|NCT01705743|minimal alveolar concentration
253238|NCT01705743|sevoflurane
253239|NCT01705743|nitrous oxide
253240|NCT01705743|isoelectric EEG
253241|NCT01705678|Males
253242|NCT01705678|Metabolic syndrome
253243|NCT01705678|Otherwise healthy
253244|NCT01705652|nexrutine
253245|NCT01705652|prostate cancer
253246|NCT01705639|diabetes
253247|NCT01705639|melatonin
253248|NCT01705639|glucose tolerance
253249|NCT01705639|sleep
253250|NCT01705626|Peripheral Nervous System Diseases
253251|NCT01705626|Neuromuscular Diseases
253252|NCT01705626|Nervous System Diseases
253253|NCT01705626|Metabolism, Inborn Errors
253254|NCT01705626|Genetic Diseases, Inborn
253255|NCT01705613|Attention Deficit/Hyperactivity Disorder
253256|NCT01705613|ADHD
253257|NCT01705613|Methylphenidate Immediate-release
253258|NCT01705613|Cost-effectiveness
253259|NCT01705613|Cost-utility
253260|NCT01705613|QALYs
253261|NCT01705600|Central Sensitization
253262|NCT01705600|Low Back Pain
253263|NCT01705600|Pain
253264|NCT01705600|Pain Catastrophizing
253265|NCT01705600|Brence
253266|NCT01705587|osteoporosis
253267|NCT01705587|atypical femoral fractures
253268|NCT01705587|prior bisphosphonate treatment
253269|NCT01705587|postmenopausal women
253270|NCT01705587|bone loss
253271|NCT01705574|HIV-1
253272|NCT01705574|HIV
253273|NCT01705574|Treatment-Naive
253274|NCT01705574|Women
253275|NCT01705574|WAVES
253276|NCT01705561|fertility
253277|NCT01705561|chemotherapy
253278|NCT01705561|breast cancer
253279|NCT01705561|latin american women
253280|NCT01705561|pre menopausal
253281|NCT01705548|Brain metastasis
253282|NCT01705535|Fecal incontinence
253283|NCT01705535|Pelvic floor muscle exercises
253284|NCT01705535|Physiotherapy
253285|NCT01705522|IBD
253286|NCT01705522|ulcerative colitis
253287|NCT01705522|Crohn's disease
253288|NCT01705522|NAFLD
253289|NCT01705522|biomarkers
253290|NCT01705522|vitamin D
253291|NCT01705509|The Effects of Ranolazine on CPET Parameters in Ischemic
253292|NCT01705509|Cardiomyopathy Patients
253293|NCT01705496|Phase II
253294|NCT01705496|FIAU
253295|NCT01705496|Fialuridine
253296|NCT01705496|Prosthetic
253297|NCT01705496|Joint
253298|NCT01705496|Infection
253299|NCT01705496|PET-CT
253300|NCT01705483|ASP9853
253301|NCT01705483|Docetaxel
253302|NCT01705483|Paclitaxel
253303|NCT01705470|Furosemide
253304|NCT01705470|Anemia
253305|NCT01705470|LV dysfunction
253306|NCT01705470|blood transfusion
253307|NCT01705457|multiple sclerosis
253308|NCT01705457|Vitamin A
253309|NCT01705457|retinoic acid receptor
253310|NCT01705457|retinoic x receptor
253311|NCT01705444|Urinary retention
253312|NCT01705444|Foley catheter
253313|NCT01705444|The Spanner
253314|NCT01705444|Quality of life
253315|NCT01705431|Emotional Disturbance
253316|NCT01705431|Behavioral Disturbance
253317|NCT01705431|EBD
253318|NCT01705431|Middle School
253319|NCT01705431|Special Education
253320|NCT01705431|School Psychology
253321|NCT01705418|Parkinson disease
253322|NCT01705418|Deep brain stimulation
253323|NCT01705418|behavior and psychiatric symptoms improvement
253324|NCT01705405|cancer
253325|NCT01705405|prostate
253326|NCT01705379|Neisseria meningitidis, conjugate vaccine, phase IV clinical trial
253327|NCT01705366|Osteoarthritis
253328|NCT01705366|Joint Disease
253329|NCT01705366|Arthritis
253330|NCT01705366|Musculoskeletal Disease
253331|NCT01705353|Stroke
253332|NCT01705353|Cerebrovascular Accident
253333|NCT01705353|HMGB-1
253334|NCT01705353|cytokines
253335|NCT01705353|functional recovery
253336|NCT01705353|inflammation
253337|NCT01705353|immune response
253338|NCT01705327|Parkinson's
253339|NCT01705327|Biomarkers
253340|NCT01705327|Neurodegenerative disorder
253341|NCT01705314|human influenza children
253342|NCT01705288|laparotomy
253343|NCT01705288|hysterectomy
253344|NCT01705262|compliance
253345|NCT01705262|Bowel preparations
253346|NCT01705262|Moviprep
253347|NCT01705262|Phosphoral
253348|NCT01705223|prophylactic
253349|NCT01705223|vaccine
253350|NCT01705184|Stop and go
253351|NCT01705184|Non-small cell lung cancer
253352|NCT01705184|Non-squamous
253353|NCT01705184|Bevacizumab
253354|NCT01705171|IBS
253355|NCT01705171|fructose intolerance
253356|NCT01705171|GLUT 5
253357|NCT01705171|GLUT 2
253358|NCT01705158|ovarian cancer in relapse
253359|NCT01705158|sensitive in platin
253360|NCT01705145|Cystic Fibrosis
253361|NCT01705119|Mechanically Ventilated
253362|NCT01705119|Critical Care
253363|NCT01705093|strawberry, cardiovascular, obesity, adolescent
253364|NCT01705080|Renal Denervation
253365|NCT01705080|Renal artery
253366|NCT01705067|Osteoarthritis, Degenerative Knee Disease, TKA
253367|NCT01705054|Angina
253368|NCT01705054|Stable ischemic heart disease
253369|NCT01705054|Quality of Life
253370|NCT01705054|Seattle Angina Questionnaire (SAQ)
253371|NCT01705015|exercise
253372|NCT01705002|phase 1
253373|NCT01705002|dose escalating
253374|NCT01705002|prodrug
253375|NCT01705002|mitomycin C
253376|NCT01705002|Capecitabine
253377|NCT01704989|Glaucoma, SLT
253378|NCT01704963|Recurrent mature B-cell neoplasms
253379|NCT01704963|B-cell malignancies
253380|NCT01704963|Bruton's Tyrosine Kinase (Btk) Inhibitor
253381|NCT01704963|PCI-32765
253382|NCT01704963|Tumor
253383|NCT01704963|Pharmacokinetics
253384|NCT01704963|Japanese
253385|NCT01704937|Fecal Microbiota Transplant
253386|NCT01704937|Clostridium difficile
253387|NCT01704937|Diarrhea
253388|NCT01704924|Prevena
253389|NCT01704924|negative pressure wound therapy
253390|NCT01704924|Incisional wound vac
253391|NCT01704911|Transradial
253392|NCT01704911|Transfemoral
253393|NCT01704911|Coronary Intervention
253394|NCT01704898|efavirenz
253395|NCT01704898|bioequivalence
253396|NCT01704898|fasting
253397|NCT01704898|healthy volunteers
253398|NCT01704885|Childhood Cancer
253399|NCT01704885|Sibling Play intervention
253400|NCT01704885|Sibling Behavioral Intervention
253401|NCT01704885|Siblings of Cancer Patients
253402|NCT01704872|Neuroblastoma
253403|NCT01704872|Refractory neuroblastoma
253404|NCT01704872|ch14.18/CHO
253405|NCT01704859|fracture
253406|NCT01704833|Psychosis
253407|NCT01704833|Paranoia
253408|NCT01704833|Cognitive Behavioral Therapy
253409|NCT01704833|Delusions
253410|NCT01704833|Group Therapy
253411|NCT01704820|Colon Polyps
253412|NCT01704820|Colon Cancer screening
253413|NCT01704820|Colonoscopy
253414|NCT01704807|Low Back Pain
253415|NCT01704807|Chronic
253416|NCT01704807|Orthotic Device
253417|NCT01704807|Applied Kinesiology
253418|NCT01704807|Manual Muscle Testing
253419|NCT01704807|Chiropractic
253420|NCT01704794|Sickle Cell Anemia
253421|NCT01704794|Quality of Life
253422|NCT01704794|Antioxidant
253423|NCT01704794|Anti inflammatory
253424|NCT01704794|Sorghum bicolor
253425|NCT01704781|CD4
253426|NCT01704781|Clinical trial
253427|NCT01704781|Dose escalation assessment lenalidomide
253428|NCT01704781|Human immunodeficiency virus-1 (HIV-1)
253429|NCT01704781|HIV
253430|NCT01704781|Immunomodulatory
253431|NCT01704781|Infection
253432|NCT01704781|Lenalidomide
253433|NCT01704781|Phase I/II
253434|NCT01704781|Vaccine
253435|NCT01704781|Vacc-4x
253436|NCT01704768|Randomized Controlled Trial
253437|NCT01704768|School-Based Intervention
253438|NCT01704755|Cirrhosis
253439|NCT01704755|Hepatitis C
253440|NCT01704755|Child Pugh A
253441|NCT01704755|Compensated Cirrhosis
253442|NCT01704755|Hepatitis C Genotype 1
253443|NCT01704755|Cirrhotic
253444|NCT01704755|Chronic Hepatitis C
253445|NCT01704755|Hepatitis C Virus
253446|NCT01704755|ombitasvir
253447|NCT01704755|paritaprevir
253448|NCT01704755|dasabuvir
253449|NCT01704755|Interferon-Free
253450|NCT01704755|Viekira Pak
253451|NCT01704742|Non-Hodgkin's Lymphoma
253452|NCT01704742|Hodgkin's Lymphoma
253453|NCT01704742|Kenya
253454|NCT01704742|Epstein Barr Virus (EBV)
253455|NCT01704742|Human Immunodeficiency Virus (HIV)
253456|NCT01704742|Kaposi's Sarcoma Herpes Virus (KSHV)
253457|NCT01704729|Myopia
253458|NCT01704729|Focus groups
253459|NCT01704729|refraction
253460|NCT01704729|Glasses
253461|NCT01704729|spectacles
253462|NCT01704716|neuroblastoma
253463|NCT01704716|immunotherapy
253464|NCT01704716|MAT
253465|NCT01704716|antibody treatment
253466|NCT01704703|colorectal cancer
253467|NCT01704703|FOLFIRI
253468|NCT01704703|Panitumumab
253469|NCT01704703|KRAS, PIK3Ca,BRAF and NRAS genes
253470|NCT01704703|highly sensitive techniques
253471|NCT01704690|Esophageal cancer
253472|NCT01704690|Chemotherapy
253473|NCT01704690|Efficacy
253474|NCT01704690|Toxicity
253475|NCT01704677|Chronic low back pain
253476|NCT01704677|Degenerated disc
253477|NCT01704677|Total disc replacement
253478|NCT01704677|Multidisciplinary rehabilitation
253479|NCT01704677|Long term results
253480|NCT01704664|malnutrition,
253481|NCT01704664|perioperative artificial nutrition,
253482|NCT01704664|immunonutrition,
253483|NCT01704664|gastrectomy,
253484|NCT01704664|lymphocytes,
253485|NCT01704664|interleukin,
253486|NCT01704664|blood platelets,
253487|NCT01704664|phagocytic and bactericidal activity of blood platelets
253488|NCT01704651|Ovary
253489|NCT01704651|Ovarian
253490|NCT01704651|Fallopian
253491|NCT01704651|Peritoneal
253492|NCT01704651|Cancer
253493|NCT01704651|Gynecological
253494|NCT01704651|Female
253495|NCT01704625|pain
253496|NCT01704625|headache
253497|NCT01704612|local anesthetic
253498|NCT01704612|sciatic
253499|NCT01704612|diabetes
253500|NCT01704612|block
253501|NCT01704612|duration
253502|NCT01704599|Psoriasis
253503|NCT01704599|Adalimumab
253504|NCT01704599|B vitamins
253505|NCT01704599|Homocysteine
253506|NCT01704599|Folic acid
253507|NCT01704599|Cyanocobalamin
253508|NCT01704599|Pyridoxine
253509|NCT01704599|Vitamin B6
253510|NCT01704599|Vitamin B9
253511|NCT01704599|Vitamin B12
253512|NCT01704586|Differentiated thyroid carcinoma
253513|NCT01704586|PET/CT
253514|NCT01704586|Radioiodine Remnant Ablation
253515|NCT01704586|I-124
253516|NCT01704586|Quality of life
253517|NCT01704573|PET Scan
253518|NCT01704547|Breast cancer
253519|NCT01704547|Lumpectomy
253520|NCT01704547|Breast Irradiation
253521|NCT01704534|Hidradenitis suppurativa
253522|NCT01704534|Acne ectopica
253523|NCT01704534|Inverse acne
253524|NCT01704534|Ustekinumab
253525|NCT01704534|Stelara
253526|NCT01704521|Hepatitis C
253527|NCT01704521|HCV
253528|NCT01704521|Hemophilia
253529|NCT01704508|Falciparum malaria
253530|NCT01704508|children
253531|NCT01704508|treatment
253532|NCT01704495|Uncontrolled Asthma,
253533|NCT01704495|Exacerbation,
253534|NCT01704495|Safety
253535|NCT01704469|Opioid induced hyperalgesia
253536|NCT01704456|provoked vestibulodynia
253537|NCT01704456|dyspareunia
253538|NCT01704456|vulvodynia
253539|NCT01704456|mindfulness
253540|NCT01704456|cognitive behavioural therapy
253541|NCT01704443|provoked vestibulodynia
253542|NCT01704443|dyspareunia
253543|NCT01704443|vulvodynia
253544|NCT01704443|mindfulness
253545|NCT01704443|cognitive behavioural therapy
253546|NCT01704430|Cardiac surgery
253547|NCT01704430|Cardiac bypass
253548|NCT01704430|Intensive Care
253549|NCT01704430|Nosocomial infection
253550|NCT01704430|Glutamine
253551|NCT01704430|Randomized trial
253552|NCT01704404|Long acting muscarinic antagonist
253553|NCT01704404|Chronic Bronchitis
253554|NCT01704404|Emphysema
253555|NCT01704404|Chronic Obstructive Pulmonary Disease
253556|NCT01704404|COPD
253557|NCT01704352|Cognitive Behavioral Therapy
253558|NCT01704352|CBT-I
253559|NCT01704339|End stage renal failure
253560|NCT01704339|Neuropathic pain
253561|NCT01704339|Critical digital ischaemia
253562|NCT01704326|Deuce
253563|NCT01704326|Journey Deuce
253564|NCT01704326|Knee pain
253565|NCT01704326|Osteoarthritis
253566|NCT01704326|Bicompartmental
253567|NCT01704326|Femoral
253568|NCT01704326|Medial
253569|NCT01704313|Vascular access
253570|NCT01704313|Haemodialysis
253571|NCT01704313|Suturing technique
253572|NCT01704300|Abdominal aortic aneurysm
253573|NCT01704300|Acute Myocardial Infarction
253574|NCT01704300|Coronary heart disease not otherwise specified
253575|NCT01704300|Haemorrhagic stroke
253576|NCT01704300|Heart failure
253577|NCT01704300|Ischaemic stroke
253578|NCT01704300|Peripheral arterial disease
253579|NCT01704300|Stable angina
253580|NCT01704300|Unheralded coronary death
253581|NCT01704300|Unstable angina
253582|NCT01704300|Ventricular arrhythmias, cardiac arrest and sudden cardiac death
253583|NCT01704300|Transient Ischemic Attack
253584|NCT01704287|PD-1
253585|NCT01704287|PD1
253586|NCT01704287|PD-L1
253587|NCT01704287|PDL1
253588|NCT01704274|biochemical
253589|NCT01704274|recurrence
253590|NCT01704274|prostate
253591|NCT01704274|cancer
253592|NCT01704274|active
253593|NCT01704274|surveillence
253594|NCT01704248|eye drops self-instillation
253595|NCT01704235|screening
253596|NCT01704222|Children
253597|NCT01704222|nursery
253598|NCT01704222|CMV
253599|NCT01704222|Infection
253600|NCT01704183|relapse-remitting multiple sclerosis
253601|NCT01704183|heart rate variability
253602|NCT01704183|fingolimod
253603|NCT01704183|cardiac autonomic regulation
253604|NCT01704157|Osteoarthritis
253605|NCT01704157|knee
253606|NCT01704157|chronic pain
253607|NCT01704144|Efavirenz
253608|NCT01704144|rifampin
253609|NCT01704144|Pharmacokinetics
253610|NCT01704144|Drug-drug interactions
253611|NCT01704144|Drug-gene interactions
253612|NCT01704144|Children
253613|NCT01704131|Levosimendan
253614|NCT01704131|Children
253615|NCT01704131|Pharmacokinetics
253616|NCT01704118|I-gel
253617|NCT01704118|ProSeal laryngeal mask
253618|NCT01704118|small infants
253619|NCT01704118|neonates
253620|NCT01704105|Chlorine water treatment
253621|NCT01704105|Point-of-use water treatment
253622|NCT01704105|Household water treatment with safe storage
253623|NCT01704105|Handwashing with soap
253624|NCT01704105|Hand hygiene
253625|NCT01704105|Latrines
253626|NCT01704105|Water
253627|NCT01704105|Sanitation
253628|NCT01704105|Handwashing
253629|NCT01704105|Breast Feeding
253630|NCT01704105|Complementary Feeding
253631|NCT01704105|Micronutrients
253632|NCT01704105|Malnutrition
253633|NCT01704105|Nutrition Disorders
253634|NCT01704105|Diarrhea
253635|NCT01704105|Child Development
253636|NCT01704105|Child potties
253637|NCT01704105|Point-of-use fortification
253638|NCT01704105|Lipid-based nutrient supplement
253639|NCT01704105|Exclusive breastfeeding
253640|NCT01704105|Environmental enteropathy
253641|NCT01704105|Tropical enteropathy
253642|NCT01704105|Gut function
253643|NCT01704105|Intestinal parasitic infection
253644|NCT01704105|Soil transmitted helminths
253645|NCT01704105|Intestinal protozoans
253646|NCT01704105|Antibody response
253647|NCT01704079|Parathyroid Diseases
253648|NCT01704079|Renal Insufficiency
253649|NCT01704079|Kidney Failure, Chronic
253650|NCT01704079|Hyperparathyroidism, Secondary
253651|NCT01704079|Vitamin D
253652|NCT01704079|Hyperparathyroidism
253653|NCT01704079|Kidney Diseases
253654|NCT01704079|Kidney Failure
253655|NCT01704079|Renal Insufficiency, Chronic
253656|NCT01704066|ARDS
253657|NCT01704066|Chest radiograph
253658|NCT01704066|Berlin Definition
253659|NCT01704066|Inter-observer agreement
253660|NCT01704053|New Oral Anticoagulants
253661|NCT01704053|Dabigatran
253662|NCT01704053|Rivaroxaban
253663|NCT01704053|Thrombelastometry/-graphy (ROTEM, TEG)
253664|NCT01704053|Multiple Platelet Function Analyzer (Multiplate)
253665|NCT01704040|Healthy volunteers and asthma
253666|NCT01704040|CNTO 3157
253667|NCT01704040|Rhinovirus
253668|NCT01704027|Localized
253669|NCT01704027|High risk
253670|NCT01704014|occurrence of
253671|NCT01704001|ART-123
253672|NCT01704001|Disseminated Intravascular Coagulation
253673|NCT01704001|Pharmacokinetics
253674|NCT01703988|Spinal Muscular Atrophy
253675|NCT01703988|SMA
253676|NCT01703988|SMN
253677|NCT01703988|SMNRx
253678|NCT01703988|ISIS-SMNRx
253679|NCT01703988|ISIS 396443
253680|NCT01703975|Simulation efficiency
253681|NCT01703975|Collaborative learning
253682|NCT01703962|Glioma
253683|NCT01703962|IDH1
253684|NCT01703962|Spectroscopy
253685|NCT01703962|Plasma
253686|NCT01703936|economic intervention
253687|NCT01703936|ex-combatant
253688|NCT01703936|agriculture
253689|NCT01703936|life skills
253690|NCT01703910|Genomic expression profile in tumor samples
253691|NCT01703910|Adult patients
253692|NCT01703910|metastatic disease status and progression after two lines of systemic therapy
253693|NCT01703897|gastric by-pass surgery
253694|NCT01703884|Malria diagnosis
253695|NCT01703884|Malaria prevention in pregnancy
253696|NCT01703884|ANC services improvement
253697|NCT01702883|prescriptions
253698|NCT01702883|hypertension
253699|NCT01702883|high cholesterol
253700|NCT01702883|diabetes
253701|NCT01702883|depression
253702|NCT01702883|adherence
253703|NCT01702870|Magnetic resonance imaging
253704|NCT01702857|Dengue
253705|NCT01702857|Dengue fever
253706|NCT01702857|Dengue Hemorrhagic Fever
253707|NCT01702857|Flavivirus
253708|NCT01702844|Nab paclitaxel
253709|NCT01702844|Abraxane
253710|NCT01702844|First Line
253711|NCT01702844|Non small cell lung cancer
253712|NCT01702844|NSCLC
253713|NCT01702844|Phase II
253714|NCT01702844|Non-Randomized
253715|NCT01702844|Elderly
253716|NCT01702844|Lineberger
253717|NCT01702844|UNC
253718|NCT01702844|LCCC 1210
253719|NCT01702831|Newly Diagnosed multiple myeloma
253720|NCT01702818|Hypoactive Sexual Desire Disorder
253721|NCT01702818|HSDD
253722|NCT01702818|Cortisol
253723|NCT01702818|DHEA
253724|NCT01702818|Stress Hormones
253725|NCT01702818|Sexual Desire
253726|NCT01702818|Mood
253727|NCT01702818|Sexual Function
253728|NCT01702818|Childhood Maltreatment
253729|NCT01702818|Childhood Abuse
253730|NCT01702805|NICHD Neonatal Research Network
253731|NCT01702805|Very Low Birth Weight (VLBW)
253732|NCT01702805|Extremely Low Birth Weight (ELBW)
253733|NCT01702805|Transfusions
253734|NCT01702792|Immunotherapy, cancer vaccine, glioblastoma, hybridoma
253735|NCT01702779|Weaning from mechanical ventilation
253736|NCT01702779|Lung ultrasound
253737|NCT01702779|Oxygen inhalation therapy
253738|NCT01702740|Cutaneous lupus erythematosus
253739|NCT01702740|Systemic lupus erythematosus
253740|NCT01702740|Lupus erythematosus
253741|NCT01702740|Human anti-IL 6 monoclonal antibody
253742|NCT01702740|Sirukumab
253743|NCT01702727|Amblyopia
253744|NCT01702727|I-BiT TM
253745|NCT01702727|Interactive games
253746|NCT01702727|Binocular
253747|NCT01702675|Safety
253748|NCT01702675|Pharmacokinetics
253749|NCT01702675|Tolerability
253750|NCT01702675|Healthy men
253751|NCT01703832|acute stress reaction
253752|NCT01703832|stress
253753|NCT01703832|stress perception
253754|NCT01703832|physiological stress response
253755|NCT01703832|Neurexan
253756|NCT01703819|acute stress reaction
253757|NCT01703819|stress
253758|NCT01703819|stress perception
253759|NCT01703819|physiological stress response
253760|NCT01703819|Neurexan
253761|NCT01703806|Mitral regurgitation
253762|NCT01703806|Mitral valve repair
253763|NCT01703806|Watchful waiting
253764|NCT01703767|patient satisfaction
253765|NCT01703767|Gulf War 1 Veteran
253766|NCT01703767|Desert Storm Veteran
253767|NCT01703754|Genetically Modified Organism
253768|NCT01703754|Metastatic Breast Cancer
253769|NCT01703754|Recurrent Breast Cancer
253770|NCT01703754|Breast Cancer
253771|NCT01703754|Palifosfamide
253772|NCT01703754|INXN1001
253773|NCT01703754|INXN2001
253774|NCT01703754|Adenoviral vector
253775|NCT01703715|Hydration
253776|NCT01703715|Elderly patients
253777|NCT01703715|Age 65 years and over
253778|NCT01703715|Admitted acutely to medical admissions ward
253779|NCT01703689|Quality indicators
253780|NCT01703689|quality of care
253781|NCT01703689|nursing home
253782|NCT01703689|long-term care unit
253783|NCT01703689|nursing home organisation
253784|NCT01703689|nursing home structure
253785|NCT01703689|disability
253786|NCT01703689|dependence
253787|NCT01703689|functional decline
253788|NCT01703689|functional impairment
253789|NCT01703689|older adults
253790|NCT01703689|elderly
253791|NCT01703689|audit and feedback
253792|NCT01703689|cooperative work
253793|NCT01703689|geriatrician
253794|NCT01703689|medication
253795|NCT01703689|hospitalisation
253796|NCT01703689|comorbidity
253797|NCT01703676|Hypogonadism, Klinefelter Syndrome, Cardiovascular Risk, Epigenetics, Methylation of Genes
253798|NCT01703676|Cardiovascular risk factors
253799|NCT01703676|Gonadal status
253800|NCT01703676|Gene expression
253801|NCT01703676|Methylation
253802|NCT01703663|Stroke
253803|NCT01703663|Sleep Apnea
253804|NCT01703650|CT
253805|NCT01703650|pancreas adenocarcinoma
253806|NCT01703650|RECIST
253807|NCT01703650|perfusion
253808|NCT01703637|Sitagliptin
253809|NCT01703637|Vildagliptin
253810|NCT01703637|Saxagliptin
253811|NCT01703637|Diabetes Mellitus, Type 2
253812|NCT01703624|glycopyrronium bromide
253813|NCT01703624|glycopyrrolate
253814|NCT01703624|oral inhalation
253815|NCT01703624|COPD
253816|NCT01703624|chronic obstructive pulmonary disease
253817|NCT01703624|lung function
253818|NCT01703624|pharmacokinetics
253819|NCT01703624|tolerability
253820|NCT01703624|safety
253821|NCT01703624|cross-over
253822|NCT01703624|single-dose
253823|NCT01703624|dose-ranging
253824|NCT01703611|Nutrition
253825|NCT01703611|Medical Nutrition Therapy
253826|NCT01703611|Diabetes Mellitus
253827|NCT01703611|Nutrition outcomes
253828|NCT01703611|Evidence Based Guidelines
253829|NCT01703598|Parkinson's disease
253830|NCT01703598|Deep Brain Stimulation
253831|NCT01703585|genomic analysis
253832|NCT01703585|genome
253833|NCT01703585|tumor
253834|NCT01703585|tissue
253835|NCT01703585|archival
253836|NCT01703585|biopsy
253837|NCT01703585|core needle
253838|NCT01703585|fine needle
253839|NCT01703585|DNA
253840|NCT01703585|gene
253841|NCT01703585|expression
253842|NCT01703585|sequencing
253843|NCT01703572|Phase 1
253844|NCT01703572|Dose escalation
253845|NCT01703572|relapsed or refractory
253846|NCT01703572|lymphoid malignancies
253847|NCT01703559|Glare
253848|NCT01703559|Starburst
253849|NCT01703559|Halos
253850|NCT01703559|Reduced contrast sensitivity
253851|NCT01703546|Morbid Obesity
253852|NCT01703546|Weight Loss Surgery
253853|NCT01703546|Laparoscopic Adjustable Gastric Band
253854|NCT01703546|Laparoscopic Gastric Plication
253855|NCT01703546|Imbrication
253856|NCT01703533|Autism
253857|NCT01703533|Rett's Syndrome
253858|NCT01703533|Rett Disorder
253859|NCT01703533|Rett's Disorder
253860|NCT01703533|Ataxia
253861|NCT01703520|Males breast cancer
253862|NCT01703520|Finasteride
253863|NCT01703520|PROSCAR®
253864|NCT01703520|PROPECIA®
253865|NCT01703494|C. difficile
253866|NCT01703494|fecal transplant
253867|NCT01703494|stool transplant
253868|NCT01703494|fecal flora reconstitution
253869|NCT01703494|fecal microbiota transplant
253870|NCT01703494|FMT
253871|NCT01703481|Tumor
253872|NCT01703481|Fibroblast Growth Factor Receptor (FGFR)
253873|NCT01703481|Non-Small Cell Lung Cancer (NSCLC)
253874|NCT01703481|Small Cell Lung Cancer (SCLC)
253875|NCT01703481|JNJ-42756493
253876|NCT01703455|Salivary gland cancer metastatic disease recurrent disease clinical trial
253877|NCT01703429|Multiple Sclerosis
253878|NCT01703429|MS
253879|NCT01703429|Complementary and Alternative
253880|NCT01703429|CAM
253881|NCT01703416|COPD
253882|NCT01703416|GOLD group C and D
253883|NCT01703416|CDLM questionnaire
253884|NCT01703416|visual scale - physician evaluation
253885|NCT01703403|physical therapy
253886|NCT01703403|treated at NTUH and received rehabilitation at the PTC in recent ten years.
253887|NCT01703390|metastatic colorectal cancer
253888|NCT01703390|mCRC
253889|NCT01703390|ERCC-1
253890|NCT01703390|ERCC1
253891|NCT01703390|AGMT
253892|NCT01703364|CLL
253893|NCT01703364|Lenalidomide
253894|NCT01703364|Revlimid
253895|NCT01703364|AGMT
253896|NCT01703364|T cell
253897|NCT01703351|pain control, VATS
253898|NCT01703338|assessment model
253899|NCT01703338|biomechanical changes
253900|NCT01703338|functional activities
253901|NCT01703338|magnetic resonance imaging (MRI)
253902|NCT01703338|causal relationship
253903|NCT01703338|core muscles activation pattern
253904|NCT01703338|pathological changes
253905|NCT01703338|early rehabilitation
253906|NCT01703338|core stability exercise
253907|NCT01703338|minimally invasive lumbar spinal fusion surgery
253908|NCT01703325|Psoriatic nails
253909|NCT01703325|Triamcinolone injection
253910|NCT01703325|clobetasol propionate
253911|NCT01703312|Allergies, asthma, IgE
253912|NCT01703299|imipenem
253913|NCT01703299|ertapenem
253914|NCT01703299|resistance
253915|NCT01703299|commensal flora
253916|NCT01703273|Extreme Obesity Keywords: obesity, adiposity, psychosocial, healthcare, co-morbidities, low key intervention, quality of life
253917|NCT01703260|Drug therapy
253918|NCT01703247|Arrhythmias
253919|NCT01703247|Ablation
253920|NCT01703234|FGF-23 , ramipril, endothelial dysfunction
253921|NCT01703195|Vaginal Cancer
253922|NCT01703195|Malignancies involving the vagina
253923|NCT01703195|Middle third and the distal third of the vagina
253924|NCT01703195|Pre and post radiation therapy
253925|NCT01703195|Diffusion weighted magnetic resonance imaging
253926|NCT01703195|DWMR
253927|NCT01703195|Magnetic resonance imaging
253928|NCT01703195|MRI
253929|NCT01703195|Tumor involvement
253930|NCT01703195|Response to radiation therapy
253931|NCT01703195|XRT
253932|NCT01703182|transcutaneous oximetry
253933|NCT01703182|transcutaneous carbon dioxide
253934|NCT01703182|leg amputation
253935|NCT01703182|wound healing failure
253936|NCT01703182|amputation revision
253937|NCT01703169|severe aplastic anemia
253938|NCT01703169|very severe aplastic anemia
253939|NCT01703169|moderate aplastic anemia
253940|NCT01703169|bleeding
253941|NCT01703156|Low Risk ACS, Acute Coronary Syndrome, Stress Testing, Non-Stress Testing
253942|NCT01703130|ISPB
253943|NCT01703130|Brachial Plexus Block
253944|NCT01703130|Anesthesia
253945|NCT01703130|Pain Management
253946|NCT01703130|Surgery
253947|NCT01703117|Alzheimer's Disease
253948|NCT01703117|Dementia
253949|NCT01703104|Sorghum bicolor
253950|NCT01703104|sickle cell anaemia
253951|NCT01703104|haematological parameters
253952|NCT01703065|Prostate cancer
253953|NCT01703065|Bone metastases
253954|NCT01703039|Major Depression
253955|NCT01703039|Major Depressive Disorder
253956|NCT01703039|Depression
253957|NCT01703039|Riluzole
253958|NCT01703039|Glutamate
253959|NCT01703039|Sertraline
253960|NCT01703013|Demonstrate that DEFA4 is a reliable biomarker for the prediction of adrenal insufficiency
253961|NCT01703000|drug eluting coronary stent
253962|NCT01702987|ubiquinol (coenzyme Q10)
253963|NCT01702974|HIV
253964|NCT01702974|cholecalciferol
253965|NCT01702974|sodium phenylbutyrate
253966|NCT01702974|antimicrobial peptides
253967|NCT01702974|immune response
253968|NCT01702974|inflammation
253969|NCT01702961|Lymphoma
253970|NCT01702961|Hodgkin's Disease
253971|NCT01702948|Functional Magnetic Resonance Imaging (fMRI)
253972|NCT01702948|Nicotine
253973|NCT01702948|Repetitive TMS (rTMS)
253974|NCT01702948|fMRI
253975|NCT01702935|Ovarian Failure
253976|NCT01702935|Premature Ovarian Failure
253977|NCT01702935|Infertility
253978|NCT01702935|Primary Ovarian Insufficiency
253979|NCT01702935|Stem Cells
253980|NCT01702922|Stress
253981|NCT01702922|Marriage
253982|NCT01702922|Dyadic Coping
253983|NCT01702922|Mother
253984|NCT01702922|Father
253985|NCT01702909|Metastatic Renal Cell
253986|NCT01702909|Metastatic Kidney Cancer
253987|NCT01702896|Metastatic Melanoma
253988|NCT01702636|Intracerebral Hemorrhage
253989|NCT01702636|ICH
253990|NCT01702636|Stroke
253991|NCT01702636|Cerebrovascular Disorders
253992|NCT01702636|Brain Diseases
253993|NCT01702636|Central Nervous System Diseases
253994|NCT01702636|Nervous System Diseases
253995|NCT01702636|Vascular Diseases
253996|NCT01702636|Cardiovascular Diseases
253997|NCT01702636|Tranexamic Acid
253998|NCT01702636|Antifibrinolytic Agents
253999|NCT01702636|Fibrin Modulating Agents
254000|NCT01702636|Pharmacologic Actions
254001|NCT01702636|Cardiovascular Agents
254002|NCT01702636|Therapeutic Uses
254003|NCT01702636|Hematologic Agents
254004|NCT01702636|Hemostatics
254005|NCT01702636|Contrast Media
254006|NCT01702636|Angiography
254007|NCT01702636|Cerebral Angiography
254008|NCT01702636|Tomography, X-Ray Computed
254009|NCT01702584|stent
254010|NCT01702584|intracranial aneurysm
254011|NCT01702584|embolization
254012|NCT01702584|adverse event
254013|NCT01702532|provoked craving
254014|NCT01702506|Dacomitinib
254015|NCT01702506|PF-00299804
254016|NCT01702506|fed
254017|NCT01702506|fasted
254018|NCT01702506|antacid
254019|NCT01702506|relative Bioavailability
254020|NCT01702493|SRT2104
254021|NCT01702493|Modified Release
254022|NCT01702493|Bioavailability
254023|NCT01702493|Crossover
254024|NCT01702480|Consumer Healthcare
254025|NCT01702480|Ketones
254026|NCT01702480|Medium Chain Triglycerides
254027|NCT01702480|Age related cognitive decline
254028|NCT01702480|GSK Nutrition
254029|NCT01702467|Lp-PLA2
254030|NCT01702467|Alzheimer's disease
254031|NCT01702454|GSK Biologicals quadrivalent influenza vaccine
254032|NCT01702454|Influenza
254033|NCT01702454|Children
254034|NCT01702454|Safety
254035|NCT01702454|Immunogenicity
254036|NCT01702428|Safety
254037|NCT01702428|Consistency study
254038|NCT01702428|Measles, mumps and rubella diseases
254039|NCT01702428|Healthy children
254040|NCT01702428|Immunogenicity
254041|NCT01702415|Cystic fibrosis
254042|NCT01702415|Bone density
254043|NCT01702402|intervention
254044|NCT01702389|opioid induced hyperalgesia
254045|NCT01702389|Pain
254046|NCT01702389|Postoperative pain
254047|NCT01702389|Hyperalgesia
254048|NCT01702363|Chronic Obstructive Pulmonary Disease (COPD), GSK573719, Pharmacogenetics
254049|NCT01702350|Healthy Subjects
254050|NCT01702350|Relative Bioavailability
254051|NCT01702350|Pharmacokinetics
254052|NCT01702350|Elderly Subjects
254053|NCT01702337|Gardasil
254054|NCT01702337|Prevalence-model
254055|NCT01702337|Cervarix
254056|NCT01702337|economic
254057|NCT01702337|health
254058|NCT01702324|Psoriasis Vulgaris
254059|NCT01702324|Plaque
254060|NCT01702324|Topical
254061|NCT01702324|Treatment
254062|NCT01702311|Diabetes
254063|NCT01702311|Point of care testing
254064|NCT01702311|Hypoglycemia
254065|NCT01702311|Basal bolus insulin
254066|NCT01702285|Advanced Solid Tumors
254067|NCT01702285|EGFR
254068|NCT01702285|HDAC
254069|NCT01702285|Her2
254070|NCT01702285|Open-Label
254071|NCT01702285|Dose-Escalation
254072|NCT01702246|sickle cell disease
254073|NCT01702246|statins
254074|NCT01702246|vaso-occlusive pain
254075|NCT01702246|inflammation
254076|NCT01702246|biomarkers
254077|NCT01702220|Generalized Anxiety Disorder
254078|NCT01702220|Geriatric
254079|NCT01702207|Prograf®
254080|NCT01702207|Advagraf®
254081|NCT01702207|tacrolimus
254082|NCT01702207|kidney transplant
254083|NCT01702207|renal transplant
254084|NCT01702207|cardiovascular risk
254085|NCT01702207|Framingham Risk
254086|NCT01702207|Reynolds Risk
254087|NCT01702207|immunosuppression
254088|NCT01702194|OIC
254089|NCT01702194|Opioid Induced Constipation
254090|NCT01702194|Constipation
254091|NCT01702181|Atopic Dermatitis, Eczema
254092|NCT01702168|PTSD
254093|NCT01702168|EBT
254094|NCT01702168|EST
254095|NCT01702168|Community
254096|NCT01702168|Latino
254097|NCT01702142|Addiction Treatment
254098|NCT01702129|EGFR
254099|NCT01702129|liposomes
254100|NCT01702129|immunoliposomes
254101|NCT01702116|rectal adenocarcinoma
254102|NCT01702116|Standard APR
254103|NCT01702116|Extralevator APR
254104|NCT01702090|HIV-1
254105|NCT01702090|TMC114
254106|NCT01702090|Darunavir
254107|NCT01702090|PREZISTA
254108|NCT01702090|Ritonavir
254109|NCT01702090|Antiretrovirals
254110|NCT01702090|Early access
254111|NCT01702090|Early treatment
254112|NCT01702090|Treatment naive
254113|NCT01702077|neurofeedback
254114|NCT01702077|biofeedback
254115|NCT01702077|real-time fMRI
254116|NCT01702077|rt-fMRI
254117|NCT01702077|functional connectivity
254118|NCT01702077|fMRI
254119|NCT01702064|CML
254120|NCT01702064|CP-CML
254121|NCT01702064|Chronic Phase-CML (CP-CML)
254122|NCT01702064|chronic myeloid leukemia
254123|NCT01702051|Pancreatogenic diabetes
254124|NCT01702051|Autologou Islet Transplantation
254125|NCT01702051|Pancreas
254126|NCT01702051|Pancreatectomy
254127|NCT01702025|Hypoxia
254128|NCT01702025|Altitude
254129|NCT01702025|Exercise
254130|NCT01702012|Diabetes-Obesity
254131|NCT01701999|Botulism Vaccine
254132|NCT01701986|Lymphoma
254133|NCT01701986|Aggressive lymphomas
254134|NCT01701986|Allogeneic stem-cell transplant
254135|NCT01701986|alloSCT
254136|NCT01701986|Refractory B-cell
254137|NCT01701986|T-cell
254138|NCT01701986|Non-Hodgkin's lymphoma
254139|NCT01701986|Hodgkin's lymphoma
254140|NCT01701986|Gemcitabine
254141|NCT01701986|Gemcitabine Hydrochloride
254142|NCT01701986|Gemzar
254143|NCT01701986|Clofarabine
254144|NCT01701986|Clofarex
254145|NCT01701986|Clolar
254146|NCT01701986|Busulfan
254147|NCT01701986|Busulfex
254148|NCT01701986|Myleran
254149|NCT01701986|Anti-Thymocyte Globulin
254150|NCT01701986|ATG
254151|NCT01701986|Thymoglobulin
254152|NCT01701986|Rituximab
254153|NCT01701986|Rituxan
254154|NCT01701986|Filgrastim
254155|NCT01701986|G-CSF
254156|NCT01701986|Neupogen
254157|NCT01701986|Tacrolimus
254158|NCT01701986|Prograf
254159|NCT01701986|Mycophenolate Mofetil
254160|NCT01701986|MMF
254161|NCT01701986|CellCept
254162|NCT01701973|obesity
254163|NCT01701973|growth hormone
254164|NCT01701947|Factor XI deficiency
254165|NCT01701947|EAP
254166|NCT01701947|postpartum hemorrhage
254167|NCT01701947|surgery
254168|NCT01701947|delivery
254169|NCT01701947|Child birth
254170|NCT01701934|COPD
254171|NCT01701934|Intrabdominal adiposity
254172|NCT01701934|Body composition
254173|NCT01701934|Triglycerides
254174|NCT01701934|Cholesterol
254175|NCT01701921|cardiac surgery
254176|NCT01701921|pregabalin
254177|NCT01701921|postoperative pain
254178|NCT01701908|PPCs
254179|NCT01701908|abdominal surgery
254180|NCT01701908|postoperative infections
254181|NCT01701908|postoperative residual curarization
254182|NCT01701908|tracheal re-intubation
254183|NCT01701908|mortality
254184|NCT01701908|ICU stay
254185|NCT01701895|Complera
254186|NCT01701895|short-term
254187|NCT01701895|long-term
254188|NCT01701895|compliance
254189|NCT01701895|caloric
254190|NCT01701895|intake
254191|NCT01701895|HIV
254192|NCT01701895|positive
254193|NCT01701895|women
254194|NCT01701856|relapsing-remitting multiple sclerosis
254195|NCT01701856|natalizumab
254196|NCT01701856|de-escalation
254197|NCT01701856|interferon beta-1b
254198|NCT01701830|omentin-1
254199|NCT01701830|carotid atherosclerosis
254200|NCT01701830|kidney disease
254201|NCT01701817|Atrial Fibrillation
254202|NCT01701817|Irregular heart beat
254203|NCT01701804|Failed Back Surgery Syndrome
254204|NCT01701791|Depression
254205|NCT01701791|Primary care
254206|NCT01701791|Computerized decision support system
254207|NCT01701791|General practitioner
254208|NCT01701778|Dexmedetomidine
254209|NCT01701778|Postoperative pain reaction
254210|NCT01701778|anesthesia
254211|NCT01701778|children
254212|NCT01701765|Severe mental disorders
254213|NCT01701765|Discharge
254214|NCT01701765|Outcome evaluation
254215|NCT01701752|Influenza A
254216|NCT01701726|Essential Hypertension
254217|NCT01701726|Acupuncture
254218|NCT01701726|Specificity
254219|NCT01701726|Acupoints effect
254220|NCT01701726|randomized controlled trials
254221|NCT01701713|TDCS
254222|NCT01701713|STROKE
254223|NCT01701713|APHASIA
254224|NCT01701713|NAMING
254225|NCT01701700|portable electronic magnifiers
254226|NCT01701687|Cirrhosis
254227|NCT01701687|Alcoholic liver disease
254228|NCT01701687|Decompensated liver cirrhosis
254229|NCT01701687|Hazardous alcohol
254230|NCT01701674|skin cancer
254231|NCT01701661|venous surgery
254232|NCT01701661|compression therapy
254233|NCT01701648|Vitiligo, amniotic membrane, malanocytes, C02 laser.
254234|NCT01701635|Disclosure
254235|NCT01701635|HIV-infected children
254236|NCT01701635|Resource-limited settings
254237|NCT01701622|Blood Pressure
254238|NCT01701622|Gout
254239|NCT01701622|allopurinol
254240|NCT01701622|febuxostat
254241|NCT01701622|uric acid
254242|NCT01701609|early-onset schizophrenia
254243|NCT01701609|adolescents
254244|NCT01701609|cognition
254245|NCT01701609|cognitive remediation therapy
254246|NCT01701596|Rotational atherectomy
254247|NCT01701596|Coronary dissection
254248|NCT01701596|Percutaneous coronary intervention
254249|NCT01701596|Calcification
254250|NCT01701583|Chronic Idiopathic Urticaria
254251|NCT01701583|CIU
254252|NCT01701583|Urticaria
254253|NCT01701583|Chronic Hives
254254|NCT01701583|Xolair
254255|NCT01701570|Type 2 Diabetes
254256|NCT01701570|Exercise
254257|NCT01701570|Rate of Perceived Exertion
254258|NCT01701557|Ketoacidosis Fluids
254259|NCT01701518|Ozurdex
254260|NCT01701518|Dexamethasone
254261|NCT01701518|Epiretinal membrane
254262|NCT01701518|Macular edema
254263|NCT01701505|operative
254264|NCT01701505|dental procedure
254265|NCT01701492|pediatric
254266|NCT01701492|hematopoietic stem cell transplantation
254267|NCT01701492|allogeneic bone marrow transplantation
254268|NCT01701479|Neuroblastoma
254269|NCT01701479|Refractory neuroblastoma
254270|NCT01701479|Relapsed neuroblastoma
254271|NCT01701479|ch14.18/CHO
254272|NCT01701479|Aldesleukin (IL-2)
254273|NCT01701466|Patients
254274|NCT01701466|with
254275|NCT01701453|duration of DAPT
254276|NCT01701427|Hyperalgesia
254277|NCT01701427|Persistent pain
254278|NCT01701427|deep pain
254279|NCT01701427|electrical stimulation
254280|NCT01701427|groin hernia
254281|NCT01701414|Femur
254282|NCT01701414|Hip
254283|NCT01701414|Fracture
254284|NCT01701414|Femoral neck
254285|NCT01701414|Femoral head
254286|NCT01701401|HCV genotype 1 (GT-1)
254287|NCT01701401|HCV
254288|NCT01701401|Sustained Virologic Response
254289|NCT01701401|Direct Acting Antiviral
254290|NCT01701401|Combination Therapy
254291|NCT01701401|GS-7977
254292|NCT01701401|GS-5885
254293|NCT01701401|Ribavirin
254294|NCT01701401|Open Label
254295|NCT01701401|Sofosbuvir
254296|NCT01701401|Additional relevant MeSH terms:
254297|NCT01701401|Hepatitis
254298|NCT01701401|Hepatitis, Chronic
254299|NCT01701401|Hepatitis C
254300|NCT01701401|Hepatitis C, Chronic
254301|NCT01701401|Liver Diseases
254302|NCT01701401|Digestive System Diseases
254303|NCT01701401|Hepatitis, Viral, Human
254304|NCT01701401|Virus Diseases
254305|NCT01701401|Enterovirus Infections
254306|NCT01701401|Picornaviridae Infections
254307|NCT01701401|RNA Virus Infections
254308|NCT01701401|Flaviviridae Infections
254309|NCT01701401|Antiviral Agents
254310|NCT01701401|Anti-Infective Agents
254311|NCT01701401|Therapeutic Uses
254312|NCT01701401|Pharmacologic Actions
254313|NCT01701401|Antimetabolites
254314|NCT01701401|Molecular Mechanisms of Pharmacological Action
254315|NCT01701388|Ekso
254316|NCT01701388|Exoskeleton
254317|NCT01701388|Spinal Cord Injury
254318|NCT01701388|Motor Complete Incomplete
254319|NCT01701362|post-traumatic peripheral neuropathic pain
254320|NCT01701349|ATC
254321|NCT01701349|Anaplastic Thyroid Cancer
254322|NCT01701349|Stage IVC Anaplastic Thyroid Cancer
254323|NCT01701349|Thyroid Cancer
254324|NCT01701349|Head and Neck Tumors
254325|NCT01701336|Hepatitis
254326|NCT01701336|Hepatitis C
254327|NCT01701336|HCV
254328|NCT01701336|vaccine
254329|NCT01701336|adenovirus
254330|NCT01701336|MVA
254331|NCT01701336|T cells
254332|NCT01701336|ELISpot
254333|NCT01701310|Adenocarcinoma
254334|NCT01701310|Anemia
254335|NCT01701310|Blood Transfusion
254336|NCT01701310|Colorectal surgery
254337|NCT01701310|Preoperative care
254338|NCT01701310|Perioperative care
254339|NCT01701310|Postoperative care
254340|NCT01701310|Iron
254341|NCT01701310|Hematinics
254342|NCT01701310|Hepcidin
254343|NCT01701310|Quality of life
254344|NCT01701310|Postoperative complications
254345|NCT01701297|Cirrhosis, ascites, infection
254346|NCT01701284|repetitive Transcranial Magnetic Stimulation
254347|NCT01701284|Cancer Survivors
254348|NCT01701284|Depression
254349|NCT01701284|Anxiety
254350|NCT01701271|Baldness
254351|NCT01701271|Androgenetic Alopecia
254352|NCT01701271|Alopecia
254353|NCT01701258|Depression
254354|NCT01701258|Childhood Sexual Abuse
254355|NCT01701258|Dopamine
254356|NCT01701258|MRI
254357|NCT01701258|PET
254358|NCT01701258|ERP
254359|NCT01701258|Stress
254360|NCT01701258|Reward
254361|NCT01701258|Childhood trauma
254362|NCT01701245|vagus nerve stimulation
254363|NCT01701245|vagal nerve stimulation
254364|NCT01701245|nVNS
254365|NCT01701245|VNS
254366|NCT01701245|cluster headache
254367|NCT01701245|chronic
254368|NCT01701245|non invasive
254369|NCT01701245|gammacore
254370|NCT01701232|lymphoma, non-Hodgkin's
254371|NCT01701219|Staphylococcus aureus bacteremia
254372|NCT01701219|Methicillin-resistant Staphylococcus aureus bacteremia
254373|NCT01701219|MRSA bacteremia
254374|NCT01701219|Blood
254375|NCT01701219|Adult
254376|NCT01701219|Infections
254377|NCT01701219|Blood Culture
254378|NCT01701206|HIV
254379|NCT01701206|social networking
254380|NCT01701206|at-risk populations
254381|NCT01701206|sexual risk behaviors
254382|NCT01701180|Male Volunteers
254383|NCT01701154|Pompe respiratory
254384|NCT01701141|Positron Emission Tomography (PET)
254385|NCT01701141|Magnetic resonance imaging (MRI)
254386|NCT01701141|reward
254387|NCT01701141|stress
254388|NCT01701141|learning
254389|NCT01701141|Major Depressive Disorder
254390|NCT01701141|Anhedonia
254391|NCT01701128|Physical activity, treadmill training, rehabilitation
254392|NCT01701115|Interscalene Block
254393|NCT01701076|Relapsed / refractory multiple myeloma
254394|NCT01701076|2nd line treatment
254395|NCT01701050|circulating tumor cells
254396|NCT01701050|CTC
254397|NCT01701050|metastatic breast cancer
254398|NCT01701050|endocrine therapy
254399|NCT01701050|hormone therapy
254400|NCT01701037|Melanoma, B-RAF, biomarkers, targeted therapy, resistance
254401|NCT01701024|Acne
254402|NCT01701011|coping
254403|NCT01701011|intervention
254404|NCT01701011|waiting-period
254405|NCT01700985|psoriasis
254406|NCT01700985|plaque psoriasis
254407|NCT01700985|122-0551
254408|NCT01700985|steroid
254409|NCT01700959|Melatonin
254410|NCT01700959|Neurocognitive impairment
254411|NCT01700959|Sleep disturbance
254412|NCT01700959|Childhood cancer survivors
254413|NCT01700946|leukemia
254414|NCT01700946|lymphoma
254415|NCT01700946|Non-Hodgkins
254416|NCT01700920|Osteonecrosis of the femoral head
254417|NCT01700920|Stem Cell
254418|NCT01700920|Mesenchymal Stem Cells
254419|NCT01700920|Femoral Head
254420|NCT01700907|Postoperative cognitive dysfunction
254421|NCT01700907|elderly patients
254422|NCT01700907|long surgery
254423|NCT01700894|Physical Activity
254424|NCT01700894|African American
254425|NCT01700894|Adherence
254426|NCT01700881|Rheumatoid Arthritis, Diet, Fat-Restricted, Diet, Vegetarian
254427|NCT01700868|Diabetes Mellitus, Type 2
254428|NCT01700868|Diet, Vegetarian
254429|NCT01700868|Diet, Fat-Restricted
254430|NCT01700868|Glycemic Index
254431|NCT01700855|Electroacupuncture
254432|NCT01700855|Analgesia
254433|NCT01700855|Anesthesia
254434|NCT01700855|Nasal septoplasty
254435|NCT01700855|Mammaplasty
254436|NCT01700842|ceftaroline, infection, CAPB, CAP, ABSSSI, cSSTI
254437|NCT01700829|Ketamine
254438|NCT01700829|Midazolam
254439|NCT01700829|Major Depressive Disorder
254440|NCT01700829|Suicidal ideation
254441|NCT01700829|Suicide
254442|NCT01700829|Depression
254443|NCT01700829|Treatment
254444|NCT01700829|Ketamine Treatment
254445|NCT01700816|Delirium
254446|NCT01700816|Hematopoietic stem cell transplantation
254447|NCT01700816|Bone marrow transplantation
254448|NCT01700816|Bright Light Therapy
254449|NCT01700803|Betadine
254450|NCT01700803|Povidine Iodine
254451|NCT01700803|Hand scrubbing
254452|NCT01700803|Cesarean section wound infections
254453|NCT01700803|post cesarean section
254454|NCT01700790|HIV
254455|NCT01700790|AIDS
254456|NCT01700790|Tuberculosis
254457|NCT01700790|Rifampin
254458|NCT01700790|Lopinavir
254459|NCT01700790|Pharmacokinetic
254460|NCT01700777|bimanual training
254461|NCT01700777|lower limb
254462|NCT01700777|intensive rehabilitation
254463|NCT01700777|regular rehabilitation
254464|NCT01700777|hemiplegia
254465|NCT01700725|Gulf War Illness
254466|NCT01700725|xylitol
254467|NCT01700725|nasal irrigation
254468|NCT01700725|Desert Storm
254469|NCT01700725|Persian Gulf Conflicts
254470|NCT01700725|neti pot
254471|NCT01700725|cytokines
254472|NCT01700725|nasal mucus
254473|NCT01700725|inflammatory mediator
254474|NCT01700725|lactoferrin
254475|NCT01700725|lysozyme
254476|NCT01700712|Caries, probiotic bacteria
254477|NCT01700699|thyroid cancer
254478|NCT01700699|tyrosine kinase inhibitors
254479|NCT01700699|BRAF
254480|NCT01700699|Sorafenib
254481|NCT01700699|Pazopanib
254482|NCT01700699|Sunitinib
254483|NCT01700699|Cabozantinib
254484|NCT01700673|maintenance treatment
254485|NCT01700673|stem cell transplant
254486|NCT01700673|cytarabine-based chemotherapy
254487|NCT01700647|Larynx cancer
254488|NCT01700647|Volatile organic compounds
254489|NCT01700647|Diagnosis
254490|NCT01700647|Bronchoscopy
254491|NCT01700647|Cancer staging
254492|NCT01700634|fMRI, BOLD, pressure stimuli
254493|NCT01700621|rotavirus
254494|NCT01700582|lung cancer
254495|NCT01700582|biomarkers
254496|NCT01700582|EGFR
254497|NCT01700582|KRAS
254498|NCT01700582|ALK
254499|NCT01700582|HER2
254500|NCT01700582|PI3K
254501|NCT01700582|BRAF
254502|NCT01700569|high-grade
254503|NCT01700569|glioma
254504|NCT01700569|epigenetic
254505|NCT01700556|Alzheimer Disease
254506|NCT01700556|Family Caregiver
254507|NCT01700556|Caregiver Burden
254508|NCT01700556|Home Care Services
254509|NCT01700556|Assistive Technologies
254510|NCT01700543|Stemless shoulder implant
254511|NCT01700543|Osteoarthritis
254512|NCT01700543|Rheumatoid Arthritis
254513|NCT01700543|Hemi Shoulder Arthroplasty
254514|NCT01700543|Total Shoulder Arthroplasty
254515|NCT01700543|Prospective
254516|NCT01700543|Multi-center
254517|NCT01700543|Europe
254518|NCT01700543|Non-Controlled
254519|NCT01700543|Good Bone Stock
254520|NCT01700530|mitochondria
254521|NCT01700530|fitness
254522|NCT01700530|statins
254523|NCT01700530|cholesterol
254524|NCT01700530|metabolic syndrome
254525|NCT01700517|total knee arthroplasty, analgesia, ultrasonography
254526|NCT01700504|Axillary drainage volume
254527|NCT01700504|Lavage with gentamicin solution
254528|NCT01700491|Paravertebral Catheter
254529|NCT01700491|Epidural Catheter
254530|NCT01700491|Analgesia
254531|NCT01700491|Hypotension
254532|NCT01700491|Analgesia,Epidural
254533|NCT01700491|Analgesia,Paravertebral
254534|NCT01700478|Myomectomy
254535|NCT01700465|Hemodialysis
254536|NCT01700465|Hemodynamics
254537|NCT01700452|Lung cancer
254538|NCT01700452|Pulmonary nodules
254539|NCT01700452|FISH Test
254540|NCT01700439|Aortic valve
254541|NCT01700439|Heart valve
254542|NCT01700439|Tissue valve
254543|NCT01700439|Bioprosthesis
254544|NCT01700439|Valve disorder
254545|NCT01700439|Valve disease
254546|NCT01700439|Cardiac surgery
254547|NCT01700439|Less invasive cardiac surgery
254548|NCT01700439|Aortic valve stenosis
254549|NCT01700439|Aortic valve regurgitation
254550|NCT01700439|Bovine pericardium
254551|NCT01700426|Iron Deficiency
254552|NCT01700426|Iron Deficiency Anemia
254553|NCT01700413|acute
254554|NCT01700413|myeloid
254555|NCT01700413|leukemia
254556|NCT01700413|CETLAM
254557|NCT01700413|Idarubicin
254558|NCT01700400|Lung Cancer
254559|NCT01700400|Non Small Cell Lung Cancer
254560|NCT01700400|Advanced Lung Cancer
254561|NCT01700387|Migraine
254562|NCT01700387|Chronic Migraine
254563|NCT01700387|Cognitive Efficiency
254564|NCT01700387|Pilot Study
254565|NCT01700387|Long Term Effect
254566|NCT01700374|pregnancy
254567|NCT01700374|stress, psychological
254568|NCT01700374|stress, physiological
254569|NCT01700374|maternal-fetal relations
254570|NCT01700361|sexual arousal
254571|NCT01700361|pelvic floor sEMG
254572|NCT01700348|moderate gingivitis
254573|NCT01700322|Coronary artery disease
254574|NCT01700322|coronary stenting
254575|NCT01700322|platelet aggregation
254576|NCT01700309|Obesity prevention; Adolescent; Physical activity; Health counselling
254577|NCT01700283|Colorectal Cancer、Fatigue、Muscle strength、Metabolomics
254578|NCT01700257|Lung cancer screening
254579|NCT01700257|Smokers or former smokers
254580|NCT01700257|Family history of lung cancer
254581|NCT01700231|hepatorenal syndrome, liver regeneration, liver dysfunction
254582|NCT01700218|telemonitoring
254583|NCT01700205|Formula Feeding
254584|NCT01700205|Mother
254585|NCT01700205|Moms
254586|NCT01700205|Infants
254587|NCT01700205|Babies
254588|NCT01700205|Baby
254589|NCT01700205|growth
254590|NCT01700205|energy balance
254591|NCT01700166|Autologous
254592|NCT01700166|Cord Blood
254593|NCT01700166|Stem Cells
254594|NCT01700166|Pediatric stroke
254595|NCT01700166|Children with ischemic stroke
254596|NCT01700166|Cerebral Palsy
254597|NCT01700166|Perinatal AIS
254598|NCT01700153|Robotic-assisted therapy
254599|NCT01700153|cerebral palsy
254600|NCT01700153|ICF
254601|NCT01700127|immune response
254602|NCT01700127|infants
254603|NCT01700127|rotavirus vaccine
254604|NCT01700114|Pigmented Skin Lesions
254605|NCT01700114|Dermatology
254606|NCT01700114|Skin Cancer
254607|NCT01700114|Melanoma
254608|NCT01700114|MelaFind
254609|NCT01700088|hypoxemia
254610|NCT01700088|Post Pulmonary Resection
254611|NCT01700075|atherosclerosis, development of concept, weight loss therapy
254612|NCT01700062|medium-calorie
254613|NCT01700062|standard calorie
254614|NCT01700062|parenteral nutrition
254615|NCT01700049|advanced BCC
254616|NCT01700049|high risk
254617|NCT01700049|locally advanced
254618|NCT01700023|acute heart failure
254619|NCT01700010|Urothelial
254620|NCT01700010|Bladder
254621|NCT01700010|Cancer
254622|NCT01699997|Schizophrenia
254623|NCT01699997|Oxytocin
254624|NCT01699997|RCT
254625|NCT01699984|Cognitive impairment.
254626|NCT01699984|Geriatrics.
254627|NCT01699984|Hospital admission.
254628|NCT01699984|Hospital discharge.
254629|NCT01699958|Problem solving therapy
254630|NCT01699958|Behavior change
254631|NCT01699945|Verbal autopsies
254632|NCT01699945|Maternal deaths
254633|NCT01699945|Still births
254634|NCT01699919|perioperative lignocaine infusion
254635|NCT01699919|elective open abdominal surgeries
254636|NCT01699919|postoperative pain
254637|NCT01699906|Obesity
254638|NCT01699880|tracheal intubation
254639|NCT01699880|preoxygenation
254640|NCT01699880|desaturation
254641|NCT01699880|hypoxemia
254642|NCT01699880|oxygen therapy
254643|NCT01699880|high flow nasal cannula oxygen therapy
254644|NCT01699867|lumpectomy
254645|NCT01699867|breast cancer
254646|NCT01699867|optical coherence tomography
254647|NCT01699867|tumor margin
254648|NCT01699867|imaging
254649|NCT01699828|buspirone
254650|NCT01699828|smoking cessation
254651|NCT01699828|dopamine
254652|NCT01699828|PET imaging
254653|NCT01699828|[11C]-(+)-PHNO
254654|NCT01699815|acetaminophen
254655|NCT01699815|timing
254656|NCT01699815|arthroplasty
254657|NCT01699789|Community Partnered Participatory Research
254658|NCT01699789|Community Engagement
254659|NCT01699789|Implementation
254660|NCT01699789|Community Based Participatory Research
254661|NCT01699789|Quality Improvement
254662|NCT01699789|Evidence Based Practice
254663|NCT01699789|Patient Centered Outcomes Research
254664|NCT01699776|Digoxin
254665|NCT01699776|Ivabradine
254666|NCT01699776|with atrial fibrillation.
254667|NCT01699750|contact lenses
254668|NCT01699750|contact lens solution
254669|NCT01699750|myopia
254670|NCT01699750|astigmatism
254671|NCT01699737|Diabetes
254672|NCT01699724|JZoloft
254673|NCT01699724|Sertraline hydrochloride
254674|NCT01699724|ODT
254675|NCT01699724|bioequivalence
254676|NCT01699711|APP function (amyloid precursor protein, cognitive stimulation, alzheimer disease. program
254677|NCT01699698|Pancreatic adenocarcinoma
254678|NCT01699685|Moderate to severe COPD patients are included
254679|NCT01699685|NVA
254680|NCT01699685|QAB
254681|NCT01699672|Patient education
254682|NCT01699672|information
254683|NCT01699672|communication
254684|NCT01699659|Allergic Rhinitis
254685|NCT01699659|Allergen Immunotherapy
254686|NCT01699646|Intrapartum fetal surveillance
254687|NCT01699646|CTG
254688|NCT01699646|cardiotocography
254689|NCT01699646|STAN
254690|NCT01699646|ST-Analysis
254691|NCT01699646|metabolic acidosis in umbilical artery
254692|NCT01699646|operative delivery
254693|NCT01699633|Drug-drug interactions
254694|NCT01699633|Drug-gene interactions
254695|NCT01699633|Nevirapine
254696|NCT01699633|Rifampicin
254697|NCT01699633|children
254698|NCT01699620|Bone anchored hearing aid
254699|NCT01699620|Soft tissue healing
254700|NCT01699620|Implant stability
254701|NCT01699620|Linear incision
254702|NCT01699620|Dermatome technique
254703|NCT01699620|Hearing Aids
254704|NCT01699620|Implants, Artificial
254705|NCT01699620|Surgical Procedures, Operative
254706|NCT01699607|Cigarette Smokers
254707|NCT01699607|Healthy Non Smokers
254708|NCT01699607|Amphetamine
254709|NCT01699607|PET
254710|NCT01699607|Controls
254711|NCT01699594|asthma
254712|NCT01699594|allergies
254713|NCT01699594|mannitol
254714|NCT01699594|methacholine
254715|NCT01699581|Hodgkin's Lymphoma
254716|NCT01699581|Multiple Myeloma
254717|NCT01699581|Non-Hodgkin's Lymphoma
254718|NCT01699568|dental implant stability
254719|NCT01699568|dental implant surface treatment
254720|NCT01699568|resonance frequence analysis
254721|NCT01699555|Multiple sclerosis
254722|NCT01699555|GNbAC1
254723|NCT01699555|Monoclonal antibody
254724|NCT01699555|Multiple Sclerosis Associated Retrovirus (MSRV)
254725|NCT01699542|Refractory Anastomotic esophageal strictures
254726|NCT01699516|allogeneic transplantation; intestinal graft-vs.-host disease; contrast enhanced ultrasound sonography
254727|NCT01699503|Dementia
254728|NCT01699503|Alzheimer's Disease
254729|NCT01699503|Mild Cognitive Impairment
254730|NCT01699503|Screening
254731|NCT01699490|Major Depressive Disorder
254732|NCT01699490|Antidepressants
254733|NCT01699490|Insulin
254734|NCT01699490|Fluoxetine
254735|NCT01699477|FUS
254736|NCT01699477|focused ultrasound
254737|NCT01699477|functional brain disorders
254738|NCT01699477|neuropathic pain
254739|NCT01699477|movement disorders
254740|NCT01699464|Glaucoma
254741|NCT01699438|Irritable Bowel Syndrome
254742|NCT01699438|Inflammation
254743|NCT01699438|Mesalazine
254744|NCT01699425|Stress urinary incontinence.
254745|NCT01699425|Suburethral sling.
254746|NCT01699425|Single-incision suburethral sling.
254747|NCT01699425|Ajust.
254748|NCT01699425|Transobturator tape.
254749|NCT01699412|Bone Marrow Transplantation
254750|NCT01699412|Graft vs Host Disease
254751|NCT01699412|Oral Manifestations
254752|NCT01699399|colonoscopy
254753|NCT01699399|pain
254754|NCT01699399|sedation
254755|NCT01699399|water
254756|NCT01699360|Kidney Transplantation
254757|NCT01699360|Immunosuppressive Agents
254758|NCT01699360|Hydrocortisone
254759|NCT01699360|Cortisone
254760|NCT01699347|OK432, CYSTIC MALFORMATION
254761|NCT01699334|Whiplash injuries
254762|NCT01699334|patient education
254763|NCT01699334|illness perceptions
254764|NCT01699334|RCT
254765|NCT01699334|motor vehicle accidents
254766|NCT01699321|physical activity
254767|NCT01699321|barbershop
254768|NCT01699321|cancer prevention
254769|NCT01699321|exercise
254770|NCT01699321|men's health
254771|NCT01699321|African American men
254772|NCT01699308|Traumatic Brain Injury
254773|NCT01699308|Growth Hormone
254774|NCT01699308|Neuroimaging
254775|NCT01699295|academic achievement
254776|NCT01699295|elementary school
254777|NCT01699295|physical activity
254778|NCT01699295|exercise
254779|NCT01699282|oral anticoagulant
254780|NCT01699282|in the long term (> 12 months)
254781|NCT01699269|High grade brain tumor
254782|NCT01699269|Glioma
254783|NCT01699269|Glioblastoma Multiform
254784|NCT01699269|Brain Cancer
254785|NCT01699269|Diffusion-Weighted Magnetic Resonance Imaging
254786|NCT01699269|High order diffusion tensor
254787|NCT01699269|Imaging guided biopsy
254788|NCT01699269|Histopathologic evaluation
254789|NCT01699269|Infiltration percentage
254790|NCT01699256|General Practice
254791|NCT01699256|Low Back Pain
254792|NCT01699256|Guideline
254793|NCT01699256|Health Plan Implementation
254794|NCT01699256|Referral and Consultation
254795|NCT01699243|pregnancy
254796|NCT01699243|labor
254797|NCT01699243|epidural
254798|NCT01699243|fetal intervention
254799|NCT01699230|Elective cardiac surgery
254800|NCT01699230|with sternotomy and
254801|NCT01699230|cardiopulmonary bypass
254802|NCT01699230|for coronary artery
254803|NCT01699230|bypass graft.
254804|NCT01699217|Chronic Myeloid Leukaemia
254805|NCT01699217|Philadelphia positive
254806|NCT01699217|BCR-ABL positive
254807|NCT01699204|Air pollution
254808|NCT01699204|Diesel exhaust
254809|NCT01699204|Airway responsiveness
254810|NCT01699204|Asthma
254811|NCT01699204|Anti-oxidant
254812|NCT01699191|Irritable Bowel Syndrome
254813|NCT01699191|Celiac Desease
254814|NCT01699191|Probiotic
254815|NCT01699191|Lactobacillus plantarum
254816|NCT01699191|Bifidobacterium breve
254817|NCT01699191|Lactobacillus casei
254818|NCT01699191|Bifidobacterium animalis
254819|NCT01699165|rhinitis
254820|NCT01699165|allergic
254821|NCT01699165|seasonal
254822|NCT01699165|double blind
254823|NCT01699165|doubleblind
254824|NCT01699165|randomized
254825|NCT01699165|randomised
254826|NCT01699165|placebo
254827|NCT01699165|crossover
254828|NCT01699165|clinical
254829|NCT01699165|nasal
254830|NCT01699165|filter
254831|NCT01699165|controlled
254832|NCT01699165|trial
254833|NCT01699165|hayfever
254834|NCT01699165|hay
254835|NCT01699165|fever
254836|NCT01699165|efficacy
254837|NCT01699165|safety
254838|NCT01699165|prevention
254839|NCT01699165|adult
254840|NCT01699165|grass
254841|NCT01699165|pollen
254842|NCT01699165|symptom
254843|NCT01699165|Total nasal symptom score
254844|NCT01699165|acoustic rhinometry
254845|NCT01699152|Chronic Lymphocytic Leukemia
254846|NCT01699152|Small Lymphocytic Lymphoma
254847|NCT01699139|supine position
254848|NCT01699126|Obstructive Sleep Apnea
254849|NCT01699126|CPAP
254850|NCT01699126|Endothelium dysfunction
254851|NCT01699126|Hypertension
254852|NCT01699113|YF476
254853|NCT01699113|gastrin receptor antagonist
254854|NCT01699113|gastric pH
254855|NCT01699113|gastrin
254856|NCT01699113|rabeprazole
254857|NCT01699113|proton-pump inhibitor
254858|NCT01699113|gastric function
254859|NCT01699113|healthy subjects
254860|NCT01699100|offloading
254861|NCT01699100|plantar pressure
254862|NCT01699100|insole
254863|NCT01699100|foot ulcer
254864|NCT01699074|Korean White Ginseng
254865|NCT01699074|Type 2 diabetes
254866|NCT01699074|Metabolic syndrome
254867|NCT01699048|CAD,PCI,MIDCAB,CABG
254868|NCT01699035|stroke
254869|NCT01699035|work
254870|NCT01699035|vocational rehabilitation
254871|NCT01699022|Contraceptive
254872|NCT01699022|Injectable
254873|NCT01699009|Migraines, diet, vegan, vegetarian, plant-based
254874|NCT01698996|abscess
254875|NCT01698996|packing
254876|NCT01698996|emergency medicine
254877|NCT01698996|wound care
254878|NCT01698996|incision and drainage
254879|NCT01698970|Probiotic
254880|NCT01698970|capsules
254881|NCT01698970|Crohn's disease
254882|NCT01698970|recurrent endoscopic ileo-colonic lesions
254883|NCT01698957|Pregnant women
254884|NCT01698957|Uterine Artery Doppler Velocimetry
254885|NCT01698918|metastatic breast cancer, locally advanced breast cancer, HER2-, ER+, everolimus, Afinitor
254886|NCT01698905|Phase II, single arm, open label, nilotinib, treatment-free remission, MR4.5, confirmed loss of MR4, loss of MMR, Ph+ CML-CP
254887|NCT01698892|I.V. sedation, midazolam, bronchoscopy
254888|NCT01698866|Low grade lymphoma
254889|NCT01698866|follicular lymphoma
254890|NCT01698866|indolent lymphoproliferative disorders
254891|NCT01698866|Vaccin GenHevac B Pasteur
254892|NCT01698840|Vitamin D
254893|NCT01698840|Transitional Formula
254894|NCT01698827|gastrostomy
254895|NCT01698827|tube
254896|NCT01698827|endoscopic
254897|NCT01698827|replacement
254898|NCT01698827|tube rupture
254899|NCT01698827|durability
254900|NCT01698827|tube loss
254901|NCT01698827|balloon rupture
254902|NCT01698814|ocular safety
254903|NCT01698814|allergic conjunctivitis
254904|NCT01698801|Lenalidomide
254905|NCT01698801|dexamethasone
254906|NCT01698801|newly diagnosed multiple myeloma
254907|NCT01698788|diabetic macular edema
254908|NCT01698788|taut posterior hyaloid membrane
254909|NCT01698788|ozurdex
254910|NCT01698762|Musculoskeletal Diseases
254911|NCT01698762|Osteoarthritis
254912|NCT01698762|OA
254913|NCT01698762|Rheumatoid Arthritis
254914|NCT01698762|RA
254915|NCT01698762|Osteoporosis
254916|NCT01698762|OP
254917|NCT01698762|Multimedia Patient Decision Aids
254918|NCT01698762|MM-PtDAs
254919|NCT01698762|DVD
254920|NCT01698762|Comparative Effectiveness Research Summary Guide
254921|NCT01698762|CERSG
254922|NCT01698762|Booklet
254923|NCT01698762|Questionnaires
254924|NCT01698762|Surveys
254925|NCT01698749|Ozurdex
254926|NCT01698749|Diabetic macular edema
254927|NCT01698749|Central macular thickness
254928|NCT01698736|ABO isoagglutinins
254929|NCT01698736|ABO incompatible transplantation
254930|NCT01698736|immunoadsorption
254931|NCT01698736|membrane filtration
254932|NCT01698736|plasmapheresis
254933|NCT01698723|ACLF
254934|NCT01698723|HEV
254935|NCT01698723|Ribavirin
254936|NCT01698710|Premalignant
254937|NCT01698710|Malignant
254938|NCT01698684|ED
254939|NCT01698645|quality of life
254940|NCT01698645|PecFent
254941|NCT01698645|Lazanda
254942|NCT01698645|fentanyl
254943|NCT01698645|intranasal
254944|NCT01698645|breakthrough cancer pain
254945|NCT01698632|Adnexal masses
254946|NCT01698632|Ovarian cysts
254947|NCT01698632|Ovarian tumors
254948|NCT01698606|childhood obesity
254949|NCT01698606|multidisciplinary
254950|NCT01698606|preschool children
254951|NCT01698606|community-based
254952|NCT01698606|lifestyle intervention
254953|NCT01698606|family-centered
254954|NCT01698593|Bupivacaine
254955|NCT01698593|digital nerve block
254956|NCT01698593|epinephrine
254957|NCT01698593|duration of action
254958|NCT01698593|pain
254959|NCT01698593|touch
254960|NCT01698593|pressure
254961|NCT01698593|temperature
254962|NCT01698580|accidental falls
254963|NCT01698580|aged
254964|NCT01698580|aged, 80 and over
254965|NCT01698580|prevention and control
254966|NCT01698567|Infants
254967|NCT01698567|Cardiopulmonary bypass
254968|NCT01698567|anticoaglution
254969|NCT01698541|Renal
254970|NCT01698541|Transplantation
254971|NCT01698541|Elderly
254972|NCT01698528|Diabetes
254973|NCT01698528|diabetes technologies
254974|NCT01698528|telemedicine
254975|NCT01698502|Incretin
254976|NCT01698502|Training
254977|NCT01698502|Glucagon like peptide
254978|NCT01698502|glucose dependent insulinotropic peptide
254979|NCT01698502|Gut
254980|NCT01698502|Exercise
254981|NCT01698502|Insulin
254982|NCT01698502|Focus:
254983|NCT01698502|Gut hormone
254984|NCT01698502|adaptations
254985|NCT01698476|pulmonary TB
254986|NCT01698476|cholecalciferol
254987|NCT01698476|sodium phenylbutyrate
254988|NCT01698476|antimicrobial peptides
254989|NCT01698476|immune response
254990|NCT01698463|Falls, Fractures, Osteoporosis, Frailty, Older Adults.
254991|NCT01698450|FUS
254992|NCT01698450|focused ultrasound
254993|NCT01698450|functional brain disorder
254994|NCT01698450|neuropathic pain
254995|NCT01698450|movement disorders
254996|NCT01698450|malignant brain tumors
254997|NCT01698437|FUS
254998|NCT01698437|focused ultrasound
254999|NCT01698437|functional brain disorders
255000|NCT01698437|neuropathic pain
255001|NCT01698437|movement disorders
255002|NCT01698437|malignant of brain tumors
255003|NCT01698411|hypertension
255004|NCT01698411|sleep
255005|NCT01698411|insomnia
255006|NCT01698372|Cardiac surgery.
255007|NCT01698372|Wound healing.
255008|NCT01698372|Leg wound infection.
255009|NCT01698372|Wound care.
255010|NCT01698346|Pertussis
255011|NCT01698346|Infants
255012|NCT01698346|Vaccination
255013|NCT01698346|Pregnancy
255014|NCT01698333|122-0551
255015|NCT01698333|steroid
255016|NCT01698333|HPA
255017|NCT01698307|Crohn's Disease
255018|NCT01698307|Deep Remission
255019|NCT01698307|Complications
255020|NCT01698294|gut microbiome
255021|NCT01698294|hormones
255022|NCT01698294|women
255023|NCT01698294|race
255024|NCT01698294|phytoestrogens
255025|NCT01698255|Depression
255026|NCT01698255|Geriatrics
255027|NCT01698242|Heart failure
255028|NCT01698242|Self-Management
255029|NCT01698242|Behavioral Clinical Trial
255030|NCT01698229|Cerebrospinal fluid
255031|NCT01698229|Lumbar puncture
255032|NCT01698229|Spinal tap
255033|NCT01698229|Late infantile neuronal ceroid lipofuscinosis
255034|NCT01698229|Batten disease
255035|NCT01698216|Paliperidone
255036|NCT01698216|Palmitate
255037|NCT01698216|switching
255038|NCT01698216|schizophrenia
255039|NCT01698216|subjective well-being
255040|NCT01698177|Influenza
255041|NCT01698177|Cancer
255042|NCT01698177|Vaccination
255043|NCT01698177|Immune response to influenza vaccination
255044|NCT01698164|lipid profiles
255045|NCT01698164|coronary heart disease
255046|NCT01698164|menopausal syndrome
255047|NCT01698164|MMSE
255048|NCT01698164|MENQOL
255049|NCT01698164|HAD
255050|NCT01698151|Chronic obstructive Pulmonary Disease
255051|NCT01698151|COPD
255052|NCT01698138|Spinal cord injury
255053|NCT01698138|Neurogenic overactive bladder
255054|NCT01698138|Onabotulinum toxin A
255055|NCT01698138|Prevention
255056|NCT01698138|Botulinum Toxins, Type A
255057|NCT01698125|Delirium
255058|NCT01698125|Autonomic cardiovascular control
255059|NCT01698125|Abdominal surgery
255060|NCT01698125|Tilt-test
255061|NCT01698086|Multiple Sclerosis
255062|NCT01698086|Balance
255063|NCT01698086|Fatigue
255064|NCT01698086|Eye movement
255065|NCT01698073|Teen pregnancy prevention
255066|NCT01698073|American Indian
255067|NCT01698073|Group-randomized trial
255068|NCT01698060|Prevention of Avian Influenza
255069|NCT01698047|Depressive symptoms
255070|NCT01698047|sub-threshold depression
255071|NCT01698047|resiliency
255072|NCT01698047|Health Promotion
255073|NCT01698047|minority health
255074|NCT01698034|volunteering
255075|NCT01698034|cardiovascular health
255076|NCT01698021|Creatine Kinase, MB form
255077|NCT01698021|Troponin
255078|NCT01698021|Acute coronary syndrome
255079|NCT01698021|myocardial infarction
255080|NCT01698021|Unstable angina
255081|NCT01697995|right ventricle
255082|NCT01697995|radiotracer uptake
255083|NCT01697995|Myocardial Perfusion Imaging
255084|NCT01697995|balanced ischemia
255085|NCT01697982|pilot study
255086|NCT01697982|psychosocial intervention
255087|NCT01697982|advanced cancer
255088|NCT01697969|allergic conjunctivitis
255089|NCT01697969|Pataday
255090|NCT01697969|Olopatadine
255091|NCT01697956|Pediatric Subjects
255092|NCT01697943|Gastric Malignant Tumor
255093|NCT01697943|Total Gastrectomy
255094|NCT01697943|Reconstruction
255095|NCT01697930|PET Imaging
255096|NCT01697930|18F] 4-L-Fluoroglutam (2S,4R)
255097|NCT01697930|12-168
255098|NCT01697917|Adenocarcinoma of Esophagogastric Junction
255099|NCT01697917|Total Gastrectomy
255100|NCT01697917|Proximal Gastrectomy
255101|NCT01697891|Radiation Treatment
255102|NCT01697891|Head and Neck Cancer
255103|NCT01697891|Dysphagia
255104|NCT01697878|obstructive sleep apnea
255105|NCT01697878|obesity
255106|NCT01697878|respiratory function
255107|NCT01697878|weight loss surgery
255108|NCT01697865|Reverse total shoulder
255109|NCT01697852|vector control
255110|NCT01697852|LLIN
255111|NCT01697852|IRS
255112|NCT01697826|Clindamycin
255113|NCT01697826|Clotrimazole
255114|NCT01697826|Vaginal formulation
255115|NCT01697826|Bacterial vaginosis
255116|NCT01697826|Candidiasis
255117|NCT01697826|Trichomoniasis
255118|NCT01697826|Mixed vaginitis
255119|NCT01697826|Infective vaginitis
255120|NCT01697787|Treatment, diagnosis
255121|NCT01697761|Crohn's disease,acupuncture,moxibustion,inflammation factors
255122|NCT01697722|Primary care
255123|NCT01697722|Asthma management
255124|NCT01697722|Inhaled corticosteroids
255125|NCT01697722|Extra-fine hydrofluoroalkane
255126|NCT01697722|Long-acting beta-agonist
255127|NCT01697722|Fixed-dose combination therapy
255128|NCT01697709|cannabis
255129|NCT01697709|marijuana
255130|NCT01697709|pharmacotherapy
255131|NCT01697696|COPD, NVA237, QAB149, glycopyrronium bromide
255132|NCT01697605|Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R
255133|NCT01697566|Gynecology
255134|NCT01697566|Endometrial Cancer Chemoprevention
255135|NCT01697566|Obese
255136|NCT01697566|Body Mass Index (BMI) >/= 35 kg.m2
255137|NCT01697566|Post-menopausal
255138|NCT01697566|Hyperinsulinemia
255139|NCT01697566|Metformin
255140|NCT01697566|Placebo
255141|NCT01697566|Sugar pill
255142|NCT01697566|Lifestyle intervention
255143|NCT01697566|Diet
255144|NCT01697566|Exercise
255145|NCT01697514|recurrent medulloblastoma
255146|NCT01697397|Irritable bowel syndrome
255147|NCT01697397|IBS
255148|NCT01697397|Gastrointestinal pain
255149|NCT01697397|Gastrointestinal functional disorder
255150|NCT01697384|prostate cancer, PSA
255151|NCT01697358|FBSS
255152|NCT01697358|post laminectomy syndrome
255153|NCT01697358|SCS
255154|NCT01697358|RCT
255155|NCT01697358|back pain
255156|NCT01697345|Vaginal Testosterone
255157|NCT01697345|Vaginal atrophy
255158|NCT01697345|Female Sexual Dysfunction
255159|NCT01697345|Aromatase Inhibitors
255160|NCT01697332|COPD
255161|NCT01697319|Mucopolysaccharidosis IVA Type A
255162|NCT01697319|MPS IVA Type A
255163|NCT01697319|Mucopolysaccharidosis IVA
255164|NCT01697319|MPS IVA
255165|NCT01697319|Morquio A Syndrome
255166|NCT01697319|Lysosomal Storage Disorder
255167|NCT01697319|LSD
255168|NCT01697319|N-acetylgalactosamine-6-sulfatase
255169|NCT01697319|N-acetylgalactosamine-6-sulfate
255170|NCT01697319|sulfatase
255171|NCT01697319|galactose-6-sulfatase
255172|NCT01697319|GALNS
255173|NCT01697319|enzyme replacement therapy
255174|NCT01697319|ERT
255175|NCT01697319|MOR-006
255176|NCT01697319|CPET
255177|NCT01697319|Limited ambulation
255178|NCT01697319|Grip/ Pinch
255179|NCT01697306|non muscle invasive bladder cancer
255180|NCT01697280|Polio supplementary immunization activities
255181|NCT01697280|Routine EPI vaccine
255182|NCT01697280|Integration of polio NID and routine EPI
255183|NCT01697267|vasculitis
255184|NCT01697267|ANCA vasculitis
255185|NCT01697267|microscopic polyangiitis
255186|NCT01697267|granulomatosis
255187|NCT01697267|Wegener's
255188|NCT01697267|AAV
255189|NCT01697267|vasculitides
255190|NCT01697241|Exercise Therapy
255191|NCT01697241|Education
255192|NCT01697241|Osteoarthritis
255193|NCT01697241|Hip
255194|NCT01697241|Hip replacement
255195|NCT01697228|Diabetes
255196|NCT01697228|Vitamin D
255197|NCT01697228|Proinflammatory markers
255198|NCT01697189|professional drivers
255199|NCT01697189|sleepiness
255200|NCT01697189|stress
255201|NCT01697189|safe driving
255202|NCT01697189|training
255203|NCT01697163|De Novo Resistance
255204|NCT01697163|Iressa
255205|NCT01697163|EGFR mutation
255206|NCT01697163|lung cancer
255207|NCT01697150|Type 1 diabetes mellitus
255208|NCT01697150|closed loop artificial pancreas
255209|NCT01697124|Physical activity
255210|NCT01697124|children
255211|NCT01697124|Head Start
255212|NCT01697124|SPARK-EC
255213|NCT01697111|YAZ
255214|NCT01697111|Flexible regimen
255215|NCT01697111|Drospirenone
255216|NCT01697111|Ethinylestradiol Betadex
255217|NCT01697111|Endometriosis
255218|NCT01697111|Dienogest
255219|NCT01697111|Japanese Patients
255220|NCT01697098|Dexamethasone
255221|NCT01697098|preterm labour
255222|NCT01697098|respiratory distress
255223|NCT01697085|sea buckthorn
255224|NCT01697085|mucous membrane
255225|NCT01697085|dryness
255226|NCT01697085|metabolic syndrome
255227|NCT01697085|vaginal atrophy
255228|NCT01697072|Gastric Cancer
255229|NCT01697072|First Line Treatment Gastroesophageal Junction (GEJ)
255230|NCT01697072|Gastroesophageal Junction Cancer (GEJ)
255231|NCT01697072|GEJ Cancer
255232|NCT01697059|appendicitis
255233|NCT01697046|peri-exposure
255234|NCT01697046|chemoprophylaxis
255235|NCT01696942|Crohn's disease
255236|NCT01696942|certolizumab
255237|NCT01696942|mesalamine
255238|NCT01696942|recurrence
255239|NCT01696929|tocilizumab
255240|NCT01696929|safety
255241|NCT01696929|tolerability
255242|NCT01696929|efficacy
255243|NCT01696929|schizophrenia
255244|NCT01696929|improvement
255245|NCT01696929|cognition
255246|NCT01696929|psychotic symptoms
255247|NCT01696929|baseline IL-6 levels
255248|NCT01696916|COPD
255249|NCT01696916|carbon dioxide
255250|NCT01696916|6-minute walking test
255251|NCT01696903|Postoperative pancreatic fistula
255252|NCT01696903|Pancreatic texture
255253|NCT01696903|Pancreatic duct diameter
255254|NCT01696903|Pancreatic consistency
255255|NCT01696903|Pancreaticoduodenectomy
255256|NCT01696890|chronic heart failure
255257|NCT01696890|telemonitoring
255258|NCT01696890|first line practitioners
255259|NCT01696890|integrated approach
255260|NCT01696890|efficacy
255261|NCT01696838|Crohn's disease
255262|NCT01696838|acupuncture
255263|NCT01696838|moxibustion
255264|NCT01696838|fMRI
255265|NCT01696838|Gut
255266|NCT01696812|electrodeposition
255267|NCT01696812|Subthalamic Nucleus
255268|NCT01696812|Deep Brain Stimulation
255269|NCT01696812|Parkinson Disease
255270|NCT01696773|tomato
255271|NCT01696773|tangerine tomato
255272|NCT01696773|carotenoids
255273|NCT01696773|lycopene
255274|NCT01696773|flavonoids
255275|NCT01696747|gastroparesis
255276|NCT01696747|idiopathic gastroparesis
255277|NCT01696747|diabetic gastroparesis
255278|NCT01696747|post-Nissen gastroparesis
255279|NCT01696734|Gastrointestinal diseases
255280|NCT01696734|GI
255281|NCT01696734|Compassionate use
255282|NCT01696734|GI motility disorders
255283|NCT01696734|GI disorders
255284|NCT01696734|Gastroparesis
255285|NCT01696734|Gastroesophageal reflux disease
255286|NCT01696734|GERD
255287|NCT01696734|Chronic nausea and vomiting
255288|NCT01696734|Questionnaires
255289|NCT01696734|Surveys
255290|NCT01696734|Phone calls
255291|NCT01696734|Domperidone
255292|NCT01696721|Proton Therapy
255293|NCT01696721|Pediatrics
255294|NCT01696721|Radiation Oncology
255295|NCT01696682|minimally invasive esophagectomy
255296|NCT01696682|anastomotic leakage
255297|NCT01696682|gastric conduit
255298|NCT01696669|Ewing's Sarcoma
255299|NCT01696669|P6 protocol MSKCC
255300|NCT01696669|Gemcitabine
255301|NCT01696669|Docetaxel
255302|NCT01696656|Gastrointestinal drugs
255303|NCT01696656|Antibiotics
255304|NCT01696656|Vitamins
255305|NCT01696656|Minerals
255306|NCT01696656|Intestinal insufficiency
255307|NCT01696656|Short Bowel syndrome
255308|NCT01696656|Adjuvant therapy
255309|NCT01696656|Antacids
255310|NCT01696656|Gastrointestinal motility modifiers
255311|NCT01696656|Micronutrients
255312|NCT01696643|Opioid
255313|NCT01696643|Constipation
255314|NCT01696643|Chronic
255315|NCT01696643|Pain
255316|NCT01696630|anesthesia, epidural anagesia, colorectal surgery, xenon, hemodynamic change
255317|NCT01696604|safety
255318|NCT01696604|pharmacokinetics
255319|NCT01696604|FTIH
255320|NCT01696604|SARM
255321|NCT01696591|Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood
255322|NCT01696578|PTSD
255323|NCT01696578|Depression
255324|NCT01696578|Anxiety
255325|NCT01696578|Chronic pain
255326|NCT01696578|Anger
255327|NCT01696578|Heart rate variability
255328|NCT01696578|Disability
255329|NCT01696565|myelosuppression
255330|NCT01696565|chemotherapy
255331|NCT01696565|Astragalus membranaceus
255332|NCT01696565|hematopoietic response
255333|NCT01696552|Gonarthritis
255334|NCT01696552|TKR
255335|NCT01696552|Conventional
255336|NCT01696552|Positioning Guides
255337|NCT01696552|PSPG
255338|NCT01696552|CT Perth
255339|NCT01696539|Prostate Cancer
255340|NCT01696526|vitamin D
255341|NCT01696526|bioeffiency
255342|NCT01696526|vitamin d fortified fish
255343|NCT01696500|IVIG in Stevens-Johnson syndrome
255344|NCT01696500|Toxic Epidermal Necrolysis
255345|NCT01696500|Patients with Stevens-Johnson syndrome
255346|NCT01696500|Toxic Epidermal Necrolysis unresponsive to corticosteroids
255347|NCT01696487|non-alcoholic fatty liver disease
255348|NCT01696487|non-alcoholic steatohepatitis
255349|NCT01696487|NAFLD
255350|NCT01696487|NASH
255351|NCT01696474|Refractory cold agglutinin disease
255352|NCT01696474|Bortezomib
255353|NCT01696474|blood-transfusion
255354|NCT01696448|Appetite Suppression
255355|NCT01696448|CAR-191
255356|NCT01696435|Depression
255357|NCT01696435|Depressive Symptoms
255358|NCT01696435|Mood
255359|NCT01696435|Geriatric
255360|NCT01696435|Prevention
255361|NCT01696422|Dengue
255362|NCT01696422|tetravalent attenuated Vaccine
255363|NCT01696422|Healthy adults
255364|NCT01696396|IBD, Crohn's Disease
255365|NCT01696383|Intraocular Pressure (IOP)
255366|NCT01696383|Glaucoma
255367|NCT01696383|Ocular hypertension
255368|NCT01696383|DuoTrav
255369|NCT01696383|Prostaglandin analogue
255370|NCT01696383|Beta-blocker
255371|NCT01696370|Trimetazidine
255372|NCT01696357|Asthma
255373|NCT01696357|Adolescents
255374|NCT01696357|Self-monitoring
255375|NCT01696357|Quality of life
255376|NCT01696357|Biomedical device
255377|NCT01696357|Symptom monitoring
255378|NCT01696357|Self-management
255379|NCT01696344|LSPAF
255380|NCT01696344|AF termination
255381|NCT01696344|PVAI
255382|NCT01696344|nonPV triggers
255383|NCT01696344|Long-standing persistent
255384|NCT01696305|Thyroid disease
255385|NCT01696305|Hyalobarrier
255386|NCT01696305|Thyroidectomy
255387|NCT01696305|anti-adhesive effect
255388|NCT01696240|Pulmonary Hypertension
255389|NCT01696240|Exercise Capacity
255390|NCT01696240|Cardiopulmonary Exercise Test
255391|NCT01696240|Udenafil (Zydena)
255392|NCT01696240|Phosphodiesterase Type 5 Inhibitors
255393|NCT01696227|Nissle 1917
255394|NCT01696227|Probiotic
255395|NCT01696227|Uropathogen
255396|NCT01696214|asthma,smokers
255397|NCT01696201|Pregnancy, outcomes, depression, mood, physical exercise
255398|NCT01696188|Interscalene
255399|NCT01696188|nerve block
255400|NCT01696188|nerve catheter
255401|NCT01696188|in-plane
255402|NCT01696188|out-of-plane
255403|NCT01696188|anterolateral approach
255404|NCT01696188|posterior approach
255405|NCT01696188|shoulder surgery
255406|NCT01696175|ScvO2
255407|NCT01696175|venous
255408|NCT01696175|oxymetry
255409|NCT01696175|lactate
255410|NCT01696175|children
255411|NCT01696175|PICU
255412|NCT01696175|Admission parameters of shock
255413|NCT01696162|Knee pain
255414|NCT01696162|Anterior knee pain
255415|NCT01696162|Patellofemoral
255416|NCT01696162|Patellofemoral syndrome
255417|NCT01696162|Runners knee
255418|NCT01696149|TENS, sympathetic skin response, skin temperature
255419|NCT01696136|Ablation
255420|NCT01696136|Multi-electrode catheter
255421|NCT01696136|Single-tip catheter
255422|NCT01696136|Holter
255423|NCT01696123|Alzheimer disease
255424|NCT01696123|Cholinesterase inhibitors
255425|NCT01696123|MLC601
255426|NCT01696123|NeuroAiD
255427|NCT01696123|neuroprotection
255428|NCT01696123|neuroregeneration
255429|NCT01696110|Bivalirudin
255430|NCT01696110|Acute myocardial infarction
255431|NCT01696110|percutaneous transluminal coronary angioplasty
255432|NCT01696084|AML
255433|NCT01696084|Acute Myeloid Leukemia
255434|NCT01696084|high risk AML
255435|NCT01696084|secondary AML
255436|NCT01696084|AML in elderly
255437|NCT01696032|Ovarian Cancer
255438|NCT01696019|magnetic resonance imaging
255439|NCT01696019|cognition
255440|NCT01696019|Tai Chi
255441|NCT01696019|physical exercise
255442|NCT01696019|mental exercise
255443|NCT01696019|intervention trial
255444|NCT01696019|prevention
255445|NCT01696019|dementia
255446|NCT01696019|Alzheimer disease
255447|NCT01696019|mild cognitive impairment
255448|NCT01696006|perfusion computed tomography
255449|NCT01696006|coronary artery disease
255450|NCT01695993|Nausea
255451|NCT01695993|Quality of life
255452|NCT01695993|Chemotherapy
255453|NCT01695993|Expectancy
255454|NCT01695980|adenotonsillectomy
255455|NCT01695967|nasal obstruction
255456|NCT01695954|HIV
255457|NCT01695954|Hyperlipidemia
255458|NCT01695954|Pharmacokinetics
255459|NCT01695954|Statins
255460|NCT01695954|Darunavir
255461|NCT01695954|Efavirenz
255462|NCT01695954|Pitavastatin
255463|NCT01695928|Velocity
255464|NCT01695928|Location
255465|NCT01695928|Periodontal status
255466|NCT01695915|constipation
255467|NCT01695915|children
255468|NCT01695915|healthy
255469|NCT01695915|rectal diameter
255470|NCT01695863|Miralax with gatorade and dulcolax
255471|NCT01695863|Movi pre
255472|NCT01695863|Patient satisfaction and efficacy
255473|NCT01695850|Randomized controlled trial
255474|NCT01695850|Drugs,Chinese Herbal
255475|NCT01695850|Constipation/drug therapy
255476|NCT01695837|Diet counseling
255477|NCT01695837|primary care
255478|NCT01695824|catheter ablation
255479|NCT01695811|Keratoconus, PKP, femtosecond laser assisted keratoplasty
255480|NCT01695798|poliomyelitis
255481|NCT01695798|oral polio vaccine
255482|NCT01695798|OPV
255483|NCT01695798|seroconversion
255484|NCT01695798|mucosal immunity
255485|NCT01695798|malnutrition
255486|NCT01695798|IPV
255487|NCT01695798|Inactivated polio vaccine
255488|NCT01695798|Pakistan
255489|NCT01695759|Anemia Secondary
255490|NCT01695759|Chronic Kidney Disease
255491|NCT01695720|Knee Injuries
255492|NCT01695720|Meniscus Injuries
255493|NCT01695720|Articular Cartilage Injuries
255494|NCT01695720|Orthopaedic Diagnostic
255495|NCT01695720|Magnetic Resonance Imaging
255496|NCT01695707|atopic dermatitis
255497|NCT01695707|eczema
255498|NCT01695681|Quality of life
255499|NCT01695681|Celiac Disease/diet therapy
255500|NCT01695681|Celiac Disease/diagnosis
255501|NCT01695681|Prospective Studies
255502|NCT01695668|Graft versus Host Disease (GVHD)
255503|NCT01695668|dry eyes
255504|NCT01695668|Bone marrow transplant (BMT)
255505|NCT01695668|Restasis
255506|NCT01695668|Lotemax
255507|NCT01695642|lasik, intralase, microkeratome
255508|NCT01695603|Brain injury
255509|NCT01695603|Controlled ventilation
255510|NCT01695603|Intellivent
255511|NCT01695603|Capnia control
255512|NCT01695590|Myeloma
255513|NCT01695590|PRLX93936
255514|NCT01695577|Traumatic brain injury
255515|NCT01695577|Dizziness
255516|NCT01695577|Vestibular rehabilitation
255517|NCT01695577|Balance rehabilitation
255518|NCT01695564|atrial enlargement
255519|NCT01695564|left atrial appendage
255520|NCT01695551|Radiofrequency ablation
255521|NCT01695551|fast heart rhythm
255522|NCT01695551|ventricle
255523|NCT01695551|catheter ablation
255524|NCT01695551|ablation
255525|NCT01695538|Yoga
255526|NCT01695538|atrial tachycardia
255527|NCT01695525|Neurocardiogenic Syncope
255528|NCT01695525|Yoga
255529|NCT01695486|BIS
255530|NCT01695486|Comfort
255531|NCT01695486|open muscle biopsy
255532|NCT01695473|Prostate cancer
255533|NCT01695473|High-risk prostate cancer
255534|NCT01695473|Radical prostatectomy
255535|NCT01695473|BKM120
255536|NCT01695460|Migraine
255537|NCT01695460|Vitamin D
255538|NCT01695434|multiple sclerosis
255539|NCT01695434|MRI
255540|NCT01695434|Copaxone
255541|NCT01695434|healthy controls
255542|NCT01695434|glatiramer acetate
255543|NCT01695421|Transcutaneous Electric Nerve Stimulation
255544|NCT01695421|Oxygen Consumption
255545|NCT01695421|Heart Failure
255546|NCT01695408|Drug Treatment
255547|NCT01695408|Treatment pathways
255548|NCT01695408|Clinical routine
255549|NCT01695408|Registry
255550|NCT01695408|Outcomes
255551|NCT01695408|Survival
255552|NCT01695408|Patient-related outcomes
255553|NCT01695408|Quality of life
255554|NCT01695408|Steroids
255555|NCT01695408|Azathioprine
255556|NCT01695408|N-Acetylcysteine
255557|NCT01695408|Pirfenidone
255558|NCT01695408|Tyrosine kinase inhibitors
255559|NCT01695408|Nintedanib
255560|NCT01695408|multicenter
255561|NCT01695408|Germany
255562|NCT01695408|Safety
255563|NCT01695408|Adverse event
255564|NCT01695395|intellectual disability
255565|NCT01695395|mental disorder
255566|NCT01695395|dual diagnosis
255567|NCT01695395|provision
255568|NCT01695395|needs assessment
255569|NCT01695395|quality of life
255570|NCT01695382|Cancer
255571|NCT01695382|Palliative Care
255572|NCT01695382|Patient Navigation
255573|NCT01695356|Melasma
255574|NCT01695356|sunscreens
255575|NCT01695356|visible light
255576|NCT01695356|ultraviolet light
255577|NCT01695343|Cystic Fibrosis
255578|NCT01695343|Pseudomonas aeruginosa (Pa)
255579|NCT01695343|CF
255580|NCT01695330|Multiple Myeloma
255581|NCT01695330|Relapsed
255582|NCT01695330|Refractory
255583|NCT01695330|Bortezomib
255584|NCT01695330|Subcutaneous
255585|NCT01695330|Oncotherapeutics
255586|NCT01695317|Migraine
255587|NCT01695317|Preventive medication
255588|NCT01695304|Cryptosporidiosis
255589|NCT01695304|Waterborne disease
255590|NCT01695304|Diarrheal disease
255591|NCT01695304|Ceramic water filters
255592|NCT01695304|infants
255593|NCT01695304|young children
255594|NCT01695304|drinking water
255595|NCT01695304|Kenya
255596|NCT01695291|Obsessive compulsive disorder
255597|NCT01695278|motivational interviewing
255598|NCT01695278|telephone counseling
255599|NCT01695278|medical education
255600|NCT01695278|diabetes self management
255601|NCT01695265|Airflow Obstruction
255602|NCT01695226|Celecoxib
255603|NCT01695226|Clinical trial, Phase II
255604|NCT01695226|Oligonucleotide Array Sequence Analysis
255605|NCT01695213|uncemented hip
255606|NCT01695213|bone remodeling
255607|NCT01695213|DEXA
255608|NCT01695213|clinical evaluation
255609|NCT01695187|Herpes, Herpes Labialis, nanoemulsion, NanoBio, NB-001
255610|NCT01695174|Primary Sclerosing Cholangitis
255611|NCT01695174|Xifaxan
255612|NCT01695161|Mucopolysaccharidosis
255613|NCT01695161|Fabry disease
255614|NCT01695148|beta-carotene biofortified maize
255615|NCT01695148|micronutrients
255616|NCT01695148|vitamin A
255617|NCT01695148|serum retinol
255618|NCT01695148|dark adaptation
255619|NCT01695135|Prostate neoplasms
255620|NCT01695135|Prostate cancer
255621|NCT01695135|Metastatic castration resistant prostate cancer
255622|NCT01695135|Abiraterone acetate
255623|NCT01695135|JNJ-212082
255624|NCT01695122|Head and Neck Cancer
255625|NCT01695122|Oropharyngeal cancer
255626|NCT01695122|Oral cavity cancer
255627|NCT01695122|Chemoradiation
255628|NCT01695122|valproic acid
255629|NCT01695122|histone deacetylase
255630|NCT01695109|GLP1
255631|NCT01695109|obesity
255632|NCT01695109|fMRI
255633|NCT01695109|ghrelin
255634|NCT01695083|Non alcoholic steatohepatitis
255635|NCT01695083|Liver fibrosis,Steatosis
255636|NCT01695083|Liver inflammation
255637|NCT01695083|Morbid obesity
255638|NCT01695083|Non invasive tests
255639|NCT01695031|Urban adolescents
255640|NCT01695031|Acute asthma
255641|NCT01695031|Emergency department
255642|NCT01695031|Computer tailoring
255643|NCT01695031|Web-based intervention
255644|NCT01695018|oral epithelial dysplasia
255645|NCT01695018|p16 methylation
255646|NCT01695018|diagnostic reagents
255647|NCT01695018|early diagnosis
255648|NCT01694992|Stroke
255649|NCT01694992|Early Ambulation
255650|NCT01694992|Rehabilitation
255651|NCT01694992|Physical Therapy
255652|NCT01694992|Randomized controlled trial
255653|NCT01694979|Pelvic floor
255654|NCT01694979|Rehabilitation
255655|NCT01694979|Respiration
255656|NCT01694979|Urinary incontinence
255657|NCT01694953|MNGIE
255658|NCT01694953|Mitochondrial
255659|NCT01694953|Mitochondrial Neurogastrointestinal encephalopathy
255660|NCT01694940|mitochondrial disorders
255661|NCT01694940|Mito Disease
255662|NCT01694940|Mitochondria
255663|NCT01694940|Mitochondrial disease
255664|NCT01694940|MELAS
255665|NCT01694940|MERRF
255666|NCT01694940|LHON
255667|NCT01694940|Leigh Syndrome
255668|NCT01694940|NARP
255669|NCT01694940|Kearns Sayre syndrome
255670|NCT01694940|CPEO
255671|NCT01694940|Alpers Huttenlocher
255672|NCT01694940|Pearson
255673|NCT01694940|MNGIE
255674|NCT01694940|Barth Syndrome
255675|NCT01694940|CoQ Deficiency
255676|NCT01694940|DAD
255677|NCT01694940|Diabetes and Deafness
255678|NCT01694940|Encephalopathy
255679|NCT01694940|Encephalomyopathy
255680|NCT01694940|FBSN
255681|NCT01694940|Hepatocerebral Disease
255682|NCT01694940|Leukoencephalopathy
255683|NCT01694940|MILS
255684|NCT01694940|Complex I Deficiency
255685|NCT01694940|Complex II Deficiency
255686|NCT01694940|Complex III Deficiency
255687|NCT01694940|Complex IV Deficiency
255688|NCT01694940|Complex V Deficiency
255689|NCT01694940|mitochondrial DNA depletion syndrome
255690|NCT01694940|mtDNA depletion syndrome
255691|NCT01694927|Mesenchymal stem cell
255692|NCT01694927|Spinal cord injury
255693|NCT01694914|Corneal Transplantation
255694|NCT01694914|corneal organ culture medium
255695|NCT01694914|free animal compound medium
255696|NCT01694888|Students practice, Lecture; Nursing records; Nursing education; Midwifery
255697|NCT01694875|cervix cancer
255698|NCT01694875|HPV
255699|NCT01694875|APTIMA
255700|NCT01694862|quasi experimental
255701|NCT01694862|evaluation
255702|NCT01694862|intervention
255703|NCT01694862|service integration
255704|NCT01694862|cost analysis
255705|NCT01694862|HIV
255706|NCT01694862|FP
255707|NCT01694862|PNC
255708|NCT01694862|Sub-Saharan Africa
255709|NCT01694849|PPARs
255710|NCT01694849|NASH
255711|NCT01694849|Non-Alcoholic Steatohepatitis
255712|NCT01694849|Liver Diseases
255713|NCT01694849|Fibrosis
255714|NCT01694836|Allergic rhinitis
255715|NCT01694836|Allergic rhinoconjunctivitis
255716|NCT01694836|Allergy induced asthma
255717|NCT01694836|Birch (Betula alba)
255718|NCT01694836|Hayfever
255719|NCT01694836|Immunotherapy
255720|NCT01694823|Cartilage repair
255721|NCT01694823|Cartilage defects
255722|NCT01694823|cell sheet
255723|NCT01694823|Autologous chondrocyte implantation
255724|NCT01694810|acne vulgaris
255725|NCT01694758|Benchmarking could improve quality of patient care
255726|NCT01694758|ESC and ATP III Guidelines
255727|NCT01694745|Newborns
255728|NCT01694745|Premature
255729|NCT01694745|Pain
255730|NCT01694745|Pain assessment
255731|NCT01694745|Endotracheal Intubation
255732|NCT01694745|Analgesia
255733|NCT01694745|Sedation
255734|NCT01694745|Longterm effects of pain
255735|NCT01694745|Epidemiology
255736|NCT01694732|Chronic obstructive pulmonary disease
255737|NCT01694732|Varenicline
255738|NCT01694732|Smoking cessation
255739|NCT01694719|Depression
255740|NCT01694719|Major Depressive Disorder
255741|NCT01694719|Behavioral Activation
255742|NCT01694719|Cognitive Training
255743|NCT01694680|AMD
255744|NCT01694680|Lutein
255745|NCT01694680|Visual function
255746|NCT01694680|Early signs of AMD
255747|NCT01694680|AREDS-category 2
255748|NCT01694641|time lapse monitoring
255749|NCT01694641|blastocyst
255750|NCT01694641|single embryo transfer
255751|NCT01694641|clinical pregnancy
255752|NCT01694641|implantation rate
255753|NCT01694615|Lung Transplantation
255754|NCT01694615|Acute Rejection
255755|NCT01694602|Cachexia
255756|NCT01694602|Sarcopenia
255757|NCT01694602|De Novo
255758|NCT01694602|Deuterated
255759|NCT01694589|pancreatic cancer
255760|NCT01694589|resectable pancreatic cancer
255761|NCT01694576|Nasopharyngeal carcinoma staged N2-3M0
255762|NCT01694576|Adjuvant chemotherapy
255763|NCT01694563|Atrial Fibrillation
255764|NCT01694550|pacemaker
255765|NCT01694550|ICD / CRTD
255766|NCT01694550|corrected QT-interval
255767|NCT01694537|lumbrokinase
255768|NCT01694537|fibrinolytic
255769|NCT01694537|plasmin-antiplasmin complex
255770|NCT01694537|euglobulin clot lysis time
255771|NCT01694537|platelet aggregation
255772|NCT01694511|Endoscopy, Gastrointestinal
255773|NCT01694485|Ulcerative Colitis, IBD
255774|NCT01694459|angioplasty
255775|NCT01694459|heparin
255776|NCT01694459|trial
255777|NCT01694446|Intestinal lipoprotein
255778|NCT01694446|Apo B48 and apoB100
255779|NCT01694446|Pancreatic clamp
255780|NCT01694407|Prevention
255781|NCT01694394|atrial fibrillation
255782|NCT01694394|implantable cardiac monitor
255783|NCT01694394|left atrial enlargement
255784|NCT01694394|CHA2DS2 VASc Score
255785|NCT01694394|cardiovascular risk
255786|NCT01694381|Acute Ischemic Stroke
255787|NCT01694381|TS01
255788|NCT01694381|Mutant pro-urokinase
255789|NCT01694381|M5
255790|NCT01694381|C1 inhibitor
255791|NCT01694381|Safety
255792|NCT01694381|Stroke
255793|NCT01694381|Tolerability
255794|NCT01694381|Ischemia
255795|NCT01694381|Cerebral Infarction
255796|NCT01694381|Cerebrovascular Disorders
255797|NCT01694381|Vascular Diseases
255798|NCT01694381|Cardiovascular Diseases
255799|NCT01694381|Brain Infarction
255800|NCT01694381|Brain Ischemia
255801|NCT01694381|Fibrinolytic Agents
255802|NCT01694381|Thrombolytic Agents
255803|NCT01694381|Molecular Mechanisms of Pharmacological Action
255804|NCT01694381|Pharmacologic Actions
255805|NCT01694381|Cardiovascular Agents
255806|NCT01694381|Therapeutic Uses
255807|NCT01694381|Hematologic Agents
255808|NCT01694368|Near infrared spectroscopy; lipid core; vulnerable plaque
255809|NCT01694329|Streptococcus pneumoniae
255810|NCT01694329|Pneumococcal Conjugate Vaccines
255811|NCT01694329|Immunization
255812|NCT01694329|Otitis media
255813|NCT01694316|Computerized neurobehavioral intervention
255814|NCT01694277|Gastrointestinal Stromal Tumour
255815|NCT01694277|GIST
255816|NCT01694277|non-resectable
255817|NCT01694277|metastatic
255818|NCT01694277|second line treatment
255819|NCT01694277|resistance to imatinib
255820|NCT01694264|HBV surface antigen
255821|NCT01694264|Anti-HBc positive
255822|NCT01694264|Anti-TNFα Treatment
255823|NCT01694264|Reactivation
255824|NCT01694251|mitral valve area
255825|NCT01694251|pressure half time
255826|NCT01694251|3 dimensional transesophageal echocardiography
255827|NCT01694251|computed tomography
255828|NCT01694238|Colostomy
255829|NCT01694238|Surgical technique
255830|NCT01694225|Breast cancer
255831|NCT01694225|Anti-estrogen therapy
255832|NCT01694212|Macular edema
255833|NCT01694212|Cataract
255834|NCT01694212|Diabetic retinopathy
255835|NCT01694212|Anti-inflammatory agents,Non-steroidal
255836|NCT01694199|Pulsed Radiofrequency Energy (PRFE)
255837|NCT01694199|Pain
255838|NCT01694199|Post surgical
255839|NCT01694199|Opioids
255840|NCT01694199|Pain relief
255841|NCT01694199|Medical device
255842|NCT01694199|Endorphins
255843|NCT01694173|Type 2 diabetes mellitus, F18-FDG labelled stem cells
255844|NCT01694160|kidney transplant patients
255845|NCT01694160|Albuminuria
255846|NCT01694147|relationship
255847|NCT01694147|endothelial injury
255848|NCT01694147|vascular permeability
255849|NCT01694147|severe sepsis related ALI/ARDS
255850|NCT01694134|Discopathy
255851|NCT01694134|Modic I
255852|NCT01694134|Corticoids
255853|NCT01694134|Local Anaesthetic
255854|NCT01694134|Intradiscal injection
255855|NCT01694121|HIV prevention
255856|NCT01694121|African American men
255857|NCT01694121|evaluation study
255858|NCT01694095|Geographic atrophy, prognosis, risk factors, natural history
255859|NCT01694082|brief intervention
255860|NCT01694082|web-based interventions
255861|NCT01694082|computer-based interventions
255862|NCT01694082|harm reduction
255863|NCT01694082|young adult
255864|NCT01694082|college student
255865|NCT01694069|piperacillin
255866|NCT01694069|tazobactam
255867|NCT01694069|pseudomonas aeruginosa
255868|NCT01694069|cystic fibrosis
255869|NCT01694069|pulmonary exacerbation
255870|NCT01694069|continuous infusion
255871|NCT01694069|beta lactam
255872|NCT01694030|Attachment security priming
255873|NCT01694030|depressed mood
255874|NCT01694017|HIV,treatment,cost effectiveness,drug toxicity,QOL,costs
255875|NCT01694004|Nutrient absorption
255876|NCT01694004|Duodenal feeding tube
255877|NCT01694004|Gut-brain-gut axis
255878|NCT01693978|PTSD
255879|NCT01693978|Prolonged Exposure
255880|NCT01693978|Comorbidity
255881|NCT01693978|Treatment
255882|NCT01693978|Methadone Maintenance
255883|NCT01693978|Substance Use Disorder
255884|NCT01693939|Lasik
255885|NCT01693939|Myopia
255886|NCT01693939|Femtosecond Laser
255887|NCT01693926|Obesity
255888|NCT01693926|Children
255889|NCT01693926|Physical activity
255890|NCT01693926|Stress
255891|NCT01693926|Snacking
255892|NCT01693887|IFI
255893|NCT01693887|empirical therapy
255894|NCT01693887|preemptive therapy
255895|NCT01693887|Itraconazole
255896|NCT01693874|anxiety
255897|NCT01693874|depression
255898|NCT01693874|cognition
255899|NCT01693874|MBSR
255900|NCT01693874|mindfulness
255901|NCT01693874|stress
255902|NCT01693874|elderly
255903|NCT01693861|Colorectal
255904|NCT01693861|Cancer
255905|NCT01693861|Metastatic
255906|NCT01693861|Chronotherapy
255907|NCT01693861|Urine
255908|NCT01693861|Nucleosides
255909|NCT01693861|Chemotherapy
255910|NCT01693861|Treated with chemotherapy
255911|NCT01693848|Colorectal
255912|NCT01693848|Cancer
255913|NCT01693848|Metastatic
255914|NCT01693848|Control
255915|NCT01693848|Urine
255916|NCT01693848|Nucleosides
255917|NCT01693848|Surgery
255918|NCT01693848|General anesthesia
255919|NCT01693848|Scheduled for surgery
255920|NCT01693835|Colorectal
255921|NCT01693835|Cancer
255922|NCT01693835|Metastatic
255923|NCT01693835|Healthy
255924|NCT01693835|Control
255925|NCT01693835|Circadian
255926|NCT01693835|Urine
255927|NCT01693835|Nucleosides
255928|NCT01693822|metastatic renal cell carcinoma
255929|NCT01693822|predominant clear cell histology
255930|NCT01693822|Unsuitable for nephrectomy
255931|NCT01693822|unsuitable for 'watch and wait' policy
255932|NCT01693809|Caffeine
255933|NCT01693809|Vestibular Evoked Myogenic Potentials
255934|NCT01693809|dizziness
255935|NCT01693809|vertigo
255936|NCT01693809|tinnitus
255937|NCT01693770|Bone Metastasis
255938|NCT01693770|Pain Palliation
255939|NCT01693770|High Intensity Focused Ultrasound
255940|NCT01693757|Anterior Cruciate Ligament
255941|NCT01693757|Hamstrings versus patellar tendon
255942|NCT01693757|Hop test
255943|NCT01693757|Return to sports
255944|NCT01693744|Pseudoexfoliation, chronic kidney disease
255945|NCT01693731|Breast cancer
255946|NCT01693731|Periodontal Diseases
255947|NCT01693731|Aromatase Inhibitors
255948|NCT01693731|Oral Health Related Quality of Life
255949|NCT01693718|cancer
255950|NCT01693718|advanced
255951|NCT01693718|oral cavity
255952|NCT01693718|larynx
255953|NCT01693705|Tracheostomy
255954|NCT01693692|Fibromyalgia
255955|NCT01693679|Tebivudine eGFR non-Tebivudine
255956|NCT01693666|Pregnancy
255957|NCT01693666|Obesity
255958|NCT01693666|Weight gain
255959|NCT01693666|Obstetric complications
255960|NCT01693666|Lifestyle intervention
255961|NCT01693653|Behcet's syndrome
255962|NCT01693653|oral ulcers
255963|NCT01693640|Behcet's
255964|NCT01693614|Diffuse large B-cell lymphoma, Mantle cell lymphoma, Follicular lymphoma, PI3K inhibitor, Non-Hodgkin lymphoma, NHL
255965|NCT01693601|Myelofibrosis
255966|NCT01693601|Panobinostat
255967|NCT01693601|Ruxolitinib
255968|NCT01693588|Pain
255969|NCT01693588|Postoperative Pain
255970|NCT01693588|Surgical Pain
255971|NCT01693588|Neurosurgical Pain
255972|NCT01693575|Small pupil cataract surgery
255973|NCT01693575|Intraoperative floppy iris syndrome (IFIS)
255974|NCT01693562|Advanced solid tumors
255975|NCT01693549|HER-2 negative
255976|NCT01693549|Metastatic breast adenocarcinoma
255977|NCT01693536|Elderly
255978|NCT01693536|Sodium reduction
255979|NCT01693536|Fitness increase
255980|NCT01693536|Primary Care
255981|NCT01693523|Pancreatic Cancer
255982|NCT01693523|Pancreatic adenocarcinoma
255983|NCT01693523|Locally advanced
255984|NCT01693523|Metastatic disease
255985|NCT01693523|Symptom reduction
255986|NCT01693523|Minocycline
255987|NCT01693523|Dynacin
255988|NCT01693523|Minocin
255989|NCT01693523|Minocin PAC
255990|NCT01693523|Myrac
255991|NCT01693523|Solodyn
255992|NCT01693523|Placebo
255993|NCT01693523|Sugar Pill
255994|NCT01693523|Questionnaires
255995|NCT01693523|Surveys
255996|NCT01693510|Excess gestational weight gain (GWG)
255997|NCT01693510|Obesity
255998|NCT01693510|Type 2 diabetes
255999|NCT01693510|Elevated fats in the blood
256000|NCT01693510|High blood pressure
256001|NCT01693497|Posttraumatic Stress Disorder
256002|NCT01693497|PTSD
256003|NCT01693497|psychotherapy
256004|NCT01693497|randomized trial
256005|NCT01693497|gestalt
256006|NCT01693484|Calcaneus
256007|NCT01693484|Fracture
256008|NCT01693484|Indocyanine Green
256009|NCT01693484|Angiography
256010|NCT01693484|Open Reduction and Internal Fixation
256011|NCT01693471|asthma
256012|NCT01693471|SF-36
256013|NCT01693471|HRQOL
256014|NCT01693458|HIV
256015|NCT01693458|prevention
256016|NCT01693458|HIV-positive
256017|NCT01693458|education
256018|NCT01693445|Gastrointestinal neoplasms
256019|NCT01693445|Oxaliplatin
256020|NCT01693445|Irinotecan
256021|NCT01693445|S-1
256022|NCT01693432|Esophageal neoplasms
256023|NCT01693432|Docetaxel
256024|NCT01693432|S-1
256025|NCT01693419|pancreas neoplasm
256026|NCT01693419|gemcitabine
256027|NCT01693419|erlotinib
256028|NCT01693419|S-1
256029|NCT01693406|human milk
256030|NCT01693406|infant growth
256031|NCT01693406|obesity
256032|NCT01693406|diabetes
256033|NCT01693406|breastfeeding
256034|NCT01693393|primary Sjogren´s Syndrome
256035|NCT01693393|Cyclosporine
256036|NCT01693380|Influenza
256037|NCT01693380|Vaccination
256038|NCT01693380|Vaccines
256039|NCT01693380|Schoolchildren
256040|NCT01693380|Effectiveness
256041|NCT01693380|Intervention studies
256042|NCT01693380|Adolescents
256043|NCT01693380|Laboratory Confirmed Influenza
256044|NCT01693367|Femoral fracture
256045|NCT01693367|Periprosthetic fracture
256046|NCT01693367|Fracture fixation, internal
256047|NCT01693367|Distal femur fractures
256048|NCT01693367|Dynamic Locking Screw
256049|NCT01693367|WOMAC
256050|NCT01693354|dialysis
256051|NCT01693354|mortality
256052|NCT01693354|cardiovascular stability
256053|NCT01693354|inflammation
256054|NCT01693354|quality of life
256055|NCT01693341|Chronic stroke patients
256056|NCT01693341|Stroke rehabilitation
256057|NCT01693341|Caregiver
256058|NCT01693341|Caregiver-mediated intervention
256059|NCT01693328|quality of life
256060|NCT01693328|PecFent
256061|NCT01693328|Lazanda
256062|NCT01693328|fentanyl
256063|NCT01693328|intranasal
256064|NCT01693328|breakthrough cancer pain
256065|NCT01693302|Blood Glucose
256066|NCT01693302|Meal insulin
256067|NCT01693289|Metformin
256068|NCT01693289|letrozole
256069|NCT01693289|ovarian drilling
256070|NCT01693289|clomiphene resistance
256071|NCT01693289|polycystic ovary.
256072|NCT01693276|pancreatic cancer
256073|NCT01693263|end stage renal disease (ESRD)
256074|NCT01693263|brachiocephalic fistula (BCF)
256075|NCT01693263|cephalic arch stenosis (CAS)
256076|NCT01693263|dialysis
256077|NCT01693250|technology
256078|NCT01693250|healthy weight management
256079|NCT01693250|primary care setting
256080|NCT01693224|Tests, Diagnostic
256081|NCT01693224|Mycobacterium tuberculosis
256082|NCT01693224|Mycobacterium tuberculosis antigens
256083|NCT01693224|TB
256084|NCT01693224|Tuberculosis
256085|NCT01693224|Tuberculosis, Pulmonary
256086|NCT01693224|Tuberculosis, Miliary
256087|NCT01693224|Lipoarabinomannan
256088|NCT01693211|femtosecond laser
256089|NCT01693211|cataract
256090|NCT01693211|control study
256091|NCT01693211|prospective
256092|NCT01693198|allergy
256093|NCT01693198|cyanobacteria
256094|NCT01693198|sweet water swimming
256095|NCT01693185|colonoscopy
256096|NCT01693185|remifentanil
256097|NCT01693185|midazolam
256098|NCT01693185|meperidine
256099|NCT01693172|exercise
256100|NCT01693172|neoplasm
256101|NCT01693159|Painful cetuximab-induced rhagades
256102|NCT01693159|Radioimmunotherapy
256103|NCT01693159|Head and neck cancer
256104|NCT01693146|Oxygen
256105|NCT01693146|High Flow
256106|NCT01693146|COPD
256107|NCT01693146|Hypercapnia
256108|NCT01693120|ablation
256109|NCT01693120|atrial fibrillation
256110|NCT01693120|Radio frequency
256111|NCT01693107|Atrial Fibrillation
256112|NCT01693107|Catheter Ablation
256113|NCT01693107|Electrophysiology
256114|NCT01693107|Cardiac Arrhythmias
256115|NCT01693081|Parkinson's disease
256116|NCT01693081|inhaled apomorphine
256117|NCT01693081|"convert off to on"
256118|NCT01693068|Cutaneous Melanoma
256119|NCT01693068|Dacarbazine
256120|NCT01693068|Pimasertib
256121|NCT01693068|N-Ras
256122|NCT01693055|orbital Computed Tomography
256123|NCT01693055|baggy eyelids
256124|NCT01693055|orbital fat prolapse
256125|NCT01693055|UltheraTM
256126|NCT01693055|high intensity focused ultrasound
256127|NCT01693042|heart failure
256128|NCT01693042|old myocardial infarction
256129|NCT01693042|bone marrow-derived mononuclear cells
256130|NCT01693042|chronic
256131|NCT01693042|ischemic
256132|NCT01693029|erythropoietin alfa
256133|NCT01693029|CKD 5d
256134|NCT01693016|non-invasive Hb measurement in children
256135|NCT01693003|COPD
256136|NCT01692990|Appetite
256137|NCT01692990|Fish oil
256138|NCT01692990|Long-chain n-3 fatty acids
256139|NCT01692912|Psoriatic Arthritis
256140|NCT01692912|Randomized
256141|NCT01692912|Single blind
256142|NCT01692912|Treat to target
256143|NCT01692899|Retention Rates
256144|NCT01692899|of Adalimumab
256145|NCT01692899|Etanercept and Infliximab
256146|NCT01692899|as First and Second-Line Biotherapy
256147|NCT01692899|in Patients with Rheumatoid Arthritis
256148|NCT01692899|in Daily Practice.
256149|NCT01692899|TNF inhibitors
256150|NCT01692899|biotherapy
256151|NCT01692899|retrospective study
256152|NCT01692886|13vPnC
256153|NCT01692886|7vPnC
256154|NCT01692886|Healthy subjects
256155|NCT01692886|China
256156|NCT01692873|pancreatic tumor
256157|NCT01692860|the impact of a higher dairy-based protein diet in
256158|NCT01692860|combination with energy restriction on muscle health,
256159|NCT01692860|metabolic health (including blood pressure) in overweight
256160|NCT01692860|and obese, middle aged adults
256161|NCT01692847|patient deterioration
256162|NCT01692847|rapid response teams
256163|NCT01692847|acute care teams
256164|NCT01692847|early warning scoring
256165|NCT01692834|bioequivalence
256166|NCT01692834|pharmacokinetics
256167|NCT01692834|tolerability
256168|NCT01692834|safety
256169|NCT01692834|ciclosporin
256170|NCT01692834|cyclosporine
256171|NCT01692834|cyclosporine A
256172|NCT01692834|Sandimmune
256173|NCT01692834|Sandimmun
256174|NCT01692834|CicloMulsion
256175|NCT01692834|NeuroSTAT
256176|NCT01692821|retinal oxygen saturation
256177|NCT01692821|retinal blood flow
256178|NCT01692821|hyperoxia
256179|NCT01692821|hypoxia
256180|NCT01692808|Crohn
256181|NCT01692808|vitamin D
256182|NCT01692808|remission
256183|NCT01692808|inflammation
256184|NCT01692808|tolerance
256185|NCT01692795|Myocardial infarction
256186|NCT01692795|Antiplatelets
256187|NCT01692795|Lipid lowering agents
256188|NCT01692795|ACE inhibitors
256189|NCT01692795|Angiotensin Receptor Blockers
256190|NCT01692795|Beta blockers
256191|NCT01692795|Blood pressure lowering drugs
256192|NCT01692782|ADHD
256193|NCT01692782|Attention deficit hyperactivity disorder
256194|NCT01692769|Trauma
256195|NCT01692769|Pediatric
256196|NCT01692769|Intravenous Fluid
256197|NCT01692769|Normal Saline
256198|NCT01692769|Ringer's Lactate
256199|NCT01692743|Telemedicine
256200|NCT01692743|Inflammatory bowel disease
256201|NCT01692743|Crohn's disease
256202|NCT01692743|Ulcerative colitis
256203|NCT01692743|Quality of life
256204|NCT01692743|Health care utilization
256205|NCT01692730|Smoking Cessation
256206|NCT01692730|Web Assisted Tobacco Intervention
256207|NCT01692691|Melanoma Metastatic
256208|NCT01692678|Advanced or Metastatic liposarcoma or leiomyosarcoma
256209|NCT01692678|Sarcoma
256210|NCT01692678|L-sarcoma
256211|NCT01692678|Liposarcoma
256212|NCT01692678|Leiomyosarcoma
256213|NCT01692678|Trabectedin
256214|NCT01692678|Dacarbazine
256215|NCT01692678|Yondelis
256216|NCT01692678|Chinese patients
256217|NCT01692678|Overall survival
256218|NCT01692678|Pharmacokinetics
256219|NCT01692665|meibomian gland dysfunction
256220|NCT01692665|keratometric value
256221|NCT01692665|ocular aberration
256222|NCT01692626|Cetuximab rash
256223|NCT01692626|Erbitux rash
256224|NCT01692626|Rash
256225|NCT01692626|Pimecrolimus
256226|NCT01692626|1% Topical pimecrolimus cream
256227|NCT01692600|Late oral radiation toxicity
256228|NCT01692600|head and neck cancer patients
256229|NCT01692600|optical coherence tomography
256230|NCT01692600|subsurface imaging
256231|NCT01692600|mirometer-resolution imaging
256232|NCT01692600|vascular imaging
256233|NCT01692600|Doppler optical coherence tomography
256234|NCT01692600|speckle variance optical coherence tomography
256235|NCT01692587|PSA
256236|NCT01692587|protein
256237|NCT01692587|prostate
256238|NCT01692574|depression and obesity treatment
256239|NCT01692561|Dysautonomia
256240|NCT01692561|Postural orthostatic tachycardic hypotension
256241|NCT01692561|Neurocardiogenic vasovagal syncope
256242|NCT01692509|Non invasive ventilation
256243|NCT01692509|Respiratory failure
256244|NCT01692509|Respiratory comfort
256245|NCT01692496|Advanced
256246|NCT01692496|Metastatic
256247|NCT01692496|Liposarcoma
256248|NCT01692496|Pazopanib
256249|NCT01692483|Prostate neoplasms
256250|NCT01692483|Prostate cancer
256251|NCT01692483|Castration resistant prostate cancer
256252|NCT01692483|Hormone refractory prostate cancer
256253|NCT01692483|Abiraterone acetate
256254|NCT01692483|Taxane
256255|NCT01692470|Human immunodeficiency virus type 1 (HIV-1) infection
256256|NCT01692470|HIV-1
256257|NCT01692470|Anti-retroviral naive
256258|NCT01692470|ARV
256259|NCT01692470|Filipino patients
256260|NCT01692470|Rilpivirine hydrochloride
256261|NCT01692470|Edurant
256262|NCT01692457|Rheumatoid Arthritis
256263|NCT01692457|Psoriatic Arthritis
256264|NCT01692457|Ankylosing Spondylitis
256265|NCT01692457|Arthritis
256266|NCT01692457|Spondylitis
256267|NCT01692457|Joint pain
256268|NCT01692457|CNTO148
256269|NCT01692457|Golimumab
256270|NCT01692457|Simponi
256271|NCT01692457|Filipino
256272|NCT01692457|Post-Marketing
256273|NCT01692457|Surveillance
256274|NCT01692444|Chronic Obstructive Pulmonary Disease
256275|NCT01692444|Fibrosis
256276|NCT01692444|Fibroblast
256277|NCT01692444|Lung attenuation
256278|NCT01692444|Pletysmography
256279|NCT01692418|Anaemia
256280|NCT01692418|Blood transfusion
256281|NCT01692418|Surgery
256282|NCT01692418|Iron
256283|NCT01692418|Ferric carboxymaltose
256284|NCT01692392|Pectus carinatum
256285|NCT01692392|Quality of life
256286|NCT01692392|Pain, postoperative
256287|NCT01692392|Somatosensory disorders
256288|NCT01692379|Acute ischemic stroke
256289|NCT01692379|endovascular treatment
256290|NCT01692379|clinical trial
256291|NCT01692353|Flow mediated dilation
256292|NCT01692353|Carotid intima-media thickness
256293|NCT01692353|Ankle-brachial index
256294|NCT01692353|Smokeless tobacco
256295|NCT01692353|Biological markers
256296|NCT01692353|Nicotine
256297|NCT01692353|Tobacco-specific nitrosamines
256298|NCT01692353|Polycyclic aromatic hydrocarbons
256299|NCT01692353|Aromatic amines
256300|NCT01692353|Mercapturic acid metabolites
256301|NCT01692353|Cholesterol
256302|NCT01692353|Blood lipids
256303|NCT01692353|Oxidative stress
256304|NCT01692353|Inflammation
256305|NCT01692353|Cytokines
256306|NCT01692340|tomato
256307|NCT01692340|prostate cancer
256308|NCT01692340|metabolism
256309|NCT01692327|glucose intolerance (20)
256310|NCT01692327|Control (20)
256311|NCT01692314|Endothelial function
256312|NCT01692314|Microvascular reactivity
256313|NCT01692314|Obesity
256314|NCT01692314|Adolescents
256315|NCT01692301|hypertension, elderly, central aortic pulse pressure, central pulse pressure, pulse wave velocity
256316|NCT01692262|Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
256317|NCT01692262|adenocarcinoma of the prostate,
256318|NCT01692262|prostate cancer,
256319|NCT01692262|progressive disease,
256320|NCT01692262|advanced disease.
256321|NCT01692249|chronic shoulder pain
256322|NCT01692249|rotator cuff tendinopathy
256323|NCT01692249|sap therapy
256324|NCT01692249|balneotherapy
256325|NCT01692236|MRI
256326|NCT01692236|HIV
256327|NCT01692236|Neurocognitive Disorders
256328|NCT01692236|Major Depression
256329|NCT01692236|Vasculopathy
256330|NCT01692223|Personal genomics
256331|NCT01692223|Genome Sequencing Results
256332|NCT01692223|12-167
256333|NCT01692210|Breast Cancer
256334|NCT01692210|Dexmedetomidine
256335|NCT01692210|Unilateral mastectomy
256336|NCT01692210|Blood sample collections
256337|NCT01692210|Immune system
256338|NCT01692210|White blood cell levels
256339|NCT01692197|Leukemia
256340|NCT01692197|Acute Myeloid Leukemia
256341|NCT01692197|Acute Myelogenous Leukemia
256342|NCT01692197|AML
256343|NCT01692197|Relapsed or Refractory
256344|NCT01692197|High-Risk Myelodysplastic Syndromes
256345|NCT01692197|HRMDS
256346|NCT01692197|E7070
256347|NCT01692197|Idarubicin
256348|NCT01692197|Idamycin
256349|NCT01692197|Cytarabine
256350|NCT01692197|ARA-C
256351|NCT01692197|Cytosar
256352|NCT01692197|DepoCyt
256353|NCT01692197|Cytosine Arabinosine Hydrochloride
256354|NCT01692197|Dexamethasone
256355|NCT01692197|Decadron
256356|NCT01692184|AVL-292
256357|NCT01692184|Safety
256358|NCT01692184|Pharmacokinetics
256359|NCT01692184|Pharmacodynamics
256360|NCT01692184|Pharmacology, Clinical
256361|NCT01692171|Subjects
256362|NCT01692158|subjects
256363|NCT01692145|Dry eye syndromes
256364|NCT01692145|Corneal diseases
256365|NCT01692145|Conjunctival diseases
256366|NCT01692132|Chronic Constipation
256367|NCT01692132|Prucalopride
256368|NCT01692132|Post Marketing Surveillance
256369|NCT01692119|chronic heart failure
256370|NCT01692119|medication adherence
256371|NCT01692119|pharmacy
256372|NCT01692119|interdisciplinary care
256373|NCT01692119|randomized controlled trial
256374|NCT01692119|mortality
256375|NCT01692119|hospitalization
256376|NCT01692106|Heller myotomy
256377|NCT01692093|SCORAD
256378|NCT01692093|Atopic dermatits
256379|NCT01692093|Skin health
256380|NCT01692067|Rape
256381|NCT01692067|Women
256382|NCT01692067|Military
256383|NCT01692067|Veterans
256384|NCT01692067|Post-traumatic Stress Disorder
256385|NCT01692067|Traumatic Brain Injury
256386|NCT01692041|asthma
256387|NCT01692041|children
256388|NCT01692028|vitamin D
256389|NCT01692028|Associational study
256390|NCT01691976|Mild cognitive impairment
256391|NCT01691976|Androgen deprivation therapy
256392|NCT01691963|Epiglottis
256393|NCT01691963|Intubation
256394|NCT01691963|Laryngoscopy
256395|NCT01691950|Trauma
256396|NCT01691950|Limb reconstruction
256397|NCT01691950|Amputation
256398|NCT01691950|Functional outcome
256399|NCT01691950|Sensing
256400|NCT01691937|Thoracic paravertebral block
256401|NCT01691937|Postoperative pain
256402|NCT01691937|Right lobe hepatectomy
256403|NCT01691937|Patient controlled analgesia
256404|NCT01691924|Adenosine A2a receptor antagonist
256405|NCT01691924|adenosine receptor modulator
256406|NCT01691924|Cancer
256407|NCT01691911|Vascular disease
256408|NCT01691911|Open aortic aneurysm repair
256409|NCT01691911|Endovascular aneurysm repair
256410|NCT01691911|Carotid endartrectomy
256411|NCT01691911|Lower limb surgical revascularisation
256412|NCT01691911|Major lower limb amputation
256413|NCT01691859|extension study
256414|NCT01691859|Severe refractory asthma
256415|NCT01691859|safety
256416|NCT01691859|SB-240563
256417|NCT01691859|mepolizumab
256418|NCT01691859|eosinophils
256419|NCT01691833|Vitamin D
256420|NCT01691833|nonunion
256421|NCT01691833|long bone fracture
256422|NCT01691833|hypovitaminosis D
256423|NCT01691820|Adolescent females
256424|NCT01691820|Cytomegalovirus (CMV)
256425|NCT01691807|Non-Hodgkin's Lymphoma
256426|NCT01691807|drug-drug interaction
256427|NCT01691807|ofatumumab
256428|NCT01691807|bendamustine
256429|NCT01691781|Hyperparathyroidism
256430|NCT01691781|Renin-angiotensin-aldosterone system
256431|NCT01691781|ACE inhibitors
256432|NCT01691768|microbicides
256433|NCT01691768|women
256434|NCT01691768|HIV prevention
256435|NCT01691768|PrEP
256436|NCT01691768|Tenofovir gel
256437|NCT01691742|Postoperative constipation
256438|NCT01691742|Urogynecologic Surgery
256439|NCT01691742|MiraLax
256440|NCT01691742|Docusate Sodium
256441|NCT01691716|Achilles tendinopathy
256442|NCT01691716|Tendoactive
256443|NCT01691716|Eccentric training
256444|NCT01691703|Fiber Optic Technology/methods
256445|NCT01691703|Intubation, Intratracheal/methods
256446|NCT01691703|Laryngoscopy/methods
256447|NCT01691664|Esophageal Cancer
256448|NCT01691664|DC-CIK
256449|NCT01691664|immunotherapy
256450|NCT01691664|cellular therapy
256451|NCT01691664|radiation therapy
256452|NCT01691651|Keratoconus
256453|NCT01691651|Tetanus toxin
256454|NCT01690650|Preterm
256455|NCT01690650|Newborn
256456|NCT01690650|Neonate
256457|NCT01690650|Cerebral oxygenation
256458|NCT01690650|Oxygen
256459|NCT01690637|Oseltamivir
256460|NCT01690637|Tamiflu
256461|NCT01690611|Balance Training
256462|NCT01690611|Walking
256463|NCT01690611|Falls
256464|NCT01690598|Epithelial ovarian cancer
256465|NCT01690598|BRCA mutation
256466|NCT01690598|Platinum resistant
256467|NCT01690598|Platinum sensitive
256468|NCT01690598|Relapsed ovarian cancer
256469|NCT01690572|drug eluting balloon
256470|NCT01690572|constrictive remodeling
256471|NCT01690559|Ciprofloxacin
256472|NCT01690559|sepsis
256473|NCT01690559|infection
256474|NCT01690559|pneumonia
256475|NCT01690559|peritonitis
256476|NCT01690559|cholecystitis
256477|NCT01690559|cholangitis
256478|NCT01690559|anthrax
256479|NCT01690546|Opioid Addiction
256480|NCT01690546|Addiction
256481|NCT01690546|Drug Dependence
256482|NCT01690533|Avelox
256483|NCT01690533|Laryngopharyngitis
256484|NCT01690533|Tonsillitis
256485|NCT01690533|Bronchitis acute
256486|NCT01690533|Pneumonia
256487|NCT01690533|Secondary infection in chronic respiratory diseases Sinusitis
256488|NCT01690507|demethylating agent
256489|NCT01690507|immunogenicity
256490|NCT01690494|STI
256491|NCT01690494|sexually transmitted infection
256492|NCT01690494|HIV
256493|NCT01690494|criminal justice
256494|NCT01690494|probation
256495|NCT01690494|couples
256496|NCT01690494|drug use
256497|NCT01691625|Locally advanced esophageal carcinoma
256498|NCT01691625|DC-CIK
256499|NCT01691625|Immunotherapy
256500|NCT01691612|Role of Pin-1 enzyme in Asthma
256501|NCT01691599|Infection
256502|NCT01691599|Open tibia fractures
256503|NCT01691599|Closed tibia fractures
256504|NCT01691599|Wound infection
256505|NCT01691586|implantable defibrillators
256506|NCT01691586|remote patient monitoring
256507|NCT01691586|patient-reported outcomes
256508|NCT01691586|cost-effectiveness
256509|NCT01691573|ablation
256510|NCT01691573|procedure
256511|NCT01691573|pediatric
256512|NCT01691573|european
256513|NCT01691573|cardiac
256514|NCT01691573|arrhythmias
256515|NCT01691573|registry
256516|NCT01691573|observational
256517|NCT01691573|prospective
256518|NCT01691573|catheter
256519|NCT01691573|cryoablation
256520|NCT01691573|atrioventricular
256521|NCT01691547|GW642444 (Vilanterol)
256522|NCT01691547|pharmacokinetics
256523|NCT01691547|pharmacodynamics
256524|NCT01691547|GSK573719 (Umeclidinium)
256525|NCT01691547|healthy subjects
256526|NCT01691547|GW685698 (Fluticasone Furoate)
256527|NCT01691534|Tuberculosis
256528|NCT01691534|EBA
256529|NCT01691534|PA824
256530|NCT01691534|pretomanid
256531|NCT01691534|TMC207
256532|NCT01691521|safety
256533|NCT01691521|SB-240563
256534|NCT01691521|efficacy
256535|NCT01691521|placebo
256536|NCT01691521|eosinophils
256537|NCT01691521|mepolizumab
256538|NCT01691521|Severe refractory asthma
256539|NCT01691508|Safety
256540|NCT01691508|Steroid Reduction
256541|NCT01691508|Efficacy
256542|NCT01691508|SB-240563
256543|NCT01691508|Eosinophils
256544|NCT01691508|Quality of Life
256545|NCT01691508|Mepolizumab
256546|NCT01691508|Severe Refractory Asthma
256547|NCT01691495|Physician Adherence
256548|NCT01691495|superficial vein thrombosis
256549|NCT01691495|Fondaparinux
256550|NCT01691469|Bioequivalence
256551|NCT01691469|Montelukast Sodium
256552|NCT01691469|crossover
256553|NCT01691456|Bioequivalence
256554|NCT01691456|Montelukast Sodium
256555|NCT01691456|crossover
256556|NCT01691404|Flavonoids
256557|NCT01691404|Quercetin
256558|NCT01691404|Epicatechin
256559|NCT01691404|Vascular function
256560|NCT01691404|Blood pressure
256561|NCT01691404|Endothelial function
256562|NCT01691391|Advanced CRC
256563|NCT01691378|Veterans
256564|NCT01691378|Window to Hope
256565|NCT01691378|Cognitive Behavioral Therapy
256566|NCT01691378|Traumatic Brain Injury
256567|NCT01691378|Hopelessness
256568|NCT01691378|Suicide
256569|NCT01691365|Antioxidant
256570|NCT01691365|vitamins
256571|NCT01691365|Diet
256572|NCT01691352|Wound infection
256573|NCT01691352|Ostomy reversal
256574|NCT01691339|Influenza
256575|NCT01691339|Influenza virus vaccine
256576|NCT01691339|Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation
256577|NCT01691339|Fluzone® High-Dose (Influenza Virus Vaccine) 2012-2013 Formulation
256578|NCT01691339|Trivalent Inactivated Influenza Vaccine
256579|NCT01691339|Fluzone® Intradermal (Influenza Virus Vaccine) 2012-2013 Formulation
256580|NCT01691326|Influenza
256581|NCT01691326|Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation
256582|NCT01691326|Influenza virus vaccine
256583|NCT01691326|Trivalent Inactivated Influenza Vaccine
256584|NCT01691313|vanoxerine
256585|NCT01691313|atrial fibrillation
256586|NCT01691313|atrial flutter
256587|NCT01691313|a-fib
256588|NCT01691300|C11-acetate PET/CT
256589|NCT01691300|Multiple myeloma
256590|NCT01691300|Pretreatment staging
256591|NCT01691300|Response assessment
256592|NCT01691287|Type 1 Diabetes
256593|NCT01691287|Metabolic Control
256594|NCT01691287|Quality of Life
256595|NCT01691274|Epilepsy
256596|NCT01691274|Phase 1
256597|NCT01691274|Multiple Dose
256598|NCT01691274|Safety
256599|NCT01691274|Pharmacokinetics
256600|NCT01691274|Toleration
256601|NCT01691248|Clostridium difficile
256602|NCT01691248|Clostridium difficile-Associated Diarrhea
256603|NCT01691248|Prophylaxis
256604|NCT01691248|Hematopoietic Stem Cell Transplantation
256605|NCT01691235|SIMpill
256606|NCT01691235|HCV
256607|NCT01691235|Chronic Hepatitis C Virus
256608|NCT01691222|Bedside percutaneous tracheostomy
256609|NCT01691222|Intensive Care Unit
256610|NCT01691222|Dedicated Double-lumen tube
256611|NCT01691222|Ineffective Airway Clearance
256612|NCT01691222|weaning failure
256613|NCT01691209|Phoenix
256614|NCT01691209|Hydrocortison
256615|NCT01691209|mild atopic dermatitis
256616|NCT01691209|efficacy
256617|NCT01691209|safety
256618|NCT01691196|Obesity
256619|NCT01691196|Peritoneal dialysis
256620|NCT01691196|Inflammation
256621|NCT01691196|Macrophages
256622|NCT01691196|Innate immunity
256623|NCT01691183|Hertel
256624|NCT01691183|exophthalmometer
256625|NCT01691183|proptosis
256626|NCT01691183|eye disease
256627|NCT01691170|Pattelofemoral pain syndrome
256628|NCT01691170|Stretching
256629|NCT01691170|Strengthening
256630|NCT01691157|Subacromial impingement syndrome
256631|NCT01691157|Rotator cuff
256632|NCT01691157|Exercise
256633|NCT01691157|Physiotherapy
256634|NCT01691144|cancer
256635|NCT01691144|gynecological
256636|NCT01691144|expectations
256637|NCT01691144|satisfaction
256638|NCT01691144|cooperation
256639|NCT01691131|Physical activity in daily life
256640|NCT01691131|Balance
256641|NCT01691131|COPD
256642|NCT01691131|Exercise training
256643|NCT01691118|Hypertension
256644|NCT01691118|Angiotensin Receptor Blocker
256645|NCT01691118|Diastolic Dysfunction
256646|NCT01691105|Tobacco Use Cessation
256647|NCT01691105|Smoking Cessation
256648|NCT01691105|Nicotine Replacement Therapy
256649|NCT01691105|Hospitalized Smokers
256650|NCT01691092|Depression
256651|NCT01691092|Ketamine
256652|NCT01691092|PET
256653|NCT01691092|PTSD
256654|NCT01691053|End stage renal disease
256655|NCT01691053|Hemodialysis
256656|NCT01691053|Spironolactone
256657|NCT01691053|Left ventricular hypertrophy
256658|NCT01691040|Hepcidin
256659|NCT01691040|Iron
256660|NCT01691040|Anemia of Chronic Disease
256661|NCT01691040|Anemia
256662|NCT01691040|Cancer
256663|NCT01691040|Interleukin-6
256664|NCT01691040|Iron restriction
256665|NCT01691040|Lymphoma
256666|NCT01691040|CLL
256667|NCT01691040|Multiple Myeloma
256668|NCT01691040|Hodgkin
256669|NCT01691040|anti-hepcidin
256670|NCT01691027|scotoma, central
256671|NCT01691027|visual motor coordination
256672|NCT01690988|Delirium
256673|NCT01690988|ketamine
256674|NCT01690988|surgery
256675|NCT01690988|neurological complications
256676|NCT01690962|diabetic neuropathy, diet, vegan, vegetarian
256677|NCT01690949|inflammation
256678|NCT01690949|COPD
256679|NCT01690949|respiratory disease
256680|NCT01690949|healthy volunteers
256681|NCT01690936|Almonds
256682|NCT01690936|Body weight
256683|NCT01690936|Snacking
256684|NCT01690910|Ventilator
256685|NCT01690910|Mobility Limitations
256686|NCT01690910|Critical Care
256687|NCT01690910|Rifton Gait Trainer
256688|NCT01690897|Female sexual desire
256689|NCT01690897|Psychoeducational intervention
256690|NCT01690897|Mindfulness
256691|NCT01690884|Adenosine
256692|NCT01690884|Ticagrelor
256693|NCT01690884|Microdialysis
256694|NCT01690871|Malignant PEComa
256695|NCT01690871|Angiomyolipoma
256696|NCT01690871|Tuberous Sclerosis Complex
256697|NCT01690871|Pi3kinase /m-tor inhibitors
256698|NCT01690858|Foetal loss
256699|NCT01690858|complement
256700|NCT01690858|antiangiogenic factors
256701|NCT01690858|Repeated fetal losses
256702|NCT01690832|Contrast induced acute kidney injury
256703|NCT01690819|Acute Respiratory Distress Syndrome
256704|NCT01690819|Acute Brain Injury
256705|NCT01690793|ASTHMA
256706|NCT01690793|ACUTE EXACERBATION OF ASTHMA
256707|NCT01690780|fracture
256708|NCT01690780|pediatric
256709|NCT01690780|oral morphine
256710|NCT01690780|ibuprofen
256711|NCT01690767|Urethral catheterization
256712|NCT01690767|Lidocaine
256713|NCT01690754|SMS
256714|NCT01690754|tuberculosis
256715|NCT01690754|impact evaluation
256716|NCT01690741|Cancer
256717|NCT01690741|Malignancy
256718|NCT01690741|Solid tumors
256719|NCT01690728|Obesity
256720|NCT01690728|Gastric bypass
256721|NCT01690715|Hepatocellular Carcinoma
256722|NCT01690715|Thrombosis
256723|NCT01690715|Portal Vein Invasion
256724|NCT01690702|breast cancer
256725|NCT01690702|tailored
256726|NCT01690702|high-risk
256727|NCT01690676|FMD
256728|NCT01690676|epicatechin
256729|NCT01690676|apple polyphenol
256730|NCT01690676|borderline hypertension
256731|NCT01690442|HIV
256732|NCT01690442|AIDS
256733|NCT01690442|Prevention
256734|NCT01690429|Arousal detection
256735|NCT01690429|Pulse Wave Amplitude
256736|NCT01690429|Obstructive Sleep Apnea
256737|NCT01690429|Daytime sleepiness
256738|NCT01690429|Cardiorespiratory risk
256739|NCT01690377|Dendritic Cells
256740|NCT01690364|Motor evoked potential monitoring
256741|NCT01690364|General Anesthesia
256742|NCT01690364|Neurosurgery
256743|NCT01690364|Cisatracurium
256744|NCT01690364|Vecuronium
256745|NCT01690338|TOFr (train of four ratio)
256746|NCT01690338|airway extubation
256747|NCT01690338|PACU (postanesthesia care unit)
256748|NCT01690338|PORC (postoperative residual curarization)
256749|NCT01690325|Neoadjuvant chemotherapy
256750|NCT01690325|Neoadjuvant cytotoxic-antiangiogenic therapy
256751|NCT01690325|Bevacizumab
256752|NCT01690325|PET
256753|NCT01690312|Humans
256754|NCT01690312|Cardiovascular Disease
256755|NCT01690312|Statins
256756|NCT01690312|Fish Oil
256757|NCT01690312|DHA
256758|NCT01690312|EPA
256759|NCT01690312|High-DHA
256760|NCT01690312|Triglycerides
256761|NCT01690312|Total cholesterol [TC]
256762|NCT01690312|Lipoproteins
256763|NCT01690312|High-density lipoprotein [HDL2, HDL3]
256764|NCT01690312|Low-density lipoprotein [LDL1+2+3+4]
256765|NCT01690312|Lipoprotein A [Lp(a)]
256766|NCT01690312|Intermediate-density lipoprotein (IDL)
256767|NCT01690312|Very low-density lipoprotein (VLDL1+2, VLDL3)
256768|NCT01690312|Remnant Lipoproteins
256769|NCT01690312|High-sensitivity C-Reactive Protein [hs-CRP]
256770|NCT01690312|Homocysteine
256771|NCT01690312|Essential Fatty Acid Profile
256772|NCT01690312|Apolipoprotein B
256773|NCT01690312|Apolipoprotein A-1
256774|NCT01690312|Glucose
256775|NCT01690312|Insulin
256776|NCT01690312|Fasted
256777|NCT01690312|Post-Prandial
256778|NCT01690299|Psoriasis
256779|NCT01690299|arthritis
256780|NCT01690299|psoriatic
256781|NCT01690299|palmoplantar
256782|NCT01690299|scalp
256783|NCT01690299|psoriasis pill
256784|NCT01690299|psoriasis tablet
256785|NCT01690299|plaque psoriasis
256786|NCT01690299|plaque type psoriasis
256787|NCT01690299|moderate to severe plaque type psoriasis
256788|NCT01690299|psoriatic arthritis
256789|NCT01690286|Healthy
256790|NCT01690286|Ketoconazole
256791|NCT01690286|JNJ-38518168
256792|NCT01690286|Pharmacokinetics
256793|NCT01690273|exercise
256794|NCT01690273|mobility
256795|NCT01690273|strengthening
256796|NCT01690273|physiotherapy
256797|NCT01690260|Bone
256798|NCT01690260|Morphogenetic
256799|NCT01690260|Protein
256800|NCT01690260|Ilizarow
256801|NCT01690260|Autologous
256802|NCT01690260|Osteoarthritis
256803|NCT01690247|mesenchymal stem cells
256804|NCT01690247|liver transplantation
256805|NCT01690247|clinical trial
256806|NCT01690247|rejection
256807|NCT01690234|Low back pain
256808|NCT01690234|Return to work
256809|NCT01690234|Sickness absence
256810|NCT01690234|Rehabilitation
256811|NCT01690234|Multidisciplinary intervention
256812|NCT01690221|Anal
256813|NCT01690221|Fissure
256814|NCT01690221|Pain
256815|NCT01690208|Diabetes
256816|NCT01690208|Structure Care
256817|NCT01690182|Gastrointestinal physiology
256818|NCT01690182|MRI
256819|NCT01690182|gastric volumes
256820|NCT01690182|satiety
256821|NCT01690156|In-plane
256822|NCT01690156|Ultrasound-guided regional anesthesia performance
256823|NCT01690156|Probe position
256824|NCT01690156|Needle visualization
256825|NCT01690130|nicotine
256826|NCT01690130|craving
256827|NCT01690130|smoking
256828|NCT01690130|TMS
256829|NCT01690130|prefrontal cortex
256830|NCT01690117|family caregiver
256831|NCT01690117|dementia
256832|NCT01690117|intervention
256833|NCT01690117|implementation
256834|NCT01690104|rifampicin
256835|NCT01690104|pregnane X receptor
256836|NCT01690104|blood pressure
256837|NCT01690091|chronic heart failure
256838|NCT01690091|type 2 diabetes
256839|NCT01690091|metformin
256840|NCT01690091|insulin resistance
256841|NCT01690078|Airway modeling
256842|NCT01690078|Pierre Robin Sequence or PRS
256843|NCT01690078|Micrognathia
256844|NCT01690078|Subglottic Stenosis or SGS
256845|NCT01690065|chronic myeloid leukemia
256846|NCT01690065|myeloid blastic phase
256847|NCT01690065|bcr-abl(+) acute myeloid leukemia
256848|NCT01690065|nilotinib
256849|NCT01690052|dry mouth
256850|NCT01690039|renal tubular acidosis
256851|NCT01690039|V-ATPase
256852|NCT01690039|kidney stones
256853|NCT01689974|Metastatic Melanoma
256854|NCT01689974|Radiation Therapy
256855|NCT01689974|Immunology
256856|NCT01689974|Abscopal
256857|NCT01689961|Nutrition
256858|NCT01689961|Physical activity
256859|NCT01689961|Gestational weight gain
256860|NCT01689961|Pregnancy outcomes
256861|NCT01689961|Birth
256862|NCT01689948|Home care, rehabilitation therapy, Alzheimer's disease
256863|NCT01689935|Acne vulgaris
256864|NCT01689935|Photodynamic Therapy
256865|NCT01689935|Side-effects
256866|NCT01689935|Pain
256867|NCT01689909|Insomnia
256868|NCT01689909|Depression
256869|NCT01689909|Suicidal ideation
256870|NCT01689909|Zolpidem CR
256871|NCT01689909|Placebo
256872|NCT01689896|Hypogonadism
256873|NCT01689896|Low testosterone
256874|NCT01689896|Pain
256875|NCT01689883|stroke
256876|NCT01689883|electrical stimulation
256877|NCT01689883|arm rehabilitation
256878|NCT01689870|OX40
256879|NCT01689870|Anti-OX40
256880|NCT01689870|Ipilimumab
256881|NCT01689870|Melanoma
256882|NCT01689857|hypertropic scar, Vancouver scar scale, silicon gel sheet
256883|NCT01689844|controlled high blood pressure
256884|NCT01689818|insomnia, elderly, exercise training
256885|NCT01689805|Atopic dermatitis
256886|NCT01689805|Filaggrin
256887|NCT01689779|vitamin D
256888|NCT01689779|surgery
256889|NCT01689779|acute stress
256890|NCT01689766|Renal Cell
256891|NCT01689753|Renal dialyse
256892|NCT01689753|Catheter, indwelling
256893|NCT01689753|Catheter-related infection
256894|NCT01689740|MDMA
256895|NCT01689740|Posttraumatic stress disorder
256896|NCT01689740|PTSD
256897|NCT01689740|Israel
256898|NCT01689740|psychotherapy
256899|NCT01689727|Pituitary Tumors
256900|NCT01689714|Ovarian Carcinoma
256901|NCT01689714|Recurrent Endometrial Carcinoma
256902|NCT01689701|Erosive Gastritis
256903|NCT01689701|Hizikia Fusiformis
256904|NCT01689675|musculoskeletal
256905|NCT01689675|pain
256906|NCT01689675|pain management
256907|NCT01689675|computer based intervention
256908|NCT01689662|Metastatic Renal Cell Carcinoma
256909|NCT01689649|Epilepsy
256910|NCT01689649|Seizures
256911|NCT01689649|Topiramate
256912|NCT01689649|Anti-epileptic drug
256913|NCT01689649|Nervous disorder
256914|NCT01689636|Ovarian Cancer
256915|NCT01689623|Healthy participants
256916|NCT01689623|TMC435
256917|NCT01689623|HMG-CoA reductase inhibitors
256918|NCT01689623|Atorvastatin
256919|NCT01689623|Simvastatin
256920|NCT01689623|Pharmacokinetic interaction
256921|NCT01689610|Nab-Paclitaxel
256922|NCT01689610|Abraxane
256923|NCT01689610|Nabucco
256924|NCT01689610|safety
256925|NCT01689610|breast cancer
256926|NCT01689610|daily routine
256927|NCT01689610|peripheral neuropathy
256928|NCT01689610|iOMEDICO
256929|NCT01689584|BRCA1
256930|NCT01689584|BRCA2
256931|NCT01689584|VUS
256932|NCT01689584|co-segregation
256933|NCT01689584|genetic counseling
256934|NCT01689571|PDE4 inhibitor
256935|NCT01689571|Allergen Challenge
256936|NCT01689571|Asthma
256937|NCT01689558|nasopharynx cancer,Image department of nose pharynx ministry
256938|NCT01689545|HIV
256939|NCT01689545|drug abuse
256940|NCT01689545|social stigma
256941|NCT01689545|Vietnam
256942|NCT01689532|Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
256943|NCT01689532|Sirukumab
256944|NCT01689532|Human Anti-IL-6 Monoclonal Antibody
256945|NCT01689519|Zelboraf
256946|NCT01689519|vemurafenib
256947|NCT01689519|RG7204
256948|NCT01689519|PLX4032
256949|NCT01689519|Genentech MEK inhibitor
256950|NCT01689519|Genentech BRAF inhibitor
256951|NCT01689519|Roche MEK inhibitor
256952|NCT01689519|Roche BRAF inhibitor
256953|NCT01689519|RO5185426
256954|NCT01689519|metastatic melanoma
256955|NCT01689519|BRAF positive melanoma
256956|NCT01689519|BRAF mutant melanoma
256957|NCT01689519|advanced melanoma
256958|NCT01689519|Genentech RAF inhibitor
256959|NCT01689519|Roche RAF inhibitor
256960|NCT01689519|BRAF V600E kinase inhibitor
256961|NCT01689519|Oncogenic BRAF inhibitor
256962|NCT01689519|BRAF kinase inhibitor
256963|NCT01689519|GDC-0973
256964|NCT01689519|XL518
256965|NCT01689519|melanoma
256966|NCT01689480|Muscular Dystrophy
256967|NCT01689480|Facioscapulohumeral
256968|NCT01689480|Physical training
256969|NCT01689480|Exercise
256970|NCT01689454|IVF
256971|NCT01689454|embryo culture
256972|NCT01689454|Ongoing pregnancy rate
256973|NCT01689454|Ongoing implantation rate
256974|NCT01689454|Miscarriage
256975|NCT01689428|IVF
256976|NCT01689428|Embryo culture
256977|NCT01689428|Ongoing Pregnancy rate
256978|NCT01689428|Ongoing Implantation rate
256979|NCT01689428|Miscarriage
256980|NCT01689415|Renal nerve denervation
256981|NCT01689389|Schizophrenia
256982|NCT01689389|Bipolar episodes
256983|NCT01689389|France
256984|NCT01689389|Xeroquel
256985|NCT01689389|Real-life
256986|NCT01689363|hyaluronidase
256987|NCT01689363|enzymes with tissue spreading activity
256988|NCT01689363|allergic reaction
256989|NCT01689363|intradermal skin testing
256990|NCT01689350|Cyclophosphamide
256991|NCT01689350|genotype-based therapy
256992|NCT01689350|prospective study
256993|NCT01689337|Microfracture surgery
256994|NCT01689337|Cartilage repair
256995|NCT01689337|Knee surgery
256996|NCT01689324|Pertussis
256997|NCT01689324|Tetanus
256998|NCT01689324|Diphtheria
256999|NCT01689324|Acellular pertussis
257000|NCT01689324|ADACEL®
257001|NCT01689324|Tdap vaccine
257002|NCT01689311|Uterine contraction
257003|NCT01689311|Dose response
257004|NCT01689311|Non-laboring
257005|NCT01689311|Laboring
257006|NCT01689311|Laboring with oxytocin augmentation
257007|NCT01689311|Oxytocin
257008|NCT01689311|Ergonovine
257009|NCT01689311|Prostaglandin F2alpha
257010|NCT01689311|Misoprostol
257011|NCT01689298|Uterine contraction
257012|NCT01689298|Dose response
257013|NCT01689298|Oxytocin pretreatment
257014|NCT01689298|Oxytocin
257015|NCT01689298|Carbetocin
257016|NCT01689285|bioequivalence
257017|NCT01689285|pharmacokinetics
257018|NCT01689285|valacyclovir
257019|NCT01689285|paediatric formulation
257020|NCT01689272|Kidney transplantation,functional status,survival.
257021|NCT01689246|Alzheimer's Disease
257022|NCT01689246|Alzheimer Disease
257023|NCT01689246|TRx0237
257024|NCT01689246|AD
257025|NCT01689246|Neurodegenerative Diseases
257026|NCT01689246|Dementia
257027|NCT01689246|Brain Diseases
257028|NCT01689233|Alzheimer's Disease
257029|NCT01689233|Alzheimer Disease
257030|NCT01689233|TRx0237
257031|NCT01689233|AD
257032|NCT01689233|Neurodegenerative Diseases
257033|NCT01689233|Dementia
257034|NCT01689233|Brain Diseases
257035|NCT01689207|Phase I, Safety, tolerability, healthy.
257036|NCT01689155|Meningitis
257037|NCT01689155|Meningococcal Infection
257038|NCT01689155|Menactra®
257039|NCT01689103|Alcohol use disorders
257040|NCT01689103|Treatment
257041|NCT01689103|Outpatient
257042|NCT01689103|Therapeutic alliance
257043|NCT01689051|Type 2 diabetes
257044|NCT01689051|Blod pressure
257045|NCT01689051|Glucagon-like peptide-1
257046|NCT01689051|Human physiology
257047|NCT01689051|Blood flow
257048|NCT01688999|Kidney Cancer
257049|NCT01688999|Tyrosine Kinase Inhibitor
257050|NCT01688999|Bladder Cancer
257051|NCT01688986|Complex Disease
257052|NCT01688986|DNA Biorepository
257053|NCT01688986|Genotype-Phenotype Correlation
257054|NCT01688986|Genetics
257055|NCT01688986|Environmental Factors
257056|NCT01688947|Pain
257057|NCT01688947|Neuralgia, Postherpetic
257058|NCT01688934|Pain
257059|NCT01688934|Osteoarthritis
257060|NCT01688934|Knee
257061|NCT01688921|Injections, Jet
257062|NCT01688921|Influenza Vaccines
257063|NCT01688908|Esophageal Squamous Cell carcinomas
257064|NCT01688908|Endoscopy Screening
257065|NCT01688908|High risk region
257066|NCT01688908|China
257067|NCT01688895|erythropoietic
257068|NCT01688895|protoporphyria
257069|NCT01688895|cutaneous
257070|NCT01688895|porphyria
257071|NCT01688882|bullous pemphigoid
257072|NCT01688882|QGE031
257073|NCT01688869|brain concussion
257074|NCT01688856|hand
257075|NCT01688856|arm
257076|NCT01688856|stroke
257077|NCT01688856|hemiplegia
257078|NCT01688856|electrical stimulation
257079|NCT01688856|recovery
257080|NCT01688856|rehabilitation
257081|NCT01688843|bradycardia
257082|NCT01688843|sinus node dysfunction
257083|NCT01688817|Colorectal Neoplasms
257084|NCT01688817|Colonoscopy
257085|NCT01688817|Early Detection of Cancer
257086|NCT01688817|Patient Selection
257087|NCT01688817|Patient Participation
257088|NCT01688817|Physicians, Primary Care
257089|NCT01688817|Conscious Sedation
257090|NCT01688804|Sedentary behavior
257091|NCT01688804|Physical activity
257092|NCT01688804|Obesity
257093|NCT01688804|Mobile health
257094|NCT01688804|Smartphone
257095|NCT01688778|Type 2 diabetes
257096|NCT01688778|Quality of life
257097|NCT01688778|Lifestyle intervention
257098|NCT01688778|Telemedicine
257099|NCT01688778|Videoconference
257100|NCT01688765|Schizophrenia
257101|NCT01688765|Schizoaffective disorder
257102|NCT01688765|Bipolar disorder
257103|NCT01688739|Migraine
257104|NCT01688726|Dry eye
257105|NCT01688726|Ocular surface
257106|NCT01688726|Vision complaint
257107|NCT01688726|Tear film stability
257108|NCT01688726|Time controlled functional visual acuity
257109|NCT01688726|Tear film kinetics
257110|NCT01688700|Esophageal Squamous Cell Carcinoma
257111|NCT01688700|neoadjuvant therapy
257112|NCT01688700|Nimotuzumab
257113|NCT01688648|Coronary artery bypass graft
257114|NCT01688648|dexmedetomidine
257115|NCT01688648|lidocaine
257116|NCT01688648|myocardial injury
257117|NCT01688648|arrhythmia
257118|NCT01688648|blood electrolyte balance
257119|NCT01688635|Volunteers
257120|NCT01688596|Local
257121|NCT01688596|Anesthesia
257122|NCT01688596|Pain
257123|NCT01688596|Laparoscopic hysterectomy
257124|NCT01688596|Trocar site
257125|NCT01688596|Port site
257126|NCT01688583|Chronic pain
257127|NCT01688583|Chronic non-cancer pain
257128|NCT01688583|Fentanyl matrix
257129|NCT01688583|Transdermal system
257130|NCT01688570|neuromuscular fatigue
257131|NCT01688570|motor impairment
257132|NCT01688557|narrow band imaging
257133|NCT01688557|dual focus
257134|NCT01688557|responsive insertion technique
257135|NCT01688557|scope guide
257136|NCT01688557|colonoscopy
257137|NCT01688557|colorectal cancer screening
257138|NCT01688544|Ilaprazole
257139|NCT01688544|Intragastric pH
257140|NCT01688544|Serum Gastrin
257141|NCT01688544|Pharmacokinetics
257142|NCT01688518|Evaluation
257143|NCT01688518|Depth and Duration
257144|NCT01688518|Anesthesia
257145|NCT01688505|cerebral small vessel diseases
257146|NCT01688505|cognitive impairment
257147|NCT01688505|Blood pressure variability
257148|NCT01688492|MDX-010 (Ipilimumab)
257149|NCT01688492|ABIRATERONE ACETATE (CB 7630)
257150|NCT01688492|PREDNISONE
257151|NCT01688492|Immunotherapy-naïve
257152|NCT01688492|castration resistant prostate cancer (CRPC)
257153|NCT01688492|12-120
257154|NCT01688479|Postoperative radiotherapy
257155|NCT01688479|breast cancer
257156|NCT01688466|Immune Modulatory
257157|NCT01688466|Systemic Absorption
257158|NCT01688466|Oral Agent
257159|NCT01688453|overweight/obesity
257160|NCT01688453|adolescence
257161|NCT01688453|care management
257162|NCT01688440|Endotracheal Cares
257163|NCT01688440|Neonate
257164|NCT01688440|TAC's
257165|NCT01688440|Endotracheal Suctioning
257166|NCT01688440|Tracheal Aspirate Culture
257167|NCT01688440|Oral Cares
257168|NCT01688440|Neonate oxygen Therapy
257169|NCT01688401|diffuse intrinsic pontine glioma (DIPG)
257170|NCT01688401|intra-arterial chemotherapy
257171|NCT01688401|angiography
257172|NCT01688388|Breast Cancer
257173|NCT01688388|Carcinoma
257174|NCT01688388|Radiotherapy
257175|NCT01688388|Intraoperative Radiotherapy
257176|NCT01688388|IORT
257177|NCT01688375|obstructive jaundice
257178|NCT01688375|ursodeoxycholic acid
257179|NCT01688362|Prospective Randomized Controlled Double Blinded Trial
257180|NCT01688362|Rotator Cuff Tear
257181|NCT01688362|Platelet Rich Plasma
257182|NCT01688362|Corticosteroid
257183|NCT01688362|Ultrasound
257184|NCT01688349|Glucocorticoids
257185|NCT01688349|adipose tissue
257186|NCT01688349|Cushing
257187|NCT01688349|lipodystrophy
257188|NCT01688349|11 beta-HSD1
257189|NCT01688336|Pancreatic
257190|NCT01688336|Phase II
257191|NCT01688336|FOLFIRINOX
257192|NCT01688336|Unresectable
257193|NCT01688336|Regimen
257194|NCT01688336|First-line
257195|NCT01688336|Resectable
257196|NCT01688336|Borderline
257197|NCT01688336|Oxaliplatin
257198|NCT01688336|Leucovorin
257199|NCT01688336|Irinotecan
257200|NCT01688336|5FU
257201|NCT01688336|Lineberger
257202|NCT01688336|University of North Carolina
257203|NCT01688323|Geriatrics
257204|NCT01688323|Oncology
257205|NCT01688323|Biological Markers
257206|NCT01688323|Survey Instruments
257207|NCT01688323|p16
257208|NCT01688323|Geriatric Oncology
257209|NCT01688323|Biological Markers of Aging
257210|NCT01688323|Symptom Assessment
257211|NCT01688323|Cancer
257212|NCT01688323|Older Persons
257213|NCT01688323|Head and Neck Cancer
257214|NCT01688310|Gomco clamp instrument
257215|NCT01688310|Tissue adhesive
257216|NCT01688310|Open surgical circumcision
257217|NCT01688310|Minimally-invasive circumcision
257218|NCT01688297|Influenza
257219|NCT01688297|H1N1
257220|NCT01688297|flu
257221|NCT01688297|seasonal
257222|NCT01688284|uterine natural killer cells
257223|NCT01688284|recurrent miscarriages
257224|NCT01688284|alloimmunity
257225|NCT01688271|simulation
257226|NCT01688271|ultrasound
257227|NCT01688271|perineural infusion
257228|NCT01688271|continuous peripheral nerve block
257229|NCT01688245|young adults
257230|NCT01688245|alcohol consumption
257231|NCT01688245|mobile health
257232|NCT01688245|text message
257233|NCT01688232|colorectal cancer
257234|NCT01688232|tumor resection
257235|NCT01688232|immunoscore
257236|NCT01688232|lymphocytic density
257237|NCT01688232|CD3
257238|NCT01688232|CD8
257239|NCT01688232|CD45RO
257240|NCT01688232|biopsy
257241|NCT01688232|genetic feature of the tumor
257242|NCT01688232|relapse
257243|NCT01688232|immunohistochemistry
257244|NCT01688232|image analysis software
257245|NCT01688219|SAPHO syndrome
257246|NCT01688219|Innate immunity
257247|NCT01688219|TNF alpha
257248|NCT01688219|Polymorphonuclear neutrophils
257249|NCT01688219|Propionibacterium acnes
257250|NCT01688219|Interleukin-8
257251|NCT01688180|bronchiectasis
257252|NCT01688180|depression
257253|NCT01688180|anxiety
257254|NCT01688167|HIV
257255|NCT01688167|Male circumcision
257256|NCT01688167|Sexual risk reduction
257257|NCT01688167|Stages of change
257258|NCT01688141|CKD
257259|NCT01688128|Mild cognitive impairment
257260|NCT01688128|Cognitive rehabilitation
257261|NCT01688128|Cognitive therapy
257262|NCT01688128|Spaced retrieval Training
257263|NCT01688128|Alzheimer's disease
257264|NCT01688128|Memory enhancement
257265|NCT01688128|U-healthcare
257266|NCT01688089|volunteer
257267|NCT01688089|study
257268|NCT01688063|Skin Elasticity
257269|NCT01688063|Scar Elasticity
257270|NCT01688063|Cutometer
257271|NCT01688063|Dermal Torque Meter
257272|NCT01688050|Blunt thoracic aortic injury
257273|NCT01688050|Transection
257274|NCT01688050|Endovascular graft
257275|NCT01688024|mitomycin C
257276|NCT01688011|Myelodysplastic Syndromes
257277|NCT01688011|MDS
257278|NCT01688011|Acute Myeloid Leukemia
257279|NCT01688011|AML
257280|NCT01688011|Registry
257281|NCT01688011|Connect®
257282|NCT01687972|cesarean section
257283|NCT01687972|insorb staples
257284|NCT01687972|absorbable staples
257285|NCT01687972|transverse skin incision
257286|NCT01687959|cholelithiasis
257287|NCT01687959|laparoscopic cholecystectomy
257288|NCT01687959|endoscopic sphincterotomy
257289|NCT01687959|choledocholithiasis
257290|NCT01687946|Biology of Fibrosis
257291|NCT01687933|Labor pain
257292|NCT01687933|Virtual reality
257293|NCT01687933|the first stage of labor
257294|NCT01687933|Pain relief
257295|NCT01687933|Simulator
257296|NCT01687920|Cardiac disorders
257297|NCT01687907|fear of childbirth
257298|NCT01687907|outcome of delivery
257299|NCT01687907|music
257300|NCT01687907|mother-baby relationship
257301|NCT01687894|cerebral oxygen saturation
257302|NCT01687894|beach chair position
257303|NCT01687894|hemodynamic
257304|NCT01687894|jugular venous oximetry
257305|NCT01687881|Chiropractic
257306|NCT01687881|Manipulative therapy
257307|NCT01687881|Cervicogenic headache
257308|NCT01687855|Obstructive Sleep
257309|NCT01687855|Apnoea
257310|NCT01687855|tongue
257311|NCT01687855|alteration
257312|NCT01687829|Macular Holes
257313|NCT01687829|Internal limiting membrane
257314|NCT01687829|peeling
257315|NCT01687829|Surgery
257316|NCT01687816|Influenza-Like-Illness
257317|NCT01687816|nasal swabs
257318|NCT01687816|Detection of influenza
257319|NCT01687816|sensitivity of detection assays
257320|NCT01687803|Obesity
257321|NCT01687803|Sedentary lifestyle
257322|NCT01687803|Body weight
257323|NCT01687803|Physical fitness
257324|NCT01687790|molecular breast imaging
257325|NCT01687790|breast disease
257326|NCT01687790|breast biopsy
257327|NCT01687777|Supraspinatus tendon
257328|NCT01687777|Mesenchymal stem cells
257329|NCT01687777|OrthADAPT
257330|NCT01687777|Rotator cuff
257331|NCT01687764|Generalized Anxiety Disorder (GAD)
257332|NCT01687764|Separation Anxiety Disorder (SeAD)
257333|NCT01687764|Social Anxiety Disorder (SoAD)
257334|NCT01687751|feasibility studies
257335|NCT01687751|conscious sedation/
257336|NCT01687751|dexmedetomidine/
257337|NCT01687751|midazolam/
257338|NCT01687751|infusions, subcutaneous/
257339|NCT01687751|palliative care/
257340|NCT01687751|terminal care/
257341|NCT01687751|terminally ill/
257342|NCT01687751|neoplasms/
257343|NCT01687751|treatment outcome
257344|NCT01687751|Precedex
257345|NCT01687751|"end of life"
257346|NCT01687751|Dying
257347|NCT01687751|Advanced cancer
257348|NCT01687751|mood/delirium/delirious
257349|NCT01687738|non small cell lung cancer
257350|NCT01687738|health disparities
257351|NCT01687712|IVF
257352|NCT01687712|In vitro fertilization
257353|NCT01687712|Controlled ovarian stimulation
257354|NCT01687712|Follitropin
257355|NCT01687712|AFOLIA
257356|NCT01687712|Finox
257357|NCT01687699|cardiovascular event
257358|NCT01687699|hemodialysis
257359|NCT01687699|spironolactone
257360|NCT01687673|Advanced HCC
257361|NCT01687673|Temsirolimus
257362|NCT01687673|TORISEL
257363|NCT01687673|Sorafenib
257364|NCT01687660|acupuncture
257365|NCT01687660|migraine prophylaxis
257366|NCT01687647|Lung cancer screening
257367|NCT01687647|Asbestos exposed workers
257368|NCT01687647|Sputum analysis
257369|NCT01687647|Automated cytometry
257370|NCT01687647|Predictive biomarkers
257371|NCT01687634|pregnancy
257372|NCT01687634|home healthcare visits
257373|NCT01687634|breast feeding
257374|NCT01687634|nutrition
257375|NCT01687634|community health workers
257376|NCT01687621|Omphalitis
257377|NCT01687621|Neonate
257378|NCT01687621|Zambia
257379|NCT01687621|Neonatal mortality
257380|NCT01687621|Umbilical cord infection
257381|NCT01687608|Hemophilia B
257382|NCT01687608|factor IX deficiency
257383|NCT01687608|gene therapy
257384|NCT01687595|herpes simplex virus type 2,
257385|NCT01687595|genital herpes
257386|NCT01687582|type 2 diabetes
257387|NCT01687582|psoriasis
257388|NCT01687582|exenatide
257389|NCT01687582|liraglutide
257390|NCT01687569|Glycaemic Response
257391|NCT01687556|EGCG
257392|NCT01687556|green tea
257393|NCT01687543|Clostridium difficile
257394|NCT01687543|WBC
257395|NCT01687543|CRP
257396|NCT01687543|Lactate
257397|NCT01687543|Urea
257398|NCT01687543|Creatinine
257399|NCT01687517|sarcoidosis
257400|NCT01687517|healthy volunteers
257401|NCT01687504|pharmacokinetics
257402|NCT01687504|children
257403|NCT01687504|HIV
257404|NCT01687504|Tuberculosis
257405|NCT01687504|Pharmacogenetics
257406|NCT01687491|Enoxaparin
257407|NCT01687491|Acute Coronary Syndrome
257408|NCT01687491|Factor X
257409|NCT01687465|glaucoma
257410|NCT01687465|laser
257411|NCT01687465|SLT
257412|NCT01687465|ALT
257413|NCT01687374|proximal humeral fracture
257414|NCT01687335|chemotherapy
257415|NCT01687322|quality of life
257416|NCT01687322|functioning
257417|NCT01687296|PEF
257418|NCT01687296|inhaled
257419|NCT01687296|Fluticasone Propionate
257420|NCT01687296|safety
257421|NCT01687296|prednisone
257422|NCT01687296|acute exacerbation
257423|NCT01687296|asthma
257424|NCT01687296|efficacy
257425|NCT01687283|fluticasone propionate inhalation solution
257426|NCT01687283|budesonide suspension for inhalation
257427|NCT01687283|efficacy
257428|NCT01687283|severe persistent asthma
257429|NCT01687283|pharmacokinetics
257430|NCT01687283|safety
257431|NCT01687244|BCG Refractory or Relapsed Superficial Bladder Cancer
257432|NCT01687244|rAd-IFN
257433|NCT01687244|Syn3
257434|NCT01687244|Intravesical
257435|NCT01687244|transitional cell carcinoma of the bladder
257436|NCT01687244|superficial non-muscle invasive tumor
257437|NCT01687244|Interferon alpha2b
257438|NCT01687244|INSTILADRIN
257439|NCT01687231|Neutropenic Diet, Non-Neutropenic Diet, Allogeneic SCT
257440|NCT01687192|Seroconversion
257441|NCT01687192|Immunosuppressed treatment
257442|NCT01687192|HPV vaccination
257443|NCT01687192|Immunogenicity
257444|NCT01687179|LAM
257445|NCT01687179|TSC
257446|NCT01687179|lymphangioleiomyomatosis
257447|NCT01687166|Paroxysmal Atrial Fibrillation
257448|NCT01687166|Cardiac Arrhythmias
257449|NCT01687166|Heart Disease
257450|NCT01687166|Cardiovascular Disease
257451|NCT01687166|Radiofrequency Ablation
257452|NCT01687153|traumatic brain injury (TBI)
257453|NCT01687153|post traumatic stress disorder (PTSD)
257454|NCT01687153|Alzheimer's disease (AD)
257455|NCT01687153|mild cognitive impairment (MCI)
257456|NCT01687153|dementia
257457|NCT01687153|biomarkers
257458|NCT01687153|amyloid
257459|NCT01687153|neuroimaging
257460|NCT01687153|cognition disorder
257461|NCT01687153|tau
257462|NCT01687127|folic acid
257463|NCT01687127|folate
257464|NCT01687127|5-methyltetrahydrofolate
257465|NCT01687127|supplements
257466|NCT01687127|women
257467|NCT01687127|one-carbon metabolism
257468|NCT01687127|methionine
257469|NCT01687127|DNA methylation
257470|NCT01687127|in vivo kinetics
257471|NCT01687114|compliance, proanthocyanidin, phenoic acids, cranberry
257472|NCT01687101|acute migraine
257473|NCT01687101|acute migraine treatment
257474|NCT01687101|topical treatment
257475|NCT01687075|coronary angioplasty
257476|NCT01687075|de novo lesion
257477|NCT01687062|NaFeEDTA
257478|NCT01687062|phytate
257479|NCT01687062|injera
257480|NCT01687062|iron absorption
257481|NCT01687049|nonmetastatic
257482|NCT01687049|localized
257483|NCT01687049|prostate
257484|NCT01687049|active surveillance
257485|NCT01687036|Atrial fibrillation
257486|NCT01687036|Cryoablation
257487|NCT01687023|Tai Chi
257488|NCT01687023|Wearable sensors
257489|NCT01687023|Movement
257490|NCT01687010|CRP, PCT, IL-6, Diagnosis, Prediction
257491|NCT01686997|Bariatric surgery
257492|NCT01686997|Roux-en-Y Gastric Bypass
257493|NCT01686958|Prostate Cancer
257494|NCT01686958|High intensity transurethral ultrasound ablation
257495|NCT01686958|MRI-guided
257496|NCT01686958|Minimally invasive
257497|NCT01686958|Real-time temperature feedback control
257498|NCT01686932|vildagliptin
257499|NCT01686932|sitagliptin
257500|NCT01686932|continuous glucose monitoring (CGM)
257501|NCT01686932|glycemic fluctuations
257502|NCT01686932|MAGE
257503|NCT01686932|impact of hypoglycemia on heart function (cardiac dysfuction measured via ECG)
257504|NCT01686932|difference in glycemic profile of vildagliptin compared to sitagliptin
257505|NCT01686919|Gastric bypass
257506|NCT01686919|Questionnaires
257507|NCT01686919|Diet
257508|NCT01686919|Milk
257509|NCT01686906|Keratoconus
257510|NCT01686906|Bowman layer
257511|NCT01686893|Oxygen, Insufflation, COPD, High Flow Treatment
257512|NCT01686880|Hepatocellular Carcinoma
257513|NCT01686880|Liver Cirrhosis
257514|NCT01686880|radioembolization
257515|NCT01686880|SIRT
257516|NCT01686880|TARE
257517|NCT01686880|Sirspheres
257518|NCT01686880|neoadjuvant
257519|NCT01686880|liver cancer
257520|NCT01686867|improved cookstove
257521|NCT01686867|ventilated cookstove
257522|NCT01686867|behavior change
257523|NCT01686867|adoption
257524|NCT01686867|indoor air pollution
257525|NCT01686867|DLCO
257526|NCT01686867|spirometry
257527|NCT01686867|biomass fuel
257528|NCT01686854|cognitive-behavioral approach
257529|NCT01686854|obesity treatment
257530|NCT01686841|Lipolysis
257531|NCT01686841|Cryolipolysis
257532|NCT01686841|Fat Reduction
257533|NCT01686828|insulin
257534|NCT01686828|androgens
257535|NCT01686828|insulin resistance
257536|NCT01686828|testosterone
257537|NCT01686828|estradiol
257538|NCT01686828|obesity
257539|NCT01686815|metabolic side effects
257540|NCT01686815|atypical antipsychotics
257541|NCT01686815|FSIVGTT
257542|NCT01686802|oral morphine
257543|NCT01686802|ibuprofen
257544|NCT01686802|post-operative pain
257545|NCT01686776|Plasma albumine
257546|NCT01686776|Plasma volume
257547|NCT01686776|Transcapillary escape rate
257548|NCT01686776|Inflammation
257549|NCT01686776|Circulation
257550|NCT01686750|HIV
257551|NCT01686750|injection drug use
257552|NCT01686750|men who have sex with men
257553|NCT01686750|voluntary counselling and testing
257554|NCT01686750|risk reduction
257555|NCT01686750|sexually transmitted infections
257556|NCT01686750|community viral load
257557|NCT01686750|antiretroviral therapy
257558|NCT01686724|Attention Deficit Hyperactivity Disorder
257559|NCT01686724|Psychosocial Intervention
257560|NCT01686724|Behavioral Intervention
257561|NCT01686724|School-home collaborative intervention
257562|NCT01686698|cirrhosis, VSL#3, cognitive function, falls, quality of life
257563|NCT01686685|ASD
257564|NCT01686685|autism
257565|NCT01686685|prematurity
257566|NCT01686685|oxygen-dependant gene activation
257567|NCT01686685|CXCR4
257568|NCT01686685|Language delay
257569|NCT01686685|Cognitive delay
257570|NCT01686672|Cystic Fibrosis
257571|NCT01686672|Behavioral Intervention
257572|NCT01686672|Children
257573|NCT01686659|Transfusion
257574|NCT01686659|Continuous Hemoglobin Monitoring
257575|NCT01686659|SpHb
257576|NCT01686646|alertness
257577|NCT01686633|asthma
257578|NCT01686633|pharmacogenetics
257579|NCT01686633|adult
257580|NCT01686633|vilanterol
257581|NCT01686633|adolescents
257582|NCT01686633|fluticasone furoate
257583|NCT01686620|Mealtime insulin
257584|NCT01686620|Ultra-rapid acting insulin
257585|NCT01686620|Prandial insulin
257586|NCT01686607|Antifungals (parenteral)
257587|NCT01686607|Micafungin
257588|NCT01686607|Hepatocellular carcinoma
257589|NCT01686607|Hepatic toxicity
257590|NCT01686607|Renal toxicity
257591|NCT01686594|Mycosis fungoides
257592|NCT01686594|Psoralen and UVA (PUVA)
257593|NCT01686594|Photochemotherapy
257594|NCT01686594|Maintenance treatment
257595|NCT01686594|Immune function
257596|NCT01686542|atrial fibrillation
257597|NCT01686529|Pterygium
257598|NCT01686529|bevacizumab
257599|NCT01686529|autoconjunctival graft
257600|NCT01686516|age
257601|NCT01686516|microstructure
257602|NCT01686516|diffusion MRI
257603|NCT01686490|AICD
257604|NCT01686490|focus groups
257605|NCT01686490|cognitive-behavioral video/workbook training
257606|NCT01686490|pre-implant concern/distress about upcoming AICD
257607|NCT01686464|magnetic
257608|NCT01686464|oxygen
257609|NCT01686464|Bell's Palsy
257610|NCT01686464|acupuncture
257611|NCT01686438|cost effectiveness
257612|NCT01686438|patient satisfaction
257613|NCT01686425|Cholestasis
257614|NCT01686425|Malignancy
257615|NCT01686425|ERCP
257616|NCT01686425|PTC
257617|NCT01686425|EUS-BD
257618|NCT01686412|Breast Cancer
257619|NCT01686412|Hepatocellular carcinoma
257620|NCT01686399|Sustainable diet
257621|NCT01686399|Health promotion
257622|NCT01686399|Obesity
257623|NCT01686386|Relapsed
257624|NCT01686386|Multiple Myeloma
257625|NCT01686386|Lenalidomide
257626|NCT01686386|Bendamustine
257627|NCT01686373|Aphasia
257628|NCT01686373|Brain
257629|NCT01686373|Stimulation
257630|NCT01686373|Communication
257631|NCT01686373|Stoke
257632|NCT01686373|Post
257633|NCT01686373|Phase II Clinical Trial
257634|NCT01686373|Treatment
257635|NCT01686373|tDCS
257636|NCT01686373|Fridriksson
257637|NCT01686347|epidural analgesia
257638|NCT01686347|fetal cardiac rythm
257639|NCT01686347|ropivacaine
257640|NCT01686347|sufentanil
257641|NCT01686334|in complete remission
257642|NCT01686334|older then 65 years
257643|NCT01686321|elderly patients
257644|NCT01686321|bendamustine
257645|NCT01686308|cataract
257646|NCT01686308|circadian rhythm
257647|NCT01686308|pupillometry
257648|NCT01686308|blue light transmission
257649|NCT01686308|questionnaire
257650|NCT01686308|sleep
257651|NCT01686295|androgenetic alopecia
257652|NCT01686295|Baldness
257653|NCT01686282|Blood pressure
257654|NCT01686282|Arterial Stiffness
257655|NCT01686282|Blueberry Supplementation
257656|NCT01686282|Aortic Blood Pressure
257657|NCT01686282|Hypertension
257658|NCT01686282|Postmenopausal
257659|NCT01686282|Pulse Wave Velocity
257660|NCT01686269|Endothelial progenitor cell
257661|NCT01686269|coronary artery bypass
257662|NCT01686256|Ovarian Cancer
257663|NCT01686256|Endometrial Cancer
257664|NCT01686243|epidural
257665|NCT01686230|acupuncture
257666|NCT01686230|Angina
257667|NCT01686230|Stable Angina Pectoris
257668|NCT01686217|ASP015K Extended Release
257669|NCT01686217|ASP015K Immediate Release
257670|NCT01686217|Food Effect
257671|NCT01686217|Healthy Volunteers
257672|NCT01686204|Yogurt
257673|NCT01686204|Intestine
257674|NCT01686204|Inflammation
257675|NCT01686204|Obese
257676|NCT01686191|heart transplantation
257677|NCT01686191|chronic renal insufficiency
257678|NCT01686191|pharmacogenomics
257679|NCT01686191|cyclosporine
257680|NCT01686191|tacrolimus
257681|NCT01686178|Smoking
257682|NCT01686178|Smoking Cessation
257683|NCT01686178|Tobacco Use Cessation
257684|NCT01686178|Social Networks
257685|NCT01686178|Social Control, Informal
257686|NCT01686139|Diabetic mellitus
257687|NCT01686139|Diabetic foot ulcers
257688|NCT01686139|Ischemic Limb
257689|NCT01686126|endometrial hyperplasia
257690|NCT01686126|endometrial adenocarcinoma
257691|NCT01686126|Gynecological Cancer
257692|NCT01686113|Taste
257693|NCT01686113|Fat Taste
257694|NCT01686113|Threshold Testing
257695|NCT01686100|Coronary artery bypass grafting
257696|NCT01686100|Saphenous vein grafts
257697|NCT01686074|Motor control
257698|NCT01686074|walking
257699|NCT01686074|physical activity
257700|NCT01686074|Muscle activity
257701|NCT01686022|Grass
257702|NCT01686022|Major allergen
257703|NCT01686022|cross-reactivity
257704|NCT01686009|pain
257705|NCT01686009|analgesia
257706|NCT01686009|ketamine
257707|NCT01686009|intranasal
257708|NCT01686009|emergency
257709|NCT01685996|tobacco
257710|NCT01685996|smoking cessation
257711|NCT01685996|nicotine
257712|NCT01685996|cigarettes
257713|NCT01685996|nicotine withdrawal
257714|NCT01685983|Prostate Cancer
257715|NCT01685983|Metastatic-castration resistant prostate cancer
257716|NCT01685983|Prostate specific antigen
257717|NCT01685983|Abiraterone acetate
257718|NCT01685983|JNJ-212082
257719|NCT01685983|Abiraterone
257720|NCT01685983|Prednisolone
257721|NCT01685983|Androgen Deprivation
257722|NCT01685983|Docetaxel-based chemotherapy
257723|NCT01685970|Bowel preparation
257724|NCT01685970|colonoscopy
257725|NCT01685970|polyethylene glycol
257726|NCT01685970|picosulfate
257727|NCT01685957|Weight loss
257728|NCT01685957|Dietary intervention
257729|NCT01685957|Self-help book
257730|NCT01685957|Cooking
257731|NCT01685957|Dietitian
257732|NCT01685957|Dietary therapy
257733|NCT01685931|Schizophrenia
257734|NCT01685931|Paliperidone Palmitate
257735|NCT01685931|Oral Antipsychotics
257736|NCT01685931|Invega Sustenna
257737|NCT01685918|Rheumatoid arthritis
257738|NCT01685918|aged
257739|NCT01685905|rheumatic disease, latent tuberculosis
257740|NCT01685879|postprandial glycemic response
257741|NCT01685879|postprandial insulin response
257742|NCT01685879|rice
257743|NCT01685879|appetite
257744|NCT01685879|hunger
257745|NCT01685866|anesthesia
257746|NCT01685866|venous access
257747|NCT01685840|Heart Failure
257748|NCT01685814|multiple myeloma
257749|NCT01685814|autologous stem cell transplant
257750|NCT01685814|allogeneic stem cell transplant
257751|NCT01685814|lenalidomide
257752|NCT01685814|bortezomib
257753|NCT01685775|Gallbladder
257754|NCT01685775|cholecystectomy
257755|NCT01685775|NOTES
257756|NCT01685775|natural orifice transluminal endoscopic surgery
257757|NCT01685775|gallstone
257758|NCT01685762|Endometrial hyperplasia
257759|NCT01685762|Uterus
257760|NCT01685762|Pilot
257761|NCT01685762|Metformin
257762|NCT01685723|Cancer patients
257763|NCT01685723|Smoking cessation
257764|NCT01685723|Risk communication
257765|NCT01685710|Arteriovenous fistula
257766|NCT01685710|Patency
257767|NCT01685710|GTN patch
257768|NCT01685684|Low back pain
257769|NCT01685684|Chronic back pain
257770|NCT01685684|Back pain
257771|NCT01685684|Opioid
257772|NCT01685684|Oxycodone
257773|NCT01685684|DETERx
257774|NCT01685684|Chronic pain
257775|NCT01685684|Chronic low back pain
257776|NCT01685684|CLBP
257777|NCT01685671|CKD-11101
257778|NCT01685671|NESP
257779|NCT01685671|Darbepoetin alfa
257780|NCT01685671|Anemia
257781|NCT01685671|subcutaneous
257782|NCT01685671|Pharmacokinetics
257783|NCT01685671|Phase 1
257784|NCT01685632|intra peritonal chemo hyperthermia
257785|NCT01685632|peritoneal carcinomatosis
257786|NCT01685632|colorectal cancer
257787|NCT01685632|ovarian cancer
257788|NCT01685619|AML
257789|NCT01685619|Acute Myeloid Leukemia
257790|NCT01685619|MDS
257791|NCT01685619|Myelodysplastic Syndrome
257792|NCT01685619|Prognostic
257793|NCT01685619|Economic
257794|NCT01685606|Leukemia
257795|NCT01685606|Lymphoma
257796|NCT01685606|Mantle cell
257797|NCT01685606|DLBCL
257798|NCT01685606|DLBC
257799|NCT01685606|Diffuse large B cell
257800|NCT01685606|T cell
257801|NCT01685606|AML
257802|NCT01685606|ALL
257803|NCT01685593|abdominal binder
257804|NCT01685580|primary lung cancer
257805|NCT01685580|lobectomy
257806|NCT01685580|pneumonectomy
257807|NCT01685580|non-invasive ventilation
257808|NCT01685567|carotid artery disease
257809|NCT01685567|reverse flow
257810|NCT01685554|perfusion
257811|NCT01685554|cardiopulmonary bypass
257812|NCT01685554|hypothermia
257813|NCT01685554|cerebral oxygenation
257814|NCT01685528|Anxiety
257815|NCT01685528|Depression
257816|NCT01685528|Geriatric
257817|NCT01685528|Veteran
257818|NCT01685502|Glucobay OD
257819|NCT01685502|Diabetes Mellitus
257820|NCT01685489|Prostate
257821|NCT01685489|Neoplasm
257822|NCT01685489|Adenocarcinoma
257823|NCT01685489|Cancer
257824|NCT01685489|Metastatic
257825|NCT01685489|Castrate resistant
257826|NCT01685489|Docetaxel
257827|NCT01685489|PSK
257828|NCT01685489|Krestin
257829|NCT01685489|Trametes versicolor
257830|NCT01685489|Safety
257831|NCT01685489|Maximum tolerated dose
257832|NCT01685489|Mushroom
257833|NCT01685489|Natural
257834|NCT01685489|Immunotherapy
257835|NCT01685476|Cochlear microphonic potential
257836|NCT01685476|non invasive method
257837|NCT01685476|indirect monitoring
257838|NCT01685476|intracranial pressure
257839|NCT01685463|methamphetamine, craving, TMS, cortical excitability, prefrontal cortex
257840|NCT01685450|Cochlear microphonic potential
257841|NCT01685450|non invasive method
257842|NCT01685450|indirect measurement
257843|NCT01685450|intracranial pressure
257844|NCT01685450|adults
257845|NCT01685437|Peyronie's disease, penile plaque, penile curvature
257846|NCT01685424|Etoricoxib
257847|NCT01685424|ARCOXIA
257848|NCT01685424|Osteoarthritis
257849|NCT01685424|Rheumatoid Arthritis
257850|NCT01685424|Ankylosing Spondylitis
257851|NCT01685424|Gout
257852|NCT01685424|Arthritis
257853|NCT01685385|Dyspnoea
257854|NCT01685385|BNP
257855|NCT01685385|Chronic heart failure
257856|NCT01685385|congestive heart failure
257857|NCT01685346|advanced (stage IV) non-small cell lung cancer (NSCLC)
257858|NCT01685346|biofeedback-mediated stress management (BFSM)
257859|NCT01685333|subject
257860|NCT01685320|Force
257861|NCT01685320|Pressure
257862|NCT01685320|Intubation
257863|NCT01685320|laryngoscopy
257864|NCT01685307|ileal digestibility
257865|NCT01685307|metabolism
257866|NCT01685307|stable isotopes
257867|NCT01685294|Major Depressive Disorder (MDD)
257868|NCT01685294|Suicidality
257869|NCT01685294|Incarcerated Populations
257870|NCT01685294|Prisons
257871|NCT01685294|Interpersonal Psychotherapy (IPT)
257872|NCT01685281|ADHD , Inattention
257873|NCT01685268|Prostate Cancer
257874|NCT01685255|FIGO Stage III or IV EOC
257875|NCT01685255|PPC FTC
257876|NCT01685255|increasing CA 125
257877|NCT01685216|VPRIV
257878|NCT01685216|velaglucerase alfa
257879|NCT01685203|Hepatitis C Virus
257880|NCT01685203|Ribavirin-Free
257881|NCT01685203|Hepatitis C Genotype 1
257882|NCT01685203|Hepatitis C
257883|NCT01685203|Interferon-Free
257884|NCT01685203|Chronic Hepatitis C
257885|NCT01685203|Compensated cirrhosis
257886|NCT01685203|Hepatitis C Genotype 4
257887|NCT01685203|Paritaprevir
257888|NCT01685203|Ombitasvir
257889|NCT01685203|Ritonavir
257890|NCT01685203|Ribavirin
257891|NCT01685177|Morbid obesity
257892|NCT01685177|Sleeve gastrectomy
257893|NCT01685177|Duodenal Switch
257894|NCT01685177|SADI-S
257895|NCT01685164|nulliparous
257896|NCT01685164|IUD
257897|NCT01685164|IUS
257898|NCT01685164|insertion
257899|NCT01685164|expulsion
257900|NCT01685151|Drug therapy
257901|NCT01685138|Non-Small Cell Lung Cancer, ALK, LDK378
257902|NCT01685112|adults
257903|NCT01685112|ECMO
257904|NCT01685099|diagnosis, inflammation-associated markers, pleural effusion, tuberculosis, tuberculous pleurisy
257905|NCT01685086|latent tuberculosis infection, tuberculosis, chronic kidney disease, peritoneal dialysis, hemodialysis
257906|NCT01685073|marijuana
257907|NCT01685073|cannabis
257908|NCT01685073|treatment
257909|NCT01685073|insomnia
257910|NCT01685073|relapse
257911|NCT01685060|Non-Small Cell Lung Cancer, ALK, LDK378
257912|NCT01685047|Coronary Artery Disease
257913|NCT01685047|Ventricular Arrhythmias
257914|NCT01685047|ST Segment Changes
257915|NCT01685034|Eosinophilic esophagitis
257916|NCT01685034|Environmental allergens
257917|NCT01685034|Allergy immunotherapy
257918|NCT01685034|Tolerance
257919|NCT01685034|Allergic rhinitis
257920|NCT01685034|Asthma
257921|NCT01685034|Seasonal variation
257922|NCT01685021|B-ALL
257923|NCT01685021|CD19
257924|NCT01685021|MOR208
257925|NCT01685021|MOR00208
257926|NCT01685021|Xmab5574
257927|NCT01685021|B-cell acute lymphoblastic leukemia
257928|NCT01685021|Fc-optimized Anti-CD19 Antibody
257929|NCT01685008|NHL
257930|NCT01685008|CD19
257931|NCT01685008|MOR208
257932|NCT01685008|MOR00208
257933|NCT01685008|Xmab5574
257934|NCT01685008|B-Cell Non-Hodgkin´s Lymphoma
257935|NCT01685008|Fc-optimized Anti-CD19 Antibody
257936|NCT01684982|Primary PCI
257937|NCT01684982|Drug Eluting Stent
257938|NCT01684969|Nausea
257939|NCT01684969|vomiting
257940|NCT01684969|gastrointestinal symptoms
257941|NCT01684969|palliative care
257942|NCT01684956|intradermal
257943|NCT01684956|pharmacokinetics
257944|NCT01684956|microneedle
257945|NCT01684956|insulin
257946|NCT01684956|glucagon
257947|NCT01684943|Pharmacokinetics
257948|NCT01684930|Cardiovascular Diseases
257949|NCT01684930|Vascular Diseases
257950|NCT01684930|Arterial Occlusive Diseases
257951|NCT01684930|Exercise
257952|NCT01684930|Functional Capacity
257953|NCT01684852|dry eye, sicca, HA, Hyaluronic Acid, ectoin, ectoine, bitop
257954|NCT01684839|Painful digital neuroma
257955|NCT01684839|nerve defect
257956|NCT01684839|dorsal branch of the digital nerve
257957|NCT01684839|digital nerve
257958|NCT01684839|pedicled nerve flap
257959|NCT01684839|Pain Disorder Associated with Psychological and Physical Factors
257960|NCT01684826|X-rays
257961|NCT01684826|Image processing
257962|NCT01684826|Cardiovascular procedure
257963|NCT01684813|Diabetes mellitus.
257964|NCT01684813|Acute coronary syndrome.
257965|NCT01684813|Percutaneous coronary intervention.
257966|NCT01684787|chronic hepatitis C
257967|NCT01684787|normal ALT
257968|NCT01684787|HIV/HCV patients
257969|NCT01684761|Multicenter Study
257970|NCT01684761|Randomized Controlled Trial
257971|NCT01684761|Individualized Medicine
257972|NCT01684761|Immunotherapy
257973|NCT01684761|Myelin Proteins
257974|NCT01684761|Biological Agents
257975|NCT01684748|angiotensin II
257976|NCT01684748|obesity
257977|NCT01684748|diabetes
257978|NCT01684735|diffusion-weighted magnetic resonance imaging
257979|NCT01684722|vitamin D3
257980|NCT01684722|omega-3 fatty acids
257981|NCT01684722|fish oil
257982|NCT01684722|diabetes
257983|NCT01684722|kidney disease
257984|NCT01684722|albuminuria
257985|NCT01684722|urine albumin excretion
257986|NCT01684722|glomerular filtration rate
257987|NCT01684722|diabetic kidney disease
257988|NCT01684709|Type 2 Diabetes
257989|NCT01684709|Informal Caregivers
257990|NCT01684709|Self Care
257991|NCT01684709|Quality of Life
257992|NCT01684709|Health Information Technology
257993|NCT01684696|Lung cancer
257994|NCT01684696|stigma
257995|NCT01684696|virtual intervention
257996|NCT01684696|mHealth
257997|NCT01684683|Bronchiectasis
257998|NCT01684683|Theophylline
257999|NCT01684683|Therapeutic Uses
258000|NCT01684683|HDAC
258001|NCT01684683|HAT
258002|NCT01684683|Random placebo study
258003|NCT01684657|Stuttering
258004|NCT01684644|ADHD
258005|NCT01684644|Parent Training
258006|NCT01684644|RCT
258007|NCT01684644|Preschool
258008|NCT01684618|Preterm
258009|NCT01684618|Neonate
258010|NCT01684618|Newborn
258011|NCT01684618|Cerebral oxygenation
258012|NCT01684618|CPAP
258013|NCT01684605|CKD-11101
258014|NCT01684605|NESP
258015|NCT01684605|Darbepoetin alfa
258016|NCT01684605|Anemia
258017|NCT01684605|intravenous
258018|NCT01684605|Pharmacokinetics
258019|NCT01684605|Phase 1
258020|NCT01684592|smoking cessation
258021|NCT01684592|relapse prevention
258022|NCT01684592|pregnancy
258023|NCT01684592|postpartum
258024|NCT01684579|Breast Cancer
258025|NCT01684579|African-American Women
258026|NCT01684579|Aerobic Exercise
258027|NCT01684553|Eating speed
258028|NCT01684553|energy intake
258029|NCT01684540|sinusitis, rhinosinusitis, ectoin, ectoine, bitop, SNS, SNS01
258030|NCT01684514|confocal laser endomicroscopy
258031|NCT01684514|inflammatory bowel disease
258032|NCT01684514|colitis, ulcerative
258033|NCT01684501|prosthesis
258034|NCT01684501|amputees
258035|NCT01684501|gait
258036|NCT01684488|Depression/therapy;
258037|NCT01684488|Developing Countries;
258038|NCT01684488|Interpersonal Relations;
258039|NCT01684488|Life Change Events;
258040|NCT01684488|Psychotherapy, Group;
258041|NCT01684488|Resilience, Psychological;
258042|NCT01684488|Sierra Leone;
258043|NCT01684488|Survivors/psychology;
258044|NCT01684488|Social Adjustment;
258045|NCT01684488|Social Behavior;
258046|NCT01684488|War
258047|NCT01684475|Novel Treatment Parkinson's disease
258048|NCT01684462|Acute Ischemic Stroke
258049|NCT01684462|Albumin
258050|NCT01684449|Soft tissue sarcoma
258051|NCT01684449|Gemcitabine
258052|NCT01684449|Rapamycin
258053|NCT01684449|Sirolimus
258054|NCT01684449|mTOR inhibitor
258055|NCT01684449|Molecular biomarkers
258056|NCT01684410|Cystic Fibrosis
258057|NCT01684410|Alpha1-proteinase inhibitor
258058|NCT01684410|Alpha1-antitrypsin
258059|NCT01684384|Pulmonary Disease, Chronic Obstructive
258060|NCT01684384|COPD
258061|NCT01684384|Exacerbation
258062|NCT01684384|Functional Respiratory Imaging
258063|NCT01684384|High Resolution Computed Tomography
258064|NCT01684384|HRCT scan
258065|NCT01684384|Patient Reported Outcome
258066|NCT01684384|PRO
258067|NCT01684384|Computational Fluid Dynamic
258068|NCT01684384|CFD
258069|NCT01684384|Lung function parameters
258070|NCT01684371|Osteoarthritis
258071|NCT01684371|Osteoarthritic pain
258072|NCT01684371|Arthritic pain
258073|NCT01684371|Arthritis
258074|NCT01684371|joint inflammation
258075|NCT01684371|Arthralgia
258076|NCT01684358|Prostate-specific antigen
258077|NCT01684358|Contraceptive implant
258078|NCT01684358|Biological marker
258079|NCT01684358|Condoms
258080|NCT01684358|Women
258081|NCT01684345|Uveitis
258082|NCT01684345|Non-infectious Uveitis
258083|NCT01684345|Intermediate Uveitis
258084|NCT01684345|Posterior Uveitis
258085|NCT01684345|Panuveitis
258086|NCT01684332|Antioxidant
258087|NCT01684332|glucose metabolism
258088|NCT01684332|jam
258089|NCT01684332|polyphenols
258090|NCT01684332|postprandial
258091|NCT01684332|strawberry
258092|NCT01684319|Constipation
258093|NCT01684319|Gastroeosphageal reflux
258094|NCT01684319|Colics
258095|NCT01684306|RsfMRI, brain plasticity, cognitive enhancer
258096|NCT01684293|Cocaine
258097|NCT01684293|Cognitive Impairment
258098|NCT01684293|Cognitive Rehabilitation
258099|NCT01684280|abdominal adipose tissue; microRNA
258100|NCT01684267|Stroke
258101|NCT01684267|Gait
258102|NCT01684267|Rehabilitation
258103|NCT01684254|Cerebral Palsy
258104|NCT01684254|Home monitoring
258105|NCT01684254|Gait
258106|NCT01684254|Sensorized Shoe
258107|NCT01684241|Biontech
258108|NCT01684241|Biontech RNA Pharmaceuticals GmbH
258109|NCT01684241|Biontech RNA
258110|NCT01684241|MERIT
258111|NCT01684241|RNA
258112|NCT01684241|Immuno Therapy
258113|NCT01684241|RB_0001-01
258114|NCT01684241|Ribological
258115|NCT01684241|Melanoma
258116|NCT01684241|RBL001
258117|NCT01684241|RBL002
258118|NCT01684241|cancer vaccine
258119|NCT01684228|End stage renal disease
258120|NCT01684228|hemodialysis
258121|NCT01684228|breath test
258122|NCT01684228|volatile organic compound
258123|NCT01684228|dialysis adequacy
258124|NCT01684215|Phase 1/2
258125|NCT01684215|PD-0332991
258126|NCT01684215|palbociclib
258127|NCT01684215|Cyclin Dependent Kinase 4/6 inhibitor
258128|NCT01684215|Japanese
258129|NCT01684215|solid tumors
258130|NCT01684215|breast cancer
258131|NCT01684215|A5481010
258132|NCT01684176|Stroke
258133|NCT01684176|Ischemic Attack, Transient
258134|NCT01684176|Medication adherence
258135|NCT01684176|Motivational interviewing
258136|NCT01684176|Stroke prevention
258137|NCT01684163|depression
258138|NCT01684163|MDD
258139|NCT01684163|GLYX-13
258140|NCT01684163|HDRS-17
258141|NCT01684163|HAMD-17
258142|NCT01684150|Leukemia
258143|NCT01684150|Advanced hematologic malignancies
258144|NCT01684150|Epizyme
258145|NCT01684150|Phase 1
258146|NCT01684150|Mixed Lineage Leukemia (MLL)
258147|NCT01684137|Food supplements
258148|NCT01684137|Asthma bronchiale
258149|NCT01684124|oxygen
258150|NCT01684124|critical illness
258151|NCT01684124|mechanical ventilation
258152|NCT01684111|Non Small Cell Lung Cancer - Stage IV
258153|NCT01684111|NSCLC Stage IV
258154|NCT01684098|recurrent or metastatic cancer
258155|NCT01684098|head and neck cancer
258156|NCT01684098|pancreas cancer
258157|NCT01684098|bladder cancer
258158|NCT01684098|testicular cancer
258159|NCT01684085|sleep deprivation, PTSD,prevention
258160|NCT01684072|varicella vaccine
258161|NCT01684072|gelatin
258162|NCT01684046|multi-purpose solution
258163|NCT01684046|silicone hydrogel
258164|NCT01684046|contact lenses
258165|NCT01684046|comfort
258166|NCT01684046|Opti-Free
258167|NCT01684046|RevitaLens
258168|NCT01684033|multi-purpose solution
258169|NCT01684033|silicone hydrogel
258170|NCT01684033|contact lenses
258171|NCT01684033|comfort
258172|NCT01684033|Opti-Free
258173|NCT01684033|Biotrue
258174|NCT01684020|rhinoplasty
258175|NCT01684020|external rhinoplasty
258176|NCT01684020|open rhinoplasty
258177|NCT01684020|nose job
258178|NCT01684007|Intraocular lens
258179|NCT01684007|Multifocal intraocular lens (MIOL)
258180|NCT01683994|Angiogenesis Inhibitors
258181|NCT01683994|Small Molecules
258182|NCT01683994|Tyrosine Kinase Inhibitor
258183|NCT01683981|Idiopathic Pulmonary Arterial Hypertension
258184|NCT01683981|Eisenmenger Syndrome
258185|NCT01683981|Exercise Capacity
258186|NCT01683981|Quality of Life
258187|NCT01683955|Tranexamic Acid
258188|NCT01683955|Blood transfusion
258189|NCT01683955|Total hip arthroplasty
258190|NCT01683942|cup disc ratio measurement
258191|NCT01683942|digital stereo optic disc images
258192|NCT01683929|Obesity
258193|NCT01683929|Overweight
258194|NCT01683929|Sugar consumption
258195|NCT01683929|Metabolic syndrome
258196|NCT01683929|Artificially sweetened foods and beverages
258197|NCT01683916|spinal cord injury
258198|NCT01683916|stress hormone
258199|NCT01683916|surgery
258200|NCT01683916|bispectral index value
258201|NCT01683916|volatile anesthetic
258202|NCT01683903|heart failure
258203|NCT01683903|cardiac rehabilitation
258204|NCT01683903|myocardial infarction
258205|NCT01683890|Bladder symptoms
258206|NCT01683890|Sexual function
258207|NCT01683890|Quality of life
258208|NCT01683890|Simple hysterectomy
258209|NCT01683851|pediatric
258210|NCT01683851|conscious sedation
258211|NCT01683851|mouthpiece
258212|NCT01683851|airway
258213|NCT01683851|isolite system
258214|NCT01683838|spinal cord injury
258215|NCT01683838|muscle spasticity
258216|NCT01683825|Amyloidosis
258217|NCT01683825|Cardiac
258218|NCT01683825|Heart
258219|NCT01683825|Imaging
258220|NCT01683825|Diagnosis
258221|NCT01683799|Osteoarthritis
258222|NCT01683799|Insomnia
258223|NCT01683799|Chronic pain
258224|NCT01683799|Cognitive Behavioral Therapy for Insomnia
258225|NCT01683799|Inflammation
258226|NCT01683799|Inflammatory cytokines
258227|NCT01683773|Tuberculosis
258228|NCT01683773|Phase I
258229|NCT01683773|MVA85A
258230|NCT01683773|AERAS-402
258231|NCT01683760|Fluconazole
258232|NCT01683747|sepsis
258233|NCT01683747|shock
258234|NCT01683747|placebo controlled
258235|NCT01683747|double blinded
258236|NCT01683747|interventional
258237|NCT01683708|sepsis
258238|NCT01683708|jaundice
258239|NCT01683708|symbiotic
258240|NCT01683708|translocation
258241|NCT01683708|abdominal collection
258242|NCT01683708|morbidity
258243|NCT01683695|Lupus Arthritis, Systemic Lupus Erythematosus, AMG 557, Lupus
258244|NCT01683682|Non-Small Lung Cancer
258245|NCT01683682|NSCLC Stage IV
258246|NCT01683669|ALI
258247|NCT01683669|ARDS
258248|NCT01683669|Noisy pressure support ventilation
258249|NCT01683656|HIV
258250|NCT01683656|Atherosclerosis
258251|NCT01683656|Niacin/laropiprant
258252|NCT01683656|HDL
258253|NCT01683630|Influenza
258254|NCT01683630|Influenza type A
258255|NCT01683630|Influenza type B
258256|NCT01683630|hospitalization
258257|NCT01683630|Manitoba
258258|NCT01683630|Canada
258259|NCT01683617|Psychological stress
258260|NCT01683591|Acute stroke
258261|NCT01683591|Dysphagia
258262|NCT01683591|High-resolution manometry
258263|NCT01683578|mechanical ventilation
258264|NCT01683578|lung function
258265|NCT01683578|abdominal surgery, open
258266|NCT01683578|systemic inflammation
258267|NCT01683552|ITCH
258268|NCT01683539|Schizophrenia
258269|NCT01683539|Chronic Mental Disorder
258270|NCT01683539|Employment
258271|NCT01683539|Cognitive remediation
258272|NCT01683539|Vocational rehabilitation
258273|NCT01683526|Urgent endotrachel intubation
258274|NCT01683526|Direct laryngoscopy
258275|NCT01683526|Video laryngoscopy
258276|NCT01683526|Glidescope
258277|NCT01683526|Critical Care
258278|NCT01683513|OHSS
258279|NCT01683513|mataphase II oocytes (MII)
258280|NCT01683513|good quality embryo's
258281|NCT01683513|pregnancy
258282|NCT01683474|aortic valve stenosis
258283|NCT01683474|Calcification
258284|NCT01683474|TAVI
258285|NCT01683474|aortic valve Prosthesis
258286|NCT01683461|HIV
258287|NCT01683461|AIDS
258288|NCT01683448|Perioperative medications
258289|NCT01683448|cardiac surgery
258290|NCT01683448|outcomes
258291|NCT01683396|Erosive Osteoarthritis
258292|NCT01683396|Osteoarthritis
258293|NCT01683396|Osteoarthritis of the Hand
258294|NCT01683383|Hypoxic ischemic encephalopathy
258295|NCT01683383|Therapeutic hypothermia
258296|NCT01683383|Whole body cooling
258297|NCT01683383|Transport cooling
258298|NCT01683357|Liver Metastases
258299|NCT01683357|Surgery
258300|NCT01683357|Intraoperative Ultrasound
258301|NCT01683344|chronic, sub-acute wounds
258302|NCT01683331|Kidney transplant
258303|NCT01683331|New onset diabetes
258304|NCT01683331|Prevention
258305|NCT01683331|Insulin
258306|NCT01683305|biomarker,
258307|NCT01683305|NAF
258308|NCT01683305|Subjects
258309|NCT01683292|apomorphine
258310|NCT01683292|inhaled
258311|NCT01683292|motor fluctuations
258312|NCT01683279|pediatric
258313|NCT01683279|acute lymphoblastic leukemia
258314|NCT01683279|CD19
258315|NCT01683279|Chimeric Antigen Receptor
258316|NCT01683240|cholangiography
258317|NCT01683240|cholangioscopy
258318|NCT01683240|mother-baby
258319|NCT01683240|cholangioscope
258320|NCT01683240|Frimberger cholangioscope
258321|NCT01683240|short access cholangioscopy
258322|NCT01683240|ERCP
258323|NCT01683240|gallstone therapy
258324|NCT01683227|drug use; emergency department; brief intervention
258325|NCT01683201|Total hip replacement
258326|NCT01683201|Functional exercise class
258327|NCT01683201|Randomised controlled trial
258328|NCT01683188|melanoma
258329|NCT01683188|skin cancer
258330|NCT01683188|Stage IV
258331|NCT01683175|Erlotinib
258332|NCT01683175|adjuvant therapy
258333|NCT01683175|radical operation
258334|NCT01683175|IIIA NSCLC
258335|NCT01683175|EGFR mutation
258336|NCT01683162|parenteral nutrition
258337|NCT01683162|lipid emulsion
258338|NCT01683162|olive oil
258339|NCT01683162|liver function
258340|NCT01683162|fatty acid
258341|NCT01683162|clinical outcomes
258342|NCT01683149|Refractory
258343|NCT01683149|Relapsed
258344|NCT01683149|Recurrent
258345|NCT01683149|Pediatric
258346|NCT01683149|Malignancy
258347|NCT01683123|Allogeneic HSCT
258348|NCT01683123|Busulfan
258349|NCT01683123|Fludarabina
258350|NCT01683084|Abdominal Aortic Aneurysm
258351|NCT01683084|AAA
258352|NCT01683084|telmisartan
258353|NCT01683071|Total knee arthroplasty
258354|NCT01683071|Analgesia
258355|NCT01683071|Pain management
258356|NCT01683058|Schizophrenia
258357|NCT01683045|non-paroxysmal atrial fibrillation
258358|NCT01683045|persistent atrial fibrillation
258359|NCT01683045|atrial fibrillation
258360|NCT01683045|heart palpitations
258361|NCT01683045|irregular heart beat
258362|NCT01683045|temperature-controlled radiofrequency ablation
258363|NCT01683045|radiofrequency energy
258364|NCT01683045|TCRF energy
258365|NCT01683045|RF energy
258366|NCT01683045|epicardial and endocardial lesions
258367|NCT01683045|concomitant heart surgery
258368|NCT01683045|surgical ablation
258369|NCT01683019|Depression
258370|NCT01683019|magnetic field
258371|NCT01683019|alpha frequency
258372|NCT01683019|EEG
258373|NCT01683019|NeoSync EEG Synchronization Therapy
258374|NCT01682993|corneal cross linking
258375|NCT01682993|topography guided excimer laser
258376|NCT01682993|Keratoconus
258377|NCT01682993|Pellucid marginal degeneration
258378|NCT01682993|Post Excimer ectasia
258379|NCT01682980|Osteoarthritis
258380|NCT01682980|Pain
258381|NCT01682980|Exercise
258382|NCT01682980|Function
258383|NCT01682980|Cartilage quality
258384|NCT01682967|Parturients
258385|NCT01682967|Analgesia, epidural
258386|NCT01682967|Headache, post-dural puncture
258387|NCT01682954|lifestyle risk reduction
258388|NCT01682941|soy, isoflavones, functional food, prostate cancer
258389|NCT01682928|Oligohydramnios
258390|NCT01682928|Hydrotherapy
258391|NCT01682928|Pregnancy
258392|NCT01682915|ADHD
258393|NCT01682915|endophenotype
258394|NCT01682915|executive function
258395|NCT01682915|diffusion spectrum imaging
258396|NCT01682915|resting-state fMRI
258397|NCT01682915|frontostriatal and frontoparietal circuitries
258398|NCT01682915|DAT1
258399|NCT01682876|Prevention of meningococcal disease, children, vaccine
258400|NCT01682863|COPD, QAB149, QVA149, indacaterol maleate, gylcopyrronium bromide
258401|NCT01682850|COPD
258402|NCT01682850|Chronic Obstructive Lung Disease
258403|NCT01682850|lung cancer
258404|NCT01682850|emphysema
258405|NCT01682850|Pulmonary Rehabilitation
258406|NCT01682824|Central Nervous System
258407|NCT01682824|CNS
258408|NCT01682824|CNS tumor
258409|NCT01682824|Adolescent or Young Adult
258410|NCT01682824|AYA
258411|NCT01682824|Survivors
258412|NCT01682824|Eating Questionnaire-Ecological Momentary Assessment
258413|NCT01682824|EQ-EMA
258414|NCT01682824|Cognitive restraint
258415|NCT01682824|CR
258416|NCT01682824|Uncontrollable eating
258417|NCT01682824|UE
258418|NCT01682824|Three Factor Eating Questionnaire-R18v2
258419|NCT01682824|TFEQ-R18v2
258420|NCT01682824|Web-based questionnaire
258421|NCT01682824|Multifactor Screener
258422|NCT01682785|Major depressive disorder
258423|NCT01682785|Metabolic syndrome
258424|NCT01682785|Thyroid dysfunction
258425|NCT01682785|incidence
258426|NCT01682772|Olaparib
258427|NCT01682772|Adenocarcinoma
258428|NCT01682772|Prostate
258429|NCT01682759|diabetes
258430|NCT01682746|Brain Tumor
258431|NCT01682746|Photodynamic Therapy
258432|NCT01682746|Photochemotherapy
258433|NCT01682746|Astrocytoma
258434|NCT01682746|Pilocytic Astrocytoma
258435|NCT01682746|Low grade Astrocytoma
258436|NCT01682746|Anaplastic Astrocytoma
258437|NCT01682746|Glioblastoma
258438|NCT01682746|GBM
258439|NCT01682746|Chordoma
258440|NCT01682746|Germinoma
258441|NCT01682746|Germ Cell Tumor
258442|NCT01682746|Non-germinaoma
258443|NCT01682746|CNS Lymphoma
258444|NCT01682746|Craniopharyngioma
258445|NCT01682746|Brain Stem Glioma
258446|NCT01682746|Ependymoma
258447|NCT01682746|Mixed Glioma
258448|NCT01682746|Optic Nerve Glioma
258449|NCT01682746|Subependymoma
258450|NCT01682746|Medulloblastoma
258451|NCT01682746|Meningioma
258452|NCT01682746|Metastatic Brain Tumors
258453|NCT01682746|Oligodendroglioma
258454|NCT01682746|Pituitary Tumors
258455|NCT01682746|Primitive Neuroectodermal
258456|NCT01682746|PNET
258457|NCT01682746|Desmoplastic Neuroepithelial Tumor
258458|NCT01682746|DNET
258459|NCT01682733|Obesity
258460|NCT01682733|Weight loss
258461|NCT01682733|Gastric reduction (volume)
258462|NCT01682733|BMI 30-40
258463|NCT01682720|HCV
258464|NCT01682720|Genotype 2
258465|NCT01682720|Genotype 3
258466|NCT01682707|intubation
258467|NCT01682707|coronary disease
258468|NCT01682707|hemodynamic response
258469|NCT01682707|anesthesia with tracheal intubation
258470|NCT01682707|assessment of hemodynamic response
258471|NCT01682681|Epilepsy
258472|NCT01682681|Topiramate
258473|NCT01682681|Topmax
258474|NCT01682668|parkinson's disease
258475|NCT01682668|subthalamic nucleus
258476|NCT01682668|akinesia
258477|NCT01682668|gait initiation
258478|NCT01682668|neuronal activity
258479|NCT01682668|before STN stimulation
258480|NCT01682668|with STN stimulation
258481|NCT01682668|functional MRI
258482|NCT01682642|endometriosis
258483|NCT01682642|pregnancy
258484|NCT01682642|In Vitro Fertilization (IVF)/Intra Cytoplastic Sperm Injection (ICSI)
258485|NCT01682642|peritoneal implants
258486|NCT01682642|embryo quality
258487|NCT01682629|Pediatric
258488|NCT01682629|Cardiac
258489|NCT01682629|Arrest
258490|NCT01682629|Simulation
258491|NCT01682629|Debriefing
258492|NCT01682629|Realism
258493|NCT01682616|Venetoclax
258494|NCT01682616|ABT-199
258495|NCT01682616|Rituximab
258496|NCT01682616|Maximum Tolerated Dose
258497|NCT01682616|Efficacy
258498|NCT01682616|Preliminary
258499|NCT01682616|Pharmacokinetics
258500|NCT01682616|Tolerability
258501|NCT01682616|Chronic Lymphocytic Leukemia
258502|NCT01682616|Small Lymphocytic Lymphoma
258503|NCT01682616|Safety
258504|NCT01682616|Cancer
258505|NCT01682603|Nerve growth factor
258506|NCT01682603|P2X3 receptor
258507|NCT01682603|Transient Receptor Potential Vanilloid 1 (TRPV-1) receptor
258508|NCT01682603|Bladder function
258509|NCT01682603|Glomerular filtration rate
258510|NCT01682603|Detrusor overactivity
258511|NCT01682603|Spinal cord injury
258512|NCT01682590|septic shock; acute renal failure; renal remplacement therapy; mortality; intensive care; critical care; acute kidney injury
258513|NCT01682577|Perindopril
258514|NCT01682577|Perindoprilat
258515|NCT01682577|Bioequivalence
258516|NCT01682577|Pharmacokinetic
258517|NCT01682577|Angiotensin-converting enzyme inhibitor
258518|NCT01682564|Candemore
258519|NCT01682564|Atacand
258520|NCT01682564|Candesartan cilexetil
258521|NCT01682564|Primary Hypertension
258522|NCT01682564|Congestive Hypertension
258523|NCT01682551|High altitude illness
258524|NCT01682551|Chinese medicine body constitution
258525|NCT01682551|Chinese Medicine
258526|NCT01682551|High altitude medicine
258527|NCT01682551|Mountain trekking
258528|NCT01682538|Orfadin
258529|NCT01682538|Nitisinone
258530|NCT01682538|Bioequivalence
258531|NCT01682538|Bioavailability
258532|NCT01682525|Fertility preservation
258533|NCT01682525|Ovarian Tissue
258534|NCT01682525|Cryopreservation
258535|NCT01682525|Assisted Reproductive Technology
258536|NCT01682499|neuropathy
258537|NCT01682499|taxane
258538|NCT01682499|paclitaxel
258539|NCT01682499|calcium
258540|NCT01682499|magnesium
258541|NCT01682499|prevention
258542|NCT01682486|Medical device
258543|NCT01682486|Endotracheal Tube(s), ETT
258544|NCT01682486|Bactiguard Coated ETT
258545|NCT01682486|Tolerability
258546|NCT01682486|Safety
258547|NCT01682486|Performance
258548|NCT01682486|Bacterial colonization on ETT surface
258549|NCT01682486|Hospital Acquired Infections, HAI
258550|NCT01682486|Ventilator Associated Pneumonia, VAP
258551|NCT01682473|PI3K inhibitor
258552|NCT01682473|clinical trial
258553|NCT01682447|COPD
258554|NCT01682447|Cognitive Dysfunction
258555|NCT01682447|Pulmonary Rehabilitation
258556|NCT01682447|Quality of life
258557|NCT01682447|Cognitive rehabilitation
258558|NCT01682408|R406,
258559|NCT01682408|Fostamatinib,
258560|NCT01682408|Phase I,
258561|NCT01682408|Healthy Subjects,
258562|NCT01682408|Pharmacokinetics,
258563|NCT01682408|Fed/Fasted
258564|NCT01682395|Intestinal volvulus
258565|NCT01682395|Colon, sigmoid
258566|NCT01682395|Anastomosis, surgical
258567|NCT01682395|Anastomotic leak
258568|NCT01682395|Malawi
258569|NCT01682395|Developing Country
258570|NCT01682382|age-related macular degeneration
258571|NCT01682382|choroidal neovascular age-related macular degeneration
258572|NCT01682382|genetics
258573|NCT01682382|macular pigment optical density (MPOD)
258574|NCT01682356|heart failure
258575|NCT01682356|hypertension, pulmonary
258576|NCT01682356|oxygen consumption
258577|NCT01682356|exercise tolerance
258578|NCT01682317|eating frequency
258579|NCT01682304|preeclampsia
258580|NCT01682304|hypertension
258581|NCT01682304|blood pressure
258582|NCT01682304|pregnancy induced hypertension
258583|NCT01682304|chronic hypertension
258584|NCT01682291|Prehypertension
258585|NCT01682291|Life-style modifications
258586|NCT01682291|Dietary supplementation
258587|NCT01682278|Health complaints
258588|NCT01682278|Amalgam
258589|NCT01682278|Mercury
258590|NCT01682278|Plasma
258591|NCT01682278|Cytokine
258592|NCT01682226|CYCLOPHOSPHAMIDE (CYTOXAN)
258593|NCT01682226|CYCLOSPORINE
258594|NCT01682226|FLUDARABINE
258595|NCT01682226|G-CSF
258596|NCT01682226|MYCOPHENOLATE MOFETIL (MMF)
258597|NCT01682226|Cord Blood Transplantation
258598|NCT01682226|CliniMACS
258599|NCT01682226|12-153
258600|NCT01682213|Dabrafenib
258601|NCT01682213|(GSK2118436)
258602|NCT01682213|BRAFV600E/K
258603|NCT01682213|Resected AJCC Stage IIIC
258604|NCT01682213|12-124
258605|NCT01682200|moderate
258606|NCT01682200|facial acne
258607|NCT01682200|acne vulgaris
258608|NCT01682161|Schizophrenia
258609|NCT01682161|Paliperidone Palmitate
258610|NCT01682161|Invega Sustenna
258611|NCT01682161|Antipsychotics
258612|NCT01682161|Atypical antipsychotics
258613|NCT01682161|Medication Satisfaction and Adherence
258614|NCT01682122|Blood Pressure
258615|NCT01682122|Pediatrics
258616|NCT01682122|Infant, Newborn
258617|NCT01682122|Cardiology
258618|NCT01682109|prophylaxis
258619|NCT01682109|herpes zoster
258620|NCT01682109|herpes simplex
258621|NCT01682109|valacyclovir
258622|NCT01682109|palatability
258623|NCT01682109|paediatric
258624|NCT01682096|Chest pain
258625|NCT01682096|Emergency room
258626|NCT01682096|Acute coronary syndrome
258627|NCT01682096|Computed tomography coronary angiography
258628|NCT01682096|Stress echocardiography
258629|NCT01682083|MEK inhibitor
258630|NCT01682083|trametinib
258631|NCT01682083|Oncology
258632|NCT01682083|adjuvant melanoma
258633|NCT01682083|dabrafenib
258634|NCT01682083|dabrafenib and trametinib combination therapy
258635|NCT01682083|BRAF mutation-positive melanoma
258636|NCT01682083|BRAF inhibitor
258637|NCT01682070|Sublingual immunotherapy
258638|NCT01682070|Dose range finding
258639|NCT01682070|Dose tolerability
258640|NCT01682070|grass pollen
258641|NCT01682070|Allergic rhinitis/rhinoconjunctivitis
258642|NCT01682070|Safety
258643|NCT01682070|Immunogenicity
258644|NCT01682057|High Blood Pressure
258645|NCT01682057|Hypertension
258646|NCT01682057|Resistant Hypertension
258647|NCT01682018|emphysema
258648|NCT01682018|lung transplantation
258649|NCT01682005|Cost
258650|NCT01682005|Children
258651|NCT01682005|Rotavirus
258652|NCT01682005|Rotavirus vaccination
258653|NCT01682005|Clinical
258654|NCT01681992|Safety
258655|NCT01681992|Measles, mumps and rubella diseases
258656|NCT01681992|Immunogenicity
258657|NCT01681979|fluticasone propionate
258658|NCT01681979|asthma
258659|NCT01681979|pregnancy
258660|NCT01681979|major congenital malformations
258661|NCT01681927|idiopathic edema nocturia
258662|NCT01681914|adult HIV positive patients
258663|NCT01681875|Biomarkers of exposure
258664|NCT01681875|Compensatory smoking
258665|NCT01681875|Nicotine dependence
258666|NCT01681875|Reduced nicotine cigarettes
258667|NCT01681875|Tobacco withdrawal
258668|NCT01681862|Hypertension
258669|NCT01681862|African American
258670|NCT01681862|Personal Health Record
258671|NCT01681862|Faith-based Organizations
258672|NCT01681849|PTSD
258673|NCT01681849|childhood abuse
258674|NCT01681823|Prostate Cancer
258675|NCT01681823|Prostatic Neoplasms
258676|NCT01681823|Prostate Specific Antigen
258677|NCT01681823|Modified Citrus Pectin
258678|NCT01681823|PectaSol-C
258679|NCT01681823|Biochemical Relapse
258680|NCT01681797|fluorescent angiography
258681|NCT01681797|reconstructive surgery
258682|NCT01681797|perforator flap
258683|NCT01681784|lower urinary tract symptoms
258684|NCT01681784|biomarkers
258685|NCT01681784|urodynamic studies
258686|NCT01681758|cardiac surgery
258687|NCT01681758|Pulse pressure variation
258688|NCT01681758|intravenous fluids
258689|NCT01681732|Asthma
258690|NCT01681732|child
258691|NCT01681732|pediatric
258692|NCT01681719|VO2
258693|NCT01681719|VCO2
258694|NCT01681719|VE/VO2
258695|NCT01681719|heart rate
258696|NCT01681706|HIV
258697|NCT01681706|Indicator disease
258698|NCT01681654|Head/Neck Cancer
258699|NCT01681654|Exercise
258700|NCT01681654|Progressive Strength Training
258701|NCT01681654|Quality of Life
258702|NCT01681654|Cancer
258703|NCT01681654|Randomized Controlled Trial
258704|NCT01681654|Nutrition
258705|NCT01681654|Lifestyle Intervention
258706|NCT01681641|Patients
258707|NCT01681641|Nursing
258708|NCT01681641|Parkinsons disease
258709|NCT01681641|Deep Brain Stimulation
258710|NCT01681641|Spouses
258711|NCT01681628|Thought Field Therapy.
258712|NCT01681628|Post-traumatic stress disorder.
258713|NCT01681628|Post-traumatic stress disorder check list for Civilians.
258714|NCT01681628|Uganda
258715|NCT01681628|Ugandan therapists.
258716|NCT01681628|Community treatment.
258717|NCT01681615|Challenge test for Aspirin Hypersensitivity
258718|NCT01681615|Challenge test for Acetylsalicylic Hypersensitivity
258719|NCT01681602|Alzheimer Disease
258720|NCT01681602|Exercise
258721|NCT01681602|Cognition
258722|NCT01681602|Quality of life
258723|NCT01681602|Cardiovascular fitness
258724|NCT01681602|Behavioural or psychological symptoms
258725|NCT01681602|Physical fitness
258726|NCT01681589|TBI
258727|NCT01681589|Traumatic Brain Injury
258728|NCT01681589|Rehabilitation
258729|NCT01681589|Therapy
258730|NCT01681576|hypertension, salt sensitivity, valsartan, LCZ696
258731|NCT01681537|Relapsed
258732|NCT01681537|Refractory
258733|NCT01681524|Flurpiridaz F18 Injection
258734|NCT01681524|Positron Emission Tomography Myocardial Perfusion Imaging
258735|NCT01681524|Single Positron Emission Computed Tomography
258736|NCT01681524|Coronary Artery Disease
258737|NCT01681524|Myocardia Ischemia
258738|NCT01681524|Coronary Disease
258739|NCT01681524|Heart Diseases
258740|NCT01681524|Cardiovascular Diseases
258741|NCT01681524|Arteriosclerosis
258742|NCT01681524|Arterial Occlusive Diseases
258743|NCT01681524|Vascular Diseases
258744|NCT01681511|Catheter Associated Urinary Tract Infections
258745|NCT01681511|CAUTI
258746|NCT01681498|pregnant
258747|NCT01681498|fetal ecg
258748|NCT01681498|ecg
258749|NCT01681485|Traditional Chinese medicine
258750|NCT01681485|Non small cell lung cancer
258751|NCT01681485|Surgery
258752|NCT01681485|Chemotherapy
258753|NCT01681485|Radiation therapy
258754|NCT01681472|Colon cancer
258755|NCT01681472|5,10-methylenetetrahydrofolate
258756|NCT01681472|Rectal Neoplasms
258757|NCT01681472|Colorectal Neoplasms
258758|NCT01681472|Intestinal Neoplasms
258759|NCT01681472|Gastrointestinal Neoplasms
258760|NCT01681472|Digestive System Neoplasms
258761|NCT01681472|Gastrointestinal Diseases
258762|NCT01681472|Therapeutic Uses
258763|NCT01681472|Pharmacokinetics
258764|NCT01681472|Pharmacodynamics
258765|NCT01681459|Free fatty acid
258766|NCT01681459|Triglyceride
258767|NCT01681459|Gastric emptying
258768|NCT01681459|Satiety hormones
258769|NCT01681459|Appetite
258770|NCT01681459|Severe obesity
258771|NCT01681446|hepatocellular carcinoma
258772|NCT01681446|interferon-alpha
258773|NCT01681446|miR-26
258774|NCT01681433|OGX-427
258775|NCT01681433|Abiraterone Acetate
258776|NCT01681420|HIV counseling
258777|NCT01681420|Blood donor HIV testing
258778|NCT01681420|Brazil
258779|NCT01681420|Blood banks
258780|NCT01681420|Blood donors
258781|NCT01681407|Depression
258782|NCT01681407|Selective Serotonin Reuptake Inhibitors
258783|NCT01681407|MicroRNAs
258784|NCT01681407|Proteome
258785|NCT01681368|NF-Kappa B Pathway
258786|NCT01681368|Response Biomarkers
258787|NCT01681368|Progression-Free Survival
258788|NCT01681368|Pharmacokinetics
258789|NCT01681368|Pharmacodynamics
258790|NCT01681355|Healthy, term, Asian infants
258791|NCT01681355|Infant formula
258792|NCT01681342|stade Ib to IV cervix cancer
258793|NCT01681342|ambulatory high dose rate brachytherapy
258794|NCT01681329|Cognitive-behavioral therapy
258795|NCT01681329|Interpretation modification training
258796|NCT01681329|Randomized clinical trial
258797|NCT01681329|Adults
258798|NCT01681316|Chronic Stable Angina
258799|NCT01681316|Randomized Controlled Trial
258800|NCT01681316|Traditional Chinese Medicine
258801|NCT01681264|Pain
258802|NCT01681264|Pain Management
258803|NCT01681264|Back pain
258804|NCT01681264|Neck pain
258805|NCT01681238|perioperative fluid optimization
258806|NCT01681238|goal-directed therapy
258807|NCT01681238|elderly
258808|NCT01681238|high-risk surgery
258809|NCT01681225|ARDS
258810|NCT01681225|mechanical ventilation
258811|NCT01681225|ALI
258812|NCT01681225|esophageal pressure
258813|NCT01681199|statin
258814|NCT01681199|atherosclerosis
258815|NCT01681199|Coronary heart disease
258816|NCT01681199|OPN
258817|NCT01681199|OPG
258818|NCT01681173|Nutritional support
258819|NCT01681173|Diet therapy
258820|NCT01681173|Diabetes prevention
258821|NCT01681173|Insoluble fiber
258822|NCT01681173|Healthy life style
258823|NCT01681173|Weight loss
258824|NCT01681160|MAGGOT THERAPY
258825|NCT01681160|DIABETIC FOOT
258826|NCT01681160|NURSING CARE
258827|NCT01681160|DRESSING
258828|NCT01681147|Gestational Diabetes
258829|NCT01681147|postpartum
258830|NCT01681147|nutrition
258831|NCT01681147|exercise
258832|NCT01681134|tacrolimus
258833|NCT01681134|Advagraf®
258834|NCT01681134|Prograf®
258835|NCT01681134|Glomerular Filtration Rate
258836|NCT01681134|Effective Renal Plasma Flow
258837|NCT01681134|Pharmacokinetics
258838|NCT01681134|Pharmacodynamics
258839|NCT01681095|Physiological Effects of Drugs
258840|NCT01681095|Cardiovascular Agents
258841|NCT01681095|Therapeutic Uses
258842|NCT01681095|Pharmacologic Actions
258843|NCT01681095|Mannitol
258844|NCT01681095|Cardiac Surgery
258845|NCT01681095|Cardioplegic Solutions
258846|NCT01681095|HTK solution
258847|NCT01681095|Myocardial protection
258848|NCT01681095|Coronary Artery Disease
258849|NCT01681095|Myocardial Ischemia
258850|NCT01681095|Coronary Disease
258851|NCT01681095|Heart Diseases
258852|NCT01681056|autosuggestion
258853|NCT01681056|quality of life
258854|NCT01681056|geriatric
258855|NCT01681056|serum cortisol
258856|NCT01681056|Interferon gamma
258857|NCT01681056|interleukin-2
258858|NCT01681056|interleukin-6
258859|NCT01681056|neuroplasticity
258860|NCT01681043|Sleep
258861|NCT01681017|Perinatal Mortality
258862|NCT01681017|Asphyxia
258863|NCT01681017|Stillbirth
258864|NCT01681017|Neonatal Death
258865|NCT01681017|Resuscitation
258866|NCT01681017|Helping Babies Breathe
258867|NCT01681017|among births greater than one thousand five hundred grams
258868|NCT01681004|si joint
258869|NCT01681004|si joint pain
258870|NCT01681004|si joint injury
258871|NCT01681004|si joint treatment
258872|NCT01681004|si joint injections
258873|NCT01681004|si joint inflammation
258874|NCT01681004|si joint problems
258875|NCT01681004|si joint symptoms
258876|NCT01681004|hypermobile si joint
258877|NCT01681004|si joint arthritis
258878|NCT01681004|si joint pain treatment
258879|NCT01681004|inflamed si joint
258880|NCT01681004|si joint sclerosis
258881|NCT01681004|locked si joint
258882|NCT01681004|si joint injuries
258883|NCT01681004|si joint disease
258884|NCT01681004|si joint infection
258885|NCT01681004|sacroiliac joint pelvic pain
258886|NCT01681004|sacroiliac joint arthritis treatment
258887|NCT01680965|Graft vs. Host Disease
258888|NCT01680965|GVHD
258889|NCT01680965|chronic graft versus host disease (cGVHD)
258890|NCT01680965|Allogeneic Transplant
258891|NCT01680965|Ofatumumab
258892|NCT01680952|RECORD study
258893|NCT01680939|Pediatrics
258894|NCT01680939|Obstructive Sleep Apnea
258895|NCT01680939|Adenotonsillectomy
258896|NCT01680939|Analgesia
258897|NCT01680926|type 2 diabetes mellitus
258898|NCT01680926|insulin
258899|NCT01680926|hbA1c
258900|NCT01680926|body weight
258901|NCT01680900|menopause
258902|NCT01680900|hot flashes
258903|NCT01680900|vilazodone
258904|NCT01680887|Cocaine dependence
258905|NCT01680874|Clostridium difficile
258906|NCT01680874|Diarrhea
258907|NCT01680874|Infection
258908|NCT01680874|Lactobacilli
258909|NCT01680874|Bifidobacteria
258910|NCT01680874|Lactobacillus acidophilus
258911|NCT01680874|Lactobacillus paracasei
258912|NCT01680874|Bifidobacterium lactis
258913|NCT01680874|Yogurt
258914|NCT01680874|Probiotics
258915|NCT01680861|Kidney transplant patients
258916|NCT01680848|Dental caries,
258917|NCT01680848|Caries diagnosis,
258918|NCT01680848|Caries treatment,
258919|NCT01680848|Caries risk,
258920|NCT01680848|Practice pattern,
258921|NCT01680848|Clinical epidemiology,
258922|NCT01680848|Dental Practice-Based Research Network
258923|NCT01680822|Nontuberculous, Atypical, Mycobacterial
258924|NCT01680809|Venous insufficiency
258925|NCT01680809|Venous stasis ulcerations
258926|NCT01680809|Compression stockings
258927|NCT01680809|Compression stocking compliance
258928|NCT01680796|Multiple Myeloma
258929|NCT01680796|Relapsed Multiple Myeloma
258930|NCT01680796|Refractory Multiple Myeloma
258931|NCT01680783|noninvasive ventilation
258932|NCT01680783|acute hypoxemic respiratory failure
258933|NCT01680783|Acute respiratory distress syndrome
258934|NCT01680783|shock
258935|NCT01680770|shock
258936|NCT01680770|transthoracic echocardiography
258937|NCT01680770|critical care
258938|NCT01680757|Left Atrial Appendage
258939|NCT01680757|LARIAT
258940|NCT01680757|atrial fibrillation
258941|NCT01680757|contraindication to oral anticoagulation therapy
258942|NCT01680744|Transplantation
258943|NCT01680744|Terminal creatinine
258944|NCT01680744|Renal function
258945|NCT01680744|GFR
258946|NCT01680731|Pelvic floor injury
258947|NCT01680731|Levator ani muscle
258948|NCT01680718|oxytocin
258949|NCT01680718|vasopressin
258950|NCT01680718|intranasal administration
258951|NCT01680718|healthy sample
258952|NCT01680705|Chronic Rhinosinusitis
258953|NCT01680705|Endoscopic Sinus Surgery
258954|NCT01680705|Sinonasal saline irrigation
258955|NCT01680705|Frequency
258956|NCT01680705|Postoperative
258957|NCT01680705|High Volume
258958|NCT01680705|Randomized Control Trial
258959|NCT01680705|Single Blinded
258960|NCT01680705|Prospective Study
258961|NCT01680705|Quality of Life
258962|NCT01680705|Endoscopic Sinus Score
258963|NCT01680692|Analgesia TKA
258964|NCT01680692|Total knee arthroplasty
258965|NCT01680692|Continuous femoral catheter
258966|NCT01680692|Continuous tibial catheter
258967|NCT01680692|Single shot sciatic
258968|NCT01680679|Influenza
258969|NCT01680679|India
258970|NCT01680679|Children
258971|NCT01680679|Trivalent Influenza Vaccine (TIV)
258972|NCT01680679|Inactivated poliovirus vaccine (IPV)
258973|NCT01680679|Direct influenza vaccine effectiveness
258974|NCT01680679|Total influenza vaccine effectiveness
258975|NCT01680679|Indirect influenza vaccine effectiveness
258976|NCT01680640|non alcoholic fatty liver disease
258977|NCT01680640|NAFLD
258978|NCT01680640|synbiotic
258979|NCT01680640|gut microbiota
258980|NCT01680640|intervention
258981|NCT01680640|RCT
258982|NCT01680640|biomarkers
258983|NCT01680588|Alzheimer
258984|NCT01680575|Neutropenia
258985|NCT01680575|Paclitaxel
258986|NCT01680575|Carboplatin
258987|NCT01680575|Epithelial ovarian cancer
258988|NCT01680562|in-vivo skin imaging
258989|NCT01680562|non-invasive non-melanoma skin cancer diagnostics
258990|NCT01680523|cervical cancer
258991|NCT01680523|bulky early-stage
258992|NCT01680523|locally advanced
258993|NCT01680523|radical hysterectomy
258994|NCT01680523|concurrent chemoradiation therapy
258995|NCT01680484|non-stress test
258996|NCT01680471|emergence agitation
258997|NCT01680471|midazolam
258998|NCT01680471|sevoflurane
258999|NCT01680471|strabismus
259000|NCT01680458|antifungal treatment
259001|NCT01680458|prophylaxis
259002|NCT01680458|administration
259003|NCT01680458|Japanese
259004|NCT01680458|infants
259005|NCT01680458|fluconazole
259006|NCT01680458|Diflucan
259007|NCT01680458|Regulatory Post Marketing Commitment Plan.
259008|NCT01680445|osteoarthritis, arthritis
259009|NCT01680432|constipation
259010|NCT01680432|probiotics
259011|NCT01680432|bifidobacterium
259012|NCT01680432|cheese
259013|NCT01680419|Veterans
259014|NCT01680419|Reintegration
259015|NCT01680419|Resilience
259016|NCT01680419|Marital
259017|NCT01680419|Spouse
259018|NCT01680419|Behavioral intervention
259019|NCT01680419|PTSD
259020|NCT01680419|Integrative therapies
259021|NCT01680419|Complementary therapies
259022|NCT01680419|Massage
259023|NCT01680419|Meditation
259024|NCT01680419|Mindfulness
259025|NCT01680419|Compassion
259026|NCT01680419|Mental health
259027|NCT01680406|Plasmodium vivax
259028|NCT01680406|malaria
259029|NCT01680406|Ethiopia
259030|NCT01680406|Sub-Saharan Africa
259031|NCT01680406|primaquine
259032|NCT01680406|artemether lumefantrine
259033|NCT01680406|chloroquine
259034|NCT01680380|sleep apnea
259035|NCT01680380|snoring
259036|NCT01680315|Satiety,
259037|NCT01680315|satiation,
259038|NCT01680315|anticipation,
259039|NCT01680315|food intake
259040|NCT01680302|Atrial fibrillation
259041|NCT01680302|Prevention
259042|NCT01680302|Exercise
259043|NCT01680289|Dentin bonding agents
259044|NCT01680289|Composite restorations
259045|NCT01680289|Dental restoration failure
259046|NCT01680276|intellectual disability
259047|NCT01680276|developmental disability
259048|NCT01680276|challenging behaviour
259049|NCT01680276|behavioural intervention
259050|NCT01680276|training
259051|NCT01680263|Kinesiotaping
259052|NCT01680263|pes anserinus tendino-bursitis
259053|NCT01680263|nonsteroidal anti-inflammatory drugs
259054|NCT01680263|physical therapy
259055|NCT01680250|Total liver volume
259056|NCT01680250|Liver cyst
259057|NCT01680237|cognitive behavior therapy
259058|NCT01680237|exposure in-vivo
259059|NCT01680237|panic disorder with agoraphobia
259060|NCT01680224|Obesity
259061|NCT01680224|Weight Gain
259062|NCT01680224|Dissonance
259063|NCT01680224|College,University Students
259064|NCT01680224|Eating Disorders
259065|NCT01680224|Obesity Prevention
259066|NCT01680224|Selective Prevention
259067|NCT01680224|Effectiveness
259068|NCT01680211|Blood Sugar,
259069|NCT01680211|Lipoproteins,
259070|NCT01680211|Salacia,
259071|NCT01680211|Sesame,
259072|NCT01680211|Prediabetes,
259073|NCT01680211|Hyperlipidemia,
259074|NCT01680211|Herbal supplement
259075|NCT01680198|Vitamin D
259076|NCT01680198|Paracalcitol
259077|NCT01680198|Chronic kidney disease
259078|NCT01680198|Endothelial dysfunction
259079|NCT01680198|Flow mediated vasodilation
259080|NCT01680185|Hyperglycemia
259081|NCT01680185|NODAT
259082|NCT01680185|Insulin pump
259083|NCT01680185|Semiclosed loop
259084|NCT01680172|cancer
259085|NCT01680172|depression
259086|NCT01680172|anxiety
259087|NCT01680172|palliative care
259088|NCT01680159|Infliximab
259089|NCT01680159|REMICADE
259090|NCT01680159|TA-650
259091|NCT01680159|psoriasis
259092|NCT01680107|d-cycloserine, cognitive-behaviour therapy, panic disorder
259093|NCT01680094|HIV Infection
259094|NCT01680094|Panobinostat
259095|NCT01680094|Lentivirus Infections
259096|NCT01680094|Retroviridae Infections
259097|NCT01680094|RNA Virus Infections
259098|NCT01680094|Virus Diseases
259099|NCT01680094|Sexually Transmitted Diseases, Viral
259100|NCT01680094|Sexually Transmitted Diseases
259101|NCT01680094|Immunologic Deficiency Syndromes
259102|NCT01680094|Immune System Diseases
259103|NCT01680094|Histone Deacetylase Inhibitors
259104|NCT01680094|Therapeutic Uses
259105|NCT01680068|Macular hole
259106|NCT01680068|Vitreoretinal surgery
259107|NCT01680068|Macular surgery
259108|NCT01680068|Air tamponade
259109|NCT01680042|inflammatory halo
259110|NCT01680042|VAS
259111|NCT01680016|Rabies virus, postexposure, vaccine schedule, children, older adults
259112|NCT01679964|HIV infection
259113|NCT01679964|Raltegravir
259114|NCT01679964|Adverse event
259115|NCT01679964|Life quality
259116|NCT01679951|Rheumatoid arthritis
259117|NCT01679951|Swollen and tender joints
259118|NCT01679951|Methotrexate
259119|NCT01679951|Immunology
259120|NCT01679951|Dose range finding study
259121|NCT01679938|obesity prevention
259122|NCT01679938|cluster-randomized controlled trial
259123|NCT01679938|preschool-aged children
259124|NCT01679925|Early puberty
259125|NCT01679925|Psychosocial impact
259126|NCT01679925|Qualitative assessment
259127|NCT01679912|Hereditary angioedema
259128|NCT01679912|Emergency Medical Service
259129|NCT01679912|Health care coast
259130|NCT01679912|Telephone
259131|NCT01679899|diabetes
259132|NCT01679899|type 2 diabetes mellitus
259133|NCT01679899|osteopenia
259134|NCT01679899|osteoporosis
259135|NCT01679899|glycemic variability
259136|NCT01679899|bone markers
259137|NCT01679899|osteocalcin
259138|NCT01679899|NTX
259139|NCT01679899|CTX
259140|NCT01679899|BALP
259141|NCT01679886|Position emission tomography;
259142|NCT01679886|Rubidium;
259143|NCT01679886|Women;
259144|NCT01679886|Overweighted patients
259145|NCT01679873|confidence
259146|NCT01679873|funding sources
259147|NCT01679873|conflicts of interests
259148|NCT01679873|general practitioner
259149|NCT01679847|Elemene
259150|NCT01679847|pharmacokinetics
259151|NCT01679847|Blood-brain barrier
259152|NCT01679821|Temporomandibular disorders.
259153|NCT01679821|Dental prosthesis.
259154|NCT01679821|Dental students
259155|NCT01679808|copd
259156|NCT01679808|airway obstruction
259157|NCT01679808|Tracheobronchomalacia
259158|NCT01679795|hormone replacement therapy; Dopplervelocimetry; Flow-mediated dilation; menopause; tibolone
259159|NCT01679782|COPD, nervous system, peripheral muscle dysfunction
259160|NCT01679756|Colorectal cancer
259161|NCT01679756|Laparoscopic right hemicolectomy
259162|NCT01679756|Intracorporeal anastomosis
259163|NCT01679743|Metastatic Breast Cancer
259164|NCT01679743|Metastatic Lung Cancer
259165|NCT01679743|Monoclonal Antibody
259166|NCT01679743|18FLT
259167|NCT01679743|Surgery
259168|NCT01679717|Osteoarthritis
259169|NCT01679717|CMC1-joint
259170|NCT01679717|Postoperative therapy
259171|NCT01679717|Interposition arthroplasty of the thumb
259172|NCT01679717|Occupational therapy
259173|NCT01679652|Essential hypertension
259174|NCT01679652|Nitric oxide
259175|NCT01679652|Nebivolol
259176|NCT01679652|Fractional excretion of sodium
259177|NCT01679626|cricoid pressure (CP)
259178|NCT01679626|backward upward rightward pressure (BURP)
259179|NCT01679626|AP-rima distances
259180|NCT01679626|Glottic area
259181|NCT01679626|Extralaryngeal manoeuvres
259182|NCT01679600|Rehabilitation
259183|NCT01679600|Robotics-assisted Treadmill Exercise
259184|NCT01679600|Aerobic Capacity
259185|NCT01679600|Exercise Testing
259186|NCT01679574|PCO
259187|NCT01679561|implantation failure
259188|NCT01679561|recurrent abortion
259189|NCT01679561|intralipid
259190|NCT01679535|Infant nutrition disorder
259191|NCT01679535|Child nutrition disorders
259192|NCT01679535|Malnutrition
259193|NCT01679535|Protein-energy malnutrition
259194|NCT01679522|endometrial cancer
259195|NCT01679522|laparoscopic surgical staging
259196|NCT01679522|single-port
259197|NCT01679522|four-port
259198|NCT01679496|LDL-cholesterol
259199|NCT01679470|cancer
259200|NCT01679470|lung
259201|NCT01679470|laser
259202|NCT01679470|ablation
259203|NCT01679470|airway obstruction
259204|NCT01679444|MRS
259205|NCT01679444|Heavy dose drinkers
259206|NCT01679444|Alcohol
259207|NCT01679444|NIAAA
259208|NCT01679431|Aortic Stenosis
259209|NCT01679431|Obesity, Abdominal
259210|NCT01679431|Metabolic Syndrome X
259211|NCT01679431|Insulin Resistance
259212|NCT01679431|Echocardiography, Doppler
259213|NCT01679431|Multidetector Computed Tomography
259214|NCT01679431|Magnetic Resonance Imaging
259215|NCT01679418|PONV
259216|NCT01679418|thyroid
259217|NCT01679418|surgery
259218|NCT01679418|nausea and vomiting
259219|NCT01679418|postoperative
259220|NCT01679405|metastatic biliary tract cancer
259221|NCT01679392|Transversus abdominis plane block
259222|NCT01679392|Ultrasound guided nerve block
259223|NCT01679379|Cesarean Section
259224|NCT01679379|Obese Women
259225|NCT01679379|Surgical Site Infection
259226|NCT01679353|inguinal hernia, caudal analgesia, magnesium
259227|NCT01679340|Gastric cancer
259228|NCT01679340|D2 surgery
259229|NCT01679340|S-1
259230|NCT01679340|Oxaliplatin
259231|NCT01679340|cisplatin
259232|NCT01679314|COPD
259233|NCT01679314|vagus nerve stimulation
259234|NCT01679314|vagal nerve stimulation
259235|NCT01679314|nVNS
259236|NCT01679314|VNS
259237|NCT01679314|non invasive
259238|NCT01679314|gammacore
259239|NCT01679301|oxygen
259240|NCT01679288|Hand-Held ultrasonography
259241|NCT01679288|Abdominal Aortic Aneurysm
259242|NCT01679288|Abdominal Aortic Atherosclerosis
259243|NCT01679288|Cardiovascular risk
259244|NCT01679288|Primary Health Care
259245|NCT01679275|Heart Defects, congenital
259246|NCT01679275|Patient Monitoring
259247|NCT01679275|Infant, Newborn
259248|NCT01679275|Physiology
259249|NCT01679249|extracellular fluid volume
259250|NCT01679249|hypotension
259251|NCT01679249|hemodialysis
259252|NCT01679236|Smoking
259253|NCT01679236|Smoking cessation
259254|NCT01679236|Nicotine
259255|NCT01679236|Tobacco
259256|NCT01679236|Mindfulness
259257|NCT01679236|Meditation
259258|NCT01679236|MBSR
259259|NCT01679236|Mindfulness Training
259260|NCT01679236|Behavioral Intervention
259261|NCT01679236|Alcohol
259262|NCT01679236|Young Adults
259263|NCT01679223|Breast reconstruction
259264|NCT01679223|Hydroxyproline concentration
259265|NCT01679223|neoangiogenesis
259266|NCT01679223|collagen deposition
259267|NCT01679197|Nonalcoholic fatty liver disease
259268|NCT01679197|NAFLD
259269|NCT01679197|Nonalcoholic steatohepatitis
259270|NCT01679197|NASH
259271|NCT01679197|Lipodystrophy
259272|NCT01679197|Leptin
259273|NCT01679197|Metreleptin
259274|NCT01679197|Hypertriglyceridemia
259275|NCT01679197|Diabetes mellitus
259276|NCT01679171|Elderly
259277|NCT01679171|Intensive care unit
259278|NCT01679171|Outcome
259279|NCT01679171|Comprehensive geriatric assessment
259280|NCT01679158|Using POSE as a treatment for Obesity
259281|NCT01679145|Reward- based learning
259282|NCT01679145|Pavlovian-to-instrumental transfer
259283|NCT01679145|Functional imaging
259284|NCT01679145|Relapse risk
259285|NCT01679132|Hypertension
259286|NCT01679132|High Blood Pressure
259287|NCT01679132|Blood Pressure
259288|NCT01679132|Cardiovascular Disease
259289|NCT01679132|Resistant Hypertension
259290|NCT01679119|Diffuse large b cell lymphoma
259291|NCT01679119|Inotuzumab Ozogamicin
259292|NCT01679119|Gemcitabine
259293|NCT01679119|Rituximab
259294|NCT01679119|Cyclophosphamide
259295|NCT01679119|Vincristine
259296|NCT01679119|Prednisolone
259297|NCT01679106|renal transplant
259298|NCT01679106|flank incision
259299|NCT01679093|postoperative analgesia
259300|NCT01679093|paracetamol
259301|NCT01679093|5-HT3 antagonist
259302|NCT01679093|ondansetron
259303|NCT01679093|PainMatcher
259304|NCT01679080|Drug therapy
259305|NCT01679080|Adult
259306|NCT01679067|HIV
259307|NCT01679067|GALT
259308|NCT01679054|Neoplasm
259309|NCT01679054|Gastric Cancer
259310|NCT01679054|Cost
259311|NCT01679028|T89 Safety in Healthy Japanese population
259312|NCT01679015|Burning
259313|NCT01679015|Dryness
259314|NCT01679015|Itching
259315|NCT01679015|Blurry Vision
259316|NCT01679002|Epilepsy
259317|NCT01679002|Oxcarbazepine
259318|NCT01679002|Eslicarbazepine Acetate
259319|NCT01679002|BIA 2-093
259320|NCT01678989|Bipolar disorder
259321|NCT01678989|Children
259322|NCT01678989|Cranial MRI
259323|NCT01678976|Eslicarbazepine acetate
259324|NCT01678976|Epilepsy
259325|NCT01678976|Oxcarbazepine
259326|NCT01678963|Neovascular AMD
259327|NCT01678963|Wet AMD
259328|NCT01678963|AMD
259329|NCT01678963|Age related macular degeneration
259330|NCT01678950|Cardiac output monitoring
259331|NCT01678950|Echocardiography
259332|NCT01678950|Pulse contour system
259333|NCT01678937|Immunosuppression
259334|NCT01678911|Pelvic Pain
259335|NCT01678911|Chronic Pelvic Pain
259336|NCT01678911|Irritable Bowel Syndrome
259337|NCT01678911|IBS
259338|NCT01678911|Ulcerative Colitis
259339|NCT01678911|UC
259340|NCT01678911|Interstitial Cystitis
259341|NCT01678911|IC
259342|NCT01678911|Prostatitis
259343|NCT01678911|Pain
259344|NCT01678898|Fabry disease
259345|NCT01678898|Alpha galactosidase deficiency
259346|NCT01678898|Metabolic storage disease
259347|NCT01678859|infertility
259348|NCT01678859|cervical
259349|NCT01678859|mucus
259350|NCT01678859|sperm
259351|NCT01678859|interaction
259352|NCT01678846|corporal punishment
259353|NCT01678846|violence
259354|NCT01678846|education
259355|NCT01678846|depression
259356|NCT01678846|anxiety
259357|NCT01678846|conduct disorder
259358|NCT01678833|Drug Abuse/Dependence
259359|NCT01678794|Chronic heart failure (CHF)
259360|NCT01678794|cardiac and renal dysfunction
259361|NCT01678781|Abdominal pain
259362|NCT01678781|Diarrhea
259363|NCT01678781|Mebeverine hydrochloride
259364|NCT01678781|Constipation
259365|NCT01678781|Pinaverium bromide
259366|NCT01678781|Irritable bowel syndrome
259367|NCT01678781|Bloating
259368|NCT01678781|Quality of life
259369|NCT01678755|schizophrenia
259370|NCT01678742|Diet
259371|NCT01678742|Incretins
259372|NCT01678742|Gastrointestinal Hormones
259373|NCT01678742|Fish Proteins
259374|NCT01678729|refractive surgery
259375|NCT01678729|pupil
259376|NCT01678729|Pupil size
259377|NCT01678716|Anemia
259378|NCT01678716|Breastfeeding
259379|NCT01678716|Complementary feeding
259380|NCT01678716|Stunting
259381|NCT01678716|Wasting
259382|NCT01678716|Underweight
259383|NCT01678716|Micronutrient powder
259384|NCT01678716|Behavior change counseling
259385|NCT01678716|Frontline health worker
259386|NCT01678703|late abortion
259387|NCT01678703|laminaria
259388|NCT01678703|Misoprostol
259389|NCT01678703|Cervical preparation
259390|NCT01678677|non-typeable Haemophilus influenzae
259391|NCT01678677|immunogenicity
259392|NCT01678677|reactogenicity
259393|NCT01678677|safety
259394|NCT01678664|cancer
259395|NCT01678664|neuroendocrine tumors
259396|NCT01678664|gastrointestinal tract
259397|NCT01678664|metastases
259398|NCT01678664|liver
259399|NCT01678664|hepatic
259400|NCT01678651|time-lapse, FSH, kinetics
259401|NCT01678638|inguinal hernia
259402|NCT01678638|premature infants
259403|NCT01678638|anesthesia safety
259404|NCT01678638|neurodevelopmental outcome
259405|NCT01678638|preterm infants
259406|NCT01678638|neonatal prematurity
259407|NCT01678625|Residual neuromuscular blockade
259408|NCT01678625|Train-of-four
259409|NCT01678625|Acceleromyography
259410|NCT01678625|Electromyography
259411|NCT01678612|Copper
259412|NCT01678612|Health-Acquired Infections
259413|NCT01678612|Bacterial Load
259414|NCT01678612|Intensive Care Units, Pediatric
259415|NCT01678599|Chagas Disease
259416|NCT01678599|PCR
259417|NCT01678599|diagnosis
259418|NCT01678586|Pain
259419|NCT01678586|Pain management
259420|NCT01678573|Healthy
259421|NCT01678573|Pharmacokinetics
259422|NCT01678573|Abiraterone acetate
259423|NCT01678573|Abiraterone
259424|NCT01678573|JNJ-212082
259425|NCT01678573|Zytiga
259426|NCT01678573|Chinese
259427|NCT01678573|Fasted
259428|NCT01678560|Obstructive sleep apnea PAP adherence efficacy economics
259429|NCT01678547|Stroke
259430|NCT01678547|Robot
259431|NCT01678547|Treatment
259432|NCT01678547|Rehabilitation
259433|NCT01678534|Cerebral infarction
259434|NCT01678534|Cellular therapy
259435|NCT01678521|Hypercholesterolemia
259436|NCT01678521|LDL-apheresis
259437|NCT01678521|Coronary artery disease
259438|NCT01678521|PTX3
259439|NCT01678521|CRP
259440|NCT01678521|IL6
259441|NCT01678521|IL10
259442|NCT01678482|Acne, LED, blue light
259443|NCT01678456|Atrial Fibrillation
259444|NCT01678456|Critical Event Committee
259445|NCT01678456|Serious adverse events
259446|NCT01678456|Thromboembolic complications
259447|NCT01678456|Cardiac and noncardiac complications
259448|NCT01678456|Bleeding complications
259449|NCT01678456|Acute heart failure
259450|NCT01678456|Syncope
259451|NCT01678456|Resuscitation
259452|NCT01678430|Chronic Lymphocytic Leukaemia
259453|NCT01678430|Less fit
259454|NCT01678430|CD20 antibody
259455|NCT01678430|Ofatumumab
259456|NCT01678430|Chlorambucil
259457|NCT01678430|Bendamustine
259458|NCT01678378|Adolescent
259459|NCT01678378|Intervention
259460|NCT01678378|Female
259461|NCT01678378|Male
259462|NCT01678378|Interpersonal Relations
259463|NCT01678378|School Health Services
259464|NCT01678378|Community-Based Participatory Research
259465|NCT01678378|Randomized Controlled Trial
259466|NCT01678378|Health Care Provider
259467|NCT01678378|Training Program
259468|NCT01678378|Harm Reduction
259469|NCT01678378|Prevention
259470|NCT01678378|Reproductive Coercion
259471|NCT01678378|Tech-Based Abuse
259472|NCT01678378|Social Environment
259473|NCT01678378|Sexual Partners
259474|NCT01678365|complicated appendicitis
259475|NCT01678365|Children
259476|NCT01678365|conservative therapy
259477|NCT01678365|Study population: Children 1 month - 14 years with Complicated appendicitis
259478|NCT01678365|Type of the study: prospective, open randomized
259479|NCT01678352|Glioma
259480|NCT01678352|Vaccine
259481|NCT01678352|Immunotherapy
259482|NCT01678352|WHO Grade II
259483|NCT01678339|ACS
259484|NCT01678339|AMI
259485|NCT01678326|Diseases Classified Elsewhere
259486|NCT01678313|Benign prostatic hyperplasia (BPH)
259487|NCT01678313|Lower urinary tract symptoms (LUTS)
259488|NCT01678313|Prostatic specific antigen (PSA)
259489|NCT01678313|Cyclooxygenase-2 (COX-2)
259490|NCT01678300|Ulcerative Colitis
259491|NCT01678287|ASP1941
259492|NCT01678274|Turner Syndrome
259493|NCT01678274|Aortic Aneurysm
259494|NCT01678274|Ischemic heart disease
259495|NCT01678274|Hypertension
259496|NCT01678274|Congenital Heart Defect
259497|NCT01678274|Pulse Wave Velocity
259498|NCT01678274|Augmentation Index
259499|NCT01678274|Central Blood Pressure
259500|NCT01678274|Agatston Score
259501|NCT01678274|Segment involvement score
259502|NCT01678261|Sex chromosome
259503|NCT01678261|Turner Syndrome
259504|NCT01678261|Klinefelter Syndrome
259505|NCT01678261|Triple X Syndrome
259506|NCT01678261|47 XYY syndrome
259507|NCT01678261|Aortic Aneurysm
259508|NCT01678261|Epigenetics
259509|NCT01678261|Transcriptome
259510|NCT01678261|non-coding RNA
259511|NCT01678235|diabetes
259512|NCT01678235|insulin pump
259513|NCT01678235|glulisine
259514|NCT01678235|aspart
259515|NCT01678235|glycemic index
259516|NCT01678222|Lymphocyte
259517|NCT01678222|Cyclooxygenase 2
259518|NCT01678222|Eicosanoid
259519|NCT01678222|Prostaglandin
259520|NCT01678209|Attention Deficit Hyperactivity Disorder
259521|NCT01678209|Stimulant
259522|NCT01678209|Non-stimulant
259523|NCT01678209|Drug
259524|NCT01678209|Methylphenidate
259525|NCT01678209|Atomoxetine
259526|NCT01678209|Strattera
259527|NCT01678209|Concerta
259528|NCT01678209|MACRO
259529|NCT01678209|Medication
259530|NCT01678209|Treatment
259531|NCT01678209|Youth
259532|NCT01678209|Adolescent
259533|NCT01678209|Functional Magnetic Resonance Imaging
259534|NCT01678209|Brain scan
259535|NCT01678209|Imaging
259536|NCT01678209|Response inhibition
259537|NCT01678209|Inattentive
259538|NCT01678209|Hyperactive
259539|NCT01678209|Combined
259540|NCT01678209|Medication Treatment
259541|NCT01678209|Brain Imaging
259542|NCT01678196|Family Members
259543|NCT01678196|Community Outreach
259544|NCT01678196|Internet
259545|NCT01678170|blood-oxygen functional imaging technology
259546|NCT01678170|diagnosis
259547|NCT01678157|Esophageal Hernia
259548|NCT01678157|Hernia, Esophageal
259549|NCT01678157|Hernia, Paraesophageal
259550|NCT01678157|Hiatal Hernia
259551|NCT01678157|Paraesophageal Hiatal Hernia
259552|NCT01678157|Sliding Esophageal Hernia
259553|NCT01678157|Sliding Hiatal Hernia
259554|NCT01678144|mitral valve
259555|NCT01678144|mitral surgery
259556|NCT01678144|mitral repair
259557|NCT01678144|mitral annuloplasty
259558|NCT01678118|Patient Navigation
259559|NCT01678118|Tobacco dependent
259560|NCT01678118|smoking
259561|NCT01678118|Cessation
259562|NCT01678118|11-028
259563|NCT01678105|Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
259564|NCT01678105|Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
259565|NCT01678105|Salivary Gland Cancers
259566|NCT01678105|ACC
259567|NCT01678105|Dovitinib
259568|NCT01678105|TKI258
259569|NCT01678105|RTK Inhibitor
259570|NCT01678079|Pregnancy
259571|NCT01678079|Micronutrient Powder
259572|NCT01678079|Calcium
259573|NCT01678079|Iron
259574|NCT01678079|Bangladesh
259575|NCT01678066|Noninvasive cardiac output.
259576|NCT01678066|Pediatrics.
259577|NCT01678053|Botulinum Toxins, Type A
259578|NCT01678040|Ventricular Volume
259579|NCT01678040|Cardiac Magnetic Resonance
259580|NCT01678040|Echocardiogram
259581|NCT01678027|Family history
259582|NCT01678014|Anorexia
259583|NCT01678014|DBS
259584|NCT01678014|Capsulotomy
259585|NCT01678014|Signs and Symptoms
259586|NCT01678001|plantar fascia
259587|NCT01678001|plantar fascitis
259588|NCT01678001|botulinum toxin
259589|NCT01678001|Xeomin
259590|NCT01677988|NEOADJUVANT FOLFIRINOX CHEMOTHERAPY
259591|NCT01677988|LOCALIZED PANCREATIC HEAD ADENOCARCINOMA
259592|NCT01677988|RADIATION THERAPY
259593|NCT01677962|locally advanced, unresectable pancreatic adenocarcinoma
259594|NCT01677962|Poly ICLC
259595|NCT01677962|dendritic cells
259596|NCT01677936|diabetes
259597|NCT01677936|blood pressure
259598|NCT01677936|lipid
259599|NCT01677936|waist circumference
259600|NCT01677936|BMI
259601|NCT01677923|weight
259602|NCT01677923|body mass index
259603|NCT01677923|lipid profile
259604|NCT01677923|glucose profile
259605|NCT01677845|Localized Prostate Cancer
259606|NCT01677845|Radiation
259607|NCT01677806|Percutaneous vertebroplasty
259608|NCT01677741|Children and Adolescents
259609|NCT01677741|BRAF
259610|NCT01677741|dabrafenib
259611|NCT01677741|dose escalation
259612|NCT01677741|BRF116013
259613|NCT01677741|V600-mutation positive
259614|NCT01677741|BRF
259615|NCT01677728|colorectal liver metastases
259616|NCT01677728|chemotherapy
259617|NCT01677728|cetuximab
259618|NCT01677728|bevacizumab
259619|NCT01677689|oral temperature
259620|NCT01677689|respiratory symptom
259621|NCT01677689|cough
259622|NCT01677689|nasal obstruction
259623|NCT01677689|sore throat
259624|NCT01677689|fever
259625|NCT01677676|Influenza A
259626|NCT01677663|autism
259627|NCT01677663|clinical phenotypes
259628|NCT01677663|neuropsychology
259629|NCT01677663|imaging endophenotypes
259630|NCT01677663|family-based cohort
259631|NCT01677663|knoutout mice
259632|NCT01677650|Spinal Fusion
259633|NCT01677650|Opioid Analgesia
259634|NCT01677637|osteopenia, postmenopausal
259635|NCT01677624|Hypervascular tumor
259636|NCT01677624|arteriovenous malformation
259637|NCT01677624|arterial embolization
259638|NCT01677611|Resveratrol
259639|NCT01677611|SIRT1
259640|NCT01677611|AMPK
259641|NCT01677598|Plaque Psoriasis
259642|NCT01677598|Ustekinumab
259643|NCT01677598|CNTO 1275
259644|NCT01677598|Asia-Pacific
259645|NCT01677546|diabetes
259646|NCT01677546|insulin pump
259647|NCT01677546|bolus calculator
259648|NCT01677546|Contour Link
259649|NCT01677533|Panel management
259650|NCT01677533|Clinical microsystems
259651|NCT01677533|Hypertension management
259652|NCT01677533|Smoking cessation
259653|NCT01677533|Continuing medical education
259654|NCT01677533|Quality improvement,
259655|NCT01677533|Population health
259656|NCT01677520|adipose-derived stem cells
259657|NCT01677520|viable ADSCs
259658|NCT01677520|apoptosis
259659|NCT01677520|necrosis
259660|NCT01677520|cryopreservation
259661|NCT01677507|glaucoma
259662|NCT01677507|aqueous humor dynamics
259663|NCT01677507|intraocular pressure
259664|NCT01677468|Hepatocellular carcinoma
259665|NCT01677468|Transarterial chemoembolization
259666|NCT01677455|Hsp90 inhibitor
259667|NCT01677455|ganetespib
259668|NCT01677455|STA 9090
259669|NCT01677442|nonintubated
259670|NCT01677442|anaesthesia
259671|NCT01677442|VATS
259672|NCT01677429|panic disorder
259673|NCT01677429|balance impairment
259674|NCT01677429|virtual reality
259675|NCT01677416|Rheumatoid arthritis
259676|NCT01677416|Ultrasonography
259677|NCT01677416|Synovitis
259678|NCT01677416|Foot joints
259679|NCT01677403|Bronchiectasis
259680|NCT01677403|Tobramycin
259681|NCT01677403|nebulised
259682|NCT01677390|Antibody-Drug Conjugate
259683|NCT01677390|monomethylauristatin F
259684|NCT01677390|Carcinoma, Renal Cell
259685|NCT01677390|Antigens, CD70
259686|NCT01677390|Drug Therapy
259687|NCT01677377|Schizophrenia
259688|NCT01677377|Schizophrenic
259689|NCT01677377|Schizophrenias
259690|NCT01677364|induction of labour
259691|NCT01677364|heart disease patients
259692|NCT01677351|clonidine
259693|NCT01677351|cataract surgery
259694|NCT01677351|arrythmia
259695|NCT01677351|anesthesic medication
259696|NCT01677286|AL Amyloidosis
259697|NCT01677286|Primary Amyloidosis
259698|NCT01677286|Hereditary Amyloidosis
259699|NCT01677286|Familial Amyloidosis
259700|NCT01677286|SSA Amyloidosis
259701|NCT01677286|Senile Systemic Amyloidosis
259702|NCT01677286|AA Amyloidosis
259703|NCT01677286|Secondary Amyloidosis
259704|NCT01677286|Localized Amyloidosis
259705|NCT01677286|Systemic Amyloidosis
259706|NCT01677273|Respiratory chambers
259707|NCT01677273|Energy expenditure
259708|NCT01677273|Appetite
259709|NCT01677273|Dairy proteins
259710|NCT01677273|Diet induced thermogenesis
259711|NCT01677273|Obesity
259712|NCT01677260|Biguanide
259713|NCT01677260|anti-hyperglycaemic
259714|NCT01677260|bioavailability
259715|NCT01677260|bioequivalence
259716|NCT01677260|metformin
259717|NCT01677260|pharmacokinetics
259718|NCT01677247|sulphonylurea
259719|NCT01677247|anti-hyperglycaemic
259720|NCT01677247|bioavailability
259721|NCT01677247|bioequivalence
259722|NCT01677247|glimepiride
259723|NCT01677247|pharmacokinetics
259724|NCT01677234|Blood pressure
259725|NCT01677221|acne
259726|NCT01677221|inflammatory acne
259727|NCT01677221|intense pulsed light
259728|NCT01677208|Acute Ischemic Stroke
259729|NCT01677208|Randomized Controlled Trial
259730|NCT01677208|Traditional Chinese Medicine
259731|NCT01677195|Mycotoxins
259732|NCT01677195|Aflatoxin
259733|NCT01677195|Fumonisin
259734|NCT01677195|Aflatoxicosis
259735|NCT01677195|Dietary
259736|NCT01677195|Cancer
259737|NCT01677182|Drug therapy
259738|NCT01677143|Local anesthetic
259739|NCT01677143|Preemptive analgesia
259740|NCT01677143|Postoperative pain
259741|NCT01677143|Laparoscopy
259742|NCT01677143|Gynecological surgery
259743|NCT01677143|Day-case surgery
259744|NCT01677130|Clinical efficacy
259745|NCT01677130|safety
259746|NCT01677130|of HFOV treatment
259747|NCT01677130|of patients
259748|NCT01677104|GLP-1
259749|NCT01677104|DPP-IV inhibitor
259750|NCT01677104|microcirculation
259751|NCT01677104|Exenatide
259752|NCT01677104|Liraglutide
259753|NCT01677104|Linagliptin
259754|NCT01677091|Balance,Hemiplegia,Cervical vibration,Prism adaptation,Rehabilitation
259755|NCT01677078|Major depressive disorder
259756|NCT01677078|rTMS
259757|NCT01677078|Neuronavigation
259758|NCT01677065|Bioavailability
259759|NCT01677065|Oxycodone
259760|NCT01677065|Healthy Volunteers
259761|NCT01677039|Bioavailability
259762|NCT01677039|oxycodone
259763|NCT01677039|ethanol interaction
259764|NCT01677039|healthy volunteers
259765|NCT01677013|Type 2; diabetes mellitus; stem cell; safety; efficacy
259766|NCT01677000|bone infection
259767|NCT01677000|staphylococcus aureus
259768|NCT01677000|registry
259769|NCT01676987|Asthma
259770|NCT01676987|Budesonide
259771|NCT01676987|Adrenergic beta-2 receptor agonists.
259772|NCT01676974|Drug Resistance, Microbial
259773|NCT01676974|Enterobacteriaceae
259774|NCT01676974|ESBL
259775|NCT01676974|Carbapenemase
259776|NCT01676974|Travel
259777|NCT01676948|SJIA
259778|NCT01676948|Systemic Juvenile Idiopathic Arthritis
259779|NCT01676948|children
259780|NCT01676948|systemic autoinflammatory disease, ACZ885, canakinumab
259781|NCT01676948|human monoclonal anti-interleukin-1β (IL-1 β) antibody
259782|NCT01676948|hildhood immunizations vaccinations
259783|NCT01676909|self-management
259784|NCT01676896|children
259785|NCT01676896|asthma
259786|NCT01676896|quality of life
259787|NCT01676896|self-management
259788|NCT01676883|Body constitution
259789|NCT01676883|Anthropometry
259790|NCT01676883|Electric impedance
259791|NCT01676870|exercise training
259792|NCT01676870|exercise therapy
259793|NCT01676870|physical fitness
259794|NCT01676870|risk factors
259795|NCT01676857|chronic pain, prostatitis, pelvic pain
259796|NCT01676844|Phosphorus
259797|NCT01676844|Phosphate
259798|NCT01676844|Hypophosphataemia
259799|NCT01676844|Osteopenia
259800|NCT01676844|Prematurity
259801|NCT01676805|Developing Novel Treatment Approaches
259802|NCT01676805|Developing Therapeutic Agents
259803|NCT01676805|Analysis of Genetic and Genomic Biology
259804|NCT01676805|New Prognostic and Diagnostic Models
259805|NCT01676805|Analysis of Cellular and Molecular Biology
259806|NCT01676792|condyloma acuminate
259807|NCT01676792|ano-genital warts
259808|NCT01676792|genital warts
259809|NCT01676792|cutaneous condyloma
259810|NCT01676792|Vulva pre-cancerous lesions
259811|NCT01676792|Vulvar Intraepitheral Neoplasia
259812|NCT01676792|VIN
259813|NCT01676792|EGW
259814|NCT01676779|melanoma
259815|NCT01676779|no evidence of disease
259816|NCT01676779|resection
259817|NCT01676779|macro-metastases
259818|NCT01676766|Stargardt Disease
259819|NCT01676766|Macular degeneration
259820|NCT01676766|Retinal dystrophy
259821|NCT01676740|hematinic therapy
259822|NCT01676740|blood transfusion
259823|NCT01676740|joint replacement
259824|NCT01676727|Transcatheter Aortic valve Implantation
259825|NCT01676727|Heart Valve Diseases
259826|NCT01676727|Cardiovascular Diseases
259827|NCT01676714|Dovitinib
259828|NCT01676714|Fibroblast Growth Factor Receptor Biomarkers
259829|NCT01676714|Anti-Vascular Endothelial Growth Factor Therapy
259830|NCT01676688|alpha-1 antitrypsin
259831|NCT01676688|deficiency
259832|NCT01676688|Alfalastin
259833|NCT01676688|safety
259834|NCT01676675|whole virus
259835|NCT01676675|inactivated
259836|NCT01676675|influenza
259837|NCT01676675|H5N1 vaccine
259838|NCT01676675|safety
259839|NCT01676675|immunogenicity
259840|NCT01676662|Urinary Incontinence
259841|NCT01676662|Urinary Incontinence, Stress
259842|NCT01676662|Urination Disorders
259843|NCT01676662|Urologic Diseases
259844|NCT01676662|Urological Manifestations
259845|NCT01676662|Signs and Symptoms
259846|NCT01676636|Pregnancy
259847|NCT01676636|Calcium
259848|NCT01676636|Supplements
259849|NCT01676623|Child nutrition
259850|NCT01676623|Stunting
259851|NCT01676623|Exclusive breastfeeding
259852|NCT01676623|Complementary feeding
259853|NCT01676623|Social franchise
259854|NCT01676623|Mass media
259855|NCT01676623|Counseling
259856|NCT01676623|Facility-based
259857|NCT01676610|Pulse Oximetry
259858|NCT01676610|Pediatrics
259859|NCT01676610|Pakistan
259860|NCT01676610|Hypoxemia
259861|NCT01676610|Neonatal Sepsis
259862|NCT01676610|Pneumonia
259863|NCT01676558|diffuse large B cell lymphoma
259864|NCT01676558|radioimmunotherapy
259865|NCT01676558|131I-rituximab
259866|NCT01676532|School Board Health Center
259867|NCT01676532|Pediatrics
259868|NCT01676506|Wet AMD
259869|NCT01676506|genetic polymorphisms
259870|NCT01676506|Ranibizumab
259871|NCT01676480|Prostate cancer
259872|NCT01676480|ADT
259873|NCT01676480|Endurance training
259874|NCT01676454|Vasopressin
259875|NCT01676454|Trauma
259876|NCT01676454|Injury
259877|NCT01676441|spinal cord injury
259878|NCT01676441|mesenchymal stem cell
259879|NCT01676428|Kidney
259880|NCT01676428|Renal
259881|NCT01676428|Radiotherapy
259882|NCT01676428|Stereotactic
259883|NCT01676428|Cancer
259884|NCT01676415|Sinus disease
259885|NCT01676415|Sinonasal complaints
259886|NCT01676415|Chronic sinusitis
259887|NCT01676415|Nasal polyps
259888|NCT01676415|Chronic rhinosinusitis without nasal polyps
259889|NCT01676415|Glucocorticoids
259890|NCT01676415|Prednisone
259891|NCT01676415|Topical mometasone
259892|NCT01676415|Anti-inflammatory agents
259893|NCT01676402|Influenza A (H1)
259894|NCT01676402|Influenza A (H3)
259895|NCT01676402|Influenza B
259896|NCT01676402|DNA Vaccine
259897|NCT01676402|Trivalent Inactivated Vaccine (TIV)
259898|NCT01676402|Healthy Adults
259899|NCT01676402|Intradermal (ID)
259900|NCT01676389|Autism Spectrum Disorders
259901|NCT01676376|CABG
259902|NCT01676376|SVG
259903|NCT01676376|nitinol mesh
259904|NCT01676376|external saphenous vein graft support
259905|NCT01676363|diflunisal
259906|NCT01676363|anti-inflammatory agents, non-steroidal
259907|NCT01676363|antiviral agents
259908|NCT01676350|Intraosseous (IO) vascular access
259909|NCT01676337|Text messaging
259910|NCT01676337|Clinic appointment attendance
259911|NCT01676337|Emergency department
259912|NCT01676337|Primary care
259913|NCT01676324|Fecal Calprotectin
259914|NCT01676311|cognition
259915|NCT01676311|seizures
259916|NCT01676311|electroencephalography
259917|NCT01676311|transcranial magnetic stimulation
259918|NCT01676311|huperzine
259919|NCT01676311|chinese club moss
259920|NCT01676298|Cyp2C19
259921|NCT01676298|Genotyping
259922|NCT01676298|Spartan
259923|NCT01676298|Reproducibility
259924|NCT01676285|Cirrhosis
259925|NCT01676285|cirrhotic cardiomyopathy
259926|NCT01676285|cardiac remodeling
259927|NCT01676285|cardiomyopathy
259928|NCT01676285|metoprolol succinate
259929|NCT01676285|betablockers
259930|NCT01676259|siRNA
259931|NCT01676259|RNA interference (RNAi)
259932|NCT01676259|Cancer
259933|NCT01676259|Pancreatic ductal adenocarcinoma
259934|NCT01676259|Locally Advanced Pancreatic cancer
259935|NCT01676259|Solid tumor
259936|NCT01676259|Non operable pancreatic ductal adenocarcinoma
259937|NCT01676207|coronary collateral circulation
259938|NCT01676207|extracardiac coronary collaterals
259939|NCT01676207|coronary artery disease
259940|NCT01676207|coronary circulation
259941|NCT01676207|internal mammary artery
259942|NCT01676194|Transarterial Chemoembolization
259943|NCT01676194|Liver transplantation
259944|NCT01676194|Hepatocellular carcinoma
259945|NCT01676181|Obstructive sleep apnea syndrome
259946|NCT01676181|Children
259947|NCT01676181|Polysomnography
259948|NCT01676181|Surgery
259949|NCT01676181|Coblation
259950|NCT01676181|Tonsils
259951|NCT01676181|Tonsillectomy
259952|NCT01676155|Tuberculosis, latent tuberculosis infection, apoptosis, predictor
259953|NCT01676129|temporomandibular joint disorders
259954|NCT01676129|nocipoint
259955|NCT01676129|physical therapy
259956|NCT01676103|Parkinson's Disease (PD)
259957|NCT01676103|Orthostatic hypotension (OH)
259958|NCT01676077|LGMD2B
259959|NCT01676077|Miyoshi Myopathy
259960|NCT01676077|Dysferlin
259961|NCT01676077|Dysferlinopathy
259962|NCT01676077|Limb Girdle muscular dystrophy type 2b
259963|NCT01676077|Muscular Dystrophy
259964|NCT01676064|intraocular pressure
259965|NCT01676064|perioperative fluid
259966|NCT01676064|trendelenburg position
259967|NCT01676064|laparoscopic gynecologic surgery
259968|NCT01676038|Total Knee Replacement, Computer-Assisted Surgery
259969|NCT01676025|pheochromocytoma
259970|NCT01676025|aldosteronism
259971|NCT01676025|cushing's syndrome
259972|NCT01676025|adrenal incidentaloma
259973|NCT01676025|Conn's syndrome
259974|NCT01675999|Neoadjuvant chemotherapy
259975|NCT01675999|Locally advanced malignant neoplasm
259976|NCT01675999|colon cancer
259977|NCT01675973|Ranolazine
259978|NCT01675973|renal impairment
259979|NCT01675960|chronic irritability
259980|NCT01675960|chronic pain
259981|NCT01675960|Neurologically impaired
259982|NCT01675960|gabapentin
259983|NCT01675921|Asthma
259984|NCT01675921|Facebook
259985|NCT01675921|teenagers
259986|NCT01675921|ACT
259987|NCT01675895|Hyperbaric Levobupivacaine
259988|NCT01675895|İntrathecal
259989|NCT01675895|Lidocaine
259990|NCT01675895|TUR-P
259991|NCT01675882|Food allergy
259992|NCT01675882|Immediate hypersensitivity
259993|NCT01675882|Whole peanut extract
259994|NCT01675882|Allergenic product
259995|NCT01675882|Specific Immunotherapy
259996|NCT01675882|Epicutaneous Immunotherapy (EPIT)
259997|NCT01675869|Attention-Deficit/Hyperactivity Disorder
259998|NCT01675869|Executive function
259999|NCT01675869|Preschooler
260000|NCT01675869|Metacognition
260001|NCT01675856|Glasgow-Blatchford score
260002|NCT01675856|Gastrointestinal bleeding
260003|NCT01675843|Infertility
260004|NCT01675843|PCOS
260005|NCT01675843|IUI
260006|NCT01675817|heparin rebound
260007|NCT01675817|protamine
260008|NCT01675817|cardiopulmonary bypass
260009|NCT01675817|cardiac surgery
260010|NCT01675817|anti-Xa
260011|NCT01675817|anti-IIa
260012|NCT01675804|ADHD
260013|NCT01675778|hydromorphone
260014|NCT01675778|acute pain
260015|NCT01675778|emergency department
260016|NCT01675765|Cancer
260017|NCT01675765|Cancer vaccine
260018|NCT01675765|Listeria monocytogenes
260019|NCT01675765|Listeria-based vaccines
260020|NCT01675765|Pemetrexed
260021|NCT01675765|Cisplatin
260022|NCT01675765|T regulatory cells
260023|NCT01675765|Mesothelin
260024|NCT01675765|Malignant Pleural Mesothelioma
260025|NCT01675765|Chemotherapy
260026|NCT01675765|Standard of care
260027|NCT01675765|Naive
260028|NCT01675765|Front-line
260029|NCT01675765|Immunotherapy
260030|NCT01675765|MPM
260031|NCT01675752|colonoscopy, narrow-band imaging
260032|NCT01675739|colonoscopy
260033|NCT01675739|bowel preparation
260034|NCT01675739|short message service
260035|NCT01675713|Lifestyle
260036|NCT01675713|Physical activity
260037|NCT01675700|Myofascial pain
260038|NCT01675700|Trigger point
260039|NCT01675700|Nitroglycerin
260040|NCT01675687|dietary habits and obesity
260041|NCT01675687|exercise habits and obesity
260042|NCT01675687|cognition and obesity
260043|NCT01675674|Mucopolysaccharidoses
260044|NCT01675674|Prevalence
260045|NCT01675674|Pediatric
260046|NCT01675674|Rheumatology
260047|NCT01675674|Mucopolysaccharidosis I
260048|NCT01675674|Mucopolysaccharidosis II
260049|NCT01675674|Mucopolysaccharidosis IV
260050|NCT01675674|Mucopolysaccharidosis VI
260051|NCT01675648|Opiate dependent
260052|NCT01675648|inpatient detoxification
260053|NCT01675622|Cancer Pain
260054|NCT01675596|Aortic Stenosis
260055|NCT01675596|Transfemoral
260056|NCT01675596|Transcatheter Heart Valve
260057|NCT01675583|Diabetic Wounds
260058|NCT01675583|Hyperbaric Oxygen
260059|NCT01675583|Laser Speckle Imaging
260060|NCT01675583|Hyperbaric Oxygenation
260061|NCT01675570|RX-10045
260062|NCT01675570|Dry Eye Disease
260063|NCT01675557|chronic kidney disease
260064|NCT01675544|Heart failure
260065|NCT01675531|Targin
260066|NCT01675531|Chemotherapy Induced Peripheral Neuropathy (CIPN)
260067|NCT01675518|Plasma concentration
260068|NCT01675518|ASP7991
260069|NCT01675518|food effect
260070|NCT01675518|PTH (parathyroid hormone)
260071|NCT01675492|Astigmatism
260072|NCT01675492|refractive
260073|NCT01675492|error
260074|NCT01675492|LASIK
260075|NCT01675479|refractive
260076|NCT01675479|errors
260077|NCT01675466|non-specific abdominal pain
260078|NCT01675466|undifferentiated abdominal pain
260079|NCT01675466|appendicitis
260080|NCT01675466|appendicectomy
260081|NCT01675466|appendectomy
260082|NCT01675466|surgery
260083|NCT01675466|laparoscopy
260084|NCT01675466|antibiotics
260085|NCT01675466|randomised controlled trial
260086|NCT01675466|randomized controlled trial
260087|NCT01675466|controlled clinical trial
260088|NCT01675466|randomised
260089|NCT01675466|placebo
260090|NCT01675453|Organ dysfunction
260091|NCT01675453|Hypertonic solution
260092|NCT01675453|Extravascular water
260093|NCT01675453|Cardiopulmonary Bypass
260094|NCT01675414|ASD
260095|NCT01675414|autism
260096|NCT01675414|gastrointestinal
260097|NCT01675414|gastrointestinal conditions in children with ASD
260098|NCT01675401|Body Weight
260099|NCT01675401|Obesity
260100|NCT01675401|Weight Loss
260101|NCT01675401|Vascular Function Markers
260102|NCT01675388|Neonatal hypoxemic respiratory failure
260103|NCT01675388|Extra Corporeal Membrane Oxygenation
260104|NCT01675388|Neurodevelopmental outcomes
260105|NCT01675388|Neuroimaging
260106|NCT01675362|Extracorporeal shockwave lithotripsy (ESWL)
260107|NCT01675362|Kidney calculi
260108|NCT01675362|Renal protection
260109|NCT01675362|Antioxidants
260110|NCT01675362|Calcium channel blockers
260111|NCT01675362|Angiotensin receptor blockers
260112|NCT01675349|Standardization
260113|NCT01675349|Immunotherapy
260114|NCT01675349|Skin prick test
260115|NCT01675323|Restless Legs Syndrome
260116|NCT01675323|RLS
260117|NCT01675310|obesity, polycystic ovary syndrome, gestational diabetes
260118|NCT01675297|Risedronate, cholecalciferol, BMD
260119|NCT01675284|Avian Influenza
260120|NCT01675284|Influenza A Virus Subtype H5N1
260121|NCT01675284|Inactivated H5N1 Influenza Virion Vaccine
260122|NCT01675284|Phase I
260123|NCT01675284|Preventive H5N1 vaccination
260124|NCT01675271|gestational diabetes
260125|NCT01675271|inflammation
260126|NCT01675271|autonomic nervous system
260127|NCT01675245|Multiple Myeloma
260128|NCT01675245|Cancer
260129|NCT01675245|Velcade
260130|NCT01675245|Bortezomib
260131|NCT01675245|Chinese patients
260132|NCT01675232|Atopic dermatitis
260133|NCT01675232|Topical corticosteroid
260134|NCT01675232|Pediatric
260135|NCT01675232|Eczema
260136|NCT01675219|bladder cancer
260137|NCT01675219|recurrence
260138|NCT01675219|photodynamic diagnosis
260139|NCT01675219|PDD
260140|NCT01675219|cost analysis
260141|NCT01675206|Vascular calcification
260142|NCT01675206|Hemodialysis
260143|NCT01675206|Matrix Gla Protein
260144|NCT01675206|Vitamin K2
260145|NCT01675193|Amblyopia
260146|NCT01675193|Vision-Screening
260147|NCT01675180|pregnancy, oral health, attitude, awareness, streptococcus mutans, lactobacilli
260148|NCT01675167|CLBP
260149|NCT01675167|Chronic Low Back Pain
260150|NCT01675167|Chronic Pain
260151|NCT01675167|Back Pain
260152|NCT01675154|hypertriglyceridemia
260153|NCT01675141|NK Cell Function
260154|NCT01675141|Immunomodulatory Drugs
260155|NCT01675141|T Cell Activity
260156|NCT01675141|Immune Stimulatory Effects
260157|NCT01675141|Extended Dosing
260158|NCT01675128|Human Eukaryotic Translation Initiation Factor 4E (eIF4E) protein
260159|NCT01675128|Refractory
260160|NCT01675128|Oncogene
260161|NCT01675128|Maximum Tolerated Dose
260162|NCT01675128|Safety
260163|NCT01675115|Ischemic stroke
260164|NCT01675115|Traditional Chinese Medication
260165|NCT01675115|Aspirin
260166|NCT01675102|del 17p
260167|NCT01675102|chronic lymphocytic leukemia
260168|NCT01675102|cll
260169|NCT01675102|mutation
260170|NCT01675102|p53
260171|NCT01675089|bone disease
260172|NCT01675089|kidney transplantation
260173|NCT01675089|bisphosphonates
260174|NCT01675076|Hematoma
260175|NCT01675076|novel oral anti-coagulant (NOAC)
260176|NCT01675076|Device surgery
260177|NCT01675037|hypothalamic
260178|NCT01675037|pituitary,
260179|NCT01675037|endoscopic third ventriculostomy
260180|NCT01675037|hydrocephalus
260181|NCT01675024|Neupro, Pharmacokinetics, healthy Chinese subjects
260182|NCT01674998|REM Sleep Behavior Disorder
260183|NCT01674998|RBD
260184|NCT01674998|Dream
260185|NCT01674998|Dreams
260186|NCT01674985|Decitabine
260187|NCT01674985|microtransplantation
260188|NCT01674985|myelodysplastic syndromes
260189|NCT01674985|chemotherapy
260190|NCT01674972|NAFLD
260191|NCT01674972|NASH
260192|NCT01674972|GLP-1
260193|NCT01674959|gastric cancer
260194|NCT01674959|radiation
260195|NCT01674959|chemotherapy
260196|NCT01674946|GI-physiology
260197|NCT01674946|CDCA
260198|NCT01674946|bile acids
260199|NCT01674946|TGR5
260200|NCT01674946|satiation peptides
260201|NCT01674933|dental
260202|NCT01674933|prevention
260203|NCT01674933|caries
260204|NCT01674933|oral
260205|NCT01674933|children
260206|NCT01674920|Pediatric obesity
260207|NCT01674920|resiliency
260208|NCT01674920|physical activity
260209|NCT01674920|dietary patterns
260210|NCT01674920|children
260211|NCT01674881|Mindfulness
260212|NCT01674881|breast cancer
260213|NCT01674881|chronic pain
260214|NCT01674881|mediators
260215|NCT01674881|distress
260216|NCT01674881|Breast cancer survivors
260217|NCT01674881|Effectiveness of MBCT on chronic pain
260218|NCT01674881|Potential mediators and moderators
260219|NCT01674881|Effectiveness of MBCT on psychological symptoms
260220|NCT01674868|stroke
260221|NCT01674868|recovery
260222|NCT01674868|fluoxetine
260223|NCT01674868|aphasia
260224|NCT01674868|neglect
260225|NCT01674868|motor
260226|NCT01674855|PEG-G-CSF
260227|NCT01674842|Triple negative
260228|NCT01674842|Stage II
260229|NCT01674842|Stage III
260230|NCT01674803|drug-eluting stent
260231|NCT01674803|zotarolimus
260232|NCT01674803|everolimus
260233|NCT01674803|sirolimus
260234|NCT01674803|all comers population
260235|NCT01674803|target vessel failure
260236|NCT01674803|coronary artery disease
260237|NCT01674803|durable polymer
260238|NCT01674803|biodegradable polymer
260239|NCT01674777|ASP1941
260240|NCT01674777|Food effect
260241|NCT01674777|Pharmacokinetics
260242|NCT01674751|pre-ordering
260243|NCT01674751|healthy eating
260244|NCT01674751|mindfulness
260245|NCT01674751|incentives
260246|NCT01674751|employees
260247|NCT01674738|Non Small Cell Lung Cancer
260248|NCT01674738|NSCLC Stage IV
260249|NCT01674738|Non-Squamous Advanced Non-Small-Cell Lung-Cancer (Stage IV)
260250|NCT01674725|Hepatitis C virus
260251|NCT01674725|Hepatitis C Genotype 1
260252|NCT01674725|Hepatitis C
260253|NCT01674725|Interferon-Free
260254|NCT01674725|Chronic Hepatitis C
260255|NCT01674725|Ombitasvir
260256|NCT01674725|Ribavirin
260257|NCT01674725|Viekira PAK
260258|NCT01674725|Dasabuvir
260259|NCT01674725|Paritaprevir
260260|NCT01674712|Fibrates
260261|NCT01674712|Dyslipidemia
260262|NCT01674686|Vasospasm
260263|NCT01674686|Sarpogrelate
260264|NCT01674686|Statin
260265|NCT01674673|panic disorder
260266|NCT01674673|SSRIs pharmacotherapy
260267|NCT01674673|Cognitive Behavioral therapy
260268|NCT01674660|hemodialysis
260269|NCT01674660|blood pressure variability
260270|NCT01674660|volume status
260271|NCT01674647|rivaroxaban
260272|NCT01674647|oral anticoagulant
260273|NCT01674647|nonvalvular atrial fibrillation
260274|NCT01674647|cardioversion
260275|NCT01674647|stroke
260276|NCT01674647|transient ischemic attack
260277|NCT01674647|thromboembolism
260278|NCT01674647|cardiovascular event
260279|NCT01674634|XIAFLEX
260280|NCT01674634|XIAPEX
260281|NCT01674634|Dupuytren's disease
260282|NCT01674634|contracture
260283|NCT01674621|BA058
260284|NCT01674621|Abaloparatide-SC
260285|NCT01674621|abaloparatide
260286|NCT01674621|Abaloparatide-TD
260287|NCT01674621|Osteo
260288|NCT01674621|Osteoporosis
260289|NCT01674621|Transdermal
260290|NCT01674621|Patch
260291|NCT01674608|intensive care
260292|NCT01674608|mobilization
260293|NCT01674608|rehabilitation
260294|NCT01674608|critical care
260295|NCT01674595|Olea sensitization
260296|NCT01674582|Glioma
260297|NCT01674582|Brain tumors
260298|NCT01674582|Brain metastases
260299|NCT01674582|MRI
260300|NCT01674582|Cognitive measurement
260301|NCT01674582|Neuropsychological evaluation
260302|NCT01674582|DW-MRI
260303|NCT01674582|P-MRI
260304|NCT01674582|MRS
260305|NCT01674569|VEGF
260306|NCT01674569|PDGF
260307|NCT01674569|AMD
260308|NCT01674556|pancreatic
260309|NCT01674556|cancer
260310|NCT01674556|adenocarcinoma
260311|NCT01674556|Ultrasound
260312|NCT01674556|CEUS
260313|NCT01674543|Physical exercise
260314|NCT01674543|Schizophrenia
260315|NCT01674543|symptoms
260316|NCT01674543|IGF-1
260317|NCT01674517|Bioequivalence
260318|NCT01674517|Montelukast Sodium
260319|NCT01674517|crossover
260320|NCT01674504|Bioequivalence
260321|NCT01674504|Montelukast Sodium
260322|NCT01674504|crossover
260323|NCT01674478|NEC, SBS, enterostomy, fish oil, Microlipid, Intralipid,
260324|NCT01674478|enteral fat
260325|NCT01674465|Kidney fibrosis
260326|NCT01674465|Kidney hypoxia
260327|NCT01674465|Calcineurin inhibitors
260328|NCT01674452|Stroke
260329|NCT01674452|Exercise and Physical Fitness
260330|NCT01674439|Adipose-derived regenerative cells
260331|NCT01674439|Cell therapy
260332|NCT01674439|Autologous fat transfer
260333|NCT01674439|Tissue engineering
260334|NCT01674439|Craniofacial microsomia
260335|NCT01674426|functional hypothalamic amenorrhea
260336|NCT01674426|stress induced anovulation
260337|NCT01674413|Crohn's Disease
260338|NCT01674413|Crohn's
260339|NCT01674413|Crohns
260340|NCT01674413|Inflammatory Bowel Disease
260341|NCT01674413|IBD
260342|NCT01674413|Humira
260343|NCT01674413|Adalimumab
260344|NCT01674413|Adalimumab injection
260345|NCT01674413|Higgins
260346|NCT01674413|Calprotectin
260347|NCT01674413|biomarkers
260348|NCT01674413|Gastroenterology
260349|NCT01674413|University of Michigan
260350|NCT01674413|U of M
260351|NCT01674387|electroacupuncture therapy
260352|NCT01674387|neck pain
260353|NCT01674387|McGill Pain Questionnaire
260354|NCT01674387|Acupuncture Therapy
260355|NCT01674387|Electroacupuncture
260356|NCT01674387|Meridians
260357|NCT01674348|Diabetes Mellitus
260358|NCT01674335|Fibromyalgia
260359|NCT01674335|Chronic pain
260360|NCT01674335|Chronic fatigue
260361|NCT01674335|Activity pacing
260362|NCT01674335|Operant learning
260363|NCT01674335|Energy conservation
260364|NCT01674335|Treatment
260365|NCT01674335|Intervention
260366|NCT01674335|Biopsychosocial factors
260367|NCT01674335|Coping
260368|NCT01674335|Mood
260369|NCT01674335|Quality of life
260370|NCT01674322|Healthy participants
260371|NCT01674322|Ibrutinib
260372|NCT01674322|PCI-32765
260373|NCT01674322|B-cell malignancies
260374|NCT01674322|CYP3A4
260375|NCT01674296|Body Weight/physiology*
260376|NCT01674296|Diet*/statistics & numerical data
260377|NCT01674296|Diet*/trends
260378|NCT01674296|Exercise/physiology*
260379|NCT01674296|Female
260380|NCT01674296|Humans
260381|NCT01674296|Longitudinal Studies
260382|NCT01674296|Middle Aged
260383|NCT01674296|Obesity/epidemiology*
260384|NCT01674296|Seasons*
260385|NCT01674296|Time Factors
260386|NCT01674257|Atherosclerosis
260387|NCT01674257|Stroke
260388|NCT01674257|Positron-emission tomography
260389|NCT01674257|Ferumoxytol
260390|NCT01674257|Magnetic resonance imaging
260391|NCT01674257|Genetics
260392|NCT01674257|Calcification
260393|NCT01674257|Inflammation
260394|NCT01674257|Flurodeoxyglucose F18
260395|NCT01674257|Radiopharmaceuticals
260396|NCT01674218|tuberculosis, safety, PA-824, QTc interval, moxifloxacin, healthy volunteers, crossover
260397|NCT01674179|Fibromyalgia
260398|NCT01674179|qEEG
260399|NCT01674179|Sleep
260400|NCT01674179|Pain
260401|NCT01674153|Intra-dialytic exercise
260402|NCT01674153|Toxin removal
260403|NCT01674153|Hemodiafiltration
260404|NCT01674153|Inter-compartmental resistance
260405|NCT01674153|Cardiac output
260406|NCT01674140|estrogen receptor-positive breast cancer
260407|NCT01674140|HER2-negative breast cancer
260408|NCT01674140|stage IA breast cancer
260409|NCT01674140|stage IB breast cancer
260410|NCT01674140|stage II breast cancer
260411|NCT01674140|stage IIIA breast cancer
260412|NCT01674140|stage IIIB breast cancer
260413|NCT01674140|stage IIIC breast cancer
260414|NCT01674140|progesterone receptor-positive breast cancer
260415|NCT01674140|male breast cancer
260416|NCT01674114|Cesarean Section
260417|NCT01674114|Anesthetics, Local
260418|NCT01674101|Lower extremity malignancy
260419|NCT01674088|Irritable Bowel Syndrome
260420|NCT01674088|breath testing
260421|NCT01674088|carbon-13
260422|NCT01674075|safety
260423|NCT01674075|J-Tip Delivery System
260424|NCT01674075|pharmacokinetic profile
260425|NCT01674049|nutrition
260426|NCT01674049|nutrient
260427|NCT01674049|timing
260428|NCT01674049|diabetes
260429|NCT01674049|family history
260430|NCT01674049|dairy
260431|NCT01673971|hemangioma
260432|NCT01673958|Eccentric exercise
260433|NCT01673958|Aging
260434|NCT01673958|Heart failure
260435|NCT01673958|Muscle strength loss
260436|NCT01673958|Sarcopenia
260437|NCT01673945|EUS-FNA, Forward viewing EUS scope, accuracy, Curvilinear EUS scope
260438|NCT01673932|stroke
260439|NCT01673932|chronic stroke
260440|NCT01673932|ischemic stroke
260441|NCT01673932|umbilical cord blood
260442|NCT01673932|mononuclear cell
260443|NCT01673932|transplant
260444|NCT01673906|positron-emission tomography
260445|NCT01673906|neuroendocrine tumors
260446|NCT01673906|endosonography
260447|NCT01673906|tomography, X-ray computed
260448|NCT01673906|biopsy, fine needle
260449|NCT01673906|sensitivity and sensibility
260450|NCT01673893|ClearWay
260451|NCT01673893|Glycoprotein
260452|NCT01673893|Primary Coronary Intervention
260453|NCT01673893|Abciximab
260454|NCT01673893|ST Elevation Myocardial Infarction
260455|NCT01673893|Non-ST Elevation Myocardial Infarction
260456|NCT01673893|STEMI
260457|NCT01673893|NSTEMI
260458|NCT01673893|Medicare
260459|NCT01673893|Medicaid
260460|NCT01673893|Registry
260461|NCT01673893|catheterization
260462|NCT01673893|readmission
260463|NCT01673893|Acute Coronary Syndrome
260464|NCT01673893|ClearwayRx Catheter
260465|NCT01673841|bypass grafting
260466|NCT01673828|Brain Injuries
260467|NCT01673828|Pregnanolone
260468|NCT01673828|Epilepsy
260469|NCT01673815|optic disk
260470|NCT01673815|fundoscopy
260471|NCT01673815|pediatric
260472|NCT01673815|clinical examination
260473|NCT01673802|Cholangiocarcinoma
260474|NCT01673789|Stem Cell Educator
260475|NCT01673789|Cord blood stem cells
260476|NCT01673789|Immune modulation
260477|NCT01673789|Alopecia Areata
260478|NCT01673776|Proximal femoral fracture
260479|NCT01673776|multimodal intervention
260480|NCT01673776|goal directed therapy (GDT)
260481|NCT01673776|hemodynamic intervention
260482|NCT01673776|outcome
260483|NCT01673763|ERCP
260484|NCT01673763|endoscopy
260485|NCT01673763|pancreatitis
260486|NCT01673750|Adolescents
260487|NCT01673750|Body Image
260488|NCT01673698|obesity
260489|NCT01673698|weight loss
260490|NCT01673685|COPD
260491|NCT01673685|Oxygen cylinder
260492|NCT01673685|Portable oxygen cylinder
260493|NCT01673685|Battery powered delivery device
260494|NCT01673685|mobility
260495|NCT01673685|dyspnoea
260496|NCT01673685|Quality of Life
260497|NCT01673685|Cost effectiveness
260498|NCT01673646|SOM230, Pasireotide, acromegaly, Phase II
260499|NCT01673594|ADHD
260500|NCT01673594|Naltrexone
260501|NCT01673594|SODAS MPH
260502|NCT01673594|Stimulant-Induced Euphoria
260503|NCT01673594|Substance Abuse
260504|NCT01673594|Adults
260505|NCT01673581|Low Risk
260506|NCT01673555|GSK1278863
260507|NCT01673555|Pulmonary artery pressure
260508|NCT01673529|Pruritus
260509|NCT01673529|TRPV1
260510|NCT01673529|Cowhage
260511|NCT01673529|Atopic Dermatitis
260512|NCT01673529|Capsaicin
260513|NCT01673529|Itch
260514|NCT01673529|Histamine
260515|NCT01673529|healthy volunteers
260516|NCT01673529|SB705498
260517|NCT01673529|Clinical
260518|NCT01673516|Renal sympathetic denervation
260519|NCT01673516|Impedance cardiography
260520|NCT01673503|Myopia
260521|NCT01673503|refractive surgery
260522|NCT01673503|all femtosecond laser
260523|NCT01673503|ReLEx flex
260524|NCT01673503|ReLEx smile
260525|NCT01673490|Benign Prostatic Hyperplasia
260526|NCT01673490|dutasteride and tamsulosin
260527|NCT01673464|mild Traumatic Brain Injury
260528|NCT01673464|mTBI
260529|NCT01673464|Concussion
260530|NCT01673451|insomnia
260531|NCT01673438|solid tumor
260532|NCT01673438|aldoxorubicin
260533|NCT01673438|phase 1
260534|NCT01673438|INNO-206
260535|NCT01673438|doxorubicin
260536|NCT01673425|Influenza
260537|NCT01673425|Influenza Vaccines
260538|NCT01673425|Vaccines, Attenuated
260539|NCT01673425|Immunity, Mucosal
260540|NCT01673412|venous leg ulcer healing prognostic factors
260541|NCT01673399|repeated implantation failure (RIF)
260542|NCT01673399|atosiban
260543|NCT01673399|pregnancy
260544|NCT01673386|Tivozanib hydrochloride
260545|NCT01673386|renal cell carcinoma
260546|NCT01673386|subject preference
260547|NCT01673386|quality of life
260548|NCT01673373|Renal Artery Stenosis
260549|NCT01673373|Renal Artery Obstruction
260550|NCT01673373|Renovascular Hypertension
260551|NCT01673373|Resistant Hypertension
260552|NCT01673373|Renal Revascularization
260553|NCT01673373|Atherosclerotic Renal Artery Stenosis
260554|NCT01673373|ARAS (Atherosclerotic Renal Artery Stenosis)
260555|NCT01673373|RAS (Renal Artery Stenosis)
260556|NCT01673373|Uncontrolled hypertension
260557|NCT01673373|Hypertension
260558|NCT01673373|systolic blood pressure
260559|NCT01673373|blood pressure
260560|NCT01673360|vaginal repair
260561|NCT01673360|urinary slings
260562|NCT01673360|POP
260563|NCT01673360|SUI
260564|NCT01673360|prolapse
260565|NCT01673360|incontinence
260566|NCT01673334|Pancreas Tumor EUS FNA Core Biopsy Procore FNB
260567|NCT01673321|Yogurt
260568|NCT01673321|Milk
260569|NCT01673321|Protein
260570|NCT01673321|Food intake
260571|NCT01673321|Appetite
260572|NCT01673321|Glucose
260573|NCT01673321|Insulin
260574|NCT01673295|Lupus Nephritis
260575|NCT01673295|Rituximab
260576|NCT01673282|Lacosamide
260577|NCT01673282|Vimpat
260578|NCT01673282|Focal Epilepsy
260579|NCT01673282|Drug Load
260580|NCT01673282|AED
260581|NCT01673282|SP1065
260582|NCT01673269|ERCP
260583|NCT01673269|Direct cholangioscopic examination of the common bile duct
260584|NCT01673269|Choledocholithiasis
260585|NCT01673269|Cholangiocarcinoma
260586|NCT01673269|Benign stricture of common bile duct
260587|NCT01673243|Smoking cessation
260588|NCT01673243|Household smoking bans
260589|NCT01673243|Cancer
260590|NCT01673243|Sickle cell disease
260591|NCT01673204|surrogate marker,
260592|NCT01673204|circulating soluble TNF receptor,
260593|NCT01673204|diabetic nephropathy
260594|NCT01673178|Type 2 diabetes
260595|NCT01673178|safety
260596|NCT01673178|multiple dose
260597|NCT01673178|intravenous
260598|NCT01673152|Obesity
260599|NCT01673152|Overweight
260600|NCT01673152|Satiety
260601|NCT01673152|Oligofructose
260602|NCT01673152|Prebiotic
260603|NCT01673139|Atrial fibrillation
260604|NCT01673139|Exercise
260605|NCT01673126|vegetative state
260606|NCT01673126|minimally conscious state
260607|NCT01673126|disorders of consciousness
260608|NCT01673126|transcranial direct current stimulation
260609|NCT01673113|cryolipolysis, sensory nerve function, Zeltiq
260610|NCT01673100|physical activity
260611|NCT01673100|percutaneous coronary intervention
260612|NCT01673100|heart disease
260613|NCT01673087|stress biology
260614|NCT01673087|cortisol
260615|NCT01673087|adrenocorticotropin
260616|NCT01673087|salivary biomarkers
260617|NCT01673061|Abscess
260618|NCT01673061|Boils
260619|NCT01673061|Anesthetics, Local
260620|NCT01673061|Lidocaine
260621|NCT01673061|Vapocoolant
260622|NCT01673061|1,1,1,3,3-Pentafluoropropane
260623|NCT01673061|1,1,1,2-Tetrafluoroethane
260624|NCT01673048|Elastic stable intramedullary nailing
260625|NCT01673048|biomechanical testing
260626|NCT01673048|fracture
260627|NCT01673048|femur
260628|NCT01673048|treatment
260629|NCT01673048|children
260630|NCT01673048|adolescents
260631|NCT01673009|Gleevec
260632|NCT01672996|Use in Abdominal
260633|NCT01672996|Contrast Enhanced
260634|NCT01672996|Computed Tomography
260635|NCT01672996|Optimize concentration
260636|NCT01672996|dosage of Ioforminol Injection
260637|NCT01672983|Japanese
260638|NCT01672983|Hepatitis C
260639|NCT01672983|Genotype 2
260640|NCT01672983|Genotype 1b
260641|NCT01672983|paritaprevir
260642|NCT01672983|ombitasvir
260643|NCT01672983|ritonavir
260644|NCT01672983|VIEKIRAX Combination Tablets
260645|NCT01672944|Biological specimen banks
260646|NCT01672944|Health education
260647|NCT01672944|Tissue banks
260648|NCT01672944|Health care survey
260649|NCT01672944|Tissue
260650|NCT01672918|PET/CT
260651|NCT01672918|Lymphoma
260652|NCT01672918|Lymphadenopathy
260653|NCT01672918|ALPS
260654|NCT01672905|recurrent prostate cancer
260655|NCT01672905|stage I prostate cancer
260656|NCT01672905|stage IIA prostate cancer
260657|NCT01672905|stage IIB prostate cancer
260658|NCT01672905|stage III prostate cancer
260659|NCT01672892|gastrointestinal complications
260660|NCT01672892|perioperative/postoperative complications
260661|NCT01672892|radiation toxicity
260662|NCT01672892|urinary complications
260663|NCT01672892|urinary tract toxicity
260664|NCT01672892|endometrial clear cell carcinoma
260665|NCT01672892|endometrial papillary serous carcinoma
260666|NCT01672892|stage IA endometrial carcinoma
260667|NCT01672892|stage IB endometrial carcinoma
260668|NCT01672892|stage II endometrial carcinoma
260669|NCT01672892|stage IIIA endometrial carcinoma
260670|NCT01672892|stage IIIB endometrial carcinoma
260671|NCT01672892|stage IIIC endometrial carcinoma
260672|NCT01672892|endometrial adenocarcinoma
260673|NCT01672892|cervical adenocarcinoma
260674|NCT01672892|stage IB cervical cancer
260675|NCT01672892|stage IIA cervical cancer
260676|NCT01672892|stage IIB cervical cancer
260677|NCT01672879|NASH
260678|NCT01672879|cirrhosis
260679|NCT01672879|Compensated Liver disease
260680|NCT01672879|Monoclonal antibody
260681|NCT01672879|LOXL2
260682|NCT01672879|Simtuzumab
260683|NCT01672879|Nonalcoholic Steatohepatitis
260684|NCT01672879|Hepatic venous pressure gradient
260685|NCT01672879|HVPG
260686|NCT01672879|NAFLD
260687|NCT01672879|MRE
260688|NCT01672879|Liver biopsy
260689|NCT01672866|NASH
260690|NCT01672866|non cirrhotic
260691|NCT01672866|Monoclonal antibody
260692|NCT01672866|LOXL2
260693|NCT01672866|Simtuzumab
260694|NCT01672866|Nonalcoholic Steatohepatitis
260695|NCT01672866|NAFLD
260696|NCT01672866|Liver biopsy
260697|NCT01672866|MRE
260698|NCT01672853|PSC
260699|NCT01672853|Sclerosis
260700|NCT01672853|Monoclonal antibody
260701|NCT01672853|LOXL2
260702|NCT01672853|Simtuzumab
260703|NCT01672853|Primary sclerosing cholangitis
260704|NCT01672853|Liver fibrosis
260705|NCT01672853|Liver disease
260706|NCT01672853|MRCP
260707|NCT01672853|MRE
260708|NCT01672853|Liver biopsy
260709|NCT01672840|Stage 1 Hypertension
260710|NCT01672840|cocoa consumption
260711|NCT01672840|Blood pressure
260712|NCT01672840|Endothelial function
260713|NCT01672840|arterial stiffness
260714|NCT01672827|Alzheimer's Disease
260715|NCT01672827|Mild Cognitive Impairment
260716|NCT01672827|Positron Emission Tomography (PET)
260717|NCT01672827|PET Images
260718|NCT01672814|Keratoconus
260719|NCT01672814|Collagen Crosslinking
260720|NCT01672814|Riboflavin
260721|NCT01672814|Microwave
260722|NCT01672814|Keraflex
260723|NCT01672775|Renal Cell Carcinoma
260724|NCT01672775|AGS-16C3F
260725|NCT01672775|Pharmacokinetics of AGS-16C3F
260726|NCT01672762|diabetes mellitus
260727|NCT01672762|serum Insulin
260728|NCT01672762|blood glucose
260729|NCT01672762|glucose excretion
260730|NCT01672762|hypoglycemic agents
260731|NCT01672762|ipragliflozin
260732|NCT01672749|Scoliosis [MESH]
260733|NCT01672749|Pediatrics [MESH]
260734|NCT01672749|Early onset
260735|NCT01672749|Growth guidance
260736|NCT01672749|Growing rod
260737|NCT01672749|Trolley
260738|NCT01672749|Dual growing rod technique
260739|NCT01672736|Relapsed or relapse/refractory Multiple Myeloma
260740|NCT01672723|opioids
260741|NCT01672723|social connection
260742|NCT01672710|Hubbard detoxification
260743|NCT01672710|Exercise
260744|NCT01672710|Sauna therapy
260745|NCT01672710|Niacin
260746|NCT01672697|anal incontinence
260747|NCT01672697|genital trauma
260748|NCT01672697|physical therapy
260749|NCT01672697|anal manometry
260750|NCT01672684|quality of life
260751|NCT01672658|TBI,
260752|NCT01672658|vestibular
260753|NCT01672645|Smoking cessation
260754|NCT01672645|vaccine
260755|NCT01672645|Phase 1
260756|NCT01672619|craniosynostoses
260757|NCT01672619|Osteogenesis Distraction
260758|NCT01672619|craniotomy
260759|NCT01672593|Autologous platelet rich fibrin glue;
260760|NCT01672593|Enterocutaneous fistulas;
260761|NCT01672593|Single low output GI fistulas;
260762|NCT01672580|social networks
260763|NCT01672580|nutrition
260764|NCT01672580|vitamins
260765|NCT01672580|chlorine
260766|NCT01672567|Coronary Artery Disease
260767|NCT01672567|Egg Consumption
260768|NCT01672567|Endothelial Function
260769|NCT01672554|Schizophrenia
260770|NCT01672554|Anxiety disorder
260771|NCT01672541|dating violence
260772|NCT01672541|healthy relationship behaviors
260773|NCT01672528|Patient Reported Outcome Measures
260774|NCT01672528|PROMs
260775|NCT01672528|Cardiac arrhythmia
260776|NCT01672528|Cardiac ablation
260777|NCT01672502|sleep
260778|NCT01672502|firefighter
260779|NCT01672502|fire
260780|NCT01672502|apnea
260781|NCT01672502|insomnia
260782|NCT01672502|shift
260783|NCT01672502|narcolepsy
260784|NCT01672502|restless leg
260785|NCT01672502|rls
260786|NCT01672502|fatigue
260787|NCT01672502|Optalert
260788|NCT01672502|actigraph
260789|NCT01672502|actigraphy
260790|NCT01672502|actiwatch
260791|NCT01672502|safety
260792|NCT01672502|sleepiness
260793|NCT01672502|sleepy
260794|NCT01672502|work
260795|NCT01672502|hours
260796|NCT01672502|FEMA
260797|NCT01672502|drowsy
260798|NCT01672489|Drowsy
260799|NCT01672489|Drive
260800|NCT01672489|Driving
260801|NCT01672489|Shift Work Disorder
260802|NCT01672489|SWD
260803|NCT01672489|EEG
260804|NCT01672489|ECG
260805|NCT01672489|Actiwatch
260806|NCT01672489|Diary
260807|NCT01672489|Bioharness
260808|NCT01672489|Q-Sensor
260809|NCT01672489|Q Sensor
260810|NCT01672489|Liberty Mutual
260811|NCT01672489|sleep
260812|NCT01672489|impaired
260813|NCT01672489|Optalert
260814|NCT01672489|tracker
260815|NCT01672489|vehicle
260816|NCT01672489|questionnaire
260817|NCT01672489|survey
260818|NCT01672476|Fimasartan
260819|NCT01672450|Histologically or cytologically proven melanoma; Stages III-IV; accessible cutaneous, subcutaneous, and/or nodal lesions; ECOG performance status 0 to 2
260820|NCT01672437|Birth and parent preparation
260821|NCT01672437|Parenting stress
260822|NCT01672437|Depression
260823|NCT01672437|self-efficacy
260824|NCT01672437|social network and support
260825|NCT01672424|NPO
260826|NCT01672424|Gastric Emptying
260827|NCT01672424|Ice Chips
260828|NCT01672424|Protein Drink
260829|NCT01672424|Ultrasound
260830|NCT01672411|prostate cancer, PSA, markers, diagnosis, prognosis, pro-PSA
260831|NCT01672398|CarePartner
260832|NCT01672398|informal caregiver
260833|NCT01672398|interactive voice response
260834|NCT01672398|transition
260835|NCT01672398|post-discharge
260836|NCT01672398|chronic illness
260837|NCT01672398|readmission
260838|NCT01672398|self-care
260839|NCT01672385|CarePartner
260840|NCT01672385|informal caregiver
260841|NCT01672385|interactive voice response
260842|NCT01672385|transition
260843|NCT01672385|post-discharge
260844|NCT01672385|chronic illness
260845|NCT01672385|readmission
260846|NCT01672385|self-care
260847|NCT01672359|cognitive functioning
260848|NCT01672359|immune function
260849|NCT01672359|cytokines
260850|NCT01672359|growth factors
260851|NCT01672359|quality of life
260852|NCT01672359|dietary supplementation
260853|NCT01672359|Ginkgo biloba
260854|NCT01672359|Improvement of cognitive function
260855|NCT01672346|PAF
260856|NCT01672320|Robotic
260857|NCT01672320|Arthroplasty
260858|NCT01672320|Total Hip Arthroplasty
260859|NCT01672320|Cup Positioning
260860|NCT01672320|Outcomes
260861|NCT01672307|hypotrichosis of eyebrows
260862|NCT01672307|thinning eyebrows
260863|NCT01672307|minoxidil
260864|NCT01672307|placebo
260865|NCT01672307|randomized
260866|NCT01672294|caregiver
260867|NCT01672294|end of life
260868|NCT01672294|self-disclosure
260869|NCT01672268|cardiac computed tomography
260870|NCT01672268|Transcatheter Aortic Valve Implantation
260871|NCT01672268|safety and efficacy
260872|NCT01672255|exercise
260873|NCT01672255|diabetes
260874|NCT01672255|SSRIs
260875|NCT01672216|Exercise Therapy
260876|NCT01672216|Biofeedback (Psychology)
260877|NCT01672216|Adult
260878|NCT01672216|Chronic Obstipation/*therapy
260879|NCT01672216|EMG - Biofeedback
260880|NCT01672216|EMG - Triggered Stimulation
260881|NCT01672216|Augmented biofeedback
260882|NCT01672177|Geriatrics
260883|NCT01672177|Aged
260884|NCT01672177|Aging
260885|NCT01672177|Chronic disease
260886|NCT01672177|Self management
260887|NCT01672164|proteogenomic biomarker panels
260888|NCT01672151|Refractory Immune Thrombocytopenic Purpura
260889|NCT01672151|rapamycin
260890|NCT01672151|regulatory T cells
260891|NCT01672138|PVAI
260892|NCT01672138|CFAE
260893|NCT01672138|NPAF
260894|NCT01672112|analgesic efficacy
260895|NCT01672112|oral codeine
260896|NCT01672112|oral oxycodone
260897|NCT01672112|postcraniotomy
260898|NCT01672099|vitamin K2
260899|NCT01672099|menaquinone-7
260900|NCT01672099|vascular health
260901|NCT01672073|pressure
260902|NCT01672073|waveform
260903|NCT01672073|arterial
260904|NCT01672047|The 25(OH) vitamin D level
260905|NCT01672047|The 1.25(OH) vitamin D level
260906|NCT01672047|The intact PTH level
260907|NCT01672047|The calcification score of coronary artery
260908|NCT01672047|The microalbuminuria level
260909|NCT01672021|Breast Cancer
260910|NCT01672021|MRI PET-CT
260911|NCT01672008|NOX-100
260912|NCT01671995|Heart failure
260913|NCT01671995|Quality of life
260914|NCT01671969|determine effects of diet on renal and other parameters
260915|NCT01671956|IBD
260916|NCT01671956|UC
260917|NCT01671956|Colitis
260918|NCT01671956|Ulcerative Colitis
260919|NCT01671943|small malignant invasive breast tumors
260920|NCT01671917|Total knee arthroplasty
260921|NCT01671917|Total knee replacement
260922|NCT01671917|Knee osteoarthritis
260923|NCT01671917|Education
260924|NCT01671917|Exercise
260925|NCT01671917|Handicap
260926|NCT01671917|Function
260927|NCT01671917|Cost-effectiveness
260928|NCT01671917|Cost-utility
260929|NCT01671917|Quality of life
260930|NCT01671891|rectal cancer
260931|NCT01671891|circulating tumor cells
260932|NCT01671891|predict responses
260933|NCT01671865|FSHD
260934|NCT01671865|magnetic resonance imaging
260935|NCT01671865|magnetic resonance spectroscopy
260936|NCT01671826|Multiple Myeloma
260937|NCT01671826|Autologous Stem Cell Transplantation
260938|NCT01671826|Elderly Patients
260939|NCT01671813|positive
260940|NCT01671813|diffuse
260941|NCT01671813|B-Cell
260942|NCT01671813|elderly
260943|NCT01671813|EBV
260944|NCT01671813|DLBCL
260945|NCT01671813|malignant
260946|NCT01671813|pilot
260947|NCT01671800|Hyperhidrosis
260948|NCT01671800|Botulinum Toxin
260949|NCT01671800|Amputation
260950|NCT01671800|Phantom limb pain
260951|NCT01671787|Hepatitis B
260952|NCT01671787|HBV
260953|NCT01671787|GS-7340
260954|NCT01671787|TDF
260955|NCT01671787|Tenofovir disoproxil fumarate
260956|NCT01671787|Gilead
260957|NCT01671787|Viread
260958|NCT01671761|Healthy
260959|NCT01671761|Control
260960|NCT01671748|Venous Leg Ulcer
260961|NCT01671748|Varicose Ulcer
260962|NCT01671748|Chronic ulcer
260963|NCT01671748|Chronic wound
260964|NCT01671748|Ultrasound therapy
260965|NCT01671748|MIST device
260966|NCT01671748|Wound healing
260967|NCT01671748|Low frequency non contact ultrasound
260968|NCT01671735|prevention
260969|NCT01671735|diabetes
260970|NCT01671722|Bioequivalence
260971|NCT01671722|Montelukast Sodium
260972|NCT01671722|crossover
260973|NCT01671709|Bioequivalence
260974|NCT01671709|Montelukast Sodium
260975|NCT01671709|crossover
260976|NCT01671683|rectal cancer
260977|NCT01671683|neoadjuvant chemoradiotherapy
260978|NCT01671683|Capecitabine
260979|NCT01671670|Functional dyspepsia
260980|NCT01671670|postprandial distress syndrome
260981|NCT01671657|In vitro fertilization
260982|NCT01671657|Assisted reproductive therapy
260983|NCT01671657|Time-lapse image recording
260984|NCT01671657|Image analysis software
260985|NCT01671644|In vitro fertilization
260986|NCT01671644|Assisted reproductive therapy
260987|NCT01671644|Time-lapse image recording
260988|NCT01671644|Image analysis software
260989|NCT01671618|Aortic dissection
260990|NCT01671618|Aortic dilation
260991|NCT01671618|Aortic Aneurysm
260992|NCT01671618|ultrasound
260993|NCT01671618|point-of-care
260994|NCT01671618|echocardiography
260995|NCT01671592|Cancer
260996|NCT01671592|colorectal
260997|NCT01671592|tumor
260998|NCT01671592|neoplasms
260999|NCT01671592|carcinoma
261000|NCT01671592|vaccine
261001|NCT01671566|Congenital Heart defect
261002|NCT01671566|Exercise and Physical fitness
261003|NCT01671566|Rehabilitation
261004|NCT01671566|Quality of life
261005|NCT01671566|Behaviour
261006|NCT01671540|COPD
261007|NCT01671540|IPV
261008|NCT01671527|Deep Brain Stimulation
261009|NCT01671527|DBS
261010|NCT01671527|Transcranial Magnetic Stimulation
261011|NCT01671527|TMS
261012|NCT01671527|Cervical Dystonia
261013|NCT01671527|Dystonia
261014|NCT01671527|Control
261015|NCT01671527|Healthy
261016|NCT01671514|mitochondrial biogenesis
261017|NCT01671514|skeletal muscle
261018|NCT01671514|epicatechin
261019|NCT01671501|HIV
261020|NCT01671501|Acquired Immunodeficiency Syndrome
261021|NCT01671501|Alcoholism
261022|NCT01671501|Alcoholic Intoxication
261023|NCT01671501|Substance-Related Disorders
261024|NCT01671501|Intervention Studies
261025|NCT01671501|Primary Health Care
261026|NCT01671501|therapy
261027|NCT01671501|prevention & control
261028|NCT01671488|Anal Cancer
261029|NCT01671488|Mitomycin
261030|NCT01671488|5-Fluorouracil
261031|NCT01671488|5-FU
261032|NCT01671488|IMRT
261033|NCT01671488|ADXS11-001
261034|NCT01671475|Altered Mental Status
261035|NCT01671475|Non-convulsive seizure
261036|NCT01671475|Electroencephalography
261037|NCT01671462|HPV
261038|NCT01671462|Cervical Cancer
261039|NCT01671462|Cervical Neoplasms
261040|NCT01671449|Gastric cancer
261041|NCT01671449|S-1
261042|NCT01671449|Cisplatin
261043|NCT01671449|Oxaliplatin
261044|NCT01671436|Depression
261045|NCT01671436|Guided Imagery
261046|NCT01671436|Psychotherapy
261047|NCT01671436|Meditation
261048|NCT01671423|Cellulitis
261049|NCT01671423|Skin infection
261050|NCT01671423|Prednisone
261051|NCT01671423|Steroid
261052|NCT01671423|Anti-inflammatory
261053|NCT01671410|Neonatal Abstinence Syndrome
261054|NCT01671410|buprenorphine
261055|NCT01671410|morphine
261056|NCT01671410|benzodiazepine
261057|NCT01671397|Obesity
261058|NCT01671397|weight loss
261059|NCT01671397|sleep hygiene
261060|NCT01671397|diet
261061|NCT01671397|exercise
261062|NCT01671384|Valproate
261063|NCT01671384|levocarnitine
261064|NCT01671384|SMA
261065|NCT01671384|physiotherapy
261066|NCT01671384|placebo
261067|NCT01671371|syncope
261068|NCT01671371|point of care
261069|NCT01671371|ultrasound
261070|NCT01671371|echocardiography
261071|NCT01671358|MRSA
261072|NCT01671358|Contamination
261073|NCT01671358|Isolation
261074|NCT01671332|Carcinoma, non small cell lung
261075|NCT01671332|Second line
261076|NCT01671332|Third line
261077|NCT01671319|breast cancer
261078|NCT01671319|female
261079|NCT01671319|women
261080|NCT01671319|adjuvant
261081|NCT01671306|Coronary collaterals
261082|NCT01671306|diabetes mellitus
261083|NCT01671306|monocyte subsets
261084|NCT01671280|community-acquired pneumonia
261085|NCT01671280|pelvic inflammatory disease
261086|NCT01671280|Zithromax
261087|NCT01671280|Zithromac
261088|NCT01671280|Japanese
261089|NCT01671280|Regulatory Post Marketing Commitment Plan
261090|NCT01671228|dialysis
261091|NCT01671228|chronic kidney failure
261092|NCT01671228|informed choice
261093|NCT01671228|patient decision making
261094|NCT01671228|decision aid
261095|NCT01671215|endometrium
261096|NCT01671215|myometrium
261097|NCT01671215|fibroids
261098|NCT01671215|uterine malformations
261099|NCT01671176|Wide diameter implant
261100|NCT01671176|ISQ
261101|NCT01671176|Ponto
261102|NCT01671176|Bone anchored implant
261103|NCT01671163|Cancer
261104|NCT01671163|Radiation therapy
261105|NCT01671163|Fiducial markers
261106|NCT01671150|inflammation
261107|NCT01671150|depression
261108|NCT01671150|social cognition
261109|NCT01671150|neural activity
261110|NCT01671137|Lactobacillus GG
261111|NCT01671137|Functional Abdominal Pain
261112|NCT01671137|Children
261113|NCT01671137|Acute
261114|NCT01671137|Gastroenteritis
261115|NCT01671124|TG
261116|NCT01671124|TC
261117|NCT01671124|HDL
261118|NCT01671124|LDL
261119|NCT01671124|Albumin
261120|NCT01671124|Hemoglobin
261121|NCT01671124|Hematocrit
261122|NCT01671124|Uric acid
261123|NCT01671124|Sodium
261124|NCT01671124|Potassium
261125|NCT01671124|Calcium
261126|NCT01671098|nitric oxide
261127|NCT01671098|sinuplasty
261128|NCT01671072|Chondrocyte cells
261129|NCT01671072|Osteoarthritis
261130|NCT01671072|Gene therapy
261131|NCT01671033|Panic disorder
261132|NCT01671033|cognitive behavior therapy
261133|NCT01671033|Internet
261134|NCT01671020|fimasartan
261135|NCT01671020|absolute bioavailability
261136|NCT01670994|cancer
261137|NCT01670994|immunotherapy
261138|NCT01670994|immunochemotherapy
261139|NCT01670994|targeted
261140|NCT01670994|metastatic
261141|NCT01670994|interleukin-2
261142|NCT01670994|antitumor
261143|NCT01670994|TCR
261144|NCT01670994|T-cell receptor
261145|NCT01670994|p53
261146|NCT01670994|p53 gene
261147|NCT01670994|p53 tumor supressor protein
261148|NCT01670994|HLA-A2 positive
261149|NCT01670994|HLA-A*0201/p53 aa264-272
261150|NCT01670994|HLA complex
261151|NCT01670994|multiple myeloma
261152|NCT01670994|IFN-γ and TNF-α
261153|NCT01670994|refractory
261154|NCT01670994|relapsed
261155|NCT01670981|Ischemic dilated cardiomyopathy
261156|NCT01670981|Heart failure
261157|NCT01670981|ixCELL
261158|NCT01670981|ixCELL DCM
261159|NCT01670981|IDCM
261160|NCT01670981|DCM
261161|NCT01670981|stem cells
261162|NCT01670981|MSC
261163|NCT01670981|cell therapy
261164|NCT01670955|Anemia
261165|NCT01670955|preoperative
261166|NCT01670955|gynecological patients
261167|NCT01670955|Sorghum bicolor
261168|NCT01670955|Packed Cells Volume
261169|NCT01670942|pneumothorax
261170|NCT01670942|trauma
261171|NCT01670942|commercial air travel
261172|NCT01670929|recurrent miscarriages
261173|NCT01670929|progesterone
261174|NCT01670916|Necrotizing enterocolitis
261175|NCT01670916|Probiotics
261176|NCT01670916|Preterm
261177|NCT01670916|Infant
261178|NCT01670890|temozolomide(TMZ)
261179|NCT01670890|cisplatin(CDDP)
261180|NCT01670890|recurrent malignant gliomas
261181|NCT01670851|eLAPE,
261182|NCT01670851|perineum,
261183|NCT01670851|pelvic floor reconstruction
261184|NCT01670838|subarachnoid haemorrhage
261185|NCT01670838|cardiopulmonary complications
261186|NCT01670825|Occipital neuralgia
261187|NCT01670825|corticosteroid injection
261188|NCT01670825|pulsed radiofrequency
261189|NCT01670812|chronic lymphocytic leukemia
261190|NCT01670812|ultra-high risk
261191|NCT01670812|fresh frozen plasma
261192|NCT01670812|methylprednisolone
261193|NCT01670812|rituximab
261194|NCT01670799|Ketorolac
261195|NCT01670799|Bioavailability
261196|NCT01670799|Pain
261197|NCT01670760|Deep Tissue Temperature
261198|NCT01670760|Zero Heat Flux Thermometry
261199|NCT01670760|Thermometry
261200|NCT01670760|Core Temperature
261201|NCT01670708|Substance Use
261202|NCT01670708|Illicit Drug Use
261203|NCT01670708|Criminal Behavior
261204|NCT01670695|IgG4-related disease
261205|NCT01670695|IgG4-RD
261206|NCT01670682|Stage III
261207|NCT01670643|AMD
261208|NCT01670643|vision rehabilitation
261209|NCT01670643|video camera magnifier
261210|NCT01670643|IVI
261211|NCT01670643|DASS
261212|NCT01670630|speculum
261213|NCT01670630|vagina
261214|NCT01670630|cervix
261215|NCT01670630|examination
261216|NCT01670578|P.R.P.
261217|NCT01670578|viscosupplementation
261218|NCT01670578|double-blind randomized
261219|NCT01670578|intra-articular injections
261220|NCT01670578|knee degenerative pathology
261221|NCT01670578|early osteoarthritis
261222|NCT01670565|Diffuse cutaneous systemic sclerosis
261223|NCT01670565|Early Diffuse cutaneous systemic sclerosis
261224|NCT01670539|Lung Cancer
261225|NCT01670539|Telemonitoring
261226|NCT01670539|Rural
261227|NCT01670539|Nursing
261228|NCT01670526|Traumatic Brain Injury
261229|NCT01670526|Cognitive Impairment
261230|NCT01670526|Rivastigmine
261231|NCT01670526|Pharmacologic Actions
261232|NCT01670526|TBI
261233|NCT01670526|Memory
261359|NCT01668953|Platelet Rich Plasma
261234|NCT01670526|Cholinesterase Inhibitors
261235|NCT01670526|Cognition
261236|NCT01670526|Head Trauma
261237|NCT01670513|Psoriasis
261238|NCT01670500|germline mutation
261239|NCT01670500|BRCA1 mutation
261240|NCT01670500|BRCA2 mutation
261241|NCT01670487|Vapocoolant
261242|NCT01670474|Temporary hemodialysis catheters
261243|NCT01670474|Non-cuffed hemodialysis catheters
261244|NCT01670474|Thrombolysis
261245|NCT01670474|rt-PA
261246|NCT01670474|Thrombosis
261247|NCT01670474|Lifespan
261248|NCT01670474|Blood flow rate
261249|NCT01670474|Catheter related bacteriemia
261250|NCT01670461|advance care planning, palliative care, pediatric
261251|NCT01670448|Postoperative pain
261252|NCT01670448|Chronic pain prevention
261253|NCT01670448|Regional anesthesia
261254|NCT01670448|Mastectomy
261255|NCT01670435|Ciprofloxacin
261256|NCT01670435|sepsis
261257|NCT01670435|infection
261258|NCT01670435|pneumonia
261259|NCT01670435|peritonitis
261260|NCT01670435|cholecystitis
261261|NCT01670435|cholangitis
261262|NCT01670435|anthrax
261263|NCT01670422|CSOJ
261264|NCT01670422|recurrence
261265|NCT01670422|life-threatening complications
261266|NCT01670422|risk factors
261267|NCT01670409|Esophageal squamous cell carcinoma
261268|NCT01670409|SMART
261269|NCT01670409|IMRT
261270|NCT01670409|Chemotherapy
261271|NCT01670396|coronary stent implant
261272|NCT01670396|polymorphism
261273|NCT01670396|G protein
261274|NCT01670396|drug-eluting stent
261275|NCT01670396|restenosis
261276|NCT01670383|Cardiac Arrest
261277|NCT01670383|Sepsis
261278|NCT01670383|Biological Markers
261279|NCT01670383|Anti-Inflammation Agents
261280|NCT01670383|Antioxidants
261281|NCT01670370|Rituximab
261282|NCT01670370|Gemcitabine
261283|NCT01670370|Oxaliplatin
261284|NCT01670370|aggressive B cell lymphoma
261285|NCT01670357|Dry Eye Syndrome
261286|NCT01670318|Chronic total occlusion
261287|NCT01670318|Bifurcation lesion
261288|NCT01670318|Left main trunk lesion
261289|NCT01670318|Small vessel disease
261290|NCT01670318|Multi vessel disease
261291|NCT01670292|Low Back Pain
261292|NCT01670279|Major Depressive Disorder (MDD)
261293|NCT01670266|ONO-9054
261294|NCT01670266|ocular hypertension
261295|NCT01670266|OHT
261296|NCT01670266|Open angle-glaucoma
261297|NCT01670266|OAG
261298|NCT01670266|Glaucoma
261299|NCT01670266|Eye diseases
261300|NCT01670240|IPAA
261301|NCT01670240|Pouchitis
261302|NCT01670240|Ulcerative colitis
261303|NCT01670240|Pouch
261304|NCT01670240|Adalimumab
261305|NCT01670240|Humira
261306|NCT01670227|EARLY CHILDHOOD
261307|NCT01670227|UNIVERSAL PREVENTION
261308|NCT01670214|RM
261309|NCT01670214|R-CM
261310|NCT01670214|based on ICHD-2 criteria
261311|NCT01670188|Pneumatic sequential compression device (SCD)
261312|NCT01670188|Peripherally Inserted Central Catheters (PICC)
261313|NCT01670175|Histologic verification of solid tumor, including lymphomas
261314|NCT01670175|Original diagnosis or relapse
261315|NCT01670162|Pigment Epithelium of Eye
261316|NCT01670162|Wet macular degeneration
261317|NCT01670162|Macular degeneration
261318|NCT01670149|Clostridium difficile
261319|NCT01670149|Diarrhoea
261320|NCT01670149|Rifaximin
261321|NCT01670136|sildenafil
261322|NCT01670136|preterm infants
261323|NCT01670136|persistent pulmonary hypertension of the newborn
261324|NCT01670123|Mobile phone
261325|NCT01670123|electronic intervention
261326|NCT01670123|behavioral intervention
261327|NCT01670123|telehealth
261328|NCT01670123|bipolar disorder
261329|NCT01670110|Polycystic Liver Disease
261330|NCT01670110|Autosomal dominant polycystic kidney disease
261331|NCT01670110|Autosomal dominant polycystic liver disease
261332|NCT01670110|Somatostatin analogs
261333|NCT01670110|Pasireotide LAR
261334|NCT01670110|SOM230
261335|NCT01670097|Advanced Cancers
261336|NCT01670097|Hematologic Disorder
261337|NCT01670097|Solid Tumors
261338|NCT01670097|Dyspnea
261339|NCT01670097|Difficulty breathing
261340|NCT01670097|Shortness of breath
261341|NCT01670097|Dexamethasone
261342|NCT01670097|Decadron
261343|NCT01670097|Placebo
261344|NCT01670097|Sugar pill
261345|NCT01670097|Questionnaires
261346|NCT01670097|Surveys
261347|NCT01670097|Spirometer
261348|NCT01670097|Phone calls
261349|NCT01670071|Schizophrenia
261350|NCT01670071|Paliperidone
261351|NCT01670071|Risperidone
261352|NCT01670071|Paliperidone extended-release (ER)
261353|NCT01670071|Risperidone immediate-release (IR)
261354|NCT01670019|Depression
261355|NCT01670019|Antidepressant
261356|NCT01670019|Antipsychotic
261357|NCT01668953|Lateral Epicondylitis
261358|NCT01668953|Tennis Elbow
261360|NCT01668953|Whole Blood
261361|NCT01668953|Tendon Fenestration
261362|NCT01668940|Morning Sickness
261363|NCT01668940|Lillipops Iced Soothies
261364|NCT01668940|Pregnancy
261365|NCT01668940|Obstetrics
261366|NCT01668914|Breast Cancer
261367|NCT01668914|Clinically Axillary Node -Positive
261368|NCT01668914|Sentinel Lymph Node Biopsy
261369|NCT01668914|Internal Mammary
261370|NCT01668901|warfarin
261371|NCT01668901|aspirin
261372|NCT01669993|Outcomes
261373|NCT01669993|Quality improvement
261374|NCT01669993|Patient Safety
261375|NCT01669993|PACU
261376|NCT01669993|Complications
261377|NCT01669993|Adverse events
261378|NCT01669993|Respiratory arrest
261379|NCT01669993|Pain
261380|NCT01669993|PONV
261381|NCT01669993|Age
261382|NCT01669993|Neonate
261383|NCT01669993|Infant
261384|NCT01669993|Child
261385|NCT01669993|Ambulatory
261386|NCT01669993|Inpatient
261387|NCT01669993|General Anesthesia
261388|NCT01669993|Otolaryngology
261389|NCT01669993|Tonsillectomy
261390|NCT01669993|Obstructive sleep apnea
261391|NCT01669980|Infections
261392|NCT01669980|Pediatrics
261393|NCT01669980|Teflaro
261394|NCT01669980|Ceftriaxone
261395|NCT01669980|cephalosporin
261396|NCT01669980|Vancomycin
261397|NCT01669980|Clindamycin
261398|NCT01669980|Amoxicillin Clavulanate
261399|NCT01669980|Linezolid
261400|NCT01669980|MRSA
261401|NCT01669980|pneumonia
261402|NCT01669954|HIV
261403|NCT01669954|Bone mineral density
261404|NCT01669954|Osteoporosis
261405|NCT01669954|Vitamin D
261406|NCT01669954|Fractures
261407|NCT01669941|Pregnancy
261408|NCT01669941|Plasmodium
261409|NCT01669941|Malaria
261410|NCT01669941|Prevention
261411|NCT01669941|Kenya
261412|NCT01669941|Piperaquine
261413|NCT01669941|Dihydroartemisinin-Piperaquine
261414|NCT01669941|Sulfadoxine Pyrimethamine
261415|NCT01669876|Randomized
261416|NCT01669876|Double-Blind
261417|NCT01669876|Dietary Supplements
261418|NCT01669863|ARDS
261419|NCT01669850|Chronic kidney disease
261420|NCT01669850|Arteriovenous fistula
261421|NCT01669850|Surgical anastomosis
261422|NCT01669850|Complications
261423|NCT01669850|Patency
261424|NCT01669850|Dialysis access
261425|NCT01669837|Inguinal hernia
261426|NCT01669837|Laparoscopy
261427|NCT01669837|Surgical tissue glue
261428|NCT01669811|Refractory Reflux Esophagitis,
261429|NCT01669811|Japanese,
261430|NCT01669811|Nexium,
261431|NCT01669811|twice daily,
261432|NCT01669811|oral administration
261433|NCT01669798|Recurrent epithelial ovarian carcinoma
261434|NCT01669798|Persistent epithelial ovarian carcinoma
261435|NCT01669798|Bevacizumab resistant epithelial ovarian carcinoma
261436|NCT01669746|Androgenetic Alopecia
261437|NCT01669746|Male Pattern Baldness
261438|NCT01669746|Female Pattern Baldness
261439|NCT01669746|Hair Loss
261440|NCT01669746|Baldness
261441|NCT01669733|Breast Surgery
261442|NCT01669733|Breast Biopsy
261443|NCT01669733|Music Therapy
261444|NCT01669720|Metastatic
261445|NCT01669720|Colorectal
261446|NCT01669720|Colorectal Cancer
261447|NCT01669720|Resected or Ablated Metastatic Colorectal Cancer
261448|NCT01669707|Endostar
261449|NCT01669707|advanced Non-small cell lung cancer
261450|NCT01669707|Continued Pumping into vein
261451|NCT01669707|Gemcitabine
261452|NCT01669707|Carboplatin
261453|NCT01669694|Pelvic Pain
261454|NCT01669694|Pelvic Floor Physical Therapy
261455|NCT01669694|Biomarkers
261456|NCT01669681|Severe asthma
261457|NCT01669681|Medical economic
261458|NCT01669681|care
261459|NCT01669681|Cost efficiency
261460|NCT01669681|CPAM
261461|NCT01669681|EQ5D
261462|NCT01669642|ketamine sedation
261463|NCT01669642|pediatric
261464|NCT01669642|abscess drainage
261465|NCT01669642|fracture reduction
261466|NCT01669616|Type 2 Diabetes
261467|NCT01669616|Adults 18 years and older
261468|NCT01669603|Common cold
261469|NCT01669577|predictors
261470|NCT01669577|trauma
261471|NCT01669577|mortality
261472|NCT01669564|Quality of Life
261473|NCT01669564|Tobacco Use Cessation
261474|NCT01669564|Physical Activity
261475|NCT01669538|Galantamine
261476|NCT01669538|Nicotine Bitartrate
261477|NCT01669538|Nicotine Tartrate
261478|NCT01669538|Nicotine dependence
261479|NCT01669538|Tobacco Dependence
261480|NCT01669512|Malaria vaccine
261481|NCT01669512|Matrix M
261482|NCT01669499|Bone metastases, radiotherapy, dexamethasone, pain flare
261483|NCT01669486|Pain
261484|NCT01669486|ICU
261485|NCT01669486|Mechanical ventilation
261486|NCT01669486|CPOT
261487|NCT01669486|BPS
261488|NCT01669473|Diabetes
261489|NCT01669447|dmri, mnvc, lucentis
261490|NCT01669434|Perioperative Period
261491|NCT01669421|Alpha 1
261492|NCT01669408|ischemic stroke
261493|NCT01669408|hemorrhagic stroke
261494|NCT01669408|prehospital cooling
261495|NCT01669408|induction of cooling
261496|NCT01669408|ambulance
261497|NCT01669408|emergency room
261498|NCT01669408|cold infusions
261499|NCT01669408|hypothermia
261500|NCT01669408|normothermia
261501|NCT01669395|Severe heart failure
261502|NCT01669395|Homebased rehabilitation
261503|NCT01669395|Physical exercise
261504|NCT01669395|Activities of daily living
261505|NCT01669395|Intersectoral Cooperation
261506|NCT01669382|AngioSeal, ExoSeal, PCI, puncture site
261507|NCT01669369|Lithium Carbonate
261508|NCT01669369|Chemotherapy
261509|NCT01669369|prognosis
261510|NCT01669356|malnutrition
261511|NCT01669356|parenteral supplement
261512|NCT01669356|rest metabolic rate
261513|NCT01669356|postoperative complications
261514|NCT01669343|Aromatase Inhibitors
261515|NCT01669330|Gastroesophageal Reflux
261516|NCT01669330|Fundoplication
261517|NCT01669330|Surgical Procedures
261518|NCT01669317|Cherry Juice Pilot
261519|NCT01669304|migraine variant
261520|NCT01669304|chronic dizziness
261521|NCT01669304|pharmacologic dissection
261522|NCT01669278|sheath
261523|NCT01669278|flexible
261524|NCT01669278|endoscopy
261525|NCT01669278|otolaryngology
261526|NCT01669278|office
261527|NCT01669265|Breast cancer
261528|NCT01669265|OSNA
261529|NCT01669265|sentinel lymph node
261530|NCT01669252|Breast cancer
261531|NCT01669252|Eribulin
261532|NCT01669252|Neoadjuvant
261533|NCT01669252|PAM50
261534|NCT01669252|Triple-negative
261535|NCT01669252|Luminal A
261536|NCT01669252|Luminal B
261537|NCT01669239|Breast Cancer
261538|NCT01669239|HER2 positive
261539|NCT01669239|Neoadjuvant
261540|NCT01669239|Liposomal doxorubicin
261541|NCT01669239|Paclitaxel
261542|NCT01669239|Trastuzumab
261543|NCT01669239|Pertuzumab
261544|NCT01669239|Safety
261545|NCT01669226|Ovarian Cancer
261546|NCT01669226|intraperitoneal chemotherapy
261547|NCT01669213|5-HT3 receptor antagonist
261548|NCT01669213|hypotension
261549|NCT01669213|spinal anesthesia
261550|NCT01669174|Chronic Obstructive Pulmonary Disease
261551|NCT01669174|COPD; cachexia; muscle wasting
261552|NCT01669161|Upper
261553|NCT01669161|Limb
261554|NCT01669161|Deficits
261555|NCT01669161|Rehabilitation
261556|NCT01669161|VNS
261557|NCT01669148|breast cancer
261558|NCT01669148|imaging
261559|NCT01669135|cerebral oximetry
261560|NCT01669135|cesarean delivery
261561|NCT01669109|Yoga
261562|NCT01669109|Colorectal Neoplasms
261563|NCT01669109|Quality of Life
261564|NCT01669109|Randomized Controlled Trial
261565|NCT01669096|adults
261566|NCT01669096|healthy
261567|NCT01669096|Tuberculosis vaccine
261568|NCT01669096|mRNA expression
261569|NCT01669096|HIV negative
261570|NCT01669083|Oxytocin Antagonist
261571|NCT01669083|Embryo/Blastocyst Implantation
261572|NCT01669070|bioavailability
261573|NCT01669070|Fluticasone Furoate
261574|NCT01669070|pharmacokinetics
261575|NCT01669070|dose proportionality
261576|NCT01669057|Congenital heart disease
261577|NCT01669057|DNA variation
261578|NCT01669057|methylation
261579|NCT01669057|risk factors
261580|NCT01669057|supplements
261581|NCT01669031|automated perimetry
261582|NCT01669031|visual fields
261583|NCT01669031|reliability
261584|NCT01669031|vision tests/standards
261585|NCT01669031|randomized controlled trial
261586|NCT01669031|false positive reactions
261587|NCT01669031|false negative reactions
261588|NCT01669031|fixation, ocular
261589|NCT01669031|mean deviation
261590|NCT01669031|variability
261591|NCT01669031|program
261592|NCT01669031|software
261593|NCT01669031|glaucoma/diagnosis
261594|NCT01669031|visual field tests/methods
261595|NCT01669031|aged
261596|NCT01669031|humans
261597|NCT01669031|female
261598|NCT01669031|male
261599|NCT01669031|prospective studies
261600|NCT01669031|reproducibility of results
261601|NCT01669005|neutropenia
261602|NCT01669005|multiplex PCR
261603|NCT01669005|infection
261604|NCT01668992|Parenting
261605|NCT01668992|Discipline
261606|NCT01668992|Family interventions
261607|NCT01668992|Thailand
261608|NCT01668992|Migration
261609|NCT01668875|head down postural drainage
261610|NCT01668849|Plant exosomes
261611|NCT01668849|Grape exosomes
261612|NCT01668849|Grape extract
261613|NCT01668849|Oral mucositis
261614|NCT01668849|Head and Neck Cancer
261615|NCT01668849|Immune response
261616|NCT01668836|sirtuin
261617|NCT01668836|atherosclerosis
261618|NCT01668836|longevity
261619|NCT01668836|calorie restriction
261620|NCT01668836|resveratrol
261621|NCT01668836|vascular reactivity
261622|NCT01668810|prescription
261623|NCT01668810|schizophrenia
261624|NCT01668810|depression
261625|NCT01668810|bipolar disorder
261626|NCT01668771|Self-Affirmation
261627|NCT01668771|Affect
261628|NCT01668771|Alcohol
261629|NCT01668758|Near Infrared Spectroscopy
261630|NCT01668758|Traumatic Brain Injury
261631|NCT01668745|Child mortality
261632|NCT01668745|Measles vaccine
261633|NCT01668745|Non-specific effects
261634|NCT01668693|Endometrial receptivity
261635|NCT01668693|recurrent implantation failure
261636|NCT01668693|predictor tool
261637|NCT01668693|ERA
261638|NCT01668693|customized microarray
261639|NCT01668693|personalized embryo transfer
261640|NCT01668680|Metronomic Chemotherapy
261641|NCT01668680|Anti-Angiogenic
261642|NCT01668680|Maintenance Treatment
261643|NCT01668680|Colorectal Cancer Metastatic
261644|NCT01668667|gabapentin enacarbil
261645|NCT01668667|Horizant
261646|NCT01668654|Epilepsy
261647|NCT01668654|Partial Onset epilepsy
261648|NCT01668654|Lennox-Gastaut Syndrome
261649|NCT01668654|Open-label extension study
261650|NCT01668641|Methotrexate insufficient responders
261651|NCT01668628|quality of life
261652|NCT01668628|depression
261653|NCT01668628|BCM (body composition minitor)
261654|NCT01668628|hydrational status
261655|NCT01668615|idiopathicthrombocytopenic purpura
261656|NCT01668615|all-trans retinoic acid
261657|NCT01668615|regulory T cells
261658|NCT01668576|mesenchymal stem cells
261659|NCT01668576|Lung transplantation
261660|NCT01668563|Aneurysm
261661|NCT01668563|Intracranial Aneurysm
261662|NCT01668563|Vascular Diseases
261663|NCT01668563|Cardiovascular Diseases
261664|NCT01668563|Intracranial Arterial Diseases
261665|NCT01668563|Cerebrovascular Disorders
261666|NCT01668563|Brain Diseases
261667|NCT01668563|Central Nervous System Diseases
261668|NCT01668563|Nervous System Diseases
261669|NCT01668550|Phase I
261670|NCT01668550|Src/Abl inhibitor
261671|NCT01668550|Solid Tumours
261672|NCT01668550|Cancer
261673|NCT01668511|Immunogenicity
261674|NCT01668511|Safety
261675|NCT01668511|Tolerability
261676|NCT01668511|Osteoarthritis
261677|NCT01668511|Pharmacokinetics
261678|NCT01668498|Can preemptive treatment of panitumumab mediated skin
261679|NCT01668498|toxicity with oral doxycycline be replaced by local treatment with erythromycin?
261680|NCT01668498|Panitumumab
261681|NCT01668485|Type 1 diabetes mellitus
261682|NCT01668485|hypoglycemia counterregulation,
261683|NCT01668485|pancreatic islet transplantation
261684|NCT01668472|Pregnant
261685|NCT01668472|leaking fluid
261686|NCT01668459|Transitional cell carcinoma
261687|NCT01668459|Bladder cancer
261688|NCT01668459|Cancer
261689|NCT01668459|Oncology
261690|NCT01668459|Cabazitaxel
261691|NCT01668446|Sildenafil
261692|NCT01668446|Endometrial thickness
261693|NCT01668446|Frozen embryo transfer
261694|NCT01668446|ultrasonographic endometrial thickness
261695|NCT01668446|endometrial pattern
261696|NCT01668446|Implantation rate
261697|NCT01668446|chemical pregnancy rate
261698|NCT01668433|G6PD
261699|NCT01668433|Primaquine
261700|NCT01668433|Methylene blue
261701|NCT01668420|thermal stimulation
261702|NCT01668420|lower extremity
261703|NCT01668420|temperature
261704|NCT01668420|efficacy
261705|NCT01668407|Parkinson's disease
261706|NCT01668407|PSP
261707|NCT01668407|Robot
261708|NCT01668407|Gait rehabilitation
261709|NCT01668381|hepatocellular carcinoma
261710|NCT01668381|Catheter Ablation
261711|NCT01668381|T-Lymphocytes, Regulatory
261712|NCT01668381|IL-10
261713|NCT01668381|TGF-β
261714|NCT01668381|IFN-γ
261715|NCT01668368|ARDS
261716|NCT01668368|Esophageal pressure
261717|NCT01668368|pleural pressure
261718|NCT01668368|pulmonary compliance
261719|NCT01668355|Delivery of Healthcare
261720|NCT01668355|Health Services Research
261721|NCT01668355|Integrated Healthcare Systems
261722|NCT01668355|Healthcare Quality, Access, and Evaluation
261723|NCT01668329|Septic shock
261724|NCT01668329|Inflammatory process
261725|NCT01668329|Cytokines
261726|NCT01668329|Hormonal response
261727|NCT01668329|Oxydative stress
261728|NCT01668316|Overweight
261729|NCT01668316|Obese
261730|NCT01668316|Postpartum
261731|NCT01668316|Weight loss
261732|NCT01668316|Inflammation
261733|NCT01668316|Obesity
261734|NCT01668316|Cardiovascular
261735|NCT01668303|juvenile drug court
261736|NCT01668303|adolescents
261737|NCT01668303|substance abuse
261738|NCT01668303|delinquency
261739|NCT01668303|family therapy
261740|NCT01668303|multidimensional family therapy
261741|NCT01668290|Coronary Artery Disease
261742|NCT01668290|Stress Echocardiography
261743|NCT01668290|Single Photon Emission Computed Tomography
261744|NCT01668290|Cardiac Computed Tomographic Angiography
261745|NCT01668290|outcomes
261746|NCT01668277|Pulmonary Hypertensive Crisis
261747|NCT01668277|Pediatrics
261748|NCT01668277|Hypertonic Saline
261749|NCT01668264|Pediatrics
261750|NCT01668264|Congenital Heart Disease
261751|NCT01668264|Diastolic Function
261752|NCT01668264|Echocardiograph
261753|NCT01668264|MRI
261754|NCT01668251|Turner syndrome
261755|NCT01668251|Diagnosis, prenatal
261756|NCT01668238|Thyroid tumor
261757|NCT01668238|Breast tumor
261758|NCT01668238|Fourier Transform Infrared Spectrometry
261759|NCT01668238|Tumor Diagnosis
261760|NCT01668186|Peroxisome biogenesis disorders
261761|NCT01668186|PBD
261762|NCT01668186|Zellweger spectrum
261763|NCT01668186|Rhizomelic chondrodysplasia punctata
261764|NCT01668186|RCDP
261765|NCT01668173|HSP90 Inhibitor
261766|NCT01668173|AUY922
261767|NCT01668173|12-076
261768|NCT01668160|clinical outcomes
261769|NCT01668160|radiographic outcomes
261770|NCT01668160|total hip arthroplasty
261771|NCT01668160|survivorship
261772|NCT01668147|PET Imaging
261773|NCT01668147|Efavirenz
261774|NCT01668147|Ritonavior
261775|NCT01668147|[11C] desmethyl-loperamide
261776|NCT01668147|Healthy volunteers
261777|NCT01668108|carcinoma
261778|NCT01668108|breast cancer
261779|NCT01668108|non-small cell lung cancer
261780|NCT01668108|ovarial cancer
261781|NCT01668108|ambulant chemotherapy
261782|NCT01668108|treatment cycles
261783|NCT01668108|Paclitaxel
261784|NCT01668108|Paclitaxel onkovis
261785|NCT01668108|Quantity of Paclitaxel
261786|NCT01668108|Packaging Sizes
261787|NCT01668082|Patients with newly identified brain mass
261788|NCT01668069|nausea
261789|NCT01668069|vomiting
261790|NCT01668069|pregnancy
261791|NCT01668069|ondansetron
261792|NCT01668069|doxylamine
261793|NCT01668069|vitamin B6
261794|NCT01668069|pyridoxine
261795|NCT01668056|in vitro fertilization
261796|NCT01668056|ovarian stimulation
261797|NCT01668056|follicular waves
261798|NCT01668056|luteal phase
261799|NCT01668043|HIV-1
261800|NCT01668043|CD4
261801|NCT01668043|antibody
261802|NCT01668043|immunotherapy
261803|NCT01668030|Facial
261804|NCT01668030|Partial thickness
261805|NCT01668017|Advanced solid tumors
261806|NCT01668017|Hepatocellular carcinoma
261807|NCT01668017|cancer, liver
261808|NCT01667991|Colonization
261809|NCT01667991|infection
261810|NCT01667991|multidrug-resistant bacteria
261811|NCT01667991|guideline
261812|NCT01667978|contraception
261813|NCT01667978|mini pill
261814|NCT01667978|norethindrone
261815|NCT01667978|atazanavir
261816|NCT01667978|ritonavir
261817|NCT01667978|norvir
261818|NCT01667978|reyataz
261819|NCT01667978|pregnancy prevent
261820|NCT01667978|birth control
261821|NCT01667978|HIV
261822|NCT01667978|AIDS
261823|NCT01667978|antiviral
261824|NCT01667978|antiretroviral
261825|NCT01667965|palliative radiation
261826|NCT01667965|12-172
261827|NCT01667952|Family History Questionnaire (FHQ)
261828|NCT01667952|Blood sample
261829|NCT01667952|Salvia sample
261830|NCT01667952|12-145
261831|NCT01667939|adequacy
261832|NCT01667939|diet
261833|NCT01667939|pregnancy
261834|NCT01667913|Hip Fracture
261835|NCT01667913|6-minutes walking test
261836|NCT01667913|Reliability
261837|NCT01667887|Far Cortical Locking
261838|NCT01667887|Distal Femur Fracture
261839|NCT01667887|Locking Plate
261840|NCT01667887|MotionLoc
261841|NCT01667887|Fracture Fixation
261842|NCT01667874|Randomized controlled trial
261843|NCT01667874|early joint infection
261844|NCT01667874|gentamicin impregnated sponges
261845|NCT01667861|Glaucoma
261846|NCT01667861|Wind instruments
261847|NCT01667848|pain
261848|NCT01667835|yoga
261849|NCT01667835|postmenopausal, sedentary South Asian women
261850|NCT01667796|Multiple sclerosis
261851|NCT01667796|Healthy controls
261852|NCT01667796|Pharmacokinetics
261853|NCT01667796|Vitamin D
261854|NCT01667783|Obesity
261855|NCT01667783|Diabetes
261856|NCT01667757|coronary atherosclerosis
261857|NCT01667757|drug eluting stent
261858|NCT01667757|intravascular ultrasound
261859|NCT01667757|fractional flow reserve
261860|NCT01667744|Angina
261861|NCT01667744|Acute Coronary Syndrome
261862|NCT01667744|Emotional Distress
261863|NCT01667744|Citalopram
261864|NCT01667744|Health Care Utilization
261865|NCT01667731|Hepatitis C
261866|NCT01667731|Chronic
261867|NCT01667731|HCV
261868|NCT01667731|HIV
261869|NCT01667731|Human Immunodeficiency Virus
261870|NCT01667731|Co-Infected
261871|NCT01667718|eradication
261872|NCT01667718|helicobacter pylori
261873|NCT01667718|bismuth
261874|NCT01667705|Stress
261875|NCT01667705|Anxiety
261876|NCT01667705|Skyceiling
261877|NCT01667705|Nature
261878|NCT01667692|H-pylori
261879|NCT01667692|eradication
261880|NCT01667692|azithromycin
261881|NCT01667692|clarithromycin
261882|NCT01667679|Migraine
261883|NCT01667679|Headaches
261884|NCT01667679|Sumatriptan
261885|NCT01667666|trauma
261886|NCT01667666|acute lung injury
261887|NCT01667666|adult respiratory distress syndrome
261888|NCT01667640|Brain metastases
261889|NCT01667640|radiation
261890|NCT01667640|sector
261891|NCT01667640|singular
261892|NCT01667640|solitary
261893|NCT01667640|neurocognition
261894|NCT01667627|IBS
261895|NCT01667627|Probiotic
261896|NCT01667627|hs-CRP
261897|NCT01667627|Cholinergic status
261898|NCT01667627|Micro-inflammation
261899|NCT01667601|mindfulness-based program
261900|NCT01667601|Psychoeducation
261901|NCT01667601|schizophrenia
261902|NCT01667601|Chinese
261903|NCT01667601|outpatients
261904|NCT01667588|Chronic Kidney Disease (CKD)
261905|NCT01667588|Pediatrics
261906|NCT01667588|Sleep Disorders
261907|NCT01667549|Breastfeeding
261908|NCT01667549|Flavor learning
261909|NCT01667549|Mother
261910|NCT01667549|Moms
261911|NCT01667549|Infants
261912|NCT01667549|Babies
261913|NCT01667549|Baby
261914|NCT01667549|Food Habits
261915|NCT01667549|Fruits
261916|NCT01667549|Vegetables
261917|NCT01667536|PROSTATE CANCER
261918|NCT01667536|HIGH-RISK
261919|NCT01667536|PROSTATECTOMY SURGERY
261920|NCT01667536|NEWLY DIAGNOSED
261921|NCT01667523|capsaicin
261922|NCT01667523|cinnamaldehyde
261923|NCT01667510|Prehypertension
261924|NCT01667510|anti oxidation
261925|NCT01667510|lycopene
261926|NCT01667497|Cognitive fatigue
261927|NCT01667497|multiple sclerosis
261928|NCT01667484|Cognitive Impairment
261929|NCT01667484|Multiple Sclerosis
261930|NCT01667484|Processing Speed
261931|NCT01667484|Treatment
261932|NCT01667445|total knee arthroplasty
261933|NCT01667445|epimorph
261934|NCT01667445|analgesia
261935|NCT01667406|kisspeptin
261936|NCT01667406|infertility
261937|NCT01667406|in vitro fertilisation
261938|NCT01667354|Parental Childhood Vaccine Hesitancy
261939|NCT01667341|HSV
261940|NCT01667341|Herpes
261941|NCT01667341|genital infection
261942|NCT01667341|vaccine
261943|NCT01667328|Anxiety
261944|NCT01667328|Presurgical anxiety
261945|NCT01667328|Breast Cancer
261946|NCT01667302|NK/T-cell lymphoma
261947|NCT01667302|Radiotherapy
261948|NCT01667302|Adjuvant chemotherapy
261949|NCT01667289|NK/T-cell lymphoma
261950|NCT01667289|Methotrexate
261951|NCT01667289|Radiotherapy
261952|NCT01667289|Concurrent chemoradiation
261953|NCT01667276|AE adverse event
261954|NCT01667276|AIDS acquired immunodeficiency syndrome
261955|NCT01667276|ALT (SGPT) alanine aminotransferase
261956|NCT01667276|ART antiretroviral therapy
261957|NCT01667276|AST (SGOT) aspartate aminotransferase
261958|NCT01667276|DCF data collection forms
261959|NCT01667276|DMC Data Monitoring Committee
261960|NCT01667276|FDA (U.S.) Food and Drug Administration
261961|NCT01667276|GCP Good Clinical Practice guidelines
261962|NCT01667276|HB sAg Hepatitis B surface antigen
261963|NCT01667276|ICH International Conference of Harmonisation
261964|NCT01667276|IND Investigational New Drug Application
261965|NCT01667276|IRB Institutional Review Board
261966|NCT01667276|IU international units
261967|NCT01667276|mg milligram(s)
261968|NCT01667276|mm3 cubic millimeter(s)
261969|NCT01667276|PCR polymerase chain reaction
261970|NCT01667276|SAE serious adverse event
261971|NCT01667276|µg microgram
261972|NCT01667276|ULN upper limit of the normal range
261973|NCT01667276|WB Western Blot
261974|NCT01667263|all-trans retinoid acid
261975|NCT01667263|primary immune thrombocytopenia
261976|NCT01667263|corticosteroid-resistant
261977|NCT01667263|refractory
261978|NCT01667263|danazol
261979|NCT01667250|vagus nerve stimulation
261980|NCT01667250|vagal nerve stimulation
261981|NCT01667250|nVNS
261982|NCT01667250|VNS
261983|NCT01667250|chronic migraine
261984|NCT01667250|migraine
261985|NCT01667250|non invasive
261986|NCT01667250|gammacore
261987|NCT01667237|Pulmonary rehabilitation program
261988|NCT01667237|Lung cancer
261989|NCT01667237|Lung resection surgery
261990|NCT01667237|Home-based
261991|NCT01667224|Actiponin
261992|NCT01667224|Obesity
261993|NCT01667224|Abdominal fat
261994|NCT01667211|Advanced uterine cervical cancer
261995|NCT01667185|pediatric
261996|NCT01667185|diabetes mellitus
261997|NCT01667159|Depression
261998|NCT01667159|Alcohol Use
261999|NCT01667159|Outpatient Therapy
262000|NCT01667133|Leukemia
262001|NCT01667133|Leukemia, Myeloid
262002|NCT01667133|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
262003|NCT01667133|Neoplasms by Histologic Type
262004|NCT01667133|Neoplasms
262005|NCT01667133|Lymphoproliferative Disorders
262006|NCT01667133|Lymphatic Diseases
262007|NCT01667133|Immunoproliferative Disorders
262008|NCT01667133|Immune System Diseases
262009|NCT01667133|Myeloproliferative Disorders
262010|NCT01667133|Bone Marrow Diseases
262011|NCT01667133|Hematologic Diseases
262012|NCT01667120|Ketorolac
262013|NCT01667120|postoperative pain
262014|NCT01667120|bleeding events
262015|NCT01667094|Pulmonary exacerbation
262016|NCT01667094|Continuous infusion
262017|NCT01667094|Antipseudomonal beta-lactams
262018|NCT01667068|Cardiac Diseases
262019|NCT01667068|HIV-Infection
262020|NCT01667068|AIDS
262021|NCT01667068|Antiretroviral Therapy
262022|NCT01667068|Cardiovascular Medication
262023|NCT01667068|Risk Factors
262024|NCT01667068|coronary heart disease
262025|NCT01667068|heart failure
262026|NCT01667068|metabolic syndrome
262027|NCT01667055|drug allergy
262028|NCT01667055|drug hypersensitivity
262029|NCT01667055|beta-lactam allergy
262030|NCT01667055|penicillin allergy
262031|NCT01667055|adverse drug reaction
262032|NCT01667042|Scleroderma Lung
262033|NCT01667042|Gastroesophageal Reflux
262034|NCT01667042|Microaspiration
262035|NCT01667042|Cough
262036|NCT01667016|International
262037|NCT01667016|Multicenter
262038|NCT01667016|Observational registry
262039|NCT01667016|Orsiro Drug Eluting Stent (DES)
262040|NCT01667016|Stenting
262041|NCT01667016|Treatment of Coronary Artery Disease
262042|NCT01667016|Coronary revascularization
262043|NCT01667016|Percutaneous Coronary Intervention
262044|NCT01667016|STEMI
262045|NCT01667016|NSTEMI
262046|NCT01667016|Ischemia
262047|NCT01667016|Angina
262048|NCT01667016|Subgroups
262049|NCT01667016|Acute Myocardial Infarction
262050|NCT01667016|Diabetes
262051|NCT01667016|Small Vessels
262052|NCT01667016|Chronic Total Occlusion (CTO)
262053|NCT01667003|International
262054|NCT01667003|Multicenter
262055|NCT01667003|Observational registry
262056|NCT01667003|Orsiro Drug Eluting Stent (DES)
262057|NCT01667003|Stenting
262058|NCT01667003|Treatment of Coronary Artery Disease
262059|NCT01667003|Coronary revascularization
262060|NCT01667003|Percutaneous Coronary Intervention
262061|NCT01667003|STEMI
262062|NCT01667003|NSTEMI
262063|NCT01667003|Ischemia
262064|NCT01667003|Angina
262065|NCT01667003|Subgroups
262066|NCT01667003|Acute Myocardial Infarction
262067|NCT01667003|Diabetes
262068|NCT01667003|Small Vessels
262069|NCT01666990|Tripterygium wilfordii Hook F (TwHF)
262070|NCT01666990|HIV
262071|NCT01666990|CD4
262072|NCT01666990|immune over-activation
262073|NCT01666964|Traumatic brain injury
262074|NCT01666964|hypopituitarism
262075|NCT01666938|Diabetes Mellitus
262076|NCT01666938|Telephone
262077|NCT01666938|Physical activity
262078|NCT01666912|adolescence
262079|NCT01666912|contraception
262080|NCT01666912|postpartum
262081|NCT01666912|rapid repeat pregnancy
262082|NCT01666873|osteoarthritis
262083|NCT01666860|anterior lumbar interbody fusion
262084|NCT01666847|Umbilical Cord Milking
262085|NCT01666847|Extremely Low Birth Weight Infant (ELBW)
262086|NCT01666834|mechanical ventilation, ARDS, Ventilator strategy, outcome
262087|NCT01666821|macular degeneration; choroidal neovascularization
262088|NCT01666782|Influenza vaccine
262089|NCT01666782|Oncology
262090|NCT01666782|Chemotherapy
262091|NCT01666769|Extracorporeal membrane oxygenation
262092|NCT01666769|ECMO
262093|NCT01666769|Extracorporeal life support
262094|NCT01666769|Micafungin
262095|NCT01666769|Mycamine
262096|NCT01666769|Pharmacokinetics
262097|NCT01666743|Community-Acquired Pneumonia
262098|NCT01666743|Lung
262099|NCT01666743|Adult
262100|NCT01666743|Infections
262101|NCT01666691|Obese
262102|NCT01666691|Obesity
262103|NCT01666691|Overweight
262104|NCT01666691|Weight loss
262105|NCT01666691|Weight reduction
262106|NCT01666691|Beloranib
262107|NCT01666678|Bioequivalence
262108|NCT01666665|Burn
262109|NCT01666652|Dengue
262110|NCT01666652|Dengue fever
262111|NCT01666652|Dengue Hemorrhagic Fever
262112|NCT01666652|Flavivirus
262113|NCT01666626|crohn's disease
262114|NCT01666626|ultrasound
262115|NCT01666626|intestinal fibrosis
262116|NCT01666626|shear wave imaging
262117|NCT01666626|acoustic radiation force impulse
262118|NCT01666613|Phase I, Healthy volunteers, pharmacokinetics
262119|NCT01666613|Bioavailability
262120|NCT01666613|AUC
262121|NCT01666548|haemolytic uraemic syndrome
262122|NCT01666548|complications of HUS
262123|NCT01666548|renal replacement treatment
262124|NCT01666548|renal function outcome
262125|NCT01666548|neuropsychological sequelae
262126|NCT01666548|psychological adjustment
262127|NCT01666548|quality of life
262128|NCT01666535|Influenza vaccine
262129|NCT01666535|Immune response
262130|NCT01666535|Remicade (infliximab)
262131|NCT01666535|Inflammatory bowel disease
262132|NCT01666522|sarcopenia
262133|NCT01666522|osteopenia/osteoporosis
262134|NCT01666522|older adults
262135|NCT01666522|vitamin D supplementation
262136|NCT01666522|physical activity
262137|NCT01666496|Adolescent
262138|NCT01666496|risk
262139|NCT01666496|HIV
262140|NCT01666496|video games
262141|NCT01666483|hysterectomy
262142|NCT01666483|single-port
262143|NCT01666483|micro-laparoscopy
262144|NCT01666470|Quality of life
262145|NCT01666457|Supporting Oral Feeding in Fragile Infants (SOFFI)
262146|NCT01666457|Infant Oral Feeding
262147|NCT01666457|Infant Growth
262148|NCT01666457|Preterm infant oral feeding
262149|NCT01666457|Preterm infant growth
262150|NCT01666457|Neonatal Intensive Care Unit (NICU)
262151|NCT01666444|recurrent epithelial ovarian cancer
262152|NCT01666444|recurrent fallopian tube cancer
262153|NCT01666444|recurrent primary peritoneal cavity cancer
262154|NCT01666444|ovarian serous cystadenocarcinoma
262155|NCT01666444|ovarian endometrioid adenocarcinoma
262156|NCT01666444|ovarian mucinous cystadenocarcinoma
262157|NCT01666444|ovarian undifferentiated adenocarcinoma
262158|NCT01666444|ovarian clear cell cystadenocarcinoma
262159|NCT01666444|ovarian mixed epithelial carcinoma
262160|NCT01666444|Brenner tumor
262161|NCT01666405|Fecal Incontinence
262162|NCT01666405|Bowel Incontinence
262163|NCT01666392|Omega-3 fatty acid
262164|NCT01666392|Fish oil
262165|NCT01666392|Muscle mass
262166|NCT01666392|Muscle strength
262167|NCT01666392|Older adults
262168|NCT01666392|Circulating inflammatory cytokines
262169|NCT01666392|Skeletal muscle mass
262170|NCT01666392|Upper body strength
262171|NCT01666392|Lower body strength
262172|NCT01666379|Hallux valgus
262173|NCT01666379|Forefoot
262174|NCT01666379|transdermal fentanyl
262175|NCT01666340|Exercise
262176|NCT01666340|Elderly
262177|NCT01666340|Mortality
262178|NCT01666340|Morbidity
262179|NCT01666340|Prognosis
262180|NCT01666340|Longevity
262181|NCT01666327|Crohn's Disease
262182|NCT01666327|Ulcerative Colitis
262183|NCT01666314|castrate resistant prostate cancer,
262184|NCT01666314|CRPC,
262185|NCT01666314|orteronel,
262186|NCT01666314|TAK-700
262187|NCT01666301|Erythropoietin stimulating agents
262188|NCT01666301|Hemoglobin
262189|NCT01666301|Reticulocytes
262190|NCT01666301|Variability
262191|NCT01666262|FLU
262192|NCT01666262|H1N1
262193|NCT01666262|GPO
262194|NCT01666262|PLAIV
262195|NCT01666249|FMH; anti-Rh; efficacy
262196|NCT01666236|Age-Related Macular Degeneration
262197|NCT01666236|Pigment Epithelial Detachment
262198|NCT01666236|Polypoidal Choroidal Vasculopathy
262199|NCT01666223|Type 2 diabetes
262200|NCT01666223|GLP-1
262201|NCT01666223|Bile acid
262202|NCT01666223|TGR-5
262203|NCT01666197|Acute Joint Pain
262204|NCT01666184|Biomarkers study
262205|NCT01666171|estrogen receptor-negative breast cancer
262206|NCT01666171|progesterone receptor-negative breast cancer
262207|NCT01666171|stage IB breast cancer
262208|NCT01666171|stage II breast cancer
262209|NCT01666171|stage IIIA breast cancer
262210|NCT01666171|stage IIIC breast cancer
262211|NCT01666145|Hepatocellular Cancer
262212|NCT01666145|Hepatocellular Carcinoma
262213|NCT01666145|Hepatoma
262214|NCT01666145|Liver Cancer, Adult
262215|NCT01666145|Liver Cell Carcinoma, Adult
262216|NCT01666132|LVEF < 40%
262217|NCT01666119|Opioid dependence
262218|NCT01666119|Suboxone
262219|NCT01666119|addiction
262220|NCT01666119|BEMA Buprenorphine NX
262221|NCT01666119|oral transmucosal
262222|NCT01666093|peripheral artery disease
262223|NCT01666093|endovascular procedure
262224|NCT01666093|non-healing ulcer
262225|NCT01666080|second stem cell transplant
262226|NCT01666080|donor hematopoietic engraftment
262227|NCT01666080|hematopoietic stem cell transplantation
262228|NCT01666080|inherited metabolic disorder
262229|NCT01666067|insulin resistance
262230|NCT01666054|Weaning
262231|NCT01666054|mechanical ventilation
262232|NCT01666054|Proportional Assist Ventilation
262233|NCT01666041|insulin resistance
262234|NCT01666028|Type 1 Diabetes
262235|NCT01666028|Closed Loop glucose control
262236|NCT01666028|Artificial Pancreas
262237|NCT01666028|CSII
262238|NCT01666028|CGM
262239|NCT01666015|pediatric
262240|NCT01666015|exercise
262241|NCT01666015|hematopoietic stem cell transplantation
262242|NCT01666015|cancer
262243|NCT01666015|quality of life
262244|NCT01666015|immune system
262245|NCT01666015|physical activity levels
262246|NCT01665937|liver cancer
262247|NCT01665937|advanced liver cancer
262248|NCT01665937|advanced hepatocellular cancer
262249|NCT01665911|Caries
262250|NCT01665898|cold biopsy forceps
262251|NCT01665898|cold snare biopsy
262252|NCT01665885|hypothermia
262253|NCT01665885|induction of hypothermia
262254|NCT01665885|non invasive cooling
262255|NCT01665885|external cooling
262256|NCT01665885|surface cooling
262257|NCT01665885|endovascular cooling
262258|NCT01665885|cooling catheter
262259|NCT01665885|stroke
262260|NCT01665885|shivering
262261|NCT01665885|neuro monitoring
262262|NCT01665885|coagulation
262263|NCT01665872|Mothers
262264|NCT01665872|Depression
262265|NCT01665872|Stress
262266|NCT01665872|Trauma
262267|NCT01665872|Public Housing
262268|NCT01665859|readmission
262269|NCT01665859|recurrence
262270|NCT01665859|umbilical
262271|NCT01665859|epigastric
262272|NCT01665859|hernia
262273|NCT01665859|outcome
262274|NCT01665859|morbidity
262275|NCT01665846|HIV associated neurocognitive disorders
262276|NCT01665846|MRI
262277|NCT01665846|Ferumoxytol
262278|NCT01665833|Angina
262279|NCT01665833|SYNTAX
262280|NCT01665833|Coronary
262281|NCT01665833|PCI
262282|NCT01665833|CABG
262283|NCT01665820|chest
262284|NCT01665820|pathology
262285|NCT01665807|influenza
262286|NCT01665807|vaccine
262287|NCT01665807|administration
262288|NCT01665781|Hemoglobin
262289|NCT01665781|Erythropoietin
262290|NCT01665781|Acute Mountain sickness
262291|NCT01665742|Obesity
262292|NCT01665742|Chronic inflammation
262293|NCT01665742|Anti-inflammatory dietary intervention
262294|NCT01665742|Genetic susceptibility
262295|NCT01665729|etiology
262296|NCT01665729|pathogenesis
262297|NCT01665729|minor ischaemic stroke
262298|NCT01665729|types
262299|NCT01665729|intervention
262300|NCT01665703|[18F]
262301|NCT01665703|Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging
262302|NCT01665703|FDG-PET-MRI
262303|NCT01665703|Renal Cell Carcinoma
262304|NCT01665703|Pilot Study
262305|NCT01665703|LCCC 1213
262306|NCT01665703|UNC Lineberger
262307|NCT01665690|patient delivered partner therapy
262308|NCT01665690|expedited partner therapy
262309|NCT01665690|partner notification
262310|NCT01665690|gonorrhea
262311|NCT01665690|chlamydia
262312|NCT01665677|Graft vs Host Disease
262313|NCT01665677|GVHD
262314|NCT01665677|Allogeneic hematopoietic stem cell transplantation
262315|NCT01665677|HSCT
262316|NCT01665677|Atorvastatin
262317|NCT01665664|Indirect calorimetry
262318|NCT01665664|hypocaloric feeding
262319|NCT01665638|Healthy
262320|NCT01665638|Clearance
262321|NCT01665638|Canagliflozin
262322|NCT01665638|JNJ-28431754
262323|NCT01665638|Placebo
262324|NCT01665638|Somatostatin
262325|NCT01665638|C-peptide
262326|NCT01665625|Pancreatic cancer
262327|NCT01665625|Intra-arterial infusion
262328|NCT01665625|Gemcitabine
262329|NCT01665612|Contact lens
262330|NCT01665612|Care solution
262331|NCT01665612|MPDS
262332|NCT01665612|comfort
262333|NCT01665586|dexmedetomidine
262334|NCT01665586|sedation in elderly patient
262335|NCT01665586|spinal anesthesia
262336|NCT01665573|Fear Conditioning
262337|NCT01665573|Cannabinoids
262338|NCT01665573|Fear Response
262339|NCT01665560|smoking
262340|NCT01665560|fMRI
262341|NCT01665560|odors
262342|NCT01665560|taste
262343|NCT01665547|clomiphene resistant
262344|NCT01665547|pcos
262345|NCT01665547|induction of ovulation
262346|NCT01665547|l-carnitine
262347|NCT01665534|hypertension
262348|NCT01665534|inflammation
262349|NCT01665534|salt intake
262350|NCT01665521|Acute Coronary Syndrome
262351|NCT01665521|Chest pain
262352|NCT01665521|Risk Stratification
262353|NCT01665521|HEART Pathway
262354|NCT01665521|Emergency Department
262355|NCT01665508|angina
262356|NCT01665508|cardiopulmonary testing
262357|NCT01665508|metabolomics
262358|NCT01665508|nebivolol
262359|NCT01665495|pericardial effusion
262360|NCT01665495|cardiac tamponade
262361|NCT01665495|pericardiocentesis
262362|NCT01665495|pericardial drainage
262363|NCT01665495|prevention
262364|NCT01665482|Inflammation
262365|NCT01665482|Insulin sensitivity
262366|NCT01665482|Interleukin-6 (IL-6)
262367|NCT01665482|C-peptide
262368|NCT01665482|Saturated fatty acid (SFA)
262369|NCT01665482|Monounsaturated fatty acid (MUFA)
262370|NCT01665482|Carbohydrate (CARB)
262371|NCT01665469|anti oxidation
262372|NCT01665469|lycopene
262373|NCT01665469|Ox-LDL
262374|NCT01665456|complications
262375|NCT01665417|Icotinib
262376|NCT01665417|EGFR positive mutation
262377|NCT01665417|First-line treatment
262378|NCT01665417|Maintenance treatment
262379|NCT01665378|prepregnancy
262380|NCT01665378|micronutrient
262381|NCT01665378|supplementation
262382|NCT01665378|maternal
262383|NCT01665378|child
262384|NCT01665378|health
262385|NCT01665365|Myocardial infarction
262386|NCT01665365|Remote ischemic conditioning
262387|NCT01665365|Clinical outcome
262388|NCT01665339|preload
262389|NCT01665339|anthropometric measures
262390|NCT01665339|cardiovascular risk factors
262391|NCT01665326|Pompe disease
262392|NCT01665326|Glycogen Storage Disease Type II
262393|NCT01665326|Acid Maltase Deficiency
262394|NCT01665326|CRIM Status
262395|NCT01665326|Acid Alpha-Glucosidase Deficiency
262396|NCT01665326|Alglucosidase alfa
262397|NCT01665326|Myozyme
262398|NCT01665326|Enzyme replacement therapy
262399|NCT01665326|Immune Tolerance Induction
262400|NCT01665313|attention
262401|NCT01665300|myocardial deformation imaging
262402|NCT01665300|Trastuzumab
262403|NCT01665287|Cerebral Oximetry
262404|NCT01665287|Near infrared spectroscopy
262405|NCT01665287|Fullterm
262406|NCT01665287|Infant
262407|NCT01665274|xelox
262408|NCT01665274|advanced gastric cancer
262409|NCT01665261|Congenital heart disease
262410|NCT01665261|Newborn
262411|NCT01665261|Pulse oximetry
262412|NCT01665261|Screening
262413|NCT01665248|18-F Sodium Fluoride
262414|NCT01665248|Acute coronary syndrome
262415|NCT01665248|Stable Angina
262416|NCT01665196|IgG4-related disease
262417|NCT01665196|IgG4-RD
262418|NCT01665196|18F-FDG
262419|NCT01665196|PET/CT
262420|NCT01665183|argininosuccinate synthetase
262421|NCT01665183|arginine
262422|NCT01665183|arginine deiminase
262423|NCT01665170|Pascoflair
262424|NCT01665170|tsst
262425|NCT01665170|passiflora incarnata
262426|NCT01665170|non smoking male
262427|NCT01665170|and female volunteers
262428|NCT01665157|Diet Control before Colonoscopy
262429|NCT01665144|Secondary Progressive Multiple Sclerosis
262430|NCT01665118|Radio frequency
262431|NCT01665118|thigh
262432|NCT01665118|circumference
262433|NCT01665118|reduction
262434|NCT01665105|Pulse Rate Variability
262435|NCT01665105|Skin Blood Flow
262436|NCT01665105|Skin Temperature
262437|NCT01665105|Electroacupuncture
262438|NCT01665105|Zusanli
262439|NCT01665105|Yanglingquan
262440|NCT01665079|anaesthetics iv
262441|NCT01665079|propofol
262442|NCT01665079|pharmacokinetics
262443|NCT01665079|pharmacodynamic
262444|NCT01665053|Drug-Eluting Stents
262445|NCT01665040|neurostimulation
262446|NCT01665040|spinal cord stimulation
262447|NCT01665040|peripheral nerve stimulation
262448|NCT01665027|caesarean section,
262449|NCT01665027|vacuum,
262450|NCT01665027|fetal head extraction,
262451|NCT01665027|maternal complication,
262452|NCT01665027|fetal complication
262453|NCT01665014|autologous hematopoietic stem cell transplantation
262454|NCT01665014|total marrow irradiation
262455|NCT01665014|melphalan
262456|NCT01665014|multiple myeloma
262457|NCT01665001|Acute lymphoblastic leukemia
262458|NCT01665001|Induction
262459|NCT01665001|Consolidation
262460|NCT01665001|Minimal residual disease
262461|NCT01665001|Hematopoietic stem cell transplantation
262462|NCT01664975|Peripheral T-cell lymphoma;chemotherapy;
262463|NCT01664975|RR;PFS;OS
262464|NCT01664936|18F-FDG PET/CT scan
262465|NCT01664936|131I therapy
262466|NCT01664936|Cerenkov Luminescence Imaging
262467|NCT01664936|12-050
262468|NCT01664936|Lymphoma
262469|NCT01664936|Leukemia
262470|NCT01664936|Metastatic Lymph Nodes
262471|NCT01664923|prostate cancer
262472|NCT01664923|enzalutamide
262473|NCT01664923|MDV3100
262474|NCT01664910|Lymphoma
262475|NCT01664910|CD22 Positive-Lymphoid Malignancies
262476|NCT01664910|Leukemia
262477|NCT01664910|Allogeneic stem cell transplant
262478|NCT01664910|CMC-544
262479|NCT01664910|Inotuzumab Ozogamicin
262480|NCT01664910|Fludarabine
262481|NCT01664910|Fludarabine Phosphate
262482|NCT01664910|Fludara
262483|NCT01664910|Bendamustine
262484|NCT01664910|Bendamustine Hydrochloride
262485|NCT01664910|Bendamustine HCL
262486|NCT01664910|CEP-18083
262487|NCT01664910|SDX105
262488|NCT01664910|Treanda
262489|NCT01664910|G-CSF
262490|NCT01664910|Filgrastim
262491|NCT01664910|Neupogen
262492|NCT01664910|Methotrexate
262493|NCT01664910|Rituximab
262494|NCT01664910|Rituxan
262495|NCT01664910|Thymoglobulin
262496|NCT01664910|ATG
262497|NCT01664910|Antithymocyte Globulin
262498|NCT01664910|Tacrolimus
262499|NCT01664910|Prograf
262500|NCT01664897|Leukemia
262501|NCT01664897|Acute myeloid leukemia
262502|NCT01664897|AML
262503|NCT01664897|refractory
262504|NCT01664897|relapsed
262505|NCT01664897|Erlotinib
262506|NCT01664897|Erlotinib Hydrochloride
262507|NCT01664897|OSI-774
262508|NCT01664897|CP358774
262509|NCT01664897|Tarceva
262510|NCT01664884|INTERNALIZED STIGMA
262511|NCT01664884|INSIGHT
262512|NCT01664884|SOCIAL ADEQUACY
262513|NCT01664884|BIPOLAR DISORDER
262514|NCT01664884|SCHIZOPHRENIA
262515|NCT01664858|Coronary Heart Disease
262516|NCT01664858|Ischaemic Heart Disease
262517|NCT01664858|Angina
262518|NCT01664858|Cardiac Magnetic Resonance Imaging
262519|NCT01664845|hepatitis c
262520|NCT01664845|metformin
262521|NCT01664845|pegylated interferon
262522|NCT01664832|Premature Infants
262523|NCT01664832|snychronized ventilation
262524|NCT01664832|non-invasive ventilation
262525|NCT01664832|RDS
262526|NCT01664806|Electrosurgery
262527|NCT01664806|Radiofrequency energy
262528|NCT01664806|Monopolar instruments
262529|NCT01664806|Capacitive coupling
262530|NCT01664806|Thermal injury
262531|NCT01664806|Surgical complications
262532|NCT01664793|influenza
262533|NCT01664793|vaccination
262534|NCT01664793|strategies
262535|NCT01664793|children/adolescents
262536|NCT01664780|standard
262537|NCT01664780|values
262538|NCT01664780|share
262539|NCT01664780|wave velocity
262540|NCT01664780|in ARFI imaging
262541|NCT01664767|COPD
262542|NCT01664767|Thermal water
262543|NCT01664767|Oxidative stress
262544|NCT01664767|Inflammation
262545|NCT01664741|Nicotine dependence
262546|NCT01664741|cigarette
262547|NCT01664741|smoking
262548|NCT01664741|nicotine replacement therapy
262549|NCT01664741|positron emission tomography
262550|NCT01664728|Prostate neoplasms
262551|NCT01664728|Hormone refractory prostate cancer
262552|NCT01664728|Castration resistant prostate cancer
262553|NCT01664728|Castration refractory prostate cancer
262554|NCT01664728|Abiraterone acetate
262555|NCT01664728|CB7630
262556|NCT01664715|Overweight
262557|NCT01664715|Obesity
262558|NCT01664715|Exercise
262559|NCT01664715|Weight Loss
262560|NCT01664702|Dairy
262561|NCT01664702|obesity
262562|NCT01664676|liraglutide
262563|NCT01664676|victoza
262564|NCT01664676|GLP-1
262565|NCT01664676|kidney
262566|NCT01664676|diabetes
262567|NCT01664676|renal
262568|NCT01664676|diabetic nephropathy
262569|NCT01664663|Radiotherapy
262570|NCT01664663|Dose escalation
262571|NCT01664663|Normal tissue constraints
262572|NCT01664663|Locally advanced disease
262573|NCT01664663|Good performance status
262574|NCT01664650|menopause
262575|NCT01664650|pre-diabetes
262576|NCT01664637|diabetic gastroparesis
262577|NCT01664637|delayed gastric emptying
262578|NCT01664637|gastroparesis
262579|NCT01664637|diabetes mellitus, Type 1
262580|NCT01664637|diabetes mellitus, Type 2
262581|NCT01664624|Drug Therapy
262582|NCT01664611|Remote Ischaemic Conditioning
262583|NCT01664611|Remodeling
262584|NCT01664611|Heart Failure
262585|NCT01664611|Myocardial Infarction
262586|NCT01664611|Ischaemia/Reperfusion Injury
262587|NCT01664611|successful primary percutaneous coronary intervention following a first STEMI
262588|NCT01664585|headache
262589|NCT01664585|women
262590|NCT01664585|exercise
262591|NCT01664585|fear avoidance
262592|NCT01664585|physical activity
262593|NCT01664572|laser Doppler flowmetry, skin blood flow
262594|NCT01664559|intrauterine device
262595|NCT01664559|ketorolac
262596|NCT01664559|toradol
262597|NCT01664559|mirena
262598|NCT01664559|paragard
262599|NCT01664559|pain control
262600|NCT01664520|Subarachnoid hemorrhage
262601|NCT01664520|Dexmedetomidine
262602|NCT01664520|Autoregulation
262603|NCT01664520|Intracranial pressure
262604|NCT01664520|Cerebral oxygenation
262605|NCT01664507|croup, dose, epinephrine
262606|NCT01664273|electroporation
262607|NCT01664273|gen electrotransfer
262608|NCT01664273|muscle
262609|NCT01664273|plasmid AMEP
262610|NCT01664260|Posttraumatic Stress Disorder
262611|NCT01664260|N-acetylcysteine
262612|NCT01664260|Magnetic Resonance Imaging
262613|NCT01664234|infants with cleft palate
262614|NCT01664234|Pierre Robin
262615|NCT01664234|Treacher Collins
262616|NCT01664234|trisomy 21
262617|NCT01664221|subject
262618|NCT01664195|subjects
262619|NCT01664169|adenocarcinoma of the pancreas
262620|NCT01664169|recurrent pancreatic cancer
262621|NCT01664169|stage III pancreatic cancer
262622|NCT01664169|stage IV pancreatic cancer
262623|NCT01664169|stage IIB pancreatic cancer
262624|NCT01664156|Cold hypersensitivity
262625|NCT01664156|Korean red ginseng
262626|NCT01664156|Infrared thermography
262627|NCT01664156|Cold stress test
262628|NCT01664156|Distal-dorsal difference
262629|NCT01664091|tissue expander
262630|NCT01664091|acellular dermal matrix
262631|NCT01664078|Abdominal Aortic Aneurysm
262632|NCT01664065|Patient Safety
262633|NCT01664065|Tolerability
262634|NCT01664065|Pharmacokinetics
262635|NCT01664039|Glaucoma
262636|NCT01664039|Ocular hypertension
262637|NCT01664000|Tumors
262638|NCT01664000|carcinoma
262639|NCT01664000|apoptosis
262640|NCT01664000|p53
262641|NCT01664000|p21
262642|NCT01664000|Caspase3
262643|NCT01664000|PARP
262644|NCT01664000|MDM2
262645|NCT01664000|PUMA
262646|NCT01663974|Bipolar Disorders
262647|NCT01663974|Sub-syndromal symptoms
262648|NCT01663974|Acute depressive episode
262649|NCT01663974|Symptomatic remission
262650|NCT01663974|Functioning remission
262651|NCT01663961|Phase I
262652|NCT01663961|Pharmacokinetics
262653|NCT01663961|YM178 Oral Controlled Absorption System (OCAS)
262654|NCT01663961|Digoxin (Lanoxin)
262655|NCT01663961|DDI (Drug-drug interaction)
262656|NCT01663961|Open-label
262657|NCT01663961|Steady-state
262658|NCT01663961|subjects
262659|NCT01663948|Plastic bronchitis
262660|NCT01663948|PB
262661|NCT01663935|levodopa
262662|NCT01663935|Albinism
262663|NCT01663935|dopamine
262664|NCT01663935|oculocutaneous albinism
262665|NCT01663935|vision
262666|NCT01663935|retina function
262667|NCT01663909|Pain
262668|NCT01663909|Scoliosis
262669|NCT01663909|Rehabilitation
262670|NCT01663909|Cognitive-behavioral interventions
262671|NCT01663909|Adolescents
262672|NCT01663883|Blood flow autoregulation
262673|NCT01663883|optic nerve head blood flow
262674|NCT01663883|isometric exercise
262675|NCT01663883|Autoregulation
262676|NCT01663883|ocular physiology
262677|NCT01663870|Cancer Prevention
262678|NCT01663870|Breast cancer survivors
262679|NCT01663870|Cancer survivorship clinic
262680|NCT01663870|eHealth technology
262681|NCT01663870|Internet
262682|NCT01663870|HealthATM website
262683|NCT01663870|Questionnaire
262684|NCT01663870|Clinic stakeholders
262685|NCT01663870|Clinic nurses
262686|NCT01663870|Physicians
262687|NCT01663870|Case managers
262688|NCT01663870|Oncology patient navigators
262689|NCT01663870|Audio recorded interviews
262690|NCT01663844|Cognitive behavior therapy
262691|NCT01663844|Internet treatment
262692|NCT01663844|Self-help treatment
262693|NCT01663844|Insomnia
262694|NCT01663844|Depression
262695|NCT01663844|ICBT
262696|NCT01663844|CBT-i
262697|NCT01663844|CBT-d
262698|NCT01663831|Outdoor Malaria Transmission
262699|NCT01663831|Anopheles
262700|NCT01663831|Topical repellent
262701|NCT01663831|Early biting vector
262702|NCT01663831|Long Lasting Insecticidal Net (LLIN)
262703|NCT01663831|Cambodia
262704|NCT01663805|Extended Criteria Donor
262705|NCT01663805|Delayed Graft Function
262706|NCT01663805|DGF
262707|NCT01663805|Deceased donors aged ≥ 60 years
262708|NCT01663805|aged between 50 and 59 years
262709|NCT01663805|history of systemic hypertension
262710|NCT01663805|terminal creatinine levels > 1.5 mg/dL
262711|NCT01663805|death by a cerebrovascular accident
262712|NCT01663792|urokinase receptor
262713|NCT01663792|protein expression
262714|NCT01663792|seaweed (Undaria pinnatifida)
262715|NCT01663766|GVHD (acute or chronic)
262716|NCT01663766|acute myeloid or lymphoblastic leukemia (AML or ALL)
262717|NCT01663766|myelodysplastic syndrome
262718|NCT01663766|Chronic myelogenous leukemia (CML)
262719|NCT01663766|Multiple Myeloma (MM)
262720|NCT01663766|Non-Hodgekin lymphoma (NHL-both follicular & diffuse large cell)
262721|NCT01663766|Chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL)
262722|NCT01663753|2-fluoro-2-deoxy-d-glucose-positron emission tomography
262723|NCT01663753|Positron emission tomography
262724|NCT01663753|Magnetic resonance imaging
262725|NCT01663753|Diffusion weighted MRI
262726|NCT01663753|Squamous-cell cervical carcinoma
262727|NCT01663753|Sensitivity
262728|NCT01663714|Non-Hodgkin's Lymphoma
262729|NCT01663714|tositumomab and iodine I 131 tositumomab
262730|NCT01663714|Bexxar
262731|NCT01663714|cycolophosphamide, vacristine, and pednisone
262732|NCT01663701|Sepsis
262733|NCT01663701|Severe sepsis
262734|NCT01663701|Tuberculosis
262735|NCT01663701|Bundle
262736|NCT01663701|Zambia
262737|NCT01663675|Down syndrome
262738|NCT01663649|Depression
262739|NCT01663649|Online-Therapy
262740|NCT01663649|Deprexis
262741|NCT01663649|Self-help
262742|NCT01663636|vaccines
262743|NCT01663636|SMS
262744|NCT01663636|mobile phones
262745|NCT01663623|Wegener's Granulomatosis
262746|NCT01663623|anti-MPO
262747|NCT01663623|WG
262748|NCT01663623|Belimumab
262749|NCT01663623|GPA
262750|NCT01663623|anti-proteinase 3
262751|NCT01663623|anti-neutrophil cytoplasmic antibody
262752|NCT01663623|anti-myeloperoxidase
262753|NCT01663623|Granulomatosis with polyangiitis
262754|NCT01663623|Vasculitis
262755|NCT01663623|Autoimmune Diseases
262756|NCT01663623|Microscopic Polyangiitis
262757|NCT01663623|anti-PR3
262758|NCT01663623|ANCA
262759|NCT01663623|MPA
262760|NCT01663623|Systemic Vasculitis
262761|NCT01663584|Spinal Muscular Atrophy (SMA)
262762|NCT01663584|Carrier Screening
262763|NCT01663584|Genetic Testing
262764|NCT01663558|anal dysplasia
262765|NCT01663558|HPV
262766|NCT01663558|HIV
262767|NCT01663558|MSM
262768|NCT01663545|Epilepsy
262769|NCT01663545|Epileptic Focus
262770|NCT01663545|Inflammation
262771|NCT01663545|P-Glycoprotein
262772|NCT01663545|PET Imaging
262773|NCT01663532|Schizophrenia
262774|NCT01663519|Diabetic foot
262775|NCT01663519|Offloading
262776|NCT01663519|Prevention
262777|NCT01663519|Orthotics
262778|NCT01663467|tinnitus
262779|NCT01663467|smartphone
262780|NCT01663467|Web
262781|NCT01663441|Chemotherapy
262782|NCT01663441|Thrombocytopenia
262783|NCT01663441|Interleukin-11
262784|NCT01663441|Platelet
262785|NCT01663428|birth related brachial plexus injury
262786|NCT01663428|brachial plexus
262787|NCT01663428|splint
262788|NCT01663415|MDV3100
262789|NCT01663415|prostate
262790|NCT01663415|cancer
262791|NCT01663415|enzalutamide
262792|NCT01663389|mass balance
262793|NCT01663389|radiolabel
262794|NCT01663389|oral
262795|NCT01663389|IV
262796|NCT01663389|GSK1322322
262797|NCT01663389|healthy volunteer
262798|NCT01663389|antibiotic
262799|NCT01663363|refractive
262800|NCT01663363|LASIK
262801|NCT01663337|Posttraumatic Stress Disorder
262802|NCT01663337|PTSD
262803|NCT01663337|Alcohol Abuse
262804|NCT01663337|Alcohol Dependance
262805|NCT01663337|Alcoholism
262806|NCT01663337|Comorbid
262807|NCT01663337|Relapse Prevention (RP)
262808|NCT01663337|Cognitive Processing Therapy (CPT)
262809|NCT01663324|Tinnitus
262810|NCT01663324|chronic subjective Tinnitus
262811|NCT01663324|transcranial magnetic stimulation
262812|NCT01663324|rTMS
262813|NCT01663324|hearing disorders
262814|NCT01663311|rTMS
262815|NCT01663311|repetitive transcranial magnetic stimulation
262816|NCT01663311|chronic tinnitus
262817|NCT01663311|subjective tinnitus
262818|NCT01663311|double cone coil
262819|NCT01663298|DNA methylation
262820|NCT01663298|FGF2
262821|NCT01663298|Wound healing
262822|NCT01663298|Smoking
262823|NCT01663298|Diabetes
262824|NCT01663298|Implant
262825|NCT01663285|Urothelial
262826|NCT01663285|Bladder
262827|NCT01663285|Cancer
262828|NCT01663272|oncology
262829|NCT01663272|pancrease
262830|NCT01663233|Essential hypertension
262831|NCT01663233|High blood pressure
262832|NCT01663220|type 2 diabetes
262833|NCT01663220|beta cell function
262834|NCT01663220|meal tolerance test
262835|NCT01663220|maximum stimulation test
262836|NCT01663220|method standardization
262837|NCT01663220|insulin secretion
262838|NCT01663220|prediabetes
262839|NCT01663220|insulin sensitivity
262840|NCT01663207|type 2 diabetes
262841|NCT01663207|beta cell function
262842|NCT01663207|meal tolerance test
262843|NCT01663207|maximum stimulation test
262844|NCT01663207|method standardization
262845|NCT01663207|insulin secretion
262846|NCT01663207|prediabetes
262847|NCT01663207|insulin sensitivity
262848|NCT01663194|N/L ratio, STEMI, primary PCI, Long-term mortality
262849|NCT01663168|HIV
262850|NCT01663168|Tuberculosis
262851|NCT01663168|Rifabutin
262852|NCT01663168|HIV Protease Inhibitors
262853|NCT01663168|EARNEST trial
262854|NCT01663168|Randomized Controlled Trial
262855|NCT01663168|Pilot Projects
262856|NCT01663168|Second-line ART
262857|NCT01663168|Drug Toxicity
262858|NCT01663168|Pharmacokinetics
262859|NCT01663168|Drug Interactions
262860|NCT01663155|lung cancer
262861|NCT01663155|chest x-ray
262862|NCT01663155|CT scan
262863|NCT01663155|computer aided detection (CAD)
262864|NCT01663155|screening
262865|NCT01663155|smokers
262866|NCT01663142|Crohn's disease
262867|NCT01663142|gastrointestinal tract
262868|NCT01663129|Children
262869|NCT01663129|Osteoporosis
262870|NCT01663129|Vertebral Compression Fractures
262871|NCT01663129|Chronic Illness
262872|NCT01663129|Glucocorticoids
262873|NCT01663129|Bone Fragility
262874|NCT01663116|Rheumatoid arthritis
262875|NCT01663116|Expanded adipose derived allogeneic adult stem cells (eASCs)
262876|NCT01663103|Interleukin-1
262877|NCT01663103|Endothelium, Vascular
262878|NCT01663103|Vascular Stiffness
262879|NCT01663103|Oxidative Stress
262880|NCT01663103|Inflammation
262881|NCT01663103|Endothelial cells
262882|NCT01663090|Newly diagnosed
262883|NCT01663077|Clozapine
262884|NCT01663077|Schizophrenia
262885|NCT01663077|Remissia
262886|NCT01663077|polymorphism
262887|NCT01663064|Abdominal aortic aneurysm
262888|NCT01663064|Endovascular
262889|NCT01663064|Fenestration
262890|NCT01663064|Juxtarenal
262891|NCT01663064|Off-the-shelf
262892|NCT01663064|Pararenal
262893|NCT01663038|Clopidogrel
262894|NCT01663038|Aspirin
262895|NCT01663038|Combination
262896|NCT01663038|Pharmacokinetics
262897|NCT01663038|Phase 1
262898|NCT01663025|Randomised controlled trial
262899|NCT01663025|Pain
262900|NCT01663025|Anxiety
262901|NCT01663025|Ambulatory surgery
262902|NCT01663025|Hand massage
262903|NCT01663025|Local anaesthetic
262904|NCT01662973|Primary Biliary Cirrhosis
262905|NCT01662973|Mesenchymal Stem Cells
262906|NCT01662973|Serum alkaline phosphatase
262907|NCT01662973|Serum Bilirubin
262908|NCT01662960|stroke
262909|NCT01662960|hemiparesis
262910|NCT01662960|arm movement
262911|NCT01662960|sensory functioning
262912|NCT01662947|blood pressure
262913|NCT01662934|dysmenorrhea
262914|NCT01662934|transcutaneous electrical nerve stimulation
262915|NCT01662934|heat therapy
262916|NCT01662921|bolus treatment
262917|NCT01662895|Brain hemorrhage
262918|NCT01662895|Cerebral Hemorrhage
262919|NCT01662895|Deferoxamine
262920|NCT01662895|Hi-DEF Trial
262921|NCT01662856|Peripheral Vascular Surgery
262922|NCT01662856|Fibrin Sealant
262923|NCT01662856|Polytetrafluoroethylene (PTFE) grafts
262924|NCT01662843|Dyspnea
262925|NCT01662843|Ultrasonography
262926|NCT01662843|Emergencies
262927|NCT01662843|Critical Care
262928|NCT01662830|Obesity
262929|NCT01662830|Meal replacements
262930|NCT01662804|INTERLEUKIN 2
262931|NCT01662804|MAB 3F8
262932|NCT01662804|GD2-positive tumor
262933|NCT01662804|12-116
262934|NCT01662791|Parkinson's Disease
262935|NCT01662791|Small Bowel Bacterial Overgrowth
262936|NCT01662791|Weight Loss
262937|NCT01662791|Gastrointestinal
262938|NCT01662791|Rifaximin
262939|NCT01662778|Monodisperse aerosols
262940|NCT01662778|Asthmatics
262941|NCT01662778|Pharmacokinetics
262942|NCT01662778|AMP Challenge
262943|NCT01662778|Multiple Breath Nitrogen Washout
262944|NCT01662765|Umbilical pilonidal sinus
262945|NCT01662765|Treatment
262946|NCT01662765|Surgery
262947|NCT01662765|Conservative
262948|NCT01662765|Investigational treatment
262949|NCT01662765|After care
262950|NCT01662752|Early colonic cancer
262951|NCT01662752|Sentinel lymph node mapping
262952|NCT01662752|Sentinel lymph node biopsy
262953|NCT01662752|Near infrared imaging
262954|NCT01662752|Indocyanine green
262955|NCT01662752|Laparoscopic
262956|NCT01662739|Population-Based Cancer Registry
262957|NCT01662739|Stomach
262958|NCT01662739|Epidemiology
262959|NCT01662739|Risk Factor
262960|NCT01662739|Biomolecular Features
262961|NCT01662713|skin cancer
262962|NCT01662713|optical imaging
262963|NCT01662713|optical coherence tomography
262964|NCT01662713|optical frequency domain imaging
262965|NCT01662700|P. vivax infection
262966|NCT01662700|Artesunate
262967|NCT01662700|Chloroquine
262968|NCT01662700|Primaquine
262969|NCT01662661|Healthy participants
262970|NCT01662661|Hepatitis C
262971|NCT01662661|Relative bioavailability
262972|NCT01662661|Bioavailability
262973|NCT01662661|Pharmacokinetics
262974|NCT01662661|JNJ-47910382
262975|NCT01662648|Schizophrenia
262976|NCT01662648|Paliperidone
262977|NCT01662648|Paliperidone extended-release (ER)
262978|NCT01662635|Non-small cell lung cancer.
262979|NCT01662635|Diagnosis,
262980|NCT01662635|Adenocarcinoma,
262981|NCT01662635|ALK,
262982|NCT01662635|FISH,
262983|NCT01662635|IHC
262984|NCT01662635|RT-qPCR
262985|NCT01662622|anaesthesia
262986|NCT01662622|middle aged
262987|NCT01662622|minimal alveolar concentration
262988|NCT01662622|sevoflurane
262989|NCT01662622|isoelectric EEG
262990|NCT01662609|pancreas
262991|NCT01662609|high-risk
262992|NCT01662596|Risk factors,
262993|NCT01662596|prenatal diagnosis,
262994|NCT01662596|fetal malformations
262995|NCT01662583|Influenza
262996|NCT01662583|text message
262997|NCT01662583|vaccination
262998|NCT01662570|Pediatric Obesity
262999|NCT01662570|Child Overweight
263000|NCT01662557|Pediatric Obesity
263001|NCT01662544|Infants
263002|NCT01662544|Bronchiolitis
263003|NCT01662544|Hypoxia
263004|NCT01662544|Emergency Department
263005|NCT01662544|Length of Stay
263006|NCT01662544|Pediatrics
263007|NCT01661413|Acute Leukemia
263008|NCT01661413|Pediatrics
263009|NCT01661413|Intrathecal methotrexate
263010|NCT01661413|Chemotherapy
263011|NCT01661413|Nausea
263012|NCT01661413|Vomiting
263013|NCT01661400|Glioma includes ependymoma and medulloblastoma
263014|NCT01661387|Adrenal insufficiency
263015|NCT01661387|DuoCort
263016|NCT01661387|Congenital adrenal hyperplasia (CAH)
263017|NCT01661387|Modified release
263018|NCT01661387|Hydrocortisone
263019|NCT01661361|vancomycin
263020|NCT01661361|levels
263021|NCT01661361|central venous port device
263022|NCT01661361|peripherally obtained levels
263023|NCT01661361|dose adjustments
263024|NCT01661361|TDM
263025|NCT01661348|Cesarian section
263026|NCT01661348|Pregnancy
263027|NCT01661348|Incision management
263028|NCT01661335|Nausea
263029|NCT01661335|Vomiting
263030|NCT01661335|Children
263031|NCT01661335|Aprepitant
263032|NCT01661335|Emend®
263033|NCT01661322|Acute ischaemic stroke
263034|NCT01661322|TIA
263035|NCT01661309|Hyperhomocysteinemia
263036|NCT01661309|Methylcobalamin
263037|NCT01661309|Cardiovascular disease
263038|NCT01661309|Plasma total homocysteine
263039|NCT01661309|Vegetarians
263040|NCT01661296|cutaneous leishmaniasis, heat therapy, antimony
263041|NCT01662466|testosterone
263042|NCT01662466|DHEA
263043|NCT01662466|IVF
263044|NCT01662466|egg quality
263045|NCT01662466|pregnancy rates
263046|NCT01662453|epilepsy
263047|NCT01662453|seizures
263048|NCT01662453|mortality
263049|NCT01662453|sudep
263050|NCT01662453|risk factors
263051|NCT01662440|Rabies
263052|NCT01662440|JE
263053|NCT01662440|accelerated schedule
263054|NCT01662427|Quality of life
263055|NCT01662427|Noctural Parkinson's Disease Symptoms
263056|NCT01662401|children
263057|NCT01662401|laparoscopic appendectomy
263058|NCT01662401|iliohypogastric nerve block
263059|NCT01662401|rectus sheath nerve block
263060|NCT01662401|ilioinguinal nerve block
263061|NCT01662388|proximal caries, composite restoration, proximal contact
263062|NCT01662362|Chagas Disease
263063|NCT01662362|Trypanosoma cruzi
263064|NCT01662362|American trypanosomiasis
263065|NCT01662362|South American trypanosomiasis
263066|NCT01662362|kissing bugs
263067|NCT01662362|reduviid bugs
263068|NCT01662336|Human Immunodeficiency Virus infection
263069|NCT01662323|Heart failure, general practitioner, medical therapy, quality of live
263070|NCT01662310|Schizophrenia
263071|NCT01662310|Paliperidone
263072|NCT01662310|Paliperidone Extended-Release
263073|NCT01662297|Quetiapine
263074|NCT01662297|Trazodone
263075|NCT01662297|Insomnia
263076|NCT01662297|Dual Diagnosis
263077|NCT01662271|obesity
263078|NCT01662271|adiposity
263079|NCT01662271|psychosocial
263080|NCT01662271|healthcare
263081|NCT01662271|co-morbidities
263082|NCT01662271|youth with extreme obesity
263083|NCT01662271|weight loss
263084|NCT01662258|Community-acquired pneumonia
263085|NCT01662258|Targeted strategy
263086|NCT01662258|Empiric therapy
263087|NCT01662232|Green tea
263088|NCT01662232|EGCG
263089|NCT01662232|Cardiovascular diseases
263090|NCT01662232|Endothelial function
263091|NCT01662232|Flow-mediated dilation
263092|NCT01662219|superficial cervical plexus block
263093|NCT01662219|quality of recovery
263094|NCT01662206|adults
263095|NCT01662206|probiotics
263096|NCT01662206|immune function
263097|NCT01662206|microbiota
263098|NCT01662206|digestive health
263099|NCT01662193|Cholecalciferol
263100|NCT01662193|Calciol
263101|NCT01662193|vitamin D3
263102|NCT01662193|Diabetes Mellitus
263103|NCT01662193|Diabetes Mellitus Type 2
263104|NCT01662193|glucose metabolism disorders
263105|NCT01662193|ergocalciferol
263106|NCT01662193|calcium
263107|NCT01662193|adipicytokines
263108|NCT01662193|inflammatory biomarkers
263109|NCT01662180|subfertility, IUI, rec FSH, FSH, E2, AMH
263110|NCT01662141|Cardiac output
263111|NCT01662141|Perivascular Probe
263112|NCT01662128|Breast Cancer
263113|NCT01662115|ILEUS
263114|NCT01662089|Female pattern hair loss
263115|NCT01662076|Cancer
263116|NCT01662076|Fatigue
263117|NCT01662076|Chemotherapy
263118|NCT01662076|Pediatrics
263119|NCT01662076|Homeopathy
263120|NCT01662050|MCL
263121|NCT01662050|Mantle Cell Lymphoma
263122|NCT01662050|Older
263123|NCT01662037|Pulmonary vascular resistance
263124|NCT01662037|Heart defects, Congenital
263125|NCT01662037|Receptors, endothelin
263126|NCT01662037|Bosentan
263127|NCT01662024|Obesity
263128|NCT01662024|BMI
263129|NCT01662024|Weight loss
263130|NCT01662024|Gastric restriction
263131|NCT01662024|Bariatrics
263132|NCT01662011|patient-ventilator interaction
263133|NCT01662011|neurally adjusted ventilatory assist
263134|NCT01662011|diaphragm electrical activity
263135|NCT01662011|pressure support ventilation
263136|NCT01661998|Adolescent Idiopathic Scoliosis
263137|NCT01661998|Spinal Deformity
263138|NCT01661998|Treatment Outcomes
263139|NCT01661985|Mycoplasma genitalium
263140|NCT01661985|Chlamydia trachomatis
263141|NCT01661985|Treatment
263142|NCT01661985|Antibiotic resistance
263143|NCT01661972|colorectal cancer
263144|NCT01661972|all solid tumors
263145|NCT01661972|metastatic
263146|NCT01661972|refractory
263147|NCT01661972|advanced solid tumors
263148|NCT01661959|Scoliosis
263149|NCT01661959|Multi-center Database Registry
263150|NCT01661959|Spinal Deformity
263151|NCT01661959|Adolescent Idiopathic Scoliosis
263152|NCT01661946|vascular endothelial growth factor
263153|NCT01661946|macular edema
263154|NCT01661946|diabetic retinopathy
263155|NCT01661933|celiac disease
263156|NCT01661933|hookworm
263157|NCT01661933|probiotic
263158|NCT01661920|Community Acquired Pneumonia.
263159|NCT01661920|Treatment duration
263160|NCT01661907|Elderly
263161|NCT01661907|Anesthesia and postoperative analgesia
263162|NCT01661907|Postoperative period
263163|NCT01661907|Delirium
263164|NCT01661907|Postoperative complications
263165|NCT01661881|Newly diagnosed
263166|NCT01661868|BRCA1 mutation
263167|NCT01661868|BRCA2 mutation
263168|NCT01661855|Autism Spectrum Disorders
263169|NCT01661842|Autoimmune Hepatitis
263170|NCT01661842|Mesenchymal stem cells
263171|NCT01661842|serum albumin
263172|NCT01661842|serum Tbil
263173|NCT01661842|serum immunoglobulin G(IgG)
263174|NCT01661816|breast cancer
263175|NCT01661816|everyday issues
263176|NCT01661816|couple
263177|NCT01661803|bupivacaine
263178|NCT01661803|clonidine
263179|NCT01661803|pediatric spinal
263180|NCT01661803|efficacy
263181|NCT01661803|duration
263182|NCT01661803|quality
263183|NCT01661803|side effects
263184|NCT01661803|intrathecal bupivacaine alone
263185|NCT01661803|bupivacaine plus clonidine
263186|NCT01661790|Bevacizumab;
263187|NCT01661790|non-small cell lung cancer;
263188|NCT01661790|malignant pleural effusion;
263189|NCT01661790|intrapleural administration
263190|NCT01661777|Eustachian tube dysfunction
263191|NCT01661777|Endolymphatic hydrops
263192|NCT01661777|Diuretic
263193|NCT01661777|Low salt diet
263194|NCT01661777|Myringotomy
263195|NCT01661777|Pressure equalization tube
263196|NCT01661777|Ear tube
263197|NCT01661777|Ear fullness
263198|NCT01661777|Ear pressure
263199|NCT01661777|Allergy
263200|NCT01661777|Nasal steroid
263201|NCT01661777|Antihistamine
263202|NCT01661764|Colorectal Neoplasm
263203|NCT01661751|Group ACYW135 Meninigococcal Polysaccharide Vaccine
263204|NCT01661738|Group ACYW135 Meninigococcal Polysaccharide Vaccine
263205|NCT01661725|Group ACYW135 Meningococcal Polysaccharide Vaccine
263206|NCT01661712|obstructive sleep apnoea,
263207|NCT01661712|continuous transcutaneous electrical stimulation
263208|NCT01661699|Obstructive Sleep Apnea
263209|NCT01661686|esophageal cancer
263210|NCT01661686|esophageal stenosis
263211|NCT01661686|stent
263212|NCT01661686|endoscopy
263213|NCT01661634|Acute decompensated heart failure
263214|NCT01661621|Lower urinary tract symptoms (LUTS)
263215|NCT01661621|International Prostate Symptom Score (IPSS)
263216|NCT01661621|Antimuscarinics
263217|NCT01661621|α-blockers
263218|NCT01661608|Gastric Restriction
263219|NCT01661595|Fatigue
263220|NCT01661595|Fatigability
263221|NCT01661595|Surface Electromyography (sEMG)
263222|NCT01661595|cyclic guanosine monophosphate (cGMP)
263223|NCT01661595|Nitric Oxide (NO)
263224|NCT01661595|NO-cGMP
263225|NCT01661595|Phosphodiesterase (PDE)
263226|NCT01661595|Sildenafil
263227|NCT01661595|Tadalafil
263228|NCT01661595|Isotope
263229|NCT01661595|Infusion
263230|NCT01661595|Anabolism
263231|NCT01661595|Upregulation
263232|NCT01661595|Accelerometer
263233|NCT01661595|Placebo
263234|NCT01661595|Nitrosylation
263235|NCT01661582|Air Pollution
263236|NCT01661582|Myocardial Ischaemia
263237|NCT01661582|Coronary Blood Flow
263238|NCT01661582|Diesel Exhaust
263239|NCT01661582|Troponin
263240|NCT01661582|Electrocardiography
263241|NCT01661569|Mindfulness
263242|NCT01661569|meditation
263243|NCT01661569|stress
263244|NCT01661569|well-being
263245|NCT01661569|work stress
263246|NCT01661569|blood pressure
263247|NCT01661569|cortisol
263248|NCT01661556|Melasma, miconazole, hydroquinone
263249|NCT01661530|asthma
263250|NCT01661530|pregnancy
263251|NCT01661530|diet
263252|NCT01661530|vitamin E
263253|NCT01661517|substance use treatment
263254|NCT01661439|Recurrent miscarriages
263255|NCT01661439|recurrent pregnancy loss
263256|NCT01661439|aps
263257|NCT01661439|anti coagulants in pregnancy
263258|NCT01661283|MPNST
263259|NCT01661283|malignant peripheral nerve sheath tumors
263260|NCT01661283|RAD001
263261|NCT01661283|Everolimus
263262|NCT01661283|Bevacizumab
263263|NCT01661283|Sarcoma
263264|NCT01661283|Avastin
263265|NCT01661283|mTOR inhibitor
263266|NCT01661257|Crohn's disease
263267|NCT01661257|Infliximab
263268|NCT01661257|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)
263269|NCT01661231|Vascular intervention
263270|NCT01661231|Endovascular
263271|NCT01661231|Peripheral stent
263272|NCT01661218|catheters
263273|NCT01661218|Central Venous
263274|NCT01661218|complications
263275|NCT01661218|cancer
263276|NCT01661205|Persistent AF
263277|NCT01661205|Longstanding Persistent AF
263278|NCT01661205|Ablation
263279|NCT01661205|catheter ablation
263280|NCT01661192|Type 1 Diabetes
263281|NCT01661192|newly diagnosed
263282|NCT01661192|Beta cell preservation
263283|NCT01661179|Medullary Thyroid Carcinoma
263284|NCT01661179|Medullary Thyroid Cancer
263285|NCT01661179|Vandetanib
263286|NCT01661166|Male adult subjects
263287|NCT01661166|aged 30-90 years
263288|NCT01661166|RARP
263289|NCT01661166|AUA symptom score greater than 7 will be included
263290|NCT01661114|Gemcitabine, Infusional 5-Fluorouracil,Cisplatin
263291|NCT01661114|Advanced Pancreatic and Biliary Cancers
263292|NCT01661114|untreated & previously treated pancreatic & biliary cancer.
263293|NCT01661101|Perioperative myocardial infarction
263294|NCT01661101|Myocardial injury
263295|NCT01661101|noncardiac surgery
263296|NCT01661088|Neoadjuvant FOLFIRINOX
263297|NCT01661088|FDR-Gemcitabine
263298|NCT01661088|Concurrent
263299|NCT01661088|IMRT
263300|NCT01661088|Borderline Resectable Pancreatic Cancer
263301|NCT01661075|mTBI
263302|NCT01661075|concussion
263303|NCT01661075|mild traumatic brain injury
263304|NCT01661075|athlete
263305|NCT01661075|college
263306|NCT01661075|football
263307|NCT01661075|soccer
263308|NCT01661036|Cognitive Testing
263309|NCT01661036|Survey
263310|NCT01661036|Interview
263311|NCT01661023|Breast Cancer
263312|NCT01661023|Epidemiology
263313|NCT01661010|Infertility
263314|NCT01661010|Male Factor Infertility
263315|NCT01661010|Female Factor Infertility
263316|NCT01661010|Unexplained Infertility
263317|NCT01661010|Sex Chromosome
263318|NCT01661010|Klinefelter Syndrome
263319|NCT01661010|Turner's Syndrome
263320|NCT01661010|XXY
263321|NCT01661010|Y Chromosome Deletion
263322|NCT01661010|Aneuploidy
263323|NCT01660997|Proteasome Inhibitor
263324|NCT01660997|Induction Combination Therapy
263325|NCT01660997|Maintenance Strategy
263326|NCT01660997|Potent Anti-Myeloma Effect
263327|NCT01660997|Precursor Disease
263328|NCT01660984|Thyroid Tumor
263329|NCT01660984|Multiple Endocrine Neoplasia 2
263330|NCT01660984|Pheochromocytoma
263331|NCT01660984|RET Mutations
263332|NCT01660958|Micronutrient Deficiencies
263333|NCT01660958|Early Child Development
263334|NCT01660958|Infant Growth
263335|NCT01660958|Iron Deficiency
263336|NCT01660945|statins, insulin resistance
263337|NCT01660932|insulin resistance
263338|NCT01660919|insulin resistance
263339|NCT01660893|operative
263340|NCT01660893|dental procedure
263341|NCT01660867|hospital admission within 7 days of 3% NaCl nebulizer vs dexamethasone
263342|NCT01660854|Plasmodium
263343|NCT01660854|falciparum
263344|NCT01660854|malaria
263345|NCT01660854|heterologous
263346|NCT01660854|immunity
263347|NCT01660841|Magnetic resonance imaging
263348|NCT01660841|central nervous system
263349|NCT01660841|contrast media
263350|NCT01660841|gadobutrol
263351|NCT01660828|Exercise induced (high sensitive) troponin release
263352|NCT01660828|Ischemia reperfusion injury
263353|NCT01660828|Remote ischemic preconditioning
263354|NCT01660789|Obesity
263355|NCT01660789|Diabetes
263356|NCT01660789|Physical activity
263357|NCT01660776|diffuse large B-cell lymphoma (DLBCL)
263358|NCT01660776|Hodgkin lymphoma
263359|NCT01660776|metastatic breast cancer.
263360|NCT01660776|non-small cell lung cancer
263361|NCT01660750|newly diagnosed multiple myeloma
263362|NCT01660750|transplant eligible multiple myeloma
263363|NCT01660737|Hay fever
263364|NCT01660737|Pascallerg
263365|NCT01660711|neoadjuvant
263366|NCT01660711|chemotherapy
263367|NCT01660711|resectable
263368|NCT01660711|adjuvant
263369|NCT01660711|pancreas
263370|NCT01660711|cancer
263371|NCT01660711|adenocarcinoma
263372|NCT01660711|surgery
263373|NCT01660685|Weight loss
263374|NCT01660685|Web-based
263375|NCT01660685|Journaling
263376|NCT01660685|Body Mass Index between 27 and 45
263377|NCT01660659|Indoor air pollution
263378|NCT01660659|pneumococcal carriage
263379|NCT01660646|Tuberculosis case finding
263380|NCT01660633|Multiple Myeloma
263381|NCT01660633|High-Dose Melphalan
263382|NCT01660633|Propylene Glycol-Free
263383|NCT01660633|Autologous Stem Cell Transplantation
263384|NCT01660633|Captisol
263385|NCT01660620|betaxolol/ retinopathy of prematurity
263386|NCT01660594|coronary disease
263387|NCT01660594|tomography, x-ray computed
263388|NCT01660594|calcium
263389|NCT01660594|exercise test
263390|NCT01660581|CD133+
263391|NCT01660581|stem cells
263392|NCT01660581|Coronary Artery Disease
263393|NCT01660581|Stable Angina Pectoris
263394|NCT01659788|Advanced Reproductive Age
263395|NCT01659788|poor ovarian response
263396|NCT01659788|Mitochondrial dysfunction
263397|NCT01659788|Mitochondrial nutrients
263398|NCT01659788|Coenzyme Q10
263399|NCT01659788|Electron transfer chain
263400|NCT01659762|inflammatory bowel disease
263401|NCT01659762|Crohn's disease
263402|NCT01659749|Genetics
263403|NCT01659749|Metabolic
263404|NCT01659749|Nutrition
263405|NCT01659749|Maternal PKU
263406|NCT01659749|Phenylketonuria (PKU)
263407|NCT01659723|Radio therapy
263408|NCT01659723|STRI
263409|NCT01659723|Urinary bladder
263410|NCT01659723|Hyperbaric Oxygen
263411|NCT01659697|lifestyle
263412|NCT01659697|diabetes prevention
263413|NCT01659697|BMI
263414|NCT01659697|physical activity
263415|NCT01659684|congenital CMV infection
263416|NCT01659684|standard immunoglobulins
263417|NCT01659684|immunoglobulin therapy
263418|NCT01659684|IgG CMV avidity index
263419|NCT01659684|Cytomegalovirus
263420|NCT01659658|MLN9708
263421|NCT01659658|Amyloidosis
263422|NCT01659658|Light Chain
263423|NCT01659658|IXAZOMIB
263424|NCT01659658|Tourmaline AL1
263425|NCT01659658|Drug Therapy
263426|NCT01659606|dyskeratosis congenita
263427|NCT01659606|bone marrow failure
263428|NCT01659606|aplastic anemia
263429|NCT01659606|bone marrow transplantation
263430|NCT01659606|reduced intensity conditioning
263431|NCT01659606|campath
263432|NCT01659606|fludarabine
263433|NCT01659606|telomere
263434|NCT01659593|cognitive disorders
263435|NCT01659593|multiple sclerosis
263436|NCT01659593|neuropsychology
263437|NCT01659580|Angina Pectoris Treatment Prevention
263438|NCT01659554|Primary peritoneal
263439|NCT01660555|Microbiota
263440|NCT01660555|HITChip
263441|NCT01660555|biopsies
263442|NCT01660555|colon
263443|NCT01660555|protected biopsies
263444|NCT01660529|Subjects with metastatic breast cancer who have failed at least one standard
263445|NCT01660529|of care regimen
263446|NCT01660516|Camellia sinensis
263447|NCT01660516|flavonoids
263448|NCT01660516|cardiovascular risk
263449|NCT01660516|flow mediated dilation
263450|NCT01660503|Calcium absorption
263451|NCT01660503|Osteoporosis
263452|NCT01660503|Bone Health
263453|NCT01660503|Adolescent
263454|NCT01660490|Radiographic Image Enhancement,
263455|NCT01660490|Intraoperative Care
263456|NCT01660490|Femoral Fractures
263457|NCT01660490|Femoral Neck Fractures
263458|NCT01660490|Hip Fractures, Internal Fixators
263459|NCT01660490|Fracture Fixation Internal
263460|NCT01660490|Fracture Fixation Intramedullary
263461|NCT01660490|Fractures Bone
263462|NCT01660477|Isavuconazole
263463|NCT01660477|Lopinavir/ritonavir
263464|NCT01660477|Healthy Volunteers
263465|NCT01660477|BAL8557
263466|NCT01660477|Kaletra ®
263467|NCT01660464|Program evaluation
263468|NCT01660464|ADHD
263469|NCT01660451|Clinical trial, phase II
263470|NCT01660451|Phosphatidylinositol 3-Kinase
263471|NCT01660451|Class I, Non-Hodgkin's lymphoma
263472|NCT01660438|Stress urinary incontinence
263473|NCT01660438|Suburethral sling
263474|NCT01660425|Attention deficit-/hyperactivity disorder
263475|NCT01660425|parenting enhancement training
263476|NCT01660425|guided self-help
263477|NCT01660425|methylphenidate
263478|NCT01660412|Pain
263479|NCT01660412|Alkalinization
263480|NCT01660412|Technetium 99m Sulfur Colloid
263481|NCT01660412|sentinel lymphoscintigraphy?
263482|NCT01660399|salvage chemotherapy
263483|NCT01660399|advanced squamous cell lung cancer
263484|NCT01660399|Boanmycin
263485|NCT01660386|Type 2 Diabetes
263486|NCT01660386|Dpp-4 inhibitor
263487|NCT01660386|Sulfonylurea
263488|NCT01660386|beta cell function
263489|NCT01660373|ticagrelor
263490|NCT01660373|tirofiban
263491|NCT01660373|glycoprotein IIa/IIIa inhibitors
263492|NCT01660373|P2Y12 blockers
263493|NCT01660373|acute coronary syndrome
263494|NCT01660360|Tanibirumab Phase I trial
263495|NCT01660334|Systemic Mycosis
263496|NCT01660334|Scedosporium infection
263497|NCT01660334|Scedosporisis
263498|NCT01660334|Japanese
263499|NCT01660334|voriconazole
263500|NCT01660334|VFEND
263501|NCT01660334|Regulatory Post Marketing Commitment Plan.
263502|NCT01660321|Pediculosis capitis
263503|NCT01660321|Head Lice
263504|NCT01660295|Severe renal insufficiency certoparin
263505|NCT01660295|Severe renal insufficiency
263506|NCT01660243|Pruritus
263507|NCT01660243|Renal dialysis
263508|NCT01660243|Receptors, Opioid, kappa
263509|NCT01660243|Sleep Disorders
263510|NCT01660243|Quality of Life
263511|NCT01660230|APC, 3K3A, 3K3A-APC, volunteer, healthy
263512|NCT01660217|atopic dermatitis
263513|NCT01660217|eczema action plan
263514|NCT01660217|patient education
263515|NCT01660217|written handout
263516|NCT01660217|investigator's global assessment
263517|NCT01660217|randomized controlled trial
263518|NCT01660204|pneumonia, anti-bacterial agents, (cost)efficacy
263519|NCT01660191|LDL, HDL
263520|NCT01660178|newborns
263521|NCT01660178|intensive care unit
263522|NCT01660178|early stimulation
263523|NCT01660165|Nutritional status
263524|NCT01660165|Mental Health
263525|NCT01660165|Omega-3
263526|NCT01660165|Pregnancy
263527|NCT01660165|Postpartum depression
263528|NCT01660152|male erectile disorder
263529|NCT01660152|prostate cancer
263530|NCT01660152|Laparoscopic prostatectomy
263531|NCT01660126|Aged
263532|NCT01660126|Cardiovascular disease
263533|NCT01660126|Levothyroxine
263534|NCT01660126|Randomised controlled trial
263535|NCT01660126|Quality of life
263536|NCT01660126|Subclinical hypothyroidism
263537|NCT01660100|Atrial fibrillation ablation
263538|NCT01660087|Exhaled breath condensate (EBC) method
263539|NCT01660087|Volatile Organic Compounds (VOCs)
263540|NCT01660087|Endobronchial Ultrasound (EBUS)
263541|NCT01660087|Confocal Endoscopy
263542|NCT01660087|Exhaled alveolar gas
263543|NCT01660074|glycemic index, resistant starch, glycemic response
263544|NCT01660061|Antiphospholipid syndrome
263545|NCT01660061|Antiphospholipid antibodies
263546|NCT01660061|Vitamin-K antagonists
263547|NCT01660061|International normalized ratio
263548|NCT01660061|Chromogenic factor X
263549|NCT01660048|Laparoscopic total extraperitoneal Inguinal hernia repair
263550|NCT01660022|Healthy
263551|NCT01660022|Volunteers
263552|NCT01660009|Endothelial Function
263553|NCT01660009|Hypoglycemia
263554|NCT01660009|Mitochondria
263555|NCT01659996|Meningitis
263556|NCT01659996|Meningococcal Infection
263557|NCT01659996|Diphtheria
263558|NCT01659996|Pertussis
263559|NCT01659996|Menactra®
263560|NCT01659996|Pentacel®
263561|NCT01659983|complicated appendicitis
263562|NCT01659983|wound closure
263563|NCT01659983|infection
263564|NCT01659957|Alcoholism
263565|NCT01659957|Couples
263566|NCT01659944|Drug-drug interaction
263567|NCT01659879|Parents
263568|NCT01659879|Caregivers
263569|NCT01659879|Anxiety
263570|NCT01659879|Consumer satisfaction
263571|NCT01659866|Infection
263572|NCT01659866|Antibiotic resistance
263573|NCT01659866|Prostate biopsy
263574|NCT01659840|laser,
263575|NCT01659840|quality of life,
263576|NCT01659840|orofacial pain
263577|NCT01659814|Major Depressive Disorder
263578|NCT01659814|Anhedonia
263579|NCT01659814|Dopamine
263580|NCT01659814|Electroencephalography (EEG)
263581|NCT01659814|Positron Emission Tomography (PET)
263582|NCT01659814|Reward
263583|NCT01659801|cataract
263584|NCT01659801|cataract surgery
263585|NCT01659801|intaocular lens
263586|NCT01659801|toric lens
263587|NCT01659541|spinal cord injury
263588|NCT01659541|paralysis
263589|NCT01659541|cough
263590|NCT01659541|cervical spinal cord injury
263591|NCT01659541|thoracic spinal cord injury
263592|NCT01659528|Penis
263593|NCT01659528|Micropenis
263594|NCT01659528|Nomograms
263595|NCT01659528|Ultrasound
263596|NCT01659528|Fetus
263597|NCT01659502|Patients
263598|NCT01659489|adnexal torsion
263599|NCT01659489|laparoscopy
263600|NCT01659476|methacholine
263601|NCT01659476|deep inspiration
263602|NCT01659476|bronchoprotective effect
263603|NCT01659476|bronchodilating effect
263604|NCT01659463|CARIES INFILTRATION
263605|NCT01659463|CARIES LESION
263606|NCT01659463|INFILTRANT
263607|NCT01659450|overweight
263608|NCT01659450|obesity
263609|NCT01659450|low energy dense
263610|NCT01659437|M. ulcerans
263611|NCT01659437|Buruli ulcer
263612|NCT01659437|drug trial
263613|NCT01659437|clarithromycin
263614|NCT01659424|Rectal cancer
263615|NCT01659411|Congenital Heart Disease
263616|NCT01659411|Pulmonary Arterial Hypertension
263617|NCT01659398|Alzheimer's Disease
263618|NCT01659398|cerebral blood flow
263619|NCT01659398|ophthalmic blood flow
263620|NCT01659398|blood viscosity
263621|NCT01659372|temporomandibular disorder
263622|NCT01659372|myofascial pain syndrome
263623|NCT01659333|Peritoneal, Dialysis
263624|NCT01659307|Acute Lung Injury
263625|NCT01659307|Acute Respiratory Distress Syndrome
263626|NCT01659307|Aspirin
263627|NCT01659294|Type 2 diabetes
263628|NCT01659294|outcomes
263629|NCT01659294|case management
263630|NCT01659281|Artesunate
263631|NCT01659281|Mefloquine
263632|NCT01659281|Plasmodium Falciparum
263633|NCT01659281|Thailand
263634|NCT01659281|Uncomplicated Plasmodium Falciparum malaria
263635|NCT01659268|teaching
263636|NCT01659268|patient simulation
263637|NCT01659268|laryngeal masks
263638|NCT01659268|baccalaureate nursing education
263639|NCT01659268|teaching strategies
263640|NCT01659268|simulation
263641|NCT01659242|Rheumatoid arthritis
263642|NCT01659242|Ultrasound
263643|NCT01659242|Magnetic Resonance Imaging
263644|NCT01659229|knee osteoarthritis
263645|NCT01659216|Electrical Pudendal Nerve Stimulation
263646|NCT01659216|Urgency-Frequency Syndrome
263647|NCT01659216|long-term efficacy
263648|NCT01659203|extraskeletal chondrosarcoma
263649|NCT01659164|Cognitive Behavioral Therapy
263650|NCT01659164|Dialectical Behavioral Therapy
263651|NCT01659164|Group Treatment
263652|NCT01659164|ADHD
263653|NCT01659151|metastatic
263654|NCT01659151|melanoma
263655|NCT01659151|cell transfer
263656|NCT01659151|ACT
263657|NCT01659151|T-cell
263658|NCT01659151|immunotherapy
263659|NCT01659151|antibodies
263660|NCT01659151|lymphocytes
263661|NCT01659112|core stabilization, upper extremity, kinetic chain, movement
263662|NCT01659099|DLBCL
263663|NCT01659099|aa-IPI > or equal to 1
263664|NCT01659099|Diagnosis
263665|NCT01659099|18 to 60 years
263666|NCT01659099|Lymphoma
263667|NCT01659086|Immunogenicity
263668|NCT01659086|Influenza
263669|NCT01659086|H9N2
263670|NCT01659086|Safety
263671|NCT01659073|Caloric Vestibular Stimulation
263672|NCT01659073|Functional Imaging
263673|NCT01659060|Cacao
263674|NCT01659060|Chocolate
263675|NCT01659060|Theobromine
263676|NCT01659060|Flavonoids
263677|NCT01659060|Pregnant women
263678|NCT01659060|Hypertension pregnancy-induced
263679|NCT01659060|Pre-eclampsia
263680|NCT01659060|Epicatechin
263681|NCT01659047|Chronic Lymphocytic Leukemia
263682|NCT01659047|CLL
263683|NCT01659047|CAL-101
263684|NCT01659047|Ofatumumab
263685|NCT01659034|Anti-platelet therapy
263686|NCT01659021|CLL
263687|NCT01659021|Chronic Lymphocytic Leukemia
263688|NCT01659021|GS-1101
263689|NCT01659021|CAL-101
263690|NCT01659021|Ofatumumab
263691|NCT01659008|acute cyclical heavy menstrual bleeding
263692|NCT01658995|Implanon
263693|NCT01658995|Etonogestrel subdermal implant
263694|NCT01658995|Nexplanon
263695|NCT01658995|Contraception
263696|NCT01658995|Irregular Bleeding
263697|NCT01658995|Menometrorrhagia
263698|NCT01658956|GCSF
263699|NCT01658956|Chemotherapy
263700|NCT01658956|Breast cancer
263701|NCT01658956|Prophylaxis
263702|NCT01658917|Tissue Acquisition
263703|NCT01658904|Autologous Transplant
263704|NCT01658904|Proteasome Inhibitor
263705|NCT01658904|Melphalan
263706|NCT01658904|Filgrastim
263707|NCT01658839|pediatric glaucoma
263708|NCT01658839|pediatric ocular hypertension
263709|NCT01658839|travoprost
263710|NCT01658826|AIC316
263711|NCT01658826|Viral shedding
263712|NCT01658813|Metastatic Gastrointestinal
263713|NCT01658813|Metastatic Kidney
263714|NCT01658813|Metastatic Lung
263715|NCT01658800|H5N1 Influenza
263716|NCT01658800|H5N1 Influenza vaccine
263717|NCT01658787|Aorta
263718|NCT01658761|Myopic traction maculopathy
263719|NCT01658761|vitrectomy
263720|NCT01658761|internal limiting membrane
263721|NCT01658761|Retrospective, case control study
263722|NCT01658748|Pilot Study
263723|NCT01658748|Longitudinal Study
263724|NCT01658748|Amygdaloid Body
263725|NCT01658748|Insula of Reil
263726|NCT01658748|Cortex, prefrontal
263727|NCT01658748|Stimulation, Deep Brain
263728|NCT01658748|Chronic Post Traumatic Stress Disorder
263729|NCT01658748|Combat Stress Disorder
263730|NCT01658748|Social Adjustments
263731|NCT01658748|Positron-Emission Tomography, Computed Tomography
263732|NCT01658735|Chronic low back pain
263733|NCT01658735|Electrotherapy
263734|NCT01658735|H-Wave
263735|NCT01658735|H wave
263736|NCT01658735|TENS
263737|NCT01658735|Trial
263738|NCT01658683|Coronary Artery Disease
263739|NCT01658683|Cardiac Rehabilitation
263740|NCT01658683|Exercise Maintenance
263741|NCT01658683|Facilitator
263742|NCT01658683|Managed Home Exercise
263743|NCT01658683|Community Based Exercise
263744|NCT01658670|Heart failure
263745|NCT01658670|exercise
263746|NCT01658670|adherence
263747|NCT01658670|quality of life
263748|NCT01658644|Patient satisfaction
263749|NCT01658644|Memory recall
263750|NCT01658644|Patient-clinician communication
263751|NCT01658644|health communication
263752|NCT01658644|clinical care team recall
263753|NCT01658644|hospital quality of care
263754|NCT01658618|Venous leg ulcer
263755|NCT01658618|ulcer
263756|NCT01658618|venous stasis
263757|NCT01658618|compression
263758|NCT01658618|venous
263759|NCT01658618|venous stasis ulcer
263760|NCT01658618|vlu
263761|NCT01658618|hp802-247-09-029
263762|NCT01658605|GSK1605786
263763|NCT01658605|ulcerative colitis
263764|NCT01658605|CCR9 antagonist
263765|NCT01658605|proof of concept
263766|NCT01658592|Alcohol Addiction;
263767|NCT01658592|Deep Brain Stimulation;
263768|NCT01658592|Nucleus Accumbens;
263769|NCT01658592|Ventral Anterior Internal capsule;
263770|NCT01658553|solid tumors
263771|NCT01658540|Drug Eluting Balloon (DEB) technology
263772|NCT01658540|long SFA lesions disease
263773|NCT01658527|metastatic
263774|NCT01658527|prostate cancer
263775|NCT01658488|Iron deficiency anemia
263776|NCT01658488|rice
263777|NCT01658475|IgG titer
263778|NCT01658475|periodontopathic bacteria
263779|NCT01658462|locally recurrent or metastatic breast cancer
263780|NCT01658462|Docetaxel
263781|NCT01658462|Nintedanib
263782|NCT01658436|advanced pancreatic neuroendocrine tumor
263783|NCT01658436|BEZ235
263784|NCT01658436|pNET
263785|NCT01658423|pubic hair
263786|NCT01658423|sprint velocity
263787|NCT01658423|vertical jump height
263788|NCT01658423|body composition
263789|NCT01658423|maximal voluntary torque
263790|NCT01658410|Coronary artery disease
263791|NCT01658410|bypass grafting
263792|NCT01658397|Healthy subjects
263793|NCT01658397|Fasting
263794|NCT01658397|Weight loss
263795|NCT01658371|HIV
263796|NCT01658358|ErbB receptor
263797|NCT01658358|tyrosine kinase inhibitor
263798|NCT01658358|Anthracycline
263799|NCT01658345|aortic stenosis
263800|NCT01658345|asymptomatic
263801|NCT01658345|microvascular dysfunction
263802|NCT01658345|Cardiac MRI
263803|NCT01658332|lung cancer
263804|NCT01658332|circulating tumor cells
263805|NCT01658332|prospective
263806|NCT01658332|monocentrique trial
263807|NCT01658306|remote ischemic preconditioning
263808|NCT01658306|random-controlled
263809|NCT01658306|double blind
263810|NCT01658306|RIPC
263811|NCT01658293|stroke
263812|NCT01658293|follow up
263813|NCT01658293|upper limb
263814|NCT01658293|rehabilitation
263815|NCT01658280|transbronchial needle aspiration
263816|NCT01658280|ultrasound guided transbronchial needle aspiration
263817|NCT01658280|sensitivity
263818|NCT01658280|hilar/mediastinal adenopathy
263819|NCT01658254|Clinical trials
263820|NCT01658254|Basic results
263821|NCT01658254|Registry
263822|NCT01658228|Depression
263823|NCT01658228|Dysthymia
263824|NCT01658228|Cognitive Impairment
263825|NCT01658228|Cognitive Decline
263826|NCT01658228|Memory
263827|NCT01658215|Smoking cessation
263828|NCT01658215|Nicotine
263829|NCT01658215|Tobacco Use Disorder
263830|NCT01658215|Central Nervous System Agents
263831|NCT01658202|Smoking cessation
263832|NCT01658202|Nicotine
263833|NCT01658202|Tobacco Use Disorder
263834|NCT01658202|Central Nervous System Agents
263835|NCT01658176|Estrogen receptor positive
263836|NCT01658176|Her-2 negative
263837|NCT01658176|advanced breast cancer
263838|NCT01658176|Breast Cancer
263839|NCT01658163|abdominoplasty,
263840|NCT01658163|skin closure, dressings
263841|NCT01658150|Cognition
263842|NCT01658150|Schizophrenia
263843|NCT01658150|Schizoaffective disorder
263844|NCT01658137|diet
263845|NCT01658137|dietary pattern
263846|NCT01658137|gene
263847|NCT01658137|gene expression
263848|NCT01658137|epigenomics
263849|NCT01658137|diet-gene interaction
263850|NCT01658137|inflammation
263851|NCT01658137|9p21
263852|NCT01658137|fruits
263853|NCT01658137|vegetables
263854|NCT01658124|haemorrhage,antifibrinolytic, clinical trial,
263855|NCT01658111|Stroke
263856|NCT01658111|Robots
263857|NCT01658111|EEG
263858|NCT01658111|EMG
263859|NCT01658098|postpartum
263860|NCT01658098|depression
263861|NCT01658098|edinburgh postpartum depression scale
263862|NCT01658098|mexican population
263863|NCT01658085|Thyroidectomy
263864|NCT01658085|Multinodular goiter
263865|NCT01658085|Harmonic Focus
263866|NCT01658085|budget impact
263867|NCT01658085|Harmonic scalpel
263868|NCT01658072|Total Hip Arthroplasty
263869|NCT01658072|Total Hip Replacement
263870|NCT01658046|COPD
263871|NCT01658046|exercise
263872|NCT01658046|neuromuscular electrical stimulation
263873|NCT01658033|Metastatic Breast Cancer, Her-2 negative Breast Cancer
263874|NCT01658033|Avastin, FOLFOX regimen
263875|NCT01658020|Acute exacerbation of Chronic obstructive pulmonary disease
263876|NCT01658020|Acute Exacerbation
263877|NCT01658020|Chronic obstructive pulmonary disease(COPD)
263878|NCT01658020|Zabofloxacin
263879|NCT01658020|Moxifloxacin
263880|NCT01657994|cerebral palsy
263881|NCT01657994|gait training
263882|NCT01657994|robotic
263883|NCT01657994|functional electrical stimulation
263884|NCT01657981|Pharmacokinetics
263885|NCT01657981|Phase 1
263886|NCT01657981|14C-labeled
263887|NCT01657968|Acute tonsillitis
263888|NCT01657968|Procalcitonin
263889|NCT01657968|Streptococcal antigen test
263890|NCT01657968|Centor Criteria
263891|NCT01657968|Infection marker
263892|NCT01657942|MRgFUS
263893|NCT01657942|Prostate Lesions
263894|NCT01657942|Low and Intermediate Risk Prostate Lesions
263895|NCT01657942|Localized Prostate Lesions
263896|NCT01657942|InSightec
263897|NCT01657942|ExAblate
263898|NCT01657929|Influenza
263899|NCT01657929|Avian
263900|NCT01657929|H5N1
263901|NCT01657929|H5-VLP
263902|NCT01657929|GLA
263903|NCT01657929|GLA-AF
263904|NCT01657916|mid-urethral sling
263905|NCT01657916|Align urethral support system
263906|NCT01657916|tension free vaginal tape
263907|NCT01657916|cough stress test
263908|NCT01657916|pelvic exam
263909|NCT01657916|PFDI-20
263910|NCT01657916|PFIQ
263911|NCT01657916|SSQ
263912|NCT01657916|Urinary retention
263913|NCT01657916|mesh erosion
263914|NCT01657916|urodynamics
263915|NCT01657890|isavuconazole
263916|NCT01657890|BAL8557
263917|NCT01657864|Aseptic Meningitis
263918|NCT01657864|Epidemiology
263919|NCT01657864|Bipolar Disorder
263920|NCT01657864|Lamotrigine
263921|NCT01657864|Epilepsy
263922|NCT01657838|Isavuconazole
263923|NCT01657838|Ketoconazole
263924|NCT01657838|Healthy Volunteers
263925|NCT01657838|BAL8557
263926|NCT01657838|BAL4815
263927|NCT01657825|isavuconazole
263928|NCT01657825|warfarin
263929|NCT01657825|Healthy Volunteers
263930|NCT01657825|BAL8557
263931|NCT01657825|Coumadin
263932|NCT01657812|dexmedetomidine
263933|NCT01657812|Epidural Anesthesia
263934|NCT01657812|stress response
263935|NCT01657812|anesthesia recovery
263936|NCT01657786|ondanstron
263937|NCT01657786|gene polymorphism
263938|NCT01657786|postoperative nausea and vomiting
263939|NCT01657786|laparoscopic surgery under general anesthesia
263940|NCT01657760|craving
263941|NCT01657760|dopamine
263942|NCT01657760|citalopram
263943|NCT01657760|ssri
263944|NCT01657747|Ovarian carcinoma
263945|NCT01657747|Staging
263946|NCT01657747|Early treatment follow-up
263947|NCT01657747|Identifying tumor recurrence
263948|NCT01657747|Whole body diffusion-weighted MRI
263949|NCT01657734|therapy-induced inflammatory response with
263950|NCT01657734|magnetic resonance imaging
263951|NCT01657695|HCC
263952|NCT01657695|Computed tomography
263953|NCT01657695|Gene expression
263954|NCT01657695|Fractional growth
263955|NCT01657682|FLT3
263956|NCT01657682|Crenolanib
263957|NCT01657682|Acute
263958|NCT01657682|Myeloid
263959|NCT01657682|AML
263960|NCT01657669|Choroidal neovascularization due to AMD
263961|NCT01657643|Health related quality of life
263962|NCT01657643|Functional Status
263963|NCT01657630|Insulin Pump Therapy
263964|NCT01657630|Type 1 Diabetes
263965|NCT01657630|Treatment Satisfaction
263966|NCT01657604|CML
263967|NCT01657604|Tasigna
263968|NCT01657604|Nilotinib
263969|NCT01657604|Interferon
263970|NCT01657591|skin cancer
263971|NCT01657591|unresectable
263972|NCT01657591|BRAF
263973|NCT01657578|neonates
263974|NCT01657578|reflux disease
263975|NCT01657578|population pharmacokinetics, omeprazole
263976|NCT01657565|LOS
263977|NCT01657565|Ileus
263978|NCT01657565|Fever
263979|NCT01657565|reoperation
263980|NCT01657552|Drug interaction
263981|NCT01657552|INCIVEK (telaprevir),
263982|NCT01657552|SB-497115 (eltrombopag)
263983|NCT01657552|Pharmacokinetics
263984|NCT01657552|Thrombocytopenia
263985|NCT01657552|VICTRELIS (boceprevir)
263986|NCT01657526|Healthy adults
263987|NCT01657526|Safety
263988|NCT01657526|Reactogenicity
263989|NCT01657526|Immunogenicity
263990|NCT01657526|Non-typeable H. Influenzae (NTHi)
263991|NCT01657513|psoriasis
263992|NCT01657513|treatment failure
263993|NCT01657513|tnf-alfa
263994|NCT01657500|endothelial keratoplasty
263995|NCT01657487|COPD
263996|NCT01657487|Fluticasone/Salmeterol
263997|NCT01657487|high dose
263998|NCT01657448|Symptom of Dysuria
263999|NCT01657435|Total hip replacement
264000|NCT01657435|Total hip arthroplasty
264001|NCT01657435|Hip joint replacement
264002|NCT01657435|Hip prosthesis replacement
264003|NCT01657422|Nutrition
264004|NCT01657422|Physical Activity
264005|NCT01657422|Adolescents
264006|NCT01657409|botulinum toxin
264007|NCT01657409|detrusor overactivity
264008|NCT01657396|Oral Care
264009|NCT01657396|Oral Hygiene
264010|NCT01657396|Intensive Care
264011|NCT01657396|Mechanical Ventilation
264012|NCT01657396|Chlorhexidine
264013|NCT01657331|Hodgkin Lymphoma
264014|NCT01657331|Hodgkin Disease
264015|NCT01657331|Hodgkin's Disease
264016|NCT01657331|Anaplastic Large Cell Lymphoma
264017|NCT01657331|ALCL
264018|NCT01657331|SGN+Benda
264019|NCT01657331|Bendamustine
264020|NCT01657331|Brentuximab Vedotin
264021|NCT01657318|diabetic foot
264022|NCT01657318|leg ulcer
264023|NCT01657305|Split-Thickness Skin Graft Donor Site
264024|NCT01657305|Split-thickness skin graft
264025|NCT01657305|STSG
264026|NCT01657305|Wound healing
264027|NCT01657305|Skin grafting
264028|NCT01657305|Superficial wound
264029|NCT01657305|Partial-thickness wound
264030|NCT01657305|Time to wound closure
264031|NCT01657292|Wound healing
264032|NCT01657292|Burn wound
264033|NCT01657292|Superficial partial-thickness burn wound
264034|NCT01657292|Grade 2a burn wounds
264035|NCT01657292|Time to wound closure
264036|NCT01657279|stroke
264037|NCT01657279|risk score
264038|NCT01657279|iScore
264039|NCT01657279|outcomes
264040|NCT01657279|mortality
264041|NCT01657279|disability
264042|NCT01657279|institutionalization
264043|NCT01657227|diabetes
264044|NCT01657227|self-management
264045|NCT01657227|lifestyle
264046|NCT01657227|diet
264047|NCT01657227|physical exercise
264048|NCT01657227|computer-assisted decision support systems
264049|NCT01657188|Heart failure, congestive
264050|NCT01657188|Sleep apnea syndromes
264051|NCT01657188|Adaptive servoventilation
264052|NCT01657188|Prognosis
264053|NCT01657188|Cheyne-Stokes respiration
264054|NCT01657175|Cancer
264055|NCT01657175|long-term follow-up
264056|NCT01657175|quality of life
264057|NCT01657175|Surgery
264058|NCT01657175|Nursing
264059|NCT01657162|BA058
264060|NCT01657162|Abaloparatide-SC
264061|NCT01657162|abaloparatide
264062|NCT01657162|ACTIVExtend
264063|NCT01657162|osteoporosis
264064|NCT01657162|fracture
264065|NCT01657162|bone loss
264066|NCT01657136|Inappropriate sinus tachycardia
264067|NCT01657136|ivabradine
264068|NCT01657136|beta blockers
264069|NCT01657123|exercise capacity
264070|NCT01657123|Addison's disease
264071|NCT01657110|acne
264072|NCT01657110|inflamed lesions
264073|NCT01657110|non-inflamed lesions
264074|NCT01657110|complementary medicine
264075|NCT01657110|essential oil
264076|NCT01657058|soluble fiber
264077|NCT01657058|second meal effect
264078|NCT01657058|glycemia
264079|NCT01657058|satiety
264080|NCT01657058|Individuals
264081|NCT01657045|Cicatrix
264082|NCT01657045|Wound healing
264083|NCT01657032|diarrhea
264084|NCT01657032|probiotics
264085|NCT01657032|diosmectite
264086|NCT01657006|Heart rate variability
264087|NCT01657006|ischemic heart disease
264088|NCT01657006|myocardial ischemia
264089|NCT01656993|Aspirin
264090|NCT01656993|ASA
264091|NCT01656993|aortopulmonary shunt
264092|NCT01656993|cavopulmonary shunt
264093|NCT01656993|shunt
264094|NCT01656993|TEG
264095|NCT01656993|Antiplatelet
264096|NCT01656967|Laryngeal Mask Airway
264097|NCT01656967|LMA
264098|NCT01656967|Intubation
264099|NCT01656967|AMBU
264100|NCT01656967|AScope
264101|NCT01656967|Aura-I
264102|NCT01656967|Fastrach
264103|NCT01656967|Fiberoptic
264104|NCT01656967|Disposable Fiberoptic
264105|NCT01656967|Blind Intubation
264106|NCT01656967|Fiberoptic Intubation
264107|NCT01656954|stroke volume
264108|NCT01656954|cardiac output
264109|NCT01656954|pulse pressure variance
264110|NCT01656954|stroke volume variance
264111|NCT01656954|passive leg raise
264112|NCT01656954|fluid challenge
264113|NCT01656954|central venous pressure
264114|NCT01656941|neonate
264115|NCT01656941|congenital heart disease
264116|NCT01656941|single ventricle cardiac disease
264117|NCT01656941|hypoplastic left heart syndrome
264118|NCT01656941|hypoplastic right heart syndrome
264119|NCT01656941|d-Transposition of the Great Arteries
264120|NCT01656915|inflammation
264121|NCT01656915|response
264122|NCT01656915|resilience
264123|NCT01656915|cytokines
264124|NCT01656915|pre-diabetes
264125|NCT01656902|Autologous Chondrocyte Transplantation
264126|NCT01656902|NOVOCART 3D plus
264127|NCT01656902|knee joint pain
264128|NCT01656902|safety
264129|NCT01656902|efficacy
264130|NCT01656902|treatment
264131|NCT01656902|TETEC
264132|NCT01656902|cartilage
264133|NCT01656902|ACT
264134|NCT01656902|cartilage repair
264135|NCT01656902|tissue
264136|NCT01656902|MOCART
264137|NCT01656889|Venous leg ulcer
264138|NCT01656889|ulcer
264139|NCT01656889|venous stasis
264140|NCT01656889|compression
264141|NCT01656889|venous
264142|NCT01656889|venous stasis ulcer
264143|NCT01656889|vlu
264144|NCT01656876|Comparative effectiveness research
264145|NCT01656876|Mirror therapy
264146|NCT01656876|Stroke rehabilitation
264147|NCT01656876|Clinical evaluation
264148|NCT01656876|Kinematic analysis
264149|NCT01656876|Mesh glove
264150|NCT01656876|Combined therapy
264151|NCT01656863|Dehydration
264152|NCT01656850|hyperglycemia
264153|NCT01656850|hyperinsulinemia
264154|NCT01656837|Substance Abuse
264155|NCT01656837|Child Maltreatment
264156|NCT01656837|Multisystemic Therapy
264157|NCT01656837|Child Trauma
264158|NCT01656824|Bv8/PK-2
264159|NCT01656824|MDSC Myeloid Derived Suppressor Cells
264160|NCT01656824|BMDC Bone Marrow Derived Cells
264161|NCT01656824|Angiogenesis
264162|NCT01656824|Pancreatic Cancer
264163|NCT01656785|stroke
264164|NCT01656785|cerebrovascular disease
264165|NCT01656785|angiogenesis imaging
264166|NCT01656785|68Ga-BNOTA-PRGD2
264167|NCT01656785|PET/CT
264168|NCT01656772|magnetic navigation
264169|NCT01656772|robotic control
264170|NCT01656772|RMT ThermoCool catheter
264171|NCT01656759|Blood Loss
264172|NCT01656759|Hemoglobin
264173|NCT01656759|Hematocrit
264174|NCT01656759|Blood Transfusions
264175|NCT01656746|Colorectal Disease
264176|NCT01656746|SILS
264177|NCT01656746|colorectal surgery
264178|NCT01656733|Smoking Cessation
264179|NCT01656733|Pregnancy
264180|NCT01656733|Nicotrol Inhaler
264181|NCT01656733|Placebo Inhaler
264182|NCT01656733|Nicotine Inhaler
264183|NCT01656720|Faecal Incontinence
264184|NCT01656720|Suppository
264185|NCT01656720|Wexner score
264186|NCT01656707|Adolescents
264187|NCT01656707|Substance Use Disorders
264188|NCT01656694|Osteoarthritis
264189|NCT01656694|Knee
264190|NCT01656694|Replacement
264191|NCT01656694|Unicompartmental
264192|NCT01656694|DePuy
264193|NCT01656694|Sigma HP
264194|NCT01656668|Chronic
264195|NCT01656668|Acute
264196|NCT01656668|Persistent
264197|NCT01656668|Longterm
264198|NCT01656668|Cough
264199|NCT01656655|ptsd, parenting
264200|NCT01656642|PD-L1
264201|NCT01656642|PD-1
264202|NCT01656642|PDL1
264203|NCT01656642|antiPD-L1
264204|NCT01656642|MPDL3280A
264205|NCT01656642|Melanoma
264206|NCT01656642|BRAF
264207|NCT01656642|MPDL320A
264208|NCT01656616|Pharmacoeconomics
264209|NCT01656616|Cost effectiveness
264210|NCT01656616|Cyanide
264211|NCT01656616|Fire
264212|NCT01656616|Emergency Medical Services
264213|NCT01656616|Smoke Inhalation
264214|NCT01656603|cord blood
264215|NCT01656603|transplantation
264216|NCT01656603|stem cells
264217|NCT01656603|adverse event
264218|NCT01656590|Pompe disease
264219|NCT01656590|Acid Maltase Deficiency
264220|NCT01656577|CRF1 antagonist
264221|NCT01656577|Stress
264222|NCT01656577|Eating Behavior
264223|NCT01656577|Food Craving
264224|NCT01656564|HIV
264225|NCT01656564|Pediatric
264226|NCT01656564|ART
264227|NCT01656564|Longitudinal
264228|NCT01656564|Outcomes
264229|NCT01656551|elderly
264230|NCT01656551|chemotherapy
264231|NCT01656512|ALL
264232|NCT01656512|zoledronic acid
264233|NCT01656512|Osteoporosis
264234|NCT01656486|Pancreas
264235|NCT01656486|Pancreatic fistula
264236|NCT01656486|Stereotactic radiation
264237|NCT01656473|Concurrent Disorders
264238|NCT01656473|Adolescents
264239|NCT01656473|Motivational Interviewing
264240|NCT01656473|Dialectical Behaviour Therapy
264241|NCT01656473|Caregiver Burden
264242|NCT01656460|Lung Cancer
264243|NCT01656447|Scleroderma
264244|NCT01656447|Scleroderma Registry
264245|NCT01656447|Hospital for Special Surgery Scleroderma
264246|NCT01656434|Combined Oral Contraceptives
264247|NCT01656382|ABLC
264248|NCT01656382|cryptococcosis
264249|NCT01656369|Delorme operation,incontinence
264250|NCT01656356|Avian Flu
264251|NCT01656356|H5N2
264252|NCT01656330|Healthy
264253|NCT01656330|Rivaroxaban
264254|NCT01656330|JNJ-39039039
264255|NCT01656330|BAY59-7939
264256|NCT01656330|Prothrombin Complex Concentrate (PCC)
264257|NCT01656317|SAH
264258|NCT01656317|Early rehabilitation
264259|NCT01656317|Mobilisation
264260|NCT01656278|Arthritis, Rheumatoid/drug therapy
264261|NCT01656278|Arthritis, Rheumatoid/pathology
264262|NCT01656278|Disease Progression
264263|NCT01656278|Longitudinal Studies
264264|NCT01656278|Prospective Studies
264265|NCT01656278|Imaging, Magnetic Resonance
264266|NCT01656278|Remission Induction
264267|NCT01656278|Synovitis/immunology
264268|NCT01656278|Synovitis/pathology
264269|NCT01656278|Wrist Joint/pathology
264270|NCT01656278|Wrist Joint/physiopathology
264271|NCT01656252|Acute Leukemia
264272|NCT01656252|Complete Remission
264273|NCT01656252|Consolidation
264274|NCT01656252|Consolidation Chemotherapy
264275|NCT01656252|Cytarabine
264276|NCT01656252|Eltrombopag
264277|NCT01656252|Leukemia
264278|NCT01656252|Thrombocytopenia
264279|NCT01656252|Thrombopoietin
264280|NCT01656239|VA106483, fedovapagon, Nocturia, males, nocturnal voids, anti-diuretic
264281|NCT01656226|Actinic Keratosis
264282|NCT01656226|AK
264283|NCT01656213|Stroke
264284|NCT01656213|End Stage Renal Disease
264285|NCT01656213|Recovery
264286|NCT01656213|Haemodialysis
264287|NCT01656200|Japanese encephalitis
264288|NCT01656200|Japanese encephalitis vaccine
264289|NCT01656200|T lymphocyte
264290|NCT01656200|Immune response
264291|NCT01656187|memantine
264292|NCT01656187|cognition
264293|NCT01656187|corticosteroid
264294|NCT01656187|prednisone
264295|NCT01656187|memory
264296|NCT01656187|hippocampus
264297|NCT01656148|Multiple sclerosis
264298|NCT01656148|Walking disablility
264299|NCT01656148|Mobility
264300|NCT01656148|Six Spot Step Test
264301|NCT01656148|Outcome measures
264302|NCT01656148|Fampridine-SR
264303|NCT01656148|Fampyra
264304|NCT01656135|gold standard treatment
264305|NCT01656135|immune monitoring
264306|NCT01656135|acute rejection
264307|NCT01656135|graft rejection
264308|NCT01656135|living-donor
264309|NCT01656135|renal transplantation
264310|NCT01656135|kidney transplantation
264311|NCT01656122|pharmacokinetic paramters
264312|NCT01656122|abacavir
264313|NCT01656122|lamuvidine
264314|NCT01656122|HIV-infected children
264315|NCT01656109|pharmacokinetics
264316|NCT01656109|atazanavir/ritonavir
264317|NCT01656109|HIV-infected children
264318|NCT01656083|Mobile phone text messaging (SM)
264319|NCT01656083|Varenicline
264320|NCT01656083|The compliance
264321|NCT01656083|The abstinence rate
264322|NCT01656070|HIV
264323|NCT01656070|children
264324|NCT01656070|adolescents
264325|NCT01656070|Vitamin D
264326|NCT01656070|immunity
264327|NCT01656070|T cell phenotype
264328|NCT01656057|Bile acids
264329|NCT01656057|Gall bladder emptying
264330|NCT01656057|Human
264331|NCT01656057|Glucagon like peptide 1
264332|NCT01656057|GLP-1
264333|NCT01656031|recurrent adult acute lymphoblastic leukemia
264334|NCT01656031|recurrent adult acute myeloid leukemia
264335|NCT01656031|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
264336|NCT01656031|adult acute myeloid leukemia with inv(16)(p13;q22)
264337|NCT01656031|adult acute myeloid leukemia with t(16;16)(p13;q22)
264338|NCT01656031|adult acute myeloid leukemia with t(8;21)(q22;q22)
264339|NCT01656031|adult acute basophilic leukemia
264340|NCT01656031|adult acute eosinophilic leukemia
264341|NCT01656031|adult erythroleukemia (M6a)
264342|NCT01656031|adult pure erythroid leukemia (M6b)
264343|NCT01656031|adult acute megakaryoblastic leukemia (M7)
264344|NCT01656031|adult acute minimally differentiated myeloid leukemia (M0)
264345|NCT01656031|adult acute monoblastic leukemia (M5a)
264346|NCT01656031|adult acute monocytic leukemia (M5b)
264347|NCT01656031|adult acute myeloblastic leukemia with maturation (M2)
264348|NCT01656031|adult acute myeloblastic leukemia without maturation (M1)
264349|NCT01656031|adult acute myelomonocytic leukemia (M4)
264350|NCT01656018|Healthy
264351|NCT01656018|TMC278
264352|NCT01656018|Human Immunodeficiency Virus Type 1
264353|NCT01656018|HIV-1
264354|NCT01656018|Pharmacokinetics
264355|NCT01656018|Ex-vivo pharmacodynamics
264356|NCT01656005|COPD
264357|NCT01656005|Beta blockers
264358|NCT01656005|Cardioselective
264359|NCT01656005|Non-cardioselective
264360|NCT01656005|Impulse oscillometry
264361|NCT01655992|capecitabine
264362|NCT01655992|Tegafur，Gimeracil and Oteracil Potassium Capsules
264363|NCT01655966|chronic hepatitis c
264364|NCT01655966|hcv
264365|NCT01655966|vitamin d
264366|NCT01655927|Neoplasms
264367|NCT01655927|Tranexamic Acid
264368|NCT01655927|Brain Tumors
264369|NCT01655901|Active video games
264370|NCT01655901|Food intake
264371|NCT01655901|Energy balance
264372|NCT01655901|Adolescents
264373|NCT01655888|Tremelimumab
264374|NCT01655888|anti-CTLA-4 monoclonal antibody
264375|NCT01655888|malignant mesothelioma
264376|NCT01655875|Allogeneic Blood and Marrow Transplantation
264377|NCT01655823|Pain
264378|NCT01655823|Puffer fish
264379|NCT01655823|Tetrodotoxin
264380|NCT01655823|TTX
264381|NCT01655823|Neuropathy
264382|NCT01655823|Chemotherapy
264383|NCT01655823|WEX Pharmaceuticals
264384|NCT01655797|insomnia
264385|NCT01655797|cognitive behavior therapy
264386|NCT01655797|primary care
264387|NCT01655784|aneurysm
264388|NCT01655784|intracranial aneurysm
264389|NCT01655784|cerebral aneurysm
264390|NCT01655784|intracranial embolization
264391|NCT01655784|aneurysm embolization
264392|NCT01655784|intracranial coil
264393|NCT01655784|eighteen coils
264394|NCT01655784|bare platinum coils
264395|NCT01655784|GDC Coil
264396|NCT01655784|Target Coil
264397|NCT01655771|Opioid induced constipation
264398|NCT01655771|Constipation
264399|NCT01655758|glaucoma
264400|NCT01655758|24-hour IOP
264401|NCT01655758|outflow drugs
264402|NCT01655758|inflow drugs
264403|NCT01655745|[18F]
264404|NCT01655745|FDG Positron Emission Tomography-Magnetic Resonance Imaging
264405|NCT01655745|FDG-PET-MRI
264406|NCT01655745|Muscle-Invasive Bladder Cancer
264407|NCT01655745|Pilot Study
264408|NCT01655745|LCCC 1209
264409|NCT01655745|UNC Lineberger
264410|NCT01655745|MDCT
264411|NCT01655732|Pregnancy
264412|NCT01655706|major depression
264413|NCT01655706|major depressive disorder
264414|NCT01655706|biomarkers
264415|NCT01655706|escitalopram
264416|NCT01655706|aripiprazole
264417|NCT01655706|MDD
264418|NCT01655706|neuroimaging
264419|NCT01655706|proteomic
264420|NCT01655706|genomics
264421|NCT01655693|Intermediate/advanced hepatocellular carcinoma
264422|NCT01655693|After failure or intolerance to Sorafenib.
264423|NCT01655680|Schizophrenia
264424|NCT01655667|Diagnosis
264425|NCT01655667|Primary Care
264426|NCT01655667|Comorbidities
264427|NCT01655667|Healthcare utilisation
264428|NCT01655654|Hypertension
264429|NCT01655654|Acute hospital staff
264430|NCT01655654|Exercise
264431|NCT01655654|Diet
264432|NCT01655641|Blood transfusion
264433|NCT01655641|Bleeding
264434|NCT01655641|Major Gastro-intestinal surgery
264435|NCT01655641|Tranexamic Acid
264436|NCT01655628|nasopharyngeal carcinoma
264437|NCT01655628|metastasis
264438|NCT01655628|gemcitabine
264439|NCT01655628|CIK cells
264440|NCT01655615|Adolescent cognitive development
264441|NCT01655615|mental disorders
264442|NCT01655615|Mood disorders
264443|NCT01655615|Alcohol-Related disorders
264444|NCT01655615|Mental disorders diagnosed in childhood
264445|NCT01655615|Substance related disorders
264446|NCT01655602|Trichophytic closure
264447|NCT01655602|hair transplantation
264448|NCT01655602|donor site
264449|NCT01655602|Androgenetic alopecia
264450|NCT01655576|drainage
264451|NCT01655576|pregnancy
264452|NCT01655576|active management
264453|NCT01655576|postpartum hemorrhage
264454|NCT01655563|Transplant
264455|NCT01655563|Pediatrics
264456|NCT01655563|Tacrolimus
264457|NCT01655563|Prograf
264458|NCT01655537|fibromyalgia
264459|NCT01655537|cognitive dysfunction
264460|NCT01655524|Regadenoson
264461|NCT01655524|Aminophylline
264462|NCT01655524|ASSUAGE
264463|NCT01655524|Myocardial Perfusion Imaging (MPI)
264464|NCT01655511|Pharmacokinetic
264465|NCT01655511|pharmacodynamic
264466|NCT01655498|fecal incontinence
264467|NCT01655498|bowel control
264468|NCT01655485|child anxiety
264469|NCT01655485|challenging behaviors
264470|NCT01655485|time
264471|NCT01655485|Parent anxiety
264472|NCT01655472|schizophrenia
264473|NCT01655472|imaging
264474|NCT01655459|ultrasound, LMA, fiberoptic bronchoscopy
264475|NCT01655446|Comparative effectiveness research
264476|NCT01655446|Robotic rehabilitation
264477|NCT01655446|Mirror therapy
264478|NCT01655446|Functional electrical therapy
264479|NCT01655446|Combined therapy
264480|NCT01655446|Stroke rehabilitation
264481|NCT01655446|Translational science
264482|NCT01655433|ST-elevation MI
264483|NCT01655433|Hypothermia
264484|NCT01655420|Myopia
264485|NCT01655420|Hyperopia
264486|NCT01655420|Astigmatism
264487|NCT01655420|Patient-reported outcomes
264488|NCT01655420|Patient satisfaction
264489|NCT01655420|Refractive Error
264490|NCT01655420|Emmetropia
264491|NCT01655420|Dry eyes
264492|NCT01655420|Glare
264493|NCT01655420|Halos
264494|NCT01655420|Patient expectations
264495|NCT01655407|Split-thickness Autograft
264496|NCT01655407|Engraftment
264497|NCT01655407|Wound Closure
264498|NCT01655407|Engineered Skin Substitute
264499|NCT01655407|ESS-W
264500|NCT01655407|Cultured Skin Substitutes
264501|NCT01655407|Burn
264502|NCT01655342|pulpotomy
264503|NCT01655342|primary teeth
264504|NCT01655342|Biodentine®
264505|NCT01655342|formocresol
264506|NCT01655329|Image Processing
264507|NCT01655329|tubes
264508|NCT01655329|lines
264509|NCT01655329|catheters
264510|NCT01655329|wires
264511|NCT01655329|Bedside
264512|NCT01655329|chest
264513|NCT01655329|radiographs
264514|NCT01655264|Stroke
264515|NCT01655264|Tele-health
264516|NCT01655264|Rehabilitation
264517|NCT01655264|Intervention
264518|NCT01655264|Gesture recognition system
264519|NCT01655251|children
264520|NCT01655251|fever
264521|NCT01655251|emergency department
264522|NCT01655225|Advanced Breast Cancer
264523|NCT01655225|Advanced Lung Cancer
264524|NCT01655225|Mesothelioma
264525|NCT01655225|Lymphoma
264526|NCT01655212|Cytomegalovirus
264527|NCT01655212|Congenital infection
264528|NCT01655212|Sensorineural hearing loss
264529|NCT01655212|Randomized controlled trial
264530|NCT01655212|Valganciclovir
264531|NCT01655199|Chronic Obstructive Pulmonary Disease
264532|NCT01655199|Lung function
264533|NCT01655199|Exertional dyspnea
264534|NCT01655199|Exercise capacity
264535|NCT01655199|Pulmonary function
264536|NCT01655199|Pleural pressures
264537|NCT01655186|Chronic Kidney Disease
264538|NCT01655186|Type 2 Diabetes Mellitus
264539|NCT01655173|Asperger syndrome
264540|NCT01655173|Autistic disorder
264541|NCT01655173|Adult
264542|NCT01655173|Psychotherapy
264543|NCT01655160|Stroke rehabilitation
264544|NCT01655160|Mirror therapy
264545|NCT01655160|Functional performance
264546|NCT01655160|Kinematic analysis
264547|NCT01655160|Functional magnetic resonance image
264548|NCT01655160|Motor recovery
264549|NCT01655147|Healthy
264550|NCT01655147|Pharmacokinetics
264551|NCT01655147|Abiraterone acetate
264552|NCT01655147|Abiraterone
264553|NCT01655147|JNJ-589485
264554|NCT01655147|JNJ-212082
264555|NCT01655147|Zytiga
264556|NCT01655147|Rifampicin
264557|NCT01655147|Rifadin
264558|NCT01655147|CYP3A4 inducer
264559|NCT01655134|Heart Failure
264560|NCT01655134|Telemonitoring systems for congestive HF
264561|NCT01655134|Biomarkers
264562|NCT01655108|Androgenetic Alopecia
264563|NCT01655108|Mesotherapy
264564|NCT01655108|Minoxidil
264565|NCT01655108|Trichogram
264566|NCT01655095|Colon capsule
264567|NCT01655095|Picosalax
264568|NCT01655095|PEG
264569|NCT01655095|Prucalopride
264570|NCT01655082|Smoking cessation
264571|NCT01655082|Nicotine
264572|NCT01655082|Tobacco Use Disorder
264573|NCT01655082|Central Nervous System Agents
264574|NCT01655069|Overactive bladder (OAB)
264575|NCT01655069|Pediatric
264576|NCT01655069|Solifenacin succinate suspension
264577|NCT01655069|Phase 3
264578|NCT01655056|Pharmacokinetics
264579|NCT01655056|Pharmacodynamics
264580|NCT01655056|Phase 1
264581|NCT01655056|YM150
264582|NCT01655056|Dose-escalating
264583|NCT01655056|Ethnicity
264584|NCT01655056|Caucasian
264585|NCT01655056|Japanese
264586|NCT01655043|Magnetic Resonance Imaging
264587|NCT01655043|regadenoson
264588|NCT01655017|Obesity
264589|NCT01655017|adipose tissue fibrosis
264590|NCT01655017|Adipose tissue inflammation
264591|NCT01655017|Low grade systemic inflammation
264592|NCT01655017|non invasive device
264593|NCT01655017|Bariatric surgery
264594|NCT01655004|hormone receptor positive
264595|NCT01655004|breast cancer
264596|NCT01654939|HIV
264597|NCT01654939|hepatitis C
264598|NCT01654926|Feasibility of using the FlexFlowTM ultrafiltration pump in a non hospital environment
264599|NCT01654913|hemoglobin determination
264600|NCT01654913|oxygen
264601|NCT01654887|Comparative Effectiveness
264602|NCT01654887|Lung Ultrasound versus Chest X-ray
264603|NCT01654887|Pneumonia
264604|NCT01654887|Emergency Department
264605|NCT01654848|liver transplantation
264606|NCT01654848|thrombocytes
264607|NCT01654848|heparin-induced thrombocytopenia
264608|NCT01654848|multivariate analysis of associated factors of HIT 2 after OLT
264609|NCT01654848|laboratory investigations of HIT-antibodies
264610|NCT01654822|HPV
264611|NCT01654822|cervix
264612|NCT01654796|Depression
264613|NCT01654796|Treatment Resistant Depression
264614|NCT01654783|5-ASA, ulcerative colitis, active, remission, adherence
264615|NCT01654770|VCE, DBE,OGIB
264616|NCT01654770|consecutive
264617|NCT01654770|patients
264618|NCT01654731|PBC
264619|NCT01654731|Bezafibrate
264620|NCT01654692|metastatic melanoma
264621|NCT01654692|Ipilimumab
264622|NCT01654679|wound infection
264623|NCT01654679|surgery
264746|NCT01654068|Female Breast Cancer
264624|NCT01654679|surgical wound infection rate
264625|NCT01654679|wound healing
264626|NCT01654666|Remote ischemic preconditioning
264627|NCT01654666|Stroke secondary prevention
264628|NCT01654666|Carotid artery stenting
264629|NCT01654666|Carotid stenosis
264630|NCT01654666|Inflammation
264631|NCT01654653|Heart disease
264632|NCT01654653|cardiac surgery
264633|NCT01654653|CABG
264634|NCT01654653|Totilac
264635|NCT01654653|Voluven
264636|NCT01654653|6% HES
264637|NCT01654640|schizophrenia
264638|NCT01654640|obesity
264639|NCT01654640|clozapine
264640|NCT01654640|metformin
264641|NCT01654627|Guided Tissue Regeneration
264642|NCT01654627|Dental Implants
264643|NCT01654627|Membrane, Synthetic
264644|NCT01654614|Keratoconus match index
264645|NCT01654614|keratoconus probability index
264646|NCT01654614|ocular response analyzer
264647|NCT01654614|Pentacam
264648|NCT01654614|forme fruste keratoconus
264649|NCT01654601|Schizophrenia
264650|NCT01654588|BRONCHIAL CHALLANGE TEST, ASTHMA, METACHLINE, ADENOSINE
264651|NCT01654575|Methotrexate
264652|NCT01654575|Knee Osteoarthritis
264653|NCT01654575|Synovitis
264654|NCT01654575|Pain reduction
264655|NCT01654575|Function scores
264656|NCT01654549|Steatohepatitis,
264657|NCT01654549|Helicobacter pylori,
264658|NCT01654549|Insulin resistance,
264659|NCT01654549|Alanine aminotransferase,
264660|NCT01654549|Aspartate aminotransferase,
264661|NCT01654536|PAR
264662|NCT01654523|Trichotillomania
264663|NCT01654497|Brain
264664|NCT01654497|Glioma
264665|NCT01654497|glioblastoma
264666|NCT01654497|metastases
264667|NCT01654497|cancer
264668|NCT01654497|ETS2101
264669|NCT01654497|leptomeningeal
264670|NCT01654497|astrocytoma
264671|NCT01654497|oligodendroglioma
264672|NCT01654497|meningioma
264673|NCT01654471|Walking Impairment Questionnaire
264674|NCT01654471|Peripheral arterial occlusive disease
264675|NCT01654471|Korean version
264676|NCT01654458|Sexual Dysfunctions, Psychological
264677|NCT01654458|Psychotherapy, Group
264678|NCT01654458|Genital Neoplasms, Female
264679|NCT01654458|Endometrial Neoplasms
264680|NCT01654458|Fallopian Tube Neoplasms
264681|NCT01654458|Ovarian Neoplasms
264682|NCT01654458|Urogenital Neoplasms
264683|NCT01654458|Uterine Cervical Neoplasms
264684|NCT01654458|Uterine Neoplasms
264685|NCT01654458|Vaginal Neoplasms
264686|NCT01654458|Vulvar Neoplasms
264687|NCT01654445|Minor stroke
264688|NCT01654419|sliding jig
264689|NCT01654419|Class II malocclusion
264690|NCT01654419|Distalization mechanics
264691|NCT01654419|Intermaxillary elastics
264692|NCT01654406|Cesarian scar
264693|NCT01654406|Fractional CO2 laser
264694|NCT01654393|Triage nurse
264695|NCT01654393|Ottawa ankle rules
264696|NCT01654354|Qualitative Evaluation of abdominal CT image using 4 point scale: Excellent(4)/ Good(3) / Fair(2) / Unacceptable(1)
264697|NCT01654328|contrast media
264698|NCT01654328|kidney injury
264699|NCT01654328|hydration
264700|NCT01654315|RTP Only Group
264701|NCT01654315|Myomo Only Group
264702|NCT01654315|Myom0 + RTP Group
264703|NCT01654289|respiratory tract infections
264704|NCT01654289|common cold
264705|NCT01654289|exercise
264706|NCT01654289|influenza
264707|NCT01654289|meditation
264708|NCT01654263|13-valent,23-valent,elderly,parent protocol,Pneumococcal infections,vaccine
264709|NCT01654250|ADHD
264710|NCT01654250|methylphenidate extended-release
264711|NCT01654237|work
264712|NCT01654237|WMSD
264713|NCT01654237|prevalence
264714|NCT01654237|occupational risks
264715|NCT01654237|industry
264716|NCT01654237|questionnaires
264717|NCT01654237|musculoskeletal pain
264718|NCT01654237|lifestyle
264719|NCT01654224|Influenza in Long Term Care Setting
264720|NCT01654224|High dose Inactivated influenza vaccine
264721|NCT01654224|Standard dose inactivated influenza vaccine
264722|NCT01654172|Diabetes
264723|NCT01654172|peripheral neuropathy
264724|NCT01654172|Cocoa flavanols
264725|NCT01654159|intraocular lenses
264726|NCT01654159|evaluation
264727|NCT01654159|cataract
264728|NCT01654146|Ovarian cancer
264729|NCT01654146|Epithelial ovarian carcinoma
264730|NCT01654146|Fallopian tube carcinoma
264731|NCT01654146|Primary serous peritoneal carcinoma
264732|NCT01654146|Gynaecological carcinoma
264733|NCT01654146|Randomised controlled trial
264734|NCT01654133|Aortic Aneurysm, abdominal
264735|NCT01654120|insulin
264736|NCT01654120|Type II Diabetes
264737|NCT01654120|liraglutide
264738|NCT01654120|Glucagon-Like Peptide 1
264739|NCT01654107|tobacco
264740|NCT01654107|smoking cessation
264741|NCT01654107|nicotine dependence
264742|NCT01654081|Lung Cancer
264743|NCT01654081|POSITIVE NON SMALL CELL CARCINOMA
264744|NCT01654081|ISG15
264745|NCT01654081|IRINOTECAN
264747|NCT01654068|Kidney Cancer
264748|NCT01654068|Lung Cancer
264749|NCT01654068|Prostate Cancer
264750|NCT01654068|Vertebral metastasis
264751|NCT01654055|Morphine - Adverse events - Predictive factors
264752|NCT01654042|anticoagulation
264753|NCT01654042|warfarin
264754|NCT01654042|monitoring
264755|NCT01654042|bleeding
264756|NCT01654042|thromboembolism
264757|NCT01654029|Stroke
264758|NCT01654029|Communication impairments
264759|NCT01654029|Nurse-patient communication
264760|NCT01654029|Patient-centred care
264761|NCT01654016|varicose veins
264762|NCT01654016|inflammation
264763|NCT01654003|Goal-directed therapy
264764|NCT01654003|severe sepsis
264765|NCT01654003|emergency surgery
264766|NCT01654003|vasopressor
264767|NCT01654003|dynamic flow-related parameters
264768|NCT01653977|Hypovolemic shock
264769|NCT01653977|trauma
264770|NCT01653977|emergency
264771|NCT01653977|surgery
264772|NCT01653977|GDT
264773|NCT01653977|Picco
264774|NCT01653964|suspicious
264775|NCT01653964|lesion
264776|NCT01653964|breast
264777|NCT01653964|cancer
264778|NCT01653964|screening
264779|NCT01653964|mammogram
264780|NCT01653964|negative
264781|NCT01653938|CHF
264782|NCT01653925|Prostatic Neoplasms
264783|NCT01653925|Low grade prostate cancer
264784|NCT01653912|cancer
264785|NCT01653912|ovarian
264786|NCT01653912|platinum-resistant
264787|NCT01653899|Type I Diabetes
264788|NCT01653886|Palatability
264789|NCT01653886|Taste
264790|NCT01653873|fracture
264791|NCT01653873|vertebral column
264792|NCT01653873|osteoporosis
264793|NCT01653873|predictor
264794|NCT01653873|vertebroplasty
264795|NCT01653860|Behavior therapy
264796|NCT01653860|Group therapy
264797|NCT01653847|transplant
264798|NCT01653847|kidney
264799|NCT01653847|renal disease
264800|NCT01653834|lymphopenia
264801|NCT01653821|carotid body
264802|NCT01653821|heart failure
264803|NCT01653821|chemoreceptor
264804|NCT01653821|hypersensitivity
264805|NCT01653808|CKD dialysis
264806|NCT01653808|hemodialysis
264807|NCT01653808|hemodiafiltration
264808|NCT01653808|Elisio dialyzer
264809|NCT01653808|efficacy
264810|NCT01653808|biocompatibility
264811|NCT01653782|LPB
264812|NCT01653782|RCT
264813|NCT01653782|Intervention study
264814|NCT01653782|Cost effectiveness
264815|NCT01653782|Yoga
264816|NCT01653782|evidence based
264817|NCT01653782|advice to stay active
264818|NCT01653782|exercise training
264819|NCT01653769|CoSeal
264820|NCT01653769|Surgical bleeding
264821|NCT01653769|hemostasis
264822|NCT01653769|Aortic anastamoses
264823|NCT01653769|bleeding
264824|NCT01653769|Cardiac surgery
264825|NCT01653769|Aneurysms
264826|NCT01653769|Aortic Dissection
264827|NCT01653756|Asthma
264828|NCT01653756|Allergen Challenge
264829|NCT01653743|Japanese
264830|NCT01653730|portable oxygen concentrator
264831|NCT01653730|6-minute walk test
264832|NCT01653730|chronic obstructive lung disease
264833|NCT01653730|pulmonary fibrosis
264834|NCT01653730|long term oxygen therapy
264835|NCT01653717|Advanced Cancers
264836|NCT01653717|Leukemia
264837|NCT01653717|B-cell Chronic Lymphocytic Leukemia
264838|NCT01653717|B-CLL
264839|NCT01653717|CD19 positivity
264840|NCT01653717|CD19-specific T cells
264841|NCT01653717|T-Cell Infusion
264842|NCT01653717|Gene Transfer
264843|NCT01653717|Leukapheresis
264844|NCT01653717|Fludarabine
264845|NCT01653717|Fludarabine Phosphate
264846|NCT01653717|Fludara
264847|NCT01653717|Cyclophosphamide
264848|NCT01653717|Cytoxan
264849|NCT01653717|Neosar
264850|NCT01653691|Pediatric
264851|NCT01653691|Burns
264852|NCT01653691|Scars
264853|NCT01653691|Pulse Dye laser
264854|NCT01653678|vitamin D-3
264855|NCT01653678|omega-3 fatty acids
264856|NCT01653678|fish oil
264857|NCT01653678|hypertension
264858|NCT01653678|blood pressure
264859|NCT01653652|grass pollen
264860|NCT01653652|allergic rhinitis
264861|NCT01653652|TNSS
264862|NCT01653652|miniRQLQ
264863|NCT01653639|BAY14-2222
264864|NCT01653639|Pharmacokinetics
264865|NCT01653613|B-cell adult acute lymphoblastic leukemia
264866|NCT01653613|B-cell childhood acute lymphoblastic leukemia
264867|NCT01653613|untreated adult acute lymphoblastic leukemia
264868|NCT01653613|untreated childhood acute lymphoblastic leukemia
264869|NCT01653600|peripheral arterial disease
264870|NCT01653600|atherosclerosis
264871|NCT01653600|nitinol
264872|NCT01653600|stents
264873|NCT01653587|Transradial Approach
264874|NCT01653587|Transfemoral Approach
264875|NCT01653587|Vascular Closure Device
264876|NCT01653574|Famitinib Malate
264877|NCT01653574|Metastatic Breast Cancer
264878|NCT01653574|HER-2 negative
264879|NCT01653561|Metastatic breast cancer
264880|NCT01653561|Apatinib
264881|NCT01653561|non-triple-negative
264882|NCT01653548|emotion dysregulation
264883|NCT01653548|borderline personality disorder
264884|NCT01653548|anxiety
264885|NCT01653548|depression
264886|NCT01653548|negative emotions
264887|NCT01653548|outpatient interventions for negative emotions
264888|NCT01653548|psychological distress
264889|NCT01653548|emotion regulation problems
264890|NCT01653535|Prevention
264891|NCT01653535|Health Service Use
264892|NCT01653535|Behavioral Intervention
264893|NCT01653535|Conduct Problems
264894|NCT01653535|Anti-Social Behavior
264895|NCT01653509|cold sore
264896|NCT01653496|Gastric cancer
264897|NCT01653496|Perioperative care
264898|NCT01653496|Enhanced recovery after surgery
264899|NCT01653496|Multimodal rehabilitation
264900|NCT01653496|Fast track surgery
264901|NCT01653496|Gastrectomy
264902|NCT01653483|Asthma
264903|NCT01653483|Umeclidinium
264904|NCT01653483|Adolescent
264905|NCT01653483|Pharmacokinetics
264906|NCT01653457|Fibromyalgia
264907|NCT01653457|Magnetic Resonance Spectroscopy
264908|NCT01653457|Memantine
264909|NCT01653457|electroencephalic cordance
264910|NCT01653405|anticoagulants
264911|NCT01653405|pharmacists
264912|NCT01653405|quality improvement
264913|NCT01653405|quality of health care
264914|NCT01653392|Maternal Mortality
264915|NCT01653392|Obstetric Labor, Premature
264916|NCT01653392|Eclampsia
264917|NCT01653392|Pre-Eclampsia
264918|NCT01653392|Abortion, Spontaneous
264919|NCT01653392|Diabetes, Gestational
264920|NCT01653392|Pregnancy, Ectopic
264921|NCT01653392|Hydatidiform Mole
264922|NCT01653392|Fetal death
264923|NCT01653392|Live birth
264924|NCT01653392|Still birth
264925|NCT01653392|Premature Birth
264926|NCT01653392|Sex ratio
264927|NCT01653392|Birth weight
264928|NCT01653366|Breast Cancer
264929|NCT01653353|nursing home
264930|NCT01653353|vitamin D supplements
264931|NCT01653353|calcium supplements
264932|NCT01653353|guideline adherence
264933|NCT01653340|Refractory Chronic Migraine
264934|NCT01653340|Medically Intractable Chronic Migraine
264935|NCT01653340|High Frequency Spinal Cord Stimulator
264936|NCT01653327|mucositis
264937|NCT01653327|head and neck
264938|NCT01653327|cancer
264939|NCT01653327|radiation therapy
264940|NCT01653327|chemoradiation
264941|NCT01653327|oral
264942|NCT01653327|pain
264943|NCT01653275|Mediterranean Diet
264944|NCT01653275|Bone turnover
264945|NCT01653275|postmenopausal women
264946|NCT01653262|Brivaracetam
264947|NCT01653262|Levetiracetam
264948|NCT01653262|Epilepsy
264949|NCT01653262|Nonpsychotic behavior
264950|NCT01653249|human papillomavirus (HPV)
264951|NCT01653249|vaccine
264952|NCT01653249|treatment
264953|NCT01653210|Insulin Pump
264954|NCT01653210|Continuous Glucose Monitor
264955|NCT01653210|Premenopausal women
264956|NCT01653184|AMD
264957|NCT01653184|Vision loss
264958|NCT01653184|omega-3
264959|NCT01653184|supplement
264960|NCT01653184|age related macular degeneration
264961|NCT01653171|Acetylcysteine, Simethicone, Stomach Neoplasms
264962|NCT01653158|non-hematologic cancer
264963|NCT01653158|advanced solid tumors
264964|NCT01653158|prostrate cancer
264965|NCT01653145|Appetite
264966|NCT01653145|Satiety
264967|NCT01653132|PD
264968|NCT01653119|Acute coronary syndrome
264969|NCT01653119|Diabetes mellitus
264970|NCT01653119|Statins
264971|NCT01653119|High loading dose
264972|NCT01653119|Recurrent events
264973|NCT01653106|cryotherapy
264974|NCT01653106|Melphalan
264975|NCT01653106|Mucositis
264976|NCT01653080|Solid Tumor
264977|NCT01653080|Eye
264978|NCT01653080|Orbit
264979|NCT01653067|Non Hodgkin´s Lymphoma
264980|NCT01653067|Diffuse Large B-Cell Lymphoma
264981|NCT01653067|Aggressive Lymphoma
264982|NCT01653067|Aggressive Non Hodgkin´s Lymphoma
264983|NCT01653067|NHL
264984|NCT01653067|aNHL
264985|NCT01653067|Temsirolimus
264986|NCT01653067|Torisel
264987|NCT01653067|Relapsed Non Hodgkin´s Lymphoma
264988|NCT01653067|Relapsed Diffuse Large B-Cell Lymphoma
264989|NCT01653067|aggressive NHL
264990|NCT01653067|B-NHL
264991|NCT01653067|aggressive B-NHL
264992|NCT01653041|immunosuppression, identical HLA, kidney transplantation, everolimus
264993|NCT01653002|Lung cancer
264994|NCT01653002|EBUS-TBNA
264995|NCT01653002|Epigenetics
264996|NCT01653002|shox2 protein, human
264997|NCT01652989|weight loss
264998|NCT01652989|weight loss maintenance
264999|NCT01652989|community based participatory research
265000|NCT01652989|overweight
265001|NCT01652976|Metastatic
265002|NCT01652976|Pancreatic Cancer
265003|NCT01652976|Adenocarcinoma
265004|NCT01652950|Physical activity
265005|NCT01652950|health-insured
265006|NCT01652950|Financial Incentives
265007|NCT01652950|Benefits design
265008|NCT01652937|Rheumatoid Arthritis
265009|NCT01652937|DMARD-IR
265010|NCT01652924|mechanical ventilation
265011|NCT01652924|manual ventilation
265012|NCT01652911|Islet Transplantation
265013|NCT01652911|Cell Pouch
265014|NCT01652898|PK
265015|NCT01652885|atopic dermatitis
265016|NCT01652872|anemia
265017|NCT01652872|chronic kidney disease
265018|NCT01652872|kidney disease
265019|NCT01652872|renal failure
265020|NCT01651806|Blood loss
265021|NCT01651806|transfusion rates
265022|NCT01651806|complications
265023|NCT01651793|cacao
265024|NCT01651793|theobromine
265025|NCT01651793|flavanols
265026|NCT01651793|caffeine
265027|NCT01651793|sustained attention
265028|NCT01651793|vigilance
265029|NCT01651793|vigor
265030|NCT01651793|vitality
265031|NCT01651793|energy
265032|NCT01651793|fatigue
265033|NCT01651780|Transcatheter aortic valve replacement
265034|NCT01651780|aortic valve replacement
265035|NCT01651780|aortic valve insufficiency
265036|NCT01651780|severe aortic stenosis
265037|NCT01651767|Chronic hepatitis C virus infection
265038|NCT01651767|JNJ-47910382
265039|NCT01651767|Pharmacokinetics
265040|NCT01651767|Caucasian genotype-1
265041|NCT01651767|Non-structural protein 5A (NS5A) inhibitor
265042|NCT01651741|Intestinal Microbiota
265043|NCT01651741|Probiotics
265044|NCT01651741|Seaweed
265045|NCT01651741|Healthy Subject
265046|NCT01651728|Simvastatin
265047|NCT01651728|Pneumonia
265048|NCT01651728|Elderly
265049|NCT01651728|TNF-α
265050|NCT01651728|IFN-ϒ
265051|NCT01651728|PAI-1
265052|NCT01651728|CRP
265053|NCT01651702|Arrhythmia
265054|NCT01651702|Electroanatomical mapping
265055|NCT01651689|Scalp biopsy
265056|NCT01651689|Hair count
265057|NCT01651689|Vertical section
265058|NCT01651689|Horizontal section
265059|NCT01651689|Thais
265060|NCT01651676|VQ11 questionnaire
265061|NCT01651676|COPD
265062|NCT01651676|LBD
265063|NCT01652833|Metastatic Colorectal Cancer
265064|NCT01652820|LUNG
265065|NCT01652820|DOCETAXEL
265066|NCT01652820|GEMCITABINE
265067|NCT01652820|CARBOPLATIN
265068|NCT01652820|RADIOTHERAPY
265069|NCT01652781|myelodysplastic syndrome
265070|NCT01652781|azacitidine
265071|NCT01652781|dosing schedule
265072|NCT01652768|Malignant Brain Tumors
265073|NCT01652768|Malignant Glioma
265074|NCT01652768|High-grade Gliomas
265075|NCT01652768|Oncology
265076|NCT01652768|Cancer
265077|NCT01652768|Patient Caregiver
265078|NCT01652768|Caregiver Stress, Anxiety, Depression
265079|NCT01652768|Palliative Care Intervention
265080|NCT01652755|cystatin C,acute kidney injury,
265081|NCT01652729|Diabetes, Type 2, exenatide, Sitagliptin
265082|NCT01652703|Japanese, hypercholesterolemia, high risk for cardiovascular events
265083|NCT01652677|navigation transcranial magnetic stimulation
265084|NCT01652677|stroke rehabilitation
265085|NCT01652651|Learning Disorders
265086|NCT01652638|subjects
265087|NCT01652625|Yunnan Baiyao
265088|NCT01652625|recurrent aphthous stomatitis
265089|NCT01652625|clinical trial
265090|NCT01652612|positive end expiratory pressure
265091|NCT01652599|Eltrombopag
265092|NCT01652599|Dexamethasone
265093|NCT01652599|High-dose
265094|NCT01652599|ITP
265095|NCT01652586|cardiac ablation
265096|NCT01652573|X linked hypophosphatemia
265097|NCT01652573|calcitonin
265098|NCT01652573|FGF twenty three
265099|NCT01652560|bevacizumab
265100|NCT01652560|neoadjuvant chemotherapy
265101|NCT01652560|HER2-negative breast cancer
265102|NCT01652547|Melanoma
265103|NCT01652547|Merkel cell carcinoma
265104|NCT01652547|Metastatic skin cancer
265105|NCT01652534|Freezing of gait
265106|NCT01652534|gait dysfunction
265107|NCT01652521|lung compliance
265108|NCT01652521|pleural effusion
265109|NCT01652521|esophageal pressure
265110|NCT01652508|smoking cessation
265111|NCT01652508|Acceptance and Commitment Therapy
265112|NCT01652508|primary care setting
265113|NCT01652508|randomised controlled trial
265114|NCT01652495|rotatory cuff calcific tendonitis
265115|NCT01652495|corticosteroids
265116|NCT01652495|US guided percutaneous treatment
265117|NCT01652495|methylprednisolone
265118|NCT01652495|triamcinolone
265119|NCT01652495|hypothalamus pituitary adrenal axis
265120|NCT01652469|squamous cell
265121|NCT01652469|NSCLC
265122|NCT01652469|TKI
265123|NCT01652469|Erlotinib
265124|NCT01652469|Docetaxel
265125|NCT01652469|VeriStrat
265126|NCT01652469|protein signature
265127|NCT01652456|addiction support
265128|NCT01652456|addiction specialist
265129|NCT01652456|lung cancer
265130|NCT01652456|head and neck cancer
265131|NCT01652443|OEF/OIF Veterans
265132|NCT01652443|Relationships
265133|NCT01652430|PTSD
265134|NCT01652430|Suicidal ideation
265135|NCT01652430|Cognitive processes
265136|NCT01652417|Methylprednisolone
265137|NCT01652417|prednisone
265138|NCT01652417|renal sarcoidosis treatment
265139|NCT01652404|ICU
265140|NCT01652404|sepsis
265141|NCT01652404|antibiotic therapy
265142|NCT01652404|procalcitonin
265143|NCT01652378|cocaine addiction
265144|NCT01652378|neuroimaging
265145|NCT01652378|functional magnetic resonance imaging (fMRI)
265146|NCT01652365|Malaria Diagnosis
265147|NCT01652365|Rapid Diagnostic Tests
265148|NCT01652365|RDTs
265149|NCT01652365|Private Sector
265150|NCT01652365|Retail Sector
265151|NCT01652365|Drug Shops
265152|NCT01652352|Disabled
265153|NCT01652352|Disability
265154|NCT01652352|Power wheelchair
265155|NCT01652352|Wheelchair
265156|NCT01652352|Wheelchair mounted robotic arm
265157|NCT01652352|WMRA
265158|NCT01652352|Assistive
265159|NCT01652352|Assistive robot
265160|NCT01652352|Assistive robotics
265161|NCT01652352|Rehabilitation robot
265162|NCT01652352|Rehabilitation engineering
265163|NCT01652352|Rehabilitation robotics
265164|NCT01652300|Oral health
265165|NCT01652300|education
265166|NCT01652300|knowledge
265167|NCT01652300|attitude
265168|NCT01652300|performance
265169|NCT01652274|Child Passenger Safety
265170|NCT01652274|Parental perception of vulnerability
265171|NCT01652274|Neonatology
265172|NCT01652274|Newborn
265173|NCT01652261|advanced stage
265174|NCT01652248|Heart failure
265175|NCT01652248|Pacemaker
265176|NCT01652248|cardiac resynchronization therapy
265177|NCT01652235|Abdominal aortic aneurysm
265178|NCT01652235|Endovascular
265179|NCT01652235|Fenestration
265180|NCT01652235|Juxtarenal
265181|NCT01652235|Off-the-shelf
265182|NCT01652235|Pararenal
265183|NCT01652222|Alzheimer
265184|NCT01652222|caregiver
265185|NCT01652222|dementia
265186|NCT01652222|social support
265187|NCT01652222|Montessori
265188|NCT01652222|Therapeutic game
265189|NCT01652196|colorectal cancer
265190|NCT01652196|rectal cancer
265191|NCT01652196|FOLFOX
265192|NCT01652196|Aflibercept
265193|NCT01652183|Intravenous paracetamol
265194|NCT01652183|catheter related bladder discomfort
265195|NCT01652183|urologic surgery
265196|NCT01652157|prospective
265197|NCT01652157|pancreatic insufficiency
265198|NCT01652157|fibrosing colonopathy
265199|NCT01652157|observational
265200|NCT01652157|pancreatic enzyme replacement therapy
265201|NCT01652131|general anesthesia
265202|NCT01652131|volume kinetics
265203|NCT01652118|bronchopulmonary dysplasia
265204|NCT01652118|clarithromycin
265205|NCT01652118|preterm babies
265206|NCT01652105|Gastric bypass
265207|NCT01652105|Preoperative diet
265208|NCT01652105|Prodimed
265209|NCT01652092|immunodeficiency disorder
265210|NCT01652092|histiocytic disorder
265211|NCT01652079|Epithelial
265212|NCT01652079|Primary
265213|NCT01652053|InterCushion
265214|NCT01652040|Spinal Cord Injury
265215|NCT01652040|Rehabilitation
265216|NCT01652040|Electrical Stimulation
265217|NCT01652040|Testosterone
265218|NCT01652040|Body Composition
265219|NCT01652040|Lipid and Glucose profile
265220|NCT01652040|Ectopic Adiposity
265221|NCT01652027|FVIII inhibitors
265222|NCT01652014|Transplantation
265223|NCT01652014|Hematopoietic Stem Cell Transplantation
265224|NCT01652001|Xerostomia
265225|NCT01652001|Antidepressant agents
265226|NCT01652001|Antihypertensive agents
265227|NCT01651988|ketamine
265228|NCT01651988|propofol anesthesia
265229|NCT01651975|Dysphagia
265230|NCT01651975|Thickening liquid
265231|NCT01651975|Thickening agent
265232|NCT01651975|Fluoroscopic swallow study
265233|NCT01651975|Aspiration
265234|NCT01651975|History of dysphagia
265235|NCT01651975|DSS
265236|NCT01651975|Age > 18
265237|NCT01651975|comprehensive DSS
265238|NCT01651975|informed consent
265239|NCT01651962|Labor Pain
265240|NCT01651962|Analgesia, Epidural
265241|NCT01651923|subjects
265242|NCT01651910|Cancer Pain
265243|NCT01651910|Breakthrough Pain
265244|NCT01651910|Unmet Needs
265245|NCT01651910|Supportive care needs
265246|NCT01651897|delirium
265247|NCT01651897|emergency department
265248|NCT01651897|natural course
265249|NCT01651897|outcomes
265250|NCT01651897|elderly
265251|NCT01651884|Stroke
265252|NCT01651884|Anomia
265253|NCT01651871|Agents, anti allergic
265254|NCT01651871|Nasal congestion
265255|NCT01651871|Sneezing
265256|NCT01651871|Nasal discharge
265257|NCT01651871|D prostanoid (DP) receptor antagonist
265258|NCT01651832|Colorectal Neoplasms/*drug therapy/*secondary
265259|NCT01651832|Health Services Accessibility
265260|NCT01651832|Humans
265261|NCT01651832|Supportive Care Needs
265262|NCT01651832|Psychooncology
265263|NCT01651832|Rural Population
265264|NCT01651832|Primary Health Care/*methods
265265|NCT01651832|Treatment Outcome
265266|NCT01651832|Socioeconomic Factors
265267|NCT01651832|Quality Assurance, Health Care
265268|NCT01651832|Quality of Life
265269|NCT01651832|Adult
265270|NCT01651832|Aged
265271|NCT01651832|Aged, 80 and over
265272|NCT01651819|HTLV-1
265273|NCT01651819|neurogenic bladder
265274|NCT01651819|physical therapy
265275|NCT01651819|Tropical Spastic Paraparesis
265276|NCT01651663|Influenza
265277|NCT01651650|Asthma
265278|NCT01651650|PIF
265279|NCT01651637|Respiratory Distress syndrome
265280|NCT01651637|Complications of prematurity
265281|NCT01651624|Colorectal Cancer
265282|NCT01651624|Screening
265283|NCT01651624|Fecal Occult Blood Test
265284|NCT01651624|CT Colonography
265285|NCT01651624|Virtual Colonoscopy
265286|NCT01651624|Colonoscopy
265287|NCT01651611|Tobacco Cessation
265288|NCT01651611|Public Housing
265289|NCT01651611|Community Health Workers
265290|NCT01651611|Motivational Interviewing
265291|NCT01651611|Patient centered
265292|NCT01651611|Low-income
265293|NCT01651611|Tobacco Treatment Advocates
265294|NCT01651611|Social Epidemiology
265295|NCT01651611|Smoking cessation predictors
265296|NCT01651611|Behavioral Intervention
265297|NCT01651611|Non-pharmacologic
265298|NCT01651585|viral disease
265299|NCT01651585|cytomegalovirus infection
265300|NCT01651585|is the first cause
265301|NCT01651585|of congenital
265302|NCT01651585|neurological handicap
265303|NCT01651585|of infectious origin.
265304|NCT01651572|Postoperative residual curarization
265305|NCT01651572|Residual neuromuscular block
265306|NCT01651572|Complications
265307|NCT01651572|Postoperative
265308|NCT01651572|Neuromuscular function
265309|NCT01651572|Neuromuscular block
265310|NCT01651559|modified PASI
265311|NCT01651559|narrow band UVB phototherapy
265312|NCT01651559|Dead Sea Minerals
265313|NCT01651559|Skin auto-Fluorescence
265314|NCT01651559|Skin wash samples
265315|NCT01651546|Clean Intermittent Self Catheterization
265316|NCT01651546|acceptance
265317|NCT01651546|test
265318|NCT01651533|Mental practice group
265319|NCT01651533|Active control group
265320|NCT01651520|Neurodegeneration
265321|NCT01651520|Disability
265322|NCT01651520|Cognition
265323|NCT01651520|Prognosis
265324|NCT01651507|Pulmonary Langerhans cell histiocytosis
265325|NCT01651494|Influenza, DAS181, Multi-Dose, inpatient clinic, recombinant neuraminidase, inhalation
265326|NCT01651481|Rhinitis
265327|NCT01651468|mild bleeding disorder
265328|NCT01651455|Cystic Fibrosis
265329|NCT01651455|Pseudomonas Aeruginosa
265330|NCT01651429|Sleep Deprivation
265331|NCT01651416|Home management of malaria
265332|NCT01651416|Seasonal malaria chemoprevention
265333|NCT01651403|Hepatitis
265334|NCT01651403|Hepatitis B
265335|NCT01651403|HBV
265336|NCT01651390|Restenosis
265337|NCT01651390|Drug coated balloon
265338|NCT01651390|Drug eluting stent
265339|NCT01651390|Paclitaxel
265340|NCT01651390|Sirolimus
265341|NCT01651377|Pramipexole
265342|NCT01651377|Mirapex
265343|NCT01651377|Cocaine
265344|NCT01651364|Cocaine
265345|NCT01651364|Cabergoline
265346|NCT01651351|Condition:
265347|NCT01651351|for this study
265348|NCT01651351|Focus
265349|NCT01651351|volunteers
265350|NCT01651338|Acupuncture
265351|NCT01651338|quality of life
265352|NCT01651325|Isavuconazole
265353|NCT01651325|dextromethorphan
265354|NCT01651325|dextrorphan
265355|NCT01651325|DXM
265356|NCT01651325|Healthy Volunteers
265357|NCT01651325|BAL4815
265358|NCT01651312|Radioactivity
265359|NCT01651312|Excretion rate
265360|NCT01651312|Human subjects
265361|NCT01651312|Pharmacokinetics
265362|NCT01651312|YM178
265363|NCT01651312|Radio-labeled
265364|NCT01651312|Phase 1
265365|NCT01651299|copperhead snake envenomation
265366|NCT01651286|General anesthesia
265367|NCT01651286|Positive-pressure ventilation
265368|NCT01651286|Masks
265369|NCT01651247|Toddlers
265370|NCT01651247|Retrospective
265371|NCT01651247|Porcine circovirus type 1 (PCV-1)
265372|NCT01651247|Infants
265373|NCT01651247|Laboratory evaluations
265374|NCT01651247|IPV
265375|NCT01651221|gustatory response
265376|NCT01651221|olfactory response
265377|NCT01651208|Coronary stents
265378|NCT01651208|Medication adherence
265379|NCT01651208|Antiplatelet medications
265380|NCT01651208|Motivational Interviewing
265381|NCT01651182|Blood transfusion
265382|NCT01651182|Blood loss
265383|NCT01651182|Postoperative complications
265384|NCT01651182|Outcome
265385|NCT01651169|Paired Transcranial Magnetic Stimulation
265386|NCT01651169|Methamphetamine abuse, ADHD, Methylphenidate
265387|NCT01651169|We study the effect of Methamphetamine abuse on Intracortical Inhibition, in ADHD patients, treated with Methylphenidate.
265388|NCT01651130|pregnancy
265389|NCT01651130|postpartum hemorrhage
265390|NCT01651130|Cesarean delivery
265391|NCT01651130|carbetocin
265392|NCT01651117|Diabetes Mellitus
265393|NCT01651117|Mentors
265394|NCT01651117|Glucose control
265395|NCT01651117|Hemoglobin A, Glycosylated
265396|NCT01651117|Randomized Controlled Trial
265397|NCT01651117|Veterans
265398|NCT01651104|Influenza, Trivalent, Adjuvanted, Adjuvant, MF59, MF-59, Fluad, Seasonal
265399|NCT01651078|Metastatic Brain Tumors
265400|NCT01651078|Progression
265401|NCT01651078|Radiation Necrosis
265402|NCT01651078|Quality of Life
265403|NCT01651052|Aortic valve replacement/regurgitation
265404|NCT01651039|Panobinostat
265405|NCT01651039|Lenalidomide
265406|NCT01651039|Dexamethasone
265407|NCT01651000|Parathyroid Diseases
265408|NCT01651000|Renal Insufficiency
265409|NCT01651000|Kidney Failure, Chronic
265410|NCT01651000|Hyperparathyroidism, Secondary
265411|NCT01651000|Vitamin D
265412|NCT01651000|Hyperparathyroidism
265413|NCT01651000|Kidney Diseases
265414|NCT01651000|Kidney Failure
265415|NCT01651000|Renal Insufficiency, Chronic
265416|NCT01650987|carcinoma
265417|NCT01650987|uterus
265418|NCT01650987|Not metastatic
265419|NCT01650974|high flow nasal oxygen therapy
265420|NCT01650974|diagnostic bronchoscopy
265421|NCT01650948|age-related macular degeneration
265422|NCT01650948|AMD
265423|NCT01650935|Nephrolithiasis
265424|NCT01650935|Recurrent stone former
265425|NCT01650935|DASH
265426|NCT01650935|Urine oxalate
265427|NCT01650935|Urine calcium oxalate supersaturation
265428|NCT01650896|Delirium
265429|NCT01650896|Dementia
265430|NCT01650896|Instrumental activities of daily living
265431|NCT01650883|Vitamin D3
265432|NCT01650883|Vitamin D 25 OH
265433|NCT01650870|Cathartics
265434|NCT01650870|Laxatives
265435|NCT01650870|Lactulose
265436|NCT01650870|Gastrointestinal Agents
265437|NCT01650870|Therapeutic Uses
265438|NCT01650870|Pharmacologic Actions
265439|NCT01650857|Pulmonary hypertension
265440|NCT01650857|Rehabilitation
265441|NCT01650857|Exercise capacity
265442|NCT01650857|Body composition
265443|NCT01650857|Health related Quality of Life
265444|NCT01650831|Helicobacter Pylori
265445|NCT01650831|13C Urea Breath Test
265446|NCT01650831|BreathID
265447|NCT01650818|Amyotrophic lateral sclerosis
265448|NCT01650818|Aerobic training
265449|NCT01650818|Peak oxygen consumption
265450|NCT01650818|Quality of life
265451|NCT01650805|Leukemia
265452|NCT01650805|Leukemia, Myeloid
265453|NCT01650805|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
265454|NCT01650805|Neoplasms by Histologic Type
265455|NCT01650805|Neoplasms
265456|NCT01650805|Lymphoproliferative Disorders
265457|NCT01650805|Lymphatic Diseases
265458|NCT01650805|Immunoproliferative Disorders
265459|NCT01650805|Immune System Diseases
265460|NCT01650805|Myeloproliferative Disorders
265461|NCT01650805|Bone Marrow Diseases
265462|NCT01650805|Hematologic Diseases
265463|NCT01650792|Chagas disease
265464|NCT01650792|Heart failure
265465|NCT01650792|Stroke
265466|NCT01650792|Dementia
265467|NCT01650779|alpha-galactosidase A
265468|NCT01650779|a-GAL
265469|NCT01650779|Fabry
265470|NCT01650779|GL-3
265471|NCT01650779|Fabrazyme
265472|NCT01650701|follicular lymphoma
265473|NCT01650701|non-hodgkins follicular lymphoma
265474|NCT01650701|treatment for follicular lymphoma
265475|NCT01650701|rituximab treatment
265476|NCT01650701|rituximab and lenalidomide treatment
265477|NCT01650688|Epiblepharon, general anesthesia, positional change
265478|NCT01650675|pregnancy
265479|NCT01650675|screening
265480|NCT01650675|motivation
265481|NCT01650662|Acute Myocardial Infarction
265482|NCT01650662|Cyclosporine A
265483|NCT01650662|Reperfusion
265484|NCT01650662|Clinical Trial
265485|NCT01650649|lofexidine
265486|NCT01650649|methadone
265487|NCT01650649|interaction
265488|NCT01650649|pharmacodynamic
265489|NCT01650649|ECG
265490|NCT01650649|QTc
265491|NCT01650636|Videophone-delivered stress management intervention
265492|NCT01650636|Chronic fatigue syndrome
265493|NCT01650636|Symptoms
265494|NCT01650636|Neuroimmune processes
265495|NCT01650636|Psychosocial
265496|NCT01650623|Parkinson´s Disease
265497|NCT01650623|Rehabilitation
265498|NCT01650623|Cognition
265499|NCT01650610|Parkinson´s Disease
265500|NCT01650610|Rehabilitation
265501|NCT01650610|Cognition
265502|NCT01650597|Healthy volunteers
265503|NCT01650597|Pharmacokinetics
265504|NCT01650597|Free fatty amides
265505|NCT01650558|Malaria
265506|NCT01650558|HIV
265507|NCT01650558|Prophylaxis
265508|NCT01650558|Antiretroviral therapy
265509|NCT01650545|case-control study
265510|NCT01650545|aerosolized liposomal cyclosporine A
265511|NCT01650545|bronchiolitis obliterans syndrome
265512|NCT01650545|Lung Transplantation
265513|NCT01650545|Lung function
265514|NCT01650519|knee surgery, arthroscopy; orthopaedic, orthopedic surgery
265515|NCT01650506|Triple Negative
265516|NCT01650506|Basal-like
265517|NCT01650493|remineralization
265518|NCT01650493|demineralzation
265519|NCT01650493|in situ
265520|NCT01650493|dentrifice
265521|NCT01650480|COPD
265522|NCT01650480|holistic
265523|NCT01650480|pilot
265524|NCT01650480|intervention
265525|NCT01650467|abl polymorphisms
265526|NCT01650454|Alzheimer
265527|NCT01650454|Sleep
265528|NCT01650454|Somnolence
265529|NCT01650441|Asthma
265530|NCT01650441|NEXThaler®
265531|NCT01650441|Formoterol
265532|NCT01650441|Beclomethasone Dipropionate
265533|NCT01650441|Computational Fluid Dynamics
265534|NCT01650441|Functional Imaging
265535|NCT01650441|Central and Peripheral Airways
265536|NCT01650441|Asthma Control Test (ACT™)
265537|NCT01650441|Asthma Control Questionnaire (ACQ)
265538|NCT01650428|Rectal Cancer
265539|NCT01650428|Bevacizumab
265540|NCT01650428|Neoadjuvant
265541|NCT01650428|Chemotherapy
265542|NCT01650428|Randomised
265543|NCT01650415|Cerebral Palsy
265544|NCT01650415|Erythropoietin
265545|NCT01650415|Rehabilitation
265546|NCT01650402|Hypertension, systolic
265547|NCT01650402|Elderly (> or equal to 75 years)
265548|NCT01650402|Cerebrovascular disease
265549|NCT01650389|Tuberculosis
265550|NCT01650389|HIV
265551|NCT01650389|BCG
265552|NCT01650389|Infant
265553|NCT01650376|Ovarian Neoplasms
265554|NCT01650376|Cancer of the Ovary
265555|NCT01650376|Ovarian Cancer
265556|NCT01650376|Uterine Neoplasms
265557|NCT01650376|Cancer of the Uterus
265558|NCT01650376|Uterine Cancer
265559|NCT01650376|Olaparib
265560|NCT01650376|AZD2281
265561|NCT01650376|Carboplatin
265562|NCT01650376|Paclitaxel
265563|NCT01650376|Relapsed
265564|NCT01650363|Complementary and alternative medicine
265565|NCT01650363|Post operative recovery
265566|NCT01650363|Cardio- thoracic surgery
265567|NCT01650350|Melanoma
265568|NCT01650350|Prostate Cancer
265569|NCT01650350|Renal Cancer
265570|NCT01650324|DBPR108
265571|NCT01650324|DPP4
265572|NCT01650324|Diabetes
265573|NCT01650324|GLP-1
265574|NCT01650324|Incretins
265575|NCT01650311|IBD, CD, UC, Serotonin, 5-HT
265576|NCT01650285|Prostate Cancer
265577|NCT01650285|Radical prostatectomy
265578|NCT01650207|electroacupuncture
265579|NCT01650207|TENS
265580|NCT01650207|shoulder disorder
265581|NCT01650207|hemiplegia
265582|NCT01650194|MDV3100
265583|NCT01650194|prostate
265584|NCT01650194|cancer
265585|NCT01650194|enzalutamide
265586|NCT01650194|abiraterone acetate
265587|NCT01650194|prednisone
265588|NCT01650181|nafld, nash, fatty liver
265589|NCT01650168|NOMAC-E2
265590|NCT01650168|Nomegestrol acetate
265591|NCT01650168|Estradiol
265592|NCT01650168|Levonorgestrel
265593|NCT01650168|Safety
265594|NCT01650142|Neurofibromatosis 1
265595|NCT01650142|Phenotype
265596|NCT01650142|Modifiers
265597|NCT01650116|hypovolemia
265598|NCT01650116|renal hypoperfusion
265599|NCT01650116|liver transplantation
265600|NCT01650116|sodium
265601|NCT01650116|chloride
265602|NCT01650116|PuCO2
265603|NCT01650116|ScvO2
265604|NCT01650116|PiCCO
265605|NCT01650116|O2-delivery
265606|NCT01650116|hemodynamic indexes
265607|NCT01650103|hypovolemia
265608|NCT01650103|renal hypoperfusion
265609|NCT01650103|major surgery
265610|NCT01650103|sodium
265611|NCT01650103|potassium
265612|NCT01650103|chloride
265613|NCT01650103|ScvO2
265614|NCT01650103|hemodynamic indexes
265615|NCT01650090|Pulmonary relapse
265616|NCT01650090|Osteosarcoma
265617|NCT01650090|Lung metastases
265618|NCT01650090|Pediatric osteosarcoma
265619|NCT01650090|Inhaled chemotherapy
265620|NCT01650090|Inhaled Lipid Cisplatin
265621|NCT01650077|Soft tissue sarcoma
265622|NCT01650077|Yondelis
265623|NCT01650077|Intolerance to doxorubicin/ifosfamide
265624|NCT01650077|CHOI criteria
265625|NCT01650064|Hip fracture
265626|NCT01650064|Mortality
265627|NCT01650038|faecal transplantation
265628|NCT01650038|ulcerative colitis
265629|NCT01650038|inflammatory bowel disease
265630|NCT01650025|probiotic, obesity, BMI, metabolic profile, metabolomics
265631|NCT01649999|Rheumatoid Arthritis
265632|NCT01649999|ASP015K
265633|NCT01649986|Hyperlipidemia
265634|NCT01649986|Non-pharmacologic prevention
265635|NCT01649960|Aging
265636|NCT01649960|Biomarkers
265637|NCT01649960|CAD
265638|NCT01649947|Lung cancer
265639|NCT01649947|Non-small cell lung cancer
265640|NCT01649947|Advanced non-small cell lung cancer
265641|NCT01649947|Recurrent non-small cell lung cancer
265642|NCT01649934|Appointments and Schedules
265643|NCT01649921|Sepsis
265644|NCT01649921|SIRS
265645|NCT01649921|Septic shock
265646|NCT01649921|Immunoparalysis
265647|NCT01649921|Interferon-gamma
265648|NCT01649895|Obsessive-compulsive disorder
265649|NCT01649895|internet
265650|NCT01649895|cognitive-behaviour therapy
265651|NCT01649895|D-Cycloserine
265652|NCT01649882|endotracheal tube position
265653|NCT01649882|intubation
265654|NCT01649843|Peroral endoscopic myotomy
265655|NCT01649843|Esophageal Achalasia
265656|NCT01649830|low-grade glioma
265657|NCT01649830|radiotherapy
265658|NCT01649830|chemotherapy
265659|NCT01649765|SLE Flare Index
265660|NCT01649765|SRI
265661|NCT01649765|belimumab
265662|NCT01649765|efficacy
265663|NCT01649765|safety
265664|NCT01649765|B lymphocyte
265665|NCT01649765|BLyS
265666|NCT01649765|SELENA SLEDAI
265667|NCT01649765|BILAG
265668|NCT01649765|Lupus
265669|NCT01649765|Systemic Lupus Erythematosus (SLE)
265670|NCT01649765|PGA
265671|NCT01649765|Pharmacokinetics
265672|NCT01649765|placebo
265673|NCT01649765|PRINTO
265674|NCT01649752|Stem cells
265675|NCT01649752|Uterine cavity
265676|NCT01649752|Implantation
265677|NCT01649752|ICSI
265678|NCT01649739|PAH
265679|NCT01649713|Fluval AB
265680|NCT01649713|influenza
265681|NCT01649713|vaccine
265682|NCT01649713|immunization
265683|NCT01649713|infections
265684|NCT01649661|MRI
265685|NCT01649661|12-125
265686|NCT01649661|premenopausal women
265687|NCT01649661|postmenopausal women
265688|NCT01649661|questionnaire
265689|NCT01649648|Hypoxic ischemic encephalopathy
265690|NCT01649648|Autologous cord blood
265691|NCT01649622|Leukemia
265692|NCT01649622|Lymphoma
265693|NCT01649622|Acute Lymphoblastic Leukemia/Lymphoma
265694|NCT01649622|ALL
265695|NCT01649622|Relapsed or primary refractory B-cell/T-cell
265696|NCT01649622|Bendamustine
265697|NCT01649622|Bendamustine Hydrochloride
265698|NCT01649622|Bendamustine HCL
265699|NCT01649622|CEP-18083
265700|NCT01649622|SDX-105
265701|NCT01649622|Treanda
265702|NCT01649609|BK Viremia
265703|NCT01649609|BK Nephropathy
265704|NCT01649609|mTOR inhibitor
265705|NCT01649609|renal transplant
265706|NCT01649557|Schizophrenia
265707|NCT01649544|Mitral valvulopathy
265708|NCT01649544|Atrial Fibrillation
265709|NCT01649544|Amiodarone
265710|NCT01649544|Paroxysmal Atrial Fibrillation
265711|NCT01649544|Chronic Atrial Fibrillation
265712|NCT01649544|Ultrasound Technique
265713|NCT01649492|diclofenac
265714|NCT01649492|CYP2C9
265715|NCT01649492|bromelain
265716|NCT01649492|pineapple juice
265717|NCT01649479|Obstetrical antiphospholipid syndrome
265718|NCT01649479|Thrombophilia
265719|NCT01649466|Type 2 diabetes mellitus, diabetes
265720|NCT01649453|Neoplasms
265721|NCT01649453|Neoplasm Metastasis
265722|NCT01649453|Neoplastic Processes
265723|NCT01649453|Pathologic Processes
265724|NCT01649440|Metabolomics
265725|NCT01649440|serum
265726|NCT01649440|sepsis
265727|NCT01649440|biomarkers
265728|NCT01649427|Pharmacokinetics Study
265729|NCT01649427|Tacroliums
265730|NCT01649427|GFR
265731|NCT01649427|kdney
265732|NCT01649401|nebulizer
265733|NCT01649401|PARI LC Spring SP
265734|NCT01649388|Kidney transplant
265735|NCT01649388|Delayed tolerance
265736|NCT01649388|Marrow/enriched hematopoetic stem cell transplant
265737|NCT01649375|Ankylosing spondylitis
265738|NCT01649375|AS
265739|NCT01649375|Chronic inflammatory disease
265740|NCT01649375|Inflammatory back pain
265741|NCT01649375|Secukinumab
265742|NCT01649375|Prefilled syringe (PFS)
265743|NCT01649375|Subcutaneous injection
265744|NCT01649375|AIN457
265745|NCT01649375|AIN457F
265746|NCT01649375|AIN457F2310
265747|NCT01649362|preterm infant
265748|NCT01649362|feeding difficulties
265749|NCT01649362|prefeeding oral stimulation
265750|NCT01649310|Chronic obstructive pulmonary disease (COPD)
265751|NCT01649310|Muscle strenght
265752|NCT01649310|Aged
265753|NCT01649245|Chronic hepatitis C
265754|NCT01649245|Egyptian patients
265755|NCT01649245|pegylated interferon
265756|NCT01649245|Ribavirin
265757|NCT01649245|Reiferon retard
265758|NCT01649232|tdcs
265759|NCT01649232|tms
265760|NCT01649232|qeeg
265761|NCT01649232|neuroplasticity
265762|NCT01649232|brain networks
265763|NCT01649232|add
265764|NCT01649232|adhs
265765|NCT01649219|Prediabetes, objectively measured exercise, glucose and lipid metabolism, dose response, muscle metabolism.
265766|NCT01649206|Thyroid Nodule
265767|NCT01649206|Radiofrequency Thermal Ablation
265768|NCT01649206|Pressure symptoms
265769|NCT01649206|Hyperthyroidism
265770|NCT01649193|Rehabilitation [E02.831]
265771|NCT01649193|Exercise [G11.427.394.380]
265772|NCT01649193|Health Education [I02.233.332]
265773|NCT01649193|[C08]
265774|NCT01649193|[C08.381]
265775|NCT01649180|RCC
265776|NCT01649180|Clear Cell Renal Cell Carcinoma
265777|NCT01649180|ccRCC
265778|NCT01649180|Metastatic RCC
265779|NCT01649180|Recurrent RCC
265780|NCT01649180|Kidney Cancer
265781|NCT01649180|Kidney Neoplasms
265782|NCT01649180|Axitinib
265783|NCT01649180|AG-013736
265784|NCT01649180|Tyrosine Kinase Inhibition
265785|NCT01649180|TKI
265786|NCT01649167|body mass index
265787|NCT01649167|gestational diabetes
265788|NCT01649167|leptin
265789|NCT01649167|obesity
265790|NCT01649167|pregnancy.
265791|NCT01649141|posttraumatic stress disorder
265792|NCT01649141|trauma-focused cognitive behavioral therapy
265793|NCT01649141|trauma
265794|NCT01649141|child abuse
265795|NCT01649128|preeclampsia
265796|NCT01649115|obesity
265797|NCT01649115|overweight
265798|NCT01649115|childhood obesity
265799|NCT01649115|prevention
265800|NCT01649115|Z score
265801|NCT01649115|weight for length
265802|NCT01649115|WFL
265803|NCT01649115|body mass index
265804|NCT01649115|BMI
265805|NCT01649115|prenatal
265806|NCT01649115|maternal
265807|NCT01649115|nutrition education
265808|NCT01649115|health education
265809|NCT01649115|health literacy
265810|NCT01649115|health numeracy
265811|NCT01649115|passport
265812|NCT01649115|healthy lifestyles
265813|NCT01649115|growth
265814|NCT01649115|growth chart
265815|NCT01649102|Chronic hemodialysis
265816|NCT01649102|Tunneled cuffed catheter
265817|NCT01649102|Catheter-related bloodstream infection
265818|NCT01649102|Mechanical catheter dysfunction
265819|NCT01649102|impact of catheter design on outcome
265820|NCT01649063|Uterine contraction;
265821|NCT01649063|Shape; Frequency;
265822|NCT01649063|First stage labor;
265823|NCT01649063|Fall
265824|NCT01649063|Rise ratio.
265825|NCT01649050|Spasticity
265826|NCT01649050|Multiple Sclerosis
265827|NCT01649024|Tremelimumab
265828|NCT01649024|Malignant Mesothelioma
265829|NCT01649024|anti-CTLA-4 mAb
265830|NCT01649011|Oswestry Disability Index
265831|NCT01649011|ODI
265832|NCT01649011|Roland Morris Disability Questionnaire
265833|NCT01649011|RMDQ
265834|NCT01648998|Mineralocorticoid receptor
265835|NCT01648998|Fludrocortisone
265836|NCT01648998|Information Processing
265837|NCT01648998|Cognition
265838|NCT01648998|Depression
265839|NCT01648946|Strategies of transfusion
265840|NCT01648946|Red blood cells
265841|NCT01648946|Liberal
265842|NCT01648946|Restrictive
265843|NCT01648946|Oncologic critically ill patients
265844|NCT01648933|sarcoidosis
265845|NCT01648933|heart
265846|NCT01648933|Rubidium
265847|NCT01648933|PET
265848|NCT01648920|Asthma
265849|NCT01648920|Suspected but undiagnosed asthma
265850|NCT01648907|DESIR
265851|NCT01648907|SPONDYLARTHRITIS
265852|NCT01648907|EARLY INFLAMMATORY RACHIIALGIA
265853|NCT01648907|BACK PAIN
265854|NCT01648894|Rectal cancer
265855|NCT01648894|radiochemotherapy
265856|NCT01648894|complete pathological response
265857|NCT01648868|TMSAutism
265858|NCT01648868|Eye-tracking
265859|NCT01648868|Social perception
265860|NCT01648868|Social cognition
265861|NCT01648855|Circulating antiangiogenic factors
265862|NCT01648855|Preeclampsia
265863|NCT01648855|Developing lung
265864|NCT01648855|Bronchopulmonary dysplasia
265865|NCT01648842|Preeclampsia
265866|NCT01648842|Vitamin D deficiency
265867|NCT01648842|Pregnancy
265868|NCT01648842|First trimester
265869|NCT01648777|Pneumonia
265870|NCT01648777|Postoperative infection
265871|NCT01648777|Cardiac surgery
265872|NCT01648777|Multiperforated catheter
265873|NCT01648777|Analgesia
265874|NCT01648751|Pelvic organ prolapse
265875|NCT01648751|Pelvic floor physical therapy
265876|NCT01648751|Vaginal estrogen
265877|NCT01648751|Placebo
265878|NCT01648738|Subacute low back pain
265879|NCT01648738|Chronic low back pain
265880|NCT01648738|Low back pain
265881|NCT01648738|Disability
265882|NCT01648738|Education
265883|NCT01648738|Exercise
265884|NCT01648738|Spa therapy
265885|NCT01648738|Physiotherapy
265886|NCT01648738|Multidisciplinary
265887|NCT01648738|Cost-effectiveness
265888|NCT01648738|Sick leave
265889|NCT01648725|Hypnosis
265890|NCT01648725|Anesthesia
265891|NCT01648725|Propofol
265892|NCT01648725|Closed-loop
265893|NCT01648712|extracorporeal circuit, platelet function
265894|NCT01648699|Pain
265895|NCT01648699|Cancer
265896|NCT01648699|Osmotic Release Oral System
265897|NCT01648699|OROS Hydromorphone
265898|NCT01648699|Jurnista
265899|NCT01648686|Alendronate
265900|NCT01648686|Dental extraction
265901|NCT01648686|Bone healing
265902|NCT01648686|postmenopausal women
265903|NCT01648686|dental radiography
265904|NCT01648673|Coronary Artery Disease
265905|NCT01648673|Cardiac Rehabilitation
265906|NCT01648634|Nebivolol
265907|NCT01648634|beta-blockade treatment
265908|NCT01648621|COPD
265909|NCT01648621|case management
265910|NCT01648595|Fentanyl
265911|NCT01648595|analgesia
265912|NCT01648595|duration of the active phase
265913|NCT01648595|pain severity
265914|NCT01648556|Purpura thrombopenic
265915|NCT01648556|Medullary cytogenetics
265916|NCT01648556|Myelodysplasic syndrome
265917|NCT01648556|bone marrow biopsy
265918|NCT01648517|on-small cell lung carcinoma
265919|NCT01648517|chemotherapy naive patient
265920|NCT01648504|Colonoscopy
265921|NCT01648504|Screening colonoscopy
265922|NCT01648504|Electronic education
265923|NCT01648504|Ipad
265924|NCT01648504|Patient education
265925|NCT01648478|IRAP
265926|NCT01648478|insulin sensitivity marker
265927|NCT01648465|metastatic
265928|NCT01648465|unresectable
265929|NCT01648465|well or moderately differentiated
265930|NCT01648465|advanced
265931|NCT01648452|Achromatopsia
265932|NCT01648452|Ciliary Neurotrophic Factor
265933|NCT01648452|CNTF
265934|NCT01648322|Breast Cancer
265935|NCT01648322|Taxotere Chemotherapy
265936|NCT01648322|Neulasta
265937|NCT01648322|efficacy and safety
265938|NCT01648322|single cycle doses of F-627
265939|NCT01648322|pegfilgrastim
265940|NCT01648309|aortic stenosis
265941|NCT01648309|TAVI
265942|NCT01648309|neuropsychological
265943|NCT01648309|cognitive
265944|NCT01648309|candidates for TAVI
265945|NCT01648296|Heart Failure
265946|NCT01648296|Obesity
265947|NCT01648296|Type 2 Diabetes Mellitus
265948|NCT01648296|Health Normal Volunteer Subjects
265949|NCT01648283|methadone polymorphisms
265950|NCT01648270|buprenorphine concentration-effect (miosis) relationship
265951|NCT01648257|healthy subjects
265952|NCT01648257|relative bioavailability
265953|NCT01648257|HIV
265954|NCT01648257|GSK1265744
265955|NCT01648244|DM, T2DM, Diabetes
265956|NCT01648231|Healthy Volunteer
265957|NCT01648218|glucocorticoid
265958|NCT01648218|diabetes mellitus
265959|NCT01648218|post-transplant
265960|NCT01648218|insulin
265961|NCT01648205|ranolazine
265962|NCT01648205|clinical trial
265963|NCT01648179|GSK1322322, relative bioavailability, healthy subjects, open label, food effect, weight effect
265964|NCT01648166|trace
265965|NCT01648166|element
265966|NCT01648166|lung
265967|NCT01648166|cancer
265968|NCT01648166|Appalachia
265969|NCT01648153|Efficacy
265970|NCT01648153|Obese
265971|NCT01648153|T2DM
265972|NCT01648153|IL-18
265973|NCT01648153|Monoclonal antibody (mAb)
265974|NCT01648140|Genotype 4
265975|NCT01648140|GSK2336805
265976|NCT01648140|pegylated interferon
265977|NCT01648140|telaprevir
265978|NCT01648140|Genotype 1
265979|NCT01648140|chronic hepatitis C
265980|NCT01648140|ribavirin
265981|NCT01648140|NS5A inhibitor
265982|NCT01648140|hepatitis C virus (HCV) infection
265983|NCT01648127|Ceftaroline
265984|NCT01648127|Pharmacokinetics
265985|NCT01648127|Obesity
265986|NCT01648114|breastfeeding
265987|NCT01648114|pregnancy
265988|NCT01648114|antenatal
265989|NCT01648114|exclusive breastfeeding
265990|NCT01648114|education
265991|NCT01648101|Retigabine IR
265992|NCT01648101|Asian Subjects
265993|NCT01648101|Adjunctive Therapy
265994|NCT01648101|Efficacy
265995|NCT01648101|Drug-Resistant
265996|NCT01648101|Safety & tolerability
265997|NCT01648101|Partial-Onset Seizures
265998|NCT01648101|Epilepsy
265999|NCT01648088|staphylococcus aureus
266000|NCT01648088|prosthetic joint implantation
266001|NCT01648075|caries
266002|NCT01648075|probiotics
266003|NCT01648075|lactobacilli
266004|NCT01648062|Sleep
266005|NCT01648062|self-regulation
266006|NCT01648062|Implementation intentions
266007|NCT01648062|intervention
266008|NCT01648062|mental simulation
266009|NCT01648023|LC Bead
266010|NCT01648023|Irinotecan
266011|NCT01648023|ONCOZENE BEAD
266012|NCT01648010|Non Muscle Invasive Bladder Cancer
266013|NCT01648010|Carcinoma of urinary bladder, invasive
266014|NCT01648010|Intravesical instillation
266015|NCT01648010|Mitomycin C
266016|NCT01648010|Hydrogel
266017|NCT01648010|Reverse thermal gelation
266018|NCT01648010|Drug retention
266019|NCT01648010|radical cystectomy
266020|NCT01647997|bacterial lipopolysaccharides
266021|NCT01647997|hyperlactatemia
266022|NCT01647997|muscle lactate
266023|NCT01647984|Arrhythmias
266024|NCT01647984|Life quality
266025|NCT01647971|Lymphoma
266026|NCT01647971|Rituxan
266027|NCT01647971|Relapsed
266028|NCT01647971|Refractory
266029|NCT01647958|TEMPO
266030|NCT01647958|TIF
266031|NCT01647958|Transoral Incisionless Fundoplication
266032|NCT01647958|EsophyX System
266033|NCT01647958|refractory symptoms
266034|NCT01647958|proton pump inhibitors
266035|NCT01647958|EndoGastric Solutions
266036|NCT01647958|EGS
266037|NCT01647958|Acid Reflux
266038|NCT01647958|Heartburn
266039|NCT01647958|Regurgitation
266040|NCT01647945|PAH WHO group 1
266041|NCT01647932|Heart Failure
266042|NCT01647932|Diuretics
266043|NCT01647932|Diuretic resistance
266044|NCT01647919|Cognition
266045|NCT01647919|Attention
266046|NCT01647919|Memory
266047|NCT01647919|Mood
266048|NCT01647867|Met fragments expression
266049|NCT01647854|emergency medical service
266050|NCT01647854|telemedicine
266051|NCT01647854|teleconsultation
266052|NCT01647854|safety
266053|NCT01647828|Newly diagnosed Stage IV Pancreatic Cancer
266054|NCT01647815|Axillary vein ultrasound
266055|NCT01647815|Subclavian vein ultrasound
266056|NCT01647802|standing devices
266057|NCT01647802|transfer devices
266058|NCT01647789|prostate cancer, castration resistant,
266059|NCT01647776|Colon Neoplasia
266060|NCT01647776|Colorectal carcinoma
266061|NCT01647776|colon cancer
266062|NCT01647776|colon polyp
266063|NCT01647776|colonoscopy
266064|NCT01647776|sDNA test
266065|NCT01647776|FIT tests (fecal immunochemical test)
266066|NCT01647776|relating colon neoplasia to obesity, type 2 diabetes
266067|NCT01647776|colonoscopy and pathology confirmed advanced adenomas
266068|NCT01647763|Hemorrhoids
266069|NCT01647737|Xerostomia
266070|NCT01647737|Sjogren syndrome
266071|NCT01647737|dry mouth
266072|NCT01647724|cervical cancer
266073|NCT01647724|prevention
266074|NCT01647724|screening
266075|NCT01647698|Parkinson Disease
266076|NCT01647698|near transfer
266077|NCT01647698|far transfer
266078|NCT01647698|working memory
266079|NCT01647698|fluid intelligence
266080|NCT01647698|cognitive training
266081|NCT01647698|dual n-back
266082|NCT01647685|Vesselwall inflammation
266083|NCT01647685|liposomal prednisolone
266084|NCT01647659|MEK inhibitor GSK1120212
266085|NCT01647659|pharmacokinetics
266086|NCT01647659|powder for oral solution
266087|NCT01647659|Solid Tumors
266088|NCT01647659|pediatric formulation
266089|NCT01647646|asthma
266090|NCT01647646|SMART
266091|NCT01647646|fixed dose
266092|NCT01647633|rhinitis
266093|NCT01647633|stuffy nose
266094|NCT01647633|congestion
266095|NCT01647633|Sneezing
266096|NCT01647607|Breast Cancer
266097|NCT01647607|Young Women
266098|NCT01647607|Fertility
266099|NCT01647607|Physical Activity
266100|NCT01647607|Survivorship
266101|NCT01647594|Breast cancer
266102|NCT01647594|Young women
266103|NCT01647594|Fertility
266104|NCT01647594|Physical activity
266105|NCT01647594|Survivorship
266106|NCT01647581|hemoclip
266107|NCT01647581|colonoscopy
266108|NCT01647581|post-polypectomy bleed
266109|NCT01647555|Cetuximab
266110|NCT01647555|radiotherapy
266111|NCT01647555|epidermoid head and neck cancer
266112|NCT01647542|Drug therapy
266113|NCT01647529|Cytomegalovirus
266114|NCT01647529|uveitis
266115|NCT01647529|endotheliitis
266116|NCT01647529|ganciclovir
266117|NCT01647503|parathyroid gland
266118|NCT01647503|primary hyperparathyroidism
266119|NCT01647503|proteins
266120|NCT01647477|non treated cancer
266121|NCT01647477|oral cavity
266122|NCT01647477|oropharynx
266123|NCT01647477|hypopharynx
266124|NCT01647477|larynx
266125|NCT01647477|first consultation
266126|NCT01647438|South Asians
266127|NCT01647438|Diabetes
266128|NCT01647438|Physical Activity
266129|NCT01647438|Coronary Heart Disease
266130|NCT01647438|Lifestyle
266131|NCT01647425|head and neck cancer
266132|NCT01647425|lung cancer
266133|NCT01647425|tobacco use disorder
266134|NCT01647425|alcoholism
266135|NCT01647412|Crohn's disease
266136|NCT01647412|Inflammatory Bowel Disease
266137|NCT01647412|Growth Hormone
266138|NCT01647412|Nutraceuticals
266139|NCT01647399|Obesity
266140|NCT01647399|Asthma
266141|NCT01647399|Vitamin D
266142|NCT01647399|Allergy
266143|NCT01647399|Genetic
266144|NCT01647399|Childhood
266145|NCT01647399|Pediatric
266146|NCT01647399|cohort
266147|NCT01647399|observational
266148|NCT01647399|prospective
266149|NCT01647399|molecular
266150|NCT01647373|retinal detachment
266151|NCT01647373|scleral buckle
266152|NCT01647373|silicone sponge
266153|NCT01647373|axial length
266154|NCT01647373|surgery included silicone sponge scleral buckling
266155|NCT01647373|retina currently attached
266156|NCT01647373|at least 6 months after surgery
266157|NCT01647360|Metrorrhagia
266158|NCT01647360|Menorrhagia
266159|NCT01647347|bacteria
266160|NCT01647347|bacteremia
266161|NCT01647347|PVP-iodine
266162|NCT01647347|periodontitis
266163|NCT01647321|SPMS
266164|NCT01647295|visual exploration
266165|NCT01647295|pupil size
266166|NCT01647295|social interactions
266167|NCT01647295|faces
266168|NCT01647295|human motion
266169|NCT01647256|Bioavailability
266170|NCT01647256|Fed
266171|NCT01647256|Fasting
266172|NCT01647243|Knee osteoarthritis
266173|NCT01647243|Total knee arthroplasty
266174|NCT01647243|Preoperative training
266175|NCT01647243|Strength training
266176|NCT01647230|Anaesthesia, spinal
266177|NCT01647230|Cerebral oximetry
266178|NCT01647230|Blood pressure
266179|NCT01647230|Heart rate
266180|NCT01647230|Cognitive Symptom
266181|NCT01647217|Blepharitis
266182|NCT01647217|Demodex
266183|NCT01647217|Mites
266184|NCT01647217|Tea Tree oil
266185|NCT01647217|Terpinen
266186|NCT01647204|Nutrition
266187|NCT01647204|older
266188|NCT01647204|hospital
266189|NCT01647204|volunteer
266190|NCT01647191|HCV，
266191|NCT01647191|drug users，
266192|NCT01647191|intervention
266193|NCT01647165|Maintenance Strategy
266194|NCT01647165|Plasma Cell Neoplasm
266195|NCT01647165|Proteasome Inhibitor
266196|NCT01647165|Immunomodulatory Drugs
266197|NCT01647165|Novel Therapy
266198|NCT01647152|Uveitis
266199|NCT01647152|Ustekinumab
266200|NCT01647152|IL 12/23
266201|NCT01647152|Stelara
266202|NCT01646866|autism
266203|NCT01646866|siblings
266204|NCT01646866|genetic test
266205|NCT01646866|screening
266206|NCT01646840|PF-04958242
266207|NCT01646840|bioequivalence
266208|NCT01646840|pharmacokinetics
266209|NCT01646840|Schizophrenia
266210|NCT01646827|Schizophrenia, extended release antipsychotic
266211|NCT01646814|Healthy volunteer
266212|NCT01646814|comparison of incidence of
266213|NCT01646814|treatment groups.
266214|NCT01646775|opioid
266215|NCT01646775|malignancy
266216|NCT01646775|epidural
266217|NCT01646749|Energy intake
266218|NCT01646749|Beef protein
266219|NCT01646749|Satiety
266220|NCT01646749|Protein leverage hypothesis
266221|NCT01646736|Lupus Nephritis
266222|NCT01646736|Cyclophosphamide
266223|NCT01646736|Tripterygium
266224|NCT01646710|Tool
266225|NCT01646710|FBR
266226|NCT01646710|Advocacy
266227|NCT01646710|Development of a tool
266228|NCT01646710|advocacy materials
266229|NCT01646697|pancreatic cancer
266230|NCT01646697|adenocarcinoma
266231|NCT01646697|pancreatic resection
266232|NCT01646684|Prostate cancer, pasireotide LAR, castration resistant prostatate cancer, CRPC, SOM230 LAR
266233|NCT01646671|Hypertension, Severe, LCZ696
266234|NCT01646645|CMVpp65 specific T-cells
266235|NCT01646645|Stem Cell Transplantation
266236|NCT01646645|12-086
266237|NCT01646632|institutionalized ADL fitness care-dependency
266238|NCT01646619|Hypoxic Ischemic Encephalopathy
266239|NCT01646619|Therapeutic Hypothermia
266240|NCT01646619|Therapeutic Hypothermia plus Adjuvant Therapy
266241|NCT01646619|Cooling
266242|NCT01646606|Bronchiolitis
266243|NCT01646606|Length of stay
266244|NCT01646606|Pilot Projects
266245|NCT01646606|Oxygen saturation monitoring
266246|NCT01646580|dermatomycoses, tinea, candidiasis, children
266247|NCT01646567|psoriasis
266248|NCT01646554|Liver metastases
266249|NCT01646554|Colorectal Cancer
266250|NCT01646554|KRAS mutated
266251|NCT01646554|FOLFOX
266252|NCT01646554|Aflibercept
266253|NCT01646554|Randomized
266254|NCT01646554|Phase II-III
266255|NCT01646554|Perioperative treatment
266256|NCT01646554|Adjuvant
266257|NCT01646554|Neo-adjuvant
266258|NCT01646554|Surgery
266259|NCT01646554|Progression Free Survival
266260|NCT01646528|Gastric Intestinal Metaplasia
266261|NCT01646528|Confocal Laser Endomicroscopy
266262|NCT01646515|systolic heart failure
266263|NCT01646515|udenafil
266264|NCT01646515|exercise capacity
266265|NCT01646502|chronic wound
266266|NCT01646502|treatment
266267|NCT01646502|biofilms
266268|NCT01646502|venous insufficiency
266269|NCT01646502|Esp
266270|NCT01646489|Antisense
266271|NCT01646489|miR-122 antagonist
266272|NCT01646489|Safety in healthy volunteers
266273|NCT01646489|Hepatitis C
266274|NCT01646463|mindfulness
266275|NCT01646463|stress
266276|NCT01646463|coping
266277|NCT01646463|emotion
266278|NCT01646463|depression
266279|NCT01646463|group medical visits
266280|NCT01646463|prenatal healthcare
266281|NCT01646463|preterm birth
266282|NCT01646463|birth weight
266283|NCT01646463|postpartum depression
266284|NCT01646463|cortisol
266285|NCT01646463|neuroendocrine function
266286|NCT01646463|blood pressure
266287|NCT01646463|health disparities
266288|NCT01646450|NSCLC
266289|NCT01646450|EGFR Mutation
266290|NCT01646450|Elder patients
266291|NCT01646424|COPD,
266292|NCT01646424|Patient satisfaction,
266293|NCT01646424|fix combination,
266294|NCT01646424|NIS Turkey,
266295|NCT01646424|turbuhaler,
266296|NCT01646424|FSI-10
266297|NCT01646411|cytomegalovirus (CMV) IgM &IgG
266298|NCT01646411|Lyme
266299|NCT01646411|Toxoplasma
266300|NCT01646411|Rubella
266301|NCT01646411|Rubeola IgM
266302|NCT01646411|Rocky mountain Spotted Fever IgM
266303|NCT01646411|Ebv IgM
266304|NCT01646411|Herpes
266305|NCT01646411|Babesia
266306|NCT01646411|Measles
266307|NCT01646411|Tetanus
266308|NCT01646411|Mumps
266309|NCT01646411|Mycoplasma
266310|NCT01646411|Legionella
266311|NCT01646411|Giardia
266312|NCT01646411|Syphilis
266313|NCT01646411|Bordetella Pertussis
266314|NCT01646411|H Pylori
266315|NCT01646411|Antibody Titre
266316|NCT01646411|Elevated IgG
266317|NCT01646411|Abnormal IgM
266318|NCT01646411|SLE
266319|NCT01646398|13VPNC
266320|NCT01646398|23VPS
266321|NCT01646385|observational
266322|NCT01646385|non-interventional
266323|NCT01646385|cohort
266324|NCT01646385|retrospective
266325|NCT01646385|register
266326|NCT01646385|rheumatoid arthritis
266327|NCT01646372|Medical Education
266328|NCT01646372|Cognitive Aid
266329|NCT01646372|Crisis Resource Management
266330|NCT01646372|Advanced Cardiac Life Support
266331|NCT01646372|Skills Retention
266332|NCT01646346|Breast Cancer
266333|NCT01646346|Radiation for Breast Cancer
266334|NCT01646333|Parkinson Disease
266335|NCT01646333|Mild Cognitive Impairment
266336|NCT01646333|Cognition
266337|NCT01646333|Executive Function
266338|NCT01646333|Learning
266339|NCT01646333|Memory
266340|NCT01646333|Problem Solving
266341|NCT01646294|Pharmacokinetics
266342|NCT01646294|Phase I
266343|NCT01646294|YM178
266344|NCT01646294|Modified release (Oral Controlled Absorption System (OCAS))
266345|NCT01646294|Immediate release (IR)
266346|NCT01646294|Fasted conditions
266347|NCT01646294|Fed conditions
266348|NCT01646281|Atrial fibrillation
266349|NCT01646281|Vernakalant
266350|NCT01646281|Flecainide
266351|NCT01646281|Echocardiography
266352|NCT01646268|Rotigotine
266353|NCT01646268|Neupro phase 3
266354|NCT01646268|Early phase
266355|NCT01646268|Idiopathic Parkinson's Disease
266356|NCT01646255|Rotigotine
266357|NCT01646255|Neupro phase 3
266358|NCT01646255|Advanced-stage
266359|NCT01646255|Idiopathic Parkinson's Disease
266360|NCT01646229|Hemoperfusion
266361|NCT01646229|Polymyxin-B
266362|NCT01646229|Emergency abdominal surgery
266363|NCT01646229|Sepsis
266364|NCT01646229|Endotoxin
266365|NCT01646216|stroke
266366|NCT01646216|treadmill
266367|NCT01646216|walking
266368|NCT01646216|hemiparesis
266369|NCT01646216|training
266370|NCT01646203|Advanced Solid Tumors
266371|NCT01646190|Fast-track
266372|NCT01646190|multimodal perioperative care
266373|NCT01646190|enhanced recovery
266374|NCT01646190|colorectal surgery
266375|NCT01646190|elderly patients
266376|NCT01646190|seniors
266377|NCT01646164|Dill seed
266378|NCT01646164|Pattern of uterus contractions
266379|NCT01646164|Active phase of labor
266380|NCT01646138|H1N1
266381|NCT01646138|Influenza
266382|NCT01646138|Human
266383|NCT01646138|Challenge Study
266384|NCT01646138|Healthy Volunteer
266385|NCT01646125|HSP90, AUY922, Pemetrexed, Docetaxel, EGFR TKI, EGFR mutations, NSCLC, non small cell lung cancer
266386|NCT01646112|Uncertainty
266387|NCT01646112|HNPCC
266388|NCT01646112|Lynch Syndrome
266389|NCT01646112|Genetic Tests
266390|NCT01646099|Kidney transplant
266391|NCT01646099|Renal transplant
266392|NCT01646099|Sun protection
266393|NCT01646099|Skin cancer
266394|NCT01646086|Weight Loss
266395|NCT01646086|Self-Weighing
266396|NCT01646086|Weight Tracking
266397|NCT01646073|Plaque Psoriasis
266398|NCT01646073|Psoriasis
266399|NCT01646073|Placebo Controlled
266400|NCT01646073|Skin Disease
266401|NCT01646073|Double Blind
266402|NCT01646060|blood
266403|NCT01646060|loss
266404|NCT01646060|healthy
266405|NCT01646060|volume
266406|NCT01646060|To evaluate the ability of the Zynex BVM to non-invasively detect blood loss in healthy subjects during a blood draw.
266407|NCT01646047|diabetes
266408|NCT01646047|diabetic retinopathy
266409|NCT01646047|nutritional supplements
266410|NCT01646047|visual function
266411|NCT01646047|macular pigment
266412|NCT01646047|macular threshold sensitivity
266413|NCT01646047|contrast sensitivity
266414|NCT01646047|color vision
266415|NCT01646047|optical coherence tomography
266416|NCT01646034|oligo metastatic
266417|NCT01646034|HRD deficiency
266418|NCT01646021|Mantle cell lymphoma
266419|NCT01646021|Relapsed mantle cell lymphoma
266420|NCT01646021|Refractory mantle cell lymphoma
266421|NCT01646021|Ibrutinib
266422|NCT01646021|Bruton's tyrosine kinase inhibitor
266423|NCT01646021|Temsirolimus
266424|NCT01645956|obesity
266425|NCT01645956|exercise
266426|NCT01645956|energy intake
266427|NCT01645956|physical activity
266428|NCT01645943|Non-ST-elevation acute myocardial infarction
266429|NCT01645943|Comorbidities
266430|NCT01645930|Relapsed multiple myeloma,
266431|NCT01645930|Refractory multiple myeloma,
266432|NCT01645930|MLN9708,
266433|NCT01645930|Proteasome inhibitor
266434|NCT01645917|paroxysmal atrial fibrillation
266435|NCT01645904|Hereditary Diseases
266436|NCT01645904|Genetic
266437|NCT01645904|Lynch syndrome
266438|NCT01645904|Positive or indeterminate test results for Lynch syndrome
266439|NCT01645904|Social media
266440|NCT01645904|Internet-based program
266441|NCT01645904|Questionnaire
266442|NCT01645904|Survey
266443|NCT01645904|My Family Garden website
266444|NCT01645904|Interview
266445|NCT01645904|Focus group
266446|NCT01645904|Website Analysis and MeasureMent Inventory
266447|NCT01645904|WAMMI
266448|NCT01645891|Diabetic Foot Ulcer
266449|NCT01645878|Primiparous Mothers
266450|NCT01645878|self-efficacy,
266451|NCT01645878|hands off,
266452|NCT01645878|hands on ,
266453|NCT01645878|social cognitive theory
266454|NCT01645865|HIV
266455|NCT01645865|AIDS
266456|NCT01645865|PMTCT
266457|NCT01645865|Mobile Phone
266458|NCT01645865|SMS
266459|NCT01645839|Leptomeningeal metastasis
266460|NCT01645839|Intrathecal chemotherapy
266461|NCT01645839|Depocyte
266462|NCT01645800|Lysozyme hydrochloride
266463|NCT01645800|COPD
266464|NCT01645787|Spinal Muscular Atrophy
266465|NCT01645787|4-aminopyridine
266466|NCT01645787|dalfampridine
266467|NCT01645787|Ampyra
266468|NCT01645774|subcutaneous injection heparin
266469|NCT01645774|injection duration
266470|NCT01645774|bruising pain
266471|NCT01645774|decrease pain
266472|NCT01645774|decrease bruising
266473|NCT01645761|Helicobacter pylori eradication
266474|NCT01645761|Peptic ulcer
266475|NCT01645748|head and neck cancer
266476|NCT01645748|docetaxel
266477|NCT01645748|cisplatin
266478|NCT01645748|S-1
266479|NCT01645735|Infections
266480|NCT01645735|Teflaro
266481|NCT01645735|cephalosporin
266482|NCT01645735|Ceftaroline
266483|NCT01645735|antibiotics
266484|NCT01645735|pneumonia
266485|NCT01645722|Fat Grafts
266486|NCT01645722|Autogenous Fat Transfers (AFT)
266487|NCT01645722|Wounded warriors
266488|NCT01645722|Amputation pain
266489|NCT01645696|Diabetes
266490|NCT01645696|Type 1 Diabetes
266491|NCT01645696|Continuous glucose monitoring
266492|NCT01645696|Blood glucose
266493|NCT01645696|Blood glucose sensor
266494|NCT01645696|Glucose Binding Protein (GBP)
266495|NCT01645566|cardiopulmonary resuscitation
266496|NCT01645566|stress
266497|NCT01645566|intervention
266498|NCT01645475|enuresis
266499|NCT01645449|Bioequivalence
266500|NCT01645449|Atorvastatin calcium
266501|NCT01645449|crossover
266502|NCT01645436|randomized controlled trial
266503|NCT01645436|in-hospital exercise
266504|NCT01645436|children
266505|NCT01645436|cancer
266506|NCT01645423|Bioequivalence
266507|NCT01645423|Atorvastatin calcium
266508|NCT01645423|crossover
266509|NCT01645410|Bioequivalence
266510|NCT01645410|Atorvastatin calcium
266511|NCT01645410|crossover
266512|NCT01645397|Asthma
266513|NCT01645397|Deep inhalation
266514|NCT01645397|Exhaled nitric oxide
266515|NCT01645384|Bioequivalence
266516|NCT01645384|Atorvastatin calcium
266517|NCT01645384|crossover
266518|NCT01645371|opioid-induced constipation
266519|NCT01645358|COPD
266520|NCT01645358|NIV
266521|NCT01645358|Acute Hypercapnic Respiratory Failure
266522|NCT01645358|COPD patients with hypercapnic respiratory failure
266523|NCT01645345|wrinkles
266524|NCT01645345|acne scars
266525|NCT01645332|DLBS3233
266526|NCT01645332|new onset
266527|NCT01645332|type-2-diabetes mellitus
266528|NCT01645332|oral anti-hyperglycemic agent
266529|NCT01645280|Active rheumatoid arthritis
266530|NCT01645280|Ustekinumab
266531|NCT01645280|STELARA
266532|NCT01645280|CNTO 1959
266533|NCT01645254|healthy volunteers
266534|NCT01645254|pharmacokinetics
266535|NCT01645254|malaria
266536|NCT01645254|Argemone mexicana
266537|NCT01645241|Ovarian stimulation
266538|NCT01645241|Luteal phase
266539|NCT01645241|Egg donors
266540|NCT01645241|Fertility preservation
266541|NCT01645202|Aortic stenosis
266542|NCT01645202|TAVI
266543|NCT01645202|Device success
266544|NCT01645202|Aortic regurgitation
266545|NCT01645189|Hunter syndrome
266546|NCT01645189|idursulfase-beta
266547|NCT01645189|Hunterase
266548|NCT01645189|GC1111
266549|NCT01645176|OA
266550|NCT01645176|Knee
266551|NCT01645163|mHealth
266552|NCT01645163|Complementary feeding
266553|NCT01645163|ICDS
266554|NCT01645150|physical activity
266555|NCT01645150|exercise
266556|NCT01645150|training
266557|NCT01645150|fatigue
266558|NCT01645150|cancer
266559|NCT01645150|TKI
266560|NCT01645150|tyrosine kinase inhibitor
266561|NCT01645137|prematurity
266562|NCT01645137|OMT
266563|NCT01645137|complementary and alternative medicine
266564|NCT01645137|neonates
266565|NCT01645137|length of stay
266566|NCT01645124|Polycythemia
266567|NCT01645124|Hematocrit
266568|NCT01645124|Thrombosis
266569|NCT01645085|R406
266570|NCT01645085|Fostamatinib
266571|NCT01645085|Phase I
266572|NCT01645085|Healthy Subjects
266573|NCT01645085|Pharmacokinetics
266574|NCT01645085|Bioequivalence
266575|NCT01645072|Drug refractory epilepsy
266576|NCT01645072|Dietary therapy
266577|NCT01645072|ketogenic diet
266578|NCT01645072|childhood epilepsy
266579|NCT01645033|Cognitive Behavioral Therapy
266580|NCT01645033|computer
266581|NCT01645020|absorbable mesh
266582|NCT01645020|Partially absorbed Mesh
266583|NCT01645020|Prolift
266584|NCT01645020|Prolift + M
266585|NCT01645020|mesh related complications
266586|NCT01645007|Hepatitis B
266587|NCT01645007|Prevalence
266588|NCT01645007|HBsAg
266589|NCT01645007|Vaccination
266590|NCT01645007|Galilee
266591|NCT01644968|metastatic carcinoma
266592|NCT01644968|lymphoma
266593|NCT01644968|sarcoma
266594|NCT01644968|anti-OX40
266595|NCT01644955|Gliomas
266596|NCT01644955|Carboplatin
266597|NCT01644942|Obese
266598|NCT01644942|insulin sensitive
266599|NCT01644942|insulin resistant
266600|NCT01644942|myotubes
266601|NCT01644942|lipid accumulation
266602|NCT01644929|hemiparesis
266603|NCT01644929|bihemispheric transcranial direct current stimulation
266604|NCT01644929|ischemic stroke
266605|NCT01644929|subacute
266606|NCT01644929|rehabilitation
266607|NCT01644929|physiotherapy
266608|NCT01644929|ergotherapy
266609|NCT01644916|COPD
266610|NCT01644916|Integrated care
266611|NCT01644916|IPCL
266612|NCT01644890|NK105, Paclitaxel, Breast cancer, Micelle
266613|NCT01644851|veterans
266614|NCT01644851|neuropsychology
266615|NCT01644851|neuroimaging
266616|NCT01644851|attention
266617|NCT01644851|working memory
266618|NCT01644851|inhibition
266619|NCT01644851|magnetic resonance imaging, functional
266620|NCT01644851|trauma
266621|NCT01644851|stress
266622|NCT01644851|anxiety
266623|NCT01644851|emotion
266624|NCT01644851|prefrontal cortex
266625|NCT01644838|Hyoscine,
266626|NCT01644838|Promethazine,
266627|NCT01644838|The first stage of labor,
266628|NCT01644838|Labor pain
266629|NCT01644825|platinum resistant
266630|NCT01644825|platinum refractory
266631|NCT01644799|recurrent grade 1 follicular lymphoma
266632|NCT01644799|recurrent grade 2 follicular lymphoma
266633|NCT01644799|recurrent grade 3 follicular lymphoma
266634|NCT01644786|head and neck
266635|NCT01644786|HNSCC
266636|NCT01644786|orophaynx
266637|NCT01644786|hypopharynx
266638|NCT01644786|larynx
266639|NCT01644786|nasopharynx
266640|NCT01644786|oral cavity
266641|NCT01644786|prospective study
266642|NCT01644786|predictive models for HNSCC
266643|NCT01644786|genomic analyses
266644|NCT01644786|outcome prediction
266645|NCT01644760|Diaphragmatic excursion
266646|NCT01644760|normality
266647|NCT01644747|Resistant Depression
266648|NCT01644747|Moods disorders
266649|NCT01644747|Unipolar depression
266650|NCT01644747|Bipolar disorder
266651|NCT01644747|tDCS
266652|NCT01644721|Child mortality
266653|NCT01644721|Measles vaccine
266654|NCT01644721|Non-specific effects
266655|NCT01644708|Obesity
266656|NCT01644708|Overweight
266657|NCT01644708|Individual empowerment
266658|NCT01644708|Physical parameters
266659|NCT01644708|Self esteem
266660|NCT01644695|BARS
266661|NCT01644695|Bony Anchoring Reinforcement System
266662|NCT01644695|Hernia
266663|NCT01644695|Incisional
266664|NCT01644695|Recurrent
266665|NCT01644695|abdominal wall reconstruction
266666|NCT01644695|abdominal wall defect
266667|NCT01644695|mesh
266668|NCT01644695|component separation
266669|NCT01644682|Visceral leishmaniasis
266670|NCT01644682|insecticide
266671|NCT01644682|wall lining
266672|NCT01644682|KO TAB123
266673|NCT01644682|Household
266674|NCT01644682|Kala-azar endemic area
266675|NCT01644656|portal hypertension
266676|NCT01644656|cirrhosis
266677|NCT01644656|ARFI
266678|NCT01644656|diagnostic study
266679|NCT01644643|Ceftazidime,
266680|NCT01644643|avibactam,
266681|NCT01644643|metronidazone,
266682|NCT01644643|Anti-Infectives
266683|NCT01644604|Hypertension
266684|NCT01644604|Vascular Diseases
266685|NCT01644604|Cardiovascular Diseases
266686|NCT01644604|Renal denervation
266687|NCT01644591|Melanoma
266688|NCT01644591|Malignant melanoma
266689|NCT01644591|Brain Metastases
266690|NCT01644591|Stereotactic Radiosurgery
266691|NCT01644591|SRS
266692|NCT01644591|XRT
266693|NCT01644591|Questionnaires
266694|NCT01644591|Surveys
266695|NCT01644578|MRI
266696|NCT01644578|real-time imaging
266697|NCT01644578|workflow
266698|NCT01644552|aniridia
266699|NCT01644552|positive angle kappa
266700|NCT01644539|Satiation
266701|NCT01644539|Brain activation
266702|NCT01644539|Gut peptides
266703|NCT01644526|dialysis
266704|NCT01644526|vascular access
266705|NCT01644526|arteriovenous grafts
266706|NCT01644526|valve system
266707|NCT01644513|Age Related Macular Degeneration
266708|NCT01644513|Choroidal Neovascular
266709|NCT01644513|anti-VEGF Therapy
266710|NCT01644409|OAB
266711|NCT01644409|Overactive bladder
266712|NCT01644409|Urgency
266713|NCT01644409|Incontinence
266714|NCT01644396|Moderate to Severe Plaque Psoriasis
266715|NCT01644383|meaning of life
266716|NCT01644383|logotherapy
266717|NCT01644383|HIV-infected teenagers
266718|NCT01644383|adherence
266719|NCT01644370|HIV-infected children
266720|NCT01644370|T cell response
266721|NCT01644370|asthma
266722|NCT01644292|Mobility Impairment
266723|NCT01644292|Manual Wheelchair
266724|NCT01644292|Older Adults
266725|NCT01644279|aging
266726|NCT01644279|sarcopenia
266727|NCT01644279|mitochondria
266728|NCT01644279|skeletal muscle
266729|NCT01644279|apoptosis
266730|NCT01644253|chronic lymphocytic leukemia
266731|NCT01644253|CLL
266732|NCT01644253|previously untreated chronic lymphocytic leukemia
266733|NCT01644227|Hip surgery
266734|NCT01644227|dual mobility cup
266735|NCT01644227|dislocation
266736|NCT01644227|total hip arthroplasty
266737|NCT01644214|Pelvic organ prolapse
266738|NCT01644214|Pessary
266739|NCT01644162|Non-Invasive Positive-Pressure Ventilation
266740|NCT01644162|Disease Exacerbation
266741|NCT01644162|Respiratory Failure
266742|NCT01644149|Jet Injector
266743|NCT01644149|Stratis®
266744|NCT01644149|PharmaJet
266745|NCT01644149|Jet Injection
266746|NCT01644123|Spasticity
266747|NCT01644123|Diagnostic Algorithm
266748|NCT01644097|Quality of Life
266749|NCT01644084|albumin
266750|NCT01644084|hydroxyethyl starch 130/0.4
266751|NCT01644084|cardiopulmonary bypass
266752|NCT01644071|violent video games
266753|NCT01644071|serotonergic system
266754|NCT01644045|Asthma
266755|NCT01644045|COPD
266756|NCT01644045|emergency medical service
266757|NCT01644045|teleconsultation
266758|NCT01644045|telemedicine
266759|NCT01644032|telemedicine
266760|NCT01644032|teleconsultation
266761|NCT01644032|analgesia
266762|NCT01644032|emergency
266763|NCT01644032|prehospital
266764|NCT01644019|stroke
266765|NCT01644019|teleconsultation
266766|NCT01644019|telemedicine
266767|NCT01644019|emergency medical service
266768|NCT01644006|acute coronary syndrome
266769|NCT01644006|telemedicine
266770|NCT01644006|teleconsultation
266771|NCT01644006|emergency medical service
266772|NCT01643993|IVF
266773|NCT01643993|embryo
266774|NCT01643967|Ozone
266775|NCT01643967|Sunflower oil
266776|NCT01643967|diabetes Mellitus
266777|NCT01643954|prostatectomy
266778|NCT01643954|surgery
266779|NCT01643954|prostate cancer
266780|NCT01643941|Staphylococcus aureus
266781|NCT01643941|vaccine
266782|NCT01643941|Staphylococcal infection
266783|NCT01643928|extension trial
266784|NCT01643928|rheumatoid arthritis
266785|NCT01643928|rituximab
266786|NCT01643915|Audiovisual distraction
266787|NCT01643915|Pediatric dentistry
266788|NCT01643902|Stroke
266789|NCT01643902|Wake up
266790|NCT01643902|IV tPA
266791|NCT01643902|Thrombolytic
266792|NCT01643889|Healthy
266793|NCT01643889|Domperidone
266794|NCT01643889|Cardiac Repolarization
266795|NCT01643876|Denture stomatitis
266796|NCT01643876|Denture Plaque
266797|NCT01643876|Oral Candidiasis
266798|NCT01643876|Oral Hygiene
266799|NCT01643850|Pigmented Villonodular Synovitis
266800|NCT01643850|PVNS
266801|NCT01643850|Giant cell tumor of the tendon sheath
266802|NCT01643850|GCCTS
266803|NCT01643850|Tenosynovial giant cell tumor (localized or diffused type)
266804|NCT01643850|MCS110
266805|NCT01643837|Mastalgia
266806|NCT01643837|Breast Pain
266807|NCT01643837|Osteopathic Manipulative Medicine
266808|NCT01643837|Osteopathic Manipulative Treatment
266809|NCT01643811|early gastric cancer, diabetes, hypertension
266810|NCT01643785|therapeutic efficacy endonase addictive effect
266811|NCT01643759|osteoarthritis disorders
266812|NCT01643733|Angioplasty
266813|NCT01643707|Sick Sinus Syndrome
266814|NCT01643707|Bradycardia
266815|NCT01643616|Sciatic Nerve
266816|NCT01643616|Ultrasound
266817|NCT01643616|Anesthesia, Regional
266818|NCT01643616|Orthopedic Surgery
266819|NCT01643603|accelerated phase chronic myelogenous leukemia
266820|NCT01643603|adult acute lymphoblastic leukemia in remission
266821|NCT01643603|adult acute myeloid leukemia in remission
266822|NCT01643603|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
266823|NCT01643603|adult acute myeloid leukemia with del(5q)
266824|NCT01643603|adult acute myeloid leukemia with inv(16)(p13;q22)
266825|NCT01643603|adult acute myeloid leukemia with t(15;17)(q22;q12)
266826|NCT01643603|adult acute myeloid leukemia with t(16;16)(p13;q22)
266827|NCT01643603|adult acute myeloid leukemia with t(8;21)(q22;q22)
266828|NCT01643603|adult grade III lymphomatoid granulomatosis
266829|NCT01643603|adult nasal type extranodal NK/T-cell lymphoma
266830|NCT01643603|anaplastic large cell lymphoma
266831|NCT01643603|angioimmunoblastic T-cell lymphoma
266832|NCT01643603|blastic phase chronic myelogenous leukemia
266833|NCT01643603|chronic phase chronic myelogenous leukemia
266834|NCT01643603|contiguous stage II adult Burkitt lymphoma
266835|NCT01643603|contiguous stage II adult diffuse large cell lymphoma
266836|NCT01643603|contiguous stage II adult diffuse mixed cell lymphoma
266837|NCT01643603|contiguous stage II adult diffuse small cleaved cell lymphoma
266838|NCT01643603|contiguous stage II adult immunoblastic large cell lymphoma
266839|NCT01643603|contiguous stage II adult lymphoblastic lymphoma
266840|NCT01643603|contiguous stage II grade 1 follicular lymphoma
266841|NCT01643603|contiguous stage II grade 2 follicular lymphoma
266842|NCT01643603|contiguous stage II grade 3 follicular lymphoma
266843|NCT01643603|contiguous stage II mantle cell lymphoma
266844|NCT01643603|contiguous stage II marginal zone lymphoma
266845|NCT01643603|contiguous stage II small lymphocytic lymphoma
266846|NCT01643603|cutaneous B-cell non-Hodgkin lymphoma
266847|NCT01643603|de novo myelodysplastic syndromes
266848|NCT01643603|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
266849|NCT01643603|hepatosplenic T-cell lymphoma
266850|NCT01643603|intraocular lymphoma
266851|NCT01643603|nodal marginal zone B-cell lymphoma
266852|NCT01643603|noncontiguous stage II adult Burkitt lymphoma
266853|NCT01643603|noncontiguous stage II adult diffuse large cell lymphoma
266854|NCT01643603|noncontiguous stage II adult diffuse mixed cell lymphoma
266855|NCT01643603|noncontiguous stage II adult diffuse small cleaved cell lymphoma
266856|NCT01643603|noncontiguous stage II adult immunoblastic large cell lymphoma
266857|NCT01643603|noncontiguous stage II adult lymphoblastic lymphoma
266858|NCT01643603|noncontiguous stage II grade 1 follicular lymphoma
266859|NCT01643603|noncontiguous stage II grade 2 follicular lymphoma
266860|NCT01643603|noncontiguous stage II grade 3 follicular lymphoma
266861|NCT01643603|noncontiguous stage II mantle cell lymphoma
266862|NCT01643603|noncontiguous stage II marginal zone lymphoma
266863|NCT01643603|noncontiguous stage II small lymphocytic lymphoma
266864|NCT01643603|noncutaneous extranodal lymphoma
266865|NCT01643603|peripheral T-cell lymphoma
266866|NCT01643603|previously treated myelodysplastic syndromes
266867|NCT01643603|recurrent adult acute lymphoblastic leukemia
266868|NCT01643603|recurrent adult acute myeloid leukemia
266869|NCT01643603|recurrent adult Burkitt lymphoma
266870|NCT01643603|recurrent adult diffuse large cell lymphoma
266871|NCT01643603|recurrent adult diffuse mixed cell lymphoma
266872|NCT01643603|recurrent adult diffuse small cleaved cell lymphoma
266873|NCT01643603|recurrent adult grade III lymphomatoid granulomatosis
266874|NCT01643603|recurrent adult Hodgkin lymphoma
266875|NCT01643603|recurrent adult immunoblastic large cell lymphoma
266876|NCT01643603|recurrent adult lymphoblastic lymphoma
266877|NCT01643603|recurrent adult T-cell leukemia/lymphoma
266878|NCT01643603|recurrent cutaneous T-cell non-Hodgkin lymphoma
266879|NCT01643603|recurrent grade 1 follicular lymphoma
266880|NCT01643603|recurrent grade 2 follicular lymphoma
266881|NCT01643603|recurrent grade 3 follicular lymphoma
266882|NCT01643603|recurrent mantle cell lymphoma
266883|NCT01643603|recurrent marginal zone lymphoma
266884|NCT01643603|recurrent mycosis fungoides/Sezary syndrome
266885|NCT01643603|recurrent small lymphocytic lymphoma
266886|NCT01643603|refractory chronic lymphocytic leukemia
266887|NCT01643603|refractory hairy cell leukemia
266888|NCT01643603|relapsing chronic myelogenous leukemia
266889|NCT01643603|small intestine lymphoma
266890|NCT01643603|splenic marginal zone lymphoma
266891|NCT01643603|stage I adult Burkitt lymphoma
266892|NCT01643603|stage I adult diffuse large cell lymphoma
266893|NCT01643603|stage I adult diffuse mixed cell lymphoma
266894|NCT01643603|stage I adult diffuse small cleaved cell lymphoma
266895|NCT01643603|stage I adult Hodgkin lymphoma
266896|NCT01643603|stage I adult immunoblastic large cell lymphoma
266897|NCT01643603|stage I adult lymphoblastic lymphoma
266898|NCT01643603|stage I adult T-cell leukemia/lymphoma
266899|NCT01643603|stage I chronic lymphocytic leukemia
266900|NCT01643603|stage I cutaneous T-cell non-Hodgkin lymphoma
266901|NCT01643603|stage I grade 1 follicular lymphoma
266902|NCT01643603|stage I grade 2 follicular lymphoma
266903|NCT01643603|stage I grade 3 follicular lymphoma
266904|NCT01643603|stage I mantle cell lymphoma
266905|NCT01643603|stage I marginal zone lymphoma
266906|NCT01643603|stage I small lymphocytic lymphoma
266907|NCT01643603|stage IA mycosis fungoides/Sezary syndrome
266908|NCT01643603|stage IB mycosis fungoides/Sezary syndrome
266909|NCT01643603|stage II adult Hodgkin lymphoma
266910|NCT01643603|stage II chronic lymphocytic leukemia
266911|NCT01643603|stage II cutaneous T-cell non-Hodgkin lymphoma
266912|NCT01643603|stage IIA mycosis fungoides/Sezary syndrome
266913|NCT01643603|stage IIB mycosis fungoides/Sezary syndrome
266914|NCT01643603|stage III adult Burkitt lymphoma
266915|NCT01643603|stage III adult diffuse large cell lymphoma
266916|NCT01643603|stage III adult diffuse mixed cell lymphoma
266917|NCT01643603|stage III adult diffuse small cleaved cell lymphoma
266918|NCT01643603|stage III adult Hodgkin lymphoma
266919|NCT01643603|stage III adult immunoblastic large cell lymphoma
266920|NCT01643603|stage III adult lymphoblastic lymphoma
266921|NCT01643603|stage III adult T-cell leukemia/lymphoma
266922|NCT01643603|stage III chronic lymphocytic leukemia
266923|NCT01643603|stage III cutaneous T-cell non-Hodgkin lymphoma
266924|NCT01643603|stage III grade 1 follicular lymphoma
266925|NCT01643603|stage III grade 2 follicular lymphoma
266926|NCT01643603|stage III grade 3 follicular lymphoma
266927|NCT01643603|stage III mantle cell lymphoma
266928|NCT01643603|stage III marginal zone lymphoma
266929|NCT01643603|stage III small lymphocytic lymphoma
266930|NCT01643603|stage IIIA mycosis fungoides/Sezary syndrome
266931|NCT01643603|stage IIIB mycosis fungoides/Sezary syndrome
266932|NCT01643603|stage IV adult Burkitt lymphoma
266933|NCT01643603|stage IV adult diffuse large cell lymphoma
266934|NCT01643603|stage IV adult diffuse mixed cell lymphoma
266935|NCT01643603|stage IV adult diffuse small cleaved cell lymphoma
266936|NCT01643603|stage IV adult Hodgkin lymphoma
266937|NCT01643603|stage IV adult immunoblastic large cell lymphoma
266938|NCT01643603|stage IV adult lymphoblastic lymphoma
266939|NCT01643603|stage IV adult T-cell leukemia/lymphoma
266940|NCT01643603|stage IV chronic lymphocytic leukemia
266941|NCT01643603|stage IV cutaneous T-cell non-Hodgkin lymphoma
266942|NCT01643603|stage IV grade 1 follicular lymphoma
266943|NCT01643603|stage IV grade 2 follicular lymphoma
266944|NCT01643603|stage IV grade 3 follicular lymphoma
266945|NCT01643603|stage IV mantle cell lymphoma
266946|NCT01643603|stage IV marginal zone lymphoma
266947|NCT01643603|stage IV small lymphocytic lymphoma
266948|NCT01643603|stage IVA mycosis fungoides/Sezary syndrome
266949|NCT01643603|stage IVB mycosis fungoides/Sezary syndrome
266950|NCT01643603|T-cell large granular lymphocyte leukemia
266951|NCT01643603|testicular lymphoma
266952|NCT01643603|Waldenström macroglobulinemia
266953|NCT01643577|Idiopathic
266954|NCT01643577|gastroparesis
266955|NCT01643577|delayed gastric emptying
266956|NCT01643577|nausea
266957|NCT01643577|vomiting
266958|NCT01643577|abdominal pain
266959|NCT01643577|bloating
266960|NCT01643564|Transplant
266961|NCT01643564|Cytokines
266962|NCT01643564|Graft Dysfunction
266963|NCT01643551|Heart Failure
266964|NCT01643551|Left Ventricular Assist Device
266965|NCT01643551|Reperfusion Injury
266966|NCT01643551|Neuron Specific Enolase
266967|NCT01643538|physical activity
266968|NCT01643538|adults age 65 and older
266969|NCT01643538|financial incentives
266970|NCT01643525|Ischemic Stroke
266971|NCT01643486|peritoneal dialysis
266972|NCT01643486|phosphate
266973|NCT01643486|iTouch
266974|NCT01643473|Hypertension
266975|NCT01643473|Latinos
266976|NCT01643473|Medication Adherence
266977|NCT01643473|Blood Pressure Control
266978|NCT01643473|Patient-centered
266979|NCT01643473|Black
266980|NCT01643460|Intraductal papillary mucinous neoplasms (IPMNs)
266981|NCT01643460|Mucinous cystadenomas [MCN])
266982|NCT01643460|Invasive IPMNs or mucinous cystadenocarcinomas) tumors
266983|NCT01643447|Hepatocellular Carcinoma
266984|NCT01643447|Ulinastatin
266985|NCT01643447|Hepatic Failure
266986|NCT01643434|Resistant Hypertension
266987|NCT01643408|Acute Lymphoblastic Leukemia
266988|NCT01643408|Lymphoblastic Lymphoma
266989|NCT01643408|Erwinaze
266990|NCT01643408|asparaginase
266991|NCT01643408|Eusa Pharma
266992|NCT01643408|Pharmacokinetic study
266993|NCT01643408|NSAA
266994|NCT01643395|Trauma
266995|NCT01643395|vertebral
266996|NCT01643395|compression fracture
266997|NCT01643395|spinal
266998|NCT01643395|acute
266999|NCT01643395|vertebroplasty
267000|NCT01643395|conservative treatment
267001|NCT01643382|diabetes
267002|NCT01643382|kidney transplant
267003|NCT01643382|end stage renal disease
267004|NCT01643382|delayed draft function
267005|NCT01643369|meditation
267006|NCT01643369|compassion
267007|NCT01643369|inflammation
267008|NCT01643369|immune system
267009|NCT01643356|weight
267010|NCT01643356|pregnancy
267011|NCT01643356|behavioral intervention
267012|NCT01643356|obesity
267013|NCT01643343|autism spectrum disorders
267014|NCT01643343|autism
267015|NCT01643343|joint attention
267016|NCT01643343|imitation
267017|NCT01643343|fluency
267018|NCT01643330|Cardiomegaly
267019|NCT01643330|Heart Diseases
267020|NCT01643330|Cardiovascular Diseases
267021|NCT01643304|Menorrhagia
267022|NCT01643304|Heavy menstrual bleeding
267023|NCT01643304|Uterine Hemorrhage
267024|NCT01643304|Menstruation Disturbancies
267025|NCT01643252|Corneal Ectasia
267026|NCT01643252|Refractive surgery
267027|NCT01643252|Cross-Linking
267028|NCT01643239|Modified constraint-induced therapy
267029|NCT01643239|Children with cerebral palsy
267030|NCT01643239|Kinematic analysis
267031|NCT01643239|Group therapy
267032|NCT01643200|Erectile Dysfunction
267033|NCT01643200|Male
267034|NCT01643200|Zotarolimus
267035|NCT01643200|Stent
267036|NCT01643200|Stenosis
267037|NCT01643200|Erection
267038|NCT01643200|PDE5 Inhibitors
267039|NCT01643148|biomarker
267040|NCT01643148|BMI
267041|NCT01643148|breast cancer
267042|NCT01643148|CA-15-3
267043|NCT01643148|leptin
267044|NCT01643135|tranexamic acid
267045|NCT01643135|bleeding
267046|NCT01643135|blood transfusion
267047|NCT01643135|spine surgery
267048|NCT01643122|Endometriosis, Validation study
267049|NCT01643109|Cerebral Palsy
267050|NCT01643109|Hemiplegia
267051|NCT01643109|Constraint Induced Movement Therapy
267052|NCT01643096|Zataria multiflora Boiss Sumac TEF temperament
267053|NCT01643083|Post-prandial distress syndrome
267054|NCT01643070|Rectal cancer
267055|NCT01643070|Liver metastases
267056|NCT01643070|Capecitabine
267057|NCT01643070|Oxaliplatin
267058|NCT01643057|Apnea
267059|NCT01643057|Prematurity
267060|NCT01643057|Biomarkers
267061|NCT01643057|Stochastic Resonance
267062|NCT01643057|Neonatal
267063|NCT01643044|pregnancy
267064|NCT01643044|screening
267065|NCT01643044|motivation
267066|NCT01643031|Diabetes
267067|NCT01643031|Platelets aggregation inhibitors
267068|NCT01643031|Platelet function tests
267069|NCT01643018|cystic echinococcosis
267070|NCT01643018|liver cyst hydatique
267071|NCT01643018|treatment
267072|NCT01643018|surgery
267073|NCT01643018|laparoscopy
267074|NCT01643005|HIV
267075|NCT01642992|Coronary bifurcation lesion
267076|NCT01642992|Drug-eluting stent
267077|NCT01642979|Paroxysmal Nocturnal Hemoglobinuria
267078|NCT01642979|Anemia
267079|NCT01642979|Hematologic Diseases
267080|NCT01642979|bone marrow failure
267081|NCT01642979|Immunologic Factors
267082|NCT01642979|Physiological Effects of Drugs
267083|NCT01642979|Levamisole
267084|NCT01642979|cyclosporine A
267085|NCT01642966|ticagrelor
267086|NCT01642966|doppler echocardiography
267087|NCT01642953|Gastric cancer surgery
267088|NCT01642953|Early oral feeding
267089|NCT01642953|Fast track surgery
267090|NCT01642927|LVAD
267091|NCT01642927|IABP
267092|NCT01642927|Heart Failure
267093|NCT01642927|Thrombosis
267094|NCT01642927|Hemorrhage
267095|NCT01642914|Chronic Constipation
267096|NCT01642914|Abdominal Bloating
267097|NCT01642914|Linaclotide
267098|NCT01642901|spinal cord injury
267099|NCT01642901|bone mineral density
267100|NCT01642875|Periampullary tumor
267101|NCT01642875|Chronic pancreatitis
267102|NCT01642875|Pancreatoduodenectomy
267103|NCT01642875|Oral Nutrition
267104|NCT01642875|Enteral Nutrition
267105|NCT01642849|high protein diet
267106|NCT01642849|high carbohydrate diet
267107|NCT01642849|weight loss
267108|NCT01642849|oxidative stress
267109|NCT01642849|inflammation
267110|NCT01642849|cardiovascular risk factors
267111|NCT01642823|retinoblastoma
267112|NCT01642810|Online treatment for Fibromyalgia Syndrome
267113|NCT01642810|Acceptance-based behavioural treatment
267114|NCT01642797|confocal laser endomicroscopy
267115|NCT01642797|gastric intestinal metaplasia
267116|NCT01642797|gastric intraepithelial neoplasia
267117|NCT01642797|gastric carcinoma
267118|NCT01642784|STEMI
267119|NCT01642784|NSTEMI
267120|NCT01642784|revascularization
267121|NCT01642784|stents
267122|NCT01642771|Triple-negative Breast Cancer
267123|NCT01642771|Post-operative adjuvant Chemotherapy
267124|NCT01642771|Docetaxel
267125|NCT01642771|Capecitabine
267126|NCT01642771|Epirubicin
267127|NCT01642771|Cyclophosphamide
267128|NCT01642771|Fluorouracil
267129|NCT01642758|Thalassemia intermedia
267130|NCT01642758|Fetal hemoglobin
267131|NCT01642758|Hemoglobin
267132|NCT01642732|Prostate
267133|NCT01642732|Cancer
267134|NCT01642732|Everolimus
267135|NCT01642732|Radiation
267136|NCT01642719|Sleep disturbance
267137|NCT01642719|Aging
267138|NCT01642719|Sleep restriction
267139|NCT01642719|Health status
267140|NCT01642719|Glucose tolerance
267141|NCT01642719|Inflammation
267142|NCT01642706|Regulatory B cells
267143|NCT01642706|Rheumatoid arthritis
267144|NCT01642706|Biomarker
267145|NCT01642693|root resorption
267146|NCT01642693|low-power laser
267147|NCT01642693|orthodontic tooth movement
267148|NCT01642693|pulp changes
267149|NCT01642680|Physical activity program
267150|NCT01642680|Chemotherapy
267151|NCT01642680|Metabolic syndrome
267152|NCT01642680|Reducing cardiovascular risk factors
267153|NCT01642680|low physical activity level
267154|NCT01642628|Mirror
267155|NCT01642628|Body Image
267156|NCT01642628|Mastectomy
267157|NCT01642615|Drug therapy
267158|NCT01642602|Drug Therapy
267159|NCT01642589|Meningitis
267160|NCT01642589|Meningococcal disease
267161|NCT01642589|Menactra®
267162|NCT01642589|Adacel®
267163|NCT01642576|obesity
267164|NCT01642576|men
267165|NCT01642576|sexual function
267166|NCT01642576|urinary tract symptoms
267167|NCT01642576|endothelial function
267168|NCT01642576|inflammation
267169|NCT01642576|quality of life
267170|NCT01642563|Platelet transfusion
267171|NCT01642563|Leukemia
267172|NCT01642563|Transfusion transmissible infections
267173|NCT01642563|Chemotherapy
267174|NCT01642563|Allogeneic hemopoietic stem cell transplant
267175|NCT01642550|Anorexia nervosa
267176|NCT01642550|Anorexia
267177|NCT01642550|Eating disorders
267178|NCT01642524|resuscitation
267179|NCT01642511|Breast Cancer
267180|NCT01642511|Sentinel Lymph Node Biopsy
267181|NCT01642511|Internal Mammary
267182|NCT01642511|Lymphoscintigraphy
267183|NCT01642498|High Blood Pressure
267184|NCT01642498|Hypertension
267185|NCT01642498|Resistant Hypertension
267186|NCT01642485|Insulin clamp
267187|NCT01642485|Glucose clamp
267188|NCT01642485|Moxifloxacin
267189|NCT01642485|Fed
267190|NCT01642485|Fasted
267191|NCT01642485|QT/QTC interval
267192|NCT01642485|TQT
267193|NCT01642485|ECG
267194|NCT01642485|Meal effects
267195|NCT01642485|C Peptide
267196|NCT01642485|Japanese Caucasian bridging
267197|NCT01642485|TQT bridging
267198|NCT01642485|FDA standard breakfast
267199|NCT01642485|Adaptive study design
267200|NCT01642459|arteriovenous fistula
267201|NCT01642459|hemodialysis
267202|NCT01642459|aneurysm
267203|NCT01642459|vascular stenosis
267204|NCT01642459|cannulation
267205|NCT01642446|precise hepatectomy
267206|NCT01642446|hepatocellular carcinoma
267207|NCT01642446|cirrhotic
267208|NCT01642446|portal hypertension
267209|NCT01642446|safety
267210|NCT01642446|combined interventional treatment
267211|NCT01642394|Diabetes Mellitus
267212|NCT01642394|Chronic Disease
267213|NCT01642394|Education
267214|NCT01642394|Primary Care
267215|NCT01642394|Self care
267216|NCT01642394|Self Management
267217|NCT01642381|Drinking
267218|NCT01642381|Alcohol Problems
267219|NCT01642381|Alcoholism
267220|NCT01642381|Moderation-Oriented Treatment
267221|NCT01642381|Controlled Drinking
267222|NCT01642381|Reduced Drinking
267223|NCT01642381|Heavy Drinking
267224|NCT01642381|Problematic Drinking
267225|NCT01642381|Non-Abstinence-based Drinking
267226|NCT01642368|Omega-3 fatty acids
267227|NCT01642368|Omega-3 to omega-6 ratio
267228|NCT01642368|Cognitive response
267229|NCT01642368|Physical performance
267230|NCT01642329|Myocardial Infarction
267231|NCT01642329|Angina, Unstable
267232|NCT01642316|washback, reading comprehension
267233|NCT01642303|vodcasting,listening,language education
267234|NCT01642277|Overactive Bladder
267235|NCT01642277|OAB
267236|NCT01642277|Urinary Tract Infection
267237|NCT01642277|UTI
267238|NCT01642277|Microbiome
267239|NCT01642277|Bacteria
267240|NCT01642277|Solifenacin
267241|NCT01642277|16S rRNA sequence
267242|NCT01642264|Tobacco Cessation
267243|NCT01642264|Continuing Education
267244|NCT01642264|Pediatric
267245|NCT01642264|Respiratory Therapist
267246|NCT01642264|Nurse
267247|NCT01642238|Antiplatelet
267248|NCT01642238|ticagrelor
267249|NCT01642238|clopidogrel
267250|NCT01642238|bivalirudin
267251|NCT01642238|thrombosis
267252|NCT01642212|EoE
267253|NCT01642199|obesity
267254|NCT01642199|weight loss
267255|NCT01642199|lay health coach
267256|NCT01642199|peer coach
267257|NCT01642199|mentor coach
267258|NCT01642199|reduced intensity weight loss program
267259|NCT01642186|LETROZOLE
267260|NCT01642186|LUPRON DEPOT
267261|NCT01642186|RAD001 (EVEROLIMUS)
267262|NCT01642186|11-211
267263|NCT01642147|Cerebral blood flow
267264|NCT01642147|Transcranial Doppler
267265|NCT01642147|Emergence from general anesthesia
267266|NCT01642134|Antiplatelet
267267|NCT01642134|Anticoagulation
267268|NCT01642056|Fibroblasts
267269|NCT01642056|Mitochondria
267270|NCT01642056|Energy
267271|NCT01642056|Redox
267272|NCT01642056|Metabolic Disease
267273|NCT01642043|greater trochanteric pain syndrome
267274|NCT01642043|trochanteric bursitis
267275|NCT01642043|lateral hip pain
267276|NCT01642030|Quantitative sensory testing
267277|NCT01642030|Cold pressor test
267278|NCT01642030|Opioid dependence
267279|NCT01642030|Methadone maintenance
267280|NCT01642030|Buprenorphine maintenance
267281|NCT01642030|Abuse liability
267282|NCT01642030|DNIC
267283|NCT01642030|Temporal Summation
267284|NCT01642017|Phase I, Pazopanib, Frail elderly patients, Pharmacokinetics
267285|NCT01641991|Bacillus anthracis, anthrax, vaccine, BioThrax®, dose-sparing
267286|NCT01641913|Eosinophilic Esophagitis
267287|NCT01641900|sleep
267288|NCT01641900|memory
267289|NCT01641900|schizophrenia
267290|NCT01641900|eszopiclone
267291|NCT01641887|GERD
267292|NCT01641887|Heartburn
267293|NCT01641887|Decision Aid
267294|NCT01641874|Knee
267295|NCT01641874|Osteoarthritis
267296|NCT01641874|McKenzie system
267297|NCT01641874|Exercise
267298|NCT01641874|Mechanical Diagnosis and Therapy
267299|NCT01641874|Directional preference
267300|NCT01641861|Chemo-mechanical caries removal
267301|NCT01641861|Papacarie®
267302|NCT01641848|Total Ankle Arthroplasty
267303|NCT01641809|HIV -1
267304|NCT01641809|GSK1265744
267305|NCT01641809|maintenance phase
267306|NCT01641809|dose selection
267307|NCT01641796|Cutaneous Leishmaniasis
267308|NCT01641796|CL
267309|NCT01641796|Lesion
267310|NCT01641796|Topical
267311|NCT01641796|Treatment
267312|NCT01641796|Cream
267313|NCT01641796|Expanded Access
267314|NCT01641783|advanced
267315|NCT01641783|paclitaxel
267316|NCT01641783|capecitabine
267317|NCT01641783|first line therapy
267318|NCT01641757|hemodialysis
267319|NCT01641757|periodontitis
267320|NCT01641744|Parent Child Relationship
267321|NCT01641744|Maltreatment
267322|NCT01641744|Risk Behaviors
267323|NCT01641744|Social and Emotional Development
267324|NCT01641744|Violence and Abuse
267325|NCT01641744|Policy
267326|NCT01641731|cow's milk protein allergy
267327|NCT01641731|oral tolerance induction
267328|NCT01641718|Hernia, Inguinal
267329|NCT01641705|rheumatoid arthritis
267330|NCT01641705|respiratory mechanics
267331|NCT01641705|time of disease
267332|NCT01641692|Asthma
267333|NCT01641692|Pharmacokinetics
267334|NCT01641692|GSK573719
267335|NCT01641692|Adults
267336|NCT01641692|Pharmacogenetics
267337|NCT01641679|Recurrent differentiated thyroid cancer
267338|NCT01641679|I124-PET/CT
267339|NCT01641679|FDG-PET/CT
267340|NCT01641653|Nondiabetics undergoing hernia repair.
267341|NCT01641640|HCV genotype 1 (GT-1)
267342|NCT01641640|HCV genotype 4 (GT-4)
267343|NCT01641640|HCV genotype 5 (GT-5)
267344|NCT01641640|HCV genotype 6 (GT-6)
267345|NCT01641640|HCV
267346|NCT01641640|Sustained Virologic Response
267347|NCT01641640|Direct Acting Antiviral
267348|NCT01641640|Combination Therapy
267349|NCT01641640|Treatment-Naïve
267350|NCT01641640|GS-7977
267351|NCT01641640|Ribavirin
267352|NCT01641640|RBV
267353|NCT01641640|Peginterferon Alfa 2a
267354|NCT01641640|PEG
267355|NCT01641627|knee arthritis
267356|NCT01641627|muscle atrophy
267357|NCT01641627|proprioceptive stimulation
267358|NCT01641627|vibrations
267359|NCT01641614|Mitral valve
267360|NCT01641614|valve replacement
267361|NCT01641614|arrested heart
267362|NCT01641614|beating heart
267363|NCT01641601|Induction of labor
267364|NCT01641601|Outpatient cervical ripening
267365|NCT01641588|cognitive executive function
267366|NCT01641588|posture
267367|NCT01641588|cognitive performance
267368|NCT01641588|heart rate
267369|NCT01641588|eeg
267370|NCT01641575|CO-1.01
267371|NCT01641575|CO-101
267372|NCT01641575|gemcitabine elaidate
267373|NCT01641575|hENT1
267374|NCT01641575|nucleoside equilibrative transporter
267375|NCT01641575|solid tumor
267376|NCT01641575|non-small-cell lung cancer
267377|NCT01641575|NSCLC
267378|NCT01641575|lung cancer
267379|NCT01641562|BREAST CANCER,
267380|NCT01641562|TAXANES,
267381|NCT01641562|SUBCLINICAL CARDIAC DYSFUNCTION ,
267382|NCT01641562|DIAGNOSTIC TOOLS,
267383|NCT01641562|PREDICTIVE MODELS
267384|NCT01641549|Prosthetic valve thrombosis
267385|NCT01641549|Fibrinolytic therapy
267386|NCT01641549|Emergency surgery
267387|NCT01641536|Hepatitis, Chronic
267388|NCT01641536|Virus Diseases
267389|NCT01641536|DNA Virus Infections
267390|NCT01641536|Hepatitis B
267391|NCT01641536|Liver
267392|NCT01641536|Chronic Disease
267393|NCT01641536|HBV
267394|NCT01641523|Cranioplasty prosthesis
267395|NCT01641523|Hydroxyapatite
267396|NCT01641523|PolyMethylMethacrylate
267397|NCT01641523|Autologous Bone
267398|NCT01641510|reduced-function CYP2C19 allele
267399|NCT01641510|high platelet reactivity
267400|NCT01641510|clopidogrel
267401|NCT01641510|prasugrel
267402|NCT01641497|endometrial cancer
267403|NCT01641497|IMRT
267404|NCT01641497|age over 70
267405|NCT01641471|Total Knee Arthroplasty (TKA)
267406|NCT01641471|Transcutaneous Electrical Nerve Stimulation (TENS)
267407|NCT01641471|Pain
267408|NCT01641471|Function
267409|NCT01641471|Knee Osteoarthritis
267410|NCT01641458|Genotyping
267411|NCT01641458|Area-under-the concentration-time curve
267412|NCT01641458|Toxicity
267413|NCT01641458|5-fluorouracil
267414|NCT01641458|Capecitabine
267415|NCT01641419|Pain
267416|NCT01641419|Ropivacaine
267417|NCT01641419|sciatic block
267418|NCT01641419|dexamethasone
267419|NCT01641406|NAC Protocol
267420|NCT01641406|NAC and Oncotype Guided Hormonal therapy for breast cancer
267421|NCT01641406|Neoadjuvant and Oncotype
267422|NCT01641406|NAC CCAM 1101
267423|NCT01641393|Exocrine Pancreatic Insufficiency
267424|NCT01641393|Cystic Fibrosis
267425|NCT01641393|Pancreatic Insufficiency
267426|NCT01641380|Depoprovera
267427|NCT01641380|Contraception
267428|NCT01641380|Appointment adherence/attendance
267429|NCT01641380|Pregnancy Prevention
267430|NCT01641354|Hemiepiphysiodesis
267431|NCT01641341|Irritable Bowel Syndrome
267432|NCT01641341|Genova Diagnostics kit
267433|NCT01641341|Stool test
267434|NCT01641341|Rome III
267435|NCT01641341|Practice-based research
267436|NCT01641341|treatable parasite
267437|NCT01641341|Pancreatic insufficiency
267438|NCT01641341|Bowel dysbiosis
267439|NCT01641341|High levels of inflammation, C. difficile, or H. pylori
267440|NCT01641328|Mild Cognitive Impairment
267441|NCT01641328|MCI
267442|NCT01641328|Meditation
267443|NCT01641328|Mindfulness
267444|NCT01641328|Cognitive Activation
267445|NCT01641328|Cognitive Training
267446|NCT01641328|Tai Chi
267447|NCT01641315|rabies
267448|NCT01641315|rabies immunoglobulin
267449|NCT01641289|Falciparum malaria
267450|NCT01641289|Paracetamol
267451|NCT01641289|Renal function
267452|NCT01641289|Oxidative stress
267453|NCT01641276|biofeedback response
267454|NCT01641263|Depression Prevention
267455|NCT01641263|Sleep Disturbances
267456|NCT01641263|Inflammatory Markers
267457|NCT01641263|Treatments for Sleep Problems
267458|NCT01641224|Irritable bowel syndrome,
267459|NCT01641224|Pinaverium
267460|NCT01641224|Herbal medication for IBS,
267461|NCT01641224|Tong Xie Yao Fang (Formula for pain and diarrhea)
267462|NCT01641198|Dental implants, bone healing, fixed dental prostheses, implant surface
267463|NCT01641185|prostate
267464|NCT01641185|IPI
267465|NCT01641185|hypofractionation
267466|NCT01641185|carbon ions
267467|NCT01641185|proton
267468|NCT01641172|taste
267469|NCT01641172|smell
267470|NCT01641172|cancer
267471|NCT01641172|nutrition
267472|NCT01641159|Cocaine
267473|NCT01641159|Crack
267474|NCT01641159|Buspirone
267475|NCT01641159|Relapse Prevention
267476|NCT01641146|HIV risk reduction
267477|NCT01641146|Stress reduction
267478|NCT01641146|Trauma reduction
267479|NCT01641146|PTSD
267480|NCT01641133|pneumococcal conjugate vaccine
267481|NCT01641133|Synflorix™
267482|NCT01641133|Prevenar 13™
267483|NCT01641133|Pneumococcal diseases
267484|NCT01641120|Multiple Sclerosis
267485|NCT01641120|Intramuscular Injections
267486|NCT01641120|Relapsing Remitting
267487|NCT01641107|Ph+
267488|NCT01641107|BCR-ABL+
267489|NCT01641107|ALL
267490|NCT01641107|Ponatinib
267491|NCT01641107|stem cell transplantation
267492|NCT01641094|Hepatitis C
267493|NCT01641094|Liver
267494|NCT01641094|Immunology
267495|NCT01641094|Genotype 1
267496|NCT01641094|Treatment
267497|NCT01641094|Chronic
267498|NCT01641094|RNA Virus Infections
267499|NCT01641094|Ribavirin
267500|NCT01641094|Peginterferon alfa-2a
267501|NCT01641094|Protease Inhibitors
267502|NCT01641094|Telaprevir
267503|NCT01641068|Memory
267504|NCT01641068|Attention
267505|NCT01641068|Chemo-brain
267506|NCT01641068|Survivor
267507|NCT01641068|Treatment
267508|NCT01641042|Neisseria meningitidis
267509|NCT01641042|Meningococcal vaccines
267510|NCT01641042|Immunocompromised patient
267511|NCT01641042|Vaccines, conjugate
267512|NCT01641016|short cycle therapy
267513|NCT01641016|young people
267514|NCT01641016|HIV
267515|NCT01641003|cancer stem cells
267516|NCT01640990|Healthy male volunteers, intravenous infusion, GW328267X, dose escalation,
267517|NCT01640977|Open PLIF
267518|NCT01640977|MAS PLIF
267519|NCT01640977|Lumbar spine
267520|NCT01640964|Portal hypertension, cirrhosis, TIPSS, MRI, MRA, portal pressure, portal pressure gradient
267521|NCT01640925|nosocomial infection
267522|NCT01640925|hospital acquired infection
267523|NCT01640925|chlorhexidine
267524|NCT01640925|pneumonia, ventilator-associated
267525|NCT01640925|catheter-related infections
267526|NCT01640925|urinary tract infections, catheter-related
267527|NCT01640925|surgical site infection
267528|NCT01640912|Scar
267529|NCT01640912|Scar prevention
267530|NCT01640912|Fibrosis
267531|NCT01640899|Orthotic Devices
267532|NCT01640899|Activities of Daily Living
267533|NCT01640899|Pain Measurement
267534|NCT01640899|Lower Extremity
267535|NCT01640899|Foot
267536|NCT01640899|Personal Satisfaction
267537|NCT01640886|Staphylococcus aureus
267538|NCT01640886|methicillin resistant
267539|NCT01640886|MRSA
267540|NCT01640886|MSSA
267541|NCT01640886|Blood Culture
267542|NCT01640886|Diagnostic
267543|NCT01640873|Type 2 Diabetes
267544|NCT01640860|docetaxel
267545|NCT01640860|cisplatin
267546|NCT01640860|combined modality therapy
267547|NCT01640847|Painful bone metastases
267548|NCT01640847|Bone Cancer
267549|NCT01640847|Bone Cancer Pain
267550|NCT01640847|Patients with
267551|NCT01640821|Health-At-Every-Size intervention
267552|NCT01640782|adenocarcinoma of the stomach
267553|NCT01640782|adenocarcinoma of the gastroesophageal junction
267554|NCT01640769|Cardiomyopathy
267555|NCT01640769|Cardiac Resynchronization Therapy
267556|NCT01640756|Glaucoma Implant
267557|NCT01640756|Trabeculectomy
267558|NCT01640756|POAG
267559|NCT01640743|Kidney transplantation
267560|NCT01640743|Regulatory T cells
267561|NCT01640743|Tolerance
267562|NCT01640743|Tacrolimus
267563|NCT01640743|Rejection
267564|NCT01640691|pandemic influenza
267565|NCT01640691|pandemic influenza vaccine
267566|NCT01640691|Influenza
267567|NCT01640691|Orthomyxoviruses
267568|NCT01640691|A/H5N1
267569|NCT01640665|histologically
267570|NCT01640665|unresectable
267571|NCT01640665|metastatic
267572|NCT01640665|Phase 1
267573|NCT01640665|Breast Cancer
267574|NCT01640665|GI Tumors
267575|NCT01640665|Sorafenib
267576|NCT01640665|Capecitabine
267577|NCT01640639|left ventricular function
267578|NCT01640626|Health Education
267579|NCT01640626|Soil-transmitted helminthiasis
267580|NCT01640626|Ascaris
267581|NCT01640626|Trichuris
267582|NCT01640626|Hookworm
267583|NCT01640626|Prevention and control
267584|NCT01640613|carotid endarterectomy
267585|NCT01640613|regional anaesthesia
267586|NCT01640613|ultrasound guided block
267587|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have more behavioral problems.
267588|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have more cognitive problems.
267589|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have poorer motor development.
267590|NCT01640587|Uncomplicated falciparum infection
267591|NCT01640587|Mefloquine-artesunate
267592|NCT01640587|Dihydroartemisinin-piperaquine
267593|NCT01640574|Vivax
267594|NCT01640574|Chloroquine
267595|NCT01640574|Primaquine
267596|NCT01640574|Dihydroartemisinin-Piperaquine
267597|NCT01640561|HIV affected
267598|NCT01640561|Child Neurodevelopment
267599|NCT01640561|Low and Middle Income Country
267600|NCT01640535|PAR
267601|NCT01640522|Hepatocellular carcinoma
267602|NCT01640522|Cholangio carcinoma
267603|NCT01640522|Primary Liver Cancer
267604|NCT01640522|Bile Duct CancerPancreatic Cancer
267605|NCT01640522|Gallbladder Cancer
267606|NCT01640522|Colorectal Carcinoma
267607|NCT01640522|Other Primary Cancers with Liver Metastases
267608|NCT01640509|Radiotherapy, Targeted
267609|NCT01640496|Ulcerative Colitis
267610|NCT01640496|Inflammatory Bowel disease
267611|NCT01640496|IBD
267612|NCT01640496|Vitamin D
267613|NCT01640470|assistive technology
267614|NCT01640470|environmental modification
267615|NCT01640470|caregiver
267616|NCT01640470|client-centred
267617|NCT01640457|degenerative disc
267618|NCT01640457|herniated disc
267619|NCT01640457|sequestrectomy
267620|NCT01640457|Autologous Disc Chondrocyte Transplantation
267621|NCT01640457|nucleotomy
267622|NCT01640457|safety
267623|NCT01640457|efficacy
267624|NCT01640457|treatment
267625|NCT01640457|lumbar spine
267626|NCT01640457|low back pain
267627|NCT01640457|adjacent degenerative disc
267628|NCT01640457|black disc
267629|NCT01640457|NOVOCART
267630|NCT01640444|colorectal carcinoma
267631|NCT01640444|BRAF and PIK3K
267632|NCT01640444|FOLFIRI -Bevacizumab -Cetuximab
267633|NCT01640444|circulating tumor cells
267634|NCT01640431|lumbar disc herniation
267635|NCT01640431|clinical trial
267636|NCT01640431|exercise therapy
267637|NCT01640431|TENS
267638|NCT01640418|pressure ulcer
267639|NCT01640418|dressing
267640|NCT01640418|prevention
267641|NCT01640418|higher risk patients
267642|NCT01640405|colorectal cancer
267643|NCT01640405|FOLFOX
267644|NCT01640405|Bevacizumab
267645|NCT01640405|FOLFOXIRI
267646|NCT01640405|circulating tumor cell
267647|NCT01640392|Gay men
267648|NCT01640392|African American males
267649|NCT01640392|Unprotected anal sex
267650|NCT01640392|HIV risk
267651|NCT01640392|behavioral intervention
267652|NCT01640392|group-level intervention
267653|NCT01640379|Pelvic Inflammatory Disease (PID)
267654|NCT01640379|Community Health Nursing
267655|NCT01640379|Text Messaging
267656|NCT01640379|mHealth
267657|NCT01640379|Adolescents
267658|NCT01640366|surgical incision
267659|NCT01640366|reduction mammoplasty
267660|NCT01640366|healing complications
267661|NCT01640366|negative pressure wound therapy
267662|NCT01640353|si joint
267663|NCT01640353|si joint pain
267664|NCT01640353|si joint injury
267665|NCT01640353|si joint treatment
267666|NCT01640353|si joint injections
267667|NCT01640353|si joint inflammation
267668|NCT01640353|si joint problems
267669|NCT01640353|si joint symptoms
267670|NCT01640353|hypermobile si joint
267671|NCT01640353|si joint arthritis
267672|NCT01640353|si joint pain treatment
267673|NCT01640353|inflamed si joint
267674|NCT01640353|si joint sclerosis
267675|NCT01640353|locked si joint
267676|NCT01640353|si joint injuries
267677|NCT01640353|si joint disease
267678|NCT01640353|si joint infection
267679|NCT01640353|sacroiliac joint pelvic pain
267680|NCT01640353|sacroiliac joint arthritis treatment
267681|NCT01640340|ondansetron
267682|NCT01640340|palonosetron
267683|NCT01640340|emetogenic chemotherapy
267684|NCT01640340|HEC
267685|NCT01640327|Interpandemic influenza
267686|NCT01640327|Adult
267687|NCT01640327|Elderly
267688|NCT01640327|Safety
267689|NCT01640327|Tolerability
267690|NCT01640327|Immunology
267691|NCT01640314|Influenza
267692|NCT01640314|Adults
267693|NCT01640314|Elderly
267694|NCT01640314|Immunology
267695|NCT01640314|Safety
267696|NCT01640288|COPD
267697|NCT01640288|Pulmonary Function Testing
267698|NCT01640288|MRI
267699|NCT01640288|Normal Lung Function
267700|NCT01640288|Current Smoker
267701|NCT01640288|Non Smoker
267702|NCT01640288|Ex Smoker
267703|NCT01640275|General Anesthesia
267704|NCT01640275|Alzheimers Disease
267705|NCT01640275|Cognitive decline
267706|NCT01640262|prostate biopsy
267707|NCT01640262|prostate cancer
267708|NCT01640262|Magnetic Resonance Imaging
267709|NCT01640262|Neoplasm Staging
267710|NCT01640236|Ocular flare
267711|NCT01640197|Cognitive performance
267712|NCT01640197|Cerebral blood flow
267713|NCT01640197|Subjective sleep
267714|NCT01640197|Subjective mood
267715|NCT01640197|Subjective health
267716|NCT01640184|hyperparathyroidism
267717|NCT01640184|vitamin D
267718|NCT01640184|ultrasonic ablation
267719|NCT01640184|surgery
267720|NCT01640171|anesthesia
267721|NCT01640171|pain
267722|NCT01640171|intravitreal
267723|NCT01640171|anti-vegf
267724|NCT01640158|mild Traumatic Brain Injury
267725|NCT01640158|Cognitive remediation
267726|NCT01640158|computer
267727|NCT01640119|metabolic acidosis
267728|NCT01640119|renal death
267729|NCT01640106|Language
267730|NCT01640106|Fatty acids
267731|NCT01640106|Nutrition
267732|NCT01640106|Developmental delay
267733|NCT01640093|Healthy participants
267734|NCT01640093|Bioavailability
267735|NCT01640093|Pharmacokinetics
267736|NCT01640093|Abiraterone acetate
267737|NCT01640093|Abiraterone
267738|NCT01640080|Major depressive disorder
267739|NCT01640080|Treatment resistant depression
267740|NCT01640080|Depression
267741|NCT01640080|Esketamine
267742|NCT01640067|amyotrophic lateral sclerosis
267743|NCT01640067|motor neuron disease
267744|NCT01640067|stem cells
267745|NCT01640067|safety
267746|NCT01640067|ALS-FRS-Functional scale R and FVC (%) variation
267747|NCT01640067|Survival analysis
267748|NCT01640067|Changes in quality of life scales
267749|NCT01640054|Rheumatoid Arthritis
267750|NCT01640015|Blood pressure
267751|NCT01640015|eating episode
267752|NCT01640015|eating frequency
267753|NCT01640015|insulin sensitivity
267754|NCT01640002|overactive bladder
267755|NCT01640002|HTLV-1
267756|NCT01640002|Propantheline
267757|NCT01640002|anticholinergic
267758|NCT01639989|Doppler, Pregnancy
267759|NCT01639976|Missed abortion, early pregnancy loss.
267760|NCT01639950|Self-Report
267761|NCT01639950|Survey Scale
267762|NCT01639950|Validate
267763|NCT01639950|Pain Severity
267764|NCT01639950|Reliability
267765|NCT01639937|Cardiac MRI
267766|NCT01639937|Congestive Heart Failure
267767|NCT01639937|Cardiac Fibrosis
267768|NCT01639937|Late Gadolinium Enhancement
267769|NCT01639924|Small Bowel Disease
267770|NCT01639924|Digestive Disease
267771|NCT01639924|Gastrointestinal Disease
267772|NCT01639924|Lower GI Disease
267773|NCT01639911|malignant solid tumor
267774|NCT01639911|advanced non-hematologic
267775|NCT01639898|POEMS
267776|NCT01639898|VEGF
267777|NCT01639898|Free light
267778|NCT01639898|lenalidomide
267779|NCT01639898|dexamethasone
267780|NCT01639885|p53 overexpression
267781|NCT01639885|platinum-resistant
267782|NCT01639872|Schizophrenia
267783|NCT01639872|Cannabis Abuse
267784|NCT01639872|Cannabis Dependence
267785|NCT01639872|Dual Diagnosis
267786|NCT01639872|Clozapine
267787|NCT01639872|Risperidone
267788|NCT01639859|prostate cancer
267789|NCT01639859|elastography
267790|NCT01639859|elasticity
267791|NCT01639820|Cervical cancer
267792|NCT01639820|early stage carcinoma
267793|NCT01639820|FIGO IA1 IA2 IB1 IIA
267794|NCT01639820|sentinel lymph node biopsy
267795|NCT01639820|pelvic lymphadenectomy
267796|NCT01639820|Surgery of uterine cervical carcinoma
267797|NCT01639820|medico economic impact
267798|NCT01639820|quality of life
267799|NCT01639807|Open Angle Glaucoma or Ocular hypertension
267800|NCT01639794|LUTS (Lower Urinary Tract Symptoms)
267801|NCT01639794|Overactive Bladder (OAB)Vesitirim
267802|NCT01639794|Solifenacin
267803|NCT01639794|Anti-muscarinic treatment
267804|NCT01639794|Cholinergic receptor antagonist
267805|NCT01639794|Storage Symptom improvement
267806|NCT01639781|flavanols
267807|NCT01639781|age related cardiovascular effects
267808|NCT01639768|Sublingual immunotherapy
267809|NCT01639768|Dose range finding
267810|NCT01639768|Dose tolerability
267811|NCT01639768|Birch pollen
267812|NCT01639768|Allergic rhinitis/rhinoconjunctivitis
267813|NCT01639768|Safety
267814|NCT01639768|Immunogenicity
267815|NCT01639729|pharmacokinetics
267816|NCT01639729|area under curve
267817|NCT01639729|time to maximum concentration
267818|NCT01639716|Survey, interleukin status
267819|NCT01639703|CT perfusion
267820|NCT01639703|Hepatocellular Carcinoma
267821|NCT01639703|Xenetix
267822|NCT01639703|Contrast agent
267823|NCT01639690|BUSULFAN
267824|NCT01639690|G-CSF
267825|NCT01639690|CliniMACS-CD34 Reagent System
267826|NCT01639690|Blood transfusion
267827|NCT01639690|10-164
267828|NCT01639690|Autologous CD34+ cells transduced with TNS9.3.55, a lentiviral vector encoding the human β-globin gene
267829|NCT01639677|Obesity
267830|NCT01639677|weight loss
267831|NCT01639677|surgery
267832|NCT01639677|gastric bypass
267833|NCT01639677|VBG
267834|NCT01639651|Physical Therapy
267835|NCT01639651|Glenohumeral Internal Rotation Deficits
267836|NCT01639651|Joint Mobilization
267837|NCT01639651|Posterior capsule
267838|NCT01639651|Capsular contracture
267839|NCT01639638|Recurrent and non-recurrent genital condyloma
267840|NCT01639612|Stem Cell
267841|NCT01639612|Grade IV Malignant Glioma
267842|NCT01639599|non-smoker
267843|NCT01639599|female
267844|NCT01639599|IV PCA
267845|NCT01639599|patient-controlled analgesia
267846|NCT01639573|Patients with Scleroderma
267847|NCT01639560|smoking
267848|NCT01639560|tobacco dependence
267849|NCT01639560|nicotine dependence
267850|NCT01639547|PEGASYS® PLUS RIBAVIRIN
267851|NCT01639534|Biomarkers of ischemia
267852|NCT01639534|Carotid Stenting procedure
267853|NCT01639534|Levels Xanthine Hypoxanthine and Inosine
267854|NCT01639534|peripheral blood
267855|NCT01639508|Lung
267856|NCT01639508|XL184 (CABOZANTINIB)
267857|NCT01639508|KIF5B/RET Positive
267858|NCT01639508|RET Fusion Positive
267859|NCT01639508|12-097
267860|NCT01639508|Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
267861|NCT01639495|Drug refractory
267862|NCT01639495|Atrial fibrillation
267863|NCT01639495|Antiarrhythmic drug failure
267864|NCT01639495|Atrial tachyarrhythmias
267865|NCT01639469|Parkinson Disease
267866|NCT01639469|Quality of Life
267867|NCT01639469|Exercise Therapy
267868|NCT01639456|acute myelogenous leukemia
267869|NCT01639443|quality improvement
267870|NCT01639443|Organization and Administration
267871|NCT01639443|Costs and cost analysis
267872|NCT01639443|Patient satisfaction
267873|NCT01639443|Health plan implementation
267874|NCT01639404|Cerebral Palsy
267875|NCT01639404|Umbilical Cord Blood
267876|NCT01639404|Rehabilitation
267877|NCT01639365|Ventricular tachycardia
267878|NCT01639365|Catheter ablation
267879|NCT01639365|Tissue contact
267880|NCT01639352|Hepatocellular Carcinoma
267881|NCT01639352|HCC
267882|NCT01639352|SOMO230
267883|NCT01639352|Pasireotide LAR
267884|NCT01639339|Antibodies
267885|NCT01639339|Systemic Lupus Erythematosus
267886|NCT01639339|Autoimmune Disease
267887|NCT01639339|Glomerulonephritis
267888|NCT01639339|Belimumab
267889|NCT01639339|Lupus
267890|NCT01639339|Nephritis
267891|NCT01639339|Kidney Diseases
267892|NCT01639339|SLE
267893|NCT01639300|Relapsing Forms of Multiple Sclerosis
267894|NCT01639300|Progressive Forms of Multiple Sclerosis
267895|NCT01639300|GNbAC1
267896|NCT01639300|Monoclonal antibody
267897|NCT01639300|Multiple Sclerosis Associated Retrovirus (MSRV)
267898|NCT01639261|steroid-refractory
267899|NCT01639261|bronchiolitis obliterans
267900|NCT01639261|allogeneic stem cell transplantation
267901|NCT01639261|interferon gamma
267902|NCT01639248|Breast Cancer
267903|NCT01639235|Secondhand Smoke
267904|NCT01639235|Flight Attendants
267905|NCT01639235|Lung function
267906|NCT01639235|Cardiac function
267907|NCT01639235|Reproductive health
267908|NCT01639222|Drug therapy
267909|NCT01639222|Increase in calcium urinary excretion and PTH decrease in serum
267910|NCT01639209|Retinal detachment
267911|NCT01639209|Pneumatic retinopexy
267912|NCT01639209|Vitrectomy
267913|NCT01639196|Chronic pain
267914|NCT01639196|Psychological adjustment
267915|NCT01639196|Writing
267916|NCT01639196|Brief intervention
267917|NCT01639196|Online
267918|NCT01639196|Internet interventions
267919|NCT01639183|oral inflammation
267920|NCT01639183|systemic inflammation
267921|NCT01639183|compliance
267922|NCT01639183|power toothbrushing
267923|NCT01639183|nursing home residents
267924|NCT01639170|Pneumoperitoneum
267925|NCT01639170|Free air
267926|NCT01639170|Surgery
267927|NCT01639170|Perforation
267928|NCT01639170|Radiograph
267929|NCT01639144|Infection
267930|NCT01639144|delayed wound healing
267931|NCT01639144|platelet-rich plasma
267932|NCT01639131|Gemcitabine
267933|NCT01639131|Docetaxel
267934|NCT01639131|Filgrastim
267935|NCT01639131|Pegfilgrastim
267936|NCT01639118|primary ventral hernia repair with mesh
267937|NCT01639118|umbilical hernia repair
267938|NCT01639118|epigastric hernia repair
267939|NCT01639118|C-Qur V-patch
267940|NCT01639118|Size tailored repair
267941|NCT01639118|preperitoneal repair
267942|NCT01639118|abdominal hernia
267943|NCT01639118|dual sided mesh
267944|NCT01639092|Resistance of Entecavir
267945|NCT01639079|cigarette smoking behavior
267946|NCT01639079|smoking cessation
267947|NCT01639079|Latino smoking cessation
267948|NCT01639066|Resistance of Adefovir
267949|NCT01639053|Breast Augmentation
267950|NCT01639053|Breast Reconstruction
267951|NCT01639053|Breast Revision
267952|NCT01639053|Silicone breast implants
267953|NCT01639001|Crizotinib
267954|NCT01639001|ALK positive
267955|NCT01639001|ALK
267956|NCT01639001|Anaplastic Lymphoma Kinase
267957|NCT01639001|NSCLC
267958|NCT01639001|Non-Small Cell Lung Cancer
267959|NCT01639001|Frontline
267960|NCT01639001|1L
267961|NCT01639001|Previously Untreated
267962|NCT01639001|East Asian
267963|NCT01639001|Non-Squamous
267964|NCT01638962|Exercise Therapy
267965|NCT01638962|Gait
267966|NCT01638962|Joint load
267967|NCT01638962|Knee Joint
267968|NCT01638962|Middle Aged
267969|NCT01638962|Osteoarthritis, Knee/therapy
267970|NCT01638962|Pain Management
267971|NCT01638949|Alzheimer's disease
267972|NCT01638949|MCI
267973|NCT01638949|genetic
267974|NCT01638949|AV45-PET
267975|NCT01638936|Combination
267976|NCT01638936|Multiple Myeloma
267977|NCT01638923|Heavy Menstrual Bleeding
267978|NCT01638923|Efficacy
267979|NCT01638923|Safety
267980|NCT01638923|Oral contraceptive
267981|NCT01638923|Estradiol valerate
267982|NCT01638923|Dienogest
267983|NCT01638910|Efficacy
267984|NCT01638910|Safety
267985|NCT01638910|oral contraception
267986|NCT01638910|estradiol valerate
267987|NCT01638910|dienogest
267988|NCT01638897|ICD
267989|NCT01638897|CRTD
267990|NCT01638897|DF4
267991|NCT01638884|Prospective Memory
267992|NCT01638884|Healthy Aging
267993|NCT01638884|Alzheimer Disease
267994|NCT01638884|Brain Imaging
267995|NCT01638832|NASH; coronary artery disease
267996|NCT01638806|Acute Coronary Syndrome
267997|NCT01638806|Myocardial infarction
267998|NCT01638806|Angioplasty
267999|NCT01638806|Prehospital emergency care
268000|NCT01638806|Biological markers
268001|NCT01638806|Troponin
268002|NCT01638806|Point-of-Care systems
268003|NCT01638767|In Vitro Fertilization long protocol
268004|NCT01638767|NuvaRing
268005|NCT01638767|Marvelon
268006|NCT01638767|In vitro fertilization
268007|NCT01638715|Rheumatoid Arthritis
268008|NCT01638715|Biologic therapies
268009|NCT01638715|Biomarker
268010|NCT01638715|Mode of Action
268011|NCT01638702|Catheterisation, Central Venous
268012|NCT01638702|Catheters, Indwelling
268013|NCT01638689|Mechanism of Action of escitalopram
268014|NCT01638676|Unresectable melanoma
268015|NCT01638676|Stage IIIC and Stage IV BRAFV600E+ Melanoma
268016|NCT01638663|Tolvaptan
268017|NCT01638663|L-NMMA
268018|NCT01638663|Healthy subjects
268019|NCT01638663|Nephrology
268020|NCT01638663|Cardiology
268021|NCT01638624|Propofol
268022|NCT01638624|antioxidant capacity
268023|NCT01638624|total knee arthroplasty
268024|NCT01638624|Propofol,antioxidant
268025|NCT01638611|Healthy male volunteers
268026|NCT01638572|Neuroblastoma
268027|NCT01638572|B4GALNT3
268028|NCT01638572|Prognosis
268029|NCT01638559|liver transplant
268030|NCT01638559|allograft function
268031|NCT01638559|anti-rejection
268032|NCT01638559|immunosuppression withdrawal
268033|NCT01638520|Immune Therapy
268034|NCT01638520|Interleukin 4
268035|NCT01638520|monoclonal antibody
268036|NCT01638507|TARGET LESION REVASCULARIZATION (TLR)
268037|NCT01638507|TARGET VESSEL REVASCULARIZATION (TVR)
268038|NCT01638507|Coronary Artery Disease
268039|NCT01638507|MYOCARDIAL INFARCTION (MI)
268040|NCT01638507|PERCUTANEOUS CORONARY INTERVENTION (PCI)
268041|NCT01638507|STENT THROMBOSIS
268042|NCT01638507|TARGET LESION FAILURE (TLF)
268043|NCT01638494|25-Hydroxyvitamin D
268044|NCT01638494|dietary counseling
268045|NCT01638494|pediatrics
268046|NCT01638494|allergy
268047|NCT01638494|bone metabolism
268048|NCT01638468|Pulmonary Embolism
268049|NCT01638468|Acute Pulmonary Embolism
268050|NCT01638468|Sub-massive Pulmonary Embolism
268051|NCT01638468|Massive Pulmonary Embolism
268052|NCT01638468|Pulmonary Thromboembolism
268053|NCT01638442|Male subjects, healthy
268054|NCT01638403|narcolepsy
268055|NCT01638403|excessive daytime sleepiness
268056|NCT01638403|cataplexy
268057|NCT01638377|Back on Track
268058|NCT01638377|convicted drinking drivers
268059|NCT01638377|naltrexone
268060|NCT01638377|alcohol dependence
268061|NCT01638351|Diabetes mellitus
268062|NCT01638351|Resistance exercise
268063|NCT01638351|Elderly
268064|NCT01638351|Skeletal muscle dysfunction
268065|NCT01638351|Metabolomics
268066|NCT01638338|Alcohol
268067|NCT01638338|Risky drinking
268068|NCT01638338|Web site
268069|NCT01638338|Primary Care
268070|NCT01638338|General Practice
268071|NCT01638338|Local Community
268072|NCT01638338|Mayors
268073|NCT01638312|HIV, fructose
268074|NCT01638299|Type 1 Diabetes Mellitus
268075|NCT01638299|Artificial Pancreas
268076|NCT01638273|Pregabalin, GLARS
268077|NCT01638260|NEAT
268078|NCT01638260|liraglutide
268079|NCT01638260|glycemic control
268080|NCT01638247|Male breast cancer
268081|NCT01638247|neoadjuvant, adjuvant or metastatic situation
268082|NCT01638247|anti-hormonal therapy
268083|NCT01638234|atopic dermatitis
268084|NCT01638234|eczema
268085|NCT01638182|phylloquinone,
268086|NCT01638182|menaquinone-7
268087|NCT01638182|vitamin K-status
268088|NCT01638182|efficacy
268089|NCT01638156|Aortic stenosis
268090|NCT01638143|vitamin K2
268091|NCT01638143|menaquinone-7
268092|NCT01638143|bioavailability
268093|NCT01638091|Narrow band imaging
268094|NCT01638091|Screening colonoscopy
268095|NCT01638091|Histology
268096|NCT01638078|coronary restenosis
268097|NCT01638065|vein identification
268098|NCT01638065|vascular access
268099|NCT01638052|Tympanomastoid Surgery
268100|NCT01638052|Cochlear Implant
268101|NCT01638052|Mastoidectomy
268102|NCT01638052|Cholesteatoma
268103|NCT01638052|Pediatrics
268104|NCT01638052|Clonidine
268105|NCT01638052|Bupivacaine
268106|NCT01638052|Greater Auricular Nerve Block
268107|NCT01638052|Regional Anesthesia
268108|NCT01638026|Gnrh agonist
268109|NCT01638013|Rheumatoid Arthritis
268110|NCT01638013|ASP015K
268111|NCT01638000|Vesitrim
268112|NCT01638000|Frequency
268113|NCT01638000|Urgency
268114|NCT01638000|Urgency incontinence
268115|NCT01638000|Urinary incontinence
268116|NCT01638000|Overactive Bladder (OAB)
268117|NCT01638000|Micturition
268118|NCT01638000|Mirabegron
268119|NCT01638000|YM178
268120|NCT01638000|Vesicare
268121|NCT01638000|Solifenacin
268122|NCT01637987|Peripheral intravenous catheter
268123|NCT01637987|Vein visualization
268124|NCT01637987|Transillumination
268125|NCT01637987|Near infrared light
268126|NCT01637948|Chinese medicine
268127|NCT01637948|gingivitis
268128|NCT01637948|cytokine
268129|NCT01637948|microbial
268130|NCT01637935|Drug therapy
268131|NCT01637909|Prehypertension, Hypertension
268132|NCT01637883|benzydamine HCl
268133|NCT01637883|endotracheal tube
268134|NCT01637883|postoperative sore throat
268135|NCT01637870|Cesarean delivery
268136|NCT01637870|Postpartum infection
268137|NCT01637870|Wound complications
268138|NCT01637870|Wound seroma
268139|NCT01637870|Wound separation
268140|NCT01637870|Wound infection
268141|NCT01637870|Negative pressure
268142|NCT01637857|foof hypersensitivity
268143|NCT01637857|anal fissures
268144|NCT01637857|ano-rectal manometry
268145|NCT01637844|Pregnant women
268146|NCT01637844|HBsAg positive
268147|NCT01637844|HBeAg positive
268148|NCT01637844|Telbivudine
268149|NCT01637831|Obstructive Sleep Apnea
268150|NCT01637831|Idiopathic Pulmonary Fibrosis
268151|NCT01637818|Inguinal hernia repair
268152|NCT01637818|long-term follow-up
268153|NCT01637818|Surgical technique
268154|NCT01637792|peritoneal dialysis
268155|NCT01637792|dose
268156|NCT01637792|residual kidney function
268157|NCT01637792|technique survival
268158|NCT01637792|patient survival
268159|NCT01637792|peritonitis
268160|NCT01637779|randomized controlled trial
268161|NCT01637779|parent education
268162|NCT01637779|pain management
268163|NCT01637779|infant
268164|NCT01637779|immunization
268165|NCT01637766|Spinal Metastases
268166|NCT01637766|Spinal Metastatic Disease
268167|NCT01637766|Cord Compression
268168|NCT01637766|Intra-arterial Chemotherapy
268169|NCT01637766|Spinal Tumors
268170|NCT01637740|myopia
268171|NCT01637740|pseudoexfoliation syndrome
268172|NCT01637740|optical low coherence reflectometry
268173|NCT01637740|ocular optical components
268174|NCT01637740|cataract
268175|NCT01637727|Long term effects of gestational diabetes mellitus in a population of parous women
268176|NCT01637727|Gestational diabetes mellitus- GDM is defined as glucose intolerance diagnosed during pregnancy and not present shortly after birth
268177|NCT01637701|benign prostatic hypertrophy
268178|NCT01637701|bipolar transurethral resection of the prostate
268179|NCT01637701|plasmakinetic enucleation of the prostate
268180|NCT01637688|cow milk allergy
268181|NCT01637688|amino acid formula
268182|NCT01637675|sodium tanshinone IIA sulfonate
268183|NCT01637675|pulmonary hypertension
268184|NCT01637649|dysphagia,diaphragm, ultrasonography, inspiration, expiration,
268185|NCT01637636|rifampin,
268186|NCT01637636|ketoconazole,
268187|NCT01637636|CYP3A4,
268188|NCT01637636|tasimelteon,
268189|NCT01637636|VEC-162
268190|NCT01637636|Pharmacokinetics
268191|NCT01637623|Hypertension
268192|NCT01637623|High Blood Pressure
268193|NCT01637623|Sleep Apnea
268194|NCT01637623|Obstructive Sleep Apnea
268195|NCT01637623|OSA
268196|NCT01637610|placental alpha microglobulin-1
268197|NCT01637610|AmniSure
268198|NCT01637610|preterm
268199|NCT01637610|rupture of fetal membranes
268200|NCT01637597|Non-small cell lung cancer(NSCLC)
268201|NCT01637571|GERD
268202|NCT01637571|NCCP
268203|NCT01637571|chest pain
268204|NCT01637571|reflux
268205|NCT01637571|GERD related non-cardiac chest pain
268206|NCT01637545|facial bones
268207|NCT01637545|Post operative nasea vomiting
268208|NCT01637545|fractures
268209|NCT01637545|reduction
268210|NCT01637519|kidney stones
268211|NCT01637519|ureteral stones
268212|NCT01637519|stent
268213|NCT01637506|urine
268214|NCT01637506|stool
268215|NCT01637506|kidney stones
268216|NCT01637493|Pegylation
268217|NCT01637493|G-CSF
268218|NCT01637493|Pharmacokinetics
268219|NCT01637493|Pharmacodynamics
268220|NCT01637467|critical illness
268221|NCT01637467|myopathy
268222|NCT01637467|electrical muscle stimulation
268223|NCT01637454|noradrenaline terlipressin type 2 HRS
268224|NCT01637441|bladder prolapse (cystocele)
268225|NCT01637441|Pelvic organ prolapse repair
268226|NCT01637441|coelioscopic
268227|NCT01637441|prosthetic surgery
268228|NCT01637441|vaginal approach
268229|NCT01637441|Randomized study
268230|NCT01637441|laparoscopic sacropexy
268231|NCT01637441|vaginal mesh surgery
268232|NCT01637441|Stage II
268233|NCT01637441|Clavien Dindo
268234|NCT01637415|alcohol withdrawal syndrome
268235|NCT01637415|prediction
268236|NCT01637415|severity
268237|NCT01637415|alcohol use disorder
268238|NCT01637415|complicated alcohol withdrawal
268239|NCT01637415|alcohol withdrawal seizures
268240|NCT01637415|delirium tremens
268241|NCT01637415|PAWSS
268242|NCT01637402|CRPC
268243|NCT01637402|prostate
268244|NCT01637402|cancer
268245|NCT01637376|Lung neoplasms
268246|NCT01637376|Non Small cell lung carcinoma
268247|NCT01637376|Non small cell lung cancer
268248|NCT01637376|Large cell carcinoma
268249|NCT01637376|squamous cell carcinoma
268250|NCT01637376|adenocarcinoma
268251|NCT01637363|Psychoeducation
268252|NCT01637363|Stress
268253|NCT01637363|Sickness absence
268254|NCT01637363|Psychiatric symptoms
268255|NCT01637363|Locus of control
268256|NCT01637363|Self reported health
268257|NCT01637324|To assess VCT and linkage into care
268258|NCT01637324|nPEP
268259|NCT01637324|STIs
268260|NCT01637324|anal dysplasia/cancer
268261|NCT01637324|hyperlipidemia
268262|NCT01637324|diabetes
268263|NCT01637324|Proportion of first-time MSM clients attending multidisciplinary services who undergo HIV testing
268264|NCT01637324|Proportion of MSM clients who have repeated HIV testing during the first six months after the first negative HIV test
268265|NCT01637324|Proportion of HIV-positive MSM who receive HIV care within three months after HIV diagnosis or enrolment
268266|NCT01637324|Proportion of HIV-positive MSM who still remain in HIV care at six months after enrollment
268267|NCT01637311|Peroral endoscopic myotomy
268268|NCT01637311|Heller myotomy
268269|NCT01637311|persistent/recurrent achalasia.
268270|NCT01637298|Histological HGAIN
268271|NCT01637298|detected biomarkers
268272|NCT01637298|MSM population
268273|NCT01637298|HPV subtypes
268274|NCT01637298|AIN study
268275|NCT01637298|HIV-positive and HIV-negative MSM
268276|NCT01637298|anal cytology and biomarkers
268277|NCT01637298|likelihood of AIN development at month 12 and yearly thereafter
268278|NCT01637272|Dumping syndrome
268279|NCT01637259|proteinuria
268280|NCT01637259|HIV
268281|NCT01637233|HIV-1 infection
268282|NCT01637233|neurocognitive function
268283|NCT01637233|switch study
268284|NCT01637220|Anaphylaxis
268285|NCT01637220|Neutrophils
268286|NCT01637220|Platelet activating factor
268287|NCT01637220|Neutrophil Extracellular Traps (NETs)
268288|NCT01637168|Disorders of cognitive function
268289|NCT01637155|Cholecalciferol
268290|NCT01637129|Childhood stroke
268291|NCT01637129|Perinatal stroke
268292|NCT01637129|Pediatric stroke
268293|NCT01637129|Presumed perinatal stroke
268294|NCT01637129|Children who have hemiparesis
268295|NCT01637103|Cancer
268296|NCT01637103|Depression
268297|NCT01637103|Anxiety
268298|NCT01637103|Fatigue
268299|NCT01637103|Sleep
268300|NCT01637103|Quality of life
268301|NCT01637103|Cognitive therapy
268302|NCT01637103|Bright light therapy
268303|NCT01637064|Myositis
268304|NCT01637064|Acthar treatment
268305|NCT01637038|ischemia/reperfusion injury
268306|NCT01637038|remote ischemic postconditioning
268307|NCT01637012|ALEX
268308|NCT01637012|coronary stent
268309|NCT01637012|cobalt-chromium
268310|NCT01637012|sirolimus
268311|NCT01637012|OCT
268312|NCT01636999|Sedara
268313|NCT01636999|Nitrous Oxide
268314|NCT01636999|Butorphanol
268315|NCT01636999|Visual Analog Scale
268316|NCT01636986|myopia
268317|NCT01636986|contact lenses
268318|NCT01636986|dry eyes
268319|NCT01636986|comfort
268320|NCT01636986|replacement
268321|NCT01636973|Lung cancer
268322|NCT01636947|chemotherapy
268323|NCT01636947|nausea
268324|NCT01636947|vomiting
268325|NCT01636947|emetogenic
268326|NCT01636947|cancer
268327|NCT01636947|antiemetics
268328|NCT01636947|tumor
268329|NCT01636934|Lung Cancer
268330|NCT01636934|Non Small Cell Lung Cancer
268331|NCT01636934|NSCLC
268332|NCT01636934|Symptom Burden
268333|NCT01636934|Chemoradiation
268334|NCT01636934|CXRT
268335|NCT01636934|Minocycline
268336|NCT01636934|Dynacin
268337|NCT01636934|Minocin
268338|NCT01636934|Minocin PAC
268339|NCT01636934|Myrac
268340|NCT01636934|Solodyn
268341|NCT01636934|Placebo
268342|NCT01636934|Sugar Pill
268343|NCT01636934|Questionnaires
268344|NCT01636934|Surveys
268345|NCT01636921|Non-Small Cell Lung Cancer
268346|NCT01636921|Lung Cancer
268347|NCT01636921|NSCLC
268348|NCT01636921|Radiation Therapy
268349|NCT01636921|Sorafenib
268350|NCT01636921|BAY 43-9006
268351|NCT01636921|Thoracic Radiation
268352|NCT01636895|malaria
268353|NCT01636895|pregnancy
268354|NCT01636895|prevention
268355|NCT01636895|treatment
268356|NCT01636895|molecular markers
268357|NCT01636882|Melanoma
268358|NCT01636882|CALM
268359|NCT01636869|bupivacaine level
268360|NCT01636869|periarticular block
268361|NCT01636869|total knee arthroplasty
268362|NCT01636856|oropharyngeal exercises, obstructive sleep apnea, speech therapy, magnetic resonance, PCRIT, negative expiratory pressure, snore
268363|NCT01636830|Toothbrushing
268364|NCT01636830|gingival recession
268365|NCT01636804|Quicksite
268366|NCT01636804|Quickflex
268367|NCT01636804|St. Jude Medical
268368|NCT01636778|Thrombocytopenia
268369|NCT01636778|Hepatitis C, chronic
268370|NCT01636739|Intussusceptions
268371|NCT01636739|Special Drug Use Investigation
268372|NCT01636739|Rotavirus
268373|NCT01636726|COPD
268374|NCT01636726|AMI
268375|NCT01636726|Asthma
268376|NCT01636726|LABAs
268377|NCT01636700|Tramadol infiltration
268378|NCT01636700|Analgesic effect
268379|NCT01636700|Serum IL-6
268380|NCT01636687|Psoriasis
268381|NCT01636687|Moderate to Severe Plaque-type Psoriasis
268382|NCT01636674|positron emission tomography
268383|NCT01636674|computed tomography
268384|NCT01636674|fluordeoxyglucose
268385|NCT01636674|colon cancer
268386|NCT01636674|cancer
268387|NCT01636674|staging
268388|NCT01636674|imaging
268389|NCT01636648|Aortic Valve Replacement
268390|NCT01636648|Aortic Valve Bioprosthesis
268391|NCT01636622|Advanced Cancers
268392|NCT01636622|Advanced Malignancy
268393|NCT01636622|BRAF Mutation
268394|NCT01636622|Advanced solid tumor
268395|NCT01636622|Lymphoma
268396|NCT01636622|Vemurafenib
268397|NCT01636622|PLX4032
268398|NCT01636622|RO5185426
268399|NCT01636622|Carboplatin
268400|NCT01636622|Paraplatin
268401|NCT01636622|Paclitaxel
268402|NCT01636622|Taxol
268403|NCT01636609|Leukemia
268404|NCT01636609|Acute Myeloid Leukemia
268405|NCT01636609|AML
268406|NCT01636609|Myelodysplastic Syndromes
268407|NCT01636609|MDS
268408|NCT01636609|Relapsed
268409|NCT01636609|Refractory
268410|NCT01636609|Cytarabine
268411|NCT01636609|ARA-C
268412|NCT01636609|Cytosar
268413|NCT01636609|DepoCyt
268414|NCT01636609|Cytosine Arabinosine
268415|NCT01636609|5-Azacytidine
268416|NCT01636609|Azacitidine
268417|NCT01636609|5-aza
268418|NCT01636609|Vidaza
268419|NCT01636609|5-AZC
268420|NCT01636609|AZA-CR
268421|NCT01636609|Ladakamycin
268422|NCT01636609|NSC-102816
268423|NCT01636609|Tosedostat
268424|NCT01636596|Alzheimer's Disease
268425|NCT01636596|Mild Cognitive Impairment
268426|NCT01636596|Insulin
268427|NCT01636596|Pulsatile
268428|NCT01636583|zinc
268429|NCT01636583|absorption
268430|NCT01636583|bio-availability
268431|NCT01636583|aqueous zinc
268432|NCT01636583|zinc deficiency
268433|NCT01636583|zinc fortification
268434|NCT01636570|Vitamin D
268435|NCT01636570|Cholecalciferol
268436|NCT01636570|Heart Failure
268437|NCT01636570|Congestive heart failure
268438|NCT01636570|Cardiomyopathy
268439|NCT01636570|Strength
268440|NCT01636570|Parathyroid Hormone
268441|NCT01636570|Calcium
268442|NCT01636570|Quality of Life
268443|NCT01636570|C reactive protein
268444|NCT01636570|Cardiopulmonary exercise testing
268445|NCT01636570|Prognosis
268446|NCT01636557|Rheumatoid arthritis
268447|NCT01636557|sirukumab
268448|NCT01636557|CNTO 136
268449|NCT01636557|CYP450 enzyme
268450|NCT01636557|anti-interleukin-6 monoclonal antibody
268451|NCT01636466|Chronic allograft failure
268452|NCT01636466|Kidney Transplantation
268453|NCT01636453|wide-neck
268454|NCT01636453|saccular
268455|NCT01636453|intracranial aneurysms
268456|NCT01636453|ICA
268457|NCT01636453|Stent assisted coiling
268458|NCT01636453|Liberty Stent
268459|NCT01636440|Conditioned Pain Modulation
268460|NCT01636427|myocardial infarction
268461|NCT01636427|coronary angiography
268462|NCT01636427|STEMI
268463|NCT01636427|NSTEMI
268464|NCT01636414|Total joint arthroplasty, blood loss
268465|NCT01636388|Relapsed Hodgkins Lymphoma
268466|NCT01636388|Refractory Hodgkins Lymphoma
268467|NCT01636388|Allogeneic Stem Cell Transplantation
268468|NCT01636388|Adoptive Immunotherapy
268469|NCT01636388|Cellular Therapy
268470|NCT01636388|Cytotoxic T cell lymphocytes
268471|NCT01636362|Partial-thickness second degree burns
268472|NCT01636362|Mepitel Ag
268473|NCT01636362|Silver dressing
268474|NCT01636349|Type 2 diabetes
268475|NCT01636349|hypertension
268476|NCT01636349|obesity
268477|NCT01636349|metabolic syndrome
268478|NCT01636297|Parkinson's disease
268479|NCT01636297|Exercise
268480|NCT01636284|Liver Cancer
268481|NCT01636284|HCC
268482|NCT01636284|first line HCC
268483|NCT01636284|Pexa-Vec
268484|NCT01636284|JX-594
268485|NCT01636271|CV Risk
268486|NCT01636271|Cardiovascular Disease
268487|NCT01636271|Atherosclerosis
268488|NCT01636271|Acute coronary syndrome
268489|NCT01636258|Prediabetes
268490|NCT01636258|Overweight
268491|NCT01636258|African American
268492|NCT01636258|Women
268493|NCT01636258|Cooking
268494|NCT01636258|Nutrition
268495|NCT01636258|Exercise
268496|NCT01636258|Stress Management
268497|NCT01636245|71 vaccine
268498|NCT01636245|HFMD
268499|NCT01636245|consistency of three consecutive lots
268500|NCT01636245|immunogenicity
268501|NCT01636232|Vitamin D
268502|NCT01636232|infection
268503|NCT01636232|disease severity
268504|NCT01636232|mortality
268505|NCT01636232|critically ill
268506|NCT01636232|sepsis
268507|NCT01636219|Spirometry,
268508|NCT01636219|Cough
268509|NCT01636193|Rotavirus
268510|NCT01636193|Rotarix
268511|NCT01636193|Drug Use Investigation
268512|NCT01636193|Safety
268513|NCT01636180|STEMI
268514|NCT01636180|NSTEMI
268515|NCT01636180|clopidogrel
268516|NCT01636180|Areplex
268517|NCT01636180|REL-0609
268518|NCT01636154|fire-heat syndrome
268519|NCT01636154|blood stasis syndrome
268520|NCT01636154|method of clearing heat
268521|NCT01636154|method of promoting blood circulation
268522|NCT01636154|medicinal fractions-based herbal combinations
268523|NCT01636141|Safety
268524|NCT01636141|Tolerability
268525|NCT01636141|Pharmacokinetics
268526|NCT01636141|Dose escalation
268527|NCT01636141|Randomized
268528|NCT01636141|Healthy volunteers
268529|NCT01636141|Topical
268530|NCT01636141|OLT1177
268531|NCT01636141|Olatec
268532|NCT01636141|Pain
268533|NCT01636141|Inflammation
268534|NCT01636128|Urinary
268535|NCT01636128|biomarkers
268536|NCT01636128|DFMO
268537|NCT01636128|sulindac
268538|NCT01636102|Influenza
268539|NCT01636102|Adults
268540|NCT01636102|Elderly
268541|NCT01636102|Immunology
268542|NCT01636102|Safety
268543|NCT01636089|intensive care unit
268544|NCT01636076|COPD
268545|NCT01636063|Induced Abortion
268546|NCT01636063|Abortion Techniques
268547|NCT01636063|Mifepristone
268548|NCT01636063|Misoprostol
268549|NCT01636063|Initial Cervical Dilation
268550|NCT01636050|squat exercise
268551|NCT01636037|schizophrenia
268552|NCT01636037|negative symptoms
268553|NCT01636037|deficit syndrome
268554|NCT01636037|SANS
268555|NCT01636037|Sinemet
268556|NCT01636037|L-dopa
268557|NCT01636037|levodopa
268558|NCT01636037|carbidopa
268559|NCT01636037|augmentation
268560|NCT01636037|antipsychotics
268561|NCT01636024|Phase 1,
268562|NCT01636024|healthy volunteers,
268563|NCT01636024|safety,
268564|NCT01636024|tolerability,
268565|NCT01636024|pharmacokinetics,
268566|NCT01636024|pharmacodynamics,
268567|NCT01636024|single ascending dose study,
268568|NCT01636024|multiple
268569|NCT01636011|Parkinson's Disease
268570|NCT01636011|Osteopathic Manipulative Medicine
268571|NCT01636011|Speech
268572|NCT01636011|Pulmonary Function
268573|NCT01635998|renal sympathetic denervation
268574|NCT01635998|renal catheter ablation
268575|NCT01635998|hypertension
268576|NCT01635985|Phase I, Healthy male volunteers, pharmacokinetics
268577|NCT01635972|Isavuconazole
268578|NCT01635972|Bupropion
268579|NCT01635972|Bupropion hydrochloride
268580|NCT01635972|Healthy Volunteers
268581|NCT01635972|BAL8557
268582|NCT01635972|BAL4815
268583|NCT01635972|BAL8728
268584|NCT01635959|upper gastro-intestinal symptoms, GERD
268585|NCT01635946|Isavuconazole
268586|NCT01635946|Atorvastatin
268587|NCT01635946|Healthy Volunteers
268588|NCT01635946|BAL8557
268589|NCT01635946|BAL4815
268590|NCT01635946|BAL8728
268591|NCT01635933|contact lenses
268592|NCT01635933|color contact lenses
268593|NCT01635933|myopia
268594|NCT01635920|contact lenses
268595|NCT01635920|color contact lenses
268596|NCT01635920|myopia
268597|NCT01635894|female pelvic floor condition
268598|NCT01635894|pelvic floor training
268599|NCT01635894|supervised pelvic floor training
268600|NCT01635894|practice nurse
268601|NCT01635894|nurse specialist
268602|NCT01635842|Patient
268603|NCT01635842|information leaflet
268604|NCT01635842|informed consent
268605|NCT01635842|awareness
268606|NCT01635829|Healthy participants
268607|NCT01635829|Hepatitis C virus
268608|NCT01635829|Telaprevir
268609|NCT01635829|Phenytoin
268610|NCT01635829|Carbamazepine
268611|NCT01635829|HCV
268612|NCT01635829|Interaction
268613|NCT01635816|Immunogenicity
268614|NCT01635816|SA 14-14-2 JE vaccine
268615|NCT01635816|Bangladesh
268616|NCT01635803|bevacizumab
268617|NCT01635803|ranibizumab
268618|NCT01635803|retinal vein occlusions
268619|NCT01635803|randomized clinical trial
268620|NCT01635803|Macular edema
268621|NCT01635790|bevacizumab
268622|NCT01635790|ranibizumab
268623|NCT01635790|diabetic macular edema
268624|NCT01635790|randomized clinical trial
268625|NCT01635777|PKDL
268626|NCT01635777|miltefosine
268627|NCT01635764|hidradenitis suppurativa
268628|NCT01635764|adalimumab
268629|NCT01635764|open-label
268630|NCT01635764|HS
268631|NCT01635764|acne inversa
268632|NCT01635764|PIONEER (OPEN-LABEL EXTENSION)
268633|NCT01635764|acne
268634|NCT01635764|tumor necrosis factor
268635|NCT01635764|boil
268636|NCT01635751|Pregabalin
268637|NCT01635751|GLARS
268638|NCT01635738|Probiotics
268639|NCT01635738|Lactobacillus paracasei GMNL-133
268640|NCT01635738|Lactobacillus fermentum GM-090
268641|NCT01635738|Atopic dermatitis
268642|NCT01635738|Asthma
268643|NCT01635738|Lactobacillus paracasei
268644|NCT01635738|Lactobacillus fermentum
268645|NCT01635738|efficacy and safety
268646|NCT01635725|colonoscopy
268647|NCT01635725|bowel cleanliness
268648|NCT01635725|bowel rating scale
268649|NCT01635712|Hematological Malignancy
268650|NCT01635712|Hsp90
268651|NCT01635699|DNA oxidation
268652|NCT01635699|obstructive sleep apnea
268653|NCT01635699|lipid peroxidation
268654|NCT01635699|oxidative stresses
268655|NCT01635673|Exercise
268656|NCT01635673|Latino
268657|NCT01635673|Hispanic
268658|NCT01635673|Boys
268659|NCT01635660|Out-of-hospital
268660|NCT01635660|airway management
268661|NCT01635660|intubation
268662|NCT01635660|video laryngoscope
268663|NCT01635634|Fibromyalgia
268664|NCT01635634|Cupping
268665|NCT01635621|Olokizumab
268666|NCT01635621|OKZ
268667|NCT01635621|CDP6038
268668|NCT01635621|Crohn's Disease
268669|NCT01635621|CDAI
268670|NCT01635621|IBDQ
268671|NCT01635608|Pharmacokinetics
268672|NCT01635608|Talinolol
268673|NCT01635608|Amoxicillin
268674|NCT01635608|Acetaminophen
268675|NCT01635608|Magnetic Resonance Imaging
268676|NCT01635582|Hand exercises
268677|NCT01635582|Hand function
268678|NCT01635582|Computer based exercises
268679|NCT01635582|Therapeutic gaming
268680|NCT01635569|Obsessive-compulsive disorder
268681|NCT01635569|Pediatric
268682|NCT01635569|Group-based
268683|NCT01635569|Cognitive-behavioural therapy
268684|NCT01635556|borderline personality disorder
268685|NCT01635556|dialectical behavior therapy
268686|NCT01635556|psychological treatment
268687|NCT01635517|Diuretics
268688|NCT01635517|Vasopressins
268689|NCT01635517|Sodium
268690|NCT01635504|HIV lipoatrophy
268691|NCT01635504|masseter hypertrophy
268692|NCT01635504|parotid enlargement
268693|NCT01635504|botulinum toxin
268694|NCT01635491|Gastrointestinal Motility
268695|NCT01635491|Transit time
268696|NCT01635426|Aspirin
268697|NCT01635426|Clopidogrel
268698|NCT01635426|Unexplained recurrent pregnancy loss
268699|NCT01635426|Uterine artery pulsatility index
268700|NCT01635400|Irinotecan
268701|NCT01635400|UGT1A1 Gene Polymorphisms
268702|NCT01635400|Small Cell Carcinoma of Lung
268703|NCT01635348|gait speed
268704|NCT01635348|cognitive processing speed
268705|NCT01635335|HIV prevention
268706|NCT01635335|adolescents
268707|NCT01635335|Latinos
268708|NCT01635335|Hispanics
268709|NCT01635335|family
268710|NCT01635335|health promotion
268711|NCT01635335|disease prevention
268712|NCT01635335|family communication
268713|NCT01635335|parental supervision
268714|NCT01635322|deformity
268715|NCT01635322|adult
268716|NCT01635322|lumbar
268717|NCT01635322|thoraco-lumbar
268718|NCT01635322|Sagittal vertebral Alignement (SVA)
268719|NCT01635322|Oswestry Disability Index (ODI)
268720|NCT01635257|pulmonary embolism diagnosis
268721|NCT01635257|ultrasound
268722|NCT01635244|Aortic valve prosthesis
268723|NCT01635244|Aortic valve hemodynamics
268724|NCT01635244|Prosthesis-patient mismatch
268725|NCT01635244|Left ventricular diastolic function
268726|NCT01635244|Left ventricular remodeling
268727|NCT01635231|Nephrology
268728|NCT01635231|sodium-channels
268729|NCT01635231|water-channels
268730|NCT01635231|BCM
268731|NCT01635231|central blood pressure
268732|NCT01635218|Depression
268733|NCT01635218|Perimenopause
268734|NCT01635218|Postmenopause
268735|NCT01635218|Homeopathy
268736|NCT01635205|Paraspinous block
268737|NCT01635205|Non-responsive chronic pelvic pain
268738|NCT01635192|renin
268739|NCT01635192|angiotensin
268740|NCT01635192|probiotic
268741|NCT01635192|glucose absorption
268742|NCT01635192|intestinal
268743|NCT01635179|Videolaryngoscopy
268744|NCT01635179|Bronchial Aspiration
268745|NCT01635179|Hypoxia
268746|NCT01635166|Arthroplasty
268747|NCT01635166|Replacement
268748|NCT01635166|Hip
268749|NCT01635166|Cementless
268750|NCT01635166|Ceramic on Ceramic
268751|NCT01635153|HIV
268752|NCT01635153|Tuberculosis
268753|NCT01635153|Nutrition
268754|NCT01635140|DIPG
268755|NCT01635140|Hypofractionated Radiotherapy
268756|NCT01635140|Radiotherapy
268757|NCT01635140|Median survival
268758|NCT01635101|Moderate to severe acute pain following surgery or trauma
268759|NCT01635088|Asthma
268760|NCT01635088|FEV1 and IOS change after mometasone for asthma
268761|NCT01635075|psychiatric
268762|NCT01635075|comorbidity
268763|NCT01635075|craving
268764|NCT01635075|tobacco
268765|NCT01635049|in vitro fertilization
268766|NCT01635049|assisted reproduction techniques
268767|NCT01635049|noninvasive imaging of embryos
268768|NCT01635049|time lapse imaging of embryos
268769|NCT01635049|traditional morphological grading of embryos
268770|NCT01635049|prediction of blastocysts
268771|NCT01635049|infertility
268772|NCT01635049|preimplantation genetic diagnosis
268773|NCT01635049|comprehensive chromosome screening
268774|NCT01635036|in vitro fertilization
268775|NCT01635036|assisted reproduction techniques
268776|NCT01635036|noninvasive imaging of embryos
268777|NCT01635036|time lapse imaging of embryos
268778|NCT01635036|traditional morphological grading of embryos
268779|NCT01635036|prediction of blastocyst formation
268780|NCT01635036|infertility
268781|NCT01635036|male factor female factor
268782|NCT01635036|embryo viability
268783|NCT01635023|Phase I
268784|NCT01635023|healthy volunteers
268785|NCT01635023|AZD6244
268786|NCT01635023|pharmacokinetics
268787|NCT01635023|AUC
268788|NCT01635023|Cmax
268789|NCT01635023|tmax
268790|NCT01635023|AUC(0-t)
268791|NCT01635010|obstructive sleep apnea
268792|NCT01635010|inflammation
268793|NCT01635010|oxidative stress
268794|NCT01635010|arterial stiffness
268795|NCT01634997|Screening for Type 2 Diabetes
268796|NCT01634984|expression of CDK5RAP2
268797|NCT01634971|Postoperative pancreatic fistula(POPF);
268798|NCT01634971|Postpancreatectomy hemorrhage(PPH);
268799|NCT01634971|Delayed gastric emptying (DGE);
268800|NCT01634971|Bile leakage after pancreatic surgery;
268801|NCT01634971|Anastomotic leakage
268802|NCT01634958|Allergic Rhinitis
268803|NCT01634958|Hayfever
268804|NCT01634958|Immunotherapy
268805|NCT01634958|Dose-Finding-Study
268806|NCT01634945|anemia
268807|NCT01634945|malaria
268808|NCT01634945|malnutrition
268809|NCT01634945|iron fortification
268810|NCT01634945|intermittent preventive treatment
268811|NCT01634945|subsaharan africa
268812|NCT01634945|ivory coast
268813|NCT01634945|young children
268814|NCT01634932|Iron deficiency
268815|NCT01634932|Biofortification
268816|NCT01634932|Pearl Millet
268817|NCT01634932|Benin
268818|NCT01634919|Chronic hepatitis C
268819|NCT01634919|Liver fibrosis
268820|NCT01634919|ARFI(Acoustic radiation force impulse)
268821|NCT01634906|Apolipoprotein B, erythrocytes, statins
268822|NCT01634893|Refractory or Relapsed Solid Tumors
268823|NCT01634880|Salivary Gland Malignancies
268824|NCT01634880|Panitumumab
268825|NCT01634880|Postoperative
268826|NCT01634880|Radiotherapy
268827|NCT01634841|walnuts
268828|NCT01634841|age related cognitive decline
268829|NCT01634841|age related macular degeneration
268830|NCT01634841|healthy elderly subjects
268831|NCT01634802|Clinical Decision Support Systems
268832|NCT01634802|Electronic Medical Record
268833|NCT01634802|Resource constrained countries
268834|NCT01634802|HIV
268835|NCT01634789|bioavailability
268836|NCT01634763|Phase I, open-label, dose escalation, oral LDK378, Japanese patients with tumors characterized by ALK genetic alterations
268837|NCT01634750|N-Acetyl-D-mannosamine (ManNAc)
268838|NCT01634750|HIBM
268839|NCT01634750|GNE Myopathy
268840|NCT01634737|shellfish
268841|NCT01634737|tropomyosin
268842|NCT01634737|mites
268843|NCT01634737|food allergy
268844|NCT01634724|GnRH agonist withdrawal
268845|NCT01634724|OHSS
268846|NCT01634724|E2
268847|NCT01634724|VEGF
268848|NCT01634711|ACL
268849|NCT01634711|Anterior Cruciate Ligament
268850|NCT01634711|Ligament
268851|NCT01634711|Resorbable polymer
268852|NCT01634711|Knee ligament
268853|NCT01634698|chronic liver disease
268854|NCT01634698|cirrhosis
268855|NCT01634698|vitamin A
268856|NCT01634698|RDR test
268857|NCT01634698|retinol-binding protein
268858|NCT01634685|Rectal cancer
268859|NCT01634685|Bavituximab
268860|NCT01634685|Capecitabine
268861|NCT01634685|Radiation Therapy
268862|NCT01634672|Gastroesophageal Reflux Disease
268863|NCT01634672|peritoneal dialysis
268864|NCT01634672|hemodialysis
268865|NCT01634659|contact lenses
268866|NCT01634659|myopia
268867|NCT01634646|Observational study
268868|NCT01634633|Endometrial nerve fibres
268869|NCT01634620|Chronic Obstructive Pulmonary Disease (COPD)
268870|NCT01634620|Chronic Obstructive Airways Disease
268871|NCT01634620|Chronic Bronchitis
268872|NCT01634620|Chronic Emphysema
268873|NCT01634620|Asthma
268874|NCT01634607|osteopenia
268875|NCT01634607|vitamin D deficiency
268876|NCT01634607|HIV-infected patients
268877|NCT01634607|bone health
268878|NCT01634607|Bone mineral density (BMD)
268879|NCT01634607|HIV-uninfected patients
268880|NCT01634607|effects of TDF on the patients' bone
268881|NCT01634594|Deliberate hypotension, QTc, Tp-e, heart rate variability
268882|NCT01634555|Advanced Malignant Solid Tumors
268883|NCT01634516|Diet
268884|NCT01634516|Pregnant
268885|NCT01634503|3+3 design
268886|NCT01634503|Phase 1
268887|NCT01634503|Cervical Intraepithelial Neoplasia
268888|NCT01634503|Adult
268889|NCT01634503|Safety
268890|NCT01634503|Dose Finding
268891|NCT01634490|cow's milk allergy
268892|NCT01634490|formulas
268893|NCT01634490|probiotics
268894|NCT01634477|morbidity
268895|NCT01634477|mortality
268896|NCT01634477|HIV-infected patients
268897|NCT01634477|prospective cohort study
268898|NCT01634477|highly active antiretroviral therapy (HAART)
268899|NCT01634477|opportunistic infections
268900|NCT01634477|Non HIV-related illness
268901|NCT01634477|cardiovascular disease (CVD)
268902|NCT01634477|HIV negative patients
268903|NCT01634477|Thai HIV-infected patients
268904|NCT01634451|Sedation
268905|NCT01634451|Quality
268906|NCT01634438|coronary angiography
268907|NCT01634425|NSTEMI
268908|NCT01634425|Point of Care Biomarkers
268909|NCT01634334|Secondhand smoke
268910|NCT01634295|CKD-828
268911|NCT01634295|Hypertension
268912|NCT01634295|Stage 2 Hypertension
268913|NCT01634295|S-Amlodipine
268914|NCT01634295|Telmisartan
268915|NCT01634269|Valvular Heart Disease
268916|NCT01634269|Severe Aortic Stenosis
268917|NCT01634269|Aortic Valve Replacement
268918|NCT01634243|SPM 962
268919|NCT01634243|rotigotine
268920|NCT01634243|Parkinson's disease
268921|NCT01634204|weight reduction
268922|NCT01634204|web-based intervention
268923|NCT01634204|cost-effective
268924|NCT01634204|overweight
268925|NCT01634204|obesity
268926|NCT01634204|cardiovascular risk
268927|NCT01634191|Apremilast
268928|NCT01634191|pharmacokinetic
268929|NCT01634191|safety
268930|NCT01634191|Pharmacokinetics and safety in healthy volunteer subjects
268931|NCT01634178|Apremilast,
268932|NCT01634178|pharmacokinetic
268933|NCT01634178|safety
268934|NCT01634178|Safety and pharmacokinetics in healthy volunteer subjects
268935|NCT01634126|Colon
268936|NCT01634126|Rectal
268937|NCT01634126|Cancer
268938|NCT01634126|Screening
268939|NCT01634126|FIT
268940|NCT01634126|Fecal
268941|NCT01634061|Castration-resistant prostate cancer, abiraterone acetate, BEZ235, BKM120, dose escalation, abiraterone acetate failure
268942|NCT01634048|high protein diet
268943|NCT01634048|meal replacements
268944|NCT01634048|low calorie diet
268945|NCT01634048|intra hepatocellular lipid
268946|NCT01634035|glycated hemoglobin
268947|NCT01634035|mean plasma glucose
268948|NCT01634022|Acupuncture
268949|NCT01634022|Antidepressant
268950|NCT01634022|Monotherapy
268951|NCT01634022|Depression
268952|NCT01634022|Alternative treatments
268953|NCT01634009|Severe acute malnutrition
268954|NCT01634009|Ready to use therapeutic food
268955|NCT01634009|Soy protein
268956|NCT01634009|Community based management
268957|NCT01634009|Efficacy
268958|NCT01634009|Management of Children with SAM in Bangladesh
268959|NCT01633996|Acupuncture
268960|NCT01633996|Antidepressant
268961|NCT01633996|Augmentation
268962|NCT01633996|Depression
268963|NCT01633983|Central Serous Chorioretinopathy
268964|NCT01633983|Methotrexate
268965|NCT01633957|anticoagulation
268966|NCT01633957|bleeding
268967|NCT01633957|CYP2C9
268968|NCT01633957|CYP4F2
268969|NCT01633957|VKORC1
268970|NCT01633957|warfarin dosing
268971|NCT01633957|Heart Valve Diseases
268972|NCT01633957|pharmacogenomics
268973|NCT01633944|CLBP
268974|NCT01633944|Chronic Low Back Pain
268975|NCT01633944|Chronic Pain
268976|NCT01633944|Back Pain
268977|NCT01633918|intervention
268978|NCT01633918|health education
268979|NCT01633918|physical activity
268980|NCT01633918|sedentary behavior
268981|NCT01633918|health promotion
268982|NCT01633918|evaluation
268983|NCT01633918|RE-AIM
268984|NCT01633905|alcohol-dependence
268985|NCT01633905|event-related potentials
268986|NCT01633905|emotion
268987|NCT01633905|crossmodal
268988|NCT01633905|peripheral processing
268989|NCT01633892|Craniomaxillofacial (CMF)
268990|NCT01633892|Battle-injured (BI)
268991|NCT01633892|Facial Trauma
268992|NCT01633892|Fat Grafts
268993|NCT01633892|Autogenous Fat Transfers (AFT)
268994|NCT01633892|Wounded warriors
268995|NCT01633892|Adipose Tissue
268996|NCT01633879|parenting, prevention, HIV/AIDS, adolescents, Latino
268997|NCT01633866|Magnetic Resonance Imaging
268998|NCT01633853|chronic kidney disease mineral and bone disorder
268999|NCT01633853|vitamin D2
269000|NCT01633853|parathyroid hormone
269001|NCT01633840|double-blind placebo-controlled food challenges
269002|NCT01633840|food allergy
269003|NCT01633840|food hypersensitivity
269004|NCT01633840|triangle test
269005|NCT01633840|validated recipes
269006|NCT01633814|Physiological Processes
269007|NCT01633814|Exercise
269008|NCT01633814|Hormone replacement therapy
269009|NCT01633775|Refractory primary open angle glaucoma
269010|NCT01633775|trabeculectomy
269011|NCT01633775|ahmed valve implant
269012|NCT01633749|Influenza
269013|NCT01633749|Vaccine
269014|NCT01633749|CHMP criteria
269015|NCT01633736|single blinded
269016|NCT01633736|randomised
269017|NCT01633736|controlled
269018|NCT01633736|physiotherapy
269019|NCT01633736|children
269020|NCT01633736|cerebral palsy
269021|NCT01633710|Ankle brachial pressure index
269022|NCT01633710|Colour duplex ultrasound
269023|NCT01633710|Diabetes
269024|NCT01633710|Photoplethysmography
269025|NCT01633697|emphysema
269026|NCT01633697|chronic bronchitis
269027|NCT01633684|diabetes mellitus
269028|NCT01633684|bone
269029|NCT01633671|Misadventures to Patients During Surgical and Medical Care
269030|NCT01633671|Pulmonary Embolism Without Acute Cor Pulmonale
269031|NCT01633671|Pulmonary Embolism Without Mention of Acute Cor Pulmonale
269032|NCT01633658|vitamin D
269033|NCT01633632|Smoking cessation
269034|NCT01633632|Yoga
269035|NCT01633632|Cognitive behavioral therapy
269036|NCT01633619|Prosthetic Joint Infection
269037|NCT01633606|severity of illness
269038|NCT01633606|scoring
269039|NCT01633606|medium care
269040|NCT01633606|intensive care
269041|NCT01633606|staffing
269042|NCT01633580|ICSI
269043|NCT01633580|GnRH antagonist
269044|NCT01633580|corifollitropin alfa
269045|NCT01633567|Smoking Cessation
269046|NCT01633567|Cigarette Smoking
269047|NCT01633567|Tobacco
269048|NCT01633567|LGBT
269049|NCT01633567|LGBTQ
269050|NCT01633554|ST-2, IL-33, prediction, fibrosis, hepatitis B
269051|NCT01633528|low dose aspirin endometrial thickness pregnancy rate ICSI IVF embryo transfer
269052|NCT01633515|Basal cell carcinoma (BCC)
269053|NCT01633515|Cryotherapy
269054|NCT01633515|Cryosurgery
269055|NCT01633476|CMV
269056|NCT01633476|ANCA associated vasculitis
269057|NCT01633476|CD4+CD28- T-cells
269058|NCT01633476|Valaciclovir
269059|NCT01633463|EMERGENCY CANCER PAIN, ASSESSMENT, TREATMENT ADEQUACY.
269060|NCT01633437|tyramine
269061|NCT01633437|MAOI
269062|NCT01633437|cheese effect
269063|NCT01633437|depression
269064|NCT01633398|Heart Failure
269065|NCT01633398|HF
269066|NCT01633385|bronchial inflammation
269067|NCT01633385|Bronchiolitis obliterans
269068|NCT01633385|Sputum
269069|NCT01633385|Blood
269070|NCT01633385|Inflammation
269071|NCT01633385|adaptive immune system
269072|NCT01633385|innate immune system
269073|NCT01633372|Primary Myelofibrosis
269074|NCT01633372|PMF
269075|NCT01633372|Post Polycythemia Vera Fibrosis
269076|NCT01633372|PPV-MF
269077|NCT01633372|Post Essential Thrombocythemia Myelofibrosis
269078|NCT01633372|PET-MF
269079|NCT01633333|Colonoscopy
269080|NCT01633333|Colorectal cancer
269081|NCT01633333|Colorectal adenomas
269082|NCT01633333|Pain
269083|NCT01633320|Analgesia/Nociception index
269084|NCT01633307|education
269085|NCT01633307|intravenous infusion
269086|NCT01633294|premature rupture of membranes
269087|NCT01633294|term pregnancy
269088|NCT01633294|chorioamnionitis
269089|NCT01633294|endometritis
269090|NCT01633294|neonatal sepsis
269091|NCT01633294|antibiotic prophylaxis
269092|NCT01633281|peripheral neuropathy
269093|NCT01633281|acupuncture
269094|NCT01633281|Bortezomib
269095|NCT01633281|Thalidomide
269096|NCT01633268|MRI (Magnetic Resonance Imaging)
269097|NCT01633268|Traumatic Brain Injury
269098|NCT01633255|Anti-Angiogenic
269099|NCT01633255|Dynamic Contrast Enhanced Magnetic Resonance Imaging
269100|NCT01633255|PET/CT Imaging Studies
269101|NCT01633242|MRI
269102|NCT01633242|Muscular Dystrophy
269103|NCT01633242|Cardiac
269104|NCT01633242|Myocardium
269105|NCT01633242|Intramyocardial fat
269106|NCT01633229|Immune Suppression
269107|NCT01633229|BMSC
269108|NCT01633229|GVHD
269109|NCT01633229|Marrow Failure
269110|NCT01633229|Regimen Related Toxicity
269111|NCT01633229|Graft-Versus-Host Disease
269112|NCT01633216|poliovirus,
269113|NCT01633216|trivalent oral polio vaccine,
269114|NCT01633216|bivalent oral polio vaccine,
269115|NCT01633216|monovalent oral polio vaccine
269116|NCT01633203|gastric cancer
269117|NCT01633203|combination chemotherapy
269118|NCT01633203|HER-2 gene
269119|NCT01633203|quality of life
269120|NCT01633190|Surveillance
269121|NCT01633190|Rotavirus
269122|NCT01633190|Gastroenteritis
269123|NCT01633177|vitamin D
269124|NCT01633177|omega-3 fatty acids
269125|NCT01633177|Type 2 diabetes
269126|NCT01633177|Oral glucose tolerance test (OGTT)
269127|NCT01633177|Insulin sensitivity
269128|NCT01633177|Beta-cell function
269129|NCT01633164|Spinal Cord Injury
269130|NCT01633164|Self-Efficacy
269131|NCT01633164|Life Satisfaction
269132|NCT01633164|Community Participation
269133|NCT01633138|cognitive remediation therapy
269134|NCT01633138|substance abuse treatment
269135|NCT01633125|Group music therapy
269136|NCT01633125|prisoners
269137|NCT01633125|Anxiety
269138|NCT01633125|Depression
269139|NCT01633125|Self-esteem
269140|NCT01633099|decitabine
269141|NCT01633099|acute myeloid leukemia
269142|NCT01633099|elderly patient
269143|NCT01633060|BKM120
269144|NCT01633060|fulvestrant
269145|NCT01633060|breast cancer
269146|NCT01633060|metastatic
269147|NCT01633060|locally advanced
269148|NCT01633060|AI treated
269149|NCT01633060|mTOR inhibitor
269150|NCT01633060|PI3K
269151|NCT01633060|PIK3CA
269152|NCT01633060|PTEN
269153|NCT01633060|HER2-
269154|NCT01633060|HR+
269155|NCT01633047|Anterior Cruciate Ligament
269156|NCT01633047|Electric Stimulation Therapy
269157|NCT01633034|intervertebral disc degeneration
269158|NCT01633034|back pain
269159|NCT01633034|spine surgery
269160|NCT01633021|Family Study
269161|NCT01633021|Social Networks
269162|NCT01633021|Diabetes
269163|NCT01633008|Modified Brief Pain Inventory
269164|NCT01633008|Quality of Life
269165|NCT01633008|Pain-Related Coping
269166|NCT01633008|Pain-Related Anxiety
269167|NCT01633008|Depression
269168|NCT01632982|opioid abuse
269169|NCT01632982|substance abuse
269170|NCT01632982|methadone maintenance treatment
269171|NCT01632982|mobile technology
269172|NCT01632982|technology-based intervention
269173|NCT01632982|behavioral intervention
269174|NCT01632982|psychosocial treatment
269175|NCT01632969|12-136
269176|NCT01632956|Support Groups
269177|NCT01632956|Breast cancer
269178|NCT01632956|Mandarin speaking
269179|NCT01632956|12-105
269180|NCT01632943|Uncontrolled Hypertension
269181|NCT01632930|diagnosis
269182|NCT01632930|prostate cancer
269183|NCT01632930|urine
269184|NCT01632930|medical economics
269185|NCT01632917|Healthy volunteers
269186|NCT01632904|Polycythemia Vera
269187|NCT01632904|PV
269188|NCT01632878|Secondary prevention post MI
269189|NCT01632865|occlusion
269190|NCT01632865|recanalization
269191|NCT01632865|stenting
269192|NCT01632839|PISQ-R
269193|NCT01632839|new sexuality questionnaire
269194|NCT01632826|Relapsed
269195|NCT01632826|refractory multiple myeloma
269196|NCT01632826|pomalidomide
269197|NCT01632813|neurocognitive testing
269198|NCT01632813|critical illness
269199|NCT01632813|executive function
269200|NCT01632813|intelligence
269201|NCT01632800|Magnetic fields discomfort
269202|NCT01632787|Anxiety
269203|NCT01632787|Binocular
269204|NCT01632787|Chronic Headache
269205|NCT01632787|Dizziness
269206|NCT01632787|Vertical Heterophoria
269207|NCT01632787|Vision Dysfunction
269208|NCT01632761|anemia
269209|NCT01632761|vitamin D3
269210|NCT01632761|omega-3 fatty acids
269211|NCT01632761|fish oil
269212|NCT01632761|primary prevention
269213|NCT01632735|Continuing Care
269214|NCT01632735|Youth Substance Abuse
269215|NCT01632735|Recovery Support
269216|NCT01632735|Mobile Texting
269217|NCT01632722|colorectal cancer, liver metastasis, bevacizumab, perioperative/postoperative chemotherapy
269218|NCT01632696|Antibodies, Monoclonal
269219|NCT01632696|Biologics
269220|NCT01632696|F(ab')2
269221|NCT01632696|Positron-emission tomography (PET)
269222|NCT01632696|Phosphatidylserine (PS)
269223|NCT01632696|Solid Tumors
269224|NCT01632696|Tumor Imaging
269225|NCT01632683|difficult airway
269226|NCT01632683|video laryngoscopy
269227|NCT01632670|music
269228|NCT01632670|cardiac catheterization
269229|NCT01632670|endothelial function
269230|NCT01632631|suitable for endovascular exclusion
269231|NCT01632605|ADPKD
269232|NCT01632605|Autosomal dominant polycystic kidney disease
269233|NCT01632605|Sirolimus
269234|NCT01632605|Rapamune
269235|NCT01632605|Polycystic liver disease
269236|NCT01632605|Rapamycin
269237|NCT01632605|Mammalian target of rapamycin
269238|NCT01632605|m-TOR
269239|NCT01632605|m-TOR inhibition
269240|NCT01632553|Observation
269241|NCT01632553|Domestic Violence
269242|NCT01632553|Partner Abuse
269243|NCT01632553|Spousal Abuse
269244|NCT01632553|Battered Women
269245|NCT01632553|Abused Women
269246|NCT01632553|Cortisol
269247|NCT01632553|Mental Health
269248|NCT01632553|Depression
269249|NCT01632553|Anxiety
269250|NCT01632553|Posttraumatic Stress Disorders
269251|NCT01632527|Age-Related Macular Degeneration
269252|NCT01632527|Dry AMD with GA
269253|NCT01632527|Geographic Atrophy of Age-Related Macular Degeneration
269254|NCT01632527|Stem Cell Transplantation
269255|NCT01632527|Stem Cell transplant
269256|NCT01632527|Stem cells for AMD
269257|NCT01632527|Human neural stem cells
269258|NCT01632527|multipotent stem cells
269259|NCT01632527|Macular Degeneration
269260|NCT01632527|Dry AMD
269261|NCT01632527|Human central nervous system stemcells
269262|NCT01632527|dry age-related macular degeneration
269263|NCT01632514|hypocalcemia
269264|NCT01632514|vitamin D deficiency
269265|NCT01632514|cholecalciferol
269266|NCT01632514|thyroidectomy
269267|NCT01632488|Irritable Bowel Syndrome
269268|NCT01632488|Inflammatory Bowel Disease
269269|NCT01632488|Confocal Laser Endomicroscopy
269270|NCT01632475|Human umbilical cord blood-derived mesenchymal stem cells
269271|NCT01632475|Premature infants
269272|NCT01632475|Bronchopulmonary dysplasia
269273|NCT01632475|Lung injury
269274|NCT01632475|Lung diseases
269275|NCT01632475|Hyperplasia
269276|NCT01632475|Ventilator-induced lung injury
269277|NCT01632475|Respiratory lung diseases
269278|NCT01632475|Pathologic Processes
269279|NCT01632475|Infant, Premature, Diseases
269280|NCT01632475|Infant, Newborn, Diseases
269281|NCT01632462|Crohn's disease
269282|NCT01632462|VSL#3
269283|NCT01632462|probiotics
269284|NCT01632462|metabolic profile
269285|NCT01632449|bioequivalence
269286|NCT01632436|Hepatic impairment
269287|NCT01632436|Metastatic Cancer
269288|NCT01632410|autonomic nerve system
269289|NCT01632410|post stroke
269290|NCT01632410|focus of study: to describe the autonomic nerve system function post stroke
269291|NCT01632410|autonomic nervous system
269292|NCT01632397|PrEP
269293|NCT01632397|HIV
269294|NCT01632397|Adherence
269295|NCT01632397|MSM
269296|NCT01632397|Men having sex with men
269297|NCT01632384|Smoker
269298|NCT01632384|Non-Smoker
269299|NCT01632384|Healthy
269300|NCT01632384|Drug free
269301|NCT01632384|MRI
269302|NCT01632371|In-stent Restenosis
269303|NCT01632371|Drug Eluting Stent
269304|NCT01632371|Paclitaxel Coated Balloon
269305|NCT01632371|Scoring Balloon
269306|NCT01632371|Cutting Balloon
269307|NCT01632371|Angiographic follow-up
269308|NCT01632371|Optical coherence tomography (OCT)
269309|NCT01632358|safety
269310|NCT01632358|tolerability
269311|NCT01632358|pharmacokinetics
269312|NCT01632280|Obesity
269313|NCT01632280|Gastric Banding
269314|NCT01632280|Transcranial Direct Current Stimulation
269315|NCT01632241|Systemic Lupus Erythematosus
269316|NCT01632241|African Continental Ancestry Group
269317|NCT01632241|Autoimmune Disease
269318|NCT01632241|Antibodies
269319|NCT01632241|Minority Groups
269320|NCT01632241|Black Race
269321|NCT01632241|African Americans
269322|NCT01632241|SLE
269323|NCT01632241|Belimumab
269324|NCT01632241|Lupus
269325|NCT01632215|gabapentine
269326|NCT01632215|postoperative pain
269327|NCT01632202|submucosal myomas
269328|NCT01632202|intrauterine adhesions
269329|NCT01632202|hysteroscopic myomectomy
269330|NCT01632202|seprafilm
269331|NCT01632189|Varenicline
269332|NCT01632189|PET imaging
269333|NCT01632189|[11C]-(+)-PHNO PET
269334|NCT01632189|neuroimaging in smokers
269335|NCT01632176|dating abuse
269336|NCT01632176|dating violence
269337|NCT01632176|domestic violence
269338|NCT01632176|sexual violence
269339|NCT01632176|sexual assault
269340|NCT01632176|youth violence
269341|NCT01632176|underage alcohol use
269342|NCT01632176|alcohol use
269343|NCT01632098|psychosocial
269344|NCT01632098|healthcare
269345|NCT01632098|co-morbidities
269346|NCT01632098|extremely obese adolescents
269347|NCT01632059|ADMA
269348|NCT01632059|DDAH II
269349|NCT01632059|SAPS
269350|NCT01632059|SOFA
269351|NCT01632059|Sepsis
269352|NCT01632059|Procalcitonin
269353|NCT01632059|ICU
269354|NCT01632059|mortality
269355|NCT01632059|length of stay
269356|NCT01632046|peritoneal dialysis
269357|NCT01632046|bicarbonate/lactate buffer
269358|NCT01632046|peritoneal transport capacity
269359|NCT01632046|ultrafiltration
269360|NCT01632046|children
269361|NCT01632033|Peripheral artery disease
269362|NCT01632033|claudication
269363|NCT01632033|walking
269364|NCT01632033|questionnaire
269365|NCT01632020|colorectal tumor
269366|NCT01632020|colorectal cancer
269367|NCT01632020|colorectal carcinoma
269368|NCT01632020|neoplasms, colorectal
269369|NCT01632020|Metformin
269370|NCT01631994|metoclopramide video capsule endoscopy gastric transit time
269371|NCT01631955|Acute cystitis
269372|NCT01631955|Antibiotics
269373|NCT01631955|Quality of life
269374|NCT01631929|Diabetes
269375|NCT01631929|Ketoacidosis
269376|NCT01631929|Children
269377|NCT01631916|community-acquired pneumonia
269378|NCT01631916|children
269379|NCT01631916|respiratory infections
269380|NCT01631864|Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696
269381|NCT01631851|Autism
269382|NCT01631851|Irritability
269383|NCT01631851|Disruptive Behavior
269384|NCT01631851|Aggression
269385|NCT01631851|Behavior Therapy
269386|NCT01631851|Cognitive Behavioral Therapy
269387|NCT01631838|Tocotrienols
269388|NCT01631838|Platelet aggregation
269389|NCT01631838|Metabolic syndrome
269390|NCT01631838|Platelet activation
269391|NCT01631838|Thrombosis
269392|NCT01631825|SPM 962
269393|NCT01631825|rotigotine
269394|NCT01631825|Parkinson's disease
269395|NCT01631825|concomitant use of L-dopa
269396|NCT01631812|SPM 962
269397|NCT01631812|rotigotine
269398|NCT01631812|Parkinson's disease
269399|NCT01631812|concomitant use of L-dopa
269400|NCT01631799|epidural anesthesia
269401|NCT01631799|femoral block
269402|NCT01631799|patient control analgesia
269403|NCT01631786|Ovaries
269404|NCT01631786|Imaging
269405|NCT01631786|Ultrasonography
269406|NCT01631786|Synchrotron
269407|NCT01631786|Histology
269408|NCT01631773|Aspirin-exacerbated respiratory disease
269409|NCT01631773|Nasal polyp
269410|NCT01631760|Asthma
269411|NCT01631760|Asthma Exacerbations
269412|NCT01631747|Pregnancy
269413|NCT01631747|Weight gain
269414|NCT01631747|Obesity
269415|NCT01631747|Pregnancy and weight gain
269416|NCT01631721|adolescent couple decision-making
269417|NCT01631721|parenting practices
269418|NCT01631721|sexual risk behavior
269419|NCT01631708|Hereditary haemochromatosis
269420|NCT01631708|Moderate iron overload
269421|NCT01631708|Serum ferritin
269422|NCT01631708|Treatment
269423|NCT01631682|Posttraumatic Stress Disorder
269424|NCT01631682|PTSD
269425|NCT01631682|Anxiety
269426|NCT01631682|Fear of spiders
269427|NCT01631682|Reconsolidation
269428|NCT01631682|Reconsolidation blockade
269429|NCT01631669|Ossification
269430|NCT01631669|Heterotopic Ossification
269431|NCT01631656|Rosacea, Mild, Moderate, Combination Therapy, Laser, Finacea Gel, Azelaic Acid,
269432|NCT01631643|Blood glucose monitor
269433|NCT01631643|Pattern management
269434|NCT01631643|Pattern guide
269435|NCT01631643|Education
269436|NCT01631630|Alcohol
269437|NCT01631630|Alcohol Dependence
269438|NCT01631630|Alcohol Use
269439|NCT01631630|Nicotine Dependence
269440|NCT01631630|Nicotine
269441|NCT01631617|Investigator-Blinded
269442|NCT01631617|Skin Biopsy
269443|NCT01631617|Randomized
269444|NCT01631617|Antibiotics
269445|NCT01631617|Topical
269446|NCT01631604|risk of falling
269447|NCT01631604|gait patterns
269448|NCT01631604|muscle activity
269449|NCT01631604|fall prevention
269450|NCT01631604|motor impairment
269451|NCT01631578|mitochondrial injection
269452|NCT01631565|Palliative Care
269453|NCT01631565|Survival
269454|NCT01631565|Quality of life
269455|NCT01631552|Colorectal (CRC)
269456|NCT01631552|Gastric adenocarcinoma (GC)
269457|NCT01631552|Esophageal cancer (EC)
269458|NCT01631552|Hepatocellular carcinoma (HCC)
269459|NCT01631552|Non-small cell lung cancer (NSCLC)
269460|NCT01631552|Small cell lung cancer (SCLC)
269461|NCT01631552|Ovarian epithelial cancer (OEC)
269462|NCT01631552|Triple-negative breast cancer (TNBC)
269463|NCT01631552|Hormone-refractory prostate cancer (HRPC)
269464|NCT01631552|Pancreatic ductal adenocarcinoma (PDC)
269465|NCT01631552|Head and neck cancers- squamous cell (SCCHN)
269466|NCT01631552|Renal cell cancer -clear cell (RCC)
269467|NCT01631552|Bladder cancer
269468|NCT01631552|Endometrial Cancer
269469|NCT01631552|Cervical Cancer
269470|NCT01631552|Breast cancer
269471|NCT01631552|Metastatic non-triple negative breast cancer
269472|NCT01631552|Glioblastoma multiforme
269473|NCT01631552|Follicular thyroid cancer
269474|NCT01631539|chemoembolization
269475|NCT01631539|DC Bead™
269476|NCT01631539|Irinotecan
269477|NCT01631539|Cetuximab
269478|NCT01631539|5FU/LV
269479|NCT01631539|KRAS
269480|NCT01631539|metastatic colorectal cancer
269481|NCT01631526|Lung cancer
269482|NCT01631526|vitamin D
269483|NCT01631526|pharmacokinetics
269484|NCT01631513|Chronic Low Back Pain
269485|NCT01631513|Osteoarthritis Pain In The Hip or Knee
269486|NCT01631513|Oxycodone
269487|NCT01631513|Morphine, Hydrocodone
269488|NCT01631513|Tapentadol
269489|NCT01631513|NUCYNTA ER
269490|NCT01631500|Integrative medicine
269491|NCT01631500|Acupuncture
269492|NCT01631500|Minor mental health problems
269493|NCT01631500|Medically unexplained symptoms
269494|NCT01631500|Minor mental health problems (e.g. minor depression and anxiety) and Medically unexplained symptoms (e.g. IBS, fibromyalgia, etc)
269495|NCT01631487|Healthy
269496|NCT01631487|JNJ-39439335
269497|NCT01631487|Japanese
269498|NCT01631487|Caucasian
269499|NCT01631487|Male
269500|NCT01631474|Intrepid
269501|NCT01631474|acne
269502|NCT01631474|antiandrogen
269503|NCT01631461|pain
269504|NCT01631461|breast feeding
269505|NCT01631461|yeast
269506|NCT01631461|candida albicance
269507|NCT01631461|staphylococcus aureus
269508|NCT01631461|Signs and symptoms
269509|NCT01631448|Fibrin sealant
269510|NCT01631448|renal transplantation
269511|NCT01631448|surgical complication
269512|NCT01631435|All subjects will have evidence of active symptoms associated with Crohn's disease
269513|NCT01631409|clinical research
269514|NCT01631409|coronary heart disease
269515|NCT01631409|cardiac shock wave therapy
269516|NCT01631409|ischemic heart disease
269517|NCT01631409|myocardial revascularization
269518|NCT01631409|observational research
269519|NCT01631409|prospective research
269520|NCT01631396|Morbid obesity
269521|NCT01631396|Bariatric Surgery
269522|NCT01631396|Neuromuscular block reversal
269523|NCT01631383|Cocaine Use
269524|NCT01631305|Euthyroid Sick Syndromes
269525|NCT01631305|Thyroxine
269526|NCT01631305|Intensive care
269527|NCT01631279|NSCLC
269528|NCT01631279|non-small cell lung cancer
269529|NCT01631279|non-squamous, non-small cell lung cancer
269530|NCT01631279|solid tumors
269531|NCT01631279|lung cancer
269532|NCT01631240|Sodium
269533|NCT01631240|Potassium
269534|NCT01631240|Iodine
269535|NCT01631240|Creatinine
269536|NCT01631214|Osteoporosis, Osteoporosis-postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
269537|NCT01631201|Chlamydia
269538|NCT01631188|Minimally Invasive Surgery
269539|NCT01631188|Port Access Surgery
269540|NCT01631188|Heart
269541|NCT01631188|Pacing
269542|NCT01631188|Wire
269543|NCT01631188|MICS
269544|NCT01631188|Cardiac Bypass
269545|NCT01631188|Epicardial pacing
269546|NCT01631188|pacing catheter
269547|NCT01631188|pacing wire
269548|NCT01631188|pacing swan
269549|NCT01631188|pacing pulmonary catheter
269550|NCT01631188|Pulmonary Endovent
269551|NCT01631188|Catheter
269552|NCT01631188|Aortic Valve Surgery
269553|NCT01631188|Edwards Lifesciences
269554|NCT01631175|sarcoma
269555|NCT01631175|distress
269556|NCT01631175|tumor
269557|NCT01631175|quality of life
269558|NCT01631175|cancer
269559|NCT01631162|Asthma
269560|NCT01631162|COPD
269561|NCT01631149|urology
269562|NCT01631149|muscle relaxation
269563|NCT01631149|laparoscopy
269564|NCT01631149|anesthesia
269565|NCT01631149|rocuronium
269566|NCT01631136|Non Small Cell Lung Cancer
269567|NCT01631136|IFCT
269568|NCT01631136|Maintenance
269569|NCT01631136|Switch
269570|NCT01631123|Twins
269571|NCT01631123|High carbohydrat diet
269572|NCT01631123|High fat diet
269573|NCT01631123|Isocaloric
269574|NCT01631123|Nutrigenomics
269575|NCT01631110|Influenza
269576|NCT01631110|Virus
269577|NCT01631110|Vaccination
269578|NCT01631110|Inflexal V
269579|NCT01631084|Diabetes
269580|NCT01631084|Structured care
269581|NCT01631071|Influenza
269582|NCT01631071|Virus
269583|NCT01631071|Vaccination
269584|NCT01631071|Virosomal influenza vaccine
269585|NCT01631058|kidney transplantation
269586|NCT01631058|chronic renal failure
269587|NCT01631058|immunosuppressive therapy
269588|NCT01631058|elderly
269589|NCT01631058|pharmacokinetic
269590|NCT01631058|tacrolimus
269591|NCT01631058|everolimus
269592|NCT01631058|mycophenolate sodium
269593|NCT01631058|serious adverse events
269594|NCT01631058|biopsy
269595|NCT01631058|Cystatin C
269596|NCT01631058|metabolic effects
269597|NCT01631058|Left Ventricular Mass (LVM)
269598|NCT01631058|Left Ventricle Ejection Fraction
269599|NCT01631045|Obesity
269600|NCT01631032|Allergic rhinitis
269601|NCT01631032|Chinese herbal products
269602|NCT01631032|Qi deficiency
269603|NCT01631019|Chronic Obstructive Pulmonary Disease
269604|NCT01631019|Pulmonary Rehabilitation
269605|NCT01631019|Mobile phone
269606|NCT01631019|Biomarker
269607|NCT01631006|CPAP
269608|NCT01631006|Hypertrophic cardiomyopathy
269609|NCT01631006|Blood Pressure
269610|NCT01631006|The focus of the present study is to evaluate the acute hemodynamic effects of CPAP in patients with non-obstructive and obstructive hypertrophic cardiomyopathy
269611|NCT01630993|umbilical cord milking
269612|NCT01630993|umbilical cord stripping
269613|NCT01630993|umbilical cord clamping
269614|NCT01630993|placental transfusion
269615|NCT01630993|placental residual blood volume
269616|NCT01630980|Systematic review and meta-analysis
269617|NCT01630980|Evidence-based medicine (EBM)
269618|NCT01630980|Evidence-based nutrition (EBN)
269619|NCT01630980|Clinical practice guidelines
269620|NCT01630980|Clinical trials
269621|NCT01630980|Tree nuts
269622|NCT01630980|Cardiometabolic risk factors
269623|NCT01630980|Triglycerides
269624|NCT01630980|Cholesterol
269625|NCT01630980|Glycemic control
269626|NCT01630980|Insulin resistance
269627|NCT01630980|Body weight
269628|NCT01630980|Blood pressure
269629|NCT01630967|castrate resistance
269630|NCT01630967|PSA progression
269631|NCT01630967|LHRH antagonism
269632|NCT01630954|Hydatidiform mole
269633|NCT01630954|Molar pregnancy
269634|NCT01630954|H Mole
269635|NCT01630954|GTN
269636|NCT01630954|GTD
269637|NCT01630941|Osteoarthritis of the hip
269638|NCT01630941|Uncemented Total Hip Arthroplasty
269639|NCT01630941|DXA
269640|NCT01630941|BMD
269641|NCT01630941|PET
269642|NCT01630941|CT
269643|NCT01630941|Biochemical bone markers
269644|NCT01630928|Renal denervation
269645|NCT01630928|Resistant Hypertension
269646|NCT01630928|Cardiovascular disease
269647|NCT01630928|Diabetes
269648|NCT01630928|Quality of LIfe
269649|NCT01630889|Kidney
269650|NCT01630889|ESRD
269651|NCT01630889|End Stage Renal Disease
269652|NCT01630889|Anemia
269653|NCT01630889|Oral anemia treatment
269654|NCT01630889|Hemoglobin levels
269655|NCT01630889|Hemodialysis
269656|NCT01630889|CKD
269657|NCT01630889|Chronic Kidney Disease
269658|NCT01630889|Peritoneal
269659|NCT01630889|HD
269660|NCT01630889|PD
269661|NCT01630889|Hb
269662|NCT01630889|Erythropoietin
269663|NCT01630889|Blood count
269664|NCT01630876|Epiretinal membrane
269665|NCT01630876|triamcinolone acetonide
269666|NCT01630863|Central serous chorioretinopathy
269667|NCT01630863|photodynamic therapy
269668|NCT01630863|safe and effective dose
269669|NCT01630824|education program
269670|NCT01630824|kidney transplantation
269671|NCT01630824|renal transplantation
269672|NCT01630824|evaluation
269673|NCT01630811|Adults
269674|NCT01630798|barrett's esophgus
269675|NCT01630798|High grade dysplasia
269676|NCT01630798|Esophageal adenocarcinoma
269677|NCT01630772|women with preeclampsia
269678|NCT01630772|physical therapy
269679|NCT01630772|maternal-fetal hemodynamics
269680|NCT01630772|perinatal outcomes
269681|NCT01630759|Gestational diabetes
269682|NCT01630759|telemonitoring
269683|NCT01630759|telehealth
269684|NCT01630759|feasibility study
269685|NCT01630733|Metastatic
269686|NCT01630733|Stage IV
269687|NCT01630733|Advanced
269688|NCT01630733|lung cancer
269689|NCT01630720|ascorbic acid
269690|NCT01630720|cholecalciferol
269691|NCT01630720|vitamin C
269692|NCT01630720|vitamin D
269693|NCT01630720|hypovitaminosis
269694|NCT01630720|mood
269695|NCT01630720|distress
269696|NCT01630694|Difficult airway management
269697|NCT01630694|anesthesia
269698|NCT01630694|difficult intubation
269699|NCT01630629|Lactation
269700|NCT01630629|Weaning
269701|NCT01630629|Bone Density
269702|NCT01630629|Endocrine
269703|NCT01630629|Physiological Properties
269704|NCT01630629|Bone Metabolism
269705|NCT01630590|Prostate Cancer
269706|NCT01630590|Metastatic Prostate Cancer
269707|NCT01630590|Prostate adenocarcinoma
269708|NCT01630590|Androgen-Dependent Prostate Cancer
269709|NCT01630590|Cabozantinib
269710|NCT01630590|XL 184
269711|NCT01630590|Androgen Ablation
269712|NCT01630577|acute circulatory failure
269713|NCT01630577|hemodynamic stability
269714|NCT01630577|hypovolemia
269715|NCT01630564|Blood And Marrow Transplantation
269716|NCT01630564|Leukemia
269717|NCT01630564|Lymphoma
269718|NCT01630564|Myeloproliferative Diseases
269719|NCT01630564|Relapsed hematological malignancies
269720|NCT01630564|Post-Transplant Relapsed Patients
269721|NCT01630564|Cord Blood Lymphocyte Infusion
269722|NCT01630564|Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion
269723|NCT01630551|tears
269724|NCT01630551|dry eyes
269725|NCT01630551|ocular surface disease
269726|NCT01630538|Transplantation
269727|NCT01630525|Alzheimer's disease
269728|NCT01630525|neurodegenerative signs
269729|NCT01630499|Cancer
269730|NCT01630499|Breast cancer
269731|NCT01630499|Breast cancer prevention
269732|NCT01630499|Breast cancer recurrence
269733|NCT01630499|Weight loss
269734|NCT01630499|Weight management
269735|NCT01630499|Overweight
269736|NCT01630499|Obesity
269737|NCT01630486|renal progression
269738|NCT01630486|mortality
269739|NCT01630486|complications
269740|NCT01630486|risk factors
269741|NCT01630486|role of biochemical parameters
269742|NCT01630486|genetic influence
269743|NCT01630473|Tooth crowding
269744|NCT01630473|Teeth malpositions
269745|NCT01630473|corticotomy
269746|NCT01630473|orthodontics
269747|NCT01630473|tooth movement
269748|NCT01630473|periodontal parameters
269749|NCT01630460|Craniometaphyseal dysplasia
269750|NCT01630460|bone
269751|NCT01630460|hyperostosis
269752|NCT01630460|osteoblast
269753|NCT01630460|osteoclast
269754|NCT01630447|cherubism
269755|NCT01630447|bone
269756|NCT01630447|autoinflammatory disorder
269757|NCT01630447|osteoblast
269758|NCT01630447|osteoclast
269759|NCT01630447|mandible
269760|NCT01630447|maxilla
269761|NCT01630421|Aplasia cutis congenita
269762|NCT01630421|bone
269763|NCT01630421|osteoblast
269764|NCT01630421|osteoclast
269765|NCT01630421|skin
269766|NCT01630408|Preserved ejection fraction
269767|NCT01630408|Left ventricular hypertrophy
269768|NCT01630408|Activated vitamin D
269769|NCT01630408|Cardiac lusitropic effect
269770|NCT01630408|Hospitalizations
269771|NCT01630356|Secondhand Smoke
269772|NCT01630356|Nicotine
269773|NCT01630356|Indoor Air Pollution
269774|NCT01630343|Geriatric hip fracture
269775|NCT01630343|pain management
269776|NCT01630304|telecommunications
269777|NCT01630304|Africa
269778|NCT01630304|randomized controlled trial
269779|NCT01630278|Prematurity
269780|NCT01630278|patent ductus arteriosus
269781|NCT01630278|ibuprofen
269782|NCT01630265|Discharge Instructions
269783|NCT01630265|Video Discharge Instructions
269784|NCT01630265|Video
269785|NCT01630265|Emergency Department Discharge Instructions
269786|NCT01630265|ED Discharge
269787|NCT01630226|BRCA1
269788|NCT01630226|pathological complete response
269789|NCT01630226|neoadjuvant chemotherapy
269790|NCT01630213|Vitamin D3
269791|NCT01630213|Left ventricular mass
269792|NCT01630213|Echocardiography
269793|NCT01630213|Left ventricular systolic and diastolic function
269794|NCT01630200|COPD
269795|NCT01630200|comorbidity
269796|NCT01630200|arterial stiffness
269797|NCT01630200|roflumilast
269798|NCT01630187|Carbetocin
269799|NCT01630187|Uterotonic drug
269800|NCT01630187|elective cesarean section
269801|NCT01630174|IMRT,Pemetrexed,Cisplatin , Esophageal Cancer
269802|NCT01630161|relapse
269803|NCT01630161|prevention
269804|NCT01630161|smoking
269805|NCT01630161|habit
269806|NCT01630161|Forever Free
269807|NCT01630148|Thromboprophylaxis
269808|NCT01630148|Bemiparin
269809|NCT01630148|Low Molecular Weight Heparin
269810|NCT01630148|Major Gynaecological Surgeries
269811|NCT01630148|Benign Gynaecological Surgeries
269812|NCT01630122|Trans-thoracic Needle Biopsy (TNB)
269813|NCT01630122|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)
269814|NCT01630122|Trans-esophageal Ultrasound Scanning with FNA (EUS-FNA)
269815|NCT01630070|Critical limb ischemia
269816|NCT01630070|Rest pain
269817|NCT01630070|Minor tissue loss
269818|NCT01630070|Below the knee
269819|NCT01630031|atrial fibrillation
269820|NCT01630031|paroxysmal
269821|NCT01630031|contact force
269822|NCT01630031|radiofrequency
269823|NCT01630031|catheter ablation
269824|NCT01630031|pulmonary vein isolation
269825|NCT01630031|recurrence
269826|NCT01630031|follow-up
269827|NCT01630018|Epithelial Ovarian Cancer
269828|NCT01630018|Belotecan
269829|NCT01630018|Topotecan
269830|NCT01629992|Vomiting
269831|NCT01629992|Nausea
269832|NCT01629992|Postoperative pain
269833|NCT01629992|Feeling
269834|NCT01629966|Generalized Anxiety Disorder
269835|NCT01629966|GAD
269836|NCT01629940|X-linked Hypohidrotic Ectodermal Dysplasia
269837|NCT01629940|Hypohidrotic Ectodermal Dysplasia
269838|NCT01629940|XLHED
269839|NCT01629940|HED
269840|NCT01629927|X-linked hypohidrotic ectodermal dysplasia
269841|NCT01629927|Hypohidrotic ectodermal dysplasia
269842|NCT01629927|HED
269843|NCT01629927|XLHED
269844|NCT01629914|Attention-deficit/hyperactivity disorder
269845|NCT01629914|executive functioning
269846|NCT01629914|mindfulness meditation
269847|NCT01629914|magnetic resonance imaging
269848|NCT01629914|healthy
269849|NCT01629901|Healthy volunteer
269850|NCT01629888|Plant sterol
269851|NCT01629888|Hypercholesterolemia
269852|NCT01629888|dairy
269853|NCT01629810|Motion platform at appropriate settings.
269854|NCT01629810|Relief of pain.
269855|NCT01629810|Improvement in quality of life, cognition, and mood.
269856|NCT01629810|Effects of WBPA on cognition, mood, behavior, and functioning.
269857|NCT01629810|Dose response effect .
269858|NCT01629810|Gather data for long-term (2 year) study
269859|NCT01629745|B-cell childhood acute lymphoblastic leukemia
269860|NCT01629745|untreated childhood acute lymphoblastic leukemia
269861|NCT01629693|contact lenses
269862|NCT01629693|myopia
269863|NCT01629693|astigmatism
269864|NCT01629680|moxaverine
269865|NCT01629680|ocular blood flow
269866|NCT01629654|Poststroke fatigue
269867|NCT01629654|Health promotion
269868|NCT01629654|Patient education
269869|NCT01629641|goniometry
269870|NCT01629641|outcome measures
269871|NCT01629641|shoulder assessment
269872|NCT01629628|Crohn Disease
269873|NCT01629628|Colitis Granulomatous
269874|NCT01629628|Crohn's Disease
269875|NCT01629628|Enteritis Regional
269876|NCT01629628|Ileitis Regional
269877|NCT01629628|Ileitis Terminal
269878|NCT01629628|Ileocolitis
269879|NCT01629615|breast cancer
269880|NCT01629615|metastatic
269881|NCT01629615|triple negative breast cancer
269882|NCT01629615|BKM120
269883|NCT01629615|SOLTI
269884|NCT01629615|PI3K inhibitor
269885|NCT01629602|defect;
269886|NCT01629602|dorsal branch of the proper digital nerve;
269887|NCT01629602|proper digital nerve;
269888|NCT01629602|vascularized nerve graft
269889|NCT01629589|Adacel® vaccine
269890|NCT01629589|Tetanus
269891|NCT01629589|Diphtheria
269892|NCT01629589|whooping cough
269893|NCT01629589|Pertussis
269894|NCT01629589|BOOSTRIX® vaccine
269895|NCT01629537|Post Traumatic Stress Disorder
269896|NCT01629511|Leukemia
269897|NCT01629511|Chronic lymphocytic leukemia
269898|NCT01629511|CLL
269899|NCT01629511|Allogeneic hematopoietic cell transplantation
269900|NCT01629511|HCT
269901|NCT01629511|Methotrexate
269902|NCT01629511|Filgrastim
269903|NCT01629511|G-CSF
269904|NCT01629511|Neupogen
269905|NCT01629511|Tacrolimus
269906|NCT01629511|Prograf
269907|NCT01629511|Busulfan
269908|NCT01629511|Busulfex
269909|NCT01629511|Myleran
269910|NCT01629511|Clofarabine
269911|NCT01629511|Clofarex
269912|NCT01629511|Clolar
269913|NCT01629511|Gemcitabine
269914|NCT01629511|Gemcitabine Hydrochloride
269915|NCT01629511|Gemzar
269916|NCT01629511|Thymoglobulin
269917|NCT01629511|ATG
269918|NCT01629511|Antithymocyte Globulin
269919|NCT01629498|Lung cancer
269920|NCT01629498|Non-small cell lung cancer
269921|NCT01629498|NSCLC
269922|NCT01629498|Image-guided intensity-modulated scanning beam proton therapy
269923|NCT01629498|IMPT
269924|NCT01629498|Simultaneous integrated boost
269925|NCT01629498|SIB
269926|NCT01629498|Gross tumor volume
269927|NCT01629498|GTV
269928|NCT01629498|Chemotherapy
269929|NCT01629498|Questionnaire
269930|NCT01629498|Survey
269931|NCT01629485|Mastery Learning
269932|NCT01629485|Surgical Education
269933|NCT01629485|Laparoscopic Hernia Repair
269934|NCT01629485|Part vs Whole Task
269935|NCT01629485|Contextual Interference
269936|NCT01629485|laparoscopy
269937|NCT01629485|training
269938|NCT01629485|curriculum
269939|NCT01629472|Gender norms
269940|NCT01629472|Financial Autonomy
269941|NCT01629472|Economic Well-being
269942|NCT01629459|exercise
269943|NCT01629459|strength
269944|NCT01629459|training
269945|NCT01629459|barth syndrome
269946|NCT01629459|mitochondria
269947|NCT01629459|amino acid
269948|NCT01629459|protein
269949|NCT01629446|Phase 1
269950|NCT01629446|Normal healthy volunteers
269951|NCT01629446|Mass Balance
269952|NCT01629433|idiopathic detrusor overactivity
269953|NCT01629433|neurogenic dysfunction
269954|NCT01629433|onabotulinumtoxinA
269955|NCT01629420|Gonadotropin-Releasing Hormone (GnRH) antagonist
269956|NCT01629381|knee arthroscopy
269957|NCT01629381|venous thromboembolism
269958|NCT01629381|prevention
269959|NCT01629355|Auditory Brainstem Response
269960|NCT01629355|ABR
269961|NCT01629355|SD-BERA
269962|NCT01629329|Headache
269963|NCT01629329|prochlorperazine
269964|NCT01629329|excedrin migraine
269965|NCT01629329|treatment efficacy
269966|NCT01629329|pain scores
269967|NCT01629316|HIV
269968|NCT01629316|prisoners
269969|NCT01629316|test
269970|NCT01629316|treat
269971|NCT01629316|link coordination
269972|NCT01629316|retain
269973|NCT01629316|behavioral
269974|NCT01629316|intervention
269975|NCT01629316|text reminders
269976|NCT01629316|motivational interviewing
269977|NCT01629316|medication adherence
269978|NCT01629303|constipation
269979|NCT01629303|sacral nerve modulation
269980|NCT01629277|Closed-loop insulin delivery
269981|NCT01629277|Non-compliant behaviours during adolescence
269982|NCT01629264|Cornea
269983|NCT01629264|biomechanics
269984|NCT01629264|pregnancy
269985|NCT01629264|keratoconus
269986|NCT01629264|refractive surgery
269987|NCT01629251|Closed-loop insulin delivery
269988|NCT01629251|Post-prandial hypoglycaemia
269989|NCT01629251|Meal insulin dosing
269990|NCT01629238|cardiovascular risk
269991|NCT01629238|dairy enriched product with plant sterols
269992|NCT01629238|general practitioners
269993|NCT01629238|adults followed by general practitioners
269994|NCT01629225|men and women
269995|NCT01629225|in southwestern Han Chinese
269996|NCT01629186|CPR
269997|NCT01629186|flexible bronchoscope
269998|NCT01629186|resuscitation
269999|NCT01629186|ventilation
270000|NCT01629173|plantar pressure
270001|NCT01629173|metatarsalgia
270002|NCT01629173|insole
270003|NCT01629147|Constipation
270004|NCT01629108|Normative Data
270005|NCT01629108|Vestibular
270006|NCT01629108|Auditory
270007|NCT01629108|Healthy Volunteers
270008|NCT01629108|Hearing
270009|NCT01629095|Fatty Liver
270010|NCT01629095|Liver Transplant
270011|NCT01629095|Non-Alcoholic Steato-Hepatitis
270012|NCT01629095|Steatosis
270013|NCT01629095|Cirrhosis
270014|NCT01629095|Cryptogenic Cirrhosis
270015|NCT01629095|Liver Failure
270016|NCT01629095|Non-Alcoholic Fatty Liver Disease
270017|NCT01629082|Myelodysplastic Syndromes
270018|NCT01629082|Acute Myeloid Leukemia (AML)
270019|NCT01629082|Chronic Myelomonocytic Leukemia (CMML)
270020|NCT01629069|stress
270021|NCT01629069|mindfulness
270022|NCT01629069|coping
270023|NCT01629056|atrial fibrillation
270024|NCT01629056|ablation
270025|NCT01629056|contact
270026|NCT01629043|Parkinson's
270027|NCT01629043|Quality of Care
270028|NCT01629043|Improvement
270029|NCT01629043|Mobility
270030|NCT01629043|Cognition
270031|NCT01629043|Caregiver burden
270032|NCT01629043|Center difference
270033|NCT01629030|sternal wound infection
270034|NCT01629030|coronary artery bypass graft
270035|NCT01629030|risk factor
270036|NCT01629004|colorectal cancer
270037|NCT01629004|screening
270038|NCT01629004|fecal occult blood testing
270039|NCT01629004|mailed invitation
270040|NCT01628991|Behavioral Intervention Program
270041|NCT01628991|Vaginal Cones
270042|NCT01628991|Stress Urinary Incontinence
270043|NCT01628991|treatment
270044|NCT01628991|Women
270045|NCT01628978|depth of endotracheal tube placement
270046|NCT01628978|endotracheal intubation
270047|NCT01628978|endobronchial intubation
270048|NCT01628965|SPM 962
270049|NCT01628965|rotigotine
270050|NCT01628965|Parkinson's disease
270051|NCT01628965|monotherapy
270052|NCT01628939|low back pain
270053|NCT01628939|facet joint pain
270054|NCT01628913|Pancreatic
270055|NCT01628913|Neuroendocrine tumors
270056|NCT01628913|PNET
270057|NCT01628913|BEZ235
270058|NCT01628913|Everolimus
270059|NCT01628900|pyelonephritis
270060|NCT01628900|Infection
270061|NCT01628900|Antibiotic treatment
270062|NCT01628887|Breast Cancer
270063|NCT01628874|Lumbar Puncture
270064|NCT01628874|J-Tip
270065|NCT01628874|Jet injection
270066|NCT01628874|Local Analgesia
270067|NCT01628861|occupation
270068|NCT01628861|work
270069|NCT01628861|sitting
270070|NCT01628861|sedentary behaviour
270071|NCT01628861|office worker
270072|NCT01628861|adult
270073|NCT01628861|education
270074|NCT01628861|point-of-choice prompt
270075|NCT01628848|SPM 962
270076|NCT01628848|rotigotine
270077|NCT01628848|Parkinson's disease
270078|NCT01628848|concomitant use of L-dopa
270079|NCT01628835|overweight
270080|NCT01628835|pregnancy
270081|NCT01628835|diet counselling
270082|NCT01628835|glycemic
270083|NCT01628822|Fibromyalgia
270084|NCT01628822|Relaxation
270085|NCT01628822|Improving the quality of life
270086|NCT01628809|MBSR
270087|NCT01628809|mindfulness
270088|NCT01628809|stress
270089|NCT01628783|Depression
270090|NCT01628783|emotional processing
270091|NCT01628783|fMRI
270092|NCT01628783|autobiographic memory
270093|NCT01628783|moderator of treatment response
270094|NCT01628783|mediator of treatment response
270095|NCT01628770|iron
270096|NCT01628770|monofer
270097|NCT01628770|Pakistan
270098|NCT01628731|loop diuretics
270099|NCT01628731|fluid balance
270100|NCT01628731|urine output
270101|NCT01628731|acute renal dysfunction
270102|NCT01628718|OEF/OIF
270103|NCT01628718|Veterans
270104|NCT01628718|Psychotherapy
270105|NCT01628718|PTSD
270106|NCT01628705|Green tea
270107|NCT01628705|oxLDL
270108|NCT01628705|fat mass
270109|NCT01628679|provoked
270110|NCT01628679|vulvar
270111|NCT01628679|vestibulodynia
270112|NCT01628679|vestibulitis
270113|NCT01628666|Arrhythmia
270114|NCT01628666|Device Procedure
270115|NCT01628666|Antibiotics
270116|NCT01628666|Infection
270117|NCT01628666|Cluster
270118|NCT01628653|Mild cognitive impairment
270119|NCT01628653|Cognitive rehabilitation
270120|NCT01628653|Cognitive therapy
270121|NCT01628653|Spaced retrieval Training
270122|NCT01628653|Alzheimer's disease
270123|NCT01628653|Memory enhancement
270124|NCT01628653|U-healthcare
270125|NCT01628627|Diabetic Neuropathy, Painful
270126|NCT01628575|periodontally accelerated orthodontics PAO
270127|NCT01628562|Remifentanil
270128|NCT01628562|Esmolol
270129|NCT01628562|Intracranial surgery
270130|NCT01628562|Heart rate
270131|NCT01628562|Blood pressure
270132|NCT01628549|acne
270133|NCT01628536|Black Cohosh
270134|NCT01628536|Ductal Carcinoma in situ
270135|NCT01628536|Breast Cancer
270136|NCT01628523|Respiratory failure
270137|NCT01628523|Mechanical ventilation
270138|NCT01628523|Acute lung injury
270139|NCT01628510|preterm
270140|NCT01628471|Phase I b : advanced solid malignancy
270141|NCT01628471|Phase II a: stage III b or IV, Non Small Cell Lung Cancer
270142|NCT01628458|Pancreatic cancer
270143|NCT01628458|locally advanced
270144|NCT01628458|irresectable
270145|NCT01628458|Radiofrequency
270146|NCT01628458|RFA
270147|NCT01628445|Diabetes
270148|NCT01628445|Insulin
270149|NCT01628419|Health promotion
270150|NCT01628419|Intervention
270151|NCT01628419|Workplace
270152|NCT01628419|Exercise program
270153|NCT01628380|HIPEC
270154|NCT01628380|Ovarian Cancer
270155|NCT01628380|Cytoreductive Surgery
270156|NCT01628354|Choroidal neovascularization
270157|NCT01628354|Lucentis
270158|NCT01628328|colonic stenting
270159|NCT01628328|colorectal cancer obstruction
270160|NCT01628328|circulating tumor cell
270161|NCT01628315|Multiple Sclerosis
270162|NCT01628315|ASA
270163|NCT01628315|MRI
270164|NCT01628315|Lesion activity
270165|NCT01628302|Hypertension,plasma renin activity,salt consumption
270166|NCT01628289|diabetic retinopathy
270167|NCT01628289|screening
270168|NCT01628289|co-payment
270169|NCT01628289|health service
270170|NCT01628276|Multiple Sclerosis
270171|NCT01628276|MRI Scans
270172|NCT01628263|PICU
270173|NCT01628263|Follow up
270174|NCT01628263|PTSD
270175|NCT01628224|Task saturation
270176|NCT01628211|hyperthermic chemotherapy
270177|NCT01628211|intraperitoneal chemotherapy
270178|NCT01628211|second-look laparoscopy
270179|NCT01628211|peritoneal carcinosis
270180|NCT01628211|mucinous colorectal cancer
270181|NCT01628198|Hypertension
270182|NCT01628198|renal denervation
270183|NCT01628198|renal ablation
270184|NCT01628198|uncontrolled high blood pressure
270185|NCT01628172|renal sympathetic denervation
270186|NCT01628172|renal catheter ablation
270187|NCT01628172|hypertension
270188|NCT01628146|Presbyopia
270189|NCT01628146|hyperopia
270190|NCT01628146|Supracor
270191|NCT01628146|contrast sensitivity
270192|NCT01628133|Transfusion
270193|NCT01628133|Neonate
270194|NCT01628133|Infant, Very Low Birth Weight
270195|NCT01628133|Patent Ductus Arteriosus
270196|NCT01628133|Packed Red Blood Cell
270197|NCT01628120|Chronic renal failure
270198|NCT01628120|Hemodialysis
270199|NCT01628107|Chronic renal failure
270200|NCT01628107|hemodialysis
270201|NCT01628081|psoriasis
270202|NCT01628081|Alga Dunaliella Bardawil
270203|NCT01628068|Left atrial appendage occlusion
270204|NCT01628068|gastrointestinal bleeding
270205|NCT01628055|IVIg
270206|NCT01628055|Acute Ischemic Stroke
270207|NCT01628055|Stroke
270208|NCT01628055|CVA
270209|NCT01628055|Cerebrovascular Accident
270210|NCT01628029|Advanced Cancers
270211|NCT01628029|Metastatic
270212|NCT01628029|Locally advanced
270213|NCT01628029|Sleep disturbance
270214|NCT01628029|Sleep problems
270215|NCT01628029|Litebook
270216|NCT01628029|Melatonin
270217|NCT01628029|Methylphenidate
270218|NCT01628029|Methylphenidate hydrochloride
270219|NCT01628029|Ritalin
270220|NCT01628029|Concerta
270221|NCT01628029|Placebo
270222|NCT01628029|Supportive counseling
270223|NCT01628029|Questionnaires
270224|NCT01628029|Study Diaries
270225|NCT01628016|depression
270226|NCT01628016|attention
270227|NCT01628016|training
270228|NCT01628016|modification
270229|NCT01628003|Traumatic Brain Injury
270230|NCT01628003|long-term outcome
270231|NCT01628003|Brain Reserves
270232|NCT01628003|Cognitive Reserves
270233|NCT01628003|Emotional Reserves
270234|NCT01628003|Patients 1 year or more after Moderate or Severe Traumatic Brain Injury
270235|NCT01627990|cytotoxic chemotherapy
270236|NCT01627990|G-CSF
270237|NCT01627990|Solid tumour
270238|NCT01627990|Malignant haematological tumour
270239|NCT01627977|chromovitrectomy
270240|NCT01627977|epiretinal membrane
270241|NCT01627964|Heart Wall Motion Function
270242|NCT01627951|Plasmodium falciparum
270243|NCT01627951|malaria
270244|NCT01627938|Multiple Sclerosis
270245|NCT01627938|MS
270246|NCT01627938|Mitoxantrone
270247|NCT01627938|Dexrazoxane
270248|NCT01627938|Cardioxane
270249|NCT01627938|cardiotoxicity
270250|NCT01627938|cardiac toxicity
270251|NCT01627938|cardiotoxic side effects
270252|NCT01627938|cardiac MRI
270253|NCT01627938|cranial MRI
270254|NCT01627938|LVEF
270255|NCT01627938|neurological outcome
270256|NCT01627925|nasal positive airway pressure
270257|NCT01627925|upper airway obstruction
270258|NCT01627925|mask ventilation
270259|NCT01627912|wine
270260|NCT01627912|inflammation
270261|NCT01627912|oxidative stress
270262|NCT01627912|randomized control trial
270263|NCT01627912|postprandial intervention
270264|NCT01627912|platelet aggregation
270265|NCT01627912|haemostasis
270266|NCT01627912|robola
270267|NCT01627912|cabernet sauvignon
270268|NCT01627912|alcohol
270269|NCT01627912|PAF metabolism
270270|NCT01627899|Blood glucose monitor
270271|NCT01627899|Pattern management
270272|NCT01627899|Pattern guide
270273|NCT01627899|Education
270274|NCT01627886|Bioequivalence
270275|NCT01627886|Ibandronate Sodium
270276|NCT01627886|crossover
270277|NCT01627873|Major abdominal surgery
270278|NCT01627873|analgesic method
270279|NCT01627873|Fentanyl
270280|NCT01627873|Remifentanyl
270281|NCT01627873|Postoperative cognitive disorder
270282|NCT01627873|Pro and anti inflammatory cytokines
270283|NCT01627860|Epilepsy
270284|NCT01627860|Topiramate
270285|NCT01627860|Neuro-surgical patients
270286|NCT01627860|Nervous disorder
270287|NCT01627860|Seizures
270288|NCT01627847|Bioequivalence
270289|NCT01627847|Ropinirole Hydrochloride
270290|NCT01627847|crossover
270291|NCT01627834|Bioequivalence
270292|NCT01627834|Ropinirole Hydrochloride
270293|NCT01627834|crossover
270294|NCT01627821|Heart Failure
270295|NCT01627808|intraoperative monitoring
270296|NCT01627808|fluid management
270297|NCT01627795|Malignant Mesothelioma
270298|NCT01627795|Cancer
270299|NCT01627795|Anti cancer agents
270300|NCT01627782|Major depressive disorder
270301|NCT01627782|Treatment-resistant depression
270302|NCT01627782|Ketamine
270303|NCT01627769|scars
270304|NCT01627769|blisters
270305|NCT01627769|second degree burns
270306|NCT01627769|cryosurgery
270307|NCT01627769|keloid scars
270308|NCT01627769|hypertrophic scars
270309|NCT01627756|Thoracic Surgery
270310|NCT01627756|Endotoxins
270311|NCT01627756|Respiration, Artificial
270312|NCT01627756|Immune System
270313|NCT01627743|CDLM
270314|NCT01627743|visual scale - physician evaluation
270315|NCT01627743|COPD
270316|NCT01627743|GOLD group C and D
270317|NCT01627717|maraviroc
270318|NCT01627717|boceprevir
270319|NCT01627717|HIV
270320|NCT01627717|HCV
270321|NCT01627717|drug interaction
270322|NCT01627717|pharmacokinetics
270323|NCT01627704|PET/CT,fluoroestradiol (18F)
270324|NCT01627704|breast cancer
270325|NCT01627704|metastatic
270326|NCT01627704|prediction of response
270327|NCT01627704|hormone therapy
270328|NCT01627678|HIV-1, Vacc-C5
270329|NCT01627665|dabigatran
270330|NCT01627665|rivaroxaban
270331|NCT01627665|PKC
270332|NCT01627665|PKD
270333|NCT01627665|p-glycoprotein
270334|NCT01627665|polymorphism
270335|NCT01627652|hypoxia
270336|NCT01627626|xerostomia
270337|NCT01627626|pilocarpine mouthwash
270338|NCT01627626|minor salivary gland secretion
270339|NCT01627600|stroke
270340|NCT01627600|myocardial infarction
270341|NCT01627600|cardiovascular health
270342|NCT01627600|population study
270343|NCT01627587|preterm labor
270344|NCT01627574|Pregnancy
270345|NCT01627574|STI prevention
270346|NCT01627574|adolescents
270347|NCT01627574|probation
270348|NCT01627561|Immune response
270349|NCT01627561|Human papillomavirus
270350|NCT01627561|HPV vaccine
270351|NCT01627561|Safety
270352|NCT01627548|PTSD
270353|NCT01627548|Couples
270354|NCT01627548|Combat Veteran
270355|NCT01627548|Warfighter
270356|NCT01627548|OEF
270357|NCT01627548|OIF
270358|NCT01627548|OND
270359|NCT01627548|Structured Approach Therapy
270360|NCT01627548|Trauma
270361|NCT01627535|Brain Tumor
270362|NCT01627509|continuous glucose monitoring system
270363|NCT01627509|hypoglycemia
270364|NCT01627509|insulin regimen
270365|NCT01627509|basal bolus therapy
270366|NCT01627509|modern premixed insulin
270367|NCT01627509|diabetes control
270368|NCT01627496|malnutrition
270369|NCT01627496|elderly care
270370|NCT01627496|quality of life
270371|NCT01627496|hospital
270372|NCT01627483|elderly
270373|NCT01627483|hip fracture
270374|NCT01627483|osteoporosis
270375|NCT01627483|fall risk
270376|NCT01627483|medication review
270377|NCT01627470|non-invasive arterial pressure
270378|NCT01627470|emergency
270379|NCT01627470|intensive care
270380|NCT01627457|Coronary Artery Disease
270381|NCT01627457|Guided Exercise System including ECG Vest with vital signs sensors and PDA
270382|NCT01627457|Validation Telemedical Device in regard to accuracy and safety of data
270383|NCT01627457|Homely Rehabilitation
270384|NCT01627457|Practicability and technical problems at home
270385|NCT01627444|Acupuncture
270386|NCT01627444|Anxiety
270387|NCT01627444|Human Milk
270388|NCT01627444|Very low birth weight infants
270389|NCT01627444|Mother of very low birth weight infants
270390|NCT01627431|PAD
270391|NCT01627431|Peripheral revascularization
270392|NCT01627431|Antiplatelet therapy
270393|NCT01627431|Residual platelet activity
270394|NCT01627418|COPD
270395|NCT01627418|CORD
270396|NCT01627418|COAD
270397|NCT01627379|nonresectable
270398|NCT01627379|advanced
270399|NCT01627379|metastatic esophageal squamous cell cancer
270400|NCT01627379|Panitumumab
270401|NCT01627353|Hysterectomy
270402|NCT01627353|Pain Prevention
270403|NCT01627353|Wound Infiltration
270404|NCT01627340|hepatitis B
270405|NCT01627340|adults
270406|NCT01627340|Type 2 diabetes mellitus
270407|NCT01627340|Engerix™-B
270408|NCT01627327|Cardiovascular event
270409|NCT01627327|Cardiovascular disease
270410|NCT01627275|Naive T Cell Depletion
270411|NCT01627275|Donor Lymphocyte Infusion
270412|NCT01627275|Allogeneic Hematopoietic Stem Cell Transplant
270413|NCT01627262|diverticular disease
270414|NCT01627262|colonic diverticulosis
270415|NCT01627262|mesalamine
270416|NCT01627262|placebo
270417|NCT01627262|randomized
270418|NCT01627249|Diabetic Macular Edema
270419|NCT01627249|anti-vascular endothelial growth factor
270420|NCT01627223|Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B
270421|NCT01627223|Lamivudine (Zeffix®)
270422|NCT01627223|Entecavir (Baraclude®)
270423|NCT01627210|Diabetes Mellitus
270424|NCT01627197|Effects of Chemotherapy
270425|NCT01627145|overactive bladder syndrome
270426|NCT01627145|derusor overactivity
270427|NCT01627145|urodynamic studies
270428|NCT01627145|bladder oversensitivity
270429|NCT01627119|CTGF
270430|NCT01627119|Peritoneal metastasis
270431|NCT01627093|Head and Neck Cancer
270432|NCT01627093|Head and Neck Malignancies
270433|NCT01627093|Chart Review
270434|NCT01627093|Proton Radiation Therapy
270435|NCT01627080|Esophagus
270436|NCT01627080|Esophageal Cancer
270437|NCT01627080|Radiation therapy
270438|NCT01627080|RT
270439|NCT01627080|Chemotherapy
270440|NCT01627080|Mid thoracic tumor
270441|NCT01627080|Distal esophageal tumor
270442|NCT01627080|Gastroesophageal junction tumor
270443|NCT01627080|Cardiac biomarkers
270444|NCT01627067|Breast Cancer
270445|NCT01627067|Hormone Receptor Positive Metastatic Breast Cancer
270446|NCT01627067|Hormone-sensitive
270447|NCT01627067|Postmenopausal
270448|NCT01627067|Body Mass Index
270449|NCT01627067|BMI
270450|NCT01627067|Everolimus
270451|NCT01627067|Afinitor
270452|NCT01627067|RAD001
270453|NCT01627067|Exemestane
270454|NCT01627067|Aromasin
270455|NCT01627067|Metformin
270456|NCT01627028|Thai traditional massage
270457|NCT01627028|Bone formation
270458|NCT01627028|Bone resorption
270459|NCT01627015|Fully formula fed
270460|NCT01627002|Phase 1
270461|NCT01627002|First in Human
270462|NCT01627002|Healthy Volunteers
270463|NCT01627002|Lipopolysaccharide Challenge
270464|NCT01626976|safety
270465|NCT01626976|tolerability
270466|NCT01626976|pharmacokinetics
270467|NCT01626976|oral
270468|NCT01626976|single ascending dose
270469|NCT01626976|placebo-controlled
270470|NCT01626976|healthy subjects
270471|NCT01626963|single-port access
270472|NCT01626963|laparoscopic surgery
270473|NCT01626963|surgical trauma
270474|NCT01626950|Breast cancer
270475|NCT01626950|living conditions
270476|NCT01626950|social fragility
270477|NCT01626937|Acute respiratory failure
270478|NCT01626937|Chronic obstructive pulmonary disease
270479|NCT01626937|Non invasive ventilation
270480|NCT01626937|Out of hospital
270481|NCT01626924|Perinatal Asphyxia
270482|NCT01626924|Neonatal encephalopathy
270483|NCT01626924|Oxygen shortage at birth
270484|NCT01626924|Antenatal asphyxia
270485|NCT01626924|hypoxia-ischaemia
270486|NCT01626924|birth asphyxia
270487|NCT01626924|asphyxia neonatorum
270488|NCT01626911|severe acute pancreatitis;
270489|NCT01626911|continuous regional arterial infusion;
270490|NCT01626911|low molecular weight heparin
270491|NCT01626885|Schizophrenia
270492|NCT01626885|Antipsychotic Agents
270493|NCT01626885|Mental Disorder
270494|NCT01626885|Psychotropic Drugs
270495|NCT01626885|Dopamine Agents
270496|NCT01626885|Central Nervous System Agents
270497|NCT01626872|Schizophrenia
270498|NCT01626872|Antipsychotic Agents
270499|NCT01626872|Mental Disorder
270500|NCT01626872|Psychotropic Drugs
270501|NCT01626872|Dopamine Agents
270502|NCT01626872|Risperidone
270503|NCT01626872|Central Nervous System Agents
270504|NCT01626859|Schizophrenia
270505|NCT01626859|Antipsychotic Agents
270506|NCT01626859|Mental Disorder
270507|NCT01626859|Psychotropic Drugs
270508|NCT01626859|Dopamine Agents
270509|NCT01626859|Central Nervous System Agents
270510|NCT01626846|Neurofibromatosis
270511|NCT01626833|anorexia nervosa
270512|NCT01626833|GH
270513|NCT01626833|Growth velocity
270514|NCT01626820|Immunogenicity
270515|NCT01626820|Influenza
270516|NCT01626820|Safety
270517|NCT01626820|Adults
270518|NCT01626820|Fluviral
270519|NCT01626807|Safe Routes to School
270520|NCT01626807|Walking School Bus
270521|NCT01626807|Cluster Randomized Controlled Trial
270522|NCT01626807|Physical Activity
270523|NCT01626807|Obesity
270524|NCT01626807|Overweight
270525|NCT01626755|Phantom limb pain
270526|NCT01626755|Chronic pain
270527|NCT01626755|Amputation
270528|NCT01626755|Peripheral vascular disease
270529|NCT01626729|Food Labeling
270530|NCT01626677|Umbilical Cord Blood
270531|NCT01626677|Mesenchymal Stem Cells
270532|NCT01626677|Cartilage injury
270533|NCT01626677|Osteoarthritis
270534|NCT01626664|Adult T cell Leukemia-Lymphoma (ATL)
270535|NCT01626651|Healthy
270536|NCT01626651|Ketoconazole
270537|NCT01626651|Ibrutinib
270538|NCT01626638|Patients with malignant and pre-malignant pharyngo laryngeal tumors
270539|NCT01626625|nonunion
270540|NCT01626625|stem cells
270541|NCT01626625|autograft
270542|NCT01626625|hydroxyapatite
270543|NCT01626599|ECG
270544|NCT01626599|Accelerometer
270545|NCT01626599|Device
270546|NCT01626586|Youth
270547|NCT01626586|Family
270548|NCT01626586|Group Therapy
270549|NCT01626586|Type 1 Diabetes Mellitus
270550|NCT01626586|Self-Management
270551|NCT01626573|Rheumatoid Arthritis
270552|NCT01626573|RA
270553|NCT01626573|Active
270554|NCT01626547|symptomatic anameia
270555|NCT01626508|breast milk
270556|NCT01626508|breast-milk bank
270557|NCT01626508|plasma profile
270558|NCT01626508|essential fatty acids
270559|NCT01626495|Biological: CART19
270560|NCT01626443|PCOS
270561|NCT01626443|Metabolic disorders
270562|NCT01626443|Ovarian functionality
270563|NCT01626443|Myo-inositol
270564|NCT01626443|D-chiro-inositol
270565|NCT01626430|Gamma delta TRF
270566|NCT01626430|Insulin sensitivity
270567|NCT01626430|Postprandial lipaemia
270568|NCT01626430|Inflammatory markers
270569|NCT01626430|NF-κB
270570|NCT01626417|Stroke
270571|NCT01626417|Tibion
270572|NCT01626417|Bionics
270573|NCT01626417|Rehab
270574|NCT01626417|Therapy
270575|NCT01626417|Robotics
270576|NCT01626417|Intention
270577|NCT01626404|Thoratec Corporation
270578|NCT01626391|Alzheimer's Disease
270579|NCT01626391|TRx0237
270580|NCT01626391|Safety Study
270581|NCT01626391|AD
270582|NCT01626378|Behavioral Variant Frontotemporal Dementia
270583|NCT01626378|bvFTD
270584|NCT01626378|Frontotemporal Dementia
270585|NCT01626365|double-lumen tube
270586|NCT01626365|intubation
270587|NCT01626365|thermosoftening
270588|NCT01626352|Diffuse Large B-Cell Lymphoma
270589|NCT01626352|Ofatumumab
270590|NCT01626352|Bendamustine
270591|NCT01626339|Anti vascular endothelial growth factor
270592|NCT01626339|retinal vessels
270593|NCT01626326|smoking
270594|NCT01626326|smoking cessation
270595|NCT01626326|mobile app
270596|NCT01626313|Veteran families
270597|NCT01626313|OEF
270598|NCT01626313|OIF
270599|NCT01626313|OND
270600|NCT01626313|Resiliency
270601|NCT01626313|Psycho educational training
270602|NCT01626313|Stress
270603|NCT01626313|Military
270604|NCT01626287|perineal
270605|NCT01626287|postpartum
270606|NCT01626287|pain
270607|NCT01626287|treatment
270608|NCT01626287|ice and black tea
270609|NCT01626287|maternal satisfaction
270610|NCT01626274|Polysomnography
270611|NCT01626274|Long term vital signs monitoring
270612|NCT01626274|In-ear sensor system
270613|NCT01626274|Photoplethysmographic micro-optic device
270614|NCT01626274|High wearing comfort
270615|NCT01626248|Immunological
270616|NCT01626248|biomarkers
270617|NCT01626248|observational
270618|NCT01626248|RRMS
270619|NCT01626248|Relapsing
270620|NCT01626248|Remitting Multiple Sclerosis
270621|NCT01626235|pain control
270622|NCT01626235|fractures
270623|NCT01626235|sprains
270624|NCT01626235|strains
270625|NCT01626235|dysmenorrhea
270626|NCT01626235|kidney stones
270627|NCT01626235|gouty arthritis
270628|NCT01626235|opioids
270629|NCT01626235|NSDAIDs
270630|NCT01626235|Emergency Department
270631|NCT01626235|patient reported outcomes
270632|NCT01626222|Postmenopausal
270633|NCT01626222|Estrogen Receptor Positive
270634|NCT01626222|HER2 negative
270635|NCT01626222|Locally Advanced
270636|NCT01626222|Metastatic Breast Cancer
270637|NCT01626222|Everolimus (RAD001)
270638|NCT01626222|Exemestane
270639|NCT01626209|Breast cancer, NSCLC, SCCHN, esophageal cancer
270640|NCT01626183|T-cell childhood acute lymphoblastic leukemia
270641|NCT01626183|recurrent childhood acute lymphoblastic leukemia
270642|NCT01626144|Exemestane
270643|NCT01626144|Metabolism
270644|NCT01626144|Metabolizing enzyme genotype
270645|NCT01626144|Breast cancer
270646|NCT01626131|combat disorders
270647|NCT01626131|exercise therapy
270648|NCT01626105|Hemophilia A
270649|NCT01626105|Factor VIII
270650|NCT01626105|Inhibitors
270651|NCT01626105|Immunogenicity
270652|NCT01626105|Pharmacogenetics
270653|NCT01626105|Mutation
270654|NCT01626105|Nonsynonymous Single Nucleotide Polymorphisms
270655|NCT01626105|Class II Human Leukocyte Antigens
270656|NCT01626092|bone marrow transplantation
270657|NCT01626092|reduced intensity conditioning
270658|NCT01626092|Adrenoleukodystrophy
270659|NCT01626092|Metachromatic Leukodystrophy
270660|NCT01626092|Globoid Cell Leukodystrophy
270661|NCT01626092|Wolman's disease
270662|NCT01626092|GM1 gangliosidosis
270663|NCT01626092|Tay Sachs disease
270664|NCT01626092|Sanfilippo syndrome
270665|NCT01626092|Sandhoff disease
270666|NCT01626092|inherited metabolic
270667|NCT01626092|I-cell disease
270668|NCT01626092|mucolipidosis II
270669|NCT01626079|Functional Mitral Regurgitation
270670|NCT01626079|Mitral Valve Regurgitation
270671|NCT01626079|Symptomatic Heart Failure
270672|NCT01626079|Functional MR
270673|NCT01626079|MitraClip
270674|NCT01626079|Mitral Valve Insufficiency
270675|NCT01626079|Cardiopulmonary exercise testing
270676|NCT01626053|psychological
270677|NCT01626053|intervention
270678|NCT01626053|stages of change
270679|NCT01626053|motivational interviewing
270680|NCT01626053|coping skills
270681|NCT01626053|HbA1C
270682|NCT01626053|psychological testing
270683|NCT01626053|integrated care
270684|NCT01626053|behavioral health
270685|NCT01626027|Coronary Heart Disease
270686|NCT01626027|Depression
270687|NCT01626027|Health Care Services
270688|NCT01626014|Stage III ovarian cancer
270689|NCT01626014|Stage IV ovarian cancer
270690|NCT01626014|recurrent ovarian cancer
270691|NCT01626014|primary peritoneal cancer
270692|NCT01626014|fallopian tube cancer
270693|NCT01626001|Esophagus Cancer
270694|NCT01626001|Lung Cancer
270695|NCT01626001|4-dimensional computed tomography
270696|NCT01626001|4D CT
270697|NCT01625975|Growth modulation
270698|NCT01625975|Eight plate
270699|NCT01625975|Leg length discrepancy
270700|NCT01625975|Varus/valgus deformities
270701|NCT01625975|Pediatric
270702|NCT01625962|PTSD
270703|NCT01625962|mTBI
270704|NCT01625962|mild TBI
270705|NCT01625962|extracranial injury
270706|NCT01625962|ECI
270707|NCT01625962|Brain Indices
270708|NCT01625949|myocardial infarction
270709|NCT01625936|metastatic
270710|NCT01625936|locally advanced
270711|NCT01625936|unresectable
270712|NCT01625923|Gastroparesis
270713|NCT01625923|Idiopathic
270714|NCT01625923|Olanzapine
270715|NCT01625910|Childhood obesity treatment
270716|NCT01625910|Motivational interviewing
270717|NCT01625897|Schizophrenia
270718|NCT01625897|Antipsychotic Agents
270719|NCT01625897|Mental Disorder
270720|NCT01625897|Psychotropic Drugs
270721|NCT01625897|Dopamine Agents
270722|NCT01625897|Risperidone
270723|NCT01625897|Central Nervous System Agents
270724|NCT01625884|Statin
270725|NCT01625884|Hypercholesterolemia
270726|NCT01625871|malaria
270727|NCT01625871|vivax
270728|NCT01625871|artemether/lumefantrine
270729|NCT01625871|Sudan
270730|NCT01625858|LMA Supreme
270731|NCT01625845|Major Depressive Disorder
270732|NCT01625845|Depression
270733|NCT01625845|Depressive Symptoms
270734|NCT01625845|Cardiovascular Disease (CVD)
270735|NCT01625845|Coronary Artery Disease (CAD)
270736|NCT01625845|Heart Disease
270737|NCT01625845|Endothelial Function
270738|NCT01625845|Inflammation
270739|NCT01625832|intermittent coronary sinus occlusion
270740|NCT01625832|collateral flow index
270741|NCT01625832|collateral circulation
270742|NCT01625832|coronary artery occlusion
270743|NCT01625819|Tai Chi
270744|NCT01625793|Hepatitis C
270745|NCT01625793|interferon
270746|NCT01625793|stress
270747|NCT01625793|social behavior
270748|NCT01625767|Nicotine
270749|NCT01625767|Smoking
270750|NCT01625767|Adolescent
270751|NCT01625767|Tobacco
270752|NCT01625754|Ceramides
270753|NCT01625754|Lipids
270754|NCT01625728|Voice
270755|NCT01625728|aerodynamics
270756|NCT01625728|acoustics
270757|NCT01625715|peanut allergy
270758|NCT01625702|no-prior chemotherapy
270759|NCT01625689|Influenza vaccines
270760|NCT01625689|Influenza, Human
270761|NCT01625689|Live Attenuated Influenza Vaccine
270762|NCT01625676|Aphasia
270763|NCT01625676|Rehabilitation of Speech and Language Disorders
270764|NCT01625663|barth syndrome
270765|NCT01625663|heart failure
270766|NCT01625663|mitochondria
270767|NCT01625663|metabolism
270768|NCT01625663|amino acid
270769|NCT01625650|Rheumatoid Arthritis
270770|NCT01625650|Registry
270771|NCT01625650|RA
270772|NCT01625650|Biologic
270773|NCT01625650|Medications
270774|NCT01625650|Rheumatology
270775|NCT01625637|Nicotine
270776|NCT01625637|Smoking
270777|NCT01625637|Adolescent
270778|NCT01625637|Tobacco
270779|NCT01625611|Alcohol
270780|NCT01625611|Drinking
270781|NCT01625611|Drinkers
270782|NCT01625611|Alcohol Drinking
270783|NCT01625611|Naltrexone
270784|NCT01625611|Alcohol Dependence
270785|NCT01625611|Alcohol Abuse
270786|NCT01625611|Alcohol-Related Disorders
270787|NCT01625611|Ethanol
270788|NCT01625611|Alcoholism
270789|NCT01625598|Nonproliferative diabetic retinopathy
270790|NCT01625598|diabetic macular edema
270791|NCT01625598|proliferative diabetic retinopathy
270792|NCT01625598|ophthalmologists
270793|NCT01625598|dilated eye exam
270794|NCT01625585|Push-and-Pull Enteroscopy
270795|NCT01625585|Single-Balloon-Enteroscopy
270796|NCT01625572|general anaesthesia
270797|NCT01625572|epidural catheter
270798|NCT01625572|intravenous pain therapy
270799|NCT01625546|Major Depressive Disorder
270800|NCT01625546|Whole Body Hyperthermia
270801|NCT01625533|Coronary Angiography
270802|NCT01625533|Rotational Coronary Angiography
270803|NCT01625533|Contrast media
270804|NCT01625533|Radiation
270805|NCT01625520|Progressive metastatic
270806|NCT01625520|postoperative persistent
270807|NCT01625468|Secondhand smoke exposure
270808|NCT01625468|Smoke-free homes
270809|NCT01625468|Smoke-free home bans
270810|NCT01625455|Sezary Syndrome
270811|NCT01625455|Pruritus
270812|NCT01625455|Aprepitant
270813|NCT01625455|Neurokinin-1
270814|NCT01625442|Metabolic syndrome
270815|NCT01625442|hypercholesterolemia
270816|NCT01625442|hypertriglyceridemia
270817|NCT01625442|hyperglycemia
270818|NCT01625416|Posttraumatic Stress Disorder
270819|NCT01625416|Depression
270820|NCT01625416|Suicide
270821|NCT01625416|Traumatic Brain Injury
270822|NCT01625416|Alcohol Use
270823|NCT01625416|Drug Use
270824|NCT01625416|Information Technology
270825|NCT01625403|Recombinant BNP
270826|NCT01625403|Diuretics
270827|NCT01625403|Acute decompensated heart failure
270828|NCT01625403|Acute renal injury
270829|NCT01625403|Heart function
270830|NCT01625403|Renal function
270831|NCT01625390|hemophilia, haemophilia, inhibitor, FVIIa, Factor VII activated, bypassing
270832|NCT01625377|Everolimus,
270833|NCT01625377|liver transplantation,
270834|NCT01625377|early introduction,
270835|NCT01625377|renal function
270836|NCT01625364|Health Education
270837|NCT01625364|Health Counseling
270838|NCT01625364|Patient Education
270839|NCT01625338|HCV genotype 2 (GT-2)
270840|NCT01625338|HCV genotype 3 (GT-3)
270841|NCT01625338|HCV
270842|NCT01625338|Sustained Virologic Response
270843|NCT01625338|Direct Acting Antiviral
270844|NCT01625338|Combination Therapy
270845|NCT01625338|GS-7977
270846|NCT01625338|Ribavirin
270847|NCT01625338|Open Label
270848|NCT01625325|obesity, adiposity, psychosocial, healthcare, co-morbidities, low key intervention, quality of life
270849|NCT01625299|intestinal permeability
270850|NCT01625299|diet
270851|NCT01625299|gluten
270852|NCT01625299|dairy
270853|NCT01625286|advanced breast cancer,
270854|NCT01625286|metastatic breast cancer,
270855|NCT01625286|ER+ve breast cancer,
270856|NCT01625286|Estrogen receptor positive breast cancer,
270857|NCT01625286|PIK3CA mutated advanced or metastatic breast cancer
270858|NCT01625286|AKT inhibitor
270859|NCT01625273|F19
270860|NCT01625273|Lactobacillus paracasei paracasei
270861|NCT01625260|cancer
270862|NCT01625260|immunotherapy
270863|NCT01625260|targeted
270864|NCT01625260|non-muscle invasive
270865|NCT01625260|interleukin-2
270866|NCT01625260|antitumor
270867|NCT01625260|TCR
270868|NCT01625260|T-cell receptor
270869|NCT01625260|p53
270870|NCT01625260|p53 gene
270871|NCT01625260|p53 tumor supressor protein
270872|NCT01625260|urothelial cancer
270873|NCT01625260|bladder cancer
270874|NCT01625260|HLA-A2 positive
270875|NCT01625260|HLA-A*0201/p53 aa264-272
270876|NCT01625260|HLA complex
270877|NCT01625260|refractory
270878|NCT01625260|relapsed
270879|NCT01625260|BCG
270880|NCT01625260|multi-focal
270881|NCT01625260|carcinoma in situ
270882|NCT01625260|transitional cell carcinoma
270883|NCT01625260|gemcitabine
270884|NCT01625234|Cancer
270885|NCT01625234|Tumors
270886|NCT01625234|ALK
270887|NCT01625234|NSCLC
270888|NCT01625234|Advanced Malignancies
270889|NCT01625234|Carcinoma, Non-Small-Cell Lung
270890|NCT01625234|Inflammatory Myofibroblastic Tumors
270891|NCT01625221|FENIX
270892|NCT01625182|chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, FTY720, fingolimod.
270893|NCT01625169|Pharmacokinetics
270894|NCT01625169|HIV
270895|NCT01625169|Breast milk
270896|NCT01625130|sulforaphane
270897|NCT01625130|ozone
270898|NCT01625130|airway inflammation
270899|NCT01625130|broccoli sprouts
270900|NCT01625130|NRF2
270901|NCT01625130|controls
270902|NCT01625117|Treatment of ex-combatants
270903|NCT01625117|Narrative Exposure Therapy for ex-combatants
270904|NCT01625117|Appetitive Aggression
270905|NCT01625117|Posttraumatic Stress Disorder
270906|NCT01625104|Myocardial Infarction
270907|NCT01625104|Time to Treatment
270908|NCT01625104|Door to Balloon Time
270909|NCT01625091|HIV
270910|NCT01625091|women
270911|NCT01625091|drinking
270912|NCT01625091|Naltrexone
270913|NCT01625078|Baska Mask
270914|NCT01625078|Supraglottic airway device
270915|NCT01625078|Children
270916|NCT01625078|Pediatric
270917|NCT01625065|medication compliance
270918|NCT01625065|adherence
270919|NCT01625065|toxicological analyzes
270920|NCT01625065|GC-MS
270921|NCT01625065|HPLC
270922|NCT01625065|pain patients
270923|NCT01625065|opioid misuse
270924|NCT01625065|patients with current pain
270925|NCT01625052|mask size
270926|NCT01625052|Baska mask
270927|NCT01625052|supraglottic airway
270928|NCT01625052|airway management
270929|NCT01625039|Occupational health
270930|NCT01625039|cognitive behavioural therapy
270931|NCT01625039|physiotherapy
270932|NCT01625039|physical activity
270933|NCT01625026|Morbidly obesity
270934|NCT01625026|Gastric bypass
270935|NCT01625026|Cholecystolithiasis
270936|NCT01625013|osteoarthritis
270937|NCT01625013|viscosupplementation
270938|NCT01625013|Active
270939|NCT01625013|Knee
270940|NCT01625013|Synvisc-One
270941|NCT01625000|Schizophrenia
270942|NCT01625000|Antipsychotic Agents
270943|NCT01625000|Acute Schizophrenia
270944|NCT01625000|Mental Disorder
270945|NCT01625000|Psychotropic Drugs
270946|NCT01625000|Dopamine Agents
270947|NCT01625000|Risperidone
270948|NCT01625000|Central Nervous System Agents
270949|NCT01624987|Treatment of ex-combatants
270950|NCT01624987|FORNET for ex-combatants
270951|NCT01624987|Appetitive Aggression
270952|NCT01624987|Post-traumatic Stress Disorder
270953|NCT01624961|Controlled human malaria infection (CHMI)
270954|NCT01624961|Malaria challenge
270955|NCT01624961|Plasmodium falciparum
270956|NCT01624961|PfSPZ Challenge
270957|NCT01624948|BK virus
270958|NCT01624948|Kidney Transplantation
270959|NCT01624948|Immunologic Monitoring
270960|NCT01624935|PTSD
270961|NCT01624935|earthquake
270962|NCT01624935|disaster
270963|NCT01624935|global mental health
270964|NCT01624935|disaster mental health
270965|NCT01624935|depression
270966|NCT01624870|Aortic Valve Stenonis
270967|NCT01624870|Valvular Heart Disease
270968|NCT01624870|Transcatheter Aortic Valve Implantation
270969|NCT01624844|ultrasound
270970|NCT01624831|Psychosis
270971|NCT01624831|schizophrenia
270972|NCT01624831|schizoaffective disorder
270973|NCT01624831|Bipolar disorder with psychotic features
270974|NCT01624831|Major depression with psychotic features
270975|NCT01624831|Psychosis NOS
270976|NCT01624831|Social Cognition
270977|NCT01624818|coping
270978|NCT01624818|physical activity
270979|NCT01624818|psychosocial
270980|NCT01624818|children
270981|NCT01624818|heart disease
270982|NCT01624818|habilitation
270983|NCT01624805|Leukemia
270984|NCT01624805|Aplastic Anemia
270985|NCT01624805|AA
270986|NCT01624805|Low/Int-1 Risk Myelodysplastic Syndrome
270987|NCT01624805|MDS
270988|NCT01624805|hATG
270989|NCT01624805|Horse Antithymocyte Globulin
270990|NCT01624805|ATG
270991|NCT01624805|Antithymocyte Globulin
270992|NCT01624805|Thymoglobulin
270993|NCT01624805|Cyclosporine
270994|NCT01624805|Sandimmune
270995|NCT01624805|CYA
270996|NCT01624805|Cyclosporin A
270997|NCT01624805|Methylprednisone
270998|NCT01624805|Methylprednisolone
270999|NCT01624805|Depo-Medrol
271000|NCT01624805|Medrol
271001|NCT01624805|Solu-Medrol
271002|NCT01624805|pegfilgrastim
271003|NCT01624805|Neulasta
271004|NCT01624805|PEG-G-CSF
271005|NCT01624805|Filgrastim
271006|NCT01624805|C-CSF
271007|NCT01624805|Neupogen
271008|NCT01624792|Protein metabolism
271009|NCT01624792|casein protein
271010|NCT01624792|EPA
271011|NCT01624792|Fish oil
271012|NCT01624779|autologous adipose tissue
271013|NCT01624766|Advanced Cancers
271014|NCT01624766|Advanced Malignancies
271015|NCT01624766|Metastatic Cancers
271016|NCT01624766|Everolimus
271017|NCT01624766|Afinitor
271018|NCT01624766|RAD001
271019|NCT01624766|Anakinra
271020|NCT01624766|Kineret
271021|NCT01624766|Denosumab
271022|NCT01624766|AMG 162
271023|NCT01624753|interstitial lung disease
271024|NCT01624753|interstitial pneumonia
271025|NCT01624753|idiopathic pulmonary fibrosis
271026|NCT01624727|Coronary heart disease
271027|NCT01624727|metabolic syndrome
271028|NCT01624727|CT angiography
271029|NCT01624714|Treatment Refractory
271030|NCT01624701|Cord blood
271031|NCT01624701|unrelated donor
271032|NCT01624701|allogeneic
271033|NCT01624701|cell dose
271034|NCT01624688|Tattoo
271035|NCT01624688|Tattoo Removal
271036|NCT01624675|Autistic disorder in children and adolescents
271037|NCT01624675|Risperidone (R064766)
271038|NCT01624675|Children
271039|NCT01624675|Adolescents
271040|NCT01624675|Irritability
271041|NCT01624675|Autistic disorder
271042|NCT01624649|Attention-deficit hyperactivity disorder
271043|NCT01624649|Developmental disorder
271044|NCT01624649|Atomoxetine
271045|NCT01624649|Methylphenidate
271046|NCT01624649|Psychiatric disorder
271047|NCT01624636|AMD
271048|NCT01624636|Age-related Macular Degeneration
271049|NCT01624636|Wet AMD
271050|NCT01624636|Neovascular AMD
271051|NCT01624623|radiation
271052|NCT01624623|Calypso
271053|NCT01624623|prostatectomy
271054|NCT01624610|Irritable bowel syndrome
271055|NCT01624610|Diarrhea
271056|NCT01624610|abdominal pain
271057|NCT01624610|diet
271058|NCT01624610|nutrition
271059|NCT01624597|Road traffic safety
271060|NCT01624584|child
271061|NCT01624584|anxiety
271062|NCT01624584|CBT
271063|NCT01624558|malignant hyperthermia
271064|NCT01624545|chronic subdural hematoma
271065|NCT01624545|burr hole trepanation
271066|NCT01624545|radiologic follow-up
271067|NCT01624545|outcome
271068|NCT01624545|recurrence
271069|NCT01624532|Anthrax vaccine
271070|NCT01624519|Arterial Lactate
271071|NCT01624519|Central Venous Lactate
271072|NCT01624519|Peripheral Venous Lactate
271073|NCT01624506|GERD
271074|NCT01624506|Fundoplication
271075|NCT01624506|Magnetic Sphincter Augmentation
271076|NCT01624493|Vascular Disrupting Agents
271077|NCT01624493|BNC105P
271078|NCT01624493|Partially platinum sensitive
271079|NCT01624480|Pediatric Narcolepsy
271080|NCT01624467|Advanced Solid Tumors
271081|NCT01624454|colonoscopy
271082|NCT01624454|bowel cleansing
271083|NCT01624428|Tobacco
271084|NCT01624428|Adolescent
271085|NCT01624428|Nicotine
271086|NCT01624428|Magnetic Resonance Imaging
271087|NCT01624428|Varenicline
271088|NCT01624389|[18F]AV-45 PET amyloid binding imaging
271089|NCT01624389|Alzheimer's disease
271090|NCT01624376|non-invasive management
271091|NCT01624376|Fistula
271092|NCT01624376|Crohn's Disease
271093|NCT01624376|local administration
271094|NCT01624376|non-invasive
271095|NCT01624363|Pancreatic cysts incidentally found during EUS
271096|NCT01624350|Anorectal Fistulas
271097|NCT01624337|Plasmodium falciparum
271098|NCT01624337|Plasmodium vivax
271099|NCT01624324|aminoglycoside
271100|NCT01624324|KIM-1
271101|NCT01624324|DPOAE
271102|NCT01624324|nephrotoxicity
271103|NCT01624324|ototoxicity
271104|NCT01624311|High ammonia level
271105|NCT01624311|Hyperammonemia
271106|NCT01624311|Poor suck
271107|NCT01624311|Lethargy
271108|NCT01624311|Coma
271109|NCT01624311|Encephalopathy
271110|NCT01624311|Seizures
271111|NCT01624311|Brain edema
271112|NCT01624311|Urea Cycle Disorder
271113|NCT01624311|Ornithine Transcarbamylase Deficiency
271114|NCT01624311|Carbamoyl Phosphate Synthetase Deficiency
271115|NCT01624311|Citrullinemia
271116|NCT01624311|Argininosuccinic Aciduria
271117|NCT01624311|Organic Acidemia
271118|NCT01624311|Propionic Aciduria
271119|NCT01624311|Methylmalonic Aciduria
271120|NCT01624311|Isovaleric Aciduria
271121|NCT01624298|Randomized controlled trial
271122|NCT01624298|Traumatized youth
271123|NCT01624298|HIV risk
271124|NCT01624272|Physical Therapy
271125|NCT01624272|Respiratory Muscle Training
271126|NCT01624272|Elderly
271127|NCT01624220|Spinal tumor
271128|NCT01624220|Tumor of the mid or lower spine
271129|NCT01624220|Non-small cell lung cancer
271130|NCT01624220|Breast cancer
271131|NCT01624220|Prostate cancer
271132|NCT01624220|Renal cell cancer
271133|NCT01624220|Melanoma
271134|NCT01624220|Gastrointestinal cancer
271135|NCT01624220|Sarcoma
271136|NCT01624220|Thyroid cancer
271137|NCT01624220|Head and neck primary cancer
271138|NCT01624220|Carcinoma of unknown primary
271139|NCT01624220|Fiducial markers
271140|NCT01624220|Gold seed markers
271141|NCT01624220|Spinal stereotactic body radiation therapy
271142|NCT01624220|Spinal SBRT
271143|NCT01624220|Stereotactic Radiotherapy
271144|NCT01624207|Atorva
271145|NCT01624207|generic
271146|NCT01624207|atorvastatin
271147|NCT01624207|hypercholesterolemia
271148|NCT01624181|ion mobility spectrometry
271149|NCT01624181|hospital-acquired pneumonia
271150|NCT01624181|microbiological investigation
271151|NCT01624181|intensive care
271152|NCT01624168|anxiety
271153|NCT01624168|sleep quality
271154|NCT01624168|tai chi chuan
271155|NCT01624168|young adults
271156|NCT01624155|teratogens
271157|NCT01624155|contraception
271158|NCT01624155|electronic medical record
271159|NCT01624142|Hypercholesterolemia
271160|NCT01624142|Elevated Cholesterol
271161|NCT01624142|High Cholesterol
271162|NCT01624142|Homozygous Familial Hypercholesterolemia
271163|NCT01624142|PCSK9 mutations
271164|NCT01624142|Severe Familial Hypercholesterolemia
271165|NCT01624103|Arm Injuries
271166|NCT01624103|Wounds and Injuries
271167|NCT01624103|Lidocaine
271168|NCT01624103|Levobupivacaine
271169|NCT01624103|Bupivacaine
271170|NCT01624103|Anesthetics
271171|NCT01624103|Central Nervous System Depressants
271172|NCT01624103|Physiological Effects of Drugs
271173|NCT01624090|Cancer Stem Cell
271174|NCT01624090|Thoracic Malignancies
271175|NCT01624090|Mythramycin Treatment
271176|NCT01624090|Lung Tumors
271177|NCT01624090|Metastatic Lung Tumors
271178|NCT01624077|Regulatory T cells
271179|NCT01624077|Liver Transplantation
271180|NCT01624077|Rejection
271181|NCT01624077|Tolerance
271182|NCT01624077|Cell tolerance
271183|NCT01624077|Survival
271184|NCT01624064|Renal Insufficiency, Chronic
271185|NCT01624064|Uncertain aetiology
271186|NCT01624064|ACEI
271187|NCT01624051|cisplatin based chemotherapy
271188|NCT01624051|non-small cell lung cancer
271189|NCT01624051|lean body mass
271190|NCT01624051|sarcopenia
271191|NCT01624038|Hydroxyurea
271192|NCT01624038|Erythropoitin therapy
271193|NCT01624038|Thalassemia intermedia
271194|NCT01624025|AGC, second-line, docetaxel, epirubicin
271195|NCT01624012|NIV NAVA
271196|NCT01624012|non-invasive ventilation
271197|NCT01623973|hemiparetic
271198|NCT01623973|cognitive
271199|NCT01623973|balance
271200|NCT01623960|severe haemophilia
271201|NCT01623960|quality of life
271202|NCT01623947|glutamine
271203|NCT01623947|cycling performance
271204|NCT01623947|mental function
271205|NCT01623934|Gestational diabetes
271206|NCT01623934|Adiponectin
271207|NCT01623934|Leptin
271208|NCT01623934|Single Nucleotides Polymorphisms
271209|NCT01623934|Insulin resistance
271210|NCT01623921|Lung
271211|NCT01623921|Contusion
271212|NCT01623921|Injury
271213|NCT01623921|Cyclooxygenase
271214|NCT01623921|Statin
271215|NCT01623908|Breast neoplasms
271216|NCT01623908|Zoledronate
271217|NCT01623908|Bone loss
271218|NCT01623882|Diabetes Mellitus
271219|NCT01623882|Wounds
271220|NCT01623882|Ulcers
271221|NCT01623843|FAI
271222|NCT01623843|randomized
271223|NCT01623843|hip arthroscopy
271224|NCT01623843|lavage
271225|NCT01623843|osteochondroplasty
271226|NCT01623830|reconsolidation
271227|NCT01623830|fear of flying
271228|NCT01623830|virtual reality
271229|NCT01623830|virtual reality exposure therapy
271230|NCT01623804|Ultrasound therapy
271231|NCT01623804|Tibiofemoral joint, medial
271232|NCT01623804|Nonsurgical
271233|NCT01623791|Pre-eclampsia
271234|NCT01623791|Proteinuria
271235|NCT01623791|Protein - creatinine ratio
271236|NCT01623791|Dipstick proteinuria
271237|NCT01623791|Severity of disease
271238|NCT01623778|HBeAg seroconversion
271239|NCT01623778|Peginterferon alfa-2a
271240|NCT01623778|chronic hepatitis B(CHB
271241|NCT01623778|Optimal therapy
271242|NCT01623778|Response guild treatment(RGT);
271243|NCT01623765|Endobronchial ultrasound, lung cancer
271244|NCT01623739|Dental implants
271245|NCT01623739|Esthetic score
271246|NCT01623739|Immediate implants
271247|NCT01623739|Early placement
271248|NCT01623726|Transcranial Direct Current Stimulation
271249|NCT01623726|Schizophrenia
271250|NCT01623713|schizophrenia
271251|NCT01623713|iloperidone
271252|NCT01623713|Risperidone
271253|NCT01623713|Efficacy
271254|NCT01623713|Safety
271255|NCT01623700|clopidogrel
271256|NCT01623700|aspirin
271257|NCT01623700|percutaneous coronary intervention
271258|NCT01623700|coronary stenting
271259|NCT01623700|antiplatelet
271260|NCT01623687|total hip arthroplasty
271261|NCT01623687|bone metabolism
271262|NCT01623687|mineralisation
271263|NCT01623674|Sleep deprivation in surgeons during night shifts and the effect on performance.
271264|NCT01623661|Nephrology
271265|NCT01623661|chronic kidney disease
271266|NCT01623661|sodium-channels
271267|NCT01623661|water-channels
271268|NCT01623661|BCM
271269|NCT01623648|whey protein
271270|NCT01623648|hunger
271271|NCT01623609|Phase 1
271272|NCT01623609|Healthy volunteers
271273|NCT01623609|Naloxegol
271274|NCT01623609|Bioequivalence
271275|NCT01623583|lidocaine
271276|NCT01623583|tetracaine
271277|NCT01623583|Renal dialysis
271278|NCT01623570|Luteinizing Hormone
271279|NCT01623570|Hypogonadotropic Hypogonadism
271280|NCT01623570|Ovulation Induction
271281|NCT01623570|Chorionic Gonadotropin
271282|NCT01623557|Malaria
271283|NCT01623557|Vaccine
271284|NCT01623557|Plasmodium
271285|NCT01623557|falciparum
271286|NCT01623544|Asthma
271287|NCT01623544|Comparative Effectiveness
271288|NCT01623544|Symbicort
271289|NCT01623531|Fibrinogen
271290|NCT01623531|cardiac surgery
271291|NCT01623531|high risk
271292|NCT01623531|cardiopulmonary bypass
271293|NCT01623531|bleeding
271294|NCT01623531|blood transfusion
271295|NCT01623505|Smoking Cessation
271296|NCT01623505|Psychiatric Illness
271297|NCT01623505|Pharmacotherapy
271298|NCT01623492|Eisenmenger
271299|NCT01623466|PK and Safety
271300|NCT01623453|crohn's disease
271301|NCT01623453|fistula
271302|NCT01623453|complex
271303|NCT01623427|pediatric
271304|NCT01623427|laparoscopy
271305|NCT01623427|vacuum
271306|NCT01623427|dressing
271307|NCT01623362|Dentifrices
271308|NCT01623362|Dental Caries
271309|NCT01623362|Fluorides
271310|NCT01623362|Nails
271311|NCT01623362|pH
271312|NCT01623349|Recurrent
271313|NCT01623349|High Grade
271314|NCT01623349|Serous
271315|NCT01623349|Triple Negative
271316|NCT01623336|HEPATITIS
271317|NCT01623336|HEPATITIS C
271318|NCT01623336|PEGINTERFERON
271319|NCT01623336|BIOEQUIVALENCE
271320|NCT01623336|TREATMENT
271321|NCT01623297|Laparoscopy
271322|NCT01623297|Surgery
271323|NCT01623297|Acute Phase Reaction
271324|NCT01623297|Aged
271325|NCT01623297|Aged 80 and over
271326|NCT01623297|Confusion
271327|NCT01623297|Inflammation
271328|NCT01623297|Delirium
271329|NCT01623284|aphasia
271330|NCT01623284|apraxia of speech
271331|NCT01623284|language
271332|NCT01623271|CRPS I
271333|NCT01623232|vaccine
271334|NCT01623232|influenzavirus A
271335|NCT01623232|influenzavirus B
271336|NCT01623232|adjuvant
271337|NCT01623219|PTSD
271338|NCT01623219|trauma
271339|NCT01623219|combat trauma
271340|NCT01623219|veterans
271341|NCT01623219|telemedicine
271342|NCT01623219|prolonged exposure
271343|NCT01623193|Cardioplegia
271344|NCT01623193|Blood transfusion
271345|NCT01623193|Cardiac function
271346|NCT01623193|Myocardial edema
271347|NCT01623193|Coronary artery disease
271348|NCT01623193|Valve disease
271349|NCT01623180|DES
271350|NCT01623180|coronary stent
271351|NCT01623180|bare metal stent
271352|NCT01623180|high bleeding
271353|NCT01623180|MI
271354|NCT01623180|angina
271355|NCT01623167|T-cells
271356|NCT01623167|Immunosuppression
271357|NCT01623167|Hematopoesis
271358|NCT01623167|Autoimmunity
271359|NCT01623167|Thrombocytopenia
271360|NCT01623154|Helicobacter pylori
271361|NCT01623141|CRPS
271362|NCT01623141|TPBS
271363|NCT01623141|Pressure pain thresholds
271364|NCT01623141|limb pain of other origin
271365|NCT01623128|Breastfeeding initiation
271366|NCT01623128|Breastfeeding duration
271367|NCT01623128|WIC
271368|NCT01623128|Video education
271369|NCT01623128|Breastfeeding rates
271370|NCT01623115|PCSK9
271371|NCT01623102|Bevacizumab
271372|NCT01623102|gemcitabine
271373|NCT01623102|cisplatin
271374|NCT01623102|EGFR wild-type
271375|NCT01623089|severe asthma, phenotype, data
271376|NCT01623076|Neuromyelitis Optica
271377|NCT01623076|Neuromyelitis Optica Spectrum Disorder
271378|NCT01623076|Transverse Myelitis
271379|NCT01623076|Optic Neuritis
271380|NCT01623076|Biorepository
271381|NCT01623063|endometrium
271382|NCT01623063|infertility
271383|NCT01623063|uterus
271384|NCT01623063|histeroscopy
271385|NCT01623037|Lipolysis
271386|NCT01623037|Cryolipolysis
271387|NCT01623037|Fat Reduction
271388|NCT01623011|Shoulder
271389|NCT01623011|Sub-acromial
271390|NCT01623011|Rotator Cuff
271391|NCT01623011|Impingement
271392|NCT01622998|Pharmacotherapy
271393|NCT01622998|Titration
271394|NCT01622998|Smoking Cessation
271395|NCT01622959|emergency departement
271396|NCT01622959|acute pain
271397|NCT01622959|acupuncture
271398|NCT01622959|morphine
271399|NCT01622946|total hip arthroplasty
271400|NCT01622946|tranexamic acid
271401|NCT01622946|postoperative blood loss
271402|NCT01622933|melanoma
271403|NCT01622933|recurrent
271404|NCT01622933|metastatic
271405|NCT01622920|enamel erosion
271406|NCT01622920|ultrasound
271407|NCT01622920|reproducibility
271408|NCT01622920|human central incisor
271409|NCT01622920|reliability
271410|NCT01622907|Catheter ablation, radiofrequency
271411|NCT01622907|Epicardially applied radiofrequency ablation
271412|NCT01622907|Minimally invasive surgical approach
271413|NCT01622894|Alzheimer genetics
271414|NCT01622855|Rape
271415|NCT01622855|Secondary prevention
271416|NCT01622855|Intervention
271417|NCT01622842|Impedance
271418|NCT01622842|Electrical
271419|NCT01622842|Tissue
271420|NCT01622842|Excitation frequency
271421|NCT01622842|arterial distension
271422|NCT01622842|distension wave form
271423|NCT01622777|Rosuvastatin
271424|NCT01622777|Diabetic polyneuropathy
271425|NCT01622777|Nerve conduction
271426|NCT01622777|Oxidative stress
271427|NCT01622777|Nerve growth factor
271428|NCT01622764|RO5323441
271429|NCT01622764|bevacizumab
271430|NCT01622764|PET imaging
271431|NCT01622764|recurrent glioblastoma
271432|NCT01622751|REM sleep
271433|NCT01622751|Adiponectin
271434|NCT01622751|Prader-Willi syndrome
271435|NCT01622725|ventral hernia
271436|NCT01622712|inguinal hernia
271437|NCT01622699|Jaundice
271438|NCT01622699|Neonatal Jaundice
271439|NCT01622699|Hyperbilirubinemia
271440|NCT01622699|Transcutaneous bilirubin measurement
271441|NCT01622699|Transcutaneous bilirubinometry
271442|NCT01622699|jaundice meter
271443|NCT01622699|Visual assessment of bilirubin
271444|NCT01622699|Newborn
271445|NCT01622686|Prescription Labels
271446|NCT01622686|Low Health Literacy
271447|NCT01622686|Limited English Proficiency
271448|NCT01622686|Spanish
271449|NCT01622660|URETER
271450|NCT01622660|URINARY BLADDER
271451|NCT01622660|renal pelvis
271452|NCT01622660|GEMCITABINE
271453|NCT01622660|GW786034 (PAZOPANIB)
271454|NCT01622660|11-191
271455|NCT01622647|NCPAP
271456|NCT01622634|cardiovascular disease
271457|NCT01622634|diabetes mellitus
271458|NCT01622621|Lung
271459|NCT01622621|Cancer
271460|NCT01622608|Adolescent vaccination
271461|NCT01622608|Immunization rates
271462|NCT01622608|Informational kiosk
271463|NCT01622608|Tailored health messaging
271464|NCT01622608|Barriers to vaccination
271465|NCT01622608|Attitudes
271466|NCT01622608|Intentions
271467|NCT01622595|Aspergillosis
271468|NCT01622595|Candidemia
271469|NCT01622595|Candidiasis
271470|NCT01622595|C. Difficile
271471|NCT01622595|cytomegalovirus
271472|NCT01622595|respiratory syncytial virus (RSV)
271473|NCT01622595|Influenza
271474|NCT01622595|CONS
271475|NCT01622582|Multiple Myeloma, Engraftment syndrome
271476|NCT01622556|Chronic Myeloid Leukemia
271477|NCT01622556|Acute Myeloid Leukemia
271478|NCT01622556|Acute Lymphoblastic Leukemia
271479|NCT01622556|Non-Hodgkins Lymphoma
271480|NCT01622556|Hodgkin's Disease
271481|NCT01622556|Myelodysplastic Syndromes
271482|NCT01622556|Myeloproliferative Disorder
271483|NCT01622504|Intranasal
271484|NCT01622504|nasal spray
271485|NCT01622504|opioid
271486|NCT01622504|overdose
271487|NCT01622491|H1N1
271488|NCT01622491|pandemic
271489|NCT01622491|influenza
271490|NCT01622491|pneumonia
271491|NCT01622491|vaccine
271492|NCT01622491|effectiveness
271493|NCT01622491|Manitoba
271494|NCT01622491|Canada
271495|NCT01622478|sentinel lymph node biopsy
271496|NCT01622478|neoadjuvant chemotherapy
271497|NCT01622478|breast cancer
271498|NCT01622478|locally advanced breast cancer
271499|NCT01622478|positive axillary lymph node
271500|NCT01622478|negative conversion
271501|NCT01622465|Hip arthroplasty
271502|NCT01622465|Aged
271503|NCT01622465|Rehabilitation
271504|NCT01622465|Exercise therapy
271505|NCT01622452|Postoperative cognitive dysfunction
271506|NCT01622452|Cognitive decline
271507|NCT01622452|Valve surgery
271508|NCT01622452|Cardiac surgery
271509|NCT01622452|Diffusion Tensor Imaging
271510|NCT01622452|Brain Morphometry
271511|NCT01622452|1H-Magnetic Resonance Spectroscopy
271512|NCT01622439|Lymphoma
271513|NCT01622439|Diffuse large B-cell lymphoma
271514|NCT01622439|Valproate
271515|NCT01622439|R-CHOP
271516|NCT01622439|CD 20
271517|NCT01622413|lumbar spine
271518|NCT01622413|herniated disc
271519|NCT01622413|slipped disc
271520|NCT01622413|disc herniation
271521|NCT01622413|discectomy
271522|NCT01622413|nucleotomy
271523|NCT01622413|disc surgery
271524|NCT01622413|endoscopy
271525|NCT01622413|spine
271526|NCT01622400|Cardiovascular risk, Therapeutic education, General practice
271527|NCT01622387|Coronary artery bypass surgery
271528|NCT01622387|Arteries
271529|NCT01622387|Veins
271530|NCT01622387|Conduits
271531|NCT01622374|Music
271532|NCT01622374|dental anxiety
271533|NCT01622374|"music for the mind"
271534|NCT01622374|mozart
271535|NCT01622374|iranian traditional music
271536|NCT01622361|Neoadjuvant
271537|NCT01622361|endocrine therapy
271538|NCT01622361|premenopausal
271539|NCT01622361|hormone responsive
271540|NCT01622361|HER2 negative
271541|NCT01622361|lymph node positive
271542|NCT01622348|Psoriasis
271543|NCT01622348|Plaque Psoriasis
271544|NCT01622309|Oxidative Stress
271545|NCT01622309|Obesity
271546|NCT01622309|Solanum melongena
271547|NCT01622218|Medical clown
271548|NCT01622192|Probing
271549|NCT01622192|manual probe
271550|NCT01622192|automated probe
271551|NCT01622192|Periodontal disease
271552|NCT01622179|surgery
271553|NCT01622179|suture method
271554|NCT01622179|blood supply
271555|NCT01622140|T-SPOT.TB
271556|NCT01622140|QuantiFERON-TB Gold In-Tube
271557|NCT01622140|Latent tuberculosis infection
271558|NCT01622140|Tuberculin skin test
271559|NCT01622140|Discordance
271560|NCT01622140|Predictive value
271561|NCT01622140|Tuberculosis disease development
271562|NCT01622114|Obesity
271563|NCT01622114|Weight reduction
271564|NCT01622114|premenopausal Women
271565|NCT01622114|Menstrual cycle
271566|NCT01622114|quality of life
271567|NCT01622114|food cravings
271568|NCT01622101|Energy expenditure
271569|NCT01622101|Appetite
271570|NCT01622101|Bioactive herbal compounds
271571|NCT01622101|blood pressure
271572|NCT01622088|ALS, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
271573|NCT01622062|Rabies
271574|NCT01622062|Verorab®
271575|NCT01622062|Favirab®
271576|NCT01622036|Malnutrition
271577|NCT01622036|pre-cachexia
271578|NCT01622036|cancer
271579|NCT01622036|cachexia
271580|NCT01622036|MNA
271581|NCT01622036|weight loss
271582|NCT01622023|insemination
271583|NCT01622023|donor sperm
271584|NCT01622023|natural cycle
271585|NCT01622010|Heart Failure
271586|NCT01622010|Patient Education as Topic
271587|NCT01622010|Physical Therapy Specialty
271588|NCT01621997|peritoneal dialysis
271589|NCT01621997|retraining
271590|NCT01621997|peritonitis
271591|NCT01621984|Cerebral palsy
271592|NCT01621984|brain injury
271593|NCT01621984|spinal cord injuries
271594|NCT01621984|muscular disease
271595|NCT01621971|inhaled milrinone
271596|NCT01621971|pulmonary hypertension
271597|NCT01621971|mitral regurgitation
271598|NCT01621971|mitral valve surgery
271599|NCT01621958|balance loss
271600|NCT01621958|dynamic stability
271601|NCT01621958|motor learning
271602|NCT01621958|plasticity
271603|NCT01621945|Neisseria meningitidis B:14, P1-7, 16
271604|NCT01621945|Serum bactericidal activity
271605|NCT01621945|OMV vaccine
271606|NCT01621932|Anterior approach
271607|NCT01621906|Breast
271608|NCT01621906|brain metastases
271609|NCT01621906|18F-FLT-PET Imaging
271610|NCT01621906|FLT(3'DEOXY-3'FLUOROTHYMIDINE)
271611|NCT01621906|MR Imaging
271612|NCT01621906|12-039
271613|NCT01621893|bone marrow edema
271614|NCT01621893|bone marrow defects
271615|NCT01621880|radiation-induced brain necrosis
271616|NCT01621880|nasopharyngeal carcinoma
271617|NCT01621880|Bevacizumab
271618|NCT01621880|Methylprednisolone
271619|NCT01621867|Cystic fibrosis
271620|NCT01621867|Gene therapy
271621|NCT01621867|CFTR gene
271622|NCT01621867|Gene expression
271623|NCT01621867|Non-viral
271624|NCT01621867|Multi dose
271625|NCT01621854|cancer
271626|NCT01621854|nucleoside analogue
271627|NCT01621854|advanced solid tumours
271628|NCT01621828|pre-operative anxiety
271629|NCT01621828|multimedia information
271630|NCT01621828|operating theatre
271631|NCT01621815|ADHD
271632|NCT01621815|Attention Deficit/Hyperactivity Disorder
271633|NCT01621815|Conduct
271634|NCT01621815|Depression
271635|NCT01621815|Anxiety
271636|NCT01621815|PDD
271637|NCT01621815|Pervasive Developmental Disorders
271638|NCT01621802|Safety
271639|NCT01621802|Measles, mumps and rubella diseases
271640|NCT01621802|Immunogenicity
271641|NCT01621789|lutein
271642|NCT01621789|zeaxanthin
271643|NCT01621789|trypan blue
271644|NCT01621789|dye
271645|NCT01621776|post-prandial hyperglycemia
271646|NCT01621737|oxytocin
271647|NCT01621724|Gene therapy
271648|NCT01621724|WT1 TCR
271649|NCT01621724|AML
271650|NCT01621724|CML
271651|NCT01621711|substance abuse
271652|NCT01621711|Substance Dependence
271653|NCT01621711|Substance, addiction
271654|NCT01621711|Alcohol Abuse
271655|NCT01621711|prevention and control
271656|NCT01621711|preventative health services
271657|NCT01621711|patient centered care
271658|NCT01621698|VATS
271659|NCT01621698|Paravertebral blocks.
271660|NCT01621698|Thoracoscopic surgery.
271661|NCT01621698|Analgesia.
271662|NCT01621685|Capsaicin
271663|NCT01621685|Cough
271664|NCT01621685|Cough reflex
271665|NCT01621685|Inhalation agents
271666|NCT01621685|Inhalation challenge
271667|NCT01621685|TRPV1 receptor
271668|NCT01621672|Revlimid
271669|NCT01621672|progression free
271670|NCT01621672|Lenalidomide
271671|NCT01621659|multidisciplinary team
271672|NCT01621659|exercise
271673|NCT01621659|nutrition
271674|NCT01621659|cardiology
271675|NCT01621659|physiotherapy
271676|NCT01621659|imaging
271677|NCT01621646|lutein
271678|NCT01621646|eggs
271679|NCT01621646|mild cognitive impairment
271680|NCT01621646|elderly
271681|NCT01621633|hepatic impairment
271682|NCT01621607|fMRI
271683|NCT01621607|Monoamines
271684|NCT01621607|Environment
271685|NCT01621607|Genes
271686|NCT01621607|Reward Learning
271687|NCT01621594|Cardiac
271688|NCT01621594|Computed Tomography
271689|NCT01621594|Radiation Reduction
271690|NCT01621594|Iterative Reconstruction
271691|NCT01621581|Gene Therapy
271692|NCT01621581|Parkinson's Disease
271693|NCT01621581|Convection-Ehanced Delivery
271694|NCT01621581|Viral Vector
271695|NCT01621568|VEGF
271696|NCT01621568|Anti-Angiogenesis
271697|NCT01621568|Targeted Agent
271698|NCT01621555|shoulder surgery
271699|NCT01621555|Pain sensitivity
271700|NCT01621555|Rowe score
271701|NCT01621555|Constant Score
271702|NCT01621555|Surgical Outcome
271703|NCT01621555|Postoperative pain
271704|NCT01621542|Cancer
271705|NCT01621542|Vaccine
271706|NCT01621542|Oncology
271707|NCT01621542|Malignancies
271708|NCT01621542|Wilms' Tumor
271709|NCT01621542|WT1
271710|NCT01621542|Ovarian
271711|NCT01621542|Glioblastoma [GBM]
271712|NCT01621542|Acute myeloid leukemia [AML]
271713|NCT01621529|Positron-Emission Tomography
271714|NCT01621529|PET Scan
271715|NCT01621529|FDG
271716|NCT01621529|SUV
271717|NCT01621529|Invasive Breast cancer
271718|NCT01621529|Surgery compare
271719|NCT01621529|Tumor measurement
271720|NCT01621516|Beta-cell function
271721|NCT01621516|Liver/small bowel transplant
271722|NCT01621516|Donor pancreas
271723|NCT01621516|Diabetes
271724|NCT01621516|Long-term immunesuppression
271725|NCT01621477|Hematologic malignancy
271726|NCT01621477|Hematopoietic cell transplant
271727|NCT01621464|Neuromediated syncope
271728|NCT01621464|Tilt test
271729|NCT01621464|Pacemaker
271730|NCT01621464|CLS sensor
271731|NCT01621438|coronary artery
271732|NCT01621438|atherosclerosis
271733|NCT01621438|angina pectoris
271734|NCT01621425|breast cancer
271735|NCT01621425|prostate carcinoma
271736|NCT01621425|docetaxel
271737|NCT01621425|lean body mass
271738|NCT01621425|Body Surface Area
271739|NCT01621425|body weight
271740|NCT01621425|dexascan
271741|NCT01621412|Medication Adherence
271742|NCT01621412|HIV infection
271743|NCT01621412|Disclosure
271744|NCT01621373|neonatology
271745|NCT01621373|intratracheal intubation
271746|NCT01621373|propofol
271747|NCT01621360|Randomized controlled trial
271748|NCT01621360|Intention to treat
271749|NCT01621347|HIV
271750|NCT01621347|Pregnancy
271751|NCT01621347|Postpartum
271752|NCT01621347|Women
271753|NCT01621347|Medication Adherence
271754|NCT01621308|Diabetes Mellitus type 1
271755|NCT01621308|Intraperitoneal insulin administration
271756|NCT01621308|Subcutaneous insulin administration
271757|NCT01621308|Continuous intraperitoneal insulin infusion
271758|NCT01621282|journal club
271759|NCT01621269|Multiple Sclerosis
271760|NCT01621269|MS
271761|NCT01621269|Fingolimod
271762|NCT01621269|Gilenya
271763|NCT01621269|Neutralizing Antibodies
271764|NCT01621269|NAb
271765|NCT01621243|necuparanib
271766|NCT01621243|gemcitabine
271767|NCT01621243|heparin
271768|NCT01621243|low molecular weight heparin
271769|NCT01621243|nab-Paclitaxel
271770|NCT01621230|Bupivacaine
271771|NCT01621230|Fentanyl
271772|NCT01621230|Epidural
271773|NCT01621230|Second Stage of Labor
271774|NCT01621230|Randomized Controlled Trial
271775|NCT01621217|Anal cancer
271776|NCT01621217|Locally advanced anal cancer
271777|NCT01621217|Cetuximab
271778|NCT01621217|5-fluoruracil
271779|NCT01621217|Mitomycin C
271780|NCT01621217|Radiotherapy
271781|NCT01621204|Thrombocytopenia
271782|NCT01621204|ITP
271783|NCT01621204|Platelets
271784|NCT01621204|Bleeding
271785|NCT01621204|Immune
271786|NCT01621204|Eltrombopag
271787|NCT01621204|IVIG
271788|NCT01621165|treatment of bipolar, mania
271789|NCT01621165|double-blind, placebo-controlled study
271790|NCT01621165|drug intervention
271791|NCT01621165|add-on study
271792|NCT01621165|prazosin
271793|NCT01621165|alpha-1 adrenergic antagonist
271794|NCT01621152|Acute renal failure
271795|NCT01621152|acute kidney injury
271796|NCT01621152|electronic surveillance
271797|NCT01621152|AKI
271798|NCT01621152|sniffer
271799|NCT01621152|AKIN
271800|NCT01621152|improvement in the process of care and outcomes
271801|NCT01621126|Shoulder instability
271802|NCT01621126|Latarjet procedure
271803|NCT01621126|Nerve injury
271804|NCT01621113|Spinal Cord Injuries
271805|NCT01621113|4-Aminopyridine
271806|NCT01621113|Physical Therapy Modalities
271807|NCT01621113|Randomized Controlled Trial
271808|NCT01621113|Rehabilitation
271809|NCT01621113|Walking
271810|NCT01621100|Cancer pain
271811|NCT01621100|OROS
271812|NCT01621100|Osmotic release oral system
271813|NCT01621100|Hydromorphone
271814|NCT01621100|Painkiller
271815|NCT01621100|Opioid analgesic
271816|NCT01621100|Korean patients
271817|NCT01621061|high altitude illness
271818|NCT01621061|pulmonary hypertension
271819|NCT01621061|sleep apnea
271820|NCT01621061|hypoxia
271821|NCT01621048|Head and Neck Neoplasmsr
271822|NCT01621048|Radiotherapy
271823|NCT01621048|Xerostomia
271824|NCT01621048|Deglutition Disorders
271825|NCT01621022|smoking cessation
271826|NCT01621022|tobacco dependence
271827|NCT01621009|smoking cessation medications
271828|NCT01621009|smoking cessation counseling
271829|NCT01620996|preintervention and postintervention cohort longitudinal prospective study
271830|NCT01620983|arthroplasty
271831|NCT01620983|pain
271832|NCT01620970|Transitional Cell Carcinoma
271833|NCT01620970|Metastatic disease
271834|NCT01620970|Bladder tumors, Recurrent
271835|NCT01620970|Angiogenesis
271836|NCT01620970|PF03446962
271837|NCT01620970|Transforming growth factor beta
271838|NCT01620970|Activin receptor like kinase 1
271839|NCT01620970|Monoclonal Antibody
271840|NCT01620970|Locally advanced or metastatic disease
271841|NCT01620970|Failure of one platinum-based chemotherapy
271842|NCT01620970|Measurable disease
271843|NCT01620957|Default-mode network
271844|NCT01620957|Difussion tensor imaging
271845|NCT01620957|Cortical thickness
271846|NCT01620957|Coma
271847|NCT01620957|Vegetative state
271848|NCT01620957|Minimally conscious state
271849|NCT01620957|Neural correlate of consciousness
271850|NCT01620892|unicondylar knee arthroplasty
271851|NCT01620892|partial knee replacement
271852|NCT01620866|EMDR
271853|NCT01620866|bipolar disorder
271854|NCT01620866|trauma
271855|NCT01620866|subsyndromal symptoms
271856|NCT01620866|PTSD
271857|NCT01620853|Non-small cell lung cancer (NSCLC)
271858|NCT01620853|ALK probe
271859|NCT01620853|FISH
271860|NCT01620853|Chromosomal aberrations
271861|NCT01620840|oral administration of Lacosamide is not possible or adequate
271862|NCT01620827|follow up
271863|NCT01620827|cell phone
271864|NCT01620827|hospital landline
271865|NCT01620814|misoprostol
271866|NCT01620814|dinoprostone
271867|NCT01620814|cervical ripening
271868|NCT01620814|diagnostic hysteroscopy
271869|NCT01620801|AAV
271870|NCT01620801|AAV8
271871|NCT01620801|Adeno-associated virus
271872|NCT01620801|Adeno-associated viral vectors
271873|NCT01620801|Hemophilia
271874|NCT01620801|Hemophilia B
271875|NCT01620801|Severe hemophilia B
271876|NCT01620801|Factor IX deficiency
271877|NCT01620801|Factor IX
271878|NCT01620801|FIX
271879|NCT01620762|Cat allergy
271880|NCT01620762|Rhinoconjunctivitis
271881|NCT01620749|melanoma metastatic diagnosis
271882|NCT01620736|Raltegravir
271883|NCT01620736|HTLV
271884|NCT01620736|Integrase
271885|NCT01620723|Breastfeeding
271886|NCT01620723|Breastfeeding self efficacy
271887|NCT01620710|prostatectomy
271888|NCT01620658|Occupational Exposure to Radiation
271889|NCT01620632|laparoscopy assisted ERCP
271890|NCT01620632|altered gastric anatomy
271891|NCT01620619|Shoulder
271892|NCT01620619|Bankart
271893|NCT01620619|Anterior Instability
271894|NCT01620619|Rotator Cuff
271895|NCT01620606|FAP
271896|NCT01620606|RAP
271897|NCT01620606|Abdominal Pain
271898|NCT01620606|IBS
271899|NCT01620593|Prostate Cancer
271900|NCT01620593|Metformin
271901|NCT01620593|Castration therapy
271902|NCT01620580|sleep disturbance
271903|NCT01620580|tiredness
271904|NCT01620580|itching & numbness
271905|NCT01620567|lutein
271906|NCT01620567|avocados
271907|NCT01620567|chickpeas
271908|NCT01620567|potatoes
271909|NCT01620567|elderly
271910|NCT01620554|Sleep disorder
271911|NCT01620554|Obstructive Sleep Apnoea
271912|NCT01620554|Excessive Daytime Sleepiness
271913|NCT01620528|Gonadotropin-Releasing Hormone Antagonist
271914|NCT01620528|Endometriosis associated pain
271915|NCT01620528|Dysmenorrhea (DYS)
271916|NCT01620528|Non-Menstrual Pelvic Pain (NMPP)
271917|NCT01620528|Elagolix
271918|NCT01620515|Prostate
271919|NCT01620515|Prostate Cancer
271920|NCT01620515|Localized Prostate Cancer
271921|NCT01620515|T1c Prostate Cancer
271922|NCT01620515|Focal Therapy
271923|NCT01620515|NX-1207
271924|NCT01620411|Active Duty
271925|NCT01620411|Comprehensive Medical Management
271926|NCT01620411|Spinal Cord Stimulator
271927|NCT01620411|Veteran
271928|NCT01620411|sustained
271929|NCT01620411|military
271930|NCT01620398|cardiovascular diseases
271931|NCT01620398|secondary prevention
271932|NCT01620398|diet
271933|NCT01620385|Cochlear implants
271934|NCT01620359|Breast cancer
271935|NCT01620359|Breast tumor
271936|NCT01620359|stage 1 disease
271937|NCT01620359|T1 M0 N0
271938|NCT01620346|advanced maternal age
271939|NCT01620346|infertility
271940|NCT01620346|IMSI
271941|NCT01620346|ICSI
271942|NCT01620346|implantation
271943|NCT01620320|Left main coronary artery
271944|NCT01620320|Coronary artery disease
271945|NCT01620320|Stress echography
271946|NCT01620320|Intrastent stenosis
271947|NCT01620307|H1N1 patients with severe hypoxemia requiring ventilator support
271948|NCT01620294|surgical site infection
271949|NCT01620294|elective colorectal surgery
271950|NCT01620294|level of surgical site infection
271951|NCT01620294|complication of surgical site infection
271952|NCT01620294|type of changed bandage
271953|NCT01620294|frequency of bandage changing
271954|NCT01620281|Back Pain
271955|NCT01620268|leflunomide
271956|NCT01620268|orotic acid
271957|NCT01620268|Polyoma BK Viruria
271958|NCT01620268|Polyoma BK Viremia
271959|NCT01620268|Polyoma BK Nephropathy
271960|NCT01620268|Renal Allograft Rejection
271961|NCT01620242|recurrent or metastatic head and neck cancer
271962|NCT01620242|cabazitaxel
271963|NCT01620203|Premature infants
271964|NCT01620203|Intracranial hemorrhage
271965|NCT01620203|Intraventricular hemorrhage
271966|NCT01620203|Cerebral oxygenation
271967|NCT01620203|Brain function
271968|NCT01620203|Cerebral perfusion
271969|NCT01620177|Cannabis
271970|NCT01620177|Marijuana
271971|NCT01620177|Marihuana
271972|NCT01620177|Alcohol
271973|NCT01620177|Driving
271974|NCT01620164|three-dimensional vision
271975|NCT01620164|Parkinson
271976|NCT01620151|Post-operative pain
271977|NCT01620151|Wound bleeding requiring exploration
271978|NCT01620151|PTH
271979|NCT01620151|RLN complication
271980|NCT01620151|Hypocalcaemia complication
271981|NCT01620138|Non-functioning pituitary adenomas
271982|NCT01620138|Prolactinomas
271983|NCT01620138|Cabergoline
271984|NCT01620138|Pasireotide
271985|NCT01620138|somatostatin receptors
271986|NCT01620138|Dopamine receptors
271987|NCT01620125|Lactobacillus
271988|NCT01620125|Gut microbiota
271989|NCT01620125|Diabetes mellitus
271990|NCT01620112|brachial plexus
271991|NCT01620112|lidocaine
271992|NCT01620112|alfa 2 adrenergic receptor clonidine
271993|NCT01620112|orthopedic procedure
271994|NCT01620099|Asthma
271995|NCT01620099|Cigarette smoke
271996|NCT01620099|Small airways
271997|NCT01620099|Lung function
271998|NCT01620099|Asthma control
271999|NCT01620086|Schizophrenia
272000|NCT01620086|Auditory hallucinations (AH)
272001|NCT01620086|Phantom sound perception
272002|NCT01620086|repetitive transcranial magnetic stimulation (rTMS)
272003|NCT01620086|Percent habituation in the P50 amplitude with 250 ms ISI
272004|NCT01620073|Male partner
272005|NCT01620073|HIV counseling and testing
272006|NCT01620073|Home based
272007|NCT01620073|Pregnancy
272008|NCT01620060|Schizophrenia
272009|NCT01620060|autism
272010|NCT01620060|bipolar
272011|NCT01620060|Lurasidone
272012|NCT01620060|Latuda
272013|NCT01620047|Regional Anesthesia
272014|NCT01620047|Post-operative pain management
272015|NCT01620047|Femoral Nerve Block
272016|NCT01620047|Total Knee Replacement
272017|NCT01620021|wearable sensors
272018|NCT01620021|kinematics
272019|NCT01620021|gait
272020|NCT01620008|cord clamping (delayed or immediate)
272021|NCT01620008|Myelin content
272022|NCT01620008|Ferritin
272023|NCT01619995|urge incontinence
272024|NCT01619956|dental implants
272025|NCT01619956|osteotome sinus floor elevation
272026|NCT01619956|survival rate
272027|NCT01619956|sinus grafting
272028|NCT01619956|bone remodeling
272029|NCT01619956|RCT
272030|NCT01619956|radiographic analysis
272031|NCT01619943|Minor head injury
272032|NCT01619943|CT scan
272033|NCT01619943|Canadian CT Head Rules
272034|NCT01619943|The New Orleans Criteria
272035|NCT01619930|Depression
272036|NCT01619930|Behavioral activation
272037|NCT01619917|burn
272038|NCT01619917|scar
272039|NCT01619917|laser
272040|NCT01619917|fractional
272041|NCT01619917|vascular
272042|NCT01619904|Pancreas Transplantation
272043|NCT01619904|Goal-directed therapy
272044|NCT01619904|Outcomes
272045|NCT01619904|Immunometric
272046|NCT01619878|plasmodium
272047|NCT01619878|P. falciparum
272048|NCT01619878|malaria
272049|NCT01619878|infant
272050|NCT01619878|neonate
272051|NCT01619865|GA-68
272052|NCT01619865|Gallium 68
272053|NCT01619865|GA-68 PET
272054|NCT01619852|Surgery
272055|NCT01619852|Breast
272056|NCT01619852|Pain
272057|NCT01619852|Chronic Pain
272058|NCT01619852|Lidocaine
272059|NCT01619852|Anesthesia
272060|NCT01619852|Gynecologic
272061|NCT01619852|Urologic
272062|NCT01619839|Nektar
272063|NCT01619839|NKTR-181
272064|NCT01619826|physical activity
272065|NCT01619826|fitness
272066|NCT01619826|brain health
272067|NCT01619826|cognition
272068|NCT01619826|scholastic achievement
272069|NCT01619826|preadolescent children
272070|NCT01619800|Chronotropic Incompetence
272071|NCT01619800|Pacemaker
272072|NCT01619800|Mount Sinai School of Medicine
272073|NCT01619774|Melanoma
272074|NCT01619774|Metastatic melanoma
272075|NCT01619774|Refractory or Resistant to BRAF Inhibitor
272076|NCT01619774|Advanced melanoma
272077|NCT01619774|GSK2118436
272078|NCT01619774|GSK1120212
272079|NCT01619761|Leukemia
272080|NCT01619761|Chronic Lymphocytic Leukemia
272081|NCT01619761|CLL
272082|NCT01619761|Cord blood
272083|NCT01619761|CB
272084|NCT01619761|Umbilical cord blood
272085|NCT01619761|UCB
272086|NCT01619761|Natural killer cells
272087|NCT01619761|NK
272088|NCT01619761|Graft versus host disease
272089|NCT01619761|GVHD
272090|NCT01619761|Lenalidomide
272091|NCT01619761|CC-5013
272092|NCT01619761|Revlimid
272093|NCT01619761|Fludarabine
272094|NCT01619761|Fludarabine Phosphate
272095|NCT01619761|Fludara
272096|NCT01619761|Melphalan
272097|NCT01619761|Alkeran
272098|NCT01619761|Rituximab
272099|NCT01619761|Rituxan
272100|NCT01619735|Kidney Calculi
272101|NCT01619735|Kidney Stones
272102|NCT01619735|Nephrolithiasis
272103|NCT01619735|Renal Stones
272104|NCT01619722|PKU
272105|NCT01619722|Osteoporosis
272106|NCT01619722|HMP
272107|NCT01619722|Life quality
272108|NCT01619722|Neuropsychological
272109|NCT01619722|Nutritial evaluation
272110|NCT01619722|Phenylketonuria
272111|NCT01619722|Hyperphenylalaninemia
272112|NCT01619709|Intracerebral Hemorrhage
272113|NCT01619709|Cerebral Amyloid angiopathy
272114|NCT01619709|Amyloid imaging
272115|NCT01619709|18F-AV-45
272116|NCT01619696|chemotherapy
272117|NCT01619696|rectal adenocarcinoma
272118|NCT01619696|proctectomy
272119|NCT01619696|Fmiso TEP
272120|NCT01619696|MRI
272121|NCT01619657|Cystic Fibrosis
272122|NCT01619657|Hypertonic Saline
272123|NCT01619657|Infant
272124|NCT01619657|Newborn
272125|NCT01619657|Prevention
272126|NCT01619644|RTS
272127|NCT01619644|Rubinstein Taybi
272128|NCT01619644|explorative phase 2
272129|NCT01619644|clinical approach
272130|NCT01619644|biological approach
272131|NCT01619644|motor skills
272132|NCT01619631|Depression
272133|NCT01619631|Tai Chi
272134|NCT01619631|Alternative medicine
272135|NCT01619631|Mind body medicine
272136|NCT01619618|recurrent squamous cell carcinoma of the hypopharynx
272137|NCT01619618|stage IV squamous cell carcinoma of the hypopharynx
272138|NCT01619618|recurrent squamous cell carcinoma of the larynx
272139|NCT01619618|stage IVA squamous cell carcinoma of the larynx
272140|NCT01619618|stage IVB squamous cell carcinoma of the larynx
272141|NCT01619618|stage IVC squamous cell carcinoma of the larynx
272142|NCT01619618|recurrent squamous cell carcinoma of the lip and oral cavity
272143|NCT01619618|stage IVA squamous cell carcinoma of the lip and oral cavity
272144|NCT01619618|stage IVB squamous cell carcinoma of the lip and oral cavity
272145|NCT01619618|stage IVC squamous cell carcinoma of the lip and oral cavity
272146|NCT01619618|recurrent metastatic squamous neck cancer with occult primary
272147|NCT01619618|recurrent squamous cell carcinoma of the nasopharynx
272148|NCT01619618|stage IV squamous cell carcinoma of the nasopharynx
272149|NCT01619618|recurrent squamous cell carcinoma of the oropharynx
272150|NCT01619618|stage IVA squamous cell carcinoma of the oropharynx
272151|NCT01619618|stage IVB squamous cell carcinoma of the oropharynx
272152|NCT01619618|stage IVC squamous cell carcinoma of the oropharynx
272153|NCT01619618|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
272154|NCT01619618|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
272155|NCT01619618|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
272156|NCT01619618|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
272157|NCT01619618|recurrent salivary gland cancer
272158|NCT01619618|stage IVA salivary gland cancer
272159|NCT01619618|stage IVB salivary gland cancer
272160|NCT01619618|stage IVC salivary gland cancer
272161|NCT01619605|tryptases
272162|NCT01619605|anaphylaxis
272163|NCT01619605|shrimp allergy
272164|NCT01619592|patients
272165|NCT01619592|adaptable
272166|NCT01619592|insulin
272167|NCT01619592|schemes
272168|NCT01619579|Fibromyalgia
272169|NCT01619579|Pain
272170|NCT01619579|Non-Invasive
272171|NCT01619579|Arthritis
272172|NCT01619579|Rheumatoid Disease
272173|NCT01619566|Fibromyalgia
272174|NCT01619566|Duloxetine
272175|NCT01619566|Cymbalta
272176|NCT01619566|Pain
272177|NCT01619566|Peripheral Nerve
272178|NCT01619566|Biopsy
272179|NCT01619566|Predictive
272180|NCT01619553|keloid
272181|NCT01619553|fibrosis
272182|NCT01619553|wound healing
272183|NCT01619553|scar
272184|NCT01619540|COPD
272185|NCT01619540|Left Ventricular Failure
272186|NCT01619540|Valsalva Manoeuver
272187|NCT01619527|Healthy participants
272188|NCT01619527|Darunavir
272189|NCT01619527|Cobicistat
272190|NCT01619527|Bioequivalence
272191|NCT01619527|Fixed dose combination
272192|NCT01619527|Pharmacokinetics
272193|NCT01619527|Human immunodeficiency virus
272194|NCT01619527|Protease inhibitor
272195|NCT01619488|Lap-Band
272196|NCT01619488|morbid obesity
272197|NCT01619488|adolescents
272198|NCT01619475|Living Donor
272199|NCT01619475|Liver Transplantation
272200|NCT01619475|Quality of Life
272201|NCT01619475|Biosamples
272202|NCT01619475|Liver Recipient
272203|NCT01619462|pneumococcal
272204|NCT01619462|vaccine
272205|NCT01619462|papua new guinea
272206|NCT01619449|Acute Kidney Injury
272207|NCT01619449|Continuous Renal Replacement Therapy
272208|NCT01619449|Liver Transplant
272209|NCT01619423|Metastatic colorectal cancer
272210|NCT01619423|stage IV
272211|NCT01619423|FOLFOX6
272212|NCT01619423|Chemotherapy
272213|NCT01619423|PledOx
272214|NCT01619423|Mangafodipir
272215|NCT01619423|Febrile neutropenia
272216|NCT01619423|Oxidative stress
272217|NCT01619423|Antioxidant
272218|NCT01619423|neutropenia
272219|NCT01619423|neuropathy
272220|NCT01619397|Condom
272221|NCT01619397|Medical Device
272222|NCT01619384|posttraumatic stress
272223|NCT01619384|irritable bowel
272224|NCT01619371|breast pump
272225|NCT01619371|engorgement
272226|NCT01619371|lactation
272227|NCT01619332|Healthy volunteers,
272228|NCT01619332|Diabetes
272229|NCT01619332|Glucose
272230|NCT01619332|Pharmacokinetics
272231|NCT01619319|schizophrenia prodrome
272232|NCT01619319|clinical high risk of psychosis
272233|NCT01619293|CCT
272234|NCT01619293|brain
272235|NCT01619293|trauma
272236|NCT01619293|injury
272237|NCT01619280|Acute Lung Injury
272238|NCT01619280|Acute Respiratory Distress Syndrome
272239|NCT01619280|Sodium Nitroprusside
272240|NCT01619280|adult
272241|NCT01619280|Safety
272242|NCT01619280|Dose Finding
272243|NCT01619280|Phase 1
272244|NCT01619280|3 + 3 design
272245|NCT01619280|Nebulizers and Vaporizers
272246|NCT01619280|High-Frequency Ventilation
272247|NCT01619280|nitric oxide
272248|NCT01619280|lung injury
272249|NCT01619280|Pulmonary Gas Exchange
272250|NCT01619280|Pulmonary Alveoli
272251|NCT01619267|pacemaker defibrillator infection
272252|NCT01619254|Intestinal parasitic infections
272253|NCT01619254|Anaemia
272254|NCT01619254|School-aged children
272255|NCT01619254|Hand washing and nail clipping
272256|NCT01619241|lung cancer
272257|NCT01619241|F-18 FLT PET/CT
272258|NCT01619228|premature infant
272259|NCT01619228|neonate
272260|NCT01619228|skin maturation
272261|NCT01619228|stratum corneum maturation
272262|NCT01619228|ontogeny of neonatal skin maturation
272263|NCT01619228|sunflower oil
272264|NCT01619228|effect of Vitamin B3 on premature skin maturation
272265|NCT01619228|skin acidity
272266|NCT01619228|stratum corneum barrier integrity
272267|NCT01619228|stratum corneum lipid composition
272268|NCT01619228|stratum corneum biomarkers
272269|NCT01619228|stratum corneum cytokines
272270|NCT01619228|stratum corneum structural proteins
272271|NCT01619202|accident prevention
272272|NCT01619202|Adolescent
272273|NCT01619202|examination, automobile driver
272274|NCT01619202|Driving simulator
272275|NCT01619202|Young drivers
272276|NCT01619202|Driving education
272277|NCT01619189|Cell therapy
272278|NCT01619189|Limbal deficiency
272279|NCT01619189|Limbal stem cell
272280|NCT01619189|Transplantation
272281|NCT01619176|Rheumatoid Arthritis
272282|NCT01619176|blood
272283|NCT01619176|gut intestinal microbiome
272284|NCT01619163|Prednisolone,
272285|NCT01619163|pain,
272286|NCT01619163|inflammation,
272287|NCT01619163|mobility
272288|NCT01619163|Function
272289|NCT01619150|knee
272290|NCT01619150|osteoarthritis
272291|NCT01619150|central sensitization
272292|NCT01619150|mechanical detection
272293|NCT01619150|pain threshold
272294|NCT01619150|quantitative sensory testing
272295|NCT01619150|pain biomarkers
272296|NCT01619150|COX-2 inhibitors
272297|NCT01619150|etoricoxib.
272298|NCT01619137|ununion wound
272299|NCT01619137|soap
272300|NCT01619137|irrigation
272301|NCT01619137|Povidone-iodine
272302|NCT01619137|normal salin
272303|NCT01619124|osteonecrosis
272304|NCT01619124|children
272305|NCT01619124|pediatric
272306|NCT01619124|acute lymphoblastic leukaemia
272307|NCT01619124|lymphoblastic lymphoma
272308|NCT01619111|metastatic breast cancer
272309|NCT01619111|circulating tumor cells
272310|NCT01619111|lapatinib
272311|NCT01619098|Hospital readmission
272312|NCT01619098|Care transition
272313|NCT01619098|Discharge-transfer intervention
272314|NCT01619098|Community health worker
272315|NCT01619098|Patient Navigatgor
272316|NCT01619072|postpartum hemorrhage
272317|NCT01619072|treatment
272318|NCT01619072|misoprostol
272319|NCT01619072|home births
272320|NCT01619046|GreenGene™F, Previously Treated Patients
272321|NCT01619033|Renal impairment
272322|NCT01619020|Healthy
272323|NCT01619020|Colon
272324|NCT01619007|Treatment of Venous Thromboembolism
272325|NCT01619007|Thromboembolism
272326|NCT01619007|Venous Thromboembolism
272327|NCT01619007|Embolism and Thrombosis
272328|NCT01619007|Vascular Diseases
272329|NCT01619007|Cardiovascular Diseases
272330|NCT01619007|Thrombosis
272331|NCT01618994|Robotic Simulator
272332|NCT01618994|EBL
272333|NCT01618994|Robotic Surgeons
272334|NCT01618994|Intuitive Surgical
272335|NCT01618994|simulation modules
272336|NCT01618994|benchmarks
272337|NCT01618994|Morristown Protocol
272338|NCT01618994|Study Surgeons
272339|NCT01618994|Control Surgeons
272340|NCT01618994|Expert Surgeons
272341|NCT01618994|dual-console daVinci system
272342|NCT01618994|blinded skill assessment
272343|NCT01618981|Heart failure with preserved ejection fraction
272344|NCT01618981|atrial dyssynchrony syndrome
272345|NCT01618981|left atrio-ventricular asynchrony
272346|NCT01618981|pacemaker
272347|NCT01618981|left atrial pacing therapy
272348|NCT01618929|Food allergy
272349|NCT01618929|Asthma
272350|NCT01618929|Children
272351|NCT01618929|Montelukast
272352|NCT01618929|Inflammation
272353|NCT01618903|Keppra Levetiracetam intravenous
272354|NCT01618903|Oral tablets
272355|NCT01618903|Bioequivalence
272356|NCT01618903|Pharmacokinetics
272357|NCT01618903|Safety
272358|NCT01618903|Chinese healthy volunteers
272359|NCT01618890|Prevention
272360|NCT01618890|Esophageal variceal bleeding
272361|NCT01618890|Hepatic Venous Pressure Gradient
272362|NCT01618890|Betablocker therapy
272363|NCT01618877|Keppra Levetiracetam intravenous
272364|NCT01618877|Multiple dose
272365|NCT01618877|Safety
272366|NCT01618877|Pharmacokinetics
272367|NCT01618877|Chinese healthy volunteers
272368|NCT01618851|prostate cancer
272369|NCT01618838|prostate cancer
272370|NCT01618812|Artificial bone graft
272371|NCT01618812|Hydroxyapatite
272372|NCT01618812|Children
272373|NCT01618812|Osteotomy
272374|NCT01618812|Pes plano valgus
272375|NCT01618812|Flatfeet
272376|NCT01618786|Falls
272377|NCT01618786|Fall injuries
272378|NCT01618786|Bone fracture
272379|NCT01618786|Hip fracture
272380|NCT01618786|Skull fracture
272381|NCT01618786|Wounds
272382|NCT01618786|Closed head injury
272383|NCT01618786|Traumatic brain injury
272384|NCT01618786|Concussion
272385|NCT01618786|Spinal cord injury
272386|NCT01618786|Trauma
272387|NCT01618786|Older adults
272388|NCT01618786|Long-term care
272389|NCT01618786|Compliant flooring
272390|NCT01618786|Safety floors
272391|NCT01618786|Balance
272392|NCT01618786|Injury biomechanics
272393|NCT01618786|Biomedical engineering
272394|NCT01618786|Environmental hazards
272395|NCT01618786|Environmental interventions
272396|NCT01618786|Fall prevention
272397|NCT01618786|Gerontology
272398|NCT01618773|acne
272399|NCT01618773|Epiduo
272400|NCT01618773|adapalene/ benzoyl peroxide
272401|NCT01618734|Immune Thrombocytopenia
272402|NCT01618734|Thrombopoietin receptor agonist
272403|NCT01618721|Chronic obstructive lung disease;
272404|NCT01618721|Interstitial lung disease;
272405|NCT01618721|Ultrasound Doppler;
272406|NCT01618721|Lung disease diagnosis;
272407|NCT01618695|Partial-onset Seizures
272408|NCT01618695|partial seizures
272409|NCT01618695|seizure
272410|NCT01618695|epilepsy
272411|NCT01618682|hand transplant
272412|NCT01618682|hand replant
272413|NCT01618669|Coronary Artery Disease (CAD)
272414|NCT01618669|regadenoson
272415|NCT01618669|pharmacologic stress
272416|NCT01618643|Barrett's
272417|NCT01618643|High grade dysplasia
272418|NCT01618643|HGD
272419|NCT01618643|IMC
272420|NCT01618643|Intramucosal cancer
272421|NCT01618643|Acetic acid
272422|NCT01618643|Chromoendoscopy
272423|NCT01618630|burn injury
272424|NCT01618630|children
272425|NCT01618630|nutrition
272426|NCT01618630|lipid metabolism
272427|NCT01618630|insulin sensitivity
272428|NCT01618630|amino acids
272429|NCT01618630|stable isotopes
272430|NCT01618617|Constipation
272431|NCT01618617|Probiotic
272432|NCT01618617|Randomized Controlled Trial
272433|NCT01618604|Conditioned Pain Modulation
272434|NCT01618604|Quantitative Sensory Testing
272435|NCT01618604|duration
272436|NCT01618604|correlation
272437|NCT01618591|diarrhea
272438|NCT01618591|travelers' diarrhea
272439|NCT01618591|watery diarrhea
272440|NCT01618591|enteric illness
272441|NCT01618591|dysentery
272442|NCT01618591|gastrointestinal
272443|NCT01618578|rubber hand illusion
272444|NCT01618578|CRPS
272445|NCT01618578|body image
272446|NCT01618578|body ownership
272447|NCT01618565|shoulder dystocia
272448|NCT01618565|training
272449|NCT01618565|To assess the effectiveness of hands-on training versus expert demonstration
272450|NCT01618552|Chronic disease
272451|NCT01618552|Cluster randomization
272452|NCT01618552|Comorbidity
272453|NCT01618552|Depression
272454|NCT01618552|Diabetes
272455|NCT01618552|Medical history taking
272456|NCT01618552|Office visits
272457|NCT01618552|Patient acceptance of health care
272458|NCT01618552|Patient compliance
272459|NCT01618552|Patient simulation
272460|NCT01618552|Physician patient relations
272461|NCT01618552|Primary health care
272462|NCT01618552|Randomized controlled trials
272463|NCT01618552|Self care
272464|NCT01618552|Self efficacy
272465|NCT01618539|Total intravenous anesthesia, Bispectral Index Score
272466|NCT01618526|Dietary fibers
272467|NCT01618526|Butyrate
272468|NCT01618526|Short Chain Fatty Acids
272469|NCT01618526|Colon
272470|NCT01618526|Metabolic Syndrome
272471|NCT01618513|Acromegaly
272472|NCT01618513|Somatostatin analogs
272473|NCT01618513|Treatment
272474|NCT01618500|Normal Pressure Hydrocephalus
272475|NCT01618500|Neuropsychological Test
272476|NCT01618500|Assessment of cognitive disorders/dementia
272477|NCT01618500|Neuropsychological assessment
272478|NCT01618487|tennis elbow
272479|NCT01618487|lateral epicondylitis
272480|NCT01618474|gastric cancer
272481|NCT01618474|adjuvant chemotherapy
272482|NCT01618461|Prescription drug information
272483|NCT01618461|Medication management
272484|NCT01618435|Fusion surgery
272485|NCT01618435|Degenerative olisthesis
272486|NCT01618435|i-FACTOR
272487|NCT01618435|ODI
272488|NCT01618435|Spinal stenosis
272489|NCT01618422|DOTS plus
272490|NCT01618422|DOTS
272491|NCT01618422|multidrug resistant tuberculosis (MDR TB)
272492|NCT01618409|PictureRx
272493|NCT01618409|Health Literacy
272494|NCT01618409|Limited English Proficiency
272495|NCT01618409|Latinos
272496|NCT01618409|Spanish
272497|NCT01618396|Microcirculation
272498|NCT01618396|Hypnotics and Sedatives,
272499|NCT01618396|Propofol,
272500|NCT01618396|Midazolam
272501|NCT01618383|Parkinson's disease
272502|NCT01618383|gut
272503|NCT01618383|colon
272504|NCT01618383|biopsies
272505|NCT01618383|LRRK2
272506|NCT01618370|Radium 223
272507|NCT01618370|Alpharadin
272508|NCT01618370|Prostate Cancer
272509|NCT01618370|Bone metastases
272510|NCT01618370|Castrate resistant prostate cancer
272511|NCT01618370|Hormone refractory prostate cancer
272512|NCT01618357|Veliparib
272513|NCT01618357|ABT-888
272514|NCT01618357|Radiation
272515|NCT01618357|POPI
272516|NCT01618344|neoplasms
272517|NCT01618344|adolescent
272518|NCT01618344|young adult
272519|NCT01618344|medication adherence
272520|NCT01618331|FSHD
272521|NCT01618331|Endurance exercise
272522|NCT01618331|Protein supplementation
272523|NCT01618331|Placebo RCT
272524|NCT01618318|Asthma
272525|NCT01618318|Allergy
272526|NCT01618318|Diagnosis
272527|NCT01618318|Correlation study
272528|NCT01618292|pelvic organ prolapse
272529|NCT01618292|constipation
272530|NCT01618292|bowel dysfunction
272531|NCT01618292|irritable bowel syndrome (IBS)
272532|NCT01618292|CRADI-8
272533|NCT01618292|CRAIQ-7
272534|NCT01618292|splinting with defecation
272535|NCT01618292|excessive straining
272536|NCT01618292|bowel movements
272537|NCT01618292|fecal incontinence
272538|NCT01618292|bowel symptoms
272539|NCT01618279|tryptase
272540|NCT01618279|coronary
272541|NCT01618279|stemi
272542|NCT01618279|nstemi
272543|NCT01618253|Transarterial Chemoembolization
272544|NCT01618253|TACE
272545|NCT01618253|Sorafenib Tosylate
272546|NCT01618253|Sorafenib
272547|NCT01618253|Nexavar
272548|NCT01618253|External Beam Radiation Therapy
272549|NCT01618253|Radiation Therapy
272550|NCT01618253|Radiotherapy
272551|NCT01618253|Radiation
272552|NCT01618240|FEES
272553|NCT01618240|PAS
272554|NCT01618240|VPSR
272555|NCT01618240|MRC
272556|NCT01618201|Inflammation
272557|NCT01618201|Migraine
272558|NCT01618201|Headache
272559|NCT01618175|Bronchiolitis, Viral
272560|NCT01618175|Home oxygen therapy
272561|NCT01618175|Home Nursing
272562|NCT01618175|Outcome and Process Assessment (Health Care)
272563|NCT01618175|bronchiolitis severity score
272564|NCT01618149|osteoarthritis
272565|NCT01618149|periprosthetic bone loss
272566|NCT01618149|dual energy x-ray absorptiometry
272567|NCT01618136|PARP inhibitors
272568|NCT01618136|Malignant Solid Tumour
272569|NCT01618136|ovarian cancer
272570|NCT01618136|triple negative breast cancer
272571|NCT01618136|advanced melanoma
272572|NCT01618123|Endothelial function
272573|NCT01618123|Coronary disease
272574|NCT01618123|Atherosclerosis
272575|NCT01618123|Chest pain
272576|NCT01618110|ADHD
272577|NCT01618110|Attention Deficit/Hyperactivity Disorder
272578|NCT01618110|TMS
272579|NCT01618110|Transcranial Magnetic Stimulation
272580|NCT01618097|Osteoarthritis
272581|NCT01618097|Decision Aids
272582|NCT01618097|Health Literacy
272583|NCT01618084|hipreplacement
272584|NCT01618084|uncemented
272585|NCT01618084|migration
272586|NCT01618084|boneremodeling
272587|NCT01618071|n-3 PUFA
272588|NCT01618071|Endothelial cells
272589|NCT01618071|Nitric oxide
272590|NCT01618071|Oxidative stress
272591|NCT01618071|Blood pressure
272592|NCT01618071|Vasodilation
272593|NCT01618071|Lipemia
272594|NCT01618071|Unsaturated dietary fats
272595|NCT01618058|HIV Infections
272596|NCT01618058|Anti-HIV Agents
272597|NCT01618058|HIV-1
272598|NCT01618045|Diabetes
272599|NCT01618045|FPP
272600|NCT01618045|fermented papaya preparation
272601|NCT01618019|n-3 PUFA
272602|NCT01618019|rheumatoid arthritis
272603|NCT01618019|inflammation
272604|NCT01618019|eicosanoids
272605|NCT01618019|bone turnover markers
272606|NCT01617993|in vitro fertilization
272607|NCT01617993|assisted reproduction
272608|NCT01617993|noninvasive imaging of embryos
272609|NCT01617993|time lapse imaging of embryos
272610|NCT01617993|traditional morphological grading of embryos
272611|NCT01617993|prediction of blastocysts
272612|NCT01617993|infertility
272613|NCT01617993|Genital Diseases, Male
272614|NCT01617993|Genital Diseases, Female
272615|NCT01617980|Hypoxia imaging
272616|NCT01617980|FMISO-PET
272617|NCT01617980|functional MRI
272618|NCT01617980|Intensity modulated radiation therapy
272619|NCT01617967|RNAi therapeutic
272620|NCT01617941|non-chronic migraine, migraine prevention
272621|NCT01617902|Hyperbilirubinemia
272622|NCT01617902|cardiac
272623|NCT01617902|surgery
272624|NCT01617902|aorta
272625|NCT01617902|prognosis
272626|NCT01617876|Stomach Neoplasms
272627|NCT01617876|early gastric cancer
272628|NCT01617876|magnifying endoscopy
272629|NCT01617876|narrow band imaging
272630|NCT01617876|acetic acid
272631|NCT01617876|indigocarmine
272632|NCT01617837|Postoperative nausea and vomiting
272633|NCT01617837|P6 acupressure
272634|NCT01617837|Craniotomy.
272635|NCT01617824|Diabetes
272636|NCT01617824|Kidney
272637|NCT01617824|Inflammation
272638|NCT01617824|Metabolism
272639|NCT01617772|Non-alcoholic steatohepatitis, Atorvastatin, L-Carnitine
272640|NCT01617746|Asthma
272641|NCT01617746|Endothelin
272642|NCT01617746|Airway hyperreactivity
272643|NCT01617720|mitral
272644|NCT01617720|valve
272645|NCT01617720|annuloplasty
272646|NCT01617720|mitral regurgitation
272647|NCT01617707|sedation
272648|NCT01617707|endoscopy
272649|NCT01617707|midazolam
272650|NCT01617707|propofol
272651|NCT01617707|chronic alcoholics
272652|NCT01617694|dexmedetomidine
272653|NCT01617694|remifentanil
272654|NCT01617694|target-controlled infusion
272655|NCT01617681|Hypertension; CKD; Pediatric
272656|NCT01617668|Breast cancer,
272657|NCT01617668|LCL161,
272658|NCT01617668|paclitaxel,
272659|NCT01617668|neoadjuvant,
272660|NCT01617668|triple negative breast cancer
272661|NCT01617642|Porphyria
272662|NCT01617642|Inflammation
272663|NCT01617642|Diet
272664|NCT01617642|Iron status
272665|NCT01617629|Cvac
272666|NCT01617603|diabetes type 2
272667|NCT01617603|insulin resistance
272668|NCT01617603|glycaemic control
272669|NCT01617603|Endothelial function
272670|NCT01617603|Cocoa Polyphenols
272671|NCT01617590|RA
272672|NCT01617590|Leflunomide
272673|NCT01617590|Methotrexate
272674|NCT01617577|G-CSF
272675|NCT01617577|granulocyte colony stimulating factor
272676|NCT01617577|Filgrastim
272677|NCT01617564|medical abortion
272678|NCT01617564|second trimester
272679|NCT01617564|para cervical blockage
272680|NCT01617564|pain management
272681|NCT01617551|Essential hypertension
272682|NCT01617551|Nitric oxide
272683|NCT01617551|Renal denervation
272684|NCT01617551|Sodium
272685|NCT01617551|GFR
272686|NCT01617538|atherosclerosis
272687|NCT01617538|stenosis
272688|NCT01617538|statin therapy
272689|NCT01617538|Signs and Symptoms
272690|NCT01617538|Circulatory; Change
272691|NCT01617499|physical activity
272692|NCT01617499|pedometer
272693|NCT01617499|worksite
272694|NCT01617499|wellness
272695|NCT01617499|cardiovascular
272696|NCT01617499|lifestyle program
272697|NCT01617460|Autistic Disorder, children and adolescents
272698|NCT01617460|aripiprazole
272699|NCT01617460|Long-term safety study
272700|NCT01617460|children and adolescents
272701|NCT01617447|Autistic Disorder, children and adolescents
272702|NCT01617447|Aripiprazole
272703|NCT01617447|Double-blind
272704|NCT01617447|Randomized
272705|NCT01617447|children and adolescents
272706|NCT01617421|Yoga
272707|NCT01617421|Arthritis
272708|NCT01617408|Theta Burst Stimulation
272709|NCT01617408|Transcranial Magnetic Stimulation (TMS)
272710|NCT01617408|Visual Cortex
272711|NCT01617408|Visual Processing
272712|NCT01617395|Multiple Sclerosis
272713|NCT01617395|Magnetic Resonance Imaging (MRI)
272714|NCT01617382|HIPEC
272715|NCT01617382|Hyperthermic (heated) chemotherapy after debulking
272716|NCT01617356|TMD
272717|NCT01617356|temporomandibular
272718|NCT01617356|dextrose
272719|NCT01617356|prolotherapy
272720|NCT01617330|Particulate matter
272721|NCT01617330|Air pollution
272722|NCT01617330|Diesel exhaust
272723|NCT01617330|Allergic rhinitis
272724|NCT01617317|H1N1 2009
272725|NCT01617317|hyperimmune IVIG
272726|NCT01617317|mortality
272727|NCT01617317|length of stay
272728|NCT01617317|viral load
272729|NCT01617317|cytokine
272730|NCT01617304|advanced glycation end products
272731|NCT01617304|insulin sensitivity
272732|NCT01617304|obesity
272733|NCT01617304|inflammation
272734|NCT01617304|metabolomics
272735|NCT01617304|appetite
272736|NCT01617304|CVD
272737|NCT01617291|Pre-hospital hypothermia
272738|NCT01617291|Induced therapeutic hypothermia
272739|NCT01617291|Cardiac arrest
272740|NCT01617278|Colonoscopy
272741|NCT01617278|I Scan
272742|NCT01617278|High definition white light
272743|NCT01617278|Adenomas
272744|NCT01617265|intensive care
272745|NCT01617265|mechanical ventilation
272746|NCT01617265|sedatives
272747|NCT01617265|morphinics
272748|NCT01617265|oversedation
272749|NCT01617265|mortality
272750|NCT01617265|midazolam
272751|NCT01617265|propofol
272752|NCT01617265|pain
272753|NCT01617265|agitation
272754|NCT01617252|Cardiac surgery
272755|NCT01617252|Acute respiratory failure
272756|NCT01617252|High flow oxygen therapy
272757|NCT01617239|Influenza
272758|NCT01617239|Vaccination
272759|NCT01617239|Virosomal influenza vaccine
272760|NCT01617213|Multiple Myeloma
272761|NCT01617174|prostate
272762|NCT01617174|pain assessment
272763|NCT01617174|12-110
272764|NCT01617161|Low Risk
272765|NCT01617161|Intermediate Risk
272766|NCT01617148|Exudative Macular Degeneration
272767|NCT01617148|Aflibercept
272768|NCT01617135|Parkinson's disease
272769|NCT01617135|Motor fluctuations
272770|NCT01617135|levodopa
272771|NCT01617135|inhaled drugs
272772|NCT01617135|"Motor fluctuation (off episodes)"
272773|NCT01617122|PID
272774|NCT01617122|PIDD
272775|NCT01617122|antibody deficiency
272776|NCT01617122|CVID
272777|NCT01617122|recurrent infections
272778|NCT01617109|Vitamin D
272779|NCT01617109|Calcium
272780|NCT01617109|Parathyroid hormone
272781|NCT01617109|Bone
272782|NCT01617109|Bone formation
272783|NCT01617109|Bone resorption
272784|NCT01617109|Micronutrients
272785|NCT01617109|Trace Elements
272786|NCT01617096|HIV Infections
272787|NCT01617096|Anti-HIV agents
272788|NCT01617096|HIV-1
272789|NCT01617083|PANS
272790|NCT01617083|PANDAS
272791|NCT01617083|OCD
272792|NCT01617083|Tics
272793|NCT01617083|Azithromycin
272794|NCT01617083|Antibiotic Treatment
272795|NCT01617070|Tetrahydrobiopterin
272796|NCT01617070|Kuvan
272797|NCT01617070|Phenylketonuria (PKU)
272798|NCT01617070|Large Neutral Amino Acids
272799|NCT01617070|Serotonin
272800|NCT01617070|Dopamine
272801|NCT01617070|Melatonin
272802|NCT01617057|otosclerosis
272803|NCT01617057|inner ear
272804|NCT01617057|tiludronic acid
272805|NCT01617044|Iron
272806|NCT01617044|Deficiency
272807|NCT01617044|Restless
272808|NCT01617044|Leg
272809|NCT01617031|aspirin
272810|NCT01617031|diabetes mellitus
272811|NCT01617031|coronary artery disease
272812|NCT01617018|Psoriasis; Biological therapy; Methotrexate; Cyclosporine
272813|NCT01616979|Off-pump coronary artery bypass surgery
272814|NCT01616979|Transesophageal echocardiography
272815|NCT01616966|hoarseness
272816|NCT01616966|sore throat
272817|NCT01616966|vocal cord injuries
272818|NCT01616953|dental implants
272819|NCT01616927|ADPKD
272820|NCT01616927|lanreotide
272821|NCT01616927|polycystic kidney
272822|NCT01616927|polycystic liver
272823|NCT01616914|delirium
272824|NCT01616914|outcome
272825|NCT01616901|Obese
272826|NCT01616901|Intensive Care
272827|NCT01616901|Respiratory weaning
272828|NCT01616901|Spontaneous Breathing trial
272829|NCT01616901|Work of breathing
272830|NCT01616888|drug eluting balloon with paclitaxel
272831|NCT01616888|in stent restenosis
272832|NCT01616888|femoropopliteal arteries
272833|NCT01616888|angioplasty
272834|NCT01616875|Bladder cancer
272835|NCT01616875|Transitional cell carcinoma
272836|NCT01616875|Urothelial cancer
272837|NCT01616875|Cisplatin
272838|NCT01616875|Cabazitaxel
272839|NCT01616875|Chemotherapy
272840|NCT01616875|Neo adjuvant chemotherapy
272841|NCT01616862|Pseudomonas aeruginosa
272842|NCT01616862|cystic fibrosis
272843|NCT01616823|Human immunodeficiency virus (HIV) positive women
272844|NCT01616810|urinary tract
272845|NCT01616784|Adult
272846|NCT01616784|Diabetes Mellitus
272847|NCT01616784|Type 1
272848|NCT01616784|Humans
272849|NCT01616784|Hypoglycemic Agents
272850|NCT01616784|Administration and Dosage
272851|NCT01616784|Insulin
272852|NCT01616784|Self Care
272853|NCT01616784|Health Education
272854|NCT01616784|Insulin Infusion Systems
272855|NCT01616784|Randomised controlled trial
272856|NCT01616784|Patient Education as Topic
272857|NCT01616784|Hemoglobin A
272858|NCT01616784|Glycosylated
272859|NCT01616771|laryngoscopes
272860|NCT01616745|NTM Lung disease
272861|NCT01616745|NTM Lung disease patients enrolled in SNUH
272862|NCT01616693|rotavirus
272863|NCT01616693|polio
272864|NCT01616693|zinc supplement
272865|NCT01616693|probiotic supplement
272866|NCT01616693|rotavirus vaccine shedding
272867|NCT01616667|Controlled Clinical Trial
272868|NCT01616667|Operative Surgical Procedures
272869|NCT01616667|Treatment Outcome
272870|NCT01616667|Pain Measurement
272871|NCT01616667|Quality of Life
272872|NCT01616667|Questionnaires/standards
272873|NCT01616667|Activities of Daily Living
272874|NCT01616667|Biomechanics
272875|NCT01616667|Gait*
272876|NCT01616667|Hip Joint/physiology*
272877|NCT01616667|Hip Joint/surgery*
272878|NCT01616667|Recovery of Function/physiology
272879|NCT01616641|rheumatoid arthritis
272880|NCT01616641|bite force
272881|NCT01616641|grip strenght
272882|NCT01616641|oral health
272883|NCT01616641|quality of life
272884|NCT01616628|Incentives
272885|NCT01616628|Fruit
272886|NCT01616628|Vegetables
272887|NCT01616602|patients
272888|NCT01616602|presenting
272889|NCT01616602|elective
272890|NCT01616602|colonoscopy.
272891|NCT01616589|Fragile X syndrome
272892|NCT01616589|Fragile X full mutation
272893|NCT01616589|Fragile X premutation
272894|NCT01616589|Fragile X intermediate
272895|NCT01616589|CGG repeat length
272896|NCT01616576|cochlear implant
272897|NCT01616576|adults
272898|NCT01616576|HiResolution™
272899|NCT01616576|Fidelity 120™
272900|NCT01616576|listening benefits
272901|NCT01616576|noise
272902|NCT01616576|cochlear implant benefit
272903|NCT01616563|central obesity
272904|NCT01616563|abdominal obesity
272905|NCT01616563|hypertension
272906|NCT01616563|cardiovascular disease
272907|NCT01616563|high cholesterol
272908|NCT01616563|high triglycerides
272909|NCT01616563|insulin resistance
272910|NCT01616563|diabetes mellitus
272911|NCT01616550|analgesia
272912|NCT01616550|thoracic surgery
272913|NCT01616537|solid tumors
272914|NCT01616537|hematological malignancy
272915|NCT01616472|hypertension
272916|NCT01616472|avascular necrosis
272917|NCT01616472|systemic lupus erythematosus
272918|NCT01616472|osteoporosis
272919|NCT01616472|Steroid
272920|NCT01616472|diabetes
272921|NCT01616472|cataracts
272922|NCT01616459|Streptococcus pneumoniae
272923|NCT01616459|Haemophilus influenzae
272924|NCT01616459|Pneumococcal vaccine
272925|NCT01616459|Infants
272926|NCT01616459|Safety
272927|NCT01616459|Immunogenicity
272928|NCT01616446|cyclosporin
272929|NCT01616446|nephrotic syndrome
272930|NCT01616446|pharmacokinetics
272931|NCT01616446|children
272932|NCT01616433|Arthritis
272933|NCT01616433|Preventive Behaviors
272934|NCT01616420|HIV
272935|NCT01616420|prevention
272936|NCT01616420|treatment
272937|NCT01616420|cost-effectiveness
272938|NCT01616420|assisted partner notification services
272939|NCT01616420|Kenya
272940|NCT01616420|linkage to HIV care
272941|NCT01616420|case-finding
272942|NCT01616407|Effects of psychostimulants on emotion recognition and empathy
272943|NCT01616355|denture, complete;
272944|NCT01616355|sodium hypochlorite;
272945|NCT01616355|disinfection;
272946|NCT01616355|surface roughness;
272947|NCT01616355|color stability.
272948|NCT01616329|alloimmunization
272949|NCT01616329|RBC
272950|NCT01616329|clinicalfactors
272951|NCT01616329|Risk
272952|NCT01616303|ovarian
272953|NCT01616303|cancer
272954|NCT01616303|neoplasm
272955|NCT01616303|adenocarcinoma
272956|NCT01616303|CA125
272957|NCT01616290|peripheral artery disease
272958|NCT01616290|PAD
272959|NCT01616290|claudication
272960|NCT01616290|angioplasty
272961|NCT01616290|percutaneous transluminal angioplasty
272962|NCT01616290|PTA
272963|NCT01616290|superficial femoral artery
272964|NCT01616290|SFA
272965|NCT01616290|popliteal artery
272966|NCT01616290|PA
272967|NCT01616290|PRT-201
272968|NCT01616290|restenosis
272969|NCT01616290|vonapanitase
272970|NCT01616264|Tuberculosis
272971|NCT01616264|Pleural Effusion
272972|NCT01616264|Computed Tomography
272973|NCT01616251|Protein sources
272974|NCT01616251|Appetite
272975|NCT01616251|Dietary fibers
272976|NCT01616251|Meat
272977|NCT01616251|Egg
272978|NCT01616251|Legumes
272979|NCT01616225|Infertility
272980|NCT01616225|Poor Responder
272981|NCT01616225|In Vitro Fertilization
272982|NCT01616225|Growth Hormone
272983|NCT01616212|Teens
272984|NCT01616212|Parenting
272985|NCT01616212|Substance Abuse
272986|NCT01616212|Treatment Efficacy
272987|NCT01616199|PX-866
272988|NCT01616199|BRAF-mutant cancers
272989|NCT01616199|Advanced melanoma
272990|NCT01616199|BRAF inhibitor
272991|NCT01616199|Vemurafenib
272992|NCT01616199|Zelboraf
272993|NCT01616199|PI-3K inhibitor
272994|NCT01616186|Renal Cell Carcinoma
272995|NCT01616173|Nerve Block
272996|NCT01616173|Anesthesia Recovery Period
272997|NCT01616160|Nasal polyps
272998|NCT01616147|Intensive Lifestyle Intervention
272999|NCT01616134|overweight,
273000|NCT01616134|ginseng
273001|NCT01616108|strabismus
273002|NCT01616108|diplopia
273003|NCT01616095|Growth hormone deficiency
273004|NCT01616095|hrGH therapy
273005|NCT01616095|metabolic health
273006|NCT01616095|adipose tissue metabolism
273007|NCT01616095|adipose tissue inflammation
273008|NCT01616095|adipokines
273009|NCT01616082|fatty acid oxidation
273010|NCT01616082|Proton magnetic resonance spectroscopy
273011|NCT01616069|CABG
273012|NCT01616069|Echocardiography
273013|NCT01616069|Heart Failure
273014|NCT01616069|Heart Function
273015|NCT01616056|Chronic graft-versus-host disease
273016|NCT01616056|eye
273017|NCT01616043|scar quality
273018|NCT01616030|Hip fractures
273019|NCT01616030|Strength training
273020|NCT01616017|Cardiac output
273021|NCT01616017|ultrasound dilution
273022|NCT01616017|thermodilution
273023|NCT01615965|prostate cancer
273024|NCT01615965|lymph node
273025|NCT01615965|micrometastasis
273026|NCT01615952|Supraclavicular Block
273027|NCT01615939|Sciatic Nerve Block
273028|NCT01615939|Continuous Nerve Block
273029|NCT01615926|dyspnea
273030|NCT01615926|shortness of breath
273031|NCT01615926|respiratory rate
273032|NCT01615926|orthopnea
273033|NCT01615913|onychomycosis
273034|NCT01615913|terbinafine
273035|NCT01615913|ketoconazole
273036|NCT01615913|transdermal topical therapy
273037|NCT01615900|Renal graft
273038|NCT01615900|Teleconsultation
273039|NCT01615900|Kidney transplant failure score
273040|NCT01615848|polycystic Ovary syndrome (PCOS)
273041|NCT01615848|diet
273042|NCT01615848|mediterranean diet
273043|NCT01615848|high protein diet
273044|NCT01615822|Malaria
273045|NCT01615822|PK
273046|NCT01615822|OZ439
273047|NCT01615822|Mefloquine
273048|NCT01615822|Healthy Volunteers
273049|NCT01615809|Invasive pulmonary aspergillosis
273050|NCT01615809|IFI
273051|NCT01615809|Leukaemia
273052|NCT01615809|Leukemia
273053|NCT01615809|Pediatric
273054|NCT01615809|Paediatrics
273055|NCT01615809|Amphotericin B
273056|NCT01615809|Aspergillosis
273057|NCT01615809|Pulmonary Aspergillosis
273058|NCT01615809|Invasive Aspergillosis
273059|NCT01615809|Antifungal agents
273060|NCT01615809|Fungal infections
273061|NCT01615809|Invasive Fungal Infection
273062|NCT01615796|GSK2140944
273063|NCT01615796|antibiotics
273064|NCT01615796|first time in human
273065|NCT01615796|pharmacokinetics
273066|NCT01615796|intravenous
273067|NCT01615796|safety
273068|NCT01615796|absolute bioavailability
273069|NCT01615796|Bacterial Type II
273070|NCT01615796|tolerability
273071|NCT01615796|infection
273072|NCT01615783|Chronic Obstructive Pulmonary Disease
273073|NCT01615783|Costs
273074|NCT01615783|Resource utilization
273075|NCT01615783|Medicaid
273076|NCT01615757|AML
273077|NCT01615757|Acute Myeloid Leukemia
273078|NCT01615757|Cytarabine dose
273079|NCT01615757|Ara-c dose
273080|NCT01615757|Consolidation
273081|NCT01615744|calcaneal fractures
273082|NCT01615744|surgical treatment
273083|NCT01615744|conservative treatment
273084|NCT01615744|VAS scoring
273085|NCT01615744|SF-36
273086|NCT01615744|AOFAS
273087|NCT01615744|Olerud-Molander score
273088|NCT01615744|outcome
273089|NCT01615731|Mifepristone
273090|NCT01615731|Induced Abortion
273091|NCT01615731|Dilation and Evacuation
273092|NCT01615731|Cervical preparation
273093|NCT01615731|Osmotic dilators
273094|NCT01615718|noninvasive stimulation
273095|NCT01615718|motor function
273096|NCT01615718|transcranial stimulation
273097|NCT01615718|transcranial ultrasound
273098|NCT01615718|brain stimulation
273099|NCT01615705|Postphlebitic Syndrome
273100|NCT01615705|Post-Thrombotic Syndrome
273101|NCT01615705|Biomarkers
273102|NCT01615705|Markers of Inflammation
273103|NCT01615705|Genetic Thrombophilia
273104|NCT01615705|Coagulation Activation
273105|NCT01615692|Elastic Stockings
273106|NCT01615692|Stockings, Compression
273107|NCT01615692|Randomized Controlled Trials
273108|NCT01615692|Quality of Life
273109|NCT01615679|Non-interventional study
273110|NCT01615679|Attention Deficit/Hyperactivity Disorder
273111|NCT01615679|ADHD
273112|NCT01615666|Alzheimer's disease
273113|NCT01615666|Mild Cognitive Impairment
273114|NCT01615666|Frontotemporal dementia
273115|NCT01615666|fMRI
273116|NCT01615666|functional neuroimaging
273117|NCT01615666|Memory
273118|NCT01615653|Pancreatic cancer
273119|NCT01615653|Pancreas cancer
273120|NCT01615653|Pain
273121|NCT01615653|Celiac Plexus
273122|NCT01615653|Neurolysis
273123|NCT01615640|Osteosarcoma
273124|NCT01615640|Response of chemotherapy
273125|NCT01615640|Dynamic contrast medium examination
273126|NCT01615640|Diffusion-weighted MR imaging
273127|NCT01615627|Subcutaneous Treprostinil
273128|NCT01615614|Rilpivirine
273129|NCT01615614|Rifabutin
273130|NCT01615614|Pharmacokinetics
273131|NCT01615614|Healthy participants
273132|NCT01615601|Human Immunodeficiency Virus
273133|NCT01615601|HIV
273134|NCT01615601|HIV-1
273135|NCT01615601|HIV type 1
273136|NCT01615601|Darunavir
273137|NCT01615601|PREZISTA
273138|NCT01615601|Etravirine
273139|NCT01615601|INTELENCE
273140|NCT01615601|HIV symptom Distress Module
273141|NCT01615601|HIV-SDM
273142|NCT01615601|Antiretroviral therapy
273143|NCT01615601|HIV Symptom Index (HSI),
273144|NCT01615588|manuka honey
273145|NCT01615588|glycaemic index
273146|NCT01615588|blood glucose control
273147|NCT01615588|individuals
273148|NCT01615588|current disease
273149|NCT01615588|medication use
273150|NCT01615562|Polycystic Ovary Syndrome
273151|NCT01615562|PCOS
273152|NCT01615562|Infertility
273153|NCT01615549|Cholecystectomy
273154|NCT01615549|Virtual reality device
273155|NCT01615549|Training
273156|NCT01615536|chronic rhinosinusitis
273157|NCT01615536|canine fossa trephine
273158|NCT01615536|canine fossa puncture
273159|NCT01615523|Executive functions
273160|NCT01615497|cognitive behavior therapy
273161|NCT01615497|computer assisted instruction
273162|NCT01615497|alcohol abuse therapy
273163|NCT01615497|educational resource design and development
273164|NCT01615484|Lung Transplant
273165|NCT01615484|Emphysema
273166|NCT01615484|Chronic Obstructive Pulmonary Disease (COPD)
273167|NCT01615484|Cystic Fibrosis
273168|NCT01615484|Pulmonary Fibrosis
273169|NCT01615484|Bronchiectasis
273170|NCT01615484|Sarcoidosis
273171|NCT01615484|Pulmonary Hypertension
273172|NCT01615484|Alpha-1 Antitrypsin Deficiency
273173|NCT01615471|Obesity
273174|NCT01615471|Lifestyle Intervention
273175|NCT01615471|Group treatment
273176|NCT01615471|Internet Intervention
273177|NCT01615458|Care Management
273178|NCT01615458|Implementation
273179|NCT01615458|Intervention
273180|NCT01615458|Mood Disorders
273181|NCT01615380|smoking cessation
273182|NCT01615380|Aerobic Exercise
273183|NCT01615380|Women
273184|NCT01615380|YMCA
273185|NCT01615367|Bipolar disorder
273186|NCT01615367|Nutrition
273187|NCT01615367|Exercise
273188|NCT01615367|Symptoms
273189|NCT01615367|Functioning
273190|NCT01615341|Kidney transplantation
273191|NCT01615341|Subclinical Viral Infection
273192|NCT01615341|Renal Allograft Injury
273193|NCT01615328|anterior cervical discectomy and fusion
273194|NCT01615328|bone graft substitute
273195|NCT01615328|PEEK cage
273196|NCT01615328|hydroxyapatite
273197|NCT01615328|demineralized bone matrix
273198|NCT01615328|b-tricalcium phosphate
273199|NCT01615328|Bonion
273200|NCT01615328|Cervios ChronOs
273201|NCT01615315|aspirin
273202|NCT01615315|screening
273203|NCT01615315|microscopic hematuria
273204|NCT01615302|Rectal Fistula
273205|NCT01615302|Peri-anal Fistula
273206|NCT01615302|Platelet-Rich Plasma
273207|NCT01615302|Mucosa advancement flap
273208|NCT01615276|Neuromuscular Electrical Stimulation
273209|NCT01615276|Ageing
273210|NCT01615276|Protein ingestion
273211|NCT01615263|Video-assisted thoracoscopic surgery (VATS)
273212|NCT01615263|One lung ventilation
273213|NCT01615263|Bronchial blocker
273214|NCT01615263|Lung collapse
273215|NCT01615263|Double lumen tube
273216|NCT01615224|missed abortion
273217|NCT01615224|miscarriage
273218|NCT01615211|Abortion
273219|NCT01615211|medical abortion
273220|NCT01615211|termination of pregnancy
273221|NCT01615211|Mifepristone
273222|NCT01615211|misoprostol
273223|NCT01615211|letrozole
273224|NCT01615211|trilostane
273225|NCT01615211|femara
273226|NCT01615211|Modrenal
273227|NCT01615198|Hypertension, blood pressure, LCZ696, dual inhibitor, neprilysin, NEP inhibition, vasopeptidase, ARNi, angiotensin receptor
273228|NCT01615185|schizophrenia
273229|NCT01615185|amisulpride
273230|NCT01615185|sulpiride
273231|NCT01615185|antipsychotic combination
273232|NCT01615159|Sodium
273233|NCT01615159|Diet
273234|NCT01615159|Urinary sodium excretion
273235|NCT01615159|Feeding study
273236|NCT01615159|Diet maintenance
273237|NCT01615146|Myelodysplasia
273238|NCT01615146|Leukemia
273239|NCT01615146|Thrombocytopenia
273240|NCT01615146|Platelet
273241|NCT01615146|transfusions
273242|NCT01615146|Outpatient
273243|NCT01615081|Malt extract
273244|NCT01615081|carbohydrate
273245|NCT01615081|glucose response
273246|NCT01615081|insulin response
273247|NCT01615081|Appetite
273248|NCT01615081|Appetite regulating hormones
273249|NCT01615055|Chemotherapy
273250|NCT01615055|Cognitive
273251|NCT01615055|Prozac
273252|NCT01615055|Fluoxetine
273253|NCT01615055|FDG
273254|NCT01615055|PET
273255|NCT01615042|Acute Leukemia
273256|NCT01615042|Bone Marrow Transplant
273257|NCT01615042|High Dose Lenalidomide
273258|NCT01615029|Multiple Myeloma
273259|NCT01615029|Daratumumab
273260|NCT01615029|Lenalidomide
273261|NCT01615029|Dexamethasone
273262|NCT01615029|Dose-escalation
273263|NCT01615029|Relapsed multiple myeloma
273264|NCT01615029|Relapsed and refractory multiple myeloma
273265|NCT01615016|Preterm infant
273266|NCT01615016|Surfactant application
273267|NCT01615016|Respiratory Distress Syndrome
273268|NCT01615016|Minimally invasive Surfactant Application
273269|NCT01615016|INSURE (Intubate-Surfactant-Extubate)
273270|NCT01615003|MicroRNA
273271|NCT01615003|coronary heart disease
273272|NCT01615003|unstable angina
273273|NCT01615003|blood stasis syndrome
273274|NCT01615003|Xuesaitong soft capsule
273275|NCT01614977|nontuberculous mycobacteria
273276|NCT01614977|corticosteroids
273277|NCT01614977|children
273278|NCT01614977|lymphadeniti
273279|NCT01614977|Therapeutic intervention in immunocompetent children with nontuberculous mycobacterial lymphadenitis.
273280|NCT01614964|Plasmodium falciparum
273281|NCT01614964|pharmacokinetics
273282|NCT01614964|antimalarials (antimalarial drugs)
273283|NCT01614964|chloroquine (chloroquine-resistant)
273284|NCT01614964|QT (QTc) interval
273285|NCT01614938|Nasopharyngeal carcinoma
273286|NCT01614938|Locally advanced
273287|NCT01614938|Cetuximab
273288|NCT01614938|Weekly cisplatin chemotherapy
273289|NCT01614938|Intensity-modulated radiotherapy
273290|NCT01614886|Rivastigmine, Alzheimer's disease, Transdermal patch
273291|NCT01614873|Breathing Pattern
273292|NCT01614873|Mechanical Ventilation
273293|NCT01614873|Pressure support ventilation
273294|NCT01614873|Neurally Adjusted Ventilatory Assist
273295|NCT01614860|Aldosterone
273296|NCT01614860|Echocardiography
273297|NCT01614860|Neurohormones
273298|NCT01614847|dry eye
273299|NCT01614847|artificial tears
273300|NCT01614847|tear osmolarity
273301|NCT01614847|residence time
273302|NCT01614834|urticaria
273303|NCT01614834|disease control
273304|NCT01614834|severity
273305|NCT01614834|test
273306|NCT01614821|Relapsed
273307|NCT01614821|Refractory
273308|NCT01614743|Rosacea
273309|NCT01614730|EMS
273310|NCT01614730|Modified Device
273311|NCT01614717|Hypertrophic Obstructive Cardiomyopathy
273312|NCT01614717|Cardiac Resynchronization Therapy
273313|NCT01614704|Breast cancer
273314|NCT01614704|Fertility
273315|NCT01614678|myopia
273316|NCT01614665|Transplant
273317|NCT01614665|Prograf
273318|NCT01614665|Heart
273319|NCT01614665|Advagraf
273320|NCT01614665|Tacrolimus
273321|NCT01614665|Immunosuppression
273322|NCT01614665|Kidney
273323|NCT01614665|Liver
273324|NCT01614665|Pharmacokinetic
273325|NCT01614665|Pediatric
273326|NCT01614652|Congestive Heart Failure Due to LV Systolic Dysfunction
273327|NCT01614639|Acupuncture
273328|NCT01614639|fMRI
273329|NCT01614639|CLBP
273330|NCT01614639|Pain
273331|NCT01614639|Low Back Pain
273332|NCT01614639|Back Pain
273333|NCT01614626|HIV
273334|NCT01614626|Alcohol Use
273335|NCT01614626|Microbial Translocation
273336|NCT01614626|Inflammation
273337|NCT01614626|Altered Coagulation
273338|NCT01614626|Russia
273339|NCT01614600|contact lens
273340|NCT01614600|dry eye syndrome
273341|NCT01614600|symptomatic
273342|NCT01614600|daily disposable
273343|NCT01614600|myopia
273344|NCT01614587|pelvic organ prolapse
273345|NCT01614587|recurrence of pelvic organ prolapse
273346|NCT01614587|genetic predisposition
273347|NCT01614587|SNP microarray analysis
273348|NCT01614587|pelvic floor
273349|NCT01614587|genetic factors
273350|NCT01614587|adequate prolapse repair
273351|NCT01614587|polymorphisms
273352|NCT01614587|surgical failure
273353|NCT01614587|reoperation
273354|NCT01614587|DNA
273355|NCT01614587|buccal swabs
273356|NCT01614587|TaqMan SNP allelic discriminiation assays
273357|NCT01614587|duplex real-time PCR
273358|NCT01614587|genome-wide SNP microarrays
273359|NCT01614587|next-generation sequencing
273360|NCT01614561|Hypercholesterolemia
273361|NCT01614561|Lipid lowering drugs
273362|NCT01614561|Cholesterol level in blood
273363|NCT01614561|Target cholesterol levels guidelines for the management of high blood cholesterol
273364|NCT01614548|Prostatic Neoplasms
273365|NCT01614548|Prostate Cancer
273366|NCT01614548|Disease Management
273367|NCT01614548|Rural
273368|NCT01614548|Urban
273369|NCT01614522|Metastatic gastro-oesophageal carcinoma
273370|NCT01614522|Recurrent gastro-oesophageal carcinoma
273371|NCT01614522|Gastric cancer
273372|NCT01614522|HER-1
273373|NCT01614522|HER-2
273374|NCT01614509|branch retinal vein occlusion
273375|NCT01614509|bevacizumab
273376|NCT01614509|triamcinolone acetonide
273377|NCT01614483|Vitamin A deficiency
273378|NCT01614483|Biofortification
273379|NCT01614483|Cassava
273380|NCT01614483|B-carotene
273381|NCT01614483|School children
273382|NCT01614483|Kenya
273383|NCT01614431|renal function
273384|NCT01614431|before and after N acetyl cysteine
273385|NCT01614431|Cystinosis patients
273386|NCT01614405|PBC
273387|NCT01614392|Resistance Exercise
273388|NCT01614392|Physical Activity
273389|NCT01614392|Mobility disability
273390|NCT01614392|Physical function
273391|NCT01614392|Muscle Strength
273392|NCT01614392|Older Adults
273393|NCT01614392|Mobility-Limited
273394|NCT01614392|Peak power and strength
273395|NCT01614366|amlodipine
273396|NCT01614366|DMTA07
273397|NCT01614366|hypertension
273398|NCT01614353|Multiple Chronic Conditions
273399|NCT01614353|Older Adults
273400|NCT01614353|New Prescription
273401|NCT01614340|Home care
273402|NCT01614340|Cognitive-Behavioral techniques
273403|NCT01614340|Physical Therapy
273404|NCT01614340|Pain
273405|NCT01614340|Older Adults
273406|NCT01614327|Diabetes Type One
273407|NCT01614327|Diabetes Type Two
273408|NCT01614327|PreDiabetes
273409|NCT01614327|Retinal Screening
273410|NCT01614327|RiskAnalyzer
273411|NCT01614327|Retinal Imaging
273412|NCT01614327|Algorithm
273413|NCT01614327|Diabetic Retinopathy
273414|NCT01614327|Microaneurysms
273415|NCT01614327|Neovascularization
273416|NCT01614327|Intraretinal microvascular abnormalities
273417|NCT01614314|Preceptorship, simulation, nursing, catheters
273418|NCT01614301|advanced Melanoma
273419|NCT01614288|HTO
273420|NCT01614288|Arthroscopy
273421|NCT01614288|Quality-of-Life
273422|NCT01614288|Gait Analysis
273423|NCT01614275|Autism
273424|NCT01614275|Early Intervention
273425|NCT01614275|Parent Training
273426|NCT01614275|EIBI
273427|NCT01614275|Applied Behavior Analysis
273428|NCT01614249|Omega-3
273429|NCT01614249|EPA
273430|NCT01614249|Depression
273431|NCT01614249|HIV infected
273432|NCT01614249|Pregnant women
273433|NCT01614236|pregabalin
273434|NCT01614236|analgesia
273435|NCT01614236|postoperative pain
273436|NCT01614236|orthopedic oncology patients
273437|NCT01614223|Plantar fasciitis
273438|NCT01614223|Autologous Conditioned Plasma
273439|NCT01614197|Relapse
273440|NCT01614197|Lymphoblastic
273441|NCT01614197|Leukemia
273442|NCT01614197|Refractory
273443|NCT01614197|Temsirolimus
273444|NCT01614197|Acute
273445|NCT01614197|Childhood
273446|NCT01614197|Pediatric
273447|NCT01614197|ALL
273448|NCT01614197|NHL
273449|NCT01614197|LL
273450|NCT01614197|PTL
273451|NCT01614171|osteoporosis pseudoglioma
273452|NCT01614171|OPPG
273453|NCT01614171|growth hormone
273454|NCT01614171|osteoporosis
273455|NCT01614158|N-AION
273456|NCT01614158|perimetry
273457|NCT01614158|visual field loss
273458|NCT01614158|Mean Defect
273459|NCT01614158|Total Loss Volume
273460|NCT01614158|D-BCVA
273461|NCT01614158|RAPD
273462|NCT01614158|retinal nerve fibre thickness/volume
273463|NCT01614158|optic nerve head
273464|NCT01614132|medulloblastoma
273465|NCT01614132|CNS
273466|NCT01614132|malignant neoplasm
273467|NCT01614132|NOA
273468|NCT01614132|neuroectodermal tumor
273469|NCT01614132|Vincristin
273470|NCT01614132|CCNU
273471|NCT01614132|Cisplatin
273472|NCT01614119|Cerebral
273473|NCT01614119|Oxygenation
273474|NCT01614119|Performance
273475|NCT01614119|Exercise
273476|NCT01614106|HIV/AIDS
273477|NCT01614106|Drug Users
273478|NCT01614106|Crack-Cocaine Use
273479|NCT01614106|HIV Primary Care
273480|NCT01614093|Schizophrenia
273481|NCT01614093|Appetite
273482|NCT01614093|Oxytocin
273483|NCT01614080|Stroke
273484|NCT01614080|Ischemic stroke
273485|NCT01614080|thrombolysis
273486|NCT01614080|toxicity of t-PA
273487|NCT01614067|DOR
273488|NCT01614067|Infertility
273489|NCT01614067|IVF
273490|NCT01614067|ART
273491|NCT01614067|GnRHa
273492|NCT01614067|GnRH Antagonist Protocol
273493|NCT01614067|Ganirelix
273494|NCT01614054|Smoking cessation
273495|NCT01614054|Nicotine replacement therapy
273496|NCT01614054|NRT
273497|NCT01614054|Inpatient
273498|NCT01614054|General Medicine
273499|NCT01614041|Generalized Anxiety Disorder
273500|NCT01614015|Recording
273501|NCT01614015|Supervision
273502|NCT01614015|Observation
273503|NCT01614002|carcinoma
273504|NCT01614002|breast cancer
273505|NCT01614002|non-small cell lung cancer
273506|NCT01614002|prostata cancer
273507|NCT01614002|adenocarcinoma of the stomach
273508|NCT01614002|squamous cell carcinoma of the head and neck region
273509|NCT01614002|ambulant chemotherapy
273510|NCT01614002|treatment cycles
273511|NCT01614002|Docetaxel
273512|NCT01614002|Doce onkovis
273513|NCT01614002|Quantity of Docetaxel
273514|NCT01614002|Packaging Sizes
273515|NCT01613989|Hip arthroplasty
273516|NCT01613989|navigation
273517|NCT01613976|Myelodysplastic Syndromes
273518|NCT01613976|MDS
273519|NCT01613976|Chronic Myelomonocytic Leukemia
273520|NCT01613976|CMML
273521|NCT01613976|Acute Myeloid Leukemia
273522|NCT01613976|AML
273523|NCT01613976|Panobinostat
273524|NCT01613976|LBH589
273525|NCT01613976|5-Aza
273526|NCT01613976|Azacitidine
273527|NCT01613963|Uveitis
273528|NCT01613963|Scleritis
273529|NCT01613950|gastric cancer advanced gastric or metastatic gastric cancer PI3K PIK3CA mutation Her2 amplification HSP90 inhibitor PI3K inhibitor PIK3CA amplification
273530|NCT01613937|Latinas
273531|NCT01613937|Gestational Diabetes
273532|NCT01613937|Prevention
273533|NCT01613911|Epilepsy
273534|NCT01613911|Invasive monitoring
273535|NCT01613911|Human sensory perception
273536|NCT01613898|Cerebrotendinous xanthomatosis (CTX),
273537|NCT01613898|lipoprotein,atherosclerosis,
273538|NCT01613898|carotid artery intima-media thickness (cIMT).
273539|NCT01613833|Alpha2 macroglobulin
273540|NCT01613833|Osteoarthritis
273541|NCT01613833|plasma and synovium
273542|NCT01613807|gestational diabetes mellitus
273543|NCT01613807|insulin analogues in pregnancy
273544|NCT01613794|Deep vein thrombosis
273545|NCT01613794|Pulmonary embolism
273546|NCT01613794|Rosuvastatin treatment
273547|NCT01613794|Pharmacologic actions
273548|NCT01613781|hemifacial spasm
273549|NCT01613781|microvascular decompression
273550|NCT01613781|neuromuscular blockade
273551|NCT01613781|electromyography
273552|NCT01613755|Effect Dipyridamole on pharmacokinetics of metformin
273553|NCT01613729|Dyslipidemia
273554|NCT01613729|Rosuvastatin
273555|NCT01613729|Efficacy
273556|NCT01613729|Safety
273557|NCT01613716|Diabetes
273558|NCT01613716|Macular Edema
273559|NCT01613716|Epiretinal Membrane
273560|NCT01613716|Vitrectomy
273561|NCT01613703|ONO-2952
273562|NCT01613703|Healthy adult subjects
273563|NCT01613703|single doe
273564|NCT01613703|PET study
273565|NCT01613703|Safety
273566|NCT01613703|Tolerability
273567|NCT01613690|Renal impairment
273568|NCT01613690|NVA237
273569|NCT01613690|Pharmacokinetics
273570|NCT01613677|advanced cervical cancer, BKM 120, progression free survival
273571|NCT01613664|obesity
273572|NCT01613664|surgical management
273573|NCT01613664|sleeve gastrectomy
273574|NCT01613638|congenital malformation
273575|NCT01613638|pollutants
273576|NCT01613586|Interstitial Cystitis
273577|NCT01613586|Bladder Pain Syndrome
273578|NCT01613586|Painful Bladder Syndrome
273579|NCT01613586|ASP3652
273580|NCT01613573|pegylated Somatropin
273581|NCT01613573|PEG-GH
273582|NCT01613573|Phase 1 study
273583|NCT01613573|Pharmacokinetics
273584|NCT01613534|chronic radiation proctopathy
273585|NCT01613534|argon plasma coagulation
273586|NCT01613534|sucralfate
273587|NCT01613521|DCE-MRI
273588|NCT01613521|18F-FMISO PET
273589|NCT01613521|11-174
273590|NCT01613495|obesity
273591|NCT01613469|fluorouracil
273592|NCT01613469|leucovorin
273593|NCT01613469|radiotherapy
273594|NCT01613469|neoadjuvant therapy
273595|NCT01613443|Dabigatran, Rivaroxaban, Point of Care-testing
273596|NCT01613417|Have confirmed or are highly suspected of brain disease
273597|NCT01613404|Chronic kidney disease
273598|NCT01613404|Hemodialysis
273599|NCT01613404|Eprex
273600|NCT01613404|Aranesp
273601|NCT01613404|ESA
273602|NCT01613404|Anemia
273603|NCT01613391|Visfatin
273604|NCT01613391|Resistin
273605|NCT01613391|Apelin
273606|NCT01613391|roux-en-y gastric bypass
273607|NCT01613391|laparoscopic adjustable gastric banding
273608|NCT01613391|morbid obesity
273609|NCT01613352|Early breast cancer surgery
273610|NCT01613352|Psychosocial wellbeing
273611|NCT01613352|Ambulatory surgery
273612|NCT01613339|stroke
273613|NCT01613339|postural control
273614|NCT01613339|body awareness therapy
273615|NCT01613326|COPD
273616|NCT01613313|Lipoma
273617|NCT01613313|Fatty Tumor
273618|NCT01613300|hodgkin
273619|NCT01613300|disease
273620|NCT01613300|ofatumumab
273621|NCT01613287|Pulmonary Hypertension
273622|NCT01613287|Pulmonary Arterial Hypertension
273623|NCT01613287|TheraSorb
273624|NCT01613287|immunoadsorption
273625|NCT01613274|colon resection
273626|NCT01613261|TAK-733,
273627|NCT01613261|alisertib,
273628|NCT01613261|MLN8237,
273629|NCT01613261|Oral MEK Inhibitor,
273630|NCT01613261|Oral Aurora A Kinase Inhibitor
273631|NCT01613235|subarachnoid hemorrhage
273632|NCT01613235|ischemia
273633|NCT01613235|vasospasm
273634|NCT01613235|CT
273635|NCT01613235|perfusion
273636|NCT01613235|induced hypertension
273637|NCT01613235|delayed cerebral ischemia
273638|NCT01613209|Hypertension
273639|NCT01613209|ABPM
273640|NCT01613209|office blood pressure
273641|NCT01613209|olmesartan
273642|NCT01613209|amlodipine
273643|NCT01613209|fixed combination
273644|NCT01613209|time of intake
273645|NCT01613196|Extrapulmonary tuberculosis
273646|NCT01613196|FDG-TEP
273647|NCT01613196|cohorts
273648|NCT01613170|Overactive Bladder
273649|NCT01613170|Vaginal Estrogen
273650|NCT01613170|Anticholinergics
273651|NCT01613170|Antimuscarinics
273652|NCT01613157|pharmacokinetics
273653|NCT01613157|HIV infected women
273654|NCT01613118|Primary FSGS
273655|NCT01613118|Nephrotic syndrome
273656|NCT01613118|Steroid Resistant
273657|NCT01613105|Diabetes Mellitus
273658|NCT01613105|Type-2
273659|NCT01613105|Acarbose
273660|NCT01613105|Drug Therapy
273661|NCT01613105|Combination
273662|NCT01613092|Arrhythmia
273663|NCT01613092|Device Procedure
273664|NCT01613092|High risk patients
273665|NCT01613092|Antibiotics
273666|NCT01613092|Infection
273667|NCT01613092|Cluster
273668|NCT01613079|Rheumatoid Arthritis
273669|NCT01613079|Methotrexate
273670|NCT01613079|Tripterygium
273671|NCT01613066|Haematological malignancies
273672|NCT01613066|Allogeneic Cord Blood transplantation
273673|NCT01613066|Intrabone
273674|NCT01613053|Gastrointestinal Stromal Tumor, GIST
273675|NCT01613014|Alcohol
273676|NCT01613014|Alcohol Dependence
273677|NCT01613014|Alcohol Abuse
273678|NCT01613014|Alcohol Use Disorders
273679|NCT01613014|Alcoholism
273680|NCT01612988|B-cell chronic lymphocytic leukemia
273681|NCT01612988|relapse
273682|NCT01612988|Bendamustine
273683|NCT01612988|Ofatumumab
273684|NCT01612988|Méthylprednisolone
273685|NCT01612975|Chest tubes
273686|NCT01612975|Length of stay
273687|NCT01612975|Pleural effusion
273688|NCT01612975|Lung resection
273689|NCT01612975|Post-operative
273690|NCT01612975|Lung cancer
273691|NCT01612949|endotracheal intubation
273692|NCT01612949|facial structure
273693|NCT01612949|Mallampati score
273694|NCT01612949|computerized facial analysis
273695|NCT01612936|Asthma
273696|NCT01612936|Allergic
273697|NCT01612936|Inflammation
273698|NCT01612936|Constriction
273699|NCT01612936|Airway
273700|NCT01612936|Challenge
273701|NCT01612936|Chemokines
273702|NCT01612923|abortion
273703|NCT01612923|medical abortion
273704|NCT01612910|estrogen receptor-negative breast cancer
273705|NCT01612910|HER2-negative breast cancer
273706|NCT01612910|progesterone receptor-negative breast cancer
273707|NCT01612910|recurrent breast cancer
273708|NCT01612910|stage II breast cancer
273709|NCT01612910|stage IIIA breast cancer
273710|NCT01612910|stage IIIB breast cancer
273711|NCT01612910|stage IIIC breast cancer
273712|NCT01612910|triple-negative breast cancer
273713|NCT01612897|autism
273714|NCT01612897|well child care
273715|NCT01612897|screening
273716|NCT01612897|computer
273717|NCT01612897|reminders
273718|NCT01612871|Breast cancer,
273719|NCT01612871|hormonotherapy,
273720|NCT01612871|miRNAs,
273721|NCT01612871|biomarkers
273722|NCT01612871|hormone therapy
273723|NCT01612858|Lipodystrophy
273724|NCT01612858|Insulin resistance
273725|NCT01612858|HIV infection
273726|NCT01612845|rotator cuff
273727|NCT01612845|shoulder
273728|NCT01612845|platelet rich plasma
273729|NCT01612845|fibrin
273730|NCT01612793|COPD
273731|NCT01612780|Sinusitis
273732|NCT01612780|Sinus balloon dilation patients
273733|NCT01612767|de novo coronary lesions
273734|NCT01612767|restenotic coronary lesions
273735|NCT01612767|coronary arteries
273736|NCT01612754|Reduction of noise pollution
273737|NCT01612754|Specifically enforced workplace rules
273738|NCT01612754|Stress
273739|NCT01612754|Sound Ears (TM)
273740|NCT01612754|Error
273741|NCT01612741|Diabetes Mellitus, Type-2
273742|NCT01612741|Acarbose
273743|NCT01612741|Drug Therapy
273744|NCT01612741|Combination
273745|NCT01612728|Aromatase Inhibitors
273746|NCT01612715|Asthma, allergen challenge, T cells, Fel d 1.
273747|NCT01612702|postoperative nausea and vomiting
273748|NCT01612702|postoperative pain
273749|NCT01612689|Accelerometer
273750|NCT01612689|EMU
273751|NCT01612689|Ambulatory
273752|NCT01612689|ECG
273753|NCT01612689|Heart rate
273754|NCT01612663|Knee pain
273755|NCT01612663|Acupuncture
273756|NCT01612663|Sham acupuncture
273757|NCT01612650|breast cancer
273758|NCT01612650|surveillance
273759|NCT01612650|diagnosis
273760|NCT01612650|2D mammography
273761|NCT01612650|3D mammography
273762|NCT01612637|Pelvic organ prolapse
273763|NCT01612637|Pelvic floor muscle training
273764|NCT01612637|Prolapse symptoms
273765|NCT01612637|Pelvic organ prolapse quantification system
273766|NCT01612637|Ultrasonography
273767|NCT01612637|Predictors
273768|NCT01612520|type 2 Diabetes Mellitus
273769|NCT01612520|telenursing
273770|NCT01612520|RCT
273771|NCT01612520|economic analysis
273772|NCT01612507|Phase 1
273773|NCT01612507|healthy volunteers
273774|NCT01612507|Parallel Group Study
273775|NCT01612507|ceftaroline fosamil different doses
273776|NCT01612507|safety
273777|NCT01612507|Cmax
273778|NCT01612507|tmax
273779|NCT01612507|AUC
273780|NCT01612481|soft tissue sarcoma
273781|NCT01612481|lung metastasis
273782|NCT01612481|surveillance
273783|NCT01612468|Diabetes
273784|NCT01612468|Liraglutide
273785|NCT01612468|Hypoglycaemia
273786|NCT01612468|Hyperglycaemia
273787|NCT01612468|CIMT
273788|NCT01612468|PWV
273789|NCT01612468|Food preference
273790|NCT01612468|Blood pressure
273791|NCT01612455|HIV
273792|NCT01612455|drug addiction
273793|NCT01612455|Russia
273794|NCT01612455|case management
273795|NCT01612442|complementary feeding
273796|NCT01612442|mothers
273797|NCT01612442|6-24 months children
273798|NCT01612442|community health volunteers
273799|NCT01612442|nutrition education
273800|NCT01612442|agricultural education
273801|NCT01612429|Carbamylation
273802|NCT01612429|Albumin
273803|NCT01612429|Protein structure
273804|NCT01612429|Kidney disease
273805|NCT01612416|Ganglion Cell complex, Retinal Nerve Fiber Layer,Glaucoma
273806|NCT01612403|zinc binding protein
273807|NCT01612390|postpartum hemorrhage
273808|NCT01612377|Moderate to Severe
273809|NCT01612364|CRPS I
273810|NCT01612351|Head and neck cancer
273811|NCT01612351|Squamous Cell Carcinoma
273812|NCT01612351|Phase II
273813|NCT01612351|Transoral Surgery
273814|NCT01612351|Induction Chemotherapy
273815|NCT01612351|Carboplatin
273816|NCT01612351|Paclitaxel
273817|NCT01612351|Lapatinib
273818|NCT01612338|breast cancer
273819|NCT01612338|young age of onset
273820|NCT01612338|family history
273821|NCT01612338|screening interventions
273822|NCT01612338|family support
273823|NCT01612325|liver tumors
273824|NCT01612312|Non-ST-elevation myocardial infarction
273825|NCT01612312|thrombectomy
273826|NCT01612312|magnetic resonance imaging
273827|NCT01612312|microvascular obstruction
273828|NCT01612286|Recombinant human endostatin
273829|NCT01612286|nasopharyngeal carcinoma
273830|NCT01612286|chemotherapy
273831|NCT01612273|Vasospastic syndrome
273832|NCT01612273|Vascular dysregulation
273833|NCT01612260|heart failure
273834|NCT01612260|ventricular premature complex
273835|NCT01612260|Shensong Yangxin capsule
273836|NCT01612247|Breast Cancer
273837|NCT01612247|Neoadjuvant therapy
273838|NCT01612234|humans
273839|NCT01612234|lean
273840|NCT01612234|obese
273841|NCT01612234|saturated fat
273842|NCT01612234|monounsaturated fat
273843|NCT01612234|insulin sensitivity
273844|NCT01612234|inflammation
273845|NCT01612234|oxidant stress
273846|NCT01612195|anal fistula
273847|NCT01612195|anal continence
273848|NCT01612195|health-related quality of life
273849|NCT01612182|end-stage renal disease
273850|NCT01612182|renal replacement therapy
273851|NCT01612169|HIV patients
273852|NCT01612169|Hospitalized patients
273853|NCT01612169|Substance Users
273854|NCT01612169|Drug Users
273855|NCT01612156|Urodynamic testing
273856|NCT01612156|pelvic floor examination
273857|NCT01612156|Lidocaine gel
273858|NCT01612156|Surgical lubricant
273859|NCT01612156|Pain
273860|NCT01612156|Embarrassment
273861|NCT01612117|renal failure
273862|NCT01612117|cardiology
273863|NCT01612117|contrast-induced nephropathy
273864|NCT01612104|Post Traumatic Stress Disorder
273865|NCT01612104|Anxiety symptoms
273866|NCT01612104|Depressive symptoms
273867|NCT01612104|Externalizing behavior
273868|NCT01612104|Reduced quality of life
273869|NCT01612091|Expert System
273870|NCT01612091|Intensive Care
273871|NCT01612091|Telemedicine
273872|NCT01612091|Equipment Design
273873|NCT01612065|Office hysteroscopy
273874|NCT01612065|Cervical priming
273875|NCT01612065|Misoprostol
273876|NCT01612052|Vascular Surgery
273877|NCT01612039|ulcerative colitis
273878|NCT01612013|N-acetylcysteine
273879|NCT01612013|angiography
273880|NCT01612013|contrast medium
273881|NCT01612013|contrast-induced nephropathy
273882|NCT01612013|sodium bicarbonate
273883|NCT01612000|Influenza
273884|NCT01611974|CMV
273885|NCT01611974|cytomegalovirus
273886|NCT01611974|resistant
273887|NCT01611974|refractory
273888|NCT01611974|transplant
273889|NCT01611974|treatment
273890|NCT01611961|Docetaxel
273891|NCT01611961|Lipid Microsphere
273892|NCT01611961|Neoplasms
273893|NCT01611961|Antineoplastic Agents
273894|NCT01611961|Pharmacologic Actions
273895|NCT01611961|Therapeutic Uses
273896|NCT01611935|trauma
273897|NCT01611935|shock
273898|NCT01611935|vasopressin
273899|NCT01611935|blood transfusion
273900|NCT01611922|eye
273901|NCT01611922|eyelid
273902|NCT01611922|contact lenses
273903|NCT01611922|dry eye disease
273904|NCT01611909|p-menthane-3,8-diol oil extract
273905|NCT01611909|topical therapy
273906|NCT01611896|Graves' hyperthyroidism
273907|NCT01611896|Graves' disease
273908|NCT01611896|Selenium
273909|NCT01611896|Quality of Life
273910|NCT01611896|ThyPRO
273911|NCT01611896|Autoimmunity
273912|NCT01611870|COPD
273913|NCT01611857|Advanced solid tumors
273914|NCT01611857|First-Line Metastatic GE cancer
273915|NCT01611857|c-Met Inhibitor
273916|NCT01611857|Tivantinib
273917|NCT01611857|FOLFOX
273918|NCT01611844|delayed-type hypersensitivity reaction to tuberculin intradermal injection
273919|NCT01611844|tuberculosis skin test
273920|NCT01611844|BD micro-needle
273921|NCT01611844|medical device
273922|NCT01611844|spectroscopy
273923|NCT01611831|fibromyalgia
273924|NCT01611831|Acceptation & Commitment Therapy
273925|NCT01611831|randomized controlled trial
273926|NCT01611818|Depression
273927|NCT01611818|Computer-delivered psychotherapy
273928|NCT01611818|Randomized-controlled trial
273929|NCT01611792|Stabilization exercise
273930|NCT01611792|Strength and conditioning exercise
273931|NCT01611792|Physical therapy
273932|NCT01611792|Rehabilitation
273933|NCT01611779|obstructive sleep apnea
273934|NCT01611779|tongue suspension
273935|NCT01611766|secondary cytoreductive surgery
273936|NCT01611766|Ovarian Cancer
273937|NCT01611766|surgery
273938|NCT01611766|recurrence
273939|NCT01611753|Shock, Septic
273940|NCT01611753|Erythrocyte Transfusion
273941|NCT01611753|Ischemia
273942|NCT01611740|Preterm infant
273943|NCT01611740|Bacterial infection
273944|NCT01611740|Diagnosis of proven or suspected bacterial infection
273945|NCT01611727|BRCA1
273946|NCT01611727|survival
273947|NCT01611727|metastatic disease
273948|NCT01611727|cisplatin
273949|NCT01611714|Racial/ethnic disparities
273950|NCT01611714|Imaging
273951|NCT01611714|Emergency
273952|NCT01611714|Headache
273953|NCT01611675|Metastatic
273954|NCT01611675|Unresectable
273955|NCT01611675|Clearly progressive
273956|NCT01611675|BRAF mutation
273957|NCT01611649|infant formula
273958|NCT01611649|dairy lipids
273959|NCT01611649|omega-3
273960|NCT01611636|allergy
273961|NCT01611636|autoimmune diseases
273962|NCT01611636|rheumatic diseases
273963|NCT01611623|Solid tumor malignancy
273964|NCT01611623|Hsp90
273965|NCT01611610|outcome measures
273966|NCT01611610|spinal muscular atrophy
273967|NCT01611597|accelerometry
273968|NCT01611597|neuromuscular disease
273969|NCT01611584|ALA
273970|NCT01611584|Florescence
273971|NCT01611584|Lung cancer
273972|NCT01611571|osteoporosis
273973|NCT01611571|male
273974|NCT01611545|Pharmacogenomics
273975|NCT01611545|Pharmacogenetics
273976|NCT01611545|Clopidogrel
273977|NCT01611545|Plavix
273978|NCT01611532|Acute pancreatitis
273979|NCT01611532|Intraabdominal pressure
273980|NCT01611532|Critical illness
273981|NCT01611519|urinary bladder
273982|NCT01611519|urinary catheterization
273983|NCT01611519|epidural analgesia
273984|NCT01611519|catheters, indwelling
273985|NCT01611493|Dental Implants
273986|NCT01611493|Jaw, Edentulous, Partially/rehabilitation
273987|NCT01611493|Jaw, Edentulous, Partially/surgery
273988|NCT01611493|randomised Clinical Trials
273989|NCT01611493|Humans
273990|NCT01611467|CC-223
273991|NCT01611467|safety
273992|NCT01611467|tolerability
273993|NCT01611467|pharmacokinetic
273994|NCT01611467|AME (Absorption, Metabolism, and Excretion)
273995|NCT01611467|FE (Food Effect)
273996|NCT01611454|Occupational Exposure to Radiation
273997|NCT01611441|Osteoarthritis of the knee
273998|NCT01611441|Biomarkers
273999|NCT01611428|Ipragliflozin
274000|NCT01611428|Healthy
274001|NCT01611428|Absolute Bioavailability
274002|NCT01611428|Pharmacokinetics
274003|NCT01611415|Phase 1
274004|NCT01611415|Ipragliflozin
274005|NCT01611415|Furosemide
274006|NCT01611415|Pharmacokinetics
274007|NCT01611415|Pharmacodynamics
274008|NCT01611402|Tuberculosis
274009|NCT01611402|HIV Infection
274010|NCT01611402|Transcriptional Signature
274011|NCT01611402|IRIS
274012|NCT01611376|impedance cardiography
274013|NCT01611376|Flotrac/Vigileo
274014|NCT01611376|cardiac output
274015|NCT01611363|Phase 1
274016|NCT01611363|Diabetes Mellitus
274017|NCT01611363|Healthy
274018|NCT01611363|Ipragliflozin
274019|NCT01611363|Pharmacokinetics
274020|NCT01611363|Pharmacodynamics
274021|NCT01611350|Indoor Air Pollution
274022|NCT01611350|Marketing Methods for Increasing Technology Adoption
274023|NCT01611350|Optimal Contracts for Technology Adoption
274024|NCT01611337|schizophrenia, insight
274025|NCT01611324|Varicose Veins
274026|NCT01611324|Phlebectomy
274027|NCT01611324|Local Anesthesia
274028|NCT01611298|allogeneic stem cell transplant
274029|NCT01611298|malignant diseases
274030|NCT01611298|Acute lymphoblastic leukemia
274031|NCT01611298|acute myelogenous leukemia
274032|NCT01611298|Chronic myelogenous leukemia
274033|NCT01611298|myelodysplastic syndrome
274034|NCT01611298|Hodgkin lymphoma
274035|NCT01611298|non-Hodgkin lymphoma
274036|NCT01611298|myeloproliferative disorder
274037|NCT01611298|non-malignant disease
274038|NCT01611285|UPHOLD
274039|NCT01611285|robotic surgery
274040|NCT01611285|decision analysis
274041|NCT01611285|FDA
274042|NCT01611285|decision node
274043|NCT01611285|outcome node
274044|NCT01611272|Unstable angina
274045|NCT01611259|MALT Lymphoma
274046|NCT01611259|Lenalidomide
274047|NCT01611259|Rituximab
274048|NCT01611233|metal on metal
274049|NCT01611233|hip replacement
274050|NCT01611233|ASR
274051|NCT01611233|DePuy
274052|NCT01611220|Anorexia Nervosa
274053|NCT01611220|Relapse prevention
274054|NCT01611220|Cognitive Dissonance
274055|NCT01611220|Inpatient treatment
274056|NCT01611220|Cognitive behavior therapy
274057|NCT01611207|wound healing impairments,
274058|NCT01611207|negative pressure wound therapy,
274059|NCT01611207|health services research,
274060|NCT01611207|germany
274061|NCT01611194|HBO2
274062|NCT01611194|HBOT
274063|NCT01611194|mTBI
274064|NCT01611194|Brain injury
274065|NCT01611194|PCS
274066|NCT01611194|PTSD
274067|NCT01611194|hyperbaric oxygen
274068|NCT01611181|Iron supplementation
274069|NCT01611181|Iron deficiency
274070|NCT01611181|Hip arthroplasty
274071|NCT01611181|Knee arthroplasty
274072|NCT01611142|Monoclonal antibody
274073|NCT01611142|Peripheral T-cell Lymphoma
274074|NCT01611142|cancer
274075|NCT01611142|hematologic malignancy
274076|NCT01611129|Disability Evaluation
274077|NCT01611103|Cognitive Enhancement
274078|NCT01611103|tDCS
274079|NCT01611103|stimulation
274080|NCT01611103|elderly
274081|NCT01611103|older adults
274082|NCT01611090|Chronic lymphocytic leukemia
274083|NCT01611090|Small lymphocytic lymphoma
274084|NCT01611090|Relapsed or refractory chronic lymphocytic leukemia
274085|NCT01611090|Relapsed or refractory small lymphocytic lymphoma
274086|NCT01611090|Ibrutinib
274087|NCT01611090|PCI-32765
274088|NCT01611090|JNJ-54179060
274089|NCT01611090|Bruton's tyrosine kinase inhibitor
274090|NCT01611090|Bendamustine
274091|NCT01611090|Rituximab
274092|NCT01611064|Hand
274093|NCT01611064|Surgery
274094|NCT01611064|Tourniquet
274095|NCT01611064|Pain
274096|NCT01611064|Oxygen
274097|NCT01611051|breast cancer
274098|NCT01611051|neutropenia
274099|NCT01611051|febrile neutropenia
274100|NCT01611012|Asthma
274101|NCT01611012|Inflammation
274102|NCT01611012|Phenotype
274103|NCT01611012|Sputum
274104|NCT01610986|Fructose
274105|NCT01610986|Exercise
274106|NCT01610986|Lactic acid
274107|NCT01610986|Monocarboxylic Acid Transporters
274108|NCT01610973|Fuch's dystrophy
274109|NCT01610973|Corneal graft
274110|NCT01610960|Non invasive ventilation
274111|NCT01610960|Helmet
274112|NCT01610960|NEXT Helmet
274113|NCT01610960|Work of breathing
274114|NCT01610960|Intensive care
274115|NCT01610947|Spondyloarthritis
274116|NCT01610947|Anti-TNF
274117|NCT01610947|Adalimumab
274118|NCT01610947|Etanercept
274119|NCT01610947|Infliximab
274120|NCT01610934|MODY
274121|NCT01610934|Monogenic diabetes
274122|NCT01610934|Non-autoimmune diabetes
274123|NCT01610934|MODY3
274124|NCT01610921|asthma
274125|NCT01610921|small airways disease
274126|NCT01610921|inflammation
274127|NCT01610921|provocation
274128|NCT01610921|adenosine
274129|NCT01610908|Adolescent
274130|NCT01610908|Idiopathic
274131|NCT01610908|Scoliosis
274132|NCT01610908|Schroth
274133|NCT01610908|Exercises
274134|NCT01610908|Conservative treatment
274135|NCT01610895|Colonoscopy
274136|NCT01610895|low fibre diet
274137|NCT01610895|clear fluids
274138|NCT01610895|Bowel Preparation
274139|NCT01610869|Recurrence
274140|NCT01610869|Ovarian Neoplasms
274141|NCT01610869|Ovarian Diseases
274142|NCT01610869|Fallopian Tube Neoplasms
274143|NCT01610869|Neoplasms
274144|NCT01610869|Carcinoma
274145|NCT01610869|Neoplasms by site
274146|NCT01610856|bowel preparation
274147|NCT01610856|bowel purgative
274148|NCT01610856|bowel cleansing
274149|NCT01610856|colonoscopy
274150|NCT01610843|Sarcoidosis
274151|NCT01610843|WISE
274152|NCT01610843|Sarcoid Study
274153|NCT01610843|Worldwide Sarcoidosis Research Study
274154|NCT01610830|Purpura, Schoenlein-Henoch
274155|NCT01610830|adults
274156|NCT01610830|children
274157|NCT01610830|pronostic factors
274158|NCT01610817|Patient information and active participation
274159|NCT01610817|Patient safety
274160|NCT01610817|Health education
274161|NCT01610817|Adverse drug event
274162|NCT01610817|Primary care
274163|NCT01610817|Antihypertensive drugs
274164|NCT01610765|HSV
274165|NCT01610765|pharmacokinetics
274166|NCT01610765|herpes
274167|NCT01610765|neonates
274168|NCT01610752|Pregnancy
274169|NCT01610752|Gestational weight gain
274170|NCT01610726|colon
274171|NCT01610726|rectum
274172|NCT01610726|recovery
274173|NCT01610726|surgery
274174|NCT01610674|Diabetes mellitus
274175|NCT01610674|Surgery
274176|NCT01610674|Implementation
274177|NCT01610674|Quality of care
274178|NCT01610674|Quality indicators
274179|NCT01610661|carbohydrate
274180|NCT01610661|inflammation
274181|NCT01610661|glucose homeostasis
274182|NCT01610661|gene expression
274183|NCT01610648|OSA
274184|NCT01610648|metabolic syndrome
274185|NCT01610648|Apnea-hypopnea index
274186|NCT01610648|Oxygen desaturation index
274187|NCT01610635|RCT
274188|NCT01610635|blood donation frequency
274189|NCT01610635|quality of life
274190|NCT01610635|iron deficiency
274191|NCT01610622|Cardiac Output
274192|NCT01610622|Blood volumes
274193|NCT01610622|Neonates
274194|NCT01610609|Statin treatment
274195|NCT01610609|Cardiovascular disease
274196|NCT01610609|High cholesterol
274197|NCT01610609|Care management
274198|NCT01610596|Psoriasis
274199|NCT01610596|Skin Diseases
274200|NCT01610596|Halobetasol
274201|NCT01610596|Vasoconstrictor Agents
274202|NCT01610596|Therapeutic Uses
274203|NCT01610596|Pharmacologic Actions
274204|NCT01610596|Anti-Inflammatory Agents
274205|NCT01610596|Physiological Effects of Drugs
274206|NCT01610583|Genetic Literacy
274207|NCT01610583|Latino
274208|NCT01610570|Dose Limiting Toxicity
274209|NCT01610570|Maximum Tolerated Dose
274210|NCT01610570|Radiographic Response
274211|NCT01610570|Time to Progression
274212|NCT01610570|Bone Tumors
274213|NCT01610557|Diabetic Macular Edema
274214|NCT01610557|Ranibizumab
274215|NCT01610557|Bevacizumab
274216|NCT01610544|Thymoma
274217|NCT01610544|Insulin Growth Factor
274218|NCT01610544|Cell Proliferation
274219|NCT01610544|Non Small Cell Lung Cancer
274220|NCT01610544|PET/CT Imaging Sessions
274221|NCT01610531|Cohort
274222|NCT01610531|Melanoma
274223|NCT01610531|targeted screening
274224|NCT01610531|risks function
274225|NCT01610531|cost effectiveness
274226|NCT01610518|postprandial blood glucose
274227|NCT01610518|dietary fiber
274228|NCT01610518|beta-glucan
274229|NCT01610505|Knee Osteoarthritis
274230|NCT01610505|Knee pain
274231|NCT01610505|Arthritis
274232|NCT01610505|KineSpring
274233|NCT01610505|High Tibial Osteotomy
274234|NCT01610492|IMGN
274235|NCT01610492|anti-PLA2R antibodies
274236|NCT01610492|pharmacokinetics
274237|NCT01610492|belimumab
274238|NCT01610492|Benlysta
274239|NCT01610492|Idiopathic Membranous Glomerulonephropathy
274240|NCT01610492|safety
274241|NCT01610492|GSK1550188
274242|NCT01610492|Lymphostat-B
274243|NCT01610492|membrane attack complex
274244|NCT01610466|Education
274245|NCT01610466|Simulation
274246|NCT01610466|Technical skills training
274247|NCT01610466|Laparoscopy
274248|NCT01610466|Bariatric Surgery
274249|NCT01610453|prolonged labor
274250|NCT01610453|cesarean section
274251|NCT01610453|duration of labor
274252|NCT01610440|Duchenne muscular dystrophy
274253|NCT01610440|Human Umbilical Cord Mesenchymal Stem Cells
274254|NCT01610427|CMI
274255|NCT01610427|HIV
274256|NCT01610427|Antiretroviral therapy-naïve
274257|NCT01610414|Observer-blind
274258|NCT01610414|Efficacy
274259|NCT01610414|Immunogenicity
274260|NCT01610414|Vaccination
274261|NCT01610414|Safety
274262|NCT01610414|Adult autologous haematopoietic cell transplant recipients
274263|NCT01610414|Herpes Zoster
274264|NCT01610388|healthy subjects
274265|NCT01610388|double-blind
274266|NCT01610388|FTIH
274267|NCT01610388|dose-escalation
274268|NCT01610388|absolute bioavailability
274269|NCT01610388|GSK1322322
274270|NCT01610388|BAL
274271|NCT01610375|Endometrial cancer
274272|NCT01610362|rabies
274273|NCT01610362|immunoglobulin
274274|NCT01610362|dosage
274275|NCT01610336|EGFR
274276|NCT01610336|c-MET
274277|NCT01610336|Lung cancer
274278|NCT01610336|Gefitinib
274279|NCT01610336|Erlotinib
274280|NCT01610323|Pregnancy
274281|NCT01610323|Obesity
274282|NCT01610323|Physical activity
274283|NCT01610323|Cardiorespiratory fitness
274284|NCT01610323|Muscular Fitness
274285|NCT01610323|Weight gain
274286|NCT01610323|Fetal growth
274287|NCT01610310|SC
274288|NCT01610310|PEG
274289|NCT01610310|Inteferon
274290|NCT01610310|PK
274291|NCT01610310|Subcutaneous
274292|NCT01610310|PEGylated
274293|NCT01610310|Autoinjector
274294|NCT01610310|Injectable
274295|NCT01610310|MS
274296|NCT01610297|hematopoietic stem cell transplantation, beta-thalassemia major, deferasirox, iron overload
274297|NCT01610284|Breast cancer
274298|NCT01610284|Hormone receptor positive
274299|NCT01610284|HER2-negative
274300|NCT01610284|Metastatic
274301|NCT01610284|Locally advanced
274302|NCT01610284|PI3K
274303|NCT01610284|Fulvestrant
274304|NCT01610284|Refractory
274305|NCT01610284|Aromatase inhibitor
274306|NCT01610271|Prevention
274307|NCT01610271|Surgical Site Infection
274308|NCT01610271|Air Barrier System
274309|NCT01610271|Implant Infection
274310|NCT01610258|pregnancy, chorioamnionitis, PPROM, Treg
274311|NCT01610245|Influenza
274312|NCT01610232|Infrared LED
274313|NCT01610232|Treadmill Training
274314|NCT01610232|Strength Muscle
274315|NCT01610232|Fatigue Muscle
274316|NCT01610232|Aerobic Capacity
274317|NCT01610232|Cellulite
274318|NCT01610232|Osteoporosis
274319|NCT01610206|recurrent
274320|NCT01610206|persistent
274321|NCT01610193|Pancreatic Stone Protein
274322|NCT01610193|Abdominal pain
274323|NCT01610193|Acute appendicitis
274324|NCT01610193|Alvarado score
274325|NCT01610193|Appendectomy
274326|NCT01610193|Sensitivity and specificity
274327|NCT01610180|Eltrombopag
274328|NCT01610180|ITP
274329|NCT01610180|LPD
274330|NCT01610180|leukemia
274331|NCT01610180|Immune ThrombocytoPenia
274332|NCT01610154|glucagon
274333|NCT01610154|dipeptidyl peptidase-4 inhibitor
274334|NCT01610141|warfarin metabolism
274335|NCT01610141|pharmacogenetics
274336|NCT01610141|CYP2C9
274337|NCT01610141|genotyping
274338|NCT01610141|VKORC1
274339|NCT01610141|CYP4F2
274340|NCT01610141|anticoagulation
274341|NCT01610141|atrial fibrillation
274342|NCT01610141|deep vein thrombosis
274343|NCT01610141|pulmonary embolism
274344|NCT01610141|Artificial Heart Valve
274345|NCT01610128|urticaria, patient reported outcome
274346|NCT01610115|Pregnancy
274347|NCT01610102|clinical follow-up
274348|NCT01610102|up to 7 years
274349|NCT01610102|all patients enrolled in the main study
274350|NCT01610089|citrullinemia
274351|NCT01610089|argininosuccinate synthetase deficiency
274352|NCT01610089|nitric oxide
274353|NCT01610089|urea
274354|NCT01610076|Code Status
274355|NCT01610076|Do not resuscitate (DNR)
274356|NCT01610076|Do not intubate (DNI)
274357|NCT01610076|CPR
274358|NCT01610076|Cardiopulmonary resuscitation
274359|NCT01610076|video
274360|NCT01610076|advanced directives
274361|NCT01610063|Algorithm
274362|NCT01610063|Depression
274363|NCT01610063|Assurex
274364|NCT01610063|GeneSight
274365|NCT01610050|castration-resistant prostate cancer, advanced breast cancer
274366|NCT01610037|chronic obstructive pulmonary disease
274367|NCT01610037|COPD
274368|NCT01610037|QVA149
274369|NCT01610037|QAB149
274370|NCT01610037|NVA237
274371|NCT01610037|Indacaterol maleate
274372|NCT01610037|Glycopyronnium bromide
274373|NCT01610011|Schizophrenia
274374|NCT01610011|Psychotic Disorders
274375|NCT01610011|N-methyl-D-aspartate receptor
274376|NCT01610011|Glycine augmentation
274377|NCT01610011|Glycine
274378|NCT01610011|Glycine Pharmacodynamics
274379|NCT01610011|Glycine Bioavailability
274380|NCT01610011|Magnetic Resonance Spectroscopy
274381|NCT01610011|Glycine Decarboxylase
274382|NCT01610011|Glycine Decarboxylase Mutation
274383|NCT01609998|Influenza A (H1)
274384|NCT01609998|Influenza A (H3)
274385|NCT01609998|Influenza B
274386|NCT01609998|DNA Vaccine
274387|NCT01609998|Trivalent Inactivated Vaccine (TIV)
274388|NCT01609998|Healthy Adolescents
274389|NCT01609998|Healthy Children
274390|NCT01609985|Cardiac Resynchronization Therapy Defibrillator (CRT-D) Devices
274391|NCT01609972|Back pain
274392|NCT01609972|Spinal Cord Stimulation
274393|NCT01609959|Hypertension
274394|NCT01609959|Angiotensin II Receptor Blocker
274395|NCT01609959|Azilsartan
274396|NCT01609959|Valsartan
274397|NCT01609946|presenting for FNAB or surgery
274398|NCT01609933|Hepatitis C
274399|NCT01609933|Hepatitis C Genotype 1
274400|NCT01609933|Chronic Hepatitis C
274401|NCT01609933|HCV
274402|NCT01609920|MRI
274403|NCT01609920|lymph node metastases
274404|NCT01609920|breast cancer
274405|NCT01609920|gadofosveset
274406|NCT01609907|Drug interaction
274407|NCT01609907|YH14700
274408|NCT01609907|Rosuvastatin
274409|NCT01609907|Valsartan
274410|NCT01609907|Yuhan
274411|NCT01609894|Postnatal development
274412|NCT01609894|Breast milk fortification
274413|NCT01609894|Composition of breast milk
274414|NCT01609881|Inflammation
274415|NCT01609868|premature infant feeding protein
274416|NCT01609855|Adenoma Detection Rate
274417|NCT01609855|Anti-spasmotic drug
274418|NCT01609842|Acute Coronary Syndrome
274419|NCT01609842|adherence
274420|NCT01609816|adult grade III lymphomatoid granulomatosis
274421|NCT01609816|adult nasal type extranodal NK/T-cell lymphoma
274422|NCT01609816|anaplastic large cell lymphoma
274423|NCT01609816|angioimmunoblastic T-cell lymphoma
274424|NCT01609816|contiguous stage II adult Burkitt lymphoma
274425|NCT01609816|contiguous stage II adult diffuse large cell lymphoma
274426|NCT01609816|contiguous stage II adult diffuse mixed cell lymphoma
274427|NCT01609816|contiguous stage II adult diffuse small cleaved cell lymphoma
274428|NCT01609816|contiguous stage II adult immunoblastic large cell lymphoma
274429|NCT01609816|contiguous stage II adult lymphoblastic lymphoma
274430|NCT01609816|contiguous stage II grade 1 follicular lymphoma
274431|NCT01609816|contiguous stage II grade 2 follicular lymphoma
274432|NCT01609816|contiguous stage II grade 3 follicular lymphoma
274433|NCT01609816|contiguous stage II mantle cell lymphoma
274434|NCT01609816|contiguous stage II marginal zone lymphoma
274435|NCT01609816|contiguous stage II small lymphocytic lymphoma
274436|NCT01609816|cutaneous B-cell non-Hodgkin lymphoma
274437|NCT01609816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
274438|NCT01609816|hepatosplenic T-cell lymphoma
274439|NCT01609816|intraocular lymphoma
274440|NCT01609816|nodal marginal zone B-cell lymphoma
274441|NCT01609816|noncontiguous stage II adult Burkitt lymphoma
274442|NCT01609816|noncontiguous stage II adult diffuse large cell lymphoma
274443|NCT01609816|noncontiguous stage II adult diffuse mixed cell lymphoma
274444|NCT01609816|noncontiguous stage II adult diffuse small cleaved cell lymphoma
274445|NCT01609816|noncontiguous stage II adult immunoblastic large cell lymphoma
274446|NCT01609816|noncontiguous stage II adult lymphoblastic lymphoma
274447|NCT01609816|noncontiguous stage II grade 1 follicular lymphoma
274448|NCT01609816|noncontiguous stage II grade 2 follicular lymphoma
274449|NCT01609816|noncontiguous stage II grade 3 follicular lymphoma
274450|NCT01609816|noncontiguous stage II mantle cell lymphoma
274451|NCT01609816|noncontiguous stage II marginal zone lymphoma
274452|NCT01609816|noncontiguous stage II small lymphocytic lymphoma
274453|NCT01609816|noncutaneous extranodal lymphoma
274454|NCT01609816|peripheral T-cell lymphoma
274455|NCT01609816|recurrent adult Burkitt lymphoma
274456|NCT01609816|recurrent adult diffuse large cell lymphoma
274457|NCT01609816|recurrent adult diffuse mixed cell lymphoma
274458|NCT01609816|recurrent adult diffuse small cleaved cell lymphoma
274459|NCT01609816|recurrent adult grade III lymphomatoid granulomatosis
274460|NCT01609816|recurrent adult Hodgkin lymphoma
274461|NCT01609816|recurrent adult immunoblastic large cell lymphoma
274462|NCT01609816|recurrent adult lymphoblastic lymphoma
274463|NCT01609816|recurrent adult T-cell leukemia/lymphoma
274464|NCT01609816|recurrent cutaneous T-cell non-Hodgkin lymphoma
274465|NCT01609816|recurrent grade 1 follicular lymphoma
274466|NCT01609816|recurrent grade 2 follicular lymphoma
274467|NCT01609816|recurrent grade 3 follicular lymphoma
274468|NCT01609816|recurrent mantle cell lymphoma
274469|NCT01609816|recurrent marginal zone lymphoma
274470|NCT01609816|recurrent mycosis fungoides/Sezary syndrome
274471|NCT01609816|recurrent small lymphocytic lymphoma
274472|NCT01609816|refractory hairy cell leukemia
274473|NCT01609816|refractory multiple myeloma
274474|NCT01609816|small intestine lymphoma
274475|NCT01609816|splenic marginal zone lymphoma
274476|NCT01609816|stage I adult Burkitt lymphoma
274477|NCT01609816|stage I adult diffuse large cell lymphoma
274478|NCT01609816|stage I adult diffuse mixed cell lymphoma
274479|NCT01609816|stage I adult diffuse small cleaved cell lymphoma
274480|NCT01609816|stage I adult Hodgkin lymphoma
274481|NCT01609816|stage I adult immunoblastic large cell lymphoma
274482|NCT01609816|stage I adult lymphoblastic lymphoma
274483|NCT01609816|stage I adult T-cell leukemia/lymphoma
274484|NCT01609816|stage I cutaneous T-cell non-Hodgkin lymphoma
274485|NCT01609816|stage I grade 1 follicular lymphoma
274486|NCT01609816|stage I grade 2 follicular lymphoma
274487|NCT01609816|stage I grade 3 follicular lymphoma
274488|NCT01609816|stage I mantle cell lymphoma
274489|NCT01609816|stage I marginal zone lymphoma
274490|NCT01609816|stage I multiple myeloma
274491|NCT01609816|stage I small lymphocytic lymphoma
274492|NCT01609816|stage IA mycosis fungoides/Sezary syndrome
274493|NCT01609816|stage IB mycosis fungoides/Sezary syndrome
274494|NCT01609816|stage II adult Hodgkin lymphoma
274495|NCT01609816|stage II adult T-cell leukemia/lymphoma
274496|NCT01609816|stage II cutaneous T-cell non-Hodgkin lymphoma
274497|NCT01609816|stage II multiple myeloma
274498|NCT01609816|stage IIA mycosis fungoides/Sezary syndrome
274499|NCT01609816|stage IIB mycosis fungoides/Sezary syndrome
274500|NCT01609816|stage III adult Burkitt lymphoma
274501|NCT01609816|stage III adult diffuse large cell lymphoma
274502|NCT01609816|stage III adult diffuse mixed cell lymphoma
274503|NCT01609816|stage III adult diffuse small cleaved cell lymphoma
274504|NCT01609816|stage III adult Hodgkin lymphoma
274505|NCT01609816|stage III adult immunoblastic large cell lymphoma
274506|NCT01609816|stage III adult lymphoblastic lymphoma
274507|NCT01609816|stage III adult T-cell leukemia/lymphoma
274508|NCT01609816|stage III cutaneous T-cell non-Hodgkin lymphoma
274509|NCT01609816|stage III grade 1 follicular lymphoma
274510|NCT01609816|stage III grade 2 follicular lymphoma
274511|NCT01609816|stage III grade 3 follicular lymphoma
274512|NCT01609816|stage III mantle cell lymphoma
274513|NCT01609816|stage III marginal zone lymphoma
274514|NCT01609816|stage III multiple myeloma
274515|NCT01609816|stage III small lymphocytic lymphoma
274516|NCT01609816|stage IIIA mycosis fungoides/Sezary syndrome
274517|NCT01609816|stage IIIB mycosis fungoides/Sezary syndrome
274518|NCT01609816|stage IV adult Burkitt lymphoma
274519|NCT01609816|stage IV adult diffuse large cell lymphoma
274520|NCT01609816|stage IV adult diffuse mixed cell lymphoma
274521|NCT01609816|stage IV adult diffuse small cleaved cell lymphoma
274522|NCT01609816|stage IV adult Hodgkin lymphoma
274523|NCT01609816|stage IV adult immunoblastic large cell lymphoma
274524|NCT01609816|stage IV adult lymphoblastic lymphoma
274525|NCT01609816|stage IV adult T-cell leukemia/lymphoma
274526|NCT01609816|stage IV cutaneous T-cell non-Hodgkin lymphoma
274527|NCT01609816|stage IV grade 1 follicular lymphoma
274528|NCT01609816|stage IV grade 2 follicular lymphoma
274529|NCT01609816|stage IV grade 3 follicular lymphoma
274530|NCT01609816|stage IV mantle cell lymphoma
274531|NCT01609816|stage IV marginal zone lymphoma
274532|NCT01609816|stage IV small lymphocytic lymphoma
274533|NCT01609816|stage IVA mycosis fungoides/Sezary syndrome
274534|NCT01609816|stage IVB mycosis fungoides/Sezary syndrome
274535|NCT01609816|T-cell large granular lymphocyte leukemia
274536|NCT01609816|testicular lymphoma
274537|NCT01609816|Waldenström macroglobulinemia
274538|NCT01609751|probiotic
274539|NCT01609751|lactobacillus
274540|NCT01609751|colonic diseases
274541|NCT01609751|dietary fibre
274542|NCT01609738|Cardiac pacing
274543|NCT01609738|Left ventricular septal pacing
274544|NCT01609738|Feasibility and safety
274545|NCT01609738|Lead stability
274546|NCT01609738|Hemodynamics
274547|NCT01609738|Left ventricular dyssynchrony
274548|NCT01609738|Pacing for heart failure
274549|NCT01609738|Cardiac resynchronization therapy
274550|NCT01609725|Coronary artery disease
274551|NCT01609725|C reactive protein
274552|NCT01609725|Periodontitis
274553|NCT01609725|Periodontal therapy
274554|NCT01609725|Flow-mediated dilation
274555|NCT01609712|Improvement of lung function (FEV1, PEF)
274556|NCT01609712|Visual Analog Scale
274557|NCT01609712|Oswestry Disability Index
274558|NCT01609712|Radiographs pre and post Op
274559|NCT01609699|body circumference
274560|NCT01609699|Non-Invasive Reduction
274561|NCT01609686|cardiac surgery
274562|NCT01609686|renal dysfunction
274563|NCT01609686|pharmacokinetics
274564|NCT01609686|tranexamic acid
274565|NCT01609673|Immunosuppression
274566|NCT01609673|Chronic Kidney Disease
274567|NCT01609673|Renal Transplant
274568|NCT01609660|probiotics
274569|NCT01609660|cytokine
274570|NCT01609660|short chain fatty acids
274571|NCT01609660|complications
274572|NCT01609660|colorectal surgery
274573|NCT01609647|High plate reactivity unit after loading dose of clopidogrel
274574|NCT01609634|Healthy
274575|NCT01609634|Term infants
274576|NCT01609634|Growth
274577|NCT01609634|Body composition
274578|NCT01609595|Thalassemia
274579|NCT01609595|Anemia
274580|NCT01609595|Fetal hemoglobin
274581|NCT01609582|Drug therapy
274582|NCT01609556|FOLR solid tumors
274583|NCT01609530|verruca
274584|NCT01609530|vulgaris
274585|NCT01609530|hands
274586|NCT01609530|feet
274587|NCT01609530|Nd:YAG
274588|NCT01609530|laser
274589|NCT01609530|cryotherapy
274590|NCT01609517|Spinal anesthesia
274591|NCT01609517|determinant
274592|NCT01609517|duration
274593|NCT01609504|Rectal cancer
274594|NCT01609504|Radiochemotherapy
274595|NCT01609504|Transanal Endoscopic Microsurgery
274596|NCT01609504|Laparoscopic Resection
274597|NCT01609478|asthma
274598|NCT01609465|CAD
274599|NCT01609465|stable angina
274600|NCT01609465|STEMI
274601|NCT01609465|NSTEMI
274602|NCT01609465|CVD
274603|NCT01609465|secondary prevention
274604|NCT01609452|Immune Thrombocytopenic Purpura
274605|NCT01609452|Idiopathic Thrombocytopenic Purpura
274606|NCT01609452|Chronic ITP
274607|NCT01609439|Permanent
274608|NCT01609439|temporary
274609|NCT01609439|hypocalcemia
274610|NCT01609426|Proteinuria
274611|NCT01609426|idiopathic
274612|NCT01609426|nephrotic syndrome
274613|NCT01609426|herpesvirus
274614|NCT01609426|epidemiology
274615|NCT01609426|immune response
274616|NCT01609426|interferon
274617|NCT01609426|steroid dependency
274618|NCT01609426|nephrotic disease: Idiopathic nephrotic syndrome
274619|NCT01609387|Vitamine
274620|NCT01609387|mineral
274621|NCT01609387|obese patients
274622|NCT01609387|Vitamine en mineral shortage in obese patients
274623|NCT01609374|Spinal Kinetics
274624|NCT01609374|artificial cervical disc
274625|NCT01609374|cervical radiculopathy
274626|NCT01609374|ACDF
274627|NCT01609374|neck pain
274628|NCT01609374|cervical spine
274629|NCT01609374|degenerative disc disease
274630|NCT01609361|Rehabilitation program
274631|NCT01609361|Fast track surgery
274632|NCT01609361|Laparoscopic colorectal resection
274633|NCT01609361|Colorectal cancer
274634|NCT01609361|Morbidity
274635|NCT01609348|Depression
274636|NCT01609348|Alzheimer's Disease
274637|NCT01609322|fear of falling
274638|NCT01609322|agoraphobia
274639|NCT01609309|Stomach Neoplasms
274640|NCT01609309|Laparoscopy
274641|NCT01609296|Peripheral Arterial Disease
274642|NCT01609296|Drug coated balloon
274643|NCT01609296|Superficial Femoral Artery
274644|NCT01609296|Popliteal Femoral Artery
274645|NCT01609296|Atherosclerosis
274646|NCT01609244|Sleep apnea
274647|NCT01609244|central sleep apnea
274648|NCT01609244|bilevel
274649|NCT01609244|servoventilation
274650|NCT01609244|CPAP
274651|NCT01609192|sickle-cell anemia
274652|NCT01609192|spermatogenesis
274653|NCT01609192|hydroxyurea
274654|NCT01609166|Hand-foot Syndrome
274655|NCT01609166|capecitabine
274656|NCT01609166|allopurinol
274657|NCT01609153|schizophrenia
274658|NCT01609153|amisulpride
274659|NCT01609153|olanzapine
274660|NCT01609153|polypharmacy
274661|NCT01609140|Hyperlipidemia
274662|NCT01609140|Dyslipidemia
274663|NCT01609114|phenomena and mechanism of RT-PK
274664|NCT01609114|fact for different anticancer drugs
274665|NCT01609114|different part in human
274666|NCT01609101|Videolaryngoscopy
274667|NCT01609101|Palatopharyngeal distance
274668|NCT01609101|Trauma
274669|NCT01609088|endothelium
274670|NCT01609088|diabetes mellitus
274671|NCT01609088|oxidative stress
274672|NCT01609062|Mucopolysaccharidosis IVA Type A
274673|NCT01609062|MPS IVA Type A
274674|NCT01609062|Mucopolysaccharidosis IVA
274675|NCT01609062|MPS IVA
274676|NCT01609062|Morquio A Syndrome
274677|NCT01609062|Lysosomal Storage Disorder
274678|NCT01609062|LSD
274679|NCT01609062|N-acetylgalactosamine-6-sulfatase
274680|NCT01609062|N-acetylgalactosamine-6-sulfate
274681|NCT01609062|sulfatase
274682|NCT01609062|galactose-6-sulfatase
274683|NCT01609062|GALNS
274684|NCT01609062|enzyme replacement therapy
274685|NCT01609062|ERT
274686|NCT01609062|MOR-008
274687|NCT01609062|CPET
274688|NCT01609062|MST
274689|NCT01609062|muscle strength test
274690|NCT01609062|physiological effect
274691|NCT01608984|remote ischemic preconditioning
274692|NCT01608984|coronary artery bypass grafting
274693|NCT01608984|myocardial injury
274694|NCT01608971|Protamine
274695|NCT01608971|heparin level
274696|NCT01608971|haemostasis
274697|NCT01608971|thromboelastometry
274698|NCT01608971|cardiac surgery
274699|NCT01608971|Patients undergoing cardiac surgery
274700|NCT01608958|Postpartum hemorrhage
274701|NCT01608958|Oxytocin
274702|NCT01608958|Third stage of labor
274703|NCT01608958|Hemoglobin
274704|NCT01608958|Prevention
274705|NCT01608958|Intravenous
274706|NCT01608958|Intramuscular
274707|NCT01608945|steroid
274708|NCT01608945|liver function
274709|NCT01608945|prognosis
274710|NCT01608906|venous thrombosis
274711|NCT01608906|heparin
274712|NCT01608906|pulmonary embolism
274713|NCT01608906|ICU
274714|NCT01608867|Phase 1
274715|NCT01608867|dose escalation
274716|NCT01608867|histologically confirmed
274717|NCT01608867|malignancy
274718|NCT01608867|metastatic
274719|NCT01608854|surgical site infection
274720|NCT01608854|spinal surgery
274721|NCT01608854|prophylactic antibiotics
274722|NCT01608854|postoperative spinal drains
274723|NCT01608815|Salmonella infections
274724|NCT01608815|Typhoid fever
274725|NCT01608815|Bacterial infections
274726|NCT01608815|Typhoid vaccine
274727|NCT01608802|HIV
274728|NCT01608802|Antiretroviral therapy
274729|NCT01608802|Palliative care
274730|NCT01608802|Pain
274731|NCT01608789|Male sling
274732|NCT01608789|Stress Urinary Incontinence
274733|NCT01608789|Urination Disorders
274734|NCT01608789|Urologic Diseases
274735|NCT01608724|Type 2 DM
274736|NCT01608711|Gemcitabine
274737|NCT01608711|AGS-1C4D4
274738|NCT01608711|Pancreatic Cancer
274739|NCT01608711|ASP6182
274740|NCT01608698|chlormadinone acetate
274741|NCT01608698|drospirenone
274742|NCT01608698|contraceptive pills
274743|NCT01608685|Tuberculosis
274744|NCT01608685|Latent tuberculosis infection
274745|NCT01608685|Immunosuppression
274746|NCT01608685|Renal transplant recipient
274747|NCT01608646|S-1
274748|NCT01608646|Oxaliplatin
274749|NCT01608646|Dihydropyrimidine Dehydrogenase
274750|NCT01608620|Systematic review and meta-analysis
274751|NCT01608620|Evidence-based medicine (EBM)
274752|NCT01608620|Evidence-based nutrition (EBN)
274753|NCT01608620|Clinical practice guidelines
274754|NCT01608620|Clinical trials
274755|NCT01608620|Dietary sugars
274756|NCT01608620|Fructose
274757|NCT01608620|High fructose corn syrup
274758|NCT01608620|Fruit
274759|NCT01608620|Isocaloric
274760|NCT01608620|Hypercaloric
274761|NCT01608620|Cardiometabolic risk factors
274762|NCT01608620|Triglycerides
274763|NCT01608620|Cholesterol
274764|NCT01608620|Glycemic control
274765|NCT01608620|Insulin resistance
274766|NCT01608620|Body weight
274767|NCT01608620|Uric acid
274768|NCT01608620|Blood pressure
274769|NCT01608607|Systematic review and meta-analysis
274770|NCT01608607|Evidence-based medicine (EBM)
274771|NCT01608607|Evidence-based nutrition (EBN)
274772|NCT01608607|Clinical practice guidelines
274773|NCT01608607|Clinical trials
274774|NCT01608607|Dietary sugars
274775|NCT01608607|Fructose
274776|NCT01608607|High fructose corn syrup
274777|NCT01608607|sucrose
274778|NCT01608607|Isocaloric
274779|NCT01608607|Hypercaloric
274780|NCT01608607|Glycemic control
274781|NCT01608607|Insulin resistance
274782|NCT01608607|Body weight
274783|NCT01608607|body mass index
274784|NCT01608607|waist circumference
274785|NCT01608581|prevention
274786|NCT01608581|burn
274787|NCT01608581|adult
274788|NCT01608581|health promotion
274789|NCT01608581|evaluation
274790|NCT01608581|media
274791|NCT01608568|Sutures
274792|NCT01608568|Pelvic Organ Prolapse
274793|NCT01608568|Sacrocolpopexy
274794|NCT01608568|Robotic Assisted Laparoscopy
274795|NCT01608555|cystic fibrosis
274796|NCT01608555|bacterial load
274797|NCT01608555|inhaled tobramycin
274798|NCT01608542|fostamatinib
274799|NCT01608542|FosD
274800|NCT01608542|Japanese Healthy volunteers
274801|NCT01608542|Phase 1
274802|NCT01608542|Single and Multiple Dose Study
274803|NCT01608529|Restriction device ventilatory nasal flow
274804|NCT01608529|oronasal breathing
274805|NCT01608529|nasal breathing.
274806|NCT01608516|PET/CT
274807|NCT01608516|68Ga-NODAGA-RGD
274808|NCT01608516|18F-FDG
274809|NCT01608516|MRI
274810|NCT01608516|US ultrasound
274811|NCT01608516|inflammatory atheromatous plaque
274812|NCT01608516|endarterectomy
274813|NCT01608503|subclavian vein
274814|NCT01608503|ultrasound
274815|NCT01608503|distance between the subclavian vein and the lung
274816|NCT01608490|COPD
274817|NCT01608490|RePneu
274818|NCT01608477|Heart Transplantation
274819|NCT01608477|Medication Adherence
274820|NCT01608477|Behavior System Factor
274821|NCT01608464|Randomized trial,
274822|NCT01608464|Pre-operative chemo-RT with CDDP and 5-FU
274823|NCT01608464|Multicenter study
274824|NCT01608438|Body-machine interface
274825|NCT01608438|Customization
274826|NCT01608438|Upper-body motion
274827|NCT01608438|Motor learning
274828|NCT01608438|Assistive Devices
274829|NCT01608438|Wheelchair
274830|NCT01608438|Computer keyboard
274831|NCT01608425|diabetic foot ulcer
274832|NCT01608425|ulcer monitoring
274833|NCT01608425|telemedicine consultations
274834|NCT01608425|cross-sectoral collaboration
274835|NCT01608412|renal transplantation
274836|NCT01608412|everolimus
274837|NCT01608412|tacrolimus
274838|NCT01608412|molecular evaluation
274839|NCT01608399|major depressive disorder
274840|NCT01608399|psychotherapy
274841|NCT01608399|metacognitive therapy
274842|NCT01608386|Anterior approach
274843|NCT01608386|infrahepatic inferior vena cava clamping
274844|NCT01608386|hepatic resection
274845|NCT01608373|Pain
274846|NCT01608373|Lidocaine
274847|NCT01608373|Intravenous
274848|NCT01608373|Intraperitoneum
274849|NCT01608373|Laparoscopic cholecystectomy
274850|NCT01608360|Pain
274851|NCT01608360|Lidocaine
274852|NCT01608360|Intravenous
274853|NCT01608360|Thyroidectomy
274854|NCT01608347|LMWH
274855|NCT01608347|enoxaparin
274856|NCT01608347|recurrent miscarriage
274857|NCT01608347|continuing fetal viability beyond 20 weeks gestation
274858|NCT01608321|Chronic Pain
274859|NCT01608321|Gulf War Illness
274860|NCT01608321|Gulf War Syndrome
274861|NCT01608321|Fibromyalgia
274862|NCT01608321|repetitive Transcranial Magnetic Stimulation
274863|NCT01608321|Transcranial Magnetic Stimulation
274864|NCT01608321|Veterans
274865|NCT01608308|Chronic Sinusitis
274866|NCT01608308|Pain Relief
274867|NCT01608308|Post-Operative Opioid Requirement
274868|NCT01608308|IV Acetaminophen
274869|NCT01608308|Functional Endoscopic Sinus Surgery
274870|NCT01608308|FESS
274871|NCT01608295|depressed
274872|NCT01608295|geriatric
274873|NCT01608295|older adults
274874|NCT01608295|antidepressants
274875|NCT01608295|depression
274876|NCT01608295|anxious
274877|NCT01608295|major depressive disorder
274878|NCT01608295|MDD
274879|NCT01608282|Osteoarthritis
274880|NCT01608282|Arthritis
274881|NCT01608282|Knee
274882|NCT01608282|Exercise
274883|NCT01608282|Physical Activity
274884|NCT01608282|Web-based
274885|NCT01608256|mild cognitive impairment
274886|NCT01608256|Automobile Driving
274887|NCT01608256|cognitive aspects
274888|NCT01608217|Behavioural disturbances
274889|NCT01608217|Pain
274890|NCT01608217|Dementia
274891|NCT01608217|Alzheimer's dementia
274892|NCT01608217|Vascular dementia
274893|NCT01608217|THC
274894|NCT01608217|Cannabis
274895|NCT01608204|Pharmacokinetics
274896|NCT01608204|Busulfan
274897|NCT01608204|Polymorphism
274898|NCT01608204|GST
274899|NCT01608204|MDR-1(p-Glycoprotein)
274900|NCT01608204|Acute Myeloid Leukemia adult patients
274901|NCT01608178|Pediatric Neurotransmitter Disorders
274902|NCT01608178|Succinic Semialdehyde Dehydrogenase
274903|NCT01608178|GABA
274904|NCT01608178|Epilepsy
274905|NCT01608165|Small renal cancer mass
274906|NCT01608152|Leukemia
274907|NCT01608152|Lymphoma
274908|NCT01608152|Game mechanics
274909|NCT01608152|Stem cell transplant survivors
274910|NCT01608152|Hematopoietic stem cell transplantation
274911|NCT01608152|HSCT
274912|NCT01608152|Internet-based
274913|NCT01608152|Interactive and personalized intervention
274914|NCT01608152|Questionnaires
274915|NCT01608152|Focus groups
274916|NCT01608152|Interviews
274917|NCT01608139|Advanced Cancers
274918|NCT01608139|Advanced Solid Tumors
274919|NCT01608139|Curcumin
274920|NCT01608139|Sorafenib
274921|NCT01608139|Nexavar
274922|NCT01608139|Bay 43-9006
274923|NCT01608139|Vorinostat
274924|NCT01608139|SAHA
274925|NCT01608139|Suberoylanilide Hydroxamic Acid
274926|NCT01608139|MSK-390
274927|NCT01608139|Zolinza
274928|NCT01608126|Ultrasound
274929|NCT01608126|Cervical Plexus
274930|NCT01608126|Anesthesia, Conduction
274931|NCT01608126|Surgical Procedures, Elective
274932|NCT01608126|Atherectomy
274933|NCT01608113|neovascular AMD
274934|NCT01608113|Optical coherence tomography
274935|NCT01608113|reading acuity
274936|NCT01608113|contrast sensitivity
274937|NCT01608074|BRCA1
274938|NCT01608074|BRCA2
274939|NCT01608074|Prophylactic surgery
274940|NCT01608074|Salpingectomy
274941|NCT01608074|Fimbriectomy
274942|NCT01608061|Mild probable Alzheimer's Disease
274943|NCT01608048|In-vitro Fertilization
274944|NCT01608048|transcutaneous electrical acupoint stimulation
274945|NCT01608035|sciatic catheter
274946|NCT01608035|stump catheter
274947|NCT01608035|below knee amputation
274948|NCT01608009|platinum resistant
274949|NCT01608009|ovarian cancer
274950|NCT01607996|Epidural anesthesia
274951|NCT01607996|pancreatic perfusion
274952|NCT01607996|pancreatic necrosectomy
274953|NCT01607983|nitric oxide
274954|NCT01607983|ventricular-arterial coupling
274955|NCT01607983|congenital heart disease
274956|NCT01607970|Oxytocin
274957|NCT01607970|Startle
274958|NCT01607970|moral dilemma
274959|NCT01607970|oxytocin receptor gene
274960|NCT01607957|Refractory, metastatic colorectal cancer
274961|NCT01607931|Exercise
274962|NCT01607931|Physical activity
274963|NCT01607931|Type 2 diabetes
274964|NCT01607931|Obesity
274965|NCT01607931|Incretin effect
274966|NCT01607931|GLP-1
274967|NCT01607931|GIP
274968|NCT01607931|Insulin secretion
274969|NCT01607931|Glucagon
274970|NCT01607931|Beta-cell function
274971|NCT01607931|Disposition Index
274972|NCT01607918|H pylori, eradication
274973|NCT01607905|Selinexor
274974|NCT01607905|KPT-330
274975|NCT01607905|Squamous Cell Carcinoma
274976|NCT01607905|Glioblastoma multiforme
274977|NCT01607905|Adenocarcinoma
274978|NCT01607905|Melanoma
274979|NCT01607892|Selinexor
274980|NCT01607892|KPT-330
274981|NCT01607892|Multiple Myeloma
274982|NCT01607892|non-Hodgkin Lymphoma
274983|NCT01607892|Chronic Lymphocytic Leukemia
274984|NCT01607892|Waldenström's macroglobulinemia
274985|NCT01607892|Peripheral T-Cell Lymphoma
274986|NCT01607892|Cutaneous T-Cell Lymphoma
274987|NCT01607892|Chronic Myelocytic Leukemia
274988|NCT01607892|Acute Lymphoblastic Leukemia
274989|NCT01607879|Prostate Cancer
274990|NCT01607879|Men
274991|NCT01607879|Androgen Deprivation Therapy
274992|NCT01607879|Elderly
274993|NCT01607879|Geriatric
274994|NCT01607879|Nutritional supplementation
274995|NCT01607840|Schizophrenia
274996|NCT01607840|Cognitive Improvement
274997|NCT01607840|tDCS
274998|NCT01607840|stimulation
274999|NCT01607827|polypectomy
275000|NCT01607827|colonoscopy
275001|NCT01607827|polyp miss rate
275002|NCT01607827|surveillance
275003|NCT01607827|colorectal cancer
275004|NCT01607814|cirrhosis
275005|NCT01607814|oxidative stress
275006|NCT01607814|NADPH oxidase
275007|NCT01607814|isoprostanes
275008|NCT01607814|PUFA balance
275009|NCT01607814|platelet activation
275010|NCT01607814|coagulation abnormalities
275011|NCT01607801|umbilical hernia repair
275012|NCT01607801|recurrence
275013|NCT01607801|choice of suture
275014|NCT01607801|mesh
275015|NCT01607801|mesh/non-mesh
275016|NCT01607788|Selection criteria
275017|NCT01607788|Liver transplantation
275018|NCT01607788|Hepatocellular carcinoma
275019|NCT01607762|Healthy
275020|NCT01607762|Antipsychotics
275021|NCT01607762|Aripiprazole
275022|NCT01607762|Paliperidone
275023|NCT01607762|Risperidone
275024|NCT01607762|Quetiapine
275025|NCT01607762|Olanzapine
275026|NCT01607749|Asthma Control
275027|NCT01607749|Quality of life
275028|NCT01607749|Children
275029|NCT01607749|Asthma education
275030|NCT01607736|falls
275031|NCT01607736|walking
275032|NCT01607736|healthy older individuals
275033|NCT01607736|virtual gait training
275034|NCT01607723|Sleep pattern
275035|NCT01607723|Mechanical ventilation
275036|NCT01607723|weaning
275037|NCT01607723|Intensive Care
275038|NCT01607723|NAVA (Neurally Adjusted Ventilatory Assist)
275039|NCT01607723|PAV+ (Proportional Assist Ventilation Plus)
275040|NCT01607710|fMRI
275041|NCT01607710|Generalized Anxiety Disorder
275042|NCT01607697|Parkinson's Disease
275043|NCT01607671|Ischemic
275044|NCT01607671|Optic Neuropathy
275045|NCT01607671|Non-Arteritic Anterior Ischemic Optic Neuropathy
275046|NCT01607671|NAION
275047|NCT01607671|Ischemic Optic Neuropathy
275048|NCT01607671|Intraocular Pressure
275049|NCT01607658|Testosterone
275050|NCT01607632|posttraumatic stress
275051|NCT01607632|depression
275052|NCT01607619|CRP
275053|NCT01607593|Retrospective
275054|NCT01607593|Sertraline
275055|NCT01607593|Posttraumatic stress disorder
275056|NCT01607554|Lung
275057|NCT01607554|non small cell
275058|NCT01607554|NSCLC
275059|NCT01607554|Irinotecan
275060|NCT01607541|HIV/AIDS
275061|NCT01607541|vulnerable populations
275062|NCT01607541|heterosexuals at high risk
275063|NCT01607541|peer-driven intervention
275064|NCT01607541|tailored intervention
275065|NCT01607541|African-American
275066|NCT01607541|Latino/Hispanic
275067|NCT01607541|Seek, test, treat, and retain (STTR)
275068|NCT01607515|Pulmonary hypertension
275069|NCT01607515|Cardiac index
275070|NCT01607515|impedance cardiography
275071|NCT01607502|Pulmonary hypertension
275072|NCT01607502|database
275073|NCT01607502|biomarker
275074|NCT01607489|Early diagnosis of pulmonary arterial hypertension
275075|NCT01607489|dynamic dual-energy computed tomography
275076|NCT01607463|pain
275077|NCT01607463|transcutaneous electrical nerve stimulation
275078|NCT01607450|Type 2 diabetes mellitus
275079|NCT01607450|lean healthy control
275080|NCT01607424|cognitive rehabilitation
275081|NCT01607424|schizophrenia
275082|NCT01607398|Japan
275083|NCT01607398|COPD
275084|NCT01607398|CAT
275085|NCT01607398|placebo
275086|NCT01607398|serum
275087|NCT01607398|Adoair250
275088|NCT01607398|anti-inflammatory
275089|NCT01607398|sputum
275090|NCT01607385|pharmacokinetic
275091|NCT01607385|intestinal bile acid transporter inhibitor
275092|NCT01607385|GSK2330672
275093|NCT01607385|pharmacodynamic
275094|NCT01607385|GSK1614235
275095|NCT01607385|dose escalation
275096|NCT01607372|TLR7 agonist, Respiratory Allergies, Allergic Rhinitis, Mild Allergic Asthma, Repeat Dose Safety, Reduction of Allergic Reactivity
275097|NCT01607359|atrial fibrillation
275098|NCT01607359|catheter ablation
275099|NCT01607359|dabigatran
275100|NCT01607359|warfarin
275101|NCT01607359|oral anticoagulation
275102|NCT01607346|Urinary Retention
275103|NCT01607333|Antiepileptics
275104|NCT01607333|suicidality
275105|NCT01607320|PCOS
275106|NCT01607320|Infertility
275107|NCT01607320|Anovulation
275108|NCT01607307|daikenchuto
275109|NCT01607307|postoperative ileus
275110|NCT01607307|pancreaticoduodenectomy
275111|NCT01607281|anatomical landmark
275112|NCT01607281|internal jugular vein canulation
275113|NCT01607268|autonomic failure
275114|NCT01607268|mangenetic resonance
275115|NCT01607268|neurochemistry
275116|NCT01607268|neurotransmitter
275117|NCT01607268|glutamate
275118|NCT01607255|adenoma detection
275119|NCT01607255|screening colonoscopy
275120|NCT01607255|water exchange method
275121|NCT01607255|chromoendoscopy
275122|NCT01607242|total thyroidectomy
275123|NCT01607242|voice handicap index
275124|NCT01607242|swallowing disorders
275125|NCT01607242|thyroid surgery
275126|NCT01607242|voice disorders
275127|NCT01607229|multi-frequency
275128|NCT01607229|bioelectrical impedance
275129|NCT01607229|body composition
275130|NCT01607229|hydration
275131|NCT01607216|Prematurity
275132|NCT01607216|Respiratory Illness
275133|NCT01607216|Lung Function
275134|NCT01607216|Lung Disease
275135|NCT01607203|ovarian hyper stimulation syndrome (OHSS)
275136|NCT01607203|metaphase II oocytes (MII)
275137|NCT01607203|good quality embryo's
275138|NCT01607203|implantation
275139|NCT01607203|pregnancy
275140|NCT01607190|type 2 diabetes mellitus
275141|NCT01607190|nonproliferative diabetic retinopathy
275142|NCT01607164|Mood management
275143|NCT01607164|self-help
275144|NCT01607164|depression
275145|NCT01607164|prevention
275146|NCT01607164|cognitive behavioral
275147|NCT01607151|hypothermia
275148|NCT01607151|normothermia
275149|NCT01607151|hyperthermia
275150|NCT01607138|laryngectomy
275151|NCT01607138|swallowing disturbances
275152|NCT01607138|speech disturbances
275153|NCT01607138|speech intelligibility
275154|NCT01607138|voice prothesis
275155|NCT01607112|Influenza
275156|NCT01607112|Healthy
275157|NCT01607112|Immunogenicity
275158|NCT01607112|Elderly
275159|NCT01607112|Safety
275160|NCT01607112|Adults
275161|NCT01607099|colonoscopy
275162|NCT01607099|bowel cleansing
275163|NCT01607099|bowel cleanness
275164|NCT01607099|efficiency
275165|NCT01607099|compatibility
275166|NCT01607086|Lamotrigine
275167|NCT01607086|placebo
275168|NCT01607086|properties
275169|NCT01607086|characteristics
275170|NCT01607073|Dravet
275171|NCT01607073|seizures
275172|NCT01607073|verapamil
275173|NCT01607060|Critically ill patients
275174|NCT01607060|intestinal failure
275175|NCT01607047|leptospirosis
275176|NCT01607047|qPCR
275177|NCT01607047|cohort
275178|NCT01607047|french west indies
275179|NCT01607047|blood sample collection
275180|NCT01607047|pronostic
275181|NCT01607047|diagnosis
275182|NCT01607021|Chronic hepatitis C
275183|NCT01607021|interleukin 28
275184|NCT01607021|Children
275185|NCT01606995|Stroke
275186|NCT01606995|Embolism
275187|NCT01606995|Atrial fibrillation
275188|NCT01606982|prostate
275189|NCT01606982|MDV3100
275190|NCT01606982|cancer
275191|NCT01606969|Dexmedetomidine
275192|NCT01606969|epinephrine
275193|NCT01606969|lidocaine
275194|NCT01606969|scalp infiltration
275195|NCT01606969|craniotomy
275196|NCT01606943|Aortic dissection
275197|NCT01606943|Risk factor
275198|NCT01606943|Feature
275199|NCT01606943|Management
275200|NCT01606943|Outcome
275201|NCT01606930|Patient Satisfaction
275202|NCT01606930|Patient Doctor Communication
275203|NCT01606930|Shared Decision Making
275204|NCT01606930|Patient Activation
275205|NCT01606891|preschooler obesity prevention
275206|NCT01606891|community home visiting parents
275207|NCT01606891|preschooler excess BMI gain
275208|NCT01606891|multi-setting/component intervention
275209|NCT01606852|sedation
275210|NCT01606852|mechanical ventilation
275211|NCT01606852|anxiety
275212|NCT01606852|respiratory failure
275213|NCT01606826|Severe
275214|NCT01606787|Kidney
275215|NCT01606787|MANNITOL
275216|NCT01606787|PLACEBO
275217|NCT01606787|Partial Nephrectomy
275218|NCT01606787|12-079
275219|NCT01606761|Arthritis, Rheumatoid
275220|NCT01606761|Active rheumatoid arthritis despite anti-TNF-alpha therapy
275221|NCT01606761|Sirukumab
275222|NCT01606761|Human Anti-IL-6 monoclonal antibody
275223|NCT01606748|Advanced Malignant Solid Tumors
275224|NCT01606748|Solid Cancers
275225|NCT01606748|Non-small Cell Lung Cancer
275226|NCT01606748|NSCLC
275227|NCT01606748|Breast Cancer
275228|NCT01606735|cataract surgery
275229|NCT01606735|ocular inflammation
275230|NCT01606722|Antiretroviral therapy
275231|NCT01606722|Boosted-Darunavir monotherapy
275232|NCT01606722|Resistance
275233|NCT01606722|Proviral DNA-HIV
275234|NCT01606709|GnRHa trigger
275235|NCT01606709|endometrial gene profile
275236|NCT01606709|quality of life
275237|NCT01606696|CAD
275238|NCT01606696|cardiac rehabilitation
275239|NCT01606696|fitness
275240|NCT01606683|Acidified milk
275241|NCT01606683|Beta-palmitate
275242|NCT01606683|Bifidobacteria
275243|NCT01606683|Breastfeeding
275244|NCT01606683|Infant formula
275245|NCT01606683|Galacto-oligosaccharides
275246|NCT01606683|Growth
275247|NCT01606683|Infants
275248|NCT01606683|Metabolomics
275249|NCT01606683|Prebiotics
275250|NCT01606670|Rotigotine
275251|NCT01606670|Neupro®
275252|NCT01606657|I&D
275253|NCT01606657|Abscess
275254|NCT01606657|Irrigation
275255|NCT01606657|Cutaneous Abscess
275256|NCT01606644|radiation sequelae
275257|NCT01606644|hyperbaric oxygen
275258|NCT01606631|severe sepsis
275259|NCT01606631|toxic shock
275260|NCT01606618|Self-esteem
275261|NCT01606618|Spina Bifida
275262|NCT01606618|Spinal cord injury
275263|NCT01606605|Lymphoma
275264|NCT01606605|Prognosis
275265|NCT01606605|Relapse
275266|NCT01606605|Gene
275267|NCT01606605|microRNA
275268|NCT01606579|Leukemia
275269|NCT01606579|acute myeloid leukemia
275270|NCT01606579|AML
275271|NCT01606579|chronic myeloid leukemia
275272|NCT01606579|CML
275273|NCT01606579|MDS
275274|NCT01606579|myelodysplastic syndrome
275275|NCT01606579|myeloproliferative neoplasia
275276|NCT01606579|MPN
275277|NCT01606566|Recurrent
275278|NCT01606566|Head and Neck
275279|NCT01606566|Neoplasms
275280|NCT01606566|Squamous Cell Carcinoma
275281|NCT01606566|Amphinex
275282|NCT01606566|Cancer
275283|NCT01606566|Photodynamic therapy
275284|NCT01606566|Chemotherapy
275285|NCT01606566|Bleomycin
275286|NCT01606553|chronic heart failure
275287|NCT01606553|respiratory muscle weakness
275288|NCT01606553|inspiratory muscle training
275289|NCT01606540|Colles fracture
275290|NCT01606540|Non-steroid antiinflammatory drugs
275291|NCT01606540|Bone healing
275292|NCT01606527|Spectrum of Altitude-associated acute mountain sickness
275293|NCT01606527|hypoxia
275294|NCT01606527|high altitude headache
275295|NCT01606527|high altitude cerebral edemat is.....
275296|NCT01606488|Postoperative Cognitive Dysfunction
275297|NCT01606488|Postoperative Cognitive Decline
275298|NCT01606488|POCD
275299|NCT01606488|Alzheimer's disease
275300|NCT01606488|Florbetapir F 18 (18F-AV-45)
275301|NCT01606475|Islet transplant
275302|NCT01606475|Diabetes Mellitus
275303|NCT01606475|Hypoglycemia
275304|NCT01606462|oxytocin
275305|NCT01606462|social cognition
275306|NCT01606462|fMRI
275307|NCT01606462|oxytocin receptor gene
275308|NCT01606449|Gastroesophageal reflux diseases
275309|NCT01606449|Hiatal Hernia
275310|NCT01606449|Paraesophageal Hernia
275311|NCT01606358|Ovarian Cancer
275312|NCT01606358|Patient with ovarian cancer
275313|NCT01606345|Upper Tract Urothelial Carcinoma
275314|NCT01606345|UTUC
275315|NCT01606345|Kidney
275316|NCT01606345|Cancer
275317|NCT01606345|Renal
275318|NCT01606319|Asthma
275319|NCT01606319|Wheezing
275320|NCT01606319|Ibuprofen
275321|NCT01606319|Acetaminophen
275322|NCT01606319|exacerbations
275323|NCT01606319|pain
275324|NCT01606319|fever
275325|NCT01606306|Asthma
275326|NCT01606306|Wheezing
275327|NCT01606306|Fluticasone
275328|NCT01606306|Montelukast
275329|NCT01606306|Preschool-age
275330|NCT01606293|Small cell carcinomas of the cervix
275331|NCT01606293|Large cell carcinomas of the cervix
275332|NCT01606293|Online surveys
275333|NCT01606293|Electronic surveys
275334|NCT01606293|Questionnaires
275335|NCT01606293|Facebook
275336|NCT01606293|Social networking support groups
275337|NCT01606280|Amyloidosis
275338|NCT01606267|Integrated Community Case Management
275339|NCT01606267|Pneumonia
275340|NCT01606267|Ethiopia
275341|NCT01606254|Schizophrenia
275342|NCT01606254|Paliperidone Palmitate
275343|NCT01606254|JNS010
275344|NCT01606228|Schizophrenia
275345|NCT01606228|Paliperidone ER
275346|NCT01606228|Treatment naive patients
275347|NCT01606228|Newly diagnosed patients
275348|NCT01606215|multiple sclerosis
275349|NCT01606215|mesenchymal stem cells
275350|NCT01606215|bone marrow
275351|NCT01606215|rapidly evolving
275352|NCT01606150|neonate
275353|NCT01606150|late preterm
275354|NCT01606150|lumbar puncture
275355|NCT01606150|analgesia
275356|NCT01606150|pain
275357|NCT01606150|lidocaine
275358|NCT01606098|Surgery
275359|NCT01606098|Chemotherapy
275360|NCT01606085|Diabetes
275361|NCT01606085|Heart Failure
275362|NCT01606085|Quality of Life
275363|NCT01606085|Self Care
275364|NCT01606072|DDAVP
275365|NCT01606033|stress
275366|NCT01606033|Life quality
275367|NCT01606033|adjustment strategy
275368|NCT01606033|receiving an antitumor treatment
275369|NCT01606033|within a clinical trial (case)
275370|NCT01606033|according to a standard treatment (control)
275371|NCT01606020|effects of sleep deprivation
275372|NCT01606020|Transcranial Magnetic Stimulation
275373|NCT01606020|male, healthy volunteers
275374|NCT01605981|Nilotinib
275375|NCT01605981|CML patients
275376|NCT01605981|accelerated phase
275377|NCT01605968|Obstetrics
275378|NCT01605968|Gynecology
275379|NCT01605968|Wound healing
275380|NCT01605955|SPO2
275381|NCT01605929|Anesthetics, local/administration & dosage
275382|NCT01605929|Brachial Plexus/ultrasonography
275383|NCT01605929|Humans
275384|NCT01605929|Nerve Block/methods
275385|NCT01605929|Upper Extremity/surgery
275386|NCT01605929|Catheters, Indwelling
275387|NCT01605929|Anesthesia, Conduction/methods
275388|NCT01605929|Analgesia/methods
275389|NCT01605929|Nerve Block/adverse effects
275390|NCT01605916|Cancer,
275391|NCT01605916|Tumour,
275392|NCT01605916|Metastatic,
275393|NCT01605916|Lung cancer,
275394|NCT01605916|Non-Small Cell Lung Cancer
275395|NCT01605903|Tonsillectomy
275396|NCT01605903|adenoidectomy
275397|NCT01605903|bleeding
275398|NCT01605903|bleeding rates
275399|NCT01605903|Tonsillectomy with and without adenoidectomy
275400|NCT01605890|HIV-2
275401|NCT01605877|Cataracts
275402|NCT01605877|Intraocular lens
275403|NCT01605877|Multifocal
275404|NCT01605877|Presbyopia
275405|NCT01605864|pneumonia
275406|NCT01605864|community acquired bacterial pneumonia
275407|NCT01605864|CAP
275408|NCT01605864|CABP
275409|NCT01605864|bacterial pneumonia
275410|NCT01605851|PFO
275411|NCT01605851|closure
275412|NCT01605838|TBI
275413|NCT01605812|IOL;
275414|NCT01605812|capsule；
275415|NCT01605812|PCO;
275416|NCT01605812|OCT
275417|NCT01605799|PTSD
275418|NCT01605799|Mental Health
275419|NCT01605799|War
275420|NCT01605799|Veterans
275421|NCT01605786|Malaria
275422|NCT01605786|Plasmodium falciparum
275423|NCT01605786|vaccine
275424|NCT01605786|ADCI
275425|NCT01605786|sporozoite challenge
275426|NCT01605786|pre-erythrocytic
275427|NCT01605786|erythrocytic
275428|NCT01605760|immunotherapy
275429|NCT01605760|elderly
275430|NCT01605734|hepatocellular carcinoma
275431|NCT01605734|transarterial chemoembolization
275432|NCT01605734|sorafenib
275433|NCT01605721|Everolimus
275434|NCT01605721|XIENCE PRIME
275435|NCT01605721|Drug eluting stent
275436|NCT01605708|Itching
275437|NCT01605695|reference range
275438|NCT01605695|plasma
275439|NCT01605695|inducible nitric oxide synthase
275440|NCT01605695|iNOS
275441|NCT01605695|healthy adults
275442|NCT01605682|effect of different berry doses on mood and cognition
275443|NCT01605682|adults
275444|NCT01605669|Auscultation
275445|NCT01605669|Aortic stenosis
275446|NCT01605669|computer assisted auscultation
275447|NCT01605669|Aortic Stenosis Acceleration Index
275448|NCT01605656|Cancer Prevention
275449|NCT01605656|Cervix
275450|NCT01605656|Questionnaires
275451|NCT01605656|Focus groups
275452|NCT01605656|Surveys
275453|NCT01605656|Interviews
275454|NCT01605643|cancer
275455|NCT01605643|tobacco use
275456|NCT01605643|pregnancy
275457|NCT01605604|mindfulness EQ adolescents
275458|NCT01605591|left-side double lumen bronchial tube
275459|NCT01605591|bending type
275460|NCT01605591|GlideScope videolaryngoscope
275461|NCT01605552|Depression
275462|NCT01605552|Depressive Symptoms
275463|NCT01605552|Cardiovascular Disease (CVD)
275464|NCT01605552|Coronary Artery Disease (CAD)
275465|NCT01605552|Heart Disease
275466|NCT01605513|recombinant interferon, tolerated, effective
275467|NCT01605500|ICD
275468|NCT01605474|foley catheter
275469|NCT01605474|foley bulb
275470|NCT01605474|induction of labor
275471|NCT01605474|labor
275472|NCT01605448|Mild Cognitive Impairment
275473|NCT01605448|Alzheimer's disease
275474|NCT01605448|Meditation
275475|NCT01605448|Default Mode Network
275476|NCT01605422|Systematic review and meta-analysis
275477|NCT01605422|Evidence-based medicine (EBM)
275478|NCT01605422|Evidence-based nutrition (EBN)
275479|NCT01605422|Clinical practice guidelines
275480|NCT01605422|Clinical trials
275481|NCT01605422|Dietary pulses
275482|NCT01605422|legumes
275483|NCT01605422|Beans, peas, chickpeas, lentils
275484|NCT01605422|glycemic index
275485|NCT01605422|postprandial glycemia
275486|NCT01605422|insulin resistance
275487|NCT01605422|body weight
275488|NCT01605422|appetite
275489|NCT01605422|food intake regulation
275490|NCT01605422|satiety
275491|NCT01605422|satiation
275492|NCT01605409|Refractory cardiac arrest
275493|NCT01605409|Emergency cardiopulmonary bypass
275494|NCT01605409|Extracorporeal life support in cardiac arrest
275495|NCT01605383|Avascular Necrosis of Femur Head
275496|NCT01605383|Osteonecrosis of the hip
275497|NCT01605383|Osteonecrosis of the femoral head
275498|NCT01605383|Mesenchymal Stem Cells
275499|NCT01605383|Bone marrow
275500|NCT01605383|Tissue engineering
275501|NCT01605383|Bone Diseases
275502|NCT01605383|Musculoskeletal Diseases
275503|NCT01605370|Hypertension, Left Ventricular Mass
275504|NCT01605357|Brain Injuries
275505|NCT01605357|Hematoma, subdural
275506|NCT01605357|Decompressive Craniectomy
275507|NCT01605357|Saline solution, hypertonic
275508|NCT01605357|Hypernatremia
275509|NCT01605357|Intracranial hemorrhages
275510|NCT01605357|Head Injuries, closed
275511|NCT01605357|Intracranial pressure
275512|NCT01605357|Brain edema
275513|NCT01605357|Critical care
275514|NCT01605357|Brain Diseases
275515|NCT01605357|Central Nervous System Diseases
275516|NCT01605357|Nervous System Diseases
275517|NCT01605357|Wounds and Injuries
275518|NCT01605357|Physiological Effects of Drugs
275519|NCT01605357|Pharmacologic Actions
275520|NCT01605344|Advanced colon cancer
275521|NCT01605344|Advanced rectal cancer
275522|NCT01605344|Metastatic colon cancer
275523|NCT01605344|Metastatic rectal cancer
275524|NCT01605344|Lipitor
275525|NCT01605344|Atorvastatin
275526|NCT01605344|FOLFIRI
275527|NCT01605331|Adults
275528|NCT01605331|GH deficiency
275529|NCT01605318|metastatic colorectal cancer
275530|NCT01605318|colon cancer
275531|NCT01605318|rectal cancer
275532|NCT01605318|previously treated
275533|NCT01605292|Transradial catheterization
275534|NCT01605292|Ultrasound
275535|NCT01605292|Radial artery
275536|NCT01605279|Low superior vena cava flow
275537|NCT01605279|Functional echocardiography
275538|NCT01605266|pediatric
275539|NCT01605266|kidney disease
275540|NCT01605266|minimal change disease
275541|NCT01605266|focal segmental glomerulosclerosis
275542|NCT01605266|nephrotic syndrome
275543|NCT01605253|Post-traumatic stress disorder
275544|NCT01605253|sleep disturbance
275545|NCT01605253|insomnia
275546|NCT01605253|cytokines
275547|NCT01605253|anxiety
275548|NCT01605253|traumatic event
275549|NCT01605253|memory
275550|NCT01605240|Fracture pain
275551|NCT01605240|Fracture reduction
275552|NCT01605240|Analgesia
275553|NCT01605240|Acetaminophen
275554|NCT01605240|Ibuprofen
275555|NCT01605240|Codeine
275556|NCT01605240|Pediatric
275557|NCT01605240|Fracture Pain Analgesia in Pediatric population
275558|NCT01605227|prostate cancer
275559|NCT01605227|castration resistant prostate cancer
275560|NCT01605227|bone pain
275561|NCT01605227|CRPC
275562|NCT01605214|Extravascular Lung Water
275563|NCT01605214|Transpulmonary Thermodilution
275564|NCT01605214|Primary Graft Dysfunction
275565|NCT01605214|Ischemia Reperfusion Injury
275566|NCT01605201|Chondral lesions in the knee after traumatic injury
275567|NCT01605175|Inflammatory Bowel Disease
275568|NCT01605175|Predictors Mucosal Healing
275569|NCT01605149|Diabetes
275570|NCT01605136|Erythropoietic Protoporphyria
275571|NCT01605136|EPP
275572|NCT01605136|Afamelanotide
275573|NCT01605123|endothelial function
275574|NCT01605123|children
275575|NCT01605123|obesity
275576|NCT01605123|cardiovascular dysfunction
275577|NCT01605123|carotid intima media thickness
275578|NCT01605123|blood pressure
275579|NCT01605123|oral glucose tolerance test
275580|NCT01605110|blepharoplasty
275581|NCT01605110|hyperbaric
275582|NCT01605110|oxygen
275583|NCT01605110|ecchymosis
275584|NCT01605110|edema
275585|NCT01605110|wound
275586|NCT01605110|healing
275587|NCT01605097|prostate neoplasms
275588|NCT01605097|interstitial radiation
275589|NCT01605097|High dose rate prostate brachytherapy
275590|NCT01605097|dose escalation
275591|NCT01605071|menopause
275592|NCT01605071|estrogen
275593|NCT01605071|insulin sensitivity
275594|NCT01605071|estrogen receptors
275595|NCT01605045|Cardiac catheterization
275596|NCT01605045|Radiation
275597|NCT01605019|Ventricular Assist Devices
275598|NCT01605019|Heart assist pumps
275599|NCT01605019|heart pumps
275600|NCT01605019|sealant agents
275601|NCT01605006|amyotrophic lateral sclerosis
275602|NCT01605006|ALS
275603|NCT01605006|motor neuron disease
275604|NCT01605006|diaphragm
275605|NCT01605006|diaphragm pacing
275606|NCT01605006|diaphragmatic pacing
275607|NCT01605006|phrenic pacing
275608|NCT01605006|phrenic nerve
275609|NCT01605006|phrenic nerve stimulation
275610|NCT01605006|NeuRx DPS
275611|NCT01605006|DPS
275612|NCT01605006|chronic hypoventilation
275613|NCT01605006|respiration
275614|NCT01605006|ventilation
275615|NCT01605006|breathing
275616|NCT01605006|Humanitarian Device Exemption
275617|NCT01605006|HDE
275618|NCT01605006|post-approval study
275619|NCT01604993|Dietary Nitrates
275620|NCT01604993|Arterial Stiffness
275621|NCT01604993|Vascular
275622|NCT01604993|Blood pressure
275623|NCT01603914|burns, catheter related bacteremia,
275624|NCT01603914|infection, central venous catheter,
275625|NCT01603914|catheter-related bloodstream, adult critically ill patients
275626|NCT01603888|children with heart disease
275627|NCT01603888|infants
275628|NCT01603888|healthy newborns
275629|NCT01603875|CPRV
275630|NCT01603875|SPEEDA
275631|NCT01603875|intradermal
275632|NCT01603875|pre-exposure
275633|NCT01603875|booster
275634|NCT01603849|Prophylactic Cranial Irradiation
275635|NCT01603849|Lung Cancer
275636|NCT01603849|Non Small Cell Lung Cancer
275637|NCT01603849|Carcinoembryonic Antigen
275638|NCT01603836|Lumbar spine
275639|NCT01603836|Posterolateral fusion
275640|NCT01603836|Allograft
275641|NCT01603836|Bone marrow concentrate
275642|NCT01603836|Mesenchymal stem cells
275643|NCT01603836|Fusion rate
275644|NCT01603823|vitrectomy
275645|NCT01603823|cataract
275646|NCT01603823|macular edema
275647|NCT01603810|Basal cell carcinoma
275648|NCT01603810|Optical Coherence Tomography
275649|NCT01603797|internetdelivered CBT
275650|NCT01603797|chronic pain
275651|NCT01603797|acceptance and commitment therapy
275652|NCT01603797|mindfulness
275653|NCT01603797|guided self help
275654|NCT01603784|exercise
275655|NCT01603784|cognition
275656|NCT01603784|memory
275657|NCT01603784|adult
275658|NCT01603771|Adult
275659|NCT01603771|Exercise
275660|NCT01603771|Cognition
275661|NCT01603771|MRI
275662|NCT01603758|Cholesterol
275663|NCT01603758|Spectrometry, mass
275664|NCT01603758|Deuterium
275665|NCT01603758|Kinetics
275666|NCT01603758|Cholesterol absorption
275667|NCT01603758|Coronary Heart Disease
275668|NCT01603745|PCOS
275669|NCT01604954|Food labeling
275670|NCT01604928|Overactive Bladder
275671|NCT01604928|YM178
275672|NCT01604928|Mirabegron
275673|NCT01604928|Frequency
275674|NCT01604928|Urinary urge incontinence
275675|NCT01604928|Urgency
275676|NCT01604928|Urinary incontinence
275677|NCT01604928|Micturition
275678|NCT01604902|Psoriasis mRNA and miRNA
275679|NCT01604889|Melanoma, Skin Cancer, Oncology
275680|NCT01604876|Parkinson's disease
275681|NCT01604876|depression
275682|NCT01604876|light therapy
275683|NCT01604876|sleeping problems
275684|NCT01604863|Solid Tumors
275685|NCT01604863|Cancer
275686|NCT01604863|Lung Cancer
275687|NCT01604863|Prostate Cancer
275688|NCT01604863|Mesothelioma
275689|NCT01604863|Small Cell lung Cancer
275690|NCT01604850|HCV genotype 2 (GT-2)
275691|NCT01604850|HCV genotype 3 (GT-3)
275692|NCT01604850|HCV
275693|NCT01604850|Sustained Virologic Response
275694|NCT01604850|Direct Acting Antiviral
275695|NCT01604850|Combination Therapy
275696|NCT01604850|Treatment Experienced
275697|NCT01604850|GS-7977
275698|NCT01604850|Ribavirin
275699|NCT01604837|superior hypogastric plexus block
275700|NCT01604837|pelvic malignancy
275701|NCT01604837|chronic pelvic pain
275702|NCT01604798|proteomics
275703|NCT01604798|serum peptides
275704|NCT01604798|colorectal cancer
275705|NCT01604798|MALDI-TOF MS
275706|NCT01604785|Migraine Headache
275707|NCT01604785|Pediatric
275708|NCT01604759|Mouth Neoplasms
275709|NCT01604759|Mouth Diseases
275710|NCT01604733|Multi-Center Survey
275711|NCT01604733|patients currently on lipid-lowering pharmacological treatment
275839|NCT01604200|measurement
275712|NCT01604733|level of Control of Hypercholesterolemia in Egypt
275713|NCT01604720|sample size
275714|NCT01604720|liver disease
275715|NCT01604707|stress
275716|NCT01604707|anxiety
275717|NCT01604707|depression
275718|NCT01604707|quality of life
275719|NCT01604694|Abdominoplasty
275720|NCT01604694|Transversus Abdominis Plane (TAP) Block
275721|NCT01604694|levobupivacaine
275722|NCT01604694|Placebo
275723|NCT01604681|Linseed Oil
275724|NCT01604681|Oxidative Stress
275725|NCT01604681|Polymorphism, Genetic
275726|NCT01604681|Cardiovascular Diseases
275727|NCT01604655|Chest pain
275728|NCT01604655|shortness of breath
275729|NCT01604655|suspected acute coronary syndrome
275730|NCT01604655|stress testing
275731|NCT01604655|coronary computed tomography angiography
275732|NCT01604629|Spondylarthropathies
275733|NCT01604629|Persistent clinical remission with anti-TNF therapy
275734|NCT01604629|Standardized protocol for dose reduction anti-TNF therapy
275735|NCT01604590|Glioblastoma
275736|NCT01604590|Imaging Biomarkers
275737|NCT01604590|Bevacizumab
275738|NCT01604590|MRI
275739|NCT01604577|health literacy
275740|NCT01604577|health numeracy
275741|NCT01604564|Registry
275742|NCT01604564|Colitis Ulcerosa (CU)
275743|NCT01604564|Familial Adenomatous Polyposis(FAP)
275744|NCT01604564|IPAA
275745|NCT01604512|Brain tumor
275746|NCT01604512|MRI Perfusion
275747|NCT01604512|FDG PET/CT
275748|NCT01604512|12-067
275749|NCT01604499|Healthy eating
275750|NCT01604499|Incentives
275751|NCT01604499|Feedback
275752|NCT01604486|Myocardial infarction
275753|NCT01604486|Ischaemic preconditioning
275754|NCT01604486|Myocardial Ischaemia National Audit Project
275755|NCT01604486|General Practice Research Database
275756|NCT01604486|Hospital Episode Statistics
275757|NCT01604486|Office for National Statistics
275758|NCT01604473|Chronic Kidney Disease
275759|NCT01604473|CKD
275760|NCT01604473|ESRD
275761|NCT01604473|AV Fistula
275762|NCT01604473|Arterio-venous fistula
275763|NCT01604473|hemodialysis
275764|NCT01604460|Hypothermia
275765|NCT01604460|Newborn
275766|NCT01604460|Plastic bag
275767|NCT01604460|Resuscitation
275768|NCT01604447|Hypothermia
275769|NCT01604447|Newborn
275770|NCT01604447|Incubator
275771|NCT01604447|Plastic bag
275772|NCT01604447|Normothermia
275773|NCT01604434|Hypothermia
275774|NCT01604434|Low birth Weight
275775|NCT01604434|Newborn
275776|NCT01604434|Incubator
275777|NCT01604434|Plastic bag
275778|NCT01604421|Hypothermia
275779|NCT01604421|Low birth weight
275780|NCT01604421|Newborn
275781|NCT01604421|Plastic bag
275782|NCT01604421|Thermoregulation
275783|NCT01604395|GHD
275784|NCT01604395|TS
275785|NCT01604395|CRF
275786|NCT01604395|SGA
275787|NCT01604395|ISS
275788|NCT01604382|Total Knee Arthroplasty (TKA)
275789|NCT01604369|Atrial flutter
275790|NCT01604369|Cryoablation
275791|NCT01604369|Cavotricuspid isthmus
275792|NCT01604369|Visual analogue scale
275793|NCT01604356|retinitis pigmentosa
275794|NCT01604343|Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy
275795|NCT01604343|Sirukumab
275796|NCT01604343|Human Anti-IL-6 monoclonal antibody
275797|NCT01604330|High dose baclofen
275798|NCT01604330|Alcoholism
275799|NCT01604330|Abstinence
275800|NCT01604330|Low risk consumption
275801|NCT01604330|Craving
275802|NCT01604317|Hypothermia
275803|NCT01604317|Low birth Weight
275804|NCT01604317|Newborn
275805|NCT01604317|Resuscitation
275806|NCT01604317|Plastic bag
275807|NCT01604304|stone
275808|NCT01604304|calculi
275809|NCT01604304|kidney
275810|NCT01604304|renal treatment
275811|NCT01604304|flexible ureteroscopy
275812|NCT01604304|extracoporeal shockwave lithotripsy
275813|NCT01604304|retrograde intra renal surgery
275814|NCT01604278|Indacaterol
275815|NCT01604278|Glycopyrronium Bromide
275816|NCT01604278|COPD
275817|NCT01604278|bronchodilation
275818|NCT01604239|Osteoarthritis
275819|NCT01604239|Shinbaro
275820|NCT01604239|Herbal drug
275821|NCT01604226|total intravenous anesthesia
275822|NCT01604226|Bispectral index monitoring
275823|NCT01604226|propofol
275824|NCT01604226|remifentanil
275825|NCT01604213|Type 2 diabetes mellitus
275826|NCT01604213|vildagliptin
275827|NCT01604213|metformin
275828|NCT01604213|atherosclerosis
275829|NCT01604213|inflammation
275830|NCT01604213|interleukin-6
275831|NCT01604213|TNF
275832|NCT01604213|atherothrombosis
275833|NCT01604213|adiponectin
275834|NCT01604213|MMP-9
275835|NCT01604213|hs-CRP
275836|NCT01604200|hypertension
275837|NCT01604200|dentistry
275838|NCT01604200|blood pressure
275840|NCT01604200|screening
275841|NCT01604200|qualitative research
275842|NCT01604187|sublingual fentanyl
275843|NCT01604187|pain in coloscopy
275844|NCT01604187|The efficacy and safety of fentanyl transmucosal tablet to placebo in patients having colonoscopy.
275845|NCT01604174|knee
275846|NCT01604174|osteoarthritis
275847|NCT01604174|arthroplasty
275848|NCT01604174|rehabilitation
275849|NCT01604148|Holmium Laser Enucleation of Prostate
275850|NCT01604135|Collagen crosslinking
275851|NCT01604135|Keratoconus
275852|NCT01604122|Survey
275853|NCT01604122|burden of illness
275854|NCT01604122|caregivers
275855|NCT01604122|TTR-FAP
275856|NCT01604122|TTR-CM
275857|NCT01604122|familial amyloid polyneuropathy
275858|NCT01604122|observational
275859|NCT01604122|transthyretin familial amyloidosis
275860|NCT01604109|Caries detection/diagnosis/prevention
275861|NCT01604109|Preventive Dentistry
275862|NCT01604109|Casien Phosphopeptide
275863|NCT01604109|Remineralization
275864|NCT01604109|Clinical trial
275865|NCT01604096|Information
275866|NCT01604096|campaign
275867|NCT01604096|antibiotics
275868|NCT01604096|bacterial resistance
275869|NCT01604096|primary care
275870|NCT01604083|transfusion
275871|NCT01604083|packed red blood cells (PRBC)
275872|NCT01604083|Transfusion Practice
275873|NCT01604083|Transfusion habits
275874|NCT01604083|Outcome
275875|NCT01604083|elective surgery
275876|NCT01604083|ETPOS
275877|NCT01604083|ESA
275878|NCT01604083|European Society of Anaesthesiology
275879|NCT01604070|Hammertoe deformity
275880|NCT01604070|podiatry
275881|NCT01604031|B-CLL
275882|NCT01604031|vaccine
275883|NCT01604031|Lenalidomide
275884|NCT01604031|CTL
275885|NCT01604018|Cat Allergy
275886|NCT01604018|Rhinoconjunctivitis
275887|NCT01604005|Mesothelioma
275888|NCT01604005|radiotherapy
275889|NCT01604005|prophylactic irradiation of tracts
275890|NCT01603992|Cannabis
275891|NCT01603992|Craving
275892|NCT01603992|Questionnaire
275893|NCT01603992|Non-Treatment
275894|NCT01603992|Drug Use
275895|NCT01603979|AV203
275896|NCT01603979|Solid Tumors
275897|NCT01603979|ERBB3
275898|NCT01603979|Monoclonal Antibody
275899|NCT01603979|HER3
275900|NCT01603966|platelet
275901|NCT01603966|aggregation
275902|NCT01603966|aspirin
275903|NCT01603966|inhibition
275904|NCT01603966|reactivity
275905|NCT01603940|Hypertension
275906|NCT01603940|Diabetes Mellitus
275907|NCT01603940|Vascular stiffness
275908|NCT01603940|Endothelial function
275909|NCT01603732|Strep exposure and heart defects
275910|NCT01603719|infant formula
275911|NCT01603719|prebiotics
275912|NCT01603719|beta-palmitate
275913|NCT01603719|stool flora
275914|NCT01603719|bifidogenic
275915|NCT01603706|Heart failure
275916|NCT01603706|Cardiac Resynchronization Therapy
275917|NCT01603706|CRT
275918|NCT01603706|Radial strain echocardiography
275919|NCT01603706|Ischemic cardiomyopathy
275920|NCT01603693|Guided bone regeneration
275921|NCT01603693|Bio Oss
275922|NCT01603693|BondBone
275923|NCT01603693|computerized tomography
275924|NCT01603693|histological examination
275925|NCT01603680|Ultrasonography
275926|NCT01603680|Block nerve
275927|NCT01603680|Anaesthesia
275928|NCT01603680|Carpal tunnel syndrome
275929|NCT01603654|Colon preparation
275930|NCT01603654|Colonoscopy
275931|NCT01603654|Polyethylene glycol
275932|NCT01603654|Sodium Picosulphate
275933|NCT01603589|coronary artery disease
275934|NCT01603589|coronary artery bypass grafting
275935|NCT01603589|cardiopulmonary bypass
275936|NCT01603589|minimal extracorporeal circulation
275937|NCT01603563|Stepped Care
275938|NCT01603563|Trauma-Focused Cognitive Behavioral Therapy
275939|NCT01603563|Preschool children
275940|NCT01603550|energy restriction
275941|NCT01603550|sleep deprivation
275942|NCT01603550|cognitive performance
275943|NCT01603550|brain function
275944|NCT01603537|Traumatic injuries
275945|NCT01603537|Prehospital Trauma Life Support
275946|NCT01603537|Traffic accidents
275947|NCT01603524|Ottawa Model for Smoking Cessation
275948|NCT01603524|Primary Care
275949|NCT01603511|rewarming
275950|NCT01603511|core cooling
275951|NCT01603511|afterdrop
275952|NCT01603511|pre-hospital treatment
275953|NCT01603511|hypothermia
275954|NCT01603498|pain measurement,
275955|NCT01603498|edema,
275956|NCT01603498|trismus
275957|NCT01603485|Bioavailability
275958|NCT01603485|Pharmacokinetics
275959|NCT01603485|Lersivirine
275960|NCT01603485|Modified-release
275961|NCT01603472|pediatric
275962|NCT01603472|parenteral nutrition
275963|NCT01603472|bone disease
275964|NCT01603472|long-term PN
275965|NCT01603446|pediatric
275966|NCT01603446|MELAS
275967|NCT01603446|mechanism of action of L-arginine
275968|NCT01603420|prostate
275969|NCT01603420|cancer
275970|NCT01603420|radiation
275971|NCT01603420|proton
275972|NCT01603420|chemotherapy
275973|NCT01603420|high risk
275974|NCT01603407|prednisone
275975|NCT01603407|deflazacort
275976|NCT01603407|muscular dystrophy
275977|NCT01603407|neuromuscular disease
275978|NCT01603407|multi-center
275979|NCT01603368|Probiotics
275980|NCT01603368|Lactobacillus reuteri
275981|NCT01603368|Prematures
275982|NCT01603368|Enteral feeding
275983|NCT01603368|Motility
275984|NCT01603368|Necrotizing enterocolitis
275985|NCT01603368|Sepsis
275986|NCT01603368|Weight
275987|NCT01603355|JIA
275988|NCT01603329|medication adherence
275989|NCT01603329|diabetes
275990|NCT01603329|hypertension
275991|NCT01603329|cholesterol
275992|NCT01603329|statins
275993|NCT01603316|Food pantry
275994|NCT01603316|Food voucher
275995|NCT01603316|Grocery delivery
275996|NCT01603316|12-099
275997|NCT01603303|Breast Cancer
275998|NCT01603303|Localized breast cancer
275999|NCT01603303|Postmenopausal women
276000|NCT01603303|Aromatase inhibitor
276001|NCT01603303|AI
276002|NCT01603303|Questionnaires
276003|NCT01603303|Surveys
276004|NCT01603303|Luvena
276005|NCT01603303|Internet based website
276006|NCT01603303|Phone counseling
276007|NCT01603303|Water-based vaginal lubricant
276008|NCT01603303|Hyalo-Gyn
276009|NCT01603290|Acute leukemia,
276010|NCT01603290|Chemotherapy,
276011|NCT01603290|Cancer-Related Fatigue,
276012|NCT01603290|Physical Fitness
276013|NCT01603277|Asthma
276014|NCT01603277|GM-CSF
276015|NCT01603277|Moderate-to-Severe Asthma
276016|NCT01603264|Bioequivalence
276017|NCT01603264|Biosimilarity
276018|NCT01603264|Similarity
276019|NCT01603264|PK
276020|NCT01603264|Phase I
276021|NCT01603264|Trastuzumab
276022|NCT01603264|Healthy Male Volunteers
276023|NCT01603264|Single-dose
276024|NCT01603264|HER-2
276025|NCT01603264|Oncology
276026|NCT01603251|transmission
276027|NCT01603251|anopheles
276028|NCT01603225|Autism
276029|NCT01603225|tDCS
276030|NCT01603212|Melanoma
276031|NCT01603212|Metastatic melanoma
276032|NCT01603212|Advanced melanoma
276033|NCT01603212|Vemurafenib
276034|NCT01603212|PLX4032
276035|NCT01603212|RO5185426
276036|NCT01603212|IL-2
276037|NCT01603212|Interleukin-2
276038|NCT01603212|Aldesleukin
276039|NCT01603212|Proleukin
276040|NCT01603212|Interferon Alfa-2b
276041|NCT01603212|Intron A
276042|NCT01603160|Sickle Cell Disease
276043|NCT01603160|Emergency Department
276044|NCT01603160|Quality Improvement
276045|NCT01603147|methamphetamine
276046|NCT01603147|monoclonal antibody
276047|NCT01603121|lisofylline
276048|NCT01603108|Liver Transplant Recipient
276049|NCT01603108|Recurrent Fibrosis
276050|NCT01603095|Achondroplasia
276051|NCT01603095|dwarfism
276052|NCT01603069|Parkinson's disease
276053|NCT01603069|Safety
276054|NCT01603069|Tolerability
276055|NCT01603056|House dust mite induced allergic rhinitis.
276056|NCT01603043|Geographic Atrophy
276057|NCT01603043|Age-Related Macular Degeneration
276058|NCT01603043|Intravitreal injection
276059|NCT01603030|Moxifloxacin
276060|NCT01603030|Prednisolone
276061|NCT01603030|LASIK
276062|NCT01603017|Magnetic Resonance Therapy
276063|NCT01603017|Osteoarthrosis
276064|NCT01603017|Osteoarthritis
276065|NCT01603004|MRI
276066|NCT01603004|CT
276067|NCT01603004|12-058
276068|NCT01602991|Obesity
276069|NCT01602991|Endoscopy
276070|NCT01602991|Nasopharyngoesophagogastroscopy
276071|NCT01602991|Bariatric Surgery
276072|NCT01602991|Gastric Bypass Surgery
276073|NCT01602965|obesity
276074|NCT01602965|counselling
276075|NCT01602965|weight loss
276076|NCT01602952|Radotinib
276077|NCT01602952|CML-CP, AP
276078|NCT01602939|Mast cell
276079|NCT01602939|Mastocytosis
276080|NCT01602939|Mast cell disease
276081|NCT01602926|hallux valgus
276082|NCT01602913|Pravastatin
276083|NCT01602913|Adverse Events
276084|NCT01602913|Type II Diabetes Mellitus
276085|NCT01602913|Incidence
276086|NCT01602913|Paroxetine
276087|NCT01602887|BA/BE
276088|NCT01602887|PK
276089|NCT01602887|PD-0332991
276090|NCT01602887|PF-05089326
276091|NCT01602887|Breast Cancer
276092|NCT01602874|children
276093|NCT01602874|pediatry
276094|NCT01602874|pneumonia
276095|NCT01602874|intra-abdominal
276096|NCT01602874|infection
276097|NCT01602861|Fibrosis
276098|NCT01602861|calcineurin inhibitor
276099|NCT01602861|kidney transplant
276100|NCT01602861|chronic rejection
276101|NCT01602848|Medicaid
276102|NCT01602848|frequent users
276103|NCT01602848|heavy users
276104|NCT01602848|high risk
276105|NCT01602848|high cost
276106|NCT01602848|intervention to improve care and reduce Medicaid expenditures
276107|NCT01602835|Alport syndrome
276108|NCT01602835|proteinuria
276109|NCT01602835|glomerular disease
276110|NCT01602835|hereditary nephropathy
276111|NCT01602835|nephropathy
276112|NCT01602822|HIV Prevention
276113|NCT01602822|NPEP
276114|NCT01602822|PEP
276115|NCT01602809|Perfusion
276116|NCT01602809|Microvessels
276117|NCT01602809|Ultrasound
276118|NCT01602809|Sickle Cell Disease
276119|NCT01602783|Radical Prostatectomy
276120|NCT01602770|Oral contraceptives
276121|NCT01602770|Adverse events
276122|NCT01602770|Safety profile
276123|NCT01602770|Contraceptive Agents
276124|NCT01602744|STOPP screening tool
276125|NCT01602744|START screening tool
276126|NCT01602744|MIP-medication inappropriate prescription
276127|NCT01602744|PIM-Potentially inappropriate medication
276128|NCT01602731|medication adherence
276129|NCT01602718|physical activity
276130|NCT01602718|physical performance
276131|NCT01602718|ESRD
276132|NCT01602718|home dialysis
276133|NCT01602705|Feedback (NOT MESH)
276134|NCT01602705|Medication errors
276135|NCT01602705|Medication review
276136|NCT01602705|Inappropriate medication
276137|NCT01602705|Randomised controlled trial
276138|NCT01602705|Primary Health Care
276139|NCT01602705|Family Practice
276140|NCT01602692|Pain, postoperative
276141|NCT01602692|Postoperative Nausea and Vomiting
276142|NCT01602692|Patient Readmission
276143|NCT01602692|Time to Discharge
276144|NCT01602640|sedation
276145|NCT01602640|critical care
276146|NCT01602640|morphine
276147|NCT01602640|fentanyl
276148|NCT01602640|analgesic based sedation
276149|NCT01602601|Hunter syndrome, immunogenicity, antibodies
276150|NCT01602575|IBS, FMRI, MBSR
276151|NCT01602562|Herpes simplex infection
276152|NCT01602562|valaciclovir
276153|NCT01602562|herpes simplex virus
276154|NCT01602562|hematopoietic stem cell transplantation
276155|NCT01602536|twitter
276156|NCT01602536|quit smoking
276157|NCT01602536|smoking cessation
276158|NCT01602536|social media
276159|NCT01602536|peer support
276160|NCT01602523|Emphysema
276161|NCT01602523|COPD
276162|NCT01602523|Sleep
276163|NCT01602497|Borderline personality disorder
276164|NCT01602497|repetitive transcranial magnetic stimulation
276165|NCT01602471|Endarterectomy
276166|NCT01602471|K5-C200
276167|NCT01602471|RGD-K5
276168|NCT01602471|angiogenesis
276169|NCT01602471|Carotid CT Angiogram
276170|NCT01602458|Preventative Scar Management
276171|NCT01602458|Skin Grafts
276172|NCT01602458|Silicone Therapy
276173|NCT01602458|Silicone Pressure Garment Therapy
276174|NCT01602445|Venous Thrombosis
276175|NCT01602445|Coagulation factors
276176|NCT01602445|Cancer
276177|NCT01602445|Blood
276178|NCT01602432|Venous Thrombosis
276179|NCT01602432|Cancer
276180|NCT01602432|Coagulation factors
276181|NCT01602432|Blood
276182|NCT01602406|Advanced HER2-positive Breast cancer or Gastric cancer
276183|NCT01602380|hormone receptor positive breast cancer
276184|NCT01602380|endocrine
276185|NCT01602380|no hormone therapy
276186|NCT01602380|hormone
276187|NCT01602380|breast
276188|NCT01602380|cancer
276189|NCT01602380|neoplasm
276190|NCT01602380|metastatic
276191|NCT01602380|tumour
276192|NCT01602354|Endotoxin Activity Assay
276193|NCT01602354|Gram negative
276194|NCT01602354|Septic Shock
276195|NCT01602354|EAA
276196|NCT01602341|atopic dermatitis
276197|NCT01602328|Acute Kidney Injury
276198|NCT01602328|Acute renal failure
276199|NCT01602328|Human mesenchymal stem cells
276200|NCT01602328|Allogeneic stem cells
276201|NCT01602315|BYL719
276202|NCT01602315|PI3K inhibitor
276203|NCT01602315|PIK3CA
276204|NCT01602315|cetuximab
276205|NCT01602315|EGFR
276206|NCT01602315|HNSCC
276207|NCT01602315|RM HNSCC
276208|NCT01602315|platinum-based chemotherapy
276209|NCT01602315|(RM HNSCC) patients
276210|NCT01602315|resistant or ineligible/intolerant to platinum-based chemotherapy
276211|NCT01602315|swallowing dysfunction
276212|NCT01602315|G-tube
276213|NCT01602302|rheumatoid arthritis
276214|NCT01602302|ultrasound
276215|NCT01602302|remission
276216|NCT01602302|biological DMARD
276217|NCT01602276|Parkinson's disease
276218|NCT01602276|Lewy body dementia
276219|NCT01602276|Korsakoff's syndrome
276220|NCT01602276|Subcortical Dementia
276221|NCT01602276|Huntington's Disease
276222|NCT01602263|Normal cognitive function
276223|NCT01602263|Aphasia
276224|NCT01602263|Autism
276225|NCT01602263|Schizophrenia
276226|NCT01602250|Anesthetics, local
276227|NCT01602250|Toxicity
276228|NCT01602250|Adverse effects
276229|NCT01602211|stem cell transplant
276230|NCT01602211|cancer survivors
276231|NCT01602211|internet
276232|NCT01602211|social media
276233|NCT01602211|distress
276234|NCT01602211|health care adherence
276235|NCT01602185|NMDA (N-Methyl-D-Aspartate) antagonists
276236|NCT01602185|ketamine
276237|NCT01602185|memantine
276238|NCT01602185|dextromethorphan
276239|NCT01602185|Neuropathic pain
276240|NCT01602172|alcohol consumption
276241|NCT01602172|inpatients
276242|NCT01602172|risk reduction behavior
276243|NCT01602172|counseling
276244|NCT01602172|nurses
276245|NCT01602172|brief intervention
276246|NCT01602159|Claudication
276247|NCT01602159|SFA
276248|NCT01602159|Open Bypass
276249|NCT01602159|Angioplasty
276250|NCT01602159|Stenting
276251|NCT01602146|ultramarathon central fatigue,
276252|NCT01602133|venous puncture
276253|NCT01602133|seldinger technique
276254|NCT01602133|ultrasound guidance
276255|NCT01602107|Stress
276256|NCT01602107|Urinary
276257|NCT01602107|Incontinence
276258|NCT01602107|Pelvic
276259|NCT01602107|Physiotherapy
276260|NCT01602094|measles
276261|NCT01602094|antibody
276262|NCT01602094|prevalence
276263|NCT01602094|predictors
276264|NCT01602094|Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old
276265|NCT01602094|Measles antibody levels
276266|NCT01602094|Predictors of adequate measles antibody levels and inadequate measles antibody levels
276267|NCT01602081|Anal fistula
276268|NCT01602081|Ligation of the intersphincteric fistula tract
276269|NCT01602081|LIFT
276270|NCT01602081|Tissue graft
276271|NCT01602068|Iontophoresis
276272|NCT01602068|Cataract Surgery
276273|NCT01602068|Ophthalmology
276274|NCT01602042|essential tremor
276275|NCT01602042|motion sensors
276276|NCT01602042|tremor
276277|NCT01602029|Anti inflammatory
276278|NCT01602029|Schizophrenia
276279|NCT01602029|Simvastatin
276280|NCT01602029|Ondansetron
276281|NCT01602016|ASD
276282|NCT01602016|PDD-NOS
276283|NCT01601977|COPD
276284|NCT01601977|Respiratory failure
276285|NCT01601977|NIV
276286|NCT01601977|OSA
276287|NCT01601964|VEGF, ectopic pregnancy.
276288|NCT01601951|Osteoarthritis
276289|NCT01601951|Stem Cell Injections
276290|NCT01601951|Bone Marrow
276291|NCT01601951|Autologous
276292|NCT01601938|Sepsis
276293|NCT01601938|Shock, Septic
276294|NCT01601938|Selenium
276295|NCT01601938|Survival
276296|NCT01601912|Whiplash Injuries
276297|NCT01601912|Chronic Pain
276298|NCT01601912|Exercise
276299|NCT01601912|Cognition
276300|NCT01601899|trial
276301|NCT01601899|stavudine
276302|NCT01601899|tenofovir
276303|NCT01601899|mitochondria
276304|NCT01601899|insulin resistance
276305|NCT01601899|lipids
276306|NCT01601899|HOMA
276307|NCT01601886|Intubation, Intratracheal
276308|NCT01601886|Continuous Positive Airway Pressure
276309|NCT01601886|Historical Cohort Studies
276310|NCT01601886|Clinical Trial
276311|NCT01601873|Arteriovenous graft
276312|NCT01601873|Propaten
276313|NCT01601873|Heparin-bonded
276314|NCT01601873|hemodialysis vascular access
276315|NCT01601873|Surgical
276316|NCT01601873|Arteriovenous Shunt
276317|NCT01601860|Labor
276318|NCT01601860|vaginal delivery
276319|NCT01601860|pain
276320|NCT01601834|Phase 1
276321|NCT01601834|Single Dose
276322|NCT01601834|Pharmacokinetics
276323|NCT01601834|Safety
276324|NCT01601834|Toleration
276325|NCT01601795|Cardioprotection
276326|NCT01601769|Cervical preinvasive disease
276327|NCT01601769|Colposcopy
276328|NCT01601769|Exocolposcopy
276329|NCT01601769|Leep
276330|NCT01601756|revision knee arthroplasty
276331|NCT01601756|navigation
276332|NCT01601756|joint line
276333|NCT01601743|Cocaine
276334|NCT01601743|Exercise
276335|NCT01601730|Cocaine
276336|NCT01601730|Modafinil
276337|NCT01601730|Escitalopram
276338|NCT01601717|RTI-336
276339|NCT01601717|Methamphetamine
276340|NCT01601704|Body Weight
276341|NCT01601704|Bupropion
276342|NCT01601704|Cardiovascular Diseases
276343|NCT01601704|Diabetes Mellitus
276344|NCT01601704|Diabetes Mellitus, Type 2
276345|NCT01601704|Endocrine System Diseases
276346|NCT01601704|Glucose Metabolism Disorders
276347|NCT01601704|Heart Diseases
276348|NCT01601704|Metabolic Diseases
276349|NCT01601704|Narcotic Antagonists
276350|NCT01601704|Naltrexone
276351|NCT01601704|Nutrition Disorders
276352|NCT01601704|Obesity
276353|NCT01601704|Overnutrition
276354|NCT01601704|Overweight
276355|NCT01601691|prostate cancer
276356|NCT01601691|brachytherapy
276357|NCT01601691|spacer
276358|NCT01601691|side effect
276359|NCT01601678|Achalasia
276360|NCT01601678|Heller Myotomy
276361|NCT01601678|Dysphagia
276362|NCT01601678|Peroral Endoscopic Myotomy
276363|NCT01601665|Intraocular lens
276364|NCT01601665|Cataracts
276365|NCT01601665|Astigmatism
276366|NCT01601665|Toric
276367|NCT01601652|cholestasis
276368|NCT01601652|PNAC
276369|NCT01601652|Parenteral Nutrition Associated Cholestasis
276370|NCT01601652|PNALD
276371|NCT01601652|Parenteral Nutrition Associated Liver Disease
276372|NCT01601639|Gastric Antral Vascular Ectasia
276373|NCT01601639|Argon plasma Coagulation
276374|NCT01601639|Endoscopic Band Ligation
276375|NCT01601639|GAVE
276376|NCT01601587|Introductory Seminar
276377|NCT01601587|Waiting list
276378|NCT01601587|Community Mental Health Centre
276379|NCT01601574|Type 2 diabetes
276380|NCT01601574|HbA1c
276381|NCT01601574|Overweight
276382|NCT01601574|Obesity
276383|NCT01601561|Insulin
276384|NCT01601561|Protein metabolism
276385|NCT01601561|Stress response
276386|NCT01601483|AMD
276387|NCT01601483|Dry AMD
276388|NCT01601483|Nonexudative AMD
276389|NCT01601483|MC-1101
276390|NCT01601470|LCZ696, sildenafil, pharmacokinetics, mild to moderate hypertension
276391|NCT01601444|To assess pleural effusion by measuring internal thoracic impedance
276392|NCT01601431|Screening colonoscopy
276393|NCT01601418|YF476
276394|NCT01601418|gastrin receptor antagonist
276395|NCT01601418|pentagastrin
276396|NCT01601418|gastric acid
276397|NCT01601418|healthy subjects
276398|NCT01601405|YF476
276399|NCT01601405|gastrin receptor antagonist
276400|NCT01601405|gastrin
276401|NCT01601405|gastric aspiration
276402|NCT01601405|healthy subjects
276403|NCT01601392|Ischemic stroke
276404|NCT01601392|direct current stimulation
276405|NCT01601392|motor threshold
276406|NCT01601392|National institutes of Health Stroke Scale
276407|NCT01601392|Barthel index scale
276408|NCT01601392|Measurement of motor power improvement
276409|NCT01601379|Observational
276410|NCT01601379|GERD
276411|NCT01601379|Gastroesophageal Reflux Disease
276412|NCT01601379|Gastro-oesophageal Reflux
276413|NCT01601379|Heartburn
276414|NCT01601366|Adenomyosis
276415|NCT01601366|Intrauterine levonorgestrel
276416|NCT01601366|Dysmenorrhea
276417|NCT01601366|Oral contraceptives
276418|NCT01601366|Uterus
276419|NCT01601353|Erectile Dysfunction
276420|NCT01601327|hypogonadism
276421|NCT01601327|treatment
276422|NCT01601327|testis volume
276423|NCT01601301|Limb
276424|NCT01601301|Lengthening
276425|NCT01601301|PRECICE
276426|NCT01601301|Ellipse
276427|NCT01601301|Technologies
276428|NCT01601301|Distraction
276429|NCT01601301|Osteogenesis
276430|NCT01601301|Femur
276431|NCT01601301|Tibia
276432|NCT01601301|Intramedullary
276433|NCT01601301|Nail
276434|NCT01601301|Device
276435|NCT01601301|Medical
276436|NCT01601301|Orthopedic
276437|NCT01601301|Implant
276438|NCT01601288|obstructive lung disease
276439|NCT01601288|restrictive lung disease
276440|NCT01601288|cough
276441|NCT01601288|dyspnea
276442|NCT01601275|tuberculosis
276443|NCT01601262|ED
276444|NCT01601262|LI-ESWT
276445|NCT01601249|IVF, embryo selection, polarized light
276446|NCT01601236|H.P. Acthar Gel
276447|NCT01601236|Acthar
276448|NCT01601236|diabetic nephropathy
276449|NCT01601236|proteinuria
276450|NCT01601236|nephrotic syndrome
276451|NCT01601223|Ventilatory Management
276452|NCT01601223|Mechanical Ventilation
276453|NCT01601223|Post Operative pulmonary complications
276454|NCT01601223|Intra-operative complications
276455|NCT01601223|General Anesthesia
276456|NCT01601223|Surgery
276457|NCT01601223|LAS VEGAS
276458|NCT01601223|ESA (European Society of Anaesthesiology)
276459|NCT01601223|European Society of Anaesthesiology
276460|NCT01601197|immunization
276461|NCT01601197|pain management
276462|NCT01601197|infants
276463|NCT01601197|tactile stimulation
276464|NCT01601184|medulloblastoma
276465|NCT01601184|sonic hedgehog pathway
276466|NCT01601184|vismodegib
276467|NCT01601171|GnRH deficiency
276468|NCT01601171|hypogonadism
276469|NCT01601171|anosmia
276470|NCT01601171|infertility
276471|NCT01601171|cleft lip
276472|NCT01601171|cleft palate
276473|NCT01601171|cryptorchidism
276474|NCT01601171|microphallus
276475|NCT01601158|Global developmental delay
276476|NCT01601158|Umbilical cord blood
276477|NCT01601158|Rehabilitation
276478|NCT01601145|Lactobacillus Brevis CD2
276479|NCT01601145|schoolchildren
276480|NCT01601145|dental caries
276481|NCT01601145|Gingivatis
276482|NCT01601132|pharmacokinetics
276483|NCT01601132|colchicine
276484|NCT01601132|theophylline
276485|NCT01601119|Multiple Sclerosis
276486|NCT01601119|Patient reported outcome
276487|NCT01601119|Patient reported experience
276488|NCT01601106|Atherosclerosis, inflammation
276489|NCT01601093|Respiratory and urinary tract infections
276490|NCT01601093|Ceftazidime and Sulbactam Sodium for Injection (2:1)
276491|NCT01601093|Phase Ⅱ
276492|NCT01601080|Adherence
276493|NCT01601080|Multiple Sclerosis
276494|NCT01601067|posttraumatic stress disorder
276495|NCT01601067|psychotherapy
276496|NCT01601067|alcoholism
276497|NCT01601054|spine
276498|NCT01601054|deformity
276499|NCT01601054|instrumentation
276500|NCT01601054|ALIF
276501|NCT01601041|Urinary Tract Infection
276502|NCT01601041|Bacteriuria
276503|NCT01601041|Pyuria
276504|NCT01601041|Prostatitis
276505|NCT01601041|Intermittent Catheterization
276506|NCT01601041|Spinal Cord Injuries
276507|NCT01601041|Residual Urine
276508|NCT01601028|Autoimmune Diseases
276509|NCT01601028|Sjogren's Syndrome
276510|NCT01601028|Hydroxychloroquine
276511|NCT01601015|Tension-type headache, Effectiveness, Manual therapy
276512|NCT01601002|Mirtazapine
276513|NCT01600989|shock septic
276514|NCT01600989|monocytes
276515|NCT01600989|lymphocytes
276516|NCT01600989|mitochondria
276517|NCT01600989|interleukins
276518|NCT01600989|Tumor Necrosis Factor-alpha
276519|NCT01600989|Hypoxia-Inducible Factor 1, alpha Subunit
276520|NCT01600976|Hepatic impairment
276521|NCT01600976|Hepatitis C
276522|NCT01600976|Telaprevir
276523|NCT01600976|VX-950
276524|NCT01600976|Pharmacokinetics
276525|NCT01600976|Safety
276526|NCT01600976|Unbound plasma concentrations
276527|NCT01600976|Child-Pugh score
276528|NCT01600963|Multi-drug resistant tuberculosis
276529|NCT01600963|Pre-extensively drug resistant tuberculosis
276530|NCT01600963|TMC207
276531|NCT01600963|Background regimen
276532|NCT01600937|diabetes mellitus
276533|NCT01600937|diabetes education
276534|NCT01600937|behavioral therapy
276535|NCT01600937|behavior modification
276536|NCT01600937|physical activity
276537|NCT01600937|supervised exercise
276538|NCT01600937|physical fitness
276539|NCT01600937|HbA1c
276540|NCT01600937|modifiable cardiovascular risk factors
276541|NCT01600937|quality of life
276542|NCT01600924|diabetes mellitus
276543|NCT01600924|muscle strength
276544|NCT01600924|bone strength
276545|NCT01600924|cardiovascular risk factors
276546|NCT01600924|diabetic complications
276547|NCT01600911|metabolomics
276548|NCT01600911|nutri-metabolomics
276549|NCT01600911|plant food
276550|NCT01600911|blood pressure
276551|NCT01600898|Asymptomatic carriers of a BMPR2 mutation
276552|NCT01600898|follow up study
276553|NCT01600885|Guanfacine
276554|NCT01600885|Ketamine
276555|NCT01600885|Functional Magnetic Resonance Imaging
276556|NCT01600885|Prefrontal Cortex Activity
276557|NCT01600885|Receptors, N-Methyl-D-Aspartate
276558|NCT01600885|Receptors, Adrenergic, alpha-2
276559|NCT01600885|Memory, Short-Term
276560|NCT01600885|Schizophrenia
276561|NCT01600872|EDCs
276562|NCT01600872|PCOS
276563|NCT01600872|TAS
276564|NCT01600872|TOS
276565|NCT01600872|ROS
276566|NCT01600872|Oxidative Stress, Endocrine-Disrupting Chemicals, Polycystic Ovary syndrome
276567|NCT01600846|Pharmacogenetic testing
276568|NCT01600846|pharmacokinetics
276569|NCT01600846|Pharmacogenomics
276570|NCT01600846|genetics
276571|NCT01600846|pharmacy
276572|NCT01600846|drug response
276573|NCT01600833|PCOS
276574|NCT01600833|Ferritin
276575|NCT01600833|Homocysteine
276576|NCT01600833|Insulin Resistance
276577|NCT01600833|Metabolic Syndrome
276578|NCT01600820|Plant sterol
276579|NCT01600820|Hypercholesterolemia
276580|NCT01600820|diet
276581|NCT01600820|dairy
276582|NCT01600820|LDL-C
276583|NCT01600820|Mildly hypercholesterolemic subjects
276584|NCT01600807|Metastatic
276585|NCT01600807|Pancreas
276586|NCT01600807|Cancer
276587|NCT01600807|Adenocarcinoma
276588|NCT01600794|In Vitro Fertilization (IVF)
276589|NCT01600794|androgens
276590|NCT01600794|ovary function
276591|NCT01600794|This study include the patients who are evaluated by the doctors and are sure to process the In Vitro Fertilization cycle.
276592|NCT01600781|Improve the nutritional status
276593|NCT01600781|QOL
276594|NCT01600781|children
276595|NCT01600781|enhance immune response
276596|NCT01600781|induction chemotherapy
276597|NCT01600781|fewer side effects
276598|NCT01600768|focus of study
276599|NCT01600755|Cell Therapy
276600|NCT01600755|Autologous Cell Transplantation
276601|NCT01600755|Muscle-derived Cell
276602|NCT01600755|Anal Incontinence
276603|NCT01600755|Rectal Diseases
276604|NCT01600755|Intestinal Diseases
276605|NCT01600755|Gastrointestinal Diseases
276606|NCT01600755|Urinary Incontinence
276607|NCT01600703|Intestinal lipoprotein
276608|NCT01600703|Apolipoprotein B48 and apolipoprotein B100
276609|NCT01600703|Pancreatic clamp
276610|NCT01600703|DPPIV inhibitor
276611|NCT01600690|Stem cells
276612|NCT01600690|Regeneration
276613|NCT01600690|Inflammation
276614|NCT01600677|Experimental; Computerized medication delivery unit
276615|NCT01600664|Type 1 diabetes
276616|NCT01600664|"My Diabetic friend"
276617|NCT01600664|interactive computer game
276618|NCT01600651|Receptor for advanced glycation end products (RAGE)
276619|NCT01600651|Soluble RAGE (sRAGE)
276620|NCT01600651|Recruitment Maneuver
276621|NCT01600651|Acute respiratory distress syndrome (ARDS)
276622|NCT01600651|Alveolar epithelium
276623|NCT01600651|Electrical Impedance Tomography
276624|NCT01600651|Mechanical ventilation
276625|NCT01600651|Intensive Care Unit (ICU)
276626|NCT01600638|Lipolysis
276627|NCT01600638|Cryolipolysis
276628|NCT01600638|Fat Reduction
276629|NCT01600625|meibomian gland dysfunction
276630|NCT01600625|inflammatory tear cytokine
276631|NCT01600625|minocycline
276632|NCT01600612|postpartum hemorrhage, oxytocin, carbetocin, misopristol
276633|NCT01600586|NICU
276634|NCT01600586|Music therapy
276635|NCT01600586|Premature infant
276636|NCT01600586|Oral feeds
276637|NCT01600586|Non-Nutritive Sucking
276638|NCT01600586|Suck rate
276639|NCT01600586|Suck efficiency
276640|NCT01600586|Contingent music
276641|NCT01600586|Mother's voice
276642|NCT01600573|ovarian cancer
276643|NCT01600534|gestational diabetes
276644|NCT01600508|stoma care
276645|NCT01600508|videoconference
276646|NCT01600508|costs
276647|NCT01600508|quality of life
276648|NCT01600495|pain
276649|NCT01600495|electric stimulation
276650|NCT01600495|nervous
276651|NCT01600495|transcutaneous
276652|NCT01600495|humanized childbirth
276653|NCT01600482|Hemostasis.
276654|NCT01600482|Percutaneous coronary interventions.
276655|NCT01600482|Closure Device
276656|NCT01600469|Alzheimer's disease
276657|NCT01600469|mild cognitive impairment
276658|NCT01600469|NMDA
276659|NCT01600456|PTSD
276660|NCT01600456|Antidepressants
276661|NCT01600456|Cognitive behavior therapy
276662|NCT01600430|Vitamin D
276663|NCT01600430|Newborn
276664|NCT01600430|Preterm
276665|NCT01600430|Supplementation
276666|NCT01600430|Respiratory
276667|NCT01600417|low back pain
276668|NCT01600417|spine
276669|NCT01600417|lumbar spine
276670|NCT01600417|lumbar instability
276671|NCT01600417|radiology
276672|NCT01600417|functional radiology
276673|NCT01600404|Mild Cognitive Impairment
276674|NCT01600404|Muscarinic Antagonists
276675|NCT01600404|Spinal Cord Injuries
276676|NCT01600404|Urinary Bladder, Neurogenic
276677|NCT01600404|Urinary Bladder, Overactive
276678|NCT01600404|Overactive Detrusor
276679|NCT01600391|Stroke
276680|NCT01600391|Visual cues
276681|NCT01600391|Gait rehabilitation
276682|NCT01600391|Walking adaptability
276683|NCT01600391|Turning
276684|NCT01600391|Overground walking
276685|NCT01600391|Treadmill training
276686|NCT01600378|diffuse parenchymal lung disease
276687|NCT01600378|interstitial lung disease
276688|NCT01600378|idiopathic pulmonary fibrosis
276689|NCT01600365|Conjunctivitis
276690|NCT01600365|adenovirus.
276691|NCT01600352|interstitial lung disease
276692|NCT01600352|idiopathic pulmonary fibrosis
276693|NCT01600313|rice bran oil
276694|NCT01600313|diet
276695|NCT01600313|cardiovascular disease
276696|NCT01600313|low density lipoprotein
276697|NCT01600313|total cholesterol
276698|NCT01600300|Age-related macular degeneration
276699|NCT01600300|electrical stimulation
276700|NCT01600300|randomized
276701|NCT01600300|double blind
276702|NCT01600287|bispectral index
276703|NCT01600287|propofol
276704|NCT01600287|paediatric cardiac surgery
276705|NCT01600287|closed loop anaesthesia delivery system
276706|NCT01600261|without eye disease
276707|NCT01600248|Chronic Pain
276708|NCT01600248|Military
276709|NCT01600248|Veteran
276710|NCT01600248|Online
276711|NCT01600248|Acceptance
276712|NCT01600235|Stroke, ischemic
276713|NCT01600235|Progression
276714|NCT01600235|Induced-hypertension
276715|NCT01600235|Phenylephrine
276716|NCT01600209|Cancer
276717|NCT01600209|Colorectal Cancer
276718|NCT01600209|Neoplasm
276719|NCT01600209|Colorectal Neoplasm
276720|NCT01600209|Intestinal Neoplasms
276721|NCT01600209|Gastrointestinal Neoplasms
276722|NCT01600209|Digestive System Neoplasms
276723|NCT01600209|Neoplasms by Site
276724|NCT01600209|Neoplasms
276725|NCT01600209|Digestive System Diseases
276726|NCT01600209|Gastrointestinal Diseases
276727|NCT01600209|Colonic Diseases
276728|NCT01600209|Intestinal Diseases
276729|NCT01600209|Rectal Diseases
276730|NCT01600196|Hepatectomy
276731|NCT01600196|Thrombectomy
276732|NCT01600196|Hepatocellular carcinoma
276733|NCT01600196|Portal vein tumor thrombus
276734|NCT01600183|MTA
276735|NCT01600183|metatarsus
276736|NCT01600183|Metatarsus Adductus, also known as Metatarsus Varus
276737|NCT01600170|HIV
276738|NCT01600170|monocytes
276739|NCT01600170|CD16+
276740|NCT01600170|statins
276741|NCT01600170|mcp1
276742|NCT01600170|inflammation
276743|NCT01599169|Burnout syndrome
276744|NCT01599169|Depression work-related
276745|NCT01599169|Food supplement
276746|NCT01599156|Chronic constipation
276747|NCT01599156|Reflexology
276748|NCT01599156|Complementary medicine
276749|NCT01599143|Mindfulness
276750|NCT01599143|Pain Disorder (Chronic physical or mental health complaints:
276751|NCT01599143|Fibromyalgia; Migraines; Back Pain; etc)
276752|NCT01599143|Anxiety Disorder/Anxiety State
276753|NCT01599130|Hepatitis B
276754|NCT01599130|sequential peg-interferon-2a to entecavir
276755|NCT01599117|Heart Failure with Preserved Ejection Fraction
276756|NCT01599117|Diastolic Heart Failure
276757|NCT01599117|Exercise Capacity
276758|NCT01599117|Cardiopulmonary Exercise Test
276759|NCT01599117|Udenafil (Zydena)
276760|NCT01599117|Phosphodiesterase Type 5 Inhibitors
276761|NCT01599104|Essential hypertension
276762|NCT01599104|LCZ696
276763|NCT01599091|Fibroblasts
276764|NCT01599091|Periodontal ligament
276765|NCT01599091|Gingiva
276766|NCT01599091|Porphyromonas gingivalis
276767|NCT01599091|Chronic periodontitis
276768|NCT01599091|( patients undergoing tooth extraction will be asked permission to use extracted tooth and gingiva for periodontal disease basic research)
276769|NCT01599078|Restenosis
276770|NCT01599078|Angioplasty
276771|NCT01599078|Stent
276772|NCT01599078|Atherectomy
276773|NCT01599078|Femoral Artery
276774|NCT01599078|Popliteal Artery
276775|NCT01599078|Paclitaxel
276776|NCT01599065|ICD
276777|NCT01599065|internal cardioverter defibrillator
276778|NCT01599065|electrocautery
276779|NCT01599052|Social Cognition
276780|NCT01599052|Theory of Mind
276781|NCT01599052|Emotion Recognition
276782|NCT01599052|Social competence
276783|NCT01599052|Brain Tumour
276784|NCT01599039|early diagnostics
276785|NCT01599039|lymphedema
276786|NCT01599039|breast cancer
276787|NCT01599039|breast cancer related lymphedema
276788|NCT01599039|measuring methods
276789|NCT01599039|inverse water volumetry
276790|NCT01599039|prevention
276791|NCT01599026|cardiology
276792|NCT01599026|fetus of diabetic mother
276793|NCT01599013|urothelial carcinoma
276794|NCT01599013|bladder cancer
276795|NCT01599013|vinflunine
276796|NCT01599013|transitional cell carcinoma
276797|NCT01599013|advanced or metastatic
276798|NCT01599013|unfit
276799|NCT01599013|ineligible to cisplatin
276800|NCT01599013|renal impairment
276801|NCT01599013|renal insufficiency
276802|NCT01599013|urologic neoplasms
276803|NCT01599013|urogenital neoplasm
276804|NCT01599013|urinary neoplasms
276805|NCT01599013|cisplatin
276806|NCT01599013|tubulin inhibitors
276807|NCT01599000|malaria
276808|NCT01599000|Plasmodium
276809|NCT01599000|Papua New Guinea
276810|NCT01599000|artemether/lumefantrine
276811|NCT01598987|Paediatric liver transplantation
276812|NCT01598987|Everolimus
276813|NCT01598987|Reduced calcineurin inhibitor
276814|NCT01598987|Cyclosporine, tacrolimus
276815|NCT01598987|Renal function
276816|NCT01598987|Composite efficacy endpoint (treated biopsy proven acute rejection death, graft loss)
276817|NCT01598987|Liver transplant
276818|NCT01600144|data mammography
276819|NCT01600118|tooth mobility
276820|NCT01600118|periodontal status
276821|NCT01600118|irregularity index
276822|NCT01600118|pulpal blood flow
276823|NCT01600105|liver fibrosis
276824|NCT01600105|liver cirrhosis
276825|NCT01600105|chronic hepatitis
276826|NCT01600105|magnetic resonance imaging
276827|NCT01600079|Varicella-zoster vaccine
276828|NCT01600079|herpes zoster
276829|NCT01600079|shingles
276830|NCT01600079|Varicella-zoster virus
276831|NCT01600079|postherpetic neuralgia
276832|NCT01600079|Herpesviridae Infections
276833|NCT01600079|DNA Virus Infections
276834|NCT01600079|Virus Diseases
276835|NCT01600053|Chronic
276836|NCT01600053|Lymphocytic
276837|NCT01600053|Leukemia
276838|NCT01600040|metastatic
276839|NCT01600027|Fascia iliaca block
276840|NCT01600027|dexmetomidine
276841|NCT01600027|fracture femur
276842|NCT01600027|α2 agonist
276843|NCT01600001|Chronic Idiopathic Constipation (CIC)
276844|NCT01600001|Constipation
276845|NCT01600001|Functional gastrointestinal disorders
276846|NCT01599975|HAND
276847|NCT01599975|HIV Associated Neurocognitive Disorder
276848|NCT01599975|Methylphenidate
276849|NCT01599975|HIV Dementia
276850|NCT01599949|Mantle cell lymphoma
276851|NCT01599949|Ibrutinib
276852|NCT01599949|Bruton's tyrosine kinase inhibitor
276853|NCT01599949|Rituximab
276854|NCT01599949|Bortezomib
276855|NCT01599936|scorpion sting
276856|NCT01599936|envenomation
276857|NCT01599936|Anascorp
276858|NCT01599923|scorpion
276859|NCT01599923|envenomation
276860|NCT01599923|Alacramyn
276861|NCT01599910|Scribes
276862|NCT01599910|Physician Productivity
276863|NCT01599910|Electronic Documentation
276864|NCT01599897|Tuberculosis
276865|NCT01599897|TB
276866|NCT01599897|Pulmonary
276867|NCT01599897|Vaccine
276868|NCT01599884|Chronic obstructive pulmonary disease
276869|NCT01599884|Chronic bronchitis
276870|NCT01599884|N-acetylcysteine
276871|NCT01599871|COPD
276872|NCT01599858|YF476
276873|NCT01599858|gastrin receptor antagonist
276874|NCT01599858|gastric pH
276875|NCT01599858|healthy subjects
276876|NCT01599858|omeprazole
276877|NCT01599845|Lung
276878|NCT01599845|Alveoli
276879|NCT01599845|Nanoparticles
276880|NCT01599845|Particulate matter
276881|NCT01599845|Exhaled breath condensate
276882|NCT01599845|Induced sputum
276883|NCT01599845|Forced expiratory volume
276884|NCT01599845|Force vital capacity
276885|NCT01599806|Ceftazidime, Avibactam, Doripenem, Ciprofloxacin, sulfamethoxazole/trimethoprim, Anti-Infective Agents, Complicated Urinary Tract Infection,Acute Pyelonephritis
276886|NCT01599793|castrate resistant prostate cancer
276887|NCT01599793|CRPC
276888|NCT01599793|cabozantinib
276889|NCT01599793|XL184
276890|NCT01599780|preterm
276891|NCT01599780|premature
276892|NCT01599780|prematurity
276893|NCT01599780|children
276894|NCT01599780|child
276895|NCT01599780|kid
276896|NCT01599780|toddler
276897|NCT01599780|infant
276898|NCT01599780|baby
276899|NCT01599780|language
276900|NCT01599780|development
276901|NCT01599780|skills
276902|NCT01599780|listening
276903|NCT01599780|talking
276904|NCT01599780|communication
276905|NCT01599780|speech
276906|NCT01599780|processing
276907|NCT01599767|transcranial stimulation
276908|NCT01599767|direct current
276909|NCT01599754|renal cell carcinoma
276910|NCT01599754|axitinib
276911|NCT01599754|tyrosine kinase inhibitor
276912|NCT01599741|X-rays
276913|NCT01599741|Endovascular angiography
276914|NCT01599741|Image processing
276915|NCT01599728|Urocortin 2
276916|NCT01599728|Urocortin 3
276917|NCT01599728|Forearm venous occlusion plethysmography
276918|NCT01599728|Heart failure
276919|NCT01599728|Endothelium
276920|NCT01599728|Substance P
276921|NCT01599715|Urinary Incontinence
276922|NCT01599715|Weak bladder
276923|NCT01599715|Frequent urination
276924|NCT01599715|Overactive bladder
276925|NCT01599715|Urine leakage
276926|NCT01599715|Stress incontinence
276927|NCT01599715|Urge Incontinence
276928|NCT01599715|Pelvic Floor weakness
276929|NCT01599715|Pelvic Floor Muscle Exercises
276930|NCT01599715|Kegel exercises
276931|NCT01599715|Self-Care
276932|NCT01599702|IBD
276933|NCT01599702|IDA
276934|NCT01599702|Subjects
276935|NCT01599702|diagnosis
276936|NCT01599689|Delirium
276937|NCT01599689|Delirium, Dementia, Amnestic, Cognitive Disorders
276938|NCT01599689|Confusion
276939|NCT01599689|Neurobehavioral Manifestations
276940|NCT01599689|Neurologic Manifestations
276941|NCT01599689|Nervous System Diseases
276942|NCT01599689|Signs and Symptoms
276943|NCT01599689|Mental Disorders
276944|NCT01599689|Cardiac Surgery
276945|NCT01599689|Mirrors
276946|NCT01599676|Citrulline
276947|NCT01599676|protein-energy malnutrition
276948|NCT01599676|amino acids
276949|NCT01599676|muscle strength
276950|NCT01599676|resistance training
276951|NCT01599663|Pain management
276952|NCT01599663|Pain assessment
276953|NCT01599663|Intensive care unit
276954|NCT01599663|Adult
276955|NCT01599650|Macular Edema, Branch Retinal Vein Occlusion, visual impairment
276956|NCT01599637|Chronic idiopathic urticaria
276957|NCT01599637|CIU
276958|NCT01599637|Xolair
276959|NCT01599637|IGE025
276960|NCT01599637|FcεRI
276961|NCT01599637|IgE
276962|NCT01599624|Resilience
276963|NCT01599624|Perceived stress
276964|NCT01599624|PTSD symptoms
276965|NCT01599624|Depression
276966|NCT01599624|Anxiety
276967|NCT01599624|Sleep quality
276968|NCT01599624|United States Navy service members
276969|NCT01599611|Neonatal hyperbilirubinemia
276970|NCT01599611|Follow-up
276971|NCT01599611|Motor development
276972|NCT01599611|Hearing
276973|NCT01599611|Executive function
276974|NCT01599598|perceived stress
276975|NCT01599598|depression
276976|NCT01599598|anxiety
276977|NCT01599598|posttraumatic stress disorder
276978|NCT01599598|military
276979|NCT01599598|school
276980|NCT01599598|training environment
276981|NCT01599598|heart rate variability
276982|NCT01599598|progressive muscle relaxation
276983|NCT01599598|psychophysiological coherence
276984|NCT01599598|coherence advantage
276985|NCT01599598|stress reduction
276986|NCT01599598|stress regulation
276987|NCT01599598|independent duty corpsmen
276988|NCT01599585|Depression
276989|NCT01599585|Behavioral Activation
276990|NCT01599585|Tele-medicine
276991|NCT01599572|zinc supplementation
276992|NCT01599572|serum zinc concentration
276993|NCT01599572|lymphocyte proliferation
276994|NCT01599559|previously
276995|NCT01599559|untreated
276996|NCT01599546|Preterm
276997|NCT01599546|Full term
276998|NCT01599546|Reading
276999|NCT01599546|Dyslexia
277000|NCT01599546|Brain
277001|NCT01599546|Diffusion tensor imaging
277002|NCT01599520|cancer
277003|NCT01599520|stress
277004|NCT01599520|stress management
277005|NCT01599520|Latinas
277006|NCT01599520|Hispanics
277007|NCT01599507|Anemia
277008|NCT01599507|Renal
277009|NCT01599481|Common mental illness
277010|NCT01599481|Supported Employment
277011|NCT01599481|Anxiety
277012|NCT01599481|Depression
277013|NCT01599481|Sickness absence
277014|NCT01599468|post partum hemorrhage
277015|NCT01599468|transfusion
277016|NCT01599468|tranexamic acid
277017|NCT01599455|pediatric spinal cord injury
277018|NCT01599455|blood pressure
277019|NCT01599455|heart rate
277020|NCT01599455|baseline
277021|NCT01599429|AML / LMA
277022|NCT01599416|Oral Probiotics
277023|NCT01599416|HPV DNA Index Test
277024|NCT01599416|Vaginal infection
277025|NCT01599403|Rib Fracture
277026|NCT01599403|Intercostal Nerve Block
277027|NCT01599403|Paravertebral Nerve Block
277028|NCT01599390|United States
277029|NCT01599390|Burden of Disease
277030|NCT01599390|Influenza
277031|NCT01599364|HIV infection
277032|NCT01599364|Atazanavir
277033|NCT01599364|Lamivudine
277034|NCT01599364|Ritonavir
277035|NCT01599364|virological suppression
277036|NCT01599364|non-inferiority
277037|NCT01599364|Combined antiretroviral therapy
277038|NCT01599351|Radiation exposure
277039|NCT01599351|ERCP
277040|NCT01599338|Liraglutide
277041|NCT01599338|GLP-1 analogue
277042|NCT01599338|Food preference
277043|NCT01599338|Gustative perception
277044|NCT01599338|Liking
277045|NCT01599338|wanting
277046|NCT01599338|T2DM
277047|NCT01599338|body mass composition
277048|NCT01599338|leptin
277049|NCT01599338|ghrelin
277050|NCT01599312|Videolaryngoscopy
277051|NCT01599312|Forces
277052|NCT01599312|Teeth
277053|NCT01599299|ultrasound
277054|NCT01599299|left and right jugular vein
277055|NCT01599299|comparison
277056|NCT01599286|Hyperammonia
277057|NCT01599286|propionic acidemia (PA)
277058|NCT01599286|methylmalonic acidemia (MMA)
277059|NCT01599286|late-onset CPS1 deficiency (CPSD)
277060|NCT01599286|late-onset Ornithine transcarbamylase deficiency (OTCD)
277061|NCT01599286|Carbaglu
277062|NCT01599273|thyroid-associated ophthalmopathy
277063|NCT01599273|triamcinolone
277064|NCT01599273|retraction
277065|NCT01599273|swelling
277066|NCT01599247|Suicide
277067|NCT01599247|Optimism
277068|NCT01599247|Hopelessness
277069|NCT01599221|Femoral fractures
277070|NCT01599221|Nail
277071|NCT01599221|Implant
277072|NCT01599221|Elderly
277073|NCT01599221|Orthopaedics
277074|NCT01599195|carotid stenosis
277075|NCT01599195|femoral artery ischemia
277076|NCT01599195|carotid bruit asymptomatic
277077|NCT01599195|carotid murmur
277078|NCT01598974|Lower Back Pain
277079|NCT01598974|Acupuncture
277080|NCT01598948|hypercholesterolemia
277081|NCT01598948|apheresis
277082|NCT01598948|coronary heart disease
277083|NCT01598948|cerebrovascular disease
277084|NCT01598948|peripheral arterial disease
277085|NCT01598922|Depression
277086|NCT01598922|Internet Cognitive Behavioral Therapy
277087|NCT01598922|fMRI
277088|NCT01598922|Neuroimaging
277089|NCT01598909|blepharoplasty
277090|NCT01598909|arnica
277091|NCT01598909|homeopathy
277092|NCT01598896|Cannabis Dependence
277093|NCT01598896|Marijuana Dependence
277094|NCT01598896|Cannabis Use Disorders
277095|NCT01598896|Cannabis Withdrawal
277096|NCT01598896|Dronabinol
277097|NCT01598896|Clonidine
277098|NCT01598896|Schizophrenia
277472|NCT01597167|magnesium sulfate
277099|NCT01598870|Spontaneous bacterial peritonitis.
277100|NCT01598857|granulomatosis with polyangiitis
277101|NCT01598857|microscopic polyangiitis
277102|NCT01598857|anti-neutrophil cytoplasmic antibodies
277103|NCT01598857|ANCA-associated vasculitis
277104|NCT01598857|Wegener Granulomatosis
277105|NCT01598831|sepsis
277106|NCT01598818|Vision Nearsighted
277107|NCT01598818|Vision Farsighted
277108|NCT01598805|venous thromboembolism/prevention & control
277109|NCT01598779|genital warts
277110|NCT01598779|HPV types
277111|NCT01598779|Sexually Transmitted Diseases
277112|NCT01598779|Skin Diseases, Viral
277113|NCT01598779|Tumor Virus Infections
277114|NCT01598779|Skin Diseases, Infectious
277115|NCT01598779|Skin Diseases
277116|NCT01598779|Papillomavirus Infections
277117|NCT01598779|DNA Virus Infections
277118|NCT01598779|Virus Diseases
277119|NCT01598779|Sexually Transmitted Diseases, Viral
277120|NCT01598727|parathyroid surgery
277121|NCT01598701|Acetaminophen
277122|NCT01598701|Intravenous Acetaminophen
277123|NCT01598701|Opioid Requirement
277124|NCT01598701|Pain
277125|NCT01598701|Post-Operative Pain
277126|NCT01598701|Craniotomy
277127|NCT01598701|Post-Craniotomy Pain
277128|NCT01598688|Bone marrow transplantation
277129|NCT01598688|Hematopoietic stem cell transplantation
277130|NCT01598688|Medication management
277131|NCT01598688|Nursing care
277132|NCT01598675|stroke
277133|NCT01598675|Gait
277134|NCT01598675|walking
277135|NCT01598662|IUD placement
277136|NCT01598662|contraception
277137|NCT01598662|postpartum
277138|NCT01598662|intrauterine device
277139|NCT01598662|expulsion
277140|NCT01598649|Dietary protein
277141|NCT01598649|Lupin protein
277142|NCT01598649|Cholesterol metabolism
277143|NCT01598649|Protein metabolism
277144|NCT01598649|Hypercholesterolemia
277145|NCT01598649|Protein-enriched foods
277146|NCT01598584|Mirtazapine
277147|NCT01598584|gemcitabine
277148|NCT01598584|placebo
277149|NCT01598584|RCT
277150|NCT01598584|pancreatic cancer
277151|NCT01598571|Phase 1
277152|NCT01598571|Healthy male volunteers
277153|NCT01598571|pharmacokinetics
277154|NCT01598571|fostamatinib
277155|NCT01598571|Bioavailability
277156|NCT01598571|R406 plasma AUC and Cmax
277157|NCT01598571|R406 plasma AUC0-t
277158|NCT01598571|t1/2λz
277159|NCT01598571|tmax
277160|NCT01598532|mild traumatic brain injury
277161|NCT01598532|mild TBI
277162|NCT01598532|mTBI
277163|NCT01598519|school-based
277164|NCT01598519|adolescent suicide
277165|NCT01598519|intervention
277166|NCT01598519|screening
277167|NCT01598493|Burns
277168|NCT01598493|Wound Healing
277169|NCT01598480|Burns
277170|NCT01598480|Wound Healing
277171|NCT01598467|pelvic organ prolapse
277172|NCT01598467|POP
277173|NCT01598467|sacrocolpopexy
277174|NCT01598467|sacrohysteropexy
277175|NCT01598467|promontofixation
277176|NCT01598467|colpopexy
277177|NCT01598467|robotic surgery
277178|NCT01598467|surgical complications
277179|NCT01598467|mesh
277180|NCT01598467|prolapse repair
277181|NCT01598441|pulmonary hypertension, pulmonary hypertensive crisis
277182|NCT01598428|age related cataract
277183|NCT01598428|phacoemulsification
277184|NCT01598428|anterior capsule polishing
277185|NCT01598428|optical coherence tomography
277186|NCT01598428|anterior chamber depth
277187|NCT01598402|LAHNC
277188|NCT01598402|Locally Advanced Head and Neck Cancer
277189|NCT01598376|entropion
277190|NCT01598376|suture
277191|NCT01598376|granuloma
277192|NCT01598376|tissue reaction
277193|NCT01598350|Gait
277194|NCT01598350|Orthoses
277195|NCT01598350|Down syndrome
277196|NCT01598324|magnetic resonance imaging
277197|NCT01598324|magnetic resonance spectroscopy
277198|NCT01598324|depression
277199|NCT01598324|escitalopram
277200|NCT01598324|selective serotonin reuptake inhibitor
277201|NCT01598324|treatment-resistant depression
277202|NCT01598324|ziprasidone
277203|NCT01598311|CDAD
277204|NCT01598311|Clostridium difficile Associated Diarrhea
277205|NCT01598311|CDI
277206|NCT01598311|Clostridium difficile Infection
277207|NCT01598311|Diarrhea
277208|NCT01598298|estrogen receptor-positive breast cancer
277209|NCT01598298|progesterone receptor-positive breast cancer
277210|NCT01598298|stage IA breast cancer
277211|NCT01598298|stage IB breast cancer
277212|NCT01598298|stage II breast cancer
277213|NCT01598298|stage IIIA breast cancer
277214|NCT01598298|stage IIIB breast cancer
277215|NCT01598298|stage IIIC breast cancer
277216|NCT01598298|pain
277217|NCT01598298|musculoskeletal complications
277218|NCT01598285|Genome-Wide
277219|NCT01598285|GWAS
277220|NCT01598285|microRNA
277221|NCT01598285|miRNA
277222|NCT01598285|Bevacizumab Response Predictors
277223|NCT01598285|Metastatic Breast Cancer
277224|NCT01598272|Ginseng
277225|NCT01598272|Cordyceps
277226|NCT01598272|Pomegranate
277227|NCT01598272|Red Orange
277228|NCT01598272|Grape Seed
277229|NCT01598272|Broccoli Seed
277230|NCT01598246|Extubation failures
277231|NCT01598246|Sedation
277232|NCT01598220|schizophrenia
277233|NCT01598220|cognitive remediation therapy
277234|NCT01598220|cognition
277235|NCT01598220|quality of life
277236|NCT01598194|solid pancreatic mass lesions
277237|NCT01598194|22-gauge core biopsy needle
277238|NCT01598194|reverse bevel design
277239|NCT01598194|endoscopic ultrasound
277240|NCT01598194|EUS
277241|NCT01598194|guided
277242|NCT01598194|fine needle aspiration
277243|NCT01598194|FNA
277244|NCT01598168|rivaroxaban
277245|NCT01598168|treatment
277246|NCT01598168|venous thromboembolism
277247|NCT01598168|arterial thromboembolism
277248|NCT01598168|thrombocytopenia
277249|NCT01598155|dental biofilm
277250|NCT01598155|periodontitis
277251|NCT01598155|maintenance
277252|NCT01598155|randomized clinical trial
277253|NCT01598155|biomarkers
277254|NCT01598155|bacterias
277255|NCT01598155|gingival crevicular fluid
277256|NCT01598142|Endoscopic retrograde cholangiopancreatography (ERCP)
277257|NCT01598142|Guidewires
277258|NCT01598142|Cannulation
277259|NCT01598142|Single-operator
277260|NCT01598142|C-Hook
277261|NCT01598129|Phase I
277262|NCT01598129|Dose escalation
277263|NCT01598129|oncolytic virus
277264|NCT01598103|Neurogenic detrusor overactivity
277265|NCT01598103|spinal cord lesions
277266|NCT01598103|spinal cord injury
277267|NCT01598077|Breast cancer, gastric cancer, squamous cell carcinoma of head and neck, esophageal squamous cell carcinoma
277268|NCT01598077|Breast cancer
277269|NCT01598077|Gastric cancer
277270|NCT01598077|Squamous cell carcinoma of head and neck
277271|NCT01598077|Esophageal squamous cell carcinoma
277272|NCT01598051|Xarelto
277273|NCT01598051|SPAF
277274|NCT01598051|QOL
277275|NCT01598038|cancer
277276|NCT01598038|renal
277277|NCT01598038|Afinitor
277278|NCT01598038|pharmacokinetics
277279|NCT01598025|ANTITHYMOCYTE GLOBULIN:ATG
277280|NCT01598025|FLUDARABINE
277281|NCT01598025|THI0TEPA
277282|NCT01598025|CliniMACS-CD34 Reagent System
277283|NCT01598025|12-053
277284|NCT01598012|Ayurved Siriraj Prasaplai
277285|NCT01598012|primary dysmenorrhea
277286|NCT01597986|isavuconazole
277287|NCT01597986|ethinyl estradiol
277288|NCT01597986|norethindrone
277289|NCT01597986|contraceptive
277290|NCT01597986|Healthy Volunteers
277291|NCT01597986|BAL8557
277292|NCT01597986|BAL4815
277293|NCT01597934|Chronic hepatitis B
277294|NCT01597934|Partial virologic response
277295|NCT01597934|YMDD mutation
277296|NCT01597921|Breast conserving surgery
277297|NCT01597921|Radiation dermatitis
277298|NCT01597908|BRAF inhibitor
277299|NCT01597908|Metastatic Melanoma
277300|NCT01597908|Cancer
277301|NCT01597908|MEK inhibitor
277302|NCT01597895|maraviroc
277303|NCT01597895|boceprevir
277304|NCT01597895|telaprevir
277305|NCT01597895|drug interaction
277306|NCT01597895|pharmacokinetics
277307|NCT01597895|HIV
277308|NCT01597882|case management
277309|NCT01597882|long term conditions
277310|NCT01597882|aged sixty five and over
277311|NCT01597843|education
277312|NCT01597843|self care
277313|NCT01597843|peer group
277314|NCT01597843|Computers
277315|NCT01597843|Attitude to computers
277316|NCT01597830|knee
277317|NCT01597830|osteoarthritis
277318|NCT01597830|loading
277319|NCT01597817|Atopic dermatitis
277320|NCT01597817|Eczema
277321|NCT01597817|Textiles
277322|NCT01597791|Urinary Retention
277323|NCT01597791|Urinary Catheter
277324|NCT01597791|Bacteriuria
277325|NCT01597778|Haplo identical transplant
277326|NCT01597778|Cord blood transplant
277327|NCT01597778|Reduced intensity conditioning regimen
277328|NCT01597778|Lymphoma
277329|NCT01597778|Leukemia
277330|NCT01597765|Thalassemia
277331|NCT01597765|Oxidative stress
277332|NCT01597765|antioxidant cocktail
277333|NCT01597752|Immunotherapy
277334|NCT01597752|Skin prick test
277335|NCT01597752|Standardization
277336|NCT01597752|Blomia tropicalis
277337|NCT01597739|Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy
277338|NCT01597739|Disease-modifying antirheumatic drugs
277339|NCT01597726|Abortion, Induced
277340|NCT01597726|Laminaria
277341|NCT01597726|Misoprostol
277342|NCT01597726|Pregnancy Trimester, Second
277343|NCT01597687|pertussis infection
277344|NCT01597687|Prevalence
277345|NCT01597687|health economic burden
277346|NCT01597687|prolonged cough
277347|NCT01597674|YF476
277348|NCT01597674|gastrin receptor antagonist
277349|NCT01597674|gastric pH
277350|NCT01597674|gastrin
277351|NCT01597674|healthy subjects
277352|NCT01597661|first trimester
277353|NCT01597661|left outflow tract obstruction
277354|NCT01597661|Bupropion
277355|NCT01597661|cardiovascular malformation
277356|NCT01597661|antidepressants
277357|NCT01597661|pregnancy
277358|NCT01597661|cardiovascular defect
277359|NCT01597661|congenital malformation
277360|NCT01597648|Combivir™, HIV, bioequivalence, Combined Formulated Tablet, Combined Formulated Tablet, HIV, bioequivalence, Combivir, Selzentry™, Celsentri™, lamivudine, zidov
277361|NCT01597635|rhACE2
277362|NCT01597635|Acute Respiratory Distress Syndrome (ARDS)
277363|NCT01597635|Acute Lung Injury
277364|NCT01597635|GSK2586881
277365|NCT01597635|critical care
277366|NCT01597622|SELENA
277367|NCT01597622|belimumab
277368|NCT01597622|Lupus
277369|NCT01597622|systemic lupus erythematosus
277370|NCT01597622|PGA
277371|NCT01597622|BLys
277372|NCT01597622|SLE Flare Index
277373|NCT01597622|continuation
277374|NCT01597622|phase III
277375|NCT01597622|BILAG
277376|NCT01597622|extension
277377|NCT01597622|efficacy
277378|NCT01597622|SRI
277379|NCT01597622|B cell
277380|NCT01597622|SLEDAI
277381|NCT01597622|safety
277382|NCT01597622|Asia
277383|NCT01597622|B lymphocyte
277384|NCT01597557|Atrial Fibrillation
277385|NCT01597557|Electrical Cardioversion
277386|NCT01597557|Magnesium Sulfate
277387|NCT01597544|Voiding dysfunction
277388|NCT01597544|bladder catheter
277389|NCT01597544|prolapse surgery
277390|NCT01597544|patient satisfaction
277391|NCT01597531|Liraglutide
277392|NCT01597531|Orlistat
277393|NCT01597518|Riluzole
277394|NCT01597518|spinal cord injury
277395|NCT01597518|treatment
277396|NCT01597505|CDAD
277397|NCT01597505|Clostridium difficile Associated Diarrhea
277398|NCT01597505|CDI
277399|NCT01597505|Clostridium difficile Infection
277400|NCT01597505|Diarrhea
277401|NCT01597492|Antibodies
277402|NCT01597492|Vaccines
277403|NCT01597492|SLE
277404|NCT01597492|Immune System Diseases
277405|NCT01597492|Biological Therapy
277406|NCT01597492|Autoimmune Diseases
277407|NCT01597492|Pneumococcal Vaccines
277408|NCT01597492|Lupus
277409|NCT01597492|Immunoglobulins
277410|NCT01597492|Vaccination
277411|NCT01597492|Belimumab
277412|NCT01597492|Biological Agents
277413|NCT01597492|Immunization
277414|NCT01597479|Ultrasound guided distal peripheral nerve blocks
277415|NCT01597453|Young ischemic stroke
277416|NCT01597453|Families
277417|NCT01597453|Long-term follow-up
277418|NCT01597440|Propionic acidemia (PA)
277419|NCT01597440|Methylmalonic acidemia (MMA)
277420|NCT01597440|Carbaglu NCG
277421|NCT01597440|Hyperammonia
277422|NCT01597427|Clonidine
277423|NCT01597427|Hypertension Pulmonary
277424|NCT01597427|Cardiac Surgical Procedures
277425|NCT01597401|Antisickling Agents
277426|NCT01597388|Estrogen receptor positive
277427|NCT01597388|Advanced metastatic breast cancer
277428|NCT01597388|Estrogen receptor positive advanced metastatic breast cancer
277429|NCT01597375|Aspirin
277430|NCT01597375|Prasugrel
277431|NCT01597375|Asthma
277432|NCT01597375|AERD
277433|NCT01597375|Aspirin challenge
277434|NCT01597375|Aspirin desensitization
277435|NCT01597375|Aspirin induced asthma
277436|NCT01597362|laparoscopy
277437|NCT01597362|trocars
277438|NCT01597362|veress
277439|NCT01597362|open
277440|NCT01597362|direct
277441|NCT01597336|abscess
277442|NCT01597336|tPA
277443|NCT01597323|Wrinkle Reduction
277444|NCT01597323|Skin Resurfacing
277445|NCT01597323|Skin Texture Improvement
277446|NCT01597284|Oral therapies
277447|NCT01597284|Cancer
277448|NCT01597284|cognitive function
277449|NCT01597284|compliance
277450|NCT01597258|Safety
277451|NCT01597258|All cases surveillance in Japan
277452|NCT01597258|ALK-positive unresectable advanced and/or recurrent non-small cell lung cancer
277453|NCT01597232|Transfusion trigger
277454|NCT01597232|Hemoglobin level
277455|NCT01597219|Haploidentical transplant
277456|NCT01597219|Haematological malignancy
277457|NCT01597219|Myeloablative
277458|NCT01597219|Reduced intensity
277459|NCT01597206|randomized controlled trial
277460|NCT01597206|intervention
277461|NCT01597206|posterior reduced dental arch
277462|NCT01597206|patient satisfaction
277463|NCT01597206|sequential sampling
277464|NCT01597193|enzalutamide
277465|NCT01597193|MDV3100
277466|NCT01597193|breast cancer
277467|NCT01597180|contraception
277468|NCT01597180|HIV
277469|NCT01597180|pharmacokinetics
277470|NCT01597180|pharmacodynamics
277471|NCT01597167|mild moderate treatment-resistant depression
277473|NCT01597154|Adolescent
277474|NCT01597154|Type 2 Diabetes
277475|NCT01597154|Peer mentorship
277476|NCT01597141|Prodromal
277477|NCT01597141|Schizophrenia
277478|NCT01597141|Psychosis
277479|NCT01597141|Family psychoeducation
277480|NCT01597141|Assertive community treatment
277481|NCT01597141|Supported employment
277482|NCT01597141|Supported education
277483|NCT01597128|Hernia
277484|NCT01597128|human tissue
277485|NCT01597128|mesh
277486|NCT01597115|duplex study
277487|NCT01597115|hemodialysis access
277488|NCT01597115|maturation rate
277489|NCT01597115|endovascular intervention
277490|NCT01597102|encephalopathy, hepatic
277491|NCT01597102|autoregulation, cerebrovascular
277492|NCT01597102|liver failure
277493|NCT01597102|liver transplantation
277494|NCT01597089|Specificity
277495|NCT01597089|Bronchoalveolar Lavage
277496|NCT01597089|Film Array Assay
277497|NCT01597089|Nasopharyngeal Swab
277498|NCT01597089|Sensitivity
277499|NCT01597076|Morinda citrifolia
277500|NCT01597076|noni
277501|NCT01597076|advanced glycation end products
277502|NCT01597076|oxidative stress
277503|NCT01597076|quality of life
277504|NCT01597076|metabolic syndrome
277505|NCT01597076|safety
277506|NCT01597050|Discoid Lupus Erythematosus
277507|NCT01597050|Systemic Lupus Erythematosus
277508|NCT01597037|Aphasia
277509|NCT01597037|Speech Rehabilitation
277510|NCT01597024|appetite
277511|NCT01597024|food
277512|NCT01597024|gut
277513|NCT01597024|brain
277514|NCT01597024|satiety
277515|NCT01597024|hunger
277516|NCT01597024|gut hormones
277517|NCT01597011|Hernia, Inguinal
277518|NCT01597011|Hernia repair
277519|NCT01597011|Fibrin Tissue Adhesive
277520|NCT01597011|Tisseel
277521|NCT01597011|Tissucol
277522|NCT01597011|Recurrence
277523|NCT01597011|Chronic Pain
277524|NCT01597011|Dysejaculation
277525|NCT01596998|anesthesia, conduction
277526|NCT01596998|transversus abdominis plane block
277527|NCT01596998|Vasoconstrictor Agents
277528|NCT01596998|Ultrasonography
277529|NCT01596985|Endometrioma
277530|NCT01596985|Endometriosis
277531|NCT01596985|Cystectomy
277532|NCT01596985|Ablation
277533|NCT01596985|Plasma energy
277534|NCT01596959|atrial flutter
277535|NCT01596959|ablation
277536|NCT01596959|irrigation
277537|NCT01596959|contact
277538|NCT01596959|ECI
277539|NCT01596946|contact tracing
277540|NCT01596946|home sampling
277541|NCT01596946|cluster randomisation
277542|NCT01596933|head and neck cancer
277543|NCT01596933|omega-3 fatty acid supplementation
277544|NCT01596933|echium oil
277545|NCT01596933|weight loss
277546|NCT01596933|cancer cachexia
277547|NCT01596933|body composition
277548|NCT01596933|biomarker
277549|NCT01596933|quality of life
277550|NCT01596920|Chronic DFUs
277551|NCT01596920|Diabetic Foot Ulcers
277552|NCT01596907|resting energy expenditure
277553|NCT01596907|fat free mass
277554|NCT01596907|lean body mass
277555|NCT01596907|bariatric surgery
277556|NCT01596907|morbid obesity
277557|NCT01596907|ephedrine
277558|NCT01596907|caffeine
277559|NCT01596907|Low metabolic rate
277560|NCT01596907|Low lean body mass
277561|NCT01596907|Weight loss rate
277562|NCT01596894|Pediatric
277563|NCT01596894|Crohn's disease
277564|NCT01596894|Azithromycin
277565|NCT01596894|Metronidazole
277566|NCT01596894|Mild to moderate Crohn's Disease
277567|NCT01596881|Multiple sclerosis
277568|NCT01596881|Blood flow
277569|NCT01596881|Optical Coherence Tomography
277570|NCT01596881|Imaging
277571|NCT01596868|Advanced Nasopharyngeal Carcinoma
277572|NCT01596868|treatment
277573|NCT01596868|Northwest China
277574|NCT01596855|Anemia
277575|NCT01596855|Renal
277576|NCT01596842|Omega-3 fatty acid
277577|NCT01596842|vitamin D
277578|NCT01596842|ergocalciferol
277579|NCT01596842|hemodialysis
277580|NCT01596829|antibiotic
277581|NCT01596829|probiotic
277582|NCT01596829|antibiotic-associated diarrhoea
277583|NCT01596829|faecal microbiota
277584|NCT01596816|prostate cancer
277585|NCT01596803|FSHD
277586|NCT01596803|Antioxidants
277587|NCT01596803|Oxidative stress
277588|NCT01596803|Muscle function
277589|NCT01596803|Quality of life
277590|NCT01596803|Activity
277591|NCT01596803|(FSHD;4q35)
277592|NCT01596790|Bevacizumab
277593|NCT01596790|Circulating tumor cells
277594|NCT01596790|Treatment efficiency
277595|NCT01596777|Loperamide-induced obstipation
277596|NCT01596777|Methylnaltrexone
277597|NCT01596777|oro-cecal transit time
277598|NCT01596777|whole gut transit time
277599|NCT01596777|Pharmacokinetics
277600|NCT01596764|whole-gut transit time
277601|NCT01596764|oro-cecal transit time
277602|NCT01596764|colon transit time
277603|NCT01596764|loperamide-induced obstipation
277604|NCT01596764|pharmacokinetics
277605|NCT01596764|Methylnaltrexone
277606|NCT01596764|Naloxone
277607|NCT01596751|metastatic
277608|NCT01596751|breast
277609|NCT01596751|cancer
277610|NCT01596751|triple
277611|NCT01596751|negative
277612|NCT01596751|PLX
277613|NCT01596751|Eribulin
277614|NCT01596738|Coronary Artery Disease
277615|NCT01596738|Coronary Artery Bypass Graft
277616|NCT01596738|Platelet Aggregation Inhibitors
277617|NCT01596738|Tranexamic Acid
277618|NCT01596712|Allergy,
277619|NCT01596712|Asthma,
277620|NCT01596712|Atopic dermatitis,
277621|NCT01596712|Japanese,
277622|NCT01596712|QGE031,
277623|NCT01596712|IgE
277624|NCT01596699|conditioning
277625|NCT01596699|allogeneic
277626|NCT01596699|hematopoietic
277627|NCT01596699|cell
277628|NCT01596699|transplantation
277629|NCT01596699|HCT
277630|NCT01596660|Tap block
277631|NCT01596660|laparoscopic hysterectomy
277632|NCT01596660|pain
277633|NCT01596647|cancer, tumors, phase I, drug-drug interaction, pharmacokinetic, probe drug, caffeine, diclofenac, omeprazole, midazolam, CYP1A2, CYP2C9, CYP2C19, CYP3A4
277634|NCT01596621|Bendamustine hydrochloride
277635|NCT01596621|CEP-18083
277636|NCT01596621|Treanda®
277637|NCT01596621|Non-Hodgkin Lymphoma
277638|NCT01596608|Magnetic seizure therapy
277639|NCT01596608|Treatment resistance
277640|NCT01596608|Open-label trial
277641|NCT01596608|Treatment resistant depression
277642|NCT01596608|Treatment resistant schizophrenia
277643|NCT01596608|Treatment resistant obsessive-compulsive disorder
277644|NCT01596595|ICD
277645|NCT01596595|CRT-D
277646|NCT01596595|Defibrillation lead
277647|NCT01596582|Colorectal cancer screening
277648|NCT01596582|Shared decision-making
277649|NCT01596582|Patient preferences
277650|NCT01596582|Risk assessment
277651|NCT01596582|Advanced colorectal neoplasia
277652|NCT01596569|Blast Traumatic Brain Injury
277653|NCT01596569|Cognitive Rehabilitation
277654|NCT01596569|Transcranial Magnetic Stimulation
277655|NCT01596569|Combined Treatment
277656|NCT01596556|smoking
277657|NCT01596556|exercise
277658|NCT01596556|heat tolerance
277659|NCT01596556|heat stroke
277660|NCT01596543|sleep
277661|NCT01596543|HTT
277662|NCT01596543|heat illness
277663|NCT01596530|Breast Neoplasm
277664|NCT01596530|Breast Cancer
277665|NCT01596530|Breast Tumour
277666|NCT01596530|Cancer of Breast
277667|NCT01596530|Cancer of the Breast
277668|NCT01596491|peripheral nerve injury
277669|NCT01596491|postherpetic neuralgia
277670|NCT01596491|PNI
277671|NCT01596491|PHN
277672|NCT01596491|Capsaicin
277673|NCT01596491|QST
277674|NCT01596491|quantitative sensory testing
277675|NCT01596491|sensory profile
277676|NCT01596491|neuropathic pain
277677|NCT01596478|Gambling
277678|NCT01596478|Pathological Gambling
277679|NCT01596439|Healthy women
277680|NCT01596439|consisting of a friend or relative of the patient
277681|NCT01596426|CINV
277682|NCT01596413|CINV
277683|NCT01596400|CINV
277684|NCT01596387|anaesthetics iv
277685|NCT01596387|propofol
277686|NCT01596387|pharmacokinetics
277687|NCT01596387|pharmacodynamic
277688|NCT01596348|Exercise
277689|NCT01596348|Barriers
277690|NCT01596348|Benefits
277691|NCT01596348|Preferences
277692|NCT01596348|Stages of change
277693|NCT01596335|Infliximab
277694|NCT01596335|REMICADE
277695|NCT01596335|TA-650
277696|NCT01596335|intravenous immunoglobulin
277697|NCT01596335|Kawasaki disease
277698|NCT01596335|IVIG
277699|NCT01596322|HIV/AIDS in resource limited setting
277700|NCT01596322|HIV treatment outcomes in resource limited setting
277701|NCT01596322|Adherence to HIV treatment in resource limited setting
277702|NCT01596322|ART resistance in resource limited setting
277703|NCT01596309|cardiovascular risk
277704|NCT01596309|Elderly population
277705|NCT01596309|cocoa extract
277706|NCT01596309|overweight and obesity
277707|NCT01596309|Glycemic profile
277708|NCT01596309|lipid profile
277709|NCT01596309|antioxidant status
277710|NCT01596309|inflammatory state
277711|NCT01596309|Cardiovascular Risk factors in elder population
277712|NCT01596296|labor induction
277713|NCT01596296|transcervical foley catheter
277714|NCT01596296|dinoprostone
277715|NCT01596296|parous women
277716|NCT01596283|Perioperative Fluid Management
277717|NCT01596283|liver resection
277718|NCT01596283|12-056
277719|NCT01596257|CliniMACS-CD34 Reagent System
277720|NCT01596257|Acute Leukemia
277721|NCT01596257|Myelodysplastic syndrome
277722|NCT01596257|Non Hodgkins Lymphoma
277723|NCT01596257|Hodgkins Disease
277724|NCT01596257|Multiple Myeloma
277725|NCT01596257|12-016
277726|NCT01596244|Diabetes Mellitus, Type II
277727|NCT01596244|Disease management
277728|NCT01596244|Chronic disease
277729|NCT01596244|Prevention and control
277730|NCT01596244|Education
277731|NCT01596231|Alcohol consumption
277732|NCT01596231|Kudzu extract
277733|NCT01596218|Steroid Refractory
277734|NCT01596218|Acute
277735|NCT01596205|cognitive therapy
277736|NCT01596192|allogeneic transplantation, GVHD
277737|NCT01596192|Patients with acute GVHD after allogeneic hematopoietic cell transplantation
277738|NCT01596179|treatment adherence
277739|NCT01596179|fatigue
277740|NCT01596179|symptom management
277741|NCT01596166|migraine
277742|NCT01596166|pediatric
277743|NCT01596166|childhood
277744|NCT01596166|emergency department
277745|NCT01596166|ketorolac
277746|NCT01596166|metoclopramide
277747|NCT01596166|intravenous
277748|NCT01596140|Vemurafenib
277749|NCT01596140|Everolimus
277750|NCT01596140|Afinitor
277751|NCT01596140|RAD001
277752|NCT01596140|temsirolimus
277753|NCT01596140|BRAF gene mutation
277754|NCT01596140|solid tumor
277755|NCT01596140|relapsed BRAF mutation positive malignant melanoma
277756|NCT01596140|refractory BRAF mutation positive malignant melanoma
277757|NCT01596127|relapsed CD20+ lymphoid malignancies
277758|NCT01596127|refractory CD20+ lymphoid malignancies
277759|NCT01596127|Rituximab
277760|NCT01596127|Intrathecal Rituximab
277761|NCT01596127|CNS
277762|NCT01596127|Leptomeningeal disease
277763|NCT01596127|LMD
277764|NCT01596127|central nervous system disease
277765|NCT01596127|Relapsed lymphoid malignancies
277766|NCT01596127|refractory lymphoid malignancies
277767|NCT01596127|CNS leukemia
277768|NCT01596127|intrathecal chemotherapy
277769|NCT01596127|cerebrospinal fluid
277770|NCT01596127|CSF
277771|NCT01596127|lumbar puncture
277772|NCT01596127|LP
277773|NCT01596114|TKI
277774|NCT01596114|CML
277775|NCT01596114|Stopping
277776|NCT01596114|chronic phase
277777|NCT01596114|in remission
277778|NCT01596088|Extravasation
277779|NCT01596088|Anthracyclines
277780|NCT01596075|Cannabidiol
277781|NCT01596075|GVHD
277782|NCT01596075|Allogeneic transplantation
277783|NCT01596062|Basiliximab
277784|NCT01596062|renal transplantation
277785|NCT01596062|CNI-free
277786|NCT01596062|everolimus
277787|NCT01596036|cardiac rehabilitation
277788|NCT01596036|referral
277789|NCT01596036|enrollment
277790|NCT01596036|timing
277791|NCT01596023|COPD
277792|NCT01595997|safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into psoriatic lesion of mild-to-moderate psoriatic patients
277793|NCT01595984|kidney
277794|NCT01595984|transplantation
277795|NCT01595984|graft
277796|NCT01595984|creatinin
277797|NCT01595971|Asthma
277798|NCT01595971|Continuing education
277799|NCT01595971|Primary health care
277800|NCT01595958|Cardiac arrest
277801|NCT01595958|heart arrest
277802|NCT01595958|cyclosporine A
277803|NCT01595958|post cardiac arrest syndrome
277804|NCT01595958|protective agent
277805|NCT01595958|multiple organ failure
277806|NCT01595958|mitochondrial permeability transition pore
277807|NCT01595958|mitochondria
277808|NCT01595958|cardio-pulmonary resuscitation
277809|NCT01595958|cardioprotection
277810|NCT01595958|ischemia reperfusion
277811|NCT01595958|postconditioning
277812|NCT01595945|Caloric restriction
277813|NCT01595945|Obesity
277814|NCT01595945|Gastric bypass
277815|NCT01595945|Resting metabolic rate
277816|NCT01595932|irritable bowel syndrome (IBS)
277817|NCT01595932|bloating
277818|NCT01595932|abdominal distension
277819|NCT01595932|flatulence
277820|NCT01595932|α-Galactosidase
277821|NCT01595906|Helmet
277822|NCT01595906|Heat Tolerance Test
277823|NCT01595906|ventilation System
277824|NCT01595893|Polymorphic light eruption
277825|NCT01595893|Vitamin D3
277826|NCT01595893|Photo provocation
277827|NCT01595893|Immune function
277828|NCT01595867|abuse liability
277829|NCT01595867|abuse potential
277830|NCT01595867|morphine
277831|NCT01595867|intranasal administration
277832|NCT01595867|snorting
277833|NCT01595867|opioid abuse
277834|NCT01595867|pharmacodynamic
277835|NCT01595867|recreational drug use
277836|NCT01595841|hemodialysis
277837|NCT01595841|stenosis
277838|NCT01595841|angioplasty
277839|NCT01595841|sirolimus
277840|NCT01595815|Fertilization failure, calcium ionophore, SrCl2
277841|NCT01595802|Cerebral vasospasm
277842|NCT01595789|Coronary Artery Disease
277843|NCT01595789|Diabetes Mellitus
277844|NCT01595789|Left ventricular ejection fraction
277845|NCT01595789|Beta-cell function
277846|NCT01595776|CLI, PAD, Buerger disease
277847|NCT01595763|Deep vein thrombosis
277848|NCT01595763|Primary care
277849|NCT01595763|Diagnosis
277850|NCT01595763|Clinical model
277851|NCT01595750|Post-bronchodilator FEV1<70% reference
277852|NCT01595750|Chronic bronchitis
277853|NCT01595750|Presence of estavlished CVD,
277854|NCT01595750|CVD equivalent or diabetes mellitus
277855|NCT01595724|Non-interventional study
277856|NCT01595724|Endometriosis,
277857|NCT01595724|Quality of life
277858|NCT01595698|Physical exercise
277859|NCT01595698|IGF-1
277860|NCT01595698|Schizophrenia
277861|NCT01595698|neuroplasticity
277862|NCT01595685|HBeAg-positive
277863|NCT01595672|severe acute pancreatitis
277864|NCT01595672|organ failure
277865|NCT01595672|multiple organ dysfunction syndrome
277866|NCT01595672|systemic complications
277867|NCT01595672|continuous veno-venous hemofiltration
277868|NCT01595672|blood purification
277869|NCT01595672|continuous renal replacement therapy
277870|NCT01595659|Risk
277871|NCT01595659|Young drivers
277872|NCT01595659|Alcohol
277873|NCT01595659|Passengers
277874|NCT01595659|Gender
277875|NCT01595646|Memory
277876|NCT01595646|Intranasal insulin
277877|NCT01595646|Alzheimer's disease
277878|NCT01595646|Mild Cognitive Impairment
277879|NCT01595633|nucleoside analogue
277880|NCT01595633|adefovir
277881|NCT01595633|tenofovir
277882|NCT01595633|hepatitis B
277883|NCT01595620|Cannabis
277884|NCT01595620|THC
277885|NCT01595620|Pain
277886|NCT01595594|Periodontal Diseases
277887|NCT01595594|Type 2 Diabetes Mellitus
277888|NCT01595594|hemoglobin A1c protein
277889|NCT01595581|Testosterone
277890|NCT01595581|ACL Reconstruction
277891|NCT01595581|Clinical outcomes
277892|NCT01595581|Lean mass
277893|NCT01595581|Strength
277894|NCT01595581|Muscle atrophy
277895|NCT01595568|Adolescents
277896|NCT01595568|Dual Diagnosis
277897|NCT01595568|Mental Disorders
277898|NCT01595568|Substance Use Problems
277899|NCT01595568|Prevention
277900|NCT01595555|stress
277901|NCT01595555|relaxation
277902|NCT01595555|mindfulness
277903|NCT01595555|web-based
277904|NCT01595555|online
277905|NCT01595555|social media
277906|NCT01595555|discussion board
277907|NCT01595529|Urinary tract infection
277908|NCT01595529|Antibiotic resistance
277909|NCT01595529|Short course antibiotics
277910|NCT01595529|Pediatrics
277911|NCT01595529|Controlled clinical trial
277912|NCT01595529|Anti Infective Agents
277913|NCT01595529|Trimethoprim Sulfamethoxazole Combination
277914|NCT01595529|Cefixime
277915|NCT01595529|Cephalexin
277916|NCT01595529|Trimethoprim-Sulfamethoxazole Combination
277917|NCT01595529|Trimethoprim
277918|NCT01595529|Sulfamethoxazole
277919|NCT01595503|Schizophrenia, auditory hallucination
277920|NCT01595451|Acupuncture
277921|NCT01595451|Back Pain
277922|NCT01595451|Lower Back Pain
277923|NCT01595451|Brigham and Women's Hospital
277924|NCT01595451|Massachusetts General Hospital
277925|NCT01595451|Effects of Acupuncture
277926|NCT01595438|Ceftazidime, Avibactam, Doripenem, Ciprofloxacin, sulfamethoxazole/trimethoprim, Anti-Infective Agents, Complicated Urinary Tract Infection,Acute Pyelonephritis
277927|NCT01595425|Bioequivalence,
277928|NCT01595425|pharmacokinetics,
277929|NCT01595425|safety,
277930|NCT01595425|esomeprazole,
277931|NCT01595425|Japanese,
277932|NCT01595425|healthy subject,
277933|NCT01595425|homo-EM
277934|NCT01595412|Laparoscopic surgery
277935|NCT01595412|Colorectal Surgery
277936|NCT01595412|Quality of Life
277937|NCT01595412|Rectal Prolapse
277938|NCT01595412|Anorectal Physiology
277939|NCT01595399|bradycardia
277940|NCT01595399|hypoxemia
277941|NCT01595399|intubation
277942|NCT01595399|premedication
277943|NCT01595373|Ghrelin
277944|NCT01595373|Microdialysis
277945|NCT01595373|Controls
277946|NCT01595373|Metabolic effects of ghrelin
277947|NCT01595360|TT-173
277948|NCT01595360|Topical Hemostatics
277949|NCT01595360|Hemostasis
277950|NCT01595347|Pressure Ulcer
277951|NCT01595347|Primary Prevention
277952|NCT01595347|Fatty Acids
277953|NCT01595347|Vegetable Fats
277954|NCT01595347|Olive oil
277955|NCT01595347|"Pressure Ulcer[prevention and control][Mesh]"
277956|NCT01595334|IVF-ET
277957|NCT01595334|ICSI
277958|NCT01595334|Gonadotrophins
277959|NCT01595334|rFSH
277960|NCT01595334|rLH
277961|NCT01595334|Cetrorelix
277962|NCT01595334|Leuprolide acetate
277963|NCT01595321|Adjuvant therapy
277964|NCT01595321|Immunotherapy
277965|NCT01595321|Cytoxan
277966|NCT01595321|Cyclophosphamide
277967|NCT01595321|Pancreatic Vaccine
277968|NCT01595321|Stereotactic radiation therapy
277969|NCT01595321|SBRT
277970|NCT01595321|FOLFIRINOX
277971|NCT01595308|Male infertility
277972|NCT01595295|CMML
277973|NCT01595295|MDS
277974|NCT01595295|AML
277975|NCT01595295|registry
277976|NCT01595295|Vidaza
277977|NCT01595282|pain
277978|NCT01595282|suction curettage
277979|NCT01595269|Diabetes
277980|NCT01595269|eHealth
277981|NCT01595269|Type 2 Diabetes
277982|NCT01595269|Education
277983|NCT01595269|Calgary Health Region
277984|NCT01595256|colorectal cancer,fatigue,6-minute walking test
277985|NCT01595243|hepatocellular carcinoma
277986|NCT01595243|Needs
277987|NCT01595243|Telephone consultation
277988|NCT01595230|Internal Hernias
277989|NCT01595230|Clips
277990|NCT01595230|Gastric Bypass
277991|NCT01595230|Avoid
277992|NCT01595217|Biliary Tract Neoplasm
277993|NCT01595217|MRI
277994|NCT01595217|DWI
277995|NCT01595217|Diagnosis
277996|NCT01595204|Cancer of Ovary, laparoscopy, operability , score.
277997|NCT01595178|smoking
277998|NCT01595178|drinking
277999|NCT01595178|SBIRT
278000|NCT01595178|BNI
278001|NCT01595178|counseling intervention
278002|NCT01595178|emergency department
278003|NCT01595178|adults
278004|NCT01595165|laparoscopic cholecystectomy
278005|NCT01595165|ultrasound
278006|NCT01595165|transversus abdominis plane block
278007|NCT01595152|Urgency, urgency incontinence,USIQ
278008|NCT01595100|Waist circumference
278009|NCT01595100|Visceral adipose tissue
278010|NCT01595100|Intra-abdominal fat
278011|NCT01595100|Pediatrics
278012|NCT01595087|CRPC
278013|NCT01595035|Day surgery
278014|NCT01595035|Orthopedic surgery
278015|NCT01595035|Breast reconstruction surgery
278016|NCT01594996|Seroquel XR
278017|NCT01594996|Quetiapine XR
278018|NCT01594996|Drug utilization
278019|NCT01594996|Major depressive disorder (MDD)
278020|NCT01594983|hypertriglyceridemia
278021|NCT01594983|Non familial Chylocmicronemia Syndrome (non-FCS)
278022|NCT01594957|LCQ908,
278023|NCT01594957|Hepatic Impairment,
278024|NCT01594957|Pharmacokinetics
278025|NCT01594931|malaria
278026|NCT01594931|antimalarial
278027|NCT01594931|artemisinin based combination therapy
278028|NCT01594918|metastatic
278029|NCT01594918|CRPC
278030|NCT01594918|prostate
278031|NCT01594918|CAMP
278032|NCT01594905|To explore
278033|NCT01594905|adequate management
278034|NCT01594905|CHB
278035|NCT01594905|Multidrug resistance
278036|NCT01594892|Spinal metastases
278037|NCT01594892|Vertebral metastases
278038|NCT01594892|Radiosurgery
278039|NCT01594892|Radiotherapy
278040|NCT01594892|Stereotactic body radiotherapy
278041|NCT01594892|Pain
278042|NCT01594879|Endometrial cancer
278043|NCT01594879|LNG-IUS
278044|NCT01594879|oral MPA
278045|NCT01594866|Major depressive disorder, remission, escitalopram
278046|NCT01594853|exercise
278047|NCT01594853|women
278048|NCT01594853|training
278049|NCT01594853|rehabilitation
278050|NCT01594853|leukodystrophy
278051|NCT01594840|language development
278052|NCT01594840|parental interaction
278053|NCT01594827|Methicillin-resistant Staphylococcus aureus
278054|NCT01594827|Vancomycin
278055|NCT01594814|AVNRT
278056|NCT01594814|AVRT
278057|NCT01594814|WPW
278058|NCT01594801|DM
278059|NCT01594801|insulin
278060|NCT01594801|injections
278061|NCT01594762|Diabetic Foot Ulcer Infection
278062|NCT01594749|NK-1 Receptor Antagonist, CINV, Emesis, MEC
278063|NCT01594684|restenosis
278064|NCT01594684|stent
278065|NCT01594684|drug eltuing balloon
278066|NCT01594684|peripheral arterial disease
278067|NCT01594671|primary knee arthroplasty
278068|NCT01594671|tranexamic acid
278069|NCT01594671|topical
278070|NCT01594658|Ultrasound-guided foam sclerotherapy; chronic venous ulcers
278071|NCT01594632|AE adverse event
278072|NCT01594632|AIDS acquired immunodeficiency syndrome
278073|NCT01594632|ALT (SGPT) alanine aminotransferase
278074|NCT01594632|ART antiretroviral therapy
278075|NCT01594632|AST (SGOT) aspartate aminotransferase
278076|NCT01594632|DCF data collection forms
278077|NCT01594632|DMC Data Monitoring Committee
278078|NCT01594632|FDA (U.S.) Food and Drug Administration
278079|NCT01594632|GCP Good Clinical Practice guidelines
278080|NCT01594632|HB sAg Hepatitis B surface antigen
278081|NCT01594632|ICH International Conference of Harmonization
278082|NCT01594632|IND Investigational New Drug Application
278083|NCT01594632|IRB Institutional Review Board
278084|NCT01594632|IU International units
278085|NCT01594632|mg milligram(s)
278086|NCT01594632|mm3 cubic millimeter(s)
278087|NCT01594632|PCR polymerase chain reaction
278088|NCT01594632|SAE serious adverse event
278089|NCT01594632|µg microgram
278090|NCT01594632|ULN upper limit of the normal range
278091|NCT01594632|WB Western Blot
278092|NCT01594619|Phase 1
278093|NCT01594619|Healthy male and female volunteers
278094|NCT01594619|Drug-drug interaction
278095|NCT01594619|Pharmacokinetics
278096|NCT01594619|Naloxegol
278097|NCT01594606|Animal-assisted intervention
278098|NCT01594606|adjudicated adolescents
278099|NCT01594606|empathy
278100|NCT01594593|prostate cancer
278101|NCT01594593|behavioral
278102|NCT01594593|acceptance and commitment therapy
278103|NCT01594593|distress
278104|NCT01594567|Systematic review and meta-analysis
278105|NCT01594567|Evidence-based medicine (EBM)
278106|NCT01594567|Evidence-based nutrition (EBN)
278107|NCT01594567|Clinical practice guidelines
278108|NCT01594567|Clinical trials
278109|NCT01594567|Dietary pulses
278110|NCT01594567|legumes
278111|NCT01594567|Beans, peas, chickpeas, lentils
278112|NCT01594567|Cardiometabolic risk factors
278113|NCT01594567|Triglycerides
278114|NCT01594567|Cholesterol
278115|NCT01594567|Glycemic control
278116|NCT01594567|Insulin resistance
278117|NCT01594567|Body weight
278118|NCT01594567|Uric acid
278119|NCT01594567|Blood pressure
278120|NCT01594554|HCV viral genotypes
278121|NCT01594554|host genotypes
278122|NCT01594554|IL28B
278123|NCT01594554|Outcome
278124|NCT01594554|Follow-Up
278125|NCT01594554|ITPA
278126|NCT01594554|RNA
278127|NCT01594554|China
278128|NCT01594541|hyperhomocysteinemia
278129|NCT01594541|dementia
278130|NCT01594541|depression
278131|NCT01594541|vitamin B12
278132|NCT01594541|mild cognitive impairment
278133|NCT01594541|alzheimer's
278134|NCT01594528|schizophrenia
278135|NCT01594528|major depression
278136|NCT01594528|pain
278137|NCT01594528|behavior
278138|NCT01594502|prostate cancer
278139|NCT01594502|dutasteride
278140|NCT01594476|Postpartum
278141|NCT01594476|Contraception
278142|NCT01594476|Intrauterine device
278143|NCT01594476|Intrauterine system
278144|NCT01594476|Mirena
278145|NCT01594476|Paragard
278146|NCT01594476|Uterine involution
278147|NCT01594463|Intrauterine growth restriction
278148|NCT01594463|Screening
278149|NCT01594463|Ultrasound
278150|NCT01594463|Perinatal morbidity
278151|NCT01594463|Maternal complications
278152|NCT01594450|incisional ventral hernia
278153|NCT01594450|infected field
278154|NCT01594450|biological mesh
278155|NCT01594437|Cytomegalovirus
278156|NCT01594437|Monoclonal antibody
278157|NCT01594424|Donor-Specific Anti-HLA Antibodies
278158|NCT01594424|Kidney Transplantation
278159|NCT01594411|Coronary Artery Disease
278160|NCT01594411|Chest Pain
278161|NCT01594411|Diagnosis of cardiovascular disease
278162|NCT01594398|carcinoma,non small cell lung
278163|NCT01594398|lung diseases
278164|NCT01594398|lung neoplasms
278165|NCT01594398|Respiratory
278166|NCT01594398|Carcinoma, Bronchogenic
278167|NCT01594398|Bronchial Neoplasms
278168|NCT01594398|Respiratory Tract Neoplasms
278169|NCT01594398|Thoracic Neoplasms
278170|NCT01594398|Neoplasms by Site
278171|NCT01594398|Respiratory Tract Diseases
278172|NCT01594398|Erlotinib
278173|NCT01594398|Protein Kinase Inhibitors
278174|NCT01594398|Breast Neoplasms
278175|NCT01594398|Neoplasms
278176|NCT01594398|Breast Diseases
278177|NCT01594398|Exemestane
278178|NCT01594398|Aromatase Inhibitors
278179|NCT01594385|Open Abdomen
278180|NCT01594385|Damage Control
278181|NCT01594385|Trauma
278182|NCT01594385|Wound healing
278183|NCT01594385|Gun shot wounds
278184|NCT01594385|Stab wounds
278185|NCT01594385|Automobile accidents
278186|NCT01594372|Uterine Prolapse
278187|NCT01594372|Laparoscopy
278188|NCT01594372|Hysterectomy, vaginal
278189|NCT01594359|Ferritin
278190|NCT01594346|Vitamin E
278191|NCT01594346|alpha-tocopherol
278192|NCT01594346|cognitive decline
278193|NCT01594346|Down syndrome
278194|NCT01594346|Aging
278195|NCT01594346|Dementia
278196|NCT01594333|Myocardial Infarction
278197|NCT01594333|Stroke
278198|NCT01594333|Cardiovascular death
278199|NCT01594333|Type 2 Diabetes
278200|NCT01594333|Metabolic Syndrome
278201|NCT01594333|Cardiovascular Inflammation
278202|NCT01594333|Atherothrombosis
278203|NCT01594307|BP
278204|NCT01594294|CLEAR CARE®
278205|NCT01594294|AOSEPT® Plus
278206|NCT01594294|ReNu MultiPlus®
278207|NCT01594294|silicone hydrogel
278208|NCT01594294|hydrogel
278209|NCT01594294|ACUVUE® 2®
278210|NCT01594294|AIR OPTIX® AQUA
278211|NCT01594294|eyelid response
278212|NCT01594294|wettability
278213|NCT01594294|contamination
278214|NCT01594294|contact lenses
278215|NCT01594281|Panretinal photocoagulation
278216|NCT01594281|Ranibizumab
278217|NCT01594268|kidney transplant
278218|NCT01594268|Certican
278219|NCT01594255|Healthy volunteer
278220|NCT01594255|QT intervals
278221|NCT01594255|ECG
278222|NCT01594255|QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs
278223|NCT01594242|multiple myeloma
278224|NCT01594242|bortezomib
278225|NCT01594242|proteasome inhibitor
278226|NCT01594229|ABT-199
278227|NCT01594229|Cancer
278228|NCT01594229|Preliminary Efficacy
278229|NCT01594229|Non-Hodgkin's Lymphoma
278230|NCT01594229|Rituximab
278231|NCT01594229|Bendamustine
278232|NCT01594229|Pharmacokinetics
278233|NCT01594229|Maximum Tolerated Dose
278234|NCT01594229|Safety
278235|NCT01594216|Postmenopausal female
278236|NCT01594203|Soft Tissue Sarcoma
278237|NCT01594203|Pazopanib
278238|NCT01594203|F18-FDG PET/CT
278239|NCT01594177|DAFNE
278240|NCT01594177|GBG 70
278241|NCT01594177|GBG
278242|NCT01594177|German Breast Group
278243|NCT01594177|GBG Forschungs GmbH
278244|NCT01594177|Afatinib
278245|NCT01594177|neo-adjuvant
278246|NCT01594177|HER-2 positive breast cancer
278247|NCT01594177|BIBW 2992
278248|NCT01594177|1200.159
278249|NCT01594164|High Resolution Computed Tomography
278250|NCT01594164|Cone Beam Computed Tomography
278251|NCT01594164|upper airway
278252|NCT01594164|geometry
278253|NCT01594151|asthma
278254|NCT01594151|controlled
278255|NCT01594151|Cone Beam Computed Tomography
278256|NCT01594151|upper airway
278257|NCT01594151|paediatric
278258|NCT01594112|Remote monitoring
278259|NCT01594112|Home monitoring
278260|NCT01594112|Defibrillators, Implantable cardioverter-defibrillator
278261|NCT01594112|Shock
278262|NCT01594112|Inappropriate diagnoses and Therapies
278263|NCT01594112|Corrective actions
278264|NCT01594112|ID recurrences
278265|NCT01594112|Medical reaction time
278266|NCT01594099|cervical cancer
278267|NCT01594099|elderly women
278268|NCT01594099|concurrent chemotherapy
278269|NCT01594086|green tea
278270|NCT01594086|aging
278271|NCT01594086|atherosclerosis
278272|NCT01594086|homocysteine
278273|NCT01594086|cognitive impairment
278274|NCT01594073|implantable defibrillator
278275|NCT01594073|ventricular arrhythmias
278276|NCT01594073|cardiac death
278277|NCT01594047|hyperalgesia
278278|NCT01594047|Patient controlled analgesia
278279|NCT01594047|morphine
278280|NCT01594047|methadone
278281|NCT01594047|ketamine
278282|NCT01594021|propofol
278283|NCT01594021|anesthesia, induction
278284|NCT01594021|hypotension
278285|NCT01594021|cardiac output
278286|NCT01594008|Toll like receptors
278287|NCT01594008|Inflammation
278288|NCT01594008|Anthocyanins
278289|NCT01594008|Blueberries
278290|NCT01593995|Erlotinib
278291|NCT01593995|Skin side effect
278292|NCT01593995|EGF ointment
278293|NCT01593982|Repetitive Transcranial Magnetic Stimulation
278294|NCT01593982|Cocaine Dependence
278295|NCT01593982|Cocaine Addicts
278296|NCT01593982|Attention Deficit Hyperactivity Disorder
278297|NCT01593982|Cognitive Function
278298|NCT01593969|Essential Fatty Acid
278299|NCT01593969|Seed oil
278300|NCT01593969|Fish oil
278301|NCT01593969|Dietary deficiency
278302|NCT01593943|contraception
278303|NCT01593943|india
278304|NCT01593943|rural
278305|NCT01593930|Pulp Anesthesia
278306|NCT01593930|Articaine
278307|NCT01593930|Lidocaine
278308|NCT01593917|Aortic valve
278309|NCT01593917|Heart valve
278310|NCT01593917|Tissue valve
278311|NCT01593917|Bioprosthesis
278312|NCT01593904|CCSVI, Flow, Perfusion in MS
278313|NCT01593891|IVUS, CCSVI
278314|NCT01593865|Coronary Artery Bypass Grafting
278315|NCT01593865|Mammary Artery Grafts
278316|NCT01593865|Bilateral Mammary Artery Grafting
278317|NCT01593865|Clinical Outcomes
278318|NCT01593852|X-rays
278319|NCT01593852|Cardiac Electrophysiology
278320|NCT01593852|Image Processing, Computer-Assisted
278321|NCT01593852|Catheter Ablation
278322|NCT01593813|Pronator quadratus
278323|NCT01593813|distal radius fracture
278324|NCT01593813|volar plating
278325|NCT01593800|Probiotics
278326|NCT01593800|Lactose
278327|NCT01593787|Hypertension
278328|NCT01593787|Renal dysfunction
278329|NCT01593787|LCZ696
278330|NCT01593774|Melatonin
278331|NCT01593774|Olanzapine
278332|NCT01593774|Metabolic side effects
278333|NCT01593774|Psychosis
278334|NCT01593774|Hyperlipidemia
278335|NCT01593774|Hyperglycemia
278336|NCT01593774|Weight gain
278337|NCT01593774|Diabetes
278338|NCT01593761|cABSSSI
278339|NCT01593761|MRSA
278340|NCT01593748|Sarcoma
278341|NCT01593748|Soft Tissue Sarcoma
278342|NCT01593722|Loa loa
278343|NCT01593722|Immune Response
278344|NCT01593722|Therapy
278345|NCT01593709|Healthy Volunteers
278346|NCT01593696|CD 19 Expressing B Cells
278347|NCT01593696|B Cell Lymphoma
278348|NCT01593696|ALL
278349|NCT01593696|Anti-CD19 Chimeric Antigen Receptor
278350|NCT01593696|Adoptive Immunotherapy
278351|NCT01593683|Oncology service
278352|NCT01593683|Nursing staff
278353|NCT01593683|Psychosocial intervention
278354|NCT01593683|Coping skills
278355|NCT01593670|high risk myelodysplastic syndrome
278356|NCT01593670|natural killer cells
278357|NCT01593644|Dipyridamole/adenosine combination given intravenously
278358|NCT01593644|slow bolus and low doses
278359|NCT01593644|coronary flow reserve assessment
278360|NCT01593644|transthoracic echodoppler
278361|NCT01593644|Patients
278362|NCT01593644|stable
278363|NCT01593631|lactose malabsorption
278364|NCT01593631|lactose intolerance
278365|NCT01593631|lactose digestion
278366|NCT01593631|lactose maldigestion
278367|NCT01593631|acid lactase
278368|NCT01593631|yoghurt bacteria
278369|NCT01593618|cancer survivor
278370|NCT01593605|Impaired glucose tolerance, pre-diabetes,glycemic control,
278371|NCT01593605|supplements
278372|NCT01593592|Helicobacter pylori
278373|NCT01593592|Lactobacillus reuteri
278374|NCT01593592|dyspeptic patients
278375|NCT01593592|eradication
278376|NCT01593579|melanoma
278377|NCT01593579|autonomic failure
278378|NCT01593579|hypotension
278379|NCT01593579|akt therapy
278380|NCT01593566|femoral nerve block
278381|NCT01593553|Screening
278382|NCT01593553|Stroke prevention
278383|NCT01593553|Cost effectiveness
278384|NCT01593527|Frequent flares
278385|NCT01593527|Frequent attacks
278386|NCT01593527|gout
278387|NCT01593527|gouty arthritis
278388|NCT01593527|Chronic kidney disease
278389|NCT01593527|renal impairment
278390|NCT01593527|Anti-interleukin-1β monoclonal antibody
278391|NCT01593527|anti-inflammatory therapy
278392|NCT01593514|Vaccines
278393|NCT01593514|Meningitis
278394|NCT01593514|Meningococcal
278395|NCT01593501|vitamin D
278396|NCT01593501|cholecalciferol
278397|NCT01593501|bone mineral density
278398|NCT01593501|Magnesium deficiency
278399|NCT01593501|Calcium metabolism disorders
278400|NCT01593488|recurrent
278401|NCT01593488|CNS disease
278402|NCT01593488|intrathecal therapy
278403|NCT01593436|insomnia,menopause, polysomnography, mindfulness
278404|NCT01593410|Efficacy/Safety
278405|NCT01593410|Lenalidomide and Low-Dose Dexamethasone
278406|NCT01593410|Chinese Subjects
278407|NCT01593410|Relapsed/Refractory Multiple Myeloma
278408|NCT01593397|Obesity
278409|NCT01593397|Insulin Resistance
278410|NCT01593384|Breast Cancer
278411|NCT01593384|Digital Breast Tomosynthesis (DBT)
278412|NCT01593384|Digital Mammography (DM)
278413|NCT01593371|Adipokines
278414|NCT01593371|leptin
278415|NCT01593371|chemerin
278416|NCT01593371|omentin
278417|NCT01593371|metformin
278418|NCT01593371|type 2 diabetes mellitus
278419|NCT01593358|CCSVI
278420|NCT01593345|Elderly
278421|NCT01593345|mobility limitations
278422|NCT01593345|self-management
278423|NCT01593345|exercise
278424|NCT01593332|Rituximab
278425|NCT01593332|Rheumatoid arthritis
278426|NCT01593332|Biologics
278427|NCT01593332|Anti-tumour necrosis factor
278428|NCT01593332|Disease-modifying anti-rheumatic drugs
278429|NCT01593332|DAS28
278430|NCT01593332|European League Against Rheumatism response
278431|NCT01593293|Elderly patients
278432|NCT01593293|Non-squamous Non-small Cell Lung Cancer
278433|NCT01593293|Pemetrexed
278434|NCT01593293|Carboplatin
278435|NCT01593280|anesthesia
278436|NCT01593280|regional anesthetic techniques: transversus abdominis plane block,
278437|NCT01593280|pain, postoperative
278438|NCT01593280|surgery, cesarean section
278439|NCT01593280|quality of recovery
278440|NCT01593267|intracranial aneurysm
278441|NCT01593267|subarachnoid hemorrhage
278442|NCT01593267|randomized trial
278443|NCT01593267|coil embolization
278444|NCT01593267|clip occlusion
278445|NCT01593267|vascular disorders
278446|NCT01593241|Seminoma IIA/B
278447|NCT01593241|Carboplatin
278448|NCT01593241|RT
278449|NCT01593215|genetics
278450|NCT01593215|type 2 diabetes
278451|NCT01593215|insulin secretion
278452|NCT01593189|developmental disabilities
278453|NCT01593189|school readiness
278454|NCT01593189|literacy
278455|NCT01593189|social emotional skills
278456|NCT01593189|self regulation
278457|NCT01593189|caregiver involvement
278458|NCT01593176|Femur
278459|NCT01593176|Fracture
278460|NCT01593176|Radiostereometric Analysis
278461|NCT01593163|Functional echocardiography
278462|NCT01593163|power Doppler cranial ultrasonography
278463|NCT01593163|N-terminal probrain natriuretic peptide
278464|NCT01593163|Patent ductus arteriosus
278465|NCT01593150|Atrial Fibrillation
278466|NCT01593150|TEE
278467|NCT01593150|Early versus late DC cardioversion.
279101|NCT01590498|Carcinoma
278468|NCT01593124|Vaginal innate immune and inflammatory responses
278469|NCT01593111|Allergies
278470|NCT01593111|Asthma
278471|NCT01593111|Environmental
278472|NCT01593111|NYC
278473|NCT01593111|Manhattan
278474|NCT01593111|Harlem
278475|NCT01593111|Bronx
278476|NCT01593111|Brooklyn
278477|NCT01593111|Breathing
278478|NCT01593111|eNO
278479|NCT01593111|IgE
278480|NCT01593111|Allergens
278481|NCT01593111|Cockroach
278482|NCT01593111|Dust mites
278483|NCT01593111|Pets
278484|NCT01593098|siblings
278485|NCT01593098|advanced neoplasm
278486|NCT01593098|mRNA
278487|NCT01593098|TaqMan microRNA expression assays
278488|NCT01593085|palliative cares
278489|NCT01593085|cancer
278490|NCT01593085|suicide risk
278491|NCT01593072|Multiple Ascending Dose (MAD)
278492|NCT01593072|Ebola Virus
278493|NCT01593072|Post Exposure Prophylaxis
278494|NCT01593072|EHF
278495|NCT01593059|International
278496|NCT01593059|Multicenter
278497|NCT01593059|Observational registry
278498|NCT01593059|Orsiro Drug Eluting Stent (DES)
278499|NCT01593059|Stenting
278500|NCT01593059|Treatment of Coronary Artery Disease
278501|NCT01593059|Coronary revascularization
278502|NCT01593059|Percutaneous Coronary Intervention
278503|NCT01593059|STEMI
278504|NCT01593059|NSTEMI
278505|NCT01593059|Ischemia
278506|NCT01593059|Angina
278507|NCT01593059|Subgroups
278508|NCT01593059|Acute Myocardial Infarction
278509|NCT01593059|Diabetes
278510|NCT01593059|Small Vessels
278511|NCT01593059|Chronic Total Occlusion (CTO)
278512|NCT01593046|GSK1265744 LAP
278513|NCT01593046|integrase inhibitor
278514|NCT01593046|healthy subjects
278515|NCT01593046|TMC278 LA
278516|NCT01593046|GSK1265744LAP
278517|NCT01593046|long acting retroviral
278518|NCT01593046|HIV-1 infection
278519|NCT01593020|Breast cancer
278520|NCT01593020|Early Stage Breast Cancer Not Overexpressing HER-2
278521|NCT01593020|Primary invasive adenocarcinoma of the breast
278522|NCT01593020|Paclitaxel
278523|NCT01593020|Taxol
278524|NCT01593020|Eribulin
278525|NCT01593020|E7389
278526|NCT01593020|5-Fluorouracil
278527|NCT01593020|5-FU
278528|NCT01593020|Adrucil
278529|NCT01593020|Efudex
278530|NCT01593020|Epirubicin
278531|NCT01593020|Ellence
278532|NCT01593020|Cyclophosphamide
278533|NCT01593020|Cytoxan
278534|NCT01593020|Neosar
278535|NCT01593020|Doxorubicin
278536|NCT01593020|Doxorubicin hydrochloride
278537|NCT01593020|Adriamycin PFS
278538|NCT01593020|Adriamycin RDF
278539|NCT01593020|Adriamycin
278540|NCT01593020|Rubex
278541|NCT01593007|Heart failure
278542|NCT01593007|respiratory muscles
278543|NCT01593007|optoelectronic plethysmography
278544|NCT01592994|HIV
278545|NCT01592994|condom use
278546|NCT01592994|India
278547|NCT01592994|women
278548|NCT01592981|Waldenstrom's macroglobulinaemia
278549|NCT01592981|bortezomib
278550|NCT01592981|cyclophosphamide
278551|NCT01592981|rituximab
278552|NCT01592968|Brain Neoplasms
278553|NCT01592968|Non-melanoma brain metastases
278554|NCT01592968|Stereotactic radiosurgery
278555|NCT01592968|SRS
278556|NCT01592968|Whole brain radiation therapy
278557|NCT01592968|WBRT
278558|NCT01592955|Glaucoma
278559|NCT01592955|Cyclocoagulation
278560|NCT01592955|HIFU High Intensity Focused Ultrasound
278561|NCT01592942|inguinal hernia
278562|NCT01592942|mesh fixation
278563|NCT01592942|glue
278564|NCT01592942|Lichtenstein
278565|NCT01592929|Functional Respiratory Imaging
278566|NCT01592929|Magnetic Resonance Imaging
278567|NCT01592929|MRI
278568|NCT01592929|Pharyngometry
278569|NCT01592929|Upper Airway
278570|NCT01592929|Mouthpiece of Inhaler
278571|NCT01592929|Cone Beam Computed Tomography
278572|NCT01592929|CBCT
278573|NCT01592929|Computed Tomography
278574|NCT01592929|CT
278575|NCT01592916|Fibromyalgia
278576|NCT01592916|Pain
278577|NCT01592916|Women
278578|NCT01592916|Exercise
278579|NCT01592916|IGF1
278580|NCT01592903|Uterine fibroids
278581|NCT01592903|somatic stem cell
278582|NCT01592903|Side Population
278583|NCT01592877|UWB
278584|NCT01592877|non-contact
278585|NCT01592877|patient monitor
278586|NCT01592838|Belgium
278587|NCT01592838|Quality of hospital care
278588|NCT01592838|Rotavirus vaccination
278589|NCT01592825|Breast Cancer
278590|NCT01592825|Prognostic factor
278591|NCT01592825|uPA/PA-1
278592|NCT01592825|cohort
278593|NCT01592799|Influenza
278594|NCT01592799|Children
278595|NCT01592799|Hospitalizations
278596|NCT01592799|Spain
278597|NCT01592799|Burden
279102|NCT01590498|Prostatic Diseases
278598|NCT01592786|Autism Spectrum Disorder (ASD)
278599|NCT01592786|Autism
278600|NCT01592786|Autistic Disorder
278601|NCT01592786|Asperger's Disorder
278602|NCT01592786|Asperger's
278603|NCT01592786|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
278604|NCT01592786|Memantine
278605|NCT01592786|Pediatric Disorder
278606|NCT01592773|Autistic Disorder
278607|NCT01592773|Asperger's Disorder
278608|NCT01592773|Asperger's
278609|NCT01592773|Pediatric Autism
278610|NCT01592773|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
278611|NCT01592773|Pervasive Child Development Disorder
278612|NCT01592760|air-Q SP
278613|NCT01592760|air-Q
278614|NCT01592760|i-gel
278615|NCT01592760|supraglottic airway device
278616|NCT01592760|laryngeal mask airway
278617|NCT01592747|Asperger's
278618|NCT01592747|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
278619|NCT01592747|Memantine
278620|NCT01592747|Pervasive Child Development Disorder
278621|NCT01592747|Pediatric Disorder
278622|NCT01592747|Randomized Controlled Trial
278623|NCT01592734|chronic constipation
278624|NCT01592734|faecal impaction
278625|NCT01592734|PEG-only laxative
278626|NCT01592721|Carcinoma
278627|NCT01592721|Squamous cell carcinoma
278628|NCT01592721|Head and neck neoplasms
278629|NCT01592721|Cetuximab
278630|NCT01592708|orthognathic surgery
278631|NCT01592708|maxillary osteotomy
278632|NCT01592708|post operative nausea vomiting
278633|NCT01592708|post discharge nausea vomiting
278634|NCT01592708|anesthesia
278635|NCT01592695|Nicotine dependence
278636|NCT01592695|Smoking cessation
278637|NCT01592695|Telehealth
278638|NCT01592695|Alcohol use
278639|NCT01592695|Depression
278640|NCT01592695|Body weight
278641|NCT01592682|tobacco
278642|NCT01592682|secondhand smoke
278643|NCT01592682|Chinese
278644|NCT01592682|NNAL
278645|NCT01592669|Passive leg raising, blood pressure, heart rate
278646|NCT01592656|Chronic Obstructive Pulmonary Disease
278647|NCT01592656|GOLD stages II, III and IV
278648|NCT01592656|Computed Tomography scan
278649|NCT01592656|Functional Respiratory Imaging
278650|NCT01592656|Non-Invasive Ventilation
278651|NCT01592656|Arterial Blood Gas
278652|NCT01592656|Hypercapnic
278653|NCT01592656|Health Related Quality of Life
278654|NCT01592656|Lung compliance
278655|NCT01592643|Corneal shield
278656|NCT01592643|PRK
278657|NCT01592643|Myopia
278658|NCT01592643|Pain
278659|NCT01592643|Vision
278660|NCT01592617|cancer vaccine
278661|NCT01592617|HLA-A*24:02
278662|NCT01592617|lung cancer
278663|NCT01592617|CTL
278664|NCT01592604|fracture
278665|NCT01592604|fifth metatarsal
278666|NCT01592604|functioanl outcome
278667|NCT01592578|gastroesophgeal variceal bleeding
278668|NCT01592578|liver cirrhosis
278669|NCT01592578|portal hypertension
278670|NCT01592552|Alzheimer's Disease
278671|NCT01592552|Multiple Sclerosis
278672|NCT01592552|Parkinson's Disease
278673|NCT01592552|Huntington's Disease
278674|NCT01592552|Amyotrophic Lateral Sclerosis (ALS)
278675|NCT01592539|Type 1 Diabetes
278676|NCT01592539|Bone
278677|NCT01592526|Systemic inflammatory response.
278678|NCT01592526|Autonomic nervous regulation.
278679|NCT01592526|Cholinergic antiinflammatory pathway
278680|NCT01592500|GHD
278681|NCT01592500|r-hGH
278682|NCT01592500|Long-acting
278683|NCT01592474|Multiple Sclerosis
278684|NCT01592474|Avonex
278685|NCT01592474|Brain atrophy
278686|NCT01592474|MRI
278687|NCT01592474|Interferon-beta 1a
278688|NCT01592474|IFN Beta 1-a
278689|NCT01592474|Clinically isolated syndrome
278690|NCT01592474|CIS
278691|NCT01592461|Substance abuse treatment outcomes
278692|NCT01592461|Opioid dependence
278693|NCT01592461|Suboxone
278694|NCT01592461|Methadone
278695|NCT01592448|Acetaminophen
278696|NCT01592448|Patient Safety
278697|NCT01592448|Health Literacy
278698|NCT01592435|LLI
278699|NCT01592422|Small cell lung cancer
278700|NCT01592422|Maintenance therapy
278701|NCT01592422|Immunotherapy
278702|NCT01592422|Autologous cytokine-induced killer cell
278703|NCT01592409|cannabis impaired driving
278704|NCT01592409|driving simulation
278705|NCT01592409|acute psychopharmacologic effects of cannabis
278706|NCT01592409|residual effects of cannabis
278707|NCT01592409|young drivers
278708|NCT01592396|Tralokinumab
278709|NCT01592396|CAT-354
278710|NCT01592396|Asthma
278711|NCT01592357|cardiac rehabilitation
278712|NCT01592357|gait speed
278713|NCT01592357|mind body exercise
278714|NCT01592357|tai chi
278715|NCT01592357|cardiac disease
278716|NCT01592357|frail elderly
278717|NCT01592344|Chronic pain
278718|NCT01592344|peripheral nerve
278719|NCT01592344|neuralgia
279103|NCT01590485|pain
278720|NCT01592344|somatosensory nervous system
278721|NCT01592266|FLT
278722|NCT01592266|PET
278723|NCT01592266|bone marrow
278724|NCT01592266|AML
278725|NCT01592240|PF-04950615
278726|NCT01592240|RN316
278727|NCT01592227|healthy volunteer
278728|NCT01592227|pharmacokinetics
278729|NCT01592227|paracetamol
278730|NCT01592214|Staphylococcus aureus, nasal decolonization, XF-73, gel formulation
278731|NCT01592201|Schizophrenia
278732|NCT01592201|Paliperidone ER
278733|NCT01592201|Antipsychotics
278734|NCT01592201|Mental disorder
278735|NCT01592201|Comparative study
278736|NCT01592188|meditation, inflammation, children, attention
278737|NCT01592149|Appetite
278738|NCT01592136|Ponatinib
278739|NCT01592136|Tyrosine kinase inhibitor
278740|NCT01592123|anxiety
278741|NCT01592123|septal surgery
278742|NCT01592123|septum deviation
278743|NCT01592123|sleep
278744|NCT01592110|Schizophrenia
278745|NCT01592097|Multiple Sclerosis
278746|NCT01592097|MS
278747|NCT01592097|Autoimmune
278748|NCT01592084|lipid lowering therapy
278749|NCT01592084|survival
278750|NCT01592084|ALSFRS
278751|NCT01592084|age
278752|NCT01592084|BMI
278753|NCT01592084|weight
278754|NCT01592071|food sensitivity
278755|NCT01592071|IgG
278756|NCT01592071|obesity
278757|NCT01592071|overweight
278758|NCT01592071|body composition
278759|NCT01592071|reactive foods
278760|NCT01592058|weight change
278761|NCT01592058|contraception
278762|NCT01592058|birth control
278763|NCT01592058|progestin
278764|NCT01592058|progestin only
278765|NCT01592058|weight gain
278766|NCT01592058|depo
278767|NCT01592058|Depo Provera
278768|NCT01592058|DMPA
278769|NCT01592058|IUD
278770|NCT01592058|IUC
278771|NCT01592058|Mirena
278772|NCT01592058|Paragard
278773|NCT01592058|Implanon
278774|NCT01592058|implant
278775|NCT01592032|Antibiotic-lock technique.
278776|NCT01592032|In vivo antimicrobial concentration.
278777|NCT01592032|Antimicrobial bioactivity.
278778|NCT01592006|hepatitis C virus
278779|NCT01592006|liver transplant recipient
278780|NCT01591993|Sensitive skin
278781|NCT01591993|Lactic acid test
278782|NCT01591993|Transepidermal water loss
278783|NCT01591993|Colorimetry
278784|NCT01591993|Capacitance
278785|NCT01591980|post-craniotomy pain
278786|NCT01591980|pregabalin
278787|NCT01591980|chronic post-craniotomy headache
278788|NCT01591980|Craniotomy
278789|NCT01591967|Chiropractic
278790|NCT01591967|Blood pressure
278791|NCT01591967|Pulse Rate
278792|NCT01591967|Thoracic
278793|NCT01591941|ACL, Knee , Injury,
278794|NCT01591928|Pediatrics
278795|NCT01591928|Congenital heart disease
278796|NCT01591928|Heterotaxy syndrome
278797|NCT01591928|Intestinal malrotation
278798|NCT01591915|Breast cancer, Mindfulness Based Stress Reduction, RCT, mood, cooping, health related quality of life
278799|NCT01591876|exercise
278800|NCT01591876|kidney disease
278801|NCT01591876|vascular function
278802|NCT01591876|haemodialysis
278803|NCT01591863|Clostridium difficile-associated diarrhea
278804|NCT01591863|CDAD
278805|NCT01591863|Pediatric
278806|NCT01591798|Rectal cancer
278807|NCT01591798|Robotic surgery
278808|NCT01591798|Laparoscopic surgery
278809|NCT01591785|Hand
278810|NCT01591785|Foot
278811|NCT01591785|Eczema
278812|NCT01591785|Atopic Dermatitis
278813|NCT01591772|FALLOPIAN TUBE
278814|NCT01591772|OVARY
278815|NCT01591772|PERITONEUM
278816|NCT01591772|Quality of Life
278817|NCT01591772|structural MRI
278818|NCT01591772|functional MRI
278819|NCT01591772|neuropsychological assessment
278820|NCT01591772|12-075
278821|NCT01591759|citicoline
278822|NCT01591759|cognitive function
278823|NCT01591759|function magnetic resonance imaging
278824|NCT01591759|magnetic resonance spectroscopy
278825|NCT01591759|diffusion tensor imaging
278826|NCT01591746|Mastectomy
278827|NCT01591746|Mammaplasty
278828|NCT01591746|Breast reconstruction
278829|NCT01591746|Tissue expansion
278830|NCT01591746|Botulinum toxins, Type A
278831|NCT01591746|Quality of Life
278832|NCT01591746|Acellular dermal matrix
278833|NCT01591733|Borderline resectable
278834|NCT01591707|autism spectrum disorders
278835|NCT01591707|school
278836|NCT01591707|language
278837|NCT01591707|social
278838|NCT01591694|child trauma
278839|NCT01591694|maltreatment
278840|NCT01591694|physical abuse
278841|NCT01591694|sexual abuse
278842|NCT01591694|emotional abuse
278843|NCT01591694|abandonment
278844|NCT01591694|domestic violence
278845|NCT01591694|community violence
278846|NCT01591681|Type 1 Diabetes
278847|NCT01591681|Hypoglycemia
278848|NCT01591681|Continuous Glucose Monitoring
278849|NCT01591681|Pump Suspension
278850|NCT01591668|Hepatitis
278851|NCT01591668|Hepatitis C
278852|NCT01591668|Chronic HCV
278853|NCT01591668|HCV
278854|NCT01591668|Treatment Naive
278855|NCT01591668|Gilead
278856|NCT01591668|GS-9620
278857|NCT01591642|physical activity
278858|NCT01591642|functional fitness
278859|NCT01591642|quality of life
278860|NCT01591629|Cannabis
278861|NCT01591629|Marijuana
278862|NCT01591629|Naloxone
278863|NCT01591629|THC
278864|NCT01591629|Psychotic Disorders
278865|NCT01591590|Colorectal Cancer
278866|NCT01591590|Cancer
278867|NCT01591590|Colon Cancer
278868|NCT01591590|Rectal Cancer
278869|NCT01591590|PET
278870|NCT01591590|PET-CT
278871|NCT01591590|MRI
278872|NCT01591590|Diffusion MRI
278873|NCT01591590|Apparent Diffusion Coefficient
278874|NCT01591590|ADC
278875|NCT01591590|Metabolic Progression Index
278876|NCT01591564|interpersonal psychotherapy
278877|NCT01591564|severe mood dysregulation
278878|NCT01591538|Prevalence
278879|NCT01591538|MDRGNB
278880|NCT01591538|Acquisition
278881|NCT01591538|Middle stay
278882|NCT01591538|Endemic area
278883|NCT01591525|Type II Diabetes
278884|NCT01591525|Minorities
278885|NCT01591525|Diabetes Mellitus
278886|NCT01591525|Community based screening
278887|NCT01591512|Small Cell Lung Cancer
278888|NCT01591512|SCLC
278889|NCT01591512|Lung Cancer
278890|NCT01591512|Subjects diagnosed with SCLC who will undergo treatment
278891|NCT01591486|Helicobacter pylori (Hp)
278892|NCT01591486|ASA users
278893|NCT01591486|peptic ulcer bleeding
278894|NCT01591486|cohorts
278895|NCT01591473|Influenza
278896|NCT01591473|Ampligen
278897|NCT01591473|Poly I:Poly C12U
278898|NCT01591473|Rintatolimod
278899|NCT01591473|FluMist
278900|NCT01591408|EEG biofeedback
278901|NCT01591408|neurofeedback
278902|NCT01591408|therapy
278903|NCT01591408|adjunct
278904|NCT01591395|inguinal hernia
278905|NCT01591395|laparoscopy
278906|NCT01591395|laparoendoscopic single-site surgery
278907|NCT01591382|Ketamine
278908|NCT01591382|Postoperative pain
278909|NCT01591382|Opioid dependent patients
278910|NCT01591382|Acute pain control
278911|NCT01591356|Advanced Cancers
278912|NCT01591356|Advanced solid tumors
278913|NCT01591356|siRNA/EphA2
278914|NCT01591343|Specific immunotherapy
278915|NCT01591343|Allergic rhinitis
278916|NCT01591343|Allergic rhinoconjunctivitis
278917|NCT01591343|Asthma
278918|NCT01591304|Ulthera® System
278919|NCT01591304|Ultherapy™ Treatment
278920|NCT01591304|Ulthera, Inc.
278921|NCT01591291|alcohol dependence
278922|NCT01591291|alcohol addiction
278923|NCT01591265|Compensatory dental extraction
278924|NCT01591265|Children 7-11 years old
278925|NCT01591252|HIV
278926|NCT01591252|Bone mineral density
278927|NCT01591252|bone turnover
278928|NCT01591252|fracture
278929|NCT01591252|inflammation
278930|NCT01591239|Adolescent
278931|NCT01591239|Parent
278932|NCT01591239|Substance Abuse
278933|NCT01591239|Parent Training
278934|NCT01591239|Addiction
278935|NCT01591239|Family Intervention
278936|NCT01591239|Brief Intervention
278937|NCT01591239|Home Intervention
278938|NCT01591226|caffeine
278939|NCT01591226|sodium citrate
278940|NCT01591226|exercise performance
278941|NCT01591226|wheelchair athletes
278942|NCT01591226|1500m
278943|NCT01591213|Cancer education
278944|NCT01591213|Prevention education
278945|NCT01591213|Volunteers
278946|NCT01591200|Alcoholic
278947|NCT01591200|Liver
278948|NCT01591200|Cirrhosis
278949|NCT01591200|Stem
278950|NCT01591200|Cells
278951|NCT01591187|Text messaging
278952|NCT01591187|Secondhand smoke exposure
278953|NCT01591174|Functional Dyspepsia
278954|NCT01591174|Postprandial Distress Syndrome
278955|NCT01591174|ghrelin
278956|NCT01591174|C-13 acetate
278957|NCT01591148|Pharmacokinetics
278958|NCT01591148|Pharmacodynamics
278959|NCT01591135|Esophageal squamous cell carcinoma
278960|NCT01591135|chemoradiotherapy
278961|NCT01591122|Prostate cancer
278962|NCT01591122|Metastatic Castration Resistant Prostate Cancer
278963|NCT01591122|Abiraterone acetate
278964|NCT01591122|Prednisone
278965|NCT01591122|Zytiga
278966|NCT01591096|Stroke
278967|NCT01591096|Childhood
278968|NCT01591096|Thrombolysis
278969|NCT01591083|Peptic ulcer rebleeding, double dose of esomeprazole
278970|NCT01591070|Facial seborrhoeic dermatitis, tacrolimus
278971|NCT01591057|fruit
278972|NCT01591057|vegetables
278973|NCT01591057|biomarkers
278974|NCT01591057|randomised controlled feeding study
279104|NCT01590485|root canal therapy
278975|NCT01591057|Fruit and vegetable intake biomarkers in healthy adults
278976|NCT01591031|laryngeal injuries
278977|NCT01591031|vocal cord injuries
278978|NCT01591031|hoarseness
278979|NCT01591031|sore throat
278980|NCT01591018|sonolysis, brain infarction, prevention, cardiac surgery
278981|NCT01591005|sonolysis
278982|NCT01591005|carotid
278983|NCT01591005|endarterectomy
278984|NCT01591005|stenting
278985|NCT01590992|Somatoform disorder
278986|NCT01590992|Functional Somatic Syndrome
278987|NCT01590992|Functional Somatic Symptoms
278988|NCT01590992|Somatic Symptom Disorder
278989|NCT01590992|globus sensation
278990|NCT01590992|globus pharynges
278991|NCT01590992|globus hystericus
278992|NCT01590979|Atrial Fibrillation New Onset
278993|NCT01590979|Ranolazine
278994|NCT01590979|CABG
278995|NCT01590979|valve repair/replacement
278996|NCT01590979|Cardiac Surgery
278997|NCT01590966|spondyloarthritis
278998|NCT01590966|Rheumatoid arthritis
278999|NCT01590927|pelvic floor
279000|NCT01590927|ultrasonography
279001|NCT01590914|Roux-en-Y Bariatric surgery,
279002|NCT01590914|Gastric banding,
279003|NCT01590914|fMRI,
279004|NCT01590914|food cues
279005|NCT01590901|Pharmacokinetics
279006|NCT01590901|Probucol
279007|NCT01590901|healthy male subjects
279008|NCT01590875|atrial fibrillation
279009|NCT01590875|ablation
279010|NCT01590875|pulmonary veins
279011|NCT01590875|adenosine
279012|NCT01590862|Obesessive Compulsive Disorder
279013|NCT01590862|Major Depressive Disorder
279014|NCT01590862|Deep Brain Stimulation
279015|NCT01590849|contraceptive agents
279016|NCT01590849|autonomic nervous system
279017|NCT01590849|blood pressure
279018|NCT01590849|risk
279019|NCT01590823|pharmacokinetics
279020|NCT01590784|Depression
279021|NCT01590784|Schizophrenia
279022|NCT01590758|Diabetic Foot Ulcer Infection
279023|NCT01590745|Ultrasound therapy
279024|NCT01590745|Nerve Conduction studies
279025|NCT01590745|Boston and Levine Questionnaire
279026|NCT01590745|Neutral Angle Wrist Splint
279027|NCT01590745|Canterbury CTS scale
279028|NCT01590732|Lymphoma
279029|NCT01590732|Peripheral T-Cell Lymphoma
279030|NCT01590732|PTCL
279031|NCT01590732|Relapsed or refractory T-Cell Lymphoma
279032|NCT01590732|TCL
279033|NCT01590732|Peripheral TCL-NOS
279034|NCT01590732|Angioimmunoblastic TCL
279035|NCT01590732|Anaplastic large cell lymphoma
279036|NCT01590732|Hepatosplenic TCL
279037|NCT01590732|Enteropathy-associated TCL
279038|NCT01590732|Romidepsin
279039|NCT01590732|Istodax
279040|NCT01590732|Depsipeptide
279041|NCT01590732|FK228
279042|NCT01590732|Etoposide
279043|NCT01590732|VePesid
279044|NCT01590732|Carboplatin
279045|NCT01590732|Paraplatin
279046|NCT01590732|Mesna
279047|NCT01590732|Mesnex
279048|NCT01590706|Genotype-Phenotype Association
279049|NCT01590706|Aged
279050|NCT01590706|Middle Aged
279051|NCT01590706|Mild Cognitive Impairment
279052|NCT01590706|Heart Rate Control
279053|NCT01590706|Biomarkers
279054|NCT01590693|Gait
279055|NCT01590667|Fat excretion
279056|NCT01590654|Hepatitis
279057|NCT01590654|Hepatitis B
279058|NCT01590654|Hepatitis B Virus
279059|NCT01590654|HBV
279060|NCT01590654|GS-9620
279061|NCT01590654|Toll-like receptor (TLR)-7 Agonist
279062|NCT01590641|Hepatitis
279063|NCT01590641|Hepatitis B
279064|NCT01590641|Hepatitis B Virus
279065|NCT01590641|HBV
279066|NCT01590641|GS-9620
279067|NCT01590641|Toll-like receptor (TLR)-7 Agonist
279068|NCT01590628|Sickle Cell Disease & Thalassemia
279069|NCT01590628|Genetic disorder
279070|NCT01590615|Hepatitis
279071|NCT01590615|Hepatitis B
279072|NCT01590615|HBV
279073|NCT01590615|OLT
279074|NCT01590615|MELD
279075|NCT01590615|Renal Safety
279076|NCT01590615|Liver Transplant
279077|NCT01590602|Huntington's Disease
279078|NCT01590602|European Huntington's Disease Network
279079|NCT01590602|Juvenile HD
279080|NCT01590602|EHDN
279081|NCT01590602|REGISTRY
279082|NCT01590589|Huntington Disease
279083|NCT01590589|European HD Network
279084|NCT01590589|Cohort
279085|NCT01590589|REGISTRY
279086|NCT01590589|EHDN
279087|NCT01590576|women
279088|NCT01590550|Pediatric hemodialysis
279089|NCT01590550|Anticoagulation
279090|NCT01590537|non-interventional
279091|NCT01590537|Mirena
279092|NCT01590537|Contraception
279093|NCT01590537|Russian Federation
279094|NCT01590524|Parent
279095|NCT01590524|childhood cancer
279096|NCT01590524|Complementary and Alternative
279097|NCT01590511|mini fluid challenge
279098|NCT01590511|subaortic velocity time integral
279099|NCT01590498|Adenocarcinoma
279100|NCT01590498|Prostatic Neoplasms
279105|NCT01590472|Genetics of Mesothelioma
279106|NCT01590472|Mesothelioma Consortium
279107|NCT01590472|GWAS
279108|NCT01590472|Asbestos
279109|NCT01590446|Achondroplasia
279110|NCT01590433|Obesity
279111|NCT01590433|Overweight
279112|NCT01590433|Exenatide
279113|NCT01590433|Diet
279114|NCT01590433|Women
279115|NCT01590420|OSA
279116|NCT01590420|Sleep
279117|NCT01590420|CPAP
279118|NCT01590420|Cost
279119|NCT01590394|obstruction
279120|NCT01590394|bile duct
279121|NCT01590394|malignant
279122|NCT01590342|Pulmonary embolism
279123|NCT01590342|Right ventricular dysfunction
279124|NCT01590342|Prognosis
279125|NCT01590342|Inflammation
279126|NCT01590329|Skin surgery
279127|NCT01590329|Micrografting
279128|NCT01590329|Hypo-pigmentation
279129|NCT01590316|Brain Injuries
279130|NCT01590316|Infant, Premature
279131|NCT01590316|Spectroscopy, Near-Infrared
279132|NCT01590316|Randomized Controlled Trial
279133|NCT01590303|severe sepsis
279134|NCT01590264|tinnitus
279135|NCT01590264|bimodal stimulation
279136|NCT01590264|rTMS
279137|NCT01590264|Repetitive Transcranial Magnetic Stimulation
279138|NCT01590251|Pain
279139|NCT01590251|Addiction
279140|NCT01590251|Buprenorphine
279141|NCT01590251|Counseling
279142|NCT01590251|Methadone
279143|NCT01590251|Yoga
279144|NCT01590238|alopecia
279145|NCT01590186|Pain
279146|NCT01590186|Front foot
279147|NCT01590186|Flat foot
279148|NCT01590186|Metatarsalgia
279149|NCT01590173|Low molecular weight heparin
279150|NCT01590173|Prednisolone
279151|NCT01590173|Glucocorticoids
279152|NCT01590173|Recurrent implantation failure
279153|NCT01590173|Pregnancy rate
279154|NCT01590134|volunteers
279155|NCT01590134|Pilot study
279156|NCT01590134|There are no pre registration evaluations.
279157|NCT01590134|Inclusion criteria: to be a healthy, consenting volunteer not currently receiving iron supplements.
279158|NCT01590134|Exclusion criteria: 1) Needle phobia; 2) Currently receiving iron supplements; 3) Unable to provide informed consent
279159|NCT01590121|Previous flight by aeroplane
279160|NCT01590108|Idiopathic Pulmonary Arterial Hypertension
279161|NCT01590108|IPAH
279162|NCT01590108|Apelin
279163|NCT01590108|APJ receptor
279164|NCT01590095|Chlorine water treatment
279165|NCT01590095|Point-of-use water treatment
279166|NCT01590095|Household water treatment with safe storage
279167|NCT01590095|Hand washing with soap
279168|NCT01590095|Hand hygiene
279169|NCT01590095|Latrines
279170|NCT01590095|Child potties
279171|NCT01590095|Point-of-use fortification
279172|NCT01590095|Lipid-based nutrient supplement
279173|NCT01590095|Environmental enteropathy
279174|NCT01590095|Tropical enteropathy
279175|NCT01590095|Gut function
279176|NCT01590095|Intestinal parasitic infection
279177|NCT01590095|Soil transmitted helminths
279178|NCT01590095|Intestinal protozoans
279179|NCT01590095|Antibody response
279180|NCT01590095|Water
279181|NCT01590095|Sanitation
279182|NCT01590095|Hand washing
279183|NCT01590095|Breast Feeding
279184|NCT01590095|Complementary Feeding
279185|NCT01590095|Micronutrients
279186|NCT01590095|Malnutrition
279187|NCT01590095|Nutrition Disorders
279188|NCT01590095|Diarrhea
279189|NCT01590095|Child Development
279190|NCT01590082|Melanoma
279191|NCT01590082|Metastatic Melanoma
279192|NCT01590082|Advanced melanoma
279193|NCT01590082|Doxycycline
279194|NCT01590082|Ipilimumab
279195|NCT01590082|Yervoy
279196|NCT01590082|MDX010
279197|NCT01590082|BMS-734016
279198|NCT01590082|Temozolomide
279199|NCT01590082|Temodar
279200|NCT01590069|Sarcoma
279201|NCT01590069|Solid Tumors
279202|NCT01590069|Pulmonary Metastases
279203|NCT01590069|Lung metastases
279204|NCT01590069|Osteosarcomas
279205|NCT01590069|Ewing sarcoma
279206|NCT01590069|IL-2
279207|NCT01590069|Interleukin-2
279208|NCT01590069|Aldesleukin
279209|NCT01590069|Proleukin
279210|NCT01590069|Aerosol IL-2
279211|NCT01590069|Spirometry
279212|NCT01590069|Nebulizer
279213|NCT01590069|Pulse oximeter
279214|NCT01590056|Mapping limbic areas of the STN
279215|NCT01590056|neuronal responses to stimuli during surgery
279216|NCT01590017|stage IB cervical cancer
279217|NCT01590017|stage IIA cervical cancer
279218|NCT01590017|stage IIB cervical cancer
279219|NCT01590017|stage III cervical cancer
279220|NCT01590017|stage IVA cervical cancer
279221|NCT01590017|cervical adenocarcinoma
279222|NCT01590017|cervical adenosquamous cell carcinoma
279223|NCT01590017|cervical squamous cell carcinoma
279224|NCT01590017|HIV infection
279225|NCT01590004|LumbarCool system
279226|NCT01590004|Cooled radiofrequency medial ablation
279227|NCT01590004|Cooled-RF neurotomy
279228|NCT01589991|toothpastes
279229|NCT01589991|bioavailability
279230|NCT01589991|sodium fluoride
279231|NCT01589991|monofluorphosphate
279232|NCT01589991|low-fluoride
279233|NCT01589978|drug-eluting stent
279234|NCT01589978|DES
279235|NCT01589978|atherosclerosis
279236|NCT01589978|everolimus
279237|NCT01589965|HIV/AIDS
279238|NCT01589965|STIs
279239|NCT01589965|Lottery
279240|NCT01589952|Pegalyted interferon
279241|NCT01589952|Entecavir
279242|NCT01589939|Reduced Planning Target Volume
279243|NCT01589939|radiation therapy
279244|NCT01589939|Calypso
279245|NCT01589913|Implantable Cardioverter Defibrillators
279246|NCT01589913|Heart Failure
279247|NCT01589913|Anxiety
279248|NCT01589913|Depression
279249|NCT01589913|Quality of Life
279250|NCT01589913|Remote Care
279251|NCT01589913|Prevention
279252|NCT01589900|colorectal cancer
279253|NCT01589900|invasion
279254|NCT01589900|metastasis
279255|NCT01589900|IHC
279256|NCT01589874|hepcidin
279257|NCT01589874|anemia
279258|NCT01589874|acute inflammation
279259|NCT01589874|IL-6
279260|NCT01589874|cytokines
279261|NCT01589848|vWD
279262|NCT01589809|Congenital, familial and genetic disorders
279263|NCT01589809|Nervous System Diseases
279264|NCT01589796|anesthesia
279265|NCT01589796|regional anesthetic techniques: transversus abdominis plane block, ilioinguinal nerve block, iliohypogastric nerve block
279266|NCT01589796|surgery, inguinal herniorrhaphy
279267|NCT01589796|pain, postoperative
279268|NCT01589796|surgery, inguinal hernia repair
279269|NCT01589783|Pregnancy
279270|NCT01589783|Vitamin D
279271|NCT01589770|rheumatoid arthritis
279272|NCT01589770|inflammation
279273|NCT01589757|"glycaemic index"
279274|NCT01589757|"glycemic index"
279275|NCT01589757|hyperglycaemia
279276|NCT01589757|hyperglycemia
279277|NCT01589757|pregnancy
279278|NCT01589757|"dietary intervention"
279279|NCT01589757|"education evaluation"
279280|NCT01589757|antioxidant
279281|NCT01589757|"Impaired Glucose Tolerance of Pregnancy"
279282|NCT01589757|"Gestational Diabetes Mellitus"
279283|NCT01589757|"Breast Milk"
279284|NCT01589744|medical device
279285|NCT01589731|Allergenicity
279286|NCT01589731|Cow's milk allergy
279287|NCT01589731|Leukocyte adherence inhibition test
279288|NCT01589731|Polymerization
279289|NCT01589718|Proliferative Diabetic Retinopathy
279290|NCT01589718|Tractional Retinal Detachment
279291|NCT01589718|Vitreous Hemorrhage
279292|NCT01589705|Uric acid
279293|NCT01589705|polycystic kidney disease
279294|NCT01589692|WRIST
279295|NCT01589692|Distal Radius Fracture
279296|NCT01589692|DRF
279297|NCT01589692|elderly
279298|NCT01589692|internal fixation
279299|NCT01589692|VLPS
279300|NCT01589692|External Fixation
279301|NCT01589692|Multi center randomized trial
279302|NCT01589666|Entegrion
279303|NCT01589666|Spray-dried Solvent/Detergent Plasma
279304|NCT01589666|Fresh Frozen Plasma
279305|NCT01589666|Transfusion
279306|NCT01589666|Resuscitation
279307|NCT01589666|Hemorrhage
279308|NCT01589666|Coagulopathy
279309|NCT01589627|distal radius fracture
279310|NCT01589627|wrist contracture
279311|NCT01589627|dynasplint
279312|NCT01589601|Congestive Heart Failure
279313|NCT01589601|Heart Failure
279314|NCT01589601|Palliative Care
279315|NCT01589601|Palliative Medicine
279316|NCT01589588|acute treatment
279317|NCT01589575|Intensive Care Unit
279318|NCT01589549|Acute graft versus host disease
279319|NCT01589549|Bone marrow transplantation
279320|NCT01589549|Mesenchymal stromal cells
279321|NCT01589536|psychocardiological
279322|NCT01589536|interval intervention
279323|NCT01589536|disability pension
279324|NCT01589536|risk profile
279325|NCT01589536|mental comorbidity
279326|NCT01589484|Tomography
279327|NCT01589484|Urinary Lithiasis
279328|NCT01589484|Kidney Calculi
279329|NCT01589471|Low anterior resection syndrome
279330|NCT01589471|Botulinum toxin A
279331|NCT01589471|Quality of life
279332|NCT01589471|Incontinence
279333|NCT01589471|Rectal cancer
279334|NCT01589471|Anorectal manometry
279335|NCT01589458|toothpastes
279336|NCT01589458|saliva
279337|NCT01589458|dental caries
279338|NCT01589458|fluoride
279339|NCT01589445|Bangladesh
279340|NCT01589445|T2DM
279341|NCT01589445|Pioglitazone
279342|NCT01589445|Metformin
279343|NCT01589445|Insulin secretion and Sensitivity
279344|NCT01589432|Diabetic peripheral neuropathy
279345|NCT01589419|DLT
279346|NCT01589419|radiation
279347|NCT01589419|veliparib
279348|NCT01589419|locally advanced rectal cancer
279349|NCT01589419|ABT-888
279350|NCT01589419|capecitabine
279351|NCT01589419|MTD
279352|NCT01589419|PARP
279353|NCT01589406|Gynaecological Cancer
279354|NCT01589406|Quality of Life
279355|NCT01589406|Sexuality
279356|NCT01589393|Trauma
279357|NCT01589393|Thromboprophylaxis
279358|NCT01589393|Intracranial haemorrhage
279359|NCT01589393|Deep vein Thrombosis
279360|NCT01589380|Aortic stenosis
279361|NCT01589380|Exercise performance
279362|NCT01589380|cardiopulmonary exercise test
279363|NCT01589380|fimasartan
279364|NCT01589367|neoadjuvant endocrine therapy
279365|NCT01589367|metformin
279366|NCT01589367|postmenopausal breast cancer
279367|NCT01589328|pancreatic cancer
279368|NCT01589328|biliary tract cancer
279369|NCT01589328|cancer pain
279370|NCT01589328|depression
279371|NCT01589315|ECT
279372|NCT01589315|FEAST
279373|NCT01589315|brain stimulation
279374|NCT01589315|depression
279375|NCT01589302|Bruton's Tyrosine Kinase
279376|NCT01589302|CLL
279377|NCT01589302|SLL
279378|NCT01589302|B-PLL
279379|NCT01589289|Diagnostic research
279380|NCT01589289|Rapid diagnostic tests
279381|NCT01589289|Neurological disorders
279382|NCT01589289|Neglected Tropical Diseases
279383|NCT01589289|Developing countries
279384|NCT01589263|Benign Prostatic Hyperplasia
279385|NCT01589263|Lower Urinary Track Symptoms
279386|NCT01589263|BPH
279387|NCT01589263|LUTS
279388|NCT01589237|Familial Chylomicronemia Syndrome (FCS) (HLP type I)
279389|NCT01589237|LCQ908
279390|NCT01589211|smoking
279391|NCT01589211|cessation
279392|NCT01589211|intervention
279393|NCT01589211|brief
279394|NCT01589198|Asthma
279395|NCT01589185|Pneumonia
279396|NCT01589185|Monoclonal antibody
279397|NCT01589185|Staphylococcus aureus
279398|NCT01589146|colon-rectal cancer
279399|NCT01589146|heparin
279400|NCT01589146|prophylaxis
279401|NCT01589146|laparoscopy
279402|NCT01589133|Irregular antibody screening
279403|NCT01589120|CHF
279404|NCT01589120|video decision aid
279405|NCT01589094|CISPLATIN
279406|NCT01589094|GEMCITABINE
279407|NCT01589094|GM-CSF
279408|NCT01589094|radical cystectomy
279409|NCT01589094|12-071
279410|NCT01589003|low GI milk mood behaviour cognitive function children
279411|NCT01588964|HIPEC
279412|NCT01588964|ovarian cancer
279413|NCT01588964|recurrence
279414|NCT01588938|radiation therapy
279415|NCT01588938|Calypso
279416|NCT01588925|Cochlear implantation
279417|NCT01588925|Dexamethasone
279418|NCT01588925|Acid, Hyaluronic
279419|NCT01588912|chronic hepatitis B
279420|NCT01588912|HBeAg positive
279421|NCT01588912|telbivudine
279422|NCT01588912|tenofovir
279423|NCT01588912|entecavir
279424|NCT01588912|roadmap
279425|NCT01588899|Uterine Leiomyomas
279426|NCT01588899|Fibroids
279427|NCT01588899|HIFU
279428|NCT01588899|Ablation
279429|NCT01588899|High Intensity Focused Ultrasound
279430|NCT01588886|Proton pump inhibitors
279431|NCT01588886|Pneumonia
279432|NCT01588886|Retrospective cohort study
279433|NCT01588873|Oral contraceptive pill
279434|NCT01588873|Hormonal contraceptive ring
279435|NCT01588873|Polycystic ovary syndrome
279436|NCT01588847|perioperative immunoediting
279437|NCT01588847|potential predictive biomarkers
279438|NCT01588847|lymph node dissection
279439|NCT01588821|Metastatic
279440|NCT01588821|Refractory
279441|NCT01588821|Relapsed
279442|NCT01588808|Immobilization
279443|NCT01588808|Protein supplementation
279444|NCT01588795|Diabetic nephropathy
279445|NCT01588795|renal denervation
279446|NCT01588795|nephroprotection
279447|NCT01588795|Renal failure
279448|NCT01588795|Renal injury
279449|NCT01588795|End stage renal disease
279450|NCT01588782|Healthy volunteers
279451|NCT01588782|Pharmacology
279452|NCT01588782|Pharmacokinetics
279453|NCT01588782|Pharmacodynamics
279454|NCT01588782|Drug-drug interactions
279455|NCT01588782|CYP3A4
279456|NCT01588782|Abiraterone acetate
279457|NCT01588782|JNJ-589485
279458|NCT01588782|JNJ-212082
279459|NCT01588782|Ketoconazole
279460|NCT01588769|Glioblastoma Multiforme
279461|NCT01588769|Brain cancer
279462|NCT01588769|Immunotherapy
279463|NCT01588769|Cell based therapy
279464|NCT01588769|Autologous cell based therapy
279465|NCT01588769|Adoptive immunotherapy
279466|NCT01588769|Cytotoxic T cells
279467|NCT01588769|Natural Killer cells
279468|NCT01588756|Chronic kidney disease
279469|NCT01588756|GFR
279470|NCT01588756|Inulin
279471|NCT01588756|51Cr-EDTA
279472|NCT01588756|ASDKP-NH2
279473|NCT01588756|Healthy male 18-35 yrs old, non smokers, non allergic
279474|NCT01588756|Or Male/female 18-80 yrs old with chronic Kidney disease
279475|NCT01588730|PF
279476|NCT01588730|Dynasplint
279477|NCT01588730|ADFD
279478|NCT01588730|AFD
279479|NCT01588730|Plantar Fasciitis
279480|NCT01588730|plantar Fasciopathy
279481|NCT01588717|Hyperhydrosis
279482|NCT01588717|Excessive Sweating
279483|NCT01588717|Sweating
279484|NCT01588717|Depression
279485|NCT01588717|Antidepressant
279486|NCT01588704|lung cancer
279487|NCT01588704|lung adenocarcinoma
279488|NCT01588704|bevacizumab
279489|NCT01588704|adjuvant chemotherapy
279490|NCT01588704|surgical resection rate
279491|NCT01588704|safety
279492|NCT01588704|feasibility
279493|NCT01588691|Traumatic Brain Injury
279494|NCT01588678|endometrial
279495|NCT01588678|prostate
279496|NCT01588678|breast
279497|NCT01588678|gastric
279498|NCT01588678|cervical
279499|NCT01588678|ovarian
279500|NCT01588678|neuroendocrine cancers
279501|NCT01588678|soft-tissue sarcoma
279502|NCT01588678|squamous cell NSCLC
279503|NCT01588678|renal cell carcinoma
279504|NCT01588678|non-Hodgkin lymphoma
279505|NCT01588665|pregnancy
279506|NCT01588665|stable isotopes
279507|NCT01588665|red blood cell catabolism
279508|NCT01588639|Recombinant human insulin
279509|NCT01588639|T2DM
279510|NCT01588639|Safety
279511|NCT01588639|Efficacy
279512|NCT01588626|Healthy volunteer
279513|NCT01588626|Japanese males
279514|NCT01588626|PK study
279515|NCT01588600|food intake, satiety, fiber
279516|NCT01588548|Advanced solid malignancies
279517|NCT01588548|Malignant lymphoma
279518|NCT01588535|pain
279519|NCT01588535|pain measurement
279520|NCT01588535|ear, middle
279521|NCT01588535|otitis media
279522|NCT01588522|alopecia
279523|NCT01588509|AMG 785, bone mineral density, alendronate
279524|NCT01588496|hypercholesterolemia
279525|NCT01588496|familial hypercholesterolemia
279526|NCT01588496|homozygous familial hypercholesterolemia
279527|NCT01588470|diastolic function
279528|NCT01588470|intramyocellular fat
279529|NCT01588470|mitochondria
279530|NCT01588470|pioglitazone
279531|NCT01588444|tooth extraction
279532|NCT01588444|bone grafting
279533|NCT01588431|Locally advanced head and neck cancer
279534|NCT01588431|Squamous cell carcinoma of the head and neck
279535|NCT01588418|Impaired glucose tolerance
279536|NCT01588418|diabetes
279537|NCT01588405|Pulmonary Arterial Hypertension
279538|NCT01588405|UT-15C SR
279539|NCT01588405|PAH
279540|NCT01588392|Physical activity
279541|NCT01588392|preschoolers
279542|NCT01588353|AK160, collagenase clostridium histolyticum
279543|NCT01588314|Fabry disease
279544|NCT01588314|neuropathic pain
279545|NCT01588314|gabapentin
279546|NCT01588301|Cervical Cancer Screening
279547|NCT01588301|Human Papillomavirus (HPV)
279548|NCT01588301|Self-collected vaginal sample
279549|NCT01588301|Cervical Smear
279550|NCT01588288|Diagnosis
279551|NCT01588288|Galectin 3
279552|NCT01588288|Puncture
279553|NCT01588288|Goiter, nodular
279554|NCT01588288|Surgery
279555|NCT01588275|cost-effectiveness
279556|NCT01588275|effectiveness
279557|NCT01588275|treatment
279558|NCT01588275|CPAP
279559|NCT01588275|MRA
279560|NCT01588210|caries
279561|NCT01588210|sealant
279562|NCT01588210|fluoride
279563|NCT01588210|prevention
279564|NCT01588210|community dentistry
279565|NCT01588197|Pain
279566|NCT01588197|fMRI
279567|NCT01588197|real time
279568|NCT01588171|Deep vein thrombosis
279569|NCT01588171|Pulmonary embolism
279570|NCT01588171|Low molecular weight heparin
279571|NCT01588171|Enoxaparin
279572|NCT01588171|Bemiparin
279573|NCT01588158|carpal tunnel syndrome
279574|NCT01588158|Tylenol
279575|NCT01588158|Vicodin
279576|NCT01588158|pain
279577|NCT01588145|NSCLC
279578|NCT01588145|HM61713
279579|NCT01588145|EGFR-TKI
279580|NCT01588145|Phase II
279581|NCT01588145|olmutinib
279582|NCT01588041|Microscope mounted SDOCT
279583|NCT01587976|Health related quality of life
279584|NCT01587976|Colorectal liver metastasis
279585|NCT01587976|surveillance
279586|NCT01587963|hypovolemic or septic
279587|NCT01587950|dentinal sensitivity
279588|NCT01587950|potassium nitrate
279589|NCT01587950|dental pain
279590|NCT01587937|Antibiotic stewardship.
279591|NCT01587937|Clostridium difficile infection.
279592|NCT01587937|Antibiotic resistance.
279593|NCT01587924|Renal Impairment
279594|NCT01587924|Anemia
279595|NCT01587924|pharmacokinetics
279596|NCT01587924|hemodialysis
279597|NCT01587924|Chronic kidney disease
279598|NCT01587924|GSK1278863
279599|NCT01587924|hemoglobin
279600|NCT01587924|Prolyl hydroxylase inhibitor
279601|NCT01587924|recombinant human erythropoietin
279602|NCT01587924|erythropoiesis stimulating agents
279603|NCT01587924|Dialysis, Renal
279604|NCT01587911|Satiety
279605|NCT01587911|Food intake regulation
279606|NCT01587911|Appetite regulation
279607|NCT01587911|Dairy Protein
279608|NCT01587898|Anemia
279609|NCT01587898|Prolyl hydroxylase inhibitor
279610|NCT01587898|Hemoglobin
279611|NCT01587898|Chronic kidney disease
279612|NCT01587898|pharmacokinetics
279613|NCT01587898|recombinant human erythropoietin
279614|NCT01587898|GSK1278863
279615|NCT01587885|Frequent Heartburn
279616|NCT01587885|Omeprazole
279617|NCT01587885|Omeprazole, sodium bicarbonate drug combination
279618|NCT01587885|Gastrointestinal Agents
279619|NCT01587885|Therapeutic Uses
279620|NCT01587885|Pharmacologic Actions
279621|NCT01587885|Enzyme Inhibitors
279622|NCT01587885|Molecular Mechanisms of Pharmacological Action
279623|NCT01587885|Proton Pump Inhibitors
279624|NCT01587872|Colonoscopy
279625|NCT01587872|Colorectal cancer
279626|NCT01587872|Screening colonoscopy
279627|NCT01587859|esophagus
279628|NCT01587859|gastro-esophageal reflux disease
279629|NCT01587859|type II-IV hiatal hernia
279630|NCT01587859|esophageal surgery
279631|NCT01587859|minimally invasive surgery
279632|NCT01587846|abdominal pain, constipation, Lactobacillus reuteri
279633|NCT01587833|Benzodiazepines
279634|NCT01587833|hip/femur fracture
279635|NCT01587820|cisplatin
279636|NCT01587820|RADPLAT
279637|NCT01587820|intra-arterial chemotherapy
279638|NCT01587820|head and neck cancer
279639|NCT01587807|Infection, Quality of Life, lung injury
279640|NCT01587794|Rhegmatogenous retinal detachment
279641|NCT01587794|thickness of retinal layer
279642|NCT01587794|outer nuclear layer
279643|NCT01587794|photoreceptor layer
279644|NCT01587781|Pharmacokinetics of enoxaparin
279645|NCT01587768|Acute liver injury
279646|NCT01587768|antibiotics
279647|NCT01587742|Calcium channel blockers
279648|NCT01587742|cancer
279649|NCT01587729|Hip/femur fracture
279650|NCT01587729|antidepressants
279651|NCT01587716|Safety and tolerability, pharmacokinetics, cough, voltage gated sodium channels (VGSC), anaesthesia
279652|NCT01587703|BRD3
279653|NCT01587703|GSK525762
279654|NCT01587703|NUT Midline Carcinoma
279655|NCT01587703|MYCN-amplified Solid Tumor
279656|NCT01587703|BRD4
279657|NCT01587703|BET inhibitor
279658|NCT01587703|bromodomains
279659|NCT01587703|NMC
279660|NCT01587703|Colorectal C ancer
279661|NCT01587703|Small Cell Lung Cancer
279662|NCT01587703|Multiple Myeloma
279663|NCT01587703|Neuroblastoma
279664|NCT01587703|Oncology
279665|NCT01587677|Tuberculosis
279666|NCT01587664|Swallowing disorders
279667|NCT01587664|Aspiration
279668|NCT01587651|CAD
279669|NCT01587651|prasugrel
279670|NCT01587651|ticagrelor
279671|NCT01587651|antiplatelet
279672|NCT01587651|thienopyridine
279673|NCT01587651|P2Y12 Inhibitors
279674|NCT01587638|new-onset diabetes
279675|NCT01587638|carvedilol
279676|NCT01587638|claims analysis
279677|NCT01587638|beta-blocker
279678|NCT01587638|Diabetes Mellitus
279679|NCT01587625|Delayed labour
279680|NCT01587625|dystocia
279681|NCT01587625|oxytocin augmentation
279682|NCT01587625|primiparous women
279683|NCT01587625|childbirth
279684|NCT01587625|childbirth experience
279685|NCT01587625|progress
279686|NCT01587612|Pain
279687|NCT01587612|Foot
279688|NCT01587599|pharmaceutical care
279689|NCT01587599|drug-related problems
279690|NCT01587599|elderly
279691|NCT01587599|Pharmaceutical care of elderly patients with diabetes
279692|NCT01587586|Hepatitis C, Chronic
279693|NCT01587586|Interferon-alpha
279694|NCT01587586|Hepatitis C Virus
279695|NCT01587573|salivary biomarkers
279696|NCT01587560|Shoulder
279697|NCT01587560|Arthroplasty
279698|NCT01587560|Pyrocarbon
279699|NCT01587560|Randomized controlled trial
279700|NCT01587560|Shoulder resurfacing
279701|NCT01587547|ART
279702|NCT01587547|IVF
279703|NCT01587547|ICSI
279704|NCT01587547|embryo selection
279705|NCT01587534|Unresectable Pancreatic cancer
279706|NCT01587521|Metabolic syndrome
279707|NCT01587521|Prevalence
279708|NCT01587521|Quality of life
279709|NCT01587521|Depression
279710|NCT01587521|Antipsychotics
279711|NCT01587482|Superficial femoral artery
279712|NCT01587482|endovascular
279713|NCT01587482|Drug eluting balloon
279714|NCT01587482|Paclitaxel
279715|NCT01587456|Osteoporosis
279716|NCT01587430|acute myeloid leukemia
279717|NCT01587430|anthracyclines
279718|NCT01587430|high dose cytarabine
279719|NCT01587430|maintenance
279720|NCT01587404|Atrial Fibrillation
279721|NCT01587404|Electrogram
279722|NCT01587404|Ablation
279723|NCT01587404|Contact Force
279724|NCT01587378|miscarriage
279725|NCT01587378|preterm birth
279726|NCT01587378|prevention
279727|NCT01587326|cytokine, depression, escitalopram
279728|NCT01587313|hydralazine
279729|NCT01587313|isosorbide
279730|NCT01587313|bidil
279731|NCT01587313|volunteers
279732|NCT01587313|pharmacokinetic profile
279733|NCT01587287|Anterior corneal power
279734|NCT01587287|Placido topographer
279735|NCT01587287|Scheimpﬂug
279736|NCT01587287|Precision
279737|NCT01587287|Agreement
279738|NCT01587274|low back pain
279739|NCT01587261|Burns
279740|NCT01587261|Vitamin C
279741|NCT01587261|Thermal Injury
279742|NCT01587261|Fluid Resuscitation
279743|NCT01587248|Breast cancer,
279744|NCT01587248|Harmonic scalpel,
279745|NCT01587248|Electrocautery,
279746|NCT01587248|Modified Radical Mastectomy,
279747|NCT01587248|Randomized Controlled Trial
279748|NCT01587209|decompression
279749|NCT01587209|intravascular bubbles
279750|NCT01587209|neutrophil activation
279751|NCT01587196|prescription opiates/medications
279752|NCT01587196|vivitrol
279753|NCT01587196|brain imaging
279754|NCT01587183|Running
279755|NCT01587183|Blood pressure
279756|NCT01587170|spasticity
279757|NCT01587170|spinal cord injury
279758|NCT01587170|zolmitriptan
279759|NCT01587144|GBM
279760|NCT01587131|Universal Influenza
279761|NCT01587131|Intradermal DNA-Based Vaccine
279762|NCT01587131|Senior
279763|NCT01587131|Electroporation
279764|NCT01587131|H1
279765|NCT01587131|Influenza
279766|NCT01587131|FVH1
279767|NCT01587118|PTSD
279768|NCT01587118|Posttraumatic Stress Disorder
279769|NCT01587118|Asenapine
279770|NCT01587118|Adjunctive
279771|NCT01587118|antidepressant
279772|NCT01587118|neuroleptic
279773|NCT01587092|walking
279774|NCT01587092|physical activity
279775|NCT01587092|sedentary behavior
279776|NCT01587092|workplace
279777|NCT01587079|COPD
279778|NCT01587027|Altitude Sickness
279779|NCT01587027|High Altitude Sickness
279780|NCT01587001|Sarcoidosis
279781|NCT01587001|oxidative stress
279782|NCT01587001|anti-oxidant
279783|NCT01586988|HIV
279784|NCT01586988|Parenting
279785|NCT01586988|self-care
279786|NCT01586988|disclosure
279787|NCT01586988|medication adherence
279788|NCT01586988|mother
279789|NCT01586988|child
279790|NCT01586988|adolescent
279791|NCT01586962|paracetamol
279792|NCT01586962|pseudoephedrine
279793|NCT01586962|syrup
279794|NCT01586962|upper respiratory tract infection
279795|NCT01586949|well-being
279796|NCT01586949|web-based intervention
279797|NCT01586949|social networks
279798|NCT01586923|Anemia
279799|NCT01586923|Transfusion
279800|NCT01586923|RBC storage age
279801|NCT01586923|Tissue oxygenation
279802|NCT01586923|Malaria
279803|NCT01586897|health information technology
279804|NCT01586897|primary care
279805|NCT01586897|visit-independent
279806|NCT01586897|medication monitoring
279807|NCT01586884|LV Pacing
279808|NCT01586884|LV Lead Placement
279809|NCT01586884|LV Pacing Site
279810|NCT01586884|CRT Device Placement
279811|NCT01586871|MPS I
279812|NCT01586871|MPS II
279813|NCT01586871|MPS VI
279814|NCT01586871|Mucopolysaccharidoses
279815|NCT01586858|Vasculitis
279816|NCT01586858|ANCA
279817|NCT01586858|Rituximab
279818|NCT01586858|Small vessel vasculitis
279819|NCT01586845|Randomized Controlled Trials
279820|NCT01586845|Immunosuppression
279821|NCT01586845|Adult
279822|NCT01586845|Kidney Transplantation
279823|NCT01586845|Treatment Outcome
279824|NCT01586832|Hospital Supplies
279825|NCT01586832|Stocking of Supplies
279826|NCT01586806|Dexamethasone
279827|NCT01586806|Glucocorticoids
279828|NCT01586806|Physiological Effects of Drugs
279829|NCT01586806|Therapeutic Uses
279830|NCT01586806|Anterior Cruciate Ligament Reconstruction
279831|NCT01586806|Regional Anesthesia, nerve block
279832|NCT01586806|Ultrasonic Imaging
279833|NCT01586806|Post-Operative Complications: muscle weakness, pain, nausea and vomiting
279834|NCT01586806|Dexamethasone (as local anesthetic additive)
279835|NCT01586793|Repetitive transcranial magnetic stimulation
279836|NCT01586793|Bipolar depression
279837|NCT01586793|Randomized trial
279838|NCT01586793|rTMS
279839|NCT01586793|Neuromodulation
279840|NCT01586780|Whey protein
279841|NCT01586780|Soy protein
279842|NCT01586780|Insulinogenic amino acids
279843|NCT01586780|Incretins
279844|NCT01586780|Glycaemia
279845|NCT01586780|Insulinaemia
279846|NCT01586767|Nasal cavity
279847|NCT01586767|Salivary gland tumors
279848|NCT01586767|Hard palate
279849|NCT01586767|Sinus
279850|NCT01586767|Soft Palate
279851|NCT01586767|Lacrimal Apparatus
279852|NCT01586754|metabolic syndrome
279853|NCT01586754|obesity
279854|NCT01586754|endothelial damage
279855|NCT01586754|homocysteine
279856|NCT01586754|microalbumin
279857|NCT01586754|carotis intima-media thickness
279858|NCT01586728|Cystic fibrosis
279859|NCT01586728|oxygen therapy
279860|NCT01586728|sleep
279861|NCT01586715|Extremely complex perianal fistula
279862|NCT01586715|Adipose Derived Stem Cells
279863|NCT01586702|Stroke, TIA, secondary prevention, support program, multifactorial intervention
279864|NCT01586689|Oxford House
279865|NCT01586689|recovery
279866|NCT01586689|substance abuse
279867|NCT01586689|alcohol abuse
279868|NCT01586689|addiction
279869|NCT01586676|supervision
279870|NCT01586676|motivational interviewing
279871|NCT01586676|substance abuse
279872|NCT01586676|dissemination
279873|NCT01586663|Diffuse Systemic Sclerosis
279874|NCT01586663|Hand
279875|NCT01586663|Range of motion
279876|NCT01586663|Splint
279877|NCT01586650|ankylosing spondylitis
279878|NCT01586650|aerobic exercise
279879|NCT01586637|Fibromyalgia
279880|NCT01586637|Art Therapy
279881|NCT01586637|Pain
279882|NCT01586637|Quality of life
279883|NCT01586637|Body Image
279884|NCT01586624|Phase I
279885|NCT01586624|Drug evaluation
279886|NCT01586624|Oncology
279887|NCT01586624|Vandetanib
279888|NCT01586624|Selumetinib
279889|NCT01586624|Dose escalation
279890|NCT01586624|Clinical trial
279891|NCT01586624|Vascular Endothelial Growth Factor(VEGFR) inhibitor
279892|NCT01586624|Epidermal Growth Factor Receptor(EGFR)inhibitor
279893|NCT01586624|Mitogen Activated Kinase (MEK) inhibitor
279894|NCT01586624|Non small cell lung cancer
279895|NCT01586598|Mandibular Nerve
279896|NCT01586598|Orthognathic Surgery
279897|NCT01586598|Sagittal Split Osteotomy
279898|NCT01586598|Sensory Retraining
279899|NCT01586572|Polio virus type 1,2,3
279900|NCT01586572|Poliovaccine-Oral
279901|NCT01586572|Poliovaccine
279902|NCT01586572|Trivalent Oral Polio vaccine
279903|NCT01586572|Monovalent oral polio vaccine
279904|NCT01586572|Bivalent Oral polio vaccine
279905|NCT01586546|Mind-body
279906|NCT01586546|Psychosocial
279907|NCT01586546|Meditation
279908|NCT01586546|Breathing Exercises
279909|NCT01586546|Guided Imagery
279910|NCT01586546|Visualization
279911|NCT01586533|ulcerative colitis
279912|NCT01586533|UC
279913|NCT01586533|left-sided ulcerative colitis
279914|NCT01586533|distal ulcerative colitis
279915|NCT01586533|Zoenasa
279916|NCT01586533|mesalamine
279917|NCT01586533|mesalazine
279918|NCT01586533|5-ASA
279919|NCT01586533|5-aminosalicylic acid
279920|NCT01586533|N-acetylcysteine
279921|NCT01586533|acetylcysteine
279922|NCT01586533|NAC
279923|NCT01586533|enema
279924|NCT01586533|rectal gel
279925|NCT01586520|thyroid cancer, papillary, follicular, proteomics, genetic markers
279926|NCT01586507|Pain
279927|NCT01586507|ULTRAM ER
279928|NCT01586507|Tramadol hydrochloride
279929|NCT01586507|Adolescents
279930|NCT01586494|Pain
279931|NCT01586494|ULTRAM ER
279932|NCT01586494|Tramadol hydrochloride
279933|NCT01586494|Children
279934|NCT01586481|Diabetic foot ulcer
279935|NCT01586481|Off loading
279936|NCT01586481|Compliance
279937|NCT01586481|Healing duration
279938|NCT01586481|Amputation rate
279939|NCT01586455|umbilical cord blood
279940|NCT01586455|stem cell transplantation
279941|NCT01586455|placental stem cell
279942|NCT01586455|inborn errors of metabolism
279943|NCT01586455|marrow failure
279944|NCT01586455|Severe Combined Immunodeficiency Disease
279945|NCT01586455|AML
279946|NCT01586455|ALL
279947|NCT01586455|MDS
279948|NCT01586429|comparing the analgesic efficacy of ultrasound-guided nerve block catheter compared with epidural analgesia
279949|NCT01586416|Colonic neoplasms
279950|NCT01586416|Older adults
279951|NCT01586416|Psychosocial Intervention
279952|NCT01586416|Chemotherapy adherence
279953|NCT01586403|Melanoma
279954|NCT01586403|Gene Therapy
279955|NCT01586403|Adoptive T-Cell Transfer
279956|NCT01586403|IL-2
279957|NCT01586390|Ankle Sprain
279958|NCT01586390|Ankle Distortion
279959|NCT01586390|Functional treatment
279960|NCT01586390|Brace treatment
279961|NCT01586377|Complex regional pain syndrome
279962|NCT01586377|Near Infrared Spectroscopy
279963|NCT01586377|Vascular Occlusion Test
279964|NCT01586364|Menopausal symptoms
279965|NCT01586364|Vulvar and vaginal atrophy in menopausal women
279966|NCT01586364|Vaginal atrophy
279967|NCT01586364|Urogenital atrophy
279968|NCT01586351|Rotator cuff tears
279969|NCT01586351|ACP
279970|NCT01586351|DX Reinforcement Matrix
279971|NCT01586325|Chronic hepatitis C infection
279972|NCT01586325|Asian genotype 1 chronic hepatitis C infection
279973|NCT01586325|JNJ-47910382
279974|NCT01586325|Non-structural protein 5A (NS5A) inhibitor
279975|NCT01586312|Knee degenerative disease
279976|NCT01586312|osteoarthritis
279977|NCT01586312|gonarthrosis
279978|NCT01586312|stem cell
279979|NCT01586312|cellular therapy
279980|NCT01586312|regenerative therapy
279981|NCT01586312|Mesenchymal stem cells
279982|NCT01586312|Bone marrow
279983|NCT01586312|musculoskeletal Diseases
279984|NCT01586312|Mesenchymal Stromal Cells (allogenic)
279985|NCT01586299|pleuropneumonia children
279986|NCT01586299|non steroidal anti inflammatory drugs
279987|NCT01586299|pleural effusion
279988|NCT01586299|severe pneumonia
279989|NCT01586286|Levator Myalgia
279990|NCT01586286|Pelvic Pain
279991|NCT01586286|Vaginismus
279992|NCT01586286|Myofascial pain syndromes
279993|NCT01586260|Neuroblastoma in remission
279994|NCT01586260|Relapsed Neuroblastoma
279995|NCT01586260|Refractory Neuroblastoma
279996|NCT01586234|Fuchs' endothelial dystrophy
279997|NCT01586234|DSAEK
279998|NCT01586234|Descemet's stripping automated endothelial keratoplasty
279999|NCT01586221|Rehabilitation
280000|NCT01586221|Fingers
280001|NCT01586221|Grasp
280002|NCT01586221|Strength
280003|NCT01586221|Brain Function
280004|NCT01586221|Physiopathology
280005|NCT01586221|Functional Laterality
280006|NCT01586221|Psychomotor Performance
280007|NCT01586221|Biomechanis
280008|NCT01586221|Touch
280009|NCT01586221|Music Therapy
280010|NCT01586221|Weight-Bearing
280011|NCT01586208|refractory status epilepticus
280012|NCT01586208|valproic acid
280013|NCT01586208|phenytoin
280014|NCT01586208|benzodiazepines
280015|NCT01586208|Valproic acid initial dosage in status treatment
280016|NCT01586182|poor prognosis
280017|NCT01586169|Albendazole
280018|NCT01586169|Ivermectin
280019|NCT01586169|Azithromycin
280020|NCT01586169|Lymphatic filariasis
280021|NCT01586169|Trachoma
280022|NCT01586169|Safety
280023|NCT01586143|Paracetamol by permucosal route,
280024|NCT01586143|Paracetamol by intraveinous route,
280025|NCT01586143|Pain.
280026|NCT01586143|Patient with minor trauma of lower limb and/or superior limb (sprains, muscle contusions, …).
280027|NCT01586130|Knee Osteoarthritis
280028|NCT01586130|Exercise
280029|NCT01586130|Isokinetic
280030|NCT01586130|Muscle strength
280031|NCT01586130|Rehabilitation
280032|NCT01586117|rectal cancer
280033|NCT01586117|amifostine
280034|NCT01586117|pre-operative chemo-radiation
280035|NCT01586065|type 1 diabetes
280036|NCT01586065|adolescents
280037|NCT01586065|poor control
280038|NCT01586065|CGM
280039|NCT01586052|Cerebral Palsy
280040|NCT01586052|Erythropoietin
280041|NCT01586052|Rehabilitation
280042|NCT01586039|Melatonin
280043|NCT01586039|Sleep
280044|NCT01586039|Light
280045|NCT01586039|Alertness
280046|NCT01586039|Circadian Rhythms
280047|NCT01586026|Ports
280048|NCT01586026|Catheters
280049|NCT01586026|Distal Valved Catheters
280050|NCT01586026|Maintenance Flush
280051|NCT01586026|subjects
280052|NCT01586026|routine maintenance flushes
280053|NCT01586013|propofol
280054|NCT01586013|pharmacodynamic
280055|NCT01586013|age
280056|NCT01586013|ke0
280057|NCT01586000|vaginal ring
280058|NCT01585974|Renal Cell Carcinoma
280059|NCT01585974|TKI
280060|NCT01585974|Turkey
280061|NCT01585974|Observational
280062|NCT01585961|Symptomatic paroxysmal
280063|NCT01585961|Atrial fibrillation
280064|NCT01585961|Observational
280065|NCT01585961|Acute procedural outcomes
280066|NCT01585961|Ablation
280067|NCT01585961|Drug refractory
280068|NCT01585961|Arrhythmia Recurrent
280069|NCT01585961|Symptomatic
280070|NCT01585935|Infant, Extremely Low Birth Weight
280071|NCT01585935|Parenteral Nutrition
280072|NCT01585935|Fish Oils
280073|NCT01585935|Cholestasis
280074|NCT01585935|Psychomotor Disorders, Developmental
280075|NCT01585922|noninvasive positive pressure ventilation
280076|NCT01585896|Hoarding
280077|NCT01585896|Compulsive Hoarding
280078|NCT01585896|Self-Help
280079|NCT01585883|Lung cancer
280080|NCT01585883|Breathlessness
280081|NCT01585883|Self-management
280082|NCT01585870|Safety
280083|NCT01585870|Tolerability
280084|NCT01585870|Pharmacokinetics
280085|NCT01585870|Clinical benefit
280086|NCT01585870|Sorafenib
280087|NCT01585870|Eribulin
280088|NCT01585870|advanced metastatic solid tumors
280089|NCT01585844|sleep apnea
280090|NCT01585844|pregnancy
280091|NCT01585844|obesity
280092|NCT01585831|Klinefelter syndrome
280093|NCT01585831|XXY syndrome
280094|NCT01585831|Sex Chromosome Abnormality
280095|NCT01585831|Testosterone replacement therapy
280096|NCT01585818|Glycemic Index
280097|NCT01585818|Type 2 Diabetes Mellitus
280098|NCT01585818|Diet
280099|NCT01585818|Glucose Variability
280100|NCT01585818|Metabolic Response
280101|NCT01585818|Glucose Response
280102|NCT01585766|MAb, B cell, depletion, RMS
280103|NCT01585753|cardiovascular function
280104|NCT01585753|maraviroc
280105|NCT01585740|Hyperchloraemic metabolic acidosis
280106|NCT01585740|Neonatal acidosis
280107|NCT01585740|Neonatal hyperchloraemia
280108|NCT01585740|Base excess
280109|NCT01585740|Metabolic acidosis
280110|NCT01585740|Caesarean section
280111|NCT01585740|Normal saline
280112|NCT01585740|Ringer's Lactate
280113|NCT01585740|Postoperative morbidity
280114|NCT01585727|Rectal cancer
280115|NCT01585727|total mesorectal excision
280116|NCT01585727|pelvic autonomic nerve preservation
280117|NCT01585727|neurostimulation
280118|NCT01585727|urogenital function
280119|NCT01585727|quality of life
280120|NCT01585701|Phase I
280121|NCT01585701|Oncology
280122|NCT01585701|AGC Kinase inhibitor
280123|NCT01585701|Protein Kinase inhibitor
280124|NCT01585701|Clinical Trial
280125|NCT01585701|Multiple protein kinases
280126|NCT01585688|NHL
280127|NCT01585688|CLL
280128|NCT01585675|Lung Cancer
280129|NCT01585662|EUS
280130|NCT01585662|pancreatic pseudocyst
280131|NCT01585662|drainage
280132|NCT01585636|SQ109
280133|NCT01585636|Tuberculosis
280134|NCT01585610|smoking
280135|NCT01585610|smoking cessation
280136|NCT01585610|disabled persons
280137|NCT01585610|behavioral research
280138|NCT01585597|Ischemic Stoke
280139|NCT01585597|Endovascular Reperfusion
280140|NCT01585597|Reperfusion Injury
280141|NCT01585597|Mild hypothermia
280142|NCT01585584|Boceprevir
280143|NCT01585584|Hepatitis C Genotype 3
280144|NCT01585571|Balance
280145|NCT01585571|Posture
280146|NCT01585571|Virtual Environment
280147|NCT01585571|Cerebral Palsy
280148|NCT01585571|Adults
280149|NCT01585558|Menopausal symptoms
280150|NCT01585558|Urogenital atrophy
280151|NCT01585558|Vulvar and vaginal atrophy in menopausal women
280152|NCT01585558|Vaginal atrophy
280153|NCT01585545|CT
280154|NCT01585545|PET CT
280155|NCT01585545|MRI
280156|NCT01585545|cancer genomics
280157|NCT01585545|Radiomics
280158|NCT01585545|Radiogenomics
280159|NCT01585532|Tuberculosis
280160|NCT01585532|Urine
280161|NCT01585532|Nucleic acid
280162|NCT01585532|Alere
280163|NCT01585532|Borstel
280164|NCT01585519|High Epicatechin Apples
280165|NCT01585519|Low Epicatechin Apples
280166|NCT01585519|Apple Extract
280167|NCT01585519|Apple Granules
280168|NCT01585519|Blood Pressure
280169|NCT01585519|Cholesterol
280170|NCT01585493|Lifestyle
280171|NCT01585493|Smoking
280172|NCT01585493|Dietary
280173|NCT01585493|Exercise
280174|NCT01585480|Obesity
280175|NCT01585480|Weight Gain Prevention
280176|NCT01585480|Workplace
280177|NCT01585480|Intervention
280178|NCT01585480|Diet
280179|NCT01585480|Exercise
280180|NCT01585467|Anterior Shoulder Dislocation
280181|NCT01585467|Shoulder Dislocation
280182|NCT01585467|Shoulder Pain
280183|NCT01585467|Shoulder Deformity
280184|NCT01585454|Pregnancy
280185|NCT01585454|Diabetes Mellitus
280186|NCT01585454|Weight Gain
280187|NCT01585454|Diabetes
280188|NCT01585441|Finasteride
280189|NCT01585441|Central Serous Chorioretinopathy
280190|NCT01585428|Immunotherapy
280191|NCT01585428|HPV-Associated Cancers
280192|NCT01585428|Cervical Cancer
280193|NCT01585428|Oropharyngeal Cancer
280194|NCT01585428|HPV Infection
280195|NCT01585415|Tumor Infiltrating Lymphocytes
280196|NCT01585415|Immunotherapy
280197|NCT01585415|Adoptive Cell Therapy
280198|NCT01585415|B Raf Inhibitor
280199|NCT01585402|NT5E
280200|NCT01585402|Biphosphonates
280201|NCT01585402|Vascular Calcifications
280202|NCT01585402|Joint Capsule Calcifications
280203|NCT01585402|Inherited Disease
280204|NCT01585389|adult brain tumor
280205|NCT01585389|childhood brain tumor
280206|NCT01585376|alveolar childhood rhabdomyosarcoma
280207|NCT01585376|embryonal childhood rhabdomyosarcoma
280208|NCT01585350|melanoma
280209|NCT01585350|peptide vaccine
280210|NCT01585350|polyICLC
280211|NCT01585350|lipopolysaccharide (LPS)
280212|NCT01585350|immunotherapy
280213|NCT01585311|Subarachnoid Hemorrhage (SAH)
280214|NCT01585311|tachycardia
280215|NCT01585311|Outcome
280216|NCT01585298|Multiple Sclerosis
280217|NCT01585298|MS
280218|NCT01585298|Fingolimod
280219|NCT01585298|Gilenya
280220|NCT01585298|ECG
280221|NCT01585298|Bradyarrythmia
280222|NCT01585298|conduction abnormalities
280223|NCT01585298|first dose observation
280224|NCT01585285|Coronary artery bypass grafting
280225|NCT01585285|Left internal mammary artery
280226|NCT01585285|Composite grafting
280227|NCT01585285|Multislice Spiral Computed Tomography Scanner
280228|NCT01585285|Graft patency assessment
280229|NCT01585272|Alzheimer's dementia, AD
280230|NCT01585259|anti-platelet;
280231|NCT01585259|safety;
280232|NCT01585259|efficacy
280233|NCT01585246|Prostate Cancer
280234|NCT01585246|Radiation Therapy
280235|NCT01585246|Quality of Life
280236|NCT01585246|Symptom Management
280237|NCT01585233|Moderate Psoriasis
280238|NCT01585233|Severe Psoriasis
280239|NCT01585233|Skin disease
280240|NCT01585233|ASKP1240
280241|NCT01585233|CD40 antigen
280242|NCT01585233|Anti-CD40 monoclonal antibody
280243|NCT01585220|WSRS
280244|NCT01585220|GAIS
280245|NCT01585220|HA filler
280246|NCT01585220|filler
280247|NCT01585207|Tourette's Disorder
280248|NCT01585207|vigabatrin
280249|NCT01585194|Melanoma
280250|NCT01585194|History of Uveal Melanoma
280251|NCT01585194|Metastatic
280252|NCT01585194|Ipilimumab
280253|NCT01585194|Yervoy
280254|NCT01585194|BMS-734016
280255|NCT01585194|MDX010
280256|NCT01585194|Nivolumab
280257|NCT01585194|BMS-936558
280258|NCT01585194|Opdivo
280259|NCT01585181|Vaccine, Bacterial disease condition, Cholera
280260|NCT01585168|Reward Circuitry
280261|NCT01585168|Impulsivity
280262|NCT01585168|Family History of Alcoholism
280263|NCT01585168|NMDA/DA Interactions
280264|NCT01585155|Infliximab
280265|NCT01585155|REMICADE
280266|NCT01585155|TA-650
280267|NCT01585090|Ankle positions
280268|NCT01585090|pelvic floor muscles strength
280269|NCT01585090|relaxation of pelvic floor muscles syndrome
280270|NCT01585090|doing strengthening exercises of pelvic floor muscles
280271|NCT01585077|Plasmodium vivax
280272|NCT01585077|Malaria
280273|NCT01585077|Challenge
280274|NCT01585077|Anopheles albimanus
280275|NCT01585064|Rheumatoid Arthritis (RA)
280276|NCT01585064|Anti-TNF therapy
280277|NCT01585064|Adalimumab
280278|NCT01585064|Disease activity
280279|NCT01585064|Treating to target
280280|NCT01585051|vitamin D
280281|NCT01585051|blood pressure
280282|NCT01585051|typ 2 diabetes mellitus
280283|NCT01585051|blood glucose
280284|NCT01585051|HbA1c
280285|NCT01585038|endothelium
280286|NCT01585038|inflammation
280287|NCT01585038|oxidative stress
280288|NCT01585038|HIV-1
280289|NCT01585025|Primary bile acid malabsorption
280290|NCT01585025|Secondary bile acid malabsorption
280291|NCT01585025|Chronic diarrhoea
280292|NCT01585025|Obeticholic acid
280293|NCT01585025|SeHCAT
280294|NCT01585025|FXR
280295|NCT01585025|FGF19
280296|NCT01585012|Cervical cap insemination
280297|NCT01585012|Collection condom
280298|NCT01585012|Instructions for Use
280299|NCT01585012|Safety during intercourse
280300|NCT01585012|Acceptability of the cervical cap with condom sheath
280301|NCT01585012|slip
280302|NCT01585012|break
280303|NCT01585012|ease of conversion
280304|NCT01585012|adequate sample collection
280305|NCT01584947|Oral pain
280306|NCT01584947|Local anesthetic
280307|NCT01584947|Bupivacaine hydrochloride
280308|NCT01584934|fatigue
280309|NCT01584934|sleep quality
280310|NCT01584934|Chronic, disabling, unexplained fatigue with at least 4 minor criteria for CFS, according to the 1994 Fukuda case definition
280311|NCT01584921|Erythropoietin
280312|NCT01584921|Glomerular filtration rate
280313|NCT01584921|Tubular reabsorption
280314|NCT01584921|Renal function
280315|NCT01584921|Renal perfusion
280316|NCT01584908|kidney transplant recipients
280317|NCT01584882|Clinical decision support (CDS)
280318|NCT01584882|Tobacco
280319|NCT01584882|Behavioral
280320|NCT01584882|Dental hygienist
280321|NCT01584882|Dentist
280322|NCT01584882|Smoking
280323|NCT01584882|Electronic health record
280324|NCT01584869|GI-bleeding
280325|NCT01584869|capsule endoscopy
280326|NCT01584843|Neuromuscular Agents
280327|NCT01584843|Strabismus
280328|NCT01584843|Botulinum Toxin Type A
280329|NCT01584830|Regorafenib
280330|NCT01584830|Colorectal
280331|NCT01584830|Metastatic
280332|NCT01584817|colonoscopy
280333|NCT01584817|bowel preparation
280334|NCT01584817|education
280335|NCT01584804|Su Huang antitussive capsule
280336|NCT01584804|Cough variant asthma
280337|NCT01584804|Placebo
280338|NCT01584791|CAD
280339|NCT01584791|PCI
280340|NCT01584791|Percutaneous Coronary Intervention
280341|NCT01584778|Behçet's disease
280342|NCT01584778|Eosinophil cationic protein
280343|NCT01584778|Eosinophils
280344|NCT01584765|liver injury
280345|NCT01584765|Rechallenge
280346|NCT01584765|Kaiser Permanente California
280347|NCT01584739|Safety
280348|NCT01584739|tolerability
280349|NCT01584739|healthy
280350|NCT01584739|COPD (chronic obstructive pulmonary disease)
280351|NCT01584739|pharmacokinetic
280352|NCT01584739|pharmacodynamic
280353|NCT01584739|inhaled
280354|NCT01584726|magnesium
280355|NCT01584726|nebulization
280356|NCT01584726|asthma
280357|NCT01584726|sulfate
280358|NCT01584726|children
280359|NCT01584726|pediatric
280360|NCT01584713|Enterocutaneous fistula
280361|NCT01584713|Adipose Derived Stem Cells
280362|NCT01584700|NYHA class III or IV
280363|NCT01584700|Maximal medical therapy
280364|NCT01584700|Not eligible for CRT
280365|NCT01584687|asthma
280366|NCT01584687|difficult-to-control asthma
280367|NCT01584687|mRNA expression
280368|NCT01584687|biomarker
280369|NCT01584687|real time PCR
280370|NCT01584687|ACT
280371|NCT01584687|ACQ
280372|NCT01584648|Randomized study
280373|NCT01584648|combination therapy
280374|NCT01584648|BRAF inhibitor
280375|NCT01584648|GSK1120212
280376|NCT01584648|BRAF V600E/K mutation-positive cutaneous melanoma
280377|NCT01584648|trametinib
280378|NCT01584648|GSK2118436
280379|NCT01584648|MEK inhibitor
280380|NCT01584648|Phase III
280381|NCT01584648|dabrafenib
280382|NCT01584635|Less invasive treatment for Achalasia
280383|NCT01584609|ischemic stroke
280384|NCT01584609|large vessel occlusion
280385|NCT01584609|mechanical thrombectomy
280386|NCT01584609|revascularization
280387|NCT01584609|Penumbra System
280388|NCT01584609|Separator 3D
280389|NCT01584596|physical activity
280390|NCT01584596|dietary
280391|NCT01584596|adults
280392|NCT01584596|pedometer
280393|NCT01584596|education
280394|NCT01584583|BP
280395|NCT01584570|dexmedetomidine
280396|NCT01584570|heart rate variability
280397|NCT01584570|QTc interval
280398|NCT01584544|rectal neoplasms
280399|NCT01584544|aged
280400|NCT01584544|chemoradiotherapy
280401|NCT01584544|clinical trials, phase I
280402|NCT01584544|capecitabine
280403|NCT01584531|rigosertib sodium
280404|NCT01584531|rigosertib
280405|NCT01584531|ON 01910.Na
280406|NCT01584531|oral rigosertib
280407|NCT01584505|COPD
280408|NCT01584479|periodontitis
280409|NCT01584466|Schizophrenia
280410|NCT01584466|Substance Abuse
280411|NCT01584427|Dietary fibers
280412|NCT01584427|Resistent Starch
280413|NCT01584427|Arabinoxylans
280414|NCT01584427|Postprandial lipaemia
280415|NCT01584427|Insulin sensitivity
280416|NCT01584427|Body composition
280417|NCT01584427|Gene expression
280418|NCT01584427|Metabolic rate
280419|NCT01584427|Blood pressure
280420|NCT01584414|Zetiq CellDetect ® stain
280421|NCT01584414|distinct red/purple color to the cytoplasm of neoplastic
280422|NCT01584414|distinguishes green/blue stained non-neoplastic cells and tissues
280423|NCT01584401|Body temperature
280424|NCT01584401|Thermometers
280425|NCT01584401|Non invasive
280426|NCT01584401|Medisim's non invasive thermometers
280427|NCT01584388|Type 1 autoimmune pancreatitis
280428|NCT01584388|IgG4-related sclerosing cholangitis
280429|NCT01584388|Chronic sclerosing sialadenitis
280430|NCT01584388|Lacrimal glands
280431|NCT01584388|Orbital pseudotumor
280432|NCT01584388|IgG4-related tubulointerstitial nephritis
280433|NCT01584388|Lymphadenopathy
280434|NCT01584388|Pachymeningitis
280435|NCT01584388|Aorta
280436|NCT01584388|Peri-aortitis
280437|NCT01584388|Retroperitoneal fibrosis
280438|NCT01584388|Riedel's thyroiditis
280439|NCT01584375|Intraventricular hemorrhage
280440|NCT01584375|Preterm infant
280441|NCT01584375|Midline head position
280442|NCT01584375|Lateral head Position
280443|NCT01584362|Taenia solium
280444|NCT01584362|neurocysticercosis
280445|NCT01584362|oxfendazole
280446|NCT01584362|clinical trial, phase 1
280447|NCT01584362|safety
280448|NCT01584362|pharmacokinetics
280449|NCT01584336|Gastric cancer, laparoscopy-assisted total gastrectomy
280450|NCT01584323|Preterm premature rupture of membranes
280451|NCT01584323|pomgranate
280452|NCT01584323|oxidative stress
280453|NCT01584323|pregnant women with Preterm premature rupture of membranes
280454|NCT01584310|Nutritional assessment
280455|NCT01584310|children
280456|NCT01584310|malnutrition
280457|NCT01584297|Granulosa Cell Tumour
280458|NCT01584284|Genelux
280459|NCT01584284|Genelux Corporation
280460|NCT01584284|GL-ONC1
280461|NCT01584284|Vaccinia
280462|NCT01584284|Vaccinia Virus
280463|NCT01584284|Oncolytic virus
280464|NCT01584284|Oncolytic Virotherapy
280465|NCT01584284|Head and Neck Cancer
280466|NCT01584284|Squamous Cell Carcinoma
280467|NCT01584271|AOE
280468|NCT01584271|Ear Comfort
280469|NCT01584271|Dex Otic
280470|NCT01584271|Otidin
280471|NCT01584258|Prostate cancer
280472|NCT01584258|Prostate adenocarcinoma
280473|NCT01584258|Early stage prostate cancer
280474|NCT01584258|Organ-confined prostate cancer
280475|NCT01584258|Low-risk prostate cancer
280476|NCT01584258|Intermediate-risk prostate cancer
280477|NCT01584232|Glucagon-like peptide-1 (GLP-1)
280478|NCT01584206|Sitosterolemia
280479|NCT01584206|Ezetimibe
280480|NCT01584206|Plant sterol
280481|NCT01584206|Cholesterol
280482|NCT01584193|central venous access port
280483|NCT01584193|ultrasound-guided venous puncture
280484|NCT01584193|suclavian vein
280485|NCT01584193|cephalic vein
280486|NCT01584180|hypothermia
280487|NCT01584180|induction of hypothermia
280488|NCT01584180|cold infusion
280489|NCT01584180|local neck cooling
280490|NCT01584180|external cooling
280491|NCT01584180|surface cooling
280492|NCT01584180|non invasive cooling
280493|NCT01584180|stroke
280494|NCT01584180|intracranial hemorrhage
280495|NCT01584180|cerebrovascular disease
280496|NCT01584180|neuro intensive care
280497|NCT01584167|hypothermia
280498|NCT01584167|induction of hypothermia
280499|NCT01584167|cold infusion
280500|NCT01584167|whole-body cooling
280501|NCT01584167|external cooling
280502|NCT01584167|surface cooling
280503|NCT01584167|non invasive cooling
280504|NCT01584167|stroke
280505|NCT01584167|intracranial hemorrhage
280506|NCT01584167|cerebrovascular disease
280507|NCT01584167|neuro intensive care
280508|NCT01584141|Leukemia
280509|NCT01584141|Lymphoma
280510|NCT01584141|Occupational Epidemiology
280511|NCT01584141|Molecular Epidemiology
280512|NCT01584141|Genetic Polymorphisms
280513|NCT01584115|Cancer.
280514|NCT01584115|Melanoma.
280515|NCT01584115|Ovarian cancer.
280516|NCT01584115|Lung cancer.
280517|NCT01584115|NY-ESO-1.
280518|NCT01584115|MPLA (monophosphoryl lipid A).
280519|NCT01584115|Tumor antigen.
280520|NCT01584115|Bordetella pertussis.
280521|NCT01584102|Randomized controlled trial
280522|NCT01584102|obesity
280523|NCT01584102|community-based participatory research
280524|NCT01584102|minority health
280525|NCT01584102|rural health
280526|NCT01584102|health promotion
280527|NCT01584076|Amblyopia
280528|NCT01584076|Donepezil
280529|NCT01584063|Mexican Americans
280530|NCT01584063|Pregnancy
280531|NCT01584063|Diabetes Mellitus Type 2
280532|NCT01584063|Prevention
280533|NCT01584063|Community health workers
280534|NCT01584063|Community based participatory research
280535|NCT01584063|Behavioral Intervention
280536|NCT01584063|Lifestyle Intervention
280537|NCT01584037|Adenovirus
280538|NCT01584037|Adenovirus Type 4
280539|NCT01584037|Adenovirus Type 7
280540|NCT01584037|Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
280541|NCT01584024|Dental caries
280542|NCT01584024|Proximal surfaces
280543|NCT01584024|Posterior teeth
280544|NCT01584024|Carious lesions
280545|NCT01584024|Tooth diseases
280546|NCT01584024|Preventive therapy
280547|NCT01584011|Taste
280548|NCT01584011|Chorda tympani nerve
280549|NCT01583998|Major Depressive Disorder
280550|NCT01583998|MDD
280551|NCT01583998|Depression
280552|NCT01583998|Measurement Based Care
280553|NCT01583998|MBC
280554|NCT01583998|electronic health records
280555|NCT01583998|EHR
280556|NCT01583998|electronic medical records
280557|NCT01583998|EMR
280558|NCT01583985|opioid analgesics
280559|NCT01583985|chronic pain
280560|NCT01583985|musculoskeletal pain
280561|NCT01583972|Vitamin A deficiency
280562|NCT01583972|Vitamin A
280563|NCT01583972|retinyl palmitate
280564|NCT01583972|malnutrition
280565|NCT01583972|vaccine
280566|NCT01583972|vaccination
280567|NCT01583972|BCG
280568|NCT01583972|tuberculosis
280569|NCT01583972|polio virus
280570|NCT01583972|tetanus toxoid
280571|NCT01583972|hepatitis B virus
280572|NCT01583972|thymus
280573|NCT01583972|T lymphocyte
280574|NCT01583972|B lymphocyte
280575|NCT01583972|antibody
280576|NCT01583972|bacterial translocation
280577|NCT01583972|T-cell receptor excision circle
280578|NCT01583959|rheumatoid arthritis
280579|NCT01583959|folic acid
280580|NCT01583959|methotrexate
280581|NCT01583946|subjective well-being
280582|NCT01583946|life transitions
280583|NCT01583946|health-related quality of life
280584|NCT01583946|health
280585|NCT01583946|healthcare costs
280586|NCT01583933|Dental stability
280587|NCT01583933|Occlusal stability
280588|NCT01583933|Retainers
280589|NCT01583920|prostatic neoplasms
280590|NCT01583920|brachytherapy
280591|NCT01583920|salvage therapy
280592|NCT01583920|recurrent prostate cancer
280593|NCT01583907|cow's milk allergy
280594|NCT01583881|Patients with diastolic heart failure and hypertension
280595|NCT01583855|Remote catheter ablation
280596|NCT01583855|Atrial fibrillation
280597|NCT01583842|neuroblastoma
280598|NCT01583842|imaging
280599|NCT01583842|124I-MIBG
280600|NCT01583842|131I-MIBG
280601|NCT01583842|PET/CT
280602|NCT01583829|ADHD
280603|NCT01583829|neurofeedback
280604|NCT01583829|biofeedback
280605|NCT01583829|computer attention training
280606|NCT01583816|Actinic Keratosis
280607|NCT01583816|Resiquimod
280608|NCT01583790|Laparoscopic Sleeve Gastrectomy
280609|NCT01583790|Bariatric surgery
280610|NCT01583790|Morbid Obesity
280611|NCT01583777|Belinostat
280612|NCT01583751|pilonidal sinus
280613|NCT01583751|new technique
280614|NCT01583751|videoendoscopic
280615|NCT01583725|Obesity
280616|NCT01583725|Bariatric surgery
280617|NCT01583725|Weight loss
280618|NCT01583725|fMRI
280619|NCT01583725|gut peptides
280620|NCT01583712|Confocal laser endomicroscopy
280621|NCT01583712|Small bowel imaging
280622|NCT01583712|Graft-versus-host disease
280623|NCT01583712|HSCT
280624|NCT01583699|MALT-lymphoma
280625|NCT01583699|Confocal laser endomicroscopy
280626|NCT01583699|Gastrointestinal endoscopy
280627|NCT01583686|Metastatic Cancer
280628|NCT01583686|Immunotherapy
280629|NCT01583686|Gene Therapy
280630|NCT01583686|Mesothelioma
280631|NCT01583686|Pancreatic Cancer
280632|NCT01583660|NSAIDs
280633|NCT01583660|Anti-inflammatory
280634|NCT01583660|elderly hip fracture
280635|NCT01583660|mortality
280636|NCT01583608|Drug eluting stent
280637|NCT01583608|Bioabsorbable
280638|NCT01583608|Bioresorbable
280639|NCT01583608|Coronary Stent
280640|NCT01583608|Scaffold
280641|NCT01583608|Stents
280642|NCT01583608|Angioplasty
280643|NCT01583608|Coronary Artery Disease
280644|NCT01583608|Stentthrombosis
280645|NCT01583595|Chronic Lung Disease
280646|NCT01583595|Exercise
280647|NCT01583595|Self-efficacy
280648|NCT01583582|randomized double-blind placebo-controlled study
280649|NCT01583582|peptide concentrate
280650|NCT01583582|Coldwater Shrimp
280651|NCT01583582|antihypertensive effect
280652|NCT01583582|mild hypertension
280653|NCT01583582|moderate hypertension
280654|NCT01583582|blood pressure
280655|NCT01583569|Complex Dynamic Systems
280656|NCT01583569|Biomarkers
280657|NCT01583569|Mood Disorders
280658|NCT01583556|Adult
280659|NCT01583556|English speaking
280660|NCT01583556|Fractures
280661|NCT01583556|Excellent prognosis
280662|NCT01583556|Upper Extremity
280663|NCT01583543|Recurrent
280664|NCT01583543|Metastatic
280665|NCT01583530|Belimumab
280666|NCT01583530|Injections, Subcutaneous
280667|NCT01583530|Drug Administration Routes
280668|NCT01583530|Injections
280669|NCT01583530|Lupus Erythematosus, Systemic
280670|NCT01583530|Lupus
280671|NCT01583530|SLE
280672|NCT01583530|Systemic Lupus Erythematosus
280673|NCT01583530|Antibodies
280674|NCT01583530|Autoimmune Disease
280675|NCT01583530|Biological Therapy
280676|NCT01583530|Immune System Diseases
280677|NCT01583530|Pharmacokinetics
280678|NCT01583530|Biological Availability
280679|NCT01583517|Acute pancreatitis
280680|NCT01583517|ERCP
280681|NCT01583517|Sphincterotomy
280682|NCT01583517|Manometry
280683|NCT01583517|Sphincter of Oddi dysfunction
280684|NCT01583504|Achilles
280685|NCT01583504|Tendinopathy
280686|NCT01583504|Tendonitis
280687|NCT01583504|Injection
280688|NCT01583491|platelet rich fibrin
280689|NCT01583491|mandibular third molar
280690|NCT01583491|periodontal problem
280691|NCT01583478|incobotulinumtoxinA
280692|NCT01583478|wrinkles
280693|NCT01583478|glabellar
280694|NCT01583478|rhytids
280695|NCT01583478|frown
280696|NCT01583478|lines
280697|NCT01583465|randomized controlled trial
280698|NCT01583465|Blood loss, surgical
280699|NCT01583465|Blood loss, postoperative
280700|NCT01583465|Wound healing
280701|NCT01583452|Post operative ileus
280702|NCT01583452|Gastrointestinal surgery
280703|NCT01583452|Chewing gum
280704|NCT01583439|HIV Infections
280705|NCT01583439|Acquired Immunodeficiency Syndrome
280706|NCT01583439|Anti-HIV Agents
280707|NCT01583439|Sexually Transmitted Diseases, Viral
280708|NCT01583439|Immunologic Deficiency Syndromes
280709|NCT01583439|Immune System Diseases
280710|NCT01583439|Anti-Retroviral Agents
280711|NCT01583439|Antiviral Agents
280712|NCT01583426|GeparSepto
280713|NCT01583426|GBG 69
280714|NCT01583426|GBG
280715|NCT01583426|German Breast Group
280716|NCT01583426|neo-adjuvant
280717|NCT01583426|GBG Forschungs GmbH
280718|NCT01583426|Tubular breast cancer stage II
280719|NCT01583426|Mucinous breast cancer stage II
280720|NCT01583426|Invasive ductal breast cancer
280721|NCT01583426|Tubular breast cancer stage III
280722|NCT01583426|HER-2 positive breast cancer
280723|NCT01583426|Inflammatory breast cancer
280724|NCT01583413|Ventilator-associated pneumonia
280725|NCT01583400|Depressive Disorder, Major
280726|NCT01583400|Depressive Disorder, Minor
280727|NCT01583400|Dysthymic Disorder
280728|NCT01583387|healthy adults
280729|NCT01583387|urinary adducts
280730|NCT01583387|water intake
280731|NCT01583374|spondylitis
280732|NCT01583374|spondyloarthritis
280733|NCT01583374|Spondyloarthropathy
280734|NCT01583374|Oral preparation
280735|NCT01583361|two arms
280736|NCT01583361|D2 lymphadenectomy
280737|NCT01583361|chemotherapy before and after surgery
280738|NCT01583361|disease free survival
280739|NCT01583348|transvaginal
280740|NCT01583348|NOTES
280741|NCT01583348|cholecystectomy
280742|NCT01583348|cholangiography
280743|NCT01583348|symptomatic gallstone disease
280744|NCT01583335|Overweight
280745|NCT01583335|Obesity
280746|NCT01583335|Predisposition
280747|NCT01583335|Prevention
280748|NCT01583335|Diet
280749|NCT01583335|Physical activity
280750|NCT01583335|Sleep
280751|NCT01583335|Family stress
280752|NCT01583322|ovarian cancer
280753|NCT01583322|debulking surgery
280754|NCT01583322|interval debulking
280755|NCT01583322|vargatef
280756|NCT01583322|nintedanib
280757|NCT01583322|maintenance
280758|NCT01583322|first line
280759|NCT01583322|paclitaxel
280760|NCT01583322|carboplatin
280761|NCT01583309|blood pressure
280762|NCT01583309|cardiovascular instability
280763|NCT01583309|symptomatic hypotension
280764|NCT01583309|online hemofiltration
280765|NCT01583309|online hemodiafiltration
280766|NCT01583283|Multiple Myeloma
280767|NCT01583283|Relapsed
280768|NCT01583283|Refractory
280769|NCT01583283|Histone deacetylase inhibitors
280770|NCT01583283|Lenalidomide
280771|NCT01583283|Revlimid
280772|NCT01583283|Dexamethasone
280773|NCT01583270|Arabinxylan
280774|NCT01583270|Rye kernels
280775|NCT01583270|whole grain
280776|NCT01583270|Dietary fibre
280777|NCT01583270|Metabolic syndrome
280778|NCT01583270|Glycemic response
280779|NCT01583270|Colon fermentation
280780|NCT01583270|Second meal effekt
280781|NCT01583270|Satiety
280782|NCT01583218|Phase III
280783|NCT01583205|ALS
280784|NCT01583205|Coping Effectiveness Training
280785|NCT01583205|Distress
280786|NCT01583205|Care Giver
280787|NCT01583192|infection
280788|NCT01583192|skin preparation
280789|NCT01583192|fore-foot surgery
280790|NCT01583192|chloride-hexidine
280791|NCT01583192|povidine-jodine
280792|NCT01583192|alcohol
280793|NCT01583179|nerve block
280794|NCT01583179|outpatient surgery
280795|NCT01583140|physical activity
280796|NCT01583140|Latinas
280797|NCT01583127|Problem Behavior
280798|NCT01583114|dilated cardiomyopathy
280799|NCT01583114|heart failure
280800|NCT01583114|genetics
280801|NCT01583114|mutation carrier
280802|NCT01583114|ACE treatment
280803|NCT01583114|preclinical
280804|NCT01583088|Amyotrophic lateral sclerosis,
280805|NCT01583088|Diaphragm
280806|NCT01583088|Mechanical ventilation
280807|NCT01583088|Phrenic nerve stimulation
280808|NCT01583088|Respiratory insufficiency
280809|NCT01583062|Surgical Wound Infection
280810|NCT01583062|Facial Injuries
280811|NCT01583062|Orbital Fractures
280812|NCT01583062|Zygomatic Fractures
280813|NCT01583062|Mandibular Fractures
280814|NCT01583062|Jaw Injuries
280815|NCT01583023|bipolar disorder
280816|NCT01583023|repetitive transcranial magnetic stimulation (rtms)
280817|NCT01583023|bupropion
280818|NCT01583023|lithium a/o Epival
280819|NCT01583010|ultrasound guided regional anaesthesia needle visualization
280820|NCT01582997|BRAF
280821|NCT01582997|Advance solid tumors
280822|NCT01582984|consent
280823|NCT01582984|Patient Understanding
280824|NCT01582984|Knee Arthroplasty
280825|NCT01582971|Breast Cancer
280826|NCT01582971|Reflexology
280827|NCT01582971|Complementary
280828|NCT01582958|Osteopathic Manipulative Treatment
280829|NCT01582958|Pulmonary Function Tests
280830|NCT01582958|Biochemical Alterations
280831|NCT01582945|Treatment resistant
280832|NCT01582945|suicidal ideation
280833|NCT01582945|major depressive disorder
280834|NCT01582932|plaque psoriasis
280835|NCT01582919|dementia
280836|NCT01582919|Alzheimer's Disease
280837|NCT01582919|diagnostic
280838|NCT01582919|biomarkers
280839|NCT01582919|neuroimaging
280840|NCT01582919|PET
280841|NCT01582919|MRI
280842|NCT01582919|mild cognitive impairment
280843|NCT01582893|inflammation
280844|NCT01582893|dialysis
280845|NCT01582880|Keratoprosthesis
280846|NCT01582880|sterile cornea ulcer
280847|NCT01582867|Hemodiafiltration
280848|NCT01582867|Hemodialysis
280849|NCT01582867|Sodium
280850|NCT01582867|Artis
280851|NCT01582867|renal failure
280852|NCT01582854|Post-Stroke Cognitive Impairment (PSCI)
280853|NCT01582854|Stroke
280854|NCT01582854|Actovegin
280855|NCT01582854|Cognition disorders
280856|NCT01582841|Colon Cancer
280857|NCT01582841|Lynch Syndrome
280858|NCT01582841|Genetic Screening
280859|NCT01582828|atrial
280860|NCT01582828|fibrillation
280861|NCT01582828|pvi
280862|NCT01582828|vats
280863|NCT01582828|ablation
280864|NCT01582828|hybrid
280865|NCT01582815|Major Depressive Disorder
280866|NCT01582815|Depression
280867|NCT01582815|Anxiety symptoms
280868|NCT01582815|JNJ-40411813
280869|NCT01582763|Guillain-Barré syndrome
280870|NCT01582763|Polyneuropathy
280871|NCT01582763|Autoimmune Diseases
280872|NCT01582763|Immune System Diseases
280873|NCT01582763|Neuromuscular Diseases
280874|NCT01582763|Outcome
280875|NCT01582763|Quality of life
280876|NCT01582763|Disability
280877|NCT01582763|Prognostic Determinants
280878|NCT01582763|Treatment
280879|NCT01582763|Immunoglobulins
280880|NCT01582763|Prognosis
280881|NCT01582763|Infections
280882|NCT01582763|Anti-ganglioside antibodies
280883|NCT01582763|Genetic polymorphisms
280884|NCT01582763|Electrophysiology
280885|NCT01582763|Cerebrospinal Fluid
280886|NCT01582763|Serum
280887|NCT01582750|endoscopic ultrasound
280888|NCT01582750|pre-operative concurrent chemoradiotherapy
280889|NCT01582737|Xarelto
280890|NCT01582737|SPAF
280891|NCT01582724|Menstrual pain
280892|NCT01582724|Primary dysmenorrhea
280893|NCT01582724|Self-care acupressure
280894|NCT01582711|LTBI
280895|NCT01582711|LTB
280896|NCT01582711|Latent TB
280897|NCT01582711|TB infection
280898|NCT01582685|Breast Cancer
280899|NCT01582685|Obesity
280900|NCT01582685|Exercise
280901|NCT01582685|Angiogenesis
280902|NCT01582672|RCC
280903|NCT01582672|Kidney Cancer
280904|NCT01582659|constipation
280905|NCT01582659|children
280906|NCT01582659|outpatient
280907|NCT01582633|vaccine
280908|NCT01582633|influenza
280909|NCT01582633|needle free jet injector
280910|NCT01582633|Intradermal
280911|NCT01582633|sparing dose
280912|NCT01582620|Cerebrovascular disorders
280913|NCT01582620|Telemedicine
280914|NCT01582620|remote consultation
280915|NCT01582620|rural
280916|NCT01582620|thrombolysis therapy
280917|NCT01582620|plasminogen activators
280918|NCT01582620|stroke care
280919|NCT01582620|stroke management
280920|NCT01582594|1000 residual serum/plasma samples
280921|NCT01582594|anti-HCV seronegative or seropositive
280922|NCT01582581|mental health
280923|NCT01582581|depression
280924|NCT01582581|behavioral health
280925|NCT01582581|cognitive behavioral therapy
280926|NCT01582581|CBT
280927|NCT01582581|computer-assisted psychotherapy
280928|NCT01582555|mucolysis
280929|NCT01582555|QOL
280930|NCT01582555|endoscopy
280931|NCT01582555|sinus surgery
280932|NCT01582529|Developmental Outcomes
280933|NCT01582529|Psychosocial Outcomes
280934|NCT01582529|Hypoplastic Left Heart Syndrome
280935|NCT01582529|Congenital Heart Disease
280936|NCT01582516|brain tumor
280937|NCT01582516|virotherapy
280938|NCT01582516|glioblastoma
280939|NCT01582516|replication competent adenovirus
280940|NCT01582490|Mammoplasty
280941|NCT01582490|Postoperative pain
280942|NCT01582490|Analgesia
280943|NCT01582477|TAP, robot-assisted prostatectomy
280944|NCT01582464|Protective Headwear
280945|NCT01582464|Social Marketing
280946|NCT01582464|Theory of Planned Behavior
280947|NCT01582425|isavuconazole
280948|NCT01582425|methadone
280949|NCT01582425|Healthy Volunteers
280950|NCT01582425|BAL8557
280951|NCT01582412|Isavuconazole
280952|NCT01582412|Digoxin
280953|NCT01582412|Healthy Volunteers
280954|NCT01582412|BAL8557
280955|NCT01582399|Healthy Volunteers
280956|NCT01582399|CD40 receptor occupancy
280957|NCT01582399|Co-stimulation blockade
280958|NCT01582399|CD40 antigen
280959|NCT01582399|Anti-CD40
280960|NCT01582399|ASKP1240
280961|NCT01582360|critical illness
280962|NCT01582360|pharmacokinetics
280963|NCT01582360|CRRT
280964|NCT01582360|CVVH
280965|NCT01582360|CVVHD
280966|NCT01582360|CVVHDF
280967|NCT01582360|antiinfectives
280968|NCT01582360|antibiotics
280969|NCT01582360|minimum inhibitory concentration
280970|NCT01582360|bacterial killing
280971|NCT01582360|pharmacodynamics
280972|NCT01582360|PK/PD index
280973|NCT01582347|Opioid dependence
280974|NCT01582334|Growth disorders
280975|NCT01582334|Saizen
280976|NCT01582334|Easypod
280977|NCT01582334|Growth hormone
280978|NCT01582334|Pediatric subject
280979|NCT01582321|vascular ultrasound
280980|NCT01582321|flow cytometry
280981|NCT01582321|platelet aggregation
280982|NCT01582295|Bone disease
280983|NCT01582282|Type II NIDDM
280984|NCT01582243|Diabetes Mellitus, type 2
280985|NCT01582243|vildagliptin
280986|NCT01582230|Type 2 diabetes mellitus
280987|NCT01582230|Vildagliptin
280988|NCT01582217|Bleeding
280989|NCT01582217|Risk Score
280990|NCT01582217|Outcomes
280991|NCT01582217|Prasugrel
280992|NCT01582204|clear cell carcinoma
280993|NCT01582204|Kidney
280994|NCT01582204|MAB-124I-CG250
280995|NCT01582204|PET scan
280996|NCT01582204|CT scan
280997|NCT01582204|sunitinib
280998|NCT01582204|pazopanib
280999|NCT01582204|11-134
281000|NCT01582191|Advanced Cancers
281001|NCT01582191|Advanced solid cancer
281002|NCT01582191|Metastatic cancer
281003|NCT01582191|Vandetanib
281004|NCT01582191|ZD 6474
281005|NCT01582191|Zactima
281006|NCT01582191|Caprelsa
281007|NCT01582191|Everolimus
281008|NCT01582191|Afinitor
281009|NCT01582191|RAD001
281010|NCT01582191|Multi-kinase Inhibitor
281011|NCT01582178|colonoscopy
281012|NCT01582178|warm water immersion
281013|NCT01582178|cool water immersion
281014|NCT01582152|Brain Neoplasms
281015|NCT01582152|Central Nervous System Neoplasms
281016|NCT01582152|Recurrent Glioblastoma
281017|NCT01582152|Glioblastoma multiforme
281018|NCT01582152|GBM
281019|NCT01582152|Gliosarcoma
281020|NCT01582152|TPI287
281021|NCT01582152|Bevacizumab
281022|NCT01582152|Avastin
281023|NCT01582152|Anti-VEGF Monoclonal Antibody
281024|NCT01582152|rhuMAb-VEGF
281025|NCT01582139|Artificial Pancreas Project
281026|NCT01582139|AP Platform
281027|NCT01582139|Insulin Pump
281028|NCT01582139|Continuous Glucose Monitor
281029|NCT01582139|Closed-Loop Control
281030|NCT01582139|Control-to-Range
281031|NCT01582126|multiple sclerosis
281032|NCT01582126|physical therapy
281033|NCT01582126|postural control
281034|NCT01582087|acute hepatic failure
281035|NCT01582087|chronic hepatic failure
281036|NCT01582087|coma
281037|NCT01582074|Ultrasound Tomography
281038|NCT01582074|Tamoxifen
281039|NCT01582074|Breast Cancer
281040|NCT01582074|Estrogen Receptor Positive
281041|NCT01582074|Breast Density
281042|NCT01582061|Cushing's disease
281043|NCT01582061|Hormone disorder
281044|NCT01582061|Cortisol
281045|NCT01582061|Adrenocorticotropic hormone
281046|NCT01582061|Pituitary tumor
281047|NCT01582035|Hepatitis C
281048|NCT01582035|TMC647055HPC1005
281049|NCT01582035|TMC647055
281050|NCT01582035|telaprevir
281051|NCT01581996|Chronic renal failure
281052|NCT01581996|End-stage renal disease
281053|NCT01581996|Chronic peritoneal dialysis
281054|NCT01581996|Serum phosphorus
281055|NCT01581996|Hyperphosphatemia
281056|NCT01581996|Phosphate binders
281057|NCT01581996|Phosphate
281058|NCT01581970|head and neck cancer
281059|NCT01581970|metastatic squamous cell cancer
281060|NCT01581957|Enteral nutrition, critically ill patients
281061|NCT01581944|myomectomy
281062|NCT01581944|GnRH
281063|NCT01581944|blood loss
281064|NCT01581905|Hysterectomy
281065|NCT01581905|Laparoscopy
281066|NCT01581905|Robotics
281067|NCT01581892|bone nonunion
281068|NCT01581892|bone marrow
281069|NCT01581892|mononuclear
281070|NCT01581892|fracture
281071|NCT01581879|Bioequivalence
281072|NCT01581879|Ziprasidone hydrochloride
281073|NCT01581879|crossover
281074|NCT01581866|Bioequivalence
281075|NCT01581866|Ziprasidone hydrochloride
281076|NCT01581866|crossover
281077|NCT01581853|HIV
281078|NCT01581853|AIDS
281079|NCT01581853|MONOTHERAPY
281080|NCT01581853|PILOT
281081|NCT01581853|LOPINAVIR/RITONAVIR
281082|NCT01581840|anus
281083|NCT01581840|carcinoma
281084|NCT01581840|panitumumab
281085|NCT01581840|mitomycine
281086|NCT01581840|5Fu
281087|NCT01581840|radiotherapy
281088|NCT01581827|Heart Failure
281089|NCT01581827|BNP
281090|NCT01581827|NT-proBNP
281091|NCT01581814|PCOS
281092|NCT01581801|gastric bypass
281093|NCT01581801|sleeve gastrectomy
281094|NCT01581801|reactive hypoglycemia
281095|NCT01581788|Bioequivalence
281096|NCT01581788|Divalproex Sodium
281097|NCT01581788|Crossover
281098|NCT01581775|Bioequivalence
281099|NCT01581775|Divalproex Sodium
281100|NCT01581775|Crossover
281101|NCT01581762|EUS, FNA
281102|NCT01581749|low risk prostate cancer
281103|NCT01581749|intermediate risk prostate cancer
281104|NCT01581749|stereotactic radiosurgery
281105|NCT01581736|insulin resistance
281106|NCT01581736|mitochondria
281107|NCT01581723|urinary bladder tumor
281108|NCT01581723|monopolar TURBT
281109|NCT01581723|bipolar TURBT
281110|NCT01581710|Leukotriene Antagonists
281111|NCT01581710|Bronchial Hyperreactivity
281112|NCT01581697|oat
281113|NCT01581697|cholesterol
281114|NCT01581697|children
281115|NCT01581697|adolescent
281116|NCT01581697|Level reduction of ceric cholesterol
281117|NCT01581645|Parkinson's disease
281118|NCT01581645|Parkinsonism
281119|NCT01581645|Gait problems
281120|NCT01581645|Freezing gait
281121|NCT01581632|atherosclerosis
281122|NCT01581632|endothelial dysfunction
281123|NCT01581632|coronary vasospasm
281124|NCT01581619|Early Invasive N0
281125|NCT01581619|Non-Invasive
281126|NCT01581606|Age Related Macular Degeneration
281127|NCT01581606|Teleophthalmology
281128|NCT01581606|Screening
281129|NCT01581606|Diagnosis
281130|NCT01581606|Timing
281131|NCT01581606|Treatment
281132|NCT01581593|Primary Immunodeficiency
281133|NCT01581593|PID
281134|NCT01581593|Agammaglobulinemia
281135|NCT01581593|Hypogammaglobulinemia
281136|NCT01581593|Antibody deficiency
281137|NCT01581580|Parkinson's Disease
281138|NCT01581580|Deep Brain Stimulation
281139|NCT01581580|Neurophysiology
281140|NCT01581580|Movement Disorder
281141|NCT01581580|Essential Tremor
281142|NCT01581580|Parkinson Disease
281143|NCT01581567|Storage
281144|NCT01581567|Repository
281145|NCT01581567|Samples
281146|NCT01581567|Data
281147|NCT01581554|Hepatitis B
281148|NCT01581554|Treatment
281149|NCT01581554|Nucleoside/Nucleotide Analogue
281150|NCT01581541|Targeted Therapy
281151|NCT01581541|Solid Tumors
281152|NCT01581541|Lymphoma
281153|NCT01581541|Non-Hodgkin Lymphoma
281154|NCT01581541|Solid Tumor
281155|NCT01581528|T-cell childhood acute lymphoblastic leukemia
281156|NCT01581528|untreated adult acute lymphoblastic leukemia
281157|NCT01581528|T-cell adult acute lymphoblastic leukemia
281158|NCT01581528|untreated childhood acute lymphoblastic leukemia
281159|NCT01581502|Anticoagulation
281160|NCT01581502|Recurrent stroke
281161|NCT01581502|Bleeding
281162|NCT01581489|Cord clamping
281163|NCT01581489|iron deficiency
281164|NCT01581489|Neurodevelopment
281165|NCT01581476|Adolescence
281166|NCT01581463|pharmacokinetics of oral T3
281167|NCT01581450|Hyperalgesia and pain
281168|NCT01581437|atrial fibrillation
281169|NCT01581437|cardiac ablation
281170|NCT01581424|Fabry disease
281171|NCT01581424|kidney function
281172|NCT01581424|kidney structure morphometry
281173|NCT01581424|Fabry kidney disease
281174|NCT01581424|Podocytes
281175|NCT01581411|central retinal vein occlusion
281176|NCT01581411|macular edema
281177|NCT01581411|vision loss
281178|NCT01581411|rtelative afferent papillary defect
281179|NCT01581398|Peginterferon
281180|NCT01581398|Pegasys
281181|NCT01581398|Sustained virus response
281182|NCT01581398|HCV
281183|NCT01581385|atherosclerosis
281184|NCT01581385|carotid artery
281185|NCT01581385|carotid endarterectomy
281186|NCT01581359|Endometriosis
281187|NCT01581359|GnRH treatment
281188|NCT01581359|Infertility
281189|NCT01581359|IVF
281190|NCT01581346|NSCLC
281191|NCT01581346|exercise intervention
281192|NCT01581346|quality of life
281193|NCT01581333|febrile neutropenia
281194|NCT01581333|antimicrobial treatment
281195|NCT01581333|procalcitonin
281196|NCT01581307|liver
281197|NCT01581307|pancreas
281198|NCT01581307|chemotherapy
281199|NCT01581307|radiotherapy
281200|NCT01581294|Rheumatoid arthritis
281201|NCT01581294|Psoriatic arthritis
281202|NCT01581294|Ankylosing spondylitis
281203|NCT01581294|Spondyloarthritis
281204|NCT01581281|Pediatric
281205|NCT01581281|Children
281206|NCT01581281|Adolescent
281207|NCT01581281|Headache
281208|NCT01581281|Migraine
281209|NCT01581255|acute respiratory distress syndrome
281210|NCT01581255|high frequency oscillation ventilation
281211|NCT01581255|ventilator-induced lung injury
281212|NCT01581255|biomarkers
281213|NCT01581242|Clevudine and Adefovir dipivoxil
281214|NCT01581242|pharmacokinetic drug drug interaction
281215|NCT01581242|oral administration
281216|NCT01581242|male subjects
281217|NCT01581229|ALI;noninvasive positive pressure ventilation
281218|NCT01581216|Fatigue
281219|NCT01581216|Palliative Care
281220|NCT01581216|Exercise
281221|NCT01581190|Bananas
281222|NCT01581190|Exercise
281223|NCT01581190|Metabolomics
281224|NCT01581190|Oxidative stress
281225|NCT01581190|Inflammation
281226|NCT01581190|Immune function
281227|NCT01581177|asthma
281228|NCT01581177|mild-to-moderate persistent asthma
281229|NCT01581177|mild asthma
281230|NCT01581177|moderate asthma
281231|NCT01581177|persistent asthma
281232|NCT01581164|blood
281233|NCT01581164|hematopoietic
281234|NCT01581164|stem
281235|NCT01581164|cell
281236|NCT01581164|transplant
281237|NCT01581164|vaccine
281238|NCT01581164|vaccination
281239|NCT01581164|recovery
281240|NCT01581164|immune
281241|NCT01581164|system
281242|NCT01581151|retinal vein occlusion
281243|NCT01581151|ozurdex
281244|NCT01581151|lucentis
281245|NCT01581151|BCVA
281246|NCT01581151|foveal thickness
281247|NCT01581125|Inpatients
281248|NCT01581125|Health Normalcy
281249|NCT01581125|circadian rhythm
281250|NCT01581099|Atherosclerosis
281251|NCT01581099|Cardiovascular risk factors
281252|NCT01581099|Calorie restriction
281253|NCT01581099|Bariatric Surgery
281254|NCT01581086|HIV
281255|NCT01581086|COPD
281256|NCT01581086|Pulmonary disease
281257|NCT01581073|renal anemia
281258|NCT01581073|erythropoiesis stimulating agent
281259|NCT01581073|hemoglobin
281260|NCT01581073|non-diabetes
281261|NCT01581073|CKD
281262|NCT01581073|Chronic Kidney Disease patients without diabetes
281263|NCT01581047|amoxicillin
281264|NCT01581047|clavulanic acid
281265|NCT01581047|cefuroxime
281266|NCT01581047|Patients in the intensive care unit, with an infection which requires amoxicillin/clavulanic acid or cefuroxime
281267|NCT01581034|endothelial function
281268|NCT01581034|biomarkers
281269|NCT01581034|autonomic nervous system
281270|NCT01581034|coronary artery disease
281271|NCT01581021|randomized
281272|NCT01581021|controlled
281273|NCT01581021|hooks
281274|NCT01581021|screws
281275|NCT01581008|palliative care
281276|NCT01581008|heart failure
281277|NCT01581008|delivery of health care
281278|NCT01580995|Chronic hepatitis C infection
281279|NCT01580982|Oncogenes
281280|NCT01580982|Lung and Other Thoracic Cancers
281281|NCT01580969|glioma
281282|NCT01580956|Acute respiratory failure
281283|NCT01580956|Critical illness
281284|NCT01580956|Mechanical ventilation
281285|NCT01580956|Ventilation weaning
281286|NCT01580956|Intensive Care Unit
281287|NCT01580956|Variable (NOISY) PSV
281288|NCT01580956|PSV
281289|NCT01580943|Chlorhexidine
281290|NCT01580943|Cetyl pyridinium chloride
281291|NCT01580943|Mouth rinse
281292|NCT01580943|Antiplaque Efficacy
281293|NCT01580943|Self Efficacy
281294|NCT01580943|Taste Sweet
281295|NCT01580943|Side Effects
281296|NCT01580930|physical inactivity
281297|NCT01580930|exercise training
281298|NCT01580930|sedentary time
281299|NCT01580930|habitual physical activity
281300|NCT01580917|laser doppler anemometry
281301|NCT01580917|dynamic testing of tissue mechanical property
281302|NCT01580917|diabetic foot complications
281303|NCT01580917|ulcer genesis
281304|NCT01580904|Pharmaceutical Care
281305|NCT01580904|Diabetics patients
281306|NCT01580904|Clinical trial
281307|NCT01580891|Naftifine HCl Cream 1%
281308|NCT01580891|Naftin® (Naftifine HCl) Cream 1%
281309|NCT01580891|Tinea Pedis
281310|NCT01580891|Efficacy and safety
281311|NCT01580878|Butenafine Hydrochloride Cream, 1%
281312|NCT01580878|Lotrimin Ultra® Cream, 1%
281313|NCT01580878|Interdigital Tinea Pedis
281314|NCT01580878|Safety and Bioequivalence
281315|NCT01580865|Lupus nephritis
281316|NCT01580865|Tacrolimus
281317|NCT01580865|Mycophenolate mofetil
281318|NCT01580865|Complete remission
281319|NCT01580839|ischemic stroke
281320|NCT01580839|ischemic penumbra
281321|NCT01580839|magnetic resonance imaging
281322|NCT01580839|MRI
281323|NCT01580839|diffusion imaging
281324|NCT01580839|DWI
281325|NCT01580839|perfusion imaging
281326|NCT01580839|PWI
281327|NCT01580839|thrombolysis
281328|NCT01580839|alteplase
281329|NCT01580839|tPA
281330|NCT01580839|EPITHET
281331|NCT01580826|pasteurization
281332|NCT01580826|human milk
281333|NCT01580826|very low birth weight infants
281334|NCT01580813|diabetes
281335|NCT01580813|exercise
281336|NCT01580813|cardiovascular
281337|NCT01580813|heart
281338|NCT01580813|insulin sensitivity
281339|NCT01580787|Parkinson´s disease
281340|NCT01580787|Postural Balance
281341|NCT01580787|virtual reality
281342|NCT01580735|NSCLC
281343|NCT01580735|c-MET
281344|NCT01580735|EGFR mutation-positive
281345|NCT01580735|gefitinib
281346|NCT01580735|erlotinib
281347|NCT01580735|EGFR-TKI resistance
281348|NCT01580722|Anterior Cruciate Ligament,Early,Delay,Reconstruction
281349|NCT01580709|stricture
281350|NCT01580709|cholangiocarcinoma
281351|NCT01580709|pancreatic adenocarcinoma
281352|NCT01580709|bile duct
281353|NCT01580709|ERCP
281354|NCT01580696|Folate binding protein
281355|NCT01580696|E39 vaccine
281356|NCT01580696|Stage I-IV ovarian cancer
281357|NCT01580696|Stage I-IV endometrial cancer
281358|NCT01580683|Atrial Fibrillation
281359|NCT01580683|Ascorbic Acid
281360|NCT01580683|Thoracic Surgery
281361|NCT01580683|Cardiac Arrhythmias
281362|NCT01580683|Cardiac Surgery
281363|NCT01580683|Vitamin C
281364|NCT01580683|Postoperative Complications
281365|NCT01580683|Antioxidants
281366|NCT01580683|Inflammation
281367|NCT01580670|Infliximab
281368|NCT01580670|REMICADE
281369|NCT01580670|TA-650
281370|NCT01580670|pediatric Crohn's disease
281371|NCT01580657|HIV
281372|NCT01580657|Prevention
281373|NCT01580657|Methods
281374|NCT01580657|Assessment reactivity
281375|NCT01580657|South Africa
281376|NCT01580657|Youth
281377|NCT01580631|Narrow band imaging
281378|NCT01580631|Barrett's esophagus
281379|NCT01580631|Gastroesophageal reflux disease
281380|NCT01580618|pleural effusion
281381|NCT01580618|malignancy
281382|NCT01580618|loculated
281383|NCT01580579|Radiation pneumonitis
281384|NCT01580579|locally advanced lung cancer
281385|NCT01580579|Respiratory function tests
281386|NCT01580566|Myocardial Infarction (MI)
281387|NCT01580566|Kidney function
281388|NCT01580566|bio-markers
281389|NCT01580553|Heart failure
281390|NCT01580553|L-carnitine
281391|NCT01580553|injection
281392|NCT01580553|safety
281393|NCT01580553|efficacy
281394|NCT01580527|postoperative artificial nutrition
281395|NCT01580527|parenteral nutrition
281396|NCT01580527|enteral nutrition
281397|NCT01580527|postoperative complications
281398|NCT01580527|cephalic pancreatoduodenectomy
281399|NCT01580514|myocardial infarction
281400|NCT01580514|percutaneous coronary intervention
281401|NCT01580514|exenatide
281402|NCT01580514|reperfusion injury
281403|NCT01580514|cardiac magnetic resonance
281404|NCT01580475|glycemic control,
281405|NCT01580475|exercise training,
281406|NCT01580475|detraining,
281407|NCT01580475|retraining,
281408|NCT01580475|body composition,
281409|NCT01580475|strength and fitness
281410|NCT01580462|continuous subcutaneous insulin infusion (CSII)
281411|NCT01580462|children
281412|NCT01580462|adolescent
281413|NCT01580436|Tricuspid Valve Insufficiency
281414|NCT01580436|Cardiac Valve Annuloplasty
281415|NCT01580436|Outcome Assessment (Health Care)
281416|NCT01580423|dyspnea
281417|NCT01580397|Pancreatic cancer
281418|NCT01580397|INNO-206
281419|NCT01580397|Doxorubicin-EMCH
281420|NCT01580358|cancer
281421|NCT01580358|radiotherapy
281422|NCT01580358|chemotherapy
281423|NCT01580358|Traditional Chinese Medicine
281424|NCT01580358|Safety
281425|NCT01580345|DHA
281426|NCT01580345|Omega 3 fatty acid
281427|NCT01580345|Decosa hexaenoic acid
281428|NCT01580345|Pregnancy
281429|NCT01580345|Newborn outcome
281430|NCT01580345|Supplementation
281431|NCT01580345|Birth size
281432|NCT01580345|gestational age
281433|NCT01580345|India
281434|NCT01580345|Randomized controlled trial
281435|NCT01580345|RCT
281436|NCT01580332|biomarkers
281437|NCT01580332|lung cancer
281438|NCT01580332|solitary pulmonary nodules
281439|NCT01580332|SPN
281440|NCT01580332|breath analysis
281441|NCT01580332|VOC
281442|NCT01580332|volatile organic compounds
281443|NCT01580332|sputum
281444|NCT01580332|auto-antibodies
281445|NCT01580319|obesity
281446|NCT01580319|cholesterol
281447|NCT01580319|cholesterol, LDL
281448|NCT01580319|cholesterol, HDL
281449|NCT01580319|blood glucose
281450|NCT01580319|Triglyceride
281451|NCT01580319|C-Reactive Protein - hs
281452|NCT01580319|blood pressure
281453|NCT01580319|physical activity
281454|NCT01580319|Sedentary Lifestyle
281455|NCT01580293|Hemophilia A, factor VIII, prophylaxis
281456|NCT01580280|Cervicogenic
281457|NCT01580280|Headache
281458|NCT01580280|Neck Pain
281459|NCT01580280|Manipulation
281460|NCT01580280|Mobilization
281461|NCT01580280|Exercise
281462|NCT01580267|Anemia in trauma
281463|NCT01580254|Latanoprost
281464|NCT01580254|IOP
281465|NCT01580215|Valves
281466|NCT01580215|Endobronchial
281467|NCT01580215|Endoscopic lung volume reduction
281468|NCT01580215|Pulmonx
281469|NCT01580215|Zephyr
281470|NCT01580215|Chartis
281471|NCT01580215|Emphysema
281472|NCT01580215|COPD
281473|NCT01580202|malignancy
281474|NCT01580202|hepatitis B
281475|NCT01580202|lamivudine
281476|NCT01580202|entecavir
281477|NCT01580202|prophylaxis
281478|NCT01580189|Lean tissue
281479|NCT01580189|Strength condition
281480|NCT01580189|Protein
281481|NCT01580189|Amino Acid
281482|NCT01580163|the opioid dependence in rehabilitation phase
281483|NCT01580163|community
281484|NCT01580150|Berries
281485|NCT01580150|Starch
281486|NCT01580150|Sucrose
281487|NCT01580150|Glucose
281488|NCT01580150|Insulin
281489|NCT01580150|Postprandial
281490|NCT01580137|acute respiratory tract infection
281491|NCT01580137|common cold
281492|NCT01580137|acute bacterial rhinosinusitis
281493|NCT01580137|adult
281494|NCT01580137|conscript
281495|NCT01580111|Blood
281496|NCT01580111|Storage
281497|NCT01580111|Age
281498|NCT01580111|Transfusion
281499|NCT01580111|Lactic acidosis
281500|NCT01580085|Sleep disordered breathing
281501|NCT01580085|gender
281502|NCT01580085|hypercoagulability
281503|NCT01580046|Chronic Kidney Disease
281504|NCT01580046|Coronary Angiography
281505|NCT01580046|Contrast Media
281506|NCT01580046|Percutaneous Coronary Intervention
281507|NCT01580046|Serum Creatinine
281508|NCT01580046|Glomerular Filtration Rate
281509|NCT01580046|Iodixanol
281510|NCT01580046|Iopromide
281511|NCT01580033|immunogenicity
281512|NCT01580033|safety
281513|NCT01580033|group A, C polysaccharide meningitis
281514|NCT01580033|type b haemophilus Influenza
281515|NCT01580020|Macular Degeneration
281516|NCT01580020|Macular Edema
281517|NCT01580020|Retinal Vein Occlusion
281518|NCT01580020|Choroidal Neovascularization
281519|NCT01580020|Signs and Symptoms
281520|NCT01580020|Retinal Degeneration
281521|NCT01580020|Retinal Diseases
281522|NCT01580020|Eye Diseases
281523|NCT01580020|Venous Thrombosis Sensation Disorders
281524|NCT01580020|Dexamethasone acetate
281525|NCT01580020|Dexamethasone
281526|NCT01580020|Dexamethasone 21-phosphate
281527|NCT01580020|BB 1101
281528|NCT01580020|Anti-Inflammatory Agents
281529|NCT01580020|Therapeutic Uses
281530|NCT01580020|Vision, Low
281531|NCT01580020|Signs
281532|NCT01580020|Vision Disorders
281533|NCT01580007|tuberculosis
281534|NCT01580007|phenylbutyrate
281535|NCT01580007|vitamin D
281536|NCT01580007|cathelicidin
281537|NCT01580007|antimicrobial peptide
281538|NCT01580007|in adults
281539|NCT01579994|adenocarcinoma
281540|NCT01579994|Lung
281541|NCT01579994|Metastatic
281542|NCT01579994|Crizotinib
281543|NCT01579994|Ganetespib
281544|NCT01579994|STA-9090
281545|NCT01579994|ALK Positive Lung Cancers
281546|NCT01579994|12-015
281547|NCT01579981|RYGB
281548|NCT01579981|Bariatric Surgery
281549|NCT01579981|Glucagon-like-peptide 1
281550|NCT01579942|EEG
281551|NCT01579942|Biomarker
281552|NCT01579942|Major Depressive Disorder
281553|NCT01579942|Healthy Control
281554|NCT01579929|Extensive Stage Small Cell Lung Cancer (ES-SCLC)
281555|NCT01579929|CISPLATIN
281556|NCT01579929|ETOPOSIDE (VP-16)
281557|NCT01579929|LDE-225
281558|NCT01579929|STAR
281559|NCT01579929|Symptom Tracking and Reporting for Patients
281560|NCT01579929|11-206
281561|NCT01579916|Trivalent, Influenza, FluMist, Vaccine, Prevention
281562|NCT01579903|Hemophilia A
281563|NCT01579903|moroctocog alfa (AF-CC)
281564|NCT01579903|ReFacto AF
281565|NCT01579903|dual-chamber syringe
281566|NCT01579903|bioavailability
281567|NCT01579877|Xerostomia
281568|NCT01579877|Yukmijihwang-tang
281569|NCT01579877|Yin-Deficiency
281570|NCT01579877|Visual analogue scale
281571|NCT01579877|Dry mouth symptom questionnaire
281572|NCT01579812|Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
281573|NCT01579786|post operative pain
281574|NCT01579786|acupuncture
281575|NCT01579760|radiation
281576|NCT01579760|retinopathy
281577|NCT01579760|macular edema
281578|NCT01579760|anti-VEGF
281579|NCT01579760|VEGF-Trap
281580|NCT01579760|aflibercept
281581|NCT01579747|nerve stimulation
281582|NCT01579747|ultrasound
281583|NCT01579747|sciatic nerve block
281584|NCT01579747|popliteal block
281585|NCT01579747|obese
281586|NCT01579734|breast cancer chemoprevention postmenopause
281587|NCT01579708|Diet
281588|NCT01579708|Physical activity
281589|NCT01579708|Knowledge
281590|NCT01579708|Attitudes
281591|NCT01579708|Habits
281592|NCT01579708|Lifestyle
281593|NCT01579708|School-based
281594|NCT01579695|HIV with lipohypertrophy
281595|NCT01579682|Eating Disorder
281596|NCT01579682|Anorexia Nervosa
281597|NCT01579682|Eating Disorder Not Otherwise Specified
281598|NCT01579682|Maudsley
281599|NCT01579682|Family-Based Therapy
281600|NCT01579682|FBT
281601|NCT01579682|Family Therapy
281602|NCT01579669|Autism Spectrum Disorder
281603|NCT01579669|Primary Care Services
281604|NCT01579669|Patient-Provider Communication
281605|NCT01579669|Adults
281606|NCT01579643|cornea
281607|NCT01579643|opacity
281608|NCT01579643|congenital
281609|NCT01579630|NSCLC
281610|NCT01579630|Nonsquamous
281611|NCT01579630|Maintenance therapy
281612|NCT01579617|pregnancy
281613|NCT01579617|STI
281614|NCT01579617|STD
281615|NCT01579604|Loss of upper extremities functions
281616|NCT01579604|Nerve transfer
281617|NCT01579578|Metastatic Gastric Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status
281618|NCT01579565|cataract
281619|NCT01579565|lens replacement
281620|NCT01579552|Questionnaires
281621|NCT01579552|telephone counseling session
281622|NCT01579552|10-104
281623|NCT01579552|Childhood Cancer Survivor Women Post Chest Radiation
281624|NCT01579539|Methylprednisolone
281625|NCT01579539|Dry Eye Syndrome
281626|NCT01579539|Tear Film
281627|NCT01579539|Thyroid-associated ophthalmopathy
281628|NCT01579526|Safety and Pharmacokinetics of FP01 in Healthy Volunteers
281629|NCT01579513|Cardiopulmonary Bypass (CPB)
281630|NCT01579513|System Inflammatory Response
281631|NCT01579513|inflammation
281632|NCT01579513|Methylprednisolone
281633|NCT01579513|Neonates
281634|NCT01579513|Steroid
281635|NCT01579513|Cardiac Surgical Procedures
281636|NCT01579513|Children
281637|NCT01579513|Infants
281638|NCT01579513|Pediatrics
281639|NCT01579513|Glucocorticoid
281640|NCT01579513|Heart Disease
281641|NCT01579513|Heart Defects, Congenital
281642|NCT01579513|Cardiovascular Diseases
281643|NCT01579513|Cardiovascular Abnormalities
281644|NCT01579513|Corticosteroid
281645|NCT01579513|methylprednisolone Hemisuccinate
281646|NCT01579513|Hormones
281647|NCT01579513|Physiological Effects of Drugs
281648|NCT01579513|Randomized Clinical Trial
281649|NCT01579487|Lipolysis
281650|NCT01579487|Cryolipolysis
281651|NCT01579487|Fat Reduction
281652|NCT01579461|Pharmacokinetics
281653|NCT01579461|mirabegron
281654|NCT01579461|hepatic impairment
281655|NCT01579461|Phase 1
281656|NCT01579448|killed oral cholera vaccine
281657|NCT01579448|boosting vaccine regimen
281658|NCT01579448|safety and immunogenicity
281659|NCT01579435|essential tremor
281660|NCT01579435|primary motor cortex
281661|NCT01579435|cerebellum
281662|NCT01579435|transcranial direct current stimulation
281663|NCT01579435|electrophysiology
281664|NCT01579422|schizophrenia
281665|NCT01579422|treatment
281666|NCT01579422|social cognition
281667|NCT01579409|Nutrition
281668|NCT01579409|Arterial stiffness
281669|NCT01579409|Endothelial dysfunction
281670|NCT01579409|Microcirculation
281671|NCT01579409|Cardiac autonomic system.
281672|NCT01579396|septeX
281673|NCT01579396|high cut-off
281674|NCT01579396|Thoracic Surgery
281675|NCT01579396|Renal Replacement Therapy
281676|NCT01579383|Migraine Disorders
281677|NCT01579383|Phase 1
281678|NCT01579383|ALD403
281679|NCT01579370|healthcare associated infections
281680|NCT01579370|multidrug resistant organisms
281681|NCT01579370|methicillin resistant staphylococcus aureus
281682|NCT01579370|vancomycin resistant enterococcus
281683|NCT01579370|clostridium difficile
281684|NCT01579370|acinetobacter
281685|NCT01579357|colorectal carcinoma
281686|NCT01579357|K-ras wild type
281687|NCT01579357|Capecitabine
281688|NCT01579357|Cetuximab
281689|NCT01579357|Oxaliplatin
281690|NCT01579357|Pharmacokinetics
281691|NCT01579357|exclude a possible influence of CETUX
281692|NCT01579357|plasma disposition
281693|NCT01579357|metabolic activation
281694|NCT01579357|CCB
281695|NCT01579357|OxPt
281696|NCT01579344|Iodine Radioisotopes
281697|NCT01579344|Nasolacrimal Duct
281698|NCT01579344|radiation effects
281699|NCT01579331|IOP
281700|NCT01579331|Tonometry
281701|NCT01579331|Pascal
281702|NCT01579331|Goldmann
281703|NCT01579331|DCT
281704|NCT01579331|Dynamic Contour
281705|NCT01579279|Diabetic neuropathic pain
281706|NCT01579279|Active controlled phase 2 study
281707|NCT01579266|Writer's Cramp
281708|NCT01579266|Focal Hand Dystonia
281709|NCT01579266|Writer Cramp
281710|NCT01579266|Dystonia
281711|NCT01579253|Recurrent glioblastoma
281712|NCT01579253|Radiotherapy
281713|NCT01579253|PET-MRI
281714|NCT01579253|FET-PET
281715|NCT01579240|physical activity
281716|NCT01579240|older adults
281717|NCT01579240|Internet
281718|NCT01579240|sedentary
281719|NCT01579240|multi-week
281720|NCT01579240|internet intervention
281721|NCT01579227|Healthy participants
281722|NCT01579214|HIV
281723|NCT01579214|Africa south of the sahara
281724|NCT01579214|Knowledge of results
281725|NCT01579214|Communication barriers
281726|NCT01579214|Cellular Phones
281727|NCT01579201|Postpartum Hemorrhage
281728|NCT01579201|Uterine Atony
281729|NCT01579201|Obstetric Anesthesia
281730|NCT01579201|Cesarean Section
281731|NCT01579201|Carbetocin
281732|NCT01579188|NSCLC
281733|NCT01579162|Hepatitis
281734|NCT01579162|Fatty Liver
281735|NCT01579123|Laser atherectomy
281736|NCT01579123|Critical Limb Ischemia
281737|NCT01579123|Angioplasty
281738|NCT01579110|autoimmune hemolytic anemia
281739|NCT01579110|hemolytic anemia
281740|NCT01579110|Levamisole
281741|NCT01579110|Treatment of autoimmune hemolytic anemia
281742|NCT01579110|warm antibody dependant autoimmune hemolytic anemia
281743|NCT01579097|(PN) Parenteral nutrition
281744|NCT01579097|oral/enteral not possible
281745|NCT01579058|aortic stenosis
281746|NCT01579058|beta-blocker
281747|NCT01579032|CKD,
281748|NCT01578980|Artificial Pancreas
281749|NCT01578980|Type 1 Diabetes Mellitus
281750|NCT01578980|Control-to-Range
281751|NCT01578980|Closed-Loop Control
281752|NCT01578980|Continuous Glucose Monitor
281753|NCT01578967|Hodgkin's lymphoma
281754|NCT01578967|Hodgkin lymphoma
281755|NCT01578954|Leukemia
281756|NCT01578954|Acute Myeloid Leukemia
281757|NCT01578941|menstrual migraine
281758|NCT01578941|migraine
281759|NCT01578941|treximet
281760|NCT01578928|renal, impairment, endstage renal disease
281761|NCT01578928|renal
281762|NCT01578928|impairment
281763|NCT01578928|endstage renal disease
281764|NCT01578902|Prostatic Neoplasms
281765|NCT01578902|Radiotherapy
281766|NCT01578902|Hypofractionation
281767|NCT01578902|Low Risk Prostate Cancer
281768|NCT01578876|coronary artery disease
281769|NCT01578876|angina pectoris
281770|NCT01578876|myocardial ischemia
281771|NCT01578876|cardiac shock wave therapy
281772|NCT01578863|Childhood obesity
281773|NCT01578863|Adolescence
281774|NCT01578863|Predictors
281775|NCT01578863|Success
281776|NCT01578863|Intervention program
281777|NCT01578850|rheumatoid arthritis
281778|NCT01578850|etanercept
281779|NCT01578850|methotrexate
281780|NCT01578850|DMARDs
281781|NCT01578824|Rickets
281782|NCT01578824|Vitamin D
281783|NCT01578824|airway hyperreactivity
281784|NCT01578824|Exhaled breath condensate
281785|NCT01578772|HIV
281786|NCT01578772|Flow-mediated dialation (FMD)
281787|NCT01578772|Telmisartan
281788|NCT01578772|Cardiovascular disease (CVD)
281789|NCT01578772|HIV+ men and women age > 50 at risk for heart disease
281790|NCT01578759|ovarian function tests
281791|NCT01578746|Coxarthrosis
281792|NCT01578746|Hip arthroplasty
281793|NCT01578746|Anterior approach
281794|NCT01578746|Direct lateral approach
281795|NCT01578746|Hardinge approach
281796|NCT01578746|Smith-Petersen approach
281797|NCT01578746|Osteoarthrosis
281798|NCT01578733|protein requirement
281799|NCT01578733|female elderly
281800|NCT01578733|healthy female subject's protein requirements
281801|NCT01578707|Chronic
281802|NCT01578707|SLL
281803|NCT01578707|CLL
281804|NCT01578707|Ofatumumab
281805|NCT01578707|ibrutinib
281806|NCT01578707|RESONATE
281807|NCT01578707|Phase III
281808|NCT01578707|Leukemia
281809|NCT01578707|Lymphoma
281810|NCT01578681|bronchiectasis
281811|NCT01578681|respiratory therapy
281812|NCT01578681|airway clearance
281813|NCT01578668|lung adenocarcinoma
281814|NCT01578668|brain metastases
281815|NCT01578668|erlotinib
281816|NCT01578668|pemetrexed
281817|NCT01578655|custirsen sodium
281818|NCT01578655|prostate cancer
281819|NCT01578655|metastatic castrate resistant prostate cancer
281820|NCT01578655|overall survival
281821|NCT01578642|GERD
281822|NCT01578642|LES Pressure
281823|NCT01578642|Electrical Stimulation
281824|NCT01578629|stroke
281825|NCT01578629|ischemia
281826|NCT01578629|TIA
281827|NCT01578616|Coronary artery disease
281828|NCT01578616|Endothelial function
281829|NCT01578616|Optical coherence tomography
281830|NCT01578616|Thin cap fibroatheroma
281831|NCT01578603|prevention & control
281832|NCT01578603|Xylitol
281833|NCT01578603|casein phosphopeptide amorphous calcium phosphate complex
281834|NCT01578603|Streptococcus mutans
281835|NCT01578603|saliva
281836|NCT01578603|dental plaque
281837|NCT01578603|gingivitis
281838|NCT01578577|Medication Therapy Management
281839|NCT01578577|Hypertension
281840|NCT01578577|Health Literacy
281841|NCT01578577|Medication Reconciliation
281842|NCT01578577|Medication Adherence
281843|NCT01578564|Cancer
281844|NCT01578564|Ovarian Cancer
281845|NCT01578564|TRPV6 Calcium channel
281846|NCT01578551|Carcinoma, Non-Small-Cell Lung
281847|NCT01578551|Lung adenocarcinoma
281848|NCT01578538|hernia, abdominal, strangulation, emergency, wall
281849|NCT01578525|medication safety
281850|NCT01578525|elderly
281851|NCT01578525|pharmaceutical care
281852|NCT01578525|hospital readmission
281853|NCT01578525|drug-related readmission
281854|NCT01578525|Health Services for the Aged
281855|NCT01578499|brentuximab vedotin
281856|NCT01578499|ALCANZA
281857|NCT01578486|Schizophrenia
281858|NCT01578486|Cognition
281859|NCT01578486|Metabolism
281860|NCT01578486|Antipsychotics
281861|NCT01578486|Psychopathology
281862|NCT01578473|low testosterone
281863|NCT01578473|penile curvature
281864|NCT01578460|Pregnancy
281865|NCT01578460|Gestational Diabetes
281866|NCT01578460|Type 2 Diabetes Mellitus
281867|NCT01578460|Continuous Glucose Monitor
281868|NCT01578460|Glucose
281869|NCT01578447|injectable contraception
281870|NCT01578447|acceptability
281871|NCT01578447|intramuscular
281872|NCT01578447|subcutaneous
281873|NCT01578434|Nutritional Rickets
281874|NCT01578434|Calcium
281875|NCT01578434|Vitamin D
281876|NCT01578408|Femoral neck fractures
281877|NCT01578408|Uncemented
281878|NCT01578408|Hydroxyapatite
281879|NCT01578408|Coated
281880|NCT01578408|Femoral
281881|NCT01578408|Stems
281882|NCT01578408|Hip fractures
281883|NCT01578408|THA
281884|NCT01578408|THR
281885|NCT01578408|Cemented
281886|NCT01578408|Fat embolism
281887|NCT01578408|Cognition
281888|NCT01578408|Inflammatory response
281889|NCT01578408|Mobilization
281890|NCT01578382|Martorell hypertensive ischemic leg ulcer
281891|NCT01578382|Calciphylaxis (calcific uremic arteriolopathy)
281892|NCT01578382|Ischemic subcutaneous arteriolosclerosis
281893|NCT01578382|Hypertension
281894|NCT01578382|Diabetes
281895|NCT01578382|Medial calcinosis
281896|NCT01578382|Wound healing
281897|NCT01578369|Urinary incontinence
281898|NCT01578369|Pregnancy
281899|NCT01578369|Pelvic floor muscle training
281900|NCT01578356|Prostate cancer
281901|NCT01578343|fludarabine
281902|NCT01578343|mitoxantrone
281903|NCT01578343|dexamethasone
281904|NCT01578343|relapsed or refractory mantle cell lymphoma
281905|NCT01578343|FND regimen
281906|NCT01578343|vorinostat
281907|NCT01578343|autologous stem cell transplantation
281908|NCT01578330|Relapsing remitting multiple sclerosis
281909|NCT01578330|Fingolimod
281910|NCT01578330|FTY720
281911|NCT01578317|H5N1 Vaccine
281912|NCT01578317|H5N1 Immunization
281913|NCT01578317|MF59 Adjuvant
281914|NCT01578317|Biologic Sample Collection
281915|NCT01578317|Laboratory Research Specimens
281916|NCT01578317|Healthy Volunteer
281917|NCT01578317|HV
281918|NCT01578304|Overactive bladder
281919|NCT01578291|Play therapy
281920|NCT01578291|Urinary tract infections
281921|NCT01578291|Children
281922|NCT01578291|Vesicoureteral reflux
281923|NCT01578239|Neuroendocrine tumour
281924|NCT01578239|177Lu-Dota0-Tyr3-octreotate
281925|NCT01578226|Cirrhosis
281926|NCT01578226|Ascites
281927|NCT01578226|Decompensation
281928|NCT01578226|Bacterial infection
281929|NCT01578226|Sepsis
281930|NCT01578226|Procalcitonin
281931|NCT01578226|PCT
281932|NCT01578200|CKD-MBD
281933|NCT01578200|phosphate-binder
281934|NCT01578200|vascular calcification
281935|NCT01578200|mortality
281936|NCT01578200|dialysis
281937|NCT01578200|Hemodialysis patients with hyperphosphatemia
281938|NCT01578187|hair reduction
281939|NCT01578187|hair removal
281940|NCT01578187|hair clearance
281941|NCT01578148|Cervical pain
281942|NCT01578148|Cervicalgia,
281943|NCT01578148|Cervicodynia
281944|NCT01578148|Neck ache
281945|NCT01578148|Neckache
281946|NCT01578148|Shoulder pain
281947|NCT01578148|Shoulder impingement syndrome
281948|NCT01578122|post-thrombotic syndrome
281949|NCT01578122|prevention
281950|NCT01578122|deep vein thrombosis
281951|NCT01578122|elastic compression stockings
281952|NCT01578122|compliance
281953|NCT01578122|quality of life
281954|NCT01578096|Type 2 Diabetes
281955|NCT01578083|Chemotherapy
281956|NCT01578083|Breast Cancer
281957|NCT01578083|Cognitive Impairment
281958|NCT01578083|Chemo brain
281959|NCT01578070|Other and Unspecified Vaccines and Biological Substances Causing Adverse Effects in Therapeutic Use
281960|NCT01578057|alcohol
281961|NCT01578044|Anti-coagulation
281962|NCT01578031|Sleep Apnea
281963|NCT01578031|Obesity
281964|NCT01578018|lung cancer
281965|NCT01578018|smoking
281966|NCT01578005|acute coronary syndrome
281967|NCT01578005|IVUS
281968|NCT01578005|atherosclerotic plaque
281969|NCT01577992|subjective pain
281970|NCT01577992|Multiple System Atrophy
281971|NCT01577979|Vaccination
281972|NCT01577979|Medical Home
281973|NCT01577979|Adolescents
281974|NCT01577966|Patients with brain tumors associated with seizures
281975|NCT01577953|Antisense oligonucleotide
281976|NCT01577953|Asthma
281977|NCT01577953|Patients with asthma
281978|NCT01577953|Phase 1b
281979|NCT01577953|Transcription factor GATA-3
281980|NCT01577953|Oral inhalation
281981|NCT01577940|Transversus abdominis plane block
281982|NCT01577940|postoperative pain
281983|NCT01577940|Postoperative pain management
281984|NCT01577927|weaning
281985|NCT01577927|severe chronic diseases
281986|NCT01577927|UTIR
281987|NCT01577901|Pregnancy
281988|NCT01577862|ACINETOBACTER BAUMANNII
281989|NCT01577862|COLISTIN
281990|NCT01577862|RIFAMPICIN
281991|NCT01577862|THERAPY
281992|NCT01577862|RESISTANCE
281993|NCT01577836|Radical prostatectomie
281994|NCT01577836|Robotic assistance
281995|NCT01577836|Laparotomy
281996|NCT01577810|NIRS
281997|NCT01577810|near infrared spectroscopy
281998|NCT01577810|heart failure
281999|NCT01577810|cardiac output
282000|NCT01577810|outpatient
282001|NCT01577810|pediatric
282002|NCT01577797|Methamphetamine
282003|NCT01577797|Drug Abuse
282004|NCT01577797|Substance Abuse
282005|NCT01577797|Amphetamine
282006|NCT01577797|Dependence
282007|NCT01577797|Addiction
282008|NCT01577797|Craving
282009|NCT01577797|Cognitive Behavioral Therapy
282010|NCT01577797|Text Messaging
282011|NCT01577784|Advanced renal cell carcinoma
282012|NCT01577784|second-line treatment with pazopanib
282013|NCT01577784|first line of treatment with a Tyrosine Kinase Inhibitor
282014|NCT01577771|Pneumococcal conjugate vaccine
282015|NCT01577771|Immunogenicity
282016|NCT01577771|Reactogenicity
282017|NCT01577758|Phase 1,
282018|NCT01577758|Advanced gastrointestinal malignancies,
282019|NCT01577758|MLN0264,
282020|NCT01577758|Guanylyl Cyclase C(GCC),
282021|NCT01577758|Antibody Drug Conjugate(ADC)
282022|NCT01577745|Cancer
282023|NCT01577732|booster
282024|NCT01577732|Infanrix-IPV+HibTM
282025|NCT01577732|DTPa-IPV/Hib
282026|NCT01577732|Vietnamese toddlers
282027|NCT01577719|Cardiovascular
282028|NCT01577719|Prevention
282029|NCT01577719|Ethnicity
282030|NCT01577719|Culture
282031|NCT01577719|Internet
282032|NCT01577719|Text Message
282033|NCT01577706|GABA
282034|NCT01577706|glutamate
282035|NCT01577706|glutamine
282036|NCT01577706|spectroscopy
282037|NCT01577706|brain
282038|NCT01577706|imaging
282039|NCT01577706|alprazolam
282040|NCT01577706|dextroamphetamine
282041|NCT01577706|placebo
282042|NCT01577693|dutasteride
282043|NCT01577693|cross over study
282044|NCT01577693|bioavailability
282045|NCT01577680|healthy subjects
282046|NCT01577680|pharmacokinetics
282047|NCT01577680|vilanterol
282048|NCT01577680|tolerability
282049|NCT01577680|safety
282050|NCT01577680|hepatic impairment
282051|NCT01577680|GW642444
282052|NCT01577680|GSK573719
282053|NCT01577667|automation
282054|NCT01577667|closed loop
282055|NCT01577667|oxygenation
282056|NCT01577667|ventilation
282057|NCT01577654|adenocarcinoma
282058|NCT01577654|squamous
282059|NCT01577654|adenosquamous
282060|NCT01577654|adenocarcinoma with other NSCLC variants
282061|NCT01577654|EC145
282062|NCT01577654|EC20
282063|NCT01577654|Vintafolide
282064|NCT01577654|Etarfolatide
282065|NCT01577628|Dermatitis
282066|NCT01577628|Eczema
282067|NCT01577628|Skin diseases
282068|NCT01577628|Skin barrier
282069|NCT01577628|Prevention
282070|NCT01577628|Infant
282071|NCT01577628|Moisturizer
282072|NCT01577628|Emollient
282073|NCT01577628|Asthma
282074|NCT01577628|Food allergy
282075|NCT01577628|Allergic rhinitis
282076|NCT01577615|Preterm Infant
282077|NCT01577615|Neurobehavioral
282078|NCT01577615|Development
282079|NCT01577602|Medication reconciliation
282080|NCT01577602|Self report
282081|NCT01577602|Electronic medical record medication list
282082|NCT01577589|Phase 1
282083|NCT01577589|healthy volunteers
282084|NCT01577589|cross-over study
282085|NCT01577589|ceftaroline fosamil
282086|NCT01577589|various infusion volumes
282087|NCT01577589|local tolerability
282088|NCT01577589|Cmax
282089|NCT01577589|tmax
282090|NCT01577589|AUC
282091|NCT01577576|Athletes
282092|NCT01577576|Sedentary volunteers
282093|NCT01577563|osteoarthritis (OA)
282094|NCT01577563|rheumatoid arthritis (RA)
282095|NCT01577563|ankylosing spondylitis (AS)
282096|NCT01577563|gastrointestinal risk factors
282097|NCT01577563|NSAIDs
282098|NCT01577550|ABBV-066
282099|NCT01577550|BI 655066
282100|NCT01577550|risankizumab
282101|NCT01577537|SPL7013
282102|NCT01577537|VivaGel
282103|NCT01577537|bacterial vaginosis
282104|NCT01577537|BV
282105|NCT01577511|invasive potential
282106|NCT01577511|molecular characterisation of circulating cells
282107|NCT01577498|Skeletal age
282108|NCT01577498|Chronological age
282109|NCT01577498|Adolescent
282110|NCT01577472|female infertility
282111|NCT01577472|poor ovarian response
282112|NCT01577472|controlled ovarian hyperstimulation
282113|NCT01577472|IVF
282114|NCT01577472|Antagonist protocol
282115|NCT01577446|CRT
282116|NCT01577446|heart failure
282117|NCT01577446|narrow QRS
282118|NCT01577446|dyssynchrony
282119|NCT01577433|HeartMate II
282120|NCT01577433|heart-assist device
282121|NCT01577433|left ventricular assist device
282122|NCT01577433|driveline infection
282123|NCT01577433|LVAD
282124|NCT01577433|HMII LVAS driveline
282125|NCT01577433|silicone portion
282126|NCT01577433|Thoratec Corporation
282127|NCT01577420|Reflexology
282128|NCT01577420|Breast Cancer
282129|NCT01577420|Complementary
282130|NCT01577407|Dyspnea
282131|NCT01577407|Pain
282132|NCT01577394|Alzheimer disease
282133|NCT01577394|Lewy Body Disease
282134|NCT01577394|Cognitive Disorders
282135|NCT01577394|Neurodegenerative Diseases
282136|NCT01577394|Differential diagnosis
282137|NCT01577394|Eye movement
282138|NCT01577381|Phase 2
282139|NCT01577381|Advanced Dry Age-Related Macular Degeneration
282140|NCT01577381|Geographic Atrophy
282141|NCT01577381|RN6G
282142|NCT01577368|Pseudomonas
282143|NCT01577368|Piperacillin
282144|NCT01577368|Beta-lactams
282145|NCT01577368|Continuous infusion
282146|NCT01577368|Intermittent infusion
282147|NCT01577368|Pharmacokinetics
282148|NCT01577329|meditation
282149|NCT01577329|Chronic Obstructive Pulmonary Disease
282150|NCT01577329|Mindfulness
282151|NCT01577329|Anxiety
282152|NCT01577329|Breathing Patterns
282153|NCT01577316|vaccination
282154|NCT01577316|Influenza
282155|NCT01577316|Immunogenicity
282156|NCT01577316|Safety
282157|NCT01577303|social phobia
282158|NCT01577303|social anxiety
282159|NCT01577303|cognitive bias modification
282160|NCT01577290|Anxiety
282161|NCT01577290|Depression
282162|NCT01577290|Insomnia
282163|NCT01577290|Mindfulness
282164|NCT01577290|Internet
282165|NCT01577277|Metabolic Syndrome X
282166|NCT01577277|Fatty Acids, Omega-3
282167|NCT01577277|Learning
282168|NCT01577277|Attention
282169|NCT01577277|Nutritional Status
282170|NCT01577277|Nutrition Assessments
282171|NCT01577277|Body Weight
282172|NCT01577277|Physical Activity
282173|NCT01577277|Sleep
282174|NCT01577277|Child Nutrition Sciences
282175|NCT01577264|Certolizumab Pegol
282176|NCT01577264|Cimzia
282177|NCT01577238|SPL7013
282178|NCT01577238|VivaGel
282179|NCT01577238|bacterial vaginosis
282180|NCT01577238|BV
282181|NCT01577225|Clean surgery
282182|NCT01577212|stage III NSCLC
282183|NCT01577212|(chemo)radiotherapy
282184|NCT01577212|individualized dose-escalation
282185|NCT01577199|IVF
282186|NCT01577199|poor responder
282187|NCT01577199|low ovarian reserve
282188|NCT01577199|ART
282189|NCT01577199|ovarian stimulation
282190|NCT01577199|IVF protocols
282191|NCT01577186|Schizophrenia
282192|NCT01577186|Paliperidone Extended Release
282193|NCT01577160|Schizophrenia
282194|NCT01577160|Paliperidone Extended Release (ER)
282195|NCT01577147|pregnancy
282196|NCT01577134|multimorbidity
282197|NCT01577134|autonomy
282198|NCT01577134|older adults
282199|NCT01577134|physical activity
282200|NCT01577134|intervention
282201|NCT01577134|behavior change
282202|NCT01577121|Preterm labor
282203|NCT01577108|31-32 Weeks of Gestation Completed
282204|NCT01577108|Group B Streptococcal Infection
282205|NCT01577108|Streptococcus Group B Infection of the Infant
282206|NCT01577095|electroacupuncture
282207|NCT01577095|rosiglitazone
282208|NCT01577095|plasma glucose
282209|NCT01577095|insulin resistance
282210|NCT01577095|free fatty acid
282211|NCT01577082|Adults, not adequately controlled, pre-dose morning PEF
282212|NCT01577069|Hepatitis C
282213|NCT01577069|Direct Antiviral agent (DAA)
282214|NCT01577069|Ultra-deep pyrosequencing
282215|NCT01577069|Single polynucleotide polymorphisms
282216|NCT01577069|Treatment-resistant mutants
282217|NCT01577069|Hepatitis C Virus Protease Inhibitor
282218|NCT01577056|Familial hypercholesterolaemia
282219|NCT01577056|Postprandial dyslipidaemia
282220|NCT01577056|Fish oil treatment
282221|NCT01577056|Cardiovascular disease
282222|NCT01577043|acute diarrhea
282223|NCT01577043|Racecadotril
282224|NCT01577043|children
282225|NCT01577017|ovulation induction, clomiphene citrate, letrozole
282226|NCT01576978|LUMBAR BACK pain
282227|NCT01576978|PELVIC PAIN
282228|NCT01576978|PREGNANCY
282229|NCT01576978|HATHA YOGA
282230|NCT01576965|Laparoscopic hysterectomy,laparoscopic sacrocolpopexy,bowel prep
282231|NCT01576926|Sleep apnea, obstructive
282232|NCT01576926|Deglutition Disorders
282233|NCT01576913|exercise testing
282234|NCT01576913|music
282235|NCT01576913|VO2 max
282236|NCT01576900|behavior therapy
282237|NCT01576900|nocturia
282238|NCT01576900|polyuria
282239|NCT01576874|nicotine dependence
282240|NCT01576874|hormones
282241|NCT01576848|muscle metabolism
282242|NCT01576848|intrinsically labeled protein
282243|NCT01576848|protein synthesis
282244|NCT01576848|insulin
282245|NCT01576848|perfusion
282246|NCT01576835|Non-contrast
282247|NCT01576822|Detoxification
282248|NCT01576822|Sauna
282249|NCT01576809|Paracetamol
282250|NCT01576809|acetaminophen
282251|NCT01576809|phenylephrine
282252|NCT01576809|guaifenesin
282253|NCT01576809|syrup
282254|NCT01576809|URTI
282255|NCT01576809|productive cough
282256|NCT01576796|Radiotherapy
282257|NCT01576796|Fmiso
282258|NCT01576796|FDG PETSCAN
282259|NCT01576796|FMISO PETSCAN
282260|NCT01576796|complement dose
282261|NCT01576796|lung cancer
282262|NCT01576796|NSCLC
282263|NCT01576796|hypoxic lesion
282264|NCT01576770|propofol
282265|NCT01576770|Pain
282266|NCT01576770|Synera Patch
282267|NCT01576770|Gebauer's Ethyl Chloride topical anesthetic
282268|NCT01576757|Stem cell therapy
282269|NCT01576744|HE4
282270|NCT01576744|IVF
282271|NCT01576744|Biomarker
282272|NCT01576744|Ovarian cancer
282273|NCT01576744|Infertility
282274|NCT01576731|HIV Infection
282275|NCT01576731|Postexposure prophylaxis
282276|NCT01576718|Dose ranging
282277|NCT01576718|Fluticasone Propionate
282278|NCT01576718|Dry Powder Inhaler (DPI)
282279|NCT01576718|High Dose ICS
282280|NCT01576718|Asthma
282281|NCT01576705|Down syndrome
282282|NCT01576705|Young children
282283|NCT01576705|Psychomotor development
282284|NCT01576705|Thyroid hormone
282285|NCT01576705|Folinic acid
282286|NCT01576705|Psychometric tests
282287|NCT01576705|GMDS
282288|NCT01576705|Griffiths
282289|NCT01576705|Genetic factors
282290|NCT01576705|Biochemical factors
282291|NCT01576692|recurrent neuroblastoma
282292|NCT01576692|refractory neuroblastoma
282293|NCT01576692|natural killer cells
282294|NCT01576679|intra-abdominal
282295|NCT01576679|abscess
282296|NCT01576679|tPA
282297|NCT01576679|alteplase
282298|NCT01576679|cathflo
282299|NCT01576666|Dose escalation
282300|NCT01576666|Maximum Tolerated Dose
282301|NCT01576666|MTD
282302|NCT01576666|Safety Expansion
282303|NCT01576666|Safety
282304|NCT01576666|Preliminary Efficacy
282305|NCT01576666|Objective Response Rate
282306|NCT01576666|Early progression rate
282307|NCT01576666|PI3K activation
282308|NCT01576666|Combination Treatment
282309|NCT01576666|Hedgehog Signaling Pathway
282310|NCT01576666|Smoothened inhibitor
282311|NCT01576666|Phosphoinositide-3' kinase
282312|NCT01576666|Phosphatase signaling pathway
282313|NCT01576666|Advanced solid tumors
282314|NCT01576666|metastatic breast cancer
282315|NCT01576666|advanced pancreatic adenocarcinoma
282316|NCT01576666|metastatic colorectal cancer
282317|NCT01576666|recurrent glioblastoma multiforme
282318|NCT01576666|gastric cancer
282319|NCT01576666|gastroesophageal junction cancer
282320|NCT01576666|triple negative metastatic breast cancer
282321|NCT01576666|hormone receptor positive (ER+/PR+, and Her2-) metastatic breast cancer
282322|NCT01576653|IFI
282323|NCT01576640|Nicotine Dependence
282324|NCT01576640|Smoking Cessation
282325|NCT01576640|Relapse Prevention
282326|NCT01576640|Cognitive Behavioral Therapy
282327|NCT01576640|Schizophrenia
282328|NCT01576614|Comparing telephone VS RTP in SICU rounding practices
282329|NCT01576601|pediatrics
282330|NCT01576601|acute pain
282331|NCT01576601|neurosurgery
282332|NCT01576601|Pediatric patients (0-18)
282333|NCT01576601|postoperative management
282334|NCT01576588|Chronic lymphocytic leukemia, relapsed, elderly or unfit patients, methylprednisolone, rituximab
282335|NCT01576575|to determine how people absorb and break down (metabolize) and eliminate buprenorphine and if CYP3A is involved.
282336|NCT01576562|Implantable Cardioverter Defibrillator
282337|NCT01576562|Ventricular Assist Device
282338|NCT01576536|Myocardial infarction
282339|NCT01576536|Platelet aggregation
282340|NCT01576536|cold pressor test
282341|NCT01576536|Genetics
282342|NCT01576497|EUS, EUS-FNA, Pancreatic masses
282343|NCT01576471|T. suis ova
282344|NCT01576471|Trichuris suis ova
282345|NCT01576471|Inflammatory Bowel Disease
282346|NCT01576471|TRUST-I
282347|NCT01576471|TRUSTI
282348|NCT01576471|TRUST-1
282349|NCT01576471|TRUST1
282350|NCT01576458|ursodeoxycholic acid
282351|NCT01576458|intrahepatic cholestasis
282352|NCT01576458|pregnancy
282353|NCT01576445|Total Knee Arthroplasty
282354|NCT01576445|function
282355|NCT01576432|Pain
282356|NCT01576432|Breastfeeding
282357|NCT01576432|Heel prick
282358|NCT01576432|Sucrose
282359|NCT01576432|Skin-to-skin contact
282360|NCT01576432|Newborn
282361|NCT01576419|PG201
282362|NCT01576419|Non-inferiority
282363|NCT01576419|100mm pain VAS
282364|NCT01576406|crizotinib
282365|NCT01576406|xalkori
282366|NCT01576406|PF-02341066
282367|NCT01576406|hepatic impairment
282368|NCT01576406|pharmacokinetics
282369|NCT01576406|advanced cancer
282370|NCT01576393|substance abuse
282371|NCT01576393|treatment
282372|NCT01576393|families
282373|NCT01576380|Solid tumors
282374|NCT01576380|Advanced scirrhous gastric carcinoma
282375|NCT01576380|Gastric Cancer
282376|NCT01576380|Second-line or third-line treatment
282377|NCT01576380|VEGF
282378|NCT01576380|FGFR
282379|NCT01576380|Neoplasms
282380|NCT01576380|Gastric Neoplasms
282381|NCT01576380|Cancer
282382|NCT01576380|Carcinoma
282383|NCT01576380|Gastric Diseases
282384|NCT01576380|Female Genital Diseases
282385|NCT01576380|Tumors
282386|NCT01576380|Oral Administration
282387|NCT01576380|Capsules
282388|NCT01576380|TKI258
282389|NCT01576380|TKI-258
282390|NCT01576380|TKI 258
282391|NCT01576367|Cryopyrin-associated periodic syndromes (CAPS)
282392|NCT01576367|Familial Cold Autoinflammatory Syndrome (FCAS)
282393|NCT01576367|Muckle-Wells Syndrome (MWS)
282394|NCT01576367|Neonatal Onset Multisystem Inflammatory Disease (NOMID)
282395|NCT01576367|children, systemic autoinflammatory disease
282396|NCT01576367|CIAS-1 gene
282397|NCT01576367|NALP-3
282398|NCT01576367|NLRP3
282399|NCT01576367|ACZ885
282400|NCT01576367|canakinumab
282401|NCT01576367|human monoclonal anti-human interleukin-1 antibody
282402|NCT01576367|autosomal dominant
282403|NCT01576367|familial autoinflammatory syndrome
282404|NCT01576367|childhood immunizations vaccinations
282405|NCT01576354|Multiple Sclerosis
282406|NCT01576354|walking function
282407|NCT01576354|fampridine
282408|NCT01576341|Epoetin alfa, ESA, HX575, CKD
282409|NCT01576315|cystic fibrosis
282410|NCT01576315|Aspergillus
282411|NCT01576315|itraconazole
282412|NCT01576315|voriconazole
282413|NCT01576302|Rumination
282414|NCT01576289|Esophagus
282415|NCT01576289|Gastroesophageal reflux
282416|NCT01576289|Reflux esophagitis
282417|NCT01576289|Barrett's esophagus
282418|NCT01576289|Stomach
282419|NCT01576289|Intestinal metaplasia stomach
282420|NCT01576289|Helicobacter pylori infection
282421|NCT01576289|Proton pump inhibitor
282422|NCT01576289|Duodenum
282423|NCT01576289|Duodenal bulb
282424|NCT01576289|Celiac disease diagnosis
282425|NCT01576263|Anaesthesia
282426|NCT01576263|Infiltration
282427|NCT01576263|Blood transfusion
282428|NCT01576263|Autologous
282429|NCT01576263|Arthroplasty
282430|NCT01576263|Replacement
282431|NCT01576263|Ropivacaine
282432|NCT01576237|hemovigilance
282433|NCT01576237|hemapheresis
282434|NCT01576237|donor vigilance
282435|NCT01576237|plasmapheresis
282436|NCT01576237|platelet apheresis
282437|NCT01576237|leukapheresis
282438|NCT01576237|stem cell apheresis
282439|NCT01576237|granulocyte apheresis
282440|NCT01576237|monocyte apheresis
282441|NCT01576237|red cell apheresis
282442|NCT01576224|Volar locking plate osteosynthesis
282443|NCT01576224|Early mobilization
282444|NCT01576224|DASH
282445|NCT01576211|Wilms tumor and other childhood kidney tumors
282446|NCT01576198|Wilms tumor and other childhood kidney tumors
282447|NCT01576159|Biochemical Marker
282448|NCT01576159|Fitness Exercises
282449|NCT01576159|Impact
282450|NCT01576159|Articular Cartilage
282451|NCT01576146|Clinical Trial, Phase 2
282452|NCT01576146|Renal Dialysis
282453|NCT01576146|Secondary Hyperparathyroidism
282454|NCT01576146|Chronic kidney disease-mineral and bone disorder
282455|NCT01576146|Parathyroid hormone
282456|NCT01576133|Quality of Life
282457|NCT01576120|Known, active Crohn's disease
282458|NCT01576120|Iieocolonic or colonic involvement
282459|NCT01576120|proven patency of the GI tract
282460|NCT01576107|Different cancer entities
282461|NCT01576094|congenital heart disease
282462|NCT01576081|bone density
282463|NCT01576081|weight bearing
282464|NCT01576081|muscle atrophy
282465|NCT01576081|vascular degeneration
282466|NCT01576081|gravitational loading
282467|NCT01576081|muscular unloading
282468|NCT01576068|COPD
282469|NCT01576068|Pharmacy
282470|NCT01576068|Spirometry
282471|NCT01576068|Case finding
282472|NCT01576055|Peripheral Arterial Disease
282473|NCT01576055|Superficial Femoral Artery
282474|NCT01576055|Proximal Popliteal Artery
282475|NCT01576055|PAD
282476|NCT01576055|SFA
282477|NCT01576055|PPA
282478|NCT01576055|Stent
282479|NCT01576055|Gore
282480|NCT01576055|Bare Metal Stent
282481|NCT01576055|LifeStent
282482|NCT01576055|atherosclerosis
282483|NCT01576055|Heparin
282484|NCT01576055|claudication
282485|NCT01576055|leg pain
282486|NCT01576042|Ischemic heart disease
282487|NCT01576042|Implantable Cardioverter Defibrillator
282488|NCT01576042|Ventricular Tachycardia
282489|NCT01576042|Patient with Implantable Cardioverter Defibrillator (ICD)
282490|NCT01576016|bradycardia
282491|NCT01576016|MRI scans
282492|NCT01576003|Short Bowel Syndrome
282493|NCT01576003|Necrotizing Entercolitis (NEC)
282494|NCT01576003|Atresia
282495|NCT01576003|Parenteral Nutrition
282496|NCT01576003|Biological Markers
282497|NCT01576003|Growth
282498|NCT01575990|Colon cancer screening
282499|NCT01575990|Decision support interventions
282500|NCT01575990|Health status
282501|NCT01575990|Patient-centered care
282502|NCT01575990|Age
282503|NCT01575990|Randomized controlled trial
282504|NCT01575990|Double blind
282505|NCT01575990|UNC
282506|NCT01575938|HIV infection
282507|NCT01575925|Pomalidomide for multiple myeloma
282508|NCT01575925|renal impairment
282509|NCT01575925|multiple myeloma patients with renal impairment
282510|NCT01575925|Pomalidomide for patients with renal impairment due to multiple myeloma
282511|NCT01575925|Pomalidomide
282512|NCT01575925|dexamethasone
282513|NCT01575925|RRMM
282514|NCT01575925|impaired renal function in multiple myeloma
282515|NCT01575925|hemodialysis
282516|NCT01575925|dialysis
282517|NCT01575925|POM
282518|NCT01575925|Pomalyst
282519|NCT01575925|MM
282520|NCT01575925|severe renal impairment
282521|NCT01575925|CrCl ≤ 30 mL/min
282522|NCT01575925|Creatinine less than 30
282523|NCT01575925|clinical trial in subjects with multiple myeloma with renal impairement
282524|NCT01575912|Schizophrenia
282525|NCT01575912|Major depression
282526|NCT01575912|Pain
282527|NCT01575912|Past pain experience
282528|NCT01575899|Helicobacter pylori
282529|NCT01575899|Levofloxacin
282530|NCT01575899|Amoxicillin/clavulanate
282531|NCT01575899|Rabeprazole
282532|NCT01575899|Eastern Taiwan
282533|NCT01575886|clinician patient communication
282534|NCT01575886|smoking cessation
282535|NCT01575886|weight management
282536|NCT01575886|primary care
282537|NCT01575886|health behavior change advice
282538|NCT01575873|GIOP, Glucocorticoid, osteporosis, denosumab, BMD, Bone Mineral Density
282539|NCT01575860|biopsy-proven diagnosis
282540|NCT01575860|completed at least 2 cycles of salvage chemotherapy
282541|NCT01575860|showing PET positive residual lesions
282542|NCT01575847|Acetaminophen
282543|NCT01575847|Acetaminophen Toxicity
282544|NCT01575834|Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
282545|NCT01575821|children, cough, honey
282546|NCT01575808|Symptomatic PAD
282547|NCT01575808|stenosed or occluded lesions
282548|NCT01575808|totaling at least 10 cm in length
282549|NCT01575808|Rutherford scores 2-5
282550|NCT01575795|Ticagrelor
282551|NCT01575795|ST elevation acute myocardial infarction
282552|NCT01575795|Platelet reactivity
282553|NCT01575782|small cell lung cancer
282554|NCT01575782|stage I-III
282555|NCT01575782|chloroquine
282556|NCT01575782|Phase I
282557|NCT01575730|Peritoneal carcinomatosis from colorectal or appendiceal origin
282558|NCT01575717|Vitamin D
282559|NCT01575717|hepatocellular carcinoma
282560|NCT01575717|liver neoplasms
282561|NCT01575717|liver transplantation
282562|NCT01575704|Exercise
282563|NCT01575704|Hematopoetic cell transplantation
282564|NCT01575704|Children
282565|NCT01575691|Combination Chemotherapy
282566|NCT01575691|MDS
282567|NCT01575691|High-Risk Myelodysplastic Syndrome
282568|NCT01575691|AML
282569|NCT01575691|Acute myelogenous leukemia
282570|NCT01575691|valproic acid
282571|NCT01575691|VPA
282572|NCT01575691|Depakene
282573|NCT01575691|5-azacytidine
282574|NCT01575691|5-aza
282575|NCT01575691|Azacitidine
282576|NCT01575691|5-AZC
282577|NCT01575691|Vidaza
282578|NCT01575691|AZA-CR
282579|NCT01575691|Ladakamycin
282580|NCT01575691|NSC-102816
282581|NCT01575691|All-trans retinoic acid
282582|NCT01575691|ATRA
282583|NCT01575691|Tretinoin
282584|NCT01575691|Vesanoid
282585|NCT01575678|enuresis
282586|NCT01575678|melatonin
282587|NCT01575678|circadian rhythm
282588|NCT01575678|children
282589|NCT01575678|blood pressure
282590|NCT01575678|urine production
282591|NCT01575678|activity
282592|NCT01575678|sleep
282593|NCT01575665|Hyperventilation
282594|NCT01575665|Chronic Idiopathic Hyperventilation
282595|NCT01575665|Dysfunctional Breathing
282596|NCT01575665|Respiratory Alkalosis
282597|NCT01575665|Respiratory Acidosis
282598|NCT01575652|peritoneal dialysis
282599|NCT01575652|protein losses
282600|NCT01575613|malaria
282601|NCT01575613|heterogeneity
282602|NCT01575613|transmission
282603|NCT01575613|elimination
282604|NCT01575587|Pharmacology
282605|NCT01575587|Pharmacokinetics
282606|NCT01575587|Pharmacodynamics
282607|NCT01575587|Abiraterone acetate
282608|NCT01575587|Food intake
282609|NCT01575587|Caucasion
282610|NCT01575587|Japanese
282611|NCT01575587|Healthy
282612|NCT01575561|Lurasidone
282613|NCT01575561|Latuda
282614|NCT01575561|Bipolar Disorder
282615|NCT01575535|untreated adult acute myeloid leukemia
282616|NCT01575535|adult acute basophilic leukemia
282617|NCT01575535|adult acute eosinophilic leukemia
282618|NCT01575535|adult erythroleukemia (M6a)
282619|NCT01575535|adult pure erythroid leukemia (M6b)
282620|NCT01575535|adult acute megakaryoblastic leukemia (M7)
282621|NCT01575535|adult acute minimally differentiated myeloid leukemia (M0)
282622|NCT01575535|adult acute monoblastic leukemia (M5a)
282623|NCT01575535|adult acute monocytic leukemia (M5b)
282624|NCT01575535|adult acute myeloblastic leukemia with maturation (M2)
282625|NCT01575535|adult acute myeloblastic leukemia without maturation (M1)
282626|NCT01575535|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
282627|NCT01575535|adult acute myeloid leukemia with del(5q)
282628|NCT01575535|adult acute myeloid leukemia with inv(16)(p13;q22)
282629|NCT01575535|adult acute myeloid leukemia with t(16;16)(p13;q22)
282630|NCT01575535|adult acute myeloid leukemia with t(8;21)(q22;q22)
282631|NCT01575535|adult acute myelomonocytic leukemia (M4)
282632|NCT01575496|Tinnitus
282633|NCT01575496|Transcranial direct current stimulation
282634|NCT01575496|Transcranial magnetic stimulation
282635|NCT01575470|Traumatic Brain Injury
282636|NCT01575470|TBI
282637|NCT01575470|stem cells
282638|NCT01575457|Adolescent Violence Prevention
282639|NCT01575444|Pap test
282640|NCT01575444|HPV testing
282641|NCT01575444|cervical cancer
282642|NCT01575431|coronary artery disease
282643|NCT01575431|endothelial progenitor cells
282644|NCT01575392|creatinine
282645|NCT01575392|chronic kidney disease
282646|NCT01575392|creatinine clearance
282647|NCT01575392|estimated glomerular filtration rate
282648|NCT01575379|allopurinol
282649|NCT01575379|uric acid
282650|NCT01575379|diabetes
282651|NCT01575379|nephropathy
282652|NCT01575340|inflammatory markers
282653|NCT01575340|colorectal cancer
282654|NCT01575340|cytokines
282655|NCT01575340|fish oil
282656|NCT01575314|stapling device
282657|NCT01575314|lobectomy
282658|NCT01575314|cost utility
282659|NCT01575301|GLP-1R agonist
282660|NCT01575301|biomarker
282661|NCT01575288|arterial function
282662|NCT01575288|cardiovascular
282663|NCT01575288|aging
282664|NCT01575288|endothelial function
282665|NCT01575288|arterial stiffness
282666|NCT01575288|vascular function
282667|NCT01575288|Trehalose
282668|NCT01575262|behaviour change
282669|NCT01575262|incentives
282670|NCT01575262|nudging
282671|NCT01575262|physical activity
282672|NCT01575262|self-monitoring
282673|NCT01575249|progression
282674|NCT01575249|moderate aortic stenosis
282675|NCT01575249|asymptomatic
282676|NCT01575249|symptomatic
282677|NCT01575223|saline irrigation
282678|NCT01575223|chronic rhinosinusitis
282679|NCT01575223|endoscopic sinus surgery
282680|NCT01575223|high volume saline irrigation
282681|NCT01575184|internal jugular vein cannulation
282682|NCT01575184|common carotid artery
282683|NCT01575184|infants
282684|NCT01575132|Parkinson's Disease
282685|NCT01575132|Stimulation, Deep Brain
282686|NCT01575132|Study, Follow-Up
282687|NCT01575132|Adverse Effects
282688|NCT01575119|Cigarette smoker
282689|NCT01575119|Elective surgery
282690|NCT01575093|Healthy volunteers
282691|NCT01574040|Lifestyle
282692|NCT01574040|Lifestyle modification
282693|NCT01574040|Behavior
282694|NCT01574040|Primary prevention
282695|NCT01574040|Healthy staff and visitors of an Academic Hospital
282696|NCT01574027|Assess the efficacy of vitamin D for preventing colorectal cancer and identifying the populations likely (or unlikely) to benefit from vitamin D-based therapy.
282697|NCT01574027|Evaluate the ability of Vitamin D3 (cholecalciferol) to reduce ACF's in humans.
282698|NCT01574014|Anxiety Disorder
282699|NCT01574014|Phobic Disorders
282700|NCT01574001|ischemic stroke
282701|NCT01574001|smoking cessation
282702|NCT01574001|antismoking interventions
282703|NCT01573988|Nutrition
282704|NCT01573988|Eating frequency
282705|NCT01573988|Food intake
282706|NCT01573988|Eating behavior
282707|NCT01573988|Satiety
282708|NCT01573988|Ghrelin
282709|NCT01573975|Helicobacter pylori
282710|NCT01573975|antibiotic resistance
282711|NCT01573975|sequential therapy
282712|NCT01573975|Taiwan
282713|NCT01575067|BP
282714|NCT01575041|sodium
282715|NCT01575041|salt
282716|NCT01575041|potassium
282717|NCT01575041|blood pressure
282718|NCT01575041|flow-mediated dilatation
282719|NCT01575041|endothelial function
282720|NCT01575041|renal function
282721|NCT01575041|controlled feeding study
282722|NCT01575041|dietary intervention
282723|NCT01575028|Transversus abdominis plane block
282724|NCT01575028|TAP block
282725|NCT01575028|Local anesthetic infiltration
282726|NCT01575028|Appendectomy
282727|NCT01575028|Laparoscopic appendectomy
282728|NCT01575015|Liver transplantation (E04.210.650)
282729|NCT01575015|Renal replacement therapy (E05.196.353)
282730|NCT01575015|Intra-operative period (E04.614.374)
282731|NCT01575015|Safety (N06.850.135.060.075)
282732|NCT01575015|Efficacy
282733|NCT01575002|transcranial stimulation
282734|NCT01575002|direct current stimulation
282735|NCT01574989|direct current stimulation
282736|NCT01574989|magnetic stimulation
282737|NCT01574989|transcranial stimulation
282738|NCT01574976|ADHD
282739|NCT01574976|probabilistic
282740|NCT01574976|choice
282741|NCT01574976|feedback
282742|NCT01574976|practice
282743|NCT01574963|Coronary artery disease
282744|NCT01574963|OPG
282745|NCT01574963|RANKL
282746|NCT01574963|bone disease
282747|NCT01574950|Delirium
282748|NCT01574937|Castration Resistant
282749|NCT01574937|Post Chemotherapy
282750|NCT01574924|Personality change
282751|NCT01574924|Perfectionism
282752|NCT01574924|Coping
282753|NCT01574924|Medical Specialty
282754|NCT01574924|Medical Residency
282755|NCT01574911|volumetry 3D
282756|NCT01574911|Displacement of water
282757|NCT01574911|lymphoedema
282758|NCT01574911|Venous chronic insufficiency
282759|NCT01574898|Smoking cessation
282760|NCT01574898|Nicotine
282761|NCT01574898|Tobacco Use Disorder
282762|NCT01574898|Central Nervous System Agents
282763|NCT01574885|sleep apnea
282764|NCT01574885|adenotonsillar hypertrophy
282765|NCT01574885|salt
282766|NCT01574885|sodium chloride
282767|NCT01574872|psoriasis
282768|NCT01574872|salt
282769|NCT01574872|sodium chloride
282770|NCT01574859|central hypothyroidism
282771|NCT01574859|hypopituitarism
282772|NCT01574859|levothyroxine replacement
282773|NCT01574859|lipids
282774|NCT01574859|body composition
282775|NCT01574820|prediabetes
282776|NCT01574820|coronary artery disease
282777|NCT01574820|insulin resistance
282778|NCT01574820|glucose intolerance
282779|NCT01574807|mepivacaine
282780|NCT01574807|lidocaine
282781|NCT01574807|inferior alveolar nerve block
282782|NCT01574807|pulpal anesthesia
282783|NCT01574807|pain of injection
282784|NCT01574807|mepivacaine/lidocaine
282785|NCT01574807|lidocaine/lidocaine
282786|NCT01574781|Down syndrome
282787|NCT01574781|Trisomy 13
282788|NCT01574781|Trisomy 18
282789|NCT01574781|Microdeletions
282790|NCT01574781|Pregnancy
282791|NCT01574781|Non-invasive
282792|NCT01574755|gastric inlet patches
282793|NCT01574755|argon plasma coagulation
282794|NCT01574755|globus sensations
282795|NCT01574729|p53 gene therapy
282796|NCT01574729|non-small cell lung cancer
282797|NCT01574729|post-surgery
282798|NCT01574729|chemotherapy
282799|NCT01574703|smoking cessation
282800|NCT01574703|psychiatric disease
282801|NCT01574703|cardiovascular events
282802|NCT01574690|central venous pressure
282803|NCT01574690|right heart catheter (RHC)
282804|NCT01574690|non-invasive monitor
282805|NCT01574690|physical exam of jugular venous pressure
282806|NCT01574690|heart failure (HF)
282807|NCT01574677|Colorectal cancer
282808|NCT01574677|fecal immunochemical test
282809|NCT01574677|Septin 9
282810|NCT01574677|screening
282811|NCT01574651|QVA149
282812|NCT01574651|Health related quality of life
282813|NCT01574651|Formoterol
282814|NCT01574651|Tiotropium
282815|NCT01574651|COPD
282816|NCT01574612|Xerese
282817|NCT01574612|acyclovir hydrocortisone cream
282818|NCT01574612|herpes labialis
282819|NCT01574612|pediatric
282820|NCT01574599|Stroke
282821|NCT01574599|weakness
282822|NCT01574599|rehabilitation
282823|NCT01574599|chronic stroke
282824|NCT01574586|True Bifurcation stenosis
282825|NCT01574573|Obesity
282826|NCT01574573|GERD
282827|NCT01574573|Weight loss
282828|NCT01574560|smoke-free
282829|NCT01574560|tobacco exposure
282830|NCT01574560|biomarker feedback
282831|NCT01574560|nicotine
282832|NCT01574560|cotinine
282833|NCT01574560|secondhand smoke
282834|NCT01574547|Cat Scratch Colon.
282835|NCT01574547|Mucosal tears.
282836|NCT01574547|Mucosal erosion.
282837|NCT01574547|Colonoscopy.
282838|NCT01574508|efficacy
282839|NCT01574508|safety
282840|NCT01574508|intensive insulin therapy
282841|NCT01574495|stroke
282842|NCT01574495|error augmentation
282843|NCT01574495|arm recovery
282844|NCT01574495|massed practice
282845|NCT01574482|Plant sterol - Hypercholesterolemia - diet - dairy
282846|NCT01574469|Plant sterol - Cholesterol absorption - diet - dairy - LDL
282847|NCT01574443|Epilepsy
282848|NCT01574417|Plant stanols
282849|NCT01574417|Gene expression profile
282850|NCT01574417|Microbiota
282851|NCT01574404|PGS,PGD, IVF, Polar Body Biopsy, FISH, Microarray analysis
282852|NCT01574378|Abdominoplasty
282853|NCT01574365|CKD patients with type 2 diabetes
282854|NCT01574352|Children
282855|NCT01574352|Overweight
282856|NCT01574352|Obesity
282857|NCT01574352|BMI
282858|NCT01574352|Physical activity
282859|NCT01574352|Cognitive function
282860|NCT01574352|Intervention study
282861|NCT01574352|Randomized controlled trial
282862|NCT01574352|Day camp
282863|NCT01574352|Risk factors
282864|NCT01574339|GERD
282865|NCT01574339|LES Pressure
282866|NCT01574339|Electrical Stimulation
282867|NCT01574326|Chronic Kidney Disease
282868|NCT01574326|Pediatric
282869|NCT01574326|Sevelamer Carbonate
282870|NCT01574326|Hyperphosphatemia
282871|NCT01574313|stellate ganglion block.
282872|NCT01574313|Meniere's disease.
282873|NCT01574313|electrocochleography.
282874|NCT01574313|vertigo.
282875|NCT01574313|hearing impairment.
282876|NCT01574300|Small Cell Lung Cancer (SCLC)
282877|NCT01574300|Non-Small Cell Lung Cancer (NSCLC)
282878|NCT01574300|M1A or B NSCLC
282879|NCT01574261|Polycystic Ovary Syndrome
282880|NCT01574261|Cardiovascular risk
282881|NCT01574261|Metabolic Syndrome
282882|NCT01574248|ACE inhibitor
282883|NCT01574248|Angioedema
282884|NCT01574248|Bradykinin
282885|NCT01574248|Swelling
282886|NCT01574222|Stages IIIB, IV, and recurrent NSCLC
282887|NCT01574222|Carcinoma, Non-small cell lung
282888|NCT01574222|Lung Neoplasms
282889|NCT01574222|Carcinoma, Bronchogenic
282890|NCT01574222|Thoracic Neoplasms
282891|NCT01574222|Neoplasms by Site
282892|NCT01574222|Neoplasms
282893|NCT01574222|Lung Diseases
282894|NCT01574209|Celiac disease
282895|NCT01574209|IBS
282896|NCT01574209|Intestinal barrier
282897|NCT01574209|Intestinal permeability
282898|NCT01574209|GI peptides
282899|NCT01574196|Childhood cancer
282900|NCT01574196|Cancer
282901|NCT01574196|Sequels
282902|NCT01574196|Complications
282903|NCT01574196|Chemotherapy
282904|NCT01574196|Radiotherapy
282905|NCT01574196|Surgery
282906|NCT01574196|Autonomic nervous system
282907|NCT01574196|Parasympathetic Nervous System
282908|NCT01574196|Sympathetic Nervous System
282909|NCT01574183|Marijuana
282910|NCT01574183|Vilazodone
282911|NCT01574183|Contingency management
282912|NCT01574183|Motivational enhancement therapy
282913|NCT01574170|Breast cancer,
282914|NCT01574170|Third line metastatic
282915|NCT01574170|Chemotherapy,
282916|NCT01574170|Overall survival,
282917|NCT01574170|Quality of life.
282918|NCT01574144|Heart Failure
282919|NCT01574131|Burn
282920|NCT01574131|Fenofibrate
282921|NCT01574131|PPAR alpha agonist
282922|NCT01574131|insulin sensitivity
282923|NCT01574131|mitochondrial
282924|NCT01574118|PTSD
282925|NCT01574118|Posttraumatic Stress Disorder
282926|NCT01574118|Exposure Therapy
282927|NCT01574118|Prolonged Exposure
282928|NCT01574118|Fear Memory Retrieval
282929|NCT01574118|Compound extinction
282930|NCT01574118|Deepened extinction
282931|NCT01574118|Psychotherapy
282932|NCT01574105|Heparin Dose
282933|NCT01574105|Heparin Resistance
282934|NCT01574105|Chest Tube Losses
282935|NCT01574105|Transfusion Events
282936|NCT01574092|Pediatric
282937|NCT01574092|Pediatrics
282938|NCT01574092|Gliomas
282939|NCT01574092|Glioma
282940|NCT01574092|Brain tumor
282941|NCT01574092|Brain cancer
282942|NCT01574092|Cisplatin
282943|NCT01574092|Cisplatino
282944|NCT01574092|Irinotecan
282945|NCT01574092|Brain stem tumor
282946|NCT01574092|Brainstem gliomas
282947|NCT01574092|Intrinsic brain stem tumor
282948|NCT01574092|PAEDIATRIC HIGH GRADE GLIOMA
282949|NCT01574092|Childhood brain stem glioma
282950|NCT01574066|Community-acquired pneumonia
282951|NCT01574066|Diagnosis
282952|NCT01574066|Emergency medicine
282953|NCT01574066|Chest CT-scan
282954|NCT01574053|Huntington's Disease
282955|NCT01574053|Huntington Disease
282956|NCT01574053|Juvenile Huntington's Disease
282957|NCT01574053|Registry
282958|NCT01574053|Cohort
282959|NCT01574053|CHDI
282960|NCT01573962|Kidney Renal
282961|NCT01573949|Heart Failure
282962|NCT01573949|Diabetes
282963|NCT01573949|Pre-diabetes
282964|NCT01573949|Early type II diabetes
282965|NCT01573949|Metformin
282966|NCT01573949|Pharmacotherapy with metformin for prevention of DM in HF patients with pre-diabetes (pre-DM) and glycemic control in HF patients with early type II DM
282967|NCT01573936|acquired brain injury
282968|NCT01573936|health-related quality of life
282969|NCT01573936|poliomyelitis survivor
282970|NCT01573936|rehabilitation
282971|NCT01573936|spinal cord injury
282972|NCT01573936|completed the WHOQOL-BREF
282973|NCT01573923|Umbilical Mesenchymal Stem Cells; Liver cirrhosis
282974|NCT01573910|Bacterial conjunctivitis
282975|NCT01573910|Anti-infective
282976|NCT01573910|Antibiotics
282977|NCT01573897|Diabetes
282978|NCT01573897|Sleep apnea
282979|NCT01573897|Diabetic foot
282980|NCT01573897|microcirculation
282981|NCT01573858|Infertility
282982|NCT01573858|Polycystic Ovary Syndrome
282983|NCT01573858|Clomiphene citrate
282984|NCT01573858|Acupuncture
282985|NCT01573845|child
282986|NCT01573845|communication
282987|NCT01573845|diet
282988|NCT01573845|food
282989|NCT01573845|health communication
282990|NCT01573845|nutrition
282991|NCT01573845|parents
282992|NCT01573845|primary schools
282993|NCT01573845|school age population
282994|NCT01573845|school health
282995|NCT01573819|repeat dose
282996|NCT01573819|PDE4
282997|NCT01573819|healthy volunteers
282998|NCT01573819|GSK356278
282999|NCT01573806|sepsis
283000|NCT01573806|septic shock
283001|NCT01573806|children
283002|NCT01573806|incretins
283003|NCT01573806|exenatide
283004|NCT01573806|pharmacokinetics
283005|NCT01573806|pharmacodynamics
283006|NCT01573806|glucose homeostasis
283007|NCT01573806|inflammation
283008|NCT01573806|cytokines
283009|NCT01573806|health-related quality of life
283010|NCT01573806|functional status
283011|NCT01573754|Porphyria, rare disease, orphan disease, iron metabolism
283012|NCT01573741|depressive ketamine antidepressant
283013|NCT01573728|Depression
283014|NCT01573728|Biomarkers
283015|NCT01573728|Exercise
283016|NCT01573702|Non small cell lung cancer
283017|NCT01573702|EGFR mutant
283018|NCT01573702|Phase II
283019|NCT01573702|erlotinib
283020|NCT01573702|tarceva
283021|NCT01573702|cyberknife
283022|NCT01573702|Lineberger
283023|NCT01573689|bereaved children, mutual aid group, death, group intervention.
283024|NCT01573676|bariatric surgery
283025|NCT01573676|sleep apnea
283026|NCT01573676|overweight
283027|NCT01573663|Ambroxol
283028|NCT01573663|Levodropropizine
283029|NCT01573663|Drug-drug interaction
283030|NCT01573637|schizophrenia
283031|NCT01573637|negative schizophrenia
283032|NCT01573637|schizophrenia in post-menopausal women
283033|NCT01573637|schizophrenia in women
283034|NCT01573637|ralixifene
283035|NCT01573637|raloxifen
283036|NCT01573637|raloxifeno
283037|NCT01573637|negative symptoms of schizophrenia
283038|NCT01573637|negative symptoms in schizophrenia
283039|NCT01573637|schizophrenia symptoms
283040|NCT01573637|negative symptoms of psychosis
283041|NCT01573624|Vilanterol (VI),
283042|NCT01573624|, Fluticasone Furoate (FF),
283043|NCT01573624|Adults
283044|NCT01573624|Asthma
283045|NCT01573624|GSK573719,
283046|NCT01573611|mild cognitive impairment
283047|NCT01573611|dementia
283048|NCT01573611|positron emission tomography (PET)
283049|NCT01573611|F-18 Fluorodeoxyglucose (FDG)
283050|NCT01573611|cerebral metabolism
283051|NCT01573611|dietary supplement
283052|NCT01573598|Major Depressive Disorder
283053|NCT01573598|Depression
283054|NCT01573585|Physical Therapy
283055|NCT01573585|Exercise therapy
283056|NCT01573559|Ambulatory adults with no apparent health conditions
283057|NCT01573533|Treatment Resistant Idiopathic FSGS
283058|NCT01573533|Glomerulosclerosis
283059|NCT01573533|Proteinuria
283060|NCT01573533|Rituximab
283061|NCT01573520|compliance
283062|NCT01573520|dialysis
283063|NCT01573520|hyperparathyroidism
283064|NCT01573507|traumatic brain injury
283065|NCT01573507|lactate
283066|NCT01573507|brain metabolism
283067|NCT01573507|cerebral microdialysis
283068|NCT01573507|subarachnoid hemorrhage
283069|NCT01573507|transcranial doppler
283070|NCT01573494|Cancer
283071|NCT01573494|Melanoma
283072|NCT01573494|Circulating Tumor Cells
283073|NCT01573481|WEANING
283074|NCT01573481|PRESSURE CONTROLLED CONTINOUS VENTILATION
283075|NCT01573481|PRESSURE VENTILATION SUPPORT
283076|NCT01573481|SLEEP
283077|NCT01573481|POLYGRAPHIC RECORD
283078|NCT01573442|hot flashes
283079|NCT01573442|musculoskeletal complications
283080|NCT01573442|sexual dysfunction
283081|NCT01573442|estrogen receptor-positive breast cancer
283082|NCT01573442|progesterone receptor-positive breast cancer
283083|NCT01573442|arthralgia
283084|NCT01573442|stage IA breast cancer
283085|NCT01573442|stage IB breast cancer
283086|NCT01573442|stage II breast cancer
283087|NCT01573442|stage IIIA breast cancer
283088|NCT01573442|stage IIIB breast cancer
283089|NCT01573442|stage IIIC breast cancer
283090|NCT01573429|Biologic Sample Collection
283091|NCT01573429|Metabolism
283092|NCT01573429|Healthy Volunteer
283093|NCT01573429|HV
283094|NCT01573416|Alcohol
283095|NCT01573416|Abuse
283096|NCT01573416|Drugs
283097|NCT01573416|Brief intervention
283098|NCT01573416|ASSIST
283099|NCT01573403|Proton pump inhibitor (PPI)
283100|NCT01573403|DLBS2411
283101|NCT01573403|gastric pH
283102|NCT01573390|Non-invasive
283103|NCT01573390|tissue-oxygenation
283104|NCT01573390|hyperspectral
283105|NCT01573390|CWC imaging system
283106|NCT01573377|polycystic ovary syndrome
283107|NCT01573377|insulin resistance
283108|NCT01573364|Distal Airways
283109|NCT01573364|Hyperinflation
283110|NCT01573364|Reversibility
283111|NCT01573338|Cyclin dependent kinases
283112|NCT01573338|Drug therapy, combination
283113|NCT01573338|Small cell lung carcinoma
283114|NCT01573338|Etoposide
283115|NCT01573338|Cisplatin
283116|NCT01573338|Carboplatin
283117|NCT01573325|Cirrhosis of the liver
283118|NCT01573325|Pre-liver transplant Candidate
283119|NCT01573325|Depression
283120|NCT01573325|Poor social support
283121|NCT01573325|Liver disease symptoms
283122|NCT01573325|Health releated quality of life
283123|NCT01573312|influenza, vaccine, H5N1, monovalent, adjuvant, ASO3
283124|NCT01573299|Cerebral Infarction, Mobilization, Recovery
283125|NCT01573286|Infant Nutrition Disorders
283126|NCT01573286|Childhood nutrition disorders
283127|NCT01573286|malnutrition
283128|NCT01573286|post surgical syndromes
283129|NCT01573286|necrotising enterocolitis
283130|NCT01573286|intestinal atresia
283131|NCT01573286|gastroschisis
283132|NCT01573273|cocaine
283133|NCT01573273|substance abuse
283134|NCT01573273|drug abuse
283135|NCT01573273|cocaine dependence
283136|NCT01573273|drug addiction
283137|NCT01573260|Parkinson's Disease
283138|NCT01573260|Tango
283139|NCT01573247|Acute myeloid leukemia
283140|NCT01573247|Refractory Acute myeloid leukemia
283141|NCT01573247|FLT3 inhibitor
283142|NCT01573247|kinase inhibitor
283143|NCT01573234|MySkin patch
283144|NCT01573234|Hydrogel bandage
283145|NCT01573234|Occlusive dressing
283146|NCT01573208|Knee osteoarthritis
283147|NCT01573195|deescalation
283148|NCT01573195|best practice alert
283149|NCT01573195|antimicrobial stewardship
283150|NCT01573182|Zostavax
283151|NCT01573182|Herpes Zoster
283152|NCT01573182|VZV vaccination
283153|NCT01573182|Allogeneic haemopoietic stem cell transplantation
283154|NCT01573169|hemorrhagic stroke
283155|NCT01573169|venous thromboembolism
283156|NCT01573169|prevention
283157|NCT01573156|renal cancer
283158|NCT01573156|photodynamic therapy
283159|NCT01573156|wst 11
283160|NCT01573143|Surgical Procedures, Cardiac
283161|NCT01573143|Hydroxymethylglutaryl-CoA Reductase Inhibitors
283162|NCT01573143|Rosuvastatin
283163|NCT01573143|Post operative atrial fibrillation
283164|NCT01573130|Depression
283165|NCT01573130|Physical exercise
283166|NCT01573130|Internet
283167|NCT01573117|hypothermia
283168|NCT01573117|induction of hypothermia
283169|NCT01573117|cold infusion
283170|NCT01573117|nasopharyngeal cooling
283171|NCT01573117|stroke
283172|NCT01573117|intracranial hemorrhage
283173|NCT01573117|cerebrovascular disease
283174|NCT01573117|neuro intensive care
283175|NCT01573104|Diagnosis
283176|NCT01573104|Acute Kidney Injury
283177|NCT01573091|Cardiac resynchronization therapy
283178|NCT01573091|Heart failure
283179|NCT01573078|Crohn's disease
283180|NCT01573078|IBS
283181|NCT01573078|Dissociation
283182|NCT01573078|Emotional processing
283183|NCT01573065|alcohol consumption
283184|NCT01573065|sexual risk behaviors
283185|NCT01573065|young, unhealthy drinkers
283186|NCT01573039|Kidney transplantation
283187|NCT01573039|PCR quantitative
283188|NCT01573039|cytomegalovirus
283189|NCT01573039|antigenemia
283190|NCT01573026|Dental Implants
283191|NCT01573026|Dental Implantation
283192|NCT01573026|Osseointegration
283193|NCT01573013|iron deficiency
283194|NCT01573013|Lead poisoning
283195|NCT01573013|cognitive development
283196|NCT01573013|motor activity
283197|NCT01573000|Bexxar
283198|NCT01573000|Non-Hodgkin's Lymphoma
283199|NCT01573000|Tositumomab
283200|NCT01573000|Anti-B1 Antibody
283201|NCT01573000|Radioimmunotherapy
283202|NCT01573000|Iodine I-131
283203|NCT01573000|Iodine-131
283204|NCT01572987|Barrett's Esophagus
283205|NCT01572987|Esophageal neoplasms
283206|NCT01572987|Radiofrequency ablation
283207|NCT01572987|Endoscopic mucosal resection
283208|NCT01572974|Barrett's esophagus
283209|NCT01572974|Gastroesophageal reflux disease
283210|NCT01572974|Quality of life
283211|NCT01572961|Laser Doppler flowmetry, skin, microcirculation
283212|NCT01572935|childhood obesity prevalence
283213|NCT01572922|Sickle cell disease
283214|NCT01572922|Thalassemia
283215|NCT01572922|Hemochromatosis
283216|NCT01572922|Cancer
283217|NCT01572909|Myocardial Reperfusion
283218|NCT01572909|Primary PCI
283219|NCT01572909|Stenting for ST-segment Elevation Myocardial Infarction
283220|NCT01572896|adoloescent
283221|NCT01572896|internet self-management
283222|NCT01572896|managing JIA
283223|NCT01572883|adjuvant treatment with Radiotherapy and trastuzumab
283224|NCT01572870|Chit1
283225|NCT01572870|Cystic Fibrosis
283226|NCT01572870|Allergic Bronchopulmonary Aspergillosis (ABPA)
283227|NCT01572870|Aspergillus
283228|NCT01572857|multiple myeloma
283229|NCT01572857|Proteinuria
283230|NCT01572857|Albuminuria
283231|NCT01572857|Urinary FLC
283232|NCT01572857|Urine creatinine
283233|NCT01572844|Dermatomyositis
283234|NCT01572844|Superficial calcinosis
283235|NCT01572844|Fractional carbon dioxide laser
283236|NCT01572844|Sodium thiosulfate
283237|NCT01572831|antibiotic cessation rules
283238|NCT01572831|procalcitonin
283239|NCT01572831|infection
283240|NCT01572831|critical care
283241|NCT01572818|Phlebotomy
283242|NCT01572818|Insulin Resistance
283243|NCT01572818|Iron Overload
283244|NCT01572805|Post partum haemorrhage
283245|NCT01572805|Cesarean
283246|NCT01572805|Pain
283247|NCT01572792|COPD
283248|NCT01572792|Chronic Obstructive Pulmonary Disease
283249|NCT01572792|Chronic Bronchitis
283250|NCT01572792|Emphysema
283251|NCT01572792|Airflow Obstruction, Chronic
283252|NCT01572792|Chronic Airflow Obstruction
283253|NCT01572792|Chronic Obstructive Airway Disease
283254|NCT01572792|Chronic Obstructive Lung Disease
283255|NCT01572779|dorsavi
283256|NCT01572779|vimove
283257|NCT01572779|biofeedback
283258|NCT01572779|objective movement data
283259|NCT01572779|back pain
283260|NCT01572766|Osteoporosis
283261|NCT01572766|Pharmacist
283262|NCT01572766|Behavior Change
283263|NCT01572766|FRAX
283264|NCT01572766|Osteopenia
283265|NCT01572727|BKM120
283266|NCT01572727|paclitaxel
283267|NCT01572727|breast cancer
283268|NCT01572727|metastatic
283269|NCT01572727|locally advanced
283270|NCT01572727|PI3K
283271|NCT01572727|PIK3CA
283272|NCT01572727|PTEN
283273|NCT01572714|Exercise
283274|NCT01572714|Self Care
283275|NCT01572714|Fatigue
283276|NCT01572675|Pharmacoepidemiological
283277|NCT01572675|Longitudinal
283278|NCT01572675|Observational
283279|NCT01572662|Leukemia
283280|NCT01572662|Acute myeloid leukemia
283281|NCT01572662|Acute lymphocytic leukemia
283282|NCT01572662|Chronic myeloid leukemia
283283|NCT01572662|Chronic lymphocytic leukemia
283284|NCT01572662|Myeloproliferative Diseases
283285|NCT01572662|Non-Hodgkins Lymphoma
283286|NCT01572662|Hodgkins lymphoma
283287|NCT01572662|Multiple myeloma
283288|NCT01572662|Myelodysplastic syndrome
283289|NCT01572662|MDS
283290|NCT01572662|Fludarabine monophosphate
283291|NCT01572662|Fludarabine phosphate
283292|NCT01572662|Fludara
283293|NCT01572662|Busulfan
283294|NCT01572662|Busulfex
283295|NCT01572662|Myleran
283296|NCT01572662|Tacrolimus
283297|NCT01572662|Prograf
283298|NCT01572662|Methotrexate
283299|NCT01572662|G-CSF
283300|NCT01572662|Filgrastim
283301|NCT01572662|Neupogen
283302|NCT01572662|Stem cell transplant
283303|NCT01572662|Allogeneic Transplantation
283304|NCT01572636|Hurler Syndrome
283305|NCT01572623|Therapeutic strategies for carotid artery stenting
283306|NCT01572610|CKD patients with type 2 diabetes
283307|NCT01572597|Helicobacter pylori
283308|NCT01572597|antibiotic resistance
283309|NCT01572597|N-acetylcystein
283310|NCT01572597|biofilm
283311|NCT01572597|second-line eradication treatment
283312|NCT01572584|Pneumothorax
283313|NCT01572584|Lung ultrasound
283314|NCT01572584|Chest sonography
283315|NCT01572571|Emergency ultrasound
283316|NCT01572571|Focused ultrasound
283317|NCT01572571|Point-of-care ultrasound
283318|NCT01572571|Undifferentiated hypotension
283319|NCT01572558|Appendectomy
283320|NCT01572558|Nonsurgical treatment with antibiotics
283321|NCT01572545|bone turnover
283322|NCT01572545|denosumab
283323|NCT01572545|postmenopausal osteoporosis
283324|NCT01572545|sclerostin
283325|NCT01572545|zolendronic acid
283326|NCT01572532|Adverse Perinatal Outcomes
283327|NCT01572532|Treatment of abnormal vaginal flora
283328|NCT01572519|Relapsed Hodgkin lymphoma
283329|NCT01572519|Refractory Hodgkin lymphoma
283330|NCT01572519|JNJ-40346527
283331|NCT01572519|Dose-escalation
283332|NCT01572519|Pharmacokinetics
283333|NCT01572506|Anemia
283334|NCT01572506|Elderly
283335|NCT01572506|Mechanisms
283336|NCT01572506|Red Cell Survival
283337|NCT01572493|Pharmacokinetics of lL-15
283338|NCT01572493|Cytokine Therapy
283339|NCT01572493|Effects of rhlL-15 on T-cells and NK cells
283340|NCT01572493|Immunotherapy
283341|NCT01572480|Proteasome Inhibitor
283342|NCT01572480|Anti-Myeloma Inhibitor
283343|NCT01572480|Immunomodulatory Agents
283344|NCT01572480|Combination Therapy
283345|NCT01572480|Smoldering Multiple Myeloma
283346|NCT01572480|SMM
283347|NCT01572467|Leydig cell tumor
283348|NCT01572467|ovarian stromal cancer
283349|NCT01572467|childhood malignant testicular germ cell tumor
283350|NCT01572467|childhood malignant ovarian germ cell tumor
283351|NCT01572454|coronary artery bypass graft
283352|NCT01572454|hypokalemia
283353|NCT01572454|cardiac arrhythmia
283354|NCT01572454|dexmedetomidine
283355|NCT01572454|remifentanil
283356|NCT01572428|Proximal Colon Cancer
283357|NCT01572428|Serrated Colon Lesions
283358|NCT01572428|Narrow Band Imaging
283359|NCT01572415|Screening for Type 2 diabetes
283360|NCT01572402|Diet
283361|NCT01572402|Gastrointestinal peptides
283362|NCT01572402|Insulin secretion
283363|NCT01572402|Oxidative stress
283364|NCT01572402|Plasma lipids
283365|NCT01572402|Postprandial
283366|NCT01572402|Type 2 diabetes
283367|NCT01572389|Diabetes Mellitus
283368|NCT01572389|Depression
283369|NCT01572389|Affective Symptoms
283370|NCT01572389|Self Care
283371|NCT01572389|Telemedicine
283372|NCT01572389|Psychotherapy
283373|NCT01572376|Pressure ulcers
283374|NCT01572376|Chronic wounds
283375|NCT01572376|Spinal cord injury patients
283376|NCT01572376|Bone marrow
283377|NCT01572376|Mononuclear
283378|NCT01572376|Debridement
283379|NCT01572363|Fontan
283380|NCT01572363|Cardiac magnetic resonance imaging
283381|NCT01572363|Sildenafil
283382|NCT01572337|NIV
283383|NCT01572337|acute respiratory failure
283384|NCT01572337|hypoxia
283385|NCT01572337|hypercapnia
283386|NCT01572337|non-invasive ventilation
283387|NCT01572337|hospital ward
283388|NCT01572324|Cholangiocarcinoma
283389|NCT01572324|gallbladder cancer
283390|NCT01572324|Infusions
283391|NCT01572324|Intra-Arterial
283392|NCT01572311|Aerobic exercise
283393|NCT01572311|Cognition
283394|NCT01572311|Dual Task
283395|NCT01572311|Gait Training
283396|NCT01572311|Group-based exercise
283397|NCT01572311|Older adults
283398|NCT01572285|Hemiplegic
283399|NCT01572285|Shoulder Pain
283400|NCT01572285|Transforaminal
283401|NCT01572285|Treatment
283402|NCT01572285|Interventional
283403|NCT01572272|Distal Capnography
283404|NCT01572272|CO2
283405|NCT01572272|neonates
283406|NCT01572272|conventional ventilation
283407|NCT01572246|electrosurgery
283408|NCT01572246|Cardiac surgical procedures
283409|NCT01572246|Surgical procedures, operative
283410|NCT01572246|Defibrillators
283411|NCT01572233|Fatigue,Physical Activity,Hepatitis C Virus Infection
283412|NCT01572220|Hospitalized patients
283413|NCT01572207|Multiple Sclerosis
283414|NCT01572207|Exercise
283415|NCT01572207|Physical activity
283416|NCT01572207|Quality of life
283417|NCT01572194|CF
283418|NCT01572168|Fatigue
283419|NCT01572142|Parkinson disease
283420|NCT01572142|smell
283421|NCT01572142|cognitive
283422|NCT01572116|sufentanil
283423|NCT01572116|irreversible pulpitis
283424|NCT01572116|intra ligament injection
283425|NCT01572090|Body mass index
283426|NCT01572090|Body fat
283427|NCT01572090|Obesity
283428|NCT01572090|Bariatric surgery
283429|NCT01572090|Conventional dietary treatment
283430|NCT01572090|Diabetes Mellitus, Type 2
283431|NCT01572090|Cardiometabolic risk factors
283432|NCT01572090|Inflammation
283433|NCT01572090|Adipokines
283434|NCT01572090|Gastrointestinal hormones
283435|NCT01572090|Comorbidity improvement
283436|NCT01572090|Energy intake
283437|NCT01572090|Energy expenditure
283438|NCT01572090|Physical activity
283439|NCT01572064|MRI
283440|NCT01572064|liver biopsy
283441|NCT01572064|serological markers
283442|NCT01572051|osteoarthritis
283443|NCT01572051|knee osteoarthritis
283444|NCT01572051|education
283445|NCT01572012|Pharmacokinetics
283446|NCT01572012|Safety
283447|NCT01572012|Healthy Volunteers
283448|NCT01572012|tolerability
283449|NCT01571999|pharmacokinetics
283450|NCT01571999|GW642444
283451|NCT01571999|GSK573719
283452|NCT01571999|vilanterol
283453|NCT01571999|renal impairment
283454|NCT01571999|safety
283455|NCT01571999|COPD
283456|NCT01571986|NIV
283457|NCT01571986|acute respiratory failure
283458|NCT01571986|hypoxia
283459|NCT01571986|hypercapnia
283460|NCT01571986|non-invasive ventilation
283461|NCT01571986|hospital ward
283462|NCT01571973|pharmaceutical care
283463|NCT01571973|depression
283464|NCT01571973|compliance
283465|NCT01571973|pharmacist's intervention
283466|NCT01571973|Dáder
283467|NCT01571947|Insulinaemia
283468|NCT01571947|inflammatory markers
283469|NCT01571947|gastrointestinal peptides
283470|NCT01571947|SFA
283471|NCT01571947|dietary fats
283472|NCT01571947|carbohydrate
283473|NCT01571947|insulin sensitivity
283474|NCT01571934|Hemophilia A
283475|NCT01571908|rocuronium
283476|NCT01571908|succinylcholine
283477|NCT01571908|magnesiumsulphate
283478|NCT01571908|intubation conditions
283479|NCT01571895|Autoimmune inflammatory blistering disorder
283480|NCT01571882|Plant sterol - Policosanols - Hypercholesterolemia - Dairy
283481|NCT01571869|Plant sterol - hypercholesterolemia - dairy - meal
283482|NCT01571856|Acute Diarrhea
283483|NCT01571856|Zinc
283484|NCT01571856|Children
283485|NCT01571843|Hyperparathyroidism, Primary
283486|NCT01571843|Bone Diseases, Metabolic
283487|NCT01571843|Osteoporosis, Postmenopausal
283488|NCT01571843|Bone Loss, Postmenopausal
283489|NCT01571830|food allergy
283490|NCT01571830|nutrient intake
283491|NCT01571830|growth
283492|NCT01571817|Insulin Dependent
283493|NCT01571804|Anesthesia
283494|NCT01571804|pregabalin
283495|NCT01571804|sevoflurane
283496|NCT01571804|laparoscopic cholecystectomy
283497|NCT01571791|Ketorolac
283498|NCT01571791|lidocaine
283499|NCT01571791|valvular hear diseases
283500|NCT01571791|cesarean section
283501|NCT01571778|Hand Hygiene
283502|NCT01571778|Non-sterile Glove Use
283503|NCT01571765|maternal
283504|NCT01571765|newborn
283505|NCT01571765|child
283506|NCT01571752|Drug Abuse/Dependence
283507|NCT01571752|Drug Abuse
283508|NCT01571752|Drug Dependence
283509|NCT01571739|Biomarker
283510|NCT01571739|Latent Tuberculosis
283511|NCT01571739|IGRA
283512|NCT01571739|Isoniazid
283513|NCT01571739|TB Lymphadenopathy
283514|NCT01571739|Tuberculosis
283515|NCT01571739|TB
283516|NCT01571726|(18)-Fluciclatide PET/CT
283517|NCT01571726|Serum M-Protein
283518|NCT01571726|Percentage of Plasma Cells in the Bone Marrow
283519|NCT01571726|Ratio of Normal/Abnormal Percentage of Plasma Cells in the Bone Marrow
283520|NCT01571726|Multiple Myeloma
283521|NCT01571700|Mechanical Dysynchrony
283522|NCT01571700|Electrical Dysynchrony
283523|NCT01571687|expedition
283524|NCT01571687|hypoxia
283525|NCT01571687|blood coagulation disorders
283526|NCT01571687|cell-derived microparticles
283527|NCT01571687|oxidative stress
283528|NCT01571687|N-Acetylcystein
283529|NCT01571687|vitamins
283530|NCT01571674|Cervical
283531|NCT01571674|Clinical Prediction Rule
283532|NCT01571674|Exercise
283533|NCT01571674|Manipulation
283534|NCT01571674|Manual therapy
283535|NCT01571674|Mobilization
283536|NCT01571674|Physical Therapy
283537|NCT01571674|Prognosis
283538|NCT01571674|Shoulder pain
283539|NCT01571674|Thoracic
283540|NCT01571661|KGT-1142
283541|NCT01571661|safety
283542|NCT01571661|pharmacokinetics
283543|NCT01571661|single-dose escalation
283544|NCT01571661|tolerability
283545|NCT01571635|Beta-Thalassaemia
283546|NCT01571622|Whey protein
283547|NCT01571622|type 2 diabetes
283548|NCT01571596|XLH
283549|NCT01571583|Chronic HCV infection
283550|NCT01571583|Genotype 1 chronic HCV
283551|NCT01571583|Liver transplantation
283552|NCT01571583|Hepatitis C
283553|NCT01571583|Hep C
283554|NCT01571583|HCV
283555|NCT01571583|Telaprevir
283556|NCT01571583|Pegylated-Interferon-alfa-2a
283557|NCT01571583|Ribavirin
283558|NCT01571570|Healthy volunteers
283559|NCT01571570|Food effect
283560|NCT01571570|Capsule
283561|NCT01571570|Formulations
283562|NCT01571570|Liquid formulation
283563|NCT01571570|Concept K
283564|NCT01571570|Concept L
283565|NCT01571570|Oral suspension
283566|NCT01571570|Oral solution
283567|NCT01571570|TMC435HPC1002
283568|NCT01571570|TMC435
283569|NCT01571570|HPC
283570|NCT01571518|G-CSF
283571|NCT01571518|neutropenia
283572|NCT01571518|TAC
283573|NCT01571505|Oral vaccines
283574|NCT01571505|Vaccine Responsiveness
283575|NCT01571505|Tropical Enteropathy
283576|NCT01571492|Postoperative Pain
283577|NCT01571492|Nerve block
283578|NCT01571492|Total Hip Arthroplasty
283579|NCT01571492|Postoperative analgesia
283580|NCT01571492|Lumbar Plexus Catheters
283581|NCT01571492|L2 Paravertebral Catheters
283582|NCT01571479|laparoscopic cholecystectomy
283583|NCT01571479|mini-instrument
283584|NCT01571466|HIV Seronegativity
283585|NCT01571466|HIV Preventive Vaccine
283586|NCT01571453|MDD
283587|NCT01571440|Bone
283588|NCT01571440|adolescents
283589|NCT01571440|fiber
283590|NCT01571440|healthy
283591|NCT01571440|boys
283592|NCT01571440|girls
283593|NCT01571440|camp
283594|NCT01571440|calcium
283595|NCT01571427|Behavioral intervention
283596|NCT01571427|Social engagement
283597|NCT01571427|Conversational engagement
283598|NCT01571427|Social network
283599|NCT01571427|Cognitive Reserve
283600|NCT01571427|Alzheimer's disease
283601|NCT01571401|Kidney cancer survivors
283602|NCT01571401|Randomized Controlled Trial
283603|NCT01571401|Physical Activity
283604|NCT01571401|Theory of Planned Behaviour
283605|NCT01571401|Quality of life
283606|NCT01571388|dacomitinib
283607|NCT01571388|PF-00299804
283608|NCT01571388|hepatic impairment
283609|NCT01571388|pharmacokinetics
283610|NCT01571375|Traumatic Brain Injury
283611|NCT01571375|HEMS
283612|NCT01571375|Out-of-hospital
283613|NCT01571375|Finland
283614|NCT01571362|oxycodone
283615|NCT01571362|naltrexone
283616|NCT01571362|chronic pain
283617|NCT01571362|low back pain
283618|NCT01571349|rebalanced hemostasis
283619|NCT01571349|idiopathic thrombocytopenic purpura
283620|NCT01571349|coagulation status
283621|NCT01571323|post partum haemorrhage at cesarean section
283622|NCT01571297|Diabetes Mellitus
283623|NCT01571297|Delayed Gastric Emptying
283624|NCT01571297|Gastroparesis
283625|NCT01571297|Gastrointestinal Motility Disorder
283626|NCT01571271|biliary
283627|NCT01571271|lithotripsy
283628|NCT01571271|gall stones
283629|NCT01571271|bile duct
283630|NCT01571271|Biliary stones
283631|NCT01571258|SMS
283632|NCT01571258|Obesity
283633|NCT01571258|Text Messaging
283634|NCT01571258|Intervention
283635|NCT01571258|Mobile Phone
283636|NCT01571245|Heart rate variability
283637|NCT01571245|Attentional Bias
283638|NCT01571232|Macular Edema
283639|NCT01571232|DME
283640|NCT01571232|PDR
283641|NCT01571232|NPDR
283642|NCT01571232|Ozurdex
283643|NCT01571232|Dexamethasone
283644|NCT01571232|Avastin
283645|NCT01571232|Bevacizumab
283646|NCT01571219|RA
283647|NCT01571219|Biosimilar
283648|NCT01571206|AS
283649|NCT01571206|Biosimilar
283650|NCT01571180|Obesity
283651|NCT01571180|Gastric bypass
283652|NCT01571180|Medication
283653|NCT01571180|Medication counseling
283654|NCT01571180|Dietary pattern
283655|NCT01571180|Follow-up of patients
283656|NCT01571167|Methamphetamine
283657|NCT01571167|Chantix
283658|NCT01571167|Varenicline
283659|NCT01571141|HPV
283660|NCT01571141|polyhexamethylene biguanide
283661|NCT01571141|intraepithelial lesions
283662|NCT01571141|regression rate
283663|NCT01571128|HIV
283664|NCT01571128|Prevention & Control
283665|NCT01571128|Intervention Studies
283666|NCT01571128|Adolescent
283667|NCT01571128|Gender
283668|NCT01571128|Combination prevention
283669|NCT01571128|Pre-Exposure Prophylaxis
283670|NCT01571128|Cash Transfer
283671|NCT01571128|Medical Male Circumcision
283672|NCT01571128|HIV Testing
283673|NCT01571128|Mobile Health
283674|NCT01571115|insomnia
283675|NCT01571115|resistance physical exercise
283676|NCT01571115|stretching
283677|NCT01571089|Dialectical behavior therapy
283678|NCT01571089|cognitive behavioral therapy
283679|NCT01571089|emotion regulation
283680|NCT01571089|emotion dysregulation
283681|NCT01571089|anxiety disorders
283682|NCT01571089|skills training
283683|NCT01571076|PGS
283684|NCT01571076|CGH
283685|NCT01571076|Aneuploidy
283686|NCT01571076|Advanced maternal age
283687|NCT01571076|Male factor
283688|NCT01571050|toothpastes
283689|NCT01571050|dental fluorosis
283690|NCT01571050|fluoride
283691|NCT01571050|bioavailability
283692|NCT01571037|mechanical circulatory assist device
283693|NCT01571024|FOLFOX6
283694|NCT01571024|BKM120
283695|NCT01571024|Advanced Solid Tumors
283696|NCT01571024|Metastatic
283697|NCT01571024|Colorectal Cancer
283698|NCT01571024|Pancreatic Cancer
283699|NCT01571011|Adolescent
283700|NCT01571011|Randomized Trial
283701|NCT01571011|Internet
283702|NCT01571011|Depressive Disorder
283703|NCT01571011|Primary Care
283704|NCT01571011|Prevention
283705|NCT01570998|Disease-Free Survival
283706|NCT01570998|Female
283707|NCT01570998|Humans
283708|NCT01570998|Intraoperative Care
283709|NCT01570998|Mastectomy Segmental
283710|NCT01570998|Middle Aged
283711|NCT01570998|Neoplasm Recurrence Local
283712|NCT01570998|Radiotherapy Dosage
283713|NCT01570998|Radiotherapy Adjuvant
283714|NCT01570985|shoulder capsulitis
283715|NCT01570985|frozen shoulder
283716|NCT01570985|adhesive capsulitis
283717|NCT01570985|distension
283718|NCT01570985|corticosteroid injection
283719|NCT01570985|intraarticular injection
283720|NCT01570972|schizophrenia
283721|NCT01570972|schizoaffective disorder
283722|NCT01570972|bipolar disorder with psychotic features
283723|NCT01570972|major depression with psychotic features
283724|NCT01570972|recent-onset psychosis
283725|NCT01570972|first-episode psychosis
283726|NCT01570972|cognitive behavioral therapy
283727|NCT01570972|multifamily group psychoeducation
283728|NCT01570946|Lifestyle changes to prevent type 2 diabetes
283729|NCT01570933|cardio-pulmonary bypass
283730|NCT01570920|Activity limitations
283731|NCT01570920|restriction of participation
283732|NCT01570920|chronic stroke survival
283733|NCT01570920|physical activity
283734|NCT01570920|walking
283735|NCT01570881|postoperative delirium
283736|NCT01570881|melatonin
283737|NCT01570881|sevoflurane
283738|NCT01570868|Leukemia
283739|NCT01570868|Chronic Myeloid Leukemia
283740|NCT01570868|CML
283741|NCT01570868|Chronic Phase
283742|NCT01570868|Cytogenetic response
283743|NCT01570868|CCyR
283744|NCT01570868|Major molecular response
283745|NCT01570868|MMR
283746|NCT01570868|Complete molecular response
283747|NCT01570868|CMR
283748|NCT01570868|Ponatinib
283749|NCT01570868|AP24534
283750|NCT01570855|Lung cancer
283751|NCT01570855|chemosensitivity
283752|NCT01570842|Gastroesophageal reflux disease
283753|NCT01570842|GERD
283754|NCT01570842|Barrett's esophagus
283755|NCT01570816|spinal cord injury
283756|NCT01570816|partial paralysis
283757|NCT01570816|gait correction
283758|NCT01570816|functional electrical stimulation
283759|NCT01570816|paraplegia
283760|NCT01570816|tetraplegia
283761|NCT01570803|peripheral arterial disease,
283762|NCT01570803|atherosclerosis,
283763|NCT01570803|nitinol,
283764|NCT01570803|stents
283765|NCT01570777|Resistant hypertension
283766|NCT01570777|Renal denervation
283767|NCT01570777|Standardized medication regimen
283768|NCT01570777|Endovascular
283769|NCT01570777|Primary hypertension
283770|NCT01570777|Cardiovascular diseases
283771|NCT01570777|Vascular diseases
283772|NCT01570764|Systemic sclerosis
283773|NCT01570764|Interstitial lung disease
283774|NCT01570764|Worsening
283775|NCT01570764|Cyclophosphamide
283776|NCT01570764|Intravenous
283777|NCT01570738|sleep disorders
283778|NCT01570738|sleep apnea
283779|NCT01570738|ambulatory device
283780|NCT01570738|polysomnography
283781|NCT01570738|WatchPAT
283782|NCT01570725|Immersive virtual reality
283783|NCT01570725|e-health
283784|NCT01570725|surgery
283785|NCT01570725|anxiety
283786|NCT01570725|relaxation
283787|NCT01570725|Patients who undergo ambulatory surgical operations
283788|NCT01570699|Cross-sectional observational study
283789|NCT01570699|COMT polymorphism
283790|NCT01570699|Opiate-users
283791|NCT01570699|Opiate dependence
283792|NCT01570686|Food effect, hypertension, aliskiren
283793|NCT01570673|quality of life
283794|NCT01570673|urinary bladder
283795|NCT01570673|symptoms
283796|NCT01570673|children
283797|NCT01570634|Clostridium difficile
283798|NCT01570634|infection
283799|NCT01570634|diarrhea
283800|NCT01570634|cramping
283801|NCT01570621|achalasia
283802|NCT01570621|peroral endoscopic myotomy
283803|NCT01570621|LES pressure
283804|NCT01570621|postoperative complication
283805|NCT01570621|symptom relief
283806|NCT01570621|esophageal barium
283807|NCT01570608|Ranibizumab
283808|NCT01570608|Bevacizumab
283809|NCT01570608|Verteporfin
283810|NCT01570608|age-related macular degeneration
283811|NCT01570595|Tobacco Use Cessation
283812|NCT01570595|Tobacco Cessation
283813|NCT01570595|Tobacco Use Disorder
283814|NCT01570595|Tobacco Dependence
283815|NCT01570595|Tobacco-Use Disorder
283816|NCT01570595|Virus, Human Immunodeficiency
283817|NCT01570582|recurrent ovarian
283818|NCT01570582|ECG
283819|NCT01570582|GOG performance
283820|NCT01570582|Hematologic g
283821|NCT01570582|Blood chemistry and urinalysis h
283822|NCT01570569|Volunteers
283823|NCT01570556|Hemodialysis
283824|NCT01570556|Inflammation
283825|NCT01570556|Bacteriuria
283826|NCT01570556|Interleukin 6
283827|NCT01570556|C reactive protein
283828|NCT01570543|implants
283829|NCT01570543|knee implants
283830|NCT01570543|hip implants
283831|NCT01570543|metallic implants
283832|NCT01570504|Strongyloidiasis
283833|NCT01570504|Strongyloides stercoralis
283834|NCT01570504|Ivermectin
283835|NCT01570465|AML
283836|NCT01570465|adult
283837|NCT01570465|AML1310 GIMEMA study
283838|NCT01570452|matrilysin
283839|NCT01570452|MMP-7
283840|NCT01570452|colorectal cancer
283841|NCT01570452|adenoma
283842|NCT01570452|lymph nodes
283843|NCT01570426|Bipolar disorder
283844|NCT01570426|Mood disorders
283845|NCT01570426|ADHD
283846|NCT01570426|Attention Deficit Disorder with Hyperactivity
283847|NCT01570426|Attention Deficit Disorder without Hyperactivity
283848|NCT01570426|Anxiety disorders
283849|NCT01570426|Generalized anxiety disorder
283850|NCT01570426|Magnetic resonance imaging
283851|NCT01570426|Mental disorders
283852|NCT01570426|Mental disorders diagnosed in childhood
283853|NCT01570426|affective neuroscience
283854|NCT01570426|emotion
283855|NCT01570426|MRI
283856|NCT01570426|fMRI
283857|NCT01570426|neurocognitive tasks
283858|NCT01570426|imaging
283859|NCT01570426|Healthy controls
283860|NCT01570426|typical development
283861|NCT01570400|social phobia
283862|NCT01570400|social anxiety
283863|NCT01570400|cognitive bias modification
283864|NCT01570374|Cognitive behavioral therapy
283865|NCT01570374|Internet
283866|NCT01570374|Anxiety
283867|NCT01570374|Generalized anxiety disorder
283868|NCT01570361|Atrial Fibrillation
283869|NCT01570361|Arrhythmias, Cardiac
283870|NCT01570361|Heart Diseases
283871|NCT01570361|Cardiovascular Diseases
283872|NCT01570361|Pathologic Processes
283873|NCT01570348|Crohn's Disease
283874|NCT01570348|Allogeneic bone marrow transplantation
283875|NCT01570348|Hematopoietic cell transplantation
283876|NCT01570335|SBAR,
283877|NCT01570335|SAQ,
283878|NCT01570335|Team Resource Management
283879|NCT01570322|Dementia - Alzheimer - Quality of life
283880|NCT01570309|vitamin D,
283881|NCT01570309|vitamin D deficiency
283882|NCT01570309|coronary artery disease
283883|NCT01570309|ergocalciferol
283884|NCT01570309|endothelial function
283885|NCT01570309|adhesion molecules
283886|NCT01570309|inflammation
283887|NCT01570309|IL-12
283888|NCT01570309|interferon-gamma
283889|NCT01570309|CXCL-10
283890|NCT01570309|reactive hyperemia peripheral arterial tonometry
283891|NCT01570309|endothelial dysfunction
283892|NCT01570309|cytokines
283893|NCT01570309|chemokines
283894|NCT01570296|Advanced Non-Small Cell Lung Cancer
283895|NCT01570296|tumors harbor molecular
283896|NCT01570296|alterations of PI3K pathway
283897|NCT01570296|known to overexpress EGFR
283898|NCT01570283|post allogeneic hematopoietic stem cell transplant
283899|NCT01570283|cytotoxic T lymphocytes
283900|NCT01570283|Cytomegalovirus
283901|NCT01570283|CMV
283902|NCT01570283|adenovirus
283903|NCT01570283|Epstein-Barr virus
283904|NCT01570283|EBV
283905|NCT01570283|Human polyomavirus type I
283906|NCT01570283|BK virus
283907|NCT01570283|Human herpesvirus 6
283908|NCT01570283|HHV6
283909|NCT01570270|Hypercholesterolemia
283910|NCT01570270|Endocannabinoids
283911|NCT01570257|normal pressure hydrocephalus
283912|NCT01570257|ventriculoperitoneal shunt
283913|NCT01570257|overdrainage
283914|NCT01570257|subdural effusion
283915|NCT01570231|remote ischemic preconditioning
283916|NCT01570231|octogenarian
283917|NCT01570231|intracranial arterial stenosis
283918|NCT01570231|stroke recurrence
283919|NCT01570218|breast cancer
283920|NCT01570218|gynecological cancer
283921|NCT01570218|radiotherapy
283922|NCT01570218|fatigue
283923|NCT01570218|musicotherapy
283924|NCT01570192|gram negative pathogens
283925|NCT01570192|Pseudomonas aeruginosa
283926|NCT01570192|Acinetobacter
283927|NCT01570192|HCAP
283928|NCT01570192|VABP
283929|NCT01570192|HABP
283930|NCT01570179|bariatric surgery
283931|NCT01570179|residual paralysis
283932|NCT01570179|surgical conditions
283933|NCT01570166|Hepatocellular Carcinoma
283934|NCT01570166|RFA
283935|NCT01570166|HR
283936|NCT01570127|Individualized Acupuncture
283937|NCT01570127|Standardized Acupuncture
283938|NCT01570127|Low Back Pain
283939|NCT01570127|Randomized Controlled Trial
283940|NCT01570114|Covered metallic stent
283941|NCT01570114|colon
283942|NCT01570114|benign stricture
283943|NCT01570075|Hepatocellular Carcinoma
283944|NCT01570075|RFA
283945|NCT01570075|HR
283946|NCT01570062|Inflammation
283947|NCT01570062|Pathologic Processes
283948|NCT01570049|Single arm
283949|NCT01570049|Open label
283950|NCT01570049|Bendamustine HCl
283951|NCT01570049|Non-hodgkin's lymphoma
283952|NCT01570036|stage I breast cancer
283953|NCT01570036|stage II breast cancer
283954|NCT01570036|stage IIIA breast cancer
283955|NCT01570036|stage IIIB breast cancer
283956|NCT01570036|stage IIIC breast cancer
283957|NCT01570036|male breast cancer
283958|NCT01570023|Deglutition
283959|NCT01570023|Exercise
283960|NCT01569997|Dementia
283961|NCT01569997|emergency hospitalization
283962|NCT01569997|nursing home
283963|NCT01569997|multidisciplinary meeting
283964|NCT01569997|cognitive decline
283965|NCT01569997|disability
283966|NCT01569997|residents
283967|NCT01569997|facilities
283968|NCT01569997|long term care unit
283969|NCT01569997|health policy
283970|NCT01569997|general practitioner
283971|NCT01569997|prevention
283972|NCT01569984|Colorectal
283973|NCT01569971|Transition Program
283974|NCT01569971|Perspectives
283975|NCT01569932|chemobrain, chemotherapy, cognitive impairments, fcMRI, neurocognitive Assessments
283976|NCT01569919|Phase II
283977|NCT01569919|Single arm
283978|NCT01569919|Vaccine
283979|NCT01569906|Atopic Dermatitis
283980|NCT01569893|Telemonitoring
283981|NCT01569893|Telemedicine
283982|NCT01569893|Diabetes mellitus
283983|NCT01569880|Blood gas response
283984|NCT01569880|Exercise
283985|NCT01569880|Gas exchange
283986|NCT01569880|Hypoxia altitude simulation test
283987|NCT01569880|Pulmonary function
283988|NCT01569828|LCZ696
283989|NCT01569828|pharmacokinetics
283990|NCT01569815|Renal Impairment,
283991|NCT01569815|LCZ696
283992|NCT01569802|breast cancer screening
283993|NCT01569802|tomosynthesis
283994|NCT01569802|FFDM
283995|NCT01569789|cytokines
283996|NCT01569789|inflammation
283997|NCT01569789|vagus nerve
283998|NCT01569789|TNF
283999|NCT01569776|Cow milk allergy
284000|NCT01569776|CMA
284001|NCT01569763|endometrial ablation
284002|NCT01569750|CD20-positive B-cell non-Hodgkin lymphoma
284003|NCT01569750|Diffuse large B-cell lymphoma
284004|NCT01569750|Mantle cell lymphoma
284005|NCT01569750|Follicular lymphoma
284006|NCT01569750|Ibrutinib
284007|NCT01569750|R-CHOP
284008|NCT01569750|Rituximab
284009|NCT01569750|Cyclophosphamide
284010|NCT01569750|Doxorubicin
284011|NCT01569750|Vincristine
284012|NCT01569750|Prednisone
284013|NCT01569737|ella
284014|NCT01569737|ulipristal acetate
284015|NCT01569737|pregnancy
284016|NCT01569737|emergency contraception
284017|NCT01569724|hypertriglyceridemia
284018|NCT01569724|bexarotene
284019|NCT01569711|chronic and resistant major depressive disorder
284020|NCT01569711|deep brain stimulation
284021|NCT01569698|pediatric
284022|NCT01569698|acute renal failure
284023|NCT01569698|acute extra renal replacement therapy
284024|NCT01569698|Intermittent Hemodialysis
284025|NCT01569698|Continuous Renal Replacement Therapies
284026|NCT01569698|Peritoneal Dialysis
284027|NCT01569685|PTSD
284028|NCT01569685|Traumatic Stress
284029|NCT01569685|Depressions
284030|NCT01569685|Refugees
284031|NCT01569672|Navigator
284032|NCT01569659|Schizophrenia
284033|NCT01569659|Refractory
284034|NCT01569659|Treatment resistant
284035|NCT01569659|Lurasidone
284036|NCT01569646|monocytes
284037|NCT01569646|culprit vessels
284038|NCT01569620|Colorectal Cancer Screening
284039|NCT01569620|CRC
284040|NCT01569620|Screening Colonoscopy
284041|NCT01569620|Hispanics
284042|NCT01569620|Latinos
284043|NCT01569607|Neurophysiology
284044|NCT01569607|Transcranial Magnetic Stimulation (TMS)
284045|NCT01569607|Neurology
284046|NCT01569607|Stroke
284047|NCT01569607|Physical Medicine and Rehabilitation
284048|NCT01569581|Human Enterovirus 71 (EV71)
284049|NCT01569581|Hand, Foot and Mouth Disease (HFMD)
284050|NCT01569581|Inactivated Vaccine
284051|NCT01569581|Human Diploid cell (KMB17)
284052|NCT01569581|Adverse reactions associated with vaccine
284053|NCT01569581|Efficacy
284054|NCT01569568|Neuroimaging
284055|NCT01569568|MRI
284056|NCT01569568|Urea cycle
284057|NCT01569568|hyperammonemia
284058|NCT01569568|cognitive function
284059|NCT01569568|ornithine transcarbamylase deficiency
284060|NCT01569516|Alzheimer's Disease
284061|NCT01569516|Octohydroaminoacridine Succinate
284062|NCT01569503|Crohn's Disease
284063|NCT01569503|VNS
284064|NCT01569503|vagus nerve stimulation
284065|NCT01569503|inflammation
284066|NCT01569503|Inflammatory bowel diseases
284067|NCT01569503|TNF
284068|NCT01569464|Rotigotine
284069|NCT01569464|Restless Legs Syndrome
284070|NCT01569464|Neupro®
284071|NCT01569451|Multiple Sclerosis
284072|NCT01569451|Glatiramer Acetate
284073|NCT01569451|Rituximab
284074|NCT01569451|Relapsing forms of Multiple Sclerosis
284075|NCT01569451|Relapsing Multiple Sclerosis
284076|NCT01569425|PCOS
284077|NCT01569399|Alcohol dependance
284078|NCT01569399|rTMS
284079|NCT01569399|craving
284080|NCT01569399|alcohol consumption
284081|NCT01569386|pulse wave velocity
284082|NCT01569386|low intensity physical activity
284083|NCT01569386|hemiplegia
284084|NCT01569373|Allogeneic stem cell transplant
284085|NCT01569373|Graft versus Host Disease
284086|NCT01569373|GVHD
284087|NCT01569360|Spinal cord injury
284088|NCT01569360|Tetraplegia
284089|NCT01569360|Paraplegia
284090|NCT01569360|Respiratory function
284091|NCT01569360|Corset
284092|NCT01569347|Cocaine
284093|NCT01569347|Cocaine-induced psychosis
284094|NCT01569347|Genetic
284095|NCT01569347|Clinical
284096|NCT01569347|Biological
284224|NCT01568840|Posture
284225|NCT01568840|Muscle Stretching Exercises
284097|NCT01569334|identify early non invasive markers that index the endothelial lesion/ regeneration potential in association with CAV in heart transplanted recipients (HTR)
284098|NCT01569308|Cardiac output
284099|NCT01569308|Pulse pressure variation
284100|NCT01569308|Fluid responsiveness
284101|NCT01569308|Low tidal volume
284102|NCT01569295|Zydelig
284103|NCT01569295|CLL
284104|NCT01569295|CAL 101
284105|NCT01569295|CAL-101
284106|NCT01569295|GS 1101
284107|NCT01569295|GS-1101
284108|NCT01569295|PI3K
284109|NCT01569295|Rituxan
284110|NCT01569295|Rituximab
284111|NCT01569295|Bendamustine
284112|NCT01569295|Leukemia
284113|NCT01569295|idelalisib
284114|NCT01569282|Surgical bypass
284115|NCT01569282|Hepaticojejunostomy
284116|NCT01569282|Gastrojejunostomy
284117|NCT01569282|Biliary stent
284118|NCT01569282|Enteral stent
284119|NCT01569269|chemotherapy induced peripheral neuropathy
284120|NCT01569269|cancer
284121|NCT01569269|psychological distress
284122|NCT01569269|mindfulness
284123|NCT01569269|complementary and alternative
284124|NCT01569243|Diabetes mellitus
284125|NCT01569243|Text messaging
284126|NCT01569243|Physical activity
284127|NCT01569230|Knee osteoarthritis
284128|NCT01569230|acupuncture
284129|NCT01569230|sham acupuncture
284130|NCT01569217|Diaphragm
284131|NCT01569217|Abdomen
284132|NCT01569217|Breathing pattern
284133|NCT01569217|dyspnea
284134|NCT01569191|Ocular allergy
284135|NCT01569191|Tear supplement
284136|NCT01569191|Cold compress
284137|NCT01569178|stem cells
284138|NCT01569178|acute myocardial infarction
284139|NCT01569178|heart failure
284140|NCT01569178|heart attack
284141|NCT01569178|bone marrow
284142|NCT01569178|intracoronary reinfusion
284143|NCT01569178|bone marrow derived mononuclear cells
284144|NCT01569178|Left ventricular function improvement
284145|NCT01569178|mortality
284146|NCT01569165|Acidogenicity
284147|NCT01569165|Acidulated phosphate fluoride
284148|NCT01569165|dental plaque
284149|NCT01569165|water rinsing
284150|NCT01569139|Validation
284151|NCT01569139|Concordance
284152|NCT01569139|Myocardial infarction
284153|NCT01569139|Myocardial Ischaemia National Audit Project
284154|NCT01569139|General Practice Research Database
284155|NCT01569139|Hospital Episode Statistics
284156|NCT01569139|ONS mortality
284157|NCT01569113|ella
284158|NCT01569113|ellaOne
284159|NCT01569113|quickstart
284160|NCT01569113|contraception
284161|NCT01569113|combined oral pill
284162|NCT01569113|microgynon
284163|NCT01569087|empegfilgrastim
284164|NCT01569087|pegylated filgrastim
284165|NCT01569087|neutropenia
284166|NCT01569087|febrile neutropenia
284167|NCT01569087|chemotherapy-associated neutropenia
284168|NCT01569087|breast cancer
284169|NCT01569087|docetaxel
284170|NCT01569087|doxorubicin
284171|NCT01569074|Rheumatoid Arthritis
284172|NCT01569061|overactive bladder
284173|NCT01569061|laser therapy
284174|NCT01569061|urinary incontinence
284175|NCT01569061|urinary urgency
284176|NCT01569035|oligohudramnios
284177|NCT01569035|oral anti coagulant
284178|NCT01569035|Dopplar ultrasound
284179|NCT01569022|post traumatic stress disorder
284180|NCT01569022|continuous positive airway pressure
284181|NCT01569022|oral appliance
284182|NCT01569009|Bronchiectasis
284183|NCT01569009|Physical activity
284184|NCT01569009|Activity monitor
284185|NCT01569009|Pedometer
284186|NCT01568996|atypical nevi
284187|NCT01568996|melanoma
284188|NCT01568996|sulforaphane
284189|NCT01568996|broccoli
284190|NCT01568996|lesions
284191|NCT01568996|STAT1
284192|NCT01568996|STAT3
284193|NCT01568970|rehabilitation
284194|NCT01568970|return to work
284195|NCT01568970|sick leave
284196|NCT01568957|Gait
284197|NCT01568957|Dual-task
284198|NCT01568957|Obstacle avoidance
284199|NCT01568957|Attention allocation
284200|NCT01568944|periodontal
284201|NCT01568944|disease
284202|NCT01568944|dendritic
284203|NCT01568944|cells
284204|NCT01568944|antibiotics
284205|NCT01568931|thrombectomy
284206|NCT01568905|smoker
284207|NCT01568905|smoking
284208|NCT01568905|nicotine levels
284209|NCT01568905|tobacco
284210|NCT01568905|nicotine
284211|NCT01568892|ART-experienced
284212|NCT01568892|GSK1349572
284213|NCT01568892|Integrase inhibitor resistance
284214|NCT01568892|Dolutegravir
284215|NCT01568879|Recurrent gout
284216|NCT01568879|Tophaceous gout
284217|NCT01568879|Gout flares
284218|NCT01568879|Arthritis
284219|NCT01568879|Joint Diseases
284220|NCT01568879|Rheumatic Diseases
284221|NCT01568866|multiple myeloma
284222|NCT01568866|relapsed multiple myeloma
284223|NCT01568840|Physical Therapy Modalities
284226|NCT01568840|Dyskinesias
284227|NCT01568840|Neck pain
284228|NCT01568814|colonoscopy
284229|NCT01568814|bowel preparation
284230|NCT01568814|polyethylene glycol
284231|NCT01568814|low residue meal
284232|NCT01568801|Integrated Services
284233|NCT01568801|Health Services for the Elderly
284234|NCT01568801|Community Services
284235|NCT01568788|Respiratory Tract Infections; Orthomyxoviridae Infections
284236|NCT01568775|End Stage Renal Disease
284237|NCT01568775|Dialysis
284238|NCT01568775|aliskiren
284239|NCT01568775|SPP100A
284240|NCT01568762|Asthma
284241|NCT01568762|VAK694
284242|NCT01568762|QAX576
284243|NCT01568762|QBX258
284244|NCT01568762|pharmacokinetics
284245|NCT01568749|otc
284246|NCT01568749|Analgesia
284247|NCT01568749|Paracetamol
284248|NCT01568736|Hyper IgD Syndrome (HIDS)
284249|NCT01568736|Mevalonate Kinase Deficiency (MKD)
284250|NCT01568723|Barrett's esophagus
284251|NCT01568723|high grade dysplasia
284252|NCT01568723|ablation
284253|NCT01568723|radiofrequency ablation
284254|NCT01568723|esophageal cancer
284255|NCT01568710|Blood Flow
284256|NCT01568710|Endothelium
284257|NCT01568710|Nitric Oxide
284258|NCT01568710|Oximetry
284259|NCT01568710|Laser Doppler
284260|NCT01568710|Sickle Cell Disease
284261|NCT01568697|Oral Microbiome
284262|NCT01568697|Periodontitis
284263|NCT01568697|Oral Mucosal Immunity
284264|NCT01568697|Oral Infection
284265|NCT01568697|Immune Disorder
284266|NCT01568697|Periodontal Disease
284267|NCT01568697|Gum Disease
284268|NCT01568697|Healthy Volunteer
284269|NCT01568697|HV
284270|NCT01568684|Magnetic Resonance Spectroscopy
284271|NCT01568684|Depression
284272|NCT01568684|Depression Treatment
284273|NCT01568684|Major Depression
284274|NCT01568684|Unipolar Depression
284275|NCT01568671|Adult
284276|NCT01568671|Body Fat Distribution
284277|NCT01568671|Healthy
284278|NCT01568671|Metabolic Rate
284279|NCT01568671|Thermophysiology
284280|NCT01568671|Brown Fat
284281|NCT01568671|Healthy Volunteer
284282|NCT01568671|HV
284283|NCT01568658|Hereditary Myopathies
284284|NCT01568658|Neuropathology
284285|NCT01568658|Muscular Dystrophy
284286|NCT01568658|Inherited Neuromuscular Condition
284287|NCT01568658|Inherited Neuropathy
284288|NCT01568658|Inherited Myopathy
284289|NCT01568658|Hereditary Spastic Paraplegia
284290|NCT01568658|Healthy Volunteer
284291|NCT01568658|HV
284292|NCT01568645|Sickle Cell Anemia
284293|NCT01568645|Tyrosine Kinase Inhibitor
284294|NCT01568645|Platelet Derived Growth Factor
284295|NCT01568645|Beta Adrenergic Receptor Blocker
284296|NCT01568645|Pulmonary Vascular Disease
284297|NCT01568645|Sickle Cell Disease
284298|NCT01568645|Pulmonary Hypertension
284299|NCT01568632|Dose Limiting Toxicity
284300|NCT01568632|Maximum Tolerated Dose
284301|NCT01568632|Telomerase Inhibitor
284302|NCT01568632|Safety
284303|NCT01568632|Solid Tumor
284304|NCT01568632|Lymphoma
284305|NCT01568619|cardiopulmonary exercise test
284306|NCT01568619|cardiac output
284307|NCT01568606|Heart Failure
284308|NCT01568606|Obesity
284309|NCT01568606|Implantable Cardioverter Defibrillator
284310|NCT01568580|Hemophilia A
284311|NCT01568580|Factor VIII
284312|NCT01568580|Recombinant
284313|NCT01568567|safety
284314|NCT01568567|tolerance
284315|NCT01568567|lactobacillus Reuteri
284316|NCT01568541|children
284317|NCT01568541|dentifrice
284318|NCT01568541|fluoride
284319|NCT01568541|dental fluorosis
284320|NCT01568515|HPV vaccine
284321|NCT01568515|Vaccine adherence
284322|NCT01568515|Vaccine utilization
284323|NCT01568515|Electronic Messaging
284324|NCT01568502|dobutamine stress
284325|NCT01568502|inducible ischemia
284326|NCT01568502|CAD
284327|NCT01568476|Regional anesthesia
284328|NCT01568476|Sciatic nerve block
284329|NCT01568476|foot surgery
284330|NCT01568476|ankle surgery
284331|NCT01568476|Interneural local anesthetic
284332|NCT01568463|Inter-scalene Block
284333|NCT01568463|Regional Anesthesia
284334|NCT01568463|shoulder surgeries
284335|NCT01568450|Oxycodone, controlled release formulation
284336|NCT01568437|Laparoscopic gastric-bypass surgery
284337|NCT01568437|TAP block
284338|NCT01568424|Heart Failure
284339|NCT01568424|Right Ventricular Failure
284340|NCT01568424|Levitronix
284341|NCT01568411|None - normal volunteers
284342|NCT01568398|Gastric or duodenal ulcer
284343|NCT01568385|Gastric or duodenal ulcer
284344|NCT01568372|pediatric
284345|NCT01568372|tonsillectomy
284346|NCT01568372|pain management
284347|NCT01568372|nurse follow-up
284348|NCT01568346|Newly diagnosed
284349|NCT01568346|Early stage
284350|NCT01568333|Decitabine
284351|NCT01568333|Immune thrombocytopenia
284352|NCT01568320|Aorta
284353|NCT01568320|Thoracic
284354|NCT01568320|Aortic dissection
284355|NCT01568320|Rupture
284356|NCT01568320|Type B
284357|NCT01568320|DeBakey type III
284358|NCT01568320|Endovascular
284359|NCT01568307|Major depressive disorder
284360|NCT01568307|Serotonin transporter
284361|NCT01568307|Sympathetic nervous system activation
284362|NCT01568307|Cardiovascular risk factors
284363|NCT01568307|Serotonin re-uptake inhibitor
284364|NCT01568281|Bioequivalence
284365|NCT01568281|pharmacokinetics
284366|NCT01568281|safety
284367|NCT01568281|anastrozole
284368|NCT01568281|Arimidex
284369|NCT01568281|Japanese
284370|NCT01568281|healthy subject
284371|NCT01568268|palonosetron
284372|NCT01568268|postoperative nausea and vomiting
284373|NCT01568255|myopathic symptoms
284374|NCT01568242|Cataract
284375|NCT01568242|Phacoemulsification
284376|NCT01568242|Temperature
284377|NCT01568242|Vitreous
284378|NCT01568229|schizophrenia negative symptoms
284379|NCT01568216|schizophrenia negative symptoms
284380|NCT01568203|single dose, safety, healthy subjects, schizoaffective disorder, AMG 579
284381|NCT01568190|House dust mites sensitisation
284382|NCT01568177|MCD
284383|NCT01568164|Epicardial Catheter-based Restoration
284384|NCT01568164|Surgical/Left Ventricular Reconstruction
284385|NCT01568164|Ventricular Remodeling
284386|NCT01568164|Dor
284387|NCT01568151|Colorectal Cancer
284388|NCT01568151|Screening
284389|NCT01568151|Education
284390|NCT01568151|Testing
284391|NCT01568138|Ventricular Remodeling
284392|NCT01568112|BG00012
284393|NCT01568112|gastrointestinal events
284394|NCT01568112|flushing events
284395|NCT01568112|dose titration
284396|NCT01568112|pre-medication
284397|NCT01568112|aspirin
284398|NCT01568073|Parkinson
284399|NCT01568073|PD
284400|NCT01568073|Wearing-off
284401|NCT01568073|Levodopa/DDCI
284402|NCT01568060|Safety
284403|NCT01568060|Infanrix-IPV
284404|NCT01568060|Post-marketing surveillance
284405|NCT01568060|Diphtheria, tetanus, pertussis and poliomyelitis
284406|NCT01568047|Parkinson Disease
284407|NCT01568047|BIA 9-1067
284408|NCT01568034|Parkinson's Disease
284409|NCT01568034|BIA 9-1067
284410|NCT01567995|eczematous
284411|NCT01567995|dermatitis
284412|NCT01567982|tDCS
284413|NCT01567982|brain stimulation
284414|NCT01567982|addiction
284415|NCT01567982|substance dependence
284416|NCT01567982|craving
284417|NCT01567982|cognition
284418|NCT01567969|mental health services
284419|NCT01567969|child behavior disorders
284420|NCT01567969|child psychiatry
284421|NCT01567956|Ulcerative colitis
284422|NCT01567943|alcohol abuse
284423|NCT01567943|drug abuse
284424|NCT01567943|schizophrenia
284425|NCT01567943|bipolar disorder
284426|NCT01567943|major depressive disorder
284427|NCT01567943|contingency management
284428|NCT01567943|psychosocial treatment
284429|NCT01567930|Temsirolimus
284430|NCT01567930|HCC
284431|NCT01567930|Advanced hepatocellular carcinoma
284432|NCT01567917|Venous thromboembolism
284433|NCT01567917|Colorectal cancer
284434|NCT01567917|Postoperative period
284435|NCT01567917|detected on 5th~14th days after surgery (by doppler US) or the follow-up period of postoperative 1 month
284436|NCT01567904|thrombosis
284437|NCT01567904|Central Venous Line
284438|NCT01567904|CVL
284439|NCT01567891|Ovarian Cancer
284440|NCT01567891|Cell Therapy
284441|NCT01567891|T Cell Therapy
284442|NCT01567891|NY-ESO-1
284443|NCT01567891|Immuno-oncology
284444|NCT01567891|Metastatic
284445|NCT01567891|Previously treated
284446|NCT01567891|T Cell Receptor
284447|NCT01567878|ultrasound
284448|NCT01567878|MASEI index
284449|NCT01567878|clinical and ultrasound correlation
284450|NCT01567878|enthesis ultrasound
284451|NCT01567878|articular ultrasound
284452|NCT01567878|ankylosing spondylitis ultrasound
284453|NCT01567878|radiographic and ultrasound correlation
284454|NCT01567852|orientation
284455|NCT01567852|post-anesthesia recovery
284456|NCT01567852|electroconvulsive therapy
284457|NCT01567839|degree of pulpal anesthesia obtained
284458|NCT01567839|primary infiltration in the lower first molar
284459|NCT01567826|YELLO
284460|NCT01567826|Atorvastatin
284461|NCT01567826|Simvastatin
284462|NCT01567826|Rosuvastatin
284463|NCT01567826|lipid therapy
284464|NCT01567826|Statin therapy
284465|NCT01567826|Coronary artery disease
284466|NCT01567826|CHD
284467|NCT01567813|Warts
284468|NCT01567813|Papillomavirus infections
284469|NCT01567813|DNA virus infections
284470|NCT01567813|Virus diseases
284471|NCT01567813|Skin diseases, viral
284472|NCT01567813|Tumor virus infections
284473|NCT01567813|Skin diseases, infectious
284474|NCT01567813|Skin diseases
284475|NCT01567800|Procedure/Surgery: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
284476|NCT01567787|Proton Radiation Therapy
284477|NCT01567787|Spinal tumors
284478|NCT01567787|Neurofibroma(NF1)
284479|NCT01567787|Malignant peripheral nerve sheath tumor(MPNST)
284480|NCT01567774|Coronary artery disease
284481|NCT01567774|dual antiplatelet therapy
284482|NCT01567774|atorvastatin
284483|NCT01567774|rosuvastatin
284484|NCT01567761|IOP
284485|NCT01567748|CABG
284486|NCT01567748|Coronary Artery Bypass
284487|NCT01567748|Central Aortic Pressure
284488|NCT01567748|Peripheral Arterial Waveform
284489|NCT01567735|Hepatitis C
284490|NCT01567735|TMC435HPC3011
284491|NCT01567735|TMC435
284492|NCT01567722|HIV infection
284493|NCT01567722|adult diffuse large cell lymphoma
284494|NCT01567722|anal cancer
284495|NCT01567722|cervical cancer
284496|NCT01567722|non-small cell lung cancer
284497|NCT01567722|AIDS-related diffuse large cell lymphoma
284498|NCT01567696|Revision,
284499|NCT01567683|Safety and Tolerability of Limtop and vehicle
284500|NCT01567683|of Limtop and vehicle
284501|NCT01567657|Sedation in TEE
284502|NCT01567657|Blood pressure drop during TEE
284503|NCT01567657|Safety of sedation in TEE
284504|NCT01567644|Extracorporeal Shockwave Therapy
284505|NCT01567644|Myocardial Ischemia
284506|NCT01567644|Refractory Angina
284507|NCT01567631|Classical Procedure
284508|NCT01567631|Intrahepatic Glisson's Approach
284509|NCT01567631|laparoscopic hepatectomy
284510|NCT01567631|Minimal invasive surgery
284511|NCT01567631|Endoscopic stapling devices
284512|NCT01567618|Docetaxel
284513|NCT01567618|Fluorouracil
284514|NCT01567618|First line therapy
284515|NCT01567618|Gastric cancer
284516|NCT01567605|spinal cord injury
284517|NCT01567605|autonomic dysreflexia
284518|NCT01567605|blood pressure
284519|NCT01567605|bowel care management
284520|NCT01567605|defecation
284521|NCT01567592|Extracorporeal Shockwave Therapy
284522|NCT01567592|Myocardial Ischemia
284523|NCT01567592|Refractory Angina
284524|NCT01567579|congenital heart defects
284525|NCT01567566|home based daily exercise program
284526|NCT01567566|local lumbopelvic stabilizer muscles
284527|NCT01567566|hip stabilizer muscles
284528|NCT01567566|real time ultrasound imaging
284529|NCT01567553|inflammatory disease of the central nervous system
284530|NCT01567553|early clinical deficit
284531|NCT01567553|multiple sclerosis (MS)
284532|NCT01567540|Chronic Hepatitis C
284533|NCT01567540|Interferon protein 10
284534|NCT01567540|Chemokine gradients
284535|NCT01567540|Sitagliptin
284536|NCT01567527|Aripiprazole
284537|NCT01567527|Intramuscular (IM) Depot
284538|NCT01567527|Bipolar
284539|NCT01567514|Deep occlusal caries restored with resin composite
284540|NCT01567514|on Pit and Fissure Surface Penetrating Into Dentin
284541|NCT01567488|Advanced
284542|NCT01567488|Non functioning
284543|NCT01567488|Well differentiated
284544|NCT01567462|bladder cancer
284545|NCT01567462|transurethral resection of bladder tumors
284546|NCT01567423|Malaria
284547|NCT01567423|Plasmodium falciparum
284548|NCT01567423|Children
284549|NCT01567423|Efficacy
284550|NCT01567423|Uncomplicated malaria
284551|NCT01567410|e-learning
284552|NCT01567410|education
284553|NCT01567384|cancer
284554|NCT01567384|neoplasms
284555|NCT01567384|tumors
284556|NCT01567345|Pain
284557|NCT01567345|cancer
284558|NCT01567345|Intrathecal
284559|NCT01567345|analgesia
284560|NCT01567345|Morphine
284561|NCT01567345|Implantable pump
284562|NCT01567319|Sensitization
284563|NCT01567319|Skin Prick Test
284564|NCT01567319|Standardization
284565|NCT01567319|sources of: D. glomerata, L. perenne, S. cereale and O. europaea
284566|NCT01567306|Allergy
284567|NCT01567306|Allergic rhinoconjunctivitis
284568|NCT01567306|Subcutaneous Immunotherapy
284569|NCT01567306|Phleum pratense pollen extract
284570|NCT01567267|Evidence-based Medicine
284571|NCT01567267|Good Scientific Practice
284572|NCT01567267|Problem-based Learning
284573|NCT01567267|Critical health literacy
284574|NCT01567267|Educational intervention
284575|NCT01567254|guided imaginary
284576|NCT01567241|clinical hypnosis
284577|NCT01567241|relaxation music
284578|NCT01567241|reproduction techniques
284579|NCT01567241|insemination
284580|NCT01567241|embryo transfer
284581|NCT01567241|pregnancy rate
284582|NCT01567228|obesity
284583|NCT01567228|overweight
284584|NCT01567228|dental caries
284585|NCT01567228|school problems
284586|NCT01567228|school failure
284587|NCT01567228|child BMI > 85th percentile
284588|NCT01567228|Needing dental preventive services
284589|NCT01567228|Needing academic support for school problems
284590|NCT01567215|granuloma umbilical
284591|NCT01567202|Brain tumor
284592|NCT01567202|Glioma
284593|NCT01567202|Glioblastoma
284594|NCT01567202|Tumor stem cells
284595|NCT01567202|Immunotherapy
284596|NCT01567202|Vaccine
284597|NCT01567189|Exercise therapy
284598|NCT01567189|cost effectiveness
284599|NCT01567189|cardiac rehabilitation
284600|NCT01567189|home-based exercise
284601|NCT01567176|Sirtuins
284602|NCT01567176|Aging
284603|NCT01567176|Metabolic disease
284604|NCT01567163|Advanced Malignant Solid Tumors
284605|NCT01567124|Schizophrenia
284606|NCT01567124|Moxonidine
284607|NCT01567124|Sympathetic nervous system activation
284608|NCT01567124|Cardiometabolic side effects of antipsychotics
284609|NCT01567111|Primary aldosteronism
284610|NCT01567111|Aldosterone producing adenoma
284611|NCT01567111|Bilateral adrenal hyperplasia
284612|NCT01567111|Metomidate-Positron emission tomography
284613|NCT01567072|NSAID
284614|NCT01567072|bone fracture
284615|NCT01567072|heal
284616|NCT01567033|Diabetes
284617|NCT01567033|Obesity
284618|NCT01567033|Home visiting
284619|NCT01567020|Central Auditory Processing
284620|NCT01567020|Traumatic Brain Injury
284621|NCT01567020|Hearing Loss
284622|NCT01567007|pedometer
284623|NCT01567007|physical activity
284624|NCT01567007|workplace
284625|NCT01566994|smoking cessation
284626|NCT01566981|Diabetes mellitus tip II
284627|NCT01566981|eHealth solution
284628|NCT01566981|Health Information Technology
284629|NCT01566981|quality of life
284630|NCT01566981|family medicine
284631|NCT01566981|satisfaction with e-health care
284632|NCT01566981|primary care
284633|NCT01566968|COPD
284634|NCT01566968|Asthma
284635|NCT01566968|Healthy volunteers
284636|NCT01566968|Chronic cough
284637|NCT01566968|Smokers
284638|NCT01566968|Cough challenge
284639|NCT01566968|Cough challenge testing.
284640|NCT01566955|transgastric
284641|NCT01566955|NOTES
284642|NCT01566955|Gastrotomy
284643|NCT01566955|BRCA 1/2
284644|NCT01566942|FOLFIRI
284645|NCT01566942|FOLFOX
284646|NCT01566942|adjuvant chemotherapy
284647|NCT01566942|advanced colorectal cancer
284648|NCT01566929|Obesity
284649|NCT01566929|In vitro fertilization
284650|NCT01566929|Low calorie diet (LCD)
284651|NCT01566929|Obstetric outcome
284652|NCT01566929|Weight reduction
284653|NCT01566903|arterial stenosis
284654|NCT01566903|arteriovenous malformations
284655|NCT01566903|Post-treatment follow-up
284656|NCT01566890|sickle cell
284657|NCT01566890|sickle cell crisis
284658|NCT01566890|sickle cell pain crisis
284659|NCT01566890|vaso-occlusive crisis
284660|NCT01566890|vaso-occlusion
284661|NCT01566890|sickle cell anemia
284662|NCT01566890|sickle cell disease
284663|NCT01566890|genetic diseases
284664|NCT01566890|adenosine 2A Receptor Agonists
284665|NCT01566890|Lexiscan
284666|NCT01566890|Regadenoson
284667|NCT01566890|contrast-enhanced ultrasound
284668|NCT01566890|Hydroxyurea
284669|NCT01566877|Multiple Ascending Dose (MAD)
284670|NCT01566877|Marburg Virus
284671|NCT01566877|Post Exposure Prophylaxis
284672|NCT01566864|hypertension
284673|NCT01566864|disparities
284674|NCT01566864|care management
284675|NCT01566864|provider education
284676|NCT01566864|audit and feedback
284677|NCT01566864|Omron
284678|NCT01566864|African Americans
284679|NCT01566864|organizational change
284680|NCT01566864|implementation research
284681|NCT01566838|Visual analog pain score
284682|NCT01566838|Length of stay
284683|NCT01566838|Hospital Cost
284684|NCT01566838|Subpleural pain catheter
284685|NCT01566838|Bupivacaine
284686|NCT01566825|amitriptyline
284687|NCT01566825|sleep dependent memory consolidation
284688|NCT01566812|Breast Feeding
284689|NCT01566812|Cardiovascular Risk
284690|NCT01566799|Locally advanced breast cancer
284691|NCT01566799|Neoadjuvant chemotherapy
284692|NCT01566799|Metformin
284693|NCT01566799|Pathologic Complete Response
284694|NCT01566773|COPD
284695|NCT01566760|food effect
284696|NCT01566760|bioavailability
284697|NCT01566760|pharmacokinetics
284698|NCT01566760|fesoterodine
284699|NCT01566760|5-hydroxymethyl tolterodine
284700|NCT01566760|treatment of overactive bladder
284701|NCT01566734|Surgical Wound Infection
284702|NCT01566734|cefazolin
284703|NCT01566734|Cesarean Section
284704|NCT01566708|Acute Tinnitus
284705|NCT01566708|Recent Onset Tinnitus
284706|NCT01566708|Music Therapy
284707|NCT01566708|fMRI
284708|NCT01566708|Therapy Evaluation
284709|NCT01566682|Lung Lesion
284710|NCT01566682|Lung Mass
284711|NCT01566682|Lung Nodule
284712|NCT01566682|Lung Cancer
284713|NCT01566682|Low-Dose CT
284714|NCT01566682|CT
284715|NCT01566682|Diagnostic
284716|NCT01566682|Evaluation
284717|NCT01566682|Bioconductance
284718|NCT01566682|ProLung
284719|NCT01566669|Cyclooxygenase inhibitors
284720|NCT01566669|Morphine
284721|NCT01566669|Analgesia
284722|NCT01566669|patient-controlled
284723|NCT01566669|Gynecologic surgical procedures
284724|NCT01566656|Allogeneic hematopoietic stem cell transplantation
284725|NCT01566656|Non-myeloablative preparative regimen
284726|NCT01566656|Total lymphoid irradiation
284727|NCT01566656|Anti-thymocyte globulin
284728|NCT01566656|Lymphoid malignancies
284729|NCT01566643|Helicobacter pylori
284730|NCT01566643|antibiotic resistance
284731|NCT01566643|sequential-concomitant hybrid therapy
284732|NCT01566630|human recombinant RLX030
284733|NCT01566630|Pre-eclampsia
284734|NCT01566630|hemodynamics
284735|NCT01566630|Pharmacokinetics
284736|NCT01566604|Chronic obstructive pulmonary disease (COPD)
284737|NCT01566604|NVA237
284738|NCT01566591|Bipolar Depression
284739|NCT01566552|AMBISOME
284740|NCT01566552|VISCERAL LEISHMANIASIS
284741|NCT01566552|SINGLE DOSE
284742|NCT01566539|Social cooperation
284743|NCT01566539|Oxytocin
284744|NCT01566539|Vasopressin
284745|NCT01566539|Prisoner's Dilemma game
284746|NCT01566539|Empathy
284747|NCT01566539|fMRI
284748|NCT01566513|Peer Support
284749|NCT01566513|Cost Effectiveness
284750|NCT01566513|Reducing Hospital use
284751|NCT01566513|Serious Mental Illness
284752|NCT01566500|Epilepsy
284753|NCT01566500|Medication Adherence
284754|NCT01566487|Bioequivalence
284755|NCT01566487|Quetiapine fumarate
284756|NCT01566487|crossover
284757|NCT01566461|Drug-Coated Angioplasty Balloon
284758|NCT01566461|Drug Coated Angioplasty Balloon
284759|NCT01566461|Peripheral Artery Disease
284760|NCT01566461|Experimental
284761|NCT01566461|Percutaneous Transluminal Angioplasty (PTA)
284762|NCT01566448|Ketamine
284763|NCT01566448|Mucositis
284764|NCT01566448|Oral ketamine rinse
284765|NCT01566409|Constipation
284766|NCT01566409|Maintenance treatment
284767|NCT01566409|Ultrasound of rectum
284768|NCT01566396|Fractional,
284769|NCT01566396|RF,
284770|NCT01566396|Wrinkles
284771|NCT01566396|Safety
284772|NCT01566396|Efficacy
284773|NCT01566396|treatment
284774|NCT01566370|alcoholism
284775|NCT01566370|alcohol use disorder
284776|NCT01566370|alcohol dependence
284777|NCT01566370|alcohol abuse
284778|NCT01566370|bipolar
284779|NCT01566370|anticonvulsant
284780|NCT01566370|zonisamide
284781|NCT01566357|dental erosion
284782|NCT01566357|enamel
284783|NCT01566357|dentin
284784|NCT01566344|Premature Ventricular Complex
284785|NCT01566344|Cardiomyopathy
284786|NCT01566344|Left ventricular dysfunction
284787|NCT01566344|Catheter Ablation
284788|NCT01566344|Anti-Arrhythmic Agents
284789|NCT01566344|Randomized Clinical Trial
284790|NCT01566331|Safe Delivery
284791|NCT01566331|reduction of pain
284792|NCT01566331|reduction stage of labor
284793|NCT01566318|Depression
284794|NCT01566318|Anxiety
284795|NCT01566318|Geriatric mental health
284796|NCT01566279|solid tumors
284797|NCT01566279|all comers
284798|NCT01566279|everolimus
284799|NCT01566279|biomarker
284800|NCT01566279|next generation sequencing
284801|NCT01566266|gut flora
284802|NCT01566266|antibiotics
284803|NCT01566266|lipid metabolism
284804|NCT01566266|LDL cholesterol
284805|NCT01566253|planned caesarian section, analgesic, PCOA
284806|NCT01566240|cervical cancer
284807|NCT01566240|Chemotherapy
284808|NCT01566240|Paclitaxel
284809|NCT01566240|Carboplatin
284810|NCT01566240|Cisplatin
284811|NCT01566240|Radiotherapy
284812|NCT01566240|Chemoradiation
284813|NCT01566240|Brachytherapy
284814|NCT01566240|Stage IB2 Cervical Cancer
284815|NCT01566240|Stage IIA Cervical Cancer
284816|NCT01566240|Stage IIB Cervical Cancer
284817|NCT01566240|Stage IIIB Cervical Cancer
284818|NCT01566240|Stage IVA Cervical Cancer
284819|NCT01566227|overdenture
284820|NCT01566227|implant
284821|NCT01566227|edentulism
284822|NCT01566214|coronary heart disease (CHD)
284823|NCT01566214|myocardial infarction (MI)
284824|NCT01566214|acute coronary syndromes (ACS)
284825|NCT01566201|Arterial stiffness
284826|NCT01566201|Endothelial function
284827|NCT01566201|Left ventricular function
284828|NCT01566201|Apoptosis
284829|NCT01566201|Nitrooxidative stress
284830|NCT01566175|Neovasc Reducer
284831|NCT01566175|Coronary Sinus
284832|NCT01566175|Refractory Angina Pectoris
284833|NCT01566175|angina class 3-4
284834|NCT01566162|Lurasidone
284835|NCT01566162|Latuda
284836|NCT01566162|Schizophrenia
284837|NCT01566136|hip fracture patients
284838|NCT01566136|cognitive impairment
284839|NCT01566136|rehabilitation model of care
284840|NCT01566123|retroperitoneal soft tissue sarcoma
284841|NCT01566123|IMRT
284842|NCT01566123|IORT
284843|NCT01566110|pediatric
284844|NCT01566110|dietary treatment
284845|NCT01566110|celiac disease
284846|NCT01566110|T1D
284847|NCT01566097|Cluster randomized trial
284848|NCT01566097|Decision aids
284849|NCT01566097|Culturally-appropriate decision aids
284850|NCT01566058|Post partum
284851|NCT01566058|mother-child relationships
284852|NCT01566045|Prostate Cancer
284853|NCT01566045|Biopsy
284854|NCT01566032|pulmonary air leak
284855|NCT01566032|Thopaz
284856|NCT01566032|analog
284857|NCT01566032|digital
284858|NCT01566006|Mycophenolate mofetil (MMF)
284859|NCT01566006|Diabetic Nephropathy
284860|NCT01566006|proteinuria
284861|NCT01566006|Diabetic Nephropathy in Chronic Kidney Disease patients stages 2-4
284862|NCT01565980|Lung cancer
284863|NCT01565980|mindfulness therapy
284864|NCT01565980|active treatment (radiation and/or chemotherapy)
284865|NCT01565967|AutoLog
284866|NCT01565967|Post market release
284867|NCT01565967|Non-interventional
284868|NCT01565954|Sickle Cell Disease
284869|NCT01565954|Respiration Disorders
284870|NCT01565954|Polysomnography
284871|NCT01565941|Cardiovascular
284872|NCT01565941|Respiratory
284873|NCT01565941|Failure
284874|NCT01565941|Heart
284875|NCT01565941|Lung
284876|NCT01565941|Continuous glucose monitoring
284877|NCT01565941|Tight glycemic control
284878|NCT01565941|Subcutaneous
284879|NCT01565941|Insulin
284880|NCT01565941|Algorithm
284881|NCT01565928|Prostate cancer
284882|NCT01565928|docetaxel
284883|NCT01565928|MDV3100
284884|NCT01565928|enzalutamide
284885|NCT01565928|Xtandi
284886|NCT01565902|BAF312
284887|NCT01565902|Pharmacokinetics
284888|NCT01565902|Hepatic impairment
284889|NCT01565876|weight bearing
284890|NCT01565876|physiological load
284891|NCT01565863|Perceived Disability
284892|NCT01565863|Mental Wellness
284893|NCT01565863|Employment
284894|NCT01565863|Social Integration and Engagement
284895|NCT01565863|Goal Achievement
284896|NCT01565850|HIV-1
284897|NCT01565850|HIV
284898|NCT01565850|Treatment-Naive
284899|NCT01565837|Melanoma
284900|NCT01565837|Malignant Melanoma
284901|NCT01565837|Metastatic
284902|NCT01565837|Oligometastatic
284903|NCT01565837|Radiosurgery
284904|NCT01565837|Radiosurgery, Stereotactic
284905|NCT01565837|Stereotactic Radiosurgery
284906|NCT01565837|Ipilimumab
284907|NCT01565837|Yervoy
284908|NCT01565837|MDX-010
284909|NCT01565837|Circulating Tumor Cells
284910|NCT01565811|colon neoplasm, rectal neoplasm, liver metastasis
284911|NCT01565798|healthcare-acquired infections
284912|NCT01565798|colonization
284913|NCT01565798|copper-alloy surfaces
284914|NCT01565785|Child parent home self-management
284915|NCT01565772|Lung cancer
284916|NCT01565772|Stage III
284917|NCT01565759|Gene expression
284918|NCT01565759|Lithium
284919|NCT01565759|Healthy volunteers
284920|NCT01565759|Lymphoblastoid cell lines
284921|NCT01565746|BAY88-8223
284922|NCT01565746|radium-223 dichloride
284923|NCT01565746|prostate cancer
284924|NCT01565720|Isavuconazole
284925|NCT01565720|Healthy Volunteers
284926|NCT01565720|BAL8557
284927|NCT01565707|Pediatric
284928|NCT01565707|Solifenacin succinate suspension
284929|NCT01565707|Phase 3
284930|NCT01565707|Pharmacokinetics
284931|NCT01565707|Overactive bladder (OAB)
284932|NCT01565694|Cognitive Function
284933|NCT01565694|Phase 3
284934|NCT01565694|Neurogenic Detrusor Overactivity
284935|NCT01565694|Pharmacokinetics
284936|NCT01565694|Ocular Accommodation
284937|NCT01565694|Urodynamics
284938|NCT01565681|Healthy Volunteers
284939|NCT01565681|B cell CD40 receptor occupancy
284940|NCT01565681|anti-CD40 monoclonal antibody
284941|NCT01565668|FLT3-ITD positive Acute Myeloid Leukemia (AML)
284942|NCT01565668|AC220
284943|NCT01565668|Relapse
284944|NCT01565668|Refractory
284945|NCT01565655|Rheumatoid Arthritis
284946|NCT01565655|ASP015K
284947|NCT01565642|Dementia, decision making
284948|NCT01565629|Autism
284949|NCT01565629|Asperger's Syndrome
284950|NCT01565629|Treatment
284951|NCT01565629|Cognitive-behavioral therapy
284952|NCT01565629|Anxiety
284953|NCT01565629|Children
284954|NCT01565629|Therapy
284955|NCT01565616|Severe Sickle Cell Disease
284956|NCT01565616|HCT
284957|NCT01565616|Hematopoietic Stem Cell Therapy
284958|NCT01565616|Bone Marrow Transplant
284959|NCT01565616|Hematologic Diseases
284960|NCT01565616|Genetic Diseases
284961|NCT01565616|Anemia
284962|NCT01565616|Hemolytic
284963|NCT01565616|Congenital
284964|NCT01565616|Human Leukocyte Antigen
284965|NCT01565616|HLA
284966|NCT01565603|Hypoxia
284967|NCT01565603|Exercise
284968|NCT01565603|Sleep
284969|NCT01565603|Brain
284970|NCT01565603|Neuromuscular function
284971|NCT01565603|Heart
284972|NCT01565590|aneurysmal subarachnoid hemorrhage
284973|NCT01565590|dexmedetomidine
284974|NCT01565590|cytokines
284975|NCT01565577|Neisseria meningitidis B:14, P1-7, 16
284976|NCT01565577|Serum bactericidal activity
284977|NCT01565577|Menbvac
284978|NCT01565564|Gestational diabetes mellitus
284979|NCT01565564|intervention
284980|NCT01565564|shared care
284981|NCT01565564|pregnancy outcome
284982|NCT01565564|macrosomia
284983|NCT01565564|pregnancy-induced hypertension
284984|NCT01565551|Traumatic Brain Injury
284985|NCT01565551|Common Data Elements
284986|NCT01565551|Prognostic Models
284987|NCT01565551|Neuroimaging
284988|NCT01565551|Biomarkers
284989|NCT01565551|Genetic Variants
284990|NCT01565551|Concussion
284991|NCT01565551|Psychological Health
284992|NCT01565538|Cancer
284993|NCT01565538|Non-small-cell lung cancer
284994|NCT01565538|Adenocarcinoma
284995|NCT01565538|EGFR gene mutation
284996|NCT01565538|Chemotherapy
284997|NCT01565538|Pemetrexed
284998|NCT01565538|Erlotinib
284999|NCT01565525|well child visit
285000|NCT01565525|anticipatory guidance
285001|NCT01565525|obesity prevention
285002|NCT01565525|infant feeding
285003|NCT01565512|randomized trial
285004|NCT01565512|robotic prostatectomy
285005|NCT01565512|prostate cancer
285006|NCT01565512|foley catheter discomfort
285007|NCT01565499|Neoadjuvant nab-paclitaxel luminal breast cancer
285008|NCT01565486|operation time
285009|NCT01565486|complication rate
285010|NCT01565486|costs
285011|NCT01565486|admission time
285012|NCT01565486|RFS
285013|NCT01565486|OS
285014|NCT01565473|non-motor symptoms
285015|NCT01565460|pancreas
285016|NCT01565460|biliary
285017|NCT01565460|stricture
285018|NCT01563510|Hepatolithiasis
285019|NCT01563510|Minimal invasive surgery
285020|NCT01563510|Laparoscopic hepatectomy
285021|NCT01563510|Choledochoscope
285022|NCT01563484|Primary Hepatocellular Carcinoma(HCC)
285023|NCT01563484|Transarterial chemoembolization (TACE)
285024|NCT01563484|Liver function
285025|NCT01563484|Renal function
285026|NCT01565421|Cancer
285027|NCT01565421|Neoplasms
285028|NCT01565421|Solid Tumor
285029|NCT01565421|Ovarian Cancer
285030|NCT01565421|Solid Malignancies
285031|NCT01565395|ALS
285032|NCT01565395|PD
285033|NCT01565382|Amyloid imaging
285034|NCT01565382|Positron Emission Tomography
285035|NCT01565382|18F-AV-45
285036|NCT01565382|florbetapir F 18
285037|NCT01565382|Diagnostic imaging
285038|NCT01565369|Amyloid imaging
285039|NCT01565369|Positron Emission Tomography
285040|NCT01565369|18F-AV-45
285041|NCT01565369|florbetapir F 18
285042|NCT01565369|Diagnostic imaging
285043|NCT01565356|Amyloid imaging
285044|NCT01565356|Positron Emission Tomography
285045|NCT01565356|18F-AV-45
285046|NCT01565356|florbetapir F 18
285047|NCT01565356|Diagnostic imaging
285048|NCT01565343|Amyloid imaging
285049|NCT01565343|Positron Emission Tomography
285050|NCT01565343|18F-AV-45
285051|NCT01565343|florbetapir F 18
285052|NCT01565343|Diagnostic imaging
285053|NCT01565330|Amyloid imaging
285054|NCT01565330|Positron Emission Tomography
285055|NCT01565330|18F-AV-45
285056|NCT01565330|florbetapir F 18
285057|NCT01565330|Diagnostic imaging
285058|NCT01565304|Teen pregnancy
285059|NCT01565304|Sexually transmitted infections
285060|NCT01565304|Sexual risk behaviors
285061|NCT01565291|Amyloid imaging
285062|NCT01565291|Positron Emission Tomography
285063|NCT01565291|18F-AV-45
285064|NCT01565291|florbetapir F 18
285065|NCT01565291|Diagnostic imaging
285066|NCT01565278|Parenteral nutrition
285067|NCT01565278|fish oil
285068|NCT01565278|liver disease
285069|NCT01565278|Omegaven
285070|NCT01565278|hepatic
285071|NCT01565278|liver biopsy
285072|NCT01565278|bilirubin
285073|NCT01565265|ovarian hyperstimulation
285074|NCT01565265|GnRH antagonist
285075|NCT01565265|GnRH agonist
285076|NCT01565265|assisted reproduction
285077|NCT01565265|FSH
285078|NCT01565265|LH
285079|NCT01565252|Egg,Omega 3, Omega 6
285080|NCT01565239|Warfarin
285081|NCT01565239|Monitoring
285082|NCT01565239|prothrombin time
285083|NCT01565239|Fiix prothrombin time
285084|NCT01565239|international normalized ratio (INR)
285085|NCT01565239|new test
285086|NCT01565226|Capnography
285087|NCT01565226|CO2
285088|NCT01565226|neonates
285089|NCT01565226|High Frequency ventilation (HFV)
285090|NCT01565213|primary health care,common mental disorders,
285091|NCT01565213|group therapy
285092|NCT01565200|HER2
285093|NCT01565200|Metastatic Breast Cancer
285094|NCT01565187|Hand Transplantation
285095|NCT01565174|cannabis
285096|NCT01565174|THC
285097|NCT01565174|COMT
285098|NCT01565174|psychosis
285099|NCT01565174|D2
285100|NCT01565161|Obesity
285101|NCT01565161|Overweight
285102|NCT01565148|DME
285103|NCT01565109|NESC
285104|NCT01565109|NEOADJUVANT
285105|NCT01565109|GASTRIC
285106|NCT01565070|Osteoarthritis
285107|NCT01565070|Pain
285108|NCT01565070|Quality of life
285109|NCT01565057|emulsion
285110|NCT01565057|emptying
285111|NCT01565057|protein
285112|NCT01565057|layering
285113|NCT01565044|Stroke
285114|NCT01565044|hemiplegia
285115|NCT01565044|automatic pilot
285116|NCT01565044|upper-limb rehabilitation
285117|NCT01565031|Asthma
285118|NCT01565018|Rotigotine
285119|NCT01565018|Neupro®
285120|NCT01565018|Transdermal Patch
285121|NCT01565018|Bioequivalence
285122|NCT01565005|MCPH
285123|NCT01565005|FANCONI ANEMIA
285124|NCT01564992|Parkinson's disease
285125|NCT01564992|Pharmacogenetics
285126|NCT01564992|Genetics
285127|NCT01564979|botulinum toxin
285128|NCT01564979|facial nerve
285129|NCT01564979|hemifacial spasm
285130|NCT01564979|tears
285131|NCT01564966|transplantation
285132|NCT01564966|inflammation
285133|NCT01564966|endothelial dysfunction
285134|NCT01564953|vitamin D
285135|NCT01564953|calcium
285136|NCT01564953|magnesium
285137|NCT01564940|Cervical cap insemination
285138|NCT01564940|Usability Study
285139|NCT01564927|deqi electroacupuncture
285140|NCT01564927|BP HR HRV
285141|NCT01564875|Simvast CR
285142|NCT01564875|Zocor
285143|NCT01564862|Drug Therapy
285144|NCT01564849|Pomegranate fruit extract
285145|NCT01564849|Sinusitis
285146|NCT01564849|rhinitis
285147|NCT01564849|nasal polyps
285148|NCT01564823|Crohn´s disease
285149|NCT01564823|Metronidazole
285150|NCT01564823|Azathioprine
285151|NCT01564823|Adalimumab
285152|NCT01564823|post-chirurgic recurrence
285153|NCT01564810|liver metastasis
285154|NCT01564810|colorectal cancer
285155|NCT01564810|cetuximab
285156|NCT01564810|chemotherapy
285157|NCT01564797|Diabetes
285158|NCT01564797|haemoglobin A1C
285159|NCT01564797|Hispanic
285160|NCT01564797|Behavioural Intervention
285161|NCT01564771|Pneumococcal serotypes
285162|NCT01564771|Community Acquired Pneumonia (CAP)
285163|NCT01564758|non-interventional
285164|NCT01564758|non-comparative
285165|NCT01564758|open-label study
285166|NCT01564758|safety
285167|NCT01564758|Linezolid
285168|NCT01564758|gram positive infections
285169|NCT01564758|Filipino
285170|NCT01564732|morbid obesity
285171|NCT01564732|gastric band
285172|NCT01564719|clergy
285173|NCT01564719|weight loss
285174|NCT01564719|holistic
285175|NCT01564719|stress
285176|NCT01564719|spiritual
285177|NCT01564706|Amyloid imaging
285178|NCT01564706|Positron Emission Tomography
285179|NCT01564706|18F-AV-45
285180|NCT01564706|florbetapir F 18
285181|NCT01564706|Diagnostic imaging
285182|NCT01564693|anorexia
285183|NCT01564693|cancer
285184|NCT01564693|hypothalamus
285185|NCT01564693|inflammation
285186|NCT01564680|Lower abdominal surgery
285187|NCT01564680|Paracetamol
285188|NCT01564680|Lornoxicam
285189|NCT01564680|Morphine
285190|NCT01564667|PTSD
285191|NCT01564667|Posttraumatic Stress
285192|NCT01564667|Post Traumatic Stress
285193|NCT01564667|Attention Bias
285194|NCT01564667|Threat Bias
285195|NCT01564667|Combat
285196|NCT01564667|Warzone
285197|NCT01564641|knee
285198|NCT01564641|osteoarthritis
285199|NCT01564641|bicompartmental
285200|NCT01564641|arthroplasty
285201|NCT01564641|joint diseases
285202|NCT01564628|CAD
285203|NCT01564615|Catheter related bloodstream infection
285204|NCT01564615|Umbilical venous catheter
285205|NCT01564615|Silver
285206|NCT01564615|Preterm infants
285207|NCT01564602|2-channel single port laparoscopy
285208|NCT01564602|multiple-channel port laparoscopy
285209|NCT01563432|crossover
285210|NCT01563432|pharmacokinetic
285211|NCT01563432|hyperuricemia
285212|NCT01563432|gout
285213|NCT01563419|Insulin
285214|NCT01563419|Diabetes
285215|NCT01563419|Low vision
285216|NCT01563406|Needleless connectors
285217|NCT01563406|catheter hubs
285218|NCT01563393|tool for nutritional evaluation
285219|NCT01563393|children
285220|NCT01563393|malnutrition
285221|NCT01563380|total knee arthroplasty
285222|NCT01563380|osteoarthritis
285223|NCT01563380|autologous Platelet rich plasma
285224|NCT01563380|complications
285225|NCT01563380|blood loss
285226|NCT01563380|Pain
285227|NCT01563380|functional outcome
285228|NCT01563367|Anaemia
285229|NCT01563367|Cardiac surgery
285230|NCT01563354|neuroendocrine carcinoma; lung; thymus; pasireotide LAR; everolimus
285231|NCT01564576|Laparoscopic surgery
285232|NCT01564576|Anesthesiology
285233|NCT01564576|Neuromuscular blockade
285234|NCT01564550|Type 2 diabetes
285235|NCT01564550|Very-low-density-lipoprotein(VLDL)
285236|NCT01564550|VLDL1
285237|NCT01564550|VLDL2
285238|NCT01564550|hyperinsulinemia
285239|NCT01564550|diet
285240|NCT01564537|Drug therapy
285241|NCT01564524|Craniomaxillofacial (CMF) Battle-injured (BI)
285242|NCT01564524|Facial Trauma
285243|NCT01564524|Fat Grafts
285244|NCT01564524|Autogenous Fat Transfers (AFT)
285245|NCT01564524|Wounded warriors
285246|NCT01564511|Multiple Sclerosis
285247|NCT01564511|Robotic Rahabilitation
285248|NCT01564511|Fatigue
285249|NCT01564511|Gait disorder
285250|NCT01564498|anthocyanins
285251|NCT01564498|antioxidant
285252|NCT01564498|polyphenols
285253|NCT01564498|bioavailability
285254|NCT01564498|cholesterol
285255|NCT01564498|insulin sensitivity
285256|NCT01564498|glucose tolerance
285257|NCT01564498|atherosclerosis
285258|NCT01564498|metabolic syndrome
285259|NCT01564446|medication
285260|NCT01564446|discharge
285261|NCT01564446|adherence
285262|NCT01564446|compliance
285263|NCT01564446|secure message
285264|NCT01564433|robotics
285265|NCT01564433|rehabilitation
285266|NCT01564433|gait
285267|NCT01564433|cerebral palsy
285268|NCT01564420|pharmacokinetic/pharmacodynamic modeling
285269|NCT01564420|intrathecal morphine
285270|NCT01564420|postoperative analgesia
285271|NCT01564420|patient-controlled analgesia device
285272|NCT01564407|ICX‐RHY‐013
285273|NCT01564407|Restrictive scar contracture
285274|NCT01564407|Restrictive hypertrophic scar
285275|NCT01564407|Burn Scar
285276|NCT01564407|Burn Scar contractures
285277|NCT01564407|Scar
285278|NCT01564394|qigong
285279|NCT01564394|mindfulness meditation
285280|NCT01564394|fatigue
285281|NCT01564394|prostate cancer
285282|NCT01564381|Cardiovascular disease
285283|NCT01564368|stage II breast cancer
285284|NCT01564368|stage IIIA breast cancer
285285|NCT01564368|stage IIIB breast cancer
285286|NCT01564368|stage IIIC breast cancer
285287|NCT01564368|stage IV breast cancer
285288|NCT01564368|HER2-negative breast cancer
285289|NCT01564368|HER2-positive breast cancer
285290|NCT01564342|wound irrigation
285291|NCT01564342|tap water irrigation
285292|NCT01564342|wound infection
285293|NCT01564342|wound irrigation solution
285294|NCT01564329|endostar
285295|NCT01564329|CT Perfusion
285296|NCT01564329|Advanced Primary Lung Adenocarcinoma
285297|NCT01564303|Carnitine
285298|NCT01564303|Phosphodiesterase type 5 (PDE5) inhibitor
285299|NCT01564303|Contrast Media-induced Nephropathy (CMN)
285300|NCT01564290|acute diarrhea
285301|NCT01564290|probiotics
285302|NCT01564290|children
285303|NCT01564264|Uterine Neoplasms
285304|NCT01564264|Sentinel Lymph Node Biopsy
285305|NCT01564238|calcium retention
285306|NCT01564238|sodium retention
285307|NCT01564225|XLHED
285308|NCT01564212|heat loss
285309|NCT01564212|laminar airflow
285310|NCT01564212|operating rooms
285311|NCT01564160|Fish Oil
285312|NCT01564160|EPA
285313|NCT01564160|DHA
285314|NCT01564160|Omega-Score
285315|NCT01564160|Omega-3 Fatty Acids
285316|NCT01564160|Green-Lipped Mussel
285317|NCT01564160|Omega-score < 5.2%
285318|NCT01564147|Therapeutic Education, Rheumatoid Arthritis
285319|NCT01564134|response vaccination
285320|NCT01564108|Intravitreal Ranibizumab
285321|NCT01564108|Non-infectious uveitis
285322|NCT01564108|Refractory Cystoid Macular Oedema
285323|NCT01564108|Lucentis
285324|NCT01564108|LIMO
285325|NCT01564095|Liver transplantation
285326|NCT01564095|EDC
285327|NCT01564095|IRI
285328|NCT01564095|graft survival
285329|NCT01564095|graft function
285330|NCT01564095|graft preconditioning
285331|NCT01564095|Tacrolimus rinse
285332|NCT01564095|randomised multicenter trial
285333|NCT01564082|endotracheal intubation
285334|NCT01564082|GlideScope
285335|NCT01564069|Chronic pain
285336|NCT01564069|Intrathecal pain management
285337|NCT01564056|Adjuvant systemic treatment
285338|NCT01564056|Breast cancer
285339|NCT01564056|Elderly patients
285340|NCT01564030|Pregnancy
285341|NCT01564030|Respiratory aspiration
285342|NCT01564030|Gastric contents
285343|NCT01564030|Ultrasound
285344|NCT01564017|Allergy
285345|NCT01564017|Allergic rhinoconjunctivitis
285346|NCT01564017|Immunotherapy
285347|NCT01564017|D. pteronyssinus
285348|NCT01564017|house dust allergy
285349|NCT01564004|breech presentation at term
285350|NCT01564004|pregnancy
285351|NCT01564004|external cephalic version (ECV)
285352|NCT01564004|clinical hypnosis
285353|NCT01564004|neuro-linguistic programming (NLP)
285354|NCT01563991|surgery
285355|NCT01563991|fluid
285356|NCT01563991|morbidity
285357|NCT01563978|Rheumatoid Arthritis
285358|NCT01563965|Preoperative fasting
285359|NCT01563965|Acute phase proteins
285360|NCT01563965|Carbohydrates
285361|NCT01563965|Protein hydrolizate
285362|NCT01563965|Inflammatory response
285363|NCT01563965|Surgery
285364|NCT01563939|Labour analgesia
285365|NCT01563939|Pregnancy
285366|NCT01563939|IVPCA
285367|NCT01563913|Parkinsons disease
285368|NCT01563913|supplement
285369|NCT01563913|DHA
285370|NCT01563913|dyskinesia
285371|NCT01563913|abnormal movements
285372|NCT01563900|fatigue
285373|NCT01563900|multiple sclerosis
285374|NCT01563900|sleep apnea
285375|NCT01563900|CPAP
285376|NCT01563887|Type 1 Diabetes
285377|NCT01563887|Hypoglycemia
285378|NCT01563887|Driving
285379|NCT01563887|Driving safety
285380|NCT01563887|Internet
285381|NCT01563887|Web
285382|NCT01563887|Treatment
285383|NCT01563887|Intervention
285384|NCT01563874|Antibodies
285385|NCT01563874|Reverse Phase Microarrays
285386|NCT01563874|Epigenetics
285387|NCT01563874|Acetylation
285388|NCT01563874|Methylation
285389|NCT01563874|Lymphoma
285390|NCT01563861|contiguous stage II adult diffuse large cell lymphoma
285391|NCT01563861|noncontiguous stage II adult diffuse large cell lymphoma
285392|NCT01563861|stage III adult diffuse large cell lymphoma
285393|NCT01563861|stage IV adult diffuse large cell lymphoma
285394|NCT01563835|Termination of pregnancy
285395|NCT01563835|Epidural
285396|NCT01563835|IV PCA
285397|NCT01563822|Follicular Fluid
285398|NCT01563822|uterine cavity
285399|NCT01563822|Implantation rates
285400|NCT01563822|ICSI
285401|NCT01563796|bladder cancer
285402|NCT01563796|TCC
285403|NCT01563796|urine
285404|NCT01563796|protein ELISA
285405|NCT01563783|Fibroids
285406|NCT01563783|Myomas
285407|NCT01563783|leiomyomata
285408|NCT01563783|menorrhagia
285409|NCT01563783|Acessa Procedure
285410|NCT01563783|Radiofrequency Ablation
285411|NCT01563783|RFA
285412|NCT01563770|Hyperlipidemia
285413|NCT01563770|Hypertension
285414|NCT01563770|Vasodilation
285415|NCT01563770|Oxidative stress
285416|NCT01563770|Inflammation
285417|NCT01563770|Hemostasis
285418|NCT01563770|Hemorheology
285419|NCT01563770|Cardiovascular diseases
285420|NCT01563770|Cardiovascular agents
285421|NCT01563770|Salvia miltiorrhiza
285422|NCT01563770|Danshen
285423|NCT01563770|Danshen root extract
285424|NCT01563770|Molecular Mechanisms of Pharmacological Action
285425|NCT01563770|Therapeutic Uses
285426|NCT01563744|colonoscopy
285427|NCT01563744|bowel preparation
285428|NCT01563744|tolerability
285429|NCT01563744|EGD-assisted
285430|NCT01563731|Blood pressure medicines
285431|NCT01563731|Lipid lowering medicines
285432|NCT01563731|Hypertension
285433|NCT01563731|Stroke
285434|NCT01563731|Dementia
285435|NCT01563731|Heart attack
285436|NCT01563731|Heart failure
285437|NCT01563705|Neuromuscular Disorders
285438|NCT01563705|GSD III
285439|NCT01563705|glycogen storage disease
285440|NCT01563692|RSV
285441|NCT01563692|Immune response
285442|NCT01563679|cancer
285443|NCT01563679|locoregional therapies
285444|NCT01563679|RFA
285445|NCT01563679|Cryoablation
285446|NCT01563679|Microwave ablation
285447|NCT01563679|chemical ablation
285448|NCT01563679|Irreversible electroporation
285449|NCT01563653|predicting surgical success
285450|NCT01563653|simple diagnostic test device
285451|NCT01563640|dengue
285452|NCT01563588|breast cancer
285453|NCT01563588|chemotherapy
285454|NCT01563588|first line treatment
285455|NCT01563588|treatments include a chemotherapy
285456|NCT01563588|last treatment not performed more than 9 months earlier
285457|NCT01563575|Recognition Process
285458|NCT01563575|Health Promotion
285459|NCT01563575|HPH
285460|NCT01563575|WHO
285461|NCT01563575|Hospitals
285462|NCT01563575|Health Services
285463|NCT01563575|Health Gain
285464|NCT01563575|Service Delivery
285465|NCT01563575|Quality Management
285466|NCT01563536|Hepatitis C,Genotype 1
285467|NCT01563328|Dolutegravir, GSK1349572, DTG, BCV, TVR, drug interaction
285468|NCT01563315|Community-Acquired Infections
285469|NCT01563315|Pneumonia/microbiology
285470|NCT01563315|Pneumonia/diagnosis
285471|NCT01563315|Prognosis
285472|NCT01563315|Prospective Studies
285473|NCT01563302|Advanced Cancers
285474|NCT01563302|DLBCL
285475|NCT01563302|Advanced Lymphoma
285476|NCT01563276|Progressive Supranuclear Palsy
285477|NCT01563276|PSP
285478|NCT01563276|Falls
285479|NCT01563276|Gait
285480|NCT01563276|Balance
285481|NCT01563276|Parkinson's Disease
285482|NCT01563276|PD
285483|NCT01563263|IC43
285484|NCT01563263|Pseudomonas Aeruginosa
285485|NCT01563263|mechanically ventilated ICU patients
285486|NCT01563263|ICU patients
285487|NCT01563250|Acute Coronary Syndrome
285488|NCT01563250|Cardiac Biomarkers
285489|NCT01563250|point of care testing
285490|NCT01563224|GABA-B
285491|NCT01563211|breast cancer therapy
285492|NCT01563211|toxicity
285493|NCT01563211|side effect profile
285494|NCT01563198|MRI departments and facilities
285495|NCT01563198|Noncompletion of MRI
285496|NCT01563185|JIA
285497|NCT01563185|ibuprofen
285498|NCT01563185|famotidine
285499|NCT01563185|pediatrics
285500|NCT01563185|for > 1 month
285501|NCT01563159|Belgium
285502|NCT01563159|hospitals
285503|NCT01563159|Rotavirus
285504|NCT01563146|Rotavirus
285505|NCT01563146|hospitals
285506|NCT01563146|Belgium
285507|NCT01563133|endomicroscopy
285508|NCT01563133|needle-based
285509|NCT01563133|pancreatic
285510|NCT01563133|cyst
285511|NCT01563133|mass
285512|NCT01563133|EUSFNA
285513|NCT01563107|Orthostatic Intolerance
285514|NCT01563107|Tachycardia
285515|NCT01563107|Orthostatic Hypotension
285516|NCT01563107|Sodium
285517|NCT01563094|Bone Density
285518|NCT01563094|Lactation
285519|NCT01563094|Bone Turnover Markers
285520|NCT01563081|Allergic rhinitis
285521|NCT01563081|Pediatric
285522|NCT01563081|Pruritus
285523|NCT01563081|Levocetirizine
285524|NCT01563068|plaque psoriasis
285525|NCT01563042|immunogenicity
285526|NCT01563042|GSK2434735
285527|NCT01563042|pharmacokinetics (PK)
285528|NCT01563042|PK
285529|NCT01563042|biospecific antibody
285530|NCT01563016|schizophrenia
285531|NCT01563016|Psychotic Disorders
285532|NCT01563016|Psychoses
285533|NCT01563003|Autism
285534|NCT01563003|Asperger's Syndrome
285535|NCT01563003|Pervasive Developmental Disorder Not Otherwise Specified
285536|NCT01563003|Treatment
285537|NCT01563003|Cognitive-behavioral therapy
285538|NCT01563003|Anxiety
285539|NCT01563003|Children
285540|NCT01563003|Therapy
285541|NCT01562951|Crohn's disease
285542|NCT01562951|mucosal inflammation
285543|NCT01562951|lesions
285544|NCT01562938|Respiratory Syncytial Virus
285545|NCT01562912|radiofrequency
285546|NCT01562912|ablation
285547|NCT01562912|atrial fibrillation
285548|NCT01562912|PVAC
285549|NCT01562899|MEK162
285550|NCT01562899|AMG 479
285551|NCT01562899|Ganitumab
285552|NCT01562899|colorectal adenocarcinoma
285553|NCT01562899|pancreatic adenocarcinoma
285554|NCT01562899|melanoma
285555|NCT01562899|KRAS
285556|NCT01562899|BRAF
285557|NCT01562886|Rilpivirine CSF pharmacokinetics
285558|NCT01562873|pSTAT3+
285559|NCT01562860|median nerve
285560|NCT01562860|carpal tunnel syndrome
285561|NCT01562860|Pronator Teres Release
285562|NCT01562782|Elevated triglycerides
285563|NCT01562782|Diabetes Mellitus
285564|NCT01562782|Dyslipidemia
285565|NCT01562782|Lipid Metabolic Disorders
285566|NCT01562782|Body Weight
285567|NCT01562730|Coronary Artery Disease
285568|NCT01562730|Myocardial Ischemia
285569|NCT01562730|Coronary Disease
285570|NCT01562730|Heart Diseases
285571|NCT01562730|Cardiovascular Diseases
285572|NCT01562730|Arteriosclerosis
285573|NCT01562730|Arterial Occlusive Diseases
285574|NCT01562730|Vascular Diseases
285575|NCT01562730|iECG
285576|NCT01562730|12 leads ECG
285577|NCT01562704|mechanism of action of paracetamol in the brain structures
285578|NCT01562691|nasal packing
285579|NCT01562691|nasal airway
285580|NCT01562691|septoplasty
285581|NCT01562691|oxygen saturation
285582|NCT01562691|postoperative pain
285583|NCT01562678|fMRI
285584|NCT01562678|Liraglutide
285585|NCT01562678|diabetes
285586|NCT01562678|GLP-1
285587|NCT01562665|All patients with NSCLC attending participating hospitals
285588|NCT01562639|maintenance therapy,
285589|NCT01562639|repeatedly recurring,
285590|NCT01562639|relapsing reflux oesophagitis,
285591|NCT01562639|Nexium
285592|NCT01562613|Stroke
285593|NCT01562613|Hypertension
285594|NCT01562600|NSAIDs
285595|NCT01562600|Gastric ulcer or duodenal ulcer
285596|NCT01562600|Nexium
285597|NCT01562548|upper back/neck/shoulder muscle spasm
285598|NCT01562535|pulled elbow
285599|NCT01562535|nursemaid elbow
285600|NCT01562509|Non-Hodgkin lymphoma (NHL)
285601|NCT01562509|Quality of health care
285602|NCT01562509|Oncology Service Hospital
285603|NCT01562509|Patient-centredness
285604|NCT01562509|PROMs
285605|NCT01562496|Parkinson's disease
285606|NCT01562496|Neuroprotective
285607|NCT01562496|Intensive exercise
285608|NCT01562483|postsurgical pain
285609|NCT01562483|abdominal pain
285610|NCT01562483|visceral pain
285611|NCT01562483|chronic pain
285612|NCT01562470|cellulite
285613|NCT01562470|reduction
285614|NCT01562470|cream
285615|NCT01562470|thighs
285616|NCT01562470|women
285617|NCT01562444|Long term immunogenicity study
285618|NCT01562418|Ergonomics
285619|NCT01562418|musculoskeletal symptoms
285620|NCT01562418|kinematics
285621|NCT01562405|Relapsed
285622|NCT01562405|Refractory
285623|NCT01562392|dietary prevention
285624|NCT01562392|cognitive performance
285625|NCT01562392|metabolic syndrome
285626|NCT01562392|colonic fermentation
285627|NCT01562392|sub clinical inflammation
285628|NCT01562392|cognition and metabolism
285629|NCT01562379|complementary food supplements
285630|NCT01562379|stunting
285631|NCT01562379|wasting
285632|NCT01562379|growth
285633|NCT01562379|Bangladesh
285634|NCT01562379|infant feeding
285635|NCT01562366|Iliotibial Band Release
285636|NCT01562366|Trochanteric Bursectomy
285637|NCT01562366|Micro debridement
285638|NCT01562353|Opioid Dependence
285639|NCT01562353|Opioids for the treatment of pain
285640|NCT01562340|Hemodialysis
285641|NCT01562340|End stage renal disease
285642|NCT01562340|Oxidative stress
285643|NCT01562340|Inflammation
285644|NCT01562340|Endothelial dysfunction
285645|NCT01562340|Cardiovascular disease
285646|NCT01562340|Antioxidants
285647|NCT01562340|Flavonoids
285648|NCT01562314|Mild to Moderate Ulcerative Colitis
285649|NCT01562301|chemotherapeutic agent toxicity
285650|NCT01562301|recurrent non-small cell lung cancer
285651|NCT01562301|stage IIIA non-small cell lung cancer
285652|NCT01562301|stage IIIB non-small cell lung cancer
285653|NCT01562301|stage IV non-small cell lung cancer
285654|NCT01562301|carboplatin
285655|NCT01562301|Paraplatin
285656|NCT01562301|docetaxel
285657|NCT01562301|Taxotere
285658|NCT01562301|Anvirzel
285659|NCT01562301|nerium oleander
285660|NCT01562301|Advanced Non-Small Cell Lung Cancer
285661|NCT01562301|NSCLC
285662|NCT01562288|HER2-positive breast cancer
285663|NCT01562288|HER2-negative breast cancer
285664|NCT01562288|stage IA breast cancer
285665|NCT01562288|stage IB breast cancer
285666|NCT01562288|stage II breast cancer
285667|NCT01562288|stage IIIA breast cancer
285668|NCT01562275|GDC0973
285669|NCT01562275|MEK
285670|NCT01562275|MEK inhibitor
285671|NCT01562275|GDC0068
285672|NCT01562275|Akt
285673|NCT01562275|Akt inhibitor
285674|NCT01562262|Apnea
285675|NCT01562262|PVT
285676|NCT01562262|Reaction Time
285677|NCT01562249|clinical evaluation
285678|NCT01562249|controlled clinical trial
285679|NCT01562249|electromyography
285680|NCT01562249|exercise program
285681|NCT01562249|motor control
285682|NCT01562223|stage IIA prostate cancer
285683|NCT01562223|stage IIB prostate cancer
285684|NCT01562223|stage III prostate cancer
285685|NCT01562223|stage IV prostate cancer
285686|NCT01562223|adenocarcinoma of the prostate
285687|NCT01562210|NSCLC
285688|NCT01562210|Olaparib
285689|NCT01562210|CCRT
285690|NCT01562197|axitinib
285691|NCT01562197|glioblastoma
285692|NCT01562197|recurrent
285693|NCT01562171|Overweight
285694|NCT01562171|Obese
285695|NCT01562171|Obesity
285696|NCT01562171|Cholesterol
285697|NCT01562171|Hypercholesterolemia
285698|NCT01562171|LDL-Cholesterol
285699|NCT01562145|Rotator cuff tear, matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, partial-thickness tear, full-thickness tear, plasma.
285700|NCT01562132|cryptococcus
285701|NCT01562132|HIV
285702|NCT01562119|Burns
285703|NCT01562119|Wound repair
285704|NCT01562119|Skin substitutes
285705|NCT01562106|Cancer of Endometrium
285706|NCT01562106|Cancer of the Endometrium
285707|NCT01562106|Carcinoma of Endometrium
285708|NCT01562106|Endometrial Carcinoma
285709|NCT01562106|Endometrium Cancer
285710|NCT01562106|Neoplasms, Endometrial
285711|NCT01562093|Adrenal Cortex Hormones
285712|NCT01562093|Spirometry
285713|NCT01562093|Administration, Intranasal
285714|NCT01562093|Nasal blockage
285715|NCT01562093|Nasal sprays
285716|NCT01562080|hyperlipidemia
285717|NCT01562080|metabolic syndrome
285718|NCT01562080|yeast red
285719|NCT01562080|berberine
285720|NCT01562080|policosanol
285721|NCT01562080|astaxanthin
285722|NCT01562067|Cervical tumors,vascular changes,Sonographic characteristics
285723|NCT01562041|Cardiovascular disease
285724|NCT01562041|Exercise Treadmill Test
285725|NCT01562041|Ranolazine
285726|NCT01562041|Angina
285727|NCT01562041|Myocardial ischemia
285728|NCT01562028|non small cell lung cancer
285729|NCT01562028|advanced
285730|NCT01562028|non-squamous
285731|NCT01562028|EGFR
285732|NCT01562028|mutations
285733|NCT01562002|limbus
285734|NCT01562002|cornea
285735|NCT01562002|insufficiency syndrome
285736|NCT01562002|stem cell transplant
285737|NCT01561963|Apremilast
285738|NCT01561963|drug interaction
285739|NCT01561963|pharmacokinetics
285740|NCT01561911|Clinical Trial
285741|NCT01561911|Phase I
285742|NCT01561911|Antibodies
285743|NCT01561911|Monoclonal
285744|NCT01561898|Schizophrenia
285745|NCT01561898|JNS007ER
285746|NCT01561898|Paliperidone extended-release
285747|NCT01561885|Clinical Pathways
285748|NCT01561885|Length of Stay
285749|NCT01561885|Patient-Centered Care
285750|NCT01561885|Pragmatic Randomized Controlled Trial
285751|NCT01561859|Early Course Schizophrenia
285752|NCT01561859|Cognitive Enhancement Therapy
285753|NCT01561859|Enriched Supportive Therapy
285754|NCT01561846|Conjugated Linoleic Acid
285755|NCT01561846|LDL-cholesterol
285756|NCT01561846|Endocannabinoids
285757|NCT01561833|relapsed or refractory T cell lymphoma
285758|NCT01561820|mild cognitive impairment
285759|NCT01561820|cognitive disorders
285760|NCT01561820|exercise
285761|NCT01561794|Ciprofloxacin
285762|NCT01561794|Bacterial pneumonia
285763|NCT01561794|Community Acquired Pneumonia (CAP)
285764|NCT01561794|Hospital Acquired Pneumonia (HAP)
285765|NCT01561794|Secondary infection of chronic respiratory disease
285766|NCT01561794|400 mg BID/TID
285767|NCT01561781|Phase 1
285768|NCT01561781|healthy volunteers
285769|NCT01561781|pharmacokinetics
285770|NCT01561781|vandetanib
285771|NCT01561781|digoxin
285772|NCT01561755|HIV associated myelopathy
285773|NCT01561742|minocycline, augmentation, schizophrenia
285774|NCT01561729|nasogastric tube
285775|NCT01561729|orogastric tube
285776|NCT01561729|RightSpot pH Indicator
285777|NCT01561729|suction tube
285778|NCT01561729|RightBio Metrics
285779|NCT01561729|RightLevel
285780|NCT01561729|RightSpot Infant
285781|NCT01561729|NG Tube
285782|NCT01561729|pH
285783|NCT01561729|Gastric Acidity
285784|NCT01561716|video games
285785|NCT01561716|energy expenditure
285786|NCT01561716|physical activity
285787|NCT01561716|exercise physiology
285788|NCT01561703|Healthcare utilization
285789|NCT01561703|Tonsillectomy
285790|NCT01561703|Adenoidectomy/Tonsillectomy
285791|NCT01561703|Antibiotics
285792|NCT01561677|obstructive sleep apnea
285793|NCT01561677|syndrome survival
285794|NCT01561677|ischemic stroke
285795|NCT01561677|continuous positive airway pressure
285796|NCT01561677|handicap
285797|NCT01561664|obesity
285798|NCT01561664|insulin resistance
285799|NCT01561651|cardiac surgery
285800|NCT01561651|left atrial appendage
285801|NCT01561651|atrial fibrillation
285802|NCT01561651|stroke
285803|NCT01561651|non-CNS systemic embolism
285804|NCT01561638|Pulsed
285805|NCT01561638|radiofrequency
285806|NCT01561638|single-dose
285807|NCT01561638|shoulder pain
285808|NCT01561638|Pain lasts more than one month
285809|NCT01561638|patients referred to the pain clinic from the shoulder clinic
285810|NCT01561638|Failed all conservative therapies available
285811|NCT01561625|COPD
285812|NCT01561625|exercise training
285813|NCT01561612|Breastfeeding
285814|NCT01561612|Child Health
285815|NCT01561612|Obesity
285816|NCT01561612|Blood Pressure
285817|NCT01561612|Asthma
285818|NCT01561612|Cognitive Development
285819|NCT01561612|Behavior
285820|NCT01561612|Eczema
285821|NCT01561612|Lung Function
285822|NCT01561612|Spirometry
285823|NCT01561599|hepatocyte growth factor mimetic
285824|NCT01561599|hepatocyte growth factor(HGF)
285825|NCT01561599|Delayed Graft Function (DGF)
285826|NCT01561599|Kidney transplantation
285827|NCT01561586|Cervical cancer
285828|NCT01561586|Concurrent chemoradiation
285829|NCT01561586|Cisplatin
285830|NCT01561573|Point of Care Ultrasound
285831|NCT01561573|Emergency Ultrasound
285832|NCT01561573|Colles Fracture
285833|NCT01561573|Fracture Reduction
285834|NCT01561573|Bedside Ultrasound
285835|NCT01561560|DAILIES TOTAL1
285836|NCT01561560|contact lenses
285837|NCT01561560|myopia
285838|NCT01561547|pain
285839|NCT01561547|preterm neonate
285840|NCT01561547|sucrose
285841|NCT01561547|kangaroo mother care
285842|NCT01561534|fibula flap
285843|NCT01561534|oral implants
285844|NCT01561534|computer-guided
285845|NCT01561508|diabetes mellitus
285846|NCT01561508|children
285847|NCT01561495|scheduled to receive RT either pre- or postoperatively
285848|NCT01561482|Prostate carcinoma
285849|NCT01561482|Prostate cancer
285850|NCT01561482|Prostate Specific Antigen
285851|NCT01561482|PSA
285852|NCT01561482|Metformin
285853|NCT01561482|Simvastatin
285854|NCT01561482|Radiation therapy
285855|NCT01561482|Prostatectomy
285856|NCT01561469|Linezolid
285857|NCT01561469|Vancomycin
285858|NCT01561469|Ventilator-Associated Pneumonia
285859|NCT01561469|Respiratory Tract Infections
285860|NCT01561456|non-small-cell lung cancer
285861|NCT01561456|squamous cell carcinoma
285862|NCT01561456|adenocarcinoma of the lung
285863|NCT01561456|IGF-1 inhibitor
285864|NCT01561456|docetaxel
285865|NCT01561456|AXL1717
285866|NCT01561456|NSCLC
285867|NCT01561456|SCC
285868|NCT01561456|AC
285869|NCT01561443|Breast cancer,
285870|NCT01561443|hormone positive,
285871|NCT01561430|beta-secretase inhibitor
285872|NCT01561326|cervical cancer
285873|NCT01561326|follow-up
285874|NCT01561326|Pap test
285875|NCT01561326|Medical management
285876|NCT01561326|Colposcopy
285877|NCT01561313|On label Humira users
285878|NCT01561313|Pain
285879|NCT01561313|Rheumatoid Arthritis,
285880|NCT01561300|Black tea
285881|NCT01561300|Flow Mediated Dilation
285882|NCT01561300|Vascular function
285883|NCT01561300|India
285884|NCT01561261|fasciotomy
285885|NCT01561261|ACS
285886|NCT01561248|EHEC
285887|NCT01561248|O104:H4
285888|NCT01561248|German
285889|NCT01561248|outbreak
285890|NCT01561248|polyethylene glycol
285891|NCT01561248|Bowel lavage
285892|NCT01561235|Protein
285893|NCT01561235|Appetite
285894|NCT01561235|Satiety
285895|NCT01561235|Energi intake
285896|NCT01561235|Appetite regulating hormones
285897|NCT01561235|Dose-response
285898|NCT01561222|calcitrol
285899|NCT01561222|Bone mineral density
285900|NCT01561222|Osteoprotegin
285901|NCT01561222|Vascular calcification
285902|NCT01561209|amitryptiline
285903|NCT01561209|Chronic pain
285904|NCT01561209|Neck pain
285905|NCT01561196|arteria cannulation
285906|NCT01561196|Ultrasound
285907|NCT01561196|pain
285908|NCT01561196|complications
285909|NCT01561183|Vital pulp therapy
285910|NCT01561183|Pulp cap
285911|NCT01561183|pulpotomy
285912|NCT01561183|calcium enriched mixture
285913|NCT01561183|CEM cement
285914|NCT01561183|Endodontic
285915|NCT01561170|Electromagnetic
285916|NCT01561170|Field therapy
285917|NCT01561170|Chronically venous ulcer
285918|NCT01561170|Venous insufficiens
285919|NCT01561157|porphyria
285920|NCT01561157|acute intermittent
285921|NCT01561157|coproporphyria
285922|NCT01561157|variegate
285923|NCT01561157|erythropoietic
285924|NCT01561157|protoporphyria
285925|NCT01561157|hepatoerythropoietic
285926|NCT01561157|cutanea tarda
285927|NCT01561157|AIP
285928|NCT01561157|HCP
285929|NCT01561157|VP
285930|NCT01561157|ADP
285931|NCT01561157|ALAD
285932|NCT01561157|PCT
285933|NCT01561157|HEP
285934|NCT01561157|CEP
285935|NCT01561157|EPP
285936|NCT01561157|XLP
285937|NCT01561144|Defibrillators, Implantable
285938|NCT01561144|Cardiac arrhythmias
285939|NCT01561144|Heart Disease
285940|NCT01561131|Obesity
285941|NCT01561131|Protein intake
285942|NCT01561131|Calcium intake
285943|NCT01561131|Weight loss
285944|NCT01561131|Weight maintenance
285945|NCT01561131|Blood lipid profile
285946|NCT01561131|Diet induced thermogenesis
285947|NCT01561118|hemodialysis
285948|NCT01561118|dialysis efficacy
285949|NCT01561118|cardiorespiratory capacity
285950|NCT01561118|exercise capacity
285951|NCT01561118|children and adolescents
285952|NCT01561092|Stroke
285953|NCT01561092|RCT
285954|NCT01561092|SSRI
285955|NCT01561092|Outcome
285956|NCT01561079|Buprenorphine
285957|NCT01561079|Methadone
285958|NCT01561079|Fetal neurobehavior
285959|NCT01561079|Infant neurobehavior
285960|NCT01561066|Fibrin glue
285961|NCT01561066|Platelet
285962|NCT01561066|Autologous derivation
285963|NCT01561066|Prospective randomized trial
285964|NCT01561066|Fistulas
285965|NCT01561053|Alzheimer's disease
285966|NCT01561053|AB peptide
285967|NCT01561053|Albumin
285968|NCT01561053|Intravenous immune globulin
285969|NCT01561053|IGIV
285970|NCT01561040|Dry Eye syndrome
285971|NCT01561040|tear film deficiency
285972|NCT01561040|Essential Fatty Acid nutritional supplements
285973|NCT01561040|Omega three supplements
285974|NCT01560988|Asthma
285975|NCT01560988|Borage
285976|NCT01560988|Echium
285977|NCT01560988|Botanical
285978|NCT01560949|Pancreatic Cancer
285979|NCT01560949|Adenocarcinoma of the Pancreas
285980|NCT01560949|High Risk Resectable
285981|NCT01560949|Borderline Resectable
285982|NCT01560949|Chemotherapy
285983|NCT01560949|Chemoradiation therapy
285984|NCT01560949|Oxaliplatin
285985|NCT01560949|Eloxatin
285986|NCT01560949|Irinotecan
285987|NCT01560949|CPT-11
285988|NCT01560949|Camptosar
285989|NCT01560949|5-FU
285990|NCT01560949|5-Fluorouracil
285991|NCT01560949|Adrucil
285992|NCT01560949|Efudex
285993|NCT01560949|Gemcitabine
285994|NCT01560949|Gemcitabine Hydrochloride
285995|NCT01560949|Gemzar
285996|NCT01560949|Radiation Therapy
285997|NCT01560949|XRT
285998|NCT01560949|RT
285999|NCT01560949|External Beam Radiation Therapy
286000|NCT01560936|bacterial contamination
286001|NCT01560923|hormone refractory prostate cancer
286002|NCT01560910|with or without GERD symptoms
286003|NCT01560910|presenting to gastrointestinal clinic of Maharaj Nakorn Chiangmai Hospital
286004|NCT01560910|November 2009 to November 2010
286005|NCT01560910|GERD
286006|NCT01560910|NERD
286007|NCT01560871|Heart failure
286008|NCT01560871|inspiratory muscle training
286009|NCT01560871|physical activity
286010|NCT01560845|autologous bone marrow stem cells
286011|NCT01560845|portal hypertension
286012|NCT01560845|surgery
286013|NCT01560845|liver cirrhosis
286014|NCT01560819|ulcerative colitis, gut microbial transplantation
286015|NCT01560806|hypertension
286016|NCT01560806|cardiovascular risk factor
286017|NCT01560806|lifestyle
286018|NCT01560793|Influenza
286019|NCT01560793|Vaccines
286020|NCT01560793|H5N1
286021|NCT01560780|Coronary Artery Bypass
286022|NCT01560780|thrombosis
286023|NCT01560780|prasugrel
286024|NCT01560767|Pain relief
286025|NCT01560767|Arthroplasty
286026|NCT01560767|periarticular knee infiltration
286027|NCT01560754|Randomized
286028|NCT01560754|Placebo-controlled
286029|NCT01560754|Double-blind
286030|NCT01560754|Multi-center
286031|NCT01560754|Disease-modifying potential
286032|NCT01560754|transdermal nicotine
286033|NCT01560741|Chronic respiratory failure
286034|NCT01560741|Noninvasive Mechanical Ventilation
286035|NCT01560741|Home-care
286036|NCT01560741|Telemedicine
286037|NCT01560741|COPD
286038|NCT01560728|Post Traumatic Stress Disorder
286039|NCT01560728|Major Depressive Disorder
286040|NCT01560728|Dysthymia
286041|NCT01560728|Generalized Anxiety Disorder
286042|NCT01560728|Social Phobia
286043|NCT01560728|Panic Disorder
286044|NCT01560715|Retinitis pigmentosa
286045|NCT01560715|stem cell
286046|NCT01560715|bone marrow
286047|NCT01560715|retinal dysprophy
286048|NCT01560702|autologous blood
286049|NCT01560702|epinephrine
286050|NCT01560702|endoscopy
286051|NCT01560702|ulcer
286052|NCT01560702|hemostasis
286053|NCT01560689|bone marrow transplantation
286054|NCT01560689|obstructive lung disease
286055|NCT01560689|bronchodilators
286056|NCT01560689|inhaled steroids
286057|NCT01560689|late-onset pulmonary complication
286058|NCT01560676|Internet
286059|NCT01560676|School based
286060|NCT01560676|Obesity Prevention Program
286061|NCT01560676|Adolescents
286062|NCT01560663|Breast Cancer
286063|NCT01560663|Neoadjuvant therapy
286064|NCT01560663|Triple negative
286065|NCT01560663|predictor of response
286066|NCT01560663|predictor of resistance
286067|NCT01560663|Continuous Renal Replacement Therapy
286068|NCT01560650|CRRT
286069|NCT01560650|cardiac surgery associated acute kidney injury
286070|NCT01560650|Intensity
286071|NCT01560637|PAH
286072|NCT01560637|PH
286073|NCT01560637|FREEDOM
286074|NCT01560637|6 minute walk test
286075|NCT01560637|treprostinil
286076|NCT01560637|open label
286077|NCT01560624|PAH
286078|NCT01560624|PH
286079|NCT01560624|Clinical Worsening
286080|NCT01560624|Freedom
286081|NCT01560624|Freedom-Ev
286082|NCT01560624|Treprostinil
286083|NCT01560624|UT-15C
286084|NCT01560624|6 Minute walk test
286085|NCT01560598|GERD
286086|NCT01560598|reflux esophagitis
286087|NCT01560598|adipokine
286088|NCT01560598|especially
286089|NCT01560598|endoscopically proven
286090|NCT01560585|Isotretinoin
286091|NCT01560585|Alzheimer's disease
286092|NCT01560585|Dementia
286093|NCT01560585|Retinoid
286094|NCT01560572|kidney transplantation
286095|NCT01560572|immunosuppression
286096|NCT01560572|steroids
286097|NCT01560572|tacrolimus OD
286098|NCT01560559|Primary esophageal achalasia
286099|NCT01560559|endoscopic myotomy
286100|NCT01560559|high resolution manometry
286101|NCT01560520|acute ischemic stroke
286102|NCT01560520|accelerometer
286103|NCT01560481|metformin glycinate
286104|NCT01560481|pharmacokinetics
286105|NCT01560481|pharmacodynamics
286106|NCT01560468|Hepatitis C Virus Infection
286107|NCT01560468|Liver Transplantation
286108|NCT01560455|stent
286109|NCT01560455|bifurcation
286110|NCT01560455|coronary
286111|NCT01560442|Analgesics, opioids
286112|NCT01560442|Opiate substitution treatment
286113|NCT01560442|Methadone
286114|NCT01560442|Buprenorphine
286115|NCT01560442|Hyperalgesia
286116|NCT01560442|Pupil
286117|NCT01560442|Pain
286118|NCT01560442|Psychophysics
286119|NCT01560442|previous illicit drug intake, under a substitution program
286120|NCT01560429|anesthesia and analgesia
286121|NCT01560429|Epidural Anesthesia
286122|NCT01560429|administration schedules, drug
286123|NCT01560416|Metastatic
286124|NCT01560416|HR positive
286125|NCT01560416|ER positive
286126|NCT01560403|Short bowel syndrome
286127|NCT01560403|Parenteral nutrition
286128|NCT01560403|PN
286129|NCT01560403|HPN
286130|NCT01560403|TPN
286131|NCT01560403|SBS
286132|NCT01560390|Sedation
286133|NCT01560390|ICU
286134|NCT01560390|Ketamine
286135|NCT01560390|Confusion
286136|NCT01560390|Hyperalgesia
286137|NCT01560377|Laparoscopic low anterior colon resection
286138|NCT01560377|Laparoscopic left colectomy
286139|NCT01560377|Colectomy
286140|NCT01560377|Rectal cancer
286141|NCT01560377|Colon cancer
286142|NCT01560377|Crohn's Disease
286143|NCT01560377|Polyp
286144|NCT01560377|Procidentia
286145|NCT01560377|Diverticulitis
286146|NCT01560364|Renal replacement therapy
286147|NCT01560364|Hemofilter clotting
286148|NCT01560364|Clotting risk factor
286149|NCT01560364|Hemofilter clotting prevention
286150|NCT01560351|Pathological gambling
286151|NCT01560351|craving
286152|NCT01560351|repeated Transcranial Magnetic Stimulation
286153|NCT01560351|craving cues
286154|NCT01560338|Pharmacokinetics
286155|NCT01560338|Midazolam
286156|NCT01560338|Morphine
286157|NCT01560338|Cardiac Arrest
286158|NCT01560338|Hypothermia
286159|NCT01560325|Solid Tumor, Tubulin inhibitor
286160|NCT01560312|Renal denervation
286161|NCT01560312|Resistant hypertension
286162|NCT01560312|Spironolactone
286163|NCT01560312|Long-term Outcome
286164|NCT01560299|hyperthyroidism
286165|NCT01560299|radio-iodine
286166|NCT01560299|I-131
286167|NCT01560299|methimazole
286168|NCT01560299|graves disease
286169|NCT01560286|PKU
286170|NCT01560286|Injections
286171|NCT01560286|PEG-PAL
286172|NCT01560286|PAL
286173|NCT01560247|Stroke
286174|NCT01560247|Ischemic Stroke
286175|NCT01560247|Revascularization
286176|NCT01560247|Mechanical thrombectomy
286177|NCT01560247|Neurothrombectomy
286178|NCT01560234|Safety
286179|NCT01560234|tolerability
286180|NCT01560234|healthy
286181|NCT01560234|pharmacokinetic
286182|NCT01560234|pharmacodynamic
286183|NCT01560234|inhaled
286184|NCT01560208|infectious keratitis
286185|NCT01560208|infective keratitis
286186|NCT01560208|prospective multicentre study
286187|NCT01560208|Asia
286188|NCT01560195|neutropenia
286189|NCT01560195|febrile neutropenia
286190|NCT01560195|chemotherapy
286191|NCT01560182|Metachromatic Leukodystrophy
286192|NCT01560182|Lentiviral vector
286193|NCT01560182|Gene Therapy
286194|NCT01560169|Celiac Disease
286195|NCT01560169|Coeliac Disease
286196|NCT01560169|Celiac Sprue
286197|NCT01560169|Keilakia Disease
286198|NCT01560117|AGMT
286199|NCT01560117|NHL
286200|NCT01560104|Randomized
286201|NCT01560104|metastatic
286202|NCT01560104|ABT-888
286203|NCT01560104|paclitaxel
286204|NCT01560104|non-small cell lung cancer
286205|NCT01560104|PARP
286206|NCT01560104|veliparib
286207|NCT01560104|progression free survival
286208|NCT01560104|carboplatin
286209|NCT01560091|clearance rate
286210|NCT01560078|Tuberculosis
286211|NCT01560078|Pleural effusion
286212|NCT01560078|Category 3
286213|NCT01560052|end stage kidney disease
286214|NCT01560052|IgA nephropathy
286215|NCT01560039|Neuropathic pain
286216|NCT01560039|neurostimulation
286217|NCT01560026|ovarian preservation
286218|NCT01560013|Alcohol
286219|NCT01560013|naltrexone
286220|NCT01560013|cue reactivity
286221|NCT01560013|PET
286222|NCT01560000|The focus of this study is to determine satiety
286223|NCT01559987|plaque removal methods
286224|NCT01559987|oral hygiene devices
286225|NCT01559974|Peripheral arterial disease
286226|NCT01559974|PAOD
286227|NCT01559974|Vitamin D
286228|NCT01559974|Walking impairment
286229|NCT01559961|bladder
286230|NCT01559961|cystitis
286231|NCT01559961|frequency
286232|NCT01559961|nocturia
286233|NCT01559961|pain
286234|NCT01559961|urgency
286235|NCT01559948|Low back pain
286236|NCT01559948|Sacroiliac joint pain
286237|NCT01559948|Lumbopelvic stabilization program
286238|NCT01559948|Pelvic compression belt
286239|NCT01559948|Deep abdominal muscles
286240|NCT01559935|Multiple Myeloma
286241|NCT01559922|Acne
286242|NCT01559909|Lower limb loss
286243|NCT01559909|Leg amputation
286244|NCT01559909|walking study
286245|NCT01559909|socket technology
286246|NCT01559896|egg protein hydrolysate
286247|NCT01559883|cancer
286248|NCT01559883|thrombosis
286249|NCT01559883|pulmonary embolism
286250|NCT01559883|anticoagulation
286251|NCT01559883|low molecular weight heparin
286252|NCT01559870|cardiac surgery
286253|NCT01559870|cytokine
286254|NCT01559870|clinical scoring system
286255|NCT01559870|risk factor
286256|NCT01559857|Depression
286257|NCT01559857|Insulin resistance
286258|NCT01559857|Mood disorder
286259|NCT01559844|Hepatitis
286260|NCT01559844|Chronic
286261|NCT01559844|hepatocellular carcinoma
286262|NCT01559844|HCC
286263|NCT01559844|transplant
286264|NCT01559831|Japanese Encephalitis
286265|NCT01559831|IXIARO
286266|NCT01559831|Japanese Encephalitis Vaccine
286267|NCT01559805|HIV
286268|NCT01559805|Viral Load
286269|NCT01559805|Risk
286270|NCT01559805|Patient Compliance
286271|NCT01559805|Homosexuality, Male
286272|NCT01559805|Anti-Retroviral Agents
286273|NCT01559779|Obesity
286274|NCT01559779|Roux-en-Y gastric bypass
286275|NCT01559779|Incretin hormones
286276|NCT01559779|Beta cell function
286277|NCT01559766|Vitamin A
286278|NCT01559766|Dietary requirement
286279|NCT01559766|Dietary records
286280|NCT01559766|Deuterated retinol dilution technique
286281|NCT01559766|Chinese children
286282|NCT01559766|Dietary intake of vitamin A
286283|NCT01559766|Vitamin A liver reserves
286284|NCT01559753|Antibiotic
286285|NCT01559753|treatment
286286|NCT01559753|ventilator associated pneumonia
286287|NCT01559753|duration
286288|NCT01559740|regional anesthesia
286289|NCT01559740|children
286290|NCT01559740|postoperative pain relief
286291|NCT01559727|heart failure
286292|NCT01559727|diuresis
286293|NCT01559727|prednisone
286294|NCT01559714|Troponin
286295|NCT01559714|Exercise
286296|NCT01559714|MRI
286297|NCT01559701|Safety
286298|NCT01559701|PF-00345439
286299|NCT01559701|Remoxy
286300|NCT01559701|PTI-821
286301|NCT01559675|Corticosteroids
286302|NCT01559675|perioperative
286303|NCT01559675|colorectal surgery
286304|NCT01559662|chewing gum
286305|NCT01559662|ileus
286306|NCT01559662|gastrointestinal function
286307|NCT01559662|colorectal surgery
286308|NCT01559662|abdominal surgery
286309|NCT01559649|Stroke
286310|NCT01559649|Deglutition
286311|NCT01559649|Deglutition Disorders
286312|NCT01559649|Nurse Screening
286313|NCT01559636|seroconversion
286314|NCT01559636|oral polio vaccine
286315|NCT01559636|OPV
286316|NCT01559636|poliomyelitis
286317|NCT01559636|diarrhea
286318|NCT01559636|seroimmunity
286319|NCT01559610|cardiac surgery
286320|NCT01559610|orientation
286321|NCT01559610|nursing
286322|NCT01559597|controlled temperature chain
286323|NCT01559597|outside the cold chain
286324|NCT01559597|vaccination
286325|NCT01559597|prevention of mother to child transmission
286326|NCT01559584|Alopecia
286327|NCT01559584|Areata
286328|NCT01559584|Phototherapy
286329|NCT01559584|Phototoxic
286330|NCT01559584|Ultraviolet A
286331|NCT01559584|Randomized controlled trial
286332|NCT01559584|Interferon gamma
286333|NCT01559584|Transforming growth factor beta-1
286334|NCT01559584|Insulin like growth factor-1
286335|NCT01559571|Retinopathy of Prematurity
286336|NCT01559545|Clostridium difficile associated diarrhea
286337|NCT01559545|Metronidazole
286338|NCT01559545|CDAD
286339|NCT01559532|Deep vein thrombosis
286340|NCT01559532|Thromboembolism
286341|NCT01559532|Tourniquet
286342|NCT01559532|Knee prosthesis.
286343|NCT01559519|TIPS
286344|NCT01559519|albumin
286345|NCT01559519|hepatic encephalopathy
286346|NCT01559519|hyponatremia
286347|NCT01559519|hypovolemia
286348|NCT01559519|cirrhosis
286349|NCT01559506|CFU
286350|NCT01559506|surgery site
286351|NCT01559493|atherosclerotic lesion assessment
286352|NCT01559480|Endometriosis
286353|NCT01559480|Desogestrel
286354|NCT01559480|Placebo
286355|NCT01559467|Myocardial infarction
286356|NCT01559467|Randomized Controlled Trial
286357|NCT01559467|Magnetic Resonance Imaging
286358|NCT01559467|Coronary Angiography
286359|NCT01559467|Tomography, X-Ray Computed
286360|NCT01559467|Mortality
286361|NCT01559467|Complications
286362|NCT01559467|Quality of Life
286363|NCT01559467|Cost-Benefit Analysis
286364|NCT01559454|chronic pain
286365|NCT01559454|opioid dependence
286366|NCT01559454|methadone
286367|NCT01559454|buprenorphine
286368|NCT01559454|substance use disorder
286369|NCT01559441|beetroot juice
286370|NCT01559441|nitrate
286371|NCT01559441|vascular activity
286372|NCT01559441|postprandial state
286373|NCT01559428|Plant sterols
286374|NCT01559428|Plant stanols
286375|NCT01559428|Oxyphytosterols
286376|NCT01559428|Cardiovascular Disease
286377|NCT01559415|Adipocytes
286378|NCT01559389|Urge Urinary Incontinence
286379|NCT01559389|Vesicare
286380|NCT01559389|Urinary Incontinence
286381|NCT01559389|Sexual function
286382|NCT01559350|OPCAB
286383|NCT01559337|defect
286384|NCT01559337|dorsal branch of the proper digital nerve
286385|NCT01559337|proper digital nerve
286386|NCT01559337|nerve transfer
286387|NCT01559337|finger sensory reconstruction
286388|NCT01559311|Bradycardia
286389|NCT01559298|Transcatheter aortic valve implantation
286390|NCT01559298|Antithrombotic treatment
286391|NCT01559298|Clopidogrel
286392|NCT01559298|Aspirin
286393|NCT01559298|Myocardial Infarction
286394|NCT01559298|Ischemic stroke
286395|NCT01559298|Major bleeding
286396|NCT01559272|Schizophrenia
286397|NCT01559272|Paliperidone palmitate
286398|NCT01559272|R092670
286399|NCT01559272|Paliperidone
286400|NCT01559272|3-month formulation
286401|NCT01559272|Pharmacokinetics
286402|NCT01559259|ibuprofen
286403|NCT01559259|acetaminophen
286404|NCT01559259|pain
286405|NCT01559259|molar extraction
286406|NCT01559246|Cardiac Arrhythmia Monitoring
286407|NCT01559246|Holter Monitoring
286408|NCT01559246|Continuous ECG monitoring
286409|NCT01559246|Event monitoring
286410|NCT01559246|Observational
286411|NCT01559207|nucleosome
286412|NCT01559207|plasma nucleosome concentrations
286413|NCT01559207|free DNA
286414|NCT01559207|plasma free DNA concentrations
286415|NCT01559181|Offspring of mothers with type 1 diabetes
286416|NCT01559181|Pregnancy and programing
286417|NCT01559181|Intrauterine hyperglycaemia
286418|NCT01559181|Study focuses on offspring of mothers with type 1 diabetes
286419|NCT01559155|proteasomes
286420|NCT01559155|proteasome concentration
286421|NCT01559155|disease activity
286422|NCT01559155|proteolytic activity
286423|NCT01559155|autoantibodies
286424|NCT01559155|proteasome autoantibody
286425|NCT01559142|Crohn Disease
286426|NCT01559142|infliximab
286427|NCT01559142|azathioprine
286428|NCT01559103|Rheumatoid Arthritis
286429|NCT01559103|Phase I
286430|NCT01559103|Biologic
286431|NCT01559090|Japan
286432|NCT01559090|Phase2
286433|NCT01559090|Safety
286434|NCT01559090|Tolerability
286435|NCT01559090|Systemic Lupus Erythematosus
286436|NCT01559090|SLE, MEDI-546
286437|NCT01559077|ATTR
286438|NCT01559051|COPD
286439|NCT01559051|Pulmonary
286440|NCT01559051|Lungs
286441|NCT01559038|Assessing Effectiveness in Psoriatic Arthritis
286442|NCT01559025|Type 1 diabetes
286443|NCT01559025|Vildagliptin
286444|NCT01559025|Galvus
286445|NCT01559012|Hyperemesis Gravidarum
286446|NCT01559012|treatment
286447|NCT01559012|transdermal clonidine
286448|NCT01558986|Antibiotic prophylaxis
286449|NCT01558986|surgical site infection
286450|NCT01558986|modified radical mastectomy
286451|NCT01558986|Prevention of surgical site infection (SSI) in patients undergoing MRM for breast cancer
286452|NCT01558960|Retinoblastoma
286453|NCT01558947|gastric cancer
286454|NCT01558947|Peri-operative chemotherapy
286455|NCT01558934|lofexidine
286456|NCT01558934|methadone
286457|NCT01558934|interaction
286458|NCT01558934|pharmacodynamic
286459|NCT01558934|ECG
286460|NCT01558934|QTc
286461|NCT01558921|rectal cancer
286462|NCT01558921|radiotherapy
286463|NCT01558921|chemotherapy
286464|NCT01558921|5x5
286465|NCT01558921|capecitbine
286466|NCT01558921|oxaliplatin
286467|NCT01558921|CAPOX
286468|NCT01558921|FOLFOX
286469|NCT01558921|folinic acid
286470|NCT01558921|fluorouracil
286471|NCT01558908|critical limb ischemia
286472|NCT01558895|Infrared ray heat treatment
286473|NCT01558895|liver cirrhosis
286474|NCT01558895|refractory ascites
286475|NCT01558882|Essure
286476|NCT01558882|Change in uterine cytokines
286477|NCT01558882|Change in uterine natural killer cells
286478|NCT01558882|cytokine
286479|NCT01558882|natural killer cell
286480|NCT01558856|refractory overactive bladder
286481|NCT01558856|neuromodulation
286482|NCT01558856|sacral nerves
286483|NCT01558843|Sodium Management
286484|NCT01558843|Neurointensive Care
286485|NCT01558843|Hyponatremia
286486|NCT01558830|amiodarone
286487|NCT01558830|ranolazine
286488|NCT01558830|safety
286489|NCT01558830|arrhythmia
286490|NCT01558817|CPR
286491|NCT01558817|Palliative
286492|NCT01558817|Outcome
286493|NCT01558804|Streptococcus pyogenes
286494|NCT01558804|Streptococcus
286495|NCT01558791|PTSD
286496|NCT01558791|patient education handout
286497|NCT01558765|Rehabilitation
286498|NCT01558765|Integrated rehabilitation programme
286499|NCT01558765|Exercise training
286500|NCT01558765|Psycho-educational care
286501|NCT01558752|Total hip replacement
286502|NCT01558752|Bone mineral density (BMD)
286503|NCT01558739|Ruxolitinib
286504|NCT01558739|INC424
286505|NCT01558739|myelofibrosis
286506|NCT01558739|PMF
286507|NCT01558739|post polycythemia myelofibrosis
286508|NCT01558739|PPV MF
286509|NCT01558739|post-essential thrombocythemia myelofibrosis
286510|NCT01558739|PET-MF
286511|NCT01558739|Primary Myelofibrosis
286512|NCT01558739|Polycythemia
286513|NCT01558739|Thrombocythemia
286514|NCT01558739|Essential Thrombocytosis
286515|NCT01558739|myeloproliferative Disorders
286516|NCT01558739|Bone Marrow Diseases
286517|NCT01558739|Haematologic Diseases
286518|NCT01558739|Blood Coagulation Disorders
286519|NCT01558739|Blood Platelet Disorders
286520|NCT01558739|Haemorrhagic Disorders
286521|NCT01558726|Case Management
286522|NCT01558726|Crack abuse/dependents
286523|NCT01558726|Evaluation
286524|NCT01558726|Inpatient
286525|NCT01558726|ASI
286526|NCT01558726|Treatment retention
286527|NCT01558726|Abstinence
286528|NCT01558713|parturient
286529|NCT01558700|osteoarthritis
286530|NCT01558700|pain
286531|NCT01558700|brain
286532|NCT01558700|gray matter
286533|NCT01558687|Oncology
286534|NCT01558687|newly diagnosed inoperable glioblastoma
286535|NCT01558687|temolozomide
286536|NCT01558687|radiotherapy
286537|NCT01558687|dynamic MRI
286538|NCT01558687|Positron emission tomography
286539|NCT01558687|[18]FET tracer
286540|NCT01558687|cilengitide
286541|NCT01558687|World Health Organization [WHO] Grade IV
286542|NCT01558661|axitinib (AG-013736)
286543|NCT01558661|recurrent
286544|NCT01558661|metastatic
286545|NCT01558661|12-004
286546|NCT01558648|Minimally Invasive Esophagectomy
286547|NCT01558648|Open Esophagectomy
286548|NCT01558648|Quality of Life
286549|NCT01558648|12-003
286550|NCT01558635|Atrial Fibrillation
286551|NCT01558635|Surgical ablation
286552|NCT01558635|Maze procedure
286553|NCT01558635|AF
286554|NCT01558622|postoperative analgesia
286555|NCT01558622|dexketoprofen trometamol
286556|NCT01558622|tramadol hydrochloride
286557|NCT01558622|pethidine
286558|NCT01558622|laparoscopic Nissen fundoplication
286559|NCT01555697|Schizophrenia
286560|NCT01555697|prepulse inhibition
286561|NCT01555697|neurocognition
286562|NCT01555697|working memory
286563|NCT01555697|memantine
286564|NCT01555697|MATRICS Consensus Cognitive Battery
286565|NCT01555684|MS
286566|NCT01555684|CCSVI
286567|NCT01555671|labor,
286568|NCT01555671|meperidine,
286569|NCT01555671|active phase,
286570|NCT01555671|duration of labor
286571|NCT01555658|Long Lesions
286572|NCT01555658|Stent Implantation
286573|NCT01555645|Breast cancer
286574|NCT01555645|Stress management
286575|NCT01555645|Stepped care
286576|NCT01555645|Randomized
286577|NCT01555619|Left heart pacing lead
286578|NCT01555619|Cardiac resynchronization therapy (CRT)
286579|NCT01555619|Heart Failure
286580|NCT01555619|Quadripolar pacing
286581|NCT01555606|Psoriasis
286582|NCT01555606|Patient-reported outcome
286583|NCT01555606|Quality of Life
286584|NCT01558583|Colon
286585|NCT01558583|Prostate
286586|NCT01558583|Cancer
286587|NCT01558544|Ovarian tissue cryopreservation
286588|NCT01558544|Ovarian tissue transplantation
286589|NCT01558544|Fertility preservation
286590|NCT01558544|Risk of premature ovarian failure
286591|NCT01558531|peripheral arterial disease
286592|NCT01558531|drug-eluting balloon
286593|NCT01558531|restenosis
286594|NCT01558518|Handheld echocardiography
286595|NCT01558518|V-scan
286596|NCT01558518|Handheld ultrasound
286597|NCT01558518|Portable ultrasound
286598|NCT01558505|critical limb ischemia
286599|NCT01558505|drug-eluting balloon
286600|NCT01558505|restenosis
286601|NCT01558492|Metastatic Castrate Resistant Prostate Cancer
286602|NCT01558492|CRPC
286603|NCT01558479|Parkinson's Disease
286604|NCT01558479|Genetics
286605|NCT01558479|Family Research
286606|NCT01558479|Hereditary Neurodegenerative Diseases
286607|NCT01558466|newborn
286608|NCT01558466|INO
286609|NCT01558466|Sildenafil
286610|NCT01558466|PPHN
286611|NCT01558440|Nutrition rehabilitation
286612|NCT01558440|severe malnutrition
286613|NCT01558440|infant formula
286614|NCT01558440|F-100
286615|NCT01558414|Cholecystectomy
286616|NCT01558414|Minimally invasive surgery
286617|NCT01558414|Laparoscopic surgery
286618|NCT01558414|Single incision surgery
286619|NCT01558401|physical activity
286620|NCT01558401|elderly
286621|NCT01558401|women
286622|NCT01558401|efficiency
286623|NCT01558362|myocardial perfusion imaging
286624|NCT01558362|single photon emission tomography
286625|NCT01558362|Coronary artery disease
286626|NCT01558362|gamma camera imaging
286627|NCT01558362|Phase 1 clinical trial
286628|NCT01558362|cyclotron
286629|NCT01558349|Epispot
286630|NCT01558349|CellSearch
286631|NCT01558349|Circulating melanoma cells
286632|NCT01558349|circulating cells
286633|NCT01558336|Schistosoma haematobium
286634|NCT01558336|schoolchildren
286635|NCT01558336|Central Sudan
286636|NCT01558336|Praziquantel
286637|NCT01558323|LCQ908, Renal Impairment, Pharmacokinetics
286638|NCT01558284|Irritable bowel syndrome
286639|NCT01558284|Neu-P11
286640|NCT01558284|Melatonin
286641|NCT01558284|D-IBS
286642|NCT01558271|GLP-1
286643|NCT01558245|ischemic stroke; in-stent restenosis; tissue kallikrein;
286644|NCT01558245|the middle cerebral artery; atherosclerotic stenosis
286645|NCT01558232|Stroke
286646|NCT01558232|Tibion
286647|NCT01558232|Bionics
286648|NCT01558232|Rehab
286649|NCT01558232|Therapy
286650|NCT01558232|Robotics
286651|NCT01558232|Intention
286652|NCT01558219|Metastatic prostate cancer
286653|NCT01558206|PTE
286654|NCT01558206|Emergency bedside ultrasonography
286655|NCT01558206|pulmonary CT Angiography
286656|NCT01558206|Pulmonary Wedge infarction
286657|NCT01558206|Pulmonary Thromboembolism
286658|NCT01558193|Aggression DHA
286659|NCT01558193|Docosahexaenoic acid
286660|NCT01558193|Impulsivity
286661|NCT01558193|Minerals
286662|NCT01558193|Vitamins
286663|NCT01558167|Dose limiting toxicity of Lenalidomide
286664|NCT01558167|Chronic lymphocytic leukemia
286665|NCT01558154|depression
286666|NCT01558154|Chinese herb
286667|NCT01558154|acupuncture
286668|NCT01558154|Psychotherapy
286669|NCT01558154|Transcranial magnetic stimulation
286670|NCT01558141|IVF stimulation.
286671|NCT01558141|Poor responders.
286672|NCT01558141|IVF patients with poor response to stimulation
286673|NCT01558115|Columbia University
286674|NCT01558115|Primary hyperparathyroidism
286675|NCT01558115|Low bone density
286676|NCT01558115|Denosumab
286677|NCT01558115|Prolia
286678|NCT01558102|brain aneurysm PED Pipeline
286679|NCT01558076|Sickle cell anemia
286680|NCT01558076|exercise testing
286681|NCT01558076|cardiopulmonary disease
286682|NCT01558063|Ketamine
286683|NCT01558063|Major Depressive Disorder
286684|NCT01558063|Treatment
286685|NCT01558063|Depression
286686|NCT01558037|transplant
286687|NCT01558037|solid organ transplant
286688|NCT01558037|kidney transplant
286689|NCT01558037|liver transplant
286690|NCT01558037|pancreas transplant
286691|NCT01558037|heart transplant
286692|NCT01558037|CMV
286693|NCT01558037|Cytomegalovirus
286694|NCT01558024|compression stockings
286695|NCT01558024|physiopathology
286696|NCT01558011|gastric adenocarcinoma
286697|NCT01558011|Capecitabine and oxaliplatin (XELOX)
286698|NCT01558011|Docetaxel and capecitabine (TX)
286699|NCT01558011|Using genetic polymorphisms
286700|NCT01558011|drug metabolism and immunohistochemical stain
286701|NCT01558011|predict the efficacy
286702|NCT01557998|Test and linkage to care
286703|NCT01557998|Injecting drug user (IDU)
286704|NCT01557998|Prevention with positives
286705|NCT01557998|ART adherence
286706|NCT01557998|point of care CD4 counts
286707|NCT01557998|Peer case management
286708|NCT01557998|Conditional cash transfer
286709|NCT01557985|children
286710|NCT01557985|regional anesthesia
286711|NCT01557985|postoperative pain management
286712|NCT01557985|local anesthetic solution
286713|NCT01557985|toxicity
286714|NCT01557933|ECT
286715|NCT01557933|Bipolar Disorder
286716|NCT01557920|apnea
286717|NCT01557920|airway collapsibility
286718|NCT01557920|healthy
286719|NCT01557920|hypercapnia
286720|NCT01557920|general anesthesia
286721|NCT01557920|breathing-swallow coordination
286722|NCT01557920|aspiration
286723|NCT01557907|Diabetes
286724|NCT01557907|Diabetes Mellitus
286725|NCT01557907|Type 1 diabetes
286726|NCT01557907|Insulin Pump users
286727|NCT01557907|Intradermal insulin
286728|NCT01557894|Social anxiety disorders
286729|NCT01557894|Social phobia
286730|NCT01557894|Anxiety sensitivity
286731|NCT01557894|Irrational thinking
286732|NCT01557894|Guided self-help
286733|NCT01557894|Internet-delivered treatment
286734|NCT01557842|Ischemic
286735|NCT01557842|Ventricular Tachycardia
286736|NCT01557842|Implantable Cardioverter Defibrillators
286737|NCT01557842|Antiarrhythmic Drug Therapy
286738|NCT01557842|Ablation
286739|NCT01557842|Electrophysiology
286740|NCT01557829|spondylolisthesis
286741|NCT01557829|disc degeneration
286742|NCT01557829|lumbar interbody fusion
286743|NCT01557829|randomized controlled trial
286744|NCT01557829|ceramic interbody spacer
286745|NCT01557816|osteoarthritis
286746|NCT01557816|knee
286747|NCT01557816|Naproxen
286748|NCT01557803|Immune reconstitution inflammatory syndrome
286749|NCT01557803|Biomarkers
286750|NCT01557803|HIV
286751|NCT01557803|ART
286752|NCT01557803|predictive factors
286753|NCT01557803|epidemiological pattern
286754|NCT01557803|Gabon
286755|NCT01557790|Adult male
286756|NCT01557790|18 years or older
286757|NCT01557790|clinical diagnosis
286758|NCT01557751|Total knee arthroplasty
286759|NCT01557751|Total knee replacement
286760|NCT01557751|Genetics of pain
286761|NCT01557738|Exercise
286762|NCT01557738|Blood Flow
286763|NCT01557738|Nitric Oxide
286764|NCT01557738|Aging
286765|NCT01557738|Antioxidant
286766|NCT01557738|Flavanol
286767|NCT01557738|Young (18-30 yrs)
286768|NCT01557738|Aging (60 - 80 yrs)
286769|NCT01557725|Knee Replacement, Total
286770|NCT01557725|Hip Replacement, Total
286771|NCT01557725|Thromboembolism, Venous
286772|NCT01557725|prophylaxis
286773|NCT01557725|Enhanced recovery
286774|NCT01557686|Cancer Related fatigue
286775|NCT01557686|Quality of Life
286776|NCT01557686|Psychosocial Intervention
286777|NCT01557686|Rehabilitation
286778|NCT01557686|Physical Fitness
286779|NCT01557686|Physical Activity
286780|NCT01557686|Exercise Therapy
286781|NCT01557686|Exercise
286782|NCT01557686|Hematologic
286783|NCT01557686|Hematological
286784|NCT01557686|Leukemia, Myeloid, Acute
286785|NCT01557686|Acute Myeloid Leukemia
286786|NCT01557686|Acute Lymphoblastic Leukemia
286787|NCT01557686|Acute Leukemia
286788|NCT01557673|Nasogastric
286789|NCT01557673|Small bowel water
286790|NCT01557673|Diarrhoea
286791|NCT01557673|Mesenteric blood flow
286792|NCT01557673|Enteral feeding
286793|NCT01555593|COPD
286794|NCT01555593|FeNO
286795|NCT01555593|Bronchial inflammation
286796|NCT01555593|Small airways
286797|NCT01555593|Decubitus
286798|NCT01555580|myasthenia gravis
286799|NCT01555580|autoimmune
286800|NCT01555580|GM-CSF
286801|NCT01555567|ACL
286802|NCT01555567|muscle
286803|NCT01555567|quadriceps
286804|NCT01555567|strength
286805|NCT01555554|Post-traumatic stress disorder
286806|NCT01555554|Propranolol
286807|NCT01555554|surgery
286808|NCT01555554|anesthesia
286809|NCT01555541|relapsed
286810|NCT01555541|refractory
286811|NCT01555541|DLBCL
286812|NCT01555541|lymphoma
286813|NCT01555541|B-cell
286814|NCT01555541|diffuse
286815|NCT01555528|Growth disorders
286816|NCT01555528|Saizen
286817|NCT01555528|Easypod
286818|NCT01555528|Growth hormone
286819|NCT01555528|Pediatric subject
286820|NCT01557621|Immunization reminder/recall
286821|NCT01557621|Reminder/Recall systems
286822|NCT01557621|Population based Recall
286823|NCT01557621|Practice based Recall
286824|NCT01557608|cancer
286825|NCT01557608|chemotherapy
286826|NCT01557608|photon stimulation
286827|NCT01557608|neuropathy
286828|NCT01557608|pain
286829|NCT01557582|IPAH
286830|NCT01557582|HPAH
286831|NCT01557582|APAH CTD
286832|NCT01557582|APAH HIV
286833|NCT01557582|APAH PoPH
286834|NCT01557582|APAH Drugs/Toxins
286835|NCT01557582|APAH CHD repaired
286836|NCT01557582|APAH CHD unrepaired
286837|NCT01557569|methamphetamine
286838|NCT01557569|addiction
286839|NCT01557569|relapse
286840|NCT01557569|atomoxetine
286841|NCT01557556|CRH Antagonist
286842|NCT01557556|Nicotine
286843|NCT01557556|Nicotine Dependence
286844|NCT01557556|Smoking
286845|NCT01557556|Stress
286846|NCT01557543|Coronary Artery Bypass Grafting
286847|NCT01557543|Coronary Artery Disease
286848|NCT01557543|Transmyocardial Revascularization
286849|NCT01557543|Bone Marrow Stromal Cells
286850|NCT01557517|cGVHD
286851|NCT01557517|Oral cGVHD
286852|NCT01557517|Topical
286853|NCT01557517|Oral Rinse
286854|NCT01557517|Clobetasol
286855|NCT01557517|Oral Graft-Versus-Host Disease
286856|NCT01557517|GVHD
286857|NCT01557491|Alopecia
286858|NCT01557491|Coronal Incision
286859|NCT01557491|Scar Quality
286860|NCT01557478|breast cancer
286861|NCT01557478|melatonin
286862|NCT01557478|adjuvant therapy
286863|NCT01557478|quality of life
286864|NCT01557478|pain
286865|NCT01557478|sleep
286866|NCT01557478|survival
286867|NCT01557478|adverse events
286868|NCT01557452|JIA
286869|NCT01557426|skin
286870|NCT01557426|soft tissue
286871|NCT01557426|infection
286872|NCT01557426|cellulitis
286873|NCT01557426|abscess
286874|NCT01557413|Humerus
286875|NCT01557413|fracture
286876|NCT01557413|nail
286877|NCT01557413|plate
286878|NCT01557413|tuberosity
286879|NCT01557400|Duchenne muscular dystrophy
286880|NCT01557400|Becker muscular dystrophy
286881|NCT01557400|Nonsense mutation
286882|NCT01557400|Premature stop codon
286883|NCT01557400|DMD
286884|NCT01557400|BMD
286885|NCT01557400|nmDBMD
286886|NCT01557400|DBMD
286887|NCT01557400|Ataluren
286888|NCT01557400|PTC124
286889|NCT01557387|Pseudopolyp
286890|NCT01557387|Inflammatory bowel disease
286891|NCT01557374|Rheumatoid arthritis
286892|NCT01557374|Disease activity
286893|NCT01557374|Remission
286894|NCT01557374|Lowest Effective DOse
286895|NCT01557374|Abatacept Tocilizumab
286896|NCT01557374|ACR-EULAR 2010
286897|NCT01557361|renal replacement therapy
286898|NCT01557361|dialysis
286899|NCT01557361|acute kidney injury
286900|NCT01557361|hemodialysis
286901|NCT01557361|critical illness
286902|NCT01557335|To evaluate adenosine diphosphate (ADP)-induced platelet aggregation
286903|NCT01557309|traumatic rotator cuff tear
286904|NCT01557309|arthroscopic rotator cuff repair
286905|NCT01557309|age
286906|NCT01557309|early rotator cuff repair
286907|NCT01557296|Diet
286908|NCT01557296|Dietary treatment
286909|NCT01557296|Particle size
286910|NCT01557296|Gastroparesis
286911|NCT01557296|Diabetes Mellitus
286912|NCT01557257|single- and multiple-dose pharmacokinetics
286913|NCT01557257|ALO-02
286914|NCT01557257|OxyContin
286915|NCT01557244|neurogenic detrusor overactivity
286916|NCT01557244|neurogenic bladder
286917|NCT01557244|neuropathic bladder
286918|NCT01557244|neurologic disease
286919|NCT01557244|fesoterodine
286920|NCT01557231|OA
286921|NCT01557231|osteoarthritis
286922|NCT01557231|pain
286923|NCT01557231|variability
286924|NCT01557231|activity
286925|NCT01557231|treatment
286926|NCT01557218|Dietary variety
286927|NCT01557218|Vegetable intake
286928|NCT01557218|Fruit intake
286929|NCT01557205|optical coherence tomography
286930|NCT01557205|cell imaging
286931|NCT01557192|Depression
286932|NCT01557192|Bipolar Depression
286933|NCT01557192|LFMS
286934|NCT01557192|Electromagnetic Stimulation
286935|NCT01557166|OSA
286936|NCT01557153|Late-life Unremitted Depression
286937|NCT01557140|Chagas cardiomyopathy,
286938|NCT01557140|Renin-angiotensin system,
286939|NCT01557140|Beta-blockers,
286940|NCT01557140|Enalapril,
286941|NCT01557140|Carvedilol,
286942|NCT01557140|Renin-angiotensin system inhibitors,
286943|NCT01557140|Brain natriuretic peptide level,
286944|NCT01557140|Left ventricular ejection fraction,
286945|NCT01557140|Chemokines
286946|NCT01557127|Renal cell carcinoma,
286947|NCT01557127|Sorafenib
286948|NCT01557127|Dosing
286949|NCT01557114|unresectable Stage III or stage IV advanced malignant melanoma
286950|NCT01557088|coronary artery disease
286951|NCT01557088|coronary artery spasm
286952|NCT01557088|small vessel coronary artery disease
286953|NCT01557075|High dose statin
286954|NCT01557062|Fibromyalgia
286955|NCT01557062|Hydrotherapy
286956|NCT01557062|Sleep
286957|NCT01557062|Pain
286958|NCT01557062|Body Temperature
286959|NCT01557049|chronic low back pain
286960|NCT01557049|Postural global reeducation
286961|NCT01557049|randomized
286962|NCT01557049|physical rehabilitation
286963|NCT01557036|Brain Aneurysm
286964|NCT01556997|Hypertension
286965|NCT01556997|Essential Hypertension
286966|NCT01556984|diabetic foot
286967|NCT01556984|digital subtraction angiography
286968|NCT01556984|endothelial function
286969|NCT01556984|Patients with diabetes
286970|NCT01556984|Age 40 to 70 years old
286971|NCT01556984|Endothelial function are determined
286972|NCT01556945|P. falciparum
286973|NCT01556945|vaccine
286974|NCT01556945|healthy volunteers
286975|NCT01556919|GERD
286976|NCT01556919|Esophagitis
286977|NCT01556893|Flap Creation
286978|NCT01556893|Femtosecond Laser
286979|NCT01556893|corneal flap prior to LASIK procedure
286980|NCT01556880|Drivers
286981|NCT01556880|Chinese
286982|NCT01556880|Short Message Service
286983|NCT01556880|Cellular Phone
286984|NCT01556867|Umbilical cord care
286985|NCT01556867|dry cord care
286986|NCT01556867|antiseptic
286987|NCT01556867|Omphalitis
286988|NCT01556867|umbilical cord drop
286989|NCT01556867|hospitalized in maternity hospital
286990|NCT01556854|ginkgo leaves
286991|NCT01556854|butylphthalide
286992|NCT01556854|edaravone
286993|NCT01556854|citicoline
286994|NCT01556854|cerebrolysin
286995|NCT01556854|piracetam
286996|NCT01556854|Neuroprotectants
286997|NCT01556841|Randomised
286998|NCT01556841|Controlled
286999|NCT01556841|Trovax
287000|NCT01556841|MVA-5T4
287001|NCT01556841|5T4
287002|NCT01556841|Immunotherapy
287003|NCT01556841|Relapsed
287004|NCT01556841|Asymptomatic
287005|NCT01556841|Epithelial
287006|NCT01556841|Ovarian
287007|NCT01556841|Fallopian
287008|NCT01556841|Peritoneal
287009|NCT01556815|Hepatocellular Carcinoma
287010|NCT01556815|Sorafenib
287011|NCT01556815|Transarterial Chemoembolization
287012|NCT01556815|HBV
287013|NCT01556802|stroke
287014|NCT01556802|sequelaes
287015|NCT01556802|minocicline
287016|NCT01556789|ONT-10
287017|NCT01556789|MUC1
287018|NCT01556789|Vaccine
287019|NCT01556789|Phase 1
287020|NCT01556789|Solid Tumors
287021|NCT01556789|Dose escalation
287022|NCT01556776|CLL
287023|NCT01556776|High Risk
287024|NCT01556776|Maintenance
287025|NCT01556763|Schizophrenia
287026|NCT01556763|Schizoaffective
287027|NCT01556763|CNS
287028|NCT01555489|Pancreatic Neoplasms
287029|NCT01555489|Pancreatic Cancer cells
287030|NCT01555489|Digestive System Neoplasms
287031|NCT01555489|Neoplasms by Site
287032|NCT01555489|Neoplasms
287033|NCT01555489|Endocrine Gland Neoplasms
287034|NCT01555489|Digestive System Diseases
287035|NCT01555489|Pancreatic Diseases
287036|NCT01555489|Endocrine System Diseases
287037|NCT01555489|Ascorbic Acid
287038|NCT01555489|Gemcitabine Vitamins
287039|NCT01555489|Vitamin C
287040|NCT01555489|Antioxidants
287041|NCT01555489|Molecular Mechanisms of Pharmacological Action
287042|NCT01555489|Pharmacologic Actions
287043|NCT01555489|Protective Agents
287044|NCT01555489|Physiological Effects of Drugs
287045|NCT01555489|Micronutrients
287046|NCT01555489|Growth Substances
287047|NCT01555489|Erlotinib
287048|NCT01555489|Integrative Medicine
287049|NCT01555489|Alternative Medicine
287050|NCT01555489|Complementary Medicine
287051|NCT01555476|Pharmacokinetics
287052|NCT01555463|Rosacea
287053|NCT01555450|Colorectal cancer screening
287054|NCT01555450|Social inequalities
287055|NCT01555450|Patient Navigator
287056|NCT01556737|isoflavone
287057|NCT01556737|supplement
287058|NCT01556737|daidzein
287059|NCT01556737|genistein
287060|NCT01556737|gene expression
287061|NCT01556724|Peripheral nerve blocks
287062|NCT01556724|Ropivacaine concentrations in lumbar plexus catheters
287063|NCT01556724|Postoperative pain
287064|NCT01556724|Total hip replacement
287065|NCT01556711|Head Injury
287066|NCT01556711|Head Trauma
287067|NCT01556711|TBI (Traumatic Brain Injury)
287068|NCT01556711|Emergency Department
287069|NCT01556698|Acne Vulgaris
287070|NCT01556698|Acne
287071|NCT01556672|small bowel lesions
287072|NCT01556672|Crohn's Disease
287073|NCT01556672|Plaque psoriasis
287074|NCT01556672|adalimumab
287075|NCT01556672|capsule endoscopy
287076|NCT01556659|Left ventricular thrombus
287077|NCT01556659|Acute myocardial infarction
287078|NCT01556659|Anticoagulation
287079|NCT01556646|Cirrhosis
287080|NCT01556646|Hepatic Encephalopathy
287081|NCT01556646|Hyponatremia
287082|NCT01556646|Brain MRI
287083|NCT01556646|Health-related quality of life
287084|NCT01556646|cognitive function
287085|NCT01556620|PtiO2
287086|NCT01556620|NIRS
287087|NCT01556607|Respiratory Syncytial Virus Infection
287088|NCT01556607|RSV
287089|NCT01556594|Hypoglycemia
287090|NCT01556594|Diabetes mellitus
287091|NCT01556581|back pain
287092|NCT01556581|primary care
287093|NCT01556581|physical therapy
287094|NCT01556568|Noonan Syndrome, hypertrophic cardiomyopathy.
287095|NCT01556555|Sclerosing cholangitis
287096|NCT01556555|Spyglass
287097|NCT01556555|Endoscopic retrograde cholangiopancreaticography
287098|NCT01556542|peripheral arterial disease
287099|NCT01556542|drug-eluting balloon
287100|NCT01556542|restenosis
287101|NCT01556477|MDS
287102|NCT01556477|AML
287103|NCT01556477|Azacitidine
287104|NCT01556477|Lenalidomide
287105|NCT01556477|del5q
287106|NCT01556464|Obstructive sleep apnea
287107|NCT01556464|CPAP
287108|NCT01556412|endoscopic ultrasound
287109|NCT01556412|primary sclerosing cholangitis
287110|NCT01556412|EUS
287111|NCT01556412|cholestatic hepatopathy
287112|NCT01556399|Duodenal adenoma
287113|NCT01556399|Ampullary adenoma
287114|NCT01556386|acute lymphoblastic leukemia
287115|NCT01556386|single nucleotide polymorphism
287116|NCT01556373|acute systemic inflammation
287117|NCT01556373|arterial stiffness
287118|NCT01556373|Carotid-femoral pulse wave velocity
287119|NCT01556360|genetic hemochromatosis
287120|NCT01556360|Iron overload
287121|NCT01556360|C282 homozygosity
287122|NCT01556347|alloantibody
287123|NCT01556347|immunologic
287124|NCT01556347|memory
287125|NCT01556347|heart
287126|NCT01556347|transplant
287127|NCT01556347|desensitization
287128|NCT01556334|premature ruptured membranes
287129|NCT01556334|azithromycin
287130|NCT01556334|erythromycin
287131|NCT01556334|latency
287132|NCT01556334|antibiotics
287133|NCT01556321|Obesity
287134|NCT01556321|Body weight
287135|NCT01556321|Gut flora
287136|NCT01556321|Fat absorption
287137|NCT01556308|Dowling Meara
287138|NCT01556308|Epidermolysis bullosa
287139|NCT01556308|inflammation
287140|NCT01556295|Nurses
287141|NCT01556295|Low back pain
287142|NCT01556295|Gesture behavior
287143|NCT01556295|Knowlegde
287144|NCT01556282|Hepatocellular Carcinoma
287145|NCT01556282|portal vein thrombosis
287146|NCT01556282|HCC
287147|NCT01556243|stage IA breast cancer
287148|NCT01556243|stage IB breast cancer
287149|NCT01556243|stage II breast cancer
287150|NCT01556243|ductal breast carcinoma in situ
287151|NCT01556243|lobular breast carcinoma in situ
287152|NCT01556230|pituitary gland
287153|NCT01556230|pituitary adenoma
287154|NCT01556230|pituitary tumor
287155|NCT01556230|hypophysis
287156|NCT01556230|endocrine
287157|NCT01556230|neuroendocrine
287158|NCT01556230|hormone
287159|NCT01556217|Healthy volunteers
287160|NCT01556217|JNJ-39393406-aaa
287161|NCT01556217|Pharmacokinetics
287162|NCT01556217|Central brain penetrance
287163|NCT01556217|Cerebral spinal fluid
287164|NCT01556204|Endometriosis
287165|NCT01556191|lung cancer
287166|NCT01556191|women
287167|NCT01556178|Hydrocephalus
287168|NCT01556178|Survivin
287169|NCT01556178|miRNA
287170|NCT01556165|Rasagiline
287171|NCT01556165|Azilect
287172|NCT01556165|Parkinson´s Disease
287173|NCT01556165|Motor fluctuations
287174|NCT01556139|Endurance
287175|NCT01556139|exercise training
287176|NCT01556139|6-min walking test
287177|NCT01556126|Coronary artery disease
287178|NCT01556126|Drug Eluting Stent
287179|NCT01556126|All comers patients
287180|NCT01556113|fatty liver
287181|NCT01556113|hypertriglyceridemia
287182|NCT01556113|elevated liver enzymes
287183|NCT01556100|18F-DTBZ AV-133 imaging
287184|NCT01556087|opioids
287185|NCT01556087|distress tolerance
287186|NCT01556087|buprenorphine
287187|NCT01556074|Post traumatic stress disorder
287188|NCT01556074|PTSD
287189|NCT01556074|Insomnia
287190|NCT01556074|Sleep
287191|NCT01556074|Yoga
287192|NCT01556074|Meditation
287193|NCT01556074|Mental Health
287194|NCT01556074|Sleep Quality
287195|NCT01556074|Actigraphy
287196|NCT01556074|Sleep Diaries
287197|NCT01556074|Autonomic
287198|NCT01556074|Social Health
287199|NCT01556074|Interoception
287200|NCT01556074|Attention Regulation
287201|NCT01556074|Emotion Regulation
287202|NCT01556061|Laryngoscopy
287203|NCT01556061|Airway Management
287204|NCT01556061|Intubation
287205|NCT01556048|Behavior therapy
287206|NCT01556048|Bereavement
287207|NCT01556048|Complicated grief
287208|NCT01556048|Depression
287209|NCT01556048|Posttraumatic Stress Disorder
287210|NCT01556035|oncodermatology
287211|NCT01556035|hematology
287212|NCT01556035|cutaneous B cell lymphoma
287213|NCT01556035|lenalidomide
287214|NCT01556022|Ischemic heart disease
287215|NCT01556022|Coronary artery disease
287216|NCT01556022|Chronic heart failure
287217|NCT01556022|Cardiovascular disease
287218|NCT01556022|Adult stem cells
287219|NCT01556022|Adipose derived regenerative cells
287220|NCT01556009|Basal Cell Carcinoma
287221|NCT01556009|Photodynamic Therapy
287222|NCT01555996|older
287223|NCT01555996|delirium
287224|NCT01555996|cognitive status
287225|NCT01555996|occupational therapy
287226|NCT01555996|critically ill patients
287227|NCT01555983|cannabis
287228|NCT01555983|central neuropathic pain
287229|NCT01555983|analgesia
287230|NCT01555970|Obsessive-compulsive disorder
287231|NCT01555970|Treatment
287232|NCT01555970|Glutamate
287233|NCT01555970|N-Acetylcysteine
287234|NCT01555918|Pharmacokinetics
287235|NCT01555918|Healthy volunteers
287236|NCT01555918|Isavuconazole
287237|NCT01555918|BAL4815
287238|NCT01555918|BAL8728
287239|NCT01555918|BAL8557
287240|NCT01555905|Respiratory Muscle Strength
287241|NCT01555892|EBV
287242|NCT01555892|Hodgkin's Lymphoma
287243|NCT01555892|Non-Hodgkin's Lymphoma
287244|NCT01555892|Lymphoma Relapse
287245|NCT01555892|Autologous or Syngeneic Stem Cell Transplant
287246|NCT01555892|T/NK-lymphoproliferative disease
287247|NCT01555892|LMP
287248|NCT01555892|BARF1
287249|NCT01555892|EBNA1
287250|NCT01555879|Retrospective
287251|NCT01555879|Database
287252|NCT01555879|Data warehouse
287253|NCT01555879|Data mining
287254|NCT01555879|Collaborative effectiveness
287255|NCT01555879|Comparative effectiveness
287256|NCT01555879|Outcome based medicine
287257|NCT01555879|Evidence based medicine
287258|NCT01555866|isavuconazole
287259|NCT01555866|BAL4815
287260|NCT01555866|BAL8557
287261|NCT01555866|BAL8728
287262|NCT01555840|Magnetically guided capsule endoscopy (MGCE)
287263|NCT01555840|Gastroscopy
287264|NCT01555827|Retina
287265|NCT01555827|ALzheimer's disease
287266|NCT01555827|neurodegenerative signs
287267|NCT01555814|dopamine
287268|NCT01555814|first episode
287269|NCT01555814|reward
287270|NCT01555814|cognition
287271|NCT01555814|MRI
287272|NCT01555814|fMRI
287273|NCT01555814|PPI
287274|NCT01555814|P300
287275|NCT01555814|P50 gating
287276|NCT01555814|endophenotypes
287277|NCT01555801|esophageal cancer
287278|NCT01555801|early cancer
287279|NCT01555801|ultrasonography (EUS)
287280|NCT01555801|stage
287281|NCT01555788|type 1 diabetes,
287282|NCT01555788|diaport,
287283|NCT01555788|artificial pancreas,
287284|NCT01555788|zone mpc algorithm,
287285|NCT01555788|ap system,
287286|NCT01555788|intraperitoneal insulin
287287|NCT01555775|exercise-induced muscle damage
287288|NCT01555775|nutritional recovery
287289|NCT01555775|nutritional supplement
287290|NCT01555775|natural food
287291|NCT01555736|allergic rhinitis
287292|NCT01555736|perennial immunotherapy
287293|NCT01555736|preseasonal immunotherapy
287294|NCT01555437|capsule endoscopy scoring index
287295|NCT01555437|Harvey-Bradshaw index
287296|NCT01555437|C-reactive protein
287297|NCT01555437|serum albumin
287298|NCT01555437|hemoglobin
287299|NCT01555424|25-hydroxyvitamin D
287300|NCT01555424|Institutionalized seniors
287301|NCT01555424|SF-36 survey
287302|NCT01555424|Winter
287303|NCT01555411|Cardiovascular epidemiology
287304|NCT01555411|Prospective, observational cohort study
287305|NCT01555411|Biomarkers
287306|NCT01555411|Cardio- and cerebrovascular imaging
287307|NCT01555398|Fenofibric acid
287308|NCT01555398|HIP0901
287309|NCT01555398|food effect
287310|NCT01555385|Mental workload
287311|NCT01555385|Multitasking
287312|NCT01555385|Protein
287313|NCT01555385|Tryptophan
287314|NCT01555372|unstable distal clavicular fractures (Neer 2b)
287315|NCT01555372|Study Protocol
287316|NCT01555372|Fracture Fixation
287317|NCT01555346|Down syndrome
287318|NCT01555346|fetal aneuploidy
287319|NCT01555346|trisomy
287320|NCT01555346|noninvasive prenatal test
287321|NCT01555307|total hip arthroplasty
287322|NCT01555307|total knee arthroplasty
287323|NCT01555307|balance exercises
287324|NCT01555307|force plate
287325|NCT01555307|berg balance scale
287326|NCT01555307|timed up and go test
287327|NCT01555294|(subclinical)atherosclerosis
287328|NCT01555294|non-invasive measurements
287329|NCT01555294|intima-media thickness
287330|NCT01555294|flow-mediated dilation
287331|NCT01555294|pulse wave velocity and analysis
287332|NCT01555294|fatal and non-fatal cardiovascular events
287333|NCT01555294|ankle-brachial index (at rest and after exercise)
287334|NCT01555294|general population
287335|NCT01555294|Familial Combined Hyperlipidemia
287336|NCT01555281|Multiple Myeloma
287337|NCT01555281|Kahler Disease
287338|NCT01555281|Lenalidomide
287339|NCT01555281|Revlimid
287340|NCT01555281|Nelfinavir
287341|NCT01555281|Viracept
287342|NCT01555281|Dexamethasone
287343|NCT01555255|malaria
287344|NCT01555255|pregnancy
287345|NCT01555255|placental malaria
287346|NCT01555255|malaria in pregnancy
287347|NCT01555255|birth weight
287348|NCT01555255|anemia
287349|NCT01555242|Advanced Cancer
287350|NCT01555242|Lymphoma
287351|NCT01555242|Refractory
287352|NCT01555229|Secretion drainage
287353|NCT01555229|Ventilator-associated pneumonia
287354|NCT01555229|Tracheal fibroscopy
287355|NCT01555216|Forefoot surgery
287356|NCT01555190|myo-inositol
287357|NCT01555190|folic acid
287358|NCT01555177|Peri-operative myocardial infarction
287359|NCT01555177|Non-ST elevation myocardial infarction
287360|NCT01555177|Optical coherence tomography
287361|NCT01555151|Asthma
287362|NCT01555138|Chronic Obstructive Pulmonary Disease
287363|NCT01555138|Indacaterol
287364|NCT01555138|Salmeterol/fluticasone propionate
287365|NCT01555125|Psoriasis
287366|NCT01555099|COPD, FEV1, AZD5423
287367|NCT01555086|Lymphadenectomy
287368|NCT01555086|Prostate cancer
287369|NCT01555060|hemoglobin recovery
287370|NCT01555060|iron recovery
287371|NCT01555060|iron supplements
287372|NCT01555034|obesity
287373|NCT01555034|movement therapy
287374|NCT01555034|exercise
287375|NCT01555034|behaviour
287376|NCT01554995|LCB01-0371
287377|NCT01554982|Participation Limited
287378|NCT01554982|Long Term
287379|NCT01554982|Safety Extension
287380|NCT01554956|Plasminogen Deficiency
287381|NCT01554956|Ligneous Conjunctivitis
287382|NCT01554956|Plasminogen
287383|NCT01554956|Ligneous Conjunctivitis in Plasminogen Deficient Patients
287384|NCT01554943|CMF
287385|NCT01554943|HEC
287386|NCT01554943|EC
287387|NCT01554943|node positive
287388|NCT01554943|breast cancer
287389|NCT01554930|HFMD
287390|NCT01554930|Traditional Chinese Medicine
287391|NCT01554930|Xiyanping
287392|NCT01554917|Rheumatoid Arthritis
287393|NCT01554917|Iguratimod
287394|NCT01554904|Sleep Study
287395|NCT01554904|Snoring
287396|NCT01554904|Sleep Apnea
287397|NCT01554904|Muscle Laxity
287398|NCT01554904|Oral Appliance
287399|NCT01554904|Facial Muscles
287400|NCT01554904|Neck Muscles
287401|NCT01554904|Upper Airway
287402|NCT01554904|Muscle Strength
287403|NCT01554904|Dynamic Resistance
287404|NCT01554904|Oral Exercise
287405|NCT01554904|Facial Toning
287406|NCT01554904|Facial Muscle Strength
287407|NCT01554904|Strap Muscles of the Neck
287408|NCT01554904|Apnea-Hypopnea
287409|NCT01554891|brain injuries, traumatic
287410|NCT01554891|military personnel
287411|NCT01554891|classification
287412|NCT01554891|diagnosis
287413|NCT01554891|instrumentation
287414|NCT01554878|osteochondral defect of the knee
287415|NCT01554865|obesity
287416|NCT01554865|men
287417|NCT01554865|sexual function
287418|NCT01554865|urinary tract symptoms
287419|NCT01554865|endothelial function
287420|NCT01554865|inflammation
287421|NCT01554865|quality of life
287422|NCT01554852|myeloma
287423|NCT01554852|lenalidomide
287424|NCT01554852|Revlimid
287425|NCT01554852|cyclophosphamide
287426|NCT01554852|dexamethasone
287427|NCT01554852|bortezomib
287428|NCT01554852|Velcade
287429|NCT01554852|vorinostat
287430|NCT01554852|Zolinza
287431|NCT01554852|stem cell
287432|NCT01554852|carfilzomib
287433|NCT01554852|Kyprolis
287434|NCT01554826|Pediatric influenza vaccine
287435|NCT01554813|Influenza Vaccine, Vaccination,
287436|NCT01554800|Lecithin Cholesterol Acyl Transferase
287437|NCT01554800|LCAT
287438|NCT01554800|rhLCAT
287439|NCT01554800|Enzyme replacement therapy
287440|NCT01554800|High-Density Lipoprotein (HDL)
287441|NCT01554800|Cholesterol
287442|NCT01554800|Cholesterol ester
287443|NCT01554800|LCAT Deficiency
287444|NCT01554787|After stroke with fatigue
287445|NCT01554774|COPD
287446|NCT01554774|PVR
287447|NCT01554761|astigmatism
287448|NCT01554761|pseudophakia
287449|NCT01554748|total joint arthroplasty
287450|NCT01554748|thumb
287451|NCT01554748|trapeziometacarpal joint
287452|NCT01554748|osteoarthritis
287453|NCT01554735|obesity
287454|NCT01554735|men
287455|NCT01554735|sexual function
287456|NCT01554735|urinary tract symptoms
287457|NCT01554735|endothelial function
287458|NCT01554735|inflammation
287459|NCT01554735|quality of life
287460|NCT01554722|Ultrasound guidance
287461|NCT01554722|Femoral nerve block
287462|NCT01554722|Needle placement
287463|NCT01554722|Intraneural needle insertion
287464|NCT01554709|bypass
287465|NCT01554709|cannula
287466|NCT01554696|Rheumatoid Arthritis
287467|NCT01554696|ASP015K
287468|NCT01554683|Alzheimer's Disease
287469|NCT01554683|Seizures
287470|NCT01554683|Memory
287471|NCT01554683|Executive
287472|NCT01554670|Arthroscopic subacromial decompression
287473|NCT01554670|Bipolar radiofrequency
287474|NCT01554670|Tendon debridement
287475|NCT01554670|Shoulder surgery
287476|NCT01554657|Pneumonia, Bacterial
287477|NCT01554644|Cleansing
287478|NCT01554644|Chronic Leg Ulcers
287479|NCT01554644|Diabetic Patients
287480|NCT01554631|Bioequivalence
287481|NCT01554631|Acarbose
287482|NCT01554631|ODT
287483|NCT01554618|exenatide
287484|NCT01554618|type 2 diabetes
287485|NCT01554618|GLP-1 receptor agonist
287486|NCT01554592|Heart Failure
287487|NCT01554592|Statin withdrawal
287488|NCT01554566|honey
287489|NCT01554566|diabetes
287490|NCT01554566|lipids
287491|NCT01554566|c-peptide
287492|NCT01554553|Sleeve gastrectomy
287493|NCT01554553|Posterior crural repair
287494|NCT01554540|Treprostinil
287495|NCT01554540|Scleroderma
287496|NCT01554540|Iontophoresis
287497|NCT01554527|polysomnography
287498|NCT01554527|child
287499|NCT01554527|continuous positive airway pressure
287500|NCT01554527|tonsillectomy
287501|NCT01554527|neuropsychological tests
287502|NCT01554527|cognition
287503|NCT01554527|sleepiness
287504|NCT01554527|behavior
287505|NCT01554514|ADAMTS13
287506|NCT01554514|Rituximab
287507|NCT01554514|Thrombotic thrombocytopenic purpura
287508|NCT01554514|TTP
287509|NCT01554514|Plasma exchange
287510|NCT01554501|stress
287511|NCT01554501|self-control
287512|NCT01554501|emotion regulation
287513|NCT01554501|health
287514|NCT01554488|asthma
287515|NCT01554488|COPD
287516|NCT01554488|sleep apnea, obstructive
287517|NCT01554475|herbal drugs
287518|NCT01554475|dietary supplements
287519|NCT01554475|drug interactions
287520|NCT01554462|Attention
287521|NCT01554462|Cognitive control
287522|NCT01554462|ADHD
287523|NCT01554462|Healthy
287524|NCT01554462|EPA
287525|NCT01554462|Eicosapentaenoic acid
287526|NCT01554462|DHA
287527|NCT01554462|Docosahexaenoic acid
287528|NCT01554462|PUFA
287529|NCT01554462|Omega-3
287530|NCT01554449|Stroke
287531|NCT01554449|Upper arm
287532|NCT01554449|Rehabilitation
287533|NCT01554449|Motor function
287534|NCT01554449|Video games
287535|NCT01554449|Virtual reality
287536|NCT01554449|Occupational Therapy
287537|NCT01554449|Functional MRI
287538|NCT01554436|Smoking
287539|NCT01554436|Neuropsychology
287540|NCT01554436|Abstinence
287541|NCT01554436|Prognosis
287542|NCT01554436|Nicotine Dependence, Cigarettes, with Other Nicotine-induced Disorders
287543|NCT01554423|HIV Prevention Intervention
287544|NCT01554410|Cervical
287545|NCT01554410|Carcinoma
287546|NCT01554410|Gemcitabine
287547|NCT01554410|Gemzar
287548|NCT01554410|Cisplatin
287549|NCT01554410|IMRT
287550|NCT01554410|Radiation
287551|NCT01554410|External Beam
287552|NCT01554410|Brachytherapy
287553|NCT01554397|Cervical
287554|NCT01554397|Carcinoma
287555|NCT01554397|Cisplatin
287556|NCT01554397|IMRT
287557|NCT01554397|Radiation
287558|NCT01554397|INTERTECC
287559|NCT01554397|International
287560|NCT01554397|External Beam
287561|NCT01554397|Brachytherapy
287562|NCT01554397|LDR
287563|NCT01554397|HDR
287564|NCT01554397|IGRT
287565|NCT01554397|CBCT
287566|NCT01554384|Tuberculosis
287567|NCT01554384|diagnosis
287568|NCT01554384|Xpert MTB/RIF
287569|NCT01554384|point-of-treatment
287570|NCT01554384|randomized controlled trial
287571|NCT01554371|Solid tumor
287572|NCT01554371|Metastatic breast cancer
287573|NCT01554371|Unresectable or metastatic carcinoma
287574|NCT01554371|Neuropathy
287575|NCT01554371|Eribulin
287576|NCT01554371|Cyclophosphamide
287577|NCT01554358|Gestational diabetes mellitus
287578|NCT01554358|Lifestyle intervention
287579|NCT01554332|Motor Cortex Stimulation
287580|NCT01554332|Neuropathic pain
287581|NCT01554319|Antisense oligonucleotide
287582|NCT01554319|Asthma
287583|NCT01554319|Healthy subjects
287584|NCT01554319|Phase 1
287585|NCT01554319|Transcription factor GATA-3
287586|NCT01554319|Oral inhalation
287587|NCT01554280|Stricture
287588|NCT01554280|Dysphagia
287589|NCT01554267|Mastectomy skin flap necrosis
287590|NCT01554267|Breast reconstruction
287591|NCT01554267|Indocyanine Green Dye
287592|NCT01554254|Cord blood transplant
287593|NCT01554254|hematological malignancy
287594|NCT01554254|inherited metabolic disease
287595|NCT01554254|Mucositis
287596|NCT01554254|Neutrophil engraftment
287597|NCT01554254|Platelet recovery
287598|NCT01554254|Immune reconstitution
287599|NCT01554241|vitamin D3
287600|NCT01554241|D3
287601|NCT01554241|cholecalciferol
287602|NCT01554241|25-OH vitamin D
287603|NCT01554241|elderly
287604|NCT01554241|nursing home resident
287605|NCT01554215|parenting
287606|NCT01554215|child behavior
287607|NCT01554215|attachment
287608|NCT01554202|Alzheimer's disease
287609|NCT01554202|MCI
287610|NCT01554202|genetic
287611|NCT01554202|AV45-PET
287612|NCT01554176|Current depressive episode
287613|NCT01554176|moderate to severe
287614|NCT01554163|Osteoarthritis
287615|NCT01554163|Celecoxib
287616|NCT01554163|Etoricoxib
287617|NCT01554150|Primary Health Care
287618|NCT01554150|Mental Health
287619|NCT01554150|Cognitive Therapy
287620|NCT01554124|Meningitis
287621|NCT01554124|Neonates
287622|NCT01554124|Meropenem
287623|NCT01554111|Bowel Evacuants
287624|NCT01554111|Purgatives
287625|NCT01554098|Polyp detection
287626|NCT01554098|Supine
287627|NCT01554098|Colonoscope withdrawal
287628|NCT01554098|Patient position
287629|NCT01554098|Dynamic position change
287630|NCT01554072|home-based
287631|NCT01554072|pulmonary rehabilitation
287632|NCT01554072|COPD
287633|NCT01554059|Rectal cancer
287634|NCT01554059|Adenocarcinoma
287635|NCT01554059|Bevacizumab
287636|NCT01554059|Chemoradiation
287637|NCT01554046|Attention Deficit Hyperactivity Disorder (ADHD)
287638|NCT01554046|Methylphenidate- RITALIN IR (Immediate Release)
287639|NCT01554033|European Huntington's Disease Network
287640|NCT01554033|Huntington patients in KOREA
287641|NCT01554020|Blood glucose
287642|NCT01554020|Insulin sensitivity
287643|NCT01554020|Oral glucose tolerance
287644|NCT01554007|Crohn's disease
287645|NCT01553981|Interstitial lung disease
287646|NCT01553981|Scleroderma
287647|NCT01553955|PRP,
287648|NCT01553955|Platelet
287649|NCT01553955|Manual
287650|NCT01553942|NSCLC
287651|NCT01553929|MCI
287652|NCT01553903|Hormonal therapy
287653|NCT01553903|Breast Cancer
287654|NCT01553903|AEBS
287655|NCT01553903|Oxysterols
287656|NCT01553890|SSc= scleroderma
287657|NCT01553890|ICF+ informed consent form
287658|NCT01553890|age 18 to 85
287659|NCT01553890|healthy
287660|NCT01553838|prostate biopsy
287661|NCT01553838|MRI guided biopsy
287662|NCT01553838|TRUS guided biopsy
287663|NCT01553812|forced oscillation technique
287664|NCT01553812|COPD
287665|NCT01553812|elderly
287666|NCT01553812|airway resistance
287667|NCT01553812|airtrapping
287668|NCT01553786|T-cell lymphoma
287669|NCT01553786|CHOp
287670|NCT01553786|lenalidomide
287671|NCT01553773|Hyaluroic acid
287672|NCT01553773|Estradiol
287673|NCT01553773|Isoflavone
287674|NCT01553773|Skin
287675|NCT01553773|Postmenopause
287676|NCT01553760|Cataract
287677|NCT01553760|TRI-MICS
287678|NCT01553760|ACM
287679|NCT01553760|MICS
287680|NCT01553760|phacoemulsification
287681|NCT01553747|Irritable bowel syndrome with diarrhea
287682|NCT01553747|Irritable bowel syndrome
287683|NCT01553747|Diarrhea predominant irritable bowel syndrome
287684|NCT01553747|Colonic diseases
287685|NCT01553747|Colonic diseases, functional
287686|NCT01553747|Digestive system disease
287687|NCT01553747|Gastrointestinal disease
287688|NCT01553747|Intestinal disease
287689|NCT01553747|Colonic pseudo-obstruction
287690|NCT01553747|Diarrhea
287691|NCT01553747|Signs and symptoms, Digestive
287692|NCT01553734|QT prolongation
287693|NCT01553734|Azithromycin
287694|NCT01553734|macrolide
287695|NCT01553734|pneumonia
287696|NCT01553734|ECG changes
287697|NCT01553708|Wound healing
287698|NCT01553708|Epithelialization
287699|NCT01553708|Safety
287700|NCT01553695|Touble
287701|NCT01553695|deficit
287702|NCT01553695|attention
287703|NCT01553695|hyperactivity
287704|NCT01553695|Touble deficit attention with hyperactivity
287705|NCT01553682|HIV
287706|NCT01553682|STDs
287707|NCT01553682|African American Females
287708|NCT01553682|Alcohol
287709|NCT01553656|Advanced cancer
287710|NCT01553656|Metastatic
287711|NCT01553656|NSCLC
287712|NCT01553643|Huang-Chi-Wu-Wu-Tang
287713|NCT01553643|Intracranial arterial prominent stenosis
287714|NCT01553630|Fractures
287715|NCT01553630|distal femur fractures
287716|NCT01553630|distal tibial fracures
287717|NCT01553604|breast prosthesis implantation
287718|NCT01553604|bandages
287719|NCT01553604|skin colonization
287720|NCT01553604|surgical site infection
287721|NCT01553604|augmentation mammaplasty
287722|NCT01553604|dressing wear time
287723|NCT01553591|Irritable bowel syndrome with diarrhea
287724|NCT01553591|Irritable bowel syndrome
287725|NCT01553591|Diarrhea Predominant Irritable Bowel Syndrome
287726|NCT01553591|Colonic diseases
287727|NCT01553591|Colonic diseases, functional
287728|NCT01553591|Digestive system disease
287729|NCT01553591|Gastrointestinal disease
287730|NCT01553591|Intestinal disease
287731|NCT01553591|Colonic pseudo-obstruction
287732|NCT01553591|Diarrhea
287733|NCT01553591|Signs and symptoms, Digestive
287734|NCT01553565|10 mm in diameter
287735|NCT01553565|antithrombotic agents
287736|NCT01553552|Schistosoma haematobium
287737|NCT01553552|schistosoma mansoni
287738|NCT01553552|Anemia
287739|NCT01553552|Underweight
287740|NCT01553552|stunting
287741|NCT01553552|Blastocystis
287742|NCT01553526|International
287743|NCT01553526|Multicenter
287744|NCT01553526|Observational registry
287745|NCT01553526|All-comers open label registry
287746|NCT01553526|Orsiro Drug Eluting Stent (DES)
287747|NCT01553526|Stenting
287748|NCT01553526|Treatment of Coronary Artery Disease
287749|NCT01553526|Coronary revascularization
287750|NCT01553526|Percutaneous Coronary Intervention
287751|NCT01553526|STEMI
287752|NCT01553526|NSTEMI
287753|NCT01553526|Ischemia
287754|NCT01553526|Angina
287755|NCT01553526|Subgroups
287756|NCT01553526|Acute Myocardial Infarction
287757|NCT01553526|Diabetes
287758|NCT01553526|Small Vessels
287759|NCT01553526|Chronic Total Occlusion (CTO)
287760|NCT01553513|PET
287761|NCT01553513|Coronary Artery Disease
287762|NCT01553513|Inflammation
287763|NCT01553513|Plaque
287764|NCT01553513|Atherosclerosis
287765|NCT01553500|NAFLD
287766|NCT01553500|insulin resistance
287767|NCT01553500|children
287768|NCT01553487|vibration
287769|NCT01553487|muscle strength
287770|NCT01553487|bone loss
287771|NCT01553487|immobilization
287772|NCT01553487|fracture
287773|NCT01553474|Age-Related Macular Degeneration (AMD)
287774|NCT01553474|Eye Diseases
287775|NCT01553461|Transplant
287776|NCT01553461|Umbilical Cord Blood
287777|NCT01553461|Graft Rejection
287778|NCT01553461|Graft Versus Host Disease
287779|NCT01553448|disseminated neuroblastoma
287780|NCT01553448|hereditary neuroblastoma
287781|NCT01553448|localized resectable neuroblastoma
287782|NCT01553448|localized unresectable neuroblastoma
287783|NCT01553448|stage 4S neuroblastoma
287784|NCT01553435|Dextromethorphan
287785|NCT01553435|Morphine
287786|NCT01553435|Fentanyl
287787|NCT01553435|Opioid
287788|NCT01553435|analgesia
287789|NCT01553435|Efficacy
287790|NCT01553422|Intrabdominal Pressure
287791|NCT01553422|Emergency Bedside Ultrasonography
287792|NCT01553422|Abdominal Compartment Syndrome
287793|NCT01553409|Hypertension
287794|NCT01553409|Ferritin
287795|NCT01553409|Phlebotomy
287796|NCT01553409|Blood donation
287797|NCT01553383|OSA
287798|NCT01553357|Plasma cell leukemia
287799|NCT01553357|Lenalidomide
287800|NCT01553357|Dexamethasone
287801|NCT01553357|Multiple myeloma
287802|NCT01553357|Bortezomib
287803|NCT01553357|Stem cell transplantation
287804|NCT01553344|sclerostin
287805|NCT01553344|osteomalacia
287806|NCT01553344|vitamin D deficiency
287807|NCT01553331|laparoscopic cholecystectomy
287808|NCT01553318|Fibromyalgia
287809|NCT01553318|FMS
287810|NCT01553305|exercise programme
287811|NCT01553292|Respiratory distress syndrome
287812|NCT01553292|Preterm infants
287813|NCT01553292|Vascular catheter
287814|NCT01553292|Surfactant
287815|NCT01553292|CPAP
287816|NCT01553292|ECALMIST
287817|NCT01553266|Diabetes Mellitus
287818|NCT01553266|diabetes care
287819|NCT01553266|diabetes self-management education
287820|NCT01553266|primary care physicians
287821|NCT01553266|interprofessional collaboration
287822|NCT01553266|diabetes education programs
287823|NCT01553266|qualitative
287824|NCT01553266|quantitative
287825|NCT01553266|implementation
287826|NCT01553266|evaluation
287827|NCT01553266|health services
287828|NCT01553266|coordinated care
287829|NCT01553266|integrated care
287830|NCT01553266|patient care processes
287831|NCT01553253|Postcholecystectomy Pain
287832|NCT01553253|Chronic Postoperative Pain
287833|NCT01553253|Visceral Pain
287834|NCT01553253|Referred pain
287835|NCT01553253|Somatic pain
287836|NCT01553253|Quantitative Sensory Testing
287837|NCT01553240|TMS
287838|NCT01553240|functional MRI
287839|NCT01553240|Supplementary motor cortex
287840|NCT01553240|Right Temporoparietal junction( RTPJ)
287841|NCT01553227|OSAHS: Obstructive Sleep Apnea hypopnea Syndrome
287842|NCT01553227|OHS: Obesity Hypoventilation Syndrome
287843|NCT01553227|Auto-trilevel ventilation
287844|NCT01553227|BiPAP ventilation
287845|NCT01553214|Healthy Volunteers
287846|NCT01553214|Granulocyte Transfusion
287847|NCT01553214|Granulocytapheresis
287848|NCT01553214|Leukapheresis
287849|NCT01553214|Cytokine Stimulation
287850|NCT01553214|Healthy Volunteer
287851|NCT01553214|HV
287852|NCT01553201|Quality of Life
287853|NCT01553201|Endometriosis
287854|NCT01553201|Botulinum Toxin A
287855|NCT01553201|Pelvic Pain Spasm
287856|NCT01553201|Chronic Pelvic Pain
287857|NCT01553188|Anti-Angiogenesis
287858|NCT01553188|Ang 1
287859|NCT01553188|Ang 2
287860|NCT01553188|Peptide-Fc fusion protein
287861|NCT01553188|Small Molecule
287862|NCT01553175|childhood atypical teratoid/rhabdoid tumor
287863|NCT01553175|rhabdoid tumor of the kidney
287864|NCT01553162|B-cell childhood acute lymphoblastic leukemia
287865|NCT01553162|untreated childhood acute lymphoblastic leukemia
287866|NCT01553136|alcohol-related disorders
287867|NCT01553136|Cholinergic Drugs
287868|NCT01553136|varenicline
287869|NCT01553136|Chantix
287870|NCT01553123|Leiomyomas
287871|NCT01553110|Cold
287872|NCT01553110|Acute Rhinosinusitis
287873|NCT01553110|Allergic Rhinitis
287874|NCT01553097|Breast Cancer
287875|NCT01553097|Neurocognitive Impairment
287876|NCT01553097|Quality of Life
287877|NCT01553097|Cytokines
287878|NCT01553084|Smoking Cessation
287879|NCT01553084|Smoking
287880|NCT01553084|Nicotine
287881|NCT01553071|Malignancy, Relapsed
287882|NCT01553071|Chemotherapy, Intravenous
287883|NCT01553058|Psoriasis
287884|NCT01553058|Cardiovascular Disease
287885|NCT01553058|FDG/PET-CT
287886|NCT01553058|NB-UVB Phototherapy
287887|NCT01553058|Vascular Inflammation
287888|NCT01553058|Lipid Biomarkers
287889|NCT01553045|symptom burden
287890|NCT01553045|atrial fibrillation
287891|NCT01553045|biomarkers
287892|NCT01553045|intracardiac pressures
287893|NCT01553032|Immuno-(Chemo-)and Radiotherapy
287894|NCT01553032|Erbitux®
287895|NCT01553032|Skin changes in Head and neck cancer
287896|NCT01553019|Proton radiation
287897|NCT01553019|Chemotherapy
287898|NCT01553019|Pancreatic cancer
287899|NCT01553019|Postoperative
287900|NCT01553006|rhinosinusitis
287901|NCT01553006|cefditoren pivoxil
287902|NCT01552993|prematurity
287903|NCT01552993|retinopathy
287904|NCT01552993|pain
287905|NCT01552993|acetaminophen
287906|NCT01552980|Gastric cancer
287907|NCT01552980|Adenocarcinoma
287908|NCT01552980|SOX
287909|NCT01552967|Colorectal cancer
287910|NCT01552967|Adenocarcinoma
287911|NCT01552967|XELOX
287912|NCT01552954|hypertension
287913|NCT01552954|Chronic kidney disease
287914|NCT01552954|albuminuria
287915|NCT01552954|low salt diet
287916|NCT01552954|Angiotensin II receptor blocker
287917|NCT01552941|Vagus Nerve
287918|NCT01552941|Vagal Nerve Stimulation
287919|NCT01552941|Rheumatoid Arthritis
287920|NCT01552941|Implantable Medical Device
287921|NCT01552915|ADHD
287922|NCT01552902|ADHD
287923|NCT01552863|pharmacokinetics
287924|NCT01552863|bioavailability
287925|NCT01552863|oxycodone.
287926|NCT01552850|pharmacokinetics
287927|NCT01552850|relative bioavailability
287928|NCT01552850|oxycodone
287929|NCT01552837|Diffusion Tensor Imaging,
287930|NCT01552837|quetiapine
287931|NCT01552837|Bipolar Disorder
287932|NCT01552837|hippocampus
287933|NCT01552837|Volume Brain Morphometry
287934|NCT01552837|Magnetic Resonance Spectroscopy
287935|NCT01552837|effect of quetiapine on hippocampal neurogenesis
287936|NCT01552824|LUTO
287937|NCT01552824|posterior urethral valves
287938|NCT01552824|urethral atresia
287939|NCT01552772|Safety
287940|NCT01552772|Tolerability
287941|NCT01552772|Schizophrenia
287942|NCT01552772|Aripiprazole
287943|NCT01552759|Appetite Hormones
287944|NCT01552759|Binge Eating Disorder
287945|NCT01552759|Obesity
287946|NCT01552759|Cortisol
287947|NCT01552759|Stress
287948|NCT01552746|Postoperative shoulder pain
287949|NCT01552746|Persisting postoperative pain
287950|NCT01552720|aorta
287951|NCT01552720|dissection
287952|NCT01552720|feature
287953|NCT01552707|Spondylolisthesis
287954|NCT01552707|Degenerative discopathy
287955|NCT01552707|Mesenchymal Stem Cells
287956|NCT01552707|Bone marrow
287957|NCT01552707|Tissue engineering
287958|NCT01552707|Spinal fusion
287959|NCT01552694|cardiometabolic complications
287960|NCT01552681|baminercept treatment
287961|NCT01552668|Clostridium difficile infection
287962|NCT01552668|fidaxomicin
287963|NCT01552655|Dual-time PET/CT
287964|NCT01552655|Breast cancer recurrence
287965|NCT01552655|Bone scintigraphy
287966|NCT01552655|CT thorax upper abdomen
287967|NCT01552642|Comprehensive Health Enhancement Support System (CHESS)
287968|NCT01552629|Atopic dermatitis
287969|NCT01552629|Atopic eczema
287970|NCT01552629|Skin Diseases
287971|NCT01552629|QGE031
287972|NCT01552603|glucose sensors
287973|NCT01552603|artificial pancreas
287974|NCT01552603|Diabetes Mellitus
287975|NCT01552577|Post-Concussion Syndrome
287976|NCT01552577|Concussion
287977|NCT01552577|Brain Injury
287978|NCT01552577|TBI
287979|NCT01552577|Military Personnel
287980|NCT01552577|Eye-tracking
287981|NCT01552577|Neurocognitive Function
287982|NCT01552577|Assessment
287983|NCT01552551|Falls
287984|NCT01552551|exercise
287985|NCT01552551|safety
287986|NCT01552551|injury
287987|NCT01552551|Older adults
287988|NCT01552538|Rheumatoid Arthritis
287989|NCT01552538|Vagus Nerve
287990|NCT01552538|Vagal Nerve Stimulation
287991|NCT01552525|acute kidney injury
287992|NCT01552525|asymmetric dimethylarginine
287993|NCT01552525|symmetric dimethylarginine
287994|NCT01552525|l-arginine
287995|NCT01552525|arterial stiffness
287996|NCT01552525|augmentation index
287997|NCT01552525|pulse wave velocity
287998|NCT01552512|Stunting
287999|NCT01552512|Hidden Hunger
288000|NCT01552512|Diarrhea
288001|NCT01552512|Vitamin A Deficiency
288002|NCT01552486|chiropractic
288003|NCT01552486|manipulation
288004|NCT01552486|radiculopathy
288005|NCT01552486|sciatica
288006|NCT01552486|lumbar
288007|NCT01552486|disc
288008|NCT01552486|herniation
288009|NCT01552486|protrusion
288010|NCT01552473|TBI
288011|NCT01552473|Traumatic Brain Injury
288012|NCT01552473|combat related injury
288013|NCT01552473|blast injury
288014|NCT01552473|concussion
288015|NCT01552473|sleep problems
288016|NCT01552473|attention problems
288017|NCT01552473|memory problems
288018|NCT01552473|headaches
288019|NCT01552473|dizziness
288020|NCT01552473|OEF
288021|NCT01552473|OIF
288022|NCT01552473|Veterans
288023|NCT01552473|Civilian
288024|NCT01552460|Autism Spectrum Disorders
288025|NCT01552460|Brain Imaging
288026|NCT01552460|Genetics
288027|NCT01552434|Advanced Cancers
288028|NCT01552434|Advanced Malignancy
288029|NCT01552434|Metastatic cancer
288030|NCT01552434|Temsirolimus
288031|NCT01552434|CCI-779
288032|NCT01552434|Torisel
288033|NCT01552434|Bevacizumab
288034|NCT01552434|Avastin
288035|NCT01552434|rhuMAb-VEGF
288036|NCT01552434|Anti-VEGF Monoclonal Antibody
288037|NCT01552434|Cetuximab
288038|NCT01552434|C225
288039|NCT01552434|Erbitux
288040|NCT01552434|IMC-C225
288041|NCT01552434|Valproic Acid
288042|NCT01552434|Depakene
288043|NCT01552421|Cholecystectomy
288044|NCT01552421|Natural Orifice Transluminal Endoscopic Surgery
288045|NCT01552421|Transvaginal cholecystectomy
288046|NCT01552421|Postoperative outcome
288047|NCT01552408|Non Proliferative Diabetic Retinopathy
288048|NCT01552408|Diabetic Retinopathy
288049|NCT01552408|Macular Edema
288050|NCT01552408|Background Diabetic Retinopathy
288051|NCT01552408|Pre Proliferative Diabetic Retinopathy
288052|NCT01552382|vitamin D
288053|NCT01552382|25-hydroxyvitamin D
288054|NCT01552382|MACCE
288055|NCT01552382|mortality
288056|NCT01552382|cardiac
288057|NCT01552382|cerebrovascular
288058|NCT01552369|liver transplantation
288059|NCT01552369|CMV disease
288060|NCT01552369|valgancyclovir
288061|NCT01552369|prophylaxis
288062|NCT01552369|preemptive therapy
288063|NCT01552330|Primaquine
288064|NCT01552330|Pyronaridine-artesunate
288065|NCT01552317|chronic kidney disease
288066|NCT01552304|Obstructive sleep apnea
288067|NCT01552304|Oxygen therapy
288068|NCT01552304|Surgery
288069|NCT01552304|Anesthesia
288070|NCT01552291|Malnourishment
288071|NCT01552291|Gastrointestinal tumors
288072|NCT01552291|Immunocompetence
288073|NCT01552265|Mild Cognitive Impairment
288074|NCT01552265|Alzheimer's Disease
288075|NCT01552252|POs-Ca
288076|NCT01552252|calcium additives
288077|NCT01552252|drink
288078|NCT01552239|Soft tissue sarcoma
288079|NCT01552239|Intensity-Modulated Radiation Therapy (IMRT)
288080|NCT01552239|Tomotherapy
288081|NCT01552239|Safety Margins
288082|NCT01552239|Image-guided Radiation Therapy
288083|NCT01552239|Brachytherapy
288084|NCT01552239|interstitial
288085|NCT01552200|Colorectal Cancer
288086|NCT01552200|Polyp
288087|NCT01552200|Adenoma
288088|NCT01552200|Detection Rate
288089|NCT01552200|Colonoscopy
288090|NCT01552200|NaviAid™ G-Eye procedure
288091|NCT01552200|NaviAid™ G-Eye system
288092|NCT01552200|G-Eye procedure
288093|NCT01552200|G-Eye system
288094|NCT01552187|cardiac surgery
288095|NCT01552187|post-pericardiotomy syndrome
288096|NCT01552187|atrial fibrillation
288097|NCT01552187|pericardial effusion
288098|NCT01552187|pleural effusion
288099|NCT01552187|prevention
288100|NCT01552187|colchicine
288101|NCT01552174|MGD
288102|NCT01552174|ocular surface pathologies
288103|NCT01552161|Angiography
288104|NCT01552161|Atherosclerosis
288105|NCT01552161|Asthma
288106|NCT01552161|Tryptase
288107|NCT01552161|Eosinophil cationic protein
288108|NCT01552135|titanium dioxide
288109|NCT01552135|nanoparticles
288110|NCT01552135|skin
288111|NCT01552135|penetrate
288112|NCT01552109|symptomatic stable angina
288113|NCT01552109|subjects with symptomatic stable angina visiting non-interventional consulting physicians for treatment and meets the inclusion/exclusion criteria
288114|NCT01552096|Anaesthesia
288115|NCT01552096|tonsillectomy
288116|NCT01552096|inflammatory response
288117|NCT01552096|stress response
288118|NCT01552096|tramadol
288119|NCT01552096|lidocaine
288120|NCT01552083|sleep apnea
288121|NCT01552083|screening
288122|NCT01552083|community pharmacy
288123|NCT01552044|retina
288124|NCT01552031|COPD exacerbations
288125|NCT01552031|FOT variability
288126|NCT01551992|Sutures
288127|NCT01551992|Pelvic Organ Prolapse
288128|NCT01551992|Sacrocolpopexy
288129|NCT01551992|Laparoscopy
288130|NCT01551979|Schizophrenia
288131|NCT01551979|repetitive Transcranial Magnetic Stimulation
288132|NCT01551966|Esophageal varices
288133|NCT01551966|Portal hypertension in children
288134|NCT01551966|Wireless capsule endoscopy
288135|NCT01551953|chronic bronchitis
288136|NCT01551953|emphysema
288137|NCT01551953|pulmonary
288138|NCT01551953|COPD
288139|NCT01551940|Sialorrhea
288140|NCT01551940|Amyotrophic lateral sclerosis
288141|NCT01551940|Botulinum toxin
288142|NCT01551927|expectations
288143|NCT01551914|Ultrasonic scissors
288144|NCT01551914|thyroidectomy
288145|NCT01551901|Back pain
288146|NCT01551901|Spinal fusion
288147|NCT01551901|Degenerative disc disease (DDD)
288148|NCT01551901|Lower back pain
288149|NCT01551901|Fusion
288150|NCT01551888|COPD
288151|NCT01551888|Chronic Obstructive Pulmonary Disease
288152|NCT01551888|Chronic Bronchitis
288153|NCT01551888|Emphysema
288154|NCT01551888|Airflow Obstruction, Chronic
288155|NCT01551888|Chronic Airflow Obstruction
288156|NCT01551888|Chronic Obstructive Airway Disease
288157|NCT01551888|Chronic Obstructive Lung Disease
288158|NCT01551875|CIMT
288159|NCT01551875|cardiovascular disease
288160|NCT01551875|correlation with cardiovascular Risk factors
288161|NCT01551862|lower body lift
288162|NCT01551862|body contouring surgery
288163|NCT01551862|massive weight loss
288164|NCT01551836|pharmacokinetics
288165|NCT01551836|paracetamol
288166|NCT01551823|Influenza Virus Vaccine (Split Virion, Inactivated)
288167|NCT01551823|Influenza
288168|NCT01551810|Influenza Virus Vaccine (Split Virion, Inactivated)
288169|NCT01551810|Influenza
288170|NCT01551784|Statin treatment
288171|NCT01551784|Cardiovascular disease
288172|NCT01551784|Statin treatment induced HDL changes and the effect on cardiovascular disease
288173|NCT01551771|CCR3 antagonist
288174|NCT01551758|Exacerbation
288175|NCT01551758|Adult
288176|NCT01551758|COPD
288177|NCT01551758|Respiratory
288178|NCT01551745|Papillary Serous Ovarian Cancer
288179|NCT01551745|Endometrioid Ovarian Cancer
288180|NCT01551745|Epithelial Ovarian Cancer
288181|NCT01551732|Anger
288182|NCT01551732|Aggression
288183|NCT01551732|Biofeedback
288184|NCT01551732|Videogame
288185|NCT01551719|Bacterial infection of skin or soft tissues
288186|NCT01551706|Total antioxidant capacity
288187|NCT01551706|SOD
288188|NCT01551706|8-OHdG
288189|NCT01551706|8-isoprostane
288190|NCT01551706|oxLDL
288191|NCT01551693|Stage III
288192|NCT01551693|Stage IV
288193|NCT01551693|Unresectable
288194|NCT01551693|Metastatic
288195|NCT01551667|S. aureus
288196|NCT01551654|Pain
288197|NCT01551654|Colonoscopy
288198|NCT01551654|TENS
288199|NCT01551654|Acupuncture
288200|NCT01551641|Esophageal Cancer
288201|NCT01551641|Chemoradiotherapy
288202|NCT01551641|VEGF
288203|NCT01551641|Thalidomide
288204|NCT01551615|Phase 1
288205|NCT01551615|healthy volunteers
288206|NCT01551615|pharmacokinetics
288207|NCT01551615|vandetanib
288208|NCT01551615|metformin
288209|NCT01551615|AUC(0-t)
288210|NCT01551615|t1/2
288211|NCT01551615|tmax
288212|NCT01551615|CL/F
288213|NCT01551615|Vz/F
288214|NCT01551615|Cmax
288215|NCT01551602|AK159
288216|NCT01551602|teriparatide acetate
288217|NCT01551589|Esophageal squamous cell carcinoma
288218|NCT01551589|Concurrent chemoradiotherapy
288219|NCT01551589|Clinical target volume
288220|NCT01551589|Safety
288221|NCT01551589|Prognosis
288222|NCT01551550|Glaucoma Drainage Device, Tube Exposure, Amniotic Membrane
288223|NCT01551537|Healthy females
288224|NCT01551537|Post-marketing surveillance (PMS)
288225|NCT01551537|Human papillomavirus vaccine
288226|NCT01551537|Sri Lanka
288227|NCT01551537|Cervarix
288228|NCT01551524|Leukemia
288229|NCT01551524|Lymphoma
288230|NCT01551524|C240588.448
288231|NCT01551524|C115.378.400
288232|NCT01551511|chronic pancreatitis
288233|NCT01551511|abdominal pain
288234|NCT01551511|visceral pain
288235|NCT01551511|chronic pain
288236|NCT01551498|Hashimoto Disease
288237|NCT01551498|Thyroiditis
288238|NCT01551459|Uveal
288239|NCT01551459|Melanoma
288240|NCT01551459|Metastatic
288241|NCT01551459|Sunitinib
288242|NCT01551433|esophagectomy
288243|NCT01551433|ESOPHAGUS
288244|NCT01551433|Wipox instrument
288245|NCT01551433|Tissue Oxygenation
288246|NCT01551433|Anastomotic Leak
288247|NCT01551433|11-192
288248|NCT01551420|Amputation
288249|NCT01551420|Prosthetic Design
288250|NCT01551420|Upper Extremity
288251|NCT01551407|Hexvix
288252|NCT01551407|bladder cancer
288253|NCT01551407|cystoscopy
288254|NCT01551407|Patients with known or suspicion of bladder cancer
288255|NCT01551394|sepsis
288256|NCT01551394|neonates
288257|NCT01551394|meropenem
288258|NCT01551381|Safety
288259|NCT01551381|Tolerability
288260|NCT01551381|Pharmacokinetics
288261|NCT01551381|Pharmacodynamics
288262|NCT01551368|male factor
288263|NCT01551368|intrauterine insemination
288264|NCT01551368|LH surge
288265|NCT01551368|controlled ovarian stimulation
288266|NCT01551368|clomiphene citrate
288267|NCT01551368|letrozole
288268|NCT01551368|human menopausal gonadotropins
288269|NCT01551355|behavioral modification
288270|NCT01551355|health communication
288271|NCT01551355|prevention
288272|NCT01551342|bladder cancer
288273|NCT01551342|Transitional cell carcinoma (TCC)
288274|NCT01551329|depression
288275|NCT01551329|alcohol
288276|NCT01551329|comorbidity
288277|NCT01551329|ketamine
288278|NCT01551329|glutamate
288279|NCT01551329|NMDA
288280|NCT01551316|safety
288281|NCT01551316|pharmacokinetics
288282|NCT01551316|spirometry
288283|NCT01551290|Ulcerative colitis
288284|NCT01551290|UC
288285|NCT01551290|Remicade
288286|NCT01551290|Infliximab
288287|NCT01551290|Chinese patients
288288|NCT01551290|Mayo score
288289|NCT01551290|Mucosal healing
288290|NCT01551290|Rectal bleeding
288291|NCT01551290|Inflammatory bowel disease
288292|NCT01551290|IBD
288293|NCT01551238|Energy expenditure
288294|NCT01551238|Sleep
288295|NCT01551238|Protein
288296|NCT01551238|Carbohydrate
288297|NCT01551225|Randomized controlled trial
288298|NCT01551225|Escitalopram
288299|NCT01551225|Irritable bowel syndrome
288300|NCT01551225|Panic disorder
288301|NCT01551212|Liver transplantation
288302|NCT01551212|everolimus
288303|NCT01551212|kidney function
288304|NCT01551186|Probiotics
288305|NCT01551173|Dyslipidemias
288306|NCT01551173|Fluvastatin sodium
288307|NCT01551173|Chinese
288308|NCT01551160|Non-technical skills
288309|NCT01551160|Crisis resource management
288310|NCT01551160|Medical Emergency Team
288311|NCT01551160|Rapid Response Team
288312|NCT01551147|asthma
288313|NCT01551147|ONO-6950
288314|NCT01551147|asthma in adult patients
288315|NCT01551134|Gastroesophageal Reflux
288316|NCT01551134|Fundoplication
288317|NCT01551134|Randomized Controlled Trial
288318|NCT01551134|General Surgery
288319|NCT01551134|Child
288320|NCT01551134|Laparoscopy
288321|NCT01551108|Children
288322|NCT01551108|physical activity
288323|NCT01551095|PEGJ
288324|NCT01551095|PEG-J
288325|NCT01551095|percutaneous endoscopic gastrostomy
288326|NCT01551095|feeding tube
288327|NCT01551095|gastroparesis
288328|NCT01551095|acute pancreatitis
288329|NCT01551095|stroke
288330|NCT01551095|respiratory failure
288331|NCT01551095|GERD
288332|NCT01551095|balloon
288333|NCT01551095|self-propelled
288334|NCT01551043|adult patients
288335|NCT01551043|aged 18
288336|NCT01551043|CD19+ ALL relapsed
288337|NCT01551043|after allogeneic SCT
288338|NCT01551030|KIDNEY
288339|NCT01551030|URETER
288340|NCT01551030|URINARY BLADDER
288341|NCT01551030|Buparlisib
288342|NCT01551030|11-060
288343|NCT01551017|total knee endoprostheses
288344|NCT01551017|swelling
288345|NCT01551017|mobilisation
288346|NCT01551004|C. difficile, Clostridium difficile, C. diff, CRS3123
288347|NCT01550965|Quality of Life
288348|NCT01550965|Costs of Ulcerative Colitis
288349|NCT01550965|Health Care Utilization
288350|NCT01550939|Biometry of the Eye
288351|NCT01550939|Intraocular Lens Implantation
288352|NCT01550939|IOL
288353|NCT01550926|orlistat
288354|NCT01550926|overweight
288355|NCT01550926|bioequivalence
288356|NCT01550913|Substance use
288357|NCT01550913|perinatal depression
288358|NCT01550913|pregnant
288359|NCT01550900|Colorectum
288360|NCT01550900|Metachronous ctalColonic Neoplastic Polyps
288361|NCT01550900|Chemoprevention
288362|NCT01550900|Colonic adenoma(s)
288363|NCT01550900|Pre-cancerous tumor(s) on the colon
288364|NCT01550900|Metformin ER
288365|NCT01550900|Extended Release
288366|NCT01550900|Placebo
288367|NCT01550900|Sugar pill
288368|NCT01550874|Physical Activity
288369|NCT01550874|Epilepsy
288370|NCT01550874|Children
288371|NCT01550861|infertility
288372|NCT01550861|in vitro maturation (IVM)
288373|NCT01550861|in vitro fertilization (IVF)
288374|NCT01550861|natural cycle
288375|NCT01550835|Symptomatic carotid artery stenosis
288376|NCT01550822|stroke, lifestyle habits
288377|NCT01550809|T1DM
288378|NCT01550809|CSII
288379|NCT01550809|CGM
288380|NCT01550809|postprandial control
288381|NCT01550809|glycemic variability
288382|NCT01550809|Prandial insulin dosing in Type 1 diabetes treated with continuous subcutaneous insulin infusion
288383|NCT01550796|Tinnitus
288384|NCT01550796|Brain Fitness Program
288385|NCT01550796|Posit Science
288386|NCT01550796|D-cycloserine
288387|NCT01550796|Cognitive Training
288388|NCT01550783|Cervical cancer
288389|NCT01550783|Atypical squamous cells of undetermined significance
288390|NCT01550783|Stage 0 cervical cancer
288391|NCT01550783|Cervical intraepithelial neoplasia grade 1
288392|NCT01550783|Cervical
288393|NCT01550783|intraepithelial neoplasia grade 2
288394|NCT01550783|Cervical intraepithelial neoplasia grade 3
288395|NCT01550783|Human papillomavirus
288396|NCT01550783|HPV
288397|NCT01550744|Psoriasis
288398|NCT01550744|Ustekinumab
288399|NCT01550744|STELARA
288400|NCT01550744|Skin disease
288401|NCT01550744|Monoclonal
288402|NCT01550731|advance care planning
288403|NCT01550731|health communication
288404|NCT01550731|aging
288405|NCT01550718|Aerobic Exercise
288406|NCT01550718|Alzheimer's Disease
288407|NCT01550718|Burden and Stress
288408|NCT01550718|Caregiving Issues
288409|NCT01550718|Quality of Life
288410|NCT01550718|Early Stage Memory Loss
288411|NCT01550705|Protoporphyria
288412|NCT01550705|Porphyria
288413|NCT01550705|Porphyrins
288414|NCT01550666|negative symptoms
288415|NCT01550653|Memory
288416|NCT01550653|GLP-1
288417|NCT01550653|Liraglutide
288418|NCT01550653|energy output
288419|NCT01550653|Memory facilitation
288420|NCT01550653|GLP-1 analogue
288421|NCT01550640|remifentanil
288422|NCT01550640|Caesarean operation
288423|NCT01550640|general anaesthesia
288424|NCT01550640|hypertension
288425|NCT01550640|newborn's adaptation
288426|NCT01550640|pharmacogenetics
288427|NCT01550627|preterm infants < 32 weeks of gestation
288428|NCT01550614|Angina Pectoris
288429|NCT01550614|Myocardial Ischemia
288430|NCT01550614|Chest Pain
288431|NCT01550614|Coronary Artery Disease
288432|NCT01550614|Heart Diseases
288433|NCT01550614|Cardiovascular Diseases
288434|NCT01550614|Myocardial Perfusion
288435|NCT01550614|Reversible Perfusion Defect Size
288436|NCT01550614|SPECT-MIBI
288437|NCT01550614|Anti-Anginal Medication
288438|NCT01550614|Quality of Life
288439|NCT01550601|morbid obesity
288440|NCT01550601|gastrectomy
288441|NCT01550601|gastrinaemia
288442|NCT01550601|comorbidity
288443|NCT01550601|gastric antrum
288444|NCT01550588|PFO
288445|NCT01550588|Stroke
288446|NCT01550549|Amyloid imaging
288447|NCT01550549|Positron Emission Tomography
288448|NCT01550549|18F-AV-45
288449|NCT01550549|florbetapir F 18
288450|NCT01550549|Diagnostic imaging
288451|NCT01550536|basal metabolic rate
288452|NCT01550536|resting energy expenditure
288453|NCT01550536|menopause
288454|NCT01550536|physical activity
288455|NCT01550536|metabolic syndrome
288456|NCT01550523|Brain Tumor
288457|NCT01550510|Stage IV Colorectal cancer
288458|NCT01550510|Colorectal Neoplasms
288459|NCT01550510|Intestinal Neoplasms
288460|NCT01550510|Gastrointestinal Neoplasms
288461|NCT01550510|Digestive System Neoplasms
288462|NCT01550510|Neoplasms by Site
288463|NCT01550510|Neoplasms
288464|NCT01550510|Digestive System Diseases
288465|NCT01550510|Gastrointestinal Diseases
288466|NCT01550510|Colonic Diseases
288467|NCT01550510|Intestinal Diseases
288468|NCT01550510|Rectal Diseases
288469|NCT01550510|Ascorbic Acid
288470|NCT01550510|Vitamins
288471|NCT01550510|Irinotecan
288472|NCT01550510|Integrative Medicine
288473|NCT01550510|Complementary Medicine
288474|NCT01550510|Alternative Medicine Antioxidants
288475|NCT01550510|Molecular Mechanisms of Pharmacological Action
288476|NCT01550510|Pharmacologic Actions
288477|NCT01550510|Protective Agents
288478|NCT01550510|Physiological Effects of Drugs
288479|NCT01550510|Micronutrients
288480|NCT01550510|Growth Substances
288481|NCT01550510|Antineoplastic Agents, Phytogenic
288482|NCT01550510|Antineoplastic Agents
288483|NCT01550510|Therapeutic Uses
288484|NCT01550510|Radiation-Sensitizing Agents
288485|NCT01550510|Topoisomerase I Inhibitors
288486|NCT01550510|Topoisomerase Inhibitors
288487|NCT01550510|Enzyme Inhibitors
288488|NCT01550497|back pain
288489|NCT01550497|scoliosis
288490|NCT01550497|home exercise program
288491|NCT01550471|Mild asthma and allergic rhinitis
288492|NCT01550458|Clinical Trial, Phase I
288493|NCT01550458|Human Volunteers
288494|NCT01550458|Healthy Volunteers
288495|NCT01550458|mibefradil
288496|NCT01550458|Posicor®
288497|NCT01550445|Steroid withdrawal, Kidney transplantation
288498|NCT01550419|Ventilator-associated pneumonia
288499|NCT01550419|Ischemic stroke
288500|NCT01550419|Atorvastatin
288501|NCT01550419|Morbidity
288502|NCT01550419|Mortality
288503|NCT01550406|Pancreatic fistula
288504|NCT01550406|distal Pancreatectomy
288505|NCT01550393|stage II Wilms tumor
288506|NCT01550393|stage III Wilms tumor
288507|NCT01550393|recurrent Wilms tumor and other childhood kidney tumors
288508|NCT01550380|Endometrial cancer
288509|NCT01550341|HIV
288510|NCT01550341|AIDS
288511|NCT01550341|Opiate Addiction
288512|NCT01550341|Drug Dependence
288513|NCT01550341|Buprenorphine
288514|NCT01550328|Screening for Type 2 diabetes
288515|NCT01550315|POTS
288516|NCT01550315|endothelial function
288517|NCT01550315|high salt vs low salt diet
288518|NCT01550315|PAT protocol
288519|NCT01550315|Calf blood flow
288520|NCT01550315|forearm mediated dilation
288521|NCT01550302|Superficial Cervical Plexus Block
288522|NCT01550302|Thoracic Surgery
288523|NCT01550302|Thoracotomy
288524|NCT01550302|Video-Assisted Thoracoscopic Surgery
288525|NCT01550289|Dengue Fever
288526|NCT01550289|Dengue Hemorrhagic Fever
288527|NCT01550289|CYD Dengue Vaccine
288528|NCT01550289|Dengue Virus
288529|NCT01550289|Flavivirus
288530|NCT01550276|Effectiveness
288531|NCT01550276|Tension-type headache
288532|NCT01550276|Manual therapy
288533|NCT01550263|Hip Preservation
288534|NCT01550263|Hip Arthroscopy
288535|NCT01550263|Hip Pain
288536|NCT01550263|Psychological distress
288537|NCT01550250|Breast cancer
288538|NCT01550250|Arm lymphedema
288539|NCT01550250|Compression therapy
288540|NCT01550237|radiotherapy, image-guided
288541|NCT01550237|adverse effects
288542|NCT01550237|position verification
288543|NCT01550237|safety margins
288544|NCT01550198|newborn
288545|NCT01550198|shock
288546|NCT01550198|hemodynamics
288547|NCT01550198|cardiac output
288548|NCT01550198|blood pressure
288549|NCT01550172|dementia caregivers
288550|NCT01550172|caregivers
288551|NCT01550172|Alzheimer's caregivers
288552|NCT01550172|caregiver sleep
288553|NCT01550172|heart disease risk
288554|NCT01550172|dementia
288555|NCT01550172|Alzheimer's Disease
288556|NCT01550159|Postoperative Cognitive Dysfunction
288557|NCT01550159|Cardiac Surgery
288558|NCT01550159|General Anesthesia
288559|NCT01550159|Neuropsychological Tests
288560|NCT01550146|Fractured neck of femur
288561|NCT01550146|Dexamethasone
288562|NCT01550133|Peptides
288563|NCT01550133|Hormones
288564|NCT01550133|Appetite
288565|NCT01550133|Humans
288566|NCT01550133|Obese
288567|NCT01550133|Beverage
288568|NCT01550133|Solid food
288569|NCT01550133|cephalic phase
288570|NCT01550120|taste
288571|NCT01550120|fat
288572|NCT01550120|threshold
288573|NCT01550120|sensitivity
288574|NCT01550120|human
288575|NCT01550107|Sarcopenia
288576|NCT01550107|Allopurinol
288577|NCT01550107|Xanthine Oxidase
288578|NCT01550107|MR Spectroscopy
288579|NCT01550094|obese
288580|NCT01550094|regional anesthesia
288581|NCT01550094|anesthesia
288582|NCT01550094|anesthesiology
288583|NCT01550094|surgery
288584|NCT01550094|foot
288585|NCT01550094|foot surgery
288586|NCT01550094|ankle
288587|NCT01550094|ankle surgery
288588|NCT01550094|orthopedics
288589|NCT01550094|orthopedic surgery
288590|NCT01550094|sports medicine
288591|NCT01550094|sports medicine surgery
288592|NCT01550094|Ochsner Hospital
288593|NCT01550094|Ochsner Clinic
288594|NCT01550094|New Orleans
288595|NCT01550094|Louisiana
288596|NCT01550094|Jefferson
288597|NCT01550094|Soberon
288598|NCT01550081|exercise intensity
288599|NCT01550081|aerobic interval training
288600|NCT01550081|cardiac rehabilitation
288601|NCT01550081|group exercise
288602|NCT01550068|Rheumatic Heart Disease
288603|NCT01550055|KRAS wild-type
288604|NCT01550055|Metastatic Colorectal Cancer
288605|NCT01550055|CMAB009 Plus Irinotecan
288606|NCT01550055|Phase II/III
288607|NCT01550029|Smoking
288608|NCT01550029|Tobacco
288609|NCT01550029|Nicotine
288610|NCT01550029|Bipolar
288611|NCT01550016|dengue warning signs
288612|NCT01550016|latin america
288613|NCT01550016|south east asia
288614|NCT01550016|other febrile illnesses
288615|NCT01550016|dengue classification
288616|NCT01550003|Cimzia
288617|NCT01550003|JIA
288618|NCT01550003|Polyarticular
288619|NCT01550003|Oligoarticular
288620|NCT01550003|Enthesitis-related-Arthritis
288621|NCT01550003|Juvenile Idiopathic Arthritis
288622|NCT01550003|Juvenile Psoriatic Arthritis
288623|NCT01550003|Certolizumab Pegol
288624|NCT01550003|PASCAL
288625|NCT01550003|CDP870
288626|NCT01549977|Drug Therapy
288627|NCT01549964|Drug Therapy
288628|NCT01549951|Metastatic castrate resistant prostate cancer, mCRPC, orteronel, TAK-700, Phase 2, QT, QTc
288629|NCT01549938|Vitamin D
288630|NCT01549938|Cholecalciferol
288631|NCT01549938|Respiratory tract infection
288632|NCT01549912|Rotator Cuff Tears
288633|NCT01549912|Dislocation
288634|NCT01549912|Shoulder Dislocation
288635|NCT01549899|Insomnia
288636|NCT01549899|Cognitive
288637|NCT01549899|Behavioral
288638|NCT01549899|Therapy
288639|NCT01549899|Internet
288640|NCT01549899|Depression
288641|NCT01549899|Substance Use
288642|NCT01549899|Post-Tramatic Stress Disorder
288643|NCT01549886|Non-Hodgkin's Lymphoma
288644|NCT01549886|Zevalin
288645|NCT01549886|Motexafin Gadolinium
288646|NCT01549860|Venous Insufficiency
288647|NCT01549860|Reflux
288648|NCT01549860|Lower Extremity Ulcer
288649|NCT01549847|Postpoliomyelitis Syndrome
288650|NCT01549847|Piracetam
288651|NCT01549847|L-Carnitine
288652|NCT01549808|ADL
288653|NCT01549808|activities of daily living
288654|NCT01549808|level of function
288655|NCT01549795|Liver transplantation
288656|NCT01549795|Neoadjuvant radio- chemo-therapy
288657|NCT01549782|Prebiotics
288658|NCT01549782|Microbiota
288659|NCT01549782|Radiotherapy
288660|NCT01549782|Gynaecological Cancer
288661|NCT01549756|stage 4 stomach cancer
288662|NCT01549756|stage 4 gastric cancer
288663|NCT01549717|Early warning score
288664|NCT01549717|Physiological score
288665|NCT01549717|Track and trigger score
288666|NCT01549717|Scoring system
288667|NCT01549717|Physiological model
288668|NCT01549717|Monitoring
288669|NCT01549717|Patient monitoring
288670|NCT01549717|Wireless monitoring
288671|NCT01549717|Wearable monitor
288672|NCT01549704|Total knee arthroplasty
288673|NCT01549704|Adductor canal blockade (ACB)
288674|NCT01549704|High pain responders
288675|NCT01549704|US-guided nerve block
288676|NCT01549691|Premedication
288677|NCT01549691|Benzodiazepine
288678|NCT01549691|Anti-anxiety agents
288679|NCT01549691|Anxiety
288680|NCT01549691|Surgery
288681|NCT01549691|Adult
288682|NCT01549691|Human
288683|NCT01549678|Plantar fasciitis
288684|NCT01549678|foot pain
288685|NCT01549678|insoles
288686|NCT01549678|foot function
288687|NCT01549678|electronic baropodometer
288688|NCT01549678|plantar pressure
288689|NCT01549678|gait analysis
288690|NCT01549665|Graft-Versus-Host Disease
288691|NCT01549665|GVHD
288692|NCT01549665|Hematopoietic Stem Cell Transplantation
288693|NCT01549665|Stem Cell Transplantation
288694|NCT01549665|Allogeneic hematopoietic transplant
288695|NCT01549665|Mesenchymal Stem Cells
288696|NCT01549665|Unrelated Donors
288697|NCT01549665|Cord Blood Stem Cell Transplantation
288698|NCT01549639|Propofol
288699|NCT01549639|Target controlled infusion
288700|NCT01549639|General anaesthesia
288701|NCT01549626|Flaxseed
288702|NCT01549626|Women
288703|NCT01549626|Obesity
288704|NCT01549626|No smokers
288705|NCT01549574|crizotinib
288706|NCT01549574|pharmacokinetics
288707|NCT01549574|esomeprazole
288708|NCT01549574|proton pump inhibitor
288709|NCT01549574|drug drug interaction
288710|NCT01549574|healthy volunteers
288711|NCT01549561|behavior problems
288712|NCT01549561|foster care
288713|NCT01549561|parent training
288714|NCT01549561|youth skills training
288715|NCT01549548|CML
288716|NCT01549522|patients or caregivers
288717|NCT01549522|for caregivers, loved one must still be living
288718|NCT01549496|HCV
288719|NCT01549496|pharmacokinetics
288720|NCT01549496|boceprevir
288721|NCT01549496|hypertension
288722|NCT01549496|amlodipine
288723|NCT01549496|diltiazem
288724|NCT01549483|asthma
288725|NCT01549483|airway hyperresponsiveness
288726|NCT01549483|asymptomatic airway hyperresponsiveness
288727|NCT01549483|small airways
288728|NCT01549457|latent tuberculosis
288729|NCT01549457|text message interventions
288730|NCT01549457|medication adherence
288731|NCT01549444|renin
288732|NCT01549444|aldosterone
288733|NCT01549444|neonate
288734|NCT01549431|Multiple Myeloma
288735|NCT01549418|Gastrointestinal bleeding
288736|NCT01549418|Lower gastrointestinal bleeding (LGIB)
288737|NCT01549418|Polypectomy
288738|NCT01549418|Large colorectal polyps
288739|NCT01549418|ASA
288740|NCT01549418|Aspirin
288741|NCT01549418|Acetylsalicylic acid
288742|NCT01549418|Colorectal Neoplasms
288743|NCT01549418|Intestinal Neoplasms
288744|NCT01549418|Gastrointestinal Neoplasms
288745|NCT01549418|Digestive System Neoplasms
288746|NCT01549418|Neoplasms by Site
288747|NCT01549418|Neoplasms
288748|NCT01549418|Digestive System Diseases
288749|NCT01549418|Gastrointestinal Diseases
288750|NCT01549418|Colonic Diseases
288751|NCT01549418|Intestinal Diseases
288752|NCT01549418|Rectal Diseases
288753|NCT01549405|percutanous nephrolitotomy,intercostal nerve block, Ultrasound
288754|NCT01549392|dynamic enhanced ct scan
288755|NCT01549392|mri spectroscopy
288756|NCT01549392|recurrent gliomas
288757|NCT01549379|Head and neck cancer
288758|NCT01549379|Radiation
288759|NCT01549379|Chemotherapy
288760|NCT01549379|Surgery
288761|NCT01549379|Dynamic contrast enhanced computed tomography
288762|NCT01549340|Rhinitis
288763|NCT01549340|Allergen immunotherapy
288764|NCT01549327|Virtual Patient Navigation
288765|NCT01549327|Randomized Clinical Trial
288766|NCT01549327|Empowerment
288767|NCT01549327|Cost-Effectiveness
288768|NCT01549327|Cancer Information Preferences
288769|NCT01549314|Cystic fibrosis related bone disease
288770|NCT01549314|Cystic fibrosis
288771|NCT01549314|Ivacaftor
288772|NCT01549249|cone outer segment tips line
288773|NCT01549249|inner segment/outer segment junction line
288774|NCT01549249|optical coherence tomography
288775|NCT01549249|epiretinal membrane
288776|NCT01549236|Chagas Disease
288777|NCT01549236|Trypanosoma Cruzi
288778|NCT01549236|T.Cruzi
288779|NCT01549223|Uterine Atony
288780|NCT01549223|Hypotension
288781|NCT01549223|Cesarean Delivery
288782|NCT01549223|Hemorrhage
288783|NCT01549223|Phenylephrine
288784|NCT01549223|Ephedrine
288785|NCT01549210|gout
288786|NCT01549210|gouty arthritis
288787|NCT01549197|PTSD
288788|NCT01549184|secondary ITP
288789|NCT01549184|hydroxychloroquine
288790|NCT01549184|Systemic Lupus Erythematosus
288791|NCT01549171|Human ART
288792|NCT01549171|Prostacyclin
288793|NCT01549171|Iloprost
288794|NCT01549171|Pregnancy
288795|NCT01549158|loop diuretics
288796|NCT01549158|torasemide prolonged release
288797|NCT01549158|torasemide immediate release
288798|NCT01549158|Sutril Neo
288799|NCT01549158|pharmacodynamic profile of Torasemide-PR
288800|NCT01549145|Severe
288801|NCT01549145|Ongoing
288802|NCT01549145|Unilateral
288803|NCT01549145|present for more than 6 months
288804|NCT01549132|Clinically significant macular oedema
288805|NCT01549132|Retinal Oximetry
288806|NCT01549132|Spectral imaging
288807|NCT01549132|Retinal Laser therapy
288808|NCT01549132|Intravitreal Anti-VEGF Injection therapy
288809|NCT01549119|HIV-1
288810|NCT01549119|HIV
288811|NCT01549119|immunotherapy
288812|NCT01549119|active immunotherapy
288813|NCT01549119|vaccine
288814|NCT01549119|virulence
288815|NCT01549119|innate immunity
288816|NCT01549119|NK cells
288817|NCT01549093|Non-small cell lung cancer
288818|NCT01549093|Endostar
288819|NCT01549093|Continued Pumping into
288820|NCT01549093|Gemcitabine
288821|NCT01549093|Carboplatin
288822|NCT01549080|traditional chinese medicine and thalassemia
288823|NCT01549067|Advanced
288824|NCT01549067|Colorectal Cancer
288825|NCT01549067|Targeted chemotherapy
288826|NCT01549067|Surgery
288827|NCT01549067|Radiotherapy
288828|NCT01549041|schizophrenia
288829|NCT01549041|asenapine
288830|NCT01549041|Once daily
288831|NCT01549041|twice daily
288832|NCT01549015|Urea Cycle Defects
288833|NCT01549015|CPSD
288834|NCT01549015|OTCD
288835|NCT01549015|ASSD
288836|NCT01549015|ASLD
288837|NCT01549002|Abscess
288838|NCT01549002|Pain
288839|NCT01549002|Administration intranasal
288840|NCT01549002|Infusions intravenous
288841|NCT01548989|linguistic validation of a new questionnaire
288842|NCT01548976|linguistic validation of the PISQ-R questionnaire
288843|NCT01548963|Tight glycemia control
288844|NCT01548963|Model Predictive Control algorithm
288845|NCT01548963|Cardiac surgery patients
288846|NCT01548950|Congenital heart disease
288847|NCT01548950|Pulmonary arterial hypertension
288848|NCT01548950|Sildenafil
288849|NCT01548950|Bosentan
288850|NCT01548950|Pediatric cardiac surgery
288851|NCT01548937|I-123 ADAM Serotonin transporter imaging
288852|NCT01548924|Patients with malignant solid tumors of any histologically confirmed, not susceptible of cure, which have received the standard treatment available
288853|NCT01548872|HTk solution
288854|NCT01548872|Cardioplegia
288855|NCT01548872|myocardial protection
288856|NCT01548872|pediatric cardiac surgery
288857|NCT01548859|Myocardial protection
288858|NCT01548859|Myocardial injury
288859|NCT01548859|Anaesthetic preconditioning
288860|NCT01548859|Pediatric cardiac surgery
288861|NCT01548859|Troponin I
288862|NCT01548859|Sevoflurane
288863|NCT01548859|Midazolam
288864|NCT01548846|tomotherapy
288865|NCT01548846|xerostomy
288866|NCT01548846|head and neck squamous cell carcinoma
288867|NCT01548833|Myopia
288868|NCT01548833|Contact Lenses
288869|NCT01548820|Hepatitis B virus
288870|NCT01548820|Lamivudine
288871|NCT01548820|Resistance to treatment
288872|NCT01548794|spinal anesthesia
288873|NCT01548794|bupivacaine
288874|NCT01548794|lidocaine
288875|NCT01548794|local infiltration anesthesia
288876|NCT01548794|recovery
288877|NCT01548794|duration of anesthesia
288878|NCT01548794|outpatient herniorrhaphy
288879|NCT01548781|arm
288880|NCT01548781|strength
288881|NCT01548781|coordination
288882|NCT01548781|physical therapy
288883|NCT01548781|robotics
288884|NCT01548781|stroke
288885|NCT01548781|synergy
288886|NCT01548768|Rheumatoid Arthritis
288887|NCT01548768|Cardiovascular disease
288888|NCT01548768|Myocardium
288889|NCT01548768|TNF-alpha inhibitors
288890|NCT01548768|ESCAPE
288891|NCT01548768|Co-morbidities
288892|NCT01548768|RHYTHM
288893|NCT01548755|Home monitoring
288894|NCT01548755|cardiomessenger
288895|NCT01548755|ICD
288896|NCT01548742|Meditation
288897|NCT01548729|Cystic Fibrosis
288898|NCT01548729|Diabetes Related Cystic Fibrosis
288899|NCT01548729|Lung transplantation
288900|NCT01548729|Pancreatic islets
288901|NCT01548716|Pruritis in hemodialysis patients
288902|NCT01548716|25-Vitamin D in chronic kidney disease
288903|NCT01548703|metabotropic glutamate receptors 2 and 3
288904|NCT01548703|antagonist
288905|NCT01548703|mGluR
288906|NCT01548703|ketamine
288907|NCT01548703|BDNF
288908|NCT01548703|Depression
288909|NCT01548703|Major Depressive Disorder
288910|NCT01548703|Treatment Resistant Depression
288911|NCT01548703|Mood Disorder
288912|NCT01548703|Phase 1 safety, tolerability and pharmacokinetics study
288913|NCT01548690|ornithine
288914|NCT01548690|phenylacetate
288915|NCT01548690|acetaminophen toxicity
288916|NCT01548690|acute liver failure
288917|NCT01548690|hepatitis B
288918|NCT01548690|autoimmune hepatitis
288919|NCT01548690|drug-induced liver injury
288920|NCT01548677|Circulating Tumour Cells
288921|NCT01548677|HER2 negative primary breast cancer
288922|NCT01548677|HER2 positive CTC
288923|NCT01548677|Trastuzumab
288924|NCT01548664|Total knee replacement
288925|NCT01548664|Outpatient
288926|NCT01548664|Randomized controlled trial
288927|NCT01548664|Video games
288928|NCT01548638|Tobacco
288929|NCT01548638|Smoking
288930|NCT01548638|Galantamine
288931|NCT01548625|risk of cardiovascular events
288932|NCT01548612|Schizophrenia
288933|NCT01548612|Nitric oxide
288934|NCT01548612|Sodium nitroprusside
288935|NCT01548599|HIV
288936|NCT01548599|Malnutrition
288937|NCT01548599|Food Security
288938|NCT01548599|Kenya
288939|NCT01548586|tDCS
288940|NCT01548586|Diaphragm
288941|NCT01548586|Cortical Excitability
288942|NCT01548586|MEPs
288943|NCT01548586|TMS
288944|NCT01548573|multiple myeloma
288945|NCT01548573|POEMS (Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
288946|NCT01548573|amyloidosis
288947|NCT01548573|bone marrow transplant
288948|NCT01548573|autologous
288949|NCT01548560|HIV Infections
288950|NCT01548560|Anti-HIV agents
288951|NCT01548560|HIV-1
288952|NCT01548547|intravenous line
288953|NCT01548547|simulation education
288954|NCT01548534|Metastatic Breast Cancer
288955|NCT01548534|First-Line chemotherapy
288956|NCT01548534|Taxane or Anthracycline
288957|NCT01548534|DHA
288958|NCT01548534|PUFA
288959|NCT01548534|Dietary supplementation
288960|NCT01548534|First-Line Taxane or Anthracycline based chemotherapy
288961|NCT01548521|Prader-Willi, neonates, poor suckling
288962|NCT01548508|Advanced Chronic Heart Failure, physical therapy, Exercise
288963|NCT01548495|MDS
288964|NCT01548495|Autoantibodies
288965|NCT01548495|Erythropoietin
288966|NCT01548495|Autoantibodies in MDS patients treated with EPO
288967|NCT01548469|Mild periodontitis
288968|NCT01548469|Bio Mineral toothpaste
288969|NCT01548469|Geumjin Thermal Water
288970|NCT01548456|femur fracture
288971|NCT01548456|internal fixation
288972|NCT01548456|intramedullary nailing
288973|NCT01548443|Wound Healing
288974|NCT01548443|hydrocolloid
288975|NCT01548443|Wound Dressing
288976|NCT01548443|Medifoam H
288977|NCT01548443|Duoderm THIN
288978|NCT01548443|Mild Acute Trauma
288979|NCT01548417|Alcohol
288980|NCT01548417|Relapse
288981|NCT01548378|HGF
288982|NCT01548378|Gene
288983|NCT01548378|Critical Limb Ischemia
288984|NCT01548365|Nursing Services
288985|NCT01548365|Catheterization, Central Venous
288986|NCT01548365|Catheters Indwelling
288987|NCT01548365|Catheterization, Peripheral
288988|NCT01548352|Syncope
288989|NCT01548352|Unconsciousness
288990|NCT01548352|Syncope, vasovagal, neurally-mediated
288991|NCT01548352|Syncope, cardiogenic
288992|NCT01548352|Cardiac arrhythmia
288993|NCT01548352|Sudden cardiac death
288994|NCT01548352|Syncopal episode
288995|NCT01548326|Vaccination Failure
288996|NCT01548326|Nonresponder
288997|NCT01548326|Hepatitis B virus
288998|NCT01548326|Atorvastatin
288999|NCT01548326|Immunization against viral Hepatitis
289000|NCT01548313|human milk
289001|NCT01548313|nutrition
289002|NCT01548313|breastfed child
289003|NCT01548313|microbiota
289004|NCT01548313|fatty acids
289005|NCT01548313|intestinal microbiota
289006|NCT01548313|probiotics
289007|NCT01548300|cardiometabolic disease
289008|NCT01548287|Mild Cognitive Impairment
289009|NCT01548287|Mild Alzheimer's disease
289010|NCT01548287|Safety
289011|NCT01548287|Tolerability
289012|NCT01548274|endothelial progenitor cells
289013|NCT01548261|obtain the oral mucosal tissue from healthy donors
289014|NCT01548222|type 2 diabetes
289015|NCT01548222|continuous glucose
289016|NCT01548222|basal insulin
289017|NCT01548196|nephrolithotomy
289018|NCT01548170|Pharmacokinetic
289019|NCT01548170|Sunitinib
289020|NCT01548170|Ketoconazol
289021|NCT01548170|interaction, Phase I
289022|NCT01548157|HCP1007
289023|NCT01548157|Rosuvastatin
289024|NCT01548157|Omega-3
289025|NCT01548144|Advanced Cancers
289026|NCT01548144|Advanced Malignancies
289027|NCT01548144|Crizotinib
289028|NCT01548144|PF-02341066
289029|NCT01548144|Pazopanib
289030|NCT01548144|Gw786034
289031|NCT01548144|Pemetrexed
289032|NCT01548144|LY231514
289033|NCT01548144|Alimta
289034|NCT01548144|MTA
289035|NCT01548144|Multitargeted Antifolate
289036|NCT01548144|NSC-698037
289037|NCT01548131|fear of childbirth
289038|NCT01548131|delivery mode
289039|NCT01548131|delivery satisfaction
289040|NCT01548118|Human papillomavirus
289041|NCT01548118|vaccine
289042|NCT01548118|cervical infection
289043|NCT01548118|cervical cancer
289044|NCT01548105|Pelvic organ prolapse
289045|NCT01548105|smoking and collagen metabolism
289046|NCT01548092|Recto-vaginal fistula
289047|NCT01548092|Adipose Derived Stem Cells
289048|NCT01548079|ursodeoxycholic acid
289049|NCT01548079|fatty liver disease
289050|NCT01548079|morbid obesity
289051|NCT01548079|bariatric surgery
289052|NCT01548079|NAFLD
289053|NCT01548053|Primary care
289054|NCT01548053|Dementia
289055|NCT01548053|Knowledge translation
289056|NCT01548053|Quality of care
289057|NCT01548053|Qualitative methods
289058|NCT01548053|Alzheimer's disease
289059|NCT01548040|NMES
289060|NCT01548040|Muscle
289061|NCT01548040|strength
289062|NCT01548040|TKA
289063|NCT01548040|Focus to show shorter muscle recovery after Knee operation
289064|NCT01548027|TAP block
289065|NCT01548027|postoperative analgesia
289066|NCT01548014|Crohn's disease
289067|NCT01548014|VSL #3
289068|NCT01548014|infliximab
289069|NCT01548001|Rheumatoid Arthritis
289070|NCT01548001|Iguratimod
289071|NCT01548001|Methotrexate
289072|NCT01547988|Aging
289073|NCT01547988|Falls
289074|NCT01547988|Balance Control
289075|NCT01547988|Voluntary Step Execution Test
289076|NCT01547988|Dual-Task
289077|NCT01547988|Self-reported function
289078|NCT01547975|surgical outcomes after corneal transplantation
289079|NCT01547975|Retrospective analysis
289080|NCT01547975|corneal transplantation
289081|NCT01547949|pain
289082|NCT01547949|inflammation
289083|NCT01547949|muscle damage
289084|NCT01547923|Colorectal Cancer
289085|NCT01547923|DihydroPyrimidine Dehydrogenase
289086|NCT01547923|Lethal toxicity
289087|NCT01547923|Fluoropyrimidine
289088|NCT01547910|fatty liver
289089|NCT01547910|hepatitis
289090|NCT01547910|insulin resistance
289091|NCT01547910|unsaturated fatty acids
289092|NCT01547910|NAFLD, children
289093|NCT01547884|Immune Responses
289094|NCT01547884|Mycobacterial Antigens
289095|NCT01547884|Tissue-invasive Helminth Parasites
289096|NCT01547871|Natural History Study
289097|NCT01547871|Spinal Muscular Atrophy (SMA)
289098|NCT01547871|Natural History
289099|NCT01547858|Hematotoxicity
289100|NCT01547858|Formaldehyde
289101|NCT01547858|Cross-Sectional Study
289102|NCT01547858|Occupational Exposure
289103|NCT01547845|Disparities
289104|NCT01547845|Patient Reported Outcomes
289105|NCT01547845|Symptoms
289106|NCT01547845|Symptom Surveillance
289107|NCT01547832|Cholesterol
289108|NCT01547832|Early Onset Parkinson's Disease
289109|NCT01547832|Fat Metabolism
289110|NCT01547832|Insulin Resistance
289111|NCT01547832|PARK2 Mutations
289112|NCT01547819|TBI
289113|NCT01547819|Magnetic Resonance Imaging (MRI)
289114|NCT01547819|PTSD
289115|NCT01547819|PET Imaging
289116|NCT01547819|11C-Flumazenil
289117|NCT01547806|Autologous Hematopoietic Cell Transplantation
289118|NCT01547806|Plasma Cell Myeloma
289119|NCT01547806|Mobilization
289120|NCT01547806|Apheresis
289121|NCT01547806|Plerixafor
289122|NCT01547793|Hemolytic Severity
289123|NCT01547793|Erythrocyte
289124|NCT01547793|Sickle Cell Disease
289125|NCT01547793|SD
289126|NCT01547780|MRI
289127|NCT01547780|Positron Emission Tomograhy (PET)
289128|NCT01547780|Inflammation
289129|NCT01547780|Microglial Activation
289130|NCT01547780|Traumatic Brain Injury
289131|NCT01547780|TBI
289132|NCT01547767|Metabolism
289133|NCT01547767|Muscle
289134|NCT01547767|Mutation
289135|NCT01547767|ISCU Myopathy
289136|NCT01547767|Myopathy
289137|NCT01547754|Neuroinflammation
289138|NCT01547754|HIV
289139|NCT01547754|Positron Emission Tomograhy (PET)
289140|NCT01547754|Mild Neurocognitive Disorder
289141|NCT01547754|P-Glycoprotein
289142|NCT01547754|Mild Cognitive Disorder
289143|NCT01547754|Healthy Volunteer
289144|NCT01547754|HV
289145|NCT01547741|estrogen receptor-negative breast cancer
289146|NCT01547741|estrogen receptor-positive breast cancer
289147|NCT01547741|HER2-negative breast cancer
289148|NCT01547741|progesterone receptor-negative breast cancer
289149|NCT01547741|progesterone receptor-positive breast cancer
289150|NCT01547741|stage IA breast cancer
289151|NCT01547741|stage IB breast cancer
289152|NCT01547741|stage II breast cancer
289153|NCT01547741|stage IIIA breast cancer
289154|NCT01547741|stage IIIC breast cancer
289155|NCT01547728|antithrombin
289156|NCT01547728|Heparin Resistant
289157|NCT01547728|Cardiac Surgery
289158|NCT01547715|Meningococcal,
289159|NCT01547715|ACWY,
289160|NCT01547715|bacterial meningitis,
289161|NCT01547715|conjugate vaccine,
289162|NCT01547715|healthy, children,
289163|NCT01547715|adolescents,
289164|NCT01547715|adults,
289165|NCT01547715|India
289166|NCT01547702|ADHD
289167|NCT01547702|attention
289168|NCT01547702|inattention
289169|NCT01547702|hyperactivity
289170|NCT01547702|classroom intervention
289171|NCT01547702|teacher education
289172|NCT01547702|web-based intervention
289173|NCT01547663|pain scale
289174|NCT01547663|craniotomy
289175|NCT01547637|Obturator nerve block
289176|NCT01547637|Regional anesthesia
289177|NCT01547637|TURBT
289178|NCT01547624|Neck
289179|NCT01547624|Spine
289180|NCT01547624|Muscles
289181|NCT01547624|Activity
289182|NCT01547624|Coordination
289183|NCT01547611|Rehabilitation
289184|NCT01547611|Cervical Spine
289185|NCT01547611|Radiculopathy
289186|NCT01547611|Disc
289187|NCT01547611|Surgery
289188|NCT01547585|Cholesterol
289189|NCT01547585|Cardiovascular disease
289190|NCT01547585|Soy
289191|NCT01547585|Dose-response
289192|NCT01547572|Video education
289193|NCT01547572|Enhanced recovery
289194|NCT01547572|Reducing hospital stay
289195|NCT01547572|Improving patient satisfaction
289196|NCT01547533|Chagas disease
289197|NCT01547533|lactation
289198|NCT01547533|breastmilk
289199|NCT01547533|postpartum period
289200|NCT01547533|infants
289201|NCT01547533|pediatric clinical pharmacology
289202|NCT01547533|developmental clinical pharmacology
289203|NCT01547533|parasitology
289204|NCT01547533|trypanosoma cruzi
289205|NCT01547520|meperidine
289206|NCT01547520|esophagogastroduodenoscopy
289207|NCT01547520|unsedated
289208|NCT01547520|minimal sedation
289209|NCT01547507|hemodynamics
289210|NCT01547507|respiratory
289211|NCT01547494|Migraines
289212|NCT01547494|Diet, Vegetarian
289213|NCT01547494|Diet, Fat-Restricted
289214|NCT01547494|Pain
289215|NCT01547468|hip fracture
289216|NCT01547468|elderly
289217|NCT01547468|delirium
289218|NCT01547468|broken hip
289219|NCT01547468|hip
289220|NCT01547468|surgery
289221|NCT01547468|orthopedic
289222|NCT01547468|orthopedic surgery
289223|NCT01547468|pain
289224|NCT01547468|anesthesia
289225|NCT01547468|Ochsner Clinic
289226|NCT01547468|Ochsner Hospital
289227|NCT01547468|Leslie Thomas MD
289228|NCT01547468|New Orleans
289229|NCT01547468|Louisiana
289230|NCT01547455|Statin
289231|NCT01547455|kidney function
289232|NCT01547455|antiinflammatory effect
289233|NCT01547442|aphakia
289234|NCT01547442|secondary intraocular lens
289235|NCT01547442|congenital cataract
289236|NCT01547442|marfan syndrome
289237|NCT01547442|pediatric cataract
289238|NCT01547442|ectopia lentis
289239|NCT01547442|subluxated lens
289240|NCT01547429|aphakia
289241|NCT01547429|secondary intraocular lens
289242|NCT01547416|Diaphragmatic dysfunction
289243|NCT01547416|General anesthesia
289244|NCT01547416|Epidural Anesthesia
289245|NCT01547403|Screening for Type 2 Diabetes
289246|NCT01547390|preeclampsia
289247|NCT01547390|Aspirin
289248|NCT01547377|atherosclerosis
289249|NCT01547377|zinc and selenium status
289250|NCT01547377|rosuvastatin
289251|NCT01547377|oxidative stress biomarkers
289252|NCT01547377|inflammation biomarkers
289253|NCT01547364|Caudal
289254|NCT01547364|Epidural
289255|NCT01547364|Dextrose
289256|NCT01547364|Analgesia
289257|NCT01547364|TRVP1
289258|NCT01547351|Relapse in multiple sclerosis
289259|NCT01547351|Psychometric properties of the patient self-report questionnaire
289260|NCT01547351|Evaluation of ARMS questionnaire
289261|NCT01547338|Breast
289262|NCT01547338|Reconstruction
289263|NCT01547299|prostate cancer
289264|NCT01547299|prostatectomy
289265|NCT01547299|neoadjuvant
289266|NCT01547286|Asthma
289267|NCT01547286|Allergen Challenge
289268|NCT01547286|Cat allergen
289269|NCT01547286|Dust mite allergen
289270|NCT01547286|Airway Hyper-responsiveness
289271|NCT01547286|PET-CT
289272|NCT01547286|Nitrogen isotopes
289273|NCT01547286|Blood flow
289274|NCT01547247|colonoscopy
289275|NCT01547247|cap-assisted colonoscopy
289276|NCT01547247|water immersion colonoscopy
289277|NCT01547234|Multiple Sclerosis
289278|NCT01547234|ambulation
289279|NCT01547234|manual function
289280|NCT01547234|Fampridine
289281|NCT01547221|otomycosis
289282|NCT01547221|3% boric acid
289283|NCT01547221|1% clotrimazole ear drop
289284|NCT01547208|ICD shocks
289285|NCT01547208|Ventricular tachycardias ablation
289286|NCT01547208|Timing of ablation
289287|NCT01547208|Electrical storm
289288|NCT01547208|Arrhythmic storm
289289|NCT01547195|fibromyalgia
289290|NCT01547195|swimming
289291|NCT01547169|memory
289292|NCT01547169|intranasal insulin
289293|NCT01547169|Alzheimer's disease
289294|NCT01547156|patient decision support
289295|NCT01547156|telemonitoring
289296|NCT01547156|self-management
289297|NCT01547156|remote patient monitoring
289298|NCT01547156|active assistance technology
289299|NCT01547156|selfcare
289300|NCT01547143|Secondary hemophagocytic lymphohistiocytosis of adults
289301|NCT01547130|Colonoscopy
289302|NCT01547130|Yoga
289303|NCT01547130|Complementary and alternative medicine
289304|NCT01547130|Bowel cleansing
289305|NCT01547130|Large bowel preparation
289306|NCT01547130|Cancer screening
289307|NCT01547130|Colorectal cancer
289308|NCT01547117|POTS
289309|NCT01547117|Orthostatic Intolerance
289310|NCT01547117|Orthostatic Tachycardia
289311|NCT01547091|Mesenchymal Stem Cells
289312|NCT01547091|Rheumatoid Arthritis
289313|NCT01547065|TEE and renal resistive index
289314|NCT01547052|DBT, child, emotion regulation, behavior problems, residential care
289315|NCT01547039|Carotid endarterectomy
289316|NCT01547039|Transcranial doppler
289317|NCT01547039|Micro embolic signals
289318|NCT01547039|Platelets
289319|NCT01547039|Aspirin
289320|NCT01547026|schizophrenia
289321|NCT01547026|exercise
289322|NCT01547026|sport
289323|NCT01547026|weight control
289324|NCT01547026|fitness
289325|NCT01547000|Tourette Syndrome
289326|NCT01547000|Tourette Disorder
289327|NCT01547000|Tics
289328|NCT01547000|Motor tics
289329|NCT01547000|Vocal tics
289330|NCT01547000|Intuniv
289331|NCT01547000|Guanfacine
289332|NCT01547000|Medication
289333|NCT01547000|Drug
289334|NCT01547000|Placebo
289335|NCT01547000|Child
289336|NCT01547000|Children
289337|NCT01547000|Adolescent
289338|NCT01546987|adenocarcinoma of the prostate
289339|NCT01546987|stage I prostate cancer
289340|NCT01546987|stage IIA prostate cancer
289341|NCT01546987|stage IIB prostate cancer
289342|NCT01546987|stage III prostate cancer
289343|NCT01546987|stage IV prostate cancer
289344|NCT01546974|Mechanical Ventilation
289345|NCT01546974|Humidification system
289346|NCT01546974|Patients submitted to mechanical ventilation for at least 48 hours
289347|NCT01546961|Chloroquine
289348|NCT01546961|Uncomplicated vivax malaria
289349|NCT01546948|Methadone
289350|NCT01546948|Hydromorphone
289351|NCT01546948|Hepatobiliary surgery
289352|NCT01546948|Postoperative pain
289353|NCT01546935|Influenza
289354|NCT01546935|Oseltamivir
289355|NCT01546935|Lower tract respiratory infection
289356|NCT01546922|Hydrocortisone
289357|NCT01546922|Cognition
289358|NCT01546922|Adrenal insufficiency
289359|NCT01546922|Quality of Life
289360|NCT01546922|Common Somatic Complaints
289361|NCT01546922|Cardiovascular/Metabolic Profile
289362|NCT01546922|Somatosensation
289363|NCT01546883|Atrial fibrillation
289364|NCT01546883|MRI
289365|NCT01546857|orthopedic pain
289366|NCT01546844|SMS
289367|NCT01546844|text
289368|NCT01546844|text messages
289369|NCT01546844|text messaging
289370|NCT01546844|diabetes
289371|NCT01546844|diabetes mellitus
289372|NCT01546844|type II diabetes
289373|NCT01546844|type II diabetes mellitus
289374|NCT01546844|type 2 diabetes
289375|NCT01546844|type 2 diabetes mellitus
289376|NCT01546844|Beacon
289377|NCT01546818|HIV
289378|NCT01546818|Vaccine
289379|NCT01546818|HIV-1 infections
289380|NCT01546805|Blepharospasm
289381|NCT01546805|Hemifacial spasm
289382|NCT01546805|Botox
289383|NCT01546805|Zinc
289384|NCT01546792|exercise
289385|NCT01546792|diet
289386|NCT01546792|lifestyle
289387|NCT01546792|sleep apnoea
289388|NCT01546792|obesity
289389|NCT01546766|Diabetes
289390|NCT01546766|Pupillary response
289391|NCT01546766|Retinal disorders
289392|NCT01546766|Midperipheral ischemia
289393|NCT01546766|Fundus photography
289394|NCT01546766|Optical coherence tomography
289395|NCT01546753|Walnut hypersensitivity
289396|NCT01546753|Tree nut hypersensitivity
289397|NCT01546753|Oral immunotherapy
289398|NCT01546753|Food allergy
289399|NCT01546753|Walnut allergy
289400|NCT01546753|tree nut allergy
289401|NCT01546740|Glaucoma, Compliance, Prevalence
289402|NCT01546727|Preschoolers
289403|NCT01546727|Obesity
289404|NCT01546727|Behavioral Treatment
289405|NCT01546675|Amputation
289406|NCT01546675|Prosthesis Design
289407|NCT01546675|Biomechanics
289408|NCT01546662|Rhinitis
289409|NCT01546636|Cerebral desaturation events
289410|NCT01546636|Cerebral oximetry
289411|NCT01546636|Beach chair position
289412|NCT01546610|Rheumatoid foot
289413|NCT01546610|foot pain
289414|NCT01546610|insoles
289415|NCT01546610|foot function
289416|NCT01546610|electronic baropodometer
289417|NCT01546610|plantar pressure
289418|NCT01546610|gait analysis
289419|NCT01546597|Metformin
289420|NCT01546597|Ranolazine
289421|NCT01546597|Type 2 Diabetes Mellitus
289422|NCT01546558|Metformin
289423|NCT01546558|Ranolazine
289424|NCT01546558|Type 2 Diabetes Mellitus
289425|NCT01546532|Heart failure
289426|NCT01546532|RLX030
289427|NCT01546532|hemodynamics
289428|NCT01546532|cardiovascular diseases
289429|NCT01546480|Chronic postoperative pain
289430|NCT01546480|Postcholecystectomy pain
289431|NCT01546480|Inflammation
289432|NCT01546480|Interleukines
289433|NCT01546467|Schizophrenia
289434|NCT01546467|Schizoaffective disorder
289435|NCT01546467|Psychosis
289436|NCT01546467|Early phase
289437|NCT01546467|Cognitive remediation
289438|NCT01546467|Functional outcome
289439|NCT01546454|Premenopausal women
289440|NCT01546454|coronary heart disease
289441|NCT01546454|menstrual cycle
289442|NCT01546454|lipids
289443|NCT01546441|primary care
289444|NCT01546441|aging
289445|NCT01546441|interprofessional care
289446|NCT01546441|multimorbidity
289447|NCT01546428|c-MET
289448|NCT01546428|Advanced solid tumor
289449|NCT01546415|Phase 4
289450|NCT01546415|Desferasirox
289451|NCT01546415|Iron Overload
289452|NCT01546415|Aplastic Anemia
289453|NCT01546389|Malaria, vaccine, PfSPZ, challenge
289454|NCT01546350|infertility, recurrent pregnancy loss, miscarriage
289455|NCT01546337|anemia
289456|NCT01546337|non-myeloid haemopathy
289457|NCT01546337|myelodysplastic syndrome
289458|NCT01546337|Erythropoiesis stimulating agents
289459|NCT01546337|predictive markers
289460|NCT01546324|Maternal Blood
289461|NCT01546324|PGD
289462|NCT01546324|PGS
289463|NCT01546324|Natera
289464|NCT01546324|Gene Security Network
289465|NCT01546324|Non-invasive prenatal diagnosis
289466|NCT01546311|prosthetic socket
289467|NCT01546311|residual limb volume fluctuation
289468|NCT01546311|instantaneous bladder
289469|NCT01546298|Contact Dermatitis
289470|NCT01546285|The focus of this study is to demonstrate that DINAMAP® SuperSTATTM NIBP algorithm has been implemented correctly without performance losses to the B40 monitor
289471|NCT01546272|Subcutaneous resorbable sutures
289472|NCT01546272|Tolerance / effectiveness of subcutaneous suture
289473|NCT01546272|Reduced operative time and anesthesia time
289474|NCT01546272|Medico-economic evaluation
289475|NCT01546272|Accidental exposure to blood
289476|NCT01546259|colonoscopy
289477|NCT01546259|water
289478|NCT01546259|female
289479|NCT01546259|BMI
289480|NCT01546259|unsedated
289481|NCT01546259|low BMI female patients
289482|NCT01546259|Intubation
289483|NCT01546246|colonoscopy
289484|NCT01546246|water
289485|NCT01546246|incomplete
289486|NCT01546246|failed
289487|NCT01546246|unsedated
289488|NCT01546233|Lung cancer
289489|NCT01546233|Chemotherapy
289490|NCT01546233|Multidisciplinary self care programme
289491|NCT01546233|Fatigue
289492|NCT01546220|colonoscopy
289493|NCT01546220|elder patient
289494|NCT01546220|water
289495|NCT01546220|unsedated
289496|NCT01546207|ventricular tachycardia
289497|NCT01546207|catheter ablation
289498|NCT01546207|VT
289499|NCT01546194|Informed consent
289500|NCT01546194|Perioperative period
289501|NCT01546194|Morning of surgery
289502|NCT01546194|Anesthesiology
289503|NCT01546181|photoreceptors
289504|NCT01546181|retinal pigment epithelium
289505|NCT01546181|adaptive optics
289506|NCT01546168|Atrial Fibrillation ablation
289507|NCT01546168|Esophageal Deviation
289508|NCT01546168|AF
289509|NCT01546116|adefovir
289510|NCT01546116|lamivudine
289511|NCT01546116|entecavir resistance
289512|NCT01546103|Vitamin D deficiency
289513|NCT01546090|Alprazolam
289514|NCT01546090|benzodiazepines
289515|NCT01546090|Inferior alveolar nerve block
289516|NCT01546090|irreversible pulpitis
289517|NCT01546090|local anesthesia
289518|NCT01546064|Bile duct anastomosis
289519|NCT01546064|Biliary complications
289520|NCT01546051|metabotropic glutamate receptors 2 and 3
289521|NCT01546051|antagonist
289522|NCT01546051|mGluR
289523|NCT01546051|ketamine
289524|NCT01546051|BDNF
289525|NCT01546051|Depression
289526|NCT01546051|Major Depressive Disorder
289527|NCT01546051|Mood Disorder
289528|NCT01546051|Treatment Resistant Depression
289529|NCT01546051|Phase 1 safety, tolerability and pharmacokinetics study
289530|NCT01546038|Hedgehog Inhibitor
289531|NCT01546038|Acute Myeloid Leukemia
289532|NCT01546038|Myelodysplastic syndrome
289533|NCT01546038|Intensive chemotherapy
289534|NCT01546038|LDAC
289535|NCT01545999|Transcranial Magnetic Stimulation (TMS)
289536|NCT01545999|Dorsolateral Prefrontal Cortex (DLPFC)
289537|NCT01545999|Schizophrenia
289538|NCT01545999|Working Memory
289539|NCT01545999|Paired Associative Stimulation (PAS)
289540|NCT01545999|Electroencephalography (EEG)
289541|NCT01545999|Cognition
289542|NCT01545986|Joint Replacement
289543|NCT01545986|Exercise
289544|NCT01545986|Power training
289545|NCT01545947|Neoplasms
289546|NCT01545947|Pulmonary
289547|NCT01545947|Lung Cancer
289548|NCT01545947|Cancer of the Lung
289549|NCT01545947|Stage IIIB Non-Small Cell Lung Cancer
289550|NCT01545947|IV Non-Small Cell Lung Cancer
289551|NCT01545947|Non-Small Cell Lung Cancer
289552|NCT01545934|Overweight
289553|NCT01545934|Obese
289554|NCT01545934|Pregnancy
289555|NCT01545934|Weight Gain
289556|NCT01545921|Quality Of Life
289557|NCT01545921|Cancer
289558|NCT01545921|End of life
289559|NCT01545921|palliative setting
289560|NCT01545908|Fecal transplant
289561|NCT01545908|induction of remission
289562|NCT01545908|active ulcerative colitis
289563|NCT01545882|prostate
289564|NCT01545882|hormone-resistant
289565|NCT01545882|degarelix
289566|NCT01545882|firmagon
289567|NCT01545882|anti-androgens
289568|NCT01545882|total androgen blockade
289569|NCT01545882|injection
289570|NCT01545869|carbon dioxide laser
289571|NCT01545869|fractional resurfacing
289572|NCT01545869|freckles
289573|NCT01545869|melanosis
289574|NCT01545856|Parkinson's Disease
289575|NCT01545856|cardiovascular events
289576|NCT01545856|Levodopa
289577|NCT01545843|depression
289578|NCT01545843|sleep
289579|NCT01545843|treatment
289580|NCT01545830|Metabolic syndrome
289581|NCT01545830|Insulin resistance
289582|NCT01545830|Vitamin D deficiency
289583|NCT01545817|Renal cell carcinoma
289584|NCT01545817|GW786034
289585|NCT01545817|Everolimus
289586|NCT01545817|Pazopanib
289587|NCT01545804|Hepatocellular carcinoma
289588|NCT01545778|Substance abuse detection
289589|NCT01545778|Opioids abuse
289590|NCT01545778|Tapentadol immediate-release (IR)
289591|NCT01545778|Oxycodone immediate-release (IR)
289592|NCT01545765|Healthy volunteers
289593|NCT01545752|elearning
289594|NCT01545752|CD-based education
289595|NCT01545739|Pacemaker therapy
289596|NCT01545739|Cardiac resynchronisation therapy (CRT)
289597|NCT01545726|Asthma
289598|NCT01545726|Sputum eosinophilia
289599|NCT01545726|CRTH2 receptor
289600|NCT01545726|PGD2 antagonist
289601|NCT01545713|renal
289602|NCT01545713|kidney
289603|NCT01545713|transplant
289604|NCT01545713|living donor
289605|NCT01545700|dexamethasone
289606|NCT01545700|hyperglycemia
289607|NCT01545700|gynecologic surgery
289608|NCT01545687|pain
289609|NCT01545687|oral complications of radiation therapy
289610|NCT01545687|weight changes
289611|NCT01545687|recurrent squamous cell carcinoma of the hypopharynx
289612|NCT01545687|recurrent squamous cell carcinoma of the larynx
289613|NCT01545687|recurrent squamous cell carcinoma of the nasopharynx
289614|NCT01545687|recurrent squamous cell carcinoma of the oropharynx
289615|NCT01545687|recurrent verrucous carcinoma of the larynx
289616|NCT01545687|stage I squamous cell carcinoma of the hypopharynx
289617|NCT01545687|stage I squamous cell carcinoma of the larynx
289618|NCT01545687|stage I squamous cell carcinoma of the nasopharynx
289619|NCT01545687|stage I squamous cell carcinoma of the oropharynx
289620|NCT01545687|stage I verrucous carcinoma of the larynx
289621|NCT01545687|stage II squamous cell carcinoma of the hypopharynx
289622|NCT01545687|stage II squamous cell carcinoma of the larynx
289623|NCT01545687|stage II squamous cell carcinoma of the nasopharynx
289624|NCT01545687|stage II squamous cell carcinoma of the oropharynx
289625|NCT01545687|stage II verrucous carcinoma of the larynx
289626|NCT01545687|stage III squamous cell carcinoma of the hypopharynx
289627|NCT01545687|stage III squamous cell carcinoma of the larynx
289628|NCT01545687|stage III squamous cell carcinoma of the nasopharynx
289629|NCT01545687|stage III squamous cell carcinoma of the oropharynx
289630|NCT01545687|stage III verrucous carcinoma of the larynx
289631|NCT01545687|stage IV squamous cell carcinoma of the hypopharynx
289632|NCT01545687|stage IV squamous cell carcinoma of the nasopharynx
289633|NCT01545687|stage IVA squamous cell carcinoma of the larynx
289634|NCT01545687|stage IVA squamous cell carcinoma of the oropharynx
289635|NCT01545687|stage IVA verrucous carcinoma of the larynx
289636|NCT01545687|stage IVB squamous cell carcinoma of the larynx
289637|NCT01545687|stage IVB squamous cell carcinoma of the oropharynx
289638|NCT01545687|stage IVB verrucous carcinoma of the larynx
289639|NCT01545687|stage IVC squamous cell carcinoma of the larynx
289640|NCT01545687|stage IVC squamous cell carcinoma of the oropharynx
289641|NCT01545687|stage IVC verrucous carcinoma of the larynx
289642|NCT01545687|stage I squamous cell carcinoma of the lip and oral cavity
289643|NCT01545687|stage I verrucous carcinoma of the oral cavity
289644|NCT01545687|stage II squamous cell carcinoma of the lip and oral cavity
289645|NCT01545687|stage II verrucous carcinoma of the oral cavity
289646|NCT01545687|stage III squamous cell carcinoma of the lip and oral cavity
289647|NCT01545687|stage III verrucous carcinoma of the oral cavity
289648|NCT01545687|stage IVA squamous cell carcinoma of the lip and oral cavity
289649|NCT01545687|stage IVA verrucous carcinoma of the oral cavity
289650|NCT01545687|stage IVB squamous cell carcinoma of the lip and oral cavity
289651|NCT01545687|stage IVB verrucous carcinoma of the oral cavity
289652|NCT01545687|stage IVC squamous cell carcinoma of the lip and oral cavity
289653|NCT01545687|stage IVC verrucous carcinoma of the oral cavity
289654|NCT01545687|recurrent squamous cell carcinoma of the lip and oral cavity
289655|NCT01545687|recurrent verrucous carcinoma of the oral cavity
289656|NCT01545674|Aneuploidy
289657|NCT01545674|Non-invasive Prenatal Diagnosis
289658|NCT01545674|Prenatal Blood Test
289659|NCT01545674|Prenatal Aneuploidy Screening
289660|NCT01545674|Trisomy 13
289661|NCT01545674|Trisomy 18
289662|NCT01545674|Trisomy 21
289663|NCT01545674|Trisomy
289664|NCT01545674|Down Syndrome
289665|NCT01545674|Turner Syndrome
289666|NCT01545674|Edwards Syndrome
289667|NCT01545661|Tuberculosis
289668|NCT01545661|diagnosis
289669|NCT01545661|sputum induction
289670|NCT01545661|primary care
289671|NCT01545648|breast
289672|NCT01545648|cancer
289673|NCT01545648|early
289674|NCT01545648|DTC
289675|NCT01545648|disseminated
289676|NCT01545648|tumor
289677|NCT01545648|cells
289678|NCT01545635|Major trauma
289679|NCT01545635|Injury Severity Score
289680|NCT01545635|ISS > 15
289681|NCT01545635|clinical signs
289682|NCT01545635|risk of blood loss
289683|NCT01545635|coagulopathy
289684|NCT01545635|rotational thrombelastometry
289685|NCT01545635|ROTEM
289686|NCT01545609|Text messaging
289687|NCT01545609|birth control
289688|NCT01545609|adolescents
289689|NCT01545596|Intraoperative Monitoring
289690|NCT01545596|Decision Support Systems
289691|NCT01545596|anesthesia outcomes
289692|NCT01545557|Volume loss
289693|NCT01545544|B-Cell Non Hodgkin Lymphomas
289694|NCT01545544|Hepatitis C
289695|NCT01545531|glomerular filtration rate
289696|NCT01545531|iohexol
289697|NCT01545531|hematopoietic cell transplant
289698|NCT01545531|kidney function
289699|NCT01545531|gold standard measure
289700|NCT01545531|cystatin C.
289701|NCT01545518|Refractory epilepsy
289702|NCT01545518|Cryptogenic epilepsy
289703|NCT01545518|Autoimmune disorders
289704|NCT01545518|IVIG
289705|NCT01545518|Immunomodulatory therapy
289706|NCT01545518|Autoantibodies
289707|NCT01545492|CHIPS
289708|NCT01545492|famine
289709|NCT01545492|reprogramming
289710|NCT01545492|developmental
289711|NCT01545492|blood
289712|NCT01545492|pressure
289713|NCT01545492|randomised
289714|NCT01545492|randomized
289715|NCT01545492|hypertension
289716|NCT01545492|anthropometry
289717|NCT01545492|measurement
289718|NCT01545492|genetics
289719|NCT01545492|epigenetics
289720|NCT01545492|methylation
289721|NCT01545492|cortisol
289722|NCT01545492|stress
289723|NCT01545492|DNA
289724|NCT01545492|growth
289725|NCT01545492|weight
289726|NCT01545492|length
289727|NCT01545492|height
289728|NCT01545479|ECA
289729|NCT01545479|BOLD-MRI
289730|NCT01545479|kidney
289731|NCT01545466|Migraines
289732|NCT01545466|Behavioral
289733|NCT01545466|Complementary and Alternative Medicine
289734|NCT01545466|Mindfulness Meditation
289735|NCT01545466|Mindfulness Based Stress Reduction
289736|NCT01545427|Scleroderma
289737|NCT01545427|Randomized controled trial
289738|NCT01545427|Pilot study
289739|NCT01545427|Gleevec (imatinib)
289740|NCT01545427|Biomarkers
289741|NCT01545414|Self-help treatment
289742|NCT01545414|Internet treatment
289743|NCT01545414|Cognitive Behavioral Therapy
289744|NCT01545414|Internet-based Cognitive Behavioral Therapy
289745|NCT01545401|chronic disease management
289746|NCT01545401|Chronic Care Model
289747|NCT01545401|multifaceted intervention
289748|NCT01545401|primary care
289749|NCT01545401|type 2 diabetes mellitus
289750|NCT01545401|hypertension
289751|NCT01545375|nasopharyngeal carriage
289752|NCT01545375|safety
289753|NCT01545375|immunogenicity
289754|NCT01545375|US
289755|NCT01545375|Pneumococcal vaccine
289756|NCT01545375|efficacy
289757|NCT01545375|Streptococcus pneumoniae
289758|NCT01545375|infants
289759|NCT01545349|LGG
289760|NCT01545349|Immune response
289761|NCT01545349|Influenza vaccine
289762|NCT01545349|Elderly
289763|NCT01545349|Healthy
289764|NCT01545349|Microbiome
289765|NCT01545323|Netherton syndrome
289766|NCT01545323|Gene therapy
289767|NCT01545323|SPINK5
289768|NCT01545297|dexmedetomidine
289769|NCT01545297|conscious sedation
289770|NCT01545297|awake craniotomy
289771|NCT01545297|brain mapping
289772|NCT01545284|chronic hand dermatitis
289773|NCT01545284|acitretin
289774|NCT01545284|PGA
289775|NCT01545271|Xenon
289776|NCT01545271|Hypothermia
289777|NCT01545271|Hypoxic Ischemic Encephalopathy
289778|NCT01545271|Newborn
289779|NCT01545271|Term
289780|NCT01545271|Neuroprotection
289781|NCT01545271|Cooling
289782|NCT01545271|HIE
289783|NCT01545245|atopic asthma
289784|NCT01545245|recurrent wheezing
289785|NCT01545245|preterm infants
289786|NCT01545245|palivizumab
289787|NCT01545245|respiratory syncytial virus
289788|NCT01545245|RSV
289789|NCT01545232|Massive Transfusion
289790|NCT01545232|Trauma
289791|NCT01545232|Coagulopathy
289792|NCT01545232|Trauma Induced Coagulopathy
289793|NCT01545232|Plasma
289794|NCT01545232|Platelets
289795|NCT01545232|Red Blood Cells
289796|NCT01545232|Mortality
289797|NCT01545232|Wounds and Injuries
289798|NCT01545232|Shock, Hemorrhagic
289799|NCT01545232|Shock
289800|NCT01545232|Pathologic Processes
289801|NCT01545232|Hemorrhage
289802|NCT01545232|Hemostatics
289803|NCT01545232|Coagulation
289804|NCT01545232|Transfusion-related acute lung injury (TRALI)
289805|NCT01545232|Inflammation
289806|NCT01545193|Elderly
289807|NCT01545193|Residual neuromuscular blockade
289808|NCT01545180|Observatory
289809|NCT01545180|Heart failure
289810|NCT01545180|Post-capillary pulmonary hypertension
289811|NCT01545180|HTPcap
289812|NCT01545167|pancreatits
289813|NCT01545141|metastatic
289814|NCT01545141|recurrent
289815|NCT01545141|peritoneal metastasis
289816|NCT01545141|cytoreductive surgery
289817|NCT01545141|hyperthermic intraperitoneal chemoperfusion
289818|NCT01545141|HIPEC
289819|NCT01545141|hepatic metastasis
289820|NCT01545141|extrahepatic metastasis
289821|NCT01545141|vaccine
289822|NCT01544153|Web based behavioral intervention
289823|NCT01544153|Adherence
289824|NCT01544153|Smoking cessation
289825|NCT01544153|Social network
289826|NCT01544153|Nicotine replacement therapy
289827|NCT01544153|Social support
289828|NCT01544140|Phase 1
289829|NCT01544140|healthy volunteers
289830|NCT01544140|pharmacokinetics
289831|NCT01544140|vandetanib
289832|NCT01544140|midazolam
289833|NCT01544127|Veterans
289834|NCT01544127|Motivational Interviewing
289835|NCT01544127|Inpatients
289836|NCT01544127|Suicide, Attempted
289837|NCT01544101|Rheumatoid Arthritis
289838|NCT01544101|Diet, Vegetarian
289839|NCT01544101|Diet, Fat-Restricted
289840|NCT01544101|Pain
289841|NCT01544088|randomized controlled trial
289842|NCT01544088|PTSD
289843|NCT01544088|cognitive behavioral treatment
289844|NCT01544088|group treatment
289845|NCT01544062|Cardiac surgery
289846|NCT01544062|Acute Pain
289847|NCT01544062|Wound Hyperalgesia
289848|NCT01544062|Intravenous Acetaminophen
289849|NCT01544062|Patient Satisfaction
289850|NCT01544049|fallopian tube removal
289851|NCT01544049|salpingectomy
289852|NCT01544049|ovarian cancer prevention
289853|NCT01544036|AKI
289854|NCT01544036|contrast nephropathy
289855|NCT01544036|renal blood flow
289856|NCT01544023|breast reconstruction
289857|NCT01544023|mesh
289858|NCT01544023|implant reconstruction
289859|NCT01544023|acellular dermal matrix
289860|NCT01544023|titanized polypropylene mesh
289861|NCT01544023|TiLOOP Bra
289862|NCT01544023|TiLOOP
289863|NCT01544023|implant based breast reconstruction
289864|NCT01544010|Transtheoretical Model
289865|NCT01544010|Tailored Print Intervention
289866|NCT01544010|Population-based
289867|NCT01544010|Behavioral Intervention
289868|NCT01545128|COPD
289869|NCT01545128|Pulmonary rehabilitation
289870|NCT01545115|Children
289871|NCT01545115|Immunity
289872|NCT01545115|Sub-Saharan
289873|NCT01545115|Pertussis
289874|NCT01545115|Malaria
289875|NCT01545115|Nutrition
289876|NCT01545115|antibodies
289877|NCT01545011|Inspiratory muscle training
289878|NCT01545011|COPD
289879|NCT01545011|Conventional respiratory rehabilitation
289880|NCT01545011|Dyspnea scale
289881|NCT01544985|pediatrics
289882|NCT01544985|emergency medicine
289883|NCT01544985|pain
289884|NCT01544985|bladder catheterization
289885|NCT01544972|Patent Ductus Arteriosus
289886|NCT01544972|Paracetamol
289887|NCT01544972|Ibuprofen
289888|NCT01544972|Serum levels
289889|NCT01544972|Preterm infant
289890|NCT01544959|Narcotic
289891|NCT01544959|Opioid
289892|NCT01544959|betablocking drug
289893|NCT01544959|postoperative pain
289894|NCT01544959|postoperative nausea and vomiting
289895|NCT01544959|breast cancer
289896|NCT01544959|hyperalgesia
289897|NCT01544959|cancer recurrence
289898|NCT01544959|anesthesia
289899|NCT01544959|mastectomy
289900|NCT01544959|chronic postsurgical pain syndrome
289901|NCT01544959|acute postoperative pain
289902|NCT01544959|postmastectomy pain syndrome
289903|NCT01544959|pain
289904|NCT01544959|ambulatory surgery
289905|NCT01544946|pediatrics
289906|NCT01544946|emergency medicine
289907|NCT01544946|pain
289908|NCT01544946|nasopharyngeal aspiration
289909|NCT01544933|spinal fractures
289910|NCT01544933|Thoracic vertebrae
289911|NCT01544933|spinal canal
289912|NCT01544933|kyphosis
289913|NCT01544907|Drug Eluting Balloon
289914|NCT01544907|Arteriovenous fistula or graft stenosis
289915|NCT01544894|Postmenopausal osteoporosis
289916|NCT01544894|Compliance
289917|NCT01544894|Bone mineral density
289918|NCT01544894|Bonemarkers
289919|NCT01544881|Pharmacokinetics
289920|NCT01544881|Pharmacodynamics
289921|NCT01544881|Hyperglycemia
289922|NCT01544881|Insulin
289923|NCT01544868|Total Energy Expenditure
289924|NCT01544868|Protein Balance
289925|NCT01544868|Burns
289926|NCT01544855|Health young participants
289927|NCT01544842|Oral lichen planus
289928|NCT01544842|Tacrolimus ointment
289929|NCT01544842|Triamcinolone paste
289930|NCT01544829|theobromine
289931|NCT01544829|heart rate
289932|NCT01544829|blood lipids
289933|NCT01544803|Randomized Controlled Trial
289934|NCT01544803|Alcohol
289935|NCT01544803|Internet
289936|NCT01544803|Screening
289937|NCT01544803|Brief intervention
289938|NCT01544803|Personalized feedback
289939|NCT01544790|Esophageal carcinoma
289940|NCT01544790|Esophageal cancer
289941|NCT01544790|Robotic surgery
289942|NCT01544790|Esophagectomy
289943|NCT01544790|Minimally invasive
289944|NCT01544777|Aphakia
289945|NCT01544777|Cataract
289946|NCT01544764|Diphtheria-Tetanus-Pertussis Vaccine
289947|NCT01544764|Measles-Mumps-Rubella Vaccine
289948|NCT01544764|Meningococcal Vaccines
289949|NCT01544764|Hepatitis B Vaccines
289950|NCT01544764|Chickenpox Vaccine
289951|NCT01544764|Papillomavirus Vaccines
289952|NCT01544751|NAFLD
289953|NCT01544751|metformin
289954|NCT01544751|atorvastatin
289955|NCT01544751|metabolic syndrome
289956|NCT01544738|Parkinson Disease
289957|NCT01544738|sensory stimulation
289958|NCT01544738|Bradykinesia
289959|NCT01544725|Procedural sedation
289960|NCT01544725|Ketamine-propofol
289961|NCT01544725|Ketamine
289962|NCT01544712|osteonecrosis
289963|NCT01544712|cell-based therapy
289964|NCT01544712|bone marrow
289965|NCT01544712|mesenchymal stem cell
289966|NCT01544712|hip
289967|NCT01544712|core decompression
289968|NCT01544699|stroke
289969|NCT01544686|neutropenia
289970|NCT01544686|cancer
289971|NCT01544686|fever
289972|NCT01544686|central venous catheter
289973|NCT01544686|infection
289974|NCT01544660|spine and hip scan
289975|NCT01544660|BMD
289976|NCT01544647|Knee osteoarthritis
289977|NCT01544647|spa therapy
289978|NCT01544647|spa modalities
289979|NCT01544634|Asthma
289980|NCT01544634|Propranolol
289981|NCT01544634|Inhaled corticosteroids
289982|NCT01544634|Steroid sparing agent
289983|NCT01544634|Airway hyper-responsiveness
289984|NCT01544621|Real life smoking cessation. NON-drug NON-intervention study
289985|NCT01544608|Acute psychotic episode of Schizophrenia
289986|NCT01544595|Psoriasis, inflammatory skin disease
289987|NCT01544595|scaly patches
289988|NCT01544595|secukinumab (AIN457)
289989|NCT01544595|Psoriasis Area and Severity Index (PASI)
289990|NCT01544595|Investigator Global Assessment (IGA) mod 2011
289991|NCT01544582|Pegylated Interferon
289992|NCT01544582|boceprevir
289993|NCT01544582|telaprevir
289994|NCT01544569|rhabdoid tumor of the kidney
289995|NCT01544556|abdominoplasty
289996|NCT01544543|COPD
289997|NCT01544530|Brain-death
289998|NCT01544530|organ donation
289999|NCT01544517|Helicobacter pylori
290000|NCT01544517|Concomitant therapy
290001|NCT01544517|Sequential therapy
290002|NCT01544517|levofloxacin
290003|NCT01544504|Radiodermatitis
290004|NCT01544504|Prevention
290005|NCT01544504|Radiotherapy
290006|NCT01544504|Breast
290007|NCT01544504|Radiation Dermatitis
290008|NCT01544491|Paediatric kidney transplantation
290009|NCT01544491|Early MMF to everolimus conversion
290010|NCT01544491|Composite efficacy (biopsy-proven acute rejection, graft loss or death)
290011|NCT01544491|Renal function
290012|NCT01544465|Parkinson's disease
290013|NCT01544465|Sleep Quality
290014|NCT01544465|Daytime sleepiness
290015|NCT01544465|physical therapy
290016|NCT01544465|exercise
290017|NCT01544452|MR
290018|NCT01544452|CT
290019|NCT01544452|ultrasonography
290020|NCT01544452|MR colonography
290021|NCT01544452|MR rectum
290022|NCT01544452|MR liver
290023|NCT01544439|Temporomandibular joint disorders
290024|NCT01544439|Stress psychological
290025|NCT01544439|Depression
290026|NCT01544439|Quality of Life
290027|NCT01544426|Office hysteroscopy,
290028|NCT01544426|intrauterine insemination
290029|NCT01544426|endometrial scrap
290030|NCT01544413|laparoscopic sentinel lymph node biopsy
290031|NCT01544413|quality control study
290032|NCT01544413|early gastric cancer
290033|NCT01544400|reverse anorexia,
290034|NCT01544400|anorexia athletics
290035|NCT01544387|Preterm Premature Rupture Of Membranes
290036|NCT01544387|PPROM
290037|NCT01544387|Pregnancy
290038|NCT01544387|Bed rest.
290039|NCT01544374|Breast Cancer
290040|NCT01544374|Treatment Disparities
290041|NCT01544374|Tracking and Feedback
290042|NCT01544374|Registry
290043|NCT01544374|Cancer Therapy Disparities
290044|NCT01544374|Adjuvant Treatment
290045|NCT01544374|Racial Disparities
290046|NCT01544374|Underuse of Adjuvant Treatment
290047|NCT01544361|Healthy subjects
290048|NCT01544361|MEDI7814
290049|NCT01544361|FTiH
290050|NCT01544348|Allergic
290051|NCT01544348|Atopic Dermatitis
290052|NCT01544348|MEDI4212
290053|NCT01544322|solid tumors
290054|NCT01544322|recurrent
290055|NCT01544322|advanced
290056|NCT01544322|metastatic
290057|NCT01544322|refractory
290058|NCT01544283|Shoulder Pain
290059|NCT01544283|Shoulder Impingement Syndrome
290060|NCT01544270|milk protein
290061|NCT01544270|probiotics
290062|NCT01544270|stress
290063|NCT01544270|cortisol
290064|NCT01544270|heart beat
290065|NCT01544257|Osteopathic manipulative treatment
290066|NCT01544257|alternative medicine
290067|NCT01544257|complementary medicine
290068|NCT01544257|neonatology
290069|NCT01544257|neonatal care
290070|NCT01544257|prematurity
290071|NCT01544257|allied health care
290072|NCT01544244|comparison of physical therapy strategies
290073|NCT01544231|Neutrophil Gelatinase Associated Lipocalin
290074|NCT01544231|predicting acute kidney failure
290075|NCT01544231|emergency room
290076|NCT01544218|Alcohol related disorders
290077|NCT01544192|Antioxidant
290078|NCT01544192|α−tocopherol
290079|NCT01544192|Vitamin E
290080|NCT01544192|Gingko Biloba
290081|NCT01544192|Glaucoma
290082|NCT01544192|Neuroprotection
290083|NCT01544192|Retina
290084|NCT01544179|Non Small Cell Lung Cancer
290085|NCT01544179|Gefitinib
290086|NCT01544179|Pemetrexed
290087|NCT01544179|Treatment Beyond Progression
290088|NCT01544166|Gadolinium, Pediatrics, MRI, contrast
290089|NCT01543984|health care workers
290090|NCT01543984|tailored physical activity
290091|NCT01543984|prevention
290092|NCT01543984|spine
290093|NCT01543984|upper body
290094|NCT01543984|pain related to Spine or Upper body
290095|NCT01543971|Peripheral blood stem cell mobilization
290096|NCT01543971|CD34+ count
290097|NCT01543945|Postoperative Nausea and Vomiting
290098|NCT01543945|Ambulatory
290099|NCT01543945|Gynecologic laparoscopy
290100|NCT01543945|Incidence of postoperative nausea and vomiting.
290101|NCT01543932|antiplatelet effect
290102|NCT01543932|prasugrel
290103|NCT01543932|clopidogrel
290104|NCT01543932|stable angina
290105|NCT01543893|neck pain
290106|NCT01543893|shoulder pain
290107|NCT01543893|resistance training
290108|NCT01543854|Heart failure
290109|NCT01543854|RLX030
290110|NCT01543854|Hemodynamics
290111|NCT01543854|Cardiovascular Diseases
290112|NCT01543841|advanced cancer
290113|NCT01543841|healthy
290114|NCT01543841|blood sample
290115|NCT01543841|TEM
290116|NCT01543841|TIE-2 expressing monocytes
290117|NCT01543841|ANG1
290118|NCT01543841|ANG2
290119|NCT01543828|COPD
290120|NCT01543828|Indacatarol
290121|NCT01543828|placebo
290122|NCT01543828|crossover
290123|NCT01543828|patient perception
290124|NCT01543815|Psychological Distress
290125|NCT01543815|Depression
290126|NCT01543815|Anxiety
290127|NCT01543815|Well-Being Therapy
290128|NCT01543815|Heart Failure
290129|NCT01543815|Quality of Life
290130|NCT01543815|Adherence
290131|NCT01543802|soft-tissue sarcoma
290132|NCT01543802|pazopanib
290133|NCT01543802|antiangiogenetic treatment
290134|NCT01543802|endothelial progenitor cells
290135|NCT01543802|preoperative therapy
290136|NCT01543789|Umbilical Hernia
290137|NCT01543763|metastatic
290138|NCT01543763|solid
290139|NCT01543763|sarcoma
290140|NCT01543763|progression
290141|NCT01543750|episodic ataxia
290142|NCT01543750|CACNA1A mutations
290143|NCT01543711|Breast cancer
290144|NCT01543711|persistent pain
290145|NCT01543711|neuropathic pain
290146|NCT01543711|lymphedema
290147|NCT01543698|Advanced solid tumor,
290148|NCT01543698|BRAF V600 mutation
290149|NCT01543672|lung
290150|NCT01543672|SBRT
290151|NCT01543672|MLD
290152|NCT01543672|toxicity
290153|NCT01543659|89Zr-DFO-huJ591
290154|NCT01543659|prostate
290155|NCT01543659|Pet scan
290156|NCT01543659|11-126
290157|NCT01543646|Hepatology
290158|NCT01543646|Liver Cirrhosis
290159|NCT01543646|Fatty Liver
290160|NCT01543620|kidney safety
290161|NCT01543620|biomarkers
290162|NCT01543620|serum creatinine
290163|NCT01543620|BUN
290164|NCT01543620|cystic fibrosis
290165|NCT01543620|head and neck cancer
290166|NCT01543620|renal injury
290167|NCT01543620|drug induced acute kidney injury
290168|NCT01543620|aminoglycoside
290169|NCT01543620|cisplatin
290170|NCT01543620|nephrotoxicity
290171|NCT01543620|biomarker qualification
290172|NCT01543607|Bile duct
290173|NCT01543607|Cholangiocarcinoma
290174|NCT01543607|Bile duct stenosis
290175|NCT01543607|Malignant bile duct obstruction
290176|NCT01543607|Malignant bile duct stricture
290177|NCT01543607|Radiofrequency ablation
290178|NCT01543607|RFA
290179|NCT01543607|Endoscopic RFA catheter
290180|NCT01543607|EndoHPB
290181|NCT01543594|Rheumatoid arthritis
290182|NCT01543594|Seronegative polyarthritis
290183|NCT01543594|Biologic drugs
290184|NCT01543594|Safety efficacy biologics polyarthritis
290185|NCT01543581|Basal Cell Carcinoma
290186|NCT01543581|Treatment of Skin Cancer
290187|NCT01543568|Age related Macular Degeneration
290188|NCT01543568|Recalcitrant Age Related Macular Degeneration
290189|NCT01543555|myocardial infarction
290190|NCT01543555|statin
290191|NCT01543555|perioperative care
290192|NCT01543555|peripheral vascular diseases
290193|NCT01543555|anesthesiology
290194|NCT01543542|1-3 brain metastases from any primary cancer
290195|NCT01543516|Asthma
290196|NCT01543516|Sputum
290197|NCT01543516|Blood
290198|NCT01543516|Inflammation
290199|NCT01543516|adaptive immune system
290200|NCT01543516|innate immune system
290201|NCT01543464|Indeolamine 2,3 dioxygenase
290202|NCT01543464|Survivin
290203|NCT01543464|Montanide
290204|NCT01543464|Imiquimod
290205|NCT01543464|GMCSF
290206|NCT01543438|ED utilization
290207|NCT01543438|video education
290208|NCT01543438|mobile health
290209|NCT01543438|streaming media
290210|NCT01543438|underserved populations
290211|NCT01543425|Neuropathic Pain
290212|NCT01543425|Adenocorticotrophic axis
290213|NCT01543425|Psychological state
290214|NCT01543412|FOLFIRI
290215|NCT01543412|Metastases
290216|NCT01543412|pancreatic adenocarcinoma
290217|NCT01543412|locally advanced or metastatic pancreatic adenocarcinoma
290218|NCT01543399|Tibolone
290219|NCT01543399|climacteric
290220|NCT01543399|Doppler
290221|NCT01543399|hormone replacement therapy
290222|NCT01543386|Polyphenol
290223|NCT01543386|Curcumin
290224|NCT01543386|Endothelium, vascular
290225|NCT01543386|Endothelium-dependant relaxing factor
290226|NCT01543386|Smoking
290227|NCT01543386|Transcriptome
290228|NCT01543373|Coronary artery disease
290229|NCT01543373|Optical Coherence Tomography
290230|NCT01543373|Tissue coverage
290231|NCT01543373|DES
290232|NCT01543360|axillary vein
290233|NCT01543360|sub clavian vein
290234|NCT01543360|comparison of strategies
290235|NCT01543347|UTI
290236|NCT01543347|ESBL
290237|NCT01543347|AmpC Enterobacteriaceae
290238|NCT01543334|intensive care
290239|NCT01543334|antibiotic levels in blood samples
290240|NCT01543321|tetrabenazine
290241|NCT01543321|movement disorders
290242|NCT01543321|tardive disorders
290243|NCT01543295|Non-Treponemal
290244|NCT01543295|Treponemal
290245|NCT01543282|endoscopic ultrasonography
290246|NCT01543282|fine needle aspiration cytology
290247|NCT01543282|22 gauge
290248|NCT01543282|25 gauge
290249|NCT01543269|Obesity
290250|NCT01543269|Lipid disorders
290251|NCT01543256|benign biliary strictures secondary to chronic pancreatitis
290252|NCT01543243|postural balance
290253|NCT01543243|strength
290254|NCT01543230|Non-Inflammatory Degenerative Joint Disease
290255|NCT01543217|COPD
290256|NCT01543204|plaque psoriasis
290257|NCT01543204|etanercept
290258|NCT01543204|adalimumab
290259|NCT01543191|Lung Diseases
290260|NCT01543191|Respiratory Tract Diseases
290261|NCT01543191|Fibrosis
290262|NCT01543178|IBS
290263|NCT01543178|IBS-D
290264|NCT01543178|IBS with diarrhea
290265|NCT01543178|Diarrhea
290266|NCT01543178|Irritable bowel syndrome with diarrhea
290267|NCT01543165|Renal colic
290268|NCT01543165|Analgesia
290269|NCT01543165|Nefopam
290270|NCT01543165|Ketorolac
290271|NCT01543152|HIV
290272|NCT01543152|autologous cell therapy
290273|NCT01543152|cyclophosphamide
290274|NCT01543113|melanoma
290275|NCT01543113|white-caucasian population
290276|NCT01543100|MGUS
290277|NCT01543074|HDAC
290278|NCT01543074|histone acetylation
290279|NCT01543074|broccoli sprout extract
290280|NCT01543074|garlic oil
290281|NCT01543074|PBMCs
290282|NCT01543048|Human Papilloma Virus (HPV)
290283|NCT01543048|Virological tests
290284|NCT01543048|CIN3
290285|NCT01543048|Cervical cancer
290286|NCT01543048|Conization
290287|NCT01543048|within women treated by conization for a CIN3
290288|NCT01543035|HIV infection
290289|NCT01543035|lipid lowering drugs
290290|NCT01543035|etravirine
290291|NCT01543035|patient
290292|NCT01543035|statin treatment
290293|NCT01543035|EFV or boosted PI antiretroviral treatment
290294|NCT01543009|child
290295|NCT01543009|venipuncture
290296|NCT01543009|pain
290297|NCT01542983|breast cancer
290298|NCT01542983|bright light
290299|NCT01542983|insomnia
290300|NCT01542983|fatigue
290301|NCT01542970|intervention
290302|NCT01542970|lactobacillus reuteri
290303|NCT01542970|omega-3 fatty acids
290304|NCT01542970|pregnancy
290305|NCT01542970|lactation
290306|NCT01542970|allergic symptoms
290307|NCT01542970|IgE associated disease
290308|NCT01542970|gastrointestinal function
290309|NCT01542957|Major Depressive Disorder
290310|NCT01542957|Dysthymic Disorder
290311|NCT01542957|Depression
290312|NCT01542957|Cognitive Behavior Therapy
290313|NCT01542957|Personal Construct Theory
290314|NCT01542957|Repertory Grid Technique
290315|NCT01542957|Cognitive Conflicts
290316|NCT01542957|Personal dilemmas
290317|NCT01542944|Acute myeloid leukemia
290318|NCT01542944|Myelodysplastic syndrome
290319|NCT01542944|Stem Cell Mobilization
290320|NCT01542944|Allogeneic Stem Cell Transplantation
290321|NCT01542931|Oral squamous cell carcinoma
290322|NCT01542931|Induction chemotherapy
290323|NCT01542931|Surgery
290324|NCT01542931|Radiotherapy
290325|NCT01542918|Recurrent
290326|NCT01542918|Refractory
290327|NCT01542918|CNS
290328|NCT01542918|Intraocular
290329|NCT01542918|Lymphoma
290330|NCT01542892|Sarcopenia
290331|NCT01542892|Nutrition
290332|NCT01542892|Vitamin D
290333|NCT01542892|Exercise
290334|NCT01542866|ranibizumab
290335|NCT01542866|Age related Macular Degeneration
290336|NCT01542866|AMD
290337|NCT01542866|Health Management Tool
290338|NCT01542866|HMT
290339|NCT01542866|Best Corrected Visual Acuity
290340|NCT01542866|Investigator's Clinical Judgement of Change
290341|NCT01542866|Choroidal Neovascularization
290342|NCT01542866|Central Retinal Subfield Thickness
290343|NCT01542866|visual function self test
290344|NCT01542840|surgery
290345|NCT01542840|orthopedic surgery
290346|NCT01542840|foot surgery
290347|NCT01542840|leg surgery
290348|NCT01542840|ankle surgery
290349|NCT01542840|leg
290350|NCT01542840|foot
290351|NCT01542840|ankle
290352|NCT01542840|anesthesia
290353|NCT01542840|local anesthesia
290354|NCT01542840|regional anesthesia
290355|NCT01542840|Ochsner Clinic
290356|NCT01542840|Ochsner Hospital
290357|NCT01542840|New Orleans
290358|NCT01542840|Louisiana
290359|NCT01542840|Kristie Osteen, MD
290360|NCT01542827|neck pain
290361|NCT01542827|menthol
290362|NCT01542814|Screening Mammogram
290363|NCT01542814|Diagnostic Mammogram
290364|NCT01542814|Benign
290365|NCT01542814|Malignant
290366|NCT01542814|BI-RADS Categories
290367|NCT01542801|Effect of Preventive Antibiotics
290368|NCT01542788|HCV genotype 2 (GT-2)
290369|NCT01542788|HCV genotype 3 (GT-3)
290370|NCT01542788|HCV
290371|NCT01542788|Sustained Virologic Response
290372|NCT01542788|Direct Acting Antiviral
290373|NCT01542788|Combination Therapy
290374|NCT01542788|Interferon intolerant
290375|NCT01542788|Interferon ineligible
290376|NCT01542788|GS-7977
290377|NCT01542788|Ribavirin
290378|NCT01542762|Deep venous thrombosis
290379|NCT01542762|Pulmonary Embolism
290380|NCT01542762|Lower leg Cast immobilization
290381|NCT01542749|BVA-100 Blood volume analyzer
290382|NCT01542749|Human serum albumin labeled with Iodine 131
290383|NCT01542723|Deep venous thrombosis
290384|NCT01542723|Pulmonary Embolism
290385|NCT01542723|Arthroscopy of the knee
290386|NCT01542697|magnesium sulpahate
290387|NCT01542697|postoperative analgesia
290388|NCT01542684|Leukemia
290389|NCT01542684|Myelodysplastic Syndrome
290390|NCT01542684|MDS
290391|NCT01542684|Azacytidine
290392|NCT01542684|5-Azacytidine
290393|NCT01542684|5-AZA
290394|NCT01542684|Vidaza
290395|NCT01542684|5-AZC
290396|NCT01542684|Aza-CR
290397|NCT01542684|Ladakamycin
290398|NCT01542684|NSC-102816
290399|NCT01542684|GM-CSF
290400|NCT01542684|Sargramostim
290401|NCT01542684|Leukine
290402|NCT01542671|lifestyle change
290403|NCT01542671|obesity treatment
290404|NCT01542671|physical activity
290405|NCT01542671|primary care
290406|NCT01542671|quality of life
290407|NCT01542645|Fentanyl
290408|NCT01542645|Methadone
290409|NCT01542645|Thoracic Surgery
290410|NCT01542632|safety and immunogenicity of dengue vaccine
290411|NCT01542606|PH
290412|NCT01542606|SCREENING
290413|NCT01542606|EARLY WARNING
290414|NCT01542606|VAGINAL HEALTH
290415|NCT01542606|VAGINAL SECRETION
290416|NCT01542606|VAGINAL PH
290417|NCT01542580|Revision surgery
290418|NCT01542567|Diclofenac
290419|NCT01542567|BCG
290420|NCT01542567|BLADDER IRRIGATIONS
290421|NCT01542554|Diabetes mellitus
290422|NCT01542554|Chinese
290423|NCT01542554|Glycaemic index
290424|NCT01542528|ADHD
290425|NCT01542528|Executive function
290426|NCT01542528|Inhibitory control
290427|NCT01542528|Computer games
290428|NCT01542528|Sports activities
290429|NCT01542528|Good Behavior Game
290430|NCT01542515|Allograft
290431|NCT01542515|Arthroplasty
290432|NCT01542515|Basal Joint
290433|NCT01542515|carpometacarpal joint
290434|NCT01542515|Thumb
290435|NCT01542515|meniscus
290436|NCT01542515|osteoarthritis
290437|NCT01542515|Patients with Stages I - III arthritis of the the thumb carpometacarpal joint
290438|NCT01542502|Heart failure with preserved ejection fraction
290439|NCT01542502|Diastolic heart failure
290440|NCT01542502|Aerobic exercise performance
290441|NCT01542437|Non-Small Cell Lung Cancer
290442|NCT01542398|community-based
290443|NCT01542398|war-affected
290444|NCT01542398|psychosocial support
290445|NCT01542398|family-focused
290446|NCT01542398|psychological distress
290447|NCT01542398|adolescents
290448|NCT01542398|Democratic Republic of Congo
290449|NCT01542398|family functioning
290450|NCT01542398|community functioning
290451|NCT01542398|daily functioning
290452|NCT01542385|Delayed stenting
290453|NCT01542385|Deferred stenting
290454|NCT01542385|Late stenting
290455|NCT01542385|postponed stenting
290456|NCT01542385|Thrombectomy
290457|NCT01542385|Percutaneous coronary intervention
290458|NCT01542385|PCI
290459|NCT01542385|Angioplasty
290460|NCT01542385|STEMI
290461|NCT01542385|acute myocardial infarction
290462|NCT01542372|PTSD
290463|NCT01542372|Cognitive behavioral therapy (CBT)
290464|NCT01542372|Medication augmentation
290465|NCT01542372|Treatment-resistant PTSD
290466|NCT01542372|Cambodian refugees
290467|NCT01542372|Culturally sensitive treatment
290468|NCT01542359|Yoga, Hypertension
290469|NCT01542359|Blood Pressure
290470|NCT01542359|Autonomic Nervous system
290471|NCT01542346|Wound closure
290472|NCT01542346|cosmetic outcome
290473|NCT01542333|recurrent Wilms tumor and other childhood kidney tumors
290474|NCT01542333|stage I Wilms tumor
290475|NCT01542333|stage II Wilms tumor
290476|NCT01542333|stage III Wilms tumor
290477|NCT01542333|stage IV Wilms tumor
290478|NCT01542333|stage V Wilms tumor
290479|NCT01542320|probiotic
290480|NCT01542320|Lactobacillus reuteri DSM 17938
290481|NCT01542320|healthy infants
290482|NCT01542307|migraine
290483|NCT01542307|oxygen therapy
290484|NCT01542294|gastric cancer
290485|NCT01542294|S-1
290486|NCT01542294|oxaliplatin
290487|NCT01542294|adjuvant chemotherapy
290488|NCT01542281|liver resection
290489|NCT01542281|hepatectomy
290490|NCT01542281|pre-habilitation
290491|NCT01542268|pentoxifylline
290492|NCT01542268|tight junction signalling
290493|NCT01542268|intestinal epithelial barrier
290494|NCT01542268|irritable bowel syndrome
290495|NCT01542255|Metronomic Therapy
290496|NCT01542255|Metastatic Melanoma
290497|NCT01542255|Vinblastine
290498|NCT01542255|Cyclophosphamide
290499|NCT01542255|Dacarbazine
290500|NCT01542242|Diabetes Mellitus Type 2
290501|NCT01542242|Prader Willi Syndrome
290502|NCT01542229|Post Traumatic Stress Disorder
290503|NCT01542229|Severe Mental Illness
290504|NCT01542203|doxorubicin
290505|NCT01542203|cyclophosphamide
290506|NCT01542203|Breast Cancer
290507|NCT01542203|BMI
290508|NCT01542190|cataract surgery
290509|NCT01542190|cystoid macular edema
290510|NCT01542190|angiography
290511|NCT01542177|hypoxia
290512|NCT01542177|pancreas
290513|NCT01542177|cancer
290514|NCT01542177|pancreatic cancer
290515|NCT01542177|18F-FAZA
290516|NCT01542177|18F-Fluoroazomycin Arabinoside
290517|NCT01542177|Positron Emission Tomography
290518|NCT01542177|PET
290519|NCT01542164|Calcium intake
290520|NCT01542164|Fat excretion
290521|NCT01542164|Energy excretion
290522|NCT01542164|Gut micro flora
290523|NCT01542151|Labor, induced
290524|NCT01542151|Sleep
290525|NCT01542151|Fatigue
290526|NCT01542151|Patient satisfaction
290527|NCT01542151|Circadian rhythm
290528|NCT01542138|Inflammatory hyperpigmentation, axillar pigmentation
290529|NCT01542125|Patients aged 3 to 16 years presenting for
290530|NCT01542125|removal of smooth percutaneous interosseus pins
290531|NCT01542125|after orthopeadic surgery
290532|NCT01542112|Patient-Centered Care
290533|NCT01542112|Patient Satisfaction
290534|NCT01542112|Interventional study
290535|NCT01542112|Patient Expectations
290536|NCT01542112|Hospitalization
290537|NCT01542086|intermediate pre-test
290538|NCT01542086|probability of significant coronary heart disease
290539|NCT01542073|myocardial infarction
290540|NCT01542073|angiogenesis
290541|NCT01542073|integrin receptor imaging
290542|NCT01542073|68Ga-BNOTA-PRGD2
290543|NCT01542047|Metastatic
290544|NCT01542047|Solid tumors
290545|NCT01542047|carboplatin
290546|NCT01542047|Paraplatin
290547|NCT01542047|Pazopanib
290548|NCT01542047|Votrient
290549|NCT01542047|Alkylating agent
290550|NCT01542047|Tyrosine kinase inhibitor
290551|NCT01542047|Metastatic disease
290552|NCT01542021|prostate
290553|NCT01542021|Degarelix
290554|NCT01542021|injections
290555|NCT01542021|radical prostatectomy
290556|NCT01542021|11-182
290557|NCT01541995|contrast medium enhanced post mortem CT
290558|NCT01541995|virtual autopsy
290559|NCT01541995|To evaluate the value of contrast medium enhanced post-mortem CT in virtual autopsy focussing on thromboembolic and vascular conditions
290560|NCT01541969|Ear
290561|NCT01541969|Hearing
290562|NCT01541956|type 2 diabetes;
290563|NCT01541956|vildagliptin;
290564|NCT01541956|metformin;
290565|NCT01541943|Atorvastatin
290566|NCT01541943|Losartan
290567|NCT01541943|Essential Hypertension
290568|NCT01541943|Hyperlipidemia
290569|NCT01541904|Ocular Allergy.
290570|NCT01541904|Seasonal Allergic Conjunctivitis
290571|NCT01541904|Perennial Allergic Conjunctivitis
290572|NCT01541904|Conjunctivitis, Allergic
290573|NCT01541904|Ocular Antihistamines.
290574|NCT01541891|PRO-148
290575|NCT01541891|Dry eye syndrome
290576|NCT01541865|hypertension, renal denervation, uncontrolled hypertension, medication resistant hypertension
290577|NCT01541852|Vascular Inflammation
290578|NCT01541852|FDG PET-CT
290579|NCT01541852|COPD
290580|NCT01541852|Atherosclerosis
290581|NCT01541852|p38 MAP kinase inhibitor
290582|NCT01541839|Nasal septum
290583|NCT01541839|Nasal surgical procedures
290584|NCT01541826|aronia
290585|NCT01541826|LDL cholesterol
290586|NCT01541826|polyphenols
290587|NCT01541826|bioavailability
290588|NCT01541826|oxidative stress
290589|NCT01541813|Rare iron overload
290590|NCT01541813|hepcidin
290591|NCT01541774|Atherectomy
290592|NCT01541774|Atherosclerosis
290593|NCT01541774|Peripheral artery disease
290594|NCT01541761|Obesity
290595|NCT01541761|Child
290596|NCT01541761|Hispanic
290597|NCT01541761|Prevention
290598|NCT01541761|Nutrition
290599|NCT01541761|Parenting
290600|NCT01541735|Diabetes
290601|NCT01541735|Insulin
290602|NCT01541735|Pantoprazole
290603|NCT01541722|Urea cycle disorders
290604|NCT01541709|This is a single-center
290605|NCT01541709|prospective
290606|NCT01541709|single-arm
290607|NCT01541709|open-label phase II study
290608|NCT01541696|zinc
290609|NCT01541696|zn
290610|NCT01541696|EZP (exchangeable zinc pools)multivitamin MN
290611|NCT01541683|PEG-electrolyte solution
290612|NCT01541683|bowel cleansing
290613|NCT01541683|Mentholyptus drops
290614|NCT01541683|Palatability
290615|NCT01541657|Ankle Instability
290616|NCT01541657|Sensorimotor Control
290617|NCT01541657|Sensory
290618|NCT01541657|Postural Control
290619|NCT01541657|Balance
290620|NCT01541657|Gait
290621|NCT01541644|Acupuncture Therapy
290622|NCT01541644|bortezomib-induced peripheral neuropathy
290623|NCT01541631|Human Immunodeficiency Virus-1
290624|NCT01541631|Schistosoma mansoni
290625|NCT01541631|Anemia
290626|NCT01541631|Immune response
290627|NCT01541631|Opportunistic infections
290628|NCT01541631|Tanzania
290629|NCT01541618|MS
290630|NCT01541618|RRMS
290631|NCT01541618|RR Multiple Sclerosis
290632|NCT01541592|Insulin resistance
290633|NCT01541592|Endothelial dysfunction
290634|NCT01541592|saturated fat
290635|NCT01541592|monounsaturated fat
290636|NCT01541592|polyunsaturated fat
290637|NCT01541579|Perianal fistulising Crohn's disease.
290638|NCT01541566|arterial hypertension
290639|NCT01541566|metabolic syndrome
290640|NCT01541566|home blood pressure
290641|NCT01541566|ambulatory blood pressure
290642|NCT01541566|office blood pressure
290643|NCT01541566|telemedicine
290644|NCT01541527|non neutralizing antibody
290645|NCT01541527|Epitopic profile
290646|NCT01541527|Clinical relevance
290647|NCT01541501|Central Corneal Thickness
290648|NCT01541501|Pachymetry
290649|NCT01541462|mechanical ventilation
290650|NCT01541462|weaning
290651|NCT01541462|pressure support
290652|NCT01541462|spontaneous breathing
290653|NCT01541462|Long-term acute care facility
290654|NCT01541462|mortality
290655|NCT01541449|AMD
290656|NCT01541449|PLAQUENIL
290657|NCT01541449|CNV
290658|NCT01541436|Remote Ischemic Preconditioning
290659|NCT01541436|Nociception
290660|NCT01541436|Central Sensitization
290661|NCT01541436|Peripheral Sensitization
290662|NCT01541397|Hyperphenylalaninemia
290663|NCT01541397|Phenylketonuria
290664|NCT01541397|Adults
290665|NCT01541397|Bone Mineral Density
290666|NCT01541384|Kidney transplant
290667|NCT01541384|Adherence
290668|NCT01541384|Electronic pill bottles
290669|NCT01541371|Schizophrenia
290670|NCT01541371|Paliperidone extended-release tablets
290671|NCT01541332|relapsed refractory
290672|NCT01541332|multiple myeloma
290673|NCT01541332|pomalidomide
290674|NCT01541332|Doxil
290675|NCT01541332|dexamethasone
290676|NCT01541332|Oncotherapeutics
290677|NCT01541319|Cardiac Surgery
290678|NCT01541319|Erythrocyte Transfusion
290679|NCT01541306|C-type natriuretic peptide
290680|NCT01541306|dwarfism
290681|NCT01541306|growth
290682|NCT01541306|achondroplasia
290683|NCT01541306|hypochondroplasia
290684|NCT01541306|biomarker
290685|NCT01541293|Abortion, Induced
290686|NCT01541293|Laminaria
290687|NCT01541293|Pain management
290688|NCT01541293|Cervical preparation
290689|NCT01541293|Dilation and Evacuation
290690|NCT01541280|Allogreffe, LAM , MDS
290691|NCT01541280|Azacitidine (VidazaÒ)
290692|NCT01541280|Injection de lymphocytes de donneur (DLI)
290693|NCT01541267|aliskiren
290694|NCT01541267|eplerenon
290695|NCT01541267|telmisartan
290696|NCT01541267|direct renin inhibitor
290697|NCT01541267|ACE inhibitor
290698|NCT01541267|mineralocorticoid inhibitor
290699|NCT01541267|proteinuria
290700|NCT01541267|chronic kidney diseases
290701|NCT01541267|renin-angiotensin-aldosterone system
290702|NCT01541254|intracranial aneurysm
290703|NCT01541254|wide-neck
290704|NCT01541254|saccular
290705|NCT01541254|endovascular treatment
290706|NCT01541254|coil embolization
290707|NCT01541254|stent
290708|NCT01541254|bare platinum
290709|NCT01541241|Intrauterine contraceptive device (IUD) is one of the most frequently used methods of birth control around the world
290710|NCT01541241|Uterine Hemodynamic changes
290711|NCT01541228|actinic keratosis
290712|NCT01541228|photodynamic therapy
290713|NCT01541228|5-aminolevulinic acid
290714|NCT01541202|chronic heart failure
290715|NCT01541202|neuregulin
290716|NCT01541202|mortality
290717|NCT01541189|hypertension
290718|NCT01541189|valsartan
290719|NCT01541176|Corticotherapy
290720|NCT01541176|Fibrosis
290721|NCT01541176|Numerical reading
290722|NCT01541176|18-70 years
290723|NCT01541176|first renal transplant was lost due to rejection
290724|NCT01541176|first or second renal transplant
290725|NCT01541163|Ischemia
290726|NCT01541163|Brain Infarction
290727|NCT01541163|Acute Stroke
290728|NCT01541163|Heart Diseases
290729|NCT01541163|Myocardial Infarction
290730|NCT01541150|Pedophilia
290731|NCT01541150|Impaired Decision making
290732|NCT01541150|Insight
290733|NCT01541150|Cognitive Distorsions
290734|NCT01541150|Impulsiveness
290735|NCT01541137|thoracotomy
290736|NCT01541137|pain
290737|NCT01541137|NSAID
290738|NCT01541137|PCA
290739|NCT01541137|TEA
290740|NCT01541137|chronic
290741|NCT01541124|cancer pain
290742|NCT01541124|analgesia
290743|NCT01541124|morphine
290744|NCT01541111|Cancer pain
290745|NCT01541111|Magnesiun
290746|NCT01541085|Human Immunodeficiency Virus; HIV; Highly Active Antiretroviral Therapy; HAART; Darunavir; Ritonavir; Efavirenz; Kinetics; Immunological Recovery
290747|NCT01541072|Lymphoma, B-cell
290748|NCT01541072|Lymphocyte reconstitution
290749|NCT01541072|Lymphocyte subsets
290750|NCT01541072|Peripheral stem cell transplantation
290751|NCT01541072|Induction chemotherapy
290752|NCT01541072|growth factor
290753|NCT01541072|Granulocyte Colony-stimulating factor
290754|NCT01541072|Pegfilgrastim
290755|NCT01541072|Filgrastim
290756|NCT01541059|Third molar extraction
290757|NCT01541059|local anesthesia
290758|NCT01541059|ropivacaine
290759|NCT01541046|pediatric
290760|NCT01541046|infantile colic
290761|NCT01541046|probiotic treatment
290762|NCT01541033|autism
290763|NCT01541033|children
290764|NCT01541007|Prostate Cancer
290765|NCT01541007|Metastatic
290766|NCT01541007|Castration Resistant
290767|NCT01540994|Neoplasms
290768|NCT01540994|Urogenital neoplasm
290769|NCT01540994|Genital neoplasms, male
290770|NCT01540955|Reduce Cognitive Complaints
290771|NCT01540955|improve cognitive function
290772|NCT01540955|post-treatment breast cancer patients
290773|NCT01540942|Crohn's disease
290774|NCT01540942|Nutrition
290775|NCT01540942|Bowel resection
290776|NCT01540942|Postoperative recurrence
290777|NCT01540942|complication
290778|NCT01540942|Active disease
290779|NCT01540929|Smallpox
290780|NCT01540929|ACAM2000®
290781|NCT01540929|Smallpox vaccine
290782|NCT01540916|acid-base equilibrium
290783|NCT01540916|renal system
290784|NCT01540916|urinary electrolytes
290785|NCT01540903|Malaria Challenge
290786|NCT01540903|Plasmodium falciparum
290787|NCT01540903|PfSPZ Challenge
290788|NCT01540903|Controlled
290789|NCT01540903|human
290790|NCT01540903|malaria infection
290791|NCT01540864|Obesity
290792|NCT01540864|Overweight
290793|NCT01540864|Body Mass Index
290794|NCT01540851|Osteoarthritis
290795|NCT01540851|Total Knee Replacement
290796|NCT01540851|total Knee Arthroplasty
290797|NCT01540851|Post operative recovery, TKA
290798|NCT01540851|Post-operative recovery TKR
290799|NCT01540851|Care Navigator
290800|NCT01540838|Bacterial meningitis
290801|NCT01540838|infusion
290802|NCT01540838|bolus
290803|NCT01540838|paracetamol
290804|NCT01540812|Acute Lymphoblastic Leukemia
290805|NCT01540799|Migraine
290806|NCT01540799|High disability migraine
290807|NCT01540799|Sphenopalatine ganglion
290808|NCT01540799|Neuromodulation
290809|NCT01540799|Neurostimulation
290810|NCT01540799|Autonomic nervous system
290811|NCT01540786|OAB
290812|NCT01540786|High Resolution Urodynamics
290813|NCT01540773|growth hormone
290814|NCT01540747|intrafollicular melatonin
290815|NCT01540747|PCOS
290816|NCT01540747|embryos quality
290817|NCT01540747|oocytes quality
290818|NCT01540734|paracetamol
290819|NCT01540734|pharmacokinetic
290820|NCT01540721|paracetamol
290821|NCT01540721|pharmacokinetics
290822|NCT01540708|Asthma
290823|NCT01540708|Respiratory
290824|NCT01540708|COPD
290825|NCT01540695|Any patient with a routine basal cell or squamous cell carcinoma
290826|NCT01540695|of the skin diagnosed on frozen histology during a Mohs procedure
290827|NCT01540682|Male and female patients with HNSCC of the oral cavity, oropharynx, hypopharynx, larynx,
290828|NCT01540682|nasopharynx or paranasal sinuses that is considered appropriate
290829|NCT01540682|for definitive cetuximab-based radiation therapy.
290830|NCT01540669|constipation
290831|NCT01540669|functional constipation
290832|NCT01540669|polydextrose
290833|NCT01540669|whole gut transit time
290834|NCT01540656|Stress incontinence
290835|NCT01540656|Incontinence
290836|NCT01540656|prostate cancer
290837|NCT01540656|Radical Prostatectomy vibration
290838|NCT01540656|nerve stimulation
290839|NCT01540643|abdominal aortic aneurysm
290840|NCT01540643|iliac leg graft
290841|NCT01540617|Low back pain
290842|NCT01540617|Proprioception
290843|NCT01540617|Postural control
290844|NCT01540617|Spine
290845|NCT01540617|Variability
290846|NCT01540617|MRI
290847|NCT01540617|Vibration
290848|NCT01540617|Brain
290849|NCT01540604|DMD
290850|NCT01540604|BMD
290851|NCT01540604|symptomatic carriers
290852|NCT01540591|repeated implantation failure
290853|NCT01540591|intralipid
290854|NCT01540552|lung cancer
290855|NCT01540552|precancerous condition
290856|NCT01540552|lung nodules
290857|NCT01540552|CT Scan
290858|NCT01540500|Pharmacokinetics
290859|NCT01540500|Drug Interaction
290860|NCT01540474|Interference of malaria infection
290861|NCT01540461|HCC
290862|NCT01540435|Colorectal cancer
290863|NCT01540435|Liver metastases
290864|NCT01540435|Perioperative treatment
290865|NCT01540435|Liver resection
290866|NCT01540422|vein grafts
290867|NCT01540422|coronary bypass
290868|NCT01540422|endoscopic harvest
290869|NCT01540422|endoscopic vein harvest
290870|NCT01540409|DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
290871|NCT01540396|Gestational Diabetes
290872|NCT01540383|Communication
290873|NCT01540383|Language
290874|NCT01540383|Treatment
290875|NCT01540383|Intervention
290876|NCT01540383|Therapy
290877|NCT01540383|Efficacy
290878|NCT01540383|Maintenance
290879|NCT01540383|Recovery
290880|NCT01540383|Outcome
290881|NCT01540383|Rehabilitation
290882|NCT01540383|Treatment Intensity
290883|NCT01540383|Language Impairment
290884|NCT01540383|Intensive Language Therapy
290885|NCT01540383|Functional Communication
290886|NCT01540383|Functional Improvement
290887|NCT01540383|Evidence-Based Intervention
290888|NCT01540383|High-Frequency
290889|NCT01540357|mindfulness-based therapy
290890|NCT01540357|chronic tinnitus;
290891|NCT01540344|peritoneal carcinomatosis
290892|NCT01540344|cytoreductive surgery
290893|NCT01540344|HIPEC
290894|NCT01540344|colorectal cancer
290895|NCT01540318|ultrasonography
290896|NCT01540318|Abdominal Injuries
290897|NCT01540318|Trauma
290898|NCT01540305|Obsessive Compulsive Disorder
290899|NCT01540305|Transcranial Magnetic Stimulation
290900|NCT01540305|Treatment
290901|NCT01540292|Crohn's disease
290902|NCT01540292|Mesenchymal Stem Cell
290903|NCT01540292|Cell therapy
290904|NCT01540292|Allogeneic
290905|NCT01540292|Inflammatory disorders
290906|NCT01540292|Autoimmune disorders
290907|NCT01540266|physician-patient communication
290908|NCT01540266|information structuring
290909|NCT01540266|emergency department
290910|NCT01540240|HIV treatment
290911|NCT01540240|zidovudine
290912|NCT01540240|dose reduction
290913|NCT01540240|anaemia
290914|NCT01540240|safety and efficacy comparison
290915|NCT01540227|Syphilis
290916|NCT01540227|Penicillin
290917|NCT01540214|Urinary Bladder, Overactive
290918|NCT01540214|Pelvic Organ Prolapse
290919|NCT01540214|Gynecologic Surgical Procedures
290920|NCT01540214|Urodynamics
290921|NCT01540201|one lung ventilation
290922|NCT01540201|gas exchange
290923|NCT01540201|inverse-ratio ventilation
290924|NCT01540188|Drug user
290925|NCT01540188|Family member
290926|NCT01540188|Intervention
290927|NCT01540188|Community
290928|NCT01540188|Support
290929|NCT01540175|Autologous stem cell transplant
290930|NCT01540175|Immune reconstitution
290931|NCT01540162|preterm newborn
290932|NCT01540162|neonatology
290933|NCT01540162|EcN
290934|NCT01540162|Nissle
290935|NCT01540162|Mutaflor
290936|NCT01540162|prophylaxis
290937|NCT01540162|infection
290938|NCT01540110|Locally Advanced or Node Positive Primary Breast Cancer
290939|NCT01540084|Cocktail sedation
290940|NCT01540084|ERCP
290941|NCT01540071|Hormone refractory prostate cancer
290942|NCT01540071|HRPC
290943|NCT01540071|Androgen independent prostate cancer
290944|NCT01540071|CRPC
290945|NCT01540071|Castration and Taxane Resistant Prostate Cancer
290946|NCT01540045|Non-Small Cell Lung Cancer
290947|NCT01540045|Dysgeusia
290948|NCT01540045|Antineoplastic Combined Chemotherapy Protocols
290949|NCT01540045|Paclitaxel
290950|NCT01540045|Cisplatin
290951|NCT01540019|anorexia
290952|NCT01540019|Paullinia cupana
290953|NCT01540019|loss of weight
290954|NCT01539993|Hepatocellular carcinoma
290955|NCT01539993|Liver metastases
290956|NCT01539993|Cholangiocarcinoma
290957|NCT01539993|Percutaneous treatments
290958|NCT01539993|RFA
290959|NCT01539993|TACE
290960|NCT01539993|DEB
290961|NCT01539980|Sericin scaffold
290962|NCT01539980|Wound healing
290963|NCT01539980|Skin graft donor
290964|NCT01539967|Laparoscopic Sleeve Gastrectomy
290965|NCT01539967|Obesity follow-up
290966|NCT01539954|Alcohol related disorders
290967|NCT01539941|Co-occurring adolescent substance use and ADHD
290968|NCT01539928|Dual time PET/CT
290969|NCT01539928|glucose-6-phosphatase
290970|NCT01539915|Psoriasis
290971|NCT01539915|Stable plaque psoriasis
290972|NCT01539915|lesions
290973|NCT01539915|TNF-alpha
290974|NCT01539915|BCT194
290975|NCT01539902|MSC for the treatment of Lupus Nephritis
290976|NCT01539876|locally advanced breast cancer patients
290977|NCT01539850|obesity
290978|NCT01539850|gastric stimulation
290979|NCT01539850|morbid obesity
290980|NCT01539837|Parkinson's disease
290981|NCT01539837|Brain Iron
290982|NCT01539837|Iron chelation
290983|NCT01539837|Oxidative stress
290984|NCT01539811|Foot Infections
290985|NCT01539811|Diabetes
290986|NCT01539811|Antibiotic
290987|NCT01539798|Saline solution
290988|NCT01539798|Sodium Chloride
290989|NCT01539798|Hypoalbuminemia
290990|NCT01539798|Weight Gain
290991|NCT01539785|HIPEC
290992|NCT01539785|Hyperthermic
290993|NCT01539785|ovarian cancer
290994|NCT01539785|recurrence
290995|NCT01539759|Postpartum Contraception
290996|NCT01539759|Intrauterine Devices
290997|NCT01539746|Aortic stenosis
290998|NCT01539746|Transcatheter aortic valve implantation
290999|NCT01539746|TAVI
291000|NCT01539746|Predilation
291001|NCT01539746|Balloon valvuloplasty
291002|NCT01539746|BAV
291003|NCT01539746|CoreValve
291004|NCT01539720|emergency contraception
291005|NCT01539720|Ella
291006|NCT01539720|Mirena IUD
291007|NCT01539720|post-coital contraception
291008|NCT01539720|Liletta IUD
291009|NCT01539707|Neurogenic Detrusor Overactivity
291010|NCT01539707|Solifenacin succinate suspension
291011|NCT01539707|Pharmacokinetics
291012|NCT01539707|Phase 1
291013|NCT01539681|Hepatocellular Carcinoma
291014|NCT01539681|Cancer, Liver
291015|NCT01539681|Sorafenib
291016|NCT01539681|Nexavar
291017|NCT01539668|Cervical Cancer
291018|NCT01539668|HPV
291019|NCT01539668|Secondary prevention
291020|NCT01539655|Phase 1
291021|NCT01539655|healthy volunteers
291022|NCT01539655|pharmacokinetics
291023|NCT01539655|vandetanib
291024|NCT01539655|omeprazole
291025|NCT01539655|ranitidine
291026|NCT01539642|In patient, post operative pain
291027|NCT01539642|Adult post-operative inpatients who are expected to require parenteral opioid analgesia for at least 48 hours after open abdominal surgery
291028|NCT01539629|Heart failure
291029|NCT01539629|Autothreshold
291030|NCT01539629|Pacing
291031|NCT01539629|CRT-D recipients
291032|NCT01539629|Left Ventricular evoked response signals
291033|NCT01539616|Hypertriglyceridemia
291034|NCT01539616|Dyslipidemia
291035|NCT01539603|drug eluting balloon
291036|NCT01539603|bare metal stent
291037|NCT01539603|drug eluting stent
291038|NCT01539603|coronary artery disease
291039|NCT01539590|hepatocyte growth factor mimetic
291040|NCT01539590|hepatocyte growth factor(HGF)
291041|NCT01539590|Myocardial Infarction
291042|NCT01539590|Acute ST Segment Elevation Myocardial Infarction (STEMI)
291043|NCT01539590|Percutaneous Coronary Intervention (PCI)
291044|NCT01539538|Adult post-operative inpatients who
291045|NCT01539538|are expected to require parenteral
291046|NCT01539538|opioid analgesia for at least 48
291047|NCT01539538|hours after open abdominal surgery
291048|NCT01539538|or hip/knee replacement surgery
291049|NCT01539512|CLL
291050|NCT01539512|CAL-101
291051|NCT01539512|GS 1101
291052|NCT01539512|PI3K
291053|NCT01539512|GS-US-312-0117
291054|NCT01539512|idelalisib
291055|NCT01539460|Axillary osmidrosis
291056|NCT01539460|liposuction
291057|NCT01539460|minimally invasive surgery
291058|NCT01539447|Hip arthroscopy
291059|NCT01539447|Femoroacetabular impingement
291060|NCT01539447|Heterotopic ossification
291061|NCT01539447|Heterotopic bone formation
291062|NCT01539434|COPD
291063|NCT01539434|Behavioral intervention
291064|NCT01539434|Physical capacity
291065|NCT01539434|Physical activity
291066|NCT01539421|COPD
291067|NCT01539421|exercise endurance
291068|NCT01539395|Relapsing Remitting
291069|NCT01539395|MS
291070|NCT01539382|cardiac surgery
291071|NCT01539382|neurocognitive assessment
291072|NCT01539382|neurocognitive function
291073|NCT01539369|dietary intervention
291074|NCT01539369|dietary fibre
291075|NCT01539369|weight loss
291076|NCT01539369|weight maintenance
291077|NCT01539356|Hepcidin
291078|NCT01539356|Preterm Infants
291079|NCT01539356|Anemia
291080|NCT01539356|Sepsis
291081|NCT01539356|Ferritin
291082|NCT01539343|Infection
291083|NCT01539343|Catheter-related bloodstream infection
291084|NCT01539343|CRBSI
291085|NCT01539343|Antimicrobial Lock Therapy
291086|NCT01539343|ALT
291087|NCT01539343|Central Line Associated Bloodstream Infection
291088|NCT01539343|CLABSI
291089|NCT01539343|Central Venous Catheter
291090|NCT01539343|CVC
291091|NCT01539343|Quantitative blood cultures
291092|NCT01539343|QBC
291093|NCT01539330|voriconazole
291094|NCT01539330|microdialysis
291095|NCT01539330|sequence therapy
291096|NCT01539330|pharmacokinetics
291097|NCT01539330|Target Site Pharmacokinetics
291098|NCT01539317|Vulvodynia
291099|NCT01539317|Dyspareunia
291100|NCT01539317|Breast Cancer
291101|NCT01539317|Menopause
291102|NCT01539317|Vaginal dryness
291103|NCT01539317|Painful intercourse
291104|NCT01539291|CLL
291105|NCT01539291|CAL-101
291106|NCT01539291|CAL 101
291107|NCT01539291|GS-1101
291108|NCT01539291|GS 1101
291109|NCT01539291|PI3K
291110|NCT01539291|Leukemia
291111|NCT01539291|GS-US-312-0116
291112|NCT01539291|idelalisib
291113|NCT01539278|Sleep Apnea, Obstructive
291114|NCT01539278|Child
291115|NCT01539278|Tonsillectomy
291116|NCT01539278|Adenoidectomy
291117|NCT01539265|urinary calculus
291118|NCT01539265|ureteral stones
291119|NCT01539265|medical expulsive therapy
291120|NCT01539252|hemodialysis
291121|NCT01539252|adequacy
291122|NCT01539252|phosphate clearance
291123|NCT01539252|double dialyzer
291124|NCT01539252|two dialyzers in parallel
291125|NCT01539239|Glaucoma
291126|NCT01539239|POAG
291127|NCT01539239|Cataract
291128|NCT01539226|HIV Infections
291129|NCT01539226|Anti-HIV agents
291130|NCT01539226|HIV-1
291131|NCT01539213|Psoriasis
291132|NCT01539213|interstitial fluid
291133|NCT01539213|open flow microperfusion
291134|NCT01539213|IL-17
291135|NCT01539213|inflammatory skin disease
291136|NCT01539213|scaly patches
291137|NCT01539213|Healthy volunteers and psoriasis patients
291138|NCT01539187|uterine fibroid RF ablation
291139|NCT01539187|intrauterine ultrasound
291140|NCT01539187|VizAblate
291141|NCT01539161|Chagas Disease
291142|NCT01539161|Chagasic
291143|NCT01539161|Reveal XT
291144|NCT01539161|Implantable Cardiac Monitor
291145|NCT01539161|ICM
291146|NCT01539148|Quality of Life
291147|NCT01539148|Qol
291148|NCT01539148|Questionnaire
291149|NCT01539148|Survey
291150|NCT01539148|Insulin Potentiation Targeted Low Dose Chemotherapy
291151|NCT01539148|IPTLD
291152|NCT01539148|Nutritional Therapy
291153|NCT01539148|Chemotherapy
291154|NCT01539148|Cancer Treatment
291155|NCT01539148|Kotsanis Institute
291156|NCT01539148|The Best Answer for Cancer Foundation
291157|NCT01539148|Liberty IRB
291158|NCT01539148|Texas
291159|NCT01539135|Aspiration, Respiratory
291160|NCT01539122|osteoarthritis
291161|NCT01539122|shoulder replacement
291162|NCT01539109|Incomplete Spinal Cord Injury
291163|NCT01539109|Quadriplegia
291164|NCT01539109|Tetraplegia
291165|NCT01539109|SCI
291166|NCT01539109|Spinal Cord Disease
291167|NCT01539109|Spinal Cord Injury
291168|NCT01539109|iSCI
291169|NCT01539109|Transcranial Direct Current Stimulation
291170|NCT01539109|tDCS
291171|NCT01539109|SCI recovery
291172|NCT01539109|brain stimulation
291173|NCT01539109|rehabilitation
291174|NCT01539096|Stroke
291175|NCT01539096|Rehabilitation
291176|NCT01539096|Paresis
291177|NCT01539096|Paralysis
291178|NCT01539096|Recovery
291179|NCT01539096|tDCS
291180|NCT01539096|Transcranial Direct Current Stimulation
291181|NCT01539096|CIMT
291182|NCT01539096|Constraint Induced Movement Therapy
291183|NCT01539096|Stroke therapy
291184|NCT01539096|MRI
291185|NCT01539096|Hand
291186|NCT01539096|CVA
291187|NCT01539096|Cerebrovascular accident
291188|NCT01539083|Multiple Myeloma
291189|NCT01539083|Bortezomib
291190|NCT01539083|VELCADE
291191|NCT01539083|Consolidation therapy
291192|NCT01539083|Subcutaneous
291193|NCT01539083|Thalidomide
291194|NCT01539083|Prednisolone
291195|NCT01539083|Autologous stem cell transplant (ASCT)
291196|NCT01539083|VELCADE, cyclophosphamide, dexamethasone (VCD) induction therapy
291197|NCT01539070|Nutritional intervention
291198|NCT01539070|Childhood obesity
291199|NCT01539070|Physical activity
291200|NCT01539070|Feeding practices
291201|NCT01539057|Liver
291202|NCT01539057|Surgery
291203|NCT01539057|hemostasis
291204|NCT01539057|coagulation
291205|NCT01539057|Fibrinogen
291206|NCT01539044|reversal
291207|NCT01539044|muscle relaxant
291208|NCT01539044|sugammadex
291209|NCT01539031|Alzheimer Disease
291210|NCT01539031|Dementia
291211|NCT01539031|Delirium
291212|NCT01539031|Amnestic
291213|NCT01539031|Cognitive Disorders
291214|NCT01539031|Donepezil
291215|NCT01539031|Brain Diseases
291216|NCT01539031|Central Nervous System Diseases
291217|NCT01539031|Nervous System Diseases
291218|NCT01539031|Tauopathies
291219|NCT01539031|Neurodegenerative Diseases
291220|NCT01539031|Mental Disorders
291221|NCT01539031|Cholinesterase Inhibitors
291222|NCT01539031|Enzy
291223|NCT01539005|Recurrence
291224|NCT01539005|Tuberculosis
291225|NCT01538992|renal denervation
291226|NCT01538992|heart failure
291227|NCT01538979|Grass pollen allergy
291228|NCT01538979|Immunotherapy
291229|NCT01538979|Recombinant vaccine
291230|NCT01538979|Rhinitis, allergic, seasonal
291231|NCT01538966|acromegaly
291232|NCT01538966|pituitary
291233|NCT01538966|pegvisomant
291234|NCT01538966|somavert
291235|NCT01538966|lanreotide
291236|NCT01538966|octreotide
291237|NCT01538953|diarrhea
291238|NCT01538953|handwashing
291239|NCT01538953|point-of-use water treatment
291240|NCT01538953|diarrhea longitudinal prevalence
291241|NCT01538940|Influenza
291242|NCT01538940|Vaccine
291243|NCT01538940|Thailand
291244|NCT01538927|fibrin sealant
291245|NCT01538927|tissue adhesive
291246|NCT01538927|wound healing
291247|NCT01538927|interleukin 1 beta
291248|NCT01538927|interleukin 8
291249|NCT01538901|actinic keratoses
291250|NCT01538901|organ transplant recipients
291251|NCT01538901|photodynamic therapy
291252|NCT01538901|imiquimod
291253|NCT01538888|WHOLE BODY VIBRATION
291254|NCT01538888|AGED
291255|NCT01538888|VO2
291256|NCT01538888|muscle strength
291257|NCT01538875|Hypertension, pregnancy induced
291258|NCT01538875|Hydralazine
291259|NCT01538875|Labetalol
291260|NCT01538823|Surgery, Renal Cell Cancer
291261|NCT01538810|CT imaging
291262|NCT01538797|YF476
291263|NCT01538797|gastrin receptor antagonist
291264|NCT01538797|gastric pH
291265|NCT01538797|healthy subjects
291266|NCT01538797|ranitidine
291267|NCT01538784|YF476
291268|NCT01538784|gastrin receptor antagonist
291269|NCT01538784|gastric pH
291270|NCT01538784|healthy subjects
291271|NCT01538771|Myocardial infarction
291272|NCT01538771|Erythropoietin
291273|NCT01538771|Myocardial reperfusion injury
291274|NCT01538758|calcifying tendinitis
291275|NCT01538758|rotator cuff
291276|NCT01538745|Pain
291277|NCT01538745|Emergency Department
291278|NCT01538745|Morphine
291279|NCT01538745|Ketamine
291280|NCT01538706|Hospital-based home care
291281|NCT01538706|Pediatric oncology
291282|NCT01538693|BDNF
291283|NCT01538693|serotonin
291284|NCT01538693|high-intensity
291285|NCT01538693|exercise
291286|NCT01538667|Lung
291287|NCT01538667|Scintigraphy
291288|NCT01538667|Pharmacokinetics
291289|NCT01538667|Inhalation
291290|NCT01538667|Ciprofloxacin
291291|NCT01538654|obesity
291292|NCT01538654|PSMF ( protein sparing modified fast)
291293|NCT01538654|Enteral nutrition
291294|NCT01538654|Tube feeding
291295|NCT01538654|VLCD ( very low calorie diet)
291296|NCT01538654|Pulmonary function tests
291297|NCT01538654|body composition
291298|NCT01538654|FFM ( fat free mass)
291299|NCT01538654|Body fat
291300|NCT01538654|Handgripstregth
291301|NCT01538628|Prostate cancer
291302|NCT01538628|Spacer
291303|NCT01538615|Family meals
291304|NCT01538615|Home food environment
291305|NCT01538615|Electronic media
291306|NCT01538602|PCOS
291307|NCT01538602|cardiovascular disorders
291308|NCT01538563|ON 01910.Na
291309|NCT01538563|rigosertib sodium
291310|NCT01538563|rogosertib
291311|NCT01538550|cancer
291312|NCT01538550|colon
291313|NCT01538550|rectum
291314|NCT01538550|adenoma
291315|NCT01538550|screening
291316|NCT01538550|iFOBT
291317|NCT01538550|flexible sigmoidoscopy
291318|NCT01538550|randomized trial
291319|NCT01538537|ON 01910.Na
291320|NCT01538537|rigosertib Sodium
291321|NCT01538537|rigosertib
291322|NCT01538498|PCI
291323|NCT01538498|Ovarian cancer
291324|NCT01538485|Vitamin D
291325|NCT01538485|regulatory T cells
291326|NCT01538485|GUT
291327|NCT01538472|Lymphoma
291328|NCT01538472|Relapse B-cell CD20+ non-Hodgkin's lymphoma
291329|NCT01538472|High-dose BEAM chemotherapy
291330|NCT01538472|Y Zevalin
291331|NCT01538472|In Zevalin
291332|NCT01538472|Rituxan
291333|NCT01538472|Rituximab
291334|NCT01538472|BCNU
291335|NCT01538472|1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea
291336|NCT01538472|Carmustine
291337|NCT01538472|BiCNU
291338|NCT01538472|VP-16
291339|NCT01538472|Ara-C
291340|NCT01538472|Cytarabine
291341|NCT01538472|Cytosar
291342|NCT01538472|DepoCyt
291343|NCT01538472|Cytosine Arabinosine Hydrochloride
291344|NCT01538472|Melphalan
291345|NCT01538472|Alkeran
291346|NCT01538472|G-CSF
291347|NCT01538472|Filgrastim
291348|NCT01538472|Neupogen
291349|NCT01538472|Stem cell infusion
291350|NCT01538472|Autologous stem cell transplantation
291351|NCT01538459|Blood Glucose
291352|NCT01538459|Bupivacaine
291353|NCT01538459|Interscalene Nerve Block
291354|NCT01538459|Regional Anesthesia
291355|NCT01538459|Pain Blockade
291356|NCT01538459|Arthroscopic Surgery
291357|NCT01538459|Arthroscopic rotator cuff repair
291358|NCT01538459|Dexamethasone
291359|NCT01538459|Anti-Inflammatory Agents
291360|NCT01538459|Therapeutic Uses
291361|NCT01538459|Physiological Effects of Drugs
291362|NCT01538459|Glucocorticoids
291363|NCT01538459|Anesthetics, Local
291364|NCT01538459|Anesthetics
291365|NCT01538459|Sensory System Agents
291366|NCT01538459|Adjuvants, Anesthesia
291367|NCT01538459|Anesthesiology
291368|NCT01538459|Injections
291369|NCT01538459|Adult
291370|NCT01538459|Analgesia/methods
291371|NCT01538459|Brachial Plexus/drug effects
291372|NCT01538459|Brachial Plexus/surgery
291373|NCT01538459|Brachial Plexus/ultrasonography
291374|NCT01538459|Bupivacaine/administration & dosage
291375|NCT01538459|Dexamethasone/administration & dosage
291376|NCT01538459|Drug Therapy, Combination
291377|NCT01538459|Female
291378|NCT01538459|Humans
291379|NCT01538459|Male
291380|NCT01538459|Nerve Block/methods
291381|NCT01538459|Pain, Postoperative/etiology
291382|NCT01538459|Pain, Postoperative/prevention & control
291383|NCT01538459|Prospective Studies
291384|NCT01538459|Time Factors
291385|NCT01538446|Elderly
291386|NCT01538446|Acute coronary syndrome
291387|NCT01538446|Percutaneous coronary intervention
291388|NCT01538446|Prasugrel
291389|NCT01538446|Platelet function test
291390|NCT01538433|diagnosis
291391|NCT01538433|IgA nephropathy
291392|NCT01538420|Safety
291393|NCT01538420|Tolerability
291394|NCT01538420|Pharmacokinetics
291395|NCT01538420|Pharmacodynamics
291396|NCT01538407|Strength training
291397|NCT01538407|Biomechanics
291398|NCT01538407|Quadriceps
291399|NCT01538407|Gait
291400|NCT01538394|smoking cessation
291401|NCT01538394|abstinence
291402|NCT01538394|clinical trial
291403|NCT01538394|varenicline
291404|NCT01538394|nicotine
291405|NCT01538381|Neoadjuvant targeted therapy
291406|NCT01538381|Preoperative targeted therapy
291407|NCT01538381|Afatinib
291408|NCT01538368|MRCP
291409|NCT01538368|ERCP
291410|NCT01538368|EUS
291411|NCT01538368|Image interpretation
291412|NCT01538368|MRCP findings
291413|NCT01538368|endoscopic intervention(s)
291414|NCT01538355|multiple sclerosis
291415|NCT01538355|diet
291416|NCT01538355|prolonged fasting
291417|NCT01538355|caloric restriction
291418|NCT01538355|ketogenic low glycemic load treatment
291419|NCT01538355|health related quality of life
291420|NCT01538355|ketogenic diet
291421|NCT01538355|neurodegeneration
291422|NCT01538355|neuroinflammation
291423|NCT01538329|Dyskinesia
291424|NCT01538329|L-DOPA
291425|NCT01538329|Early introduced treatment
291426|NCT01538329|Amantadine
291427|NCT01538316|Prostate cancer
291428|NCT01538316|dietary supplements
291429|NCT01538316|quercetin
291430|NCT01538316|genistein
291431|NCT01538316|prostate-specific antigen
291432|NCT01538316|oxidative Status
291433|NCT01538303|STEMI
291434|NCT01538303|absolute flow
291435|NCT01538303|microvascular resistance
291436|NCT01538290|Calibration
291437|NCT01538290|Validation
291438|NCT01538290|Transfer function
291439|NCT01538290|SphygmoCor
291440|NCT01538290|Arteriograph
291441|NCT01538277|contact force catheter
291442|NCT01538277|loop recorder
291443|NCT01538251|ulcerative colitis
291444|NCT01538251|propionyl-l-carnitine
291445|NCT01538225|Spasticity
291446|NCT01538212|Alzheimer's disease
291447|NCT01538212|retrospective
291448|NCT01538212|Axona
291449|NCT01538199|Device study
291450|NCT01538199|Depression
291451|NCT01538199|Major Depression
291452|NCT01538199|Major Depressive Disorder
291453|NCT01538199|MDD
291454|NCT01538199|Device for depression
291455|NCT01538199|Alternatives to medication for depression
291456|NCT01538199|Massachusetts General Hospital
291457|NCT01538199|Boston
291458|NCT01538186|Coronary intervention
291459|NCT01538186|PCI of the side branch
291460|NCT01538173|surgical side infection
291461|NCT01538173|breast reduction
291462|NCT01538173|reduction mammaplasty
291463|NCT01538173|prospective trial
291464|NCT01538173|microcirculation
291465|NCT01538173|breast surgery
291466|NCT01538160|recombinant factor VIIa
291467|NCT01538160|factor XI deficiency
291468|NCT01538147|Restless Leg Syndrome
291469|NCT01538147|Severe Preeclampsia
291470|NCT01538134|Antibodies, anticardiolipin
291471|NCT01538134|Antibodies, B2 Glycoprotein I
291472|NCT01538134|Lupus Anticoagulant
291473|NCT01538134|Fetal Growth Restriction
291474|NCT01538121|Antibodies, anticardiolipin
291475|NCT01538121|Antibodies, B2 Glycoprotein I
291476|NCT01538121|Lupus Anticoagulant
291477|NCT01538121|Severe Preeclampsia
291478|NCT01538082|Anxiety disorders
291479|NCT01538082|Depressive disorders
291480|NCT01538082|Metabolic syndrome
291481|NCT01538082|Stress disorders
291482|NCT01538082|Primary care
291483|NCT01538069|Heart failure
291484|NCT01538069|Sleep apnea syndromes
291485|NCT01538069|Exercise
291486|NCT01538069|Continuous Positive Airway Pressure
291487|NCT01538056|AAA
291488|NCT01538043|Cost-effectiveness analysis
291489|NCT01538043|Cost-utility analysis
291490|NCT01538043|Osteoarthritis
291491|NCT01538043|Spa therapy
291492|NCT01538043|Randomized clinical trial
291493|NCT01538043|Mechanisms of action
291494|NCT01538030|Fetal membranes, premature rupture
291495|NCT01538030|Cesarean section
291496|NCT01538030|Perinatal mortality
291497|NCT01538030|Neonatal sepsis
291498|NCT01538030|Amniotic Fluid Volume
291499|NCT01538004|Blood pressure determination
291500|NCT01538004|Primary health care
291501|NCT01538004|Office visits
291502|NCT01538004|Reproducibility of results
291503|NCT01537991|radiotherapy
291504|NCT01537991|non small cell lung cancer
291505|NCT01537991|isotoxic
291506|NCT01537978|spinal cord injury, video gaming, functional improvement
291507|NCT01537965|hepatitis
291508|NCT01537965|fibrosis
291509|NCT01537965|elastography
291510|NCT01537952|facial paralysis, facial nerve, borreliosis, Bell's palsy
291511|NCT01537939|Physical Activity
291512|NCT01537939|Walking
291513|NCT01537939|Pedometer
291514|NCT01537939|Body Composition
291515|NCT01537939|Aerobic Fitness
291516|NCT01537926|HALT
291517|NCT01537926|HCM
291518|NCT01537874|Secondhand smoke
291519|NCT01537874|Pediatric disease
291520|NCT01537848|EUS
291521|NCT01537848|Endoscopic ultrasound
291522|NCT01537848|abdominal collection
291523|NCT01537848|post-operative
291524|NCT01537848|post-surgical
291525|NCT01537835|healthcare
291526|NCT01537835|worker
291527|NCT01537835|uniforms
291528|NCT01537835|bacterial
291529|NCT01537835|contamination
291530|NCT01537822|intrauterine polyps
291531|NCT01537822|myomas
291532|NCT01537822|residual placental tissue
291533|NCT01537809|Vitamin D
291534|NCT01537809|Vitamin D Deficiency
291535|NCT01537809|Avitaminosis
291536|NCT01537809|Deficiency Diseases
291537|NCT01537809|Blood lipids
291538|NCT01537796|Obesity
291539|NCT01537796|Exercise
291540|NCT01537783|abscess
291541|NCT01537770|Vertebroplasty
291542|NCT01537770|Low energy osteoporotic vertebral fractures
291543|NCT01537770|of the thoracic and/or lumbar spine
291544|NCT01537744|expansion cohort
291545|NCT01537705|Medical food
291546|NCT01537705|Neuropathy
291547|NCT01537705|Diabetes
291548|NCT01537705|Neuropathic Pain
291549|NCT01537679|Caregiver
291550|NCT01537679|meditation
291551|NCT01537679|relaxation
291552|NCT01537679|stress
291553|NCT01537627|Motor activity
291554|NCT01537627|Exercise
291555|NCT01537627|Rehabilitation
291556|NCT01537601|Posterior urethral valves
291557|NCT01537601|Febrile urinary tract infection
291558|NCT01537601|Circumcision
291559|NCT01537601|Antibioprophylaxis
291560|NCT01537601|Impact on family
291561|NCT01537588|anterior cruciate ligament
291562|NCT01537588|hamstring
291563|NCT01537588|semitendinosus
291564|NCT01537588|gracilis
291565|NCT01537588|graft
291566|NCT01537562|Copper IUD
291567|NCT01537562|LNG-IUS
291568|NCT01537562|intrauterine contraception
291569|NCT01537562|medical abortion
291570|NCT01537562|postabortion contraception
291571|NCT01537549|Progressive supranuclear palsy
291572|NCT01537549|alpha-lipoic acid
291573|NCT01537549|L-acetyl carnitine
291574|NCT01537549|antioxidant
291575|NCT01537549|magnetic resonance spectroscopy
291576|NCT01537549|neurodegeneration
291577|NCT01537549|glutathione
291578|NCT01537536|Breast cancer
291579|NCT01537536|Neoadjuvant chemotherapy
291580|NCT01537536|EndoTAG-1
291581|NCT01537523|physical
291582|NCT01537523|psychological
291583|NCT01537523|fracture hip
291584|NCT01537497|Phase 1
291585|NCT01537497|Single Doses
291586|NCT01537497|Pharmacodynamics
291587|NCT01537497|Healthy Volunteers
291588|NCT01537484|massage
291589|NCT01537484|osteoarthritis
291590|NCT01537484|light touch
291591|NCT01537484|Swedish
291592|NCT01537471|PPI
291593|NCT01537471|Meclizine
291594|NCT01537471|Startle
291595|NCT01537471|Sensory processing
291596|NCT01537471|antihistamines
291597|NCT01537445|Diabetes Mellitus
291598|NCT01537445|Pancreas
291599|NCT01537445|Renal failure
291600|NCT01537445|Transplantation
291601|NCT01537432|Psoriasis, Plaque-type psoriasis
291602|NCT01537432|Plaque
291603|NCT01537432|Secukinumab
291604|NCT01537432|AIN457A
291605|NCT01537432|PASI
291606|NCT01537432|DLQI
291607|NCT01537432|IGA
291608|NCT01537419|Suicide
291609|NCT01537419|Depression
291610|NCT01537419|Family Relationships
291611|NCT01537406|BREAST IRRADIATION USING INTENSITY MODULATED RADIATION THERAPY
291612|NCT01537393|cornea
291613|NCT01537393|transplant
291614|NCT01537393|preservation
291615|NCT01537393|endothelial keratoplasty
291616|NCT01537367|Human immunodeficiency virus
291617|NCT01537367|HIV primary care
291618|NCT01537328|Total knee arthroplasty
291619|NCT01537328|quadriceps
291620|NCT01537328|muscle
291621|NCT01537328|arthroplasty
291622|NCT01537328|joint diseases
291623|NCT01537328|musculoskeletal diseases
291624|NCT01537315|Kidney Failure, Chronic
291625|NCT01537315|Cardiovascular Disease
291626|NCT01537315|Arteriosclerosis
291627|NCT01537302|Chronic Total Occlusion
291628|NCT01537302|Optimal Coherence Tomography
291629|NCT01537302|Lumivascular
291630|NCT01537289|Trauma
291631|NCT01537289|Pneumothorax
291632|NCT01537276|hysterosalpingography
291633|NCT01537276|Fluoroscopy
291634|NCT01537276|diagnostic accuracy
291635|NCT01537263|Aneurysmal Subarachnoid Hemorrhage
291636|NCT01537263|SAB
291637|NCT01537263|SAH
291638|NCT01537263|Ultrasound
291639|NCT01537263|Perfusion imaging
291640|NCT01537250|CAP
291641|NCT01537237|Atrial Fibrillation
291642|NCT01537237|Catheter-based ablation
291643|NCT01537237|Pulmonary vein isolation
291644|NCT01537237|Electro-anatomical mapping
291645|NCT01537237|Rotational angiography
291646|NCT01537224|Electrophysiology
291647|NCT01537224|Subthalamic nucleus
291648|NCT01537224|Parkinson
291649|NCT01537211|Dysvascular
291650|NCT01537211|amputation
291651|NCT01537211|above knee
291652|NCT01537211|ambulation
291653|NCT01537198|Postmarketing Drug Surveillance
291654|NCT01537172|ONO-4053 healthy subjects
291655|NCT01537172|3 part adaptive design
291656|NCT01537159|AML
291657|NCT01537146|unicompartmental
291658|NCT01537146|osteoarthritis
291659|NCT01537146|varus
291660|NCT01537146|malalignment
291661|NCT01537146|opening wedge
291662|NCT01537146|HTO
291663|NCT01537146|high
291664|NCT01537146|tibia
291665|NCT01537146|osteotomy
291666|NCT01537094|low vitamin c
291667|NCT01537094|reduced growth hormone secretion
291668|NCT01537068|Dysthymic disorder
291669|NCT01537068|Dysthymia
291670|NCT01537068|Chronic non-major depression
291671|NCT01537068|Non-major chronic depression
291672|NCT01537068|Chronic depressive disorder
291673|NCT01537068|Antidepressant treatment
291674|NCT01537055|H pylori eradication
291675|NCT01537042|Rotigotine
291676|NCT01537042|Neupro
291677|NCT01537042|Restless Legs Syndrome
291678|NCT01537042|RLS
291679|NCT01537042|End-Stage Renal Disease
291680|NCT01537029|Breast cancer
291681|NCT01537029|Pharmacokinetics
291682|NCT01537029|Obesity
291683|NCT01537029|Doxorubicin
291684|NCT01537029|Cyclophosphamide
291685|NCT01537029|Weight
291686|NCT01536977|quality of life
291687|NCT01536925|Behavioral Economics
291688|NCT01536925|Drug self administration
291689|NCT01536925|Opioid
291690|NCT01536912|HIV positive
291691|NCT01536899|HIV positive
291692|NCT01536899|Medical Marijuana
291693|NCT01536873|treatment experienced patients
291694|NCT01536873|Integrase resistance
291695|NCT01536821|Parkinson disease
291696|NCT01536821|Parkinson's Disease
291697|NCT01536821|PD
291698|NCT01536821|LRRK2
291699|NCT01536821|genetics
291700|NCT01536821|genes
291701|NCT01536808|Diabetes mellitus
291702|NCT01536808|accelerated aging
291703|NCT01536808|cellular senescence
291704|NCT01536808|diabetic cardiomyopathy
291705|NCT01536808|strain imaging
291706|NCT01536808|strain rate imaging,
291707|NCT01536808|echocardiography
291708|NCT01536795|Ointment to treat leishmania skin lesions
291709|NCT01536782|head and neck cancer
291710|NCT01536782|chemoradiation therapy
291711|NCT01536782|bolus feeding
291712|NCT01536782|gravity feeding
291713|NCT01536782|pump feeding
291714|NCT01536782|optimal enteral feeding method
291715|NCT01536782|To determine the optimal tube feeding method by analyzing percent weigtht loss.
291716|NCT01536782|To determine the optimal tube feeding method by analyzing tolerance of enteral feeds.
291717|NCT01536782|To determine the optimal tube feeding method by analyzing percent met of estimated calories and protein.
291718|NCT01536769|Metagenomic analysis
291719|NCT01536769|Microbiota
291720|NCT01536756|Depressive disorder
291721|NCT01536756|exercise
291722|NCT01536756|pain
291723|NCT01536756|physical
291724|NCT01536756|psychological
291725|NCT01536756|Chinese
291726|NCT01536756|mild to severe depressive disorders
291727|NCT01536717|atrial septal defect
291728|NCT01536717|mitral valve annuloplasty
291729|NCT01536717|aortic valve annuloplasty
291730|NCT01536717|open heart surgery
291731|NCT01536717|oxycodone consumption
291732|NCT01536717|articain
291733|NCT01536717|bupivacaine
291734|NCT01536717|pain after sternotomy
291735|NCT01536717|postoperative pain
291736|NCT01536717|wound infusion
291737|NCT01536704|nicotine lozenge
291738|NCT01536704|nicotine
291739|NCT01536704|nicotine replacement therapy
291740|NCT01536691|ramosetron
291741|NCT01536691|ondansetron
291742|NCT01536691|aprepitant
291743|NCT01536691|chemotherapy induced nausea & vomiting
291744|NCT01536587|influence of bronchodilatation with salmeterol on the autonomic nervous systems in COPD patients will be measured using MSNA.
291745|NCT01536587|Relation of COPD and sympathetic nerve activity is to be evaluated,
291746|NCT01536561|Tositumomab and/or Iodine I 131 Tositumomab
291747|NCT01536561|B-cell non-Hodgkin's lymphoma
291748|NCT01536561|Dose-limiting toxicity
291749|NCT01536561|Bexxar
291750|NCT01536548|hemodialysis
291751|NCT01536548|cannulation
291752|NCT01536548|AV-fistula
291753|NCT01536548|buttonhole technique
291754|NCT01536535|Ulcerative Colitis
291755|NCT01536535|mesalamine
291756|NCT01536535|corticosteroids
291757|NCT01536535|PROTECT
291758|NCT01536522|Asthma
291759|NCT01536522|Allergic Asthma
291760|NCT01536522|Non-allergic Asthma
291761|NCT01536496|trauma
291762|NCT01536496|hemorrhagic shock
291763|NCT01536496|thrombelastography
291764|NCT01536496|coagulopathy
291765|NCT01536496|transfusion
291766|NCT01536496|resuscitation
291767|NCT01536483|Butyrate
291768|NCT01536483|Preterms
291769|NCT01536483|Very Low Birth Weight (<1250g)
291770|NCT01536483|Rectocolonic enemas
291771|NCT01536483|Digestive maturation
291772|NCT01536483|Parenteral nutrition weaning
291773|NCT01536483|ECUN
291774|NCT01536483|Whole gut transit time
291775|NCT01536470|Intraoperative hemodynamic
291776|NCT01536470|Arterial pressure
291777|NCT01536470|Postoperative complications
291778|NCT01536470|Intraoperative fluids
291779|NCT01536470|Noradrenaline
291780|NCT01536457|asthma
291781|NCT01536457|children
291782|NCT01536457|gastroesophageal reflux
291783|NCT01536457|retrospective
291784|NCT01536457|data analysis
291785|NCT01536444|Mohs surgery
291786|NCT01536444|Excisional skin surgery
291787|NCT01536444|Micrografting
291788|NCT01536431|Diabetes
291789|NCT01536418|Crohn's disease, chemokine receptor 9 antagonist, Crohn's Disease Activity Index
291790|NCT01536418|active treatment
291791|NCT01536392|Cancer of the Cervix
291792|NCT01536392|Anti-emetic therapy
291793|NCT01536392|Granisetron
291794|NCT01536392|Transdermal patch
291795|NCT01536392|Ondansetron
291796|NCT01536392|Zofran
291797|NCT01536392|Questionnaires
291798|NCT01536392|Surveys
291799|NCT01536392|Study Drug Diary
291800|NCT01536379|Infection
291801|NCT01536379|Quality of Life
291802|NCT01536366|Parkinson Disease
291803|NCT01536366|BIA 9-1067
291804|NCT01536340|post discharge adverse events
291805|NCT01536340|discontinuities in care
291806|NCT01536340|medical injury
291807|NCT01536327|Metachromatic Leukodystrophy
291808|NCT01536327|Demyelinating Diseases
291809|NCT01536314|Pre-emptive administration
291810|NCT01536314|Post-operative administration
291811|NCT01536314|Prophylaxis
291812|NCT01536314|Memantine
291813|NCT01536314|Post-mastectomy/tumorectomy
291814|NCT01536314|Neuropathic pain
291815|NCT01536301|oxycodone
291816|NCT01536301|morphine
291817|NCT01536301|hip replacement
291818|NCT01536301|analgesia
291819|NCT01536301|post operative analgesia
291820|NCT01536288|acute mountain sickness
291821|NCT01536288|AMS
291822|NCT01536288|Rhodiola Crenulata
291823|NCT01536288|mountaineering
291824|NCT01536288|pulse oximetry
291825|NCT01536288|oxygen saturation
291826|NCT01536275|critical illness
291827|NCT01536275|children
291828|NCT01536275|nutrition
291829|NCT01536275|metabolism
291830|NCT01536236|Diabetes
291831|NCT01536236|Polyneuropathy
291832|NCT01536236|Spinal cord stimulation
291833|NCT01536223|Nasopharyngeal Carcinoma (NPC)
291834|NCT01536223|cisplatin and 5-fluorouracil (PF)
291835|NCT01536223|docetaxel,cisplatin and 5-fluorouracil(TPF)
291836|NCT01536223|Neoadjuvant Chemotherapy
291837|NCT01536223|intensity modulated radiotherapy(IMRT)
291838|NCT01536210|ADHD(attention Deficit Hyperactivity Disorder)
291839|NCT01536197|obesity
291840|NCT01536197|gastric bypass
291841|NCT01536197|gastric banding
291842|NCT01536197|weight loss
291843|NCT01536197|taste perception
291844|NCT01536184|Fetal Alcohol Spectrum Disorder
291845|NCT01536184|FASD
291846|NCT01536171|runners
291847|NCT01536171|mid-foot strike
291848|NCT01536171|fore foot strike
291849|NCT01536171|metabolic costs
291850|NCT01536171|trained runners (men,women) with a FM strike
291851|NCT01536171|shod running
291852|NCT01536171|barefoot running
291853|NCT01536158|Patent Ductus Arteriosus
291854|NCT01536158|Paracetamol
291855|NCT01536158|Ibuprofen
291856|NCT01536158|Preterm infant
291857|NCT01536145|IGF-1R inhibitor
291858|NCT01536145|CP-751871
291859|NCT01536145|multiple myeloma
291860|NCT01536132|Levosimendan
291861|NCT01536132|chronic heart failure
291862|NCT01536132|inotropic drug
291863|NCT01536119|Breastfeeding
291864|NCT01536119|Coparenting
291865|NCT01536119|Infant feeding
291866|NCT01536119|Fathers' support
291867|NCT01536119|Breastfeeding support
291868|NCT01536119|Breastfeeding support intervention
291869|NCT01536119|clinical trial
291870|NCT01536106|Cell therapy, Bone marrow stem cells, cardiac cell therapy
291871|NCT01536041|asthma
291872|NCT01536041|Adult
291873|NCT01536015|Rotigotine
291874|NCT01536015|Neupro®
291875|NCT01536015|Levodopa
291876|NCT01536015|Gastrointestinal Dysfunction
291877|NCT01536002|Bariatric surgery
291878|NCT01536002|Anesthetics, intravenous
291879|NCT01536002|Propofol
291880|NCT01536002|Pharmacokinetics
291881|NCT01535989|B-cell Non Hodgkin's Lymphomas
291882|NCT01535989|CD22 positive
291883|NCT01535950|Age-related macular degeneration
291884|NCT01535950|intravitreal, neovascular
291885|NCT01535950|anti-vascular endothelial growth factor
291886|NCT01535950|wet AMD
291887|NCT01535950|Age-related
291888|NCT01535950|Macular degeneration
291889|NCT01535950|Intravitreal
291890|NCT01535950|Neovascular
291891|NCT01535924|Hodgkin's Lymphoma
291892|NCT01535924|relapsed
291893|NCT01535924|refractory
291894|NCT01535911|ketogenic diet
291895|NCT01535911|brain tumors
291896|NCT01535898|MRI
291897|NCT01535898|MR imaging Pulse Sequence
291898|NCT01535898|High Resolution Diffusion-weighted
291899|NCT01535898|Questionnaire
291900|NCT01535898|12-033
291901|NCT01535885|Cytoxic T Lymphocytes(CTL)
291902|NCT01535885|T-cell Depleted
291903|NCT01535885|Allogeneic Transplant
291904|NCT01535885|Epstein Barr Virus
291905|NCT01535885|Adenovirus
291906|NCT01535885|Cytomegalovirus
291907|NCT01535885|Hematopoietic progenitor cell transplantation
291908|NCT01535846|taste
291909|NCT01535846|mindful eating
291910|NCT01535846|intuitive eating
291911|NCT01535846|attitude
291912|NCT01535846|behavior
291913|NCT01535833|robotic sacral colpopexy
291914|NCT01535833|Learning curve
291915|NCT01535833|Pelvic Organ Prolapse
291916|NCT01535833|Robotic Surgery
291917|NCT01535820|Healthy volunteers
291918|NCT01535820|ORTHO EVRA
291919|NCT01535820|Contraceptive hormones
291920|NCT01535820|Transdermal patch
291921|NCT01535820|Progestin norelgestromin (NGMN)
291922|NCT01535820|Estrogen ethinyl estradiol (EE)
291923|NCT01535820|JNJ-93964
291924|NCT01535820|JNJ-622206
291925|NCT01535807|Atrial Fibrillation
291926|NCT01535807|Cardiac surgery
291927|NCT01535807|Coronary Artery Bypass Graft
291928|NCT01535807|CorMatrix extra cellular matrix
291929|NCT01535807|Heart surgery
291930|NCT01535807|Inflammatory Biomarkers
291931|NCT01535807|Myocardial Infarction
291932|NCT01535807|identify proteomic inflammatory biomarkers
291933|NCT01535794|HPV vaccine
291934|NCT01535794|acceptability
291935|NCT01535794|males
291936|NCT01535794|men who have sex with men
291937|NCT01535781|pertrochanteric fracture
291938|NCT01535781|tranexamic acid
291939|NCT01535781|postoperative blood loss
291940|NCT01535781|blood loss
291941|NCT01535781|hidden blood loss
291942|NCT01535781|blood transfusions
291943|NCT01535755|noninvasive mechanical ventilation
291944|NCT01535755|ventilator weaning
291945|NCT01535742|laryngeal mask airway
291946|NCT01535742|children
291947|NCT01535742|tracheal intubation
291948|NCT01535742|fiberoptic bronchoscopy
291949|NCT01535690|Laser
291950|NCT01535690|Clinical trial
291951|NCT01535690|Non-surgical periodontal therapy
291952|NCT01535690|Periodontitis
291953|NCT01535690|bleeding on probing and radiographic bone loss
291954|NCT01535690|minimum of 2 teeth with probing depth (PD) ≥ 7 mm and
291955|NCT01535690|2 other teeth with PD ≥ 5 mm
291956|NCT01535690|mininum 16 teeth in both jaws
291957|NCT01535677|Phase 1
291958|NCT01535677|healthy volunteers
291959|NCT01535677|cross-over study
291960|NCT01535677|Bioavailability
291961|NCT01535677|Bioequivalence
291962|NCT01535677|Cmax
291963|NCT01535677|tmax
291964|NCT01535677|AUC
291965|NCT01535677|AUC(0-t)
291966|NCT01535677|λz
291967|NCT01535677|tlast
291968|NCT01535664|Multiple Sclerosis
291969|NCT01535664|MS
291970|NCT01535625|Coronary artery disease
291971|NCT01535625|Atherosclerosis
291972|NCT01535625|CAD
291973|NCT01535599|Acute Otitis Externa
291974|NCT01535586|CPAP
291975|NCT01535586|MAD
291976|NCT01535586|sleep apnea
291977|NCT01535586|PTSD
291978|NCT01535573|Cocaine
291979|NCT01535573|citalopram
291980|NCT01535573|treatment
291981|NCT01535573|serotonin
291982|NCT01535560|Acute otitis externa
291983|NCT01535547|isavuconazole
291984|NCT01535547|tacrolimus
291985|NCT01535547|Healthy Volunteers
291986|NCT01535547|BAL8557
291987|NCT01535534|sepsis
291988|NCT01535534|inflammation
291989|NCT01535534|diagnosis
291990|NCT01535534|prognosis
291991|NCT01535534|survival
291992|NCT01535534|mortality
291993|NCT01535495|beta-antagonist
291994|NCT01535495|propranolol
291995|NCT01535495|diabetic retinopathy
291996|NCT01535495|diabetes
291997|NCT01535495|angiogenesis
291998|NCT01535495|neovascularization
291999|NCT01535482|Cognitive therapy
292000|NCT01535482|Suicide
292001|NCT01535482|Older men
292002|NCT01535482|suicide ideation
292003|NCT01535469|cryptococcal meningitis
292004|NCT01535469|hiv
292005|NCT01535469|aids
292006|NCT01535469|implementation science
292007|NCT01535469|stepped wedge design
292008|NCT01535469|retention-in-care
292009|NCT01535456|MDS
292010|NCT01535456|AML
292011|NCT01535456|5 azacitidine
292012|NCT01535456|FLT PET
292013|NCT01535443|PRO-155
292014|NCT01535443|Ocular NSAIDs
292015|NCT01535443|Safety and tolerability
292016|NCT01535443|Ocular Inflammation
292017|NCT01535443|Ocular Paint
292018|NCT01535430|brain mapping
292019|NCT01535430|brain tumor
292020|NCT01535417|Osteoarthritis
292021|NCT01535391|Chronic Myeloid Leukemia,
292022|NCT01535391|Nilotinib,
292023|NCT01535391|Philadelphia positive,
292024|NCT01535391|BCR-ABL+
292025|NCT01535391|Early chronic phase
292026|NCT01535365|muscular sprain
292027|NCT01535365|acute back pain
292028|NCT01535365|acute neck pain
292029|NCT01535365|heat treatment
292030|NCT01535365|cold treatment
292031|NCT01535339|mild Traumatic Brain Injury
292032|NCT01535339|mTBI
292033|NCT01535339|Concussion
292034|NCT01535326|colonoscopy
292035|NCT01535300|Ultrasound
292036|NCT01535300|Minimal transverse tracheal diameter
292037|NCT01535300|Endotracheal tube size
292038|NCT01535300|Paediatric age-based formulas
292039|NCT01535300|Sonographic measurement of the trachea
292040|NCT01535287|Dexmedetomidine
292041|NCT01535287|Emergence Agitation
292042|NCT01535287|Myringotomy
292043|NCT01535287|Children
292044|NCT01535287|General Anesthesia
292045|NCT01535274|Cerebral oxygenation
292046|NCT01535274|Beach chair position
292047|NCT01535274|General anesthetic technique
292048|NCT01535274|Inspired oxygen fraction
292049|NCT01535274|End tidal carbon dioxide
292050|NCT01535261|Ophthalmology
292051|NCT01535261|Ranibizumab
292052|NCT01535261|Central Retinal Vein Occlusion
292053|NCT01535248|ERCP
292054|NCT01535248|Transthoracic Echocardiography
292055|NCT01535248|Air Embolus
292056|NCT01535248|ERCP associated air embolus
292057|NCT01535235|HIV
292058|NCT01535235|Lymphoid fibrosis
292059|NCT01535222|cardiac surgery
292060|NCT01535222|coronary artery bypass graft
292061|NCT01535222|cardiopulmonary bypass
292062|NCT01535222|haemostasis modulator
292063|NCT01535222|blood loss
292064|NCT01535222|direct inhibitor of plasmin and plasma kallikrein
292065|NCT01535222|CABG
292066|NCT01535222|CPB
292067|NCT01535209|Stereotactic radiotherapy
292068|NCT01535209|Whole-brain radiotherapy
292069|NCT01535209|Resection cavity
292070|NCT01535196|vitamin D
292071|NCT01535196|heart failure
292072|NCT01535183|irinotecan
292073|NCT01535183|brain tumor
292074|NCT01535183|pediatrics
292075|NCT01535183|salvage therapy
292076|NCT01535183|chemotherapy
292077|NCT01535170|lactoferrin
292078|NCT01535170|selective decontamination of digestive tract
292079|NCT01535170|antimicrobial activity
292080|NCT01535170|prolonged mechanical ventilation
292081|NCT01535170|respiratory care center
292082|NCT01535157|Chemotherapy
292083|NCT01535131|otitis media
292084|NCT01535131|cleft palate
292085|NCT01535118|Allergies
292086|NCT01535118|Immunotherapy
292087|NCT01535092|HCV recurrence
292088|NCT01535092|HCV reinfection
292089|NCT01535092|Liver transplantation
292090|NCT01535092|Legalon SIL
292091|NCT01535092|silibinin
292092|NCT01535092|viral load
292093|NCT01535079|sore throat pain
292094|NCT01535079|tonsillopharyngitis
292095|NCT01535079|upper respiratory tract infection
292096|NCT01535066|estrogen receptor-positive breast cancer
292097|NCT01535066|progesterone receptor-positive breast cancer
292098|NCT01535066|stage IA breast cancer
292099|NCT01535066|stage IB breast cancer
292100|NCT01535066|stage II breast cancer
292101|NCT01535066|stage IIIA breast cancer
292102|NCT01535066|stage IIIB breast cancer
292103|NCT01535066|stage IIIC breast cancer
292104|NCT01535066|pain
292105|NCT01535040|cancer survivor
292106|NCT01535040|stage I non-small cell lung cancer
292107|NCT01535040|stage II non-small cell lung cancer
292108|NCT01535040|tobacco use disorder
292109|NCT01535040|stage IA breast cancer
292110|NCT01535040|stage IB breast cancer
292111|NCT01535040|stage II breast cancer
292112|NCT01535040|stage IIIA breast cancer
292113|NCT01535040|stage IIIB breast cancer
292114|NCT01535040|stage IIIC breast cancer
292115|NCT01535040|stage I prostate cancer
292116|NCT01535040|stage IIA prostate cancer
292117|NCT01535040|stage IIB prostate cancer
292118|NCT01535040|stage III prostate cancer
292119|NCT01535040|stage I colon cancer
292120|NCT01535040|stage IIA colon cancer
292121|NCT01535040|stage IIB colon cancer
292122|NCT01535040|stage IIC colon cancer
292123|NCT01535040|stage IIIA colon cancer
292124|NCT01535040|stage IIIB colon cancer
292125|NCT01535040|stage IIIC colon cancer
292126|NCT01535040|stage I rectal cancer
292127|NCT01535040|stage IIA rectal cancer
292128|NCT01535040|stage IIB rectal cancer
292129|NCT01535040|stage IIC rectal cancer
292130|NCT01535040|stage IIIA rectal cancer
292131|NCT01535040|stage IIIB rectal cancer
292132|NCT01535040|stage IIIC rectal cancer
292133|NCT01535027|teriparatide
292134|NCT01535027|alendronate
292135|NCT01535027|raloxifene
292136|NCT01535027|bone mineral density
292137|NCT01535001|Osteoarthritis, Knee
292138|NCT01535001|Treatment Outcome
292139|NCT01535001|Time Factors
292140|NCT01535001|Rehabilitation
292141|NCT01535001|Combined Modality Therapy
292142|NCT01535001|Middle Aged
292143|NCT01535001|Aged
292144|NCT01535001|Aged, 80 and over
292145|NCT01535001|Male
292146|NCT01535001|Female
292147|NCT01535001|Humans
292148|NCT01535001|Analysis of Variance
292149|NCT01534975|cardiac CT
292150|NCT01534975|enhancement
292151|NCT01534975|contrast
292152|NCT01534975|safety
292153|NCT01534975|image quality
292154|NCT01534962|Atrial Fibrillation
292155|NCT01534962|Ranolazine
292156|NCT01534962|Arrhythmias, Cardiac
292157|NCT01534962|Antiarrhythmic Agents
292158|NCT01534962|Cardiac Electroversion
292159|NCT01534962|Ranexa
292160|NCT01534949|DLBCL, Biosimilar
292161|NCT01534936|schizophrenia
292162|NCT01534936|atypical antipsychotics
292163|NCT01534936|depressive symptoms
292164|NCT01534923|Doctor-Patient Communication
292165|NCT01534923|questionnaire
292166|NCT01534923|survey
292167|NCT01534923|12-017
292168|NCT01534910|garlic
292169|NCT01534910|ct angiography
292170|NCT01534910|atherosclerosis
292171|NCT01534910|carotid IMT
292172|NCT01534897|thyroid cancer
292173|NCT01534897|Tall cell PTC
292174|NCT01534897|Poorly differentiated thyroid carcinoma
292175|NCT01534897|metastatic
292176|NCT01534884|RA, Biosimilar
292177|NCT01534871|Cardiac rehabilitation
292178|NCT01534871|Exercise
292179|NCT01534871|Systemic inflammation
292180|NCT01534871|Cardiovascular disease risk
292181|NCT01534858|polyhexanide, polihexanide, PHMB, Prontosan, burns, wounds
292182|NCT01534832|surgical smoke
292183|NCT01534832|laparoscopic surgery
292184|NCT01534832|impaired vision
292185|NCT01534819|Abdominal aortic aneurysm
292186|NCT01534819|AAA
292187|NCT01534819|Endograft
292188|NCT01534819|interventional treatment of AAA
292189|NCT01534806|Migraine
292190|NCT01534793|Quality assessment
292191|NCT01534793|Benign Prostatic Hyperplasia
292192|NCT01534793|Enucleation of the prostate
292193|NCT01534793|LUMENIS
292194|NCT01534793|Laser
292195|NCT01534793|Learning Curve
292196|NCT01534728|Hepatitis C
292197|NCT01534728|CD8 epitopes
292198|NCT01534702|Acute Myeloid Leukemia
292199|NCT01534702|chemotherapy
292200|NCT01534702|clofarabine
292201|NCT01534676|iron
292202|NCT01534676|transfusion
292203|NCT01534676|red blood cells
292204|NCT01534676|sickle cell disease
292205|NCT01534676|thalassemia
292206|NCT01534676|blood donors
292207|NCT01534663|Heart Failure
292208|NCT01534663|Skeletal Muscle Function
292209|NCT01534663|Metabolism
292210|NCT01534663|Inflammation
292211|NCT01534663|Glutamine
292212|NCT01534663|Fish oil
292213|NCT01534663|Muscle Function
292214|NCT01534650|motion sensors
292215|NCT01534650|tremor
292216|NCT01534650|bradykinesia
292217|NCT01534650|gait
292218|NCT01534650|balance
292219|NCT01534650|dyskinesia
292220|NCT01534624|Induced Pluripotent Stem Cell (iPS) Cell Lines
292221|NCT01534624|Addiction
292222|NCT01534624|Addiction-Associated Human Gene Variants
292223|NCT01534624|Dopamine Transporter
292224|NCT01534598|DNA Methylation
292225|NCT01534598|Advanced Cancer
292226|NCT01534598|Methyltransferase Inhibitor
292227|NCT01534598|Epigenetics
292228|NCT01534598|Gene Re-Expression
292229|NCT01534598|Cancer
292230|NCT01534598|Solid Tumor
292231|NCT01534585|nasopharyngeal carcinoma(NPC)
292232|NCT01534585|Icotinib
292233|NCT01534585|Intensity Modulation Radiation Therapy(IMRT)
292234|NCT01534546|neoadjuvant chemotherapy
292235|NCT01534546|adjuvant chemotherapy
292236|NCT01534546|DFS
292237|NCT01534546|OS
292238|NCT01534546|safety
292239|NCT01534546|resectable locally advanced gastric carcinoma
292240|NCT01534546|potentially resectable locally advanced gastric carcinoma
292241|NCT01534533|early atherosclerosis
292242|NCT01534533|serum lutein
292243|NCT01534533|serum lycopene
292244|NCT01534533|intima-media thickness
292245|NCT01534533|arterial stiffness
292246|NCT01534533|combined effect
292247|NCT01534520|Intrauterine Device
292248|NCT01534520|Pain
292249|NCT01534520|Lidocaine
292250|NCT01534494|alcohol dependence
292251|NCT01534494|psilocybin
292252|NCT01534494|clinical trial
292253|NCT01534494|motivational enhancement therapy
292254|NCT01534481|NICHD Neonatal Research Network
292255|NCT01534481|Extremely Low Birth Weight (ELBW)
292256|NCT01534481|Prematurity
292257|NCT01534481|Neurodevelopmental Impairment
292258|NCT01534481|Donor Breast Milk
292259|NCT01534481|Preterm Formula
292260|NCT01534455|German Breast Group
292261|NCT01534455|GBG Forschungs GmbH
292262|NCT01534455|GBG
292263|NCT01534455|GBG 64
292264|NCT01534455|E-VITA
292265|NCT01534455|Breast Cancer
292266|NCT01534455|Metastatic Breast Cancer
292267|NCT01534455|Eribulin
292268|NCT01534455|Lapatinib
292269|NCT01534455|Halaven
292270|NCT01534455|Tyverb
292271|NCT01534429|pain
292272|NCT01534416|Paracervical Block
292273|NCT01534416|Laparoscopic Surgery
292274|NCT01534416|Postoperative Pain
292275|NCT01534416|Bupivacaine
292276|NCT01534416|Hysterectomy
292277|NCT01534416|Myomectomy
292278|NCT01534416|Randomized Trial
292279|NCT01534403|Lupus
292280|NCT01534403|Monoclonal antibody
292281|NCT01534403|B-cell immunotherapy
292282|NCT01534403|Epratuzumab
292283|NCT01534390|microparticles
292284|NCT01534390|in-line microfilters
292285|NCT01534390|systemic inflammation
292286|NCT01534390|organ failure
292287|NCT01534390|critical illness
292288|NCT01534390|adult
292289|NCT01534377|Depression
292290|NCT01534377|Adolescents
292291|NCT01534364|acute renal failure
292292|NCT01534364|acute kidney injury
292293|NCT01534364|diet
292294|NCT01534364|caloric restriction
292295|NCT01534364|cardiac surgery
292296|NCT01534364|cardiothoracic surgery
292297|NCT01534338|Sleep
292298|NCT01534338|inflammation
292299|NCT01534338|mindfulness
292300|NCT01534338|meditation
292301|NCT01534338|randomized controlled trial
292302|NCT01534312|Glycopeptides
292303|NCT01534312|Dietary proteins
292304|NCT01534286|Prescription Medical Food
292305|NCT01534286|Theramine
292306|NCT01534286|Knee surgery
292307|NCT01534273|Mild Cognitive Impairment
292308|NCT01534247|Phase I
292309|NCT01534247|drug to drug
292310|NCT01534247|CAZ-AVI
292311|NCT01534247|Healthy volunteer
292312|NCT01534247|pharmacokinetics
292313|NCT01534247|open label
292314|NCT01534247|metronidazole
292315|NCT01534247|safety
292316|NCT01534234|CRT-D device
292317|NCT01534234|Severe HF (NYHA Class III or ambulatory IV)
292318|NCT01534234|stable, optimal drug regimen
292319|NCT01534234|sinus rhythm
292320|NCT01534221|Ischemic Heart Disease
292321|NCT01534182|Relapsing Remitting Multiple Sclerosis (RRMS)
292322|NCT01534182|Fingolimod
292323|NCT01534182|Disease Modifying Therapy (DMT)
292324|NCT01534182|TSQM-9
292325|NCT01534169|Graves' disease
292326|NCT01534169|Dexamethasone
292327|NCT01534169|Function of regulatory T cells
292328|NCT01534169|The proportion of Th1 and Th2 cells
292329|NCT01534130|Chronic Fatigue Syndrome
292330|NCT01534130|Sleep Disorder, Adjustment
292331|NCT01534130|Acupuncture
292332|NCT01534104|fMRI
292333|NCT01534104|DTI
292334|NCT01534104|DSI
292335|NCT01534104|tractography
292336|NCT01534104|neurological/physical testing
292337|NCT01534104|Motor and Language Pathways
292338|NCT01534104|resting state fMRI
292339|NCT01534104|12-008
292340|NCT01534091|overweight
292341|NCT01534091|obese
292342|NCT01534091|children
292343|NCT01534091|exercise
292344|NCT01534091|physical activity
292345|NCT01534091|pedometer
292346|NCT01534078|non-bulky
292347|NCT01534078|limited stage
292348|NCT01534065|Hernia
292349|NCT01534065|Intervertebral Disk Displacement
292350|NCT01534065|Pathological Conditions, Anatomical
292351|NCT01534065|Spinal Diseases
292352|NCT01534065|Bone Diseases
292353|NCT01534065|Musculoskeletal Diseases
292354|NCT01534052|Prostate Cancer
292355|NCT01534052|Castration-Resistant Prostate Cancer (CRPC)
292356|NCT01534052|MDV3100
292357|NCT01534052|Androgen receptor signaling inhibitor
292358|NCT01534013|Closed loop insulin delivery
292359|NCT01534000|Cardiac CT
292360|NCT01534000|Ischemic heat disease
292361|NCT01534000|Stress test
292362|NCT01533987|Male
292363|NCT01533987|Overweight
292364|NCT01533987|Juice Plus
292365|NCT01533961|neglected disease
292366|NCT01533961|africa
292367|NCT01533961|new drug
292368|NCT01533961|oral drug
292369|NCT01533961|parasite
292370|NCT01533896|Obesity prevention
292371|NCT01533896|Primary care
292372|NCT01533896|Education
292373|NCT01533883|Mitral
292374|NCT01533883|Valve
292375|NCT01533883|Annuloplasty
292376|NCT01533883|Transatrial
292377|NCT01533883|Transapical
292378|NCT01533883|Transfemoral
292379|NCT01533883|Mitral valve insufficiency
292380|NCT01533870|Phase 1
292381|NCT01533870|Healthy male and female volunteers
292382|NCT01533870|Drug-drug interaction
292383|NCT01533870|Pharmacokinetics
292384|NCT01533870|NKTR-118
292385|NCT01533870|Bioavailability
292386|NCT01533870|Plasma AUC and Cmax
292387|NCT01533870|Plasma AUC0-t and t1/2λz and tmax
292388|NCT01533857|Black tea
292389|NCT01533857|phenolic acids
292390|NCT01533844|CDAD
292391|NCT01533844|Neonates
292392|NCT01533844|Clostridium difficile
292393|NCT01533818|Fast breathing
292394|NCT01533818|Young infants
292395|NCT01533818|Management
292396|NCT01533818|Amoxicillin
292397|NCT01533818|Placebo
292398|NCT01533805|Lumbago
292399|NCT01533805|Exercise therapy
292400|NCT01533805|Spine
292401|NCT01533792|Treatment
292402|NCT01533792|pregnant women
292403|NCT01533792|periodontitis
292404|NCT01533792|dental scaling
292405|NCT01533792|dental plaque
292406|NCT01533779|children
292407|NCT01533779|malignancy
292408|NCT01533779|neutrophil
292409|NCT01533779|neutrophil extracellular traps
292410|NCT01533779|superoxide production
292411|NCT01533779|hydrogen peroxide production
292412|NCT01533779|chemotaxis
292413|NCT01533779|myeloperoxidase
292414|NCT01533779|immunosurveillance
292415|NCT01533779|cancer cell lines
292416|NCT01533753|hot flashes
292417|NCT01533753|prostate cancer
292418|NCT01533727|Cytokine-Induced Killer Cell
292419|NCT01533727|NSCLC
292420|NCT01533727|adjuvant therapy
292421|NCT01533714|Rheumatoid Arthritis
292422|NCT01533714|Monoclonal antibody
292423|NCT01533714|Interleukin-6
292424|NCT01533714|Olokizumab
292425|NCT01533714|CDP6038
292426|NCT01533701|Hypoxia
292427|NCT01533701|Fetal blood sampling
292428|NCT01533701|Lactate
292429|NCT01533701|pH
292430|NCT01533701|base deficit
292431|NCT01533701|angiogenic factors
292432|NCT01533701|suspected fetal hypoxia
292433|NCT01533675|suture, tensile strength, wound care, saline, hydrogen peroxide, skin closure, wounds, wound healing, wound cleansing, antiseptics
292434|NCT01533662|phenylephrine
292435|NCT01533662|hypotension
292436|NCT01533662|spinal anesthesia
292437|NCT01533662|lower limb orthopedic surgery
292438|NCT01533649|Behavioral intervention
292439|NCT01533649|Seizure self-efficacy
292440|NCT01533649|Psychosocial outcomes
292441|NCT01533649|Quality of Life in Epilepsy
292442|NCT01533636|Cystic Fibrosis, Healthy
292443|NCT01533610|Post-Traumatic Stress disorder
292444|NCT01533610|Stellate ganglion
292445|NCT01533610|cervical plexus
292446|NCT01533610|local anesthesia
292447|NCT01533610|anxiety
292448|NCT01533597|Overactive bladder
292449|NCT01533597|Solifenacin succinate
292450|NCT01533597|Tamsulosin
292451|NCT01533571|Guided Bone Regeneration
292452|NCT01533571|Dental Implant
292453|NCT01533571|Alveolar Ridge Augmentation
292454|NCT01533571|Socket graft
292455|NCT01533558|caspofungin
292456|NCT01533558|pharmacokinetics
292457|NCT01533558|invasive fungal infection
292458|NCT01533558|candidiasis
292459|NCT01533558|aspergillosis
292460|NCT01533558|intensive care
292461|NCT01533545|Mepivacaine
292462|NCT01533545|Epinephrine
292463|NCT01533545|Brachial plexus block
292464|NCT01533545|Renal insufficiency
292465|NCT01533532|Gonadotropin-Releasing Hormone (GnRH) antagonist
292466|NCT01533519|Neuropeptide Y
292467|NCT01533519|Intranasal Administration
292468|NCT01533519|PTSD
292469|NCT01533519|Trauma
292470|NCT01533506|treatment with stiripentol
292471|NCT01533493|ADHD
292472|NCT01533493|Executive Function
292473|NCT01533493|Namenda
292474|NCT01533493|Concerta
292475|NCT01533480|Adenovirus
292476|NCT01533480|Conjunctivitis
292477|NCT01533480|keratoconjunctivitis
292478|NCT01533480|viral shedding
292479|NCT01533480|subepithelial infiltrate
292480|NCT01533480|bulbar injection
292481|NCT01533467|Delivery rupture
292482|NCT01533467|perineal protection device
292483|NCT01533467|reduce perineal tears
292484|NCT01533454|Obesity
292485|NCT01533454|Weight loss
292486|NCT01533454|Incentives
292487|NCT01533454|Motivation
292488|NCT01533441|anticoagulant therapy
292489|NCT01533441|INR
292490|NCT01533441|vitamin K2
292491|NCT01533441|vitamin K antagonist
292492|NCT01533428|Painful Diabetic Peripheral Neuropathy,
292493|NCT01533428|Capsaicin 8% transdermal delivery system
292494|NCT01533415|Anxiety
292495|NCT01533415|Anxiety Disorders
292496|NCT01533402|Cognitive behavior therapy
292497|NCT01533402|Internet
292498|NCT01533402|Anxiety disorders
292499|NCT01533402|Children
292500|NCT01533376|Sturge Weber
292501|NCT01533376|SWS
292502|NCT01533376|Timolol
292503|NCT01533376|Port wine mark
292504|NCT01533363|Hemorrhoids
292505|NCT01533363|Surgery
292506|NCT01533363|Hemorrhoidopexy
292507|NCT01533363|Milligan Morgan
292508|NCT01533350|Ultrasonography
292509|NCT01533350|late follicle phase
292510|NCT01533350|homogeneous endometrium
292511|NCT01533350|receptivity
292512|NCT01533350|biochemical factor
292513|NCT01533350|ultrastructure
292514|NCT01533350|endometrial echo pattern
292515|NCT01533337|dorsal digital free flap
292516|NCT01533337|dorsal branch of proper digital nerve
292517|NCT01533337|dorsal branch of proper digital artery
292518|NCT01533337|proper digital artery
292519|NCT01533324|hepatocellular carcinoma
292520|NCT01533324|S-1
292521|NCT01533324|Leucovorin
292522|NCT01533324|fluorouracil
292523|NCT01533311|nonpolypoid colorectal neoplasms(NP-CRN)
292524|NCT01533311|prevalence
292525|NCT01533311|histology
292526|NCT01533285|Major depressive disorder
292527|NCT01533285|MDD
292528|NCT01533285|Psychiatry disorders
292529|NCT01533285|Psychosocial stressor
292530|NCT01533285|Psychosocial stress
292531|NCT01533285|Typhoid vaccination
292532|NCT01533285|Typhoid vaccine
292533|NCT01533272|HIV infection
292534|NCT01533272|Postexposure prophylaxis
292535|NCT01533259|HIV-1
292536|NCT01533259|HIV
292537|NCT01533259|Treatment Experienced
292538|NCT01533233|thoracoscopy
292539|NCT01533233|lung cancer
292540|NCT01533233|lobectomy
292541|NCT01533233|epidural anesthesia
292542|NCT01533220|nasal and nasopharyngeal congestion
292543|NCT01533168|childhood acute lymphoblastic leukemia in remission
292544|NCT01533168|recurrent childhood acute lymphoblastic leukemia
292545|NCT01533168|B-cell childhood acute lymphoblastic leukemia
292546|NCT01533155|Phase 1
292547|NCT01533155|Healthy male and female volunteers
292548|NCT01533155|Drug-drug interaction
292549|NCT01533155|Pharmacokinetics
292550|NCT01533155|NKTR-118
292551|NCT01533142|lipids
292552|NCT01533129|Hypogonadism
292553|NCT01533129|Endothelial dysfunction
292554|NCT01533129|Inflammation
292555|NCT01533129|Insulin resistance
292556|NCT01533129|Testosterone replacement therapy
292557|NCT01533116|Parkinson Disease
292558|NCT01533116|BIA 9-1067
292559|NCT01533077|Parkinson Disease
292560|NCT01533077|BIA 9-1067
292561|NCT01533051|Chronic hepatitis B
292562|NCT01533051|Nucleos(t)ide analogue
292563|NCT01533051|Antiviral treatment
292564|NCT01533051|Korea
292565|NCT01533025|anterior cruciate ligament
292566|NCT01533025|Achilles
292567|NCT01533025|free tendon
292568|NCT01533025|bone-tendon
292569|NCT01533025|free tendon Achilles allograft
292570|NCT01533025|Achilles allograft with calcaneal bone block on its end
292571|NCT01532999|Posttraumatic Stress Disorder
292572|NCT01532999|Meditation
292573|NCT01532999|Present Centered Group Therapy
292574|NCT01532999|mindfulness
292575|NCT01532999|MBSR
292576|NCT01532999|complementary alternative medicine
292577|NCT01532986|Quality of Health Care
292578|NCT01532986|Nursing Care Management
292579|NCT01532986|Care Coordination
292580|NCT01532986|Randomized Trials
292581|NCT01532960|breast cancer
292582|NCT01532960|peptide vaccine
292583|NCT01532960|immunotherapy
292584|NCT01532934|substance use
292585|NCT01532934|psychopathy
292586|NCT01532934|motivational enhancement
292587|NCT01532934|criminal recidivism
292588|NCT01532908|Liver Transplantation
292589|NCT01532895|Pain
292590|NCT01532895|Cancer pain
292591|NCT01532895|Hydromorphone
292592|NCT01532895|Hydromorphone OROS
292593|NCT01532895|Narcotic analgesics
292594|NCT01532895|Opioid-naive
292595|NCT01532856|multiple myeloma
292596|NCT01532856|thalidomide
292597|NCT01532856|comparative
292598|NCT01532856|elderly
292599|NCT01532843|Hepatitis B
292600|NCT01532843|sustained response
292601|NCT01532843|peginterferon
292602|NCT01532843|nucleos(t)ide analogues
292603|NCT01532830|vagus nerve stimulation
292604|NCT01532830|vagal nerve stimulation
292605|NCT01532830|nVNS
292606|NCT01532830|VNS
292607|NCT01532830|migraine
292608|NCT01532830|non invasive
292609|NCT01532830|gammacore
292610|NCT01532804|Unresectable metastases
292611|NCT01532791|MELAS
292612|NCT01532791|mitochondrial DNA mutation
292613|NCT01532791|mtDNA mutation
292614|NCT01532791|mitochondrial DNA
292615|NCT01532791|mitochondria
292616|NCT01532791|m.3243A>G mutation
292617|NCT01532765|Internal limiting membrane
292618|NCT01532765|Indocyanine green dye
292619|NCT01531933|Prediabetic
292620|NCT01531933|Primary prevention
292621|NCT01531933|Type 2 diabetes mellitus
292622|NCT01531907|GLP2
292623|NCT01531907|Obesity
292624|NCT01531907|Premenopausal
292625|NCT01531907|Bone
292626|NCT01531907|Formation
292627|NCT01531907|Resorption
292628|NCT01531894|solid tumor
292629|NCT01531894|GSK2110183
292630|NCT01531894|hematologic malignancy
292631|NCT01531894|AKT inhibitor
292632|NCT01531894|cancer
292633|NCT01531894|safety
292634|NCT01531868|Decision making
292635|NCT01531868|Carotid stenosis
292636|NCT01531855|T1DM, Exercise
292637|NCT01531842|Conjunctival bacterial flora
292638|NCT01531842|prophylactic topical antibiotic
292639|NCT01531842|injection
292640|NCT01531842|intravitreal injection
292641|NCT01531842|bacterial resistance
292642|NCT01531842|serial injection
292643|NCT01531842|serial intravitreal injections
292644|NCT01531842|CNV
292645|NCT01531842|CRVO
292646|NCT01531842|AMD
292647|NCT01531842|BRVO
292648|NCT01531829|pulmonary embolism
292649|NCT01531829|right ventricular dysfunction
292650|NCT01531829|Thrombolysis
292651|NCT01531829|Heparin
292652|NCT01531816|Pediatrics,
292653|NCT01531816|Critically ill Children
292654|NCT01531816|immobility
292655|NCT01531790|Endostar
292656|NCT01531790|Carboplatin
292657|NCT01531790|Pemetrexed
292658|NCT01531790|NSCLC
292659|NCT01531790|Phase I
292660|NCT01531777|Advanced Colorectal Cancer
292661|NCT01531764|Metastatic breast cancer
292662|NCT01531764|intermediate HER2 expression
292663|NCT01531764|Afatinib
292664|NCT01531751|HCO-HD
292665|NCT01531751|survival
292666|NCT01531751|cardiac biomarkers
292667|NCT01531751|AL amyloidosis
292668|NCT01531751|Light Chain Amyloidosis
292669|NCT01532739|Mild Cognitive Impairment
292670|NCT01532739|Aging
292671|NCT01532739|Memory
292672|NCT01532739|Executive Function
292673|NCT01532739|Cognitive Intervention
292674|NCT01532739|Memory Training
292675|NCT01532739|Mental Health
292676|NCT01532726|Partial-Onset Seizures
292677|NCT01532726|Eslicarbazepine Acetate
292678|NCT01532726|ESL
292679|NCT01532726|BIA 2-093
292680|NCT01532726|BIAL
292681|NCT01532661|TRAUMA
292682|NCT01532661|HAEMORRHAGIC
292683|NCT01532661|rVIIa
292684|NCT01532661|Complication of Trauma hemorrhage
292685|NCT01532661|bleeding
292686|NCT01532661|rFVIIa administration for hemorrhage after trauma
292687|NCT01532648|Ulcerative Colitis
292688|NCT01532635|hematologic malignancy
292689|NCT01532635|leukemia
292690|NCT01532635|Acute lymphoblastic leukemia
292691|NCT01532635|ALL
292692|NCT01532635|Acute myelogenous leukemia
292693|NCT01532635|AML
292694|NCT01532635|Chronic lymphocytic leukemia
292695|NCT01532635|CLL
292696|NCT01532635|lymphoma
292697|NCT01532635|hodgkin's lymphoma
292698|NCT01532635|non-hodgkin's lymphoma
292699|NCT01532635|myeloma
292700|NCT01532635|allogeneic stem cell transplant
292701|NCT01532635|TJU 2-step
292702|NCT01532635|Hematopoietic stem cell transplant
292703|NCT01532635|HSCT
292704|NCT01532635|bone marrow transplant
292705|NCT01532635|Cyclophosphamide
292706|NCT01532635|MMF
292707|NCT01532635|Mycophenolate Mofetil
292708|NCT01532622|Blueberry
292709|NCT01532609|Methadone maintenance therapy
292710|NCT01532609|Behavioral intervention
292711|NCT01532609|Service provider
292712|NCT01532609|Drug use
292713|NCT01532570|Behcet's disease
292714|NCT01532570|intestinal Behcet's disease
292715|NCT01532570|neuro-Behcet's disease
292716|NCT01532570|vascular Behcet's disease
292717|NCT01532544|Severe pneumonia
292718|NCT01532531|Collateral Meridian Therapy
292719|NCT01532531|Knee Osteoarthritis
292720|NCT01532518|Feeding intolerance
292721|NCT01532518|Infant
292722|NCT01532518|tachykinin antagonist
292723|NCT01532518|Infant colic
292724|NCT01532518|Nepadutant
292725|NCT01532505|cardiopulmonary bypass
292726|NCT01532505|Postcardiotomy vasodilatory shock
292727|NCT01532505|Microcirculation
292728|NCT01532505|Catecholamines
292729|NCT01532505|Vasopressin
292730|NCT01532492|Questionnaire
292731|NCT01532492|WORC
292732|NCT01532492|Rotator cuff
292733|NCT01532492|Reliability
292734|NCT01532492|Validity
292735|NCT01532492|Responsiveness
292736|NCT01532479|Osteoradionecrosis
292737|NCT01532479|Xerostomia
292738|NCT01532466|fentanyl-induced coughing, rocuronium
292739|NCT01532401|Blood pressure
292740|NCT01532388|Randomized Controlled Trial
292741|NCT01532388|Alcohol
292742|NCT01532388|Drugs
292743|NCT01532388|Internet
292744|NCT01532388|Screening
292745|NCT01532388|Brief intervention
292746|NCT01532375|Kochujang,
292747|NCT01532375|visceral fat
292748|NCT01532375|population
292749|NCT01532349|chronic kidney disease
292750|NCT01532349|anemia
292751|NCT01532336|adenovirus
292752|NCT01532336|conjunctivitis
292753|NCT01532336|pinkeye
292754|NCT01532323|Oral disorders
292755|NCT01532310|systemic lupus erythematosus
292756|NCT01532310|belimumab
292757|NCT01532310|pregnancy
292758|NCT01532297|citrate dialysate
292759|NCT01532297|dialysis
292760|NCT01532297|calcium
292761|NCT01532284|aneuploid oocytes
292762|NCT01532284|ICSI
292763|NCT01532284|IVF
292764|NCT01532284|Polar Body Biopsy
292765|NCT01532271|mild Traumatic Brain Injury
292766|NCT01532271|mTBI
292767|NCT01532271|Concussion
292768|NCT01532258|BMI
292769|NCT01532258|Weight loss
292770|NCT01532258|Nutrition
292771|NCT01532258|Diet
292772|NCT01532258|Mediterranean diet
292773|NCT01532258|Online program
292774|NCT01532258|web-based program
292775|NCT01532258|Oxidative stress
292776|NCT01532258|F2 isoprostanes
292777|NCT01532232|PLACEBO
292778|NCT01532232|VARENICLINE (CHANTIX)
292779|NCT01532232|Self-reported cigarettes smokers
292780|NCT01532232|Smoking Cessation
292781|NCT01532232|11-136
292782|NCT01532206|Remote ischemic preconditioning
292783|NCT01532206|inflammation
292784|NCT01532180|Obstructive sleep apnea, neurostimulation, hypoglossal nerve
292785|NCT01532141|Parkinson Disease
292786|NCT01532141|BIA 9-1067
292787|NCT01532128|Parkinson Disease
292788|NCT01532128|BIA 9-1067
292789|NCT01532115|Parkinson Disease
292790|NCT01532115|BIA 9-1067
292791|NCT01532102|Genital warts
292792|NCT01532102|Anogenital warts
292793|NCT01532102|HPV
292794|NCT01532102|Human papillomavirus
292795|NCT01532102|Antiviral
292796|NCT01532076|osteoporosis
292797|NCT01532076|prox. humeral fracture
292798|NCT01532076|geriatric trauma
292799|NCT01532076|mesenchymal stem cells
292800|NCT01532063|Difficult intubation
292801|NCT01532063|Intensive care units
292802|NCT01532063|Risk factors
292803|NCT01532063|Incidence
292804|NCT01532063|Complications
292805|NCT01532063|Intubation in Intensive Care Unit
292806|NCT01532063|More than 2 attempts of intubation
292807|NCT01532063|Intubation attempts lasting more than 10 minutes
292808|NCT01532050|OSAS
292809|NCT01532050|American Academy of Sleep Medicine Task Force
292810|NCT01532037|Randomised controlled trial
292811|NCT01532037|Multiple Sclerosis
292812|NCT01532037|Fatigue
292813|NCT01532037|Cognitive Behavioural Therapy
292814|NCT01532037|Self Help
292815|NCT01532024|Optical Imaging
292816|NCT01532024|Neutrophil
292817|NCT01532024|Elastase
292818|NCT01532024|Molecular Imaging
292819|NCT01532024|Acute Lung Injury
292820|NCT01532024|ARDS
292821|NCT01532011|Advanced Cancers
292822|NCT01532011|Solid Tumors
292823|NCT01532011|Erlotinib
292824|NCT01532011|Erlotinib Hydrochloride
292825|NCT01532011|OSI-774
292826|NCT01532011|Tarceva
292827|NCT01532011|Pralatrexate
292828|NCT01532011|Folotyn
292829|NCT01532011|PDX-010
292830|NCT01531998|Myeloma
292831|NCT01531998|Multiple Myeloma
292832|NCT01531998|MM
292833|NCT01531998|Newly diagnosed
292834|NCT01531998|Lenalidomide
292835|NCT01531998|CC-5013
292836|NCT01531998|Revlimid
292837|NCT01531998|Bortezomib
292838|NCT01531998|Velcade
292839|NCT01531998|LDP-341
292840|NCT01531998|MLN341
292841|NCT01531998|PS-341
292842|NCT01531998|Siltuximab
292843|NCT01531998|CNTO 328
292844|NCT01531998|Anti-IL-6 Antibody
292845|NCT01531998|Dexamethasone
292846|NCT01531998|Decadron
292847|NCT01531998|M. D. Anderson Symptom Inventory Module
292848|NCT01531998|MDASI-MM
292849|NCT01531998|Questionnaires
292850|NCT01531998|Surveys
292851|NCT01531985|Congenital Heart Disease
292852|NCT01531985|Acute Kidney Injury
292853|NCT01531985|Cardiopulmonary Bypass
292854|NCT01531985|Biomarkers
292855|NCT01531972|Single-photon Emission Computed Tomography
292856|NCT01531972|Healthy Volunteers
292857|NCT01531972|Tomography
292858|NCT01531959|Midodrine
292859|NCT01531959|Hypotension
292860|NCT01531959|Intensive care unit
292861|NCT01531959|IV vasopressors
292862|NCT01531959|ICU discharge
292863|NCT01531946|Diffusion Tensor Imaging
292864|NCT01531738|Taste
292865|NCT01531738|bariatric surgery
292866|NCT01531738|food preferences
292867|NCT01531738|reward
292868|NCT01531738|progressive ratio task
292869|NCT01531725|Stents
292870|NCT01531712|neoadjuvant treatment
292871|NCT01531712|borderline resectability
292872|NCT01531686|intraosseous vascular access
292873|NCT01531686|CT examination
292874|NCT01531634|Borderline Personality Disorder
292875|NCT01531634|Women
292876|NCT01531634|Dynamic Cognitive Intervention
292877|NCT01531634|Recovery
292878|NCT01531634|Hope Scale
292879|NCT01531621|metastatic colorectal cancer
292880|NCT01531608|melanoma
292881|NCT01531608|imaging
292882|NCT01531608|sentinel node
292883|NCT01531608|biopsy
292884|NCT01531595|metastatic colorectal cancer
292885|NCT01531582|Angelman
292886|NCT01531582|Minocycline
292887|NCT01531582|cognitive
292888|NCT01531582|children
292889|NCT01531582|tetracycline
292890|NCT01531569|Flaxseed
292891|NCT01531569|Lignans
292892|NCT01531569|Pharmacokinetics
292893|NCT01531543|Vacuum Assisted Closure (VAC)
292894|NCT01531543|Laparostomy
292895|NCT01531543|Severe peritonitis
292896|NCT01531530|Shigella
292897|NCT01531530|Vaccine
292898|NCT01531530|Mucosal immunity
292899|NCT01531517|Pedyphar
292900|NCT01531517|Ointment
292901|NCT01531517|Healing
292902|NCT01531517|Diabetic
292903|NCT01531517|Foot Ulcer
292904|NCT01531504|hysterectomies
292905|NCT01531504|uterine manipulator
292906|NCT01531491|Emergence
292907|NCT01531491|Hypercapnia
292908|NCT01531491|Hypocapnia
292909|NCT01531491|Propofol
292910|NCT01531478|Childhood cancer
292911|NCT01531478|Cancer
292912|NCT01531478|Sequels
292913|NCT01531478|Complications
292914|NCT01531478|Chemotherapy
292915|NCT01531478|Radiotherapy
292916|NCT01531478|Surgery
292917|NCT01531465|Respiratory insufficiency
292918|NCT01531465|Infants
292919|NCT01531465|High Flow Nasal Cannula (HFNC)
292920|NCT01531465|Nasal Continuous Positive Airway Pressure (NCPAP)
292921|NCT01531452|Stomach Neoplasms
292922|NCT01531452|drug therapy
292923|NCT01531452|oxaliplatin
292924|NCT01531452|s1
292925|NCT01531439|Narcotic Antagonists
292926|NCT01531439|Naloxone infusion
292927|NCT01531439|Postoperative pruritis
292928|NCT01531439|Patient controlled analgesia
292929|NCT01531439|Pediatric
292930|NCT01531439|Children
292931|NCT01531426|resuscitation
292932|NCT01531426|hypothermia
292933|NCT01531426|outcome
292934|NCT01531387|Phase III
292935|NCT01531387|Sickle cell anemia
292936|NCT01531387|Conditional transcranial doppler velocities
292937|NCT01531387|Reduce risk of conversion to abnormally high transcranial doppler velocities
292938|NCT01531387|Pediatric patients
292939|NCT01531374|Valvular Heart Disease
292940|NCT01531374|Critical Aortic Stenosis
292941|NCT01531374|Severe Aortic Stenosis
292942|NCT01531374|Extreme Risk
292943|NCT01531374|High Risk
292944|NCT01531374|Aortic Valve Replacement
292945|NCT01531361|Advanced Cancers
292946|NCT01531361|Advanced Malignancies
292947|NCT01531361|Metastatic cancers
292948|NCT01531361|Vemurafenib
292949|NCT01531361|PLX4032
292950|NCT01531361|R05185426
292951|NCT01531361|Sorafenib
292952|NCT01531361|Nexavar
292953|NCT01531361|Bay 43-9006
292954|NCT01531361|Crizotinib
292955|NCT01531361|PF-02341066
292956|NCT01531361|Xalkori
292957|NCT01531361|Maximum tolerated dose
292958|NCT01531361|MTD
292959|NCT01531361|Dose limiting toxicity
292960|NCT01531361|DLT
292961|NCT01531348|Retinitis pigmentosa
292962|NCT01531348|Bone marrow-derived mesenchymal stem cells
292963|NCT01531348|Intravitreal injection
292964|NCT01531335|adults
292965|NCT01531322|13vPnC
292966|NCT01531322|Healthy subjects
292967|NCT01531322|China
292968|NCT01531309|Liver impairment
292969|NCT01531309|Major Depression Disorder
292970|NCT01531309|Sublingual tablet
292971|NCT01531296|MRI
292972|NCT01531296|Lower Extremity Rotational
292973|NCT01531296|Femoral Version
292974|NCT01531296|Tibial Torsion
292975|NCT01531283|unacylated ghrelin
292976|NCT01531283|beta cell function
292977|NCT01531231|heart disease
292978|NCT01531231|unstable angina
292979|NCT01531231|myocardial infarction
292980|NCT01531231|behavioral
292981|NCT01531231|cardiovascular
292982|NCT01531231|emotions
292983|NCT01531218|Campylobacter
292984|NCT01531218|concisus
292985|NCT01531218|diarrhea
292986|NCT01531218|fever
292987|NCT01531218|abdominal pain
292988|NCT01531218|vomiting
292989|NCT01531205|recurrent
292990|NCT01531205|high risk
292991|NCT01531192|Lactobacillus reuteri
292992|NCT01531192|Nystatin
292993|NCT01531192|Very Low Birth Weight Infants
292994|NCT01531192|Candida Colonization
292995|NCT01531166|Chronic hepatitis B
292996|NCT01531166|pegylated Interferon-alpha 2a
292997|NCT01531166|Korean
292998|NCT01531153|Cocaine use decreases, increases or stays the same
292999|NCT01531140|colonoscopy cleansing
293000|NCT01531140|PEG
293001|NCT01531140|sennosides
293002|NCT01531140|children
293003|NCT01531114|Diabetes mellitus
293004|NCT01531114|antiplatelet effect
293005|NCT01531114|prasugrel
293006|NCT01531114|ticagrelor
293007|NCT01531114|STEMI
293008|NCT01531114|Insulin
293009|NCT01531101|Transference work
293010|NCT01531101|Psychodynamic
293011|NCT01531101|Depression
293012|NCT01531101|Treatment
293013|NCT01531101|Adolescent
293014|NCT01531088|Nursing Home
293015|NCT01531075|HBV, Inflammatory bowel disease, immunosuppressor
293016|NCT01531062|nigella sativa
293017|NCT01531062|dyslipidemia
293018|NCT01531062|elderly
293019|NCT01531049|smoking cessation
293020|NCT01531049|young adults
293021|NCT01531049|motivational counselling
293022|NCT01531049|smoking
293023|NCT01531049|nicotine replacement therapy
293024|NCT01531049|therapy
293025|NCT01531023|Extended-Spectrum Beta-lactamase Producing Bacteria
293026|NCT01531010|Neonate
293027|NCT01531010|Premature
293028|NCT01531010|Pressure limited ventilation
293029|NCT01531010|Volume ventilation
293030|NCT01530997|Human Papilloma Virus
293031|NCT01530997|Oropharynx
293032|NCT01530997|Oropharyngeal Squamous Cell Carcinoma
293033|NCT01530997|Squamous Cell Carcinoma
293034|NCT01530997|Radiation Therapy
293035|NCT01530997|Chemotherapy
293036|NCT01530997|p16
293037|NCT01530984|prostate cancer
293038|NCT01530984|metastatic castrate resistant prostate cancer
293039|NCT01530984|Chemotherapy-naïve patients
293040|NCT01530984|Anti-CTLA4 blockade
293041|NCT01530984|systemic GM-CSF
293042|NCT01530984|Ipilimumab
293043|NCT01530971|oxygen
293044|NCT01530971|pregnancy
293045|NCT01530971|caesarean section
293046|NCT01530971|anesthetic techniques
293047|NCT01530958|CKD
293048|NCT01530958|Automated Telephone Self Management
293049|NCT01530958|Registry
293050|NCT01530958|CKD awareness
293051|NCT01530958|Self efficacy
293052|NCT01530932|sepsis
293053|NCT01530932|tissue oxygenation
293054|NCT01530932|tissue perfusion
293055|NCT01530932|immune reaction
293056|NCT01530906|Eating disorders
293057|NCT01530906|Bulimia
293058|NCT01530906|rTMS
293059|NCT01530906|Treatment
293060|NCT01530893|flavonoids
293061|NCT01530893|vascular function
293062|NCT01530893|randomised controlled trial
293063|NCT01530893|placebo controlled
293064|NCT01530880|Fever reduction
293065|NCT01530880|Fever burden
293066|NCT01530880|intravenous ibuprofen
293067|NCT01530867|Dietary Supplements
293068|NCT01530867|Physician-patient communication
293069|NCT01530867|Qualitative study
293070|NCT01530867|Audio recorded office visits
293071|NCT01530854|sepsis
293072|NCT01530854|free fatty acids
293073|NCT01530854|emergency department
293074|NCT01530841|Myotonic dystrophy type 1
293075|NCT01530841|Home ventilation
293076|NCT01530841|Respiratory insufficiency
293077|NCT01530841|Neuromuscular
293078|NCT01530828|Immunoreactive Trypsinogen
293079|NCT01530828|Nectrotizing Enterocolitis
293080|NCT01530828|Premature Infants
293081|NCT01530828|Serial IRT
293082|NCT01530802|laparoscopic myomectomy, leiomyoma, blood loss, uterine artery
293083|NCT01530789|Telemedecine
293084|NCT01530789|Telemedecine nurse
293085|NCT01530789|Delegation of tasks
293086|NCT01530789|Type 1 diabetes
293087|NCT01530776|Pregnancy
293088|NCT01530776|Postpartum
293089|NCT01530776|Weight Retention
293090|NCT01530776|Behavioral
293091|NCT01530776|Electronically-mediated
293092|NCT01530763|Infections
293093|NCT01530763|Pediatrics
293094|NCT01530763|Teflaro
293095|NCT01530763|cephalosporin
293096|NCT01530750|postoperative atrial fibrillation
293097|NCT01530750|internal loop recorder
293098|NCT01530750|risk factors
293099|NCT01530750|coronary artery bypass surgery
293100|NCT01530737|pediatric
293101|NCT01530737|Antithrombin
293102|NCT01530737|anticoagulation efficiency
293103|NCT01530737|cardiac surgery
293104|NCT01530724|abdominal obesity
293105|NCT01530698|dendritic cell vaccination
293106|NCT01530698|melanoma
293107|NCT01530698|toll like receptor ligands
293108|NCT01530698|mRNA electroporation
293109|NCT01530698|vaccines
293110|NCT01530685|cinnamon
293111|NCT01530685|chromium
293112|NCT01530685|prediabete
293113|NCT01530685|overweight
293114|NCT01530672|HIV
293115|NCT01530672|Syphilis
293116|NCT01530672|Combination
293117|NCT01530672|POC
293118|NCT01530672|point-of-care
293119|NCT01530672|MBIO
293120|NCT01530659|Retinitis pigmentosa
293121|NCT01530659|Usher syndrome type 2
293122|NCT01530659|Usher syndrome type 3
293123|NCT01530659|Cone photoreceptor
293124|NCT01530659|Vision
293125|NCT01530659|Blind
293126|NCT01530646|obesity
293127|NCT01530646|overweight
293128|NCT01530646|muscle
293129|NCT01530646|protein
293130|NCT01530646|muscle protein synthesis
293131|NCT01530646|muscle protein breakdown
293132|NCT01530646|whey
293133|NCT01530646|soy
293134|NCT01530646|caloric restriction
293135|NCT01530620|Antimuscarinics
293136|NCT01530620|Neurogenic bladder
293137|NCT01530620|Propiverine
293138|NCT01530620|Urodynamics
293139|NCT01530607|Early Stage Breast Cancer
293140|NCT01530607|Reduce Ovarian Failure Following Chemotherapy
293141|NCT01530594|Untreated
293142|NCT01530594|Without intent for immediate autologous stem cell transplant
293143|NCT01530568|Intensive care, TB, tracheal aspirates, Gene Xpert
293144|NCT01530542|bioavailability
293145|NCT01530542|food effect
293146|NCT01530542|oxycodone
293147|NCT01530542|management of acute and chronic moderate to severe pain
293148|NCT01530529|PF-05180999
293149|NCT01530529|safety
293150|NCT01530529|pharmacokinetics
293151|NCT01530529|relative bioavailability
293152|NCT01530529|Mental Disorders
293153|NCT01530529|Schizophrenia and Disorders with Psychotic Features
293154|NCT01530529|Schizophrenia
293155|NCT01530516|Malocclusion, Angle Class II
293156|NCT01530503|biliary tract cancer
293157|NCT01530503|advanced disease
293158|NCT01530503|chemotherapy
293159|NCT01530490|IVF
293160|NCT01530490|ovarian hyperstimulation syndrome
293161|NCT01530490|cabergoline
293162|NCT01530490|hydroxyethyl starch
293163|NCT01530490|prevention
293164|NCT01530477|Bone mineral density
293165|NCT01530477|weight
293166|NCT01530477|body composition
293167|NCT01530477|DEXA
293168|NCT01530477|DXA
293169|NCT01530464|High altitude induced fatigue
293170|NCT01530464|High altitude induced pulmonary Hypertension
293171|NCT01530451|Nocturia
293172|NCT01530451|Obstructive sleep Apnoea
293173|NCT01530451|Desmopressin
293174|NCT01530438|Amyotrophic lateral sclerosis
293175|NCT01530425|pediatric wheelchairs
293176|NCT01530425|low-income
293177|NCT01530425|comparisons
293178|NCT01530412|Quality of Life
293179|NCT01530412|Free-living activity
293180|NCT01530412|Exacerbation
293181|NCT01530412|Rehabilitation
293182|NCT01530386|Lacosamide
293183|NCT01530386|Vimpat
293184|NCT01530373|hot flashes
293185|NCT01530373|breast cancer
293186|NCT01530373|aromatase inhibitors
293187|NCT01530373|solifenacin
293188|NCT01530373|clonidine
293189|NCT01530373|quality of life
293190|NCT01530347|Glucose monitoring
293191|NCT01530347|non-invasive glucometer
293192|NCT01530347|Self glucose monitoring
293193|NCT01530321|cervicogenic headache
293194|NCT01530321|spinal manipulation
293195|NCT01530321|chiropractic
293196|NCT01530321|randomized controlled trial
293197|NCT01530321|dose-response
293198|NCT01530321|efficacy
293199|NCT01530308|Delirium
293200|NCT01530282|Respiratory Insufficiency [C08.618.846]
293201|NCT01530269|intermediate
293202|NCT01530269|high
293203|NCT01530269|risk
293204|NCT01530269|radiation
293205|NCT01530269|therapy
293206|NCT01530269|planning
293207|NCT01530269|surgical
293208|NCT01530269|immunotherapy
293209|NCT01530269|chemotherapy
293210|NCT01530269|hormone
293211|NCT01530256|allograph
293212|NCT01530256|steroid refractory
293213|NCT01530230|cesarean section
293214|NCT01530230|electrocardiography
293215|NCT01530230|heart
293216|NCT01530230|hypotension
293217|NCT01530230|ischemia
293218|NCT01530230|oxytocin
293219|NCT01530230|preeclampsia
293220|NCT01530230|regional anesthesia
293221|NCT01530230|ECG changes suggestive of myocardial ischemia
293222|NCT01530217|Analgesics
293223|NCT01530217|Ibuprofen
293224|NCT01530217|Inflammation
293225|NCT01530217|Tooth Bleaching
293226|NCT01530204|knee arthritis
293227|NCT01530204|knee osteoarthritis
293228|NCT01530204|knee pain
293229|NCT01530204|cognitive behavioral therapy
293230|NCT01530204|physical therapy
293231|NCT01530204|depression prevention
293232|NCT01530191|depression
293233|NCT01530191|anxiety
293234|NCT01530191|pelvic organ prolapse
293235|NCT01530191|POP
293236|NCT01530178|Diabetes Mellitus, Type 1
293237|NCT01530165|IFG
293238|NCT01530165|IGTT
293239|NCT01530152|Truwiev PCD laryngoscope
293240|NCT01530152|Macintosh laryngoscope
293241|NCT01530126|periodontitis
293242|NCT01530113|Childhood sexual abuse
293243|NCT01530113|Vaginismus
293244|NCT01530113|Partial vaginismus
293245|NCT01530113|Labor dystocia
293246|NCT01530113|Depression
293247|NCT01530100|Edema
293248|NCT01530100|Pain
293249|NCT01530100|Lower laser therapy
293250|NCT01530100|orthognathics surgery
293251|NCT01530087|colostomy
293252|NCT01530087|ileostomy
293253|NCT01530087|irritant dermatitis
293254|NCT01530087|two piece barrier
293255|NCT01530074|Mandibular nerve
293256|NCT01530074|Mental nerve
293257|NCT01530074|Mandibular incisive nerve
293258|NCT01530074|Local anesthesia
293259|NCT01530074|None, only healthy subjects will be enrolled in this study
293260|NCT01530035|cardiac
293261|NCT01530035|vascular
293262|NCT01530035|muscular
293263|NCT01530035|adaptations
293264|NCT01530035|soccer training
293265|NCT01530035|strength training
293266|NCT01530022|Lacosamide
293267|NCT01530022|Vimpat
293268|NCT01530022|Cognition
293269|NCT01530022|Mental Processes
293270|NCT01530022|Adverse Effects
293271|NCT01530009|Antroduodenal manometry
293272|NCT01530009|Child
293273|NCT01530009|Adolescent
293274|NCT01530009|Amoxicillin
293275|NCT01530009|Gastrointestinal Motility
293276|NCT01529957|Volunteers
293277|NCT01529918|Diabetes
293278|NCT01529918|Self-screening
293279|NCT01529918|Web-based technology
293280|NCT01529918|follow-up clinical care
293281|NCT01529918|randomized control trial
293282|NCT01529905|depression
293283|NCT01529905|mania
293284|NCT01529905|bipolar
293285|NCT01529905|outcome
293286|NCT01529905|cognitive
293287|NCT01529879|edentulism
293288|NCT01529879|dental implants
293289|NCT01529879|clinical study
293290|NCT01529879|Nanotite Certain Tapered implant
293291|NCT01529879|randomized
293292|NCT01529879|crestal bone level
293293|NCT01529866|clinical study
293294|NCT01529866|edentulism
293295|NCT01529866|dental implants
293296|NCT01529866|Nanotite Certain Tapered implant
293297|NCT01529866|randomized
293298|NCT01529866|crestal bone level
293299|NCT01529866|immediate loading
293300|NCT01529814|edentulism
293301|NCT01529814|dental implants
293302|NCT01529814|clinical study
293303|NCT01529814|Nanotite Certain Tapered implant
293304|NCT01529814|randomized
293305|NCT01529814|crestal bone level
293306|NCT01529814|early loading
293307|NCT01529801|edentulism
293308|NCT01529801|dental implants
293309|NCT01529801|clinical study
293310|NCT01529801|randomized
293311|NCT01529801|Osseotite Certain Tapered
293312|NCT01529801|Crestal bone level
293313|NCT01529788|abobotulinum toxin lateral orbital lines
293314|NCT01529788|BotoxCosmetic
293315|NCT01529788|Dysport
293316|NCT01529788|onabotulinum toxin
293317|NCT01529788|wrinkles
293318|NCT01529788|lateral orbital lines
293319|NCT01529775|partial edentulism
293320|NCT01529775|dental implants
293321|NCT01529775|Osseotite Certain Prevail Tapered
293322|NCT01529775|Osseotite Certain Tapered
293323|NCT01529775|Crestal bone level
293324|NCT01529775|randomized
293325|NCT01529775|clinical study
293326|NCT01529762|edentulism
293327|NCT01529762|dental implants
293328|NCT01529762|Osseotite Certain Tapered
293329|NCT01529762|randomized
293330|NCT01529762|clinical study
293331|NCT01529762|partial edentulism
293332|NCT01529762|immediate loading
293333|NCT01529762|crestal bone level
293334|NCT01529736|edentulism
293335|NCT01529736|dental implants
293336|NCT01529736|early loading
293337|NCT01529736|crestal bone level
293338|NCT01529736|high torque insertion
293339|NCT01529736|low torque insertion
293340|NCT01529736|randomized
293341|NCT01529736|Osseotite
293342|NCT01529736|clinical study
293343|NCT01529723|Stroke
293344|NCT01529723|Dysphagia screening
293345|NCT01529710|Schistosomiasis hematobium
293346|NCT01529710|Schistosomiasis mansoni
293347|NCT01529697|Asthma
293348|NCT01529697|Inhaler use
293349|NCT01529684|Cancer, solid tumors
293350|NCT01529684|oncology patients
293351|NCT01529684|OSI-906
293352|NCT01529684|mass balance
293353|NCT01529684|Absorption, Metabolism, and Excretion of OSI-906
293354|NCT01529684|Metabolic profile of 906
293355|NCT01529684|Pharmacokinetics of 14C-OSI-906
293356|NCT01529658|Renal function
293357|NCT01529658|Renal hypothermia
293358|NCT01529658|Nephrology
293359|NCT01529658|Nephrectomy
293360|NCT01529658|Renal tumor
293361|NCT01529658|Urology
293362|NCT01529658|Kidney
293363|NCT01529645|pertussis
293364|NCT01529645|booster vaccine
293365|NCT01529645|tetanus
293366|NCT01529645|diphtheria in adults
293367|NCT01529632|chronic obstructive pulmonary disease
293368|NCT01529632|COPD
293369|NCT01529632|QVA149
293370|NCT01529632|QAB149
293371|NCT01529632|NVA237
293372|NCT01529632|indacaterol
293373|NCT01529632|glycopyrronium bromide
293374|NCT01529619|Rivastigmine
293375|NCT01529619|Alzheimer's disease
293376|NCT01529619|Transdermal patch
293377|NCT01529606|dental restoration
293378|NCT01529606|dental caries
293379|NCT01529606|tooth cavity
293380|NCT01529593|Advanced Cancers
293381|NCT01529593|Metastatic cancer
293382|NCT01529593|Tumor response
293383|NCT01529593|Dose limiting toxicity
293384|NCT01529593|DLT
293385|NCT01529593|Maximum tolerated dose
293386|NCT01529593|MTD
293387|NCT01529593|Temsirolimus
293388|NCT01529593|CCI-779
293389|NCT01529593|Torisel
293390|NCT01529593|Metformin
293391|NCT01529580|Autism Spectrum Disorder
293392|NCT01529580|language
293393|NCT01529580|intervention
293394|NCT01529580|school-age
293395|NCT01529554|Acute Coronary Syndromes
293396|NCT01529554|ST-Elevation Myocardial Infarction
293397|NCT01529554|Infarct size
293398|NCT01529554|inflammation
293399|NCT01529554|everolimus
293400|NCT01529541|CWP-0403
293401|NCT01529541|Sitagliptin
293402|NCT01529541|Metformin
293403|NCT01529541|type 2 DM
293404|NCT01529528|CWP-0403
293405|NCT01529528|type 2 DM
293406|NCT01529528|Efficacy
293407|NCT01529528|Safety
293408|NCT01529528|Phase 3
293409|NCT01529515|Schizophrenia
293410|NCT01529515|R092670
293411|NCT01529515|Paliperidone Palmitate
293412|NCT01529515|Paliperidone palmitate 3 month formulation (PP3M)
293413|NCT01529502|Blood Transfusion, Autologous
293414|NCT01529502|Blood Preservation/adverse effects
293415|NCT01529502|Blood Transfusion/adverse effects
293416|NCT01529502|Endothelium, Vascular/physiopathology
293417|NCT01529502|Inflammation Mediators
293418|NCT01529502|Hemoglobins
293419|NCT01529502|Nitric Oxide
293420|NCT01529489|Chronic Obstructive Pulmonary Disease
293421|NCT01529489|Physical training
293422|NCT01529489|Oxygen uptake kinetic
293423|NCT01529489|Heart rate kinetic
293424|NCT01529476|Ofloxacin
293425|NCT01529476|Levofloxacin
293426|NCT01529476|Ofloxacin hydrochloride
293427|NCT01529463|Congestive Heart Failure
293428|NCT01529450|basal cell carcinoma, sonidegib, smoothened inhibitor, hedgehog
293429|NCT01529437|allergy
293430|NCT01529437|immunology
293431|NCT01529437|immune tolerance
293432|NCT01529437|immunotherapy
293433|NCT01529424|Hypertriglyceridemia
293434|NCT01529411|urothelium
293435|NCT01529411|transitional
293436|NCT01529411|carcinoma
293437|NCT01529411|cancer
293438|NCT01529411|metastatic
293439|NCT01529411|tract
293440|NCT01529398|knee osteoarthritis
293441|NCT01529398|exercise therapy
293442|NCT01529398|resistance training
293443|NCT01529398|proprioception
293444|NCT01529385|swollen leg
293445|NCT01529385|diabetes
293446|NCT01529385|compression stockings
293447|NCT01529385|edema
293448|NCT01529372|Hypertension
293449|NCT01529372|Blood pressure
293450|NCT01529372|Renal denervation
293451|NCT01529359|Irritable Bowel Syndrome
293452|NCT01529359|Probiotics
293453|NCT01529346|Postoperative dental pain
293454|NCT01529307|Biologic,
293455|NCT01529307|solid tumors,
293456|NCT01529307|Death Receptor 5 agonist,
293457|NCT01529307|caspase-8
293458|NCT01529294|Hepatic impairment
293459|NCT01529294|Iloperidone
293460|NCT01529294|ILO522D
293461|NCT01529294|Pharmacokinetics
293462|NCT01529268|Nonalcoholic Fatty Liver Disease (NAFLD)
293463|NCT01529268|Cysteamine bitartrate delayed release
293464|NCT01529268|Children
293465|NCT01529255|Chronic Hepatitis B
293466|NCT01529255|Compensated Chronic hepatitis B
293467|NCT01529216|DIAMOND System
293468|NCT01529216|T2DM
293469|NCT01529216|Randomized study
293470|NCT01529216|Electrical stimulation
293471|NCT01529216|Fundus
293472|NCT01529190|pregabalin
293473|NCT01529190|postoperative pain control
293474|NCT01529190|interleukin-6
293475|NCT01529190|acute pain
293476|NCT01529177|Metformin
293477|NCT01529177|Insulin resistance
293478|NCT01529177|male infertility
293479|NCT01529177|unexplained Oligozspermia
293480|NCT01529177|Clomiphene citrate
293481|NCT01529177|Unexplained azoospermia
293482|NCT01529164|endostatin
293483|NCT01529164|chemotherapy
293484|NCT01529164|antiangiogenesis agent
293485|NCT01529164|colorectal cancer
293486|NCT01529151|Dizziness
293487|NCT01529151|Vertigo
293488|NCT01529151|Benign Paroxysmal Positional Vertigo
293489|NCT01529151|Labyrinthitis
293490|NCT01529151|Osteopathic Manipulative Treatment
293491|NCT01529151|Vestibular Rehabilitation Therapy
293492|NCT01529138|Cancer
293493|NCT01529112|Locally Advanced
293494|NCT01529112|Metastatic Non-Squamous Non-Small Cell Lung Cancer
293495|NCT01529099|Osteoarthritis
293496|NCT01529099|Knee
293497|NCT01529099|Knee replacement
293498|NCT01529099|Knee implant
293499|NCT01529099|Knee arthroplasty
293500|NCT01529099|Unicompartmental
293501|NCT01529099|Primary
293502|NCT01529099|Partial
293503|NCT01529099|Patellofemoral
293504|NCT01529099|Medial
293505|NCT01529099|Lateral
293506|NCT01529099|Bicompartmental
293507|NCT01529099|Cemented
293508|NCT01529099|Post-traumatic arthritis of the tibio-femoral and/or patellofemoral articular surfaces
293509|NCT01529099|History of Gout or pseudo-gout.
293510|NCT01529086|prostate cancer
293511|NCT01529086|dutasteride
293512|NCT01529086|for cause prostate biopsy
293513|NCT01529073|HIV
293514|NCT01529073|genotype 4 HCV
293515|NCT01529073|pegylated interferon
293516|NCT01529073|ribavirin
293517|NCT01529073|nitazoxanide
293518|NCT01529060|phenylbutyrate
293519|NCT01529060|MSUD
293520|NCT01529060|Buphenyl-TM
293521|NCT01529034|Epilepsy
293522|NCT01529034|seizure clusters
293523|NCT01529034|acute repetitive seizures
293524|NCT01529034|rescue treatment
293525|NCT01529021|Pain management
293526|NCT01529021|vaccination
293527|NCT01529021|immunization
293528|NCT01529021|pediatric
293529|NCT01529021|robotics
293530|NCT01529021|human-robot interaction
293531|NCT01529008|Osteonecrosis
293532|NCT01529008|Femoral Head
293533|NCT01529008|Hip
293534|NCT01529008|Orthopedics
293535|NCT01529008|Bone
293536|NCT01529008|Musculoskeletal Disorders
293537|NCT01528995|fecal incontinence
293538|NCT01528995|anal incontinence
293539|NCT01528995|obstetric sphincter injuries
293540|NCT01528995|OASIS
293541|NCT01528995|double incontinence
293542|NCT01528995|urinary incontinence
293543|NCT01528995|sexual function
293544|NCT01528995|sacral nerve modulation
293545|NCT01528995|sacral nerve stimulation
293546|NCT01528995|Interstim
293547|NCT01528995|anal bulking injections
293548|NCT01528995|Permacol
293549|NCT01528969|oral microbiota
293550|NCT01528969|mutans streptococci
293551|NCT01528969|xylitol
293552|NCT01528956|adrenocortical carcinoma
293553|NCT01528943|To evaluate the effect of prostacycline on endothelial integrity during major abdominal surgery
293554|NCT01528930|Lung Diseases
293555|NCT01528930|Anti-Infective Agents
293556|NCT01528930|Therapeutic Uses
293557|NCT01528930|Amikacin
293558|NCT01528917|Lysosomal Storage Disease
293559|NCT01528917|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
293560|NCT01528917|Acid cholesteryl ester hydrolase deficiency, type 2
293561|NCT01528917|Acid lipase disease
293562|NCT01528917|Cholesterol ester hydrolase deficiency
293563|NCT01528917|LAL Deficiency
293564|NCT01528917|LIPA Deficiency
293565|NCT01528917|Wolman disease
293566|NCT01528904|pregnancy
293567|NCT01528904|autoimmune thyroid disease
293568|NCT01528904|fetal thyroid hormones
293569|NCT01528904|antithyroid antibodies
293570|NCT01528904|ultrasound parameters
293571|NCT01528891|tonsillectomy
293572|NCT01528891|emergence agitation
293573|NCT01528878|Liver Cancer
293574|NCT01528878|Hepatocellular Carcinoma
293575|NCT01528878|HCC
293576|NCT01528878|Metastatic Cancer to Liver
293577|NCT01528878|Metastatic Colon Cancer
293578|NCT01528878|Metastatic Colo-rectal Cancer
293579|NCT01528878|mCRC
293580|NCT01528878|Liver Function
293581|NCT01528878|Child-Pugh
293582|NCT01528865|virus
293583|NCT01528865|K(HML2)[HERV-K(HML2)]
293584|NCT01528865|Lymphoma
293585|NCT01528865|Human endogenous retrovirus-K(HLM2)[HERV-K(HML2)]
293586|NCT01528852|neonatal Mortality
293587|NCT01528852|chlorhexidine cord care
293588|NCT01528852|cord infections
293589|NCT01528852|african settings
293590|NCT01528852|clinical trials
293591|NCT01528839|Bipolar disorder
293592|NCT01528839|Bipolar depression
293593|NCT01528839|Thyroid abnormality
293594|NCT01528839|mood stabilizer
293595|NCT01528839|antidepressants
293596|NCT01528839|currently depressed
293597|NCT01528826|metastatic triple-negative breast cancer
293598|NCT01528826|vinorebine
293599|NCT01528826|oxaliplatin
293600|NCT01528813|Erbium-doped yttrium aluminium garnet laser
293601|NCT01528813|Er:YAG
293602|NCT01528813|Amorolfine lacquer
293603|NCT01528813|Dermatophytes
293604|NCT01528813|Subungual distal lateral onychomycosis
293605|NCT01528813|Drug delivery
293606|NCT01528800|Vitamin K
293607|NCT01528800|Chronic kidney disease
293608|NCT01528800|vascular calcification
293609|NCT01528800|hemodialysis
293610|NCT01528800|coronary artery calcification
293611|NCT01528787|Intraocular pressure
293612|NCT01528787|visual field
293613|NCT01528787|Ocular hypertension or open angle glaucoma
293614|NCT01528774|Melanoma
293615|NCT01528774|Circulating Tumor Cells
293616|NCT01528774|Prostate cancer
293617|NCT01528774|Sarcoma
293618|NCT01528774|Renal Cancer
293619|NCT01528774|Pancreatic neuroendocrine cancer
293620|NCT01528774|Other solid tumor
293621|NCT01528761|physical activity
293622|NCT01528761|older adults
293623|NCT01528761|physical function
293624|NCT01528761|health-related quality of life
293625|NCT01528761|prosocial behavior
293626|NCT01528761|social cognitive theory
293627|NCT01528722|Emergency laparoscopic cholecystectomy
293628|NCT01528722|Pain scores
293629|NCT01528722|Intraperitoneal local anaesthesia
293630|NCT01528722|Cholecystitis
293631|NCT01528709|Statin,
293632|NCT01528709|CABG,
293633|NCT01528709|saphenous vein graft,
293634|NCT01528709|graft occlusion,
293635|NCT01528709|lipids
293636|NCT01528696|Obesity
293637|NCT01528696|Cesarean Section
293638|NCT01528696|Wound care
293639|NCT01528657|Sick Sinus Syndrome
293640|NCT01528657|Ventricular pacing
293641|NCT01528657|Minimal ventricular pacing
293642|NCT01528657|Ventricular pacing suppression
293643|NCT01528657|Intrinsic rhythm support
293644|NCT01528657|Long term AV
293645|NCT01528644|iron
293646|NCT01528644|fortification
293647|NCT01528644|alginate
293648|NCT01528644|iron deficiency
293649|NCT01528618|Advanced Nasopharyngeal Carcinoma
293650|NCT01528618|treatment
293651|NCT01528605|lutein
293652|NCT01528605|zeaxanthin
293653|NCT01528605|age-related macular degeneration
293654|NCT01528605|supplementation
293655|NCT01528605|macular pigment optical density
293656|NCT01528605|visual function
293657|NCT01528605|serum concentration
293658|NCT01528579|Whiplash
293659|NCT01528579|Rehabilitation
293660|NCT01528579|Physiotherapy
293661|NCT01528579|Exercises
293662|NCT01528566|osteoarthritis, knee
293663|NCT01528566|Cognitive impairment
293664|NCT01528566|Tai Chi
293665|NCT01528553|genu valgus
293666|NCT01528553|lower limb
293667|NCT01528553|paediatric
293668|NCT01528553|epiphysiodesis
293669|NCT01528540|chronic pancreatitis
293670|NCT01528540|pregabalin
293671|NCT01528540|antioxidant
293672|NCT01528514|Myocardial infarction
293673|NCT01528514|Coronary artery bypass grafting
293674|NCT01528514|Anti-oxidant
293675|NCT01528514|Curcuminoids
293676|NCT01528475|Therapeutic Hypothermia
293677|NCT01528475|Cardiac arrest
293678|NCT01528462|Stroke
293679|NCT01528462|Ischemic Attack, Transient
293680|NCT01528462|Sleep Disorders
293681|NCT01528462|Sleep Apnea Syndromes
293682|NCT01528462|Restless Legs Syndrome
293683|NCT01528462|Chronobiology Disorders
293684|NCT01528449|babesia
293685|NCT01528449|blood donation
293686|NCT01528449|transfusion transmitted babesiosis
293687|NCT01528436|Cerebral Palsy
293688|NCT01528436|Umbilical Cord Blood
293689|NCT01528436|Rehabilitation
293690|NCT01528423|XtremeCT
293691|NCT01528423|Density
293692|NCT01528423|pQCT
293693|NCT01528423|Turnover
293694|NCT01528423|Bone
293695|NCT01528423|short-term reproducibility
293696|NCT01528397|defect
293697|NCT01528397|dorsal branch of the proper digital nerve
293698|NCT01528397|proper digital nerve
293699|NCT01528397|second dorsal metacarpal artery
293700|NCT01528397|pedicled nerve graft.
293701|NCT01528384|Arginine
293702|NCT01528384|Arginine deiminase
293703|NCT01528384|Argininosuccinate synthetase
293704|NCT01528384|Phase 1
293705|NCT01528384|Pediatric
293706|NCT01528384|Failed other treatments
293707|NCT01528384|Pediatric patients
293708|NCT01528371|Intravenous sedation
293709|NCT01528371|Midazolam
293710|NCT01528371|Dental treatment
293711|NCT01528371|White-coat hypertension
293712|NCT01528371|STAI
293713|NCT01528371|Dental patients
293714|NCT01528371|Transient hypertension
293715|NCT01528358|sepsis
293716|NCT01528358|tissue oximetry
293717|NCT01528358|NIRS
293718|NCT01528358|VOT
293719|NCT01528345|Breast Cancer
293720|NCT01528345|HER2-, HR+
293721|NCT01528345|post-menopausal
293722|NCT01528345|Locally advanced or metastatic Breast Cancer (HER2-, HR+)
293723|NCT01528332|Musculoskeletal pain
293724|NCT01528332|Back pain
293725|NCT01528332|Chronic pain
293726|NCT01528319|Arthroscopic Bankart repair
293727|NCT01528319|Suture anchor
293728|NCT01528319|Shoulder dislocation
293729|NCT01528306|HP802-247
293730|NCT01528306|EB (epidermolysis bullosa)
293731|NCT01528280|Shift work
293732|NCT01528280|Hepatitis A vaccination
293733|NCT01528280|humoral response
293734|NCT01528280|cellular response
293735|NCT01528267|Emphysema, lung volume reduction, autologous blood
293736|NCT01528254|Type 2 Diabetes Mellitus,
293737|NCT01528254|Vildagliptin,
293738|NCT01528254|Elderly Patients
293739|NCT01528241|ABP688
293740|NCT01528241|Tracer
293741|NCT01528241|Depression
293742|NCT01528202|Sleep, circadian cycle, melatonin
293743|NCT01528189|Insulin, surgery, infection
293744|NCT01528176|FGF-23, CKD, Cyp24, 24,25(OH)2D, vitamin D metabolism
293745|NCT01528163|Head and neck
293746|NCT01528163|Squamous cell carcinoma
293747|NCT01528163|Randomized
293748|NCT01528163|palliative treatment
293749|NCT01528098|polyethylene glycol
293750|NCT01528098|bisacodyl
293751|NCT01528085|Philadelphia chromsome
293752|NCT01528085|BCR-ABL
293753|NCT01528085|ALL
293754|NCT01528085|acute lymphoblastic leukemia
293755|NCT01528085|Nilotinib
293756|NCT01528085|Tasigna
293757|NCT01528072|Dynesys Dynamic Stabilization System
293758|NCT01528072|Spondylolithesis
293759|NCT01528072|pseudoarthrosis
293760|NCT01528072|neurologic impairment
293761|NCT01528072|failed fusion
293762|NCT01528059|Diabetes
293763|NCT01528059|Gastric cancer
293764|NCT01528059|Gastric bypass
293765|NCT01528046|central nervous system (CNS)
293766|NCT01528046|malignancy
293767|NCT01528046|relapsed
293768|NCT01528046|refractory
293769|NCT01528046|pediatric
293770|NCT01528046|recurrent
293771|NCT01528033|surgical wound
293772|NCT01528033|wound healing disorder
293773|NCT01528033|Wound healing impairment
293774|NCT01528033|post surgical wound healing disorder
293775|NCT01528033|abdominal wound healing impairment
293776|NCT01528033|Vacuum Assisted Closure
293777|NCT01528033|negative pressure wound therapy
293778|NCT01528007|Pathological gambling
293779|NCT01528007|Treatment intervention
293780|NCT01527994|Aprepitant
293781|NCT01527994|Intravenous heroin dependence
293782|NCT01527981|Depression
293783|NCT01527981|Diabetes
293784|NCT01527981|Adherence
293785|NCT01527981|Medication
293786|NCT01527981|Glucose
293787|NCT01527981|Insulin
293788|NCT01527955|Kelee
293789|NCT01527955|Meditation
293790|NCT01527955|Stress
293791|NCT01527955|Anxiety
293792|NCT01527955|Depression
293793|NCT01527955|Brain
293794|NCT01527955|Mind
293795|NCT01527942|Pain Management
293796|NCT01527903|propofol
293797|NCT01527903|midazolam
293798|NCT01527903|sedation
293799|NCT01527903|ICU
293800|NCT01527890|intravenous patient-controlled analgesia
293801|NCT01527890|IV PCA
293802|NCT01527877|BKM120
293803|NCT01527877|head and neck cancer
293804|NCT01527877|squamous cell carcinoma
293805|NCT01527864|NSCLC
293806|NCT01527851|Post-bariatric surgery
293807|NCT01527851|Excess skin
293808|NCT01527851|Physical fitness
293809|NCT01527851|Physical activity
293810|NCT01527851|Barriers to physical activity
293811|NCT01527851|Plastic surgery
293812|NCT01527851|Quality of life
293813|NCT01527851|Self-esteem
293814|NCT01527838|Hematologic malignancies
293815|NCT01527799|Sickle cell anemia
293816|NCT01527799|Exercise testing
293817|NCT01527799|Cardiopulmonary disease
293818|NCT01527786|Major Depressive Disorder, Postpartum Onset
293819|NCT01527773|COPD
293820|NCT01527773|Cardiovascular disease
293821|NCT01527773|Phenotypes
293822|NCT01527760|Essential Hypertension
293823|NCT01527760|Viscum album mother tincture
293824|NCT01527760|one group pretest post-test study
293825|NCT01527747|Type 2 Diabetes
293826|NCT01527747|Hypertriglyceridemia
293827|NCT01527747|dipeptidyl peptidase-4 (DPP-4)
293828|NCT01527747|glucagon-like peptide-1 (glp-1)
293829|NCT01527734|Comparison study
293830|NCT01527721|keratoconus
293831|NCT01527721|CxL
293832|NCT01527721|CxL combined with t-PRK
293833|NCT01527695|Phase IIa
293834|NCT01527695|AZD3241
293835|NCT01527695|microglia activation
293836|NCT01527695|safety
293837|NCT01527695|Pharmacodynamics and pharmacokinetics analyses
293838|NCT01527695|Parkinson patients
293839|NCT01527682|Intraocular pressure
293840|NCT01527682|Latanoprost
293841|NCT01527682|Dorzolamide
293842|NCT01527669|Red yeast rice
293843|NCT01527669|lovastatin
293844|NCT01527669|Pharmacokinetics
293845|NCT01527578|Healthy children
293846|NCT01527578|Healthy adults
293847|NCT01527578|individuals ages 7-60
293848|NCT01527526|DMPA
293849|NCT01527526|insulin resistance
293850|NCT01527526|cardiovascular disease
293851|NCT01527526|BMI
293852|NCT01527526|weight gain
293853|NCT01527526|thrombosis
293854|NCT01527513|Partial Epilepsy
293855|NCT01527513|eslicarbazepine acetate
293856|NCT01527513|Children
293857|NCT01527500|AMD
293858|NCT01527500|Age-related Macular Degeneration
293859|NCT01527500|geographic atrophy
293860|NCT01527500|GA
293861|NCT01527500|Dry AMD
293862|NCT01527500|Blindness
293863|NCT01527500|Drusen
293864|NCT01527500|GA lesion
293865|NCT01527487|breast cancer
293866|NCT01527487|eribulin
293867|NCT01527487|Halaven
293868|NCT01527487|taxotere
293869|NCT01527474|postpartum
293870|NCT01527474|postpartum depression
293871|NCT01527474|PPD
293872|NCT01527474|escitalopram
293873|NCT01527461|lung neoplasms
293874|NCT01527461|dogs
293875|NCT01527461|sweat
293876|NCT01527461|smell
293877|NCT01527448|postpartum
293878|NCT01527448|postpartum depression
293879|NCT01527448|PPD
293880|NCT01527448|quetiapine XR
293881|NCT01527448|quetiapine
293882|NCT01527448|seroquel
293883|NCT01527448|bipolar
293884|NCT01527448|bipolar disorder
293885|NCT01527448|bipolar disorder, type II
293886|NCT01527435|Best corrected visual acuity
293887|NCT01527435|Slit lamp examination
293888|NCT01527435|Ophthalmoscopy with contact lens/indirect ophthalmoscope
293889|NCT01527435|OCT assessment
293890|NCT01527435|Fundus photos, fluorescein angiogram, ICG angiogram
293891|NCT01527422|Aggressive Non-Hodgkin's Lymphoma
293892|NCT01527409|Exercise
293893|NCT01527409|Diet
293894|NCT01527409|Posttraumatic growth
293895|NCT01527396|endometrial cancer
293896|NCT01527396|lymph node metastasis
293897|NCT01527396|lymphadenectomy
293898|NCT01527396|risk criteria
293899|NCT01527383|Shingles
293900|NCT01527357|fibrin sealant
293901|NCT01527357|thrombin
293902|NCT01527357|fibrinogen
293903|NCT01527357|hemostasis
293904|NCT01527344|OCT
293905|NCT01527344|IVUS
293906|NCT01527344|CAV
293907|NCT01527318|NLSDM
293908|NCT01527318|Lipid accumulation
293909|NCT01527305|Schizophrenia
293910|NCT01527305|Antipsychotics
293911|NCT01527305|Paliperidone Palmitate
293912|NCT01527305|Paliperidone
293913|NCT01527305|Invega
293914|NCT01527305|Sustenna
293915|NCT01527305|Psychotic disorder
293916|NCT01527305|Psychosis
293917|NCT01527292|Vertebral Metastasis
293918|NCT01527292|pain control
293919|NCT01527292|VAP
293920|NCT01527292|SRT+VAP
293921|NCT01527279|atrial fibrillation
293922|NCT01527279|paroxysmal
293923|NCT01527279|cardioversion
293924|NCT01527279|antazoline
293925|NCT01527266|carbohydrate
293926|NCT01527266|performance
293927|NCT01527266|cycling
293928|NCT01527253|Cardiometabolic risk
293929|NCT01527253|Metabolic syndrome
293930|NCT01527253|Prebiotics
293931|NCT01527253|Legumes
293932|NCT01527253|Wholegrain cereal
293933|NCT01527253|Functional diet
293934|NCT01527253|Low glycemic index diet
293935|NCT01527240|Volume of cerebral infarction
293936|NCT01527240|Stroke
293937|NCT01527240|CsA
293938|NCT01527240|NIHSS
293939|NCT01527227|Children of mentally ill
293940|NCT01527214|Lung cancer
293941|NCT01527214|early detection
293942|NCT01527214|CT scan
293943|NCT01527214|General Practice
293944|NCT01527214|Effect of Computed Tomography scans
293945|NCT01527214|Clinical medical education
293946|NCT01527201|Arthroscopy
293947|NCT01527201|Debridement
293948|NCT01527188|HDM
293949|NCT01527188|allergic rhinitis
293950|NCT01527162|Cerebral palsy
293951|NCT01527162|orthotics
293952|NCT01527162|solid ankle foot orthoses
293953|NCT01527123|GSK2585823, benzoic acid, hippuric acid, acne vulgaris, pharmacokinetics
293954|NCT01527110|zanamivir
293955|NCT01527110|Seasonal Influenza
293956|NCT01527110|H1N1
293957|NCT01527110|intravenous
293958|NCT01527110|neuraminidase inhibitor
293959|NCT01527110|Pandemic
293960|NCT01527110|Relenza
293961|NCT01527110|Influenza B virus
293962|NCT01527110|Influenza A virus
293963|NCT01527097|Cardiovascular Diseases
293964|NCT01527097|Pharmacologic Actions
293965|NCT01527097|Endothelial Function
293966|NCT01527097|Dermatology
293967|NCT01527097|Inflammatory Disease
293968|NCT01527097|Skin Disease
293969|NCT01527058|lung cancer
293970|NCT01527058|integrin receptor
293971|NCT01527058|68Ga-BNOTA-PRGD2
293972|NCT01527058|PET/CT
293973|NCT01527058|efficacy and safety
293974|NCT01527032|amyloidosis
293975|NCT01527032|stem cell transplant
293976|NCT01527019|Acute Cystitis
293977|NCT01526967|ostomy
293978|NCT01526967|peristomal skin breakdown
293979|NCT01526967|ConvaTec Moldable Skin Barriers
293980|NCT01526928|cancer
293981|NCT01526928|metastatic
293982|NCT01526928|locally advanced
293983|NCT01526928|lung
293984|NCT01526928|non-small cell lung cancer
293985|NCT01526928|NSCLC
293986|NCT01526928|epidermal growth factor receptor
293987|NCT01526928|EGFR
293988|NCT01526928|T790M
293989|NCT01526928|CO-1686
293990|NCT01526928|unresectable
293991|NCT01526928|recurrent
293992|NCT01526928|EGFR-directed therapy
293993|NCT01526928|irreversible EGFR inhibitor
293994|NCT01526928|TIGER
293995|NCT01526928|Rociletinib
293996|NCT01526915|PRF
293997|NCT01526915|PLATELET RICH FIBRIN
293998|NCT01526915|BISPHOSPHONATES
293999|NCT01526902|contact lenses
294000|NCT01526889|Non-infectious uveitis
294001|NCT01526889|Panuveitis
294002|NCT01526889|Vitreous haze
294003|NCT01526889|Visual acuity
294004|NCT01526876|Intracranial Pressure
294005|NCT01526876|Cerebral Perfusion Pressure
294006|NCT01526876|Clevidipine Butyrate
294007|NCT01526863|Allergy
294008|NCT01526863|Egg
294009|NCT01526850|cGVHD
294010|NCT01526837|Brain tumor
294011|NCT01526837|GBM
294012|NCT01526837|Brain cancer
294013|NCT01526811|Endurant
294014|NCT01526811|Stent Graft
294015|NCT01526811|Abdominal Aortic Aneurysm
294016|NCT01526798|End-Stage Renal Disease (ESRD)
294017|NCT01526798|chronic Inflammation
294018|NCT01526798|EPO Resistance
294019|NCT01526798|ESA Resistance
294020|NCT01526798|high cut-off dialysis
294021|NCT01526798|hemodialysis
294022|NCT01526772|Transnasal
294023|NCT01526772|Transoral
294024|NCT01526772|Roux en Y gastric bypass
294025|NCT01526772|Upper Endoscopy
294026|NCT01526772|Obesity
294027|NCT01526759|dietary fiber
294028|NCT01526759|energy intake
294029|NCT01526759|satiety
294030|NCT01526759|physicochemical properties
294031|NCT01526759|men and women
294032|NCT01526759|Healthy adults
294033|NCT01526746|End stage renal disease
294034|NCT01526746|ESRD
294035|NCT01526746|kidney disease
294036|NCT01526746|renal impairment
294037|NCT01526746|renal
294038|NCT01526733|Type 1 Diabetes
294039|NCT01526733|Continuous Subcutaneous Insulin Infusion (CSII)
294040|NCT01526720|Type 2 diabetes mellitus
294041|NCT01526720|Beta cell function
294042|NCT01526720|Insulin sensitivity
294043|NCT01526720|Genetics of diabetes
294044|NCT01526707|To identify changes in FKBP51 expression with inhaled steroid treatment in asthma
294045|NCT01526694|relapsed or refractory multiple myeloma
294046|NCT01526681|Sensory Nerve
294047|NCT01526681|Mixed Nerve
294048|NCT01526681|Motor Nerve
294049|NCT01526668|Benign gynecological disease
294050|NCT01526668|Surgery
294051|NCT01526668|Postoperative follow-up strategy
294052|NCT01526668|Pain threshold
294053|NCT01526668|Chronic pelvic pain
294054|NCT01526668|[E04.950.300.399]
294055|NCT01526668|[C13.351.500]
294056|NCT01526668|[F02.463.593.710.560]
294057|NCT01526668|[N02.421.585.722.700]
294058|NCT01526668|Postoperative Care
294059|NCT01526655|Endometrial cancer
294060|NCT01526655|Robot assisted laparoscopy
294061|NCT01526655|Abdominal hysterectomy
294062|NCT01526655|Fast track program
294063|NCT01526629|ICD
294064|NCT01526629|Remote follow-up
294065|NCT01526616|PCOS
294066|NCT01526616|metformin
294067|NCT01526616|spironolactone
294068|NCT01526616|metabolic syndrome
294069|NCT01526616|hyperandrogenism
294070|NCT01526603|peripheral blood stem cell transplantation
294071|NCT01526603|autologous stem cell transplant
294072|NCT01526577|phase1
294073|NCT01526577|healthy subjects
294074|NCT01526577|antiplatelet agent
294075|NCT01526564|Chemotherapy-induced peripheral neuropathy (CIPN)
294076|NCT01526551|Human Papillomavirus
294077|NCT01526525|tramadol
294078|NCT01526525|ketamine
294079|NCT01526525|parecoxib
294080|NCT01526525|paracetamol
294081|NCT01526525|numerical rating scale (NRS)
294082|NCT01526525|McGill (SF-MPQ)
294083|NCT01526525|electronic pressure algometer
294084|NCT01526525|Spielberger State Trait Anxiety Inventory STAI Y-6 item
294085|NCT01526512|Metronomic cyclophosphamide
294086|NCT01526512|Metronomic capecitabine
294087|NCT01526512|HER2-negative breast cancer
294088|NCT01526499|Metronomic cyclophosphamide
294089|NCT01526499|metastatic breast cancer
294090|NCT01526499|first line
294091|NCT01526499|docetaxel
294092|NCT01526486|melanoma
294093|NCT01526486|urology
294094|NCT01526486|inguinal
294095|NCT01526486|lymph nodes
294096|NCT01526486|groin
294097|NCT01526486|lymphadenectomy
294098|NCT01526486|groin dissection
294099|NCT01526486|skin cancer
294100|NCT01526486|penile cancer
294101|NCT01526486|urethral cancer
294102|NCT01526486|scrotal cancer
294103|NCT01526486|Paget's disease
294104|NCT01526473|Alphavirus
294105|NCT01526473|Vaccine
294106|NCT01526473|Immunotherapy
294107|NCT01526473|HER2
294108|NCT01526460|Platelet
294109|NCT01526460|Atorvastatin
294110|NCT01526460|Rosuvastatin
294111|NCT01526460|Multiplate
294112|NCT01526460|reactivity
294113|NCT01526447|Neck Pain
294114|NCT01526447|Craniosacral Manipulation
294115|NCT01526447|Complementary Therapies
294116|NCT01526447|Randomized Controlled Trial
294117|NCT01526447|Sensory Thresholds
294118|NCT01526447|Quality of Life
294119|NCT01526434|Cimzia
294120|NCT01526434|Non-interventional
294121|NCT01526434|Multicenter
294122|NCT01526434|Postmarketing
294123|NCT01526434|Local
294124|NCT01526421|HIV
294125|NCT01526421|Antiretroviral therapy, highly active
294126|NCT01526408|Meniere's Disease
294127|NCT01526408|Vertigo
294128|NCT01526408|Hearing loss
294129|NCT01526408|Tinnitus
294130|NCT01526408|Anti-viral
294131|NCT01526408|Famciclovir
294132|NCT01526395|electroconvulsive therapy
294133|NCT01526395|ECT
294134|NCT01526395|unmodified
294135|NCT01526395|anesthesia
294136|NCT01526395|propofol
294137|NCT01526382|septic shock
294138|NCT01526382|acute respiratory distress syndrome
294139|NCT01526382|transpulmonary thermodilution technique
294140|NCT01526382|mortality
294141|NCT01526369|HER2-positive metastatic breast cancer.
294142|NCT01526356|Angiofibroma
294143|NCT01526356|Tuberous Sclerosis
294144|NCT01526356|Rapamycin
294145|NCT01526356|Sirolimus
294146|NCT01526356|mTOR
294147|NCT01526343|Patients
294148|NCT01526330|Degenerative disc disease
294149|NCT01526330|YH14618
294150|NCT01526330|Penial 2000
294151|NCT01526330|Penial 2K
294152|NCT01526317|Drug interaction
294153|NCT01526317|Rosuvastatin
294154|NCT01526317|Metformin SR
294155|NCT01526317|Pharmacokinetic
294156|NCT01526291|Myopia
294157|NCT01526291|Hyperopia
294158|NCT01526291|Astigmatism
294159|NCT01526291|Patient-reported outcomes
294160|NCT01526291|Patient satisfaction
294161|NCT01526291|Refractive Error
294162|NCT01526291|Emmetropia
294163|NCT01526291|Dry eyes
294164|NCT01526291|glare
294165|NCT01526291|halos
294166|NCT01526291|patient expectations
294167|NCT01526278|alendronate
294168|NCT01526278|Maxmarvil®
294169|NCT01526265|Smoking Cessation
294170|NCT01526265|Work-site
294171|NCT01526265|Incentives
294172|NCT01526265|Health Behavior
294173|NCT01526265|Smoking
294174|NCT01526252|speckle tracking echocardiography
294175|NCT01526252|database
294176|NCT01526239|Colorectal cancer screening
294177|NCT01526239|colon cancer screening
294178|NCT01526239|colonoscopy
294179|NCT01526226|High flow nasal cannula
294180|NCT01526226|Discomfort
294181|NCT01526200|CLM
294182|NCT01526187|Public Health and Epidemiology
294183|NCT01526187|Bacteriology
294184|NCT01526187|Infectious and Tropical
294185|NCT01526174|autoimmune
294186|NCT01526174|hearing loss
294187|NCT01526174|bilateral hearing loss
294188|NCT01526174|steroid-dependent
294189|NCT01526161|Asthma
294190|NCT01526161|Children
294191|NCT01526161|Therapy
294192|NCT01526161|Fluticasone
294193|NCT01526161|Salmeterol
294194|NCT01526161|Montelukast
294195|NCT01526135|National multicentric phase III superiority trial
294196|NCT01526122|Clopidogrel
294197|NCT01526122|Aspirin
294198|NCT01526122|coadministration
294199|NCT01526109|elderly
294200|NCT01526109|quality of life
294201|NCT01526109|functional capacity
294202|NCT01526109|cognitive function
294203|NCT01526109|physical exercise
294204|NCT01526083|Male Healthy Volunteers
294205|NCT01526057|rheumatoid arthritis
294206|NCT01526057|rituximab
294207|NCT01526057|methotrexate
294208|NCT01526057|anti-TNF
294209|NCT01526044|hyperglycemia
294210|NCT01526044|hypoglycemia
294211|NCT01526044|insulin
294212|NCT01526044|critical illness
294213|NCT01526044|intensive insulin therapy
294214|NCT01526044|continuous glucose monitoring
294215|NCT01526044|CGM
294216|NCT01526044|interstitial fluid glucose
294217|NCT01526044|intensive care unit
294218|NCT01526044|Blood glucose
294219|NCT01526031|frozen shoulder
294220|NCT01526031|bee venom acupuncture
294221|NCT01526018|Intake
294222|NCT01526018|Formula feeding
294223|NCT01525992|Community Pharmacy Services
294224|NCT01525992|Pharmacists
294225|NCT01525992|Diabetes Mellitus
294226|NCT01525992|Diabetes Mellitus, Type 2
294227|NCT01525992|Self Care
294228|NCT01525992|Randomized Controlled Trial
294229|NCT01525979|Stroke rehabilitation
294230|NCT01525979|Unilateral arm training
294231|NCT01525979|Bilateral arm training
294232|NCT01525979|Robot-assisted arm training
294233|NCT01525979|Kinematic analysis
294234|NCT01525979|Functional magnetic resonance image
294235|NCT01525979|Motor recovery
294236|NCT01525979|Quality of life
294237|NCT01525953|esophageal cancer
294238|NCT01525953|radiochemotherapy
294239|NCT01525953|prognosis
294240|NCT01525940|colon capsule endoscopy
294241|NCT01525940|CT-colonography
294242|NCT01525940|Patients
294243|NCT01525940|incomplete colonoscopy
294244|NCT01525927|Oropharyngeal Neoplasms
294245|NCT01525927|Neoplasms, Oropharyngeal
294246|NCT01525927|Oropharynx Neoplasms
294247|NCT01525914|prostate cancer
294248|NCT01525914|PSA kinetics
294249|NCT01525914|PSA doubling time
294250|NCT01525914|active surveillance
294251|NCT01525901|SHANK3
294252|NCT01525901|IGF-1
294253|NCT01525901|Autism
294254|NCT01525888|Contrast induced nephropathy
294255|NCT01525875|pseudoxanthoma elasticum
294256|NCT01525875|calcification
294257|NCT01525836|Purpura
294258|NCT01525836|Idiopathic Thrombocytopenic Purpura
294259|NCT01525797|Liver Transplant
294260|NCT01525784|rtCGMS
294261|NCT01525784|glycemic control
294262|NCT01525784|type 1 diabetes mellitus
294263|NCT01525784|youth
294264|NCT01525771|Advanced Gastric cancer
294265|NCT01525771|Xeloda (Capecitabine)
294266|NCT01525771|Cisplatin
294267|NCT01525771|Taxotere (Docetaxel)
294268|NCT01525732|Achalasia, Hypertensive LES
294269|NCT01525719|cholangiocarcinoma
294270|NCT01525719|RAD001
294271|NCT01525719|everolimus
294272|NCT01525706|Endoscopic Ultrasound
294273|NCT01525706|Pancreatic Mucinous Cystic Neoplasm
294274|NCT01525706|Fine Needle Injection
294275|NCT01525706|Ethanol Ablation
294276|NCT01525706|Paclitaxel Ablation
294277|NCT01525693|diabetes
294278|NCT01525693|diabetics
294279|NCT01525693|high glucose
294280|NCT01525693|Chinese patients
294281|NCT01525680|PTSD
294282|NCT01525667|THA
294283|NCT01525667|Muscle injury
294284|NCT01525654|Rheumatoid Arthritis
294285|NCT01525654|peer support
294286|NCT01525654|self-efficacy
294287|NCT01525654|medication adherence
294288|NCT01525602|advanced, incurable solid tumors
294289|NCT01525589|Breast cancer
294290|NCT01525589|PM01183
294291|NCT01525589|lurbinectedin
294292|NCT01525589|Pharma Mar
294293|NCT01525576|booster program
294294|NCT01525576|internet
294295|NCT01525576|cbt
294296|NCT01525576|Study the specific effects of adding a booster program
294297|NCT01525563|Duphaston Study
294298|NCT01525550|neuroendocrine tumors
294299|NCT01525550|adenoma islet cells
294300|NCT01525550|carcinoma islet cells
294301|NCT01525550|pancreatic neoplasms
294302|NCT01525550|angiogenesis inhibitors
294303|NCT01525550|sunitinib
294304|NCT01525550|neoplasms
294305|NCT01525550|carcinoma
294306|NCT01525550|adenoma
294307|NCT01525537|Anesthesia General
294308|NCT01525537|Anesthetics Inhalation
294309|NCT01525537|Diagnostic techniques and procedures
294310|NCT01525524|tDCS
294311|NCT01525524|Major Depression
294312|NCT01525524|Stroke
294313|NCT01525498|Pelvic Organ Prolapse
294314|NCT01525498|Catheterization
294315|NCT01525498|Urinary tract infection
294316|NCT01525498|Urinary retention
294317|NCT01525472|obesity
294318|NCT01525472|adipose tissue
294319|NCT01525472|angiogenesis
294320|NCT01525472|senecence
294321|NCT01525459|Glioma
294322|NCT01525459|PBMC subpopulations
294323|NCT01525459|Gene expression
294324|NCT01525459|Metabolomics
294325|NCT01525459|Immunological status
294326|NCT01525459|miRNA
294327|NCT01525459|Proteomics
294328|NCT01525446|NSCLC
294329|NCT01525446|Lung Cancer
294330|NCT01525394|lymphomas
294331|NCT01525394|Refractory solid tumors
294332|NCT01525368|mild cognitive impairment
294333|NCT01525368|Alzheimer's disease
294334|NCT01525368|cognitive intervention
294335|NCT01525368|cognitive reserve
294336|NCT01525355|EUS
294337|NCT01525355|ERCP
294338|NCT01525355|Intraoperative cholangiogram
294339|NCT01525355|Cholecystectomy
294340|NCT01525355|Common Bile Duct Stones
294341|NCT01525355|Strictures
294342|NCT01525355|Stenosis
294343|NCT01525355|Duodenum
294344|NCT01525355|Dilated Bile duct
294345|NCT01525355|Non-filling of the duodenum by contrast
294346|NCT01525329|Actinic Keratosis
294347|NCT01525329|Photodynamic Therapy
294348|NCT01525316|Late Onset Neonatal Sepsis
294349|NCT01525316|Neonates
294350|NCT01525316|Lactoferrin
294351|NCT01525316|Infections
294352|NCT01525316|Prevention
294353|NCT01525316|Neurodevelopment
294354|NCT01525303|headaches
294355|NCT01525303|behavioral treatment
294356|NCT01525303|physical activity
294357|NCT01525290|wake-up stroke
294358|NCT01525290|thrombolysis
294359|NCT01525290|magnetic resonance imaging (MRI)
294360|NCT01525290|diffusion weighted imaging (DWI)
294361|NCT01525290|fluid attenuated inversion recovery (FLAIR)
294362|NCT01525264|Mammography
294363|NCT01525251|primary caregiver
294364|NCT01525251|neuroblastoma
294365|NCT01525251|support group
294366|NCT01525251|posttraumatic stress
294367|NCT01525251|uncertainty
294368|NCT01525199|Non-Small Cell Lung Cancer,
294369|NCT01525199|Epidermal Growth Factor Receptor mutation,
294370|NCT01525199|Lung cancer,
294371|NCT01525199|Lung adenocarcinoma
294372|NCT01525186|Weight
294373|NCT01525186|Food intakes
294374|NCT01525186|Feeding
294375|NCT01525160|Clot structure
294376|NCT01525160|Haemostasis
294377|NCT01525160|Gel point
294378|NCT01525160|Fractal dimension
294379|NCT01525160|serum amyloid A
294380|NCT01525160|C-reactive protein
294381|NCT01525160|vascular cell adhesion molecule-1
294382|NCT01525160|intercellular adhesion molecule-1
294383|NCT01525134|Tests, Diagnostic
294384|NCT01525134|Mycobacterium tuberculosis
294385|NCT01525134|Mycobacterium tuberculosis antigens
294386|NCT01525134|TB
294387|NCT01525134|Tuberculosis
294388|NCT01525134|Tuberculosis, Pulmonary
294389|NCT01525134|Tuberculosis, Miliary
294390|NCT01525134|Lipoarabinomannan
294391|NCT01525121|mechanical ventilation
294392|NCT01525121|chest physiotherapy
294393|NCT01525121|critical care
294394|NCT01525121|pneumonia
294395|NCT01525121|Mechanically ventilated patients with pulmonary infection.
294396|NCT01525108|Medication adherence
294397|NCT01525108|Blood pressure
294398|NCT01525108|Home-based blood pressure measurement
294399|NCT01525108|Blood Pressure Determination
294400|NCT01525108|Blood Pressure Monitors
294401|NCT01525108|Blood Pressure Monitoring, Ambulatory
294402|NCT01525095|Candida
294403|NCT01525095|Diagnostic Assay
294404|NCT01525095|Blood culture
294405|NCT01525095|Sepsis
294406|NCT01525095|T2 Magnetic Relaxation
294407|NCT01525056|rectal cancer
294408|NCT01525056|imaging
294409|NCT01525056|PET
294410|NCT01525056|MRI
294411|NCT01525043|Epicondylitis
294412|NCT01525004|Solid organ transplant
294413|NCT01525004|Flu vaccine
294414|NCT01524965|Locking Plate
294415|NCT01524965|Physiotherapy
294416|NCT01524926|Phase 2
294417|NCT01524926|Crizotinib
294418|NCT01524926|Anaplastic large cell lymphoma
294419|NCT01524926|Inflammatory myofibroblastic tumor
294420|NCT01524926|Papillary renal cell carcinoma type 1
294421|NCT01524926|Alveolar soft part sarcoma
294422|NCT01524926|Clear cell sarcoma
294423|NCT01524926|Alveolar rhabdomyosarcoma
294424|NCT01524874|vitamin d
294425|NCT01524874|cholecalciferol
294426|NCT01524874|nutritional supplements
294427|NCT01524874|hypovitaminosis d
294428|NCT01524874|klotho
294429|NCT01524874|toll like receptor 4
294430|NCT01524861|Tako-Tsubo
294431|NCT01524861|Sympathetic heart innervation
294432|NCT01524861|MIBG
294433|NCT01524861|Alpha-lipoic acid
294434|NCT01524861|L-acetyl carnitine
294435|NCT01524848|Clinical trial
294436|NCT01524848|Investigational drugs
294437|NCT01524848|Gastrointestinal stromal tumors
294438|NCT01524848|Pazopanib
294439|NCT01524835|Tissue Donors
294440|NCT01524835|Lung
294441|NCT01524835|Transplants
294442|NCT01524835|Transplantation
294443|NCT01524822|Military
294444|NCT01524822|Traumatic Brain Injury
294445|NCT01524822|Cognitive Testing
294446|NCT01524822|Neuroimaging
294447|NCT01524822|Brain Function
294448|NCT01524796|Real-life
294449|NCT01524796|non-interventional
294450|NCT01524796|observational
294451|NCT01524796|peripheral neuropathic pain
294452|NCT01524796|Lyrica
294453|NCT01524796|pregabalin
294454|NCT01524783|Neuroendocrine tumor
294455|NCT01524783|NET
294456|NCT01524783|progressive
294457|NCT01524783|advanced
294458|NCT01524783|gastrointestinal
294459|NCT01524783|GI or lung origin
294460|NCT01524783|nonfunctional
294461|NCT01524783|everolimus
294462|NCT01524783|Advanced NET of GI origin
294463|NCT01524783|Advanced NET of lung origin
294464|NCT01524744|oral lichen planus treatment pimecrolimus
294465|NCT01524718|radiation
294466|NCT01524718|time surgery
294467|NCT01524705|Pilot Study
294468|NCT01524705|Prospective Randomized Trial
294469|NCT01524705|Comparative Effectiveness
294470|NCT01524705|Glycemic Variability
294471|NCT01524705|insulin glargine
294472|NCT01524705|exenatide
294473|NCT01524705|basal insulin
294474|NCT01524705|bolus insulin
294475|NCT01524679|chronic hepatitis B
294476|NCT01524653|VTE
294477|NCT01524653|DVT
294478|NCT01524653|Chemo
294479|NCT01524653|Metastatic
294480|NCT01524653|Advanced
294481|NCT01524653|Systemic therapy
294482|NCT01524653|statin
294483|NCT01524653|biomarkers
294484|NCT01524640|oral cholera vaccine
294485|NCT01524640|safety and immunogenicity
294486|NCT01524640|bridging study
294487|NCT01524640|ethiopia
294488|NCT01524627|Smokers
294489|NCT01524627|fMRI
294490|NCT01524627|varenicline
294491|NCT01524614|continuous positive airway pressure
294492|NCT01524614|nasal mask
294493|NCT01524614|upper airway obstruction
294494|NCT01524601|Immunosuppression
294495|NCT01524601|Everolimus
294496|NCT01524601|rosuvastatin
294497|NCT01524601|fluvastatin
294498|NCT01524601|Lipid lowering
294499|NCT01524588|Genotype
294500|NCT01524588|Phenotype
294501|NCT01524588|Genotypic Variation Between Patients
294502|NCT01524588|Genotypic Phenotypic Relationships
294503|NCT01524575|pancreatic cancer
294504|NCT01524575|ERCC1
294505|NCT01524575|oxaliplatin
294506|NCT01524575|gemcitabine
294507|NCT01524562|Fibrosis
294508|NCT01524562|Cirrhosis
294509|NCT01524562|Africa
294510|NCT01524562|Schistosomiasis
294511|NCT01524562|Aflatoxin
294512|NCT01524562|Liver Disease
294513|NCT01524549|Cardiovascular
294514|NCT01524549|P450s
294515|NCT01524549|Flow-Mediated Dilatation
294516|NCT01524549|Brachial Artery Ultrasound
294517|NCT01524549|Endothelial Cell Function
294518|NCT01524549|Healthy Volunteer
294519|NCT01524549|HV
294520|NCT01524536|Hypereosinophilia
294521|NCT01524536|Hypereosinophilic Syndrome
294522|NCT01524536|Corticosteroids
294523|NCT01524536|Therapy
294524|NCT01524536|HES
294525|NCT01524523|Gene Expression
294526|NCT01524523|Acute Pain
294527|NCT01524523|Nitric Oxide
294528|NCT01524523|Pain
294529|NCT01524523|Bone Marrow
294530|NCT01524510|OSAS
294531|NCT01524510|AHI
294532|NCT01524510|MRA
294533|NCT01524510|CFD
294534|NCT01524497|losing interest and feelings of guilt
294535|NCT01524497|poor concentration
294536|NCT01524497|loss of appetite
294537|NCT01524497|suicide
294538|NCT01524484|Data quality
294539|NCT01524484|Anesthesia
294540|NCT01524484|Quality assurance
294541|NCT01524471|Hypertensive LES
294542|NCT01524445|Bortezomib
294543|NCT01524445|Velcade
294544|NCT01524445|multiple myeloma
294545|NCT01524445|retrospective study, response rate, medical resource utilization
294546|NCT01524432|Clotrimazole
294547|NCT01524432|Microcapsules
294548|NCT01524419|spontaneous labor
294549|NCT01524419|term
294550|NCT01524419|surgical
294551|NCT01524419|mechanical
294552|NCT01524419|fetal or maternal complications
294553|NCT01524406|Muscle Atrophy
294554|NCT01524393|Assisted Reproductive Techniques
294555|NCT01524393|Pregnancy
294556|NCT01524393|Pulmonary Embolism
294557|NCT01524393|Venous Thromboembolism
294558|NCT01524380|Schizophrenia
294559|NCT01524380|clinical trial
294560|NCT01524380|risperidone
294561|NCT01524380|ginkgo biloba extract
294562|NCT01524380|antioxidant
294563|NCT01524354|depth of anesthesia
294564|NCT01524354|valve surgery
294565|NCT01524341|Acute malaria
294566|NCT01524341|KAE609
294567|NCT01524328|Complementary and alternative medicine
294568|NCT01524328|HRQoL, Inflammatory bowel disease
294569|NCT01524315|Thiamine
294570|NCT01524315|Vitamin B1
294571|NCT01524315|Thiamine Deficiency
294572|NCT01524315|Thiamine supplementation
294573|NCT01524315|Cardiac surgery
294574|NCT01524315|Lactic Acid
294575|NCT01524302|pneumonia
294576|NCT01524302|ceftaroline
294577|NCT01524302|community-aquired
294578|NCT01524250|Multiple Sclerosis
294579|NCT01524250|relapse
294580|NCT01524250|demyelination
294581|NCT01524250|treatment
294582|NCT01524250|corticosteroids
294583|NCT01524224|Metastases
294584|NCT01524224|Neoplasm
294585|NCT01524224|Advanced Cancer
294586|NCT01524224|Metastatic Cancer
294587|NCT01524211|Aortic Aneurysms
294588|NCT01524185|childhood trauma
294589|NCT01524185|intergenerational trauma
294590|NCT01524185|child neglect
294591|NCT01524185|child maltreatment
294592|NCT01524185|mental health
294593|NCT01524172|child trauma exposure
294594|NCT01524172|mental health
294595|NCT01524172|yoga
294596|NCT01524172|mood regulation
294597|NCT01524172|child maltreatment
294598|NCT01524159|cardiovascular disease
294599|NCT01524146|Unresectable Cholangiocarcinoma
294600|NCT01524146|Biliary obstruction
294601|NCT01524146|Stent obstruction
294602|NCT01524146|Biliary stricture
294603|NCT01524146|Photodynamic therapy
294604|NCT01524146|PDT
294605|NCT01524146|Ablation
294606|NCT01524133|combat-related PTSD
294607|NCT01524133|Posttraumatic stress disorder
294608|NCT01524133|prolonged exposure therapy
294609|NCT01524133|sertraline
294610|NCT01524133|military
294611|NCT01524133|veterans
294612|NCT01524133|VA hospital
294613|NCT01524133|mental illness
294614|NCT01524120|Mucosal healing
294615|NCT01524107|Prophylaxis Antibiotics
294616|NCT01524107|Maternal Complications
294617|NCT01524107|Neonatal Complications
294618|NCT01524107|Cord Prolapse
294619|NCT01524107|Elective Caesarian Section
294620|NCT01524107|Maternal Morbidity
294621|NCT01524107|Neonatal Morbidity
294622|NCT01524094|colorectal cancer
294623|NCT01524094|cytoreductive surgery
294624|NCT01524094|intraperitoneal chemotherapy
294625|NCT01524094|systemic chemotherapy
294626|NCT01524094|Peritoneal Metastatic Disease From the Colon or Rectum
294627|NCT01524081|antibiotic prophylaxis
294628|NCT01524081|emergent surgery
294629|NCT01524081|surgical site infection
294630|NCT01524068|Acute Idiopathic Pulmonary Fibrosis Exacerbations
294631|NCT01524068|Idiopathic Pulmonary Fibrosis
294632|NCT01524068|IPF
294633|NCT01524042|Satisfaction
294634|NCT01524042|colonoscopy
294635|NCT01524042|double pants
294636|NCT01524042|single pants
294637|NCT01524029|Digital Breast Tomosynthesis
294638|NCT01524029|Digital Mammography
294639|NCT01524029|Breast cancer detection
294640|NCT01524016|Oncogenic osteomalacia
294641|NCT01524016|mesenchymal tumor
294642|NCT01524016|Somatostatin receptor
294643|NCT01524016|68Ga-DOTATATE
294644|NCT01524016|PET/CT
294645|NCT01524003|community based participatory research
294646|NCT01523977|ALL
294647|NCT01523977|pediatric
294648|NCT01523977|relapse
294649|NCT01523964|DMD
294650|NCT01523964|EIM
294651|NCT01523964|Duchenne Muscular Dystrophy
294652|NCT01523964|electrical impedance myography
294653|NCT01523951|topical local anaesthesia
294654|NCT01523951|cooling
294655|NCT01523951|capsaicin 8%
294656|NCT01523951|epidermal nerve fiber density
294657|NCT01523951|treatment pain
294658|NCT01523925|Functional electrical therapy
294659|NCT01523925|Bilateral arm training
294660|NCT01523925|Constraint induced therapy
294661|NCT01523925|Stroke rehabilitation
294662|NCT01523925|Clinical evaluation
294663|NCT01523925|Kinematic analysis
294664|NCT01523912|radiofrequency ablation
294665|NCT01523912|gastric dysplasia
294666|NCT01523912|gastric neoplasia
294667|NCT01523899|SSTI
294668|NCT01523899|cutaneous abscess
294669|NCT01523899|boil
294670|NCT01523847|Hodgkin Lymphoma
294671|NCT01523847|Cardiopathic
294672|NCT01523847|elderly
294673|NCT01523847|Myocet
294674|NCT01523834|Diffuse Large B-cell Lymphoma (DLBCL)
294675|NCT01523834|Panobinostat
294676|NCT01523834|Patients with relapsed/refractory DLBCL.
294677|NCT01523808|pancreatic cancer
294678|NCT01523808|asparaginase
294679|NCT01523795|Energy intake
294680|NCT01523795|Video games
294681|NCT01523795|Television
294682|NCT01523795|Physical activity
294683|NCT01523795|Obesity
294684|NCT01523782|Acute Lymphoblastic leukemia
294685|NCT01523782|Elderly patient
294686|NCT01523782|Asparaginase
294687|NCT01523769|prematurity
294688|NCT01523769|umbilical cord milking
294689|NCT01523769|delayed cord clamping
294690|NCT01523769|neonatal transfusion
294691|NCT01523730|Schizophrenia
294692|NCT01523730|Nicotine
294693|NCT01523730|Transcranial Magnetic Stimulation
294694|NCT01523730|Cognition
294695|NCT01523730|EEG
294696|NCT01523717|procalcitonin
294697|NCT01523717|decrease over 72 hours
294698|NCT01523717|severe sepsis
294699|NCT01523717|septic shock
294700|NCT01523691|Healthy individuals
294701|NCT01523678|Ovarian Cancer
294702|NCT01523678|Endometrial Cancer
294703|NCT01523678|Endometrial Carcinoma
294704|NCT01523678|Uterine Cervical Cancer
294705|NCT01523678|Paclitaxel
294706|NCT01523678|Carboplatin
294707|NCT01523678|Neupogen
294708|NCT01523678|Filgrastim
294709|NCT01523678|Ovarian Diseases
294710|NCT01523678|Peritoneal Diseases
294711|NCT01523678|Fallopian Tube Diseases
294712|NCT01523678|Endocrine System Diseases
294713|NCT01523678|Endometrial Diseases
294714|NCT01523678|Uterine Cervical Diseases
294715|NCT01523678|Neoplasms
294716|NCT01523678|Neoplasms, Glandular and Epithelial
294717|NCT01523678|Ovarian Neoplasms
294718|NCT01523678|Peritoneal Neoplasms
294719|NCT01523678|Fallopian Tube Neoplasms
294720|NCT01523678|Neoplasms, Endometrial
294721|NCT01523678|Cervical Neoplasms
294722|NCT01523678|Genital Neoplasms, Female
294723|NCT01523678|Urogenital Neoplasms
294724|NCT01523678|Antineoplastic Agents, Phytogenic
294725|NCT01523678|Genital Diseases, Female
294726|NCT01523639|liver injury
294727|NCT01523639|steatosis
294728|NCT01523639|KRAS-Wild-Type
294729|NCT01523639|metastatic colorectal cancer
294730|NCT01523639|metformin
294731|NCT01523639|placebo
294732|NCT01523639|chemotherapy
294733|NCT01523626|Trauma
294734|NCT01523626|Injur*
294735|NCT01523626|Emergen*
294736|NCT01523626|Computed Tomography
294737|NCT01523626|Total body
294738|NCT01523626|TBCT
294739|NCT01523626|Whole body
294740|NCT01523626|WBCT
294741|NCT01523626|Full body
294742|NCT01523626|Pan CT
294743|NCT01523613|Dental caries
294744|NCT01523613|Proximal surfaces
294745|NCT01523613|Posterior teeth
294746|NCT01523613|Carious lesions
294747|NCT01523613|Tooth diseases
294748|NCT01523613|Dental restorations
294749|NCT01523613|Glass-ionomer
294750|NCT01523600|whole body vibration
294751|NCT01523600|physical functioning
294752|NCT01523600|falls
294753|NCT01523600|older people
294754|NCT01523600|prevention
294755|NCT01523574|oxaliplatin
294756|NCT01523574|vitamin e
294757|NCT01523574|neuropathy
294758|NCT01523574|peripheral
294759|NCT01523574|prophylaxis
294760|NCT01523561|dance
294761|NCT01523561|intervention
294762|NCT01523561|adolescent
294763|NCT01523561|girls
294764|NCT01523548|Carbon Monoxide
294765|NCT01523548|Hypertension, Pulmonary
294766|NCT01523522|Fecal incontinence
294767|NCT01523522|Myoblast
294768|NCT01523522|Surgery
294769|NCT01523509|Dental Caries
294770|NCT01523509|Radiography, Dental
294771|NCT01523509|Contrast media
294772|NCT01523509|Tooth
294773|NCT01523496|HIV
294774|NCT01523496|Vitamin D Deficiency
294775|NCT01523483|preterm birth
294776|NCT01523483|preterm labor
294777|NCT01523483|progesterone
294778|NCT01523483|uterine electromyography
294779|NCT01523483|cervical length
294780|NCT01523470|non-invasive ventilator
294781|NCT01523457|metastatic pancreatic cancer
294782|NCT01523457|locally advanced pancreatic cancer
294783|NCT01523457|FOLFIRINOX
294784|NCT01523457|phase II
294785|NCT01523457|progression free survival
294786|NCT01523444|Adolescents
294787|NCT01523444|Screening
294788|NCT01523444|Advice
294789|NCT01523444|Referral
294790|NCT01523431|Colorectal cancer
294791|NCT01523431|CPT-11
294792|NCT01523431|UGT1A1
294793|NCT01523431|Neutropenia
294794|NCT01523431|diarrhea
294795|NCT01523418|Xarelto
294796|NCT01523418|Thromboembolism, Venous
294797|NCT01523418|Orthopedic surgery
294798|NCT01523418|Factor Xa inhibitor
294799|NCT01523418|Observational study
294800|NCT01523405|Non Interventional Study, Type II Diabetes Mellitus, Quality of Life
294801|NCT01523392|Stable Coronary Artery Disease, CAD
294802|NCT01523379|Causalgia
294803|NCT01523379|CRPS
294804|NCT01523379|complex regional pain syndrome
294805|NCT01523379|Dynastat
294806|NCT01523379|Parecoxib
294807|NCT01523366|Stable Coronary Artery Disease, CAD
294808|NCT01523353|Prehabilitation
294809|NCT01523353|Exercise
294810|NCT01523353|Colorectal Cancer
294811|NCT01523353|Surgery
294812|NCT01523327|Uric acid
294813|NCT01523314|diabetic macular edema
294814|NCT01523314|intravitreal injection
294815|NCT01523314|dexamethasone
294816|NCT01523314|Cyclodextrin
294817|NCT01523314|eye drops
294818|NCT01523314|bevacizumab
294819|NCT01523314|macular laser
294820|NCT01523301|Rotigotine
294821|NCT01523301|Neupro
294822|NCT01523301|Depressive Symptom
294823|NCT01523301|Idiopathic Parkinson's disease
294824|NCT01523275|mitomycin-C
294825|NCT01523275|laryngotracheal stenosis
294826|NCT01523275|subglottic stenosis
294827|NCT01523275|tracheal stenosis
294828|NCT01523275|endoscopic airway surgery
294829|NCT01523262|preconditioning
294830|NCT01523262|aortic aneurysm
294831|NCT01523249|3D ultrasonography
294832|NCT01523249|epidural
294833|NCT01523249|neuraxial anesthesia
294834|NCT01523249|neuraxial analgesia
294835|NCT01523249|pregnant woman
294836|NCT01523249|parturients
294837|NCT01523236|Allergic Rhinitis
294838|NCT01523236|Bioequivalence
294839|NCT01523210|spasticity
294840|NCT01523210|Diffusor tensor imaging
294841|NCT01523210|distribution
294842|NCT01523210|botulinum toxin
294843|NCT01523210|physiotherapy
294844|NCT01523197|Obstructive Sleep Apnea hypopnea Syndrome
294845|NCT01523197|COPD
294846|NCT01523197|overlap syndrome
294847|NCT01523197|Auto-trilevel ventilation
294848|NCT01523197|BiPAP ventilation
294849|NCT01523184|Chronic constipation (CC)
294850|NCT01523184|Functional Constipation (FC)
294851|NCT01523184|Gastric Emptying
294852|NCT01523184|Colon Transit
294853|NCT01523184|multiple doses of YKP10811
294854|NCT01523184|gastrointestinal transit
294855|NCT01523184|colonic transit
294856|NCT01523158|Allergic Rhinitis
294857|NCT01523158|Immunotherapy
294858|NCT01523145|Atrial fibrillation
294859|NCT01523145|Radio Frequency Ablation
294860|NCT01523145|Rehabilitation
294861|NCT01523145|Physical capacity
294862|NCT01523145|Quality of life
294863|NCT01523145|Integrated rehabilitation
294864|NCT01523106|Crohn's disease
294865|NCT01523106|carnitine
294866|NCT01523067|Vasomera
294867|NCT01523067|PB1046
294868|NCT01523067|Hypertension
294869|NCT01523054|metoprolol, acute myocardial infarction, pharmacokinetics, pharmacodynamics
294870|NCT01523015|Adenocarcinoma
294871|NCT01523015|esophago-gastric cancer
294872|NCT01523015|chemotherapy
294873|NCT01523015|chemoradiotherapy
294874|NCT01523015|surgery
294875|NCT01522989|Cancer
294876|NCT01522989|Advanced
294877|NCT01522989|Refractory
294878|NCT01522950|hypertension
294879|NCT01522950|prevention
294880|NCT01522950|endothelial function
294881|NCT01522924|tobacco cessation treatment
294882|NCT01522924|standardized patients
294883|NCT01522924|dental students
294884|NCT01522924|tobacco cessation treatment education
294885|NCT01522898|Heart Failure
294886|NCT01522898|Atrial Fibrillation
294887|NCT01522885|Chest tube
294888|NCT01522885|placement
294889|NCT01522885|mal positioning
294890|NCT01522872|TH-302
294891|NCT01522872|Relapsed/Refractory Multiple Myeloma
294892|NCT01522872|Bortezomib
294893|NCT01522872|Phase 1/2
294894|NCT01522872|Hypoxia
294895|NCT01522872|Myeloma
294896|NCT01522872|Evofosfamide
294897|NCT01522872|Pomalidomide
294898|NCT01522872|Pimonidazole
294899|NCT01522859|COPD
294900|NCT01522859|Telehealth
294901|NCT01522859|health related quality of life
294902|NCT01522833|NSLCL
294903|NCT01522833|Erlotinib
294904|NCT01522833|Tarceva
294905|NCT01522807|Phase 1
294906|NCT01522807|Single Doses
294907|NCT01522807|Biocomparison
294908|NCT01522807|Pharmacokinetics
294909|NCT01522807|Healthy Volunteers
294910|NCT01522768|ESOPHAGUS
294911|NCT01522768|STOMACH
294912|NCT01522768|Afatinib
294913|NCT01522768|paclitaxel
294914|NCT01522768|trastuzumab
294915|NCT01522768|11-166
294916|NCT01522755|Pacing lead
294917|NCT01522755|implant
294918|NCT01522755|pacemaker
294919|NCT01522742|psoriasis
294920|NCT01522742|cardiovascular disease risk
294921|NCT01522742|atherosclerosis
294922|NCT01522742|etanercept (enbrel)
294923|NCT01522729|Chronic pulmonary obstructive disease
294924|NCT01522729|Muscle dysfunction
294925|NCT01522729|Exercise intolerance
294926|NCT01522729|Muscle afferents
294927|NCT01522729|Ventilation
294928|NCT01522703|asthma
294929|NCT01522703|allergic rhinitis
294930|NCT01522703|dietary interventions
294931|NCT01522703|mouse allergy
294932|NCT01522690|Accelerometer
294933|NCT01522690|gait analysis
294934|NCT01522690|Healthy subjects
294935|NCT01522677|tumor immunology
294936|NCT01522677|neoadjuvant
294937|NCT01522677|colonoscopy
294938|NCT01522677|photosensitization
294939|NCT01522651|Atrial Fibrillation
294940|NCT01522651|Ranolazine
294941|NCT01522651|Dronedarone
294942|NCT01522651|Dual Chamber Pacemakers
294943|NCT01522625|chronic hepatitis B
294944|NCT01522625|hepatitis B viral DNA
294945|NCT01522625|antiviral therapy
294946|NCT01522625|Tenofovir
294947|NCT01522612|KRAS Wild Type
294948|NCT01522612|Frail Elderly
294949|NCT01522612|QLQ-C30
294950|NCT01522612|QLQ-ELD14
294951|NCT01522612|CGA
294952|NCT01522612|EGFR
294953|NCT01522612|Cetuximab
294954|NCT01522612|5-FU
294955|NCT01522599|ARDS: Acute Respiratory Distress Syndrome
294956|NCT01522599|LOW FLOW ECCO2-R: EXTRA-CORPOREAL CO2 REMOVAL
294957|NCT01522599|VILI: Ventilator Induced Lung Injury
294958|NCT01522573|Cholangiocarcinoma
294959|NCT01522573|Pancreatic Cancer
294960|NCT01522573|Bile Duct Cancer
294961|NCT01522573|Biliary Stricture
294962|NCT01522573|Biliary obstruction
294963|NCT01522573|Stent obstruction
294964|NCT01522573|Proximal duct stricture
294965|NCT01522573|Distal duct stricture
294966|NCT01522573|Ampullary Cancer
294967|NCT01522573|Biliary sphincter stenosis
294968|NCT01522573|Impacted stones
294969|NCT01522573|Chronic pancreatitis
294970|NCT01522573|Peri-ampullary diverticula
294971|NCT01522573|Altered anatomy
294972|NCT01522573|Endoscopic ultrasound
294973|NCT01522573|Endoscopic Retrograde Cholangiopancreatography
294974|NCT01522573|Multicenter
294975|NCT01522560|CA2 and CA3 residents
294976|NCT01522560|Pediatric Anesthesia
294977|NCT01522547|Pomalidomide
294978|NCT01522547|Sickle Cell Disease
294979|NCT01522547|Fetal Hemoglobin
294980|NCT01522534|injuries
294981|NCT01522534|pain
294982|NCT01522534|Block, Nerve
294983|NCT01522534|morphine
294984|NCT01522534|Prehospital Emergency Care
294985|NCT01522521|AK156
294986|NCT01522508|Analgesia
294987|NCT01522508|Anesthetics
294988|NCT01522508|Diagnostic Techniques and Procedures
294989|NCT01522482|fatty acids
294990|NCT01522482|cardiovascular disease
294991|NCT01522482|genotype
294992|NCT01522482|apoE
294993|NCT01522469|FLT3
294994|NCT01522469|Crenolanib
294995|NCT01522469|Acute
294996|NCT01522469|myeloid
294997|NCT01522469|leukemia
294998|NCT01522469|relapsed
294999|NCT01522469|refractory
295000|NCT01522443|prostate cancer
295001|NCT01522443|castration resistant prostate cancer
295002|NCT01522443|bone pain
295003|NCT01522443|CRPC
295004|NCT01522430|Resistant hypertension
295005|NCT01522430|Renal denervation
295006|NCT01522430|Ambulatory blood pressure
295007|NCT01522430|Renal function
295008|NCT01522430|Simplicity catheter
295009|NCT01522430|Sham procedure
295010|NCT01522404|Mild Cognitive Impairment
295011|NCT01522404|Memory Loss
295012|NCT01522404|Alzheimer's Disease
295013|NCT01522378|cardiac resynchronization therapy
295014|NCT01522365|Dental implants
295015|NCT01522365|XiVE CAD/CAM bridge
295016|NCT01522352|Bioprosthesis,
295017|NCT01522352|aortic valve replacement
295018|NCT01522352|Magna Ease
295019|NCT01522352|Mitroflow
295020|NCT01522352|Trifecta
295021|NCT01522339|NICU
295022|NCT01522339|MRI
295023|NCT01522339|Neonatal
295024|NCT01522339|Safety
295025|NCT01522339|Efficacy
295026|NCT01522339|Cincinnati
295027|NCT01522326|Acute Mountain Sickness
295028|NCT01522326|High Altitude Headache
295029|NCT01522326|Lake Louise AMS Score
295030|NCT01522326|Visual Analog Scale
295031|NCT01522326|Ibuprofen
295032|NCT01522326|Metoclopramide
295033|NCT01522326|Nepal
295034|NCT01522300|Tomosynthesis
295035|NCT01522300|breast cancer
295036|NCT01522300|specificity
295037|NCT01522300|sensitivity
295038|NCT01522300|To assess efficacy of Tomosynthesis by evaluating its sensitivity and specificity in detecting the multicentricity of mammary tumor
295039|NCT01522287|Obsessive Compulsive Disorder
295040|NCT01522287|Computer Assisted Therapy
295041|NCT01522287|Cognitive Behavior Therapy
295042|NCT01522287|Cognitive Therapy
295043|NCT01522261|Mechanical Bowel Prep
295044|NCT01522248|influenza vaccine
295045|NCT01522248|cytokines
295046|NCT01522248|chemokines
295047|NCT01522248|symptoms
295048|NCT01522235|Autoimmune autonomic neuropathy
295049|NCT01522235|Orthostatic hypotension
295050|NCT01522235|Dysautonomia
295051|NCT01522235|Autonomic failure
295052|NCT01522235|Peripheral autonomic neuropathy
295053|NCT01522222|cardiopulmonary bypass surgery
295054|NCT01522222|CABG
295055|NCT01522222|PEEP
295056|NCT01522209|CRLM
295057|NCT01522209|Primovist MRI
295058|NCT01522209|CEIOUS
295059|NCT01522196|SCD
295060|NCT01522183|Atypical Hemolytic-Uremic Syndrome
295061|NCT01522183|aHUS
295062|NCT01522183|Thrombotic Microangiopathy
295063|NCT01522183|TMA
295064|NCT01522170|Atypical Hemolytic Uremic Syndrome
295065|NCT01522170|aHUS
295066|NCT01522170|Eculizumab
295067|NCT01522157|Diet
295068|NCT01522157|Low-carbohydrate
295069|NCT01522157|Postprandial
295070|NCT01522157|Type 2 diabetes mellitus
295071|NCT01522131|bioresorbable membrane
295072|NCT01522118|Prostate Cancer
295073|NCT01522118|High Intensity Focused Ultrasound
295074|NCT01522118|Magnetic Resonance guided Focused Ultrasound
295075|NCT01522118|Non-invasive therapy
295076|NCT01522118|Focal Disease
295077|NCT01522105|Meningitis
295078|NCT01522105|Central Nervous System Infections
295079|NCT01522105|Pediatrics
295080|NCT01522105|Daptomycin
295081|NCT01522105|Anti-Bacterial Agents
295082|NCT01522105|Therapeutic Use
295083|NCT01522105|Pharmacologic Actions
295084|NCT01522092|Exacerbations
295085|NCT01522079|spinal muscular atrophy
295086|NCT01522079|heart rate variability
295087|NCT01522079|posture
295088|NCT01522079|air stacking
295089|NCT01522040|Asthma
295090|NCT01522040|Magnesium
295091|NCT01522040|Adrenergic Receptor
295092|NCT01522014|Joint Replacement
295093|NCT01522014|Health Related Quality of Life
295094|NCT01522014|Functional Outcomes
295095|NCT01522014|Revision Rate
295096|NCT01522001|Acute Coronary Syndrome
295097|NCT01522001|Myocardial Ischemia
295098|NCT01522001|Shared Care
295099|NCT01522001|Rehabilitation
295100|NCT01522001|Community
295101|NCT01522001|Cardiac Rehabilitation
295102|NCT01522001|Hospital
295103|NCT01521988|Atrial flutter
295104|NCT01521988|Atrial fibrillation
295105|NCT01521988|Catheter ablation
295106|NCT01521975|HBV DNA
295107|NCT01521975|LdT
295108|NCT01521975|ADV
295109|NCT01521975|HBeAg negative hepatitis
295110|NCT01521975|CHB
295111|NCT01521949|Prostate Cancer
295112|NCT01521949|Nutraceutical
295113|NCT01521949|Acai Juice
295114|NCT01521923|Certolizumab Pegol - Cimzia
295115|NCT01521923|Rheumatoid Arthritis
295116|NCT01521910|survival
295117|NCT01521910|protein restriction
295118|NCT01521910|diabetic nephropathy
295119|NCT01521910|type 1 diabetes
295120|NCT01521910|GFR
295121|NCT01521910|ESRD
295122|NCT01521910|progressive renal disease
295123|NCT01521897|Pneumococcal Vaccine
295124|NCT01521897|Prevenar
295125|NCT01521897|7-valent
295126|NCT01521897|Special Use-result surveillance
295127|NCT01521871|Tissue glue
295128|NCT01521871|Cyanoacrylate
295129|NCT01521871|Wound closure
295130|NCT01521871|Living donor nephrectomy
295131|NCT01521871|Surgical wound closure
295132|NCT01521845|elective percutaneous coronary intervention
295133|NCT01521845|hs-CRP
295134|NCT01521845|CKMB and troponin I
295135|NCT01521819|AMD
295136|NCT01521819|V-Ped
295137|NCT01521819|Vascularized Pigment Epithelial Detachment
295138|NCT01521819|Iray
295139|NCT01521819|radiation
295140|NCT01521819|retina
295141|NCT01521819|macula
295142|NCT01521819|radiotherapy
295143|NCT01521806|insulin sensitivity
295144|NCT01521806|resistant starch
295145|NCT01521780|hepatocellular carcinoma
295146|NCT01521780|MRI
295147|NCT01521780|pharmacogenomics
295148|NCT01521780|beta-catenin
295149|NCT01521767|pharmacokinetics
295150|NCT01521767|relative bioavailability
295151|NCT01521767|tolterodine microspheres in powder blend
295152|NCT01521767|Overactive Urinary Bladder
295153|NCT01521741|Breast Cancer
295154|NCT01521741|Lymphedema
295155|NCT01521741|symptoms
295156|NCT01521728|ALS
295157|NCT01521728|Exercise
295158|NCT01521728|Resistance
295159|NCT01521728|Endurance
295160|NCT01521702|adenocarcinoma
295161|NCT01521702|pancreatic head
295162|NCT01521689|MRD negative CR
295163|NCT01521676|breast cancer
295164|NCT01521663|Moderate to severe idiopathic RLS
295165|NCT01521650|Probiotics
295166|NCT01521650|Anaesthesia
295167|NCT01521650|Intubation
295168|NCT01521650|Pathogenic bacteria
295169|NCT01521611|Radioimmunotherapy
295170|NCT01521611|Transplant
295171|NCT01521611|BMT
295172|NCT01521611|yttrium
295173|NCT01521611|indium
295174|NCT01521598|Diabetic Peripheral Neuropathy
295175|NCT01521572|chronic obstructive pulmonary disease,
295176|NCT01521572|bronchial reversibility,
295177|NCT01521572|bronchodilator,
295178|NCT01521572|respiratory impedance,
295179|NCT01521572|forced oscillation technique,
295180|NCT01521572|plethysmography,
295181|NCT01521572|spirometry
295182|NCT01521572|Diagnostic Techniques, Respiratory System
295183|NCT01521546|Duchenne muscular dystrophy
295184|NCT01521546|cardiomyopathy
295185|NCT01521546|aldosterone antagonist
295186|NCT01521533|Relapsed Multiple Myeloma
295187|NCT01521533|NOX-A12
295188|NCT01521533|Velcade
295189|NCT01521533|Dexamethasone
295190|NCT01521533|Spiegelmer
295191|NCT01521533|Chemosensitization
295192|NCT01521533|Stromal cell-derived factor-1 (SDF-1)
295193|NCT01521533|CXCL12
295194|NCT01521520|type 1 diabetes
295195|NCT01521520|magnetic resonance imaging
295196|NCT01521520|insulitis
295197|NCT01521520|ferumoxytol
295198|NCT01521494|Hemodialysis
295199|NCT01521494|Hyperphosphatemia
295200|NCT01521468|Coronary artery disease
295201|NCT01521468|Diagnostic accuracy
295202|NCT01521468|CT coronary angiography
295203|NCT01521468|Positron emission tomography
295204|NCT01521468|Single photon emission tomography
295205|NCT01521468|Noninvasive techniques
295206|NCT01521468|Cardiac catheterization
295207|NCT01521468|Fractional flow reserve
295208|NCT01521442|PTSD
295209|NCT01521442|Yoga
295210|NCT01521442|Complementary and Alternative Medicine (CAM)
295211|NCT01521416|Illness
295212|NCT01521416|Influenza
295213|NCT01521416|Cost
295214|NCT01521416|UK
295215|NCT01521403|Blastocystis hominis
295216|NCT01521403|Metronidazole
295217|NCT01521377|LAMA
295218|NCT01521377|Respiratory
295219|NCT01521377|COPD
295220|NCT01521377|Tolerability
295221|NCT01521377|Beta-2 Agonist
295222|NCT01521377|Safety
295223|NCT01521377|Pharmacokinetics
295224|NCT01521377|Pharmacodynamics
295225|NCT01521377|LABA
295226|NCT01521377|Muscarinic Receptor Agonist
295227|NCT01521377|Healthy subjects
295228|NCT01521377|Moxifloxacin
295229|NCT01521377|Anticholinergic
295230|NCT01521377|GW642444
295231|NCT01521377|GSK573719
295232|NCT01521377|QTc
295233|NCT01521364|pharmacokinetic
295234|NCT01521364|drug-interaction
295235|NCT01521364|linezolid
295236|NCT01521364|clarithromycin
295237|NCT01521364|Mycobacterium tuberculosis
295238|NCT01521351|microwave radiometry
295239|NCT01521351|cardiovascular events
295240|NCT01521351|carotid artery disease
295241|NCT01521351|stroke
295242|NCT01521351|myocardial infarction
295243|NCT01521338|Cystic Fibrosis
295244|NCT01521338|G551D
295245|NCT01521338|G551D Mutation
295246|NCT01521312|Impaired glucose tolerance
295247|NCT01521312|Saxagliptin
295248|NCT01521312|Cardiovascular risk integrators
295249|NCT01521312|Vago-sympathetic activity
295250|NCT01521312|Arterial stiffness
295251|NCT01521312|Endothelial function
295252|NCT01521299|hydroxyurea
295253|NCT01521299|S phase
295254|NCT01521299|G2 phase
295255|NCT01521299|pharmacokinetics
295256|NCT01521286|Spain
295257|NCT01521286|cost
295258|NCT01521286|complications
295259|NCT01521286|incidence
295260|NCT01521286|adults
295261|NCT01521286|quality of life
295262|NCT01521286|Herpes Zoster
295263|NCT01521286|Surveillance
295264|NCT01521273|beans
295265|NCT01521273|biofortification
295266|NCT01521273|phytic acid
295267|NCT01521273|iron
295268|NCT01521273|iron isotopes
295269|NCT01521273|different phytic acid concentrations
295270|NCT01521260|dental implants
295271|NCT01521260|microbiology
295272|NCT01521260|chlorhexidine
295273|NCT01521247|Asthma
295274|NCT01521247|Transition program
295275|NCT01521247|Pediatric
295276|NCT01521247|Adult
295277|NCT01521208|Out-of-Hospital cardiac arrest (OHCA)
295278|NCT01521208|Chest compressions
295279|NCT01521208|LUCAS device
295280|NCT01521195|pediatric
295281|NCT01521195|ECMO
295282|NCT01521195|extracorporeal blood flow
295283|NCT01521195|VO2
295284|NCT01521182|Probiotic - dairy product - influenza vaccination - healthy elderly
295285|NCT01521169|Plant sterol - Hypercholesterolemia - Diet - Dairy
295286|NCT01521156|Plant sterols - Hypercholesterolemia - Diet - Dairy
295287|NCT01521143|EOC
295288|NCT01521130|Benign Childhood Epilepsy With Centrotemporal Spikes
295289|NCT01521130|Benign Rolandic Epilepsy
295290|NCT01521117|donepezil
295291|NCT01521117|parkinson's disease
295292|NCT01521117|balance
295293|NCT01521117|cholinesterase inhibitor
295294|NCT01521104|narrow band imaging（NBI）
295295|NCT01521104|colorectal lesions
295296|NCT01521104|predicting histology
295297|NCT01521091|narrow band imaging（NBI）
295298|NCT01521091|indigo carmine
295299|NCT01521091|acetic acid
295300|NCT01521091|colorectal lesions
295301|NCT01521091|predicting histology
295302|NCT01521065|AMD
295303|NCT01521065|Wet AMD
295304|NCT01521039|aGVHD
295305|NCT01521039|Acute Graft-versus-Host Disease
295306|NCT01521039|allogeneic stem cell transplantation
295307|NCT01521039|Hematopoietic stem cell transplantation
295308|NCT01521039|MicroRNA Expression
295309|NCT01521000|Breast Cancer
295310|NCT01521000|Lymphedema
295311|NCT01521000|Sentinel Node Biopsy
295312|NCT01521000|Axillary Dissection
295313|NCT01520987|Parkinson Disease
295314|NCT01520987|BIA 9-1067
295315|NCT01520961|Partial Hip Arthroplasty
295316|NCT01520948|Parkinson disease
295317|NCT01520948|Incontinence
295318|NCT01520935|Office of National Statistics
295319|NCT01520935|Burden of Disease
295320|NCT01520935|Influenza
295321|NCT01520935|Hospital Episode Statistics
295322|NCT01520935|General Practitioners Research Database
295323|NCT01520922|Relapsed or Refractory Chronic Lymphocytic Leukemia
295324|NCT01520922|Chronic Lymphocytic Leukemia
295325|NCT01520922|CLL
295326|NCT01520922|Cancer
295327|NCT01520922|Lymphoid leukemia
295328|NCT01520922|Lymphoblastic leukemia
295329|NCT01520909|immune thrombocytopenic purpura
295330|NCT01520909|pediatrics
295331|NCT01520909|chronic ITP
295332|NCT01520909|idiopathic thrombocytopenic purpura
295333|NCT01520909|eltrombopag
295334|NCT01520909|Chronic Immune Thrombocytopenia
295335|NCT01520909|platelet disorder
295336|NCT01520909|thrombocytopenia
295337|NCT01520896|Phase 1
295338|NCT01520896|Healthy male and female volunteers
295339|NCT01520896|Drug-drug interaction
295340|NCT01520896|Pharmacokinetics
295341|NCT01520896|NKTR-118
295342|NCT01520870|Dacomitinib
295343|NCT01520870|PF-299804
295344|NCT01520870|Glioblastoma, Recurrent
295345|NCT01520870|EGFR
295346|NCT01520857|Laparoscopic inguinal hernia repair
295347|NCT01520857|TAPP
295348|NCT01520857|Spinal Anesthesia
295349|NCT01520857|General Anesthesia
295350|NCT01520805|acute myeloid leukemia
295351|NCT01520805|myelodysplastic syndrome
295352|NCT01520805|refractory
295353|NCT01520805|relapsed
295354|NCT01520805|hypomethylating agents
295355|NCT01520792|pharmacogenetic of paracetamol
295356|NCT01520792|Pain threshold
295357|NCT01520779|Hepatocellular cacinoma
295358|NCT01520779|Radiofrequancy ablation
295359|NCT01520779|Intrahepatic recurrence
295360|NCT01520766|glass fiber posts
295361|NCT01520766|titanium posts
295362|NCT01520766|postendodontic restoration
295363|NCT01520766|self-adhesive resin cement
295364|NCT01520740|Gold Stage III
295365|NCT01520740|Gold Stage IV
295366|NCT01520740|Chronic Obstructive Pulmonary Disease
295367|NCT01520740|COPD
295368|NCT01520740|Lung Volume Reduction Surgery
295369|NCT01520740|LVRS
295370|NCT01520740|Bronchoscopic Lung Volume Reduction
295371|NCT01520740|BLVR
295372|NCT01520740|Upper Lobe Predominant
295373|NCT01520740|ULP
295374|NCT01520740|Heterogeneous
295375|NCT01520740|Homogeneous
295376|NCT01520727|BIA 9-1067
295377|NCT01520714|Congestive Heart Failure (CHF)
295378|NCT01520714|Cardiac Resynchronization Therapy (CRT)
295379|NCT01520714|BiVentricular Implantable Cardioverter Defibrillator (BiVICD)
295380|NCT01520714|Fraction
295381|NCT01520701|head and neck cancer
295382|NCT01520701|Hydrotac®
295383|NCT01520701|radiodermatitis
295384|NCT01520701|algia
295385|NCT01520701|radiotherapy
295634|NCT01519752|Tinea Pedis
295386|NCT01520688|Mild persistent or mild intermittent asthma
295387|NCT01520675|chronic pancreatitis
295388|NCT01520675|randomized controlled trial
295389|NCT01520675|endoscopic therapy
295390|NCT01520675|surgery
295391|NCT01520675|ESWL
295392|NCT01520662|patient-centered care
295393|NCT01520662|wellness
295394|NCT01520662|preventive services
295395|NCT01520662|primary care
295396|NCT01520662|To accomplish Aim 2, we will conduct a nine-month pre-post
295397|NCT01520662|randomized controlled trial (RCT) in four primary care
295398|NCT01520662|practices. The study will focus on the impact of a patient
295399|NCT01520662|Wellness Portal on the quantity and quality of preventive
295400|NCT01520662|care patients receive in primary care practices.
295401|NCT01520649|Neurogenesis
295402|NCT01520649|hippocampal stem cells
295403|NCT01520649|depression
295404|NCT01520649|stroke
295405|NCT01520636|stroke
295406|NCT01520636|early rehabilitation
295407|NCT01520636|motor recovery
295408|NCT01520636|functional recovery
295409|NCT01520623|Allogeneic haematopoietic stem cell transplantation (HSCT)
295410|NCT01520623|Myeloablative conditioning for an haematological malignancy
295411|NCT01520623|Graft-versus-host disease (GvHD)
295412|NCT01520623|Activation of complement system
295413|NCT01520623|Gut GVHD
295414|NCT01520610|Tako-TSUBO Cardiomyopathy
295415|NCT01520610|Stress Cardiomyopathy
295416|NCT01520610|Myocardiopathies
295417|NCT01520610|Acute Coronary Syndrome
295418|NCT01520610|Gene
295419|NCT01520597|Multicentric
295420|NCT01520597|National
295421|NCT01520597|Prospective on
295422|NCT01520597|Listeriosis
295423|NCT01520597|Listeria
295424|NCT01520571|Computer Assistance
295425|NCT01520571|Total Knee Arthroplasty
295426|NCT01520571|conventional
295427|NCT01520558|Acute Myeloid Leukemia
295428|NCT01520558|High Risk Relapse
295429|NCT01520558|Complete Remission
295430|NCT01520558|Allogeneic Natural Killer Cells
295431|NCT01520545|Gablofen
295432|NCT01520545|baclofen injection
295433|NCT01520519|Leukemia
295434|NCT01520519|Chronic Lymphocytic Leukemia
295435|NCT01520519|CLL
295436|NCT01520519|Small Lymphocytic Lymphoma
295437|NCT01520519|SLL
295438|NCT01520519|Rituximab
295439|NCT01520519|Rituxan
295440|NCT01520519|PCI-32765
295441|NCT01520506|Hypertension
295442|NCT01520506|Kidney Diseases
295443|NCT01520506|Kidney Failure, Chronic
295444|NCT01520506|Vascular Diseases
295445|NCT01520506|Cardiovascular Diseases
295446|NCT01520506|Urologic Diseases
295447|NCT01520506|Renal Insufficiency, Chronic
295448|NCT01520506|Renal Insufficiency
295449|NCT01520493|pulmonary arterial hypertension
295450|NCT01520493|skeletal muscle microcirculation
295451|NCT01520493|exercise induced blood flow
295452|NCT01520480|survival after surgery
295453|NCT01520480|Pathological Subtrochanteric Fractures
295454|NCT01520467|SRS
295455|NCT01520467|PWS
295456|NCT01520467|pathological adrenarche
295457|NCT01520467|aromatase inhibitor
295458|NCT01520467|Children
295459|NCT01520454|Leptin resistance
295460|NCT01520454|Free fatty acids
295461|NCT01520454|Lipotoxicity
295462|NCT01520441|Botulinum Toxin
295463|NCT01520441|Prostate Cancer
295464|NCT01520441|BPH
295465|NCT01520441|LUTS
295466|NCT01520402|Genetic Determinants of Warfarin Dose Variability
295467|NCT01520389|cancer
295468|NCT01520389|solid tumors
295469|NCT01520389|oncology
295470|NCT01520389|Phase I
295471|NCT01520389|EGFR
295472|NCT01520389|EGF receptor (ErbB1)
295473|NCT01520389|irinotecan
295474|NCT01520363|Rett syndrome
295475|NCT01520363|RTT
295476|NCT01520363|MECP2
295477|NCT01520363|dextromethorphan
295478|NCT01520363|DM
295479|NCT01520311|Coronary Artery Disease
295480|NCT01520311|Myocardial Ischemia
295481|NCT01520311|Coronary Disease
295482|NCT01520311|Heart Diseases
295483|NCT01520311|Cardiovascular Diseases
295484|NCT01520311|Arteriosclerosis
295485|NCT01520311|Arterial Occlusive Diseases
295486|NCT01520311|Vascular Diseases
295487|NCT01520311|CABG
295488|NCT01520311|SVG
295489|NCT01520311|eSVS Mesh
295490|NCT01520311|Bypass Grafting
295491|NCT01520285|hypertension
295492|NCT01520285|Blood pressure decrease
295493|NCT01520285|efficacy
295494|NCT01520272|HPV18 Immunogenicity
295495|NCT01520272|HPV16 Immunogenicity
295496|NCT01520272|Bivalent HPV16/18 Vaccine
295497|NCT01520272|Less than 3 Dosed of the Bivalent HPV Vaccine
295498|NCT01520272|HP Vaccine
295499|NCT01520259|Gallbaldder
295500|NCT01520259|Gallstones
295501|NCT01520259|Inflammation
295502|NCT01520259|Cholecystectomy
295503|NCT01520259|Cancer
295504|NCT01520259|Gallbaldder Cancer
295505|NCT01520246|adult acute lymphoblastic leukemia
295506|NCT01520246|childhood acute lymphoblastic leukemia
295507|NCT01520246|adult T-cell leukemia/lymphoma
295508|NCT01520233|disseminated neuroblastoma
295509|NCT01520233|localized unresectable neuroblastoma
295510|NCT01520233|recurrent neuroblastoma
295511|NCT01520233|regional neuroblastoma
295512|NCT01520233|stage 4S neuroblastoma
295513|NCT01520194|genital warts
295514|NCT01520194|HPV
295515|NCT01520194|psychosocial burden
295516|NCT01520194|economic burden
295517|NCT01520194|female genital warts
295518|NCT01520168|Incisional hernia
295519|NCT01520168|Mesh
295520|NCT01520168|Surgery
295521|NCT01520168|Composix Kugel
295522|NCT01520168|IPOM technique
295523|NCT01520155|lupus erythematosus
295524|NCT01520155|cardiovascular risk
295525|NCT01520142|Healthy participants
295526|NCT01520142|Pharmacodynamic
295527|NCT01520142|Pharmacokinetics
295528|NCT01520142|Intravenous Endotoxin-Induced Model
295529|NCT01520142|Acute Inflammation
295530|NCT01520142|JNJ-26528398
295531|NCT01520142|Anti-inflammatory
295532|NCT01520129|Bipolar Disorder
295533|NCT01520129|Bipolar NOS
295534|NCT01520129|Bipolar Depression
295535|NCT01520103|Metastatic breast cancer
295536|NCT01520103|locally advanced breast cancer
295537|NCT01520103|Her2/new negative
295538|NCT01520103|HER2 negative
295539|NCT01520090|contraception
295540|NCT01520090|family planning
295541|NCT01520090|egyptian
295542|NCT01520090|knowledge
295543|NCT01520077|alopecia areata
295544|NCT01520077|vytorin
295545|NCT01520077|statin
295546|NCT01520077|hair growth
295547|NCT01520064|Emphysema
295548|NCT01520064|GOLD Stage III
295549|NCT01520064|GOLD Stage IV
295550|NCT01520064|AeriSeal System
295551|NCT01520064|Homogeneous
295552|NCT01520064|Heterogeneous
295553|NCT01520064|Upper Lobe Predominant
295554|NCT01520064|ULP
295555|NCT01520064|Chronic Obstructive Pulmonary Disease
295556|NCT01520064|COPD
295557|NCT01520064|Lung Volume Reduction Surgery
295558|NCT01520064|LVRS
295559|NCT01520064|Bronchoscopic Lung Volume Reduction
295560|NCT01520064|BLVR
295561|NCT01520051|Asthma
295562|NCT01520051|Viral
295563|NCT01520051|Infection
295564|NCT01520051|Inflammation
295565|NCT01520051|Mepolizumab
295566|NCT01520051|Eosinophilia
295567|NCT01520025|Radiopharmaceutical
295568|NCT01520025|18FDG PET
295569|NCT01520025|CTA
295570|NCT01520025|Multi-modality imaging
295571|NCT01520025|Metabolic Imaging of Ischemia
295572|NCT01520025|Myocardial blood flow
295573|NCT01520025|Myocardial blood flow reserve
295574|NCT01519999|Shared decision making
295575|NCT01519999|Ambulatory Care
295576|NCT01519999|Patient-Centered Care
295577|NCT01519999|Community-wide intervention
295578|NCT01519999|Intervention Study
295579|NCT01519999|Longitudinal Studies
295580|NCT01519986|Vitamin D
295581|NCT01519986|Cholecalciferol
295582|NCT01519986|Supplementation
295583|NCT01519986|Dietary Supplements
295584|NCT01519986|Dietary Fats
295585|NCT01519986|25-hydroxyvitamin D
295586|NCT01519973|Diagnostic imaging
295587|NCT01519973|Single Photon Emission Computed Tomography
295588|NCT01519973|Positron emission tomography
295589|NCT01519973|Computed tomography
295590|NCT01519973|Attenuation
295591|NCT01519973|Resolution
295592|NCT01519973|Scatter
295593|NCT01519973|Radiopharmaceutical
295594|NCT01519934|Ulthera® System
295595|NCT01519934|Ultherapy™ Treatment
295596|NCT01519934|Ulthera, Inc.
295597|NCT01519934|Ultrasound treatment for skin tightening
295598|NCT01519908|cardiac resynchronization therapy
295599|NCT01519908|biomarkers
295600|NCT01519908|response
295601|NCT01519895|quality of life
295602|NCT01519895|anxiety
295603|NCT01519895|stress
295604|NCT01519895|carers
295605|NCT01519895|colorectal or colon cancer
295606|NCT01519882|Rotigotine
295607|NCT01519882|Neupro
295608|NCT01519882|Polysomnography
295609|NCT01519882|Sleep efficiency
295610|NCT01519882|Advanced Idiopathic Parkinson's Disease
295611|NCT01519882|Sleep Disorder
295612|NCT01519869|peritoneal
295613|NCT01519869|carcinoma
295614|NCT01519869|ovarian
295615|NCT01519869|fallopian tube
295616|NCT01519869|neoadjuvant chemotherapy
295617|NCT01519869|surgical debulking
295618|NCT01519856|open
295619|NCT01519856|non-intervention
295620|NCT01519856|observational
295621|NCT01519843|stroke
295622|NCT01519830|Anemia, Iron-Deficiency
295623|NCT01519830|Blood Donors
295624|NCT01519817|Vaccine Therapy
295625|NCT01519817|Dose-Limiting Toxicity
295626|NCT01519817|Maximum Tolerated Dose
295627|NCT01519817|Clinical Response
295628|NCT01519817|Immune Response
295629|NCT01519817|Cancer
295630|NCT01519817|Solid Tumor
295631|NCT01519791|Certolizumab Pegol - Cimzia
295632|NCT01519791|Methotrexate
295633|NCT01519791|Rheumatoid Arthritis
295635|NCT01519713|Meningitis
295636|NCT01519713|Meningococcal Meningitis
295637|NCT01519713|Meningococcal Infections
295638|NCT01519713|Meningococcal conjugate Vaccine
295639|NCT01519713|Menactra®
295640|NCT01519700|Filgrastim
295641|NCT01519700|G-CSF, neutropenia
295642|NCT01519700|supportive care
295643|NCT01519700|breast cancer
295644|NCT01519687|hyperuricemia
295645|NCT01519687|gout
295646|NCT01519687|levotofisopam
295647|NCT01519661|Tobramycin Inhalation powder
295648|NCT01519661|Cystic fibrosis
295649|NCT01519661|Lung disease
295650|NCT01519661|Anti-bacterial agents
295651|NCT01519648|Invasive fungal infection
295652|NCT01519648|Acute leukemia (AL)
295653|NCT01519648|Hematopoietic stem cell transplantation
295654|NCT01519648|Antifungal stewardship
295655|NCT01519648|Neutropenia
295656|NCT01519648|Hematological malignancies
295657|NCT01519635|Kidney oxygenation
295658|NCT01519635|Stage 1 or 2 hypertension
295659|NCT01519635|BOLD-IRM
295660|NCT01519622|End of life decisions
295661|NCT01519622|Perception of illness
295662|NCT01519609|Bowel prep
295663|NCT01519609|Safety
295664|NCT01519609|Efficacy
295665|NCT01519583|walking
295666|NCT01519583|physical activity
295667|NCT01519583|sedentary behavior
295668|NCT01519570|Herpes Zoster vaccine
295669|NCT01519570|Electronic patient portal
295670|NCT01519570|Electronic medical record
295671|NCT01519570|Primary care
295672|NCT01519570|Immunizations
295673|NCT01519544|Sleep
295674|NCT01519544|High Altitude
295675|NCT01519544|High-altitude Sleep Disturbance
295676|NCT01519544|Acute Mountain Sickness
295677|NCT01519544|Difficulty Sleeping at High Altitude
295678|NCT01519544|Periodic Breathing
295679|NCT01519544|Actigraphy
295680|NCT01519544|Acetazolamide
295681|NCT01519544|Temazepam
295682|NCT01519544|Groningen Sleep Quality Questionnaire survey
295683|NCT01519544|Stanford Sleepiness Scale
295684|NCT01519544|Lake Louise Acute Mountain Sickness Score
295685|NCT01519518|ST elevation myocardial infarction
295686|NCT01519518|Primary percutaneous coronary intervention
295687|NCT01519518|Unfractionated heparin
295688|NCT01519518|Bivalirudin
295689|NCT01519518|primary angioplasty
295690|NCT01519505|Prevention
295691|NCT01519505|Diabetes mellitus
295692|NCT01519505|Lifestyle changes
295693|NCT01519505|Cardiovascular risk
295694|NCT01519505|Cost-effectiveness
295695|NCT01519492|Skin and Subcutaneous Tissue Bacterial Infections
295696|NCT01519479|Congestive Heart Failure
295697|NCT01519479|Heart Failure
295698|NCT01519479|Palliative Care
295699|NCT01519479|Palliative Medicine
295700|NCT01519466|Diabetes
295701|NCT01519466|SMBG
295702|NCT01519466|Insulin calculator
295703|NCT01519453|Asthma
295704|NCT01519453|Preschool
295705|NCT01519453|Health Disparities
295706|NCT01519453|Implementation
295707|NCT01519440|unintended extension
295708|NCT01519440|blunt
295709|NCT01519440|sharp
295710|NCT01519440|maternal blood loss
295711|NCT01519401|PCOS
295712|NCT01519401|drospirenone ethinylestradiol
295713|NCT01519401|androgens
295714|NCT01519401|metabolism
295715|NCT01519388|Neuromuscular disorder
295716|NCT01519388|Respiratory failure
295717|NCT01519388|Swallowing
295718|NCT01519388|Mechanical ventilation
295719|NCT01519375|Osteoarthritis
295720|NCT01519375|Rheumatoid Arthritis
295721|NCT01519375|Ankylosing Spondylitis
295722|NCT01519362|Polyacrylamide hydrogel
295723|NCT01519362|leukocytopenia
295724|NCT01519362|migration
295725|NCT01519362|complication
295726|NCT01519362|epicranial aponeurosis
295727|NCT01519362|PAAG injection
295728|NCT01519349|Becker muscular dystrophy
295729|NCT01519349|BMD
295730|NCT01519349|muscular dystrophy
295731|NCT01519349|inclusion body myositis
295732|NCT01519349|IBM
295733|NCT01519349|Follistatin
295734|NCT01519310|choline metabolism
295735|NCT01519310|gut flora
295736|NCT01519310|phosphatidylcholine
295737|NCT01519310|lecithin
295738|NCT01519297|Preeclampsia
295739|NCT01519297|Pregnancy Induced Hypertension
295740|NCT01519284|Parkinson Disease
295741|NCT01519284|BIA 9-1067
295742|NCT01519271|Parkinson's Disease
295743|NCT01519271|Mild Cognitive Impairment
295744|NCT01519271|Cognition
295745|NCT01519271|Memory
295746|NCT01519271|Attention
295747|NCT01519271|Exelon
295748|NCT01519271|Rivastigmine
295749|NCT01519258|ARDS
295750|NCT01519245|coronary artery bypass grafting
295751|NCT01519245|tranexamic acid
295752|NCT01519245|antifibrinolytic
295753|NCT01519245|administration, topical
295754|NCT01519245|operative blood salvage
295755|NCT01519232|hepatocellular carcinoma
295756|NCT01519219|hepatic irradiation
295757|NCT01519219|IC-GREEN
295758|NCT01519206|Ulthera® System
295759|NCT01519206|Ultherapy™ Treatment
295760|NCT01519206|Ulthera, Inc.
295761|NCT01519193|Aggressive Behavior
295762|NCT01519193|Appetitive Aggression
295763|NCT01519193|Post-Traumatic Stress Disorder
295764|NCT01519180|gastroparesis
295765|NCT01519180|gastric emptying
295766|NCT01519180|antro-duodenal manometry
295767|NCT01519154|deep sedation
295768|NCT01519154|propofol
295769|NCT01519154|ketamine
295770|NCT01519154|child
295771|NCT01519154|preschool child
295772|NCT01519154|infant
295773|NCT01519154|recovery and quality of sedation
295774|NCT01519141|Human Immunodeficiency Virus
295775|NCT01519141|Atherosclerosis
295776|NCT01519141|Inflammation
295777|NCT01519141|Endothelial Function
295778|NCT01519141|Thrombosis
295779|NCT01519128|Healthy
295780|NCT01519128|TMC278
295781|NCT01519128|TMC278IFD1001
295782|NCT01519128|Human immunodeficiency virus - type 1
295783|NCT01519128|Pharmacokinetics
295784|NCT01519128|Digoxin
295785|NCT01519115|deep cervical flexors
295786|NCT01519115|spine stabilization
295787|NCT01519115|posture
295788|NCT01519115|function
295789|NCT01519115|neck pain
295790|NCT01519089|chronic
295791|NCT01519089|severe
295792|NCT01519089|moderate
295793|NCT01519089|treatment
295794|NCT01519089|safety
295795|NCT01519089|efficacy
295796|NCT01519089|CP-690
295797|NCT01519089|550
295798|NCT01519089|Plaque psoriasis
295799|NCT01519089|Psoriasis Vulgaris
295800|NCT01519089|Psoriatic Arthritis
295801|NCT01519089|tofacitinib
295802|NCT01519089|Xeljanz
295803|NCT01519076|stroke
295804|NCT01519063|Alcohol
295805|NCT01519063|Drinking
295806|NCT01519063|Drinkers
295807|NCT01519063|Alcohol Drinking
295808|NCT01519063|Memantine
295809|NCT01519063|Naltrexone
295810|NCT01519063|Alcohol Dependence
295811|NCT01519063|Alcohol Abuse
295812|NCT01519063|Alcohol-Related Disorders
295813|NCT01519063|Ethanol
295814|NCT01519063|Alcoholism
295815|NCT01519037|calcimimetic agent
295816|NCT01519037|RAAS
295817|NCT01519037|renin
295818|NCT01519037|aldosterone
295819|NCT01519024|hypertrophy
295820|NCT01519024|breast
295821|NCT01519024|postural balance
295822|NCT01519011|Myelodysplastic Syndromes
295823|NCT01519011|MDS
295824|NCT01519011|Chronic Myelomonocytic Leukemia
295825|NCT01519011|CMML
295826|NCT01519011|Acute Myeloid Leukemia
295827|NCT01519011|AML
295828|NCT01519011|Vidaza
295829|NCT01519011|oral azacitidine
295830|NCT01519011|aza
295831|NCT01519011|oral aza
295832|NCT01519011|pharmacokinetics
295833|NCT01519011|hematology
295834|NCT01519011|myeloid disease
295835|NCT01519011|PK
295836|NCT01518998|Fimasartan
295837|NCT01518998|Amlodipine
295838|NCT01518998|antihypertension
295839|NCT01518972|Alcohol
295840|NCT01518972|Abuse
295841|NCT01518972|Use
295842|NCT01518972|Disorder
295843|NCT01518972|Dependence
295844|NCT01518972|Symptoms
295845|NCT01518972|Alcoholic
295846|NCT01518972|Alcoholism
295847|NCT01518972|Prazosin
295848|NCT01518972|Drug
295849|NCT01518972|Medicine
295850|NCT01518972|Medication
295851|NCT01518972|Treatment
295852|NCT01518972|Study
295853|NCT01518972|Placebo
295854|NCT01518972|Medical
295855|NCT01518972|Management
295856|NCT01518972|Craving
295857|NCT01518972|Consumption
295858|NCT01518972|Binge
295859|NCT01518972|Drinking
295860|NCT01518972|Drink
295861|NCT01518972|Heavy
295862|NCT01518972|PTSD
295863|NCT01518972|Trauma
295864|NCT01518972|Post
295865|NCT01518972|Posttraumatic
295866|NCT01518946|Symptomatic Orthostatic Hypotension
295867|NCT01518933|HCV recurrence
295868|NCT01518933|stable liver transplanted patients
295869|NCT01518920|Age related sensorineural hearing loss
295870|NCT01518920|PF-04958242
295871|NCT01518907|cellulite
295872|NCT01518907|Xiaflex
295873|NCT01518894|PF-04958242
295874|NCT01518894|multiple dose
295875|NCT01518894|Safety
295876|NCT01518894|schizophrenia
295877|NCT01518842|ischemic retinopathy, stem cell,bone marrow
295878|NCT01518829|hepatocellular carcinom
295879|NCT01518829|postablation syndrom
295880|NCT01518829|procalcitonin
295881|NCT01518816|antioxidant preterm labor
295882|NCT01518803|Obesity
295883|NCT01518803|Adolescence
295884|NCT01518803|Lipid metabolism
295885|NCT01518803|Mediterranean diet
295886|NCT01518803|Chylomicron
295887|NCT01518803|Macrophages
295888|NCT01518790|PEG 3350
295889|NCT01518790|boston bowel preparation scale
295890|NCT01518790|colonoscopy cleanout
295891|NCT01518790|bowel preparation
295892|NCT01518790|miralax
295893|NCT01518790|gatorade
295894|NCT01518790|cleanout efficacy
295895|NCT01518790|Focus of study is efficacy of PEG 3350 cleanout for improving diagnostic yield of colonoscopy.
295896|NCT01518777|Coronary Artery Disease
295897|NCT01518725|Muscle Power
295898|NCT01518725|Vitamin D
295899|NCT01518725|Vitamins
295900|NCT01518725|Cholecalciferol
295901|NCT01518712|Healthy Volunteers
295902|NCT01518712|Bioequivalence
295903|NCT01518712|Canagliflozin (JNJ-28431754)
295904|NCT01518712|Metformin IR
295905|NCT01518686|Norm values
295906|NCT01518686|semi-automated kinetic perimetry
295907|NCT01518686|isopters
295908|NCT01518686|mathematical model
295909|NCT01518686|luminance
295910|NCT01518686|test-retest reliability
295911|NCT01518686|deviation
295912|NCT01518686|age dependance
295913|NCT01518686|different age groups
295914|NCT01518686|Healthy subjects
295915|NCT01518660|Resistance Training
295916|NCT01518660|Strength Training
295917|NCT01518647|Bodily Distress Syndrome
295918|NCT01518647|Medically unexplained symptoms
295919|NCT01518647|Functional somatic symptoms
295920|NCT01518647|Functional somatic syndromes
295921|NCT01518647|Treatment
295922|NCT01518647|Acceptance and Commitment Therapy
295923|NCT01518634|Bodily Distress Syndrome
295924|NCT01518634|Medically unexplained symptoms
295925|NCT01518634|Functional somatic symptoms
295926|NCT01518634|Functional somatic syndromes
295927|NCT01518634|Treatment
295928|NCT01518634|Imipramine
295929|NCT01518634|Tricyclic antidepressant
295930|NCT01518608|Alfentanil
295931|NCT01518608|Tracheal intubation
295932|NCT01518608|Rapid sequence induction
295933|NCT01518595|patients
295934|NCT01518582|Cervicobrachial
295935|NCT01518582|neuralgia
295936|NCT01518582|symptomatic cervical discopathy
295937|NCT01518569|ulinastatin
295938|NCT01518569|systemic inflammation
295939|NCT01518569|cardiac surgery
295940|NCT01518569|cardiopulmonary bypass
295941|NCT01518556|Idarubicin
295942|NCT01518556|Remission Induction
295943|NCT01518556|Maximum Tolerated Dose
295944|NCT01518556|Survival
295945|NCT01518543|arthrodesis
295946|NCT01518543|arthrodesis in the following joints:Ankle, 1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid;
295947|NCT01518530|Chronic Neck Pain, Occiflex, Computerized Mobilization
295948|NCT01518517|acute lymphoblastic leukemia
295949|NCT01518517|relapse
295950|NCT01518517|asparaginase
295951|NCT01518504|Thoracic
295952|NCT01518504|Manipulation
295953|NCT01518504|Manual Therapy
295954|NCT01518504|Mobilization
295955|NCT01518504|Shoulder
295956|NCT01518504|Range of Motion
295957|NCT01518452|working memory training, computerized
295958|NCT01518452|clinical assessment
295959|NCT01518452|quantitative EEG
295960|NCT01518452|child, preschool
295961|NCT01518439|neuromuscular
295962|NCT01518439|cough
295963|NCT01518439|restrictive
295964|NCT01518426|Brain computer interface
295965|NCT01518426|EEG recording
295966|NCT01518426|Electrodes
295967|NCT01518413|Sora./Irino. combination therapy
295968|NCT01518400|Pediatric Cancer
295969|NCT01518400|Cancer Late Effects
295970|NCT01518400|Cancer Survivor
295971|NCT01518400|Cancer Survivorship
295972|NCT01518387|Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis
295973|NCT01518374|Male or female subjects at least 18 years of age
295974|NCT01518374|AD
295975|NCT01518374|MCI
295976|NCT01518348|Patch Test
295977|NCT01518348|Contact Dermatitis
295978|NCT01518348|Allergy
295979|NCT01518348|Children
295980|NCT01518348|PREA
295981|NCT01518335|platelet rich plasma
295982|NCT01518335|ankle
295983|NCT01518335|sprain
295984|NCT01518335|injection
295985|NCT01518335|Platelet Rich Plasma therapy
295986|NCT01518335|focal, invasive therapy for sprains
295987|NCT01518322|Asthma
295988|NCT01518322|Fractional Exhaled Nitric Oxide
295989|NCT01518322|Respiratory Symptoms
295990|NCT01518322|NIOX MINO
295991|NCT01518322|Inhaled corticosteroids
295992|NCT01518322|Nitric Oxide
295993|NCT01518296|Pelvic Organ Prolapse Quantification (POPQ)
295994|NCT01518296|POPQ
295995|NCT01518296|Urodynamic test
295996|NCT01518283|Weekly cabazitaxel.
295997|NCT01518283|Advanced Hormone-refractory prostate Cancer.
295998|NCT01518283|Unfit patients.
295999|NCT01518244|Primary open angle-glaucoma
296000|NCT01518244|Ocular hypertension
296001|NCT01518244|Pigment dispersion glaucoma
296002|NCT01518231|stroke
296003|NCT01518231|hematopoietic stem cell transplantation
296004|NCT01518218|Sickle cell disease
296005|NCT01518218|laying-on-of-hands
296006|NCT01518218|morbidity
296007|NCT01518218|mortality
296008|NCT01518205|diabetic foot ulcers,
296009|NCT01518205|peripheral arterial disease,
296132|NCT01517815|overweight
296010|NCT01518205|heparin-induced extracorporal lipid apheresis.
296011|NCT01518205|inflammatory markers
296012|NCT01518205|type 2 diabetes
296013|NCT01518205|LDL-cholesterol
296014|NCT01518192|erythema migrans
296015|NCT01518192|doxycycline
296016|NCT01518192|cefuroxime axetil
296017|NCT01518192|post-Lyme disease symptoms
296018|NCT01518192|background symptoms in general population
296019|NCT01518179|Colles' Fracture
296020|NCT01518179|Compression Bandages
296021|NCT01518179|Occupational therapy
296022|NCT01518179|Rehabilitation
296023|NCT01518179|Smith's fracture
296024|NCT01518153|Blood and Marrow Transplantation
296025|NCT01518153|Lymphoma
296026|NCT01518153|Myeloma
296027|NCT01518153|Myeloproliferative Diseases
296028|NCT01518153|Leukemia
296029|NCT01518153|Myelodysplastic syndrome
296030|NCT01518153|MDS
296031|NCT01518153|Hodgkin disease
296032|NCT01518153|Multiple myeloma
296033|NCT01518153|Fludarabine
296034|NCT01518153|Fludarabine Phosphate
296035|NCT01518153|Fludara
296036|NCT01518153|Melphalan
296037|NCT01518153|Alkeran
296038|NCT01518153|Tacrolimus
296039|NCT01518153|Prograf
296040|NCT01518153|Methotrexate
296041|NCT01518153|G-CSF
296042|NCT01518153|Filgrastim
296043|NCT01518153|NeupogenTM
296044|NCT01518153|Donor Lymphocyte Infusion
296045|NCT01518153|DLI
296046|NCT01518153|Allogeneic Stem Cell Transplantation
296047|NCT01518153|Graft-vs-host disease
296048|NCT01518153|GvHD
296049|NCT01518153|T-lymphocytes
296050|NCT01518153|T-cells
296051|NCT01518153|Alemtuzumab
296052|NCT01518153|CAMPATH-1H
296053|NCT01518153|Campath
296054|NCT01518140|Advanced Cancers
296055|NCT01518140|Locally advanced
296056|NCT01518140|Recurrent
296057|NCT01518140|Metastatic disease
296058|NCT01518140|Oxygen Delivery Modalities
296059|NCT01518140|Shortness of breath
296060|NCT01518140|Dyspnea
296061|NCT01518140|VapoTherm
296062|NCT01518140|Bilevel positive airway pressure
296063|NCT01518140|BiPAP
296064|NCT01518140|Non-rebreather mask
296065|NCT01518127|Macular Degeneration
296066|NCT01518114|Hypertrophic Cardiomyopathy
296067|NCT01518114|Exercise Training
296068|NCT01518114|Cardiac Rehabilitation
296069|NCT01518114|Heart Failure
296070|NCT01518101|patient preference
296071|NCT01518101|vildagliptin
296072|NCT01518101|liraglutide
296073|NCT01518075|Chronic Obstructive Pulmonary Disease
296074|NCT01518075|Non invasive mechanical ventilation
296075|NCT01518075|Breathing-swallowing interaction
296076|NCT01518075|Intensive Care Unit
296077|NCT01518049|Affective Disorders, Psychotic
296078|NCT01518049|Psychometrics
296079|NCT01518049|Biological Markers
296080|NCT01518023|diabetes mellitus
296081|NCT01518023|prediabetes
296082|NCT01518023|fasting blood glucose
296083|NCT01518023|HbA1c
296084|NCT01518023|Roux en Y gastric bypass
296085|NCT01518023|Cancer gastrectomy
296086|NCT01518023|Cancer colorectal surgery
296087|NCT01518010|Brain injury
296088|NCT01518010|Cognitive rehabilitation
296089|NCT01518010|Video game
296090|NCT01517997|Drug coated balloons
296091|NCT01517997|Drug eluting stents
296092|NCT01517984|recipients of living-donor kidney allografts
296093|NCT01517984|antithymocyte globulin (ATG) induction
296094|NCT01517984|calcineurin inhibitors (CNIs)
296095|NCT01517984|CNI withdrawal
296096|NCT01517971|stage IA non-small cell lung cancer
296097|NCT01517971|stage IB non-small cell lung cancer
296098|NCT01517971|adenocarcinoma of the lung
296099|NCT01517971|squamous cell lung cancer
296100|NCT01517958|Transient tachypnea of the newborn
296101|NCT01517958|Respiratory Distress Syndrome
296102|NCT01517958|Lung Ultrasound
296103|NCT01517958|Neonates
296104|NCT01517945|Survivors
296105|NCT01517945|Quality of Life
296106|NCT01517945|Questionnaire
296107|NCT01517945|11-204
296108|NCT01517919|peer support
296109|NCT01517919|peer leader
296110|NCT01517919|community health worker
296111|NCT01517919|empowerment
296112|NCT01517919|self-management
296113|NCT01517906|eating disorder behaviors
296114|NCT01517906|well being
296115|NCT01517906|functional health
296116|NCT01517893|vitiligo
296117|NCT01517893|simvastatin
296118|NCT01517880|Hereditary Inclusion Body Myopathy (HIBM)
296119|NCT01517880|GNE myopathies
296120|NCT01517880|distal myopathy with rimmed vacuoles [DMRV]
296121|NCT01517880|Nonaka disease
296122|NCT01517867|preschool children behavior problems
296123|NCT01517867|child between 2 and 5 years old
296124|NCT01517841|peritoneal dialysis
296125|NCT01517841|modality choice
296126|NCT01517841|kidney disease
296127|NCT01517828|Intubation
296128|NCT01517828|Delivery room
296129|NCT01517828|Sedation
296130|NCT01517828|Analgesia
296131|NCT01517815|Septic shock
296133|NCT01517815|critically ill
296134|NCT01517815|pharmacokinetic
296135|NCT01517815|doripenem
296136|NCT01517815|piperacillin-tazobactam
296137|NCT01517802|Metastatic castration-resistant prostate cancer
296138|NCT01517802|Metastatic breast cancer
296139|NCT01517802|Abiraterone acetate
296140|NCT01517802|Low-dose corticosteroid treatment
296141|NCT01517802|Long-term access
296142|NCT01517789|Surgery
296143|NCT01517789|Optic Nerve and Pathway Injury
296144|NCT01517789|visual event-related potential
296145|NCT01517776|High grade glioma
296146|NCT01517776|Glioblastoma multiforme
296147|NCT01517776|Anaplastic astrocytoma
296148|NCT01517776|Diffuse intrinsic pontine glioma
296149|NCT01517776|Relapse
296150|NCT01517776|refractory tumour disease
296151|NCT01517776|Relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas
296152|NCT01517763|Obstructive Sleep Apnea
296153|NCT01517763|Humidification
296154|NCT01517763|Continuous Positive Airway Pressure
296155|NCT01517763|ICON
296156|NCT01517763|ThermoSmart
296157|NCT01517763|SensAwake
296158|NCT01517750|Obstructive Sleep Apnea
296159|NCT01517750|Humidification
296160|NCT01517750|Continuous Positive Airway Pressure
296161|NCT01517750|ICON
296162|NCT01517750|ThermoSmart
296163|NCT01517724|MM
296164|NCT01517724|HDT
296165|NCT01517724|ASCT
296166|NCT01517724|consolidation
296167|NCT01517724|bortezomib
296168|NCT01517711|pharmacotherapy
296169|NCT01517711|combat disorders
296170|NCT01517685|Eicosapentaenoic acid
296171|NCT01517685|EPA
296172|NCT01517685|Docosahexaenoic acid
296173|NCT01517685|DHA
296174|NCT01517685|Omega 3 fat
296175|NCT01517685|alpha-linoleic acid
296176|NCT01517685|ALA
296177|NCT01517685|fish oil
296178|NCT01517685|flax seed oil
296179|NCT01517672|PTSD
296180|NCT01517672|domestic violence
296181|NCT01517672|intimate partner violence
296182|NCT01517672|functional MRI
296183|NCT01517672|neuroimaging
296184|NCT01517659|Lipolysis
296185|NCT01517659|Cryolipolysis
296186|NCT01517659|Fat Reduction
296187|NCT01517646|Lipolysis
296188|NCT01517646|Cryolipolysis
296189|NCT01517646|Fat Reduction
296190|NCT01517633|Amniotic fluid leakage
296191|NCT01517633|Urinary incontinence
296192|NCT01517581|Brown adipose tissue
296193|NCT01517542|diet
296194|NCT01517542|DASH
296195|NCT01517542|Stroke
296196|NCT01517542|Nutritional counseling
296197|NCT01517529|Hepatitis C
296198|NCT01517529|HCV
296199|NCT01517516|fMRI
296200|NCT01517516|resting state
296201|NCT01517516|structural MRI
296202|NCT01517516|functional MRI
296203|NCT01517477|Open angle
296204|NCT01517477|Glaucoma
296205|NCT01517477|surgery
296206|NCT01517477|Glaucoma, Open-Angle
296207|NCT01517477|Ocular Hypertension
296208|NCT01517477|Eye Diseases
296209|NCT01517464|neoplasm
296210|NCT01517464|bladder cancer
296211|NCT01517464|advances solid tumors
296212|NCT01516463|burn
296213|NCT01516463|partial thickness burn
296214|NCT01516463|second degree burn
296215|NCT01516463|minor burn
296216|NCT01516463|scar
296217|NCT01516463|Santyl
296218|NCT01516463|Bacitracin
296219|NCT01516463|outpatient burn center
296220|NCT01516463|scar appearance
296221|NCT01516463|Kansas City
296222|NCT01516463|University of Kansas Medical Center
296223|NCT01516463|KUMC
296224|NCT01516450|GSK1550188, belimumab, SLE, healthy, Japanese, pharmacokinetics, safety
296225|NCT01516437|Chronic Obstructive Pulmonary disease (COPD)
296226|NCT01516424|Blonanserin
296227|NCT01516411|Health Promotion
296228|NCT01516411|Physical Activity
296229|NCT01516411|Sedentary Time
296230|NCT01516411|Smartphones
296231|NCT01516385|spinal cord injury
296232|NCT01516385|biomarkers
296233|NCT01516385|rehabilitation
296234|NCT01516385|functional independence
296235|NCT01516385|prognosis
296236|NCT01516372|GEn, moxifloxacin, cardiac repolarisation, QT/QTc
296237|NCT01516346|Heart Failure
296238|NCT01516346|Heart failure with preserved ejection fraction (HFpEF)
296239|NCT01516346|Vasodilators
296240|NCT01516346|Isosorbide dinitrate
296241|NCT01516346|Hydralazine
296242|NCT01516346|wave reflections
296243|NCT01516346|arterial stiffness
296244|NCT01516346|hemodynamics
296245|NCT01516333|glycemic Index
296246|NCT01516320|Type 2 Diabetes
296247|NCT01516320|Gastric Bypass
296248|NCT01516320|Laparoscopic Banding
296249|NCT01516320|Vertical Sleeve Gastrectomy
296250|NCT01516294|AMD
296251|NCT01516294|PCV
296252|NCT01516294|Iray
296253|NCT01516294|radiation
296254|NCT01516294|retina
296255|NCT01516294|macula
296256|NCT01516294|radiotherapy
296257|NCT01517438|agitation, desflurane, children
296258|NCT01517399|Oncology
296259|NCT01517399|pharmacokinetics
296260|NCT01517399|PK interaction in advanced solid tumors with our drug and other drugs
296261|NCT01517386|paravertebral space
296262|NCT01517386|needle placement
296263|NCT01517386|tissue identification
296264|NCT01517386|regional
296265|NCT01517373|T2DM
296266|NCT01517373|PF-04937319
296267|NCT01517373|Phase 2
296268|NCT01517360|Schizophrenia
296269|NCT01517360|Social Cognition
296270|NCT01517360|Oxytocin
296271|NCT01517347|IL2
296272|NCT01517347|relapse
296273|NCT01517347|GVHD
296274|NCT01517347|survival
296275|NCT01517347|allogeneic stem cell transplantation
296276|NCT01517347|MRD
296277|NCT01517347|CR
296278|NCT01517308|HCV
296279|NCT01517308|Hepatitis
296280|NCT01517308|Genotype 2 or 3
296281|NCT01517308|Pegylated Interferon
296282|NCT01517308|Duration
296283|NCT01517295|Pharmacokinetics
296284|NCT01517295|Hydromorphone
296285|NCT01517295|Hydrocodone
296286|NCT01517295|APAP
296287|NCT01517269|Parent education
296288|NCT01517256|Chronic pain
296289|NCT01517256|Primary care
296290|NCT01517256|Multidisciplinary group therapy
296291|NCT01517256|Embedded mixed-methods study
296292|NCT01517243|Metastatic Renal Cell Carcinoma
296293|NCT01517243|sunitinib
296294|NCT01517243|alternating
296295|NCT01517243|temsirolimus
296296|NCT01517230|Cluster-randomised trial
296297|NCT01517230|Comprehensive mass media campaign
296298|NCT01517230|Rural community radio
296299|NCT01517230|Under-five child mortality
296300|NCT01517230|Preventive and curative behaviours
296301|NCT01517230|Burkina Faso
296302|NCT01517230|Health care seeking behavior
296303|NCT01517230|Childbirth
296304|NCT01517217|girdle
296305|NCT01517217|laparotomy
296306|NCT01517217|pulmonary function
296307|NCT01517217|postoperative pain
296308|NCT01517217|mobilisation
296309|NCT01517204|Trachway(R) intubating stylet
296310|NCT01517204|Left sided double lumen endobronchial tube
296311|NCT01517204|Efficacy
296312|NCT01517204|Intubation complication
296313|NCT01517191|Influenza
296314|NCT01517191|Respiratory Infection
296315|NCT01517165|Opioid Dependence
296316|NCT01517165|Pioglitazone
296317|NCT01517165|Buprenorphine
296318|NCT01517152|Symptoms
296319|NCT01517152|Patient-Reported Outcomes
296320|NCT01517152|Linguistic Validation
296321|NCT01517152|Toxicity
296322|NCT01517152|PRO-CTCAE
296323|NCT01517152|Adverse Events
296324|NCT01517152|Translation
296325|NCT01517152|Questionnaire
296326|NCT01517139|Diet and Nutrition
296327|NCT01517139|Pregnancy Folic Acid
296328|NCT01517139|In Utero Exposure
296329|NCT01517139|DNA Methylation
296330|NCT01517139|Physical Activity
296331|NCT01517126|Youth Suicide
296332|NCT01517126|Suicide Screening
296333|NCT01517126|Developmental Delay
296334|NCT01517126|Intellectual Disability
296335|NCT01517126|Assessment Instrument
296336|NCT01517126|Mental Retardation
296337|NCT01517126|Suicidal Thoughts
296338|NCT01517126|Suicidal Behavior
296339|NCT01517113|Endothelial Dysfunction
296340|NCT01517113|Hepatic
296341|NCT01517113|Adiposity
296342|NCT01517113|Cytokines
296343|NCT01517113|Muscle Mass
296344|NCT01517113|Coronary Artery Disease
296345|NCT01517113|Aging
296346|NCT01517113|Inflammation
296347|NCT01517100|Glucose
296348|NCT01517100|Insulin Secretion
296349|NCT01517100|Insulin Action
296350|NCT01517100|Endocannabinoids
296351|NCT01517100|Insulin
296352|NCT01517100|Metabolism
296353|NCT01517087|Motor Function
296354|NCT01517087|Magnetic Resonance Spectroscopy
296355|NCT01517087|Transcranial Magnetic Stimulation (TMS)
296356|NCT01517087|Diffusion Tensor Imaging
296357|NCT01517087|Functional Magnetic Resonance Imaging (fMRI)
296358|NCT01517087|Healthy Volunteer
296359|NCT01517087|HV
296360|NCT01517074|Sirolimus
296361|NCT01517074|Scleritis
296362|NCT01517074|Autoimmune Scleritis
296363|NCT01517061|Phantom Limb Pain
296364|NCT01517061|Genetic Polymorphisms
296365|NCT01517061|Genetic Susceptibility
296366|NCT01517061|Amputation
296367|NCT01517048|Body Composition
296368|NCT01517048|Obesity
296369|NCT01517048|Overweight
296370|NCT01517048|Energy Homeostasis
296371|NCT01517048|Nociception
296372|NCT01517048|Prader-Willi Syndrome
296373|NCT01517048|Genetic Disorder
296374|NCT01517048|Healthy Volunteer
296375|NCT01517048|HV
296376|NCT01517035|Peripheral Blood Stem Cell Transplantation
296377|NCT01517035|Stem Cell Transplant
296378|NCT01517035|Transplant
296379|NCT01517035|Myelodyplastic Syndrome
296380|NCT01517035|MDS
296381|NCT01517035|Leukemia
296382|NCT01517022|smoking cessation
296383|NCT01517022|early sputum smear conversion
296384|NCT01517009|Neo-adjuvant chemotherapy
296385|NCT01517009|D1extra-resection
296386|NCT01516996|Neoadjuvant
296387|NCT01516996|Concurrent Chemoradiotherapy,CCRT
296388|NCT01516996|Nimotuzumab
296389|NCT01516996|Locoregionally Advanced Oropharynx
296390|NCT01516996|Hypopharynx cancer
296391|NCT01516996|Randomized
296392|NCT01516996|Multicenter
296393|NCT01516983|Safety
296394|NCT01516983|EGFR-TKI
296395|NCT01516983|NSCLC
296396|NCT01516983|Icotinib
296397|NCT01516983|WBRT
296398|NCT01516970|Human Immunodeficiency Virus (HIV) Post exposure prophylaxis
296399|NCT01516970|DRV/r
296400|NCT01516970|Occupational injury
296401|NCT01516970|Non-occupational exposure
296402|NCT01516970|Prezista
296403|NCT01516970|Darunavir/r
296404|NCT01516957|Psoriatic Arthritis
296405|NCT01516957|IL-17
296406|NCT01516957|AMG 827
296407|NCT01516957|AMG827
296408|NCT01516957|Musculoskeletal Disease
296409|NCT01516957|Spondylarthropathy
296410|NCT01516944|Tegafur，Gimeracil and Oteracil Potassium Capsules
296411|NCT01516944|Capecitabine
296412|NCT01516944|Oxaliplatin
296413|NCT01516944|perioperative Chemotherapy
296414|NCT01516944|Gastric Cancer
296415|NCT01516931|repetitive Transcranial Magnetic Stimulation (rTMS)
296416|NCT01516931|Depression
296417|NCT01516931|Venlafaxine
296418|NCT01516931|Relapse
296419|NCT01516879|Cholesterol
296420|NCT01516879|High Cholesterol
296421|NCT01516879|Elevated Cholesterol
296422|NCT01516879|Raised Cholesterol
296423|NCT01516866|Androgen receptor-directed therapy
296424|NCT01516866|NaF PET/CT
296425|NCT01516866|antimicrotubule directed chemotherapy
296426|NCT01516840|acute symptomatic deep vein thrombosis
296427|NCT01516827|PTSD
296428|NCT01516827|Children and Adolescents
296429|NCT01516827|Post-Traumatic Stress Disorder in Children and Adolescents
296430|NCT01516814|acute symptomatic pulmonary embolism
296431|NCT01516801|Prostate Cancer Screening
296432|NCT01516801|Pragmatic Trial
296433|NCT01516801|Health Literacy
296434|NCT01516775|preoperative care
296435|NCT01516775|preoperative period
296436|NCT01516775|fasting
296437|NCT01516762|Radium 223
296438|NCT01516762|Alpharadin
296439|NCT01516762|Prostate Cancer
296440|NCT01516762|Bone metastases
296441|NCT01516762|Castrate resistant prostate cancer
296442|NCT01516762|Hormone refractory prostate cancer
296443|NCT01516749|hidradenitis suppurativa
296444|NCT01516749|anakinra
296445|NCT01516736|Pegfilgrastim
296446|NCT01516736|G-CSF
296447|NCT01516736|neutropenia
296448|NCT01516736|breast cancer
296449|NCT01516736|myelosuppressive chemotherapy
296450|NCT01516723|drug-eluting stent
296451|NCT01516723|chronic total occlusion
296452|NCT01516723|hybrid sirolimus-eluting stent
296453|NCT01516723|everolimus-eluting stent
296454|NCT01516710|Open liver resection
296455|NCT01516710|Laparoscopic liver resection
296456|NCT01516710|Colorectal cancer liver metastases
296457|NCT01516697|thoracic electric bioimpedance
296458|NCT01516697|cardiac output monitoring
296459|NCT01516697|cesarean section
296460|NCT01516697|spinal anesthesia
296461|NCT01516671|Subarachnoid hemorrhage
296462|NCT01516671|Cerebral vasospasm
296463|NCT01516671|Neuroinflammation
296464|NCT01516671|Bilateral Bispectral Index
296465|NCT01516658|intracranial aneurysm
296466|NCT01516658|endovascular therapy
296467|NCT01516658|detachable coil
296468|NCT01516658|recanalization
296469|NCT01516645|Squamous cell type tumor
296470|NCT01516632|Cellular Phone
296471|NCT01516632|Mobile Phone
296472|NCT01516632|Cognitive Behavior Therapy
296473|NCT01516632|Technology
296474|NCT01516632|Smoking cessation
296475|NCT01516632|young adults
296476|NCT01516619|NHL
296477|NCT01516619|chemotherapy-induced grade-4 thrombocytopenia
296478|NCT01516606|MALT
296479|NCT01516606|refractory
296480|NCT01516606|relapsed
296481|NCT01516606|extranodal
296482|NCT01516606|relapsed or refractory extranodal marginal zone lymphoma
296483|NCT01516593|HIV
296484|NCT01516593|Burkitt's lymphoma
296485|NCT01516593|intensive
296486|NCT01516593|short term
296487|NCT01516593|immuno-chemotherapy
296488|NCT01516593|HIV-positive patients with Burkitt's lymphoma
296489|NCT01516554|Multiple Sclerosis
296490|NCT01516554|Fatigue
296491|NCT01516528|COPD
296492|NCT01516528|exacerbation
296493|NCT01516528|comorbidities
296494|NCT01516528|lung function
296495|NCT01516528|burden
296496|NCT01516528|chronic bronchitis
296497|NCT01516528|emphysema
296498|NCT01516528|prevalence
296499|NCT01516528|cardiovascular disease
296500|NCT01516515|Actinic Keratosis
296501|NCT01516515|AK
296502|NCT01516502|laser therapy
296503|NCT01516502|myofascial pain syndrome
296504|NCT01516502|acupoint
296505|NCT01516502|trigger point
296506|NCT01516502|range of motion
296507|NCT01516489|screening
296508|NCT01516489|colon cancer
296509|NCT01516489|incentives
296510|NCT01516489|behavioral economics
296511|NCT01516281|TBI
296512|NCT01516281|PD
296513|NCT01516268|Cesarean Delivery
296514|NCT01516268|TAP block
296515|NCT01516268|sufentanyl
296516|NCT01516268|Narcotic dosages
296517|NCT01516216|previously untreated
296518|NCT01516203|AZD5847,dose-ranging,Mycobacterium tuberculosis,Rifafour,tuberculosis
296519|NCT01516190|stage I-III breast cancer
296520|NCT01516177|Kidney Transplantation
296521|NCT01516177|kidney transplant
296522|NCT01516177|renal transplant
296523|NCT01516177|immunosuppression
296524|NCT01516164|Laryngoscopy
296525|NCT01516164|Videolaryngoscopy
296526|NCT01516164|Ease of Intubation
296527|NCT01516151|Hypertriglyceridemia
296528|NCT01516138|Glucose-insulin-potassium
296529|NCT01516138|Cardiac surgery
296530|NCT01516125|healthy adult
296531|NCT01516125|genetic variation
296532|NCT01516125|botanical oils
296533|NCT01516125|polyunsaturated fatty acid
296534|NCT01516125|fish oil
296535|NCT01516125|fat metabolism
296536|NCT01516125|Genetic variation of fat metabolism in healthy adults
296537|NCT01516112|ICD, home monitoring, cardiomessenger, implant
296538|NCT01516099|Physical activity counselor
296539|NCT01516099|Active and healthy lifestyle
296540|NCT01516099|General Practitioner
296541|NCT01516099|Social-cultural Organization
296542|NCT01516086|Controlled
296543|NCT01516086|uncontrolled
296544|NCT01516073|partially controlled
296545|NCT01516073|uncontrolled
296546|NCT01516047|Hepatic impairment
296547|NCT01516047|Pharmacology
296548|NCT01516047|Pharmacokinetics
296549|NCT01516047|Pharmacodynamics
296550|NCT01516047|Abiraterone acetate suspension
296551|NCT01516047|JNJ-212082
296552|NCT01516034|Tattoo removal
296553|NCT01516034|ultrasound
296554|NCT01516021|Fat ingestion
296555|NCT01516021|hypothalamus
296556|NCT01516021|insula
296557|NCT01516021|fMRI
296558|NCT01516021|CBF
296559|NCT01516008|Hallux Valgus
296560|NCT01516008|Bunionectomy
296561|NCT01516008|Bunion
296562|NCT01516008|Acute pain
296563|NCT01516008|Tapentadol
296564|NCT01516008|Tapentadol IR
296565|NCT01515995|Magnesium sulfate
296566|NCT01515995|Childhood asthma
296567|NCT01515995|Emergency department
296568|NCT01515982|Alzheimer's disease
296569|NCT01515982|Aerobic exercise
296570|NCT01515982|Physical training
296571|NCT01515982|Cognitive function
296572|NCT01515982|Functional capacity.
296573|NCT01515956|Mucopolysaccharidosis IVA type A
296574|NCT01515956|MPS IVA Type A
296575|NCT01515956|Mucopolysaccharidosis IVA
296576|NCT01515956|MPS IVA
296577|NCT01515956|Morquio A Syndrome
296578|NCT01515956|Lysosomal Storage Disorder
296579|NCT01515956|LSD
296580|NCT01515956|N-acetylgalactosamine-6-sulfatase
296581|NCT01515956|N-acetylgalactosamine-6-sulfate
296582|NCT01515956|sulfatase
296583|NCT01515956|galactose-6-sulfatase
296584|NCT01515956|GALNS
296585|NCT01515956|enzyme replacement therapy
296586|NCT01515956|ERT
296587|NCT01515943|Convergence insufficiency
296588|NCT01515930|Parenting
296589|NCT01515930|Parental Monitoring
296590|NCT01515930|Diabetes
296591|NCT01515930|Care
296592|NCT01515917|Veterans
296593|NCT01515917|Traumatic Brain Injury
296594|NCT01515917|TBI
296595|NCT01515917|Substance Abuse
296596|NCT01515917|Substance Dependence
296597|NCT01515917|Veterans with traumatic brain injury (TBI)
296598|NCT01515917|Veterans with substance abuse or dependence
296599|NCT01515904|obesity management
296600|NCT01515904|adolescents
296601|NCT01515904|body mass index
296602|NCT01515904|treatment outcomes
296603|NCT01515904|program evaluation
296604|NCT01515891|Parkinson Disease
296605|NCT01515891|BIA 9-1067
296606|NCT01515852|stress level
296607|NCT01515852|stereotactic biopsy
296608|NCT01515852|brain lesion
296609|NCT01515852|general anesthesia
296610|NCT01515852|local anesthesia
296611|NCT01515839|SPECT
296612|NCT01515839|Imaging
296613|NCT01515839|Football
296614|NCT01515839|Traumatic brain injury
296615|NCT01515839|Regional cerebral blood flow
296616|NCT01515826|Cataract surgery
296617|NCT01515826|Topical therapy
296618|NCT01515826|Prevention of inflammation
296619|NCT01515826|Inflammation of infection
296620|NCT01515800|estrogen receptor-positive breast cancer
296621|NCT01515800|progesterone receptor-positive breast cancer
296622|NCT01515800|stage IA breast cancer
296623|NCT01515800|stage IB breast cancer
296624|NCT01515800|stage II breast cancer
296625|NCT01515800|stage IIIA breast cancer
296626|NCT01515787|stage IIA rectal cancer
296627|NCT01515787|stage IIIA rectal cancer
296628|NCT01515787|stage IIIB rectal cancer
296629|NCT01515774|Parkinson's disease
296630|NCT01515774|Pramipexole
296631|NCT01515722|Medication Persistence
296632|NCT01515722|Compliance
296633|NCT01515722|Health Education Intervention (HEI)
296634|NCT01515709|Cohort Studies
296635|NCT01515709|Longitudinal Studies
296636|NCT01515696|VLBW infant
296637|NCT01515696|Meconium
296638|NCT01515696|Enteral nutrition
296639|NCT01515696|Meconium passage
296640|NCT01515683|Nervousness before anesthesia
296641|NCT01515670|THA
296642|NCT01515670|TKA
296643|NCT01515670|Fast-track
296644|NCT01515670|Enhanced recovery
296645|NCT01515670|preoperative co-morbidity
296646|NCT01515670|postoperative morbidity
296647|NCT01515670|Arthroplasty
296648|NCT01515670|Replacement
296649|NCT01515670|Hip
296650|NCT01515670|Knee
296651|NCT01515670|Morbidity
296652|NCT01515644|Healthy infants
296653|NCT01515644|Infant formula
296654|NCT01515644|Prebiotics
296655|NCT01515566|Advanced Cancer
296656|NCT01515566|Dyspnea
296657|NCT01515566|Exercise-induced breakthrough dyspnea
296658|NCT01515566|Shortness of breath
296659|NCT01515566|Fentanyl
296660|NCT01515566|Sublimaze
296661|NCT01515566|Placebo
296662|NCT01515566|Normal saline
296663|NCT01515566|NS
296664|NCT01515566|Questionnaires
296665|NCT01515566|Surveys
296666|NCT01515566|Walk test
296667|NCT01515540|chronic back pain
296668|NCT01515540|placebo
296669|NCT01515540|fmri
296670|NCT01515540|brain imaging
296671|NCT01515527|Leukemia
296672|NCT01515527|Acute myeloid leukemia
296673|NCT01515527|AML
296674|NCT01515527|myelodysplastic syndrome
296675|NCT01515527|MDS
296676|NCT01515527|Cytarabine
296677|NCT01515527|Ara-C
296678|NCT01515527|Cytosar
296679|NCT01515527|DepoCyt
296680|NCT01515527|Cytosine Arabinosine Hydrochloride
296681|NCT01515527|Decitabine
296682|NCT01515527|Dacogen
296683|NCT01515527|Cladribine
296684|NCT01515527|Leustatin
296685|NCT01515527|2-CdA
296686|NCT01515514|polyps
296687|NCT01515514|inflammatory bowel disease
296688|NCT01515514|associated neoplasia
296689|NCT01515501|Constipation
296690|NCT01515501|Hirschsprung Disease
296691|NCT01515488|Triage
296692|NCT01515488|Automated
296693|NCT01515488|Admitting
296694|NCT01515488|Pediatric ED
296695|NCT01515475|Hyperopia
296696|NCT01515475|Glasses
296697|NCT01515462|Wiskott-Aldrich Syndrome
296698|NCT01515462|Lentiviral vector
296699|NCT01515462|Gene therapy
296700|NCT01515436|Rolandic Epilepsy
296701|NCT01515436|Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS)
296702|NCT01515436|Epilepsy
296703|NCT01515436|Seizures
296704|NCT01515436|Music
296705|NCT01515436|Mozart
296706|NCT01515436|Beethoven
296707|NCT01515423|Schizophrenia
296708|NCT01515423|R092670
296709|NCT01515423|Paliperidone Palmitate
296710|NCT01515423|Paliperidone palmitate 1 month formulation (PP1M)
296711|NCT01515423|Paliperidone palmitate 3 month formulation (PP3M)
296712|NCT01515410|Parkinson's disease
296713|NCT01515410|PD
296714|NCT01515410|stage2/3Parkinson's
296715|NCT01515410|Advanced Parkinson's Disease with Motor Fluctuations
296716|NCT01515345|clopidogrel-nonresponder
296717|NCT01515345|stent thrombosis
296718|NCT01515319|Obesity
296719|NCT01515319|Peptide YY
296720|NCT01515319|Food intake
296721|NCT01515319|Safety
296722|NCT01515319|Pharmacokinetics
296723|NCT01515306|Advanced Malignant Solid Tumors
296724|NCT01515280|chronic cough
296725|NCT01515267|EF
296726|NCT01515267|EDV
296727|NCT01515267|ESV
296728|NCT01515267|Biplane
296729|NCT01515267|Echocardiography
296730|NCT01515254|Children
296731|NCT01515254|Obesity Prevention
296732|NCT01515254|Child Overweight
296733|NCT01515254|Eating Behavior
296734|NCT01515254|Energy Compensation
296735|NCT01515254|Food Intake
296736|NCT01515254|Parenting Behavior
296737|NCT01515241|Heterozygous Familial Hypercholesterolemia
296738|NCT01515241|Familial Hypercholesterolemia
296739|NCT01515241|HDL mimetic
296740|NCT01515241|ApoA-1
296741|NCT01515228|requiring drug eluting stents
296742|NCT01515215|Major Depression Disorder
296743|NCT01515215|Treatment Resistance
296744|NCT01515215|repetitive Transcranial Magnetic Stimulation
296745|NCT01515150|diverticulitis
296746|NCT01515150|Out-patient management
296747|NCT01515150|Antibiotics
296748|NCT01515137|Head and Neck
296749|NCT01515137|Locally Advanced Head and Neck Squamous Cell Carcinoma
296750|NCT01515124|Lymphedema
296751|NCT01515124|Strength training intervention
296752|NCT01515124|Weight loss intervention
296753|NCT01515124|Breast cancer recurrence
296754|NCT01515124|Cost Effectiveness
296755|NCT01515111|Non-communicable diseases
296756|NCT01515111|Preventive services
296757|NCT01515111|Medical education
296758|NCT01515111|Guatemala
296759|NCT01515072|Remote Ischemic Preconditioning
296760|NCT01515072|Brain death organ donors
296761|NCT01515072|Delayed graft function
296762|NCT01515072|Donor management
296763|NCT01515072|Pulsatile perfusion
296764|NCT01515059|obesity
296765|NCT01515059|diabetes
296766|NCT01515059|bariatric surgery
296767|NCT01515059|gastric bypass
296768|NCT01515059|insulin
296769|NCT01515059|glucose
296770|NCT01515059|incretins
296771|NCT01515059|leptin
296772|NCT01515059|ghrelin
296773|NCT01515046|Vitamins
296774|NCT01515046|Complementary medicine
296775|NCT01515046|Pancreatic cancer
296776|NCT01515046|Ascorbate
296777|NCT01515046|Ascorbic Acid
296778|NCT01515046|Antioxidants
296779|NCT01515046|Gemcitabine
296780|NCT01515046|Pharmacologic actions
296781|NCT01515033|Coronary artery disease
296782|NCT01515033|Exercise
296783|NCT01515033|Ventilatory efficiency
296784|NCT01515020|bacteremia
296785|NCT01515020|meticillin-resistant Staphylococcus aureus
296786|NCT01515020|nosocomial infection
296787|NCT01515020|healthcare-associated infection
296788|NCT01515020|rapid molecular diagnostic test
296789|NCT01515007|Bronchiectasis, non-CF, Ciprofloxacin, Liposome
296790|NCT01514981|Asthma
296791|NCT01514942|PCOS
296792|NCT01514942|Insulin resistance
296793|NCT01514942|Myo-inositol
296794|NCT01514942|D-chiro-inositol
296795|NCT01514929|Thorough QT
296796|NCT01514903|anti erectile dysfunction agent
296797|NCT01514877|tumors metastatic to brain
296798|NCT01514877|non-small cell lung cancer
296799|NCT01514877|Icotinib
296800|NCT01514851|Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis
296801|NCT01514838|ASP1941
296802|NCT01514838|ipragliflozin
296803|NCT01514838|plasma glucose
296804|NCT01514838|urine glucose
296805|NCT01514825|YM150
296806|NCT01514825|Plasma concentration
296807|NCT01514825|darexaban
296808|NCT01514825|Healthy elderly subject
296809|NCT01514825|Pharmacokinetics of YM150
296810|NCT01514812|YM150
296811|NCT01514812|digoxin
296812|NCT01514812|drug-drug interaction
296813|NCT01514812|Plasma concentration
296814|NCT01514812|darexaban
296815|NCT01514812|Pharmacokinetics of digoxin
296816|NCT01514799|gastric bypass
296817|NCT01514799|morbid obesity
296818|NCT01514799|gut function
296819|NCT01514799|weight loss
296820|NCT01514786|Colorectal Cancer
296821|NCT01514786|Screening
296822|NCT01514786|Prevention
296823|NCT01514773|left ventricular systolic dysfunction
296824|NCT01514773|implantable cardioverter defibrillator
296825|NCT01514773|systolic heart failure
296826|NCT01514773|congestive heart failure
296827|NCT01514773|Ischemic cardiomyopathy
296828|NCT01514773|Nonischemic cardiomyopathy
296829|NCT01514773|ICD
296830|NCT01514773|ICD utilization
296831|NCT01514773|ICD implantation
296832|NCT01514773|defibrillator
296833|NCT01514773|defibrillator therapy
296834|NCT01514773|sudden cardiac death
296835|NCT01514760|Adolescents
296836|NCT01514760|Mobile based applications
296837|NCT01514760|Asthma action plan
296838|NCT01514760|Self Efficacy
296839|NCT01514734|Primary open-angle glaucoma
296840|NCT01514734|Ocular hypertension
296841|NCT01514734|Pigment dispersion glaucoma
296842|NCT01514721|Open-angle glaucoma
296843|NCT01514721|Ocular hypertension
296844|NCT01514721|Pigment dispersion glaucoma
296845|NCT01514708|Influenza
296846|NCT01514708|Vaccination
296847|NCT01514708|Vaccine
296848|NCT01514708|Pregnancy
296849|NCT01514695|endoscopy
296850|NCT01514695|sedation
296851|NCT01514695|opioid
296852|NCT01514695|narcotic
296853|NCT01514682|schizophrenia
296854|NCT01514682|anti-inflammatory
296855|NCT01514682|salsalate
296856|NCT01514682|statins
296857|NCT01514682|omega-3-fatty acids
296858|NCT01514643|tibial plateau fracture
296859|NCT01514643|tibial plafond fracture
296860|NCT01514643|inflammatory cytokine profile
296861|NCT01514643|synovial fluid
296862|NCT01514643|blood serum
296863|NCT01514643|Post-traumatic osteoarthritis (PTOA)
296864|NCT01514617|Leiomyoma
296865|NCT01514617|Diffusion weighted MRI
296866|NCT01514617|Perfusion MRI
296867|NCT01514617|Uterine artery embolization
296868|NCT01514617|Volumetric Response
296869|NCT01514617|Women with symptomatic leiomyomas
296870|NCT01514604|Anesthesia and analgesia
296871|NCT01514604|ultrasonography
296872|NCT01514604|education
296873|NCT01514578|safety
296874|NCT01514578|tolerability
296875|NCT01514578|TRV130A
296876|NCT01514565|Triple negative Breast Cancer
296877|NCT01514565|RB
296878|NCT01514565|PTEN
296879|NCT01514565|Chemotherapy
296880|NCT01514565|Neoadjuvant
296881|NCT01514552|Functional food
296882|NCT01514552|Strawberries
296883|NCT01514552|Gummies
296884|NCT01514552|Smoker
296885|NCT01514552|Nonsmoker
296886|NCT01514539|Human milk, Ghrelin,PYY and maternal obesity.
296887|NCT01514526|Adrenocortical carcinoma
296888|NCT01514461|Hyperlipoproteinemia (HLP Type I)
296889|NCT01514461|Fasting Triglycerides
296890|NCT01514448|Kidney cancer
296891|NCT01514448|mRCC
296892|NCT01514448|metastic renal cell carcinoma
296893|NCT01514448|everolimus
296894|NCT01514448|sunitinib
296895|NCT01514448|pazopanib
296896|NCT01514435|depression
296897|NCT01514435|FDG-PET
296898|NCT01514435|Electroconvulsive therapy
296899|NCT01514435|glucose metabolism
296900|NCT01514422|Bipolar disorder
296901|NCT01514422|depression
296902|NCT01514422|minocycline
296903|NCT01514422|mood disorders
296904|NCT01514422|bipolar depression
296905|NCT01514409|5-hydroxytryptophan
296906|NCT01514409|Mood
296907|NCT01514409|Emotional Processing
296908|NCT01514409|Emotional Cognition
296909|NCT01514409|Nutritional Supplement
296910|NCT01514409|Low mood
296911|NCT01514396|Pediatric
296912|NCT01514396|Wounds
296913|NCT01514383|wounds
296914|NCT01514370|Multiple Sclerosis
296915|NCT01514370|Relapsing
296916|NCT01514370|Interferon beta 1a
296917|NCT01514370|Curcumin
296918|NCT01514344|OAL
296919|NCT01514344|MALT
296920|NCT01514344|conjunctiva
296921|NCT01514344|indolent
296922|NCT01514344|CD20+
296923|NCT01514331|Ventilator Induced Lung Injury
296924|NCT01514331|Neonatal respiratory distress
296925|NCT01514331|Mechanical ventilation
296926|NCT01514279|Overweight
296927|NCT01514279|Obese
296928|NCT01514279|Over Nutrition
296929|NCT01514279|Nutrition Disorders
296930|NCT01514279|Body weight
296931|NCT01514279|Signs and Symptoms
296932|NCT01514266|proven diagnosis
296933|NCT01514266|COPD
296934|NCT01514266|sputum
296935|NCT01514253|glucose
296936|NCT01514253|analgesic
296937|NCT01514253|newborns
296938|NCT01514240|mild to moderate active Crohn's disease
296939|NCT01514240|affecting ileum
296940|NCT01514240|ileocecal region
296941|NCT01514240|ascending colon
296942|NCT01514240|score of 180-400 on the CDAI
296943|NCT01514214|ERCP
296944|NCT01514214|biliary stricture
296945|NCT01514214|viaduct
296946|NCT01514214|cancer
296947|NCT01514188|sarcoma
296948|NCT01514188|soft-tissue sarcoma
296949|NCT01514188|Metastatic,locally advanced, or unresectable soft tissue sarcoma
296950|NCT01514175|Ketorolac
296951|NCT01514175|Caldolor
296952|NCT01514175|Chronic Pelvic Pain
296953|NCT01514162|Trifecta Valve
296954|NCT01514149|Type 2 Diabetes Mellitus
296955|NCT01514149|T2DM
296956|NCT01514149|diabetes
296957|NCT01514149|ConjuChem
296958|NCT01514149|GLP-1
296959|NCT01514149|Glucagon-like peptide-1
296960|NCT01514149|exendin-4
296961|NCT01514149|modified exendin-4
296962|NCT01514123|VGX-100
296963|NCT01514123|Bevacizumab
296964|NCT01514123|VEGF-C
296965|NCT01514123|First-In-Human
296966|NCT01514123|Dose Escalation
296967|NCT01514123|Advanced Solid Tumors
296968|NCT01514123|Angiogenesis Inhibitors
296969|NCT01514123|Angiogenesis Modulating Agents
296970|NCT01514123|Pharmacologic Actions
296971|NCT01514123|Antibodies, Monoclonal
296972|NCT01514123|Phase 1
296973|NCT01514123|Oncology
296974|NCT01514123|Advanced malignancy
296975|NCT01514097|emergency
296976|NCT01514097|pediatric
296977|NCT01514097|fracture
296978|NCT01514097|pain
296979|NCT01514084|laceration
296980|NCT01514084|emergency
296981|NCT01514084|cosmetic outcomes
296982|NCT01514084|patient satisfaction
296983|NCT01514084|suture
296984|NCT01514071|head injury
296985|NCT01514071|CT
296986|NCT01514071|emergency
296987|NCT01514071|radiation
296988|NCT01514045|Quality of Life
296989|NCT01514019|SLCO2B1 genotype
296990|NCT01514019|effect of apple juice
296991|NCT01514006|Primary hip arthroplasty
296992|NCT01514006|postoperative anemia
296993|NCT01514006|functional outcomes
296994|NCT01513993|CHF
296995|NCT01513993|Telemonitoring
296996|NCT01513980|Chronic Obstructive Pulmonary Disease
296997|NCT01513980|Telemonitoring
296998|NCT01513967|Alzheimer,
296999|NCT01513967|dementia
297000|NCT01513954|Infertility
297001|NCT01513941|Chronic hepatitis C
297002|NCT01513941|Genotype 1 chronic hepatitis C
297003|NCT01513941|Treatment experienced with HCV-1/HIV-1 coinfection
297004|NCT01513941|Telaprevir
297005|NCT01513941|Pegylated-Interferon-alfa-2a
297006|NCT01513941|Ribavirin
297007|NCT01513941|HCV-1/HIV-1 coinfection
297008|NCT01513941|Hepatitis C
297009|NCT01513928|pharmacokinetics
297010|NCT01513928|relative bioavailability
297011|NCT01513928|formulation comparison
297012|NCT01513915|parents
297013|NCT01513915|group cognitive behavioral intervention
297014|NCT01513915|anxiety disorder
297015|NCT01513915|children
297016|NCT01513915|FRIENDS program
297017|NCT01513902|Arthritis
297018|NCT01513902|Pediatric
297019|NCT01513902|Tofacitinib
297020|NCT01513902|JIA
297021|NCT01513850|Liver Transplantation
297022|NCT01513850|HBV
297023|NCT01513850|HBV Recurrence
297024|NCT01513850|HBsAg Positive
297025|NCT01513824|stress
297026|NCT01513824|biofeed back guided treatment
297027|NCT01513824|acupressure
297028|NCT01513824|ischemic heart disease
297029|NCT01513811|bowel preparation
297030|NCT01513811|constipation
297031|NCT01513811|polyethylene glycol
297032|NCT01513811|itopride
297033|NCT01513798|Diet Therapy
297034|NCT01513798|Exercise Therapy
297035|NCT01513798|Insulin Resistance
297036|NCT01513785|H. pylori
297037|NCT01513785|Dual therapy
297038|NCT01513785|Amoxicillin
297039|NCT01513785|Rabeprazole
297040|NCT01513759|Fibrinolysis
297041|NCT01513759|catheter directed fibrinolysis
297042|NCT01513759|ultrasound accelerated fibrinolysis
297043|NCT01513759|recombinant t-PA
297044|NCT01513759|Activase
297045|NCT01513746|Type 1 Diabetes
297046|NCT01513746|Type 1 Diabetes Mellitus
297047|NCT01513746|Eating Disorders
297048|NCT01513746|Insulin Omission
297049|NCT01513720|Bioequivalence
297050|NCT01513720|Lamotrigine
297051|NCT01513720|crossover
297052|NCT01513707|kidney transplantation
297053|NCT01513707|hemodialysis
297054|NCT01513707|peritoneal dialysis
297055|NCT01513694|Mesenchymal Stem Cells
297056|NCT01513694|Stem Cells
297057|NCT01513694|Intervertebral disc disease
297058|NCT01513681|Bioequivalence
297059|NCT01513681|Lamotrigine
297060|NCT01513681|crossover
297061|NCT01513655|COPD
297062|NCT01513655|Home NIV
297063|NCT01513655|NIV
297064|NCT01513642|physiotherapy
297065|NCT01513642|cardiac surgery
297066|NCT01513642|breath Stacking
297067|NCT01513629|Autism spectrum disorders
297068|NCT01513629|structural connectivity
297069|NCT01513629|diffusion spectrum imaging
297070|NCT01513629|sibling
297071|NCT01513629|endophenotype
297072|NCT01513616|COPD
297073|NCT01513616|dyspnea
297074|NCT01513616|exercise
297075|NCT01513616|measurement
297076|NCT01513616|respiratory physiology
297077|NCT01513577|Lumbar fusion
297078|NCT01513577|Pedicular screws
297079|NCT01513577|Minimal invasive technique
297080|NCT01513577|Randomized controlled trial
297081|NCT01513564|Disc disease
297082|NCT01513564|Spondylolisthesis
297083|NCT01513538|Pacemaker programming
297084|NCT01513538|Bradyarrhythmia
297085|NCT01513499|Eating behavior
297086|NCT01513499|Appetite
297087|NCT01513499|Oxytocin
297088|NCT01513499|Neuropeptide
297089|NCT01513460|Chronic Obstructive Pulmonary Disease,
297090|NCT01513460|NVA 237,
297091|NCT01513460|glycopyrronium,
297092|NCT01513460|COPD
297093|NCT01513447|sterile water injections
297094|NCT01513447|back labor
297095|NCT01513421|Infected
297096|NCT01513421|Intra-abdominal
297097|NCT01513421|Collection
297098|NCT01513421|Drainage
297099|NCT01513421|Percutaneous
297100|NCT01513408|breast cancer
297101|NCT01513408|CD8+
297102|NCT01513408|Foxp3
297103|NCT01513408|neoadjuvant chemotherapy
297104|NCT01513395|Cervical assessment
297105|NCT01513395|Focal myometrial contractions
297106|NCT01513382|Pilonidal sinus
297107|NCT01513382|Methylene blue
297108|NCT01513382|Histopathology
297109|NCT01513382|Surgery
297110|NCT01513369|Diabetes
297111|NCT01513369|iron deficiency
297112|NCT01513356|breast
297113|NCT01513356|cancer
297114|NCT01513356|BKM120
297115|NCT01513317|Myelodysplastic Syndrome
297116|NCT01513317|MDS
297117|NCT01513317|Blood and lymphatic diseases
297118|NCT01513317|Siltuximab
297119|NCT01513317|Anemic
297120|NCT01513265|reduction polypharmacy
297121|NCT01513265|clinical outcomes
297122|NCT01513265|pharmaceutical care
297123|NCT01513265|clinical pharmacy
297124|NCT01513265|geriatrics
297125|NCT01513265|medication review
297126|NCT01513265|potentially inappropriate drugs
297127|NCT01513252|Cognitive decline
297128|NCT01513252|prevention
297129|NCT01513252|omega-3 fatty acids
297130|NCT01513252|nutrition exercise
297131|NCT01513252|cognitive training
297132|NCT01513252|social activities
297133|NCT01513252|frailty
297134|NCT01513239|Clostridium difficile
297135|NCT01513239|Clostridium difficile infection (CDI)
297136|NCT01513239|recurrent Clostridium difficile
297137|NCT01513239|vancomycin
297138|NCT01513239|metronidazole
297139|NCT01513239|monoclonal antibody
297140|NCT01513226|cycled light
297141|NCT01513226|dim light
297142|NCT01513226|circadian rhythm
297143|NCT01513226|actigraphy, sleep
297144|NCT01513226|premature infant
297145|NCT01513213|Arterial cannulation
297146|NCT01513213|Blood gas
297147|NCT01513213|Carbon dioxide
297148|NCT01513213|Arterial blood
297149|NCT01513213|Oxygen
297150|NCT01513213|Oxygen fractions
297151|NCT01513187|Advanced renal cell carcinoma
297152|NCT01513187|SOGUG
297153|NCT01513187|Pazopanib
297154|NCT01513187|Pazopanib in combination with interferon alpha 2A
297155|NCT01513174|GOAL
297156|NCT01513174|Lung
297157|NCT01513174|Non small cell lung cancer
297158|NCT01513174|EGFR mutations
297159|NCT01513161|pruritus
297160|NCT01513135|HIV,
297161|NCT01513135|HAART-treated
297162|NCT01513135|participants
297163|NCT01513135|Tat protein,
297164|NCT01513135|Therapeutic immunization
297165|NCT01513109|WT1 positive Acute Myeloid Leukemia
297166|NCT01513109|Antigen specific cancer immunotherapeutic
297167|NCT01513109|Ex vivo regulatory T cell depletion
297168|NCT01513109|In vivo regulatory T cell depletion
297169|NCT01513096|colonoscopy
297170|NCT01513096|bowel preparation
297171|NCT01513096|PEG
297172|NCT01513096|Prokinetics
297173|NCT01513070|Quick-Acting Heart Reliever
297174|NCT01513070|Coronary Artery Stenosis
297175|NCT01513070|Coronary Heart Disease
297176|NCT01513070|Suxiao Jiuxin Pill
297177|NCT01513070|Chinese Herbal Drugs
297178|NCT01513070|Traditional Chinese Medicine
297179|NCT01513070|Chinese Medicine
297180|NCT01513070|Angina Pectoris
297181|NCT01513070|Isosorbide Dinitrate
297182|NCT01513070|Myocardial Perfusion Imaging
297183|NCT01513070|Clinical Trial
297184|NCT01513057|bioequivalence
297185|NCT01513057|Mycophenolate Mofetil
297186|NCT01513057|crossover
297187|NCT01513044|bioequivalence
297188|NCT01513044|Mycophenolate Mofetil
297189|NCT01513044|crossover
297190|NCT01513031|Atrial fibrillation
297191|NCT01513031|Anti-arrhythmic medication
297192|NCT01513031|Medication adherence
297193|NCT01513018|OLV
297194|NCT01513018|one lung ventilation
297195|NCT01513005|Laparoscopic Sleeve Gastrectomy
297196|NCT01513005|obesity management
297197|NCT01512966|Diabetic Macular Edema
297198|NCT01512966|DME
297199|NCT01512966|VEGF Trap-Eye
297200|NCT01512966|best-corrected visual acuity (BCVA)
297201|NCT01512953|PPI
297202|NCT01512953|clopidogrel
297203|NCT01512953|2C19
297204|NCT01512953|Lansoprazole
297205|NCT01512940|obesity
297206|NCT01512940|Laparoscopic Greater Curvature Plication
297207|NCT01512940|Percent Excess weight Loss
297208|NCT01512940|comorbidities
297209|NCT01512940|BMI
297210|NCT01512940|Bariatric Surgery
297211|NCT01512927|electronic stethoscope
297212|NCT01512927|arteriovenous fistula
297213|NCT01512927|hemodialysis,
297214|NCT01512914|Gynecologic laparoscopic surgery
297215|NCT01512914|Postoperative pain
297216|NCT01512914|Nebulization
297217|NCT01512914|Ropivacaine
297218|NCT01512888|SCID
297219|NCT01512888|SCID-X1
297220|NCT01512888|X-linked SCID
297221|NCT01512888|immunodeficiency
297222|NCT01512888|gene therapy
297223|NCT01512875|Helicobacter pylori
297224|NCT01512875|water contamination
297225|NCT01512875|Lima, Peru
297226|NCT01512862|Calcitriol
297227|NCT01512862|Off-label
297228|NCT01512849|TA-7284
297229|NCT01512849|JNJ-28431754
297230|NCT01512849|Canagliflozin
297231|NCT01512849|Renal Impairment
297232|NCT01512849|Sodium Glucose Co-transporter2 (SGLT2) inhibitor
297233|NCT01512836|COPD
297234|NCT01512836|Case management
297235|NCT01512836|CEA
297236|NCT01512836|Health economy
297237|NCT01512836|Quality of Life
297238|NCT01512823|randomised controlled trial
297239|NCT01512823|educational intervention
297240|NCT01512823|occupational therapy
297241|NCT01512810|Endometrial
297242|NCT01512810|Cancer
297243|NCT01512810|Intraoperative Consultation
297244|NCT01512797|Januvia
297245|NCT01512797|Sitagliptin
297246|NCT01512797|Diabetes
297247|NCT01512797|Gastric-Bypass
297248|NCT01512784|Quadrivalent Human Papillomavirus Vaccine (HPV) Gardasil
297249|NCT01512784|HIV infection
297250|NCT01512784|Evaluation of quadrivalent HPV vaccine in adolescents and young adults.
297251|NCT01512758|East Asian Patients
297252|NCT01512758|Advanced solid tumors
297253|NCT01512758|Lymphomas
297254|NCT01512758|MLN8237
297255|NCT01512758|Alisertib
297256|NCT01512758|Aurora A Kinase Inhibitor
297257|NCT01512706|Human Enterovirus 71 (EV71)
297258|NCT01512706|Hand, Foot and Mouth Disease
297259|NCT01512706|Inactivated Vaccine
297260|NCT01512706|Human Diploid cell
297261|NCT01512706|Safety
297262|NCT01512706|Immunogenicity
297263|NCT01512706|Adverse reactions associated with vaccine
297264|NCT01512680|Functional Insulin Thearpy
297265|NCT01512680|Carbs counting
297266|NCT01512680|Type 1 diabetes mellitus
297267|NCT01512680|Insulin pump
297268|NCT01512680|Treatment by external insulin pump
297269|NCT01512654|diabetes
297270|NCT01512654|diadvisor
297271|NCT01512654|type 1 diabetes
297272|NCT01512654|type 2 diabetes
297273|NCT01512654|glucose prediction
297274|NCT01512654|cgm prediction
297275|NCT01512654|algorithm
297276|NCT01512654|therapy advices
297277|NCT01512641|children dissociative disorders schizophrenia
297278|NCT01512615|Rehabilitation
297279|NCT01512615|Exercise training
297280|NCT01512615|Psycho-educational care
297281|NCT01512602|Borderline Personality Disorder traits
297282|NCT01512602|Suicide prevention
297283|NCT01512602|Self-harm
297284|NCT01512602|Dialectical Behavior Therapy
297285|NCT01512602|DBT
297286|NCT01512602|Collaborative Assessment and Management of Suicidology
297287|NCT01512602|CAMS
297288|NCT01512589|Proton Beam Therapy
297289|NCT01512589|PBT
297290|NCT01512589|Intensity-Modulated Radiation Therapy
297291|NCT01512589|IMRT
297292|NCT01512589|Esophageal cancer
297293|NCT01512589|Adenocarcinoma
297294|NCT01512589|Squamous cell carcinoma
297295|NCT01512589|Cervical esophagus
297296|NCT01512589|Thoracic esophagus
297297|NCT01512589|Gastroesophageal junction
297298|NCT01512589|Cardia of stomach
297299|NCT01512589|Questionnaires
297300|NCT01512589|Surveys
297301|NCT01512589|Symptom scores
297302|NCT01512589|Quality of life
297303|NCT01512589|QOL
297304|NCT01512576|whiplash
297305|NCT01512576|chronic pain
297306|NCT01512576|sensitization
297307|NCT01512576|treatment
297308|NCT01512576|acupuncture
297309|NCT01512576|relaxation
297310|NCT01512563|paclitaxel
297311|NCT01512563|drug eluting stent
297312|NCT01512550|Radiostereometric Analysis (RSA)
297313|NCT01512550|Total hip arthroplasty (THA)
297314|NCT01512550|Hip anatomy
297315|NCT01512550|Hip biomechanics
297316|NCT01512537|Vitamin D
297317|NCT01512537|UVB
297318|NCT01512537|Vitamin D supplementation
297319|NCT01512524|Traumatic Brain Injury
297320|NCT01512524|Quality of Life (QoL)
297321|NCT01512524|hypopituitarism,GH
297322|NCT01512511|laparoscopic cholecystectomy
297323|NCT01512511|pneumoperitoneum
297324|NCT01512511|nitrous oxide
297325|NCT01512511|carbon dioxide
297326|NCT01512498|VV GVHD
297327|NCT01512498|girls
297328|NCT01512498|adolescents
297329|NCT01512498|HSCT
297330|NCT01512485|Bioequivalence
297331|NCT01512485|Clopidogrel
297332|NCT01512485|crossover
297333|NCT01512472|localized prostate cancer
297334|NCT01512472|degarelix
297335|NCT01512472|intermittent androgen deprivation therapy
297336|NCT01512459|Bioavailability
297337|NCT01512459|Venlafaxine
297338|NCT01512459|two way crossover
297339|NCT01512446|Osteoporosis
297340|NCT01512446|Osteoporotic fractures
297341|NCT01512446|Bisphosphonate
297342|NCT01512446|Pretreatment with bisphosphonates
297343|NCT01512433|acupuncture
297344|NCT01512433|methadone
297345|NCT01512407|Hepatocellular Carcinoma
297346|NCT01512407|Randomised controlled trial
297347|NCT01512407|Transarterial chemoembolisation
297348|NCT01512394|bowel preparation
297349|NCT01512381|heart failure
297350|NCT01512381|CRT
297351|NCT01512381|atrial fibrillation
297352|NCT01512381|AV junction ablation
297353|NCT01512368|Fibroblast growth factor 21 (FGF21)
297354|NCT01512368|Exercise
297355|NCT01512368|Metabolic equivalents (METs)
297356|NCT01512368|Lipolysis
297357|NCT01512368|Glucose
297358|NCT01512368|Free fatty acids (FFAs)
297359|NCT01512368|Epinephrine
297360|NCT01512342|pacing
297361|NCT01512342|activity management
297362|NCT01512342|relaxation
297363|NCT01512342|physiotherapy
297364|NCT01512342|occupational therapy
297365|NCT01512342|autonomic nervous system
297366|NCT01512329|neurology
297367|NCT01512329|physiotherapy
297368|NCT01512329|physical therapy
297369|NCT01512329|occupational therapy
297370|NCT01512329|stress management
297371|NCT01512329|activity management
297372|NCT01512329|treatment
297373|NCT01512316|Fear
297374|NCT01512316|Cycloserine
297375|NCT01512316|Conditioning
297376|NCT01512316|Functional neuroimaging
297377|NCT01512316|Anxiety disorders
297378|NCT01512303|PTSD
297379|NCT01512303|Veterans' Health
297380|NCT01512303|Meditation
297381|NCT01512303|MRI, Functional
297382|NCT01512290|Auditory verbal hallucinations
297383|NCT01512290|Transcranial Magnetic stimulation
297384|NCT01512290|Theta Burst frequency
297385|NCT01512277|vaccines
297386|NCT01512277|safety
297387|NCT01512277|drug tolerance
297388|NCT01512277|immunogenic protein
297389|NCT01512277|antibody response
297390|NCT01512277|cytokine
297391|NCT01512264|Aphasia
297392|NCT01512264|Stroke
297393|NCT01512264|functional Magnetic resonance imaging
297394|NCT01512264|fMRI
297395|NCT01512264|Language recovery after stroke
297396|NCT01512264|constraint induced aphasia therapy
297397|NCT01512264|CIAT
297398|NCT01512264|Repetitive transcranial magnetic stimulation
297399|NCT01512264|rTMS
297400|NCT01512251|BKM120
297401|NCT01512251|BRAF
297402|NCT01512251|Melanoma
297403|NCT01512251|PI3K
297404|NCT01512238|Medicine adherence
297405|NCT01512238|Drug substitution
297406|NCT01512238|Herb-drug interaction
297407|NCT01512238|Herbal medicine
297408|NCT01512238|Dietary supplements
297409|NCT01512238|Over-the-counter products
297410|NCT01512238|On-line prescription records
297411|NCT01512238|Personal electronic medicine profile
297412|NCT01512238|Intentional non-adherence
297413|NCT01512238|Unintentional non-adherence
297414|NCT01512225|breastmilk
297415|NCT01512225|domperidone
297416|NCT01512225|preterm
297417|NCT01512212|thyroid
297418|NCT01512212|fine
297419|NCT01512212|needle
297420|NCT01512212|aspiration
297421|NCT01512212|biopsy
297422|NCT01512212|new
297423|NCT01512212|technique
297424|NCT01512199|U3-1287
297425|NCT01512199|Trastuzumab
297426|NCT01512199|Paclitaxel
297427|NCT01512199|newly diagnosed HER-2 positive
297428|NCT01512199|breast cancer
297429|NCT01512199|metastatic
297430|NCT01512186|Clear cell renal cancer
297431|NCT01512173|Propranolol gel
297432|NCT01512173|Hemangioma
297433|NCT01512173|capillary neoplasm
297434|NCT01512173|vascular tissue
297435|NCT01512173|neoplasm by histologic type
297436|NCT01512173|neoplasm
297437|NCT01512173|therapeutic uses
297438|NCT01512173|pharmacologic actions
297439|NCT01512173|adrenergic beta-antagonists
297440|NCT01512173|adrenergic antagonist
297441|NCT01512173|adrenergics agent
297442|NCT01512173|neurotransmitter agent
297443|NCT01512173|molecular mechanism of pharmacological action
297444|NCT01512173|physiological effects of drugs
297445|NCT01512160|Post-surgical dental pain
297446|NCT01512147|SSEP measurements
297447|NCT01512147|MEP measurements
297448|NCT01512147|Pediatric Patients
297449|NCT01512147|Neurosurgery
297450|NCT01512147|General Anesthesia
297451|NCT01512134|Obesity
297452|NCT01512134|DBS
297453|NCT01512082|Pain
297454|NCT01512082|Delayed onset muscle soreness
297455|NCT01512082|Pulsed electromagnetic field
297456|NCT01512082|Marathon
297457|NCT01512069|randomized controlled trial
297458|NCT01512069|internet
297459|NCT01512069|diet
297460|NCT01512069|exercise
297461|NCT01512069|health planning
297462|NCT01512069|the TTM
297463|NCT01512056|Influenza vaccine
297464|NCT01512056|dialysis
297465|NCT01512056|vaccine
297466|NCT01512056|Seroprotection
297467|NCT01512056|Seroresponse
297468|NCT01512056|Seroconversion
297469|NCT01512056|Safety of the vaccine
297470|NCT01512043|Breathlessness
297471|NCT01512043|Symptoms
297472|NCT01512043|Quality of life
297473|NCT01512017|skin lesions or defects
297474|NCT01512004|Overactive Bladder
297475|NCT01512004|urgent micturition
297476|NCT01512004|frequent micturition
297477|NCT01512004|urge urinary incontinence
297478|NCT01511991|cardiac surgery
297479|NCT01511991|sevoflurane
297480|NCT01511991|tissue Doppler
297481|NCT01511978|Lambert-Eaton
297482|NCT01511978|Eaton-Lambert
297483|NCT01511978|myasthenia
297484|NCT01511978|myasthenic
297485|NCT01511978|LEMS
297486|NCT01511978|LES
297487|NCT01511978|DAP
297488|NCT01511978|diaminopyridine
297489|NCT01511978|3,4-diaminopyridine
297490|NCT01511978|3,4-DAP
297491|NCT01511952|music therapy
297492|NCT01511952|entrainment
297493|NCT01511952|premature infants
297494|NCT01511952|live music intervention
297495|NCT01511952|parent preferred lullabies
297496|NCT01511939|Knee pain
297497|NCT01511939|Anticoagulant
297498|NCT01511939|Warfarin
297499|NCT01511939|Dabigatran
297500|NCT01511939|Clopidogrel
297501|NCT01511939|Aspirin
297502|NCT01511939|Topical NSAID
297503|NCT01511939|Osteoarthritis
297504|NCT01511926|Vimovo™ treated patients and prescribing patterns
297505|NCT01511926|Risk of gastrointestinal side effects
297506|NCT01511913|Unresectable or metastatic cutaneous melanoma
297507|NCT01511887|Patent Ductus Arteriosus
297508|NCT01511887|PDA
297509|NCT01511887|Term newborns
297510|NCT01511887|Ibuprofen
297511|NCT01511874|ELIGARD
297512|NCT01511874|Prostate cancer
297513|NCT01511848|Iron chelation
297514|NCT01511848|Iron balance
297515|NCT01511848|Secondary iron overload
297516|NCT01511848|deferoxamine
297517|NCT01511848|deferasirox
297518|NCT01511848|Deferiprone
297519|NCT01511848|1- Beta-thalassemia major patients;
297520|NCT01511848|Patients with high iron stores
297521|NCT01511848|Serum ferritin consistently > 2500 mcg/l and or increasing trend over previous 12 months
297522|NCT01511848|Liver iron >14 mg/g dry weight- by R2 MRI
297523|NCT01511848|2- Sickle cell disease
297524|NCT01511848|3- Other causes of transfusional iron hemosiderosis
297525|NCT01511835|diabetes
297526|NCT01511835|pregnancy
297527|NCT01511835|myo-inositol
297528|NCT01511822|PCOS
297529|NCT01511822|Insulin resistance
297530|NCT01511822|Hyperandrogenism
297531|NCT01511822|Myo-inositol
297532|NCT01511809|HIV-1
297533|NCT01511796|stroke
297534|NCT01511796|upper limb rehabilitation function
297535|NCT01511770|Bioequivalence
297536|NCT01511770|Fluconazole
297537|NCT01511770|Crossover
297538|NCT01511757|Bioequivalence
297539|NCT01511757|Fluconazole
297540|NCT01511757|Crossover
297541|NCT01511744|Respiratory Tract Infections; Orthomyxoviridae Infections
297542|NCT01511731|Bioequivalence
297543|NCT01511731|famotidine
297544|NCT01511731|Crossover
297545|NCT01511718|Bioequivalence
297546|NCT01511718|Ondansetron
297547|NCT01511718|crossover
297548|NCT01511705|Bioequivalence
297549|NCT01511705|Ondansetron
297550|NCT01511705|crossover
297551|NCT01511679|Alcohol abuse
297552|NCT01511666|cardiac arrest
297553|NCT01511666|mechanical chest compressions
297554|NCT01511666|intraarrest cooling
297555|NCT01511666|ECLS
297556|NCT01511653|screening colonoscopy
297557|NCT01511653|colon cancer early detection
297558|NCT01511653|rectal cancer early detection
297559|NCT01511653|colorectal cancer prevention
297560|NCT01511653|biomarker validation
297561|NCT01511640|marijuana
297562|NCT01511640|addiction
297563|NCT01511640|treatment
297564|NCT01511640|pharmacotherapy
297565|NCT01511640|cannabinoid
297566|NCT01511614|fMRI
297567|NCT01511614|Nicotine Withdrawal
297568|NCT01511601|Apheresis
297569|NCT01511601|Leukocytes
297570|NCT01511601|Plasma
297571|NCT01511601|Plamodium Falciparum Malaria
297572|NCT01511601|Immunology
297573|NCT01511588|Kallmann Syndrome
297574|NCT01511588|Delayed Puberty
297575|NCT01511588|GnRH Deficiency
297576|NCT01511588|Infertility
297577|NCT01511588|Hypogonadotropic Hypogonadism
297578|NCT01511588|Amenorrhea
297579|NCT01511588|Hypogonadism
297580|NCT01511575|childhood acute myeloid leukemia in remission
297581|NCT01511575|childhood acute myeloid leukemia/other myeloid malignancies
297582|NCT01511575|childhood acute megakaryocytic leukemia (M7)
297583|NCT01511562|primary central nervous system non-Hodgkin lymphoma
297584|NCT01511562|contiguous stage II adult diffuse large cell lymphoma
297585|NCT01511562|noncontiguous stage II adult diffuse large cell lymphoma
297586|NCT01511562|stage I adult diffuse large cell lymphoma
297587|NCT01511562|stage III adult diffuse large cell lymphoma
297588|NCT01511562|stage IV adult diffuse large cell lymphoma
297589|NCT01511523|Liver
297590|NCT01511523|Fatty
297591|NCT01511523|Non Alcoholic
297592|NCT01511523|Vitamin E
297593|NCT01511523|Silymarin
297594|NCT01511523|Carnitine
297595|NCT01511523|Supplement
297596|NCT01511523|NAFLD
297597|NCT01511510|PF-04958242
297598|NCT01511510|multiple dose
297599|NCT01511510|safety
297600|NCT01511510|schizophrenia
297601|NCT01511497|Phase 1
297602|NCT01511497|PF-04427429
297603|NCT01511484|fruit
297604|NCT01511484|vegetables
297605|NCT01511484|appearance
297606|NCT01511484|skin color
297607|NCT01511484|carotenoids
297608|NCT01511484|diet
297609|NCT01511471|Ticagrelor
297610|NCT01511471|platelet reactivity
297611|NCT01511471|clopidogrel
297612|NCT01511471|haemodialysis
297613|NCT01511458|Pregnancy
297614|NCT01511458|Fetal aneuploidy
297615|NCT01511458|Trisomy 21
297616|NCT01511458|Down Syndrome
297617|NCT01511458|Prenatal screening
297618|NCT01511458|Non-invasive prenatal testing
297619|NCT01511458|First trimester
297620|NCT01511458|Combined screening
297621|NCT01511458|Nuchal translucency
297622|NCT01511458|PAPP-A
297623|NCT01511458|hCG
297624|NCT01511458|cell free DNA
297625|NCT01511458|cf DNA
297626|NCT01511458|DNA
297627|NCT01511458|Performance characteristics of non-invasive first trimester screening
297628|NCT01511458|Harmony Prenatal Test
297629|NCT01511445|Cervicobrachial pain
297630|NCT01511445|radicular pain
297631|NCT01511445|arm pain
297632|NCT01511445|myelopathy
297633|NCT01511445|radiculitis
297634|NCT01511445|Radiating pain with or without signs of myelopathy.
297635|NCT01511432|Relative bioavailability
297636|NCT01511432|telaprevir formulations
297637|NCT01511419|Influenza
297638|NCT01511419|Vaccine
297639|NCT01511419|Pandemic
297640|NCT01511419|H7N3
297641|NCT01511406|Psychosis
297642|NCT01511406|Schizophrenia
297643|NCT01511406|Cognitive behavioral therapy
297644|NCT01511406|Self esteem
297645|NCT01511406|Depression
297646|NCT01511393|GLP1
297647|NCT01511393|Glucagon like peptide
297648|NCT01511393|liraglutide
297649|NCT01511393|exenatide extended release
297650|NCT01511393|albiglutide
297651|NCT01511393|dulaglutide
297652|NCT01511380|juvenile
297653|NCT01511380|randomized trial
297654|NCT01511380|substance abuse
297655|NCT01511380|sexual risk
297656|NCT01511380|contingency management
297657|NCT01511367|moderate to severe persistent reversible asthma
297658|NCT01511354|critically ill children
297659|NCT01511354|ICU
297660|NCT01511354|24hr protein balance
297661|NCT01511354|stable isotopes
297662|NCT01511354|fed state
297663|NCT01511341|Telenursing
297664|NCT01511341|Children
297665|NCT01511341|Chronic Illness
297666|NCT01511341|Nursing
297667|NCT01511328|HPV testing
297668|NCT01511328|Primary screening
297669|NCT01511328|Cervical Cancer
297670|NCT01511315|Moderate to severe psoriasis
297671|NCT01511289|Radotinib
297672|NCT01511289|CML-CP
297673|NCT01511289|Chronic Myeloid Leukemia, chronic phase
297674|NCT01511276|Breast cancer
297675|NCT01511276|Sex hormones
297676|NCT01511276|Physical activity
297677|NCT01511263|Epigallocatechin gallate
297678|NCT01511263|AL amyloidosis
297679|NCT01511250|normal healthy adults and children
297680|NCT01511250|Safety and tolerability
297681|NCT01511250|active vaccine
297682|NCT01511250|placebo
297683|NCT01511250|Dengue virus vaccine
297684|NCT01511250|Immune response
297685|NCT01511237|HIV-1 infection
297686|NCT01511237|Prophylaxis
297687|NCT01511237|Mother-to-child transmission HIV-1
297688|NCT01511237|Thailand
297689|NCT01511237|Developing Countries
297690|NCT01511224|Bloodstream infections
297691|NCT01511224|Acinetobacter
297692|NCT01511224|Drug resistant Acinetobacter baumannii bacteremia
297693|NCT01511211|Dexamethasone
297694|NCT01511211|lower limb block
297695|NCT01511211|ultrasound guided femoral nerve block
297696|NCT01511211|ultrasound guided obturator nerve block
297697|NCT01511211|ultrasound guided sciatic nerve block
297698|NCT01511211|ropivacaine
297699|NCT01511211|total knee arthroplasty
297700|NCT01511211|Post surgical pain after total knee arthroplasty
297701|NCT01511146|oxaliplatin
297702|NCT01511146|mitomycin
297703|NCT01511146|gemcitabine
297704|NCT01511146|intrahepatic
297705|NCT01511146|liver metastasis
297706|NCT01511146|response in liver metastasis
297707|NCT01511146|downsized to operation
297708|NCT01511133|Laboratory evaluations
297709|NCT01511133|infants
297710|NCT01511133|Porcine circovirus type 1 (PCV-1)
297711|NCT01511133|serologic response
297712|NCT01511133|human rotavirus (HRV) vaccine
297713|NCT01511107|acute otitis media
297714|NCT01511107|ear infection
297715|NCT01511107|antimicrobial therapy
297716|NCT01511107|antimicrobial resistance
297717|NCT01511094|ab-interno trabeculectomy,
297718|NCT01511094|intraocular pressure,
297719|NCT01511094|open angle glaucoma
297720|NCT01511094|trabeculectomy
297721|NCT01511094|Goniocurettage
297722|NCT01511094|Non-Filtering Surgery
297723|NCT01511081|Non-small-cell lung cancer
297724|NCT01511081|NSCLC
297725|NCT01511081|Centrally-located
297726|NCT01511081|Recurrent
297727|NCT01511081|Squamous cell carcinoma
297728|NCT01511081|Adenocarcinoma
297729|NCT01511081|Large cell carcinoma
297730|NCT01511081|Bronchioloalveolar cell carcinoma
297731|NCT01511081|Non-small cell carcinoma not otherwise specified
297732|NCT01511081|Stereotactic Body Radiotherapy
297733|NCT01511081|SBRT
297734|NCT01511081|Stereotactic Body Proton Therapy
297735|NCT01511081|SBPT
297736|NCT01511068|PAP
297737|NCT01511055|Ovarian Cancer
297738|NCT01511016|lipid kinetics
297739|NCT01511016|fat oxidation
297740|NCT01511003|Tacrolimus
297741|NCT01511003|Prograf
297742|NCT01511003|calcineurin inhibitor
297743|NCT01511003|Rheumatoid arthritis (RA)
297744|NCT01510990|Non-small cell lung cancer
297745|NCT01510990|Gefitinib
297746|NCT01510990|FDG-PET
297747|NCT01510977|colonoscopy
297748|NCT01510977|bowel preparation
297749|NCT01510964|Breast cancer
297750|NCT01510964|Patient involvement
297751|NCT01510964|Question prompt-sheet
297752|NCT01510964|Doctor-patient communication
297753|NCT01510964|RCT
297754|NCT01510951|AMGEN
297755|NCT01510951|PSORIASIS
297756|NCT01510951|SAFETY
297757|NCT01510938|Children
297758|NCT01510938|Respiratory Tract Infections
297759|NCT01510938|Prevention
297760|NCT01510886|MDD, management, Andalusia, Database, PismaEP
297761|NCT01510873|Health-related quality of life
297762|NCT01510873|Fatigue
297763|NCT01510873|pITO
297764|NCT01510873|Primary Immune Thrombocytopenic Purpura
297765|NCT01510834|Computerized Tailored Intervention
297766|NCT01510834|CTI
297767|NCT01510834|Post Traumatic Stress Disorder
297768|NCT01510834|PTSD
297769|NCT01510834|Smoking
297770|NCT01510834|Anxiety
297771|NCT01510834|Depression
297772|NCT01510821|endoscopic vein harvest
297773|NCT01510821|saphenous vein graft
297774|NCT01510821|endothelial function
297775|NCT01510808|aggressive periodontitis orthodontic stability
297776|NCT01510795|Kidney transplantation
297777|NCT01510795|Mineralocorticoid receptors
297778|NCT01510795|Spironolactone
297779|NCT01510743|open heart surgery
297780|NCT01510743|lung surgery
297781|NCT01510743|spine surgery
297782|NCT01510743|hepatobiliary surgery
297783|NCT01510730|gastric tumor
297784|NCT01510730|Helicobacter pylori
297785|NCT01510730|endoscopic resection
297786|NCT01510730|metachronous neoplasms
297787|NCT01510717|Intraocular Lens
297788|NCT01510717|Monofocal
297789|NCT01510717|Multifocal
297790|NCT01510691|Oxygenation of the retinal vessels
297791|NCT01510691|vitroretinal surgery
297792|NCT01510678|Diet Quality
297793|NCT01510665|Weight gain in pregnancy
297794|NCT01510665|Metabolic and Inflammatory markers
297795|NCT01510652|Cardiac Resynchronization therapy,
297796|NCT01510652|Heart Failure,
297797|NCT01510652|Left Ventricular Lead,
297798|NCT01510652|Quadripolar Left ventricular Lead,
297799|NCT01510652|Phrenic Nerve Stimulation,
297800|NCT01510652|Intra and post operative related complications
297801|NCT01510626|Multiple food allergies
297802|NCT01510613|Pomalidomide
297803|NCT01510613|Dexamethasone
297804|NCT01510613|treatment
297805|NCT01510613|AL amyloidosis
297806|NCT01510600|stage 4S neuroblastoma
297807|NCT01510600|localized resectable neuroblastoma
297808|NCT01510600|localized unresectable neuroblastoma
297809|NCT01510600|recurrent neuroblastoma
297810|NCT01510600|regional neuroblastoma
297811|NCT01510587|obesity
297812|NCT01510587|prevention
297813|NCT01510587|preteen
297814|NCT01510587|nutrition
297815|NCT01510587|physical activity
297816|NCT01510587|body image
297817|NCT01510587|family dynamics
297818|NCT01510574|postpartum hemorrhage, PPH, misoprostol
297819|NCT01510561|metastatic pancreatic adenocarcinoma
297820|NCT01510561|pancreatic cancer
297821|NCT01510561|metastatic pancreatic cancer
297822|NCT01510548|Disc prolapse
297823|NCT01510548|Pain
297824|NCT01510548|Disability
297825|NCT01510535|Osteoartritis
297826|NCT01510535|Knee
297827|NCT01510535|LBSA0103
297828|NCT01510535|Hyruan Plus Inj.
297829|NCT01510522|Diabetes
297830|NCT01510522|Glucophage
297831|NCT01510522|Metformin
297832|NCT01510522|sachets
297833|NCT01510522|tablets
297834|NCT01510509|Drug Eluting Stent
297835|NCT01510509|Bioactive Bare Metal Stent
297836|NCT01510496|Chronic pain
297837|NCT01510496|genetic polymorphisms
297838|NCT01510496|postoperative pain
297839|NCT01510483|obesity prevention
297840|NCT01510483|tobacco prevention
297841|NCT01510483|nutrition
297842|NCT01510483|physical activity
297843|NCT01510483|sedentary activity
297844|NCT01510483|tobacco use
297845|NCT01510483|tobacco exposure
297846|NCT01510483|prevention
297847|NCT01510483|clinician intervention
297848|NCT01510483|preteen
297849|NCT01510483|adolescents
297850|NCT01510470|AstraTech Osseospeed Profile Implant
297851|NCT01510470|Marginal bone level
297852|NCT01510470|soft tissue
297853|NCT01510470|soft tissue responds
297854|NCT01510457|Knee Osteoarthritis
297855|NCT01510457|Degenerative Joint Disease
297856|NCT01510457|Chronic Pain
297857|NCT01510457|Knee Pain
297858|NCT01510418|Hemophilia
297859|NCT01510418|Spouse
297860|NCT01510418|Significant Other
297861|NCT01510418|Quality of Life
297862|NCT01510405|Subjects undergoing or who have undergone thoracic surgery for presumed lung cancer.
297863|NCT01510405|The following procedures are allowed: Wedge resection, lobectomy, bilobectomy, segmentectomy and pneumonectomy thoracic surgical operations are permitted.
297864|NCT01510392|Optical coherence tomography
297865|NCT01510392|Glaucoma
297866|NCT01510392|Macula
297867|NCT01510392|Keratoconus
297868|NCT01510392|Screening
297869|NCT01510379|nausea
297870|NCT01510379|vomiting
297871|NCT01510379|post-operative
297872|NCT01510379|foregut surgery
297873|NCT01510366|Inactivated Poliomyelitis Vaccine
297874|NCT01510366|Sabin Strains
297875|NCT01510366|poliomyelitis
297876|NCT01510340|adherence
297877|NCT01510340|HIV
297878|NCT01510340|antiretroviral therapy
297879|NCT01510340|tailored web intervention
297880|NCT01510327|drug-eluting stents
297881|NCT01510327|DES
297882|NCT01510327|atherosclerotic
297883|NCT01510301|Self-report
297884|NCT01510301|Self-management
297885|NCT01510301|Hypertension
297886|NCT01510301|Adherence
297887|NCT01510301|Cell phone
297888|NCT01510301|Drug treatment
297889|NCT01510301|Medical Adherence
297890|NCT01510288|GVAX
297891|NCT01510288|Ipilimumab
297892|NCT01510288|prostate cancer
297893|NCT01510275|cardio-thoracic surgery
297894|NCT01510275|patients
297895|NCT01510275|pulmonary volume
297896|NCT01510275|respiratory muscle performance
297897|NCT01510262|Repeat STI patients
297898|NCT01510262|HIV
297899|NCT01510262|Cost effectiveness
297900|NCT01510262|Resource scarce
297901|NCT01510262|Urban clinics
297902|NCT01510249|calcaneal spur
297903|NCT01510249|shock wave therapy
297904|NCT01510249|ultrasound therapy
297905|NCT01510236|Adolescence
297906|NCT01510236|Cancer
297907|NCT01510236|Depression
297908|NCT01510236|Anxiety
297909|NCT01510236|Self-help via internet
297910|NCT01510223|Fats
297911|NCT01510223|Macronutrients
297912|NCT01510223|appetite
297913|NCT01510223|gastric emptying
297914|NCT01510223|Gastrointestinal transit
297915|NCT01510210|Atrial Fibrillation
297916|NCT01510210|Arrhythmia
297917|NCT01510210|Rhythm control
297918|NCT01510197|Atrial Fibrillation
297919|NCT01510197|Arrhythmia
297920|NCT01510197|Rhythm control
297921|NCT01510171|platelet inhibitor
297922|NCT01510171|ST-segment elevation myocardial infarction
297923|NCT01510171|stent
297924|NCT01510171|prasugrel
297925|NCT01510171|ticagrelor
297926|NCT01510145|Glaucoma
297927|NCT01510145|Open-angle glaucoma
297928|NCT01510145|Ocular hypertension
297929|NCT01510145|Hypertension
297930|NCT01510145|Eye Diseases
297931|NCT01510145|Vascular Diseases
297932|NCT01510145|Cardiovascular Diseases
297933|NCT01510145|Travoprost
297934|NCT01510145|Antihypertensive Agents
297935|NCT01510145|Cardiovascular Agents
297936|NCT01510145|Therapeutic Uses
297937|NCT01510145|Pharmacologic Actions
297938|NCT01510132|OAG
297939|NCT01510132|OHT
297940|NCT01510093|type 2 diabetes mellitus, endogenous insulin
297941|NCT01510080|Computer-assisted live supervision
297942|NCT01510080|"Bug-in-the-eye supervision"
297943|NCT01510080|Delayed video-based supervision
297944|NCT01510080|Cognitive behavioral therapy supervision
297945|NCT01510067|CLE
297946|NCT01510067|Lupus
297947|NCT01510067|Lupus Erythematosus
297948|NCT01510054|miRNA in endometrium
297949|NCT01510041|Chronic obstructive pulmonary disease
297950|NCT01510041|Physical therapy
297951|NCT01510041|Dyspnea
297952|NCT01510041|Inspiratory muscle training
297953|NCT01510041|Activities of daily living
297954|NCT01510028|Intrathecal Drug Delivery Device (IDDD)
297955|NCT01510028|Recombinant human arylsulfatase A (rhASA)
297956|NCT01510028|Metachromatic Leukodystrophy (MLD)
297957|NCT01510015|cannabis
297958|NCT01510015|psychostimulants
297959|NCT01510015|psychosis
297960|NCT01510002|papillary thyroid cancer
297961|NCT01510002|central neck dissection
297962|NCT01510002|survival
297963|NCT01510002|locoregional control
297964|NCT01510002|morbidity
297965|NCT01509989|Adherence
297966|NCT01509989|Compliance
297967|NCT01509989|Systemic Lupus Erythematosus
297968|NCT01509989|Hydroxychloroquine
297969|NCT01509989|Blood monitoring
297970|NCT01509989|Flares
297971|NCT01509976|Triclosan
297972|NCT01509976|Triclocarban
297973|NCT01509976|Microbial flora
297974|NCT01509976|Obesity
297975|NCT01509963|MSKCC nomogram
297976|NCT01509963|Tenon score
297977|NCT01509963|metastatic SN
297978|NCT01509963|low risk of metastatic non-SN
297979|NCT01509963|additional ALND
297980|NCT01509937|end stage renal disease
297981|NCT01509937|maintenance hemodialysis
297982|NCT01509937|dry weight
297983|NCT01509937|bioimpedance spectroscopy analysis
297984|NCT01509937|body composition monitor
297985|NCT01509937|Fresenius BCM
297986|NCT01509937|Ultrafiltration
297987|NCT01509924|Walking capacity
297988|NCT01509924|Mental Fatigue
297989|NCT01509924|Quality of Life
297990|NCT01509924|Cognition
297991|NCT01509924|Motor activity
297992|NCT01509924|Exercise
297993|NCT01509872|Trauma-Focused Cognitive Behavior Therapy
297994|NCT01509872|War-affected Children
297995|NCT01509872|Post-traumatic Stress Symptoms
297996|NCT01509872|Psychosocial Distress
297997|NCT01509859|proximal femur nail
297998|NCT01509859|pfna
297999|NCT01509859|intertan
298000|NCT01509859|weight bearing
298001|NCT01509859|pertrochanteric fracture
298002|NCT01509859|femur neck fracture
298003|NCT01509846|Shigella
298004|NCT01509846|vaccine
298005|NCT01509846|shigellosis
298006|NCT01509846|dysentery
298007|NCT01509846|whole cell
298008|NCT01509833|ICSI Ovarian stimulation
298009|NCT01509833|hCG low dose
298010|NCT01509833|Oocyte maturity
298011|NCT01509833|poor respond
298012|NCT01509807|Ileostomy reversal
298013|NCT01509794|CME
298014|NCT01509794|Simulation
298015|NCT01509794|Affective engagement
298016|NCT01509794|Cognitive performance
298017|NCT01509781|simple mastectomy
298018|NCT01509781|modified radical mastectomy
298019|NCT01509781|wound care
298020|NCT01509781|suction drain
298021|NCT01509781|adaptive suture
298022|NCT01509768|MPS IIIB
298023|NCT01509729|Knee
298024|NCT01509729|Arthroscopy
298025|NCT01509729|Lidocaine patch
298026|NCT01509729|Pain management after knee arthroscopy
298027|NCT01509716|Predialysis
298028|NCT01509703|COPD
298029|NCT01509703|Nasal High Flow Therapy
298030|NCT01509703|tracheotomy stent
298031|NCT01509703|tracheotomy
298032|NCT01509690|Incident
298033|NCT01509690|Hemodialysis
298034|NCT01509677|Roflumilast
298035|NCT01509677|Chronic Obstructive Pulmonary Disease
298036|NCT01509677|COPD
298037|NCT01509651|antagonists neuromuscular block
298038|NCT01509651|neuromuscular block, monitoring
298039|NCT01509651|neuromuscular function
298040|NCT01509638|Ileostomy reversal
298041|NCT01509625|Fulvestrant
298042|NCT01509625|Faslodex
298043|NCT01509612|cancer
298044|NCT01509612|additive homeopathy
298045|NCT01509612|patients with advanced malignant tumors
298046|NCT01509599|Venous disease
298047|NCT01509599|Venous disorders
298048|NCT01509599|Venous insufficiency
298049|NCT01509599|Venous ulcers
298050|NCT01509599|Cryotherapy
298051|NCT01509586|smoking
298052|NCT01509586|smoking cessation
298053|NCT01509586|Potentially Reduced Exposure Products (PREPs)
298054|NCT01509573|prevention therapy
298055|NCT01509573|depressive symptoms
298056|NCT01509573|anxiety
298057|NCT01509573|parenting
298058|NCT01509573|family functioning
298059|NCT01509573|resilience, psychological
298060|NCT01509573|Developing countries
298061|NCT01509573|Rwanda
298062|NCT01509573|HIV/AIDS
298063|NCT01509534|pacemaker
298064|NCT01509534|implantable loop recorder
298065|NCT01509534|syncope
298066|NCT01509521|Spectroscopy, Near-Infrared
298067|NCT01509521|Fetal heartrate
298068|NCT01509521|Ephedrine
298069|NCT01509521|Phenylephrine
298070|NCT01509508|HIV
298071|NCT01509508|Prevention
298072|NCT01509508|Treatment
298073|NCT01509508|South Africa
298074|NCT01509495|Heart Failure
298075|NCT01509495|HF
298076|NCT01509482|insulin resistance
298077|NCT01509482|unexplained azoospermia
298078|NCT01509482|unexplained oligospermia
298079|NCT01509469|Ileal brake
298080|NCT01509469|Casein
298081|NCT01509469|Sucrose
298082|NCT01509469|Ileal infusion
298083|NCT01509456|bone metabolism
298084|NCT01509456|potassium bicarbonate
298085|NCT01509456|alkaline salt
298086|NCT01509456|acid base balance
298087|NCT01509456|bed rest
298088|NCT01509443|Asthma
298089|NCT01509443|Obesity
298090|NCT01509443|Breathing exercise
298091|NCT01509417|pyloric stenosis
298092|NCT01509404|CMV
298093|NCT01509404|cytomegalovirus
298094|NCT01509404|transplant
298095|NCT01509378|ICD
298096|NCT01509378|ATP therapy
298097|NCT01509378|Rescue Shock therapy
298098|NCT01509365|cardiovascular disease
298099|NCT01509365|maintenance dose
298100|NCT01509365|clopidogrel
298101|NCT01509365|overweight
298102|NCT01509365|antiplatelet agents
298103|NCT01509352|fundoplication
298104|NCT01509352|gastric reflux
298105|NCT01509339|Vancomycin
298106|NCT01509339|Inhalation
298107|NCT01509339|Nebulization
298108|NCT01509339|Pharmacokinetics
298109|NCT01509326|headache
298110|NCT01509326|chiropractic
298111|NCT01509326|manipulation
298112|NCT01509326|acupressure
298113|NCT01509326|self-care
298114|NCT01509313|endometrial polyps
298115|NCT01509313|uterine polyps
298116|NCT01509313|morcellator
298117|NCT01509313|hysteroscopy
298118|NCT01509300|TBI
298119|NCT01509300|Fludarabine
298120|NCT01509300|CD3 depletion
298121|NCT01509300|Children and adolescents
298122|NCT01509300|Haploidentical hematopoietic stem cell transplantation
298123|NCT01509287|Donnai-Barrow Syndrome (DBS)
298124|NCT01509287|metabolic testing
298125|NCT01509287|genes
298126|NCT01509287|genetic
298127|NCT01509274|Plantar fasciitis
298128|NCT01509274|Plasma
298129|NCT01509274|PRP
298130|NCT01509274|Heel pain
298131|NCT01509261|Erosive Esophagitis
298132|NCT01509261|Ilaprazole
298133|NCT01509261|GERD
298134|NCT01509248|Theophylline
298135|NCT01509235|cystic fibrosis
298136|NCT01509235|Lung function
298137|NCT01509235|physical exercise
298138|NCT01509222|Health promotion
298139|NCT01509222|Dietary Counseling
298140|NCT01509209|vasomotor
298141|NCT01509209|pseudoephedrine
298142|NCT01509209|levocetirizine
298143|NCT01509196|Fenofibric acid
298144|NCT01509196|HIP0901
298145|NCT01509196|Lipidilsupra
298146|NCT01509183|asthma
298147|NCT01509183|healthcare utilization costs
298148|NCT01509157|Type 1 diabetes
298149|NCT01509157|Continuous Glucose Monitoring
298150|NCT01509157|Nocturnal Hypoglycemia
298151|NCT01509144|Safety of this HIV vaccine
298152|NCT01509092|traumatic macular hole
298153|NCT01509092|vitrectomy
298154|NCT01509092|observation
298155|NCT01509066|vegetarian
298156|NCT01509066|vegan
298157|NCT01509066|low calorie
298158|NCT01509066|infertility
298159|NCT01509066|PCOS
298160|NCT01509053|Schizophrenia
298161|NCT01509040|Resuscitated from Out-of-Hospital Cardiac Arrest
298162|NCT01509027|hemodialysis
298163|NCT01509027|hyperphoshatemia
298164|NCT01509027|compliance
298165|NCT01509014|Statins
298166|NCT01509014|Adherence
298167|NCT01509014|Pharmacists
298168|NCT01509001|type 2 diabetes
298169|NCT01509001|metformin
298170|NCT01509001|glimepiride
298171|NCT01509001|glucose control
298172|NCT01509001|vascular reactivity
298173|NCT01509001|Adverse Reaction to Other Drugs and Medicines
298174|NCT01508988|ONO-9054
298175|NCT01508988|adult healthy volunteers
298176|NCT01508988|single dose
298177|NCT01508988|phase 1
298178|NCT01508975|satiety
298179|NCT01508975|obesity
298180|NCT01508975|food intake
298181|NCT01508962|Disease onset
298182|NCT01508962|Disease progression
298183|NCT01508884|intradermal
298184|NCT01508884|influenza
298185|NCT01508884|vaccination
298186|NCT01508845|vitamin D
298187|NCT01508845|vitamin D absorption
298188|NCT01508845|vitamin D deficiency
298189|NCT01508819|Patients over 75
298190|NCT01508819|acute pathology
298191|NCT01508819|ICU admission
298192|NCT01508793|Sleep
298193|NCT01508793|Obesity
298194|NCT01508793|Children
298195|NCT01508793|Eating behaviors
298196|NCT01508793|Activity
298197|NCT01508754|Continuous positive airway pressure
298198|NCT01508754|Ambulatory blood pressures
298199|NCT01508741|Insomnia
298200|NCT01508741|Frequent Nocturnal Awakening
298201|NCT01508741|Irritability
298202|NCT01508741|Moody
298203|NCT01508741|Moodiness
298204|NCT01508741|Coping Ability
298205|NCT01508741|Coping Behavior
298206|NCT01508741|Stress
298207|NCT01508741|Feeling Overwhelmed
298208|NCT01508728|unoperated severe sprain of the knee with partial or total rupture of the anterior
298209|NCT01508728|cruciate ligament and medial or lateral collateral ligament
298210|NCT01508715|subacromial
298211|NCT01508715|rotator cuff
298212|NCT01508715|impingement
298213|NCT01508715|physical therapy
298214|NCT01508715|eccentric exercise
298215|NCT01508715|concentric exercise
298216|NCT01508702|Gout
298217|NCT01508689|Cereal bar
298218|NCT01508689|Calcium-fortified
298219|NCT01508689|Calcium intake
298220|NCT01508676|neuropathic pain
298221|NCT01508676|postherpetic neuralgia
298222|NCT01508676|complex regional pain syndrome
298223|NCT01508676|reflex sympathetic dystrophy
298224|NCT01508663|Coronary artery disease 75years of age or older
298225|NCT01508650|heart failure
298226|NCT01508637|air pollution
298227|NCT01508637|vasoconstriction
298228|NCT01508637|blood pressure
298229|NCT01508637|diesel exhaust
298230|NCT01508624|Randomised controlled trial
298231|NCT01508624|Pain
298232|NCT01508624|Recovery
298233|NCT01508624|Office based surgery
298234|NCT01508611|dental caries
298235|NCT01508611|permanent teeth
298236|NCT01508611|silver diamine fluoride
298237|NCT01508611|tooth eruption
298238|NCT01508598|Pediatric
298239|NCT01508598|Obesity
298240|NCT01508598|Bariatric surgery
298241|NCT01508598|Cardiovascular disease
298242|NCT01508585|Bariatric surgery
298243|NCT01508585|Cognitive Behavioral Therapy
298244|NCT01508585|Telephone based CBT
298245|NCT01508585|Obesity
298246|NCT01508572|breast cancer
298247|NCT01508572|VEGF
298248|NCT01508572|optical imaging
298249|NCT01508559|HIV
298250|NCT01508559|Neurocognitive
298251|NCT01508546|breast cancer
298252|NCT01508546|axillary dissection
298253|NCT01508533|Disease burden
298254|NCT01508533|Rotavirus gastroenteritis
298255|NCT01508520|early gastric cancer
298256|NCT01508520|stomach neoplasms
298257|NCT01508520|magnifying endoscopy
298258|NCT01508520|narrow band imaging
298259|NCT01508507|Oral
298260|NCT01508507|Cholera
298261|NCT01508507|Vaccine
298262|NCT01508507|Herd
298263|NCT01508507|Risk
298264|NCT01508507|population
298265|NCT01508507|Matched
298266|NCT01508507|Control
298267|NCT01508507|Case
298268|NCT01508507|Bias
298269|NCT01508494|modification of fMRI maps after galantamine/placebo
298270|NCT01508481|Vitamin D
298271|NCT01508481|Diabetes
298272|NCT01508481|pancreas beta cell function
298273|NCT01508481|insulin resistance
298274|NCT01508481|Deficiency of Vitamin D3
298275|NCT01508468|Rituximab
298276|NCT01508468|membranous nephropathy
298277|NCT01508468|anti-PLA2R antibody
298278|NCT01508429|Postpartum hemorrhage
298279|NCT01508429|PPH
298280|NCT01508429|misoprostol
298281|NCT01508429|home deliveries
298282|NCT01508416|Multiple Myeloma
298283|NCT01508416|Newly diagnosed
298284|NCT01508416|Thrombin generation
298285|NCT01508416|TFPI
298286|NCT01508416|Tissue Factor pathway inhibitor
298287|NCT01508416|Protein S
298288|NCT01508416|Thrombosis
298289|NCT01508416|Chemotherapy
298290|NCT01508390|prostate
298291|NCT01508377|posttraumatic stress disorder
298292|NCT01508377|internet-based psychotherapy
298293|NCT01508377|cognitive restructuring
298294|NCT01508377|exposure
298295|NCT01508364|renal cell carcinoma, first targeted therapy, observational study
298296|NCT01508351|Propofol
298297|NCT01508351|Induction
298298|NCT01508351|Hypotension
298299|NCT01508351|General population
298300|NCT01508338|HMB beta-hydroxy-beta-methylbutyrate
298301|NCT01508338|ATP (adenosine-triphosphate)
298302|NCT01508338|trained athletes
298303|NCT01508325|Bisoprolol
298304|NCT01508325|Hypertension
298305|NCT01508325|Blood pressure
298306|NCT01508325|Heart rate
298307|NCT01508312|CARBOPLATIN
298308|NCT01508312|ETOPOSIDE (VP-16)
298309|NCT01508312|IFOSFAMIDE
298310|NCT01508312|SGN-35 (BRENTUXIMAB VEDOTIN)
298311|NCT01508312|11-142
298312|NCT01508299|skin test
298313|NCT01508299|raw food
298314|NCT01508299|commercial extract
298315|NCT01508286|telaprevir
298316|NCT01508286|hepatitis C
298317|NCT01508286|early access program
298318|NCT01508273|Breast Cancer
298319|NCT01508273|Breast Cancer Survivors
298320|NCT01508273|High risk cancer survivors
298321|NCT01508273|Stage II to IIIC breast cancer
298322|NCT01508273|African American
298323|NCT01508273|AA
298324|NCT01508273|Hispanic
298325|NCT01508273|Non-Hispanic White
298326|NCT01508273|Operable invasive breast carcinoma
298327|NCT01508273|Aerobic and resistance training
298328|NCT01508273|Pedometer
298329|NCT01508273|Telephone Counseling Calls
298330|NCT01508273|Physical activity report
298331|NCT01508273|PAR
298332|NCT01508273|Functional Assessment of Cancer Therapy-Breast
298333|NCT01508273|FACT-B
298334|NCT01508273|Health related quality of life
298335|NCT01508273|HRQOL
298336|NCT01508260|Leukemia
298337|NCT01508260|Aquapheresis
298338|NCT01508260|Ultrafiltration
298339|NCT01508260|Aquadex pump
298340|NCT01508260|Severe Fluid Overload
298341|NCT01508260|Diuretic therapy
298342|NCT01508260|Dyspnea
298343|NCT01508260|Orthopnea
298344|NCT01508260|Paroxysmal nocturnal dyspnea
298345|NCT01508260|PND
298346|NCT01508260|Peripheral edema
298347|NCT01508260|Rales
298348|NCT01508260|Jugular venous distension
298349|NCT01508260|JVD
298350|NCT01508260|Hypoxia
298351|NCT01508260|Pulmonary edema by chest X-ray
298352|NCT01508260|Furosemide
298353|NCT01508260|Lasix
298354|NCT01508247|efficacy
298355|NCT01508247|safety
298356|NCT01508247|inactivated vaccine (Vero Cell) against EV71
298357|NCT01508247|EV71-associated diseases
298358|NCT01508221|brain metastasis
298359|NCT01508208|Hypertension
298360|NCT01508208|24 hour urine protein
298361|NCT01508208|Protein/creatinine ratio
298362|NCT01508195|Healthy Volunteers
298363|NCT01508195|Bioequivalence
298364|NCT01508195|Canagliflozin (JNJ-28431754)
298365|NCT01508195|Metformin IR
298366|NCT01508182|Healthy Volunteers
298367|NCT01508182|Bioequivalence
298368|NCT01508182|Canagliflozin (JNJ-28431754)
298369|NCT01508182|Metformin IR
298370|NCT01508169|elderly
298371|NCT01508169|balance
298372|NCT01508169|insole
298373|NCT01508169|foot orthosis
298374|NCT01508169|orthotics
298375|NCT01508156|Hepatitis C
298376|NCT01508156|HCV
298377|NCT01508156|treatment-naive
298378|NCT01508143|Abortion
298379|NCT01508143|Pregnancy
298380|NCT01508143|Termination
298381|NCT01508143|Misoprostol
298382|NCT01508117|GBM
298383|NCT01508117|brain tumor
298384|NCT01508104|solid tumor
298385|NCT01508104|glioblastoma multiforme
298386|NCT01508104|GBM
298387|NCT01508104|brain tumor
298388|NCT01508104|neuroendocrine tumor
298389|NCT01508091|Obesity
298390|NCT01508091|ageing
298391|NCT01508052|core temperature
298392|NCT01508052|sequential compression device
298393|NCT01508052|total intravenous anesthesia
298394|NCT01508039|Intranasal
298395|NCT01508039|Chitin Micro-particles
298396|NCT01508039|Immunological Effects
298397|NCT01508039|Nasal mucosa
298398|NCT01508039|Cytokines
298399|NCT01508039|Immunological Effects from Intranasal Chitin Micro-Particles
298400|NCT01508026|Stage 1
298401|NCT01508026|Stage 2
298402|NCT01508026|Hypertension
298403|NCT01508013|Melanoma
298404|NCT01508013|Basal Cell Carcinoma
298405|NCT01508013|Squamous Cell Carcinoma
298406|NCT01508000|Liver metastases
298407|NCT01508000|Colorectal Cancer
298408|NCT01508000|KRAS wild type
298409|NCT01508000|FOLFOX
298410|NCT01508000|Bevacizumab
298411|NCT01508000|Panitumumab
298412|NCT01508000|Randomized
298413|NCT01508000|Phase II
298414|NCT01508000|Perioperative treatment
298415|NCT01508000|Adjuvant
298416|NCT01508000|Neo-adjuvant
298417|NCT01508000|Surgery
298418|NCT01508000|Progression Free Survival
298419|NCT01507987|Externalized Conductors
298420|NCT01507974|preventive
298421|NCT01507974|antibiotic treatment
298422|NCT01507974|urinary tract infection
298423|NCT01507974|pregnancy
298424|NCT01507974|puerperium
298425|NCT01507948|Posttraumatic Stress Disorder (PTSD)
298426|NCT01507948|Psychotherapy
298427|NCT01507948|non-medication treatment
298428|NCT01507948|Prolonged Exposure
298429|NCT01507948|Transcranial Magnetic Stimulation (TMS)
298430|NCT01507948|Anxiety Disorders
298431|NCT01507948|emotion
298432|NCT01507948|emotion regulation
298433|NCT01507948|functional MRI
298434|NCT01507948|Affective Symptoms
298435|NCT01507935|Healthy infants
298436|NCT01507935|Infant formula
298437|NCT01507935|Prebiotics oligosaccharides
298438|NCT01507935|Colonisation Resistance
298439|NCT01507935|Gut Microbiota
298440|NCT01507922|Fenoverine
298441|NCT01507922|Irritable Bowel Syndrome
298442|NCT01507922|Abdominal pain
298443|NCT01507922|BSS
298444|NCT01507909|EEG
298445|NCT01507909|related visual
298446|NCT01507909|and verbal cues
298447|NCT01507883|Supervision
298448|NCT01507883|embryos
298449|NCT01507883|Resulting
298450|NCT01507870|body mass index
298451|NCT01507857|EV71 vaccine
298452|NCT01507857|HFMD
298453|NCT01507857|efficacy
298454|NCT01507857|EV71 associated disease
298455|NCT01507844|COPD
298456|NCT01507844|CPAP
298457|NCT01507844|Sham
298458|NCT01507844|FEV1
298459|NCT01507844|IC
298460|NCT01507844|RV/TLC
298461|NCT01507818|Arthroscopic Rotator Cuff Repair
298462|NCT01507818|Electromagnetic field treatment
298463|NCT01507818|Pulsed Radio Frequency treatment
298464|NCT01507818|Non-invasive
298465|NCT01507818|Non-thermal
298466|NCT01507805|Electroacupuncture
298467|NCT01507805|preconditioning
298468|NCT01507805|Non-cardiac surgery
298469|NCT01507805|Coronary heart disease
298470|NCT01507792|Cough
298471|NCT01507792|Laryngismus
298472|NCT01507792|Bronchial spasm
298473|NCT01507792|Deficiency diseases
298474|NCT01507766|severe acute pancreatitis
298475|NCT01507766|intra-abdominal pressure
298476|NCT01507766|enteral nutrition
298477|NCT01507753|childhood bipolar disorder
298478|NCT01507727|hyponatremia
298479|NCT01507727|Non-hypovolemic and Non-acute hyponatremia
298480|NCT01507727|Tolvaptan
298481|NCT01507714|Preventive
298482|NCT01507714|tvt-o
298483|NCT01507714|stress incontinence
298484|NCT01507701|adolescents
298485|NCT01507688|Stroke
298486|NCT01507675|suicide
298487|NCT01507675|psychometric properties
298488|NCT01507675|military
298489|NCT01507675|veterans
298490|NCT01507675|Interpersonal needs questionnaire
298491|NCT01507675|Acquired capability for suicide
298492|NCT01507675|mental health
298493|NCT01507675|Survey of Life Principles
298494|NCT01507675|Risk assessment
298495|NCT01507662|Bone Density
298496|NCT01507662|Absorptiometry, Photon
298497|NCT01507662|Osteoporosis
298498|NCT01507662|Bone, Diseases, Metabolic
298499|NCT01507662|Patient Education as Topic
298500|NCT01507662|Fractures, Bone/Prevention and Control
298501|NCT01507649|postnatal depression
298502|NCT01507649|quality of life
298503|NCT01507636|apraxia
298504|NCT01507636|occupational therapy
298505|NCT01507636|multiple sclerosis
298506|NCT01507636|manual dexterity
298507|NCT01507623|NAPS
298508|NCT01507623|Hypoxia
298509|NCT01507623|Propofol
298510|NCT01507623|capnography
298511|NCT01507623|endoscopy
298512|NCT01507623|Sedation
298513|NCT01507610|sumatriptan
298514|NCT01507610|bioavailability
298515|NCT01507597|Glucagon-like peptide-1
298516|NCT01507597|Glucagon
298517|NCT01507597|Normal physiology
298518|NCT01507597|T2DM
298519|NCT01507597|T1DM
298520|NCT01507571|Incurable cancer
298521|NCT01507571|Palliative care
298522|NCT01507571|Dignity Therapy
298523|NCT01507571|Loss of dignity
298524|NCT01507571|Patient Dignity Intventory
298525|NCT01507571|Eortc QLQ-C15-PAL
298526|NCT01507571|Structured Interview for Symptoms and Concerns
298527|NCT01507571|Hospital Anxiety and Depression Scale
298528|NCT01507558|Peripheral Arterial Disease
298529|NCT01507558|Femoral popliteal lesions
298530|NCT01507545|mCRC
298531|NCT01507545|chemorefractory metastatic colorectal cancer
298532|NCT01507506|Glioblastoma
298533|NCT01507506|Radiotherapy
298534|NCT01507506|Intensity modulated radiation therapy (IMRT)
298535|NCT01507506|Magnetic resonance spectroscopic imaging (MRSI)
298536|NCT01507493|gene polymorphism
298537|NCT01507493|SCN9A
298538|NCT01507493|pain perception
298539|NCT01507493|postoperative pain
298540|NCT01507480|Hemorrhagic Hereditary Telangiectasia (HHT)
298541|NCT01507480|Antiangiogenic therapies
298542|NCT01507480|Bevacizumab
298543|NCT01507467|Head and neck carcinoma
298544|NCT01507467|Accelerated radiotherapy
298545|NCT01507467|Hypoxic modification with Nimorazole
298546|NCT01507441|childhood myelodysplastic syndromes
298547|NCT01507441|childhood acute myeloid leukemia/other myeloid malignancies
298548|NCT01507441|childhood acute megakaryocytic leukemia (M7)
298549|NCT01507415|Cohort Studies
298550|NCT01507415|Longitudinal Studies
298551|NCT01507415|Patient Readmission
298552|NCT01507415|Hospitalization
298553|NCT01507415|Disability Evaluation
298554|NCT01507376|Ovulation induction
298555|NCT01507376|urinary
298556|NCT01507376|hCG
298557|NCT01507376|recombinant hCG
298558|NCT01507350|obesity related glmerulopathy
298559|NCT01507350|51 Cr-EDTA clearance
298560|NCT01507350|impaired renal function
298561|NCT01507350|gastric band
298562|NCT01507350|GFR measurement
298563|NCT01507350|gastric bypass
298564|NCT01507350|sleeve gastrectomy
298565|NCT01507298|Physical activity
298566|NCT01507298|Accelerometry
298567|NCT01507298|Oesophageal pH
298568|NCT01507298|Capsule endoscopy
298569|NCT01507259|Determine effect on cerebral vasculature
298570|NCT01507246|open colectomy
298571|NCT01507233|open colectomy
298572|NCT01507233|colectomy
298573|NCT01507220|open colectomy
298574|NCT01507207|Dysphagia
298575|NCT01507207|aspiration
298576|NCT01507207|pediatric
298577|NCT01507207|injection laryngoplasty
298578|NCT01507181|suicidal ideation
298579|NCT01507181|major depression
298580|NCT01507181|treatment resistant
298581|NCT01507181|ketamine
298582|NCT01507181|glutamate
298583|NCT01507155|Major
298584|NCT01507155|Depressive
298585|NCT01507155|Disorder
298586|NCT01507155|Depression
298587|NCT01507155|MDD
298588|NCT01507155|Treatment Resistant
298589|NCT01507155|Anxiety
298590|NCT01507155|GAD
298591|NCT01507142|saliva
298592|NCT01507142|diagnostics
298593|NCT01507142|HIV
298594|NCT01507142|AIDS
298595|NCT01507129|dehydration
298596|NCT01507129|plasma
298597|NCT01507129|osmolality
298598|NCT01507129|saliva
298599|NCT01507129|urine
298600|NCT01507129|biomarkers
298601|NCT01507129|hypertonic
298602|NCT01507129|isotonic
298603|NCT01507129|hydration
298604|NCT01507103|Tecemotide (L-BLP25)
298605|NCT01507103|Cyclophosphamide (CPA)
298606|NCT01507103|Mode of action
298607|NCT01507103|Neoplasms
298608|NCT01507103|Neoplasms by Site
298609|NCT01507103|Carcinomas
298610|NCT01507103|Antineoplastic Agents
298611|NCT01507103|Neoadjuvant
298612|NCT01507103|Radiotherapy Pharmacologic Actions
298613|NCT01507103|Immunosuppressive Agents
298614|NCT01507103|Immunologic Function
298615|NCT01507103|Therapeutic Uses
298616|NCT01507103|Molecular Mechanisms of Pharmacological Action
298617|NCT01507090|children for whom there is no scale to determine weight
298618|NCT01507077|Obese
298619|NCT01507077|Obesity
298620|NCT01507077|Overweight
298621|NCT01507064|hepatocellular carcinoma
298622|NCT01507064|sorafenib
298623|NCT01507064|laser ablation
298624|NCT01507051|Rivaroxaban
298625|NCT01507051|Xa-Factors
298626|NCT01507051|Warfarin
298627|NCT01507051|Thrombosis
298628|NCT01507051|Embolism
298629|NCT01507038|Diabetes Mellitus
298630|NCT01507038|YH14617
298631|NCT01507038|Exenatide
298632|NCT01507038|Yuhan
298633|NCT01507025|hinge position
298634|NCT01507025|dry eye
298635|NCT01507012|Berry phenolics
298636|NCT01507012|mood
298637|NCT01507012|cognition
298638|NCT01507012|adults
298639|NCT01506999|Angina Pectoris
298640|NCT01506999|SNPs
298641|NCT01506999|Genetic
298642|NCT01506999|Myocardial Infarction
298643|NCT01506999|Cardiovascular Risk Factors
298644|NCT01506986|Ulcer bleeding
298645|NCT01506986|Aspirin
298646|NCT01506986|Helicobacter pylori
298647|NCT01506986|H. pylori
298648|NCT01506986|Hospitalisation for ulcer bleeding
298649|NCT01506973|histologically or cytologically documented
298650|NCT01506947|Hemodialysis
298651|NCT01506947|Secondary hyperparathyroidism,
298652|NCT01506947|Chronic kidney disease
298653|NCT01506921|racemic ketamine
298654|NCT01506921|S-ketamine
298655|NCT01506921|Cerebral blood flow
298656|NCT01506921|Magnetic resonance imaging
298657|NCT01506921|arterial spin labeling
298658|NCT01506921|healthy volunteers
298659|NCT01506908|craving
298660|NCT01506895|Diabetic Macular Edema
298661|NCT01506856|Epithelial ovarian cancer
298662|NCT01506856|Fallopian tube cancer
298663|NCT01506856|peritoneal cancer
298664|NCT01506856|intraperitoneal therapy
298665|NCT01506856|Carboplatin
298666|NCT01506856|Paclitaxel
298667|NCT01506843|IgA antibody
298668|NCT01506843|IgE antibody
298669|NCT01506843|IgG1/IgG4 subclasses
298670|NCT01506843|Mite allergy
298671|NCT01506843|Sublingual immunotherapy
298672|NCT01506843|Saliva
298673|NCT01506830|Adhesives.
298674|NCT01506830|Composites.
298675|NCT01506830|Noncarious cervical lesions.
298676|NCT01506830|Clinical performance.
298677|NCT01506830|Treatment
298678|NCT01506817|fibromyalgia
298679|NCT01506817|DCE-MRI
298680|NCT01506817|neurogenic inflammation
298681|NCT01506817|contrast-enhancement patterns
298682|NCT01506804|Shoulder
298683|NCT01506804|Impingement
298684|NCT01506804|Ultrasound
298685|NCT01506804|injection of glucocorticosteroid
298686|NCT01506804|exercise
298687|NCT01506791|Bioequivalence
298688|NCT01506791|Desloratadine and pseudoephedrine
298689|NCT01506791|crossover
298690|NCT01506778|Endometrial Sampling Procedure
298691|NCT01506778|Likert Scala
298692|NCT01506778|Pipelle
298693|NCT01506778|Tenaculum
298694|NCT01506778|Visual Analog Pain Scala
298695|NCT01506765|Schizophrenia
298696|NCT01506765|glutathione
298697|NCT01506765|NAC
298698|NCT01506765|Neurological scales
298699|NCT01506765|Magnetic Resonance Spectroscopy (MRS)
298700|NCT01506765|EEG/evoked potentials
298701|NCT01506765|fibroblasts
298702|NCT01506765|patients who receive NAC
298703|NCT01506765|patients who receive placebo
298704|NCT01506752|Bioequivalence
298705|NCT01506752|Healthy Subjects
298706|NCT01506752|Donepezil
298707|NCT01506739|Bioequivalence
298708|NCT01506739|Healthy Subjects
298709|NCT01506739|Donepezil
298710|NCT01506726|anemia
298711|NCT01506726|unexplained anemia
298712|NCT01506726|elderly
298713|NCT01506726|geriatric
298714|NCT01506726|older adults
298715|NCT01506726|UAE
298716|NCT01506726|over 65
298717|NCT01506726|salsalate
298718|NCT01506726|PACTTE
298719|NCT01506726|pactee
298720|NCT01506726|aging
298721|NCT01506726|aged
298722|NCT01506726|old
298723|NCT01506726|older
298724|NCT01506687|Colorectal cancer screening
298725|NCT01506687|50 years or older
298726|NCT01506661|Rheumatoid arthritis
298727|NCT01506661|vaccination
298728|NCT01506661|immune response
298729|NCT01506661|varicella zoster
298730|NCT01506609|temozolomide
298731|NCT01506609|Temodar
298732|NCT01506609|Paclitaxel
298733|NCT01506609|BRCA1 mutation carrier
298734|NCT01506609|Metastatic breast cancer
298735|NCT01506609|TMZ
298736|NCT01506609|Recurrent breast cancer
298737|NCT01506609|Carboplatin
298738|NCT01506609|ABT-888
298739|NCT01506609|veliparib
298740|NCT01506609|Breast cancer
298741|NCT01506609|Locally recurrent
298742|NCT01506609|Temodal
298743|NCT01506609|BRCA2 mutation carrier
298744|NCT01506609|PARP
298745|NCT01506596|Liposarcoma
298746|NCT01506583|cough
298747|NCT01506583|myalgia
298748|NCT01506583|nasal obstruction
298749|NCT01506583|sore throat
298750|NCT01506583|headache
298751|NCT01506583|fatigue
298752|NCT01506583|feverishness
298753|NCT01506583|Patients who exhibit flu-like symptoms during a flu season, including cough, myalgia, nasal obstruction, sore throat, headache, fatigue, and/or feverishness.
298754|NCT01506557|vitamin D
298755|NCT01506557|vitamin D deficiency
298756|NCT01506557|breastfeeding
298757|NCT01506557|body composition
298758|NCT01506557|bone mineral content
298759|NCT01506544|HU
298760|NCT01506544|Hydroxyurea
298761|NCT01506544|Sickle cell
298762|NCT01506544|Pediatric
298763|NCT01506531|gastroschisis
298764|NCT01506531|silo
298765|NCT01506531|primary closure
298766|NCT01506518|Muscular Dystrophy, Duchenne
298767|NCT01506518|Ultrasound
298768|NCT01506518|Imaging
298769|NCT01506518|Acoustic Radiation Force
298770|NCT01506518|Double Push
298771|NCT01506505|Cardiovascular prevention
298772|NCT01506505|Polypill
298773|NCT01506505|Combination therapy
298774|NCT01506492|Randomized controlled trial
298775|NCT01506492|Depression
298776|NCT01506492|Cancer
298777|NCT01506492|Psychotherapy
298778|NCT01506492|Quality of life
298779|NCT01506479|Parkinson Disease
298780|NCT01506479|Basal Ganglia Disease
298781|NCT01506479|Central Nervous System Diseases
298782|NCT01506479|Nervous System Diseases
298783|NCT01506479|Movement Disorders
298784|NCT01506479|Neurodegenerative Diseases
298785|NCT01506479|Brain Diseases
298786|NCT01506466|chemotherapy
298787|NCT01506466|metabolism
298788|NCT01506466|weight
298789|NCT01506466|body composition
298790|NCT01506453|Acute Lymphoblastic Leukemia
298791|NCT01506453|Neuropathy
298792|NCT01506453|Neuropathic Pain
298793|NCT01506453|Vincristine
298794|NCT01506453|TOTAL XVI Protocol
298795|NCT01506427|Newly Diagnosed
298796|NCT01506427|Head and Neck Cancer
298797|NCT01506427|PET Imaging
298798|NCT01506414|Purpura
298799|NCT01506414|Idiopathic Thrombocytopenic Purpura
298800|NCT01506401|ARDS
298801|NCT01506401|ventilator-induced lung injury
298802|NCT01506401|lung protective ventilation
298803|NCT01506401|high frequency oscillation
298804|NCT01506388|labour induction
298805|NCT01506388|Foley catheter
298806|NCT01506388|misoprostol
298807|NCT01506388|isosorbide mononitrate
298808|NCT01506375|seasonal allergic rhinoconjunctivitis
298809|NCT01506375|grass pollen
298810|NCT01506375|allergen specific immunotherapy
298811|NCT01506362|Ulcerative Colitis
298812|NCT01506362|IBD
298813|NCT01506349|celiac disease
298814|NCT01506349|gluten
298815|NCT01506349|fog
298816|NCT01506349|attention
298817|NCT01506336|GIST
298818|NCT01506336|resistant
298819|NCT01506336|imatinib
298820|NCT01506336|gastro intestinal stromal tumor resistant to imatinib
298821|NCT01506323|Complementary Therapy
298822|NCT01506323|Stress Disorders, Post-Traumatic
298823|NCT01506323|Veterans Health
298824|NCT01506323|Clinical Trials, Randomized
298825|NCT01506323|Mindfulness
298826|NCT01506323|Spirituality
298827|NCT01506323|Meditation
298828|NCT01506323|Mind-body therapy
298829|NCT01506310|gestational diabetes mellitus
298830|NCT01506310|fasting glucose
298831|NCT01506310|insulin resistance
298832|NCT01506310|birth-weight
298833|NCT01506310|Glucose values
298834|NCT01506310|Insulin concentrations
298835|NCT01506310|Cesarean sections
298836|NCT01506297|obesity
298837|NCT01506297|satiety
298838|NCT01506297|body weight management
298839|NCT01506284|Forced oscillatory technique
298840|NCT01506284|Laser interferometry
298841|NCT01506284|Intravenous anesthesia
298842|NCT01506284|Mechanical ventilation
298843|NCT01506284|Pressure controlled ventilation
298844|NCT01506284|Airways mechanical properties
298845|NCT01506284|Respiratory system reactance
298846|NCT01506284|Oscillatory mechanics
298847|NCT01506284|Atelectasis
298848|NCT01506271|Complicated Intra-abdominal Infections
298849|NCT01506258|CD34+
298850|NCT01506258|perinatal hypoxia
298851|NCT01506258|autologous hematopoietic stem cells
298852|NCT01506258|cord and placental blood
298853|NCT01506258|cerebral palsy
298854|NCT01506245|Obesity
298855|NCT01506245|Children
298856|NCT01506245|Behavior
298857|NCT01506245|Family
298858|NCT01506245|Exercise
298859|NCT01506232|ADHD
298860|NCT01506232|Pediatric Bipolar Disorder
298861|NCT01506232|Autism
298862|NCT01506232|Autism Spectrum Disorders
298863|NCT01506232|EEG
298864|NCT01506232|Brain Flow Analyses
298865|NCT01506219|Randomized controlled trial
298866|NCT01506219|Comprehensive geriatric care
298867|NCT01506219|Hospital contacts
298868|NCT01506219|Activity of daily living
298869|NCT01506219|Quality of life
298870|NCT01506219|Rehabilitation
298871|NCT01506206|Deep Brain Stimulation
298872|NCT01506206|Impulsivity
298873|NCT01506193|safety
298874|NCT01506193|healthy
298875|NCT01506193|conjugated
298876|NCT01506193|immunogenicity
298877|NCT01506193|children
298878|NCT01506193|MenC vaccine
298879|NCT01506193|MMRV vaccine
298880|NCT01506180|acute medical care
298881|NCT01506180|comprehensive geriatric assessment
298882|NCT01506180|Health Services for the Aged
298883|NCT01506180|Geriatric Assessment
298884|NCT01506180|Geriatrics
298885|NCT01506180|Aged
298886|NCT01506154|bursitis/tendonitis and/or subdeltoid bursitis
298887|NCT01506141|MPS II
298888|NCT01506141|MPS 2
298889|NCT01506141|lysosomal storage disorder
298890|NCT01506141|mps symptoms
298891|NCT01506141|enlarged adenoids
298892|NCT01506141|elaprase
298893|NCT01506141|hunter's syndrome
298894|NCT01506141|MPS2
298895|NCT01506141|hunters disease
298896|NCT01506141|hunter's disease treatment
298897|NCT01506141|hunter syndrome therapy
298898|NCT01506141|iduronate sulfatase
298899|NCT01506141|mps society
298900|NCT01506141|MPSII
298901|NCT01506141|hunter syndrome treatment
298902|NCT01506141|hunter's disease
298903|NCT01506141|iduronate 2 sulfatase
298904|NCT01506141|mucopolysaccharides
298905|NCT01506141|mps diagnosis
298906|NCT01506141|chronic ear infection
298907|NCT01506141|hunters syndrome
298908|NCT01506141|ert treatment
298909|NCT01506141|lysosomal storage disease
298910|NCT01506141|hunter disease
298911|NCT01506141|enzyme replacement therapy
298912|NCT01506141|idursulfase
298913|NCT01506141|hunter's syndrome treatment
298914|NCT01506128|HPV
298915|NCT01506128|Menstrual blood
298916|NCT01506128|HPV detection using menstrual blood
298917|NCT01506115|Hepatocellular carcinoma
298918|NCT01506115|Obstructive jaundice
298919|NCT01506115|Photodynamic therapy
298920|NCT01506089|IVF
298921|NCT01506089|infertility
298922|NCT01506089|PGD
298923|NCT01506089|embryo
298924|NCT01506089|temperature
298925|NCT01506089|incubator
298926|NCT01506089|CCS
298927|NCT01506089|culture
298928|NCT01506089|incubator-36 degrees Celsius
298929|NCT01506089|incubator-37 degrees Celsius
298930|NCT01506063|Bioequivalence
298931|NCT01506063|Levocetirizine
298932|NCT01506063|Crossover
298933|NCT01506050|Bioequivalence
298934|NCT01506050|Desloratadine
298935|NCT01506050|crossover
298936|NCT01506037|Bioequivalence
298937|NCT01506037|Desloratadine
298938|NCT01506037|crossover
298939|NCT01506024|Arthroplasty, Replacement, Hip
298940|NCT01506024|Surgical Procedures, Operative
298941|NCT01506024|Surgical Procedures, Minimally Invasive
298942|NCT01505985|Hip fracture
298943|NCT01505985|SPPB
298944|NCT01505985|Functional recovery
298945|NCT01505972|screening colonoscopy
298946|NCT01505972|attendance
298947|NCT01505972|response
298948|NCT01505972|colorectal cancer
298949|NCT01505959|Obstructive Sleep Apnea Syndrome
298950|NCT01505959|Apnea
298951|NCT01505959|Sleep Apnea
298952|NCT01505959|Telemedicine
298953|NCT01505959|CPAP compliance
298954|NCT01505946|Thrombin
298955|NCT01505946|Hemophilia
298956|NCT01505946|Inhibitors
298957|NCT01505946|Immunotolerance
298958|NCT01505946|Haemostatic
298959|NCT01505946|FVIII
298960|NCT01505946|Epitopes
298961|NCT01505946|Moderately severe Hemophilia A with inhibitor
298962|NCT01505933|upper
298963|NCT01505933|airway
298964|NCT01505933|dimensions
298965|NCT01505933|propofol
298966|NCT01505933|dexmedetomidine
298967|NCT01505907|Pharmacokinetics
298968|NCT01505907|Safety
298969|NCT01505907|Healthy Males
298970|NCT01505868|Prostate Cancer
298971|NCT01505868|Metastatic Castration-Resistant Prostate Cancer
298972|NCT01505868|mCRPC
298973|NCT01505868|Prior treatment with docetaxel
298974|NCT01505868|Cabazitaxel
298975|NCT01505868|Jevtana
298976|NCT01505868|Carboplatin
298977|NCT01505868|Paraplatin
298978|NCT01505868|Prednisone
298979|NCT01505855|Crohn's disease
298980|NCT01505855|Pneumococcal vaccination
298981|NCT01505842|Ulcerative colitis
298982|NCT01505842|Crohn's disease
298983|NCT01505842|Chromoendoscopy
298984|NCT01505842|Dysplasia
298985|NCT01505842|Neoplasia
298986|NCT01505842|Inflammatory Bowel Disease
298987|NCT01505816|Cataract
298988|NCT01505816|Vision
298989|NCT01505816|Intraocular lens
298990|NCT01505816|Multifocal
298991|NCT01505816|Toric
298992|NCT01505803|Type 2 diabetes mellitus
298993|NCT01505803|Dietary supplements
298994|NCT01505803|Hyperglycemia
298995|NCT01505803|Insulin resistance
298996|NCT01505803|Dyslipidemia
298997|NCT01505803|Inflammation
298998|NCT01505803|Oxidative stress
298999|NCT01505803|Zinc
299000|NCT01505803|Omega 3
299001|NCT01505777|irritable bowel syndrome without predominant diarrhea
299002|NCT01505777|Probiotics(Medirac) 10/mosapride 10mg
299003|NCT01505777|Probiotics(Medirac) 15/mosapride 10mg
299004|NCT01505777|Probiotics(Medirac) 15/mosapride 15mg
299005|NCT01505777|Probiotics(Medirac) 30/mosapride 15mg
299006|NCT01505777|Probiotics(Medirac) placebo/mosapride placebo
299007|NCT01505764|Cachexia
299008|NCT01505751|Outcome of cervical cancer
299009|NCT01505725|Nicotine Reinforcement
299010|NCT01505725|Tobacco Craving
299011|NCT01505725|Behavior Genetics
299012|NCT01505725|Smoking
299013|NCT01505712|stage I adult Hodgkin lymphoma
299014|NCT01505712|stage II adult Hodgkin lymphoma
299015|NCT01505712|stage III adult Hodgkin lymphoma
299016|NCT01505712|stage IV adult Hodgkin lymphoma
299017|NCT01505699|adult acute lymphoblastic leukemia in remission
299018|NCT01505699|B-cell adult acute lymphoblastic leukemia
299019|NCT01505673|Insulin
299020|NCT01505673|Glucagon-like peptide
299021|NCT01505673|Liraglutide
299022|NCT01505673|Beta-Cell
299023|NCT01505673|pancreatic steatosis
299024|NCT01505673|hepatic steatosis
299025|NCT01505660|Adherence
299026|NCT01505660|Depression
299027|NCT01505660|Care management
299028|NCT01505660|Stepped care
299029|NCT01505660|HIV
299030|NCT01505660|Patient reported outcomes
299031|NCT01505660|Antiretroviral medication adherence
299032|NCT01505621|Aging
299033|NCT01505621|Protein accumulation
299034|NCT01505621|Protein damage
299035|NCT01505569|autologous transplantation
299036|NCT01505569|high risk solid tumor
299037|NCT01505569|relapsed solid tumor
299038|NCT01505478|Sepsis
299039|NCT01505478|Clinical Prediction Rule
299040|NCT01505478|Clinical Informatics
299041|NCT01505478|Machine Learning
299042|NCT01505465|Total Knee Replacement
299043|NCT01505465|Pain
299044|NCT01505465|Confusion
299045|NCT01505465|Sleep
299046|NCT01505439|solifenacin
299047|NCT01505439|bladder symptom
299048|NCT01505426|ASP1941
299049|NCT01505426|ipragliflozin
299050|NCT01505426|metformin
299051|NCT01505426|plasma glucose
299052|NCT01505426|urine glucose
299053|NCT01505413|advanced unresectable or metastatic Pancreatic Cancer
299054|NCT01505400|Molecular profiling
299055|NCT01505400|Advanced cancer
299056|NCT01505400|Breast cancer
299057|NCT01505400|Non-small cell lung cancer
299058|NCT01505400|Colorectal cancer
299059|NCT01505400|Genitourinary cancer
299060|NCT01505400|Pancreatobiliary gastrointestinal cancer
299061|NCT01505400|Upper aerodigestive tract cancer
299062|NCT01505400|Gynecological cancers
299063|NCT01505400|Phase I
299064|NCT01505400|Phase I Clinical Trial Candidates
299065|NCT01505400|melanoma cancer
299066|NCT01505400|rare cancer
299067|NCT01505400|unknown primary cancer
299068|NCT01505387|Weight maintenance
299069|NCT01505387|Overweight
299070|NCT01505387|Obese
299071|NCT01505387|Weight management
299072|NCT01505374|Bilateral total knee replacement
299073|NCT01505374|Femoral Nerve Block
299074|NCT01505374|Saphenous Nerve Block
299075|NCT01505361|probiotic
299076|NCT01505361|Lactobacillus salivarius
299077|NCT01505361|mastitis
299078|NCT01505361|prevention
299079|NCT01505361|group B streptococci
299080|NCT01505361|intrapartum prophylaxis
299081|NCT01505348|feeding patterns
299082|NCT01505348|aerobic exercise
299083|NCT01505348|osteoclasts
299084|NCT01505335|alveolar nerve, inferior
299085|NCT01505335|ultrasound
299086|NCT01505335|digital radiography, dental
299087|NCT01505335|nerve injury
299088|NCT01505322|daily activities
299089|NCT01505309|Aortic Diseases
299090|NCT01505309|Vascular Diseases
299091|NCT01505309|Cardiovascular Diseases
299092|NCT01505309|Treatment Outcome
299093|NCT01505309|Aorta Dissection
299094|NCT01505309|Aorta Aneurysm
299095|NCT01505309|Aorta pseudoaneurysm
299096|NCT01505309|Endovascular aortic repair
299097|NCT01505296|Catheter ablation
299098|NCT01505257|Delirium
299099|NCT01505257|Dementia
299100|NCT01505257|Confusion Assessment Method
299101|NCT01505231|Shock
299102|NCT01505231|norepinephrine
299103|NCT01505231|vasopressin
299104|NCT01505231|cardiac surgery
299105|NCT01505218|Sedation
299106|NCT01505218|propofol
299107|NCT01505218|patient-controlled
299108|NCT01505218|safety
299109|NCT01505205|Gist,c-KIT,PDGFRA,DOG1,mutation
299110|NCT01505192|Those in Labor, Delivery and the Puerperium
299111|NCT01505179|HFPEF
299112|NCT01505179|Heart Failure
299113|NCT01505179|HF w/ preserved EF
299114|NCT01505179|Preserved EF
299115|NCT01505179|Preserved Ejection Fraction
299116|NCT01505179|Diastolic Dysfunction
299117|NCT01505166|colorectal carcinoma
299118|NCT01505166|colon cancer
299119|NCT01505166|liver metastases
299120|NCT01505153|Advanced cancer
299121|NCT01505153|Metastatic cancer
299122|NCT01505153|solid tumors
299123|NCT01505153|Melanoma
299124|NCT01505140|Andrology
299125|NCT01505140|Fertility
299126|NCT01505140|Reproduction
299127|NCT01505140|Diet
299128|NCT01505140|Nutritional Sciences
299129|NCT01505140|Fatty Acids
299130|NCT01505140|Antioxidants
299131|NCT01505140|Body weight changes
299132|NCT01505127|Drug Therapy
299133|NCT01505114|HIV Prevention
299134|NCT01505114|PrEP
299135|NCT01505114|Maraviroc
299136|NCT01505088|Iontophoresis
299137|NCT01505088|Non-Infectious Anterior Segment Uveitis
299138|NCT01505088|Ophthalmology
299139|NCT01505075|prostatic neoplasms
299140|NCT01505075|radiotherapy
299141|NCT01505075|hypofractionated
299142|NCT01505075|high risk prostate cancer
299143|NCT01505062|Usher Syndrome Retinitis Pigmentosa
299268|NCT01504698|Effect
299144|NCT01505062|Usher Syndrome associated Retinitis Pigmentosa
299145|NCT01505049|immunology
299146|NCT01505049|vaccination
299147|NCT01505049|human papillomavirus
299148|NCT01505036|Diabetes Mellitus
299149|NCT01505036|smart-care
299150|NCT01505036|U-health care
299151|NCT01505010|Treatment-resistant hypertension
299152|NCT01505010|Renal denervation
299153|NCT01505010|Sympathetic nervous system
299154|NCT01504997|DaVinci
299155|NCT01504997|Robot assisted surgery
299156|NCT01504997|Gastrectomy
299157|NCT01504997|Safety
299158|NCT01504997|Gastric Cancer
299159|NCT01504984|Evaluation of the pharmacokinetics equivalence
299160|NCT01504984|Healthy volunteers
299161|NCT01504984|Single dose over the period I and II(crossover)
299162|NCT01504984|Healthy male volunteers
299163|NCT01504971|Gastroesophageal Reflux;
299164|NCT01504971|Endoscopy;
299165|NCT01504971|Esophageal pH monitoring;
299166|NCT01504971|Narrow band imaging;
299167|NCT01504971|Autofluorescence imaging;
299168|NCT01504971|White light imaging;
299169|NCT01504958|Alzheimer's disease
299170|NCT01504958|Cognitive Training
299171|NCT01504958|Transcranial Magnetic Stimulation
299172|NCT01504945|chronic coronary artery disease
299173|NCT01504932|black raspberry lozenges
299174|NCT01504932|Appalachian
299175|NCT01504932|Oral Cancer
299176|NCT01504919|Psychosocial
299177|NCT01504919|Behavioral intervention
299178|NCT01504919|Nicotine patch
299179|NCT01504919|Latinos
299180|NCT01504919|Mexican American
299181|NCT01504919|Motivation and Problem Solving
299182|NCT01504919|MAPS
299183|NCT01504919|Cancer risk reduction
299184|NCT01504919|Smoking cessation
299185|NCT01504919|Overweight/obese smokers
299186|NCT01504919|BMI greater than or equal to 25
299187|NCT01504919|Wellness program
299188|NCT01504919|Questionnaires
299189|NCT01504919|Surveys
299190|NCT01504919|Self-help materials
299191|NCT01504919|Pamphlets
299192|NCT01504906|Phase 1
299193|NCT01504906|Healthy male volunteers
299194|NCT01504906|pharmacokinetics
299195|NCT01504906|cyclosporine
299196|NCT01504906|ticagrelor
299197|NCT01504906|Bioavailability (plasma AUC, Cmax, plasma AUC0-t, t1/2λz, tmax)
299198|NCT01504893|ventilation
299199|NCT01504893|PEEP
299200|NCT01504893|Acute Lung Injury
299201|NCT01504893|pneumonectomy
299202|NCT01504893|ARDS
299203|NCT01504880|Mitral Regurgitation
299204|NCT01504880|Tricuspid Regurgitation
299205|NCT01504880|Vena Contracta
299206|NCT01504867|Acute Respiratory Distress Syndrome
299207|NCT01504867|Acute Lung Injury
299208|NCT01504867|ARDS
299209|NCT01504867|ALI
299210|NCT01504867|aspirin
299211|NCT01504867|prevention
299212|NCT01504854|Alzheimer's disease
299213|NCT01504854|Dementia
299214|NCT01504854|Brain diseases
299215|NCT01504854|Resveratrol
299216|NCT01504854|Memory problems
299217|NCT01504854|Mental disorders
299218|NCT01504854|Cognitive disorders
299219|NCT01504828|Energy Metabolism
299220|NCT01504828|Ageing
299221|NCT01504828|left ventricle
299222|NCT01504828|energetics
299223|NCT01504828|function
299224|NCT01504815|advanced head and neck cancer
299225|NCT01504815|adaptive radiotherapy
299226|NCT01504815|cisplatinum
299227|NCT01504802|Growth hormone
299228|NCT01504802|C-type natriuretic peptide
299229|NCT01504802|amino-terminal propeptide of C-type natriuretic peptide
299230|NCT01504802|insulin-like growth factor-I
299231|NCT01504802|bone specific alkaline phosphatase
299232|NCT01504802|leptin
299233|NCT01504802|deoxypyridinoline
299234|NCT01504802|growth velocity
299235|NCT01504802|pharmacodynamic
299236|NCT01504802|biomarker
299237|NCT01504789|Breast Cancer
299238|NCT01504789|Breast Cancer Survivors
299239|NCT01504789|Exercise
299240|NCT01504789|Hispanic
299241|NCT01504789|Mexican-American
299242|NCT01504789|Puerto Rican
299243|NCT01504789|Culturally tailored exercise
299244|NCT01504789|Fitness tests
299245|NCT01504789|Questionnaires
299246|NCT01504789|Surveys
299247|NCT01504789|Culturally tailored written material
299248|NCT01504776|MCL
299249|NCT01504776|Lymphoma
299250|NCT01504776|Panobinostat
299251|NCT01504763|Massage
299252|NCT01504763|Chair massage
299253|NCT01504763|Relaxation
299254|NCT01504763|Nurses
299255|NCT01504750|Length of Stay [E02.760.400.480]
299256|NCT01504750|Activities of Daily Living [I03.050]
299257|NCT01504737|Exercise
299258|NCT01504737|Physical Activity
299259|NCT01504737|Physiotherapy
299260|NCT01504737|Exercise test
299261|NCT01504737|Quality of Life
299262|NCT01504737|Aortic Valve Replacement
299263|NCT01504724|central macular thickness
299264|NCT01504698|Manipulative treatment
299265|NCT01504698|Children
299266|NCT01504698|Neck pain
299267|NCT01504698|Back pain
299269|NCT01504698|Adolescence
299270|NCT01504698|Advise
299271|NCT01504698|Exercise
299272|NCT01504685|Morbid obesity
299273|NCT01504685|Obesity surgery
299274|NCT01504685|Gastric bypass
299275|NCT01504685|Banded gastric bypass
299276|NCT01504672|Drug related problems
299277|NCT01504659|bipolar disorder
299278|NCT01504659|treatment resistance
299279|NCT01504659|depression
299280|NCT01504659|ketamine
299281|NCT01504659|intranasal
299282|NCT01504659|child
299283|NCT01504646|Asthma
299284|NCT01504646|Exercise-Induced Bronchoconstriction
299285|NCT01504646|lipids
299286|NCT01504646|n-3 PUFA
299287|NCT01504646|airway inflammation
299288|NCT01504646|Bronchoconstriction
299289|NCT01504633|cognitive function
299290|NCT01504633|omega-3 PUFA (DHA)
299291|NCT01504633|iron
299292|NCT01504633|nutrigenomics
299293|NCT01504633|under-two year old children
299294|NCT01504633|Indonesia
299295|NCT01504620|diabetes mellitus
299296|NCT01504620|blood glucose self-assessment
299297|NCT01504620|Accuracy
299298|NCT01504620|Intra-Assay precision
299299|NCT01504620|Hematocrit interference
299300|NCT01504607|corneal endothelium
299301|NCT01504607|congenital cataract surgery
299302|NCT01504607|IOL implantation
299303|NCT01504594|Dilated cardiomyopathy
299304|NCT01504594|Idiopathic
299305|NCT01504594|Bone Marrow
299306|NCT01504594|Stem Cells
299307|NCT01504594|CD34 +
299308|NCT01504594|Autologous
299309|NCT01504555|hypercortisolism, dexamethasone, alcoholism,obesity.
299310|NCT01504542|Immunotherapy
299311|NCT01504529|Rotigotine (Neupro)
299312|NCT01504529|Non-Motor Symptoms
299313|NCT01504529|Advanced Parkinson's Disease
299314|NCT01504529|Local study
299315|NCT01504529|Spain
299316|NCT01504529|Observational study
299317|NCT01504529|Non-interventional study
299318|NCT01504529|Retrospective study
299319|NCT01504529|Post-marketing study
299320|NCT01504529|Multicenter study
299321|NCT01504516|Bioequivalence
299322|NCT01504516|Donepezil
299323|NCT01504516|crossover
299324|NCT01504503|Bioequivalence
299325|NCT01504503|Donepezil
299326|NCT01504503|crossover
299327|NCT01504490|Advanced cancer
299328|NCT01504477|colorectal cancer
299329|NCT01504477|relapsed
299330|NCT01504477|refractory
299331|NCT01504477|Kras wild type
299332|NCT01504464|knee joint osteoarthritis mesenchymal stem cell
299333|NCT01504451|Atrial fibrillation
299334|NCT01504451|Ablation
299335|NCT01504451|Implantable loop recorder
299336|NCT01504412|Pain
299337|NCT01504412|Diabetic Peripheral Neuropathy
299338|NCT01504399|Pituitary surgery
299339|NCT01504399|Transsphenoidal surgery
299340|NCT01504399|Anterior skull base surgery
299341|NCT01504399|Endoscopic surgery
299342|NCT01504399|Patient survey
299343|NCT01504399|Nasal complications
299344|NCT01504373|NAVA
299345|NCT01504373|neurally adjusted ventilatory support
299346|NCT01504373|lung injury
299347|NCT01504373|ventilation
299348|NCT01504373|lung volume distribution
299349|NCT01504373|oxygen cost of breathing
299350|NCT01504360|sarcoma
299351|NCT01504360|radiation therapy
299352|NCT01504360|predictive essay
299353|NCT01504321|Polycystic Ovary syndrome
299354|NCT01504321|PCOS
299355|NCT01504321|sympathetic nervous system
299356|NCT01504321|moxonidine
299357|NCT01504308|uterine fibroids
299358|NCT01504308|uterine leiomyomas
299359|NCT01504308|magnetic resonance imaging
299360|NCT01504308|focused ultrasound
299361|NCT01504256|Adenocarcinoma
299362|NCT01504256|Esophagogastric Junction
299363|NCT01504256|Peritoneal Carcinomatosis
299364|NCT01504256|Catumaxomab
299365|NCT01504256|AIO-STO-0110
299366|NCT01504243|CD163;
299367|NCT01504243|SNPs;
299368|NCT01504243|prognosis;
299369|NCT01504243|control（normal person）
299370|NCT01504230|To ascertain the mechanisms for effectively controlling balance in seniors with osteoporosis and to provide a basis for developing fall prevention programs.
299371|NCT01504230|To develop biomechanical models that control the entire body's center of mass (CoM) during upright quiet stance in seniors with osteoporosis.
299372|NCT01504230|To identify the mechanism to control the entire body's CoM after receiving a balance perturbation in seniors with osteoporosis.
299373|NCT01504217|Healthy older people over 65 years old
299374|NCT01504204|adherence
299375|NCT01504204|adapalene
299376|NCT01504204|benzoyl peroxide
299377|NCT01504204|sample
299378|NCT01504204|topical treatment
299379|NCT01504191|myocardial infarction
299380|NCT01504191|depression
299381|NCT01504191|anxiety
299382|NCT01504191|Internet‐based CBT
299383|NCT01504191|genetic disposition
299384|NCT01504178|Noradrenergic system and pain in Parkinson's disease
299385|NCT01504165|Renal impairment
299386|NCT01504165|Pharmacokinetic
299387|NCT01504165|cilengitide
299388|NCT01504165|subjects with mild
299389|NCT01504165|moderate or severe renal impairment compared to subjects with normal renal function
299390|NCT01504152|International travel
299391|NCT01504152|cancer patients
299392|NCT01504152|HSCT
299393|NCT01504152|Quality of Life
299394|NCT01504152|questionnaire
299395|NCT01504152|11-176
299396|NCT01504126|Ovarian Cancer
299397|NCT01504126|Primary peritoneal carcinoma
299398|NCT01504126|Fallopian tube cancer
299399|NCT01504126|Invasive epithelial ovarian cancer
299400|NCT01504126|Serous adenocarcinoma
299401|NCT01504126|Endometrioid adenocarcinoma
299402|NCT01504126|Mucinous adenocarcinoma
299403|NCT01504126|Undifferentiated carcinoma
299404|NCT01504126|Clear cell carcinoma
299405|NCT01504126|Mixed epithelial carcinoma
299406|NCT01504126|Adenocarcinoma not otherwise specified
299407|NCT01504126|Primary Müllerian epithelial adenocarcinoma
299408|NCT01504126|Propranolol
299409|NCT01504126|Beta-blocker
299410|NCT01504113|Target therapy
299411|NCT01504113|Biologics
299412|NCT01504113|Psoriasis
299413|NCT01504113|Latent virus
299414|NCT01504113|Human papillomaviruses
299415|NCT01504113|Cytomegalovirus
299416|NCT01504113|Epstein-Barr virus
299417|NCT01504113|Tumor necrosis factor
299418|NCT01504087|patient in critical care
299419|NCT01504074|Irvine Gass syndrome
299420|NCT01504074|multimodal imaging
299421|NCT01504074|SD-OCT
299422|NCT01504074|CME secondary to cataract surgery
299423|NCT01504074|in vivo correlation of morphology and function
299424|NCT01504061|surgical
299425|NCT01504061|scars
299426|NCT01504061|Mederma
299427|NCT01504048|Microscopic colitis
299428|NCT01504048|Intestinal Diseases
299429|NCT01504048|Inflammatory Bowel Diseases
299430|NCT01504035|Donor site pain
299431|NCT01504035|Iliac crest
299432|NCT01504035|Bone graft
299433|NCT01504035|Hemostatic putty
299434|NCT01504035|lidocaine
299435|NCT01504035|Donor site pain following harvest of iliac crest bone grafts
299436|NCT01504022|Hypertension
299437|NCT01504022|self-monitoring
299438|NCT01504022|internet
299439|NCT01504022|lifestyle modification
299440|NCT01504009|Nervous System Disease
299441|NCT01504009|Neurodegenerative Disease
299442|NCT01504009|Motor Neuron Disease
299443|NCT01504009|ALS
299444|NCT01504009|Muscle training
299445|NCT01504009|Muscle atrophy
299446|NCT01503996|dehydration
299447|NCT01503996|risk factor
299448|NCT01503996|glaucoma
299449|NCT01503996|Controls
299450|NCT01503983|Gastric Cancer with Metastasis
299451|NCT01503983|HER2-positive
299452|NCT01503970|chondral lesions
299453|NCT01503970|knee
299454|NCT01503957|Allergic rhinitis
299455|NCT01503957|Allergen
299456|NCT01503957|Allergy
299457|NCT01503957|Dustmite
299458|NCT01503931|alcohol dependence, functional magnetic resonance imaging, genetics, endophenotypes, dopamine,
299459|NCT01503931|glutamate
299460|NCT01503918|Critical Illness
299461|NCT01503918|Critical Care
299462|NCT01503918|Valganciclovir
299463|NCT01503918|Ganciclovir
299464|NCT01503918|Aciclovir
299465|NCT01503918|Valaciclovir
299466|NCT01503918|Cytomegalovirus
299467|NCT01503905|breast cancer
299468|NCT01503905|neoadjuvant chemotherapy
299469|NCT01503905|amenorrhea
299470|NCT01503892|Small Fiber Neuropathy
299471|NCT01503892|Metanx Effect on Small Fiber Neuropathy
299472|NCT01503892|Metanx Effect on Diabetic Peripheral Neuropathy
299473|NCT01503879|general anaesthesia
299474|NCT01503879|invasive mechanical ventilation
299475|NCT01503879|DLCO
299476|NCT01503879|SPB
299477|NCT01503853|Medical Costs
299478|NCT01503853|Health Care
299479|NCT01503853|Focus Groups
299480|NCT01503827|Whole Brain Radiotherapy
299481|NCT01503827|Brain metastases
299482|NCT01503827|Melanoma
299483|NCT01503827|Stage IV Metastatic Melanoma
299484|NCT01503827|Neurocognitive function
299485|NCT01503827|Quality of life
299486|NCT01503814|hypertension
299487|NCT01503814|primary care
299488|NCT01503814|cardiovascular disease prevention
299489|NCT01503814|high cardiovascular risk
299490|NCT01503814|diuretics
299491|NCT01503814|aspirin
299492|NCT01503814|smoking cessation
299493|NCT01503814|salt reduction
299494|NCT01503814|Tibet
299495|NCT01503801|Preterm neonates
299496|NCT01503801|Bronchopulmonary dysplasia
299497|NCT01503801|Chronic lung disease
299498|NCT01503801|Inhaled nitric oxide
299499|NCT01503801|Respiratory therapy
299500|NCT01503775|intracranial
299501|NCT01503775|ruptured
299502|NCT01503775|non-ruptured
299503|NCT01503775|aneurysms
299504|NCT01503775|Intracranial ruptured or non-ruptured aneurysms
299505|NCT01503762|Hand Flexor tendon Injuries
299506|NCT01503762|hand Extensor Tendon Injuries
299507|NCT01503762|Hand Joint Dislocations and subluxation
299508|NCT01503736|Kidney Diseases
299509|NCT01503736|Kidney Failure, Chronic
299510|NCT01503736|Hyperphosphatemia
299511|NCT01503736|Urologic Diseases
299512|NCT01503736|Renal Insufficiency, Chronic
299513|NCT01503736|Renal Insufficiency
299514|NCT01503736|Phosphorus Metabolism Disorders
299515|NCT01503710|Proteinuria predict outcome
299516|NCT01503710|BNP and NGAL predict outcome
299517|NCT01503710|Pre-operative GFR and proteinuria
299518|NCT01503697|Breast Cancer
299519|NCT01503697|High Risk
299520|NCT01503697|Imaging
299521|NCT01503697|Angiogenesis
299522|NCT01503684|sepsis
299523|NCT01503671|left ventricular diastolic function
299524|NCT01503671|inflammation
299525|NCT01503671|peritoneal dialysis
299526|NCT01503671|LV diastolic function changes after statin intervention
299527|NCT01503658|Clopidogrel,
299528|NCT01503658|Aspirin,
299529|NCT01503658|Pharmacogenomics
299530|NCT01503645|kidney diseases
299531|NCT01503645|drugs, Chinese herbal
299532|NCT01503645|aristolochic acid
299533|NCT01503645|polymorphism, genetic
299534|NCT01503619|small cell lung cancer
299535|NCT01503606|preterm premature rupture of membrane
299536|NCT01503606|antibiotics
299537|NCT01503606|duration
299538|NCT01503606|cefazolin
299539|NCT01503606|clarithromycin
299540|NCT01503541|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
299541|NCT01503541|adult acute myeloid leukemia with del(5q)
299542|NCT01503541|adult acute myeloid leukemia with inv(16)(p13;q22)
299543|NCT01503541|adult acute myeloid leukemia with t(15;17)(q22;q12)
299544|NCT01503541|adult acute myeloid leukemia with t(16;16)(p13;q22)
299545|NCT01503541|adult acute myeloid leukemia with t(8;21)(q22;q22)
299546|NCT01503541|adult acute myeloid leukemia
299547|NCT01503528|arthroplasty
299548|NCT01503528|wound
299549|NCT01503528|catheter
299550|NCT01503528|infusion
299551|NCT01503528|local
299552|NCT01503528|anesthesia
299553|NCT01503528|infiltration
299554|NCT01503502|Myelogenous Leukemia
299555|NCT01503502|chronce
299556|NCT01503502|Philadelphia Chromosome Positive
299557|NCT01503502|Flumatinib
299558|NCT01503489|Switch.
299559|NCT01503476|gastro esophageal reflux disease
299560|NCT01503463|Congestive Heart Failure
299561|NCT01503463|Telemedicine
299562|NCT01503385|Celecoxib
299563|NCT01503385|phase II
299564|NCT01503359|glutamic acid
299565|NCT01503359|sarcosine
299566|NCT01503359|NMDA
299567|NCT01503359|schizophrenia
299568|NCT01503346|Appetite Loss
299569|NCT01503333|exercise
299570|NCT01503333|adolescent
299571|NCT01503333|intervention
299572|NCT01503333|female
299573|NCT01503333|counseling
299574|NCT01503320|To evaluate
299575|NCT01503320|efficacy
299576|NCT01503320|enteral glutamine
299577|NCT01503307|prenatal chd diagnosis
299578|NCT01503307|postpartum chd diagnosis
299579|NCT01503307|parenting
299580|NCT01503307|internal working models
299581|NCT01503294|Temporal artery thermometer
299582|NCT01503294|Pulmonary artery thermistor
299583|NCT01503281|Children
299584|NCT01503281|Physical activity
299585|NCT01503281|Home-based treatment
299586|NCT01503281|Body mass index (z-BMI)
299587|NCT01503281|Percentage body fat
299588|NCT01503281|Waist circumference
299589|NCT01503268|Atrial fibrillation
299590|NCT01503268|Ablation
299591|NCT01503268|Percutaneous ablation
299592|NCT01503268|Minimally-invasive thoracoscopic ablation
299593|NCT01503268|Implantable loop recorder
299594|NCT01503255|CBT
299595|NCT01503255|alcohol
299596|NCT01503255|HIV
299597|NCT01503255|Kenya
299598|NCT01503255|paraprofessional
299599|NCT01503216|randomized controlled trial
299600|NCT01503216|vitamin D
299601|NCT01503216|bioavailability
299602|NCT01503203|Older
299603|NCT01503203|virtual systems
299604|NCT01503203|low back pain
299605|NCT01503203|postural balance
299606|NCT01503190|Breast Cancer
299607|NCT01503190|Young Women
299608|NCT01503190|Pregnancy Associated Breast Cancer
299609|NCT01503190|Pregnancy
299610|NCT01503190|Premenopausal Breast Cancer
299611|NCT01503164|Obstructive sleep apnea
299612|NCT01503164|Sleep Apnea
299613|NCT01503164|Sleep-disordered breathing
299614|NCT01503164|Insulin sensitivity
299615|NCT01503164|Glucose tolerance
299616|NCT01503164|Type 2 diabetes
299617|NCT01503151|attention bias modification treatment
299618|NCT01503151|interpretive bias modification
299619|NCT01503151|cognitive bias modification
299620|NCT01503151|attention training
299621|NCT01503151|social anxiety
299622|NCT01503138|Intimate Partner Violence
299623|NCT01503138|Depressive Symptoms
299624|NCT01503138|Intervention
299625|NCT01503138|Randomized Controlled Trial
299626|NCT01503138|Mainland Chinese
299627|NCT01503138|Immigrants
299628|NCT01503138|Women
299629|NCT01503125|GAN
299630|NCT01503125|Giant Axonal Neuropathy
299631|NCT01503125|Neuromuscular Disease
299632|NCT01503125|Natural History Study
299633|NCT01503125|Observational Study
299634|NCT01503112|Glucagon-Like Peptide 1, DPP4 protein, Therapeutics, Hypoglycemic Agents, C-Peptide, Type 2 Diabetes Mellitus,
299635|NCT01503099|ITB
299636|NCT01503099|PTB
299637|NCT01503099|CD
299638|NCT01503073|stroke
299639|NCT01503060|pediatrics
299640|NCT01503060|Pain
299641|NCT01503060|Immunization
299642|NCT01503034|Pregnant women
299643|NCT01503021|Soluble ferric pyrophosphate
299644|NCT01503021|Chronic kidney disease
299645|NCT01503021|Chronic hemodialysis
299646|NCT01503021|Ferric pyrophosphate citrate
299647|NCT01502995|Assistive devices
299648|NCT01502995|Freezing of gait
299649|NCT01502995|Gait disorders
299650|NCT01502995|Gait hesitation
299651|NCT01502995|Gait ignition failure
299652|NCT01502995|Laser light
299653|NCT01502995|Parkinson's disease
299654|NCT01502995|Rolling walker
299655|NCT01502995|Visual Cue
299656|NCT01502995|Walker
299657|NCT01502982|DLBCL
299658|NCT01502982|high risk
299659|NCT01502982|young
299660|NCT01502969|diarrhea
299661|NCT01502969|fever
299662|NCT01502969|nausea
299663|NCT01502969|vomit
299664|NCT01502969|irritability
299665|NCT01502956|Refractory Urinary Urge Incontinence
299666|NCT01502956|Botox A®
299667|NCT01502956|Interstim® Device
299668|NCT01502943|Complementary Therapies
299669|NCT01502943|Traditional Chinese Medicine
299670|NCT01502943|Quality of life
299671|NCT01502943|Seattle angina questionnaire (SAQ)
299672|NCT01502943|SF-12
299673|NCT01502943|Measure Your Medical Outcome Profile (MYMOP)
299674|NCT01502943|Phlegm and blood stasis Syndrome
299675|NCT01502943|Qi deficiency and blood stasis Syndrome
299676|NCT01502943|Invigorating Spleen to Remove Phlegm or replenish Qi
299677|NCT01502943|Activating blood and dissolving stasis
299678|NCT01502943|Traditional Chinese medicine SYndrome Scale (TCMsys)
299679|NCT01502943|Patients Report Outcomes(PRO)
299680|NCT01502943|clinical efficacy
299681|NCT01502943|evaluative index
299682|NCT01502917|Brain stem glioma
299683|NCT01502917|CNS
299684|NCT01502917|MAB 124I-8H9
299685|NCT01502917|infusion cannula
299686|NCT01502917|DIPG
299687|NCT01502917|Diffuse Intrinsic Pontine Glioma
299688|NCT01502917|11-011
299689|NCT01502904|SES vs BES
299690|NCT01502891|Comparative Effectiveness Research
299691|NCT01502891|Decision Support Techniques
299692|NCT01502891|Decision Making
299693|NCT01502878|Nut allergy
299694|NCT01502878|Double-blind placebo-controlled (DBPC) oral nut challenge
299695|NCT01502878|Nut oral immunotherapy (OIT)
299696|NCT01502878|Nut oral desensitization
299697|NCT01502852|OEF/OIF Veterans
299698|NCT01502852|Traumatic Brain Injury
299699|NCT01502852|Community Mental Health
299700|NCT01502826|Childhood obesity
299701|NCT01502826|Endothelial dysfunction
299702|NCT01502826|Inflammation
299703|NCT01502826|Insulin resistance
299704|NCT01502813|Neuropsychological testing
299705|NCT01502813|Dietary supplements
299706|NCT01502800|Metastatic
299707|NCT01502800|Unresectable
299708|NCT01502800|Recurrent advanced
299709|NCT01502787|hypertension
299710|NCT01502787|blood pressure
299711|NCT01502787|blood pressure medications
299712|NCT01502787|metoprolol
299713|NCT01502787|nebivolol
299714|NCT01502787|handgrip exercise
299715|NCT01502787|lower body negative pressure
299716|NCT01502787|angiotensin II
299717|NCT01502787|sympathetic nerve activity
299718|NCT01502787|flow mediated dilation
299719|NCT01502787|nitric oxide
299720|NCT01502787|microneurography
299721|NCT01502774|STEMI
299722|NCT01502774|cyclosporine
299723|NCT01502774|reperfusion injury
299724|NCT01502761|stroke
299725|NCT01502761|Magnesium
299726|NCT01502761|endovascular
299727|NCT01502748|stroke
299728|NCT01502748|Magnesium
299729|NCT01502748|Endovascular
299730|NCT01502735|dengue
299731|NCT01502735|dengue fever
299732|NCT01502735|monovalent dengue vaccine
299733|NCT01502709|Single blind
299734|NCT01502709|Randomized
299735|NCT01502709|Controlled clinical trial
299736|NCT01502696|ulcerated primary cutaneous melanoma
299737|NCT01502696|Stage II
299738|NCT01502696|PEG IFN alfa-2b
299739|NCT01502696|T(2-4)bN0M0
299740|NCT01502683|Stroke
299741|NCT01502683|neurocognitive dysfunction
299742|NCT01502683|cerebral embolic events
299743|NCT01502670|Pulmonary nodules
299744|NCT01502657|percutaneous tracheostomy
299745|NCT01502657|ultrasonography
299746|NCT01502657|echography
299747|NCT01502657|critical care
299748|NCT01502644|low back pain
299749|NCT01502644|opioids
299750|NCT01502644|mood symptoms
299751|NCT01502618|Adolescent Medicine Trials Network for HIV/AIDS Interventions
299752|NCT01502618|Human Immunodeficiency Virus
299753|NCT01502605|5-ALA
299754|NCT01502605|Aminolevulinic Acid
299755|NCT01502605|Craniotomy
299756|NCT01502605|Brain Tumor
299757|NCT01502605|Surgical Resection
299758|NCT01502605|Neurosurgery
299759|NCT01502592|MDX-010 (Ipilimumab)
299760|NCT01502592|Cryoablation
299761|NCT01502592|Total mastectomy planned
299762|NCT01502592|11-202
299763|NCT01502579|IgA nephropathy
299764|NCT01502566|educational intervention
299765|NCT01502566|dentals caries
299766|NCT01502566|population
299767|NCT01502566|new populational caries prevention strategies.
299768|NCT01502553|blood pressure
299769|NCT01502553|heart rate
299770|NCT01502540|pain
299771|NCT01502540|craniotomy
299772|NCT01502527|Vulvo vaginal atrophy
299773|NCT01502527|Femarelle
299774|NCT01502514|CHF
299775|NCT01502514|ischemia
299776|NCT01502514|Heart Failure
299777|NCT01502501|CHF
299778|NCT01502501|Heart Failure
299779|NCT01502501|Non-Ischemic
299780|NCT01502501|nonischemic
299781|NCT01502501|nonischemia
299782|NCT01502488|Autistic
299783|NCT01502488|ASC therapy
299784|NCT01502488|ADSC
299785|NCT01502475|Complementary Alternative Medicine
299786|NCT01502475|Veteran
299787|NCT01502475|Attitudes
299788|NCT01502475|Beliefs
299789|NCT01502462|Clinical course and prognostic factors in patients with severe isolated TR
299790|NCT01502449|telemedicine, telephonic, PTSD
299791|NCT01502436|posttraumatic stress disorder
299792|NCT01502436|traumatic brain injury
299793|NCT01502436|Suicide Attempt
299794|NCT01502436|Veterans
299795|NCT01502423|On label Humira users
299796|NCT01502423|Rheumatoid Arthritis
299797|NCT01502423|Pain
299798|NCT01502397|hepatitis B
299799|NCT01502397|anti-HBc
299800|NCT01502397|HBsAg
299801|NCT01502397|rituximab
299802|NCT01502397|occult HBV
299803|NCT01502384|healthy 1st degree relatives of pd patients
299804|NCT01502371|Asthma
299805|NCT01502371|Children
299806|NCT01502371|Persistent
299807|NCT01502358|dengue
299808|NCT01502358|dengue fever
299809|NCT01502358|dengue disease
299810|NCT01502358|tetravalent dengue vaccine
299811|NCT01502358|Vaxfectin®
299812|NCT01502345|HFRS
299813|NCT01502332|Mechanical ventilation
299814|NCT01502332|Open lung approach
299815|NCT01502332|Blood gases
299816|NCT01502332|Cardiac surgery
299817|NCT01502332|Pulmonary complications
299818|NCT01502306|Smoking cessation
299819|NCT01502306|Telephone
299820|NCT01502306|Self-help
299821|NCT01502306|Smoking abstinence
299822|NCT01502306|Incentives
299823|NCT01502306|Nicotine-replacement therapy
299824|NCT01502306|Medi-Cal
299825|NCT01502306|Medicaid
299826|NCT01502280|extent of resection
299827|NCT01502280|Glioma
299828|NCT01502280|5-ALA
299829|NCT01502280|tumor fluorescence
299830|NCT01502280|confocal microscopy
299831|NCT01502267|Waiting list
299832|NCT01502267|Deceased donor kidney transplantation
299833|NCT01502267|Desensitization
299834|NCT01502267|anti HLA antibody
299835|NCT01502254|Informed consent
299836|NCT01502254|Cancer clinical trials
299837|NCT01502254|Patient information
299838|NCT01502254|Knowledge
299839|NCT01502254|Questionnaire
299840|NCT01502254|Patient Eligible for a Phase II or III Cancer Clinical Trial
299841|NCT01502254|Scheduled Clinical Visit for Information About a Trial
299842|NCT01502241|elderly
299843|NCT01502241|brain tumors
299844|NCT01502241|MGMT
299845|NCT01502241|chemotherapy
299846|NCT01502241|Newly diagnosed
299847|NCT01502241|patients > 65 years
299848|NCT01502202|lung adenocarcinoma
299849|NCT01502202|never smoker
299850|NCT01502202|1st line treatment
299851|NCT01502202|Intercalation administration
299852|NCT01502202|Gefitinib
299853|NCT01502202|never smokers
299854|NCT01502189|patient education as topic
299855|NCT01502189|representational approach
299856|NCT01502189|parents
299857|NCT01502189|childhood cancer
299858|NCT01502189|paediatric oncology
299859|NCT01502189|nursing
299860|NCT01502189|parents of children with cancer
299861|NCT01502189|Stress
299862|NCT01502189|Health Knowledge
299863|NCT01502189|Attitudes
299864|NCT01502189|Practice
299865|NCT01502176|atrial fibrillation
299866|NCT01502176|registry
299867|NCT01502163|perioperative hypothermia
299868|NCT01502163|prewarming
299869|NCT01502163|forced air warming
299870|NCT01502163|insulation
299871|NCT01502150|Pediatric Cancer
299872|NCT01502150|Proton Radiation Therapy
299873|NCT01502150|Proton beam radiotherapy
299874|NCT01502150|PBT
299875|NCT01502150|Data Collection
299876|NCT01502150|Database
299877|NCT01502150|Acute and late normal tissue toxicities
299878|NCT01502150|Dosimetric data
299879|NCT01502150|Toxicity data
299880|NCT01502111|decreased level of consciousness
299881|NCT01502111|hypoxemia
299882|NCT01502111|ineffective ventilation
299883|NCT01502111|airway obstruction
299884|NCT01502111|combative or unresponsive
299885|NCT01502111|relief of pain or distress
299886|NCT01502111|cardiopulmonary arrest
299887|NCT01502085|multiple myeloma lenalidomide
299888|NCT01502072|Ribavirin
299889|NCT01502072|Ribavirin Aerosol
299890|NCT01502072|Respiratory Syncytial Virus
299891|NCT01502072|RSV
299892|NCT01502072|upper respiratory tract infection
299893|NCT01502072|URI
299894|NCT01502072|Lower respiratory tract Infection
299895|NCT01502072|LRI
299896|NCT01502072|pneumonia
299897|NCT01502072|aerosolized ribavirin
299898|NCT01502072|HSCT
299899|NCT01502072|Hematopoietic stem cell transplantation
299900|NCT01502072|oral ribavirin therapy
299901|NCT01502059|Pilates
299902|NCT01502059|Exercise
299903|NCT01502059|Treatment
299904|NCT01502059|Low back pain
299905|NCT01502059|Pain
299906|NCT01502059|Function
299907|NCT01502046|Huntington's disease, cannabinoids
299908|NCT01502033|Adolescent Depression
299909|NCT01502033|Transcranial Magnetic Stimulation
299910|NCT01502020|actinic keratoses
299911|NCT01502020|actinic keratosis
299912|NCT01502020|imiquimod, 3.75%
299913|NCT01502020|imiquimod
299914|NCT01502020|Zyclara
299915|NCT01502020|Actinic keratoses of the face or balding scalp
299916|NCT01502007|Activity Level
299917|NCT01502007|Overweight
299918|NCT01502007|Obesity
299919|NCT01501994|Activity level
299920|NCT01501994|Weight
299921|NCT01501994|Body Fat
299922|NCT01501994|Well Being
299923|NCT01501981|heart failure
299924|NCT01501981|MR-proANP
299925|NCT01501981|MR-proADM
299926|NCT01501981|decompensation
299927|NCT01501981|Copeptin
299928|NCT01501981|CT-proET1
299929|NCT01501981|NT-proBNP
299930|NCT01501968|Colistin
299931|NCT01501968|ascorbic acid
299932|NCT01501968|renal toxicity
299933|NCT01501955|Osteoarthritis
299934|NCT01501942|Asthma
299935|NCT01501942|Allergen induced asthma
299936|NCT01501942|ATS Criteria (1)
299937|NCT01501929|hypertension
299938|NCT01501929|blood pressure
299939|NCT01501929|blood pressure medications
299940|NCT01501929|metoprolol
299941|NCT01501929|nebivolol
299942|NCT01501929|vascular oxidative stress
299943|NCT01501929|nitric oxide
299944|NCT01501929|nitric oxide synthase (eNOS)
299945|NCT01501929|endothelium
299946|NCT01501929|endothelial dysfunction
299947|NCT01501929|endothelial cell protein expression
299948|NCT01501929|microvascular blood flow
299949|NCT01501929|flow mediated dilation
299950|NCT01501929|handgrip exercise
299951|NCT01501929|endothelial cell collection
299952|NCT01501929|microbubbles
299953|NCT01501929|Definity
299954|NCT01501890|Threatened Abortion
299955|NCT01501890|Progesterone
299956|NCT01501890|Subchorionic Hematoma
299957|NCT01501890|Pre-Eclampsia
299958|NCT01501890|Abruptio Placentae
299959|NCT01501890|Fetal Growth Retardation
299960|NCT01501890|Premature Birth
299961|NCT01501877|Smoking
299962|NCT01501877|Type 2 Diabetes
299963|NCT01501877|Smoking cessation
299964|NCT01501864|HIV prevention
299965|NCT01501864|HSV-2
299966|NCT01501864|Schooling
299967|NCT01501864|Kenya
299968|NCT01501864|Orphans
299969|NCT01501864|School support
299970|NCT01501799|acne
299971|NCT01501799|adapalene/benzoyl peroxide
299972|NCT01501799|Epiduo
299973|NCT01501799|Mild to severe acne vulgaris
299974|NCT01501786|children
299975|NCT01501786|sedation
299976|NCT01501786|propofol
299977|NCT01501786|ketamine
299978|NCT01501773|Acute ischemic stroke
299979|NCT01501747|Placebo effect
299980|NCT01501747|drug half life
299981|NCT01501747|pharmacokinetics
299982|NCT01501734|CHF
299983|NCT01501734|watch-pat
299984|NCT01501734|embletta x
299985|NCT01501734|endothelial function
299986|NCT01501721|prevention
299987|NCT01501721|workers
299988|NCT01501721|clinical trials
299989|NCT01501721|obesity
299990|NCT01501708|caspofungin
299991|NCT01501708|IFI
299992|NCT01501708|allogeneic hematopoietic stem cell transplantation
299993|NCT01501695|tic disorder
299994|NCT01501695|pediatric
299995|NCT01501682|ventralex
299996|NCT01501682|ventral hernia
299997|NCT01501669|irinotecan
299998|NCT01501669|capecitabine
299999|NCT01501669|metastatic breast cancer
300000|NCT01501643|Non invasive positive pressure ventilation
300001|NCT01501643|Spirometry
300002|NCT01501643|Acute chest syndrome
300003|NCT01501643|Sickle cell disease
300004|NCT01501643|Vaso-occlusive crisis
300005|NCT01501630|Comparison of imaging modalities
300006|NCT01501630|Impact on patient management
300007|NCT01501630|Optimisation of cost of the diagnostic strategy
300008|NCT01501617|Hair Loss
300009|NCT01501617|Androgenetic Alopecia
300010|NCT01501617|Baldness
300011|NCT01501617|Male pattern baldness
300012|NCT01501617|Male pattern hair loss
300013|NCT01501617|Hair Regrowth
300014|NCT01501617|Alopecia
300015|NCT01501617|Hair growth
300016|NCT01501617|Regrow Hair
300017|NCT01501604|PIK3CA mutation
300018|NCT01501604|Advanced solid tumors
300019|NCT01501591|Placebo effect
300020|NCT01501591|placebo drug interaction
300021|NCT01501591|placebo -controlled clinical trials
300022|NCT01501578|Pulmonary fibrosis
300023|NCT01501578|Telomerase mutation
300024|NCT01501565|Postoperative pain
300025|NCT01501565|Transverse abdominal blockade
300026|NCT01501565|Efficacy
300027|NCT01501565|Safety
300028|NCT01501565|Urology
300029|NCT01501552|Primary health care
300030|NCT01501552|Identification and Brief Intervention Programmes
300031|NCT01501552|Hazardous and harmful alcohol consumption
300032|NCT01501539|Hypergranulation tissue
300033|NCT01501539|Gastrostomy tube
300034|NCT01501539|Hydrocolloid dressing
300035|NCT01501539|Silver hydrocolloid dressing
300036|NCT01501539|Gastrostomy tube dislodgement
300037|NCT01501539|Wound infection
300038|NCT01501539|Peristomal skin breakdown
300039|NCT01500564|Stroke
300040|NCT01500564|transcranial direct current stimulation (tDCS)
300041|NCT01500564|motor function
300042|NCT01500551|Arthritis
300043|NCT01500551|Pediatric
300044|NCT01500551|Tofacitinib
300045|NCT01500551|Long-term
300046|NCT01500551|JIA
300047|NCT01500551|CP-690,550
300048|NCT01500551|Xeljanz
300049|NCT01500538|Follicular lymphoma
300050|NCT01500538|Marginal zone lymphoma
300051|NCT01500538|Mantle cell lymphoma
300052|NCT01500538|thrombocytopenia
300053|NCT01500538|eltrombopag
300054|NCT01500538|vorinostat
300055|NCT01500538|lymphoma
300056|NCT01500525|asthma
300057|NCT01500525|children
300058|NCT01500525|accuracy of bronchodilator response
300059|NCT01500499|adult acute myeloid leukemia
300060|NCT01500499|childhood acute myeloid leukemia/other myeloid malignancies
300061|NCT01500447|Hypogonadotropic Hypogonadism
300062|NCT01500447|Kallmann Syndrome
300063|NCT01500447|Delayed Puberty
300064|NCT01500447|Infertility
300065|NCT01500447|Hypothalamic Amenorrhea
300066|NCT01500447|Early Puberty
300067|NCT01500447|Late Puberty
300068|NCT01500447|Hypogonadism
300069|NCT01500447|Amenorrhea
300070|NCT01500447|Endocrine Diseases
300071|NCT01500434|drug-eluting stents
300072|NCT01500434|DES
300073|NCT01500434|atherosclerotic
300074|NCT01500421|Hypothermia, Induced
300075|NCT01500395|Aortic Diseases
300076|NCT01500395|Vascular Diseases
300077|NCT01500395|Cardiovascular Diseases
300078|NCT01500395|Treatment Outcome
300079|NCT01500395|Aorta Dissection
300080|NCT01500395|Aorta Aneurysm
300081|NCT01500395|Aorta pseudoaneurysm
300082|NCT01500395|Endovascular aortic repair
300083|NCT01500395|Hybrid operation
300084|NCT01500395|Debranching
300085|NCT01500369|atrial fibrillation
300086|NCT01500369|remote ischemic conditioning
300087|NCT01500356|cardiovascular disease
300088|NCT01500356|obesity
300089|NCT01500356|exercise
300090|NCT01501526|herpes esophagitis
300091|NCT01501526|dysphagia
300092|NCT01501526|vocal fold palsy
300093|NCT01501526|immunocompetent
300094|NCT01501526|husky voice
300095|NCT01501513|colonoscopy
300096|NCT01501513|bowel preparation
300097|NCT01501513|endoscopy
300098|NCT01501500|botulinum toxin type A
300099|NCT01501500|hallux valgus angle
300100|NCT01501500|foot function index
300101|NCT01501500|VAS pain scale
300102|NCT01501487|breast cancer
300103|NCT01501487|neo adjuvant therapy
300104|NCT01501474|Confocal
300105|NCT01501474|malignant biliary stricture
300106|NCT01501474|Sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
300107|NCT01501474|sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
300108|NCT01501435|Safety
300109|NCT01501435|Pharmacokinetics
300110|NCT01501422|postmenopause
300111|NCT01501422|sleep quality
300112|NCT01501422|estrogen
300113|NCT01501422|objective sleep quality
300114|NCT01501422|actigraph
300115|NCT01501409|Sodium lauryl sulfate (SLS)
300116|NCT01501409|recurrent aphthous stomatitis (RAS)
300117|NCT01501409|dentifrice
300118|NCT01501409|pain
300119|NCT01501370|Myeloma
300120|NCT01501370|Biochemical relapse
300121|NCT01501357|caries
300122|NCT01501357|primary molars
300123|NCT01501357|plaque
300124|NCT01501357|toothbrushing
300125|NCT01501344|osteoporosis
300126|NCT01501344|postmenopausal women
300127|NCT01501344|bone remodelling
300128|NCT01501344|bone turnover markers
300129|NCT01501331|Congestive Heart Failure
300130|NCT01501331|Cardiac Resynchronization Therapy
300131|NCT01501331|Internal Cardioverter Defibrillators
300132|NCT01501318|SBIRT
300133|NCT01501318|brief intervention
300134|NCT01501318|alcohol
300135|NCT01501318|drug abuse
300136|NCT01501305|influence
300137|NCT01501305|carob powder
300138|NCT01501305|probiotics
300139|NCT01501305|duration
300140|NCT01501279|pudendal nerve block
300141|NCT01501279|postoperative pain
300142|NCT01501279|bladder spasm
300143|NCT01501266|postmenopausal breast cancer
300144|NCT01501266|Faslodex
300145|NCT01501266|cohort
300146|NCT01501253|CKD-828
300147|NCT01501253|Hypertension
300148|NCT01501253|Primary Hypertension
300149|NCT01501253|S-Amlodipine
300150|NCT01501253|Telmisartan
300151|NCT01501253|Non-Responder
300152|NCT01501240|Magnetic resonance image
300153|NCT01501240|gadoxetic acid
300154|NCT01501240|hepatocellular carcinoma
300155|NCT01501240|liver cirrhosis
300156|NCT01501227|ventilator associated pneumonia
300157|NCT01501214|atosiban
300158|NCT01501214|in vitro fertilization
300159|NCT01501214|subfertility
300160|NCT01501201|Obesity
300161|NCT01501201|Diabetes
300162|NCT01501201|Bariatric Surgery
300163|NCT01501188|Chronic Venous Insufficiency
300164|NCT01501188|Kinesio Taping
300165|NCT01501188|Electromyography
300166|NCT01501188|Range of ankle motion
300167|NCT01501175|superficial vein thrombosis
300168|NCT01501175|Saint Etienne region
300169|NCT01501162|hepatitis, alcohol
300170|NCT01501149|NK/T cell lymphoma
300171|NCT01501149|chemotherapy
300172|NCT01501149|clinical trial
300173|NCT01501149|RR
300174|NCT01501149|PFS
300175|NCT01501149|OS
300176|NCT01501136|NK/T cell lymphoma
300177|NCT01501136|chemotherapy
300178|NCT01501136|clinical trial
300179|NCT01501136|RR
300180|NCT01501136|PFS
300181|NCT01501136|OS
300182|NCT01501123|Time to sedation of agitated patients
300183|NCT01501110|Euthyroid Sick Syndrome
300184|NCT01501110|low T3 syndrome
300185|NCT01501110|deiodases
300186|NCT01501110|oxidative stress
300187|NCT01501110|ischemic heart disease
300188|NCT01501084|functional MRI
300189|NCT01501084|Structural MRI
300190|NCT01501084|obesity
300191|NCT01501084|resting state networks
300192|NCT01501071|Laparoscopic Nissen fundoplication
300193|NCT01501071|Esophageal calibration
300194|NCT01501071|Postoperative dysphagia
300195|NCT01501045|TMS
300196|NCT01501045|CPM
300197|NCT01501045|headache
300198|NCT01501045|migraine
300199|NCT01501045|EEG
300200|NCT01501045|psychophysics
300201|NCT01501032|Diabetes Type 1
300202|NCT01501032|Artificial Pancreas
300203|NCT01501006|Physicians
300204|NCT01500993|Rectal cancer
300205|NCT01500993|Chemoradiotherapy
300206|NCT01500993|Capecitabine
300207|NCT01500993|phase-III trial
300208|NCT01500980|malaria
300209|NCT01500980|challenge
300210|NCT01500980|P. falciparum
300211|NCT01500980|prevention
300212|NCT01500928|Insulin Pump
300213|NCT01500928|Glycemic Control
300214|NCT01500928|Type 1 Diabetes
300215|NCT01500915|AMD
300216|NCT01500915|ranibizumab
300217|NCT01500915|antiVEGF
300218|NCT01500915|regimen of injections
300219|NCT01500915|anti VEGF regimen
300220|NCT01500915|PRN
300221|NCT01500915|treat and extend
300222|NCT01500902|Acute Coronary Syndrome (ACS)
300223|NCT01500902|Percutaneous Intervention (PCI)
300224|NCT01500902|Coronary Stent (CStent)
300225|NCT01500902|Percutaneous Transluminal Coronary Angioplasty (PTCA)
300226|NCT01500902|stent placement
300227|NCT01500902|balloon angioplasty
300228|NCT01500889|Anal fissure
300229|NCT01500889|Advancement flap
300230|NCT01500889|Internal sphincterotomy
300231|NCT01500876|lung cancer
300232|NCT01500863|endometrial receptivity
300233|NCT01500863|gene arrays
300234|NCT01500863|agonist triggering
300235|NCT01500863|Endometrial gene expression
300236|NCT01500863|OHSS
300237|NCT01500850|Type 2 Diabetes mellitus
300238|NCT01500850|NPH insulin
300239|NCT01500850|Insulin Glargine
300240|NCT01500850|cardiovascular biomarkers
300241|NCT01500850|hsCRP, adiponectin
300242|NCT01500850|intact proinsulin
300243|NCT01500850|cardiovascular risk
300244|NCT01500837|Staphylococcus aureus
300245|NCT01500837|osteoarticular infection
300246|NCT01500837|clindamycin
300247|NCT01500837|serum concentration
300248|NCT01500837|orthopedic surgery
300249|NCT01500824|Crizotinib
300250|NCT01500824|ALK
300251|NCT01500824|NSCLC
300252|NCT01500824|Non-Small Cell Lung Cancer
300253|NCT01500824|Asian
300254|NCT01500811|chondrocyte hip osteoarthritis intra articular injection
300255|NCT01500772|Hepatitis C
300256|NCT01500772|PI treatment failure
300257|NCT01500759|chronic heart failure
300258|NCT01500759|heart failure
300259|NCT01500759|hf
300260|NCT01500759|sleep-disordered breathing
300261|NCT01500759|sdb
300262|NCT01500759|nyha
300263|NCT01500759|lvef
300264|NCT01500759|cheyne stokes
300265|NCT01500759|central sleep apnoea
300266|NCT01500759|sleep apnoea
300267|NCT01500746|chronic wound treatment
300268|NCT01500746|pulse lavage
300269|NCT01500746|serial pulse lavage
300270|NCT01500746|wounds
300271|NCT01500746|bacterial colonization of wounds
300272|NCT01500733|Treatment
300273|NCT01500733|CLL (Chronic Lymphocytic Leukemia)
300274|NCT01500733|SLL (Small Lymphocytic Lymphoma)
300275|NCT01500733|Leukemia
300276|NCT01500733|Lymphocytic Leukemia
300277|NCT01500733|Chronic Lymphocytic Leukemia
300278|NCT01500733|CLL
300279|NCT01500733|Small Lymphocytic Leukemia
300280|NCT01500733|SLL
300281|NCT01500668|Botox
300282|NCT01500668|catocholamine
300283|NCT01500668|shock
300284|NCT01500668|vasomotor
300285|NCT01500668|Vasopressin
300286|NCT01500668|botulinum toxin
300287|NCT01500655|burn
300288|NCT01500655|skin graft donor site
300289|NCT01500655|analgesia for donor site
300290|NCT01500629|Allergic Rhinitis
300291|NCT01500629|Hayfever
300292|NCT01500629|Pollen Allergy
300293|NCT01500616|Chronic Hepatitis C Infection
300294|NCT01500616|Chronic Hepatitis C Co-Infected Patients
300295|NCT01500616|Hepatitis C
300296|NCT01500616|Severe Fibrosis
300297|NCT01500616|Compensated Cirrhosis
300298|NCT01500616|VX-950HPC3005
300299|NCT01500603|post-radical prostatectomy
300300|NCT01500603|stress urinary incontinence
300301|NCT01500603|periurethral Pro-ACT balloons
300302|NCT01500603|AdvanceXP retrourethral male sling
300303|NCT01500590|Diabetes
300304|NCT01500590|hypertensive
300305|NCT01500590|without albuminuria
300306|NCT01500577|Prevention
300307|NCT01500577|Breast Cancer
300308|NCT01500577|Proliferation
300309|NCT01500577|Breast Cancer Prevention
300310|NCT01500343|heart failure
300311|NCT01500343|probiotics
300312|NCT01500343|Saccharomyces boulardii
300313|NCT01500343|cardio-intestinal syndrome
300314|NCT01500343|gut
300315|NCT01500343|inflammation
300316|NCT01500317|tapentadol
300317|NCT01500317|oxycodone
300318|NCT01500317|mu-opiate
300319|NCT01500317|stomach
300320|NCT01500317|small intestine
300321|NCT01500317|colon
300322|NCT01500317|motility
300323|NCT01500317|nausea
300324|NCT01500317|constipation
300325|NCT01500304|Melanoma
300326|NCT01500304|Lymph Nodes
300327|NCT01500304|Lymph Node Dissection
300328|NCT01500304|Minimally invasive
300329|NCT01500291|anesthesia stress
300330|NCT01500278|Certolizumab Pegol
300331|NCT01500278|Cimzia
300332|NCT01500278|Adalimumab
300333|NCT01500278|Humira
300334|NCT01500278|Rheumatoid Arthritis
300335|NCT01500265|hepatitis B virus
300336|NCT01500265|early screening tools
300337|NCT01500265|renal proximal tubular tolerance
300338|NCT01500252|Total Knee Replacement
300339|NCT01500252|Patellar Resurfacing
300340|NCT01500252|Health Related Quality of Life
300341|NCT01500226|Rolapitant
300342|NCT01500226|Nausea
300343|NCT01500226|Vomiting
300344|NCT01500226|CINV
300345|NCT01500226|Chemotherapy
300346|NCT01500213|Rolapitant
300347|NCT01500213|Nausea
300348|NCT01500213|Vomiting
300349|NCT01500213|CINV
300350|NCT01500213|Chemotherapy
300351|NCT01500187|white spot lesions
300352|NCT01500187|fixed orthodontic brackets
300353|NCT01500187|fluoride varnish
300354|NCT01500187|fluoride gel
300355|NCT01500174|skin
300356|NCT01500174|decubitus
300357|NCT01500174|pressure
300358|NCT01500174|sore
300359|NCT01500174|spinal cord injury
300360|NCT01500161|Leukemia
300361|NCT01500161|Lymphoma
300362|NCT01500161|Myeloma
300363|NCT01500161|Aplastic Anemia
300364|NCT01500161|Myelodysplasia
300365|NCT01500161|AML
300366|NCT01500161|ALL
300367|NCT01500161|CLL
300368|NCT01500161|CML
300369|NCT01500148|Mitral Valve Prolapse
300370|NCT01500148|Mitral Valve Disease
300371|NCT01500148|Mitral Valve Regurgitation
300372|NCT01500148|Mitral Valve Insufficiency
300373|NCT01500148|Mitral Valve Incompetence
300374|NCT01500148|Percutaneous Mitral Valve Repair
300375|NCT01500148|Posterior leaflet prolapse
300376|NCT01500148|Mitral valve degeneration
300377|NCT01500135|Vascular Surgery
300378|NCT01500135|Secondary treatment of needle hole bleeding
300503|NCT01499667|health outcomes
300379|NCT01500135|Subjects undergoing vascular surgery and who need supportive treatment in order to control bleeding
300380|NCT01500109|cleft palate surgery
300381|NCT01500109|post-operative pain management
300382|NCT01500109|Acetaminophen
300383|NCT01500096|Fatigue
300384|NCT01500096|HIV/AIDS
300385|NCT01500096|American ginseng
300386|NCT01500096|Panax quinquefolius
300387|NCT01500096|Fatigue Severity Scale
300388|NCT01500096|CD4 count
300389|NCT01500096|plasma HIV RNA
300390|NCT01500096|cytokines
300391|NCT01500096|IL-6
300392|NCT01500096|sTNFR1
300393|NCT01500096|sTNFR2
300394|NCT01500083|iNHL
300395|NCT01500083|CLL
300396|NCT01500070|Peripheral Arterial Disease
300397|NCT01500070|Claudication
300398|NCT01500070|Drug-Eluting Stent
300399|NCT01500070|BTK
300400|NCT01500070|Everolimus
300401|NCT01500070|CLI
300402|NCT01500057|enlarged prostate
300403|NCT01500044|Radiculopathy
300404|NCT01500044|Rehabilitation
300405|NCT01500044|Mobilization
300406|NCT01500044|Exercise
300407|NCT01500044|Physical Therapy
300408|NCT01500018|Phase I
300409|NCT01500018|healthy recreational polydrug users
300410|NCT01500018|abuse liability
300411|NCT01500018|TC-5214
300412|NCT01500018|Single dose crossover study to evaluate the abuse potential of TC-5214
300413|NCT01499992|Shoulder rehabilitation
300414|NCT01499992|Rotator cuff tear
300415|NCT01499992|Physiotherapy
300416|NCT01499992|aqua therapy
300417|NCT01499992|Therapy dosage
300418|NCT01499992|adjunctive aquatic physical therapy
300419|NCT01499979|Ischemia-reperfusion injury
300420|NCT01499979|In situ hypothermic perfusion
300421|NCT01499979|In situ hypothermic preservation
300422|NCT01499966|Lateral Ankle Sprain
300423|NCT01499966|Plaster of Paris
300424|NCT01499966|Tubigrip
300425|NCT01499953|superficial vein thrombosis
300426|NCT01499953|thrombosis
300427|NCT01499953|SVT
300428|NCT01499940|peripheral neuropathy
300429|NCT01499940|vitamin D status
300430|NCT01499940|oxaliplatin
300431|NCT01499927|Early reassessment of intravenous antiinfective therapy
300432|NCT01499914|vaccination H1N1
300433|NCT01499914|cystic fibrosis
300434|NCT01499901|deafness
300435|NCT01499901|unilateral implantation
300436|NCT01499901|bilateral
300437|NCT01499901|auditory perception
300438|NCT01499888|Sickle Cell Disease
300439|NCT01499888|Subtype Hgb SS
300440|NCT01499888|Subtype Hgb SC
300441|NCT01499888|Subtype Hgb SB
300442|NCT01499888|Chronic Transfusion Therapy
300443|NCT01499888|Prior Stroke
300444|NCT01499888|Allogeneic
300445|NCT01499888|Stem Cell Transplantation
300446|NCT01499888|Alemtuzumab
300447|NCT01499888|Sirolimus
300448|NCT01499888|Total Body Irradiation
300449|NCT01499888|Hydroxyurea Intolerant
300450|NCT01499875|Pharmacokinetic
300451|NCT01499875|Pharmacodynamic
300452|NCT01499875|Phenoxymethylpenicillin
300453|NCT01499875|Children
300454|NCT01499862|Stroke
300455|NCT01499862|Tibion
300456|NCT01499862|Bionics
300457|NCT01499862|Rehab
300458|NCT01499862|Therapy
300459|NCT01499862|Robotics
300460|NCT01499862|Intention
300461|NCT01499849|Rolapitant
300462|NCT01499849|Nausea
300463|NCT01499849|Vomiting
300464|NCT01499849|CINV
300465|NCT01499849|Chemotherapy
300466|NCT01499823|Permeability Map
300467|NCT01499823|High-Grade Glioma
300468|NCT01499810|Hypertension
300469|NCT01499810|Radiofrequency Catheter Ablation
300470|NCT01499810|Renal Artery
300471|NCT01499810|Sympathetic Nerve Block
300472|NCT01499797|frailty
300473|NCT01499797|frail elders
300474|NCT01499797|multicomponent intervention
300475|NCT01499797|overall functioning
300476|NCT01499797|cost-effectiveness
300477|NCT01499797|integrated care
300478|NCT01499797|primary care
300479|NCT01499797|community dwelling
300480|NCT01499745|Idiopathic pulmonary fibrosis (IPF) patients
300481|NCT01499732|Premature endothelial dysfunction
300482|NCT01499732|Early Rheumatoid Arthritis
300483|NCT01499732|established rheumatoid arthritis
300484|NCT01499732|Premature endothelial dysfunction in early rheumatoid arthritis
300485|NCT01499732|Premature endothelial dysfunction in established rheumatoid arthritis
300486|NCT01499732|Endothelial function in healthy subjects
300487|NCT01499719|Sinusitis
300488|NCT01499719|Disease
300489|NCT01499719|Chronic
300490|NCT01499719|Sinonasal
300491|NCT01499706|Motivational Interviewing
300492|NCT01499706|Telephone
300493|NCT01499706|HIV
300494|NCT01499706|AIDS
300495|NCT01499706|Older Adults
300496|NCT01499693|Proton Pump Inhibitors
300497|NCT01499693|gastric pH
300498|NCT01499680|Degenerative Lumbar Conditions
300499|NCT01499667|Relapsing remitting multiple sclerosis
300500|NCT01499667|multiple sclerosis (MS)
300501|NCT01499667|safety
300502|NCT01499667|tolerability
300504|NCT01499667|fingolimod
300505|NCT01499667|disease control
300506|NCT01499667|MRI
300507|NCT01499654|SPECT MPI
300508|NCT01499654|Tomography, Emission-Computed, Single-Photon
300509|NCT01499654|Wide Beam Reconstruction
300510|NCT01499641|discectomy
300511|NCT01499641|methylprednisolone
300512|NCT01499641|randomized control trial
300513|NCT01499615|adverse events
300514|NCT01499615|adverse cardiovascular events
300515|NCT01499615|early warning
300516|NCT01499602|Endometrial hyperplasia,
300517|NCT01499602|LNG-IUS,
300518|NCT01499602|Progestin
300519|NCT01499589|anesthesia-controlled time
300520|NCT01499589|turnover time
300521|NCT01499576|Mass Screening
300522|NCT01499576|Endoscopy, Gastrointestinal
300523|NCT01499576|Stomach Neoplasms
300524|NCT01499576|Metaplasia
300525|NCT01499576|Diagnosis
300526|NCT01499576|Acetic acid
300527|NCT01499576|Chromoendoscopy
300528|NCT01499550|transnasal high flow therapy
300529|NCT01499550|COPD
300530|NCT01499537|Stenosis of biliary ways
300531|NCT01499524|ICP, GDM
300532|NCT01499511|Hypertension
300533|NCT01499511|Mortality
300534|NCT01499511|Morbidity
300535|NCT01499511|Coronary Heart Disease
300536|NCT01499511|Stroke
300537|NCT01499511|Diabetes
300538|NCT01499498|Healthy volunteers
300539|NCT01499485|Pulmonary Disease, Chronic Obstructive
300540|NCT01499485|Obesity Hypoventilation Syndrome
300541|NCT01499485|Alkalosis
300542|NCT01499485|Respiration, Artificial
300543|NCT01499485|Acetazolamide
300544|NCT01499485|Intensive care
300545|NCT01499485|Adult
300546|NCT01499459|liver cirrhosis
300547|NCT01499459|autologous mesenchymal stem cell transplantation
300548|NCT01499342|Stent
300549|NCT01499342|Atherosclerotic occlusive disease
300550|NCT01499342|Peripheral arterial disease
300551|NCT01499342|Superficial femoral artery
300552|NCT01499342|SFA
300553|NCT01499329|Stent therapy
300554|NCT01499316|Coronary artery disease
300555|NCT01499316|Fractional flow reserve
300556|NCT01499303|lymphoma
300557|NCT01499303|DLBCL
300558|NCT01499303|fostamatinib
300559|NCT01499303|Diffuse Large B-Cell Lymphoma (DLBCL)
300560|NCT01499290|Ceftazidime
300561|NCT01499290|Meropenem
300562|NCT01499290|Metronidazole
300563|NCT01499290|Anti-Bacterial Agents
300564|NCT01499290|Anti-Infective Agents
300565|NCT01499290|Antiprotozoal Agents
300566|NCT01499290|Antiparasitic Agents
300567|NCT01499290|cIAI, Complicated Intra-Abdominal Infection
300568|NCT01499277|complicated skin and soft tissue infections (cSSTI)
300569|NCT01499277|skin infection
300570|NCT01499277|ceftaroline
300571|NCT01499277|wound infection
300572|NCT01499277|cellulitis
300573|NCT01499277|burn infection
300574|NCT01499277|bacterial infection
300575|NCT01499277|vancomycin
300576|NCT01499264|MySkin patch
300577|NCT01499251|glioblastoma
300578|NCT01499238|Efficacy
300579|NCT01499238|safety
300580|NCT01499238|nasal SIMV
300581|NCT01499238|nasal CPAP
300582|NCT01499238|infants who are >35 gestational week with wet lung
300583|NCT01499199|cerebrospinal fluid (CSF)
300584|NCT01499199|ART-naive
300585|NCT01499199|integrase inhibitor
300586|NCT01499199|dolutegravir
300587|NCT01499199|antiretroviral therapy naive
300588|NCT01499186|Local vibration, elderly, bone, muscle, functionality
300589|NCT01499160|endocrine resistant
300590|NCT01499160|everolimus
300591|NCT01499160|lapatinib
300592|NCT01499160|letrozole
300593|NCT01499147|Acute myeloid leukemia
300594|NCT01499147|First remission
300595|NCT01499147|Acute lymphocytic leukemia
300596|NCT01499147|Acute leukemia
300597|NCT01499147|Second remission
300598|NCT01499147|Early relapse
300599|NCT01499147|Partial remission
300600|NCT01499147|Chronic myelogenous leukemia
300601|NCT01499147|Accelerated phase
300602|NCT01499147|Blast-crisis
300603|NCT01499147|Chronic phase
300604|NCT01499147|Recurrent malignant lymphoma
300605|NCT01499147|Refractory malignant lymphoma
300606|NCT01499147|Hodgkin's disease
300607|NCT01499147|Multiple myeloma.
300608|NCT01499147|Chronic lymphocytic leukemia
300609|NCT01499147|Myeloproliferative disorder
300610|NCT01499147|Polycythemia vera
300611|NCT01499147|Myelofibrosis
300612|NCT01499147|Severe aplastic anemia
300613|NCT01499108|type 2 diabetes
300614|NCT01499108|hypertension
300615|NCT01499108|liraglutide
300616|NCT01499108|kidney function
300617|NCT01499056|osteoarthritis
300618|NCT01499056|hip joint
300619|NCT01499056|mesenchymal stem cell
300620|NCT01499043|CRPC
300621|NCT01499043|Prostate Cancer
300622|NCT01499043|Bone metastasis
300623|NCT01499043|Advanced Castration-Resistant Prostate Cancer (CRPC)
300624|NCT01499017|Single Ascending Dose Study in healthy subjects
300625|NCT01499004|tofacitinib
300626|NCT01499004|CP-690
300627|NCT01499004|550
300628|NCT01499004|relative bioavailability
300629|NCT01499004|modified release
300630|NCT01499004|Phase 1
300631|NCT01498991|Incomplete Spinal Cord Injury
300632|NCT01498991|Rehabilitation
300633|NCT01498991|AMES device
300634|NCT01498991|Lower Extremity
300635|NCT01498991|Gait
300636|NCT01498991|Paraplegia
300637|NCT01498965|food allergy
300638|NCT01498965|eczema
300639|NCT01498965|Vitamin D status
300640|NCT01498965|body composition
300641|NCT01498965|obesity
300642|NCT01498965|neurodevelopmental and behavioural outcome
300643|NCT01498952|HCC, liver cancer, hepatocellular carcinoma, MEDI-573, anti-IGF
300644|NCT01498887|Multiple Sclerosis
300645|NCT01498887|Relapsing Remitting Multiple Sclerosis
300646|NCT01498887|Fingolimod
300647|NCT01498887|Early multiple sclerosis
300648|NCT01498887|Naive patients
300649|NCT01498874|Acne
300650|NCT01498874|Acne Vulgaris
300651|NCT01498835|Soft tissue sarcoma
300652|NCT01498835|Radiation therapy
300653|NCT01498835|Sunitinib
300654|NCT01498822|Levetiracetam
300655|NCT01498822|Oxcarbazepine
300656|NCT01498822|treatment failure
300657|NCT01498822|partial epilepsy
300658|NCT01498809|Orthostatic intolerance in people with spinal cord injury
300659|NCT01498744|Skin and Soft Tissue Abscess
300660|NCT01498744|Methicillin-resistant Staphylococcus aureus (MRSA)
300661|NCT01498744|Incision and Drainage
300662|NCT01498744|Clindamycin
300663|NCT01498744|Trimethoprim-sulfamethoxazole
300664|NCT01498744|Skin Infection
300665|NCT01498731|Copeptin
300666|NCT01498731|Troponin
300667|NCT01498731|Acute Coronary Syndrome
300668|NCT01498731|Rule-out of acute myocardial infarction
300669|NCT01498731|Emergency Medicine
300670|NCT01498718|Influenza A (H1N1)
300671|NCT01498718|Influenza A (H3N2)
300672|NCT01498718|Influenza B
300673|NCT01498718|Trivalent Inactivated Vaccine (TIV)
300674|NCT01498718|Healthy Adults
300675|NCT01498705|Intraventricular Hemorrhage
300676|NCT01498705|Intracerebral Hemorrhage
300677|NCT01498705|Cerebrovascular Disorders
300678|NCT01498705|Brain Diseases
300679|NCT01498705|Central Nervous System Diseases
300680|NCT01498705|Nervous System Diseases
300681|NCT01498705|Vascular Diseases
300682|NCT01498705|Procalcitonin Level
300683|NCT01498692|drug-eluting stents
300684|NCT01498692|DES
300685|NCT01498692|atherosclerotic
300686|NCT01498640|XIAFLEX
300687|NCT01498640|XIAPEX
300688|NCT01498640|Dupuytren's disease
300689|NCT01498640|contracture
300690|NCT01498627|Autoimmune diseases (AIDs)
300691|NCT01498627|Cervarix
300692|NCT01498627|PGRx information system
300693|NCT01498614|Diabetes mellitus
300694|NCT01498614|depression
300695|NCT01498614|anxiety
300696|NCT01498614|negative self image
300697|NCT01498614|alexithymia
300698|NCT01498614|metabolic control
300699|NCT01498614|diabetes complications
300700|NCT01498601|oral hygiene
300701|NCT01498601|tracheostomy
300702|NCT01498601|deglutition disorders
300703|NCT01498601|enteral nutrition
300704|NCT01498601|brain injury
300705|NCT01498601|coma
300706|NCT01498588|Breast Neoplasms
300707|NCT01498588|Breast Cancer
300708|NCT01498588|Breast Tumors
300709|NCT01498588|Cancer of the Breast
300710|NCT01498588|Neoplasms, Breast
300711|NCT01498588|Tumors, Breast
300712|NCT01498575|Teen driving
300713|NCT01498575|Behind the wheel practice driving
300714|NCT01498575|Parent supervision
300715|NCT01498549|Abstinent cocaine users
300716|NCT01498549|cognitive testing
300717|NCT01498523|Camel milk
300718|NCT01498523|Postprandial glycaemic response
300719|NCT01498523|postprandial insulinaemic response
300720|NCT01498523|Glycaemic index
300721|NCT01498510|chronic pain
300722|NCT01498510|cognitive behavior therapy
300723|NCT01498510|web-based intervention
300724|NCT01498484|EBV-specific T-cell lines
300725|NCT01498484|11-130
300726|NCT01498458|German Breast Group
300727|NCT01498458|GBG Forschungs GmbH
300728|NCT01498458|GBG
300729|NCT01498458|GBG 62
300730|NCT01498458|PazoX
300731|NCT01498458|Breast Cancer
300732|NCT01498458|Metastatic Breast Cancer
300733|NCT01498458|Pazopanib
300734|NCT01498458|Abraxane
300735|NCT01498458|Capecitabine
300736|NCT01498458|Xeloda
300737|NCT01498445|Leukemia
300738|NCT01498445|Chronic myelogenous leukemia
300739|NCT01498445|Chronic myeloid leukemia
300740|NCT01498445|CML
300741|NCT01498445|Accelerated phase
300742|NCT01498445|Blastic phase
300743|NCT01498445|Dasatinib
300744|NCT01498445|BMS-354825
300745|NCT01498445|Sprycel
300746|NCT01498445|Decitabine
300747|NCT01498445|Dacogen
300748|NCT01498419|Tuberculosis
300749|NCT01498419|Serial Sputum Colony Counts
300750|NCT01498419|Colony Forming Units
300751|NCT01498419|Time to Sputum Culture Positivity
300752|NCT01498419|PA824
300753|NCT01498419|pretomanid
300754|NCT01498406|cutaneous lupus erythematosus
300755|NCT01498406|vitamin D
300756|NCT01498406|quality of life
300757|NCT01498393|fungal nail
300758|NCT01498380|Dexmedetomidine
300759|NCT01498380|Precedex
300760|NCT01498380|TIVA
300761|NCT01498380|Rapid bolus
300762|NCT01498367|Diabetes Mellitus, Type 2
300763|NCT01498367|Telemedicine
300764|NCT01498354|Transanal endoscopic microsurgery
300765|NCT01498354|Transanal endoscopic operations
300766|NCT01498354|Rectal adenomas
300767|NCT01498354|Transanal endoscopic surgery
300768|NCT01498354|"Rectal adenocarcinomas in situ"
300769|NCT01498341|Hypoparathyroidism
300770|NCT01498341|Epidemiology
300771|NCT01498341|Prognosis
300772|NCT01498341|Symptoms
300773|NCT01498328|EGFRvIII
300774|NCT01498328|Glioblastoma
300775|NCT01498328|Rindopepimut
300776|NCT01498328|CDX-110
300777|NCT01498328|Small cell
300778|NCT01498328|Giant cell
300779|NCT01498328|Brain Cancer
300780|NCT01498328|Brain Tumor
300781|NCT01498328|Gliosarcoma
300782|NCT01498328|oligodendroglial
300783|NCT01498328|radiotherapy
300784|NCT01498328|chemoradiation
300785|NCT01498328|Tumor
300786|NCT01498328|Bevacizumab
300787|NCT01498328|Relapsed
300788|NCT01498328|Returned
300789|NCT01498328|Recurrent
300790|NCT01498328|EGFR variant III
300791|NCT01498302|childhood acute myeloid leukemia/other myeloid malignancies
300792|NCT01498289|recurrent esophageal cancer
300793|NCT01498289|stage IV esophageal cancer
300794|NCT01498289|recurrent gastric cancer
300795|NCT01498289|stage IV gastric cancer
300796|NCT01498289|adenocarcinoma of the gastroesophageal junction
300797|NCT01498289|stage IIIB gastric cancer
300798|NCT01498289|stage IIIC gastric cancer
300799|NCT01498289|stage IIIB esophageal cancer
300800|NCT01498289|stage IIIC esophageal cancer
300801|NCT01498289|adenocarcinoma of the esophagus
300802|NCT01498289|adenocarcinoma of the stomach
300803|NCT01498276|Family History
300804|NCT01498276|Family Health History
300805|NCT01498276|Disease Risk Assessment
300806|NCT01498263|Family Systems
300807|NCT01498263|Caregiving
300808|NCT01498263|Alzheimer Disease
300809|NCT01498263|Family History
300810|NCT01498263|Alzheimer's Disease
300811|NCT01498263|AD
300812|NCT01498237|Photoacoustic endoscopy
300813|NCT01498224|Cataract surgery
300814|NCT01498211|volunteer
300815|NCT01498198|Rotator Cuff
300816|NCT01498198|WCB
300817|NCT01498172|Non muscle invasive bladder cancer
300818|NCT01498159|Diabetes Mellitus
300819|NCT01498159|Pharmacists
300820|NCT01498159|Community Health Aides
300821|NCT01498146|cryptogenic stroke
300822|NCT01498146|atrial fibrillation
300823|NCT01498146|longterm monitoring
300824|NCT01498146|loop recorder
300825|NCT01498133|Skin-to-skin contact
300826|NCT01498133|Decolonization
300827|NCT01498133|MRSA
300828|NCT01498120|Rotigotine
300829|NCT01498120|Restless Legs Syndrome
300830|NCT01498120|RLS
300831|NCT01498120|Long-term
300832|NCT01498120|Adolescents
300833|NCT01498107|online intervention
300834|NCT01498107|computerized CBT
300835|NCT01498107|e-health
300836|NCT01498094|Bronchiolitis
300837|NCT01498094|High
300838|NCT01498094|Flow
300839|NCT01498094|Oxygen
300840|NCT01498094|Therapy
300841|NCT01498094|Nasal
300842|NCT01498094|Cannulae
300843|NCT01498094|Prongs
300844|NCT01498081|COPD, pulmonary disease
300845|NCT01498068|Genotype 1 chronic Hepatitis C
300846|NCT01498068|VX-950HPC3007
300847|NCT01498068|VX-950
300848|NCT01498068|Hepatitis C
300849|NCT01498068|Telaprevir
300850|NCT01498068|HCV
300851|NCT01498055|lung cancer
300852|NCT01498055|CIK cells
300853|NCT01498055|therapy
300854|NCT01498029|Cartilage, Articular
300855|NCT01498016|acute leukemia
300856|NCT01498016|allogeneic stem cell transplantation
300857|NCT01498016|busulfan
300858|NCT01498003|coronary disease
300859|NCT01498003|stents
300860|NCT01498003|thrombosis
300861|NCT01498003|myocardial infarction
300862|NCT01498003|prognosis
300863|NCT01497990|Burns
300864|NCT01497990|Ertapenem
300865|NCT01497990|Pharmacokinetics
300866|NCT01497977|phytoestrogens
300867|NCT01497977|postmenopause
300868|NCT01497977|serum lipids
300869|NCT01497925|Arginine deiminase
300870|NCT01497925|Arginine
300871|NCT01497925|Solid tumors
300872|NCT01497925|Prostate cancer
300873|NCT01497925|Phase 1 study
300874|NCT01497899|HIV-1
300875|NCT01497899|HIV
300876|NCT01497899|Treatment-Naive
300877|NCT01497886|Stroke
300878|NCT01497886|Children
300879|NCT01497886|Hip Hop Stroke
300880|NCT01497886|New York City
300881|NCT01497873|Small Cell Lung Cancer
300882|NCT01497873|Belotecan
300883|NCT01497873|Topotecan
300884|NCT01497860|pediatric
300885|NCT01497860|children
300886|NCT01497860|glioma
300887|NCT01497860|low-grade
300888|NCT01497860|vinorelbine
300889|NCT01497860|recurrent
300890|NCT01497860|progressive
300891|NCT01497847|Post-Infectious Irritable Bowel Syndrome
300892|NCT01497847|PI-IBS
300893|NCT01497834|Hepatitis C Virus Infection
300894|NCT01497821|Amgen
300895|NCT01497821|Phase 1
300896|NCT01497821|First in Human
300897|NCT01497821|Relapsed / Refractory Renal Cell Carcinoma (RCC)
300898|NCT01497821|Kidney Cancer
300899|NCT01497821|Clinical Trial
300900|NCT01497821|Antibody drug conjugate (ADC)
300901|NCT01497821|Open-label
300902|NCT01497821|Oncology
300903|NCT01497808|previously untreated
300904|NCT01497808|previously treated
300905|NCT01497808|bone, lung, liver or subcutaneous involvement
300906|NCT01497808|nodal involvement
300907|NCT01497808|without evidence of brain involvement
300908|NCT01497782|virtual reality, simulator, feedback, laparoscopy, training
300909|NCT01497769|vaccine
300910|NCT01497769|immunogenicity
300911|NCT01497743|Scleroderma
300912|NCT01497743|gastrointestinal
300913|NCT01497743|bloating
300914|NCT01497743|reflux
300915|NCT01497730|Arthroplasty, Replacement, Knee,
300916|NCT01497704|Cancer
300917|NCT01497704|Tumor
300918|NCT01497704|Oncology
300919|NCT01497704|Antiangiogenesis
300920|NCT01497691|Asthma
300921|NCT01497691|Pediatrics
300922|NCT01497691|BiPAP
300923|NCT01497691|Noninvasive Positive Pressure Ventilation
300924|NCT01497678|MTURR
300925|NCT01497678|ECM
300926|NCT01497678|Muscle Loss
300927|NCT01497678|Tendon
300928|NCT01497678|Tendon Repair
300929|NCT01497678|Muscle Repair
300930|NCT01497678|Soft Tissue Repair
300931|NCT01497678|Scaffold
300932|NCT01497678|Extracellular Matrix
300933|NCT01497665|GRN1005
300934|NCT01497665|ANG1005
300935|NCT01497665|LRP-1
300936|NCT01497665|Targeted Therapy
300937|NCT01497665|Brain Tumor
300938|NCT01497665|Blood Brain Barrier
300939|NCT01497665|Peptide-Drug Conjugate (PDC)
300940|NCT01497665|Brain Metastases
300941|NCT01497665|Paclitaxel
300942|NCT01497665|Taxol
300943|NCT01497665|NSCLC
300944|NCT01497665|Non-Small Cell Lung Cancer
300945|NCT01497652|Parkinson's Disease
300946|NCT01497652|Cognition
300947|NCT01497652|Rasagiline
300948|NCT01497652|MoCA
300949|NCT01497652|Mild Cognitive Impairment in Parkinson's Disease
300950|NCT01497639|dystonia
300951|NCT01497639|pallidal stimulation
300952|NCT01497639|deep brain stimulation
300953|NCT01497639|deep brain stimulation of GPi
300954|NCT01497639|GPi
300955|NCT01497639|interleaving stimulation
300956|NCT01497626|Advanced cancer
300957|NCT01497626|Solid tumor
300958|NCT01497613|Socialization
300959|NCT01497613|Well-being
300960|NCT01497613|Quality of Life
300961|NCT01497613|Connectivity
300962|NCT01497548|Depression
300963|NCT01497548|cancer
300964|NCT01497548|methylphenidate
300965|NCT01497548|pharmacotherapy
300966|NCT01497522|Vildagliptin
300967|NCT01497522|Type 2 diabetes
300968|NCT01497522|HbA1c
300969|NCT01497522|Fasting plasma glucose
300970|NCT01497496|leukemia
300971|NCT01497496|lymphoma
300972|NCT01497496|consolidative therapy
300973|NCT01497496|combination regimen
300974|NCT01497496|Chronic Lymphocytic Leukemia (CLL)
300975|NCT01497496|Small Lymphocytic Lymphoma (SLL)
300976|NCT01497470|paclitaxel
300977|NCT01497470|carboplatin
300978|NCT01497470|custirsen
300979|NCT01497470|drug-drug interaction
300980|NCT01497470|pharmacokinetics
300981|NCT01497470|cancer
300982|NCT01497444|recurrent adult primary liver cancer
300983|NCT01497444|recurrent renal cell cancer
300984|NCT01497444|advanced adult primary liver cancer
300985|NCT01497444|localized unresectable adult primary liver cancer
300986|NCT01497444|adult primary hepatocellular carcinoma
300987|NCT01497405|Gender-based Violence
300988|NCT01497405|HIV
300989|NCT01497405|Randomized Controlled Trial
300990|NCT01497405|Sexually Transmitted Diseases
300991|NCT01497405|Substance Abuse Detection
300992|NCT01497405|Test, Treat and Retain
300993|NCT01497379|Hereditary retinal
300994|NCT01497379|degeneration outer
300995|NCT01497379|retinal layers,
300996|NCT01497379|photoreceptor rods cones,
300997|NCT01497379|Retinitis pigmentosa,
300998|NCT01497379|blindness,
300999|NCT01497379|reading ability,
301000|NCT01497379|retina implant,
301001|NCT01497379|subretinal
301002|NCT01497366|HCV genotype 2 (GT-2)
301003|NCT01497366|HCV genotype 3 (GT-3)
301004|NCT01497353|Cord clamping
301005|NCT01497353|newborn
301006|NCT01497353|Skin contact
301007|NCT01497353|Placental transfusion
301008|NCT01497353|Delivery room
301009|NCT01497340|Cord clamping
301010|NCT01497340|newborn
301011|NCT01497340|Placental trasfusion
301012|NCT01497340|Delivery room
301013|NCT01497327|HEPATITIS C, CHRONIC
301014|NCT01497327|HCV
301015|NCT01497327|hepatic impairment
301016|NCT01497314|healthy term infants
301017|NCT01497314|growth
301018|NCT01497314|infant formula
301019|NCT01497301|Diabetes
301020|NCT01497301|Group Visit
301021|NCT01497301|Shared Medical Appointment
301022|NCT01497288|Intranasal fentanyl spray
301023|NCT01497288|Population PK
301024|NCT01497262|Multiple Sclerosis
301025|NCT01497262|Relapsing-Remitting
301026|NCT01497249|Dietary Fiber
301027|NCT01497249|Blood glucose control
301028|NCT01497249|Fermentability
301029|NCT01497249|Tolerability
301030|NCT01497223|Phase II
301031|NCT01497223|Double-Blind
301032|NCT01497223|Placebo-Controlled
301033|NCT01497223|Vulvovaginal Candidiasis
301034|NCT01497223|Moderate to Severe
301035|NCT01497223|Acute
301036|NCT01497223|Treatment of Moderate to Severe Vulvovaginal Candidiasis
301037|NCT01497197|Reproduction Techniques
301038|NCT01497197|Reproductive Medicine
301039|NCT01497197|Assisted Reproductive Technics
301040|NCT01497197|Pregnancy Rate
301041|NCT01497197|Ovulation Induction
301042|NCT01497197|Ovarian Stimulation
301043|NCT01497197|Oocytes
301044|NCT01497197|Implantation
301045|NCT01497184|Leukemia
301046|NCT01497184|Lymphoma
301047|NCT01497184|Allogeneic donor lymphocyte infusion
301048|NCT01497184|DLI
301049|NCT01497184|Hematopoietic Stem Cell Transplantation
301050|NCT01497184|HSCT
301051|NCT01497184|Bone marrow transplant
301052|NCT01497184|CD19-specific T cells
301053|NCT01497184|T cell infusion
301054|NCT01497184|B-Lineage lymphoid malignancies
301055|NCT01497184|CD19+ lymphoid malignancies
301056|NCT01497184|Acute lymphoblastic leukemia
301057|NCT01497184|ALL
301058|NCT01497184|Biphenotypic leukemia CD19+ in advanced remission
301059|NCT01497184|Non-Hodgkin's Lymphoma
301060|NCT01497184|NHL
301061|NCT01497184|Diffuse large B-cell lymphoma
301062|NCT01497184|Small lymphocytic lymphoma
301063|NCT01497184|Follicular lymphoma
301064|NCT01497184|Mantle cell lymphoma with active disease at time of transplant
301065|NCT01497171|Cystocele
301066|NCT01497171|Bladder prolapse
301067|NCT01497171|Anterior prolapse
301068|NCT01497171|Vaginal prolapse
301069|NCT01497171|Uterine prolapse
301070|NCT01497171|Urinary incontinence
301071|NCT01497158|tobacco cessation
301072|NCT01497119|Moderate atopic dermatitis
301073|NCT01497119|JNJ-39758979
301074|NCT01497119|Japanese patients
301075|NCT01497106|Insulin resistance
301076|NCT01497106|Abdominal obesity
301077|NCT01497106|Calorie restriction
301078|NCT01497093|Myeloma
301079|NCT01497093|Multiple Myeloma
301080|NCT01497093|Relapsed Multiple Myeloma
301081|NCT01497093|Relapsed and Refractory Multiple Myeloma
301082|NCT01497093|Refractory Myeloma
301083|NCT01497093|Resistant Multiple Myeloma
301084|NCT01497093|Treatment-resistant Multiple Myeloma
301085|NCT01497093|Pomalidomide
301086|NCT01497093|Lenalidomide-resistant
301087|NCT01497080|distal radius fracture
301088|NCT01497080|Condition
301089|NCT01497080|risk factors
301090|NCT01497080|adverse activity transitions following DRF
301091|NCT01497080|optimal assessment approach
301092|NCT01497054|B type natriuretic peptide
301093|NCT01497054|Patent Ductus Arteriosus
301094|NCT01497054|Preterm infant
301095|NCT01497028|Co-morbid disease resolution
301096|NCT01497002|AML
301097|NCT01496989|HIV
301098|NCT01496989|AIDS
301099|NCT01496989|HIV vaccine
301100|NCT01496989|HIV prevention
301101|NCT01496976|leukemia
301102|NCT01496976|lymphoma
301103|NCT01496976|consolidative therapy
301104|NCT01496976|combination regimen
301105|NCT01496976|CLL
301106|NCT01496976|SLL
301107|NCT01496963|Thalassemia
301108|NCT01496963|Pulmonary Arterial Hypertension
301109|NCT01496950|migraine
301110|NCT01496924|Dysphagia
301111|NCT01496924|Intensive care units
301112|NCT01496924|Deglutition disorders
301113|NCT01496924|Rehabilitation
301114|NCT01496911|Diving
301115|NCT01496911|Drugs
301116|NCT01496911|Antihistamines
301117|NCT01496911|Performance
301118|NCT01496898|Microflora
301119|NCT01496898|Vaginal
301120|NCT01496898|Cervical
301121|NCT01496898|Uterine
301122|NCT01496898|Inflammation
301123|NCT01496898|Cytokine
301124|NCT01496898|Intrauterine Device
301125|NCT01496898|Levonorgestrel
301126|NCT01496885|stroke
301127|NCT01496872|Newborn cranial somatic dysfunction
301128|NCT01496872|Newborn observational study
301129|NCT01496872|Somatic dysfunction
301130|NCT01496872|Cranial strain pattern
301131|NCT01496872|Osteopathy
301132|NCT01496859|Baska mask
301133|NCT01496859|supraglottic airway
301134|NCT01496859|airway management
301135|NCT01496846|Articaine
301136|NCT01496846|Lidocaine
301137|NCT01496846|Anesthesia, Local
301138|NCT01496846|Endodontics
301139|NCT01496846|Molar
301140|NCT01496846|Dental Pulp Diseases
301141|NCT01496833|Aortic Diseases
301142|NCT01496833|Vascular Diseases
301143|NCT01496833|Cardiovascular Diseases
301144|NCT01496833|Treatment Outcome
301145|NCT01496833|Aorta Dissection
301146|NCT01496833|Aorta Aneurysm
301147|NCT01496833|Aorta pseudoaneurysm
301148|NCT01496833|Endovascular aortic repair
301149|NCT01496807|unresectable
301150|NCT01496807|stage 3
301151|NCT01496807|stage 4
301152|NCT01496807|autoimmune
301153|NCT01496807|antibodies
301154|NCT01496781|Endoscopic Hemostasis
301155|NCT01496781|metallic hemoclip
301156|NCT01496781|EndoClot Absorbable Polysaccharide Hemostat
301157|NCT01496781|Colonic Polyps
301158|NCT01496729|Kidney transplantation
301159|NCT01496729|Transversus abdominis plane (TAP) block
301160|NCT01496716|Osteoarthritis
301161|NCT01496716|obesity
301162|NCT01496716|quality of life
301163|NCT01496703|reasons for MMF dose reduction
301164|NCT01496690|Anxiety-comorbidity to schizophrenia
301165|NCT01496690|Double-blinded randomized placebo controlled trial
301166|NCT01496690|Pregabalin
301167|NCT01496677|volunteer
301168|NCT01496651|Percutaneous coronary intervention
301169|NCT01496651|Coronary artery bypass graft operation
301170|NCT01496651|Left Main
301171|NCT01496638|PCI
301172|NCT01496638|Bifurcation lesion
301173|NCT01496625|Biological Specimens
301174|NCT01496625|Retinal Disease
301175|NCT01496625|Phenotype
301176|NCT01496625|Phenotype-Genotype correlation
301177|NCT01496625|Age-Related Macular Degeneration (AMD)
301178|NCT01496625|AMD
301179|NCT01496625|Diabetic Retinopathy
301180|NCT01496625|Healthy Volunteer
301181|NCT01496625|HV
301182|NCT01496612|Epilepsy
301183|NCT01496612|Temporal Lobe Epilepsy
301184|NCT01496612|Serotonin 1A Receptor
301185|NCT01496612|Seizures
301186|NCT01496599|Brain Imaging
301187|NCT01496599|Parkinson's Disease
301188|NCT01496599|Parkinsonism
301189|NCT01496599|Parkinson Disease
301190|NCT01496599|PD
301191|NCT01496599|Healthy Volunteer
301192|NCT01496599|HV
301193|NCT01496586|Fatigue
301194|NCT01496586|Traumatic Brain Injury
301195|NCT01496586|Motivational Incentive
301196|NCT01496586|TBI
301197|NCT01496560|colonoscopy
301198|NCT01496560|pain
301199|NCT01496560|rectal balloon
301200|NCT01496547|feasibility, effective and safety
301201|NCT01496547|intensive chemotherapy
301202|NCT01496547|RIC regimen
301203|NCT01496547|refractory or relapse leukemia
301204|NCT01496547|allogeneic stem cell transplantation
301205|NCT01496534|advanced solid tumors
301206|NCT01496534|bladder cancer
301207|NCT01496534|gemcitabine
301208|NCT01496534|cisplatin
301209|NCT01496534|carboplatin
301210|NCT01496534|solid tumors
301211|NCT01496521|Aspirin
301212|NCT01496521|polyphenols
301213|NCT01496521|Chemoprevention
301214|NCT01496508|high-frequency oscillatory ventilation
301215|NCT01496508|respiratory distress syndrome
301216|NCT01496508|preterm infants
301217|NCT01496508|neurodevelopment
301218|NCT01496508|preterm infants with severe respiratory distress syndrome
301219|NCT01496482|Dry eye Syndromes
301220|NCT01496469|Drug Therapy
301221|NCT01496456|Dental caries
301222|NCT01496456|Proximal surfaces
301223|NCT01496456|Posterior teeth
301224|NCT01496456|Carious lesions
301225|NCT01496456|Tooth diseases
301226|NCT01496456|Preventive therapy
301227|NCT01496443|Drug Therapy
301228|NCT01496430|Drug Therapy
301229|NCT01496430|Hypertension and Diabetes
301230|NCT01496417|Kidney Transplantation
301231|NCT01496417|Biopsy
301232|NCT01496417|Belatacept
301233|NCT01496404|Electrocautery
301234|NCT01496391|imaging
301235|NCT01496391|renal function
301236|NCT01496391|I-123 OIH
301237|NCT01496391|Tc-99m MAG 3
301238|NCT01496378|Chronic Pain
301239|NCT01496378|Abdominal Pain
301240|NCT01496378|Headache
301241|NCT01496378|Adolescents
301242|NCT01496378|Children
301243|NCT01496378|Parents
301244|NCT01496378|Problem-Solving Skills Training
301245|NCT01496365|Keywords: pain, diabetes, neuropathy
301246|NCT01496352|Surgical site infection
301247|NCT01496352|Colorectal surgery
301248|NCT01496326|Osteoarthritis
301249|NCT01496326|knee pain
301250|NCT01496313|medullary thyroid cancer
301251|NCT01496313|metastatic
301252|NCT01496313|thyroid cancer
301253|NCT01496313|carcinoma of the thyroid
301254|NCT01496313|receptor tyrosine kinase inhibitor
301255|NCT01496313|VEGFR
301256|NCT01496313|Unresectable locally advanced thyroid cancer
301257|NCT01496300|Navigation OrthoPilot Hip TEP THA
301258|NCT01496261|Clopidogrel
301259|NCT01496261|Aspirin
301260|NCT01496261|Combination
301261|NCT01496261|Pharmacokinetics
301262|NCT01496261|Phase 1
301263|NCT01496248|Major depressive disorder
301264|NCT01496248|Residual symptoms
301265|NCT01496248|Korean red ginseng
301266|NCT01496222|mild cognitive impairment
301267|NCT01496222|Montreal Cognitive Assessment test
301268|NCT01496209|Infarction
301269|NCT01496209|Myocardial Infarction
301270|NCT01496209|Ventricular Dysfunction, Left
301271|NCT01496209|Heart Disease
301272|NCT01496209|Cardiovascular Disease
301273|NCT01496209|Chronic Ischemia
301274|NCT01496196|hemoptisis
301275|NCT01496196|bleeding
301276|NCT01496196|tranexamic acid
301277|NCT01496157|Primary Prostate Cancer
301278|NCT01496144|Chronic non specific low back pain
301279|NCT01496144|Manual therapy
301280|NCT01496144|Active exercises
301281|NCT01496144|Pain
301282|NCT01496144|Disability
301283|NCT01496131|Tecemotide
301284|NCT01496131|Prostate Cancer
301285|NCT01496131|Goserelin
301286|NCT01496131|Cyclophosphamide
301287|NCT01496131|Radiotherapy
301288|NCT01496118|Relapsed/Refractory Multiple Myeloma
301289|NCT01496118|carfilzomib
301290|NCT01496118|panobinostat
301291|NCT01496092|Keto Acid
301292|NCT01496092|Peritoneal dialysis
301293|NCT01496092|Insulin resistance
301294|NCT01496079|Maternal immunization
301295|NCT01496079|Infant immunization
301296|NCT01496079|Influenza vaccine
301297|NCT01496079|Passive transfer of immunity
301298|NCT01496053|Cytokine levels in blood
301299|NCT01496053|Calprotectin in feces
301300|NCT01496053|Clinical symptom score.
301301|NCT01496027|cerebral oxygenation
301302|NCT01496027|NIRS
301303|NCT01496027|tissue oximeters
301304|NCT01496027|near infrared spectroscopy
301305|NCT01496027|newborn
301306|NCT01496014|open fracture wounds
301307|NCT01496014|infections
301308|NCT01496014|tibia fractures
301309|NCT01496014|antibiotic therapies in severe fractures
301310|NCT01496014|All severe open fracture of the tibia bone
301311|NCT01496001|Early unilateral breast cancer
301312|NCT01495988|Metastatic melanoma
301313|NCT01495988|BRAF-mutant
301314|NCT01495988|Stage IV melanoma
301315|NCT01495988|Vemurafenib
301316|NCT01495988|Bevacizumab
301317|NCT01495988|Cobimetinib
301318|NCT01495975|Diabetes Mellitus
301319|NCT01495975|Diabetes Mellitus, Type 2
301320|NCT01495975|Hospitalization
301321|NCT01495975|Patient Discharge
301322|NCT01495962|Damage Control Laparotomy
301323|NCT01495962|Open Abdomen
301324|NCT01495962|Botulinum Toxin A
301325|NCT01495962|Primary Fascial Closure
301326|NCT01495949|etomidate
301327|NCT01495949|cortisol level
301328|NCT01495949|inotrope
301329|NCT01495949|cardiac patients
301330|NCT01495936|One Lung Ventilation (OLV)
301331|NCT01495936|Continuous Positive Airway Pressure (CPAP)
301332|NCT01495936|Positive End Expiratory Pressure (PEEP)
301333|NCT01495936|Lung recruitment maneuver
301334|NCT01495936|Hypoxia
301335|NCT01495923|low back pain
301336|NCT01495923|radiculopathy
301337|NCT01495923|injection
301338|NCT01495910|21-hydroxylase deficiency
301339|NCT01495910|Androstenedione
301340|NCT01495910|Abiraterone acetate
301341|NCT01495910|Pharmacokinetics
301342|NCT01495910|Pharmacodynamics
301343|NCT01495910|Dose-finding
301344|NCT01495897|Dystonia
301345|NCT01495897|Cerebellar
301346|NCT01495897|ocular movements
301347|NCT01495897|DYT 11
301348|NCT01495897|sensorimotor integration
301349|NCT01495858|Naproxen sodium
301350|NCT01495858|Diphenhydramine
301351|NCT01495845|pharmacogenomics
301352|NCT01495845|feasibility
301353|NCT01495845|community pharmacy
301354|NCT01495845|personalized medicine
301355|NCT01495845|clopidogrel
301356|NCT01495845|Plavix
301357|NCT01495832|Adult Obesity
301358|NCT01495832|Cardiometabolic health
301359|NCT01495832|Pulse Foods
301360|NCT01495832|Beans, Peas, Lentils
301361|NCT01495832|Cognitive Function
301362|NCT01495819|Nicotine
301363|NCT01495819|smokers
301364|NCT01495819|vitals associated with smoking
301365|NCT01495806|functional dyspepsia
301366|NCT01495806|irritable bowel syndrome
301367|NCT01495806|functional abdominal pain
301368|NCT01495793|Rotigotine
301369|NCT01495793|Restless Legs Syndrome
301370|NCT01495793|RLS
301371|NCT01495793|Children
301372|NCT01495793|Adolescents
301373|NCT01495780|Behavioral
301374|NCT01495780|Remote monitoring
301375|NCT01495767|childhood uveitis
301376|NCT01495767|health-related quality of life
301377|NCT01495767|gender
301378|NCT01495754|coffee
301379|NCT01495754|overweight/obese
301380|NCT01495754|appetite
301381|NCT01495754|energy intake
301382|NCT01495754|inflammation
301383|NCT01495754|glucose metabolism
301384|NCT01495754|randomized controlled trial
301385|NCT01495741|Mania
301386|NCT01495741|Manic
301387|NCT01495741|Depressive
301388|NCT01495741|Manic Depressive
301389|NCT01495728|Cervical Radiculopathy
301390|NCT01495728|Neck Pain
301391|NCT01495728|Manipulation
301392|NCT01495702|HIV-1
301393|NCT01495702|HIV
301394|NCT01495702|Treatment Experienced
301395|NCT01495689|Smoking Cessation
301396|NCT01495689|respirology Out-patient setting
301397|NCT01495689|SmartCard
301398|NCT01495676|Bladder cancer
301399|NCT01495676|Organ-conserving strategy
301400|NCT01495676|Radiochemotherapy
301401|NCT01495676|non metastatic
301402|NCT01495663|refractory
301403|NCT01495663|relapsed
301404|NCT01495663|non-small cell lung cancer
301405|NCT01495663|triple-negative breast cancer
301406|NCT01495663|soft tissue sarcoma
301407|NCT01495663|colorectal cancer
301408|NCT01495663|esophageal cancer
301409|NCT01495663|prostate cancer
301410|NCT01495663|ovarian cancer
301411|NCT01495650|Comprehensive Adjuvant Care
301412|NCT01495650|Cancer-related fatigue
301413|NCT01495650|Therapeutic patient education
301414|NCT01495650|Physical Activity
301415|NCT01495650|Nutritional counselling
301416|NCT01495650|Rehabilitation
301417|NCT01495637|pediatric
301418|NCT01495637|trauma
301419|NCT01495637|critical
301420|NCT01495637|GM-CSF
301421|NCT01495637|immune
301422|NCT01495624|rotator cuff repair
301423|NCT01495624|capsular shift
301424|NCT01495624|shoulder arthroplasty
301425|NCT01495624|subacromial decompression
301426|NCT01495624|18 and 75 years
301427|NCT01495611|postoperative,
301428|NCT01495611|pediatric
301429|NCT01495611|pharmacogenetic
301430|NCT01495611|opioid
301431|NCT01495611|morphine
301432|NCT01495611|perioperative
301433|NCT01495611|respiratory depression
301434|NCT01495598|Human Herpesvirus-8/HHV8
301435|NCT01495598|Immune Modulation
301436|NCT01495598|CC-4047
301437|NCT01495598|IMiD
301438|NCT01495598|Kaposi Sarcoma
301439|NCT01495585|Hepatitis
301440|NCT01495585|Delta
301441|NCT01495585|Treatment
301442|NCT01495585|Lonafarnib
301443|NCT01495585|Hepatitis D
301444|NCT01495572|Malignant Melanoma
301445|NCT01495572|Immunotherapy
301446|NCT01495572|Cell Therapy
301447|NCT01495572|HLA-A2 Positive
301448|NCT01495572|Skin Cancer
301449|NCT01495546|total hip arthroplasty
301450|NCT01495546|THA
301451|NCT01495546|prosthesis type Lepine
301452|NCT01495520|Arrhythmias
301453|NCT01495520|palpitations
301454|NCT01495494|Nasal Strip
301455|NCT01495481|Supraventricular Tachycardia
301456|NCT01495481|SVT
301457|NCT01495481|Reentrant Tachycardia
301458|NCT01495481|Dexmedetomidine
301459|NCT01495481|Adenosine
301460|NCT01495468|pegylated somatropin
301461|NCT01495468|PEG-rhGH
301462|NCT01495468|growth hormone
301463|NCT01495468|Growth Hormone Deficiency
301464|NCT01495468|phase III study
301465|NCT01495429|catheter related large vein thrombosis
301466|NCT01495429|upper extremity deep venous thrombosis
301467|NCT01495429|central venous catheters
301468|NCT01495429|upper extremity catheter related large vein thrombosis
301469|NCT01495403|liver cirrhosis
301470|NCT01495403|muscle cramps
301471|NCT01495390|Biomarkers
301472|NCT01495390|Biological Markers
301473|NCT01495390|Surrogate Markers
301474|NCT01495390|Clinical Markers
301475|NCT01495390|Plasma
301476|NCT01495390|Cerebrospinal Fluid
301477|NCT01495390|DNA
301478|NCT01495390|Serum
301479|NCT01495390|RNA
301480|NCT01495377|swallowing difficulties
301481|NCT01495377|remifentanil
301482|NCT01495377|pulmonary aspiration
301483|NCT01495377|scintigraphy
301484|NCT01495364|STEMI
301485|NCT01495325|Firefighter
301486|NCT01495325|Woodsmoke
301487|NCT01495325|Vascular function
301488|NCT01495325|Air Pollution
301489|NCT01495325|Endothelial function
301490|NCT01495325|Thrombosis
301491|NCT01495312|IOP fluctuations
301492|NCT01495312|during two 24-hour periods
301493|NCT01495299|relationship
301494|NCT01495299|IOP fluctuations
301495|NCT01495299|glaucoma
301496|NCT01495299|cataract surgery
301497|NCT01495299|SENSIMED Triggerfish
301498|NCT01495286|newborn infant
301499|NCT01495286|acupuncture
301500|NCT01495286|safety
301501|NCT01495286|pain
301502|NCT01495260|XALD
301503|NCT01495260|AMN
301504|NCT01495247|Locally advanced
301505|NCT01495247|metastatic
301506|NCT01495247|breast cancer
301507|NCT01495247|HER2 negative
301508|NCT01495247|PI3K pathway
301509|NCT01495247|paclitaxel
301510|NCT01495247|mTOR inhibitor
301511|NCT01495234|Spinal degeneration
301512|NCT01495195|Acetylcholine
301513|NCT01495195|Cholinesterases
301514|NCT01495195|Cocaine
301515|NCT01495195|Self-Administration
301516|NCT01495182|Dietary fiber
301517|NCT01495182|Gastrointestinal toleration
301518|NCT01495182|Fecal weight
301519|NCT01495169|Antipsychotic
301520|NCT01495169|Schizophrenia
301521|NCT01495169|Bipolar disorder
301522|NCT01495169|Iloperidone
301523|NCT01495143|Glucose
301524|NCT01495143|Lactate pyruvate ratio
301525|NCT01495143|Glycerol
301526|NCT01495143|Paraspinal muscle
301527|NCT01495143|Microdialysis
301528|NCT01495117|surgical site infection
301529|NCT01495117|chlorhexidine gluconate
301530|NCT01495117|povidone iodine
301531|NCT01495091|coronary artery disease
301532|NCT01495091|cardiovascular disease
301533|NCT01495091|exercise stress testing
301534|NCT01495091|biomarkers
301535|NCT01495091|NT-pro-BNP
301536|NCT01495078|telemonitoring
301537|NCT01495078|heart failure
301538|NCT01495065|GSK2251052, healthy volunteer, safety, tolerability, pharmacokinetics, single
301539|NCT01495052|naked oat (Avena nuda L.)
301540|NCT01495052|diabetes mellitus
301541|NCT01495052|RCT
301542|NCT01495026|Healthy male subjects
301543|NCT01495026|North-East Asian ancestry
301544|NCT01495026|Bioequivalence
301545|NCT01495026|Food effect
301546|NCT01495026|Tamsulosin hydrochloride
301547|NCT01495026|Cross-over design
301548|NCT01495026|Pilot bioequivalence
301549|NCT01495026|Dutasteride (GI198745)
301550|NCT01495013|non-inferiority
301551|NCT01495013|glimepiride
301552|NCT01495013|LDL cholesterol
301553|NCT01495013|fixed dose combination
301554|NCT01495013|atorvastatin
301555|NCT01495013|Diabetes Mellitus
301556|NCT01495000|India
301557|NCT01495000|dual energy x-ray absorptiometry
301558|NCT01495000|bone mineral density
301559|NCT01495000|denosumab
301560|NCT01494987|Type 2 Diabetes Mellitus
301561|NCT01494974|Glaucoma
301562|NCT01494974|Pediatric
301563|NCT01494974|Ahmed
301564|NCT01494974|Congenital
301565|NCT01494974|FP7
301566|NCT01494974|FP8
301567|NCT01494961|Partner HIV testing
301568|NCT01494961|Couple HIV counseling
301569|NCT01494961|Couple communication on sexual and reproductive health
301570|NCT01494961|HIV incidence
301571|NCT01494961|Incidence of pregnancies
301572|NCT01494961|Disclosure
301573|NCT01494961|Condom use
301574|NCT01494922|Skin scarring
301575|NCT01494922|cicatrix
301576|NCT01494922|hypertrophic scar
301577|NCT01494922|hypertrophic scar prevention
301578|NCT01494909|protein digestion
301579|NCT01494909|fat absorption
301580|NCT01494909|gut function
301581|NCT01494909|glucose absorption
301582|NCT01494909|CF
301583|NCT01494909|pancreatic intake
301584|NCT01494909|feeding
301585|NCT01494896|Pulmonary Hypertension
301586|NCT01494896|Pulmonary Arterial Hypertension
301587|NCT01494896|COPD
301588|NCT01494896|Chronic Obstructive Pulmonary Disease
301589|NCT01494896|Tyvaso
301590|NCT01494896|Inhaled Treprostinil Sodium
301591|NCT01494896|Ventilation Perfusion Matching
301592|NCT01494896|HO Group 1 Pulmonary Arterial Hypertension
301593|NCT01494896|Concomitant Chronic Obstructive Pulmonary Disease
301594|NCT01494883|Mindfulness Based Stress Reduction
301595|NCT01494883|lung cancer
301596|NCT01494883|psychological distress
301597|NCT01494883|caretakers
301598|NCT01494870|acute coronary syndrome
301599|NCT01494870|percutaneous coronary intervention
301600|NCT01494870|left bundle branch block
301601|NCT01494857|Ulcerative colitis
301602|NCT01494857|biological treatment
301603|NCT01494857|anti-TNF
301604|NCT01494844|Patient Monitoring
301605|NCT01494844|Capnography
301606|NCT01494844|Human Engineering
301607|NCT01494818|Contact lenses
301608|NCT01494818|Contact lens solutions
301609|NCT01494805|Age-related Macular Degeneration
301610|NCT01494805|AAV
301611|NCT01494805|AMD
301612|NCT01494805|Wet AMD
301613|NCT01494805|Neovascular AMD
301614|NCT01494805|Gene Therapy
301615|NCT01494805|Ocular
301616|NCT01494805|Ocular Gene Therapy
301617|NCT01494805|Eye diseases
301618|NCT01494805|Macular Degeneration
301619|NCT01494805|Retinal Degeneration
301620|NCT01494805|Retinal Neovascularization
301621|NCT01494805|Wet Macular Degeneration
301622|NCT01494805|Retinal Diseases
301623|NCT01494779|children
301624|NCT01494766|RLS
301625|NCT01494740|H1N1
301626|NCT01494740|Vaccine
301627|NCT01494740|Immunogenicity
301628|NCT01494740|Safety
301629|NCT01494740|infants
301630|NCT01494727|Safety
301631|NCT01494727|Pharmacokinetics
301632|NCT01494714|Healthy volunteers
301633|NCT01494714|JNJ 10229570-AAA
301634|NCT01494714|Skin irritation
301635|NCT01494714|Skin photo irritation
301636|NCT01494701|Spinal Muscular Atrophy
301637|NCT01494701|SMA
301638|NCT01494701|SMN
301639|NCT01494701|SMNRx
301640|NCT01494701|ISIS-SMNRx
301641|NCT01494701|ISIS 396443
301642|NCT01494675|procalcitonin
301643|NCT01494675|duration of the antibiotic therapy
301644|NCT01494675|sepsis
301645|NCT01494662|HER2 Positive
301646|NCT01494662|BrCa
301647|NCT01494649|dentinal
301648|NCT01494649|hypersensitivity
301649|NCT01494636|Capsaicin Challenge
301650|NCT01494636|Pharmacodynamics
301651|NCT01494636|Safety
301652|NCT01494636|Pharmacokinetics
301653|NCT01494636|Oral GSK2339345
301654|NCT01494636|Tolerability
301655|NCT01494636|FTIH
301656|NCT01494636|Chronic Cough
301657|NCT01494623|working memory
301658|NCT01494623|schizophrenia
301659|NCT01494623|cognition
301660|NCT01494623|rTMS
301661|NCT01494610|safety
301662|NCT01494610|replicated cross-over design
301663|NCT01494610|pharmacodynamics
301664|NCT01494610|Fluticasone propionate/Salmeterol
301665|NCT01494610|capsule-based inhaler
301666|NCT01494610|COPD
301667|NCT01494610|asthma
301668|NCT01494610|multi dose dry powder inhaler
301669|NCT01494610|bioavailability
301670|NCT01494610|pharmacokinetics
301671|NCT01494597|Isavuconazole
301672|NCT01494597|Cyclosporine
301673|NCT01494597|Healthy Volunteers
301674|NCT01494597|BAL8557
301675|NCT01494597|Pharmacokinetics of isavuconazole
301676|NCT01494597|Pharmacokinetics of cyclosporine
301677|NCT01494558|Overall survival
301678|NCT01494545|DAILIES TOTAL1
301679|NCT01494545|Alcon
301680|NCT01494545|contact lens
301681|NCT01494519|External ring fixation
301682|NCT01494519|internal fixation
301683|NCT01494519|traumatic tibia fracture
301684|NCT01494506|Pancreatic cancer
301685|NCT01494506|MM-398
301686|NCT01494506|PEP02
301687|NCT01494506|Metastatic pancreatic cancer
301688|NCT01494506|Gemcitabine refractory pancreatic cancer
301689|NCT01494506|Second line pancreatic cancer treatment
301690|NCT01494506|Pancreatic cancer post gemcitabine therapy
301691|NCT01494493|symptomatic degenerative disc disease
301692|NCT01494480|ALS
301693|NCT01494480|stem cell
301694|NCT01494467|PPR
301695|NCT01494454|Lumbar degenerative disc disease
301696|NCT01494441|lumbar degenerative disc disease
301697|NCT01494428|symptomatic degenerative disc disease
301698|NCT01494415|Squamous Cell Lung Cancer
301699|NCT01494415|radiation therapy
301700|NCT01494415|chemotherapy
301701|NCT01494402|Healthy volunteer, Japanese males, homo-EM
301702|NCT01494389|CD4+T lymphocyte subsets
301703|NCT01494389|sepsis
301704|NCT01494389|immunoparalysis
301705|NCT01494350|cutaneous leishmaniasis
301706|NCT01494350|topical treatment
301707|NCT01494350|Tunisia
301708|NCT01494337|LASER
301709|NCT01494337|BPH
301710|NCT01494337|Prostate surgery
301711|NCT01494337|HOLEP
301712|NCT01494337|Green light PVP
301713|NCT01494324|Liver
301714|NCT01494324|Thermal Ablation
301715|NCT01494324|Dynamic CT
301716|NCT01494324|09-122
301717|NCT01494311|Arterial catheter
301718|NCT01494311|arterial cannula
301719|NCT01494311|Rapydan
301720|NCT01494311|lidocaine/tetracaine patch
301721|NCT01494311|topical anaesthesia
301722|NCT01494298|Type 2 diabetes
301723|NCT01494298|African American
301724|NCT01494298|cholesterol
301725|NCT01494298|lipoprotein
301726|NCT01494298|apolipoprotein
301727|NCT01494285|Acne Vulgaris
301728|NCT01494285|Topical
301729|NCT01494285|Foam
301730|NCT01494272|caudal epidural analgesia
301731|NCT01494272|elective circumcision
301732|NCT01494272|elective inguinal herniorrhaphy
301733|NCT01494259|immediate breast reconstruction
301734|NCT01494259|pain control
301735|NCT01494259|post mastectomy pain control
301736|NCT01494246|Adult
301737|NCT01494246|computer-assisted instruction
301738|NCT01494246|electronic mail
301739|NCT01494246|program evaluation
301740|NCT01494246|smoking cessation/methods
301741|NCT01494246|continued abstinence
301742|NCT01494220|Bispectral index; anesthesia
301743|NCT01494220|liver transplantation
301744|NCT01494220|independent factors
301745|NCT01494220|outcome
301746|NCT01494220|Living donor liver transplantation
301747|NCT01494207|worksite
301748|NCT01494207|interventions
301749|NCT01494207|motivational interviewing
301750|NCT01494207|physical activity
301751|NCT01494194|Mold sensitized
301752|NCT01494181|obstructive sleep apnea
301753|NCT01494181|vascular events
301754|NCT01494168|Hypertension
301755|NCT01494168|Arterial stiffness
301756|NCT01494168|Obesity
301757|NCT01494168|Bariatric surgery
301758|NCT01494155|resectable pancreatic cancer
301759|NCT01494155|pancreaticoduodenectomy
301760|NCT01494142|Registry
301761|NCT01494142|Atopic Dermatitis
301762|NCT01494142|Eczema Herpeticum
301763|NCT01494142|GWAS
301764|NCT01494142|Staphylococcus aureus
301765|NCT01494116|Pediatrics
301766|NCT01494116|Fluid
301767|NCT01494116|Bolus
301768|NCT01494116|Resuscitation
301769|NCT01494116|Shock
301770|NCT01494103|Acute lymphoblastic leukemia
301771|NCT01494103|Myelodysplastic syndrome
301772|NCT01494103|Acute myeloid leukemia
301773|NCT01494103|Chronic myelogenous leukemia
301774|NCT01494103|Non Hodgkin lymphoma
301775|NCT01494103|Hemophagocytic lymphohistiocytosis
301776|NCT01494103|Familial hemophagocytic lymphohistiocytosis
301777|NCT01494103|Hemophagocytic syndrome
301778|NCT01494103|Epstein Barr virus infection
301779|NCT01494103|X-linked lymphoproliferative disease
301780|NCT01494090|Venous thromboembolism
301781|NCT01494090|Hip fracture
301782|NCT01494090|Cardiovascular events
301783|NCT01494090|Statin
301784|NCT01494077|Pancreatic Cyst Fluid
301785|NCT01494077|Dilution
301786|NCT01494077|Carcinoembryonic Antigen (CEA)
301787|NCT01494051|fatty acid oxidation disorders
301788|NCT01494025|Diabetes
301789|NCT01494025|Pre-diabetes
301790|NCT01494025|Obese
301791|NCT01493999|Clopidogrel
301792|NCT01493999|prasugrel
301793|NCT01493999|HPR
301794|NCT01493999|loading dose
301795|NCT01493999|maintenance dose
301796|NCT01493999|stent thrombosis
301797|NCT01493999|platelet reactivity
301798|NCT01493999|Coronary intervention
301799|NCT01493999|stent implantation
301800|NCT01493986|Ropivacaine
301801|NCT01493986|Brachial plexus
301802|NCT01493973|Erythropoietin
301803|NCT01493973|EPO
301804|NCT01493973|Friedreich
301805|NCT01493973|Ataxia
301806|NCT01493973|Epoetin alfa
301807|NCT01493973|VO2 max
301808|NCT01493973|SARA
301809|NCT01493973|EQ-5D
301810|NCT01493973|frataxin
301811|NCT01493960|Colitis, Ulcerative
301812|NCT01493960|Gastrointestinal Diseases
301813|NCT01493960|Inflammatory Bowel Diseases
301814|NCT01493960|Immunomodulatory Therapy
301815|NCT01493960|Glucocorticoids
301816|NCT01493960|Anti-Inflammatory Agents
301817|NCT01493960|Therapeutic uses
301818|NCT01493934|metabolic syndrome
301819|NCT01493934|type 2 diabetes mellitus
301820|NCT01493934|insulin resistance
301821|NCT01493934|Scintigraphy
301822|NCT01493921|SR-T100 Clinical treatment against Actinic Keratosis
301823|NCT01493921|Actinic keratosis skin lesion treatment with SR-T100 gel
301824|NCT01493921|Skin lesion treatment with SR-T100 gel
301825|NCT01493921|SR-T100 gel treatment against skin lesion
301826|NCT01493921|Clinical efficacy study of SR-T100 gel
301827|NCT01493908|Placebo effect;
301828|NCT01493908|Pain; Analgesic;
301829|NCT01493908|Electrical shock
301830|NCT01493908|control in healthy volunteers
301831|NCT01493882|Uncontrolled Persistent Asthma, Dyspnea, Wheezing
301832|NCT01493869|Normal healthy adult subjects
301833|NCT01493869|Adult subjects with hepatic impairment
301834|NCT01493830|neuroblastoma
301835|NCT01493804|Near Infrared Spectroscopy
301836|NCT01493804|EEG
301837|NCT01493804|Brain Connectivity
301838|NCT01493804|Healthy Volunteer
301839|NCT01493804|HV
301840|NCT01493791|CDB-2914
301841|NCT01493791|Abnormal Urine Bleeding
301842|NCT01493791|Abnormal Uterine Bleeding
301843|NCT01493700|heated circuit
301844|NCT01493700|body temperature
301845|NCT01493674|folate
301846|NCT01493674|homocysteine
301847|NCT01493674|cognitive function
301848|NCT01493674|eating disorders
301849|NCT01493674|depression.
301850|NCT01493661|Sleep
301851|NCT01493661|Polysomnography
301852|NCT01493661|Reaction Time
301853|NCT01493661|Sleep Deprivation
301854|NCT01493661|Psychophysiology
301855|NCT01493661|Chronic sleep restriction
301856|NCT01493661|healthy
301857|NCT01493661|without sleep complaints
301858|NCT01493648|statins
301859|NCT01493648|side effects
301860|NCT01493648|muscle
301861|NCT01493648|vitamin D
301862|NCT01493648|biopsy
301863|NCT01493648|strength
301864|NCT01493648|fatigue
301865|NCT01493622|Schizophrenia minocycline cognition
301866|NCT01493596|Safety
301867|NCT01493596|Tolerability
301868|NCT01493583|severely obese
301869|NCT01493583|Roux-en Y gastric bypass surgery (RYGB)
301870|NCT01493583|brain activity by fMRI
301871|NCT01493583|visual presentation of food and non-food-related pictures
301872|NCT01493544|COPD
301873|NCT01493544|smokers
301874|NCT01493544|primary care
301875|NCT01493531|Gout
301876|NCT01493518|SAFETY
301877|NCT01493518|ADULT
301878|NCT01493518|PSORIASIS
301879|NCT01493518|INFLAMMATION
301880|NCT01493505|Primary Peritoneal Cancer
301881|NCT01493492|proteomics,urinary,sepsis,prognosis
301882|NCT01493466|proteomics,
301883|NCT01493466|serum,
301884|NCT01493466|sepsis,
301885|NCT01493466|potential biomarkers,
301886|NCT01493466|dynamic changes
301887|NCT01493466|normal
301888|NCT01493440|atosiban
301889|NCT01493440|clinical pregnancy
301890|NCT01493440|implantation rate
301891|NCT01493440|uterine contractility
301892|NCT01493440|IVF-ET
301893|NCT01493427|Glaucoma
301894|NCT01493427|OAG
301895|NCT01493427|OHT
301896|NCT01493414|INC424
301897|NCT01493414|Ruxolitinib
301898|NCT01493414|myelofibrosis
301899|NCT01493414|PMF
301900|NCT01493414|post polycythemia myelofibrosis
301901|NCT01493414|PPV MF
301902|NCT01493414|post-essential thrombocythemia myelofibrosis
301903|NCT01493414|PET-MF
301904|NCT01493375|Contamination, hip operation, knee operation
301905|NCT01493362|Bulimia Nervosa
301906|NCT01493362|PET Imaging
301907|NCT01493362|Dopamine
301908|NCT01493349|Colonic diverticula
301909|NCT01493349|Diverticulitis
301910|NCT01493323|Psychic pain
301911|NCT01493323|Social exclusion
301912|NCT01493323|Mood disorders
301913|NCT01493323|Suicide, attempted
301914|NCT01493323|Magnetic Resonance Imaging, Functional
301915|NCT01493323|Genetic
301916|NCT01493323|Physic pain
301917|NCT01493297|Retinyl palmitate, beta-carotene, stable isotopes, radio isotopes
301918|NCT01493284|aortic stenosis
301919|NCT01493284|aortic valve stenosis
301920|NCT01493284|valvular heart disease
301921|NCT01493284|aortic valve replacement
301922|NCT01493284|transcatheter aortic valve implantation
301923|NCT01493284|TAVI
301924|NCT01493258|Diabetes
301925|NCT01493258|Comparative Effectiveness Research
301926|NCT01493258|Interactive computer-assisted education
301927|NCT01493258|Informatics
301928|NCT01493245|Chronic Pain
301929|NCT01493245|JNS020QD
301930|NCT01493245|Fentanyl
301931|NCT01493245|Opioid analgesics
301932|NCT01493232|Lingualized occlusion
301933|NCT01493232|Complete denture occlusion
301934|NCT01493232|Fully bilateral balanced occlusion
301935|NCT01493232|Patient satisfaction of complete denture
301936|NCT01493219|Glioblastoma
301937|NCT01493219|Glioblastoma Multiforme
301938|NCT01493219|Astrocytoma
301939|NCT01493219|Gliosarcoma
301940|NCT01493219|Glioma WHO grade IV
301941|NCT01493206|intraoperative radiotherapy
301942|NCT01493167|cast
301943|NCT01493167|splint
301944|NCT01493167|circumferential casting
301945|NCT01493167|casting techniques
301946|NCT01493167|fracture in extremity
301947|NCT01493154|HPV
301948|NCT01493154|Head and Neck Cancer
301949|NCT01493154|Vaccine
301950|NCT01493154|Immunotherapy
301951|NCT01493154|Cyclophosphamide
301952|NCT01493154|Sexually Transmitted Diseases, Viral
301953|NCT01493141|MOMHR
301954|NCT01493141|THA
301955|NCT01493141|Osteoarthritis
301956|NCT01493128|atrial fibrillation
301957|NCT01493128|atrial cells
301958|NCT01493128|myocardial tissue
301959|NCT01493128|t-tubules
301960|NCT01493128|immunofluorescence
301961|NCT01493102|septic shock
301962|NCT01493102|norepinephrine
301963|NCT01493102|vasopressin
301964|NCT01493102|hypotension
301965|NCT01493076|ERCP
301966|NCT01493076|Cannulation
301967|NCT01493076|Precut
301968|NCT01493076|Mini-spincterotome
301969|NCT01493063|preterm newborns
301970|NCT01493050|Diabetic Nephropathy
301971|NCT01493050|Sevelamer Carbonate
301972|NCT01493037|STEMI
301973|NCT01493037|PICSO
301974|NCT01493037|Coronary Sinus
301975|NCT01493037|Involving Left Anterior Descending Coronary Artery
301976|NCT01492998|Hepatitis C virus
301977|NCT01492998|Biliary salts
301978|NCT01492998|Farnesoid X receptor
301979|NCT01492998|Guggulsterone
301980|NCT01492972|Prostate
301981|NCT01492972|proton
301982|NCT01492972|radiation
301983|NCT01492972|intermediate risk
301984|NCT01492946|Malnutrition
301985|NCT01492946|Post-operative outcome
301986|NCT01492946|Phase angle
301987|NCT01492946|MUST
301988|NCT01492946|Clavien Dindo classification
301989|NCT01492946|Bioelectrical impedance analysis
301990|NCT01492933|Ethanol
301991|NCT01492933|Magnetic Resonance Spectroscopy
301992|NCT01492933|Spectroscopy
301993|NCT01492933|Alcohol Use
301994|NCT01492907|Heterocyclic amine carcinogens
301995|NCT01492907|meat-borne carcinogens
301996|NCT01492881|relapsed multiple myeloma
301997|NCT01492881|refractory multiple myeloma
301998|NCT01492881|vorinostat
301999|NCT01492881|bortezomib
302000|NCT01492881|doxil
302001|NCT01492868|sinusitis
302002|NCT01492868|upper respiratory infection
302003|NCT01492855|Meniscal lesions
302004|NCT01492855|MRI
302005|NCT01492855|arthroscopic treatment
302006|NCT01492829|HIV prevention
302007|NCT01492829|sexually transmitted infection prevention
302008|NCT01492829|HIV knowledge
302009|NCT01492829|relationship power
302010|NCT01492829|depression
302011|NCT01492829|coping
302012|NCT01492829|social support
302013|NCT01492829|internally displaced persons
302014|NCT01492829|community health worker
302015|NCT01492829|HIV/STI educational video
302016|NCT01492829|substance use
302017|NCT01492829|women's health
302018|NCT01492816|HIV prevention
302019|NCT01492816|HIV positive communities
302020|NCT01492803|HIV infection
302021|NCT01492803|Probiotics
302022|NCT01492764|Ventricular Tachyarrhythmia
302023|NCT01492764|Ablation
302024|NCT01492764|Electrophysiology
302025|NCT01492764|Human
302026|NCT01492764|Mapping
302027|NCT01492751|Prostatic Neoplasms
302028|NCT01492751|Radiotherapy conformal
302029|NCT01492751|brachytherapy
302030|NCT01492751|radical prostatectomy
302031|NCT01492751|Quality of life
302032|NCT01492751|biochemical relapse
302033|NCT01492751|biochemical failure
302034|NCT01492751|survival
302035|NCT01492751|Clinically localized prostate cancer
302036|NCT01492738|Acupuncture
302037|NCT01492738|anxiety
302038|NCT01492738|memory
302039|NCT01492712|Propofol
302040|NCT01492712|Pharmacokinetics
302041|NCT01492712|Pharmacodynamics
302042|NCT01492712|Infusion Pumps
302043|NCT01492699|PTSD
302044|NCT01492699|Post Traumatic Stress Disorder
302045|NCT01492686|Amyotrophic Lateral Sclerosis (ALS)
302046|NCT01492673|Ewing's sarcoma
302047|NCT01492673|BEVACIZUMAB (AVASTIN)
302048|NCT01492673|CYCLOPHOSPHAMIDE (CYTOXAN)
302049|NCT01492673|TOPOTECAN
302050|NCT01492673|11-183
302051|NCT01492673|POETIC
302052|NCT01492660|Ultrasonography
302053|NCT01492660|nerve block
302054|NCT01492660|catheters
302055|NCT01492660|needle
302056|NCT01492660|anesthesia
302057|NCT01492647|Acne vulgaris
302058|NCT01492647|JNJ 10229570-AAA
302059|NCT01492647|Japanese patients
302060|NCT01492647|Topical treatment
302061|NCT01492634|bioimpedance
302062|NCT01492634|overhydration
302063|NCT01492634|dry weight
302064|NCT01492621|major depression
302065|NCT01492621|DTI
302066|NCT01492621|inflammatory markers
302067|NCT01492621|cognition
302068|NCT01492608|magnesium sulphate
302069|NCT01492608|preterm birth
302070|NCT01492608|cerebral palsy
302071|NCT01492595|contact
302072|NCT01492556|Recurrent
302073|NCT01492556|Metastatic
302074|NCT01492556|Breast cancer
302075|NCT01492543|Advanced
302076|NCT01492543|Metastatic
302077|NCT01492543|Breast cancer
302078|NCT01492530|Men who have sex with Men and Women
302079|NCT01492530|HIV Prevention
302080|NCT01492530|Behavioral Intervention
302081|NCT01492530|Condom use
302082|NCT01492530|African American MSMW
302083|NCT01492517|Controlled Human exposure study
302084|NCT01492517|Air Pollution
302085|NCT01492517|Gene expression
302086|NCT01492517|Epigenetic
302087|NCT01492517|Cardiovascular
302088|NCT01492491|SUPRA-HFR
302089|NCT01492491|adsorpition
302090|NCT01492491|vitamins
302091|NCT01492491|large toxins
302092|NCT01492465|Type 2 diabetes
302093|NCT01492452|guidelines for nursing
302094|NCT01492452|anxiety
302095|NCT01492452|cardiac surgery
302096|NCT01492452|pediatrics
302097|NCT01492439|Psychosis
302098|NCT01492439|Psychosis NOS
302099|NCT01492439|Schizophrenia
302100|NCT01492439|Schizoaffective Disorder
302101|NCT01492439|Bipolar Disorder
302102|NCT01492426|Hepatitis C Virus
302103|NCT01492413|Overweight
302104|NCT01492413|Obesity
302105|NCT01492387|community-acquired pneumonia
302106|NCT01492387|healthcare-associated pneumonia
302107|NCT01492387|antibiotic therapy
302108|NCT01492387|Duration of therapy
302109|NCT01492361|Coronary Artery Disease
302110|NCT01492361|Myocardial Ischemia
302111|NCT01492361|Coronary Disease
302112|NCT01492361|Heart Diseases
302113|NCT01492361|Acute Coronary Syndrome
302114|NCT01492361|Cardiovascular Diseases
302115|NCT01492361|Arteriosclerosis
302116|NCT01492361|Arterial Occlusive Diseases
302117|NCT01492361|Vascular Diseases
302118|NCT01492361|Angina Pectoris
302119|NCT01492361|Chest Pain
302120|NCT01492361|Anticholesteremic Agents
302121|NCT01492361|Hypolipidemic Agents
302122|NCT01492361|Lipid Regulating Agents
302123|NCT01492361|hypertriglyceridemia
302124|NCT01492361|omega-3 fatty acids
302125|NCT01492361|statin
302126|NCT01492361|triglycerides
302127|NCT01492361|EPA
302128|NCT01492361|docosahexaenoic acid
302129|NCT01492361|fish
302130|NCT01492361|fatty acids
302131|NCT01492361|fibrates
302132|NCT01492361|niacin
302133|NCT01492361|lipids
302134|NCT01492361|lipoprotein
302135|NCT01492361|atorvastatin
302136|NCT01492361|Lovaza
302137|NCT01492361|simvastatin
302138|NCT01492361|lovastatin
302139|NCT01492361|pravastatin
302140|NCT01492361|fluvastatin
302141|NCT01492361|rosuvastatin
302142|NCT01492361|Trilipix
302143|NCT01492361|Vytorin
302144|NCT01492361|Simcor
302145|NCT01492361|ezetimibe
302146|NCT01492361|Zetia
302147|NCT01492361|ethyl-EPA
302148|NCT01492361|ethyl icosapentate
302149|NCT01492361|Crestor
302150|NCT01492361|Zocor
302151|NCT01492361|Lipitor
302152|NCT01492361|LDL
302153|NCT01492361|HDL
302154|NCT01492361|cholesterol
302155|NCT01492361|dyslipidemia
302156|NCT01492361|AMR101
302157|NCT01492361|Cardiovascular Disease, Unspecified
302158|NCT01492361|VASCEPA
302159|NCT01492361|icosapent ethyl
302160|NCT01492348|collaborative care
302161|NCT01492348|PTSD
302162|NCT01492348|military
302163|NCT01492348|Depression
302164|NCT01492348|primary care
302165|NCT01492348|care management
302166|NCT01492348|stepped care
302167|NCT01492348|telehealth
302168|NCT01492348|OIF
302169|NCT01492348|OEF
302170|NCT01492348|preference-based treatment
302171|NCT01492348|cost effectiveness
302172|NCT01492348|web-based treatment
302173|NCT01492348|telephonic CBT
302174|NCT01492348|evidence-based treatment
302175|NCT01492335|Cognitive decline
302176|NCT01492335|Cognitive impairment
302177|NCT01492322|Smoker
302178|NCT01492322|SPECT
302179|NCT01492322|Dopamine
302180|NCT01492322|Nicotine Sated condition
302181|NCT01492322|Nicotine withdrawal condition
302182|NCT01492309|Major Depressive Disorder
302183|NCT01492309|Pregnancy
302184|NCT01492309|Brain Derived Neurotrophic Factor
302185|NCT01492309|Transcranial Magnetic Stimulation
302186|NCT01492283|NAFLD
302187|NCT01492283|Incretin hormones
302188|NCT01492270|Prostate Cancer
302189|NCT01492270|Multi parametric MRI
302190|NCT01492270|Prostate HistoScanning
302191|NCT01492270|Transperineal prostate mapping biopsy
302192|NCT01492257|shared decision making
302193|NCT01492257|decision aids
302194|NCT01492257|total joint arthroplasty
302195|NCT01492257|osteoarthritis
302196|NCT01492244|Knee pain
302197|NCT01492244|map
302198|NCT01492244|questionnaire
302199|NCT01492244|survey
302200|NCT01492231|gastroenterology
302201|NCT01492231|Endoscopy, Digestive System
302202|NCT01492231|Endosonography
302203|NCT01492231|Endoscopic Retrograde Cholangiopancreatography
302204|NCT01492231|gastrointestinal endoscopy
302205|NCT01492192|Angiogenesis
302206|NCT01492192|PET-CT
302207|NCT01492192|Perfusion-CT
302208|NCT01492179|Surgery: Abdominal hysterectomy
302209|NCT01492179|Anesthetics: Local
302210|NCT01492179|Postoperative: Pain
302211|NCT01492179|Drugs: Morphine
302212|NCT01492127|Hepatocellular carcinoma
302213|NCT01492127|cirrhosis
302214|NCT01492127|proteasome
302215|NCT01492127|alpha-fetoprotein
302216|NCT01492114|C-reactive protein
302217|NCT01492114|Resveratrol
302218|NCT01492114|Redox index
302219|NCT01492088|Pediatric
302220|NCT01492088|Lymphoma
302221|NCT01492088|Hodgkin
302222|NCT01492088|Anaplastic Large-cell
302223|NCT01492088|Relapsed
302224|NCT01492088|Refractory
302225|NCT01492075|Postoperative pain
302226|NCT01492075|Anesthetics: Local anesthetics
302227|NCT01492075|Surgery: Hysterectomy
302228|NCT01492062|Type 1 diabetes mellitus
302229|NCT01492062|artificial pancreas
302230|NCT01492062|closed-loop
302231|NCT01492049|Colorectal Neoplasms
302232|NCT01492049|Promoting Health Literacy
302233|NCT01492049|Patient education program
302234|NCT01492049|Colorectal Cancer Screening
302235|NCT01492049|CRCS
302236|NCT01492049|Patient decision aid
302237|NCT01492049|PtDA
302238|NCT01492049|Video
302239|NCT01492049|Questionnaires
302240|NCT01492049|Surveys
302241|NCT01492036|Replication-Competent Retrovirus
302242|NCT01492036|RCR
302243|NCT01492036|Gene transfer therapy
302244|NCT01492036|Registry
302245|NCT01492036|Medical information database
302246|NCT01492036|Vector or vector-treated cells
302247|NCT01492036|Blood draw
302248|NCT01492036|Computed tomography
302249|NCT01492036|CT
302250|NCT01492036|Questionnaires
302251|NCT01492036|Surveys
302252|NCT01492036|Gene Transfer Research
302253|NCT01492036|National Gene Vector Biorepository and Coordinating Center
302254|NCT01492036|NGVB
302255|NCT01492023|neuropsychological
302256|NCT01492023|rehabilitation
302257|NCT01492023|multiple sclerosis
302258|NCT01492023|RCT study
302259|NCT01492010|skeletal muscle
302260|NCT01492010|FSR
302261|NCT01492010|resistance exercise
302262|NCT01492010|leucine
302263|NCT01492010|protein
302264|NCT01491958|Leukemia
302265|NCT01491958|AML
302266|NCT01491958|ALL
302267|NCT01491958|MDS
302268|NCT01491945|Abdominal aortic aneurysm
302269|NCT01491945|Renal stent
302270|NCT01491945|Juxtarenal
302271|NCT01491945|Pararenal
302272|NCT01491945|Endovascular
302273|NCT01491932|Parkinson Disease
302274|NCT01491932|L-dopa
302275|NCT01491932|Levodopa
302276|NCT01491932|Dyskinesia
302277|NCT01491919|High Blood Pressure
302278|NCT01491919|Hypertension
302279|NCT01491919|Renal Transplantation
302280|NCT01491919|Kidney Transplantation
302281|NCT01491893|GBM
302282|NCT01491893|Brain Tumor
302283|NCT01491893|Poliovirus Vaccine
302284|NCT01491893|WHO Grade IV Malignant Glioma
302285|NCT01491880|cognitive behavior therapy
302286|NCT01491880|telemedicine
302287|NCT01491880|rural
302288|NCT01491880|Latinos
302289|NCT01491880|children
302290|NCT01491867|intraocular pressure
302291|NCT01491854|Long-term
302292|NCT01491854|safety
302293|NCT01491854|follow-up
302294|NCT01491854|growth hormone treatment
302295|NCT01491854|short children
302296|NCT01491854|Small for Gestational Age
302297|NCT01491854|Somatropin
302298|NCT01491828|Apnea
302299|NCT01491828|Sleep apnea
302300|NCT01491828|Snoring
302301|NCT01491828|Hypoglossal nerve stimulation
302302|NCT01491828|Laynx stimulation
302303|NCT01491802|COPD
302304|NCT01491802|Combination therapy
302305|NCT01491802|Anticholinergic
302306|NCT01491802|Beta2-agonist
302307|NCT01491802|Exercise
302308|NCT01491802|Dyspnea
302309|NCT01491802|Respiratory mechanics
302310|NCT01491789|spinal cord injury
302311|NCT01491789|Virtual sailing
302312|NCT01491789|Vsail
302313|NCT01491776|Group A Streptococcus
302314|NCT01491776|Strep A
302315|NCT01491776|Rapid Test
302316|NCT01491776|Pharyngitis
302317|NCT01491750|SURGERY
302318|NCT01491750|TOTAL JOINT REPLACEMENT
302319|NCT01491750|TOTAL KNEE REPLACEMENT
302320|NCT01491750|GUIDED IMAGERY
302321|NCT01491750|COMPLEMENTARY AND ALTERNATIVE THERAPY
302322|NCT01491711|Superficial basal cell carcinoma
302323|NCT01491711|Carcinoma, Basal Cell
302324|NCT01491711|Skin diseases
302325|NCT01491711|Connective tissue diseases
302326|NCT01491711|Treatment
302327|NCT01491711|Drug therapy
302328|NCT01491711|Efficacy
302329|NCT01491711|Photodynamic therapy
302330|NCT01491711|Photosensitizing Agents/therapeutic use
302331|NCT01491711|Aminolevulinic acid
302332|NCT01491711|Methylaminolevulinate
302333|NCT01491711|Pain measurement
302334|NCT01491711|Health Care Economics and Organizations
302335|NCT01491698|stomach
302336|NCT01491698|surgery
302337|NCT01491698|Total Gastrectomy
302338|NCT01491698|Roux-En-Y Pouch Reconstruction
302339|NCT01491698|Conventional Roux-En-Y Reconstruction
302340|NCT01491698|Quality of Life
302341|NCT01491698|11-170
302342|NCT01491672|Metastatic Renal Cell Carcinoma
302343|NCT01491672|Second Line
302344|NCT01491672|Everolimus
302345|NCT01491672|RAD001
302346|NCT01491646|pulmonary hypertension
302347|NCT01491646|cardiac magnetic resonance imaging
302348|NCT01491646|Characterize and quantify RV vortex flow
302349|NCT01491646|Assess feasibility of cardiac MR for RVDD diagnosis
302350|NCT01491646|Biomarker information to help diagnose
302351|NCT01491633|Lung cancer
302352|NCT01491633|NSCLC
302353|NCT01491633|Stage IIIB
302354|NCT01491633|Stage IV
302355|NCT01491620|poikiloderma of Civatte
302356|NCT01491620|red dyschromia
302357|NCT01491620|brown dyschromia
302358|NCT01491620|sun damage
302359|NCT01491620|neck
302360|NCT01491620|chest
302361|NCT01491620|dyschromia
302362|NCT01491620|pigmentation disorders
302363|NCT01491620|erythema
302364|NCT01491620|photosensitivity disorders
302365|NCT01491620|sun exposure
302366|NCT01491620|telangiectasia
302367|NCT01491620|hyperpigmentation
302368|NCT01491620|hypopigmentation
302369|NCT01491607|post-exposure prophylaxis
302370|NCT01491607|toxin neutralization assay
302371|NCT01491594|Metastatic sarcoma
302372|NCT01491594|Bone sarcoma
302373|NCT01491581|anthropometry
302374|NCT01491581|zinc
302375|NCT01491581|iodine
302376|NCT01491581|vitamin D
302377|NCT01491581|calcium
302378|NCT01491581|school children
302379|NCT01491581|food supplement
302380|NCT01491568|symptomatic degenerative disc disease at two levels
302381|NCT01491555|Duchenne Muscular Dystrophy
302382|NCT01491555|DMD
302383|NCT01491555|controls
302384|NCT01491555|EIM
302385|NCT01491555|QUS
302386|NCT01491542|Symptomatic Degenerative Disc Disease
302387|NCT01491529|Parkinson Disease
302388|NCT01491529|L-dopa
302389|NCT01491529|Levodopa
302390|NCT01491529|Dyskinesia
302391|NCT01491529|Amantadine
302392|NCT01491516|Lumbar degenerative disc disease
302393|NCT01491503|montelukast
302394|NCT01491503|levocetirizine
302395|NCT01491503|interaction
302396|NCT01491490|Schizophrenia
302397|NCT01491490|Functional psychosis
302398|NCT01491490|Schizophreniform
302399|NCT01491490|Acute psychosis
302400|NCT01491464|symptomatic degenerative disc disease
302401|NCT01491451|Degenerative lumbar disc disease
302402|NCT01491425|symptomatic degenerative disc disease
302403|NCT01491412|Schizophrenia
302404|NCT01491412|antipsychotics
302405|NCT01491412|real life treatment
302406|NCT01491412|non-interventional
302407|NCT01491386|symptomatic degenerative disc disease
302408|NCT01491373|Degenerative Disc Disease
302409|NCT01491373|Symptomatic Degenerative Disc Disease
302410|NCT01491360|Presbyopia
302411|NCT01491360|sclera
302412|NCT01491360|LaserACE
302413|NCT01491347|BDNF
302414|NCT01491347|withdrawal
302415|NCT01491347|alcohol
302416|NCT01491347|psychiatry
302417|NCT01491334|POP
302418|NCT01491334|Pelvic Floor
302419|NCT01491334|Pelvic Organ Prolapse
302420|NCT01491321|chronic low back pain
302421|NCT01491321|bee venom acupuncture
302422|NCT01491295|Lamivudine
302423|NCT01491295|adefovir add on treatment
302424|NCT01491295|tenofovir
302425|NCT01491295|chronic hepatitis B
302426|NCT01491282|human brown adipose tissue activity
302427|NCT01491282|obesity
302428|NCT01491282|energy metabolism
302429|NCT01491282|adaptive thermogenesis
302430|NCT01491269|chronic pain
302431|NCT01491269|internet delivered CBT
302432|NCT01491269|tertiary intervention
302433|NCT01491269|mindfulness
302434|NCT01491269|applied relaxation
302435|NCT01491269|guided self help
302436|NCT01491256|Index of microcirculatory resistance
302437|NCT01491256|atorvastatin
302438|NCT01491256|drug-eluting stent
302439|NCT01491256|acute coronary syndrome
302440|NCT01491243|contrast-induced nephropathy
302441|NCT01491230|cancer
302442|NCT01491230|neutrophil extracellular traps
302443|NCT01491230|autologous hematopoietic stem cell transplantation
302444|NCT01491230|allogeneic hematopoietic stem cell transplantation
302445|NCT01491230|chemotaxis
302446|NCT01491230|superoxide production
302447|NCT01491230|hydrogen peroxide production
302448|NCT01491230|myeloperoxidase
302449|NCT01491217|Oraxol®
302450|NCT01491217|oral paclitaxel
302451|NCT01491217|paclitaxel
302452|NCT01491217|HM30181A
302453|NCT01491217|MTD
302454|NCT01491217|DLT
302455|NCT01491217|RD
302456|NCT01491191|surgical pain
302457|NCT01491191|chronic pain
302458|NCT01491191|prevention
302459|NCT01491191|palmitoylethanolamide
302460|NCT01491165|umbilical cord mesenchyma stem cell
302461|NCT01491152|Cerebral Palsy
302462|NCT01491152|Whole Body Vibration
302463|NCT01491152|Infant
302464|NCT01491152|Motor development
302465|NCT01491152|Physiotherapy
302466|NCT01491139|Radiotherapy
302467|NCT01491139|Biomarkers, pharmacological
302468|NCT01491139|Pharmacokinetics
302469|NCT01491139|Genetic Markers
302470|NCT01491139|Cisplatin
302471|NCT01491139|Poly(ADP-ribose) Polymerases
302472|NCT01491139|AZD 2281
302473|NCT01491139|Radiotherapy, Intensity-Modulated
302474|NCT01491139|Head and Neck
302475|NCT01491139|Chemoradiotherapy
302476|NCT01491139|SCC
302477|NCT01491126|Gastroscopy
302478|NCT01491126|Colonoscopy
302479|NCT01491126|Anesthesia
302480|NCT01491126|Recovery
302481|NCT01491113|Levetiracetam
302482|NCT01491113|Oral administration
302483|NCT01491113|Japanese
302484|NCT01491113|Non-epileptic
302485|NCT01491113|Healthy
302486|NCT01491113|Renal impaired subjects
302487|NCT01491100|Cognition
302488|NCT01491100|Physical Activity
302489|NCT01491100|Relapsing Remitting Multiple Sclerosis
302490|NCT01491087|Pentaxim®
302491|NCT01491087|Whole-cell Pertussis vaccine
302492|NCT01491087|Acellular Pertussis vaccine
302493|NCT01491087|Haemophilus influenzae type b polysaccharide
302494|NCT01491087|Inactivated Polio vaccine
302495|NCT01491087|Pentavac®
302496|NCT01491061|periprocedural myocardial infarction
302497|NCT01491061|ranolazine
302498|NCT01491048|Hip osteoarthritis
302499|NCT01491048|Physiotherapy
302500|NCT01491048|THA
302501|NCT01491035|Children
302502|NCT01491035|Adolescents
302503|NCT01491035|Pharmacokinetic
302504|NCT01491035|Pharmacodynamic
302505|NCT01491022|parkinson's
302506|NCT01491022|gait dysfunction
302507|NCT01491022|ampyra
302508|NCT01491022|4-aminopyridine
302509|NCT01491009|Dexmedetomidine
302510|NCT01491009|midazolam
302511|NCT01491009|remifentanil
302512|NCT01491009|mini-mental state examination
302513|NCT01491009|monitored anaesthesia care
302514|NCT01491009|cystoscopy
302515|NCT01491009|sedation
302516|NCT01490996|Curcumin
302517|NCT01490996|Colorectal cancer
302518|NCT01490996|metastases
302519|NCT01490996|FOLFOX
302520|NCT01490983|Chronic Myeloid Leukemia
302521|NCT01490983|Chronic Phase CML
302522|NCT01490970|Sarcoma Database
302523|NCT01490957|HD
302524|NCT01490957|NHL
302525|NCT01490931|acute pain
302526|NCT01490931|dental pain
302527|NCT01490931|intranasal ketorolac
302528|NCT01490931|dental implant surgery
302529|NCT01490918|Type-II diabetes mellitus
302530|NCT01490918|Acarbose
302531|NCT01490918|ACADEMIC
302532|NCT01490905|Medical food
302533|NCT01490905|Theramine
302534|NCT01490905|Ibuprofen
302535|NCT01490905|Amino acids
302536|NCT01490905|Convenience Pack Kit
302537|NCT01490892|breast abnormality
302538|NCT01490892|ultrasound imaging
302539|NCT01490892|ultrasound contrast agent
302540|NCT01490892|subharmonic imaging
302541|NCT01490879|DFU
302542|NCT01490879|Diabetic Foot Ulcer
302543|NCT01490879|Ulcers
302544|NCT01490879|Foot Ulcers
302545|NCT01490879|chronic wound
302546|NCT01490879|wounds
302547|NCT01490879|Nexagon
302548|NCT01490879|CoDa
302549|NCT01490866|Colorectal Cancer
302550|NCT01490866|Axitinib
302551|NCT01490866|FOLFOX/Bevacizumab
302552|NCT01490853|Ph pos CML
302553|NCT01490853|Philadelphia positive Chronic Myeloid Leukemia
302554|NCT01490840|Fatigue
302555|NCT01490840|MS
302556|NCT01490840|Multiple Sclerosis
302557|NCT01490840|Exercise
302558|NCT01490840|Physical activity
302559|NCT01490840|Physical training
302560|NCT01490840|Fingolimod
302561|NCT01490814|PAF
302562|NCT01490814|two episodes within the last twelve months one episode documented
302563|NCT01490814|Documented treatment failure of at least one antiarrhythmic
302564|NCT01490814|drug AAD Type I or III including β-blocker and AAD intolerance
302565|NCT01490801|childhood Hodgkin lymphoma
302566|NCT01490801|childhood mixed cellularity Hodgkin lymphoma
302567|NCT01490801|hemophagocytic lymphohistiocytosis
302568|NCT01490801|Epstein-Barr virus infection
302569|NCT01490775|Chronic Myeloid Leukemia
302570|NCT01490762|PK
302571|NCT01490762|PD
302572|NCT01490749|Esophageal Cancer
302573|NCT01490749|Neoplasms, Esophageal
302574|NCT01490736|Acne
302575|NCT01490736|Sebum gland disease
302576|NCT01490723|Leukemia
302577|NCT01490723|Chronic lymphocytic leukemia
302578|NCT01490723|Lymphoma
302579|NCT01490723|CD20+ lymphoid malignancies
302580|NCT01490723|Diffuse large B-cell lymphoma
302581|NCT01490723|Allogeneic transplantation
302582|NCT01490723|Rituximab
302583|NCT01490723|Rituxan
302584|NCT01490723|In ibritumomab
302585|NCT01490723|Y ibritumomab
302586|NCT01490723|Zevalin
302587|NCT01490723|Fludarabine Phosphate
302588|NCT01490723|Fludara
302589|NCT01490723|Bendamustine Hydrochloride
302590|NCT01490723|Bendamustine HCL
302591|NCT01490723|CEP-18083
302592|NCT01490723|SDX-105
302593|NCT01490723|Treanda
302594|NCT01490723|Stem Cell Transplantation
302595|NCT01490723|Planar Scintigraphy
302596|NCT01490723|Spect Scan
302597|NCT01490723|Single Photon Emission-Computed Tomography
302598|NCT01490723|CT Scan
302599|NCT01490723|Computed Tomography
302600|NCT01490723|G-CSF
302601|NCT01490723|Filgrastim
302602|NCT01490723|Neupogen
302603|NCT01490723|Thymoglobulin
302604|NCT01490723|ATG
302605|NCT01490723|Antithymocyte Globulin
302606|NCT01490723|Methotrexate
302607|NCT01490723|Mycophenolate
302608|NCT01490723|MMF
302609|NCT01490723|Mycophenolate Mofetil
302610|NCT01490723|CellCept
302611|NCT01490723|Tacrolimus
302612|NCT01490723|Prograf
302613|NCT01490710|NAVA
302614|NCT01490710|Hemodynamic
302615|NCT01490710|Cardiac Index
302616|NCT01490710|Children with admission weight > 5kg
302617|NCT01490697|stress disorders
302618|NCT01490697|posttraumatic
302619|NCT01490697|memory
302620|NCT01490697|mifepristone
302621|NCT01490697|d-cycloserine
302622|NCT01490697|psychophysiology
302623|NCT01490684|candidiasis
302624|NCT01490684|critically ill
302625|NCT01490684|outcomes
302626|NCT01490645|ACS patients participating in a SCP
302627|NCT01490645|QoL after ACS
302628|NCT01490645|ASC Patients's needs
302629|NCT01490632|Moderate
302630|NCT01490632|Severe
302631|NCT01490632|Plaque
302632|NCT01490632|Chronic
302633|NCT01490619|Type 1 diabetes
302634|NCT01490619|Adolescent
302635|NCT01490619|Resilience
302636|NCT01490619|Prevention
302637|NCT01490619|Depression
302638|NCT01490593|Canadian
302639|NCT01490593|Eye
302640|NCT01490593|Injury
302641|NCT01490593|Registry
302642|NCT01490580|Pain
302643|NCT01490580|Newborn
302644|NCT01490580|Anaesthesia
302645|NCT01490580|opioids
302646|NCT01490580|propofol
302647|NCT01490580|neuromuscular blocker
302648|NCT01490580|atropine
302649|NCT01490567|Impaired Cognition Schizophrenia
302650|NCT01490554|Skin aging
302651|NCT01490554|fibroblasts
302652|NCT01490554|transplantation
302653|NCT01490554|autologous
302654|NCT01490541|Gastric intestinal metaplasia
302655|NCT01490528|Pediatric IBD
302656|NCT01490515|non-invasive,
302657|NCT01490515|metabolomics,
302658|NCT01490515|morphology,
302659|NCT01490515|embryo selection,
302660|NCT01490515|implantation rates
302661|NCT01490489|EG-VEGF
302662|NCT01490489|Endocrine Gland-derived Vascular Endothelial Growth Factor
302663|NCT01490489|Pre-eclampsia
302664|NCT01490489|intra-uterine growth retardation
302665|NCT01490489|prognosis
302666|NCT01490476|Neurofibromatosis Type 2 with Vestibular Schwannoma
302667|NCT01490476|Vestibular Schwannoma
302668|NCT01490476|Peripheral Nervous System Diseases
302669|NCT01490476|Otorhinolaryngologic Diseases
302670|NCT01490476|Vestibulocochlear Nerve Diseases
302671|NCT01490463|Treatment of
302672|NCT01490437|Advanced urothelial carcinoma
302673|NCT01490424|TREM-1;
302674|NCT01490424|SNPs;
302675|NCT01490424|prognosis
302676|NCT01490424|control（normal person）
302677|NCT01490411|Specific immunotherapy
302678|NCT01490411|SIT
302679|NCT01490411|SCIT
302680|NCT01490411|recombinant
302681|NCT01490398|Hypertension
302682|NCT01490398|Rosuvastatin
302683|NCT01490398|Coronary flow reserve
302684|NCT01490359|human immunodeficiency virus
302685|NCT01490359|randomized controlled trial
302686|NCT01490359|intervention studies
302687|NCT01490359|South Africa
302688|NCT01490359|men
302689|NCT01490359|sexually behavior
302690|NCT01490359|social cognitive theory
302691|NCT01490346|HIV 1
302692|NCT01490346|Pharmacokinetics
302693|NCT01490346|Drug levels
302694|NCT01490346|Treatment naive
302695|NCT01490320|Violence prevention
302696|NCT01490320|Media
302697|NCT01490320|Primary care
302698|NCT01490320|Parenting
302699|NCT01490307|parenting intervention
302700|NCT01490307|Family Check-Up
302701|NCT01490307|Anxiety Disorders
302702|NCT01490307|Depression
302703|NCT01490307|Depressive Disorder
302704|NCT01490307|Conduct Disorder
302705|NCT01490307|Mental Disorders
302706|NCT01490307|Behavioral Symptoms
302707|NCT01490307|Mood Disorders
302708|NCT01490307|Mental Disorders Diagnosed in Childhood
302709|NCT01490307|Substance-Related Disorders
302710|NCT01490294|Cardiac MRI
302711|NCT01490294|gadobutrol
302712|NCT01490281|Fibromyalgia
302713|NCT01490281|exercise
302714|NCT01490281|physical activity
302715|NCT01490281|pain
302716|NCT01490268|Pharmacokinetic-pharmacodynamic modeling
302717|NCT01490268|Patient-controlled analgesia
302718|NCT01490268|Target-controlled infusion
302719|NCT01490268|Hydromorphone
302720|NCT01490268|Sufentanil
302721|NCT01490268|after thoracotomy
302722|NCT01490268|cardiac surgery
302723|NCT01490255|platelet reactivity
302724|NCT01490255|aspirin
302725|NCT01490255|clopidogrel
302726|NCT01490229|nutraceuticals
302727|NCT01490229|statin
302728|NCT01490216|cocaine
302729|NCT01490216|lisdexamfetamine
302730|NCT01490216|vyvanse
302731|NCT01490203|Gd-EOB-DTPA
302732|NCT01490203|MRI
302733|NCT01490203|Hepatectomy
302734|NCT01490203|Hepatocellular Carcinoma
302735|NCT01490203|Liver Function Tests
302736|NCT01490177|Multiple food allergies
302737|NCT01490151|Hormone
302738|NCT01490151|Diabetes
302739|NCT01490151|Mellitus
302740|NCT01490151|Type 1
302741|NCT01490151|Immune
302742|NCT01490151|Metabolic disorder
302743|NCT01490138|β-D-Glucan test
302744|NCT01490138|IFI
302745|NCT01490125|COPD
302746|NCT01490125|Dyspnea
302747|NCT01490125|QVA149
302748|NCT01490125|tiotropium
302749|NCT01490073|Intrauterine device
302750|NCT01490073|Pain
302751|NCT01490073|Contraception
302752|NCT01490073|Nitroglycerin
302753|NCT01490073|Nitric oxide donor
302754|NCT01490073|Intrauterine device insertion
302755|NCT01490060|cancer
302756|NCT01490060|fosaprepitant
302757|NCT01490060|Ifosfamide-based Multi-day Chemotherapy
302758|NCT01490060|Chemotherapy-induced nausea and vomiting
302759|NCT01490060|CINV
302760|NCT01490060|multi-day chemotherapy regimens
302761|NCT01490060|antiemetics
302762|NCT01490060|adverse effect
302763|NCT01490060|doxorubicin plus ifosfamide
302764|NCT01490060|AI
302765|NCT01490060|AI and vincristine
302766|NCT01490060|VAI
302767|NCT01490060|aprepitant
302768|NCT01490060|prevention
302769|NCT01490060|nausea
302770|NCT01490060|vomiting
302771|NCT01490060|emetogenic chemotherapy
302772|NCT01490034|obesity
302773|NCT01490034|energy intake
302774|NCT01490034|appetite
302775|NCT01490034|food form
302776|NCT01490034|beverage
302777|NCT01490034|learning
302778|NCT01490034|dietary compensation
302779|NCT01490021|Healthy young men
302780|NCT01489995|Food effect
302781|NCT01489995|GR181413A
302782|NCT01489995|AT1001
302783|NCT01489995|migalastat hydrochloride
302784|NCT01489995|Lysosomal storage disorders
302785|NCT01489995|Pharmacokinetics
302786|NCT01489982|Parkinson's disease
302787|NCT01489982|insomnia
302788|NCT01489969|sleep latency
302789|NCT01489969|Sleep maintenance
302790|NCT01489969|Sleep fragmentation
302791|NCT01489969|Polysomnography
302792|NCT01489956|Keyhole Limpet Hemocyanin (KLH)
302793|NCT01489956|Immucothel
302794|NCT01489956|Native KLH
302795|NCT01489956|Healthy volunteers
302796|NCT01489956|Oral tolerance
302797|NCT01489956|Immunogenicity
302798|NCT01489956|Autoimmune diseases
302799|NCT01489930|Exercise
302800|NCT01489930|Aging
302801|NCT01489930|Sarcopenia
302802|NCT01489930|Mitochondria
302803|NCT01489917|radial artery occlusion
302804|NCT01489917|hemostasis
302805|NCT01489917|coronary intervention
302806|NCT01489917|radial approach
302807|NCT01489904|drooling
302808|NCT01489904|cerebral palsy
302809|NCT01489891|Esophagogastroduodenoscopy
302810|NCT01489891|Lidocaine
302811|NCT01489891|Propofol
302812|NCT01489878|Coagulase-negative staphylococci
302813|NCT01489878|Staphylococcus epidermidis
302814|NCT01489878|Staphylococcus aureus
302815|NCT01489878|Anti-bacterial agents
302816|NCT01489878|Drug resistance, Microbial
302817|NCT01489878|Methicillin resistance
302818|NCT01489878|Β-lactams
302819|NCT01489878|Fluoroquinolones
302820|NCT01489878|Macrolides
302821|NCT01489878|Synergistin
302822|NCT01489878|General practitioners
302823|NCT01489878|Antibiotic selection pressure
302824|NCT01489878|Ambulatory antibiotherapy
302825|NCT01489878|Community patients
302826|NCT01489865|Pancreas cancer
302827|NCT01489865|Veliparib
302828|NCT01489865|oxaliplatin
302829|NCT01489852|Assisted reproductive treatment
302830|NCT01489852|GnRH antagonist
302831|NCT01489852|Estrogen pre-treatment
302832|NCT01489852|Ovarian stimulation
302833|NCT01489839|periodontal disease
302834|NCT01489839|biomarkers
302835|NCT01489839|periodontal treatment
302836|NCT01489839|clinical attachment level
302837|NCT01489826|Cancer
302838|NCT01489800|feeding
302839|NCT01489800|complications
302840|NCT01489800|radical cystectomy
302841|NCT01489787|Surgery
302842|NCT01489787|Ultrasonic therapy
302843|NCT01489787|Liver
302844|NCT01489761|long lesions
302845|NCT01489761|drug eluting stents
302846|NCT01489735|GERD
302847|NCT01489735|GERD Q QUESTIONNAIRE
302848|NCT01489722|Leukemia
302849|NCT01489722|AML
302850|NCT01489722|AZD1208
302851|NCT01489709|overactive bladder
302852|NCT01489709|solifenacin
302853|NCT01489709|Overactive bladder questionnaire
302854|NCT01489709|Overactive Bladder Symptom Score
302855|NCT01489709|satisfaction score
302856|NCT01489696|Pharmacokinetics
302857|NCT01489696|Mirabegron
302858|NCT01489696|Tamsulosin
302859|NCT01489696|Phase 1
302860|NCT01489683|intubating conditions
302861|NCT01489683|propofol
302862|NCT01489683|remifentanil
302863|NCT01489683|topical lidocaine
302864|NCT01489657|Obesity
302865|NCT01489657|Bariatric Surgery
302866|NCT01489657|Sleeve Gastrectomy
302867|NCT01489657|Metabolite Profiling
302868|NCT01489631|Epidural
302869|NCT01489631|Local infiltration
302870|NCT01489631|Knee
302871|NCT01489631|Arthroplasty
302872|NCT01489618|Common variable immunodeficiency
302873|NCT01489618|pneumococcal vaccine
302874|NCT01489618|prime boost
302875|NCT01489605|Orotracheal intubation, videolaryngoscopy
302876|NCT01489566|Hepatocellular,Carcinoma,recurrence
302877|NCT01489553|Egg hypersensitivity
302878|NCT01489553|egg allergy
302879|NCT01489553|egg protein allergy
302880|NCT01489540|Burn
302881|NCT01489540|Depth
302882|NCT01489540|Diagnosis
302883|NCT01489540|Laser Doppler Imaging
302884|NCT01489527|Vaccine
302885|NCT01489527|Placebo
302886|NCT01489527|sexually transmitted infection (STI)
302887|NCT01489527|HIV
302888|NCT01489527|Human Immunodeficiency
302889|NCT01489527|Gardasil
302890|NCT01489527|HPV
302891|NCT01489527|human papillomavirus
302892|NCT01489514|peanut allergy
302893|NCT01489514|hypoallergenic peanut extracts
302894|NCT01489514|epicutaneous skin prick testing
302895|NCT01489501|Caomecs, Transplantation, Limbal stem cell deficiency,
302896|NCT01489488|Relative bioavailability study
302897|NCT01489475|children
302898|NCT01489475|congenital heart defects
302899|NCT01489475|cardiopulmonary bypass
302900|NCT01489475|modified ultrafiltration
302901|NCT01489475|angiopoietins
302902|NCT01489475|cytokines
302903|NCT01489462|Arthritis
302904|NCT01489462|Osteoarthritis
302905|NCT01489462|Strength Training
302906|NCT01489449|drug coated balloon
302907|NCT01489449|NSTEMI
302908|NCT01489436|gallstone disease
302909|NCT01489436|cholecystectomy
302910|NCT01489436|minimally invasive
302911|NCT01489436|surgical
302912|NCT01489436|laparoscopic
302913|NCT01489436|single port
302914|NCT01489436|cytokine
302915|NCT01489423|stage IIIC melanoma
302916|NCT01489423|stage IV melanoma
302917|NCT01489423|recurrent melanoma
302918|NCT01489397|Confocol laser endomicroscopy
302919|NCT01489397|Feasibility of Confocol laser endomicroscopy
302920|NCT01489384|Rheumatoid arthritis
302921|NCT01489384|DAS28
302922|NCT01489358|Vaccine-Mediated Protection
302923|NCT01489358|Antibody Response
302924|NCT01489358|Chikungunya Virus
302925|NCT01489358|Immune Response
302926|NCT01489358|Healthy Volunteer
302927|NCT01489358|Humoral Inmunity
302928|NCT01489358|Virus-like Particles
302929|NCT01489345|ONO-2952
302930|NCT01489345|Healthy adult subjects
302931|NCT01489345|Multiple dose
302932|NCT01489345|Safety
302933|NCT01489345|Tolerability
302934|NCT01489345|Pharmacokinetics
302935|NCT01489332|rectal cancer
302936|NCT01489332|capecitabine
302937|NCT01489332|radiotherapy
302938|NCT01489332|locally advanced rectal cancer
302939|NCT01489319|inflammation
302940|NCT01489319|body composition
302941|NCT01489319|hyperandrogenism
302942|NCT01489319|insulin resistance
302943|NCT01489306|Respiratory Syncytial Virus Infection
302944|NCT01489306|RSV
302945|NCT01489280|Temple Touch Pro
302946|NCT01489280|Medisim
302947|NCT01489280|temperature
302948|NCT01489280|surgery
302949|NCT01489267|cerebellar ataxia
302950|NCT01489267|hereditary disease
302951|NCT01489267|stem cell
302952|NCT01489254|Multiple Sclerosis,
302953|NCT01489254|Relapsing-Remitting Multiple Sclerosis,
302954|NCT01489254|glatiramer acetate,
302955|NCT01489254|MRI,
302956|NCT01489254|lesions,
302957|NCT01489254|MS relapse rate,
302958|NCT01489254|Copaxone
302959|NCT01489241|Pulmonary Disease, Chronic Obstructive
302960|NCT01489241|Telemedicine
302961|NCT01489228|Chagas Disease
302962|NCT01489202|drug-eluting stent
302963|NCT01489202|percutaneous coronary intervention
302964|NCT01489176|Stress Echocardiography
302965|NCT01489176|Real-Time Perfusion Imaging
302966|NCT01489176|Regadenoson
302967|NCT01489176|Optison
302968|NCT01489163|Gestational Diabetes
302969|NCT01489163|Weight Loss
302970|NCT01489163|Physical Activity
302971|NCT01489163|Pregnancy
302972|NCT01489163|Postpartum
302973|NCT01489163|Intervention
302974|NCT01489150|Acute respiratory failure
302975|NCT01489150|Hypercapnia
302976|NCT01489150|Non invasive ventilation
302977|NCT01489150|End-tidal CO2
302978|NCT01489124|Infection
302979|NCT01489124|Imipenem
302980|NCT01489124|Ventilator-Associated Pneumonia
302981|NCT01489124|pharmacokinetic
302982|NCT01489124|pharmacodynamic
302983|NCT01489098|Body composition
302984|NCT01489098|Protein Metabolism
302985|NCT01489085|ventilation
302986|NCT01489085|automated
302987|NCT01489033|Allergic rhinitis
302988|NCT01489033|Phleum pratense
302989|NCT01489033|Timothy grass pollen allergy
302990|NCT01489033|subcutaneous immunotherapy
302991|NCT01489020|Allergy
302992|NCT01489020|Immunotherapy
302993|NCT01489020|Allergic Rhinoconjunctivitis
302994|NCT01489020|D. pteronyssinus
302995|NCT01489020|house dust allergy
302996|NCT01489007|vegetarian
302997|NCT01489007|children
302998|NCT01489007|iron
302999|NCT01489007|iron absorption
303000|NCT01488981|Radio Frequency Microstimulator
303001|NCT01488981|Traumatic Brain Injury
303002|NCT01488981|TBI
303003|NCT01488981|Arm Rehabilitation
303004|NCT01488981|electrical stimulation
303005|NCT01488981|FES
303006|NCT01488968|high risk prostate cancer
303007|NCT01488968|hypofractionated radiation treatment
303008|NCT01488968|higher biological doses
303009|NCT01488968|acceptable rectal toxicity
303010|NCT01488968|Radiation Treatment
303011|NCT01488955|bacterial infection
303012|NCT01488942|HIV
303013|NCT01488942|reinforcement
303014|NCT01488942|medication adherence
303015|NCT01488942|patient compliance
303016|NCT01488942|antiretroviral therapy, highly active
303017|NCT01488916|Vitamin D
303018|NCT01488916|Postprandial Glucose
303019|NCT01488916|Type 2 Diabetes
303020|NCT01488903|genetic susceptibility
303021|NCT01488903|obesity
303022|NCT01488903|body composition
303023|NCT01488903|the metabolic syndrome
303024|NCT01488903|women
303025|NCT01488890|Dengue fever
303026|NCT01488890|Dengue Hemorrhagic Fever
303027|NCT01488890|CYD dengue vaccine
303028|NCT01488890|Yellow Fever
303029|NCT01488890|Flavivirus
303030|NCT01488877|Type 2 diabetes mellitus. albuminuria.
303031|NCT01488864|Hot flashes
303032|NCT01488864|Vasomotor symptoms
303033|NCT01488864|Menopause
303034|NCT01488864|Applied Relaxation
303035|NCT01488864|Health Related Quality of Life
303036|NCT01488864|Salivary cortisol
303037|NCT01488851|Osteo necrosis of the Jaw
303038|NCT01488812|Hip-fracture
303039|NCT01488799|Anxiety
303040|NCT01488799|Generalized Anxiety Disorder
303041|NCT01488799|Motivational Interviewing
303042|NCT01488799|Cognitive Behavioural Therapy
303043|NCT01488799|Psychotherapy
303044|NCT01488786|Assistive Technology
303045|NCT01488786|Non-Surgical Visual Prosthetic
303046|NCT01488786|Sensory Substitution
303047|NCT01488773|asthma
303048|NCT01488773|asthma control
303049|NCT01488773|inhaled glucocorticosteroid
303050|NCT01488773|ICS
303051|NCT01488773|leukotriene antagonist
303052|NCT01488773|LTRA
303053|NCT01488773|montelukast
303054|NCT01488773|fluticasone
303055|NCT01488773|salmeterol
303056|NCT01488773|observational study
303057|NCT01488773|repeated measures
303058|NCT01488773|retrospective
303059|NCT01488747|Omega-3 fatty acids
303060|NCT01488747|Phospholipid fatty acids
303061|NCT01488747|chymlomicron fatty acids
303062|NCT01488747|Bioavailability fo fish oil supplements in healthy adults
303063|NCT01488734|Vitamin D
303064|NCT01488734|Mushroom
303065|NCT01488734|Cholecalciferol
303066|NCT01488734|Prediabetes
303067|NCT01488734|Metabolic Syndrome
303068|NCT01488708|Lupus
303069|NCT01488708|SLE
303070|NCT01488708|Systemic Lupus Erythematosus
303071|NCT01488708|Immune System Disease
303072|NCT01488695|intubation
303073|NCT01488695|double lumen tube
303074|NCT01488682|Head and neck cancer
303075|NCT01488682|Neck dissection
303076|NCT01488682|Harmonic scalpel
303077|NCT01488669|head and neck neoplasms
303078|NCT01488669|neck dissection
303079|NCT01488669|robotics
303080|NCT01488656|Antioxidants
303081|NCT01488656|Dietary supplements
303082|NCT01488656|Forced vital lung capacity
303083|NCT01488656|Exhaled nitric oxide
303084|NCT01488656|Air pollution
303085|NCT01488643|Bronchospasm
303086|NCT01488643|Laparoscopic Gastrectomy
303087|NCT01488643|Obesity
303088|NCT01488630|substance abuse
303089|NCT01488630|alcohol
303090|NCT01488630|drug
303091|NCT01488630|smoking
303092|NCT01488630|HIV screening
303093|NCT01488617|Surgery
303094|NCT01488617|Psychosocial Factors
303095|NCT01488617|Psychological Distress
303096|NCT01488617|Outcome Assessment (Health Care)
303097|NCT01488578|Overactive Bladder
303098|NCT01488578|Japanese
303099|NCT01488578|Tolterodine
303100|NCT01488578|Detrusitol
303101|NCT01488578|Detrol
303102|NCT01488578|Postmarketing commitment plan.
303103|NCT01488552|pancreatic cancer
303104|NCT01488552|pancreatic adenocarcinoma
303105|NCT01488552|Stage IV pancreatic cancer
303106|NCT01488552|pancreas
303107|NCT01488552|pancreatic
303108|NCT01488539|Stress Disorders, Post-Traumatic
303109|NCT01488539|PTSD
303110|NCT01488539|Adult Survivors of Child Abuse
303111|NCT01488539|Women
303112|NCT01488539|Interpersonal violence
303113|NCT01488539|psychological trauma
303114|NCT01488526|Hepatitis B
303115|NCT01488526|Vertical transmission
303116|NCT01488526|Pregnancy
303117|NCT01488526|Antiviral treatment
303118|NCT01488513|ABC294640
303119|NCT01488513|RedHill Biopharma, Ltd.
303120|NCT01488513|ABC-101
303121|NCT01488513|Medical University of South Carolina
303122|NCT01488513|Apogee Biotechnology Corporation
303123|NCT01488500|Wood smoke
303124|NCT01488500|inflammation
303125|NCT01488500|lung function
303126|NCT01488500|arterial stiffness
303127|NCT01488500|heart rate variability
303128|NCT01488500|Respiratory and systemic inflammation following exposure to woodsmoke in healthy volunteers
303129|NCT01488487|HCC
303130|NCT01488487|Advanced Hepatocellular Carcinoma
303131|NCT01488487|Metastatic Hepatocellular Carcinoma
303132|NCT01488487|Liver Cancer
303133|NCT01488474|regional anesthesia
303134|NCT01488474|peripheral nerve stimulation
303135|NCT01488474|diabetes
303136|NCT01488474|diabetic neuropathy
303137|NCT01488461|Congenital cerebellar ataxias
303138|NCT01488461|Genetics
303139|NCT01488461|Gene ATCAY
303140|NCT01488461|Gene ABC7
303141|NCT01488461|Cerebellar atrophy
303142|NCT01488448|Hypertonic saline
303143|NCT01488448|Bronchiolitis
303144|NCT01488448|Infants
303145|NCT01488448|Wheezing
303146|NCT01488448|Nebulized
303147|NCT01488448|Bronchodilator
303148|NCT01488396|Cyclosporin
303149|NCT01488396|Stevens-Johnson syndrome
303150|NCT01488396|Dry eye
303151|NCT01488383|Hyperglycemia
303152|NCT01488383|Diabetes
303153|NCT01488383|Blood glucose
303154|NCT01488383|Hypertension
303155|NCT01488383|Anti hypertensive agents
303156|NCT01488383|Anti hypertensive drugs
303157|NCT01488383|Anti hypertensive
303158|NCT01488370|breathing tube placement
303159|NCT01488357|Breast cancer
303160|NCT01488357|UNC
303161|NCT01488357|Lineberger
303162|NCT01488357|Breast Reconstruction
303163|NCT01488357|Mastectomy
303164|NCT01488318|Cetuximab
303165|NCT01488318|Dasatinib
303166|NCT01488318|Squamous Cell
303167|NCT01488318|Head and Neck
303168|NCT01488318|After Cetuximab Containing Chemoradiotherapy
303169|NCT01488318|Recurrent
303170|NCT01488318|Metastatic
303171|NCT01488305|MNP
303172|NCT01488305|AAMA program
303173|NCT01488305|Nepal
303174|NCT01488305|HFP
303175|NCT01488305|IYCF
303176|NCT01488305|BCC
303177|NCT01488292|mental health
303178|NCT01488292|social skills
303179|NCT01488279|Pre-diabetes
303180|NCT01488279|Impaired fasting glucose
303181|NCT01488279|Impaired glucose tolerance
303182|NCT01488279|Steroid-induced hyperglycemia
303183|NCT01488266|depression
303184|NCT01488266|depressive
303185|NCT01488266|major
303186|NCT01488266|aripiprazole
303187|NCT01488266|switching
303188|NCT01488266|augmentation
303189|NCT01488266|antidepressant
303190|NCT01488253|Hematopoietic stem cell transplantation
303191|NCT01488253|Graft vs Host disease
303192|NCT01488253|Prevention
303193|NCT01488253|Sirolimus
303194|NCT01488253|Tacrolimus
303195|NCT01488240|burn
303196|NCT01488240|scar
303197|NCT01488240|laser
303198|NCT01488227|Vitamin D status in athletes
303199|NCT01488227|Vitamin D
303200|NCT01488227|25(OH)D
303201|NCT01488227|athletes
303202|NCT01488227|body composition
303203|NCT01488227|inflammatory markers
303204|NCT01488227|illness
303205|NCT01488227|injury
303206|NCT01488214|Systemic Sclerosis
303207|NCT01488214|neuropsychiatric manifestations
303208|NCT01488214|magnetic resonance imaging
303209|NCT01488201|Psoriasis
303210|NCT01488188|Influenza vaccine
303211|NCT01488188|nasal route
303212|NCT01488188|sublingual route
303213|NCT01488188|immunogenicity
303214|NCT01488188|safety
303215|NCT01488175|TKA
303216|NCT01488175|RSA
303217|NCT01488175|Tourniquet
303218|NCT01488175|Arthroplasty
303219|NCT01488175|Knee
303220|NCT01488149|Fentanyl
303221|NCT01488149|Bupivacaine
303222|NCT01488149|Nalbuphine
303223|NCT01488136|Type 1 diabetes
303224|NCT01488136|Hypoglycaemia
303225|NCT01488136|Diazoxide
303226|NCT01488123|Breast, Cancer, Survivorship, Integrative, Complementary
303227|NCT01488097|Enzyme Replacement Therapy (ERT)
303228|NCT01488097|Lysosomal Storage Disease
303229|NCT01488097|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
303230|NCT01488097|Acid cholesteryl ester hydrolase deficiency, type 2
303231|NCT01488097|Acid lipase disease
303232|NCT01488097|Cholesterol ester hydrolase deficiency
303233|NCT01488097|LAL Deficiency
303234|NCT01488097|LIPA Deficiency
303235|NCT01488097|Wolman disease
303236|NCT01488084|Saphenous vein graft patency
303237|NCT01488084|Coronary artery bypass surgery
303238|NCT01488084|Coronary artery disease
303239|NCT01488071|Depression
303240|NCT01488071|Multimodal antidepressant
303241|NCT01488045|Colonoscopy
303242|NCT01488045|Propofol
303243|NCT01488045|Cancer Screening
303244|NCT01488006|Primary Glenohumeral Osteoarthritis
303245|NCT01488006|Total shoulder arthroplasty
303246|NCT01488006|Total shoulder replacement
303247|NCT01488006|Osteoarthritis
303248|NCT01488006|Multicenter study
303249|NCT01487993|Obesity
303250|NCT01487993|Children
303251|NCT01487993|Adolescents
303252|NCT01487993|Metformin
303253|NCT01487993|Insulin resistance
303254|NCT01487967|Attention Deficit Hyperactivity Disorder
303255|NCT01487967|ADHD
303256|NCT01487967|Preferences
303257|NCT01487967|Goals
303258|NCT01487967|Decision Making
303259|NCT01487954|skin reactions secondary to radiation therapy
303260|NCT01487928|breastfed
303261|NCT01487928|human milk cream
303262|NCT01487928|human milk fat
303263|NCT01487928|caloric supplement
303264|NCT01487915|Cisplatin-unfit condition
303265|NCT01487902|Chemotherapy-naive
303266|NCT01487876|DNA vaccine
303267|NCT01487876|HBV
303268|NCT01487876|Chronic hepatitis B (CHB)
303269|NCT01487876|T-cell
303270|NCT01487863|prostate cancer
303271|NCT01487863|prostate
303272|NCT01487863|AIPC
303273|NCT01487863|androgen-independent
303274|NCT01487863|androgen independent
303275|NCT01487863|hormone insensitive
303276|NCT01487863|hormone-insensitive
303277|NCT01487863|PSA
303278|NCT01487863|prostatic adenocarcinoma
303279|NCT01487863|hormone-refractory
303280|NCT01487863|hormone refractory
303281|NCT01487863|HRPC
303282|NCT01487863|immune therapy
303283|NCT01487863|immunotherapy
303284|NCT01487863|vaccine
303285|NCT01487863|dendritic cells
303286|NCT01487863|antigen-presenting cells
303287|NCT01487863|antigen presenting cells
303288|NCT01487863|cancer vaccine
303289|NCT01487863|therapeutic vaccine
303290|NCT01487863|therapeutic cancer vaccine
303291|NCT01487863|recombinant
303292|NCT01487863|biological
303293|NCT01487863|biopharmaceutical
303294|NCT01487863|biotechnology
303295|NCT01487863|biotech
303296|NCT01487850|wind instruments
303297|NCT01487850|molds
303298|NCT01487850|hypersensitivity pneumonitis
303299|NCT01487850|fungal contamination of wind instruments
303300|NCT01487850|specific antibodies against molds in musicians' sera
303301|NCT01487850|musicians
303302|NCT01487837|Fibrinogen
303303|NCT01487837|Blood coagulation disorders
303304|NCT01487837|Postoperative bleeding
303305|NCT01487837|Transfusions
303306|NCT01487785|metastatic pancreatic cancer
303307|NCT01487785|LDE225
303308|NCT01487785|gemcitabine
303309|NCT01487785|locally advanced
303310|NCT01487785|adenocarcinoma
303311|NCT01487746|APLA
303312|NCT01487746|APS
303313|NCT01487746|Stroke
303314|NCT01487746|minor anti body
303315|NCT01487746|major anti body
303316|NCT01487746|APLA antibodies in Serum
303317|NCT01487733|metastatic squamous neck cancer with occult primary squamous cell carcinoma
303318|NCT01487733|metastatic squamous neck cancer with occult primary
303319|NCT01487733|recurrent metastatic squamous neck cancer with occult primary
303320|NCT01487733|recurrent squamous cell carcinoma of the hypopharynx
303321|NCT01487733|recurrent squamous cell carcinoma of the larynx
303322|NCT01487733|recurrent squamous cell carcinoma of the lip and oral cavity
303323|NCT01487733|recurrent squamous cell carcinoma of the nasopharynx
303324|NCT01487733|recurrent squamous cell carcinoma of the oropharynx
303325|NCT01487733|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
303326|NCT01487733|salivary gland squamous cell carcinoma
303327|NCT01487733|stage III squamous cell carcinoma of the hypopharynx
303328|NCT01487733|stage III squamous cell carcinoma of the larynx
303329|NCT01487733|stage III squamous cell carcinoma of the lip and oral cavity
303330|NCT01487733|stage III squamous cell carcinoma of the nasopharynx
303331|NCT01487733|stage III squamous cell carcinoma of the oropharynx
303332|NCT01487733|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
303333|NCT01487733|stage IV squamous cell carcinoma of the hypopharynx
303334|NCT01487733|stage IVA squamous cell carcinoma of the larynx
303335|NCT01487733|stage IVA squamous cell carcinoma of the lip and oral cavity
303336|NCT01487733|stage IVA squamous cell carcinoma of the oropharynx
303337|NCT01487733|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
303338|NCT01487733|stage IVB squamous cell carcinoma of the larynx
303339|NCT01487733|stage IVB squamous cell carcinoma of the lip and oral cavity
303340|NCT01487733|stage IVB squamous cell carcinoma of the oropharynx
303341|NCT01487733|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
303342|NCT01487733|stage IVC squamous cell carcinoma of the larynx
303343|NCT01487733|stage IVC squamous cell carcinoma of the lip and oral cavity
303344|NCT01487733|stage IVC squamous cell carcinoma of the oropharynx
303345|NCT01487733|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
303346|NCT01487733|recurrent salivary gland cancer
303347|NCT01487733|stage III salivary gland cancer
303348|NCT01487733|stage IVA salivary gland cancer
303349|NCT01487733|stage IVB salivary gland cancer
303350|NCT01487733|stage IVC salivary gland cancer
303351|NCT01487720|Castration-resistant prostate cancer
303352|NCT01487720|Docetaxel-refractory status
303353|NCT01487707|pregnancy
303354|NCT01487707|maternal mortality
303355|NCT01487707|neonatal mortality
303356|NCT01487707|community intervention
303357|NCT01487707|voluntary health worker
303358|NCT01487707|safe birth kit
303359|NCT01487707|maternal child health
303360|NCT01487694|back cohosh
303361|NCT01487694|cimicifuga racemosa
303362|NCT01487694|menopausal symptoms
303363|NCT01487694|hot flashes
303364|NCT01487694|Kupperman index
303365|NCT01487694|MENQOL
303366|NCT01487668|chronic mental disorders
303367|NCT01487668|cardiovascular disease
303368|NCT01487668|behavior change
303369|NCT01487655|Open-angle glaucoma
303370|NCT01487655|Low tension glaucoma
303371|NCT01487655|Color Doppler Imaging
303372|NCT01487629|Diabetic Retinopathy
303373|NCT01487629|Macular Edema
303374|NCT01487629|Bevacizumab
303375|NCT01487629|Ranibizumab
303376|NCT01487616|Mullerian anomalies
303377|NCT01487616|Congenital uterine malformations or anomalies
303378|NCT01487616|Arcuate
303379|NCT01487616|Septate
303380|NCT01487616|Subseptate
303381|NCT01487616|Bicornuate
303382|NCT01487616|Unicornuate
303383|NCT01487616|Didelphys
303384|NCT01487616|T-shaped
303385|NCT01487603|Patients
303386|NCT01487603|undiagnosed enlarged
303387|NCT01487603|lymph nodes
303388|NCT01487590|pregnancy
303389|NCT01487590|breech
303390|NCT01487590|acupuncture
303391|NCT01487590|moxibustion
303392|NCT01487590|version
303393|NCT01487577|Allogeneic blood and marrow transplantation (BMT)
303394|NCT01487577|Graft versus host disease
303395|NCT01487577|Mycophenolate mofetil
303396|NCT01487577|Pharmacokinetics
303397|NCT01487564|Healthy volunteers
303398|NCT01487564|Pharmacokinetics
303399|NCT01487564|OROS Hydromorphone
303400|NCT01487564|Hydromorphone
303401|NCT01487564|Taiwan
303402|NCT01487564|UGT2B7 Gene
303403|NCT01487551|Systemic sclerosis
303404|NCT01487551|Biomarkers
303405|NCT01487525|symptomatic knee osteoarthritis
303406|NCT01487525|partial blood flow restriction
303407|NCT01487525|knee extensor strength
303408|NCT01487512|Healthy Volunteers
303409|NCT01487512|Dose Proportionality
303410|NCT01487512|Pharmacokinetics
303411|NCT01487512|OROS Hydromorphone
303412|NCT01487512|Hydromorphone
303413|NCT01487512|Taiwan
303414|NCT01487486|Polycystic Ovary Syndrome
303415|NCT01487486|PCOS
303416|NCT01487486|Follicular Fluid
303417|NCT01487486|Proteomics
303418|NCT01487486|Glyco-proteomics
303419|NCT01487473|Meditation
303420|NCT01487473|Mindfulness
303421|NCT01487473|Attention
303422|NCT01487473|Chronic Pain
303423|NCT01487473|Depression
303424|NCT01487473|Anxiety
303425|NCT01487473|Stress
303426|NCT01487473|Acceptance
303427|NCT01487473|Pain intensity
303428|NCT01487473|Pain disability
303429|NCT01487460|High cholesterol levels
303430|NCT01487460|Hyperlipidemia
303431|NCT01487460|High-density Lipoprotein
303432|NCT01487460|Low-density Lipoprotein
303433|NCT01487460|Simvastatin
303434|NCT01487434|Attendance
303435|NCT01487434|Truancy
303436|NCT01487434|Student engagement
303437|NCT01487434|Mentoring
303438|NCT01487434|Monitoring
303439|NCT01487434|Case management
303440|NCT01487395|Alzheimer
303441|NCT01487395|Donepezil
303442|NCT01487395|biomarkers
303443|NCT01487395|battery
303444|NCT01487395|cognition
303445|NCT01487395|imaging
303446|NCT01487395|neurophysiological
303447|NCT01487356|Colonoscopy
303448|NCT01487356|quality assurance
303449|NCT01487356|withdrawal time
303450|NCT01487356|polyp detection rate
303451|NCT01487343|Oral Chemotherapy
303452|NCT01487343|capecitabine
303453|NCT01487343|questionnaire
303454|NCT01487343|breast
303455|NCT01487343|gastric
303456|NCT01487343|11-194
303457|NCT01487330|aortic stenosis
303458|NCT01487330|aortic valve stenosis
303459|NCT01487330|valvular heart disease
303460|NCT01487330|aortic valve replacement
303461|NCT01487330|transcatheter aortic valve implantation
303462|NCT01487330|TAVI
303463|NCT01487330|TAVR
303464|NCT01487317|Delirium
303465|NCT01487317|acetylcholinesterase inhibitor
303466|NCT01487317|Elderly
303467|NCT01487317|Emergency department
303468|NCT01487291|Thrombophilia tests
303469|NCT01487291|Hypofibrinolysis
303470|NCT01487291|Fibrinolysis
303471|NCT01487278|postpartum hemorrhage
303472|NCT01487278|prevention
303473|NCT01487278|misoprostol
303474|NCT01487278|Uniject
303475|NCT01487278|oxytocin
303476|NCT01487265|Erlotinib
303477|NCT01487265|BKM120
303478|NCT01487265|NSCLC
303479|NCT01487226|Cervical cancer
303480|NCT01487213|Medical abortion
303481|NCT01487213|Termination of pregnancy
303482|NCT01487213|Mifepristone
303483|NCT01487213|Misoprostol
303484|NCT01487213|Urine hCG
303485|NCT01487213|Follow Up
303486|NCT01487213|Termination of unwanted pregnancy. Self assessment (follow up) after medical abortion
303487|NCT01487200|Osteoarthritis
303488|NCT01487200|Knee
303489|NCT01487200|Steroid
303490|NCT01487200|intra-articular
303491|NCT01487200|injection
303492|NCT01487187|Cord-milking
303493|NCT01487187|hemodynamic
303494|NCT01487187|preterm infants
303495|NCT01487161|Osteoarthritis
303496|NCT01487161|Knee
303497|NCT01487161|pain
303498|NCT01487161|steroid
303499|NCT01487161|intra-articular
303500|NCT01487161|injection
303501|NCT01487135|Thorough QT (TQT)
303502|NCT01487135|EVP-6124
303503|NCT01487122|Diathermy
303504|NCT01487122|Neck Pain
303505|NCT01487109|Type 2 diabetes
303506|NCT01487109|chronic kidney disease
303507|NCT01487083|schizophrenia
303508|NCT01487083|LY2140023
303509|NCT01487083|pomaglumetad methionil
303510|NCT01487057|thyroid cancer
303511|NCT01487057|dislipidemia
303512|NCT01487057|cardiovascular risk
303513|NCT01487044|DME
303514|NCT01487031|Autologous Stem Cell Transplantation
303515|NCT01487031|multiple myeloma
303516|NCT01487031|non-Hodgkin
303517|NCT01487031|Hodgkin lymphoma
303518|NCT01487031|Music Therapy
303519|NCT01487031|Nausea
303520|NCT01487031|Pain
303521|NCT01487018|Zygomatic Fractures
303522|NCT01487018|Surgery, Computer-Assisted
303523|NCT01487018|Facial Asymmetry
303524|NCT01487005|ozone
303525|NCT01487005|air pollution
303526|NCT01487005|vascular function
303527|NCT01487005|cardiac function
303528|NCT01487005|inflammation
303529|NCT01486953|respiratory resistance
303530|NCT01486953|lung compliance
303531|NCT01486953|desflurane
303532|NCT01486953|sevoflurane
303533|NCT01486836|Cardiac disease (ICD indication)
303534|NCT01486810|cocaine
303535|NCT01486810|lisdexamfetamine
303536|NCT01486797|Relapsed Chronic Lymphocytic Leukemia (CLL)
303537|NCT01486797|NOX-A12
303538|NCT01486797|Bendamustine
303539|NCT01486797|Rituximab
303540|NCT01486797|Spiegelmer
303541|NCT01486797|Chemosensitization
303542|NCT01486797|Stromal cell-derived factor-1 (SDF-1)
303543|NCT01486797|CXCL12
303544|NCT01486784|equal to or greater than age 60 years
303545|NCT01486784|non-M3 AML
303546|NCT01486784|relapsed disease
303547|NCT01486784|primary refractory disease
303548|NCT01486784|not appropriate or willing candidates for aggressive therapy
303549|NCT01486784|AML
303550|NCT01486771|Proliferative Diabetic Retinopathy
303551|NCT01486732|Cerebral Palsy
303552|NCT01486732|Umbilical Cord Blood
303553|NCT01486732|FLT-PET
303554|NCT01486719|Finger pulp reconstruction
303555|NCT01486719|dorsal branch
303556|NCT01486719|proper digital nerve
303557|NCT01486719|palmar arterial arch
303558|NCT01486719|dorsal digital island flap
303559|NCT01486706|Overactive Bladder
303560|NCT01486706|Gabapentin
303561|NCT01486706|Quality of Life
303562|NCT01486706|Urodynamic
303563|NCT01486706|safety
303564|NCT01486706|Efficacy
303565|NCT01486693|cytomegalovirus
303566|NCT01486693|uveitis
303567|NCT01486680|Gastric bypass
303568|NCT01486680|Silastic ring gastric bypass
303569|NCT01486680|Roux-en-Y gastric bypass
303570|NCT01486680|Sleeve gastrectomy
303571|NCT01486680|Body composition analysis
303572|NCT01486667|focus of study instead
303573|NCT01486654|Cortical stimulation
303574|NCT01486654|Ischemic Stroke
303575|NCT01486654|Aphasia
303576|NCT01486654|Speech and Language Rehabilitation
303577|NCT01486641|femoral neck fracture
303578|NCT01486641|arthroplasty
303579|NCT01486641|surgical approach
303580|NCT01486641|anterolateral
303581|NCT01486641|posterolateral
303582|NCT01486615|premedication
303583|NCT01486615|premedicants
303584|NCT01486615|preoperative anxiety
303585|NCT01486615|melatonin
303586|NCT01486615|alprazolam
303587|NCT01486602|stage IIIA non-small cell lung cancer
303588|NCT01486602|stage IIIB non-small cell lung cancer
303589|NCT01486589|emergency care
303590|NCT01486589|cardiac autonomic function
303591|NCT01486589|deceleration capacity
303592|NCT01486537|samples
303593|NCT01486537|children
303594|NCT01486537|the age group 3-13 years
303595|NCT01486524|pharmacogenomic biomarker
303596|NCT01486524|predictive marker
303597|NCT01486524|prospective-retrospective
303598|NCT01486524|propensity score
303599|NCT01486524|matched-patients trial
303600|NCT01486511|Liver disease
303601|NCT01486511|Pulmonary embolism
303602|NCT01486511|Thrombophilia
303603|NCT01486511|Death
303604|NCT01486485|renal replacement therapy
303605|NCT01486472|Adjuvant chemotherapy
303606|NCT01486446|IEM
303607|NCT01486446|EM
303608|NCT01486446|Erythromelalgia
303609|NCT01486446|Erythermalgia
303610|NCT01486446|Red neuralgia
303611|NCT01486446|Peripheral Vascular Disease
303612|NCT01486446|Vascular Disease
303613|NCT01486446|Cardiovascular Disease
303614|NCT01486433|eicosapentaenoic acid
303615|NCT01486433|docosapentaenoic acid
303616|NCT01486433|arachidonic acid
303617|NCT01486433|hypertriglyceridemia
303618|NCT01486433|simvastatin
303619|NCT01486420|Quinell grade
303620|NCT01486420|Open surgery
303621|NCT01486420|corticosteroid injections
303622|NCT01486420|randomized controlled trial
303623|NCT01486420|Trigger finger
303624|NCT01486407|Airway management
303625|NCT01486355|Mortality
303626|NCT01486355|Morbidity
303627|NCT01486355|Hospitalisations/consultations
303628|NCT01486355|Growth
303629|NCT01486355|Measles infection
303630|NCT01486329|Pancreatic cancer
303631|NCT01486329|Cancer vaccine
303632|NCT01486329|Gemcitabine
303633|NCT01486329|Inoperable
303634|NCT01486329|Gemcitabine chemotherapy
303635|NCT01486329|Locally advanced
303636|NCT01486303|Facial Cosmetic acupuncture
303637|NCT01486303|Skin Rejuvenation
303638|NCT01486303|Skin Aging
303639|NCT01486290|Intervention
303640|NCT01486290|Cost Effective
303641|NCT01486290|Elderly
303642|NCT01486290|Glycemic Control
303643|NCT01486277|Lymphoma, T-Cell, Cutaneous
303644|NCT01486277|T-cell lymphoma
303645|NCT01486277|Lymphoma
303646|NCT01486277|Histone Deacetylase Inhibitor
303647|NCT01486277|JNJ-26481585
303648|NCT01486238|Diabetic Macular Edema
303649|NCT01486212|Ischemia-reperfusion injury
303650|NCT01486212|Oxidative markers
303651|NCT01486212|Inflammatory markers
303652|NCT01486199|cystic fibrosis
303653|NCT01486199|mucociliary clearance
303654|NCT01486199|airway surface liquid
303655|NCT01486199|nuclear medicine
303656|NCT01486186|Pulmonary Disease, Chronic Obstructive
303657|NCT01486186|Double-Blind Method
303658|NCT01486186|Medicine, Chinese Traditional
303659|NCT01486186|Humans
303660|NCT01486186|Treatment Outcome
303661|NCT01486173|PUFA
303662|NCT01486173|Iron
303663|NCT01486173|Neurological development
303664|NCT01486173|Premature infant
303665|NCT01486147|Food labeling
303666|NCT01486147|Nutrition
303667|NCT01486147|Memory
303668|NCT01486147|Diet
303669|NCT01486134|Hepatocellular carcinoma
303670|NCT01486134|Radiofrequency ablation
303671|NCT01486134|Multipolar mode
303672|NCT01486134|Recurrence
303673|NCT01486134|Cirrhosis
303674|NCT01486134|MR temperature monitoring
303675|NCT01486134|large tumor
303676|NCT01486121|Surgery
303677|NCT01486121|Critical illness
303678|NCT01486121|Mechanical ventilation
303679|NCT01486121|Organ dysfunction syndrome
303680|NCT01486121|Intensive Care Units Sedation
303681|NCT01486121|Analgesia
303682|NCT01486121|Treatment protocol
303683|NCT01486121|Nursing protocol
303684|NCT01486121|Outcome
303685|NCT01486121|Pain
303686|NCT01486121|Neurological disorders
303687|NCT01486121|Delirium
303688|NCT01486121|Muscular weakness
303689|NCT01486121|Psychological disorders
303690|NCT01486121|Anxiety
303691|NCT01486121|Depression
303692|NCT01486121|Stress disorders
303693|NCT01486121|Post-Traumatic
303694|NCT01486108|tonic, burst and placebo stimulation
303695|NCT01486082|OCA 10
303696|NCT01486082|Antibiogram
303697|NCT01486082|Eradication
303698|NCT01486069|Dentofacial Deformity
303699|NCT01486069|Orthognathic Surgery
303700|NCT01486069|Mandible
303701|NCT01486069|Orthognathic Surgical Procedures
303702|NCT01486056|epilepsy
303703|NCT01486056|ECG
303704|NCT01486056|device placement
303705|NCT01486043|Induction chemotherapy
303706|NCT01486043|Transient hyperglycemia
303707|NCT01486043|Metformin
303708|NCT01486043|Acute lymphoblastic leukemia
303709|NCT01486043|Insulin resistance
303710|NCT01486043|Hyperglycemia
303711|NCT01486043|Insulin
303712|NCT01486030|Atherosclerosis
303713|NCT01486017|ASP015K
303714|NCT01486017|healthy subjects
303715|NCT01486017|bioavailability
303716|NCT01486017|rheumatoid arthritis
303717|NCT01486017|psoriasis
303718|NCT01486017|transplantation
303719|NCT01486004|Hepatitis C Virus
303720|NCT01486004|TMC435
303721|NCT01486004|TMC435-TiDP16-C124
303722|NCT01486004|TMC435-C124
303723|NCT01486004|HCV
303724|NCT01486004|Hepatitis C
303725|NCT01486004|Hep C
303726|NCT01486004|Healthy participants
303727|NCT01485991|Hepatitis C
303728|NCT01485991|TMC435HPC3001
303729|NCT01485991|TMC435
303730|NCT01485991|Hepatitis C Virus (HCV)
303731|NCT01485991|HEP C
303732|NCT01485991|Genotype 1
303733|NCT01485991|Treatment experienced
303734|NCT01485991|Null responders
303735|NCT01485991|Partial responders
303736|NCT01485978|Alport Syndrome
303737|NCT01485978|chronic kidney disease
303738|NCT01485978|renal fibrosis
303739|NCT01485978|nephroprotection
303740|NCT01485978|pediatric study
303741|NCT01485965|Huntington Disease
303742|NCT01485965|Basal Ganglia Diseases
303743|NCT01485965|Brain Diseases
303744|NCT01485965|Central Nervous System Diseases
303745|NCT01485965|Nervous System Diseases
303746|NCT01485965|Dementia
303747|NCT01485965|Chorea
303748|NCT01485965|Dyskinesias
303749|NCT01485965|Movement Disorders
303750|NCT01485965|Heredodegenerative Disorders, Nervous System
303751|NCT01485965|Neurodegenerative Diseases
303752|NCT01485965|Genetic Diseases, Inborn
303753|NCT01485965|Cognition Disorders
303754|NCT01485965|Mental Disorders
303755|NCT01485952|Huntington Disease
303756|NCT01485952|Basal Ganglia Diseases
303757|NCT01485952|Brain Diseases
303758|NCT01485952|Central Nervous System Diseases
303759|NCT01485952|Nervous System Diseases
303760|NCT01485952|Dementia
303761|NCT01485952|Chorea
303762|NCT01485952|Dyskinesias
303763|NCT01485952|Movement Disorders
303764|NCT01485952|Heredodegenerative Disorders, Nervous System
303765|NCT01485952|Neurodegenerative Diseases
303766|NCT01485952|Genetic Diseases, Inborn
303767|NCT01485952|Cognition Disorders
303768|NCT01485952|Mental Disorders
303769|NCT01485939|lidocaine patch
303770|NCT01485939|laparoscopic cholecystectomy
303771|NCT01485913|Education
303772|NCT01485913|Diabetes
303773|NCT01485913|Prevention complications
303774|NCT01485913|Prevention of complications of diabetes
303775|NCT01485887|Venlafaxine ER
303776|NCT01485887|long-term extension
303777|NCT01485887|Japan
303778|NCT01485874|BIBF 1120
303779|NCT01485835|Multiple Myeloma
303780|NCT01485835|Bortezomib
303781|NCT01485835|Velcade
303782|NCT01485835|Ganetespib
303783|NCT01485822|Glaucoma
303784|NCT01485822|Travatan
303785|NCT01485822|Trabeculectomy
303786|NCT01485796|PIDD
303787|NCT01485783|Hypertension
303788|NCT01485757|patients
303789|NCT01485744|metastatic
303790|NCT01485744|untreated
303791|NCT01485744|advanced
303792|NCT01485731|Cervical
303793|NCT01485731|Cancer
303794|NCT01485731|Uterine Cervix
303795|NCT01485731|Squamous Cell
303796|NCT01485731|Adenocarcinoma
303797|NCT01485718|Obesity
303798|NCT01485718|Overweight
303799|NCT01485718|Weight loss
303800|NCT01485705|severe bacterial infection
303801|NCT01485692|Violence
303802|NCT01485692|Aggression
303803|NCT01485692|Psychiatric emergencies
303804|NCT01485692|Psychomotor agitation
303805|NCT01485692|Violent patient
303806|NCT01485679|18 fluoro deoxy glucose positrons emission tomography combined with computed tomography,
303807|NCT01485679|Patients with intraductal papillary mucinous tumor of the pancreas
303808|NCT01485679|intraductal papillary mucinous
303809|NCT01485679|pancreas
303810|NCT01485666|Thoratec
303811|NCT01485666|HeartMate II
303812|NCT01485666|heart-assist devices
303813|NCT01485666|driveline or percutaneous lead management
303814|NCT01485666|HeartMate II Percutaneous Lead Management
303815|NCT01485653|Brachial Plexus
303816|NCT01485653|Mepivacaine
303817|NCT01485653|Ultrasound
303818|NCT01485653|Axillary
303819|NCT01485653|Block
303820|NCT01485640|Schizophrenia
303821|NCT01485640|bipolar disorder
303822|NCT01485640|Lurasidone
303823|NCT01485640|Latuda
303824|NCT01485627|Cancer
303825|NCT01485627|Communication
303826|NCT01485627|prognosis
303827|NCT01485575|Chromovitrectomy
303828|NCT01485575|Indocyanine green
303829|NCT01485575|ICG
303830|NCT01485575|Brilliant Blue G
303831|NCT01485575|BBG
303832|NCT01485575|Trypan blue
303833|NCT01485575|TB
303834|NCT01485575|Internal limiting membrane
303835|NCT01485575|ILM
303836|NCT01485562|postpartum haemorrhage
303837|NCT01485562|misoprostol
303838|NCT01485562|treatment
303839|NCT01485562|prophylaxis
303840|NCT01485562|home births
303841|NCT01485549|Multiple system atrophy (MSA)
303842|NCT01485549|alpha-synucleinopathies
303843|NCT01485549|biological markers
303844|NCT01485549|cerebrospinal fluid
303845|NCT01485549|plasma
303846|NCT01485536|Lymphoma
303847|NCT01485536|Relapsed/refractory lymphoma
303848|NCT01485536|AUY922
303849|NCT01485523|Allergic rhinitis
303850|NCT01485523|Nasal provocation test
303851|NCT01485510|Maltreatment
303852|NCT01485510|Infant Mental Health
303853|NCT01485510|Infant mental health in maltreated children
303854|NCT01485497|APNEA
303855|NCT01485471|Middle Ear Infection
303856|NCT01485458|Incomplete spinal cord injury
303857|NCT01485458|Cervical canal stenosis
303858|NCT01485458|Ossification of the posterior longitudinal ligament
303859|NCT01485458|Surgery
303860|NCT01485458|Decompression
303861|NCT01485445|bioequivalence
303862|NCT01485445|pharmacokinetics
303863|NCT01485445|Fluticasone Furoate
303864|NCT01485445|Vilanterol
303865|NCT01485432|Renal transplant surgery
303866|NCT01485432|hemodynamic management
303867|NCT01485432|PiCCO
303868|NCT01485432|delayed graft function
303869|NCT01485419|Sex hormones
303870|NCT01485419|Testosterone
303871|NCT01485419|Estradiol
303872|NCT01485406|Haemophilus influenzae
303873|NCT01485406|Safety
303874|NCT01485406|Pneumococcal vaccine
303875|NCT01485406|Streptococcus pneumoniae
303876|NCT01485406|Immunogenicity
303877|NCT01485406|Toddlers
303878|NCT01485380|Dexmedetomidine
303879|NCT01485380|Sleep
303880|NCT01485380|MRI-PET
303881|NCT01485380|EEG
303882|NCT01485367|Senile Purpura
303883|NCT01485367|Adapalene 0.3%
303884|NCT01485354|stroke
303885|NCT01485354|Armeo
303886|NCT01485341|gluten sensitivity
303887|NCT01485328|Dyspepsia
303888|NCT01485328|Flatulence
303889|NCT01485328|Aerophagia
303890|NCT01485328|Constipation
303891|NCT01485302|mild to moderate Alzheimer's Disease
303892|NCT01485276|Parkinson's Disease
303893|NCT01485276|Deep Brain Stimulation
303894|NCT01485276|Gait
303895|NCT01485276|Electrophysiology
303896|NCT01485276|Parkinson Disease
303897|NCT01485276|PD
303898|NCT01485263|Deep Brain Stimulation
303899|NCT01485263|OCD
303900|NCT01485250|Healthy Volunteers
303901|NCT01485250|Motivations
303902|NCT01485250|Decision Making
303903|NCT01485250|Motivation
303904|NCT01485224|Hereditary hemorrhagic telangiectasia
303905|NCT01485224|Epistaxis
303906|NCT01485224|Thalidomide
303907|NCT01485211|progressive keratoconus
303908|NCT01485211|thin corneas
303909|NCT01485211|cross-linking
303910|NCT01485211|hypo-osmolar riboflavin
303911|NCT01485198|osteoarthritis
303912|NCT01485198|knee
303913|NCT01485198|stem cell therapy
303914|NCT01485198|bone marrow
303915|NCT01485198|G-CSF
303916|NCT01485185|Donepezil
303917|NCT01485185|allodynia
303918|NCT01485185|Gabapentin
303919|NCT01485185|Sural nerve stimulation
303920|NCT01485185|Electrical hyperalgesia
303921|NCT01485159|prevalence
303922|NCT01485159|COPD
303923|NCT01485159|emphysema
303924|NCT01485159|co-morbidities
303925|NCT01485159|ischemic heart disease
303926|NCT01485159|chronic bronchitis
303927|NCT01485159|spirometry
303928|NCT01485159|burden
303929|NCT01485133|colonoscopy
303930|NCT01485133|water
303931|NCT01485133|surgery
303932|NCT01485133|unsedated
303933|NCT01485120|Blood pressure (low, normal, high)
303934|NCT01485107|Ulthera® System
303935|NCT01485107|Ultherapy™ treatment
303936|NCT01485107|Ulthera, Inc.
303937|NCT01485107|Ultrasound treatment for skin tightening
303938|NCT01485094|neuralgia
303939|NCT01485094|postherpetic
303940|NCT01485081|Bifurcation
303941|NCT01485081|Drug-eluting balloon
303942|NCT01485081|Paclitaxel-eluting balloon
303943|NCT01485081|Angioplasty
303944|NCT01485081|Coronary artery disease
303945|NCT01485081|Coronary artery stenosis
303946|NCT01485068|Restenosis
303947|NCT01485068|Paclitaxel-eluting balloon
303948|NCT01485068|Angioplasty
303949|NCT01485068|Coronary artery disease
303950|NCT01485068|Coronary artery stenosis
303951|NCT01485055|aGVHD
303952|NCT01485055|GVHD
303953|NCT01485055|Graft versus host disease
303954|NCT01485055|Acute graft versus host disease
303955|NCT01485055|Steroid refractory graft versus host disease
303956|NCT01485055|Bone marrow transplant
303957|NCT01485055|BMT
303958|NCT01485055|HSCT
303959|NCT01485055|infliximab
303960|NCT01485055|basiliximab
303961|NCT01485055|Monoclonal antibody treatment
303962|NCT01485042|Phase 1
303963|NCT01485042|pazopanib
303964|NCT01485042|TH-302
303965|NCT01485042|advanced solid tumors
303966|NCT01485016|epilepsy
303967|NCT01485016|ECG
303968|NCT01485016|accelerometer
303969|NCT01484990|Parkinson's Disease
303970|NCT01484990|levodopa
303971|NCT01484990|carbidopa
303972|NCT01484990|Duodopa
303973|NCT01484990|intestinal gel
303974|NCT01484977|Lacosamide
303975|NCT01484977|Epilepsy
303976|NCT01484977|Levetiracetam
303977|NCT01484977|Sodium Channel Blockers
303978|NCT01484964|ASP015K
303979|NCT01484964|healthy subjects
303980|NCT01484964|bioavailability
303981|NCT01484964|food effect
303982|NCT01484964|rheumatoid arthritis
303983|NCT01484964|psoriasis
303984|NCT01484964|transplantation
303985|NCT01484951|Open-angle glaucoma
303986|NCT01484951|Ocular hypertension
303987|NCT01484951|Pigment dispersion glaucoma
303988|NCT01484938|Soft contact lenses
303989|NCT01484938|Multi-purpose solution
303990|NCT01484938|Corneal staining
303991|NCT01484925|Barrett's esophagus
303992|NCT01484912|Green tea polyphenols
303993|NCT01484912|Chronic Stable Angina
303994|NCT01484899|Pulmonary arterial Hypertension
303995|NCT01484899|Chronic thromboembolic pulmonary hypertension
303996|NCT01484899|smoking
303997|NCT01484886|Hemoglobin
303998|NCT01484886|Congenital heart disease
303999|NCT01484886|Cardiac surgery
304000|NCT01484886|Red blood cell transfusion
304001|NCT01484886|Number of red blood cell transfusions
304002|NCT01484873|Exenatide
304003|NCT01484873|Byetta
304004|NCT01484873|Hypothalamic Obesity
304005|NCT01484873|Obesity
304006|NCT01484873|Craniopharyngioma
304007|NCT01484860|AUY922
304008|NCT01484860|Pancreas
304009|NCT01484860|Pancreatic cancer
304010|NCT01484860|Adenocarcinoma of the pancreas
304011|NCT01484860|Cancer of the pancreas
304012|NCT01484860|Metastatic
304013|NCT01484860|Advanced
304014|NCT01484860|Advanced disease
304015|NCT01484860|Prior systemic anticancer therapy
304016|NCT01484847|advanced
304017|NCT01484847|PF-00299804
304018|NCT01484847|head and neck
304019|NCT01484847|pharmacokinetic
304020|NCT01484847|squamous cell carcinoma
304021|NCT01484847|gastrojejunostomy
304022|NCT01484847|feeding tube
304023|NCT01484834|Physical Activity
304024|NCT01484834|Occupational Health
304025|NCT01484834|Quality of Life
304026|NCT01484834|Health Promotion
304027|NCT01484834|Workplace Place or physical location of work or employment
304028|NCT01484834|Exercise Physical activity which is usually regular and done with the intention of improving or maintaining PHYSICAL FITNESS or HEALTH
304029|NCT01484821|Sarcopenia
304030|NCT01484821|ARFI
304031|NCT01484821|DEXA
304032|NCT01484821|Cancer
304033|NCT01484808|PSA Density
304034|NCT01484808|Prostate Cancer
304035|NCT01484808|Prostate Biopsy
304036|NCT01484808|PSA
304037|NCT01484795|noninvasive ventilation
304038|NCT01484795|autonomic nervous system
304039|NCT01484782|Hypertension
304040|NCT01484782|Telephone Care Management
304041|NCT01484782|Blood pressure
304042|NCT01484782|Medication adherence
304043|NCT01484782|Interactive Voice Response (IVR)
304044|NCT01484782|Cloud computing
304045|NCT01484756|respiratory infection
304046|NCT01484756|independent elderly
304047|NCT01484756|zinc
304048|NCT01484756|vitamins
304049|NCT01484743|recurrence
304050|NCT01484743|readmission
304051|NCT01484743|reoperation
304052|NCT01484743|mortality
304053|NCT01484743|morbidity
304054|NCT01484704|Carcinoma ductale mammae
304055|NCT01484678|Duchenne Muscular Dystrophy
304056|NCT01484678|Magnetic Resonance Imaging
304057|NCT01484678|Magnetic Resonance Spectroscopy
304058|NCT01484678|Muscle
304059|NCT01484665|PSA screening
304060|NCT01484665|Decision aids
304061|NCT01484652|Moderate Post-Operative Pain
304062|NCT01484652|Severe Post-Operative Pain
304063|NCT01484652|Bunionectomy
304064|NCT01484639|transfusion
304065|NCT01484639|cardiac surgery
304066|NCT01484626|Relapsed Multiple Myeloma
304067|NCT01484626|Refractory Multiple Myeloma
304068|NCT01484626|Bendamustine
304069|NCT01484626|Bortezomib
304070|NCT01484626|Lenalidomide
304071|NCT01484626|Dexamethasone
304072|NCT01484626|Treanda
304073|NCT01484626|Velcade
304074|NCT01484626|Revlimid
304075|NCT01484613|Hear Failure
304076|NCT01484613|Cardiac resynchronization
304077|NCT01484613|CRT-D
304078|NCT01484613|quadripolar
304079|NCT01484600|Volunteers
304080|NCT01484587|Moderate to Severe Plaque-Type Psoriasis
304081|NCT01484587|Psoriasis
304082|NCT01484587|Plaque-type psoriasis
304083|NCT01484587|CNTO 1959
304084|NCT01484587|Japanese participants
304085|NCT01484574|Critical limb ischemia
304086|NCT01484574|Buerger's disease
304087|NCT01484574|Critical limb ischemia due to Buerger's disease
304088|NCT01484561|Phase 1
304089|NCT01484522|Influenza
304090|NCT01484522|Perinatal
304091|NCT01484522|immunogenicity
304092|NCT01484522|Monovalent vaccine
304093|NCT01484522|Children
304094|NCT01484522|Youth
304095|NCT01484522|H1N1
304096|NCT01484522|Adolescent
304097|NCT01484522|Flu
304098|NCT01484509|walking impairment
304099|NCT01484509|claudication
304100|NCT01484509|treadmill
304101|NCT01484509|questionnaire
304102|NCT01484496|Subcutaneous
304103|NCT01484496|Lupus
304104|NCT01484496|Systemic Lupus Erythematosus
304105|NCT01484496|SLE
304106|NCT01484496|Belimumab
304107|NCT01484496|Autoimmune Disease
304108|NCT01484496|Antibodies
304109|NCT01484470|Stem cell transplantation
304110|NCT01484470|Stem Cell expansion
304111|NCT01484470|Elderly
304112|NCT01484457|Diabetes Mellitus
304113|NCT01484457|Closed Loop
304114|NCT01484457|Artificial Pancreas
304115|NCT01484418|Chronic Low Back Pain
304116|NCT01484418|Cognitive Behavioural Therapy
304117|NCT01484418|Exposure
304118|NCT01484418|Fear avoidance
304119|NCT01484418|Cognitive Behavioural Therapy in chronic low back pain
304120|NCT01484418|Exposure in vivo in chronic low back pain
304121|NCT01484405|surgical approach for total hip arthroplasty
304122|NCT01484392|open angle glaucoma
304123|NCT01484392|compliance
304124|NCT01484392|adherence
304125|NCT01484379|Primary Hyperparathyroidism
304126|NCT01484379|multigland disease
304127|NCT01484379|neck exploration
304128|NCT01484379|elderly
304129|NCT01484366|fractures of both radius and ulna
304130|NCT01484353|Diabetes
304131|NCT01484340|smoking
304132|NCT01484340|administration, cutaneous
304133|NCT01484327|Heart Failure
304134|NCT01484327|Acute Myocardial Infarction
304135|NCT01484327|LVEF
304136|NCT01484314|Relapsed
304137|NCT01484301|Chronic pain
304138|NCT01484301|Opioids
304139|NCT01484301|Tolerability
304140|NCT01484275|High-risk smoldering multiple myeloma
304141|NCT01484275|Multiple myeloma
304142|NCT01484275|Siltuximab
304143|NCT01484249|embolic
304144|NCT01484249|filters
304145|NCT01484249|brachiocephalic
304146|NCT01484249|neurovasculature
304147|NCT01484249|debris
304148|NCT01484236|Lymphangioleiomyomatosis
304149|NCT01484223|Primary Health Care
304150|NCT01484223|Somatization symptoms
304151|NCT01484223|Cognitive Behavioral Therapy
304152|NCT01484223|Nursing intervention
304153|NCT01484197|Asthma
304154|NCT01484197|Indacaterol
304155|NCT01484197|QAB149
304156|NCT01484184|Completely paralyzed
304157|NCT01484184|Chronically injured
304158|NCT01484184|Central Pattern Generator
304159|NCT01484184|Locomotion
304160|NCT01484184|Secondary complications
304161|NCT01484184|Activity-based training
304162|NCT01484184|Treadmill training
304163|NCT01484184|Spinal cord injury
304164|NCT01484184|Paraplegia
304165|NCT01484184|Tetraplegia
304166|NCT01484171|Acute Myeloid Leukemia
304167|NCT01484171|idarubicin
304168|NCT01484171|Microtransplantation
304169|NCT01484158|Myocardial Infarction
304170|NCT01484145|Onychomycosis
304171|NCT01484145|Nail fungus
304172|NCT01484145|Tinea Unguium
304173|NCT01484132|Dental Caries
304174|NCT01484132|Dental Restorative Materials
304175|NCT01484132|Dental Composite
304176|NCT01484132|Bisphenol-A
304177|NCT01484119|seasonal allergic rhinitis
304178|NCT01484093|CYCLOPHOSPHAMIDE (CYTOXAN)
304179|NCT01484093|CYTARABINE (ARA-C)
304180|NCT01484093|DOXORUBICIN/ADRIAMYCIN
304181|NCT01484093|PREDNISONE
304182|NCT01484093|RITUXIMAB
304183|NCT01484093|TOSITUMOMAB (BEXXAR)
304184|NCT01484093|Iodine
304185|NCT01484093|VINCRISTIN
304186|NCT01484093|Lymphoma
304187|NCT01484093|Chemo-Radioimmunotherapy
304188|NCT01484093|Autologous Transplantation
304189|NCT01484093|Untreated
304190|NCT01484093|11-095
304191|NCT01484067|Herpes Simplex Virus
304192|NCT01484041|Breast cancer
304193|NCT01484041|postmenopausal
304194|NCT01484002|Hip replacement
304195|NCT01484002|Crosslinked and conventional polyethylene
304196|NCT01484002|Oxidation
304197|NCT01484002|Crosslink density
304198|NCT01484002|Outcome
304199|NCT01483989|Dry Eye
304200|NCT01483989|Epithelial changes
304201|NCT01483950|Dyslipidemia
304202|NCT01483950|Statins
304203|NCT01483950|Total Cholesterol
304204|NCT01483950|Low density lipoprotein (LDL) cholesterol
304205|NCT01483950|High density lipoprotein (HDL) cholesterol
304206|NCT01483937|Keywords provided by BalanceSense, LLC:
304207|NCT01483937|Physical Therapy
304208|NCT01483937|Rehabilitation
304209|NCT01483937|Disequilibrium
304210|NCT01483937|Balance dysfunction or disorder
304211|NCT01483937|Vestibular
304212|NCT01483937|Mild Traumatic Brain Injury (mTBI)
304213|NCT01483937|Vibrotactile
304214|NCT01483924|Mild to Moderate Chronic Plaque Psoriasis
304215|NCT01483898|critical limb ischemia
304216|NCT01483898|REVIVE
304217|NCT01483898|peripheral vascular disease
304218|NCT01483898|CLI
304219|NCT01483898|PAD
304220|NCT01483898|MSC
304221|NCT01483898|stem cells
304222|NCT01483898|cell therapy
304223|NCT01483872|salvage infected hemodialysis catheters
304224|NCT01483872|novel catheter lock solution
304225|NCT01483846|Neuropathic Pain
304226|NCT01483846|Capsaicin Induced Pain
304227|NCT01483807|speech
304228|NCT01483807|speech therapy
304229|NCT01483807|apraxia of speech
304230|NCT01483794|genital warts
304231|NCT01483781|Diabetes Mellitus, Type 2
304232|NCT01483781|Plasma Volume
304233|NCT01483781|Canagliflozin
304234|NCT01483781|Metformin
304235|NCT01483781|Hemoglobin A1c
304236|NCT01483781|Hypertension
304237|NCT01483781|Angiotensin-Converting Enzyme Inhibitors (ACEIs)
304238|NCT01483781|Angiotensin Receptor Blockers (ARBs)
304239|NCT01483781|Pharmacodynamics
304240|NCT01483781|Pharmacokinetics
304241|NCT01483768|Sleeve gastrectomy
304242|NCT01483768|Obesity surgery
304243|NCT01483768|Iron deficiency
304244|NCT01483768|HEPCIDINE
304245|NCT01483755|Myocardial infarction
304246|NCT01483755|Postconditioning
304247|NCT01483690|Relapse
304248|NCT01483690|Lymphoblastic
304249|NCT01483690|Leukemia
304250|NCT01483690|Decitabine
304251|NCT01483690|Vorinostat
304252|NCT01483690|Refractory
304253|NCT01483690|Acute
304254|NCT01483690|Childhood
304255|NCT01483690|Pediatric
304256|NCT01483690|ALL
304257|NCT01483677|Laparoscopy
304258|NCT01483677|video games
304259|NCT01483677|Nintendo Wii
304260|NCT01483677|Playstation
304261|NCT01483664|patient outcomes
304262|NCT01483664|Survivorship
304263|NCT01483664|Communication Skills
304264|NCT01483664|Communication strategies
304265|NCT01483664|Physicians communication
304266|NCT01483664|11-180
304267|NCT01483651|diabetes
304268|NCT01483651|glucagon
304269|NCT01483651|insulin
304270|NCT01483651|dideuterated glucose
304271|NCT01483638|duration of disease response
304272|NCT01483638|axitinib
304273|NCT01483612|Body Weight
304274|NCT01483612|Female
304275|NCT01483612|Infertility, Female/therapy
304276|NCT01483612|Infertility, Female/physiopathology
304277|NCT01483612|Obesity/physiopathology
304278|NCT01483612|Polycystic ovary syndrome
304279|NCT01483612|Pregnancy
304280|NCT01483612|Pregnancy Outcome
304281|NCT01483612|Weight Loss
304282|NCT01483599|Moderate to Severe Plaque-Type Psoriasis
304283|NCT01483599|Psoriasis
304284|NCT01483599|Plaque-type psoriasis
304285|NCT01483599|CNTO 1959
304286|NCT01483599|adalimumab
304287|NCT01483573|low back pain
304288|NCT01483573|straight leg raise
304289|NCT01483560|REMOVAL
304290|NCT01483560|metformin
304291|NCT01483560|carotid IMT
304292|NCT01483560|LDL Cholesterol
304293|NCT01483560|endothelial function
304294|NCT01483560|retinopathy
304295|NCT01483560|HbA1c
304296|NCT01483534|Chronic Obstructive Pulmonary Disease
304297|NCT01483534|Pulmonary
304298|NCT01483534|Intervention
304299|NCT01483534|Device
304300|NCT01483534|Denervation
304301|NCT01483534|Lung
304302|NCT01483534|Holaira, Inc.
304303|NCT01483534|Innovative Pulmonary Solutions, Inc.
304304|NCT01483521|Randomized
304305|NCT01483521|Home visitation
304306|NCT01483521|Externalizing disorder
304307|NCT01483521|Parenting stress
304308|NCT01483521|Childhood externalizing disorders
304309|NCT01483521|Positional defiant
304310|NCT01483508|flavanols
304311|NCT01483508|procyanidins
304312|NCT01483508|absorption
304313|NCT01483508|cocoa polyphenols
304314|NCT01483508|Flavanol and procyanidin absorption in healthy volunteers
304315|NCT01483482|clavicle fractures
304316|NCT01483482|midshaft clavicle fractures
304317|NCT01483482|conservative treatment
304318|NCT01483482|surgical treatment
304319|NCT01483482|functional outcome
304320|NCT01483482|clinical assessment
304321|NCT01483482|adults
304322|NCT01483456|Accidental falls
304323|NCT01483456|safety management
304324|NCT01483456|aged
304325|NCT01483456|inpatient
304326|NCT01483456|stepped wedge design
304327|NCT01483443|oophrectomy
304328|NCT01483443|survival
304329|NCT01483430|Blood pressure
304330|NCT01483430|Korea red ginseng
304331|NCT01483430|Ambulatory blood pressure
304332|NCT01483430|Pulse wave velocity
304333|NCT01483417|SILS
304334|NCT01483417|Laparoscopic hysterectomy
304335|NCT01483417|Cosmetic outcome
304336|NCT01483417|Pain
304337|NCT01483404|microcirculation
304338|NCT01483404|caput femoris
304339|NCT01483391|Bipolar disorder
304340|NCT01483391|Major depressive disorder
304341|NCT01483391|Mania
304342|NCT01483391|Depression
304343|NCT01483391|Cyclothymic Disorder
304344|NCT01483313|Anesthestics
304345|NCT01483313|Minor surgery
304346|NCT01483313|Wechsler Intelligence Scale for Children
304347|NCT01483313|Cognitiion
304348|NCT01483300|breast cancer
304349|NCT01483300|gemcitabine
304350|NCT01483300|lobaplatin
304351|NCT01483300|cisplatin
304352|NCT01483287|Gastrointestinal Symptoms
304353|NCT01483287|Bloating
304354|NCT01483287|Distention
304355|NCT01483274|AML
304356|NCT01483274|vaccine
304357|NCT01483261|Trauma-Focused Cognitive Behavior Therapy
304358|NCT01483261|Sexually Exploited Girls
304359|NCT01483261|Post-traumatic Stress Symptoms
304360|NCT01483261|Psychosocial Distress
304361|NCT01483248|Menstrual blood
304362|NCT01483248|Mesenchymal stem cell
304363|NCT01483248|Liver cirrhosis
304364|NCT01483235|cardiac rehabilitation
304365|NCT01483235|prevention
304366|NCT01483235|exercise capacity
304367|NCT01483222|Low Back Pain
304368|NCT01483222|Braces
304369|NCT01483222|Prevention
304370|NCT01483209|Digital ischemia
304371|NCT01483209|Vasopressor
304372|NCT01483183|Atrial fibrillation
304373|NCT01483183|Paroxysmal Atrial fibrillation
304374|NCT01483183|Persistent Atrial fibrillation
304375|NCT01483183|A-fib
304376|NCT01483144|Familial Adenomatous Polyposis
304377|NCT01483144|Eflornithine
304378|NCT01483144|Sulindac
304379|NCT01483118|PCOS
304380|NCT01483118|Insulin resistance
304381|NCT01483118|Cinnamon extract
304382|NCT01483118|Irregular menstrual cycles
304383|NCT01483118|Ovarian cysts
304384|NCT01483105|VCUG
304385|NCT01483105|Child
304386|NCT01483105|Hypnosis
304387|NCT01483105|Relaxation
304388|NCT01483105|Voiding cystourethrography
304389|NCT01483079|donor human milk products
304390|NCT01483079|post-discharge
304391|NCT01483079|growth
304392|NCT01483079|development
304393|NCT01483053|Major depressive disorder
304394|NCT01483053|Sympathetic nervous system activation
304395|NCT01483053|Cardiovascular risk factors
304396|NCT01483053|Agomelatine
304397|NCT01483053|Escitalopram
304398|NCT01483040|wide angle view colonoscopy
304399|NCT01483040|PeerScope B System™
304400|NCT01483014|Gastrointestinal,
304401|NCT01483014|stromal,
304402|NCT01483014|neoadjuvant,
304403|NCT01483014|imatinib,
304404|NCT01483014|mesylate,
304405|NCT01483014|pre-operatory
304406|NCT01483001|Cancer Stem Cells
304407|NCT01483001|Chemo-Sensitivity Assay
304408|NCT01483001|Cancer Treatment
304409|NCT01482988|prevalence of the Dectin-1 polymorphism (Tyr238X)
304410|NCT01482975|tobacco
304411|NCT01482975|alcohol
304412|NCT01482975|diet
304413|NCT01482975|exercise
304414|NCT01482949|RCC
304415|NCT01482949|Kidney Cancer
304416|NCT01482949|Renal Cancer
304417|NCT01482949|Arcelis
304418|NCT01482923|Tobacco Use Assessment
304419|NCT01482923|smoke tobacco
304420|NCT01482923|quit smoking
304421|NCT01482923|tobacco cessation
304422|NCT01482923|HIV/AIDS
304423|NCT01482923|Community-Based Service Organizations
304424|NCT01482923|11-173
304425|NCT01482923|Low-Income Persons Living with HIV/AIDS
304426|NCT01482897|Discal sciatica, infiltrations
304427|NCT01482897|Subjects
304428|NCT01482897|evolving
304429|NCT01482884|tralokinumab
304430|NCT01482884|inflammatory bowel disease
304431|NCT01482884|moderate to severe ulcerative colitis
304432|NCT01482871|Diabetic Macular Edema
304433|NCT01482832|Randomized trial
304434|NCT01482832|Postpartum depression
304435|NCT01482832|Adolescent pregnancy
304436|NCT01482832|Interpersonal psychotherapy
304437|NCT01482806|Depression
304438|NCT01482806|Anxiety
304439|NCT01482806|Primary care
304440|NCT01482806|Cognitive Behavioral Therapy
304441|NCT01482806|Internet
304442|NCT01482806|Support groups
304443|NCT01482806|Technology assisted
304444|NCT01482741|Quality of Life
304445|NCT01482741|Focus groups
304446|NCT01482741|Risks of Ionizing Radiation
304447|NCT01482741|Risk of medical imaging
304448|NCT01482741|11-185
304449|NCT01482715|gBRCA ovarian cancer
304450|NCT01482715|platinum sensitive
304451|NCT01482715|PARP Inhibitor
304452|NCT01482715|Rucaparib
304453|NCT01482715|CO-338
304454|NCT01482715|PF 01367338
304455|NCT01482715|AG 14699
304456|NCT01482715|BRCA1
304457|NCT01482715|BRCA2
304458|NCT01482715|platinum sensitive ovarian cancer
304459|NCT01482715|platinum sensitive gBRCA ovarian cancer
304460|NCT01482715|gynecological cancer
304461|NCT01482715|relapsed disease
304462|NCT01482715|homologous recombination deficiency
304463|NCT01482715|HRD
304464|NCT01482702|breast cancer survivor
304465|NCT01482702|weight loss
304466|NCT01482702|postmenopausal
304467|NCT01482702|Weight loss for overweight postmenopausal breast cancer survivors
304468|NCT01482689|Bioavailability
304469|NCT01482689|Vitamin D metabolism
304470|NCT01482689|Bone turnover
304471|NCT01482663|Hand eczema
304472|NCT01482663|Hand dermatitis
304473|NCT01482663|Chronic hand eczema
304474|NCT01482663|Chronic hand dermatitis
304475|NCT01482663|Contact dermatitis
304476|NCT01482663|Skin disease
304477|NCT01482663|Self-management
304478|NCT01482650|Baska mask
304479|NCT01482650|LMA
304480|NCT01482650|laryngeal mask airway
304481|NCT01482650|supraglottic airway device
304482|NCT01482624|hyaluronan
304483|NCT01482624|hyaluronic acid
304484|NCT01482611|Hepatitis C Virus
304485|NCT01482611|JNJ-47910382
304486|NCT01482611|47910382HPC1001
304487|NCT01482611|HCV
304488|NCT01482611|Hepatitis C
304489|NCT01482611|Hep C
304490|NCT01482611|Healthy participants
304491|NCT01482611|Japanese
304492|NCT01482611|Caucasians
304493|NCT01482598|Heart Failure
304494|NCT01482598|Cardiac Resynchronization Therapy
304495|NCT01482598|Remote Care
304496|NCT01482598|Disease Management
304497|NCT01482585|lung adenocarcinoma
304498|NCT01482585|prognosis
304499|NCT01482585|tumor aggressiveness
304500|NCT01482585|imaging biomarker
304501|NCT01482585|genetic biomarker
304502|NCT01482572|biopsy
304503|NCT01482572|needle aspiration
304504|NCT01482572|mutational analysis
304505|NCT01482559|Dopamine
304506|NCT01482559|Intraventricular haemorrhage
304507|NCT01482559|Periventricular Leukomalacia
304508|NCT01482559|Neurodisability
304509|NCT01482559|Infant
304510|NCT01482546|colonoscopy
304511|NCT01482546|trainees
304512|NCT01482546|water
304513|NCT01482546|adenoma detection rate
304514|NCT01482546|cecal intubation rate
304515|NCT01482494|Myopathies
304516|NCT01482494|Pompe disease
304517|NCT01482494|Polymyositis
304518|NCT01482494|Respiratory Insufficiency
304519|NCT01482481|Patient Care Planning
304520|NCT01482481|Type 2 Diabetes Mellitus
304521|NCT01482481|Cardiovascular Risk Factors
304522|NCT01482481|Primary Health Care
304523|NCT01482481|Spain
304524|NCT01482455|Insulin resistance
304525|NCT01482455|vascular impairment
304526|NCT01482455|diabetes
304527|NCT01482442|Liver, HCC
304528|NCT01482442|Liver, interventional procedures
304529|NCT01482442|Liver, randomized studies
304530|NCT01482442|Liver, targeted therapy
304531|NCT01482442|Liver, RADIOEMBOLIZATION
304532|NCT01482429|ventilator weaning
304533|NCT01482429|protocol
304534|NCT01482416|hormone replacement therapy
304535|NCT01482416|Doppler velocimetry
304536|NCT01482416|Flow-mediated dilation
304537|NCT01482416|menopause
304538|NCT01482364|HOTMAN System
304539|NCT01482364|Hemodynamic integrated management
304540|NCT01482351|apnea
304541|NCT01482351|cognition
304542|NCT01482351|memory
304543|NCT01482351|function
304544|NCT01482351|amnestic mild cognitive impairment
304545|NCT01482351|older adults
304546|NCT01482351|Alzheimer's Disease
304547|NCT01482338|PMS
304548|NCT01482338|Low-dose combine contraceptives pills
304549|NCT01482338|COC
304550|NCT01482299|pS6 Ser 240/4
304551|NCT01482299|RAD001 (everolimus)
304552|NCT01482299|second-line treatment
304553|NCT01482299|advanced gastric cancer
304554|NCT01482286|Exercise
304555|NCT01482286|Diet
304556|NCT01482286|Insulin resistance
304557|NCT01482286|Weight
304558|NCT01482273|catheter-directed thrombolysis
304559|NCT01482273|ilio-femoral deep vein thrombosis
304560|NCT01482273|Postthrombotic syndrome
304561|NCT01482273|Phlebographic scores
304562|NCT01482273|Phlebography
304563|NCT01482273|Catheters
304564|NCT01482234|physical activity
304565|NCT01482234|exercise
304566|NCT01482234|walking
304567|NCT01482234|pedometers
304568|NCT01482234|goal setting
304569|NCT01482234|text messages
304570|NCT01482234|motivation
304571|NCT01482234|intrinsic motivation
304572|NCT01482234|extrinsic motivation
304573|NCT01482234|self determination theory
304574|NCT01482234|prompts
304575|NCT01482221|Major Depressive Disorder
304576|NCT01482221|MDD
304577|NCT01482221|Inadequate Response to Antidepressant Therapy
304578|NCT01482221|Channel blocker of the NMDA class of glutamate receptors
304579|NCT01482208|Dehydration
304580|NCT01482208|Hydration
304581|NCT01482208|Muscle composition
304582|NCT01482208|Diarrhea
304583|NCT01482208|Pediatrics
304584|NCT01482208|Neonatology
304585|NCT01482208|Ultrasound
304586|NCT01482195|Retinal Disease
304587|NCT01482182|Non-small cell lung cancer
304588|NCT01482182|Diffusion-weighted MRI
304589|NCT01482182|18F-FDG PET
304590|NCT01482182|Treatment response
304591|NCT01482182|Prognosis
304592|NCT01482169|Left heart catheterization
304593|NCT01482169|Fractional flow reserve
304594|NCT01482169|Adenoscan®
304595|NCT01482169|Regadenoson
304596|NCT01482156|Advanced solid tumors
304597|NCT01482156|Metastatic renal cell carcinoma (mRCC)
304598|NCT01482156|ER+/HER2-Metastatic breast cancer (MBC)
304599|NCT01482156|Dose finding study
304600|NCT01482156|mTOR
304601|NCT01482156|Pl3K
304602|NCT01482156|BEZ235
304603|NCT01482156|RAD001
304604|NCT01482156|Everolimus
304605|NCT01482156|Afinitor®
304606|NCT01482156|ER+/HER2- metastatic breast cancer
304607|NCT01482143|Fragile X Syndrome
304608|NCT01482143|pharmacokinetics
304609|NCT01482143|safety and tolerability
304610|NCT01482130|Exercise
304611|NCT01482130|osteoporosis
304612|NCT01482130|prevention
304613|NCT01482117|CYP2C19
304614|NCT01482117|CYP3A5
304615|NCT01482117|Clopidogrel
304616|NCT01482117|Cilostazol
304617|NCT01482117|Healthy
304618|NCT01482104|Photochemotherapy
304619|NCT01482104|methyl 5-aminolevulinate
304620|NCT01482091|fentanyl
304621|NCT01482091|intranasal
304622|NCT01482091|sickle cell
304623|NCT01482091|vasoocclusive crisis
304624|NCT01482091|pain crisis
304625|NCT01482091|pediatrics
304626|NCT01482078|Magnesium Sulphate
304627|NCT01482078|Neuroprotection
304628|NCT01482078|Neuraxial Anesthesia
304629|NCT01482078|Sedation
304630|NCT01482078|Respiratory function
304631|NCT01482078|Cesarean Section
304632|NCT01482078|Obstetrical Anesthesia
304633|NCT01482065|Non Alcoholic Fatty Liver Disease
304634|NCT01482065|NAFLD
304635|NCT01482065|Continuous Positive Airway Pressure
304636|NCT01482065|CPAP
304637|NCT01482065|CPAP Therapy
304638|NCT01482065|Apnea Hypopnea Index
304639|NCT01482065|Non alcoholic steatohepatitis
304640|NCT01482065|NASH
304641|NCT01482065|OSA
304642|NCT01482065|Obstructive Sleep Apnea
304643|NCT01482065|AHI
304644|NCT01482052|Central Nervous System Infections
304645|NCT01482052|Meningitis
304646|NCT01482052|toxoid
304647|NCT01482052|Meningococcal vaccine
304648|NCT01482052|conjugate vaccines
304649|NCT01482039|short cervix
304650|NCT01482039|cervical shortening
304651|NCT01482039|preterm birth
304652|NCT01482026|Epilepsy
304653|NCT01482026|Attention deficit
304654|NCT01482026|ADHD rating scale IV
304655|NCT01482000|Pulmonary Disease, Chronic Obstructive
304656|NCT01482000|Adult
304657|NCT01482000|therapeutic use
304658|NCT01482000|Humans
304659|NCT01482000|Treatment Outcome
304660|NCT01482000|daoyin therapy
304661|NCT01481987|Microperimetry
304662|NCT01481987|OCT
304663|NCT01481987|idiopathic epiretinal membrane
304664|NCT01481974|liver transplantation
304665|NCT01481974|treprostinil
304666|NCT01481961|Alzheimer's disease
304667|NCT01481961|rTMS
304668|NCT01481961|cognition
304669|NCT01481948|physical activity
304670|NCT01481948|fruit and vegetable
304671|NCT01481948|water
304672|NCT01481948|girls
304673|NCT01481948|African American
304674|NCT01481948|online
304675|NCT01481935|Antibiotic resistant bacteria
304676|NCT01481935|Colonization
304677|NCT01481935|Hospital cleaning
304678|NCT01481935|Environmental cleaning
304679|NCT01481935|Infection Control
304680|NCT01481922|Lumbar puncture
304681|NCT01481922|Flow rate
304682|NCT01481922|Backache
304683|NCT01481922|Pain
304684|NCT01481922|Undifferentiated headache
304685|NCT01481922|Post-lumbar puncture headache
304686|NCT01481909|Assessment of wheal and flare development
304687|NCT01481909|Assessment of life quality
304688|NCT01481896|Hip replacement
304689|NCT01481896|Metal-on-metal bearings
304690|NCT01481896|Osteolysis
304691|NCT01481896|Metal ion levels
304692|NCT01481896|Outcome
304693|NCT01481883|Schizophrenia
304694|NCT01481883|Mental Illness
304695|NCT01481883|SERM
304696|NCT01481883|Raloxifene
304697|NCT01481870|renal cell carcinoma
304698|NCT01481870|sorafenib
304699|NCT01481870|sunitinib
304700|NCT01481870|crossover
304701|NCT01481844|sequential therapy
304702|NCT01481844|second line treatment
304703|NCT01481844|H pylori
304704|NCT01481792|Keratorefractive Surgical Procedures
304705|NCT01481766|child development
304706|NCT01481766|screening
304707|NCT01481766|Non-anemic iron deficiency
304708|NCT01481766|primary care pediatrics
304709|NCT01481766|prevention and health promotion
304710|NCT01481740|spinal induced hypotension
304711|NCT01481740|nausea and vomiting
304712|NCT01481740|cesarean delivery
304713|NCT01481727|acute exacerbation of COPD number
304714|NCT01481727|acute exacerbation of COPD severity
304715|NCT01481714|Sodium picosulphate
304716|NCT01481714|Split-dose
304717|NCT01481714|Bowel cleansing
304718|NCT01481714|colonoscopy
304719|NCT01481714|Degree of bowel cleansing during colonoscopy
304720|NCT01481701|ovarian carcinoma
304721|NCT01481701|Bordet
304722|NCT01481701|relapse
304723|NCT01481688|Dialysis adequacy
304724|NCT01481688|Urea clearance
304725|NCT01481688|Phosphate clearance
304726|NCT01481688|Beta 2 microglobulin clearance
304727|NCT01481688|Intradialytic exercise
304728|NCT01481688|Haemodialysis patients
304729|NCT01481675|biliopancreatic diversion
304730|NCT01481675|sleeve gastrectomy
304731|NCT01481675|diabetes mellitus
304732|NCT01481675|weight loss
304733|NCT01481675|ghrelin
304734|NCT01481675|PYY
304735|NCT01481675|GLP-1
304736|NCT01481662|SUSAC's Syndrome
304737|NCT01481662|encephalopathy
304738|NCT01481662|hearing loss
304739|NCT01481662|retinal artery branch occlusions
304740|NCT01481662|Diffusion tensor MRI
304741|NCT01481649|hepatitis B
304742|NCT01481649|anti-HBc
304743|NCT01481649|HBsAg
304744|NCT01481649|HSCT
304745|NCT01481649|recipients
304746|NCT01481636|Obstructive sleep apnea
304747|NCT01481636|correlation
304748|NCT01481636|AHI
304749|NCT01481636|symptoms
304750|NCT01481636|mechanisms
304751|NCT01481623|Diabetes
304752|NCT01481623|neonatal
304753|NCT01481623|consanguinity
304754|NCT01481623|monogenic
304755|NCT01481623|metabolism
304756|NCT01481610|Kidney Failure, Chronic
304757|NCT01481610|Arthralgia
304758|NCT01481610|NSAID
304759|NCT01481610|Diclofenac
304760|NCT01481610|Lumiracoxib
304761|NCT01481610|Safety
304762|NCT01481597|deuteporfin
304763|NCT01481597|safety
304764|NCT01481597|tolerability
304765|NCT01481597|pharmacokinetics
304766|NCT01481597|healthy volunteers
304767|NCT01481584|Dietary protein
304768|NCT01481584|Canola protein
304769|NCT01481584|Protein metabolism
304770|NCT01481584|Protein-enriched drinks
304771|NCT01481584|Nitrogen balance
304772|NCT01481571|Media for vitrification/warming of human oocytes
304773|NCT01481558|Apathy
304774|NCT01481558|Alzheimer's Disease
304775|NCT01481558|Dementia
304776|NCT01481545|locally advanced
304777|NCT01481545|high risk
304778|NCT01481545|preoperative therapy
304779|NCT01481532|Antineoplastic agent
304780|NCT01481519|Conjunctivitis
304781|NCT01481519|Ocular diseases
304782|NCT01481519|Artificial tears
304783|NCT01481493|rheumatoid arthritis
304784|NCT01481480|shoulder
304785|NCT01481480|rotator cuff
304786|NCT01481480|tendon transfer
304787|NCT01481480|arthroscopic repair
304788|NCT01481467|influenza vaccination
304789|NCT01481467|intervention mapping
304790|NCT01481467|hospital care
304791|NCT01481467|respiratory infections
304792|NCT01481467|vaccination
304793|NCT01481454|Influenza
304794|NCT01481454|Quadrivalent Inactivated Influenza Vaccine
304795|NCT01481454|Trivalent Inactivated Influenza Vaccine
304796|NCT01481441|Contrast Enhanced Ultrasound (CEUS)
304797|NCT01481441|Prostate cancer
304798|NCT01481441|Quantification
304799|NCT01481441|Prostate biopsies
304800|NCT01481441|Transrectal ultrasound (TRUS)
304801|NCT01481441|Microbubbles
304802|NCT01481428|High risk behavior
304803|NCT01481428|Drug court clients
304804|NCT01481428|Substance abuse
304805|NCT01481428|HIV intervention
304806|NCT01481428|Treatment Court Clients
304807|NCT01481415|left atrial
304808|NCT01481415|three-dimensional echocardioraphy
304809|NCT01481415|left atrial function
304810|NCT01481402|Heart failure
304811|NCT01481402|Liothyronine
304812|NCT01481402|Low T3 syndrome
304813|NCT01481389|Blood lipids
304814|NCT01481389|risk factor for cardiovascular diseases
304815|NCT01481376|Parietex™ ProGrip™
304816|NCT01481376|Laparoscopic Transabdominal preperitoneal
304817|NCT01481376|TAPP
304818|NCT01481376|Inguinal hernia repair
304819|NCT01481363|dementia
304820|NCT01481363|communication
304821|NCT01481363|carers
304822|NCT01481363|caregivers
304823|NCT01481363|psychosocial support systems
304824|NCT01481363|education
304825|NCT01481337|colon
304826|NCT01481337|endoscopy
304827|NCT01481337|resection
304828|NCT01481324|Clubfoot
304829|NCT01481324|Compliance
304830|NCT01481324|Brace wear
304831|NCT01481285|Bioelectrical Impedance Measurement
304832|NCT01481285|Adults
304833|NCT01481272|Salvage therapy in DLBCL
304834|NCT01481259|Nonsquamous non-small cell lung cancer
304835|NCT01481259|Maintenance therapy
304836|NCT01481259|Immunotherapy
304837|NCT01481259|Autologous cytokine-induced killer cell
304838|NCT01481259|Pemetrexed
304839|NCT01481246|neurorehabilitation
304840|NCT01481246|cognition
304841|NCT01481246|aging
304842|NCT01481246|MCI
304843|NCT01481246|cognitive decline
304844|NCT01481233|oral colchicine
304845|NCT01481233|castrate-resistant prostate cancer
304846|NCT01481233|failed taxotere based chemotherapy
304847|NCT01481220|Myelodysplastic syndrome
304848|NCT01481220|azacitidine
304849|NCT01481220|Eltrombopag
304850|NCT01481220|Thrombopoietin-receptor agonist
304851|NCT01481220|Thrombocytopenia
304852|NCT01481220|Transfusion dependency
304853|NCT01481220|Safety study
304854|NCT01481207|magnetic resonance spectroscopy
304855|NCT01481207|magnetic resonance imaging
304856|NCT01481194|Multiple Myeloma
304857|NCT01481181|zinc water diarrhoea growth preschool children
304858|NCT01481155|actinic keratosis
304859|NCT01481155|field cancerisation
304860|NCT01481116|Drug Therapy
304861|NCT01481103|Over the counter medication
304862|NCT01481103|Acupuncture
304863|NCT01481090|Infertility
304864|NCT01481090|acupuncture
304865|NCT01481090|frozen embryos
304866|NCT01481090|endometrium
304867|NCT01481090|TCM
304868|NCT01481064|Patient centredness
304869|NCT01481064|Quality of life
304870|NCT01481064|Multifaceted approach
304871|NCT01481064|Fertility care
304872|NCT01481038|early detection
304873|NCT01481038|CRBSI
304874|NCT01481025|Climacteric
304875|NCT01481025|Depression
304876|NCT01481025|Herbal treatment
304877|NCT01481012|Heart transplantation
304878|NCT01481012|Coronary artery bypass graft (CABG) surgery
304879|NCT01481012|Left ventricular assist device implantation surgeries
304880|NCT01480999|Laparotomy
304881|NCT01480999|Open Surgery
304882|NCT01480999|Laparoscopy
304883|NCT01480999|Robotic surgery
304884|NCT01480960|lung transplantation
304885|NCT01480960|whole body vibration
304886|NCT01480960|exercise training
304887|NCT01480960|pulmonary rehabilitation
304888|NCT01480947|probiotics
304889|NCT01480947|pediatric
304890|NCT01480947|salmonella
304891|NCT01480947|rotavirus
304892|NCT01480947|gastroenteritis
304893|NCT01480934|Diabetes,posterior capsule opacification,case control study
304894|NCT01480921|heart failure
304895|NCT01480921|health related quality of life
304896|NCT01480921|exercise capacity
304897|NCT01480921|home based exercise training
304898|NCT01480921|supervised exercise training
304899|NCT01480908|Right bundle branch block
304900|NCT01480908|Ventricular septal defect
304901|NCT01480908|Echocardiography
304902|NCT01480908|MRI
304903|NCT01480908|Exercise testing
304904|NCT01480895|Diabetes Mellitus Type 2
304905|NCT01480895|Gestational Diabetes Mellitus
304906|NCT01480895|Glucose Intolerance
304907|NCT01480895|Physical exercise
304908|NCT01480895|Nutritional Habits
304909|NCT01480895|Dyslipidemia
304910|NCT01480882|Manual percussion
304911|NCT01480882|Mechanical percussion
304912|NCT01480882|Chronic bronchiectasis
304913|NCT01480882|Chronic Obstructive Pulmonary Disease
304914|NCT01480882|Wet sputum weight
304915|NCT01480882|Dry sputum weight
304916|NCT01480869|Breast cancer
304917|NCT01480869|Vitamin D supplementation
304918|NCT01480869|in neoadjuvant
304919|NCT01480869|adjuvant setting
304920|NCT01480843|simplification
304921|NCT01480843|glargine
304922|NCT01480843|elderly
304923|NCT01480830|Quality
304924|NCT01480830|indicators
304925|NCT01480804|Barriers
304926|NCT01480804|Intervention
304927|NCT01480804|Elderly
304928|NCT01480804|glycemic control
304929|NCT01480791|resistance arteries
304930|NCT01480791|endothelial dysfunction
304931|NCT01480791|aortic stiffness
304932|NCT01480778|hormonal response, levonorgestrel, ethinyl estradiol
304933|NCT01480752|In the patients with symptomatic Irreversible Pulpitis
304934|NCT01480739|Phase 1, AZD5069, safety and tolerability, healthy volunteer,
304935|NCT01480713|HIV-1
304936|NCT01480713|protease inhibitors
304937|NCT01480713|integrase inhibitors
304938|NCT01480713|raltegravir
304939|NCT01480713|viral replication
304940|NCT01480713|treatment intensification
304941|NCT01480713|viral pathogenesis
304942|NCT01480713|immune activation
304943|NCT01480700|eggs
304944|NCT01480700|Optical Macular Pigment
304945|NCT01480700|Age Macular Degeneration
304946|NCT01480700|study for the Age Macular Degeneration prevention
304947|NCT01480687|Hypertension
304948|NCT01480687|Endothelial dysfunction
304949|NCT01480687|Vascular stiffness
304950|NCT01480661|Pulmonary Disease, Chronic Obstructive
304951|NCT01480661|Computed Tomography scan
304952|NCT01480661|Functional Respiratory Imaging
304953|NCT01480661|Roflumilast
304954|NCT01480661|Health Related Quality of Life
304955|NCT01480635|Incomplete Colonoscopy
304956|NCT01480635|Efficacy of PillCam Colon2
304957|NCT01480622|healthy subjects
304958|NCT01480622|Tenofovir disoproxil fumarate
304959|NCT01480622|hepatitis
304960|NCT01480622|pharmacokinetics
304961|NCT01480583|GRN1005
304962|NCT01480583|ANG1005
304963|NCT01480583|Peptide-Drug Conjugate (PDC)
304964|NCT01480583|LRP-1
304965|NCT01480583|Targeted Therapy
304966|NCT01480583|Breast Cancer
304967|NCT01480583|Brain Metastases
304968|NCT01480583|Brain Tumor
304969|NCT01480583|Blood Brain Barrier
304970|NCT01480583|Trastuzumab
304971|NCT01480583|Herceptin
304972|NCT01480583|Paclitaxel
304973|NCT01480583|Taxol
304974|NCT01480583|Breast cancer with brain metastases
304975|NCT01480557|cataract
304976|NCT01480557|phacoemulsification
304977|NCT01480557|liquefaction
304978|NCT01480557|torsional ip
304979|NCT01480557|endothelial cell count
304980|NCT01480557|central corneal edema
304981|NCT01480557|central corneal sensitivity
304982|NCT01480544|Institutional Deliveries
304983|NCT01480544|Maternal Health
304984|NCT01480544|Infant Health
304985|NCT01480544|Private Medical Providers
304986|NCT01480544|Provider Incentives
304987|NCT01480544|Randomized Control Trial
304988|NCT01480531|aorta
304989|NCT01480531|aneurysm
304990|NCT01480531|dissection
304991|NCT01480518|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
304992|NCT01480505|Retinal detachment
304993|NCT01480505|high myopia
304994|NCT01480505|macular hole
304995|NCT01480505|axial length
304996|NCT01480505|Scleral buckling
304997|NCT01480505|Vitrectomy
304998|NCT01480505|Visual acuity
304999|NCT01480505|fundus examination results
305000|NCT01480492|HBV
305001|NCT01480492|Immune
305002|NCT01480492|antiviral therapy
305003|NCT01480479|EGFRvIII
305004|NCT01480479|Glioblastoma
305005|NCT01480479|Small cell
305006|NCT01480479|Giant cell
305007|NCT01480479|Gliosarcoma
305008|NCT01480479|oligodendroglial
305009|NCT01480479|Brain Cancer
305010|NCT01480479|Brain Tumor
305011|NCT01480479|radiotherapy
305012|NCT01480479|chemoradiation
305013|NCT01480479|Tumor
305014|NCT01480479|temozolomide
305015|NCT01480479|EGFR variant III
305016|NCT01480466|Overweight
305017|NCT01480466|Obesity
305018|NCT01480466|Body mass index
305019|NCT01480466|Weight
305020|NCT01480466|Primary care
305021|NCT01480453|Osteoarthritis
305022|NCT01480453|Rheumatoid arthritis
305023|NCT01480453|Post-traumatic arthritis
305024|NCT01480453|Ununited humeral head fracture
305025|NCT01480453|Irreducible 3- and 4-part proximal humeral fractures
305026|NCT01480453|Avascular necrosis
305027|NCT01480440|Reverse Total Shoulder Arthroplasty
305028|NCT01480440|Reverse TSA
305029|NCT01480440|Osteoarthritis
305030|NCT01480440|Rheumatoid Arthritis
305031|NCT01480440|Post-traumatic arthritis
305032|NCT01480440|Ununited humeral head fracture
305033|NCT01480440|Irreducible 3-and 4-part proximal humeral fractures
305034|NCT01480440|Avascular necrosis
305035|NCT01480440|Gross rotator cuff deficiency
305036|NCT01480440|Failed total shoulder arthroplasty (both glenoid and humeral components require revision
305037|NCT01480427|Children aged 0-12 years
305038|NCT01480427|IgE mediated food allergy
305039|NCT01480414|bone marrow mono nuclear stem cell ischemic ulcer
305040|NCT01480401|Patients with stable heart failure
305041|NCT01480388|Rheumatoid arthritis
305042|NCT01480388|Swollen and tender joints
305043|NCT01480388|Dose range finding study
305044|NCT01480388|Concurrent treatment with methotrexate
305045|NCT01480375|prostate cancer detection
305046|NCT01480375|prostate biopsy
305047|NCT01480375|3d navigation
305048|NCT01480375|trans rectal ultrasound
305049|NCT01480362|Diabetic foot wound
305050|NCT01480362|Amputation wound
305051|NCT01480362|Chronic wound
305052|NCT01480349|Post-Hemorrhagic Hydrocephalus
305053|NCT01480349|Intraventricular Hemorrhage
305054|NCT01480349|Low Birth Weight Premature Infants
305055|NCT01480336|Arrhythmia
305056|NCT01480323|Malignant melanoma
305057|NCT01480297|Pain
305058|NCT01480297|Neuropathy
305059|NCT01480297|Diabetes type 1
305060|NCT01480284|Tenofovir Disoproxil Fumarate
305061|NCT01480284|Chronic Hepatitis B
305062|NCT01480271|Allergic Rhinitis
305063|NCT01480271|Healthy Volunteers
305064|NCT01480271|Single Dose Escalation
305065|NCT01480271|TLR7 agonist
305066|NCT01480271|First Time in Human Study
305067|NCT01480258|combination vaccine
305068|NCT01480258|diphtheria
305069|NCT01480258|pertussis
305070|NCT01480258|tetanus
305071|NCT01480258|hepatitis B
305072|NCT01480258|Hep B
305073|NCT01480258|Haemophilus influenzae b
305074|NCT01480258|Hib
305075|NCT01480258|polio
305076|NCT01480258|poliovirus
305077|NCT01480245|968
305078|NCT01480245|Duchenne
305079|NCT01480245|DMD
305080|NCT01480245|drisapersen
305081|NCT01480219|voriconazole
305082|NCT01480219|non-melanoma skin cancer
305083|NCT01480219|confounding
305084|NCT01480219|statistical adjustment
305085|NCT01480219|risk adjustment
305086|NCT01480219|lung transplant
305087|NCT01480219|heart/lung transplant
305088|NCT01480219|immunosuppression
305089|NCT01480193|Tinnitus
305090|NCT01480167|VCF
305091|NCT01480167|Osteoporosis
305092|NCT01480167|Minimally Invasive
305093|NCT01480167|Non-operative management
305094|NCT01480167|Medical Management
305095|NCT01480128|Single-port
305096|NCT01480128|Laparoscopy
305097|NCT01480128|colectomy
305098|NCT01480128|Single port
305099|NCT01480128|colon cancer
305100|NCT01480128|minimally invasive surgery
305101|NCT01480115|antral follicle count
305102|NCT01480115|automated antral follicle count
305103|NCT01480115|ovarian reserve
305104|NCT01480102|Percutaneous nephrolithotomy
305105|NCT01480102|Paravertebral block
305106|NCT01480102|bupivacaine
305107|NCT01480089|Surgical Pain Management
305108|NCT01480089|Robotic surgery
305109|NCT01480089|Ropivacaine
305110|NCT01480076|Quality of Life
305111|NCT01480076|Multiple Sclerosis
305112|NCT01480050|adult giant cell glioblastoma
305113|NCT01480050|adult glioblastoma
305114|NCT01480050|adult anaplastic astrocytoma
305115|NCT01480050|adult anaplastic ependymoma
305116|NCT01480050|adult anaplastic oligodendroglioma
305117|NCT01480050|adult mixed glioma
305118|NCT01480050|recurrent adult brain tumor
305119|NCT01480024|healthy women
305120|NCT01480024|oocytes
305121|NCT01480024|in vitro fertilization
305122|NCT01480024|pregnancy
305123|NCT01480024|childbearing-age
305124|NCT01480011|Lactobacillus CD2 lozenges
305125|NCT01480011|high-dose chemotherapy induced
305126|NCT01480011|hematopoietic stem cell transplantation
305127|NCT01479998|smoking cessation
305128|NCT01479998|NRT nicotine replacement therapy
305129|NCT01479998|CBT cognitive behavioral therapy
305130|NCT01479998|contingency management
305131|NCT01479972|Tuberculosis
305132|NCT01479972|Vaccine
305133|NCT01479972|Live vaccine
305134|NCT01479972|rBCG
305135|NCT01479959|Tracheostomy
305136|NCT01479959|positive end expiratory pressure
305137|NCT01479959|speech
305138|NCT01479959|respiratory failure
305139|NCT01479959|ventilation
305140|NCT01479959|neuromuscular disorders
305141|NCT01479933|vitamin D
305142|NCT01479933|cholecalciferol
305143|NCT01479933|supplementation
305144|NCT01479933|prediabetic state
305145|NCT01479933|obesity
305146|NCT01479933|glucose metabolism
305147|NCT01479933|gene expression
305148|NCT01479933|transcriptomics
305149|NCT01479933|epigenomics
305150|NCT01479933|immunological function
305151|NCT01479933|insulin sensitivity
305152|NCT01479933|peripheral mononuclear cells
305153|NCT01479920|Depressive Disorder
305154|NCT01479920|Depressive Symptoms
305155|NCT01479920|Depressive Syndrome
305156|NCT01479920|Emotional Depression
305157|NCT01479881|Hepatitis C Virus
305158|NCT01479881|TMC435
305159|NCT01479881|TMC435-TiDP16-C120
305160|NCT01479881|TMC435-C120
305161|NCT01479881|HCV
305162|NCT01479881|Hepatitis C
305163|NCT01479881|Hep C
305164|NCT01479881|Healthy participants
305165|NCT01479868|Hepatitis C virus genotype-1
305166|NCT01479868|Human immunodeficiency virus-type 1
305167|NCT01479868|HCV-1
305168|NCT01479868|HIV-1
305169|NCT01479868|TMC435
305170|NCT01479868|Pegylated interferon alpha-2a
305171|NCT01479868|PegIFNα-2a
305172|NCT01479868|Pegasys
305173|NCT01479868|Ribavirin
305174|NCT01479868|RBV
305175|NCT01479868|Copegus
305176|NCT01479855|Mild Cognitive Impairment (MCI)
305177|NCT01479855|Alzheimers disease
305178|NCT01479855|Vitamines
305179|NCT01479855|Nutrients
305180|NCT01479829|Bipolar depression
305181|NCT01479829|Celecoxib
305182|NCT01479829|Escitalopram
305183|NCT01479829|Inflammation
305184|NCT01479816|continence
305185|NCT01479816|index
305186|NCT01479790|Visante AS-OCT
305187|NCT01479790|Cirrus AS-OCT
305188|NCT01479790|Thermography
305189|NCT01479790|Tear evaporation
305190|NCT01479790|Tear evaporimetry
305191|NCT01479777|Spinal Cord Injury
305192|NCT01479777|Functional electrical stimulation
305193|NCT01479777|Rehabilitation
305194|NCT01479751|Rocuronium
305195|NCT01479751|magnesium
305196|NCT01479751|priming
305197|NCT01479751|ketamine
305198|NCT01479751|intubation
305199|NCT01479738|arthroplasty
305200|NCT01479738|graft
305201|NCT01479738|capitate
305202|NCT01479738|artery
305203|NCT01479725|interstitial cystitis
305204|NCT01479712|Irrigation
305205|NCT01479712|Cesarean Section
305206|NCT01479712|Nausea
305207|NCT01479712|Infection
305208|NCT01479699|Olive leaf extract
305209|NCT01479699|Polyphenols
305210|NCT01479699|Vascular function
305211|NCT01479699|Bioavailability
305212|NCT01479699|Cytokines
305213|NCT01479686|GLIOMA
305214|NCT01479686|NEURONAVIGATION
305215|NCT01479686|INTERVENTIONAL MRI
305216|NCT01479673|Enteral Nutrition
305217|NCT01479673|Parenteral Nutrition
305218|NCT01479673|Indirect Calorimetry
305219|NCT01479673|Intravenous Feeding
305220|NCT01479660|Probiotics
305221|NCT01479660|ulcerative colitis
305222|NCT01479660|inflammatory bowel disease
305223|NCT01479634|HIV
305224|NCT01479634|ART
305225|NCT01479621|Dose Ranging
305226|NCT01479621|Fluticasone Propionate
305227|NCT01479621|Dry Powder Inhaler (DPI)
305228|NCT01479621|Non-steroidal
305229|NCT01479621|Asthma
305230|NCT01479595|Asthma
305231|NCT01479595|Interleukin
305232|NCT01479595|QBX258
305233|NCT01479595|QAX576
305234|NCT01479595|VAK694
305235|NCT01479582|Adult and Pediatric
305236|NCT01479582|Unlicensed Cord Blood Unit IND
305237|NCT01479582|NMDP
305238|NCT01479582|Transplant
305239|NCT01479582|Hematologic Malignancies
305240|NCT01479582|Leukemia
305241|NCT01479582|Multiple Myeloma
305242|NCT01479582|Non-Hodgkin Lymphoma
305243|NCT01479582|CML
305244|NCT01479582|Chronic Myelogenous Leukemia
305245|NCT01479582|Myelodyplastic Syndrome
305246|NCT01479582|MDS
305247|NCT01479582|Thalassemia
305248|NCT01479582|Lysosomal Storage Diseases
305249|NCT01479569|MRI Catheterization
305250|NCT01479569|Pericardiocentesis
305251|NCT01479569|MRI Safety
305252|NCT01479569|Cardiac Magnetic Resonance Imaging
305253|NCT01479556|Pregabalin
305254|NCT01479556|Neuropathic pain
305255|NCT01479556|At-level neuropathic pain
305256|NCT01479556|Non-evoked neuropathic pain
305257|NCT01479556|Evoked neuropathic pain
305258|NCT01479556|Sub-acute spinal cord injury
305259|NCT01479543|Probiotic
305260|NCT01479543|Immunity
305261|NCT01479543|Gastrointestinal symptoms
305262|NCT01479530|Rasagiline
305263|NCT01479530|Azilect
305264|NCT01479530|Parkinson´s Disease
305265|NCT01479530|Motor fluctuations
305266|NCT01479517|operative
305267|NCT01479517|dental procedure
305268|NCT01479504|Nasopharyngeal Carcinoma
305269|NCT01479504|neoadjuvant chemotherapy
305270|NCT01479504|concurrent chemoradiotherapy
305271|NCT01479504|Nedaplatin
305272|NCT01479491|Japan
305273|NCT01479491|Retrospective
305274|NCT01479491|Observational
305275|NCT01479491|Epidemiological study
305276|NCT01479491|Children aged < 12 months
305277|NCT01479491|Intussusception
305278|NCT01479465|GSI
305279|NCT01479465|Gilead
305280|NCT01479465|Gilead Sciences
305281|NCT01479465|GS-6624
305282|NCT01479465|Colorectal Cancer
305283|NCT01479465|KRAS
305284|NCT01479465|Oncology
305285|NCT01479465|monoclonal antibody
305286|NCT01479452|obesity
305287|NCT01479452|bariatric surgery
305288|NCT01479452|weight loss
305289|NCT01479426|Erectile dysfunction
305290|NCT01479426|Korean Red Ginseng
305291|NCT01479426|IIEF
305292|NCT01479426|MSHQ
305293|NCT01479413|Schizophrenia
305294|NCT01479413|Oxidative stress
305295|NCT01479413|Mitochondria
305296|NCT01479400|antipsychotic
305297|NCT01479400|schizophrenia
305298|NCT01479400|infant development
305299|NCT01479387|Zevalin
305300|NCT01479387|CD20+
305301|NCT01479387|Non-Hodgkin's lymphoma
305302|NCT01479387|Mantle cell lymphoma
305303|NCT01479374|Allergic Conjunctivitis
305304|NCT01479374|Ocular Allergy
305305|NCT01479361|Atovaquone
305306|NCT01479361|Drug Interaction
305307|NCT01479361|Pharmacokinetics
305308|NCT01479361|Efavirenz
305309|NCT01479361|Atazanavir-Ritonavir
305310|NCT01479361|HIV
305311|NCT01479348|Imaging
305312|NCT01479348|Radiopharmaceutical
305313|NCT01479348|Safety
305314|NCT01479348|Dosimetry
305315|NCT01479348|Drug Distribution
305316|NCT01479348|Cancer
305317|NCT01479322|Intima-media thickness
305318|NCT01479322|Ghrelin
305319|NCT01479322|Prader-Willi syndrome
305320|NCT01479309|Advanced Malignancies
305321|NCT01479309|Solid Tumors
305322|NCT01479309|Melanoma
305323|NCT01479309|Renal Cell Carcinoma
305324|NCT01479309|Phase I Studies
305325|NCT01479309|Sodium Stibogluconate
305326|NCT01479309|Interferon Alpha-2b
305327|NCT01479309|Intron A
305328|NCT01479309|SSG
305329|NCT01479283|Infection
305330|NCT01479283|Bone Neoplasms
305331|NCT01479283|Prosthesis
305332|NCT01479283|Anti-Bacterial Agents
305333|NCT01479283|Randomized
305334|NCT01479270|recovery
305335|NCT01479270|postoperative
305336|NCT01479270|pain
305337|NCT01479270|laparoscopy
305338|NCT01479270|hysterectomy
305339|NCT01479270|ropivacaine
305340|NCT01479270|TAP block
305341|NCT01479270|local anesthesia
305342|NCT01479257|Cancer
305343|NCT01479257|Risk factors
305344|NCT01479257|Latinos
305345|NCT01479257|Hispanic Americans
305346|NCT01479257|Hispanics
305347|NCT01479257|Latino resident
305348|NCT01479257|Houston metropolitan area
305349|NCT01479257|Spanish speaking
305350|NCT01479257|Cancer risk behaviors
305351|NCT01479257|Questionnaires
305352|NCT01479257|Surveys
305353|NCT01479257|Accelerometer
305354|NCT01479244|HER2
305355|NCT01479244|low or intermediate
305356|NCT01479244|breast cancer
305357|NCT01479244|node-positive tumors
305358|NCT01479231|GERD
305359|NCT01479231|Eosinophilic esophagitis
305360|NCT01479231|Proton pump inhibitor
305361|NCT01479231|dysphagia
305362|NCT01479205|specific immunotherapy
305363|NCT01479205|bronchial allergen provocation
305364|NCT01479205|specific IgE
305365|NCT01479205|specific IgG
305366|NCT01479205|specific IgG4
305367|NCT01479205|SIT
305368|NCT01479192|breast
305369|NCT01479192|cancer
305370|NCT01479192|prevention
305371|NCT01479192|fenretinide
305372|NCT01479179|Breast Cancer
305373|NCT01479179|Metastatic Breast Cancer
305374|NCT01479179|HER-2-overexpressing breast cancer
305375|NCT01479179|Human epidermal growth factor receptor
305376|NCT01479179|AMG 479
305377|NCT01479179|Trastuzumab
305378|NCT01479179|Herceptin
305379|NCT01479166|cystic fibrosis
305380|NCT01479166|HRCT
305381|NCT01479166|Sputum
305382|NCT01479166|Blood
305383|NCT01479166|Inflammation
305384|NCT01479166|adaptive immune system
305385|NCT01479166|innate immune system
305386|NCT01479153|Central venous catheterization
305387|NCT01479153|Major complications
305388|NCT01479153|Internal Jugular
305389|NCT01479153|Femoral
305390|NCT01479153|Subclavian
305391|NCT01479140|myocardial infarction
305392|NCT01479140|dissection
305393|NCT01479140|coronary Fibromuscular Dysplasia
305394|NCT01479140|coronary ectasia
305395|NCT01479140|atherosclerotic Coronary Artery Disease
305396|NCT01479140|coronary vasculitis
305397|NCT01479140|coronary embolism
305398|NCT01479140|congenital coronary anomaly
305399|NCT01479127|Levodopa-carbidopa intestinal gel
305400|NCT01479127|Advanced Parkinson's disease
305401|NCT01479127|Severe motor fluctuations
305402|NCT01479127|Dyskinesia
305403|NCT01479101|neo adjuvant, breast cancer
305404|NCT01479088|Cinacalcet
305405|NCT01479088|PK
305406|NCT01479088|Secondary Hyperparathyroidism
305407|NCT01479088|Paediatric
305408|NCT01479088|Chronic Kidney Disease
305409|NCT01479088|Dialysis
305410|NCT01479075|central insulin
305411|NCT01479075|insulin resistance
305412|NCT01479075|energy metabolism
305413|NCT01479062|behavior change
305414|NCT01479062|pre-diabetes
305415|NCT01479062|prevention
305416|NCT01479062|diabetes prevention
305417|NCT01479062|Hemoglobin A1c
305418|NCT01479062|glucose
305419|NCT01479062|physical activity
305420|NCT01479062|nutrition
305421|NCT01479062|email
305422|NCT01479062|web
305423|NCT01479062|obesity
305424|NCT01479049|congenital heart disease
305425|NCT01479049|cardiac surgery
305426|NCT01479049|cardiopulmonary bypass
305427|NCT01479049|cardioplegia
305428|NCT01479036|breast cancer
305429|NCT01479036|neoadjuvant chemotherapy
305430|NCT01479036|recombinant human endostatin (endostar)
305431|NCT01479036|docetaxel
305432|NCT01479036|epirubicin
305433|NCT01478984|NSTEMI
305434|NCT01478984|PCI
305435|NCT01478984|onestage
305436|NCT01478984|multistaged
305437|NCT01478971|Anemia
305438|NCT01478971|Chronic Renal Failure
305439|NCT01478971|CRF
305440|NCT01478971|Chronic Kidney Disease
305441|NCT01478971|CKD
305442|NCT01478971|Erythropoietin
305443|NCT01478971|Hematide
305444|NCT01478971|Peginesatide
305445|NCT01478971|Hemoglobin
305446|NCT01478971|Hgb
305447|NCT01478971|Red Blood Cell
305448|NCT01478971|Red Blood Cell Production
305449|NCT01478971|Dialysis
305450|NCT01478958|fatty acids
305451|NCT01478958|cardiovascular disease
305452|NCT01478958|vascular function
305453|NCT01478958|microparticles
305454|NCT01478945|vitiligo
305455|NCT01478945|early vitiligo
305456|NCT01478945|focal vitiligo
305457|NCT01478932|dyspnea
305458|NCT01478932|diaphragmatic breathing
305459|NCT01478932|Heart failure
305460|NCT01478919|Endoscopic Mucosal Resection
305461|NCT01478919|Laterally Spreading Tumor
305462|NCT01478919|Local Residual Neoplasia
305463|NCT01478919|Colonoscopy
305464|NCT01478919|Therapy
305465|NCT01478893|nicotine vaccine
305466|NCT01478893|smoking vaccine
305467|NCT01478893|smoking cessation
305468|NCT01478893|SEL-068
305469|NCT01478867|celiac disease
305470|NCT01478867|gluten-free diet
305471|NCT01478867|gluten peptides
305472|NCT01478867|feces
305473|NCT01478841|insulin resistance
305474|NCT01478841|type 2 diabetes (T2D)
305475|NCT01478841|cardiovascular complications
305476|NCT01478841|polyphenolic compounds derived from red grape marc extracts
305477|NCT01478841|oxidative stress
305478|NCT01478802|Mechanical Ventilation
305479|NCT01478802|High frequency oscillation
305480|NCT01478802|Acute Respiratory Distress syndrome
305481|NCT01478776|ASP
305482|NCT01478776|LCN2
305483|NCT01478776|RBP4
305484|NCT01478776|C5L2
305485|NCT01478763|PDRP
305486|NCT01478763|vitreous
305487|NCT01478763|protein
305488|NCT01478763|vitrectomy
305489|NCT01478750|obesity
305490|NCT01478750|fat
305491|NCT01478750|appetite
305492|NCT01478750|digestion
305493|NCT01478737|PDRP
305494|NCT01478737|vitreous hemorrhage
305495|NCT01478737|vitrectomy
305496|NCT01478698|peritoneal dialysis
305497|NCT01478698|peritoneal dialysis, continuous ambulatory
305498|NCT01478698|peritonitis
305499|NCT01478685|Relapsed or Refractory Solid Tumors
305500|NCT01478672|Promotion health
305501|NCT01478659|Diet
305502|NCT01478659|Fiber
305503|NCT01478659|Adult
305504|NCT01478659|Fructooligosaccharide
305505|NCT01478646|breathing therapy
305506|NCT01478646|reflective breathing therapy
305507|NCT01478646|COPD
305508|NCT01478646|chronic obstructive pulmonary disease
305509|NCT01478633|Alzheimer's disease
305510|NCT01478633|Dementia
305511|NCT01478633|Galantamine
305512|NCT01478633|Donepezil
305513|NCT01478607|Painful Diabetic Peripheral Neuropathy
305514|NCT01478607|Qutenza
305515|NCT01478594|metastatic colorectal cancer
305516|NCT01478594|Avastin
305517|NCT01478594|bevacizumab
305518|NCT01478594|tivozanib
305519|NCT01478594|mFOLFOX6
305520|NCT01478594|BATON-CRC
305521|NCT01478594|AV951
305522|NCT01478594|ASP4130
305523|NCT01478581|PCI-32765
305524|NCT01478581|Multiple Myeloma
305525|NCT01478581|Relapsed Refractory Multiple Myeloma
305526|NCT01478581|Bruton's Tyrosine Kinase
305527|NCT01478568|Pharmacokinetics
305528|NCT01478568|Mirabegron
305529|NCT01478568|Phase 1
305530|NCT01478555|Dry Eye
305531|NCT01478542|DLBCL
305532|NCT01478542|Liposomal Vincristine (Marqibo)
305533|NCT01478542|Optimised Rituximab
305534|NCT01478542|Toxicity
305535|NCT01478542|Elderly Patients
305536|NCT01478542|FDG-PET
305537|NCT01478542|Bulky Disease
305538|NCT01478542|Radiation
305539|NCT01478542|age >60 years
305540|NCT01478542|First line Therapy
305541|NCT01478542|Vitamin D
305542|NCT01478529|Pharmacokinetics
305543|NCT01478529|Mirabegron
305544|NCT01478529|Phase 1
305545|NCT01478516|autologous plasmin
305546|NCT01478516|macular edema
305547|NCT01478516|vitreous
305548|NCT01478503|Pharmacokinetics
305549|NCT01478503|Mirabegron
305550|NCT01478503|Phase 1
305551|NCT01478503|Dose-Escalation
305552|NCT01478490|Pharmacokinetics,
305553|NCT01478490|Mirabegron
305554|NCT01478490|Metoprolol
305555|NCT01478490|CYP2D6
305556|NCT01478490|Phase 1
305557|NCT01478477|Breast Cancer
305558|NCT01478451|DOMS
305559|NCT01478438|Unifocal
305560|NCT01478438|20mm in diameter
305561|NCT01478438|measures
305562|NCT01478438|5mm away from the skin and chest
305563|NCT01478425|Prevention
305564|NCT01478425|Pollen
305565|NCT01478425|Allergy
305566|NCT01478425|Rhinitis
305567|NCT01478412|Prostate cancer
305568|NCT01478412|Low risk
305569|NCT01478412|Intermediate risk
305570|NCT01478412|T1
305571|NCT01478412|T2a
305572|NCT01478412|T2b
305573|NCT01478412|Gleason 6
305574|NCT01478412|Gleason 7
305575|NCT01478412|PSA 10
305576|NCT01478412|PSA 20
305577|NCT01478373|GIST
305578|NCT01478373|Dovitinib
305579|NCT01478360|Asthma
305580|NCT01478360|Secukinumab
305581|NCT01478360|Therapeutic Uses
305582|NCT01478360|Respiratory
305583|NCT01478360|Lung
305584|NCT01478360|Pulmonary
305585|NCT01478360|inhaled
305586|NCT01478360|corticosteroids
305587|NCT01478347|Neisseria, Meningitis, Group B, Vaccine, At-risk, Adults
305588|NCT01478334|High intensity exercise
305589|NCT01478334|cardiovascular risk factors
305590|NCT01478321|Information Not Provided
305591|NCT01478308|prostate
305592|NCT01478308|castration resistant
305593|NCT01478308|hormone resistant
305594|NCT01478308|CRPC
305595|NCT01478295|Nursing intervention
305596|NCT01478295|Primary Health care
305597|NCT01478295|caregiver
305598|NCT01478295|strain
305599|NCT01478282|dabigatran
305600|NCT01478282|rivaroxaban
305601|NCT01478282|oral anticoagulants
305602|NCT01478282|coagulation
305603|NCT01478282|bleeding
305604|NCT01478282|plasma concentrates
305605|NCT01478269|Aggressive B-cell lymphoma
305606|NCT01478269|R-CHOP
305607|NCT01478256|blepharitis
305608|NCT01478256|topical erythromycin
305609|NCT01478256|topical besifloxocin
305610|NCT01478243|Keloid
305611|NCT01478230|Pharmacokinetics
305612|NCT01478217|lung ultrasonography
305613|NCT01478217|pressure-volume loops
305614|NCT01478217|ARDS
305615|NCT01478204|Alzheimer's disease
305616|NCT01478204|Sleep quality
305617|NCT01478204|Anticholinesterase drugs
305618|NCT01478191|Hodgkin's Lymphoma
305619|NCT01478191|Ifosfamide, Gemcitabine and Vinorelbine (IGEV)
305620|NCT01478191|High Dose Chemotherapy (HDCT)
305621|NCT01478191|Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
305622|NCT01478178|Glioma
305623|NCT01478178|Glioblastoma
305624|NCT01478178|Glioblastoma multiforme
305625|NCT01478178|GBM
305626|NCT01478178|brain tumor
305627|NCT01478178|brain cancer
305628|NCT01478178|recurrent brain tumor
305629|NCT01478178|recurrent brain cancer
305630|NCT01478178|refractory brain tumor
305631|NCT01478178|refractory brain cancer
305632|NCT01478178|recurrent GBM
305633|NCT01478178|refractory GBM
305634|NCT01478178|recurrent glioma
305635|NCT01478178|refractory glioma
305636|NCT01478178|recurrent glioblastoma
305637|NCT01478178|refractory glioblastoma
305638|NCT01478178|recurrent glioblastoma multiforme
305639|NCT01478178|refractory glioblastoma multiforme
305640|NCT01478178|failed temodar
305641|NCT01478178|failed temozolomide
305642|NCT01478178|temodar refractory
305643|NCT01478178|temozolomide refractory
305644|NCT01478178|failed avastin
305645|NCT01478178|avastin refractory
305646|NCT01478178|failed bevacizumab
305647|NCT01478178|bevacizumab refractory
305648|NCT01478178|avastin failure
305649|NCT01478178|bevacizumab failure
305650|NCT01478178|temodar failure
305651|NCT01478178|temozolomide failure
305652|NCT01478165|Palonosetron
305653|NCT01478165|PONV(postoperative nausea and vomiting)
305654|NCT01478165|TIVA(Total intravenous anesthesia)
305655|NCT01478152|Asthma
305656|NCT01478152|Ectoin
305657|NCT01478152|Ectoine
305658|NCT01478152|FeNO
305659|NCT01478152|Metacholin
305660|NCT01478152|sRaw
305661|NCT01478139|anorectal fistula
305662|NCT01478139|acellular dermal matrix
305663|NCT01478139|ligation of intersphincteric fistula tract
305664|NCT01478139|ligation of intersphincteric fistula tract and plug
305665|NCT01478139|complications of treatment
305666|NCT01478139|recurrence
305667|NCT01478113|Major Depressive Disorder
305668|NCT01478113|Therapy
305669|NCT01478113|Medication study
305670|NCT01478113|Depression
305671|NCT01478113|Therapy study
305672|NCT01478100|Coronary artery disease
305673|NCT01478100|CT
305674|NCT01478100|Computational flow dynamics
305675|NCT01478074|Acute Myeloid Leukemia
305676|NCT01478074|Relapsed leukemia
305677|NCT01478074|Refractory leukemia
305678|NCT01478074|Natural Killer Cells
305679|NCT01478074|Adoptive immunotherapy
305680|NCT01478074|NK cell infusion
305681|NCT01478074|Haploidentical
305682|NCT01478074|KIR mismatch
305683|NCT01478074|Fludarabine
305684|NCT01478074|Cytarabine
305685|NCT01478074|Ara-C
305686|NCT01478074|ALT-801
305687|NCT01478048|Relapsed/Refractory Multiple Myeloma
305688|NCT01478035|Phenytoin prophylaxis
305689|NCT01478035|Pneumococcal meningitis
305690|NCT01478035|Randomized
305691|NCT01478035|Placebo-controlled
305692|NCT01478035|Double blind
305693|NCT01478035|Patient 50 years or older
305694|NCT01478022|DMD
305695|NCT01478022|Duchenne
305696|NCT01478022|Muscular Dystrophy
305697|NCT01477996|intravitreal therapy
305698|NCT01477996|pain scales
305699|NCT01477996|gauge
305700|NCT01477996|Pain Scores
305701|NCT01477996|Visual Analog Scale
305702|NCT01477983|atrial fibrillation
305703|NCT01477983|catheter ablation
305704|NCT01477983|adenosine triphosphate
305705|NCT01477983|antiarrhythmic drugs
305706|NCT01477970|GnRH antagonists
305707|NCT01477970|OHSS
305708|NCT01477970|ovarian stimulation
305709|NCT01477957|weight loss after bariatric surgery
305710|NCT01477957|Insulin sensitivity
305711|NCT01477957|insulin resistance
305712|NCT01477944|Statins pattern of use
305713|NCT01477944|Hypercholesterolemic patients
305714|NCT01477944|Statins
305715|NCT01477931|Bupropion hydrochloride extended release
305716|NCT01477931|Wellbutrin XL
305717|NCT01477931|Major Depressive Disorder with Atypical Features
305718|NCT01477918|prevalence
305719|NCT01477918|Korea
305720|NCT01477905|priming
305721|NCT01477905|remifentanil
305722|NCT01477905|target-controlled infusion
305723|NCT01477840|Misoprostol
305724|NCT01477840|Oxytocin
305725|NCT01477840|Cesarean Delivery
305726|NCT01477840|Blood Loss
305727|NCT01477814|colorectal cancer
305728|NCT01477814|screening
305729|NCT01477814|colonoscopy
305730|NCT01477814|fecal immunochemical test
305731|NCT01477814|clinical guidelines
305732|NCT01477788|pelvic mass
305733|NCT01477788|ovarian mass
305734|NCT01477788|ultrasound
305735|NCT01477788|serum markers
305736|NCT01477788|ovarian malignancy
305737|NCT01477775|myocardial infarction
305738|NCT01477775|coronary stent
305739|NCT01477775|Oral P2Y12 receptor blocker
305740|NCT01477775|Platelet reactivity units (PRU)
305741|NCT01477762|startle response
305742|NCT01477762|fear conditioning
305743|NCT01477762|PTSD
305744|NCT01477749|prostate cancer
305745|NCT01477749|prostate
305746|NCT01477749|immune therapy
305747|NCT01477749|immunotherapy
305748|NCT01477749|vaccine
305749|NCT01477749|dendritic cells
305750|NCT01477749|antigen-presenting cells
305751|NCT01477749|antigen presenting cells
305752|NCT01477749|cancer vaccine
305753|NCT01477749|PSA
305754|NCT01477749|prostatic adenocarcinoma
305755|NCT01477736|Neurogenic bladder
305756|NCT01477736|Urodynamic
305757|NCT01477736|Quality of life
305758|NCT01477710|Mechanical ventilation
305759|NCT01477710|Tidal volume
305760|NCT01477710|Respiratory rate
305761|NCT01477697|Trauma
305762|NCT01477671|Dengue
305763|NCT01477671|Dengue Fever
305764|NCT01477671|Dengue Hemorrhagic Fever
305765|NCT01477658|Congenital Complete Atrioventricular Heart Block
305766|NCT01477658|Pacemaker
305767|NCT01477658|Cardiac pacing
305768|NCT01477658|Children
305769|NCT01477658|Heart failure
305770|NCT01477658|Ventricular dyssynchrony
305771|NCT01477658|Echocardiography
305772|NCT01477658|Quality of life
305773|NCT01477658|Six-minute walk test
305774|NCT01477658|Young adults
305775|NCT01477619|Pharmacokinetics
305776|NCT01477606|Acute myeloid leukemia
305777|NCT01477606|FLT3-ITD
305778|NCT01477606|midostaurin (PKC412)
305779|NCT01477593|circumcision, chinese children, pain
305780|NCT01477554|Women
305781|NCT01477554|Maternal morbidity
305782|NCT01477554|Maternal mortality
305783|NCT01477554|Perinatal mortality
305784|NCT01477554|Perinatal morbidity
305785|NCT01477554|Training
305786|NCT01477554|Obstetric Emergency
305787|NCT01477554|Medical team
305788|NCT01477554|Simulation
305789|NCT01477541|Prenatal care
305790|NCT01477541|Maternal mortality
305791|NCT01477541|Perinatal mortality
305792|NCT01477541|Perinatal
305793|NCT01477541|Puerperium
305794|NCT01477541|Puerperium care
305795|NCT01477541|Midwives
305796|NCT01477541|Midwife
305797|NCT01477541|Obstetric
305798|NCT01477541|Nurse
305799|NCT01477541|Integration
305800|NCT01477541|Alternative personnel
305801|NCT01477541|Skilled attendant
305802|NCT01477541|Birth attendant
305803|NCT01477541|Delivery
305804|NCT01477541|Delivery services
305805|NCT01477541|Best practices
305806|NCT01477541|Rural
305807|NCT01477528|HeartMate II
305808|NCT01477528|Anticoagulation
305809|NCT01477528|Thoratec Corporation
305810|NCT01477502|urinary tract infection
305811|NCT01477502|spinal cord injury
305812|NCT01477502|homeopathy
305813|NCT01477502|prevention
305814|NCT01477476|DKA
305815|NCT01477476|Diabetes
305816|NCT01477476|Type I Diabetes
305817|NCT01477463|quality of life
305818|NCT01477450|Hypobaric hypoxemia
305819|NCT01477450|Altitude
305820|NCT01477450|Oxygen
305821|NCT01477450|oxygen concentrator
305822|NCT01477437|teens
305823|NCT01477437|adolescents
305824|NCT01477437|Internet intervention
305825|NCT01477437|Hemophilia
305826|NCT01477424|Drug-drug interaction
305827|NCT01477424|Pharmacokinetics
305828|NCT01477424|PA21
305829|NCT01477411|Drug-drug interaction
305830|NCT01477411|Pharmacokinetics
305831|NCT01477411|PA21
305832|NCT01477385|dental caries
305833|NCT01477385|primary teeth
305834|NCT01477385|permanent teeth
305835|NCT01477385|silver diamine fluoride
305836|NCT01477372|Pregnancy
305837|NCT01477372|Exercise
305838|NCT01477372|Excessive weight gain
305839|NCT01477372|Outcomes
305840|NCT01477372|Urinary incontinence
305841|NCT01477333|Tyvaso
305842|NCT01477333|UT-15C SR
305843|NCT01477333|PAH
305844|NCT01477320|Enteral Nutrition
305845|NCT01477320|Stress Ulcer Prophylaxis
305846|NCT01477320|Critically Ill Patients
305847|NCT01477320|Overt and significant GI bleeding
305848|NCT01477320|Stress gastropathy
305849|NCT01477320|Clostridium Difficile pseudomembranous colitis
305850|NCT01477320|Vital AF
305851|NCT01477320|Small peptide fish oil structured lipids
305852|NCT01477320|Fructose oligosaccharide
305853|NCT01477307|obesity
305854|NCT01477307|non-alcoholic fatty liver disease
305855|NCT01477294|Total
305856|NCT01477294|Intra and Extracellular Water
305857|NCT01477294|Energy Expenditure, Physical Activity
305858|NCT01477294|Body Composition
305859|NCT01477294|Dilution Techniques
305860|NCT01477281|chronic venous insufficiency
305861|NCT01477281|Daflon
305862|NCT01477281|Venaflon
305863|NCT01477268|antidepressants
305864|NCT01477268|depression
305865|NCT01477268|zoloft
305866|NCT01477268|psychiatry
305867|NCT01477268|psychology
305868|NCT01477255|daily assessment
305869|NCT01477255|electronic diary
305870|NCT01477255|coping strategies
305871|NCT01477255|resiliency of cancer patients
305872|NCT01477255|psychology
305873|NCT01477242|vomiting
305874|NCT01477242|anti-emetics
305875|NCT01477242|ketamine
305876|NCT01477242|sedation
305877|NCT01477229|Rectal cancer
305878|NCT01477229|Quality of Life
305879|NCT01477229|Abdominoperineal Resection
305880|NCT01477229|Anterior Resection
305881|NCT01477229|Palliative cancer treatment
305882|NCT01477229|Radio chemotherapy
305883|NCT01477216|Glycemic index
305884|NCT01477216|Glycemic responses
305885|NCT01477216|Insulin responses
305886|NCT01477216|Insulinemic index
305887|NCT01477216|Carbohydrates
305888|NCT01477216|Methodology
305889|NCT01477216|Glucose metabolism
305890|NCT01477177|Barrett's esophagus dysplasia
305891|NCT01477164|Exercise
305892|NCT01477164|Aging
305893|NCT01477164|Sarcopenia
305894|NCT01477164|Muscle function
305895|NCT01477151|isoflurane
305896|NCT01477151|sevoflurane
305897|NCT01477151|troponin
305898|NCT01477151|anesthesia
305899|NCT01477151|cardioprotection
305900|NCT01477151|preconditioning
305901|NCT01477151|cardiac surgery
305902|NCT01477151|cardiac anesthesia
305903|NCT01477138|Sick Sinus Syndrome
305904|NCT01477138|Cardiac Pacing, Artificial
305905|NCT01477138|Cardiac Resynchronization Therapy
305906|NCT01477138|Pacemaker, Artificial
305907|NCT01477138|SSS
305908|NCT01477125|adhd
305909|NCT01477125|adults
305910|NCT01477125|working memory
305911|NCT01477125|training
305912|NCT01477125|RCT
305913|NCT01477112|Type 2 diabetes
305914|NCT01477112|β-carotene
305915|NCT01477112|Oxidative balance
305916|NCT01477112|Oxidants
305917|NCT01477112|Antioxidants
305918|NCT01477086|Sarcopenia
305919|NCT01477086|Hip fracture
305920|NCT01477086|Frailty
305921|NCT01477073|in-vitro fertilization
305922|NCT01477073|reproductive disorder
305923|NCT01477034|Vitamin D deficiency
305924|NCT01477034|Obesity
305925|NCT01477034|Inflammation
305926|NCT01477034|Low-grade, chronic inflammation
305927|NCT01477034|Adipose tissue inflammation
305928|NCT01477034|Diabetes
305929|NCT01477034|Type 2 diabetes mellitus
305930|NCT01477034|Insulin resistance
305931|NCT01477034|Intestinal permeability
305932|NCT01477008|Knee
305933|NCT01477008|Cartilage repair
305934|NCT01477008|Cartilage regeneration
305935|NCT01477008|Chondral
305936|NCT01477008|Osteochondral
305937|NCT01477008|Biphasic scaffold
305938|NCT01477008|Medical device
305939|NCT01477008|Autologous
305940|NCT01477008|Synthetic
305941|NCT01477008|Medial condyle
305942|NCT01477008|Lateral condyle
305943|NCT01477008|Trochlea
305944|NCT01476995|Cardiovascular system
305945|NCT01476995|gastrointestinal system
305946|NCT01476995|kidneys
305947|NCT01476995|liver
305948|NCT01476995|lungs
305949|NCT01476969|Ischemia reperfusion injury
305950|NCT01476969|Cardiopulmonary bypass
305951|NCT01476969|Remote Ischemic Postconditioning
305952|NCT01476969|Other Functional Disturbances Following Cardiac Surgery
305953|NCT01476930|migraine
305954|NCT01476930|prophylactic treatment
305955|NCT01476930|cupping
305956|NCT01476930|serkangabin
305957|NCT01476904|Asthma
305958|NCT01476904|Bronchial Asthma
305959|NCT01476904|Shortness of breath
305960|NCT01476891|MBSR
305961|NCT01476891|Cancer
305962|NCT01476891|Online
305963|NCT01476891|Mindfulness Meditation
305964|NCT01476891|Randomized Waitlist Controlled Trial
305965|NCT01476878|Radiosurgery
305966|NCT01476878|Frameless radiosurgery
305967|NCT01476878|Accuracy
305968|NCT01475786|nerve pain
305969|NCT01475786|diabetic nerve pain
305970|NCT01475786|throbbing
305971|NCT01475786|burning
305972|NCT01475786|painful feet
305973|NCT01475786|tingling
305974|NCT01475786|numbness
305975|NCT01475773|self-esteem
305976|NCT01475773|personality
305977|NCT01475773|quality of life
305978|NCT01475773|malocclusion
305979|NCT01475773|orthodontics
305980|NCT01475760|chronic kidney disease
305981|NCT01475760|serum phosphorus
305982|NCT01475760|salivary phosphorus
305983|NCT01475760|FGF23
305984|NCT01475734|glucose clamp
305985|NCT01475734|hypoglycemia
305986|NCT01475721|ADVAIR
305987|NCT01475721|Asthma
305988|NCT01475721|safety
305989|NCT01475721|FLOVENT
305990|NCT01475708|Lyme borreliosis
305991|NCT01475708|Erythema migrans
305992|NCT01475708|Doxycycline
305993|NCT01475708|Subjective symptoms
305994|NCT01475708|Outcome
305995|NCT01475695|Mass balance
305996|NCT01475695|intravenous
305997|NCT01475695|GSK2251052
305998|NCT01475695|Healthy volunteer
305999|NCT01475695|Antimicrobial
306000|NCT01475695|Radiolabel
306001|NCT01475682|Obstructive sleep apnea
306002|NCT01475682|cardiometabolic complications
306003|NCT01475682|Effects of CPAP treatment
306004|NCT01475643|Pediatric cataract
306005|NCT01475630|temporomandibular joint
306006|NCT01475630|rehabilitation medicine
306007|NCT01475630|joint diseases
306008|NCT01475630|physical therapy
306009|NCT01476800|Drugs, Investigational
306010|NCT01476800|pharmacokinetics
306011|NCT01476800|Urinary Bladder, Overactive
306012|NCT01476800|YM178
306013|NCT01476800|Mirabegron
306014|NCT01476787|Follicular lymphoma
306015|NCT01476787|Non-Hodgkins Follicular Lymphoma
306016|NCT01476787|treatment for Follicular Lymphoma
306017|NCT01476787|rituximab treatment
306018|NCT01476787|rituximab and lenalidomide treatment
306019|NCT01476761|Surgical tissue resection
306020|NCT01476761|Tissue dissection
306021|NCT01476761|Tissue transection
306022|NCT01476761|Anastomosis of gastrointestina tissue
306023|NCT01476722|Silicone Hydrogel
306024|NCT01476722|Soft Contact Lenses
306025|NCT01476722|Multi-Purpose Solution
306026|NCT01476709|Puncture; Instrument
306027|NCT01476709|Optics and Photonics
306028|NCT01476709|Pain
306029|NCT01476696|Sickle cell disease
306030|NCT01476696|pediatrics
306031|NCT01476696|SCD
306032|NCT01476696|children
306033|NCT01476696|child
306034|NCT01476696|kids
306035|NCT01476696|pain crisis
306036|NCT01476696|sickle cell anemia
306037|NCT01476696|sickle cell pain
306038|NCT01476683|Antidiarrheals
306039|NCT01476670|Posterior fossa brain tumor
306040|NCT01476670|Cerebral blood flow
306041|NCT01476670|Cerebral autoregulation
306042|NCT01476670|Carbon dioxide reactivity
306043|NCT01476670|Transcranial Doppler
306044|NCT01476657|Phase 1
306045|NCT01476644|Health related quality of life
306046|NCT01476644|Clinical measures of vision
306047|NCT01476618|Provider Perspectives
306048|NCT01476618|Barriers
306049|NCT01476618|OIF/OEF Veterans
306050|NCT01476605|prolotherapy
306051|NCT01476605|Platelet rich plasma
306052|NCT01476605|tennis elbow
306053|NCT01476605|lateral epicondylosis
306054|NCT01476592|gastrointestinal neuroendocrine tumor
306055|NCT01476579|Coronary CT
306056|NCT01476579|Sensitivity
306057|NCT01476579|Specificity
306058|NCT01476579|Radiation
306059|NCT01476579|Tomography, X-Ray Computed
306060|NCT01476579|Coronary angiography
306061|NCT01476566|aged
306062|NCT01476566|family practice
306063|NCT01476553|gastric cancer
306064|NCT01476553|extensive intraperitoneal lavage
306065|NCT01476553|EIPL
306066|NCT01476553|intraperitoneal tumor cells
306067|NCT01476553|peritoneal carcinomatosis
306068|NCT01476514|Hyperekplexia
306069|NCT01476514|Pain modulation
306070|NCT01476514|Glycine receptors
306071|NCT01476514|Hyperalgesia
306072|NCT01476514|Spinal inhibitory interneurons
306073|NCT01476501|vitamin D
306074|NCT01476501|bone health
306075|NCT01476501|diabetes
306076|NCT01476501|nephropathy
306077|NCT01476462|Acute lymphoblastic leukemia
306078|NCT01476462|Ponte-di-Legno consortium
306079|NCT01476462|Second cancer
306080|NCT01476462|Survival
306081|NCT01476449|Diabetic Macular Edema
306082|NCT01476449|Diabetic Retinal Swelling
306083|NCT01476449|DIabetic Eye Disease
306084|NCT01476436|Cardio vascular risk factors
306085|NCT01476423|Glanzmann's Thrombasthenia
306086|NCT01476397|full-term
306087|NCT01476397|formula-fed infants
306088|NCT01476384|Glucose
306089|NCT01476384|insulin
306090|NCT01476384|Glycocalyx
306091|NCT01476384|Muscle
306092|NCT01476384|Vascularisation
306093|NCT01476384|young
306094|NCT01476384|elderly
306095|NCT01476371|Group treatment
306096|NCT01476371|Mindfulness
306097|NCT01476371|Minor mental disorders
306098|NCT01476371|Inflammation
306099|NCT01476332|eyes
306100|NCT01476332|cis-urocanic acid
306101|NCT01476332|safety
306102|NCT01476332|tolerability
306103|NCT01476332|pharmacokinetics
306104|NCT01476306|feasibility
306105|NCT01476306|effectiveness
306106|NCT01476306|Parkinson disease care
306107|NCT01476306|care via telemedicine
306108|NCT01476293|Infiltration
306109|NCT01476293|Extravasation
306110|NCT01476293|Leaking
306111|NCT01476293|PIV Infiltration
306112|NCT01476293|IV Infiltration
306113|NCT01476293|Optical Detection of Infiltration
306114|NCT01476293|Optical Monitoring
306115|NCT01476280|antiemetics
306116|NCT01476280|ramosetron
306117|NCT01476280|palonosetron
306118|NCT01476280|PONV(postoperative nausea and vomiting)
306119|NCT01476254|Postoperative pulmonary complications
306120|NCT01476254|Laparoscopic surgery
306121|NCT01476215|paracetamol
306122|NCT01476202|craving, provoked craving, smoking cessation, nicotine replacement therapy, NRT
306123|NCT01476189|pharmacokinetic
306124|NCT01476189|paracetamol
306125|NCT01476189|Healthy volunteer
306126|NCT01476189|steady state
306127|NCT01476176|Bioequivalence
306128|NCT01476176|Pharmacokinetics
306129|NCT01476176|Healthy volunteers
306130|NCT01476176|paracetamol
306131|NCT01476176|caffeine
306132|NCT01476163|AT1001
306133|NCT01476163|Lysosomal storage disease
306134|NCT01476163|Lysosomal Storage Disorder
306135|NCT01476163|migalastat
306136|NCT01476163|Fabry disease
306137|NCT01476163|Fabry
306138|NCT01476163|Amicus
306139|NCT01476137|oncology
306140|NCT01476137|solid tumors
306141|NCT01476137|multiple myeloma
306142|NCT01476137|AKT inhibitor
306143|NCT01476137|MEK inhibitor
306144|NCT01476111|tumor antigens
306145|NCT01476111|observational
306146|NCT01476111|breast cancer
306147|NCT01476111|biomarkers
306148|NCT01476111|Neoadjuvant
306149|NCT01476059|Treatment compliance
306150|NCT01476059|Pediatric
306151|NCT01476059|Asthma
306152|NCT01476046|Acute Lung Injury (ALI)
306153|NCT01476046|Acute Respiratory Distress Syndrome (ARDS)
306154|NCT01476033|Oxidative stress
306155|NCT01476033|inflammation
306156|NCT01476033|blood flow
306157|NCT01476020|Drug eluting stent
306158|NCT01476020|Dual antiplatelet therapy
306159|NCT01476020|bleeding
306160|NCT01476020|stent thrombosis
306161|NCT01476020|follow-up of the drug eluting stent
306162|NCT01476007|primary health care
306163|NCT01476007|Vitamin B 12 Deficiency
306164|NCT01475981|JTK-853
306165|NCT01475981|single dose
306166|NCT01475942|elderly
306167|NCT01475942|probiotic
306168|NCT01475942|bowel function
306169|NCT01475942|pathogen
306170|NCT01475942|constipation
306171|NCT01475942|diarrhoea
306172|NCT01475942|Subclinical levels
306173|NCT01475929|irritable bowel syndrome
306174|NCT01475929|probiotic
306175|NCT01475916|Asthma
306176|NCT01475916|Educational program
306177|NCT01475916|Quality of life
306178|NCT01475916|School-aged children
306179|NCT01475903|Obesity
306180|NCT01475903|Sleeve gastrectomy
306181|NCT01475903|Nutritional impact
306182|NCT01475903|Vitamin deficiency
306183|NCT01475890|HIV/AIDS
306184|NCT01475890|Nutrition
306185|NCT01475877|bromfenac
306186|NCT01475877|nepafenac
306187|NCT01475877|PRK
306188|NCT01475877|epithelial healing,
306189|NCT01475864|Choledocholithiasis
306190|NCT01475864|metal stents
306191|NCT01475864|biliary duct stent
306192|NCT01475851|Tenofovir disoproxil fumarate, compensated chronic hepatitis B
306193|NCT01475838|HIV-1
306194|NCT01475838|HIV
306195|NCT01475838|Treatment Experienced
306196|NCT01475812|COPD
306197|NCT01475812|activities of daily living
306198|NCT01475812|pulmonary hyperinflation
306199|NCT01475812|exercise
306200|NCT01475604|Pulsed Radio Frequency, Electromagnetic Field therapy
306201|NCT01475591|persistent neuromusculoskeletal pain
306202|NCT01475591|neck
306203|NCT01475591|shoulder
306204|NCT01475591|back-area
306205|NCT01475591|risk
306206|NCT01475591|longlasting
306207|NCT01475591|pain syndrome
306208|NCT01475578|Vascular Dementia
306209|NCT01475565|polycystic ovary syndrome (PCOS)
306210|NCT01475565|insulin sensitivity
306211|NCT01475565|insulin resistance
306212|NCT01475565|gestational diabetes
306213|NCT01475565|pregnancy
306214|NCT01475565|estrogen
306215|NCT01475565|glucose intolerance
306216|NCT01475565|obesity
306217|NCT01475565|ovulatory disorder
306218|NCT01475565|racial differences
306219|NCT01475565|hyperandrogenism
306220|NCT01475552|platelet reactivity
306221|NCT01475552|platelet function assay
306222|NCT01475552|abciximab
306223|NCT01475552|tailored therapy
306224|NCT01475539|Polio
306225|NCT01475539|Poliovirus
306226|NCT01475539|Oral poliovirus vaccine
306227|NCT01475539|IMOVAX Polio®
306228|NCT01475526|grocery store
306229|NCT01475526|nutrition
306230|NCT01475526|Latino
306231|NCT01475526|Hispanic
306232|NCT01475513|oral contraceptive
306233|NCT01475513|birth control pill
306234|NCT01475513|women
306235|NCT01475513|healthy volunteer
306236|NCT01475513|insulin sensitivity
306237|NCT01475513|insulin resistance
306238|NCT01475513|cardiovascular risk factors
306239|NCT01475513|endothelial function
306240|NCT01475513|estrogen metabolism
306241|NCT01475513|racial difference
306242|NCT01475513|glucose intolerance
306243|NCT01475474|incontinence
306244|NCT01475474|bowel
306245|NCT01475474|movement
306246|NCT01475474|fecal
306247|NCT01475474|anal
306248|NCT01475474|diarrhea
306249|NCT01475474|stool
306250|NCT01475474|rectal
306251|NCT01475474|feces
306252|NCT01475474|uncontrolled
306253|NCT01475474|loose
306254|NCT01475474|leakage
306255|NCT01475474|rectum
306256|NCT01475474|BM
306257|NCT01475474|watery
306258|NCT01475474|urgent
306259|NCT01475474|flatulence
306260|NCT01475474|gas
306261|NCT01475461|Phase 2
306262|NCT01475461|type 2 diabetes mellitus
306263|NCT01475461|PF-04937319
306264|NCT01475448|biomechanics
306265|NCT01475448|motor control
306266|NCT01475448|movement
306267|NCT01475448|walking
306268|NCT01475448|running
306269|NCT01475448|sedentarism
306270|NCT01475448|joint moment
306271|NCT01475409|anti-TNF
306272|NCT01475409|tuberculosis
306273|NCT01475409|QuantiFERON-TB Gold In-Tube
306274|NCT01475409|tuberculin skin test
306275|NCT01475409|rheumatoid arthritis
306276|NCT01475409|spondyloarthritis
306277|NCT01475396|exercise
306278|NCT01475396|physical activity
306279|NCT01475396|cognition
306280|NCT01475396|brain
306281|NCT01475396|aging
306282|NCT01475396|BDNF
306283|NCT01475383|Tourette's Syndrome in adults
306284|NCT01475383|Safety and Efficacy
306285|NCT01475383|Randomized
306286|NCT01475383|Placebo Control
306287|NCT01475383|Cross-over
306288|NCT01475370|Acute myeloid leukemia
306289|NCT01475370|WT1
306290|NCT01475357|congenital heart defects
306291|NCT01475357|growth failure
306292|NCT01475344|Trauma patient with major bleeding
306293|NCT01475331|pancreatic cyst
306294|NCT01475331|chemotherapy
306295|NCT01475331|ethanol
306296|NCT01475331|ablation
306297|NCT01475318|complete abortion rate
306298|NCT01475318|side effects
306299|NCT01475318|induction-to-abortion interval
306300|NCT01475305|RSV, Healthy adults, MEDI-557, intranasal challenge, human model
306301|NCT01475292|COPD
306302|NCT01475279|Warfarin
306303|NCT01475279|Dantonic
306304|NCT01475279|Pharmacodynamics
306305|NCT01475279|Pharmacokinetics
306306|NCT01475279|Interaction
306307|NCT01475266|Bladder Cancer
306308|NCT01475266|NMIBC
306309|NCT01475266|TURBT
306310|NCT01475266|Apaziquone
306311|NCT01475266|EOquin
306312|NCT01475266|Immediate instillation
306313|NCT01475240|HIV
306314|NCT01475227|HIV
306315|NCT01475227|Bilirubin
306316|NCT01475214|potassium bicarbonate
306317|NCT01475214|urinary N-telopeptide
306318|NCT01475214|urinary nitrogen
306319|NCT01475214|net acid excretion
306320|NCT01475201|Type 2 diabetes
306321|NCT01475201|Hypertension
306322|NCT01475201|Primary Care
306323|NCT01475201|Physical Activity
306324|NCT01475201|Behavioural Intervention
306325|NCT01475201|Pedometer
306326|NCT01475201|Accelerometer
306327|NCT01475201|Arterial Stiffness
306328|NCT01475201|Carotid femoral pulse wave velocity
306329|NCT01475201|Vascular disease risk
306330|NCT01475201|Vascular disease prevention
306331|NCT01475201|Intervention
306332|NCT01475188|specific subcutaneous immunotherapy
306333|NCT01475188|seasonal allergic rhinitis
306334|NCT01475188|regulatory lymphocytes
306335|NCT01475188|signal transduction
306336|NCT01475188|histamine receptor
306337|NCT01475162|acute Graft versus Host Disease (aGVHD)
306338|NCT01475162|steroid refractory acute Graft versus Host Disease (aGVHD)
306339|NCT01475162|chronic Graft versus Host Disease (cGVHD)
306340|NCT01475162|corticosteroids
306341|NCT01475162|allogeneic hematopoietic stem cell transplantation
306342|NCT01475149|Antiphospholipid syndrome
306343|NCT01475149|Antiphospholipid antibodies
306344|NCT01475149|Systemic lupus erythematosus
306345|NCT01475149|Annexin A5 and Annexin A5 resistance assay
306346|NCT01475123|Nicorandil
306347|NCT01475123|Randomized control study
306348|NCT01475123|Hemodialysis
306349|NCT01475123|Coronary Artery Disease
306350|NCT01475110|Imatinib
306351|NCT01475110|Chronic Myeloid Leukaemia
306352|NCT01475110|Nilotinib
306353|NCT01475110|Adult patients
306354|NCT01475110|Imatinib resistant
306355|NCT01475097|AE - Adverse event
306356|NCT01475097|Arteriography
306357|NCT01475097|IA - Intra-arterial
306358|NCT01475097|IOCM - Iso-Osmolar Contrast Medium
306359|NCT01475097|LOCM - Low-Osmolar Contrast Medium
306360|NCT01475097|Patient Comfort
306361|NCT01475097|Body Image Disturbance
306362|NCT01475097|Patient
306363|NCT01475084|Flex-rigid pleuroscopy
306364|NCT01475084|cryobiopsy
306365|NCT01475084|pleural biopsy
306366|NCT01475084|pleural effusion
306367|NCT01475084|safety
306368|NCT01475084|thoracoscopy
306369|NCT01475045|COPD
306370|NCT01475032|Asthma
306371|NCT01475032|children
306372|NCT01475032|chronic treatment
306373|NCT01475019|Obesity
306374|NCT01475019|Polycystic Ovaries Syndrome
306375|NCT01475019|Orlistat
306376|NCT01475019|Sibutramine
306377|NCT01475019|Androgen levels
306378|NCT01475019|Insulin resistance
306379|NCT01475006|Epidermal Growth Factor Receptor Variant III
306380|NCT01475006|EGFRvIII
306381|NCT01475006|Glioma
306382|NCT01475006|Anaplastic Astrocytomas
306383|NCT01475006|Glioblastoma Multiforme
306384|NCT01475006|Antibody drug conjugate
306385|NCT01475006|brain tumor
306386|NCT01474980|Congenital Myasthenic Syndrome
306387|NCT01474980|Pregnancy
306388|NCT01474980|Outcome
306389|NCT01474967|polycystic ovary syndrome
306390|NCT01474967|lipid profile
306391|NCT01474967|metformin
306392|NCT01474954|HIV
306393|NCT01474954|Antiretroviral Medication
306394|NCT01474954|Cardiovascular Disease Risk
306395|NCT01474941|Multiple Dose Study Overweight Healthy Subjects Body Weight Modified-Release Formulation
306396|NCT01474928|Asthma
306397|NCT01474928|Community-based participatory research
306398|NCT01474928|Educational intervention
306399|NCT01474928|Ethno-cultural community
306400|NCT01474928|Video recording
306401|NCT01474928|Patient education handout
306402|NCT01474915|Neurosurgery
306403|NCT01474902|pediatric
306404|NCT01474902|asymptotic venous thrombosis
306405|NCT01474902|Enoxaparin
306406|NCT01474902|pediatric cardiac surgery
306407|NCT01474889|Hypoglycemia, Unawareness, RT-CGM, Type 1 Diabetes
306408|NCT01474876|Post-marketing observational study (PMOS) Protocol
306409|NCT01474876|Effectiveness of Adalimumab (HUMIRA®)
306410|NCT01474876|Psoriatic Arthritis
306411|NCT01474876|Ankylosing Spondylitis
306412|NCT01474850|mechanical ventilation
306413|NCT01474850|pressure control ventilation
306414|NCT01474850|lung recruitment
306415|NCT01474850|positive end expiratory pressure
306416|NCT01474850|opto-electronic plethysmography
306417|NCT01474850|chest wall volume variation
306418|NCT01474850|intravenous anesthesia
306419|NCT01474837|depressive disorders
306420|NCT01474837|exercise therapy
306421|NCT01474824|Cardiac output
306422|NCT01474824|Stroke volume
306423|NCT01474811|Hepatitis
306424|NCT01474811|Hepatitis C
306425|NCT01474811|HCV-TARGET
306426|NCT01474811|HCV
306427|NCT01474811|Observational Study
306428|NCT01474798|Acne Vulgaris
306429|NCT01474785|Obesity
306430|NCT01474785|Bariatric surgery
306431|NCT01474785|Nashville, Tennessee
306432|NCT01474772|Diabetic Peripheral Neuropathy
306433|NCT01474772|Pain on Walking
306434|NCT01474772|Pregabalin
306435|NCT01474746|Fragile X Syndrome
306436|NCT01474746|Pediatrics
306437|NCT01474746|sertraline
306438|NCT01474746|autism
306439|NCT01474733|resident education
306440|NCT01474733|health literacy
306441|NCT01474733|curriculum
306442|NCT01474720|Systemic Lupus Erythematosus
306443|NCT01474720|Lupus
306444|NCT01474720|SLE
306445|NCT01474720|Zostavax
306446|NCT01474720|shingles
306447|NCT01474707|COPD
306448|NCT01474707|Educational materials
306449|NCT01474707|Cultural background
306450|NCT01474707|Instructional videos
306451|NCT01474707|Patient education handouts
306452|NCT01474707|Lung age
306453|NCT01474694|prospective study
306454|NCT01474694|multicenter trial
306455|NCT01474694|analysis, computer assisted image
306456|NCT01474694|CE marked
306457|NCT01474694|medical devices
306458|NCT01474694|catheter ablation
306459|NCT01474681|hematologic malignancies
306460|NCT01474681|leukemia
306461|NCT01474681|lymphoma
306462|NCT01474655|epiretinal membrane
306463|NCT01474655|visual acuity
306464|NCT01474655|metamorphopsia
306465|NCT01474655|thickness of retinal layers
306466|NCT01474655|spectral domain optical coherence tomography
306467|NCT01474642|Advanced or recurrent esophageal squamous cell carcinoma
306468|NCT01474642|Randomizes phase II trial
306469|NCT01474642|Capecitabine
306470|NCT01474642|Cisplatin
306471|NCT01474642|Genexol
306472|NCT01474629|oxidative stress
306473|NCT01474629|inflammation
306474|NCT01474629|endotoxemia
306475|NCT01474629|strenuous exercise
306476|NCT01474616|Aging
306477|NCT01474616|Health Services
306478|NCT01474616|Knowledge Translation
306479|NCT01474616|Long-Term Care Facilities
306480|NCT01474616|Mobility
306481|NCT01474616|Psychosocial And Health Behaviours
306482|NCT01474603|observational study
306483|NCT01474577|stress test
306484|NCT01474577|cardiac issues
306485|NCT01474577|Rb-82 PET Myocardial Perfusion Imaging
306486|NCT01474577|11-150
306487|NCT01474577|one or more 82Rb myocardial perfusion stress tests
306488|NCT01474564|Blood draw
306489|NCT01474564|pancreas
306490|NCT01474564|Tumorigenic Cells
306491|NCT01474564|11-141
306492|NCT01474551|Vemurafenib
306493|NCT01474551|skin cancer
306494|NCT01474551|Stage IV
306495|NCT01474551|advanced stage III
306496|NCT01474551|11-091
306497|NCT01474538|diabetes
306498|NCT01474538|type 2 diabetes
306499|NCT01474538|insulin pump
306500|NCT01474538|continuous subcutaneous insulin infusion
306501|NCT01474538|CSII
306502|NCT01474538|A1C
306503|NCT01474486|thiamin
306504|NCT01474486|pyridoxine
306505|NCT01474486|vitamin D
306506|NCT01474486|zinc
306507|NCT01474486|congestive heart failure (CHF)
306508|NCT01474486|ischemic cardiomyopathy
306509|NCT01474486|nutritional injury
306510|NCT01474486|quality of life
306511|NCT01474473|CACIPLIQ20
306512|NCT01474473|Matrix Therapy
306513|NCT01474473|Diabetic foot
306514|NCT01474460|warfarin
306515|NCT01474460|phytonadione
306516|NCT01474460|INR
306517|NCT01474447|low back pain
306518|NCT01474434|coronary artery disease,
306519|NCT01474434|LCQ908,
306520|NCT01474434|hyperlipidemia,
306521|NCT01474434|hypertriglyceridemia,
306522|NCT01474434|pradigastat
306523|NCT01474421|Parkinson's disease
306524|NCT01474421|Dyskinesia
306525|NCT01474421|Movement disorders
306526|NCT01474421|L-dopa
306527|NCT01474408|Coronary artery bypass
306528|NCT01474408|Exercise therapy
306529|NCT01474408|Revascularization (PCI)
306530|NCT01474395|schizophrenia
306531|NCT01474395|cognitive remediation
306532|NCT01474395|NMDA
306533|NCT01474382|OraVerse
306534|NCT01474382|Safety
306535|NCT01474382|Efficacy
306536|NCT01474382|Pediatric
306537|NCT01474382|Reversal of dental anesthesia
306538|NCT01474369|Drug Therapy
306539|NCT01474356|brachytherapy
306540|NCT01474356|interstitial hyperthermia
306541|NCT01474356|cervical cancer
306542|NCT01474356|side effects
306543|NCT01474356|Locally advanced cervical cancer patients
306544|NCT01474343|Neurodegenerative Diseases
306545|NCT01474343|Nervous System Diseases
306546|NCT01474343|Genetic Diseases, Inborn
306547|NCT01474343|Metabolic Diseases
306548|NCT01474343|Gene Therapy
306549|NCT01474343|Adenovirus Associated Vector
306550|NCT01474330|Pomalidomide
306551|NCT01474330|safety
306552|NCT01474330|tolerability
306553|NCT01474330|pharmacokinetics
306554|NCT01474304|craniotomy
306555|NCT01474304|tumor resection
306556|NCT01474304|aneurysm
306557|NCT01474304|revascularization
306558|NCT01474304|opioid
306559|NCT01474304|nausea
306560|NCT01474304|vomiting
306561|NCT01474304|acetaminophen
306562|NCT01474265|smoking cessation
306563|NCT01474265|varenicline
306564|NCT01474265|sympathovagal balance
306565|NCT01474265|quit attempts
306566|NCT01474265|MSNA
306567|NCT01474226|lysine
306568|NCT01474226|rice
306569|NCT01474226|bioavailability
306570|NCT01474213|dexmedetomidine
306571|NCT01474213|remifentanil
306572|NCT01474213|awake nasotracheal fibreoptic intubation
306573|NCT01474213|oral maxillofacial surgery
306574|NCT01474213|difficult airway
306575|NCT01474213|adult
306576|NCT01474200|Ultrafiltration
306577|NCT01474200|Aquapheresis
306578|NCT01474200|Diuretics
306579|NCT01474200|Loop Diuretics
306580|NCT01474200|Aquadex Flexflow System
306581|NCT01474200|Gambro UF Solutions
306582|NCT01474187|Neoadjuvant chemotherapy
306583|NCT01474187|rectal cancer
306584|NCT01474187|phase I study
306585|NCT01474187|irinotecan
306586|NCT01474148|paraplegia
306587|NCT01474148|tetraplegia
306588|NCT01474148|Spinal cord injured
306589|NCT01474148|FES
306590|NCT01474135|Glaucoma
306591|NCT01474135|Ocular Hypertension
306592|NCT01474122|digital ulcers
306593|NCT01474122|systemic sclerosis
306594|NCT01474109|systemic sclerosis
306595|NCT01474109|digital ulcers
306596|NCT01474096|clinical practice guideline-primary health care
306597|NCT01474083|Type 2 diabetes mellitus
306598|NCT01474083|pharmacokinetics
306599|NCT01474083|pharmacodynamics
306600|NCT01474070|Glaucoma
306601|NCT01474070|Goldmann Tonometry
306602|NCT01474070|Dynamic Contour Tonometry
306603|NCT01474057|PTSD
306604|NCT01474057|combat trauma
306605|NCT01474057|telemedicine
306606|NCT01474057|primary care interventions
306607|NCT01474057|CBT
306608|NCT01474057|self-managed treatment
306609|NCT01474057|web-based intervention
306610|NCT01474057|internet treatment
306611|NCT01474031|total hip arthroplasty
306612|NCT01474031|biomechanics
306613|NCT01474031|direct anterior approach
306614|NCT01474005|laryngectomy
306615|NCT01474005|artificial larynx
306616|NCT01474005|breathing
306617|NCT01474005|swallowing
306618|NCT01474005|upper airway
306619|NCT01473979|cardiac surgery
306620|NCT01473979|poststernotomy wound infections
306621|NCT01473979|delayed secondary closure of sternum
306622|NCT01473927|Inflammatory bowel diseases
306623|NCT01473927|Crohn disease
306624|NCT01473927|Ficolin-2
306625|NCT01473927|C-Reactive Protein
306626|NCT01473927|Calprotectin
306627|NCT01473927|Inflammatory markers
306628|NCT01473927|SES-CD
306629|NCT01473901|BKM120
306630|NCT01473901|temozolomide
306631|NCT01473901|glioblastoma multiforme
306632|NCT01473901|GBM
306633|NCT01473901|Newly diagnosed
306634|NCT01473888|T89(Dantonic®)
306635|NCT01473888|Cooperstown 5+1 cocktail probes
306636|NCT01473888|CYP450
306637|NCT01473875|LIPA
306638|NCT01473875|Wolman Disease
306639|NCT01473875|Wolman Phenotype
306640|NCT01473875|Acid Lipase Deficiency
306641|NCT01473875|Acid Cholesteryl Hydrolase
306642|NCT01473875|Acid Lipase Disease Deficiency, type 2
306643|NCT01473875|Cholesteryl Ester Storage Disease (CESD)
306644|NCT01473875|Cholesteryl Ester Hydrolase Deficiency
306645|NCT01473875|Early Onset LAL-Deficiency (Wolman Disease)
306646|NCT01473875|LAL Deficiency
306647|NCT01473875|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
306648|NCT01473875|Wolman Disease (early onset LAL Deficiency)
306649|NCT01473875|Related Disorders:
306650|NCT01473875|Non-alcoholic Fatty Liver Disease (NAFLD)
306651|NCT01473875|Non-alcoholic Steatohepatitis (NASH)
306652|NCT01473875|Alcoholic Liver Disease
306653|NCT01473875|Cryptogenic Cirrhosis
306654|NCT01473875|Niemann-Pick Disease (NPD) Type C
306655|NCT01473875|Chanarin Dorfman Syndrome
306656|NCT01473862|adolescent
306657|NCT01473862|bereavement
306658|NCT01473862|cancer
306659|NCT01473862|coping skills
306660|NCT01473849|Cytomegalovirus
306661|NCT01473849|Liver transplantation
306662|NCT01473849|Hepatitis C virus
306663|NCT01473849|Patients who underwent first liver transplantation due to hepatopathy caused by HCV,confirmed by detection of HCV RNA previously to transplantation
306664|NCT01473836|Metronidazole
306665|NCT01473836|intra-abdominal infection
306666|NCT01473836|pelvic inflammatory disease
306667|NCT01473836|anaerobe
306668|NCT01473823|food allergy
306669|NCT01473823|eczema
306670|NCT01473823|sensitisation
306671|NCT01473823|omega-3 long chain polyunsaturated fatty acids
306672|NCT01473823|prevention
306673|NCT01473823|asthma
306674|NCT01473810|HIV
306675|NCT01473810|vaccination
306676|NCT01473810|T cells
306677|NCT01473810|mucosal immunity
306678|NCT01473810|safety
306679|NCT01473810|nasal administration
306680|NCT01473810|DTH skin test
306681|NCT01473771|Suicide
306682|NCT01473771|Suicide, Attempted
306683|NCT01473758|COPD
306684|NCT01473758|Chronic obstructive pulmonary disease
306685|NCT01473758|Roflumilast
306686|NCT01473745|Alar Base Suture; Nasolabial Change; 3D stereogrammetry
306687|NCT01473732|CNI toxicity
306688|NCT01473732|CAI
306689|NCT01473719|alcohol use
306690|NCT01473719|marijuana use
306691|NCT01473719|STI
306692|NCT01473706|Malnutrition
306693|NCT01473706|Nutrition status
306694|NCT01473706|Elderly
306695|NCT01473706|Nutrition screening
306696|NCT01473693|Quality of Life
306697|NCT01473693|Lung cancer
306698|NCT01473693|MRI
306699|NCT01473693|Surgery
306700|NCT01473693|induction chemotherapy
306701|NCT01473693|11-145
306702|NCT01473680|minority breast cancer patients
306703|NCT01473680|EEG
306704|NCT01473680|Evaluation
306705|NCT01473680|Questionnaires
306706|NCT01473680|11-139
306707|NCT01473641|Etonogestrel
306708|NCT01473641|Contraceptive implant
306709|NCT01473641|Safety
306710|NCT01473628|early stage follicular lymphoma
306711|NCT01473628|indolent non-Hodgkin's lymphomas
306712|NCT01473628|Lymphoma
306713|NCT01473628|Follicular Lymphoma
306714|NCT01473628|FL
306715|NCT01473628|Rituximab
306716|NCT01473628|Rituxan
306717|NCT01473628|Radiation
306718|NCT01473628|Radiation Therapy
306719|NCT01473628|XRT
306720|NCT01473576|type II diabetes
306721|NCT01473576|protein synthesis
306722|NCT01473576|nitrate
306723|NCT01473576|elderly
306724|NCT01473550|Mental Health
306725|NCT01473550|Smart Technology
306726|NCT01473550|Mood disorder
306727|NCT01473550|Psychotic disorder
306728|NCT01473537|dental caries/prevention and control
306729|NCT01473537|oral health
306730|NCT01473537|cariostatic agents
306731|NCT01473524|Primary Biliary Cholangitis
306732|NCT01473524|Primary Biliary Cirrhosis
306733|NCT01473524|PBC
306734|NCT01473524|Cirrhosis
306735|NCT01473524|Liver
306736|NCT01473511|Behavioural intervention
306737|NCT01473511|Distance intervention
306738|NCT01473511|Parenting intervention
306739|NCT01473498|Sepsis
306740|NCT01473498|Acute kidney injury
306741|NCT01473498|Mean arterial pressure
306742|NCT01473498|Catecholamines
306743|NCT01473498|Renal doppler
306744|NCT01473485|Brain Tumor
306745|NCT01473485|Glioma
306746|NCT01473485|Brain Cancer
306747|NCT01473485|Metastatic Brain Cancer
306748|NCT01473472|Prophylaxis
306749|NCT01473472|HIV infection
306750|NCT01473472|tenofovir
306751|NCT01473472|emtricitabine
306752|NCT01473472|men who have sex with men
306753|NCT01473459|best fertility protocol
306754|NCT01473459|(BMI > 30)
306755|NCT01473459|women
306756|NCT01473459|PCOS
306757|NCT01473446|Goal directed fluid therapy
306758|NCT01473446|perioperative fluid therapy
306759|NCT01473446|LiDCOrapid
306760|NCT01473446|Postoperative outcome
306761|NCT01473446|Open abdominal surgery
306762|NCT01473433|Regenerative medicine
306763|NCT01473433|Myocardial infarction
306764|NCT01473394|Major depressive disorder
306765|NCT01473394|Depression
306766|NCT01473381|Major Depressive Disorder
306767|NCT01473381|Depression
306768|NCT01473368|human Gut Microbiota
306769|NCT01473368|gut microbiota
306770|NCT01473368|gut microbiome
306771|NCT01473368|probiotic
306772|NCT01473368|antibiotic
306773|NCT01473368|antibiotic-associated diarrhea
306774|NCT01473368|intestinal bacterial overgrowth
306775|NCT01473342|Healthy survivorship
306776|NCT01473342|Smartphones
306777|NCT01473342|Treatment
306778|NCT01473329|diabetes care
306779|NCT01473329|diabetes education
306780|NCT01473329|diabetes control
306781|NCT01473303|stage IV pancreatic cancer
306782|NCT01473303|duct cell adenocarcinoma of the pancreas
306783|NCT01473290|diarrhea
306784|NCT01473290|constipation, impaction, and bowel obstruction
306785|NCT01473290|gastrointestinal complications
306786|NCT01473290|fatigue
306787|NCT01473290|psychosocial effects of cancer and its treatment
306788|NCT01473290|cognitive/functional effects
306789|NCT01473290|unspecified adult solid tumor, protocol specific
306790|NCT01473277|Hemiplegic shoulder pain
306791|NCT01473277|Botulinum toxin type A (BT-A)
306792|NCT01473277|Steroid
306793|NCT01473277|Intra-articular injection
306794|NCT01473277|Pain score of 45 or greater on a 0-100 mm VAS
306795|NCT01473277|Duration of HSP for at least one month
306796|NCT01473277|Pain refractoriness to conventional treatment
306797|NCT01473264|CC10
306798|NCT01473264|BPD
306799|NCT01473264|Bronchopulmonary dysplasia
306800|NCT01473264|premature infants
306801|NCT01473264|neonates
306802|NCT01473264|pulmonary inflammation
306803|NCT01473264|lung function
306804|NCT01473264|RDS
306805|NCT01473238|Desktop computer
306806|NCT01473238|Mobile
306807|NCT01473238|iPad
306808|NCT01473238|Evaluation
306809|NCT01473238|User experience
306810|NCT01473238|Benefits
306811|NCT01473238|Cost analysis
306812|NCT01473199|focal defect
306813|NCT01473199|focal lesion
306814|NCT01473199|chondral lesion
306815|NCT01473199|osteochondral lesion
306816|NCT01473186|morbid obesity
306817|NCT01473186|endometrial pathology
306818|NCT01473186|menstrual irregularities
306819|NCT01473173|Safety
306820|NCT01473173|Tolerability
306821|NCT01473173|Pharmacokinetics
306822|NCT01473173|Pharmacodynamics
306823|NCT01473147|GLP-1 analogue
306824|NCT01473147|CSII
306825|NCT01473147|insulin
306826|NCT01473147|type 2 diabetes mellitus
306827|NCT01472107|Pregnancy
306828|NCT01472107|APL female patients
306829|NCT01472068|Incontinence
306830|NCT01472068|NMES
306831|NCT01472055|Hematopoietic stem cell transplantation with fludarabine based conditioning
306832|NCT01473121|Hepatocellular carcinoma
306833|NCT01473121|Registry
306834|NCT01473121|Turkey
306835|NCT01473108|Healthy volunteers, proof-of-concept trial, PK and PD
306836|NCT01473095|AKT
306837|NCT01473095|ARQ 092
306838|NCT01473095|Targeted therapy
306839|NCT01473095|Molecular therapy
306840|NCT01473095|Biomarker
306841|NCT01473095|Phase 1
306842|NCT01473095|Phase I
306843|NCT01473095|Endometrial cancer
306844|NCT01473095|Lymphoma
306845|NCT01473095|AKT pathway
306846|NCT01473095|AKT signaling
306847|NCT01473095|AKT inhibitor
306848|NCT01473095|AKT pan inhibitor
306849|NCT01473095|AKT1
306850|NCT01473095|AKT2
306851|NCT01473095|AKT3
306852|NCT01473095|AKT1 mutation
306853|NCT01473095|AKT1-E17K
306854|NCT01473095|AKT1-E17K mutation
306855|NCT01473095|AKT 2 inhibitor
306856|NCT01473095|AKT 3 inhibitor
306857|NCT01473095|AKT 3 amplification
306858|NCT01473095|PI3K AKT mTOR signalling pathway
306859|NCT01473095|mTOR inhibitor
306860|NCT01473095|PI3K inhibitor
306861|NCT01473095|Clinical oncology
306862|NCT01473095|Tumor
306863|NCT01473095|Tumour
306864|NCT01473095|PIK3CA H1047R mutation
306865|NCT01473069|JTK-853
306866|NCT01473069|Healthy subjects
306867|NCT01473056|Hepatitis C
306868|NCT01473056|JTK-853
306869|NCT01473043|Axitinib
306870|NCT01473043|metastatic renal cell carcinoma
306871|NCT01473030|Benign prostate
306872|NCT01473030|serum DHT
306873|NCT01473030|Dutasteride
306874|NCT01473030|PSA
306875|NCT01473030|Avodart
306876|NCT01473004|Sir-spheres
306877|NCT01473004|Liver Metastases
306878|NCT01473004|Selective internal radiation
306879|NCT01473004|Yttrium-90
306880|NCT01473004|Uveal
306881|NCT01473004|Melanoma
306882|NCT01473004|Ocular melanoma
306883|NCT01472991|ADHD
306884|NCT01472978|C. difficile
306885|NCT01472965|central line
306886|NCT01472965|adolescents
306887|NCT01472965|children
306888|NCT01472965|bloodstream infection
306889|NCT01472965|antibiotic lock therapy
306890|NCT01472965|catheter lock therapy
306891|NCT01472965|ethanol lock therapy
306892|NCT01472952|sepsis
306893|NCT01472952|immune cells
306894|NCT01472952|immune reaction
306895|NCT01472952|trauma
306896|NCT01472952|Immune activation
306897|NCT01472926|acute ischaemic stroke
306898|NCT01472926|stroke
306899|NCT01472926|thrombolysis
306900|NCT01472926|thrombolytic drug therapy
306901|NCT01472926|CT perfusion
306902|NCT01472926|CT angiography
306903|NCT01472926|brain imaging
306904|NCT01472913|Prospective randomised double-blind study
306905|NCT01472913|Fibrin sealant
306906|NCT01472913|Bilateral simultaneous total knee arthroplasty
306907|NCT01472913|Blood loss
306908|NCT01472913|Postoperative pain
306909|NCT01472913|Complications
306910|NCT01472900|acne vulgaris
306911|NCT01472874|Wilson Disease
306912|NCT01472874|Trientine
306913|NCT01472874|One Daily Dosage
306914|NCT01472861|coculture
306915|NCT01472861|endometrial biopsy
306916|NCT01472861|IVF poor responders
306917|NCT01472835|sedation
306918|NCT01472835|sensitivity
306919|NCT01472835|specificity
306920|NCT01472835|validity
306921|NCT01472835|diagnostic injection
306922|NCT01472822|Omija
306923|NCT01472822|knee osteoarthritis
306924|NCT01472809|ZYGK1
306925|NCT01472809|Cadila
306926|NCT01472809|Zydus
306927|NCT01472809|ZRC
306928|NCT01472809|Zydus Research Center
306929|NCT01472809|Phase 1
306930|NCT01472809|Diabetes
306931|NCT01472796|African American
306932|NCT01472796|Vitamin D deficient
306933|NCT01472783|BRCA1 mutation
306934|NCT01472783|BRCA2 mutation
306935|NCT01472783|Ovarian cancer
306936|NCT01472783|PARP inhibitor
306937|NCT01472770|Colorectal cancer
306938|NCT01472770|Metastatic
306939|NCT01472770|Treatment resistant
306940|NCT01472744|Executive function
306941|NCT01472744|Aging
306942|NCT01472744|Physical activity
306943|NCT01472731|GC1008
306944|NCT01472731|PET imaging
306945|NCT01472731|primary brain tumors
306946|NCT01472731|recurrent high grade glioma's
306947|NCT01472705|drug-eluting coronary stent
306948|NCT01472705|percutaneous coronary intervention
306949|NCT01472692|Prehypertension
306950|NCT01472692|Gout
306951|NCT01472692|Puls Wave Velocity
306952|NCT01472692|Hypertension
306953|NCT01472692|24 hour blood pressure
306954|NCT01472679|fat mass
306955|NCT01472679|fat free mass
306956|NCT01472679|body mass index
306957|NCT01472666|Medium chain fatty acids
306958|NCT01472666|Saturated fatty acids
306959|NCT01472666|Whey protein
306960|NCT01472666|Casein protein
306961|NCT01472666|Metabolic syndrome
306962|NCT01472666|Type 2 diabetes
306963|NCT01472666|Cardiovascular disease
306964|NCT01472666|Dairy products
306965|NCT01472666|Dietary intervention
306966|NCT01472653|Head and neck Cancer
306967|NCT01472653|Radiochemotherapy
306968|NCT01472653|Radioimmunotherapy
306969|NCT01472653|Skin rush
306970|NCT01472653|locoregional control
306971|NCT01472653|Survival
306972|NCT01472653|Toxicity
306973|NCT01472640|CHF, Diabetes; Liraglutid, Ecco
306974|NCT01472627|MM
306975|NCT01472627|Bortezomib
306976|NCT01472627|Velcade
306977|NCT01472614|Type-2 diabetes mellitus
306978|NCT01472614|Add-on therapy
306979|NCT01472575|rotavirus
306980|NCT01472575|gastroenteritis
306981|NCT01472575|vaccination
306982|NCT01472575|hospitalisation
306983|NCT01472562|mantle cell lymphoma
306984|NCT01472549|Preoperative
306985|NCT01472549|Antiseptics
306986|NCT01472549|Comparative
306987|NCT01472549|Cost
306988|NCT01472549|Effectiveness
306989|NCT01472536|Influenza
306990|NCT01472536|Non pharmaceutical intervention
306991|NCT01472536|Sequestration
306992|NCT01472536|Social network
306993|NCT01472510|Diabetic
306994|NCT01472510|Macular
306995|NCT01472510|Edema
306996|NCT01472510|Ranibizumab
306997|NCT01472510|anti-VEGF
306998|NCT01472497|hypertension
306999|NCT01472497|insulin resistance
307000|NCT01472497|oral glucose tolerance test
307001|NCT01472497|AGE
307002|NCT01472497|inflammatory cytokine
307003|NCT01472484|beans
307004|NCT01472484|lpa mutant
307005|NCT01472484|polyphenols
307006|NCT01472484|phytic acid
307007|NCT01472484|stable iron isotopes
307008|NCT01472471|Childhood Asthma
307009|NCT01472471|Oxidative stress
307010|NCT01472471|Urinary 8-isoprostane
307011|NCT01472458|Cardiac arrest
307012|NCT01472458|Hypothermia
307013|NCT01472458|Post Cardiac Arrest Care
307014|NCT01472458|Survivors of cardiac arrest
307015|NCT01472445|Vitamin D
307016|NCT01472445|Obesity
307017|NCT01472432|type 2 diabetes
307018|NCT01472432|healing
307019|NCT01472432|foot ulcers
307020|NCT01472432|vildagliptin
307021|NCT01472419|metastatic esophageal squamous cell carcinoma
307022|NCT01472419|Fluoropyrimidine/platinum-based first-line chemotherapy
307023|NCT01472419|prognosis
307024|NCT01472406|type 1 diabetes mellitus
307025|NCT01472406|closed-loop artificial pancreas
307026|NCT01472393|creatine supplementation
307027|NCT01472393|bone mass
307028|NCT01472393|postmenopausal women
307029|NCT01472393|muscle function
307030|NCT01472393|bone markers
307031|NCT01472354|HIV
307032|NCT01472354|Hepatitis C
307033|NCT01472354|Decision-Making
307034|NCT01472354|chronic
307035|NCT01472328|Oxidative stress
307036|NCT01472328|Insulin resistance
307037|NCT01472315|sleep apnea
307038|NCT01472315|women
307039|NCT01472315|postmenopause
307040|NCT01472315|hormone treatment
307041|NCT01472289|CLI
307042|NCT01472289|Peripheral arterial disease
307043|NCT01472276|Behaviour change
307044|NCT01472276|Weight loss
307045|NCT01472276|Cardiovascular risk
307046|NCT01472276|Diet
307047|NCT01472276|Physical activity
307048|NCT01472276|Overweight
307049|NCT01472276|Obesity
307050|NCT01472276|Internet
307051|NCT01472263|HTLV-1
307052|NCT01472263|tropical spastic paraparesis
307053|NCT01472263|Immune System Diseases
307054|NCT01472263|Physical disability
307055|NCT01472263|pentoxifylline
307056|NCT01472250|Advanced Gastric Cancer
307057|NCT01472250|chemotherapy
307058|NCT01472250|quality of life
307059|NCT01472250|treatment expense
307060|NCT01472250|patients accepted first-line chemotherapy
307061|NCT01472224|Transcranial ultrasound
307062|NCT01472224|Haematoma expansion
307063|NCT01472198|GSI
307064|NCT01472198|Gilead
307065|NCT01472198|Gilead Sciences
307066|NCT01472198|Pancreatic Cancer
307067|NCT01472198|PC
307068|NCT01472198|Gemcitabine
307069|NCT01472198|Phase 2
307070|NCT01472198|Phase II
307071|NCT01472198|GS-6624
307072|NCT01472198|Oncology
307073|NCT01472198|Monoclonal Antibody
307074|NCT01472185|Type 2 Diabetes Mellitus
307075|NCT01472172|Flex-rigid pleuroscopy
307076|NCT01472172|cryobiopsy
307077|NCT01472172|pleural biopsy
307078|NCT01472172|pleural effusion
307079|NCT01472172|safety
307080|NCT01472172|thoracoscopy
307081|NCT01472146|Neoadjuvant therapy
307082|NCT01472146|Breast cancer HER2 positive
307083|NCT01472146|zolendronic acid
307084|NCT01472133|Respiration Rate
307085|NCT01472133|ECG
307086|NCT01472133|Pulse oximetry
307087|NCT01472133|Photoplethysmograph
307088|NCT01472133|PPG
307089|NCT01472133|Physiology
307090|NCT01472042|Traumatic Brain Injury
307091|NCT01472042|Sport Concussion
307092|NCT01472042|Head Injury
307093|NCT01472042|Sports Injury
307094|NCT01472029|Adenocarcinoma
307095|NCT01472029|Gastroesophageal junction
307096|NCT01472029|Stomach
307097|NCT01472029|HER2
307098|NCT01472016|c-Met overexpression
307099|NCT01472016|MET amplification
307100|NCT01472016|Neoplasms
307101|NCT01472016|h224G11
307102|NCT01471990|PACAP38
307103|NCT01471990|MMA
307104|NCT01471990|migraine
307105|NCT01471990|angiography
307106|NCT01471990|VIP
307107|NCT01471990|vasodilatation
307108|NCT01471912|Macular Holes
307109|NCT01471912|spectral domain optical coherence tomography
307110|NCT01471912|elongation of foveal tissue
307111|NCT01471912|M-score
307112|NCT01471873|Posterior corneal surface elevation
307113|NCT01471873|Pentacam-Scheimpflung imaging
307114|NCT01471873|variability
307115|NCT01471873|progressive keratoconus
307116|NCT01471873|corneal cross-linking
307117|NCT01471847|Locally advanced
307118|NCT01471847|metastatic
307119|NCT01471847|breast cancer
307120|NCT01471847|HER2 positive
307121|NCT01471847|PI3K
307122|NCT01471847|mTOR
307123|NCT01471847|trastuzumab
307124|NCT01471847|targeted therapy
307125|NCT01471847|LABC
307126|NCT01471847|MBC
307127|NCT01471782|ALL
307128|NCT01471782|relapsed, refractory B-precursor ALL
307129|NCT01471782|Leukemia
307130|NCT01471782|Leukemia, Lymphoid
307131|NCT01471782|Precursor Cell Lymphoblastic Leukemia
307132|NCT01471782|Neoplasms by Histologic Type
307133|NCT01471782|Neoplasms
307134|NCT01471782|Lymphoproliferative Disorders
307135|NCT01471782|Lymphatic Diseases
307136|NCT01471782|Immunoproliferative Disorders
307137|NCT01471782|Antibodies, Bispecific
307138|NCT01471769|pediatric
307139|NCT01471769|pain
307140|NCT01471756|sessile neoplasms
307141|NCT01471756|flat neoplasms
307142|NCT01471756|gastric cancer
307143|NCT01471743|nutrition
307144|NCT01471743|surgery
307145|NCT01471743|immune
307146|NCT01471730|Transfusions
307147|NCT01471730|Fresh Frozen Plasma
307148|NCT01471730|Fibrinogen
307149|NCT01471730|Prothrombin complex
307150|NCT01471717|PK
307151|NCT01471717|pharmacokinetics
307152|NCT01471717|INX08189
307153|NCT01471717|Victrelis
307154|NCT01471717|Inhibitex
307155|NCT01471704|Pharmacokinetics
307156|NCT01471704|PK
307157|NCT01471704|INX08189
307158|NCT01471704|Verapamil
307159|NCT01471704|Inhibitex
307160|NCT01471678|Cross-over design
307161|NCT01471678|Pilot bioequivalence
307162|NCT01471678|North east Asian ancestry
307163|NCT01471678|GI198745
307164|NCT01471678|Tamsulosin hydrochloride
307165|NCT01471678|healthy male subjects
307166|NCT01471678|Bioequivalence
307167|NCT01471678|Dutasteride
307168|NCT01471652|myalgic encephalopathy
307169|NCT01471652|chronic fatigue syndrome
307170|NCT01471652|post viral infection
307171|NCT01471652|fatigue
307172|NCT01471652|muscle pain
307173|NCT01471652|unrefreshing sleep
307174|NCT01471652|fuzzy thought
307175|NCT01471652|poor memory
307176|NCT01471652|forgetfulness
307177|NCT01471639|18 years and older,
307178|NCT01471639|previously healthy
307179|NCT01471639|men and nonpregnant women
307180|NCT01471639|emergency department
307181|NCT01471626|sleep apnea
307182|NCT01471626|polysomnography
307183|NCT01471626|telemedicine
307184|NCT01471613|spinal cord injury
307185|NCT01471613|umbilical cord blood cell
307186|NCT01471613|cell transplant
307187|NCT01471613|lithium carbonate
307188|NCT01471600|upper gastrointestinal endoscopy
307189|NCT01471600|general anesthesia
307190|NCT01471561|Osmolarity
307191|NCT01471561|Cataract
307192|NCT01471561|Dry Eye
307193|NCT01471548|tumor
307194|NCT01471548|cancer
307195|NCT01471548|phase1
307196|NCT01471548|TKI258
307197|NCT01471535|chronic hepatitis B
307198|NCT01471509|Glycemic Index
307199|NCT01471509|LoBAG Diet
307200|NCT01471509|Insulin
307201|NCT01471509|Glucagon
307202|NCT01471496|duodenal ulcer
307203|NCT01471496|upper gastrointestinal system bleeding
307204|NCT01471496|injection therapy
307205|NCT01471483|Geriatric Assessment
307206|NCT01471483|Quality of Life
307207|NCT01471483|11-164
307208|NCT01471483|Fallopian Tubes
307209|NCT01471470|Advanced gastric cancer
307210|NCT01471470|Neoadjuvant
307211|NCT01471470|Bevacizumab
307212|NCT01471457|bacterial
307213|NCT01471457|vaginosis
307214|NCT01471457|pessary
307215|NCT01471457|discharge
307216|NCT01471444|Blood And Marrow Transplantation
307217|NCT01471444|Leukemia
307218|NCT01471444|Allogeneic hematopoietic stem cell transplantation
307219|NCT01471444|Acute myeloid leukemia
307220|NCT01471444|AML
307221|NCT01471444|Myelodysplastic syndrome
307222|NCT01471444|MDS
307223|NCT01471444|Progression free survival
307224|NCT01471444|Rate of engraftment
307225|NCT01471444|Toxicity
307226|NCT01471444|Relapse rate
307227|NCT01471444|Graft-vs-host disease
307228|NCT01471444|GvHD
307229|NCT01471444|Progression-free survival
307230|NCT01471444|PFS
307231|NCT01471444|Overall survival
307232|NCT01471444|OS
307233|NCT01471444|Fludarabine
307234|NCT01471444|Fludarabine Phosphate
307235|NCT01471444|Fludara
307236|NCT01471444|Clofarabine
307237|NCT01471444|Clofarex
307238|NCT01471444|Clolar
307239|NCT01471444|Busulfan
307240|NCT01471444|Busulfex
307241|NCT01471444|Myleran
307242|NCT01471444|Thymoglobulin
307243|NCT01471444|ATG
307244|NCT01471444|Antithymocyte Globulin
307245|NCT01471444|Methotrexate
307246|NCT01471444|Tacrolimus
307247|NCT01471444|Prograf
307248|NCT01471418|TMJ
307249|NCT01471418|orofacial pain
307250|NCT01471418|synovitis
307251|NCT01471418|arthroscopy
307252|NCT01471392|Identigene
307253|NCT01471392|STD Test
307254|NCT01471392|Chlamydia
307255|NCT01471392|Gonorrhoeae
307256|NCT01471392|APTIMA
307257|NCT01471392|Sexually Transmitted Disease
307258|NCT01471379|Irritable Bowel Syndrome
307259|NCT01471379|IBS
307260|NCT01471379|Savella
307261|NCT01471379|Milnacipran
307262|NCT01471379|Abdominal Pain
307263|NCT01471366|Hyperlipidemias
307264|NCT01471366|Dyslipidemias
307265|NCT01471366|Fatty Acids, Omega-3
307266|NCT01471366|Fish Oils
307267|NCT01471353|Metastatic
307268|NCT01471353|Colon Cancer
307269|NCT01471353|Rectal Cancer
307270|NCT01471301|systemic lupus erythematosus
307271|NCT01471301|rheumatoid arthritis
307272|NCT01471288|well differentiated thyroid cancer
307273|NCT01471288|Carum Carvi
307274|NCT01471288|Normal controls
307275|NCT01471275|type 2 diabetes
307276|NCT01471275|obesity
307277|NCT01471275|hypertriglyceridemia
307278|NCT01471262|Complications
307279|NCT01471262|Mortality
307280|NCT01471262|Liver
307281|NCT01471262|Failure
307282|NCT01471249|esophageal stenting
307283|NCT01471249|palliative
307284|NCT01471249|dysphagia
307285|NCT01471236|cartilage
307286|NCT01471236|bone
307287|NCT01471184|Allergic Rhinitis
307288|NCT01471184|Conjunctivitis
307289|NCT01471184|Bitop
307290|NCT01471184|Eye
307291|NCT01471184|Eye Drops
307292|NCT01471184|Nasal Spray
307293|NCT01471184|Total Nasal Symptom Score
307294|NCT01471184|Total Ocular Symptom Score
307295|NCT01471184|AUC
307296|NCT01471171|COPD
307297|NCT01471171|Antimuscarinic
307298|NCT01471158|Primary open-angle glaucoma
307299|NCT01471158|ocular hypertension
307300|NCT01471158|pigment dispersion glaucoma
307301|NCT01471145|opioid dependence
307302|NCT01471145|heroin dependence
307303|NCT01471145|extended release depot naltrexone
307304|NCT01471145|functional Magnetic Resonance Imaging
307305|NCT01471145|dopamine transporter
307306|NCT01471145|Single Photon Emission Computed Tomography
307307|NCT01471119|sublingual immunotherapy
307308|NCT01471119|atopic dermatitis
307309|NCT01471119|Dermatophagoides Farinae Drops
307310|NCT01471106|Breast Cancer
307311|NCT01471106|Estrogen Receptor Negative Breast Cancer
307312|NCT01471106|Biomarker studies
307313|NCT01471106|Ki-67
307314|NCT01471106|Dasatinib
307315|NCT01471106|BMS-354825
307316|NCT01471106|Sprycel
307317|NCT01471080|laparoscopic hepatectomy
307318|NCT01471080|radio-frequency ablation
307319|NCT01471080|giant cavernous hemangiomas
307320|NCT01471080|liver
307321|NCT01471067|Blood And Marrow Transplantation
307322|NCT01471067|Leukemia
307323|NCT01471067|Lymphoma
307324|NCT01471067|Pediatrics
307325|NCT01471067|Cord blood transplant
307326|NCT01471067|Cord Blood Fucosylation
307327|NCT01471067|Hematologic Malignancies
307328|NCT01471067|Acute Myelogenous Leukemia
307329|NCT01471067|AML
307330|NCT01471067|Myelodysplastic Syndrome
307331|NCT01471067|MDS
307332|NCT01471067|High-risk cytogenetics
307333|NCT01471067|Secondary leukemia from prior chemotherapy
307334|NCT01471067|Langerhan's cell histiocytosis
307335|NCT01471067|Acute Lymphoblastic Leukemia
307336|NCT01471067|ALL
307337|NCT01471067|complete remission
307338|NCT01471067|Philadelphia chromosome
307339|NCT01471067|translocation 4;11
307340|NCT01471067|Hypodiploidy
307341|NCT01471067|Chronic Myeloid Leukemia
307342|NCT01471067|CML
307343|NCT01471067|Non-Hodgkin's Lymphoma
307344|NCT01471067|NHL
307345|NCT01471067|Hodgkin's Disease
307346|NCT01471067|HD
307347|NCT01471067|Chronic Lymphocytic Leukemia
307348|NCT01471067|CLL
307349|NCT01471067|Melphalan
307350|NCT01471067|Alkeran
307351|NCT01471067|Thiotepa
307352|NCT01471067|Fludarabine
307353|NCT01471067|Fludarabine Phosphate
307354|NCT01471067|Fludara
307355|NCT01471067|Mycophenolate Mofetil
307356|NCT01471067|MMF
307357|NCT01471067|CellCept
307358|NCT01471067|Tacrolimus
307359|NCT01471067|Prograf
307360|NCT01471067|Rituximab
307361|NCT01471067|Rituxan
307362|NCT01471067|ATG
307363|NCT01471067|Antithymocyte Globulin
307364|NCT01471067|Thymoglobulin
307365|NCT01471054|Plaque radiotherapy
307366|NCT01471054|Brachytherapy
307367|NCT01471054|Macular edema
307368|NCT01471054|Cystoid macular edema
307369|NCT01471054|Uveal melanoma
307370|NCT01471054|Radiation maculopathy
307371|NCT01471054|Radiation retinopathy
307372|NCT01471054|Ozurdex
307373|NCT01471054|Dexamethasone intravitreal implant
307374|NCT01471041|End Stage Renal Disease
307375|NCT01471041|Hemodialysis
307376|NCT01471041|AV fistula
307377|NCT01471041|Kidney failure
307378|NCT01471028|Acute alcoholic hepatitis
307379|NCT01471028|alcoholic
307380|NCT01471028|hepatitis
307381|NCT01471028|liver
307382|NCT01471015|Hypoxic Ischemic Encephalopathy
307383|NCT01471015|Cooling Therapy
307384|NCT01471015|HIE
307385|NCT01470989|gouty arthritis
307386|NCT01470976|Goal-directed therapy
307387|NCT01470976|Hemodynamic optimization
307388|NCT01470976|Cardiac surgery
307389|NCT01470963|Referral
307390|NCT01470963|Quality of Health Care
307391|NCT01470950|Functional Electrical Stimulation
307392|NCT01470950|Signalling Pathways
307393|NCT01470937|diabetes acarbose alphaglucosidase prevention
307394|NCT01470924|acute lymphoblastic leukemia
307395|NCT01470924|relapse
307396|NCT01470924|salvage
307397|NCT01470924|prognostic
307398|NCT01470911|Antisense oligonucleotide
307399|NCT01470911|Asthma
307400|NCT01470911|Healthy subjects
307401|NCT01470911|Phase 1
307402|NCT01470911|Transcription factor GATA-3
307403|NCT01470911|Oral inhalation
307404|NCT01470898|bispectral index monitoring
307405|NCT01470898|extubation
307406|NCT01470898|analgesia
307407|NCT01470898|abdominal surgery
307408|NCT01470885|glucose
307409|NCT01470885|prognosis
307410|NCT01470885|glycated hemoglobin
307411|NCT01470859|De Novo parkinson's disease
307412|NCT01470859|initial treatment
307413|NCT01470859|pramipexole
307414|NCT01470859|Levodopa
307415|NCT01470859|Parkinson's disease-related spatial covariance pattern
307416|NCT01470846|epidural analgesia
307417|NCT01470846|morphin analgesia
307418|NCT01470846|laparotomy
307419|NCT01470833|Achilles tendon
307420|NCT01470833|rupture
307421|NCT01470833|non-operative
307422|NCT01470833|treatment
307423|NCT01470820|Neonates
307424|NCT01470820|Hyperbilirubinemia
307425|NCT01470820|Phototherapy
307426|NCT01470820|Light irradiance
307427|NCT01470820|Saturation point
307428|NCT01470807|Artificial Pancreas
307429|NCT01470807|Insulin Pump
307430|NCT01470807|Continuous Glucose Monitor
307431|NCT01470807|Closed Loop
307432|NCT01470794|GBM
307433|NCT01470794|HGG
307434|NCT01470794|High grade glioma
307435|NCT01470794|Malignant glioma
307436|NCT01470794|Grade III glioma
307437|NCT01470794|Grad IV glioma
307438|NCT01470781|Bipolar Disorder
307439|NCT01470781|Psychosis
307440|NCT01470781|Cognition
307441|NCT01470781|Cognitive Remediation
307442|NCT01470755|Pediatrics
307443|NCT01470755|Bronchial wheeze
307444|NCT01470755|bronchodilator
307445|NCT01470755|lung function
307446|NCT01470755|airway resistance
307447|NCT01470729|Spinocerebellar ataxia, energy metabolism, NMR spectroscopy
307448|NCT01470716|EGFR mutation
307449|NCT01470716|NSCLC
307450|NCT01470703|Acute Respiratory Distress Syndrome,
307451|NCT01470703|ECMO, Extracorporeal Membrane Oxygenation
307452|NCT01470703|Randomized controlled trial
307453|NCT01470703|Positive-Pressure ventilation
307454|NCT01470703|Survival Rate
307455|NCT01470690|HVC infection
307456|NCT01470690|gastric acid-related disorders
307457|NCT01470690|proton pump inhibitor
307458|NCT01470690|interaction
307459|NCT01470690|pharmacokinetics
307460|NCT01470690|boceprevir
307461|NCT01470690|omeprazole
307462|NCT01470677|lymph cyst
307463|NCT01470677|lymphocele
307464|NCT01470677|fibrin
307465|NCT01470677|collagen
307466|NCT01470677|prevention
307467|NCT01470677|cancer
307468|NCT01470651|HCV+
307469|NCT01470651|HCV treatment
307470|NCT01470651|Fatigue
307471|NCT01470651|patients starting alpha interferon/ribavirin treatment
307472|NCT01470638|Flt3-L
307473|NCT01470638|CSF
307474|NCT01470625|Dying
307475|NCT01470625|Patients
307476|NCT01470625|Hospice
307477|NCT01470625|Liverpool Care Pathways
307478|NCT01470612|Ulcerative colitis
307479|NCT01470612|open-label
307480|NCT01470612|long term treatment
307481|NCT01470586|Colorectal cancer
307482|NCT01470586|Surgical resection
307483|NCT01470586|Oxidative Stress Markers
307484|NCT01470586|Controls
307485|NCT01470560|Mindfulness
307486|NCT01470560|Mindfulness-Based Stress Reduction
307487|NCT01470560|Meditation
307488|NCT01470560|Yoga
307489|NCT01470547|Liver Cirrhosis
307490|NCT01470547|Portal Vein Thrombosis
307491|NCT01470547|Cirrhosis Complications
307492|NCT01470547|Registry
307493|NCT01470547|Italian
307494|NCT01470534|Dietary supplement
307495|NCT01470534|Carbohydrate loading
307496|NCT01470534|Insulin resistance
307497|NCT01470534|Surgery
307498|NCT01470521|Multiple sclerosis
307499|NCT01470521|Hookworm larvae
307500|NCT01470521|Necator americanus
307501|NCT01470521|Treg cells
307502|NCT01470508|Bulimia
307503|NCT01470508|Binge-Eating Disorder
307504|NCT01470508|Eating Disorders
307505|NCT01470482|Total knee
307506|NCT01470482|Tourniquet
307507|NCT01470482|Blood loss
307508|NCT01470482|pain
307509|NCT01470482|range of motion
307510|NCT01470391|Adductor-Canal-Blockade
307511|NCT01470391|Femoral Nerve Block
307512|NCT01470391|Postoperative Pain
307513|NCT01470391|Total Knee Arthroplasty
307514|NCT01470378|Lymphedema
307515|NCT01470378|Magnetic Resonance Imaging
307516|NCT01470378|Plastic Surgery
307517|NCT01470352|migraine
307518|NCT01470352|pain
307519|NCT01470352|CPM
307520|NCT01470352|offset analgesia
307521|NCT01470352|fMRI
307522|NCT01470339|endogenous pain modulation
307523|NCT01470339|migraine
307524|NCT01470339|fMRI
307525|NCT01470339|duloxetine
307526|NCT01470339|preventive migraine treatment
307527|NCT01470326|Osteoporosis
307528|NCT01470326|Post menopausal women
307529|NCT01470326|SERM
307530|NCT01470326|Japanese
307531|NCT01470326|Viviant
307532|NCT01470326|Regulatory Post Marketing Commitment Plan
307533|NCT01470326|Long term treatment
307534|NCT01470313|Safety and tolerability
307535|NCT01470313|cutaneous lupus erythematosus
307536|NCT01470313|efficacy
307537|NCT01470287|Infants,
307538|NCT01470287|Immunogenicity,
307539|NCT01470287|Safety
307540|NCT01470274|Blood volume
307541|NCT01470274|CO-rebreathing
307542|NCT01470274|COPD
307543|NCT01470274|CVD
307544|NCT01470261|methylphenidate
307545|NCT01470261|ritalin
307546|NCT01470261|Attention Deficit Disorder
307547|NCT01470248|Lung Cancer
307548|NCT01470248|Carcinoma, small cell
307549|NCT01470248|Trisenox
307550|NCT01470248|Arsenic trioxide
307551|NCT01470248|phase II trial
307552|NCT01470235|screening
307553|NCT01470235|genetic
307554|NCT01470235|cancer
307555|NCT01470222|Worksite
307556|NCT01470222|group weight loss
307557|NCT01470222|behavioral components
307558|NCT01470209|lung cancer with activated mTOR/PI3K pathway
307559|NCT01470209|alterations in PIK3CA, NF1, TSC1/TSC2, mTOR, KRAS, LKB1, PTEN
307560|NCT01470196|WM
307561|NCT01470196|untreated
307562|NCT01470196|symptomatic
307563|NCT01470183|Lupus Nephritis
307564|NCT01470170|Sedative bronchoscope
307565|NCT01470170|Alfentanil doses
307566|NCT01470170|Propofol
307567|NCT01470170|Targeted controlled infusion
307568|NCT01470170|Hypoxemia
307569|NCT01470131|multiple myeloma
307570|NCT01470131|relapse
307571|NCT01470131|second line therapy
307572|NCT01470131|bortezomib
307573|NCT01470131|dexamethasone
307574|NCT01470105|questionnaire
307575|NCT01470105|11-121
307576|NCT01470092|Menopause
307577|NCT01470092|Depression
307578|NCT01470066|peripheral T cell lymphomas
307579|NCT01470066|interim PET/CT
307580|NCT01470066|prognosis
307581|NCT01470066|Positron-emission tomography/Computerized tomography
307582|NCT01470053|mometasone furoate
307583|NCT01470053|azelastine HCl
307584|NCT01470053|perennial allergic rhinitis
307585|NCT01470040|traumatic brain injury
307586|NCT01470040|chronic subdural hematoma
307587|NCT01470040|aspirin
307588|NCT01470040|antiplatelet therapy
307589|NCT01470027|magnetic resonance spectroscopy
307590|NCT01470027|N-acetylcysteine
307591|NCT01470027|antioxidant
307592|NCT01470027|glutathione
307593|NCT01470014|isolated left ventricular non-compaction
307594|NCT01470014|cardiac computed tomography
307595|NCT01470014|cardiac magnet resonance imaging
307596|NCT01470014|echocardiography
307597|NCT01469975|cancer
307598|NCT01469975|relapse or refractory
307599|NCT01469962|morbid obesity
307600|NCT01469962|bariatric surgery
307601|NCT01469962|NASH
307602|NCT01469962|Liver fibrosis
307603|NCT01469962|Fibrotest
307604|NCT01469949|Improvement of the accuracy of Lumbar repositioning
307605|NCT01469936|Fibromyalgia
307606|NCT01469936|Irritable Bowel Syndrome
307607|NCT01469923|Phase 1
307608|NCT01469923|obese
307609|NCT01469923|healthy male volunteers
307610|NCT01469923|multiple doses
307611|NCT01469923|dose escalation
307612|NCT01469923|pharmacokinetics
307613|NCT01469923|pharmakodynamics
307614|NCT01469897|JIA
307615|NCT01469897|Juvenile Idiopathic Arthritis
307616|NCT01469897|Cost of Care
307617|NCT01469897|Quality of Life
307618|NCT01469897|QOL
307619|NCT01469884|Renal allograft recipients
307620|NCT01469884|Hepatitis C virus (HCV)
307621|NCT01469884|Certican
307622|NCT01469884|Calcineurin inhibitor(tacrolimus or cyclosporin)
307623|NCT01469871|Dressing
307624|NCT01469871|Blisters
307625|NCT01469871|Silicone
307626|NCT01469845|hospital admissions
307627|NCT01469845|acute bronchiolitis
307628|NCT01469845|under one year old
307629|NCT01469845|requiring oxygen therapy
307630|NCT01469832|fundus flavimaculatus
307631|NCT01469832|Retinal Diseases
307632|NCT01469832|Macular Degeneration
307633|NCT01469832|SMD
307634|NCT01469832|juvenile macular dystrophy
307635|NCT01469819|chronic constipation
307636|NCT01469819|constipation
307637|NCT01469819|idiopathic constipation
307638|NCT01469819|SmartPill
307639|NCT01469819|Wireless Motility Capsule
307640|NCT01469819|lubiprostone (Amitiza)
307641|NCT01469819|small intestinal bacterial overgrowth
307642|NCT01469780|Pain
307643|NCT01469780|Health behavior change
307644|NCT01469780|Coronary angioplasty
307645|NCT01469780|Cardiovascular disease
307646|NCT01469780|Outcomes
307647|NCT01469780|Morbidity
307648|NCT01469780|Mortality
307649|NCT01469767|eczema
307650|NCT01469767|itch
307651|NCT01469767|scratching
307652|NCT01469767|actigraphy
307653|NCT01469767|adherence
307654|NCT01469754|lymphoma
307655|NCT01469754|survivors
307656|NCT01469754|posttraumatic growth
307657|NCT01469754|posttraumatic stress
307658|NCT01469754|longitudinal
307659|NCT01469728|VATS
307660|NCT01469728|awake thoracic surgery
307661|NCT01469728|pleurodesis
307662|NCT01469728|talc
307663|NCT01469728|TEA
307664|NCT01469728|epidural anesthesia
307665|NCT01469728|Video-Assisted
307666|NCT01469728|Anesthesia Epidural
307667|NCT01469715|Continuous Glucose Monitor
307668|NCT01469702|cat-scratch disease
307669|NCT01469702|Bartonella henselae
307670|NCT01469702|corticosteroids
307671|NCT01469702|treatment
307672|NCT01469689|People
307673|NCT01469689|living
307674|NCT01469689|community
307675|NCT01469676|Coronary Artery Bypass Surgery
307676|NCT01469676|Cardiopulmonary Bypass
307677|NCT01469676|Leukocyte Reduction Filtrations
307678|NCT01469676|Pulmonary Function
307679|NCT01469676|Systemic Inflammatory Response
307680|NCT01469663|Borderline Personality Disorder
307681|NCT01469663|Major Depression
307682|NCT01469663|Electroencephalogram
307683|NCT01469663|N2
307684|NCT01469663|Error Related Negativity
307685|NCT01469663|Emotional Processing
307686|NCT01469663|Levels of Emotional Awareness
307687|NCT01469650|vitamin D3
307688|NCT01469650|prematurity
307689|NCT01469650|parathyroid hormone
307690|NCT01469650|25(OH)D
307691|NCT01469650|NICU hospitalization
307692|NCT01469624|Contrast Induced Nephropathy
307693|NCT01469624|Pentoxifylline
307694|NCT01469624|PCI
307695|NCT01469611|advanced/metastatic colorectal carcinoma
307696|NCT01469585|continuous oral contraceptives
307697|NCT01469585|MMP expression
307698|NCT01469572|Neuroendocrine hepatic tumors
307699|NCT01469572|Liver cancer
307700|NCT01469572|Metastatic liver cancer
307701|NCT01469559|Insulin
307702|NCT01469559|Diabetic neuropathy
307703|NCT01469559|Intranasal administration
307704|NCT01469559|Pilot project
307705|NCT01469546|Squamous Cell Carcinoma of the Head and Neck
307706|NCT01469533|Spine
307707|NCT01469533|Manipulation
307708|NCT01469533|Pain Threshold
307709|NCT01469533|Electromyography.
307710|NCT01469520|HIV
307711|NCT01469520|AIDS
307712|NCT01469520|Treatment
307713|NCT01469494|DIEP flap
307714|NCT01469494|SIEA flap
307715|NCT01469494|breast reconstruction
307716|NCT01469494|objective isokinetic abdominal strength testing
307717|NCT01469494|fat necrosis
307718|NCT01469494|flap loss
307719|NCT01469494|seroma rate
307720|NCT01469494|abdominal wound breakdown
307721|NCT01469494|Breast-Q
307722|NCT01469494|abdominal wall outcome questionnaire
307723|NCT01469481|diabetes mellitus
307724|NCT01469481|ADME
307725|NCT01469455|Local metastatic melanoma
307726|NCT01469455|relapsed cutaneous/subcutaneous tumors
307727|NCT01469455|melanoma-in-transit
307728|NCT01469442|Biliary fistula
307729|NCT01469442|prevention
307730|NCT01469442|hepatectomy
307731|NCT01469442|external stent
307732|NCT01469442|Hepatectomy of more 2 segments
307733|NCT01469442|Not emergency or laparoscopy surgery
307734|NCT01469429|oral cancer
307735|NCT01469416|rosuvastatin
307736|NCT01469416|clopidogrel
307737|NCT01469416|pharmacokinetics
307738|NCT01469416|drug interaction
307739|NCT01469416|healthy volunteer
307740|NCT01469416|drug transporter
307741|NCT01469403|Osteoarthritis, knee
307742|NCT01469403|Obesity
307743|NCT01469403|Weight Loss
307744|NCT01469403|Arthroplasty
307745|NCT01469377|Major Depressive Disorder
307746|NCT01469377|Depression
307747|NCT01469364|Lung Transplant
307748|NCT01469364|Lung Transplant Recipient
307749|NCT01469351|Alzheimers disease
307750|NCT01469325|Repetitive Transcranial Magnetic Stimulation
307751|NCT01469325|Depression
307752|NCT01469325|left prefrontal
307753|NCT01469312|Low Biologically Available Glucose Diet (LoBAG diet)
307754|NCT01469312|Diabetes
307755|NCT01469312|Glycemic Index
307756|NCT01469299|Ligament Balance, Total Knee Arthroplasty, Intra-operative Sensors
307757|NCT01469286|delayed gastric emptying
307758|NCT01469286|nausea
307759|NCT01469286|vomiting
307760|NCT01469286|abdominal discomfort
307761|NCT01469273|Diarrhea
307762|NCT01469273|EcN
307763|NCT01469273|E. coli strain Nissle 1917
307764|NCT01469273|Gastrointestinal infection
307765|NCT01469273|Infant
307766|NCT01469273|Newborn
307767|NCT01469273|Probiotic drug
307768|NCT01469273|Prevention
307769|NCT01469273|Prophylaxis
307770|NCT01469260|Overweight
307771|NCT01469260|Obesity
307772|NCT01469260|Pregnancy
307773|NCT01469260|Weight gain
307774|NCT01469260|Pedometer
307775|NCT01469260|Exercise
307776|NCT01469247|Brain cancer
307777|NCT01469247|Recurrent or progressive brainstem glioma
307778|NCT01469247|Diffuse Intrinsic Pontine Glioma
307779|NCT01469247|DIPG
307780|NCT01469247|Reirradiation
307781|NCT01469247|ReRT
307782|NCT01469247|Photon radiation therapy
307783|NCT01469247|XRT
307784|NCT01469221|Bladder Cancer
307785|NCT01469221|Non-Muscle Invasive Bladder Cancer
307786|NCT01469221|NMIBC
307787|NCT01469221|Apaziquone
307788|NCT01469221|EOquin
307789|NCT01469221|GU Cancer
307790|NCT01469221|TURBT
307791|NCT01469208|Gastroschisis
307792|NCT01469208|NICU inpatients
307793|NCT01469208|Post surgical repair
307794|NCT01469208|Music Therapy
307795|NCT01469195|lead rectangle
307796|NCT01469195|radiation exposure
307797|NCT01469195|operators
307798|NCT01469195|radial approach
307799|NCT01469195|coronary procedures
307800|NCT01469195|percutaneous coronary intervention
307801|NCT01469182|Immunology
307802|NCT01469169|Iloprost
307803|NCT01469169|Inhalation
307804|NCT01469169|Pulmonary Hypertension
307805|NCT01469169|Pulmonary Artery Hypertension
307806|NCT01469169|Japanese Patients
307807|NCT01469156|polypoidal choroidal vasculopathy
307808|NCT01469156|choroidal neovascularization
307809|NCT01469156|ranibizumab
307810|NCT01469156|Lucentis
307811|NCT01469130|MEK, Advanced solid tumor
307812|NCT01469117|Developmental disabilities
307813|NCT01469117|Enteral Nutrition
307814|NCT01469117|Tube feeding
307815|NCT01469117|Nutrition support
307816|NCT01469104|Diabetes
307817|NCT01469091|Acute admittance
307818|NCT01469091|Current smoker
307819|NCT01469078|Chronic Kidney Disease
307820|NCT01469078|CKD stage 5
307821|NCT01469078|Iron deficiency
307822|NCT01469065|inpatient
307823|NCT01469065|diabetes
307824|NCT01469065|phase 1
307825|NCT01469039|Alkermes
307826|NCT01469039|schizophrenia
307827|NCT01469039|ALKS 9072
307828|NCT01469039|ALKS 9070
307829|NCT01469039|aripiprazole lauroxil
307830|NCT01468948|Essential Tremor
307831|NCT01468948|Tremor
307832|NCT01468948|Octanol
307833|NCT01468948|Octanoic Acid
307834|NCT01468935|Uterus
307835|NCT01468935|Endometrium
307836|NCT01468935|Bone Marrow Transplant
307837|NCT01468935|Gynecology
307838|NCT01468935|Healthy Volunteer
307839|NCT01468935|HV
307840|NCT01468935|Stem Cell Transplant
307841|NCT01468935|Endometriosis
307842|NCT01468922|Pazopanib
307843|NCT01468922|Tivantinib
307844|NCT01468922|MET Inhibitor
307845|NCT01468922|Advanced Cancer
307846|NCT01468922|Anti-Angiogenesis
307847|NCT01468922|Cancer
307848|NCT01468922|Solid Tumor
307849|NCT01468922|Sarcoma
307850|NCT01468883|Breast Cancer
307851|NCT01468883|Surgery
307852|NCT01468883|Radiation
307853|NCT01468857|Clinical Stress Markers
307854|NCT01468857|Chronic Stress
307855|NCT01468857|Allogeneic Hematopoietic Stem Cell Transplant
307856|NCT01468857|HSCT Caregivers
307857|NCT01468857|Cancer Caregivers
307858|NCT01468857|Stress
307859|NCT01468857|Family Caregivers
307860|NCT01468844|Central Retinal Vein Occlusion
307861|NCT01468844|Minocycline
307862|NCT01468844|Retinal Vein Occlusion
307863|NCT01468844|CRVO
307864|NCT01468831|Branch Retinal Vein Occlusion
307865|NCT01468831|Minocycline
307866|NCT01468831|Macular Edema
307867|NCT01468831|Retinal Vein Occlusion
307868|NCT01468831|BRVO
307869|NCT01468818|Metastatic Melanoma
307870|NCT01468818|Adoptive Cell Therapy
307871|NCT01468818|Skin Cancer
307872|NCT01468805|Environmental Intervention
307873|NCT01468805|Indoor Allergens
307874|NCT01468805|Cockroach
307875|NCT01468805|Health Disparities
307876|NCT01468805|Multi-Center
307877|NCT01468805|Asthma
307878|NCT01468805|Environment
307879|NCT01468792|systemic sclerosis
307880|NCT01468792|pulmonary arterial hypertension
307881|NCT01468779|Periampullary cancer
307882|NCT01468779|Surgery
307883|NCT01468779|Dietary supplementation
307884|NCT01468779|Nutritional assessment
307885|NCT01468753|Conception in HIV Discordant Couples
307886|NCT01468753|Reproduction in HIV Discordant Couples
307887|NCT01468753|Vaginal Insemination
307888|NCT01468727|dental caries
307889|NCT01468727|mutans streptococci
307890|NCT01468727|lactobacilli
307891|NCT01468727|bacterial transmission
307892|NCT01468727|bacterial colonization
307893|NCT01468714|Drug Interaction
307894|NCT01468714|pharmacokinetics
307895|NCT01468714|ketoconazole
307896|NCT01468714|CYP3A
307897|NCT01468688|Imatinib mesylate
307898|NCT01468688|BKM120
307899|NCT01468688|GIST
307900|NCT01468649|Breast Cancer
307901|NCT01468649|Sentinel Lymph Node Mapping
307902|NCT01468649|Intraoperative Imaging
307903|NCT01468636|Warts
307904|NCT01468636|HPV
307905|NCT01468636|Zinc
307906|NCT01468623|Colorectal cancer, metastatic
307907|NCT01468623|FOLFOX6
307908|NCT01468623|5-FU
307909|NCT01468623|First line
307910|NCT01468623|bevacizumab
307911|NCT01468610|depression
307912|NCT01468610|cognition
307913|NCT01468610|occupational functioning
307914|NCT01468610|productivity
307915|NCT01468610|neuropsychology
307916|NCT01468610|desvenlafaxine
307917|NCT01468610|antidepressants
307918|NCT01468597|Emergent
307919|NCT01468597|Cardiac surgery
307920|NCT01468597|On-pump
307921|NCT01468597|Platelet function
307922|NCT01468584|Genotype 2
307923|NCT01468571|Potassium Sparing Diuretics
307924|NCT01468571|Right-sided heart failure
307925|NCT01468571|Edema
307926|NCT01468558|Drug Drug Interaction Study in Normal Healthy Volunteers
307927|NCT01468545|Education
307928|NCT01468545|Ventavis
307929|NCT01468545|Adherence
307930|NCT01468545|PAH
307931|NCT01468545|Pulmonary artery hypertension
307932|NCT01468519|Diabetes mellitus, type 2
307933|NCT01468519|Erectile dysfunction
307934|NCT01468519|continuous subcutaneous insulin infusion
307935|NCT01468519|CSII
307936|NCT01468519|insulin
307937|NCT01468506|Chronic Kidney Disease
307938|NCT01468506|arteriovenous fistula
307939|NCT01468493|FSGS
307940|NCT01468493|suPAR
307941|NCT01468480|direct pulp capping
307942|NCT01468480|MTA
307943|NCT01468480|Single visit pulp cap
307944|NCT01468480|Multical
307945|NCT01468467|AC220
307946|NCT01468467|Acute Myeloid Leukemia (AML)
307947|NCT01468467|Transplantation
307948|NCT01468467|Stem Cell Transplantation
307949|NCT01468467|Allogeneic Transplantation
307950|NCT01468467|FMS-like tyrosine kinase (FLT3)
307951|NCT01468467|FMS-like tyrosine kinase (FLT3) Inhibitor
307952|NCT01468467|Kinase
307953|NCT01468467|Kinase Inhibitor
307954|NCT01468467|Pharmacokinetics
307955|NCT01468467|ASP2689
307956|NCT01468467|quizartinib
307957|NCT01468454|Congenital Hyperinsulinism (CHI)
307958|NCT01468454|hyperinsulinism
307959|NCT01468454|Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
307960|NCT01468454|CHI
307961|NCT01468454|PHHI
307962|NCT01468454|Pancreatectomy
307963|NCT01468454|18F-DOPA
307964|NCT01468454|PET/CT scan
307965|NCT01468441|ovarian stimulation
307966|NCT01468441|GnRH agonist
307967|NCT01468441|GnRH antagonist
307968|NCT01468441|hCG microdose
307969|NCT01468441|ICSI
307970|NCT01468415|Methylprednisolone
307971|NCT01468415|trans sacral block
307972|NCT01468415|phenol
307973|NCT01468402|Leiomyoma
307974|NCT01468402|uterine artery embolization
307975|NCT01468402|magnetic resonance imaging
307976|NCT01468389|Gastric Cancer
307977|NCT01468389|capecitabine
307978|NCT01468389|maintenance treatment
307979|NCT01468376|impaired glucose tolerance
307980|NCT01468376|pre-diabetes
307981|NCT01468363|Dry weight
307982|NCT01468363|Body composition monitor
307983|NCT01468363|Hemodialysis
307984|NCT01468363|Zonguldak
307985|NCT01468337|Central Serous Chorioretinopathy
307986|NCT01468337|Interferon-Gamma (IFN-Gamma)
307987|NCT01468337|Jakstat
307988|NCT01468337|Retinal Eye Disease
307989|NCT01468337|Macular Eye Disease
307990|NCT01468337|CSC
307991|NCT01468324|Brain
307992|NCT01468324|Angiogenesis
307993|NCT01468324|Radiotherapy
307994|NCT01468324|Malignant
307995|NCT01468324|Tumor
307996|NCT01468324|Glioma
307997|NCT01468324|Glioblastoma Multiforme
307998|NCT01468324|Brain Tumor
307999|NCT01468311|Immunotherapy
308000|NCT01468311|Resistant Hodgkins Lymphoma
308001|NCT01468311|Auto Stem Cell Transplant
308002|NCT01468311|Combination Chemo and Radiolabeled Monoclonal Antibody
308003|NCT01468311|Hodgkin Lymphoma
308004|NCT01468298|back pain
308005|NCT01468298|physical therapy
308006|NCT01468298|spine
308007|NCT01468298|rehabilitation
308008|NCT01468298|exercise
308009|NCT01468285|interventional,placebo controlled
308010|NCT01468272|asthma children NEXT DPI LABA ICS inhalation
308011|NCT01468246|Breast Cancer
308012|NCT01468246|Cohort
308013|NCT01468246|Young Women
308014|NCT01468246|Survivorship
308015|NCT01468246|Fertility
308016|NCT01468233|placebo controlled
308017|NCT01468233|double blind
308018|NCT01468233|adalimumab
308019|NCT01468233|TNF
308020|NCT01468233|psoriasis
308021|NCT01468233|HS
308022|NCT01468233|PIONEER II
308023|NCT01468233|hidradenitis suppurativa
308024|NCT01468233|acne inversa
308025|NCT01468233|boil
308026|NCT01468233|acne
308027|NCT01468220|tissue metabolism
308028|NCT01468220|skeletal muscle
308029|NCT01468220|adipose tissue
308030|NCT01468220|HIF
308031|NCT01468207|acne
308032|NCT01468207|psoriasis
308033|NCT01468207|hidradenitis suppurativa
308034|NCT01468207|TNF
308035|NCT01468207|HS
308036|NCT01468207|PIONEER I
308037|NCT01468207|acne inversa
308038|NCT01468207|boil
308039|NCT01468207|placebo controlled
308040|NCT01468207|Double blind
308041|NCT01468207|adalimumab
308042|NCT01468194|AMS
308043|NCT01468194|HAPE
308044|NCT01468194|high altitude
308045|NCT01468194|oxygen
308046|NCT01468194|saturation
308047|NCT01468194|mountain
308048|NCT01468194|climbing
308049|NCT01468194|breathing
308050|NCT01468181|Type 2 diabetes mellitus
308051|NCT01468181|Oral antihyperglycemic medications
308052|NCT01468181|Long-Term Safety
308053|NCT01468181|GLP 1
308054|NCT01468181|Glucagon like peptide 1
308055|NCT01468155|PVA
308056|NCT01468155|peri procedural bleeding complications
308057|NCT01468116|Type 2 diabetes
308058|NCT01468116|Gastric bypass surgery
308059|NCT01468116|Obesity
308060|NCT01468116|Mitochondrial function
308061|NCT01468103|intraocular pressure
308062|NCT01468103|Peripheral anterior synechiae
308063|NCT01468090|Inflammatory bowel disease
308064|NCT01468090|Crohn's disease
308065|NCT01468090|Ulcerative colitis
308066|NCT01468090|Disease course
308067|NCT01468090|Phenotype
308068|NCT01468090|Biological treatment
308069|NCT01468064|Central Nervous System Diseases
308070|NCT01468064|Stroke
308071|NCT01468064|Infarction, Middle Cerebral Artery
308072|NCT01468064|Cerebral Infarction
308073|NCT01468064|Cerebrovascular Accident
308074|NCT01468064|Stem Cell Transplantation
308075|NCT01468064|Mesenchymal Stem Cell Transplantation
308076|NCT01468064|Bone marrow stromal cells
308077|NCT01468064|Mesenchymal Stem Cells
308078|NCT01468064|Endothelial progenitor cells
308079|NCT01468064|Adult Stem Cells
308080|NCT01468064|Cell Therapy
308081|NCT01468051|predialysed
308082|NCT01468051|chronic
308083|NCT01468051|renal failure patients
308084|NCT01468025|NSAIDs
308085|NCT01468025|Theramine
308086|NCT01468025|naproxen
308087|NCT01468025|Low back pain
308088|NCT01468025|amino acids
308089|NCT01468025|CRP
308090|NCT01468025|Medical Food
308091|NCT01468012|cocaine dependence
308092|NCT01468012|levodopa
308093|NCT01468012|carbidopa
308094|NCT01468012|entacapone
308095|NCT01467999|cannabis dependence
308096|NCT01467999|marijuana dependence
308097|NCT01467999|guanfacine
308098|NCT01467986|neuroblastoma
308099|NCT01467986|molecular targeted therapy
308100|NCT01467986|protein kinase inhibitor
308101|NCT01467986|mTOR Inhibitor
308102|NCT01467986|cytostatic topoisomerase-I-inhibitor
308103|NCT01467986|temozolomide
308104|NCT01467986|irinotecan
308105|NCT01467986|dasatinib
308106|NCT01467986|rapamycin
308107|NCT01467973|Heart Failure
308108|NCT01467973|Heart Failure, Diastolic
308109|NCT01467973|Heart Failure, Systolic
308110|NCT01467973|Middle-East
308111|NCT01467908|Diagnosed vegetative state after stroke or traumatic brain injury
308112|NCT01467869|abnormal semen
308113|NCT01467869|assisted conception
308114|NCT01467856|Tetraplegia
308115|NCT01467843|Cognitive Behavioral Therapy
308116|NCT01467843|Mindfulness Based Stress Reduction
308117|NCT01467830|absorbable sutures efficacy
308118|NCT01467830|reducing Adverse effect to be caused from surgery
308119|NCT01467830|Inguinal Hernia repair with mesh
308120|NCT01467817|body mass
308121|NCT01467817|abdominal fat
308122|NCT01467817|whole body lean mass
308123|NCT01467817|insulin resistance
308124|NCT01467817|caloric intake
308125|NCT01467817|expenditure
308126|NCT01467817|endurance
308127|NCT01467817|Strength
308128|NCT01467817|TC:HDL ratio
308129|NCT01467817|LDL:HDL ratio
308130|NCT01467817|area under the TG response curve
308131|NCT01467817|feeding challenge
308132|NCT01467817|fasting and post-prandial whole body fat oxidation
308133|NCT01467817|HRQoL
308134|NCT01467804|efficacy,
308135|NCT01467804|safety,
308136|NCT01467804|JWXYJN
308137|NCT01467791|ambrisentan
308138|NCT01467791|Bosentan
308139|NCT01467791|Iloprost
308140|NCT01467778|skin
308141|NCT01467752|reconstruction
308142|NCT01467752|metacarpophalangeal joint
308143|NCT01467752|bone graft
308144|NCT01467752|MCP joint
308145|NCT01467726|Alzheimer's disease
308146|NCT01467726|Elderly
308147|NCT01467713|Drug Therapy
308148|NCT01467700|Drug Therapy
308149|NCT01467674|Diabetes mellitus
308150|NCT01467674|Chronic periodontitis
308151|NCT01467674|Malondialdehyde
308152|NCT01467674|Glutathione peroxidase
308153|NCT01467674|Paraoxonase
308154|NCT01467648|Infection
308155|NCT01467648|Doripenem
308156|NCT01467648|Ventilator-Associated Pneumonia
308157|NCT01467648|pharmacokinetic
308158|NCT01467648|pharmacodynamic
308159|NCT01467635|Endobronchial ultrasound
308160|NCT01467635|Transbronchial needle aspiration
308161|NCT01467635|Transbronchial biopsy forceps
308162|NCT01467635|Mediastinal lymphadenopathy
308163|NCT01467635|Hilar lymphadenopathy
308164|NCT01467622|chest tube drainage
308165|NCT01467622|pulmonary air leak
308166|NCT01467622|lung resection
308167|NCT01467609|Pillcam colon capsule endoscopy
308168|NCT01467609|conventional colonoscopy
308169|NCT01467609|ulcerative colitis
308170|NCT01467609|endoscopic manifestation
308171|NCT01467609|colonoscopy
308172|NCT01467596|Ultrasound
308173|NCT01467596|Brachial block
308174|NCT01467596|Levobupivacaine
308175|NCT01467596|Minimum
308176|NCT01467596|Volume
308177|NCT01467596|Minimum volume of Levobupivacaine 0,5%
308178|NCT01467583|Fondaparinux
308179|NCT01467583|Renal Failure
308180|NCT01467583|Critically Ill
308181|NCT01467570|diarrhea
308182|NCT01467557|adverse events
308183|NCT01467544|Tai Chi
308184|NCT01467531|HIV, GSK1265744, GSK1349572, dolutegravir, rilpivirine, drug interaction, pharmacokinetics
308185|NCT01467518|methadone
308186|NCT01467518|Opiate-dependent
308187|NCT01467492|VX-950, Incivek
308188|NCT01467466|renal
308189|NCT01467466|cardiovascular
308190|NCT01467466|kidney
308191|NCT01467466|heart
308192|NCT01467466|clinical trial
308193|NCT01467466|double-blind
308194|NCT01467466|multi-site trial
308195|NCT01467466|randomized
308196|NCT01467466|drug treatment
308197|NCT01467466|IV solutions
308198|NCT01467466|antioxidant
308199|NCT01467440|Glaucoma and Ocular Hypertension
308200|NCT01467388|patients with glaucoma or ocular hypertension
308201|NCT01467362|xerosis
308202|NCT01467362|dry skin
308203|NCT01467362|dermatitis
308204|NCT01467362|pruritus
308205|NCT01467362|eczema
308206|NCT01467362|emollient
308207|NCT01467362|corticosteroid
308208|NCT01467349|Raltegravir
308209|NCT01467349|efficacy
308210|NCT01467349|safety
308211|NCT01467349|raltegravir-containing regimens
308212|NCT01467349|HIV urban clinic setting
308213|NCT01467310|GSK1120212
308214|NCT01467310|TNBC
308215|NCT01467310|Triple Negative Breast Cancer
308216|NCT01467310|Surgical Resection
308217|NCT01467297|Chronic bronchitis
308218|NCT01467297|exacerbations
308219|NCT01467297|treatment
308220|NCT01467297|ceftidoren
308221|NCT01467297|levofloxacin
308222|NCT01467297|inflammation
308223|NCT01467284|Obesity
308224|NCT01467284|Workplace
308225|NCT01467284|Intervention
308226|NCT01467284|Diet
308227|NCT01467284|Exercise
308228|NCT01467245|Thoracoscopy
308229|NCT01467245|congenital diaphragmatic hernia
308230|NCT01467245|oesophageal atresia
308231|NCT01467245|hypercapnia
308232|NCT01467245|acidosis
308233|NCT01467245|cerebral oxygenation
308234|NCT01467245|neonates
308235|NCT01467219|early
308236|NCT01467219|high risk
308237|NCT01467206|Stroke
308238|NCT01467206|Physiotherapy
308239|NCT01467206|Motor training
308240|NCT01467206|Rehabilitation
308241|NCT01467206|Randomized Controlled Trial
308242|NCT01467180|septeX
308243|NCT01467180|CVVH
308244|NCT01467180|CVHD
308245|NCT01467180|myoglobin
308246|NCT01467167|Anesthesia
308247|NCT01467167|Smart Pilot View
308248|NCT01467167|Pain control
308249|NCT01467167|Recovery
308250|NCT01467128|Elderly
308251|NCT01467128|Hospital
308252|NCT01467128|Adverse Drug
308253|NCT01467128|Pharmacist
308254|NCT01467128|Prevention
308255|NCT01467115|loco regionally advanced
308256|NCT01467115|head and neck cancer
308257|NCT01467115|chemotherapy
308258|NCT01467115|radiation
308259|NCT01467102|chronic post surgical pain
308260|NCT01467102|Pain
308261|NCT01467102|Risk factors of chronic post surgical pain
308262|NCT01467102|predictive risk factors
308263|NCT01467102|chronic post-surgical pain (CPSP)
308264|NCT01467102|international level
308265|NCT01467102|epidemiology of CPSP
308266|NCT01467102|Europe
308267|NCT01467102|observational
308268|NCT01467102|prospective
308269|NCT01467089|Schizophrenia
308270|NCT01467089|Extrapyramidal symptoms
308271|NCT01467089|Tardive dyskinesia
308272|NCT01467089|Two Way Video Assessment
308273|NCT01467063|Type I Diabetes
308274|NCT01467063|Insulin Resistance
308275|NCT01467063|Glutamine
308276|NCT01467063|Amino Acids
308277|NCT01467063|Glucagon like peptide 1
308278|NCT01467063|Glutathione
308279|NCT01467063|Citrulline
308280|NCT01467063|Arginine
308281|NCT01467063|Nitric Oxide
308282|NCT01467050|Adverse drug event
308283|NCT01467050|Adverse drug reaction
308284|NCT01467050|Inappropriate prescribing
308285|NCT01467050|Elderly
308286|NCT01467050|Hospital-acquired
308287|NCT01467037|Rotavirus
308288|NCT01467037|Gastroenteritis
308289|NCT01467037|Vaccination
308290|NCT01467037|Pediatrics
308291|NCT01467024|HTLV
308292|NCT01467024|Confirmatory
308293|NCT01467024|Supplemental
308294|NCT01467024|Blot
308295|NCT01467024|HTLV-I
308296|NCT01467024|HTLV-II
308297|NCT01467011|Myfortic
308298|NCT01467011|Mycophenolic acid
308299|NCT01467011|Prograf
308300|NCT01467011|Tacrolimus
308301|NCT01467011|Liver transplantation
308302|NCT01466972|Advanced
308303|NCT01466972|Breast
308304|NCT01466972|Cancer
308305|NCT01466972|Hormone Resistance
308306|NCT01466972|Pazopanib
308307|NCT01466972|anastrozole
308308|NCT01466972|arimidex
308309|NCT01466972|letrozole
308310|NCT01466972|femara
308311|NCT01466959|hemodialysis
308312|NCT01466959|dialysate
308313|NCT01466959|acetate based dialysate
308314|NCT01466959|citrasate dialysate
308315|NCT01466959|heparin anticoagulation
308316|NCT01466959|hemodynamic stability
308317|NCT01466946|lung cancer
308318|NCT01466946|Hispanic/Latino patients
308319|NCT01466946|interviews
308320|NCT01466946|11-109
308321|NCT01466933|parenting intervention
308322|NCT01466933|child development
308323|NCT01466933|low and middle income countries
308324|NCT01466920|Total knee arthroplasty
308325|NCT01466907|complication
308326|NCT01466907|depression
308327|NCT01466907|follow-up
308328|NCT01466907|intervention
308329|NCT01466907|nurse-led
308330|NCT01466907|outcome
308331|NCT01466907|secondary prevention
308332|NCT01466907|stroke
308333|NCT01466894|Nonalcoholic fatty liver disease
308334|NCT01466894|NAFLD
308335|NCT01466894|Fatty liver
308336|NCT01466894|NASH
308337|NCT01466868|Diffuse Large B cell Lymphoma
308338|NCT01466868|AKT
308339|NCT01466868|MK 2206
308340|NCT01466868|objective response rate
308341|NCT01466868|progression free survival
308342|NCT01466868|overall survival
308343|NCT01466868|safety
308344|NCT01466855|Retinoblastoma
308345|NCT01466829|sternotomy
308346|NCT01466829|parathyroid hormone
308347|NCT01466829|bone healing
308348|NCT01466816|Lipid metabolism
308349|NCT01466803|Buprenorphine
308350|NCT01466803|Vorikonazole
308351|NCT01466803|Interactions
308352|NCT01466803|Pharmacokinetics
308353|NCT01466803|Pharmacodynamics
308354|NCT01466803|Voriconazole
308355|NCT01466790|Hepatitis C
308356|NCT01466790|TMC435
308357|NCT01466790|PSI-7977
308358|NCT01466790|GS7977
308359|NCT01466790|Ribavirin
308360|NCT01466790|HCV
308361|NCT01466790|Hep C
308362|NCT01466790|Genotype 1
308363|NCT01466777|Endometrium cancer
308364|NCT01466777|Robotic-assisted laparoscopy
308365|NCT01466777|Traditional laparoscopy
308366|NCT01466777|Laparoscopic surgery
308367|NCT01466777|Treatment
308368|NCT01466777|Operation time
308369|NCT01466777|Bleeding
308370|NCT01466777|Complications
308371|NCT01466777|Conversions
308372|NCT01466777|Pelvic lymph node
308373|NCT01466764|biomarkers
308374|NCT01466751|Computerized neurobehavioral intervention
308375|NCT01466738|Healthy volunteer
308376|NCT01466738|Rhinovirus
308377|NCT01466738|Cold virus
308378|NCT01466738|HRV-16
308379|NCT01466725|Lupus
308380|NCT01466725|Discoid Lupus
308381|NCT01466725|DLE
308382|NCT01466725|Cutaneous Lupus
308383|NCT01466686|Recurrent Glioblastoma Multiforme
308384|NCT01466686|Recurrent Anaplastic Astrocytoma
308385|NCT01466686|Surgery
308386|NCT01466686|Adjuvant Radiation
308387|NCT01466686|Adjuvant Temozolomide
308388|NCT01466673|Acne Vulgaris
308389|NCT01466673|Ethinyl estradiol
308390|NCT01466673|Norgestimate
308391|NCT01466673|Desogestrel
308392|NCT01466673|Tricilest
308393|NCT01466673|Oilezz
308394|NCT01466647|NSCLC
308395|NCT01466621|cardiac resynchronization therapy
308396|NCT01466621|heart failure
308397|NCT01466621|mortality
308398|NCT01466608|OATP1B1
308399|NCT01466608|Rosuvastatin
308400|NCT01466608|lipidomics
308401|NCT01466608|pharmacodynamics
308402|NCT01466582|HIV-1-infection
308403|NCT01466582|comorbidity
308404|NCT01466582|ageing
308405|NCT01466569|Advanced Solid Tumor
308406|NCT01466569|Gastric Cancer
308407|NCT01466569|Oncology
308408|NCT01466569|monoclonal Antibody
308409|NCT01466543|Vascular dementia
308410|NCT01466543|Subcortical vascular dementia
308411|NCT01466543|Phosphodiesterase 5
308412|NCT01466543|Udenafil
308413|NCT01466530|Full term pregnancy > 36 weeks
308414|NCT01466530|Cesarean delivery
308415|NCT01466530|General anesthesia
308416|NCT01466517|Relative Bioavailability Study
308417|NCT01466517|Ibuprofen
308418|NCT01466517|Alivium
308419|NCT01466504|P63
308420|NCT01466504|Sorafenib
308421|NCT01466504|Regorafenib
308422|NCT01466504|rash
308423|NCT01466504|skin toxicity
308424|NCT01466504|RCC
308425|NCT01466504|HCC
308426|NCT01466504|colorectal carcinoma
308427|NCT01466491|Pain during first-trimester surgical abortion
308428|NCT01466465|Vitamin D
308429|NCT01466465|SIT
308430|NCT01466465|Grass pollen
308431|NCT01466465|allergic rhinoconjunctivitis
308432|NCT01466439|rTMS
308433|NCT01466439|P50
308434|NCT01466439|inhibitory
308435|NCT01466439|facilitatory
308436|NCT01466439|physiological process
308437|NCT01466439|brain changes
308438|NCT01466426|Venous thromboembolic disease
308439|NCT01466426|Deep veinous thrombosis
308440|NCT01466426|Pulmonary embolism
308441|NCT01466413|Intrinsic Aging of Skin
308442|NCT01466400|health benefits of infant formula
308443|NCT01466387|Adults
308444|NCT01466387|international travel vaccination
308445|NCT01466387|Meningococcal disease
308446|NCT01466387|meningococcal meningitis
308447|NCT01466387|typhoid
308448|NCT01466387|yellow fever
308449|NCT01466387|rabies
308450|NCT01466387|Japanese encephalitis
308451|NCT01466361|Nicotine
308452|NCT01466361|Nicotine craving
308453|NCT01466348|Paracetomol
308454|NCT01466348|Caffeine
308455|NCT01466348|Common cold
308456|NCT01466322|Healthy volunteers
308457|NCT01466322|GSK2018682
308458|NCT01466322|Pharmacokinetics
308459|NCT01466322|Relapsing Remitting Multiple Sclerosis
308460|NCT01466322|Pharmacodynamics
308461|NCT01466309|AHI
308462|NCT01466309|ESS
308463|NCT01466309|VAS
308464|NCT01466309|FOSQ
308465|NCT01466309|SF-36
308466|NCT01466296|CERBRAL PALSY
308467|NCT01466296|Poststroke/CVA Paresis
308468|NCT01466296|REHABILITATION
308469|NCT01466296|WALKING
308470|NCT01466296|PERUTURBATION
308471|NCT01466283|childhood rhabdomyosarcoma
308472|NCT01466270|fatigue
308473|NCT01466270|sleep disorders
308474|NCT01466270|depression
308475|NCT01466270|anxiety disorder
308476|NCT01466270|cognitive/functional effects
308477|NCT01466270|breast cancer
308478|NCT01466270|cancer survivor
308479|NCT01466257|metastatic squamous neck cancer with occult primary squamous cell carcinoma
308480|NCT01466257|recurrent metastatic squamous neck cancer with occult primary
308481|NCT01466257|recurrent squamous cell carcinoma of the hypopharynx
308482|NCT01466257|recurrent squamous cell carcinoma of the larynx
308483|NCT01466257|recurrent squamous cell carcinoma of the lip and oral cavity
308484|NCT01466257|recurrent squamous cell carcinoma of the oropharynx
308485|NCT01466257|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
308486|NCT01466257|stage III squamous cell carcinoma of the hypopharynx
308487|NCT01466257|stage III squamous cell carcinoma of the larynx
308488|NCT01466257|stage III squamous cell carcinoma of the lip and oral cavity
308489|NCT01466257|stage III squamous cell carcinoma of the oropharynx
308490|NCT01466257|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
308491|NCT01466257|stage IV squamous cell carcinoma of the hypopharynx
308492|NCT01466257|stage IVA squamous cell carcinoma of the larynx
308493|NCT01466257|stage IVA squamous cell carcinoma of the lip and oral cavity
308494|NCT01466257|stage IVA squamous cell carcinoma of the oropharynx
308495|NCT01466257|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
308496|NCT01466257|stage IVB squamous cell carcinoma of the larynx
308497|NCT01466257|stage IVB squamous cell carcinoma of the lip and oral cavity
308498|NCT01466257|stage IVB squamous cell carcinoma of the oropharynx
308499|NCT01466257|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
308500|NCT01466257|stage IVC squamous cell carcinoma of the larynx
308501|NCT01466257|stage IVC squamous cell carcinoma of the lip and oral cavity
308502|NCT01466257|stage IVC squamous cell carcinoma of the oropharynx
308503|NCT01466257|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
308504|NCT01466257|untreated metastatic squamous neck cancer with occult primary
308505|NCT01466244|metastatic squamous neck cancer with occult primary squamous cell carcinoma
308506|NCT01466244|recurrent metastatic squamous neck cancer with occult primary
308507|NCT01466244|recurrent squamous cell carcinoma of the hypopharynx
308508|NCT01466244|recurrent squamous cell carcinoma of the larynx
308509|NCT01466244|recurrent squamous cell carcinoma of the lip and oral cavity
308510|NCT01466244|recurrent squamous cell carcinoma of the oropharynx
308511|NCT01466244|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
308512|NCT01466244|stage III squamous cell carcinoma of the hypopharynx
308513|NCT01466244|stage III squamous cell carcinoma of the larynx
308514|NCT01466244|stage III squamous cell carcinoma of the lip and oral cavity
308515|NCT01466244|stage III squamous cell carcinoma of the oropharynx
308516|NCT01466244|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
308517|NCT01466244|stage IVA squamous cell carcinoma of the larynx
308518|NCT01466244|stage IVA squamous cell carcinoma of the lip and oral cavity
308519|NCT01466244|stage IVA squamous cell carcinoma of the oropharynx
308520|NCT01466244|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
308521|NCT01466244|stage IVB squamous cell carcinoma of the larynx
308522|NCT01466244|stage IVB squamous cell carcinoma of the lip and oral cavity
308523|NCT01466244|stage IVB squamous cell carcinoma of the oropharynx
308524|NCT01466244|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
308525|NCT01466244|stage IVC squamous cell carcinoma of the larynx
308526|NCT01466244|stage IVC squamous cell carcinoma of the lip and oral cavity
308527|NCT01466244|stage IVC squamous cell carcinoma of the oropharynx
308528|NCT01466244|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
308529|NCT01466244|untreated metastatic squamous neck cancer with occult primary
308530|NCT01466231|refractory germ cell cancer
308531|NCT01466231|everolimus
308532|NCT01466218|pulmonary function abnormalities
308533|NCT01466218|pulmonary disease
308534|NCT01466218|cardiac disease
308535|NCT01466218|cardiopulmonary disease
308536|NCT01466218|obstructive sleep apnea
308537|NCT01466218|OSA
308538|NCT01466218|cardiovascular disease
308539|NCT01466218|CVD
308540|NCT01466218|particulate matter
308541|NCT01466205|schizotypal personality disorder
308542|NCT01466205|cognitive impairment
308543|NCT01466205|working memory
308544|NCT01466192|Genotype 2
308545|NCT01466179|B-ALL
308546|NCT01466179|relapsed ALL
308547|NCT01466179|refractory ALL
308548|NCT01466179|adult ALL
308549|NCT01466179|Leukemia
308550|NCT01466179|Leukemia, Lymphoid
308551|NCT01466179|precursor cell lymphoblastic leukemia-lymphoma
308552|NCT01466179|Lymphatic diseases
308553|NCT01466179|Lymphoproliferative disorders
308554|NCT01466179|bispecific antibody
308555|NCT01466179|anti-CD19
308556|NCT01466179|Immunotherapeutic treatment
308557|NCT01466179|immunoproliferative disorders
308558|NCT01466153|Chronic lymphocytic leukemia; leukemia; B-Cell malignancy; anti-CD19; monoclonal antibody; CLL; Refractory; Relapse; Non-Hodgkin's Lymphoma
308559|NCT01466140|Patient Satisfaction
308560|NCT01466140|Request for help
308561|NCT01466140|General practice
308562|NCT01466127|Effect of oxytocin on learning
308563|NCT01466114|multiple sclerosis
308564|NCT01466114|MS
308565|NCT01466114|relapsing remitting multiple sclerosis
308566|NCT01466114|RRMS
308567|NCT01466114|secondary progressive multiple sclerosis
308568|NCT01466114|SPMS
308569|NCT01466114|primary progressive multiple sclerosis
308570|NCT01466114|estrogen
308571|NCT01466114|estriol
308572|NCT01466101|Hysterectomy
308573|NCT01466101|Pain
308574|NCT01466101|Pregabalin
308575|NCT01466088|Alzheimer's Disease
308576|NCT01466088|AD
308577|NCT01466088|Dementia
308578|NCT01466062|Immunocompromised medical conditions
308579|NCT01466062|Respiratory Syncytial Virus Infection
308580|NCT01466062|Infant
308581|NCT01466062|Newborn
308582|NCT01466062|Young children
308583|NCT01466049|Ovarian Cancer
308584|NCT01466049|Adnexal Mass
308585|NCT01466049|Pelvic Mass
308586|NCT01466036|metastatic
308587|NCT01466023|thyroid metabolism during pregnancy
308588|NCT01466023|impact on neonate
308589|NCT01466010|osteoma, osteoid
308590|NCT01466010|surgical procedures, operative
308591|NCT01466010|bone neoplasms
308592|NCT01465997|Lacosamide
308593|NCT01465984|Paracetamol
308594|NCT01465984|Morphine sulfates
308595|NCT01465984|Acute pain
308596|NCT01465971|high
308597|NCT01465971|altitude
308598|NCT01465971|acute
308599|NCT01465971|mountain
308600|NCT01465971|sickness
308601|NCT01465971|sleep
308602|NCT01465971|disorder
308603|NCT01465971|periodic
308604|NCT01465971|breathing
308605|NCT01465971|hyperventilation
308606|NCT01465971|apnea
308607|NCT01465945|TEM for rectal lesions
308608|NCT01465945|Sutured defect
308609|NCT01465945|Unsutured defect
308610|NCT01465932|Nursing staff
308611|NCT01465932|Physical Therapy (Specialty)
308612|NCT01465919|depression
308613|NCT01465919|interferon
308614|NCT01465919|chronic hepatitis C
308615|NCT01465919|mirtazapine
308616|NCT01465906|COPD
308617|NCT01465893|vitamin d
308618|NCT01465880|Smoking research study
308619|NCT01465867|Selenium
308620|NCT01465867|Pregnancy
308621|NCT01465867|Auto-immune thyroiditis
308622|NCT01465867|Post-partum thyroiditis
308623|NCT01465867|Miscarriage
308624|NCT01465867|Pre-eclampsia
308625|NCT01465867|Implantation and Pregnancy rate
308626|NCT01465867|Infertility
308627|NCT01465854|lung cancer
308628|NCT01465854|smoking
308629|NCT01465854|molecular epidemiology
308630|NCT01465854|genetic polymorphism
308631|NCT01465854|risk factors
308632|NCT01465854|never smokers
308633|NCT01465854|histologically/cytologically confirmed
308634|NCT01465841|intracranial aneurysms
308635|NCT01465841|Peripheral aneurysms
308636|NCT01465841|acute treatment
308637|NCT01465841|PC 400 System
308638|NCT01465841|packing density
308639|NCT01465828|antiplatelet effect
308640|NCT01465828|prasugrel
308641|NCT01465828|clopidogrel
308642|NCT01465828|ACS
308643|NCT01465802|non-small cell lung cancer
308644|NCT01465802|advanced
308645|NCT01465802|previously treated
308646|NCT01465776|SCC of the oral cavity
308647|NCT01465776|black raspberries
308648|NCT01465763|tofacitinib
308649|NCT01465763|CP-690
308650|NCT01465763|550
308651|NCT01465763|Moderate to severe ulcerative colitis
308652|NCT01465763|phase 3 clinical trial
308653|NCT01465763|Mayo score
308654|NCT01465737|epidemiology
308655|NCT01465737|uterine cancer
308656|NCT01465737|Taiwan
308657|NCT01465724|Insulin resistance
308658|NCT01465724|Insulin sensitivity
308659|NCT01465724|HOMA-IR
308660|NCT01465724|blood pressure
308661|NCT01465724|Renal denervation
308662|NCT01465724|renal sympathetic denervation
308663|NCT01465724|renal ablation
308664|NCT01465711|Peritonitis
308665|NCT01465711|Sepsis
308666|NCT01465711|General Surgery
308667|NCT01465711|Intensive Care Units
308668|NCT01465711|Sensitivity and Specificity
308669|NCT01465698|exercise
308670|NCT01465698|counseling
308671|NCT01465698|movement control
308672|NCT01465698|fear avoidance
308673|NCT01465685|MDMA
308674|NCT01465685|pharmacokinetics
308675|NCT01465685|pharmacodynamics
308676|NCT01465685|emotions
308677|NCT01465685|Mechanism of action of MDMA
308678|NCT01465685|Interaction study
308679|NCT01465685|Effect of MDMA and methylphenidate on emotions
308680|NCT01465672|copeptin
308681|NCT01465672|SIADH
308682|NCT01465672|Diabetes insipidus
308683|NCT01465672|transphenoidal pituitary adenoma resection
308684|NCT01465672|pituitary adenoma
308685|NCT01465672|tumors close to pituitary gland
308686|NCT01465672|tumors close to hypothalamus
308687|NCT01465646|levothyroxine
308688|NCT01465646|bioavailability
308689|NCT01465633|bioavailability
308690|NCT01465633|levothyroxine
308691|NCT01465620|Peripheral Nervous System Diseases
308692|NCT01465620|Diabetic Polyneuropathy
308693|NCT01465620|Metabolic Syndrome X
308694|NCT01465607|Condom use
308695|NCT01465594|Pain Measurement
308696|NCT01465581|incontinence
308697|NCT01465581|dysfunctional voiding
308698|NCT01465581|neurogenic bladder disturbance
308699|NCT01465581|filum terminale
308700|NCT01465581|spinal cord tethering
308701|NCT01465581|conus
308702|NCT01465568|osteoporosis
308703|NCT01465568|denosumab
308704|NCT01465568|RANKL
308705|NCT01465568|glucocorticoids
308706|NCT01465555|Clinical Alert
308707|NCT01465555|Cognitive Behavioral Intervention
308708|NCT01465555|Web-based
308709|NCT01465555|Substance Abuse Treatment
308710|NCT01465542|Acetaminophen Toxicity
308711|NCT01465542|Acetaminophen Overdose
308712|NCT01465542|N-acetylcysteine
308713|NCT01465542|Liver Toxicity
308714|NCT01465503|bleeding
308715|NCT01465503|percutaneous coronary intervention
308716|NCT01465503|heparin
308717|NCT01465503|bivalirudin
308718|NCT01465490|Monitoring
308719|NCT01465490|Feedback
308720|NCT01465490|Substance Abuse Treatment
308721|NCT01465477|Fibromyalgia
308722|NCT01465477|Influenza vaccination
308723|NCT01465451|colorectal cancer
308724|NCT01465451|curative resection
308725|NCT01465451|intra-operative chemotherapy
308726|NCT01465451|5-fluorouracil
308727|NCT01465451|chemotherapy
308728|NCT01465425|extracolonic findings
308729|NCT01465425|ECFs
308730|NCT01465425|CT colonography
308731|NCT01465425|computed tomography colonography
308732|NCT01465425|National CT Colonography Trial
308733|NCT01465425|ACRIN 6664
308734|NCT01465412|Parkinson disease
308735|NCT01465373|In-Vitro Fertilization
308736|NCT01465373|Donor Egg IVF
308737|NCT01465360|Alzheimer's disease
308738|NCT01465360|AD
308739|NCT01465360|Non AD dementia
308740|NCT01465360|Mild Cognitive Impairment
308741|NCT01465360|MCI
308742|NCT01465360|Vascular dementia
308743|NCT01465360|Fronto-temporal dementia
308744|NCT01465360|Primary progressive aphasia
308745|NCT01465360|Parkinson's Disease dementia
308746|NCT01465360|Mixed dementia
308747|NCT01465360|Blood signature
308748|NCT01465360|Diagnosis
308749|NCT01465360|AclarusDx
308750|NCT01465360|Alzheimer's Disease and other non-AD dementia
308751|NCT01465360|Exonhit
308752|NCT01465347|Primary brain tumor
308753|NCT01465347|Glioblastoma
308754|NCT01465347|Glioma
308755|NCT01465347|GBM
308756|NCT01465347|Radiation therapy
308757|NCT01465334|17p Deletion CLL
308758|NCT01465308|head and neck cancer
308759|NCT01465308|radiotherapy induced xerostomia
308760|NCT01465308|radiotherapy induced oral mucositis
308761|NCT01465308|RCT
308762|NCT01465308|symptom management
308763|NCT01465295|Scoliosis
308764|NCT01465295|Adolescent Idiopathic Scoliosis (AIS)
308765|NCT01465295|Scoliosis treatment
308766|NCT01465295|Fusionless spinal surgery
308767|NCT01465295|Vertebral stapling
308768|NCT01465295|Spinal stapling
308769|NCT01465295|Non-fusion
308770|NCT01465295|Spinal curvature
308771|NCT01465295|Curvature of the spine
308772|NCT01465295|Spinal bracing alternative
308773|NCT01465295|HemiBridge
308774|NCT01465295|SpineForm
308775|NCT01465295|Dr. Eric Wall
308776|NCT01465295|Dr. George Thompson
308777|NCT01465295|Spinal clip
308778|NCT01465295|Cincinnati Children's Hospital Medical Center
308779|NCT01465295|University Hospitals Case Medical Center, Rainbow Babies
308780|NCT01465282|psoriasis vulgaris
308781|NCT01465282|topical ointment
308782|NCT01465269|TBI
308783|NCT01465269|Social Competence
308784|NCT01465256|Aspirin
308785|NCT01465256|Colon polypectomy
308786|NCT01465256|Bleeding
308787|NCT01465243|Efficacy
308788|NCT01465243|Safety
308789|NCT01465243|EGFR-TKI
308790|NCT01465243|phase IV
308791|NCT01465243|NSCLC
308792|NCT01465243|Dose escalation
308793|NCT01465230|chronic lymphocytic leukemia
308794|NCT01465230|maintenance therapy
308795|NCT01465217|medication adherence
308796|NCT01465217|African Americans
308797|NCT01465204|Behavior Change
308798|NCT01465204|Hygiene & Sanitation Marketing
308799|NCT01465191|cesarean
308800|NCT01465191|postoperative
308801|NCT01465191|morphine
308802|NCT01465191|genetics
308803|NCT01465191|opioid
308804|NCT01465178|hypovitaminosis D
308805|NCT01465178|vitamin D insufficiency
308806|NCT01465178|low vitamin D
308807|NCT01465165|Depression
308808|NCT01465165|Positron emission tomography
308809|NCT01465165|Magnetic resonance spectroscopy
308810|NCT01465165|glucose metabolism
308811|NCT01465165|ATP
308812|NCT01465165|phosphocreatine
308813|NCT01465113|Barrett's Esophagus
308814|NCT01465113|Vitamin D3
308815|NCT01465113|cholecalciferol
308816|NCT01465113|15-Prostaglandin Dehydrogenase Expression
308817|NCT01465113|metformin
308818|NCT01465100|phenylketonuria
308819|NCT01465100|hepatocyte
308820|NCT01465087|Multiple Sclerosis
308821|NCT01465087|Breath
308822|NCT01465087|Diagnosis
308823|NCT01465087|Discrimination MS/healthy subj. via exhaled breath samples
308824|NCT01465087|Discrimination MS/other neurological and autoimmune diseases
308825|NCT01465074|nicotine
308826|NCT01465074|memory
308827|NCT01465074|plasticity
308828|NCT01465074|TMS
308829|NCT01465074|Paired Associative Stimulation
308830|NCT01465061|Online social network
308831|NCT01465061|Psoriasis
308832|NCT01465061|Filipino
308833|NCT01465048|Malaria
308834|NCT01465048|Protozoan Infections
308835|NCT01465048|Parasitic Diseases
308836|NCT01465048|Malaria Challenge
308837|NCT01465022|Breastfeeding rates
308838|NCT01465022|Contraceptive continuation
308839|NCT01465022|Birth control pills
308840|NCT01465022|Lactation
308841|NCT01465009|Sore Throat
308842|NCT01464996|non-carious cervical lesions
308843|NCT01464996|bonded restorations
308844|NCT01464996|composites
308845|NCT01464996|adhesives
308846|NCT01464970|DIEP perfusion
308847|NCT01464970|Zone IV
308848|NCT01464970|Free Flap
308849|NCT01464970|Breast Cancer Reconstruction
308850|NCT01464970|Perfusion of Zone IV of DIEP flaps
308851|NCT01464957|skin cancer prevention
308852|NCT01464957|precaution adoption process model
308853|NCT01464957|semi-tailored newsletter
308854|NCT01464957|pediatric
308855|NCT01464957|behavioral intervention
308856|NCT01464944|Upper Respiratory Tract Infections
308857|NCT01464918|gastric cancer
308858|NCT01464918|colon cancer
308859|NCT01464918|endoscopic submucosal dissection
308860|NCT01464905|RRMS
308861|NCT01464892|Imagery rescripting
308862|NCT01464892|Imagery rescripting and reprocessing therapy
308863|NCT01464892|Skills Training in affective and interpersonal regulation
308864|NCT01464892|Post-traumatic Stress Disorder
308865|NCT01464892|Childhood abuse
308866|NCT01464892|Childhood sexual abuse
308867|NCT01464840|Pregnancy
308868|NCT01464840|Cesarean section
308869|NCT01464840|Antibiotic
308870|NCT01464827|Hepatitis C Genotype 1
308871|NCT01464827|Hepatitis C
308872|NCT01464827|Interferon-Free
308873|NCT01464827|HCV
308874|NCT01464827|Chronic Hepatitis C
308875|NCT01464814|probiotic
308876|NCT01464814|fish oil
308877|NCT01464814|digestion
308878|NCT01464814|viability
308879|NCT01464801|Non-alcoholic Fatty Liver Disease
308880|NCT01464801|Non-alcoholic Steatohepatitis
308881|NCT01464801|Resveratrol
308882|NCT01464801|Human study
308883|NCT01464788|stroke
308884|NCT01464788|Argatroban
308885|NCT01464788|thrombin-inhibition
308886|NCT01464788|thrombolysis
308887|NCT01464788|anticoagulation
308888|NCT01464775|Endometriosis
308889|NCT01464775|Laparoscopy
308890|NCT01464775|Narrow Band Imaging
308891|NCT01464762|Tuberculosis
308892|NCT01464762|TMC207TBC3001
308893|NCT01464762|TMC207
308894|NCT01464762|Early access
308895|NCT01464762|TB
308896|NCT01464762|Drug resistant
308897|NCT01464762|Multi drug-resistant
308898|NCT01464762|Extensively drug-resistant
308899|NCT01464749|multiple sclerosis
308900|NCT01464749|gait rehabilitation
308901|NCT01464736|aerobic exercise
308902|NCT01464736|noninvasive ventilation
308903|NCT01464736|functionality
308904|NCT01464697|hot flushes/hot flashes
308905|NCT01464697|night sweats
308906|NCT01464697|sleep problems
308907|NCT01464697|negative mood
308908|NCT01464697|anxiety
308909|NCT01464697|perimenopause
308910|NCT01464697|progesterone
308911|NCT01464697|vasomotor symptoms
308912|NCT01464697|premenopause
308913|NCT01464671|Coronary Artery Disease
308914|NCT01464671|Stable Angina
308915|NCT01464671|Percutaneous Coronary Intervention
308916|NCT01464658|panniculitis
308917|NCT01464658|panniculectomy
308918|NCT01464632|medial knee replacement
308919|NCT01464619|Parenting
308920|NCT01464619|Early Child Development
308921|NCT01464606|pleuropulmonary blastoma
308922|NCT01464606|pediatric
308923|NCT01464606|lung cysts
308924|NCT01464593|Colorectal Liver Metastasis
308925|NCT01464593|Colon Cancer
308926|NCT01464593|Liver Cancer
308927|NCT01464593|Liver Metastasis
308928|NCT01464593|Liver metastases
308929|NCT01464567|Weaning
308930|NCT01464567|Chronic Obstructive Pulmonary Disease
308931|NCT01464567|Spontaneous Breathing Trial
308932|NCT01464554|adolescents
308933|NCT01464554|alcohol
308934|NCT01464554|drugs
308935|NCT01464554|delinquency
308936|NCT01464554|intervention
308937|NCT01464541|Orbit
308938|NCT01464541|Fracture
308939|NCT01464541|measurement
308940|NCT01464541|CT
308941|NCT01464541|intraoperative
308942|NCT01464528|hysteroscopy
308943|NCT01464528|postoperative complications
308944|NCT01464528|adhesions
308945|NCT01464528|hyaluronic gel
308946|NCT01464528|prevention
308947|NCT01464515|Mild Cognitive Impairment, So Stated
308948|NCT01464515|Deep Transcranial Magnetic Stimulation
308949|NCT01464502|Heart failure
308950|NCT01464502|Cardiac resynchronisation therapy
308951|NCT01464502|Acute haemodynamic response
308952|NCT01464502|Responder
308953|NCT01464489|Intubation time
308954|NCT01464489|Atropine
308955|NCT01464489|Propofol anesthesia
308956|NCT01464463|Depression
308957|NCT01464463|Exercise
308958|NCT01464463|Psychoneuroimmunology
308959|NCT01464463|Cognitive Behavioral Therapy
308960|NCT01464463|CBASP
308961|NCT01464450|Pharmacokinetics
308962|NCT01464450|Bioavailability
308963|NCT01464450|Healthy Participants
308964|NCT01464437|diabetes
308965|NCT01464437|mellitus
308966|NCT01464437|metformin
308967|NCT01464424|Glaucoma
308968|NCT01464424|Ocular Hypertension
308969|NCT01464424|Open-Angle Glaucoma
308970|NCT01464424|Intraocular Pressure
308971|NCT01464411|chronic myelogenous leukemia
308972|NCT01464411|chronic phase
308973|NCT01464411|Phase II
308974|NCT01464411|dasatinib
308975|NCT01464398|Polycystic Ovary Syndrome
308976|NCT01464398|stress
308977|NCT01464398|mindfulness
308978|NCT01464398|meditation
308979|NCT01464398|health education
308980|NCT01464398|women
308981|NCT01464398|overweight
308982|NCT01464398|obesity
308983|NCT01464372|Urinary Incontinence, Urge
308984|NCT01464372|Peripheral Nerve Stimulation
308985|NCT01464359|umbilical cord blood transplant
308986|NCT01464346|diabetes
308987|NCT01464346|glucose sensor
308988|NCT01464346|CGM
308989|NCT01464333|Crohn's Disease
308990|NCT01464320|Safety
308991|NCT01464320|Type 2 diabetes
308992|NCT01464320|Kidney disease
308993|NCT01464294|CAD/CAM
308994|NCT01464294|crowns
308995|NCT01464294|onlays
308996|NCT01464294|composite block
308997|NCT01464294|milled restorations
308998|NCT01464281|nucleoside
308999|NCT01464281|peginterferon alfa-2a
309000|NCT01464268|Keratoconus
309001|NCT01464268|Corneal Ectasia
309002|NCT01464268|Collagen Crosslinking
309003|NCT01464268|Riboflavin
309004|NCT01464255|contact lenses
309005|NCT01464242|Cutaneous Leishmaniasis
309006|NCT01464242|pentoxifylline
309007|NCT01464242|immunomodulation
309008|NCT01464216|Functional Magnetic Resonance Imaging
309009|NCT01464216|Prostate cancer
309010|NCT01464216|FACBC PET
309011|NCT01464216|Hypoxia imaging
309012|NCT01464203|Computed tomographic coronary angiography
309013|NCT01464203|multi-slice CT
309014|NCT01464203|angina
309015|NCT01464203|cost-effectiveness
309016|NCT01464190|PA21
309017|NCT01464190|Phosphate Binder
309018|NCT01464177|malignant glioma
309019|NCT01464177|glioblastoma
309020|NCT01464177|radiotherapy
309021|NCT01464177|randomized
309022|NCT01464164|Diamond Blackfan anemia
309023|NCT01464164|DBA
309024|NCT01464164|Blackfan Diamond anemia
309025|NCT01464164|Congenital pure red cell aplasia
309026|NCT01464164|Aase-Smith II Syndrome
309027|NCT01464164|Aase Syndrome
309028|NCT01464164|Anemia, Congenital Pure Red Cell
309029|NCT01464164|Aplasia, Congenital Pure Red Cell
309030|NCT01464164|BDA
309031|NCT01464164|Congenital Hypoplastic Anemia
309032|NCT01464164|Erythrogenesis Imperfecta
309033|NCT01464164|Hypoplastic Congenital Anemia
309034|NCT01464164|Inherited Erythroblastopenia
309035|NCT01464164|pure red cell aplasia
309036|NCT01464164|bone marrow failure syndrome
309037|NCT01464151|IBD
309038|NCT01464151|colitis
309039|NCT01464151|dysplasia
309040|NCT01464151|colorectal cancer
309041|NCT01464138|Malaria
309042|NCT01464125|Malaria
309043|NCT01464125|Plasmodium falciparum
309044|NCT01464125|acute uncomplicated
309045|NCT01464112|Multiple myeloma that has relapsed or is progressive following prior therapy
309046|NCT01464112|Relapsed Multiple Myeloma
309047|NCT01464112|JNJ 26481585
309048|NCT01464112|VELCADE
309049|NCT01464112|Bortezomib
309050|NCT01464112|Dexamethasone
309051|NCT01464086|patients with Li Fraumeni syndrome
309052|NCT01464073|NIDDM
309053|NCT01464073|obesity
309054|NCT01464073|lifestyle intervention
309055|NCT01464073|physical exercise
309056|NCT01464073|diet
309057|NCT01464073|LIPOXmax
309058|NCT01464073|FATmax
309059|NCT01464073|fat oxydation rate
309060|NCT01464060|Helicobacter pylori
309061|NCT01464060|Quadruple therapy
309062|NCT01464060|Clarithromycin resistance
309063|NCT01464021|Study
309064|NCT01464021|prospective
309065|NCT01464021|Rheumatoid
309066|NCT01464021|Observational study
309067|NCT01464021|Arthritis
309068|NCT01464021|Adalimumab
309069|NCT01463995|severe neurological diseases
309070|NCT01463995|neurological intensive care unit
309071|NCT01463995|prediction
309072|NCT01463995|long-term outcome
309073|NCT01463995|biomarkers
309074|NCT01463995|prediction of long-term outcome
309075|NCT01463982|Advanced solid cancer
309076|NCT01463969|PCOS and PTX3 levels
309077|NCT01463956|Boceprevir
309078|NCT01463956|HCV infection
309079|NCT01463956|Antiviral therapy
309080|NCT01463956|Liver transplantation
309081|NCT01463930|Total Knee Replacement
309082|NCT01463930|Expectations
309083|NCT01463930|Audiovisual videodisc
309084|NCT01463917|Coronary Artery Bypass
309085|NCT01463917|Off-Pump
309086|NCT01463917|Saline Solution
309087|NCT01463917|Hypertonic
309088|NCT01463904|Morbid obesity
309089|NCT01463904|duodenal switch
309090|NCT01463904|diabetes
309091|NCT01463904|decrease in cardiac risk
309092|NCT01463904|remission of T2DM
309093|NCT01463891|Eribulin Mesylate
309094|NCT01463891|inoperable or recurrent breast cancer
309095|NCT01463878|glycemic control
309096|NCT01463878|glycemic variability
309097|NCT01463878|mean blood glucose level
309098|NCT01463852|vincristine
309099|NCT01463852|JNK
309100|NCT01463852|phosphorylation
309101|NCT01463852|cll
309102|NCT01463852|vinca alkaloid
309103|NCT01463852|apoptosis
309104|NCT01463839|sleep disorder
309105|NCT01463839|malocclusion
309106|NCT01463839|children
309107|NCT01463826|bruxism
309108|NCT01463826|children
309109|NCT01463826|oral breathing
309110|NCT01463826|dental caries
309111|NCT01463813|bone density conservation agents
309112|NCT01463813|cancer
309113|NCT01463813|cardiovascular disease
309114|NCT01463813|cholecalciferol
309115|NCT01463813|diabetes mellitus, type 2
309116|NCT01463813|dietary supplements
309117|NCT01463813|primary prevention
309118|NCT01463813|vitamin D
309119|NCT01463800|Heart Defects, congenital
309120|NCT01463787|Infertility
309121|NCT01463787|varicocelectomy
309122|NCT01463787|microsurgery
309123|NCT01463787|Chinese men
309124|NCT01463787|pregnancy rate
309125|NCT01463774|Healthy Volunteers
309126|NCT01463774|Bioequivalence
309127|NCT01463774|Canagliflozin (JNJ-28431754)
309128|NCT01463774|Metformin
309129|NCT01463761|High-level athlete
309130|NCT01463761|ANS activity
309131|NCT01463761|Overtraining
309132|NCT01463735|Cirrhotic patients
309133|NCT01463722|Respiratory distress syndrome
309134|NCT01463722|Lung maturity
309135|NCT01463722|lamellar body
309136|NCT01463709|basal cell carcinoma
309137|NCT01463709|Basal Cell Nevus Syndrome
309138|NCT01463709|Electric Field
309139|NCT01463709|Nanosecond pulse
309140|NCT01463670|LENALIDOMIDE (CC-5013)
309141|NCT01463670|BONE MARROW
309142|NCT01463670|11-107
309143|NCT01463657|Aging
309144|NCT01463644|Mepolizumab
309145|NCT01463644|COPD
309146|NCT01463644|eosinophilic bronchitis
309147|NCT01463644|exacerbation
309148|NCT01463644|anti-interleukin 5 (IL5)
309149|NCT01462799|PBL
309150|NCT01462799|patient education
309151|NCT01462799|coronary heart disease
309152|NCT01462799|empowerment
309153|NCT01462799|self-efficacy
309154|NCT01462799|self-care
309272|NCT01463215|Ambroxol
309273|NCT01463215|Type I Gaucher Disease
309155|NCT01462799|Focus on to determine the long term effectiveness of PBL in patient education by comparison of standardized homesent information in patients with CHD.
309156|NCT01462799|Further focus is on patients' self-care goals, beliefs, self-efficacy and empowerment to make lifestyle changes.
309157|NCT01463605|radiotherapy
309158|NCT01463605|targeted therapy
309159|NCT01463605|esophageal cancer
309160|NCT01463605|older
309161|NCT01463592|Renessans
309162|NCT01463592|HCV
309163|NCT01463579|Intensive Care Unit
309164|NCT01463579|Critical Illness
309165|NCT01463579|Rehabilitation
309166|NCT01463579|Exercise Programme
309167|NCT01463566|arthritis
309168|NCT01463553|primary spontaneous pneumothorax
309169|NCT01463553|VATS
309170|NCT01463553|pleurodesis
309171|NCT01463553|recurrence rate
309172|NCT01463540|Enteral nutrition
309173|NCT01463540|Gastrostomy, adverse effects
309174|NCT01463540|Gastrostomy, nursing
309175|NCT01463540|Endoscopy,gastrointestinal
309176|NCT01463540|Surgical wound infection
309177|NCT01463527|Hypoventilation during sedation
309178|NCT01463527|Hypoxia associated with hypoventilation
309179|NCT01463514|Pulmonary Hypertension,
309180|NCT01463514|NIRS,
309181|NCT01463514|Near-infrared spectroscopy,
309182|NCT01463514|cerebral tissue oxygenation,
309183|NCT01463514|cerebral blood flow
309184|NCT01463501|Esophageal cancer
309185|NCT01463501|Resectable
309186|NCT01463501|Neoadjuvant chemoradiotherapy
309187|NCT01463501|Adjuvant chemoradiotherapy
309188|NCT01463475|MSC
309189|NCT01463475|Allogeneic
309190|NCT01463475|Bone marrow cells
309191|NCT01463475|Healthy subject donors
309192|NCT01463475|Collection of MSC from bone marrow aspirate
309193|NCT01463475|Bronchiolitis obliterans syndrome (BOS)
309194|NCT01463449|Obesity
309195|NCT01463449|Soluble-CD163
309196|NCT01463449|Macrophage
309197|NCT01463449|Inflammation
309198|NCT01463436|endothelial function
309199|NCT01463436|postmenopausal
309200|NCT01463436|soy isoflavone supplementation
309201|NCT01463436|osteoporosis
309202|NCT01463384|Magnetic Resonance Imaging
309203|NCT01463384|Magnetic Resonance Spectroscopy
309204|NCT01463384|Neuroinflammation
309205|NCT01463384|Mild Cognitive Impairment
309206|NCT01463384|Alzheimer's Disease
309207|NCT01463384|Minocycline
309208|NCT01463371|Bronchiectasis
309209|NCT01463371|Oxidative stress markers
309210|NCT01463371|Airway inflammation
309211|NCT01463358|Syncope
309212|NCT01463358|Bifascicular block
309213|NCT01463358|Bradycardia pacing
309214|NCT01463345|Blood conservation
309215|NCT01463345|Transfusion
309216|NCT01463345|Hemoglobin trigger
309217|NCT01463345|Transfusion trigger
309218|NCT01463345|Cardiac surgery
309219|NCT01463345|Transfusion triggers post cardiac surgery
309220|NCT01463332|Propofol
309221|NCT01463332|Pain
309222|NCT01463332|Dexmedetomidine
309223|NCT01463319|colonoscopy
309224|NCT01463319|warm water method
309225|NCT01463319|hydrocolonoscopy
309226|NCT01463319|unsedated colonoscopy
309227|NCT01463306|safety
309228|NCT01463306|partial onset seizures
309229|NCT01463306|primary generalized tonic-clonic seizures
309230|NCT01463306|pregabalin
309231|NCT01463306|pediatric
309232|NCT01463306|adult
309233|NCT01463306|open-label
309234|NCT01463306|long term
309235|NCT01463293|constipation
309236|NCT01463293|probiotic
309237|NCT01463293|functional constipation
309238|NCT01463293|IBS-C
309239|NCT01463280|Platelets
309240|NCT01463280|Inhibition
309241|NCT01463280|Lidocaine
309242|NCT01463280|Thromboembolism
309243|NCT01463280|Prevention
309244|NCT01463280|Lidocaine effects on platelets
309245|NCT01463267|Heart Failure
309246|NCT01463254|Femplant
309247|NCT01463254|AE adverse event
309248|NCT01463254|AIDS acquired immunodeficiency syndrome
309249|NCT01463254|ALT (SGPT) alanine aminotransferase
309250|NCT01463254|ART antiretroviral therapy
309251|NCT01463254|AST (SGOT) aspartate aminotransferase
309252|NCT01463254|DCF data collection forms
309253|NCT01463254|DMC Data Monitoring Committee
309254|NCT01463254|FDA (U.S.) Food and Drug Administration
309255|NCT01463254|GCP Good Clinical Practice guidelines
309256|NCT01463254|HB sAg Hepatitis B surface antigen
309257|NCT01463254|ICH International Conference of Harmonisation
309258|NCT01463254|IND Investigational New Drug Application
309259|NCT01463254|IRB Institutional Review Board
309260|NCT01463254|IU international units
309261|NCT01463254|mg milligram(s)
309262|NCT01463254|mm3 cubic millimeter(s)
309263|NCT01463254|PCR polymerase chain reaction
309264|NCT01463254|SAE serious adverse event
309265|NCT01463254|µg microgram
309266|NCT01463254|ULN upper limit of the normal range
309267|NCT01463254|WB Western Blot
309268|NCT01463228|Healthy Volunteers
309269|NCT01463228|Bioequivalence
309270|NCT01463228|Canagliflozin (JNJ-28431754)
309271|NCT01463228|Metformin IR
309274|NCT01463202|Postpartum contraception
309275|NCT01463202|Contraceptive continuation
309276|NCT01463202|Breastfeeding
309277|NCT01463202|Postpartum depression
309278|NCT01463202|Progestins
309279|NCT01463189|arthritis
309280|NCT01463189|self management
309281|NCT01463176|Music Therapy
309282|NCT01463176|Child Psychology
309283|NCT01463176|Vaccination
309284|NCT01463163|Platelet reactivity
309285|NCT01463163|Ticagrelor
309286|NCT01463163|Prasugrel
309287|NCT01463150|Platelet reactivity
309288|NCT01463150|Clopidogrel
309289|NCT01463150|Prasugrel
309290|NCT01463137|social phobia
309291|NCT01463137|anxiety
309292|NCT01463124|School Nurse
309293|NCT01463124|Overweight
309294|NCT01463124|Obesity
309295|NCT01463124|Counseling
309296|NCT01463124|Intervention
309297|NCT01463124|Exercise
309298|NCT01463111|Bipolar
309299|NCT01463111|Manic depression
309300|NCT01463111|Mood stabilizer
309301|NCT01463111|Decision
309302|NCT01463111|Neuroeconomics
309303|NCT01463059|Rheumatoid Arthritis
309304|NCT01463059|Monoclonal Antibody
309305|NCT01463059|Interleukin-6
309306|NCT01463059|Olokizumab
309307|NCT01463059|CDP6038
309308|NCT01463046|leukemia
309309|NCT01463046|AML
309310|NCT01463046|AMS
309311|NCT01463046|panobinostat
309312|NCT01463046|cytarabine
309313|NCT01463046|daunorubicin
309314|NCT01463046|HDAC
309315|NCT01463033|Post-Traumatic epilepsy
309316|NCT01463033|Traumatic brain injury
309317|NCT01463033|Epilepsy prevention
309318|NCT01463033|Levetiracetam
309319|NCT01463020|Depression
309320|NCT01463020|Smartphone
309321|NCT01463020|Behavioural activation
309322|NCT01463020|Mindfulness
309323|NCT01463007|invasive ductal cancer
309324|NCT01463007|tubular breast cancer
309325|NCT01463007|breast cancer
309326|NCT01463007|colloid
309327|NCT01463007|ER positive
309328|NCT01463007|radiation
309329|NCT01462994|Patients with GIST treated with standard therapy harboring activating mutations of CKIT and PDGFRA
309330|NCT01462968|Heparin treatment during cardiac surgery
309331|NCT01462968|Heparin reversal after cardiac surgery
309332|NCT01462968|Thrombin generation
309333|NCT01462968|Endogenous Thrombin potential
309334|NCT01462942|COPD
309335|NCT01462942|Bronchitis
309336|NCT01462942|Chronic
309337|NCT01462942|Emphysema
309338|NCT01462929|COPD
309339|NCT01462929|antimuscarinic
309340|NCT01462916|honey
309341|NCT01462916|mucositis
309342|NCT01462916|bee products
309343|NCT01462903|TIL
309344|NCT01462903|NPC
309345|NCT01462903|hepatocellular carcinoma
309346|NCT01462903|immunotherapy
309347|NCT01462890|Ovarian Carcinoma
309348|NCT01462890|Bevacizumab
309349|NCT01462890|Paclitaxel
309350|NCT01462890|Carboplatin
309351|NCT01462877|Lipid Regulating Agents
309352|NCT01462877|Drug Therapy
309353|NCT01462877|cardiovascular diseases
309354|NCT01462877|hypertriglyceridemia
309355|NCT01462877|Hydroxymethylglutaryl-CoA Reductase Inhibitors
309356|NCT01462877|fenofibrate
309357|NCT01462877|Dyslipidemias
309358|NCT01462877|Combination
309359|NCT01462864|Polycystic Ovary Syndrome
309360|NCT01462864|Lifestyle
309361|NCT01462864|Structured Education
309362|NCT01462864|Walking Activity
309363|NCT01462864|Exercise
309364|NCT01462864|Overweight
309365|NCT01462864|Impaired Glucose Regulation
309366|NCT01462864|Diabetes Prevention
309367|NCT01462851|healthy volunteer
309368|NCT01462851|safety
309369|NCT01462851|pharmacokinetic
309370|NCT01462851|pharmacodynamic
309371|NCT01462838|advanced HPV-
309372|NCT01462838|p16INK4a-positive
309373|NCT01462838|cervical
309374|NCT01462838|vulvar,
309375|NCT01462838|vaginal
309376|NCT01462838|penile
309377|NCT01462838|anal
309378|NCT01462838|head
309379|NCT01462838|neck
309380|NCT01462825|Inflammation
309381|NCT01462825|cytokines
309382|NCT01462825|chemotaxis
309383|NCT01462825|tomatoes
309384|NCT01462825|cardiovascular disease
309385|NCT01462812|Migraine
309386|NCT01462812|Headache
309387|NCT01462812|Sumatriptan
309388|NCT01462773|malignant
309389|NCT01462773|melanoma
309390|NCT01462708|Parkinson Disease
309391|NCT01462708|Molecular NeuroImaging
309392|NCT01462682|focus group study
309393|NCT01462682|sleep deprivation
309394|NCT01462682|surgery
309395|NCT01462669|Ezogabine
309396|NCT01462669|Pharmacokinetics
309397|NCT01462669|Retigabine
309398|NCT01462656|anti-epileptic drug
309399|NCT01462656|ezogabine
309400|NCT01462656|AED polytherapy
309401|NCT01462656|epilepsy
309402|NCT01462656|AED monotherapy
309403|NCT01462656|retigabine
309404|NCT01462656|urinary retention
309405|NCT01462643|Psoriasis Plaque Test
309406|NCT01462643|topical
309407|NCT01462643|ointment
309408|NCT01462591|wave reflection
309409|NCT01462591|augmentation Index
309410|NCT01462591|heart rate variability
309411|NCT01462591|wasted left ventricular energy
309412|NCT01462578|Neoplasms benign, malignant and unspecified
309413|NCT01462578|Acute myeloid leukemia
309414|NCT01462578|AML
309415|NCT01462578|Myelodysplastic syndrome
309416|NCT01462578|MDS
309417|NCT01462565|flolan
309418|NCT01462565|pulmonary arterial hypertension
309419|NCT01462565|thermo stable formulation
309420|NCT01462565|epoprostenol sodium
309421|NCT01462565|modified sterile diluent
309422|NCT01462552|liver function testing
309423|NCT01462552|Breast cancer
309424|NCT01462552|lapatanib
309425|NCT01462513|Colon carcinoma
309426|NCT01462513|Rectum carcinoma
309427|NCT01462513|Liver metastases
309428|NCT01462500|Miltefosine
309429|NCT01462500|pharmacokinetics
309430|NCT01462500|cutaneous leishmaniasis
309431|NCT01462487|Pregnancy safety
309432|NCT01462487|zanamivir
309433|NCT01462487|influenza
309434|NCT01462474|Concurrent Chemoradiotherapy
309435|NCT01462461|Phantom Limb
309436|NCT01462461|Amputation, Traumatic
309437|NCT01462461|Electromyography
309438|NCT01462461|Visual Analog Pain Scale
309439|NCT01462448|Phantom Limb
309440|NCT01462448|Genetic Variation
309441|NCT01462448|DNA Sequence Analysis
309442|NCT01462448|Amputation, Traumatic
309443|NCT01462448|Single Nucleotide Polymorphism
309444|NCT01462448|Visual Analog Pain Scale
309445|NCT01462448|Brain-Derived Neurotrophic Factor
309446|NCT01462448|Inflammatory Antibody
309447|NCT01462448|Peripheral Nerve Damage
309448|NCT01462422|Postpartum hemorrhage
309449|NCT01462422|Prevention
309450|NCT01462422|Misoprostol
309451|NCT01462422|Developing countries
309452|NCT01462422|Nurse midwife
309453|NCT01462409|obstructive sleep apnea
309454|NCT01462409|humidification
309455|NCT01462409|mask
309456|NCT01462409|heated tubing
309457|NCT01462396|Neuroblastoma
309458|NCT01462396|Relapsed
309459|NCT01462396|Refractory
309460|NCT01462383|Advanced Cancer
309461|NCT01462383|Malignancy
309462|NCT01462383|Cardiac complications
309463|NCT01462383|Electrocardiograms
309464|NCT01462383|ECG
309465|NCT01462383|Chart Review
309466|NCT01462383|Data Review
309467|NCT01462383|Data Analysis
309468|NCT01462383|Phase I
309469|NCT01462383|Clinical Research Study
309470|NCT01462357|Human papillomavirus
309471|NCT01462357|Safety
309472|NCT01462357|HPV vaccine
309473|NCT01462357|Immune response
309474|NCT01462344|pediatric
309475|NCT01462344|ADVAIR
309476|NCT01462344|FLOVENT
309477|NCT01462344|asthma
309478|NCT01462331|Isomaltooligosaccharide
309479|NCT01462331|Human Consumption
309480|NCT01462331|Dose tolerance
309481|NCT01462331|Prebiotic
309482|NCT01462331|Short chain fatty acids
309483|NCT01462331|Blood glucose
309484|NCT01462331|Dose tolerance and prebiotic effect
309485|NCT01462318|Pre-filled syringe
309486|NCT01462318|Pharmacokinetic
309487|NCT01462318|Daclizumab High Yield Process
309488|NCT01462318|immunogenicity
309489|NCT01462305|SAD
309490|NCT01462305|Seasonal Affective Disorder
309491|NCT01462305|Winter Blues
309492|NCT01462305|Seasonal Depression
309493|NCT01462292|968
309494|NCT01462292|Duchenne Muscular Dystrophy
309495|NCT01462292|Duchenne
309496|NCT01462292|GSK
309497|NCT01462292|DMD
309498|NCT01462292|GSK2402968
309499|NCT01462279|acute respiratory failure
309500|NCT01462279|thiamine
309501|NCT01462279|oxygen consumption
309502|NCT01462279|VO2
309503|NCT01462253|Adult patients
309504|NCT01462253|Refractory
309505|NCT01462253|Relapsed
309506|NCT01462253|clofarabine
309507|NCT01462253|cyclophosphamide
309508|NCT01462253|refractory and relapsed acute lymphoblastic leukemia
309509|NCT01462253|ALL
309510|NCT01462240|arthritis
309511|NCT01462227|Hypoglycemia
309512|NCT01462227|Type 1 diabetes
309513|NCT01462201|focused ultrasound
309514|NCT01462201|mechanical fat destruction
309515|NCT01462201|Body Sculpting
309516|NCT01462188|ST-segment elevation myocardial infarction
309517|NCT01462188|Primary angioplasty
309518|NCT01462188|stent
309519|NCT01462136|PK study
309520|NCT01462097|Chronic kidney disease
309521|NCT01462097|Exercise
309522|NCT01462097|Aerobic capacity
309523|NCT01462097|Learning and memory
309524|NCT01462097|Executive function
309525|NCT01462097|Endothelial function
309526|NCT01462058|SPAQ
309527|NCT01462058|Sigh-SAD
309528|NCT01462058|Hamilton 29
309529|NCT01462058|Vitamin D3
309530|NCT01462058|p25(OH)D
309531|NCT01462045|Exercise
309532|NCT01462045|Stress
309533|NCT01462045|PTSD
309534|NCT01462045|Mindfulness
309535|NCT01462045|Breathing
309536|NCT01462045|Cortisol
309537|NCT01462032|Preschool Children
309538|NCT01462032|ADHD
309539|NCT01462032|Treatment
309540|NCT01462032|Non-pharmacological
309541|NCT01462019|nipple trauma
309542|NCT01462019|breast feeding
309543|NCT01462019|phototherapy
309544|NCT01462019|wound healing
309545|NCT01461993|vaccine
309546|NCT01461993|rLP2086
309547|NCT01461993|Gardasil
309548|NCT01461993|HPV
309549|NCT01461993|meningitis B
309550|NCT01461993|N. meningitidis serogroup B
309551|NCT01461993|adolescents
309552|NCT01461993|single-blind
309553|NCT01461993|Meningococcal Vaccines
309554|NCT01461980|vaccine
309555|NCT01461980|rLP2086
309556|NCT01461980|MCV4
309557|NCT01461980|Tdap
309558|NCT01461980|meningitis B
309559|NCT01461980|N. meningitidis serogroup B
309560|NCT01461980|adolescents
309561|NCT01461980|observer-blind
309562|NCT01461941|Dermatitis
309563|NCT01461941|Atopic
309564|NCT01461915|Pancreatic Cancer
309565|NCT01461902|traumatic brain injury
309566|NCT01461902|brain injury
309567|NCT01461902|head injury
309568|NCT01461902|vasospasm
309569|NCT01461889|transfusion-related acute lung injury
309570|NCT01461889|Blood Component Transfusion
309571|NCT01461889|Gastrointestinal Hemorrhage
309572|NCT01461889|Cirrhosis
309573|NCT01461889|Fresh frozen plasma
309574|NCT01461837|sickle cell disease
309575|NCT01461837|stem cell transplantation
309576|NCT01461837|haploidentical
309577|NCT01461824|Birth Control
309578|NCT01461824|Contraceptive Methods
309579|NCT01461824|Female Contraception
309580|NCT01461824|Weight Gain
309581|NCT01461824|Bone Density
309582|NCT01461811|toric
309583|NCT01461811|contact lenses
309584|NCT01461811|daily disposable contact lenses
309585|NCT01461811|astigmatism
309586|NCT01461811|soft contact lenses
309587|NCT01461811|contact lens comfort
309588|NCT01461798|plant stanols
309589|NCT01461798|lipids
309590|NCT01461798|cardiovascular disease
309591|NCT01461785|Platelet rich plasma
309592|NCT01461785|Dermal improvement
309593|NCT01461785|Graft survival
309594|NCT01461733|atrial fibrillation
309595|NCT01461733|amiodarone
309596|NCT01461720|Bone marrow
309597|NCT01461720|Autologous
309598|NCT01461720|Mesenchymal stem cells
309599|NCT01461720|Unilateral middle cerebral artery infarct
309600|NCT01461707|Cellular phone
309601|NCT01461707|exercise
309602|NCT01461707|pregnant women
309603|NCT01461707|obesity
309604|NCT01461707|overweight
309605|NCT01461707|physical activity
309606|NCT01461694|Hirsutism
309607|NCT01461694|Laser
309608|NCT01461694|Hair Reduction
309609|NCT01461694|IPL
309610|NCT01461694|Intense Pulsed Light
309611|NCT01461681|Palliative care
309612|NCT01461681|Symptom management
309613|NCT01461681|Heart failure
309614|NCT01461668|MRSA
309615|NCT01461668|MRSA resistant to mupirocin
309616|NCT01461642|Asthma
309617|NCT01461642|ICT Support
309618|NCT01461642|ACT
309619|NCT01461642|PEF
309620|NCT01461629|cognitive impairment
309621|NCT01461629|cognitive function
309622|NCT01461629|hospitalization
309623|NCT01461629|self-management
309624|NCT01461629|cardiac disease
309625|NCT01461629|heart failure
309626|NCT01461616|Diabetes Mellitus, Type 1
309627|NCT01461603|critical illness
309628|NCT01461603|protein metabolism
309629|NCT01461603|pharmaconutrients
309630|NCT01461564|screening
309631|NCT01461564|colonoscopy
309632|NCT01461564|carbon dioxide
309633|NCT01461564|air
309634|NCT01461564|pain score
309635|NCT01461564|complications
309636|NCT01461551|troponin I
309637|NCT01461551|creatine kinase mb
309638|NCT01461551|hospital days
309639|NCT01461551|lymphocyte apoptosis
309640|NCT01461551|intensive care unit days
309641|NCT01461538|Acute Lymphoid Leukemia
309642|NCT01461538|Myelodysplastic Syndrome
309643|NCT01461538|Acute Myeloid Leukemia
309644|NCT01461538|Solid Tumors
309645|NCT01461538|Anemia, Refractory, with Excess of Blasts
309646|NCT01461538|Antibodies, Monoclonal
309647|NCT01461538|Antibody-Drug Conjugate
309648|NCT01461538|Antigens, CD30
309649|NCT01461538|Drug Therapy
309650|NCT01461538|Hematologic Diseases
309651|NCT01461538|Immunotherapy
309652|NCT01461538|Monomethyl Auristatin E
309653|NCT01461525|Low Rectal Cancer
309654|NCT01461525|Sphincter preservation
309655|NCT01461525|Abdominoperineal resection
309656|NCT01461525|Quality of life
309657|NCT01461525|Sexual function
309658|NCT01461525|Urinary function
309659|NCT01461525|Oncologic outcome
309660|NCT01461499|Hypertension
309661|NCT01461499|Albuminuria
309662|NCT01461499|Direct renin inhibitor
309663|NCT01461499|Angiotensin receptor blocker
309664|NCT01461499|Type 2 diabetes
309665|NCT01461486|Continuous positive airway pressure
309666|NCT01461486|Oral appliance
309667|NCT01461486|mild Obstructive Sleep Apnea Syndrome
309668|NCT01461473|Obstructive Sleep Apnea
309669|NCT01461473|Obstructive Sleep Apnea Syndrome
309670|NCT01461473|Sleep Apnea Syndrome, Obstructive
309671|NCT01461473|Syndrome, Obstructive Sleep Apnea
309672|NCT01461473|Syndrome, Sleep Apnea, Obstructive
309673|NCT01461473|Syndrome, Upper Airway Resistance, Sleep Apnea
309674|NCT01461473|Upper Airway Resistance Sleep Apnea Syndrome
309675|NCT01461460|volunteer
309676|NCT01461434|atrial fibrillation
309677|NCT01461434|biomarkers
309678|NCT01461434|stroke prevention
309679|NCT01461434|implantable loop recorder
309680|NCT01461421|Obesity
309681|NCT01461421|Primary Care
309682|NCT01461421|Behavior Modification
309683|NCT01461408|HPV Vaccination
309684|NCT01461408|Beauty Salons
309685|NCT01461408|Health Education
309686|NCT01461408|Sexual Health
309687|NCT01461395|IVF
309688|NCT01461343|pulmonary hypertension, PET imaging, CT/PET
309689|NCT01461330|diabetes
309690|NCT01461330|exercise
309691|NCT01461330|DASH diet
309692|NCT01461330|ABPM
309693|NCT01461304|fatty acid oxidation
309694|NCT01461304|triheptanoin
309695|NCT01461304|long-chain fatty acid oxidation disorders
309696|NCT01461304|LCHADD
309697|NCT01461304|VLCADD
309698|NCT01461304|CPT1
309699|NCT01461304|CPT2
309700|NCT01461304|TFP
309701|NCT01461304|Glycogen Storage Disorders
309702|NCT01461304|GSD
309703|NCT01461304|Pyruvate Carboxylase
309704|NCT01461304|PC
309705|NCT01461304|ACAD9
309706|NCT01461304|Barth
309707|NCT01461291|Primary open-angle glaucoma
309708|NCT01461291|POAG
309709|NCT01461291|Trabecular meshwork
309710|NCT01461291|iStent inject
309711|NCT01461278|Primary open-angle glaucoma
309712|NCT01461278|POAG
309713|NCT01461278|Cataract surgery
309714|NCT01461278|Suprachoroidal space
309715|NCT01461278|Suprachoroidal stent
309716|NCT01461278|iStent supra
309717|NCT01461265|Painful bone metastases
309718|NCT01461265|Bone metastases
309719|NCT01461265|Metastatic bone tumors
309720|NCT01461265|Metastatic bone pain
309721|NCT01461265|Cryoablation
309722|NCT01461265|Cryotherapy
309723|NCT01461265|Cryosurgery
309724|NCT01461252|Painful bone metastases
309725|NCT01461252|Bone metastases
309726|NCT01461252|Metastatic bone tumors
309727|NCT01461252|Metastatic bone pain
309728|NCT01461252|Cryoablation
309729|NCT01461252|Cryotherapy
309730|NCT01461252|Cryosurgery
309731|NCT01461252|Radiation therapy
309732|NCT01461252|Radiotherapy
309733|NCT01461239|survival
309734|NCT01461239|debonding
309735|NCT01461239|endodontic treated teeth
309736|NCT01461226|overweight
309737|NCT01461226|cardiovascular risk factors
309738|NCT01461226|exercise training
309739|NCT01461226|endothelial function
309740|NCT01461226|endothelium
309741|NCT01461226|endothelial progenitor cells
309742|NCT01461213|Tapetoretinal degeneration, choroideraemia, X-linked
309743|NCT01461213|retinitis pigmentosa
309744|NCT01461187|Exercise
309745|NCT01461187|Pregnancy
309746|NCT01461187|Childbirth
309747|NCT01461187|Vaginal
309748|NCT01461187|Cesarean section
309749|NCT01461174|Sleep deprivation
309750|NCT01461174|Cognitive Functions
309751|NCT01461174|young male
309752|NCT01461148|UICC stage III/IV MSI-H colorectal cancer
309753|NCT01461109|Parkinson Disease
309754|NCT01461109|Alzheimer Disease
309755|NCT01461109|[18F] CFPyPB
309756|NCT01461109|GlyT1
309757|NCT01461083|Parkinson Disease
309758|NCT01461083|[18F]MPPF
309759|NCT01461070|Breast Cancer
309760|NCT01461070|Post Menopausal Estrogens
309761|NCT01461070|Fecal Microbes
309762|NCT01461031|pain
309763|NCT01461031|orthognathic
309764|NCT01461018|Immune globulin subcutaneous
309765|NCT01461018|SCIG
309766|NCT01461018|Primary immunodeficiency
309767|NCT01461018|PID
309768|NCT01461005|Spondylolisthesis
309769|NCT01461005|Neurologic impairment
309770|NCT01461005|Kyphosis
309771|NCT01461005|Pseudarthrosis
309772|NCT01460992|Pacemaker therapy
309773|NCT01460992|Magnetic Resonance Imaging (MRI)
309774|NCT01460992|EVIA/ENTOVIS
309775|NCT01460979|Ovarian Cancer
309776|NCT01460979|Endometrial Carcinoma
309777|NCT01460979|Temsirolimus
309778|NCT01460966|Distal protection device
309779|NCT01460966|Thrombus aspiration
309780|NCT01460966|Coronary Artery Disease
309781|NCT01460966|Coronary Disease
309782|NCT01460966|Acute Coronary Syndrome
309783|NCT01460953|curriculum
309784|NCT01460953|training
309785|NCT01460953|Medical student Knowledge
309786|NCT01460940|refractory Hodgkin's lymphoma
309787|NCT01460940|panobinostat
309788|NCT01460940|lenalidomide
309789|NCT01460914|ECP
309790|NCT01460914|CTCL
309791|NCT01460914|Extracorporeal photopheresis
309792|NCT01460914|Cutaneous T Cell Lymphoma
309793|NCT01460914|GVHD
309794|NCT01460914|Graft versus host disease
309795|NCT01460901|Neuroblastoma
309796|NCT01460901|Relapsed
309797|NCT01460901|Refractory
309798|NCT01460875|high risk melanoma
309799|NCT01460875|lymph node disease
309800|NCT01460862|Asthma
309801|NCT01460862|Omalizumab
309802|NCT01460849|Cystic fibrosis
309803|NCT01460836|Cystic fibrosis
309804|NCT01460823|Hearing loss
309805|NCT01460823|Cochlear Implantation
309806|NCT01460823|Image guided surgery
309807|NCT01460797|Glycemic index
309808|NCT01460797|Caloric restriction
309809|NCT01460797|Energy intake
309810|NCT01460797|Glucose
309811|NCT01460797|Lipid Metabolism
309812|NCT01460797|Cholesterol
309813|NCT01460797|HDL Cholesterol
309814|NCT01460797|LDL Cholesterol
309815|NCT01460797|Obesity
309816|NCT01460797|Metformin
309817|NCT01460784|Metabolic dysfunction
309818|NCT01460784|Insulin resistance
309819|NCT01460784|Brown adipose tissue
309820|NCT01460784|Dyslipidemia
309821|NCT01460771|childhood dystonia
309822|NCT01460758|Depression
309823|NCT01460758|Transcranial magnetic stimulation
309824|NCT01460758|rTMS
309825|NCT01460758|DLPFC
309826|NCT01460758|medial frontal cortex
309827|NCT01460758|anterior cingulate complex
309828|NCT01460745|Erbitux
309829|NCT01460745|CRC
309830|NCT01460745|mCRC
309831|NCT01460745|Liver
309832|NCT01460745|Metastases
309833|NCT01460732|Hypertension
309834|NCT01460732|Nocturnal BP dipping
309835|NCT01460732|Home Blood pressure Monitoring
309836|NCT01460732|Ambulatory Blood Pressure Monitoring
309837|NCT01460706|Glioma
309838|NCT01460706|68Ga-DOTATOC
309839|NCT01460706|PET/CT
309840|NCT01460706|Somatostatin receptor
309841|NCT01460693|Leukemia
309842|NCT01460693|Myeloid
309843|NCT01460693|Chronic
309844|NCT01460693|Chronic-Phase
309845|NCT01460693|CML
309846|NCT01460680|Fibromyalgia
309847|NCT01460680|Systemic Lupus Erythematosus
309848|NCT01460680|Omega-3 Fatty acids
309849|NCT01460680|Magnesium
309850|NCT01460667|Laparoscopic Roux-en-Y Gastric Bypass
309851|NCT01460667|Post-Operative Pain
309852|NCT01460667|IV Acetaminophen
309853|NCT01460667|Post-Operative Nausea and Vomiting
309854|NCT01460628|fatigue
309855|NCT01460628|menopausal symptoms
309856|NCT01460628|hot flashes
309857|NCT01460628|Vasomotor symptoms
309858|NCT01460628|perimenopause
309859|NCT01460628|related Quality of life
309860|NCT01460615|Postoperative pancreatitis
309861|NCT01460615|Postoperative complications
309862|NCT01460615|Delayed gastric emptying
309863|NCT01460615|Leakage
309864|NCT01460615|Fistula
309865|NCT01460615|Acinar cell
309866|NCT01460615|Risk patient
309867|NCT01460615|Pancreaticoduodenectomy
309868|NCT01460615|Whipple
309869|NCT01460615|Cortisone
309870|NCT01460602|Lymphoma
309871|NCT01460602|Follicular
309872|NCT01460602|Marginal Zone
309873|NCT01460602|Mantle Cell
309874|NCT01460602|Velcade
309875|NCT01460602|bortezomib
309876|NCT01460602|Nipent
309877|NCT01460602|pentastatin
309878|NCT01460602|Rituxan
309879|NCT01460602|rituximab
309880|NCT01460602|Turturro
309881|NCT01460602|Shreveport
309882|NCT01460589|colon cancer
309883|NCT01460589|Chemotherapy
309884|NCT01460589|adjuvant
309885|NCT01460576|prematurity
309886|NCT01460576|respiratory disease
309887|NCT01460576|bronchopulmonary dysplasia
309888|NCT01460563|craniotomy
309889|NCT01460563|sodium valproate
309890|NCT01460563|rocuronium
309891|NCT01460550|delayed gastric emptying(DGE)
309892|NCT01460550|pancreaticoduodenectomy(PD)
309893|NCT01460550|randomized controlled trial(RCT)
309894|NCT01460550|gastro- or duodeno- jejunostomy reconstruction
309895|NCT01460550|morbidity
309896|NCT01460537|phase I
309897|NCT01460537|phosphatidylinositol-3 kinase inhibitor
309898|NCT01460537|gemcitabine
309899|NCT01460537|cisplatin
309900|NCT01460537|maximum tolerated dose
309901|NCT01460524|bronchiolitis
309902|NCT01460524|saline
309903|NCT01460524|nebulization
309904|NCT01460524|hypertonic
309905|NCT01460511|Mild bronchial asthma
309906|NCT01460498|Leukemia
309907|NCT01460498|Chronic Myeloid Leukemia
309908|NCT01460498|CML
309909|NCT01460498|Complete cytogenetic remission
309910|NCT01460498|CCyR
309911|NCT01460498|Minimal residual disease
310034|NCT01460069|psoriasis
309912|NCT01460498|Philadelphia chromosome (Ph)-
309913|NCT01460498|BCR/ABL-positive
309914|NCT01460498|Tyrosine kinase inhibitor
309915|NCT01460498|TKI
309916|NCT01460498|Azacitidine
309917|NCT01460498|5-Azacytidine
309918|NCT01460498|5-AZA
309919|NCT01460498|Vidaza
309920|NCT01460498|5-AZC
309921|NCT01460498|AZA-CR
309922|NCT01460498|Ladakamycin
309923|NCT01460498|NSC-102816
309924|NCT01460472|NSCLC
309925|NCT01460472|Lung cancer, small-cell
309926|NCT01460472|advanced lung cancer
309927|NCT01460472|therapeutic vaccine
309928|NCT01460472|anti-idiotypic vaccine
309929|NCT01460472|1E10
309930|NCT01460459|diabetes
309931|NCT01460459|self-monitoring of blood glucose
309932|NCT01460459|frequency
309933|NCT01460433|HIV 1
309934|NCT01460433|Herpes Simplex Type 2
309935|NCT01460433|Treatment experienced
309936|NCT01460420|Allogeneic transplantation
309937|NCT01460420|Hematologic malignancies
309938|NCT01460420|Multiple myeloma
309939|NCT01460420|RIC (Reduced Intensity Conditioning)
309940|NCT01460394|Healthy
309941|NCT01460394|Control
309942|NCT01460355|strabismus surgery
309943|NCT01460355|botulinum toxin
309944|NCT01460355|esotropia
309945|NCT01460355|exotropia
309946|NCT01460355|blepharoptosis
309947|NCT01460342|Prostatic hyperplasia
309948|NCT01460342|Benign prostatic hyperplasia
309949|NCT01460342|Lower urinary tract
309950|NCT01460329|intensive care units
309951|NCT01460329|pediatric
309952|NCT01460329|cardiac index
309953|NCT01460329|Doppler Ultrasonography
309954|NCT01460316|Conotruncal cardiac defects
309955|NCT01460316|methylation
309956|NCT01460316|genotype
309957|NCT01460316|cobalamin
309958|NCT01460316|folates
309959|NCT01460316|nutrition
309960|NCT01460303|Transurethral catheterization
309961|NCT01460303|Urinary retention
309962|NCT01460303|Bladder dysfunction
309963|NCT01460303|Patient comfort
309964|NCT01460303|Pelvic Reconstructive Surgery
309965|NCT01460303|Postoperative bladder dysfunction
309966|NCT01460303|Postoperative urinary retention
309967|NCT01460277|hemiplegic
309968|NCT01460277|balance
309969|NCT01460277|hydrotherapy
309970|NCT01460264|Prospective Cohort Study
309971|NCT01460264|Respiratory Function Tests
309972|NCT01460264|Computed Tomography
309973|NCT01460264|Electrocardiography
309974|NCT01460264|Peripheral Arterial Disease
309975|NCT01460251|type 1 diabetes
309976|NCT01460251|beta cell
309977|NCT01460251|immunomodulation
309978|NCT01460251|immunointervention
309979|NCT01460238|Lipoprotein Lipase
309980|NCT01460238|Chronic Lymphocytic Leukemia
309981|NCT01460238|CLL
309982|NCT01460225|constipation
309983|NCT01460225|chronic idiopathic constipation
309984|NCT01460225|no prior history of surgery to the colon
309985|NCT01460225|not on any type of medication that could alter gastrointestinal motility or transit
309986|NCT01460212|Cognitive-Behavior Therapy
309987|NCT01460212|Magnetic Resonance Imaging
309988|NCT01460212|major depressive disorder
309989|NCT01460186|Germ line polymorphisms
309990|NCT01460173|alertness test
309991|NCT01460173|sleepiness
309992|NCT01460173|vigilance
309993|NCT01460173|Sleep Apnea, Obstructive
309994|NCT01460147|Hemophilia
309995|NCT01460134|CD27 expressing Hematologic Malignancies
309996|NCT01460134|CD27 expressing Solid Tumors
309997|NCT01460134|chronic lymphocytic leukemia
309998|NCT01460134|Burkett's lymphoma
309999|NCT01460134|mantle cell lymphoma
310000|NCT01460134|primary lymphoma of the central nervous system
310001|NCT01460134|marginal zone B cell lymphoma
310002|NCT01460134|solid tumor
310003|NCT01460134|metastatic melanoma
310004|NCT01460134|renal (clear) cell carcinoma
310005|NCT01460134|hormone-refractory prostate adenocarcinoma
310006|NCT01460134|ovarian cancer
310007|NCT01460134|colorectal adenocarcinoma
310008|NCT01460134|non-small cell lung cancer
310009|NCT01460121|Phobic Postural Vertigo
310010|NCT01460121|Visual Vertigo
310011|NCT01460121|Chronic Subjective Dizziness
310012|NCT01460121|Motion and Space Discomfort
310013|NCT01460121|SpotOn
310014|NCT01460108|PLVR
310015|NCT01460108|AeriSeal
310016|NCT01460108|Treatment
310017|NCT01460108|Device
310018|NCT01460108|Breathing
310019|NCT01460108|COPD
310020|NCT01460108|emphysema
310021|NCT01460108|polymeric lung volume reduction
310022|NCT01460108|heterogeneous
310023|NCT01460108|homogeneous
310024|NCT01460108|Chronic Obstructive Pulmonary Disease
310025|NCT01460095|diabetes
310026|NCT01460095|translational research
310027|NCT01460095|HbA1c
310028|NCT01460095|education
310029|NCT01460082|chronic obstructive pulmonary disease
310030|NCT01460082|acute exacerbation
310031|NCT01460082|endothelial dysfunction
310032|NCT01460082|flow mediated dilation
310033|NCT01460082|systemic inflammation
310035|NCT01460069|liraglutide
310036|NCT01460069|morbidity
310037|NCT01460069|PASI
310038|NCT01460069|DLQI
310039|NCT01460056|peritoneal dialysis
310040|NCT01460056|endotoxin-associated sterile peritonitis
310041|NCT01460030|Hypercalcemia in patients with parathyroid carcinoma or intractable PHPT
310042|NCT01460004|patellar tendinopathy
310043|NCT01460004|jumper's knee
310044|NCT01459991|walnut
310045|NCT01459991|mediterranean
310046|NCT01459978|CUmulative SUM (CUSUM)
310047|NCT01459978|quality indicators
310048|NCT01459978|obstetrics
310049|NCT01459965|Jaundice
310050|NCT01459965|Biliary stents
310051|NCT01459965|Palliation
310052|NCT01459965|Quality of Life
310053|NCT01459965|Endoscopic Retrograde Cholangiography
310054|NCT01459952|occurences of flu
310055|NCT01459952|occurences of common cold
310056|NCT01459939|Osteoarthritis
310057|NCT01459926|Opioid induced constipation
310058|NCT01459926|OIC
310059|NCT01459926|Constipation
310060|NCT01459926|Opioid side effects
310061|NCT01459926|Morphine induced constipation
310062|NCT01459926|Opioid therapy
310063|NCT01459913|VX-950
310064|NCT01459913|INCIVEK
310065|NCT01459913|INCIVO
310066|NCT01459900|Treatment Resistant Hypertension
310067|NCT01459887|untreated, CD20-positive
310068|NCT01459874|Home Monitoring
310069|NCT01459874|Remote monitoring
310070|NCT01459874|Telecardiology
310071|NCT01459874|Organizational model
310072|NCT01459874|Patient indicated for pacemaker, ICD, CRT-P, or CRT-D
310073|NCT01459861|early ambulation
310074|NCT01459861|knee arthroplasty
310075|NCT01459848|Salivary cortisol measured after DVD watching or block play
310076|NCT01459835|TV
310077|NCT01459835|Violence
310078|NCT01459835|DVDs
310079|NCT01459835|Behavior
310080|NCT01459835|Preschool children
310081|NCT01459822|sepsis
310082|NCT01459822|miRNA
310083|NCT01459783|Caregivers
310084|NCT01459783|Comparative Effectiveness Research
310085|NCT01459783|Cost Effectiveness
310086|NCT01459783|Patient Care Management
310087|NCT01459783|Social Work
310088|NCT01459770|glomerular filtration rate
310089|NCT01459770|albuminuria
310090|NCT01459770|medical therapy
310091|NCT01459770|hospital discharge
310092|NCT01459770|hospital readmission
310093|NCT01459770|CKD complications
310094|NCT01459770|CKD risk factors
310095|NCT01459757|Retrospective
310096|NCT01459757|GIST
310097|NCT01459757|sunitinib
310098|NCT01459757|mutational
310099|NCT01459744|Heart failure
310100|NCT01459744|Palliative care
310101|NCT01459744|Communication
310102|NCT01459718|Severe cardiac iron overload
310103|NCT01459718|deferasirox
310104|NCT01459718|β-thalassaemia
310105|NCT01459718|cardiac dysfunction
310106|NCT01459705|Combat Disorders
310107|NCT01459705|Exposure Therapy
310108|NCT01459705|Army Personnel
310109|NCT01459692|Seizures
310110|NCT01459692|Epilepsy
310111|NCT01459692|Auditory Stimulation
310112|NCT01459692|Music
310113|NCT01459666|Scar
310114|NCT01459666|Forehead
310115|NCT01459666|Skin Cancer
310116|NCT01459666|MOHS Surgery
310117|NCT01459666|Dermatology
310118|NCT01459653|Febrile neutropenia
310119|NCT01459653|cancer
310120|NCT01459653|chemotherapy,
310121|NCT01459653|primary prophylaxis
310122|NCT01459653|secondary prophylaxis
310123|NCT01459653|filgrastim
310124|NCT01459653|granulocyte colony stimulating factor
310125|NCT01459653|observational study
310126|NCT01459653|noninterventional study
310127|NCT01459640|Osteoarthritis
310128|NCT01459640|Bone marrow
310129|NCT01459640|Mesenchymal stem cells
310130|NCT01459640|Autologous
310131|NCT01459640|Mild osteoarthritis
310132|NCT01459640|Moderate osteoarthritis
310133|NCT01459627|DAPT- Dual Antiplatelet Therapy
310134|NCT01459627|STEMI
310135|NCT01459601|diabetes mellitus
310136|NCT01459601|FBS
310137|NCT01459601|HbA1C
310138|NCT01459601|Cabergoline
310139|NCT01459575|Acquired Immunodeficiency Syndrome
310140|NCT01459575|antiretroviral therapy
310141|NCT01459575|China
310142|NCT01459549|hepatolithiasis
310143|NCT01459549|sphincter of oddi laxity
310144|NCT01459549|choledochojejunostomy
310145|NCT01459536|Aging
310146|NCT01459523|Peripheral Nerve Block
310147|NCT01459523|Perineural Catheter
310148|NCT01459523|Orthopedic Surgery
310149|NCT01459523|Ultrasound
310150|NCT01459510|Violence prevention
310151|NCT01459510|Parenting
310152|NCT01459510|Discipline
310153|NCT01459497|non-small cell lung cancer
310154|NCT01459497|Stages II or III non-small cell lung cancer
310155|NCT01459484|Non metastatic extremities high grade osteosarcoma
310156|NCT01459458|intimate partner violence
310157|NCT01459458|gender-based violence
310158|NCT01459458|domestic violence
310159|NCT01459458|unintended pregnancy
310160|NCT01459445|ethinylestradiol 30µg-drospirenone
310161|NCT01459445|flow-mediated dilatation
310162|NCT01459445|endothelial dysfunction
310163|NCT01459445|hsCRP
310164|NCT01459445|metformin
310165|NCT01459445|polycystic ovary syndrome
310166|NCT01459406|Gastrointestinal physiology
310167|NCT01459406|Gastrointestinal response to sugars
310168|NCT01459406|MRI
310169|NCT01459406|gastrointestinal
310170|NCT01459406|stomach
310171|NCT01459406|small bowel
310172|NCT01459406|colon
310173|NCT01459406|glucose
310174|NCT01459406|fructose
310175|NCT01459406|fructan
310176|NCT01459406|FODMAP
310177|NCT01459393|Actinic keratosis
310178|NCT01459393|Photodynamic therapy
310179|NCT01459393|5-aminolevulinic acid
310180|NCT01459393|Cryotherapy
310181|NCT01459367|Drug Therapy
310182|NCT01459341|CLI Critical limb ischemia
310183|NCT01459341|PVD peripheral vascular disease
310184|NCT01459341|NIRS near infrared spectroscopy
310185|NCT01459341|TCPO2 - transcutaneous oxygen pressure
310186|NCT01459328|rectal carcinoma
310187|NCT01459328|long course chemo-radiation
310188|NCT01459328|short course chemo-rdiation
310189|NCT01459328|Locally Advanced Rectal Carcinoma
310190|NCT01459315|Healthy
310191|NCT01459315|Male
310192|NCT01459315|GSK1349572
310193|NCT01459315|Dolutegravir
310194|NCT01459315|DTG
310195|NCT01459315|Integrase
310196|NCT01459315|HIV
310197|NCT01459302|FALS
310198|NCT01459302|ALS
310199|NCT01459302|SALS
310200|NCT01459302|MND
310201|NCT01459302|SOD1
310202|NCT01459302|ALS GENES
310203|NCT01459302|PLS
310204|NCT01459302|PMA
310205|NCT01459302|ALS/FTD
310206|NCT01459302|FAMILIAL ALS
310207|NCT01459302|SPORADIC ALS
310208|NCT01459302|GENETICS
310209|NCT01459302|FTD
310210|NCT01459302|Miyoshi myopathy
310211|NCT01459276|seasonal
310212|NCT01459276|prevention
310213|NCT01459276|influenza
310214|NCT01459276|infection
310215|NCT01459276|influenza vaccine
310216|NCT01459276|vaccine
310217|NCT01459276|influenza in humans
310218|NCT01459263|GSV
310219|NCT01459263|insufficiency
310220|NCT01459263|ClariVein device
310221|NCT01459263|safety
310222|NCT01459263|efficacy
310223|NCT01459263|QOL
310224|NCT01459250|AGO178C,
310225|NCT01459250|renal impairment,
310226|NCT01459250|ESRD,
310227|NCT01459250|pharmacokinetics
310228|NCT01459237|Cushing's Disease
310229|NCT01459237|Microadenoma
310230|NCT01459237|PET Imaging
310231|NCT01459237|Cushing Disease Tumor
310232|NCT01459237|Pituitary Tumors
310233|NCT01459211|CLL
310234|NCT01459185|Non-small cell lung cancer
310235|NCT01459185|Adjuvant chemotherapy
310236|NCT01459185|oral fluoropyrimidine
310237|NCT01459185|S-1
310238|NCT01459185|Feasibility study
310239|NCT01459185|Surgery
310240|NCT01459172|breast cancer prevention
310241|NCT01459159|Hematology
310242|NCT01459159|MDS
310243|NCT01459159|Myelodysplastic Syndrome
310244|NCT01459159|Low risk MDS
310245|NCT01459159|Int-1 risk MDS
310246|NCT01459159|Transfusion dependence
310247|NCT01459159|Telintra
310248|NCT01459159|ezatiostat
310249|NCT01459159|ezatiostat hydrochloride
310250|NCT01459159|TLK199
310251|NCT01459159|Glutathione
310252|NCT01459159|Glutathione analog
310253|NCT01459159|Glutathione Transferase
310254|NCT01459159|Glutathione Transferase P1-1 inhibitor
310255|NCT01459159|GST P1-1 inhibitor
310256|NCT01459159|Apoptosis
310257|NCT01459159|Differentiation
310258|NCT01459159|Enzyme inhibitor
310259|NCT01459159|non-del (5q)
310260|NCT01459159|non-deletion 5q
310261|NCT01459146|IPT
310262|NCT01459146|malaria
310263|NCT01459146|ACT
310264|NCT01459146|schistosomiasis
310265|NCT01459146|Hemoglobin
310266|NCT01459146|Anemia
310267|NCT01459146|Sustained attention
310268|NCT01459146|Recall
310269|NCT01459146|Schoolchildren
310270|NCT01459146|Kassena-Nankana
310271|NCT01459133|investigational
310272|NCT01459133|inhaled insulin product
310273|NCT01459120|Home-based HIV-testing
310274|NCT01459120|Voluntary Counseling and Testing
310275|NCT01459120|Community based testing
310276|NCT01459120|HIV/AIDS
310277|NCT01459120|Lesotho
310278|NCT01459107|Hand Transplant
310279|NCT01459107|CTA
310280|NCT01459107|VCA
310281|NCT01459107|Composite Tissue
310282|NCT01459107|Amputation
310283|NCT01459107|Upper limb
310284|NCT01459107|Immunosuppression
310285|NCT01459094|Healthy Volunteers
310286|NCT01459094|Oral bioavailability
310287|NCT01459094|Canagliflozin (JNJ-28431754)
310288|NCT01459094|Metformin IR
310289|NCT01459029|Schizophrenia
310290|NCT01459029|NMDA receptor
310291|NCT01459029|D-serine
310292|NCT01459029|Recent onset
310293|NCT01459029|Negative symptoms
310294|NCT01459029|Cognition
310295|NCT01459016|Mild Cognitive Impairment
310296|NCT01459016|Brain Imaging Biomarkers
310297|NCT01459016|Magnetic resonance imaging biomarker
310298|NCT01459016|Positron Emission Tomography
310299|NCT01458977|Lípid-lowering effect
310300|NCT01458977|Tenofovir
310301|NCT01458977|Dyslipidemia
310302|NCT01458964|Fibromyalgia
310303|NCT01458951|Tofacitinib
310304|NCT01458951|CP-690
310305|NCT01458951|550
310306|NCT01458951|Moderate to severe ulcerative colitis
310307|NCT01458951|phase 3 clinical trial
310308|NCT01458951|Mayo score
310309|NCT01458925|Colorectal cancer
310310|NCT01458925|Colonic polyps
310311|NCT01458899|Phase 1
310312|NCT01458899|healthy male
310313|NCT01458899|nonpregnant female
310314|NCT01458899|volunteers
310315|NCT01458899|pharmacokinetics
310316|NCT01458899|TC 5214
310317|NCT01458899|The effect of food on the pharmacokinetics of TC-5214
310318|NCT01458873|infiltration
310319|NCT01458873|extravasation
310320|NCT01458847|bladder cancer
310321|NCT01458847|cis-urocanic acid
310322|NCT01458847|primary
310323|NCT01458847|recurrent
310324|NCT01458847|non-muscle
310325|NCT01458834|Smoking
310326|NCT01458834|Attentional bias
310327|NCT01458834|Craving
310328|NCT01458821|Tinnitus
310329|NCT01458808|salt
310330|NCT01458808|inflammation
310331|NCT01458808|hypervolemia
310332|NCT01458808|diet
310333|NCT01458782|Cartilage repair
310334|NCT01458782|Chondrocytes
310335|NCT01458782|Stemcells
310336|NCT01458756|liver transplant patients
310337|NCT01458756|hepatic transplantation
310338|NCT01458743|pharmacokinetics
310339|NCT01458730|PCNSL
310340|NCT01458730|Immunochemotherapy
310341|NCT01458730|Intraspinal Depocyt
310342|NCT01458730|Maintenance temozolomide
310343|NCT01458717|pancreas
310344|NCT01458717|cancer
310345|NCT01458717|borderline resectable
310346|NCT01458717|locally advanced
310347|NCT01458717|resectability
310348|NCT01458717|chemotherapy
310349|NCT01458717|radiation
310350|NCT01458717|chemoradiation
310351|NCT01458717|neoadjuvant
310352|NCT01458717|survival
310353|NCT01458717|prognosis
310354|NCT01458717|recurrence
310355|NCT01458717|response rate
310356|NCT01458652|AST-120
310357|NCT01458652|HDF
310358|NCT01458652|Replacement Volume described above
310359|NCT01458639|Pulmonary embolism
310360|NCT01458639|PE
310361|NCT01458626|mirtazapine
310362|NCT01458626|paroxetine
310363|NCT01458626|major depression
310364|NCT01458626|early improvement
310365|NCT01458613|Mucopolysaccharidoses
310366|NCT01458613|Mucopolysaccharidosis VI
310367|NCT01458613|Metabolism, Inborn Errors
310368|NCT01458613|Genetic Diseases, Inborn
310369|NCT01458613|Mucinoses
310370|NCT01458613|Connective Tissue Diseases
310371|NCT01458613|Metabolic Diseases
310372|NCT01458600|ophthalmopathy
310373|NCT01458600|prevention
310374|NCT01458600|diclofenac
310375|NCT01458587|Actinic keratosis
310376|NCT01458574|Janus kinase inhibitor
310377|NCT01458574|JAK 3 inhibitor
310378|NCT01458574|inflammatory bowel disease
310379|NCT01458574|ulcerative colitis
310380|NCT01458574|OCTAVE
310381|NCT01458574|CP-690
310382|NCT01458574|550
310383|NCT01458574|tofacitinib
310384|NCT01458574|Xeljanz
310385|NCT01458561|Hemostatic agent
310386|NCT01458561|Liver surgery
310387|NCT01458561|Hemostasis
310388|NCT01458548|1st-line therapy
310389|NCT01458548|single agent rituximab
310390|NCT01458548|CHOP
310391|NCT01458548|PTLD
310392|NCT01458535|Genotype 1
310393|NCT01458535|Genotype 2
310394|NCT01458535|Genotype 3
310395|NCT01458535|Hepatitis C Virus
310396|NCT01458535|ABT-450/r
310397|NCT01458535|Ribavirin
310398|NCT01458535|ABT-267
310399|NCT01458535|Ombitasvir
310400|NCT01458535|Paritaprevir
310401|NCT01458522|Nonconvulsive Seizures
310402|NCT01458509|Quality of Life
310403|NCT01458509|patient outcomes
310404|NCT01458509|questionaires
310405|NCT01458509|11-101
310406|NCT01458470|huntington
310407|NCT01458470|huntingtin
310408|NCT01458470|memantine
310409|NCT01458470|ebixa
310410|NCT01458470|namenda
310411|NCT01458444|Respiratory Insufficiency
310412|NCT01458444|Cardiothoracic Surgery
310413|NCT01458444|Ventilation system
310414|NCT01458431|cesarean section
310415|NCT01458431|wound infusion
310416|NCT01458431|Local anesthetic levobupivacaine
310417|NCT01458431|Pain management
310418|NCT01458418|Eosinophil
310419|NCT01458418|Esophagitis
310420|NCT01458405|Myocardial Infarction
310421|NCT01458405|Heart Attack
310422|NCT01458405|Stem cell
310423|NCT01458405|Left ventricular dysfunction
310424|NCT01458405|Congestive heart failure
310425|NCT01458366|Non-Hodgkin's Lymphoma
310426|NCT01458366|Lymphoma
310427|NCT01458366|B-Cell Lymphoma
310428|NCT01458353|Right-sided colon cancer
310429|NCT01458353|Ileocolonic anastomosis
310430|NCT01458353|stapled anastomosis
310431|NCT01458353|handsewn anastomosis
310432|NCT01458353|peritoneal contamination
310433|NCT01458353|microbiological spectrum
310434|NCT01458340|Adult ADHD
310435|NCT01458340|Attention-Deficit/Hyperactivity Disorder
310436|NCT01458327|MDMA
310437|NCT01458327|PTSD
310438|NCT01458327|psychotherapy
310439|NCT01458314|Physical exercise
310440|NCT01458314|Rehabilitation
310441|NCT01458314|NIV
310442|NCT01458301|Drug Therapy
310443|NCT01458275|Seasonal Allergic Rhinitis
310444|NCT01458275|Ciclesonide
310445|NCT01458275|Ciclesonide Nasal Aerosol
310446|NCT01458262|cerebral oxymetry
310447|NCT01458262|systemic oxymetry
310448|NCT01458262|hepatic surgery
310449|NCT01458262|liver transplantation
310450|NCT01458249|Soft Tissue Sarcoma
310451|NCT01458223|spine surgery
310452|NCT01458223|postoperative infection
310453|NCT01458223|postoperative antibiotics
310454|NCT01458197|Overactive Bladder
310455|NCT01458197|Tarafenacin
310456|NCT01458184|risk factors for complications
310457|NCT01458184|precarious medical situations
310458|NCT01458171|Immune globulin subcutaneous
310459|NCT01458171|SCIG
310460|NCT01458171|Primary immunodeficiency
310461|NCT01458171|PID
310462|NCT01458158|Gelatinases
310463|NCT01458158|kidney disease
310464|NCT01458158|diabetes mellitus type 2
310465|NCT01458132|subject follow-up
310466|NCT01458132|HIV infection
310467|NCT01458132|registry
310468|NCT01458132|seizures
310469|NCT01458132|GSK2248761
310470|NCT01458119|Fabry disease
310471|NCT01458119|Lysosomal storage disease
310472|NCT01458119|migalastat HCl
310473|NCT01458119|AT1001
310474|NCT01458080|ENABLE
310475|NCT01458080|invasive procedures
310476|NCT01458080|Thrombocytopenia
310477|NCT01458080|Thromboembolic events
310478|NCT01458080|Eltrombopag
310479|NCT01458080|Hepatitis C
310480|NCT01458080|HCV
310481|NCT01458054|pharmacokinetics
310482|NCT01458054|omeprazole
310483|NCT01458054|ritonavir
310484|NCT01458054|healthy subjects
310485|NCT01458054|drug interaction
310486|NCT01458041|Critical limb ischaemia
310487|NCT01458041|Iloprost
310488|NCT01458041|Quality of life
310489|NCT01458041|Visual analogue scale
310490|NCT01458028|BAY85-3934
310491|NCT01458028|pharmacokinetics
310492|NCT01458028|age
310493|NCT01458028|gender
310494|NCT01458015|QST
310495|NCT01458015|neuropathic pain
310496|NCT01458015|tapentadol pr
310497|NCT01458015|oxycodone
310498|NCT01457989|retention rate
310499|NCT01457989|epilepsy
310500|NCT01457989|responder rate
310501|NCT01457989|seizure freedom
310502|NCT01457989|discontinuation rate
310503|NCT01457989|safety assessment
310504|NCT01457989|reduction in seizure frequency
310505|NCT01457989|open-label
310506|NCT01457976|cancer
310507|NCT01457976|obesity
310508|NCT01457976|personal responsibility
310509|NCT01457950|denosumab
310510|NCT01457950|Republic of Korea
310511|NCT01457950|dual energy x-ray absorptiometry
310512|NCT01457937|HCV
310513|NCT01457937|Menopause
310514|NCT01457937|Peg IFN
310515|NCT01457937|Ribavirin
310516|NCT01457937|Boceprevir
310517|NCT01457924|Relapsing Remitting Multiple Sclerosis
310518|NCT01457924|Ofatumumab
310519|NCT01457898|Cardiac surgery
310520|NCT01457898|Non-invasive ventilation
310521|NCT01457885|AML
310522|NCT01457872|Heroin addiction
310523|NCT01457872|Substance use disorders
310524|NCT01457872|Substitution treatment
310525|NCT01457872|Syringe exchange
310526|NCT01457846|gastro-oesophageal junction cancer
310527|NCT01457846|gastric cancer
310528|NCT01457846|lower third oesophageal cancer
310529|NCT01457846|polysomy
310530|NCT01457846|amplification
310531|NCT01457846|FGFR
310532|NCT01457820|Allopurinol
310533|NCT01457820|Angina
310534|NCT01457820|Acute coronary syndrome
310535|NCT01457807|Phase 1
310536|NCT01457807|Parkinson's disease
310537|NCT01457807|pharmacodynamic
310538|NCT01457807|biomarkers
310539|NCT01457807|pharmacokinetics
310540|NCT01457807|extended release formulation
310541|NCT01457794|Metabolic Syndrome X
310542|NCT01457794|Fatty Acids, Omega-3
310543|NCT01457794|Learning
310544|NCT01457794|Attention
310545|NCT01457794|Nutritional Status
310546|NCT01457794|Nutrition Assessments
310547|NCT01457794|Body Weight
310548|NCT01457794|Physical Activity
310549|NCT01457794|Sleep
310550|NCT01457794|Child Nutrition Sciences
310551|NCT01457781|Inhaled nitric oxide
310552|NCT01457781|pulmonary arterial hypertension
310553|NCT01457781|pulmonary hypertension
310554|NCT01457781|PAH
310555|NCT01457768|Hepatitis C
310556|NCT01457768|HCV
310557|NCT01457768|Sustained Virologic Response
310558|NCT01457768|Direct Acting Antiviral
310559|NCT01457768|Combination Therapy
310560|NCT01457768|Tegobuvir
310561|NCT01457768|Registry
310562|NCT01457768|HCV RNA
310563|NCT01457768|Treatment experienced
310564|NCT01457768|Treatment naive
310565|NCT01457768|GS 9451
310566|NCT01457768|GS 5885
310567|NCT01457768|Sequence
310568|NCT01457768|GS 5816
310569|NCT01457768|GS 7977
310570|NCT01457768|Sofosbuvir
310571|NCT01457768|Sovaldi™
310572|NCT01457768|SOF
310573|NCT01457768|Ledipasvir
310574|NCT01457768|LDV
310575|NCT01457755|Hepatitis C
310576|NCT01457755|HCV
310577|NCT01457755|Sustained Virologic Response
310578|NCT01457755|Direct Acting Antiviral
310579|NCT01457755|Combination Therapy
310580|NCT01457755|Tegobuvir
310581|NCT01457755|Registry
310582|NCT01457755|HCV RNA
310583|NCT01457755|Treatment experienced
310584|NCT01457755|Treatment naive
310585|NCT01457755|GS 9451
310586|NCT01457755|GS 5885
310587|NCT01457755|GS 7977
310588|NCT01457755|GS 5816
310589|NCT01457755|Sofosbuvir
310590|NCT01457755|Sovaldi™
310591|NCT01457755|SOF
310592|NCT01457755|Ledipasvir
310593|NCT01457755|LDV
310594|NCT01457742|Osteoarthritis
310595|NCT01457729|ergometer
310596|NCT01457729|training
310597|NCT01457729|motivation
310598|NCT01457729|telemonitoring
310599|NCT01457729|sleep apnea
310600|NCT01457716|Healthy volunteer study
310601|NCT01457703|LH pulsatility
310602|NCT01457703|Obesity
310603|NCT01457703|Reproduction
310604|NCT01457690|Vitamin E pegylated
310605|NCT01457690|chylomicron retention
310606|NCT01457690|Familial Hypocholesterolemia
310607|NCT01457690|Hypobetalipoproteinemias
310608|NCT01457651|Recruitment
310609|NCT01457651|Coronary artery bypass grafting
310610|NCT01457651|Postoperative period
310611|NCT01457638|nasal obstruction
310612|NCT01457638|rhinoplasty
310613|NCT01457638|turbinate surgery
310614|NCT01457638|quality of life
310615|NCT01457638|acoustic rhinometry
310616|NCT01457625|fetuin A liver fat content visceral obesity mortality
310617|NCT01457612|Insulin Resistant
310618|NCT01457612|Dietary Supplements
310619|NCT01457612|Nutrition
310620|NCT01457612|Antioxidant
310621|NCT01457612|Inflammation
310622|NCT01457599|liver-colorectal metastases-computertomography-guided-wire-chemotherapy-complete response
310623|NCT01457599|Feasibility, safety
310624|NCT01457586|Heart Surgery
310625|NCT01457586|Blood Transfusion
310626|NCT01457586|Postoperative Complications
310627|NCT01457560|Oral polio vaccine (OPV)
310628|NCT01457560|DTPa-HBV-IPV/Hib vaccine
310629|NCT01457547|HEXAVACTM
310630|NCT01457547|InfanrixTM HEXA
310631|NCT01457547|DTPa-HBV-IPV-Hib
310632|NCT01457547|DTPa-HBV-IPV/Hib
310633|NCT01457521|pain
310634|NCT01457521|medical abortion
310635|NCT01457508|combination vaccine
310636|NCT01457508|DTPa-HBV-IPV
310637|NCT01457508|Hib
310638|NCT01457495|Infants
310639|NCT01457495|combined vaccine
310640|NCT01457495|DTPa-HBV-IPV/Hib
310641|NCT01457495|DTPa-IPV/Hib
310642|NCT01457495|safety
310643|NCT01457495|Immunogenicity
310644|NCT01457495|HBV
310645|NCT01457482|Fear
310646|NCT01457482|Childbirth
310647|NCT01457482|Art therapy
310648|NCT01457482|Therapeutic conversations
310649|NCT01457482|W-DEQ
310650|NCT01457456|Mucopolysaccharidoses
310651|NCT01457456|Mucopolysaccharidosis IV
310652|NCT01457456|Carbohydrate Metabolism, Inborn Errors
310653|NCT01457456|Metabolism, Inborn Errors
310654|NCT01457456|Genetic Diseases, Inborn
310655|NCT01457456|Lysosomal Storage Diseases
310656|NCT01457456|Connective Tissue Diseases
310657|NCT01457456|Metabolic Diseases
310658|NCT01457456|Musculoskeletal Diseases
310659|NCT01457443|Glycogen Storage Disease
310660|NCT01457443|Glycogen Storage Disease Type II
310661|NCT01457443|Metabolic Diseases
310662|NCT01457443|Carbohydrate Metabolism, Inborn Errors
310663|NCT01457443|Metabolism, Inborn Errors
310664|NCT01457443|Genetic Diseases, Inborn
310665|NCT01457443|Lysosomal Storage Diseases, Nervous System
310666|NCT01457417|Cancer
310667|NCT01457417|Oncology
310668|NCT01457404|integrated cognitive behavioral therapy
310669|NCT01457404|cognitive behavioral therapy
310670|NCT01457404|addiction
310671|NCT01457404|posttraumatic stress disorder (PTSD)
310672|NCT01457391|cognitive behavioral therapy
310673|NCT01457391|addiction
310674|NCT01457391|posttraumatic stress disorder (PTSD)
310675|NCT01457378|Gastrointestinal symptoms
310676|NCT01457378|healthy subjects
310677|NCT01457378|IBS
310678|NCT01457378|HRQoL
310679|NCT01457378|questionnaires
310680|NCT01457352|Baclofen, spasticity
310681|NCT01457339|Schizophrenia
310682|NCT01457326|Immersion therapy
310683|NCT01457326|early weight bearing physical therapy
310684|NCT01457300|Rehabilitation outcome
310685|NCT01457300|Aged
310686|NCT01457300|Aged, 80 and over
310687|NCT01457300|Activities of daily living
310688|NCT01457274|AMBULATORY CARE
310689|NCT01457274|AWARENESS AND RECALL
310690|NCT01457274|Propofol
310691|NCT01457274|Patient Safety and Satisfaction
310692|NCT01457274|Colonoscopy
310693|NCT01457274|Elective outpatient colonoscopy
310694|NCT01457274|Procedural sedation
310695|NCT01457261|interstitial lung disease
310696|NCT01457261|drug deposition
310697|NCT01457261|lung imaging
310698|NCT01457261|respiratory
310699|NCT01457248|after aortic surgery
310700|NCT01457235|Bipolar disorder
310701|NCT01457235|Cognitive Remediation
310702|NCT01457235|Cognition
310703|NCT01457235|Cognitive function
310704|NCT01457235|Mood disorders
310705|NCT01457235|Affective disorders
310706|NCT01457222|Mindfulness
310707|NCT01457222|Stress
310708|NCT01457222|Cognition
310709|NCT01457222|Psychological health
310710|NCT01457222|Primary prevention
310711|NCT01457209|PCOS
310712|NCT01457209|Insulin resistance
310713|NCT01457209|Acupuncture
310714|NCT01457196|Cancer Genetics
310715|NCT01457183|pulsed lavage
310716|NCT01457183|evaluate containment
310717|NCT01457183|evaluate tolerability
310718|NCT01457170|Pulmonary Hypertension
310719|NCT01457170|Heart Failure
310720|NCT01457170|Apelin
310721|NCT01457170|Haemodynamics
310722|NCT01457170|pulmonary vascular resistance
310723|NCT01457170|cardiac output
310724|NCT01457144|Mantle cell lymphoma
310725|NCT01457144|Rituximab
310726|NCT01457144|bendamustine
310727|NCT01457144|Velcade
310728|NCT01457144|Dexamethasone
310729|NCT01457131|Metastatic Cancer
310730|NCT01457131|Immunotherapy
310731|NCT01457131|Gene Therapy
310732|NCT01457131|Metastatic Melanoma
310733|NCT01457131|Metastatic Kidney Cancer
310734|NCT01457118|Open Label multicenter extension study advanced solid tumors
310735|NCT01457105|Malignant strictures of the main biliary duct
310736|NCT01457092|benign biliary strictures
310737|NCT01457092|chronic pancreatitis
310738|NCT01457079|Keloid
310739|NCT01457079|Radiation Therapy
310740|NCT01457079|Hypertrophic Scar
310741|NCT01457053|Acute decompensated heart failure
310742|NCT01457053|Myocardial blood flow
310743|NCT01457053|Coronary flow reserve
310744|NCT01457053|Ultrafiltration
310745|NCT01457053|Diuretics
310746|NCT01457040|Acute Lymphoblastic leukemia
310747|NCT01457040|Hematopoietic Stem Cell Transplantation
310748|NCT01457027|Influenza
310749|NCT01457027|Virus
310750|NCT01457027|Vaccination
310751|NCT01457027|Immunisation
310752|NCT01457014|chronic pain
310753|NCT01457014|sleep disordered breathing
310754|NCT01457014|Opioids
310755|NCT01457001|chronic haemodialysis
310756|NCT01457001|25-OH-D vitamin
310757|NCT01456975|Ascending aorta aneurism
310758|NCT01456975|Aortic insufficiency
310759|NCT01456962|Immune reconstitution
310760|NCT01456962|CD4+ T cells
310761|NCT01456949|Atrial fibrillation (AF)
310762|NCT01456949|Paroxysmal atrial fibrillation (PAF)
310763|NCT01456949|Arrythmias
310764|NCT01456949|Cardiac Arrythmias
310765|NCT01456949|Cardiac ablation
310766|NCT01456949|Cryoablation
310767|NCT01456936|smoking cessation
310768|NCT01456936|psychiatric disease
310769|NCT01456923|DNA damaging agents
310770|NCT01456910|Physical education
310771|NCT01456910|People with mental disabilities
310772|NCT01456910|muscular strength dynamometer
310773|NCT01456910|Performance Evaluation
310774|NCT01456910|Occupational health
310775|NCT01456884|Music therapy
310776|NCT01456884|Infants
310777|NCT01456884|Children
310778|NCT01456884|Adolescents
310779|NCT01456884|pediatric
310780|NCT01456884|palliative care
310781|NCT01456884|neurological impairment
310782|NCT01456884|metabolic condition
310783|NCT01456884|pain management
310784|NCT01456871|Mechanoreceptors
310785|NCT01456871|PIP joint
310786|NCT01456871|Ligamento-muscular reflexes
310787|NCT01456858|Malaria Prevention Refugee Emergency
310788|NCT01456858|Malaria, Falciparum C03.752.530.650
310789|NCT01456845|Plasma levels
310790|NCT01456845|isoniazid
310791|NCT01456845|rifampicin
310792|NCT01456845|pyrazinamide
310793|NCT01456845|hepatoxicity
310794|NCT01456832|hyponatremia
310795|NCT01456832|renal transplant
310796|NCT01456819|autologous
310797|NCT01456819|bone marrow
310798|NCT01456819|critical limb ischemia
310799|NCT01456819|efficacy
310800|NCT01456819|mesenchymal stem cells
310801|NCT01456819|mononuclear cells
310802|NCT01456806|T2DM
310803|NCT01456806|Cardiovascular risk factors
310804|NCT01456806|Metabolic control
310805|NCT01456806|Well-being
310806|NCT01456806|Cost
310807|NCT01456806|Cost-consequence
310808|NCT01456793|Pregnancy prevention
310809|NCT01456793|Pregnancy
310810|NCT01456793|Birth
310811|NCT01456793|Contraceptive use
310812|NCT01456793|Adolescents
310813|NCT01456780|Meibomian gland dysfunction
310814|NCT01456780|Blepharitis
310815|NCT01456780|Dry Eye
310816|NCT01456780|Ocular Inflammation
310817|NCT01456780|MGD
310818|NCT01456780|Zylet
310819|NCT01456780|Lotemax
310820|NCT01456780|Artificial Tear
310821|NCT01456754|Insulin Metabolism
310822|NCT01456754|Glucose Metabolism
310823|NCT01456754|Substrate Partitioning
310824|NCT01456754|Muscle Biopsies
310825|NCT01456754|Feeding Frequency
310826|NCT01456754|Insulin
310827|NCT01456741|endobronchial needle aspiration (EBNA)
310828|NCT01456741|transbronchial needle aspiration (TBNA)
310829|NCT01456741|rapid on-site evaluation (ROSE)
310830|NCT01456741|lung cancer
310831|NCT01456728|Helicobacter pylori
310832|NCT01456728|Progastria
310833|NCT01456728|Lactobacillus reuteri
310834|NCT01456728|omeprazole
310835|NCT01456728|triple therapy
310836|NCT01456728|probiotic
310837|NCT01456715|Human Papillomavirus Vaccines
310838|NCT01456715|Immunogenicity Gardasil Cervarix
310839|NCT01456715|Booster dose
310840|NCT01456702|SVV
310841|NCT01456702|hemodynamic monitoring
310842|NCT01456702|goal-directed volume therapie
310843|NCT01456689|Myeloma
310844|NCT01456689|Multiple Myeloma
310845|NCT01456689|MM
310846|NCT01456676|LDE225
310847|NCT01456676|nilotinib
310848|NCT01456676|Chronic myeloid leukemia
310849|NCT01456676|CML
310850|NCT01456676|Philadelphia positive
310851|NCT01456676|Ph+
310852|NCT01456676|resistant
310853|NCT01456676|Resistant Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
310854|NCT01456663|AFQ056
310855|NCT01456663|Hepatic impairment
310856|NCT01456663|Hepatic impaired
310857|NCT01456650|Type 2 diabetes
310858|NCT01456650|ABCA1 alleles
310859|NCT01456650|Glyburide
310860|NCT01456637|Insomnia
310861|NCT01456637|Intervention
310862|NCT01456637|Self-help
310863|NCT01456637|Internet
310864|NCT01456598|Stomach neoplasm
310865|NCT01456598|Laparoscopy
310866|NCT01456585|Histological documentation
310867|NCT01456585|primary adenocarcinoma of the pancreas
310868|NCT01456585|surgically eligible
310869|NCT01456585|tumor resection
310870|NCT01456585|curative intent
310871|NCT01456572|glucagon-like peptide-1
310872|NCT01456572|peptide tyrosine tyrosine
310873|NCT01456572|ghrelin
310874|NCT01456572|stomach
310875|NCT01456572|small intestine
310876|NCT01456572|gastric emptying
310877|NCT01456559|Hypovolemia
310878|NCT01456559|Lower body negative pressure
310879|NCT01456559|Photoplethysmography
310880|NCT01456546|CYP2C19*17
310881|NCT01456546|Pharmacokinetics
310882|NCT01456546|Pharmacodynamics
310883|NCT01456533|hyponatremia
310884|NCT01456533|hypernatremia
310885|NCT01456520|pharmacokinetics
310886|NCT01456520|bioequivalence
310887|NCT01456520|hydrocodone
310888|NCT01456520|acetaminophen
310889|NCT01456520|moderate to moderately severe pain
310890|NCT01456507|Food effect
310891|NCT01456507|bioavailability
310892|NCT01456507|oxycodone
310893|NCT01456507|sequestered Naltrexone
310894|NCT01456507|management of moderate to severe pain
310895|NCT01456494|Obstructive Lung Disease
310896|NCT01456494|COPD
310897|NCT01456494|Asthma
310898|NCT01456494|Inhaler
310899|NCT01456494|Metered-Dose Inhaler
310900|NCT01456494|Education
310901|NCT01456494|Hospital-based education
310902|NCT01456481|reflex fainting
310903|NCT01456481|vasovagal syncope
310904|NCT01456481|midodrine
310905|NCT01456468|Cholangitis, Sclerosing
310906|NCT01456468|Tretinoin
310907|NCT01456468|Ursodeoxycholic Acid
310908|NCT01456455|Central nervous system
310909|NCT01456455|pathological markers
310910|NCT01456429|invasive staging
310911|NCT01456429|mediastinal lymph nodes
310912|NCT01456429|endosonography
310913|NCT01456429|surgical staging
310914|NCT01456429|lung cancer
310915|NCT01456416|RRMS
310916|NCT01456416|Multiple Sclerosis
310917|NCT01456416|Glatiramer Acetate
310918|NCT01456416|Autoimmune Comorbidities
310919|NCT01456416|Psoriasis
310920|NCT01456416|Autoimmune Thyroiditis
310921|NCT01456416|Vasculitis
310922|NCT01456416|Rheumatoid Arthritis
310923|NCT01456403|Carotid
310924|NCT01456403|endarterectomy
310925|NCT01456403|vulnerable plaque
310926|NCT01456403|Ultrasound
310927|NCT01456403|MRI
310928|NCT01456403|PET/CT
310929|NCT01456390|Open angle glaucoma
310930|NCT01456390|Prior trabeculectomy
310931|NCT01456377|lumbar stenosis
310932|NCT01456377|systemic corticosteroids
310933|NCT01456377|outcome
310934|NCT01456377|security
310935|NCT01456364|clopidogrel low response
310936|NCT01456364|ticagrelor
310937|NCT01456364|prasugrel
310938|NCT01456364|platelet aggregation
310939|NCT01456351|Event free survival
310940|NCT01456351|Remission rates
310941|NCT01456351|Toxicity
310942|NCT01456351|Overall survival
310943|NCT01456351|Efficiency costs
310944|NCT01456351|Recurrent low grade
310945|NCT01456338|cognitive behavior therapy
310946|NCT01456338|addiction
310947|NCT01456338|posttraumatic stress disorder (PTSD)
310948|NCT01456312|Peginterferon alfa 2a
310949|NCT01456312|Entecavir
310950|NCT01456312|Response Guided Therapy
310951|NCT01456312|Chronic Hepatitis B
310952|NCT01456299|laryngeal mask airway
310953|NCT01456299|insertion
310954|NCT01456299|sevoflurane
310955|NCT01456299|remifentanil
310956|NCT01456273|biopsychosocial model
310957|NCT01456273|biomedical model
310958|NCT01456273|functional dyspepsia
310959|NCT01456260|Drug Therapy
310960|NCT01456247|Drug Therapy
310961|NCT01456221|Obesity
310962|NCT01456221|Insulin resistance
310963|NCT01456221|Omega3 long chain polyunsaturated fatty acids
310964|NCT01456195|Drug Therapy
310965|NCT01456169|High Blood Pressure
310966|NCT01456169|Drug Therapy
310967|NCT01456156|hepatocellular carcinoma
310968|NCT01456156|postoperative radiotherapy
310969|NCT01456143|Squamous Cell Carcinoma
310970|NCT01456143|Neoplasia
310971|NCT01456143|Optical imaging
310972|NCT01456143|Head and Neck Cancer
310973|NCT01456143|Oropharynx
310974|NCT01456143|Larynx
310975|NCT01456143|Oral Cavity
310976|NCT01456117|Drug Therapy
310977|NCT01456117|pharmacodynamics
310978|NCT01456117|pharmacokinetics
310979|NCT01456104|vaccine
310980|NCT01456104|stage IIB
310981|NCT01456104|stage IIC
310982|NCT01456104|stage III
310983|NCT01456104|stage IV (MIa)
310984|NCT01456104|Langerhans-type dendritic cells
310985|NCT01456104|Immune Responses
310986|NCT01456104|10-229
310987|NCT01456091|adolescent pregnancy
310988|NCT01456091|adolescent birth
310989|NCT01456091|rapid repeat pregnancy
310990|NCT01456091|rapid repeat birth
310991|NCT01456091|youth development
310992|NCT01456091|Pregnancy in Adolescence
310993|NCT01456078|Neuroendocrine tumor
310994|NCT01456078|Liver metastases
310995|NCT01456078|177Lu-DOTA-TATE
310996|NCT01456078|Safety
310997|NCT01456078|Kidney dosimetry
310998|NCT01456078|Dose escalation
310999|NCT01456078|Neuroendocrine tumors, with liver metastases.
311000|NCT01456026|Diabetes
311001|NCT01456026|Advanced glycation endproducts
311002|NCT01456026|Endothelium
311003|NCT01456000|atrial fibrillation
311004|NCT01456000|AF
311005|NCT01456000|PAF
311006|NCT01456000|PVI
311007|NCT01456000|ablation
311008|NCT01456000|paroxysmal atrial fibrillation
311009|NCT01456000|pulmonary vein isolation
311010|NCT01455987|Osteochondritis dissecans
311011|NCT01455987|Juvenile osteochondritis dissecans
311012|NCT01455987|Knee
311013|NCT01455987|Osteochondral
311014|NCT01455987|Outcome
311015|NCT01455974|hypertension
311016|NCT01455974|arterial stiffness
311017|NCT01455974|left ventricular hypertrophy
311018|NCT01455961|Real life setting
311019|NCT01455961|Bipolar Disorder
311020|NCT01455961|Registry based Data Base Audit
311021|NCT01455948|sinusitis
311022|NCT01455948|chronic
311023|NCT01455948|Functional endoscopic sinus surgery
311024|NCT01455948|balloon sinuplasty
311025|NCT01455844|Hypertriglyceridemia
311026|NCT01455792|Biopsy
311027|NCT01455792|MRI and ultrasound soft image fusion
311028|NCT01455792|Gold standard TRUS biopsy
311029|NCT01455779|Stress Urinary Incontinence
311030|NCT01455779|Incontinence
311031|NCT01455779|SUI
311032|NCT01455779|Renessa
311033|NCT01455766|postpneumonectomy pulmonary edema
311034|NCT01455766|extravascular lung water
311035|NCT01455753|Influenza
311036|NCT01455753|Proximity
311037|NCT01455740|Acquired Immunodeficiency Syndrome
311038|NCT01455740|HIV
311039|NCT01455740|Commitment
311040|NCT01455740|Financial Incentives
311041|NCT01455727|Pharmaceutical care
311042|NCT01455727|Diabetes Mellitus
311043|NCT01455714|hypertenion
311044|NCT01455714|exertional dyspnoea
311045|NCT01455714|heart failure
311046|NCT01455714|biomarkers
311047|NCT01455688|critically ill patients
311048|NCT01455688|HIV infection
311049|NCT01455688|HAART
311050|NCT01455688|mortality
311051|NCT01455675|cystic fibrosis
311052|NCT01455662|cardiac arrest
311053|NCT01455649|Kidney
311054|NCT01455649|Transplant
311055|NCT01455649|Immunosuppression
311056|NCT01455649|Everolimus
311057|NCT01455649|Graft function
311058|NCT01455636|pediatric
311059|NCT01455636|micronutrient powder
311060|NCT01455636|hand hygiene
311061|NCT01455636|low birth weight
311062|NCT01455636|infant feeding
311063|NCT01455636|hand sanitizers
311064|NCT01455623|CMT
311065|NCT01455610|Computed tomography
311066|NCT01455610|Contrast enhancement
311067|NCT01455610|Pancreas
311068|NCT01455610|Cancer
311069|NCT01455610|Resectability
311070|NCT01455597|Postmenopausal Women
311071|NCT01455597|Vaginal Dryness
311072|NCT01455597|Postmenopausal Vulvovaginal Atrophy
311073|NCT01455584|HM781-36B
311074|NCT01455558|Pharmacokinetics
311075|NCT01455545|Asthma
311076|NCT01455545|Degree of Control
311077|NCT01455545|Exhaled Nitric Oxide
311078|NCT01455545|Asthma Control Test
311079|NCT01455519|Low Back Pain
311080|NCT01455519|Back Pain
311081|NCT01455519|Chronic back pain
311082|NCT01455506|Acute Myeloid Leukemia (AML)
311083|NCT01455506|Myelodysplastic Syndrome (MDS)
311084|NCT01455506|Bone Marrow Transplant
311085|NCT01455506|Stem Cell Transplant
311086|NCT01455480|Second Degree Burn
311087|NCT01455480|partial thickness burns
311088|NCT01455467|Open angle glaucoma
311089|NCT01455467|Pigmentary glaucoma
311090|NCT01455467|Pseudoexfoliative glaucoma
311091|NCT01455441|GLP-1
311092|NCT01455441|Training
311093|NCT01455441|Exercise
311094|NCT01455441|Type 2 Diabetes
311095|NCT01455428|Pregabalin
311096|NCT01455428|Postherpetic Neuralgia ( PHN )
311097|NCT01455402|Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Observational
311098|NCT01455389|Lung Cancer
311099|NCT01455389|Non-small cell lung cancer
311100|NCT01455389|NSCLC
311101|NCT01455389|FUS1-nanoparticles
311102|NCT01455389|DOTAP:Chol-fus1
311103|NCT01455389|DOTAP:Cholesterol-Fus1 Liposome Complex
311104|NCT01455389|Erlotinib
311105|NCT01455389|Erlotinib Hydrochloride
311106|NCT01455389|OSI-774
311107|NCT01455389|Tarceva
311108|NCT01455389|Dexamethasone
311109|NCT01455389|Decadron
311110|NCT01455389|Diphenhydramine
311111|NCT01455389|Benadryl
311112|NCT01455389|Benylin Cough SyrupPharmacokinetic
311113|NCT01455389|PK
311114|NCT01455376|brain injury
311115|NCT01455376|cognitive function
311116|NCT01455376|sodium lactate
311117|NCT01455376|MMSE score
311118|NCT01455350|provoked vestibulodynia
311119|NCT01455350|multimodal physiotherapy
311120|NCT01455350|lidocaine
311121|NCT01455337|severe alcoholic hepatitis
311122|NCT01455324|prosthetic socket
311123|NCT01455324|residual limb volume fluctuation
311124|NCT01455324|conformable socket liner
311125|NCT01455311|cystic pancreatic tumors
311126|NCT01455311|cystic pancreatic lesions
311127|NCT01455311|gastrointestinal
311128|NCT01455311|GI
311129|NCT01455311|EUS-FNA
311130|NCT01455311|EchoBrush®
311131|NCT01455311|cytology brush
311132|NCT01455311|endoscopic
311133|NCT01455298|Alpha-1 AT deficiency
311134|NCT01455298|liver injury
311135|NCT01455298|Transient Elastography
311136|NCT01455298|FibroTest
311137|NCT01455285|dysmenorrhea
311138|NCT01455285|transcutaneous electrical nerve stimulation (TENS
311139|NCT01455285|analgesia
311140|NCT01455285|pain visual analog scale
311141|NCT01455285|McGill pain questionnaire
311142|NCT01455259|AdCD40L
311143|NCT01455259|Adenoviral vector
311144|NCT01455259|CD40L
311145|NCT01455259|CD154
311146|NCT01455259|malignant melanoma
311147|NCT01455246|Cirrhosis
311148|NCT01455246|Nosocomial Spontaneous Bacterial Peritonitis
311149|NCT01455246|Ascites
311150|NCT01455246|Daptomycin
311151|NCT01455246|Meropenem
311152|NCT01455246|Ceftazidime
311153|NCT01455246|Nosocomial infection
311154|NCT01455246|Multi drug resistant bacteria
311155|NCT01455246|Sepsis
311156|NCT01455246|Albumin
311157|NCT01455233|cornea
311158|NCT01455233|ocular antibiotic
311159|NCT01455233|cataract surgery
311160|NCT01455220|Multiple Sclerosis
311161|NCT01455220|Sexual Dysfunction
311162|NCT01455220|Quality of Life
311163|NCT01455207|Magnetic Resonance Imaging
311164|NCT01455207|Positon Emission Tomography
311165|NCT01455207|Behavior
311166|NCT01455194|ciclesonide
311167|NCT01455194|asthma
311168|NCT01455181|Hypoparathyroidism
311169|NCT01455181|NPSP558
311170|NCT01455181|Parathyroid Hormone 1-84
311171|NCT01455181|PTH 1-84
311172|NCT01455168|anterior capsule shrinkage
311173|NCT01455168|capsular tension ring
311174|NCT01455168|exfoliation syndrome
311175|NCT01455168|phacoemulsification and aspiration
311176|NCT01455155|stroke
311177|NCT01455155|Art therapy
311178|NCT01455155|Music therapy
311179|NCT01455155|Creative therapy
311180|NCT01455155|Efficacy
311181|NCT01455129|chronic obstructive pulmonary disease
311182|NCT01455129|COPD
311183|NCT01455129|COPD exacerbation
311184|NCT01455129|treatment
311185|NCT01455129|tiotropium
311186|NCT01455129|anticholinergic
311187|NCT01455129|acute exacerbation of COPD (AECOPD)
311188|NCT01455116|Sepsis
311189|NCT01455116|Multi organ dysfunction syndrome
311190|NCT01455116|Mild Induced Hypothermia
311191|NCT01455077|obesity
311192|NCT01455077|sleep apnea
311193|NCT01455077|portable monitoring
311194|NCT01455025|Plerixafor granulocyte-colony stimulating factor
311195|NCT01455025|Chemotherapy in relapse
311196|NCT01455025|Acute Myeloid Leukemia
311197|NCT01455012|Rotigotine
311198|NCT01455012|Neupro
311199|NCT01455012|RLS
311200|NCT01455012|Cardiovascular Risk
311201|NCT01455012|Nocturnal Blood Pressure
311202|NCT01454999|veteran
311203|NCT01454999|smoking
311204|NCT01454999|stage of change
311205|NCT01454999|cell phone
311206|NCT01454999|computerized tailored intervention
311207|NCT01454986|Healthy subjects
311208|NCT01454973|type 2 diabetes
311209|NCT01454973|beta cell function
311210|NCT01454973|meal tolerance test
311211|NCT01454973|maximum stimulation test
311212|NCT01454973|method standardization
311213|NCT01454973|insulin secretion
311214|NCT01454960|Antibiotics
311215|NCT01454960|Inappropriate Prescribing
311216|NCT01454960|Respiratory Tract Infections
311217|NCT01454960|Behavioral Research
311218|NCT01454947|Antibiotics
311219|NCT01454947|Inappropriate Prescribing
311220|NCT01454947|Respiratory Tract Infections
311221|NCT01454947|Behavioral Research
311222|NCT01454921|HIV
311223|NCT01454921|Adolescent Trials Network
311224|NCT01454908|partial knee arthroplasty
311225|NCT01454895|noise-induced hearing loss
311226|NCT01454895|prevention
311227|NCT01454895|farmers
311228|NCT01454882|Direct calorimetry
311229|NCT01454882|Indirect calorimetry
311230|NCT01454882|Energy Expenditure
311231|NCT01454869|heparin
311232|NCT01454843|Myopia
311233|NCT01454843|Astigmatism
311234|NCT01454843|Aberrations
311235|NCT01454843|Wavefront
311236|NCT01454843|LASIK
311237|NCT01454843|Wavefront LASIK
311238|NCT01454830|Social support
311239|NCT01454830|Cognition
311240|NCT01454830|Adaptation, psychological
311241|NCT01454830|Health behavior
311242|NCT01454830|Patient education
311243|NCT01454817|Quality of Life
311244|NCT01454817|Implantable Cardiac Defibrillators
311245|NCT01454817|ICDs
311246|NCT01454804|Advanced Cancers
311247|NCT01454804|Solid Tumors
311248|NCT01454804|Pazopanib
311249|NCT01454804|GW786034
311250|NCT01454804|Lapatinib
311251|NCT01454804|Tykerb
311252|NCT01454804|GW572016
311253|NCT01454804|Trastuzumab
311254|NCT01454804|Herceptin
311255|NCT01454791|multiple sclerosis
311256|NCT01454791|diclofenac
311257|NCT01454791|subcutaneous injection
311258|NCT01454791|glatiramer acetate
311259|NCT01454791|Copaxone
311260|NCT01454778|restenosis
311261|NCT01454778|peripheral vascular disease
311262|NCT01454778|lower extremity ischemia
311263|NCT01454778|claudication
311264|NCT01454752|malaria
311265|NCT01454752|anaemia
311266|NCT01454752|cognition
311267|NCT01454752|intermittent preventive treatment
311268|NCT01454752|children
311269|NCT01454752|schools
311270|NCT01454752|insecticide-treated nets
311271|NCT01454739|rFVIIIFc
311272|NCT01454739|A-LONG Extension
311273|NCT01454726|Dizziness
311274|NCT01454726|Meniere's disease
311275|NCT01454726|Diaoshi Jifa therapy
311276|NCT01454700|Type 1 diabetes mellitus
311277|NCT01454700|Albuminuria
311278|NCT01454700|Late diabetes complications
311279|NCT01454700|CSII
311280|NCT01454700|CGM
311281|NCT01454700|Glycaemic control
311282|NCT01454661|Probiotics
311283|NCT01454661|Premature infant
311284|NCT01454661|Intestinal microbiota
311285|NCT01454661|Intestinal immunity
311286|NCT01454661|Breastfeeding
311287|NCT01454648|Traumatic Brain Injury
311288|NCT01454648|EMS
311289|NCT01454648|Out-of-Hospital
311290|NCT01454635|depression
311291|NCT01454635|treatment response
311292|NCT01454635|selective serotonin reuptake inhibitor
311293|NCT01454622|Healthy Volunteers
311294|NCT01454622|Bioequivalence
311295|NCT01454622|Canagliflozin (JNJ-28431754)
311296|NCT01454622|Metformin IR
311297|NCT01454609|cervical plexus block
311298|NCT01454609|thyroidectomy
311299|NCT01454609|postoperative analgesia
311300|NCT01454596|Cell Therapy
311301|NCT01454596|Gene Therapy
311302|NCT01454596|Immunotherapy
311303|NCT01454596|Brain Cancer
311304|NCT01454596|Glioma
311305|NCT01454596|Glioblastoma
311306|NCT01454583|renin inhibitor
311307|NCT01454583|ACE inhibitor
311308|NCT01454583|ARB (AT1 receptor blockers)
311309|NCT01454583|RAS blockade
311310|NCT01454570|exoskeleton walking system
311311|NCT01454570|paraplegia
311312|NCT01454570|paralysis
311313|NCT01454557|Acquired Brain Injury
311314|NCT01454557|Heart Rate Variability (HRV)
311315|NCT01454557|Auditory Stimuli
311316|NCT01454557|Physical Activity
311317|NCT01454518|hip arthroscopy
311318|NCT01454518|post operative analgesia
311319|NCT01454505|Healthy subjects
311320|NCT01454505|Nasal allergies
311321|NCT01454505|Allergies
311322|NCT01454505|Environmental Exposure Chamber
311323|NCT01454505|EEC
311324|NCT01454505|Ragweed
311325|NCT01454492|Allergy rhinitis
311326|NCT01454492|Geographic tongue
311327|NCT01454479|Lapatinib
311328|NCT01454479|Ixabepilone
311329|NCT01454479|HER-2
311330|NCT01454479|Endometrial Carcinoma
311331|NCT01454466|prevention
311332|NCT01454466|retinal break
311333|NCT01454466|vitrectomy
311334|NCT01454466|partial posterior hyaloidectomy
311335|NCT01454453|amisulpride
311336|NCT01454453|receptor occupancy
311337|NCT01454453|antipsychotic sensitivity
311338|NCT01454440|Coronary artery disease
311339|NCT01454440|Eptifibatide
311340|NCT01454440|Percutaneous coronary intervention
311341|NCT01454440|stable coronary artery disease
311342|NCT01454440|percutaneous coronary intervention (PCI)
311343|NCT01454440|DES
311344|NCT01454375|Smoking
311345|NCT01454362|nicotine
311346|NCT01454362|inhalator
311347|NCT01454362|electronic cigarette
311348|NCT01454362|tobacco
311349|NCT01454349|Benign prostatic hyperplasia
311350|NCT01454349|BPH
311351|NCT01454349|Enlarged prostate
311352|NCT01454349|Lower urinary tract symptoms (LUTS)
311353|NCT01454336|MSCs
311354|NCT01454336|Pioglitazon
311355|NCT01454336|fibrosis
311356|NCT01454336|liver
311357|NCT01454323|Chronic Myocardial Ischemia
311358|NCT01454323|Cell therapy
311359|NCT01454323|Bone marrow mononuclear cells
311360|NCT01454310|Skin substitutes
311361|NCT01454310|Split-thickness skin graft
311362|NCT01454310|Burn wound
311363|NCT01454310|Scar formation
311364|NCT01454310|Skin quality
311365|NCT01454297|Myeloma
311366|NCT01454297|Multiple Myeloma
311367|NCT01454297|Observational
311368|NCT01454297|Longitudinal
311369|NCT01454271|Total Hip arthroplasty
311370|NCT01454271|Hip Osteoarthritis
311371|NCT01454271|Infection after Total Hip Arthroplasty
311372|NCT01454245|39439335EDI1013
311373|NCT01454245|Bioavailability
311374|NCT01454245|Pharmacokinetics
311375|NCT01454232|Obesity
311376|NCT01454232|adipose tissue inflammation
311377|NCT01454232|Low grade systemic inflammation
311378|NCT01454232|gut microbiota
311379|NCT01454232|Bariatric surgery
311380|NCT01454206|cannabis abuse
311381|NCT01454206|alcohol abuse
311382|NCT01454206|substance abuse
311383|NCT01454180|Therapeutic targets in Pancreas
311384|NCT01454167|vacum drains
311385|NCT01454167|operational wounds
311386|NCT01454167|infections
311387|NCT01454167|seroma
311388|NCT01454167|acid base
311389|NCT01454167|glucose
311390|NCT01454167|lactate
311391|NCT01454154|TBI
311392|NCT01454154|Traumatic Brain Injury
311393|NCT01454141|Depressed mood
311394|NCT01454128|exercise base rehabilitation
311395|NCT01454128|heart failure
311396|NCT01454128|periodic breathing
311397|NCT01454128|aerobic fitness
311398|NCT01454089|bladder
311399|NCT01454089|urinary tract
311400|NCT01454089|transitional cell carcinoma
311401|NCT01454089|metastatic bladder cancer
311402|NCT01454089|chemotherapy
311403|NCT01454076|Cmax: maximum plasma concentration
311404|NCT01454076|AUC0-tlast: time zero to the time of the last quantifiable concentration
311405|NCT01454063|cataract
311406|NCT01454063|lens replacement
311407|NCT01454050|ICD therapy
311408|NCT01454050|RV/LV Capture Control
311409|NCT01454050|Safety and Efficacy
311410|NCT01454011|hypogonadism
311411|NCT01454011|testosterone
311412|NCT01454011|HDL cholesterol subgroups
311413|NCT01454011|hsCRP
311414|NCT01454011|HOMA-IR
311415|NCT01453972|Exercise
311416|NCT01453972|High-intensity
311417|NCT01453972|Interval training
311418|NCT01453959|hypertension
311419|NCT01453959|salt sensitivity
311420|NCT01453959|fludrocortisone
311421|NCT01453946|Crohn's Disease
311422|NCT01453933|Anti-HIV Agents
311423|NCT01453933|Anti-Retroviral Agents
311424|NCT01453933|Antiviral Agents
311425|NCT01453933|Anti-Infective Agents
311426|NCT01453933|Lopinavir/ritonavir
311427|NCT01453920|Age Related Macular Degeneration
311428|NCT01453920|Choroidal Neovascular Membrane
311429|NCT01453894|Colorectal Cancer Screening
311430|NCT01453894|Fecal Occult Blood Testing
311431|NCT01453881|Asthma
311432|NCT01453881|pMDI
311433|NCT01453881|Beclomethasone
311434|NCT01453881|Formoterol
311435|NCT01453881|Efficacy
311436|NCT01453868|Multiple Sclerosis
311437|NCT01453868|non impact aerobics
311438|NCT01453855|Open-Angle Glaucoma
311439|NCT01453855|Ocular Hypertension
311440|NCT01453842|Glucagon-like peptide-1
311441|NCT01453842|Glucose-dependant insulinotropic polypeptide
311442|NCT01453842|Glucagon
311443|NCT01453842|Peptide PYY
311444|NCT01453842|2-oleyl glycerol
311445|NCT01453816|Renal insufficiency
311446|NCT01453816|kidney failure
311447|NCT01453803|Liposuction
311448|NCT01453803|ADSC
311449|NCT01453803|ASC
311450|NCT01453803|stem cell
311451|NCT01453803|Parkinson's Disease
311452|NCT01453803|Parkinson's
311453|NCT01453803|therapy
311454|NCT01453790|depression
311455|NCT01453790|treatment
311456|NCT01453790|motivation to seek follow up
311457|NCT01453777|diffuse brain lesion
311458|NCT01453751|Diabetes
311459|NCT01453751|Type 2 Diabetes
311460|NCT01453738|Osteoarthritis
311461|NCT01453738|Knee
311462|NCT01453738|Stem cells
311463|NCT01453738|Mesenchymal Stem Cells
311464|NCT01453712|coronary artery disease
311465|NCT01453712|coronary CT angiography
311466|NCT01453712|radiation dose
311467|NCT01453712|iterative image reconstruction
311468|NCT01453712|detection
311469|NCT01453699|Bereavement
311470|NCT01453699|early parental death
311471|NCT01453699|grief
311472|NCT01453699|affective disorders
311473|NCT01453699|depression, depressive symptoms
311474|NCT01453699|socioeconomic factors
311475|NCT01453699|suicide
311476|NCT01453699|attempted suicide
311477|NCT01453699|antidepressive agents
311478|NCT01453699|cardiovascular diseases
311479|NCT01453699|quality of life
311480|NCT01453699|Long-term health effects
311481|NCT01453699|Socioeconomic outcomes
311482|NCT01453699|Psychosocial well-being
311483|NCT01453686|Alopecia Areata
311484|NCT01453686|Hydrocortisone
311485|NCT01453686|Clobetasol Propionate
311486|NCT01453686|Randomized Controlled Trial
311487|NCT01452711|Drug Therapy
311488|NCT01452698|Drug Therapy
311489|NCT01452685|Drug Therapy
311490|NCT01453673|knee
311491|NCT01453673|Cruciate Ligament
311492|NCT01453673|Meniscus
311493|NCT01453660|Endothelial Function
311494|NCT01453660|Endo-PAT2000 system
311495|NCT01453660|11-140
311496|NCT01453647|Fibromyalgia
311497|NCT01453647|self-efficacy
311498|NCT01453647|fatigue
311499|NCT01453647|stress
311500|NCT01453647|cytokine
311501|NCT01453634|chronic kidney disease (CKD)
311502|NCT01453634|secondary hyperparathyroidism (SHPT)
311503|NCT01453634|hemodialysis (HD)
311504|NCT01453621|prediction rules
311505|NCT01453621|computerized clinical decision support
311506|NCT01453621|traumatic brain injury
311507|NCT01453621|blunt head trauma
311508|NCT01453595|Kidney
311509|NCT01453595|renal cell carcinoma
311510|NCT01453595|BEZ235
311511|NCT01453595|11-080
311512|NCT01453582|Chest stuffiness of TCM
311513|NCT01453582|Qi deficiency and blood stasis of TCM
311514|NCT01453556|Laparoscopic surgery
311515|NCT01453556|Right colectomy
311516|NCT01453556|Mechanical anastomosis
311517|NCT01453556|Post-operative ileum
311518|NCT01453530|Recovery
311519|NCT01453530|Street fitness
311520|NCT01453530|Sugammadex
311521|NCT01453530|Alertness
311522|NCT01453530|Ambulatory surgery
311523|NCT01453517|bariatric
311524|NCT01453517|obesity
311525|NCT01453517|post-surgery
311526|NCT01453517|intervention
311527|NCT01453465|childhood atypical teratoid/rhabdoid tumor
311528|NCT01453465|rhabdoid tumor of the kidney
311529|NCT01453452|weight changes
311530|NCT01453452|fatigue
311531|NCT01453452|depression
311532|NCT01453452|anxiety disorder
311533|NCT01453452|pain
311534|NCT01453452|cognitive/functional effects
311535|NCT01453452|psychosocial effects of cancer and its treatment
311536|NCT01453452|cancer survivor
311537|NCT01453452|stage IA breast cancer
311538|NCT01453452|stage IB breast cancer
311539|NCT01453452|stage II breast cancer
311540|NCT01453452|stage IIIA breast cancer
311541|NCT01453452|stage IIIB breast cancer
311542|NCT01453452|stage IIIC breast cancer
311543|NCT01453452|stage I colon cancer
311544|NCT01453452|stage IIA colon cancer
311545|NCT01453452|stage IIB colon cancer
311546|NCT01453452|stage IIC colon cancer
311547|NCT01453452|stage IIIA colon cancer
311548|NCT01453452|stage IIIB colon cancer
311549|NCT01453452|stage IIIC colon cancer
311550|NCT01453452|stage I rectal cancer
311551|NCT01453452|stage IIA rectal cancer
311552|NCT01453452|stage IIB rectal cancer
311553|NCT01453452|stage IIC rectal cancer
311554|NCT01453452|stage IIIA rectal cancer
311555|NCT01453452|stage IIIB rectal cancer
311556|NCT01453452|stage IIIC rectal cancer
311557|NCT01453439|Body dysmorphic disorder
311558|NCT01453439|Obsessive compulsive spectrum disorder
311559|NCT01453439|Body image
311560|NCT01453439|Appearance concerns
311561|NCT01453400|aspirin
311562|NCT01453400|acetylsalicylic acid
311563|NCT01453400|pharyngitis
311564|NCT01453400|sore throat
311565|NCT01453387|MEK inhibitor
311566|NCT01453387|Solid Tumor
311567|NCT01453387|Phase I
311568|NCT01453374|opioid dependence
311569|NCT01453374|VIVITROL
311570|NCT01453374|criminal justice
311571|NCT01453361|FANG
311572|NCT01453361|Melanoma
311573|NCT01453361|Vigil
311574|NCT01453348|meningococcal
311575|NCT01453348|conjugate
311576|NCT01453348|vaccine
311577|NCT01453348|adults
311578|NCT01453335|Veins
311579|NCT01453335|Catheter Segments
311580|NCT01453335|Vascular Access
311581|NCT01453335|VeinViewer Vision
311582|NCT01453322|Veins
311583|NCT01453322|Vascular Access
311584|NCT01453322|IV complications
311585|NCT01453322|VeinViewer Vision
311586|NCT01453309|lumbar fusion
311587|NCT01453309|transfusion
311588|NCT01453309|cell-saver
311589|NCT01453309|cost-effectiveness
311590|NCT01453296|Asthma
311591|NCT01453296|Tolerability
311592|NCT01453296|Safety
311593|NCT01453296|Pharmacokinetics
311594|NCT01453296|GW642444
311595|NCT01453283|DNA Repair
311596|NCT01453283|Nucleotide Excision Repair
311597|NCT01453283|Trabectedine
311598|NCT01453283|Phase I
311599|NCT01453283|Sarcoma
311600|NCT01453283|Cytotoxic
311601|NCT01453283|Chemotherapy
311602|NCT01453283|Solid Tumor
311603|NCT01453283|Malignant Tumor
311604|NCT01453283|Rhabdomyosarcoma
311605|NCT01453283|Ewing Sarcoma
311606|NCT01453283|Neuroblastoma
311607|NCT01453283|Wilm's Tumor
311608|NCT01453283|Hepatic Tumor
311609|NCT01453283|Brain Tumor
311610|NCT01453270|Sepsis
311611|NCT01453270|Emergency medicine
311612|NCT01453270|Cardiac output
311613|NCT01453270|Stroke volume
311614|NCT01453270|Lactate
311615|NCT01453257|Molecular Targets
311616|NCT01453257|Personalize Treatment
311617|NCT01453257|Colon Cancer
311618|NCT01453257|Complete Response Rate
311619|NCT01453244|Chronic hepatitis C
311620|NCT01453244|Pharmacogenomics
311621|NCT01453244|IL28B
311622|NCT01453244|ITPA
311623|NCT01453231|bariatric surgery
311624|NCT01453231|plastic surgery
311625|NCT01453231|thigh
311626|NCT01453231|obesity
311627|NCT01453231|body image
311628|NCT01453231|quality of life
311629|NCT01453218|Renal insufficiency
311630|NCT01453218|Liver transplant
311631|NCT01453218|Acute rejection
311632|NCT01453218|Infections
311633|NCT01453218|Hepatitis C recurrence
311634|NCT01453205|Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, B-Cell Malignancy, anti-CD19, monoclonal antibody, second line, ASCT, Refractory
311635|NCT01453192|Raltegravir
311636|NCT01453192|Renal transplantation
311637|NCT01453192|HIV-1
311638|NCT01453192|Acute renal graft rejection
311639|NCT01453179|actinic keratosis
311640|NCT01453179|invasive SCC
311641|NCT01453179|in situ SCC
311642|NCT01453179|histological classification
311643|NCT01453179|histological progression
311644|NCT01453179|clinical clearance
311645|NCT01453179|cryotherapy
311646|NCT01453153|pancreatic
311647|NCT01453153|Cancer
311648|NCT01453153|Stage IV
311649|NCT01453153|untreated
311650|NCT01453127|dementia
311651|NCT01453127|parkinsonism
311652|NCT01453127|mild cognitive impairment
311653|NCT01453127|REM sleep behavior disorder
311654|NCT01453114|Cognitive Behavioral Therapy
311655|NCT01453114|CBT
311656|NCT01453114|relapse
311657|NCT01453114|postpartum depression
311658|NCT01453114|depression recurrence
311659|NCT01453114|depression relapse
311660|NCT01453101|Multiple Myeloma
311661|NCT01453101|Transplant
311662|NCT01453088|multiple myeloma
311663|NCT01453088|transplant
311664|NCT01453075|hepatitis C
311665|NCT01453075|herpes simplex type 2
311666|NCT01453075|veterans
311667|NCT01453062|Ofatumumab
311668|NCT01453062|Chronic lymphocytic leukemia (CLL)
311669|NCT01453062|Arzerra
311670|NCT01453049|rosiglitazone/glimepiride, fix dose, type 2 diabetes
311671|NCT01453036|Peptic ulcer
311672|NCT01453036|Helicobacter pylori
311673|NCT01453036|Clarithromycin
311674|NCT01453036|23S rRNA
311675|NCT01453036|Resistance
311676|NCT01453023|pediatric ages 5 to 11 years
311677|NCT01453010|SaeboFlex
311678|NCT01453010|Stroke rehabilitation
311679|NCT01453010|Upper Limb Rehabilitation
311680|NCT01453010|Acute Stroke
311681|NCT01452997|mosquito
311682|NCT01452997|allergy
311683|NCT01452997|bite
311684|NCT01452997|ant-inflammatory
311685|NCT01452997|Aedes aegypti mosquito bite
311686|NCT01452984|Non-Melanoma skin cancer patients who have undergone or about to undergo Mohs surgery
311687|NCT01452984|who are treated within the University of Pennsylvania Health System
311688|NCT01452971|tumor susceptibility gene
311689|NCT01452971|glycine N-methyltransferase (GNMT)
311690|NCT01452971|polycyclic aromatic hydrocarbons (PAHs)
311691|NCT01452971|lung cancer
311692|NCT01452958|Endotoxin
311693|NCT01452958|LPS
311694|NCT01452958|TNF-α
311695|NCT01452958|insulin resistance
311696|NCT01452958|metabolism
311697|NCT01452932|Chronic obstructive pulmonary disease
311698|NCT01452932|Dyspnea
311699|NCT01452932|Exercise test
311700|NCT01452932|Endurance training
311701|NCT01452919|schizophrenia, LY2140023, pomaglumetad methionil
311702|NCT01452906|Drug-drug interaction
311703|NCT01452906|Pharmacokinetics
311704|NCT01452906|PA21
311705|NCT01452906|Drug Interaction Potentiation
311706|NCT01452880|Remifentanil
311707|NCT01452880|Lithotripsy
311708|NCT01452880|Conscious Sedation
311709|NCT01452867|Airway
311710|NCT01452867|Bag-Valve -Mask- Ventilation
311711|NCT01452867|Laryngeal Mask - Ventilation
311712|NCT01452867|Laryngeal Tube - Ventilation
311713|NCT01452854|LGG
311714|NCT01452854|Temozolomide
311715|NCT01452854|Temodar
311716|NCT01452854|Ovarian Aging
311717|NCT01452854|Infertility
311718|NCT01452854|Chemotherapy
311719|NCT01452841|grapefruit
311720|NCT01452841|weight loss
311721|NCT01452841|blood pressure
311722|NCT01452841|lipids
311723|NCT01452841|inflammation
311724|NCT01452828|Renal Impairment
311725|NCT01452815|diabetic gastroparesis
311726|NCT01452815|delayed gastric emptying
311727|NCT01452815|gastroparesis
311728|NCT01452815|diabetes mellitus, Type 1
311729|NCT01452815|diabetes mellitus, Type 2
311730|NCT01452802|HeartMate II
311731|NCT01452802|heart-assist device
311732|NCT01452802|medical management
311733|NCT01452802|optimal medical management
311734|NCT01452802|Heart Failure NYHA Class IIIB/IV
311735|NCT01452802|Thoratec Corporation
311736|NCT01452789|neonatal abstinence syndrome
311737|NCT01452789|buprenorphine
311738|NCT01452789|morphine
311739|NCT01452789|pharmacokinetics
311740|NCT01452776|Drug Therapy
311741|NCT01452763|Drug Therapy
311742|NCT01452750|Drug Therapy
311743|NCT01452737|colonoscopy
311744|NCT01452737|bowel preparation
311745|NCT01452737|Golytely
311746|NCT01452724|Drug Therapy
311747|NCT01452672|Breast cancer
311748|NCT01452672|Radiotherapy
311749|NCT01452672|Post-mastectomy
311750|NCT01452672|Molecular characterization
311751|NCT01452659|Drug Therapy
311752|NCT01452646|acute myeloid leukemia
311753|NCT01452646|risk-adapted therapy
311754|NCT01452646|MRD-directed therapy
311755|NCT01452646|young adults
311756|NCT01452633|pain
311757|NCT01452633|laparoscopy
311758|NCT01452633|reduction
311759|NCT01452620|Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
311760|NCT01452620|Abdominal Aortic aneurysm (AAA)
311761|NCT01452607|Ebselen
311762|NCT01452581|Transfusion
311763|NCT01452581|Red blood cells
311764|NCT01452581|Postoperative
311765|NCT01452581|Dizziness
311766|NCT01452581|Hip Arthroplasty
311767|NCT01452568|Thromboembolic complications
311768|NCT01452568|Bleeding complications
311769|NCT01452568|Haemorrhagic complications
311770|NCT01452568|Anticoagulant therapy
311771|NCT01452568|Aspirin
311772|NCT01452568|biological Aorta Valve
311773|NCT01452555|HIV
311774|NCT01452555|HIV Prevention
311775|NCT01452555|HIV testing
311776|NCT01452555|HIV Rapid Test
311777|NCT01452542|Genz-112638
311778|NCT01452529|Pain
311779|NCT01452529|Opioid
311780|NCT01452516|PLF
311781|NCT01452516|lumbar fusion
311782|NCT01452516|bone graft
311783|NCT01452516|biologics
311784|NCT01452503|AE adverse event
311785|NCT01452503|AIDS acquired immunodeficiency syndrome
311786|NCT01452503|ALT (SGPT) alanine aminotransferase
311787|NCT01452503|ART antiretroviral therapy
311788|NCT01452503|AST (SGOT) aspartate aminotransferase
311789|NCT01452503|DCF data collection forms
311790|NCT01452503|DMC Data Monitoring Committee
311791|NCT01452503|FDA (U.S.) Food and Drug Administration
311792|NCT01452503|GCP Good Clinical Practice guidelines
311793|NCT01452503|HB sAg Hepatitis B surface antigen
311794|NCT01452503|ICH International Conference of Harmonization
311795|NCT01452503|IND Investigational New Drug Application
311796|NCT01452503|IRB Institutional Review Board
311797|NCT01452503|IU International units
311798|NCT01452503|mg milligram(s)
311799|NCT01452503|mm3 cubic millimeter(s)
311800|NCT01452503|PCR polymerase chain reaction
311801|NCT01452503|SAE serious adverse event
311802|NCT01452503|µg microgram
311803|NCT01452503|ULN upper limit of the normal range
311804|NCT01452503|WB Western Blot
311805|NCT01452490|Onychomycosis
311806|NCT01452490|Toenail Fungus
311807|NCT01452477|Polycystic Ovary Syndrome
311808|NCT01452477|Cryptotanshinone
311809|NCT01452464|observational
311810|NCT01452464|serogroup A, B, Y, W
311811|NCT01452464|meningococcal meningitis
311812|NCT01452464|meningococcal vaccines
311813|NCT01452464|safety
311814|NCT01452464|MenACYW-CRM
311815|NCT01452464|post-marketing
311816|NCT01452464|adolescents
311817|NCT01452438|observational
311818|NCT01452438|serogroup A, B, Y, W
311819|NCT01452438|meningococcal meningitis
311820|NCT01452438|meningococcal vaccines
311821|NCT01452438|safety
311822|NCT01452438|MenACYW-CRM
311823|NCT01452438|post-marketing
311824|NCT01452438|children
311825|NCT01452425|Human volunteers
311826|NCT01452412|Alkali
311827|NCT01452412|Sodium bicarbonate
311828|NCT01452412|Kidney disease
311829|NCT01452412|Acidosis
311830|NCT01452386|Constipation
311831|NCT01452386|Stimulation Treatment
311832|NCT01452373|Hot flush(es)
311833|NCT01452373|Hot flash(es)
311834|NCT01452373|Vasomotor symptoms
311835|NCT01452373|Dehydroepiandrosterone (DHEA)
311836|NCT01452373|Prasterone
311837|NCT01452373|Acolbifene
311838|NCT01452373|Selective estrogen receptor modulator (SERM)
311839|NCT01452373|Antiestrogen
311840|NCT01452373|Menopause
311841|NCT01452373|Postmenopausal women
311842|NCT01452360|chronic kidney disease
311843|NCT01452321|Transcranial Magnetic Stimulation;
311844|NCT01452321|Postpartum Depression;
311845|NCT01452321|Clinical Performance;
311846|NCT01452321|Cognitive Performance;
311847|NCT01452321|Social Performance
311848|NCT01452308|Gilead
311849|NCT01452308|Gilead Sciences
311850|NCT01452308|GSI
311851|NCT01452308|Liver Fibrosis
311852|NCT01452308|Liver
311853|NCT01452308|Fibrosis
311854|NCT01452295|liver
311855|NCT01452295|liver failure
311856|NCT01452295|acute liver failure
311857|NCT01452295|ELAD
311858|NCT01452295|alcoholic hepatitis
311859|NCT01452295|acute on chronic hepatitis
311860|NCT01452282|Ankle Brachial Index
311861|NCT01452282|Perioperative care
311862|NCT01452282|General Surgery
311863|NCT01452282|Acute Coronary Syndromes
311864|NCT01452282|Cardiovascular Complications
311865|NCT01452243|Vitamin D
311866|NCT01452243|Calcium
311867|NCT01452243|Elderly
311868|NCT01452230|Bariatric Surgery Candidate
311869|NCT01452230|Severely obese
311870|NCT01452230|Bariatric surgery
311871|NCT01452230|Physical activity
311872|NCT01452230|Physical fitness
311873|NCT01452230|Comorbidities
311874|NCT01452230|Quality of life
311875|NCT01452230|Surgical complications
311876|NCT01452217|Pancreas
311877|NCT01452217|Chronic pancreatitis
311878|NCT01452217|Perfusion
311879|NCT01452217|Blood flow
311880|NCT01452217|Magnetic resonance imaging
311881|NCT01452204|PEMF
311882|NCT01452204|magneto
311883|NCT01452204|shoulder
311884|NCT01452204|impingement
311885|NCT01452191|Cluster Randomised Controlled Trial
311886|NCT01452191|Community Health Services
311887|NCT01452191|prevention & control
311888|NCT01452191|Accidents, Home
311889|NCT01452191|Child Health Services
311890|NCT01452178|Cardiovascular diseases
311891|NCT01452178|Glucometabolic disorders
311892|NCT01452178|Type-D personality
311893|NCT01452165|Cardiovascular diseases
311894|NCT01452165|Hypertrophy, Left ventricle
311895|NCT01452165|Echocardiography
311896|NCT01452165|Prognosis
311897|NCT01452152|Pharmacogenomics
311898|NCT01452152|Platelet Aggregation Inhibitors
311899|NCT01452139|STEMI
311900|NCT01452139|Pharmacogenetics
311901|NCT01452139|Prasugrel
311902|NCT01452139|Clopidogrel
311903|NCT01452139|Percutaneous Coronary Intervention
311904|NCT01452113|Diabetes Mellitus
311905|NCT01452113|DPP-IV protein
311906|NCT01452113|Glucagon-Like Peptide 1
311907|NCT01452113|autonomic neuropathy
311908|NCT01452100|embolism
311909|NCT01452100|cholesterol cristal
311910|NCT01452100|creatinine
311911|NCT01452100|renal insufficiency
311912|NCT01452100|prednisone
311913|NCT01452100|systemic atheroembolism
311914|NCT01452087|insulin sensitivity
311915|NCT01452087|exercise
311916|NCT01452074|Insulin Sensitivity
311917|NCT01452074|Exercise Training
311918|NCT01452074|Weight Loss
311919|NCT01452074|Fat Metabolism
311920|NCT01452061|Autism Spectrum Disorder
311921|NCT01452061|Attention Deficit/Hyperactivity Disorder
311922|NCT01452061|Developmental Delay
311923|NCT01452048|insulin sensitivity
311924|NCT01452048|fatty acid metabolism
311925|NCT01452035|insulin sensitivity
311926|NCT01452035|fatty acid metabolism
311927|NCT01452035|exercise
311928|NCT01452022|inductigraft
311929|NCT01452022|osteoinductive
311930|NCT01452022|synthetic bone graft
311931|NCT01452022|posterolateral lumbar fusion
311932|NCT01452022|post market
311933|NCT01452022|lumbar spinal stenosis
311934|NCT01452009|open angle glaucoma
311935|NCT01452009|ocular hypertension
311936|NCT01451996|direct-to-consumer advertising
311937|NCT01451983|Autism
311938|NCT01451983|PTEN
311939|NCT01451983|macrocephaly
311940|NCT01451970|high fat diet treatment
311941|NCT01451970|insulin sensitivity
311942|NCT01451957|exercise
311943|NCT01451957|fatty acid metabolism
311944|NCT01451957|insulin sensitivity
311945|NCT01451944|Asthma
311946|NCT01451944|Home Health Nursing
311947|NCT01451944|Patient education
311948|NCT01451931|kidney stone
311949|NCT01451931|urolithiasis
311950|NCT01451931|urinary tract infection
311951|NCT01451931|ultrasound
311952|NCT01451931|computed tomography
311953|NCT01451931|safety
311954|NCT01451931|cost
311955|NCT01451931|accuracy
311956|NCT01451918|Dyslipidaemia
311957|NCT01451918|Insulin resistance
311958|NCT01451918|Type 2 Diabetes
311959|NCT01451892|Obesity
311960|NCT01451892|dance
311961|NCT01451892|gait
311962|NCT01451892|balance
311963|NCT01451892|posture
311964|NCT01451892|dance therapy
311965|NCT01451879|Pompe Disease
311966|NCT01451879|Infusion Associated Reaction
311967|NCT01451879|Immune-modulation regimen
311968|NCT01451866|resistance training
311969|NCT01451866|Healthy People Programs
311970|NCT01451853|Lung Cancer
311971|NCT01451853|Head and Neck Cancer
311972|NCT01451853|Hearing Loss
311973|NCT01451853|Ototoxicity
311974|NCT01451853|Tinnitus
311975|NCT01451853|Deafness
311976|NCT01451853|SPI-1005
311977|NCT01451853|Cisplatin
311978|NCT01451853|Carboplatin
311979|NCT01451853|Ebselen
311980|NCT01451827|Kidney Disease
311981|NCT01451827|Polycystic Kidney Disease
311982|NCT01451827|Autosomal Dominant Polycystic Kidney Disease
311983|NCT01451827|PKD
311984|NCT01451827|ADPKD
311985|NCT01451814|smoking cessation
311986|NCT01451801|Hepatitis B
311987|NCT01451801|non responders
311988|NCT01451801|cellular immune response
311989|NCT01451801|cytokines
311990|NCT01451801|predictors
311991|NCT01451801|HBsAg
311992|NCT01451788|RCT
311993|NCT01451788|Gelatin matrix
311994|NCT01451788|thrombin
311995|NCT01451788|idiopathic scoliosis
311996|NCT01451788|Surgery
311997|NCT01451762|pain
311998|NCT01451762|anesthesia
311999|NCT01451762|surgery
312000|NCT01451762|postoperative
312001|NCT01451749|Mild cognitive impairment
312002|NCT01451736|First-episode Schizophrenia
312003|NCT01451736|Schizoaffective Disorder, Depressed Type (recent-onset)
312004|NCT01451736|Schizophreniform Disorder
312005|NCT01451736|oral risperidone
312006|NCT01451736|long-acting injectable paliperidone palmitate
312007|NCT01451736|functional outcome
312008|NCT01451723|Multiple Sclerosis
312009|NCT01451723|Polyphenon E
312010|NCT01451723|Green tea
312011|NCT01451723|EGCG
312012|NCT01451723|Epigallocatechin-galleate
312013|NCT01451723|Placebo
312014|NCT01451723|Randomized controlled trial
312015|NCT01451710|enough steroids
312016|NCT01451710|MCD
312017|NCT01451710|efficacy
312018|NCT01451684|pregnancy
312019|NCT01451684|fetus
312020|NCT01451684|euploid
312021|NCT01451671|fetal
312022|NCT01451671|aneuploidy
312023|NCT01451671|non-invasive
312024|NCT01451671|prenatal
312025|NCT01451671|cell free DNA
312026|NCT01451658|Variceal bleeding
312027|NCT01451658|portal hypertension
312028|NCT01451658|hepatocellular carcinoma
312029|NCT01451658|endoscopic variceal ligation
312030|NCT01451658|non-selective beta-blocker
312031|NCT01451658|rebleeding
312032|NCT01451645|Gout
312033|NCT01451632|Metastatic Colorectal cancer
312034|NCT01451632|Kras wild-type
312035|NCT01451632|Squamous cell head and neck cancer
312036|NCT01451632|Non-small cell lung cancer
312037|NCT01451632|Triple negative breast cancer
312038|NCT01451632|EGFR
312039|NCT01451632|ErbB3
312040|NCT01451632|MM-121
312041|NCT01451632|Cetuximab
312042|NCT01451632|Irinotecan
312043|NCT01451606|Chronic Pelvic Pain
312044|NCT01451606|CPP
312045|NCT01451606|Pelvic Pain
312046|NCT01451593|Optic neuritis
312047|NCT01451593|Multiple sclerosis
312048|NCT01451593|Retinal nerve fibre layer
312049|NCT01451593|Axonal loss
312050|NCT01451593|Neuroprotection
312051|NCT01451593|Phenytoin
312052|NCT01451593|MRI
312053|NCT01451593|Optical coherence tomography
312054|NCT01451593|Sodium Channel Blockers
312055|NCT01451580|Phase II
312056|NCT01451580|Metastatic Breast Cancer
312057|NCT01451567|Nurses, Workload, Musculoskeletal System, Intervention
312058|NCT01451554|weight
312059|NCT01451554|body mass index
312060|NCT01451554|obesity
312061|NCT01451554|portion control plate
312062|NCT01451554|diet
312063|NCT01451554|exercise
312064|NCT01451528|Umbilical Cord Blood
312065|NCT01451528|Allogeneic
312066|NCT01451528|Traumatic Brain Injury
312067|NCT01451515|Lymphoblastic lymphoma
312068|NCT01451502|umbilical cord blood
312069|NCT01451489|FSGS
312070|NCT01451489|FK506
312071|NCT01451489|CTX
312072|NCT01451476|Ageing
312073|NCT01451463|Huntington's Disease
312074|NCT01451463|Chorea
312075|NCT01451463|Gait
312076|NCT01451463|Balance
312077|NCT01451450|Peanut Allergy
312078|NCT01451411|Serum Sodium
312079|NCT01451411|Euvolemia
312080|NCT01451411|Hypervolemia
312081|NCT01451411|Vaprisol®
312082|NCT01451411|Conivaptan
312083|NCT01451411|YM087
312084|NCT01451372|Diabetes
312085|NCT01451372|CGM
312086|NCT01451372|CSII
312087|NCT01451346|Pilot study
312088|NCT01451333|HIV
312089|NCT01451333|Efavirenz
312090|NCT01451333|Central Nervous System (CNS)
312091|NCT01451333|Lumbar puncture
312092|NCT01451333|Dose reduction
312093|NCT01451320|Prosthetic valve
312094|NCT01451320|thrombosis
312095|NCT01451320|TROIA
312096|NCT01451320|tPA
312097|NCT01451320|TEE
312098|NCT01451307|Congenital abnormalities
312099|NCT01451307|Digestive system abnormalities
312100|NCT01451307|Neonatal surgery
312101|NCT01451307|Neonatal anesthesia
312102|NCT01451307|Bayley Scales of Infant Development II
312103|NCT01451294|Cerebral autoregulation
312104|NCT01451281|Ultrasonography
312105|NCT01451281|Muscular Dystrophy
312106|NCT01451281|Neuromuscular Disease
312107|NCT01451281|Oligonucleotide
312108|NCT01451281|Magnetic Resonance Imaging (MRI)
312109|NCT01451281|Duchenne Muscular Dystrophy
312110|NCT01451281|DND
312111|NCT01451268|60 to 150 Days After Allogeneic Stem Cell Transplantation
312112|NCT01451268|High Risk MDS
312113|NCT01451268|MDS
312114|NCT01451268|AML
312115|NCT01451255|pulsatility
312116|NCT01451255|normal subjects
312117|NCT01451255|mild pulmonary hypertension
312118|NCT01451255|exercise-associated pulmonary hypertension
312119|NCT01451242|Heart Rate Variability
312120|NCT01451242|Acquired Brain Injury
312121|NCT01451242|Physical Activity
312122|NCT01451229|pharmacokinetics
312123|NCT01451229|pharmacodynamics
312124|NCT01451216|Acquired brain injury
312125|NCT01451216|Balance control
312126|NCT01451216|Functional reach
312127|NCT01451203|Early RA
312128|NCT01451203|Certolizumab Pegol
312129|NCT01451203|Cimzia
312130|NCT01451190|Androgenetic Alopecia
312131|NCT01451190|Male Pattern Baldness
312132|NCT01451190|Female Pattern Baldness
312133|NCT01451190|Hair Loss
312134|NCT01451190|Baldness
312135|NCT01451177|Androgenetic Alopecia
312136|NCT01451177|Male Pattern Baldness
312137|NCT01451177|Female Pattern Baldness
312138|NCT01451177|Hair Loss
312139|NCT01451177|Baldness
312140|NCT01451151|Androgenetic Alopecia
312141|NCT01451151|Male Pattern Baldness
312142|NCT01451151|Female Pattern Baldness
312143|NCT01451151|Hair Loss
312144|NCT01451151|Baldness
312145|NCT01451138|Androgenetic Alopecia
312146|NCT01451138|Male Pattern Baldness
312147|NCT01451138|Female Pattern Baldness
312148|NCT01451138|Hair Loss
312149|NCT01451138|Baldness
312150|NCT01451125|Androgenetic Alopecia
312151|NCT01451125|Male Pattern Baldness
312152|NCT01451125|Female Pattern Baldness
312153|NCT01451125|Hair Loss Baldness
312154|NCT01451112|Androgenetic Alopecia
312155|NCT01451112|Male Pattern Baldness
312156|NCT01451112|Female Pattern Baldness
312157|NCT01451112|Hair Loss
312158|NCT01451112|Baldness
312159|NCT01451099|Androgenetic Alopecia
312160|NCT01451099|Male Pattern Baldness
312161|NCT01451099|Female Pattern Baldness
312162|NCT01451099|Hair Loss
312163|NCT01451099|Baldness
312164|NCT01451086|Safety
312165|NCT01451086|Immunogenicity
312166|NCT01451086|Pneumococcal vaccine
312167|NCT01451073|Androgenetic Alopecia
312168|NCT01451073|Male Pattern Baldness
312169|NCT01451073|Female Pattern Baldness
312170|NCT01451073|Hair Loss
312171|NCT01451073|Baldness
312172|NCT01451060|vasopressors
312173|NCT01451060|cesarean anesthesia
312174|NCT01451060|hypotension
312175|NCT01451047|Androgenetic Alopecia
312176|NCT01451047|Male Pattern Baldness
312177|NCT01451047|Female Pattern Baldness
312178|NCT01451047|Hair Loss
312179|NCT01451047|Baldness
312180|NCT01451034|WHYX lesion
312181|NCT01451034|endoscopic resection
312182|NCT01451034|complete resection
312183|NCT01451034|complete resection rate
312184|NCT01451034|endoscopic feature
312185|NCT01451034|Average size discrepancy
312186|NCT01451021|Androgenetic Alopecia
312187|NCT01451021|Male Pattern Baldness
312188|NCT01451021|Female Pattern Baldness
312189|NCT01451021|Hair Loss
312190|NCT01451021|Baldness
312191|NCT01451008|Anastomosis
312192|NCT01451008|Compression
312193|NCT01451008|Colon
312194|NCT01450995|Migraine
312195|NCT01450995|Headache, Migraine
312196|NCT01450982|Rheumatoid Arthritis
312197|NCT01450982|JNJ-38518168
312198|NCT01450982|Methotrexate
312199|NCT01450969|Operator Comfort Assessment
312200|NCT01450969|Radiation protection
312201|NCT01450969|Measurement of Radiation Exposure
312202|NCT01450969|Endovascular Interventional Radiology
312203|NCT01450956|congenital heart diseases
312204|NCT01450956|cardiopulmonary bypass
312205|NCT01450956|Pediatric
312206|NCT01450956|sevoflurane
312207|NCT01450943|Diabetic Foot Ulcer
312208|NCT01450943|Chronic wounds
312209|NCT01450943|Chronic ulcers
312210|NCT01450943|Oasis
312211|NCT01450943|Dermagraft
312212|NCT01450943|Adaptic
312213|NCT01450930|Adrenal insufficiency
312214|NCT01450930|Addison's disease
312215|NCT01450891|Alzheimer's disease
312216|NCT01450891|Diagnosis
312217|NCT01450891|Costs
312218|NCT01450891|Benefits
312219|NCT01450891|subjective and/or objective memory complaints
312220|NCT01450878|high dose of EPO
312221|NCT01450878|transplant kidney
312222|NCT01450878|cadaveric organ donor
312223|NCT01450878|mono-organ (kidney) retrieval
312224|NCT01450878|patient
312225|NCT01450878|kidney graft
312226|NCT01450865|neuropathy
312227|NCT01450865|axonal excitability
312228|NCT01450865|myelinated nerve
312229|NCT01450865|human
312230|NCT01450865|ectopic discharge
312231|NCT01450865|flupirtine
312232|NCT01450852|Melanocortin Receptor
312233|NCT01450852|Monocyte
312234|NCT01450852|Resistance Training
312235|NCT01450852|Inflammation
312236|NCT01450852|Markers of Inflammation
312237|NCT01450839|Transdermal Administration
312238|NCT01450839|Japanese
312239|NCT01450839|elderly
312240|NCT01450839|male
312241|NCT01450839|volunteers
312242|NCT01450826|Chemotherapy induced nausea and vomiting
312243|NCT01450826|CINV
312244|NCT01450826|Glioma
312245|NCT01450826|Temozolomide
312246|NCT01450826|Temodar
312247|NCT01450826|Aprepitant
312248|NCT01450826|Emend
312249|NCT01450826|Ondansetron
312250|NCT01450826|Zofran
312251|NCT01450826|Pro00031206
312252|NCT01450826|Affronti
312253|NCT01450826|Peters
312254|NCT01450826|Duke
312255|NCT01450826|Preston Robert Tisch Brain Tumor Center
312256|NCT01450800|urinary tract infection
312257|NCT01450800|gynecologic surgery
312258|NCT01450800|post-operative complications
312259|NCT01450800|nitrofurantoin
312260|NCT01450787|dry eyes
312261|NCT01450787|diabetes
312262|NCT01450748|sodium alginate
312263|NCT01450748|laryngopharyngeal reflux
312264|NCT01450748|combined impedance-pH monitoring
312265|NCT01450722|Chronic lower limb ischemia
312266|NCT01450722|claudication
312267|NCT01450722|chronic critical ischemia
312268|NCT01450709|Probiotics
312269|NCT01450709|Kibow Biotics
312270|NCT01450709|Dialysis
312271|NCT01450709|Gut based uremic toxin removal
312272|NCT01450670|Probiotics
312273|NCT01450670|Kibow Biotics
312274|NCT01450670|Dialysis
312275|NCT01450670|Gut based uremic toxin removal
312276|NCT01450657|Chronic Kidney failure stage three and four
312277|NCT01450657|Probiotics
312278|NCT01450657|Kibow Biotics
312279|NCT01450657|Dialysis
312280|NCT01450657|Gut based uremic toxin removal
312281|NCT01450644|Advanced
312282|NCT01450644|Progressive
312283|NCT01450644|Idiopathic Fibrotic Interstitial Lung Disease
312284|NCT01450644|Palliative Care
312285|NCT01450644|Randomised
312286|NCT01450644|Controlled
312287|NCT01450631|surgical site infection
312288|NCT01450631|nosocomial infection
312289|NCT01450631|post-operative complication
312290|NCT01450631|surgical incision risk
312291|NCT01450631|surgical incision infection
312292|NCT01450631|negative pressure wound therapy
312293|NCT01450631|wound management
312294|NCT01450631|cesarean section surgery
312295|NCT01450631|wound dehiscence
312296|NCT01450631|wound infection
312297|NCT01450631|surgical closure
312298|NCT01450631|wound disruption
312299|NCT01450631|subcutaneous approximation
312300|NCT01450631|wound separation
312301|NCT01450631|seroma
312302|NCT01450631|hematoma
312303|NCT01450631|subcutaneous closure
312304|NCT01450631|obesity
312305|NCT01450631|cesarean
312306|NCT01450631|incision
312307|NCT01450631|massive obesity
312308|NCT01450631|obese
312309|NCT01450631|pregnancy
312310|NCT01450631|cesarean delivery
312311|NCT01450631|superobesity
312312|NCT01450631|wound complication
312313|NCT01450592|Carbohydrate, Dietary
312314|NCT01450579|Recombinant Influenza HA vaccine
312315|NCT01450579|Immunogenicity of ASP7373
312316|NCT01450566|ureteroscopy (URS)
312317|NCT01450566|ureteral stent placement
312318|NCT01450566|Ureteral Calculi
312319|NCT01450566|Renal Calculi
312320|NCT01450553|Tissue Collection
312321|NCT01450553|Lung Cancer
312322|NCT01450553|Non-Small Cell Lung Cancer
312323|NCT01450553|Early Stage Lung Cancer
312324|NCT01450527|Etiology and outcomes of ARDS
312325|NCT01450488|primary progressive multiple sclerosis
312326|NCT01450488|relapse-free secondary progressive multiple sclerosis
312327|NCT01450449|GBM, fractionation, short course, standard course
312328|NCT01450423|Epilepsy
312329|NCT01450423|Physical activity
312330|NCT01450423|Cardio exercise
312331|NCT01450423|Physical fitness
312332|NCT01450423|Cognitive function
312333|NCT01450410|Dyslipemia, HDL composition
312334|NCT01450397|Dupuytren's Contracture
312335|NCT01450384|protocol specific
312336|NCT01450371|Autonomic Nervous System
312337|NCT01450371|Neuromodulation
312338|NCT01450371|Blood flow control
312339|NCT01450371|Exercise
312340|NCT01450358|Sepsis
312341|NCT01450358|Real time PCR
312342|NCT01450358|Blood culture
312343|NCT01450358|Bacteremia diagnosis
312344|NCT01450358|Fungemia diagnosis
312345|NCT01450345|Clinical diagnosis of inguinal hernia
312346|NCT01450345|Patient undergo operation under daycare basis
312347|NCT01450345|ASA I-II
312348|NCT01450345|Written consent
312349|NCT01450332|ACL
312350|NCT01450332|arthroscopy
312351|NCT01450332|ligament
312352|NCT01450332|rupture
312353|NCT01450332|reconstruction
312354|NCT01450332|ACLR
312355|NCT01450332|accelerated rehabilitation program
312356|NCT01450319|K-RAS
312357|NCT01450319|FcγRII/IIIa genotypes
312358|NCT01450319|CRC
312359|NCT01450319|Colorectal cancer
312360|NCT01450293|Immune response
312361|NCT01450267|Cystic Fibrosis
312362|NCT01450267|Glutathione
312363|NCT01450254|Hip Osteoarthritis
312364|NCT01450254|Gait Patterns
312365|NCT01450254|Neuromuscular retraining
312366|NCT01450241|Febrile neutropenia
312367|NCT01450241|Unexplained fever
312368|NCT01450241|Duration
312369|NCT01450241|Short-term antibiotic treatment
312370|NCT01450228|primary insomnia
312371|NCT01450215|Relapsed and refractory Multiple Myeloma
312372|NCT01450202|Carbon dioxide insufflation
312373|NCT01450202|Colonoscopy
312374|NCT01450202|Esophagogastroduodenoscopy
312375|NCT01450202|Bowel insufflation
312376|NCT01450202|Postprocedure pain
312377|NCT01450202|Pain Due to Certain Specified Procedures
312378|NCT01450189|Acute HIV
312379|NCT01450189|Transmission Prevention
312380|NCT01450189|Randomized Pilot study
312381|NCT01450176|eye
312382|NCT01450176|itching
312383|NCT01450176|allergies
312384|NCT01450163|Neuropathic pain
312385|NCT01450163|prevention
312386|NCT01450163|prophylaxis
312387|NCT01450163|chemotherapy
312388|NCT01450163|neuropathy
312389|NCT01450163|Oxaliplatin
312390|NCT01450163|pregabalin
312391|NCT01450150|Major Depression
312392|NCT01450150|Transcranial Direct Current Stimulation
312393|NCT01450150|Randomized, Sham-Controlled Trial
312394|NCT01450150|tDCS
312395|NCT01450137|Giant Cell Arteritis
312396|NCT01450137|Tocilizumab
312397|NCT01450137|Antibodies, Monoclonal
312398|NCT01450137|Glucocorticoids
312399|NCT01450111|Lacosamide
312400|NCT01450059|Human Immunodeficiency Virus
312401|NCT01450059|Microchimerism
312402|NCT01450059|Maternal-Fetal Exchange
312403|NCT01450059|Gestation
312404|NCT01450059|HiV-vertical transmission
312405|NCT01450046|pancreas
312406|NCT01450046|gastrointestinal
312407|NCT01450046|GI
312408|NCT01450046|prevention
312409|NCT01450046|vitamin E
312410|NCT01450033|kidney
312411|NCT01450033|renal
312412|NCT01450033|transplant
312413|NCT01450033|transplantation
312414|NCT01450033|adolescent
312415|NCT01450033|pediatric
312416|NCT01450033|mentor
312417|NCT01450033|mentoring
312418|NCT01450033|medication
312419|NCT01450033|adherence
312420|NCT01450033|immunosuppressant
312421|NCT01450033|heart
312422|NCT01450033|liver
312423|NCT01450020|cancer survivor
312424|NCT01450007|Pain blockade
312425|NCT01450007|Ropivacaine
312426|NCT01450007|Dexamethasone
312427|NCT01449994|knee
312428|NCT01449994|hip
312429|NCT01449994|ankle
312430|NCT01449994|foot
312431|NCT01449994|pain
312432|NCT01449994|lower limb
312433|NCT01449994|activator
312434|NCT01449994|instrumental
312435|NCT01449994|chiropractic
312436|NCT01449994|Painful functional conditions of the lower extremity
312437|NCT01449981|Adolescents
312438|NCT01449981|Alcohol Abuse
312439|NCT01449981|Alcohol Dependence
312440|NCT01449981|Drug Abuse
312441|NCT01449981|Drug Dependence
312442|NCT01449981|Substance Use Disorder
312443|NCT01449981|Alcoholics Anonymous
312444|NCT01449981|Motivational Enhancement Therapy
312445|NCT01449981|Cognitive Behavioral Therapy
312446|NCT01449955|PTSD
312447|NCT01449942|Nasopharyngeal carcinoma
312448|NCT01449942|EBV
312449|NCT01449942|LMP1
312450|NCT01449929|ritonavir
312451|NCT01449929|HIV
312452|NCT01449929|HAART
312453|NCT01449929|darunavir
312454|NCT01449929|antiretroviral
312455|NCT01449929|dolutegravir
312456|NCT01449929|GSK1349572
312457|NCT01449916|Sepsis
312458|NCT01449916|Severe Sepsis
312459|NCT01449916|Protocol
312460|NCT01449916|Zambia
312461|NCT01449890|follow up care
312462|NCT01449890|e-mail
312463|NCT01449890|effectiveness
312464|NCT01449890|depressive disorders
312465|NCT01449877|Ocular Toxoplasmosis
312466|NCT01449877|Retinochoroiditis
312467|NCT01449877|Prophylaxis
312468|NCT01449864|upper GI malignancies
312469|NCT01449864|concurrent chemoradiation with continuous infusion 5-Fluorouracil chemotherapy
312470|NCT01449825|hepatic safety
312471|NCT01449825|prescriber compliance
312472|NCT01449825|pazopanib
312473|NCT01449825|epidemiology
312474|NCT01449812|booster vaccination
312475|NCT01449812|combination vaccine
312476|NCT01449760|Ankle sprain
312477|NCT01449760|Balance
312478|NCT01449760|Gait
312479|NCT01449747|Type 2 diabetes mellitus
312480|NCT01449747|Dipeptidyl peptidase IV inhibitors
312481|NCT01449747|Glucagon-like peptide 1
312482|NCT01449721|Sepsis
312483|NCT01449721|Multiple organ failure
312484|NCT01449721|Resuscitation
312485|NCT01449708|Bariatric Surgery
312486|NCT01449708|TIVA
312487|NCT01449708|PONV
312488|NCT01449708|non-opioid
312489|NCT01449708|OSA
312490|NCT01449695|PAD
312491|NCT01449695|CVA
312492|NCT01449695|ACS
312493|NCT01449682|BRVO
312494|NCT01449682|CRVO
312495|NCT01449682|Macular Edema
312496|NCT01449682|Anti-VEGF
312497|NCT01449682|Ozurdex
312498|NCT01449669|pharmacokinetics
312499|NCT01449669|cefazolin
312500|NCT01449669|microdialysis sampling
312501|NCT01449669|interstitial fluid
312502|NCT01449669|skeletal muscle
312503|NCT01449669|plasma
312504|NCT01449669|children
312505|NCT01449643|Obesity
312506|NCT01449643|Diaphragm
312507|NCT01449643|Inspiratory muscular training
312508|NCT01449617|Carotid stenosis
312509|NCT01449617|Aspirin plus Clopidogrel
312510|NCT01449617|Residual platelet reactivity
312511|NCT01449604|Stereotactic radiotherapy
312512|NCT01449604|SRS
312513|NCT01449604|SRT
312514|NCT01449604|vestibular schwannoma
312515|NCT01449591|BFH772
312516|NCT01449591|rosacea
312517|NCT01449591|erythemato-telangiectatic rosacea
312518|NCT01449565|methamphetamine
312519|NCT01449565|high-risk sexual behavior
312520|NCT01449565|HIV prevention
312521|NCT01449539|Hyperbaric oxygen
312522|NCT01449539|mobilize
312523|NCT01449539|stem cells
312524|NCT01449539|growth factor
312525|NCT01449526|contact lens
312526|NCT01449500|Dyspeptic H.pylori-infection
312527|NCT01449487|Experimental pain
312528|NCT01449487|IBS
312529|NCT01449487|Rectum
312530|NCT01449461|Advanced Malignancies
312531|NCT01449461|Carcinoma, Non-Small-Cell Lung
312532|NCT01449461|Anaplastic Large Cell Lymphoma
312533|NCT01449461|Diffuse Large Cell Lymphoma
312534|NCT01449461|Inflammatory Myofibroblastic Tumors
312535|NCT01449461|Anaplastic Lymphoma Kinase (ALK)
312536|NCT01449461|Epidermal Growth Factor Receptor (EGFR)
312537|NCT01449461|Advanced Cancers
312538|NCT01449461|AP26113
312539|NCT01449448|pain relief
312540|NCT01449448|Hypermobility, Joint
312541|NCT01449448|increased strength
312542|NCT01449448|increased patient satisfaction
312543|NCT01449435|Asthma
312544|NCT01449435|children
312545|NCT01449435|predictors of exacerbation
312546|NCT01449435|Methacholine challenge
312547|NCT01449435|Pulmonary function testing
312548|NCT01449409|Uncontrolled asthma
312549|NCT01449409|Asthma risk
312550|NCT01449409|Asthma impairment
312551|NCT01449409|Real time asthma outreach program
312552|NCT01449396|acupuncture
312553|NCT01449396|in vitro fertilization
312554|NCT01449396|embryo transfer
312555|NCT01449383|cross over
312556|NCT01449383|dietary intervention
312557|NCT01449383|fibre
312558|NCT01449383|red meat
312559|NCT01449383|microbiota
312560|NCT01449370|INK1117
312561|NCT01449370|PIK3CA
312562|NCT01449370|KINASE
312563|NCT01449370|TUMOR
312564|NCT01449370|CANCER
312565|NCT01449370|Locally advanced or metastatic solid tumors
312566|NCT01449370|not eligible for standard of care therapy
312567|NCT01449357|NSCLC
312568|NCT01449357|Zalutumumab
312569|NCT01449357|Efficacy
312570|NCT01449357|Safety
312571|NCT01449344|relapsed
312572|NCT01449344|refractory
312573|NCT01449318|Pain
312574|NCT01449318|quantitative sensory testing
312575|NCT01449292|PLVR
312576|NCT01449292|ELVR
312577|NCT01449292|AeriSeal System
312578|NCT01449292|foam sealant
312579|NCT01449292|emphysematous lung sealant
312580|NCT01449292|ELS
312581|NCT01449292|COPD
312582|NCT01449292|emphysema
312583|NCT01449292|polymeric lung volume reduction
312584|NCT01449292|heterogeneous
312585|NCT01449292|Respiratory Tract Diseases
312586|NCT01449292|Lung Diseases
312587|NCT01449292|Chronic Obstructive Pulmonary Disease
312588|NCT01449266|Dotarem
312589|NCT01449266|Dialyses
312590|NCT01449266|Dialysed
312591|NCT01449266|Safety
312592|NCT01449266|Safety and dialysability of Dotarem in dialysed patients
312593|NCT01449240|Hunter syndrome
312594|NCT01449240|Mucopolysaccharidosis II
312595|NCT01449240|Iduronate 2-Sulfatase Deficiency
312596|NCT01449240|Lumbar puncture
312597|NCT01449240|Cerebrospinal fluid (CSF)
312598|NCT01449240|Pediatric
312599|NCT01449240|Adult
312600|NCT01449240|Biomarkers
312601|NCT01449227|adhesive capsulitis
312602|NCT01449227|hip
312603|NCT01449214|Thoracic epidural
312604|NCT01449214|Epidural anesthesia
312605|NCT01449214|Ultrasound
312606|NCT01449214|Palpation
312607|NCT01449214|Thoracic spine
312608|NCT01449201|PF-00299804, head and neck cancer, squamous cell carcinoma
312609|NCT01449188|ondansetron
312610|NCT01449188|moxifloxacin
312611|NCT01449188|Zofran
312612|NCT01449188|thorough QT study
312613|NCT01449188|IV
312614|NCT01449175|AeriSeal
312615|NCT01449175|treatment
312616|NCT01449175|device
312617|NCT01449175|breathing
312618|NCT01449175|COPD
312619|NCT01449175|emphysema
312620|NCT01449175|polymeric lung volume reduction (PLVR)
312621|NCT01449175|biologic lung volume reduction (BLVR)
312622|NCT01449175|heterogeneous
312623|NCT01449175|homogeneous
312624|NCT01449175|Respiratory Tract Diseases
312625|NCT01449175|Lung Diseases
312626|NCT01449175|Pulmonary Disease, Chronic Obstructive
312627|NCT01449162|severe persistent asthma
312628|NCT01449162|patients treated with oral corticosteroids
312629|NCT01449149|Age 18 or greater
312630|NCT01449149|No prior radiation
312631|NCT01449136|Antibacterial agents
312632|NCT01449136|Deciduous Teeth
312633|NCT01449136|Clinical Trial
312634|NCT01449123|Asthma
312635|NCT01449123|mannitol challenge test
312636|NCT01449123|Sweden
312637|NCT01449123|primary care
312638|NCT01449110|Primary prevention
312639|NCT01449110|Secondary prevention
312640|NCT01449110|Resveratrol
312641|NCT01449110|Grape
312642|NCT01449110|Cardiovascular
312643|NCT01449110|Nutraceutical
312644|NCT01449110|Food complement
312645|NCT01449097|Adductor-Canal-blockade,
312646|NCT01449097|human volunteers,
312647|NCT01449097|US-guided nerve block
312648|NCT01449097|femoral nerve block
312649|NCT01449084|Pancreatic duct stenting
312650|NCT01449084|Post-endoscopic pancreatitis
312651|NCT01449071|Lupus
312652|NCT01449071|Monoclonal antibody
312653|NCT01449071|B-cell immunotherapy
312654|NCT01449071|Epratuzumab
312655|NCT01449058|Advanced solid tumor,
312656|NCT01449058|AML
312657|NCT01449058|high risk and very high risk MDS
312658|NCT01449058|dose escalation,
312659|NCT01449058|RAS/BRAF mutation,
312660|NCT01449058|PI3K inhibitor,
312661|NCT01449058|MEK inhibitor,
312662|NCT01449058|BYL719,
312663|NCT01449058|MEK162
312664|NCT01449045|IPTc
312665|NCT01449045|Community Case Management
312666|NCT01449045|Home Management for malaria
312667|NCT01449032|Patients
312668|NCT01449019|GLP-1
312669|NCT01449019|Exendin(9-39)
312670|NCT01449019|Insulin
312671|NCT01449019|Glucagon
312672|NCT01449019|T2DM
312673|NCT01449019|incretin effect
312674|NCT01449019|human physiology
312675|NCT01449006|HIV
312676|NCT01449006|HAND
312677|NCT01449006|Maraviroc
312678|NCT01449006|Neurocognitive
312679|NCT01449006|Neurology
312680|NCT01449006|Human Immunodeficiency Virus
312681|NCT01449006|HIV Associated Neurocognitive Disorders
312682|NCT01448980|massage
312683|NCT01448980|stroke spasticity
312684|NCT01448928|Zevalin
312685|NCT01448928|CD20+
312686|NCT01448928|Non-Hodgkin's Lymphoma
312687|NCT01448928|Mantle Cell Lymphoma
312688|NCT01448915|HIV
312689|NCT01448915|Human immunodeficiency virus
312690|NCT01448915|Acquired Immune Deficiency Syndrome Virus
312691|NCT01448915|AIDS virus
312692|NCT01448915|Immunodeficiency Virus, Human
312693|NCT01448915|Virus, Human Immunodeficiency
312694|NCT01448915|Hepatitis C
312695|NCT01448915|Hepatitis C, chronic
312696|NCT01448915|Hepatitis C virus
312697|NCT01448915|Hepatitis C antibodies
312698|NCT01448915|Hepatitis C antigens
312699|NCT01448902|Allergic rhinitis
312700|NCT01448902|CRTH2
312701|NCT01448889|contrast induced nephropathy
312702|NCT01448889|oxigen
312703|NCT01448889|coronary angiography
312704|NCT01448876|Chlamydia trachomatis
312705|NCT01448876|anorectal
312706|NCT01448876|cervicovaginal
312707|NCT01448876|MSM
312708|NCT01448876|women
312709|NCT01448876|treatment
312710|NCT01448876|RNA
312711|NCT01448876|bacterial load
312712|NCT01448876|sexual behaviour
312713|NCT01448876|Azythromycin treated
312714|NCT01448850|Chronic Obstructive Pulmonary Disease (COPD)
312715|NCT01448850|MEDI8968
312716|NCT01448824|Low High-density Lipoprotein (HDL)
312717|NCT01448824|Cholesterol (HDL-C)
312718|NCT01448798|radical prostatectomy
312719|NCT01448798|robotic surgery
312720|NCT01448798|erectile dysfunction
312721|NCT01448798|continence
312722|NCT01448785|obesity
312723|NCT01448785|gastric stimulation
312724|NCT01448785|morbid obesity
312725|NCT01448772|Dronabinol
312726|NCT01448772|fasting
312727|NCT01448759|Patients receiving docetaxel or paclitaxel. All tumors.
312728|NCT01448746|gastric cancer
312729|NCT01448746|VTE
312730|NCT01448746|incidence
312731|NCT01448733|acne vulgaris
312732|NCT01448720|Schizophrenia
312733|NCT01448720|Paliperidone palmitate
312734|NCT01448720|Long-acting injectable antipsychotic medication
312735|NCT01448707|Darunavir (DRV)
312736|NCT01448707|TMC114
312737|NCT01448707|Prezista
312738|NCT01448707|HIV
312739|NCT01448707|virologic response
312740|NCT01448707|neurocognitive function
312741|NCT01448694|Hemorrhage
312742|NCT01448681|Intracranial Hypertension
312743|NCT01448681|Elevated ICP (Intracranial Pressure)
312744|NCT01448668|pancreatic cancer
312745|NCT01448668|mistletoe
312746|NCT01448668|supportive treatment
312747|NCT01448668|long-term study
312748|NCT01448668|non-interventional cohort study
312749|NCT01448668|controlled study with parallel groups
312750|NCT01448655|colorectal cancer
312751|NCT01448655|mistletoe
312752|NCT01448655|supportive treatment
312753|NCT01448655|long-term study
312754|NCT01448655|non-interventional cohort study
312755|NCT01448655|controlled study with parallel groups
312756|NCT01448603|Ragweed allergy
312757|NCT01448603|ToleroMune ragweed
312758|NCT01448603|immunotherapy
312759|NCT01448590|post dural puncture headache
312760|NCT01448590|accidental dural puncture
312761|NCT01448590|PDPH
312762|NCT01448590|ADP
312763|NCT01448590|spinal catheter
312764|NCT01448590|epidural catheter
312765|NCT01448590|intrathecal catheter
312766|NCT01448590|dural puncture
312767|NCT01448590|systemic review
312768|NCT01448564|Chronic Obstructive Pulmonary Disease
312769|NCT01448564|Fatigue
312770|NCT01448564|laser therapy
312771|NCT01448551|Obesity
312772|NCT01448551|Treatment
312773|NCT01448551|Adolescents
312774|NCT01448551|Text Messages
312775|NCT01448551|Mobile phones
312776|NCT01448551|Multidisciplinary
312777|NCT01448538|Medication Non-Adherence
312778|NCT01448538|Medication Persistence
312779|NCT01448538|wet macular degeneration
312780|NCT01448512|HIV
312781|NCT01448512|Pregnancy
312782|NCT01448512|Prevention
312783|NCT01448512|Couples
312784|NCT01448499|schizophrenia
312785|NCT01448499|clozapine
312786|NCT01448499|amisulpride
312787|NCT01448499|combination
312788|NCT01448499|treatment resistant
312789|NCT01448486|HIV
312790|NCT01448486|HAND
312791|NCT01448486|Human Immunodeficiency Virus
312792|NCT01448486|Raltegravir
312793|NCT01448486|HIV Associated Neurocognitive Disorders
312794|NCT01448486|Neuro-HAART
312795|NCT01448486|Neurocognitive
312796|NCT01448486|Neurology
312797|NCT01448473|Head trauma
312798|NCT01448473|Children
312799|NCT01448473|Radiography
312800|NCT01448434|Osteoarthritis
312801|NCT01448434|Knee
312802|NCT01448434|Stem cell
312803|NCT01448434|MSC
312804|NCT01448421|TAVR
312805|NCT01448408|Forme Fruste Keratoconus
312806|NCT01448408|Corneal Biomechanical properties
312807|NCT01448408|Anterior Segment Parameters
312808|NCT01448408|Diagnostic Capacity
312809|NCT01448395|Mass Balance
312810|NCT01448395|Metabolite Identification and Profiling
312811|NCT01448395|Metabolite profile and Identification of [14C]NXL104
312812|NCT01448395|Mass Balance Recovery
312813|NCT01448369|meibomian gland dysfunction
312814|NCT01448369|hot compress
312815|NCT01448369|eyelid warming
312816|NCT01448369|meibum
312817|NCT01448356|Controlled adverse chamber
312818|NCT01448356|tear film stability
312819|NCT01448356|tear film evaporation
312820|NCT01448356|tear film break up time
312821|NCT01448356|humidity
312822|NCT01448356|temperature
312823|NCT01448343|transfusion
312824|NCT01448343|potassium
312825|NCT01448330|clopidogrel
312826|NCT01448330|aspinin
312827|NCT01448330|combination
312828|NCT01448291|Contraception
312829|NCT01448291|Nuvaring
312830|NCT01448291|Vaginal inflammation
312831|NCT01448291|Bacterial vaginosis
312832|NCT01448291|Nugent score
312833|NCT01448278|Anterior cruciate ligament
312834|NCT01448278|Arthroscopy
312835|NCT01448278|Incomplete bone tunnels
312836|NCT01448278|Anterior cruciate ligament reconstruction
312837|NCT01448265|atrial fibrillation
312838|NCT01448265|catheter ablation
312839|NCT01448265|circular mapping catheter
312840|NCT01448265|cryoballoon
312841|NCT01448252|T cell vaccination
312842|NCT01448252|Immunotherapy
312843|NCT01448252|Tolerance
312844|NCT01448252|safety
312845|NCT01448252|clinical efficacy
312846|NCT01448213|DMEK
312847|NCT01448213|Rejection
312848|NCT01448213|Corticosteroid
312849|NCT01448200|hepatitis C
312850|NCT01448200|NS5A inhibitor
312851|NCT01448200|Phase 1
312852|NCT01448200|genotype-1
312853|NCT01448200|genotype-2
312854|NCT01448200|genotype-3
312855|NCT01448187|Lung cancer, France
312856|NCT01448174|salusin-alpha
312857|NCT01448174|atorvastatin
312858|NCT01448174|CD36
312859|NCT01448174|Hemodialysis
312860|NCT01448161|Pediatric
312861|NCT01448161|Adult
312862|NCT01448161|ICU
312863|NCT01448148|Mild cognitive impairment
312864|NCT01448122|Prevention of pigmentation
312865|NCT01448109|Sepsis
312866|NCT01448109|Corticosteroid
312867|NCT01448096|primary breast diffuse large B cell lymphoma
312868|NCT01448096|rituximab
312869|NCT01448096|prophylactic intrathecal chemotherapy
312870|NCT01448096|CNS recurrence
312871|NCT01448083|I-131 MIBG therapy
312872|NCT01448083|whole body I-123 MIBG scintigraphy
312873|NCT01448057|Paracetamol
312874|NCT01448057|dimethindene maleate
312875|NCT01448057|phenylephrine hydrochloride
312876|NCT01448057|cold and flu symptoms
312877|NCT01448044|hepatitis C virus
312878|NCT01448031|Acetyl Salicylic Acid
312879|NCT01448031|Bioavailability
312880|NCT01448031|Healthy Volunteers
312881|NCT01448005|Coronary Artery Bypass Grafting
312882|NCT01448005|Resuscitation
312883|NCT01448005|Sudden Cardiac Death
312884|NCT01448005|Ventricular Dysfunction
312885|NCT01447992|Artificial Pancreas
312886|NCT01447992|Insulin Pump
312887|NCT01447992|Continuous Glucose Monitor
312888|NCT01447992|Closed Loop
312889|NCT01447979|Artificial Pancreas
312890|NCT01447979|Insulin Pump
312891|NCT01447979|Continuous Glucose Monitor
312892|NCT01447979|Closed Loop
312893|NCT01447966|OCD
312894|NCT01447966|Obsessive Compulsive Disorder
312895|NCT01447966|Child
312896|NCT01447966|Pediatric
312897|NCT01447966|CBT
312898|NCT01447966|Therapy
312899|NCT01447966|ERP
312900|NCT01447966|Exposure Response Prevention
312901|NCT01447966|Preschool
312902|NCT01447966|Cognitive Behavioral
312903|NCT01447953|Activity
312904|NCT01447953|disability
312905|NCT01447953|life-role
312906|NCT01447953|multimodal rehabilitation
312907|NCT01447953|primary health care
312908|NCT01447953|persistent pain
312909|NCT01447953|randomized controlled trial
312910|NCT01447953|Musculoskeletal back pain
312911|NCT01447940|Telemedicine
312912|NCT01447940|Type 1 diabetes
312913|NCT01447940|economic cost of Type 1 diabetes
312914|NCT01447940|ePortal Meos
312915|NCT01447914|c-Met Inhibitor ARQ-197
312916|NCT01447914|tivantinib
312917|NCT01447914|multiple myeloma
312918|NCT01447914|plasma cell proliferative disorder
312919|NCT01447914|Hypercalcemia
312920|NCT01447914|hematologic malignancy
312921|NCT01447914|plasma cell dyscrasia
312922|NCT01447914|cast nephropathy
312923|NCT01447914|amyloidosis
312924|NCT01447914|osteolysis
312925|NCT01447914|Renal insufficiency
312926|NCT01447914|Anemia
312927|NCT01447914|Bone lytic lesions
312928|NCT01447914|severe osteopenia
312929|NCT01447914|pathologic fractures
312930|NCT01447914|biopsy-proven plasmacytoma
312931|NCT01447901|Hyperlipoproteinemia Type I
312932|NCT01447888|Spine surgery
312933|NCT01447888|Chronic pain
312934|NCT01447888|Opioid tolerant
312935|NCT01447888|Pain management in spine surgery patients
312936|NCT01447862|recent-onset
312937|NCT01447849|Chronic Constipation
312938|NCT01447836|indocyanine green
312939|NCT01447836|sepsis
312940|NCT01447836|liver injury
312941|NCT01447836|abdominal perfusion pressure
312942|NCT01447823|Oesophageal bolus obstruction
312943|NCT01447823|Gastroscopy
312944|NCT01447823|phmetry
312945|NCT01447810|Constraint-Induced Movement therapy
312946|NCT01447810|Pediatric
312947|NCT01447810|Hemiplegia
312948|NCT01447810|Brain Tumor
312949|NCT01447810|Rehabilitation
312950|NCT01447797|Irbesartan
312951|NCT01447797|Atorvastatin
312952|NCT01447797|combination
312953|NCT01447784|HDM allergy
312954|NCT01447784|Rhinoconunctivitis
312955|NCT01447784|Environmental Exposure Chamber
312956|NCT01447784|Immunotherapy
312957|NCT01447784|ToleroMune HDM
312958|NCT01447771|Decision making
312959|NCT01447771|Decisional aide
312960|NCT01447745|Visceral obesity
312961|NCT01447745|Cardiometabolic risk
312962|NCT01447745|Atherosclerosis
312963|NCT01447745|Ectopic fat
312964|NCT01447745|Carotid plaque
312965|NCT01447745|Magnetic resonance imaging (MRI)
312966|NCT01447745|Computed tomography (CT)
312967|NCT01447732|Monoclonal antibody (Mab)
312968|NCT01447732|Antibody dependent cellular cytotoxicity (ADCC)
312969|NCT01447732|Complement-dependent toxicity (CDC)
312970|NCT01447732|Non-fucosylated immunoglobulin G
312971|NCT01447706|Ovarian Cancer
312972|NCT01447706|Platinum-resistant
312973|NCT01447706|Platinum-refractory
312974|NCT01447706|Fallopian tube cancer
312975|NCT01447706|Peritoneal Cancer
312976|NCT01447706|Paclitaxel
312977|NCT01447706|ErbB3
312978|NCT01447706|Phase II
312979|NCT01447706|locally advanced/metastatic or recurrent
312980|NCT01447693|uremia
312981|NCT01447693|pruritus
312982|NCT01447693|oliva-omega 3
312983|NCT01447680|HIV infection
312984|NCT01447680|HCV infection
312985|NCT01447680|SMARTube
312986|NCT01447680|SMARTplasma
312987|NCT01447667|Hepatic fibrosis
312988|NCT01447667|Magnetic resonance elastography
312989|NCT01447667|Hepatocellular carcinoma
312990|NCT01447667|Recurrence
312991|NCT01447654|Hypertrophic cardiomyopathy
312992|NCT01447654|Hypertrophic obstructive cardiomyopathy
312993|NCT01447654|Hypertrophy
312994|NCT01447654|Losartan
312995|NCT01447654|Angiotensin II receptor antagonist
312996|NCT01447641|Cluster Headache
312997|NCT01447641|Trigeminal Autonomic Cephalalgias
312998|NCT01447641|Sleep
312999|NCT01447641|Circadian Rhythms
313000|NCT01447628|Idiopathic pulmonary arterial hypertension (IPAH)
313001|NCT01447628|Iron deficiency
313002|NCT01447615|Orphaned children and youth
313003|NCT01447615|Economic empowerment
313004|NCT01447615|Uganda
313005|NCT01447615|HIV/AIDS
313006|NCT01447615|Sub-Saharan Africa
313007|NCT01447602|Major Depressive Disorder (MDD)
313008|NCT01447602|Dysthymia
313009|NCT01447602|Depressive Disorder Not Otherwise Specified (DDNOS)
313010|NCT01447589|Radiosensitiser
313011|NCT01447563|Bioequivalence
313012|NCT01447563|Bioavailability
313013|NCT01447550|Bosentan
313014|NCT01447550|Buerguer disease
313015|NCT01447537|Cirrhosis
313016|NCT01447537|Exercise
313017|NCT01447537|Relaxation
313018|NCT01447537|Muscle mass
313019|NCT01447537|Effort tolerance
313020|NCT01447511|Drug Interactions
313021|NCT01447511|Warfarin
313022|NCT01447511|Genetics
313023|NCT01447511|CYP2C9
313024|NCT01447511|Healthy Volunteers
313025|NCT01447485|Hypertension, chronic kidney disease
313026|NCT01447485|nephrotic syndrome
313027|NCT01447485|pharmacokinetics
313028|NCT01447472|MDMA,
313029|NCT01447472|pharmacokinetics,
313030|NCT01447472|pharmacodynamics,
313031|NCT01447472|CYP2D6, COMT,
313032|NCT01447472|SERT, 5-HTTLPR, gender,
313033|NCT01447472|dextromethorphan,
313034|NCT01447472|caffeine.
313035|NCT01447459|Asthma
313036|NCT01447459|Asthma Education
313037|NCT01447433|Calcium Carbonate
313038|NCT01447433|Vitamin D
313039|NCT01447433|Body weight
313040|NCT01447433|Body fat
313041|NCT01447433|Metabolic parameters
313042|NCT01447433|Energy restriction
313043|NCT01447433|Very-low calcium consumers
313044|NCT01447433|Obesity
313045|NCT01447433|Overweight
313046|NCT01447407|Staphylococcal infections
313047|NCT01447407|Yeast infections
313048|NCT01447407|Candidiasis
313049|NCT01447368|chronic kidney disease
313050|NCT01447368|peritoneal dialysis
313051|NCT01447368|secondary hyperparathyroidism
313052|NCT01447368|parathyroidectomy
313053|NCT01447368|vascular calcification
313054|NCT01447368|cinacalcet
313055|NCT01447329|pain
313056|NCT01447329|acupuncture
313057|NCT01447329|knee
313058|NCT01447329|debridement
313059|NCT01447329|surgery
313060|NCT01447329|arthroscopic knee surgery debridement
313061|NCT01447316|body composition
313062|NCT01447316|gait
313063|NCT01447316|quality of life
313064|NCT01447316|Patients
313065|NCT01447316|undergoing
313066|NCT01447316|bariatric surgery.
313067|NCT01447303|knee
313068|NCT01447303|osteoarthritis
313069|NCT01447303|hyaluronic acid
313070|NCT01447303|viscosupplementation
313071|NCT01447290|preeclampsia
313072|NCT01447290|protein
313073|NCT01447290|creatinine
313074|NCT01447290|protein:creatinine ratio
313075|NCT01447277|ACL reconstruction
313076|NCT01447277|Femoral Block
313077|NCT01447277|Sciatic Block
313078|NCT01447264|Rheumatoid arthritis
313079|NCT01447264|Muscle strength
313080|NCT01447264|Body composition
313081|NCT01447264|Physical activity
313082|NCT01447264|Water exercises
313083|NCT01447264|Hydrotherapy
313084|NCT01447264|Randomized controlled clinical trial
313085|NCT01447251|Obstructive Sleep Apnea
313086|NCT01447251|Diabetes Mellitus type 2
313087|NCT01447251|DM2
313088|NCT01447251|OSA
313089|NCT01447251|CPAP
313090|NCT01447251|continuous positive airway pressure
313091|NCT01447238|pancreatic cysts
313092|NCT01447238|EUS/FNA
313093|NCT01447238|Needle-based Confocal Laser Endomicroscopy (nCLE)
313094|NCT01447238|fiber optic imaging
313095|NCT01447238|EUS/FNA of pancreatic cysts
313096|NCT01447225|Advanced-stage
313097|NCT01447225|Solid Tumors
313098|NCT01447225|MM-121
313099|NCT01447225|Carboplatin
313100|NCT01447225|Pemetrexed
313101|NCT01447225|Gemcitabine
313102|NCT01447225|Cabazitaxel
313103|NCT01447225|ErbB3
313104|NCT01447225|Phase I
313105|NCT01447225|Cancer
313106|NCT01447212|Opioid Dependence
313107|NCT01447212|Long-term Opioid Injectors
313108|NCT01447212|Opioid Substitution Treatment
313109|NCT01447212|Hydromorphone
313110|NCT01447212|Diamorphine
313111|NCT01447212|Diacetylmorphine
313112|NCT01447199|Bladder cancer
313113|NCT01447199|Colorectal cancer
313114|NCT01447199|Endometrial cancer
313115|NCT01447199|Kidney cancer
313116|NCT01447199|Skin cancer
313117|NCT01447199|Uterus cancer
313118|NCT01447199|Molecular Predisposition
313119|NCT01447199|Hereditary Nonpolyposis Colon Cancer
313120|NCT01447199|HNPCC
313121|NCT01447199|Molecular genetic testing
313122|NCT01447199|Gene mutations
313123|NCT01447199|Mutation analyses
313124|NCT01447199|Genetic polymorphisms
313125|NCT01447199|Family history of cancer
313126|NCT01447199|Early age of cancer onset
313127|NCT01447199|Little/no personal or family history of cancer
313128|NCT01447199|Spouses
313129|NCT01447199|Questionnaires
313130|NCT01447199|Blood sample
313131|NCT01447199|Saliva Sample
313132|NCT01447186|Prostate cancer screening
313133|NCT01447186|Prostate Cancer
313134|NCT01447186|Patient Decision Aid
313135|NCT01447186|Spanish Speaking Men
313136|NCT01447186|Spanish-language slide set
313137|NCT01447186|Focus group
313138|NCT01447186|Interview
313139|NCT01447186|Survey
313140|NCT01447173|Asthma
313141|NCT01447173|Pulmonary Function Test
313142|NCT01447173|Vitamin D
313143|NCT01447160|facet joint
313144|NCT01447160|back pain
313145|NCT01447160|osteoarthritis
313146|NCT01447160|infiltration
313147|NCT01447108|Trigeminal Neuralgia
313148|NCT01447108|Tic Douloureux
313149|NCT01447108|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound
313150|NCT01447095|Subarachnoid hemorrhage
313151|NCT01447095|vasospasm
313152|NCT01447095|prostacyclin
313153|NCT01447082|atypical
313154|NCT01447082|antipsychotics
313155|NCT01447082|quetiapine
313156|NCT01447069|heart failure stage 3
313157|NCT01447069|beta 2 agonist
313158|NCT01447069|N-terminal pro-brain natriuretic peptide
313159|NCT01447069|ejection fraction <35%
313160|NCT01447056|Hodgkin lymphoma
313161|NCT01447056|Non-Hodgkin lymphoma
313162|NCT01447056|Lymphoproliferative disorder
313163|NCT01447056|Nasopharyngeal carcinoma
313164|NCT01447056|Leiomyosarcoma
313165|NCT01447056|EBV Cytotoxic T Lymphocytes
313166|NCT01447043|retrospective studies
313167|NCT01447030|Biliary strictur
313168|NCT01447030|Hepatojejunostomy
313169|NCT01447030|Iatrogenic major bile duct injury
313170|NCT01446991|prostate neoplasm
313171|NCT01446991|brachytherapy
313172|NCT01446991|androgen ablation
313173|NCT01446991|benign prostatic hypertrophy
313174|NCT01446991|prostate size reduction
313175|NCT01446991|localized prostate cancer with prostate volume > 40 cc
313176|NCT01446978|hepatitis A vaccine
313177|NCT01446978|TNF-alfa inhibitory drugs
313178|NCT01446978|Rheumatoid arthritis
313179|NCT01446978|methotrexate
313180|NCT01446965|myocardial infarction, acute
313181|NCT01446965|myocardial infarction
313182|NCT01446965|ventricular dysfunction
313183|NCT01446965|death, sudden, cardiac
313184|NCT01446965|death, sudden
313185|NCT01446965|death
313186|NCT01446965|ventricular tachycardia
313187|NCT01446965|ventricular fibrillation
313188|NCT01446965|defibrillation, electric
313189|NCT01446965|cardioversion, electric
313190|NCT01446965|electric countershock
313191|NCT01446965|defibrillators, external
313192|NCT01446952|prevention
313193|NCT01446952|pancreas
313194|NCT01446939|MRI
313195|NCT01446939|Parkinson's disease
313196|NCT01446939|Essential tremor
313197|NCT01446939|Ultrasonography
313198|NCT01446939|Diagnosis
313199|NCT01446926|Pneumonia
313200|NCT01446926|Pneumococcal Infections
313201|NCT01446926|Streptococcus pneumoniae Infections
313202|NCT01446926|Pneumococcal vaccines
313203|NCT01446913|Sleep Apnea
313204|NCT01446913|CPAP adherence
313205|NCT01446913|behavioral adherence
313206|NCT01446913|stroke
313207|NCT01446900|Rituximab
313208|NCT01446900|Cladribine
313209|NCT01446900|Chronic Lymphocytic Leukaemia
313210|NCT01446900|Small Lymphocytic Lymphoma
313211|NCT01446887|Deep Vein Thrombosis
313212|NCT01446887|total hip arthroplasty
313213|NCT01446887|prophylactic anticoagulation
313214|NCT01446887|randomized study
313215|NCT01446874|Incidence of post-operative pneumonia in patients undergoing surgery for primary lung cancer or primary esophageal cancer
313216|NCT01446861|Cystic fibrosis
313217|NCT01446861|Pancreas
313218|NCT01446861|Exocrine function
313219|NCT01446861|Ultrasound
313220|NCT01446861|Contrast ultrasound
313221|NCT01446848|iron deficiency
313222|NCT01446848|pulmonary hypertension
313223|NCT01446848|iron supplements
313224|NCT01446848|ferrous sulfate
313225|NCT01446822|urinary bladder neoplasm
313226|NCT01446822|bipolar transurethral resection
313227|NCT01446822|monopolar transurethral resection
313228|NCT01446822|obturator nerve
313229|NCT01446796|Ventricular assist device
313230|NCT01446783|COL5A1
313231|NCT01446783|Collagen disorders
313232|NCT01446783|IGF-I
313233|NCT01446783|Collagen synthesis
313234|NCT01446757|quality of life
313235|NCT01446757|feeling of security
313236|NCT01446757|costs
313237|NCT01446757|multiprofessional team
313238|NCT01446757|geriatric competence
313239|NCT01446731|Prostate cancer
313240|NCT01446718|quadrivalent vaccine
313241|NCT01446718|Human Papillomavirus
313242|NCT01446692|Major depressive disorder
313243|NCT01446692|primary care
313244|NCT01446692|real-world evidence
313245|NCT01446692|database
313246|NCT01446679|Lipitor
313247|NCT01446679|HMG-CoA reductase inhibitor
313248|NCT01446666|hepatocellular carcinoma
313249|NCT01446666|surveillance
313250|NCT01446666|gadoxetic acid
313251|NCT01446666|MRI
313252|NCT01446653|Fetal Alcohol Spectrum Disorders
313253|NCT01446653|FASDs
313254|NCT01446653|AEP risk
313255|NCT01446653|binge drinking
313256|NCT01446653|ineffective contraception
313257|NCT01446627|Absorbable vicryl subcuticular staples
313258|NCT01446627|metal staples
313259|NCT01446627|wound healing
313260|NCT01446627|cesarean section
313261|NCT01446601|Apnea
313262|NCT01446601|OSA
313263|NCT01446601|Sleep Apnea Syndromes
313264|NCT01446601|Sleep Apnea, Obstructive
313265|NCT01446601|Hypoglossal Nerve Stimulation
313266|NCT01446601|Sleep Disorders
313267|NCT01446601|Tongue
313268|NCT01446575|Transverse myelitis
313269|NCT01446536|Quality
313270|NCT01446536|Improvement
313271|NCT01446523|endotoxins HE
313272|NCT01446510|VTE
313273|NCT01446510|DVT
313274|NCT01446510|PE
313275|NCT01446510|Risk assessment
313276|NCT01446510|risk score
313277|NCT01446510|risk analysis
313278|NCT01446510|Venous thromboembolism risk
313279|NCT01446497|Normal tension glaucoma
313280|NCT01446497|Antiglaucoma ophthalmic solution
313281|NCT01446497|Brimonidine
313282|NCT01446497|Timolol
313283|NCT01446497|Combination drugs
313284|NCT01446484|Renal transplantation
313285|NCT01446484|Kidney transplantation
313286|NCT01446484|CD4+CD25+CD127lowFoxP3+ T Regulatory Cells
313287|NCT01446484|T reg
313288|NCT01446484|Campath
313289|NCT01446471|Bedside Ultrasound
313290|NCT01446471|Point of care ultrasound
313291|NCT01446471|cardiac arrest
313292|NCT01446458|Cancer of Pancreas
313293|NCT01446458|Cancer of the Pancreas
313294|NCT01446458|Neoplasms, Pancreatic
313295|NCT01446458|Pancreas Cancer
313296|NCT01446458|Pancreas Neoplasms
313297|NCT01446458|Entry Term Pancreatic Cancer
313298|NCT01446445|Cytomegalovirus
313299|NCT01446445|renal transplant
313300|NCT01446432|Dupuytren's Contracture
313301|NCT01446419|chronic axial low back pain
313302|NCT01446419|vertebrogenic pain
313303|NCT01446419|Radio frequency ablation
313304|NCT01446406|Bipolar disorder
313305|NCT01446406|Electronic daily monitoring
313306|NCT01446406|Affective episodes
313307|NCT01446354|Blood component transfusion
313308|NCT01446354|Hypothermic
313309|NCT01446341|Ankle sprain
313310|NCT01446341|Functional rehabilitation
313311|NCT01446341|Immobilization
313312|NCT01446328|Antipsychotic Drugs
313313|NCT01446328|Randomized Controlled Trial
313314|NCT01446328|Treatment Effectiveness
313315|NCT01446328|Translational Research
313316|NCT01446315|asthma
313317|NCT01446315|asthma care system
313318|NCT01446315|effectiveness
313319|NCT01446315|primary care
313320|NCT01446315|practice based research network
313321|NCT01446302|Dialysis
313322|NCT01446302|Protein-energy wasting
313323|NCT01446302|Insulin-Like Growth Factor I
313324|NCT01446302|Insulin-Like Growth Factor Binding Protein 1
313325|NCT01446302|Inflammation
313326|NCT01446289|Group B streptococcus
313327|NCT01446289|GBS
313328|NCT01446289|Vaccine
313329|NCT01446289|Prevention of group B streptococcus infection
313330|NCT01446276|Obesity
313331|NCT01446276|Resveratrol
313332|NCT01446276|Nonalcoholic fatty liver disease
313333|NCT01446276|Insulin sensitivity
313334|NCT01446276|Lipid turnover
313335|NCT01446276|Liver fat content
313336|NCT01446263|Radial access
313337|NCT01446263|Femoral access
313338|NCT01446263|Coronary angiography
313339|NCT01446263|Coronary artery bypass graft
313340|NCT01446250|Chronic hepatitis C
313341|NCT01446250|Cyclophilin inhibitor
313342|NCT01446224|adverse events
313343|NCT01446224|pazopanib
313344|NCT01446224|Torsades des Pointes
313345|NCT01446224|renal cell carcinoma
313346|NCT01446224|anti-VEGF agents
313347|NCT01446224|observational data
313348|NCT01446224|cardiac ischemia
313349|NCT01446211|gusperimus
313350|NCT01446211|Wegeners granulomatosis
313351|NCT01446211|relapse
313352|NCT01446198|HPV
313353|NCT01446185|HR+, N- or pN1(mi), Her2- breast cancer adjuvant population
313354|NCT01446185|Early Breast cancer
313355|NCT01446185|Gene Expression
313356|NCT01446185|Node-Negative
313357|NCT01446185|treatment options
313358|NCT01446185|Hormone receptor positive
313359|NCT01446172|Long term outcome
313360|NCT01446159|MEDI-573, breast cancer, metastatic, aromatase inhibitor, anti-IGF
313361|NCT01446146|Posttraumatic Stress Disorder
313362|NCT01446146|PTSD Treatment
313363|NCT01446146|Decision making
313364|NCT01446146|Veterans
313365|NCT01446133|Leukemia
313366|NCT01446133|Lymphoma
313367|NCT01446133|Chronic Lymphocytic Leukemia
313368|NCT01446133|CLL
313369|NCT01446133|Small Lymphocytic Lymphoma
313370|NCT01446133|SLL
313371|NCT01446133|Initial Treatment
313372|NCT01446133|Subsequent Therapy
313373|NCT01446133|Rituximab
313374|NCT01446133|Rituxan
313375|NCT01446133|Lenalidomide
313376|NCT01446133|CC-5013
313377|NCT01446133|Revlimid
313378|NCT01446120|this is phase one study. The study population are healthy volunteers.
313379|NCT01446107|tooth decay
313380|NCT01446107|fluoride
313381|NCT01446107|sealant
313382|NCT01446107|prevention
313383|NCT01446094|Coronary artery disease
313384|NCT01446081|chemotherapy
313385|NCT01446081|exercise
313386|NCT01446081|quality of life
313387|NCT01446081|cancer-related fatigue
313388|NCT01446081|elderly
313389|NCT01446081|physical fitness
313390|NCT01446055|Peripheral arterial disease
313391|NCT01446055|Buerger's disease
313392|NCT01446055|atherosclerotic arterial occlusion
313393|NCT01446055|bone marrow mononuclear cell
313394|NCT01446055|chronic limb ischemia
313395|NCT01446029|Telemonitoring
313396|NCT01446029|Chronic Kidney Disease
313397|NCT01446016|Breast Cancer
313398|NCT01446016|Breast Tumors
313399|NCT01446016|Cancer of Breast
313400|NCT01446016|Cancer of the Breast
313401|NCT01446016|Human Mammary Carcinoma
313402|NCT01446016|Mammary Carcinoma, Human
313403|NCT01446016|Mammary Neoplasm, Human
313404|NCT01446016|Mammary Neoplasms, Human
313405|NCT01446016|Neoplasms, Breast
313406|NCT01446016|Tumors, Breast
313407|NCT01446016|Taxotere
313408|NCT01446016|Chloroquine
313409|NCT01446016|Paclitaxel
313410|NCT01446016|Taxol
313411|NCT01446016|Ixabepilone
313412|NCT01446016|Abraxane
313413|NCT01446016|Metastatic Breast Cancer
313414|NCT01446016|Advanced Breast Cancer
313415|NCT01446016|Anthracycline
313416|NCT01445990|free tissue flaps
313417|NCT01445990|lactic acid
313418|NCT01445990|glucose
313419|NCT01445990|thrombosis
313420|NCT01445990|diagnostic test
313421|NCT01445990|Pedicle postoperative complications diagnosis
313422|NCT01445977|Sonitus Medical
313423|NCT01445977|SoundBite
313424|NCT01445977|Single Sided Deafness
313425|NCT01445977|Conductive Hearing Loss
313426|NCT01445977|Unilateral Hearing Loss
313427|NCT01445964|SLCO2B1 genotype
313428|NCT01445964|effect of apple juice
313429|NCT01445886|Nail Psoriasis
313430|NCT01445886|Indigo Naturalis
313431|NCT01445886|Indirubin
313432|NCT01445886|Calcipotriol
313433|NCT01445886|Nail Psoriasis Severity Index
313434|NCT01445873|Pulmonary arterial hypertension
313435|NCT01445873|sitaxentan sodium
313436|NCT01445873|Thelin
313437|NCT01445860|DDI
313438|NCT01445860|pharmacokinetics
313439|NCT01445847|Laryngospasm
313440|NCT01445847|Lidocaine
313441|NCT01445834|outcome of pelvic floor muscle physiotherapy
313442|NCT01445834|female
313443|NCT01445834|stress urinary incontinence
313444|NCT01445834|urgency urinary incontinence
313445|NCT01445834|mixed urinary incontinence
313446|NCT01445821|systemic scleroderma
313447|NCT01445821|autologous stem cell transplantation
313448|NCT01445808|psychodynamic psychotherapy
313449|NCT01445808|coronary heart disease
313450|NCT01445808|physical activity
313451|NCT01445808|secondary prevention
313452|NCT01445795|Inhibitex
313453|NCT01445795|Chronic Hepatitis
313454|NCT01445795|Hepatitis C Virus
313455|NCT01445782|Safety
313456|NCT01445782|tolerability
313457|NCT01445782|healthy
313458|NCT01445782|inhaled
313459|NCT01445769|Myelofibrosis
313460|NCT01445769|Primary Myelofibrosis
313461|NCT01445769|PMF
313462|NCT01445769|Post-Polycythemia Vera Myelofibrosis
313463|NCT01445769|PPV-MF
313464|NCT01445769|Post-Essential Thrombocythemia Myelofibrosis
313465|NCT01445769|PET-MF
313466|NCT01445769|Open label
313467|NCT01445769|Ruxolitinib
313468|NCT01445769|18424
313469|NCT01445769|Jak inhibitor
313470|NCT01445756|Intrauterine Device
313471|NCT01445743|Tdap Vaccine
313472|NCT01445743|Pregnant woman
313473|NCT01445743|Pertussis
313474|NCT01445730|fructose
313475|NCT01445730|hypertriglyceridemia
313476|NCT01445730|postprandial lipids
313477|NCT01445730|de novo lipogenesis
313478|NCT01445730|stable isotopes
313479|NCT01445717|GBS, Streptococcus, .
313480|NCT01445717|Group B
313481|NCT01445704|Weight loss
313482|NCT01445704|Probiotics
313483|NCT01445704|Gastric Bypass
313484|NCT01445691|Benign Neoplasms, Brain
313485|NCT01445691|Brain Cancer
313486|NCT01445691|Brain Neoplasms, Benign
313487|NCT01445691|Brain Neoplasms, Malignant
313488|NCT01445691|Brain Tumor, Primary
313489|NCT01445691|Brain Tumor, Recurrent
313490|NCT01445691|Brain Tumors
313491|NCT01445691|Intracranial Neoplasms
313492|NCT01445691|Neoplasms, Brain
313493|NCT01445691|Neoplasms, Intracranial
313494|NCT01445691|Primary Brain Neoplasms
313495|NCT01445691|Primary Malignant Brain Neoplasms
313496|NCT01445691|Primary Malignant Brain Tumors
313497|NCT01445691|Gliomas
313498|NCT01445691|Glioblastoma
313499|NCT01445691|Surgery
313500|NCT01445691|5-ALA
313501|NCT01445691|Aminolevulinic acid
313502|NCT01445691|Fluorescence
313503|NCT01445678|cIAI
313504|NCT01445639|dexmedetomidine
313505|NCT01445639|sedation
313506|NCT01445639|neurosurgery
313507|NCT01445639|postoperative care
313508|NCT01445613|Carotid
313509|NCT01445613|Stent
313510|NCT01445613|Carotid Endarterectomy
313511|NCT01445600|Impetigo
313512|NCT01445600|secondarily-infected traumatic lesions
313513|NCT01445600|retapamulin
313514|NCT01445587|bortezomib
313515|NCT01445587|AKT inhibitor
313516|NCT01445587|multiple myeloma
313517|NCT01445587|GSK2110183
313518|NCT01445587|hematologic malignancies
313519|NCT01445561|Interleukin-2
313520|NCT01445561|IL-2
313521|NCT01445561|Stem Cells
313522|NCT01445561|Regulatory T Cells (T regs)
313523|NCT01445561|Natural Killer Cells (NK cells)
313524|NCT01445561|Healthy Volunteer
313525|NCT01445561|HV
313526|NCT01445548|Age-Related Macular Degeneration (AMD)
313527|NCT01445548|Geographic Atrophy
313528|NCT01445548|Bilateral Geographic Atrophy
313529|NCT01445548|Sirolimus
313530|NCT01445548|Age Related Macular Degeneration
313531|NCT01445548|AMD
313532|NCT01445535|CD2 Positive
313533|NCT01445535|Toxicity
313534|NCT01445535|EBV Lymphoma
313535|NCT01445535|Chemotherapy Naive
313536|NCT01445535|Maximum Tolerated Dose
313537|NCT01445535|Lymphoma
313538|NCT01445535|T-Cell Lymphoma
313539|NCT01445535|NK T-Cell Lymphoma
313540|NCT01445522|PARP Inhibitor
313541|NCT01445522|DNA Damage
313542|NCT01445522|Chemotherapy
313543|NCT01445522|Advanced Cancer
313544|NCT01445522|DNA Repair
313545|NCT01445509|Angiogenesis
313546|NCT01445509|VEGF
313547|NCT01445509|SRC
313548|NCT01445509|Targeted Therapy
313549|NCT01445509|Cancer
313550|NCT01445509|Solid Tumor
313551|NCT01445483|Cancer
313552|NCT01445483|Radiation
313553|NCT01445483|Brain
313554|NCT01445483|Neuropsychological Outcome
313555|NCT01445483|Metastasis
313556|NCT01445483|Brain Metastasis
313557|NCT01445444|Habit Reversal Training
313558|NCT01445444|Hair Pulling
313559|NCT01445444|Children
313560|NCT01445444|Trich
313561|NCT01445444|cognitive behavioral therapy
313562|NCT01445444|TTM
313563|NCT01445444|psychotherapy
313564|NCT01445418|Genetic
313565|NCT01445418|BRCA
313566|NCT01445418|Ovarian Cancer, sporadic epithelial ovarian cancer
313567|NCT01445418|Breast Cancer, triple negative breast cancer
313568|NCT01445418|Metastatic
313569|NCT01445418|Breast Cancer
313570|NCT01445418|Ovarian Cancer
313571|NCT01445405|Proteasome
313572|NCT01445405|Bortezomib
313573|NCT01445405|NF-kappaB
313574|NCT01445405|Cetuximab
313575|NCT01445405|Epidermal Growth Factor
313576|NCT01445405|Head and Neck Cancer
313577|NCT01445405|Squamous Cell Carcinoma
313578|NCT01445405|Oral Cancer
313579|NCT01445392|Recombinant Immunotoxin
313580|NCT01445392|Monoclonal Antibody
313581|NCT01445392|Pseudomonas Exotoxin
313582|NCT01445392|Targeted Therapy
313583|NCT01445392|Pleural Mesothelioma
313584|NCT01445392|Mesothelioma
313585|NCT01445392|Epithelial Pleural Mesothelioma
313586|NCT01445379|Solid Tumor
313587|NCT01445379|Monoclonal Antibody
313588|NCT01445379|Pediatrics
313589|NCT01445379|Pharmacokinetics
313590|NCT01445379|Immunotherapy
313591|NCT01445379|Sarcoma
313592|NCT01445379|Lymphoma
313593|NCT01445379|Neuroblastoma
313594|NCT01445340|Topical Depsi
313595|NCT01445340|Cutaneous T Cell Lymphoma
313596|NCT01445340|CTCL
313597|NCT01445340|Mycosis Fungoides
313598|NCT01445327|Blood
313599|NCT01445327|Urine
313600|NCT01445327|Stool
313601|NCT01445327|Tumor Marker
313602|NCT01445327|Radiation Therapy
313603|NCT01445327|Gastrointestinal Cancer
313604|NCT01445327|Esophageal Cancer
313605|NCT01445327|Stomach
313606|NCT01445327|Pancreatic Cancer
313607|NCT01445314|Stored Data
313608|NCT01445314|Neurobehavioral
313609|NCT01445314|Behavior
313610|NCT01445314|Quality of Life
313611|NCT01445301|twice daily
313612|NCT01445301|once daily
313613|NCT01445301|CLDM 1%-BPO 3% gel
313614|NCT01445301|Clindamycin (CLDM)
313615|NCT01445301|benzoyl peroxide (BPO)
313616|NCT01445301|inflammatory lesion
313617|NCT01445301|non-inflammatory lesion
313618|NCT01445301|acne vulgaris
313619|NCT01445288|Neurotoxicity
313620|NCT01445288|Brain Tumor
313621|NCT01445288|Children
313622|NCT01445288|Angiogenesis
313623|NCT01445288|Imaging
313624|NCT01445288|Central Nervous System Tumor
313625|NCT01445288|CNS Tumor
313626|NCT01445249|regional anaesthetic techniques
313627|NCT01445249|surgery orthopaedic
313628|NCT01445236|Operational tolerance
313629|NCT01445236|Biomarkers
313630|NCT01445236|Liver Transplantation
313631|NCT01445223|HIV
313632|NCT01445223|Antiretroviral therapy
313633|NCT01445223|efavirenz
313634|NCT01445223|lopinavir
313635|NCT01445223|atazanavir
313636|NCT01445223|randomised controlled clinical trial
313637|NCT01445210|Postoperative pain
313638|NCT01445210|Major ankle surgery
313639|NCT01445210|Continuous nerve block
313640|NCT01445210|Saphenous nerve
313641|NCT01445210|Ropivacaine
313642|NCT01445171|Aortic Valve Replacement
313643|NCT01445158|ShopTalk
313644|NCT01445158|Comprehension
313645|NCT01445158|Donors
313646|NCT01445158|Education
313647|NCT01445158|Stem Cell Transplant
313648|NCT01445158|Sibling Donor
313649|NCT01445145|End-of-Life
313650|NCT01445145|Advance Directive
313651|NCT01445145|Pediatric Cancer
313652|NCT01445145|Adolescents
313653|NCT01445145|Young Adults
313654|NCT01445132|Adoptive Immunotherapy
313655|NCT01445132|Tumor Infiltrating Lymphocytes
313656|NCT01445132|Refractory Tumor
313657|NCT01445132|Resection
313658|NCT01445132|B-Cell Malignancies
313659|NCT01445132|Chronic Lymphocytic Leukemia
313660|NCT01445132|BCL
313661|NCT01445132|B-Cell Lymphoid Malignancy
313662|NCT01445119|Brain
313663|NCT01445119|Tumor
313664|NCT01445119|Radiation
313665|NCT01445119|Antiangiogenesis
313666|NCT01445119|Chemotherapy
313667|NCT01445119|Brain Tumor
313668|NCT01445119|Glioma
313669|NCT01445106|HIV Protease Inhibitor
313670|NCT01445106|Drug Repositioning
313671|NCT01445106|Akt/Mtor Inhibitor
313672|NCT01445106|Targeted Therapy
313673|NCT01445106|Off - Label Drugs
313674|NCT01445106|Nelfinavir
313675|NCT01445106|Protease Inhibitor
313676|NCT01445106|Solid Tumor
313677|NCT01445106|Phase I
313678|NCT01445106|Malignant Tumor
313679|NCT01445080|MTD
313680|NCT01445080|Phase I/II
313681|NCT01445080|Pediatric
313682|NCT01445080|Solid Tumor
313683|NCT01445080|Leukemia
313684|NCT01445080|Chronic Myelogenous Leukemia
313685|NCT01445080|CML
313686|NCT01445080|Acute Lymphoblastic Leukemia
313687|NCT01445080|ALL
313688|NCT01445080|Acute Myeloid Leukemia
313689|NCT01445080|AML
313690|NCT01445080|Juevenile Myelomoncytic Leukemia
313691|NCT01445080|JMML
313692|NCT01445054|111 Indium Trastuzumab Imaging
313693|NCT01445054|PET
313694|NCT01445054|Breast Cancer
313695|NCT01445041|Hypoplastic Left Heart Syndrome
313696|NCT01445041|Autologous Umbilical Cord Blood
313697|NCT01445041|Newborn Infants
313698|NCT01445015|adolescents
313699|NCT01445002|grass pollen allergy
313700|NCT01445002|immunotherapy
313701|NCT01445002|recombinant vaccine
313702|NCT01444989|"Sun spots"
313703|NCT01444989|"Pre-cancerous skin lesion"
313704|NCT01444976|age range of 18-83
313705|NCT01444924|Pain control
313706|NCT01444924|Gynecologic Oncology
313707|NCT01444924|Surgery
313708|NCT01444911|Sexual Dysfunction
313709|NCT01444911|Gynecologic cancer
313710|NCT01444911|Cancer survivor
313711|NCT01444911|Vaginal dilator
313712|NCT01444898|Prader-Willi Syndrome
313713|NCT01444898|Obesity
313714|NCT01444898|Weight
313715|NCT01444898|Exenatide
313716|NCT01444898|Byetta
313717|NCT01444898|Pediatrics
313718|NCT01444898|Adolescents
313719|NCT01444885|Variant angina
313720|NCT01444885|Cilostazol
313721|NCT01444846|Temporary Auditory Threshold Shift
313722|NCT01444846|Hearing Loss
313723|NCT01444846|Deafness
313724|NCT01444846|SPI-1005
313725|NCT01444846|Ebselen
313726|NCT01444833|hypertension
313727|NCT01444833|obesity
313728|NCT01444833|metabolism
313729|NCT01444833|angiotensin
313730|NCT01444820|radiation therapy
313731|NCT01444820|hypofractionation
313732|NCT01444820|hormonal therapy
313733|NCT01444820|high risk adenocarcinoma of the prostate
313734|NCT01444807|sorafenib
313735|NCT01444807|metastatic renal cell carcinoma
313736|NCT01444807|metastasectomy
313737|NCT01444794|Lower limb spasticity
313738|NCT01444781|Diphtheria
313739|NCT01444781|Tetanus
313740|NCT01444781|Whooping Cough
313741|NCT01444781|Hepatitis B
313742|NCT01444781|Poliomyelitis
313743|NCT01444781|Pediatric combined vaccine
313744|NCT01444781|Invasive Hib infections
313745|NCT01444768|Alert Systems, Medication
313746|NCT01444768|Computerized Physician Order Entry System
313747|NCT01444768|CPOE
313748|NCT01444768|Medication Alert Systems
313749|NCT01444768|Medical Order Entry Systems
313750|NCT01444755|Locally advanced gastric cancer
313751|NCT01444755|neoadjuvant chemotherapy
313752|NCT01444742|Leukemia
313753|NCT01444742|Myeloproliferative Diseases
313754|NCT01444742|Myelodysplastic Syndrome
313755|NCT01444742|(MDS)
313756|NCT01444742|Relapsing
313757|NCT01444742|Refractory
313758|NCT01444742|Clofarabine
313759|NCT01444742|Clofarex
313760|NCT01444742|Clolar
313761|NCT01444742|Cytarabine
313762|NCT01444742|Ara-C
313763|NCT01444742|Cytosar
313764|NCT01444742|DepoCyt
313765|NCT01444742|Cytosine Arabinosine Hydrochloride
313766|NCT01444729|'Dupuytren's contracture'
313767|NCT01444729|'xiapex'
313768|NCT01444729|'surgery'
313769|NCT01444716|Advanced Cancers
313770|NCT01444716|Leukemia
313771|NCT01444716|Chronic Lymphocytic Leukemia
313772|NCT01444716|CLL
313773|NCT01444716|Elderly
313774|NCT01444716|Ofatumumab
313775|NCT01444716|Arzerra
313776|NCT01444703|Thoracic surgery
313777|NCT01444703|double-lumen endotracheal tube
313778|NCT01444703|intubation
313779|NCT01444703|extubation
313780|NCT01444703|sore throat
313781|NCT01444703|prevention of post-extubation sore throat
313782|NCT01444690|Antiretroviral therapy
313783|NCT01444690|Acquired Immunodeficiency Syndrome/complications*
313784|NCT01444690|Anti-HIV Agents/adverse effects
313785|NCT01444677|Safety
313786|NCT01444677|Tolerability
313787|NCT01444677|Pharmacokinetic
313788|NCT01444651|Tadalafil
313789|NCT01444651|Phosphodiesterase 5 Inhibitors
313790|NCT01444651|Cyclic Guanylyl Monophosphate Pathway
313791|NCT01444651|Pharmacologic Actions
313792|NCT01444651|Vasodilator Agents
313793|NCT01444651|Cardiovascular Agents
313794|NCT01444651|Obesity
313795|NCT01444651|Glycemic Traits
313796|NCT01444651|Insulin Resistance
313797|NCT01444651|Glucose Metabolism
313798|NCT01444638|pregnancy
313799|NCT01444638|Caesarian
313800|NCT01444638|section
313801|NCT01444638|spinal
313802|NCT01444625|UV radiation
313803|NCT01444625|photoprotection
313804|NCT01444625|flavanols rich chocolate
313805|NCT01444612|cancer surgery
313806|NCT01444612|venous thromboembolism
313807|NCT01444612|hospitalization
313808|NCT01444612|anticoagulants
313809|NCT01444612|costs and cost analysis
313810|NCT01444612|thromboprophylaxis
313811|NCT01444599|coronary atherosclerosis
313812|NCT01444599|virtual histology intravascular ultrasound
313813|NCT01444599|fractional flow reserve
313814|NCT01444586|non-interventional
313815|NCT01444586|Xarelto
313816|NCT01444586|knee replacement
313817|NCT01444586|hip replecement
313818|NCT01444586|Russia
313819|NCT01444573|Rate control
313820|NCT01444573|ILR
313821|NCT01444547|esophageal cancer
313822|NCT01444547|paclitaxel
313823|NCT01444547|cisplatin
313824|NCT01444534|mobile phone application
313825|NCT01444534|diabetes type 1
313826|NCT01444534|self-management
313827|NCT01444534|telemedicin
313828|NCT01444521|advanced gastric cancer
313829|NCT01444521|irinotecan
313830|NCT01444521|cisplatin
313831|NCT01444495|rectal cancer
313832|NCT01444495|radiotherapy
313833|NCT01444495|overall survival
313834|NCT01444495|recurrence rate
313835|NCT01444495|downstaging
313836|NCT01444469|Asthma exacerbations
313837|NCT01444469|Respiratory disease
313838|NCT01444469|Viral infection
313839|NCT01444469|Macrolide/ketolide antibiotics
313840|NCT01444469|Mycoplasma pneumoniae (M. pneumoniae)
313841|NCT01444469|Chlamydophila pneumoniae (C. pneumoniae)
313842|NCT01444456|Breast Cancer
313843|NCT01444456|Lung Cancer
313844|NCT01444456|Ovarian Cancer
313845|NCT01444456|Prostate Cancer
313846|NCT01444456|Colorectal Cancer
313847|NCT01444456|Aranesp
313848|NCT01444456|Chemotherapy induced anaemia
313849|NCT01444456|Chemotherapy
313850|NCT01444456|Bladder Cancer
313851|NCT01444456|Endometrial Cancer
313852|NCT01444456|Renal Cancer
313853|NCT01444456|Pancreatic Cancer
313854|NCT01444456|Esophageal Cancer
313855|NCT01444456|Gastric Cancer
313856|NCT01444443|Type 1 diabetes
313857|NCT01444443|Glucose control
313858|NCT01444443|Closed-loop
313859|NCT01444443|Insulin pump
313860|NCT01444443|Glucose sensor
313861|NCT01444430|Symbicort pMDI
313862|NCT01444430|Asthma
313863|NCT01444430|safety
313864|NCT01444430|budesonide
313865|NCT01444417|Immune (Idiopathic) Thrombocytopenic Purpura
313866|NCT01444417|Pediatric Immune (Idiopathic) Thrombocytopenic Purpura
313867|NCT01444417|Immune Thrombocytopenia
313868|NCT01444404|Solid Tumors
313869|NCT01444404|Phase 1
313870|NCT01444404|Clinical Trial
313871|NCT01444391|Tympanostomy tube placement
313872|NCT01444391|iontophoresis
313873|NCT01444378|Atherosclerosis
313874|NCT01444378|Claudication
313875|NCT01444378|PAOD
313876|NCT01444378|Peripheral Arterial Occlusive Disease
313877|NCT01444378|Stent
313878|NCT01444365|Osteoarthritis of the knee
313879|NCT01444352|Pneumococcal infections
313880|NCT01444352|Streptococcus pneumoniae Infections
313881|NCT01444352|Pneumococcal Vaccines
313882|NCT01444339|Pneumococcal Infections
313883|NCT01444339|Streptococcus Pneumoniae Infections
313884|NCT01444339|Pneumococcal Vaccine
313885|NCT01444326|Keywords;
313886|NCT01444326|Cardiovascular disease
313887|NCT01444326|Dairy
313888|NCT01444326|Inflammation
313889|NCT01444326|Blood lipids
313890|NCT01444300|multiple sclerosis
313891|NCT01444300|postural balance
313892|NCT01444300|gait
313893|NCT01444300|fatigue
313894|NCT01444261|iron deficiency
313895|NCT01444261|anemia
313896|NCT01444248|Amaryl MEX
313897|NCT01444235|CAD, ACVB
313898|NCT01444222|Myocardial contractility
313899|NCT01444222|Quantification of regurgitant flow
313900|NCT01444222|exercise capacity
313901|NCT01444209|pituitary gland
313902|NCT01444196|ACU
313903|NCT01444196|acquired cold urticaria
313904|NCT01444183|Epilepsy
313905|NCT01444183|seizures
313906|NCT01444183|stress reduction
313907|NCT01444170|eccentric exercise
313908|NCT01444170|exercise induce muscle damage
313909|NCT01444170|isometric strength
313910|NCT01444170|range of motion
313911|NCT01444170|self report symptoms
313912|NCT01444170|mechanical pain threshold
313913|NCT01444144|Ankle
313914|NCT01444144|Fracture
313915|NCT01444144|Elderly
313916|NCT01444144|At-risk Population
313917|NCT01444144|Ankle Fracture in at-risk elderly population
313918|NCT01444131|Smoking
313919|NCT01444131|Smoking cessation
313920|NCT01444131|Pharmaceutical aids
313921|NCT01444105|Open angle glaucoma
313922|NCT01444105|Pseudoexfoliative glaucoma
313923|NCT01444079|Liver transplantation
313924|NCT01444079|Rejection
313925|NCT01444079|Tolerance
313926|NCT01444040|Open angle glaucoma
313927|NCT01444040|POAG
313928|NCT01444040|Ocular hypertension
313929|NCT01444040|Pseudoexfoliative glaucoma
313930|NCT01444040|Naïve to treatment
313931|NCT01444014|YF476
313932|NCT01444014|netazepide
313933|NCT01444014|hypergastrinaemia
313934|NCT01444014|gastric carcinoids
313935|NCT01444001|Pneumococcal Infections
313936|NCT01444001|Pneumococcal Vaccines
313937|NCT01444001|pneumococcal protein
313938|NCT01443988|Open angle glaucoma
313939|NCT01443988|POAG
313940|NCT01443988|Ocular hypertension
313941|NCT01443988|Pseudoexfoliative glaucoma
313942|NCT01443988|Naïve to treatment
313943|NCT01443975|Total Hip Arthroplasty
313944|NCT01443975|Osteoarthritis
313945|NCT01443962|laparoscopic cholecystectomy
313946|NCT01443962|PEEP
313947|NCT01443962|rSO2
313948|NCT01443949|fMRI
313949|NCT01443949|Reward
313950|NCT01443949|Adolescents
313951|NCT01443949|Impulse Control
313952|NCT01443949|Cabergoline
313953|NCT01443936|Influenza Vaccine
313954|NCT01443936|H5N1 Influenza
313955|NCT01443936|Normal Volunteer
313956|NCT01443936|Adenovirus
313957|NCT01443936|Live Virus Vaccine
313958|NCT01443936|Healthy Volunteer
313959|NCT01443936|HV
313960|NCT01443923|Hepatitis
313961|NCT01443923|Immunological Response
313962|NCT01443923|Virological Response
313963|NCT01443923|Resistance Mutations
313964|NCT01443923|Viral Kinetics
313965|NCT01443923|Hepatitis C
313966|NCT01443923|HCV
313967|NCT01443910|Body Weight
313968|NCT01443910|Immersive Virtual Enviroment Technology
313969|NCT01443897|Vitamin D
313970|NCT01443871|Volunteer
313971|NCT01443858|Smoking Cessation
313972|NCT01443858|Cigarette Smoking
313973|NCT01443858|Meclizine
313974|NCT01443858|Nicotine Patch
313975|NCT01443845|COPD
313976|NCT01443845|Exacerbations
313977|NCT01443845|Roflumilast
313978|NCT01443845|Daliresp
313979|NCT01443832|ferrous sulfate
313980|NCT01443832|iron absorption
313981|NCT01443832|Beninese women
313982|NCT01443832|fonio
313983|NCT01443819|Radiculopathy
313984|NCT01443819|Transforaminal
313985|NCT01443819|Disc Protrusion
313986|NCT01443806|oseltamivir metabolism
313987|NCT01443806|Carboxylesterase 1
313988|NCT01443780|Selenium
313989|NCT01443780|Q10
313990|NCT01443780|dietary supplement
313991|NCT01443780|elderly population
313992|NCT01443780|intervention
313993|NCT01443780|All-cause mortality
313994|NCT01443780|cardiac function
313995|NCT01443767|Cardiac Output
313996|NCT01443767|esCCO
313997|NCT01443767|Pulse Wave Transit Time
313998|NCT01443767|PiCCO
313999|NCT01443767|Pulse Contour Analysis
314000|NCT01443767|Non-invasive Monitoring
314001|NCT01443767|Partial Liver Resection
314002|NCT01443741|FIT Therapy
314003|NCT01443741|Diabetes mellitus
314004|NCT01443741|Insulin pump
314005|NCT01443741|Pediatric
314006|NCT01443728|sickle cell disease
314007|NCT01443728|acute chest syndrome
314008|NCT01443728|respiratory complications
314009|NCT01443728|vitamin D
314010|NCT01443715|MDD
314011|NCT01443715|Dysthymia
314012|NCT01443715|Depressive Disorder Not Otherwise Specified (DDNOS)
314013|NCT01443702|Kidney Calculi
314014|NCT01443702|Iranian traditional medicine
314015|NCT01443702|Lapis judaicus
314016|NCT01443689|Extensive Burn
314017|NCT01443689|Human Cord Blood Mononuclear Cells
314018|NCT01443689|Human Umbilical Cord Mesenchymal Stem Cells
314019|NCT01443637|Coronary Artery Disease
314020|NCT01443637|CAD
314021|NCT01443637|Atherosclerosis
314022|NCT01443637|Myocardial Infarction
314023|NCT01443637|MI
314024|NCT01443637|CONFIRM
314025|NCT01443637|Coronary Computed Tomographic Angiography
314026|NCT01443637|CCTA
314027|NCT01443624|iron
314028|NCT01443624|critical illness
314029|NCT01443624|oxidative stress
314030|NCT01443611|Infants
314031|NCT01443598|Pulmonary arterial hypertension,
314032|NCT01443598|Interstitial lung disease at HRCT
314033|NCT01443585|Progressive Addition Lens
314034|NCT01443585|Multifocal
314035|NCT01443585|Presbyopia
314036|NCT01443572|Kasai operation under general anesthesia
314037|NCT01443559|Xenogenic
314038|NCT01443546|oocyte donor
314039|NCT01443546|oocyte recipient
314040|NCT01443546|ovulation trigger
314041|NCT01443533|Contraception
314042|NCT01443533|Contraception behavior
314043|NCT01443533|Postnatal care
314044|NCT01443533|Health education
314045|NCT01443533|Randomized controlled trial
314046|NCT01443520|Pharmacokinetics
314047|NCT01443520|Pharmacodynamics
314048|NCT01443507|aerobic capacity
314049|NCT01443507|maximal oxygen uptake
314050|NCT01443507|aerobic endurance
314051|NCT01443507|work economy
314052|NCT01443507|lactate threshold
314053|NCT01443507|endurance training
314054|NCT01443507|exercise intensity
314055|NCT01443494|septic shock
314056|NCT01443494|microcirculation
314057|NCT01443494|norepinephrine
314058|NCT01443494|fluid
314059|NCT01443481|solid tumors
314060|NCT01443481|hepatic impairment
314061|NCT01443481|Child-Pugh classification
314062|NCT01443481|pharmacokinetics
314063|NCT01443481|PK
314064|NCT01443481|RECIST 1.1
314065|NCT01443468|Tp53
314066|NCT01443468|Cancer
314067|NCT01443468|Hereditary
314068|NCT01443468|Genetic Testing
314069|NCT01443468|Screening
314070|NCT01443468|Li-Fraumeni Syndrome
314071|NCT01443468|LFS
314072|NCT01443455|menopause
314073|NCT01443455|sedentary
314074|NCT01443455|overweight
314075|NCT01443442|Conjunctivitis
314076|NCT01443442|Allergic
314077|NCT01443442|Bepotastine besilate
314078|NCT01443442|Loteprednol etabonate
314079|NCT01443429|TRK-100STP
314080|NCT01443429|PK
314081|NCT01443429|beraprost sodium
314082|NCT01443429|Japanese males and females
314083|NCT01443429|Subjects with mild/moderate/severe patients
314084|NCT01443429|renal impairment
314085|NCT01443416|pneumococcal conjugate vaccine
314086|NCT01443416|invasive pneumococcal disease
314087|NCT01443416|vaccination
314088|NCT01443416|children
314089|NCT01443403|Opioid Therapy
314090|NCT01443403|Non-Malignant Chronic Pain
314091|NCT01443403|Opioid-Induced Constipation
314092|NCT01443390|Whole genome sequencing
314093|NCT01443390|Advanced Refractory Cancer
314094|NCT01443377|Neorec
314095|NCT01443377|rectal cancer
314096|NCT01443377|KRAS
314097|NCT01443377|Panitumumab
314098|NCT01443377|neoadjuvant
314099|NCT01443377|Radiochemotherapy
314100|NCT01443377|antibody
314101|NCT01443377|locally advanced KRAS wild type rectal cancer
314102|NCT01443364|Certolizumab pegol - Cimzia
314103|NCT01443364|Rheumatoid Arthritis
314104|NCT01443364|Power Doppler Ultrasonography
314105|NCT01443364|Italy
314106|NCT01443364|Moderate-severe Rheumatoid Arthritis
314107|NCT01443351|ITP
314108|NCT01443351|romiplostim
314109|NCT01443351|eltrombopag
314110|NCT01443351|bone marrow fibrosis
314111|NCT01443351|long-term safety
314112|NCT01443338|Triptergium wilfordii
314113|NCT01443338|Acitretin
314114|NCT01443338|psoriasis vulgaris
314115|NCT01443325|Persistent Postherniorrhaphy inguinal Pain
314116|NCT01443312|Beta globin gene
314117|NCT01443312|Alfa globin gene
314118|NCT01443312|xmn1 polymorphism
314119|NCT01443273|Newborns
314120|NCT01443260|oncolytic virus
314121|NCT01443260|oncolytic
314122|NCT01443260|GL-ONC1
314123|NCT01443260|Vaccinia
314124|NCT01443260|Vaccinia virus
314125|NCT01443260|Genelux
314126|NCT01443260|Genelux GmbH
314127|NCT01443260|peritoneal
314128|NCT01443260|peritoneal carcinomatosis
314129|NCT01443260|cancer
314130|NCT01443260|abdominal cancer
314131|NCT01443260|imaging
314132|NCT01443234|Depression
314133|NCT01443234|Cognitive Bias
314134|NCT01443234|Internet
314135|NCT01443221|mitiglinide
314136|NCT01443221|metformin
314137|NCT01443221|Pharmacokinetics
314138|NCT01443221|Safety
314139|NCT01443208|pharmacokinetics
314140|NCT01443208|safety
314141|NCT01443208|desvenlafaxine
314142|NCT01443208|Korean healthy subjects
314143|NCT01443169|Pharmacokinetic
314144|NCT01443169|relative oral bioavailability
314145|NCT01443169|pregabalin
314146|NCT01443156|Diet
314147|NCT01443156|Sleep deficiency
314148|NCT01443156|Cancer
314149|NCT01443156|Obesity
314150|NCT01443156|Diabetes
314151|NCT01443156|Shift work
314152|NCT01443156|Work schedule
314153|NCT01443156|Cardiovascular disease
314154|NCT01443156|Body composition
314155|NCT01443156|Body mass index
314156|NCT01443156|Body fat percentage
314157|NCT01443143|Diabetes
314158|NCT01443143|Obesity
314159|NCT01443143|Glycemic
314160|NCT01443143|Portion-control
314161|NCT01443143|Commercial diet
314162|NCT01443130|malaria,Malawi,pregnancy
314163|NCT01443104|coronary artery disease
314164|NCT01443104|drug-eluting stents
314165|NCT01443104|polymers
314166|NCT01443091|very low birth weight infants
314167|NCT01443091|VLBW infants
314168|NCT01443091|colostrum
314169|NCT01443078|Carboplatin
314170|NCT01443078|Cisplatin
314171|NCT01443078|Pemetrexed (Altima)
314172|NCT01443078|Taxotere (Docetaxel)
314173|NCT01443078|Vinorelbine Tartrate (Navelbine)
314174|NCT01443078|Stage IB-III
314175|NCT01443078|non squamous
314176|NCT01443078|non-small cell lung cancer
314177|NCT01443078|11-106
314178|NCT01443065|Adenocarcinoma
314179|NCT01443065|Locally advanced (non operable) or metastatic
314180|NCT01443065|First line treatment
314181|NCT01443052|Gait stability
314182|NCT01443052|Spatiotemporal parameters
314183|NCT01443052|Walking
314184|NCT01443052|Elderly people
314185|NCT01443052|Stroke
314186|NCT01443052|Fallers
314187|NCT01443039|drug metabolizing enzymes and drug transporter
314188|NCT01443039|Roux-en Y-Gastric Bypass
314189|NCT01443039|Obesity
314190|NCT01443039|Drug Availability
314191|NCT01443039|BMI over 35kg/m² and comorbidities or >40kg/m²
314192|NCT01443026|Intraepithelial Prostatic Neoplasia
314193|NCT01443026|Prostatic neoplasms
314194|NCT01443026|Male urogenital disease
314195|NCT01443026|Prostate
314196|NCT01443013|Tolerance
314197|NCT01443013|Renal Transplantation
314198|NCT01443013|Chronic allograft nephropathy
314199|NCT01443000|Observational study
314200|NCT01443000|IOIS
314201|NCT01443000|Orbital Pseudotumor
314202|NCT01443000|Outcome
314203|NCT01443000|Treatment
314204|NCT01442987|Irbesartan
314205|NCT01442987|Atorvastatin
314206|NCT01442987|Hypertension
314207|NCT01442987|Hyperlipidemia
314208|NCT01442974|nab-paclitaxel
314209|NCT01442974|neoadjuvant treatment
314210|NCT01442974|SPARC
314211|NCT01442974|Pancreatic Cancer
314212|NCT01442961|pain, postoperative
314213|NCT01442961|hysterectomy, vaginal
314214|NCT01442961|surgery, gynecological
314215|NCT01442948|-CD16+ monocytes
314216|NCT01442935|Adenocarcinoma
314217|NCT01442935|Non-resectable hepatic metastases
314218|NCT01442935|First-line treatment
314219|NCT01442922|L3-L4
314220|NCT01442922|L4-L5
314221|NCT01442922|L5-S1
314222|NCT01442922|Human Meniscus Allograft
314223|NCT01442922|Nucleus pulposus
314224|NCT01442922|Minimally invasive surgery
314225|NCT01442922|Degeneration of L3-L4 Intervertebral Disc
314226|NCT01442922|Degeneration of L4-L5 Intervertebral Disc
314227|NCT01442922|Degeneration of L5-S1 Intervertebral Disc
314228|NCT01442909|lung cancer
314229|NCT01442909|docetaxel
314230|NCT01442909|pemetrexed
314231|NCT01442883|Treatment Resistant
314232|NCT01442857|Magnetic Resonance Imaging
314233|NCT01442857|Nerve Net
314234|NCT01442857|Brachial Plexus
314235|NCT01442857|Nerve block
314236|NCT01442844|Mohs
314237|NCT01442844|Scalp
314238|NCT01442831|metabolic profile of TR-700 in plasma urine
314239|NCT01442818|vaginal reconstructive surgery
314240|NCT01442805|Cognitive Behavior Therapy
314241|NCT01442805|Virtual Reality Exposure Therapy
314242|NCT01442805|Psychophysiological Measures
314243|NCT01442805|Driving Phobia
314244|NCT01442805|Flying Phobia
314245|NCT01442792|Angioplasty, Balloon, Coronary
314246|NCT01442779|Idiopathic Pulmonary Fibrosis
314247|NCT01442779|Interferon alpha
314248|NCT01442766|cholinesterase inhibitor
314249|NCT01442766|donepezil
314250|NCT01442766|motor
314251|NCT01442766|stroke
314252|NCT01442753|Spanish speaking
314253|NCT01442740|Functional Endoscopic Sinus Surgery
314254|NCT01442740|Reverse Trendelenburg Position
314255|NCT01442727|arsenical melanosis
314256|NCT01442727|arsenical melanoses
314257|NCT01442727|arsenical keratosis
314258|NCT01442727|arsenical keratoses
314259|NCT01442727|arsenical cancer
314260|NCT01442727|arsenic cancers
314261|NCT01442727|arsenic
314262|NCT01442727|arsenicosis
314263|NCT01442727|arsenic exposure
314264|NCT01442727|arsenic toxicity
314265|NCT01442727|arsenic poisoning
314266|NCT01442727|drinking water
314267|NCT01442727|selenium
314268|NCT01442727|selenite
314269|NCT01442727|sodium selenite
314270|NCT01442675|Meningitis
314271|NCT01442675|Meningococcal Infection
314272|NCT01442675|Menactra®
314273|NCT01442662|Metastatic or relapsed uterine or soft tissue leiomyosarcoma
314274|NCT01442649|Adenocarcinoma
314275|NCT01442649|Metastatic
314276|NCT01442649|Second-line treatment
314277|NCT01442649|Progressive disease after first-line treatment with bevacizumab
314278|NCT01442649|Non-mutated (wild-type) KRAS.
314279|NCT01442623|Vestibular Rehabilitation
314280|NCT01442623|Balance
314281|NCT01442623|Virtual Reality
314282|NCT01442623|Gait
314283|NCT01442623|Dizziness
314284|NCT01442610|Rasagiline
314285|NCT01442610|Sleep disorder
314286|NCT01442610|Parkinson's disease
314287|NCT01442610|Sleep Disturbances in patients with parkinsons's disease
314288|NCT01442597|cognitive behavior therapy
314289|NCT01442597|computer assisted instruction
314290|NCT01442597|drug abuse therapy
314291|NCT01442597|educational resource design and development
314292|NCT01442584|ovary
314293|NCT01442584|cortex
314294|NCT01442584|transplantation
314295|NCT01442571|Adult Men and Women, who underwent arthroscopy of the knee with cartilage injury of ICRS grade 2 or higher
314296|NCT01442558|relief
314297|NCT01442558|Intra-operative
314298|NCT01442545|Rheumatoid Arthritis
314299|NCT01442545|JNJ-39758979
314300|NCT01442545|Methotrexate
314301|NCT01442532|Healthy male volunteer
314302|NCT01442532|JNJ-38518168
314303|NCT01442532|Midazolam
314304|NCT01442519|non-muscle invasive urothelial bladder cancer
314305|NCT01442519|intravesical therapy
314306|NCT01442519|BCG
314307|NCT01442519|mitomycin
314308|NCT01442519|electromotive drug administration
314309|NCT01442519|Bladder Cancer Stage 0, Without Cancer in Situ
314310|NCT01442506|acetic acid
314311|NCT01442506|virtual chromoendosopy
314312|NCT01442493|Methadone Treatment
314313|NCT01442493|Opiate dependence
314314|NCT01442493|Services research
314315|NCT01442480|air pollution
314316|NCT01442480|fatty acid supplementation
314317|NCT01442467|mitral annular calcification
314318|NCT01442467|MAC
314319|NCT01442467|left atrial pressure
314320|NCT01442467|LAP
314321|NCT01442467|left ventricular end diastolic pressure
314322|NCT01442467|LVEDP
314323|NCT01442467|Echocardiogram
314324|NCT01442454|chronic pancreatitis
314325|NCT01442441|chronic pancreatitis
314326|NCT01442428|TB
314327|NCT01442428|AIDS
314328|NCT01442428|HIV
314329|NCT01442428|IRIS
314330|NCT01442428|immune reconstitution inflammatory syndrome
314331|NCT01442428|anti-inflammatory
314332|NCT01442428|treatment
314333|NCT01442376|Prevention of Chemotherapy-Induced Nausea and Vomiting
314334|NCT01442376|Palonosetron
314335|NCT01442376|Ondansetron
314336|NCT01442376|Pediatric
314337|NCT01442363|Crohn's disease
314338|NCT01442363|perianal
314339|NCT01442363|inflammatory bowel disease
314340|NCT01442363|fistula
314341|NCT01442350|Fabry disease
314342|NCT01442350|annexin 5
314343|NCT01442350|miosin
314344|NCT01442350|sarcoma
314345|NCT01442350|alfa-galactosidase
314346|NCT01442350|fibrosis
314347|NCT01442350|apoptosis
314348|NCT01442350|biomarkers
314349|NCT01442350|NT-proBNP
314350|NCT01442337|de novo kidney transplant
314351|NCT01442337|kidney transplant
314352|NCT01442337|ASP8597
314353|NCT01442337|diannexin
314354|NCT01442337|ischemia-reperfusion injury
314355|NCT01442324|Laparotomic surgery
314356|NCT01442324|Laparoscopic surgery
314357|NCT01442324|Percutaneos tumour ablation
314358|NCT01442324|Irreversible electroporation (IRE)
314359|NCT01442311|Hepatitis C Virus
314360|NCT01442311|Chronic Hepatitis C
314361|NCT01442311|Methadone
314362|NCT01442311|Injection Drug User
314363|NCT01442311|Adherence
314364|NCT01442311|Directly Observed Treatment
314365|NCT01442298|bloodless field
314366|NCT01442298|cuff pressure
314367|NCT01442298|limb occlusion pressure
314368|NCT01442259|Renal impairment,
314369|NCT01442259|pharmacokinetics,
314370|NCT01442259|safety
314371|NCT01442246|Benefit of
314372|NCT01442246|adjuvant
314373|NCT01442246|treatment
314374|NCT01442246|prostatectomy
314375|NCT01442233|multiple sclerosis
314376|NCT01442233|plasma exchange
314377|NCT01442207|Premature Birth
314378|NCT01442207|Placenta Previa
314379|NCT01442194|Multiple sclerosis
314380|NCT01442194|fingolimod
314381|NCT01442194|observational study
314382|NCT01442168|Uncomplicated Falciparum Malaria
314383|NCT01442168|Plasmodium falciparum
314384|NCT01442168|Antimalarial treatment
314385|NCT01442168|Sevuparin/DF02
314386|NCT01442168|Adjuvant therapy
314387|NCT01442168|Malanil
314388|NCT01442168|Peripheral blood parasitemia
314389|NCT01442168|Rosette formation
314390|NCT01442168|Maximum tolerated dose
314391|NCT01442155|Colorectal cancer
314392|NCT01442155|Adjuvant setting
314393|NCT01442155|Capecitabine
314394|NCT01442155|Oxaliplatin
314395|NCT01442142|obesity
314396|NCT01442142|pediatric
314397|NCT01442142|childhood
314398|NCT01442142|overweight
314399|NCT01442129|Heart Failure
314400|NCT01442129|Left Ventricular Assist Device
314401|NCT01442129|Heart Transplantation
314402|NCT01442129|Cardiomyopathy
314403|NCT01442129|Destination Therapy
314404|NCT01442129|Cell Therapy
314405|NCT01442064|CNV
314406|NCT01442064|Lucentis
314407|NCT01442064|AMD
314408|NCT01442064|Age-related macular degeneration
314409|NCT01442064|RVO
314410|NCT01442064|Macular edema secondary to retinal vein occlusion
314411|NCT01442051|Acute Normovolemic Hemodilution
314412|NCT01442051|Cytoreductive Surgery
314413|NCT01442051|laparotomy
314414|NCT01442051|11-149
314415|NCT01442051|advanced primary epithelial ovarian cancer
314416|NCT01442025|Crohn's Disease
314417|NCT01442025|IFX trough level
314418|NCT01442012|PONV
314419|NCT01442012|ACUPUNCTURE
314420|NCT01441999|Rigid rods
314421|NCT01441999|less rigid rods
314422|NCT01441999|prevent kyphosis
314423|NCT01441999|long constructs
314424|NCT01441986|dextromethorphan
314425|NCT01441986|amantadine
314426|NCT01441986|blood glucose lowering effect
314427|NCT01441986|oral glucose tolerance test
314428|NCT01441960|Succinylcholine
314429|NCT01441960|Rocuronium
314430|NCT01441960|ECT
314431|NCT01441947|ER+
314432|NCT01441947|PR+
314433|NCT01441947|HER2-
314434|NCT01441947|metastatic
314435|NCT01441921|pistachio intake
314436|NCT01441921|insulin resistance
314437|NCT01441921|type 2 diabetes mellitus
314438|NCT01441908|Cardiovascular
314439|NCT01441908|Multi-analyte
314440|NCT01441908|Statin
314441|NCT01441908|Dyslipidemia
314442|NCT01441895|Refractive Cataract Extraction
314443|NCT01441895|Femtosecond laser
314444|NCT01441895|arcuate relaxing incisions
314445|NCT01441895|Dry Eye post cataract refraction
314446|NCT01441869|Phase 1, Healthy male volunteers, pharmacokinetics, saxagliptin/ metformin , Diabex
314447|NCT01441856|Open
314448|NCT01441856|Laparoscopic
314449|NCT01441856|Hemihepatectomy
314450|NCT01441856|Enhanced Recovery After Surgery
314451|NCT01441856|Functional recovery
314452|NCT01441843|quality of life
314453|NCT01441843|lorazepam
314454|NCT01441843|anxiety
314455|NCT01441843|premedication
314456|NCT01441843|surgery
314457|NCT01441843|Adult patients
314458|NCT01441843|Ambulatory Surgical Procedures
314459|NCT01441843|Postoperative Period
314460|NCT01441830|shoulder
314461|NCT01441830|subacromial
314462|NCT01441830|impingement
314463|NCT01441830|tendinopathy
314464|NCT01441830|rESWT
314465|NCT01441830|shock wave
314466|NCT01441830|ESWT
314467|NCT01441830|RSWT
314468|NCT01441791|PEEP
314469|NCT01441791|Positive end-expiratory pressure
314470|NCT01441791|Recruitment maneuver
314471|NCT01441791|Open lung approach
314472|NCT01441791|Post-operative complications
314473|NCT01441791|Open abdominal surgery
314474|NCT01441778|nasal irrigation
314475|NCT01441778|allergic rhinitis
314476|NCT01441778|children
314477|NCT01441765|Kidney
314478|NCT01441765|Metastatic
314479|NCT01441765|Stage IV
314480|NCT01441726|Advanced dementia
314481|NCT01441726|Quality
314482|NCT01441726|Terminal care
314483|NCT01441713|Hormone treatment
314484|NCT01441713|castration
314485|NCT01441713|Orchiectomy
314486|NCT01441713|treatment frequency
314487|NCT01441713|treatment satisfaction
314488|NCT01441713|side effects
314489|NCT01441700|Prone emergence
314490|NCT01441700|supine emergence
314491|NCT01441700|coughing
314492|NCT01441700|haemodynamic stimulation
314493|NCT01441700|lumbar surgery
314494|NCT01441687|Health status unknown
314495|NCT01441687|healthy,no evidence of disease
314496|NCT01441674|Occupational Therapy
314497|NCT01441661|Sunitinib
314498|NCT01441661|kidney diseases
314499|NCT01441661|urogenital neoplasms
314500|NCT01441661|kidney cancer
314501|NCT01441648|conjunctival injection
314502|NCT01441648|conjunctival papillary hypertrophy
314503|NCT01441648|pannus formation
314504|NCT01441648|corneal epitheliopathy
314505|NCT01441648|Schirmer test
314506|NCT01441648|Impression cytology
314507|NCT01441648|confocal microscopy
314508|NCT01441648|Scanning electronmicroscopy (SEM)
314509|NCT01441648|bacterial adhesion determination
314510|NCT01441635|Elagolix
314511|NCT01441635|Uterine Fibroids
314512|NCT01441635|Elagolix sodium
314513|NCT01441635|Leiomyomata
314514|NCT01441635|Heavy Uterine Bleeding
314515|NCT01441635|Menorrhagia
314516|NCT01441635|ABT-620
314517|NCT01441622|Continuous Positive Airway Pressure (CPAP)
314518|NCT01441622|AL539
314519|NCT01441622|Home-monitoring
314520|NCT01441609|Th9 cells
314521|NCT01441609|IL9
314522|NCT01441609|non/poor responsiveness to hepatitis B
314523|NCT01441609|collect blood samples after vaccination
314524|NCT01441583|pacemaker, CRT-P, auto threshold
314525|NCT01441570|kidney
314526|NCT01441570|transplant
314527|NCT01441570|hypertension
314528|NCT01441570|nebivolol
314529|NCT01441570|metoprolol
314530|NCT01441570|bystolic
314531|NCT01441570|toprol
314532|NCT01441557|mechanical ventilation
314533|NCT01441544|active video games
314534|NCT01441544|Energy expenditure
314535|NCT01441531|narcotic use
314536|NCT01441531|Other Acute Pain
314537|NCT01441492|Distal pancreatectomy
314538|NCT01441492|Pancreas resection
314539|NCT01441466|bronchiolitis
314540|NCT01441466|RSV
314541|NCT01441453|Hepatocellular carcinoma
314542|NCT01441453|Cirrhosis
314543|NCT01441453|Liver resection
314544|NCT01441453|FibroScan
314545|NCT01441440|venlafaxine ER
314546|NCT01441440|Major depressive disorder
314547|NCT01441440|Japan
314548|NCT01441440|placebo-controlled
314549|NCT01441427|feeding intolerance
314550|NCT01441427|recombinant growth factors
314551|NCT01441427|G-CSF
314552|NCT01441427|EPO
314553|NCT01441427|necrotizing enterocolitis
314554|NCT01441414|CVX-060
314555|NCT01441414|PF-04856884
314556|NCT01441414|AG-013736
314557|NCT01441414|axitinib
314558|NCT01441414|mRCC
314559|NCT01441414|metastatic renal cell cancer
314560|NCT01441414|second line
314561|NCT01441414|anti-angiogenic
314562|NCT01441414|Ang-2
314563|NCT01441401|Gabapentin
314564|NCT01441401|Epilepsies
314565|NCT01441401|safety
314566|NCT01441388|Phase 1b
314567|NCT01441388|crizotinib
314568|NCT01441388|sunitinib
314569|NCT01441388|axitinib
314570|NCT01441388|sorafenib
314571|NCT01441388|bevacizumab
314572|NCT01441388|cMET inhibitor
314573|NCT01441388|VEGF inhibitor
314574|NCT01441388|crizotinib combination
314575|NCT01441375|Sickle cell anemia
314576|NCT01441362|during double-lumen
314577|NCT01441362|tube intubation
314578|NCT01441349|Simvastatin
314579|NCT01441349|SCLC
314580|NCT01441349|Extensive Disease
314581|NCT01441323|Obesity
314582|NCT01441323|Type 2 Diabetes
314583|NCT01441323|Cardiovascular Risk
314584|NCT01441323|Cancer
314585|NCT01441323|African American
314586|NCT01441323|Adolescents
314587|NCT01441323|Strength Training
314588|NCT01441323|Nutrition
314589|NCT01441310|Gastric cancer
314590|NCT01441310|Sentinel node navigation surgery
314591|NCT01441310|Dual method
314592|NCT01441310|Recurrence
314593|NCT01441297|recurrent small cell lung cancer
314594|NCT01441284|pramipexole
314595|NCT01441284|essential tremor
314596|NCT01441284|cross-over
314597|NCT01441245|acute heart failure
314598|NCT01441245|diuretics
314599|NCT01441245|BNP
314600|NCT01441245|Renal function
314601|NCT01441245|acute decompensated Heart Failure,
314602|NCT01441245|volume overload
314603|NCT01441206|rifampin
314604|NCT01441206|infants
314605|NCT01441193|HIV
314606|NCT01441193|preventive vaccine
314607|NCT01441193|Tat
314608|NCT01441193|Env
314609|NCT01441180|Direct Acting Antiviral
314610|NCT01441180|Liver
314611|NCT01441180|Hepatitis C
314612|NCT01441180|HCV
314613|NCT01441167|Healthy Subjects
314614|NCT01441167|Immunogenicity
314615|NCT01441167|Vaccine-Mediated Protection
314616|NCT01441167|Sporozoites
314617|NCT01441167|Parasitemia
314618|NCT01441167|Healthy Volunteer
314619|NCT01441167|HV
314620|NCT01441154|Hypothyroidism
314621|NCT01441154|Thyroid Cancer
314622|NCT01441154|Triiodothyronine (T3)
314623|NCT01441154|Energy Expenditure
314624|NCT01441154|Thyroid Hormone
314625|NCT01441141|GCH1
314626|NCT01441141|Pain Sensitivity
314627|NCT01441141|Quantitative Sensory Testing (QST)
314628|NCT01441141|Genetic Variation
314629|NCT01441141|Sickle Cell Anemia
314630|NCT01441128|Lung Neoplasms
314631|NCT01441128|Epithelial-Mesenchymal Transition Factor (c-Met)
314632|NCT01441128|Tyrosine Kinase Inhibitor
314633|NCT01441128|Hepatocyte Growth Factor Receptor
314634|NCT01441128|Epidermal Growth Factor Receptor
314635|NCT01441128|Non Small Cell Lung Cancer
314636|NCT01441128|NSCLC
314637|NCT01441115|Metastasis
314638|NCT01441115|Cancer
314639|NCT01441115|Radiation Therapy
314640|NCT01441115|Locally Advanced
314641|NCT01441115|Palliation
314642|NCT01441115|Metastatic Cancer
314643|NCT01441102|Diabetic Macular Edema
314644|NCT01441102|Microglia
314645|NCT01441102|Dextromethorphan
314646|NCT01441089|Pharmacogenetics
314647|NCT01441089|Pharmacokinetics
314648|NCT01441089|Pharmacodynamics
314649|NCT01441089|Clinical Outcome
314650|NCT01441089|Drug Metabolism and Transport
314651|NCT01441089|Cancer
314652|NCT01441076|Behcet's Disease
314653|NCT01441076|Aphthous Ulcer
314654|NCT01441076|Uveitis
314655|NCT01441076|IL-1
314656|NCT01441076|Autoinflammation
314657|NCT01441076|BD
314658|NCT01441063|Kaposi Sarcoma Herpesvirus
314659|NCT01441063|Human Immunodeficiency Virus
314660|NCT01441063|Tocilizumab
314661|NCT01441063|Multicentric Castleman Disease
314662|NCT01441063|Interleukin-6
314663|NCT01441063|Castleman Disease
314664|NCT01441037|Aplastic Anemia
314665|NCT01441037|Androgen
314666|NCT01441037|Telomeres
314667|NCT01441024|Immunocompromised
314668|NCT01441024|Respiratory Tract Disease
314669|NCT01441024|Viral Shedding
314670|NCT01441024|Fever
314671|NCT01441024|Pharmacokinetics
314672|NCT01441024|Parainfluenza Infection
314673|NCT01441024|Flu
314674|NCT01441011|weight loss
314675|NCT01441011|breast cancer
314676|NCT01441011|obesity
314677|NCT01441011|overweight
314678|NCT01441011|rural women
314679|NCT01441011|community based
314680|NCT01441011|Secondary Prevention
314681|NCT01440985|Tooth Staining
314682|NCT01440972|knee osteoarthritis
314683|NCT01440972|symptomatic knee osteoarthritis
314684|NCT01440972|isotonic leg-press strength
314685|NCT01440972|isokinetic knee extensor strength
314686|NCT01440972|quadriceps volume
314687|NCT01440959|This is a single-center
314688|NCT01440959|prospective
314689|NCT01440959|single-arm
314690|NCT01440959|open-label phase II study
314691|NCT01440933|sugammadex
314692|NCT01440933|rocuronium
314693|NCT01440933|magnesiumsulphate
314694|NCT01440933|neuromuscular monitoring
314695|NCT01440920|Acute myeloid leukemia
314696|NCT01440920|WT1
314697|NCT01440907|Health Information Technology
314698|NCT01440907|Health Records, Personal
314699|NCT01440907|Hospital Information Systems
314700|NCT01440907|Patient Access to Records
314701|NCT01440907|Medical Records
314702|NCT01440907|Medical Record Systems, Computerized
314703|NCT01440894|weight
314704|NCT01440894|body fat
314705|NCT01440894|total body water
314706|NCT01440894|bone mass
314707|NCT01440894|muscle mass
314708|NCT01440881|renal failure
314709|NCT01440881|cardiopulmonary bypass
314710|NCT01440868|Respiratory Distress Syndrome, Newborn
314711|NCT01440868|Delivery Rooms
314712|NCT01440868|Resuscitation
314713|NCT01440868|Premature Birth
314714|NCT01440868|Infant, Newborn
314715|NCT01440868|Respiration, Artificial
314716|NCT01440855|Survivorship
314717|NCT01440855|cancer control
314718|NCT01440855|psychosocial interventions
314719|NCT01440855|Facing Forward
314720|NCT01440842|Stress hyperglycaemia
314721|NCT01440829|Transjugular Intrahepatic Portosystemic Shunt
314722|NCT01440829|TIPS
314723|NCT01440829|Liver Cirrhosis
314724|NCT01440829|LOLA
314725|NCT01440829|L-ornithine-L-aspartate
314726|NCT01440829|Refractory Ascites
314727|NCT01440803|osteoporosis
314728|NCT01440803|premenopausal
314729|NCT01440803|forteo
314730|NCT01440803|idiopathic
314731|NCT01440803|Idiopathic Osteoporosis in Premenopausal Women
314732|NCT01440777|Insomnia
314733|NCT01440777|Sleep
314734|NCT01440777|Stress
314735|NCT01440777|Online program
314736|NCT01440777|Web-based program
314737|NCT01440777|Cognitive Behavioral Therapy for Insomnia (CBT-i)
314738|NCT01440764|dyspnea
314739|NCT01440764|Laboratory model of dyspnea in healthy subjects
314740|NCT01440751|ologen collagen matrix
314741|NCT01440751|mitomycin-C
314742|NCT01440751|trabeculectomy
314743|NCT01440751|glaucoma
314744|NCT01440751|filtering surgery
314745|NCT01440738|general population
314746|NCT01440725|muscle
314747|NCT01440725|injuries
314748|NCT01440725|platelet-rich plasma
314749|NCT01440725|autologous
314750|NCT01440725|haematoma
314751|NCT01440712|Gastrografin
314752|NCT01440712|Postoperative ileus
314753|NCT01440712|Colo-rectal surgery
314754|NCT01440712|Effects on morbidity and mortality of postoperative ileus
314755|NCT01440699|Crohn's fistula
314756|NCT01440686|Pharmacokinetics
314757|NCT01440686|Pharmacodynamics
314758|NCT01440686|Safety
314759|NCT01440686|Male
314760|NCT01440673|Postoperative Nausea and Vomiting
314761|NCT01440647|Respiration, Artificial
314762|NCT01440647|Infant, Premature
314763|NCT01440647|Bronchopulmonary Dysplasia
314764|NCT01440647|Continuous Positive Airway Pressure
314765|NCT01440647|Non-Invasive Positive-Pressure Ventilation
314766|NCT01440647|Intermittent Positive-Pressure Ventilation
314767|NCT01440647|High-Frequency Ventilation
314768|NCT01440634|Peripheral arterial disease
314769|NCT01440634|Community Medicine
314770|NCT01440634|Exercise Test
314771|NCT01440634|Exercise Therapy
314772|NCT01440621|Cancer related fatigue
314773|NCT01440621|Quality of life
314774|NCT01440621|Modafinil
314775|NCT01440621|Radiation therapy
314776|NCT01440621|Radiotherapy
314777|NCT01440582|Myeloma
314778|NCT01440582|Multiple Myeloma
314779|NCT01440582|MM
314780|NCT01440582|Newly diagnosed
314781|NCT01440582|Transplant eligible
314782|NCT01440582|Panobinostat
314783|NCT01440582|LBH589B
314784|NCT01440582|Bortezomib
314785|NCT01440582|Velcade
314786|NCT01440582|LDP-341
314787|NCT01440582|MLN341
314788|NCT01440582|PS-341
314789|NCT01440582|Lenalidomide
314790|NCT01440582|CC-5013
314791|NCT01440582|Revlimid
314792|NCT01440582|Dexamethasone
314793|NCT01440582|Decadron
314794|NCT01440582|Symptom questionnaire
314795|NCT01440582|Survey
314796|NCT01440569|HIV-1
314797|NCT01440569|HIV
314798|NCT01440569|Treatment Naïve
314799|NCT01440569|Treatment Experienced
314800|NCT01440556|Allogeneic bone marrow transplantation
314801|NCT01440556|Multiple myeloma
314802|NCT01440543|colonoscopy
314803|NCT01440543|water immersion
314804|NCT01440543|CO2 insufflation
314805|NCT01440543|patients referred for diagnostic outpatient colonoscopy
314806|NCT01440543|(screening, surveillance, symptoms)
314807|NCT01440543|patient discomfort associated with diagnostic colonoscopy
314808|NCT01440530|Diabetes Internet Education
314809|NCT01440530|Diabetes Education
314810|NCT01440530|Diabetes Self-Care
314811|NCT01440530|Diabetes Self-Management
314812|NCT01440530|Diabetes Behavior Intervention
314813|NCT01440517|CE-MRI - Contrast-enhanced magnetic resonance imaging
314814|NCT01440517|DM - Diabetes mellitus
314815|NCT01440517|EKG - Echocardiography
314816|NCT01440517|HFPEF - Heart failure preserved left ventricular ejection fraction
314817|NCT01440517|LVEF - Left Ventricular Ejection Fraction
314818|NCT01440504|Cancer
314819|NCT01440504|Ovarian
314820|NCT01440504|chemotherapy
314821|NCT01440504|BH3-mimetic
314822|NCT01440504|platin
314823|NCT01440504|ex-vivo
314824|NCT01440491|low back pain
314825|NCT01440491|exercise
314826|NCT01440491|booklet
314827|NCT01440465|chemotherapy
314828|NCT01440465|cancer
314829|NCT01440465|nausea
314830|NCT01440465|vomiting
314831|NCT01440452|TM
314832|NCT01440452|MS
314833|NCT01440452|Spinal Cord Injury
314834|NCT01440452|Functional electrical stimulation
314835|NCT01440452|Rehabilitation
314836|NCT01440452|Growth factors
314837|NCT01440452|Cytokines
314838|NCT01440439|insulin glargine
314839|NCT01440439|insulin detemir
314840|NCT01440439|hypoglycaemia
314841|NCT01440439|metabolism
314842|NCT01440439|Exercise
314843|NCT01440426|gingival recession
314844|NCT01440426|root coverage
314845|NCT01440426|periodontal surgery
314846|NCT01440426|collagen matrix
314847|NCT01440426|mucograft
314848|NCT01440426|multiple exposed teeth
314849|NCT01440413|anti-tumor immune response
314850|NCT01440413|neo-adjuvant chemotherapy
314851|NCT01440413|relapse
314852|NCT01440413|long term survival
314853|NCT01440413|histo-pathological response
314854|NCT01440413|tumor cell death
314855|NCT01440413|tumor associated antigens
314856|NCT01440413|Calreticulin
314857|NCT01440413|Localized breast cancer
314858|NCT01440400|Ultrasound
314859|NCT01440400|Spinal anesthesia
314860|NCT01440400|Cesarean section
314861|NCT01440387|Influenza
314862|NCT01440387|Phase III
314863|NCT01440387|Seasonal influenza
314864|NCT01440348|Achilles allograft
314865|NCT01440348|cruciate ligament
314866|NCT01440348|reconstruction
314867|NCT01440335|Fenoterol
314868|NCT01440335|Pharmacodynamics
314869|NCT01440335|Pharmacokinetics
314870|NCT01440335|Safety
314871|NCT01440335|Beta Adrenergic Agonist
314872|NCT01440322|Myopia
314873|NCT01440322|Contact lenses
314874|NCT01440309|biliary cirrhosis
314875|NCT01440283|Neuroblastoma
314876|NCT01440283|Radiation Therapy
314877|NCT01440270|Oral cancer
314878|NCT01440270|Oropharyngeal cancer
314879|NCT01440270|Induction chemotherapy
314880|NCT01440270|Targeted chemotherapy
314881|NCT01440270|Surgery
314882|NCT01440270|Radiotherapy
314883|NCT01440270|Effects of Chemotherapy
314884|NCT01440244|mediastinoscopy
314885|NCT01440244|pleural evaluation
314886|NCT01440244|pleural biopsy
314887|NCT01440244|pleurodesis
314888|NCT01440231|Rheumatology
314889|NCT01440231|Double-Blind
314890|NCT01440231|Placebo-Controlled
314891|NCT01440231|Multidose
314892|NCT01440231|Dose-Response
314893|NCT01440231|Phase II
314894|NCT01440231|Systemic Lupus Erythematosus
314895|NCT01440231|SLE
314896|NCT01440231|Atacicept
314897|NCT01440218|Idiopathic diseases
314898|NCT01440218|family member of the affected individual
314899|NCT01440218|unknown etiology
314900|NCT01440205|Flu Shot
314901|NCT01440192|Sarcoidosis
314902|NCT01440192|Stem cells
314903|NCT01440192|PDA001
314904|NCT01440192|Celgene
314905|NCT01440192|Human Placenta-Derived cells
314906|NCT01440192|Cenplacel-L
314907|NCT01440166|Human healthy volunteers
314908|NCT01440153|Dance
314909|NCT01440153|Injury
314910|NCT01440153|Physical condition
314911|NCT01440153|Exercise
314912|NCT01440114|emergence agitation
314913|NCT01440114|pediatric patient
314914|NCT01440114|fentanyl
314915|NCT01440114|incidence of emergence agitation
314916|NCT01440114|severity of emergence agitation
314917|NCT01440114|adverse outcome from intervention
314918|NCT01440088|TH-302
314919|NCT01440088|TH-CR-406
314920|NCT01440088|SARC021
314921|NCT01440088|Locally Advanced Soft Tissue Sarcoma
314922|NCT01440088|Metastatic Soft Tissue Sarcoma
314923|NCT01440088|Sarcoma
314924|NCT01440088|Doxorubicin
314925|NCT01440088|Evofosfamide
314926|NCT01440075|Kawasaki disease
314927|NCT01440049|patients with MI- on top of treatment add Eplerenone - assess LVEF and BP
314928|NCT01440036|carotid artery
314929|NCT01440036|Atherosclerotic plaque
314930|NCT01440036|paraoxygenase 1 PON1
314931|NCT01440036|Patients undergoing carotid artery endarterectomy CEA for carotid artery stenosis
314932|NCT01440023|tic disorder
314933|NCT01440023|tourette syndrome
314934|NCT01440023|habit reversal
314935|NCT01440023|response inhibition
314936|NCT01440023|cognitive retraining
314937|NCT01440010|IORT
314938|NCT01440010|Boost
314939|NCT01440010|Breast cancer
314940|NCT01440010|Local recurrence
314941|NCT01440010|Toxicity
314942|NCT01440010|LENT SOMA
314943|NCT01440010|TARGIT
314944|NCT01440010|Quality Control Registry
314945|NCT01439997|Nocturnal polyuria
314946|NCT01439984|PE
314947|NCT01439984|IELT
314948|NCT01439984|DCIT
314949|NCT01439971|Phase 1
314950|NCT01439971|Safety
314951|NCT01439971|Pharmacokinetic
314952|NCT01439971|Pharmacodynamic
314953|NCT01439958|Inhalation
314954|NCT01439958|Lung Transplantation
314955|NCT01439958|Cyclosporine
314956|NCT01439945|hot flashes
314957|NCT01439945|cancer survivor
314958|NCT01439945|breast cancer
314959|NCT01439932|plantar fasciitis
314960|NCT01439932|heel pain
314961|NCT01439932|manual treatment
314962|NCT01439932|dorsi flexion
314963|NCT01439906|Degenerative scoliosis
314964|NCT01439906|Pain
314965|NCT01439906|Deformity correction
314966|NCT01439906|Instrumented arthrodesis
314967|NCT01439893|Chronic heart failure
314968|NCT01439893|rhNRG-1
314969|NCT01439893|Cardiac remodeling
314970|NCT01439880|High cholesterol
314971|NCT01439880|Raised cholesterol
314972|NCT01439880|Cholesterol
314973|NCT01439880|Elevated Cholesterol
314974|NCT01439867|Dialysis
314975|NCT01439867|Sensipar
314976|NCT01439867|Mimpara
314977|NCT01439867|Hemodialysis
314978|NCT01439867|Peritoneal Dialysis
314979|NCT01439867|Renal
314980|NCT01439867|Parathyroid hormone
314981|NCT01439867|Pediatric
314982|NCT01439854|Insulin sensitivity
314983|NCT01439854|Mitochondrial function
314984|NCT01439854|Glucose toxicity
314985|NCT01439854|Glucosuria
314986|NCT01439841|HIV
314987|NCT01439841|microbial translocation
314988|NCT01439841|immune activation
314989|NCT01439841|probiotics
314990|NCT01439828|Cannabis
314991|NCT01439828|N-Acetylcystein
314992|NCT01439828|Dependence
314993|NCT01439828|Abuse
314994|NCT01439828|Craving
314995|NCT01439828|Genetic
314996|NCT01439802|Postpartum IUD
314997|NCT01439802|Cesarean Delivery
314998|NCT01439802|6 months postpartum
314999|NCT01439802|satisfaction
315000|NCT01439789|Chronic Heart Failure
315001|NCT01439789|rhNRG-1
315002|NCT01439789|NT-proBNP
315003|NCT01439776|chronic hepatitis C
315004|NCT01439776|SVR
315005|NCT01439776|Vit D
315006|NCT01439776|Peginterferon alfa 2a
315007|NCT01439776|Ribavirin
315008|NCT01439763|Bullies
315009|NCT01439763|Bully victims
315010|NCT01439763|Psychiatric symptoms
315011|NCT01439750|mantle cell lymphoma
315012|NCT01439750|lymphoma
315013|NCT01439737|Asthma
315014|NCT01439737|metabolomics
315015|NCT01439737|exhaled breath condensate
315016|NCT01439724|Oral mucositis
315017|NCT01439724|Low Level Laser Therapy
315018|NCT01439724|Head and neck cancer
315019|NCT01439711|ductal breast carcinoma in situ
315020|NCT01439711|estrogen receptor-positive breast cancer
315021|NCT01439698|Cholangiocarcinoma
315022|NCT01439698|Pancreatic Cancer
315023|NCT01439698|Bile Duct Cancer
315024|NCT01439698|Biliary Stricture
315025|NCT01439698|Bile duct obstruction
315026|NCT01439698|ENDOHPB
315027|NCT01439698|Radio Frequency Ablation
315028|NCT01439698|RFA
315029|NCT01439698|ERCP
315030|NCT01439698|Endoscopic Retrograde Cholangiopancreatography
315031|NCT01439698|Registry
315032|NCT01439698|Multicenter
315033|NCT01439685|Cholangiocarcinoma
315034|NCT01439685|PDT
315035|NCT01439685|Photodynamic Therapy
315036|NCT01439685|Bile Duct
315037|NCT01439685|Bile Duct Obstruction
315038|NCT01439685|Jaundice
315039|NCT01439685|Biliary Stent
315040|NCT01439685|ERCP
315041|NCT01439685|Obstructive Jaundice
315042|NCT01439672|Type 1 Diabetes Mellitus
315043|NCT01439659|Ovarian Cancer
315044|NCT01439659|Epithelial ovarian cancer
315045|NCT01439659|First clinical remission
315046|NCT01439659|Nutritional Supplements
315047|NCT01439659|Juice Plus +
315048|NCT01439659|Juice Plus + Complete
315049|NCT01439659|Dietary counseling
315050|NCT01439646|empirical
315051|NCT01439646|ICU
315052|NCT01439646|high risk patient
315053|NCT01439633|Barrett's Esophagus
315054|NCT01439633|Esophagus
315055|NCT01439633|OCT
315056|NCT01439633|Imaging
315057|NCT01439620|Biliary Stricture
315058|NCT01439620|OCT
315059|NCT01439620|Imaging
315060|NCT01439607|Gaucher disease
315061|NCT01439594|Barrett's Esophagus
315062|NCT01439594|Esophagus
315063|NCT01439594|OCT
315064|NCT01439594|Imaging
315065|NCT01439594|Radiofrequency Ablation
315066|NCT01439594|BARRX
315067|NCT01439581|patients
315068|NCT01439581|susceptible to
315069|NCT01439581|hospital
315070|NCT01439581|acquired pressure
315071|NCT01439568|Cancer
315072|NCT01439568|Lung
315073|NCT01439568|Metastasis
315074|NCT01439555|Early Alzheimer
315075|NCT01439555|Mild Cognitive Impairment
315076|NCT01439555|Drug treatment
315077|NCT01439555|Cerebral blood flow
315078|NCT01439555|Endothelial facilitation
315079|NCT01439555|Cognitive improvement
315080|NCT01439542|High risk prostate cancer
315081|NCT01439529|Cardiac
315082|NCT01439529|Resynchronization
315083|NCT01439529|Therapy
315084|NCT01439477|exercise
315085|NCT01439477|healthy eating
315086|NCT01439477|heart disease
315087|NCT01439477|prevention & control
315088|NCT01439477|Middle aged
315089|NCT01439477|Women
315090|NCT01439477|Health promotion
315091|NCT01439451|Balance control
315092|NCT01439451|Aging
315093|NCT01439451|Balance reactions
315094|NCT01439451|Perturbation
315095|NCT01439451|above seventy years old
315096|NCT01439425|psoriasis
315097|NCT01439425|obesity
315098|NCT01439425|body mass index
315099|NCT01439425|disease remission
315100|NCT01439425|diet
315101|NCT01439412|Low back pain
315102|NCT01439412|Acupuncture
315103|NCT01439412|General practice
315104|NCT01439399|postoperative pain
315105|NCT01439399|postoperative care
315106|NCT01439399|intravenous lidocaine
315107|NCT01439399|intravenous ketamine
315108|NCT01439399|morphine consumption
315109|NCT01439373|chronic hepatitis C
315110|NCT01439373|NS5A inhibitor
315111|NCT01439373|ribavirin
315112|NCT01439373|pegylated interferon
315113|NCT01439373|GSK2336805
315114|NCT01439360|Vaccine
315115|NCT01439360|Seasonal Flu
315116|NCT01439360|Efficacy
315117|NCT01439360|Children
315118|NCT01439347|Marqibo
315119|NCT01439347|HALLMARQ
315120|NCT01439347|leukemia
315121|NCT01439347|front-line
315122|NCT01439347|ALL
315123|NCT01439347|acute lymphoblastic leukemia
315124|NCT01439334|Brief
315125|NCT01439334|Online
315126|NCT01439334|Image
315127|NCT01439334|Interactive
315128|NCT01439334|Young Adult
315129|NCT01439334|Primary Care
315130|NCT01439321|treatment satisfaction
315131|NCT01439321|romiplostim
315132|NCT01439321|eltrombopag
315133|NCT01439321|chronic immune thrombocytopenic pupura
315134|NCT01439308|NAR
315135|NCT01439308|Capsaicin challenge
315136|NCT01439295|Ascorbyl peroxide
315137|NCT01439295|Bronchopulmonary dysplasia
315138|NCT01439295|Redox status
315139|NCT01439295|Necrotising entercolitis
315140|NCT01439295|Retinopathy of prematurity
315141|NCT01439295|Patent ductus arteriosus
315142|NCT01439295|Intraventricular hemorrhage
315143|NCT01439295|Periventricular leucomalacia
315144|NCT01439282|Estrogen Receptor-Positive Early Stage Breast Cancer
315145|NCT01439269|Separation stress
315146|NCT01439269|Family Nurture
315147|NCT01439269|Maternal Confidence
315148|NCT01439269|Maternal Competence
315149|NCT01439269|Calming Cycle
315150|NCT01439269|Kangaroo Care
315151|NCT01439269|Infant Neurodevelopment
315152|NCT01439269|Infant Psychological Development
315153|NCT01439269|Post-partum depression
315154|NCT01439269|Mother-infant Co-regulation
315155|NCT01439243|Bioequivalence
315156|NCT01439243|Healthy Subjects
315157|NCT01439243|Donepezil
315158|NCT01439230|Bioequivalence
315159|NCT01439230|Healthy Subjects
315160|NCT01439230|Donepezil
315161|NCT01439217|Acute lymphoblastic leukemia
315162|NCT01439217|Survivor
315163|NCT01439217|Sibling control
315164|NCT01439191|HER2-Overexpressed
315165|NCT01439165|Adacel vaccine
315166|NCT01439165|Tetanus
315167|NCT01439165|Diphtheria
315168|NCT01439165|whooping cough
315169|NCT01439152|Oncology
315170|NCT01439152|solid tumors
315171|NCT01439152|Antibody drug conjugate
315172|NCT01439152|Maximum tolerable dose
315173|NCT01439152|mesothelin
315174|NCT01439139|Osteoporosis
315175|NCT01439139|ultrasound
315176|NCT01439139|sonometer
315177|NCT01439139|DXA
315178|NCT01439126|Attention Deficit Hyperactivity Disorder
315179|NCT01439113|Ultrasound, Difficult access
315180|NCT01439100|Parkinson's disease
315181|NCT01439100|severe pain
315182|NCT01439100|OXN PR
315183|NCT01439100|randomised
315184|NCT01439087|Colonic Polyps
315185|NCT01439087|OCT
315186|NCT01439087|Imaging
315187|NCT01439087|Colon
315188|NCT01439087|Polyp
315189|NCT01439074|Burn injuries
315190|NCT01439074|Mepilex Ag
315191|NCT01439074|SSD Ag
315192|NCT01439074|Partial thickness
315193|NCT01439061|Growth disorders
315194|NCT01439061|Saizen
315195|NCT01439061|Easypod
315196|NCT01439061|Growth hormone
315197|NCT01439061|Pediatric subject
315198|NCT01439048|Placenta
315199|NCT01439048|Cord Blood
315200|NCT01439048|PAH
315201|NCT01439048|Environmental Markers
315202|NCT01439048|Toll-Like Receptors
315203|NCT01439035|Celiac Disease
315204|NCT01439035|Duodenal
315205|NCT01439035|OCT
315206|NCT01439035|Imaging
315207|NCT01439022|Parkinson's Disease
315208|NCT01439022|Exercise
315209|NCT01439022|Treatment Outcome
315210|NCT01439022|Patient Adherence
315211|NCT01439009|Heart failure
315212|NCT01439009|Volume overload
315213|NCT01439009|Tolvaptan
315214|NCT01439009|loop diuretics
315215|NCT01438996|Typhoid fever
315216|NCT01438996|Glycoconjugate vaccine
315217|NCT01438996|Vi polysaccharide
315218|NCT01438996|Immunogenicity
315219|NCT01438957|Dexmedetomidine
315220|NCT01438957|Sedation
315221|NCT01438957|Non-intubation
315222|NCT01438957|epidural anesthesia
315223|NCT01438957|spinal anesthesia
315224|NCT01438944|NRT
315225|NCT01438944|Patch
315226|NCT01438944|smoking
315227|NCT01438944|addiction
315228|NCT01438931|Dexmedetomidine
315229|NCT01438931|Sedation
315230|NCT01438931|Non-intubation
315231|NCT01438931|local anesthesia
315232|NCT01438918|Knee
315233|NCT01438918|Osteoarthritis
315234|NCT01438918|X-ray
315235|NCT01438918|Joint Space Narrowing
315236|NCT01438905|Ankle Sprain
315237|NCT01438905|Chronic Ankle Instability
315238|NCT01438905|Ankle Mobilization
315239|NCT01438905|Talocrural Joint Mobilization
315240|NCT01438905|Cortical Muscle Activation
315241|NCT01438905|Spinal Muscle Activation
315242|NCT01438892|rheumatoid arthritis
315243|NCT01438892|therapy compliance
315244|NCT01438879|CSF
315245|NCT01438879|PCR
315246|NCT01438879|lymphocytic herpesvirus
315247|NCT01438879|CNS
315248|NCT01438866|Dental caries
315249|NCT01438866|Fissure sealant
315250|NCT01438866|Fluoride varnish
315251|NCT01438866|Primary molar
315252|NCT01438853|Sepsis
315253|NCT01438853|Acute Lung Injury
315254|NCT01438853|Acute Respiratory Distress Syndrome
315255|NCT01438853|ALI/ARDS
315256|NCT01438853|Lung Disease
315257|NCT01438840|Chronic Immune Thrombocytopenia
315258|NCT01438788|Bethlem myopathy
315259|NCT01438788|Ullrich congenital muscular dystrophy
315260|NCT01438788|Low protein diet
315261|NCT01438788|Autophagy
315262|NCT01438788|Pilot clinical trial
315263|NCT01438775|Benign prostatic hyperplasia
315264|NCT01438775|BPH
315265|NCT01438775|Enlarged prostate
315266|NCT01438775|Lower urinary tract symptoms
315267|NCT01438775|LUTS
315268|NCT01438775|LUTS secondary to BPH
315269|NCT01438775|LUTS/BPH
315270|NCT01438775|Benign prostatic obstruction
315271|NCT01438775|BPO
315272|NCT01438775|Bladder outlet obstruction
315273|NCT01438775|BOO
315274|NCT01438762|Anterior Knee Pain
315275|NCT01438736|Focus:
315276|NCT01438736|preceding
315277|NCT01438736|desogestrel predicts
315278|NCT01438736|pattern of following
315279|NCT01438736|etonogestrel implant
315280|NCT01438723|ischemia reperfusion injury
315281|NCT01438723|CABG
315282|NCT01438723|metformin
315283|NCT01438723|Hs-troponin-I
315284|NCT01438697|sleep
315285|NCT01438697|insomnia
315286|NCT01438697|internet
315287|NCT01438697|CBT
315288|NCT01438684|chronic vegetative state
315289|NCT01438684|functional MRI
315290|NCT01438671|WiiFit
315291|NCT01438671|Standing Balance
315292|NCT01438671|Neurological Population
315293|NCT01438658|uveal melanoma
315294|NCT01438658|metastatic uveal melanoma
315295|NCT01438645|Colonoscopy
315296|NCT01438645|Colon cancer screening
315297|NCT01438632|Insulin action
315298|NCT01438632|Jet injector
315299|NCT01438632|Diabetes Mellitus
315300|NCT01438632|Pharmacodynamics
315301|NCT01438632|Pharmacokinetics
315302|NCT01438632|Insulin analogs
315303|NCT01438632|Insulin aspart
315304|NCT01438619|sodium
315305|NCT01438619|blood pressure
315306|NCT01438619|pulse wave velocity
315307|NCT01438619|random digit dialling
315308|NCT01438593|Stroke
315309|NCT01438593|Brain disease
315310|NCT01438593|Ischemia
315311|NCT01438593|Cerebral infraction
315312|NCT01438593|Cord Blood
315313|NCT01438580|atrial ﬁbrillation
315314|NCT01438580|stroke
315315|NCT01438580|warfarin
315316|NCT01438580|aspirin
315317|NCT01438567|oxycodone naloxone combination
315318|NCT01438567|severe chronic and non-malignant pain
315319|NCT01438567|Malignant and non-malignant pain that requires around-the clock opioid therapy
315320|NCT01438567|Opioid related constipation
315321|NCT01438541|No skin breakdown
315322|NCT01438541|Prevention
315323|NCT01438541|protection of the skin
315324|NCT01438528|Growth disorders
315325|NCT01438528|Saizen
315326|NCT01438528|Easypod
315327|NCT01438528|Growth hormone
315328|NCT01438528|Pediatric subject
315329|NCT01438515|MRSA
315330|NCT01438515|doxycycline
315331|NCT01438515|rifampin
315332|NCT01438515|mupirocin
315333|NCT01438515|chlorhexidine gluconate
315334|NCT01438515|decolonization
315335|NCT01438515|methicillin-resistant staphylococcus aureus
315336|NCT01438502|cardiac surgery
315337|NCT01438502|cardio-pulmonary-bypass
315338|NCT01438489|MEDI-546
315339|NCT01438489|Anifrolumab
315340|NCT01438489|Systemic Lupus Erythematosus
315341|NCT01438476|Liver Cancer
315342|NCT01438476|Pancreatic Cancer
315343|NCT01438476|Thoracic epidural analgesia
315344|NCT01438476|TEA
315345|NCT01438476|Intravenous patient-controlled analgesia
315346|NCT01438476|IVPCA
315347|NCT01438476|Pain control
315348|NCT01438476|Quality of life
315349|NCT01438476|QOL
315350|NCT01438476|Surgical resection
315351|NCT01438463|non-seasonal allergy
315352|NCT01438463|house dust mite
315353|NCT01438463|immunotherapy
315354|NCT01438463|dose response
315355|NCT01438450|Thalidomide
315356|NCT01438450|Capecitabine
315357|NCT01438450|Advanced hepatocellular carcinoma
315358|NCT01438450|Therapy
315359|NCT01438450|Supportive care
315360|NCT01438437|Hepatocellular carcinoma
315361|NCT01438437|Radiofrequency ablation
315362|NCT01438437|Percutaneous acetic acid ablation
315363|NCT01438437|Tumour response
315364|NCT01438411|Cholic Acid
315365|NCT01438411|Inborn Error
315366|NCT01438411|Bile Acid Metabolism
315367|NCT01438411|Inborn Error of Bile Acid Synthesis
315368|NCT01438398|Submucosal endoscopic myotomy
315369|NCT01438398|Per Oral Endoscopic Myotomy
315370|NCT01438398|Natural Orifice Transluminal Endoscopic Surgery
315371|NCT01438385|Pancreatico-biliary
315372|NCT01438385|Biliary
315373|NCT01438385|Bile Duct
315374|NCT01438385|Gastrointestinal disorder
315375|NCT01438385|Esophageal disorder
315376|NCT01438372|Iron Deficiency Anemia
315377|NCT01438372|Inflammatory Bowel Disease
315378|NCT01438372|Children
315379|NCT01438359|Drug-drug interaction
315380|NCT01438359|Pharmacokinetics
315381|NCT01438359|PA21
315382|NCT01438359|Drug Interaction Potentiation
315383|NCT01438346|Substance Abuse
315384|NCT01438346|Substance Addiction
315385|NCT01438346|Substance Dependence
315386|NCT01438346|Treatment program
315387|NCT01438333|Chronic Peridodontitis
315388|NCT01438333|probiotics
315389|NCT01438333|lactobacillus brevis
315390|NCT01438333|full mouth disinfection
315391|NCT01438320|Treatment naive
315392|NCT01438320|Contraindications to standard therapies
315393|NCT01438320|Alternative hepatitis C therapy
315394|NCT01438307|Non-small cell lung cancer
315395|NCT01438307|Cabazitaxel-XRP6258
315396|NCT01438307|P-glycoprotein
315397|NCT01438307|taxane
315398|NCT01438307|Advanced NSCLC
315399|NCT01438294|Asthma
315400|NCT01438294|childhood
315401|NCT01438294|exercise
315402|NCT01438281|ocular pain
315403|NCT01438281|dry eye
315404|NCT01438281|siRNA
315405|NCT01438242|Major
315406|NCT01438242|Depressive
315407|NCT01438242|Disorder
315408|NCT01438242|Depression
315409|NCT01438242|Treatment Resistant
315410|NCT01438229|Catheter-based renal artery ablation
315411|NCT01438229|Hypertension
315412|NCT01438229|Resistant to Conventional Therapy
315413|NCT01438216|Pharmacokinetics
315414|NCT01438216|Intensive Care
315415|NCT01438216|Candidemia
315416|NCT01438216|Invasive candidiasis
315417|NCT01438216|Anidulafungin
315418|NCT01438203|manipulation
315419|NCT01438203|mobilization
315420|NCT01438203|low back pain
315421|NCT01438203|treatment
315422|NCT01438177|myeloma
315423|NCT01438177|multiple myeloma
315424|NCT01438177|relapsed myeloma
315425|NCT01438177|refractory myeloma
315426|NCT01438164|FDG-PET
315427|NCT01438164|cancer
315428|NCT01438164|staging
315429|NCT01438164|Evaluate the cost impact in the evaluation of oncologic patients.
315430|NCT01438151|Crohn's disease
315431|NCT01438151|Remicade
315432|NCT01438151|infliximab
315433|NCT01438138|childhood acute myeloid leukemia in remission
315434|NCT01438138|recurrent childhood acute myeloid leukemia
315435|NCT01438138|untreated childhood acute myeloid leukemia and other myeloid malignancies
315436|NCT01438138|childhood acute basophilic leukemia
315437|NCT01438138|childhood acute eosinophilic leukemia
315438|NCT01438138|childhood acute erythroleukemia (M6)
315439|NCT01438138|childhood acute megakaryocytic leukemia (M7)
315440|NCT01438138|childhood acute monoblastic leukemia (M5a)
315441|NCT01438138|childhood acute monocytic leukemia (M5b)
315442|NCT01438138|childhood acute myeloblastic leukemia with maturation (M2)
315443|NCT01438138|childhood acute myeloblastic leukemia without maturation (M1)
315444|NCT01438138|childhood acute myelomonocytic leukemia (M4)
315445|NCT01438138|childhood acute minimally differentiated myeloid leukemia (M0)
315446|NCT01438112|cancer
315447|NCT01438112|bladder cancer
315448|NCT01438112|transitional cell
315449|NCT01438112|virus
315450|NCT01438112|oncolytic
315451|NCT01438112|GM-CSF
315452|NCT01438112|adenovirus
315453|NCT01438112|intravesical
315454|NCT01438112|neoadjuvant
315455|NCT01438112|cystectomy
315456|NCT01438112|gene therapy
315457|NCT01438112|oncolytic virus
315458|NCT01438112|carcinoma in situ
315459|NCT01438112|carcinoma in situ concurrent with papillary tumors
315460|NCT01438099|epidural analgesia
315461|NCT01438099|ultrasound
315462|NCT01438099|labor analgesia
315463|NCT01438099|labor
315464|NCT01438086|Heart Failure
315465|NCT01438086|Myocardial Infarction
315466|NCT01438047|Port Wine Stain
315467|NCT01438021|unspecified adult solid tumor, protocol specific
315468|NCT01438008|Sucrose
315469|NCT01438008|Pain
315470|NCT01437995|Asthma
315471|NCT01437995|Step down therapy
315472|NCT01437995|Inhaled corticosteroids
315473|NCT01437995|Long-acting beta agonists
315474|NCT01437995|Fluticasone Salmeterol
315475|NCT01437982|post-operative inflammation
315476|NCT01437982|conjunctivitis
315477|NCT01437982|safety
315478|NCT01437982|Seasonal allergic conjunctivitis
315479|NCT01437982|Giant papillary conjunctivitis
315480|NCT01437969|Possible association
315481|NCT01437969|between severity
315482|NCT01437969|IL28B genetic variants
315483|NCT01437969|patients
315484|NCT01437969|different HCV genotypes
315485|NCT01437956|Calcineurin
315486|NCT01437956|Bronchiolitis
315487|NCT01437956|Epithelial lung injury
315488|NCT01437956|Rhinovirus
315489|NCT01437956|Respiratory Syncytial Virus
315490|NCT01437956|Asthma
315491|NCT01437943|Transplant
315492|NCT01437943|Failure
315493|NCT01437943|Kidney
315494|NCT01437930|n-3 LC-PUFA
315495|NCT01437930|hypertriglyceridemic
315496|NCT01437930|human
315497|NCT01437930|TAG
315498|NCT01437917|glycemic index
315499|NCT01437904|Renal Calculi
315500|NCT01437904|Percutaneous nephrolithotomy (PCNL)
315501|NCT01437891|PTSD
315502|NCT01437891|Military veteran
315503|NCT01437891|Gulf War
315504|NCT01437891|Fibromyalgia
315505|NCT01437891|Gulf War Syndrome
315506|NCT01437878|PH
315507|NCT01437878|COPD
315508|NCT01437865|MRI
315509|NCT01437865|lymph node metastases
315510|NCT01437865|breast cancer
315511|NCT01437865|gadofosveset
315512|NCT01437839|Food effect study
315513|NCT01437839|Pharmacokinetics
315514|NCT01437839|Apixaban
315515|NCT01437826|chemoprevention
315516|NCT01437826|colorectal cancer
315517|NCT01437826|metachronous adenoma
315518|NCT01437826|randomized trial
315519|NCT01437813|DM2
315520|NCT01437813|glimepiride
315521|NCT01437813|metformin extended release
315522|NCT01437800|DM2
315523|NCT01437800|glimepiride
315524|NCT01437800|metformin extended release
315525|NCT01437774|Acute ischemic stroke
315526|NCT01437748|Small Airways
315527|NCT01437748|Closing volume
315528|NCT01437748|Closing Capacity
315529|NCT01437748|Tiotropium
315530|NCT01437748|Indacaterol
315531|NCT01437748|COPD
315532|NCT01437735|Asthma
315533|NCT01437735|QAW039
315534|NCT01437722|BV
315535|NCT01437722|Bacterial vaginosis
315536|NCT01437722|recurrent
315537|NCT01437722|SPL7013 Gel
315538|NCT01437722|VivaGel
315539|NCT01437709|Bendamustine HCL
315540|NCT01437709|Ofatumumab (GSK 1841157)
315541|NCT01437709|Immunotherapy
315542|NCT01437709|Chemoimmunotherapy
315543|NCT01437709|11-050
315544|NCT01437696|Aging
315545|NCT01437696|Vitamin D
315546|NCT01437696|Bone health
315547|NCT01437696|Inflammation
315548|NCT01437696|Men
315549|NCT01437683|Craniocerebral Trauma
315550|NCT01437683|Quality of life
315551|NCT01437683|Long term outcome
315552|NCT01437683|Activities of Daily Living
315553|NCT01437683|Cognitive Deficiency
315554|NCT01437683|Health Care Quality, Access, and Evaluation
315555|NCT01437644|Cerebral Palsy
315556|NCT01437644|Hip displacement
315557|NCT01437644|Hip surgery
315558|NCT01437644|Post-operative pain
315559|NCT01437644|Botulinum Toxin
315560|NCT01437631|colon polyp
315561|NCT01437631|endoscopic polypectomy
315562|NCT01437631|postpolypectomy bleeding
315563|NCT01437631|prophylactic clip application
315564|NCT01437605|Resected
315565|NCT01437605|Skin
315566|NCT01437605|Stage IV
315567|NCT01437579|interstitial cystitis
315568|NCT01437579|bladder pain syndrome
315569|NCT01437579|intratrigonal injection
315570|NCT01437579|botulinum toxin
315571|NCT01437553|IVUS
315572|NCT01437553|iMAP
315573|NCT01437553|Catheterization
315574|NCT01437553|Acute Coronary Syndrome
315575|NCT01437540|COPD
315576|NCT01437540|Chronic Obstructive Pulmonary Disease
315577|NCT01437540|Chronic Bronchitis
315578|NCT01437540|Emphysema
315579|NCT01437540|Airflow Obstruction, Chronic
315580|NCT01437540|Chronic Airflow Obstruction
315581|NCT01437540|Chronic Obstructive Airway Disease
315582|NCT01437540|Chronic Obstructive Lung Disease
315583|NCT01437527|anorexia nervosa
315584|NCT01437527|CMME-TCA Unit
315585|NCT01437527|Centre Hospitalier Sainte Anne
315586|NCT01437514|rectal cancer
315587|NCT01437514|Endosonography
315588|NCT01437514|preoperative short-course radiotherapy
315589|NCT01437514|preoperative adjuvant therapy
315590|NCT01437514|neoadjuvant therapy
315591|NCT01437514|short-term high-dose preoperative radiotherapy
315592|NCT01437514|total mesorectal excision
315593|NCT01437514|circumferential resection margin
315594|NCT01437514|local recurrence
315595|NCT01437514|overall survival
315596|NCT01437514|metastasis
315597|NCT01437514|complication
315598|NCT01437501|glucoraphanin
315599|NCT01437501|sulforaphane
315600|NCT01437501|pharmacokinetics
315601|NCT01437501|pharmacodynamics
315602|NCT01437501|broccoli sprout
315603|NCT01437501|carcinogens, environment
315604|NCT01437488|Urothelial carcinoma
315605|NCT01437488|Urothelial cancer
315606|NCT01437475|HBV
315607|NCT01437475|HIV
315608|NCT01437475|Immunization
315609|NCT01437475|HBV Immunization rate among HIV positive individuals
315610|NCT01437462|Pain, Postoperative
315611|NCT01437462|Anesthetics, intravenous
315612|NCT01437462|Anesthetics, inhalation
315613|NCT01437462|Otherwise healthy adults undergoing general anesthesia for gynecological disease.
315614|NCT01437449|Quality of Life
315615|NCT01437436|otitis media
315616|NCT01437436|obesity
315617|NCT01437436|ventilation tube
315618|NCT01437423|Diphtheria
315619|NCT01437423|Tetanus
315620|NCT01437423|Pertussis
315621|NCT01437423|Poliomyelitis
315622|NCT01437423|TETRAXIM™
315623|NCT01437397|COPD
315624|NCT01437397|Chronic Obstructive Pulmonary Disease
315625|NCT01437397|Chronic Bronchitis
315626|NCT01437397|Emphysema
315627|NCT01437397|Airflow Obstruction, Chronic
315628|NCT01437397|Chronic Airflow Obstruction
315629|NCT01437397|Chronic Obstructive Airway Disease
315630|NCT01437397|Chronic Obstructive Lung Disease
315631|NCT01437371|Heart failure
315632|NCT01437371|Aged and over 80
315633|NCT01437371|clinical trial
315634|NCT01437371|quality of life
315635|NCT01437358|Epidural catheter
315636|NCT01437358|Epidural analgesia
315637|NCT01437358|Intensive care unit
315638|NCT01437358|Safety
315639|NCT01437306|lofexidine
315640|NCT01437306|food effect
315641|NCT01437306|pharmacokinetics
315642|NCT01437306|healthy volunteer
315643|NCT01437293|cocaine
315644|NCT01437280|Tumors
315645|NCT01437280|Solid Tumors
315646|NCT01437254|99mTc Pertechnetate
315647|NCT01437254|thyroidectomy
315648|NCT01437241|HIV-infection
315649|NCT01437241|Etravirine
315650|NCT01437241|Treatment
315651|NCT01437241|Non-nucleoside reverse-transcriptase inhibitor
315652|NCT01437215|aneurysm
315653|NCT01437215|renal stent
315654|NCT01437215|juxtarenal
315655|NCT01437215|pararenal
315656|NCT01437202|imatinib
315657|NCT01437202|drug resistance
315658|NCT01437202|pharmacogenetics
315659|NCT01437189|Parkinson's disease
315660|NCT01437189|depression
315661|NCT01437189|sertraline
315662|NCT01437189|intervention
315663|NCT01437176|surgery
315664|NCT01437176|fixation
315665|NCT01437176|intramedullary nail
315666|NCT01437150|surgery
315667|NCT01437150|fixation
315668|NCT01437150|bone plate
315669|NCT01437137|elective surgery of short duration (less than 2 hr) undergoing general anesthesia using supraglottic airway
315670|NCT01437111|Osteoporosis
315671|NCT01437111|Postmenopausal
315672|NCT01437098|Valvular Heart Disease
315673|NCT01437098|Severe Aortic Stenosis
315674|NCT01437098|Aortic Valve Replacement
315675|NCT01437085|Needle deflection
315676|NCT01437085|Prostate Deformation
315677|NCT01437085|Prostate Brachytherapy
315678|NCT01437085|Needles
315679|NCT01437046|Alcohol drinking
315680|NCT01437046|Alcohol craving
315681|NCT01437033|Breath Tests
315682|NCT01437033|Human Volunteers
315683|NCT01437033|Pilot Study
315684|NCT01437033|Breath Test
315685|NCT01437020|IL-10
315686|NCT01437020|Leishmaniasis
315687|NCT01437020|Immunotherapy
315688|NCT01437007|SNALP
315689|NCT01437007|Regional Therapy
315690|NCT01437007|Stage IV Disease
315691|NCT01437007|Adenocarcinoma
315692|NCT01437007|Unresectable
315693|NCT01437007|Liver Metastases
315694|NCT01437007|Colorectal Cancer
315695|NCT01437007|Stomach Cancer
315696|NCT01437007|Gastric Cancer
315697|NCT01437007|Breast Cancer
315698|NCT01437007|Ovarian Cancer
315699|NCT01437007|Pancreatic Cancer
315700|NCT01437007|Liver Cancer
315701|NCT01436994|thyrotoxic
315702|NCT01436994|thyrotoxicosis
315703|NCT01436994|paediatric
315704|NCT01436994|endocrinology
315705|NCT01436994|block and replace
315706|NCT01436994|dose titration
315707|NCT01436994|carbimazole
315708|NCT01436981|papaverine
315709|NCT01436981|pharmacokinetic
315710|NCT01436981|CABG
315711|NCT01436981|Injury of Internal Mammary Artery
315712|NCT01436981|Complications Due to Coronary Artery Bypass Graft
315713|NCT01436968|immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy
315714|NCT01436929|silymarin
315715|NCT01436929|hepatotoxicity
315716|NCT01436929|tuberculosis
315717|NCT01436929|HREZ
315718|NCT01436916|prediabetes
315719|NCT01436916|oral cholecalciferol
315720|NCT01436903|menorrhagia
315721|NCT01436903|dysfunctional uterine bleeding
315722|NCT01436903|endometrial ablation
315723|NCT01436903|cavatermTM
315724|NCT01436903|probe
315725|NCT01436890|Chronic Persistent Asthma
315726|NCT01436877|BPH
315727|NCT01436877|bladder neck obstruction
315728|NCT01436877|Bladder neck obstruction secondary to BPH
315729|NCT01436864|Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902
315730|NCT01436864|)
315731|NCT01436864|age-related macular degeneration (AMD)
315732|NCT01436864|choroidal neovascularization (CNV)
315733|NCT01436864|intravitreal injection
315734|NCT01436864|best corrected visual acuity (BCVA)
315735|NCT01436864|central retinal thickness
315736|NCT01436851|rhinitis
315737|NCT01436851|allergy
315738|NCT01436851|occupational
315739|NCT01436851|storage mites
315740|NCT01436851|nasal lavage
315741|NCT01436851|challenge test
315742|NCT01436851|ECP
315743|NCT01436851|alfa2Macroglobuline
315744|NCT01436838|Relapsing-Remitting Multiple Sclerosis
315745|NCT01436838|Secondary Progressive Multiple Sclerosis
315746|NCT01436825|Haemophilia A
315747|NCT01436825|Factor VIII
315748|NCT01436825|Pharmacokinetic
315749|NCT01436825|Computer Tool validation
315750|NCT01436812|cerebral oxymetry
315751|NCT01436812|laparoscopy
315752|NCT01436812|PEEP
315753|NCT01436799|propofol
315754|NCT01436799|desflurane
315755|NCT01436799|cerebrovascular circulation
315756|NCT01436799|sitting
315757|NCT01436786|cytokines
315758|NCT01436786|Guided imagery
315759|NCT01436760|IBS
315760|NCT01436747|Kidney transplantation
315761|NCT01436747|Proteinuria
315762|NCT01436747|Albuminuria
315763|NCT01436747|Vitamin D
315764|NCT01436747|Paricalcitol
315765|NCT01436721|Effectiveness
315766|NCT01436721|Device success
315767|NCT01436721|Hepatectomy
315768|NCT01436708|pelvic organ prolapse
315769|NCT01436708|urinary symptoms
315770|NCT01436708|sexual function
315771|NCT01436695|seizure early detection
315772|NCT01436682|Nerve Blocks
315773|NCT01436656|BRAF mutant,
315774|NCT01436656|BRAF mutated,
315775|NCT01436656|melanoma,
315776|NCT01436656|metastatic,
315777|NCT01436656|advanced,
315778|NCT01436656|RAF kinase inhibitor
315779|NCT01436656|BRAF V600 mutation
315780|NCT01436643|Depression
315781|NCT01436643|Multiple Sclerosis
315782|NCT01436643|Fingolimod
315783|NCT01436643|Venlafaxine
315784|NCT01436643|Fluoxetine
315785|NCT01436630|Exercise Tolerance
315786|NCT01436630|Step Test
315787|NCT01436630|Stroke
315788|NCT01436630|Walking
315789|NCT01436617|cancer
315790|NCT01436617|colon
315791|NCT01436617|Head and neck
315792|NCT01436617|cetuximab
315793|NCT01436617|anti-cetuximab dosage
315794|NCT01436604|cardiac MRI
315795|NCT01436604|Cancer
315796|NCT01436604|Breast
315797|NCT01436604|Herceptin
315798|NCT01436604|LV dysfunction
315799|NCT01436591|Cancer
315800|NCT01436591|Breast
315801|NCT01436591|18FDG
315802|NCT01436591|Axillary
315803|NCT01436591|Positron Emission Tomography
315804|NCT01436552|MCI
315805|NCT01436552|Depression
315806|NCT01436552|Alzheimer
315807|NCT01436552|Life events
315808|NCT01436526|Bioequivalence
315809|NCT01436513|bioequivalence
315810|NCT01436513|menometrorrhagia
315811|NCT01436513|climacteric disturbance
315812|NCT01436513|Estrogen Replacement Therapy
315813|NCT01436513|Estrogens Conjugated
315814|NCT01436500|Hepatorenal Syndrome
315815|NCT01436500|HRS
315816|NCT01436500|ifetroban
315817|NCT01436487|ischemic stroke
315818|NCT01436487|adult stem cells
315819|NCT01436474|Varenicline
315820|NCT01436474|Chantix
315821|NCT01436474|Chronic Pain
315822|NCT01436474|Opioid dependence
315823|NCT01436448|efficacy
315824|NCT01436448|Lactobacillus Rhamnosus
315825|NCT01436448|glucose intolerance
315826|NCT01436448|feasibility
315827|NCT01436448|compliance and safety
315828|NCT01436448|reducing glucose intolerance during and after pregnancy
315829|NCT01436435|PAD
315830|NCT01436435|peripheral artery disease
315831|NCT01436435|atherectomy
315832|NCT01436422|Dengue Virus
315833|NCT01436422|Dengue Fever
315834|NCT01436422|Dengue Vaccine
315835|NCT01436422|Dengue Hemorrhagic Fever
315836|NCT01436422|Dengue Shock Syndrome
315837|NCT01436409|vaginal touch
315838|NCT01436409|deliveries assisted
315839|NCT01436409|echography
315840|NCT01436409|assisted delivery
315841|NCT01436396|Dengue
315842|NCT01436396|Dengue Hemorrhagic Fever
315843|NCT01436396|CYD Dengue Vaccines
315844|NCT01436396|Yellow Fever
315845|NCT01436396|Stamaril®
315846|NCT01436396|Flavivirus Infections
315847|NCT01436383|high altitude
315848|NCT01436383|hypobaric hypoxia
315849|NCT01436383|metabolomics
315850|NCT01436383|oxidative stress
315851|NCT01436383|acute mountain sickness
315852|NCT01436370|influenza, rheumatoid arthritis, TNF-alpha-inhibitor, Fluzone®, Fluzone® High Dose
315853|NCT01436357|AdCh3NSmut1
315854|NCT01436357|Hepatitis C
315855|NCT01436357|MVA-NSmut
315856|NCT01436357|vaccine
315857|NCT01436344|esophageal electrocardiography
315858|NCT01436344|electrocardiography
315859|NCT01436344|atrial electrogram
315860|NCT01436344|atrial function, left
315861|NCT01436331|First episode psychosis
315862|NCT01436331|Early Psychosis
315863|NCT01436331|Cognitive Behavioural therapy
315864|NCT01436331|Psychosocial Intervention
315865|NCT01436331|Assertive Community treatment
315866|NCT01436331|Family Intervention
315867|NCT01436331|Mental Disorders
315868|NCT01436331|Psychotic Disorders
315869|NCT01436331|Schizophrenia and Disorders with Psychotic Features
315870|NCT01436331|Affective Disorders, Psychotic
315871|NCT01436318|Healthy Kids
315872|NCT01436318|Respiratory
315873|NCT01436318|Volunteers
315874|NCT01436305|immunosuppressive (IS) regimens
315875|NCT01436305|long-term graft function
315876|NCT01436305|CNI (calcineurin Inhibitor )-free IS regimen
315877|NCT01436305|CNI (calcineurin Inhibitor ) IS regimen
315878|NCT01436305|corticosteroids
315879|NCT01436292|Hypoalbuminemia
315880|NCT01436292|Burns
315881|NCT01436292|Albumin
315882|NCT01436292|Organ dysfunction
315883|NCT01436292|Outcome
315884|NCT01436240|Patient-Reported Outcomes
315885|NCT01436240|Common Terminology Criteria for Adverse Events
315886|NCT01436240|PRO-CTCAE
315887|NCT01436240|Native Spanish Speaking
315888|NCT01436240|Spanish Translation
315889|NCT01436240|Cognitive Interview
315890|NCT01436240|Questionnaire
315891|NCT01436240|11-133
315892|NCT01436240|Adverse Events
315893|NCT01436240|chemotherapy
315894|NCT01436240|radiation therapy
315895|NCT01436240|treatment in previous 6 months
315896|NCT01436227|Von Hippel-Lindau Syndrome
315897|NCT01436227|VHL
315898|NCT01436227|Von Hippel-Lindau related lesion
315899|NCT01436227|Pazopanib
315900|NCT01436227|GW786034
315901|NCT01436188|Biological Markers
315902|NCT01436188|Healthy Volunteer
315903|NCT01436188|Alzheimer's Disease (AD)
315904|NCT01436188|Mild Cognitive Impairment (MCI)
315905|NCT01436188|Cerebrospinal fluid (CSF)
315906|NCT01436188|CSF proteins
315907|NCT01436136|Cardiovascular disease
315908|NCT01436136|HIV
315909|NCT01436136|Antiretroviral treatment
315910|NCT01436136|team interventions
315911|NCT01436136|Framingham risk score
315912|NCT01436123|Plasmonic Photothermal Therapy
315913|NCT01436123|Nanoparticles
315914|NCT01436123|Stem cells
315915|NCT01436123|Atherosclerosis
315916|NCT01436123|Bioengineering
315917|NCT01436123|Biodegradable stenting
315918|NCT01436123|Repair disease
315919|NCT01436097|Healthy Eating
315920|NCT01436097|Health Behavior
315921|NCT01436097|Incentive
315922|NCT01436097|Work-site
315923|NCT01436084|Leukemia
315924|NCT01436084|Myelodysplastic syndrome
315925|NCT01436084|MDS
315926|NCT01436084|SB1518
315927|NCT01436058|side effect
315928|NCT01436058|mesenchymal stem cell
315929|NCT01436058|ankle
315930|NCT01436058|osteoarthritis
315931|NCT01436045|Memory
315932|NCT01436045|Insulin glulisine
315933|NCT01436045|Alzheimer's Disease
315934|NCT01436019|Juvenile idiopathic arthritis
315935|NCT01436019|Rheumatic diseases
315936|NCT01436019|Antibodies
315937|NCT01436019|Biological therapy
315938|NCT01436006|MDCT
315939|NCT01436006|radiation
315940|NCT01436006|dose
315941|NCT01435993|Multiple Sclerosis, Secondary-Progressive with relapses
315942|NCT01435980|type 2 diabetes
315943|NCT01435980|Gastric Bypass
315944|NCT01435980|GLP-1
315945|NCT01435980|adiponectin
315946|NCT01435967|Rotarix™
315947|NCT01435967|Observational
315948|NCT01435967|ecological
315949|NCT01435954|benign prostatic hyperplasia
315950|NCT01435954|surgery
315951|NCT01435954|5-alpha-reductase inhibitor
315952|NCT01435954|enlarged prostate
315953|NCT01435954|acute urinary retention
315954|NCT01435941|mailed survey
315955|NCT01435941|non-steroidal anti-inflammatory drug
315956|NCT01435941|migraine disorders
315957|NCT01435941|headache
315958|NCT01435928|Schizophrenia
315959|NCT01435928|Lurasidone
315960|NCT01435928|Latuda
315961|NCT01435902|exercise-induced bronchospasm
315962|NCT01435902|Activity/Exercise induced bronchospasm
315963|NCT01435902|asthma
315964|NCT01435889|Acute respiratory distress syndrome
315965|NCT01435889|Children
315966|NCT01435889|Long term respiratory sequelae
315967|NCT01435889|Pulmonary function tests
315968|NCT01435889|Computed tomography, lung
315969|NCT01435850|hip arthroplasty
315970|NCT01435850|primary stability
315971|NCT01435850|secondary stability
315972|NCT01435850|EBRA
315973|NCT01435837|Voice
315974|NCT01435837|aerodynamics
315975|NCT01435837|acoustics
315976|NCT01435824|healthy adult volunteers
315977|NCT01435824|comparative bioavailability
315978|NCT01435824|amoxicillin
315979|NCT01435824|breast milk
315980|NCT01435824|Amoxicillin Bioavailability in breast milk
315981|NCT01435811|Norovirus
315982|NCT01435798|chronic pain
315983|NCT01435798|central neuropathic pain
315984|NCT01435798|spinal cord injury
315985|NCT01435798|dextromethorphan
315986|NCT01435798|lidocaine
315987|NCT01435798|combination therapy
315988|NCT01435798|analgesia
315989|NCT01435785|PKPD
315990|NCT01435785|Propofol
315991|NCT01435785|TCI
315992|NCT01435785|Elderly patients
315993|NCT01435746|liver transplantation
315994|NCT01435746|intensive care
315995|NCT01435746|red blood cell transfusion
315996|NCT01435733|ASD
315997|NCT01435733|Divorce
315998|NCT01435720|Multiple myeloma
315999|NCT01435720|B cell lymphoma
316000|NCT01435720|Hematologic disease
316001|NCT01435720|Blood protein disorder
316002|NCT01435720|Neoplasm, plasma cell
316003|NCT01435720|Mantle Cell Lymphoma
316004|NCT01435720|Diffuse Large B Cell Lymphoma
316005|NCT01435720|Plasma Cell Leukemia
316006|NCT01435720|B cell malignancy
316007|NCT01435707|epidural steroid injection
316008|NCT01435707|triamcinolone
316009|NCT01435707|fasting blood glucose
316010|NCT01435707|diabetes mellitus
316011|NCT01435694|multiple sclerosis
316012|NCT01435694|gait rehabilitation
316013|NCT01435681|DYT-1
316014|NCT01435681|DYT1
316015|NCT01435681|DYT 1
316016|NCT01435681|dystonia
316017|NCT01435681|DBS
316018|NCT01435681|deep brain stimulation
316019|NCT01435681|TMS
316020|NCT01435681|transcranial magnetic stimulation
316021|NCT01435668|alcohol
316022|NCT01435668|hazardous or harmful drinking
316023|NCT01435668|emergency department (ED)
316024|NCT01435616|diabetes mellitus
316025|NCT01435616|type 2 diabetes mellitus
316026|NCT01435616|insulin naive
316027|NCT01435616|insulin treatment
316028|NCT01435603|Prevention & Control
316029|NCT01435603|Hyperglycemia
316030|NCT01435603|Obesity
316031|NCT01435603|Diabetes Mellitus
316032|NCT01435603|Cost Benefit Analysis
316033|NCT01435577|Bunionectomy
316034|NCT01435577|Postsurgical Pain
316035|NCT01435577|Acute Pain
316036|NCT01435564|Mobile phone
316037|NCT01435564|Sedentary lifestyle
316038|NCT01435564|Physical activity
316039|NCT01435564|Prevention
316040|NCT01435564|Health Promotion
316041|NCT01435564|Exercise
316042|NCT01435564|eHealth
316043|NCT01435564|Electronic diary
316044|NCT01435551|Alzheimer
316045|NCT01435551|Dementia
316046|NCT01435538|interprofessional teamwork
316047|NCT01435538|care pathways
316048|NCT01435538|team communication
316049|NCT01435538|team coordination
316050|NCT01435538|Chronic Obstructive Pulmonary Disease Teams
316051|NCT01435538|Proximal Femur Fracture Teams
316052|NCT01435525|triple therapy
316053|NCT01435525|Helicobacter pylori
316054|NCT01435525|eradication
316055|NCT01435525|Nexium
316056|NCT01435512|PTSD
316057|NCT01435512|CBT
316058|NCT01435512|Intimate Partner Violence
316059|NCT01435512|Treatment
316060|NCT01435499|immunotherapy
316061|NCT01435499|vaccine
316062|NCT01435499|GVAX
316063|NCT01435499|GM-CSF
316064|NCT01435486|caffeine
316065|NCT01435486|apnea
316066|NCT01435486|bronchiolitis
316067|NCT01435473|pediatrics
316068|NCT01435473|thrombosis
316069|NCT01435473|thromboembolic complications
316070|NCT01435473|pediatric cardiac surgery
316071|NCT01435460|ocular allergy
316072|NCT01435447|efficacy
316073|NCT01435447|safety
316074|NCT01435447|conditioning
316075|NCT01435447|fludarabine
316076|NCT01435447|busulfan
316077|NCT01435447|cyclophosphamide
316078|NCT01435447|adult
316079|NCT01435434|subjects sustaining Non union/delayed fractures and requiring surgical intervention for treatment
316080|NCT01435408|STEMI
316081|NCT01435408|Ischemic postconditioning
316082|NCT01435408|Deferred stenting
316083|NCT01435408|Primary PCI
316084|NCT01435356|Urinary Bladder neoplasms
316085|NCT01435356|Lymphoproliferative Disorders
316086|NCT01435356|Immune System Diseases
316087|NCT01435356|Cystectomy
316088|NCT01435356|Adjuvants, Immunologic
316089|NCT01435356|Immunologic Factors
316090|NCT01435330|Safety
316091|NCT01435330|BVS857
316092|NCT01435330|insulin resistance
316093|NCT01435317|Acoustic CR®-neuromodulation
316094|NCT01435317|ANM T30 CR®-System
316095|NCT01435278|Weight maintenance
316096|NCT01435278|BMI
316097|NCT01435278|Body weight
316098|NCT01435278|Overweight
316099|NCT01435278|Obesity
316100|NCT01435278|Satiety
316101|NCT01435265|Psoriasis
316102|NCT01435265|Dermatology
316103|NCT01435265|Phase IV
316104|NCT01435265|Nurse Education
316105|NCT01435265|Adalimumab
316106|NCT01435265|Humira
316107|NCT01435226|Hepatitis C
316108|NCT01435226|HCV
316109|NCT01435226|Rapid Virologic Response
316110|NCT01435226|Sustained Virologic Response
316111|NCT01435226|Direct Acting Antiviral
316112|NCT01435226|Combination Therapy
316113|NCT01435226|Tegobuvir
316114|NCT01435226|Treatment Experienced
316115|NCT01435226|HCV RNA
316116|NCT01435226|Polymerase inhibitor
316117|NCT01435226|Protease inhibitor
316118|NCT01435226|Interferon intolerant
316119|NCT01435226|Interferon ineligible
316120|NCT01435226|GS-9190
316121|NCT01435226|GS-9451
316122|NCT01435226|GS-5885
316123|NCT01435226|Chronic Genotype 1a or 1b
316124|NCT01435213|alpha2-adrenoceptor
316125|NCT01435213|receptor occupancy
316126|NCT01435213|positron emission tomography
316127|NCT01435213|[11C]ORM-13070
316128|NCT01435213|striatum
316129|NCT01435213|brain
316130|NCT01435213|noradrenaline
316131|NCT01435213|norepinephrine
316132|NCT01435213|endogenous
316133|NCT01435213|binding
316134|NCT01435213|Validation studies
316135|NCT01435200|Intravenous iron
316136|NCT01435200|gynecologic cancer blood transfusion
316137|NCT01435174|ranolazine
316138|NCT01435174|end-stage renal disease
316139|NCT01435174|pharmacokinetics
316140|NCT01435174|cardiovascular disease
316141|NCT01435161|paroxysmal atrial fibrillation, hypertension
316142|NCT01435148|Deep Brain Stimulation
316143|NCT01435148|Treatment Resistant Depression
316144|NCT01435122|progressive advanced carcinoid tumors
316145|NCT01435122|advanced
316146|NCT01435122|unresectable
316147|NCT01435122|metastatic
316148|NCT01435122|cancerous tumors
316149|NCT01435122|neuroendocrine
316150|NCT01435122|digestive tract
316151|NCT01435122|lungs
316152|NCT01435122|renal
316153|NCT01435122|ovarian
316154|NCT01435122|thymic
316155|NCT01435122|hepatic
316156|NCT01435109|Osteoarthritis
316157|NCT01435109|Exercise
316158|NCT01435109|Diet
316159|NCT01435109|Coping Skills
316160|NCT01435109|Education, Medical
316161|NCT01435083|Nocturia
316162|NCT01435070|Colles' fracture
316163|NCT01435070|Radius fracture
316164|NCT01435070|grip strength
316165|NCT01435070|pinch strength
316166|NCT01435070|range of movement
316167|NCT01435070|PRWE
316168|NCT01435070|DASH
316169|NCT01435070|EQ-5D
316170|NCT01435070|Kirschner wire
316171|NCT01435070|Volar locking plate
316172|NCT01435057|Abdominal Obesity
316173|NCT01435057|training
316174|NCT01435057|fat
316175|NCT01435057|insulin
316176|NCT01435057|glucose
316177|NCT01435057|diet
316178|NCT01435044|Hepatitis C
316179|NCT01435044|Chronic
316180|NCT01435044|HCV
316181|NCT01435031|Angioplasty
316182|NCT01435031|Chronic Total Occlusion (CTO)
316183|NCT01435031|Chronic total coronary occlusions
316184|NCT01435031|Coronary Artery Disease (CAD)
316185|NCT01435031|Coronary artery stenosis
316186|NCT01435031|Total coronary occlusion
316187|NCT01435005|Prevention and control
316188|NCT01435005|Exercise
316189|NCT01435005|Sedentary lifestyle
316190|NCT01435005|Biological markers
316191|NCT01434966|Lumbopelvic Manipulation
316192|NCT01434966|Lumbosacral Manipulation
316193|NCT01434966|Sacroiliac Manipulation
316194|NCT01434966|TENS Spine
316195|NCT01434966|TENS Knee
316196|NCT01434966|Knee Pain
316197|NCT01434966|Chronic Knee Pain
316198|NCT01434953|Prehypertension
316199|NCT01434953|Blood pressure screening
316200|NCT01434953|White coat effect
316201|NCT01434940|Alzheimer disease
316202|NCT01434940|Depression
316203|NCT01434940|Differential diagnosis
316204|NCT01434940|Eye movement
316205|NCT01434914|Ulcus cruris
316206|NCT01434914|chronic wounds
316207|NCT01434914|octenisept®
316208|NCT01434901|Diabetes
316209|NCT01434901|Blood Sugar
316210|NCT01434901|Xenin-25
316211|NCT01434901|GIP
316212|NCT01434901|Muscarinic
316213|NCT01434888|pharmacokinetics
316214|NCT01434862|Type 1 Diabetes Mellitus
316215|NCT01434849|infantile hemangioma
316216|NCT01434849|very low birth weight infants
316217|NCT01434849|premature infants
316218|NCT01434836|Anti-depressant effects
316219|NCT01434823|nocturnal staffing
316220|NCT01434823|intensivist staffing
316221|NCT01434823|intensivist coverage
316222|NCT01434823|ICU patient-centered outcomes
316223|NCT01434823|ICU resource utilization
316224|NCT01434823|patients admitted to the medical intensive care unit
316225|NCT01434823|Sleep Deprivation
316226|NCT01434823|Inattention
316227|NCT01434823|Work Hours
316228|NCT01434810|Hyperbilirubinemia, Neonatal
316229|NCT01434797|Infection
316230|NCT01434797|Permanent central venous catheter
316231|NCT01434797|Device Related
316232|NCT01434784|lung cancer
316233|NCT01434784|quality of life
316234|NCT01434758|Mycobacterium tuberculosis
316235|NCT01434758|Culture yield
316236|NCT01434745|SLOS
316237|NCT01434745|Cholesterol Supplementation
316238|NCT01434745|Simvastatin
316239|NCT01434732|Superior vena cava flow
316240|NCT01434732|umbilical cord milking
316241|NCT01434732|hemodynamics
316242|NCT01434732|systemic blood flow
316243|NCT01434719|Streptococcus suis
316244|NCT01434719|Sepsis
316245|NCT01434719|Porcine Respiratory and Reproductive System virus
316246|NCT01434719|Pig disease
316247|NCT01434719|Epidemiology
316248|NCT01434706|HIV
316249|NCT01434706|acute infection
316250|NCT01434706|primary infection
316251|NCT01434706|seroconverters
316252|NCT01434693|T. suis ova
316253|NCT01434693|Crohn's disease
316254|NCT01434680|Meningococcal disease
316255|NCT01434680|vaccines
316256|NCT01434680|toddlers
316257|NCT01434680|prevention
316258|NCT01434680|Meningitis
316259|NCT01434667|Mild Cognitive Impairment (MCI)
316260|NCT01434667|Alzheimer's disease (AD)
316261|NCT01434667|APOE
316262|NCT01434667|genetics
316263|NCT01434667|risk assessment
316264|NCT01434667|education
316265|NCT01434667|genetic counseling
316266|NCT01434667|Mild Cognitive Impairment, So Stated
316267|NCT01434654|HAND
316268|NCT01434654|HIV
316269|NCT01434654|Neurology
316270|NCT01434654|Neurocognitive
316271|NCT01434654|Neuro-HAART
316272|NCT01434654|HIV Associated Neurocognitive Disorders (HAND)
316273|NCT01434641|myocardial perfusion SPECT
316274|NCT01434641|wide beam reconstruction
316275|NCT01434641|Tc-99m sestamibi
316276|NCT01434628|Male Circumcision
316277|NCT01434628|HIV Prevention
316278|NCT01434628|HIV Infections
316279|NCT01434615|Cardiac Resynchronization Therapy
316280|NCT01434615|Moderate to advanced
316281|NCT01434615|patients
316282|NCT01434615|current consensus guidelines
316283|NCT01434602|Chemotherapy
316284|NCT01434602|Brain Tumor
316285|NCT01434602|Glioblastoma
316286|NCT01434602|Anaplastic Glioma
316287|NCT01434589|internet addiction
316288|NCT01434589|computer game addiction
316289|NCT01434589|STICA
316290|NCT01434589|short-term treatment
316291|NCT01434589|psychotherapy
316292|NCT01434589|internet and computer game addiction
316293|NCT01434563|HIV
316294|NCT01434563|neurocognitive disorder
316295|NCT01434563|primary care
316296|NCT01434563|HIV negative
316297|NCT01434563|HAND
316298|NCT01434563|CNS
316299|NCT01434550|pancreas
316300|NCT01434550|pancreatic cancer
316301|NCT01434550|SBRT
316302|NCT01434550|stereotactic body radiation
316303|NCT01434550|radiation therapy
316304|NCT01434550|unresectable
316305|NCT01434550|non-metastatic
316306|NCT01434550|tissue, blood, research imaging
316307|NCT01434550|TBRI
316308|NCT01434537|pediatric anesthesia
316309|NCT01434537|venepuncture
316310|NCT01434537|peripheral venous access
316311|NCT01434511|hemophilia A
316312|NCT01434511|haemophilia A
316313|NCT01434511|blood coagulation disorders
316314|NCT01434511|hemorrhagic disorders
316315|NCT01434511|coagulation protein disorder
316316|NCT01434511|hematologic diseases
316317|NCT01434511|congenital hemophilia A
316318|NCT01434498|Hepatitis C
316319|NCT01434498|HCV
316320|NCT01434498|Rapid Virologic Response
316321|NCT01434498|Sustained Virologic Response
316322|NCT01434498|Direct Acting Antiviral
316323|NCT01434498|Combination Therapy
316324|NCT01434498|Tegobuvir
316325|NCT01434498|Treatment naïve
316326|NCT01434498|HCV RNA
316327|NCT01434498|Polymerase inhibitor
316328|NCT01434498|Protease inhibitor
316329|NCT01434498|Interferon intolerant
316330|NCT01434498|Interferon ineligible
316331|NCT01434498|GS-9190
316332|NCT01434498|GS-9451
316333|NCT01434498|GS-5885
316334|NCT01434485|gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome, Nexium
316335|NCT01434459|Pancreatic neoplasms
316336|NCT01434459|Cholangiocarcinoma
316337|NCT01434420|triple negative breast cancer
316338|NCT01434407|Advanced glycation endproducts
316339|NCT01434407|Satiety
316340|NCT01434407|Obesity
316341|NCT01434407|Inflammation
316342|NCT01434407|Insulin resistance
316343|NCT01434394|Oral cancer
316344|NCT01434394|Oropharyngeal cancer
316345|NCT01434394|Induction chemotherapy
316346|NCT01434394|Targeted chemotherapy
316347|NCT01434394|Surgery
316348|NCT01434394|Radiotherapy
316349|NCT01434381|Recombinant
316350|NCT01434381|Proteins
316351|NCT01434381|Antigen
316352|NCT01434381|Membrane
316353|NCT01434381|Assay
316354|NCT01434381|Malaria
316355|NCT01434368|Functional Magnetic Resonance Imaging (fMRI)
316356|NCT01434368|Normal Development
316357|NCT01434368|Puberty
316358|NCT01434368|Brain Function
316359|NCT01434368|Gonadal Steroids
316360|NCT01434368|Brain Structure
316361|NCT01434368|Healthy Volunteer
316362|NCT01434368|HV
316363|NCT01434342|stage IA non-small cell lung cancer
316364|NCT01434342|stage IB non-small cell lung cancer
316365|NCT01434342|stage IIA non-small cell lung cancer
316366|NCT01434342|stage IIB non-small cell lung cancer
316367|NCT01434342|stage IIIA non-small cell lung cancer
316368|NCT01434342|stage IIIB non-small cell lung cancer
316369|NCT01434342|limited stage small cell lung cancer
316370|NCT01434342|tobacco use disorder
316371|NCT01434342|Breast Cancer
316372|NCT01434342|Cervical Cancer
316373|NCT01434342|head & neck cancer
316374|NCT01434342|Prostate Cancer
316375|NCT01434342|All histologies
316376|NCT01434329|untreated adult acute myeloid leukemia
316377|NCT01434290|radiation toxicity
316378|NCT01434290|sexual dysfunction
316379|NCT01434290|psychosocial effects of cancer and its treatment
316380|NCT01434290|adenocarcinoma of the prostate
316381|NCT01434290|stage I prostate cancer
316382|NCT01434290|stage IIA prostate cancer
316383|NCT01434277|Preservative
316384|NCT01434277|Eye Drops
316385|NCT01434264|rehabilitation
316386|NCT01434251|Hypotension
316387|NCT01434251|premature infants
316388|NCT01434251|near infrared spectroscopy
316389|NCT01434238|infant feeding
316390|NCT01434238|HIV
316391|NCT01434238|growth
316392|NCT01434238|anemia
316393|NCT01434225|Neonatal seizures
316394|NCT01434225|Hypoxic Ischemic Encephalopathy
316395|NCT01434225|Electroencephalography
316396|NCT01434225|Bumetanide
316397|NCT01434212|HCV dynamics
316398|NCT01434212|Mathematical model
316399|NCT01434212|Interferon
316400|NCT01434212|Predict
316401|NCT01434212|Hepatitis C Virus
316402|NCT01434199|magnetic endoscope imaging
316403|NCT01434199|colonoscopy
316404|NCT01434199|caecal intubation
316405|NCT01434173|Liver Diseases
316406|NCT01434173|Anti-Bacterial Agents
316407|NCT01434173|Fluoroquinolones
316408|NCT01434173|Amoxicillin
316409|NCT01434173|Amoxicillin-Potassium Clavulanate Combination
316410|NCT01434173|Clarithromycin
316411|NCT01434173|Doxycycline
316412|NCT01434173|Cefuroxime
316413|NCT01434173|Case-Control Studies
316414|NCT01434173|Retrospective Studies
316415|NCT01434173|Cohort Studies
316416|NCT01434173|Epidemiologic Research Design
316417|NCT01434173|Epidemiologic Studies
316418|NCT01434173|HealthCore Integrated Research Database (non-MESH)
316419|NCT01434173|United States
316420|NCT01434173|Human
316421|NCT01434173|Insurance Claim Review
316422|NCT01434160|Intrauterine
316423|NCT01434160|contraception
316424|NCT01434160|adolescent
316425|NCT01434147|locally advanced rectal cancer
316426|NCT01434147|preoperative induction chemotherapy chemoradiotherapy
316427|NCT01434134|Anthracyclines
316428|NCT01434134|Trastuzumab
316429|NCT01434108|cirrhosis, gastrointestinal bleeding
316430|NCT01434095|microperimetry
316431|NCT01434095|fixation point
316432|NCT01434095|retinal sensitivity
316433|NCT01434095|photodynamic therapy
316434|NCT01434095|chronic central serous chorioretinopathy
316435|NCT01434082|sleep
316436|NCT01434082|school-age children
316437|NCT01434082|Children with and without arthritis
316438|NCT01434069|colon
316439|NCT01434069|rectum
316440|NCT01434069|small bowel
316441|NCT01434069|pancreas
316442|NCT01434069|gastric
316443|NCT01434069|esophageal
316444|NCT01434069|metastatic
316445|NCT01434069|unresectable
316446|NCT01434069|GI
316447|NCT01434069|combination therapy
316448|NCT01434069|dose escalation
316449|NCT01434069|solid tumor
316450|NCT01434056|Liver disease
316451|NCT01434056|Hepatic encephalopathy
316452|NCT01434056|MELD
316453|NCT01434056|Liver transplantation
316454|NCT01434043|Cardiac CT perfusion
316455|NCT01434043|Positron emission tomography perfusion
316456|NCT01434043|Quantitative perfusion
316457|NCT01434017|PONV
316458|NCT01434017|Dexamethasone
316459|NCT01434017|Droperidol
316460|NCT01434017|Ondansetron
316461|NCT01434017|Tonsillectomy
316462|NCT01434004|prostate cancer
316463|NCT01433965|Bone marrow transplantation
316464|NCT01433965|Maintenance lenalidomide
316465|NCT01433939|colonoscopy
316466|NCT01433939|position changes
316467|NCT01433939|patient comfort
316468|NCT01433926|Breast cancer.
316469|NCT01433926|Trastuzumab.
316470|NCT01433926|Complete remission.
316471|NCT01433900|glaucoma
316472|NCT01433900|intraocular pressure
316473|NCT01433900|ocular surface
316474|NCT01433900|benzalkonium chloride
316475|NCT01433887|Peginterferon alfa-2a
316476|NCT01433887|ribavirin
316477|NCT01433874|Shoulder pain
316478|NCT01433874|Upper abdominal pain
316479|NCT01433874|Laparoscopic surgery
316480|NCT01433874|Abdominal fullness
316481|NCT01433861|gastric cancer
316482|NCT01433861|proximal gastrectomy
316483|NCT01433861|total gastrectomy
316484|NCT01433861|laparoscopy
316485|NCT01433861|reflux esophagitis
316486|NCT01433861|double tract reconstruction
316487|NCT01433835|Cytomegalovirus
316488|NCT01433835|Antiviral
316489|NCT01433835|Safety
316490|NCT01433835|Healthy
316491|NCT01433809|thyroid cancer
316492|NCT01433809|thyroid neoplasm
316493|NCT01433809|thyroid adenoma
316494|NCT01433796|antiretroviral therapy
316495|NCT01433796|tuberculosis
316496|NCT01433796|health centres
316497|NCT01433796|Ethiopia
316498|NCT01433757|dystonia
316499|NCT01433757|DYT-1
316500|NCT01433757|AMPICILLIN
316501|NCT01433744|C-Reactive protein
316502|NCT01433744|risk
316503|NCT01433731|CTCL
316504|NCT01433731|Cutaneous T-Cell Lymphoma
316505|NCT01433718|Effectivness
316506|NCT01433718|Neuromuscular Training
316507|NCT01433718|Resistance Training
316508|NCT01433718|Modification
316509|NCT01433718|Anterior Cruciate Ligament Risk Factors
316510|NCT01433718|Drop-Jump
316511|NCT01433718|Knee Separation
316512|NCT01433718|Resistance training program
316513|NCT01433705|heart
316514|NCT01433705|perfusion
316515|NCT01433705|glucose
316516|NCT01433692|Addictions
316517|NCT01433692|Adolescents
316518|NCT01433692|Primary Health Care
316519|NCT01433692|Brief Intervention
316520|NCT01433679|Health Behavior
316521|NCT01433679|Exercise
316522|NCT01433679|Adolescent Behavior
316523|NCT01433679|Motivation
316524|NCT01433679|Biological Markers
316525|NCT01433653|Comorbid
316526|NCT01433653|Complicated
316527|NCT01433640|image on multi-modalities
316528|NCT01433640|visualize cancer lesions
316529|NCT01433640|highly suspicious lesions
316530|NCT01433627|acute coronary syndromes
316531|NCT01433627|myocardial infarction
316532|NCT01433627|access site
316533|NCT01433627|bivalirudin
316534|NCT01433627|bleedings
316535|NCT01433601|Adherence
316536|NCT01433601|Peer support
316537|NCT01433601|Treatment failure
316538|NCT01433588|Managing infant pain
316539|NCT01433588|27 - 36+6 weeks gestation
316540|NCT01433588|Preterm infants
316541|NCT01433562|breast cancer
316542|NCT01433562|neoadjuvant therapy
316543|NCT01433562|Stage II/III
316544|NCT01433536|cranial trauma with or without high velocity fracture to inferior limb
316545|NCT01433536|spinal trauma with or without high velocity fracture to inferior limb
316546|NCT01433536|high velocity fracture to inferior limb
316547|NCT01433523|HDM
316548|NCT01433523|AIT
316549|NCT01433523|asthma
316550|NCT01433523|asthma exacerbation
316551|NCT01433523|House dust mite induced asthma
316552|NCT01433510|Allergic
316553|NCT01433510|Rhinoconjunctivitis
316554|NCT01433510|Immunotherapy
316555|NCT01433497|multiple sclerosis
316556|NCT01433497|primary progressive
316557|NCT01433497|relapse-free
316558|NCT01433497|secondary progressive
316559|NCT01433484|cardiovascular disease
316560|NCT01433484|coronary heart disease
316561|NCT01433484|obesity
316562|NCT01433484|weight loss
316563|NCT01433484|genomics
316564|NCT01433471|Ulcerative Colitis
316565|NCT01433471|Trichuris Suis Ova
316566|NCT01433471|Inflammatory Bowel Disease
316567|NCT01433471|Mucus
316568|NCT01433458|Hepatic impairment
316569|NCT01433458|healthy volunteers
316570|NCT01433458|RLX030
316571|NCT01433458|pharmacokinetics
316572|NCT01433445|Myelofibrosis
316573|NCT01433445|Panobinostat
316574|NCT01433445|Ruxolitinib
316575|NCT01433445|MF
316576|NCT01433445|PMF
316577|NCT01433445|PPV
316578|NCT01433445|PPV-MF
316579|NCT01433445|PET
316580|NCT01433445|PET-MF
316581|NCT01433445|JAK2
316582|NCT01433445|DACi
316583|NCT01433432|Crohn's Disease
316584|NCT01433419|Drug Therapy
316585|NCT01433406|Drug Therapy
316586|NCT01433393|Drug Therapy
316587|NCT01433380|Phase 1
316588|NCT01433380|Single Doses
316589|NCT01433380|Pharmacodynamics
316590|NCT01433380|Healthy Volunteers
316591|NCT01433367|total disc replacement
316592|NCT01433367|cervical disc disease
316593|NCT01433354|Fragile X Syndrome
316594|NCT01433354|Martin-Bell Syndrome
316595|NCT01433354|Genetic Diseases
316596|NCT01433354|X-Linked
316597|NCT01433354|Escalante's syndrome
316598|NCT01433341|Normal young athletes
316599|NCT01433328|Remodulin
316600|NCT01433328|Treprostinil
316601|NCT01433315|sleep deprivation
316602|NCT01433315|sleep restriction
316603|NCT01433302|Breast cancer
316604|NCT01433302|Genitourinary cancer
316605|NCT01433302|Gynecological cancer
316606|NCT01433302|Malignant Female Reproductive System Neoplasm
316607|NCT01433302|Melanoma
316608|NCT01433302|Sarcoma
316609|NCT01433302|Inflammatory Response
316610|NCT01433302|Inflammatory proteins
316611|NCT01433302|Tissue Fibrosis
316612|NCT01433302|Lymphatico-venous Bypass Surgery
316613|NCT01433302|Punch biopsy
316614|NCT01433302|Lab collections
316615|NCT01433302|Th2 immune phenotype
316616|NCT01433302|Lymphedema
316617|NCT01433289|HIV
316618|NCT01433289|safety
316619|NCT01433289|toxicity
316620|NCT01433289|pharmacokinetics
316621|NCT01433289|Polyphenon E
316622|NCT01433289|EGCG
316623|NCT01433289|green tea
316624|NCT01433289|CD4
316625|NCT01433289|viral load
316626|NCT01433276|Fluid resuscitation
316627|NCT01433276|hemorrhagic shock
316628|NCT01433276|Totilac
316629|NCT01433276|Ringer's
316630|NCT01433276|trauma
316631|NCT01433263|Wasting syndrome
316632|NCT01433263|emaciation
316633|NCT01433263|lung cancer
316634|NCT01433263|adenocarcinoma
316635|NCT01433263|pancreatic cancer
316636|NCT01433250|Multiple Sclerosis,
316637|NCT01433250|demyelinating autoimmune diseases,
316638|NCT01433250|interleukin-17,
316639|NCT01433250|monoclonal human antibody
316640|NCT01433237|embryonal childhood rhabdomyosarcoma
316641|NCT01433237|adult rhabdomyosarcoma
316642|NCT01433237|alveolar childhood rhabdomyosarcoma
316643|NCT01433237|adult soft tissue sarcoma
316644|NCT01433237|childhood rhabdomyosarcoma
316645|NCT01433224|recurrent childhood malignant germ cell tumor
316646|NCT01433224|recurrent extragonadal germ cell tumor
316647|NCT01433224|recurrent malignant testicular germ cell tumor
316648|NCT01433224|recurrent ovarian germ cell tumor
316649|NCT01433185|PMTCT
316650|NCT01433185|SMS
316651|NCT01433185|HIV Infections
316652|NCT01433185|Acquired Immunodeficiency Syndrome
316653|NCT01433185|Prevention & Control
316654|NCT01433185|Patient Compliance
316655|NCT01433185|Cellular Phone
316656|NCT01433185|Randomized Controlled Trial
316657|NCT01433172|stage IV
316658|NCT01433172|adenocarcinoma
316659|NCT01433172|vaccine therapy
316660|NCT01433172|immunology
316661|NCT01433172|tumor vaccine
316662|NCT01433172|colony stimulating factor(CSF)
316663|NCT01433172|granulocyte-macrophage colony-stimulating factor (GM-CSF)
316664|NCT01433172|CC chemokine ligand 21 (CCL21)
316665|NCT01433172|Chemokine [C-C motif] ligand 21 (CCL21)
316666|NCT01433172|human leukocyte antigen serotype (HLA)
316667|NCT01433159|Pressure Ulcers
316668|NCT01433159|Spinal Cord Injury
316669|NCT01433159|Healthpoint
316670|NCT01433159|Xenaderm
316671|NCT01433159|011-101
316672|NCT01433146|Temperament
316673|NCT01433146|Anxiety
316674|NCT01433146|Depression
316675|NCT01433146|Colorectal Cancer
316676|NCT01433120|Obesity
316677|NCT01433120|Insulin resistance
316678|NCT01433120|Microbiota
316679|NCT01433120|Probiotic
316680|NCT01433120|Prebiotic
316681|NCT01433107|Tinea pedis
316682|NCT01433107|Terbinafine film forming solution
316683|NCT01433094|Adherence
316684|NCT01433094|Psychoeducation
316685|NCT01433094|Pharmacotherapy
316686|NCT01433094|Schizophrenia
316687|NCT01433094|Family support
316688|NCT01433068|Adult Soft Tissue Sarcoma of the extremities and Trunk wall
316689|NCT01433055|Schizophrenia
316690|NCT01433055|Cognitive Symptoms
316691|NCT01433055|Clozapine
316692|NCT01433042|small bowel disease
316693|NCT01433029|Surgical Procedure
316694|NCT01433029|Assessment
316695|NCT01433029|Cardiothoracic Surgery
316696|NCT01433029|Coronary artery bypass
316697|NCT01433029|CAB
316698|NCT01433029|Video recordings
316699|NCT01433029|Global rating scale
316700|NCT01433029|GRS
316701|NCT01433029|Cardiothoracic surgeon
316702|NCT01433029|Surgical trainees
316703|NCT01433016|HCC Hepatocellular carcinoma
316704|NCT01433016|OBT Octanoate Breath Test
316705|NCT01433003|Thrombotic thrombocytopenia purpura
316706|NCT01433003|hemolytic uremic syndrome
316707|NCT01433003|plasma exchange
316708|NCT01433003|Improve treatment response
316709|NCT01433003|TTP/HUS
316710|NCT01432990|SCI
316711|NCT01432990|gait
316712|NCT01432990|rehabilitation
316713|NCT01432990|robotic
316714|NCT01432964|Orbital Fractures
316715|NCT01432964|Fracture Fixation
316716|NCT01432964|Blow-out Fractures
316717|NCT01432964|Surgical Mesh
316718|NCT01432964|Titanium
316719|NCT01432964|Computer-assisted Image Processing
316720|NCT01432925|Buruli ulcer
316721|NCT01432925|Mycobacterium ulcerans
316722|NCT01432925|Streptomycin
316723|NCT01432925|Rifampicin
316724|NCT01432925|Functional limitations
316725|NCT01432925|surgery
316726|NCT01432925|Bénin
316727|NCT01432899|Neurophysiology
316728|NCT01432899|Hemidystonia
316729|NCT01432899|Childhood-onset
316730|NCT01432899|Motion Analysis
316731|NCT01432899|Neuroimaging
316732|NCT01432899|Childhood Onset Hemidystonia
316733|NCT01432899|Healthy Volunteer
316734|NCT01432899|HV
316735|NCT01432886|Breast Cancer
316736|NCT01432873|BMT
316737|NCT01432873|HSCT
316738|NCT01432860|Skin Self Examination
316739|NCT01432847|Best Disease
316740|NCT01432847|Late-Onset Retinal Degeneration (L-ORD)
316741|NCT01432847|Age-Related Macular Degeneration (AMD)
316742|NCT01432847|Induced Pluripotent Stem Cell (iPS) Cell Lines
316743|NCT01432847|Retinal Degeneration
316744|NCT01432847|Age-Related Macular Degeneration
316745|NCT01432847|AMD
316746|NCT01432834|non-anterior astigmatism correction
316747|NCT01432834|Allegretto Wave excimer laser
316748|NCT01432834|wavefront optimized ablation profile (WFO)
316749|NCT01432834|LASIK
316750|NCT01432834|PRK
316751|NCT01432821|Epilepsy,
316752|NCT01432821|dopamine
316753|NCT01432821|yawning,
316754|NCT01432821|blinking eyelids,
316755|NCT01432821|electroencephalography
316756|NCT01432795|chronic venous insufficiency
316757|NCT01432795|post-thrombotic syndrome
316758|NCT01432795|medical compression therapy
316759|NCT01432795|compression stocking
316760|NCT01432795|gliding aid
316761|NCT01432795|stocking butler
316762|NCT01432795|adherence to treatment
316763|NCT01432782|Weight loss
316764|NCT01432782|Dysphagia
316765|NCT01432782|Esophageal hypermotility
316766|NCT01432782|Chest Pain
316767|NCT01432769|enteral nutrition
316768|NCT01432769|malnutrition
316769|NCT01432769|cardiac surgery
316770|NCT01432756|HIV
316771|NCT01432743|3D mapping
316772|NCT01432743|Image integration
316773|NCT01432743|Atrial fibrillation
316774|NCT01432743|Catheter Ablation
316775|NCT01432704|MS
316776|NCT01432704|vitamin D
316777|NCT01432704|environment
316778|NCT01432691|Hip-fracture
316779|NCT01432691|RSA
316780|NCT01432678|vitamin D
316781|NCT01432678|asthma
316782|NCT01432665|HSDD
316783|NCT01432639|Myocardial infarction
316784|NCT01432639|Autonomic function
316785|NCT01432639|Arterial Stiffness
316786|NCT01432639|Endothelial function
316787|NCT01432639|Inflammation
316788|NCT01432639|Rehabilitation program
316789|NCT01432639|Exercise
316790|NCT01432626|stress induced cardiomyopathy
316791|NCT01432626|broken heart syndrome
316792|NCT01432626|Takotsubo cardiomyopathy
316793|NCT01432626|transient apical ballooning syndrome
316794|NCT01432626|apical ballooning cardiomyopathy
316795|NCT01432626|stress cardiomyopathy
316796|NCT01432626|non-ischemic cardiomyopathy
316797|NCT01432613|Myositis
316798|NCT01432613|Magnetic Resonance Imaging
316799|NCT01432613|Muscle biopsy
316800|NCT01432613|Sensitivity and Specificity
316801|NCT01432600|Multiple Myeloma
316802|NCT01432600|Relapsed
316803|NCT01432600|Refractory
316804|NCT01432600|Corticosteroids
316805|NCT01432587|Amyloidosis
316806|NCT01432587|Transthyretin
316807|NCT01432587|Neuropathies
316808|NCT01432587|Diflunisal
316809|NCT01432587|Familial
316810|NCT01432574|HPV
316811|NCT01432561|Lysosomal Storage Diseases
316812|NCT01432561|Metabolic Diseases
316813|NCT01432561|Metabolism, Inborn Errors
316814|NCT01432548|Ischemic
316815|NCT01432548|preconditioning
316816|NCT01432548|liver
316817|NCT01432548|resection
316818|NCT01432522|Intranasal epinephrine
316819|NCT01432522|Plasma epinephrine level
316820|NCT01432509|Pre-diabetes
316821|NCT01432509|Type 2 diabetes
316822|NCT01432509|Biomarkers
316823|NCT01432509|Cohort
316824|NCT01432509|Diabetes Risk Score
316825|NCT01432509|Diabetes Mellitus, Type 2
316826|NCT01432509|Glucose Intolerance
316827|NCT01432509|Prediabetic State
316828|NCT01432509|Glucose Metabolism Disorders
316829|NCT01432509|Metabolic Diseases
316830|NCT01432509|Endocrine System Diseases
316831|NCT01432509|Hyperglycemia
316832|NCT01432496|Laparoscopic
316833|NCT01432496|Colectomy
316834|NCT01432496|Nebulization
316835|NCT01432496|Ropivacaine
316836|NCT01432483|Cancer
316837|NCT01432483|ONTAK
316838|NCT01432483|Denileukin diftitox
316839|NCT01432483|persistent or recurrent disease
316840|NCT01432483|requiring continued delivery of essential cancer therapy
316841|NCT01432470|vaginal atrophy
316842|NCT01432444|Schizophrenia
316843|NCT01432418|rehabilitation
316844|NCT01432418|wheelchairs
316845|NCT01432418|safety
316846|NCT01432418|disability evaluation
316847|NCT01432418|motor skills
316848|NCT01432405|Diabetes
316849|NCT01432392|gastroesophageal reflux disease
316850|NCT01432392|GERD questionnaire
316851|NCT01432392|primary care setting
316852|NCT01432340|Influenza
316853|NCT01432340|Influenza vaccine
316854|NCT01432340|Influenza vaccine effectiveness study
316855|NCT01432327|motor activity
316856|NCT01432327|randomized controlled trial
316857|NCT01432327|feedback
316858|NCT01432314|patient's survival
316859|NCT01432314|tumor response
316860|NCT01432314|safety
316861|NCT01432301|fluorouracil overdose
316862|NCT01432301|fluorouracil toxicity
316863|NCT01432301|capecitabine overdose
316864|NCT01432301|capecitabine toxicity
316865|NCT01432275|Diabetes
316866|NCT01432275|SMBG
316867|NCT01432275|Insulin calculator
316868|NCT01432262|prevention of pneumococcal diseases
316869|NCT01432249|pediatric psoriasis
316870|NCT01432249|enbrel
316871|NCT01432249|safety
316872|NCT01432249|efficacy
316873|NCT01432236|Pregabalin
316874|NCT01432236|Lyrica
316875|NCT01432236|depression
316876|NCT01432223|Trastuzumab
316877|NCT01432223|Neoadjuvant chemotherapy
316878|NCT01432223|Primary chemotherapy
316879|NCT01432210|post-prandial absorption
316880|NCT01432210|provitamin A carotenoids
316881|NCT01432210|vitamin A
316882|NCT01432210|avocado
316883|NCT01432210|tomato
316884|NCT01432210|carrot
316885|NCT01432197|HRQOL
316886|NCT01432197|Occupational therapy
316887|NCT01432197|ADL intervention
316888|NCT01432197|Cancer patients
316889|NCT01432184|cerebral
316890|NCT01432184|hypoxia
316891|NCT01432171|Brain cancer
316892|NCT01432171|Central nervous system
316893|NCT01432171|Seizure prophylaxis
316894|NCT01432171|High-Grade Gliomas
316895|NCT01432171|HGG
316896|NCT01432171|Supratentorial high-grade glioma
316897|NCT01432171|Malignant glioma
316898|NCT01432171|Lacosamide
316899|NCT01432171|Vimpat
316900|NCT01432171|Placebo
316901|NCT01432171|Sugar pill
316902|NCT01432158|Invasive pneumococcal disease
316903|NCT01432145|BRCA defective
316904|NCT01432132|Head and Neck Cancer
316905|NCT01432132|Body Image Adaptation
316906|NCT01432132|Post surgical body image
316907|NCT01432132|Audio-recorded interview
316908|NCT01432132|Questionnaire
316909|NCT01432132|Survey
316910|NCT01432119|Advanced Cancers
316911|NCT01432119|Advanced Malignancies
316912|NCT01432119|Liver Metastases
316913|NCT01432119|SIR-Spheres
316914|NCT01432119|Selective internal radiation
316915|NCT01432119|Yttrium-90
316916|NCT01432119|Cetuximab
316917|NCT01432119|C225
316918|NCT01432119|Erbitux
316919|NCT01432119|Erlotinib
316920|NCT01432119|Erlotinib Hydrochloride
316921|NCT01432119|Tarceva
316922|NCT01432119|OSI-774
316923|NCT01432106|Hypertension
316924|NCT01432106|Metabolic Syndrome
316925|NCT01432106|African American
316926|NCT01432093|liver transplant
316927|NCT01432093|high blood sugars
316928|NCT01432093|hospital hyperglycemia
316929|NCT01432093|post-transplant hyperglycemia
316930|NCT01432093|post liver transplant
316931|NCT01432093|post liver-kidney transplant
316932|NCT01432080|Pulmonary disease, chronic obstructive
316933|NCT01432080|Viral respiratory tract infections
316934|NCT01432080|Respiratory syncytial viruses
316935|NCT01432080|Influenza virus A
316936|NCT01432080|Influenza virus B
316937|NCT01432080|Transplantation, Allogeneic
316938|NCT01432067|cancer
316939|NCT01432067|geriatry
316940|NCT01432067|curative care
316941|NCT01432067|physical activity
316942|NCT01432054|Human Tissue Repository
316943|NCT01432041|Injury prevention
316944|NCT01432041|smoke alarms
316945|NCT01432041|car seats
316946|NCT01432015|aprepitant
316947|NCT01432015|fosaprepitant
316948|NCT01432015|gynecologic cancer
316949|NCT01432015|emesis
316950|NCT01432002|breast carcinoma
316951|NCT01432002|FDG
316952|NCT01432002|PET/CT
316953|NCT01432002|PET/IRM
316954|NCT01431950|fluticasone furoate
316955|NCT01431937|Pharmacodynamics
316956|NCT01431937|Pharmacokinetics
316957|NCT01431924|outcomes
316958|NCT01431924|observational
316959|NCT01431924|retrospective
316960|NCT01431924|database
316961|NCT01431924|asthma
316962|NCT01431898|HCV RNA
316963|NCT01431898|Polymerase inhibitor
316964|NCT01431898|Treatment naïve and Treatment experienced
316965|NCT01431898|GS-9669
316966|NCT01431898|Hepatitis C
316967|NCT01431898|HCV
316968|NCT01431885|fibronectin
316969|NCT01431885|cervical length
316970|NCT01431872|Aromatase Inhibitors
316971|NCT01431859|pollen
316972|NCT01431859|allergy
316973|NCT01431859|food
316974|NCT01431859|immunotherapy
316975|NCT01431833|Hepatic Impairment
316976|NCT01431833|Matched control subjects
316977|NCT01431820|Onychomycosis
316978|NCT01431820|Toenail Fungus
316979|NCT01431820|luliconazole
316980|NCT01431820|Antifungal
316981|NCT01431820|Topical
316982|NCT01431794|Pancreatic ductal adenocarcinoma (PDA)Neoplasms
316983|NCT01431794|LDE225
316984|NCT01431794|nab-paclitaxel
316985|NCT01431794|abraxane
316986|NCT01431794|gemcitabine
316987|NCT01431794|neoadjuvant
316988|NCT01431794|cytotoxic
316989|NCT01431794|hedgehog (Hh) inhibitors
316990|NCT01431794|stromal cells
316991|NCT01431794|resectable PDA
316992|NCT01431794|Pancreatic Diseases
316993|NCT01431794|Carcinoma
316994|NCT01431768|Influenza
316995|NCT01431768|Human
316996|NCT01431768|Orthomyxoviridae infections
316997|NCT01431768|RNA Virus Infections
316998|NCT01431768|Virus Diseases
316999|NCT01431768|Respiratory Tract infections
317000|NCT01431768|Respiratory Tract Diseases
317001|NCT01431742|buccal soluble film
317002|NCT01431742|Pain
317003|NCT01431742|Back Pain
317004|NCT01431742|Low Back Pain
317005|NCT01431742|Buprenorphine
317006|NCT01431742|Analgesics, Opioid
317007|NCT01431742|Analgesics
317008|NCT01431703|narrow band imaging
317009|NCT01431703|learning curve
317010|NCT01431703|colorectal
317011|NCT01431703|differential diagnosis
317012|NCT01431703|with colorectal lesion
317013|NCT01431703|NBI with magnification
317014|NCT01431690|Eicosapentaenoic Acid
317015|NCT01431690|Docosahexaenoic Acid
317016|NCT01431690|Warfarin
317017|NCT01431690|Hypertriglyceridemia
317018|NCT01431690|Omega-3 free fatty acids
317019|NCT01431690|Omega-3 ethyl ester acids
317020|NCT01431690|Epanova
317021|NCT01431690|Lovaza
317022|NCT01431690|pharmacokinetics
317023|NCT01431690|low-fat meal
317024|NCT01431677|Muscle
317025|NCT01431677|Biopsy
317026|NCT01431677|Energetics
317027|NCT01431677|Sarcopenia
317028|NCT01431677|Frailty
317029|NCT01431664|recurrent childhood acute lymphoblastic leukemia
317030|NCT01431664|recurrent childhood acute myeloid leukemia
317031|NCT01431664|acute leukemias of ambiguous lineage
317032|NCT01431664|acute undifferentiated leukemia
317033|NCT01431664|secondary acute myeloid leukemia
317034|NCT01431651|Food and beverages
317035|NCT01431651|Food
317036|NCT01431651|Dietary supplements
317037|NCT01431638|Gout
317038|NCT01431638|arthritis
317039|NCT01431638|gout flare
317040|NCT01431638|acute gout
317041|NCT01431638|gouty
317042|NCT01431638|rheumatic disease
317043|NCT01431638|uric acid
317044|NCT01431638|podagra
317045|NCT01431625|COPD
317046|NCT01431625|Exercise Training
317047|NCT01431612|Pharmacokinetics, kidney;
317048|NCT01431612|Receptors, adrenergic;
317049|NCT01431612|Fluids, i.v.;
317050|NCT01431612|Sympathetic nervous system, esmolol;
317051|NCT01431612|Sympathetic nervous system, phenylephrine
317052|NCT01431599|Locally advanced rectal cancer
317053|NCT01431586|JDTic
317054|NCT01431586|cocaine dependence
317055|NCT01431586|kappa-opioid antagonist
317056|NCT01431573|Depression
317057|NCT01431560|ankle
317058|NCT01431560|metallic
317059|NCT01431560|biodegradable
317060|NCT01431560|Freedom
317061|NCT01431508|Hypertension
317062|NCT01431495|platelet agregation
317063|NCT01431495|clopidogrel
317064|NCT01431495|major adverse cardiac events (MACE)
317065|NCT01431482|skin symptoms
317066|NCT01431456|Prevention
317067|NCT01431456|venous thromboembolism after knee arthroplasty
317068|NCT01431443|Randomized double blind trial
317069|NCT01431443|Cocoa flavonoids
317070|NCT01431443|Endothelial function
317071|NCT01431443|Blood pressure
317072|NCT01431443|Pregnant women
317073|NCT01431443|Preeclampsia
317074|NCT01431443|Uterine artery flow
317075|NCT01431443|Pulsatility index
317076|NCT01431430|Vitamine D
317077|NCT01431430|renal transplantation
317078|NCT01431430|diabetes mellitus
317079|NCT01431430|cancer
317080|NCT01431430|cardiovascular complications
317081|NCT01431417|Shoulder
317082|NCT01431417|Outcome treatment
317083|NCT01431417|Validation Studies as topic
317084|NCT01431417|Biomechanics
317085|NCT01431417|Shoulder, Joint Instability
317086|NCT01431391|immune therapy
317087|NCT01431391|cancer vaccine
317088|NCT01431391|therapeutic vaccine
317089|NCT01431391|therapeutic cancer vaccine
317090|NCT01431391|vaccine
317091|NCT01431391|dendritic cells
317092|NCT01431391|PSA
317093|NCT01431391|androgen deprivation therapy
317094|NCT01431391|Prostatic Neoplasms
317095|NCT01431391|Genital Neoplasms, Male
317096|NCT01431391|Urogenital Neoplasms
317097|NCT01431391|Neoplasms
317098|NCT01431391|Prostatic Diseases
317099|NCT01431391|Androgens
317100|NCT01431391|Hormones
317101|NCT01431391|Adenocarcinoma
317102|NCT01431391|Carcinoma
317103|NCT01431391|Neoplasms, Glandular and Epithelial
317104|NCT01431391|immunology
317105|NCT01431391|hormone therapy
317106|NCT01431391|immunotherapy
317107|NCT01431391|LHRH
317108|NCT01431378|CT scan
317109|NCT01431378|CNS
317110|NCT01431378|Thorax
317111|NCT01431378|Abdomen
317112|NCT01431378|staging of a known or suspected lung cancer
317113|NCT01431378|suspected urolithiasis
317114|NCT01431378|known or suspected focal liver lesion
317115|NCT01431365|exercise
317116|NCT01431365|topography
317117|NCT01431365|cravings
317118|NCT01431365|smoking behaviour
317119|NCT01431352|Polycystic ovary syndrome
317120|NCT01431352|Randomized controlled trial
317121|NCT01431352|Chinese herbal medicine
317122|NCT01431352|Chinese herbal medicine granules
317123|NCT01431352|Letrozole
317124|NCT01431352|Live birth
317125|NCT01431326|infection
317126|NCT01431326|hypertension
317127|NCT01431326|pain
317128|NCT01431326|opioid addiction
317129|NCT01431326|reflux
317130|NCT01431326|UTI
317131|NCT01431326|bronchitis
317132|NCT01431326|cyanide poisoning
317133|NCT01431326|cardiac arrest
317134|NCT01431326|hypotension
317135|NCT01431326|pneumonia
317136|NCT01431326|Rocky Mountain Spotted Fever
317137|NCT01431326|Q Fever
317138|NCT01431326|Anthrax
317139|NCT01431326|Cholera
317140|NCT01431326|Tularemia
317141|NCT01431326|Trachoma
317142|NCT01431326|Psittacosis
317143|NCT01431326|Plague
317144|NCT01431326|Brucellosis
317145|NCT01431326|Bartonellosis
317146|NCT01431326|hypercholesterolemia
317147|NCT01431326|Heterozygous Familial Hypercholesterolemia (HeFH)
317148|NCT01431326|Primary Prevention of Coronary Events
317149|NCT01431326|Acute pulmonary edema
317150|NCT01431326|edema
317151|NCT01431326|ADHD
317152|NCT01431326|sedation
317153|NCT01431326|anxiolysis
317154|NCT01431326|benzodiazepine withdrawal
317155|NCT01431326|bipolar disorder
317156|NCT01431326|autistic disorder
317157|NCT01431326|schizophrenia
317158|NCT01431326|influenza
317159|NCT01431326|heart failure
317160|NCT01431326|stable angina
317161|NCT01431326|fungal infections
317162|NCT01431326|Skin Infections
317163|NCT01431326|Prostatitis
317164|NCT01431326|Urinary Tract Infection
317165|NCT01431326|Pyelonephritis
317166|NCT01431326|Infantile hemangioma
317167|NCT01431326|nausea
317168|NCT01431326|vomiting
317169|NCT01431326|Bacterial septicemia
317170|NCT01431326|Cytomegalovirus retinitis
317171|NCT01431326|Herpes simplex virus
317172|NCT01431326|HSV
317173|NCT01431326|Adenovirus
317174|NCT01431326|Streptococci
317175|NCT01431326|Pneumococci
317176|NCT01431326|Staphylococci
317177|NCT01431326|Inflammation
317178|NCT01431326|Adrenal insufficiency
317179|NCT01431326|Anxiety
317180|NCT01431326|Convulsions
317181|NCT01431326|Muscle spasms
317182|NCT01431326|Seizures
317183|NCT01431326|Epilepsy
317184|NCT01431326|Typhus fever
317185|NCT01431326|Bronchospasm
317186|NCT01431326|Hypersensitivity reaction
317187|NCT01431326|Sinusitis
317188|NCT01431326|Meningitis
317189|NCT01431326|Sepsis
317190|NCT01431326|Gastroparesis
317191|NCT01431326|Angina
317192|NCT01431326|Prophylaxis
317193|NCT01431326|Hyperlipidemia
317194|NCT01431326|Migraines
317195|NCT01431326|Headache
317196|NCT01431313|pulmonary hypertension
317197|NCT01431300|central veins
317198|NCT01431300|thorax
317199|NCT01431300|superior vena cava
317200|NCT01431300|Central vein imaging
317201|NCT01431261|Chronic neck pain
317202|NCT01431261|Whiplash
317203|NCT01431261|Whiplash Associated Disorders
317204|NCT01431261|Chronic Pain
317205|NCT01431261|Neck exercises
317206|NCT01431261|Training
317207|NCT01431261|Pacing
317208|NCT01431261|Patient Education
317209|NCT01431261|Pain Management
317210|NCT01431261|Whiplash Injuries
317211|NCT01431261|Musculoskeletal
317212|NCT01431248|Preterm Premature Rupture of Membranes
317213|NCT01431248|Erythromycin
317214|NCT01431248|Azithromycin
317215|NCT01431235|ADHD
317216|NCT01431235|SUD
317217|NCT01431235|cognitive behavioral therapy
317218|NCT01431222|severe mitral regurgitation
317219|NCT01431222|interventional mitral valve reconstruction
317220|NCT01431222|inoperable
317221|NCT01431222|EuroSCORE
317222|NCT01431222|STS Risk Score
317223|NCT01431222|MitraClip
317224|NCT01431222|fluoroscopy
317225|NCT01431222|echocardiography
317226|NCT01431222|percutaneous treatment of mitral regurgitation
317227|NCT01431196|breast cancer
317228|NCT01431196|neoadjuvant chemotherapy
317229|NCT01431196|autologous dendritic cell vaccination
317230|NCT01431183|influenza
317231|NCT01431183|vaccine
317232|NCT01431183|reminder / recall
317233|NCT01431183|immunization registry
317234|NCT01431183|immunization information systems
317235|NCT01431157|Sleep Apnea Syndrome
317236|NCT01431157|Heart Failure
317237|NCT01431157|Oxygen Inhalation Therapy
317238|NCT01431144|soft tissue thickness
317239|NCT01431144|dental implant
317240|NCT01431144|soft tissue recession
317241|NCT01431144|implant exposure
317242|NCT01431131|graft placement
317243|NCT01431131|bone resorption
317244|NCT01431118|iron metabolism
317245|NCT01431118|hepcidin
317246|NCT01431118|dragon boating
317247|NCT01431118|sport-specific stress
317248|NCT01431118|iron
317249|NCT01431118|anaemia
317250|NCT01431118|sport
317251|NCT01431105|Kawasaki disease
317252|NCT01431079|HPV
317253|NCT01431079|College men
317254|NCT01431079|HPV vaccine
317255|NCT01431079|Health belief model
317256|NCT01431079|HPV vaccine acceptance
317257|NCT01431053|exemestane
317258|NCT01431053|aspirin
317259|NCT01431053|quality of life
317260|NCT01431040|Bowel Prep
317261|NCT01431040|No bowel prep
317262|NCT01431040|Vaginal reconstructive or obliterative surgery
317263|NCT01431027|Heart Failure
317264|NCT01431027|Diastolic Heart Failure
317265|NCT01431027|Heart Failure with Normal Ejection Fraction
317266|NCT01431014|orthognathic surgery
317267|NCT01431014|steroid
317268|NCT01431014|swelling
317269|NCT01431014|3-dimensional photogrammetry
317270|NCT01431001|Depression
317271|NCT01431001|MDD
317272|NCT01431001|Transcranial Magnetic Stimulation
317273|NCT01431001|Depressive Disorder
317274|NCT01431001|TMS
317275|NCT01430988|Head Injuries
317276|NCT01430988|Head Trauma
317277|NCT01430988|TBI (Traumatic Brain Injury)
317278|NCT01430988|Emergency Department
317279|NCT01430988|Accident & Emergency
317280|NCT01430975|Radiation Exposure
317281|NCT01430975|Rubidium 82
317282|NCT01430975|Strontium 82
317283|NCT01430975|Strontium 85
317284|NCT01430962|EBUS
317285|NCT01430962|mediastinal lymph nodes
317286|NCT01430962|mediastinal masses
317287|NCT01430962|anesthesia
317288|NCT01430962|moderate sedation
317289|NCT01430949|Paroxysmal Atrial Fibrillation
317290|NCT01430949|Catheter Ablation
317291|NCT01430949|Pulmonary Vein Isolation
317292|NCT01430949|Radio Frequency Ablation
317293|NCT01430936|Vascular Diseases
317294|NCT01430936|Hypertension
317295|NCT01430936|Chronic Kidney Disease
317296|NCT01430936|COPD
317297|NCT01430923|Refrigeration free latanoprost
317298|NCT01430910|Phase 1
317299|NCT01430910|open label
317300|NCT01430910|ceftazidime
317301|NCT01430910|pharmacokinetics
317302|NCT01430910|urinary tract infection
317303|NCT01430910|intra-abdominal infection
317304|NCT01430897|d-TGA
317305|NCT01430897|dextro Transposition of the great arteries
317306|NCT01430897|systemic right ventricle
317307|NCT01430897|right ventricular failure
317308|NCT01430897|Atrial switch procedure
317309|NCT01430884|coronary aspirate blood
317310|NCT01430884|particular debris / microemboli
317311|NCT01430884|distal occlusion device
317312|NCT01430858|Fracture
317313|NCT01430858|Anabolic
317314|NCT01430858|Vibration
317315|NCT01430858|Strain Gauge
317316|NCT01430858|Focus - Osteoporosis
317317|NCT01430845|GDD
317318|NCT01430845|CP
317319|NCT01430845|MR
317320|NCT01430845|PDD
317321|NCT01430845|ASD
317322|NCT01430845|BSID
317323|NCT01430832|PTSD
317324|NCT01430832|Preterm
317325|NCT01430832|Premature
317326|NCT01430832|VLBW
317327|NCT01430819|Influenza
317328|NCT01430819|Influenza Virus Vaccine
317329|NCT01430819|Fluzone® 2011-2012 Formulation
317330|NCT01430819|Fluzone® High-Dose 2011-2012 Formulation
317331|NCT01430819|Trivalent Inactivated Influenza Vaccine
317332|NCT01430780|Coronary artery disease
317333|NCT01430780|nitrate
317334|NCT01430780|endothelium
317335|NCT01430767|adherence
317336|NCT01430754|Blindness
317337|NCT01430754|Eye Diseases
317338|NCT01430754|Nap Disorders
317339|NCT01430754|Circadian Rhythm Disorders
317340|NCT01430754|Sleep Disorders
317341|NCT01430754|Circadian Rhythm Sleep Disorders
317342|NCT01430754|Dyssomnias
317343|NCT01430754|Nervous System Diseases
317344|NCT01430741|Implementation Science
317345|NCT01430741|Supportive Housing
317346|NCT01430741|Co-occurring disorders
317347|NCT01430741|Cluster randomized controlled trial
317348|NCT01430741|Hybrid implementation-effectiveness trial
317349|NCT01430715|active video game
317350|NCT01430715|video gaming
317351|NCT01430715|accelerometery
317352|NCT01430715|MVPA
317353|NCT01430715|outdoor play
317354|NCT01430715|children
317355|NCT01430715|unstructured
317356|NCT01430715|energy expenditure
317357|NCT01430689|Influenza
317358|NCT01430689|Pregnancy
317359|NCT01430689|Neonates
317360|NCT01430676|Incisional hernia
317361|NCT01430676|recurrence
317362|NCT01430676|longterm
317363|NCT01430663|aspergillosis
317364|NCT01430663|bronchoalveolar lavage
317365|NCT01430663|galactomannan
317366|NCT01430663|pcr
317367|NCT01430663|hematological patients
317368|NCT01430650|Oral estrogens
317369|NCT01430650|transdermal estrogens
317370|NCT01430650|endometrial priming
317371|NCT01430637|childhood desmoplastic small round cell tumor
317372|NCT01430637|metastatic childhood soft tissue sarcoma
317373|NCT01430637|nonmetastatic childhood soft tissue sarcoma
317374|NCT01430637|recurrent childhood soft tissue sarcoma
317375|NCT01430637|recurrent adult soft tissue sarcoma
317376|NCT01430637|stage I adult soft tissue sarcoma
317377|NCT01430637|stage II adult soft tissue sarcoma
317378|NCT01430637|stage III adult soft tissue sarcoma
317379|NCT01430637|stage IV adult soft tissue sarcoma
317380|NCT01430637|adult desmoplastic small round cell tumor
317381|NCT01430624|Rape
317382|NCT01430624|Secondary prevention
317383|NCT01430624|Intervention
317384|NCT01430611|Meningitis
317385|NCT01430611|Neisseria meningitidis
317386|NCT01430611|Meningo A+C®
317387|NCT01430611|Meng Ling Kang®
317388|NCT01430598|Full Thickness Rotator Cuff Tear and Acromial Spur
317389|NCT01430585|Ki-67
317390|NCT01430585|postmenopausal early breast cancer
317391|NCT01430585|ER positive/HER2 negative early breast cancer
317392|NCT01430572|Advanced Cancers
317393|NCT01430572|Solid Tumors
317394|NCT01430572|PI3KCA Mutation Positive/PTEN
317395|NCT01430572|Refractory to standard therapy
317396|NCT01430572|Relapsed after standard therapy
317397|NCT01430572|Pazopanib
317398|NCT01430572|GW786034
317399|NCT01430572|Everolimus
317400|NCT01430572|Afinitor
317401|NCT01430572|RAD001
317402|NCT01430559|Validation of the WOMAC in Chinese subjects with osteoarthritis of the knee
317403|NCT01430546|Relapsed and Refractory Multiple Myeloma
317404|NCT01430533|dermal sensitization potential
317405|NCT01430507|Anti-inflammatory drugs, DMARD
317406|NCT01430481|rosehip
317407|NCT01430481|osteoarthritis
317408|NCT01430481|pain
317409|NCT01430481|knee
317410|NCT01430481|RCT
317411|NCT01430468|Glenoid component position
317412|NCT01430468|patient specific instruments
317413|NCT01430455|Major Depressive Episode
317414|NCT01430455|Depression NOS
317415|NCT01430455|Bipolar Disorder
317416|NCT01430455|Bipolar Disorder I
317417|NCT01430455|Bipolar Disorder II
317418|NCT01430455|Bipolar Depression
317419|NCT01430455|Major Depression
317420|NCT01430416|Uveal melanoma
317421|NCT01430416|phase 1
317422|NCT01430416|AEB071
317423|NCT01430416|Metastatic
317424|NCT01430403|persistent allergic asthma
317425|NCT01430403|asthma exacerbations reduction
317426|NCT01430403|Xolair® (omalizumab)
317427|NCT01430403|Flovent® Diskus® (fluticasone)
317428|NCT01430403|placebo
317429|NCT01430403|inhaled corticosteroid therapy
317430|NCT01430403|anti-immunoglobulin E therapy
317431|NCT01430403|anti-IgE therapy
317432|NCT01430390|In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic
317433|NCT01430390|T-Lymphocytes (EBV-CTLs)
317434|NCT01430390|CD19 specific T-cells
317435|NCT01430390|11-038
317436|NCT01430377|periprocedural myonecrosis
317437|NCT01430377|procedure time
317438|NCT01430377|fluoroscopy time
317439|NCT01430364|coronary bifurcation stenosis
317440|NCT01430364|dedicated bifurcation stent
317441|NCT01430364|sirolymus
317442|NCT01430364|PTS
317443|NCT01430364|BiOSS Lym
317444|NCT01430351|Brain cancer
317445|NCT01430351|Central nervous system
317446|NCT01430351|Glioblastoma Multiforme
317447|NCT01430351|GBM
317448|NCT01430351|Post Radiation Therapy
317449|NCT01430351|Post-RT
317450|NCT01430351|External beam radiotherapy
317451|NCT01430351|XRT
317452|NCT01430351|Supratentorial glioblastoma
317453|NCT01430351|Gliosarcoma
317454|NCT01430351|Grade IV astrocytoma
317455|NCT01430351|Temozolomide
317456|NCT01430351|Temodar
317457|NCT01430351|Memantine
317458|NCT01430351|Namenda
317459|NCT01430351|Mefloquine
317460|NCT01430351|Apo-Mefloquine
317461|NCT01430351|Lariam
317462|NCT01430351|Metformin
317463|NCT01430325|Hyperbaric oxygen
317464|NCT01430312|dermal irritative potential
317465|NCT01430286|Caregivers
317466|NCT01430286|Alzheimer Disease
317467|NCT01430286|Psychological stress
317468|NCT01430286|Psychological adaptation
317469|NCT01430286|Self-efficacy
317470|NCT01430286|Randomized controlled trial
317471|NCT01430273|Antiplatelet therapy
317472|NCT01430273|Surgery
317473|NCT01430273|Bleeding
317474|NCT01430273|Platelet aggregation
317475|NCT01430260|efficacy
317476|NCT01430260|ciclesonide
317477|NCT01430260|levocetirizine
317478|NCT01430260|allergic rhinitis
317479|NCT01430247|amblyopia
317480|NCT01430247|amblyogenic factors
317481|NCT01430247|screening
317482|NCT01430247|preschool children
317483|NCT01430247|visual acuity
317484|NCT01430247|prevalence
317485|NCT01430234|Chronic pancreatitis
317486|NCT01430234|Exocrine insufficiency
317487|NCT01430234|Pancreatic enzyme replacement therapy
317488|NCT01430234|Self-administration
317489|NCT01430221|prediabetes
317490|NCT01430221|severity of depressive symptoms
317491|NCT01430221|mindfulness
317492|NCT01430221|personalized health planning
317493|NCT01430221|cardiometabolic diseases prevention
317494|NCT01430208|endometrial pathology
317495|NCT01430195|vitiligo
317496|NCT01430195|depigmentation
317497|NCT01430195|phototherapy
317498|NCT01430195|non-segmental vitiligo
317499|NCT01430182|Adult
317500|NCT01430182|Female
317501|NCT01430182|Humans
317502|NCT01430182|Intraoperative Care/methods
317503|NCT01430182|Male
317504|NCT01430182|Methadone/administration & dosage
317505|NCT01430182|Analgesics/therapeutic use
317506|NCT01430182|Methadone/therapeutic use
317507|NCT01430182|Morphine/therapeutic use
317508|NCT01430182|Middle Aged
317509|NCT01430182|Pain Measurement/drug effects
317510|NCT01430182|Pain Measurement/methods
317511|NCT01430182|Pain, Postoperative/prevention & control
317512|NCT01430182|Prospective Studies
317513|NCT01430182|Double-Blind Method
317514|NCT01430182|Tibial Fractures/surgery
317515|NCT01430182|Young Adult
317516|NCT01430182|Orthopedics
317517|NCT01430169|Xiaflex
317518|NCT01430169|Xiapex
317519|NCT01430169|Collagenase clostridium histolyticum
317520|NCT01430156|Renal Transplantation
317521|NCT01430156|Ischemia-reperfusion injury
317522|NCT01430156|Heme-oxygenase 1
317523|NCT01430156|Heme arginate
317524|NCT01430143|Exercise
317525|NCT01430130|scar
317526|NCT01430130|incision
317527|NCT01430130|wound healing
317528|NCT01430130|scarring
317529|NCT01430130|scar revision
317530|NCT01430117|Immunotherapy
317531|NCT01430117|Skin prick test
317532|NCT01430117|Standardization
317533|NCT01430117|Poa pratensis
317534|NCT01430078|ASP015K
317535|NCT01430078|Healthy subjects
317536|NCT01430078|Pharmacokinetics of ASP015K
317537|NCT01430065|transplant
317538|NCT01430065|ASP015K
317539|NCT01430065|tacrolimus
317540|NCT01430065|Prograf
317541|NCT01430065|healthy volunteers
317542|NCT01430039|Crohn's disease
317543|NCT01430039|ulcerative colitis
317544|NCT01430039|Syndecan-1
317545|NCT01430026|chronic sinusitis
317546|NCT01430026|gentamicin nasal irrigation
317547|NCT01429987|Chronic Idiopathic Constipation
317548|NCT01429987|Constipation
317549|NCT01429987|Sign and Symptoms: Digestive
317550|NCT01429974|amniotic fluid
317551|NCT01429974|post term pregnancies
317552|NCT01429948|Stroke, Ischemic
317553|NCT01429948|Patent foramen ovale
317554|NCT01429948|Magnetic resonance imaging
317555|NCT01429948|Paradoxical embolism
317556|NCT01429948|Transcranial Doppler
317557|NCT01429948|Silent cerebral infarct
317558|NCT01429935|dental pain model
317559|NCT01429935|Ginger powder
317560|NCT01429935|CRP
317561|NCT01429909|Functional magnetic resonance imaging
317562|NCT01429909|T2*
317563|NCT01429909|cortex and basal ganglia
317564|NCT01429909|Parkinson's disease
317565|NCT01429896|peanut allergy
317566|NCT01429896|food allergy
317567|NCT01429896|thresholds
317568|NCT01429896|anaphylaxis
317569|NCT01429896|food labelling
317570|NCT01429896|food challenges
317571|NCT01429896|peanut challenges
317694|NCT01429363|RCT
317572|NCT01429857|Troponin concentration in heart failure
317573|NCT01429844|Calcineurin inhibitors
317574|NCT01429844|Bronchiolitis obliterans
317575|NCT01429844|Lung transplantation
317576|NCT01429844|Cyclosporine
317577|NCT01429844|Tacrolimus
317578|NCT01429844|Mycophenolate
317579|NCT01429844|Steroids
317580|NCT01429844|Chronic rejection
317581|NCT01429844|Acute rejection
317582|NCT01429844|Obliterative bronchiolitis
317583|NCT01429818|Endothelial dysfunction
317584|NCT01429818|Diabetes mellitus
317585|NCT01429818|glimepiride
317586|NCT01429818|metformin
317587|NCT01429805|Hip arthroscopy
317588|NCT01429779|General surgery
317589|NCT01429766|Breath holding times
317590|NCT01429766|Phases of respiration
317591|NCT01429766|Radiotherapy
317592|NCT01429753|Cardiac resychronisation therapy
317593|NCT01429753|Heart failure
317594|NCT01429753|Imaging guided LV lead placement
317595|NCT01429740|PF 05180999
317596|NCT01429740|safety
317597|NCT01429740|pharmacokinetics
317598|NCT01429727|Spontaneous coronary artery dissection
317599|NCT01429727|SCAD
317600|NCT01429727|coronary artery disease
317601|NCT01429727|myocardial infarction
317602|NCT01429727|coronary dissection
317603|NCT01429714|Elastic Compression Stockings
317604|NCT01429714|Deep Venous Thrombosis
317605|NCT01429714|Post Thrombotic Syndrome
317606|NCT01429701|Dermatitis
317607|NCT01429701|Dermatitis, Atopic
317608|NCT01429662|postmenopause
317609|NCT01429662|hypertension
317610|NCT01429662|relaxation
317611|NCT01429662|SBP 140-159 mmHg
317612|NCT01429662|DBP 90-99 mmHg
317613|NCT01429662|stage 1 or mild hypertension
317614|NCT01429649|pure pulmonary ground glass opacity
317615|NCT01429636|perimenopause
317616|NCT01429636|postmenopause
317617|NCT01429636|vasomotor symptoms
317618|NCT01429636|relaxation
317619|NCT01429623|Mild Cognitive Impairment
317620|NCT01429623|Early Stage Dementia
317621|NCT01429623|Conversion to Alzheimer's disease
317622|NCT01429623|Memory Impairment
317623|NCT01429610|acute lymphoblastic leukemia
317624|NCT01429610|rituximab
317625|NCT01429610|VPDL
317626|NCT01429610|CD20
317627|NCT01429597|Cerebrovascular Accident
317628|NCT01429597|Cerebrovascular Accident, Acute
317629|NCT01429597|Fabry Disease
317630|NCT01429597|Fabry´s Disease
317631|NCT01429597|Anderson-Fabry Disease
317632|NCT01429597|CVA (Cerebrovascular Accident)
317633|NCT01429597|Stroke, Acute
317634|NCT01429597|Cerebral Stroke
317635|NCT01429584|bupivacaine concentration
317636|NCT01429584|interscalene nerve block
317637|NCT01429584|diaphragm function
317638|NCT01429584|diaphragm weakness
317639|NCT01429558|treatment resistant obsessive-compulsive disorder
317640|NCT01429545|Tocolysis
317641|NCT01429545|atosiban
317642|NCT01429545|nifedipine
317643|NCT01429545|combination
317644|NCT01429532|Cataract
317645|NCT01429519|chronic wound
317646|NCT01429519|ulcerated wound
317647|NCT01429519|venous insufficiency
317648|NCT01429519|lymphatic insufficiency
317649|NCT01429519|neuropathic wound
317650|NCT01429519|diabetic ulcer
317651|NCT01429519|post- operative
317652|NCT01429519|post-traumatic chronic wound
317653|NCT01429506|Sleeve gastrectomy
317654|NCT01429506|Intensive medical management
317655|NCT01429480|Analgesia, postoperative
317656|NCT01429467|Glucose Variability
317657|NCT01429467|Continuous Glucose Monitoring
317658|NCT01429467|Hypoxia-inducible Factor (HIF)
317659|NCT01429467|Vascular Endothelial Growth Factor (VEGF)
317660|NCT01429467|Erythropoietin
317661|NCT01429467|Cortisol
317662|NCT01429454|Prodromal
317663|NCT01429454|Schizophrenia
317664|NCT01429454|Psychosis
317665|NCT01429454|Omega
317666|NCT01429428|Cellulitis
317667|NCT01429428|Skin ultra-sound images
317668|NCT01429428|Treatment
317669|NCT01429428|Infra-red light
317670|NCT01429415|pediatric
317671|NCT01429415|Acute Asthma
317672|NCT01429415|Inhaled Magnesium
317673|NCT01429402|Botulinum toxin A.
317674|NCT01429402|Cleft lip scar
317675|NCT01429389|Down syndrome
317676|NCT01429389|fetal aneuploidy
317677|NCT01429389|trisomy
317678|NCT01429389|noninvasive screening test
317679|NCT01429376|Chronic heart failure
317680|NCT01429376|Pulmonary function abnormalities/impairment
317681|NCT01429376|Restriction
317682|NCT01429376|Airway obstruction
317683|NCT01429376|Diffusion impairment
317684|NCT01429376|Pulmonary function tests
317685|NCT01429376|Chronic obstructive pulmonary disease (COPD)
317686|NCT01429376|Prevalence
317687|NCT01429376|Overdiagnosis
317688|NCT01429376|Underdiagnosis
317689|NCT01429376|Systemic inflammation
317690|NCT01429376|Diagnostic Errors
317691|NCT01429363|contained herniated lumbar discs
317692|NCT01429363|TDD
317693|NCT01429363|Case series
317695|NCT01429350|ischemic stroke
317696|NCT01429350|acute intervention
317697|NCT01429350|thrombolysis
317698|NCT01429350|rtPA
317699|NCT01429350|internal carotid artery
317700|NCT01429350|middle cerebral artery
317701|NCT01429350|mechanical thrombectomy
317702|NCT01429350|Penumbra System
317703|NCT01429350|clot length
317704|NCT01429350|mRS
317705|NCT01429350|NIHSS
317706|NCT01429337|Pharmacokinetics
317707|NCT01429337|Hepatic impaired patients
317708|NCT01429337|Healthy volunteers
317709|NCT01429337|Varying degrees of hepatic impairment
317710|NCT01429324|Near infrared spectroscopy
317711|NCT01429324|neuromonitoring
317712|NCT01429324|aortic arch surgery
317713|NCT01429311|Atopic Dermatitis
317714|NCT01429311|Eczema herpeticum
317715|NCT01429311|Interferon gamma
317716|NCT01429311|IFNγ
317717|NCT01429298|Acute
317718|NCT01429298|Pain
317719|NCT01429298|Emergency Department
317720|NCT01429298|Hydromorphone
317721|NCT01429298|Protocol
317722|NCT01429285|Pain
317723|NCT01429285|Hydromorphone
317724|NCT01429285|Acute
317725|NCT01429285|Emergency Department
317726|NCT01429272|Bipolar Disorder
317727|NCT01429272|Minocycline
317728|NCT01429259|Cystic Fibrosis
317729|NCT01429259|Acute Pulmonary Exacerbations
317730|NCT01429259|Pseudomonas aeruginosa
317731|NCT01429246|Hypertension
317732|NCT01429246|Diet Therapy
317733|NCT01429246|Sodium Chloride, Dietary
317734|NCT01429246|Tibet
317735|NCT01429246|Aged
317736|NCT01429233|Observational
317737|NCT01429233|Colombia
317738|NCT01429220|deep brain stimulation
317739|NCT01429220|monopolar review
317740|NCT01429220|motion sensors
317741|NCT01429220|tremor
317742|NCT01429220|bradykinesia
317743|NCT01429207|levodopa
317744|NCT01429207|tremor
317745|NCT01429207|bradykinesia
317746|NCT01429207|motion sensors
317747|NCT01429194|Weight Loss
317748|NCT01429194|Trans-oral Endoscopic Procedure
317749|NCT01429194|Gastric Plication
317750|NCT01429181|Peripheral Neuropathic Pain
317751|NCT01429155|End stage liver disease
317752|NCT01429155|Living donor liver transplantation
317753|NCT01429155|Hepatitis C
317754|NCT01429155|Interleukin 28B
317755|NCT01429129|Smoking
317756|NCT01429129|Nicotine
317757|NCT01429129|Nicotine Replacement Therapy
317758|NCT01429129|Nicotine Patch
317759|NCT01429129|Nicoderm
317760|NCT01429129|Mass Distribution
317761|NCT01429129|Tobacco Control
317762|NCT01429129|Randomized Controlled Trial
317763|NCT01429116|Blindness
317764|NCT01429116|Eye Diseases
317765|NCT01429116|Nap Disorders
317766|NCT01429116|Circadian Rhythm Disorders
317767|NCT01429116|Sleep Disorders
317768|NCT01429116|Circadian Rhythm Sleep Disorders
317769|NCT01429116|Dyssomnias
317770|NCT01429116|Nervous System Diseases
317771|NCT01429090|Pharmacokinetics
317772|NCT01429090|Accommodation, Ocular
317773|NCT01429090|Reflex, Pupillary
317774|NCT01429090|Salivation
317775|NCT01429077|Levodopa
317776|NCT01429077|Ischemic Stroke
317777|NCT01429077|Aphasia
317778|NCT01429077|Speech Rehabilitation
317779|NCT01429051|Break through pain
317780|NCT01429051|BTP
317781|NCT01429051|Cancer
317782|NCT01429051|Intranasal Fentanyl Spray
317783|NCT01429051|INFS
317784|NCT01429051|cancer patients
317785|NCT01429038|end-stage
317786|NCT01429038|liver diseases
317787|NCT01429038|cirrhosis
317788|NCT01429038|cancer
317789|NCT01429038|fulminant hepatic failure
317790|NCT01429038|metabolic hepatic diseases
317791|NCT01429038|congenital hepatic diseases
317792|NCT01429038|renal diseases
317793|NCT01429025|recurrent grade 1 follicular lymphoma
317794|NCT01429025|recurrent grade 2 follicular lymphoma
317795|NCT01429025|recurrent marginal zone lymphoma
317796|NCT01429025|recurrent small lymphocytic lymphoma
317797|NCT01429025|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
317798|NCT01429025|Waldenström macroglobulinemia
317799|NCT01429025|nodal marginal zone B-cell lymphoma
317800|NCT01429025|splenic marginal zone lymphoma
317801|NCT01429012|bone
317802|NCT01429012|nonunion fracture
317803|NCT01429012|atrophic nonunion fracture
317804|NCT01429012|callus
317805|NCT01429012|mesenchymal stem cells
317806|NCT01429012|cell therapy
317807|NCT01429012|autologous
317808|NCT01429012|indium
317809|NCT01429012|Pet-scan
317810|NCT01428999|probiotics
317811|NCT01428999|gastrointestinal function
317812|NCT01428999|intestinal bacteria flora
317813|NCT01428986|maraviroc
317814|NCT01428986|osteoclasts
317815|NCT01428986|Receptors, CCR5
317816|NCT01428986|Chemokine CCL5
317817|NCT01428973|Allogeneic hematopoeitic cell transplantation
317818|NCT01428973|Graft-Versus-Host Disease
317819|NCT01428973|Prophylaxis
317820|NCT01428973|Reduced-intensity conditioning
317821|NCT01428973|Immunosuppressive regimen
317822|NCT01428973|HLA-matched donor
317823|NCT01428973|Progression free survival
317824|NCT01428973|Overall survival
317825|NCT01428960|Palm mid fraction
317826|NCT01428960|Shea butter
317827|NCT01428960|sn-1, sn-3 fatty acids
317828|NCT01428960|Cholesterol
317829|NCT01428960|Postprandial lipemia,
317830|NCT01428960|Inflammatory markers
317831|NCT01428960|Satiety
317832|NCT01428960|Gut hormone
317833|NCT01428960|Insulin
317834|NCT01428921|Long-term efficacy
317835|NCT01428921|Education programme
317836|NCT01428921|Adherence
317837|NCT01428921|OSA
317838|NCT01428921|CPAP
317839|NCT01428908|immunogenicity
317840|NCT01428908|safety
317841|NCT01428908|group A, C polysaccharide meningitis
317842|NCT01428908|type b haemophilus Influenza
317843|NCT01428908|conjugate vaccine
317844|NCT01428895|Bone Metastases
317845|NCT01428895|Femoral Metastases
317846|NCT01428882|Propofol
317847|NCT01428882|Midazolam
317848|NCT01428882|Moderate sedation
317849|NCT01428882|Deep sedation
317850|NCT01428882|Colonoscopy
317851|NCT01428869|Statins
317852|NCT01428869|acetylsalicylic acid
317853|NCT01428869|dutasteride
317854|NCT01428869|Prostate Cancer
317855|NCT01428869|Lower urinary tract symptoms
317856|NCT01428869|prevention
317857|NCT01428869|drug interactions
317858|NCT01428843|Inflammatory Bowel Disease
317859|NCT01428843|Anemia
317860|NCT01428843|Anti-TNF alpha theray
317861|NCT01428843|Ferrisat perfusion
317862|NCT01428830|fistula
317863|NCT01428830|catheter
317864|NCT01428830|surgery
317865|NCT01428830|obstetrics
317866|NCT01428830|gynecology
317867|NCT01428830|urology
317868|NCT01428817|pregnancy
317869|NCT01428817|postpartum hemorrhage
317870|NCT01428817|Cesarean delivery
317871|NCT01428817|carbetocin
317872|NCT01428804|Resistant Major Depression
317873|NCT01428804|Mood disorders
317874|NCT01428804|tDCS
317875|NCT01428791|Geriatrics
317876|NCT01428791|Older adults
317877|NCT01428791|Health Disparities
317878|NCT01428791|Health Services for the Aged
317879|NCT01428791|Interdisciplinary Health Team
317880|NCT01428791|Depressive symptoms
317881|NCT01428791|Metabolic Syndrome X
317882|NCT01428791|Overweight
317883|NCT01428791|Obesity
317884|NCT01428791|Hypertension
317885|NCT01428791|Hyperglycemia
317886|NCT01428791|Dyslipidemias
317887|NCT01428778|Marathon running
317888|NCT01428778|Brain MRI
317889|NCT01428778|ECG recording
317890|NCT01428778|Blood tests
317891|NCT01428752|colonoscopy
317892|NCT01428752|colorectal neoplasms
317893|NCT01428752|screening
317894|NCT01428752|family history
317895|NCT01428739|cancer
317896|NCT01428739|MRS
317897|NCT01428739|Treatment response
317898|NCT01428726|NT-KO-003
317899|NCT01428726|RRMS
317900|NCT01428726|efficacy
317901|NCT01428726|safety
317902|NCT01428726|Phase IIa
317903|NCT01428713|menorrhagia
317904|NCT01428713|oral contraceptives
317905|NCT01428713|oral tranexamic acid
317906|NCT01428687|Weight loss
317907|NCT01428687|Sleep duration
317908|NCT01428674|Interpersonal mindful compassion
317909|NCT01428674|Loving kindness meditation
317910|NCT01428674|Autonomic Nervous System
317911|NCT01428674|Heart rate variability
317912|NCT01428674|Respiratory rate
317913|NCT01428674|Relaxation
317914|NCT01428661|tasimelteon
317915|NCT01428661|Major Depressive Disorder
317916|NCT01428661|MDD
317917|NCT01428661|depression
317918|NCT01428648|Parkinson
317919|NCT01428648|ballroom dancing
317920|NCT01428635|Leukemia
317921|NCT01428635|Thrombocytopenia
317922|NCT01428635|Tyrosine kinase therapy
317923|NCT01428635|TKI
317924|NCT01428635|Chronic myeloid leukemia
317925|NCT01428635|CML
317926|NCT01428635|Platelet count
317927|NCT01428635|Clonal evolution
317928|NCT01428635|Eltrombopag
317929|NCT01428635|Promacta
317930|NCT01428635|Myelofibrosis
317931|NCT01428635|MF
317932|NCT01428609|Amalgam
317933|NCT01428609|Mercury
317934|NCT01428609|Endodontics
317935|NCT01428609|Apicoectomy
317936|NCT01428596|HIV-1
317937|NCT01428596|therapeutic vaccine
317938|NCT01428596|immunotherapy
317939|NCT01428596|AIDS
317940|NCT01428583|Chronic noncancer pain
317941|NCT01428583|oxycodone
317942|NCT01428583|naltrexone
317943|NCT01428570|sleep apnea, obstructive
317944|NCT01428570|intubation
317945|NCT01428557|Heart Failure
317946|NCT01428557|Epidemiology
317947|NCT01428557|Evidence-Based Practice
317948|NCT01428492|AKT Inhibitor
317949|NCT01428492|hematologic malignancies
317950|NCT01428492|GSK2110183
317951|NCT01428492|bortezomib
317952|NCT01428492|multiple myeloma
317953|NCT01428492|dexamethasone
317954|NCT01428453|Alzheimer's disease
317955|NCT01428427|Gemcitabine
317956|NCT01428427|MEK inhibitor
317957|NCT01428427|GSK1120212
317958|NCT01428414|HER2
317959|NCT01428414|Breast cancer
317960|NCT01428414|neoadjuvant chemotherapy
317961|NCT01428414|efficacy
317962|NCT01428414|safety
317963|NCT01428401|Complementary therapies
317964|NCT01428401|Acute hemorrhagic stroke
317965|NCT01428388|macular edema
317966|NCT01428388|vein occlusion
317967|NCT01428388|bevacizumab
317968|NCT01428388|ranibizumab
317969|NCT01428388|vascular endothelial growth factor
317970|NCT01428375|intravenous paracetamol
317971|NCT01428375|intrapartum analgesia
317972|NCT01428375|labor pain
317973|NCT01428375|intrapartum pains
317974|NCT01428362|donepezil
317975|NCT01428362|VI-1121
317976|NCT01428349|Incarcerated offenders
317977|NCT01428349|emotionally reactive
317978|NCT01428349|emotionally stable
317979|NCT01428349|psychopathy
317980|NCT01428310|dietary supplement
317981|NCT01428310|nutraceutical
317982|NCT01428297|Atopic dermatitis
317983|NCT01428297|Eczema
317984|NCT01428297|Skin Diseases, Eczematous
317985|NCT01428297|Netherton syndrome
317986|NCT01428297|Skin Diseases, Genetic
317987|NCT01428297|BPR277
317988|NCT01428284|Healthy Volunteers
317989|NCT01428284|Canagliflozin (JNJ-28431754)
317990|NCT01428284|Pharmacokinetic
317991|NCT01428284|Probenecid
317992|NCT01428258|Diet therapy
317993|NCT01428258|Low phenylalanine diet
317994|NCT01428258|Attention
317995|NCT01428258|Executive function
317996|NCT01428232|Breastfeeding
317997|NCT01428232|Baby Friendly Hospital Initiative
317998|NCT01428232|Well-child clinics
317999|NCT01428219|Prostate
318000|NCT01428219|Cancer
318001|NCT01428219|Metastatic
318002|NCT01428206|palliative care
318003|NCT01428206|nursing homes
318004|NCT01428206|Liverpool care pathway
318005|NCT01428193|PCOS
318006|NCT01428193|hyperandrogenemia
318007|NCT01428180|preterm neonates
318008|NCT01428180|hemodynamically relevant patent ductus arteriosus
318009|NCT01428167|Thyroid cancer
318010|NCT01428167|Hashimotos thyroiditis
318011|NCT01428167|Thyroidectomy
318012|NCT01428167|Anti-inflammatory factors
318013|NCT01428154|paediatric
318014|NCT01428154|dialysis
318015|NCT01428154|CKD
318016|NCT01428154|pediatric
318017|NCT01428141|Cancer
318018|NCT01428141|Gastrointestinal Cancer
318019|NCT01428115|monoclonal
318020|NCT01428115|anxiety
318021|NCT01428115|antibodies
318022|NCT01428115|adalimumab
318023|NCT01428115|severe crohn's disease
318024|NCT01428115|quality of life
318025|NCT01428115|biological products
318026|NCT01428102|Thromboelastography
318027|NCT01428102|TEG
318028|NCT01428102|Coagulation
318029|NCT01428102|RapidTEG
318030|NCT01428102|Kaolin
318031|NCT01428089|hyperandrogenemia
318032|NCT01428076|Varicose Veins
318033|NCT01428076|SFJ Reflux
318034|NCT01428050|whipple
318035|NCT01428050|hypertonic saline
318036|NCT01428050|pancreaticoduodenectomy
318037|NCT01428050|fluid restriction
318038|NCT01428050|resuscitation strategy
318039|NCT01428037|Vaginal Misoprostol
318040|NCT01428037|Cervical Ripening
318041|NCT01428037|Labor Induced
318042|NCT01428024|efficacy
318043|NCT01428024|safety
318044|NCT01428024|Restylane
318045|NCT01428024|Lip products
318046|NCT01428024|injection techniques
318047|NCT01428011|Hypertension
318048|NCT01428011|Patient-Provider Communication
318049|NCT01428011|Medication Adherence
318050|NCT01428011|Race Concordance
318051|NCT01427998|diabetes
318052|NCT01427998|blood glucose
318053|NCT01427998|olive leaf extract
318054|NCT01427946|KRAS mutant
318055|NCT01427946|Non-Small Cell Lung Cancer
318056|NCT01427946|NSCLC
318057|NCT01427933|Breast Cancer
318058|NCT01427907|Serum phosphorus levels
318059|NCT01427894|Prematurity
318060|NCT01427894|Music
318061|NCT01427894|Kangaroo Care
318062|NCT01427894|Bonding Mother infant
318063|NCT01427868|LB80380
318064|NCT01427868|bioequivalence
318065|NCT01427855|Dietary Protein
318066|NCT01427855|Red Meat
318067|NCT01427855|White Meat
318068|NCT01427855|Vegetable Protein
318069|NCT01427855|Saturated Fat
318070|NCT01427855|LDL Subclasses
318071|NCT01427855|Cholesterol
318072|NCT01427855|Atherogenic Dyslipidemia
318073|NCT01427842|Trough concentration
318074|NCT01427842|Vancomycin
318075|NCT01427842|Pharmacokinetics
318076|NCT01427829|pilot
318077|NCT01427829|randomized controlled trial
318078|NCT01427829|RCT
318079|NCT01427829|computer
318080|NCT01427829|screening
318081|NCT01427829|community heath center
318082|NCT01427829|psychosocial
318083|NCT01427829|immigrant
318084|NCT01427816|Dry eye syndromes
318085|NCT01427816|Corneal diseases
318086|NCT01427816|Conjunctival diseases
318087|NCT01427803|Actual Use Trial
318088|NCT01427764|Dentin sensitivity
318089|NCT01427764|Dental scaling
318090|NCT01427764|Ultrasonic
318091|NCT01427764|manual and ultrasonic instrumentation
318092|NCT01427725|Digestive System Diseases
318093|NCT01427725|Therapeutic Uses
318094|NCT01427725|Pancreatectomy
318095|NCT01427725|Gastrointestinal Agents
318096|NCT01427725|Pancreatic Diseases
318097|NCT01427725|Pancrelipase
318098|NCT01427725|Exocrine Pancreatic Insufficiency
318099|NCT01427712|Digestive System Diseases
318100|NCT01427712|Cystic Fibrosis
318101|NCT01427712|Therapeutic Uses
318102|NCT01427712|Gastrointestinal Agents
318103|NCT01427712|Pancreatic Diseases
318104|NCT01427712|Pancrelipase
318105|NCT01427712|Exocrine Pancreatic Insufficiency
318106|NCT01427673|Chronic Obstructive Pulmonary Disease
318107|NCT01427673|Obstructive Sleep Apnea
318108|NCT01427673|Overlap Syndrome
318109|NCT01427673|COPD
318110|NCT01427673|OSA
318111|NCT01427660|Diabetes
318112|NCT01427660|Decision Aid
318113|NCT01427660|AntiHyperglycemic Medication
318114|NCT01427660|Tailored health information
318115|NCT01427660|Medication information
318116|NCT01427647|Laparoscopy
318117|NCT01427647|Anesthesia, Epidural
318118|NCT01427634|Heart Failure
318119|NCT01427634|Ventricular Assist Device
318120|NCT01427634|Palliative Care
318121|NCT01427595|hyperandrogenemia
318122|NCT01427569|Diabetes
318123|NCT01427569|Chronic wound
318124|NCT01427556|Food intake
318125|NCT01427556|Breakfast eating
318126|NCT01427543|behavioral intervention
318127|NCT01427543|HIV risk reduction
318128|NCT01427543|African Americans
318129|NCT01427543|incarceration
318130|NCT01427543|bisexual
318131|NCT01427543|reduce risk behaviors
318132|NCT01427530|brain activity
318133|NCT01427530|implanted with DBS electrodes
318134|NCT01427517|Parkinson's disease
318135|NCT01427517|Gaucher's disease
318136|NCT01427517|Control
318137|NCT01427504|HCV
318138|NCT01427504|HIV
318139|NCT01427478|Head and neck squamous cell carcinoma
318140|NCT01427478|Post operative radio-chemotherapy
318141|NCT01427478|Randomisation
318142|NCT01427478|Maintenance treatment
318143|NCT01427478|Afatinib
318144|NCT01427465|Brief
318145|NCT01427465|Image
318146|NCT01427465|Intervention
318147|NCT01427465|Adolescents
318148|NCT01427465|School
318149|NCT01427452|Live Donor
318150|NCT01427452|Kidney Donation
318151|NCT01427452|Living Donation
318152|NCT01427452|Live Donor Kidney Transplantation
318153|NCT01427452|Donor Nephrectomy
318154|NCT01427439|MDD
318155|NCT01427439|Non-interventional study
318156|NCT01427439|Observational study
318157|NCT01427426|Health
318158|NCT01427426|Vitality
318159|NCT01427426|Well-being
318160|NCT01427426|Nutritional Supplement
318161|NCT01427426|Phytonutrient
318162|NCT01427426|Greens
318163|NCT01427413|blastocoele fluid
318164|NCT01427413|mass spectrometry
318165|NCT01427413|metabolomics
318166|NCT01427400|Breast expander
318167|NCT01427400|Breast reconstruction
318168|NCT01427400|Implants
318169|NCT01427400|Botox
318170|NCT01427387|ASP0456
318171|NCT01427387|Pharmacokinetics
318172|NCT01427387|safety
318173|NCT01427387|tolerability
318174|NCT01427387|food effect
318175|NCT01427374|hemodialysis
318176|NCT01427374|peritoneal dialysis
318177|NCT01427374|chronic kidney disease
318178|NCT01427374|cardiovascular risk factors
318179|NCT01427374|cardiac imaging
318180|NCT01427374|dialysis
318181|NCT01427374|parathyroid hormone
318182|NCT01427374|vitamin D
318183|NCT01427374|coronary artery calcification
318184|NCT01427374|left ventricular hypertrophy
318185|NCT01427374|genetic predisposition
318186|NCT01427374|biochemical markers
318187|NCT01427374|infection
318188|NCT01427374|pharmacogenomics
318189|NCT01427335|OHSS
318190|NCT01427335|ICSI
318191|NCT01427335|calcium injection
318192|NCT01427322|lapatinib
318193|NCT01427322|radiation therapy
318194|NCT01427322|metastases
318195|NCT01427309|Influenza
318196|NCT01427309|Trivalent Inactivated Influenza Vaccine
318197|NCT01427309|High-Dose Trivalent Inactivated Influenza Vaccine
318198|NCT01427309|Fluzone® High-Dose
318199|NCT01427309|Influenza vaccines
318200|NCT01427296|Colon Cleansing
318201|NCT01427296|Bowel Prep
318202|NCT01427296|Colonoscopy
318203|NCT01427283|Low back pain
318204|NCT01427283|Chronic pain
318205|NCT01427283|Opioid
318206|NCT01427283|Constipation
318207|NCT01427283|Moderate to severe
318208|NCT01427270|Low back pain
318209|NCT01427270|Chronic pain
318210|NCT01427270|Opioid
318211|NCT01427270|Constipation
318212|NCT01427270|Moderate to severe chronic low back pain
318213|NCT01427244|HER2+
318214|NCT01427244|Histologic confirmation
318215|NCT01427244|measurable disease
318216|NCT01427244|HER2 positive
318217|NCT01427244|HER2 overexpression
318218|NCT01427244|persistent vulvar Paget's disease
318219|NCT01427244|recurrent vulvar Paget's disease
318220|NCT01427231|Cognitive performance
318221|NCT01427231|Attention
318222|NCT01427231|Memory
318223|NCT01427231|Glucose
318224|NCT01427231|Sacharose
318225|NCT01427231|Elderly
318226|NCT01427231|Memory complaints
318227|NCT01427218|pharmacist
318228|NCT01427218|medication therapy management
318229|NCT01427218|evidence based medicine
318230|NCT01427205|Head and Neck Squamous Cell Carcinoma
318231|NCT01427205|HNSCC
318232|NCT01427205|recurrent
318233|NCT01427205|metastatic
318234|NCT01427205|oral cavity
318235|NCT01427205|Cetuximab
318236|NCT01427205|C225
318237|NCT01427205|Erbitux
318238|NCT01427205|IMC-C225
318239|NCT01427205|OSI-906
318240|NCT01427205|Placebo
318241|NCT01427205|sugar pill
318242|NCT01427205|oropharynx
318243|NCT01427205|larynx
318244|NCT01427205|hypopharynx
318245|NCT01427192|Breathing-Related Sleep Disorder
318246|NCT01427192|Pulmonary Hypertension
318247|NCT01427179|Spontaneous coronary artery dissection
318248|NCT01427179|SCAD
318249|NCT01427166|Breast Cancer
318250|NCT01427166|Cording
318251|NCT01427166|Lymphedema
318252|NCT01427166|upper extremity cording
318253|NCT01427166|following treatment
318254|NCT01427153|knee osteoarthritis
318255|NCT01427153|physical therapy
318256|NCT01427153|corticosteroid
318257|NCT01427153|treatment
318258|NCT01427140|Liver fat
318259|NCT01427140|Polyunsaturated fatty acids (PUFA)
318260|NCT01427140|Saturated fatty acids (SFA)
318261|NCT01427140|Weight gain
318262|NCT01427140|Overfeed
318263|NCT01427140|Dietary fatty acids
318264|NCT01427140|Palm oil
318265|NCT01427140|Sunflower oil
318266|NCT01427114|extranodal marginal zone lymphoma
318267|NCT01427114|ocular adnexal lymphoma
318268|NCT01427114|mucosa associated lymphoid tissue
318269|NCT01427114|cyclophosphamide
318270|NCT01427114|vincristine
318271|NCT01427114|prednisolone
318272|NCT01427101|Pseudomyxoma Peritonei
318273|NCT01427101|Cytoreductive surgery
318274|NCT01427101|Debulking surgery
318275|NCT01427101|Intraperitoneal chemotherapy
318276|NCT01427088|rTMS-induced cumulative pattern of sBDNF
318277|NCT01427075|Magnetic Resonance Imaging
318278|NCT01427075|Sleep Apnea, Obstructive
318279|NCT01427075|Pharyngeal Muscles
318280|NCT01427062|parkinson's disease
318281|NCT01427062|balance
318282|NCT01427062|anticipatory postural adjustment
318283|NCT01427062|componsatory postural adjustment
318284|NCT01427062|falls
318285|NCT01427049|renal denervation
318286|NCT01427049|renal sympathetic denervation
318287|NCT01427049|renal ablation
318288|NCT01427049|resistant hypertension
318289|NCT01427049|hypertension
318290|NCT01427049|renal oxygenation
318291|NCT01427049|renal perfusion
318292|NCT01427023|APTIMA Trichomonas vaginalis Assay
318293|NCT01427023|APTIMA
318294|NCT01427023|trichomonas
318295|NCT01427023|trichomonas vaginalis
318296|NCT01426997|Major Depressive Disorder
318297|NCT01426997|Depression
318298|NCT01426971|Migraine
318299|NCT01426945|alveolar childhood rhabdomyosarcoma
318300|NCT01426945|previously treated childhood rhabdomyosarcoma
318301|NCT01426945|previously untreated childhood rhabdomyosarcoma
318302|NCT01426945|recurrent childhood rhabdomyosarcoma
318303|NCT01426945|embryonal childhood rhabdomyosarcoma
318304|NCT01426932|Vestibular Function Tests
318305|NCT01426932|Caloric Test
318306|NCT01426932|Electronystagmography
318307|NCT01426932|Prediction
318308|NCT01426919|Traumatic Brain Injury
318309|NCT01426919|Head Injury
318310|NCT01426893|Respiratory disease
318311|NCT01426893|COPD
318312|NCT01426880|GBG
318313|NCT01426880|German Breast Group
318314|NCT01426880|neo-adjuvant
318315|NCT01426880|GBG Forschungs GmbH
318316|NCT01426880|Tubular breast cancer stage II
318317|NCT01426880|Mucinous breast cancer stage II
318318|NCT01426880|Invasive ductal breast cancer
318319|NCT01426880|Tubular breast cancer stage III
318320|NCT01426880|HER-2 positive breast cancer
318321|NCT01426880|Inflammatory breast cancer stage IV
318322|NCT01426880|Inflammatory breast cancer
318323|NCT01426867|Open-Angle Glaucoma
318324|NCT01426867|Ocular Hypertension
318325|NCT01426867|Intraocular Pressure
318326|NCT01426867|Brinzolamide
318327|NCT01426867|Brimonidine
318328|NCT01426854|Cataract Surgery
318329|NCT01426854|Anti-ocular Inflammation
318330|NCT01426854|Anti-ocular Pain
318331|NCT01426841|Small cell lung cancer
318332|NCT01426841|Adaptive radiotherapy
318333|NCT01426841|Thoracic radiotherapy
318334|NCT01426828|adult
318335|NCT01426828|symptomatic multiple myeloma
318336|NCT01426828|myeloma
318337|NCT01426828|diagnosis within 12 months of initiation of systemic therapy
318338|NCT01426815|Peripheral spondylarthritis according to ASAS- criteria
318339|NCT01426802|metformin
318340|NCT01426802|vildagliptin
318341|NCT01426802|T2DM
318342|NCT01426789|Rheumatoid Arthritis
318343|NCT01426789|IgG1K monoclonal antibody
318344|NCT01426789|Interleukin-17A neutralizing
318345|NCT01426776|Cheyne-Stokes respiration
318346|NCT01426776|Heart valve disease
318347|NCT01426776|Central Sleep Apnea
318348|NCT01426763|HAE
318349|NCT01426763|C1 esterase inhibitor
318350|NCT01426763|C1 INH
318351|NCT01426763|Subcutaneous
318352|NCT01426763|hyaluronidase
318353|NCT01426763|rHuPH20
318354|NCT01426750|Nutritional support.
318355|NCT01426750|Cancer.
318356|NCT01426750|Malnutrition.
318357|NCT01426750|Child.
318358|NCT01426750|Adolescent
318359|NCT01426724|Vitamin D
318360|NCT01426724|Chronic Kidney Disease
318361|NCT01426724|Hyperparathyroidism
318362|NCT01426724|Renal Blood Flow
318363|NCT01426724|Proteinuria
318364|NCT01426724|Inflammation
318365|NCT01426724|Renin Angiotensin System
318366|NCT01426698|delayed cord clamping
318367|NCT01426698|developmental delay
318368|NCT01426685|sudden death
318369|NCT01426685|coronary artery disease
318370|NCT01426685|diabetes
318371|NCT01426672|Strabismic deviation less than 12 prism diopeters
318372|NCT01426659|language
318373|NCT01426659|constraints
318374|NCT01426659|premature
318375|NCT01426659|phonology
318376|NCT01426659|implied
318377|NCT01426659|early development (< 5 years)
318378|NCT01426646|gastric cancer
318379|NCT01426646|S-1
318380|NCT01426646|cisplatin
318381|NCT01426646|adjuvant chemotherapy
318382|NCT01426633|L-sarcomas
318383|NCT01426620|NSCLC
318384|NCT01426620|blueberry
318385|NCT01426620|salvage therapy
318386|NCT01426620|docetaxel
318387|NCT01426620|non-small cell lung cancer
318388|NCT01426620|second-line
318389|NCT01426620|polyphenol
318390|NCT01426594|Observational
318391|NCT01426594|Colombia
318392|NCT01426594|Metpure XL
318393|NCT01426581|Asthma
318394|NCT01426581|Chronic Obstructive Pulmonary Disease (COPD)
318395|NCT01426581|Pulmonary Disease, Chronic Obstructive
318396|NCT01426581|Lung Disease, Obstructive
318397|NCT01426581|Self-management
318398|NCT01426581|Health Literacy
318399|NCT01426568|Multi-Convergent Therapy
318400|NCT01426568|Mindfulness Meditation
318401|NCT01426568|Functional Abdominal Symptoms
318402|NCT01426568|Irritable Bowel Syndrome
318403|NCT01426568|Inflammatory Bowel Disease
318404|NCT01426568|Psychological Stress
318405|NCT01426555|Disorder of Bone Density and Structure, Unspecified
318406|NCT01426555|Weakening of the bone structure
318407|NCT01426542|brain injury
318408|NCT01426542|stroke
318409|NCT01426542|cerebral palsy
318410|NCT01426542|seizures
318411|NCT01426516|Treatment Resistant
318412|NCT01426516|Depression
318413|NCT01426477|Ventral hernia
318414|NCT01426477|Abdominal wall hernia
318415|NCT01426477|Incisional hernia
318416|NCT01426477|Biologic mesh
318417|NCT01426477|Veritas Collagen Matrix
318418|NCT01426477|Veritas
318419|NCT01426464|Glaucoma
318420|NCT01426464|Xalatan
318421|NCT01426464|Transdermal
318422|NCT01426451|Dramatherapy
318423|NCT01426451|Group tutoring activities
318424|NCT01426451|Impairment
318425|NCT01426451|Emotional and behavioural problems
318426|NCT01426451|Learning difficulties
318427|NCT01426425|Cardiac cryoablation
318428|NCT01426425|AVNRT
318429|NCT01426425|heart disease
318430|NCT01426425|tachycardia
318431|NCT01426425|AtrioVentricular Nodal Reentrant Tachycardia
318432|NCT01426425|Supraventricular tachycardia
318433|NCT01426425|SVT
318434|NCT01426360|dentifrice
318435|NCT01426360|potassium nitrate
318436|NCT01426360|strontium chloride
318437|NCT01426347|Rheumatoid Arthritis
318438|NCT01426347|Vitamin D deficiency
318439|NCT01426347|Disability
318440|NCT01426321|Cardiac resynchronization therapy
318441|NCT01426321|Echocardiography
318442|NCT01426321|Cardiac computed tomography
318443|NCT01426295|hematologic disease candidates for autologous or allogeneic bone marrow
318444|NCT01426282|Out-patient Compliance
318445|NCT01426282|Nurse, Heath Education
318446|NCT01426282|Cardiovascular Diseases
318447|NCT01426282|Treatment and Prevention
318448|NCT01426256|vitamin D
318449|NCT01426256|cholecalciferol
318450|NCT01426256|cystic fibrosis
318451|NCT01426256|respiratory tract infection
318452|NCT01426256|immunity
318453|NCT01426256|intervention studies
318454|NCT01426256|inflammation
318455|NCT01426256|dietary supplements
318456|NCT01426256|alpha-Defensins
318457|NCT01426256|Cytokines
318458|NCT01426256|mortality
318459|NCT01426256|biological markers
318460|NCT01426256|Biomedical Research
318461|NCT01426230|PHN
318462|NCT01426230|Post Herpetic Neuralgia
318463|NCT01426230|Shingles
318464|NCT01426230|HZ roster
318465|NCT01426204|Hepatitis C
318466|NCT01426204|Retreatment
318467|NCT01426204|Failures
318468|NCT01426204|Infergen
318469|NCT01426204|Interferon Alfacon-1
318470|NCT01426191|Cefotaxime sulbactam sodium
318471|NCT01426191|Phase IV clinical studies
318472|NCT01426191|Respiratory and urinary tract infections
318473|NCT01426178|Respiratory Insufficiency
318474|NCT01426178|Respiration, Artificial
318475|NCT01426178|Intermittent Positive-Pressure Ventilation
318476|NCT01426178|Neurally Adjusted Ventilatory Assist
318477|NCT01426178|Non Invasive Ventilation
318478|NCT01426165|hypomagnesemia
318479|NCT01426165|magnesium
318480|NCT01426165|magnesium sulfate
318481|NCT01426152|IVF
318482|NCT01426152|progesterone
318483|NCT01426152|ovulation induction
318484|NCT01426152|pregnancy rates
318485|NCT01426152|Female Infertility Due to Nonimplantation
318486|NCT01426126|urothelial carcinoma
318487|NCT01426126|gemcitabine
318488|NCT01426126|platinum
318489|NCT01426126|refractory
318490|NCT01426126|salvage chemotherapy
318491|NCT01426100|CKD-828
318492|NCT01426100|Hypertension
318493|NCT01426100|Primary Hypertension
318494|NCT01426100|S-Amlodipine
318495|NCT01426100|Telmisartan
318496|NCT01426100|Amlodipine
318497|NCT01426100|Non-Responder
318498|NCT01426061|Complementary and alternative medicine
318499|NCT01426061|Reflexology
318500|NCT01426061|Homeopathy
318501|NCT01426061|Asthma
318502|NCT01426061|Randomized controlled trial
318503|NCT01426035|SUPERFICIAL VARICOSE VEINS
318504|NCT01426022|alcohol
318505|NCT01426022|mood
318506|NCT01426022|postprandial
318507|NCT01426009|COPD
318508|NCT01425996|HCC
318509|NCT01425996|PVTT
318510|NCT01425983|stress
318511|NCT01425983|lability and irritative disturbances
318512|NCT01425983|dietary supplement
318513|NCT01425983|amino acid composition
318514|NCT01425983|psychological neurological questionnaire (PNF)
318515|NCT01425970|Inhibitex
318516|NCT01425970|Chronic Hepatitis
318517|NCT01425970|Hepatitis C Virus
318518|NCT01425957|MEMORY and COGNITIVE IMPAIRMENT
318519|NCT01425957|ALZHEIMER DISEASE CONVERSION
318520|NCT01425957|Amyloid beta-Peptides
318521|NCT01425944|Sturge Weber Syndrome
318522|NCT01425944|Biomarkers
318523|NCT01425944|DNA arrays
318524|NCT01425944|brain vessel malformations
318525|NCT01425918|Autism Spectrum Disorder
318526|NCT01425918|language
318527|NCT01425918|social
318528|NCT01425918|toddlers
318529|NCT01425905|Female
318530|NCT01425905|Depression
318531|NCT01425905|Obesity
318532|NCT01425905|Insulin Resistance
318533|NCT01425905|Adolescents
318534|NCT01425905|Overweight
318535|NCT01425905|Type 2 Diabetes Risk
318536|NCT01425905|Mood
318537|NCT01425892|Salivary Gland
318538|NCT01425892|Pathogenesis
318539|NCT01425892|Sj(SqrRoot)(Delta)gren s Syndrome
318540|NCT01425892|Sjogren Syndrome
318541|NCT01425866|Diabetes Mellitus
318542|NCT01425866|Diabetes Mellitus, Type 2
318543|NCT01425866|Structured self-management education
318544|NCT01425866|Therapeutic patient education
318545|NCT01425866|Lifestyle changes
318546|NCT01425866|Self-management Blood glucose
318547|NCT01425866|Empowerment
318548|NCT01425866|Adult learning
318549|NCT01425866|Socio-constructivism
318550|NCT01425866|Health management network
318551|NCT01425866|Reunion island
318552|NCT01425840|Lidocaine,
318553|NCT01425840|liposome encapsulation,
318554|NCT01425840|topical anesthesia,
318555|NCT01425840|palatal mucosa
318556|NCT01425827|duloxetine
318557|NCT01425827|osteoarthritis
318558|NCT01425827|pain
318559|NCT01425827|function
318560|NCT01425814|COPD
318561|NCT01425801|COPD
318562|NCT01425788|Grass pollen induced allergic rhinoconjunctivitis
318563|NCT01425775|SLE
318564|NCT01425775|disease activity markers
318565|NCT01425775|vitamin D
318566|NCT01425749|melanoma
318567|NCT01425749|MAGE-A3
318568|NCT01425749|immunotherapy
318569|NCT01425749|adjuvant
318570|NCT01425749|skin cancer
318571|NCT01425749|skin diseases
318572|NCT01425749|immunology
318573|NCT01425736|Nimotuzumab
318574|NCT01425736|Chemotherapy
318694|NCT01425268|Tissue Expansion
318575|NCT01425736|Head and Neck Squamous Cell Carcinoma
318576|NCT01425723|B-LONG
318577|NCT01425723|B-YOND
318578|NCT01425723|B-LONG Extension
318579|NCT01425723|rFIXFc
318580|NCT01425723|Severe Hemophilia B
318581|NCT01425710|Pheochromocytoma
318582|NCT01425710|Adrenalectomy
318583|NCT01425710|Cardiac output
318584|NCT01425710|Fluid managment
318585|NCT01425710|Esopagheal doppler sonography
318586|NCT01425697|Adult Cardiac surgery
318587|NCT01425697|Surgery site infections
318588|NCT01425684|MRI
318589|NCT01425684|Smoking
318590|NCT01425684|Schizophrenia
318591|NCT01425671|Schizophrenia
318592|NCT01425671|Family
318593|NCT01425671|Psychosis
318594|NCT01425658|Fentanyl
318595|NCT01425658|clonidine
318596|NCT01425658|intrathcal
318597|NCT01425658|bupivacaine
318598|NCT01425645|gestational diabetes
318599|NCT01425645|GDM
318600|NCT01425645|prevention
318601|NCT01425632|TAU-284
318602|NCT01425632|Bepotastine besilate
318603|NCT01425632|Histamine H1 receptor antagonists
318604|NCT01425619|Anxiety Disorder due to Allergy Skin Testing
318605|NCT01425580|Congestive Heart Failure
318606|NCT01425580|Type 2 Diabetes Mellitus
318607|NCT01425580|GLP-1
318608|NCT01425580|Liraglutide
318609|NCT01425567|cholestasis
318610|NCT01425567|parenteral nutrition
318611|NCT01425554|Vascular malformations in the internal jugular veins
318612|NCT01425515|hypertension
318613|NCT01425515|genomics
318614|NCT01425502|High risk prescribing
318615|NCT01425502|Primary care
318616|NCT01425502|Non-steroidal anti-inflammatory drugs
318617|NCT01425502|Anti-platelet agents
318618|NCT01425502|Stepped wedge design
318619|NCT01425502|Cluster randomised controlled trial
318620|NCT01425502|United Kingdom
318621|NCT01425489|Leukodystrophy, Globoid Cell
318622|NCT01425489|Hereditary Central Nervous System Demyelinating Diseases
318623|NCT01425489|Brain Diseases, Metabolic, Inborn
318624|NCT01425489|Central Nervous System Diseases
318625|NCT01425489|Nervous System Diseases
318626|NCT01425489|Sphingolipidoses
318627|NCT01425489|Leukoencephalopathies
318628|NCT01425489|Demyelinating Diseases
318629|NCT01425489|Metabolism, Inborn Errors
318630|NCT01425489|Genetic Diseases, Inborn
318631|NCT01425489|Lipidoses
318632|NCT01425489|Lipid Metabolism, Inborn Errors
318633|NCT01425489|Lysosomal Storage Diseases
318634|NCT01425489|Metabolic Diseases
318635|NCT01425489|Lipid Metabolism DisordersLeukodystrophy, Globoid Cell
318636|NCT01425476|breast
318637|NCT01425476|high risk women
318638|NCT01425476|biomarkers
318639|NCT01425476|vitamin D
318640|NCT01425463|Ferrous (II) Glycine Sulphate Complex
318641|NCT01425463|Polyferose
318642|NCT01425463|Ferro Sanol duodenal
318643|NCT01425463|Niferex
318644|NCT01425463|Iron Deficiency Anemia
318645|NCT01425437|Keloid
318646|NCT01425424|Vitamin D
318647|NCT01425424|Prediabetes
318648|NCT01425424|Prehypertension
318649|NCT01425411|hypertension
318650|NCT01425411|left ventricular hypertrophy
318651|NCT01425411|angiotensin receptor blocker
318652|NCT01425411|midwall mechanics
318653|NCT01425411|tissue Doppler imaging
318654|NCT01425411|Hypertension with left ventricular hypertrophy
318655|NCT01425385|liver failure
318656|NCT01425385|liver transplantation
318657|NCT01425372|vaccine
318658|NCT01425372|pneumococcal conjugate vaccine
318659|NCT01425372|immune responses
318660|NCT01425372|primary immunisation
318661|NCT01425372|Vaccine responses to primary immunisation in the UK
318662|NCT01425359|Chronic angina
318663|NCT01425359|Angina pectoris
318664|NCT01425359|Coronary artery disease
318665|NCT01425359|Type 2 Diabetes Mellitus
318666|NCT01425346|Ophthalmic, healthy eye, fluorescence, lens
318667|NCT01425333|Ovarian endometriomas
318668|NCT01425333|Laparoscopy
318669|NCT01425333|Cystectomy
318670|NCT01425333|Ablation
318671|NCT01425307|Phase III
318672|NCT01425307|Sickle cell anemia
318673|NCT01425307|Abnormally high Transcranial Doppler velocities.
318674|NCT01425307|Reduce risk of primary stroke
318675|NCT01425307|Pediatric patients
318676|NCT01425307|Chelation therapy
318677|NCT01425294|Chinese post-menopausal women
318678|NCT01425294|oestrogen receptor-positive locally advanced
318679|NCT01425294|metastatic breast cancer
318680|NCT01425294|fulvestrant 250 mg
318681|NCT01425294|failure to adjuvant anti-oestrogen therapy
318682|NCT01425281|Bioabsorbable
318683|NCT01425281|Coronary scaffold
318684|NCT01425281|Coronary Stent
318685|NCT01425281|Everolimus
318686|NCT01425281|Drug eluting stents
318687|NCT01425281|Angioplasty
318688|NCT01425281|Coronary artery disease
318689|NCT01425281|Total coronary occlusion
318690|NCT01425281|Coronary artery restenosis
318691|NCT01425281|Stent thrombosis
318692|NCT01425281|Myocardial ischemia
318693|NCT01425281|Coronary artery stenosis
318695|NCT01425268|Tissue Expander
318696|NCT01425268|Breast Tissue Expansion
318697|NCT01425268|Breast Tissue Expander
318698|NCT01425268|Breast Reconstruction
318699|NCT01425268|Two Stage Breast Reconstruction
318700|NCT01425268|2 Stage Breast Reconstruction
318701|NCT01425255|Type 1 diabetes
318702|NCT01425255|Sleep quality
318703|NCT01425255|Parents
318704|NCT01425242|inflammation
318705|NCT01425242|aneurysm
318706|NCT01425242|hypertension
318707|NCT01425242|aliskiren
318708|NCT01425229|steady state
318709|NCT01425229|bosentan
318710|NCT01425229|clarithromycin
318711|NCT01425216|Keloid
318712|NCT01425216|Patient who have extensive or massive keloids
318713|NCT01425177|Retained CBD Stones
318714|NCT01425177|Recurrent CBD Stones
318715|NCT01425164|hemodialysis
318716|NCT01425164|coronary heart disease
318717|NCT01425164|angina
318718|NCT01425164|betablocker
318719|NCT01425164|carvedilol
318720|NCT01425164|ivabradine
318721|NCT01425138|psoriasis
318722|NCT01425138|systematic review
318723|NCT01425138|meta-analyses
318724|NCT01425125|nonedematous hyponatremia
318725|NCT01425125|fractional urate excretion
318726|NCT01425112|trabeculectomy
318727|NCT01425112|bevacizumab
318728|NCT01425112|anti-VEGF
318729|NCT01425112|Efficacy
318730|NCT01425086|Incubator,
318731|NCT01425086|hypothermia,
318732|NCT01425086|preterm,
318733|NCT01425086|low-birthweight infants,
318734|NCT01425086|embrace device,
318735|NCT01425086|phase change materials
318736|NCT01425086|PCM
318737|NCT01425073|HIV
318738|NCT01425073|Co-Infections
318739|NCT01425073|Malaria
318740|NCT01425073|Pneumonia
318741|NCT01425073|Diarrhea
318742|NCT01425060|Contraception
318743|NCT01425060|Unintended pregnancy
318744|NCT01425060|HIV
318745|NCT01425060|HIV Risk
318746|NCT01425060|Sexually Transmitted Infections
318747|NCT01425060|Women
318748|NCT01425060|Pregnancy
318749|NCT01425060|Neonatal Health
318750|NCT01425060|Drug Use
318751|NCT01425060|Drug Treatment
318752|NCT01425060|Opioids
318753|NCT01425047|mangosteen
318754|NCT01425047|xanthones
318755|NCT01425047|dietary supplement
318756|NCT01425047|botanical supplement
318757|NCT01425047|bioavailability
318758|NCT01425047|Determine bioavailability of mangosteen xanthones in adults
318759|NCT01425034|Cast
318760|NCT01425034|motion
318761|NCT01425034|thumb CMC arthritis
318762|NCT01425034|Collateral Ligament of Metacarpophalangeal Joint
318763|NCT01424995|trigger thumb
318764|NCT01424995|flexor pollicis longus tendon of the thumb
318765|NCT01424995|stenosis tenosynovitis
318766|NCT01424982|Leukemia
318767|NCT01424982|Ph-positive acute lymphoblastic leukemia
318768|NCT01424982|ALL
318769|NCT01424982|Philadelphia (Ph) chromosome
318770|NCT01424982|BCR-ABL
318771|NCT01424982|Depo-Medrol
318772|NCT01424982|Medrol
318773|NCT01424982|Solu-Medrol
318774|NCT01424982|Methylprednisolone
318775|NCT01424982|Vincristine
318776|NCT01424982|Dexamethasone
318777|NCT01424982|Decadron
318778|NCT01424982|Ponatinib
318779|NCT01424982|G-CSF
318780|NCT01424982|Filgrastim
318781|NCT01424982|NeupogenTM
318782|NCT01424982|Cyclophosphamide
318783|NCT01424982|Cytoxan
318784|NCT01424982|Neosar
318785|NCT01424982|Doxorubicin
318786|NCT01424982|Doxorubicin Hydrochloride
318787|NCT01424982|Adriamycin PFS
318788|NCT01424982|Adriamycin RDF
318789|NCT01424982|Adriamycin
318790|NCT01424982|Rubex
318791|NCT01424982|Rituximab
318792|NCT01424982|Rituxan
318793|NCT01424982|Mesna
318794|NCT01424982|Mesnex
318795|NCT01424982|Cytarabine
318796|NCT01424982|Ara-C
318797|NCT01424982|Cytosar
318798|NCT01424982|DepoCyt
318799|NCT01424982|Cytosine Arabinosine Hydrochloride
318800|NCT01424982|Methotrexate
318801|NCT01424982|Leucovorin
318802|NCT01424982|Wellcovorin
318803|NCT01424982|Citrovorum
318804|NCT01424982|Prednisone
318805|NCT01424982|NeulastaTM
318806|NCT01424982|PEG-G-CSF
318807|NCT01424969|rotator cuff repair
318808|NCT01424969|arthroscopic
318809|NCT01424969|platelet-rich plasma
318810|NCT01424969|platelet-rich fibrin matrix
318811|NCT01424969|outcomes
318812|NCT01424969|tendon healing
318813|NCT01424969|magnetic resonance imaging
318814|NCT01424956|breast
318815|NCT01424956|breast cancer
318816|NCT01424956|breast screening
318817|NCT01424956|breast cancer screening
318818|NCT01424956|ultrasound
318819|NCT01424956|ultrasonography
318820|NCT01424956|mammogram
318821|NCT01424956|mammography
318822|NCT01424956|breast density
318823|NCT01424956|dense breasts
318824|NCT01424956|early detection
318825|NCT01424956|somo v
318826|NCT01424956|somo•v
318827|NCT01424956|U-Systems
318828|NCT01424956|Automated Breast Ultrasound
318829|NCT01424956|Ultrasonography, Mammary
318830|NCT01424956|Breast Neoplasms
318831|NCT01424956|Breast Density > 50% (BI-RADS III & IV)
318832|NCT01424943|prevention
318833|NCT01424943|evidence-based parenting intervention
318834|NCT01424943|children
318835|NCT01424943|disabilities
318836|NCT01424943|IDEA Part C
318837|NCT01424943|Stepping Stones Triple P
318838|NCT01424930|Metastatic castration-resistant prostate cancer
318839|NCT01424930|CRPC
318840|NCT01424930|Abiraterone Acetate
318841|NCT01424930|Prednisone
318842|NCT01424930|Food Safety
318843|NCT01424917|Cardiac Allograft Vasculopathy
318844|NCT01424904|Ergogenic aid
318845|NCT01424904|Exercise endurance
318846|NCT01424904|High performance
318847|NCT01424904|Time trial performance
318848|NCT01424904|Glutathione
318849|NCT01424878|Molecular Analysis of Medullary Thyroid Carcinoma Tissues
318850|NCT01424865|HER2-positive breast cancer
318851|NCT01424865|stage II breast cancer
318852|NCT01424865|stage IIIA breast cancer
318853|NCT01424852|Probiotics
318854|NCT01424852|Caries
318855|NCT01424852|Oral flora
318856|NCT01424839|SIOP CNS GCT II
318857|NCT01424839|Patients with the primary disease of an Intracranial Germ Cell Tumors
318858|NCT01424826|Healthy volunteers
318859|NCT01424813|Asthma
318860|NCT01424813|dry powder inhaler
318861|NCT01424813|short-acting beta2-agonist
318862|NCT01424813|SABA
318863|NCT01424813|bronchoconstriction
318864|NCT01424813|bronchodilation
318865|NCT01424813|bronchodilator
318866|NCT01424813|metered dose inhaler
318867|NCT01424774|Radiation Exposure
318868|NCT01424774|Rubidium 82
318869|NCT01424774|Strontium 82
318870|NCT01424774|Strontium 85
318871|NCT01424748|Noni juice
318872|NCT01424748|Safety
318873|NCT01424735|Best corrected Visual Acuity
318874|NCT01424735|Pupillary Reaction
318875|NCT01424735|Colour vision
318876|NCT01424735|Disc edema
318877|NCT01424722|ICD Indicated patients
318878|NCT01424722|documented CAD
318879|NCT01424709|Chemotherapy
318880|NCT01424709|Individual therapy
318881|NCT01424709|RRM1
318882|NCT01424709|BRCA1
318883|NCT01424696|growth measures
318884|NCT01424696|nutritional status
318885|NCT01424696|pulmonary infection
318886|NCT01424696|inflammatory markers
318887|NCT01424696|pancreatic enzyme replacement therapy
318888|NCT01424683|Qol
318889|NCT01424683|Quality of life
318890|NCT01424683|VAS
318891|NCT01424683|Visual Analogue Scale
318892|NCT01424683|CABG
318893|NCT01424683|Coronary Artery Bypass Graft
318894|NCT01424683|Qol conversion
318895|NCT01424683|post hoc HTA
318896|NCT01424670|Multidrug resistant tuberculosis
318897|NCT01424657|MRCP
318898|NCT01424657|ERCP
318899|NCT01424657|BILIARY OBSTRUCTION
318900|NCT01424657|EFFECTIVENESS
318901|NCT01424644|meningitis
318902|NCT01424644|human papillomavirus
318903|NCT01424644|tetanus
318904|NCT01424644|diptheria
318905|NCT01424644|pertussis
318906|NCT01424618|Donor eggs
318907|NCT01424618|Donor oocytes
318908|NCT01424618|Pregnancy
318909|NCT01424618|Embryo Implantation
318910|NCT01424618|Infertility
318911|NCT01424618|IVF
318912|NCT01424605|left-sided double lumen bronchial tube
318913|NCT01424605|GlideScope videolaryngoscope
318914|NCT01424605|direct laryngoscope
318915|NCT01424592|Portable sleep apnea testing
318916|NCT01424592|Positive airway pressure therapy
318917|NCT01424592|Polysomnography
318918|NCT01424566|cancer pain
318919|NCT01424566|opioid therapy
318920|NCT01424566|inadequate analgesia
318921|NCT01424566|optimized chronic opioid therapy
318922|NCT01424553|Low birthweight
318923|NCT01424553|Bronchopulmonary dysplasia
318924|NCT01424553|Lung development
318925|NCT01424553|Airway obstruction
318926|NCT01424553|Asthma
318927|NCT01424527|Chronic Obstructive Pulmonary Disease(COPD)
318928|NCT01424527|COPD Assessment Test(CAT)
318929|NCT01424501|Tuberculosis vaccine
318930|NCT01424501|HIV-negative
318931|NCT01424501|tuberculosis treatment
318932|NCT01424488|sugammadex
318933|NCT01424488|reversal
318934|NCT01424488|pipecuronium-induced neuromuscular blockade
318935|NCT01424462|healthy volunteers
318936|NCT01424462|firategrast
318937|NCT01424462|Pharmacokinetics
318938|NCT01424462|modified release
318939|NCT01424436|CSF sampling
318940|NCT01424436|Alzheimer's disease
318941|NCT01424436|Amyloid beta levels
318942|NCT01424423|Safety
318943|NCT01424423|GSK1223249
318944|NCT01424423|Pharmacokinetics
318945|NCT01424423|Single dose escalation
318946|NCT01424423|anti-GSK1223249 antibodies
318947|NCT01424423|Multiple Sclerosis
318948|NCT01424410|paediatric schistosomiasis morbidity immunology
318949|NCT01424384|healthy volunteers
318950|NCT01424384|Anxiety Disorder
318951|NCT01424384|neuropsychological tests
318952|NCT01424345|Kidney Transplantation
318953|NCT01424345|Immunosuppression
318954|NCT01424345|Immune monitoring
318955|NCT01424332|Pharmacodynamics
318956|NCT01424332|pharmacokinetics
318957|NCT01424332|darexaban
318958|NCT01424332|Acetyl Salicylic Acid
318959|NCT01424332|darexaban glucuronide
318960|NCT01424332|YM150
318961|NCT01424332|YM-222714
318962|NCT01424332|Phase 1
318963|NCT01424319|Endothelin Receptor Antagonists
318964|NCT01424319|Proteinuria
318965|NCT01424306|Inflammation
318966|NCT01424306|Intestinal permeability
318967|NCT01424306|Type 2 diabetes mellitus
318968|NCT01424306|Cardiovascular disease
318969|NCT01424306|Obesity
318970|NCT01424306|Sweetened beverages
318971|NCT01424306|Sugar
318972|NCT01424306|Fructose
318973|NCT01424306|Glucose
318974|NCT01424306|High-fructose corn syrup
318975|NCT01424293|Rectal Cancer
318976|NCT01424293|Colon Cancer
318977|NCT01424293|Diverticulitis
318978|NCT01424293|Anastamosis
318979|NCT01424293|colectomy
318980|NCT01424293|low anterior resection
318981|NCT01424267|low profile
318982|NCT01424267|endovascular graft
318983|NCT01424267|endovascular procedure
318984|NCT01424267|aortic aneurysm, abdominal aortic aneurysm
318985|NCT01424254|Gastrointestinal Bleeding of Obscure Origin
318986|NCT01424241|Sandostatin LAR
318987|NCT01424228|Long term
318988|NCT01424228|Constipation
318989|NCT01424228|Digestive signs and symptoms
318990|NCT01424202|Post extubation failure
318991|NCT01424202|Mechanical Insufflation-Exsufflation
318992|NCT01424202|Noninvasive Ventilation
318993|NCT01424202|Weaning
318994|NCT01424150|Postoperative fluid
318995|NCT01424150|surgery
318996|NCT01424150|anaesthesia
318997|NCT01424150|fluid
318998|NCT01424150|mortality
318999|NCT01424150|morbidity
319000|NCT01424111|Biomarkers
319001|NCT01424111|Depression
319002|NCT01424111|Major Depressive Disorder
319003|NCT01424111|Escitalopram
319004|NCT01424072|stress psychological
319005|NCT01424072|coping behavior
319006|NCT01424059|fear
319007|NCT01424059|labor
319008|NCT01424059|induction
319009|NCT01424059|amniotomy
319010|NCT01424059|WEDQ-B
319011|NCT01424059|parous
319012|NCT01424059|cesarean section
319013|NCT01424046|type 1 diabetes
319014|NCT01424046|basal insulin
319015|NCT01424046|developing world
319016|NCT01424046|comparative effectiveness
319017|NCT01424033|Interstitial lung disease
319018|NCT01424033|Connective tissue disease
319019|NCT01424033|Scleroderma
319020|NCT01424033|Rheumatoid arthritis
319021|NCT01424033|Sjogren's syndrome
319022|NCT01424033|Mixed connective tissue disease
319023|NCT01424033|Dermatomyositis
319024|NCT01424033|Polymyositis
319025|NCT01424033|Systemic lupus erythematosis
319026|NCT01424020|Questionnaire
319027|NCT01424020|peripheral artery disease
319028|NCT01424020|execise
319029|NCT01424007|Obese
319030|NCT01424007|Women
319031|NCT01424007|Weight loss
319032|NCT01424007|Exercise
319033|NCT01424007|Physical activity
319034|NCT01424007|Diet
319035|NCT01424007|Female
319036|NCT01423994|syncope
319037|NCT01423994|fainting
319038|NCT01423994|implantable loop recorder
319039|NCT01423994|pacemaker
319040|NCT01423994|heart block
319041|NCT01423994|bifascicular heart block
319042|NCT01423981|Keloid
319043|NCT01423981|Scar
319044|NCT01423981|hypertrophic scar
319045|NCT01423981|familial keloid
319046|NCT01423968|Sepsis
319047|NCT01423968|Inflammation
319048|NCT01423968|Lipopolysaccharide
319049|NCT01423968|Muscle protein turnover
319050|NCT01423968|Insulin resistance
319051|NCT01423955|Erythropoietin
319052|NCT01423955|Erythropoetin
319053|NCT01423955|Cardiac surgery
319054|NCT01423955|Ischemia
319055|NCT01423955|Reperfusion
319056|NCT01423955|Renal function
319057|NCT01423955|Cystatin C
319058|NCT01423955|Creatinine
319059|NCT01423955|Safety
319060|NCT01423929|Oxygen
319061|NCT01423929|Myocardial infarction
319062|NCT01423929|Ambulance
319063|NCT01423929|Percutaneous coronary intervention
319064|NCT01423929|Cardiac magnetic resonance imaging
319065|NCT01423916|Schizophrenia
319066|NCT01423916|QTc Interval
319067|NCT01423903|Phase I
319068|NCT01423903|STAT-3 inhibitor
319069|NCT01423903|solid tumors
319070|NCT01423890|Breast Cancer
319071|NCT01423890|Oncotype DX
319072|NCT01423890|Adjuvant! Online
319073|NCT01423890|Decisional Conflict Scale
319074|NCT01423877|bariatric surgery
319075|NCT01423877|diabetes
319076|NCT01423877|sleeve gastrectomy
319077|NCT01423877|gastric bypass
319078|NCT01423877|gastric banding
319079|NCT01423864|Acute Respiratory Distress Syndrome
319080|NCT01423864|Multi-organ Dysfunction Syndrome
319081|NCT01423864|Extracorporeal Membrane Oxygenation
319082|NCT01423851|Keywords provided by NS Pharma, Inc.:
319083|NCT01423851|JAK2 kinase inhibitor
319084|NCT01423851|NS-018
319085|NCT01423851|Myeloproliferative Neoplasms
319086|NCT01423851|Primary Myelofibrosis
319087|NCT01423851|post-Polycythemia Vera Myelofibrosis
319088|NCT01423851|post-Essential Thrombocythemia Myelofibrosis
319089|NCT01423851|Additional relevant MeSH terms:
319090|NCT01423851|Bone Marrow Diseases
319091|NCT01423851|Hematologic Diseases
319092|NCT01423851|Polycythemia Vera
319093|NCT01423851|Thrombocythemia, Essential
319094|NCT01423851|PMF
319095|NCT01423851|post-PV MF
319096|NCT01423851|post-ET MF
319097|NCT01423838|Overactive bladder
319098|NCT01423838|Solifenacin
319099|NCT01423838|Oxybutynin
319100|NCT01423812|HIV
319101|NCT01423812|treatment-experienced
319102|NCT01423812|protease inhibitor
319103|NCT01423812|adherence
319104|NCT01423812|lipids
319105|NCT01423799|Quality of life
319106|NCT01423799|Cancer
319107|NCT01423799|Immunonutrition
319108|NCT01423760|Vaccine
319109|NCT01423760|Stimuvax
319110|NCT01423760|Tecemotide
319111|NCT01423760|L-BLP25
319112|NCT01423760|Non-Small Cell Lung Carcinoma
319113|NCT01423760|Multiple Myeloma
319114|NCT01423747|ALL
319115|NCT01423747|HSCT
319116|NCT01423747|children
319117|NCT01423747|adolescents
319118|NCT01423734|ADRENAL GLAND
319119|NCT01423734|MRI
319120|NCT01423734|11-122
319121|NCT01423708|Liver Transplantation
319122|NCT01423708|Graft Rejection
319123|NCT01423708|Graft Survival
319124|NCT01423708|Transplantation Immunology
319125|NCT01423708|Anti-Rejection Therapy
319126|NCT01423708|Immunosuppression
319127|NCT01423708|Organ Transplantation
319128|NCT01423708|Host vs Graft Reaction
319129|NCT01423708|Gastroenterology
319130|NCT01423708|Hepatology
319131|NCT01423669|Psychotic Disorders
319132|NCT01423643|HIV
319133|NCT01423643|Human immunodeficiency virus
319134|NCT01423643|Acquired Immune Deficiency Syndrome Virus
319135|NCT01423643|AIDS Virus
319136|NCT01423643|Immunodeficiency Virus, Human
319137|NCT01423643|Virus, Human Immunodeficiency
319138|NCT01423643|Hepatitis C
319139|NCT01423643|Hepatitis C, chronic
319140|NCT01423643|Hepatitis C virus
319141|NCT01423643|Hepatitis C antibodies
319142|NCT01423643|Hepatitis C antigens
319143|NCT01423630|fatty liver
319144|NCT01423630|probiotics
319145|NCT01423630|Lactobacillus
319146|NCT01423630|fruit
319147|NCT01423630|fibre
319148|NCT01423630|dietary intervention
319149|NCT01423630|obesity
319150|NCT01423617|overweight
319151|NCT01423617|weight loss
319152|NCT01423617|body fat
319153|NCT01423617|waist circumference
319154|NCT01423617|satiety
319155|NCT01423617|appetite
319156|NCT01423604|Metastatic pancreatic cancer
319157|NCT01423591|Infliximab
319158|NCT01423591|polymyalgia rheumatica
319159|NCT01423591|refractory
319160|NCT01423591|double blind
319161|NCT01423591|placebo controlled
319162|NCT01423591|trial
319163|NCT01423578|craving
319164|NCT01423578|mood
319165|NCT01423578|cue reactivity
319166|NCT01423578|smoking behavior
319167|NCT01423578|quit smoking
319168|NCT01423578|prevention
319169|NCT01423578|Hatha yoga
319170|NCT01423578|cardiovascular exercise
319171|NCT01423565|Deep Brain Stimulation
319172|NCT01423565|Parkinson's Disease
319173|NCT01423565|Subthalamic Nucleus
319174|NCT01423565|Constant Current
319175|NCT01423552|Heart transplantation
319176|NCT01423552|Immunosuppression
319177|NCT01423552|Pharmacokinetics
319178|NCT01423552|Pharmacogenetics
319179|NCT01423513|ankle tape
319180|NCT01423513|Hoffmann reflex
319181|NCT01423513|Balance
319182|NCT01423500|ALL
319183|NCT01423500|HSCT
319184|NCT01423500|children
319185|NCT01423500|adolescents
319186|NCT01423487|Metformin
319187|NCT01423487|Risperidone
319188|NCT01423487|Prevention
319189|NCT01423487|weight gain
319190|NCT01423487|Amenorrhea
319191|NCT01423474|Radiotherapy
319192|NCT01423474|Hypofractionation
319193|NCT01423448|Depression
319194|NCT01423448|mental health
319195|NCT01423448|wellbeing
319196|NCT01423448|online bulletin board
319197|NCT01423448|online support group
319198|NCT01423435|TRK-100STP
319199|NCT01423435|PK
319200|NCT01423435|beraprost sodium
319201|NCT01423422|Exercise stress test
319202|NCT01423422|Effort Angina
319203|NCT01423422|Exercise induced angina
319204|NCT01423409|visual analog pain scale
319205|NCT01423409|Deaf persons
319206|NCT01423409|clinical trial
319207|NCT01423409|multicentric
319208|NCT01423396|Alzheimer's disease
319209|NCT01423396|cardiovascular risk factors
319210|NCT01423383|Keloid
319211|NCT01423370|Erectile Dysfunction
319212|NCT01423370|YHD1023
319213|NCT01423370|YCD190
319214|NCT01423370|Cialis
319215|NCT01423370|Yuhan
319216|NCT01423357|HIV prevention
319217|NCT01423357|condom distribution
319218|NCT01423357|youth peer education
319219|NCT01423357|high risk places
319220|NCT01423357|condom use
319221|NCT01423357|prevention through increased condom use
319222|NCT01423344|multiple myeloma
319223|NCT01423344|Free light chains
319224|NCT01423331|Postpartum depression
319225|NCT01423331|maternal mental health
319226|NCT01423305|Asthma
319227|NCT01423266|High Protein Diet in heart failure
319228|NCT01423266|obesity and heart failure
319229|NCT01423266|Weight management in Heart failure
319230|NCT01423266|heart failure, diabetes and obesity
319231|NCT01423253|Depression
319232|NCT01423253|Lurasidone
319233|NCT01423253|Latuda
319234|NCT01423240|Depression
319235|NCT01423240|Lurasidone
319236|NCT01423240|Latuda
319237|NCT01423227|COPD
319238|NCT01423227|exercise
319239|NCT01423227|rehabilitation
319240|NCT01423227|dyspnea
319241|NCT01423227|quality of life
319242|NCT01423227|economic evaluation
319243|NCT01423214|rectal cancer
319244|NCT01423214|robot
319245|NCT01423214|laparoscopy
319246|NCT01423214|total mesorectal excision
319247|NCT01423214|robotic surgery
319248|NCT01423201|TIA
319249|NCT01423201|triage
319250|NCT01423201|Lp-PLA2
319251|NCT01423201|Proteomic
319252|NCT01423201|Genomic
319253|NCT01423188|ApolipoproteinA1
319254|NCT01423188|HDL-C
319255|NCT01423188|Atherosclerosis
319256|NCT01423175|high risk acute myeloid leukemia
319257|NCT01423175|advanced myelodysplastic syndrome
319258|NCT01423175|allogenic stem cell transplantation
319259|NCT01423175|clofarabine
319260|NCT01423162|Iron absorption
319261|NCT01423162|Oats
319262|NCT01423162|fortified oat beverages
319263|NCT01423149|subfoveal choroidal neovascularization
319264|NCT01423149|pathologic myopia
319265|NCT01423136|Patients undergoing non-cardiac Surgery
319266|NCT01423123|Paclitaxel
319267|NCT01423123|Trastuzumab
319268|NCT01423123|Neratinib
319269|NCT01423123|Breast Cancer
319270|NCT01423123|HER2-positive
319271|NCT01423110|sporadic Inclusion Body Myositis
319272|NCT01423097|osteoarthritis symptoms
319273|NCT01423084|Meningococcal Meningitis
319274|NCT01423084|prevention, vaccination
319275|NCT01423084|adolescents
319276|NCT01423071|Pulmonary Hypertension
319277|NCT01423071|Chronic obstructive pulmonary disease
319278|NCT01423071|Prevalence
319279|NCT01423071|Quality of life
319280|NCT01423045|Chronic kidney disease
319281|NCT01423045|Urine osmolarity
319282|NCT01423045|Glomerular filtration rate
319283|NCT01423032|relapsed
319284|NCT01423019|Weight Loss
319285|NCT01423019|Body Composition
319286|NCT01423019|Fat Free Mass
319287|NCT01423019|Bone Mineral Density
319288|NCT01423019|Adipose Tissue
319289|NCT01423019|Dual-Energy X-Ray Absorptiometry
319290|NCT01423019|Body Fat
319291|NCT01423019|Eating and appetite control
319292|NCT01423019|Basal Metabolic Rate
319293|NCT01423006|Pilot
319294|NCT01423006|Ablation
319295|NCT01423006|Low Risk
319296|NCT01423006|Radio Frequency
319297|NCT01423006|RFA
319298|NCT01423006|minimally invasive
319299|NCT01423006|prostate gland
319300|NCT01422993|Oxaliplatin Induced
319301|NCT01422993|Peripheral Neuropathy
319302|NCT01422993|Strength
319303|NCT01422993|Balance
319304|NCT01422993|Training Program
319305|NCT01422993|Colon
319306|NCT01422993|Rectal
319307|NCT01422980|dairy product
319308|NCT01422980|upper gastric discomfort
319309|NCT01422980|adult
319310|NCT01422967|Osteoarthritis
319311|NCT01422967|Sleep
319312|NCT01422967|muscle strength
319313|NCT01422967|balance
319314|NCT01422928|Radiotherapy
319315|NCT01422928|Acupuncture
319316|NCT01422928|Immune System
319317|NCT01422915|Sorbent
319318|NCT01422915|Resin
319319|NCT01422915|EPP
319320|NCT01422915|Cutaneous porphyria
319321|NCT01422915|Adult
319322|NCT01422915|over age 21
319323|NCT01422915|without intercurrent illness
319324|NCT01422915|not pregnant
319325|NCT01422915|willing to participate
319326|NCT01422902|Schizophrenia
319327|NCT01422902|Cognitive deficits
319328|NCT01422902|Cognitive remediation
319329|NCT01422902|Software
319330|NCT01422902|Brain Plasticity
319331|NCT01422889|Atherosclerosis
319332|NCT01422889|Coronary Artery Disease
319333|NCT01422863|weight loss
319334|NCT01422863|exercise
319335|NCT01422863|diet
319336|NCT01422863|sleep apnea
319337|NCT01422863|aging
319338|NCT01422850|hormone-refractory prostate cancer
319339|NCT01422850|Immunotherapy
319340|NCT01422837|opioid
319341|NCT01422837|dependence
319342|NCT01422837|VIVITROL
319343|NCT01422811|Public health
319344|NCT01422811|Policy
319345|NCT01422811|Training
319346|NCT01422785|Acne Vulgaris
319347|NCT01422720|Epilepsy
319348|NCT01422720|ESL
319349|NCT01422720|Eslicarbazepine Acetate
319350|NCT01422720|BIAL
319351|NCT01422720|BIA
319352|NCT01422720|Partial-onset Seizures
319353|NCT01422694|Sacroiliitis
319354|NCT01422694|Ankylosing Spondylitis
319355|NCT01422694|Spondyloarthritis
319356|NCT01422694|HLA-B27
319357|NCT01422694|Enthesitis-Related Arthritis
319358|NCT01422681|COPD
319359|NCT01422668|Glycemic index
319360|NCT01422668|Dates
319361|NCT01422668|Diabetes
319362|NCT01422668|Coffee
319363|NCT01422629|Breast Fibroadenoma
319364|NCT01422629|High Intensity Focused Ultrasound
319365|NCT01422616|Ischemic stroke
319366|NCT01422616|High blood pressure
319367|NCT01422616|Thrombolysis
319368|NCT01422616|Antihypertensive drugs
319369|NCT01422616|Disability
319370|NCT01422616|Clinical trial
319371|NCT01422603|High risk
319372|NCT01422603|AML
319373|NCT01422603|MDS
319374|NCT01422590|sitagliptin
319375|NCT01422590|mitiglinide
319376|NCT01422590|type 2 diabetes mellitus
319377|NCT01422590|Pharmacodynamics
319378|NCT01422590|Safety
319379|NCT01422551|stress management intervention
319380|NCT01422551|breast cancer
319381|NCT01422551|quality of life
319382|NCT01422551|psychosocial adaptation
319383|NCT01422538|Ulthera® System
319384|NCT01422538|Ultherapy™ treatment
319385|NCT01422538|Ulthera, Inc.
319386|NCT01422538|Ultrasound treatment for skin tightening
319387|NCT01422538|Skin laxity on the face and neck.
319388|NCT01422512|seasonal influenza
319389|NCT01422512|vaccine
319390|NCT01422499|pediatric oncology
319391|NCT01422499|relapsed solid tumor
319392|NCT01422499|lymphoma
319393|NCT01422499|leukemia
319394|NCT01422499|vorinostat
319395|NCT01422486|Hematology
319396|NCT01422486|MDS
319397|NCT01422486|Myelodysplastic Syndrome
319398|NCT01422486|Low risk MDS
319399|NCT01422486|Intermediate-1 risk MDS
319400|NCT01422486|Int-1 risk MDS
319401|NCT01422486|Transfusion dependence
319402|NCT01422486|Lenalidomide refractory
319403|NCT01422486|Revlimid refractory
319404|NCT01422486|Lenalidomide resistant
319405|NCT01422486|Revlimid resistant
319406|NCT01422486|Telintra
319407|NCT01422486|ezatiostat
319408|NCT01422486|ezatiostat hydrochloride
319409|NCT01422486|TLK199
319410|NCT01422486|Glutathione
319411|NCT01422486|Glutathione analog
319412|NCT01422486|Glutathione Transferase
319413|NCT01422486|Glutathione Transferase P1-1 inhibitor
319414|NCT01422486|GST P1-1 inhibitor
319415|NCT01422486|Apoptosis
319416|NCT01422486|Differentiation
319417|NCT01422486|Enzyme inhibitor
319418|NCT01422473|Hemorrhoids
319419|NCT01422473|Rectal Diseases
319420|NCT01422473|Intestinal Diseases
319421|NCT01422473|Gastrointestinal Diseases
319422|NCT01422473|Digestive System Diseases
319423|NCT01422460|Osteoarthritis
319424|NCT01422460|PRP
319425|NCT01422460|PRGF
319426|NCT01422447|mental health education
319427|NCT01422447|community-based
319428|NCT01422434|A national
319429|NCT01422434|multi-centre
319430|NCT01422434|prospective
319431|NCT01422434|randomised
319432|NCT01422434|double-blind
319433|NCT01422434|active-controlled
319434|NCT01422434|3-arm
319435|NCT01422434|parallel group
319436|NCT01422434|4 week study
319437|NCT01422421|type 2 diabetes
319438|NCT01422421|coronary artery disease
319439|NCT01422421|hypertension
319440|NCT01422421|dyslipidemia
319441|NCT01422395|Vitrification
319442|NCT01422395|Egg Freezing
319443|NCT01422395|Oocyte Cryopreservation
319444|NCT01422382|Healthy Volunteers
319445|NCT01422369|Healthy Volunteers
319446|NCT01422356|cohort study
319447|NCT01422356|men who have sex with men
319448|NCT01422343|peripheral arterial disease
319449|NCT01422343|cell-derived microparticles
319450|NCT01422343|immunity, innate
319451|NCT01422343|blood coagulation
319452|NCT01422330|Human Immunodeficiency Virus (HIV) infection
319453|NCT01422330|TMC125IFD3002
319454|NCT01422330|TMC125
319455|NCT01422330|Intelence
319456|NCT01422330|HIV
319457|NCT01422317|n-3 fatty acids
319458|NCT01422317|randomized double-blind study
319459|NCT01422317|coronary events
319460|NCT01422317|serum lipids
319461|NCT01422317|antithrombotic effects of omega-3 fatty acids
319462|NCT01422317|anti-inflammatory effects of omega-3 fatty acids
319463|NCT01422317|prognostic biomarkers in myocardial infarction (MI)-patients
319464|NCT01422291|Low back pain
319465|NCT01422291|paracetamol
319466|NCT01422291|dexketoprofen
319467|NCT01422291|morphine
319468|NCT01422252|Falls Elderly persons
319469|NCT01422252|Isolated At risk for falls
319470|NCT01422252|Fall detection device
319471|NCT01422252|Precocious detection Vigi'Fall®
319472|NCT01422239|smoking
319473|NCT01422239|treatment
319474|NCT01422239|perceived risks
319475|NCT01422226|IUD
319476|NCT01422226|contraception
319477|NCT01422226|nulliparous
319478|NCT01422226|women
319479|NCT01422213|MDD
319480|NCT01422213|Cognitive dysfunction
319481|NCT01422200|DMD
319482|NCT01422200|SMA
319483|NCT01422200|CMD
319484|NCT01422200|flu vaccine
319485|NCT01422187|enzyme replacement therapy
319486|NCT01422174|Primary prevention
319487|NCT01422174|Latin America
319488|NCT01422174|Sudden death
319489|NCT01422174|Myocardial infarction
319490|NCT01422174|Ejection Fraction
319491|NCT01422174|ICD
319492|NCT01422161|Rehabilitation
319493|NCT01422161|Fingers
319494|NCT01422161|Grasp
319495|NCT01422161|Hand
319496|NCT01422161|Strength
319497|NCT01422161|Brain Infraction
319498|NCT01422161|Pathology
319499|NCT01422161|Physiopathology
319500|NCT01422161|Functional Laterality
319501|NCT01422161|Neuronal Plasticity
319502|NCT01422161|Psychomotor Performance
319503|NCT01422161|Biomechanics
319504|NCT01422161|Touch
319505|NCT01422161|Weight-Bearing
319506|NCT01422148|cardiac surgery
319507|NCT01422148|atrial fibrillation
319508|NCT01422148|minocycline
319509|NCT01422148|amiodarone
319510|NCT01422135|PK and safety
319511|NCT01422135|Pharmacokinetic profile (PK) and safety
319512|NCT01422122|vitamin D
319513|NCT01422122|pregnancy
319514|NCT01422122|periodontal health
319515|NCT01422122|biomarkers
319516|NCT01422109|YH14659
319517|NCT01422109|Aspirin
319518|NCT01422109|Clopidogrel
319519|NCT01422109|Yuhan
319520|NCT01422070|mortality
319521|NCT01422070|intensive care
319522|NCT01422070|critical care
319523|NCT01422070|intermediate care
319524|NCT01422057|diabetes
319525|NCT01422057|coronary artery disease
319526|NCT01422057|ischemic heart disease
319527|NCT01422057|autonomic function
319528|NCT01422057|heart rate turbulence
319529|NCT01422057|deceleration capacity
319530|NCT01422057|severe autonomic failure
319531|NCT01422044|aortic stenosis
319532|NCT01422044|autonomic function
319533|NCT01422031|Primary care
319534|NCT01422031|Family doctor
319535|NCT01422031|Consultation
319536|NCT01422031|utilization
319537|NCT01422031|Non-drug managements
319538|NCT01422031|Patient enablement index
319539|NCT01422018|clinically significant macular edema
319540|NCT01422018|diabetic macular edema
319541|NCT01422018|focal edema
319542|NCT01422018|focal laser photocoagulation
319543|NCT01422018|hard exudates
319544|NCT01422018|intravitreal bevacizumab
319545|NCT01422005|Rehabilitation
319546|NCT01422005|Fingers
319547|NCT01422005|Grasp
319548|NCT01422005|Hand
319549|NCT01422005|Strength
319550|NCT01422005|Brain Infraction
319551|NCT01422005|Hand Function
319552|NCT01422005|Post Stroke
319553|NCT01422005|Neural mechanisms
319554|NCT01422005|Motor Control
319555|NCT01422005|Motor Function
319556|NCT01421992|randomized
319557|NCT01421992|double-blind
319558|NCT01421992|crossover
319559|NCT01421992|methylphenidate
319560|NCT01421992|excessive daytime sleepiness
319561|NCT01421966|chronic ulcers
319562|NCT01421966|diabetic foot ulcers
319563|NCT01421953|Positron Emission Tomography
319564|NCT01421953|Computed Tomography
319565|NCT01421953|Lung cancer
319566|NCT01421940|Udenafil
319567|NCT01421940|rectal cancer
319568|NCT01421940|penile rehabilitation
319569|NCT01421940|total mesorectal excision
319570|NCT01421927|lenalidomide
319571|NCT01421914|Ultrasound
319572|NCT01421914|Axillary block
319573|NCT01421914|Bupivacaine
319574|NCT01421914|Minimum
319575|NCT01421914|Volume
319576|NCT01421914|Minimum volume of bupivacaine 0,5%
319577|NCT01421901|Acute appendicitis
319578|NCT01421901|Surgery
319579|NCT01421901|Antibiotics
319580|NCT01421901|comparison surgery and antibiotics
319581|NCT01421901|resolutions of symptoms
319582|NCT01421888|Immunity
319583|NCT01421888|Urea Cycle Disorder
319584|NCT01421888|Nutrition
319585|NCT01421888|Vaccination
319586|NCT01421888|Influenza
319699|NCT01421524|Glioblastoma multiforme
319587|NCT01421875|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
319588|NCT01421875|adult acute myeloid leukemia with del(5q)
319589|NCT01421875|adult acute myeloid leukemia with inv(16)(p13;q22)
319590|NCT01421875|adult acute myeloid leukemia with t(16;16)(p13;q22)
319591|NCT01421875|adult acute myeloid leukemia with t(8;21)(q22;q22)
319592|NCT01421875|untreated adult acute myeloid leukemia
319593|NCT01421875|adult acute myeloblastic leukemia without maturation (M1)
319594|NCT01421875|adult acute myeloblastic leukemia with maturation (M2)
319595|NCT01421875|adult acute myelomonocytic leukemia (M4)
319596|NCT01421875|adult acute monoblastic leukemia (M5a)
319597|NCT01421875|adult acute monocytic leukemia (M5b)
319598|NCT01421875|adult erythroleukemia (M6a)
319599|NCT01421875|adult pure erythroid leukemia (M6b)
319600|NCT01421875|adult acute megakaryoblastic leukemia (M7)
319601|NCT01421875|adult acute minimally differentiated myeloid leukemia (M0)
319602|NCT01421862|adult acute basophilic leukemia
319603|NCT01421862|adult acute eosinophilic leukemia
319604|NCT01421862|adult erythroleukemia (M6a)
319605|NCT01421862|adult pure erythroid leukemia (M6b)
319606|NCT01421862|adult acute minimally differentiated myeloid leukemia (M0)
319607|NCT01421862|adult acute monoblastic leukemia (M5a)
319608|NCT01421862|adult acute monocytic leukemia (M5b)
319609|NCT01421862|adult acute myeloblastic leukemia with maturation (M2)
319610|NCT01421862|adult acute myelomonocytic leukemia (M4)
319611|NCT01421862|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
319612|NCT01421862|adult acute myeloid leukemia with del(5q)
319613|NCT01421862|adult acute myeloid leukemia with inv(16)(p13;q22)
319614|NCT01421862|adult acute myeloid leukemia with t(16;16)(p13;q22)
319615|NCT01421862|adult acute myeloid leukemia with t(8;21)(q22;q22)
319616|NCT01421862|untreated adult acute myeloid leukemia
319617|NCT01421862|adult acute myeloblastic leukemia without maturation (M1)
319618|NCT01421862|adult acute megakaryoblastic leukemia (M7)
319619|NCT01421849|single implant denture
319620|NCT01421849|Elderly with an unstable mandibular denture
319621|NCT01421836|stent patency
319622|NCT01421836|EUS guided insertion
319623|NCT01421836|ERCP guided insertion
319624|NCT01421823|Fecal Incontinence
319625|NCT01421823|Alpha agonist
319626|NCT01421732|Dengue fever
319627|NCT01421732|severe dengue fever
319628|NCT01421732|NS1 detection assay
319629|NCT01421732|Prognosis
319630|NCT01421732|Diagnosis
319631|NCT01421719|Parkinson's Disease
319632|NCT01421719|Neurogenic Bladder
319633|NCT01421719|Urinary Incontinence
319634|NCT01421719|botulinum toxin
319635|NCT01421719|cystoscopy
319636|NCT01421719|Effect of Other Parasympatholytics [Anticholinergics and Antimuscarinics] and Spasmolytics
319637|NCT01421706|clarithromycin
319638|NCT01421706|sibutramine
319639|NCT01421706|clopidogrel
319640|NCT01421693|Gatifloxacin
319641|NCT01421693|Ceftriaxone
319642|NCT01421693|Enteric fever
319643|NCT01421693|Typhoid fever
319644|NCT01421667|Lymphoma, Large B-Cell, Diffuse
319645|NCT01421667|Antigens, CD30
319646|NCT01421667|Antibody-Drug Conjugate
319647|NCT01421667|Antibodies, Monoclonal
319648|NCT01421667|Lymphoma, Non-Hodgkin
319649|NCT01421667|Monomethyl auristatin E
319650|NCT01421667|Drug Therapy
319651|NCT01421667|Immunotherapy
319652|NCT01421667|Hematologic Diseases
319653|NCT01421667|Lymphoma
319654|NCT01421667|Lymphoma, B-Cell
319655|NCT01421667|Lymphoma, T-Cell
319656|NCT01421654|OSA
319657|NCT01421654|Sleep Apnea
319658|NCT01421654|PAP
319659|NCT01421654|positive airway pressure
319660|NCT01421641|Tenaculum
319661|NCT01421641|Pain
319662|NCT01421641|Lidocaine
319663|NCT01421628|older adults
319664|NCT01421628|exercise
319665|NCT01421628|stretching
319666|NCT01421628|mobility
319667|NCT01421615|Bacterial vaginosis
319668|NCT01421615|Probiotics
319669|NCT01421615|Lactobacilli
319670|NCT01421615|Pregnancy outcome
319671|NCT01421615|Randomized controlled trial
319672|NCT01421602|Inguinal Hernia
319673|NCT01421602|Self-fixating mesh
319674|NCT01421602|Progrip
319675|NCT01421602|Hernia Recurrence
319676|NCT01421602|Mesh, Surgical
319677|NCT01421602|Recurrence
319678|NCT01421589|Growth hormone
319679|NCT01421589|GH
319680|NCT01421589|Obesity
319681|NCT01421589|Mitochondrial function
319682|NCT01421589|reduced growth hormone secretion
319683|NCT01421550|umbilical
319684|NCT01421550|hernia
319685|NCT01421550|cirrhosis
319686|NCT01421550|ascites
319687|NCT01421550|conservative
319688|NCT01421550|surgery
319689|NCT01421550|optimal management
319690|NCT01421537|Thromboprophylaxis
319691|NCT01421537|enoxaparin
319692|NCT01421524|Neoplasm
319693|NCT01421524|Malignancy
319694|NCT01421524|Carcinoma
319695|NCT01421524|Lymphoma
319696|NCT01421524|Multiple Myeloma
319697|NCT01421524|DNA-PK inhibitor
319698|NCT01421524|Advanced Solid Tumors
319700|NCT01421524|Hepatocellular Carcinoma
319701|NCT01421524|Diffuse large B-cell lymphoma
319702|NCT01421524|Mantel Cell Lymphoma
319703|NCT01421524|Advanced unresectable Solid Tumors
319704|NCT01421524|Primary CNS Lymphoma
319705|NCT01421511|ABSSSI
319706|NCT01421511|Tedizolid Phosphate
319707|NCT01421511|TR-701
319708|NCT01421511|Acute Bacterial Skin and Skin Structure Infections
319709|NCT01421498|Dry Eye
319710|NCT01421498|ophthalmic delivery
319711|NCT01421472|Breast Cancer
319712|NCT01421472|Neoadjuvant
319713|NCT01421472|Her2 negative
319714|NCT01421472|Her2 non-overexpressing
319715|NCT01421472|Estrogen Receptor Positive
319716|NCT01421472|Triple Negative
319717|NCT01421472|MM-121
319718|NCT01421472|Paclitaxel
319719|NCT01421459|Diabetes
319720|NCT01421459|Type 2 Diabetes
319721|NCT01421446|Neuropsychology
319722|NCT01421433|Clonixin
319723|NCT01421433|Anti-Inflammatory Agents, Non-Steroidal
319724|NCT01421433|Cyclooxygenase Inhibitors
319725|NCT01421433|Lysine
319726|NCT01421433|L-Lysine
319727|NCT01421433|Lysine Acetate
319728|NCT01421433|Lysine Hydrochloride
319729|NCT01421433|Amitriptyline
319730|NCT01421420|Alzheimer's
319731|NCT01421420|Dementia
319732|NCT01421420|Mild Cognitive Impairment
319733|NCT01421407|Secondary hyperparathyroidism
319734|NCT01421407|End stage renal disease
319735|NCT01421407|Parathyroid hyperplasia
319736|NCT01421407|High Intensity Focused Ultrasound
319737|NCT01421394|spinal cord injury(SCI)
319738|NCT01421394|diffusion tensor imaging(DTI)
319739|NCT01421394|tractography
319740|NCT01421381|leber's hereditary optic neuropathy
319741|NCT01421381|idebenone
319742|NCT01421342|Mood Disorder
319743|NCT01421342|Depression
319744|NCT01421342|Depressive Disorder
319745|NCT01421342|Depressive Disorder, Major
319746|NCT01421342|Bupropion
319747|NCT01421342|Aripiprazole
319748|NCT01421342|Remission
319749|NCT01421342|Relapse
319750|NCT01421342|Cost-Effectiveness
319751|NCT01421342|Atypical Antipsychotic
319752|NCT01421342|Antidepressant
319753|NCT01421342|Augmentation
319754|NCT01421342|Veterans
319755|NCT01421342|Mental Health
319756|NCT01421329|Interest in Exercising More
319757|NCT01421316|Patients treated with whole brain radiotherapy in the setting of brain metastases
319758|NCT01421316|Patients treated with whole brain radiotherapy in the prophylactic treatment for small cell lung cancer (extended disease).
319759|NCT01421290|Cartilage lesions in the knee joint
319760|NCT01421264|concussion
319761|NCT01421264|gabapentin
319762|NCT01421264|neurontin
319763|NCT01421264|insomnia
319764|NCT01421251|H1N1
319765|NCT01421251|Flu
319766|NCT01421251|Influenza
319767|NCT01421251|Vaccine
319768|NCT01421251|Manitoba
319769|NCT01421251|Canada
319770|NCT01421251|Safety
319771|NCT01421238|Decision Making
319772|NCT01421238|Premature infant
319773|NCT01421238|Informed consent
319774|NCT01421238|Prematurity
319775|NCT01421238|Framing
319776|NCT01421238|Negotiation Model
319777|NCT01421225|Closed Loop Insulin Delivery
319778|NCT01421225|Diabetes
319779|NCT01421225|Type 1 Diabetes
319780|NCT01421225|Artificial pancreas
319781|NCT01421212|Liver Transplantation
319782|NCT01421212|Liver Disease
319783|NCT01421212|Hepatitis B
319784|NCT01421212|Hepatitis B Infection
319785|NCT01421212|Hepatitis B Associated Liver Disease
319786|NCT01421212|HBV
319787|NCT01421199|Otitis Media with Effusion
319788|NCT01421199|Middle Ear Effusion
319789|NCT01421186|Multiple Myeloma
319790|NCT01421186|MOR03087 (MOR202)
319791|NCT01421186|Lenalidomide
319792|NCT01421186|Pomalidomide
319793|NCT01421186|CD38
319794|NCT01421173|Lymphoma
319795|NCT01421173|Lymphoid malignancies
319796|NCT01421173|Relapsed
319797|NCT01421173|Refractory
319798|NCT01421173|Autologous hematopoietic cell support
319799|NCT01421173|Stem cell infusion
319800|NCT01421173|Hodgkin's lymphoma
319801|NCT01421173|non-Hodgkin's lymphoma
319802|NCT01421173|Vorinostat
319803|NCT01421173|SAHA
319804|NCT01421173|Suberoylanilide Hydroxamic Acid
319805|NCT01421173|MSK-390
319806|NCT01421173|Zolinza
319807|NCT01421173|Busulfan
319808|NCT01421173|Busulfex
319809|NCT01421173|Myleran
319810|NCT01421173|Gemcitabine
319811|NCT01421173|Gemcitabine Hydrochloride
319812|NCT01421173|Gemzar
319813|NCT01421173|Melphalan
319814|NCT01421173|Alkeran
319815|NCT01421173|Rituximab
319816|NCT01421173|Rituxan
319817|NCT01421173|Dexamethasone
319818|NCT01421173|Decadron
319819|NCT01421173|G-CSF
319820|NCT01421173|Filgrastim
319821|NCT01421173|NeupogenTM
319822|NCT01421173|Palifermin
319823|NCT01421173|Kepivance
319824|NCT01421160|Chronic
319825|NCT01421160|Inflammatory
319826|NCT01421160|Joint
319827|NCT01421160|Pain
319828|NCT01421147|Diabetes
319829|NCT01421147|Type 1 Diabetes
319830|NCT01421147|Diabetes Mellitus
319831|NCT01421134|depression
319832|NCT01421134|Lurasidone
319833|NCT01421134|Latuda
319834|NCT01421108|oral health
319835|NCT01421108|dental brushing
319836|NCT01421108|dental flossing
319837|NCT01421095|Fertility
319838|NCT01421095|adolescent
319839|NCT01421095|young adult
319840|NCT01421095|cancer survivors
319841|NCT01421082|LVRS (Lung Volume Reduction Surgery)
319842|NCT01421082|LVRC (Lung Volume Reduction Coil)
319843|NCT01421082|Emphysema
319844|NCT01421082|coil
319845|NCT01421082|RePneu
319846|NCT01421069|Use of etanercept to treat pediatric subjects with extended oligoarticular JIA
319847|NCT01421069|enthestitis related arthritis (ERA)
319848|NCT01421069|or psoriatic arthritis (PsA).
319849|NCT01421043|bioequivalence study
319850|NCT01421043|triazolam
319851|NCT01421043|liquid oral drops
319852|NCT01421043|tablet
319853|NCT01421030|quality of life
319854|NCT01421030|congenital heart disease
319855|NCT01421030|open heart surgery
319856|NCT01421030|percutaneous pulmonary valve implantation
319857|NCT01421030|costs
319858|NCT01421017|radiation therapy
319859|NCT01421017|combination therapy
319860|NCT01421017|immunotherapy
319861|NCT01421017|immune response modifier
319862|NCT01421017|immunostimulatory
319863|NCT01421017|immunomodulator
319864|NCT01421004|cancer
319865|NCT01421004|tumors
319866|NCT01421004|phase I
319867|NCT01421004|crossover
319868|NCT01421004|bioequivalence
319869|NCT01420965|Anti PD-1 Monoclonal Antibody
319870|NCT01420965|Vaccine
319871|NCT01420965|Autologous Cellular Immunotherapy
319872|NCT01420965|Prostate Cancer
319873|NCT01420952|Positron Emission Tomograhy (PET)
319874|NCT01420952|Metabolic Glutamate Receptors
319875|NCT01420952|Brain
319876|NCT01420939|TBI
319877|NCT01420939|Brain
319878|NCT01420939|Traumatic Brain Injury
319879|NCT01420939|Biomarkers
319880|NCT01420939|Healthy Volunteer
319881|NCT01420939|HV
319882|NCT01420913|To evaluate the pharmacokinetic characteristics of Lyrica, YHD1119 A,B,C
319883|NCT01420887|CPM
319884|NCT01420887|elbow joint surgery
319885|NCT01420887|continuous passive motion
319886|NCT01420887|Recovery after surgery to restore elbow motion
319887|NCT01420861|castrate resistant
319888|NCT01420848|stress disorders
319889|NCT01420848|anxiety disorders
319890|NCT01420835|Stress
319891|NCT01420835|Quality of life
319892|NCT01420796|Parkinson's disease
319893|NCT01420796|dysphagia
319894|NCT01420796|swallowing treatment
319895|NCT01420757|operation time
319896|NCT01420757|length of hospital stay
319897|NCT01420744|Endotracheal ventilation
319898|NCT01420744|Bacterial pneumonia
319899|NCT01420731|sexual life, back pain
319900|NCT01420718|partial pulpotomy
319901|NCT01420718|Cvek pulpotomy
319902|NCT01420718|MTA
319903|NCT01420718|iRootBP
319904|NCT01420718|dentin bridge
319905|NCT01420705|Bacille Calmette-Guérin
319906|NCT01420705|DTP
319907|NCT01420705|Vaccination
319908|NCT01420705|Allergy
319909|NCT01420705|Atopy
319910|NCT01420705|Guinea-Bissau
319911|NCT01420692|Tip 2 DM
319912|NCT01420692|Endothelium
319913|NCT01420692|Gliclazide
319914|NCT01420692|Insulin detemir
319915|NCT01420679|Lymphoproliferative Disorders
319916|NCT01420679|Lymphoma
319917|NCT01420679|Non-Hodgkin's Lymphoma
319918|NCT01420679|T-cell Lymphoma
319919|NCT01420640|Fibromyalgia
319920|NCT01420640|Tai Chi
319921|NCT01420640|mind-body exercise
319922|NCT01420640|aerobic exercise
319923|NCT01420640|exercise
319924|NCT01420640|pain
319925|NCT01420614|radial access
319926|NCT01420614|primary angioplasty
319927|NCT01420614|trial
319928|NCT01420614|randomization
319929|NCT01420614|outcome
319930|NCT01420601|Torisel
319931|NCT01420601|Long-term use
319932|NCT01420601|Regulatory Post Marketing Commitment Plan
319933|NCT01420588|Oncologic Investigations
319934|NCT01420588|Gastric Diseases
319935|NCT01420588|Gastric Cancer
319936|NCT01420588|Gastric Ulcer
319937|NCT01420588|Breath Analysis
319938|NCT01420588|Volatile Biomarkers
319939|NCT01420588|Nanosensors Array
319940|NCT01420588|Discriminant Factor Analysis
319941|NCT01420588|GC-MS
319942|NCT01420588|Breath Tests
319943|NCT01420575|Schizophrenia
319944|NCT01420575|Schizoaffective Disorder
319945|NCT01420575|Shared Decision
319946|NCT01420575|Decision Aid
319947|NCT01420575|Antipsychotic
319948|NCT01420575|Weight Gain
319949|NCT01420575|Olanzapine
319950|NCT01420575|Lexapro
319951|NCT01420575|Perphenazine
319952|NCT01420562|allogeneic HSCT
319953|NCT01420562|posaconazole
319954|NCT01420562|prophylaxis
319955|NCT01420562|mucositis
319956|NCT01420562|pharmacokinetics
319957|NCT01420549|Hypercholesterolemia
319958|NCT01420549|Dyslipidemia
319959|NCT01420536|Bilateral Balanced Occlusion
319960|NCT01420536|Canine Guidance
319961|NCT01420536|Complete Denture
319962|NCT01420536|Denture Retention
319963|NCT01420536|Dental Occlusion
319964|NCT01420536|Edentulous
319965|NCT01420536|Edentulism
319966|NCT01420536|Mandibular movement
319967|NCT01420536|Mastication
319968|NCT01420536|Patient Acceptance of Health Care
319969|NCT01420536|Patient Satisfaction
319970|NCT01420523|HIV
319971|NCT01420523|Lipohypertrophy
319972|NCT01420510|Patients satisfaction
319973|NCT01420510|Side effects
319974|NCT01420497|methylprednisolone
319975|NCT01420497|intra articular infiltration
319976|NCT01420497|glycemia
319977|NCT01420497|epidural infiltration
319978|NCT01420497|diabetes
319979|NCT01420484|CNAP
319980|NCT01420484|continuous non-invasive arterial pressure
319981|NCT01420484|IAP
319982|NCT01420484|blood pressure
319983|NCT01420484|analgosedation
319984|NCT01420484|high-risk patients
319985|NCT01420484|rapid-pacing
319986|NCT01420471|Endoscopic Sinus Surgery
319987|NCT01420471|Triamcinolone
319988|NCT01420471|Merocel Middle Meatus Spacers
319989|NCT01420458|bioequivalence
319990|NCT01420432|Ankylosing Spondylitis
319991|NCT01420432|Umbilical Cord/placenta-Derived MSC
319992|NCT01420432|Transplantation
319993|NCT01420419|nipple pain
319994|NCT01420419|breastfeeding
319995|NCT01420419|nipple damage
319996|NCT01420419|lanolin
319997|NCT01420419|clinical trial
319998|NCT01420406|lactation
319999|NCT01420406|cryptoxanthin
320000|NCT01420406|beta-carotene
320001|NCT01420406|vitamin A
320002|NCT01420393|Heart Failure
320003|NCT01420393|Atrial Fibrillation
320004|NCT01420393|Catheter Ablation
320005|NCT01420393|Anti-arrhythmic Medications
320006|NCT01420393|Cardiovascular Mortality
320007|NCT01420367|Paediatric
320008|NCT01420367|Simple
320009|NCT01420367|Non-perforated
320010|NCT01420354|Metabolic stones
320011|NCT01420354|kidney stones
320012|NCT01420354|renal calculi
320013|NCT01420354|metabolic evaluation
320014|NCT01420341|Meliodosis
320015|NCT01420341|Co-trimoxazole
320016|NCT01420341|Relapse
320017|NCT01420315|vitamin D
320018|NCT01420315|deficiency
320019|NCT01420315|alzheimer's disease
320020|NCT01420302|critical illness
320021|NCT01420302|intensive care
320022|NCT01420302|insulin
320023|NCT01420302|glucose
320024|NCT01420302|algorithm
320025|NCT01420302|blood glucose control
320026|NCT01420289|Ischemic ulcers
320027|NCT01420289|PAD
320028|NCT01420289|Intermittent Claudication Pain
320029|NCT01420276|Female sexual function
320030|NCT01420263|premature infant
320031|NCT01420263|feeding
320032|NCT01420263|residuals
320033|NCT01420263|fresh feeds
320034|NCT01420263|full feeds
320035|NCT01420263|digestive system
320036|NCT01420250|Prostate cancer
320037|NCT01420250|Adenocarcinoma of the prostate
320038|NCT01420237|Noninflammatory joint disease of the hip.
320039|NCT01420224|Air travel
320040|NCT01420224|Aircraft cabin hypoxia
320041|NCT01420224|Pulmonary artery pressure
320042|NCT01420224|Hypoxic pulmonary vasoconstriction
320043|NCT01420224|Pulmonary hypertension
320044|NCT01420211|pharmacokinetics
320045|NCT01420211|MRI
320046|NCT01420211|liver
320047|NCT01420211|drug transporter
320048|NCT01420211|Gd-EOB-DTPA
320049|NCT01420198|Diabetes type 2
320050|NCT01420198|Lifestyle intervention
320051|NCT01420198|QALY
320052|NCT01420198|Ethnic group
320053|NCT01420198|Impaired glucose tolerance
320054|NCT01420198|Impaired fasting glucose
320055|NCT01420185|estrogen receptor-positive breast cancer
320056|NCT01420185|stage II breast cancer
320057|NCT01420185|stage IIIA breast cancer
320058|NCT01420159|Pain
320059|NCT01420159|Trauma
320060|NCT01420159|Analgesia
320061|NCT01420133|Corticosteroids
320062|NCT01420133|Diet low in sugar and salt
320063|NCT01420133|Dermatological disease
320064|NCT01420133|Corticosteroids Allergy
320065|NCT01420133|3 Months
320066|NCT01420120|Biodegradable stent, PAD
320067|NCT01420107|Infant, Premature
320068|NCT01420107|Delivery Rooms
320069|NCT01420107|Video Recording
320070|NCT01420107|Outcome Assessment (Health Care)
320071|NCT01420094|Drugs, Investigational
320072|NCT01420094|Acetylsalicylic Acid
320073|NCT01420094|Aspirin
320074|NCT01420094|dental pain
320075|NCT01420081|uterine neoplasms
320076|NCT01420081|endometrial
320077|NCT01420081|uterine
320078|NCT01420081|cancer
320079|NCT01420081|PI3K
320080|NCT01420081|mTOR
320081|NCT01420081|PI3K/mTOR
320082|NCT01420081|recurrent
320083|NCT01420081|metastatic
320084|NCT01420068|Pediatric
320085|NCT01420068|hypertension
320086|NCT01420068|aliskiren
320087|NCT01420055|Multiple sclerosis
320088|NCT01420055|Fingolimod
320089|NCT01420055|Coping
320090|NCT01420055|Anxiety
320091|NCT01420055|France
320092|NCT01420055|Treatment Satisfaction Questionnaire for Medication-9 items (TSQM 9)
320093|NCT01420055|Active
320094|NCT01420029|Low birth weight neonates
320095|NCT01420029|Neurodevelopmental outcome
320096|NCT01420029|Thyroid dysfunction
320097|NCT01420029|Extrauterine growth
320098|NCT01420029|Plasticizers
320099|NCT01420016|Cardiovascular risk
320100|NCT01420003|Allergen Challenge
320101|NCT01420003|B cell activation
320102|NCT01420003|M1 prime related biomarkers
320103|NCT01419977|sickle cell disease
320104|NCT01419977|vaso-occlusive crisis
320105|NCT01419977|anticoagulation
320106|NCT01419964|Vitiligo
320107|NCT01419964|Macular depigmentation
320108|NCT01419964|Stachytarpheta cayensensis
320109|NCT01419951|Behavioral treatment
320110|NCT01419951|Preschool aged children
320111|NCT01419951|Obesity
320112|NCT01419938|Light therapy
320113|NCT01419938|circadian rhythm
320114|NCT01419938|CBT
320115|NCT01419925|influenza vaccine
320116|NCT01419925|peptide
320117|NCT01419925|universal
320118|NCT01419925|prime
320119|NCT01419925|boost
320120|NCT01419925|TIV
320121|NCT01419925|HAI
320122|NCT01419925|Hemagglutination Inhibition
320123|NCT01419925|elderly
320124|NCT01419899|Brief intervention
320125|NCT01419899|Rapid testing
320126|NCT01419873|Hyperglycaemia
320127|NCT01419873|Very low birthweight infants
320128|NCT01419873|Insulin
320129|NCT01419860|Microcirculation
320130|NCT01419860|Colon
320131|NCT01419860|Anastomosis
320132|NCT01419860|ICG
320133|NCT01419860|Gastro surgery
320134|NCT01419860|benign colon diseases requiring resection
320135|NCT01419834|CNS
320136|NCT01419834|Brain
320137|NCT01419834|MAB 3F8
320138|NCT01419834|Hu3F8
320139|NCT01419834|11-009
320140|NCT01419821|Vitamin D
320141|NCT01419821|Bone densitometry
320142|NCT01419821|Vitamin D supplementation
320143|NCT01419821|Growth
320144|NCT01419808|Scaphoid
320145|NCT01419808|Non-Union
320146|NCT01419808|Proximal pole
320147|NCT01419808|Bone Graft
320148|NCT01419808|Vascularized
320149|NCT01419808|Non-Vascularized
320150|NCT01419808|PREE
320151|NCT01419782|bone
320152|NCT01419782|osteocyte
320153|NCT01419782|rest muscle electrical activity
320154|NCT01419782|whole-body vibration
320155|NCT01419782|sclerostin
320156|NCT01419769|symptomatic pancreatic pseudocyst
320157|NCT01419769|pancreatic pseudocyst
320158|NCT01419769|transluminal drainage
320159|NCT01419769|minimally invasive
320160|NCT01419769|Nitinol stent
320161|NCT01419769|transmural endoscopic drainage
320162|NCT01419769|catheter based
320163|NCT01419743|Vitamin D deficiency
320164|NCT01419743|Supplementation
320165|NCT01419743|Infertility
320166|NCT01419743|Clinical pregnancy rates
320167|NCT01419717|cancer
320168|NCT01419717|bone metastases
320169|NCT01419717|breast cancer
320170|NCT01419717|prostate cancer
320171|NCT01419704|other hemoglobinopathies
320172|NCT01419704|chimerism
320173|NCT01419704|sickle cell
320174|NCT01419704|thalassemia
320175|NCT01419704|Marrow/Enriched Hematopoetic Stem Cell Transplant
320176|NCT01419691|auranofin
320177|NCT01419691|chronic lymphocytic leukemia
320178|NCT01419691|relapsed
320179|NCT01419691|refractory
320180|NCT01419691|CLL
320181|NCT01419691|SLL
320182|NCT01419691|PLL
320183|NCT01419678|posaconazole
320184|NCT01419678|PK blood sampling
320185|NCT01419665|Follicular Lymphoma
320186|NCT01419665|Biosimilar
320187|NCT01419665|GP13-301
320188|NCT01419665|rituximab
320189|NCT01419665|Antibodies
320190|NCT01419665|CD20
320191|NCT01419652|percutaneous coronary intervention
320192|NCT01419639|Neurofibromatosis Type II
320193|NCT01419639|cranial nerve schwannomas
320194|NCT01419639|meningiomas
320195|NCT01419639|ependymomas
320196|NCT01419613|healthy lifestyle
320197|NCT01419613|physical activity
320198|NCT01419613|behavior
320199|NCT01419613|motivational
320200|NCT01419613|interview
320201|NCT01419613|breast cancer survivor
320202|NCT01419600|Phase 1
320203|NCT01419600|healthy volunteers
320204|NCT01419600|safety
320205|NCT01419600|tolerability
320206|NCT01419600|pharmacokinetics
320207|NCT01419600|single ascending dose study
320208|NCT01419587|Carcinoma, Non-Small-Cell Lung
320209|NCT01419587|Non small cell lung cancer
320210|NCT01419587|NSCLC
320211|NCT01419587|Ketogenic Diet
320212|NCT01419587|radiotherapy
320213|NCT01419587|paclitaxel
320214|NCT01419587|carboplatin
320215|NCT01419574|Carotid Artery Plaque
320216|NCT01419574|Contrast Agents
320217|NCT01419574|Vasa Vasorum
320218|NCT01419574|MRI
320219|NCT01419574|Intraplaque Hemorrhage
320220|NCT01419574|Solid Tumor
320221|NCT01419574|Metastatic Solid Tumor
320222|NCT01419561|KSHV
320223|NCT01419561|KICS
320224|NCT01419561|HIV
320225|NCT01419561|Cytokines
320226|NCT01419561|HHV-8
320227|NCT01419561|KSHV Inflammatory Cytokine Syndrome
320228|NCT01419561|Kaposi Sarcoma Heres Virus
320229|NCT01419548|ABT-888
320230|NCT01419548|Liver Dysfunction
320231|NCT01419548|Kidney Dysfunction
320232|NCT01419548|PARP Inhibitor
320233|NCT01419548|Pharmacokinetics
320234|NCT01419548|Cancer
320235|NCT01419535|Metabolism
320236|NCT01419535|Cortisol
320237|NCT01419535|Hypercortisolism
320238|NCT01419535|Glucose Intolerance
320239|NCT01419522|Traumatic Brain Injury
320240|NCT01419522|Walking Impairment
320241|NCT01419522|Gait Training
320242|NCT01419522|TBI
320243|NCT01419509|alveolar childhood rhabdomyosarcoma
320244|NCT01419509|embryonal childhood rhabdomyosarcoma
320245|NCT01419509|embryonal-botryoid childhood rhabdomyosarcoma
320246|NCT01419509|mixed childhood rhabdomyosarcoma
320247|NCT01419509|pleomorphic childhood rhabdomyosarcoma
320248|NCT01419509|previously untreated childhood rhabdomyosarcoma
320249|NCT01419509|nonmetastatic childhood soft tissue sarcoma
320250|NCT01419496|recurrent adult acute myeloid leukemia
320251|NCT01419496|recurrent childhood acute myeloid leukemia
320252|NCT01419496|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
320253|NCT01419496|adult acute myeloid leukemia with inv(16)(p13;q22)
320254|NCT01419496|adult acute myeloid leukemia with t(15;17)(q22;q12)
320255|NCT01419496|adult acute myeloid leukemia with t(16;16)(p13;q22)
320256|NCT01419496|adult acute myeloid leukemia with t(8;21)(q22;q22)
320257|NCT01419496|adult acute myeloid leukemia with del(5q)
320258|NCT01419483|Pancreatic neoplasms
320259|NCT01419483|Pancreatic cancer
320260|NCT01419483|Ketogenic Diet
320261|NCT01419483|radiotherapy
320262|NCT01419483|gemcitabine
320263|NCT01419457|Healthy
320264|NCT01419457|hepatic impairment
320265|NCT01419457|T-705a
320266|NCT01419457|Favipiravir
320267|NCT01419444|Voice
320268|NCT01419444|Muscle Tension Dysphonia
320269|NCT01419444|Hyperfunction
320270|NCT01419444|Treatment
320271|NCT01419431|Colon cancer
320272|NCT01419418|Peripheral Arterial Disease (PAD)
320273|NCT01419418|Qualitative analysis
320274|NCT01419418|Patients' perspective
320275|NCT01419405|analgesia
320276|NCT01419405|acute experimental pain
320277|NCT01419405|cold pressor test
320278|NCT01419405|pregabalin
320279|NCT01419405|remifentanil
320280|NCT01419392|sildenafil citrate
320281|NCT01419392|Doppler Ultrasonography
320282|NCT01419392|nitric oxide
320283|NCT01419392|total antioxidant capacity
320284|NCT01419379|COPD exacerbation rate
320285|NCT01419353|Infertility, IVF, Estrogen
320286|NCT01419327|Fosrenol
320287|NCT01419327|Hyperphosphatemia
320288|NCT01419327|Hemodialysis
320289|NCT01419314|Physical Therapy
320290|NCT01419314|Splint
320291|NCT01419314|Sleep
320292|NCT01419314|Pain
320293|NCT01419314|6 min walk
320294|NCT01419314|forward reach
320295|NCT01419314|Function
320296|NCT01419301|multiple sclerosis
320297|NCT01419301|glatiramer acetate
320298|NCT01419301|stress reduction
320299|NCT01419301|medication adherence
320300|NCT01419288|Amputees
320301|NCT01419262|Vitamin D
320302|NCT01419262|Randomized Controlled Trial
320303|NCT01419262|Child, Preschool
320304|NCT01419262|Dietary Supplements
320305|NCT01419262|Respiratory Tract Infections
320306|NCT01419262|Asthma
320307|NCT01419249|Growth Hormone Deficiency
320308|NCT01419249|Turner syndrome
320309|NCT01419249|Pharmacogenetics
320310|NCT01419249|Recombinant Human Growth Hormone therapy
320311|NCT01419236|Ejaculatory Dysfunction
320312|NCT01419236|Orgasmic Dysfunction
320313|NCT01419236|Sexual Dysfunction
320314|NCT01419236|Climax Dysfunction
320315|NCT01419236|Erectile Dysfunction
320316|NCT01419236|Impotence
320317|NCT01419236|Hypogonadism
320318|NCT01419236|Low testosterone
320319|NCT01419236|Low t
320320|NCT01419223|Qualitative research
320321|NCT01419223|Health Knowledge, Attitudes, Practice
320322|NCT01419223|Refusal to Participate
320323|NCT01419210|Complementary Medicine
320324|NCT01419210|Traditional Medicine
320325|NCT01419184|Complicated Skin and Skin Structure Infections (cSSSI)
320326|NCT01419184|Methicillin-resistant Staphylococcus aureus (MRSA)
320327|NCT01419184|Daptomycin
320328|NCT01419184|Vancomycin
320329|NCT01419184|Antibiotics
320330|NCT01419158|Alpha-1 antitrypsin
320331|NCT01419158|Alpha-1 antitrypsin deficiency
320332|NCT01419158|Chronic obstructive pulmonary disease
320333|NCT01419145|cachexia
320334|NCT01419145|neoplasms
320335|NCT01419145|complications
320336|NCT01419145|combined modality therapy
320337|NCT01419145|exercise therapy
320338|NCT01419145|diet therapy
320339|NCT01419145|anti-inflammatory agents
320340|NCT01419132|furosemide
320341|NCT01419132|hypertonic saline solution
320342|NCT01419132|troponin I
320343|NCT01419119|vitamin D insufficiency
320344|NCT01419119|Cholecalciferol
320345|NCT01419119|D3
320346|NCT01419119|Parathyroid Hormone
320347|NCT01419119|25-hydroxyvitamin D3
320348|NCT01419119|RDA, recommended daily intake (nutrition policy)
320349|NCT01419119|Vitamin D
320350|NCT01419119|Hypovitaminosis-D
320351|NCT01419119|Pharmacologic treatment
320352|NCT01419106|Hypotension
320353|NCT01419106|Emergency care
320354|NCT01419106|Point of care Ultrasound
320355|NCT01419106|Shock
320356|NCT01419093|Physical Activity
320357|NCT01419093|Exercise
320358|NCT01419080|Peripheral Arterial Disease
320359|NCT01419080|Quality of Life
320360|NCT01419080|Quality of Care
320361|NCT01419067|Proton Therapy
320362|NCT01419067|Radical resection
320363|NCT01419041|renal impairment
320364|NCT01419041|crizotinib
320365|NCT01419041|pharmacokinetics
320366|NCT01419028|Hypophosphatasia
320367|NCT01419028|HPP
320368|NCT01419028|Bone disease
320369|NCT01419028|Soft bones
320370|NCT01419028|Low alkaline phosphatase
320371|NCT01419028|Genetic metabolic disorder
320372|NCT01419028|Alkaline phosphatase
320373|NCT01419028|Tissue non-specific alkaline phosphatase
320374|NCT01419028|Rickets
320375|NCT01419028|Osteomalacia
320376|NCT01419015|SAPIEN XT Valve (20mm)
320377|NCT01419015|Cardiovascular Disease
320378|NCT01419015|Valvular Heart Disease
320379|NCT01419015|Aortic Stenosis
320380|NCT01419015|Heart Valve Therapy
320381|NCT01419015|Transcatheter
320382|NCT01419015|Transfemoral
320383|NCT01419015|Efficacy endpoints
320384|NCT01419015|Indexed Aortic Valve Area
320385|NCT01419015|NYHA
320386|NCT01419002|Pancreatic Cancer
320387|NCT01419002|Adenocarcinoma
320388|NCT01419002|Neoadjuvant Radiotherapy
320389|NCT01418976|physical therapy techniques
320390|NCT01418976|brain injuries, traumatic
320391|NCT01418976|walking
320392|NCT01418976|gait
320393|NCT01418976|postural balance
320394|NCT01418950|Prematurity Counseling for pregnant women and their family
320395|NCT01418937|HPV vaccine
320396|NCT01418937|serious adverse events (SAEs)
320397|NCT01418937|medically significant conditions
320398|NCT01418937|cervical neoplasia
320399|NCT01418924|sclerostin
320400|NCT01418924|estradiol
320401|NCT01418924|progesterone
320402|NCT01418924|testosteron
320403|NCT01418924|sex hormones
320404|NCT01418898|Iron deficiency anemia
320405|NCT01418898|iron
320406|NCT01418898|zinc
320407|NCT01418898|vitamin A
320408|NCT01418898|vitamin C
320409|NCT01418898|oats
320410|NCT01418885|subcortical ischemic vascular disease
320411|NCT01418872|Obesity
320412|NCT01418872|Cardiovascular Diseases Prevention
320413|NCT01418872|Paediatrics
320414|NCT01418859|cervical cancer
320415|NCT01418859|postoperation
320416|NCT01418859|chemotherapy
320417|NCT01418859|radiotherapy
320418|NCT01418846|voriconazole
320419|NCT01418846|saliva
320420|NCT01418846|pharmacokinetics
320421|NCT01418833|voriconazole
320422|NCT01418833|therapeutic drug monitoring
320423|NCT01418833|plasma levels
320424|NCT01418833|dose adjustment
320425|NCT01418820|hemianopia
320426|NCT01418820|visual field defect
320427|NCT01418820|stroke
320428|NCT01418820|non-invasive brain stimulation
320429|NCT01418820|alternating current stimulation
320430|NCT01418794|Acute Coronary Syndromes
320431|NCT01418794|Drug eluting stent
320432|NCT01418794|Diffused lesion
320433|NCT01418781|gout
320434|NCT01418781|cost
320435|NCT01418781|utilization
320436|NCT01418768|COPD
320437|NCT01418768|CAT
320438|NCT01418768|Rehabilitation
320439|NCT01418768|chronic obstructive pulmonary disease GOLD III/IV
320440|NCT01418755|Platelet-Rich Plasma
320441|NCT01418755|Knee
320442|NCT01418755|Tibiofemoral Chondromalacia
320443|NCT01418755|Injection
320444|NCT01418742|skin toxicity
320445|NCT01418716|Disease Management
320446|NCT01418716|Quality Improvement
320447|NCT01418716|Cooperative Behavior (collaboration)
320448|NCT01418677|Unspecified Advance Solid Tumor, Protocol Specific
320449|NCT01418664|vitamin D
320450|NCT01418664|adverse pregnancy outcome
320451|NCT01418664|Pakistan
320452|NCT01418638|Major Depressive Disorder
320453|NCT01418638|Antidepressants
320454|NCT01418573|glucose, insulin, post prandial
320455|NCT01418560|renal artery
320456|NCT01418560|sympathetic nerves
320457|NCT01418560|modification
320458|NCT01418560|chronic renal failure
320459|NCT01418521|Cardiac surgery
320460|NCT01418521|Balanced 3rd generation Hydroxyethyl starch
320461|NCT01418521|Tetraspan
320462|NCT01418521|Ringer-albumin
320463|NCT01418469|COPD
320464|NCT01418469|protein metabolism
320465|NCT01418469|branched-chain amino acid metabolism
320466|NCT01418469|exercise
320467|NCT01418469|protein feeding
320468|NCT01418456|diabetes
320469|NCT01418456|antibiotics
320470|NCT01418456|clean foot ulcers
320471|NCT01418404|Stroke
320472|NCT01418404|Effects of TS in U/E motor recovery
320473|NCT01418404|Brain mapping
320474|NCT01418404|Kinematics analysis
320475|NCT01418391|minimal laparotomy
320476|NCT01418391|TAP block
320477|NCT01418391|morphine consumption
320478|NCT01418391|post-operative analgesia
320479|NCT01418378|Sigma
320480|NCT01418378|cruciate
320481|NCT01418378|retaining
320482|NCT01418378|fixed
320483|NCT01418378|primary
320484|NCT01418378|total
320485|NCT01418378|knee
320486|NCT01418378|arthroplasty
320487|NCT01418378|cemented
320488|NCT01418378|osteoarthritis
320489|NCT01418352|Tourette's Disorder
320490|NCT01418352|tic disorders
320491|NCT01418339|Tourette's Disorder
320492|NCT01418339|tic disorders
320493|NCT01418326|Cancer - breast
320494|NCT01418326|colo-rectal
320495|NCT01418326|skin
320496|NCT01418313|Atherosclerosis
320497|NCT01418313|Non-invasive imaging
320498|NCT01418313|Magnetic Resonance Imaging
320499|NCT01418313|MRI
320500|NCT01418313|Positron Emission Tomography
320501|NCT01418313|PET/CT
320502|NCT01418313|PET/MRI
320503|NCT01418313|Inflammation
320504|NCT01418313|Neovascularization
320505|NCT01418261|uncontrolled hypertension
320506|NCT01418261|renal denervation
320507|NCT01418248|cardiac catheterization
320508|NCT01418248|echocardiography
320509|NCT01418235|HIV Infections
320510|NCT01418235|Acquired Immunodeficiency Syndrome
320511|NCT01418235|Lentivirus Infections
320512|NCT01418235|Retroviridae Infections
320513|NCT01418235|RNA Virus Infections
320514|NCT01418235|Virus Diseases
320515|NCT01418235|Sexually Transmitted Diseases, Viral
320516|NCT01418235|Sexually Transmitted Diseases
320517|NCT01418235|Immunologic Deficiency Syndromes
320518|NCT01418235|Immune System Diseases
320519|NCT01418235|Slow Virus Diseases
320520|NCT01418209|Menopause
320521|NCT01418209|Vasomotor
320522|NCT01418209|Symptoms
320523|NCT01418209|Estradiol
320524|NCT01418209|Venlafaxine
320525|NCT01418196|TMAO
320526|NCT01418196|Children
320527|NCT01418196|Dietary choline
320528|NCT01418196|Cardiovascular disease risk
320529|NCT01418196|Atherogenic dyslipidemia
320530|NCT01418183|Orthognathic surgery
320531|NCT01418183|Pain control
320532|NCT01418183|Trigeminal nerve
320533|NCT01418183|Levobupivacaine
320534|NCT01418170|myofascial pain syndrome
320535|NCT01418170|myofascial trigger points
320536|NCT01418170|spinal manipulative therapy
320537|NCT01418170|algometer
320538|NCT01418170|pressure pain thresholds
320539|NCT01418157|Acute mountain sickness
320540|NCT01418157|Rapid ascent
320541|NCT01418157|High altitude headache
320542|NCT01418157|Mountain Medicine Society Nepal
320543|NCT01418131|Proctitis
320544|NCT01418131|resistant
320545|NCT01418131|ulcerative colitis
320546|NCT01418131|inflammatory bowel disease
320547|NCT01418118|noradrenaline
320548|NCT01418118|norepinephrine
320549|NCT01418118|epinephrine
320550|NCT01418118|adrenaline
320551|NCT01418118|dobutamine
320552|NCT01418118|dopexamine
320553|NCT01418118|inotrope
320554|NCT01418118|pressor
320555|NCT01418118|sympathomimetic
320556|NCT01418118|free flap
320557|NCT01418118|transplantation
320558|NCT01418118|free tissue transfer
320559|NCT01418118|microsurgery
320560|NCT01418118|survival
320561|NCT01418105|spine injuries
320562|NCT01418105|brain lesions
320563|NCT01418105|dysphagia
320564|NCT01418079|Spectroscopy, near infrared
320565|NCT01418079|cerebral oxygenation
320566|NCT01418027|NAFLD
320567|NCT01418027|exercise
320568|NCT01418027|hepatic triglycerides
320569|NCT01418001|GEMCITABINE
320570|NCT01418001|GW786034 (PAZOPANIB)
320571|NCT01418001|TAXOTERE (DOCETAXEL)
320572|NCT01418001|11-104
320573|NCT01417988|TB
320574|NCT01417975|exercise
320575|NCT01417975|smoking satisfaction
320576|NCT01417975|topography
320577|NCT01417975|cravings
320578|NCT01417962|Autopsy
320579|NCT01417962|MRI
320580|NCT01417962|Stillbirths
320581|NCT01417962|Neonatal death
320582|NCT01417962|Sudden Infant death
320583|NCT01417923|chronic musculo-skeletal pain
320584|NCT01417923|therapeutic&serology effects of vitamin D
320585|NCT01417923|CRP, IL-6, IL-8, TNF and prostaglandin E2
320586|NCT01417923|patients suffering from chronic musculo-skeletal pain
320587|NCT01417884|molecular cardiology
320588|NCT01417884|molecular epidemiology
320589|NCT01417884|platelets
320590|NCT01417884|cardiovascular disease
320591|NCT01417858|intra-ocular pressure
320592|NCT01417858|iridectomy
320593|NCT01417858|gonioscopy
320594|NCT01417858|ocular tonometry
320595|NCT01417832|Dental caries
320596|NCT01417832|Proximal surfaces
320597|NCT01417832|Preventive therapy
320598|NCT01417832|Dental radiography
320599|NCT01417832|Treatment efficacy
320600|NCT01417832|Young adults
320601|NCT01417806|small cell lung cancer
320602|NCT01417806|somatostatin
320603|NCT01417806|topotecan
320604|NCT01417793|Smoking cessation rate
320605|NCT01417767|myelodysplastic syndromes
320606|NCT01417767|Decitabine
320607|NCT01417767|homoharringtonine
320608|NCT01417767|cytarabine
320609|NCT01417767|G-CSF
320610|NCT01417754|toremifene
320611|NCT01417728|endomicroscopy
320612|NCT01417728|inflammatory bowel disease
320613|NCT01417728|mucosal healing
320614|NCT01417728|infliximab
320615|NCT01417689|glaucoma
320616|NCT01417689|randomized controlled trial
320617|NCT01417689|eye drops
320618|NCT01417689|instillation
320619|NCT01417689|compliance
320620|NCT01417676|prostate cancer
320621|NCT01417676|locally advanced
320622|NCT01417676|lymph node positive
320623|NCT01417676|radiation therapy
320624|NCT01417676|morbidity
320625|NCT01417676|early morbidity
320626|NCT01417676|late morbidity
320627|NCT01417663|Aging
320628|NCT01417663|Cardiovascular disease
320629|NCT01417663|Endothelial function
320630|NCT01417663|Physical activity
320631|NCT01417663|Advanced Glycation Endproducts
320632|NCT01417663|AGE crosslink breakers
320633|NCT01417650|temporomandibular disorder
320634|NCT01417650|laser therapy
320635|NCT01417650|osteoarthritis
320636|NCT01417637|TMD
320637|NCT01417637|myofacial pain syndrome
320638|NCT01417637|low level laser therapy
320639|NCT01417637|LLLT
320640|NCT01417624|Heart Failure
320641|NCT01417624|Cardiac Resynchronisation Therapy
320642|NCT01417611|screening colonoscopy
320643|NCT01417598|Balance
320644|NCT01417598|Gait
320645|NCT01417598|Physical activity
320646|NCT01417585|Activities of daily living
320647|NCT01417585|Caregiver burden
320648|NCT01417585|Client centered
320649|NCT01417585|Life satisfaction
320650|NCT01417585|Participation
320651|NCT01417585|Patient satisfaction
320652|NCT01417585|Rehabilitation
320653|NCT01417585|Self rated impact of stroke
320654|NCT01417585|Stroke
320655|NCT01417546|Dose-Limiting Toxicity
320656|NCT01417546|Maximum Tolerated Dose
320657|NCT01417546|Immune Response
320658|NCT01417546|Pharmacokinetics
320659|NCT01417546|Dose Escalation
320660|NCT01417546|Cancer
320661|NCT01417546|Metastatic Solid Tumor
320662|NCT01417546|Solid Tumor
320663|NCT01417533|Hereditary Inclusion Body Myopathy
320664|NCT01417533|N-Acetyl-D-mannosamine (ManNAc)
320665|NCT01417533|UDP-N-acetyglucosamine 2-epimerase (GNE)
320666|NCT01417533|Sialic Acid
320667|NCT01417533|Muscular Dystrophy
320668|NCT01417533|HIBM
320669|NCT01417520|Histiocytosis
320670|NCT01417520|Xanthomatosis
320671|NCT01417520|Fibrosis
320672|NCT01417520|Osteosclerosis
320673|NCT01417520|Erdheim-Chester Disease
320674|NCT01417520|ECD
320675|NCT01417494|adenocarcinoma of the colon
320676|NCT01417494|stage IVA colon cancer
320677|NCT01417494|stage IVB colon cancer
320678|NCT01417494|adenocarcinoma of the rectum
320679|NCT01417494|stage IVA rectal cancer
320680|NCT01417494|stage IVB rectal cancer
320681|NCT01417481|cystic fibrosis
320682|NCT01417481|glycine
320683|NCT01417481|airway inflammation
320684|NCT01417468|Cognitive Rehabilitation
320685|NCT01417468|Learning Styles
320686|NCT01417468|Learning Modes
320687|NCT01417468|Learning Modalities
320688|NCT01417468|Multiple Intelligences
320689|NCT01417468|Educational Intervention
320690|NCT01417468|Instructional Design
320691|NCT01417455|Rheumatoid arthritis
320692|NCT01417455|Ankylosing spondylitis
320693|NCT01417455|Osteoclasts
320694|NCT01417455|TNF antagonists
320695|NCT01417442|papillary thyroid carcinoma
320696|NCT01417442|BRAF V600E
320697|NCT01417442|poor prognosis
320698|NCT01417442|aggressive
320699|NCT01417429|galantamine
320700|NCT01417429|subjective nicotine
320701|NCT01417429|tobacco withdrawal symptoms
320702|NCT01417429|nicotine
320703|NCT01416415|Glaucoma, Open-Angle
320704|NCT01416415|Ophthalmic Solutions, Eye drops
320705|NCT01416415|Instructional Films and Videos
320706|NCT01416402|Hyperuricemia
320707|NCT01416402|gout
320708|NCT01416402|serum uric acid
320709|NCT01416389|Locally
320710|NCT01416389|Recurrent
320711|NCT01416389|Breast
320712|NCT01416389|Cancer
320713|NCT01417390|Nasopharyngeal Carcinoma
320714|NCT01417364|Sarcopenia
320715|NCT01417364|Aging muscle
320716|NCT01417364|Testosterone administration
320717|NCT01417364|Bone metabolism
320718|NCT01417351|pregnancy
320719|NCT01417351|immune function
320720|NCT01417338|Hypertension,pulmonary
320721|NCT01417338|Mortality
320722|NCT01417338|Risk factors
320723|NCT01417312|Multiple sclerosis
320724|NCT01417312|Green tea extract
320725|NCT01417312|Metabolism
320726|NCT01417299|chronic vegetative state
320727|NCT01417299|RPh201
320728|NCT01417299|functional MRI
320729|NCT01417273|Multiple sclerosis
320730|NCT01417273|immune system
320731|NCT01417273|vitamin A
320732|NCT01417273|(MSFC)Multiple Sclerosis Functional Composite
320733|NCT01417273|(EDSS)Expanded Disability Status Scale
320734|NCT01417273|(MRI)Magnetic resonance imaging
320735|NCT01417247|renal artery
320736|NCT01417247|sympathetic nerves
320737|NCT01417247|modification
320738|NCT01417247|metabolic syndrome
320739|NCT01417221|renal artery
320740|NCT01417221|sympathetic nerves
320741|NCT01417221|modification
320742|NCT01417221|essential hypertension
320743|NCT01417221|primary hypertension
320744|NCT01417195|Assisted Reproductive Technology
320745|NCT01417182|Patients with Advanced Prostate Cancer
320746|NCT01417143|dovitinib
320747|NCT01417130|Naproxen
320748|NCT01417130|Celecoxib
320749|NCT01417130|Anti-Inflammatory Agents, Non-Steroidal
320750|NCT01417117|Intracerebral Hemorrhage
320751|NCT01417117|Ischemic Stroke
320752|NCT01417117|Diffusion Weight Imaging Abnormalities
320753|NCT01417117|Neurologic Outcome
320754|NCT01417104|plaque
320755|NCT01417104|magnetic resonance imaging (MRI)
320756|NCT01417104|high blood pressure
320757|NCT01417104|MI
320758|NCT01417104|heart attack
320759|NCT01417104|CVA
320760|NCT01417104|stroke
320761|NCT01417104|PAD
320762|NCT01417091|Brittle bone disease
320763|NCT01417091|inherited
320764|NCT01417091|connective tissue disorder
320765|NCT01417091|fracture
320766|NCT01417065|Cancer
320767|NCT01417065|mTOR inhibitor Temsirolimus
320768|NCT01417065|Torisel
320769|NCT01417065|CCI-779
320770|NCT01417065|pharmacodynamic targets
320771|NCT01417026|Autism Spectrum Disorders
320772|NCT01417026|Oxytocin
320773|NCT01417026|Clinical Trial
320774|NCT01417026|Computer-based Intervention
320775|NCT01417026|Social Perception
320776|NCT01417026|Social Motivation
320777|NCT01417026|Social Cognition
320778|NCT01417013|Dry eye or lubricant eye drops
320779|NCT01417000|Cancer
320780|NCT01417000|Cancer vaccine
320781|NCT01417000|Listeria monocytogenes
320782|NCT01417000|Listeria-based vaccines
320783|NCT01417000|GVAX
320784|NCT01417000|Cyclophosphamide
320785|NCT01417000|Cytoxan
320786|NCT01417000|T regulatory cells
320787|NCT01417000|Heterologous Prime-Boost
320788|NCT01417000|Immunotherapy
320789|NCT01417000|Mesothelin
320790|NCT01417000|Pancreatic cancer
320791|NCT01416974|19-28Z RETROVIRUS
320792|NCT01416974|CYCLOPHOSPHAMIDE (CYTOXAN)
320793|NCT01416974|autologous T cells
320794|NCT01416974|Leukapheresis
320795|NCT01416974|11-048
320796|NCT01416961|Squamous Cell
320797|NCT01416961|Non-squamous cell
320798|NCT01416948|Cognitive Complaints, TBI, PTSD
320799|NCT01416935|Atrial Fibrillation
320800|NCT01416935|Anti-Arrhythmic Medication
320801|NCT01416909|Medication-induced
320802|NCT01416909|Constipation in Cancer
320803|NCT01416896|End stage Renal Disease
320804|NCT01416896|Hemodialysis
320805|NCT01416896|Oxidative Stress
320806|NCT01416896|Inflammation
320807|NCT01416883|oral mucosal absorption
320808|NCT01416883|pharmacokinetics
320809|NCT01416883|safety
320810|NCT01416883|bicalutamide
320811|NCT01416883|Japanese
320812|NCT01416883|healthy subject
320813|NCT01416870|Bioequivalence
320814|NCT01416870|pharmacokinetics
320815|NCT01416870|safety
320816|NCT01416870|bicalutamide
320817|NCT01416870|Casodex
320818|NCT01416870|Japanese
320819|NCT01416870|healthy subject
320820|NCT01416857|Medicare
320821|NCT01416844|Metastatic melanoma
320822|NCT01416844|anti-OX40
320823|NCT01416844|Immunostimulatory
320824|NCT01416831|metastatic melanoma
320825|NCT01416831|IL-2
320826|NCT01416831|Interleukin 2
320827|NCT01416831|Radiation
320828|NCT01416831|Stereotactic Body Radiation Treatment
320829|NCT01416831|SBRT
320830|NCT01416831|Immunotherapy
320831|NCT01416818|Depression;
320832|NCT01416818|Parkinson's disease;
320833|NCT01416818|antidepressant
320834|NCT01416805|childhood anxiety disorders
320835|NCT01416805|cognitive behavioral therapy
320836|NCT01416805|CBT
320837|NCT01416805|Generalized Anxiety Disorder
320838|NCT01416805|Social Phobia
320839|NCT01416805|Separation Anxiety Disorder
320840|NCT01416805|Psychotherapy
320841|NCT01416805|Counseling
320842|NCT01416805|Social Anxiety Disorder
320843|NCT01416779|Writing Intervention
320844|NCT01416779|Bereaved Caregivers
320845|NCT01416779|Older Adults
320846|NCT01416779|hope
320847|NCT01416779|inventory of daily widowed life
320848|NCT01416766|Blood Pressure Monitors
320849|NCT01416766|Medical Informatics
320850|NCT01416766|Disease Management
320851|NCT01416766|Comparative Effectiveness Research
320852|NCT01416753|hemodialysis
320853|NCT01416753|blood volume monitoring
320854|NCT01416740|Indirect magnetic resonance arthrogram
320855|NCT01416740|Direct magnetic resonance arthrogram
320856|NCT01416740|Diagnostic tests for shoulder pain
320857|NCT01416727|Patient Simulation
320858|NCT01416727|Education, Medical, Graduate
320859|NCT01416727|Internship and Residency
320860|NCT01416727|Psychiatry
320861|NCT01416701|COPD
320862|NCT01416701|Vitamin D
320863|NCT01416701|Pulmonary rehabilitation
320864|NCT01416688|therapy-related toxicity
320865|NCT01416688|dermatologic complications
320866|NCT01416688|stage I colon cancer
320867|NCT01416688|stage IIA colon cancer
320868|NCT01416688|stage IIB colon cancer
320869|NCT01416688|stage IIC colon cancer
320870|NCT01416688|stage IIIA colon cancer
320871|NCT01416688|stage IIIB colon cancer
320872|NCT01416688|stage IIIC colon cancer
320873|NCT01416688|stage IVA colon cancer
320874|NCT01416688|stage IVB colon cancer
320875|NCT01416688|stage I rectal cancer
320876|NCT01416688|stage IIA rectal cancer
320877|NCT01416688|stage IIB rectal cancer
320878|NCT01416688|stage IIC rectal cancer
320879|NCT01416688|stage IIIA rectal cancer
320880|NCT01416688|stage IIIB rectal cancer
320881|NCT01416688|stage IIIC rectal cancer
320882|NCT01416688|stage IVA rectal cancer
320883|NCT01416688|stage IVB rectal cancer
320884|NCT01416688|stage IA non-small cell lung cancer
320885|NCT01416688|stage IB non-small cell lung cancer
320886|NCT01416688|stage IIA non-small cell lung cancer
320887|NCT01416688|stage IIB non-small cell lung cancer
320888|NCT01416688|stage IIIA non-small cell lung cancer
320889|NCT01416688|stage IIIB non-small cell lung cancer
320890|NCT01416688|stage IV non-small cell lung cancer
320891|NCT01416688|extensive stage small cell lung cancer
320892|NCT01416688|limited stage small cell lung cancer
320893|NCT01416688|recurrent small cell lung cancer
320894|NCT01416688|recurrent colon cancer
320895|NCT01416688|recurrent rectal cancer
320896|NCT01416688|recurrent non-small cell lung cancer
320897|NCT01416662|adenocarcinoma of the pancreas
320898|NCT01416662|stage IA pancreatic cancer
320899|NCT01416662|stage IB pancreatic cancer
320900|NCT01416662|stage IIA pancreatic cancer
320901|NCT01416623|Advanced solid cancer
320902|NCT01416623|Henatinib
320903|NCT01416623|phase I
320904|NCT01416597|Influenza
320905|NCT01416597|Systematic review
320906|NCT01416597|Meta-analysis
320907|NCT01416597|Mismatched strains
320908|NCT01416597|Cross-protection
320909|NCT01416571|H5N1
320910|NCT01416571|Influenza vaccine
320911|NCT01416571|influenza infection
320912|NCT01416571|GSK1557484A
320913|NCT01416558|German Breast Group
320914|NCT01416558|GBG Forschungs GmbH
320915|NCT01416558|GBG
320916|NCT01416558|GBG 65
320917|NCT01416558|Tiffany
320918|NCT01416558|Breast Cancer
320919|NCT01416558|Metastatic Breast Cancer
320920|NCT01416558|Nab-Paclitaxel
320921|NCT01416558|Abraxane
320922|NCT01416558|Taxane Failure
320923|NCT01416545|Primary Prevention
320924|NCT01416545|Cardiovascular disease
320925|NCT01416545|Child
320926|NCT01416545|Behavior modification
320927|NCT01416545|Activities, Educational
320928|NCT01416532|coronary Atheroslcerosis
320929|NCT01416532|Computed Tomography
320930|NCT01416519|Continuous Positive Airway Pressure
320931|NCT01416519|Cough
320932|NCT01416519|Oxygen Inhalation Therapy
320933|NCT01416506|Pneumonia, surveillance
320934|NCT01416493|acute rheumatoid arthritis
320935|NCT01416480|Theobromine
320936|NCT01416480|cough
320937|NCT01416480|acute bronchitis
320938|NCT01416467|lysosomal storage disease
320939|NCT01416467|AAV vector
320940|NCT01416467|gene transfer
320941|NCT01416467|disease characterization
320942|NCT01416441|Tourette's Disorder
320943|NCT01416441|tic disorders
320944|NCT01416428|multiple myeloma
320945|NCT01416428|waldenstrom macroglobulinemia
320946|NCT01416363|firategrast
320947|NCT01416363|pharmacokinetics, modified release, firategrast,
320948|NCT01416363|simulated gastro-retentive
320949|NCT01416363|pharmacokinetics
320950|NCT01416363|healthy volunteers, simulated gastro-retentive
320951|NCT01416363|healthy volunteers
320952|NCT01416363|modified release
320953|NCT01416324|pharmacodynamics
320954|NCT01416324|first time in human
320955|NCT01416324|pharmacokinetics
320956|NCT01416298|Acute Kidney Injury
320957|NCT01416298|Critically ill children
320958|NCT01416298|Biomarkers
320959|NCT01416298|NGAL
320960|NCT01416298|Fluid Overload
320961|NCT01416298|Continuous Renal Replacement Therapy (CRRT)
320962|NCT01416285|Congestive heart failure (CHF)
320963|NCT01416285|CHF education
320964|NCT01416285|self-care training
320965|NCT01416285|CHF center
320966|NCT01416259|QTc Prolongation
320967|NCT01416246|Stem cell Infusions
320968|NCT01416246|Autologous Stem Cell Transplant
320969|NCT01416246|11-105
320970|NCT01416233|autologous
320971|NCT01416233|fat
320972|NCT01416233|orbit
320973|NCT01416233|atrophy
320974|NCT01416233|cannula
320975|NCT01416220|depression
320976|NCT01416220|bipolar disorder
320977|NCT01416220|manic depressive illness
320978|NCT01416194|Osteoporosis
320979|NCT01416181|Natalizumab
320980|NCT01416181|secondary
320981|NCT01416181|multiple sclerosis
320982|NCT01416181|MS
320983|NCT01416181|SPMS
320984|NCT01416181|Tysabri
320985|NCT01416168|Colon
320986|NCT01416168|Geriatric
320987|NCT01416168|McCorkle Model
320988|NCT01416168|Questionnaire
320989|NCT01416116|QUTENZA
320990|NCT01416116|Pre-treatment
320991|NCT01416116|Tramadol
320992|NCT01416116|Tolerability
320993|NCT01416090|syndactyly
320994|NCT01416077|fluid
320995|NCT01416077|goal-directed
320996|NCT01416077|FloTrac
320997|NCT01416077|pulse contour analysis
320998|NCT01416077|postoperative complications
320999|NCT01416077|anesthesia
321000|NCT01416077|esophagus
321001|NCT01416038|vaccine
321002|NCT01416038|immunotherapy
321003|NCT01416038|ovarian
321004|NCT01416038|fallopian tube
321005|NCT01416038|peritoneal
321006|NCT01416038|cancer
321007|NCT01416038|tumor
321008|NCT01416038|Phase 1
321009|NCT01416038|Phase 2
321010|NCT01416038|Phase I
321011|NCT01416038|Phase II
321012|NCT01416025|Voriconazole
321013|NCT01416025|Therapeutic drug monitoring
321014|NCT01416025|Hematopoietic stem cell transplant
321015|NCT01416025|Hematologic malignancy
321016|NCT01416025|Invasive mould infection
321017|NCT01415999|anthracycline
321018|NCT01415999|cardiac function
321019|NCT01415999|echocardiography
321020|NCT01415999|biomarkers
321021|NCT01415986|Advanced head and neck cancer
321022|NCT01415986|Squamous cell carcinoma
321023|NCT01415986|SCC
321024|NCT01415986|HNSCC
321025|NCT01415973|beef
321026|NCT01415973|protein
321027|NCT01415973|synergy
321028|NCT01415973|intact beef constituents
321029|NCT01415973|protein constituent
321030|NCT01415973|Nutrient Synergy
321031|NCT01415960|Prostate Cancer
321032|NCT01415960|androgen deprivation therapy.
321033|NCT01415960|Leuprolide Acetate Depot Formulation
321034|NCT01415960|Pharmacokinetics
321035|NCT01415960|testosterone
321036|NCT01415960|serum luteinizing hormone
321037|NCT01415960|follicle-stimulating hormone
321038|NCT01415960|prostate-specific antigen
321039|NCT01415947|Heart disease
321040|NCT01415947|Device
321041|NCT01415947|Mitral valve
321042|NCT01415947|leaflet prolapse
321043|NCT01415947|Heart valve disease
321044|NCT01415947|Cardiovascular disease
321045|NCT01415947|Neochordae
321046|NCT01415921|heart failure
321047|NCT01415921|autonomic function
321048|NCT01415921|sympathovagal balance
321049|NCT01415921|cholinesterase inhibitors
321050|NCT01415921|pharmacology
321051|NCT01415908|advanced degenerative disease of the lumbosacral spine
321052|NCT01415908|lumbosacral spine
321053|NCT01415908|radiculopathy
321054|NCT01415908|degenerative instability
321055|NCT01415908|spondylolisthesis
321056|NCT01415908|retrolisthesis
321057|NCT01415908|lateral listhesis
321058|NCT01415908|spinal stenosis
321059|NCT01415908|disc herniation
321060|NCT01415908|INFUSE Bone Graft
321061|NCT01415908|CD HORIZON Spinal System
321062|NCT01415908|CAPSTONE Spinal System
321063|NCT01415895|back pain
321064|NCT01415895|cervical pain
321065|NCT01415895|neuropathic pain
321066|NCT01415895|radicular pain
321067|NCT01415869|Ventricular Assist Device
321068|NCT01415869|Gastrointestinal Bleeding
321069|NCT01415869|VAD
321070|NCT01415856|pulsed electromagnetic fields device
321071|NCT01415856|Torino II
321072|NCT01415856|postoperative knee pain
321073|NCT01415856|knee replacement
321074|NCT01415830|Anti-Scorpion venom serum
321075|NCT01415830|venom
321076|NCT01415830|efficacy
321077|NCT01415830|safety
321078|NCT01415830|children
321079|NCT01415817|Quality Improvement
321080|NCT01415817|Adenoma Detection Rate
321081|NCT01415817|Polyp detection rate
321082|NCT01415817|Colonoscopy
321083|NCT01415817|Training
321084|NCT01415817|Colorectal cancer screening
321085|NCT01415804|Dissection
321086|NCT01415804|Aorta
321087|NCT01415804|Surgery
321088|NCT01415791|oral mucosal absorption
321089|NCT01415791|pharmacokinetics
321090|NCT01415791|safety
321091|NCT01415791|bicalutamide
321092|NCT01415791|Japanese
321093|NCT01415791|healthy subject
321094|NCT01415778|Bioequivalence
321095|NCT01415778|pharmacokinetics
321096|NCT01415778|safety
321097|NCT01415778|bicalutamide
321098|NCT01415778|Casodex
321099|NCT01415778|Japanese
321100|NCT01415778|healthy subject
321101|NCT01415765|Germinal Center Like B-Cell (GCB) DLBCL
321102|NCT01415765|Activated B-Cell Like (ABC) DLBCL
321103|NCT01415765|NF-KappaB Pathway
321104|NCT01415765|Drug Resistance
321105|NCT01415765|Nedd-8 Activating Enzyme Inhibitor
321106|NCT01415765|Diffuse Large B-Cell Lymphoma
321107|NCT01415765|Lymphoma
321108|NCT01415752|neurotoxicity
321109|NCT01415752|therapy-related toxicity
321110|NCT01415752|contiguous stage II mantle cell lymphoma
321111|NCT01415752|noncontiguous stage II mantle cell lymphoma
321112|NCT01415752|stage I mantle cell lymphoma
321113|NCT01415752|stage III mantle cell lymphoma
321114|NCT01415752|stage IV mantle cell lymphoma
321115|NCT01415739|stage IA non-small cell lung cancer
321116|NCT01415739|stage IB non-small cell lung cancer
321117|NCT01415739|adenocarcinoma of the lung
321118|NCT01415739|squamous cell lung cancer
321119|NCT01415726|Cord blood stem cells
321120|NCT01415726|inflammation
321121|NCT01415726|type 2 diabetes
321122|NCT01415726|stem cell educator
321123|NCT01415726|autoimmunity
321124|NCT01415726|immune modulation
321125|NCT01415713|enroll the 80 patients in this trial
321126|NCT01415700|feet STEPPAGE of central neurological origin
321127|NCT01415700|implanted functional electrical stimulation
321128|NCT01415700|feet orthosis
321129|NCT01415687|preoperative care
321130|NCT01415687|colonoscopy
321131|NCT01415687|cathartics
321132|NCT01415674|Squamous cell carcinoma of the head and neck
321133|NCT01415674|pre operative treatment
321134|NCT01415674|Afatinib
321135|NCT01415674|BIBW2992
321136|NCT01415674|Biological markers
321137|NCT01415648|with surgical indication
321138|NCT01415648|Cerebral oximetry
321139|NCT01415648|carotid endarterectomy
321140|NCT01415648|MRI
321141|NCT01415648|ischemic lesion
321142|NCT01415648|cost/effectiveness analysis
321143|NCT01415648|Neurocognitive Outcome
321144|NCT01415648|protein S-100B
321145|NCT01415635|Nutritional risk, Hospital food, Nutritional Intervention
321146|NCT01415622|plasma therapy
321147|NCT01415622|ulcus cruris
321148|NCT01415609|Gastrointestinal neoplasia
321149|NCT01415609|Submucosal resection
321150|NCT01415570|Protein-energy wasting (PEW)
321151|NCT01415570|racial disparities
321152|NCT01415570|hemodialysis
321153|NCT01415570|survival paradoxes
321154|NCT01415570|Stage 5
321155|NCT01415557|micronutrient
321156|NCT01415557|healthy children
321157|NCT01415557|vitamins
321158|NCT01415557|minerals
321159|NCT01415557|cognition
321160|NCT01415557|physical performance
321161|NCT01415557|iron
321162|NCT01415557|Micronutrient status
321163|NCT01415557|Cognitive Performance
321164|NCT01415544|Diabetes
321165|NCT01415531|Stage 1
321166|NCT01415531|Stage 2
321167|NCT01415531|Hypertension
321168|NCT01415518|Severe chronic obstructive pulmonary disease (COPD) patients
321169|NCT01415505|Stage 1
321170|NCT01415505|Stage 2
321171|NCT01415505|Hypertension
321172|NCT01415505|1 year open label safety study
321173|NCT01415492|Exercise
321174|NCT01415492|Physical activity
321175|NCT01415492|Cigarette Smoking
321176|NCT01415492|Smoking cessation
321177|NCT01415492|Multi Vitamin intake
321178|NCT01415492|Vegetable consumption
321179|NCT01415492|Fruit consumption
321180|NCT01415492|Meat consumption
321181|NCT01415479|Colon cancer
321182|NCT01415479|Screening
321183|NCT01415479|Decision-making
321184|NCT01415453|retinitis pigmentosa
321185|NCT01415453|acoustic radiation force ultrasound
321186|NCT01415453|RP
321187|NCT01415453|visual field loss
321188|NCT01415453|Photoreceptor
321189|NCT01415453|Vision loss
321190|NCT01415453|retina
321191|NCT01415453|progressive vision loss
321192|NCT01415453|ultrasound
321193|NCT01415440|ADHD
321194|NCT01415440|Vyvanse
321195|NCT01415440|stimulant medication
321196|NCT01415440|ADD
321197|NCT01415427|Mucopolysaccharidosis IV type A
321198|NCT01415427|MPS IV Type A
321199|NCT01415427|Mucopolysaccharidosis IVA
321200|NCT01415427|MPS IVA
321201|NCT01415427|Morquio A Syndrome
321202|NCT01415427|Lysosomal Storage Disorder
321203|NCT01415427|LSD
321204|NCT01415427|N-acetylgalactosamine-6-sulfatase
321205|NCT01415427|N-acetylgalactosamine-6-sulfate sulfatase
321206|NCT01415427|galactose-6-sulfatase
321207|NCT01415427|GALNS
321208|NCT01415427|enzyme replacement therapy
321209|NCT01415427|ERT
321210|NCT01415414|Image quality
321211|NCT01415414|CNR
321212|NCT01415414|SNR
321213|NCT01415414|Abdominal
321214|NCT01415414|Pelvic
321215|NCT01415401|Glaucoma
321216|NCT01415401|Ocular hypertension
321217|NCT01415401|Intraocular pressure (IOP)
321218|NCT01415401|Open angle glaucoma
321219|NCT01415401|Pigment dispersion glaucoma
321220|NCT01415401|Pigmentary
321221|NCT01415388|Maintenance of normal blood triglyceride levels
321222|NCT01415375|prostate-specific antigen (146-154)
321223|NCT01415375|prostate-specific antigen (154-163)
321224|NCT01415362|transcranial direct current stimulation
321225|NCT01415362|electroencephalography
321226|NCT01415323|Emergency services, psychiatric
321227|NCT01415323|Psychomotor agitation
321228|NCT01415323|Suicide
321229|NCT01415323|Violence
321230|NCT01415310|Geriatric Psychiatry
321231|NCT01415310|Quality register
321232|NCT01415310|Quality improvement
321233|NCT01415310|Quality control
321234|NCT01415310|Research elderly patients with psychiatric disorders
321235|NCT01415297|Phase 1
321236|NCT01415297|advanced solid tumors
321237|NCT01415284|Obstetric anesthesia
321238|NCT01415284|Spinal anesthesia
321239|NCT01415284|Hypotension
321240|NCT01415284|Fluid therapy
321241|NCT01415284|Cesarean section
321242|NCT01415284|phenylephrine
321243|NCT01415284|cardiac output
321244|NCT01415271|diabetes
321245|NCT01415271|A1c
321246|NCT01415271|internet
321247|NCT01415271|long term care
321248|NCT01415258|cancer
321249|NCT01415258|vulnerability
321250|NCT01415258|frail
321251|NCT01415232|Obesity
321252|NCT01415232|Ultrasound
321253|NCT01415219|rehabilitation
321254|NCT01415219|exercise
321255|NCT01415219|efficacy
321256|NCT01415219|functional status
321257|NCT01415206|Behavioral changes
321258|NCT01415206|Multiple risks
321259|NCT01415180|sepsis
321260|NCT01415180|health related quality of life
321261|NCT01415180|functional status
321262|NCT01415180|chronic comorbid conditions
321263|NCT01415180|organ dysfunction
321264|NCT01415154|TMS
321265|NCT01415154|Major Depressive Disorder
321266|NCT01415154|NeuroStar TMS
321267|NCT01415141|genotype 1
321268|NCT01415141|IL28B CC polymorphism
321269|NCT01415141|telaprevir
321270|NCT01415141|peginterferon
321271|NCT01415141|ribavirin
321272|NCT01415115|diabetes
321273|NCT01415115|hypertension
321274|NCT01415089|Cancer
321275|NCT01415089|Quality of life
321276|NCT01415089|Family caregiver
321277|NCT01415089|Stress and coping
321278|NCT01415089|Web-based intervention
321279|NCT01415089|Communication
321280|NCT01415063|Hepatocellular Carcinoma
321281|NCT01415063|RFA
321282|NCT01415063|TACE
321283|NCT01415050|Osteoporosis
321284|NCT01415050|Menopause
321285|NCT01415050|Raloxifane
321286|NCT01415050|Alendronate
321287|NCT01415037|Annular Array Ultrasound
321288|NCT01415037|Ultrasound Exam
321289|NCT01415037|Posterior Vitreous Detachment
321290|NCT01415037|PVD
321291|NCT01415037|Diabetic Retinopathy
321292|NCT01415024|CRT
321293|NCT01415024|Dual LV
321294|NCT01415024|Triple Ventricle stimulation
321295|NCT01415024|two leftventricular leads
321296|NCT01415024|Av VV optimization
321297|NCT01415024|Lv dp/dt measurement
321298|NCT01415011|Afatinib (BIBW2992)
321299|NCT01415011|EGFR Mutation
321300|NCT01415011|Non Small Cell Lung Cancer
321301|NCT01415011|Poor performance status
321302|NCT01415011|Elderly
321303|NCT01414985|Batten Disease
321304|NCT01414972|Atherosclerosis
321305|NCT01414972|Coronary Artery Disease
321306|NCT01414972|Vitamin A
321307|NCT01414972|CD4-Positive T-Lymphocytes
321308|NCT01414972|gene expression
321309|NCT01414959|intensive care patient
321310|NCT01414959|intubation
321311|NCT01414959|(please change wording as you like!)
321312|NCT01414920|Drug Therapy
321313|NCT01414907|Drinking Behavior
321314|NCT01414907|Harm Reduction
321315|NCT01414907|Tobacco Use Cessation
321316|NCT01414907|Smoking Cessation
321317|NCT01414907|Rehabilitation
321318|NCT01414907|Health Promotion
321319|NCT01414907|Nutrition Therapy
321320|NCT01414907|Feeding Behavior
321321|NCT01414907|Exercise
321322|NCT01414881|ApoB (Apolipoprotein B)
321323|NCT01414881|LDL (low density lipoprotein)
321324|NCT01414881|mipomersen
321325|NCT01414868|Leukotriene
321326|NCT01414868|leukotriene receptor antagonist
321327|NCT01414868|bronchial provocation test
321328|NCT01414868|therapeutic outcome
321329|NCT01414829|Peptic disease
321330|NCT01414829|Helicobacter pylori
321331|NCT01414829|Different methods
321332|NCT01414816|Multiple Sclerosis
321333|NCT01414816|Clinical Isolated Syndrome (CIS)
321334|NCT01414803|rosuvastatin, fenofibrate, creatine kinase, alanine aminotransferase
321335|NCT01414790|human acellular dermal matrix
321336|NCT01414790|parotid tumor
321337|NCT01414790|total parotidectomy
321338|NCT01414777|c-section
321339|NCT01414777|Hypotension after spinal anesthesia for C-section
321340|NCT01414764|rotator cuff tendon repair surgery
321341|NCT01414764|supraspinatus tendon repair
321342|NCT01414751|Risk communication
321343|NCT01414751|Shared decision making
321344|NCT01414751|Cardiovascular diseases
321345|NCT01414751|Hypercholesterolemia
321346|NCT01414751|Prevention
321347|NCT01414725|Multiple Sclerosis
321348|NCT01414725|Mobility
321349|NCT01414725|Balance
321350|NCT01414725|Core Stability
321351|NCT01414725|Physiotherapy
321352|NCT01414712|Low- and Intermediate-Risk Prostate Cancer
321353|NCT01414699|dietary variety
321354|NCT01414699|course sequence
321355|NCT01414699|preschool
321356|NCT01414699|child feeding
321357|NCT01414673|IUI
321358|NCT01414673|HCG
321359|NCT01414673|Spontaneous LH
321360|NCT01414673|pregnancy
321361|NCT01414660|interleukin 7
321362|NCT01414660|transplantation
321363|NCT01414660|liver
321364|NCT01414660|kidney
321365|NCT01414660|islet
321366|NCT01414660|diabetes
321367|NCT01414647|Bilberry
321368|NCT01414647|Vaccinium myrtillus
321369|NCT01414647|Metabolic syndrome
321370|NCT01414647|Glucose metabolism
321371|NCT01414647|Lipid metabolism
321372|NCT01414647|Inflammation
321373|NCT01414647|Gene expression
321374|NCT01414621|CABG
321375|NCT01414595|adenocarcinoma of the lung
321376|NCT01414595|adenosquamous cell lung cancer
321377|NCT01414595|non-small cell lung cancer
321378|NCT01414595|squamous cell lung cancer
321379|NCT01414582|tDCS
321380|NCT01414582|Stroke
321381|NCT01414582|Functional MRI
321382|NCT01414582|Motor Learning
321383|NCT01414543|violence
321384|NCT01414517|Prebiotics
321385|NCT01414517|Acute Intestinal Injury
321386|NCT01414517|Chronic radiation enteritis
321387|NCT01414504|pneumococcal,
321388|NCT01414504|pneumococcal polysaccharide vaccine,
321389|NCT01414504|challenge dose,
321390|NCT01414504|hyporesponsiveness,
321391|NCT01414504|Papua New Guinea
321392|NCT01414478|emesis
321393|NCT01414478|nausea
321394|NCT01414465|Fatty acids
321395|NCT01414465|orlistat
321396|NCT01414465|lipase
321397|NCT01414465|BMC (Body Mass Index) between 30 to 40 kg/m2
321398|NCT01414465|Women
321399|NCT01414465|18 to 45 years
321400|NCT01414465|Premenopausal stage
321401|NCT01414452|Myocardial Infarction
321402|NCT01414452|Reperfusion injury
321403|NCT01414452|Adiponectin
321404|NCT01414452|endothelial progenitor cells
321405|NCT01414413|HIV
321406|NCT01414413|AIDS
321407|NCT01414413|Antiretroviral therapy
321408|NCT01414413|Community-based study
321409|NCT01414413|Cluster-randomised trial
321410|NCT01414413|HIV testing
321411|NCT01414413|Africa
321412|NCT01414400|Bacteremia
321413|NCT01414400|Spyglass
321414|NCT01414400|Cholangioscopy
321415|NCT01414387|carotid stenosis
321416|NCT01414387|cerebral embolization
321417|NCT01414387|stents
321418|NCT01414387|stroke
321419|NCT01414374|iron
321420|NCT01414374|anemia
321421|NCT01414374|herbal medicine
321422|NCT01414374|phytotherapy
321423|NCT01414374|Centella asiatica
321424|NCT01414374|Hibiscus sabdariffa
321425|NCT01414361|Coronary artery stenosis
321426|NCT01414361|Fractional flow reserve
321427|NCT01414361|Intravascular ultrasonography
321428|NCT01414348|participation
321429|NCT01414348|activities of daily living
321430|NCT01414348|brain injuries
321431|NCT01414348|executive function
321432|NCT01414335|amino acids
321433|NCT01414335|immune system
321434|NCT01414335|vitamins
321435|NCT01414335|chronic infection
321436|NCT01414335|common cold
321437|NCT01414335|ear
321438|NCT01414335|nose
321439|NCT01414335|throat
321440|NCT01414309|Heart Failure
321441|NCT01414309|Central Sleep Apnea
321442|NCT01414309|Sleep Disordered Breathing
321443|NCT01414309|Cardiac Dysfunction
321444|NCT01413178|Myeloma
321445|NCT01413178|Multiple Myeloma
321446|NCT01413178|Light chain Multiple Myeloma
321447|NCT01413178|MM
321448|NCT01413178|Autologous Hematopoietic Stem Cell Transplantation
321449|NCT01413178|Busulfan
321450|NCT01413178|Busulfex
321451|NCT01413178|Myleran
321452|NCT01413178|Melphalan
321453|NCT01413178|Alkeran
321454|NCT01413178|G-CSF
321455|NCT01413178|Filgrastim
321456|NCT01413178|NeupogenTM
321457|NCT01413178|Questionnaire
321458|NCT01413178|Survey
321459|NCT01413178|Quality of Life
321460|NCT01413178|QOL
321461|NCT01413152|men having sex with men
321462|NCT01413139|peripheral Vascular Disease
321463|NCT01413139|claudication
321464|NCT01413139|rest pain
321465|NCT01413126|Peanut
321466|NCT01413126|Blood glucose
321467|NCT01413126|Insulin
321468|NCT01413126|Non-esterified free fatty acids
321469|NCT01413126|Glucagon-like peptide-1
321470|NCT01413126|Peptide YY
321471|NCT01413126|Cholecystokinin
321472|NCT01413126|Appetitive
321473|NCT01413126|Food intake
321474|NCT01413087|Pancreatic cancer
321475|NCT01413087|Gemcitabine
321476|NCT01413087|BC-819
321477|NCT01413087|Adenocarcinoma
321478|NCT01413087|Resectable
321479|NCT01413087|H19 gene
321480|NCT01413087|DTA-H19
321481|NCT01413087|BioCancell
321482|NCT01413074|End Stage Renal Disease
321483|NCT01413074|ESRD
321484|NCT01413074|Peritoneal Dialysis
321485|NCT01413074|PD
321486|NCT01413074|Hemodialysis
321487|NCT01413074|HD
321488|NCT01413061|Other Hindfoot Conditions requiring Subtalar Arthrodesis
321489|NCT01413061|Post-traumatic Arthritis
321490|NCT01413048|Essential Hypertension
321491|NCT01413048|Hypertension
321492|NCT01413035|Diabetes
321493|NCT01413035|Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins.
321494|NCT01413035|Umbilical Cord/placenta-Derived MSC
321495|NCT01413035|Transplantation
321496|NCT01413009|delirium
321497|NCT01413009|ICU
321498|NCT01413009|spontaneous awakening trials
321499|NCT01413009|spontaneous breathing trials
321500|NCT01413009|early mobility
321501|NCT01412970|hemodynamic monitoring
321502|NCT01412970|volume responsiveness
321503|NCT01412970|electrical impedance tomography
321504|NCT01414257|Rheumatrex
321505|NCT01414257|High Dose
321506|NCT01414231|AML
321507|NCT01414231|acute myeloid leukaemia
321508|NCT01414231|low vs intermediate dose AraC
321509|NCT01414231|CR rate
321510|NCT01414231|patients <60 years
321511|NCT01414218|elderly
321512|NCT01414218|humor
321513|NCT01414218|general well being
321514|NCT01414218|psychological distress
321515|NCT01414218|health quality of life
321516|NCT01414179|nutrition
321517|NCT01414179|environnement
321518|NCT01414179|cardiovascular pathology
321519|NCT01414153|choroidal neovascularization
321520|NCT01414153|age-related macular degeneration
321521|NCT01414153|iSONEP
321522|NCT01414153|sonepcizumab
321523|NCT01414153|Lucentis
321524|NCT01414153|ranibizumab
321525|NCT01414153|Avastin
321526|NCT01414153|bevacizumab
321527|NCT01414153|Eylea
321528|NCT01414153|aflibercept
321529|NCT01414140|Mirena, contraception
321530|NCT01414114|Clinical Trial, Phase 2
321531|NCT01414114|Renal Dialysis
321532|NCT01414114|Secondary Hyperparathyroidism
321533|NCT01414114|Chronic kidney disease-mineral and bone disorder
321534|NCT01414114|Parathyroid hormone
321535|NCT01414101|Rheumatoid Arthritis
321536|NCT01414088|Nephrology
321537|NCT01414088|ENaC
321538|NCT01414088|NCC
321539|NCT01414088|NKCC
321540|NCT01414088|Sodium channels
321541|NCT01414088|renal biomarkers
321542|NCT01414075|Kidney
321543|NCT01414075|ESRD
321544|NCT01414075|Renal
321545|NCT01414075|End-Stage Renal Disease
321546|NCT01414075|Anemia
321547|NCT01414075|Oral anemia treatment
321548|NCT01414075|Hemoglobin levels
321549|NCT01414075|Hemodialysis
321550|NCT01414075|Peritoneal
321551|NCT01414075|HD
321552|NCT01414075|PD
321553|NCT01414075|Hb
321554|NCT01414075|Erythropoietin
321555|NCT01414075|Blood count
321556|NCT01414062|Breast Cancer
321557|NCT01414062|Healthy meals
321558|NCT01414062|Cocinar
321559|NCT01414062|Dietary
321560|NCT01414062|Dietary Intervention
321561|NCT01414062|fruits and vegetables
321562|NCT01414062|Cancer survivor
321563|NCT01414062|Nutrition
321564|NCT01414049|CABG
321565|NCT01414049|Off-pump CABG
321566|NCT01414049|Beating heart
321567|NCT01414049|Graft patency
321568|NCT01414049|Computed tomography angiography
321569|NCT01414049|Angiographic evaluation of coronary graft patency
321570|NCT01414036|cigarette smoking
321571|NCT01414036|patient navigation
321572|NCT01414036|primary care
321573|NCT01414023|High OCI-R scores
321574|NCT01414010|healthy volunteers
321575|NCT01414010|gut microbiota
321576|NCT01414010|gut microbiome
321577|NCT01414010|prebiotic
321578|NCT01414010|probiotic
321579|NCT01414010|antibiotic
321580|NCT01414010|antibiotic-associated diarrhea
321581|NCT01414010|intestinal bacterial overgrowth
321582|NCT01413984|Trauma
321583|NCT01413984|incarceration
321584|NCT01413984|treatment
321585|NCT01413984|substance abuse
321586|NCT01413958|Nasal Decongestants
321587|NCT01413958|Rhinitis, Allergic, Seasonal
321588|NCT01413958|Rhinitis
321589|NCT01413958|Nose Conditions
321590|NCT01413958|Respiratory Tract Diseases
321591|NCT01413958|Phenylephrine
321592|NCT01413945|Ileocecal valve
321593|NCT01413945|Irritable bowel syndrome
321594|NCT01413945|small bowel bacteria
321595|NCT01413867|hemorrhoids
321596|NCT01413867|circular staplers
321597|NCT01413867|mucosal resection
321598|NCT01413867|hemostatic suture
321599|NCT01413841|PCI
321600|NCT01413841|oxygen
321601|NCT01413828|breast cancer
321602|NCT01413828|adjuvant chemotherapy
321603|NCT01413828|trastuzumab
321604|NCT01413828|anthracycline
321605|NCT01413815|peri-operative
321606|NCT01413815|cardiovascular risk
321607|NCT01413815|oral supplementation
321608|NCT01413815|amino acid L-arginine
321609|NCT01413802|Thyroid surgery
321610|NCT01413763|Actinic keratosis
321611|NCT01413763|Atrial ectopy
321612|NCT01413724|Administered analgesic therapy
321613|NCT01413711|IS
321614|NCT01413711|Pharmacokinetics
321615|NCT01413711|Area under the curve
321616|NCT01413711|Maximum plasma concentration
321617|NCT01413711|Time to maximum concentration
321618|NCT01413685|tacrolimus
321619|NCT01413685|calcineurin
321620|NCT01413685|pharmacodynamic
321621|NCT01413685|TDM
321622|NCT01413685|pharmacokinetics
321623|NCT01413672|ostomy
321624|NCT01413672|colostomy
321625|NCT01413672|ileostomy
321626|NCT01413672|barrier
321627|NCT01413672|irritation
321628|NCT01413659|Colorectal surgery
321629|NCT01413659|Surgical site infection
321630|NCT01413659|Symbiotic
321631|NCT01413646|obesity
321632|NCT01413646|walnuts
321633|NCT01413646|endothelial function
321634|NCT01413620|Vitamin E
321635|NCT01413620|Burn
321636|NCT01413620|Oxidation
321637|NCT01413620|Lung Dysfunction
321638|NCT01413620|Fatty Liver
321639|NCT01413620|Lipid Peroxidation
321640|NCT01413607|nephrectomy
321641|NCT01413607|self retaining sutures
321642|NCT01413607|laparoscopy
321643|NCT01413594|cerebral palsy
321644|NCT01413594|constraint-induced therapy
321645|NCT01413594|constraint-induced movement therapy
321646|NCT01413594|CP
321647|NCT01413594|hemiplegia
321648|NCT01413594|hand
321649|NCT01413594|forced use
321650|NCT01413594|motor control
321651|NCT01413594|children
321652|NCT01413594|HABIT
321653|NCT01413594|Hand-arm bimanual intensive therapy
321654|NCT01413594|bilateral training
321655|NCT01413594|bimanual training
321656|NCT01413594|functional therapy
321657|NCT01413594|physical therapy
321658|NCT01413594|occupational therapy
321659|NCT01413594|intensive
321660|NCT01413594|pediatric
321661|NCT01413594|development
321662|NCT01413594|upper extremity
321663|NCT01413594|hemiplegic
321664|NCT01413594|childhood stroke
321665|NCT01413581|rhBSSL
321666|NCT01413581|preterm infants
321667|NCT01413581|Swedish Orphan Biovitrum
321668|NCT01413581|growth velocity
321669|NCT01413581|Prevention of growth restriction
321670|NCT01413555|blood culture
321671|NCT01413555|emergency department
321672|NCT01413555|quality improvement
321673|NCT01413542|DPPIV inhibitors
321674|NCT01413542|ACE inhibitors
321675|NCT01413542|Bradykinin
321676|NCT01413542|glucagon-like peptide (GLP-1)
321677|NCT01413542|BNP
321678|NCT01413542|diabetes
321679|NCT01413542|hypertension
321680|NCT01413529|HIV infected persons with co-occurring drug use
321681|NCT01413516|Varenicline
321682|NCT01413516|Placebo
321683|NCT01413516|Inpatient
321684|NCT01413503|Pheochromocytoma
321685|NCT01413503|Paraganglioma
321686|NCT01413503|MIBG
321687|NCT01413503|131I-MIBG
321688|NCT01413503|Resistant
321689|NCT01413503|Relapsed
321690|NCT01413503|Treatment
321691|NCT01413503|UCSF
321692|NCT01413503|Pediatric
321693|NCT01413503|Adult
321694|NCT01413503|Oncology
321695|NCT01413490|hepatitis C virus
321696|NCT01413490|Interferon
321697|NCT01413490|rimantadine
321698|NCT01413490|liver
321699|NCT01413477|Allergic contact dermatitis
321700|NCT01413477|Nickel allergy
321701|NCT01413477|Desensitization therapy
321702|NCT01413464|Renal Transplant
321703|NCT01413464|Venous Thrombosis
321704|NCT01413464|Deep Vein Thrombosis
321705|NCT01413464|Prophylaxis
321706|NCT01413464|Bleeding
321707|NCT01413451|Monoclonal IgG Antibody
321708|NCT01413451|Biodistribution
321709|NCT01413451|Pharmacokinetics
321710|NCT01413451|HACA
321711|NCT01413451|Safety
321712|NCT01413451|Mesothelioma
321713|NCT01413451|Ovarian Cancer
321714|NCT01413451|Pancreatic Duct Cancer
321715|NCT01413451|Non-Small Cell Lung Cancer
321716|NCT01413438|Bevacizumab
321717|NCT01413438|Quality of Life
321718|NCT01413438|Glioblastoma Multiforme
321719|NCT01413438|Neurosurgery
321720|NCT01413438|Glioblastoma
321721|NCT01413438|GBM
321722|NCT01413438|Brain Tumor
321723|NCT01413425|Smith-Lemli-Opitz Syndrome
321724|NCT01413425|Cholesterol
321725|NCT01413425|SLOS
321726|NCT01413412|Ventral Hernia
321727|NCT01413412|Postoperative Pain
321728|NCT01413412|Ventral Hernia Pain Questionnaire
321729|NCT01413412|Postoperative Abdominal wall and muscle function
321730|NCT01413412|Biodex
321731|NCT01413386|paclitaxel
321732|NCT01413386|drug eluting stent
321733|NCT01413373|cephalometry
321734|NCT01413373|three-dimensional
321735|NCT01413373|CT scan
321736|NCT01413373|lateral radiography
321737|NCT01413373|facial symmetry
321738|NCT01413373|maxillomandibular dysmorphoses
321739|NCT01413334|Coronary artery disease
321740|NCT01413334|CT
321741|NCT01413321|Brain Injuries
321742|NCT01413321|Post Traumatic Encephalopathy
321743|NCT01413321|TBI (Traumatic Brain Injury)
321744|NCT01413321|Cerebral Stroke
321745|NCT01413321|Vascular Accidents, Brain
321746|NCT01413321|Cerebrovascular Apoplexy
321747|NCT01413321|Cerebrovascular Accident
321748|NCT01413321|hemiparesis
321749|NCT01413308|Fontan
321750|NCT01413308|lung function test
321751|NCT01413308|nitric oxide production
321752|NCT01413308|NYHA class 1-2 without acute or chronic specified lung disease
321753|NCT01413295|Colorectal Neoplasms
321754|NCT01413295|Dendritic Cells
321755|NCT01413282|Acute coronary syndrome
321756|NCT01413269|breast cancer patients
321757|NCT01413269|breast conservation surgery
321758|NCT01413269|hypofractionated radiotherapy
321759|NCT01413243|Multipe sclerosis, Trichuris suis ova
321760|NCT01413230|Systemic lupus erythematosus
321761|NCT01413230|vitamin D supplementation
321762|NCT01413230|regulatory T cells
321763|NCT01413230|Th17 cells
321764|NCT01413204|TA-7284
321765|NCT01413204|JNJ-28431754
321766|NCT01413204|Canagliflozin
321767|NCT01413204|Sodium Glucose Co-transporter (SGLT2 inhibitor)
321768|NCT01412957|Best Supportive Care
321769|NCT01412957|Panitumumab
321770|NCT01412957|Chemorefractory
321771|NCT01412957|Wild-type KRAS
321772|NCT01412957|Overall Survival
321773|NCT01412957|Phase 3
321774|NCT01412944|Psoriasis
321775|NCT01412944|plaque
321776|NCT01412944|inflammatory skin disease
321777|NCT01412944|scaly patches
321778|NCT01412944|AIN457
321779|NCT01412944|secukinumab
321780|NCT01412944|Moderate to severe
321781|NCT01412918|Tinnitus
321782|NCT01412918|Inhibitor Device
321783|NCT01412918|SCN9 gene
321784|NCT01412918|Ringing in the ears
321785|NCT01412918|Milwaukee
321786|NCT01412918|Medical College of Wisconsin
321787|NCT01412905|screening
321788|NCT01412905|diabetic retinopathy
321789|NCT01412892|Neurofibromatosis type 1
321790|NCT01412892|Everolimus
321791|NCT01412892|Plexiform neurofibromas
321792|NCT01412892|Rapamycin
321793|NCT01412879|contiguous stage II mantle cell lymphoma
321794|NCT01412879|noncontiguous stage II mantle cell lymphoma
321795|NCT01412879|stage III mantle cell lymphoma
321796|NCT01412879|stage IV mantle cell lymphoma
321797|NCT01412866|schizophrenia
321798|NCT01412866|severe mental illness
321799|NCT01412866|nicotine
321800|NCT01412866|smoking
321801|NCT01412866|motivation
321802|NCT01412866|electronic decision support system
321803|NCT01412866|motivational interviewing
321804|NCT01412853|localized
321805|NCT01412840|Ureterolithiasis
321806|NCT01412840|Pain
321807|NCT01412840|Complementary
321808|NCT01412840|RCT
321809|NCT01412827|Single-photon emission computed tomography
321810|NCT01412827|myocardial perfusion imaging
321811|NCT01412827|rest/stress
321812|NCT01412827|treadmill
321813|NCT01412827|persantine
321814|NCT01412827|half-dose
321815|NCT01412827|radiotracer
321816|NCT01412827|tetrofosmin
321817|NCT01412827|Thallium
321818|NCT01412827|cadmium zinc telluride
321819|NCT01412827|diagnostic
321820|NCT01412827|prognostic
321821|NCT01412814|Total knee arthroplasty
321822|NCT01412814|Total knee replacement
321823|NCT01412814|End-stage knee osteoarthritis
321824|NCT01412814|Gait patterns
321825|NCT01412814|Neuromuscular education
321826|NCT01412801|Group B streptococcus
321827|NCT01412801|GBS
321828|NCT01412801|Vaccine
321829|NCT01412801|Prevention of group B streptococcus infection
321830|NCT01412788|breast cancer
321831|NCT01412788|Breast Conserving Surgery
321832|NCT01412788|Peri-areolar Incision
321833|NCT01412775|stress
321834|NCT01412775|burnout
321835|NCT01412775|exhaustion
321836|NCT01412762|Surgery
321837|NCT01412762|interview
321838|NCT01412762|11-087
321839|NCT01412749|registry
321840|NCT01412749|database
321841|NCT01412749|eHNS
321842|NCT01412749|Endoscopic Head and Neck Surgery
321843|NCT01412749|Transoral Endoscopic Surgery Trial
321844|NCT01412749|TEST
321845|NCT01412749|melanoma
321846|NCT01412749|head and neck surgery
321847|NCT01412723|Iron Deficiency
321848|NCT01412723|Child, Preschool
321849|NCT01412723|Dietary Iron
321850|NCT01412723|Ferrous sulfate
321851|NCT01412723|Bis-glycino iron II
321852|NCT01412710|Type 2 Diabetes
321853|NCT01412710|Cholecalciferol
321854|NCT01412710|Vitamin D
321855|NCT01412710|Insulin resistance
321856|NCT01412710|Cardiovascular disease risk
321857|NCT01412710|Minorities
321858|NCT01412697|Rural youth
321859|NCT01412697|Theory-based intervention
321860|NCT01412697|Randomized by schools
321861|NCT01412697|Fruit and vegetable intake
321862|NCT01412697|Health classes
321863|NCT01412671|Nexavar
321864|NCT01412671|unresectable or advanced renal cell carcinoma
321865|NCT01412645|Obesity
321866|NCT01412645|Inflammation
321867|NCT01412645|Metabolic Syndrome
321868|NCT01412645|Insulin sensitivity
321869|NCT01412645|Osteoporosis
321870|NCT01412645|Bone turnover
321871|NCT01412645|Ectopic fat accumulation
321872|NCT01412645|Resveratrol
321873|NCT01412619|Neurological Outcome
321874|NCT01412619|Intraoperative intracerebral Oxygen level
321875|NCT01412619|Mean arterial blood pressure
321876|NCT01412619|Central venous blood pressure
321877|NCT01412619|Cardiac output
321878|NCT01412619|Serum Lactate
321879|NCT01412619|Venous oxygen saturation
321880|NCT01412619|Fluid balance
321881|NCT01412606|Unexplained infertility-endometrial scratching
321882|NCT01412606|effect of endometrial biopsy (scratching) on clinical pregnancy rates in women with unexplained infertility
321883|NCT01412567|Hepatitis B
321884|NCT01412567|HBsAg
321885|NCT01412567|Antenatal
321886|NCT01412567|Pregnancy
321887|NCT01412567|Vertical transmission
321888|NCT01412567|Placenta
321889|NCT01412567|HBV DNA
321890|NCT01412554|Insulin resistance
321891|NCT01412554|Diabetes mellitus
321892|NCT01412554|Adipositas
321893|NCT01412541|Arms
321894|NCT01412541|Experimental
321895|NCT01412541|Drug Coated Angioplasty Balloon
321896|NCT01412541|Active Comparator
321897|NCT01412541|Standard Angioplasty Balloon
321898|NCT01412515|mTOR inhibitors
321899|NCT01412502|Tissue Donors
321900|NCT01412502|Tissue and Organ Procurement
321901|NCT01412502|Brain death
321902|NCT01412502|Withdrawal of life support
321903|NCT01412489|Uterine synechiae
321904|NCT01412489|HyalobarrierR Gel Endo
321905|NCT01412489|Operative hysteroscopy
321906|NCT01412489|submucous myoma
321907|NCT01412450|symptomatic popliteal artery stenosis or occlusion
321908|NCT01412437|PKU
321909|NCT01412437|MRI
321910|NCT01412437|neurocognition
321911|NCT01412437|sapropterin dihydrochloride
321912|NCT01412424|acromegaly
321913|NCT01412424|IGF-1
321914|NCT01412424|growth hormone
321915|NCT01412424|Octreolin
321916|NCT01412424|octreotide
321917|NCT01412424|somatostatin analog
321918|NCT01412411|Anemia
321919|NCT01412411|Growth
321920|NCT01412411|Infants
321921|NCT01412411|Focus of the study is to assess the level of anemia and growth indicators among the infants
321922|NCT01412398|Fosrenol
321923|NCT01412398|Hyperphosphatemia
321924|NCT01412398|Continuous Cyclic Peritoneal Dialysis
321925|NCT01412372|Irritable Bowel Syndrome
321926|NCT01412372|Diarrhea
321927|NCT01412372|Mesalamine
321928|NCT01412372|Gastroenteritis
321929|NCT01412372|abdominal pain
321930|NCT01412372|hypersensitivity
321931|NCT01412359|TPN Cholestasis
321932|NCT01412346|human
321933|NCT01412346|clinical trial
321934|NCT01412346|dietary intervention study
321935|NCT01412346|blood pressure
321936|NCT01412346|cardiovascular biomarkers
321937|NCT01412346|nutritional biomarkers
321938|NCT01412346|gene expression
321939|NCT01412307|Hodgkin Lymphoma
321940|NCT01412307|Lenalidomide
321941|NCT01412307|Bendamustine
321942|NCT01412307|Salvage therapy
321943|NCT01412307|Palliation
321944|NCT01412294|gastric cancer
321945|NCT01412294|recurrent gastric cancer
321946|NCT01412294|adenocarcinoma of the stomach
321947|NCT01412294|capecitabine
321948|NCT01412294|xp
321949|NCT01412281|Influenza
321950|NCT01412281|Virus
321951|NCT01412281|Vaccination
321952|NCT01412281|Immunisation
321953|NCT01412268|Obesity
321954|NCT01412268|Bariatric surgery
321955|NCT01412268|Behavioral changes
321956|NCT01412268|Eating habits
321957|NCT01412268|Eating addiction
321958|NCT01412242|Deep vein thrombosis
321959|NCT01412242|Ultrasonography
321960|NCT01412242|Pulmonary embolism
321961|NCT01412242|D-dimer
321962|NCT01412242|Pre-test probability
321963|NCT01412229|Head and neck cancer
321964|NCT01412229|Phase II
321965|NCT01412229|Locally advanced
321966|NCT01412229|Squamous Cell
321967|NCT01412229|Carboplatin
321968|NCT01412229|Nab-paclitaxel
321969|NCT01412229|Abraxane
321970|NCT01412229|Cetuximab
321971|NCT01412229|Induction
321972|NCT01412229|Chemotherapy
321973|NCT01412216|Sedentarism
321974|NCT01412216|Physical inactivity
321975|NCT01412216|Fish oil
321976|NCT01412216|Omega-3 fatty acids
321977|NCT01412216|Endothelial dysfunction
321978|NCT01412216|Insulin resistance
321979|NCT01412216|Metabolic syndrome
321980|NCT01412216|peripheral arterial disease
321981|NCT01412203|Physical activity
321982|NCT01412203|Healthy weight
321983|NCT01412203|Healthy eating
321984|NCT01412203|Physical fitness
321985|NCT01412203|Children
321986|NCT01412203|School based
321987|NCT01412203|Community based
321988|NCT01412203|Obesity
321989|NCT01412203|Health promotion
321990|NCT01412203|Socio-ecological
321991|NCT01412203|Environment based
321992|NCT01412190|Skin rejuvenation
321993|NCT01412177|Meniere's Disease
321994|NCT01412177|Vertigo
321995|NCT01412177|Definitive vertigo
321996|NCT01412177|Vertigo episodes
321997|NCT01412177|Vertigo frequency
321998|NCT01412177|Tinnitus
321999|NCT01412177|Hearing loss
322000|NCT01412177|Aural fullness
322001|NCT01412164|DES
322002|NCT01412164|CAD
322003|NCT01412164|FIREHAWK
322004|NCT01412164|MicroPort
322005|NCT01412164|PCI
322006|NCT01412151|Symptomatic
322007|NCT01412151|Huntington's Disease
322008|NCT01412151|HD
322009|NCT01412125|Biomarkers
322010|NCT01412125|Genetic polymorphism
322011|NCT01412125|Neuroimaging markers
322012|NCT01412125|Neuropsychology
322013|NCT01412099|Exercise
322014|NCT01412099|Fast Foods
322015|NCT01412099|Fruits
322016|NCT01412099|Vegetables
322017|NCT01412099|Beverages
322018|NCT01412099|Non-traditional college students
322019|NCT01412099|Motivational Interviewing
322020|NCT01412099|Peer Counselors
322021|NCT01412099|Cancer Prevention
322022|NCT01412073|caesarean section, intrapartum haemorrhage
322023|NCT01412060|Schizophrenia
322024|NCT01412060|Schizophrenic Disorder
322025|NCT01412047|Paroxysmal Nocturnal Hemoglobinuria
322026|NCT01412047|PNH
322027|NCT01412047|Human Anti-Human Antibody
322028|NCT01412047|HAHA
322029|NCT01412047|Soliris
322030|NCT01412047|eculizumab
322031|NCT01412034|Homozygous Familial Hypercholesterolemia
322032|NCT01412034|Familial Hypercholesterolemia
322033|NCT01412034|HDL mimetic
322034|NCT01412034|ApoA-1
322035|NCT01412021|Arthritis, Juvenile Rheumatoid
322036|NCT01412008|MRI
322037|NCT01412008|Magnetic Resonance Imaging
322038|NCT01412008|Botox
322039|NCT01412008|botulinum toxin
322040|NCT01412008|neurological
322041|NCT01412008|stroke
322042|NCT01412008|spasticity
322043|NCT01412008|muscle stiffness
322044|NCT01412008|diffusion
322045|NCT01412008|Weill Cornell
322046|NCT01412008|New York Presbyterian Hospital
322047|NCT01412008|O'Dell
322048|NCT01411995|intrauterine device
322049|NCT01411995|pain
322050|NCT01411995|lidocaine gel
322051|NCT01411982|PACAP (pituitary adenylate cyclase-activating polypeptide)
322052|NCT01411982|Nephrotic syndrome
322053|NCT01411982|Thrombosis
322054|NCT01411982|Platelets
322055|NCT01411969|external nasal dilator strip
322056|NCT01411969|nasal valve
322057|NCT01411969|acoustic rhinometry
322058|NCT01411956|Health Behavior Theory
322059|NCT01411956|Patient Education
322060|NCT01411956|Hypertension
322061|NCT01411956|Health beliefs related to hypertension and hypertension treatment
322062|NCT01411943|Epigenetics
322063|NCT01411943|Inflammatory
322064|NCT01411943|Psychoneurologic Symptoms
322065|NCT01411943|Cognitive Dysfunction
322066|NCT01411943|Pain
322067|NCT01411943|Fatigue
322068|NCT01411943|Sleep Disturbance
322069|NCT01411943|Depression
322070|NCT01411943|Depressive Symptoms
322071|NCT01411943|Anxiety
322072|NCT01411943|Breast Cancer
322073|NCT01411930|Insulin resistance
322074|NCT01411930|Antipsychotics
322075|NCT01411930|Olanzapine
322076|NCT01411930|Aripiprazole
322077|NCT01411917|surgical stomas
322078|NCT01411917|Nerve block
322079|NCT01411904|Leukemia
322080|NCT01411904|magnetic needle
322081|NCT01411904|magnetic nanoparticles
322082|NCT01411904|CD34
322083|NCT01411891|Arthroplasty
322084|NCT01411891|Infection Control
322085|NCT01411878|Teen Pregnancy Prevention
322086|NCT01411865|Pragmatic randomized controlled trial
322087|NCT01411865|Cardiovascular risk reduction
322088|NCT01411865|Knowledge translation
322089|NCT01411865|Clinical practice guidelines
322090|NCT01411865|Administrative databases
322091|NCT01411852|fluid volume resuscitation
322092|NCT01411852|trauma
322093|NCT01411852|hemorrhagic shock
322094|NCT01411839|Depression
322095|NCT01411839|Latinos
322096|NCT01411839|Adherence
322097|NCT01411839|Cognitive-Behavioral Therapy
322098|NCT01411839|HIV/AIDS
322099|NCT01411826|Colon cancer screening
322100|NCT01411787|Breast cancer
322101|NCT01411787|neoadjuvant chemotherapy
322102|NCT01411787|exercise
322103|NCT01411787|Ki-67
322104|NCT01411774|Obsessive-compulsive disorder
322105|NCT01411774|OCD
322106|NCT01411761|indirect hyperbilirubinemia
322107|NCT01411761|very low birth weight infants
322108|NCT01411722|Electrical Activity of Diaphragm
322109|NCT01411722|Weaning outcome
322110|NCT01411722|NAVA
322111|NCT01411683|Cost estimates
322112|NCT01411683|Complete Denture
322113|NCT01411683|Dental Economics
322114|NCT01411683|Dental Implants
322115|NCT01411683|Dental Prosthesis, Implant-Supported
322116|NCT01411683|Denture Retention
322117|NCT01411683|Edentulous
322118|NCT01411683|Edentulism
322119|NCT01411683|Mini dental implant
322120|NCT01411683|Oral Health-Related Quality of Life
322121|NCT01411683|Overdenture
322122|NCT01411683|Patient Acceptance of Health Care
322123|NCT01411683|Quality of Health Care
322124|NCT01411683|Quality of Life
322125|NCT01411683|Patient Satisfaction
322126|NCT01411670|Human Protein C
322127|NCT01411670|Activated protein C
322128|NCT01411670|Microcirculation
322129|NCT01411670|Septic Shock
322130|NCT01411670|Sepsis
322131|NCT01411644|POF
322132|NCT01411644|IOF
322133|NCT01411644|Poor response
322134|NCT01411644|early menopause
322135|NCT01411644|Primary amenorrhea
322136|NCT01411631|Polyphenols
322137|NCT01411631|Cognition
322138|NCT01411631|Cognitive function
322139|NCT01411631|Driving performance
322140|NCT01411631|Stress
322141|NCT01411618|Antiplaque agents
322142|NCT01411618|chemical plaque control
322143|NCT01411618|oral hygiene
322144|NCT01411618|essential oils
322145|NCT01411618|alcohol
322146|NCT01411618|mouthwash
322147|NCT01411605|Obesity
322148|NCT01411605|Adolescent
322149|NCT01411605|Exercise training
322150|NCT01411605|Exercise tolerance
322151|NCT01411592|All-Ceramic
322152|NCT01411592|Resin-bonded Fixed Dental Protheses
322153|NCT01411592|Single Retainer
322154|NCT01411592|Randomized Clinical Trial
322155|NCT01411592|Resin Bond
322156|NCT01411592|Bonding System
322157|NCT01411579|liver
322158|NCT01411579|metastases
322159|NCT01411579|hepatocarcinoma
322160|NCT01411579|MR
322161|NCT01411579|DWI
322162|NCT01411579|chemotherapy
322163|NCT01411566|KLIPS
322164|NCT01411553|ICU
322165|NCT01411553|Telemetry
322166|NCT01411553|ECG lead wire monitoring
322167|NCT01411553|Infection
322168|NCT01411553|Nuisance alarms
322169|NCT01411540|Body composition
322170|NCT01411540|Health markers
322171|NCT01411540|Diet
322172|NCT01411527|Hormones
322173|NCT01411527|Endocrine Disrupters
322174|NCT01411527|Polymorphism, Genetic
322175|NCT01411514|Relapsing remittent multipse sclerosis
322176|NCT01411514|Secondary progressive multiple sclerosis
322177|NCT01411514|Clinically isolated syndrome
322178|NCT01411514|Primary progressive multiple sclerosis
322179|NCT01411501|Acupuncture
322180|NCT01411501|Functional constipation
322181|NCT01411488|Focus: anal erosion
322182|NCT01411449|Primovist
322183|NCT01411449|MRI agent
322184|NCT01411436|Nexavar
322185|NCT01411436|unresectable hepatocellular carcinoma
322186|NCT01411423|Nexavar
322187|NCT01411423|Unresectable or advanced renal cell carcinoma
322188|NCT01411410|phase I
322189|NCT01411410|phosphatidylinositol 3΄-kinase (PI3K)
322190|NCT01411410|paclitaxel
322191|NCT01411410|Maximum tolerated Dose
322192|NCT01411397|Infection
322193|NCT01411397|Prosthesis
322194|NCT01411397|Recurrence
322195|NCT01411397|Strangulation
322196|NCT01411384|Keratoconus (KC)
322197|NCT01411384|Corneal collagen cross-linking (CXL)
322198|NCT01411384|Corneal hysteresis (CH)
322199|NCT01411384|Corneal resistance factor (CRF)
322200|NCT01411384|Ocular Response Analyzer (ORA)
322201|NCT01411371|Atrial fibrillation
322202|NCT01411371|Heart failure
322203|NCT01411371|Catheter ablation
322204|NCT01411358|influenza
322205|NCT01411358|vaccine
322206|NCT01411358|immunogenicity
322207|NCT01411345|Prostate Cancer
322208|NCT01411345|Prostate Adenocarcinoma
322209|NCT01411332|Prostate Cancer
322210|NCT01411332|Prostate Adenocarcinoma
322211|NCT01411319|Prostate Cancer
322212|NCT01411319|Prostate Adenocarcinoma
322213|NCT01411293|cardiovascular disease
322214|NCT01411293|oxidative stress
322215|NCT01411293|dairy consumption
322216|NCT01411293|metabolic syndrome
322217|NCT01411293|obesity
322218|NCT01411293|endothelial function
322219|NCT01411267|Relapse
322220|NCT01411267|Lymphoblastic
322221|NCT01411267|Leukemia
322222|NCT01411267|AC220
322223|NCT01411267|Refractory
322224|NCT01411267|Myelogenous
322225|NCT01411267|Acute
322226|NCT01411267|Childhood
322227|NCT01411267|Pediatric
322228|NCT01411267|ALL
322229|NCT01411267|AML
322230|NCT01411254|DME
322231|NCT01411241|Dengue
322232|NCT01411241|Dengue Hemorrhagic Fever
322233|NCT01411241|CYD Dengue Vaccines
322234|NCT01411241|Pentaxim™
322235|NCT01411228|Gaucher disease
322236|NCT01411228|pediatrics
322237|NCT01411215|Rheumatoid arthritis
322238|NCT01411215|ankylosing spondylitis
322239|NCT01411215|observational study
322240|NCT01411202|Malignant Pleural Effusion
322241|NCT01411202|Doxycycline
322242|NCT01411202|Pleurodesis
322243|NCT01411202|Pleurx catheter
322244|NCT01411189|therapeutic upper gastrointestinal endoscopy
322245|NCT01411189|percutaneous endoscopic gastrostomy
322246|NCT01411189|endoscopic mucosal resection
322247|NCT01411189|endoscopic submucosal dissection
322248|NCT01411189|PEG
322249|NCT01411189|EMR
322250|NCT01411189|ESD
322251|NCT01411189|endoscopic hemostasis
322252|NCT01411176|upper gastrointestinal endoscopy
322253|NCT01411176|suspected gastric cancer
322254|NCT01411163|Premanifest
322255|NCT01411163|At-Risk
322256|NCT01411163|Huntington's Disease
322257|NCT01411163|HD
322258|NCT01411150|Premanifest
322259|NCT01411150|At-Risk
322260|NCT01411150|Huntington's Disease
322261|NCT01411150|HD
322262|NCT01411124|gabapentin
322263|NCT01411124|restless leg syndrome
322264|NCT01411111|Drug-drug interaction
322265|NCT01411111|rosuvastatin
322266|NCT01411111|asthma
322267|NCT01411111|FLAP inhibitor
322268|NCT01411085|Schizophrenia
322269|NCT01411085|Alcoholism
322270|NCT01411085|Dual Diagnosis
322271|NCT01411085|Desipramine
322272|NCT01411085|Risperidone
322273|NCT01411072|Biomarker directed adjuvant chemotherapy
322274|NCT01411072|resected pancreas cancer
322275|NCT01411059|yoga biomechanics seniors
322276|NCT01411046|Glucocorticoid
322277|NCT01411046|polymorphism
322278|NCT01411046|Glucocorticoid receptor gene
322279|NCT01411046|rheumatoid arthritis
322280|NCT01411046|adrenal insufficiency
322281|NCT01411046|prednisolone treatment
322282|NCT01411007|Nicotine
322283|NCT01411007|Cigarettes
322284|NCT01411007|Smoker
322285|NCT01411007|realtime fMRI
322286|NCT01411007|brain imaging
322287|NCT01411007|imaging
322288|NCT01410994|glomerular filtration rate
322289|NCT01410955|probiotics
322290|NCT01410955|diarrhoea
322291|NCT01410955|prevention
322292|NCT01410955|colon cancer
322293|NCT01410955|irinotecan
322294|NCT01410942|Prostate Cancer
322295|NCT01410942|Multimodal Therapy
322296|NCT01410942|MMT
322297|NCT01410942|Fatigue
322298|NCT01410942|Cognitive Behavioral Therapy
322299|NCT01410942|CBT
322300|NCT01410942|Radiation therapy
322301|NCT01410942|Radiotherapy
322302|NCT01410942|RT
322303|NCT01410942|Functional Assessment of Chronic Illness Therapy - Fatigue
322304|NCT01410942|FACIT-F
322305|NCT01410942|Androgen deprivation therapy
322306|NCT01410942|Methylphenidate
322307|NCT01410942|Methylphenidate Hydrochloride
322308|NCT01410942|Ritalin
322309|NCT01410942|Concerta
322310|NCT01410942|Placebo
322311|NCT01410942|Sugar Pill
322312|NCT01410929|multiple myeloma
322313|NCT01410929|VCF
322314|NCT01410929|Vertebral Compression Fracture
322315|NCT01410929|Spine
322316|NCT01410929|Kyphoplasty
322317|NCT01410929|Back pain
322318|NCT01410929|Cancer
322319|NCT01410916|STEC-HUS
322320|NCT01410916|Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome
322321|NCT01410916|uncontrolled complement activation
322322|NCT01410864|cerebrospinal fluid leaks
322323|NCT01410864|dural opening
322324|NCT01410864|dural sealing
322325|NCT01410838|Obesity
322326|NCT01410838|Food preferences
322327|NCT01410838|Eating Behavior
322328|NCT01410825|WAS
322329|NCT01410825|Wiskott
322330|NCT01410825|Gene Transfer
322331|NCT01410825|Gene Therapy
322332|NCT01410812|Interest in exercising more
322333|NCT01410799|Growth Hormone Releasing Hormone
322334|NCT01410799|Growth Hormone Insufficiency
322335|NCT01410799|Aging
322336|NCT01410799|Growth Hormone
322337|NCT01410799|Physiologic Effects of Drugs
322338|NCT01410799|Hormones, Hormone Substitutes, and Hormone Antagonists
322339|NCT01410799|Hormones
322340|NCT01410760|Imaging study
322341|NCT01410760|Perfusion Computerised Tomography
322342|NCT01410747|long-term treatment
322343|NCT01410747|tacrolimus
322344|NCT01410747|renal failure
322345|NCT01410734|cholecystectomy
322346|NCT01410734|chronic right upper quadrant pain
322347|NCT01410721|TBI
322348|NCT01410721|PTSD
322349|NCT01410721|Veterans
322350|NCT01410708|Human Breast Cancer Tissue
322351|NCT01410708|Dasatinin
322352|NCT01410695|Rheumatoid Arthritis
322353|NCT01410695|RA
322354|NCT01410695|masitinib
322355|NCT01410695|DMARD
322356|NCT01410695|methotrexate
322357|NCT01410682|oral hygiene
322358|NCT01410682|ventilator-associated pneumonia
322359|NCT01410682|infection control
322360|NCT01410682|intensive care
322361|NCT01410682|pediatric nursing
322362|NCT01410682|pediatrics
322363|NCT01410669|Self-efficacy
322364|NCT01410669|Intimate partner violence
322365|NCT01410669|Randomized clinical trial
322366|NCT01410669|Depression
322367|NCT01410656|Survivors
322368|NCT01410643|puberty
322369|NCT01410643|body composition
322370|NCT01410643|metabolism
322371|NCT01410643|obesity
322372|NCT01410643|optimization of body composition
322373|NCT01410643|pubertal transition
322374|NCT01410604|Metformin
322375|NCT01410604|Obesity
322376|NCT01410604|Insulin resistance
322377|NCT01410604|Interleukin six
322378|NCT01410604|Adiponectin
322379|NCT01410604|High sensitivity C reactive protein.
322380|NCT01410604|Tumour Necrosis Factor alpha
322381|NCT01410591|transjugular intrahepatic portosystemic shunt
322382|NCT01410591|TIPS
322383|NCT01410591|liver cirrhosis
322384|NCT01410591|variceal bleeding
322385|NCT01410591|8- or 10-mm covered stent
322386|NCT01410578|sTRE-1
322387|NCT01410578|PCT
322388|NCT01410578|CRP
322389|NCT01410578|sepsis
322390|NCT01410578|bacteremia
322391|NCT01410578|FUO
322392|NCT01410578|diagnosis
322393|NCT01410578|prognosis
322394|NCT01410565|Bladder Cancer
322395|NCT01410565|Non-Muscle Invasive Bladder Cancer
322396|NCT01410565|NMIBC
322397|NCT01410565|Apaziquone
322398|NCT01410565|EOquin
322399|NCT01410565|GU Cancer
322400|NCT01410565|TURBT
322401|NCT01410552|Primary prevention
322402|NCT01410552|Secondary prevention
322403|NCT01410539|Stent Thrombosis
322404|NCT01410539|Percutaneous Coronary Intervention
322405|NCT01410539|Bare Metal Stent
322406|NCT01410539|Drug Eluting Stent
322407|NCT01410539|Residual Platelet Reactivity
322408|NCT01410539|Optical Coherence Tomography
322409|NCT01410539|OCT
322410|NCT01410526|VAC
322411|NCT01410526|Severe abdominal sepsis
322412|NCT01410526|Peritoneal immune reaction
322413|NCT01410526|Peritonitis
322414|NCT01410526|Immune peritoneal reaction when abdominal sepsis is treated with VAC
322415|NCT01410500|multiple myeloma
322416|NCT01410487|pulmonary circulation
322417|NCT01410474|Meningococcal
322418|NCT01410474|ACWY
322419|NCT01410474|bacterial meningitis
322420|NCT01410474|conjugate vaccine
322421|NCT01410474|healthy
322422|NCT01410474|children
322423|NCT01410474|adolescents
322424|NCT01410474|Taiwan
322425|NCT01410461|painful bladder
322426|NCT01410461|physical therapy
322427|NCT01410461|levator ani
322428|NCT01410448|Immunosuppression
322429|NCT01410448|Kidney transplantation
322430|NCT01410448|everolimus
322431|NCT01410448|safety
322432|NCT01410422|COPD
322433|NCT01410422|Bronchiectasis
322434|NCT01410422|Metabolomics
322435|NCT01410409|Osteoarthritis, Knee
322436|NCT01410409|Treatment Outcome
322437|NCT01410409|Time Factors
322438|NCT01410409|Arthroplasty, Replacement
322439|NCT01410409|Rehabilitation
322440|NCT01410409|Combined Modality Therapy
322441|NCT01410409|Middle Aged
322442|NCT01410409|Aged
322443|NCT01410409|Aged, 80 and over
322444|NCT01410409|Male
322445|NCT01410409|Female
322446|NCT01410409|Humans
322447|NCT01410409|Analysis of Variance
322448|NCT01410396|Atrial Fibrillation
322449|NCT01410396|Stroke
322450|NCT01410383|hypercholesterolemia,
322451|NCT01410383|dyslipidemia,
322452|NCT01410383|thyroid,
322453|NCT01410383|safety,
322454|NCT01410383|Heterozygous Familial Hypercholesterolaemia
322455|NCT01410383|coronary artery disease
322456|NCT01410370|Endostar
322457|NCT01410370|Radiotherapy
322458|NCT01410370|Brain Metastases
322459|NCT01410357|serious mental illness
322460|NCT01410357|diabetes
322461|NCT01410344|HIV
322462|NCT01410344|ALL
322463|NCT01410344|AML
322464|NCT01410344|MDS
322465|NCT01410344|Non-Hodgkin Lymphoma
322466|NCT01410331|CLI
322467|NCT01410331|peripheral vascular disease
322468|NCT01410331|PVD
322469|NCT01410331|PAD
322470|NCT01410331|SDF-1
322471|NCT01410318|Atherosclerosis
322472|NCT01410318|PESA
322473|NCT01410318|Subclinical
322474|NCT01410318|Cardiovascular diseases
322475|NCT01410318|Coronary disease
322476|NCT01410318|Heart diseases
322477|NCT01410318|Heart Failure
322478|NCT01410318|Myocardial Infarction
322479|NCT01410318|Stroke
322480|NCT01410318|Arteriosclerosis
322481|NCT01410305|Vitamin D Deficiency
322482|NCT01410305|HIV+ Children
322483|NCT01410305|HIV+ Young Adults
322484|NCT01410292|fiber
322485|NCT01410292|glycemic index
322486|NCT01410292|glycemic response
322487|NCT01410292|diabetes
322488|NCT01410292|ghrelin
322489|NCT01410279|pulmonary hypertension
322490|NCT01410279|inspiratory muscle training
322491|NCT01410279|inspiratory muscle weakness
322492|NCT01410279|pulmonary functional
322493|NCT01410279|functional capacity
322494|NCT01410279|quality of life
322495|NCT01410266|medical abortion
322496|NCT01410266|first trimester
322497|NCT01410266|follow-up
322498|NCT01410266|pregnancy test
322499|NCT01410214|NSCLC
322500|NCT01410214|EGFR Mutation Positive
322501|NCT01410214|complete resection
322502|NCT01410214|Erlotinib Versus NVB/Cisplatin as Adjuvant treatment
322503|NCT01410201|Epiretinal Membrane
322504|NCT01410201|Macular Edema
322505|NCT01410201|Dexamethasone Intravitreal Implant (Ozurdex)
322506|NCT01410201|Pars Plana Vitrectomy
322507|NCT01410188|open-angle glaucoma
322508|NCT01410188|glaucoma
322509|NCT01410188|ocular hypertension
322510|NCT01410188|intraocular pressure
322511|NCT01410162|Renal
322512|NCT01410162|Kidney/Pancreas
322513|NCT01410162|Transplant
322514|NCT01410162|conversion
322515|NCT01410162|bioequivalence
322516|NCT01410162|Mycophenolate Acid
322517|NCT01410149|PAV (proportional assist ventilation); sleep; polysomnography; mechanical ventilation
322518|NCT01410136|Knee
322519|NCT01410136|Femur
322520|NCT01410136|Articular cartilage
322521|NCT01410136|Lesions
322522|NCT01410136|Defects
322523|NCT01410136|Osteochondral graft
322524|NCT01410136|Cartilage treatments
322525|NCT01410136|Osteochondritis Dissecans
322526|NCT01410136|OCD
322527|NCT01410110|Substance Abuse
322528|NCT01410110|Substance Dependence
322529|NCT01410110|Cognitive Impairment
322530|NCT01410084|vitamin D
322531|NCT01410084|falls
322532|NCT01410084|deficiency
322533|NCT01410084|insufficiency
322534|NCT01410071|Sphincter of Oddi Dysfunction
322535|NCT01410058|HIV
322536|NCT01410058|antiretroviral drug interaction
322537|NCT01410058|herbal medicine
322538|NCT01410058|pharmacokinetics
322539|NCT01410058|herbal pharmacology
322540|NCT01410045|Turner syndrome
322541|NCT01410045|infertility
322542|NCT01410045|ovarian insufficiency
322543|NCT01410045|ovarian cryopreservation
322544|NCT01410032|clavicle
322545|NCT01410032|clavicular
322546|NCT01410032|fracture
322547|NCT01410032|midshaft
322548|NCT01410032|plate
322549|NCT01410032|ESIN
322550|NCT01410032|intramedullary
322551|NCT01410032|flexible
322552|NCT01410032|nailing
322553|NCT01410019|X-linked Severe Combined Immunodeficiency (SCID-X1)
322554|NCT01410019|severe infection
322555|NCT01410019|gene therapy
322556|NCT01410019|HLA identical family donor
322557|NCT01410019|without HLA identical unrelated donor
322558|NCT01410006|NF1
322559|NCT01410006|neurofibromatosis
322560|NCT01410006|NF
322561|NCT01409993|BMI greater than 25
322562|NCT01409993|Elevated fasting blood sugar (100-125mg/dL)
322563|NCT01409980|delta phalanx
322564|NCT01409980|thumb reconstructed
322565|NCT01409980|triphalangeal thumbs
322566|NCT01409967|Anemia
322567|NCT01409967|Transfusion
322568|NCT01409967|Biological markers
322569|NCT01409954|Fusion
322570|NCT01409954|Spine
322571|NCT01409954|Decompression
322572|NCT01409954|Pseudarthrosis
322573|NCT01409954|bone harvest
322574|NCT01409954|Instrumented posterolateral fusion
322575|NCT01409941|cerebral oxygen saturation,
322576|NCT01409941|NTproBNP
322577|NCT01409941|hsTNT
322578|NCT01409941|GDF-15
322579|NCT01409928|obesity
322580|NCT01409928|adolescent
322581|NCT01409928|pediatric
322582|NCT01409928|weight loss
322583|NCT01409928|bariatric surgery
322584|NCT01409928|gastric banding
322585|NCT01409915|Alzheimer's disease
322586|NCT01409915|neuropsychological assessment
322708|NCT01409473|IPL
322587|NCT01409915|Granulocyte-Macrophage Colony-Stimulating Factor
322588|NCT01409915|Leukine
322589|NCT01409876|histoscanning
322590|NCT01409876|brachytherapy
322591|NCT01409863|post surgical or post traumatic scar on face or scalp
322592|NCT01409837|Oligospermia
322593|NCT01409837|Male infertility
322594|NCT01409837|Lisinopril
322595|NCT01409824|clinical decision support system
322596|NCT01409824|performance based incentives
322597|NCT01409824|quality of maternal health care services
322598|NCT01409798|Hyperparathyroidism
322599|NCT01409798|Hypercalcemia
322600|NCT01409785|supraglottic airway devices in children
322601|NCT01409759|Perforators
322602|NCT01409759|Interposition plasty
322603|NCT01409759|Contracture release
322604|NCT01409746|twin
322605|NCT01409746|brain development
322606|NCT01409746|MRI
322607|NCT01409720|bony metastases
322608|NCT01409720|physical exercise
322609|NCT01409694|Alzheimer Disease
322610|NCT01409694|Vitamin D
322611|NCT01409694|Cholecalciferol
322612|NCT01409694|Memantine
322613|NCT01409694|Cognition Disorders
322614|NCT01409655|AIDS, HIV, Adherence, Compliance, Contingency management
322615|NCT01408654|Suicidal Ideation
322616|NCT01408654|Loneliness
322617|NCT01408654|Social Support
322618|NCT01408654|Voluntary Workers
322619|NCT01408654|Friends/Companions
322620|NCT01408654|Prevention
322621|NCT01408654|Aged
322622|NCT01408641|topiramate
322623|NCT01408641|PTSD
322624|NCT01408641|drinking
322625|NCT01408641|alcohol
322626|NCT01408602|Rheumatoid Arthritis
322627|NCT01408589|alcohol
322628|NCT01408589|craving
322629|NCT01408589|mood
322630|NCT01408589|optimum dose of atomoxetine
322631|NCT01408576|Lupus
322632|NCT01408576|Monoclonal antibody
322633|NCT01408576|B-Cell immunotherapy
322634|NCT01408576|Epratuzumab
322635|NCT01408563|NHL
322636|NCT01408563|lymphoma
322637|NCT01408563|leukemia
322638|NCT01408563|myelodysplastic disorder
322639|NCT01408563|aplastic anemia
322640|NCT01408550|IVIG in pemphigoid
322641|NCT01408550|Patients with bullous pemphigoid unresponsive to corticosteroids
322642|NCT01408537|inactivated Japanese encephalitis vaccine
322643|NCT01408537|vero cell
322644|NCT01408537|children
322645|NCT01408537|immunogenicity
322646|NCT01408537|safety
322647|NCT01408524|Hypertension
322648|NCT01408524|emergence
322649|NCT01408524|craniotomy
322650|NCT01408524|Hypertension during the emergence after craniotomy
322651|NCT01408498|Testosterone
322652|NCT01408498|Social psychology
322653|NCT01408498|Human behavior
322654|NCT01408459|Prostate cancer prevention
322655|NCT01408446|Hypertension
322656|NCT01408446|Menthol
322657|NCT01408446|Metabolism
322658|NCT01408433|embryo transfer
322659|NCT01408433|in-vitro fertilization (IVF)
322660|NCT01408433|pre-implantation diagnosis (PGD)
322661|NCT01408433|infertility
322662|NCT01408433|single embryo transfer
322663|NCT01408433|two embryo transfer
322664|NCT01408433|double embryo transfer
322665|NCT01409616|Pharmacodynamics
322666|NCT01409616|darexaban
322667|NCT01409616|Acetyl Salicylic Acid
322668|NCT01409616|clopidogrel
322669|NCT01409616|YM150
322670|NCT01409616|Phase 1
322671|NCT01409603|Pharmacodynamics
322672|NCT01409603|darexaban
322673|NCT01409603|naproxen
322674|NCT01409603|YM150
322675|NCT01409603|Phase 1
322676|NCT01409590|Schizophrenia
322677|NCT01409590|weight gain
322678|NCT01409590|atypical neuroleptics
322679|NCT01409577|Coronary stenosis
322680|NCT01409577|stent
322681|NCT01409577|fractional flow reserve
322682|NCT01409564|Alzheimer's dementia
322683|NCT01409564|Cilostazol
322684|NCT01409551|Pleural effusion
322685|NCT01409551|VATS
322686|NCT01409551|hyperthermia
322687|NCT01409551|thoracostomy
322688|NCT01409551|pleurodesis
322689|NCT01409512|Heart rate variability, anti cholinergic medication
322690|NCT01409499|hepatocellular carcinoma, treatments, survival
322691|NCT01409486|Pompe disease
322692|NCT01409486|Alpha glucosidase
322693|NCT01409486|Newborn screening
322694|NCT01409486|Tandem Mass Spectrometry (LC-MS-MS)
322695|NCT01409486|The study aims:
322696|NCT01409486|To establish the control mean values of alpha glucosidase activity in Dry blood spots of Newborn babies from Israel.
322697|NCT01409486|To include the alpha glucosidase assay in the newborn screening program in Israel
322698|NCT01409473|Prostate cancer
322699|NCT01409473|Stereotactic body radiotherapy
322700|NCT01409473|Radiosurgery
322701|NCT01409473|Intensity-modulated radiotherapy
322702|NCT01409473|SBRT
322703|NCT01409473|IMRT
322704|NCT01409473|Early-stage prostate cancer
322705|NCT01409473|Low-risk prostate cancer
322706|NCT01409473|Intermediate-risk prostate cancer
322707|NCT01409473|Intraprostatic lesions
322709|NCT01409421|adherence
322710|NCT01409421|glaucoma
322711|NCT01409421|motivational interviewing
322712|NCT01409408|Hypertension
322713|NCT01409408|Diabetes Mellitus
322714|NCT01409408|Vascular stiffness
322715|NCT01409408|Endothelial function
322716|NCT01409395|Drug drug interaction
322717|NCT01409382|neonatal hypoglycemia
322718|NCT01409382|pregnancy
322719|NCT01409382|physical activity
322720|NCT01409382|sedentary lifestyle
322721|NCT01409382|high-glycemic index diet
322722|NCT01409382|take-home baby
322723|NCT01409382|recurrent miscarriages
322724|NCT01409382|preterm delivery
322725|NCT01409356|Obesity
322726|NCT01409356|Portal hypertension
322727|NCT01409356|Cirrhosis
322728|NCT01409356|Diet
322729|NCT01409356|Exercise
322730|NCT01409343|advanced solid cancers
322731|NCT01409343|metastatic solid cancers
322732|NCT01409330|insulin sensitivity
322733|NCT01409330|type 2 diabetes
322734|NCT01409330|diet intervention
322735|NCT01409317|Major Depression
322736|NCT01409317|Functional Magnetic Resonance Imaging
322737|NCT01409317|Deep Transcranial Magnetic Stimulation
322738|NCT01409317|Repetitive Transcranial Magnetic Stimulation
322739|NCT01409317|rTMS
322740|NCT01409317|DTMS
322741|NCT01409317|fMRI
322742|NCT01409317|Randomized, Sham-Controlled Trial
322743|NCT01409304|Major depression
322744|NCT01409304|Deep Transcranial Magnetic Stimulation
322745|NCT01409304|Naturalistic Trial
322746|NCT01409304|DTMS
322747|NCT01409291|low socioeconomic status
322748|NCT01409291|stress
322749|NCT01409291|women
322750|NCT01409291|children
322751|NCT01409291|cortisol
322752|NCT01409265|stroke rehabilitation
322753|NCT01409265|perceptual deficits
322754|NCT01409252|Stroke
322755|NCT01409252|intracerebral hemorrhage
322756|NCT01409252|surgery
322757|NCT01409239|hospital
322758|NCT01409239|diabetes
322759|NCT01409239|glycemic variability
322760|NCT01409239|autonomic tone
322761|NCT01409226|high-risk of breast cancer
322762|NCT01409226|BRCA1 mutation carrier
322763|NCT01409226|BRCA2 mutation carrier
322764|NCT01409226|diagnostic
322765|NCT01409226|MRI
322766|NCT01409226|BI-RADS 4
322767|NCT01409226|mammographically occult
322768|NCT01409200|Prostate cancer
322769|NCT01409200|Adenocarcinoma of the prostate
322770|NCT01409200|Ductal adenocarcinoma
322771|NCT01409200|Androgen deprivation therapy
322772|NCT01409200|ADT
322773|NCT01409200|Hormonal therapy
322774|NCT01409200|Suspected lymph node metastasis
322775|NCT01409200|TxN1M0 or TxNxM1a
322776|NCT01409200|Progression-free
322777|NCT01409200|Pathologic complete response
322778|NCT01409200|pCR
322779|NCT01409200|Systemic therapy
322780|NCT01409200|Radical prostatectomy
322781|NCT01409200|Pelvic lymph node dissection
322782|NCT01409200|Axitinib
322783|NCT01409200|AG-013736
322784|NCT01409187|Melanoma
322785|NCT01409187|Metastatic Melanoma
322786|NCT01409187|Cytotoxic Drugs
322787|NCT01409187|IPI-Biotherapy
322788|NCT01409187|Ipilimumab
322789|NCT01409187|Yervoy
322790|NCT01409187|BMS-734016
322791|NCT01409187|MDX010
322792|NCT01409187|Interferon
322793|NCT01409187|IFN Alpha-2b
322794|NCT01409187|Intron A
322795|NCT01409187|Interferon Apha-2b
322796|NCT01409187|Interleukin-2
322797|NCT01409187|IL-2
322798|NCT01409187|Aldesleukin
322799|NCT01409187|Proleukin
322800|NCT01409174|Melanoma
322801|NCT01409174|Metastatic
322802|NCT01409174|IPI-Biochemotherapy
322803|NCT01409174|Chemonaive
322804|NCT01409174|Advanced stage IV
322805|NCT01409174|Unresectable stage III melanoma
322806|NCT01409174|1.0 cm or larger
322807|NCT01409174|Ipilimumab
322808|NCT01409174|Yervoy
322809|NCT01409174|BMS-734016
322810|NCT01409174|MDX010
322811|NCT01409174|Interferon Alpha-2b
322812|NCT01409174|Intron A
322813|NCT01409174|Temozolomide
322814|NCT01409174|Temodar
322815|NCT01409174|Cisplatin
322816|NCT01409174|Platinol-AQ
322817|NCT01409174|Platinol
322818|NCT01409174|CDDP
322819|NCT01409174|Interleukin-2
322820|NCT01409174|IL-2
322821|NCT01409174|Aldesleukin
322822|NCT01409174|Proleukin
322823|NCT01409161|Leukemia
322824|NCT01409161|Acute Promyelocytic Leukemia
322825|NCT01409161|APL
322826|NCT01409161|ATRA
322827|NCT01409161|Tretinoin
322828|NCT01409161|All-trans retinoic acid
322829|NCT01409161|Vesanoid
322830|NCT01409161|ATO
322831|NCT01409161|Arsenic trioxide
322832|NCT01409161|Trisenox
322833|NCT01409161|GO
322834|NCT01409161|Gemtuzumab
322835|NCT01409161|Mylotarg
322836|NCT01409161|Gemtuzumab ozogamicin
322837|NCT01409161|Methylprednisolone
322838|NCT01409161|Depo-Medrol
322839|NCT01409161|Medrol
322840|NCT01409161|Solu-Medrol
322841|NCT01409148|Radioimmunoimaging
322842|NCT01409148|AL Amyloidosis
322843|NCT01409148|PET/CT
322844|NCT01409135|Nectin 4 protein, humans
322845|NCT01409135|Cancer
322846|NCT01409135|Pharmacokinetics of AGS-22M6E
322847|NCT01409135|Pharmacokinetics of ASG-22CE
322848|NCT01409135|Safety
322849|NCT01409135|Clinical Trial, Phase 1
322850|NCT01409135|ASG-22ME
322851|NCT01409135|AGS-22M6E
322852|NCT01409135|ASG-22CE
322853|NCT01409135|ASG-22C3
322854|NCT01409122|vasodilator
322855|NCT01409122|nitric oxide
322856|NCT01409122|sodium nitrite
322857|NCT01409122|sildenafil
322858|NCT01409122|PDE-5
322859|NCT01409122|pulmonary hypertension
322860|NCT01409122|pulmonary arterial hypertension
322861|NCT01409109|Schizophrenia
322862|NCT01409109|Schizoaffective
322863|NCT01409109|Neuroimaging
322864|NCT01409109|Magnetic Resonance Imaging (MRI)
322865|NCT01409109|Functional Magnetic Resonance Imaging (fMRI)
322866|NCT01409109|Spectroscopy
322867|NCT01409083|infiltration
322868|NCT01409083|extravasation
322869|NCT01409083|end-tidal carbon dioxide
322870|NCT01409083|sodium bicarbonate
322871|NCT01409070|MDS
322872|NCT01409057|Inflammation parameters
322873|NCT01409057|Various blood values
322874|NCT01409057|Clinical Outcome
322875|NCT01409057|Residence in ICU/ Hospital
322876|NCT01409057|SAPS-Score
322877|NCT01409057|SOFA-Score
322878|NCT01409057|Duration of artificial respiration
322879|NCT01409044|Patient-Controlled Analgesia (PCA)
322880|NCT01409044|Music Listening
322881|NCT01409044|Opioids
322882|NCT01409044|Post Surgical Intensive Care Patient
322883|NCT01409044|Patient-Controlled Analgesia
322884|NCT01409031|newborns
322885|NCT01409031|respiratory failure
322886|NCT01409031|pulmonary hypertension
322887|NCT01409031|treatment
322888|NCT01409018|pediatric
322889|NCT01409018|cancer
322890|NCT01409018|invasive fungal disease
322891|NCT01409018|antifungal agent
322892|NCT01408992|Hearing screening
322893|NCT01408992|Questionnaire
322894|NCT01408992|Hearing disability
322895|NCT01408979|Severe preeclampsia
322896|NCT01408979|magnesium sulfate
322897|NCT01408979|anticonvulsivant
322898|NCT01408966|Dark chocolate
322899|NCT01408966|Catechins
322900|NCT01408966|Intrahepatic endothelial dysfunction
322901|NCT01408966|Cirrhosis
322902|NCT01408966|Portal Hypertension
322903|NCT01408953|Keloid
322904|NCT01408927|Thienopyridine resistance
322905|NCT01408927|Aspirin resistance
322906|NCT01408927|Platelet reactivity
322907|NCT01408901|peripheral arterial disease
322908|NCT01408901|granulocyte macrophage colony stimulating factor
322909|NCT01408901|PAD
322910|NCT01408901|GM-CSF
322911|NCT01408901|sargramostim
322912|NCT01408901|leukine
322913|NCT01408901|treadmill exercise
322914|NCT01408875|Chronic Heart Failure
322915|NCT01408875|Cardiac rehabilitation
322916|NCT01408875|Exercise training
322917|NCT01408875|Peak VO2
322918|NCT01408875|Electrical myostimulation
322919|NCT01408862|GLP1
322920|NCT01408862|GIP
322921|NCT01408862|platelets
322922|NCT01408862|human
322923|NCT01408862|aggregation
322924|NCT01408849|Endoscopy
322925|NCT01408849|Herbal medicine
322926|NCT01408849|Phytotherapy
322927|NCT01408836|Vasculitis
322928|NCT01408836|ANCA
322929|NCT01408836|Therapy
322930|NCT01408836|Plasma exchange
322931|NCT01408836|Immunosuppression
322932|NCT01408823|Pediatrics
322933|NCT01408823|Scoliosis
322934|NCT01408823|Pharmacokinetics
322935|NCT01408823|Hemorrhage
322936|NCT01408823|Orthopedic Surgery
322937|NCT01408810|infliximab
322938|NCT01408810|ulcerative colitis
322939|NCT01408810|histologic remission
322940|NCT01408797|clonal deletion
322941|NCT01408797|kidney transplantation
322942|NCT01408784|calories
322943|NCT01408784|counting
322944|NCT01408784|obesity
322945|NCT01408784|overweight
322946|NCT01408784|categories
322947|NCT01408784|calorie
322948|NCT01408784|method
322949|NCT01408784|counting calories
322950|NCT01408784|lose weight
322951|NCT01408784|diet
322952|NCT01408784|energy balance
322953|NCT01408784|energy intake
322954|NCT01408784|24 hours recall
322955|NCT01408784|food intake
322956|NCT01408771|Urodynamics
322957|NCT01408771|Overactive Bladder
322958|NCT01408745|medical device
322959|NCT01408745|sternal closure
322960|NCT01408745|sternotomy
322961|NCT01408745|dehiscence
322962|NCT01408745|sternal wound healing
322963|NCT01408745|randomized trial
322964|NCT01408745|steel wire
322965|NCT01408732|Epistaxis
322966|NCT01408732|Hereditary Hemorrhagic Telangiectasia
322967|NCT01408732|HHT
322968|NCT01408732|Sclerotherapy
322969|NCT01408732|Epistaxis (nosebleeds) due to Hereditary Hemorrhagic Telangiectasia
322970|NCT01408719|Beta-Glucan
322971|NCT01408719|Barley
322972|NCT01408719|Molecular Weight
322973|NCT01408719|Viscosity
322974|NCT01408719|Cholesterol
322975|NCT01408719|Stable isotope
322976|NCT01408719|Gene-nutrient interaction
322977|NCT01408719|Gut microbiota
322978|NCT01408693|hip fracture
322979|NCT01408693|hemiarthroplasty
322980|NCT01408693|endoprosthesis
322981|NCT01408693|elderly
322982|NCT01408693|minimally invasive surgery
322983|NCT01408693|anterior approach
322984|NCT01408693|geriatric patients
322985|NCT01408680|End-stage Renal Disease
322986|NCT01408680|Hemodialysis
322987|NCT01408680|Cardiovascular Disease
322988|NCT01408680|Antioxidants
322989|NCT01408680|Atherosclerosis
322990|NCT01408680|Coenzyme Q10
322991|NCT01408667|insulin sensitivity
322992|NCT01408667|cardiometabolic risk
322993|NCT01408667|hyperinsulinemic euglycemic clamp
322994|NCT01408420|Renal insufficiency
322995|NCT01408420|Acute Kidney Injury
322996|NCT01408420|Postoperative
322997|NCT01408420|Extracorporeal Circulation
322998|NCT01408420|Heart surgery
322999|NCT01408407|Patients with anal canal, low rectal or gynecological cancer
323000|NCT01408394|safety
323001|NCT01408394|pharmacokinetics
323002|NCT01408394|controlled release
323003|NCT01408394|formulation
323004|NCT01408381|Critical Limb Ischemia (CLI)
323005|NCT01408381|Cell Therapy
323006|NCT01408381|Bone marrow mononuclear cells
323007|NCT01408368|Graves' disease
323008|NCT01408368|total thyroidectomy
323009|NCT01408368|bilateral subtotal thyroidectomy
323010|NCT01408368|Graves' ophthalmopathy
323011|NCT01408368|morbidity rate
323012|NCT01408342|Alemtuzumab
323013|NCT01408342|Rituximab
323014|NCT01408342|Aplastic anemia
323015|NCT01408342|cyclosporine
323016|NCT01408316|Healthy Volunteer
323017|NCT01408316|PX-866
323018|NCT01408316|PI3K Inhibitor
323019|NCT01408303|dyslipidemia
323020|NCT01408303|hyperlipidemia
323021|NCT01408303|cardiovascular risk
323022|NCT01408290|seasonal
323023|NCT01408290|prevention
323024|NCT01408290|influenza
323025|NCT01408290|infection
323026|NCT01408290|influenza vaccine
323027|NCT01408290|vaccine
323028|NCT01408290|influenza in humans
323029|NCT01408277|Diabetic Foot Ulcers
323030|NCT01408277|Diabetic Foot Wounds
323031|NCT01408238|Immunotherapy
323032|NCT01408238|Skin prick test
323033|NCT01408238|Standardization
323034|NCT01408238|Secale cereale
323035|NCT01408225|MGUS
323036|NCT01408225|Multiple Myeloma
323037|NCT01408225|Tissue Bank
323038|NCT01408199|Lenalidomide
323039|NCT01408199|Refractory Cutaneous Lupus
323040|NCT01408186|aspirin
323041|NCT01408186|PPI
323042|NCT01408186|H2RA
323043|NCT01408173|caffeine
323044|NCT01408173|apnea
323045|NCT01408173|prematurity
323046|NCT01408147|Postpartum weight retention
323047|NCT01408147|Low income women
323048|NCT01408147|WIC
323049|NCT01408147|Online
323050|NCT01408134|Inter-reader variability of myocardial viability imaging
323051|NCT01408121|Platelet reactivity
323052|NCT01408121|Genotyping
323053|NCT01408108|Hiatal hernia
323054|NCT01408108|Gastro-oesophageal reflux disease
323055|NCT01408108|Laparoscopic hiatal repair
323056|NCT01408108|Laparoscopic anti-reflux surgery
323057|NCT01408108|Partially absorbable lightweight mesh
323058|NCT01408095|diabetes
323059|NCT01408095|glimepiride
323060|NCT01408095|diabetes type II
323061|NCT01408095|diabetes type 2
323062|NCT01408095|Type 2 diabetes
323063|NCT01408095|diabetes mellitus
323064|NCT01408069|headache
323065|NCT01408069|migraine
323066|NCT01408056|Hemangioma
323067|NCT01408056|Infantile Hemangioma
323068|NCT01408056|Ulcerated Hemangioma
323069|NCT01408056|Timolol
323070|NCT01408056|Beta blocker
323071|NCT01408056|Vascular anomaly
323072|NCT01408030|epistaxis
323073|NCT01408030|HHT
323074|NCT01408030|bevacizumab
323075|NCT01408030|tranexamic acid
323076|NCT01408030|nosebleed
323077|NCT01408030|estrogen
323078|NCT01408004|Renal carcinoma
323079|NCT01408004|Resistance
323080|NCT01408004|Reversible
323081|NCT01408004|Translational
323082|NCT01407991|Enteral tube placement
323083|NCT01407978|Influenza
323084|NCT01407978|Pandemic vaccine
323085|NCT01407978|Seasonal vaccine
323086|NCT01407978|Prevention
323087|NCT01407978|Influenza vaccine
323088|NCT01407978|Influenza in humans
323089|NCT01407978|Pandemic influenza in humans
323090|NCT01407978|Influenza vaccine for children
323091|NCT01407978|Influenza vaccine for adolescents
323092|NCT01407978|Seasonal vaccine for children
323093|NCT01407978|Seasonal vaccine for adolescents
323094|NCT01407965|obesity
323095|NCT01407965|pharmacokinetic
323096|NCT01407965|ertapenem
323097|NCT01407965|meropenem
323098|NCT01407952|treatment trial
323099|NCT01407952|cerebral aneurysm
323100|NCT01407952|randomized
323101|NCT01407952|coils
323102|NCT01407952|endovascular
323103|NCT01407952|HEAT
323104|NCT01407952|bare platinum
323105|NCT01407952|Hydrogel
323106|NCT01407952|Hydrocoil
323107|NCT01407939|Bitter Taste
323108|NCT01407939|Bitter Blockers
323109|NCT01407939|Pediatric Medications
323110|NCT01407939|Sensory methodology
323111|NCT01407939|Children
323112|NCT01407926|Depression
323113|NCT01407926|Aging
323114|NCT01407926|Clinical Effectiveness
323115|NCT01407926|Home Care
323116|NCT01407926|Nurse-Led
323117|NCT01407900|CD NP
323118|NCT01407900|dual receptor
323119|NCT01407900|NPR A
323120|NCT01407900|NPR B
323121|NCT01407900|Adult, aged over 45
323122|NCT01407887|children
323123|NCT01407874|Gout
323124|NCT01407874|Hyperuricemia
323125|NCT01407874|Arthritis
323126|NCT01407874|Joint Disease
323127|NCT01407874|Allopurinol
323128|NCT01407874|Renal Insufficiency
323129|NCT01407835|Immunotherapy
323130|NCT01407835|Skin prick test
323131|NCT01407835|Standardization
323132|NCT01407835|Dactylis glomerata
323133|NCT01407822|Lung cancer
323134|NCT01407822|IIIA-N2
323135|NCT01407822|Neo-adjuvant treatment
323136|NCT01407822|EGFR mutations
323137|NCT01407822|Tyrosine kinase inhibitor
323138|NCT01407796|lung inflammation
323139|NCT01407796|positron emission tomography (PET)
323140|NCT01407796|fluorodeoxyglucose (FDG)
323141|NCT01407796|inducible nitric oxide synthase (iNOS)
323142|NCT01407796|lung anti-inflammatory therapy
323143|NCT01407783|Post-partum depression
323144|NCT01407783|Low-income mothers
323145|NCT01407783|home nurse visitation
323146|NCT01407770|radiation toxicity
323147|NCT01407770|skin reactions secondary to radiation therapy
323148|NCT01407770|pain
323149|NCT01407770|fatigue
323150|NCT01407770|psychosocial effects of cancer and its treatment
323151|NCT01407770|depression
323152|NCT01407770|cognitive/functional effects
323153|NCT01407770|stage IA breast cancer
323154|NCT01407770|stage IB breast cancer
323155|NCT01407770|stage II breast cancer
323156|NCT01407770|stage IIIA breast cancer
323157|NCT01407770|ductal breast carcinoma in situ
323158|NCT01407757|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
323159|NCT01407757|adult acute myeloid leukemia with del(5q)
323160|NCT01407757|adult acute myeloid leukemia with inv(16)(p13;q22)
323161|NCT01407757|adult acute myeloid leukemia with t(16;16)(p13;q22)
323162|NCT01407757|adult acute myeloid leukemia with t(8;21)(q22;q22)
323163|NCT01407757|untreated adult acute myeloid leukemia
323164|NCT01407757|untreated childhood acute myeloid leukemia and other myeloid malignancies
323165|NCT01407757|adult acute basophilic leukemia
323166|NCT01407757|childhood acute basophilic leukemia
323167|NCT01407757|adult acute eosinophilic leukemia
323168|NCT01407757|childhood acute eosinophilic leukemia
323169|NCT01407757|adult acute myeloblastic leukemia without maturation (M1)
323170|NCT01407757|childhood acute myeloblastic leukemia without maturation (M1)
323171|NCT01407757|adult acute minimally differentiated myeloid leukemia (M0)
323172|NCT01407757|childhood acute minimally differentiated myeloid leukemia (M0)
323173|NCT01407757|adult acute myeloblastic leukemia with maturation (M2)
323174|NCT01407757|childhood acute myeloblastic leukemia with maturation (M2)
323175|NCT01407757|adult acute myelomonocytic leukemia (M4)
323176|NCT01407757|childhood acute myelomonocytic leukemia (M4)
323177|NCT01407757|adult acute monoblastic leukemia (M5a)
323178|NCT01407757|adult acute monocytic leukemia (M5b)
323179|NCT01407757|childhood acute monoblastic leukemia (M5a)
323180|NCT01407757|childhood acute monocytic leukemia (M5b)
323181|NCT01407757|adult erythroleukemia (M6a)
323182|NCT01407757|adult pure erythroid leukemia (M6b)
323183|NCT01407757|childhood acute erythroleukemia (M6)
323184|NCT01407757|adult acute megakaryoblastic leukemia (M7)
323185|NCT01407757|childhood acute megakaryocytic leukemia (M7)
323186|NCT01407757|recurrent adult acute myeloid leukemia
323187|NCT01407757|recurrent childhood acute myeloid leukemia
323188|NCT01407731|disseminated neuroblastoma
323189|NCT01407731|localized resectable neuroblastoma
323190|NCT01407731|localized unresectable neuroblastoma
323191|NCT01407731|stage 4S neuroblastoma
323192|NCT01407718|Knee pain
323193|NCT01407718|tibial nailing
323194|NCT01407705|spinal cord injury with traumatic event
323195|NCT01407692|menstrual cycle
323196|NCT01407692|estrogen
323197|NCT01407679|cutaneous lupus erythematosus
323198|NCT01407679|discoid lupus erythematosus
323199|NCT01407679|subacute cutaneous lupus erythematosus
323200|NCT01407679|lupus erythematosus tumidus
323201|NCT01407666|paravertebral block
323202|NCT01407666|epidural block
323203|NCT01407666|pain management
323204|NCT01407666|liver resection
323205|NCT01407666|comparison
323206|NCT01407653|Low back pain
323207|NCT01407653|virtual reality
323208|NCT01407640|Insulin allergy
323209|NCT01407640|adverse drug reaction
323210|NCT01407640|diabetes
323211|NCT01407640|type 1 hypersensitivity
323212|NCT01407640|immediate hypersensitivity
323213|NCT01407640|type 4 hypersensitivity
323214|NCT01407640|insulin analogs
323215|NCT01407640|intradermal testing
323216|NCT01407640|insulin antibody
323217|NCT01407640|mast cell
323218|NCT01407640|CD+ TCELL
323219|NCT01407627|human
323220|NCT01407627|fructose
323221|NCT01407627|dextrose
323222|NCT01407627|renin angiotensin system
323223|NCT01407627|kidney
323224|NCT01407627|renal hemodynamics
323225|NCT01407614|Subarachnoid hemorrhage
323226|NCT01407614|delayed cerebral ischemia
323227|NCT01407614|external lumbar drainage
323228|NCT01407614|vasospasm
323229|NCT01407601|vitamin K
323230|NCT01407601|MK-7
323231|NCT01407601|Hemodialysis
323232|NCT01407601|vascular calcification
323233|NCT01407601|Matrix Gla protein
323234|NCT01407601|Osteocalcin
323235|NCT01407588|Atrial fibrillation
323236|NCT01407588|Ablation
323237|NCT01407575|Buprenorphine
323238|NCT01407575|Receptors, opioid
323239|NCT01407575|Receptors, opioid, kappa
323240|NCT01407536|Stroke
323241|NCT01407536|Thermal Stimulation
323242|NCT01407536|Upper Extremity
323243|NCT01407536|Motor Recovery
323244|NCT01407536|Transcranial Magnetic Stimulation
323245|NCT01407523|Levetiracetam
323246|NCT01407523|Infusion
323247|NCT01407523|Epilepsy
323248|NCT01407523|Partial Onset Seizures
323249|NCT01407497|HIV
323250|NCT01407497|Vaccine
323251|NCT01407497|DNA
323252|NCT01407497|Prevention
323253|NCT01407484|Infertility
323254|NCT01407484|Assisted reproductive technology
323255|NCT01407484|Double blind therapeutical trial
323256|NCT01407484|Multicentric study
323257|NCT01407484|Prospective randomized study
323258|NCT01407471|aldosterone
323259|NCT01407471|clobetasol
323260|NCT01407471|atrophy
323261|NCT01407471|skin
323262|NCT01407471|epidermis
323263|NCT01407471|wound healing
323264|NCT01407471|mineral corticoid receptor
323265|NCT01407471|spironolactone
323266|NCT01407445|Menopause
323267|NCT01407445|Sexual dysfunction
323268|NCT01407445|Tribulus
323269|NCT01407445|Sexuality
323270|NCT01407445|Phytotherapeutic Drugs
323271|NCT01407432|Male infertility
323272|NCT01407432|folic acid
323273|NCT01407432|in VITRO fertilization
323274|NCT01407432|sperm parameters
323275|NCT01407432|MTHFR genotype
323276|NCT01407419|Rheumatoid Arthritis
323277|NCT01407393|overweight
323278|NCT01407393|obesity
323279|NCT01407393|weight loss
323280|NCT01407393|body fat
323281|NCT01407393|waste cirumference
323282|NCT01407393|satiety
323283|NCT01407393|appetite
323284|NCT01407380|Advanced malignancies
323285|NCT01407380|solid tumors
323286|NCT01407380|cancer
323287|NCT01407367|patient safety
323288|NCT01407367|chronic kidney disease
323289|NCT01407367|medical errors
323290|NCT01407354|robotic weight support
323291|NCT01407354|aquatic exercise
323292|NCT01407354|incomplete motor spinal cord injury
323293|NCT01407354|ASIA C and D
323294|NCT01407328|shoulder arthroscopic surgery
323295|NCT01407328|respiratory discomfort
323296|NCT01407328|airway obstruction
323297|NCT01407328|restrictive pathology
323298|NCT01407328|diaphragm palsy
323299|NCT01407315|Continuous subcutaneous glucose monitoring
323300|NCT01407315|Type 1 Diabetes
323301|NCT01407302|Laryngeal mask airway
323302|NCT01407302|internal jugular vein cannulation
323303|NCT01407263|radical prostatectomy
323304|NCT01407263|anastomotic suturing
323305|NCT01407263|lymph node dissection
323306|NCT01407263|11-096
323307|NCT01407237|HIV-infection
323308|NCT01407237|renin
323309|NCT01407237|aldosterone
323310|NCT01407237|visceral fat
323311|NCT01407224|Exclusive Breastfeeding
323312|NCT01407224|Skin to skin contact
323313|NCT01407224|Cord Clumping
323314|NCT01407224|Prelactial feeding
323315|NCT01407211|multiple sclerosis
323316|NCT01407211|Myelin Oligodendrocyte Glycoprotein(MOG)
323317|NCT01407211|Vitamin A
323318|NCT01407211|CD4-Positive T-Lymphocytes
323319|NCT01407211|gene expression
323320|NCT01407211|Th1 Cells
323321|NCT01407211|Th2 Cells
323322|NCT01407198|High Risk Chordoma
323323|NCT01407185|heart failure
323324|NCT01407185|quality of life
323325|NCT01407185|fall prevention
323326|NCT01407185|endurance
323327|NCT01407185|resistive training
323328|NCT01407172|PAD
323329|NCT01407172|Peripheral arterial disease
323330|NCT01407172|Hydrogen Sulfide
323331|NCT01407172|Gasotransmitter
323332|NCT01407159|type b dissection
323333|NCT01407159|thoracic stentgraft
323334|NCT01407159|aortic stent
323335|NCT01407159|clinical and technical success
323336|NCT01407159|safety and feasibility of E-XL aortic stent
323337|NCT01407146|acute myocardial infarction
323338|NCT01407146|care-seeking behavior
323339|NCT01407146|acute coronary syndrome
323340|NCT01407146|care-seeking delay
323341|NCT01407146|cardiac delay
323342|NCT01407146|prehospital delay
323343|NCT01407146|acute myocardial infarction & PTSD
323344|NCT01407146|help seeking behaviors
323345|NCT01407146|seeking treatment
323346|NCT01407146|cardiac patients
323347|NCT01407146|decision time
323348|NCT01407133|Neuro-otology
323349|NCT01407133|Chronic tinnitus
323350|NCT01407133|Sensory disability
323351|NCT01407133|Repetitive transcranial magnetic stimulation
323352|NCT01407133|Dose escalation
323353|NCT01407120|Prevention
323354|NCT01407120|Divorce
323355|NCT01407107|nitroglycerin
323356|NCT01407107|5-flourouracil
323357|NCT01407107|radiation therapy
323358|NCT01407107|neo-adjuvant treatment
323359|NCT01407094|Depression, Major Depressive Disorder, Mood Disorder
323360|NCT01407081|cognitive rehabilitation
323361|NCT01407081|SMART goals
323362|NCT01407081|telehealth
323363|NCT01407055|Coronary Artery Bypass Graft Surgery (CABG)
323364|NCT01407055|Patients' Expectations
323365|NCT01407055|Coronary Heart Disease
323366|NCT01407055|Illness Perception Intervention
323367|NCT01407055|Randomized Controlled Trial
323368|NCT01407042|unicondylar knee arthroplasty
323369|NCT01407042|mobile-bearing
323370|NCT01407042|patellofemoral pain
323371|NCT01407016|metronidazole infusion
323372|NCT01407003|T2DM, blood glucose, OGTT, LIK066
323373|NCT01406990|aspirin resistance
323374|NCT01406990|hyporesponsive
323375|NCT01406990|CAD
323376|NCT01406990|women
323377|NCT01406977|Hypophosphatasia
323378|NCT01406977|HPP
323379|NCT01406977|Rathbun's disease
323380|NCT01406964|Chlamidia Antibody test, Hysterosalpyngography, Tubal disease
323381|NCT01406951|sTREM-1
323382|NCT01406951|PCT
323383|NCT01406951|CPIS
323384|NCT01406951|VAP
323385|NCT01406951|EVC
323386|NCT01406951|diagnosis
323387|NCT01406951|prognosis
323388|NCT01406938|Psoriasis
323389|NCT01406938|plaque
323390|NCT01406938|inflammatory skin disease
323391|NCT01406938|scaly patches
323392|NCT01406938|AIN457
323393|NCT01406938|secukinumab
323394|NCT01406938|Moderate to Severe Plaque-type Psoriasis
323395|NCT01406912|Stroke Rehabilitation
323396|NCT01406912|Ischemic Stroke
323397|NCT01406912|Virtual Reality
323398|NCT01406912|Nintendo Wii
323399|NCT01406912|Recreational Activity
323400|NCT01406912|Motor Function
323401|NCT01406886|Modifiable environmental
323402|NCT01406886|behavioral factors
323403|NCT01406873|Myotonic Dystrophy
323404|NCT01406873|Myotonic Dystrophy Type 1 (DM1)
323405|NCT01406873|Muscular Dystrophy
323406|NCT01406873|Mexiletine
323407|NCT01406860|Headaches
323408|NCT01406860|Migraines
323409|NCT01406860|Tension headaches
323410|NCT01406860|Cluster headaches
323411|NCT01406847|Spinal Manipulation
323412|NCT01406847|Body-based intervention
323413|NCT01406847|Experimental pain
323414|NCT01406834|PTSD
323415|NCT01406834|Veterans
323416|NCT01406834|Killing
323417|NCT01406834|Military
323418|NCT01406821|PRP
323419|NCT01406821|platelet-rich-plasma
323420|NCT01406821|platelet
323421|NCT01406821|tendinosis
323422|NCT01406821|tendinitis
323423|NCT01406821|tendonitis
323424|NCT01406821|tendinopathy
323425|NCT01406821|enthesopathy
323426|NCT01406821|muscle
323427|NCT01406821|sport
323428|NCT01406821|tendon
323429|NCT01406821|patella
323430|NCT01406821|patellar tendon
323431|NCT01406808|genetic
323432|NCT01406808|atherosclerosis
323433|NCT01406808|myocardial infarction
323434|NCT01406808|risk
323435|NCT01406808|preventive cardiology
323436|NCT01406795|Post Thrombotic Syndrome
323437|NCT01406795|Venous Stasis
323438|NCT01406795|Venous Occlusions
323439|NCT01406795|Venous Stenosis
323440|NCT01406782|stage III grade 1 follicular lymphoma
323441|NCT01406782|stage III grade 2 follicular lymphoma
323442|NCT01406782|stage IV grade 1 follicular lymphoma
323443|NCT01406782|stage IV grade 2 follicular lymphoma
323444|NCT01406743|Spine and pelvis parameters
323445|NCT01406743|Sagittal balance
323446|NCT01406743|Database
323447|NCT01406730|running exercise
323448|NCT01406730|cardiac hypertrophy
323449|NCT01406730|blood
323450|NCT01406730|maximum oxygen uptake
323451|NCT01406730|intervention
323452|NCT01406730|untrained
323453|NCT01406730|males
323454|NCT01406717|SPIL1033
323455|NCT01406717|type 2 diabetes mellitus
323456|NCT01406691|sleep
323457|NCT01406691|delayed sleep phase disorder
323458|NCT01406691|circadian
323459|NCT01406691|teen
323460|NCT01406691|adolescent
323461|NCT01406678|remote ischemic preconditioning
323462|NCT01406678|coronary artery bypass grafting
323463|NCT01406678|myocardial injury
323464|NCT01406665|diabetes
323465|NCT01406665|impaired glucose tolerance
323466|NCT01406652|septic bursitis
323467|NCT01406652|bursectomy
323468|NCT01406652|primary closure
323469|NCT01406639|Hereditary Hemorrhagic Telangiectasia (HHT)
323470|NCT01406639|Nosebleeds
323471|NCT01406639|Ranibizumab
323472|NCT01406639|Lucentis
323473|NCT01406626|HIV
323474|NCT01406626|AIDS
323475|NCT01406626|Health navigation
323476|NCT01406626|Viral load
323477|NCT01406626|Corrections
323478|NCT01406613|Observational
323479|NCT01406613|Bone Density
323480|NCT01406613|alendronate
323481|NCT01406613|ibandronate
323482|NCT01406613|risedronate
323483|NCT01406613|postmenopausal
323484|NCT01406613|osteoporosis
323485|NCT01406600|recombinant hCG
323486|NCT01406600|poor responder
323487|NCT01406600|oocyte maturity
323488|NCT01406587|Burning
323489|NCT01406587|Dysuria
323490|NCT01406587|Frequency
323491|NCT01406587|Pain
323492|NCT01406587|Uncomplicated Urinary Tract Infection
323493|NCT01406587|Uncomplicated UTI
323494|NCT01406587|Urinary Tract Infection
323495|NCT01406587|UTI
323496|NCT01406587|Burning during urination associated with uncomplicated urinary tract infection
323497|NCT01406587|Urination frequency associated with uncomplicated urinary tract infection
323498|NCT01406587|Pain associated with uncomplicated urinary tract infection
323499|NCT01406574|Hepatocellular carcinoma
323500|NCT01406561|Meniscectomy
323501|NCT01406561|Knee Pain
323502|NCT01406561|Postoperative Pain
323503|NCT01406548|Osteopenia
323504|NCT01406548|osteoporosis
323505|NCT01406548|low bone mineral density
323506|NCT01406535|Phosphodiesterase 5 inhibition
323507|NCT01406535|myocardial perfusion
323508|NCT01406535|angiogenesis
323509|NCT01406535|coronary artery disease
323510|NCT01406535|therapy refractory
323511|NCT01406522|Acetylcholine
323512|NCT01406522|Cholinesterases
323513|NCT01406522|Cocaine
323514|NCT01406522|Self-Administration
323515|NCT01406509|Safety
323516|NCT01406509|Conjugate vaccine
323517|NCT01406496|Insulin bolus
323518|NCT01406496|glucose excursions
323519|NCT01406496|post-prandial
323520|NCT01406496|timing
323521|NCT01406496|meal content
323522|NCT01406483|Platelet reactivity
323523|NCT01406483|CABG
323524|NCT01406483|Perioperative and in hospital bleeding
323525|NCT01406470|IGIV
323526|NCT01406470|Primary Immune Deficiency
323527|NCT01406470|Immunoglobulin G
323528|NCT01406457|Subarachnoid Hemorrhage
323529|NCT01406444|Anorexia Nervosa
323530|NCT01406444|Osteopenia
323531|NCT01406444|Osteoporosis
323532|NCT01406444|Bone density
323533|NCT01406431|pitavastatin
323534|NCT01406431|Livalo
323535|NCT01406418|Influenza
323536|NCT01406418|Virus
323537|NCT01406418|Monoclonal
323538|NCT01406418|Antibody
323539|NCT01406418|Immunization
323540|NCT01406418|Treatment
323541|NCT01406405|Degenerative disc disease
323542|NCT01406405|spinal stenosis
323543|NCT01406405|herniated disc
323544|NCT01406392|Misoprostol
323545|NCT01406392|Sublingual
323546|NCT01406392|Induced
323547|NCT01406392|Labor
323548|NCT01406366|Pediatric oral health
323549|NCT01406366|Bright Futures
323550|NCT01406366|Health promotion
323551|NCT01406353|Mitral Stenosis
323552|NCT01406353|Mitral Valvuloplasty
323553|NCT01406314|Phase 1
323554|NCT01406314|Patient
323555|NCT01406314|Systemic Amyloidosis
323556|NCT01406314|Amyloidosis
323557|NCT01406301|prescribing information
323558|NCT01406288|hemolytic-uremic syndrome
323559|NCT01406288|shiga-toxin-producing E. Coli
323560|NCT01406262|albiglutide
323561|NCT01406262|QT interval
323562|NCT01406262|cardiac repolarization
323563|NCT01406262|ECG study
323564|NCT01406249|unresectable gastric cancer
323565|NCT01406249|recurrent gastric cancer
323566|NCT01406249|StageIV gastric cancer
323567|NCT01406249|adenocarcinoma of the stomach
323568|NCT01406249|XP
323569|NCT01406249|SP
323570|NCT01406236|Female
323571|NCT01406236|urgent or elective percutaneous coronary intervention
323572|NCT01406236|PCI
323573|NCT01406236|diagnostic angiography
323574|NCT01406223|Nicotine addiction
323575|NCT01406223|Cigarette smoking
323576|NCT01406223|Smoking cessation
323577|NCT01406223|Zyban
323578|NCT01406223|Chantix
323579|NCT01406223|Nicotine patches
323580|NCT01406223|varenicline
323581|NCT01406223|bupropion
323582|NCT01406223|fMRI
323583|NCT01406210|Lung Transplant
323584|NCT01406210|REflux Surgery
323585|NCT01406210|Gastroesophageal Reflux Disease (GERD)
323586|NCT01406210|Fundoplication
323587|NCT01406197|Progesterone
323588|NCT01406197|Progestins
323589|NCT01406197|Preterm labor
323590|NCT01406197|Premature birth
323591|NCT01406197|Uterine electromyography
323592|NCT01406197|Uterine contractility
323593|NCT01406184|Child Abuse
323594|NCT01406184|Child Neglect
323595|NCT01406184|Child Hospital Emergency Room Presentations
323596|NCT01406184|Child Well-Care Compliance
323597|NCT01406184|Child Immunization Compliance
323598|NCT01406171|Isavuconazole
323599|NCT01406171|ASP9766
323600|NCT01406171|BAL8557
323601|NCT01406171|Midazolam
323602|NCT01406171|Healthy volunteers
323603|NCT01406158|Solifenacin succinate
323604|NCT01406158|VESIcare
323605|NCT01406158|Healthy Volunteers
323606|NCT01406158|YM905
323607|NCT01406145|Alzheimer's Disease
323608|NCT01406145|ASP0777
323609|NCT01406132|ASP015K
323610|NCT01406132|Healthy volunteers
323611|NCT01406106|Hypercholesterolemia
323612|NCT01406106|Lipids
323613|NCT01406106|Cardiovascular disease
323614|NCT01406106|Risks factors
323615|NCT01406106|Primary Care
323616|NCT01406093|Candidemia
323617|NCT01406093|Early-onset
323618|NCT01406093|Late-onset
323619|NCT01406093|Health-care associated
323620|NCT01406093|Nosocomial
323621|NCT01406080|Photoaging
323622|NCT01406080|Photodamage
323623|NCT01406080|Adapalene
323624|NCT01406080|Differin
323625|NCT01406067|social skills training,
323626|NCT01406067|social competence training,
323627|NCT01406067|Oppositional Defiant Disorder
323628|NCT01406067|peer related aggressive behavior
323629|NCT01406067|randomized controlled trial
323630|NCT01406054|athletes
323631|NCT01406054|injury prevention
323632|NCT01406054|neuromuscular training
323633|NCT01406054|public school
323634|NCT01406054|physical education
323635|NCT01406054|knee
323636|NCT01406054|sports
323637|NCT01406054|ACL
323638|NCT01406054|KIPP
323639|NCT01406041|Fluid and electrolyte imbalance
323640|NCT01406041|Hyponatremia
323641|NCT01406041|Hypernatremia
323642|NCT01406041|Electrolytes disorder
323643|NCT01406028|IVF
323644|NCT01406028|Stress
323645|NCT01406028|Infertility
323646|NCT01406015|Obesity
323647|NCT01406015|Insulin resistance
323648|NCT01406015|Mineralocorticoid receptor
323649|NCT01406002|Pharmacokinetics
323650|NCT01406002|darexaban
323651|NCT01406002|YM150
323652|NCT01406002|rifampicin
323653|NCT01406002|Phase 1
323654|NCT01405989|Pharmacokinetics
323655|NCT01405989|darexaban
323656|NCT01405989|ketoconazole
323657|NCT01405989|Phase 1
323658|NCT01405976|sleep apneas
323659|NCT01405976|noninvasive ventilation
323660|NCT01405976|CPAP
323661|NCT01405963|Amgen
323662|NCT01405963|AMG 157
323663|NCT01405963|Asthma
323664|NCT01405898|hypertension
323665|NCT01405898|nitrite
323666|NCT01405898|blood pressure
323667|NCT01405898|endothelial function
323668|NCT01405885|Universal Influenza
323669|NCT01405885|Intradermal DNA vaccine
323670|NCT01405885|Electroporation
323671|NCT01405885|H1 and H5
323672|NCT01405885|DNA Vaccination
323673|NCT01405885|Influenza
323674|NCT01405885|INO-3510
323675|NCT01405859|Tourette
323676|NCT01405859|tic
323677|NCT01405859|Tourette's
323678|NCT01405859|Tourette syndrome
323679|NCT01405859|Tourette's syndrome
323680|NCT01405807|Vasculitis
323681|NCT01405807|ANCA
323682|NCT01405807|Refractory
323683|NCT01405742|Hemophilia
323684|NCT01405742|Prophylaxis
323685|NCT01405742|Recombinant factor VIII
323686|NCT01405716|Mindfulness
323687|NCT01405716|Back Pain
323688|NCT01405716|Older adults
323689|NCT01405703|Clavicle Fractures
323690|NCT01405703|Numbness
323691|NCT01405703|Percutaneous plate fixation
323692|NCT01405703|open plate fixation
323693|NCT01405703|incision related numbness
323694|NCT01405703|union rates
323695|NCT01405703|subjective
323696|NCT01405703|questionnaire based outcomes
323697|NCT01405703|Diaphyseal
323698|NCT01405690|CAD
323699|NCT01405690|CTCA
323700|NCT01405690|multidetector computer tomography (MDCT)
323701|NCT01405677|Hepatitis A
323702|NCT01405677|Vaccination
323703|NCT01405677|Immunisation
323704|NCT01405651|ONO-6950
323705|NCT01405651|Healthy adult subjects
323706|NCT01405625|Asthma
323707|NCT01405625|Health literacy
323708|NCT01405625|Parent knowledge of appropriate action plan steps
323709|NCT01405599|Ulimorelin
323710|NCT01405599|Hepatic Impairment
323711|NCT01405586|elderly
323712|NCT01405586|chemotherapy
323713|NCT01405573|Child Pugh B
323714|NCT01405573|first line
323715|NCT01405547|Gestational Diabetes
323716|NCT01405547|Gestational Hyperglycemia
323717|NCT01405547|Gestational Insulinemia
323718|NCT01405547|Maternal Obesity
323719|NCT01405547|Human Milk
323720|NCT01405547|Lactogenesis
323721|NCT01405547|Obstetrics
323722|NCT01405547|Nutrition
323723|NCT01405547|Infant Growth
323724|NCT01405534|Catheterization, Central Venous
323725|NCT01405521|typhoid vaccine M01ZH09
323726|NCT01405521|Ty21a typhoid vaccine
323727|NCT01405508|N01258
323728|NCT01405508|Brivaracetam
323729|NCT01405508|Epilepsy
323730|NCT01405508|IV
323731|NCT01405508|intravenous
323732|NCT01405495|Posttraumatic Stress Disorder
323733|NCT01405495|Working Memory
323734|NCT01405495|Attentional Bias
323735|NCT01405495|Connectivity
323736|NCT01405495|Structural Neuroimaging
323737|NCT01405495|Functional Neuroimaging
323738|NCT01405495|Diffusion Tensor Imaging
323739|NCT01405495|Arterial Spin Labelling
323740|NCT01405495|Cortisol
323741|NCT01405495|Psychophysiology
323742|NCT01405495|Early development of
323743|NCT01405482|Botulinum Toxin Type A
323744|NCT01405482|Thoracic Outlet Syndrome
323745|NCT01405469|Achalasia
323746|NCT01405469|Heller myotomy
323747|NCT01405469|Dysphagia
323748|NCT01405469|Peroral Endoscopic Myotomy
323749|NCT01405456|HIV-infection
323750|NCT01405456|eplerenone
323751|NCT01405456|aldosterone
323752|NCT01405456|visceral fat
323753|NCT01405456|lipodystrophy
323754|NCT01405443|Simulator training
323755|NCT01405443|Flexible endoscopy
323756|NCT01405443|Gastrointestinal endoscopy
323757|NCT01405443|Colonoscopy
323758|NCT01405443|Training
323759|NCT01405443|Performance
323760|NCT01405417|Achalasia
323761|NCT01405417|Heller myotomy
323762|NCT01405417|Dysphagia
323763|NCT01405417|Peroral Endoscopic Myotomy
323764|NCT01405404|parenting childcare discounts child behavior
323765|NCT01405404|No Intervention Control
323766|NCT01405404|Intervention no childcare discount
323767|NCT01405404|Intervention with childcare discount
323768|NCT01405391|Pharma Mar
323769|NCT01405391|PM01183
323770|NCT01405391|Non-Colorectal Cancer (non-CRC)
323771|NCT01405391|Dose finding phase I
323772|NCT01405365|Periodontitis
323773|NCT01405365|Periodontal diseases
323774|NCT01405365|Obesity
323775|NCT01405365|Metronidazole
323776|NCT01405365|Prognosis
323777|NCT01405365|Probing depth
323778|NCT01405365|Periodontal attachment loss
323779|NCT01405352|obesity
323780|NCT01405352|vitamin A
323781|NCT01405352|immune system
323782|NCT01405326|rheumatoid arthritis
323783|NCT01405326|biological therapy
323784|NCT01405326|adalimumab
323785|NCT01405326|ability to work
323786|NCT01405326|sick leaves
323787|NCT01405287|stent
323788|NCT01405287|drug eluting stent
323789|NCT01405287|healing
323790|NCT01405287|endothelium
323791|NCT01405287|DES
323792|NCT01405287|OCT
323793|NCT01405287|MI
323794|NCT01405287|ACS
323795|NCT01405248|Butylphthalide
323796|NCT01405235|Paclitaxel/Topotecan
323797|NCT01405235|Cisplatin/Topotecan
323798|NCT01405222|exacerbation
323799|NCT01405222|COPD
323800|NCT01405222|Cough
323801|NCT01405209|EKG
323802|NCT01405209|AF
323803|NCT01405209|biosignals
323804|NCT01405196|double-blind
323805|NCT01405196|placebo-controlled
323806|NCT01405196|multicenter
323807|NCT01405196|dose-ranging
323808|NCT01405196|efficacy
323809|NCT01405196|safety
323810|NCT01405196|lupus.
323811|NCT01405183|Hepatitis C
323812|NCT01405183|Renal Cell Carcinoma
323813|NCT01405183|Colorectal Cancer
323814|NCT01405170|bioequivalence study
323815|NCT01405170|methylprednisolone
323816|NCT01405170|suspension
323817|NCT01405170|tablets
323818|NCT01405170|fed
323819|NCT01405157|bioequivalence study
323820|NCT01405157|methylprednisolone
323821|NCT01405157|suspension
323822|NCT01405157|tablets
323823|NCT01405157|fasting
323824|NCT01405144|Photoaging
323825|NCT01405144|Actinic keratosis
323826|NCT01405144|5-fluoruracil
323827|NCT01405144|Carcinogenesis
323828|NCT01405131|bioequivalence study
323829|NCT01405131|methylprednisolone
323830|NCT01405131|suspension
323831|NCT01405131|tablets
323832|NCT01405118|Drug-Drug Interaction Healthy Volunteers CP-690
323833|NCT01405118|550 Metformin
323834|NCT01405092|volume
323835|NCT01405092|acute kidney injury
323836|NCT01405092|continuous renal replacement
323837|NCT01405079|Lung cancer
323838|NCT01405079|II-IIIA(N1-N2)
323839|NCT01405079|Adjuvant treatment
323840|NCT01405079|EGFR mutations
323841|NCT01405079|Tyrosine kinase inhibitor
323842|NCT01405066|Computed Tomography (CT)
323843|NCT01405066|Ionizing radiation
323844|NCT01405066|Advanced medical imaging
323845|NCT01405066|Radiation Dose Audit Reports
323846|NCT01405053|Central Nervous System
323847|NCT01405040|Cardiac
323848|NCT01405040|Output
323849|NCT01405040|Preload
323850|NCT01405040|Lung
323851|NCT01405040|Water
323852|NCT01405027|HCV
323853|NCT01405027|Genotype1
323854|NCT01405027|Naive
323855|NCT01405027|Partial responder
323856|NCT01405027|Relapser
323857|NCT01405014|Hold Me Tight
323858|NCT01405014|Emotionally Focused Therapy
323859|NCT01405014|Relationship enhancement
323860|NCT01405014|Couples counseling
323861|NCT01405014|Marital therapy
323862|NCT01405014|Acquired brain injury
323863|NCT01405014|Traumatic brain injury
323864|NCT01405014|Stroke
323865|NCT01405001|Emergencies
323866|NCT01405001|War
323867|NCT01405001|Intubation, Intratracheal
323868|NCT01404988|Heart Failure
323869|NCT01404988|Telemedicine
323870|NCT01404988|Medication Adherence
323871|NCT01404975|Delirium
323872|NCT01404975|PVB
323873|NCT01404975|PCA
323874|NCT01404975|Opioid
323875|NCT01404975|Aortic Valve replacement
323876|NCT01404962|Haemophilus influenza type b
323877|NCT01404962|children
323878|NCT01404962|Korea
323879|NCT01404962|vaccine
323880|NCT01404962|Prevention of haemophilus influenza type b
323881|NCT01404949|Tretinoin
323882|NCT01404949|all-trans retinoic acid
323883|NCT01404949|ATRA
323884|NCT01404949|Vesanoid
323885|NCT01404949|Arsenic Trioxide
323886|NCT01404949|ATO
323887|NCT01404949|Trisenox
323888|NCT01404949|11-040
323889|NCT01404936|Lymphoma
323890|NCT01404936|Hodgkin's Disease
323891|NCT01404936|Stage III and IV
323892|NCT01404936|Adriamycin
323893|NCT01404936|Doxorubicin
323894|NCT01404936|Rubex
323895|NCT01404936|Bleomycin
323896|NCT01404936|Bleomycin Sulfate
323897|NCT01404936|BLM
323898|NCT01404936|Dacarbazine
323899|NCT01404936|DTIC-DOME
323900|NCT01404936|Interferon-2A
323901|NCT01404936|Interferon-Alfa-2a
323902|NCT01404936|Roferon-A
323903|NCT01404936|Velban
323904|NCT01404936|Vinblastine
323905|NCT01404910|Pregnancy
323906|NCT01404910|Preeclampsia
323907|NCT01404910|Pre-term
323908|NCT01404910|sFlt-1
323909|NCT01404910|Apheresis
323910|NCT01404910|Hypertension
323911|NCT01404910|Proteinuria
323912|NCT01404910|VEGF
323913|NCT01404897|carbohydrate
323914|NCT01404897|DASH diet
323915|NCT01404897|blood pressure
323916|NCT01404897|cholesterol
323917|NCT01404884|myopia
323918|NCT01404884|astigmatism
323919|NCT01404884|presbyopia
323920|NCT01404884|SUPRACOR
323921|NCT01404884|multifocal
323922|NCT01404871|OCD
323923|NCT01404871|pharmacogenetics
323924|NCT01404871|cortical inhibition
323925|NCT01404871|genetics
323926|NCT01404858|IVF
323927|NCT01404858|Lifestyle habits
323928|NCT01404845|exudative AMD
323929|NCT01404845|dietary supplements
323930|NCT01404845|macular pigment
323931|NCT01404845|lutein
323932|NCT01404845|zeaxanthin
323933|NCT01404845|Nutrof total
323934|NCT01404845|in one eye
323935|NCT01404832|Gastroesophageal reflux
323936|NCT01404832|Proton pump inhibitor
323937|NCT01404832|Eosinophilic esophagitis
323938|NCT01404793|Liver Transplantation
323939|NCT01404793|Solid Phase Micro Extraction
323940|NCT01404793|Rocuronium
323941|NCT01404793|Metabolomics
323942|NCT01404793|Pharmacokinetics
323943|NCT01404793|Clinical Marker
323944|NCT01404780|Double lumen ET intubation
323945|NCT01404780|Laryngoscope
323946|NCT01404780|Lung Surgery
323947|NCT01404767|Vascular surgery
323948|NCT01404767|esmolol
323949|NCT01404767|hemodynamic control
323950|NCT01404754|MDMA
323951|NCT01404754|mood
323952|NCT01404754|subjective effects
323953|NCT01404754|interpersonal closeness
323954|NCT01404741|MDS
323955|NCT01404741|CMML
323956|NCT01404741|allogeneic stem cell transplantation
323957|NCT01404741|5-azacytidine
323958|NCT01404728|Vaginal length
323959|NCT01404728|Sexual dysfunction
323960|NCT01404715|Drug drug interaction
323961|NCT01404702|Neuroblastoma
323962|NCT01404702|Pediatrics
323963|NCT01404702|Refractory
323964|NCT01404702|Immunotherapy
323965|NCT01404702|Biological therapy
323966|NCT01404702|Lymphocytes
323967|NCT01404702|Cancer
323968|NCT01404702|Bisphosphonate
323969|NCT01404689|dexmedetomidine
323970|NCT01404689|midazolam
323971|NCT01404689|ERCP
323972|NCT01404689|cholangiopancreatography
323973|NCT01404689|sedation
323974|NCT01404689|propofol
323975|NCT01404676|Glucose variability
323976|NCT01404676|Oxidative stress
323977|NCT01404676|Endothelial cell function
323978|NCT01404663|bone marrow CD133 transplantation side effects
323979|NCT01404663|side effects
323980|NCT01404650|GIST
323981|NCT01404650|Refractory
323982|NCT01404650|Gastrointestinal
323983|NCT01404650|Stromal
323984|NCT01404650|Tumor
323985|NCT01404611|with tubes
323986|NCT01404559|Amputee
323987|NCT01404559|Transtibial
323988|NCT01404559|Military
323989|NCT01404559|Gait
323990|NCT01404559|Rehabilitation
323991|NCT01404546|stroke smoking cessation cost-free pharmacotherapy
323992|NCT01404533|NTBI
323993|NCT01404533|Iron
323994|NCT01404533|Absorption
323995|NCT01404520|#14 Cancer Related fatigue
323996|NCT01404520|#13 Quality of Life
323997|NCT01404520|"#12 Psychosocial Intervention[ti/ab]"
323998|NCT01404520|#11 Rehabilitation[tw]
323999|NCT01404520|"#10 Physical Fitness[tw]"
324000|NCT01404520|"#9 Physical Activity[tw]"
324001|NCT01404520|"#8 Exercise Therapy[tw]"
324002|NCT01404520|#7 Exercise[tw]
324003|NCT01404520|#6 Hematologic[tw]
324004|NCT01404520|#5 Hematological[tw]
324005|NCT01404520|#4 Leukemia, Myeloid, Acute[mh]
324006|NCT01404520|"#3 Acute Myeloid Leukemia[tw]"
324007|NCT01404520|"#2 Acute Lymphoblastic Leukemia[tw]"
324008|NCT01404520|"#1 Acute Leukemia[tw]"
324009|NCT01404507|Acute Myocardial Infarction
324010|NCT01404494|Haptic Skills
324011|NCT01404494|Computer Assisted Interface
324012|NCT01404494|TBI
324013|NCT01404494|Traumatic Brain Injury
324014|NCT01404481|Urinary retention
324015|NCT01404481|CISC
324016|NCT01404481|Single use
324017|NCT01404481|Re use
324018|NCT01404442|midazolam
324019|NCT01404442|ketamine
324020|NCT01404442|intrathecal
324021|NCT01404442|pain
324022|NCT01404429|Rheumatoid arthritis
324023|NCT01404429|Active
324024|NCT01404390|Phase I
324025|NCT01404390|Japanese
324026|NCT01404377|breast surgery : postoperative pain; ropivacaine
324027|NCT01404364|Triamcinolone
324028|NCT01404364|Chlorpromazine
324029|NCT01404364|Refractory glaucoma
324030|NCT01404364|Blind painful eye
324031|NCT01404351|Reduction mammaplasty
324032|NCT01404351|Breast reduction
324033|NCT01404351|PlasmaBlade
324034|NCT01404351|PEAK
324035|NCT01404325|Lung transplantation
324036|NCT01404325|everolimus
324037|NCT01404325|kidney function
324038|NCT01404299|Frailty,
324039|NCT01404299|nutritional supplementation,
324040|NCT01404299|functional status
324041|NCT01404260|chemotherapy
324042|NCT01404260|maintenance therapy
324043|NCT01404260|gefitinib
324044|NCT01404247|retina
324045|NCT01404247|optic nerve
324046|NCT01404247|fovea
324047|NCT01404247|Eyes
324048|NCT01404247|Neonates
324049|NCT01404234|Cystic fibrosis
324050|NCT01404234|CF
324051|NCT01404234|PA
324052|NCT01404234|Pseudomonas aeruginosa
324053|NCT01404234|AZLI
324054|NCT01404234|aztreonam
324055|NCT01404234|Chronic Pseudomonas aeruginosa
324056|NCT01404195|Nutritional supplement
324057|NCT01404195|CaHMB
324058|NCT01404195|Barthel index
324059|NCT01404195|Frailty
324060|NCT01404182|seasonal
324061|NCT01404182|prevention
324062|NCT01404182|influenza
324063|NCT01404182|infection
324064|NCT01404182|influenza vaccine
324065|NCT01404182|vaccine
324066|NCT01404182|influenza in humans
324067|NCT01404169|Alzheimer Disease
324068|NCT01404169|Dementia
324069|NCT01404169|Delirium
324070|NCT01404169|Amnestic
324071|NCT01404169|Cognitive Disorders
324072|NCT01404169|Donepezil
324073|NCT01404169|Brain Diseases
324074|NCT01404169|Central Nervous System Diseases
324075|NCT01404169|Nervous System Diseases
324076|NCT01404169|Tauopathies
324077|NCT01404169|Neurodegenerative Diseases
324078|NCT01404169|Mental Disorders
324079|NCT01404169|Cholinesterase Inhibitors
324080|NCT01404169|Enzy
324081|NCT01404156|Esophageal cancer
324082|NCT01404156|Neoadjuvant
324083|NCT01404156|Chemotherapy
324084|NCT01404156|Chemoradiation
324085|NCT01404156|Surgery
324086|NCT01404156|Esophagectomy
324087|NCT01404156|Adenocarcinoma
324088|NCT01404156|Gastroesophageal
324089|NCT01404130|isotretinoin
324090|NCT01404130|hippocampus
324091|NCT01404130|memory
324092|NCT01404130|learning
324093|NCT01404130|CANTAB
324094|NCT01404065|transcranial direct current stimulation
324095|NCT01404052|transcranial direct current stimulation
324096|NCT01404052|transcranial ultrasound
324097|NCT01404039|learning
324098|NCT01404039|pain perception
324099|NCT01404026|Transcranial Direct Current Stimulation
324100|NCT01404013|Montelukast
324101|NCT01404013|Cough variant asthma
324102|NCT01404013|Inhaled Corticosteroid
324103|NCT01403987|Education
324104|NCT01403987|Ascites
324105|NCT01403987|Liver
324106|NCT01403987|Guidelines
324107|NCT01403922|Phase I, Randomised, Placebo-Controlled, Double-Blind,Hypertensive Patients, Blood Pressure, Calcium Channel Blockers, Beta Blockers, ACE Inhibitors
324108|NCT01403922|Scientific terminology: To determine if treatment with TC5214 alone or in combination with Anti-Hypertensive Medications has an effect on sitting blood pressure
324109|NCT01403922|Laymen terminology: Hypertension
324110|NCT01403896|Hematopoietic Stem Cell Transplantation
324111|NCT01403896|Plerixafor
324112|NCT01403896|Healthy Donors
324113|NCT01403896|Stem Cell Graft
324114|NCT01403883|Rectal cancer
324115|NCT01403883|Temporary stoma
324116|NCT01403883|Psychological disorders
324117|NCT01403870|Low Back Pain
324118|NCT01403857|Acceptability
324119|NCT01403857|liking
324120|NCT01403844|resonance Raman spectroscopy
324121|NCT01403844|Dietary Guidelines
324122|NCT01403844|fruits
324123|NCT01403844|biomarkers
324124|NCT01403844|carotenoids
324125|NCT01403844|MyPlate
324126|NCT01403844|vegetables
324127|NCT01403818|ASP1941
324128|NCT01403818|ipragliflozin
324129|NCT01403818|Mitiglinide calcium hydrate
324130|NCT01403818|Drug-Drug interaction
324131|NCT01403818|Pharmacokinetics
324132|NCT01403805|Oral care
324133|NCT01403805|Vaccine
324134|NCT01403805|Pneumonia
324135|NCT01403805|Elderly
324136|NCT01403805|Prevention
324137|NCT01403805|Primary care
324138|NCT01403792|Human Immunodeficiency Virus
324139|NCT01403792|Neutralising monoclonal antibody
324140|NCT01403779|Intensity-Modulated Radiation Therapy (IMRT)
324141|NCT01403779|Breast cancer
324142|NCT01403779|Hypofractionation
324143|NCT01403766|pediatric
324144|NCT01403766|kidney
324145|NCT01403766|transplant
324146|NCT01403766|GFR
324147|NCT01403766|creatinine
324148|NCT01403766|cystatin C
324149|NCT01403766|iohexol
324150|NCT01403753|Obesity
324151|NCT01403753|Child
324152|NCT01403753|Dietary Habits
324153|NCT01403740|acquired haemophilia
324154|NCT01403740|factor VIII
324155|NCT01403727|Biopsy of liver tumors
324156|NCT01403714|acute heart failure
324157|NCT01403701|physical therapy
324158|NCT01403701|pelvic prolapse
324159|NCT01403701|incontinence
324160|NCT01403701|quality of life
324161|NCT01403688|fertility high risk, controlled ovarian stimulation, breast cancer
324162|NCT01403675|women with cancer whose ovarian tissue has been collected and stored in liquid nitrogen before cancer therapy (surgery, chemotherapy, radiotherapy),
324163|NCT01403675|who are in remission (no recurrence of disease for 5 years),
324164|NCT01403675|who are in normal organ function and have no contraindication for surgery or pregnancy, and
324165|NCT01403675|who wish to restore ovarian function using stored ovarian tissue.
324166|NCT01403662|bipolar disorder
324167|NCT01403662|depression
324168|NCT01403662|major depression
324169|NCT01403662|bipolar I depression
324170|NCT01403662|bipolar II depression
324171|NCT01403662|bipolar I disorder
324172|NCT01403662|bipolar II disorder
324173|NCT01403662|minocycline
324174|NCT01403662|minocin
324175|NCT01403623|Hypothermia
324176|NCT01403623|Newborn
324177|NCT01403623|Resuscitation
324178|NCT01403623|Plastic bag
324179|NCT01403610|TH-302
324180|NCT01403610|Bevacizumab
324181|NCT01403610|Phase 2
324182|NCT01403610|Glioma
324183|NCT01403610|High Grade Glioma
324184|NCT01403610|CNS
324185|NCT01403597|Skin wrinkling
324186|NCT01403597|Skin aging
324187|NCT01403597|Skin pigmentation
324188|NCT01403545|Safety
324189|NCT01403545|Tolerability
324190|NCT01403545|Pharmacokinetics
324191|NCT01403545|Liposomal Curcumin
324192|NCT01403532|Hypogonadotropic Hypogonadism
324193|NCT01403532|Kallmann Syndrome
324194|NCT01403532|LH
324195|NCT01403532|FSH
324196|NCT01403506|kidney transplantation
324197|NCT01403506|N-Acetyl Cysteine
324198|NCT01403506|living donor
324199|NCT01403506|delayed graft function
324200|NCT01403493|Irritable bowel syndrome
324201|NCT01403493|Patient education
324202|NCT01403480|Basal Cell Carcinoma
324203|NCT01403467|Bronchial disease
324204|NCT01403467|asthma
324205|NCT01403467|continuous positive airway pressure (CPAP)
324206|NCT01403467|Bronchoconstriction
324207|NCT01403454|chronic kidney disease
324208|NCT01403454|web-based application
324209|NCT01403454|dialysis education
324210|NCT01403441|Refractory Bipolar Depression
324211|NCT01403428|Asthma
324212|NCT01403428|non invasive ventilation
324213|NCT01403428|pediatrics
324214|NCT01403428|noninvasive positive pressure ventilation (NPPV)
324215|NCT01403402|Eye Diseases, Hereditary
324216|NCT01403402|Retinal Dystrophies
324217|NCT01403402|Retinal Degeneration
324218|NCT01403402|Genetic Diseases, X-Linked
324219|NCT01403402|Genetic Diseases, Inborn
324220|NCT01403402|Pathologic Processes
324221|NCT01403402|Respiration Disorders
324222|NCT01403402|Eye Diseases
324223|NCT01403402|Cardiomyopathy, Hypertrophic
324224|NCT01403402|Hypertrophy
324225|NCT01403402|Cardiomyopathies
324226|NCT01403402|Heart Diseases
324227|NCT01403402|Central Nervous System Diseases
324228|NCT01403402|Nervous System Diseases
324229|NCT01403402|Muscular Diseases
324230|NCT01403402|Muscular Dystrophies
324231|NCT01403402|Myopathies, Structural, Congenital
324232|NCT01403402|Muscular Disorders, Atrophic
324233|NCT01403402|Neuromuscular Diseases
324234|NCT01403402|Myopathies, Nemaline
324235|NCT01403402|Musculoskeletal Diseases
324236|NCT01403389|Kidney Transplant
324237|NCT01403389|Delayed Graft Function
324238|NCT01403350|Malaria
324239|NCT01403350|Fever
324240|NCT01403350|Acute febrile illness
324241|NCT01403350|Pneumonia
324242|NCT01403350|Community health worker
324243|NCT01403350|Rapid diagnostic test
324244|NCT01403337|peripheral arterial disease
324245|NCT01403337|myocardial infarction
324246|NCT01403324|metastatic or locally advanced differentiated thyroid cancer
324247|NCT01403324|planned for a therapeutic activity of 131I after thyroid hormone withdrawal
324248|NCT01403311|Anaplastic astrocytoma
324249|NCT01403311|Astrocytoma
324250|NCT01403311|Brain stem glioma
324251|NCT01403311|Ependymoma
324252|NCT01403311|Glioblastoma
324253|NCT01403311|Glioblastoma multiforme
324254|NCT01403311|Gliosarcoma
324255|NCT01403311|oligodendroglioma
324256|NCT01403311|Medulloblastoma
324257|NCT01403311|Mixed astrocytoma-ependymoma
324258|NCT01403311|ALA
324259|NCT01403298|Adolescent
324260|NCT01403298|HIV
324261|NCT01403298|AIDS
324262|NCT01403298|Sexual risk
324263|NCT01403298|Family
324264|NCT01403298|Prevention
324265|NCT01403298|Juvenile Drug Court
324266|NCT01403298|Juvenile Justice
324267|NCT01403298|Drug Use
324268|NCT01403298|Marijuana
324269|NCT01403285|Glioblastoma
324270|NCT01403285|stable disease
324271|NCT01403272|pressure ulcers
324272|NCT01403272|stage 1
324273|NCT01403272|stage 2
324274|NCT01403272|stage 3
324275|NCT01403272|stage 4
324276|NCT01403272|wounds
324277|NCT01403272|sores
324278|NCT01403272|infection
324279|NCT01403272|bioburden
324280|NCT01403272|bacterial contamination
324281|NCT01403272|bed linen
324282|NCT01403272|sheets
324283|NCT01403272|underpad
324284|NCT01403272|skin assessment
324285|NCT01403272|microclimate
324286|NCT01403272|shear
324287|NCT01403272|friction
324288|NCT01403272|moisture
324289|NCT01403272|fabrics
324290|NCT01403272|long term care
324291|NCT01403272|nursing home
324292|NCT01403272|decubitus ulcer
324293|NCT01403272|bed ridden
324294|NCT01403272|anti-microbial
324295|NCT01403259|Nasopharyngeal carcinoma
324296|NCT01403259|S-1
324297|NCT01403259|Oxaliplatin
324298|NCT01403246|CLL
324299|NCT01403246|Lenalidomide
324300|NCT01403246|Chlorambucil
324301|NCT01403246|No previous treatment
324302|NCT01403233|Pharmacokinetics
324303|NCT01403233|Safety
324304|NCT01403207|Sex differences
324305|NCT01403207|knee joint
324306|NCT01403207|inflammatory mediators
324307|NCT01403207|Vitamin D
324308|NCT01403207|osteoarthritis
324309|NCT01403194|Sleep Disordered Breathing
324310|NCT01403194|CPAP
324311|NCT01403194|BiPAP
324312|NCT01403194|Cardiovascular risk markers
324313|NCT01403181|HCV
324314|NCT01403181|T cells
324315|NCT01403181|cytokines
324316|NCT01403181|cytotoxicity
324317|NCT01403181|proliferation
324318|NCT01403168|Osteopathy
324319|NCT01403168|Breast cancer
324320|NCT01403168|Pain
324321|NCT01403155|H5N1
324322|NCT01403155|Avian Influenza
324323|NCT01403155|DNA Vaccine
324324|NCT01403155|Intradermal (ID) Injection
324325|NCT01403155|Electroporation
324326|NCT01403155|Healthy Adults
324327|NCT01403142|heart transplant
324328|NCT01403142|vasculopathy
324329|NCT01403129|keratoconus
324330|NCT01403129|keratoconus-suspect
324331|NCT01403129|ultrasound exam
324332|NCT01403129|acoustic radiation force ultrasound exam
324333|NCT01403116|testosterone
324334|NCT01403116|male hypogonadism
324335|NCT01403116|low testosterone
324336|NCT01403090|Pulmonary Embolism
324337|NCT01403090|Deep Vein Thrombosis
324338|NCT01403090|Venous Thromboembolism
324339|NCT01403090|Central Line Catheter
324340|NCT01403090|Vena Cava Filters
324341|NCT01403077|Superficial femoral artery
324342|NCT01403077|Peripheral arterial disease
324343|NCT01403077|Atherosclerosis
324344|NCT01403077|Intermittent Claudication
324345|NCT01403077|Vascular Diseases
324346|NCT01403077|Cardiovascular Diseases
324347|NCT01403064|Oral mucositis; head and neck cancer; chemotherapy; radiotherapy
324348|NCT01403038|healthy volunteers
324349|NCT01403038|elagolix
324350|NCT01403038|endometriosis
324351|NCT01403038|ovarian reserve
324352|NCT01403038|gonadotropin-releasing hormone antagonist
324353|NCT01403038|ovulation
324354|NCT01403038|ovarian activity
324355|NCT01403012|To identify clinical and metabolomic markers that underlie variability in response to systemic therapy in psoriasis
324356|NCT01403012|To identify metabolomic signatures associated with psoriasis
324357|NCT01403012|To identify possible treatment-specific metabolomic signatures
324358|NCT01402999|Growth disorders
324359|NCT01402999|Saizen
324360|NCT01402999|Easypod
324361|NCT01402999|Growth hormone
324362|NCT01402999|Pediatric subject
324363|NCT01402960|High-Definition Transcranial Direct Current Stimulation
324364|NCT01402908|Hepatocellular Carcinoma
324365|NCT01402908|PI-88
324366|NCT01402908|Phase III
324367|NCT01402908|Adjuvant Therapy
324368|NCT01402908|Hepatoma
324369|NCT01402908|Liver Cancer
324370|NCT01402895|Nerve conduction
324371|NCT01402895|H-reflex, mobilizations
324372|NCT01402895|with neurodynamic component
324373|NCT01402882|traumatic brain injury
324374|NCT01402882|tranexamic acid
324375|NCT01402882|antifibrinolytic
324376|NCT01402882|randomised
324377|NCT01402882|clinical trial
324378|NCT01402869|Methemoglobin
324379|NCT01402869|Methemoglobinemia
324380|NCT01402869|Prilocaine
324381|NCT01402869|Lidocaine
324382|NCT01402856|Prevention
324383|NCT01402856|Adolescent
324384|NCT01402856|Trauma
324385|NCT01402856|Driving
324386|NCT01402843|phase III combination study
324387|NCT01402830|cancer
324388|NCT01402830|depression
324389|NCT01402830|pain
324390|NCT01402817|NF1
324391|NCT01402817|plexiform neurofibromas
324392|NCT01402817|Sunitinib
324393|NCT01402817|Sutent®
324394|NCT01402739|PoC
324395|NCT01402739|ROTEM
324396|NCT01402739|Multiplate
324397|NCT01402739|transfusion
324398|NCT01402739|cardiac surgery
324399|NCT01402739|drainage blood loss
324400|NCT01402739|chest tube output
324401|NCT01402726|renal artery
324402|NCT01402726|sympathetic nerves
324403|NCT01402726|modification
324404|NCT01402726|heart failure
324405|NCT01402700|Peripheral arterial disease
324406|NCT01402700|claudication
324407|NCT01402700|stent
324408|NCT01402700|VISI-Pro
324409|NCT01402700|Iliac artery
324410|NCT01402687|Stem Cell Transplant
324411|NCT01402687|Mucositis
324412|NCT01402674|Obesity treatment
324413|NCT01402674|Phentermine
324414|NCT01402674|Withholding treatment
324415|NCT01402674|Phentermine dependence
324416|NCT01402661|rheumatoid arthritis
324417|NCT01402661|psoriatic arthritis
324418|NCT01402661|disease registry
324419|NCT01402648|Non adenomatous mucosa
324420|NCT01402648|Estrogen Receptor beta and apoptosis
324421|NCT01402648|Adenoma recurrence
324422|NCT01402648|Screening colonoscopy every 3-5 years
324423|NCT01402648|patients at intermediate risk for CRC
324424|NCT01402635|crowding
324425|NCT01402635|Point-of-Care Systems
324426|NCT01402635|emergency medicine
324427|NCT01402609|Continuity of care
324428|NCT01402609|Patient safety
324429|NCT01402609|Communication between acute and community care providers
324430|NCT01402596|Deep Sedation
324431|NCT01402596|Pediatrics
324432|NCT01402596|Emergency Hospital Services
324433|NCT01402596|Midazolam
324434|NCT01402596|Chloral hydrate
324435|NCT01402596|Randomized controlled trial
324436|NCT01402583|Hepatitis C
324437|NCT01402583|Gender
324438|NCT01402583|Menopause
324439|NCT01402583|Sustained viral response
324440|NCT01402583|Cytokines
324441|NCT01402570|disability
324442|NCT01402570|polio
324443|NCT01402570|rehabilitation
324444|NCT01402570|wellness
324445|NCT01402557|Obesity
324446|NCT01402557|Body Weight Changes
324447|NCT01402557|Internet
324448|NCT01402544|AMD
324449|NCT01402544|Choroidal neovascularization
324450|NCT01402544|Ranibizumab
324451|NCT01402544|Age-related Macular Degeneration
324452|NCT01402544|Genome
324453|NCT01402531|Hereditary hemorrhagic telangiectasia (HHT)
324454|NCT01402531|nosebleed
324455|NCT01402531|Bevacizumab
324456|NCT01402531|Avastin
324457|NCT01402518|achalasia
324458|NCT01402518|myotomy
324459|NCT01402518|endoscopic myotomy
324460|NCT01402518|difficulty swallowing
324461|NCT01402505|obesity
324462|NCT01402505|sleeve gastrectomy
324463|NCT01402505|transvaginal NOTES
324464|NCT01402492|Cocaine-Related disorders
324465|NCT01402492|Cocaine
324466|NCT01402492|Substance-Related disorders
324467|NCT01402492|Opioid abuse
324468|NCT01402492|Opioid dependence
324469|NCT01402492|abuse
324470|NCT01402492|addiction
324471|NCT01402492|treatment
324472|NCT01402492|buprenorphine
324473|NCT01402492|naltrexone
324474|NCT01402492|Suboxone
324475|NCT01402492|Vivitrol
324476|NCT01402479|migraine,
324477|NCT01402479|ramipril,
324478|NCT01402479|hypertension
324479|NCT01402466|Drug users
324480|NCT01402466|criminal justice
324481|NCT01402466|HIV care
324482|NCT01402466|HAART
324483|NCT01402466|incarceration
324484|NCT01402453|Incentives
324485|NCT01402453|Social psychology
324486|NCT01402453|Randomized trial
324487|NCT01402453|Hypertension
324488|NCT01402453|Intervention
324489|NCT01402453|Pilot Study
324490|NCT01402440|Diffuse Large B-Cell Lymphoma,
324491|NCT01402440|Phase 1,
324492|NCT01402440|CD79 Mutation
324493|NCT01402427|Coronary Artery Disease
324494|NCT01402427|Coronary Angiography
324495|NCT01402427|Percutaneous Coronary Intervention
324496|NCT01402427|Transradial
324497|NCT01402427|Radial Artery Spasm
324498|NCT01402427|Verapamil
324499|NCT01402427|Adverse Effects
324500|NCT01402414|atopic dermatitis
324501|NCT01402414|NB-UVB
324502|NCT01402414|phototherapy
324503|NCT01402414|balneophototherapy
324504|NCT01402414|Bath-PUVA
324505|NCT01402414|SCORAD index
324506|NCT01402401|HER2+,
324507|NCT01402401|Gastric Cancer,
324508|NCT01402401|HSP90,
324509|NCT01402401|2nd-line,
324510|NCT01402401|Trastuzumab
324511|NCT01402375|Pain Management
324512|NCT01402375|Emergency Medicine
324513|NCT01402375|Extremity Injuries
324514|NCT01402362|Ethiopians
324515|NCT01402362|Diabetes Mellitus
324516|NCT01402362|Glucose tolerance
324517|NCT01402362|Israel
324518|NCT01402362|Included in the year 2000 study
324519|NCT01402349|Chronic rhinosinusitis, SNOT 22, Quality of life
324520|NCT01402336|Polycystic ovary syndrome
324521|NCT01402336|ovulation induction
324522|NCT01402336|In vitro fertilization-embryo transfer
324523|NCT01402310|Onset of labor
324524|NCT01402310|Bishop score
324525|NCT01402310|Cervical length
324526|NCT01402310|Multiple proteins
324527|NCT01402310|Cervicovaginal fluid
324528|NCT01402297|apocynin
324529|NCT01402297|COPD
324530|NCT01402284|Novel Drug Combinations
324531|NCT01402284|Protease Inhibitors
324532|NCT01402284|Decreased Peripheral Neuropathy
324533|NCT01402284|Auto Stem Cell Transplant
324534|NCT01402284|Multiple Myeloma
324535|NCT01402271|recurrent ovarian epithelial cancer
324536|NCT01402271|recurrent fallopian tube cancer
324537|NCT01402271|recurrent primary peritoneal cavity cancer
324538|NCT01402245|pneumonia
324539|NCT01402245|pneumococcal polysaccharide vaccine
324540|NCT01402245|pneumococcal conjugate vaccine
324541|NCT01402232|contrast-induced nephropathy
324542|NCT01402232|contrast medium
324543|NCT01402232|creatinine clearance
324544|NCT01402232|coronary angiography
324545|NCT01402232|diabetes
324546|NCT01402232|chronic kidney disease
324547|NCT01402232|predictive model
324548|NCT01402219|contrast-induced nephropathy
324549|NCT01402219|contrast medium
324550|NCT01402219|creatinine clearance
324551|NCT01402219|coronary angiography
324552|NCT01402219|chronic kidney disease
324553|NCT01402206|Depression
324554|NCT01402206|Intervention
324555|NCT01402206|Primary health care
324556|NCT01402193|Breast Cancer
324557|NCT01402193|Timing of Radiotherapy
324558|NCT01402193|TGF-beta1
324559|NCT01402180|Esophageal squamous cell carcinoma
324560|NCT01402180|lymph nodes recurrence
324561|NCT01402180|chemoradiation
324562|NCT01402180|Nimotuzumab
324563|NCT01402141|Chungkookjang
324564|NCT01402141|histamine
324565|NCT01402141|skin reaction
324566|NCT01402141|wheal
324567|NCT01402128|Soluble fiber
324568|NCT01402128|Polycan
324569|NCT01402128|Overweight
324570|NCT01402128|LDL-C(Low Density Lipoprotein-cholesterol)
324571|NCT01402115|Polycan
324572|NCT01402115|Bone metabolism
324573|NCT01402115|Osteocalcin
324574|NCT01402115|Deoxypyridinoline
324575|NCT01402102|Aged garlic
324576|NCT01402102|Hyperlipidemic
324577|NCT01402102|LDL
324578|NCT01402102|HDL
324579|NCT01402102|Triglyceride
324580|NCT01402089|phenotyping
324581|NCT01402089|cytochrome p450
324582|NCT01402089|erlotinib
324583|NCT01402089|sunitinib
324584|NCT01402089|lung cancer
324585|NCT01402089|renal-cell cancer
324586|NCT01402089|gastrointestinal stromal tumor
324587|NCT01402076|Pharmacokinetics
324588|NCT01402076|Drug Interaction
324589|NCT01402063|Brain Tumors
324590|NCT01402063|Glioblastoma Multiforme
324591|NCT01402063|GBM
324592|NCT01402050|Time from the start of the induction to delivery
324593|NCT01402037|type 1 diabetes
324594|NCT01402037|Prevention
324595|NCT01402037|First degree relatives
324596|NCT01402037|High risk for type 1 diabetes
324597|NCT01402011|Prolotherapy
324598|NCT01402011|regenerative injection therapy
324599|NCT01402011|dextrose injections
324600|NCT01401998|cystic kidney disease
324601|NCT01401998|polycystic kidney disease
324602|NCT01401998|congenital hepatic fibrosis
324603|NCT01401998|genetic disease
324604|NCT01401985|Opioid induced constipation
324605|NCT01401985|OIC
324606|NCT01401985|Constipation
324607|NCT01401985|Opioid side effects
324608|NCT01401985|morphine induced constipation
324609|NCT01401972|prostate
324610|NCT01401972|cancer
324611|NCT01401972|ultrasound
324612|NCT01401972|spectroscopy
324613|NCT01401959|Metastatic Breast Cancer
324614|NCT01401959|Adjuvant
324615|NCT01401959|Residual Disease
324616|NCT01401959|eribulin
324617|NCT01401959|Trastuzumab
324618|NCT01401920|internal jugular vein cannulation
324619|NCT01401920|cross-sectional area
324620|NCT01401920|passive leg elevation
324621|NCT01401920|trendelenburg position
324622|NCT01401920|open heart surgery
324623|NCT01401907|Palliative care
324624|NCT01401907|Lung
324625|NCT01401907|Gastric
324626|NCT01401907|Liver
324627|NCT01401907|Pancreatic
324628|NCT01401907|Esophageal
324629|NCT01401907|Caregiver
324630|NCT01401894|advanced cancer
324631|NCT01401868|solid tumor
324632|NCT01401868|recurrent
324633|NCT01401868|advanced
324634|NCT01401868|metastatic
324635|NCT01401855|Diagnosis
324636|NCT01401855|Fine Needle Aspiration Biopsy
324637|NCT01401842|low back muscular strength and endurance
324638|NCT01401829|endometrial cancer
324639|NCT01401829|aerobic walking
324640|NCT01401829|stretching/flexibility exercises
324641|NCT01401829|quality of life
324642|NCT01401816|Adolescents
324643|NCT01401816|Sexually Active
324644|NCT01401816|Unprotected Sex
324645|NCT01401816|Emergency Contraception
324646|NCT01401803|periorbital
324647|NCT01401803|glabella
324648|NCT01401803|ptosis
324649|NCT01401803|eyelid
324650|NCT01401803|brow
324651|NCT01401790|Children
324652|NCT01401790|Adolescents
324653|NCT01401790|Telehomecare
324654|NCT01401777|Kidney Tumors, Cryoablation, Biopsy
324655|NCT01401751|Type 1 Diabetes Mellitus
324656|NCT01401751|Artificial Pancreas
324657|NCT01400750|cystic fibrosis- P aeruginosa- eradication-child
324658|NCT01400737|ibuprofen
324659|NCT01400737|prophylaxis
324660|NCT01400737|VELBW
324661|NCT01400724|menopause
324662|NCT01400724|metabolic syndrome
324663|NCT01400724|myo-inositol
324664|NCT01400724|insulin resistance
324665|NCT01400724|cocoa polyphenols
324666|NCT01400724|isoflavones
324667|NCT01400711|Fast-tract surgery, Enhanced recovery after surgery, multimodal surgery.
324668|NCT01400698|Intra-uterine growth retardation (IUGR)
324669|NCT01400698|Saizen
324670|NCT01400698|Recombinant human growth hormone (r-hGH)
324671|NCT01400698|Final height
324672|NCT01400698|Bone age
324673|NCT01400698|SGA (Small for Gestational Age)
324674|NCT01400685|CLL
324675|NCT01400685|Leukemia
324676|NCT01400685|Untreated
324677|NCT01400685|B-CLL
324678|NCT01400685|SLL
324679|NCT01400672|Diffuse intrinsic pontine glioma
324680|NCT01400659|CSII
324681|NCT01400659|prandial insulin requirements
324682|NCT01400659|bolus calculation
324683|NCT01400659|dual-wave bolus
324684|NCT01400646|Rivaroxaban
324685|NCT01400646|JNJ-39039039
324686|NCT01400646|BAY59-7939
324687|NCT01400646|Warfarin
324688|NCT01400646|Transition
324689|NCT01400633|Myelodysplastic Syndrome
324690|NCT01400633|Dacogen
324691|NCT01400633|decitabine
324692|NCT01400633|epigenetic therapy
324693|NCT01400633|hypomethylating agent
324694|NCT01400620|oral mucositis
324695|NCT01400620|chemoradiation
324696|NCT01400620|head and neck cancer
324697|NCT01400607|cartilage
324698|NCT01400607|knee surgery
324699|NCT01400607|cartilage injury
324700|NCT01400607|knee pain
324701|NCT01400607|cartilage repair
324702|NCT01400607|cartilage damage
324703|NCT01400607|cartilage lesion
324704|NCT01400607|cartilage defect
324705|NCT01400607|articular cartilage lesion
324706|NCT01400607|articular cartilage defect
324707|NCT01400607|juvenile
324708|NCT01400607|cells
324709|NCT01400607|ISTO Technologies
324710|NCT01400607|Neocartilage
324711|NCT01400607|RevaFlex
324712|NCT01400594|Onychomycosis
324713|NCT01401738|Shoulder Arthroscopic Surgery
324714|NCT01401725|venous thromboembolism
324715|NCT01401725|thromboprophylaxis
324716|NCT01401725|anticoagulants
324717|NCT01401725|hospitalized medical patients
324718|NCT01401725|electronic order sets
324719|NCT01401725|decision support
324720|NCT01401725|knowledge translation
324721|NCT01401725|patient safety
324722|NCT01401712|ON-Q
324723|NCT01401712|epidural
324724|NCT01401712|analgesia
324725|NCT01401699|Barrett's
324726|NCT01401699|esophagus
324727|NCT01401699|OCT
324728|NCT01401699|imaging
324729|NCT01401673|Chronic Cough
324730|NCT01401673|Indantadol
324731|NCT01401660|low back pain
324732|NCT01401647|cardiac arrest
324733|NCT01401647|cardiopulmonary resuscitation
324734|NCT01401647|ventricular fibrillation
324735|NCT01401647|pulseless ventricular tachycardia
324736|NCT01401647|Non-traumatic Out of Hospital Cardiac Arrest (OOHCA)
324737|NCT01401634|Hyperglycemia Hydration
324738|NCT01401621|behavioral economics
324739|NCT01401621|nudge
324740|NCT01401621|scratch off
324741|NCT01401621|blood pressure check
324742|NCT01401621|cholesterol test
324743|NCT01401608|VT
324744|NCT01401608|ventricular tachycardia
324745|NCT01401608|ablation
324746|NCT01401608|magnetic navigation
324747|NCT01401608|robotic
324748|NCT01401582|health care
324749|NCT01401582|dementia care
324750|NCT01401582|caregiver support
324751|NCT01401582|epidemiological study
324752|NCT01401569|Exercise,
324753|NCT01401569|counseling,
324754|NCT01401569|smoking cessation,
324755|NCT01401569|depressive disorders
324756|NCT01401556|osteoporosis
324757|NCT01401556|fracture
324758|NCT01401556|treatment
324759|NCT01401556|guidelines
324760|NCT01401556|quality
324761|NCT01401543|testosterone
324762|NCT01401543|energy
324763|NCT01401543|libido
324764|NCT01401543|erectile function
324765|NCT01401543|weak muscles
324766|NCT01401530|Neoplasms
324767|NCT01401530|Neoplasms by Histologic Type
324768|NCT01401530|Lymphoma
324769|NCT01401530|Non-Hodgkin
324770|NCT01401530|T- Cell
324771|NCT01401530|Lymphatic Diseases
324772|NCT01401530|Lymphoproliferative Disorders
324773|NCT01401530|lmmune System Diseases
324774|NCT01401530|lmmunoproliferative Disorders
324775|NCT01401504|Anti-cancer
324776|NCT01401504|ASP3026
324777|NCT01401504|Anaplastic Lymphoma Kinase (ALK)
324778|NCT01401491|schizophrenia
324779|NCT01401491|clozapine
324780|NCT01401491|fluvoxamine
324781|NCT01401491|metabolic syndrome
324782|NCT01401478|Secondary Hyperparathyroidism
324783|NCT01401478|Chronic Renal Insufficiency
324784|NCT01401465|perennial allergic rhinitis
324785|NCT01401465|PAR
324786|NCT01401452|Monoclonals
324787|NCT01401452|Moderate to severe plaque psoriasis
324788|NCT01401452|Psoriasis Area & Severity Index (PASI)
324789|NCT01401452|Adalimumab
324790|NCT01401452|Biological disease modifying anti-rheumatic drugs (BDMARD)
324791|NCT01401452|Co-morbidities
324792|NCT01401452|Antibodies
324793|NCT01401452|Disease Life Quality Index (DLQI)
324794|NCT01401439|cystic fibrosis
324795|NCT01401439|body mass index
324796|NCT01401439|fat free mass
324797|NCT01401439|Children with cystic fibrosis
324798|NCT01401426|overweight
324799|NCT01401426|Obesity, Morbid
324800|NCT01401374|Vitiligo Vulgaris
324801|NCT01401374|Autoimmunity
324802|NCT01401374|Thyroid Disease
324803|NCT01401296|Depression
324804|NCT01401296|Online-Therapy
324805|NCT01401296|Deprexis
324806|NCT01401296|Self-help
324807|NCT01401257|PXT3003
324808|NCT01401257|Charcot-Marie-Tooth Disease
324809|NCT01401257|Hereditary Motor and Sensory Neuropathies
324810|NCT01401231|depression
324811|NCT01401231|pregnancy
324812|NCT01401218|thoracic aortic surgery
324813|NCT01401218|acute kidney injury
324814|NCT01401205|shoulder arthroscopic surgery
324815|NCT01401205|dyspnea
324816|NCT01401205|airway diameter
324817|NCT01401192|thymidylate synthase
324818|NCT01401179|Preterm Premature Rupture of Fetal Membranes
324819|NCT01401179|antibiotic therapy
324820|NCT01401140|Coronary Artery Bypass
324821|NCT01401140|Coronary Artery Surgery
324822|NCT01401140|Coronary Artery Bypass Graft
324823|NCT01401140|Coronary Revascularization
324824|NCT01401140|Cardiac microdialysis
324825|NCT01401140|Custodiol
324826|NCT01401140|St Thomas
324827|NCT01401140|Cardioplegic solutions
324828|NCT01401127|Type 1 Diabetes Mellitus
324829|NCT01401127|Exercise
324830|NCT01401127|Continuous Subcutaneous Insulin Infusion
324831|NCT01401127|CSII
324832|NCT01401127|Insulin Pump Therapy
324833|NCT01401114|Wellnara
324834|NCT01401114|Postmenopausal osteoporosis
324835|NCT01401101|mental health
324836|NCT01401101|PTSD
324837|NCT01401101|primary care
324838|NCT01401101|quality improvement
324839|NCT01401101|collaborative care
324840|NCT01401088|patient with refractory glaucoma
324841|NCT01401075|Quality of Life
324842|NCT01401075|QoL
324843|NCT01401075|EORTC QLQ-C30
324844|NCT01401075|EORTC QLQ-STO22
324845|NCT01401075|5-FU
324846|NCT01401075|Viscum album
324847|NCT01401062|metastatic breast cancer
324848|NCT01401062|TGF-beta
324849|NCT01401062|fresolimumab
324850|NCT01401062|monoclonal antibody
324851|NCT01401062|radiation therapy
324852|NCT01401062|abscopal response
324853|NCT01401049|Fospropofol
324854|NCT01401049|Propofol
324855|NCT01401049|Colonoscopy
324856|NCT01401049|Lusedra
324857|NCT01401036|acute myocardial infarction
324858|NCT01401036|stents
324859|NCT01401036|angioplasty
324860|NCT01401036|thrombosis
324861|NCT01401010|neutropenia
324862|NCT01401010|doripenem
324863|NCT01400997|Growth disorders
324864|NCT01400997|Saizen
324865|NCT01400997|Easypod
324866|NCT01400997|Growth hormone
324867|NCT01400997|Pediatric subject
324868|NCT01400984|Growth disorders
324869|NCT01400984|Saizen
324870|NCT01400984|Easypod
324871|NCT01400984|Growth hormone
324872|NCT01400984|Pediatric subject
324873|NCT01400971|Diabetes
324874|NCT01400971|Insulin
324875|NCT01400971|Progression
324876|NCT01400971|Patient Reported Measures
324877|NCT01400971|Adherence
324878|NCT01400971|Heterogeneity
324879|NCT01400971|Hypoglycemia
324880|NCT01400958|fatigue
324881|NCT01400958|external beam radiation
324882|NCT01400958|EBRT
324883|NCT01400958|radiation therapy
324884|NCT01400958|placebo
324885|NCT01400958|cognitive function
324886|NCT01400958|TMZ
324887|NCT01400958|Temozolomide
324888|NCT01400945|GERD
324889|NCT01400945|endoscopy
324890|NCT01400945|LA grade
324891|NCT01400945|heartburn
324892|NCT01400932|inflammatory lesion
324893|NCT01400932|Benzoyl peroxide (BPO)
324894|NCT01400932|once daily
324895|NCT01400932|acne vulgaris
324896|NCT01400932|vehicle gel
324897|NCT01400932|clindamycin (CLDM) 1%-BPO 3% gel
324898|NCT01400932|non-inflammatory lesion
324899|NCT01400919|Peripheral arterial disease
324900|NCT01400919|claudication
324901|NCT01400919|stent
324902|NCT01400919|EverFlex
324903|NCT01400919|GPS
324904|NCT01400919|Iliac Artery
324905|NCT01400893|Acute Renal Failure
324906|NCT01400893|Acute kidney injury
324907|NCT01400893|Acute tubular necrosis
324908|NCT01400893|Continuous Renal Replacement Therapy
324909|NCT01400893|Severe sepsis
324910|NCT01400893|Selective cytopheretic device
324911|NCT01400880|Maternal Fetal Monitoring
324912|NCT01400867|Infections
324913|NCT01400867|Pediatrics
324914|NCT01400867|Teflaro
324915|NCT01400867|cephalosporin
324916|NCT01400854|breakthrough cancer pain
324917|NCT01400841|Aortic Insufficiency, Aortic Regurgitation, Aortic Valve Repair
324918|NCT01400815|smoking
324919|NCT01400815|smoking cessation
324920|NCT01400815|quitting smoking
324921|NCT01400776|Postmenopausal Women, Vaginal Dryness
324922|NCT01400763|focus of study
324923|NCT01400555|Prostate Cancer
324924|NCT01400555|Metastatic Castration-Resistant Prostate Cancer
324925|NCT01400555|Abiraterone Acetate
324926|NCT01400555|Docetaxel
324927|NCT01400555|Prednisone
324928|NCT01400555|Dexamethasone
324929|NCT01400542|Early Onset Alzheimer Disease
324930|NCT01400542|Alzheimer Disease
324931|NCT01400542|Sleep Apnea Syndromes
324932|NCT01400542|Obstructive Sleep Apnea Syndromes
324933|NCT01400542|Cognitive functions
324934|NCT01400542|Continuous Positive Airway Pressure (CPAP) treatment
324935|NCT01400529|Osteoarthritis
324936|NCT01400529|knee
324937|NCT01400529|hip
324938|NCT01400529|population based
324939|NCT01400516|Rheumatoid Arthritis
324940|NCT01400516|Bone erosion
324941|NCT01400516|Osteopenia
324942|NCT01400503|Multicentric Castleman's Disease
324943|NCT01400503|Multicentric
324944|NCT01400503|Castleman
324945|NCT01400503|Siltuximab
324946|NCT01400503|Long term safety
324947|NCT01400477|Drug Trial
324948|NCT01400477|Smoking
324949|NCT01400477|Smoking Cessation
324950|NCT01400477|Cognition
324951|NCT01400477|Mental Focus
324952|NCT01400464|Giant Cell Arteritis
324953|NCT01400464|prednisone
324954|NCT01400464|pharmacokinetics
324955|NCT01400438|Herceptin
324956|NCT01400438|Breast cancer
324957|NCT01400438|Quality of life
324958|NCT01400438|fatigue
324959|NCT01400399|AJCC DCIS or T1- T2, N0
324960|NCT01400373|Hypothermia, induced
324961|NCT01400373|Intra-arrest cooling
324962|NCT01400373|Cardiac arrest
324963|NCT01400373|Prehospital emergency care
324964|NCT01400373|Emergency Medical Services
324965|NCT01400360|cerebral vasospasm
324966|NCT01400360|subarachnoid hemorrhage
324967|NCT01400360|transluminal balloon angioplasty
324968|NCT01400360|intraarterial treatment
324969|NCT01400347|Motor activity, lower extremity, physical exercise
324970|NCT01400334|Ischemic Cardiomyopathy
324971|NCT01400334|Sudden Cardiac Death
324972|NCT01400334|Positron Emission Tomography
324973|NCT01400334|Hibernating Myocardium
324974|NCT01400334|Denervated Myocardium
324975|NCT01400321|dental implant
324976|NCT01400321|soft tissue maintenance
324977|NCT01400321|bone remodelling
324978|NCT01400321|inclined atrophy
324979|NCT01400308|Methicillin Resistant Staphylococcus Aureus colonization.
324980|NCT01400308|Methicillin Resistant Staphylococcus Aureus infection.
324981|NCT01400295|contrast-induced nephropathy
324982|NCT01400295|contrast medium
324983|NCT01400295|creatinine clearance
324984|NCT01400295|coronary angiography
324985|NCT01400295|diabetes
324986|NCT01400295|chronic kidney disease
324987|NCT01400269|PACE
324988|NCT01400256|diagnostic
324989|NCT01400243|Marijuana
324990|NCT01400243|Drug withdrawal symptoms
324991|NCT01400243|Nicotine
324992|NCT01400230|computed tomography
324993|NCT01400230|intravascular ultrasound
324994|NCT01400230|coronary stenosis
324995|NCT01400230|fractional flow reserve
324996|NCT01400217|Primary Care
324997|NCT01400217|Particle size
324998|NCT01400217|beclomethasone dipropionate
324999|NCT01400217|Asthma Management
325000|NCT01400217|Maintenance Therapy
325001|NCT01400217|Metered-Dose Inhaler
325002|NCT01400204|hangover
325003|NCT01400204|next day effects
325004|NCT01400204|MDMA
325005|NCT01400204|Alcohol
325006|NCT01400191|Metformin
325007|NCT01400191|Hypoglycemic Agents
325008|NCT01400191|Diabetes Mellitus, Type 2
325009|NCT01400191|Gluconeogenesis
325010|NCT01400191|Pharmacodynamics
325011|NCT01400191|Pharmacogenetics
325012|NCT01400178|cochlear implant
325013|NCT01400178|children
325014|NCT01400178|follow up
325015|NCT01400178|results
325016|NCT01400165|Therapeutic Equivalency
325017|NCT01400165|Human Experimentation
325018|NCT01400165|Bioequivalence
325019|NCT01400165|Brand name
325020|NCT01400165|Generic
325021|NCT01400165|Healthy volunteers
325022|NCT01400152|Hypothermia, body temperature regulation,thermal comfort, active warming, passive warming, prehospital trauma care
325023|NCT01400139|Pain
325024|NCT01400139|Nonmalignant pain
325025|NCT01400139|Nonneuropathic Pain
325026|NCT01400139|Opioid
325027|NCT01400126|Ultrapure water,hemodialysis, CRP, blood pressure
325028|NCT01400113|Acute Agitation
325029|NCT01400113|schizophrenia
325030|NCT01400113|bipolar
325031|NCT01400113|psychosis
325032|NCT01400113|panss-ec
325033|NCT01400100|octreotide
325034|NCT01400100|intraarterial
325035|NCT01400100|pancreatic hardness
325036|NCT01400100|pancreatoduodenectomy
325037|NCT01400100|durometer
325038|NCT01400100|dynamometer
325039|NCT01400087|colonoscopy
325040|NCT01400087|Lower Gastrointestinal Tract
325041|NCT01400087|Cecal intubation
325042|NCT01400087|Cap-attached colonoscopy
325043|NCT01400087|Trainee
325044|NCT01400061|obesity, etiology, pathogenesis, treatment
325045|NCT01400035|acute cerebral infarction, Vinpocetine
325046|NCT01400022|lichen
325047|NCT01400022|sclerosus
325048|NCT01400022|genital
325049|NCT01400022|vulvar
325050|NCT01400022|UVA1
325051|NCT01400009|Statin
325052|NCT01400009|HMG COA Reductase Inhibitor
325053|NCT01400009|myalgia
325054|NCT01400009|vitamin D
325055|NCT01399996|probiotic
325056|NCT01399996|microbiota
325057|NCT01399996|transit time
325058|NCT01399996|immunity
325059|NCT01399996|immune function
325060|NCT01399996|constipation
325061|NCT01399996|bowel function
325062|NCT01399983|six minute walk
325063|NCT01399970|Mobile Teledermatology
325064|NCT01399970|Telemedicine
325065|NCT01399970|Acne
325066|NCT01399957|Multiple Sclerosis
325067|NCT01399957|Dalfampridine-ER
325068|NCT01399957|Walking speed
325069|NCT01399944|bitter taste
325070|NCT01399944|psychophysics
325071|NCT01399944|genetics
325072|NCT01399944|epigenetics
325073|NCT01399944|bitterness sensitivity
325074|NCT01399931|Early stage
325075|NCT01399918|Kidney
325076|NCT01399918|Everolimus
325077|NCT01399918|Bevacizumab
325078|NCT01399918|10-226
325079|NCT01399918|non-clear cell histology
325080|NCT01399918|Advanced
325081|NCT01399905|Parkinson's disease
325082|NCT01399905|Levodopa
325083|NCT01399905|Carbidopa
325084|NCT01399905|Blood brain barrier
325085|NCT01399879|Surface potential
325086|NCT01399879|Electrical
325087|NCT01399879|Motion stabilization
325088|NCT01399866|D-cycloserine
325089|NCT01399866|Smoking cues
325090|NCT01399866|Cognitive remediation
325091|NCT01399866|physiologic reactivity
325092|NCT01399866|craving
325093|NCT01399853|immunogenicity
325094|NCT01399853|safety
325219|NCT01399294|Syndrome Distribution
325095|NCT01399853|inactivated EV71 vaccine
325096|NCT01399801|Cardiac Resynchronization Therapy
325097|NCT01399801|medically refractory heart failure patients
325098|NCT01399788|Bioequivalence
325099|NCT01399788|Healthy Volunteers
325100|NCT01399775|Atrophy of Edentulous Alveolar Ridge
325101|NCT01399775|Dental Prosthesis, Implant-Supported
325102|NCT01399775|Dental Implants, Single-Tooth
325103|NCT01399762|stroke, acute
325104|NCT01399762|mechanical recanalization
325105|NCT01399762|interventional neuroradiology
325106|NCT01399762|clinical registry
325107|NCT01399749|Cartilage
325108|NCT01399749|Articular
325109|NCT01399749|Femoral
325110|NCT01399749|Knee
325111|NCT01399749|Chondrocytes
325112|NCT01399749|Adipose tissue-derived mesenchymal stem cells
325113|NCT01399736|PCI FFR STEMI MVD
325114|NCT01399736|FFR guided PCI in acute STEMI patients with MVD
325115|NCT01399723|Severe pneumonia
325116|NCT01399710|colorectal cancer
325117|NCT01399710|CT colonography
325118|NCT01399710|CAD
325119|NCT01399671|depression
325120|NCT01399671|vestibular
325121|NCT01399658|Brachytherapy
325122|NCT01399658|Gynecological cancer
325123|NCT01399645|Randomized trial
325124|NCT01399645|Open label
325125|NCT01399645|Pilot study
325126|NCT01399645|Single center
325127|NCT01399606|Excessive Daytime Sleepiness (EDS)
325128|NCT01399606|Narcolepsy
325129|NCT01399593|Antibody Mediated Rejection
325130|NCT01399593|AMR
325131|NCT01399593|Acute Humoral Rejection
325132|NCT01399593|AHR
325133|NCT01399593|Living Donor
325134|NCT01399593|Kidney Transplant
325135|NCT01399580|endothelin receptor antagonists
325136|NCT01399567|pain
325137|NCT01399567|depression
325138|NCT01399567|nursing homes
325139|NCT01399567|diffusion of innovations
325140|NCT01399567|clinical trial
325141|NCT01399541|Symptoms
325142|NCT01399541|Symptoms cluster
325143|NCT01399541|Fatigue
325144|NCT01399541|Depression
325145|NCT01399541|Sleeplessness
325146|NCT01399541|Social support
325147|NCT01399541|Stigma
325148|NCT01399515|Retinitis pigmentosa
325149|NCT01399515|Valproic acid
325150|NCT01399502|Depression
325151|NCT01399502|Self Care
325152|NCT01399489|Aerobic exercise
325153|NCT01399489|Moderate intensity
325154|NCT01399489|Ambulatory blood pressure
325155|NCT01399489|Post exercise hypotension
325156|NCT01399476|Achalasia
325157|NCT01399463|Drug Eluting Stent, Drug Eluting Balloon, Fractional Flow Reserve, DES, DEB, FFR
325158|NCT01399450|Schizophrenia, depressive symptom, paliperidone
325159|NCT01399437|Default Network
325160|NCT01399437|Schizophrenia
325161|NCT01399437|fMRI
325162|NCT01399437|Spatial Attention
325163|NCT01399437|Sentinel Function
325164|NCT01399424|Shigellosis
325165|NCT01399424|Safety and Immunogenicity
325166|NCT01399424|Conjugate Vaccine
325167|NCT01399424|Shigella
325168|NCT01399424|Vaccine
325169|NCT01399411|Self-Reported
325170|NCT01399411|Farming
325171|NCT01399411|Agriculture
325172|NCT01399411|Disease Validation
325173|NCT01399411|Autoimmune Disorders
325174|NCT01399398|Brain Scan
325175|NCT01399398|Kinetic Analysis
325176|NCT01399398|Healthy Subjects
325177|NCT01399398|Healthy Volunteer
325178|NCT01399398|HV
325179|NCT01399385|Arteriosclerosis
325180|NCT01399385|Arteriosclerosis, Narrowing of Vessels
325181|NCT01399385|Endothelial Dysfunction
325182|NCT01399385|Hardening of the arteries
325183|NCT01399385|Noninvasive Plaque Imaging
325184|NCT01399385|Cardiovascular Disease
325185|NCT01399385|Heart Disease
325186|NCT01399385|Healthy Volunteer
325187|NCT01399385|HV
325188|NCT01399372|neurotoxicity
325189|NCT01399372|chemotherapeutic agent toxicity
325190|NCT01399372|radiation toxicity
325191|NCT01399372|cognitive/functional effects
325192|NCT01399372|primary central nervous system non-Hodgkin lymphoma
325193|NCT01399359|breast cancer
325194|NCT01399346|Insulin aspart
325195|NCT01399346|Type 1 diabetes
325196|NCT01399346|Glucose clamp
325197|NCT01399346|Pharmacodynamics
325198|NCT01399346|Pharmacokinetics
325199|NCT01399346|Rapid Acting Insulin Analog
325200|NCT01399333|PDCAAS
325201|NCT01399333|Bariatric patient
325202|NCT01399320|Pilonidal disease
325203|NCT01399320|Excision
325204|NCT01399320|cyanoacrylate
325205|NCT01399307|Stem
325206|NCT01399307|Cell
325207|NCT01399307|Antria
325208|NCT01399307|Adipose
325209|NCT01399307|Stromal
325210|NCT01399307|Vascular
325211|NCT01399307|Fraction
325212|NCT01399307|Shahram
325213|NCT01399307|Shah
325214|NCT01399307|Rahimian
325215|NCT01399294|Palliative Care
325216|NCT01399294|Advanced Cancer
325217|NCT01399294|Constipation
325218|NCT01399294|Traditional Chinese Medicine
325220|NCT01399281|juvenile idiopathic arthritis, biologics, methotrexate
325221|NCT01399268|Bilateral total knee replacement
325222|NCT01399268|cytokine
325223|NCT01399268|desmosine
325224|NCT01399242|Disorder Related to Renal Transplantation
325225|NCT01399203|contrast-induced nephropathy
325226|NCT01399203|contrast medium
325227|NCT01399203|creatinine clearance
325228|NCT01399203|percutaneous coronary intervention
325229|NCT01399164|Vitamin B-12
325230|NCT01399151|Vitamin D
325231|NCT01399151|Immune function
325232|NCT01399138|Pre-diabetes
325233|NCT01399138|Metabolic syndrome
325234|NCT01399138|Diabetes
325235|NCT01399138|Hypertension
325236|NCT01399138|Blueberries
325237|NCT01399138|Anthocyanins
325238|NCT01399138|Insulin sensitivity
325239|NCT01399138|Insulin resistance
325240|NCT01399125|Alzheimer's
325241|NCT01399125|Rivastigmine
325242|NCT01399125|Patch
325243|NCT01399125|Dementia
325244|NCT01399112|Smoking Cessation
325245|NCT01399112|First episode psychosis
325246|NCT01399112|Electronic Decision Support System
325247|NCT01399099|scar
325248|NCT01399099|incision
325249|NCT01399099|wound healing
325250|NCT01399099|scarring
325251|NCT01399099|post-surgical
325252|NCT01399086|Cancer
325253|NCT01399086|Breast
325254|NCT01399086|Metastatic
325255|NCT01399086|Hormonotherapy
325256|NCT01399073|stroke
325257|NCT01399073|neglect
325258|NCT01399073|hemianopsia
325259|NCT01399073|virtual reality
325260|NCT01399060|Cough
325261|NCT01399060|tobacco smoke exposure
325262|NCT01399047|Batten Disease
325263|NCT01399034|Epigenomics
325264|NCT01399034|DNA methylation
325265|NCT01399034|MicroRNA
325266|NCT01399034|Periodontitis
325267|NCT01399034|Inflammation
325268|NCT01399034|Obesity
325269|NCT01399021|Parotidectomy
325270|NCT01399021|Drain removal
325271|NCT01399021|Timing
325272|NCT01399021|Hematoma
325273|NCT01399021|Surgical wound infection
325274|NCT01399008|Hyperuricemia
325275|NCT01398995|Type 1 Diabetes
325276|NCT01398995|Exercise
325277|NCT01398995|continuous subcutaneous insulin infusion
325278|NCT01398969|Randomized
325279|NCT01398969|Double Blind
325280|NCT01398969|Fecal Transplant
325281|NCT01398969|Recurrent
325282|NCT01398969|Clostridium difficile infection
325283|NCT01398969|CDI
325284|NCT01398969|HBT
325285|NCT01398969|Diarrhea
325286|NCT01398969|Frozen HBT
325287|NCT01398969|Thawed HBT
325288|NCT01398969|Fecal Enema
325289|NCT01398956|Levetiracetam
325290|NCT01398956|Epilepsy
325291|NCT01398956|Generalized tonic-clonic seizures
325292|NCT01398943|flow-mediated dilation
325293|NCT01398943|arterial stiffness
325294|NCT01398943|intima-media thickness
325295|NCT01398943|pulse wave velocity
325296|NCT01398943|dual energy x-ray absorptiometry
325297|NCT01398943|inflammatory markers
325298|NCT01398943|blood lipids
325299|NCT01398943|tetrahydrobiopterin
325300|NCT01398943|Salsalate
325301|NCT01398943|body mass index
325302|NCT01398943|hemoglobin A1c
325303|NCT01398943|complete blood count
325304|NCT01398943|oxidative stress biomarkers
325305|NCT01398943|pulmonary function test
325306|NCT01398943|ankle brachial index
325307|NCT01398930|acupuncture; knee osteoarthritis; adjunctive therapy; chronic pain; algometer; etoricoxib.
325308|NCT01398917|psc
325309|NCT01398917|dominant stricture
325310|NCT01398904|BDD
325311|NCT01398878|Medical education, graduate
325312|NCT01398878|Patient care
325313|NCT01398878|Outcome assessment (Health care)
325314|NCT01398878|Work schedule tolerance
325315|NCT01398865|BDD
325316|NCT01398826|Type 1 Diabetes
325317|NCT01398826|Exercise
325318|NCT01398826|Continuous glucose monitoring
325319|NCT01398813|HED
325320|NCT01398813|XLHED
325321|NCT01398774|Pseudohypoparathyroidism
325322|NCT01398774|Albright Hereditary Osteodystrophy
325323|NCT01398761|Continuity of patient care
325324|NCT01398761|Workflow
325325|NCT01398761|Quality of signout
325326|NCT01398761|Web based
325327|NCT01398761|Handoffs
325328|NCT01398761|Multi disciplinary
325329|NCT01398761|Written signout
325330|NCT01398761|Information science
325331|NCT01398748|Parkinson's disease
325332|NCT01398748|Neuroprotection
325333|NCT01398748|Glutathione
325334|NCT01398748|Intranasal
325335|NCT01398722|cardiac surgery
325336|NCT01398722|prognosis
325337|NCT01398722|intensive insulin therapy
325338|NCT01398709|Cardiopulmonary Bypass
325339|NCT01398709|Prognosis
325340|NCT01398709|Cardiac Surgery
325341|NCT01398709|Rewarming Rate
325342|NCT01398696|Patient Information Leaflets
325343|NCT01398696|primary care
325344|NCT01398696|patient behaviour
325345|NCT01398696|pharyngitis
325346|NCT01398696|gastroenteritis
325347|NCT01398670|Type I Diabetes
325348|NCT01398670|Wockhardt's Insulin analogue Lispro
325349|NCT01398670|Humalog®
325350|NCT01398670|Humalog Mix
325351|NCT01398670|Wockhardt
325352|NCT01398670|Biosimilar
325353|NCT01398670|Phase 3
325354|NCT01398657|localized
325355|NCT01398657|High risk
325356|NCT01398657|Prostate Cancer
325357|NCT01398657|Randomized
325358|NCT01398657|Cryotherapy
325359|NCT01398657|Cryoablation
325360|NCT01398657|Adjuvant
325361|NCT01398657|Androgen Deprivation Therapy
325362|NCT01398657|Hormone therapy
325363|NCT01398657|ADT
325364|NCT01398644|Phlebotomy
325365|NCT01398644|Therapeutic erythrocytapheresis
325366|NCT01398644|Hereditary Hemochromatosis
325367|NCT01398644|maintenance therapy
325368|NCT01398631|Risk scores
325369|NCT01398631|ACS
325370|NCT01398631|HEART-score
325371|NCT01398618|latent tuberculosis infection
325372|NCT01398618|tuberculosis
325373|NCT01398618|interferon-gamma release assay
325374|NCT01398618|preventive therapy
325375|NCT01398618|9-month isoniazid
325376|NCT01398618|4-month rifampin
325377|NCT01398605|Postmenopausal women
325378|NCT01398605|Physical activity
325379|NCT01398605|Cardiovascular risks
325380|NCT01398605|Cardiac function
325381|NCT01398605|Dose-response
325382|NCT01398592|Diabetes mellitus Type two
325383|NCT01398592|T2DM
325384|NCT01398592|vildagliptin
325385|NCT01398592|sitagliptin
325386|NCT01398592|FPG
325387|NCT01398592|DPP-4
325388|NCT01398579|intestinal metaplasia
325389|NCT01398579|dysplasia
325390|NCT01398579|probe-based confocal endomicroscopy
325391|NCT01398566|TBI
325392|NCT01398566|concussion
325393|NCT01398566|brain injury
325394|NCT01398553|stroke
325395|NCT01398553|tbi
325396|NCT01398553|rehabilitation
325397|NCT01398553|upper limb
325398|NCT01398527|Long-Term Care
325399|NCT01398527|Vitamin D
325400|NCT01398501|AML
325401|NCT01398501|FLT3-ITD
325402|NCT01398501|Stem cell transplant
325403|NCT01398488|Trough levels
325404|NCT01398488|Education
325405|NCT01398488|Adherence
325406|NCT01398449|thoracic esophageal squamous cell carcinoma
325407|NCT01398449|esophagectomy
325408|NCT01398449|elective nodal irradiation
325409|NCT01398449|adjuvant chemotherapy
325410|NCT01398436|Central venous saturation
325411|NCT01398436|Mixed venous saturation
325412|NCT01398436|Right atrium
325413|NCT01398436|Central Venous Catheter position
325414|NCT01398423|Hypertension
325415|NCT01398423|Diabetes mellitis
325416|NCT01398423|Nephropathy
325417|NCT01398423|Albuminuria
325418|NCT01398410|Rabeprazole
325419|NCT01398410|proton pump inhibitor
325420|NCT01398410|Acetylsalicylic Acid
325421|NCT01398410|Aspirin
325422|NCT01398410|Gastric Ulcer
325423|NCT01398410|Duodenal Ulcer
325424|NCT01398397|HED
325425|NCT01398397|XLHED
325426|NCT01398397|X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)
325427|NCT01398384|ST Elevation MI
325428|NCT01398384|STEMI
325429|NCT01398371|Heart failure
325430|NCT01398371|Digoxin withdrawal
325431|NCT01398358|obesity
325432|NCT01398358|prevention
325433|NCT01398358|children
325434|NCT01398319|prevention
325435|NCT01398319|alcohol abuse
325436|NCT01398306|Angiogenesis Inhibitors
325437|NCT01398306|Neoplasms, Glandular and Epithelial
325438|NCT01398306|Neoplasms by Histologic Type
325439|NCT01398306|Neoplasms
325440|NCT01398306|Adenocarcinoma
325441|NCT01398306|Kidney Neoplasms
325442|NCT01398306|Urologic Neoplasms
325443|NCT01398306|Urogenital Neoplasms
325444|NCT01398306|Neoplasms by Site
325445|NCT01398306|Kidney Diseases
325446|NCT01398306|Angiogenesis Inducing Agents
325447|NCT01398306|Biological Markers
325448|NCT01398280|Rosacea
325449|NCT01398280|Dermatology
325450|NCT01398280|UCSD
325451|NCT01398280|Skin disease
325452|NCT01398254|ST-Elevation Myocardial Infarction
325453|NCT01398254|Mortality
325454|NCT01398228|Quality of care
325455|NCT01398228|Acute Coronary Syndromes (ACS)
325456|NCT01398215|umbilical hernia
325457|NCT01398215|ventral hernia
325458|NCT01398202|Vitamin D status
325459|NCT01398202|25-hydroxyvitamin D
325460|NCT01398202|Vitamin D3
325461|NCT01398202|RCT
325462|NCT01398202|Bio-efficacy
325463|NCT01398189|clozapine
325464|NCT01398189|PET
325465|NCT01398189|schizophrenia
325466|NCT01398189|schizoaffective disorder
325467|NCT01398176|gamma delta T cell
325468|NCT01398176|proliferation
325469|NCT01398163|probiotics
325470|NCT01398163|digestive well-being
325471|NCT01398163|fMRI
325472|NCT01398163|brain-gut axis
325473|NCT01398150|gamma delta T cell
325474|NCT01398150|proliferation
325475|NCT01398150|cytokine secretion
325476|NCT01398150|immune function
325477|NCT01398150|antioxidant status
325478|NCT01398137|Ragweed allergy
325479|NCT01398124|early stage non-small cell lung cancer
325480|NCT01398124|non-small cell lung cancer
325481|NCT01398085|Papillary thyroid carcinoma
325482|NCT01398085|Follicular thyroid carcinoma
325483|NCT01398085|Hurthle cell carcinoma of the thyroid
325484|NCT01398085|Iodine Radioisotopes
325485|NCT01398059|Sedentary Behavior
325486|NCT01398059|Cardiometabolic Risk
325487|NCT01398059|Pediatrics
325488|NCT01398046|dasatinib
325489|NCT01398046|betaine
325490|NCT01398046|betaine hydrochloride
325491|NCT01398046|pharmacokinetics
325492|NCT01398046|healthy volunteer
325493|NCT01398033|infrapopliteal arteries
325494|NCT01398033|In-stent stenosis
325495|NCT01398033|long lesions
325496|NCT01398033|drug-coated balloon
325497|NCT01398020|Bowel Preparation
325498|NCT01398020|Patient comfort
325499|NCT01398020|Bi-Peglyte
325500|NCT01397994|Nicorandil therapy in patients of chronic stable angina
325501|NCT01397968|partial onset seizures
325502|NCT01397968|treatment resistant
325503|NCT01397968|partial epilepsy
325504|NCT01397955|Julina
325505|NCT01397955|Postmenopausal osteoporosis
325506|NCT01397942|Diet intervention
325507|NCT01397942|Type 2 diabetes
325508|NCT01397942|Vegetables
325509|NCT01397942|Phytochemicals
325510|NCT01397916|CLL
325511|NCT01397916|IDO
325512|NCT01397903|antidepressant therapy, inadequate control, add-on therapy
325513|NCT01397890|Severe chronic obstructive pulmonary disease (COPD) patients
325514|NCT01397877|endometrial cancer
325515|NCT01397877|BKM
325516|NCT01397877|monotherapy
325517|NCT01397877|metastatic
325518|NCT01397877|initial treatment
325519|NCT01397864|Hereditary Angioedema
325520|NCT01397864|HAE
325521|NCT01397864|Angioedema
325522|NCT01397864|Recombinant C1 Inhibitor
325523|NCT01397864|rhC1INH
325524|NCT01397864|registry
325525|NCT01397838|Osteopenia
325526|NCT01397812|Rejection of the Heart Transplant
325527|NCT01397812|Heart Transplant Rejection, an immune-mediated allograft injury
325528|NCT01397812|Non-cellular or humoral rejection in cardiac transplant recipients
325529|NCT01397812|Right ventricular endomyocardial biopsy to detect Heart transplant rejection
325530|NCT01397799|Acute Myelogenous Leukemia
325531|NCT01397799|AML
325532|NCT01397799|Refractory
325533|NCT01397799|Elderly
325534|NCT01397773|Hemodialysis
325535|NCT01397773|peritoneal dialysis
325536|NCT01397773|chronic kidney disease
325537|NCT01397773|inflammation
325538|NCT01397773|carotis intima media thickness
325539|NCT01397760|DIFFICULT TO CONTROL ASTHMA
325540|NCT01397760|OMALIZUMABE
325541|NCT01397747|Cancer
325542|NCT01397747|Colorectal Cancer
325543|NCT01397747|Neoplasm
325544|NCT01397747|Colorectal Neoplasm
325545|NCT01397747|Intestinal Neoplasms
325546|NCT01397747|Gastrointestinal Neoplasms
325547|NCT01397747|Digestive System Neoplasms
325548|NCT01397747|Neoplasms by Site
325549|NCT01397747|Neoplasms
325550|NCT01397747|Digestive System Diseases
325551|NCT01397747|Gastrointestinal Diseases
325552|NCT01397747|Colonic Diseases
325553|NCT01397747|Intestinal Diseases
325554|NCT01397747|Rectal Diseases
325555|NCT01397734|CML
325556|NCT01397734|Chronic myelogenous leukemia
325557|NCT01397734|Chronic Myeloid leukemia
325558|NCT01397734|Arsenic
325559|NCT01397734|Arsenic trioxide
325560|NCT01397734|Imatinib
325561|NCT01397734|Dasatinib
325562|NCT01397734|Nilotinib
325563|NCT01397734|TKI
325564|NCT01397734|Tyrosine kinase inhibitor
325565|NCT01397721|Chronic Obstructive Pulmonary Disease (COPD)
325566|NCT01397721|pulmonary vasculature
325567|NCT01397721|pulmonary hypertension
325568|NCT01397721|atherosclerosis
325569|NCT01397721|smokers
325570|NCT01397721|emphysema
325571|NCT01397708|Melanoma
325572|NCT01397708|Unresectable
325573|NCT01397682|Comprehensive Geriatric Assessment
325574|NCT01397682|Frail elderly
325575|NCT01397682|Italy/epidemiology
325576|NCT01397682|Geriatric Health Service
325577|NCT01397682|Polypharmacy
325578|NCT01397682|Biological Markers
325579|NCT01397682|Epidemiologic Research Design
325580|NCT01397656|cardiac arrest
325581|NCT01397656|CPR
325582|NCT01397656|resuscitation
325583|NCT01397656|fatigue
325584|NCT01397656|quality
325585|NCT01397565|Cholecystectomy
325586|NCT01397565|Laparoscopy
325587|NCT01397565|Minilaparoscopic surgery
325588|NCT01397565|Post-operative pain
325589|NCT01397565|Recovery time
325590|NCT01397526|Congenital heart disease
325591|NCT01397526|Cardiopulmonary bypass
325592|NCT01397526|Capillary leak
325593|NCT01397526|Colloid osmotic pressure
325594|NCT01397526|Children
325595|NCT01397513|Fibrin network structure
325596|NCT01397513|Aspirin treatment
325597|NCT01397513|Platelet microparticles
325598|NCT01397487|morphometric parameters, embryo biopsy
325599|NCT01397474|peripheral perfusion
325600|NCT01397474|critically ill patients
325601|NCT01397474|fluid administration
325602|NCT01397448|Rabeprazole
325603|NCT01397448|proton pump inhibitor
325604|NCT01397448|Acetylsalicylic Acid
325605|NCT01397448|Aspirin
325606|NCT01397448|Gastric Ulcer
325607|NCT01397448|Duodenal Ulcer
325608|NCT01397435|Lysosomal diseases
325609|NCT01397435|Magnetic resonance Spectroscopy
325610|NCT01397435|MRI
325611|NCT01397422|Levodopa-induced dyskinesia
325612|NCT01397422|Parkinsonism
325613|NCT01397370|Safety
325614|NCT01397370|Tolerability
325615|NCT01397370|Pharmacokinetics
325616|NCT01397370|Pharmacodynamics
325617|NCT01397357|Cardiac magnetic resonance
325618|NCT01397357|Myocardial Ischemia
325619|NCT01397357|Coronary Artery Disease
325620|NCT01397357|suspected Myocardial Ischemia
325621|NCT01397344|People in the outpatient waiting room
325622|NCT01397331|inhalational anesthesia
325623|NCT01397331|intravenous anesthesia
325624|NCT01397331|cardiac surgery
325625|NCT01397318|TaiChi Exercise
325626|NCT01397318|pregnant women
325627|NCT01397305|5,10-methylenetetrahydrofolate
325628|NCT01397305|neoadjuvant therapy
325629|NCT01397305|pemetrexed
325630|NCT01397305|Neoplasms
325631|NCT01397305|Rectal Neoplasms
325632|NCT01397305|Colorectal Neoplasms
325633|NCT01397305|Intestinal Neoplasms
325634|NCT01397305|Gastrointestinal Neoplasms
325635|NCT01397305|Digestive System Neoplasms
325636|NCT01397305|Neoplasms by Site
325637|NCT01397305|Rectal Diseases
325638|NCT01397305|Digestive System Diseases
325639|NCT01397305|Gastrointestinal Diseases
325640|NCT01397305|Intestinal Diseases
325641|NCT01397305|Pharmacologic Actions
325642|NCT01397305|Therapeutic Uses
325643|NCT01397305|Antineoplastic Agents
325644|NCT01397305|Enzyme Inhibitors
325645|NCT01397305|Molecular Mechanisms of Pharmacological Action
325646|NCT01397305|Folic Acid Antagonists
325647|NCT01397305|Antimetabolites, Antineoplastic
325648|NCT01397305|Antimetabolites
325649|NCT01397292|Bronchoscopy
325650|NCT01397292|Interventional Pulmonary
325651|NCT01397292|Pleuroscopy
325652|NCT01397292|Tracheostomy
325653|NCT01397279|type 2 diabetes
325654|NCT01397279|insulin sensitivity
325655|NCT01397279|hyperinsulinemic euglycemic clamp
325656|NCT01397266|Transcranial Magnetic Stimulation
325657|NCT01397266|Cocaine
325658|NCT01397266|impulsivity
325659|NCT01397266|rating scale
325660|NCT01397253|Automated Communication Tools
325661|NCT01397253|Medication errors
325662|NCT01397253|PCP communication
325663|NCT01397227|Malaria
325664|NCT01397227|Plasmodium falciparum
325665|NCT01397227|Vaccination
325666|NCT01397227|Prophylaxis
325667|NCT01397227|Adenovirus
325668|NCT01397188|PiCCO
325669|NCT01397175|Coronary artery disease
325670|NCT01397175|Percutaneous coronary intervention
325671|NCT01397175|Drug-eluting stent
325672|NCT01397149|Chronic lymphocytic leukemia
325673|NCT01397149|Thrombocytopenia
325674|NCT01397149|Alkylating agents
325675|NCT01397149|Purine derivatives
325676|NCT01397149|TPO receptor agonist
325677|NCT01397136|Human embryo
325678|NCT01397136|Culture media
325679|NCT01397136|Cell-free DNA
325680|NCT01397136|In vitro fertilization
325681|NCT01397136|Infertility
325682|NCT01397123|BMI z-score
325683|NCT01397123|children
325684|NCT01397123|overweight
325685|NCT01397123|school-based intervention
325686|NCT01397123|trained teachers
325687|NCT01397123|fruit
325688|NCT01397123|vegetables
325689|NCT01397123|Low nutrition energy dense foods
325690|NCT01397084|esomeprazole 20mg
325691|NCT01397084|heartburn
325692|NCT01397084|rabeprazole 10mg
325693|NCT01397084|reflux esophagitis
325694|NCT01397084|Phase IV
325695|NCT01397071|Avocado, antioxidant
325696|NCT01397045|Lung
325697|NCT01397045|Nodule
325698|NCT01397045|Rehabilitation
325699|NCT01397045|VATS
325700|NCT01397045|Thoracotomy
325701|NCT01397032|attention bias modification treatment
325702|NCT01397032|cognitive bias modification
325703|NCT01397032|attention training
325704|NCT01397032|social anxiety
325705|NCT01397019|Pancreatic cancer
325706|NCT01397019|Chemotherapy
325707|NCT01397019|Chemoradiotherapy
325708|NCT01397006|Fibromyalgia
325709|NCT01397006|pregabalin
325710|NCT01397006|Lyrica
325711|NCT01396980|hemodialysis
325712|NCT01396980|intensive care
325713|NCT01396980|microcirculation
325714|NCT01396967|capsulorhexis
325715|NCT01396954|Liver cirrhosis
325716|NCT01396954|Diabetes mellitus
325717|NCT01396954|Hepatogenous diabetes
325718|NCT01396954|Oral glucose tolerance test
325719|NCT01396954|Insulin resistance.
325720|NCT01396941|Diabetes
325721|NCT01396928|Low rectal adenocarcinoma
325722|NCT01396915|Skeletal muscle lipid content
325723|NCT01396915|whole muscle volume
325724|NCT01396915|fasting glucose
325725|NCT01396915|insulin
325726|NCT01396915|blood urea nitrogen
325727|NCT01396889|Upper Respiratory Tract Infections
325728|NCT01396889|Echinacea
325729|NCT01396889|viral infections
325730|NCT01396876|Medical clown
325731|NCT01396876|Pediatric emergency medicine
325732|NCT01396876|Emergency procedures
325733|NCT01396863|Renal dialysis
325734|NCT01396863|Hemodiafiltration
325735|NCT01396863|Hemodialysis
325736|NCT01396863|MRI
325737|NCT01396850|Psychotic Patients
325738|NCT01396837|Diabetic Foot Ulcer
325739|NCT01396837|Diabetic Ulcer
325740|NCT01396837|Diabetic Wound
325741|NCT01396837|Chronic Ulcer
325742|NCT01396837|Chronic Wound
325743|NCT01396837|Neuropathic Diabetic Foot Ulcer
325744|NCT01396837|Neuropathic DFU
325745|NCT01396837|DFU
325746|NCT01396824|Malnutrition
325747|NCT01396824|Undernutrition
325748|NCT01396824|Nutrition Assessment
325749|NCT01396824|Nutritional Assessment
325750|NCT01396824|Nutritional Index
325751|NCT01396824|Prognostic Nutritional Index
325752|NCT01396824|Prognostic Nutritional Index (PNI)
325753|NCT01396824|Nutritional Status
325754|NCT01396824|Prognosis
325755|NCT01396824|Heart Failure
325756|NCT01396824|Cardiovascular Diseases
325757|NCT01396824|Body Composition
325758|NCT01396824|Body Weights and Measures
325759|NCT01396811|Tinea Pedis
325760|NCT01396811|Antifungal
325761|NCT01396798|serious infections
325762|NCT01396798|meningitis
325763|NCT01396785|Tinea Pedis
325764|NCT01396785|Antifungal
325765|NCT01396772|prediabetes
325766|NCT01396772|diabetes prevention
325767|NCT01396772|adults
325768|NCT01396772|lifestyle intervention
325769|NCT01396772|Social Cognitive Theory
325770|NCT01396772|dietary intake
325771|NCT01396772|physical activity
325772|NCT01396759|Bubble CPAP
325773|NCT01396759|Humidified high flow
325774|NCT01396759|Hypoxaemia
325775|NCT01396759|Nasal prong
325776|NCT01396759|Severe pneumonia
325777|NCT01396733|thyroid
325778|NCT01396733|cancer
325779|NCT01396733|redifferentiation
325780|NCT01396733|lipoic acid
325781|NCT01396707|HER2
325782|NCT01396707|Trastuzumab
325783|NCT01396707|XELOX
325784|NCT01396707|PHASE 2
325785|NCT01396681|resected pancreatic cancer
325786|NCT01396668|locally advanced
325787|NCT01396655|breast cancer
325788|NCT01396655|neoadjuvant chemotherapy
325789|NCT01396655|molecular marker
325790|NCT01396655|FDG PET
325791|NCT01396655|locally advanced breast cancer
325792|NCT01396642|Topical Emollient Therapy
325793|NCT01396642|Emollient
325794|NCT01396642|Preterm
325795|NCT01396642|Hospital Acquired Infection
325796|NCT01396629|cartridge IOL
325797|NCT01396603|Optical Frequency Domain Imaging
325798|NCT01396603|Optical Coherence Tomography
325799|NCT01396603|Optical biopsy
325800|NCT01396603|Comprehensive Microscopy
325801|NCT01396590|Central Nervous System
325802|NCT01396577|Central Nervous System
325803|NCT01396564|Type 2 diabetes
325804|NCT01396564|Resistin
325805|NCT01396564|Inflammation
325806|NCT01396564|Insulin Resistance
325807|NCT01396551|Anchored Beacon Transponder
325808|NCT01396551|Anchored Transponder
325809|NCT01396551|Lung cancer
325810|NCT01396551|Calypso system
325811|NCT01396551|Realtime tracking
325812|NCT01396538|anti-HBc alone ；occult HBV infection
325813|NCT01396525|Atherosclerosis
325814|NCT01396525|Peripheral artery disease
325815|NCT01396525|Peripheral vascular disease
325816|NCT01396525|PAD
325817|NCT01396525|Claudication
325818|NCT01396525|Peripheral Arterial Occlusive Disease
325819|NCT01396525|Stent
325820|NCT01396525|PAOD
325821|NCT01396525|PVD
325822|NCT01396512|Japanese Encephalitis
325823|NCT01396512|Japanese Encephalitis Virus Disease
325824|NCT01396512|IMOJEV™
325825|NCT01396512|CD.JEVAX™
325826|NCT01396499|Leukemia
325827|NCT01396499|Acute leukemias
325828|NCT01396499|Relapsed/refractory leukemias
325829|NCT01396499|Acute myelogenous leukemia
325830|NCT01396499|AML
325831|NCT01396499|Acute lymphoblastic leukemia
325832|NCT01396499|ALL
325833|NCT01396499|BKM120
325834|NCT01396486|Omega-3 Fatty Acids
325835|NCT01396486|Fish Oil
325836|NCT01396486|Inositol
325837|NCT01396486|Natural supplements
325838|NCT01396486|Bipolar Spectrum Disorders
325839|NCT01396486|Mania
325840|NCT01396486|Depression
325841|NCT01396486|Children
325842|NCT01396473|afterschool
325843|NCT01396473|accelerometers
325844|NCT01396473|plate waste
325845|NCT01396473|policy
325846|NCT01396473|environment
325847|NCT01396460|respiratory quotient
325848|NCT01396460|fat oxidation
325849|NCT01396460|morbid obesity
325850|NCT01396460|bariatric
325851|NCT01396460|Bariatric Surgery
325852|NCT01396447|Bipolar I Disorder
325853|NCT01396447|Bipolar Depression
325854|NCT01396447|Depression
325855|NCT01396447|Bipolar Disorder
325856|NCT01396395|Nicorandil
325857|NCT01396395|Stable angina
325858|NCT01396382|neuroendocrine
325859|NCT01396382|neuroendocrine carcinoma
325860|NCT01396382|neuroendocrine tumor
325861|NCT01396382|carcinoid
325862|NCT01396382|carcinoid tumor
325863|NCT01396382|islet cell tumor
325864|NCT01396382|APUDoma
325865|NCT01396382|Gallium
325866|NCT01396382|PET Scan
325867|NCT01396343|Pediatric Multiple Sclerosis
325868|NCT01396343|Relapsing Remitting Multiple Sclerosis
325869|NCT01396343|Clinically Isolated Syndrome
325870|NCT01396343|Demyelinating Disease
325871|NCT01396317|PMR
325872|NCT01396317|POLYMYALGIA RHEUMATICA
325873|NCT01396317|Tocilizumab
325874|NCT01396317|Hospital for Special Surgery
325875|NCT01396317|HSS
325876|NCT01396317|Robert Spiera
325877|NCT01396304|leg ulcer
325878|NCT01396304|infection
325879|NCT01396304|closure
325880|NCT01396304|wound dressings
325881|NCT01396239|DMD
325882|NCT01396226|Atrial refractoriness
325883|NCT01396226|cardiac electrophysiology
325884|NCT01396226|IKACh
325885|NCT01396213|celiac disease
325886|NCT01396213|gastrointestinal symptoms
325887|NCT01396213|gluten-free diet
325888|NCT01396213|patients with biopsy-proven celiac disease with symptoms
325889|NCT01396187|Type 2 diabetes
325890|NCT01396187|safety
325891|NCT01396187|multiple dose
325892|NCT01396187|intravenous
325893|NCT01396174|breast cancer
325894|NCT01396174|breast tumor
325895|NCT01396161|Phase 1
325896|NCT01396161|Multiple Doses
325897|NCT01396161|Safety
325898|NCT01396161|Pharmacokinetics
325899|NCT01396161|Pharmacodynamics
325900|NCT01396161|Healthy Volunteers
325901|NCT01396161|Type 2 Diabetic Patients
325902|NCT01396148|Children and young adults with GIST
325903|NCT01396148|sunitinib malate
325904|NCT01396148|pharmacokinetics
325905|NCT01396148|tumor response
325906|NCT01396148|overall survival
325907|NCT01396148|tumor KIT mutation status
325908|NCT01396135|Phase 1
325909|NCT01396135|Pharmacokinetics
325910|NCT01396135|Healthy
325911|NCT01396135|Japanese
325912|NCT01396135|Non-smokers
325913|NCT01396135|Major Depressive Disorder
325914|NCT01396135|CP-601
325915|NCT01396135|927
325916|NCT01396096|Bariatric Surgery
325917|NCT01396083|Visual impairment
325918|NCT01396083|macular edema
325919|NCT01396083|Central retinal vein occlusion
325920|NCT01396083|Dexamethasone implant
325921|NCT01396083|Ranibizumab
325922|NCT01396057|Visual impairment
325923|NCT01396057|macular edema
325924|NCT01396057|branch retinal vein occlusion
325925|NCT01396057|Dexamethasone implant
325926|NCT01396057|Ranibizumab
325927|NCT01396044|Quality improvement
325928|NCT01396044|Checklist
325929|NCT01396044|Critical care
325930|NCT01396044|Anti-bacterial agents
325931|NCT01396044|Mechanical ventilation
325932|NCT01395966|with tubes
325933|NCT01395953|Buspirone
325934|NCT01395953|Buspar
325935|NCT01395953|Autism Spectrum Disorders
325936|NCT01395953|Pervasive Developmental Disorders
325937|NCT01395953|Children
325938|NCT01395953|Adolescents
325939|NCT01395953|Anxiety
325940|NCT01395940|Gonadotropin-Releasing Hormone (GnRH) antagonist
325941|NCT01395927|Canagliflozin
325942|NCT01395927|Rifampin
325943|NCT01395927|Pharmacokinetics
325944|NCT01395901|Prevention of Postoperative Nausea and Vomiting
325945|NCT01395901|Palonosetron
325946|NCT01395901|Ondansetron
325947|NCT01395901|Pediatric
325948|NCT01395836|Coronary Artery Bypass Grafting
325949|NCT01395836|Cardiology
325950|NCT01395836|Cardiac Electrophysiology
325951|NCT01395836|Cardiac Surgery
325952|NCT01395784|Oxycodone
325953|NCT01395784|Opioid abuse
325954|NCT01395771|Effect
325955|NCT01395771|Phone call
325956|NCT01395771|Intervention
325957|NCT01395771|Promote
325958|NCT01395771|HAART adherence
325959|NCT01395758|KRAS mutation
325960|NCT01395758|metastatic NSCLC
325961|NCT01395745|SLE
325962|NCT01395745|Lupus
325963|NCT01395745|Lupus Erythematosus, Systemic
325964|NCT01395745|Autoimmune Diseases
325965|NCT01395745|A-623
325966|NCT01395745|Blisibimod
325967|NCT01395719|renal transplantation
325968|NCT01395719|glomerular filtration rate
325969|NCT01395719|remote ischemic preconditioning
325970|NCT01395719|remote ischemic conditioning
325971|NCT01395706|Malignant Neoplasm of Breast
325972|NCT01395706|Sentinel lymph node detection
325973|NCT01395706|ICG fluorescence technique
325974|NCT01395706|Population of male and female patients with mamma carcinoma
325975|NCT01395680|cancer adolescent
325976|NCT01395680|resilience
325977|NCT01395641|Aromatic Amino Acid Decarboxylase
325978|NCT01395641|AADC
325979|NCT01395641|DDC
325980|NCT01395641|Gene Therapy
325981|NCT01395641|AAV2-AADC
325982|NCT01395641|Viral Vector
325983|NCT01395641|Gene Transfer
325984|NCT01395641|Aromatic L-Amino Acid Decarboxylase Deficiency
325985|NCT01395628|chronic phase chronic myelogenous leukemia
325986|NCT01395628|childhood acute promyelocytic leukemia (M3)
325987|NCT01395628|childhood acute myeloid leukemia/other myeloid malignancies
325988|NCT01395628|adult acute myeloid leukemia with t(8;21)(q22;q22)
325989|NCT01395628|adult acute myeloid leukemia with del(5q)
325990|NCT01395628|adult acute promyelocytic leukemia (M3)
325991|NCT01395589|vitamin D
325992|NCT01395589|emergency visits in patients with moderate to severe asthma after correction of vitamin D status.
325993|NCT01395576|Genu recurvatum
325994|NCT01395576|Knee hyper extension
325995|NCT01395576|Orthosis
325996|NCT01395576|Gait analysis
325997|NCT01395576|Post stroke
325998|NCT01395524|Non-Cancer-Related Pain
325999|NCT01395524|Opioid-Induced Constipation.
326000|NCT01395511|whiplash associated disorder,
326001|NCT01395511|Intractable Traumatic Cervical Syndrome,
326002|NCT01395511|Acupuncture,
326003|NCT01395511|Randomized controlled trial
326004|NCT01395498|CMV
326005|NCT01395498|PCP
326006|NCT01395498|bronchoalveolar lavage
326007|NCT01395485|Amgen
326008|NCT01395485|Adolescent
326009|NCT01395485|Single Dose
326010|NCT01395485|Safety
326011|NCT01395485|Pharmacokinetics
326012|NCT01395472|TBI
326013|NCT01395472|Acute physical exercise
326014|NCT01395472|Cognitive functions
326015|NCT01395472|Mood
326016|NCT01395459|screening
326017|NCT01395459|cancer prevention
326018|NCT01395459|IVR
326019|NCT01395433|Assessing the bioequivalence of escitalopram dosage forms
326020|NCT01395420|Phase 1
326021|NCT01395420|open label
326022|NCT01395420|healthy male and female (post menopausal) volunteers
326023|NCT01395420|Pharmacokinetics
326024|NCT01395420|CAZ104
326025|NCT01395420|Avibactam
326026|NCT01395420|Ceftazidime
326027|NCT01395420|open label, at least 2 different regimens, concentration of investigational product (IP), CAZ104, Avibactam, Ceftazidime, Cmax, tmax
326028|NCT01395407|Brain
326029|NCT01395407|Neoplasm
326030|NCT01395407|Neoplasm Metastasis
326031|NCT01395407|Radiosurgery
326032|NCT01395394|Phenylketonuria
326033|NCT01395394|PKU
326034|NCT01395394|tetrahydrobiopterin
326035|NCT01395394|sapropterin dihydrochloride
326036|NCT01395394|BH4
326037|NCT01395394|Kuvan
326038|NCT01395394|Oxidative stress
326039|NCT01395368|subjective
326040|NCT01395368|unilateral
326041|NCT01395368|bilateral
326042|NCT01395368|non-pulsatile
326043|NCT01395368|6 month's duration or longer
326044|NCT01395355|binge eating
326045|NCT01395355|loss of control eating
326046|NCT01395355|eating in the absence of hunger
326047|NCT01395355|emotional eating
326048|NCT01395342|Pregnant women
326049|NCT01395342|Pre-eclampsia
326050|NCT01395342|Exercise
326051|NCT01395342|Hypertension, Pregnancy-Induced
326052|NCT01395342|Parturition
326053|NCT01395303|infarction
326054|NCT01395303|stroke
326055|NCT01395303|diabetes
326056|NCT01395303|fracture
326057|NCT01395303|aortic stenosis
326058|NCT01395303|cancer
326059|NCT01395303|death
326060|NCT01395303|vitamin D
326061|NCT01395303|androgens
326062|NCT01395303|thyroid hormones
326063|NCT01395290|staphylococcus aureus
326064|NCT01395290|vitamin D
326065|NCT01395277|Nitric Oxide
326066|NCT01395277|Vascular Function
326067|NCT01395277|Aging
326068|NCT01395277|Blood Pressure
326069|NCT01395277|Arterial Stiffness
326070|NCT01395277|Cardiovascular Disease
326071|NCT01395277|Cerebral Blood Flow
326072|NCT01395251|rheumatoid arthritis
326073|NCT01395251|diagnosis
326074|NCT01395251|sensitivity
326075|NCT01395251|glucocorticoids
326076|NCT01395238|fathers
326077|NCT01395238|parenting
326078|NCT01395238|high-risk
326079|NCT01395238|child maltreatment
326080|NCT01395238|prevention
326081|NCT01395225|Fat Emulsifying
326082|NCT01395225|Radical Cystectomy
326083|NCT01395225|Pelvic Lymph Node Dissection
326084|NCT01395225|Pathological Lymph Node Processing
326085|NCT01395225|Bladder Cancer
326086|NCT01395225|Transitional Cell Carcinoma
326087|NCT01395225|Urothelial Cell Carcinoma
326088|NCT01395212|Cell-based cardiac regenerative therapy
326089|NCT01395212|Intramyocardial injections
326090|NCT01395212|NOGA procedure
326091|NCT01395212|Acute myocardial infarction
326092|NCT01395199|Magnetic resonance imaging
326093|NCT01395199|Thalassemia
326094|NCT01395199|Iron overload
326095|NCT01395186|varicocele
326096|NCT01395186|pain
326097|NCT01395173|detection
326098|NCT01395160|Attention deficit hyperactivity disorder
326099|NCT01395160|ADHD
326100|NCT01395160|Bipolar Disorder
326101|NCT01395160|Electrophysiological
326102|NCT01395160|EEG
326103|NCT01395160|ERP
326104|NCT01395160|Attention
326105|NCT01395160|Motivation
326106|NCT01395160|Mood instability
326107|NCT01395147|Drug Therapy
326108|NCT01395134|External branch of the superior laryngeal nerve,
326109|NCT01395134|Recurrent laryngeal nerve,
326110|NCT01395134|Intraoperative neuromonitoring,
326111|NCT01395134|Thyroid surgery
326112|NCT01395121|c-KIT mutation
326113|NCT01395121|advanced disease
326114|NCT01395121|tyrosine kinase inhibitors
326115|NCT01395095|cardiac rehabilitation
326116|NCT01395095|risk factor
326117|NCT01395095|lifestyle
326118|NCT01395082|Myocarditis
326119|NCT01395082|Pericarditis
326120|NCT01395082|Vaccinia virus
326121|NCT01395082|ACAM2000®
326122|NCT01395082|Smallpox vaccine
326123|NCT01395069|Post-cataract surgery
326124|NCT01395069|macular edema
326125|NCT01395056|breast neoplasm
326126|NCT01395056|Neoplasm Metastasis
326127|NCT01395056|Drug Therapy
326128|NCT01395043|Transversus Abdominis Plane catheter
326129|NCT01395043|TAP catheter
326130|NCT01395030|Liver
326131|NCT01395030|Cancer
326132|NCT01395017|Pancreatic cancer
326133|NCT01395017|Dasatinib
326134|NCT01395017|chemotherapy
326135|NCT01395017|Locally advanced
326136|NCT01394991|Epoetin alfa (EPREX, ERYPO)
326137|NCT01394978|Pleural air leak
326138|NCT01394978|Pulmonary resection
326139|NCT01394978|Open thoracotomy
326140|NCT01394965|ECG
326141|NCT01394965|Mapping
326142|NCT01394965|ecg mapping
326143|NCT01394965|arrythmias
326144|NCT01394952|Cardiovascular disease
326145|NCT01394952|Diabetes Mellitus
326146|NCT01394952|Dulaglutide
326147|NCT01394939|Vaccinia
326148|NCT01394939|Vaccinia Virus
326149|NCT01394939|JX-594
326150|NCT01394939|Jennerex
326151|NCT01394939|Colorectal Carcinoma
326152|NCT01394939|Colorectal cancer
326153|NCT01394939|Colon Cancer
326154|NCT01394939|Rectal Cancer
326155|NCT01394939|oncolytic virus
326156|NCT01394939|viral therapy
326157|NCT01394939|RAS mutant
326158|NCT01394939|Erbitux failure
326159|NCT01394939|Oxaliplatin failure
326160|NCT01394939|FOLFOX failure
326161|NCT01394939|FOLFIRI failure
326162|NCT01394939|Irinotecan failure
326163|NCT01394939|Pexa-Vec
326164|NCT01394926|CE-U/S - Contrast-Enhanced U/S
326165|NCT01394926|U/S - Ultrasound
326166|NCT01394926|Assess effectiveness
326167|NCT01394900|HIV
326168|NCT01394900|sexually transmitted infection
326169|NCT01394900|STI
326170|NCT01394900|men who have sex with men
326171|NCT01394900|MSM
326172|NCT01394900|couples
326173|NCT01394900|African American
326174|NCT01394900|Black
326175|NCT01394887|Metformin, inflammation
326176|NCT01394887|resistin
326177|NCT01394887|impaired glucose tolerance
326178|NCT01394887|children
326179|NCT01394874|osteoarthritis
326180|NCT01394874|exercise
326181|NCT01394861|Endoscopic Submucosal Dissection
326182|NCT01394861|ESD
326183|NCT01394861|EMR
326184|NCT01394861|Early Gastric Cancer
326185|NCT01394861|Flexible Endoscopic Robotic System
326186|NCT01394861|Master Slave Robot
326187|NCT01394861|Ease & Safety of ESD by Flexible Master Slave Robotic System
326188|NCT01394835|Patient after lung transplantation
326189|NCT01394809|osteoporosis
326190|NCT01394809|wrist fracture
326191|NCT01394809|mental practice
326192|NCT01394809|mirror therapy
326193|NCT01394809|immobilization
326194|NCT01394809|elderly
326195|NCT01394783|Endotracheal intubation, Teaching, Videolaryngoscope
326196|NCT01394770|hypertension
326197|NCT01394770|dialysis
326198|NCT01394770|aliskiren
326199|NCT01394770|amlodipine
326200|NCT01394770|outcome
326201|NCT01394744|metal
326202|NCT01394744|ion
326203|NCT01394744|cytokine
326204|NCT01394744|hip arthroplasty
326205|NCT01394744|blood
326206|NCT01394744|Assessment
326207|NCT01394744|cytokine profile
326208|NCT01394718|analgesic adjunct
326209|NCT01394718|acetaminophen
326210|NCT01394718|spine fusion surgery
326211|NCT01394718|opiate reduction
326212|NCT01394718|pain management after elective surgical operation
326213|NCT01394705|patients at increased risk for atherosclerosis
326214|NCT01394692|intraoperative MRI
326215|NCT01394692|glioma surgery
326216|NCT01394692|extent of resection
326217|NCT01394679|Lung Cancer
326218|NCT01394679|Recurrent Lung Cancer no treatment within 3 months
326219|NCT01394653|YM060
326220|NCT01394653|ramosetron
326221|NCT01394653|orally-disintegrating tablet
326222|NCT01394653|OD tablet
326223|NCT01394653|bioequivalence
326224|NCT01394614|Cataplexy
326225|NCT01394614|MSLT
326226|NCT01394614|Hypocretin
326227|NCT01394614|HLA typing
326228|NCT01394614|Polysomnography
326229|NCT01394614|A/H1N1 vaccine
326230|NCT01394601|Antipsychotics
326231|NCT01394601|schizophrenia
326232|NCT01394601|acute inpatient
326233|NCT01394588|Cardiac Surgery
326234|NCT01394588|Perioperative Glucose Control
326235|NCT01394575|breast cancer
326236|NCT01394575|radiotherapy
326237|NCT01394575|simultaneous integrated boost
326238|NCT01394575|tumor bed
326239|NCT01394575|IMRT
326240|NCT01394536|Post-operative
326241|NCT01394536|post-op
326242|NCT01394536|nausea
326243|NCT01394536|vomiting
326244|NCT01394510|insulin secretion
326245|NCT01394510|beta-cell function
326246|NCT01394510|oxidative stress
326247|NCT01394510|type 2 diabetes
326248|NCT01394497|Liver Transplantation
326249|NCT01394497|Graft Survival
326250|NCT01394497|Graft Rejection
326251|NCT01394497|Primary Graft Dysfunction
326252|NCT01394497|Tissue and Organ Harvesting
326253|NCT01394497|Tissue and Organ Procurement
326254|NCT01394497|Tissue Donors
326255|NCT01394497|Cold Ischemia
326256|NCT01394471|schizophrenia
326257|NCT01394471|schizoaffective disorder
326258|NCT01394471|oxytocin
326259|NCT01394471|OT
326260|NCT01394471|social cognition
326261|NCT01394471|social functioning
326262|NCT01394471|paranoia
326263|NCT01394471|psychosis
326264|NCT01394471|psychotic symptoms
326265|NCT01394471|social deficits
326266|NCT01394471|intranasal administration
326267|NCT01394458|catheter related infection
326268|NCT01394458|bacteremia
326269|NCT01394458|hemodialysis
326270|NCT01394432|Endocardial Stem Cells Injection
326271|NCT01394432|Percutaneous Coronary Intervention
326272|NCT01394393|obesity treatment
326273|NCT01394393|evidence based intervention
326274|NCT01394393|cognitive behavioral treatment
326275|NCT01394393|virtual reality environments
326276|NCT01394380|sugar
326277|NCT01394380|sweetened beverages
326278|NCT01394380|hepatic steatosis
326279|NCT01394380|visceral obesity
326280|NCT01394380|metabolic syndrome
326281|NCT01394367|respiratory therapy
326282|NCT01394367|exercise therapy
326283|NCT01394367|oxygen uptake
326284|NCT01394367|quality of life
326285|NCT01394367|right ventricular function
326286|NCT01394367|severe pulmonary hypertension
326287|NCT01394354|Multiple Myeloma relapsed refractory
326288|NCT01394341|Liraglutide
326289|NCT01394341|Uremia
326290|NCT01394341|Dialysis
326291|NCT01394341|Type 2 diabetes mellitus
326292|NCT01394341|Safety
326293|NCT01394341|Efficacy
326294|NCT01394328|Delirium
326295|NCT01394328|Dementia
326296|NCT01394328|Confusion Assessment Method
326297|NCT01394328|Elderly
326298|NCT01394315|diffuse optical tomography
326299|NCT01394315|response
326300|NCT01394315|neoadjuvant chemotherapy
326301|NCT01394315|breast cancer
326302|NCT01394302|Trigger Finger
326303|NCT01394289|Standardization
326304|NCT01394289|Immunotherapy
326305|NCT01394289|Skin prick test
326306|NCT01394263|prostate cancer
326307|NCT01394263|PSA
326308|NCT01394263|testosterone suppression
326309|NCT01394250|Pain
326310|NCT01394250|Anxiety
326311|NCT01394250|IV Cannulation
326312|NCT01394250|Topical Lidocaine
326313|NCT01394250|Buzzy
326314|NCT01394250|Face, Legs, Activity, Crying, Consolability (FLACC) scale
326315|NCT01394250|Faces Pain Scale Revised (FPS-R)
326316|NCT01394250|Child Rating of Anxiety Scale
326317|NCT01394224|Healthy volunteers
326318|NCT01394224|Japanese
326319|NCT01394198|Osteopathic Manipulative Medicine (OMM)
326320|NCT01394198|Neuromuscular Medicine (NMM)
326321|NCT01394198|Somatic Dysfunction
326322|NCT01394198|Correlational Study
326323|NCT01394198|Endoscopy
326324|NCT01394185|marijuana
326325|NCT01394185|dronabinol
326326|NCT01394185|pharmacotherapy
326327|NCT01394172|Tidal Volume
326328|NCT01394172|Pediatric
326329|NCT01394172|Difficult airway
326330|NCT01394172|Ventilation
326331|NCT01394172|Airway management
326332|NCT01394159|passes required to establish diagnosis
326333|NCT01394146|phosphorus-based food additives
326334|NCT01394146|phosphorus metabolism
326335|NCT01394133|HIV Infected Women
326336|NCT01394120|Pancreas cancer
326337|NCT01394120|Targeted Therapy
326338|NCT01394107|Thromboprophylaxis
326339|NCT01394107|Effect of LMWH on coagulation
326340|NCT01394107|Pregnancy
326341|NCT01394107|Neuraxial anesthesia
326342|NCT01394107|Spinal haematoma
326343|NCT01394094|Gum chewing
326344|NCT01394094|Bowel function
326345|NCT01394094|benign gynecologic surgery
326346|NCT01394081|Veterans
326347|NCT01394081|Health Care Utilization
326348|NCT01394081|Rural Health
326349|NCT01394081|Patient Navigation
326350|NCT01394081|Motivational Interviewing
326351|NCT01394068|Selenium level
326352|NCT01394068|Various blood values
326353|NCT01394068|Duration of artificial respiration
326354|NCT01394068|Residence in ICU/ Hospital
326355|NCT01394068|SOFA-Score
326356|NCT01394068|SAPS-Score
326357|NCT01394055|Diabetes Mellitus Type 1 and 2
326358|NCT01394055|Delayed Gastric Emptying
326359|NCT01394055|Gastroparesis
326360|NCT01394055|Gastrointestinal Motility Disorder
326361|NCT01394042|Biopsy proven primary prostate cancer
326362|NCT01394029|iron overload
326363|NCT01394029|iron chelation
326364|NCT01394029|deferasirox
326365|NCT01394029|observational
326366|NCT01394003|Advanced cancer
326367|NCT01393977|Spinal Cord Injuries
326368|NCT01393977|Stem Cell Transplantation
326369|NCT01393977|Rehabilitation
326370|NCT01393951|Recombinant Influenza hemagglutinin vaccine
326371|NCT01393938|Mullerian Duct Anomaly
326372|NCT01393938|3-dimensional Ultrasound
326373|NCT01393938|Magnetic Resonance Imaging
326374|NCT01393912|crenolanib
326375|NCT01393912|radiation therapy
326376|NCT01393912|malignant brain tumors
326377|NCT01393912|pediatric
326378|NCT01393899|tofacitinib
326379|NCT01393899|Xeljanz
326380|NCT01393899|CP-690,550
326381|NCT01393899|maintenance therapy
326382|NCT01393886|Obesity Surgery
326383|NCT01393873|Obesity
326384|NCT01393873|Type 2 DM
326385|NCT01393860|Diabetes
326386|NCT01393860|aliskiren
326387|NCT01393860|hypertension
326388|NCT01393860|renal impairment
326389|NCT01393847|Sickle Cell
326390|NCT01393847|Pain
326391|NCT01393847|Genetics
326392|NCT01393847|Sickle Cell Disease
326393|NCT01393847|Healthy Volunteer
326394|NCT01393847|HV
326395|NCT01393834|Delayed cord clamping
326396|NCT01393834|Umbilical cord
326397|NCT01393834|Preterm
326398|NCT01393834|Cord milking
326399|NCT01393808|Type 2 diabetes
326400|NCT01393808|Paricalcitol
326401|NCT01393808|Proteinuria
326402|NCT01393808|Sodium intake
326403|NCT01393795|Pulmonary Hypertension
326404|NCT01393795|Pain
326405|NCT01393782|high output shock
326406|NCT01393782|distributive shock
326407|NCT01393782|warm shock
326408|NCT01393782|septic shock
326409|NCT01393782|pressor
326410|NCT01393782|angiotensin
326411|NCT01393782|ATII
326412|NCT01393782|vasopressor
326413|NCT01393769|Retinoblastoma
326414|NCT01393769|RTB
326415|NCT01393769|Ocular tumour
326416|NCT01393769|Melfalan
326417|NCT01393769|Enucleation
326418|NCT01393769|Tumor of the eye
326419|NCT01393769|Eye
326420|NCT01393769|Ocular cancer
326421|NCT01393769|Ocular chemotherapy
326422|NCT01393769|Ophthalmic artery
326423|NCT01393769|Intra-arterial chemotherapy
326424|NCT01393743|Central Nervous System
326425|NCT01393730|prostate
326426|NCT01393730|metastatic
326427|NCT01393730|castrate resistant
326428|NCT01393704|myomectomy
326429|NCT01393704|vasopressin
326430|NCT01393704|blood loss
326431|NCT01393691|nighttime fears
326432|NCT01393691|anxiety
326433|NCT01393691|sleep
326434|NCT01393691|actigraphy
326435|NCT01393691|intervention
326436|NCT01393652|Pharmacokinetics Safety Tolerability Pharmacodynamics
326437|NCT01393639|treatment of rheumatoid arthritis
326438|NCT01393639|treatment of RA
326439|NCT01393639|patients on methotrexate for rheumatoid arthritis
326440|NCT01393639|prednisone for rheumatoid arthritis
326441|NCT01393587|Oxidative Stress
326442|NCT01393587|Laproscopy
326443|NCT01393561|Rhinitis
326444|NCT01393561|Common cold
326445|NCT01393561|Nasal symptoms
326446|NCT01393561|Children
326447|NCT01393548|Rhinitis
326448|NCT01393548|common cold
326449|NCT01393548|nasal symptoms
326450|NCT01393548|children
326451|NCT01393535|Adiponectin
326452|NCT01393535|Prognosis
326453|NCT01393535|Cardiac Surgery
326454|NCT01393522|headache
326455|NCT01393522|migraine
326456|NCT01393509|PU-H71
326457|NCT01393509|Solid Tumor
326458|NCT01393509|Lymphoma
326459|NCT01393509|11-041
326460|NCT01393509|incurable, locally advanced or metastatic solid tumor malignancy or lymphoma
326461|NCT01393496|prematurity
326462|NCT01393496|anemia
326463|NCT01393496|transfusion
326464|NCT01393483|esophagectomy
326465|NCT01393483|endoscopy
326466|NCT01393483|biopsy
326467|NCT01393483|Tissue mesothelin
326468|NCT01393483|Serum mesothelin
326469|NCT01393483|11-037
326470|NCT01393470|HPV
326471|NCT01393470|Vaccine
326472|NCT01393470|long-term efficacy
326473|NCT01393470|registry-based study
326474|NCT01393470|Evaluation of long-term HPV vaccine efficacy: a population-based, registry-based cohort study in Finland.
326475|NCT01393457|cocaine
326476|NCT01393457|cognition
326477|NCT01393457|medication
326478|NCT01393457|treatment
326479|NCT01393444|Electrocorticography
326480|NCT01393444|Tetraplegia
326481|NCT01393444|Spinal cord injury
326482|NCT01393444|Brainstem stroke
326483|NCT01393444|Neuroprosthetic
326484|NCT01393444|Brain-computer interface
326485|NCT01393444|Direct brain interface
326486|NCT01393444|Neural activity
326487|NCT01393444|Motor cortex
326488|NCT01393431|Exhaled breath condensate pH
326489|NCT01393431|Predictive value of pH
326490|NCT01393418|Erythropoietin
326491|NCT01393418|Cardiac Surgery
326492|NCT01393418|Renal Biomarker
326493|NCT01393418|Acute Kidney Injury
326494|NCT01393418|Hypothermic Circulatory Arrest
326495|NCT01393392|smoking cessation
326496|NCT01393392|methadone treatment
326497|NCT01393392|nicotine addiction
326498|NCT01393392|drug treatment
326499|NCT01393392|drug addiction
326500|NCT01393392|tobacco dependence
326501|NCT01393327|physical training
326502|NCT01393327|remaining post-operative pulmonary vascular changes
326503|NCT01393327|right ventricular pump function
326504|NCT01393327|PEA
326505|NCT01393301|Nicotine dependence
326506|NCT01393301|Smoking, cessation
326507|NCT01393301|Quitting
326508|NCT01393301|Anxiety symptoms
326509|NCT01393301|Cognitive-behavioral therapy
326510|NCT01393275|diabetes
326511|NCT01393275|exercise
326512|NCT01393275|intervention
326513|NCT01393275|rehabilitation
326514|NCT01393275|metabolic rate
326515|NCT01393275|sport
326516|NCT01393249|Acute Lymphoblastic Leukemia
326517|NCT01393249|Pediatric
326518|NCT01393249|Asparaginase
326519|NCT01393249|Pancreatitis
326520|NCT01393223|Interstitial Cystitis
326521|NCT01393223|Painful Bladder Syndrome
326522|NCT01393223|Bladder Pain Syndrome
326523|NCT01393223|Liposome
326524|NCT01393223|LP-08
326525|NCT01393210|insulin sensitivity
326526|NCT01393210|adipose tissue
326527|NCT01393210|inflammation
326528|NCT01393197|HCC
326529|NCT01393197|TACE
326530|NCT01393184|Target therapy
326531|NCT01393171|Anterior Vaginal Prolapse
326532|NCT01393171|Cystocele
326533|NCT01393171|Pelvic Organ Prolapse
326534|NCT01393145|Chronic obstructive pulmonary disease (COPD)
326535|NCT01393145|salmeterol
326536|NCT01393145|fluticasone
326537|NCT01393145|formoterol
326538|NCT01393145|FEV1
326539|NCT01393145|Moderate-to-severe
326540|NCT01393132|Dry Eye
326541|NCT01393132|Sjogren's Syndrome
326542|NCT01393132|Graft vs. Host Disease
326543|NCT01393132|Rheumatoid arthritis
326544|NCT01393132|Systemic lupus erythematosus
326545|NCT01393132|Scleroderma
326546|NCT01393106|HL
326547|NCT01393106|idelalisib
326548|NCT01393106|CAL-101
326549|NCT01393106|GS-1101
326550|NCT01393106|PI3K
326551|NCT01393093|HCC
326552|NCT01393093|TACE
326553|NCT01393080|nimotuzumab
326554|NCT01393080|non-small cell lung cancer
326555|NCT01393080|chemotherapy
326556|NCT01393067|cSEMS
326557|NCT01393067|NEPS
326558|NCT01393067|ERCP
326559|NCT01393067|biliary stricture
326560|NCT01393067|biliary stenosis
326561|NCT01393067|liver transplantation
326562|NCT01393054|Nigella sativa seed extract
326563|NCT01393054|hypertension
326564|NCT01393054|elderly
326565|NCT01393028|coronary artery disease
326566|NCT01393028|angina pectoris
326567|NCT01393028|Stable chest pain complaints
326568|NCT01393015|automatic
326569|NCT01393015|automation
326570|NCT01393015|oxygen
326571|NCT01393015|weaning
326572|NCT01393015|COPD
326573|NCT01393015|exacerbation
326574|NCT01393002|intensive care
326575|NCT01393002|candidemia
326576|NCT01393002|fungal infection
326577|NCT01392976|cancer
326578|NCT01392976|advanced
326579|NCT01392976|solid
326580|NCT01392976|tumor
326581|NCT01392976|gemcitabine
326582|NCT01392976|human equilibrative nucleoside transporter-1 (hENT1)
326583|NCT01392976|CO-1.01
326584|NCT01392976|CO-101
326585|NCT01392976|CO101
326586|NCT01392963|botox
326587|NCT01392963|depression
326588|NCT01392950|silicone hydrogel contact lenses for daily wear
326589|NCT01392937|AIOL
326590|NCT01392937|multipurpose solution
326591|NCT01392937|silicone hydrogel lenses
326592|NCT01392937|The safety and efficacy of the All-in-One Light multipurpose care regimen by comparison with the Aquify care regimen
326593|NCT01392911|Dose Ranging
326594|NCT01392911|Extended Early Bactericidal Activity
326595|NCT01392911|Maximum tolerable dose
326596|NCT01392911|Pharmacokinetics
326597|NCT01392911|Pulmonary Tuberculosis
326598|NCT01392911|Rifampicin
326599|NCT01392911|Rifafour
326600|NCT01392911|Safety
326601|NCT01392911|Tolerability
326602|NCT01392911|Max Tolerable Dose
326603|NCT01392898|liraglutide
326604|NCT01392898|insulin
326605|NCT01392898|type 2 diabetes mellitus
326606|NCT01392885|Schizophrenia
326607|NCT01392885|Schizoaffective Disorder
326608|NCT01392885|Brain Health
326609|NCT01392885|Exercise
326610|NCT01392885|Mental Health
326611|NCT01392885|Poor memory
326612|NCT01392872|Immunosuppressant
326613|NCT01392872|Quality of life
326614|NCT01392872|Cognitive function
326615|NCT01392872|Relapsing Multiple Sclerosis
326616|NCT01392846|Coronary artery disease requiring drug eluting stents
326617|NCT01392833|iga nephropathy
326618|NCT01392833|chronic kidney disease
326619|NCT01392833|proteinuria
326620|NCT01392833|steroids
326621|NCT01392833|azathioprine
326622|NCT01392820|Phase I
326623|NCT01392820|Japan
326624|NCT01392820|Elderly
326625|NCT01392820|PK
326626|NCT01392820|SAD
326627|NCT01392820|MAD
326628|NCT01392807|Phase 1
326629|NCT01392807|volunteers with hepatic impairment
326630|NCT01392807|pharmacokinetics
326631|NCT01392807|NKTR-118
326632|NCT01392807|Child-Pugh scale
326633|NCT01392807|AUC
326634|NCT01392807|Cmax
326635|NCT01392807|tmax
326636|NCT01392807|t1/2
326637|NCT01392794|YM060
326638|NCT01392794|ramosetron
326639|NCT01392794|orally-disintegrating tablet
326640|NCT01392794|OD tablet
326641|NCT01392794|bioequivalence
326642|NCT01392781|PCOS
326643|NCT01392781|hsC-RP
326644|NCT01392781|Lp-PLA2
326645|NCT01392781|cardiovascular risk
326646|NCT01392768|Epilepsy
326647|NCT01392768|Partial
326648|NCT01392768|Seizures
326649|NCT01392768|Adjunctive
326650|NCT01392690|No condition
326651|NCT01392690|Primary prevention
326652|NCT01392690|Anxiety
326653|NCT01392677|dapagliflozin
326654|NCT01392677|diabetes
326655|NCT01392677|hyperglycaemia
326656|NCT01392651|Urinary stress incontinence
326657|NCT01392651|TVT
326658|NCT01392638|Sildenafil
326659|NCT01392638|Nitric oxide synthase
326660|NCT01392638|Polymorphism
326661|NCT01392638|Hemodynamics
326662|NCT01392625|Non ischemic dilated cardiomyopathy
326663|NCT01392625|Dilated cardiomyopathy
326664|NCT01392625|Heart failure
326665|NCT01392625|Cardiac Stem Cell Transplantation
326666|NCT01392625|Stem Cells
326667|NCT01392612|thrombosis
326668|NCT01392612|hypertension
326669|NCT01392612|gender
326670|NCT01392612|endothelium
326671|NCT01392599|CRPS Type II
326672|NCT01392599|Pain
326673|NCT01392599|Surgery
326674|NCT01392599|Regional Subcutaneous Venous Sympathectomy(RSVS)
326675|NCT01392599|Sudeck
326676|NCT01392599|Reflex sympathetic dystrophy (RSD)
326677|NCT01392599|Causalgia
326678|NCT01392599|Algodystrophy
326679|NCT01392586|survival
326680|NCT01392586|systemic therapy
326681|NCT01392586|upfront surgery
326682|NCT01392534|Hypertension
326683|NCT01392534|Telmisartan
326684|NCT01392534|Hydrochlorothiazide
326685|NCT01392534|Potassium
326686|NCT01392534|Glucose metabolism
326687|NCT01392534|Lipid metabolism
326688|NCT01392521|Safety
326689|NCT01392521|Tolerability
326690|NCT01392521|Pharmacokinetics
326691|NCT01392495|Pulmonary arterial hypertension
326692|NCT01392495|imatinib
326693|NCT01392495|6MWD
326694|NCT01392482|Schizophrenia
326695|NCT01392482|Bipolar Disorder
326696|NCT01392469|Pulmonary arterial hypertension
326697|NCT01392469|pulmonary vascular resistance
326698|NCT01392469|imatinib
326699|NCT01392469|bosentan
326700|NCT01392469|sildenafil
326701|NCT01392456|OHIP-EDENT, VALIDATION, OVERDENTURE, ROMANIAN
326702|NCT01392443|INC424
326703|NCT01392443|Ruxolitinib
326704|NCT01392443|Myelofibrosis
326705|NCT01392443|MF
326706|NCT01392430|Primary prophylaxis
326707|NCT01392430|Secondary prophylaxis
326708|NCT01392430|Discontinuation
326709|NCT01392391|Stroke
326710|NCT01392391|Exercise
326711|NCT01392391|Protein synthesis
326712|NCT01392391|Protein breakdown
326713|NCT01392391|Muscle atrophy
326714|NCT01392391|Muscle phenotype
326715|NCT01392391|Inflammation
326716|NCT01392391|Insulin resistance
326717|NCT01392391|Fitness
326718|NCT01392378|Prevenar 13
326719|NCT01392378|13vPnC
326720|NCT01392378|Antipyretic medication
326721|NCT01392378|Healthy subjects
326722|NCT01392365|Crohn's disease
326723|NCT01392365|Intestinal tuberculosis
326724|NCT01392365|Diagnosis, Differential
326725|NCT01392352|pazopanib
326726|NCT01392352|hypertension
326727|NCT01392352|forearm blood flow
326728|NCT01392339|Obstructive Sleep Apnea
326729|NCT01392339|CPAP
326730|NCT01392339|hypoxia
326731|NCT01392339|sleep
326732|NCT01392339|translational science
326733|NCT01392339|gene expression
326734|NCT01392326|Psoriatic arthritis
326735|NCT01392326|PsA
326736|NCT01392326|ACR
326737|NCT01392326|CASPAR
326738|NCT01391559|breathing difficulty
326739|NCT01391520|Acute Kidney Injury
326740|NCT01391520|Contrast-Induced Nephropathy
326741|NCT01391520|Labile Iron
326742|NCT01391520|Iron Chelation
326743|NCT01391520|Deferiprone
326744|NCT01391507|Anti-beta1-receptor autoantibodies
326745|NCT01391507|COR-1
326746|NCT01391507|Heart failure
326747|NCT01391494|Human Enterovirus 71 (EV71)
326748|NCT01391494|Hand, Foot and Mouth Disease
326749|NCT01391494|Inactivated Vaccine
326750|NCT01391494|Human Diploid cell
326751|NCT01391494|Safety
326752|NCT01391494|Immunogenicity
326753|NCT01391494|Adverse reactions associated with vaccine
326754|NCT01392313|carnitine, kidney
326755|NCT01392287|Geriatric
326756|NCT01392287|Older adults
326757|NCT01392287|Major Depressive Disorder
326758|NCT01392287|Magnetic Resonance Spectroscopy
326759|NCT01392287|memantine hydrochloride
326760|NCT01392287|N-Acetylaspartylglutamate
326761|NCT01392287|NAAG
326762|NCT01392287|Cognitive impairment
326763|NCT01392248|EEG
326764|NCT01392248|breast cancer surgery
326765|NCT01392248|prediction
326766|NCT01392248|acute postoperative pain
326767|NCT01392248|chronic pain
326768|NCT01392235|Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
326769|NCT01392222|focus group
326770|NCT01392222|11-108
326771|NCT01392209|BEVACIZUMAB
326772|NCT01392209|HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY
326773|NCT01392209|Brain
326774|NCT01392209|CNS
326775|NCT01392209|anti-VEGF antibody
326776|NCT01392209|11-057
326777|NCT01392196|Renal Impairment
326778|NCT01392183|Kidney cancer
326779|NCT01392183|Renal Cell Carcinoma
326780|NCT01392183|Poor-Risk Clear-Cell Renal Cell Carcinoma
326781|NCT01392183|RCC
326782|NCT01392183|Metastatic
326783|NCT01392183|Locally advanced
326784|NCT01392183|Complete response
326785|NCT01392183|CR
326786|NCT01392183|Partial Response
326787|NCT01392183|PR
326788|NCT01392183|Overall survival
326789|NCT01392183|OS
326790|NCT01392183|Time to progression
326791|NCT01392183|TTP
326792|NCT01392183|Pazopanib
326793|NCT01392183|GW786034
326794|NCT01392183|Temsirolimus
326795|NCT01392183|CCI-779
326796|NCT01392183|Torisel
326797|NCT01392183|Benadryl
326798|NCT01392183|Diphenhydramine
326799|NCT01392183|TemPa
326800|NCT01392170|Leukemia
326801|NCT01392170|Chronic Myeloid Leukemia
326802|NCT01392170|CML
326803|NCT01392170|Tyrosine Kinase Inhibitors
326804|NCT01392170|TKI
326805|NCT01392170|Complete cytogenetic remission
326806|NCT01392170|CCyR
326807|NCT01392170|Minimal residual disease
326808|NCT01392170|MRD
326809|NCT01392170|PEG-IFNa-2a
326810|NCT01392170|Pegasys
326811|NCT01392170|Peginterferon Alpha-2a
326812|NCT01392170|Philadelphia chromosome (Ph)-positive
326813|NCT01392170|BCR-ABL1-positive
326814|NCT01392144|Radiation pneumonitis
326815|NCT01392144|RP
326816|NCT01392144|Nitric oxide
326817|NCT01392144|NO
326818|NCT01392144|Thoracic
326819|NCT01392144|Esophagus cancer
326820|NCT01392144|Lung cancer
326821|NCT01392144|Radiation therapy
326822|NCT01392144|radiotherapy
326823|NCT01392144|RT
326824|NCT01392144|XRT
326825|NCT01392144|Airway
326826|NCT01392144|Alveolar
326827|NCT01392144|Nitric oxide breath analyzer
326828|NCT01392144|Questionnaires
326829|NCT01392131|Oncoxin
326830|NCT01392131|Safety of Oncoxin
326831|NCT01392131|Therapeutic efficacy of Oncoxin
326832|NCT01392131|Improvement of quality of life with Oncoxin
326833|NCT01392131|Survival benefit with Oncoxin
326834|NCT01392105|Mesenchymal stem cells
326835|NCT01392105|Myocardial infarction
326836|NCT01392105|Left ventricular dysfunction
326837|NCT01392092|Contingency Management
326838|NCT01392092|Drug Self-Administration
326839|NCT01392079|CLL
326840|NCT01392079|17p deletion
326841|NCT01392079|refractory to fludarabine
326842|NCT01392079|subcutaneous alemtuzumab
326843|NCT01392079|CLL with 17p- or refractory to fludarabine
326844|NCT01392066|breast neoplasms
326845|NCT01392066|spouses/partners
326846|NCT01392066|couples
326847|NCT01392066|interpersonal relations
326848|NCT01392066|psychosocial adjustment
326849|NCT01392066|psychological adaptation
326850|NCT01392066|depression
326851|NCT01392066|quality of life
326852|NCT01392066|dyadic coping
326853|NCT01392066|coping behavior
326854|NCT01392066|cohort
326855|NCT01392066|questionnaire
326856|NCT01392053|labor
326857|NCT01392053|pain
326858|NCT01392053|massage
326859|NCT01392027|Pancreatic Cancer
326860|NCT01392027|Chronic Pancreatitis
326861|NCT01392027|Diseases of the pancreas
326862|NCT01392014|malaria
326863|NCT01392014|DHP
326864|NCT01392014|PQ
326865|NCT01392014|gametocytes
326866|NCT01391975|arteriovenous fistula
326867|NCT01391975|surveillance
326868|NCT01391975|arterial stenosis
326869|NCT01391975|venous stenosis
326870|NCT01391962|Pharmacodynamics
326871|NCT01391962|VEGF Inhibitor
326872|NCT01391962|Alveolar Soft Part Sarcoma
326873|NCT01391962|Anti-Angiogenesis
326874|NCT01391962|Gene Expression Profiling
326875|NCT01391949|disability
326876|NCT01391949|walking
326877|NCT01391949|feedback
326878|NCT01391949|exercise
326879|NCT01391923|Lipolysis
326880|NCT01391923|Cryolipolysis
326881|NCT01391923|Fat Reduction
326882|NCT01391910|rhinosinusitis
326883|NCT01391897|somatoform disorders
326884|NCT01391897|PTSD
326885|NCT01391897|epigenetics
326886|NCT01391897|psychotherapy
326887|NCT01391897|psychosomatics
326888|NCT01391884|Incretin hormones
326889|NCT01391884|GLP-1
326890|NCT01391884|GIP
326891|NCT01391884|Uremia
326892|NCT01391884|Dialysis
326893|NCT01391858|Pregabalin
326894|NCT01391858|Postoperative pain
326895|NCT01391858|Mastectomy
326896|NCT01391845|progesterone
326897|NCT01391845|glycodelin-A
326898|NCT01391845|ulipristal acetate
326899|NCT01391832|rTMS
326900|NCT01391832|PTSD
326901|NCT01391832|Post Traumatic Stress Disorder
326902|NCT01391832|repetitive transcranial magnetic stimulation
326903|NCT01391832|combat related PTSD
326904|NCT01391832|OEF
326905|NCT01391832|OIF
326906|NCT01391832|Veterans
326907|NCT01391832|operation enduring freedom
326908|NCT01391832|operation iraqi freedom
326909|NCT01391832|CPT
326910|NCT01391832|cognitive processing therapy
326911|NCT01391819|Brazil
326912|NCT01391819|Incidence
326913|NCT01391819|Dengue virus
326914|NCT01391819|Dengue
326915|NCT01391819|Dengue infection
326916|NCT01391806|Breast cancer
326917|NCT01391806|Preoperative breast MRI
326918|NCT01391806|Breast-conserving surgery
326919|NCT01391806|Mastectomy
326920|NCT01391806|Prospective study
326921|NCT01391793|Renal scarring
326922|NCT01391793|Dexamethasone
326923|NCT01391793|Child
326924|NCT01391793|Corticosteroids
326925|NCT01391793|Pediatric
326926|NCT01391793|Urinary tract infection
326927|NCT01391793|Escherichia Coli Urinary Tract Infection
326928|NCT01391780|pelvic floor evaluation,
326929|NCT01391780|women,
326930|NCT01391780|stress urinary incontinence;
326931|NCT01391780|urgency urinary incontinence.
326932|NCT01391767|Ridge Preservation
326933|NCT01391767|Dental Implant
326934|NCT01391767|Histology
326935|NCT01391754|child abuse
326936|NCT01391741|Parkinson´s Disease
326937|NCT01391741|Walking
326938|NCT01391741|Exercise
326939|NCT01391741|Automaticity
326940|NCT01391741|Dual Task
326941|NCT01391741|Visual Cues
326942|NCT01391741|Cueing
326943|NCT01391741|Neuroplasticity
326944|NCT01391741|Gait analysis
326945|NCT01391715|Gastroesophageal reflux disease
326946|NCT01391715|Proton pump inhibitor
326947|NCT01391715|standard dose
326948|NCT01391715|Double dose
326949|NCT01391676|glaucoma
326950|NCT01391676|trabeculectomy
326951|NCT01391676|filtering bleb
326952|NCT01391676|spectral domain optical coherence tomography
326953|NCT01391663|Drug Therapy
326954|NCT01391650|ACL
326955|NCT01391650|double-bundle
326956|NCT01391650|navigation system
326957|NCT01391637|Long term follow-up
326958|NCT01391637|HuCNS-SC cells
326959|NCT01391637|human central nervous system stem cells
326960|NCT01391624|chocolate
326961|NCT01391624|craving
326962|NCT01391624|addiction
326963|NCT01391624|compulsion
326964|NCT01391598|fibromyalgia
326965|NCT01391598|intravenous lidocaine
326966|NCT01391598|substance P
326967|NCT01391598|interleukins
326968|NCT01391585|Text
326969|NCT01391585|SMS
326970|NCT01391585|diabetes
326971|NCT01391585|self-monitoring
326972|NCT01391585|self-management
326973|NCT01391585|adherence
326974|NCT01391572|thoracic esophageal squamous cell carcinoma
326975|NCT01391572|esophagectomy
326976|NCT01391572|radiation
326977|NCT01391572|tumor bed
326978|NCT01391572|elective nodal irradiation
326979|NCT01391481|Perfluorocarbon
326980|NCT01391481|Acute Respiratory Distress Syndrome
326981|NCT01391481|Acute lung injury
326982|NCT01391455|Inguinal hernia repair
326983|NCT01391455|Mesh
326984|NCT01391455|Groin pain
326985|NCT01391455|Testicular pain
326986|NCT01391442|follow up of troop,
326987|NCT01391442|MRI, Echocardiography, Functional indices
326988|NCT01391416|Hyperhomocysteinemia
326989|NCT01391416|Chronic kidney disease
326990|NCT01391403|Schizophrenia
326991|NCT01391403|Risperidone
326992|NCT01391403|Artemisinin
326993|NCT01391403|Toxoplasma
326994|NCT01391403|Immune
326995|NCT01391390|Tardive Dyskinesia
326996|NCT01391390|Schizophrenia
326997|NCT01391390|Melatonin
326998|NCT01391390|Oxidative Stress
326999|NCT01391390|Antioxidant
327000|NCT01391377|HDL
327001|NCT01391377|High density Lipoprotein
327002|NCT01391377|Peripheral arterial disease
327003|NCT01391377|Tredaptive
327004|NCT01391377|Niacin
327005|NCT01391377|Laropiprant
327006|NCT01391377|Plaque
327007|NCT01391377|Atherosclerosis
327008|NCT01391377|Lipid content
327009|NCT01391351|carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage
327010|NCT01391351|chemotherapy with Taxol and Carboplatin
327011|NCT01391351|predictors of therapeutic response
327012|NCT01391351|serum miRNA
327013|NCT01391351|identification of polymorphisms or SNPs (Single Nucleotide Polymorphism)
327014|NCT01391338|Prostatitis
327015|NCT01391338|Chronic
327016|NCT01391338|Pelvic Pain
327017|NCT01391338|NIH-CPSI
327018|NCT01391338|Pain domain score in NIH-CPSI
327019|NCT01391260|Locally Advanced NSCLC
327020|NCT01391260|EGFR Mutation Positive
327021|NCT01391260|Radiotherapy combined Gefitinib
327022|NCT01391247|open angle glaucoma
327023|NCT01391247|low tension glaucoma
327024|NCT01391247|oximetry
327025|NCT01391234|Metastatic bone disease
327026|NCT01391234|Bone metastases
327027|NCT01391234|Radiation therapy
327028|NCT01391234|TomoTherapy
327029|NCT01391221|Depression
327030|NCT01391221|Inflammation
327031|NCT01391221|Cognition
327032|NCT01391221|Pain
327033|NCT01391221|Allostatic load
327034|NCT01391208|Barrett's Esophagus with High Grade Dysplasia
327035|NCT01391208|Esophageal adenocarcinoma
327036|NCT01391195|low level laser therapy
327037|NCT01391195|muscle performance
327038|NCT01391195|fatigue index
327039|NCT01391195|endurance training
327040|NCT01391195|ventilatory threshold
327041|NCT01391195|VO2Max
327042|NCT01391195|VO2Peak
327043|NCT01391182|Epsilon Aminocaproic Acid
327044|NCT01391182|blood loss
327045|NCT01391182|total hip arthroplasty
327046|NCT01391182|reduction in blood transfusions
327047|NCT01391182|Amicar
327048|NCT01391156|minoxidil
327049|NCT01391156|finasteride
327050|NCT01391156|topical
327051|NCT01391156|lotion
327052|NCT01391156|male pattern hair loss
327053|NCT01391156|androgenetic alopecia
327054|NCT01391143|Prostate cancer
327055|NCT01391143|Melanoma
327056|NCT01391143|Renal cell carcinoma
327057|NCT01391143|Triple-negative breast cancer
327058|NCT01391143|Head and neck cancer
327059|NCT01391143|Bladder cancer
327060|NCT01391143|Non-small cell lung cancer
327061|NCT01391143|Squamous cell carcinoma
327062|NCT01391130|Cancer
327063|NCT01391130|Tumor
327064|NCT01391130|Metastasis
327065|NCT01391117|TMC649128
327066|NCT01391117|HCV
327067|NCT01391117|TMC649128HPC1002
327068|NCT01391117|Hepatitis C
327069|NCT01391117|Hep C
327070|NCT01391104|Pulmonary Hypertension
327071|NCT01391104|Pulmonary Arterial Hypertension
327072|NCT01391104|Exercise
327073|NCT01391104|Six-minute walk test
327074|NCT01391104|sildenafil
327075|NCT01391078|glaucoma
327076|NCT01391078|IOP
327077|NCT01391078|Sensimed Triggerfish
327078|NCT01391078|Goldmann Applanation Tonometry
327079|NCT01391078|fluctuation
327080|NCT01391078|comparison
327081|NCT01391065|Diffusion Weighted MRI
327082|NCT01391065|FLT PET
327083|NCT01391065|F-Miso PET
327084|NCT01391065|Image Guided Brachytherapy
327085|NCT01391065|Cervix
327086|NCT01391065|Postoperative Residual Disease/Postoperative recurrences
327087|NCT01391052|Intrauterine system
327088|NCT01391052|reproductive age
327089|NCT01391052|menstrual bleeding
327090|NCT01391039|Ductal Carcinoma In-situ
327091|NCT01391039|Contrast Ultrasound
327092|NCT01391039|Microinvasion
327093|NCT01391039|Elastography
327094|NCT01391026|Medical informatics
327095|NCT01391026|Health services accessibility
327096|NCT01391013|Human immunodeficiency virus 1
327097|NCT01391013|Acquired immunodeficiency syndrome
327098|NCT01391013|Immunologic deficiency syndrome
327099|NCT01391013|Darunavir/ritonavir
327100|NCT01391013|Darunavir
327101|NCT01391013|Ritonavir
327102|NCT01391013|Nucleoside reverse transcriptase inhibitors (NRTIs)
327103|NCT01391013|Prezista
327104|NCT01391000|rotator cuff surgery
327105|NCT01391000|pain
327106|NCT01391000|exercise therapy
327107|NCT01390974|ACS
327108|NCT01390974|PCI
327109|NCT01390974|thienopyridines
327110|NCT01390974|prasugrel therapy
327111|NCT01390974|clopidogrel therapy
327112|NCT01390961|Allergic conjunctivitis
327113|NCT01390935|guideline adherence
327114|NCT01390935|systolic heart failure
327115|NCT01390909|epilepsy
327116|NCT01390909|anti-epileptic drug
327117|NCT01390909|polytherapy
327118|NCT01390909|adherence
327119|NCT01390909|Medicaid
327120|NCT01390870|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, adherence
327121|NCT01390818|MEK inhibitor (Pimasertib)
327122|NCT01390818|PI3K/mTOR Inhibitor
327123|NCT01390818|Solid Tumor
327124|NCT01390818|Phase I
327125|NCT01390766|Antirejection
327126|NCT01390740|Transthoracic echocardiography
327127|NCT01390727|hypertension
327128|NCT01390727|device-guided breathing
327129|NCT01390727|autonomic function
327130|NCT01390727|Resperate
327131|NCT01390714|Proton Pump Inhibitors
327132|NCT01390714|Gastroesophageal Reflux Disease
327133|NCT01390714|pharmacokinetics
327134|NCT01390714|pharmacodynamics
327135|NCT01390701|randomized
327136|NCT01390701|cross-over
327137|NCT01390701|transcutaneous electrical nerve stimulation
327138|NCT01390701|felodipin
327139|NCT01390701|hypertension
327140|NCT01390701|blood pressure
327141|NCT01390701|treatment
327142|NCT01390688|Brain-derived Neurotrophic factor
327143|NCT01390688|Low-grade inflammation
327144|NCT01390688|Cognitive dysfunction
327145|NCT01390662|serum 25-hydroxyvitamin d,vitamin D supplement, depression,
327146|NCT01390662|parathyroid hormone
327147|NCT01390649|ITP
327148|NCT01390636|Continuous Glucose Monitoring
327149|NCT01390636|Type 1 Diabetes and an Eating Disorder
327150|NCT01390636|Eating Disorder Only
327151|NCT01390623|Acute Uncomplicated Pyelonephritis
327152|NCT01390623|Short-term antibiotic
327153|NCT01390623|Ceftriaxone
327154|NCT01390623|Cefixime
327155|NCT01390623|Women
327156|NCT01390623|Efficacy
327157|NCT01390610|Continuous Glucose Monitoring
327158|NCT01390610|Self Monitored Blood Glucose
327159|NCT01390610|Type 2 Diabetes
327160|NCT01390597|peripheral T-cell lymphoma
327161|NCT01390597|stage I adult T-cell leukemia/lymphoma
327162|NCT01390597|stage II adult T-cell leukemia/lymphoma
327163|NCT01390597|stage III adult T-cell leukemia/lymphoma
327164|NCT01390597|stage IV adult T-cell leukemia/lymphoma
327165|NCT01390597|anaplastic large cell lymphoma
327166|NCT01390584|stage I adult Hodgkin lymphoma
327167|NCT01390584|stage II adult Hodgkin lymphoma
327168|NCT01390584|adult favorable prognosis Hodgkin lymphoma
327169|NCT01390584|adult mixed cellularity Hodgkin lymphoma
327170|NCT01390584|adult nodular sclerosis Hodgkin lymphoma
327171|NCT01390584|adult lymphocyte depletion Hodgkin lymphoma
327172|NCT01390584|adult unfavorable prognosis Hodgkin lymphoma
327173|NCT01390571|adult glioblastoma
327174|NCT01390571|adult giant cell glioblastoma
327175|NCT01390571|adult gliosarcoma
327176|NCT01390571|recurrent adult brain tumor
327177|NCT01390558|Down Syndrome
327178|NCT01390558|Orthotics
327179|NCT01390558|Gait Analysis
327180|NCT01390545|Rheumatoid arthritis
327181|NCT01390545|anti-CD20 antibody
327182|NCT01390545|subcutaneous
327183|NCT01390532|Left Ventricular Dyssynchrony
327184|NCT01390532|Gated blood-pool
327185|NCT01390532|D-SPECT
327186|NCT01390532|Pharmacological stress
327187|NCT01390532|NYHA III/IV
327188|NCT01390532|LVEF < 35 %
327189|NCT01390532|QRS > 120 ms
327190|NCT01390532|optimal medical treatment
327191|NCT01390532|cardiac resynchronization therapy
327192|NCT01390519|mRCC,
327193|NCT01390519|observational,
327194|NCT01390519|Afinitor,
327195|NCT01390519|everolimus,
327196|NCT01390519|2.line
327197|NCT01390506|cardiac arrest
327198|NCT01390506|resuscitation
327199|NCT01390506|neurological outcome
327200|NCT01390493|neurofeedback, alpha, anorexia nervosa
327201|NCT01390480|vitamin D
327202|NCT01390480|Autoimmune disease
327203|NCT01390480|diabetes
327204|NCT01390467|Paracetamol
327205|NCT01390467|Cognitive impact
327206|NCT01390441|Rheumatoid arthritis
327207|NCT01390441|RA
327208|NCT01390441|Rituximab
327209|NCT01390441|Rituxan
327210|NCT01390441|MabThera
327211|NCT01390441|Methotrexate
327212|NCT01390441|Rheumatrex
327213|NCT01390441|Trexall
327214|NCT01390441|MK-8808
327215|NCT01390402|Alloreactive haploidentical NK cells
327216|NCT01390402|Natural killer cells
327217|NCT01390402|Stem Cell Transplantation
327218|NCT01390402|Immune cells
327219|NCT01390402|Chronic myelogenous leukemia
327220|NCT01390402|CML
327221|NCT01390402|Human leukocyte antigen
327222|NCT01390402|HLA
327223|NCT01390402|Graft-vs-host disease
327224|NCT01390402|GVHD
327225|NCT01390402|Antithymocyte globulin
327226|NCT01390402|ATG
327227|NCT01390402|Thymoglobulin
327228|NCT01390402|Interleukin-2
327229|NCT01390402|IL-2
327230|NCT01390402|Aldesleukin
327231|NCT01390402|Proleukin
327232|NCT01390402|Fludarabine
327233|NCT01390402|Fludarabine phosphate
327234|NCT01390402|Fludara
327235|NCT01390402|Tacrolimus
327236|NCT01390402|Prograf
327237|NCT01390402|Busulfan
327238|NCT01390402|Busulfex
327239|NCT01390402|Myleran
327240|NCT01390402|Methotrexate
327241|NCT01390389|Geriatric bipolar depression
327242|NCT01390389|MR Spectroscopy
327243|NCT01390389|Coenzyme Q10
327244|NCT01390389|Mitochondrial Dysfunction
327245|NCT01390376|Schizophrenia
327246|NCT01390376|NMDA
327247|NCT01390376|DAAOI
327248|NCT01390376|Clozapine resistant schizophrenia
327249|NCT01390363|immunization
327250|NCT01390363|reminder systems
327251|NCT01390350|Schnitzler syndrome
327252|NCT01390350|autoinflammatory syndrome
327253|NCT01390337|AC220
327254|NCT01390337|Acute Myeloid Leukemia (AML)
327255|NCT01390337|De Novo Acute Myeloid Leukemia (AML)
327256|NCT01390337|Newly diagnosed Acute Myeloid Leukemia (AML)
327257|NCT01390337|FMS-like tyrosine kinase (FLT3)
327258|NCT01390337|FMS-like tyrosine kinase (FLT3) Inhibitor
327259|NCT01390337|Kinase
327260|NCT01390337|Kinase Inhibitor
327261|NCT01390337|Pharmacokinetics
327262|NCT01390337|ASP2689
327263|NCT01390337|quizartinib
327264|NCT01390324|Migraine
327265|NCT01390324|Naratriptan
327266|NCT01390324|Naproxen
327267|NCT01390298|chronic pain after knee replacement surgery
327268|NCT01390272|Hypertension
327269|NCT01390272|Telephone
327270|NCT01390272|Disease Management
327271|NCT01390272|Veterans
327272|NCT01390272|Pharmacists
327273|NCT01390272|Nurses
327274|NCT01390246|Pregnancy
327275|NCT01390246|Tobacco use disorder
327276|NCT01390246|Smoking cessation
327277|NCT01390246|Bupropion SR
327278|NCT01390246|Zyban
327279|NCT01390233|Labor, obstetric
327280|NCT01390233|Labor, induced
327281|NCT01390220|Epilepsy
327282|NCT01390220|seizure clusters
327283|NCT01390220|acute repetitive seizures
327284|NCT01390220|rescue treatment
327285|NCT01390220|ARTEMIS
327286|NCT01390207|hCG triggering
327287|NCT01390207|pregnancy
327288|NCT01390207|GnRH antagonist
327289|NCT01390194|liver disease
327290|NCT01390194|hepatocellular carcinoma
327291|NCT01390155|Electrocardiography
327292|NCT01390155|Coronary Artery Disease
327293|NCT01390155|Atrial Fibrillation
327294|NCT01390155|Heart Atria
327295|NCT01390155|Coronary Circulation
327296|NCT01390155|Ischemia
327297|NCT01390116|gamma delta T cell
327298|NCT01390116|natural killer cell
327299|NCT01390116|proliferation
327300|NCT01390116|cytokine secretion
327301|NCT01390116|Improvement in immune cell function in healthy humans
327302|NCT01390103|hip pain
327303|NCT01390090|piriformis muscle
327304|NCT01390077|homogentisic acid
327305|NCT01390051|birth weight
327306|NCT01390051|thrombosis
327307|NCT01390051|anticoagulant therapy
327308|NCT01390025|Influenza
327309|NCT01390025|Monoclonal antibody
327310|NCT01389973|Diseases [C] - Digestive System Diseases [C06]
327311|NCT01389973|primary biliary cirrhosis
327312|NCT01389973|ursodeoxycholic acid (UDCA)
327313|NCT01389973|STELARA
327314|NCT01389973|ustekinumab
327315|NCT01389947|mesenteric ischemia
327316|NCT01389947|extracorporeal circulation
327317|NCT01389947|microcirculation
327318|NCT01389947|cardiac surgery
327319|NCT01389947|IFABP
327320|NCT01389947|citrullinemia
327321|NCT01389947|glycocalyx
327322|NCT01389947|vascular occlusion test
327323|NCT01389947|NIRS probe on thenar eminence
327324|NCT01389934|levo-bupicaine
327325|NCT01389934|Radical
327326|NCT01389934|Mastectomy
327327|NCT01389921|lower urinary tract
327328|NCT01389921|sensory evoked potential
327329|NCT01389921|contact heat evoked potential stimulation
327330|NCT01389921|electroencephalogram
327331|NCT01389921|cortical processing
327332|NCT01389921|bladder sensations
327333|NCT01389921|lower urinary tract dysfunction
327334|NCT01389921|overactive bladder
327335|NCT01389895|Lupus
327336|NCT01389895|Cutaneous lupus
327337|NCT01389882|mechanical ventilation
327338|NCT01389882|diaphragm electrical activity
327339|NCT01389882|pressure support
327340|NCT01389869|Emotional tears
327341|NCT01389869|Postprandial plasma
327342|NCT01389869|Chemosignal
327343|NCT01389869|Obesity
327344|NCT01389869|Appetite
327345|NCT01389869|Food intake
327346|NCT01389856|Persistent pulmonary hypertension, newborn
327347|NCT01389856|PPHN
327348|NCT01389843|Heart failure
327349|NCT01389843|Registry
327350|NCT01389843|Cohort
327351|NCT01389843|Heart Disease
327352|NCT01389843|Cardiovascular Diseases
327353|NCT01389830|End of Life
327354|NCT01389830|EOL
327355|NCT01389830|Latinos
327356|NCT01389830|Hispanic American
327357|NCT01389830|Medicare beneficiaries
327358|NCT01389830|stage III diagnosis
327359|NCT01389830|Breast cancer
327360|NCT01389830|Colorectal cancer
327361|NCT01389830|Prostate cancer
327362|NCT01389830|Lung cancer
327363|NCT01389830|Cancer Prevention and Treatment Demonstration
327364|NCT01389830|CPTD
327365|NCT01389804|transplant, pediatric
327366|NCT01389791|muscle relaxation
327367|NCT01389791|magnesium sulfate
327368|NCT01389791|rocuronium
327369|NCT01389739|continuity of care
327370|NCT01389739|interprofessional collaboration
327371|NCT01389726|custodial grandparents
327372|NCT01389726|kinship caregivers
327373|NCT01389726|grandparents raising grandchildren
327374|NCT01389726|grandmothers
327375|NCT01389726|grandchildren
327376|NCT01389726|psychological well-being
327377|NCT01389713|ovarian reserve
327378|NCT01389713|ovarian stimulation
327379|NCT01389713|clomifene citrate
327380|NCT01389713|high doses Follicle Stimulating Hormone (FSH)
327381|NCT01389687|Poliomyelitis
327382|NCT01389687|Inactivated polio vaccine
327383|NCT01389687|Polio
327384|NCT01389687|Poliovirus
327385|NCT01389674|coronary stenosis
327386|NCT01389674|Angina pectoris
327387|NCT01389674|left ventricular wall motion abnormalities
327388|NCT01389661|Maxillary bone cysts
327389|NCT01389661|Cell therapy
327390|NCT01389661|Mesenchymal stem cells
327391|NCT01389661|Autologous serum scaffold
327392|NCT01389648|adult
327393|NCT01389635|Abdominoplasty
327394|NCT01389635|Epidural
327395|NCT01389622|Acupuncture
327396|NCT01389622|smoking cessation
327397|NCT01389609|Bioequivalence
327398|NCT01389609|Orally-disintegrating Tablet
327399|NCT01389596|safety
327400|NCT01389596|efficacy
327401|NCT01389596|partial onset seizures
327402|NCT01389596|pediatric
327403|NCT01389596|pregabalin
327404|NCT01389596|placebo-controlled
327405|NCT01389596|double-blind
327406|NCT01389583|GIST(Gastrointestinal stromal tumor)
327407|NCT01389583|HSP(Heat Shock Protein)
327408|NCT01389583|Biomarker
327409|NCT01389557|malaria
327410|NCT01389557|DHP
327411|NCT01389557|PQ
327412|NCT01389557|MST
327413|NCT01389518|Symptomatic treatment
327414|NCT01389518|Common Cold
327415|NCT01389518|flu syndrome
327416|NCT01389505|Proliferative Diabetic Retinopathy
327417|NCT01389505|Bevacizumab
327418|NCT01389505|Panretinal Photocoagulation
327419|NCT01389492|meat
327420|NCT01389492|LDL
327421|NCT01389492|MDA
327422|NCT01389466|Avian influenza
327423|NCT01389453|umbilical cord mesenchyma stem cell transplantation
327424|NCT01389440|Resectable pancreatic adenocarcinoma
327425|NCT01389440|Gemcitabine
327426|NCT01389440|Erlotinib
327427|NCT01389440|Radiotherapy
327428|NCT01389440|Neoadjuvant treatment
327429|NCT01389414|cholangiocarcinoma
327430|NCT01389414|biliary
327431|NCT01389414|gallbladder
327432|NCT01389414|intrahepatic
327433|NCT01389414|extrahepatic
327434|NCT01389401|Larynx
327435|NCT01389401|GERD
327436|NCT01389401|saliva
327437|NCT01389401|epidermal growth factor
327438|NCT01389388|Carotid plaques
327439|NCT01389388|inflammatory joint disease
327440|NCT01389388|statins
327441|NCT01389388|inflammation
327442|NCT01389388|lipoprotein components
327443|NCT01389375|Closure Device
327444|NCT01389375|Coronary Angiography
327445|NCT01389362|Diabetes
327446|NCT01389362|foot ulcer
327447|NCT01389362|Chinese herbal medicine
327448|NCT01389349|tonsillectomy
327449|NCT01389349|adenotonsillectomy
327450|NCT01389349|acupuncture
327451|NCT01389349|children
327452|NCT01389349|postoperative pain
327453|NCT01389349|postoperative nausea
327454|NCT01389336|Fibromyalgia Syndrome
327455|NCT01389336|Fibromyalgia
327456|NCT01389336|Ayurveda
327457|NCT01389336|Traditional Indian Medicine
327458|NCT01389336|CAM
327459|NCT01389336|Pain
327460|NCT01389336|Chronic Widespread Pain
327461|NCT01389297|alcohol dependence intervention
327462|NCT01389297|Internet delivered intervention
327463|NCT01389297|alcohol dependence treatment
327464|NCT01389297|Internet delivered treatment
327465|NCT01389284|Naproxen Sodium,
327466|NCT01389284|dental pain
327467|NCT01389271|Pulmonary hypertension
327468|NCT01389271|Inhaled iloprost
327469|NCT01389271|Efficacy
327470|NCT01389271|Safety
327471|NCT01389271|Tolerability
327472|NCT01389271|Survival
327473|NCT01389271|NYHA class III and IV
327474|NCT01389219|Post partum
327475|NCT01389219|Neonate
327476|NCT01389219|community health care workers
327477|NCT01389193|ibudilast
327478|NCT01389193|migraine
327479|NCT01389193|glial cell
327480|NCT01389154|diagnostic yield
327481|NCT01389154|Electromagnetic Tip Tracked
327482|NCT01389154|peripheral lung lesion
327483|NCT01389141|ovary
327484|NCT01389141|follicle
327485|NCT01389141|hormones
327486|NCT01389141|bone
327487|NCT01389141|muscle
327488|NCT01389128|labor
327489|NCT01389128|pain
327490|NCT01389128|massage
327491|NCT01389128|natural birth
327492|NCT01389115|liver cirrhosis
327493|NCT01389115|oxidative stress
327494|NCT01389115|liver transplant
327495|NCT01389102|Postmenopause
327496|NCT01389102|Hot Flashes
327497|NCT01389102|Estradiol
327498|NCT01389102|Polyestradiol phosphate
327499|NCT01389102|Estradiol valerate
327500|NCT01389102|Estradiol 3-benzoate
327501|NCT01389102|Estradiol 17 beta-cypionate
327502|NCT01389102|Estrogens
327503|NCT01389102|Hormones
327504|NCT01389102|Hormones, Hormone Substitutes
327505|NCT01389102|Hormone Antagonists
327506|NCT01389089|edema reduction
327507|NCT01389089|ice
327508|NCT01389089|multi-layer compression bandage
327509|NCT01389089|A-V Impulse compression
327510|NCT01389089|ankle
327511|NCT01389076|Previously Untreated, Advanced-Stage, Follicular Lymphoma
327512|NCT01389063|endothelial function
327513|NCT01389063|CCR5 receptor
327514|NCT01389063|Maraviroc
327515|NCT01389063|Abacavir
327516|NCT01389063|Flow Mediated Dilatation
327517|NCT01389063|EndoPAT
327518|NCT01389037|African American
327519|NCT01389037|High blood pressure
327520|NCT01389024|sickle cell disease
327521|NCT01389024|stroke
327522|NCT01389024|silent cerebral infarct
327523|NCT01389024|children
327524|NCT01389011|PI
327525|NCT01389011|PVI
327526|NCT01389011|Interscalene block
327527|NCT01388998|fluid management
327528|NCT01388998|fluid therapy
327529|NCT01388998|dPP
327530|NCT01388998|difference in pulse pressure
327531|NCT01388998|PVI
327532|NCT01388998|pleth variability index
327533|NCT01388998|external pressure applied on the caval vein
327534|NCT01388985|Rabies
327535|NCT01388985|Vaccination
327536|NCT01388985|Boostability
327537|NCT01388972|Community nutritional environment
327538|NCT01388972|Physical activity
327539|NCT01388946|acute postoperative pain
327540|NCT01388946|late pain
327541|NCT01388946|chronic pain
327542|NCT01388946|wound irrigation with local anesthetic
327543|NCT01388933|Crohn's Disease
327544|NCT01388933|natural
327545|NCT01388933|herbal
327546|NCT01388933|Kampo
327547|NCT01388933|inflammatory bowel disease
327548|NCT01388933|Adult ages 18 to 75
327549|NCT01388933|Male and female subjects
327550|NCT01388920|COPD
327551|NCT01388920|Muscle wasting
327552|NCT01388907|myomectomy
327553|NCT01388907|adhesion prevention
327554|NCT01388907|pregnancy rate
327555|NCT01388881|reading difficulties
327556|NCT01388868|infusion dose
327557|NCT01388868|vecuronium
327558|NCT01388868|motor evoked potential
327559|NCT01388868|neuromuscular blocking agent
327560|NCT01388855|Heart Failure
327561|NCT01388855|Vitamin D
327562|NCT01388855|Pain
327563|NCT01388855|Pilot Study
327564|NCT01388855|RCT
327565|NCT01388842|severe malaria
327566|NCT01388842|children
327567|NCT01388842|adjunctive treatment
327568|NCT01388829|formulation comparison
327569|NCT01388816|Randomized
327570|NCT01388816|Double-Blind
327571|NCT01388816|Placebo Controlled
327572|NCT01388816|Parallel Arm
327573|NCT01388816|Type II Hyperlipidemia
327574|NCT01388816|Cholesteryl Ester Transferase Protein Inhibitor
327575|NCT01388816|CETP Inhibitor
327576|NCT01388803|bronchial blocker
327577|NCT01388803|VATS
327578|NCT01388790|Gastric Cancer
327579|NCT01388790|Cetuximab
327580|NCT01388790|EMD271786
327581|NCT01388790|TS-1
327582|NCT01388790|Cisplatin
327583|NCT01388777|Breast Cancer
327584|NCT01388777|Breast Carcinoma
327585|NCT01388777|Cryoablation
327586|NCT01388777|The Visica 2™ Treatment System
327587|NCT01388777|Unifocal primary invasive ductal breast carcinoma
327588|NCT01388777|Cryoprobe
327589|NCT01388764|L-arginine supplement study
327590|NCT01388751|Mallet Finger splinting
327591|NCT01388738|Navigation Brain Stimulation (NEXSTIM)
327592|NCT01388738|cerebroprotective drug effectiveness
327593|NCT01388738|acute ischemic stroke
327594|NCT01388725|sTREM-1
327595|NCT01388725|sCD163
327596|NCT01388725|PCT
327597|NCT01388725|CRP
327598|NCT01388725|WBC count
327599|NCT01388725|SOFA score
327600|NCT01388725|SIRS
327601|NCT01388725|sepsis
327602|NCT01388725|severity
327603|NCT01388725|prognosis
327604|NCT01388712|Probiotics
327605|NCT01388712|constipation
327606|NCT01388712|children
327607|NCT01388699|Migraine with aura
327608|NCT01388686|sepsis
327609|NCT01388686|catheter
327610|NCT01388686|blood stream infection
327611|NCT01388686|blood culture
327612|NCT01388673|prior RYGB procedure
327613|NCT01388673|regained weight over time
327614|NCT01388673|dilated pouch and/or stoma
327615|NCT01388660|Healthy
327616|NCT01388660|Platelet Aggregation Inhibitors
327617|NCT01388660|Pharmacokinetics
327618|NCT01388647|Neoadjuvant Treatment
327619|NCT01388647|HER-2 Positive Breast Cancer
327620|NCT01388634|Length of hospital stay
327621|NCT01388634|readmission
327622|NCT01388634|ventral hernia
327623|NCT01388621|ovarian cancer
327624|NCT01388621|fallopian cancer
327625|NCT01388621|recurrent
327626|NCT01388621|platinum-sensitive
327627|NCT01388621|KRAS-Wildtype
327628|NCT01388608|rheumatoid arthritis
327629|NCT01388608|etanercept
327630|NCT01388608|step activity measure
327631|NCT01388582|contraceptives
327632|NCT01388582|hormonal
327633|NCT01388582|breastfeeding
327634|NCT01388582|infant weight
327635|NCT01388569|stage IV melanoma
327636|NCT01388556|exercise
327637|NCT01388556|Parkinson disease
327638|NCT01388556|motor symptoms
327639|NCT01388556|gait
327640|NCT01388556|balance
327641|NCT01388543|Pharmacokinetics
327642|NCT01388543|Clinical Pharmacology
327643|NCT01388543|Pharmacogenomics
327644|NCT01388543|HIV
327645|NCT01388517|Pityriasis alba
327646|NCT01388517|Tacrolimus
327647|NCT01388517|Calcitriol
327648|NCT01388517|Petrolatum
327649|NCT01388491|Contraception
327650|NCT01388491|Hemostasis
327651|NCT01388491|Blood Coagulation
327652|NCT01388478|Safety
327653|NCT01388478|Tolerability
327654|NCT01388478|R(+)Pramipexole
327655|NCT01388478|Alzheimer's
327656|NCT01388465|Adherence
327657|NCT01388465|Intervention
327658|NCT01388452|HIV
327659|NCT01388452|routine HIV testing
327660|NCT01388452|provider-initiated HIV testing and counseling
327661|NCT01388452|early infant diagnosis
327662|NCT01388452|Africa South of the Sahara
327663|NCT01388439|oseltamivir
327664|NCT01388439|influenza
327665|NCT01388439|neonate
327666|NCT01388439|premature
327667|NCT01388439|pharmacokinetics
327668|NCT01388413|neurogenic bladder
327669|NCT01388413|urinary tract infection
327670|NCT01388400|stroke
327671|NCT01388400|rehabilitation
327672|NCT01388400|virtual reality
327673|NCT01388400|upper limb
327674|NCT01388387|pharmacogenetics
327675|NCT01388387|pharmacokinetics
327676|NCT01388387|tacrolimus
327677|NCT01388387|genetic polymorphism
327678|NCT01388387|CYP3A5
327679|NCT01388387|liver transplantation
327680|NCT01388374|Delivery of Health Care
327681|NCT01388374|Nurse Practitioners
327682|NCT01388374|Out of Hours Medical Care
327683|NCT01388374|Primary Health Care
327684|NCT01388374|Emergency Medical Services
327685|NCT01388348|benign prostatic hyperplasia (BPH)
327686|NCT01388348|acoustic vibration
327687|NCT01388322|Pregnancy
327688|NCT01388322|Preeclampsia
327689|NCT01388322|Placental insufficiency
327690|NCT01388283|prognostic marker
327691|NCT01388270|Hemodialysis
327692|NCT01388270|Anticoagulation
327693|NCT01388270|Clotting
327694|NCT01388270|Coagulation
327695|NCT01388270|dalteparin
327696|NCT01388270|Clotting in the extracorporeal system during HD
327697|NCT01388270|Antithrombogenic property of Evodial HD filter
327698|NCT01388270|Anticoagulation during HD
327699|NCT01388257|Crohn Disease
327700|NCT01388257|Anoperineal fistula
327701|NCT01388257|Anal fistula
327702|NCT01388257|Proctology
327703|NCT01388257|Drainage
327704|NCT01388257|Colorectal Surgery
327705|NCT01388257|Fistulotomy
327706|NCT01388257|Plug
327707|NCT01388257|Advancement flap
327708|NCT01388257|Glue
327709|NCT01388257|Anti Tumor Necrosis Factor-alpha
327710|NCT01388257|Adalimumab
327711|NCT01388244|Screening
327712|NCT01388244|Risk Assessment
327713|NCT01388244|Fractures
327714|NCT01388244|Absorptiometry, Photon
327715|NCT01388244|Fracture prevention
327716|NCT01388244|Women
327717|NCT01388244|Patient prespective
327718|NCT01388231|social phobia, cognitive-behavioral therapy, treatment
327719|NCT01388218|Physical Activity
327720|NCT01388218|Patient Reported Outcome (PRO)
327721|NCT01388218|Chronic obstructive pulmonary disease (COPD)
327722|NCT01388218|Innovative Medicines Initiative - Joint Undertaking (IMI-JU)
327723|NCT01388205|Myopia
327724|NCT01388205|Outdoor activity
327725|NCT01388205|Physical activity
327726|NCT01388205|Randomized Controlled Trial
327727|NCT01388205|Pedometer
327728|NCT01388205|Behavior modification
327729|NCT01388205|Obesity
327730|NCT01388192|Pancreaticoduodenectomy
327731|NCT01388192|diabetes
327732|NCT01388192|sugar metabolism
327733|NCT01388179|Autism
327734|NCT01388179|TMS
327735|NCT01388153|Bioequivalence, acarbose, ODT
327736|NCT01388140|dissociation
327737|NCT01388140|psychosis
327738|NCT01388140|trauma
327739|NCT01388140|parenting
327740|NCT01388140|executive functions
327741|NCT01388114|Procalcitonin Measurement
327742|NCT01388101|LECT2
327743|NCT01388088|Hypertension
327744|NCT01388088|Potassium
327745|NCT01388088|Blood-pressure
327746|NCT01388075|induction
327747|NCT01388075|CYP2C9
327748|NCT01388075|Genetic variability
327749|NCT01388075|Expression
327750|NCT01388062|influenza virus
327751|NCT01388049|EV71
327752|NCT01388036|heart rate
327753|NCT01388023|SmellX
327754|NCT01388023|malodor
327755|NCT01388023|halitosis
327756|NCT01388023|herbal formulation
327757|NCT01388023|natural medicinals
327758|NCT01388023|slow release delivery system
327759|NCT01388023|gingivitis
327760|NCT01388023|Bad Breath
327761|NCT01388010|probiotics
327762|NCT01388010|gastrointestinal well being
327763|NCT01388010|digestive symptoms
327764|NCT01388010|healthy population
327765|NCT01387997|HPV
327766|NCT01387984|Type 2 diabetes mellitus
327767|NCT01387984|Diabetic complications
327768|NCT01387984|YKL-40
327769|NCT01387971|impression cytology
327770|NCT01387971|ocular surface disorders
327771|NCT01387971|ocular surface cells' variation
327772|NCT01387971|Limbal insufficiency
327773|NCT01387958|Hepatitis C virus
327774|NCT01387958|Chronically infected
327775|NCT01387958|treatment naive
327776|NCT01387958|non responders to prior therapy
327777|NCT01387945|Home blood pressure monitoring
327778|NCT01387945|Patient activation
327779|NCT01387945|Patient-centered care
327780|NCT01387945|Community Health Aides
327781|NCT01387945|Primary Health Care
327782|NCT01387932|Hepatocellular carcinoma
327783|NCT01387932|TACE
327784|NCT01387932|HepaSphere Microspheres
327785|NCT01387932|QuadraSphere Microspheres
327786|NCT01387932|Doxorubicin
327787|NCT01387919|Set time points during 48 hours of fasting
327788|NCT01387906|mild
327789|NCT01387906|moderate
327790|NCT01387893|Benign Prostatic Hyperplasia
327791|NCT01387893|BPH
327792|NCT01387893|Lower Urinary Tract Symptoms
327793|NCT01387893|LUTS
327794|NCT01387893|Self-Administered Maneuver
327795|NCT01387893|Symptomatic Relief
327796|NCT01387893|Digital Repetitive Infrapubic Pressure maneuver
327797|NCT01387880|Metastatic colorectal cancer
327798|NCT01387880|Third line therapy
327799|NCT01387880|Fourth line therapy
327800|NCT01387880|KRAS mutation status
327801|NCT01387880|Cetuximab
327802|NCT01387880|Everolimus
327803|NCT01387880|Irinotecan
327804|NCT01387867|Exercise
327805|NCT01387867|Hip osteoarthritis
327806|NCT01387867|Randomized controlled trial
327807|NCT01387841|yoga
327808|NCT01387841|chemotherapy
327809|NCT01387841|nausea
327810|NCT01387841|vomiting
327811|NCT01387828|Splenic artery
327812|NCT01387828|Aneurysm
327813|NCT01387828|laparoscopic
327814|NCT01387828|Vascular reconstruction
327815|NCT01387828|Splenectomy
327816|NCT01387815|Adalimumab
327817|NCT01387815|Psoriasis
327818|NCT01387815|Topical Agents
327819|NCT01387815|Observational
327820|NCT01387815|Traditional Systemic Agents
327821|NCT01387815|Prospective
327822|NCT01387815|Comparative
327823|NCT01387815|Effectiveness
327824|NCT01387802|Assessing Effectiveness in Ankylosing Spondylitis
327825|NCT01387789|Product Surveillance
327826|NCT01387789|Postmarketing
327827|NCT01387750|Acute Pain
327828|NCT01387750|Musculoskeletal Pain
327829|NCT01387750|Topical Analgesic
327830|NCT01387737|TA-7284
327831|NCT01387737|JNJ-28431754
327832|NCT01387737|Canagliflozin
327833|NCT01387737|Sodium Glucose Co-Transporter (SGLT2 inhibitor)
327834|NCT01387724|disseminated neuroblastoma
327835|NCT01387724|localized resectable neuroblastoma
327836|NCT01387724|localized unresectable neuroblastoma
327837|NCT01387724|regional neuroblastoma
327838|NCT01387724|stage 4S neuroblastoma
327839|NCT01387672|postmenopausal
327840|NCT01387672|osteoporosis
327841|NCT01387672|bone turnover
327842|NCT01387672|nitrate
327843|NCT01387672|headache
327844|NCT01387659|Myfortic
327845|NCT01387659|Simulect
327846|NCT01387659|Steroids
327847|NCT01387659|Diabetes
327848|NCT01387659|Transplant
327849|NCT01387659|Gastric emptying
327850|NCT01387659|Gastric motility
327851|NCT01387646|STI, abuse, substance use, unintended pregnancy
327852|NCT01387633|Nursing care
327853|NCT01387633|Diabetes mellitus
327854|NCT01387633|Health Education
327855|NCT01387633|Patient compliance
327856|NCT01387633|Social support
327857|NCT01387633|Self-efficacy
327858|NCT01387633|Adaptation strategy
327859|NCT01387620|Phacoemulsification
327860|NCT01387620|Corneal Edema
327861|NCT01387620|Corneal Endothelium
327862|NCT01387620|Viscoelastic Substances
327863|NCT01387607|Pregabalin
327864|NCT01387607|fibromyalgia
327865|NCT01387594|Crohn's disease lumbar puncture anti-MAdCAM monoclonal antibody PF-00547659 Ulcerative Colitis
327866|NCT01387555|liver cancer
327867|NCT01387555|liver tumor
327868|NCT01387555|advanced hcc
327869|NCT01387555|hepatocellular cancer
327870|NCT01387555|Jennerex
327871|NCT01387555|HCC
327872|NCT01387555|sorafenib
327873|NCT01387555|sorafenib failure
327874|NCT01387555|sorafenib intolerant
327875|NCT01387555|Nexavar
327876|NCT01387555|Nexavar failure
327877|NCT01387555|JX594
327878|NCT01387555|oncolytic virus
327879|NCT01387555|vaccinia
327880|NCT01387555|viral therapy
327881|NCT01387555|JX
327882|NCT01387555|Biotherapeutics
327883|NCT01387555|HEP018
327884|NCT01387555|traverse
327885|NCT01387555|biologic
327886|NCT01387555|Pexa-Vec
327887|NCT01387542|Schizophrenia
327888|NCT01387542|Paliperidone Extended Release (ER)
327889|NCT01387542|INVEGA
327890|NCT01387529|Reference Values
327891|NCT01387516|nicotine
327892|NCT01387516|juveniles
327893|NCT01387516|detention
327894|NCT01387503|Hepatocellular Carcinoma
327895|NCT01387503|Liver Transplantation
327896|NCT01387503|Downstaging
327897|NCT01387503|Trans-arterial chemoembolization (TACE)
327898|NCT01387503|Radiofrequency ablation (RFA)
327899|NCT01387503|Liver resection
327900|NCT01387503|Sorafenib
327901|NCT01387490|Mild Traumatic Brain Injury
327902|NCT01387490|Telephone counseling
327903|NCT01387477|hypoglycemia
327904|NCT01387477|lactate
327905|NCT01387477|glucose
327906|NCT01387477|ICU
327907|NCT01387464|bromfenac concentrations
327908|NCT01387464|ISV-303
327909|NCT01387464|Bromday
327910|NCT01387451|Brown adipose tissue
327911|NCT01387451|Different regions
327912|NCT01387451|Chinese adults
327913|NCT01387438|Brown Adipose Tissue
327914|NCT01387438|Cross sectional study
327915|NCT01387438|Chinese Adults
327916|NCT01387438|Factor
327917|NCT01387425|Smoking cessation of diabetic smoker
327918|NCT01387412|genital warts
327919|NCT01387412|HIV
327920|NCT01387412|MSM
327921|NCT01387412|Peru
327922|NCT01387412|HPV
327923|NCT01387399|ovarian cancer
327924|NCT01387399|recurrence
327925|NCT01387399|platinum-sensitive recurrent ovarian cancer
327926|NCT01387399|HIPEC
327927|NCT01387399|intraperitoneal chemotherapy
327928|NCT01387399|hyperthermic intraperitoneal chemoperfusion
327929|NCT01387399|cisplatin
327930|NCT01387373|breast cancer
327931|NCT01387373|metastatic
327932|NCT01387373|liver metastases
327933|NCT01387373|intrahepatic
327934|NCT01387373|chemotherapy
327935|NCT01387360|Myopia
327936|NCT01387360|Hyperopia
327937|NCT01387360|Presbyopia
327938|NCT01387360|Pseudophakia
327939|NCT01387360|LASIK
327940|NCT01387347|Thymosin beta 4
327941|NCT01387347|Dry eye syndrome
327942|NCT01387347|Dry eye
327943|NCT01387334|resistive exercise
327944|NCT01387334|Resistance Exercise Training Program
327945|NCT01387334|Rubber Bands
327946|NCT01387334|Glycemic Control
327947|NCT01387334|Type 2 Diabetes Mellitus
327948|NCT01387321|Pi3K
327949|NCT01387321|Advanced solid tumor
327950|NCT01387308|Phase 1
327951|NCT01387308|Healthy male volunteers
327952|NCT01387308|pharmacokinetics
327953|NCT01387308|fostamatinib
327954|NCT01387308|Scientific Terminology: Bioavailability, R406 plasma AUC and C_maxR406 plasma AUC0-t, t1/2λz and t_max
327955|NCT01387308|Laymen Terminology: Amount of R406 in blood
327956|NCT01387295|breast cancer
327957|NCT01387295|liver metastases
327958|NCT01387295|intrahepatic chemotherapy
327959|NCT01387256|abortion
327960|NCT01387256|mifepristone
327961|NCT01387256|misoprostol
327962|NCT01387256|with gestations > 63 days LMP
327963|NCT01387243|behavior modification
327964|NCT01387243|overweight
327965|NCT01387243|orlistat
327966|NCT01387230|chronic obstructive pulmonary disease
327967|NCT01387230|long acting muscarinic antagonist
327968|NCT01387217|GSK2018682
327969|NCT01387217|First Time in Human
327970|NCT01387217|Healthy Volunteer
327971|NCT01387204|MEK inhibitor
327972|NCT01387204|elimination
327973|NCT01387204|Phase 1
327974|NCT01387204|GSK1120212
327975|NCT01387204|cancer
327976|NCT01387204|Pharmacokinetics
327977|NCT01387204|oncology
327978|NCT01387204|radiolabeled ADME
327979|NCT01387178|chronic obstructive pulmonary disease
327980|NCT01387178|cost and cost analysis
327981|NCT01387178|bronchodilators
327982|NCT01387178|healthcare utilization
327983|NCT01387178|fluticasone propionate/salmeterol
327984|NCT01387178|tiotropium
327985|NCT01387165|Latin America
327986|NCT01387165|diabetes complications
327987|NCT01387165|patient compliance
327988|NCT01387165|Diabetes mellitus, type 2
327989|NCT01387165|health services accessibility
327990|NCT01387152|chest pain
327991|NCT01387152|myocardial perfusion scintigraphy
327992|NCT01387152|nuclear stress testing
327993|NCT01387152|low radiation dose
327994|NCT01387139|Ketamine
327995|NCT01387139|Propofol
327996|NCT01387139|Procedural Sedation and Analgesia
327997|NCT01387113|stroke
327998|NCT01387113|tPA
327999|NCT01387113|Thrombolysis
328000|NCT01387113|rt-PA
328001|NCT01387113|Ischemic
328002|NCT01387113|CTP
328003|NCT01387113|Imaging
328004|NCT01387113|CT Perfusion Imaging
328005|NCT01387113|Perfusion
328006|NCT01387113|CTA
328007|NCT01387113|CT Angiography
328008|NCT01387113|Acute ischemic stroke
328009|NCT01387113|Acute stroke therapy
328010|NCT01387113|(AIS)
328011|NCT01387100|supportive employment
328012|NCT01387100|vocational rehabilitation
328013|NCT01387087|ASP015K
328014|NCT01387087|Healthy subjects
328015|NCT01387087|Pharmacodynamics
328016|NCT01387087|Maximum tolerated dose
328017|NCT01387061|liver resection
328018|NCT01387061|hepatic resection
328019|NCT01387061|intraoperative ultrasound
328020|NCT01387048|acne vulgaris
328021|NCT01387048|late-type acne
328022|NCT01387048|Skinoren
328023|NCT01387048|maintenance
328024|NCT01387022|Antiretroviral treatment
328025|NCT01387022|Tenofovir
328026|NCT01387022|Drug resistance
328027|NCT01387022|Treatment outcome
328028|NCT01386021|allograft
328029|NCT01386021|coronary
328030|NCT01386021|patency
328031|NCT01386021|morbidity
328032|NCT01385969|overinflation of LMAs
328033|NCT01385956|metastatic
328034|NCT01385956|locally advanced
328035|NCT01385956|combination therapy
328036|NCT01385956|dose escalation
328037|NCT01385956|epithelial cancer
328038|NCT01385956|adenocarcinoma
328039|NCT01385956|exocrine pancreas
328040|NCT01386983|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, acute urinary retention, surgery, early, costs
328041|NCT01386983|benign prostatic hyperplasia
328042|NCT01386970|Pharmacokinetics
328043|NCT01386970|antiretroviral therapy
328044|NCT01386970|nucleoside analogs
328045|NCT01386970|mitochondrial toxicity
328046|NCT01386970|clinical pharmacology
328047|NCT01386970|cellular pharmacology
328048|NCT01386970|pharmacogenetics
328049|NCT01386957|Nephrotic Syndrome
328050|NCT01386957|Steroid treatment
328051|NCT01386957|Proteinuria
328052|NCT01386957|Child
328053|NCT01386944|Rotigotine
328054|NCT01386944|Neupro®
328055|NCT01386944|Augmentation
328056|NCT01386944|Restless Legs Syndrome
328057|NCT01386944|Moderate to severe
328058|NCT01386944|idiopathic
328059|NCT01386944|adults
328060|NCT01386931|Biopsy, Fine-Needle
328061|NCT01386931|Endoscopic Ultrasonography
328062|NCT01386931|cytopathology
328063|NCT01386918|Hallucinations
328064|NCT01386918|Schizophrenia
328065|NCT01386905|Obesity
328066|NCT01386879|suction
328067|NCT01386879|aspiration
328068|NCT01386879|general anesthesia
328069|NCT01386879|intubation
328070|NCT01386879|endotracheal tube
328071|NCT01386879|respiratory complications
328072|NCT01386866|AMG 706
328073|NCT01386866|Motesanib
328074|NCT01386866|Amgen
328075|NCT01386866|Phase 1
328076|NCT01386853|Hyperlipidemia
328077|NCT01386853|Pitavastatin
328078|NCT01386853|Atorvastatin
328079|NCT01386840|Efficacy of Treatment
328080|NCT01386840|Severe
328081|NCT01386840|home treatment
328082|NCT01386840|treatment at hospital
328083|NCT01386827|Ixiaro
328084|NCT01386827|japanese encephalitis vaccine
328085|NCT01386827|booster
328086|NCT01386801|Diabetes
328087|NCT01386801|Controls
328088|NCT01386801|Biospecimen
328089|NCT01386788|Smoke, cyanide, closed space fires
328090|NCT01386775|X-Linked Hypohidrotic Ectodermal Dysplasia
328091|NCT01386775|XLHED
328092|NCT01386775|Hypohidrotic Ectodermal Dysplasia
328093|NCT01386775|HED
328094|NCT01386762|paralysis
328095|NCT01386762|paraplegia
328096|NCT01386762|obesity
328097|NCT01386749|Vibration treatment
328098|NCT01386749|Fracture healing
328099|NCT01386749|Muscular function
328100|NCT01386736|insulin resistance
328101|NCT01386736|obesity
328102|NCT01386736|adolescence
328103|NCT01386736|vitamin D supplementation
328104|NCT01386723|eltrombopag
328105|NCT01386723|promacta
328106|NCT01386723|immune thrombocytopenia (ITP)
328107|NCT01386710|GBM
328108|NCT01386710|AA
328109|NCT01386710|AO
328110|NCT01386710|Brain
328111|NCT01386710|Tumors
328112|NCT01386710|Malignant
328113|NCT01386710|Glioblastoma
328114|NCT01386710|Multiforme
328115|NCT01386710|Anaplastic
328116|NCT01386710|Astrocytoma
328117|NCT01386684|Prostate Cancer
328118|NCT01386671|Type 2 Diabetes
328119|NCT01386671|metformin glycinate
328120|NCT01386671|metabolic control
328121|NCT01386658|Efficacy
328122|NCT01386658|Hereditary angioedema
328123|NCT01386658|HAE
328124|NCT01386658|Pediatric
328125|NCT01386658|Children
328126|NCT01386658|Pharmacokinetics
328127|NCT01386658|Safety
328128|NCT01386658|Firazyr
328129|NCT01386658|icatibant
328130|NCT01386645|impaired glucose tolerance
328131|NCT01386645|prediabetes
328132|NCT01386645|dietary glycemic index
328133|NCT01386645|beta-cell function
328134|NCT01386645|insulin secretion
328135|NCT01386645|oxidative stress
328136|NCT01386645|glycemic variability
328137|NCT01386632|Stage III-IV Squamous Cell Carcinoma
328138|NCT01386593|Cytochrome
328139|NCT01386593|Phenotyping
328140|NCT01386593|Pharmacokinetics
328141|NCT01386580|Brain Neoplasms
328142|NCT01386580|Neoplasm Metastasis
328143|NCT01386580|Neoplasms
328144|NCT01386580|Central Nervous System Neoplasms
328145|NCT01386580|Nervous System Neoplasms
328146|NCT01386580|Neoplasms by Site
328147|NCT01386580|Brain Diseases
328148|NCT01386580|Central Nervous System Diseases
328149|NCT01386580|Nervous System Diseases
328150|NCT01386580|Neoplastic Processes
328151|NCT01386580|Pathologic Processes
328152|NCT01386567|hypogonadism
328153|NCT01386567|low testosterone
328154|NCT01386567|low T
328155|NCT01386554|H.P. Acthar Gel
328156|NCT01386554|Acthar
328157|NCT01386554|nephrotic syndrome
328158|NCT01386554|idiopathic membranous nephropathy
328159|NCT01386554|proteinuria
328160|NCT01386515|Adaptation
328161|NCT01386515|Duchenne Muscular Dystrophy
328162|NCT01386515|Communication about Duchenne Muscular Dystrophy
328163|NCT01386515|Sibling
328164|NCT01386502|Solid Tumors
328165|NCT01386502|Monoclonal Antibody
328166|NCT01386502|Peptide Vaccine
328167|NCT01386502|Toxicity
328168|NCT01386502|PD-1 ligand
328169|NCT01386502|Solid Tumor
328170|NCT01386502|Breast Cancer
328171|NCT01386502|Ovarian Cancer
328172|NCT01386502|Pancreatic Cancer
328173|NCT01386502|Colon Cancer
328174|NCT01386502|Sarcoma
328175|NCT01386489|HIV-uninfected
328176|NCT01386489|Mucosal Immunity
328177|NCT01386489|Kinetics
328178|NCT01386489|Cytokines
328179|NCT01386489|Chemokines
328180|NCT01386489|Healthy Volunteer
328181|NCT01386489|HV
328182|NCT01386476|5-HT1A Receptors
328183|NCT01386476|Blood Brain Barrier
328184|NCT01386476|Drug Resistance
328185|NCT01386476|Healthy Volunteer
328186|NCT01386476|HV
328187|NCT01386437|Fungal Infection
328188|NCT01386437|Immunopathogenesis
328189|NCT01386437|Genetics
328190|NCT01386437|Fungal Infections
328191|NCT01386437|Mucocutaneous Fungal Infection
328192|NCT01386437|Invasive Fungal Infection
328193|NCT01386424|Influenza
328194|NCT01386424|Human
328195|NCT01386424|Challenge Study
328196|NCT01386424|Healthy Volunteer
328197|NCT01386424|HV
328198|NCT01386411|Genetic testing
328199|NCT01386411|BRCA testing
328200|NCT01386411|Ashkenazi descent
328201|NCT01386411|11-086
328202|NCT01386398|stage II mycosis fungoides/Sezary syndrome
328203|NCT01386398|stage III mycosis fungoides/Sezary syndrome
328204|NCT01386398|stage IV mycosis fungoides/Sezary syndrome
328205|NCT01386398|stage II cutaneous T-cell non-Hodgkin lymphoma
328206|NCT01386398|stage III cutaneous T-cell non-Hodgkin lymphoma
328207|NCT01386398|stage IV cutaneous T-cell non-Hodgkin lymphoma
328208|NCT01386398|recurrent mycosis fungoides/Sezary syndrome
328209|NCT01386398|recurrent cutaneous T-cell non-Hodgkin lymphoma
328210|NCT01386372|Hyponatremia
328211|NCT01386372|Vasopressin
328212|NCT01386372|Tolvaptan
328213|NCT01386372|SIADH
328214|NCT01386346|gastroesophageal junction
328215|NCT01386346|GEJ
328216|NCT01386346|esophageal
328217|NCT01386346|esophagus
328218|NCT01386333|Frontotemporal Dementia
328219|NCT01386333|oxytocin
328220|NCT01386333|Pick's disease
328221|NCT01386320|anaesthetic techniques, regional; surgery orthopaedic
328222|NCT01386307|Pain
328223|NCT01386307|Hospitalization
328224|NCT01386281|Julina
328225|NCT01386281|Postmenopausal osteoporosis
328226|NCT01386268|Kogenate FS
328227|NCT01386268|Hemophilia A
328228|NCT01386255|GERD
328229|NCT01386242|Colorectal Cancer
328230|NCT01386242|Novaferon
328231|NCT01386229|hemodynamic stability
328232|NCT01386229|etomidate
328233|NCT01386229|ketamine
328234|NCT01386229|coronary artery bypass surgery after induction of anesthesia, hemodynamic stability
328235|NCT01386216|Critical limb ischemia
328236|NCT01386216|Peripheral vascular disease
328237|NCT01386216|platelet-rich plasma
328238|NCT01386203|lung cancer
328239|NCT01386203|biomarkers
328240|NCT01386203|breath
328241|NCT01386203|early detection
328242|NCT01386190|preterm infant, body composition, exercise
328243|NCT01386177|MDMA
328244|NCT01386177|doxazosin
328245|NCT01386177|norepinephrine
328246|NCT01386177|alpha1- receptor
328247|NCT01386177|ecstasy
328248|NCT01386177|stimulants
328249|NCT01386151|Moderate asthmatic, uncontrolled
328250|NCT01386138|HIV
328251|NCT01386138|HIV Risk
328252|NCT01386138|Sexually Transmitted Infections
328253|NCT01386138|Women
328254|NCT01386138|Pregnancy
328255|NCT01386138|Neonatal Health
328256|NCT01386138|Drug Use
328257|NCT01386138|Drug Treatment
328258|NCT01386138|Gender-specific Treatment
328259|NCT01386138|Methamphetamine
328260|NCT01386138|Opioids
328261|NCT01386138|Cocaine
328262|NCT01386138|Injection Drugs
328263|NCT01386138|Stimulants
328264|NCT01386138|Alcohol
328265|NCT01386138|Mandrax
328266|NCT01386138|Marijuana
328267|NCT01386138|Nicotine
328268|NCT01386086|Aripiprazole
328269|NCT01386086|adjunctive therapy
328270|NCT01386086|mood stabilizers
328271|NCT01386086|major depressive disorder
328272|NCT01386086|postpartum
328273|NCT01386086|Augmentation therapy
328274|NCT01386086|resistant
328275|NCT01386060|Stress
328276|NCT01386060|Mindfulness
328277|NCT01386060|Meditation
328278|NCT01386047|Clinical Prediction Rules
328279|NCT01386047|Electronic Health Records
328280|NCT01386047|Walsh Clinical Prediction Rule
328281|NCT01386047|Heckerling Clinical Prediction Rule
328282|NCT01386034|Nutrition, protein metabolism, stable isotopes, mass spectrometry, intestinal failure
328283|NCT01385943|Reflectance Confocal Microscopy
328284|NCT01385943|Dermoscopy
328285|NCT01385943|Clinical Photos
328286|NCT01385943|Telemedicine
328287|NCT01385930|Overweight
328288|NCT01385930|Obesity
328289|NCT01385930|lifestyle counseling
328290|NCT01385917|Duchenne Muscular Dystrophy
328291|NCT01385917|strength and function tests
328292|NCT01385917|MRI
328293|NCT01385878|Microcoaxial phacoemulsification, 1.8mm, 2.2mm
328294|NCT01385852|CME
328295|NCT01385852|OCT
328296|NCT01385852|Optical coherence tomography
328297|NCT01385852|macular thickness
328298|NCT01385839|Alopecia
328299|NCT01385839|Hair transplantation
328300|NCT01385839|Needle irritation
328301|NCT01385839|Medical needling
328302|NCT01385826|Uveitis
328303|NCT01385826|Juvenile arthritis
328304|NCT01385826|Anti-tumor necrosis factor alpha monoclonal antibody
328305|NCT01385826|treatment
328306|NCT01385813|pre-eclampsia
328307|NCT01385813|inflammatory markers
328308|NCT01385813|serological biobank
328309|NCT01385813|To assess whether the inflammatory markers could be useful
328310|NCT01385813|in order to identify pregnant women at risk to
328311|NCT01385813|develop preeclampsia
328312|NCT01385800|Grass allergy
328313|NCT01385800|Rhinoconjunctivitis
328314|NCT01385800|Environmental Exposure Unit
328315|NCT01385800|Immunotherapy
328316|NCT01385800|ToleroMune Grass
328317|NCT01385787|Pediatric (ages 0-21 years)
328318|NCT01385787|myeloablative HCT
328319|NCT01385787|PBMTC sites
328320|NCT01385774|Intermittent Claudication
328321|NCT01385774|Percutaneous Transluminal Angioplasty
328322|NCT01385774|Supervised Exercise Therapy
328323|NCT01385774|Peripheral Arterial Disease
328324|NCT01385761|Supraglottic airway devices
328325|NCT01385735|Parkinson Disease
328326|NCT01385735|Emotion
328327|NCT01385735|mood
328328|NCT01385735|executive function
328329|NCT01385709|Lithium
328330|NCT01385709|Sertraline
328331|NCT01385683|Healthy volunteer
328332|NCT01385683|Pharmacokinetic
328333|NCT01385683|pharmacodynamic
328334|NCT01385683|Polymorphism, Genetic
328335|NCT01385670|Patent Foramen Ovale
328336|NCT01385670|PFO
328337|NCT01385644|Mesenchymal stem cells
328338|NCT01385644|Idiopathic pulmonary fibrosis
328339|NCT01385631|ST-Segment Elevation Myocardial Infarction
328340|NCT01385631|Intravascular ultrasound
328341|NCT01385631|IVUS
328342|NCT01385631|Optical coherence tomography
328343|NCT01385631|OCT
328344|NCT01385631|Ezetimibe
328345|NCT01385631|Hydroxymethylglutaryl-CoA Reductase Inhibitors
328346|NCT01385631|Atorvastatin
328347|NCT01385631|Randomized trial
328348|NCT01385631|Hypolipidemic Agents
328349|NCT01385631|Molecular Mechanisms of Pharmacological Action
328350|NCT01385631|Pharmacologic Actions
328351|NCT01385631|Enzyme Inhibitors
328352|NCT01385631|Lipid Regulating Agents
328353|NCT01385631|Therapeutic Uses
328354|NCT01385592|Parkinson Disease
328355|NCT01385592|L-dopa
328356|NCT01385592|Levodopa
328357|NCT01385592|Dyskinesia
328358|NCT01385592|Anti-Dyskinesia Agents
328359|NCT01385579|colorectal cancer screening
328360|NCT01385579|fecal occult blood testing (FOBT)
328361|NCT01385579|vulnerable populations
328362|NCT01385579|community health center
328363|NCT01385540|Tinnitus, fMRI, task-based fMRI, attention network
328364|NCT01385488|lymphedema
328365|NCT01385488|breast cancer
328366|NCT01385488|self care
328367|NCT01385488|bioelectrical impedance
328368|NCT01385488|monitoring
328369|NCT01385475|Resistance Training
328370|NCT01385475|Physical Function
328371|NCT01385475|Older Adults
328372|NCT01385449|nerve block
328373|NCT01385449|shoulder surgery
328374|NCT01385449|physical therapy
328375|NCT01385436|human papillomavirus (HPV)
328376|NCT01385436|cervical cancer
328377|NCT01385436|high grade cervical squamous intraepithelial lesion (HSIL)
328378|NCT01385423|acute myelogenous leukemia
328379|NCT01385423|natural killer cells
328380|NCT01385423|haploidentical donor
328381|NCT01385410|breastfeeding exclusively
328382|NCT01385397|Health system organization
328383|NCT01385345|Vitamin D deficiency
328384|NCT01385345|Insulin resistance
328385|NCT01385332|Metaphase II
328386|NCT01385332|Ovarian stimulation
328387|NCT01385332|Egg donors
328388|NCT01385319|Bare metal stent
328389|NCT01385319|zotarolimus eluting stent
328390|NCT01385319|triple anti-thrombotic therapy
328391|NCT01385319|high bleeding riskduration of dual anti-platelet therapy
328392|NCT01385293|BKM120
328393|NCT01385293|prostate cancer
328394|NCT01385293|metastatic castrate-resistant prostate cancer (mCRPC)
328395|NCT01385254|very low birthweight
328396|NCT01385254|premature
328397|NCT01385254|sibling adjustment
328398|NCT01385254|preterm
328399|NCT01385241|Human Immunodeficiency Virus (HIV)
328400|NCT01385241|Stigma
328401|NCT01385241|Safe disclosure of seropositive status
328402|NCT01385241|HIV positive women
328403|NCT01385241|Self-efficacy
328404|NCT01385228|prostate cancer
328405|NCT01385228|metastatic
328406|NCT01385228|pazopanib
328407|NCT01385228|docetaxel
328408|NCT01385228|metastatic prostate cancer
328409|NCT01385215|Vaccination
328410|NCT01385215|Mucosal Immunity
328411|NCT01385215|Nasal Immunization
328412|NCT01385202|Atrial Fibrillation
328413|NCT01385202|Paroxysmal Atrial Fibrillation
328414|NCT01385189|Human Hookworm Vaccine Initiative
328415|NCT01385189|HHVI
328416|NCT01385189|Human Hookworm
328417|NCT01385189|Hookworm
328418|NCT01385189|Hookworm Disease
328419|NCT01385189|N. americanus
328420|NCT01385189|Soil-transmitted helminth infection
328421|NCT01385189|Intestinal blood loss
328422|NCT01385189|Iron deficiency anemia
328423|NCT01385176|Heart failure
328424|NCT01385176|Congestive heart failure
328425|NCT01385176|New York Heart Association Class II-III
328426|NCT01385176|Vagal therapy
328427|NCT01385176|Vagal nerve stimulation
328428|NCT01385163|mental health
328429|NCT01385163|gender-based violence
328430|NCT01385163|Africa
328431|NCT01385150|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
328432|NCT01385150|adult acute myeloid leukemia with inv(16)(p13;q22)
328433|NCT01385150|adult acute myeloid leukemia with t(16;16)(p13;q22)
328434|NCT01385150|adult acute myeloid leukemia with t(8;21)(q22;q22)
328435|NCT01385150|untreated adult acute myeloid leukemia
328436|NCT01385150|adult acute basophilic leukemia
328437|NCT01385150|adult acute eosinophilic leukemia
328438|NCT01385150|adult erythroleukemia (M6a)
328439|NCT01385150|adult pure erythroid leukemia (M6b)
328440|NCT01385150|adult acute minimally differentiated myeloid leukemia (M0)
328441|NCT01385150|adult acute monoblastic leukemia (M5a)
328442|NCT01385150|adult acute monocytic leukemia (M5b)
328443|NCT01385150|adult acute myeloblastic leukemia with maturation (M2)
328444|NCT01385150|adult acute myeloblastic leukemia without maturation (M1)
328445|NCT01385150|adult acute myelomonocytic leukemia (M4)
328446|NCT01385137|estrogen receptor-positive breast cancer
328447|NCT01385137|progesterone receptor-positive breast cancer
328448|NCT01385137|stage I breast cancer
328449|NCT01385137|stage II breast cancer
328450|NCT01385137|stage IIIA breast cancer
328451|NCT01385137|pain
328452|NCT01385137|arthralgia
328453|NCT01385124|Cannabidiol
328454|NCT01385124|GVHD
328455|NCT01385124|Allogeneic transplantation
328456|NCT01385124|Prophylaxis
328457|NCT01385111|endobronchial ultrasound
328458|NCT01385111|endoscopic ultrasound
328459|NCT01385111|EBUS-TBNA
328460|NCT01385111|EUS-FNA
328461|NCT01385111|EUS-B-FNA
328462|NCT01385111|lung cancer
328463|NCT01385111|staging
328464|NCT01385098|Vitamin D
328465|NCT01385098|Bariatric surgery
328466|NCT01385098|Roux-en Y surgery
328467|NCT01385098|Gastric sleeve surgery
328468|NCT01385098|Parathyroid Hormone
328469|NCT01385085|Vitamin D
328470|NCT01385085|Sunlight
328471|NCT01385085|Deficiency
328472|NCT01385072|acute leukemia
328473|NCT01385072|relapse
328474|NCT01385072|induction failure
328475|NCT01385072|allogeneic transplantation
328476|NCT01385072|graft versus leukemia effect
328477|NCT01385046|physical inactivity
328478|NCT01385046|poor diet
328479|NCT01385020|Red yeast rice
328480|NCT01385020|Gemfibrozil
328481|NCT01385020|Drug-drug interaction
328482|NCT01385020|Pharmacokinetics
328483|NCT01385007|Rural
328484|NCT01385007|Veterans
328485|NCT01385007|Dementia
328486|NCT01385007|Pain
328487|NCT01385007|Aggression
328488|NCT01385007|residence in a VA designated rural area
328489|NCT01385007|presence of a caregiver
328490|NCT01384994|Colorectal Cancer
328491|NCT01384994|PARLIM
328492|NCT01384994|KRAS Wildtype
328493|NCT01384994|Liver metastases
328494|NCT01384981|chronic obstructive pulmonary rehabilitation
328495|NCT01384981|COPD
328496|NCT01384981|non invasive ventilation
328497|NCT01384981|NIV
328498|NCT01384981|exercise capacity
328499|NCT01384981|pulmonary rehabilitation
328500|NCT01384968|nitrite
328501|NCT01384968|exercise
328502|NCT01384968|cycling
328503|NCT01384955|scoliosis
328504|NCT01384955|physical therapy
328505|NCT01384955|long term outcome
328506|NCT01384955|pulmonary function
328507|NCT01384955|physical fitness
328508|NCT01384955|health related quality of life
328509|NCT01384955|psychopathology
328510|NCT01384942|Bereavement
328511|NCT01384942|Grief
328512|NCT01384942|Mourning
328513|NCT01384942|Loss
328514|NCT01384942|Death
328515|NCT01384942|Meaning
328516|NCT01384942|Group
328517|NCT01384942|Counseling
328518|NCT01384942|Psychotherapy
328519|NCT01384942|Uncomplicated
328520|NCT01384942|Support
328521|NCT01384916|depression
328522|NCT01384916|yoga
328523|NCT01384916|health education
328524|NCT01384916|antidepressant
328525|NCT01384877|Pain
328526|NCT01384877|Cancer
328527|NCT01384877|Lidocaine
328528|NCT01384877|Sodium Channel Blockers
328529|NCT01384864|barrett's esophagus
328530|NCT01384864|intraepithelial neoplasia
328531|NCT01384864|cross polarized reflectance examination
328532|NCT01384864|vital-dye enhanced fluorescence examination
328533|NCT01384838|breast cancer
328534|NCT01384838|physical activity
328535|NCT01384838|sports
328536|NCT01384838|exercise
328537|NCT01384825|Multiple Sclerosis
328538|NCT01384825|Other Neurodegenerative Diseases
328539|NCT01384825|Chronic CerebroSpinal Venous Insufficiency
328540|NCT01384825|Prevalence
328541|NCT01384825|Case-control
328542|NCT01384773|Keratoconus
328543|NCT01384773|Ectasia
328544|NCT01384773|UVA light
328545|NCT01384773|riboflavin
328546|NCT01384773|post-LASIK (laser in situ keratomileusis)
328547|NCT01384773|pellucid marginal degeneration
328548|NCT01384773|irregular astigmatism
328549|NCT01384721|Computed Tomography Coronary Angiography
328550|NCT01384721|Coronary Artery Disease
328551|NCT01384721|Prevalence Of Disease
328552|NCT01384721|Prognosis
328553|NCT01384721|Risk Stratification
328554|NCT01384708|squamous cell cancer
328555|NCT01384708|squamous cell neoplasia
328556|NCT01384695|Barrett's esophagus
328557|NCT01384695|confocal microendoscopy
328558|NCT01384617|distal pancreatectomy
328559|NCT01384617|pancreatic fistula
328560|NCT01384617|pancreaticojejunostomy
328561|NCT01384617|Roux-en-Y anastomosis
328562|NCT01384617|stapling closure
328563|NCT01384604|Schizophrenia
328564|NCT01384604|Schizoaffective disorder
328565|NCT01384604|Bipolar disorder
328566|NCT01384604|Psychosis
328567|NCT01384604|Genetics
328568|NCT01384604|Phenotype
328569|NCT01384591|oxidative stress
328570|NCT01384591|blood flow
328571|NCT01384591|antioxidant
328572|NCT01384591|muscle
328573|NCT01384591|elderly
328574|NCT01384552|normal weight
328575|NCT01384552|overweight
328576|NCT01384552|dietary restraint
328577|NCT01384552|package unit size
328578|NCT01384552|food intake
328579|NCT01384539|chronic kidney disease
328580|NCT01384539|vitamin D deficiency
328581|NCT01384526|hormone therapy
328582|NCT01384526|ovarian aging
328583|NCT01384526|ovarian reserve
328584|NCT01384526|fertility
328585|NCT01384526|breast cancer
328586|NCT01384513|Allogeneic HSCT
328587|NCT01384513|Hematopoietic stem cell transplantation
328588|NCT01384487|Viewing and axial cross sectional imaging of ocular
328589|NCT01384487|structures, including the anterior chamber
328590|NCT01384474|Crew Resource Management
328591|NCT01384474|Surgical safety checklist
328592|NCT01384474|Postoperative complications
328593|NCT01384448|stress echocardiography
328594|NCT01384448|coronary ct angiography
328595|NCT01384435|Spinocerebellar degeneration (SCD)
328596|NCT01384435|Thyrotropin-Releasing Hormone (TRH)
328597|NCT01384422|methotrexate-refractory
328598|NCT01384383|Chronic Hepatitis C
328599|NCT01384383|IL28B CC Genotype
328600|NCT01384383|Treatment naive
328601|NCT01384383|Peginterferon α-2a (PEG)
328602|NCT01384383|Genotype 1a/b
328603|NCT01384383|GS 9451
328604|NCT01384383|GS 5885
328605|NCT01384383|Ribavirin (RBV)
328606|NCT01384383|HCV NS5A inhibitor
328607|NCT01384383|HCV NS3 protease inhibitor
328608|NCT01384357|lymphadenopathy
328609|NCT01384357|needle biopsy
328610|NCT01384357|sonography
328611|NCT01384331|Implanon users
328612|NCT01384331|Frequent bleeding
328613|NCT01384331|Prolonged bleeding
328614|NCT01384331|Comparison of treatments
328615|NCT01384331|Placebo controlled
328616|NCT01384331|Randomly allocated tretment
328617|NCT01384292|Cancer-Related Pain
328618|NCT01384292|Opioid-Induced Constipation
328619|NCT01384292|OIC
328620|NCT01384279|metformin
328621|NCT01384279|topiramate
328622|NCT01384279|obesity
328623|NCT01384279|metabolic syndrome
328624|NCT01384266|Intraocular Inflammation following routine Cataract Surgery
328625|NCT01384253|HER2+
328626|NCT01384253|HER-2 positive
328627|NCT01384253|intraperitoneal
328628|NCT01384253|intra-abdominal
328629|NCT01384253|Lead 212
328630|NCT01384253|Radio Immunotherapy
328631|NCT01384253|Alpha particle
328632|NCT01384253|Antibodies
328633|NCT01384253|Immunoglobulins
328634|NCT01384253|Antibodies, Monoclonal
328635|NCT01384253|Immunologic Factors
328636|NCT01384253|Physiological Effects of Drugs
328637|NCT01384253|Pharmacologic Actions
328638|NCT01384253|RIT
328639|NCT01384240|colon polyps
328640|NCT01384240|colonic dysplasia
328641|NCT01384240|anal dysplasia
328642|NCT01384240|microendoscopy
328643|NCT01384227|Barrett's esophagus
328644|NCT01384227|in vivo imaging
328645|NCT01384227|image guide microscope
328646|NCT01384201|intestinal metaplasia, gastric cancer
328647|NCT01384175|Epidural Analgesia
328648|NCT01384175|OPCAB
328649|NCT01384175|PCEA
328650|NCT01384162|ALS
328651|NCT01384162|VEGF165
328652|NCT01384162|Safety
328653|NCT01384162|Intracerebroventricular
328654|NCT01384162|Infusion
328655|NCT01384162|Implantable
328656|NCT01384149|intra ocular pressure
328657|NCT01384149|open angle glaucoma
328658|NCT01384149|selective laser trabeculoplasty
328659|NCT01384149|external laser treatment
328660|NCT01384123|stable pulmonary sarcoidosis with no change in medication during the last 3 months/
328661|NCT01384110|Amylase
328662|NCT01384110|Glucosidase
328663|NCT01384110|Glycemic response
328664|NCT01384110|Sucrose
328665|NCT01384110|Seaweed
328666|NCT01384097|haemodynamic
328667|NCT01384097|goal-directed therapy
328668|NCT01384097|surgery
328669|NCT01384097|anaesthesia
328670|NCT01384084|pelvic organ prolapse
328671|NCT01384084|urinary incontinence
328672|NCT01384084|sacropexy
328673|NCT01384084|sling
328674|NCT01384071|Low back pain
328675|NCT01384071|Unstable shoes
328676|NCT01384071|Gait
328677|NCT01384071|Balance
328678|NCT01384058|atherogenic lipoprotein
328679|NCT01384058|cardiovascular disease
328680|NCT01384058|coronary artery disease
328681|NCT01384058|type 2 diabetes
328682|NCT01384058|small, dense LDL
328683|NCT01384045|Type II Diabetes
328684|NCT01384045|Diabetes
328685|NCT01384032|CVD, LDL-C, apoE, SFA, DHA
328686|NCT01384019|ST-elevation myocardial infarction
328687|NCT01384019|percutaneous coronary intervention
328688|NCT01384019|cardiac magnetic resonance imaging
328689|NCT01384019|microvascular occlusion
328690|NCT01384019|myocardial salvage
328691|NCT01384006|Pancreas transplantation
328692|NCT01384006|extended donor criteria
328693|NCT01384006|organ survival
328694|NCT01383993|Open-Label
328695|NCT01383993|Pharmacokinetics
328696|NCT01383993|Intravenous to oral switch
328697|NCT01383993|Safety
328698|NCT01383993|Voriconazole
328699|NCT01383993|Immunocompromise
328700|NCT01383993|Children
328701|NCT01383993|High Risk For Systemic Fungal Infection
328702|NCT01383980|Enteral Nutrition
328703|NCT01383980|Enteral Feeding
328704|NCT01383980|nasogastric tubes
328705|NCT01383980|gastrostomy tubes
328706|NCT01383980|jejunostomy tubes
328707|NCT01383954|knee osteoarthritis
328708|NCT01383941|asthma
328709|NCT01383941|rhinitis
328710|NCT01383941|difficult-to-treat asthmatic
328711|NCT01383941|phenotypes
328712|NCT01383889|Physical exercise
328713|NCT01383889|Pregnancy
328714|NCT01383889|Fetal well being
328715|NCT01383876|cervical
328716|NCT01383876|laminectomy
328717|NCT01383876|fusion
328718|NCT01383876|neurological compression
328719|NCT01383876|spondylosis
328720|NCT01383850|preterm infants
328721|NCT01383850|nasal continuous positive airway pressure
328722|NCT01383850|heliox
328723|NCT01383850|bronchopulmonary dysplasia.
328724|NCT01383837|HIV/STI
328725|NCT01383837|Prevention
328726|NCT01383837|Adolescents
328727|NCT01383837|Substance Use Disorders
328728|NCT01383837|Family-based intervention
328729|NCT01383824|Hip Replacement
328730|NCT01383824|Femoral Component
328731|NCT01383811|Treatment Resistant Depression
328732|NCT01383811|Exercise
328733|NCT01383798|iron deficiency, physical performance, female athletes
328734|NCT01383785|Primary PTCA
328735|NCT01383785|Thrombus Aspiration Catheter
328736|NCT01383785|Intracoronary Abciximab
328737|NCT01383772|Proliferative diabetic retinopathy
328738|NCT01383772|Pan retinal photocoagulation
328739|NCT01383772|Multi-spot Photocoagulator
328740|NCT01383772|Visual field tests
328741|NCT01383759|BORTEZOMIB (VELCADE)
328742|NCT01383759|CYCLOPHOSPHAMIDE (CYTOXAN)
328743|NCT01383759|DEXAMETHASONE
328744|NCT01383759|MELPHALAN
328745|NCT01383759|11-061
328746|NCT01383746|Cholangiocarcinoma
328747|NCT01383746|RADIOEMBOLIZATION
328748|NCT01383746|tumor response
328749|NCT01383746|progression-free survival
328750|NCT01383746|safety
328751|NCT01383746|second-line therapy
328752|NCT01383720|Aortic Valve Stenosis
328753|NCT01383720|Transcatheter Aortic Valve Replacement
328754|NCT01383655|wheezy bronchitis
328755|NCT01383655|asthma
328756|NCT01383655|rhinovirus
328757|NCT01383655|magnesium
328758|NCT01383629|Vitrectomy
328759|NCT01383629|Local anaesthesia
328760|NCT01383629|Counselling
328761|NCT01383629|Fear
328762|NCT01383629|Visual perception
328763|NCT01383616|osteoporosis
328764|NCT01383616|vertebral compression fractures
328765|NCT01383603|Cat Allergy
328766|NCT01383603|Rhinoconjunctivitis
328767|NCT01383603|Immunotherapy
328768|NCT01383603|Cat-PAD
328769|NCT01383590|Cat allergy
328770|NCT01383590|Rhinoconjunctivitis
328771|NCT01383590|Immunotherapy
328772|NCT01383590|Cat-PAD
328773|NCT01383577|Hemorrhoids
328774|NCT01383577|Ligation
328775|NCT01383577|Pain
328776|NCT01383577|Morbidity
328777|NCT01383577|Patient Satisfaction
328778|NCT01383577|Cost-Benefit Analysis
328779|NCT01383551|Depression
328780|NCT01383551|Marital relationship
328781|NCT01383551|Parental competence
328782|NCT01383538|pancreas
328783|NCT01383538|cancer
328784|NCT01383538|adenocarcinoma
328785|NCT01383538|Oxaliplatin
328786|NCT01383538|Leucovorin
328787|NCT01383538|Irinotecan
328788|NCT01383538|5-FU
328789|NCT01383538|IPI-926
328790|NCT01383525|SLT, LTP
328791|NCT01383525|non contact
328792|NCT01383525|Trabeculoplasty
328793|NCT01383525|Laser
328794|NCT01383525|intraocular pressure
328795|NCT01383512|stroke
328796|NCT01383512|rehabilitation
328797|NCT01383512|robotics
328798|NCT01383512|motor control
328799|NCT01383512|upper limb
328800|NCT01383486|Self Selection Tria
328801|NCT01383473|cancer therapy
328802|NCT01383473|school attendance
328803|NCT01383473|cancer diagnosis
328804|NCT01383473|perception
328805|NCT01383460|Acute-on-chronic liver failure
328806|NCT01383460|ACLF
328807|NCT01383460|cirrhosis
328808|NCT01383460|acute hepatitis
328809|NCT01383421|Rheumatoid Arthritis
328810|NCT01383421|Patient Support Program
328811|NCT01383421|adalimumab
328812|NCT01383408|breath sample analysis
328813|NCT01383408|exhalation analysis
328814|NCT01383408|volatile organic compounds
328815|NCT01383408|screening
328816|NCT01383408|lung cancer
328817|NCT01383408|breast cancer
328818|NCT01383408|ovarian cancer
328819|NCT01383408|canine scent detection
328820|NCT01383382|Heart Diseases
328821|NCT01383382|Cardiovascular Diseases
328822|NCT01383382|Acute Myocardial Infarction
328823|NCT01383382|Decision Making
328824|NCT01383382|Percutaneous Coronary Intervention
328825|NCT01383382|Informed Consent
328826|NCT01383382|Quality of Care
328827|NCT01383330|megesterol
328828|NCT01383317|Remote Ischemic Preconditioning
328829|NCT01383317|Acute Pain
328830|NCT01383304|Platelet aggregation
328831|NCT01383304|Aspirin
328832|NCT01383304|Drug resistance
328833|NCT01383304|Thromboxane B2
328834|NCT01383304|Pharmacologic Actions
328835|NCT01383304|Platelet Aggregation Inhibitors
328836|NCT01383291|pelvic floor prolapse
328837|NCT01383291|prolift
328838|NCT01383291|IVS
328839|NCT01383291|Surgery
328840|NCT01383278|tobacco
328841|NCT01383278|smoking
328842|NCT01383278|smoking cessation
328843|NCT01383265|screening colonoscopy
328844|NCT01383265|adenoma
328845|NCT01383265|water method
328846|NCT01383252|water method
328847|NCT01383252|air method
328848|NCT01383252|unsedated colonoscopy
328849|NCT01383252|adenoma detection
328850|NCT01383239|Rotator Cuff Tear Repair
328851|NCT01383239|Rotator Cuff Tear Repair and postoperative treatment
328852|NCT01383226|endosonography
328853|NCT01383226|enlarged thoracic lymph adenopathies
328854|NCT01383226|non-cancer patient
328855|NCT01383213|Acute Respiratory Failure
328856|NCT01383213|Pneumonia
328857|NCT01383213|Continuous Positive Airway Pressure
328858|NCT01383200|efficacy
328859|NCT01383200|comfort
328860|NCT01383187|Deep Burn Trauma
328861|NCT01383187|Dermo-Epidermal Graft
328862|NCT01383187|Platelet Rich Plasma Concentrate (PRP)
328863|NCT01383187|Vancouver Scar Score
328864|NCT01383187|Scarring
328865|NCT01383187|Hypertrophic Scarring
328866|NCT01383174|Breast cancer
328867|NCT01383174|Latinas
328868|NCT01383174|Peer support counselor
328869|NCT01383174|Spanish speaking
328870|NCT01383174|Community based
328871|NCT01383161|Curcumin
328872|NCT01383161|Turmeric
328873|NCT01383161|Memory
328874|NCT01383161|Cognitive Impairment
328875|NCT01383161|Brain Imaging
328876|NCT01383161|Supplement
328877|NCT01383148|NSCLC
328878|NCT01383135|Healthy volunteers
328879|NCT01383122|Pulsed electromagnetic field device
328880|NCT01383122|Cesarean section
328881|NCT01383109|Mass Balance
328882|NCT01383109|Accelerated Mass Spectrometry (AMS)
328883|NCT01383109|microdose
328884|NCT01383109|Focus of the study: ADME
328885|NCT01383096|OZ439
328886|NCT01383096|Bioavailability
328887|NCT01383096|Food Effect
328888|NCT01383083|Pulmonary arterial hypertension
328889|NCT01383083|Congenital heart disease
328890|NCT01383083|Eisenmenger physiology
328891|NCT01383070|Timely initiation of breast feeding
328892|NCT01383070|Exclusive breast feeding
328893|NCT01383070|Timely introduction of complimentary feeding
328894|NCT01383070|Breast Feeding, Exclusive
328895|NCT01383070|Childbirth and the Puerperium
328896|NCT01383044|Carvedilol
328897|NCT01383044|Banding ligation with Carvedilol
328898|NCT01383044|the efficacy & safety of combining EVL and carvedilol in prevention of first variceal bleeding
328899|NCT01383031|laparoscopic cholecystectomy
328900|NCT01383031|single site
328901|NCT01383031|randomized controlled trail
328902|NCT01383018|Erectile Dysfunction (ED)
328903|NCT01383018|Penile Implant
328904|NCT01383018|Impotence
328905|NCT01383018|Penile Prosthesis
328906|NCT01383018|Registry
328907|NCT01383005|Treatment satisfaction
328908|NCT01383005|Adherence to treatment
328909|NCT01382992|Carcinoma, Non-Small-Cell Lung
328910|NCT01382992|erbB-1
328911|NCT01382979|Alcohol misuse prevention
328912|NCT01382979|College students
328913|NCT01382979|Intervention and control
328914|NCT01382966|sclerostin
328915|NCT01382966|arteriovenous fistula thrombosis
328916|NCT01382966|carpal tunnel syndrome
328917|NCT01382966|echocardiography
328918|NCT01382953|Holter Monitor, Ambulatory Electrocardiography Monitoring
328919|NCT01382888|Haemodialysis
328920|NCT01382888|Arteriovenous fistula
328921|NCT01382888|Severe chronic kidney disease
328922|NCT01382888|Newly constructed primary arteriovenous fistulas in patients planned for haemodialysis
328923|NCT01382875|Multi-disciplinary management program
328924|NCT01382875|Conventional care program
328925|NCT01382875|Balance Ability
328926|NCT01382875|Quality of Life
328927|NCT01382862|acute ischemic stroke
328928|NCT01382862|thrombolysis
328929|NCT01382862|prehospital
328930|NCT01382862|emergency medicine
328931|NCT01382862|suspected acute stroke
328932|NCT01382862|telemedicine
328933|NCT01382849|amyloid
328934|NCT01382849|cerebral amyloid angiopathy
328935|NCT01382849|hemorrhages
328936|NCT01382849|cerebral spot sign
328937|NCT01382810|dry eye signs and symptoms
328938|NCT01382771|low back pain
328939|NCT01382771|zygapophysial joint pain
328940|NCT01382771|medial branch block
328941|NCT01382771|> 6 months duration
328942|NCT01382771|non-radicular
328943|NCT01382758|Near Infrared Spectroscopy (NIRS)
328944|NCT01382758|Acute kidney injury (AKI)
328945|NCT01382732|Pre-eclampsia
328946|NCT01382732|Postpartum hemorrhage
328947|NCT01382732|Carbetocin
328948|NCT01382732|Oxytocin
328949|NCT01382719|FSAD
328950|NCT01382719|HSDD
328951|NCT01382719|female sexual dysfunction
328952|NCT01382719|FSD
328953|NCT01382719|Female Sexual Arousal Disorder
328954|NCT01382719|Hypoactive Sexual Desire Disorder
328955|NCT01382693|Behavioral symptoms
328956|NCT01382693|Long-term care
328957|NCT01382667|mucositis
328958|NCT01382667|dyspepsia
328959|NCT01382667|chemotherapy
328960|NCT01382667|GLP-2
328961|NCT01382667|questionnaire
328962|NCT01382641|Cataract surgery
328963|NCT01382628|Diabetes
328964|NCT01382628|Ulcers
328965|NCT01382628|Equinus Deformity
328966|NCT01382628|Amputation
328967|NCT01382628|Achilles Tendon
328968|NCT01382628|Limb Loss
328969|NCT01382615|Multiple Myeloma
328970|NCT01382602|Urinary Incontinence, Stress
328971|NCT01382602|Tissue Therapy (Cell Therapy)
328972|NCT01382602|Transplantation, Autologous
328973|NCT01382589|vitiligo
328974|NCT01382589|depigmentation
328975|NCT01382589|phototherapy
328976|NCT01382589|non-segmental vitiligo
328977|NCT01382576|polycystic ovary syndrome
328978|NCT01382576|chitotriosidase activity
328979|NCT01382563|Eosinophilic Gastrointestinal Disorders
328980|NCT01382563|EGID
328981|NCT01382563|Eosinophilic Esophagitis
328982|NCT01382563|Registry
328983|NCT01382563|Eosinophils
328984|NCT01382563|Eosinophilia
328985|NCT01382563|Eosinophilic enteropathy
328986|NCT01382563|Eosinophilic enteritis
328987|NCT01382563|Eosinophilic gastritis
328988|NCT01382563|Eosinophilic gastroenteritis
328989|NCT01382563|Eosinophilic gastroenteropathy
328990|NCT01382550|antithrombin
328991|NCT01382550|venous thrombosis
328992|NCT01382550|thrombosis risk factors
328993|NCT01382550|thrombophilia
328994|NCT01382537|Neck
328995|NCT01382537|Chronic
328996|NCT01382537|Musculoskeletal
328997|NCT01382537|Shoulder
328998|NCT01382524|PIV therapy
328999|NCT01382498|Endothelin-1 high sensitivity CRP
329000|NCT01382485|non union
329001|NCT01382485|bone defect
329002|NCT01382485|tibia non union
329003|NCT01382485|femur non union
329004|NCT01382485|bone graft
329005|NCT01382472|STEMI
329006|NCT01382472|PPCI
329007|NCT01382472|Statins
329008|NCT01382472|Infarct size
329009|NCT01382459|children
329010|NCT01382446|Trauma
329011|NCT01382446|Mechanical Ventilation
329012|NCT01382446|Ventilator Associated Pneumonia
329013|NCT01382446|Oral Care
329014|NCT01382433|Chronic Cannabis Users
329015|NCT01382433|negative symptoms
329016|NCT01382433|cognitive electrophysiology functions
329017|NCT01382420|subclinical cushing syndrome
329018|NCT01382420|hypercortisolism
329019|NCT01382420|adrenal incidentaloma
329020|NCT01382420|adrenalectomy
329021|NCT01382407|skin rash reaction
329022|NCT01382407|ERBITUX® (cetuximab)
329023|NCT01382407|acne
329024|NCT01382394|Sepsis
329025|NCT01382394|heart failure
329026|NCT01382394|BNP
329027|NCT01382394|IL-6
329028|NCT01382394|Procalcitonin
329029|NCT01382394|Prognosis
329030|NCT01382368|Post Pneumonectomy Patients
329031|NCT01382368|IPF
329032|NCT01382368|COPD
329033|NCT01382355|Kidney transplant
329034|NCT01382355|Kidney/Pancreas transplant
329035|NCT01382355|Antibody
329036|NCT01382355|Monitoring
329037|NCT01382342|Parkinson's disease
329038|NCT01382342|cognition
329039|NCT01382342|executive function
329040|NCT01382342|rasagiline
329041|NCT01382329|Prophylaxis of influenza infection caused by a pandemic influenza virus (H5N1)
329042|NCT01382316|12-step facilitation
329043|NCT01382316|Alcoholics Anonymous
329044|NCT01382316|Narcotics Anonymous
329045|NCT01382316|AA
329046|NCT01382316|Self-help
329047|NCT01382303|Type 2 Diabetes
329048|NCT01382303|pentoxifylline
329049|NCT01382303|proteinuria
329050|NCT01382290|MRI
329051|NCT01382290|Spine
329052|NCT01382290|Diffusion
329053|NCT01382264|Poorly controlled diabetes Type 2
329054|NCT01382264|Computer Assisted Decision Support
329055|NCT01382264|Primary Care Providers
329056|NCT01382251|Activities of Daily Living
329057|NCT01382251|Caregivers
329058|NCT01382251|Ambulatory Surgical Procedures
329059|NCT01382238|dolutegravir
329060|NCT01382238|pediatric
329061|NCT01382238|granule formulation
329062|NCT01382238|GSK1349572
329063|NCT01382238|HIV
329064|NCT01382225|Dry eyes
329065|NCT01382225|Ocular discomfort
329066|NCT01382212|Evaluate safety through the evaluation of the incidence of hypercalcemia in pediatric subjects
329067|NCT01382199|Antibiotic Associated Diarrhea in Adult Patients
329068|NCT01382186|Qualitative
329069|NCT01382186|User, Computer Interface
329070|NCT01382186|quantitative
329071|NCT01382186|survey
329072|NCT01382186|telemedicine
329073|NCT01382173|Knee injury
329074|NCT01382173|Osteoarthritis
329075|NCT01382173|Anterior Cruciate Ligament injury
329076|NCT01382173|Patellar dislocation
329077|NCT01382160|Rheumatoid arthritis
329078|NCT01382160|adalimumab
329079|NCT01382160|pharmacokinetic-pharmacodynamic relationship
329080|NCT01382160|immunogenicity
329081|NCT01382160|Fc gamma receptors polymorphisms
329082|NCT01382134|Platelet dysfunction
329083|NCT01382134|Hemodilution
329084|NCT01382134|Mild hypothermia
329085|NCT01382134|NSAID
329086|NCT01382134|Desmopressin
329087|NCT01382121|Peer modeling
329088|NCT01382121|Observational learning
329089|NCT01382121|Obesity
329090|NCT01382121|Adolescents
329091|NCT01382121|Maximum ventilatory oxygen
329092|NCT01382121|Aerobic fitness
329093|NCT01382121|Health behaviour
329094|NCT01382095|ETEC
329095|NCT01382095|Diarrhea
329096|NCT01382095|Vaccine
329097|NCT01382082|cognitive function
329098|NCT01382082|memory
329099|NCT01382082|attention
329100|NCT01382082|breast cancer
329101|NCT01382082|lymphoma
329102|NCT01382069|androgen
329103|NCT01382069|male contraception
329104|NCT01382069|dimethandrolone
329105|NCT01382069|healthy men
329106|NCT01382056|Peripheral Artery Disease
329107|NCT01382056|Pulses
329108|NCT01382056|Beans
329109|NCT01382056|PAD
329110|NCT01382043|percutaneous coronary angioplasty
329111|NCT01382043|zotarolimus-eluting stent
329112|NCT01382043|sirolimus-eluting stent
329113|NCT01382043|biodegradable polymer
329114|NCT01382043|biocompatible polymer
329115|NCT01382030|Soft tissue sarcoma
329116|NCT01382030|High-risk
329117|NCT01382030|Neoadjuvant
329118|NCT01382030|Adjuvant
329119|NCT01382030|Chemotherapy
329120|NCT01382030|Radiotherapy
329121|NCT01382017|lacosamide
329122|NCT01382017|carbamazepine
329123|NCT01382017|placebo
329124|NCT01382017|transcranial magnetic stimulation
329125|NCT01382017|TMS
329126|NCT01382017|motor cortex
329127|NCT01382017|sodium channel
329128|NCT01382017|inhibition
329129|NCT01382017|threshold
329130|NCT01382004|Neglected diseases
329131|NCT01382004|Children
329132|NCT01381991|Gastroesophageal Reflux Disease
329133|NCT01381991|Reflux esophagitis
329134|NCT01381991|i-scan
329135|NCT01381978|Nutritional status of scholars
329136|NCT01381978|Risk factors of obesity
329137|NCT01381978|Socioeconomical status
329138|NCT01381978|Physical activity habits
329139|NCT01381965|spectral-domain optical coherence tomography
329140|NCT01381965|idiopathic macular hole
329141|NCT01381965|cone outer segment tips line
329142|NCT01381965|vitrectomy
329143|NCT01381952|X-ray
329144|NCT01381952|Image processing
329145|NCT01381952|Neuro angiography
329146|NCT01381952|Radiation exposure
329147|NCT01381939|Intrahepatic Cholestasis of Pregnancy
329148|NCT01381939|Induction of labor
329149|NCT01381939|Pregnancy
329150|NCT01381939|Caesarian section
329151|NCT01381939|Pruritus
329152|NCT01381939|IUFD
329153|NCT01381926|Type 2 diabetes, exenatide, Byetta
329154|NCT01381913|Gastric cancer
329155|NCT01381913|Chemoradiotherapy
329156|NCT01381913|Adjacent tissue invasion
329157|NCT01381913|Feasibility trial
329158|NCT01381900|Canagliflozin
329159|NCT01381900|Placebo
329160|NCT01381900|Type 2 diabetes mellitus
329161|NCT01381887|Canagliflozin
329162|NCT01381887|Placebo
329163|NCT01381887|Type 2 diabetes mellitus
329164|NCT01381874|Breast cancer
329165|NCT01381874|Abiraterone
329166|NCT01381874|Postmenopausal
329167|NCT01381874|Metastatic
329168|NCT01381848|Doripenem
329169|NCT01381848|DORIPED1003
329170|NCT01381848|Intravenous
329171|NCT01381848|Infection
329172|NCT01381848|Colonization
329173|NCT01381848|Prophylaxis
329174|NCT01381848|Pediatric
329175|NCT01381848|Antibiotic
329176|NCT01381848|Pharmacokinetics
329177|NCT01381835|TMC435-TiDP16-C126
329178|NCT01381835|TMC435-C126
329179|NCT01381835|TMC435
329180|NCT01381835|HCV
329181|NCT01381835|Hepatitis C
329182|NCT01381835|Hep C
329183|NCT01381835|severe renal impairement
329184|NCT01381822|TH-302
329185|NCT01381822|Advanced Renal Cell Carcinoma
329186|NCT01381822|RCC
329187|NCT01381822|Gastrointestinal Stromal Tumors
329188|NCT01381822|GIST
329189|NCT01381822|Phase 1
329190|NCT01381822|Sunitinib
329191|NCT01381822|Pancreatic Neuroendocrine Tumors
329192|NCT01381822|PNET
329193|NCT01381809|Myelodysplastic Syndromes
329194|NCT01381809|Myeloproliferative Disorders
329195|NCT01381809|Bone Marrow disease
329196|NCT01381809|Anemia
329197|NCT01381809|Epoetin Alfa
329198|NCT01381809|Eprex
329199|NCT01381809|Erypo
329200|NCT01381809|Erythropoiesis-stimulating agent
329201|NCT01381783|topical anaesthesia
329202|NCT01381783|Phacoemulsification
329203|NCT01381770|muscular lesions grade 2
329204|NCT01381770|muscular lesions grade 3
329205|NCT01381757|Extensively Drug-Resistant Tuberculosis
329206|NCT01381757|First-Line Antituberculous Drugs
329207|NCT01381757|Second-Line Antituberculous Drugs
329208|NCT01381757|Middlebrook Culture
329209|NCT01381757|Agar Proportion Method
329210|NCT01381744|Yersinia pestis, vaccine, plague, Flagellin/F1/V, Parent Protocol of 15-0104
329211|NCT01381731|post PRK wound healing
329212|NCT01381718|childhood brain tumor
329213|NCT01381718|neurotoxicity
329214|NCT01381718|fatigue
329215|NCT01381718|cognitive/functional effects
329216|NCT01381718|psychosocial effects of cancer and its treatment
329217|NCT01381705|recurrent grade 1 follicular lymphoma
329218|NCT01381705|recurrent grade 2 follicular lymphoma
329219|NCT01381653|sexual risk
329220|NCT01381653|substance use
329221|NCT01381653|HIV prevention
329222|NCT01381653|intervention acceptability and feasibility
329223|NCT01381653|young men who have sex with men
329224|NCT01381640|paracetamol
329225|NCT01381640|healthy volunteer
329226|NCT01381640|pharmacoscintography
329227|NCT01381627|EBUS-TBNA
329228|NCT01381627|Dexmedetomidine
329229|NCT01381627|Precedex
329230|NCT01381627|Remifentanil
329231|NCT01381627|Ultiva
329232|NCT01381627|Monitored Anesthesia Care
329233|NCT01381627|Sedation
329234|NCT01381627|Bronchoscopy
329235|NCT01381627|Lung cancer
329236|NCT01381627|Mediastinal node
329237|NCT01381627|Cancer staging
329238|NCT01381627|Anesthesia
329239|NCT01381627|Remote location
329240|NCT01381614|retrospective database analysis
329241|NCT01381614|economic burden
329242|NCT01381601|retrospective database analysis
329243|NCT01381601|economic burden
329244|NCT01381575|HPV infection
329245|NCT01381575|Human Papillomavirus
329246|NCT01381575|Cervical cancer
329247|NCT01381575|HPV-16
329248|NCT01381575|HPV-18
329249|NCT01381575|vaccine
329250|NCT01381562|intra-abdominal infection
329251|NCT01381562|belly
329252|NCT01381562|Gram-negative pathogen
329253|NCT01381562|abscess
329254|NCT01381562|peritonitis
329255|NCT01381549|Gram-negative
329256|NCT01381549|uropathogens
329257|NCT01381549|complicated lower urinary tract infection
329258|NCT01381549|pyelonephritis
329259|NCT01381536|Anti Blys Antibody
329260|NCT01381523|resource utilization
329261|NCT01381523|naproxen sodium
329262|NCT01381523|cost and cost analysis
329263|NCT01381523|triptan
329264|NCT01381523|migraine
329265|NCT01381510|Benign prostatic hyperplasia
329266|NCT01381510|Adherence
329267|NCT01381510|Acute urinary retention
329268|NCT01381510|Enlarged prostate
329269|NCT01381510|5-alpha reductase inhibitor
329270|NCT01381510|Surgery
329271|NCT01381510|Cost and cost analysis
329272|NCT01381497|presenteeism
329273|NCT01381497|migraine disorders
329274|NCT01381497|work productivity
329275|NCT01381497|triptan
329276|NCT01381497|sumatriptan and naproxen sodium
329277|NCT01381497|absenteeism
329278|NCT01381484|Periorbital wrinkles
329279|NCT01381484|Efficacy and safety
329280|NCT01381432|Antirejection
329281|NCT01381419|pharmacokinetics
329282|NCT01381419|safety
329283|NCT01381419|positron emission tomography (PET)
329284|NCT01381419|single ascending dose
329285|NCT01381393|osteoporosis
329286|NCT01381393|ibandronate
329287|NCT01381380|myofascial pain
329288|NCT01381380|trigger point injection
329289|NCT01381380|manual therapy
329290|NCT01381367|Chronic obstructive pulmonary disease
329291|NCT01381367|Inhaled corticosteroid
329292|NCT01381367|Pneumococcal vaccine
329293|NCT01381367|Acute exacerbation
329294|NCT01381367|High-dose daily inhaled corticosteroid usage
329295|NCT01381367|Efficacy of the PPSV23 pneumococcal vaccine
329296|NCT01381354|Secondary Progressive Multiple Sclerosis, primary progressive multiple sclerosis
329297|NCT01381328|HIV-1 infected patients
329298|NCT01381328|RALTEGRAVIR regimen
329299|NCT01381328|genotypic evaluations
329300|NCT01381328|phenotypic evaluations
329301|NCT01381315|Sentinel lymph node biopsy
329302|NCT01381315|Axillary lymph node dissection
329303|NCT01381315|Prevention of lymphedema
329304|NCT01381302|Severity of disease
329305|NCT01381276|Vitamin A
329306|NCT01381250|Pathological gambling according to DSM and having gambled at least once the past month.
329307|NCT01381250|Being atleast 18 years old
329308|NCT01381237|Balance
329309|NCT01381237|Postural
329310|NCT01381237|Rehabilitation
329311|NCT01381237|Therapy
329312|NCT01381237|computer-assisted
329313|NCT01381237|Video Games
329314|NCT01381237|Center of Pressure
329315|NCT01381224|low back pain
329316|NCT01381224|lumbar
329317|NCT01381224|injection
329318|NCT01381224|lumbar pain
329319|NCT01381211|Intermediate stage hepatocellular carcinoma
329320|NCT01381198|cerebral palsy
329321|NCT01381198|distal rectus femoris transfer
329322|NCT01381198|stiff knee gait pattern
329323|NCT01381198|gait analysis
329324|NCT01381198|single event multilevel surgery
329325|NCT01381198|randomized trial
329326|NCT01381198|crouch gait
329327|NCT01381185|myocardial infarction
329328|NCT01381185|percutaneous coronary intervention (PCI)
329329|NCT01381185|high platelet reactivity (HPR)
329330|NCT01381172|Heart Failure
329331|NCT01381172|Congestive Heart Failure
329332|NCT01381172|Chronic heart disease
329333|NCT01381172|Cardiac contractility modulation
329334|NCT01381172|CCM
329335|NCT01381172|CHF
329336|NCT01381159|Adherence
329337|NCT01381159|Asthma Control
329338|NCT01381159|Asthma Quality Of Life
329339|NCT01381159|Motivational Communication
329340|NCT01381159|Motivational Interviewing
329341|NCT01381146|criminal behavior
329342|NCT01381146|substance abuse
329343|NCT01381146|HIV risk behavior
329344|NCT01381146|criminogenic thinking
329345|NCT01381146|shame
329346|NCT01381146|guilt
329347|NCT01381146|empathy
329348|NCT01381146|jail inmates
329349|NCT01381146|restorative justice
329350|NCT01381146|Crime
329351|NCT01381133|Substance abuse
329352|NCT01381133|Adolescent outpatient treatment
329353|NCT01381133|Continuing care
329354|NCT01381133|Outcomes
329355|NCT01381120|Flank Pain
329356|NCT01381120|Lower Urinary Tract Symptoms
329357|NCT01381120|LUTS
329358|NCT01381120|Urgency
329359|NCT01381120|Nocturia
329360|NCT01381120|Frequency
329361|NCT01381120|Ureteroscopy
329362|NCT01381120|Kidney Stones
329363|NCT01381120|Stent
329364|NCT01381120|Incontinence
329365|NCT01381120|VESIcare
329366|NCT01381120|Ureter
329367|NCT01381120|Urinary Bladder, Overactive
329368|NCT01381120|OAB
329369|NCT01381120|Overactive Bladder Syndrome
329370|NCT01381094|anemia
329371|NCT01381094|chronic kidney disease
329372|NCT01381094|CKD
329373|NCT01381094|chronic renal insufficiency
329374|NCT01381094|renal impairment
329375|NCT01381094|erythropoietin
329376|NCT01381094|safety
329377|NCT01381094|efficacy
329378|NCT01381094|tolerability
329379|NCT01381094|pharmacokinetics
329380|NCT01381081|knee osteoarthritis
329381|NCT01381081|comparing platelet-rich plasma
329382|NCT01381081|intra-articular knee injections
329383|NCT01381068|ventilation
329384|NCT01381068|end tidal carbon dioxide
329385|NCT01381068|hypercapnia
329386|NCT01381068|hypocapnia
329387|NCT01381068|positive pressure ventilation
329388|NCT01381068|neonates
329389|NCT01381068|delivery room resuscitation
329390|NCT01381055|Cutaneous leishmaniasis
329391|NCT01381055|Pentoxifylline
329392|NCT01381055|Meglumine antimoniate
329393|NCT01381055|L. braziliensis
329394|NCT01381042|Brown Adipose Tissue
329395|NCT01381042|Incidence
329396|NCT01381042|Factor
329397|NCT01381042|Human
329398|NCT01381016|LH pulsatility
329399|NCT01381016|Obesity
329400|NCT01381016|Reproduction
329401|NCT01381003|Chronic Granulomatous Disease
329402|NCT01381003|Gene therapy
329403|NCT01381003|X-CGD
329404|NCT01381003|NADPH-oxidase
329405|NCT01381003|gp91-phox
329406|NCT01380977|crime
329407|NCT01380977|substance abuse
329408|NCT01380977|HIV risk
329409|NCT01380977|criminogenic thinking
329410|NCT01380977|shame
329411|NCT01380977|guilt
329412|NCT01380977|restorative justice
329413|NCT01380977|victim impact group
329414|NCT01380964|Duchenne Muscular Dystrophy
329415|NCT01380964|biomarkers
329416|NCT01380964|transcriptomics
329417|NCT01380964|mironics
329418|NCT01380964|proteomics
329419|NCT01380951|liver cirrhosis
329420|NCT01380951|chronic hepatitis B
329421|NCT01380951|antiviral therapy
329422|NCT01380951|telbivudine
329423|NCT01380938|genotypes 2 and 3
329424|NCT01380938|combination treatment
329425|NCT01380938|individualized treatment
329426|NCT01380912|breast cancer
329427|NCT01380912|mastectomy
329428|NCT01380912|methylprednisoloneacetate
329429|NCT01380912|seroma
329430|NCT01380912|numbers of punctures
329431|NCT01380899|Parkinson Disease
329432|NCT01380899|Parkinsonian Disorders
329433|NCT01380899|Lewy Bodies
329434|NCT01380899|alpha-Synuclein
329435|NCT01380860|mesh
329436|NCT01380860|hernia
329437|NCT01380847|Kidney Transplantation
329438|NCT01380847|Allograft
329439|NCT01380847|Kidney failure
329440|NCT01380847|Chronic allograft nephropathy
329441|NCT01380847|Monitoring
329442|NCT01380847|Urine
329443|NCT01380834|paravertebral nerve blocks
329444|NCT01380834|laparoscopic cholecystectomy
329445|NCT01380821|clinical indication for myocardial SPECT
329446|NCT01380821|suspected or known coronary artery disease
329447|NCT01380795|non-small cell lung cancer carcinoma
329448|NCT01380795|circulating tumor cells
329449|NCT01380795|EGFR
329450|NCT01380795|K-ras
329451|NCT01380782|brain tumor
329452|NCT01380782|recurrent disease
329453|NCT01380756|Amgen
329454|NCT01380756|Phase 1
329455|NCT01380756|Clinical Trial
329456|NCT01380756|Aurora kinase inhibitor
329457|NCT01380756|Open label
329458|NCT01380756|Oncology
329459|NCT01380756|Hematology
329460|NCT01380743|Pompe disease
329461|NCT01380730|Hypercholesterolemia
329462|NCT01380730|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
329463|NCT01380704|Depression
329464|NCT01380678|bevacizumab
329465|NCT01380678|pterygium
329466|NCT01380678|treatment
329467|NCT01380678|elevation
329468|NCT01380665|Prevena
329469|NCT01380665|Incision
329470|NCT01380665|Management
329471|NCT01380665|System
329472|NCT01380665|total
329473|NCT01380665|knee
329474|NCT01380665|hip
329475|NCT01380665|replacement
329476|NCT01380665|Surgery
329477|NCT01380665|Negative
329478|NCT01380665|Pressure
329479|NCT01380665|dressing
329480|NCT01380665|KCI
329481|NCT01380652|COPD III/IV
329482|NCT01380652|Activity Monitoring
329483|NCT01380652|SenseWear
329484|NCT01380652|Vibration training
329485|NCT01380652|Galileo
329486|NCT01380652|Pulmonary rehabilitation
329487|NCT01380639|COPD III/IV
329488|NCT01380639|6-Minutes-Walking-Distance
329489|NCT01380639|Vibration training
329490|NCT01380639|Galileo
329491|NCT01380639|Pulmonary rehabilitation
329492|NCT01380626|alpha-1-antitrypsin-deficiency
329493|NCT01380626|COPD
329494|NCT01380626|exercise training
329495|NCT01380626|muscle biopsy
329496|NCT01380613|HIV
329497|NCT01380613|depression
329498|NCT01380613|drug use,
329499|NCT01380613|risk reduction
329500|NCT01380600|Vaccinia
329501|NCT01380600|Vaccinia Virus
329502|NCT01380600|JX-594
329503|NCT01380600|Jennerex
329504|NCT01380600|Colorectal Carcinoma
329505|NCT01380600|Colorectal cancer
329506|NCT01380600|Colon Cancer
329507|NCT01380600|Rectal Cancer
329508|NCT01380600|Pexa-Vec
329509|NCT01380587|ALL
329510|NCT01380587|XCL1
329511|NCT01380587|Cytokines
329512|NCT01380587|Prognosis
329513|NCT01380574|atrial fibrillation
329514|NCT01380574|cardioversion
329515|NCT01380574|stroke
329516|NCT01380574|thromboembolism
329517|NCT01380561|asimadoline
329518|NCT01380561|pharmacokinetic
329519|NCT01380561|excretion of 14C-derived radioactivity
329520|NCT01380561|metabolite profile
329521|NCT01380561|14C-asimadoline
329522|NCT01380561|metabolites
329523|NCT01380561|single and multiple oral doses
329524|NCT01380535|Extracorporeal photopheresis therapy
329525|NCT01380535|Methoxsalen
329526|NCT01380535|UVADEX
329527|NCT01380535|Chronic graft versus host disease (cGvHD): National Institute Health Consensus Criteria
329528|NCT01380522|Bioequivalence, single-dose, fed
329529|NCT01380509|Bioequivalence, single-dose, fasting
329530|NCT01380496|bioequivalence
329531|NCT01380496|doxycycline monohydrate
329532|NCT01380496|fed
329533|NCT01380483|bioequivalence
329534|NCT01380483|doxycycline monohydrate
329535|NCT01380483|fasting
329536|NCT01380470|Chronic Obstructive Pulmonary Disease
329537|NCT01380470|Diagnosis differential
329538|NCT01380470|Dyspnea/classification
329539|NCT01380470|Dyspnea/etiology
329540|NCT01380457|bioequivalence
329541|NCT01380457|dronabinol
329542|NCT01380457|fasting
329543|NCT01380444|Intertrochanteric fracture
329544|NCT01380444|Gamma3 intramedullary nail
329545|NCT01380444|Sliding hip screw
329546|NCT01380431|bioequivalence, lisinopril, fed
329547|NCT01380418|Obesity
329548|NCT01380405|Inhalators
329549|NCT01380405|Education
329550|NCT01380405|Primary care
329551|NCT01380392|Liver cancer
329552|NCT01380392|Uncertainty
329553|NCT01380392|Personality
329554|NCT01380392|coping strategies
329555|NCT01380379|physical violence
329556|NCT01380379|sexual violence
329557|NCT01380366|Malabsorption
329558|NCT01380353|Women undergoing total mastectomy
329559|NCT01380353|Breast cancer prevention
329560|NCT01380340|Seniors
329561|NCT01380340|Driving
329562|NCT01380340|Group work
329563|NCT01380327|cockroach
329564|NCT01380327|immunotherapy
329565|NCT01380327|sublingual immunotherapy (SLIT)
329566|NCT01380327|inner city asthma
329567|NCT01380314|leishmaniasis
329568|NCT01380314|cutaneois leishmaniasis
329569|NCT01380314|miltefosine
329570|NCT01380314|oral therapy
329571|NCT01380314|treatment
329572|NCT01380314|imiquimod
329573|NCT01380301|Leishmaniasis
329574|NCT01380301|Miltefosine
329575|NCT01380301|Antimony
329576|NCT01380301|Therapy
329577|NCT01380288|Alzheimer's disease
329578|NCT01380288|rivastigmine patch
329579|NCT01380288|white matter change
329580|NCT01380275|recurrent, refractory, bone, soft tissue, sarcomas
329581|NCT01380262|Colorectal Cancer
329582|NCT01380262|Skin Rash
329583|NCT01380262|Pre-emptive treatment
329584|NCT01380262|Doxycycline
329585|NCT01380262|Anti-EGFR antibody
329586|NCT01380262|Cetuximab
329587|NCT01380262|Panitumumab
329588|NCT01380249|Phase I
329589|NCT01380249|Phase I multiple doses
329590|NCT01380249|PDM08
329591|NCT01380249|Cancer Treatment
329592|NCT01380249|Pharmacokinetics and Pharmacodynamics
329593|NCT01380249|Advanced Solid Tumors
329594|NCT01380249|Prodimed
329595|NCT01379443|Children
329596|NCT01379443|Rehabilitation
329597|NCT01379443|Family Functioning
329598|NCT01379443|Mental Health
329599|NCT01379443|Costs
329600|NCT01379443|Integration
329601|NCT01379430|Vaccine
329602|NCT01379430|Immune response
329603|NCT01379417|Prematurity
329604|NCT01379417|Nutrition
329605|NCT01379417|Growth
329606|NCT01379404|sepsis, fluid status, BIA, CVP
329607|NCT01379391|Allogeneic Hematopoietic Stem Cell Transplantation
329608|NCT01379391|Platelet Engraftment
329609|NCT01379391|TPO
329610|NCT01379365|wrinkle rhytid aging
329611|NCT01379352|liver transplantation
329612|NCT01379352|vecuronium
329613|NCT01379339|Cabazitaxel
329614|NCT01379339|Cabazitaxel and Cisplatin
329615|NCT01379339|Phase I
329616|NCT01379339|PF Induction Chemotherapy
329617|NCT01379339|Squamous Cell Carcinoma
329618|NCT01379339|Head and Neck
329619|NCT01379339|Sanofi-Aventis Oncology
329620|NCT01379339|Locally Advanced
329621|NCT01379313|laparoscopic gynecologic surgery
329622|NCT01379313|gas exchange
329623|NCT01379313|inspiratory time
329624|NCT01379313|expiratory time
329625|NCT01379313|I:E ratio
329626|NCT01379300|Hemophilia B
329627|NCT01379287|Iso-Fludelone
329628|NCT01379287|KOS-1803
329629|NCT01379287|Dose-Escalation
329630|NCT01379287|10-202
329631|NCT01379274|MDS
329632|NCT01379274|Low risk disease
329633|NCT01379274|IPSS
329634|NCT01379261|STEMI
329635|NCT01379261|primary PCI
329636|NCT01379261|Hypothermia
329637|NCT01379261|Endovascular cooling
329638|NCT01379261|Cardiac MRI
329639|NCT01379235|independent 65 years old and above
329640|NCT01379222|AAA
329641|NCT01379222|Abdominal Aortic Aneurysm
329642|NCT01379222|EVAR
329643|NCT01379222|Endovascular aneurysm repair
329644|NCT01379209|AHSCT
329645|NCT01379209|Bone Marrow Transplant
329646|NCT01379209|Leukemia
329647|NCT01379209|myelodysplastic syndrome
329648|NCT01379209|hematological malignancies
329649|NCT01379209|Graft-versus-host-disease
329650|NCT01379209|GvHD
329651|NCT01379209|Hematopoietic Stem Cell Transplantation
329652|NCT01379209|Stem Cell
329653|NCT01379209|Transplantation
329654|NCT01379196|Graves Orbitopathy
329655|NCT01379196|Macrolide antibiotics
329656|NCT01379196|Inflammation
329657|NCT01379196|Clinical Activity Score
329658|NCT01379183|Healthy
329659|NCT01379183|Men
329660|NCT01379183|Women
329661|NCT01379183|No known gastrointestinal disease
329662|NCT01379183|Aged between 18-70 years
329663|NCT01379170|brown adipose tissue
329664|NCT01379170|mitochondrial dysfunction
329665|NCT01379170|insulin resistance
329666|NCT01380210|Carbon dioxide intoxication
329667|NCT01380210|Diffusion weighted images(DWI)
329668|NCT01380197|pain
329669|NCT01380197|sickle cell
329670|NCT01380197|nubain
329671|NCT01380197|morphine
329672|NCT01380197|acute chest
329673|NCT01380197|side effects
329674|NCT01380184|Relapsed cancer
329675|NCT01380158|pessary
329676|NCT01380158|preterm birth
329677|NCT01380158|short cervix
329678|NCT01380158|cervical incompetence
329679|NCT01380145|multiple myeloma
329680|NCT01380145|MAGE-A3
329681|NCT01380145|autologous stem cell transplant
329682|NCT01380132|Fecal incontinence
329683|NCT01380132|Treatment
329684|NCT01380132|Surgery
329685|NCT01380119|sputum conversion
329686|NCT01380119|liver biochemistry
329687|NCT01380119|weight loss
329688|NCT01380119|quality of life
329689|NCT01380106|Multiple myeloma
329690|NCT01380106|Relapsed
329691|NCT01380106|Revlimid
329692|NCT01380093|abuse potential
329693|NCT01380093|abuse liability
329694|NCT01380093|recreational opioid use
329695|NCT01380093|morphine
329696|NCT01380067|Inguinal hernia
329697|NCT01380067|Lateral umbilicus ligament
329698|NCT01380067|Recurrence
329699|NCT01380054|Pulmonary Hypertension
329700|NCT01380054|Quality of life
329701|NCT01380054|Coping
329702|NCT01380054|Depression
329703|NCT01380054|Anxiety
329704|NCT01380054|Social support
329705|NCT01380054|Control beliefs
329706|NCT01380041|Multiple sclerosisCerebrospinal fluidBiomarkerCytokineArray
329707|NCT01380028|chronic subdural hematomas
329708|NCT01380028|corticosteroid
329709|NCT01380028|treatment
329710|NCT01380028|neurosurgery
329711|NCT01380028|recurrence, adjuvant
329712|NCT01380015|osteoarthritis
329713|NCT01380015|spearmint
329714|NCT01380015|rosmarinic acid
329715|NCT01380002|care needs
329716|NCT01379976|lung
329717|NCT01379976|cancer
329718|NCT01379976|non small cell lung cancer
329719|NCT01379976|Advanced or metastatic non small cell lung cancer
329720|NCT01379937|influenza
329721|NCT01379937|H5N1
329722|NCT01379937|vaccine
329723|NCT01379937|children
329724|NCT01379911|Satiety
329725|NCT01379911|Food intake
329726|NCT01379911|Yogurt
329727|NCT01379898|Pheochromocytoma
329728|NCT01379898|Doxazosin
329729|NCT01379898|Phenoxybenzamine
329730|NCT01379885|Pain
329731|NCT01379885|immunization
329732|NCT01379885|distraction
329733|NCT01379885|hypnosis
329734|NCT01379885|injections
329735|NCT01379885|anxiety
329736|NCT01379872|Prostate
329737|NCT01379872|Head and Neck
329738|NCT01379872|Anal
329739|NCT01379846|Immunostimulation
329740|NCT01379846|Haemophilus b conjugate vaccine
329741|NCT01379846|HIB
329742|NCT01379833|Chronic Inflammatory Demyelinating Polyneuropathy
329743|NCT01379833|Neurotrophic corneal ulcer
329744|NCT01379820|NEONATAL RESPIRATORY FAILURE
329745|NCT01379820|OROTRACHEAL cpap
329746|NCT01379820|NASAL cpap
329747|NCT01379820|MECHANICAL VENTILATION
329748|NCT01379820|PNEUMOTHORAX
329749|NCT01379820|COMPENSATION BAG
329750|NCT01379781|prevention
329751|NCT01379781|postpartum depression
329752|NCT01379755|stability
329753|NCT01379755|single-radius
329754|NCT01379755|multi-radius
329755|NCT01379755|total knee arthroplasty
329756|NCT01379742|prostate cancer
329757|NCT01379742|prostate brachytherapy
329758|NCT01379729|Type 1 Diabetes
329759|NCT01379729|Transplantation
329760|NCT01379729|Beta Cells
329761|NCT01379729|Encapsulation
329762|NCT01379703|HIV-1 infected patients
329763|NCT01379703|Protease inhibitor
329764|NCT01379703|Kaletra®
329765|NCT01379690|HbA1c
329766|NCT01379677|Coronary Artery Disease
329767|NCT01379677|Myocardial perfusion imaging
329768|NCT01379677|Rubidium
329769|NCT01379677|Technetium
329770|NCT01379664|Sevoflurane
329771|NCT01379664|Isoflurane
329772|NCT01379664|volatile anesthetic
329773|NCT01379664|duration of hospitalization
329774|NCT01379651|Egg allergy,specific oral tolerance induction
329775|NCT01379638|cardiopulmonary bypass
329776|NCT01379638|cardiac output
329777|NCT01379638|flow rate
329778|NCT01379638|lactate
329779|NCT01379625|fatty acid oxidation
329780|NCT01379625|triheptanoin
329781|NCT01379625|long-chain fatty acid oxidation disorders
329782|NCT01379625|LCHADD
329783|NCT01379625|VLCADD
329784|NCT01379625|CPT2
329785|NCT01379625|TFP
329786|NCT01379612|Ultrasound elastography
329787|NCT01379612|Rectal cancer
329788|NCT01379612|Preoperative chemoradiation
329789|NCT01379599|cocaine
329790|NCT01379599|heroin
329791|NCT01379599|STIs
329792|NCT01379599|HIV
329793|NCT01379599|brief motivational intervention
329794|NCT01379599|voluntary testing and counseling
329795|NCT01379586|ONO-4053
329796|NCT01379586|Healthy adult subjects
329797|NCT01379586|First time in humans
329798|NCT01379573|hydroxychloroquine
329799|NCT01379573|Plaquenil
329800|NCT01379573|congenital heart block
329801|NCT01379573|neonatal lupus
329802|NCT01379573|systemic lupus erythematosus
329803|NCT01379573|Sjogren's syndrome
329804|NCT01379573|autoantibodies
329805|NCT01379573|SSA/Ro
329806|NCT01379573|SSB/La
329807|NCT01379573|autoimmunity
329808|NCT01379573|pregnancy
329809|NCT01379573|immunoglobulin
329810|NCT01379547|Procalcitonin
329811|NCT01379547|sepsis
329812|NCT01379547|ICU
329813|NCT01379547|antibiotic
329814|NCT01379547|antibiotic duration
329815|NCT01379547|Antibiotic treatment duration
329816|NCT01379534|Solid tumors,
329817|NCT01379534|advanced endometrial cancer,
329818|NCT01379534|Endometrial Cancer,
329819|NCT01379534|Second-line treatment,
329820|NCT01379534|VEGF,
329821|NCT01379534|Neoplasms,
329822|NCT01379534|Endometrial Neoplasms,
329823|NCT01379534|Uterine Neoplasms,
329824|NCT01379534|Female Genital Neoplasms,
329825|NCT01379534|Cancer,
329826|NCT01379534|Carcinoma,
329827|NCT01379534|Uterine Diseases,
329828|NCT01379534|Female Genital Diseases,
329829|NCT01379534|Tumors,
329830|NCT01379534|Oral Administration,
329831|NCT01379534|Capsules,
329832|NCT01379534|Tablets,
329833|NCT01379534|CHIR258,
329834|NCT01379534|CHIR-258,
329835|NCT01379534|CHIR 258,
329836|NCT01379534|TKI258,
329837|NCT01379534|TKI-258,
329838|NCT01379534|TKI 258
329839|NCT01379521|Localised
329840|NCT01379521|unresectable
329841|NCT01379521|chemoembolization
329842|NCT01379495|burns
329843|NCT01379495|rehabilitation
329844|NCT01379482|Peritoneal carcinomatosis from gastric cancer
329845|NCT01379469|Carbamazepine (Tegretol) use
329846|NCT01379469|severe liver disease
329847|NCT01379469|alpha-1-antitrypsin deficiency
329848|NCT01379157|Patients with ventilator-associated pneumonia
329849|NCT01379131|Manifestation
329850|NCT01379131|Coronary Heart Disease
329851|NCT01379131|Myocardial infarction
329852|NCT01379131|Angina pectoris
329853|NCT01379131|Unheralded
329854|NCT01379131|General Practice Research Database
329855|NCT01379131|Myocardial Ischaemia National Audit Project
329856|NCT01379131|CALIBER
329857|NCT01379118|Total knee replacement
329858|NCT01379105|Electromyography
329859|NCT01379105|Muscle Stretching Exercises
329860|NCT01379105|Neuromuscular agents
329861|NCT01379105|Sedentary Lifestyle
329862|NCT01379092|Radiography
329863|NCT01379092|Breast Specimen Imaging
329864|NCT01379066|Mycobacterium tuberculosis
329865|NCT01379066|Pulmonary tuberculosis
329866|NCT01379066|Electronic nose
329867|NCT01379066|Gas chromatography
329868|NCT01379053|Staphylococcus aureus
329869|NCT01379053|Methicillin-resistant staphylococcus aureus
329870|NCT01379053|Nosocomial disease
329871|NCT01379053|Electronic nose
329872|NCT01379053|Gas chromatography
329873|NCT01379040|Cystic Fibrosis
329874|NCT01379040|Pseudomonas aeruginosa
329875|NCT01379040|Volatile Organic Compounds
329876|NCT01379040|Electronic nose
329877|NCT01379040|Gas Chromatography
329878|NCT01379027|Depression
329879|NCT01379027|Website intervention
329880|NCT01379027|CBT
329881|NCT01379014|Decisional conflict
329882|NCT01379014|Disclosure
329883|NCT01379014|Mental Health history
329884|NCT01379014|Mental health service users
329885|NCT01379014|Decision Aid Tool
329886|NCT01379014|Vocational Specialists
329887|NCT01379001|cholinergic function
329888|NCT01379001|aging
329889|NCT01379001|pharmacologic MRI
329890|NCT01378949|pain score
329891|NCT01378936|criminal behavior
329892|NCT01378936|substance abuse
329893|NCT01378936|HIV risk behavior
329894|NCT01378936|criminogenic thinking
329895|NCT01378936|shame
329896|NCT01378936|guilt
329897|NCT01378936|empathy
329898|NCT01378936|jail inmates
329899|NCT01378936|restorative justice
329900|NCT01378936|crime
329901|NCT01378923|Mindfulness
329902|NCT01378923|Values
329903|NCT01378923|Jail Inmates
329904|NCT01378923|Impulsivity
329905|NCT01378923|Substance Abuse
329906|NCT01378923|HIV risk behavior
329907|NCT01378923|Anxiety
329908|NCT01378923|Depression
329909|NCT01378923|Criminogenic Thinking
329910|NCT01378910|HIV
329911|NCT01378910|TROPISM
329912|NCT01378910|PBMC
329913|NCT01378910|GENOTYPE
329914|NCT01378910|454 SEQUENCING
329915|NCT01378897|bariatric surgery
329916|NCT01378897|gastric bypass surgery
329917|NCT01378884|Gastroparesis
329918|NCT01378884|Domperidone
329919|NCT01378884|Motilium
329920|NCT01378871|T Cell
329921|NCT01378871|T-Cell
329922|NCT01378871|Leukemia
329923|NCT01378871|Lymphoma
329924|NCT01378871|Leukemia/Lymphoma
329925|NCT01378871|ATL
329926|NCT01378858|Smoking
329927|NCT01378858|Substance-Related Disorders
329928|NCT01378858|medication adherence
329929|NCT01378858|Methadone
329930|NCT01378845|Morbus Raynaud
329931|NCT01378845|Ulcera Hands, Toes
329932|NCT01378845|Vasospastic disorder
329933|NCT01378845|Raynaud's phenomenon
329934|NCT01378832|Intra-abdominal abscess
329935|NCT01378832|wound infection
329936|NCT01378832|colorectal surgery
329937|NCT01378819|laparoscopic cholecystectomy
329938|NCT01378819|Postoperative pain
329939|NCT01378806|overweight
329940|NCT01378806|obesity
329941|NCT01378806|adults
329942|NCT01378806|children
329943|NCT01378793|Acupressure
329944|NCT01378793|Insomnia
329945|NCT01378793|Sleep Disorders
329946|NCT01378780|Stroke
329947|NCT01378780|hypertension
329948|NCT01378780|diet
329949|NCT01378780|sodium
329950|NCT01378780|physical activity
329951|NCT01378767|Dietary restriction
329952|NCT01378767|oxidative stress
329953|NCT01378767|fasting
329954|NCT01378754|hydrodilation
329955|NCT01378754|general anesthetic
329956|NCT01378741|delirium
329957|NCT01378741|cardiac surgery
329958|NCT01378741|postoperative sedation
329959|NCT01378728|Optical imaging
329960|NCT01378728|Fluorescence imaging
329961|NCT01378728|Chronic and acute wounds
329962|NCT01378728|Wound bacteria
329963|NCT01378728|Bacterial biofilms
329964|NCT01378728|Pathogenic bacteria
329965|NCT01378728|Microorganisms
329966|NCT01378728|Wound infection
329967|NCT01378728|Wound healing
329968|NCT01378728|Treatment response assessment
329969|NCT01378715|coronary artery disease
329970|NCT01378715|percutaneous coronary intervention
329971|NCT01378715|statins
329972|NCT01378715|periprocedural myocardial infarction
329973|NCT01378702|Mistletoe
329974|NCT01378702|Anthroposophical medicine
329975|NCT01378663|Congenital cardiac surgery
329976|NCT01378663|Postoperative pain management
329977|NCT01378650|Tinnitus
329978|NCT01378650|Medication therapy management
329979|NCT01378650|Cilostazol
329980|NCT01378650|Antiplatelet agents
329981|NCT01378637|Leg
329982|NCT01378637|Robotic device
329983|NCT01378637|AMES
329984|NCT01378637|Stroke
329985|NCT01378637|Cerebrovascular Accident
329986|NCT01378637|Rehabilitation
329987|NCT01378611|intractable childhood epilepsy
329988|NCT01378611|VNS
329989|NCT01378611|immune system
329990|NCT01378598|erlotinib
329991|NCT01378598|educational intervention
329992|NCT01378598|direct care nurse
329993|NCT01378585|DLBS1033
329994|NCT01378585|safety
329995|NCT01378585|fibrinolytic
329996|NCT01378585|fibrinogenolytic
329997|NCT01378585|antiplatelet
329998|NCT01378572|ICD
329999|NCT01378572|sudden cardiac death
330000|NCT01378572|mapping
330001|NCT01378559|Penis prosthesis
330002|NCT01378559|Titan
330003|NCT01378559|Satisfaction
330004|NCT01378559|Complications
330005|NCT01378533|triple-negative breast cancer
330006|NCT01378533|dose-dense
330007|NCT01378533|epirubicin and cyclophosphamide followed by paclitaxel（AC-T）
330008|NCT01378533|paclitaxel plus carboplatin（PC）
330009|NCT01378533|3 years DFS
330010|NCT01378533|the tolerance
330011|NCT01378520|breathlessness
330012|NCT01378520|resistive load breathing
330013|NCT01378520|beta-endorphins
330014|NCT01378507|endoscopic submucosal dissection
330015|NCT01378507|gastrointestinal neoplasm
330016|NCT01378494|osteoporosis
330017|NCT01378494|bone
330018|NCT01378494|HIV
330019|NCT01378494|antiretrovirals
330020|NCT01378494|inflammation
330021|NCT01378455|handwriting
330022|NCT01378455|cerebral palsy
330023|NCT01378455|visual perception
330024|NCT01378455|sensory function
330025|NCT01378455|motor function
330026|NCT01378455|computerized handwriting programs
330027|NCT01378442|Cerebral palsy
330028|NCT01378442|bone density
330029|NCT01378442|bone strength
330030|NCT01378429|Perennial Allergic Rhinitis
330031|NCT01378429|PAR
330032|NCT01378416|Acute myelogenous leukemia
330033|NCT01378416|myelodysplastic Syndrome
330034|NCT01378416|cancer
330035|NCT01378403|Schizophrenia
330036|NCT01378403|Cognitive deficites
330037|NCT01378403|Degraded objects
330038|NCT01378403|Magnocellular pathway
330039|NCT01378390|Complex perianal fistula
330040|NCT01378390|Crohn disease
330041|NCT01378390|Adipose-derived stem cells
330042|NCT01378390|Liposuction
330043|NCT01378377|MEK inhibitor
330044|NCT01378377|Temsirolimus
330045|NCT01378377|Solid Tumor
330046|NCT01378377|Phase I
330047|NCT01378377|Pimasertib
330048|NCT01378338|GERD
330049|NCT01378338|Comparison between ERD and NERD
330050|NCT01378338|Rate of complete resolution
330051|NCT01378338|rate of recurrence
330052|NCT01378338|QOL
330053|NCT01378338|To investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI
330054|NCT01378338|The aim of this study is to investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI
330055|NCT01378325|spinal
330056|NCT01378325|cesarean delivery
330057|NCT01378325|phenylephrine
330058|NCT01378325|hypotension
330059|NCT01378312|vaccine
330060|NCT01378312|TB
330061|NCT01378312|tuberculosis
330062|NCT01378299|testosterone
330063|NCT01378273|neuroprotection
330064|NCT01378273|erythropoietin
330065|NCT01378273|Epo
330066|NCT01378273|ELGANs
330067|NCT01378273|preterm
330068|NCT01378273|neonate
330069|NCT01378260|Peripheral Arterial Disease
330070|NCT01378260|Claudication
330071|NCT01378260|Comparative Effectiveness Research
330072|NCT01378260|PAD Study
330073|NCT01378260|PAD
330074|NCT01378260|atherosclerosis
330075|NCT01378260|Intermittent claudication
330076|NCT01378260|leg pain
330077|NCT01378247|Heart Failure
330078|NCT01378247|Family Nursing
330079|NCT01378247|Health-Related Quality of Life
330080|NCT01378247|Heart Failure Clinic
330081|NCT01378221|vitamin D
330082|NCT01378221|cardiac surgery
330083|NCT01378221|inflammation
330084|NCT01378221|immune system
330085|NCT01378221|age
330086|NCT01378208|Intermittent fasting
330087|NCT01378208|Meal frequency
330088|NCT01378208|body composition
330089|NCT01378208|cognitive function
330090|NCT01378208|glucose metabolism
330091|NCT01378195|Alzheimer's Disease
330092|NCT01378195|Dementia
330093|NCT01378195|caregiving
330094|NCT01378195|caregiver
330095|NCT01378195|coping
330096|NCT01378195|coping with caregiving
330097|NCT01378195|stress
330098|NCT01378182|Transplantation,Stem Cell
330099|NCT01378182|Wilson's Disease
330100|NCT01378169|SIRS
330101|NCT01378169|Sepsis
330102|NCT01378169|Severe Sepsis
330103|NCT01378169|Septic Shock
330104|NCT01378169|Inflammatory processes
330105|NCT01378169|Cytokines
330106|NCT01378169|HLA-DR
330107|NCT01378169|HLA type II
330108|NCT01378169|Chemokines
330109|NCT01378169|TLR expression
330110|NCT01378169|mRNA expression in whole blood
330111|NCT01378169|Bacterial DNA detection
330112|NCT01378169|Prognosis factors
330113|NCT01378169|Infection
330114|NCT01378169|Diagnosis
330115|NCT01378156|Therapy for HIV Infection
330116|NCT01378156|Suppressive ART with no failures
330117|NCT01378156|Treatment interruption
330118|NCT01378143|Colorectal Cancer
330119|NCT01378143|Pentamidine bis(2-hydroxyethanesulfonate)
330120|NCT01378143|OCZ103-OS
330121|NCT01378143|Standard of Care
330122|NCT01378130|CCS
330123|NCT01378130|CSC
330124|NCT01378130|Subretinal Fluid
330125|NCT01378130|multimodal imaging
330126|NCT01378117|diabetes
330127|NCT01378117|non critical care setting
330128|NCT01378117|hyperglycemia
330129|NCT01378117|treatment
330130|NCT01378117|oral antidiabetic agents
330131|NCT01378117|subcutaneous insulin
330132|NCT01378104|reducing dose of peginterferon
330133|NCT01378104|chronic hepatitis c
330134|NCT01378104|Koreans
330135|NCT01378104|IL28B polymorphism
330136|NCT01378091|Androgen Independent Prostate Cancer
330137|NCT01378078|schizophrenia
330138|NCT01378078|negative syndrome
330139|NCT01378078|PANSS
330140|NCT01378065|POP
330141|NCT01378065|pelvic organ prolapse
330142|NCT01378065|anterior prolapse
330143|NCT01378065|posterior prolapse
330144|NCT01378065|vaginal prolapse
330145|NCT01378065|vaginal floor reconstruction
330146|NCT01378039|COPD
330147|NCT01378039|Asthma
330148|NCT01378039|Pathophysiology
330149|NCT01378039|Genetics
330150|NCT01378039|Phenotype
330151|NCT01378039|Treatment response
330152|NCT01378026|Amyotrophic Lateral Sclerosis
330153|NCT01378026|G72
330154|NCT01378026|SNP
330155|NCT01378013|Metabonomics
330156|NCT01378013|Systems biology
330157|NCT01378013|Intelligent knife
330158|NCT01378013|Colorectal cancer
330159|NCT01378013|NMR
330160|NCT01378013|Mass spectrometry
330161|NCT01377974|Leishmaniasis
330162|NCT01377974|Mucocutaneous Leishmaniasis
330163|NCT01377974|Therapeutics
330164|NCT01377974|meglumine antimoniate
330165|NCT01377974|miltefosine
330166|NCT01377948|Anger
330167|NCT01377948|Aggression
330168|NCT01377948|CBT
330169|NCT01377948|Videogame
330170|NCT01377948|biofeedback
330171|NCT01377909|chronic hepatitis C, interferon
330172|NCT01377883|Needle, Anxiety, Pain, Clowns
330173|NCT01377870|multiple sclerosis mesenchymal stem cell intravenous injection
330174|NCT01377844|Diabetes mellitus
330175|NCT01377818|COPD
330176|NCT01377818|Exercise trainig
330177|NCT01377805|Multiple Sclerosis hydrocephalus
330178|NCT01377792|hypertonic saline
330179|NCT01377792|cystic fibrosis
330180|NCT01377792|pulmonary inflammation
330181|NCT01377792|pulmonary exacerbation
330182|NCT01377779|Oxiplex/AP gel
330183|NCT01377779|Prevention of Asherman's syndrome
330184|NCT01377779|Intra uterine adhesions
330185|NCT01377766|Bell's palsy
330186|NCT01377766|psychological stress
330187|NCT01377766|personality factors
330188|NCT01377766|psychological factors
330189|NCT01377753|Toxicity
330190|NCT01377753|Thermal Ablation/Damage
330191|NCT01377753|Localized Prostate Cancer
330192|NCT01377753|Laser Ablation
330193|NCT01377753|PSA Levels
330194|NCT01377753|Prostate Cancer
330195|NCT01377740|Lipolysis
330196|NCT01377740|Cryolipolysis
330197|NCT01377740|Fat Reduction
330198|NCT01377701|pituitary adenomas
330199|NCT01377701|recovery of vision
330200|NCT01377701|trans-sphenoidal surgery
330201|NCT01377688|DKD
330202|NCT01377636|Isoproterenol
330203|NCT01377636|Bispectral index (BIS)
330204|NCT01377636|electrophysiology studies (EPS)
330205|NCT01377623|Spinal fusion
330206|NCT01377623|Inflammatory response
330207|NCT01377623|Inflammatory markers
330208|NCT01377623|Dexmedetomidine
330209|NCT01377610|Outpatient detoxification
330210|NCT01377610|Opioid dependence
330211|NCT01377610|Naltrexone
330212|NCT01377610|Vivitrol
330213|NCT01377610|Buprenorphine
330214|NCT01377597|retinal vein occlusion
330215|NCT01377597|branch retinal vein occlusion
330216|NCT01377597|central retinal vein occlusion
330217|NCT01377597|visual impairment
330218|NCT01377597|macular edema
330219|NCT01377597|ranibizumab
330220|NCT01377584|Continuous Positive Airway Pressure
330221|NCT01377584|Patient Compliance
330222|NCT01377584|Intervention Studies
330223|NCT01377584|Spouses
330224|NCT01377571|diarrhea
330225|NCT01377571|fever
330226|NCT01377571|nausea
330227|NCT01377571|vomit
330228|NCT01377571|irritability
330229|NCT01377558|aerobic training
330230|NCT01377558|resistance training
330231|NCT01377558|combination of aerobic and resistance training
330232|NCT01377558|diabetes
330233|NCT01377558|type 2 diabetes
330234|NCT01377558|HbA1c
330235|NCT01377558|endothelial dysfunction
330236|NCT01377558|inflammation markers
330237|NCT01377558|Parodontitis
330238|NCT01377558|Exercise intervention
330239|NCT01377558|training
330240|NCT01377545|Infraclavicular
330241|NCT01377545|Nerve Block
330242|NCT01377545|Needle
330243|NCT01377545|Perineural Catheter
330244|NCT01377545|Volunteer
330245|NCT01377545|Upper Extremity Nerve Block
330246|NCT01377545|Sensation
330247|NCT01377545|Strength
330248|NCT01377532|Pheochromocytoma
330249|NCT01377532|Paraganglioma
330250|NCT01377532|MIBG
330251|NCT01377532|131I-MIBG
330252|NCT01377532|Resistant
330253|NCT01377532|Relapsed
330254|NCT01377532|Treatment
330255|NCT01377532|UCSF
330256|NCT01377532|Pediatric
330257|NCT01377532|Adult
330258|NCT01377532|Oncology
330259|NCT01377519|Fibroids
330260|NCT01377519|Uterine
330261|NCT01377519|Focused Ultrasound
330262|NCT01377519|Magnetic Resonance focused ultrasound
330263|NCT01377519|HIFU
330264|NCT01377519|NOninvasive
330265|NCT01377519|Treatment
330266|NCT01377506|behavioral weight control
330267|NCT01377506|lifestyle intervention
330268|NCT01377506|memory training
330269|NCT01377506|cognitive training
330270|NCT01377506|community-based
330271|NCT01377493|chewing-gum
330272|NCT01377493|enamel subsurface lesion
330273|NCT01377493|calcium additives
330274|NCT01377493|fluoride
330275|NCT01377493|in situ
330276|NCT01377467|Osteoporosis
330277|NCT01377467|Osteopenia
330278|NCT01377467|Denosumab
330279|NCT01377467|Transplantation
330280|NCT01377467|Kidney
330281|NCT01377454|mTBI
330282|NCT01377454|concussion
330283|NCT01377454|mild Traumatic Brain Injury
330284|NCT01377454|balance
330285|NCT01377454|sensors
330286|NCT01377441|Ibuprofen
330287|NCT01377441|Cytokines
330288|NCT01377441|Recovery
330289|NCT01377441|IV ibuprofen
330290|NCT01377441|major surgery
330291|NCT01377428|COPD
330292|NCT01377428|Indacaterol
330293|NCT01377428|Formoterol
330294|NCT01377415|arthroscopy
330295|NCT01377415|shoulder surgery
330296|NCT01377415|subacromial
330297|NCT01377415|continuous bupivacaine
330298|NCT01377389|Prostate cancer
330299|NCT01377389|Castrate sensitive prostate carcinoma
330300|NCT01377389|Metastatic prostate carcinoma
330301|NCT01377389|Androgen deprivation therapy
330302|NCT01377389|ADT
330303|NCT01377389|Prostate-specific antigen
330304|NCT01377389|PSA
330305|NCT01377389|Ipilimumab
330306|NCT01377389|Yervoy
330307|NCT01377389|BMS-734016
330308|NCT01377389|MDX010
330309|NCT01377389|Leuprolide
330310|NCT01377389|Lupron Depot
330311|NCT01377389|Leuprolide Acetate
330312|NCT01377389|Goserelin
330313|NCT01377389|Zoladex
330314|NCT01377389|Degarelix
330315|NCT01377389|Firmagon
330316|NCT01377363|metastatic breast cancer
330317|NCT01377363|primary breast cancer
330318|NCT01377350|Heart failure
330319|NCT01377350|monitoring
330320|NCT01377337|cardiac arrest
330321|NCT01377337|cardiopulmonary resuscitation
330322|NCT01377337|(sodium) bicarbonate
330323|NCT01377337|return of spontaneous circulation
330324|NCT01377337|outcome
330325|NCT01377324|Breast cancer
330326|NCT01377324|Fulvestrant
330327|NCT01377324|FES
330328|NCT01377324|PET
330329|NCT01377324|Positron
330330|NCT01377324|Emission
330331|NCT01377324|Tomography
330332|NCT01377324|Fluoroestradiol
330333|NCT01377324|FES-PET
330334|NCT01377324|Molecular Imaging
330335|NCT01377324|Estrogen Receptor
330336|NCT01377311|limbal stem cell
330337|NCT01377311|amniotic membrane
330338|NCT01377311|ex vivo expansion of autologous limbal stem cell
330339|NCT01377311|unilateral limbal stem cell insufficiency
330340|NCT01377285|chronic kidney disease
330341|NCT01377285|pentoxifylline
330342|NCT01377285|angiotensin receptor blockers(ARB)
330343|NCT01377272|HIV/AIDS
330344|NCT01377272|spatial epidemiology
330345|NCT01377272|geographic information system
330346|NCT01377272|HIV-infection/Aids
330347|NCT01377259|changes
330348|NCT01377259|tissue
330349|NCT01377259|oxygenation
330350|NCT01377259|saturation
330351|NCT01377259|between
330352|NCT01377259|upper
330353|NCT01377259|lower
330354|NCT01377259|extremities
330355|NCT01377259|patients
330356|NCT01377259|Adverse Effect
330357|NCT01377259|Spinal and Epidural
330358|NCT01377246|Somatostatin.
330359|NCT01377246|Polycystic kidney disease.
330360|NCT01377246|Renal insufficiency.
330361|NCT01377233|Schizophrenia
330362|NCT01377233|Antipsychotic
330363|NCT01377233|Zicronapine
330364|NCT01377233|Lu 31-310
330365|NCT01377220|Hepatocellular carcinoma
330366|NCT01377220|Positron Emission Tomography/computed tomography (PET-CT)
330367|NCT01377220|11C-Choline
330368|NCT01377220|alpha fetoprotein
330369|NCT01377220|Dynamic magnetic resonance imaging
330370|NCT01377220|Abdomen computed tomography
330371|NCT01377220|Tumoral liver biopsy
330372|NCT01377207|ST segment Elevation Myocardial Infarction
330373|NCT01377207|Optical Coherence Tomography
330374|NCT01377207|Percutaneous Coronary Intervention
330375|NCT01377207|Thrombus hystopathology
330376|NCT01377207|Gender differences
330377|NCT01377194|Depression
330378|NCT01377194|Major Depressive Disorder
330379|NCT01377181|Inguinal hernia
330380|NCT01377181|Laparoscope
330381|NCT01377181|Lateral us ligament
330382|NCT01377181|Recurrence
330383|NCT01377181|Pediatric
330384|NCT01377181|unilateral inguinal hernia
330385|NCT01377155|basal insulin
330386|NCT01377155|hypoglycemia
330387|NCT01377155|diabetes mellitus type two
330388|NCT01377142|Uterovaginal prolapse
330389|NCT01377142|hysteropexy
330390|NCT01377142|mesh
330391|NCT01377129|Residual Rotational Laxity
330392|NCT01377103|heart failure
330393|NCT01377103|hypogonadism
330394|NCT01377103|testosterone
330395|NCT01377077|vitiligo
330396|NCT01377077|piebaldism
330397|NCT01377077|punchgrafting
330398|NCT01377077|minigrafting
330399|NCT01377077|stable for at least 12 months
330400|NCT01377064|HIV
330401|NCT01377064|physical activity
330402|NCT01377064|cardiovascular disease risk
330403|NCT01377051|COPD
330404|NCT01377051|Inspiratory capacity
330405|NCT01377051|Residual volume
330406|NCT01377051|Total lung resistance
330407|NCT01377051|Arterial Oxygen
330408|NCT01377038|Osteoarthritis
330409|NCT01377038|Chronic pain
330410|NCT01377038|Central pain
330411|NCT01377012|Rheumatoid Arthritis
330412|NCT01377012|RA
330413|NCT01377012|ACR
330414|NCT01377012|inflammatory joints
330415|NCT01376999|Sterility
330416|NCT01376999|FSH-r
330417|NCT01376999|intrauterine insemination
330418|NCT01376999|unexplained sterility
330419|NCT01376973|stress, temporomandibular disorders.
330420|NCT01376960|forefoot surgery
330421|NCT01376960|Ankle Block
330422|NCT01376960|Popliteal Fossa Block
330423|NCT01376947|IUD device insertion
330424|NCT01376947|Nulliparous
330425|NCT01376947|Multiparous
330426|NCT01376947|Pain
330427|NCT01376934|hysteroscopy
330428|NCT01376934|saline solution
330429|NCT01376934|carbon dioxide
330430|NCT01376934|compare two techniques in office hysteroscopy co2 and saline solution
330431|NCT01376921|Growth disorders
330432|NCT01376921|Saizen
330433|NCT01376921|Easypod
330434|NCT01376921|Growth hormone
330435|NCT01376921|Pediatric subject
330436|NCT01376908|Phenylketonuria (PKU)
330437|NCT01376908|Kuvan® (Sapropterin)
330438|NCT01376908|Phe-restricted diet
330439|NCT01376908|Paediatric <4 years old
330440|NCT01376908|responders to BH4
330441|NCT01376908|Phe tolerance
330442|NCT01376895|Black MSM/W
330443|NCT01376895|HIV
330444|NCT01376882|Caffeine
330445|NCT01376882|Withdrawal
330446|NCT01376882|Cognitive function
330447|NCT01376882|Mood
330448|NCT01376882|Cerebral haemodynamics
330449|NCT01376869|Hops
330450|NCT01376869|Mood
330451|NCT01376869|Cognitive Function
330452|NCT01376869|Bioavailability
330453|NCT01376869|Satiety
330454|NCT01376869|Blood Pressure
330455|NCT01376869|Heart rate
330456|NCT01376856|mediastinal lymph node with false positive FDG PET/CT results in lung cancer staging
330457|NCT01376843|latent tuberculosis in health care workers
330458|NCT01376830|COPD
330459|NCT01376830|Exacerbations
330460|NCT01376830|Viruses
330461|NCT01376817|Severe acute pancreatitis
330462|NCT01376817|total parenteral nutrition
330463|NCT01376817|fat emulsions
330464|NCT01376817|omega 3 fatty acids
330465|NCT01376791|Periodontal disease
330466|NCT01376791|Atherosclerosis
330467|NCT01376791|Oral Pathogens
330468|NCT01376791|Native Americans
330469|NCT01376791|Inflammatory cytokines
330470|NCT01376791|Microbial metagenomics
330471|NCT01376778|Perinatology
330472|NCT01376778|Cytomegalovirus immune globulin
330473|NCT01376778|Cytogam
330474|NCT01376778|CMVIG infusions
330475|NCT01376765|SARS, coronavirus, vaccine, adjuvant, Alhydrogel®, severe acute respiratory syndrome
330476|NCT01376739|Magnevist
330477|NCT01376739|MR angiography
330478|NCT01376713|Melanoma
330479|NCT01376687|Osteopathic Medicine
330480|NCT01376687|Cervical Spine
330481|NCT01376687|Kinetics
330482|NCT01376674|localised
330483|NCT01376674|prostate cancer
330484|NCT01376674|radiotherapy
330485|NCT01376674|immunology
330486|NCT01376661|Prostate Cancer
330487|NCT01376661|Active Surveillance
330488|NCT01376661|Low risk prostate cancer
330489|NCT01376635|Chronic Kidney Disease
330490|NCT01376635|Autonomic Dysfunction
330491|NCT01376609|Stroke
330492|NCT01376609|Ischaemic Stroke
330493|NCT01376609|Cerebral Infarction
330494|NCT01376609|Cerebrovascular Disorders
330495|NCT01376609|Brain Diseases
330496|NCT01376609|Nervous System Diseases
330497|NCT01376609|Vascular Diseases
330498|NCT01376609|Brain Infarction
330499|NCT01376609|Brain Ischemia
330500|NCT01376609|mismatch
330501|NCT01376609|PWI/DWI mismatch
330502|NCT01376609|ischaemic penumbra
330503|NCT01376609|image analysis
330504|NCT01376596|Remission
330505|NCT01376596|Psychosocial Functioning
330506|NCT01376596|Symptoms reduction
330507|NCT01376583|Breast cancer
330508|NCT01376583|Exercise
330509|NCT01376583|Myokines
330510|NCT01376583|AMPK
330511|NCT01376570|HIV
330512|NCT01376570|Opiate dependence
330513|NCT01376570|Opiate replacement therapy
330514|NCT01376570|Cocaine-related disorders
330515|NCT01376570|Risk Reduction Behavior
330516|NCT01376570|Medication Adherence
330517|NCT01376570|Motivation
330518|NCT01376557|diabetes mellitus
330519|NCT01376544|Neonate
330520|NCT01376544|Weaning
330521|NCT01376544|Assist control ventilation
330522|NCT01376544|Pressure support ventilation
330523|NCT01376531|acute renal failure
330524|NCT01376531|cerebrovascular autoregulation
330525|NCT01376531|transcranial Doppler
330526|NCT01376531|continuous veno-venous hemodialysis
330527|NCT01376518|acute respiratory distress syndrome
330528|NCT01376518|acute lung injury
330529|NCT01376518|cerebrovascular autoregulation
330530|NCT01376518|transcranial Doppler
330531|NCT01376518|ventilation
330532|NCT01376505|Vaccine Therapy
330533|NCT01376492|Schizophrenia
330534|NCT01376492|Sleep disturbances
330535|NCT01376492|Quality of sleep
330536|NCT01376492|Functioning level
330537|NCT01376492|Antipsychotic therapy.
330538|NCT01376479|HFMD
330539|NCT01376479|EV71
330540|NCT01376479|Enterovirus
330541|NCT01376479|INV21
330542|NCT01376479|Encephalitis
330543|NCT01376466|acute appendicitis
330544|NCT01376466|diagnosis
330545|NCT01376466|computed tomography
330546|NCT01376453|External Radiation Therapy
330547|NCT01376453|Locally Advanced Rectal
330548|NCT01376453|Adenocarcinoma
330549|NCT01376440|three or more loss stools in 24 hours
330550|NCT01376414|dyspepsia
330551|NCT01376414|abdominal
330552|NCT01376414|pain
330553|NCT01376414|helicobacter
330554|NCT01376414|pylori
330555|NCT01376414|[C06.405.748.398]
330556|NCT01376414|[C06.405.748.586]
330557|NCT01376414|[C06.405.748.586.698]
330558|NCT01376414|[C06.405.748.586.849]
330559|NCT01376388|Chronic Obstructive Pulmonary Disease (COPD)
330560|NCT01376388|Pharmacogenetics
330561|NCT01376388|GSK573719/GW642444
330562|NCT01376375|Acupuncture
330563|NCT01376375|Low Back Pain
330564|NCT01376362|Cystoid Macular Edema
330565|NCT01376362|Intermediate Uveitis
330566|NCT01376362|Uveitis
330567|NCT01376362|OCT
330568|NCT01376362|Interferon-Gamma (IFN-Gamma)
330569|NCT01376349|depression
330570|NCT01376349|anxiety disorder
330571|NCT01376349|cognitive/functional effects
330572|NCT01376349|sexual dysfunction
330573|NCT01376349|cancer survivor
330574|NCT01376349|breast cancer
330575|NCT01376349|cervical cancer
330576|NCT01376349|fallopian tube cancer
330577|NCT01376349|uterine sarcoma
330578|NCT01376349|vaginal cancer
330579|NCT01376349|vulvar cancer
330580|NCT01376349|ovarian epithelial cancer
330581|NCT01376349|ovarian germ cell tumor
330582|NCT01376349|ovarian sarcoma
330583|NCT01376349|ovarian stromal cancer
330584|NCT01376349|primary peritoneal cavity cancer
330585|NCT01376349|endometrial cancer
330586|NCT01376336|environmental health
330587|NCT01376336|diarrhea
330588|NCT01376336|water
330589|NCT01376336|HIV
330590|NCT01376323|Safety
330591|NCT01376323|Dose Ranging
330592|NCT01376323|Efficacy
330593|NCT01376258|benign prostatic hyperplasia
330594|NCT01376258|acute urinary retention
330595|NCT01376258|adherence
330596|NCT01376258|5-alpha reductase inhibitor
330597|NCT01376258|enlarged prostate
330598|NCT01376258|surgery
330599|NCT01376232|Anaemia
330600|NCT01376232|Drug- Drug Interaction
330601|NCT01376219|GINA
330602|NCT01376219|direct / indirect costs
330603|NCT01376219|exacerbations
330604|NCT01376219|European
330605|NCT01376219|asthma control
330606|NCT01376219|Asthma Control Test (TM - QualityMetric Incorporated)
330607|NCT01376102|osteoporosis
330608|NCT01376102|ibandronate
330609|NCT01376089|Safety
330610|NCT01376076|schizophrenia
330611|NCT01376076|QTc
330612|NCT01376076|cardiac repolarization
330613|NCT01376050|venous stasis ulcer
330614|NCT01376050|leg ulcer
330615|NCT01376037|upper arm
330616|NCT01376037|body contouring
330617|NCT01376037|body shaping
330618|NCT01376024|Carpometacarpal arthritis
330619|NCT01376024|Basal joint arthritis
330620|NCT01376024|CMC arthritis
330621|NCT01376024|Osteoarthritis
330622|NCT01376011|quercetin
330623|NCT01376011|brain blood flow
330624|NCT01376011|aging
330625|NCT01376011|memory
330626|NCT01375998|YAZ
330627|NCT01375998|Dysmenorrhea
330628|NCT01375972|biliary cancer
330629|NCT01375972|systemic chemotherapy
330630|NCT01375972|S-1
330631|NCT01375972|gemcitabine
330632|NCT01375972|cisplatin
330633|NCT01375959|resveratrol
330634|NCT01375959|glucose intolerance
330635|NCT01375959|insulin resistance
330636|NCT01375959|endothelial function
330637|NCT01375946|Pharmacokinetic Profile (PK) and Safety
330638|NCT01375946|PK analysis of EE and LNG
330639|NCT01375933|Smoking
330640|NCT01375933|NicVAX
330641|NCT01375933|Smoking vaccine
330642|NCT01375920|Depression
330643|NCT01375920|Antiglucocorticoid
330644|NCT01375920|Anti-depressants
330645|NCT01375907|blood cell counts
330646|NCT01375907|BUN
330647|NCT01375907|ALT
330648|NCT01375907|AST
330649|NCT01375907|diarrhea
330650|NCT01375907|fever
330651|NCT01375907|vomit
330652|NCT01375907|nausea
330653|NCT01375907|loss of appetite
330654|NCT01375907|irritability
330655|NCT01375881|HIV
330656|NCT01375881|darunavir
330657|NCT01375881|ritonavir
330658|NCT01375881|Prezista
330659|NCT01375881|naive
330660|NCT01375881|experienced
330661|NCT01375868|HPV
330662|NCT01375868|recurrent respiratory papillomatosis
330663|NCT01375868|antibodies
330664|NCT01375855|Late stent malapposition
330665|NCT01375855|stent thrombosis
330666|NCT01375855|IVUS
330667|NCT01375855|non-polimeric stent
330668|NCT01375842|PD-L1
330669|NCT01375842|PD-1
330670|NCT01375842|lymphoma
330671|NCT01375842|esophageal cancer
330672|NCT01375842|antiPD-L1
330673|NCT01375842|MPDL3280A
330674|NCT01375842|Solid tumor
330675|NCT01375842|Renal cell Carcinoma (RCC)
330676|NCT01375842|Melanoma (MEL)
330677|NCT01375842|Non-small Cell Lung Cancer (NSCLC)
330678|NCT01375842|Breast Cancer
330679|NCT01375842|Gastric Cancer
330680|NCT01375842|Head and Neck Cancer
330681|NCT01375842|Colorectal Cancer
330682|NCT01375842|Heme Malignancies
330683|NCT01375842|Non-Hodgkin Lymphoma
330684|NCT01375842|Multiple Myeloma
330685|NCT01375842|MPDL320A
330686|NCT01375816|adenocarcinoma of the colon
330687|NCT01375816|recurrent colon cancer
330688|NCT01375816|stage IV colon cancer
330689|NCT01375816|adenocarcinoma of the rectum
330690|NCT01375816|recurrent rectal cancer
330691|NCT01375816|stage IV rectal cancer
330692|NCT01375803|dietary fiber
330693|NCT01375803|fiber
330694|NCT01375803|insulin sensitivity
330695|NCT01375803|insulin resistance
330696|NCT01375803|glucose metabolism
330697|NCT01375790|whole-body vibration
330698|NCT01375790|older people
330699|NCT01375790|exercise
330700|NCT01375790|body balance
330701|NCT01375790|muscle performance
330702|NCT01375790|falls
330703|NCT01375790|physiotherapy
330704|NCT01375777|High cholesterol
330705|NCT01375777|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
330706|NCT01375777|Treatment for high cholesterol
330707|NCT01375777|Lowering cholesterol
330708|NCT01375777|Lowering high cholesterol
330709|NCT01375777|Hypercholesterolemia
330710|NCT01375764|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
330711|NCT01375764|Cholesterol
330712|NCT01375764|High Cholesterol
330713|NCT01375764|Raised Cholesterol
330714|NCT01375764|Elevated Cholesterol
330715|NCT01375764|Statin intolerant
330716|NCT01375764|Hypercholesterolemia
330717|NCT01375751|Heterozygous Familial Hypercholesterolemia
330718|NCT01375751|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
330719|NCT01375738|Early gastric cancer
330720|NCT01375712|Hard or lumpy stools
330721|NCT01375712|Stool consistency
330722|NCT01375712|Stool frequency
330723|NCT01375712|Constipation related symptoms
330724|NCT01375712|Constipation related quality of life
330725|NCT01375699|Breast cancer
330726|NCT01375699|Gastrointestinal cancer
330727|NCT01375699|Genitourinary cancer
330728|NCT01375699|Sarcoma
330729|NCT01375699|Gynecologic cancer
330730|NCT01375686|Diabetes
330731|NCT01375673|Exercise
330732|NCT01375673|Heart Failure
330733|NCT01375673|Mixed Effects Modeling
330734|NCT01375660|Vitamin D
330735|NCT01375660|Glucose intolerance
330736|NCT01375660|African American men
330737|NCT01375647|Oral Vaccines
330738|NCT01375647|Vaccine Responsiveness
330739|NCT01375647|Tropical Enteropathy
330740|NCT01375634|Intubation
330741|NCT01375634|Gastrointestinal
330742|NCT01375621|Farming
330743|NCT01375621|Antibiotic Resistant
330744|NCT01375621|Bacteria
330745|NCT01375608|Neutropenia
330746|NCT01375608|Hemaglobin
330747|NCT01375608|Coagulation Disorders
330748|NCT01375608|Thrombocytosis
330749|NCT01375608|Red Blood Cells
330750|NCT01375608|Sickle Cell Disease
330751|NCT01375595|Working Memory
330752|NCT01375595|Repetitive TMS (rTMS)
330753|NCT01375595|Language
330754|NCT01375595|Healthy Volunteer
330755|NCT01375595|HV
330756|NCT01375582|Dry Eye
330757|NCT01375582|tear film
330758|NCT01375582|lipid
330759|NCT01375582|tear volume
330760|NCT01375582|environmental chamber
330761|NCT01375582|thermal imaging
330762|NCT01375569|CD105
330763|NCT01375569|Monoclonal Antibody
330764|NCT01375569|Anti-Angiogenic
330765|NCT01375569|Chimeric
330766|NCT01375569|Apoptosis
330767|NCT01375569|Liver Cancer
330768|NCT01375556|Alcohol Clamp
330769|NCT01375556|Pharmacogenetics
330770|NCT01375556|Family History of Alcoholism
330771|NCT01375556|Pharmacodynamics
330772|NCT01375556|Healthy Volunteer
330773|NCT01375556|HV
330774|NCT01375543|Gene Identification
330775|NCT01375543|Genetics
330776|NCT01375543|Genetic Disorders
330777|NCT01375530|Prevention
330778|NCT01375530|Vaccine
330779|NCT01375530|Immunity
330780|NCT01375530|Evaluate
330781|NCT01375530|Screen
330782|NCT01375530|Healthy Volunteer
330783|NCT01375530|HV
330784|NCT01375504|Obesity
330785|NCT01375504|Body Mass Index
330786|NCT01375504|Mindfulness Training
330787|NCT01375504|Attention and Interpretation Therapy
330788|NCT01375491|doxycycline
330789|NCT01375491|insulin resistance
330790|NCT01375491|obesity
330791|NCT01375491|inflammation
330792|NCT01375439|Pregnancy
330793|NCT01375439|vulvovaginitis
330794|NCT01375439|uterine cervicitis
330795|NCT01375439|pregnancy outcome
330796|NCT01375426|Non-severe pneumonia
330797|NCT01375426|Treatment failure
330798|NCT01375426|Double dose amoxicillin
330799|NCT01375426|Children
330800|NCT01375413|Parkinson's disease
330801|NCT01375413|Gait
330802|NCT01375413|Rehabilitation
330803|NCT01375413|Cognition
330804|NCT01375413|Freezing of gait
330805|NCT01375400|aspirin
330806|NCT01375400|platelet
330807|NCT01375387|Vimpat
330808|NCT01375387|Pharmacokinetics
330809|NCT01375387|Healthy Japanese male
330810|NCT01375387|Healthy Chinese male
330811|NCT01375374|Vimpat
330812|NCT01375374|Partial seizures
330813|NCT01375374|Carbamazepine
330814|NCT01375374|Hormone levels
330815|NCT01375374|Lipid levels
330816|NCT01375374|Lacosamide
330817|NCT01375361|albuterol
330818|NCT01375348|Cognitive function
330819|NCT01375348|Experimental pain
330820|NCT01375335|Postoperative
330821|NCT01375335|Dobutamine
330822|NCT01375335|Inotropes
330823|NCT01375335|Stunning
330824|NCT01375335|Heart failure
330825|NCT01375309|probiotics
330826|NCT01375309|preterm infants
330827|NCT01375309|enteral feeding
330828|NCT01375309|Bifidobacterium on enteral feeding
330829|NCT01375270|diabetes
330830|NCT01375270|incretin
330831|NCT01375270|beta-cell function
330832|NCT01375270|glucolipotoxicity
330833|NCT01375270|glucagon-like peptide 1
330834|NCT01375270|glucose-dependent insulinotropic polypeptide
330835|NCT01375244|bioequivalence
330836|NCT01375244|lisinopril
330837|NCT01375244|fasting
330838|NCT01375205|atopic dermatitis
330839|NCT01375205|skin care
330840|NCT01375179|Inflammatory Bowel disease
330841|NCT01375179|Ulcerative colitis
330842|NCT01375153|BNP administration
330843|NCT01375153|appetite
330844|NCT01375153|ghrelin
330845|NCT01375153|PYY
330846|NCT01375140|Myeloproliferative Diseases
330847|NCT01375140|Myelofibrosis
330848|NCT01375140|Post essential thrombocythemia/polycythemia vera
330849|NCT01375140|Ruxolitinib
330850|NCT01375140|INCB018424
330851|NCT01375140|Lenalidomide
330852|NCT01375140|CC-5013
330853|NCT01375140|Revlimid
330854|NCT01375140|Prednisone
330855|NCT01375140|Interactive Voice Response System
330856|NCT01375140|IVR
330857|NCT01375127|Observational
330858|NCT01375127|clinical follow-up data
330859|NCT01375114|Advanced Cancers
330860|NCT01375114|Solid Tumors
330861|NCT01375114|Cancer related fatigue
330862|NCT01375114|CRF
330863|NCT01375114|Panax ginseng
330864|NCT01375114|Placebo
330865|NCT01375114|Sugar pill
330866|NCT01375114|Functional Assessment of Chronic Illness Therapy-Fatigue
330867|NCT01375114|FACIT-F
330868|NCT01375114|Quality of life
330869|NCT01375114|QOL
330870|NCT01375114|FACT-G
330871|NCT01375114|Hospital Anxiety and Depression Inventory
330872|NCT01375114|Neurocognitive function
330873|NCT01375114|SDMT
330874|NCT01375114|Global Symptom Evaluation
330875|NCT01375114|GSE
330876|NCT01375101|lichen planus
330877|NCT01375101|quercetin
330878|NCT01375088|propolis
330879|NCT01375088|mucositis
330880|NCT01375088|radiotherapy
330881|NCT01375088|cancer
330882|NCT01375049|Cystic fibrosis
330883|NCT01375049|CF
330884|NCT01375049|PA
330885|NCT01375049|Pseudomonas aeruginosa
330886|NCT01375049|AZLI
330887|NCT01375049|aztreonam
330888|NCT01375036|Cystic fibrosis
330889|NCT01375036|PA
330890|NCT01375036|Pseudomonas aeruginosa
330891|NCT01375036|CF
330892|NCT01375036|aztreonam
330893|NCT01375023|Allogenic Haematopoietic Cell Transplantation
330894|NCT01375023|Total Lymphoid Irradiation
330895|NCT01375023|Anti-Thymocyte Globulin
330896|NCT01375023|Triple Negative Breast Cancer
330897|NCT01375010|HIV
330898|NCT01375010|Postmenopausal women
330899|NCT01375010|Vitamin D
330900|NCT01374984|smallpox
330901|NCT01374984|vaccination
330902|NCT01374984|complications
330903|NCT01374971|Rheumatoid Arthritis
330904|NCT01374971|Cimzia
330905|NCT01374971|Certolizumab Pegol
330906|NCT01374971|Arthroscopic Synovial biopsy
330907|NCT01374971|Office Based Procedure
330908|NCT01374971|Biologic
330909|NCT01374971|Tumor Necrosis Factor (TNF)
330910|NCT01374971|Anti-TNF
330911|NCT01374932|Asthma
330912|NCT01374932|Obstructive Sleep Apnea Syndrome
330913|NCT01374919|Intravenous iron
330914|NCT01374919|ferumoxytol
330915|NCT01374919|iron deficiency anemia
330916|NCT01374919|Treatment of iron deficiency
330917|NCT01374919|Intolerance of or ineffectiveness of oral iron
330918|NCT01374906|Cushing's Disease
330919|NCT01374906|Mean Urinary Free Cortisol
330920|NCT01374906|Pasireotide
330921|NCT01374893|Function, hospitalization, elderly
330922|NCT01374880|Heart failure
330923|NCT01374880|Dyspnea
330924|NCT01374880|Heart disease
330925|NCT01374880|Pulmonary disease
330926|NCT01374880|Natriuretic peptide
330927|NCT01374880|Rehabilitation
330928|NCT01374867|Cardiogenic shock
330929|NCT01374867|Myocardial infarction
330930|NCT01374867|Low-output syndrome
330931|NCT01374867|Prognosis
330932|NCT01374867|Biomarkers
330933|NCT01374867|Pathophysiology
330934|NCT01374854|type 1 diabetes mellitus
330935|NCT01374854|umbilical mesenchymal stem cell
330936|NCT01374854|mononuclear cell
330937|NCT01374841|Hematopoietic Stem Cell Transplantation
330938|NCT01374841|High-Risk Hematologic Neoplasms
330939|NCT01374841|Haploidentical Donors
330940|NCT01374841|Cyclophosphamide
330941|NCT01374828|Toradol
330942|NCT01374828|Ketorolac
330943|NCT01374828|Normal saline
330944|NCT01374828|Laparoscopic
330945|NCT01374828|Postoperative pain control
330946|NCT01374828|Incisional analgesia
330947|NCT01374815|Children's diet quality
330948|NCT01374815|Health-related social problems
330949|NCT01374763|Naloxone
330950|NCT01374763|Oxycodone
330951|NCT01374763|Constipation
330952|NCT01374763|Pain, postoperative
330953|NCT01374763|Physiological effects of drugs
330954|NCT01374763|Analgesics, Opioid
330955|NCT01374724|Tobacco Use
330956|NCT01374724|Relapse Prevention
330957|NCT01374724|Military
330958|NCT01374724|Smokeless Tobacco Use
330959|NCT01374724|Dual Use
330960|NCT01374711|Endotoxin
330961|NCT01374711|Inflammation
330962|NCT01374711|Sepsis
330963|NCT01374711|GM-CSF
330964|NCT01374711|IFN-y
330965|NCT01374698|PCI
330966|NCT01374698|Aspirin
330967|NCT01374698|Reload
330968|NCT01374685|BRCA1
330969|NCT01374685|BRCA2
330970|NCT01374685|Breast Cancer
330971|NCT01374685|African American
330972|NCT01374685|Women
330973|NCT01374659|124-I PET
330974|NCT01374659|FDG-PET
330975|NCT01374659|PET/CT
330976|NCT01374659|recurrence
330977|NCT01374659|differentiated thyroid carcinoma
330978|NCT01374659|diagnostic value
330979|NCT01374646|Childhood Obesity
330980|NCT01374646|Group Treatment
330981|NCT01374646|Community-based Programs
330982|NCT01374633|Sevoflurane
330983|NCT01374633|Brain injury
330984|NCT01374633|Intra cranial pressure
330985|NCT01374633|Sedation
330986|NCT01374633|Brain injury with initial Glasgow score less than 9
330987|NCT01374620|Cancer
330988|NCT01374607|acute coronary syndrome
330989|NCT01374607|myocardial ischemia
330990|NCT01374607|high-sensitivity cardiac troponin T
330991|NCT01374581|retreatment
330992|NCT01374581|artemisinin-based combination
330993|NCT01374581|malaria
330994|NCT01374581|resistant
330995|NCT01374568|Type 2 diabetes
330996|NCT01374568|sitagliptin
330997|NCT01374568|Januvia
330998|NCT01374555|Coronary artery disease
330999|NCT01374542|Bronchoscopy
331000|NCT01374542|Thoracoscopy
331001|NCT01374516|Dengue Virus
331002|NCT01374516|Dengue fever
331003|NCT01374516|Dengue Hemorrhagic Fever
331004|NCT01374516|CYD dengue vaccine
331005|NCT01374516|Flavivirus
331006|NCT01374516|Dengue Disease
331007|NCT01374490|HIV +
331008|NCT01374490|HIV positive
331009|NCT01374490|HIV associated diarrhea
331010|NCT01374490|AIDS
331011|NCT01374490|Diarrhea
331012|NCT01374477|Preeclampsia in Adolescence
331013|NCT01374477|Adolescent
331014|NCT01374477|Primipaternity
331015|NCT01374464|Interscalene brachial plexus nerve block
331016|NCT01374464|Nerve block
331017|NCT01374451|Pancreatic
331018|NCT01374451|Neuroendocrine tumors
331019|NCT01374451|PNET
331020|NCT01374451|Pasireotide
331021|NCT01374451|Everolimus
331022|NCT01374451|Advanced progressive pancreatic neuroendocrine tumor
331023|NCT01374438|Alzheimer's disease
331024|NCT01374438|cognitive function
331025|NCT01374438|brain glucose utilization
331026|NCT01374438|FDG-PET
331027|NCT01374399|allogeneic stem cell transplantation
331028|NCT01374399|exercise
331029|NCT01374399|survival
331030|NCT01374399|fatigue
331031|NCT01374399|quality of life
331032|NCT01374399|cancer
331033|NCT01374399|physical performance
331034|NCT01374386|adolescent obesity
331035|NCT01374373|Chemotherapy
331036|NCT01374373|Anemia
331037|NCT01374373|Epoetin alfa
331038|NCT01374373|Erythropoiesis stimulating agent (ESA)
331039|NCT01374360|PNH
331040|NCT01374360|Paroxysmal Nocturnal hemoglobinuria
331041|NCT01374360|Soliris
331042|NCT01374360|Eculizumab
331043|NCT01374308|NASVAC
331044|NCT01374308|Pegylated Interferon-2b
331045|NCT01374308|CHB
331046|NCT01374269|NSAIDS (Nonsteroidal anti-inflammatory drugs)
331047|NCT01374269|Exercise
331048|NCT01374269|Physiotherapy
331049|NCT01374269|Subacute Low Back Pain
331050|NCT01374269|Pain
331051|NCT01374269|Visual Analogue Scale
331052|NCT01374269|oswesrty
331053|NCT01374269|Roland Morris
331054|NCT01374269|SF-36
331055|NCT01374269|Quality of life
331056|NCT01374256|carbapenem
331057|NCT01374256|sulbactam
331058|NCT01374256|Acinetobacter baumannii
331059|NCT01374230|clinical outcomes
331060|NCT01374230|radiographic outcomes
331061|NCT01374230|total knee arthroplasty
331062|NCT01374230|survivorship
331063|NCT01374204|Epilepsy
331064|NCT01374204|Stigma
331065|NCT01374191|botox
331066|NCT01374191|neuroma pain
331067|NCT01374191|pain
331068|NCT01374191|chronic pain
331069|NCT01374191|botulinum toxin
331070|NCT01374191|botulinum toxin A
331071|NCT01374191|botox and pain
331072|NCT01374191|botox and neuroma
331073|NCT01374191|botox treatment
331074|NCT01374191|onabotulinum
331075|NCT01374191|onabotulinum toxin
331076|NCT01374191|onabotulinum toxin type A
331077|NCT01374165|SCD
331078|NCT01374152|stroke
331079|NCT01374152|upper extremity
331080|NCT01374152|rehabilitation
331081|NCT01374152|perfetti
331082|NCT01374139|Bosutinib
331083|NCT01374139|Bioequivalence and Food Effect Studies
331084|NCT01374113|safinamide
331085|NCT01374113|pharmacokinetics
331086|NCT01374113|renal impairment
331087|NCT01374113|Moderate and Severe Renal Impairment
331088|NCT01374100|Qigong
331089|NCT01374100|Complementary Medicine
331090|NCT01374100|Exercise
331091|NCT01374100|Traditional Chinese Medicine
331092|NCT01374100|Meditation
331093|NCT01374100|Standard Exercise
331094|NCT01374100|Chemotherapy
331095|NCT01374100|Advanced cancer
331096|NCT01374100|Quality of Life
331097|NCT01374100|Functional Assessment of Cancer Therapy
331098|NCT01374100|Hospital Anxiety and Depression Scale
331099|NCT01374100|Anxiety
331100|NCT01374100|Depression
331101|NCT01374100|Cancer Nutrition-Rehabilitation Program
331102|NCT01374100|Edmonton Symptom Assessment Scale
331103|NCT01374100|Simmonds Functional Assessment
331104|NCT01374074|Barrett's Esophagus (BE)
331105|NCT01374074|Intestinal metaplasia
331106|NCT01374074|Gastroesophageal reflux disease (GERD)
331107|NCT01374074|Racial Disparity
331108|NCT01374061|Emergency intubation
331109|NCT01374061|Glide scope Ranger
331110|NCT01374061|Pre hospital
331111|NCT01374035|Health Service
331112|NCT01374035|Coordination
331113|NCT01374035|Referral letters
331114|NCT01374035|Mental Health
331115|NCT01374035|Adults
331116|NCT01374022|Respiratory Distress Syndrome, Adult
331117|NCT01374022|Randomized Controlled Trial
331118|NCT01374022|Respiration, Artificial
331119|NCT01373996|Invasive blood pressure monitoring
331120|NCT01373996|Intensive care unit
331121|NCT01373996|Wireless Technology
331122|NCT01373983|Neuropathic pain
331123|NCT01373983|Intrathecal analgesia
331124|NCT01373983|Ziconotide
331125|NCT01373983|Bolus
331126|NCT01373983|trauma
331127|NCT01373983|central
331128|NCT01373983|severe
331129|NCT01373983|chronic
331130|NCT01373970|Functional Dyspepsia
331131|NCT01373970|Protonpump inhibitor
331132|NCT01373970|Rebound Acid HyperSecretion
331133|NCT01373957|Acute Coronary Syndrome
331134|NCT01373957|antithrombotic management
331135|NCT01373957|STEMI
331136|NCT01373957|NSTE-ACS
331137|NCT01373944|MPI
331138|NCT01373944|SPECT
331139|NCT01373944|Stress-Only
331140|NCT01373944|Spectrum Dynamics Camera
331141|NCT01373944|Anger
331142|NCT01373918|cholestasis
331143|NCT01373918|neonates
331144|NCT01373918|parenteral nutrition
331145|NCT01373918|gastrointestinal disorders
331146|NCT01373905|ARDS
331147|NCT01373905|PEEP
331148|NCT01373905|Recruitment maneuver
331149|NCT01373879|Vaccine
331150|NCT01373879|Immune response
331151|NCT01373866|Repetitive Transcranial Magnetic Stimulation
331152|NCT01373866|Neuronavigation
331153|NCT01373866|Functional Magnetic Resonance Imaging
331154|NCT01373866|Diffusion Tensor Imaging
331155|NCT01373853|Lens Fragmentation
331156|NCT01373853|Cataract
331157|NCT01373853|Phacoemulsification
331158|NCT01373853|Femtosecond Laser
331159|NCT01373840|focal
331160|NCT01373840|dystonia
331161|NCT01373840|dopamine
331162|NCT01373840|receptor
331163|NCT01373827|VASER
331164|NCT01373827|VASERShape
331165|NCT01373827|MC1
331166|NCT01373827|ultrasound
331167|NCT01373801|Postpartum women, after surgical repair of vaginal and cervical lacerations
331168|NCT01373775|Heart failure
331169|NCT01373775|Revisit
331170|NCT01373775|Emergency room
331171|NCT01373762|Adherence
331172|NCT01373762|Motivation
331173|NCT01373762|Health-related fitness
331174|NCT01373762|Exercise videogames
331175|NCT01373762|Physical Activity
331176|NCT01373749|PPHN
331177|NCT01373749|NO inhalation
331178|NCT01373749|Sildenafil
331179|NCT01373749|Treatment
331180|NCT01373749|Safety
331181|NCT01373723|Uterine Cervical Neoplasms
331182|NCT01373723|cancer screening
331183|NCT01373723|Costs and Cost Analysis
331184|NCT01373723|cost-effectiveness analysis
331185|NCT01373723|Clinical Trial
331186|NCT01373723|Primary Health Care
331187|NCT01373710|Adverse Reaction to Trastuzumab Administered by intrathecal
331188|NCT01373697|Ibuprofen
331189|NCT01373697|muscle pain
331190|NCT01373697|sprains
331191|NCT01373697|contusions
331192|NCT01373697|tendonitis
331193|NCT01373684|Chronic hepatitis B
331194|NCT01373684|HBeAg-negative
331195|NCT01373671|Mammography
331196|NCT01373671|Screening
331197|NCT01373671|Diagnostic
331198|NCT01373632|significant stenosis (>70% of lumen stenosis)
331199|NCT01373632|epicardial coronary arteries
331200|NCT01373632|clinical ischemic
331201|NCT01373619|Heart failure with normal ejection fraction
331202|NCT01373619|hemodialysis patients
331203|NCT01373619|ivabradine
331204|NCT01373619|Echocardiography
331205|NCT01373619|NYHA class
331206|NCT01373619|6-minutes walking test
331207|NCT01373593|persistent postherniorrhaphy pain
331208|NCT01373580|presbyopia
331209|NCT01373580|LASIK
331210|NCT01373580|loss of accommodation
331211|NCT01373580|Emmetrope
331212|NCT01373567|Plaque Psoriasis
331213|NCT01373528|Sinonasal Budesonide
331214|NCT01373528|Endoscopic sinus surgery
331215|NCT01373528|Hypothalamic-Pituitary-Adrenal Axis Function
331216|NCT01373515|DCOne
331217|NCT01373515|DCP-001
331218|NCT01373515|Second complete remission of AML
331219|NCT01373515|Relapse AML
331220|NCT01373489|type 2 diabetes
331221|NCT01373489|nurse case management
331222|NCT01373489|telemedicine
331223|NCT01373476|Diabetic Retinopathy
331224|NCT01373476|Traditional Chinese medicine
331225|NCT01373476|Diabetic Eye Problems
331226|NCT01373476|Retinal Disorders
331227|NCT01373463|resectable
331228|NCT01373437|Ultrasonography
331229|NCT01373437|US
331230|NCT01373437|Confirming
331231|NCT01373437|Confirmation
331232|NCT01373437|Proper
331233|NCT01373437|Position
331234|NCT01373437|Endotracheal tube
331235|NCT01373437|ETT
331236|NCT01373437|Emergency department
331237|NCT01373437|ED
331238|NCT01373437|Applicability
331239|NCT01373437|Accuracy
331240|NCT01373424|Observational study
331241|NCT01373424|Cross-sectional and Prospective study
331242|NCT01373424|Cohort and case-control study
331243|NCT01373411|CABG
331244|NCT01373411|Ticagrelor
331245|NCT01373411|Coronary Artery Bypass Surgery
331246|NCT01373398|bladder cancer
331247|NCT01373398|EO9
331248|NCT01373398|Apaziquone
331249|NCT01373385|pediatric urology
331250|NCT01373385|vesicoureteral reflux
331251|NCT01373385|ureteral reimplant
331252|NCT01373385|Deflux
331253|NCT01373372|functional dyspepsia
331254|NCT01373372|GI
331255|NCT01373359|Misoprostol, oxytocin, postpartum blood loss, hemoglobin
331256|NCT01373346|type II diabetes
331257|NCT01373346|Gastric cancer
331258|NCT01373346|Long limb Roux-en Y
331259|NCT01373320|Smoking cessation
331260|NCT01373320|Cancer screening
331261|NCT01373320|Appalachia
331262|NCT01373320|Group-randomized trial
331263|NCT01373320|Faith-placed
331264|NCT01373307|Overweight
331265|NCT01373307|obesity
331266|NCT01373307|Appalachian
331267|NCT01373307|intergenerational
331268|NCT01373307|families
331269|NCT01373307|energy balance
331270|NCT01373307|group-randomized trial
331271|NCT01373294|non-muscle-invasive
331272|NCT01373294|transitional cell
331273|NCT01373294|oral lenalidomide
331274|NCT01373294|intravesical
331275|NCT01373281|Dengue
331276|NCT01373281|Dengue fever
331277|NCT01373281|Dengue Hemorrhagic Fever
331278|NCT01373281|CYD dengue vaccine
331279|NCT01373281|Flavivirus
331280|NCT01373255|Placenta accreta
331281|NCT01373255|Internal iliac artery catheterization
331282|NCT01373255|Post partum bleeding
331283|NCT01373229|Chronic Lymphocytic Leukemia
331284|NCT01373229|CLL
331285|NCT01373203|Acute Lung Injury(ALI)
331286|NCT01373190|epilepsy
331287|NCT01373190|thermography
331288|NCT01373164|Neoplasms
331289|NCT01373164|Neoplasm Metastasis
331290|NCT01373164|Pancreatic Cancer
331291|NCT01373138|Bioequivalence
331292|NCT01373138|Desloratadine and pseudoephedrine
331293|NCT01373138|crossover
331294|NCT01373125|Barrett's Esophagus
331295|NCT01373125|Intestinal metaplasia
331296|NCT01373125|Gastroesophageal reflux disease (GERD)
331297|NCT01373125|Neosquamous epithelium
331298|NCT01373125|Radiofrequency ablation (RFA)
331299|NCT01373112|arthroplasty
331300|NCT01373112|knee replacement
331301|NCT01373112|Osteoarthritis
331302|NCT01373112|knee Infection
331303|NCT01373112|Prosthetic Joint Infection
331304|NCT01373112|Complications; Arthroplasty, Infection or Inflammation
331305|NCT01373112|Complications; Arthroplasty
331306|NCT01373099|arthroplasty
331307|NCT01373099|hip replacement
331308|NCT01373099|Osteoarthritis
331309|NCT01373099|knee Infection
331310|NCT01373099|Prosthetic Joint Infection
331311|NCT01373099|Complications; Arthroplasty, Infection or Inflammation
331312|NCT01373099|Complications; Arthroplasty
331313|NCT01373086|Hypertension,
331314|NCT01373086|mild hypertension,
331315|NCT01373086|moderate hypertension,
331316|NCT01373086|high blood pressure,
331317|NCT01373086|uncomplicated hypertension.
331318|NCT01373060|ASP1941
331319|NCT01373060|ipragliflozin
331320|NCT01373060|plasma glucose
331321|NCT01373060|urine glucose
331322|NCT01373047|liver metastases
331323|NCT01373047|immunotherapy
331324|NCT01373047|regional therapy
331325|NCT01373047|T cells
331326|NCT01373008|Inhaled steroids
331327|NCT01373008|bronchopulmonary dysplasia
331328|NCT01373008|Infants with moderate to severe BPD
331329|NCT01372995|critical care
331330|NCT01372995|nosocomial infection
331331|NCT01372995|antiAntimicrobial peptide expression
331332|NCT01372995|LL-37
331333|NCT01372995|hBD-2
331334|NCT01372995|cathelicidin
331335|NCT01372995|microbial peptide
331336|NCT01372956|LDL-C, cholesterol, risk factor
331337|NCT01372943|Clostridium difficile
331338|NCT01372943|recurrent
331339|NCT01372943|infection
331340|NCT01372930|Etanercept
331341|NCT01372930|acute ST segment elevated myocardial infarction
331342|NCT01372930|percutaneous coronary intervention
331343|NCT01372930|myocardial reperfusion injury
331344|NCT01372904|Cisplatin
331345|NCT01372904|Hearing loss
331346|NCT01372904|Ototoxicity
331347|NCT01372904|Intratympanic injection
331348|NCT01372904|Dexamethasone
331349|NCT01372904|Steroids
331350|NCT01372904|Prevention
331351|NCT01372891|Contrast Induced Nephropathy
331352|NCT01372891|percutaneous coronary interventions
331353|NCT01372878|Polyps
331354|NCT01372878|Capsule endoscopy
331355|NCT01372878|Colonoscopy
331356|NCT01372852|Diabetes mellitus
331357|NCT01372839|Myocardial Infarction
331358|NCT01372839|Unstable Angina
331359|NCT01372826|Phase 1
331360|NCT01372826|Pharmacokinetics
331361|NCT01372826|NKTR-118
331362|NCT01372826|renal impairment
331363|NCT01372826|parallel study
331364|NCT01372826|QTcF Interval
331365|NCT01372826|AUC(0-t)
331366|NCT01372826|Cmax
331367|NCT01372826|tmax
331368|NCT01372813|Advanced Clear Cell Renal Cell Carcinoma
331369|NCT01372813|Cancer
331370|NCT01372813|Renal
331371|NCT01372813|Renal Cell Carcinoma
331372|NCT01372813|Kidney Cancer
331373|NCT01372800|adiponectin
331374|NCT01372800|cardiovascular diseases
331375|NCT01372800|cerebrovascular diseases
331376|NCT01372774|neurotoxicity
331377|NCT01372774|radiation toxicity
331378|NCT01372774|cognitive/functional effects
331379|NCT01372774|tumors metastatic to brain
331380|NCT01372774|unspecified adult solid tumor, protocol specific
331381|NCT01372761|Obese
331382|NCT01372761|Obesity
331383|NCT01372761|Overweight
331384|NCT01372748|cardiac arrest
331385|NCT01372748|cardiopulmonary resuscitation
331386|NCT01372735|pancreatic cancer
331387|NCT01372735|intensity-modulated radiation therapy
331388|NCT01372735|intraoperative radiation therapy
331389|NCT01372722|treatment resistant
331390|NCT01372709|abdominal
331391|NCT01372709|aortic
331392|NCT01372709|aneurysm
331393|NCT01372683|Appetite
331394|NCT01372683|Satiety
331395|NCT01372683|Subjective energy
331396|NCT01372683|Oats
331397|NCT01372670|Treating meal related anxiety
331398|NCT01372657|cataract
331399|NCT01372657|refraction
331400|NCT01372657|iol
331401|NCT01372657|calculation
331402|NCT01372657|formula
331403|NCT01372631|Reduction mammoplasty
331404|NCT01372631|mastectomy
331405|NCT01372631|partial mastectomy
331406|NCT01372631|lumpectomy
331407|NCT01372631|breast conserving surgery
331408|NCT01372631|breast cancer
331409|NCT01372605|Depression
331410|NCT01372605|HIV
331411|NCT01372605|Adherence
331412|NCT01372605|Collaborative care
331413|NCT01372605|Measurement-Based Care
331414|NCT01372553|Primary care
331415|NCT01372553|Family History
331416|NCT01372553|Risk Stratification
331417|NCT01372553|Cancer
331418|NCT01372553|Thrombosis
331419|NCT01372540|Relapsed/Refractory Multiple Myeloma
331420|NCT01372540|MM
331421|NCT01372540|Plasma Cell Leukemia
331422|NCT01372540|PCL
331423|NCT01372540|Arry-520
331424|NCT01372540|Carfilzomib
331425|NCT01372540|Dexamethasone
331426|NCT01372540|Decadron
331427|NCT01372540|Filgrastim
331428|NCT01372540|G-CSF
331429|NCT01372540|Neupogen
331430|NCT01372527|medical informatics
331431|NCT01372527|health IT
331432|NCT01372527|primary care
331433|NCT01372527|screening
331434|NCT01372527|cervical cancer
331435|NCT01372527|colorectal cancer
331436|NCT01372527|breast cancer
331437|NCT01372527|mammography
331438|NCT01372527|colonoscopy
331439|NCT01372527|pap smear
331440|NCT01372514|Thromboembolism
331441|NCT01372514|Venous Thromboembolism
331442|NCT01372514|Pulmonary Embolism
331443|NCT01372501|Obesity
331444|NCT01372488|Suture self removal
331445|NCT01372488|non-absorbable sutures
331446|NCT01372475|Osteoarthritis
331447|NCT01372475|Knee
331448|NCT01372475|Hyaluronan
331449|NCT01372475|Hyaluronic Acid
331450|NCT01372475|Viscoelastic
331451|NCT01372475|Hydrogel
331452|NCT01372462|COPD
331453|NCT01372462|Ventilator
331454|NCT01372462|Constant work rate
331455|NCT01372449|Autism
331456|NCT01372449|Psychopharmacology
331457|NCT01372449|Clinical Trial
331458|NCT01372449|Children
331459|NCT01372436|dental decay
331460|NCT01372436|DMFT
331461|NCT01372436|Individual Caries Risk
331462|NCT01372436|Risk factors
331463|NCT01372410|Long acting muscarinic antagonist
331464|NCT01372410|Tiotropium
331465|NCT01372410|Chronic Bronchitis
331466|NCT01372410|Emphysema
331467|NCT01372410|Chronic Obstructive Pulmonary Disease
331468|NCT01372371|Vancomycin, Gentamycin
331469|NCT01372371|Local Powder Antibiotic's Efficacy in Controlling Post Surgical Infection
331470|NCT01372332|homonymous hemianopia
331471|NCT01372332|quality of life (QoL)
331472|NCT01372332|visual exploration
331473|NCT01372332|on-road car driving
331474|NCT01372332|driving simulator
331475|NCT01372332|useful field of view (UFOV)
331476|NCT01372332|modified field of view (MAFOV)
331477|NCT01372319|glaucoma
331478|NCT01372319|binocular visual field loss
331479|NCT01372319|semi-automated kinetic perimetry (SKP)
331480|NCT01372319|quality of life (QoL)
331481|NCT01372319|visual exploration
331482|NCT01372319|on-road car driving
331483|NCT01372319|driving simulator
331484|NCT01372293|PCOS
331485|NCT01372293|oral contraceptive pill
331486|NCT01372293|polymorphisms
331487|NCT01372267|Cognitive Behavioral Therapy
331488|NCT01372267|Chronic Pain
331489|NCT01372267|Substance Use Disorders
331490|NCT01372267|Psychoeducational control group
331491|NCT01372254|Cigarette Smoking
331492|NCT01372254|Drug Use
331493|NCT01372254|Depressed Mood
331494|NCT01372241|Papanicolaou test
331495|NCT01372241|Cervical cancer screening
331496|NCT01372241|Randomized controlled trial
331497|NCT01372241|Faith-placed
331498|NCT01372241|Appalachia
331499|NCT01372228|hematopoietic stem cell transplant, chimerism, leukodystrophy
331500|NCT01372215|Breast mass
331501|NCT01372215|Breast lesion
331502|NCT01372202|Operable
331503|NCT01372202|Based on CHFR Methylation Status
331504|NCT01372202|Diagnostic Biopsies
331505|NCT01372189|molecular imaging
331506|NCT01372189|epidermal growth factor receptor
331507|NCT01372189|colorectal neoplasia
331508|NCT01372189|confocal laser endomicroscopy
331509|NCT01372176|Intensive care unit
331510|NCT01372176|Critical illness
331511|NCT01372176|Mortality
331512|NCT01372176|Reduced quality of life
331513|NCT01372176|Loss of lean body mass
331514|NCT01372176|Loss of physical function
331515|NCT01372176|Optimised nutritional support
331516|NCT01372176|Early initiation of nutrition
331517|NCT01372176|Indirect calorimetry
331518|NCT01372163|Phase 1
331519|NCT01372163|Multiple Ascending Doses
331520|NCT01372163|Safety
331521|NCT01372163|Pharmacokinetics
331522|NCT01372163|Healthy Volunteers
331523|NCT01372163|Type 2 Diabetic Patients
331524|NCT01372150|major depressive disorder
331525|NCT01372150|MDD
331526|NCT01372150|depression
331527|NCT01372137|NOX-H94
331528|NCT01372137|Hepcidin
331529|NCT01372137|Anemia
331530|NCT01372137|Inflammation
331531|NCT01372124|Renal impairment
331532|NCT01372124|NOX-E36
331533|NCT01372111|Stg III or IVa Squamous Cell Carcinoma.
331534|NCT01372111|Advanced
331535|NCT01372098|Domestic Violence
331536|NCT01372098|Spouse Abuse
331537|NCT01372072|chronic respiratory hypercapnic failure
331538|NCT01372046|technology transfer
331539|NCT01372046|skill development
331540|NCT01372046|organizational change
331541|NCT01372033|drug treatment
331542|NCT01372033|substance abuse
331543|NCT01372033|offenders
331544|NCT01372033|high risk
331545|NCT01372020|Varicose ulcer
331546|NCT01372020|wound healing
331547|NCT01372020|electrical stimulation
331548|NCT01372007|Rectal carcinoma
331549|NCT01371994|Radical Robotic Arm
331550|NCT01371994|Post Prostatectomy Incontinence
331551|NCT01371994|Vesicare
331552|NCT01371994|YM905
331553|NCT01371968|Alfentanil
331554|NCT01371968|optimal dose
331555|NCT01371968|laryngeal mask airway
331556|NCT01371955|diabetic nephropathy
331557|NCT01371955|CYBA
331558|NCT01371955|p22phox
331559|NCT01371955|RAGE
331560|NCT01371955|12LOX
331561|NCT01371955|genetic
331562|NCT01371955|Type 1 Diabetes Mellitus with Diabetic Dermatitis
331563|NCT01371955|caucasian
331564|NCT01371955|more than twenty years of diabetes duration
331565|NCT01371955|older than 18 years
331566|NCT01371955|no nephropathy other than diabetic nephropathy
331567|NCT01371942|Colorectal cancer(CRC)
331568|NCT01371916|tuberculous meningitis
331569|NCT01371916|early secretory antigenic target 6
331570|NCT01371916|diagnosis
331571|NCT01371903|morphine
331572|NCT01371903|fentanyl
331573|NCT01371903|dilaudid
331574|NCT01371903|opioid
331575|NCT01371903|capnography
331576|NCT01371890|hemodialysis
331577|NCT01371890|end-stage renal disease
331578|NCT01371890|hypertension
331579|NCT01371877|urticaria
331580|NCT01371877|angioedema
331581|NCT01371877|hive
331582|NCT01371877|swelling
331583|NCT01371864|Congenital cardiac disease
331584|NCT01371864|Teamwork
331585|NCT01371864|Communication
331586|NCT01371864|Peri-operative
331587|NCT01371838|Community-Acquired Bacterial Pneumonia
331588|NCT01371825|LIPA
331589|NCT01371825|Wolman Disease
331590|NCT01371825|Wolman Phenotype
331591|NCT01371825|Acid Lipase Deficiency
331592|NCT01371825|Acid Cholesteryl Hydrolase
331593|NCT01371825|Acid Lipase Disease Deficiency, type 2
331594|NCT01371825|Cholesteryl Ester Storage Disease (CESD)
331595|NCT01371825|Cholesteryl Ester Hydrolase Deficiency
331596|NCT01371825|Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
331597|NCT01371825|LAL Deficiency
331598|NCT01371825|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
331599|NCT01371825|Wolman Disease (early onset LAL Deficiency)
331600|NCT01371825|Related Disorders:
331601|NCT01371825|Non-alcoholic Fatty Liver Disease (NAFLD)
331602|NCT01371825|Non-alcoholic Steatohepatitis (NASH)
331603|NCT01371825|Alcoholic Liver Disease
331604|NCT01371825|Cryptogenic Cirrhosis
331605|NCT01371825|Niemann-Pick Disease (NPD) Type C
331606|NCT01371825|Chanarin Dorfman Syndrome
331607|NCT01371799|Schizophrenia
331608|NCT01371786|Ciclesonide
331609|NCT01371786|Allergic Rhinitis
331610|NCT01371760|Multiple sclerosis
331611|NCT01371760|Chronic cerebrospinal venous insufficiency
331612|NCT01371760|Percutaneous Transluminal Angioplasty (PTA)
331613|NCT01371760|Internal jugular vein
331614|NCT01371760|Azygous vein
331615|NCT01371747|Hyperkalemia
331616|NCT01371747|Chronic Kidney Disease
331617|NCT01371747|Treatment of Hyperkalemia
331618|NCT01371747|Hypertension
331619|NCT01371747|Diabetic Nephropathy
331620|NCT01371734|Major Depressive Disorder
331621|NCT01371734|MDD
331622|NCT01371734|Depression
331623|NCT01371721|Major Depressive Disorder
331624|NCT01371721|MDD
331625|NCT01371721|Depression
331626|NCT01371708|Major Depressive Disorder
331627|NCT01371708|MDD
331628|NCT01371708|Depression
331629|NCT01371695|IGF-II levels
331630|NCT01371669|Pulmonary arterial hypertension
331631|NCT01371669|Chronic post embolic disease
331632|NCT01371669|Sleep hypoxemia
331633|NCT01371669|polysomnography
331634|NCT01371669|sleep apnea
331635|NCT01371669|periodic respiration
331636|NCT01371630|Leukemia
331637|NCT01371630|Acute Lymphoblastic Leukemia
331638|NCT01371630|ALL
331639|NCT01371630|pre-B, Philadelphia chromosome (Ph-) negative
331640|NCT01371630|Maximum tolerated dose
331641|NCT01371630|Inotuzumab Ozogamycin
331642|NCT01371630|CMC-544
331643|NCT01371630|Vincristine
331644|NCT01371630|Rituximab
331645|NCT01371630|Rituxan
331646|NCT01371630|Cyclophosphamide
331647|NCT01371630|Cytoxan
331648|NCT01371630|Neosar
331649|NCT01371630|Dexamethasone
331650|NCT01371630|Decadron
331651|NCT01371630|Mesna
331652|NCT01371630|Mesnex
331653|NCT01371630|Pegfilgrastim
331654|NCT01371630|Neulasta
331655|NCT01371630|PEG-G-CSF
331656|NCT01371630|Ara-C
331657|NCT01371630|Cytarabine
331658|NCT01371630|Cytosar
331659|NCT01371630|DepoCyt
331660|NCT01371630|Cytosine Arabinosine Hydrochloride
331661|NCT01371630|6-Mercaptopurine
331662|NCT01371630|Mercaptopurine
331663|NCT01371630|Purinethol
331664|NCT01371630|6-MP
331665|NCT01371630|Methotrexate
331666|NCT01371630|Otrexup
331667|NCT01371630|Rasuvo
331668|NCT01371630|Rheumatrex
331669|NCT01371630|Trexall
331670|NCT01371630|Amethopterin
331671|NCT01371630|Methotrexate Sodium
331672|NCT01371630|MTX
331673|NCT01371630|Oncovin
331674|NCT01371630|Vincristine Sulfate
331675|NCT01371630|Vincasar Pfs
331676|NCT01371630|Prednisone
331677|NCT01371630|Deltasone
331678|NCT01371630|Sterapred
331679|NCT01371630|Rayos
331680|NCT01371630|Meticorten
331681|NCT01371630|Citrovorum
331682|NCT01371630|Leucovorin
331683|NCT01371630|Wellcovorin
331684|NCT01371630|Calcium Leucovorin
331685|NCT01371630|Folinic Acid
331686|NCT01371630|Citrovorum Factor
331687|NCT01371617|IPI-926
331688|NCT01371617|926
331689|NCT01371617|Myelofibrosis
331690|NCT01371617|Hedgehog
331691|NCT01371617|Infinity Pharmaceuticals
331692|NCT01371617|Post Essential thrombocythemia
331693|NCT01371617|Post Polycythemia vera
331694|NCT01371604|Hepatitis C
331695|NCT01371604|HCV
331696|NCT01371604|treatment-naive
331697|NCT01371591|Bleeding
331698|NCT01371591|gastrointestinal
331699|NCT01371591|hemorrhage
331700|NCT01371591|ulcer
331701|NCT01371591|varix
331702|NCT01371591|varices
331703|NCT01371591|ulcers
331704|NCT01371591|GI
331705|NCT01371591|stomach
331706|NCT01371591|esophagus
331707|NCT01371591|duodenum
331708|NCT01371591|melena
331709|NCT01371591|hematemesis
331710|NCT01371591|coffee-ground
331711|NCT01371578|Hepatitis C
331712|NCT01371578|HCV
331713|NCT01371578|Rapid Virologic Response
331714|NCT01371578|Sustained Virologic Response
331715|NCT01371578|Direct Acting Antiviral
331716|NCT01371578|Combination Therapy HCV RNA
331717|NCT01371578|Polymerase inhibitor
331718|NCT01371578|Protease inhibitor
331719|NCT01371578|Treatment naïve
331720|NCT01371578|GS-5885
331721|NCT01371578|GS-9190
331722|NCT01371578|Tegobuvir
331723|NCT01371578|GS-9451
331724|NCT01371565|Cushing's Disease
331725|NCT01371565|Cushing's Syndrome
331726|NCT01371565|Cushings
331727|NCT01371565|Pituitary
331728|NCT01371565|Ectopic ACTH secretion
331729|NCT01371539|Myopia
331730|NCT01371539|Presbyopia
331731|NCT01371513|Serum prostate specific antigen
331732|NCT01371422|Paravertebral nerve blockade
331733|NCT01371422|Percutaneous nephrolithotomy/nephrolithotripsy
331734|NCT01371422|opioids
331735|NCT01371422|pain
331736|NCT01371409|Stroke
331737|NCT01371409|TMS
331738|NCT01371409|Paired Pulse
331739|NCT01371409|EEG
331740|NCT01371409|Motor Learning
331741|NCT01371396|Metabolic syndrome
331742|NCT01371396|Non-alcoholic fatty liver disease
331743|NCT01371396|Obesity Metabolism
331744|NCT01371396|Stable isotopes
331745|NCT01371396|Dietary weight loss
331746|NCT01371370|low intensity resistance exercise training
331747|NCT01371370|hypocaloric diet
331748|NCT01371370|prehypertension
331749|NCT01371370|hypertension
331750|NCT01371370|obesity
331751|NCT01371370|arterial function
331752|NCT01371370|arterial stiffness
331753|NCT01371370|pulse wave velocity
331754|NCT01371370|autonomic function
331755|NCT01371370|endothelial function
331756|NCT01371370|adipocytokines
331757|NCT01371357|Remethylation
331758|NCT01371357|Human Subjects
331759|NCT01371357|Clinical Trial
331760|NCT01371357|B-vitamin
331761|NCT01371357|Creatine
331762|NCT01371344|Kidney Transplantation
331763|NCT01371344|Liver Transplantation
331764|NCT01371344|Heart Transplantation
331765|NCT01371344|Pharmacokinetics
331766|NCT01371331|Kidney Transplantation
331767|NCT01371331|Liver Transplantation
331768|NCT01371331|Heart Transplantation
331769|NCT01371331|Pharmacokinetics
331770|NCT01371318|diabetic foot ulcer
331771|NCT01371318|amputation
331772|NCT01371318|wounds
331773|NCT01371318|diabetic foot
331774|NCT01371318|diabetes complications
331775|NCT01371292|Physical activity
331776|NCT01371292|Transformational leadership
331777|NCT01371292|Physical education
331778|NCT01371266|Glucose intolerance
331779|NCT01371266|Insulin resistance
331780|NCT01371266|Insulin
331781|NCT01371266|metabolic syndrome
331782|NCT01371266|honey
331783|NCT01371266|Inflammation
331784|NCT01371266|oxidative stress
331785|NCT01371253|Nintendo wii
331786|NCT01371253|postural balance
331787|NCT01371253|muscle strength
331788|NCT01371253|elderly
331789|NCT01371240|pancreas cancer
331790|NCT01371240|MRI
331791|NCT01371240|CT scan
331792|NCT01371227|Multiple myeloma
331793|NCT01371227|Relapsed or refractory multiple myeloma
331794|NCT01371227|JNS002
331795|NCT01371227|Bortezomib
331796|NCT01371214|exercise
331797|NCT01371214|exercise movement techniques
331798|NCT01371214|activities of daily living
331799|NCT01371175|HIV
331800|NCT01371123|serum aluminum
331801|NCT01371123|parenteral nutrition
331802|NCT01371123|children
331803|NCT01371110|OCD
331804|NCT01371110|Obsessive-Compulsive Disorder
331805|NCT01371110|ketamine
331806|NCT01371110|treatment
331807|NCT01371097|Barthel Index
331808|NCT01371097|elderly hospitalised patients
331809|NCT01371097|progressive resistance training
331810|NCT01371071|Clinically isolated syndrome (CIS)
331811|NCT01371071|Multiple sclerosis (MS)
331812|NCT01371071|Immunomodulatory therapy
331813|NCT01371071|Prognostic markers
331814|NCT01371071|MRI
331815|NCT01371071|OCT
331816|NCT01371058|high on-treatment platelet reactivity
331817|NCT01371058|percutaneous coronary intervention
331818|NCT01371058|stent thrombosis
331819|NCT01371045|Acromegaly
331820|NCT01371045|Growth Hormone
331821|NCT01371045|Carcinoid Syndrome
331822|NCT01371045|Somatostatin
331823|NCT01371019|Preterm Birth, Proteomics
331824|NCT01370993|Hypoxemia
331825|NCT01370993|Model
331826|NCT01370993|Bronchoscopes
331827|NCT01370993|Monitored anesthesia care
331828|NCT01370980|Medication Adherence
331829|NCT01370980|Patient Compliance
331830|NCT01370980|Patient Acceptance of Health Care
331831|NCT01370980|Administration, Oral
331832|NCT01370980|Cancer
331833|NCT01370980|Letrozol
331834|NCT01370980|Exemestan
331835|NCT01370980|Imatinib
331836|NCT01370980|Sunitinib
331837|NCT01370980|Nilotinib
331838|NCT01370980|Everolimus
331839|NCT01370980|Deferasirox
331840|NCT01370967|infant
331841|NCT01370967|term birth
331842|NCT01370967|human milk
331843|NCT01370967|infant formula
331844|NCT01370967|breast feeding
331845|NCT01370967|bottle feeding
331846|NCT01370967|gastrointestinal tract
331847|NCT01370967|quality of life
331848|NCT01370967|infant development
331849|NCT01370954|CerefolinNAC
331850|NCT01370954|early memory loss
331851|NCT01370954|pre-alzheimer's disease
331852|NCT01370954|cognitive function
331853|NCT01370954|folic acid
331854|NCT01370954|folate
331855|NCT01370954|L-methylfolate
331856|NCT01370954|vitamin B12
331857|NCT01370954|methylcobalamin
331858|NCT01370954|N-acetylcysteine
331859|NCT01370954|NAC
331860|NCT01370954|oxidative stress
331861|NCT01370954|memory deficit
331862|NCT01370954|antioxidant
331863|NCT01370941|Chymosin
331864|NCT01370941|24H urine calcium excretion
331865|NCT01370941|Calcium absorption
331866|NCT01370941|Intestinal Absorption of Calcium
331867|NCT01370928|Colonoscopy performance
331868|NCT01370928|Pain
331869|NCT01370928|Discomfort
331870|NCT01370928|Screening
331871|NCT01370928|Colorectal cancer
331872|NCT01370928|Colorectal cancer screening, diagnostics of adenomas
331873|NCT01370915|postoperative pain, nasal septum surgery, pregabalin
331874|NCT01370876|Oxaliplatin
331875|NCT01370876|Head and Neck cancer
331876|NCT01370863|GERD
331877|NCT01370863|Gastroesophageal reflux disease
331878|NCT01370863|SPD557
331879|NCT01370863|Proton pump inhibitors
331880|NCT01370850|Retina pathology
331881|NCT01370824|Diagnosis
331882|NCT01370824|Clinical
331883|NCT01370824|Punch biopsy
331884|NCT01370824|Surgical excision
331885|NCT01370824|Histology
331886|NCT01370824|Histopathology
331887|NCT01370824|Observed agreement
331888|NCT01370824|Diagnostic value
331889|NCT01370824|Accuracy
331890|NCT01370824|Interobserver variability
331891|NCT01370824|Intraobserver variability
331892|NCT01370811|oxybutynin
331893|NCT01370811|clonidine
331894|NCT01370811|OC Oral Solution
331895|NCT01370811|sialorrhoea
331896|NCT01370811|Parkinson's disease
331897|NCT01370798|Severe hypospadias
331898|NCT01370798|local oestrogen
331899|NCT01370798|promestriene
331900|NCT01370798|Onlay-tube-onlay urethroplasty
331901|NCT01370798|post-operative complications
331902|NCT01370798|fistula dehiscence
331903|NCT01370772|B CLL
331904|NCT01370772|Fist line treatment
331905|NCT01370759|bowel prep
331906|NCT01370759|PillCam
331907|NCT01370733|TMS,
331908|NCT01370733|MDD,
331909|NCT01370733|Depression,
331910|NCT01370733|sTMS,
331911|NCT01370733|NEST,
331912|NCT01370733|NeoSync,
331913|NCT01370733|EEG,
331914|NCT01370733|synchronous,
331915|NCT01370733|non-invasive neuromodulation,
331916|NCT01370733|transcranial magnetic stimulation,
331917|NCT01370733|antidepressant,
331918|NCT01370720|IBS
331919|NCT01370720|mast cell activation
331920|NCT01370720|low grade inflammation
331921|NCT01370720|visceral hyperalgesia
331922|NCT01370668|functional remediation
331923|NCT01370668|psychoeducation
331924|NCT01370668|neurocognition
331925|NCT01370629|atrial fibrillation
331926|NCT01370629|cardioversion
331927|NCT01370616|Infection
331928|NCT01370616|Diabetes complications
331929|NCT01370616|Diabetes wound infection
331930|NCT01370616|Soft tissue infection
331931|NCT01370616|Osteomyelitis
331932|NCT01370616|Diabetes mellitus
331933|NCT01370577|Predictors for asthma control
331934|NCT01370577|Asthma Exacerbation rate
331935|NCT01370577|Mean frequency of PFT
331936|NCT01370577|sputum assessments
331937|NCT01370577|refill adherence(%)
331938|NCT01370577|prescription persistence
331939|NCT01370564|Heart failure
331940|NCT01370564|Cardiac filling pressure
331941|NCT01370538|Heartburn
331942|NCT01370525|Heartburn
331943|NCT01370486|Lennox-Gastaut syndrome
331944|NCT01370486|Epileptic encephalopathy
331945|NCT01370486|Melatonin
331946|NCT01370486|Tonic seizures
331947|NCT01370486|Interictal discharges
331948|NCT01370486|Quality of sleep
331949|NCT01370473|Hyponatremia
331950|NCT01370460|Tranexamic Acid
331951|NCT01370460|Blood transfusion
331952|NCT01370460|Total knee arthroplasty
331953|NCT01370447|Leigh syndrome
331954|NCT01370447|MELAS
331955|NCT01370447|Kearns-Sayre
331956|NCT01370447|Alper's
331957|NCT01370447|Inherited mitochondrial disease
331958|NCT01370447|Friedreich's ataxia
331959|NCT01370447|POLG1 deficiency
331960|NCT01370434|MM
331961|NCT01370408|Autologous stem cell transplant
331962|NCT01370408|BEAM
331963|NCT01370408|Oral busulfan
331964|NCT01370408|Cyclophosphamide
331965|NCT01370408|Etoposide
331966|NCT01370408|Carboplatin
331967|NCT01370408|melphalan
331968|NCT01370395|geriatrics
331969|NCT01370395|troponin
331970|NCT01370395|electrocardiography
331971|NCT01370395|diagnosis
331972|NCT01370395|myocardial infarction
331973|NCT01370382|geriatrics
331974|NCT01370382|troponin
331975|NCT01370382|electrocardiography
331976|NCT01370382|diagnosis
331977|NCT01370382|myocardial infarction
331978|NCT01370356|smoking reduction
331979|NCT01370356|smoking cessation
331980|NCT01370330|Neuroblastoma
331981|NCT01370330|MIBG
331982|NCT01370330|131I-MIBG
331983|NCT01370330|Resistant
331984|NCT01370330|Relapsed
331985|NCT01370330|Treatment
331986|NCT01370330|UCSF
331987|NCT01370330|Pediatric
331988|NCT01370330|Oncology
331989|NCT01370304|repetitive Transcranial Magnetic Stimulation (rTMS)
331990|NCT01370304|Depression
331991|NCT01370304|Venlafaxine
331992|NCT01370304|fMRI
331993|NCT01370291|rTMS
331994|NCT01370291|Risperidone
331995|NCT01370278|Central airway obstruction
331996|NCT01370278|lumen obstruction
331997|NCT01370278|Sodium bicarbonate
331998|NCT01370278|Baking soda
331999|NCT01370278|Normal saline
332000|NCT01370278|Salt water
332001|NCT01370278|Airway stents
332002|NCT01370278|Bronchoscopy
332003|NCT01370278|mucus obstruction
332004|NCT01370265|Regadenoson (Lexiscan)
332005|NCT01370265|PET N-13 ammonia imaging
332006|NCT01370265|Myocardial Blood Flow (MBF)
332007|NCT01370265|Regadenoson Stress
332008|NCT01370252|ankle arthrodesis
332009|NCT01370252|pain
332010|NCT01370252|arthroscopic technique
332011|NCT01370252|ankle osteoarthritis
332012|NCT01370239|monoclonal antibody
332013|NCT01370239|Lewis
332014|NCT01370239|breast cancer
332015|NCT01370213|non-myeloablative haploidentical transplant
332016|NCT01370213|hematopoietic cell transplant
332017|NCT01370213|natural killer cells
332018|NCT01370213|adoptive cellular therapy
332019|NCT01370200|citrate
332020|NCT01370200|anticoagulation
332021|NCT01370200|plasma exchange
332022|NCT01370200|efficacy
332023|NCT01370187|Bronchiolitis
332024|NCT01370187|Postbronchiolitis wheezing
332025|NCT01370187|Montelukast
332026|NCT01370174|Falls
332027|NCT01370174|Balance
332028|NCT01370174|Protective Stepping
332029|NCT01370174|Lateral Balance
332030|NCT01370174|Elderly
332031|NCT01370161|transjugular intrahepatic portosystemic shunt
332032|NCT01370161|TIPS
332033|NCT01370161|variceal bleeding
332034|NCT01370161|liver cirrhosis
332035|NCT01370161|hepatitis B
332036|NCT01370148|Pharmacokinetics
332037|NCT01370148|Protein Binding
332038|NCT01370148|Conivaptan
332039|NCT01370148|Vaprisol
332040|NCT01370148|Liver Disease
332041|NCT01370148|YM087
332042|NCT01370135|neovascular glaucoma
332043|NCT01370135|rubeosis
332044|NCT01370135|anterior chamber
332045|NCT01370135|intraocular
332046|NCT01370135|intravitreal injections
332047|NCT01370135|Lucentis
332048|NCT01370135|Ranibizumab
332049|NCT01370135|short ans longterm effects
332050|NCT01370135|best corrected visual acuity
332051|NCT01370135|gonioscopy
332052|NCT01370135|BCVA
332053|NCT01370135|quality of life
332054|NCT01370122|Women over the age of 20
332055|NCT01370083|Dysphagia
332056|NCT01370083|Viscosity
332057|NCT01370083|Tongue
332058|NCT01370083|Pressure
332059|NCT01370057|Adolescent Idiopathic Scoliosis
332060|NCT01370057|Scoliosis
332061|NCT01370057|AIS
332062|NCT01370057|Brace
332063|NCT01370057|TLSO
332064|NCT01370044|Febrile Seizure
332065|NCT01370044|Carbon Dioxide
332066|NCT01370044|Carbogen
332067|NCT01370044|Respiratory Alkalosis
332068|NCT01370031|Asthma
332069|NCT01370031|PK
332070|NCT01370031|Adults
332071|NCT01370018|CD4 counts
332072|NCT01369992|Metastatic Cancer
332073|NCT01369979|Lumped constant
332074|NCT01369979|FDG
332075|NCT01369979|PET
332076|NCT01369966|Smoking Cessation
332077|NCT01369966|Schizophrenic Smokers
332078|NCT01369966|fMRI
332079|NCT01369966|Neural Circuits
332080|NCT01369953|Civic Ideals/Social Norms
332081|NCT01369953|Genetic Counseling
332082|NCT01369953|Genetic Disorders
332083|NCT01369953|Genetic Testing
332084|NCT01369953|Whole Genome Sequencing
332085|NCT01369940|Growth Discordancy
332086|NCT01369940|Fetal Growth
332087|NCT01369940|Twin Growth
332088|NCT01369927|Shigellosis
332089|NCT01369927|Safety and Immunogenicity
332090|NCT01369927|Conjugate Vaccine
332091|NCT01369914|Graft-Versus-Host Disease
332092|NCT01369914|Natural History Study
332093|NCT01369914|Hematopoietic Stem Cell Transplant
332094|NCT01369914|GVHD
332095|NCT01369901|Exercise
332096|NCT01369901|Spinal Bulbar Muscular Atrophy
332097|NCT01369901|Spinal and Bulbar Muscular Atrophy
332098|NCT01369901|SBMA
332099|NCT01369901|Motor Neuron Disease
332100|NCT01369888|Immunotherapy
332101|NCT01369888|Cell Therapy
332102|NCT01369888|IL-15 Cytokine
332103|NCT01369888|Melanoma
332104|NCT01369888|Metastatic Melanoma
332105|NCT01369888|Skin Cancer
332106|NCT01369875|Immunotherapy
332107|NCT01369875|Cell Therapy
332108|NCT01369875|Metastatic Cancer
332109|NCT01369875|Melanoma
332110|NCT01369875|Metastatic Melanoma
332111|NCT01369875|Skin Cancer
332112|NCT01369862|live attenuated flu vaccines
332113|NCT01369862|influenza A (H1N1)
332114|NCT01369862|intranasal application
332115|NCT01369862|replication-deficient influenza virus
332116|NCT01369836|Tafamidis
332117|NCT01369836|Pharmacokinetics
332118|NCT01369836|TTR stabilization
332119|NCT01369823|HbA1c
332120|NCT01369823|Paradigm 522/722 Infusion Pump
332121|NCT01369823|Transmitter (MMT-7703WW)
332122|NCT01369823|Sensor MMT-7002 (i.e. Glucose Sensor)
332123|NCT01369823|Levels of HbA1c at enrollment higher than 7
332124|NCT01369810|Epidemiological
332125|NCT01369810|asthma
332126|NCT01369810|COPD
332127|NCT01369810|reimbursement
332128|NCT01369810|switch
332129|NCT01369810|outcomes associated with the change in reimbursement
332130|NCT01369797|UPSAV
332131|NCT01369797|autonomy
332132|NCT01369797|the elderly of 75 years and older
332133|NCT01369784|Diffuse large B-cell Lymphoma
332134|NCT01369784|R-IPI
332135|NCT01369771|Confocal microscopic findings
332136|NCT01369771|Ocular Hypertension
332137|NCT01369771|Open-Angle Glaucoma
332138|NCT01369771|Preservative-free eye drops
332139|NCT01369758|morcellator
332140|NCT01369758|hysteroscope
332141|NCT01369758|myomectomy
332142|NCT01369758|polypectomy
332143|NCT01369758|uterine fibroids
332144|NCT01369758|uterine polyps
332145|NCT01369745|Rheumatoid Arthritis
332146|NCT01369745|Moderate to severe
332147|NCT01369719|Thalassemia
332148|NCT01369719|Iron overload
332149|NCT01369719|transfusion
332150|NCT01369719|osveral
332151|NCT01369719|desferal
332152|NCT01369706|electromagnetic interference
332153|NCT01369706|hand-held metal detector
332154|NCT01369706|pacemaker
332155|NCT01369706|cardioverter-defibrillator
332156|NCT01369693|smokeless tobacco
332157|NCT01369693|Nicotine
332158|NCT01369693|Cadmium
332159|NCT01369693|lead
332160|NCT01369693|Tobacco Specific Nitrosamines
332161|NCT01369680|Ketamine
332162|NCT01369680|Chronic pain
332163|NCT01369680|Children
332164|NCT01369680|Oral pain medication
332165|NCT01369654|hysterectomy with Bilateral Salpingo Oophorectomy
332166|NCT01369654|Oophorectomy
332167|NCT01369654|Gynecologic condition
332168|NCT01369641|cisplatin
332169|NCT01369641|STS
332170|NCT01369641|sodium thiosulfate
332171|NCT01369641|Adults
332172|NCT01369641|dose range of 80-120mg/m2
332173|NCT01369628|Open label
332174|NCT01369628|Dose Escalating
332175|NCT01369628|Phase Ib
332176|NCT01369615|Malignant pain
332177|NCT01369615|Nonmalignant pain
332178|NCT01369615|Pain
332179|NCT01369615|Pediatric
332180|NCT01369615|Opioid
332181|NCT01369615|Moderate to severe
332182|NCT01369589|Xerostomia
332183|NCT01369589|dry mouth
332184|NCT01369589|Sjogren's Syndrome
332185|NCT01369563|rhinitis
332186|NCT01369563|ciclesonide
332187|NCT01369563|intermittent rhinitis
332188|NCT01369563|persistent rhinitis
332189|NCT01369524|fluid responsiveness
332190|NCT01369524|microcirculation
332191|NCT01369524|Intensive Care
332192|NCT01369511|Disuse Atrophy
332193|NCT01369511|Muscle
332194|NCT01369511|Strength
332195|NCT01369511|Arthroplasty
332196|NCT01369511|Hip
332197|NCT01369511|Joint Replacement
332198|NCT01369498|Hematology
332199|NCT01369498|Myelofibrosis
332200|NCT01369498|Thrombocythemia Myelofibrosis
332201|NCT01369498|Bone Marrow Diseases
332202|NCT01369498|Hematologic Diseases
332203|NCT01369498|Blood Diseases
332204|NCT01369498|Leukemia
332205|NCT01369498|Blood Disorders
332206|NCT01369485|Urinary Incontinence
332207|NCT01369485|Overactive Bladder
332208|NCT01369485|Frequency
332209|NCT01369485|Urgency
332210|NCT01369459|Comorbid
332211|NCT01369459|ADHD
332212|NCT01369459|SUD
332213|NCT01369459|ASU
332214|NCT01369446|In vitro fertilization
332215|NCT01369446|Assisted reproduction
332216|NCT01369446|Noninvasive imaging of embryos
332217|NCT01369446|Time lapse imaging of embryos
332218|NCT01369446|Traditional morphological grading of embryos
332219|NCT01369446|Prediction of blastocysts
332220|NCT01369433|tivozanib
332221|NCT01369420|locoregional cancer therapy
332222|NCT01369420|pancreatic cancer
332223|NCT01369420|unresectable pancreatic cancer
332224|NCT01369420|pancreatic adenocarcinoma
332225|NCT01369420|locally advanced, unresectable pancreatic cancer
332226|NCT01369420|pancreatic cancer tumor ablation
332227|NCT01369420|NanoKnife tumor ablation for pancreatic cancer
332228|NCT01369420|NanoKnife LEDC system tumor ablation
332229|NCT01369420|Non thermal ablation
332230|NCT01369420|Irreversible electroporation for pancreatic cancer treatment
332231|NCT01369420|IRE for unresectable pancreatic cancer
332232|NCT01369407|Heart failure
332233|NCT01369407|HF
332234|NCT01369407|Heart Diseases
332235|NCT01369407|Cardiovascular Diseases
332236|NCT01369407|Heart Failure NYHA class III
332237|NCT01369407|Advanced heart failure
332238|NCT01369407|Systolic Heart Failure
332239|NCT01369394|Measles
332240|NCT01369394|Mumps
332241|NCT01369394|Rubella
332242|NCT01369394|MMR
332243|NCT01369394|Prevention
332244|NCT01369394|Tailoring
332245|NCT01369394|Persuasive communication
332246|NCT01369394|Children
332247|NCT01369381|Cervical spine
332248|NCT01369381|Endotracheal intubation
332249|NCT01369381|Laryngoscope
332250|NCT01369381|Biomechanics
332251|NCT01369368|Acute myeloid leukemia
332252|NCT01369368|Allogeneic stem cell transplantation
332253|NCT01369368|Relapse
332254|NCT01369368|Disease stabilization, survival
332255|NCT01369355|Ustekinumab
332256|NCT01369355|Stelara, Moderately to severely active Crohn's Disease
332257|NCT01369355|IBD, Crohn's
332258|NCT01369355|UNITI
332259|NCT01369355|colitis
332260|NCT01369355|IL-12
332261|NCT01369355|IL-23
332262|NCT01369342|ustekinumab
332263|NCT01369342|moderately to severely active Crohn's Disease
332264|NCT01369342|Stelara
332265|NCT01369342|IBD
332266|NCT01369342|colitis
332267|NCT01369342|crohn
332268|NCT01369342|UNITI
332269|NCT01369342|Crohn's
332270|NCT01369329|ustekinumab
332271|NCT01369329|moderately to severely active Crohn's Disease
332272|NCT01369329|tumor necrosis factor, Stelara
332273|NCT01369329|Crohn
332274|NCT01369329|Crohn's
332275|NCT01369329|IBD
332276|NCT01369329|UNITI
332277|NCT01369303|HIV
332278|NCT01369290|Depression
332279|NCT01369290|Antidepressant Medication
332280|NCT01369290|CBT
332281|NCT01369277|PF-04991532
332282|NCT01369277|safety and tolerability
332283|NCT01369277|PK
332284|NCT01369277|Japanese and Western population
332285|NCT01369264|Repetitive Transcranial Magnetic Stimulation (rTMS)
332286|NCT01369264|Electroencephalography (EEG)
332287|NCT01369264|Magnetic Resonance Imaging
332288|NCT01369264|Quantitative EEG (QEEG)
332289|NCT01369238|bee venom acupuncture
332290|NCT01369238|east west collaborative medicine
332291|NCT01369238|whiplash associated disorder
332292|NCT01369225|Randomized
332293|NCT01369225|Safety Study
332294|NCT01369225|Open Label
332295|NCT01369199|Hepatitis B
332296|NCT01369199|immune-tolerant hepatitis b
332297|NCT01369199|HBV
332298|NCT01369173|Healthy
332299|NCT01369147|SICU
332300|NCT01369147|calories
332301|NCT01369147|TPN
332302|NCT01369147|tube feeding
332303|NCT01369147|Optimum Energy Dose in SICU
332304|NCT01369134|self-etch adhesive
332305|NCT01369134|selective enamel etching
332306|NCT01369134|Adper Easy Bond
332307|NCT01369134|Supreme Ultra
332308|NCT01369134|Molar and premolar teeth
332309|NCT01369134|Adult
332310|NCT01369134|Class I and II cavities
332311|NCT01369121|peritumoral brain edema
332312|NCT01369121|edema
332313|NCT01369121|malignant brain tumor
332314|NCT01369121|brain tumor
332315|NCT01369121|dexamethasone
332316|NCT01369121|Decadron
332317|NCT01369108|small Class I
332318|NCT01369108|molar and premolar
332319|NCT01369108|low stress flowable composite
332320|NCT01369108|adult
332321|NCT01369108|Restoration
332322|NCT01369108|small caries lesions
332323|NCT01369082|islet allograft function
332324|NCT01369082|c-peptide production
332325|NCT01369082|maintenance immunosuppressive medications
332326|NCT01369069|stroke
332327|NCT01369069|diabetes
332328|NCT01369069|hyperglycemia
332329|NCT01369056|antiretroviral therapy, highly active
332330|NCT01369056|treatment adherence
332331|NCT01369043|Vitamin E
332332|NCT01369043|Vitamin C
332333|NCT01369043|Exercise
332334|NCT01369043|Antioxidant
332335|NCT01369030|L-methylfolate
332336|NCT01369030|Deplin
332337|NCT01369030|depression
332338|NCT01369030|antidepressant
332339|NCT01369030|combination therapy
332340|NCT01369030|augmentation
332341|NCT01369030|folate
332342|NCT01369030|folic acid
332343|NCT01369030|homocysteine
332344|NCT01369030|methionine
332345|NCT01369030|MTHFR genotype
332346|NCT01369030|C677T mutation
332347|NCT01369030|vitamin B6
332348|NCT01369030|vitamin B12
332349|NCT01369017|healthy volunteer
332350|NCT01369017|endotoxin
332351|NCT01369004|self-weighing
332352|NCT01369004|self-monitoring
332353|NCT01369004|weight loss
332354|NCT01369004|obesity
332355|NCT01368991|Coronary Artery Bypass Grafts
332356|NCT01368991|Sternal Closure
332357|NCT01368991|Biologic Bone cement
332358|NCT01368978|TIDM
332359|NCT01368952|Obstructive Sleep Apnea
332360|NCT01368952|Prone positioning
332361|NCT01368952|Positional Treatment
332362|NCT01368952|Hypoxemia
332363|NCT01368939|breast imaging
332364|NCT01368939|MBI
332365|NCT01368939|dose reduction
332366|NCT01368939|Tc-99m
332367|NCT01368939|imaging
332368|NCT01368939|cardiac
332369|NCT01368900|Ultherapy™ Treatment
332370|NCT01368900|Ulthera, Inc.
332371|NCT01368900|Ultrasound treatment for skin tightening
332372|NCT01368887|psoriasis
332373|NCT01368887|scalp psoriasis
332374|NCT01368861|infant
332375|NCT01368861|immunizations
332376|NCT01368861|pain
332377|NCT01368861|pain management
332378|NCT01368861|vaccines
332379|NCT01368861|analgesia
332380|NCT01368848|AGMT
332381|NCT01368848|NSCLC
332382|NCT01368848|non-small cell lung cancer
332383|NCT01368848|bevacizumab
332384|NCT01368848|Avastin
332385|NCT01368848|Cisplatin
332386|NCT01368848|Docetaxel
332387|NCT01368848|Taxotere
332388|NCT01368848|Inoperable
332389|NCT01368848|stages IIIB and IV
332390|NCT01368809|Ambulatory surgery
332391|NCT01368809|Pain management
332392|NCT01368809|Perioperative outcomes
332393|NCT01368809|Fentanyl
332394|NCT01368809|Coughing during insertion of an LMA
332395|NCT01368809|Ambulatory surgery procedures
332396|NCT01368796|Vaccine
332397|NCT01368796|Influenza vaccine
332398|NCT01368796|Adjuvanted Influenza vaccine
332399|NCT01368796|Intradermal Influenza vaccine
332400|NCT01368796|Seniors
332401|NCT01368796|Acceptability of vaccines
332402|NCT01368796|Influenza
332403|NCT01368757|Chronic myelomonocytic leukemia
332404|NCT01368757|CMML
332405|NCT01368757|Lenalidomide
332406|NCT01368757|Revlimid
332407|NCT01368744|Breast Neoplasms
332408|NCT01368744|Breast Diseases
332409|NCT01368705|Infants
332410|NCT01368705|Nitrogen Balance
332411|NCT01368705|Cardiothoracic surgery
332412|NCT01368705|Congenital heart disease
332413|NCT01368705|Malnutrition
332414|NCT01368692|subclavian vein catheterization success rate
332415|NCT01368679|Aortic Aneurysm, Abdominal
332416|NCT01368679|Abdominal Aortic
332417|NCT01368666|Aortic valve replacement
332418|NCT01368666|Aortic stenosis
332419|NCT01368666|Biological valve
332420|NCT01368666|Sutureless valve
332421|NCT01368666|Stented valve
332422|NCT01368666|Aortic Valve Disease
332423|NCT01368653|Tobacco
332424|NCT01368653|Smoking
332425|NCT01368653|Smoking Cessation
332426|NCT01368653|Tobacco Dependence
332427|NCT01368653|Tobacco Use
332428|NCT01368653|Nicotine Dependence
332429|NCT01368627|Coronary Artery Disease
332430|NCT01368627|Restenosis
332431|NCT01368627|Stent thrombosis
332432|NCT01368627|Coronary stents
332433|NCT01368627|Angioplasty
332434|NCT01368627|Drug Eluting Stents(DES)
332435|NCT01368614|OHS
332436|NCT01368601|Lung Cancer
332437|NCT01368601|CPAP
332438|NCT01368601|PPC
332439|NCT01368601|lobectomy
332440|NCT01368601|One-lung ventilation
332441|NCT01368588|adenocarcinoma of the prostate
332442|NCT01368588|stage I prostate cancer
332443|NCT01368588|stage IIA prostate cancer
332444|NCT01368588|stage IIB prostate cancer
332445|NCT01368588|stage III prostate cancer
332446|NCT01368575|Ischemic
332447|NCT01368575|Mitral
332448|NCT01368575|Valve
332449|NCT01368575|Insufficiency
332450|NCT01368575|SVR
332451|NCT01368549|Metanx
332452|NCT01368549|diabetes
332453|NCT01368549|neuropathy
332454|NCT01368549|folic acid
332455|NCT01368549|folate
332456|NCT01368549|L-methylfolate
332457|NCT01368549|vitamin B6
332458|NCT01368549|Pyridoxal 5'-phosphate
332459|NCT01368549|vitamin B12
332460|NCT01368549|methylcobalamin
332461|NCT01368549|DPN
332462|NCT01368536|High blood pressure
332463|NCT01368536|diabetes
332464|NCT01368523|Chronic Myelogenous Leukemia
332465|NCT01368523|chronic phase
332466|NCT01368523|accelerated phase
332467|NCT01368523|blastic phase
332468|NCT01368523|nilotinib
332469|NCT01368510|obsessive-compulsive disorder (OCD)
332470|NCT01368510|cognitive-behavioral therapy (CBT)
332471|NCT01368510|magnetic resonance spectroscopy (MRS)
332472|NCT01368510|glutamate
332473|NCT01368510|cingulate gyrus
332474|NCT01368471|STEMI
332475|NCT01368471|myocardial infarction
332476|NCT01368471|stent
332477|NCT01368432|TBI
332478|NCT01368432|Depression
332479|NCT01368432|Mood
332480|NCT01368432|Behavior
332481|NCT01368419|Endostar
332482|NCT01368419|Radiotherapy
332483|NCT01368419|Esophageal Cancer
332484|NCT01368406|schizophrenia
332485|NCT01368406|weight gain
332486|NCT01368406|intervention
332487|NCT01368380|Breast cancer
332488|NCT01368380|Partners
332489|NCT01368380|Couples
332490|NCT01368380|Attachment
332491|NCT01368380|Intervention
332492|NCT01368367|Burns
332493|NCT01368354|Community Led Total Sanitation
332494|NCT01368354|Open Defecation
332495|NCT01368354|Cysticercosis
332496|NCT01368354|Soil transmitted helminths
332497|NCT01368354|Zambia
332498|NCT01368341|Antibiotics
332499|NCT01368341|General Practice
332500|NCT01368341|Erythema migrans
332501|NCT01368341|Borrelia
332502|NCT01368341|Ticks
332503|NCT01368328|Type 2 Diabetes
332504|NCT01368328|Chromium
332505|NCT01368328|Insulin resistance
332506|NCT01368302|attention bias modification treatment
332507|NCT01368302|cognitive bias modification
332508|NCT01368302|attention training
332509|NCT01368302|anxiety
332510|NCT01368276|Melanoma
332511|NCT01368276|Stage IIIb, IIIc and IV Disease
332512|NCT01368276|oncolytic
332513|NCT01368276|OncoVex
332514|NCT01368276|OncoVEX^GM-CSF
332515|NCT01368250|Aortic
332516|NCT01368250|Stenosis
332517|NCT01368250|Valve
332518|NCT01368250|VARC
332519|NCT01368250|Transcatheter
332520|NCT01368250|Minimal-invasive
332521|NCT01368237|Computed tomography
332522|NCT01368237|Myocardial perfusion
332523|NCT01368237|Coronary heart disease
332524|NCT01368224|Skin sensitivity
332525|NCT01368224|Trans-epidermal water loss
332526|NCT01368224|Clinical score
332527|NCT01368224|skin moisturization factors
332528|NCT01368224|serum immune-regulatory cytokine
332529|NCT01368224|Evaluation of intestinal flora composition
332530|NCT01368211|Mirasol
332531|NCT01368211|Thrombocytopenic
332532|NCT01368211|Pathogen reduction
332533|NCT01368211|Platelets
332534|NCT01368211|Thromboelastography
332535|NCT01368211|CCI
332536|NCT01368211|Corrected Count Increment
332537|NCT01368198|Ocular Emulsion
332538|NCT01368198|OPTIVE™ Lubricant
332539|NCT01368198|Tear Film Break Up Time
332540|NCT01368185|Essential hypertension Uric acid Retrospective Hyzaar
332541|NCT01368172|spinal cord injury
332542|NCT01368172|physical activity
332543|NCT01368172|physical fitness
332544|NCT01368133|acromegaly
332545|NCT01368133|pituitary tumor
332546|NCT01368107|IL-7
332547|NCT01368107|metastatic breast cancer patients
332548|NCT01368107|lymphopenia
332549|NCT01368094|Pancreaticoduodenectomy
332550|NCT01368094|Drainage
332551|NCT01368094|Surgical site infection
332552|NCT01368068|Perimenopause
332553|NCT01368068|Depression
332554|NCT01368055|Proton Radiation, Prostate Cancer
332555|NCT01368042|Quality of Life changes
332556|NCT01368042|Secondary Hyperparathyroidism
332557|NCT01368042|Chronic Kidney Disease
332558|NCT01368042|Hemodialysis
332559|NCT01368042|Paricalcitol intravenous treatment
332560|NCT01368029|LGG
332561|NCT01368029|Immune response
332562|NCT01368029|Influenza vaccine
332563|NCT01368029|Elderly
332564|NCT01368029|Healthy
332565|NCT01368029|Microbiome
332566|NCT01368016|Smoking Cessation
332567|NCT01368016|Nicotine Pharmacodynamics
332568|NCT01368003|Castration resistant prostate cancer
332569|NCT01367990|alopecia
332570|NCT01367990|hair loss
332571|NCT01367990|prevention
332572|NCT01367990|radiotherapy
332573|NCT01367990|head & neck cancer
332574|NCT01367990|radiodermatitis
332575|NCT01367990|radiation dermatitis
332576|NCT01367990|radiation-induced alopecia
332577|NCT01367977|Ehlers Danlos Syndrome
332578|NCT01367977|External Communicating Hydrocephalus
332579|NCT01367977|Dysautonomia
332580|NCT01367977|Postural orthostatic tachycardia syndrome
332581|NCT01367977|Chronic cerebrospinal venous insufficiency
332582|NCT01367964|Hypsarrhythmia
332583|NCT01367964|Spasms, Infantile
332584|NCT01367964|West Syndrome
332585|NCT01367951|unstable chest injury
332586|NCT01367951|flail chest
332587|NCT01367951|chest wall injury
332588|NCT01367951|rib fracture
332589|NCT01367938|Osteoarthritis
332590|NCT01367938|Total Knee Replacement
332591|NCT01367925|Osteoarthritis
332592|NCT01367925|Total Knee Replacement
332593|NCT01367912|Luteal phase support
332594|NCT01367912|estradiol supplementation
332595|NCT01367912|IVF/ICSI
332596|NCT01367912|clinical pregnancy rate
332597|NCT01367899|Safety
332598|NCT01367899|Efficacy
332599|NCT01367886|Urine proteomics
332600|NCT01367886|overactive bladder
332601|NCT01367860|spine surgery
332602|NCT01367860|low back pain
332603|NCT01367860|herniated disk
332604|NCT01367847|Parenting
332605|NCT01367847|Parent-Child Relations
332606|NCT01367847|Child Behavior
332607|NCT01367834|Turner Syndrome
332608|NCT01367834|growth hormone
332609|NCT01367834|brain development
332610|NCT01367821|Obstructive jaundice
332611|NCT01367821|ERCP
332612|NCT01367821|Immune dysfunction
332613|NCT01367821|Endotoxin tolerance
332614|NCT01367821|Quorum sensing
332615|NCT01367808|Buprenorphine
332616|NCT01367808|Vorikonazole
332617|NCT01367808|Posakonazole
332618|NCT01367808|Interactions
332619|NCT01367795|palliation
332620|NCT01367795|quality of life
332621|NCT01367795|surgery
332622|NCT01367795|surgery; palliative
332623|NCT01367795|lifestyle
332624|NCT01367782|UPDRS
332625|NCT01367769|Deep vein thrombosis
332626|NCT01367769|superficial thrombophlebitis
332627|NCT01367769|contrast ultrasound
332628|NCT01367743|myocardial infarction
332629|NCT01367743|epinephrine
332630|NCT01367743|norepinephrine
332631|NCT01367743|cardiac output
332632|NCT01367730|osteopenia and osteoporosis
332633|NCT01367717|Creatine
332634|NCT01367717|Creatinine
332635|NCT01367717|Serum Creatinine
332636|NCT01367717|Urine Creatinine
332637|NCT01367717|Creatine Monohydrate
332638|NCT01367717|Creatine Ethyl Ester
332639|NCT01367717|Acute Kidney Injury
332640|NCT01367717|Renal
332641|NCT01367717|Kidney
332642|NCT01367704|gender-based violence
332643|NCT01367704|intimate partner violence
332644|NCT01367704|relationship abuse
332645|NCT01367704|sexual harassment
332646|NCT01367704|sexual violence
332647|NCT01367691|CRT
332648|NCT01367691|heart failure
332649|NCT01367691|CMR
332650|NCT01367691|safety
332651|NCT01367639|BRCA 1/2 Carriers
332652|NCT01367639|IBSR
332653|NCT01367639|The Work
332654|NCT01367639|Randomized clinical trial
332655|NCT01367613|Advanced medical illness
332656|NCT01367600|Advanced medical illness
332657|NCT01367574|Opioid-induced bowel dysfunction
332658|NCT01367444|Stargardt Disease
332659|NCT01367431|Xanthohumol
332660|NCT01367431|Metabolic syndrome
332661|NCT01367418|Analgesia: Thoracic epidural, patient controlled
332662|NCT01367418|Surgery: Radical retropubic prostatectomy
332663|NCT01367418|Immune system
332664|NCT01367418|Inflammation
332665|NCT01367405|Surgical decompression
332666|NCT01367405|conservative treatment
332667|NCT01367405|incomplete spinal cord lesion
332668|NCT01367405|recovery
332669|NCT01367379|Physician
332670|NCT01367379|duty loading
332671|NCT01367379|stress response
332672|NCT01367379|Physician with different amount of duty area
332673|NCT01367366|malignant mediastinal lymphadenopathy
332674|NCT01367366|positron emission tomography
332675|NCT01367366|endobronchial ultrasound
332676|NCT01367366|transbronchial needle aspiration
332677|NCT01367327|Exercise
332678|NCT01367288|locally advanced breast cancer
332679|NCT01367288|neoadjuvant chemotherapy
332680|NCT01367288|HER2-negative breast cancer
332681|NCT01367288|stage IIb breast cancer
332682|NCT01367288|stage IIIa breast cancer
332683|NCT01367288|Zoledronic acid
332684|NCT01367288|bisphosphonate
332685|NCT01367288|zometa
332686|NCT01367288|therapeutic response
332687|NCT01367288|VEGF serum
332688|NCT01367288|tumors markers
332689|NCT01367288|neoangiogenesis
332690|NCT01367288|apoptosis
332691|NCT01367288|proliferation
332692|NCT01367288|disseminated tumors cells
332693|NCT01367288|gamma-delta T cells activation
332694|NCT01367275|colon
332695|NCT01367275|Colorectum
332696|NCT01367275|Colorectal Cancer
332697|NCT01367275|Plasma FGF
332698|NCT01367275|Colorectal adenocarcinoma
332699|NCT01367275|Bevacizumab
332700|NCT01367275|Brivanib
332701|NCT01367275|BMS-582664
332702|NCT01367275|Irinotecan
332703|NCT01367275|CPT-11
332704|NCT01367275|Camptosar
332705|NCT01367275|Fibroblast Growth Factor
332706|NCT01367275|bFGF
332707|NCT01367275|tyrosine kinase receptors
332708|NCT01367275|vascular endothelial growth factor receptors
332709|NCT01367275|VEGFR
332710|NCT01367275|fibroblast growth factor receptors
332711|NCT01367275|FGFR
332712|NCT01367262|Absorption
332713|NCT01367262|Distribution
332714|NCT01367262|Metabolism
332715|NCT01367262|Excretion
332716|NCT01367249|cataract surgery
332717|NCT01367223|inflammatory response
332718|NCT01367223|parenteral nutrition
332719|NCT01367223|glutamine
332720|NCT01367223|amino acid
332721|NCT01367223|pediatric
332722|NCT01367223|intensive care
332723|NCT01367223|systemic infection
332724|NCT01367223|abdominal surgery
332725|NCT01367223|polytraumatised
332726|NCT01367223|mortality
332727|NCT01367223|mean stay in the intensive care unit
332728|NCT01367223|occurrence of infections
332729|NCT01367210|HIV
332730|NCT01367210|AIDS
332731|NCT01367210|Highly Active AntiRetroviral Therapy
332732|NCT01367210|Simplification
332733|NCT01367210|Maraviroc
332734|NCT01367210|Darunavir
332735|NCT01367210|Treatment experienced
332736|NCT01367210|Tropism
332737|NCT01367197|exercise training
332738|NCT01367197|atrial fibrillation
332739|NCT01367184|VTE
332740|NCT01367184|Inferior vena cava
332741|NCT01367184|Venous thrombo-embolism
332742|NCT01367184|Outcome data
332743|NCT01367184|IVC Filters
332744|NCT01367158|Meningococcal disease
332745|NCT01367158|vaccines
332746|NCT01367158|adolescents
332747|NCT01367158|prevention
332748|NCT01367158|Meningitis
332749|NCT01367145|OMEGA-3 polyunsaturated fatty-acids
332750|NCT01367145|Peripheral Arterial Disease
332751|NCT01367145|Endothelial Function
332752|NCT01367145|Inflammation
332753|NCT01367145|Platelet Function
332754|NCT01367132|ultrasound
332755|NCT01367132|first trimester
332756|NCT01367132|umbilical cord
332757|NCT01367119|Depression
332758|NCT01367119|Electroconvulsive therapy
332759|NCT01367119|Ketamine
332760|NCT01367119|Methohexital
332761|NCT01367106|offspring of 21-hydroxylase enzyme block
332762|NCT01367093|BIOLOGICAL MARKERS
332763|NCT01367093|INTENSIVE CARE UNIT
332764|NCT01367093|MORTALITY
332765|NCT01367093|QUALITY OF LIFE
332766|NCT01367093|CARDIOVASCULAR
332767|NCT01367080|depression
332768|NCT01367067|claustrophobia
332769|NCT01367067|magnetic resonance imaging
332770|NCT01367067|MRI
332771|NCT01367067|anxiety
332772|NCT01367067|anxious patients
332773|NCT01367067|phobic disorders
332774|NCT01367067|anxiety disorders
332775|NCT01367067|mental disorders
332776|NCT01367054|Metformine
332777|NCT01367054|adverse events
332778|NCT01367054|bioequivalence
332779|NCT01367041|bone
332780|NCT01367041|muscle electrical activity
332781|NCT01367041|whole-body vibration
332782|NCT01367028|HER2-positive early breast cancer
332783|NCT01367015|Preterm
332784|NCT01367015|SGA
332785|NCT01367015|AREDF
332786|NCT01367015|Early feeding
332787|NCT01367015|Late feeding
332788|NCT01367015|Feed intolerance
332789|NCT01367015|Necrotizing enterocolitis
332790|NCT01367015|Days to achieve Full Feeds defined as 150 mL/kg
332791|NCT01367002|Uterine serous papillary carcinoma
332792|NCT01367002|Type II endometrial cancer
332793|NCT01367002|HER2/neu
332794|NCT01367002|Paclitaxel, Carboplatin, Trastuzumab
332795|NCT01366989|Total Ankle Arthroplasty
332796|NCT01366976|oxidative stress
332797|NCT01366976|cardiopulmonary bypass
332798|NCT01366976|acetaminophen
332799|NCT01366976|hemolysis
332800|NCT01366963|postural tachycardia syndrome
332801|NCT01366963|brain fog
332802|NCT01366963|cognitive dysfunction
332803|NCT01366937|vitamin B12
332804|NCT01366937|egg
332805|NCT01366937|14C
332806|NCT01366937|fecal excretion
332807|NCT01366924|protein turnover
332808|NCT01366924|whole body protein turnover
332809|NCT01366924|essential amino acids
332810|NCT01366924|leucine
332811|NCT01366911|stem cells
332812|NCT01366911|QCT testing
332813|NCT01366911|Bone density findings
332814|NCT01366911|mesenchymal stem cells
332815|NCT01366885|Autism
332816|NCT01366885|Pregnancy
332817|NCT01366885|Newborn siblings
332818|NCT01366872|ankle
332819|NCT01366872|arthritis
332820|NCT01366872|total ankle arthroplasty
332821|NCT01366872|Agility LP,
332822|NCT01366859|Autism
332823|NCT01366859|Children
332824|NCT01366859|Behavior
332825|NCT01366859|Glutathione
332826|NCT01366859|Whey Protein
332827|NCT01366859|Immunocal
332828|NCT01366859|Antioxidant
332829|NCT01366846|Peanut
332830|NCT01366833|Dysphagia
332831|NCT01366833|Esophagus
332832|NCT01366833|Cancer
332833|NCT01366833|Esophageal Cancer
332834|NCT01366794|Gut hormones
332835|NCT01366794|Insulin secretion
332836|NCT01366781|Gut hormones
332837|NCT01366781|Insulin secretion
332838|NCT01366768|Gut hormones
332839|NCT01366768|Insulin secretion
332840|NCT01366768|Normal physiology
332841|NCT01366729|hemiplegia
332842|NCT01366729|walking
332843|NCT01366729|canes
332844|NCT01366729|TheraTogs
332845|NCT01366729|EMG
332846|NCT01366729|balance
332847|NCT01366729|Timed up and go
332848|NCT01366716|Contingency Management
332849|NCT01366716|Cash
332850|NCT01366716|Substance Abuse
332851|NCT01366716|Ethics
332852|NCT01366703|heart failure
332853|NCT01366703|implantable loop recorder
332854|NCT01366690|HIV
332855|NCT01366690|community health workers
332856|NCT01366690|randomized trial
332857|NCT01366690|task shifting
332858|NCT01366690|Uganda
332859|NCT01366690|retention
332860|NCT01366690|operations research
332861|NCT01366690|implementation research
332862|NCT01366664|Premature Ejaculation
332863|NCT01366664|Selective Serotonin Reuptake Inhibitor
332864|NCT01366664|Dapoxetine
332865|NCT01366664|PRILIGY
332866|NCT01366664|Terazosin
332867|NCT01366664|Pharmacodynamic
332868|NCT01366664|Pharmacokinetic
332869|NCT01366651|Doripenem
332870|NCT01366651|DORIPED1002
332871|NCT01366651|Intravenous
332872|NCT01366651|Pediatric
332873|NCT01366651|Antibiotic
332874|NCT01366651|Meningitis
332875|NCT01366638|Hepatitis C, Chronic
332876|NCT01366638|TMC435
332877|NCT01366638|Hepatitis C
332878|NCT01366638|Hepatitis C virus
332879|NCT01366638|Interferon Alfa-2b
332880|NCT01366638|Ribavirin
332881|NCT01366638|Viral ribonucleic acid
332882|NCT01366625|hypertension, resistant
332883|NCT01366625|obstructive sleep apnea
332884|NCT01366625|renal denervation
332885|NCT01366625|continuous positive airway pressure therapy
332886|NCT01366612|Allogeneic Stem Cell Transplant
332887|NCT01366612|AML
332888|NCT01366612|CML
332889|NCT01366612|MDS
332890|NCT01366599|highly emetogenic chemotherapy
332891|NCT01366599|HEC
332892|NCT01366599|moderately emetogenic chemotherapy
332893|NCT01366599|MEC
332894|NCT01366573|Pharmacokinetics
332895|NCT01366573|mu-opioid receptors
332896|NCT01366573|Addiction
332897|NCT01366573|Pharmacodynamics
332898|NCT01366573|Alcohol
332899|NCT01366547|Bioavailability
332900|NCT01366547|Lamivudine
332901|NCT01366547|Dolutegravir
332902|NCT01366547|integrase
332903|NCT01366547|Abacavir
332904|NCT01366534|Vaccine
332905|NCT01366534|efficacy
332906|NCT01366534|sporozoite challenge
332907|NCT01366534|immunogenicity
332908|NCT01366534|safety
332909|NCT01366534|Phase 1/2
332910|NCT01366534|Malaria
332911|NCT01366495|Seek
332912|NCT01366495|Test
332913|NCT01366495|Treat
332914|NCT01366482|Peripheral arterial disease,
332915|NCT01366482|claudication,
332916|NCT01366482|atherectomy,
332917|NCT01366482|plaque excision,
332918|NCT01366482|drug-coated balloon
332919|NCT01366482|drug-eluting balloon
332920|NCT01366469|coronary artery bypass grafting
332921|NCT01366469|coronary artery disease
332922|NCT01366469|chronic obstructive pulmonary disease
332923|NCT01366456|Temperature Change
332924|NCT01366456|Moxibustion
332925|NCT01366456|Warming effect
332926|NCT01366443|ROM PLUS
332927|NCT01366443|conventional clinical tests of rupture of membranes (ROM)
332928|NCT01366443|speculum exam
332929|NCT01366443|visualization of leakage
332930|NCT01366443|pooling of amniotic fluid in the posterior fornix
332931|NCT01366443|nitrazine testing
332932|NCT01366443|ferning
332933|NCT01366430|BPPV(benign paroxysmal positional vertigo)
332934|NCT01366430|HC-BPPV(BPPV involving the horizontal semicircular canal)
332935|NCT01366430|Nystagmus
332936|NCT01366430|Treatment outcome
332937|NCT01366430|Horizontal Canal Benign Paroxysmal Positional Vertigo
332938|NCT01366404|FFR
332939|NCT01366391|polycystic ovary syndrome
332940|NCT01366391|metformin
332941|NCT01366391|pharmacokinetic
332942|NCT01366313|paracetamol
332943|NCT01366313|morphine
332944|NCT01366313|median effective dose
332945|NCT01366313|pain
332946|NCT01366287|Relative bioavailability
332947|NCT01366287|food effect
332948|NCT01366287|tablet
332949|NCT01366287|suspension
332950|NCT01366287|single dose
332951|NCT01366287|crossover
332952|NCT01366287|healthy subjects
332953|NCT01366274|Trauma
332954|NCT01366261|Flex-rigid pleuroscopy
332955|NCT01366261|pleural biopsy
332956|NCT01366261|pleural effusion
332957|NCT01366261|safety
332958|NCT01366261|thoracoscopy
332959|NCT01366222|asthma
332960|NCT01366209|Pirfenidone
332961|NCT01366209|ASCEND
332962|NCT01366209|IPF
332963|NCT01366209|FVC
332964|NCT01366196|Orthopedic Procedures
332965|NCT01366196|Spinal Fusions
332966|NCT01366196|Pregabalin
332967|NCT01366196|Gamma-Aminobutyric Acid
332968|NCT01366196|Analgesics
332969|NCT01366196|Sensory System Agents
332970|NCT01366196|Peripheral Nervous System Agents
332971|NCT01366196|Physiological Effects of Drugs
332972|NCT01366196|Pharmacologic Actions
332973|NCT01366196|Central Nervous System Agents
332974|NCT01366196|Therapeutic Uses
332975|NCT01366196|Anticonvulsants
332976|NCT01366196|GABA Agents
332977|NCT01366196|Neurotransmitter Agents
332978|NCT01366196|Molecular Mechanisms of Pharmacological Action
332979|NCT01366170|childhood anaplastic large cell lymphoma
332980|NCT01366157|childhood favorable prognosis Hodgkin lymphoma
332981|NCT01366157|stage I childhood Hodgkin lymphoma
332982|NCT01366157|stage II childhood Hodgkin lymphoma
332983|NCT01366157|stage III childhood Hodgkin lymphoma
332984|NCT01366157|stage IV childhood Hodgkin lymphoma
332985|NCT01366157|childhood lymphocyte depletion Hodgkin lymphoma
332986|NCT01366157|childhood lymphocyte predominant Hodgkin lymphoma
332987|NCT01366157|childhood mixed cellularity Hodgkin lymphoma
332988|NCT01366157|childhood nodular lymphocyte predominant Hodgkin lymphoma
332989|NCT01366157|childhood nodular sclerosis Hodgkin lymphoma
332990|NCT01366118|Rectal cancer, Chemoradiotherapy, target therapy
332991|NCT01366105|Wound healing
332992|NCT01366105|Negative Pressure Wound Therapy
332993|NCT01366105|V.A.C.
332994|NCT01366105|Incision
332995|NCT01366092|stem cell transplant
332996|NCT01366092|GVHD
332997|NCT01366092|bone marrow transplant
332998|NCT01366092|cord blood transplant
332999|NCT01366092|regulatory T cell
333000|NCT01366092|interleukin
333001|NCT01366066|Stress incontinence
333002|NCT01366066|urge incontinence
333003|NCT01366066|overactive bladder syndrome
333004|NCT01366066|vibration
333005|NCT01366066|nerve stimulation
333006|NCT01366053|Prostate Cancer
333007|NCT01366053|Androgen Deprivation Therapy
333008|NCT01366053|Agonist
333009|NCT01366053|Antagonist
333010|NCT01366053|PSA Failure
333011|NCT01366053|PSA Rise
333012|NCT01366040|Patient Satisfaction
333013|NCT01366040|Multiple Sclerosis
333014|NCT01366040|Autoinjector
333015|NCT01366040|Avonex
333016|NCT01366027|pseudobulbar affect
333017|NCT01366014|osteoarthritis
333018|NCT01366014|knee
333019|NCT01366014|pain
333020|NCT01366014|NSAID
333021|NCT01366001|Opioid
333022|NCT01366001|Cocaine
333023|NCT01366001|Dependence
333024|NCT01366001|Abuse
333025|NCT01366001|Intravenous
333026|NCT01366001|Buprenorphine
333027|NCT01365988|fMRI
333028|NCT01365988|Risk-Taking
333029|NCT01365988|Decision-Making
333030|NCT01365988|Memory
333031|NCT01365988|Resting-State Functional Connectivity
333032|NCT01365975|Cohort Study
333033|NCT01365975|Folinic Acid, peri-conception
333034|NCT01365975|Pediatric Leukemia
333035|NCT01365975|Pediatric Cancer
333036|NCT01365962|alveolar childhood rhabdomyosarcoma
333037|NCT01365962|embryonal childhood rhabdomyosarcoma
333038|NCT01365962|previously treated childhood rhabdomyosarcoma
333039|NCT01365962|previously untreated childhood rhabdomyosarcoma
333040|NCT01365962|recurrent childhood rhabdomyosarcoma
333041|NCT01365949|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
333042|NCT01365936|IVF
333043|NCT01365936|ICSI
333044|NCT01365936|OHSS
333045|NCT01365936|PCOS
333046|NCT01365936|recFSH
333047|NCT01365936|HMG
333048|NCT01365897|Modafinil
333049|NCT01365897|Memory
333050|NCT01365897|Executive Functions
333051|NCT01365897|Memory, Short-Term
333052|NCT01365897|Attention
333053|NCT01365897|University Students
333054|NCT01365897|Stroop Effect
333055|NCT01365897|Digit Span
333056|NCT01365897|Backwards Digit Span
333057|NCT01365897|Biber Cognitive Estimation Test
333058|NCT01365871|prostate biopsy
333059|NCT01365871|pain
333060|NCT01365845|Proton Radiation
333061|NCT01365845|Breast Cancer
333062|NCT01365819|Crystal meth dependence
333063|NCT01365819|crystal meth
333064|NCT01365819|methamphetamine dependence
333065|NCT01365819|substance abuse
333066|NCT01365806|heart transplantation
333067|NCT01365806|allograft rejection
333068|NCT01365806|QT interval
333069|NCT01365806|electrocardiogram (ECG)
333070|NCT01365793|cerebral edema
333071|NCT01365793|diabetic ketoacidosis
333072|NCT01365793|pediatric diabetes
333073|NCT01365793|fluid therapy
333074|NCT01365780|microcirculation, O2c
333075|NCT01365767|Crohn disease
333076|NCT01365767|Ultrasonography, contrast enhanced
333077|NCT01365767|Elasticity Imaging Techniques
333078|NCT01365767|Small intestine
333079|NCT01365767|Magnetic Resonance Imaging
333080|NCT01365767|CDAI
333081|NCT01365767|Calprotectin
333082|NCT01365767|IBD
333083|NCT01365767|Sonography
333084|NCT01365754|Lumbar degenerative disease
333085|NCT01365741|PCI
333086|NCT01365741|STEMI
333087|NCT01365741|Interventions
333088|NCT01365741|Heart disease
333089|NCT01365741|Thrombocytic inhibition
333090|NCT01365741|Cross-over study
333091|NCT01365741|Percutaneous coronary intervention
333092|NCT01365728|Femtosecond Laser
333093|NCT01365728|FS60
333094|NCT01365728|iFS
333095|NCT01365728|Intralase
333096|NCT01365728|Wavefront-guided LASIK
333097|NCT01365728|IntraLASIK
333098|NCT01365728|LASIK
333099|NCT01365728|Myopia
333100|NCT01365728|Nearsightedness
333101|NCT01365715|Preoperative embolization
333102|NCT01365715|Transcatheter arterial embolization
333103|NCT01365715|Therapeutic angiography
333104|NCT01365715|Embolization
333105|NCT01365715|Surgical blood loss
333106|NCT01365715|Spinal metastases
333107|NCT01365715|Spinal neoplasms
333108|NCT01365715|Vertebral metastases
333109|NCT01365715|metastatic spine surgery
333110|NCT01365715|Spinal surgery
333111|NCT01365702|COPD
333112|NCT01365702|tiotropium
333113|NCT01365702|tuberculous destroyed lung
333114|NCT01364636|1-Heart Failure
333115|NCT01364636|2-Acute Heart Failure
333116|NCT01364636|3-Acute Decompensated Heart Failure
333117|NCT01364636|4-Worsening Renal Function
333118|NCT01364636|5-Acute Kidney Injury
333119|NCT01364636|6-Cardiorenal Syndrome
333120|NCT01364623|testosterone
333121|NCT01364623|pharmacokinetics
333122|NCT01364610|diagnosis
333123|NCT01364610|pH measurement
333124|NCT01364610|catheter
333125|NCT01364610|wireless
333126|NCT01364597|Brivaracetam
333127|NCT01364597|Epilepsy
333128|NCT01364597|Child
333129|NCT01364597|Infant
333130|NCT01364597|Adolescents
333131|NCT01364571|Staphylococcus aureus
333132|NCT01364571|vaccine
333133|NCT01364571|staphylococcal infection
333134|NCT01365676|Edema
333135|NCT01365676|Depression
333136|NCT01365676|Hot Flashes
333137|NCT01365676|Anxiety
333138|NCT01365676|Irritability
333139|NCT01365676|PMS
333140|NCT01365663|Hypercholesterolemia
333141|NCT01365663|LDL
333142|NCT01365663|HDL
333143|NCT01365663|apoB
333144|NCT01365663|hyperlipidemia
333145|NCT01365663|LNA-oligonucleotide
333146|NCT01365637|safety
333147|NCT01365637|tolerability
333148|NCT01365637|pharmacokinetics
333149|NCT01365637|PF-05089771
333150|NCT01365598|malaria
333151|NCT01365598|uncomplicated malaria
333152|NCT01365598|gametocytocidal drug
333153|NCT01365598|gametocytocidal
333154|NCT01365598|gametocyte
333155|NCT01365598|primaquine
333156|NCT01365598|transmission blocking
333157|NCT01365598|malaria transmission
333158|NCT01365598|sexual parasite
333159|NCT01365598|sexual stage
333160|NCT01365598|Uganda
333161|NCT01365598|Africa
333162|NCT01365585|Pulmonary arterial hypertension
333163|NCT01365585|sildenafil citrate
333164|NCT01365585|Revatio
333165|NCT01365572|Drug-eluting stent
333166|NCT01365559|multiple myeloma
333167|NCT01365559|carfilzomib
333168|NCT01365559|relapsed
333169|NCT01365559|refractory
333170|NCT01365559|bortezomib
333171|NCT01365559|Oncotherapeutics
333172|NCT01365533|Airway Inflammation
333173|NCT01365533|Roflumilast
333174|NCT01365494|Rabies
333175|NCT01365494|rabies vaccines
333176|NCT01365494|post-exposure prophylaxis
333177|NCT01365481|Hypertension, pediatric
333178|NCT01365481|Hypertension with or without chronic kidney disease
333179|NCT01365468|RAD001,
333180|NCT01365468|Everolimus,
333181|NCT01365468|Plexiform Neurofibroma,
333182|NCT01365468|Neurofibromatosis Type 1
333183|NCT01365455|Psoriasis
333184|NCT01365455|plaque
333185|NCT01365455|plaque-type psoriasis
333186|NCT01365455|IL-17 blocker
333187|NCT01365455|subcutaneous
333188|NCT01365455|psoriatic arthritis
333189|NCT01365455|injection
333190|NCT01365455|AIN457
333191|NCT01365455|AIN457A
333192|NCT01365455|secukinumab
333193|NCT01365442|Cholera
333194|NCT01365442|Vaccination
333195|NCT01365442|Oral cholera vaccine
333196|NCT01365442|Mass vaccination
333197|NCT01365442|Oral whole cell cholera vaccine
333198|NCT01365429|Lung Transplant, Transplantation Lung
333199|NCT01365416|diabetes
333200|NCT01365416|diabetes remission
333201|NCT01365416|obesity
333202|NCT01365416|bariatric surgery
333203|NCT01365416|gene expression
333204|NCT01365416|genetic variation
333205|NCT01365416|metabolomics
333206|NCT01365416|metabonomics
333207|NCT01365416|epigenetic variation
333208|NCT01365416|mutations
333209|NCT01365390|prospective
333210|NCT01365390|Incidence
333211|NCT01365390|otitis
333212|NCT01365390|observational
333213|NCT01365390|Epidemiological
333214|NCT01365390|retrospective
333215|NCT01365377|Anxiety
333216|NCT01365377|Depression
333217|NCT01365377|Post-traumatic stress disorders
333218|NCT01365377|Quality of life
333219|NCT01365377|Family
333220|NCT01365377|ICU
333221|NCT01365364|PLM
333222|NCT01365364|dopamine
333223|NCT01365364|physical exercise
333224|NCT01365338|schizophrenia fMRI cognition working memory ASL
333225|NCT01365312|Central line associated infection
333226|NCT01365312|PICC associated infection
333227|NCT01365312|Neonatal central line associated sepsis
333228|NCT01365312|Central line colonization
333229|NCT01365312|Ethanol Lock
333230|NCT01365286|asthma, chronic obstructive pulmonary disease, COPD, ivabradine, heart rate
333231|NCT01365273|Split thickness skin grafts
333232|NCT01365273|Mepitel One
333233|NCT01365273|Bridal Veil and staples
333234|NCT01365273|Pain
333235|NCT01365247|Co-morbid substance disorders and PTSD
333236|NCT01365247|Trauma
333237|NCT01365247|Alcohol and other drug use disorders
333238|NCT01365247|Treatment outcome
333239|NCT01365247|Post-Traumatic Stress Disorder (PTSD)
333240|NCT01365247|Co-morbid Alcohol and other drug use disorders (AOD)
333241|NCT01365247|Behavioral Treatment
333242|NCT01365221|Acute Coronary Syndrome
333243|NCT01365221|Clopidogrel
333244|NCT01365221|Prasugrel
333245|NCT01365195|opioid
333246|NCT01365195|Fentanyl
333247|NCT01365195|Anesthetic adjuvant
333248|NCT01365195|Pain management
333249|NCT01365195|Perioperative outcomes
333250|NCT01365195|Constipation
333251|NCT01365195|Ileus
333252|NCT01365195|Colorectal
333253|NCT01365182|prostate cancer
333254|NCT01365182|urinary incontinence
333255|NCT01365182|pelvic floor muscle exercise
333256|NCT01365182|self-management
333257|NCT01365182|behavioral intervention
333258|NCT01365182|quality of life
333259|NCT01365169|Cyberinfrastructure
333260|NCT01365169|CI
333261|NCT01365169|CYCORE
333262|NCT01365169|Quality of Life
333263|NCT01365169|QOL
333264|NCT01365169|Head and Neck
333265|NCT01365169|H&N
333266|NCT01365169|Carbon Monoxide
333267|NCT01365169|CO
333268|NCT01365169|Colorectal Cancer
333269|NCT01365169|Oropharyngeal Cancer
333270|NCT01365169|Laryngeal Cancer
333271|NCT01365169|Hypopharyngeal Cancer
333272|NCT01365169|Nasopharyngeal Cancer
333273|NCT01365169|Smoker
333274|NCT01365169|Recent Smoking Cessation
333275|NCT01365156|locally advanced cervical cancer
333276|NCT01365156|pretherapeutic para-aortic surgical staging
333277|NCT01365156|radiologic staging
333278|NCT01365156|pretherapeutic surgical staging
333279|NCT01365156|para-aortic metastatic disease
333280|NCT01365130|esophageal cancer
333281|NCT01365130|gastroesophageal cancer
333282|NCT01365130|gastric cancer
333283|NCT01365104|brain blood flow
333284|NCT01365104|stroke
333285|NCT01365104|cerebrovascular
333286|NCT01365104|aging
333287|NCT01365104|cerebrovascular hemodynamics
333288|NCT01365078|n-3 polyunsaturated fatty acids
333289|NCT01365078|Stearidonic acid
333290|NCT01365078|Lipid metabolism
333291|NCT01365078|Serum triacylglycerol
333292|NCT01365052|Maximum Use Safety Trial
333293|NCT01365039|contact lens
333294|NCT01365026|Healthy Lifestyle
333295|NCT01365026|Health promotion
333296|NCT01365026|Counselling
333297|NCT01365026|Action Plan
333298|NCT01365026|Primary Health Care
333299|NCT01365013|Lifestyle
333300|NCT01365013|Prediabetic State
333301|NCT01365013|Patient Education
333302|NCT01365013|Primary Health Care
333303|NCT01365000|Phase 1
333304|NCT01365000|Pharmacokinetics
333305|NCT01365000|NKTR-118
333306|NCT01365000|fasting or fed state
333307|NCT01365000|cross-over study
333308|NCT01365000|AUC(0-t)
333309|NCT01365000|Cmax
333310|NCT01365000|tmax
333311|NCT01365000|QTcF Interval
333312|NCT01364987|transplant
333313|NCT01364987|ASP015K
333314|NCT01364987|healthy subjects
333315|NCT01364974|ASP015K
333316|NCT01364974|Healthy subjects
333317|NCT01364961|Resveratrol
333318|NCT01364961|FMD
333319|NCT01364961|PWV
333320|NCT01364961|HDL-cholesterol
333321|NCT01364961|Macrovasculature
333322|NCT01364961|Microvasculature
333323|NCT01364948|Preterm
333324|NCT01364948|VLBW
333325|NCT01364948|Coconut Oil application
333326|NCT01364948|Trans epidermal water loss
333327|NCT01364948|Weight gain
333328|NCT01364909|Sepsis
333329|NCT01364909|Severe sepsis
333330|NCT01364909|Septic shock
333331|NCT01364909|Septicaemia
333332|NCT01364909|Bacteremia
333333|NCT01364896|Non-corticosteroid immunosuppressive agent
333334|NCT01364883|Vaccine
333335|NCT01364883|Immune response
333336|NCT01364870|Knee OA
333337|NCT01364870|TENS
333338|NCT01364870|Total knee replacement
333339|NCT01364870|Knee arthroplasty
333340|NCT01364870|total unilateral knee replacement
333341|NCT01364857|port wine stain of a limb
333342|NCT01364831|sleep time
333343|NCT01364831|athletic performance
333344|NCT01364792|schizophrenia
333345|NCT01364792|treatment
333346|NCT01364792|inflammation
333347|NCT01364792|neuroinflammation
333348|NCT01364792|hippocampal
333349|NCT01364779|aspirin
333350|NCT01364779|Chronic kidney disease
333351|NCT01364753|Memory
333352|NCT01364753|Aviation
333353|NCT01364714|ICU acquired weakness
333354|NCT01364701|Erectile dysfunction
333355|NCT01364701|combination therapy
333356|NCT01364701|Sildenafil
333357|NCT01364701|tadalafil
333358|NCT01364701|PDE5i
333359|NCT01364701|No Conditions
333360|NCT01364688|coronary calcification
333361|NCT01364688|vascular calcification
333362|NCT01364688|active vitamin D
333363|NCT01364688|alfacalcidol
333364|NCT01364675|Impaired fasting glucose
333365|NCT01364675|Impaired glucose tolerance
333366|NCT01364675|Pre-diabetes
333367|NCT01364675|Pre-hypertensives
333368|NCT01364675|Cardiovascular events
333369|NCT01364662|Impulsive Aggression
333370|NCT01364662|Attention Deficit Hyperactivity Disorder
333371|NCT01364662|ADHD
333372|NCT01364649|Sexual Dysfunction, Physiological
333373|NCT01364649|Depressive Disorder, Major
333374|NCT01364649|Depression
333375|NCT01364649|Antidepressive Agents
333376|NCT01364649|Drug Therapy
333377|NCT01364532|transulnar arterial access
333378|NCT01364532|transradial arterial access
333379|NCT01364532|percutaneous coronary intervention
333380|NCT01364519|COPD
333381|NCT01364506|Cardiovascular capacity
333382|NCT01364506|Water exercise
333383|NCT01364506|Hydrokinetic Therapy
333384|NCT01364506|Pregnancy
333385|NCT01364506|Perinatal outcomes
333386|NCT01364493|HER2-positive
333387|NCT01364493|adenocarcinoma of the stomach or gastro-esophageal junction
333388|NCT01364493|Inoperable
333389|NCT01364493|locally advanced
333390|NCT01364493|recurrent
333391|NCT01364493|metastatic
333392|NCT01364480|Tetraplegia
333393|NCT01364480|Spinal cord injury
333394|NCT01364480|Brainstem or spinal stroke
333395|NCT01364480|Neuroprosthetic
333396|NCT01364480|Brain-machine interface
333397|NCT01364480|Brain-computer interface
333398|NCT01364480|Neural activity
333399|NCT01364454|Colorectal Cancer Screening
333400|NCT01364454|Faecal Occult Blood test
333401|NCT01364454|General Practitioners Involvement
333402|NCT01364454|Patient's Participation
333403|NCT01364454|Reminder
333404|NCT01364441|ONO-2950
333405|NCT01364441|healthy adult subjects
333406|NCT01364441|first in human
333407|NCT01364441|safety
333408|NCT01364441|tolerability
333409|NCT01364441|pharmacokinetics
333410|NCT01364415|MTD
333411|NCT01364415|pasireotide
333412|NCT01364415|LAR
333413|NCT01364415|NETs
333414|NCT01364415|advanced neuroendocrine tumors
333415|NCT01364402|scheduled for PCI
333416|NCT01364389|Polymyalgia Rheumatica
333417|NCT01364389|Inflammatory Disease
333418|NCT01364389|Rheumatic Disease
333419|NCT01364376|Gastric Cancer
333420|NCT01364363|Transplant
333421|NCT01364363|Allogeneic
333422|NCT01364363|Allogeneic transplant
333423|NCT01364363|Unrelated donor transplant
333424|NCT01364363|MUD
333425|NCT01364363|HSCT
333426|NCT01364363|Stem cell transplant
333427|NCT01364350|type 2 diabetes mellitus
333428|NCT01364350|pediatrics
333429|NCT01364350|post-intervention study
333430|NCT01364350|metformin
333431|NCT01364350|complications
333432|NCT01364337|Hypertension
333433|NCT01364324|tuberculosis
333434|NCT01364324|pharmacokinetics
333435|NCT01364324|first-line drugs
333436|NCT01364324|gastrectomy
333437|NCT01364311|Dry Eye Syndromes
333438|NCT01364311|Dietary Supplements
333439|NCT01364311|Vitamac® Tag and Nacht capsules
333440|NCT01364311|Lutein
333441|NCT01364311|Vitamin C
333442|NCT01364311|Zinc
333443|NCT01364311|ginkgo biloba
333444|NCT01364311|Flavinoids
333445|NCT01364311|Fishoil
333446|NCT01364311|Zeaxanthin
333447|NCT01364311|Vitamin E
333448|NCT01364311|Copper
333449|NCT01364311|Selen
333450|NCT01364311|Alpha Lipon acid
333451|NCT01364311|Break up time (BUT)
333452|NCT01364311|Improvement of subjective symptoms of dry eye syndrome
333453|NCT01364311|Visual Acuity
333454|NCT01364311|Tear film osmolarity
333455|NCT01364311|OSI (Objective Scattering Index)
333456|NCT01364311|Schirmer I test
333457|NCT01364311|Staining of the cornea with fluorescein
333458|NCT01364311|Impression cytology
333459|NCT01364311|Tear cytokines/chemokines
333460|NCT01364311|Data from patient diary how often Hylo-Comod® eye drops were used
333461|NCT01364298|Gabapentin/B complex
333462|NCT01364298|Pregabalin
333463|NCT01364298|Pain
333464|NCT01364298|Neuropathic
333465|NCT01364298|Gavindo
333466|NCT01364298|Lyrica
333467|NCT01364259|tic douloureux
333468|NCT01364246|Progressive Multiple Sclerosis
333469|NCT01364246|neuromyelitis optica
333470|NCT01364246|Umbilical Cord Mesenchymal Stem Cell
333471|NCT01364220|Additional relevant MeSH terms
333472|NCT01364220|Stroke
333473|NCT01364220|Cerebral Infarction
333474|NCT01364220|Cerebrovascular Disorders
333475|NCT01364220|Hydroxymethylglutaryl-CoA Reductase Inhibitors
333476|NCT01364220|Magnetic Resonance Imaging
333477|NCT01364220|Recurrence
333478|NCT01364194|Post operative pain
333479|NCT01364194|Total knee replacement
333480|NCT01364194|Total knee arthroplasty
333481|NCT01364194|Bupivacaine
333482|NCT01364194|Periarticular injection
333483|NCT01364194|Placebo
333484|NCT01364194|Morphine consumption
333485|NCT01364181|Udenafil
333486|NCT01364181|Chronic obstructive pulmonary disease
333487|NCT01364181|pulmonary hypertension
333488|NCT01364181|Phosphodiesterase 5 inhibitors
333489|NCT01364181|Exercise
333490|NCT01364181|Dyspnea
333491|NCT01364129|Diabetes
333492|NCT01364129|Diabetic Retinopathy Screening
333493|NCT01364129|Ophthalmic Telemedicine
333494|NCT01364129|Comparative Effectiveness Research
333495|NCT01364116|Pulse CO-Oximetry™
333496|NCT01364116|children
333497|NCT01364116|noninvasive
333498|NCT01364103|pulse pressure variation
333499|NCT01364103|systolic pressure variation
333500|NCT01364103|central venous pressure
333501|NCT01364103|aortic blood flow velocity variation
333502|NCT01364103|pleth variability index
333503|NCT01364090|hepatitis C
333504|NCT01364090|treatment
333505|NCT01364090|injection drug users or receiving opiate substitution therapy
333506|NCT01364077|Heart rate
333507|NCT01364077|Dialysis
333508|NCT01364077|ESRD
333509|NCT01364077|ivabradine
333510|NCT01363973|oropharyngeal dysphagia
333511|NCT01363973|post-stroke
333512|NCT01363960|Incidence
333513|NCT01363960|neonatal care
333514|NCT01363960|retinopathy of prematurity
333515|NCT01363960|risk factors
333516|NCT01363934|Erythropoietin
333517|NCT01363934|EPO-hFC
333518|NCT01363921|CKD5
333519|NCT01363921|dialysis
333520|NCT01363921|high porous membranes
333521|NCT01363921|micro-inflammation
333522|NCT01363908|Beta-Thalassemia
333523|NCT01363908|Sickle Cell Anemia
333524|NCT01363908|Transfusional iron overload
333525|NCT01363908|Iron Overload
333526|NCT01363908|Iron Chelation
333527|NCT01363895|atrial fibrillation
333528|NCT01363895|catheter ablation
333529|NCT01363895|percutaneous closure of LAA
333530|NCT01363895|intervention
333531|NCT01363882|Amyotrophic Lateral Sclerosis
333532|NCT01363882|Noninvasive Ventilation
333533|NCT01363882|Respiratory Dysfunction
333534|NCT01363882|Positive Pressure Ventilation
333535|NCT01363869|hyperuricemia
333536|NCT01363869|gout
333537|NCT01363869|uric acid
333538|NCT01363869|xanthine oxidase inhibitor
333539|NCT01363869|green tea
333540|NCT01363869|catechins
333541|NCT01363869|antioxidant
333542|NCT01363856|first ever stroke
333543|NCT01363843|neoadjuvant
333544|NCT01363843|chemo/radiation
333545|NCT01363843|rectal cancer
333546|NCT01363843|rectum cancer
333547|NCT01363843|colon cancer
333548|NCT01363843|colorectal cancer
333549|NCT01363830|Disc
333550|NCT01363830|lumbar
333551|NCT01363830|herniation
333552|NCT01363804|AV-951
333553|NCT01363804|Tivozanib
333554|NCT01363804|Healthy Subjects
333555|NCT01363804|rifampin
333556|NCT01363804|Pharmacokinetics
333557|NCT01363791|Systematic review and meta-analysis
333558|NCT01363791|Evidence-based medicine (EBM)
333559|NCT01363791|Evidence-based nutrition (EBN)
333560|NCT01363791|Clinical practice guidelines
333561|NCT01363791|Clinical trials
333562|NCT01363791|Dietary sugars
333563|NCT01363791|Fructose
333564|NCT01363791|High fructose corn syrup
333565|NCT01363791|Fruit
333566|NCT01363791|Isocaloric
333567|NCT01363791|Hypercaloric
333568|NCT01363791|Cardiometabolic risk factors
333569|NCT01363791|Triglycerides
333570|NCT01363791|Cholesterol
333571|NCT01363791|Glycemic control
333572|NCT01363791|Insulin resistance
333573|NCT01363791|Body weight
333574|NCT01363791|Uric acid
333575|NCT01363791|Blood pressure
333576|NCT01363791|Fatty liver
333577|NCT01363791|Fasting
333578|NCT01363791|Postprandial
333579|NCT01363778|AV-951
333580|NCT01363778|Tivozanib
333581|NCT01363778|Healthy Subjects
333582|NCT01363778|ketoconazole
333583|NCT01363778|Pharmacokinetics
333584|NCT01363765|diagnosis
333585|NCT01363765|polymerase chain reaction
333586|NCT01363765|sputum smear
333587|NCT01363765|stepped-wedge design
333588|NCT01363765|cost-effectiveness
333589|NCT01363765|Xpert MTB/Rif
333590|NCT01363752|Kidney
333591|NCT01363752|Transplant
333592|NCT01363752|Immunosuppression
333593|NCT01363752|Kidney Failure, Acute
333594|NCT01363752|Advagraf
333595|NCT01363752|Tacrolimus
333596|NCT01363752|Astagraf XL
333597|NCT01363739|VEGF polymorphism Bevacizumab
333598|NCT01363726|surveillance Rotavirus Gastroenteritis Children
333599|NCT01363726|< 5 years of age
333600|NCT01363726|southern Israel
333601|NCT01363726|Signed informed concent
333602|NCT01363674|Growth disorders
333603|NCT01363674|Saizen
333604|NCT01363674|Easypod
333605|NCT01363674|Growth hormone
333606|NCT01363674|Pediatric subject
333607|NCT01363661|angina pectoris
333608|NCT01363661|atherosclerosis
333609|NCT01363661|endothelial dysfunction
333610|NCT01363648|VCI-HS
333611|NCT01363648|stroke
333612|NCT01363648|choline alphoscerate
333613|NCT01363635|severe sepsis/septic shock
333614|NCT01363635|organ failure
333615|NCT01363635|AKI
333616|NCT01363635|PMI
333617|NCT01363635|ALI
333618|NCT01363635|Stroke
333619|NCT01363635|ICU death
333620|NCT01363622|Vaspin
333621|NCT01363622|LGA
333622|NCT01363622|SGA
333623|NCT01363622|Insulin
333624|NCT01363622|Blood glucose
333625|NCT01363596|Infertility
333626|NCT01363596|Fertility
333627|NCT01363596|Reproductive Medicine
333628|NCT01363596|Pregnancy
333629|NCT01363596|Conception
333630|NCT01363596|Miscarriage
333631|NCT01363596|Ovulation Detection
333632|NCT01363596|Cervical Mucus
333633|NCT01363596|IVF Alternative
333634|NCT01363583|traumatic brain injury
333635|NCT01363570|Macular Degeneration
333636|NCT01363570|Age related macular degeneration
333637|NCT01363570|Macula Risk
333638|NCT01363570|Genetic test
333639|NCT01363570|Anti-inflammatory
333640|NCT01363570|Anti-vascular endothelial growth factor (Anti-VEGF)
333641|NCT01363570|Lucentis
333642|NCT01363570|Ranibizumab
333643|NCT01363570|Vision loss
333644|NCT01363557|Randomized
333645|NCT01363557|Brain Radiation Therapy
333646|NCT01363557|Lung Cancer
333647|NCT01363557|Brain Metastasis
333648|NCT01363557|Gefitinib
333649|NCT01363544|ADHD
333650|NCT01363544|neurofeedback
333651|NCT01363544|exercise
333652|NCT01363544|neurophysiology
333653|NCT01363531|Prescription
333654|NCT01363531|Antibiotic
333655|NCT01363531|Acute respiratory infections
333656|NCT01363531|Satisfaction
333657|NCT01363531|Perception
333658|NCT01363531|Pharyngitis and/or acute tonsillitis
333659|NCT01363531|Rhinosinusitis
333660|NCT01363531|Acute bronchitis
333661|NCT01363531|Acute exacerbation of chronic obstructive pulmonary disease (mild to moderate)
333662|NCT01363518|humerus
333663|NCT01363518|fracture
333664|NCT01363518|operative treatment
333665|NCT01363518|non-operative treatment
333666|NCT01363492|agalsidase alfa
333667|NCT01363492|Replagal
333668|NCT01363492|Enzyme Replacement Therapy
333669|NCT01363440|Diabetic Macular Edema
333670|NCT01363440|Diabetic Retinopathy
333671|NCT01363414|Dry eye
333672|NCT01363414|Ocular aberration
333673|NCT01363401|Amyotrophic lateral sclerosis
333674|NCT01363401|ALS
333675|NCT01363401|Motor neuron disease
333676|NCT01363401|MND
333677|NCT01363401|HYNR-CS inj
333678|NCT01363401|Autologous bone marrow derived stem cell
333679|NCT01363401|Intrathecal injection
333680|NCT01363375|Plantar fascia
333681|NCT01363375|Plantar fasciitis
333682|NCT01363375|Foot orthosis
333683|NCT01363375|Finite element analysis
333684|NCT01363375|Gait analysis
333685|NCT01363375|Plantar pressure measurement
333686|NCT01363362|Selective Laser Trabeculoplasty
333687|NCT01363362|pulsatile ocular blood flow
333688|NCT01363336|Adalat
333689|NCT01363336|Hypertension
333690|NCT01363336|Diabetes
333691|NCT01363336|Chronic kidney disease
333692|NCT01363297|Relapsed/Refractory Acute Lymphocytic Leukemia (ALL)
333693|NCT01363258|Elderly
333694|NCT01363258|Dementia
333695|NCT01363258|Care-resistant behavior
333696|NCT01363258|Oral health
333697|NCT01363258|Long-term care
333698|NCT01363245|cost effectiveness
333699|NCT01363245|behavioral health counseling
333700|NCT01363232|BKM120
333701|NCT01363232|MEK162
333702|NCT01363232|RAS RAF mutations
333703|NCT01363232|triple negative breast cancer
333704|NCT01363232|pancreatic cancer, ovarian cancer
333705|NCT01363232|NSCLC progressed on EGFR TKI
333706|NCT01363232|PI3K inhibitor
333707|NCT01363232|MEK inhibitor
333708|NCT01363206|Melanoma
333709|NCT01363206|GM-CSF
333710|NCT01363206|Ipilimumab
333711|NCT01363206|Immunologic Response
333712|NCT01363193|Weight-based heparin dosing
333713|NCT01363193|Obesity
333714|NCT01363193|Body Mass Index
333715|NCT01363193|Venous thromboembolism
333716|NCT01363193|Atrial fibrillation
333717|NCT01363193|Lean body weight
333718|NCT01363193|Unfractionated heparin
333719|NCT01363193|heparin
333720|NCT01363167|vitamin D
333721|NCT01363167|preterm infants
333722|NCT01363167|calcium
333723|NCT01363167|bone
333724|NCT01363167|parathyroid hormone
333725|NCT01363154|Children's Health
333726|NCT01363154|Pediatrics
333727|NCT01363154|Epilepsy
333728|NCT01363154|Photoparoxysmal
333729|NCT01363154|Photosensitive
333730|NCT01363154|Music
333731|NCT01363154|Mozart
333732|NCT01363154|K-448
333733|NCT01363141|Cardiovascular Diseases
333734|NCT01363141|Type 2 Diabetes Mellitus
333735|NCT01363141|Abdominal Fat
333736|NCT01363141|Atherogenic Dyslipidemia
333737|NCT01363141|Hypertension
333738|NCT01363141|Hyperglycemia
333739|NCT01363141|Insulin Resistance
333740|NCT01363141|Thrombosis state
333741|NCT01363128|Leukemia
333742|NCT01363128|Acute Lymphoblastic Leukemia
333743|NCT01363128|CD-20 Positive Acute Lymphoblastic Leukemia
333744|NCT01363128|Any level of CD20 expression
333745|NCT01363128|Lymphoblastic lymphoma
333746|NCT01363128|Central Venous Catheter
333747|NCT01363128|CVC
333748|NCT01363128|HCVAD
333749|NCT01363128|Cyclophosphamide
333750|NCT01363128|Cytoxan
333751|NCT01363128|Neosar
333752|NCT01363128|Mesna
333753|NCT01363128|Mesnex
333754|NCT01363128|Doxorubicin
333755|NCT01363128|Adriamycin
333756|NCT01363128|Rubex
333757|NCT01363128|Vincristine
333758|NCT01363128|Dexamethasone
333759|NCT01363128|Decadron
333760|NCT01363128|Ofatumumab
333761|NCT01363128|Arzerra
333762|NCT01363128|Methotrexate
333763|NCT01363128|Cytarabine
333764|NCT01363128|Ara-C
333765|NCT01363128|Cytosar
333766|NCT01363128|DepoCyt
333767|NCT01363128|Cytosine Arabinosine Hydrochloride
333768|NCT01363115|Body Weight
333769|NCT01363115|Dietary Supplement
333770|NCT01363115|Calcium
333771|NCT01363115|Vitamin D
333772|NCT01363102|Muscle strength
333773|NCT01363102|functional mobility
333774|NCT01363102|outcome
333775|NCT01363102|intensive care unit
333776|NCT01363102|quality of life
333777|NCT01363037|HIV infections
333778|NCT01363037|Anti-HIV agents
333779|NCT01363037|HIV-1
333780|NCT01363024|Solid Cancers
333781|NCT01363011|HIV-1
333782|NCT01363011|Treatment Naive
333783|NCT01363011|Treatment Experienced
333784|NCT01362998|fentanyl, morphine, duramorph, Cesarean section, epidural
333785|NCT01362959|Delirium
333786|NCT01362959|Psychomotor Agitation
333787|NCT01362959|Substance Withdrawal Syndrome
333788|NCT01362959|Nicotine replacement therapy
333789|NCT01362946|Conduct problems
333790|NCT01362946|callous-unemotional traits
333791|NCT01362946|disruptive behavior disorders
333792|NCT01362933|PE
333793|NCT01362933|DVT
333794|NCT01362933|SVT
333795|NCT01362933|LMWH
333796|NCT01362933|VKA
333797|NCT01362933|international Venous Thromboembolism Recommendations
333798|NCT01362920|Sepsis
333799|NCT01362920|Septic shock
333800|NCT01362920|Procalcitonin
333801|NCT01362920|PCT
333802|NCT01362881|Early
333803|NCT01362881|Onset
333804|NCT01362881|Scoliosis
333805|NCT01362868|Glaucoma
333806|NCT01362868|Triggerfish
333807|NCT01362868|Water drinking test
333808|NCT01362855|Advance Care Planning
333809|NCT01362855|End of life
333810|NCT01362855|Knowledge translation
333811|NCT01362855|Goals of care
333812|NCT01362855|Advance directive
333813|NCT01362855|Lining will
333814|NCT01362842|Lung Cancer
333815|NCT01362842|Symptom distress
333816|NCT01362842|Post-operation
333817|NCT01362842|Anxiety
333818|NCT01362842|Depression
333819|NCT01362842|Uncertainty
333820|NCT01362842|Fear of recurrence
333821|NCT01362842|Self-efficacy
333822|NCT01362842|Needs
333823|NCT01362803|Maximum Tolerated Dose
333824|NCT01362803|Pharmacokinetics
333825|NCT01362803|Pharmacodynamics
333826|NCT01362803|Response Rate
333827|NCT01362803|pain, quality of life and physical functioning
333828|NCT01362803|Neurofibromatosis Type 1
333829|NCT01362803|NF1
333830|NCT01362803|Plexiform Neurofibroma
333831|NCT01362790|Immune Therapy
333832|NCT01362790|Immunotoxin
333833|NCT01362790|T-Cell Depletion
333834|NCT01362790|Mesothelioma
333835|NCT01362777|Obstructive Sleep Apnea/Hypopnea Syndrome
333836|NCT01362777|Exercise training program
333837|NCT01362777|Inflammation
333838|NCT01362777|Oxidative Stress
333839|NCT01362777|Resistance to insulin
333840|NCT01362764|Abiraterone Acetate
333841|NCT01362764|ZYTIGA
333842|NCT01362738|Long-standing persistent atrial fibrillation
333843|NCT01362725|spinal cord stimulation
333844|NCT01362725|systolic heart failure
333845|NCT01362712|breast cancer
333846|NCT01362712|radiotherapy
333847|NCT01362712|chemoradiotherapy
333848|NCT01362712|radiation
333849|NCT01362712|chemoradiation
333850|NCT01362712|[F-18]
333851|NCT01362699|Alcoholism
333852|NCT01362699|Alcohol-Related Disorders
333853|NCT01362699|Substance-Related Disorders
333854|NCT01362699|Mental Disorders
333855|NCT01362699|Alcohol Dependence
333856|NCT01362699|JNJ-31001074
333857|NCT01362699|Bavisant
333858|NCT01362686|diagnosis of Alzheimer's disease
333859|NCT01362686|medication adherence
333860|NCT01362673|Phase 1
333861|NCT01362673|Pharmacokinetics
333862|NCT01362673|food effect
333863|NCT01362673|Healthy Japanese
333864|NCT01362673|rheumatoid arthritis
333865|NCT01362660|post-natal monitoring
333866|NCT01362660|exposure in utero
333867|NCT01362647|Muscle Relaxation
333868|NCT01362634|HIV/AIDS
333869|NCT01362634|substance use
333870|NCT01362634|club drugs
333871|NCT01362634|sexual risk
333872|NCT01362621|Allergic asthma
333873|NCT01362621|Pediatrics
333874|NCT01362621|Exacerbations
333875|NCT01362621|Perennial aeroallergens
333876|NCT01362621|Inhaled corticosteroids
333877|NCT01362608|Gout
333878|NCT01362608|Inflammatory gout
333879|NCT01362608|acute gout
333880|NCT01362595|leucine administration
333881|NCT01362595|red blood cell transfusion
333882|NCT01362595|Diamond Blackfan anemia
333883|NCT01362582|Pancreatic cancer
333884|NCT01362582|progression under chemotherapy
333885|NCT01362582|parenteral nutrition
333886|NCT01362582|pancreatic adenocarcinoma
333887|NCT01362582|chemotherapy
333888|NCT01362569|endotoxin
333889|NCT01362569|neutrophil function
333890|NCT01362569|albumin function
333891|NCT01362543|PTSD
333892|NCT01362543|Depression
333893|NCT01362543|Refugees
333894|NCT01362543|Trauma
333895|NCT01362517|Vaccination
333896|NCT01362517|Immunisation
333897|NCT01362517|Virus
333898|NCT01362517|Diphtheria
333899|NCT01362517|Pertussis
333900|NCT01362517|Tetanus
333901|NCT01362517|Hepatitis B
333902|NCT01362517|Haemophilus Influenzae
333903|NCT01362517|Immunity
333904|NCT01362504|Pro-adrenomedullin
333905|NCT01362504|Neonatal sepsis
333906|NCT01362504|Prognosis
333907|NCT01362504|Sepsis marker
333908|NCT01362504|Clinical sepsis
333909|NCT01362504|Proven sepsis
333910|NCT01362491|Headache
333911|NCT01362478|schizophrenia
333912|NCT01362478|gene promoter
333913|NCT01362478|methylation
333914|NCT01362478|endophenotype
333915|NCT01362478|epigenetic
333916|NCT01362452|Leukemia
333917|NCT01362452|Lymphoma
333918|NCT01362452|CD19-specific T cells
333919|NCT01362452|Umbilical cord blood transplantation
333920|NCT01362452|B-Lineage Lymphoid Malignancies
333921|NCT01362452|B-cell leukemia
333922|NCT01362452|Acute Lymphoblastic Leukemia
333923|NCT01362452|ALL
333924|NCT01362452|Biphenotypic Leukemia
333925|NCT01362452|Non-Hodgkin's Lymphoma
333926|NCT01362452|NHL
333927|NCT01362452|Small Lymphocytic Lymphoma
333928|NCT01362452|SLL
333929|NCT01362452|Chronic Lymphocytic Leukemia
333930|NCT01362452|CLL
333931|NCT01362452|White blood cells
333932|NCT01362452|T cells
333933|NCT01362452|Melphalan
333934|NCT01362452|Alkeran
333935|NCT01362452|Thiotepa
333936|NCT01362452|Fludarabine
333937|NCT01362452|Fludarabine Phosphate
333938|NCT01362452|Fludara
333939|NCT01362452|ATG
333940|NCT01362452|Antithymocyte Globulin
333941|NCT01362452|Thymoglobulin
333942|NCT01362452|Rituxan
333943|NCT01362452|Rituximab
333944|NCT01362452|Cyclophosphamide
333945|NCT01362452|Cytoxan
333946|NCT01362452|Neosar
333947|NCT01362439|Schizophrenia
333948|NCT01362439|Paliperidone
333949|NCT01362426|schizophrenia
333950|NCT01362426|paliperidone palmitate
333951|NCT01362426|INVEGA SUSTENNA
333952|NCT01362426|registries
333953|NCT01362426|quality of healthcare
333954|NCT01362413|pseudarthrosis
333955|NCT01362413|mineralization
333956|NCT01362413|platelet-rich-plasma
333957|NCT01362413|serum
333958|NCT01362400|LUNG NEOPLASMS
333959|NCT01362400|LARGE CELL CARCINOMA
333960|NCT01362400|SQUAMOUS CELL CARCINOMA
333961|NCT01362387|Medical abortion
333962|NCT01362387|abortion follow-up
333963|NCT01362361|Second line colorectal cancer
333964|NCT01362348|Age-related Macular Degeneration
333965|NCT01362322|dTpa
333966|NCT01362322|Boostrix
333967|NCT01362309|Alcohol
333968|NCT01362309|Cues
333969|NCT01362309|Extinction
333970|NCT01362309|D-Cycloserine
333971|NCT01362296|NRAS
333972|NCT01362296|docetaxel
333973|NCT01362296|NSCLC
333974|NCT01362296|GSK1120212
333975|NCT01362296|MEK inhibitor
333976|NCT01362296|targeted therapy
333977|NCT01362296|KRAS
333978|NCT01362296|BRAF
333979|NCT01362270|Anxiolytics
333980|NCT01362270|Sedatives
333981|NCT01362270|Acupuncture Therapy
333982|NCT01362244|Quality of Life
333983|NCT01362244|Intranasal Steroids
333984|NCT01362244|Severe Nasal Polyposis
333985|NCT01362244|Polyp Relapse
333986|NCT01362244|Endoscopic Polyp Score
333987|NCT01362244|Surgery
333988|NCT01362231|Fibrosis
333989|NCT01362231|Pulmonary Fibrosis
333990|NCT01362231|Lung Diseases
333991|NCT01362231|Interstitial
333992|NCT01362205|Severe Alcohol Withdrawal Delirium Tremens
333993|NCT01362192|Telangiectasis
333994|NCT01362192|Spider Veins
333995|NCT01362192|Excel V
333996|NCT01362192|Cutera
333997|NCT01362192|Laser
333998|NCT01362192|Leg Veins
333999|NCT01362192|Venulectasia
334000|NCT01362192|Lower Extremity veins
334001|NCT01362192|Laser light
334002|NCT01362192|KTP
334003|NCT01362192|532nm
334004|NCT01362179|malignant myeloid hematologic disorders
334005|NCT01362179|filgrastim
334006|NCT01362179|long term incidence
334007|NCT01362179|donors who received and in those who did not receive filgrastim.
334008|NCT01362166|Chinese medicine
334009|NCT01362166|channel
334010|NCT01362166|acupuncture
334011|NCT01362166|ZuSanLi
334012|NCT01362166|XianGu
334013|NCT01362166|frequency response
334014|NCT01362166|resonance
334015|NCT01362166|male volunteer
334016|NCT01362166|aged within 20-35 years old
334017|NCT01362153|Golimumab
334018|NCT01362153|Simponi
334019|NCT01362153|Rheumatoid Arthritis
334020|NCT01362153|PK
334021|NCT01362153|PD
334022|NCT01362140|Randomized
334023|NCT01362140|Darbepoetin alfa
334024|NCT01362140|Myelodysplastic Syndromes
334025|NCT01362140|Placebo-controlled
334026|NCT01362140|low risk MDS
334027|NCT01362140|intermediate-1 risk MDS
334028|NCT01362140|International Prognostic Scoring System
334029|NCT01362127|Histologically confirmed squamos cell carcinoma or adenocarcinoma of the esophagus and gastric cardia.Suitable for surgery.
334030|NCT01362114|Hwa-byung
334031|NCT01362114|Sihogayonggolmoryeo-tang
334032|NCT01362114|Anxiety
334033|NCT01362101|cue reactivity
334034|NCT01362101|physiologic activation
334035|NCT01362101|craving
334036|NCT01362101|smoking cues
334037|NCT01362101|Behavioral therapy
334038|NCT01362088|microcirculation
334039|NCT01362088|intensive care
334040|NCT01362088|ultrafiltration
334041|NCT01362088|CVVH
334042|NCT01362075|Shoulder Arthroplasty
334043|NCT01362075|Local infiltration analgesia
334044|NCT01362049|Stabilization exercise
334045|NCT01362049|Physical therapy
334046|NCT01362049|Rehabilitation
334047|NCT01362049|Movement System Impairment exercise
334048|NCT01362010|Acne
334049|NCT01362010|Acne Vulgaris
334050|NCT01362010|Topical
334051|NCT01362010|Minocycline
334052|NCT01362010|Foam
334053|NCT01362010|Phase II
334054|NCT01361997|Antiseptics
334055|NCT01361997|Hemoculture contamination
334056|NCT01361997|Anti-infecting agents, local
334057|NCT01361984|Chronic Obstructive Pulmonary Disease
334058|NCT01361984|COPD
334059|NCT01361984|Emphysema
334060|NCT01361984|Chronic Bronchitis
334061|NCT01361984|Brovana
334062|NCT01361984|Serevent
334063|NCT01361971|Insulin resistance
334064|NCT01361971|Inflammation
334065|NCT01361971|Hypoxia
334066|NCT01361945|ER+
334067|NCT01361945|HER2+
334068|NCT01361945|Breast
334069|NCT01361919|compressions
334070|NCT01361919|quality
334071|NCT01361919|teaching method
334072|NCT01361919|feedback
334073|NCT01361919|CPR performance - how well do students perform CPR when taught with feedback?
334074|NCT01361919|Cardiopulmonary resuscitation (CPR)
334075|NCT01361906|Musculoskeletal and Neural Physiological Phenomena
334076|NCT01361906|Postural Balance
334077|NCT01361906|Eye/hand coordination
334078|NCT01361893|SIDS
334079|NCT01361893|African American
334080|NCT01361893|Infants
334081|NCT01361893|Disparity
334082|NCT01361880|African American
334083|NCT01361880|Anticipatory Guidance
334084|NCT01361880|Health Promotion
334085|NCT01361880|Infant Mortality
334086|NCT01361880|Injury Prevention
334087|NCT01361880|Nurses
334088|NCT01361880|Parent Education
334089|NCT01361880|sudden Infant Death Syndrome
334090|NCT01361867|motor adaptation
334091|NCT01361867|force-field adaptation paradigm
334092|NCT01361867|lower extremity motor learning
334093|NCT01361854|polysomnography
334094|NCT01361854|portable monitoring
334095|NCT01361854|sleep
334096|NCT01361854|sleep disordered breathing
334097|NCT01361854|home based polysomnography
334098|NCT01361841|Latanoprost
334099|NCT01361841|bimatoprost
334100|NCT01361841|travoprost
334101|NCT01361841|non responders
334102|NCT01361828|Bevacizumab
334103|NCT01361828|VEP
334104|NCT01361828|ERG
334105|NCT01361828|Optic nerve and retinal functions following intravitreal bevacizumab
334106|NCT01361815|Depression
334107|NCT01361815|MDD
334108|NCT01361815|SSRIs
334109|NCT01361815|TMS
334110|NCT01361789|Arthroscopic reconstruction
334111|NCT01361789|Anterior crucial ligament
334112|NCT01361789|Coxib
334113|NCT01361789|Dexamethasone
334114|NCT01361776|immune response
334115|NCT01361776|TBE-vaccine
334116|NCT01361776|elderly
334117|NCT01361776|additional doses
334118|NCT01361763|Dabigatran
334119|NCT01361763|Microbleeds
334120|NCT01361763|Microthrombi
334121|NCT01361763|CADASIL
334122|NCT01361763|Small Vessel Disease
334123|NCT01361737|Preeclampsia
334124|NCT01361737|serological bio-bank
334125|NCT01361737|adiponectin
334126|NCT01361737|suPAR
334127|NCT01361724|Parkinson's disease
334128|NCT01361724|PD
334129|NCT01361724|Exercise
334130|NCT01361724|Balance
334131|NCT01361724|Mobility
334132|NCT01361698|recovery
334133|NCT01361698|illness management
334134|NCT01361698|rehabilitation
334135|NCT01361698|mental illness
334136|NCT01361698|psychosocial intervention
334137|NCT01361698|Clinical recovery (increase in functioning, decrease in symptoms)
334138|NCT01361698|Personal recovery (Hope, optimism, living a fulfilling life)
334139|NCT01361659|anginal complaints
334140|NCT01361659|Lithotripsy
334141|NCT01361659|no option patients
334142|NCT01361633|d-cycloserine
334143|NCT01361633|geriatric
334144|NCT01361633|neuropsychology
334145|NCT01361633|cognition
334146|NCT01361633|cognitive-enhancer
334147|NCT01361633|aging
334148|NCT01361633|neuropsychological functioning
334149|NCT01361620|genomic markers
334150|NCT01361620|aspirin resistance
334151|NCT01361607|Cancer pain
334152|NCT01361607|Opioid therapy
334153|NCT01361607|Inadequate analgesia
334154|NCT01361607|Optimized chronic opioid therapy
334155|NCT01361594|Diabetes
334156|NCT01361594|Coronary Artery Bypass Surgery
334157|NCT01361594|Glycemic control
334158|NCT01361594|Insulin infusion
334159|NCT01361581|Acute renal failure
334160|NCT01361581|Anticoagulation
334161|NCT01361581|Citrate
334162|NCT01361581|Haemodiafiltration
334163|NCT01361581|Haemofiltration
334164|NCT01361581|Renal replacement therapy
334165|NCT01361568|pain
334166|NCT01361568|acute pain
334167|NCT01361568|visceral pain
334168|NCT01361568|kappa agonist
334169|NCT01361568|opioid analgesics
334170|NCT01361568|peripheral nervous system agents
334171|NCT01361568|physiological effects of drugs
334172|NCT01361568|surgery
334173|NCT01361568|hysterectomy
334174|NCT01361568|post-operative
334175|NCT01361568|post-operative complications
334176|NCT01361542|TNF
334177|NCT01361542|BMD
334178|NCT01361542|Ankylosing spondylitis
334179|NCT01361542|bone health
334180|NCT01361542|Anti TNF therapy
334181|NCT01361542|Disease activity
334182|NCT01361529|dose escalation
334183|NCT01361516|Urolithiasis
334184|NCT01361516|ESWL
334185|NCT01361516|Stone Fragmentation efficacy
334186|NCT01361516|Sedation
334187|NCT01361516|General Anaesthesia
334188|NCT01361503|Autism Spectrum Disorders
334189|NCT01361503|Pervasive Developmental Disorders
334190|NCT01361503|Asperger's Syndrome
334191|NCT01361503|Adolescents
334192|NCT01361503|Magnetic Resonance Spectroscopy
334193|NCT01361503|Diffusion Tensor Imaging
334194|NCT01361477|General surgical ICU
334195|NCT01361477|ICU Siamitra
334196|NCT01361477|ICU Salad-Samung
334197|NCT01361477|Data registry
334198|NCT01361477|ICU refusal
334199|NCT01361477|ICU complications
334200|NCT01361477|ICU resource utilization
334201|NCT01361477|Adverse events
334202|NCT01361477|ICU readmission
334203|NCT01361451|parasternal electromyogram
334204|NCT01361451|neural respiratory drive
334205|NCT01361451|chronic obstructive pulmonary disease
334206|NCT01361451|respiratory physiology
334207|NCT01361451|Acute exacerbation
334208|NCT01361425|hypertension
334209|NCT01361425|ultrasonography
334210|NCT01361425|preeclampsia
334211|NCT01361425|clinical trials
334212|NCT01361425|treatment
334213|NCT01361425|methyldopa
334214|NCT01361412|ragweed allergy
334215|NCT01361412|immunotherapy
334216|NCT01361399|Sore Throat
334217|NCT01361386|Long-term follow up
334218|NCT01361386|Antithrombotic management patterns
334219|NCT01361386|Acute Coronary Syndrome
334220|NCT01361386|Asia
334221|NCT01361386|quality of life
334222|NCT01361347|milk allergy
334223|NCT01361347|desensitization
334224|NCT01361347|anaphylaxis
334225|NCT01361347|school-age
334226|NCT01361334|(other than AML M3)
334227|NCT01361321|follow up
334228|NCT01361321|Guided bone regeneration
334229|NCT01361321|Micro computerized tomography
334230|NCT01361321|histological examination
334231|NCT01361308|Menopause
334232|NCT01361308|Vasomotor Symptoms
334233|NCT01361308|Hot Flashes Perimenopause
334234|NCT01361308|Climacteric Symptoms
334235|NCT01361308|Mesafem
334236|NCT01361308|Low-Dose Mesylate salt of Paroxetine (LDMP)
334237|NCT01361295|Atrial fibrillation
334238|NCT01361295|cerebral embolism
334239|NCT01361295|catheter ablation
334240|NCT01361282|Total Corneal Power
334241|NCT01361282|Optical Coherence Tomography
334242|NCT01361282|Descemet Stripping Endothelial Keratoplasty
334243|NCT01361256|Macular Degeneration
334244|NCT01361256|Visual Impairment
334245|NCT01361256|Implantable Telescope
334246|NCT01361243|Pediatric Overweight
334247|NCT01361243|Pediatric Obesity
334248|NCT01361217|Fluoxetine
334249|NCT01361217|CYP3A4
334250|NCT01361217|CYP2D6
334251|NCT01361217|CYP2C19
334252|NCT01361217|Drug-Drug Interaction
334253|NCT01361217|Multi-CYP Inhibition
334254|NCT01361204|stress
334255|NCT01361204|students
334256|NCT01361204|pharmacy practice
334257|NCT01361204|theanine
334258|NCT01361204|pharmacy training
334259|NCT01361191|DLBCL
334260|NCT01361191|PET
334261|NCT01361191|IPI
334262|NCT01361191|R-MegaCHOP
334263|NCT01361191|Autologous stem cell transplantation
334264|NCT01361165|Pediatric
334265|NCT01361165|Data Analysis
334266|NCT01361152|total knee arthroplasty
334267|NCT01361152|fixed-bearing
334268|NCT01361152|mobile-bearing
334269|NCT01361152|long-term
334270|NCT01361139|Chronic obstructive lung disease
334271|NCT01361139|Interstitial lung disease
334272|NCT01361139|Asthma
334273|NCT01361139|Sarcoidosis
334274|NCT01361139|Pulmonary hypertension
334275|NCT01361139|Ultrasound
334276|NCT01361139|Doppler
334277|NCT01361139|Lung disease diagnosis
334278|NCT01361113|Renal Cell Carcinoma
334279|NCT01361113|RCC
334280|NCT01361113|Votrient
334281|NCT01361113|Pazopanib
334282|NCT01361113|Nephrectomy
334283|NCT01361113|Neoadjuvant
334284|NCT01361113|Phase II
334285|NCT01361113|LCCC 1028
334286|NCT01361113|Lineberger Comprehensive Cancer Center
334287|NCT01361100|Otolaryngology
334288|NCT01361087|TGF-B blood levels Atenolol vs, Losartan Study, NIH, NIHLB and NMF
334289|NCT01361074|Virtual reality
334290|NCT01361074|Augmented reality
334291|NCT01361074|In vivo exposure
334292|NCT01361074|One session treatment
334293|NCT01361074|ICT
334294|NCT01361074|Efficacy
334295|NCT01361074|Specific phobia
334296|NCT01361074|Anxiety disorders
334297|NCT01361061|liver cirrhosis
334298|NCT01361061|screening
334299|NCT01361061|hepatocellular carcinoma
334300|NCT01361061|liver cancer markers: AFP, AFP-L3% and DCP
334301|NCT01361048|trichomonas
334302|NCT01361035|health literacy
334303|NCT01361035|cancer screening
334304|NCT01361035|doctor-patient communication
334305|NCT01361035|standardized patient
334306|NCT01361035|continuing medical education
334307|NCT01360996|PCOS
334308|NCT01360970|hepatitis A vaccine
334309|NCT01360970|TNF-alfa inhibitory drugs
334310|NCT01360970|Rheumatoid arthritis
334311|NCT01360970|methotrexate
334312|NCT01360957|Obesity
334313|NCT01360944|PPT, topical, psoriasis
334314|NCT01360931|Lung cancer
334315|NCT01360931|Chronic obstructive pulmonary disease
334316|NCT01360905|PTL
334317|NCT01360905|Multiples
334318|NCT01360892|Hepatitis B virus
334319|NCT01360892|Hepatitis C virus
334320|NCT01360892|Chronic hepatitis
334321|NCT01360892|Liver chlorosis
334322|NCT01360892|Liver stiffness
334323|NCT01360892|Liver fibrosis
334324|NCT01360879|Hepatitis B virus
334325|NCT01360879|Hepatitis C virus
334326|NCT01360879|Chronic hepatitis
334327|NCT01360879|Liver cirrhosis
334328|NCT01360879|Liver stiffness
334329|NCT01360879|Liver fibrosis
334330|NCT01360866|OPC-34712
334331|NCT01360866|brexpiprazole
334332|NCT01360866|Major Depressive Disorder
334333|NCT01360866|Adjunctive Treatment
334334|NCT01360853|pancreatic cancer
334335|NCT01360853|gemcitabine
334336|NCT01360853|ON 01910.Na
334337|NCT01360853|rigosertib sodium
334338|NCT01360840|Asymptomatic
334339|NCT01360840|mildly symptomatic
334340|NCT01360840|metastatic castrate-resistant prostate cancer
334341|NCT01360840|mCRPC
334342|NCT01360827|Safety
334343|NCT01360827|tolerability
334344|NCT01360827|maximum tolerated dose of EMD 1201081
334345|NCT01360827|TLR9 agonists
334346|NCT01360827|squamous cell carcinoma of the head and neck
334347|NCT01360827|First line subjects
334348|NCT01360827|recurrent/metastatic
334349|NCT01360788|chronic obstructive pulmonary disease
334350|NCT01360788|lung function
334351|NCT01360788|symptoms
334352|NCT01360788|activity-related dyspnea
334353|NCT01360788|quadriceps muscle function
334354|NCT01360788|exercise capacity
334355|NCT01360788|physical activity in daily life
334356|NCT01360788|muscle biopsy
334357|NCT01360788|systemic inflammation
334358|NCT01360788|GOLD stage I
334359|NCT01360788|pulmonary function
334360|NCT01360775|Nutritional status
334361|NCT01360775|Dependent patients
334362|NCT01360775|Nutritional educational intervention
334363|NCT01360775|Caregivers
334364|NCT01360775|Clinical assay
334365|NCT01360762|Secondary prophylaxis
334366|NCT01360762|Visceral leishmaniasis
334367|NCT01360762|Relapses
334368|NCT01360762|HIV co-infection
334369|NCT01360762|Pentamidine
334370|NCT01360762|Ethiopia
334371|NCT01360749|Pain management
334372|NCT01360749|Lidocaine
334373|NCT01360736|Suicide Prevention
334374|NCT01360736|Suicide Attempt
334375|NCT01360736|Suicide Ideation
334376|NCT01360736|Randomized Controlled Trial
334377|NCT01360736|Safety Planning
334378|NCT01360710|male age 18-30 years old
334379|NCT01360710|presence of central obesity
334380|NCT01360710|no history of cardiovascular disease, depression
334381|NCT01360710|not on any medication
334382|NCT01360697|Diabetes
334383|NCT01360697|Structured care
334384|NCT01360671|PPHN
334385|NCT01360671|persistent pulmonary hypertension of the newborn
334386|NCT01360671|sildenafil
334387|NCT01360671|iv
334388|NCT01360658|Intravenous immunoglobulins
334389|NCT01360658|Solar urticaria
334390|NCT01360658|Minimal urticaria dose
334391|NCT01360658|Quality of life
334392|NCT01360658|Safety
334393|NCT01360645|OPC-34712
334394|NCT01360645|brexpiprazole
334395|NCT01360645|Major Depressive Disorder
334396|NCT01360645|Adjunctive Treatment
334397|NCT01360632|OPC-34712
334398|NCT01360632|brexpiprazole
334399|NCT01360632|Major Depressive Disorder
334400|NCT01360632|Adjunctive Treatment
334401|NCT01360619|To demonstrate that multifunction Keito is as effective, as safe and accurate as the predicate K014009 on its body fat measurement.
334402|NCT01360606|Liver
334403|NCT01360606|Mets
334404|NCT01360593|Pancreas
334405|NCT01360567|green tea
334406|NCT01360567|EGCG
334407|NCT01360567|type 2 diabetes
334408|NCT01360567|hyperlipidemia
334409|NCT01360554|comparative study of PF-00299804 and Erlotinib
334410|NCT01360554|Double-Blind Phase 3 trial of TKI
334411|NCT01360541|Barrett oesophagus
334412|NCT01360541|Low grade dysplasia
334413|NCT01360541|Radiofrequency ablation
334414|NCT01360528|Folic acid replacement
334415|NCT01360528|Folic acid
334416|NCT01360528|Preterm neonate
334417|NCT01360515|esophagoscope
334418|NCT01360515|esophageal disease
334419|NCT01360515|gastroesophageal reflux
334420|NCT01360515|esophageal varices
334421|NCT01360502|capsule endoscopy
334422|NCT01360502|cardiac pacemaker
334423|NCT01360502|implantable cardiac defibrillator
334424|NCT01360476|hypertension
334425|NCT01360476|left ventricular hypertrophy
334426|NCT01360476|Vitamin D
334427|NCT01360476|African-Americans
334428|NCT01360463|drug abuse counseling
334429|NCT01360463|HIV risk reduction counseling
334430|NCT01360463|HIV infection
334431|NCT01360463|injection drug users
334432|NCT01360463|AIDS
334433|NCT01360450|opioid withdrawal
334434|NCT01360450|NPASS
334435|NCT01360450|duraclon
334436|NCT01360437|coronary angioplasty
334437|NCT01360437|clopidogrel hyporesponsiveness
334438|NCT01360437|prasugrel
334439|NCT01360437|ticagrelor
334440|NCT01360437|CAD
334441|NCT01360437|ACS
334442|NCT01360424|osteoporosis
334443|NCT01360424|teriparatide
334444|NCT01360424|bone turnover
334445|NCT01360424|New forms of inherited low-turnover osteoporosis
334446|NCT01360411|elastography
334447|NCT01360411|strain ratio
334448|NCT01360411|pancreas
334449|NCT01360411|GI wall lesions
334450|NCT01360411|lymph nodes
334451|NCT01360398|pathogen
334452|NCT01360398|Chronic Obstructive Pulmonary Disease
334453|NCT01360398|Acute Exacerbations of Chronic Obstructive Pulmonary Disease
334454|NCT01360398|COPD
334455|NCT01360398|respiratory
334456|NCT01360398|AECOPD
334457|NCT01360398|exacerbation
334458|NCT01360385|Central retinal rein occlusion
334459|NCT01360385|Retinal oximetry
334460|NCT01360385|Oxymap Retinal Oximeter
334461|NCT01360385|Visual acuity
334462|NCT01360385|Central retinal thickness
334463|NCT01360372|Hydrogen breath test value and gastric residual volume measurements
334464|NCT01360372|Tube feeding tolerance while taking a stable dose of opiate
334465|NCT01360359|low back pain
334466|NCT01360359|core stabilization
334467|NCT01360359|trunk muscle exercises
334468|NCT01360359|physical therapy
334469|NCT01360359|RCT
334470|NCT01360346|Enteral Sedation
334471|NCT01360346|Intravenous Sedation
334472|NCT01360346|Critically ill ICU patient
334473|NCT01360346|Conscious Sedation
334474|NCT01360346|Deep Sedation
334475|NCT01360346|RASS
334476|NCT01360346|CAM-ICU
334477|NCT01360346|VNR
334478|NCT01360346|BPS
334479|NCT01360346|Propofol
334480|NCT01360346|Midazolam
334481|NCT01360346|Hydroxyzine
334482|NCT01360346|Lorazepam
334483|NCT01360346|Melatonin
334484|NCT01360333|Dehydration
334485|NCT01360333|Hydration
334486|NCT01360320|Green tea
334487|NCT01360320|polyphenol
334488|NCT01360320|catechin
334489|NCT01360320|EGCG
334490|NCT01360320|Epigallocatechin gallate
334491|NCT01360320|colorectal adenoma
334492|NCT01360320|adenoma prevention
334493|NCT01360320|colon cancer prevention
334494|NCT01360307|psychometric validation
334495|NCT01360307|major depressive disorder
334496|NCT01360307|patient-reported outcome
334497|NCT01360294|Asthma
334498|NCT01360294|Small airways disease
334499|NCT01360294|Questionnaire
334500|NCT01360281|Quadriceps strength
334501|NCT01360281|osteoarthritis rehabilitation
334502|NCT01360281|NMES
334503|NCT01360255|Hepatocellular Carcinoma
334504|NCT01360255|transarterial chemoembolisation
334505|NCT01360255|liver cancer markers: AFP, AFP-L3% and DCP
334506|NCT01360242|Acute STEMI
334507|NCT01360242|Thrombus aspiration
334508|NCT01360242|Angioplasty
334509|NCT01360242|Primary Percutaneous Coronary Intervention
334510|NCT01360229|Parkinsons Disease
334511|NCT01360229|Fatigue
334512|NCT01360216|Long-acting reversible contraception
334513|NCT01360216|Intrauterine contraception
334514|NCT01360216|Intrauterine devices
334515|NCT01360216|Single-rod implant
334516|NCT01360216|Hormonal contraception
334517|NCT01360190|MDD
334518|NCT01360190|major depressive disorder
334519|NCT01360190|QEEG
334520|NCT01360190|electroencephalograph
334521|NCT01360190|fluoxtine
334522|NCT01360190|placebo
334523|NCT01360164|Human Umbilical Cord Mesenchymal Stem Cells
334524|NCT01360151|VEGF (Vascular endothelial growth factor)
334525|NCT01360125|adult acute basophilic leukemia
334526|NCT01360125|adult acute eosinophilic leukemia
334527|NCT01360125|adult acute erythroid leukemia (M6)
334528|NCT01360125|adult acute megakaryoblastic leukemia (M7)
334529|NCT01360125|adult acute minimally differentiated myeloid leukemia (M0)
334530|NCT01360125|adult acute monoblastic leukemia (M5a)
334531|NCT01360125|adult acute monocytic leukemia (M5b)
334532|NCT01360125|adult acute myeloblastic leukemia with maturation (M2)
334533|NCT01360125|adult acute myeloblastic leukemia without maturation (M1)
334534|NCT01360125|adult acute myeloid leukemia in remission
334535|NCT01360125|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
334536|NCT01360125|adult acute myeloid leukemia with del(5q)
334537|NCT01360125|adult acute myeloid leukemia with inv(16)(p13;q22)
334538|NCT01360125|adult acute myeloid leukemia with t(16;16)(p13;q22)
334539|NCT01360125|adult acute myeloid leukemia with t(8;21)(q22;q22)
334540|NCT01360125|adult acute myelomonocytic leukemia (M4)
334541|NCT01360112|Mosquito
334542|NCT01360112|Membrane
334543|NCT01360112|Feeding
334544|NCT01360112|Parasites
334545|NCT01360112|Infection
334546|NCT01360112|Malaria
334547|NCT01360099|Atypical Hip Fracture
334548|NCT01360099|Biosphosphonates
334549|NCT01360099|Subtrochanteric Hip Fracture
334550|NCT01360099|Osteoporosis
334551|NCT01360086|adenocarcinoma of the gastroesophageal junction
334552|NCT01360086|adenocarcinoma of the stomach
334553|NCT01360086|stage IB gastric cancer
334554|NCT01360086|stage IIA gastric cancer
334555|NCT01360086|stage IIB gastric cancer
334556|NCT01360086|stage IIIA gastric cancer
334557|NCT01360086|stage IIIB gastric cancer
334558|NCT01360086|stage IIIC gastric cancer
334559|NCT01360073|MI
334560|NCT01360073|low dose aspirin
334561|NCT01360073|PPI
334562|NCT01360073|epidemiology
334563|NCT01360073|Nonfatal MI and coronary death
334564|NCT01360047|MI
334565|NCT01360047|low dose aspirin
334566|NCT01360047|PPI
334567|NCT01360047|epidemiology
334568|NCT01360034|Obstetric labor, premature
334569|NCT01360034|Short cervix
334570|NCT01360034|Nifedipine
334571|NCT01360034|Indomethacin
334572|NCT01360008|Cardiac arrhythmia
334573|NCT01360008|Catheter ablation
334574|NCT01360008|Cohort Study
334575|NCT01360008|cryoballoon
334576|NCT01360008|radiofrequency
334577|NCT01359995|cytomegalovirus endotheliitis
334578|NCT01359982|Advanced Solid Tumors
334579|NCT01359982|Lymphomas
334580|NCT01359982|Safety
334581|NCT01359982|Blood flow
334582|NCT01359982|Nitric oxide
334583|NCT01359982|Cancer
334584|NCT01359982|Dynamic contrast enhanced MRI (DCE-MRI)
334585|NCT01359982|Contrast Enhanced Ultrasound (CEUS)
334586|NCT01359969|Hereditary Angioedema
334587|NCT01359969|HAE
334588|NCT01359969|Angioedema
334589|NCT01359969|Recombinant C1 Inhibitor
334590|NCT01359969|rhC1INH
334591|NCT01359969|Pediatrics
334592|NCT01359943|Rheumatoid Arthritis
334593|NCT01359943|RA
334594|NCT01359943|secukinumab
334595|NCT01359943|AIN457
334596|NCT01359943|inflammatory joints
334597|NCT01359943|American College of Rheumatology
334598|NCT01359943|ACR
334599|NCT01359904|dialysate glucose
334600|NCT01359904|glycemic control
334601|NCT01359904|hypoglycemic episodes
334602|NCT01359878|Postpartum haemorrhage
334603|NCT01359878|Postpartum bleeding
334604|NCT01359878|Postnatal bleeding
334605|NCT01359878|Fibrinogen concentrate
334606|NCT01359878|Transfusion
334607|NCT01359878|Haemostatis
334608|NCT01359878|Thrombelastography
334609|NCT01359865|Total hip arthroplasty
334610|NCT01359865|lumbar plexus block
334611|NCT01359865|spinal anesthesia
334612|NCT01359865|range of motion
334613|NCT01359865|Anesthetic Technique
334614|NCT01359865|Post-operative Pain Scores
334615|NCT01359852|JNJ-42491293
334616|NCT01359852|JNJ-40411813
334617|NCT01359852|Metabotropic glutamate subtype 2 receptor (mGlu2R)
334618|NCT01359852|Positive allosteric modulator (PAM)
334619|NCT01359852|positron emission tomography (PET)
334620|NCT01359826|Systemic Lupus Erythematosus
334621|NCT01359826|Widespread Pain
334622|NCT01359826|Fibromyalgia
334623|NCT01359826|Fatigue
334624|NCT01359826|Pain
334625|NCT01359826|Quality of Life
334626|NCT01359800|HIV
334627|NCT01359800|HAART
334628|NCT01359774|Energy
334629|NCT01359774|Metabolism
334630|NCT01359774|Spectroscopy
334631|NCT01359761|Suicide
334632|NCT01359761|Cognitive Therapy
334633|NCT01359761|Inpatient
334634|NCT01359761|Military
334635|NCT01359748|Non Invasive Blood Pressure measurement study.
334636|NCT01359735|Wound
334637|NCT01359735|non-melanoma skin cancer
334638|NCT01359735|Mohs micrographic surgery
334639|NCT01359735|Head or neck
334640|NCT01359722|N-acetylcysteine
334641|NCT01359722|Myocardial Revascularization
334642|NCT01359722|Acute Renal Failure
334643|NCT01359722|Oxidative Stress
334644|NCT01359696|solid cancers
334645|NCT01359670|Duchenne
334646|NCT01359670|muscular dystrophy
334647|NCT01359670|tadalafil
334648|NCT01359670|sildenafil
334649|NCT01359670|muscle ischemia
334650|NCT01359670|exercise
334651|NCT01359657|Relapsed
334652|NCT01359657|Refractory
334653|NCT01359631|Chronic Cluster Headache
334654|NCT01359618|Phase I
334655|NCT01359618|Safety
334656|NCT01359618|tolerability
334657|NCT01359618|healthy
334658|NCT01359618|major depressive disorder
334659|NCT01359618|thorough QT
334660|NCT01359618|maximum tolerated dose
334661|NCT01359618|elimination
334662|NCT01359618|heart electrical signal
334663|NCT01359605|ADME
334664|NCT01359605|Healthy volunteers
334665|NCT01359592|stage I adult diffuse large cell lymphoma
334666|NCT01359592|contiguous stage II adult diffuse large cell lymphoma
334667|NCT01359592|noncontiguous stage II adult diffuse large cell lymphoma
334668|NCT01359592|stage III adult diffuse large cell lymphoma
334669|NCT01359592|stage IV adult diffuse large cell lymphoma
334670|NCT01359579|renal impairment
334671|NCT01359579|phase 1
334672|NCT01359579|healthy volunteers
334673|NCT01359540|Total Hip Arthroplasty
334674|NCT01359540|Bone Loss
334675|NCT01359540|Femoral Remodeling
334676|NCT01359527|Total Hip Replacement
334677|NCT01359527|Hip Resurfacing
334678|NCT01359527|Femoral Remodeling
334679|NCT01359527|Bone Loss
334680|NCT01359501|patients receiving chemotherapy
334681|NCT01359488|Growth Hormone Deficiency
334682|NCT01359488|rhGH
334683|NCT01359488|hGH
334684|NCT01359488|Versartis
334685|NCT01359488|AGHD
334686|NCT01359488|Hormones
334687|NCT01359488|Hormone substitute
334688|NCT01359488|Endocrin System disease
334689|NCT01359488|Bone disease
334690|NCT01359488|Bone disease, developmental
334691|NCT01359488|Bone diseases
334692|NCT01359488|Musculoskeletal diseases
334693|NCT01359488|Bone diseases, endocrine
334694|NCT01359488|Metabolism diseases
334695|NCT01359488|Hypopituitarism
334696|NCT01359488|Pituitary disease
334697|NCT01359488|Hypothalmic disease
334698|NCT01359488|Brain disease
334699|NCT01359488|Growth Hormone Releasing Hormone
334700|NCT01359488|Hormone replacement therapy
334701|NCT01359488|IGF-I
334702|NCT01359488|IGFBP-3
334703|NCT01359475|Acetal crowns
334704|NCT01359475|Primary molars
334705|NCT01359475|The retention of acetal crowns in primary dentition
334706|NCT01359475|Color changes of acetal crowns
334707|NCT01359462|hepatic cirrhosis patients with ascites
334708|NCT01359449|Meningitis
334709|NCT01359449|Meningococcal Infection
334710|NCT01359449|Menactra®
334711|NCT01359449|MenC
334712|NCT01359410|Pancreas adenocarcinoma
334713|NCT01359410|Precancerous lesions of the pancreas (mucinous cystic neoplasms, IPMN)
334714|NCT01359410|Pancreas neuroendocrine cancer
334715|NCT01359397|Adenoca. stomach/gastr. Junct.
334716|NCT01359384|severe primary immune deficieny
334717|NCT01359371|Smoking Cessation
334718|NCT01359371|Telephone
334719|NCT01359371|Hospital Volunteers
334720|NCT01359358|MRSA
334721|NCT01359358|MLST
334722|NCT01359358|PFGE
334723|NCT01359358|Resistance
334724|NCT01359358|isolated from colonization
334725|NCT01359345|NSF
334726|NCT01359345|ESRD
334727|NCT01359345|MRA
334728|NCT01359345|MRI
334729|NCT01359345|occurrence of NSF
334730|NCT01359345|Use of Gadollinum
334731|NCT01359332|Convulsive status EPILEPTICUS
334732|NCT01359332|hypothermia therapy
334733|NCT01359332|(defined as continuous SEIZURING for longer than 5 min or three seizures
334734|NCT01359332|not separated by recovery of normal consciousness
334735|NCT01359332|or of the level of consciousness present before the
334736|NCT01359332|seizures)
334737|NCT01359319|Phase 1 Safety and Pharmacokinetic Study
334738|NCT01359306|Acute myocardial infarction
334739|NCT01359306|Right ventricular infarction
334740|NCT01359306|Cardiovascular Magnetic Resonance
334741|NCT01359306|Prognosis
334742|NCT01359280|HIV
334743|NCT01359280|AIDS
334744|NCT01359280|Medication
334745|NCT01359280|Adherence
334746|NCT01359241|dysglycemia
334747|NCT01359241|diabetes
334748|NCT01359241|closed loop insulin delivery
334749|NCT01359228|Rosacea
334750|NCT01359202|Stroke
334751|NCT01359202|ICH
334752|NCT01359202|Intracerebral hemorrhage
334753|NCT01359202|acute stroke
334754|NCT01359202|rfVIIa
334755|NCT01359202|Niastase
334756|NCT01359189|Suspected Primary Prostate Cancer
334757|NCT01359163|bioequivalence study
334758|NCT01359163|marketed vs reformulation tablets
334759|NCT01359163|Femulen
334760|NCT01359137|Behavior
334761|NCT01359137|Drug users
334762|NCT01359137|Criminal Justice
334763|NCT01359137|Probation
334764|NCT01359124|Osteoarthritis, Knee
334765|NCT01359124|Exercise Therapies
334766|NCT01359111|Intradermal injections
334767|NCT01359111|Vaccination
334768|NCT01359098|swimmer's ear
334769|NCT01359098|ear drops
334770|NCT01359098|ear foam
334771|NCT01359098|otic foam
334772|NCT01359098|ear infection
334773|NCT01359098|ear pain
334774|NCT01359098|ear inflammation
334775|NCT01359085|To compare postoperative pain relief by pregabalin versus ISBPB following arthroscopic rotator cuff repair
334776|NCT01359085|To compare postoperative opioid consumption and opioid related AEs
334777|NCT01359085|To compare patients recovery profile and patients satisfaction
334778|NCT01359072|coping
334779|NCT01359072|psychological distress
334780|NCT01359072|self-administered intervention
334781|NCT01359059|assess the beneficial effects of PGL administered either pre or post surgery
334782|NCT01359059|assess the satisfaction rate in the orthopedic oncologic patients
334783|NCT01359046|CAUTI
334784|NCT01359046|UTI
334785|NCT01359033|Myocardial Infarction
334786|NCT01359033|UK
334787|NCT01359033|Sweden
334788|NCT01359033|National audit registry
334789|NCT01359033|MINAP
334790|NCT01359033|RIKS-HIA
334791|NCT01359020|Fever
334792|NCT01359020|Ibuprofen
334793|NCT01359020|Acetaminophen
334794|NCT01359020|Dipyrone
334795|NCT01359007|Locally advanced unresectable adenocarcinoma of pancreas
334796|NCT01359007|Borderline resectable adenocarcinoma of pancreas
334797|NCT01358994|metformin
334798|NCT01358994|type 2 diabetes
334799|NCT01358994|e-GFR
334800|NCT01358994|creatinine
334801|NCT01358994|lactic acidosis
334802|NCT01358955|mild cognitive impairment
334803|NCT01358955|cognitive therapy
334804|NCT01358955|prevention
334805|NCT01358916|antimicrobial resistance
334806|NCT01358916|antibiotic prescription
334807|NCT01358916|primary health care
334808|NCT01358916|cluster-randomized trial
334809|NCT01358890|over weight
334810|NCT01358890|obesity
334811|NCT01358838|Patients with either hypertrophic or atrophic scars
334812|NCT01358838|Efficacy of ablative 10600nm fractional laser therapy
334813|NCT01358838|Laser therapy compared to no treatment of (part of) the scar
334814|NCT01358825|Infanrix-IPV/Hib
334815|NCT01358825|Long-term follow up
334816|NCT01358825|Persistence
334817|NCT01358825|Infanrix hexa
334818|NCT01358812|RAS Wild-Type
334819|NCT01358812|BRAF Wild-Type
334820|NCT01358799|Chlamydia trachomatis
334821|NCT01358799|APTIMA Assay for Chlamydia trachomatis
334822|NCT01358786|Quilting suture
334823|NCT01358786|seroma
334824|NCT01358786|Procedure
334825|NCT01358786|Surgery
334826|NCT01358773|Obesity
334827|NCT01358773|Therapy
334828|NCT01358773|Interdisciplinary
334829|NCT01358760|Vulvar/vaginal atrophy
334830|NCT01358760|Atrophic Vaginitis
334831|NCT01358760|Dehydroepiandrosterone
334832|NCT01358760|DHEA
334833|NCT01358760|Prasterone
334834|NCT01358760|Vaginorm
334835|NCT01358760|Menopause
334836|NCT01358734|AML
334837|NCT01358734|elderly
334838|NCT01358734|acute myelogenous leukemia
334839|NCT01358734|vidaza
334840|NCT01358734|azacitidine
334841|NCT01358734|elderly AML
334842|NCT01358734|revlimid
334843|NCT01358734|lenalidomide
334844|NCT01358695|Lateral Canthal Lines
334845|NCT01358695|Crow's Feet
334846|NCT01358669|Denosumab
334847|NCT01358669|Total Hip Arthroplasty
334848|NCT01358643|OEF/OIF
334849|NCT01358643|Physical Activity
334850|NCT01358643|Preferences
334851|NCT01358630|Periodontitis
334852|NCT01358630|Vascular disease
334853|NCT01358630|Proinflammatory cytokines
334854|NCT01358604|localized resectable neuroblastoma
334855|NCT01358604|recurrent neuroblastoma
334856|NCT01358604|regional neuroblastoma
334857|NCT01358604|stage 4S neuroblastoma
334858|NCT01358604|localized unresectable neuroblastoma
334859|NCT01358578|Psoriasis,
334860|NCT01358578|inflammatory skin disease,
334861|NCT01358578|scaly patches
334862|NCT01358578|Psoriasis
334863|NCT01358578|inflammatory skin disease
334864|NCT01358552|Neevo
334865|NCT01358552|Neevo DHA
334866|NCT01358552|L-methylfolate
334867|NCT01358552|anemia during pregnancy
334868|NCT01358552|folic acid
334869|NCT01358552|vitamin B12
334870|NCT01358552|prenatal vitamins
334871|NCT01358552|hemoglobin
334872|NCT01358552|iron deficiency
334873|NCT01358552|Pregnancy
334874|NCT01358539|palliation
334875|NCT01358539|pain education
334876|NCT01358526|Low back pain
334877|NCT01358526|Chronic pain
334878|NCT01358526|Opioid
334879|NCT01358526|Moderate to severe chronic low back pain
334880|NCT01358513|Positron Emission Tomography
334881|NCT01358513|Inflammation
334882|NCT01358513|Calcification
334883|NCT01358500|opioid dependence
334884|NCT01358500|tolerant
334885|NCT01358500|dependent
334886|NCT01358487|Major depression
334887|NCT01358487|Cognitive Behavioral preventive intervention
334888|NCT01358487|Mood Management
334889|NCT01358487|Self-help
334890|NCT01358487|Internet
334891|NCT01358474|Parkinson disease
334892|NCT01358474|idiopathic rapid eye movement sleep disorder
334893|NCT01358474|Gaucher disease
334894|NCT01358474|healthy volunteer
334895|NCT01358448|Treatment of childhood obesity
334896|NCT01358422|Prospective observational study
334897|NCT01358422|major adverse cardiac events (MACE)
334898|NCT01358422|clinically significant bleeding events
334899|NCT01358422|Dual anti-platelet therapy
334900|NCT01358422|aspirin alone therapy
334901|NCT01358422|non-cardiac surgery
334902|NCT01358422|percutaneous coronary intervention (PCI)
334903|NCT01358422|placement of a bare metal or drug eluting stent
334904|NCT01358422|OBTAIN
334905|NCT01358422|Simon Howell
334906|NCT01358422|ESA
334907|NCT01358422|European Society of Anaesthesiology
334908|NCT01358409|steatosis
334909|NCT01358409|MR spectroscopy
334910|NCT01358409|Nebivolol
334911|NCT01358409|cardiac MRI
334912|NCT01358396|Diabetic Macular Edema, Glycemic Control
334913|NCT01358383|Juvenile Idiopathic Arthritis
334914|NCT01358383|Pharmacokinetics
334915|NCT01358383|VIMOVO
334916|NCT01358383|fasting state
334917|NCT01358383|Amount of VIMOVO in the blood
334918|NCT01358383|taken on empty stomach
334919|NCT01358370|LAL Deficiency
334920|NCT01358370|LIPA
334921|NCT01358370|Wolman disease
334922|NCT01358370|Wolman Phenotype
334923|NCT01358370|Early Onset LAL Deficiency
334924|NCT01358370|Acid Lipase Deficiency
334925|NCT01358357|Lurasidone
334926|NCT01358357|Latuda
334927|NCT01358357|Bipolar I
334928|NCT01358318|obesity
334929|NCT01358318|satiety
334930|NCT01358318|soy protein
334931|NCT01358318|soy fiber
334932|NCT01358318|control appetite
334933|NCT01358318|reduce food intake
334934|NCT01358305|muscle
334935|NCT01358305|synthesis
334936|NCT01358305|mTOR
334937|NCT01358305|antioxidant
334938|NCT01358305|inflammatory markers
334939|NCT01358305|soy protein
334940|NCT01358305|whey
334941|NCT01358305|casein
334942|NCT01358292|Intramedullary tibia nailing
334943|NCT01358292|Anterior Knee Pain
334944|NCT01358292|Nail positioning
334945|NCT01358253|Rituximab
334946|NCT01358253|HyperCVAD
334947|NCT01358240|Econazole Nitrate
334948|NCT01358240|Foam
334949|NCT01358240|Quinnova
334950|NCT01358240|Tinea Pedis
334951|NCT01358214|Sub-urethral Sling
334952|NCT01358214|Treatment Outcome
334953|NCT01358214|Quality of Life
334954|NCT01358201|Acute Lymphoblastic Leukemia
334955|NCT01358188|Gaucher disease
334956|NCT01358188|immunity
334957|NCT01358188|inflammation
334958|NCT01358188|macrophage activation
334959|NCT01358175|Ankylosing spondylitis
334960|NCT01358175|AS
334961|NCT01358175|ASAS
334962|NCT01358175|inflammatory back pain
334963|NCT01358162|Tuberculosis
334964|NCT01358136|Thyroidectomy
334965|NCT01358136|Mitochondria
334966|NCT01358123|liver cirrhosis
334967|NCT01358123|portal hypertension
334968|NCT01358123|survival
334969|NCT01358123|von willebrand factor
334970|NCT01358123|hepatic venous pressure gradient
334971|NCT01358110|palliative care
334972|NCT01358110|cancer
334973|NCT01358110|emergency medicine
334974|NCT01358110|end- of- life care
334975|NCT01358097|Head and neck cancer
334976|NCT01358097|Oropharyngeal cancer
334977|NCT01358097|Human papillomavirus
334978|NCT01358097|Squamous cell carcinoma
334979|NCT01358097|Radiation treatment
334980|NCT01358097|Chemotherapy
334981|NCT01358097|Induction chemotherapy
334982|NCT01358097|Immune status
334983|NCT01358097|Immune monitoring
334984|NCT01358097|head and neck robotic surgery
334985|NCT01358084|Malignant Pleural Mesothelioma
334986|NCT01358084|MPM
334987|NCT01358084|Maintenance treatment
334988|NCT01358084|NGR-hTNF
334989|NCT01358071|NGR-hTNF
334990|NCT01358071|Pegylated liposomal doxorubicin
334991|NCT01358071|Doxorubicin
334992|NCT01358071|Platinum-resistant
334993|NCT01358071|Progression or recurrence Ovarian Cancer
334994|NCT01358071|Ovarian Cancer
334995|NCT01358071|Advanced or metastatic
334996|NCT01358058|Brain tumors
334997|NCT01358058|Radiation
334998|NCT01358058|Proton
334999|NCT01358058|Gliomas
335000|NCT01358045|Topical
335001|NCT01358045|Diclofenac
335002|NCT01358045|Vitamin D3
335003|NCT01358032|Fear of falling
335004|NCT01358032|Cognitive behavioral therapy
335005|NCT01358032|Randomized controlled trial
335006|NCT01358032|Frailty
335007|NCT01358032|Accidental Falls
335008|NCT01358006|JNJ-40411813
335009|NCT01358006|Positron Emission Tomography (PET)
335010|NCT01358006|Serotonin-2A (5-HT2A) receptor antagonist
335011|NCT01358006|Male Volunteers
335012|NCT01357993|Methylphenidate hydrochloride
335013|NCT01357993|Concerta
335014|NCT01357993|Adults
335015|NCT01357993|Attention-Deficit / Hyperactivity Disorder
335016|NCT01357993|ADHD
335017|NCT01357993|Long term safety
335018|NCT01357980|Detrusor Muscle Overactivity
335019|NCT01357954|Postural control
335020|NCT01357954|Targeted Training
335021|NCT01357954|Gross motor function
335022|NCT01357954|Cerebral palsy
335023|NCT01357941|venous thromboembolism
335024|NCT01357941|thromboembolism
335025|NCT01357941|deep vein thrombosis
335026|NCT01357941|pulmonary embolism
335027|NCT01357941|thromboprophylaxis
335028|NCT01357941|thrombosis
335029|NCT01357941|embolism and thrombosis
335030|NCT01357941|cardiovascular diseases
335031|NCT01357941|venous thrombosis
335032|NCT01357941|vascular diseases
335033|NCT01357941|anticoagulants
335034|NCT01357941|hematologic agents
335035|NCT01357941|cardiovascular agents
335036|NCT01357941|enoxaparin
335037|NCT01357941|dalteparin
335038|NCT01357941|tinzaparin
335039|NCT01357941|pregnancy complications
335040|NCT01357928|TEG
335041|NCT01357928|Thromboelastography
335042|NCT01357928|Coagulation
335043|NCT01357915|Cytomegalovirus
335044|NCT01357915|Vaccine
335045|NCT01357889|pharmacokinetics
335046|NCT01357889|pharmacodynamics
335047|NCT01357889|GSK716155
335048|NCT01357889|albiglutide
335049|NCT01357863|Lapatinib
335050|NCT01357863|Observational Study
335051|NCT01357863|Trastuzumab
335052|NCT01357863|Brazil
335053|NCT01357863|Metastatic Breast Cancer
335054|NCT01357837|Osteoarthritis, knee
335055|NCT01357837|Analgesia
335056|NCT01357837|Pain
335057|NCT01357837|Painful
335058|NCT01357824|Intubation
335059|NCT01357824|Sellick´s maneuver
335060|NCT01357824|aspiration
335061|NCT01357824|[E05.497.578]
335062|NCT01357811|Genz-112638
335063|NCT01357811|digoxin
335064|NCT01357798|Headache
335065|NCT01357798|Allodynia
335066|NCT01357798|Botulinum Toxin Type A
335067|NCT01357785|Periodontal ligament stem cells
335068|NCT01357785|Periodontal regeneration
335069|NCT01357785|Clinical trial
335070|NCT01357785|Deep intraosseous defects
335071|NCT01357746|Pulmonary arterial blood pressure doppler
335072|NCT01357733|Diffuse, Large B-Cell, Lymphoma
335073|NCT01357733|18F Fluorodeoxyglucose
335074|NCT01357733|Radionuclide-Emission Computed Tomography
335075|NCT01357720|Vaccination
335076|NCT01357720|Immunisation
335077|NCT01357720|Virus
335078|NCT01357720|Diphtheria
335079|NCT01357720|Pertussis
335080|NCT01357720|Tetanus
335081|NCT01357720|Hepatitis B
335082|NCT01357720|Haemophilus Influenzae
335083|NCT01357720|Immunity
335084|NCT01357694|psychotherapy
335085|NCT01357694|depression
335086|NCT01357694|anxiety
335087|NCT01357694|surgical patients
335088|NCT01357681|Huntington Disease
335089|NCT01357681|Cognition
335090|NCT01357681|Motor
335091|NCT01357681|Behaviour
335092|NCT01357681|Functional Capacity
335093|NCT01357681|Quality of Life
335094|NCT01357681|Biomarker
335095|NCT01357681|MRI
335096|NCT01357681|Huntingtin
335097|NCT01357681|EGCG
335098|NCT01357655|Myelogenous
335099|NCT01357655|Chronic
335100|NCT01357655|BCR-ABL Positive
335101|NCT01357642|asthma
335102|NCT01357642|bronchial asthma
335103|NCT01357642|shortness of breath
335104|NCT01357629|Vaccination follow-up
335105|NCT01357616|Glaucoma
335106|NCT01357616|Open-angle glaucoma
335107|NCT01357616|Ocular hypertension
335108|NCT01357616|OAG
335109|NCT01357616|OH
335110|NCT01357590|aneurysm, penetrating ulcer, descending thoracic aorta
335111|NCT01357577|PTSD
335112|NCT01357577|Substance Use Disorders
335113|NCT01357564|dementia
335114|NCT01357564|caregivers
335115|NCT01357564|tailored activity
335116|NCT01357551|obesity
335117|NCT01357551|intervention studies
335118|NCT01357551|patient adherence
335119|NCT01357538|Bibrocathol
335120|NCT01357538|eye ointment
335121|NCT01357538|blepharitis
335122|NCT01357538|eye lid
335123|NCT01357525|Pancreas
335124|NCT01357525|Resected
335125|NCT01357512|prostate cancer diagnosis
335126|NCT01357512|magnetic resonance imaging
335127|NCT01357512|prostate biopsy
335128|NCT01357486|Hepatocellular Carcinoma
335129|NCT01357486|CHILD B
335130|NCT01357486|palliative management
335131|NCT01357486|Sorafenib
335132|NCT01357486|Pravastatin
335133|NCT01357473|hormonal values
335134|NCT01357473|menstruations
335135|NCT01357473|pregnancy
335136|NCT01357473|antagonist
335137|NCT01357460|Emphysema
335138|NCT01357460|alpha1 antitrypsin deficiency
335139|NCT01357460|endoscopic lung volume reduction
335140|NCT01357447|Sjogren's syndrome
335141|NCT01357447|Cough
335142|NCT01357408|without an indication for ICD or CRT
335143|NCT01357408|left ventricular function greater than or equal to 40%
335144|NCT01357395|Small Cell Lung Carcinoma
335145|NCT01357382|low fat diet
335146|NCT01357382|low carbohydrate diet
335147|NCT01357369|bacteria infections
335148|NCT01357343|Low back pain
335149|NCT01357343|Chiropractic
335150|NCT01357343|Acupuncture
335151|NCT01357343|Integrated care
335152|NCT01357330|locally advanced or metastatic
335153|NCT01357317|Kidney disease
335154|NCT01357317|Hyperphosphatemia
335155|NCT01357317|Parathyroid hormone
335156|NCT01357304|Group treatment
335157|NCT01357304|Physical activity referral
335158|NCT01357304|Type 2 diabetes
335159|NCT01357304|Hypertension
335160|NCT01357291|Behavior
335161|NCT01357291|Drug users
335162|NCT01357291|Inmates
335163|NCT01357278|osteoporosis
335164|NCT01357278|exercise
335165|NCT01357278|intervention
335166|NCT01357278|rehabilitation
335167|NCT01357278|bone mineral density
335168|NCT01357278|muscle strength
335169|NCT01357265|Seasonal Influenza
335170|NCT01357265|vaccine
335171|NCT01357252|Diabetes mellitus
335172|NCT01357252|vildagliptin
335173|NCT01357239|Fragile X Syndrome
335174|NCT01357239|Martin-Bell Syndrome
335175|NCT01357239|Genetic Diseases
335176|NCT01357239|X-Linked
335177|NCT01357239|Escalante's syndrome
335178|NCT01357226|measurement in two environments
335179|NCT01357213|Botulism, Clostridium
335180|NCT01357187|Lumbar pathology
335181|NCT01357187|requiring elective lumbar interbody fusion
335182|NCT01357096|intervention
335183|NCT01357096|CABG or PTCA
335184|NCT01357083|Melatonin
335185|NCT01357083|Periodicity
335186|NCT01357083|Depressive disorder, major
335187|NCT01357083|Serum
335188|NCT01357083|Depression
335189|NCT01357057|Medical records
335190|NCT01357057|Outcome scale
335191|NCT01357057|Biological biomarkers
335192|NCT01357044|Semen quality
335193|NCT01357044|Plant extracts
335194|NCT01357031|Amitriptyline
335195|NCT01357031|Placebo
335196|NCT01357031|Melatonin
335197|NCT01357031|Migraine
335198|NCT01357031|Headache
335199|NCT01357031|Drug therapy
335200|NCT01357031|Preventive treatment of migraine
335201|NCT01357018|Ankylosing spondylitis
335202|NCT01357018|Disease activity
335203|NCT01357018|EQ-5D
335204|NCT01357018|Quality of life
335205|NCT01357018|Rheumatoid arthritis
335206|NCT01356992|non-inferiority phase III study
335207|NCT01356992|Low-Molecular Weight Heparin
335208|NCT01356992|Versa® (enoxaparin - Eurofarma)
335209|NCT01356992|Clexane® (enoxaparin - Sanofi-Aventis)
335210|NCT01356992|Acute coronary syndrome without ST-segment elevation
335211|NCT01356979|Medical thoracoscopy
335212|NCT01356979|Pleural effusion
335213|NCT01356979|Malignant pleural diseases
335214|NCT01356979|Tuberculous pleuritis
335215|NCT01356979|Fibrinous pleuritis
335216|NCT01356953|Aerobic Exercise
335217|NCT01356953|Blood Pressure
335218|NCT01356940|Ambulation
335219|NCT01356927|long acting reversible contraception
335220|NCT01356927|medical abortion
335221|NCT01356927|DMPA
335222|NCT01356927|etonogestrel implant
335223|NCT01356927|Implanon
335224|NCT01356927|contraceptive continuation
335225|NCT01356875|myelodysplastic syndrome
335226|NCT01356875|Transfusion
335227|NCT01356875|Hydralazine
335228|NCT01356875|valproic acid
335229|NCT01356862|mastectomy
335230|NCT01356862|axillary node dissection
335231|NCT01356862|adjuvant or neoadjuvant
335232|NCT01356849|Endothelin Receptor Antagonists
335233|NCT01356849|Proteinuria
335234|NCT01356836|Coronary collateral development
335235|NCT01356836|monocyte subsets
335236|NCT01356836|collateralization
335237|NCT01356823|Human Papilloma Virus 16
335238|NCT01356823|Human Papilloma Virus 18
335239|NCT01356823|vaccine
335240|NCT01356823|Cervical Intraepithelial Neoplasia
335241|NCT01356823|cervical Cancer
335242|NCT01356810|Delirium
335243|NCT01356810|Primary Prevention
335244|NCT01356810|Elderly
335245|NCT01356797|knee arthroscopy
335246|NCT01356797|hyperbaric bupivacaine
335247|NCT01356797|hypobaric levobupivacaine plus fentanyl
335248|NCT01356784|Sick-listed
335249|NCT01356784|Tailored physical activity
335250|NCT01356784|Patient education
335251|NCT01356784|Returning to work
335252|NCT01356784|DK-Sønderborg Municipality
335253|NCT01356784|columna
335254|NCT01356784|upper body
335255|NCT01356771|Risk Assessment
335256|NCT01356771|Intervention
335257|NCT01356745|premixed nitrous oxide and oxygen
335258|NCT01356745|acute pain
335259|NCT01356745|prehospital setting
335260|NCT01356732|mechanical ventilation
335261|NCT01356732|Midazolam
335262|NCT01356732|Ramsay
335263|NCT01356732|Sufentanil
335264|NCT01356719|Tracheostomy
335265|NCT01356719|adverse effects
335266|NCT01356719|Critical Care
335267|NCT01356719|standards
335268|NCT01356719|safety
335269|NCT01356706|liver metastases
335270|NCT01356706|colorectal cancer
335271|NCT01356706|surgery
335272|NCT01356706|prognosis
335273|NCT01356693|Cough
335274|NCT01356693|Common cold
335275|NCT01356693|Child
335276|NCT01356693|Adolescent
335277|NCT01356680|Hodgkin Lymphoma
335278|NCT01356680|intermediate stage
335279|NCT01356680|PET
335280|NCT01356667|American Indians
335281|NCT01356667|Native Americans
335282|NCT01356667|substance abuse
335283|NCT01356667|culture
335284|NCT01356654|Stroke
335285|NCT01356654|TDCS
335286|NCT01356654|Gait
335287|NCT01356654|Balance
335288|NCT01356654|loss of postural balance
335289|NCT01356641|Antibiotic treatment
335290|NCT01356641|Non perforated appendicitis
335291|NCT01356641|Children
335292|NCT01356628|Advanced Hepatocellular Carcinoma
335293|NCT01356628|HCC
335294|NCT01356628|Liver Cancer
335295|NCT01356628|PD-0332991
335296|NCT01356615|anticoagulation
335297|NCT01356615|hemodialysis
335298|NCT01356615|heparin
335299|NCT01356615|lipids
335300|NCT01356615|low molecular weight heparins
335301|NCT01356602|Gout
335302|NCT01356602|arthritis
335303|NCT01356602|gout flare
335304|NCT01356602|acute gout
335305|NCT01356602|gouty
335306|NCT01356602|rheumatic disease
335307|NCT01356602|uric acid
335308|NCT01356563|hemodialysis
335309|NCT01356563|pharmacist
335310|NCT01356563|medication-related problems
335311|NCT01356563|compliance
335312|NCT01356511|Purpura, Thrombocytopenic, Idiopathic
335313|NCT01356498|gout
335314|NCT01356498|chronic gout
335315|NCT01356485|Sickle cell anemia
335316|NCT01356485|Sickle cell disease
335317|NCT01356485|Sickling crisis
335318|NCT01356485|Vaso-occlusive crisis
335319|NCT01356485|Carboxyhemoglobin
335320|NCT01356485|Oxygen therapeutic
335321|NCT01356485|Hemoglobin solutions
335322|NCT01356485|Pegylated hemoglobin
335323|NCT01356472|Methicillin-resistant Staphylococcus aureus
335324|NCT01356472|Pneumonia, Ventilator-Associated
335325|NCT01356472|linezolid
335326|NCT01356472|imipenem/cilastatin
335327|NCT01356459|Pressure ulcers
335328|NCT01356459|ICU
335329|NCT01356459|Prevention
335330|NCT01356446|safety
335331|NCT01356446|team
335332|NCT01356446|team performance
335333|NCT01356446|surgery
335334|NCT01356446|outcome
335335|NCT01356433|dialysis,inflammation,vitamin C
335336|NCT01356420|SLOS
335337|NCT01356394|Obesity
335338|NCT01356394|Metabolic Syndrome
335339|NCT01356394|Microalbuminuria
335340|NCT01356394|Chronic Kidney Disease
335341|NCT01356381|Diabetes mellitus
335342|NCT01356381|vildagliptin
335343|NCT01356368|Lung cancer
335344|NCT01356355|Stent discomfort
335345|NCT01356355|Herbmed plus
335346|NCT01356355|Tolterodine
335347|NCT01356342|Influenza
335348|NCT01356342|Vaccine
335349|NCT01356342|Immunogenicity
335350|NCT01356329|Gynecologic malignancy ,major surgery
335351|NCT01356316|Influenza
335352|NCT01356316|Vaccine
335353|NCT01356316|Immunogenicity
335354|NCT01356303|Lung cancer
335355|NCT01356290|Medulloblastoma
335356|NCT01356290|Relapse
335357|NCT01356290|Children
335358|NCT01356290|antiangiogenic
335359|NCT01356290|metronomic
335360|NCT01356290|intrathecal
335361|NCT01356277|renal
335362|NCT01356277|allograft
335363|NCT01356277|immunosuppressive
335364|NCT01356277|immunosuppression
335365|NCT01356277|adherence
335366|NCT01356277|medication
335367|NCT01356277|compliance
335368|NCT01356264|colorectal cancer
335369|NCT01356264|colorectal surgery
335370|NCT01356264|prehabilitation
335371|NCT01356264|surgical recovery
335372|NCT01356264|exercise
335373|NCT01356264|referred for scheduled resection
335374|NCT01356251|Quality of life
335375|NCT01356251|support group
335376|NCT01356251|questionnaires
335377|NCT01356251|Internet-based support group
335378|NCT01356251|11-066
335379|NCT01356225|pain following dental impaction surgery
335380|NCT01356199|Gonalgia
335381|NCT01356199|Quality of Life
335382|NCT01356199|Dietary supplement
335383|NCT01356199|Nutrition
335384|NCT01356186|Suicide
335385|NCT01356186|Cognitive Therapy
335386|NCT01356186|Inpatient
335387|NCT01356186|Military
335388|NCT01356173|solid cancers
335389|NCT01356160|Hepatitis C
335390|NCT01356160|HCV
335391|NCT01356160|Rapid Virologic Response
335392|NCT01356160|Sustained Virologic Response
335393|NCT01356160|Direct Acting Antiviral
335394|NCT01356160|Combination Therapy HCV RNA
335395|NCT01356160|Protease inhibitor
335396|NCT01356160|Treatment naïve
335397|NCT01356160|GS-5885
335398|NCT01356160|GS-9451
335399|NCT01356147|ventilator associated pulmonary infections
335400|NCT01356134|multiple sclerosis
335401|NCT01356134|ehlers danlos syndrome
335402|NCT01356134|CCSVI
335403|NCT01356134|chronic cerebrospinal venous insufficiency
335404|NCT01356134|fundus
335405|NCT01356134|retina
335406|NCT01356108|Conduit
335407|NCT01356108|Pulmonic
335408|NCT01356108|Stenosis
335409|NCT01356108|Regurgitation
335410|NCT01356108|Dysfunctional
335411|NCT01356095|Tuberculosis
335412|NCT01356095|Treatment Adherence
335413|NCT01356095|knowledge translation
335414|NCT01356095|Educational outreach
335415|NCT01356069|BPD
335416|NCT01356069|MHS
335417|NCT01356069|heavy users
335418|NCT01356069|sequential psychotherapy
335419|NCT01356004|severe resistant
335420|NCT01355991|Spinal Cord Injury
335421|NCT01355991|Tetraplegia
335422|NCT01355991|Pulmonary Function
335423|NCT01355991|Bronchodilator
335424|NCT01355965|completed standard first line therapy
335425|NCT01355965|platinum based double regimen
335426|NCT01355965|Progressive Disease
335427|NCT01355965|chosen not to pursue primary standard of care therapy
335428|NCT01355952|Obesity
335429|NCT01355952|Weight Loss
335430|NCT01355952|Schizophrenia
335431|NCT01355952|Alpha Lipoic Acid
335432|NCT01355939|Hernia
335433|NCT01355939|Adhesiolysis
335434|NCT01355939|Adhesions
335435|NCT01355939|Intraperitoneal Mesh
335436|NCT01355939|Abdominal Re-exploration
335437|NCT01355939|Mesh
335438|NCT01355939|Barrier-Coated Mesh
335439|NCT01355939|Non-Barrier-Coated Mesh
335440|NCT01355939|Laparoscopic Approach
335441|NCT01355939|Open Approach
335442|NCT01355939|Abdominal Re-Exploration Surgery
335443|NCT01355926|Flexible Fiber-based CO2 Laser
335444|NCT01355926|Monopolar Cautery
335445|NCT01355926|Oral Cavity Lesions
335446|NCT01355926|Quality of life
335447|NCT01355926|Assessing Pain
335448|NCT01355926|11-034
335449|NCT01355913|Myelodysplastic syndromes (MDS)
335450|NCT01355913|chromosmal aberrations
335451|NCT01355913|cytogenetics
335452|NCT01355913|Fluorescence in situ hybridization (FISH)
335453|NCT01355913|CD34+ cells
335454|NCT01355913|peripheral blood
335455|NCT01355900|Total knee arthroplasty
335456|NCT01355900|Tourniquet
335457|NCT01355900|Blood loss
335458|NCT01355900|Volume loading test
335459|NCT01355887|blood loss
335460|NCT01355887|hepatectomy
335461|NCT01355887|prospective study
335462|NCT01355887|PTC
335463|NCT01355874|Internal Symptomatic Hemorrhoids
335464|NCT01355861|sarcopenia
335465|NCT01355861|aging
335466|NCT01355861|rehabilitation
335467|NCT01355861|exercise
335468|NCT01355848|Suicide
335469|NCT01355848|Brief Intervention
335470|NCT01355848|Youth
335471|NCT01355848|Acute Medical Setting
335472|NCT01355848|Readiness to Change
335473|NCT01355848|Suicidality
335474|NCT01355835|Parkinson's disease
335475|NCT01355835|gait
335476|NCT01355835|deep brain stimulation
335477|NCT01355835|substantia nigra pars reticulata
335478|NCT01355835|subthalamic nucleus
335479|NCT01355822|abortion
335480|NCT01355822|perinatal death
335481|NCT01355822|IUGR
335482|NCT01355822|preterm birth
335483|NCT01355822|placental abruption
335484|NCT01355822|preeclampsia
335485|NCT01355809|Six-Minute Walk Test
335486|NCT01355757|shoulder arthroscopy
335487|NCT01355757|24-week follow-up
335488|NCT01355757|quality of life
335489|NCT01355757|rehabilitation achievement
335490|NCT01355757|rotator cuff repair
335491|NCT01355744|humans
335492|NCT01355744|insect bites
335493|NCT01355731|Registered Nurse
335494|NCT01355731|Behaviors
335495|NCT01355731|Attitudes
335496|NCT01355692|DME
335497|NCT01355692|Laser
335498|NCT01355692|Selective laser therapy
335499|NCT01355692|photocoagulation
335500|NCT01355666|pressure ulcers
335501|NCT01355666|stage 1
335502|NCT01355666|stage 2
335503|NCT01355666|stage 3
335504|NCT01355666|stage 4
335505|NCT01355666|wounds
335506|NCT01355666|sores
335507|NCT01355666|infection
335508|NCT01355666|bioburden
335509|NCT01355666|bacterial contamination
335510|NCT01355666|bed linen
335511|NCT01355666|sheets
335512|NCT01355666|underpad
335513|NCT01355666|skin assessment
335514|NCT01355666|microclimate
335515|NCT01355666|shear
335516|NCT01355666|friction
335517|NCT01355666|moisture
335518|NCT01355666|fabrics
335519|NCT01355666|long term care
335520|NCT01355666|nursing home
335521|NCT01355666|decubitus ulcer
335522|NCT01355666|bed ridden
335523|NCT01355666|anti-microbial
335524|NCT01355653|heat
335525|NCT01355653|device
335526|NCT01355653|safety
335527|NCT01355653|performance
335528|NCT01355653|heatwrap
335529|NCT01355653|elderly
335530|NCT01355653|overweight
335531|NCT01355640|heel lance
335532|NCT01355640|pain
335533|NCT01355640|newborn
335534|NCT01355627|CSF leaks
335535|NCT01355627|Skull base surgery
335536|NCT01355627|pseudomeningocele
335537|NCT01355627|TachoSil®
335538|NCT01355627|Prevention
335539|NCT01355627|post-operative
335540|NCT01355614|Crohn's Disease
335541|NCT01355614|Fistula
335542|NCT01355575|Microbiota
335543|NCT01355575|Insulin resistance
335544|NCT01355575|Bacterial endotoxin
335545|NCT01355575|Hepatic triglyceride
335546|NCT01355575|Inflammation
335547|NCT01355549|Shoulder pain
335548|NCT01355549|Rotator cuff disease
335549|NCT01355549|Spinal cord injuries
335550|NCT01355549|Platelet-rich plasma therapy
335551|NCT01355549|Rehabilitation
335552|NCT01355536|Preterm birth
335553|NCT01355536|Preterm labour
335554|NCT01355536|Polycystic Ovary Syndrome
335555|NCT01355536|PCOS
335556|NCT01355536|Diabetes Mellitus
335557|NCT01355536|Hyperandrogenism
335558|NCT01355536|Hirsutism
335559|NCT01355536|Ovarian cysts
335560|NCT01355536|Anti Muller Hormone
335561|NCT01355536|Hypertension
335562|NCT01355523|Breast cancer surgery
335563|NCT01355523|Melatonin
335564|NCT01355523|Depression
335565|NCT01355523|Anxiety
335566|NCT01355523|Sleep disturbances
335567|NCT01355523|Cognitive function
335568|NCT01355471|rosacea
335569|NCT01355458|rosacea
335570|NCT01355419|Obstructive sleep apnea
335571|NCT01355419|CPAP
335572|NCT01355419|actigraphy
335573|NCT01355419|sleep
335574|NCT01355419|physical activity
335575|NCT01355406|FlexStent
335576|NCT01355406|Superficial Femoral Artery or SFA
335577|NCT01355406|Self Expanding Stent
335578|NCT01355406|Stent
335579|NCT01355406|Bare Metal Stent
335580|NCT01355393|Breast Cancer
335581|NCT01355393|HER2+
335582|NCT01355393|Vaccine
335583|NCT01355393|Stage II
335584|NCT01355393|Stage III
335585|NCT01355393|Stage IV
335586|NCT01355380|Pulmonary arterial hypertension
335587|NCT01355380|Inhaled iloprost
335588|NCT01355380|Quality of life
335589|NCT01355367|BAYA1040 CR
335590|NCT01355367|Nifedipine
335591|NCT01355367|Essential hypertension
335592|NCT01355367|Japanese Patients
335593|NCT01355367|Phase III
335594|NCT01355367|Extension study
335595|NCT01355354|Phase 1
335596|NCT01355354|healthy volunteers
335597|NCT01355354|pharmacokinetics
335598|NCT01355354|Rheumatoid arthritis
335599|NCT01355354|RA, Fostamatinib
335600|NCT01355354|Digoxin, drug-drug interaction
335601|NCT01355354|Scientific terminology: Rheumatoid arthritis
335602|NCT01355354|Fostamatinib
335603|NCT01355354|Digoxin
335604|NCT01355354|drug-drug interaction
335605|NCT01355354|Laymen terminology: Rheumatoid arthritis
335606|NCT01355354|Amount of Digoxin in blood
335607|NCT01355341|RENAL CALCULI HERBMED PLUS
335608|NCT01354340|Cholesterol
335609|NCT01354340|LDL-cholesterol
335610|NCT01354340|Coronary artery disease
335611|NCT01354340|Red yeast rice
335612|NCT01354340|Plants extract
335613|NCT01354340|Cholesterol excess
335614|NCT01354340|Delivery of Health Care
335615|NCT01354327|Delivery of Health Care
335616|NCT01354327|Cholesterol
335617|NCT01354327|LDL-cholesterol
335618|NCT01354327|Coronary artery disease
335619|NCT01354327|Red yeast rice
335620|NCT01354327|Plants extract
335621|NCT01354327|Cholesterol excess
335622|NCT01354314|HIV
335623|NCT01354314|Neurocognitive impairment
335624|NCT01354314|Memory
335625|NCT01354314|Dementia
335626|NCT01354314|CSF marker
335627|NCT01354314|Functional assessment
335628|NCT01354314|MRS
335629|NCT01354314|Magnetic resonance spectroscopy
335630|NCT01354314|Arterial spin labeling
335631|NCT01354314|SSRI
335632|NCT01354301|kidney transplantation
335633|NCT01354301|thymoglobulin
335634|NCT01354301|everolimus
335635|NCT01354288|Diabetes
335636|NCT01354288|Children
335637|NCT01354288|Disease management
335638|NCT01354288|Ketosis
335639|NCT01354288|Hypoglycemia
335640|NCT01354288|Parents
335641|NCT01354288|Education
335642|NCT01354275|PCOS
335643|NCT01354275|IVF/ICSI
335644|NCT01354275|Clinical Pregnancy rates
335645|NCT01354275|GnRH Antagonist
335646|NCT01354275|GnRH Agonist
335647|NCT01354262|Diabetes
335648|NCT01354262|Vitamin D deficiency
335649|NCT01354262|Hemoglobin A1c
335650|NCT01354249|preoperative fasting
335651|NCT01354249|insulin resistance
335652|NCT01354249|carbohydrates
335653|NCT01354249|whey protein
335654|NCT01354249|inflammatory response
335655|NCT01355328|light
335656|NCT01355315|EECP
335657|NCT01355315|ischemic cardiomyopathy
335658|NCT01355315|endothelin-1
335659|NCT01355315|ischemia coronary artery diseases
335660|NCT01355315|congestive heart failure not amenable to standard procedures
335661|NCT01355302|Cancer
335662|NCT01355302|Solid Tumors
335663|NCT01355302|Gastric
335664|NCT01355302|Phase I
335665|NCT01355302|Phase II
335666|NCT01355289|Chronic Hepatitis C related
335667|NCT01355276|Cinitapride
335668|NCT01355276|efficacy
335669|NCT01355276|safety
335670|NCT01355276|mild to moderate functional dyspepsia
335671|NCT01355263|vitamin a
335672|NCT01355263|preschool children
335673|NCT01355263|iron metabolic homeostasis
335674|NCT01355263|supplementation effect
335675|NCT01355237|Complementary and alternative medicine (CAM)
335676|NCT01355224|obesity
335677|NCT01355224|genetics
335678|NCT01355224|risk assessment
335679|NCT01355224|health behaviors
335680|NCT01355224|randomized controlled trial
335681|NCT01355211|Altered Mental Status
335682|NCT01355211|non-convulsive seizure
335683|NCT01355211|status epilepticus
335684|NCT01355211|electroencephalography
335685|NCT01355185|Seed movement
335686|NCT01355185|implants
335687|NCT01355185|prostate brachytherapy
335688|NCT01355185|localized
335689|NCT01355172|Influenza
335690|NCT01355172|Vaccine
335691|NCT01355172|Immunogenicity
335692|NCT01355159|Pregnancy
335693|NCT01355159|Folic Acid supplementation
335694|NCT01355159|Preeclampsia
335695|NCT01355146|Patients with proven Fabry's Disease
335696|NCT01355133|Urinary incontinence
335697|NCT01355133|Myoblasts
335698|NCT01355133|Muscle derived cells
335699|NCT01355133|Stem cells
335700|NCT01355120|advanced ocular melanoma
335701|NCT01355107|selenium level measurement
335702|NCT01355094|temporary abdomen closure
335703|NCT01355094|peritoneal vacuum therapy
335704|NCT01355094|open abdomen
335705|NCT01355094|abdominal compartment syndrome
335706|NCT01355094|intra-abdominal sepsis
335707|NCT01355094|intra-abdominal hypertension
335708|NCT01355094|critical care
335709|NCT01355081|Drug Therapy
335710|NCT01355068|phenytoin
335711|NCT01355068|chewable tablets
335712|NCT01355068|dilantin
335713|NCT01355068|epanutin
335714|NCT01355068|infatabs
335715|NCT01355068|bioequivalence
335716|NCT01355068|Partial seizure
335717|NCT01355068|Tonic-clonic seizure
335718|NCT01355029|Stroke caregivers
335719|NCT01355029|Family Caregivers
335720|NCT01355029|Stroke
335721|NCT01355016|RSV
335722|NCT01354977|Diabetes Mellitus, Type 2
335723|NCT01354977|Glucose Metabolism Disorders
335724|NCT01354977|Metabolic Diseases
335725|NCT01354977|Diabetes Mellitus
335726|NCT01354977|Endocrin System Diseases
335727|NCT01354977|Resveratrol
335728|NCT01354977|Therapeutic Uses
335729|NCT01354964|Glucose Metabolism Disorders
335730|NCT01354964|Insulin Resistance
335731|NCT01354964|Endocrine System
335732|NCT01354964|Vitamin D
335733|NCT01354951|Focal Brachytherapy
335734|NCT01354951|Endorectal coil MRI
335735|NCT01354951|Quality of Life
335736|NCT01354951|11-056
335737|NCT01354938|Bronchitis
335738|NCT01354925|Diabetes type 2
335739|NCT01354925|Fasting
335740|NCT01354925|Ramadan
335741|NCT01354925|Insulin analogues
335742|NCT01354912|mycobacterial infection
335743|NCT01354912|culture
335744|NCT01354912|ct scan
335745|NCT01354886|in-vitro fertilization
335746|NCT01354886|reproductive disorder
335747|NCT01354873|Colonoscopy
335748|NCT01354873|Colon Polyps
335749|NCT01354860|knee osteoarthritis
335750|NCT01354847|extracorporeal circulation
335751|NCT01354847|platelet dysfunction
335752|NCT01354847|Multiplate electrode aggregometry analyses
335753|NCT01354847|Multiplate
335754|NCT01354821|Aorta
335755|NCT01354821|Aneurysm
335756|NCT01354821|endovascular
335757|NCT01354821|stent-graft
335758|NCT01354808|Cilostazol
335759|NCT01354808|Platelet
335760|NCT01354808|Inflammation
335761|NCT01354808|Myonecrosis
335762|NCT01354795|EUS FNA
335763|NCT01354795|stylet
335764|NCT01354795|suction
335765|NCT01354782|Pharmacokinetic
335766|NCT01354782|Roflumilast
335767|NCT01354756|sleep apnea
335768|NCT01354756|polysomnography
335769|NCT01354756|obesity
335770|NCT01354756|bariatric surgery
335771|NCT01354743|atrophy
335772|NCT01354743|rhytids
335773|NCT01354743|glabellar
335774|NCT01354743|periorbital
335775|NCT01354730|incidence
335776|NCT01354730|nature
335777|NCT01354730|seriousness
335778|NCT01354730|ADRs
335779|NCT01354730|vaccination
335780|NCT01354704|deep veinous thrombosis
335781|NCT01354704|enoxaparin
335782|NCT01354691|Alzheimer's Disease
335783|NCT01354691|Dementia
335784|NCT01354691|Memory Loss
335785|NCT01354691|Cognitive Impairment
335786|NCT01354691|Brain Diseases
335787|NCT01354691|Central Nervous System Diseases
335788|NCT01354691|Nervous System Diseases
335789|NCT01354691|Neurodegenerative Diseases
335790|NCT01354691|Delirium, Dementia, Amnestic, Cognitive Disorders
335791|NCT01354691|Mental Disorders
335792|NCT01354691|Depression
335793|NCT01354691|Anxiety
335794|NCT01354678|heart failure
335795|NCT01354678|bone marrow mononuclear cells
335796|NCT01354665|Multiple sclerosis
335797|NCT01354665|Interferon beta-1b
335798|NCT01354665|Fatigue
335799|NCT01354665|Depression
335800|NCT01354652|lactic acidosis
335801|NCT01354652|entecavir
335802|NCT01354652|lamivudine
335803|NCT01354626|Hepatic fat accumulation
335804|NCT01354626|Dietary protein
335805|NCT01354626|NAFLD
335806|NCT01354600|Obesity
335807|NCT01354600|Appetite
335808|NCT01354600|Hormones
335809|NCT01354600|Exercise
335810|NCT01354600|Body Weight
335811|NCT01354587|immunodeficiency
335812|NCT01354574|energy metabolism
335813|NCT01354574|lipids
335814|NCT01354574|lipoproteins
335815|NCT01354574|satiety
335816|NCT01354574|glycemic load
335817|NCT01354574|insulin
335818|NCT01354561|respiratory physiotherapy
335819|NCT01354561|cardiac autonomic modulation
335820|NCT01354561|paediatric patients
335821|NCT01354548|Trismus
335822|NCT01354548|Cancer
335823|NCT01354548|Radiotherapy
335824|NCT01354548|Quality of life
335825|NCT01354535|periprosthetic
335826|NCT01354535|femur fractures
335827|NCT01354535|Vancouver B1
335828|NCT01354509|Normothermia
335829|NCT01354509|fever control
335830|NCT01354509|Outcome study
335831|NCT01354496|Healthy Volunteers
335832|NCT01354496|Bioavailability
335833|NCT01354483|spinal cord injury
335834|NCT01354483|umbilical cord blood mononuclear cell
335835|NCT01354483|lithium carbonate
335836|NCT01354470|Meth
335837|NCT01354470|Methamphetamine Addiction
335838|NCT01354470|Methamphetamine Treatment
335839|NCT01354470|Modafinil
335840|NCT01354457|Patient with relapsing or refractory CD22+B-acute lymphoblastic leukemia (ALL)
335841|NCT01354444|Memory problems
335842|NCT01354444|Alzheimer's Disease
335843|NCT01354431|Advanced/Metastatic
335844|NCT01354431|clear cell component
335845|NCT01354392|Relapsed or refractory
335846|NCT01354392|Large B-Cell
335847|NCT01354392|Diffuse
335848|NCT01354223|silicone hydrogel contact lens
335849|NCT01354223|SHCL
335850|NCT01354223|stenfilcon A
335851|NCT01354223|ocufilcon B
335852|NCT01354223|daily disposable
335853|NCT01354223|substantial equivalence
335854|NCT01354223|CooperVision ClearSight™ 1 Day SCL
335855|NCT01354210|Patient Adherence
335856|NCT01354210|HIV
335857|NCT01354197|Adverse events
335858|NCT01354197|Mortality
335859|NCT01354197|Readmission
335860|NCT01354197|Surgical intensive care unit
335861|NCT01354171|active surveillance
335862|NCT01354171|low risk prostate cancer
335863|NCT01354132|schizophrenia
335864|NCT01354132|schizoaffective
335865|NCT01354132|schizophreniform
335866|NCT01354132|early schizophrenia spectrum psychosis
335867|NCT01354106|Skin condition after wear
335868|NCT01354093|MacTel
335869|NCT01354093|Macular telangiectasia type 2
335870|NCT01354080|constipation
335871|NCT01354080|massage
335872|NCT01354080|tensegrity
335873|NCT01354067|Pulmonary Disease, Chronic Obstructive
335874|NCT01354067|Lung Diseases, Obstructive
335875|NCT01354067|Single Limb
335876|NCT01354067|Elastic Resistance
335877|NCT01354067|Resistance Training
335878|NCT01354067|Minor Muscle Mass
335879|NCT01354067|Local muscle training
335880|NCT01354054|Knee OA
335881|NCT01354054|TENS
335882|NCT01354041|fear and health worries about cancer recurrence
335883|NCT01354028|premature infant
335884|NCT01354028|massage therapy
335885|NCT01354028|sleep induction
335886|NCT01354028|relaxation
335887|NCT01354015|Diabetes
335888|NCT01354015|Technology
335889|NCT01354002|human biological samples
335890|NCT01354002|tissue banking
335891|NCT01353989|hepatitis A
335892|NCT01353989|vaccination
335893|NCT01353989|elderly
335894|NCT01353989|protection to hepatitis A after vaccination
335895|NCT01353976|Econazole Nitrate
335896|NCT01353976|Foam
335897|NCT01353976|Quinnova
335898|NCT01353976|Tinea Pedis
335899|NCT01353950|Costimulatory molecules
335900|NCT01353950|Cystic Fibrosis
335901|NCT01353950|Biomarkers
335902|NCT01353937|wound healing
335903|NCT01353924|Allergy
335904|NCT01353924|Vaccine
335905|NCT01353924|rBet v 1
335906|NCT01353924|Prevention
335907|NCT01353885|Primary Osteoarthritis, Hip
335908|NCT01353885|Total Hip Arthroplasty
335909|NCT01353885|Anterior Approach
335910|NCT01353885|Posterior Approach
335911|NCT01353885|Anterolateral Approach
335912|NCT01353885|Cohort Study
335913|NCT01353885|Outcomes, Complication Rate
335914|NCT01353885|Outcomes, Quality of Life
335915|NCT01353872|Fatigue
335916|NCT01353872|Tennis
335917|NCT01353872|Nutrition
335918|NCT01353872|Tournament simulation
335919|NCT01353872|Delivery of Health Care
335920|NCT01353846|oocyte donation program
335921|NCT01353846|natural cycle
335922|NCT01353846|hormone replacement therapy
335923|NCT01353820|Midly hypercholesterolemic subjects
335924|NCT01353820|Probiotic
335925|NCT01353820|Cholesterol lowering
335926|NCT01353820|Dairy
335927|NCT01353807|Fish oil
335928|NCT01353807|Pregnancy
335929|NCT01353807|RCT
335930|NCT01353807|Birth weight
335931|NCT01353807|Gestational age
335932|NCT01353807|Asthma and allergies
335933|NCT01353807|Metabolic syndrome
335934|NCT01353807|Obesity
335935|NCT01353794|SORAFENIB
335936|NCT01353794|RENAL CELL CARCINOMA
335937|NCT01353794|TYROSINE KINASE INHIBITOR
335938|NCT01353794|OBSERVATIONAL STUDY
335939|NCT01353781|Phase 1
335940|NCT01353781|advanced solid tumor
335941|NCT01353781|AKT
335942|NCT01353781|Ascending
335943|NCT01353781|Japanese
335944|NCT01353768|Influenza
335945|NCT01353755|specific immunotherapy
335946|NCT01353755|SIT
335947|NCT01353729|12-lead ECG
335948|NCT01353729|cardiac repolarization
335949|NCT01353729|QTc
335950|NCT01353729|influenza
335951|NCT01353729|GR121167
335952|NCT01353729|zanamivir
335953|NCT01353703|Infanrix hexa™
335954|NCT01353703|Primary vaccination
335955|NCT01353703|India
335956|NCT01353703|combination vaccine
335957|NCT01353703|infants
335958|NCT01353690|Cell Therapy
335959|NCT01353690|Heart Failure
335960|NCT01353690|Heart Disease
335961|NCT01353690|Myocardial Infarction
335962|NCT01353690|Myocardial Ischemia
335963|NCT01353690|Autologous
335964|NCT01353690|Muscle-derived Cell
335965|NCT01353677|Hematopoietic stem cell transplantation
335966|NCT01353677|QOL
335967|NCT01353664|rollover protocol
335968|NCT01353664|romidepsin
335969|NCT01353664|Gloucester Pharmaceuticals
335970|NCT01353664|Celgene Corporation
335971|NCT01353664|continuing treatment
335972|NCT01353638|Peritoneal dialysis
335973|NCT01353638|Alanyl-Glutamine-Dipeptide
335974|NCT01353638|Heat shock protein
335975|NCT01353638|Peritoneal cells
335976|NCT01353638|functional maintenance of the peritoneal membrane
335977|NCT01353625|Neoplasm
335978|NCT01353625|Malignancy
335979|NCT01353625|Carcinoma
335980|NCT01353625|Lymphoma
335981|NCT01353625|Leukemia
335982|NCT01353625|Multiple myeloma
335983|NCT01353625|mTOR kinase inhibitor
335984|NCT01353625|Castration-resistant prostate cancer
335985|NCT01353625|Hormone-resistant prostate cancer
335986|NCT01353625|Diffuse Large B-cell lymphoma
335987|NCT01353599|Spinal Cord Injury
335988|NCT01353599|Tetraplegia
335989|NCT01353599|Pulmonary Function
335990|NCT01353573|Brain Neoplasms
335991|NCT01353573|Neoplasm Metastasis
335992|NCT01353573|Neoplasms
335993|NCT01353560|integrative medicine
335994|NCT01353560|barriers to utilization
335995|NCT01353560|communication
335996|NCT01353534|Immunogenicity and Safety
335997|NCT01353521|complex renal cysts
335998|NCT01353521|Contrast enhanced ultrasound
335999|NCT01353508|Sodium excretion,
336000|NCT01353508|LCZ696
336001|NCT01353495|Diabetic Foot Ulcers
336002|NCT01353482|mesothelioma
336003|NCT01353482|vorinostat
336004|NCT01353456|Ambulation
336005|NCT01353456|Side effects
336006|NCT01353456|Serum sCD40L
336007|NCT01353456|Bowel function
336008|NCT01353456|Postoperative pain
336009|NCT01353443|Abdominal Aortic Aneurysm
336010|NCT01353443|AAA
336011|NCT01353430|IBMPFD - Inclusion Body Myopathy associated with
336012|NCT01353430|Paget's disease of bone and Frontotemporal Dementia
336013|NCT01353430|VCP gene - Valosin-containing protein gene
336014|NCT01353417|Grafting, kidney
336015|NCT01353417|Transplantation, kidney
336016|NCT01353391|Diabetes
336017|NCT01353391|MiTy
336018|NCT01353391|Metformin in Women
336019|NCT01353391|Type 2 Diabetes Pregnancy
336020|NCT01353378|dexmedetomidine
336021|NCT01353378|emergence delirium
336022|NCT01353378|sevoflurane anesthesia
336023|NCT01353378|preschool children
336024|NCT01353378|oral maxillofacial surgery
336025|NCT01353352|Evaluation
336026|NCT01353352|C-Spine
336027|NCT01353352|Nursing
336028|NCT01353352|Clinical Decision Rule
336029|NCT01353339|Kidney Transplant
336030|NCT01353339|BK Polyomavirus Infection
336031|NCT01353326|non-inflammatory degenerative joint disease
336032|NCT01353326|hip resurfacing
336033|NCT01353326|bone mineral density
336034|NCT01353326|cemented
336035|NCT01353326|cementless
336036|NCT01353313|NICHD Neonatal Research Network
336037|NCT01353313|Extremely Low Birth Weight (ELBW)
336038|NCT01353313|Very Low Birth Weight (VLBW)
336039|NCT01353313|Prematurity
336040|NCT01353313|Mechanical ventilation
336041|NCT01353313|Intubation
336042|NCT01353313|Neurodevelopmental impairment
336043|NCT01353300|embryonal childhood rhabdomyosarcoma
336044|NCT01353300|cystic nephroma
336045|NCT01353300|neuroblastoma
336046|NCT01353300|childhood medulloblastoma
336047|NCT01353300|childhood hepatoblastoma
336048|NCT01353300|stromal predominant Wilms tumor
336049|NCT01353300|hereditary Wilms tumor
336050|NCT01353300|pleuropulmonary blastoma
336051|NCT01353287|Transcatheter Aortic Valve Intervention (TAVI)
336052|NCT01353287|Live case transmission
336053|NCT01353261|Platelet reactivity
336054|NCT01353248|Hepatitis C
336055|NCT01353248|HCV
336056|NCT01353248|Rapid Virologic Response
336057|NCT01353248|Sustained Virologic Response
336058|NCT01353248|Direct Acting Antiviral
336059|NCT01353248|Combination Therapy
336060|NCT01353248|HCV RNA
336061|NCT01353248|Polymerase inhibitor
336062|NCT01353248|Protease inhibitor
336063|NCT01353248|Treatment naïve
336064|NCT01353248|GS-5885
336065|NCT01353248|GS-9451
336066|NCT01353248|Tegobuvir
336067|NCT01353235|COPD
336068|NCT01353235|acute respiratory failure
336069|NCT01353235|mechanical ventilation
336070|NCT01353235|non invasive ventilation
336071|NCT01353235|steroids
336072|NCT01353222|Bladder cancer
336073|NCT01353222|Renal pelvis cancer
336074|NCT01353222|Ureteral cancer
336075|NCT01353222|Urethral cancer
336076|NCT01353222|Bladder
336077|NCT01353222|Renal pelvis
336078|NCT01353222|Ureter
336079|NCT01353222|Urethra
336080|NCT01353222|Immune therapy
336081|NCT01353222|Immunotherapy
336082|NCT01353222|Vaccine
336083|NCT01353222|Dendritic cells
336084|NCT01353222|Antigen-presenting cells
336085|NCT01353222|Antigen presenting cells
336086|NCT01353222|Cancer vaccine
336087|NCT01353222|Urothelial carcinoma
336088|NCT01353222|Urothelial neoplasms
336089|NCT01353222|Neoplasms by site
336090|NCT01353222|Neoplasms
336091|NCT01353196|carotid
336092|NCT01353196|atherosclerosis
336093|NCT01353196|cognitive function
336094|NCT01353183|biopsies, enteric nervous system, biomarker
336095|NCT01353170|Serum calcium
336096|NCT01353170|Dialysate
336097|NCT01353170|Mass balance
336098|NCT01353170|Blood pressure
336099|NCT01353157|cytokine
336100|NCT01353157|cardiac surgery
336101|NCT01353157|clinical scoring system
336102|NCT01353144|aspirin
336103|NCT01353144|peptic ulcer
336104|NCT01353131|electrocardiogram,
336105|NCT01353131|cardiac magnetic resonance
336106|NCT01353131|heart failure
336107|NCT01353131|sudden cardiac death
336108|NCT01353131|ECG scoring
336109|NCT01353131|Delayed enhancement
336110|NCT01353118|diabetes
336111|NCT01353118|bariatric surgery
336112|NCT01353118|Roux-en-y gastric bypass
336113|NCT01353118|retinopathy
336114|NCT01353118|neuropathy
336115|NCT01353118|nephropathy
336116|NCT01353105|cystic fibrosis
336117|NCT01353105|chronic obstructive pulmonary disease
336118|NCT01353105|pulmonary fibrosis
336119|NCT01353092|Randomized Controlled Trial
336120|NCT01353092|Major depression
336121|NCT01353092|Hamilton
336122|NCT01353092|PEMF
336123|NCT01353066|Type 2 Diabetes Mellitus
336124|NCT01353066|BMI 30.0-34.9 kg/m2
336125|NCT01353053|Immunosuppression
336126|NCT01353053|Cytomegalovirus
336127|NCT01353053|Renal Transplant
336128|NCT01353053|Atrophy/interstitial
336129|NCT01353053|Conversion of tacrolimus everolimus
336130|NCT01353014|Nutrigenomics
336131|NCT01353014|Diet
336132|NCT01353014|Nutrition
336133|NCT01353001|Intervention Studies
336134|NCT01353001|Magnetic Resonance Imaging
336135|NCT01353001|C-Reactive Protein
336136|NCT01352988|C17.300.475
336137|NCT01352988|C17.800.480
336138|NCT01352975|Age Related Macular Degeneration (AMD)
336139|NCT01352975|Dark Adaptation
336140|NCT01352975|Age Related Macular Degeneration
336141|NCT01352975|AMD
336142|NCT01352962|Dose Limiting Toxicity
336143|NCT01352962|Urethra Cancer
336144|NCT01352962|Carcinoma of the Bladder
336145|NCT01352962|Cancer of the Renal Pelvis
336146|NCT01352962|Ureter Cancer
336147|NCT01352962|Urethral Cancer
336148|NCT01352962|Solid Tumor
336149|NCT01352962|Pancreatic Cancer
336150|NCT01352962|Ovarian Cancer
336151|NCT01352962|Non-Small Cell Lung Cancer
336152|NCT01352949|Anthropometry
336153|NCT01352949|Stereophotogrammetry
336154|NCT01352949|Torso
336155|NCT01352949|Spinal Deformity
336156|NCT01352949|Chest Wall Deformity
336157|NCT01352949|Overweight
336158|NCT01352949|Obese
336159|NCT01352949|Healthy Volunteer
336160|NCT01352949|HV
336161|NCT01352936|nephrotoxicity
336162|NCT01352936|hospital cost
336163|NCT01352936|Staphylococcus aureus
336164|NCT01352936|bacteremia
336165|NCT01352936|vancomycin
336166|NCT01352936|teicoplanin
336167|NCT01352923|PEAR1 gene
336168|NCT01352923|whether and how PEAR 1 modulate intracellular signaling pathways relevant for platelet function
336169|NCT01352897|Cholesterol
336170|NCT01352897|rosuvastatin
336171|NCT01352897|retrospective
336172|NCT01352884|Cancer
336173|NCT01352884|Carcinoma
336174|NCT01352884|Tumor
336175|NCT01352884|Solid tumor
336176|NCT01352884|Metastatic
336177|NCT01352884|Melanoma
336178|NCT01352871|Immunity, Innate
336179|NCT01352871|Attention
336180|NCT01352871|Concentration
336181|NCT01352858|Arthritis
336182|NCT01352858|RA
336183|NCT01352858|Auto-immune disorders
336184|NCT01352832|Chronic NSAID use
336185|NCT01352806|accuracy of identifying intralaminar space
336186|NCT01352793|phase 3 safety study
336187|NCT01352793|5700 healthy subjects
336188|NCT01352793|3 vaccine doses at month 0
336189|NCT01352793|2
336190|NCT01352793|and 6
336191|NCT01352793|control HAV/saline/HAV
336192|NCT01352780|motivational interviewing
336193|NCT01352780|psoriasis
336194|NCT01352780|self management
336195|NCT01352767|insulin injection
336196|NCT01352754|Hip fracture
336197|NCT01352754|Troponin T
336198|NCT01352754|myocardial infarction
336199|NCT01352741|low back pain
336200|NCT01352741|neuropathic
336201|NCT01352741|pain assessment
336202|NCT01352741|centrally acting tapentadol pregabalin
336203|NCT01352741|severe chronic
336204|NCT01352728|Unresectable
336205|NCT01352689|CKD-828
336206|NCT01352689|Hypertension
336207|NCT01352689|Primary Hypertension
336208|NCT01352689|Healthy Volunteer
336209|NCT01352689|S-Amlodipine
336210|NCT01352689|Telmisartan
336211|NCT01352689|Amlodipine
336212|NCT01352689|Pharmacokinetic
336213|NCT01352689|Phase 1
336214|NCT01352676|renal colic
336215|NCT01352676|flank pain
336216|NCT01352676|back pain
336217|NCT01352663|Type I Diabetes
336218|NCT01352663|Wockhardt
336219|NCT01352663|Insulin Analogue
336220|NCT01352650|leukemia
336221|NCT01352637|Traumatic Event
336222|NCT01352637|Trauma Survivor
336223|NCT01352637|Exposure Therapy
336224|NCT01352637|PTSD DCS
336225|NCT01352637|Virtual Reality Exposure
336226|NCT01352637|Veteran
336227|NCT01352637|Combat-related PTSD
336228|NCT01352611|Tactile Defensiveness
336229|NCT01352611|Autistic Disorder
336230|NCT01352598|prostate cancer
336231|NCT01352598|stereotactic radiotherapy
336232|NCT01352572|Antidepressant Response
336233|NCT01352572|Signal Transduction
336234|NCT01352572|Lymphocyte
336235|NCT01352572|Biomarkers
336236|NCT01352572|Depressed Patients
336237|NCT01352572|Antidepressant Drug Adverse Reaction
336238|NCT01352559|Pharmacogenomics
336239|NCT01352559|Prediction of Antidepressant Response
336240|NCT01352559|Depressed Patients
336241|NCT01352559|biomarkers
336242|NCT01352559|phenotype
336243|NCT01352559|Antidepressant Response
336244|NCT01352559|Adverse Reaction to Drug
336245|NCT01352546|vaginismus
336246|NCT01352546|painful sex
336247|NCT01352546|painful intercourse
336248|NCT01352546|dyspareunia
336249|NCT01352546|inability to have intercourse
336250|NCT01352546|inability to consummate marriage
336251|NCT01352546|vaginal spasm
336252|NCT01352546|"hitting a wall"
336253|NCT01352546|pain during sex
336254|NCT01352546|pain during intercourse
336255|NCT01352546|burning with intercourse
336256|NCT01352520|systemic therapy
336257|NCT01352520|cutaneous anaplastic large T cell lymphoma
336258|NCT01352520|ALCL
336259|NCT01352520|lymphomatoid papulosis
336260|NCT01352520|LyP
336261|NCT01352520|mycosis fungoides
336262|NCT01352520|MF
336263|NCT01352520|SGN-35 (brentuximab vedotin)
336264|NCT01352520|skin lymphomas
336391|NCT01351935|leukemia
336265|NCT01352520|CD30-positive lymphoproliferative disorders
336266|NCT01352520|tumor lymphocytes
336267|NCT01352520|cutaneous lymphomas
336268|NCT01352520|CD30+ expression
336269|NCT01352520|Hematologic Disorder
336270|NCT01352520|Lymphoma
336271|NCT01352494|locally advanced breast cancer
336272|NCT01352494|docetaxel
336273|NCT01352494|gemcitabine
336274|NCT01352481|Speech sound development
336275|NCT01352468|ADHD
336276|NCT01352468|cognitive training
336277|NCT01352455|Hemodialysis
336278|NCT01352455|Pediatric
336279|NCT01352455|Outcomes
336280|NCT01352455|Comparative Effectiveness
336281|NCT01352455|End Stage Renal Disease
336282|NCT01352442|Presbyopia
336283|NCT01352442|Accommodation
336284|NCT01352442|Near visual acuity
336285|NCT01352442|LASIK
336286|NCT01352429|adult
336287|NCT01352429|histologically confirmed
336288|NCT01352416|Suppress Atrial Fibrillation
336289|NCT01352416|heart bypass surgery
336290|NCT01352416|heart valve surgery
336291|NCT01352403|obesity
336292|NCT01352403|bariatric surgery
336293|NCT01352403|gastric bypass
336294|NCT01352403|life style intervention
336295|NCT01352403|cardiac function
336296|NCT01352390|behavioral economics
336297|NCT01352390|nudge
336298|NCT01352390|artwork
336299|NCT01352390|Pap smear
336300|NCT01352390|Blood pressure check
336301|NCT01352390|Cholesterol test
336302|NCT01352390|Fasting plasma glucose test
336303|NCT01352364|Physiotherapy.
336304|NCT01352364|Deafness.
336305|NCT01352364|Postural balance.
336306|NCT01352364|Motor skills.
336307|NCT01352351|Breast feeding Exclusive
336308|NCT01352351|Initiation of breastfeeding
336309|NCT01352338|REPEAT
336310|NCT01352338|multiple myeloma
336311|NCT01352338|revlimid
336312|NCT01352338|lenalidomide
336313|NCT01352338|cyclophosphamide
336314|NCT01352338|endoxan
336315|NCT01352338|prednisone
336316|NCT01352338|lenalidomide refractory
336317|NCT01352312|Chronic Lymphocytic Leukemia
336318|NCT01352312|Non-Hodgkin's Lymphoma
336319|NCT01352312|B-cell
336320|NCT01352312|leukemia
336321|NCT01352312|lymphoma
336322|NCT01352312|bendamustine
336323|NCT01352312|pentostatin
336324|NCT01352312|ofatumumab
336325|NCT01352312|NHL
336326|NCT01352312|CLL
336327|NCT01352299|Macintosh laryngoscope blade
336328|NCT01352299|MacCoy laryngoscope blade
336329|NCT01352299|Miller laryngoscope blade
336330|NCT01352299|TrueView laryngoscope
336331|NCT01352286|Multiple myeloma
336332|NCT01352286|Autologous stem cell transplantation
336333|NCT01352286|Received initial treatment previously
336334|NCT01352273|advanced Solid tumors
336335|NCT01352273|harboring RAS
336336|NCT01352273|harboring BRAFV600E
336337|NCT01352260|Near Infrared Spectroscopy
336338|NCT01352260|Neuromonitoring
336339|NCT01352260|Aortic Arch Replacement
336340|NCT01352221|iron deficiency
336341|NCT01352221|anaemia
336342|NCT01352221|inflammatory bowel disease
336343|NCT01352221|Crohn's Disease
336344|NCT01352208|ASP9521
336345|NCT01352208|Castrate Resistant Prostate Cancer
336346|NCT01352208|Phase 1/2
336347|NCT01352195|Forever Free
336348|NCT01352143|Neonates
336349|NCT01352130|Postoperative nausea and vomiting
336350|NCT01352130|Ondansetron
336351|NCT01352130|Granisetron
336352|NCT01352130|QTc interval
336353|NCT01352104|Externalizing Problem Behaviour in Preschoolers
336354|NCT01352091|breast cancer
336355|NCT01352091|adjuvant endocrine therapy
336356|NCT01352091|AI
336357|NCT01352091|Zoladex
336358|NCT01352078|Non healing ulcer
336359|NCT01352078|Wound
336360|NCT01352065|Pharmacokinetics
336361|NCT01352065|Exercise performance
336362|NCT01352065|Athletes
336363|NCT01352052|chronic widespread pain
336364|NCT01352052|fibromyalgia
336365|NCT01352052|outcome assessment
336366|NCT01352052|functional ability
336367|NCT01352052|AMPS
336368|NCT01352052|rehabilitation
336369|NCT01352039|Heparin Sodium
336370|NCT01352039|Thromboprophylaxis
336371|NCT01352039|Hip Fracture Surgery.
336372|NCT01352013|Fibromyalgia
336373|NCT01352013|Omega-3
336374|NCT01352013|Chronic Pain
336375|NCT01352013|Fatigue
336376|NCT01352013|Mood
336377|NCT01352013|docosahexaenoic acid (DHA)
336378|NCT01352013|eicosapentaenoic acid (EPA)
336379|NCT01352000|self help
336380|NCT01352000|smoking cessation
336381|NCT01352000|cancer prevention
336382|NCT01351987|Benign Prostatic Hyperplasia
336383|NCT01351974|breast cancer
336384|NCT01351974|sentinel lymph node biopsy
336385|NCT01351974|axillary recurrence
336386|NCT01351961|Hypertension
336387|NCT01351961|Cognitive function
336388|NCT01351948|Immune response
336389|NCT01351935|non-hodgkin's lymphoma
336390|NCT01351935|lymphoma
336392|NCT01351935|chronic lymphocytic leukemia
336393|NCT01351935|b-cell malignancies
336394|NCT01351935|Btk inhibitor
336395|NCT01351935|Phase 1b
336396|NCT01351935|Avila Therapeutics
336397|NCT01351935|Waldenstrom Macroglobulinemia
336398|NCT01351883|immunomodulating diet
336399|NCT01351883|postoperative infection
336400|NCT01351857|Type 1 Diabetes
336401|NCT01351857|17 to 20 years of age
336402|NCT01351844|Aromatase inhibitor
336403|NCT01351844|Arthralgia Syndrome
336404|NCT01351844|Exercise
336405|NCT01351831|Arthroplasty, Replacement, Knee
336406|NCT01351831|Resistance training
336407|NCT01351831|Physical Therapy Modalities
336408|NCT01351831|Randomized Controlled Trial
336409|NCT01351805|vitamin D
336410|NCT01351805|omega-3 fatty acid
336411|NCT01351805|fish oil
336412|NCT01351805|prevention
336413|NCT01351805|trial
336414|NCT01351805|autoimmune disease
336415|NCT01351805|rheumatoid arthritis
336416|NCT01351805|psoriasis
336417|NCT01351805|systemic inflammation
336418|NCT01351805|Interleukin-6
336419|NCT01351805|C-reactive peptide
336420|NCT01351805|tumor necrosis factor
336421|NCT01351805|osteoarthritis
336422|NCT01351779|Intraocular pressure
336423|NCT01351779|Contact lens sensor
336424|NCT01351779|Optic disc hemorrhage
336425|NCT01351766|Behavioral Activation
336426|NCT01351753|Obesity
336427|NCT01351753|Metabolic Syndrome X
336428|NCT01351753|Hypertension
336429|NCT01351753|Dyslipidemia
336430|NCT01351753|Impaired glucose tolerance
336431|NCT01351740|HIV
336432|NCT01351740|Anti-HIV Agents
336433|NCT01351740|HIV Protease Inhibitors
336434|NCT01351727|seniors
336435|NCT01351727|seizures
336436|NCT01351727|epilepsy
336437|NCT01351727|quality of life
336438|NCT01351714|D3 resection
336439|NCT01351714|right colectomy
336440|NCT01351714|MDCT angiography
336441|NCT01351714|lymphadenectomy
336442|NCT01351714|safe
336443|NCT01351714|right colon
336444|NCT01351714|preoperative
336445|NCT01351701|Diabetic foot
336446|NCT01351701|Bacteriological epidemiology
336447|NCT01351701|Wagner's Grading
336448|NCT01351701|eastern India
336449|NCT01351688|Phase 1
336450|NCT01351688|Metastatic
336451|NCT01351688|Castration resistant
336452|NCT01351688|Prostate cancer
336453|NCT01351688|Androgen receptor
336454|NCT01351688|Down regulation
336455|NCT01351688|Japanese
336456|NCT01351675|Chronic kidney disease
336457|NCT01351675|Type 2 diabetes
336458|NCT01351675|Diabetic nephropathy
336459|NCT01351662|Lupus
336460|NCT01351662|stress
336461|NCT01351649|exercise
336462|NCT01351649|adolescent
336463|NCT01351649|intervention
336464|NCT01351649|female
336465|NCT01351649|counseling
336466|NCT01351636|chronic kidney disease
336467|NCT01351636|hypertension
336468|NCT01351623|PR-171 (CARFILZOMIB)
336469|NCT01351623|Chemotherapy
336470|NCT01351623|10-228
336471|NCT01351610|Critical Limb Ischemia
336472|NCT01351610|Peripheral Arterial Occlusive Disease
336473|NCT01351610|Peripheral Artery Disease
336474|NCT01351610|Peripheral Vascular Disease
336475|NCT01351610|Stem Cell Therapy
336476|NCT01351610|Mesenchymal Stem Cells
336477|NCT01351597|recurrent breast cancer
336478|NCT01351597|metastatic breast cancer
336479|NCT01351597|docetaxel
336480|NCT01351597|oxaliplatin
336481|NCT01351584|Breast Cancer
336482|NCT01351584|Advanced Breast Cancer
336483|NCT01351584|Epidemiology
336484|NCT01351584|Registry
336485|NCT01351584|Health Services Research
336486|NCT01351584|Germany
336487|NCT01351584|Palliative Treatment
336488|NCT01351584|Adjuvant Drug Therapy
336489|NCT01351584|Nutrition Assessment
336490|NCT01351584|Physical Activity
336491|NCT01351519|Glioma
336492|NCT01351519|Glioblastoma
336493|NCT01351519|Glioblastoma Multiforme
336494|NCT01351519|Astrocytoma
336495|NCT01351519|Brain Tumor
336496|NCT01351506|Body weight
336497|NCT01351506|Body mass index
336498|NCT01351506|Weight change
336499|NCT01351506|ICU outcomes
336500|NCT01351493|pressure sore
336501|NCT01351493|nitric oxide
336502|NCT01351480|Auto-immune Disease
336503|NCT01351480|Arthritis
336504|NCT01351480|Rheumatoid Arthritis
336505|NCT01351467|Parkinson's
336506|NCT01351467|genetic
336507|NCT01351467|online
336508|NCT01351467|GWAS
336509|NCT01351467|genome wide association
336510|NCT01351454|Major Depressive Disorder
336511|NCT01351454|Substance Use
336512|NCT01351454|HIV Medication Adherence
336513|NCT01351454|Behavioral Activation
336514|NCT01351441|Geriatric
336515|NCT01351441|Pharmacoeconomics
336516|NCT01351441|Health Literacy
336517|NCT01351441|Adherence
336518|NCT01351428|Non invasive cardiac output monitor
336519|NCT01351428|NICOM
336520|NCT01351428|Hypertension
336521|NCT01351428|Pregnancy
336522|NCT01351428|Pre-Eclampsia
336523|NCT01351402|Massage
336524|NCT01351402|Rest
336525|NCT01351389|Brief
336526|NCT01351389|Alcohol
336527|NCT01351389|Intervention
336528|NCT01351389|Sex
336529|NCT01351389|Risk
336530|NCT01351376|Lymphedema, Low Level Laser, Breast Cancer
336531|NCT01351363|Arthroscopic shoulder surgery
336532|NCT01351363|Pain threshold
336533|NCT01351350|Solid tumor, mTORC1/2 inhibitors, HER2
336534|NCT01351337|Diffusion tensor imaging, Glioma, Intraoperative monitoring, Pyramidal tract, Subcortical
336535|NCT01351337|stimulation, Tractography
336536|NCT01351324|Endothelial function
336537|NCT01351324|Non-esterified fatty acids
336538|NCT01351324|Insulin sensitivity
336539|NCT01351311|treatment
336540|NCT01351311|exercise
336541|NCT01351311|resistance training
336542|NCT01351311|swiss ball
336543|NCT01351311|functional capacity
336544|NCT01351259|Mechanical ventilation
336545|NCT01351259|Intubation
336546|NCT01351259|Cuff pressure
336547|NCT01351259|Microaspiration
336548|NCT01351246|Program Evaluation
336549|NCT01351246|ADHD
336550|NCT01351233|Cataract
336551|NCT01351220|CRC screening
336552|NCT01351220|Prevention and early detection of CRC
336553|NCT01351220|Filipino
336554|NCT01351220|Dissemination
336555|NCT01351194|Hepatocellular Carcinoma
336556|NCT01351194|RFA
336557|NCT01351194|HR
336558|NCT01351181|Diabetes
336559|NCT01351168|Parkinson's disease
336560|NCT01351168|zolpidem
336561|NCT01351155|acute respiratory failure
336562|NCT01351155|noninvasive ventilation
336563|NCT01351129|formulation comparison
336564|NCT01351116|brachytherapy
336565|NCT01351116|external beam radiation
336566|NCT01351116|high dose rate intraluminal brachytherapy
336567|NCT01351116|lung cancer
336568|NCT01351116|quality of life
336569|NCT01351116|radiation treatment
336570|NCT01351116|bronchus
336571|NCT01351103|LGK974
336572|NCT01351103|pancreatic adenocarcinoma
336573|NCT01351103|BRAF mutant colorectal cancer
336574|NCT01351103|other tumor types with documented genetic alterations upstream in the Wnt signaling pathway
336575|NCT01351103|RNF43 mutation
336576|NCT01351103|RSPO fusion
336577|NCT01351077|Developmental Delay
336578|NCT01351064|ADHD
336579|NCT01351012|Canola oil
336580|NCT01351012|High oleic canola oil
336581|NCT01351012|Flax oil
336582|NCT01351012|ALA
336583|NCT01351012|DHA
336584|NCT01351012|Metabolic syndrome
336585|NCT01351012|Cardiovascular disease
336586|NCT01351012|Endothelial function
336587|NCT01351012|FADS1
336588|NCT01351012|Gut microbiome
336589|NCT01351012|Body composition
336590|NCT01351012|Psychosocial status
336591|NCT01351012|Cholesterol
336592|NCT01351012|Lipids
336593|NCT01351012|Lipoproteins
336594|NCT01351012|Inflammation
336595|NCT01351012|Lipid peroxidation
336596|NCT01350999|Drug Therapy
336597|NCT01350986|Controlled Clinical Trials, Randomized
336598|NCT01350973|Drug Therapy
336599|NCT01350960|hypercholesterolemia
336600|NCT01350960|hyperlipidemia
336601|NCT01350960|LDL
336602|NCT01350960|HDL
336603|NCT01350960|PCSK9
336604|NCT01350960|LNA-oligonucleotide
336605|NCT01350947|Chronic Myelomonocytic Leukemia
336606|NCT01350947|CMML
336607|NCT01350921|phase 1
336608|NCT01350921|ticagrelor
336609|NCT01350921|venlafaxine
336610|NCT01350895|Polycystic ovarian syndrome (PCOS)
336611|NCT01350882|kidney transplantation
336612|NCT01350882|acute humoral rejection
336613|NCT01350882|rituximab
336614|NCT01350856|Uncomplicated P. falciparum malaria
336615|NCT01350843|Men
336616|NCT01350843|Orange Juice
336617|NCT01350843|Cholesterol
336618|NCT01350843|Obesity
336619|NCT01350830|inguinal hernia
336620|NCT01350830|groin hernia
336621|NCT01350830|chronic pain
336622|NCT01350830|mesh repair
336623|NCT01350804|Rheumatoid Arthritis
336624|NCT01350804|RA
336625|NCT01350804|ACR
336626|NCT01350804|inflammatory joints
336627|NCT01350778|Coronary artery disease requiring drug eluting stents
336628|NCT01350765|Birth asphyxia
336629|NCT01350765|Low birth weight
336630|NCT01350765|neonatal sepsis
336631|NCT01350765|mortality
336632|NCT01350765|community based interventions
336633|NCT01350752|cost effectiveness
336634|NCT01350752|provider knowledge
336635|NCT01350752|schools
336636|NCT01350726|Cirrhosis
336637|NCT01350726|Hepatic Carcinoma
336638|NCT01350713|skin
336639|NCT01350713|burn
336640|NCT01350713|povidone iodine
336641|NCT01350713|cold water
336642|NCT01350700|QOL
336643|NCT01350687|Calcium Phosphore
336644|NCT01350687|Renagel
336645|NCT01350674|mediastinal tuberculosis
336646|NCT01350674|endoscopy
336647|NCT01350674|EBUS
336648|NCT01350674|tuberculous lymphadenopathy
336649|NCT01350674|endobronchial ultrasound
336650|NCT01350661|Asthma
336651|NCT01350661|Questionnaires
336652|NCT01350648|Viral Hepatitis
336653|NCT01350648|Prospective Cohort
336654|NCT01350648|Hepatocellular Carcinoma
336655|NCT01350648|HIV-HCV Co-Infection
336656|NCT01350648|HIV-HBV Co-Infection
336657|NCT01350648|Hepatitis B
336658|NCT01350648|Hepatitis C
336659|NCT01350648|Hepatitis
336660|NCT01350635|Specific Immunotherapy
336661|NCT01350635|Grass pollen vaccine
336662|NCT01350635|Allergy
336663|NCT01350635|Grass Pollen Allergy
336664|NCT01350622|pain management
336665|NCT01350609|essential hypertension, blood pressure, nifedipine, candesartan, FDC
336666|NCT01350596|Bioequivalence Study
336667|NCT01350596|Ibuprofen
336668|NCT01350596|Alivium
336669|NCT01350583|tumor related pain
336670|NCT01350570|acupuncture
336671|NCT01350570|loperamide
336672|NCT01350570|functional diarrhea
336673|NCT01350570|IBS
336674|NCT01350557|Elderly
336675|NCT01350557|Hip fracture
336676|NCT01350557|Intervention program
336677|NCT01350544|HIV
336678|NCT01350544|Adherence
336679|NCT01350544|African American/Black
336680|NCT01350544|Disparities
336681|NCT01350531|Obesity
336682|NCT01350531|African American adolescents
336683|NCT01350531|Motivation
336684|NCT01350518|Intra-Abdominal Fat
336685|NCT01350518|Metabolic Syndrome
336686|NCT01350518|Hepatic steatosis
336687|NCT01350505|Postural Balance
336688|NCT01350505|Sleep Initiation and Maintenance Disorders
336689|NCT01350492|pain
336690|NCT01350492|brain imaging
336691|NCT01350492|exercise
336692|NCT01350479|Cross infection
336693|NCT01350479|Long term care
336694|NCT01350466|Chronic rhinosinusitis
336695|NCT01350453|CIT
336696|NCT01350453|Stroke
336697|NCT01350427|leucine supplementation
336698|NCT01350427|BCCA supplementation
336699|NCT01350427|resistance exercise-induced muscle remodeling
336700|NCT01350401|Melanoma
336701|NCT01350401|Cell Therapy
336702|NCT01350401|T Cell Therapy
336703|NCT01350401|NY-ESO-1
336704|NCT01350401|Immuno-oncology
336705|NCT01350401|Metastatic
336706|NCT01350401|Previously treated
336707|NCT01350401|T Cell Receptor
336708|NCT01350388|Chronic Kidney Disease
336709|NCT01350388|Diabetes
336710|NCT01350388|Febuxostat
336711|NCT01350388|Inflammation
336712|NCT01350388|Hyperuricemia
336713|NCT01350362|tideglusib
336714|NCT01350362|Alzheimer
336715|NCT01350362|NP-12
336716|NCT01350362|NP031112
336717|NCT01350362|ARGO
336718|NCT01350362|Noscira
336719|NCT01350349|Depression
336720|NCT01350349|Dementia
336721|NCT01350349|Geriatrics
336722|NCT01350310|Heart failure
336723|NCT01350310|Dilated cardiomyopathy
336724|NCT01350310|Stem cells
336725|NCT01350297|tetraplegia
336726|NCT01350297|reinnervation
336727|NCT01350297|phrenic nerve
336728|NCT01350284|Antioxidants
336729|NCT01350284|Glucose Intolerance prevention and control
336730|NCT01350284|Diabetes Mellitus prevention and control
336731|NCT01350271|Hookworm
336732|NCT01350271|Necator americanus
336733|NCT01350271|Mebendazole
336734|NCT01350258|allogeneic HSCT
336735|NCT01350258|Hematopoietic stem cell transplantation
336736|NCT01350245|Acute Myeloid Leukemia
336737|NCT01350245|Myelodysplastic Syndromes
336738|NCT01350245|Biphenotypic Leukemia
336739|NCT01350245|Acute Lymphocytic Leukemia
336740|NCT01350245|Chronic Myeloid Leukemia
336741|NCT01350245|Chronic Lymphocytic Leukemia
336742|NCT01350245|Plasma Cell Neoplasms
336743|NCT01350245|Lymphoma
336744|NCT01350245|Hodgkin's Disease
336745|NCT01350245|Aplastic Anemia
336746|NCT01350245|Hematopoietic stem cell transplant (HSCT)
336747|NCT01350245|myeloablative haploidentical HSCT
336748|NCT01350245|graft versus host disease (GVHD)
336749|NCT01350232|sickle cell
336750|NCT01350232|SS disease
336751|NCT01350232|SC disease
336752|NCT01350232|S-thalassemia
336753|NCT01350232|transplant
336754|NCT01350232|bone marrow transplant
336755|NCT01350232|stem cell transplant
336756|NCT01350232|matched sibling
336757|NCT01350232|haploidentical
336758|NCT01350232|hemoglobinopathy
336759|NCT01350232|anemia
336760|NCT01350232|desensitization
336761|NCT01350219|Cord blood stem cells
336762|NCT01350219|Immune modulation
336763|NCT01350219|Stem cell educator
336764|NCT01350219|Autoimmunity
336765|NCT01350219|Islet beta cell regeneration
336766|NCT01350219|Type 1 diabetes
336767|NCT01350206|Carcinoma,Hepatocellular
336768|NCT01350206|Liver Neoplasms
336769|NCT01350206|Therapeutic
336770|NCT01350206|Chemoembolization,
336771|NCT01350206|TACE
336772|NCT01350206|hepatic resection
336773|NCT01350193|Manuka Honey
336774|NCT01350193|Irrigation
336775|NCT01350193|Endoscopic Sinus Surgery
336776|NCT01350180|biochemical failure
336777|NCT01350180|hormonal therapy
336778|NCT01350167|Hepatocellular Carcinoma
336779|NCT01350167|Liver Cancer
336780|NCT01350167|Ultrasound
336781|NCT01350167|Computed Tomography
336782|NCT01350167|Alpha fetoprotein
336783|NCT01350167|Cirrhosis
336784|NCT01350167|Screening
336785|NCT01350167|Advanced Liver Disease
336786|NCT01350154|clinical trial
336787|NCT01350154|sildenafil
336788|NCT01350154|revatio
336789|NCT01350154|muscular dystrophy
336790|NCT01350154|adult
336791|NCT01350154|nNOS
336792|NCT01350141|Hypercholesterolemia
336793|NCT01350141|dyslipidemia
336794|NCT01350141|high cholesterol
336795|NCT01350141|LDL
336796|NCT01350141|antibody
336797|NCT01350141|PCSK9
336798|NCT01350141|PF-04950615
336799|NCT01350141|RN316
336800|NCT01350128|COPD
336801|NCT01350115|Basal Cell Carcinoma
336802|NCT01350115|Gorlin Syndrome,
336803|NCT01350115|Gorlin-Goltz Syndrome,
336804|NCT01350115|Basal Cell Nevus Syndrome,
336805|NCT01350115|Nevoid Basal Cell Carcinoma Syndrome,
336806|NCT01350115|Basal Cell Carcinoma Nevus Syndrome
336807|NCT01350115|Smo inhibitor,
336808|NCT01350115|Hedgehog pathway inhibitor
336809|NCT01350115|BCCs
336810|NCT01350102|Adult
336811|NCT01350089|energy drinks
336812|NCT01350089|alcohol intoxication
336813|NCT01350076|intraoperative fluid
336814|NCT01350076|pediatric
336815|NCT01350076|goal directed therapy
336816|NCT01350076|pediatric with major abdominal surgery
336817|NCT01350076|ASA less than or equal to 3
336818|NCT01350076|Duration of surgery less than 2 hours
336819|NCT01350076|Body weight more than or equal to 15 kg
336820|NCT01350063|water
336821|NCT01350063|tubewell
336822|NCT01350063|diarrhea
336823|NCT01350063|chlorination
336824|NCT01350063|safe storage
336825|NCT01350050|topical pharyngeal anesthesia
336826|NCT01350050|articaine
336827|NCT01350037|patient-controlled sedation
336828|NCT01350037|propofol
336829|NCT01350037|alfentanil
336830|NCT01350037|remifentanil
336831|NCT01350037|endoscopic retrograde cholangiopancreatography
336832|NCT01350024|Conjunctival Mullerectomy
336833|NCT01350024|Blepharoptosis
336834|NCT01350024|Ptosis surgery
336835|NCT01350024|Pain Control
336836|NCT01350011|Nicotine Replacement Therapy
336837|NCT01350011|Buprenorphine
336838|NCT01350011|Varenicline
336839|NCT01350011|Smoking Cessation
336840|NCT01350011|Addiction
336841|NCT01350011|The Innovative System (IS) Treatment
336842|NCT01350011|The Standard Treatment Control (STC)
336843|NCT01349985|Naltrexone
336844|NCT01349985|problem drinking
336845|NCT01349985|medication adherence
336846|NCT01349985|adherence
336847|NCT01349985|smartphone
336848|NCT01349920|biological markers
336849|NCT01349920|endoscopy
336850|NCT01349920|gastrointestinal
336851|NCT01349881|Eflornithine/sulindac prevention trial
336852|NCT01349868|COPD
336853|NCT01349829|Hepatitis A
336854|NCT01349829|Vaccination
336855|NCT01349829|Immunity
336856|NCT01349816|COPD
336857|NCT01349803|COPD
336858|NCT01349790|ITP
336859|NCT01349790|Primary immune thrombocytopenia
336860|NCT01349777|antiplatelet therapy post drug eluting stents
336861|NCT01349764|vitamin D replacement
336862|NCT01349764|Urolithiasis
336863|NCT01349764|deficiency
336864|NCT01349764|insufficiency
336865|NCT01349751|abdominal incision
336866|NCT01349751|hyperbaric
336867|NCT01349751|isobaric
336868|NCT01349751|levobupivacaine
336869|NCT01349751|spinal anaesthesia
336870|NCT01349725|Safety
336871|NCT01349699|endotoxemia
336872|NCT01349699|inflammation
336873|NCT01349699|iron
336874|NCT01349699|iron chelation
336875|NCT01349699|cytokines
336876|NCT01349686|Food
336877|NCT01349686|Fluids
336878|NCT01349686|Labor
336879|NCT01349673|Open-label
336880|NCT01349673|Proctitis
336881|NCT01349673|Proctosigmoiditis
336882|NCT01349673|Ulcerative
336883|NCT01349673|Salix
336884|NCT01349673|Budesonide foam
336885|NCT01349673|Budesonide
336886|NCT01349673|Rectal
336887|NCT01349673|Gastrointestinal
336888|NCT01349673|Colitis
336889|NCT01349673|UC
336890|NCT01349673|UP
336891|NCT01349673|UPS
336892|NCT01349673|Additional relevant MeSH terms:
336893|NCT01349673|Proctocolitis
336894|NCT01349673|Ulcer
336895|NCT01349673|Colitis, Ulcerative
336896|NCT01349673|Gastroenteritis
336897|NCT01349673|Gastrointestinal Diseases
336898|NCT01349673|Digestive System Diseases
336899|NCT01349673|Rectal Diseases
336900|NCT01349673|Intestinal Diseases
336901|NCT01349673|Colonic Diseases
336902|NCT01349673|Sigmoid Diseases
336903|NCT01349673|Pathologic Processes
336904|NCT01349673|Inflammatory Bowel Diseases
336905|NCT01349673|Bronchodilator Agents
336906|NCT01349673|Autonomic Agents
336907|NCT01349673|Peripheral Nervous System Agents
336908|NCT01349673|Physiological Effects of Drugs
336909|NCT01349673|Pharmacologic Actions
336910|NCT01349673|Anti-Asthmatic Agents
336911|NCT01349673|Respiratory System Agents
336912|NCT01349673|Therapeutic Uses
336913|NCT01349673|Glucocorticoids
336914|NCT01349673|Hormones
336915|NCT01349673|Hormones, Hormone Substitutes and Hormone Antagonists
336916|NCT01349673|Anti-inflammatory Agents
336917|NCT01349660|Glioblastoma multiforme
336918|NCT01349660|GBM
336919|NCT01349660|Bevacizumab
336920|NCT01349660|PI3K Pathway
336921|NCT01349660|BKM120
336922|NCT01349647|FUCOSYL-GM1-KLH
336923|NCT01349647|GLOBO H-KLH CONJUGATE
336924|NCT01349647|OPT-821
336925|NCT01349647|POLYSIALIC ACID - KLH
336926|NCT01349647|Vaccine
336927|NCT01349647|08-095
336928|NCT01349634|iodine
336929|NCT01349634|goiter
336930|NCT01349634|cretinism
336931|NCT01349634|child nutrition
336932|NCT01349634|cognition
336933|NCT01349621|Abnormal Pap results
336934|NCT01349621|Colposcopy
336935|NCT01349608|Chronic Obstructive Pulmonary Disease
336936|NCT01349608|Motivational Interviewing
336937|NCT01349608|Health Coaching
336938|NCT01349608|Physical Activity
336939|NCT01349582|flow diversion
336940|NCT01349582|endovascular treatment
336941|NCT01349582|symptomatic aneurysm
336942|NCT01349582|cavernous carotid aneurysm
336943|NCT01349582|ophthalmic aneurysm
336944|NCT01349582|vertebral aneurysm
336945|NCT01349556|cancer
336946|NCT01349556|chemotherapy
336947|NCT01349556|EGFR inhibitors
336948|NCT01349556|tretinoin
336949|NCT01349556|EGFRi drug rash
336950|NCT01349543|Respiratory syncytial virus
336951|NCT01349543|RSV
336952|NCT01349543|Immunology
336953|NCT01349543|Viral infection
336954|NCT01349543|Bronchiolitis
336955|NCT01349543|Viral challenge
336956|NCT01349543|Viral lung disease
336957|NCT01349530|Usual medical care
336958|NCT01349530|Anticoagulation by VKAs: COUMADINE® & PREVISCAN®
336959|NCT01349530|Anticoagulation clinic care, CREATIF
336960|NCT01349517|health-related quality of life(HRQL)
336961|NCT01349517|Esophageal Cancer
336962|NCT01349491|Atrial Fibrillation
336963|NCT01349491|Ranolazine
336964|NCT01349478|paraplegia
336965|NCT01349478|tetraplegia
336966|NCT01349478|passive gait training
336967|NCT01349478|O2 consumption
336968|NCT01349478|exercise capacity
336969|NCT01349478|CVD risk factors
336970|NCT01349478|spasticity
336971|NCT01349478|pain
336972|NCT01349478|bladder, bowel
336973|NCT01349478|well being
336974|NCT01349465|Hepatitis C
336975|NCT01349465|Hepatitis
336976|NCT01349465|TMC435
336977|NCT01349465|Liver disease
336978|NCT01349465|Virus Infection
336979|NCT01349452|Conjunctivitis, Viral
336980|NCT01349452|Adenoviridae Infections
336981|NCT01349452|Ganciclovir
336982|NCT01349452|Adenovirus Keratoconjunctivitis
336983|NCT01349452|Treatment of viral conjunctivitis
336984|NCT01349426|Lung resection
336985|NCT01349426|Parenchymal pneumostasis, haemostasis
336986|NCT01349426|Fissure closure
336987|NCT01349426|Automatic staplers,LigaSure, Force Triad Generator
336988|NCT01349426|Bipolar fusion
336989|NCT01349426|Procedure cost
336990|NCT01349413|Functional dyspepsia
336991|NCT01349413|symptom response
336992|NCT01349413|postprandial fullness
336993|NCT01349413|gastroesophageal reflux disease
336994|NCT01349413|acid suppression
336995|NCT01349400|asymptomatic
336996|NCT01349400|minimally symptomatic
336997|NCT01348386|Potassium hydroxide.
336998|NCT01348386|Molluscum Contagiosum
336999|NCT01348373|drug eluting stents
337000|NCT01348334|Sling surgery
337001|NCT01348334|synthetic meshes
337002|NCT01348334|ultrapromesh®
337003|NCT01348334|mix mesh
337004|NCT01348334|incontinence
337005|NCT01348334|The Ultrapromesh® synthetic sling procedures have lower complications incidence and higher success rates than the other synthetic slings in 3-year follow-up.
337006|NCT01348308|Late diagnosed HIV-1 infected patients
337007|NCT01348308|AIDS-defining events
337008|NCT01348308|Immune restoration
337009|NCT01348295|Mechanical ventilation
337010|NCT01348295|Children
337011|NCT01348295|Neonates
337012|NCT01348295|Pediatric intensive care
337013|NCT01348282|Neurocognitive Impairment
337014|NCT01348282|Controlled Randomized Trial
337015|NCT01348282|Coadjunctive Treatments
337016|NCT01348282|Lithium; Rivastigmine
337017|NCT01348282|Antiretroviral Therapy
337018|NCT01348282|HIV Infection
337019|NCT01348269|bone marrow edema
337020|NCT01348269|Aclasta
337021|NCT01348256|colorectal carcinoma
337022|NCT01348256|resectable hepatic metastasis
337023|NCT01348256|adjuvant treatment
337024|NCT01348256|dendritic cells
337025|NCT01348230|Premature prolonged rupture of membranes
337026|NCT01348230|Premature labor
337027|NCT01348230|Uromodulin
337028|NCT01348230|Glycosylation
337029|NCT01348217|unoperated cancers
337030|NCT01348217|oesophagus
337031|NCT01348217|radiochemotherapy
337032|NCT01348217|with and without increased doses
337033|NCT01348204|Cystic Fibrosis
337034|NCT01348191|Thyrotrophin
337035|NCT01348191|Pregnancy
337036|NCT01348191|Human myometrium
337037|NCT01348191|Relaxation
337038|NCT01348191|Contractility
337039|NCT01349348|Tolvaptan treatment to ascites and hepatic cirrhosis
337040|NCT01349322|stage IA breast cancer
337041|NCT01349322|stage IB breast cancer
337042|NCT01349322|stage II breast cancer
337043|NCT01349322|estrogen receptor-negative breast cancer
337044|NCT01349322|estrogen receptor-positive breast cancer
337045|NCT01349322|progesterone receptor-negative breast cancer
337046|NCT01349322|progesterone receptor-positive breast cancer
337047|NCT01349322|ductal breast carcinoma in situ
337048|NCT01349309|Prophylactic Swallowing Exercises
337049|NCT01349309|Head and Neck Cancer
337050|NCT01349309|Dysphagia
337051|NCT01349296|Solid Tumors
337052|NCT01349283|Hepatitis B Vaccine
337053|NCT01349283|Hepatitis B Virus
337054|NCT01349283|Antigen
337055|NCT01349283|Antibody
337056|NCT01349283|Vaccination
337057|NCT01349270|chronic inflammatory demyelinating polyneuropathy
337058|NCT01349270|immunoglobulin
337059|NCT01349270|prednisone
337060|NCT01349257|Asthmatic patients
337061|NCT01349244|hydronephrosis
337062|NCT01349244|CT
337063|NCT01349244|POC US
337064|NCT01349231|obsessive-compulsive disorder
337065|NCT01349231|ketamine
337066|NCT01349231|glutamate
337067|NCT01349218|Potassium
337068|NCT01349218|Infants
337069|NCT01349218|Heel Stick
337070|NCT01349218|Less than or equal to 6 months of age
337071|NCT01349218|IV catheter blood samples
337072|NCT01349218|perioperatively
337073|NCT01349218|elective surgical procedures
337074|NCT01349205|OSA
337075|NCT01349205|Caffeine
337076|NCT01349205|Tonsillectomy
337077|NCT01349205|Adenoidectomy
337078|NCT01349205|Sleep Study
337079|NCT01349192|MRSA
337080|NCT01349192|Cystic Fibrosis
337081|NCT01349192|Early Infection
337082|NCT01349192|Treatment
337083|NCT01349179|Hip
337084|NCT01349179|Arthroplasty
337085|NCT01349179|Metal on metal
337086|NCT01349179|operated on 2002
337087|NCT01349166|Obesity
337088|NCT01349166|Type 2 diabetes
337089|NCT01349166|glucose intolerance
337090|NCT01349166|Physical Activity
337091|NCT01349166|Inflammation
337092|NCT01349166|HPA axis
337093|NCT01349166|Cytokines
337094|NCT01349153|Physical Activity
337095|NCT01349153|Young Adults
337096|NCT01349153|Cancer Survivors
337097|NCT01349127|Vitamin D
337098|NCT01349127|Cholecalciferol
337099|NCT01349127|Nutrient requirements
337100|NCT01349127|Randomised Controlled Trial
337101|NCT01349127|Lactation
337102|NCT01349127|pregnancy
337103|NCT01349127|Cord blood
337104|NCT01349127|Human milk
337105|NCT01349127|serum 25-hydroxyvitamin D
337106|NCT01349127|deficiency
337107|NCT01349127|insufficiency
337108|NCT01349127|nutrition
337109|NCT01349114|aliskiren
337110|NCT01349114|endothelial function
337111|NCT01349114|hypertension
337112|NCT01349101|hematopoietic stem cell transplantation
337113|NCT01349101|HSCT
337114|NCT01349101|allogeneic marrow transplantation
337115|NCT01349101|cyclophosphamide
337116|NCT01349101|graft-versus-host disease
337117|NCT01349101|GVHD
337118|NCT01349088|breast cancer
337119|NCT01349088|metastatic breast cancer
337120|NCT01349088|stage IV breast cancer
337121|NCT01349088|motesanib
337122|NCT01349088|ixabepilone
337123|NCT01349088|capecitabine
337124|NCT01349075|Unresectable
337125|NCT01349075|Hepatocellular Carcinoma
337126|NCT01349075|TheraSphere
337127|NCT01349075|Yttrium-90
337128|NCT01349062|Prolonged Viral Suppression
337129|NCT01349062|HIV Infections
337130|NCT01349049|AML
337131|NCT01349049|relapsed
337132|NCT01349049|refractory
337133|NCT01349036|GBM
337134|NCT01349036|Glioblastoma
337135|NCT01349036|brain cancer
337136|NCT01349023|energy content
337137|NCT01349023|energy density
337138|NCT01349023|energy intake
337139|NCT01349023|pre-portioned entrees
337140|NCT01349010|hyperlipidemia
337141|NCT01348997|cancer
337142|NCT01348997|cancer survivors
337143|NCT01348997|internet
337144|NCT01348997|depression
337145|NCT01348997|anxiety
337146|NCT01348984|postoperative
337147|NCT01348984|pain score
337148|NCT01348984|morphine consumption
337149|NCT01348971|sodium nitrate
337150|NCT01348971|coronary artery bypass surgery
337151|NCT01348971|ischemia-reperfusion
337152|NCT01348971|myocardial injury
337153|NCT01348958|Patello femoral
337154|NCT01348958|osteoarthritis
337155|NCT01348958|arthroplasty
337156|NCT01348945|Partial tear ACL
337157|NCT01348945|Stump preserved ACL surgery
337158|NCT01348932|asthma
337159|NCT01348932|Chitinase 3-like 1 (CHI3L1)
337160|NCT01348932|YKL-40
337161|NCT01348932|single nucleotide polymorphism(SNP)
337162|NCT01348932|Real time PCR
337163|NCT01348932|gene
337164|NCT01348919|Cancer
337165|NCT01348919|Multiple myeloma
337166|NCT01348919|CEP-18770
337167|NCT01348919|Lenalidomide
337168|NCT01348919|Dexamethasone
337169|NCT01348906|cardiopulmonary bypass
337170|NCT01348893|Mental health
337171|NCT01348893|Education
337172|NCT01348893|Mind Body Therapies
337173|NCT01348880|drug-drug interaction
337174|NCT01348867|Diabetes
337175|NCT01348867|Structured Care
337176|NCT01348854|astigmatism
337177|NCT01348841|community wound care
337178|NCT01348841|systematic wound team referral
337179|NCT01348841|Advanced in-home nurse wound training
337180|NCT01348828|Abdominal Aortic Aneurysm
337181|NCT01348828|Fenestrated
337182|NCT01348828|Renal Stent
337183|NCT01348828|Juxtarenal
337184|NCT01348828|Pararenal
337185|NCT01348828|Endologix
337186|NCT01348828|Renal
337187|NCT01348802|Knowledge Translation
337188|NCT01348802|Push-out Evidence
337189|NCT01348802|Technology-Based Knowledge Translation
337190|NCT01348802|Pain
337191|NCT01348802|Interdisciplinary
337192|NCT01348802|Physician
337193|NCT01348802|Rehabilitation
337194|NCT01348802|Nursing
337195|NCT01348802|Knowledge Uptake
337196|NCT01348789|Hair removal
337197|NCT01348789|Hair Clearance
337198|NCT01348789|Epilation
337199|NCT01348776|hair reduction
337200|NCT01348776|hair removal
337201|NCT01348776|hair clearance
337202|NCT01348750|PTSD
337203|NCT01348750|Healing Touch
337204|NCT01348750|Guided Imagery
337205|NCT01348750|Military
337206|NCT01348750|Complementary Medicine
337207|NCT01348737|Phase 1
337208|NCT01348737|healthy volunteers
337209|NCT01348737|double-blind
337210|NCT01348737|placebo-controlled
337211|NCT01348737|AZD3839
337212|NCT01348737|pharmacokinetics
337213|NCT01348737|Alzheimer's Disease
337214|NCT01348724|Radioactive carbon
337215|NCT01348724|Absorption
337216|NCT01348724|Distribution
337217|NCT01348724|Metabolism
337218|NCT01348724|Excretion
337219|NCT01348724|Healthy Volunteers
337220|NCT01348711|Pre-eclampsia
337221|NCT01348698|Adrenal Cancer
337222|NCT01348698|Pheochromocytoma
337223|NCT01348698|Functioning Tumor
337224|NCT01348698|Nonfunctioning Tumor
337225|NCT01348698|Gene Expression
337226|NCT01348698|Adrenal Tumor
337227|NCT01348672|Age related macular degeneration
337228|NCT01348672|Glaucoma
337229|NCT01348672|Diabetic retinopathy
337230|NCT01348672|Retinal oxygen saturation
337231|NCT01348672|Blood flow
337232|NCT01348672|Vascular function
337233|NCT01348672|High resolution imaging
337234|NCT01348659|Hypertonic saline
337235|NCT01348659|Extracellular fluid
337236|NCT01348659|cardiopulmonary bypass
337237|NCT01348646|Smoking
337238|NCT01348646|Adolescence
337239|NCT01348646|Brief intervention
337240|NCT01348633|Doppler SD-OCT Blood Flow Technology
337241|NCT01348633|Retinal and choroidal blood flow
337242|NCT01348633|Canon Laser Blood Flowmeter
337243|NCT01348620|single port cholecystectomy
337244|NCT01348607|psychosocial effects of cancer and its treatment
337245|NCT01348607|sleep disorders
337246|NCT01348607|fatigue
337247|NCT01348607|childhood craniopharyngioma
337248|NCT01348594|Vitamin D
337249|NCT01348594|In vitro Fertilization
337250|NCT01348581|Adult
337251|NCT01348581|Aged
337252|NCT01348581|Aged, 80 and over
337253|NCT01348581|Bandages
337254|NCT01348581|Biological Dressings
337255|NCT01348581|Chronic Disease
337256|NCT01348581|Collagen
337257|NCT01348581|Epithelium
337258|NCT01348581|Extracellular Matrix
337259|NCT01348581|Fibroblasts
337260|NCT01348581|Granulation Tissue
337261|NCT01348581|Humans
337262|NCT01348581|Leg Ulcer
337263|NCT01348581|Middle Aged
337264|NCT01348581|Prospective Studies
337265|NCT01348581|Soft Tissue Injuries
337266|NCT01348581|Treatment Outcome
337267|NCT01348581|Varicose Ulcer
337268|NCT01348581|Wound Healing
337269|NCT01348581|Wounds and Injuries
337270|NCT01348555|COPD
337271|NCT01348542|Chronic Insomnia
337272|NCT01348542|Short Sleep Duration
337273|NCT01348542|Trazodone
337274|NCT01348542|Cognitive Behavioral Therapy
337275|NCT01348542|Efficacy
337276|NCT01348529|OCD
337277|NCT01348529|CBT
337278|NCT01348529|Reducing OCD symptoms
337279|NCT01348516|HIV
337280|NCT01348490|PMF
337281|NCT01348490|PPV-MF
337282|NCT01348490|PET-MF
337283|NCT01348477|inguinal
337284|NCT01348477|hernia
337285|NCT01348477|pain
337286|NCT01348477|inguinodynia
337287|NCT01348477|mesh
337288|NCT01348464|appendectomy
337289|NCT01348464|appendicitis
337290|NCT01348464|laparoscopic surgery
337291|NCT01348451|Human spinal cord derived neural stem cell transplantation
337292|NCT01348451|ALS
337293|NCT01348438|high risk
337294|NCT01348438|surgical valve replacement
337295|NCT01348425|PAD
337296|NCT01348412|non resectable metastases
337297|NCT01348412|liver of colic or rectal origin
337298|NCT01348412|after failure of the conventional treatments
337299|NCT01348399|Coronary artery disease requiring drug eluting stents
337300|NCT01348152|Gastric Emptying
337301|NCT01348139|Asthma
337302|NCT01348139|patients
337303|NCT01348139|lung function
337304|NCT01348126|Advanced non-small cell lung cancer
337305|NCT01348126|NSCLC
337306|NCT01348126|Lung cancer
337307|NCT01348113|Alcohol Use Disorders Identification Test
337308|NCT01348113|alcohol dependence
337309|NCT01348113|Alcohol problem
337310|NCT01348100|Schizophrenia
337311|NCT01348100|Iloperidone
337312|NCT01348100|Depot
337313|NCT01348100|Injection
337314|NCT01348087|Fragile X Syndrome
337315|NCT01348087|Martin-Bell Syndrome
337316|NCT01348087|Genetic Diseases
337317|NCT01348087|X-Linked
337318|NCT01348087|Escalante's syndrome
337319|NCT01348074|warfarin
337320|NCT01348074|surgery
337321|NCT01348074|management
337322|NCT01348074|thromboembolism
337323|NCT01348074|bleeding
337324|NCT01348061|Alzheimers Disease
337325|NCT01348061|Progressive Supranuclear Palsy
337326|NCT01348061|CSF
337327|NCT01348061|Cerebrospinal Fluid
337328|NCT01348061|Biomarker
337329|NCT01348061|Heavy Water
337330|NCT01348061|Cargo proteins
337331|NCT01348048|palliative care
337332|NCT01348048|end-of-life care
337333|NCT01348048|randomized clinical trial
337334|NCT01348048|quality of life
337335|NCT01348048|needs assessment
337336|NCT01348048|patient satisfaction
337337|NCT01348048|cost-effectiveness
337338|NCT01348048|Screening
337339|NCT01348035|Autosomal Dominant Polycystic Kidney Disease.
337340|NCT01348035|Arginine vasopressin
337341|NCT01348035|Total Kidney Volume
337342|NCT01348035|Glomerular Filtration Rate
337343|NCT01348009|Gastric cancer
337344|NCT01348009|First-line therapy
337345|NCT01348009|Tesetaxel
337346|NCT01348009|Taxane
337347|NCT01348009|Capecitabine
337348|NCT01348009|Oral fluoropyrimidine
337349|NCT01348009|Cisplatin
337350|NCT01348009|Platinum
337351|NCT01347996|AML
337352|NCT01347996|Leukemia
337353|NCT01347996|Acute Myeloid Leukemia
337354|NCT01347996|Minimal Residual Disease
337355|NCT01347996|Ceplene
337356|NCT01347996|Histamine
337357|NCT01347996|interleukin 2
337358|NCT01347983|RA
337359|NCT01347970|childhood cancer survivor
337360|NCT01347970|CHF
337361|NCT01347970|risk of congestive heart failure
337362|NCT01347944|MORE
337363|NCT01347944|Monitoring Revlimid
337364|NCT01347944|Myelodysplastic Syndrome
337365|NCT01347944|Transfusion-dependent anemia
337366|NCT01347944|5q deletion
337367|NCT01347944|lenalidomide
337368|NCT01347918|Fluorine MRI, small intestinal transit and motor activity
337369|NCT01347892|Talar injury
337370|NCT01347892|ankle
337371|NCT01347892|lesion
337372|NCT01347892|defect
337373|NCT01347892|cartilage repair
337374|NCT01347879|Acne vulgaris
337375|NCT01347879|PDT
337376|NCT01347866|Advanced metastatic cancer (solid tumors)
337377|NCT01347866|PI3K
337378|NCT01347866|mTOR
337379|NCT01347866|MEK
337380|NCT01347840|Obesity Gastric Bypass Roux en Y
337381|NCT01347827|Coronary artery bypass surgery
337382|NCT01347827|Oximetry
337383|NCT01347827|Brain metabolism
337384|NCT01347814|Domperidone
337385|NCT01347814|gastric emptying
337386|NCT01347814|obesity
337387|NCT01347814|diabetes mellitus
337388|NCT01347814|Domperidone/pharmacology
337389|NCT01347814|Pharmacologic Actions
337390|NCT01347814|Physiological Effects of Drugs
337391|NCT01347814|Gastrointestinal Agents
337392|NCT01347814|Humans
337393|NCT01347801|GLP-1
337394|NCT01347801|Inflammation
337395|NCT01347801|Glucose
337396|NCT01347788|Prostate cancer
337397|NCT01347788|Castration Resistant
337398|NCT01347788|Bone Metastases
337399|NCT01347775|Renal failure
337400|NCT01347775|Respiratory muscles
337401|NCT01347775|Resistance training
337402|NCT01347762|cannabis dependence
337403|NCT01347762|marijuana dependence
337404|NCT01347762|cannabis use disorders
337405|NCT01347762|cannabis withdrawal
337406|NCT01347762|nabilone
337407|NCT01347749|Meditation
337408|NCT01347749|Mindfulness
337409|NCT01347749|Compassion
337410|NCT01347749|Group Psychotherapy
337411|NCT01347749|Emotional Regulation
337412|NCT01347749|fMRI
337413|NCT01347710|Coronary Artery Disease.
337414|NCT01347710|Positron Emission Tomography Myocardial Perfusion Imaging.
337415|NCT01347710|Single Positron Emission Computed Tomography.
337416|NCT01347710|Flurpiridaz F18 Injection.
337417|NCT01347697|rectal neoplasms
337418|NCT01347697|reconstructive surgical procedure
337419|NCT01347697|bioprosthesis
337420|NCT01347697|surgical flaps
337421|NCT01347697|locomotion
337422|NCT01347697|lesser pelvis
337423|NCT01347684|headache
337424|NCT01347684|elavil
337425|NCT01347684|splints
337426|NCT01347684|physical therapy
337427|NCT01347684|behavioral therapy
337428|NCT01347671|analgesia
337429|NCT01347671|analgesics
337430|NCT01347671|pain
337431|NCT01347671|chronic pain
337432|NCT01347671|neuropathic pain
337433|NCT01347658|etravirine
337434|NCT01347658|Echinacea purpurea
337435|NCT01347658|interaction
337436|NCT01347645|locally advanced
337437|NCT01347645|metastatic colon
337438|NCT01347645|rectal cancer
337439|NCT01347632|Bacterial Vaginosis
337440|NCT01347632|Vaginal discharge
337441|NCT01347632|Vaginal infections
337442|NCT01347619|Comparative Effectiveness Research Summary Guide (CERSG)
337443|NCT01347619|anti-psychotic use
337444|NCT01347619|Nursing Home
337445|NCT01347619|Long-term care
337446|NCT01347619|Qualitative assessment of influences on CERSG adoption in NH
337447|NCT01347619|Development of toolkit of CERSG-based products for NHs
337448|NCT01347619|Evaluation of 3 implementation strategies of the toolkit
337449|NCT01347606|thyroid
337450|NCT01347606|secure
337451|NCT01347606|surgery
337452|NCT01347606|methylene
337453|NCT01347606|blue
337454|NCT01347593|ceftizoxime
337455|NCT01347593|Cesarean
337456|NCT01347593|post caesarean febrile morbidity
337457|NCT01347580|Heart attack
337458|NCT01347580|heart disease
337459|NCT01347580|cardiovascular disease
337460|NCT01347580|stroke
337461|NCT01347580|reperfusion
337462|NCT01347580|pre hospital settings
337463|NCT01347580|ticagrelor
337464|NCT01347580|Percutaneous Coronary Intervention
337465|NCT01347567|Fingerstick BNP test
337466|NCT01347567|Home Health Management System
337467|NCT01347567|Acute Decompensated Heart Failure
337468|NCT01347567|Hospital Readmission
337469|NCT01347567|Prevention
337470|NCT01347554|drug-eluting stent
337471|NCT01347554|everolimus
337472|NCT01347554|zotarolimus
337473|NCT01347554|myocardial ischemia
337474|NCT01347554|cardiovascular diseases
337475|NCT01347554|MACE
337476|NCT01347554|safety
337477|NCT01347541|PTSD
337478|NCT01347528|Medication adherence
337479|NCT01347528|Heart failure
337480|NCT01347528|Telemonitoring
337481|NCT01347528|Determinants of adherence
337482|NCT01347515|Phenol-enriched olive oil
337483|NCT01347515|bioavailability
337484|NCT01347515|bioactivity
337485|NCT01347489|gender
337486|NCT01347476|prostate-specific antigen
337487|NCT01347476|radical prostatectomy
337488|NCT01347450|Flavonoids
337489|NCT01347450|cacao
337490|NCT01347450|lipid peroxidation
337491|NCT01347450|plasma
337492|NCT01347437|HIV
337493|NCT01347437|antiretroviral medication
337494|NCT01347437|adherence
337495|NCT01347437|adolescent
337496|NCT01347424|NSCLC
337497|NCT01347424|NPC
337498|NCT01347398|Sleep apnoea
337499|NCT01347398|Diagnosis
337500|NCT01347398|Blood pressure
337501|NCT01347398|Body mass index
337502|NCT01347398|Breath analysis
337503|NCT01347385|Fibroids
337504|NCT01347385|Laparoscopic myomectomy
337505|NCT01347385|Barbed suture
337506|NCT01347372|peer support
337507|NCT01347372|peer mentoring
337508|NCT01347372|peer counselling
337509|NCT01347372|arthritis
337510|NCT01347372|chronic disease
337511|NCT01347372|inflammatory arthritis
337512|NCT01347372|early inflammatory arthritis
337513|NCT01347372|rheumatoid arthritis
337514|NCT01347359|Peer support
337515|NCT01347359|Peer mentoring
337516|NCT01347359|Peer counselling
337517|NCT01347359|Arthritis
337518|NCT01347359|Inflammatory arthritis
337519|NCT01347359|Early inflammatory arthritis
337520|NCT01347359|Rheumatoid arthritis
337521|NCT01347359|Chronic disease
337522|NCT01347346|Wiskott-Aldrich Syndrome
337523|NCT01347346|Primary immune deficiency
337524|NCT01347346|ex vivo gene therapy
337525|NCT01347346|hematopoietic stem cells
337526|NCT01347333|liver metastases
337527|NCT01347333|stereotactic radiosurgery
337528|NCT01347320|Prostate cancer
337529|NCT01347320|preoperative staging
337530|NCT01347320|MRI
337531|NCT01347320|Free surgical margins
337532|NCT01347307|stereotactic radiotherapy
337533|NCT01347307|spinal metastases
337534|NCT01347307|vertebral metastases
337535|NCT01347307|benign spinal tumors
337536|NCT01347281|Cancer of the Head and Neck
337537|NCT01347281|[18F]HX4
337538|NCT01347281|hypoxia
337539|NCT01347281|PET
337540|NCT01347281|phase II trial
337541|NCT01347268|coasting
337542|NCT01347268|withdrawing GnRH agonist
337543|NCT01347268|GnRH antagonist
337544|NCT01347268|IVF
337545|NCT01347242|Wiskott-Aldrich Syndrome
337546|NCT01347242|Primary immune deficiency
337547|NCT01347242|ex vivo gene therapy
337548|NCT01347242|hematopoietic stem cells
337549|NCT01347229|Glaucoma
337550|NCT01347229|Triggerfish
337551|NCT01347229|body position
337552|NCT01347216|Drug treatment
337553|NCT01347216|Treatment pathways
337554|NCT01347216|Clinical routine
337555|NCT01347216|Registry
337556|NCT01347216|Treatment outcomes
337557|NCT01347216|Endothelin receptor antagonist
337558|NCT01347216|Phosphodiesterase-V inhibitor
337559|NCT01347216|Prostanoid
337560|NCT01347216|Sildenafil
337561|NCT01347216|Bosentan
337562|NCT01347216|Macitentan
337563|NCT01347216|Sitaxentan
337564|NCT01347216|Ambrisentan
337565|NCT01347216|Imatinib
337566|NCT01347216|Epoprostenol
337567|NCT01347216|Treprostinil
337568|NCT01347216|Iloprost
337569|NCT01347216|Infusion pump
337570|NCT01347216|Riociguat
337571|NCT01347216|soluble guanylate cyclase stimulator
337572|NCT01347216|Quality of life
337573|NCT01347216|Patient-related outcomes
337574|NCT01347216|Economic model
337575|NCT01347216|Adverse event
337576|NCT01347216|Safety
337577|NCT01347216|Combination therapy
337578|NCT01347216|Internet
337579|NCT01347216|Europe
337580|NCT01347216|Australia
337581|NCT01347216|Japan
337582|NCT01347216|Eisenmenger
337583|NCT01347216|Adults
337584|NCT01347216|Children
337585|NCT01347216|Selexipag
337586|NCT01347203|phase I
337587|NCT01347203|healthy volunteers
337588|NCT01347203|crossover study
337589|NCT01347203|pharmacokinetics
337590|NCT01347203|pharmacodynamics
337591|NCT01347190|Cystic Fibrosis
337592|NCT01347164|bisexual
337593|NCT01347164|HIV prevention
337594|NCT01347151|Glide scope
337595|NCT01347151|Pentax
337596|NCT01347151|C spine movement
337597|NCT01347138|Screening
337598|NCT01347138|depression
337599|NCT01347138|case management
337600|NCT01347125|DHF (diastolic heart failure)
337601|NCT01347125|HFNEF (heart failure with normal ejection fraction
337602|NCT01347112|smoking
337603|NCT01347112|tobacco dependence
337604|NCT01347112|alcohol dependence
337605|NCT01347099|CBT
337606|NCT01347099|OCD
337607|NCT01347099|Internet
337608|NCT01347099|Reduce symptom burden
337609|NCT01347073|Urea Cycle Disorder
337610|NCT01347073|UCD
337611|NCT01347073|GT4P
337612|NCT01347073|Buphenyl
337613|NCT01347073|hyperammonemia
337614|NCT01347073|sodium phenylbutyrate
337615|NCT01347060|Asthma
337616|NCT01347060|treatment
337617|NCT01347060|Advair and inhaled corticosteroids
337618|NCT01347060|Medicare
337619|NCT01347060|Outcomes
337620|NCT01347060|costs
337621|NCT01347047|Amyloidosis
337622|NCT01347047|Known or Suspected
337623|NCT01347034|radiation
337624|NCT01347034|neoadjuvant
337625|NCT01347034|intratumoral
337626|NCT01347034|autologous
337627|NCT01347034|dendritic cells
337628|NCT01347021|vaginal colpopexy sacrospinous
337629|NCT01347021|vaginal colpopexy uterosacral
337630|NCT01347008|Sildenafil
337631|NCT01347008|Endothelial Progenitor Cells
337632|NCT01347008|Laser Doppler Imaging
337633|NCT01346982|Darunavir
337634|NCT01346982|Silimarine
337635|NCT01346982|interaction
337636|NCT01346969|Skin scarring
337637|NCT01346969|cicatrix
337638|NCT01346969|breast scar
337639|NCT01346956|Cigarette
337640|NCT01346956|Smoking
337641|NCT01346956|Cardiovascular Effects
337642|NCT01346956|2D Echocardiography
337643|NCT01346956|Doppler
337644|NCT01346943|Abdominal Aortic Aneurysms, AAA
337645|NCT01346930|Idiopathic pulmonary fibrosis
337646|NCT01346930|IPF
337647|NCT01346930|pulmonary fibrosis
337648|NCT01346917|Colorectal cancer
337649|NCT01346917|Laparoscopic surgery
337650|NCT01346917|Postoperative ileus
337651|NCT01346917|Lidocaine
337652|NCT01346917|Early oral feeding
337653|NCT01346878|Ultra deep sequencing
337654|NCT01346878|Virological failure
337655|NCT01346878|Salvage antiretroviral therapy
337656|NCT01346865|triple anti-platelet therapy
337657|NCT01346865|dual antiplatelet therapy
337658|NCT01346865|DES
337659|NCT01346865|Coronary Artery Disease
337660|NCT01346852|pediatrics
337661|NCT01346852|Medicaid
337662|NCT01346852|asthma
337663|NCT01346852|outcomes
337664|NCT01346852|asthma medication ratio
337665|NCT01346839|Diagnostic delay
337666|NCT01346839|Prevention
337667|NCT01346839|Diagnostic errors
337668|NCT01346826|Crohn's disease
337669|NCT01346826|Ulcerative colitis
337670|NCT01346826|Infliximab
337671|NCT01346826|Infusion reaction
337672|NCT01346813|Newborns
337673|NCT01346813|Premature
337674|NCT01346813|Pain
337675|NCT01346813|Pain assessment
337676|NCT01346813|Painful Procedures
337677|NCT01346813|Stressful Procedures
337678|NCT01346813|Endotracheal Intubation
337679|NCT01346813|Analgesia
337680|NCT01346813|Sedation
337681|NCT01346813|Longterm effects of pain
337682|NCT01346813|Epidemiology
337683|NCT01346787|carfilzomib
337684|NCT01346787|dexamethasone
337685|NCT01346787|cyclophosphamide
337686|NCT01346787|multiple myeloma
337687|NCT01346787|newly diagnosed
337688|NCT01346774|cystitis
337689|NCT01346774|pyelonephritis
337690|NCT01346774|bladder infection
337691|NCT01346774|kidney infection
337692|NCT01346761|Genetic Counseling
337693|NCT01346761|Genetic Counseling Interventions
337694|NCT01346761|Genetic Testing
337695|NCT01346761|BRCA1 gene
337696|NCT01346761|BRCA2 gene
337697|NCT01346761|Risk Communication
337698|NCT01346748|vasospasm prevention
337699|NCT01346735|Ventilator associated pneumonia
337700|NCT01346735|Catheter related blood stream infection
337701|NCT01346735|Catheter associated urinary tract infection
337702|NCT01346735|ICU-related infections (VAP, CAUTI and CRBSI)
337703|NCT01346735|India
337704|NCT01346709|Operative surgical procedures
337705|NCT01346709|Postoperative pulmonary complications (PPC)
337706|NCT01346709|Epidemiological Study
337707|NCT01346709|ARISCAT score
337708|NCT01346709|Risk Score
337709|NCT01346709|Europe
337710|NCT01346709|PERISCOPE
337711|NCT01346709|observational study
337712|NCT01346709|Mild respiratory failure
337713|NCT01346709|Severe respiratory failure
337714|NCT01346709|acute lung injury (ALI)
337715|NCT01346709|Acute respiratory distress syndrome (ARDS)
337716|NCT01346709|Suspected pulmonary infection
337717|NCT01346709|Pulmonary infiltrate
337718|NCT01346709|Pleural effusion
337719|NCT01346709|Atelectasis
337720|NCT01346709|Pneumothorax
337721|NCT01346709|Bronchospasm
337722|NCT01346709|Aspiration Pneumonitis
337723|NCT01346709|Cardiopulmonary edema
337724|NCT01346709|Prospective Evaluation
337725|NCT01346709|nonobstetric in-hospital surgical procedure
337726|NCT01346709|general or regional anaesthesia
337727|NCT01346709|continued 7-day period recruitment
337728|NCT01346670|Red yeast rice
337729|NCT01346670|Lovastatin
337730|NCT01346670|Bioavailability
337731|NCT01346657|Nifidipine
337732|NCT01346657|red yeast rice
337733|NCT01346657|drug-drug interaction
337734|NCT01346644|Probiotic
337735|NCT01346644|infant nutrition
337736|NCT01346644|safety
337737|NCT01346644|infections
337738|NCT01346618|bone age
337739|NCT01346618|children
337740|NCT01346618|x-ray
337741|NCT01346618|ultrasound
337742|NCT01346618|ultrasound based method
337743|NCT01346618|safe
337744|NCT01346618|valid
337745|NCT01346618|reproducable
337746|NCT01346605|Cardiac CT, heart disease
337747|NCT01346592|Adjuvanted Trivalent Subunit Influenza Vaccine
337748|NCT01346592|vaccine
337749|NCT01346592|influenza
337750|NCT01346592|adjuvant
337751|NCT01346592|MF-59
337752|NCT01346592|pediatric
337753|NCT01346579|stage IA breast cancer
337754|NCT01346579|stage IB breast cancer
337755|NCT01346579|estrogen receptor-positive breast cancer
337756|NCT01346566|Cionni Ring
337757|NCT01346566|In-the-bag IOL
337758|NCT01346566|Subluxated lenses
337759|NCT01346566|Intraoperative Performance
337760|NCT01346566|Postoperative Outcome
337761|NCT01346553|Chronic Venous Insufficiency (CVI)
337762|NCT01346527|diabetes
337763|NCT01346527|pregnancy
337764|NCT01346527|left ventricular dysfunction
337765|NCT01346527|neonatal
337766|NCT01346527|lipid
337767|NCT01346527|lipotoxicity
337768|NCT01346527|neurodevelopment
337769|NCT01346514|Homeless Persons
337770|NCT01346514|Housing
337771|NCT01346514|Case Management
337772|NCT01346514|Veterans
337773|NCT01346514|Substance Related Disorders
337774|NCT01346514|Mental Disorders
337775|NCT01346514|Social Adjustment
337776|NCT01346501|Rheumatoid arthritis
337777|NCT01346488|Rheumatoid arthritis
337778|NCT01346449|Obesity
337779|NCT01346423|Sick leave
337780|NCT01346423|musculoskeletal pain
337781|NCT01346423|return to work
337782|NCT01346423|multidisciplinary intervention
337783|NCT01346423|randomised controlled trial
337784|NCT01346410|pancreatic cancer
337785|NCT01346397|rejection
337786|NCT01346397|survival
337787|NCT01346397|alemtuzumab
337788|NCT01346397|cyclosporine
337789|NCT01346397|tacrolimus
337790|NCT01346384|intracuff pressure
337791|NCT01346384|laryngeal tube
337792|NCT01346384|nitrous oxide
337793|NCT01346371|Allergic
337794|NCT01346371|conjunctivitis
337795|NCT01346371|Allergic conjunctivitis
337796|NCT01346358|Advanced Solid Tumors
337797|NCT01346345|Recession
337798|NCT01346319|dose escalating
337799|NCT01346293|Tetanus
337800|NCT01346293|Diphtheria
337801|NCT01346293|Pertussis
337802|NCT01346293|DTap-IPV
337803|NCT01346293|DAPTACEL®
337804|NCT01346293|VARIVAX®
337805|NCT01346280|Adherence to Evidence-Based Guidelines
337806|NCT01346280|Multidisciplinary Care
337807|NCT01346280|Patient Experiences
337808|NCT01346280|Quality of Care Outcomes
337809|NCT01346267|nausea and vomiting
337810|NCT01346267|unspecified childhood solid tumor
337811|NCT01346267|childhood central nervous system embryonal tumor
337812|NCT01346267|childhood central nervous system germ cell tumor
337813|NCT01346267|childhood central nervous system germinoma
337814|NCT01346267|childhood central nervous system mixed germ cell tumor
337815|NCT01346267|childhood central nervous system teratoma
337816|NCT01346267|childhood central nervous system yolk sac tumor
337817|NCT01346267|childhood mixed glioma
337818|NCT01346267|childhood oligodendroglioma
337819|NCT01346267|untreated childhood brain stem glioma
337820|NCT01346267|untreated childhood visual pathway and hypothalamic glioma
337821|NCT01346267|untreated childhood visual pathway glioma
337822|NCT01346267|childhood high-grade cerebellar astrocytoma
337823|NCT01346267|childhood high-grade cerebral astrocytoma
337824|NCT01346267|childhood low-grade cerebellar astrocytoma
337825|NCT01346267|childhood low-grade cerebral astrocytoma
337826|NCT01346267|untreated childhood cerebellar astrocytoma
337827|NCT01346267|untreated childhood cerebral astrocytoma
337828|NCT01346267|untreated childhood subependymal giant cell astrocytoma
337829|NCT01346267|childhood ependymoblastoma
337830|NCT01346267|untreated childhood medulloblastoma
337831|NCT01346267|untreated childhood pineoblastoma
337832|NCT01346267|childhood choroid plexus tumor
337833|NCT01346267|childhood craniopharyngioma
337834|NCT01346267|childhood supratentorial ependymoma
337835|NCT01346267|childhood supratentorial primitive neuroectodermal tumor
337836|NCT01346267|childhood medulloepithelioma
337837|NCT01346267|childhood infratentorial ependymoma
337838|NCT01346267|newly diagnosed childhood ependymoma
337839|NCT01346267|childhood meningioma
337840|NCT01346254|after
337841|NCT01346241|Panic
337842|NCT01346241|Anxiety
337843|NCT01346228|Panic
337844|NCT01346228|Panic Disorder
337845|NCT01346228|Anxiety
337846|NCT01346215|heparin
337847|NCT01346215|renal insufficiency, chronic
337848|NCT01346215|extracorporeal dialysis
337849|NCT01346215|fibrinolytic agents
337850|NCT01346215|anticoagulants
337851|NCT01346215|aPTT
337852|NCT01346202|multi-modal pain therapy, chronic pain
337853|NCT01346189|Cardiovascular Disease
337854|NCT01346163|Schizophrenia
337855|NCT01346163|Cognitive Impairment
337856|NCT01346163|Electrophysiology
337857|NCT01346163|H3 receptor antagonist
337858|NCT01346137|ovulation
337859|NCT01346137|unruptured luteinized follicle
337860|NCT01346137|meloxicam
337861|NCT01346124|radiation
337862|NCT01346124|IMRT
337863|NCT01346124|IMPT
337864|NCT01346098|diabetes
337865|NCT01346098|islet transplantation
337866|NCT01346098|pancreas
337867|NCT01346098|pancreatectomy
337868|NCT01346085|islet transplantation
337869|NCT01346085|brittle diabetes
337870|NCT01346085|type 1 diabetes
337871|NCT01346072|tolvaptan
337872|NCT01346072|copeptin
337873|NCT01346072|heart failure
337874|NCT01346072|vasopressin antagonist
337875|NCT01346059|Clostridium
337876|NCT01346059|Colitis
337877|NCT01346059|Intracolonic vancomycin
337878|NCT01346059|psuedomembranous colitis
337879|NCT01346046|Type 2 Diabetes
337880|NCT01346046|Adults 18 years and older
337881|NCT01346046|Taking Control of Your Diabetes Health Fair
337882|NCT01346033|Type 2 Diabetes
337883|NCT01346033|Adults 18 years and older
337884|NCT01346033|Taking Control of Your Diabetes Health Fair
337885|NCT01345968|anemia
337886|NCT01345968|transfusion
337887|NCT01345968|intravenous ferric carboxymaltose
337888|NCT01345929|cUTI
337889|NCT01345890|swallowing
337890|NCT01345890|stroke
337891|NCT01345890|aspiration
337892|NCT01345890|human
337893|NCT01345890|electrical stimulation
337894|NCT01345890|post stroke dysphagia
337895|NCT01345877|burn injury
337896|NCT01345877|cold pressor test
337897|NCT01345877|gender
337898|NCT01345877|pain
337899|NCT01345877|pain sensitivity
337900|NCT01345877|pain prediction
337901|NCT01345877|psychometrics
337902|NCT01345877|quantitative sensory testing
337903|NCT01345864|attention cognition memory problem solving scopolamine challenge
337904|NCT01345825|osteoarthrosis
337905|NCT01345825|unicompartmental knee replacement
337906|NCT01345825|knee
337907|NCT01345825|resistance training
337908|NCT01345825|Muscle power
337909|NCT01345825|gait analysis
337910|NCT01345825|gait
337911|NCT01345825|physiotherapy
337912|NCT01345825|Gyro sensor
337913|NCT01345812|ART
337914|NCT01345812|IVF
337915|NCT01345812|Timelapse
337916|NCT01345799|Crohn's Disease Activity Index
337917|NCT01345799|Crohn's Disease
337918|NCT01345799|Inflammatory Bowel Disease
337919|NCT01345760|Basal Cell Carcinoma
337920|NCT01345760|Squamous Cell Carcinoma
337921|NCT01345760|Actinic Keratosis
337922|NCT01345760|microRNA
337923|NCT01345760|Dicer
337924|NCT01345760|Drosha
337925|NCT01345760|RISC
337926|NCT01345760|microprocessor complex
337927|NCT01345760|Argonaute
337928|NCT01345760|DGCR8
337929|NCT01345760|TARBP
337930|NCT01345747|laryngeal tube suction
337931|NCT01345747|gynecology
337932|NCT01345747|laparoscopic surgery
337933|NCT01345721|Meningococcal
337934|NCT01345721|ACWY
337935|NCT01345721|Conjugate Vaccine
337936|NCT01345721|Meningitis
337937|NCT01345721|Toddlers
337938|NCT01345721|Children
337939|NCT01345721|Persistence
337940|NCT01345721|Boost
337941|NCT01345708|Low dose rituximab
337942|NCT01345708|WAIHA
337943|NCT01345708|CHD
337944|NCT01345695|Childhood diarrhea
337945|NCT01345695|childhood pneumonia
337946|NCT01345695|telemedicine
337947|NCT01345695|cluster
337948|NCT01345695|treatment-control trial
337949|NCT01345656|Chronic Heart Failure
337950|NCT01345643|Transfusion
337951|NCT01345643|Hemoglobin level
337952|NCT01345630|Double-blind
337953|NCT01345630|comparative
337954|NCT01345630|trial
337955|NCT01345630|maraviroc
337956|NCT01345630|versus
337957|NCT01345630|emtricitabine/tenofovir
337958|NCT01345630|both with darunavir/ritonavir
337959|NCT01345630|antiretroviral-naive
337960|NCT01345630|Ccr5 tropic
337961|NCT01345630|Hiv 1
337962|NCT01345630|patients.
337963|NCT01345591|BTI
337964|NCT01345591|Craniomaxillofacial (CMF) Battle-injured (BI)
337965|NCT01345591|Facial Trauma
337966|NCT01345591|Fat Grafts
337967|NCT01345591|Autogenous Fat Transfers (AFT)
337968|NCT01345591|Wounded warriors
337969|NCT01345578|Urea Cycle Disorders
337970|NCT01345578|Carbamoyl-Phosphate Synthase I Deficiency Disease
337971|NCT01345578|Citrullinemia
337972|NCT01345578|Ornithine Carbamoyltransferase Deficiency Disease
337973|NCT01345578|Crigler-Najjar Syndrome
337974|NCT01345565|fulminant hepatic failure
337975|NCT01345552|Oligo mets
337976|NCT01345552|Oligometastatic disease
337977|NCT01345539|Oligo mets
337978|NCT01345539|Oligometastatic disease
337979|NCT01345513|Genomic Analysis
337980|NCT01345513|Sequencing
337981|NCT01345513|Genetic
337982|NCT01345513|Biopsy
337983|NCT01345513|Solid tumors
337984|NCT01345500|Overweight
337985|NCT01345500|Obese
337986|NCT01345500|Type 2 Diabetic
337987|NCT01345500|Diabetes
337988|NCT01345500|Weight loss
337989|NCT01345500|Physical activity
337990|NCT01345500|Diet
337991|NCT01345500|Prepackaged meals
337992|NCT01345487|appetite
337993|NCT01345487|protein
337994|NCT01345487|legumes
337995|NCT01345487|meat
337996|NCT01345474|noise-induced hearing loss
337997|NCT01345474|hearing loss
337998|NCT01345474|tinnitus
337999|NCT01345474|weapons training
338000|NCT01345474|hearing protection
338001|NCT01345474|impulse noise
338002|NCT01345448|Glaucoma
338003|NCT01345448|Brimonidine
338004|NCT01345448|Transdermal
338005|NCT01345435|telemonitoring
338006|NCT01345435|usual care
338007|NCT01345435|telemedicine
338008|NCT01345435|telehealth
338009|NCT01345435|home care
338010|NCT01345435|Health Care Quality
338011|NCT01345435|Access
338012|NCT01345435|Evaluation
338013|NCT01345409|Musculoskeletal pain
338014|NCT01345409|Chronic pain
338015|NCT01345409|Acupuncture
338016|NCT01345409|Chiropractic
338017|NCT01345396|Asthma
338018|NCT01345396|Health education
338019|NCT01345396|Pregnancy
338020|NCT01345383|smoking
338021|NCT01345383|bronchoscopy
338022|NCT01345383|cough
338023|NCT01345370|Glioblastoma
338024|NCT01345357|Solid tumors
338025|NCT01345357|mantle cell lymphoma
338026|NCT01345357|Gemcitabine
338027|NCT01345357|Cisplatin
338028|NCT01345357|Cancer
338029|NCT01345357|Neoplasms
338030|NCT01345357|Antineoplastic agents
338031|NCT01345318|Crohn's Disease
338032|NCT01345318|safety
338033|NCT01345318|efficacy
338034|NCT01345318|pharmacokinetics
338035|NCT01345318|pharmacodynamics
338036|NCT01345318|Crohn's Disease Activity Index (CDAI)
338037|NCT01345305|Sturge-Weber Syndrome
338038|NCT01345305|Biomarkers
338039|NCT01345305|Quantitative EEG
338040|NCT01345305|Transcranial Doppler Ultrasound
338041|NCT01345305|Medical Rehabilitation Scales
338042|NCT01345305|Optical Coherence Tomography
338043|NCT01345266|Pharyngometry
338044|NCT01345266|Novel Dry Powder Inhaler
338045|NCT01345266|HRCT
338046|NCT01345266|Inhalation Profiles
338047|NCT01345253|SLEDAI
338048|NCT01345253|Asia
338049|NCT01345253|placebo
338050|NCT01345253|BLys
338051|NCT01345253|PGA
338052|NCT01345253|BILAG
338053|NCT01345253|systemic lupus erythematosus
338054|NCT01345253|SELENA
338055|NCT01345253|Lupus
338056|NCT01345253|SRI
338057|NCT01345253|efficacy
338058|NCT01345253|B cell
338059|NCT01345253|SLE Flare Index
338060|NCT01345253|belimumab
338061|NCT01345253|safety
338062|NCT01345253|phase III
338063|NCT01345253|B lymphocyte
338064|NCT01345240|Africa
338065|NCT01345240|Plasmodium falciparum
338066|NCT01345240|Malaria vaccine
338067|NCT01345240|hepatitis B
338068|NCT01345240|EPI
338069|NCT01345227|Type 1 diabetes
338070|NCT01345227|islet transplantation
338071|NCT01345227|autotransplantation
338072|NCT01345214|ONO-7746
338073|NCT01345214|Chemotherapy Induced Thrombocytopenia
338074|NCT01345214|Thrombocytopenia
338075|NCT01345201|Phase 1
338076|NCT01345201|dose escalation
338077|NCT01345201|histologically confirmed
338078|NCT01345201|malignancy metastatic
338079|NCT01345175|rectal
338080|NCT01345175|colon
338081|NCT01345175|PLACEBO
338082|NCT01345175|RIFAXIMIN
338083|NCT01345175|metronidazole
338084|NCT01345175|11-045
338085|NCT01345162|Herniotomy
338086|NCT01345149|Obesity
338087|NCT01345149|Pregnancy
338088|NCT01345149|Intervention
338089|NCT01345149|Diet
338090|NCT01345149|Physical activity
338091|NCT01345136|Neurofibromatosis Type 2
338092|NCT01345136|Vestibular schwannoma
338093|NCT01345136|Hearing
338094|NCT01345110|dementia
338095|NCT01345110|mild cognitive impairment
338096|NCT01345110|prevalence
338097|NCT01345110|incidence
338098|NCT01345110|elderly
338099|NCT01345110|longitudinal study
338100|NCT01345110|population study
338101|NCT01345097|short, metaphyseal-fitting femoral stem
338102|NCT01345097|cementless anatomical femoral stem
338103|NCT01345097|young patient
338104|NCT01345097|elderly patient
338105|NCT01345071|Rheumatoid Arthritis
338106|NCT01345071|Pregnancy
338107|NCT01345071|Anti-TNF
338108|NCT01345071|Preconceptional counselling
338109|NCT01345071|Disease activity
338110|NCT01345058|Epilepsy
338111|NCT01345058|antiepileptic drug
338112|NCT01345058|polytherapy
338113|NCT01345045|Diabetic Asymmetric Polyneuropathy
338114|NCT01345045|Symmetric Diabetic Proximal Motor Neuropathy
338115|NCT01345045|Diabetic Mononeuropathy Simplex,
338116|NCT01345045|Diabetic Autonomic Neuropathy,
338117|NCT01345045|Diabetic Amyotrophy
338118|NCT01345045|Mononeuropathy
338119|NCT01345045|Diabetic Neuropathy
338120|NCT01345045|Asymmetric Diabetic Proximal Motor Neuropathy
338121|NCT01345045|Diabetic Polyneuropathy
338122|NCT01345045|Painful
338123|NCT01345045|Diabetic Mononeuropathy
338124|NCT01345045|Neuralgia
338125|NCT01345019|zoledronic acid
338126|NCT01345019|hematologic malignancies
338127|NCT01345019|SRE
338128|NCT01345019|skeletal-related event
338129|NCT01345019|blood cancer
338130|NCT01345019|lytic bone lesions
338131|NCT01345019|bone metastases
338132|NCT01345019|myeloma
338133|NCT01345019|fractures
338134|NCT01345019|spinal cord compression
338135|NCT01345019|radiation to bone
338136|NCT01345019|surgery to bone
338137|NCT01345019|bisphosphonates
338138|NCT01345019|Neoplasms, Plasma Cell
338139|NCT01345019|Paraproteinemias
338140|NCT01345019|Neoplasms
338141|NCT01345019|Neoplasm Metastasis
338142|NCT01345019|Bone Neoplasms
338143|NCT01345019|Bone Marrow Diseases
338144|NCT01345019|Blood Protein Disorders
338145|NCT01345019|Hematologic Diseases
338146|NCT01345019|multiple myeloma
338147|NCT01345019|denosumab
338148|NCT01345019|Neoplastic Processes
338149|NCT01345019|Bone Diseases
338150|NCT01345019|Diphosphonates
338151|NCT01345019|Bone Density Conservation Agents
338152|NCT01345006|juvenile macular dystrophy
338153|NCT01345006|SMD
338154|NCT01345006|fundus flavimaculatus
338155|NCT01344993|Dry AMD
338156|NCT01344993|Geographic atrophy
338157|NCT01344941|Vaccine response
338158|NCT01344941|Human Lymphocytes
338159|NCT01344915|Patella
338160|NCT01344915|Knee
338161|NCT01344915|Brace
338162|NCT01344876|multiple myeloma [MM]
338163|NCT01344876|non-Hodgkin lymphoma [NHL]
338164|NCT01344876|acute myeloid leukemia [AML]
338165|NCT01344876|acute lymphoid leukemia [ALL]
338166|NCT01344876|chronic myeloid leukemia [CML]
338167|NCT01344824|recurrent non-small cell lung cancer
338168|NCT01344824|stage IIIB non-small cell lung cancer
338169|NCT01344824|stage IV non-small cell lung cancer
338170|NCT01344824|adenocarcinoma of the lung
338171|NCT01344824|bronchoalveolar cell lung cancer
338172|NCT01344824|large cell lung cancer
338173|NCT01344811|telemonitoring
338174|NCT01344811|usual care
338175|NCT01344811|telehealth
338176|NCT01344811|home care
338177|NCT01344811|Health Care Quality
338178|NCT01344811|Access
338179|NCT01344811|Evaluation
338180|NCT01344798|limb girdle muscular dystrophy type 2C
338181|NCT01344798|gamma-sarcoglycanopathy
338182|NCT01344798|gene therapy
338183|NCT01344798|AAV vector
338184|NCT01344798|neuromuscular disease
338185|NCT01344798|orphan disease
338186|NCT01344785|Intertrochanteric Fractures
338187|NCT01344785|Intramedullary nailing
338188|NCT01344785|Hip function
338189|NCT01344785|Pain
338190|NCT01344772|femoral neck fracture
338191|NCT01344772|total hip arthroplasty
338192|NCT01344772|internal fixation
338193|NCT01344759|Obstructive Sleep Apnea
338194|NCT01344759|MRI
338195|NCT01344759|Pediatrics
338196|NCT01344759|Dexmedetomidine
338197|NCT01344759|Propofol
338198|NCT01344759|Anesthesia
338199|NCT01344746|sleep-disordered breathing
338200|NCT01344733|Major Depressive Disorder
338201|NCT01344733|MDD
338202|NCT01344720|Low Back Pain
338203|NCT01344720|Etoricoxib
338204|NCT01344720|Oxycodone
338205|NCT01344707|Hematologic Malignancies
338206|NCT01344707|Acute Myeloid Leukemia (AML)
338207|NCT01344707|Acute Lymphocytic Leukemia (ALL)
338208|NCT01344707|Chronic Lymphocytic Leukemia (CLL)
338209|NCT01344707|Multiple Myeloma (MM)
338210|NCT01344707|Myelodysplastic Syndrome (MDS)
338211|NCT01344707|Malignant Lymphomas
338212|NCT01344707|Histone Deacetylase (HDAC)
338213|NCT01344707|4SC-202
338214|NCT01344707|Phase I
338215|NCT01344694|Epicardial fat
338216|NCT01344694|Visceral fat
338217|NCT01344694|atherosclerosis
338218|NCT01344694|coronary computed tomography angiography
338219|NCT01344694|Carotid Doppler ultrasound
338220|NCT01344668|Diabetes
338221|NCT01344642|HIV
338222|NCT01344642|RNA
338223|NCT01344616|computer-based behavioral support
338224|NCT01343641|Kidney Disease
338225|NCT01343641|Chronic Kidney Disease
338226|NCT01343641|Growth Hormone
338227|NCT01343628|Alcohol, atomoxetine, Strattera, alcohol dependence, alcoholism
338228|NCT01343602|stroke
338229|NCT01343602|Constraint Induced Movement Therapy
338230|NCT01343602|participation
338231|NCT01343602|Physical Therapy
338232|NCT01343602|Occupational Therapy
338233|NCT01343563|Depression
338234|NCT01343563|Major Depressive Disorder (MDD)
338235|NCT01343563|EEG
338236|NCT01343563|Trigeminal Nerve Stimulation
338237|NCT01343550|Borderline Personality Disorder
338238|NCT01343550|Borderline Personality
338239|NCT01343550|Borderline
338240|NCT01343537|Brain Bleed
338241|NCT01343537|SAH
338242|NCT01343537|Vasospasm
338243|NCT01343524|cystic fibrosis
338244|NCT01343524|spirometry
338245|NCT01343524|PFT's
338246|NCT01343524|pulmonary function test
338247|NCT01343511|Autism
338248|NCT01343511|human cord blood mononuclear cells
338249|NCT01343511|human umbilical cord mesenchymal stem cells
338250|NCT01343498|Solid Tumor Malignancy
338251|NCT01343498|Advanced Solid Tumors
338252|NCT01343498|BEZ235
338253|NCT01343498|mTOR Inhibitor
338254|NCT01343485|Human papillomavirus (HPV) vaccine
338255|NCT01343485|Gardasil vaccine
338256|NCT01343472|Behavior
338257|NCT01343472|Drug users
338258|NCT01343459|Hypofractionated Whole breast irradiation
338259|NCT01343459|Hypofractionated Whole breast irradiation long term results
338260|NCT01343459|Breast conserving therapy
338261|NCT01343459|IORT with electrons in breast cancer
338262|NCT01343459|IOERT as anticipated Boost
338263|NCT01343459|IOERT and hypofractionated whole breast irradiation
338264|NCT01343446|Sleep impairment, Coping Style, Diabetes Mellitus
338265|NCT01343433|Delirium
338266|NCT01343433|Intensive Care Unit Syndrome
338267|NCT01343433|Bright light therapy
338268|NCT01343433|Intensive Care Unit
338269|NCT01343420|Skin tests
338270|NCT01343420|Dog Hair
338271|NCT01343420|Allergy Extract
338272|NCT01344603|cardiac surgery
338273|NCT01344603|cardiac anesthesia
338274|NCT01344603|epidural
338275|NCT01344590|central line associated blood stream infections
338276|NCT01344577|Buccal Plate Augmentation technique
338277|NCT01344577|socket preservation
338278|NCT01344577|porcine biomaterial
338279|NCT01344564|Prostate cancer
338280|NCT01344564|Hormone therapy
338281|NCT01344564|Testosterone measures
338282|NCT01344538|ginger
338283|NCT01344538|Zingiber officinale
338284|NCT01344538|Cancer Risk Reductive
338285|NCT01344538|Eicosanoids
338286|NCT01344538|Colorectal Cancer
338287|NCT01344538|Inflammation
338288|NCT01344525|obesity therapy
338289|NCT01344525|metabolic syndrome
338290|NCT01344525|gastrointestinal tract
338291|NCT01344525|microbiota
338292|NCT01344525|metabolomics
338293|NCT01344525|micronutrients
338294|NCT01344525|outcome
338295|NCT01344525|sustainability
338296|NCT01344512|Pharmacokinetic
338297|NCT01344512|Population
338298|NCT01344512|Children
338299|NCT01344512|Ceftazidime
338300|NCT01344512|Ciprofloxacin
338301|NCT01344512|Voriconazole
338302|NCT01344512|Pediatric
338303|NCT01344499|women
338304|NCT01344499|laparoscopic subtotal hysterectomy
338305|NCT01344486|women undergoing laparoscopic surgery
338306|NCT01344473|Remineralisation
338307|NCT01344473|White Spot Lesions
338308|NCT01344473|Orthodontic treatment
338309|NCT01344473|Tooth Mousse creme
338310|NCT01344473|Casein Phosphopeptide
338311|NCT01344460|magnetic resonance angiography (MRA) of the renal arteries
338312|NCT01344447|Supra-aortic vascular disease
338313|NCT01344447|MRA
338314|NCT01344447|CTA
338315|NCT01344447|Males and females aged 18 years or older
338316|NCT01344447|Stroke
338317|NCT01344447|Transient Ischemic Attack (TIA)
338318|NCT01344421|Movement capture system
338319|NCT01344421|Movement analysis
338320|NCT01344421|Hip dysplasia
338321|NCT01344421|Hip pain
338322|NCT01344421|Quality of life
338323|NCT01344421|Physical function
338324|NCT01344408|Dizziness
338325|NCT01344408|rehabilitation
338326|NCT01344408|geriatric
338327|NCT01344408|IT-technology
338328|NCT01344382|Adolescent
338329|NCT01344382|Parent
338330|NCT01344382|Substance Abuse
338331|NCT01344382|Parent Training
338332|NCT01344382|Community Reinforcement and Family Training
338333|NCT01344382|CRAFT
338334|NCT01344382|Community Reinforcement Approach
338335|NCT01344382|Addiction
338336|NCT01344382|Family Intervention
338337|NCT01344369|Healthy Subjects
338338|NCT01344369|Bioequivalence
338339|NCT01344356|stereotactic radiosurgery
338340|NCT01344356|head and neck tumors
338341|NCT01344356|squamous cell carcinoma of head and neck
338342|NCT01344330|Colon cancer
338343|NCT01344330|Prevention
338344|NCT01344330|Cruciferous vegetables
338345|NCT01344330|Histone status
338346|NCT01344304|aprepitant therapy
338347|NCT01344304|fosaprepitant therapy
338348|NCT01344304|5HT3-receptor antagonist
338349|NCT01344304|dexamethasone
338350|NCT01344304|colorectal cancer
338351|NCT01344304|FOLFOX
338352|NCT01344304|XELOX
338353|NCT01344304|SOX
338354|NCT01344291|hyperprolactinoma
338355|NCT01344291|turmeric
338356|NCT01344291|amenorrhea
338357|NCT01344265|B-type natriuretic peptide
338358|NCT01344265|global end diastolic volume
338359|NCT01344239|aortic aneurysm
338360|NCT01344239|ischemia/reperfusion
338361|NCT01344239|preconditioning
338362|NCT01344239|pulmonary injury
338363|NCT01344239|intestinal injury
338364|NCT01344226|steroid responder
338365|NCT01344213|Pregabalin
338366|NCT01344213|Celecoxib
338367|NCT01344213|Intrathecal morphine
338368|NCT01344213|Total knee arthroplasty
338369|NCT01344200|Pharmacokinetics
338370|NCT01344200|Celecoxib
338371|NCT01344200|Pediatric
338372|NCT01344200|Peds QL
338373|NCT01344200|CYP2C9
338374|NCT01344174|Acute-on-chronic liver failure
338375|NCT01344174|HBV
338376|NCT01344174|Dexamethasone
338377|NCT01344174|Prognosis
338378|NCT01344161|Vitamin D
338379|NCT01344161|Metabolic profile
338380|NCT01344161|Overweight
338381|NCT01344161|Obesity
338382|NCT01344148|Anti- TB
338383|NCT01344148|HAART
338384|NCT01344148|choice of the right moment
338385|NCT01344135|Pulmonary Disease, Chronic Obstructive
338386|NCT01344135|Muscular Atrophy
338387|NCT01344135|Nutritional rehabilitation
338388|NCT01344135|Counselling
338389|NCT01344096|Gaucher disease
338390|NCT01344096|Thrombocytopathy
338391|NCT01344096|Imiglucerase
338392|NCT01344070|innovator formulations
338393|NCT01344070|generic formulations
338394|NCT01344070|bioequivalence
338395|NCT01344070|interchangeability
338396|NCT01344070|inter-patch variation
338397|NCT01344070|quality of generic drug formulations on the market
338398|NCT01344070|Interchangeability between marketed generic formulations
338399|NCT01344070|prevalence of large intrasubject variability despite average bioequivalence
338400|NCT01344070|Causes of large intrasubject variability
338401|NCT01344057|Seasonal Influenza, vaccine
338402|NCT01344044|Brain-Computer Interface
338403|NCT01344018|adult angiosarcoma
338404|NCT01344018|adult fibrosarcoma
338405|NCT01344018|adult leiomyosarcoma
338406|NCT01344018|adult liposarcoma
338407|NCT01344018|adult malignant fibrous histiocytoma
338408|NCT01344018|adult malignant mesenchymoma
338409|NCT01344018|stage I adult soft tissue sarcoma
338410|NCT01344018|stage II adult soft tissue sarcoma
338411|NCT01344018|stage III adult soft tissue sarcoma
338412|NCT01344005|non-small cell lung cancer
338413|NCT01344005|small cell lung cancer
338414|NCT01344005|tobacco use disorder
338415|NCT01343992|Embryo transfer
338416|NCT01343992|Implantation rate
338417|NCT01343992|Pregnancy rate
338418|NCT01343992|bedrest
338419|NCT01343992|neutral
338420|NCT01343992|benevolent
338421|NCT01343992|deterious
338422|NCT01343992|implantation
338423|NCT01343992|gestation rates
338424|NCT01343953|severe aplastic anemia
338425|NCT01343953|cord blood transplantation
338426|NCT01343940|RCT
338427|NCT01343940|randomized block repeated measures design
338428|NCT01343940|efficacy trial
338429|NCT01343940|high risk population
338430|NCT01343927|Chronic low back pain
338431|NCT01343927|Community health center
338432|NCT01343927|Yoga
338433|NCT01343927|Physical therapy
338434|NCT01343927|Minority populations
338435|NCT01343927|Health education
338436|NCT01343862|moderate traumatic brain injury
338437|NCT01343862|brain contusion
338438|NCT01343849|breast cancer
338439|NCT01343849|auto antibodies
338440|NCT01343836|autologous tenocytes
338441|NCT01343836|cell therapy
338442|NCT01343836|eccentric exercises
338443|NCT01343810|Mindfulness-Based Stress Reduction
338444|NCT01343810|Meditation
338445|NCT01343810|Psychological stress
338446|NCT01343810|Sleep quality
338447|NCT01343810|Cardiovascular disease
338448|NCT01343810|Inflammation
338449|NCT01343797|Glycemic index
338450|NCT01343797|Insulinemic index
338451|NCT01343797|Fructo-oligosaccharide syrup
338452|NCT01343797|Fructose syrup
338453|NCT01343797|Aged between eighteen and fifty years old
338454|NCT01343797|BMI between nineteen and twenty five kg/m²
338455|NCT01343797|Non diabetic or pre-diabetic
338456|NCT01343797|Without liver, renal or gastro-intestinal disorder
338457|NCT01343797|Non-smoker
338458|NCT01343784|Voiding trial
338459|NCT01343784|sling
338460|NCT01343784|post-operative assessment
338461|NCT01343784|urinary retention
338462|NCT01343771|Anorexia Nervosa (AN)
338463|NCT01343771|bone density
338464|NCT01343771|DHEA
338465|NCT01343771|estrogen therapy
338466|NCT01343771|eating disorder
338467|NCT01343693|DDD
338468|NCT01343693|Deformity
338469|NCT01343693|Tumor
338470|NCT01343693|Fracture
338471|NCT01343693|Cervical
338472|NCT01343667|GORE Neuro Protection System
338473|NCT01343667|GORE Flow Reversal System
338474|NCT01343667|carotid artery stenosis
338475|NCT01343667|embolic protection device
338476|NCT01343667|reverse flow
338477|NCT01343667|proximal occlusion device
338478|NCT01343667|GNPS
338479|NCT01343667|Parodi
338480|NCT01343667|EMPiRE
338481|NCT01343667|distal embolization
338482|NCT01343667|minimizing risks of CAS
338483|NCT01343667|PAES
338484|NCT01343667|embolic filter
338485|NCT01343654|HIV medication adherence
338486|NCT01343654|drug use
338487|NCT01343654|rural
338488|NCT01343654|nonadherence to HIV medications
338489|NCT01343394|Autologous
338490|NCT01343394|Stem Cells
338491|NCT01343394|Hearing Loss
338492|NCT01343394|Children
338493|NCT01343381|Heparin
338494|NCT01343381|Coronary artery bypass graft surgery
338495|NCT01343381|Anti-coagulation efficacy
338496|NCT01343368|Post-menarchal
338497|NCT01343355|Tropical Spastic Paraparesis
338498|NCT01343355|HAM
338499|NCT01343355|TSP
338500|NCT01343342|omega-3
338501|NCT01343342|PUFA
338502|NCT01343342|fatty acids
338503|NCT01343342|cardiovascular disease
338504|NCT01343342|gene expression
338505|NCT01343329|Traumatic Brain Injury
338506|NCT01343329|Dysautonomia
338507|NCT01343329|Brain Injury
338508|NCT01343329|Sympathetic hyperactivity
338509|NCT01343316|Enteral Feeds
338510|NCT01343316|Supplemental Feeds
338511|NCT01343316|Transpyloric Tube
338512|NCT01343316|Nasogastric Tube
338513|NCT01343303|Osteoarthritis, knee
338514|NCT01343303|knee pain
338515|NCT01343303|pain measurement
338516|NCT01343290|Canagliflozin (JNJ-28431754)
338517|NCT01343290|Pharmacokinetic
338518|NCT01343290|Oral Bioavailability
338519|NCT01343290|Food effect
338520|NCT01343277|Advanced Liposarcoma or Leiomyosarcoma
338521|NCT01343277|Trabectedin
338522|NCT01343277|Yondelis
338523|NCT01343277|Dacarbazine
338524|NCT01343277|Anthracycline
338525|NCT01343277|L-sarcoma
338526|NCT01343264|Radical Pleurectomy
338527|NCT01343264|Pleurectomy/decortication
338528|NCT01343264|Cisplatin
338529|NCT01343264|Pemetrexed
338530|NCT01343264|Radiation
338531|NCT01343251|dialysis
338532|NCT01343251|HeRO graft
338533|NCT01343251|catheter
338534|NCT01343251|chronic renal failure
338535|NCT01343251|end stage renal disease
338536|NCT01343251|renal insufficiency
338537|NCT01343238|obesity
338538|NCT01343238|diet
338539|NCT01343238|exercise
338540|NCT01343225|African american vitamin d bone density
338541|NCT01343225|African American male or female treatment naive
338542|NCT01343212|hepatocellular carcinoma
338543|NCT01343212|stiffness
338544|NCT01343186|Peginterferon
338545|NCT01343186|Healthy subject
338546|NCT01343186|Pharmacokinetics
338547|NCT01343186|Pharmacodynamics
338548|NCT01343186|Safety
338549|NCT01343173|Leukemia
338550|NCT01343173|Adult Chronic
338551|NCT01343173|Myeloid
338552|NCT01343147|Hyperthermia
338553|NCT01343147|Microwave diathermy
338554|NCT01343147|Hot packs
338555|NCT01343147|Pain
338556|NCT01343147|Physical function
338557|NCT01343134|Retina
338558|NCT01343134|Rhegmatogenous retinal detachment
338559|NCT01343134|Macular detachment
338560|NCT01343134|Spectral domain OCT
338561|NCT01343134|Microperimetry
338562|NCT01343121|Radiotherapy
338563|NCT01343121|GemX Chemoradiotherapy
338564|NCT01343121|Bladder Cancer
338565|NCT01343108|Emotional Labor
338566|NCT01343108|Burnout
338567|NCT01343108|Job Satisfaction
338568|NCT01343108|Emotional Intelligence
338569|NCT01343108|Job stress
338570|NCT01343108|Job involvement
338571|NCT01343095|ICU Delirium
338572|NCT01343095|Delirium
338573|NCT01343095|Sleep Quality
338574|NCT01343095|Sleep Efficiency
338575|NCT01343095|ICU Noise
338576|NCT01343095|Noise Reduction
338577|NCT01343095|Earplugs
338578|NCT01343095|Noise Canceling Headphones
338579|NCT01343069|safety
338580|NCT01343069|team
338581|NCT01343069|team performance
338582|NCT01343069|surgery
338583|NCT01343069|outcome
338584|NCT01343056|Diabetes Self Management Education (DSME)
338585|NCT01343056|Diabetes
338586|NCT01343056|Self Management Support (SMS)
338587|NCT01343043|Sarcoma
338588|NCT01343043|Cell Therapy
338589|NCT01343043|T Cell Therapy
338590|NCT01343043|NY-ESO-1
338591|NCT01343043|Immuno-oncology
338592|NCT01343043|Metastatic
338593|NCT01343043|Previously treated
338594|NCT01343043|T Cell Receptor
338595|NCT01343017|Anaesthesia
338596|NCT01343017|Pulmonary gas exchange
338597|NCT01343017|Functional residual capacity
338598|NCT01343017|Cardiac output
338599|NCT01343017|Sevoflurane
338600|NCT01343004|BA058
338601|NCT01343004|abaloparatide
338602|NCT01343004|Abaloparatide-SC
338603|NCT01343004|osteoporosis
338604|NCT01343004|postmenopausal
338605|NCT01343004|bone loss
338606|NCT01343004|ACTIVE
338607|NCT01343004|fracture
338608|NCT01342991|Haemorrhoids
338609|NCT01342991|Haemorrhoidectomy
338610|NCT01342991|Laser Haemorrhoidectomy
338611|NCT01342991|Milligan-Morgan Haemorrhoidectomy
338612|NCT01342991|Open Haemorrhoidectomy
338613|NCT01342978|HPV
338614|NCT01342978|HNSCC
338615|NCT01342952|pulmonary arterial hypertension
338616|NCT01342952|pediatrics
338617|NCT01342939|Monogenetic diabetes
338618|NCT01342939|Diabetes mellitus
338619|NCT01342926|age-related macular degeneration
338620|NCT01342926|geographic atrophy
338621|NCT01342926|dry AMD
338622|NCT01342900|tissue oxygenation
338623|NCT01342900|higk risk surgery
338624|NCT01342900|high risk patient
338625|NCT01342900|postoperative complications
338626|NCT01342874|inositol
338627|NCT01342874|gestational diabetes mellitus
338628|NCT01342874|obstetric adverse outcomes
338629|NCT01342861|protein supplementation
338630|NCT01342861|caloric intake
338631|NCT01342861|breakfast
338632|NCT01342861|transthyretin (prealbumin)
338633|NCT01342861|albumin
338634|NCT01342861|Length of stay
338635|NCT01342848|NSTE-ACS
338636|NCT01342848|PCI
338637|NCT01342848|Thrombus Aspiration
338638|NCT01342848|IVUS
338639|NCT01342848|Periprocedural Myocardial Infarction
338640|NCT01342835|propofol
338641|NCT01342835|sevoflurane
338642|NCT01342835|postoperative pain
338643|NCT01342835|children
338644|NCT01342822|Heart disease
338645|NCT01342822|Coronary Revascularization
338646|NCT01342809|Depression
338647|NCT01342809|Hopelessness
338648|NCT01342809|Suicidal ideation
338649|NCT01342796|Cell mediated immunity
338650|NCT01342796|cell mediated immune response
338651|NCT01342796|Children
338652|NCT01342796|adjuvanted
338653|NCT01342783|metastatic childhood soft tissue sarcoma
338654|NCT01342783|nonmetastatic childhood soft tissue sarcoma
338655|NCT01342783|recurrent childhood soft tissue sarcoma
338656|NCT01342783|previously treated childhood rhabdomyosarcoma
338657|NCT01342783|previously untreated childhood rhabdomyosarcoma
338658|NCT01342783|recurrent childhood rhabdomyosarcoma
338659|NCT01342744|Cardiovascular risk factors
338660|NCT01342731|Tigecycline
338661|NCT01342731|A.baumannii
338662|NCT01342731|Drug safety
338663|NCT01342718|Irritable bowel syndrome
338664|NCT01342718|Herbal medicine
338665|NCT01342718|Probiotics
338666|NCT01342679|chronic myeloid leukemia
338667|NCT01342679|dasatinib
338668|NCT01342679|complete molecular response
338669|NCT01342666|High density lipoprotein cholesterol
338670|NCT01342666|Tomato
338671|NCT01342666|Lycopene
338672|NCT01342666|Hypoalphalipoproteinemia
338673|NCT01342666|Dyslipidemia
338674|NCT01342653|Peritoneal
338675|NCT01342653|Carcinomatosis
338676|NCT01342653|Gastric
338677|NCT01342653|Cancer
338678|NCT01342653|NIPS
338679|NCT01342653|HIPEC
338680|NCT01342627|Renal Carcinoma
338681|NCT01342627|Metastatic
338682|NCT01342627|Sorafenib
338683|NCT01342627|Elderly
338684|NCT01342614|Hypertension
338685|NCT01342614|Insulin Resistance
338686|NCT01342614|Hyperinsulinemia
338687|NCT01342614|Metformin
338688|NCT01342614|Fosinopril
338689|NCT01342588|Pedicle screws
338690|NCT01342588|safety
338691|NCT01342575|ACDF
338692|NCT01342549|Alcohol Use Disorders
338693|NCT01342549|Traumatic Brain Injury
338694|NCT01342549|Mood and Anxiety Disorders
338695|NCT01342536|Depression
338696|NCT01342523|Smoking Cessation
338697|NCT01342523|Smoking
338698|NCT01342523|Nicotine
338699|NCT01342510|Intravenous Anesthesia
338700|NCT01342510|General Anesthesia
338701|NCT01342497|diabetic foot ulcer
338702|NCT01342471|Physical activity intervention
338703|NCT01342471|walking
338704|NCT01342471|TV
338705|NCT01342471|sedentary
338706|NCT01342458|Knee osteoarthritis
338707|NCT01342458|Shoes
338708|NCT01342458|Gait
338709|NCT01342458|Biomechanics
338710|NCT01342432|low back pain
338711|NCT01342432|balance reeducation
338712|NCT01342432|pain
338713|NCT01342432|function
338714|NCT01342367|Prostate cancer
338715|NCT01342367|Quality of Life
338716|NCT01342354|Pancreatic Cancer
338717|NCT01342354|Stereotactic Radiation
338718|NCT01342328|Sleep disruption
338719|NCT01342328|Sleep hygiene
338720|NCT01342328|Sedative agents and sleep
338721|NCT01342328|Electroencephalography
338722|NCT01342328|REM sleep
338723|NCT01342328|Magnetoencephalography
338724|NCT01342315|Tinea Cruris, antifungal
338725|NCT01342302|Breast Cancer
338726|NCT01342302|Couples
338727|NCT01342302|Distress
338728|NCT01342302|Online Support
338729|NCT01342302|e-health
338730|NCT01342302|Intervention
338731|NCT01342302|Relationships
338732|NCT01342289|Nonmyeloablative
338733|NCT01342289|Allogeneic
338734|NCT01342289|Bone Marrow Transplant (BMT)
338735|NCT01342289|Tacrolimus
338736|NCT01342289|Cyclophosphamide
338737|NCT01342276|Heart failure
338738|NCT01342276|Self-management
338739|NCT01342276|Telehealth
338740|NCT01342276|Internet
338741|NCT01342263|Chronic disease management
338742|NCT01342263|Ischemic heart disease
338743|NCT01342263|Heart failure
338744|NCT01342263|Chronic kidney disease
338745|NCT01342263|Diabetes
338746|NCT01342263|Chronic obstructive pulmonary disease
338747|NCT01342263|Telehealth
338748|NCT01342263|Internet
338749|NCT01342250|Decompensated Liver Cirrhosis
338750|NCT01342250|Umbilical Cord Mesenchymal Stem Cells
338751|NCT01342237|Brain tumors
338752|NCT01342237|Stem cell transplantation
338753|NCT01342237|topotecan
338754|NCT01342237|thiotepa
338755|NCT01342237|carboplatin
338756|NCT01342237|melphalan
338757|NCT01342237|etoposide
338758|NCT01342224|pancreatic
338759|NCT01342224|cancer
338760|NCT01342224|adenocarcinoma
338761|NCT01342224|vaccine
338762|NCT01342211|PF-04950615
338763|NCT01342211|RN316
338764|NCT01342198|pregabalin
338765|NCT01342198|pharmacokinetics
338766|NCT01342198|bioavailability
338767|NCT01342198|bioequivalence
338768|NCT01342185|Medical ozone therapy
338769|NCT01342185|chronic hepatitis B
338770|NCT01342172|Bladder Cancer
338771|NCT01342172|Urothelial Cancer
338772|NCT01342172|Chemotherapy
338773|NCT01342172|First-line
338774|NCT01342172|Metastatic
338775|NCT01342159|bevacizumab, diabetic macular edema, triamcinolone
338776|NCT01342146|pegylated Somatropin
338777|NCT01342146|PEG-GH
338778|NCT01342146|Growth hormone
338779|NCT01342146|PEG-rhGH
338780|NCT01342146|Growth hormone deficiency (GHD)
338781|NCT01342146|Phase 2 study
338782|NCT01342120|atypical antipsychotics
338783|NCT01342120|quetiapine
338784|NCT01342107|Contact Lenses
338785|NCT01342107|Contact Lens Care
338786|NCT01342107|Multi-Purpose Solution Wettability
338787|NCT01342107|Myopia
338788|NCT01342094|Primary open angle glaucoma or ocular hypertension
338789|NCT01342081|Primary open angle glaucoma or ocular hypertension
338790|NCT01342068|Thoracic outlet syndrome
338791|NCT01342068|Osteopathic medicine
338792|NCT01342068|Osteopathic Manual Manipulations
338793|NCT01342068|OMT
338794|NCT01342068|Wright's Test
338795|NCT01342068|Adson's Test
338796|NCT01342068|Halstead's Maneuver
338797|NCT01342068|TOS
338798|NCT01342068|Vascular Sonography
338799|NCT01342042|diabetes
338800|NCT01342042|rRE-4
338801|NCT01342042|exenatide
338802|NCT01342042|metformin
338803|NCT01342042|CSPC ZhongQi
338804|NCT01342029|Microvascular Coronary Dysfunction (MCD)
338805|NCT01342016|prograf
338806|NCT01342016|nephritis
338807|NCT01342016|leflunomide
338808|NCT01342016|immunosuppressant
338809|NCT01342003|HCV infection
338810|NCT01342003|genotype 1a
338811|NCT01342003|genotype 1 b
338812|NCT01341990|Contact Lenses
338813|NCT01341990|Contact Lens Care
338814|NCT01341990|Multi-Purpose Solution
338815|NCT01341977|Contact Lenses
338816|NCT01341977|Contact Lens Care
338817|NCT01341977|Multi-Purpose Solution
338818|NCT01341964|Clopidogrel
338819|NCT01341964|Aspirin
338820|NCT01341964|Interaction
338821|NCT01341951|liver failure, Acute
338822|NCT01341938|Smokeless Tobacco Use
338823|NCT01341925|childhood depression
338824|NCT01341899|Type 1 diabetes
338825|NCT01341899|stem cell
338826|NCT01341899|C-peptide
338827|NCT01341899|Immune function
338828|NCT01341886|differentiated thyroid cancer
338829|NCT01341886|THS suppression
338830|NCT01341886|metformin
338831|NCT01341834|Nasopharyngeal carcinoma, antiangiogenesis, HDACi, mTOR, Phase Ib
338832|NCT01341821|Leadership Style
338833|NCT01341821|Team Climate
338834|NCT01341808|Crohn's disease
338835|NCT01341808|Ulcerative colitis
338836|NCT01341808|Hepatitis A
338837|NCT01341808|vaccine
338838|NCT01341795|Newly diagnosed type 2 diabetes patients
338839|NCT01341782|Secondary hyperparathyroidism
338840|NCT01341782|Paricalcitol
338841|NCT01341782|Hemodialysis
338842|NCT01341782|Maxacalcitol
338843|NCT01341756|Gastric Cancer
338844|NCT01341756|Radiotherapy
338845|NCT01341756|palliation
338846|NCT01341756|bleeding
338847|NCT01341756|pain
338848|NCT01341756|obstruction
338849|NCT01341743|chronic hepatitis B
338850|NCT01341743|inadequate response
338851|NCT01341743|NUC therapy
338852|NCT01341730|Atherosclerosis
338853|NCT01341730|Pioglitazone
338854|NCT01341730|Atorvastatin
338855|NCT01341730|PET CT
338856|NCT01341717|Diabetes Mellitus, Type 2
338857|NCT01341717|Sitagliptin
338858|NCT01341717|Insulin
338859|NCT01341704|malaria
338860|NCT01341704|vaccine
338861|NCT01341704|clinical trials
338862|NCT01341704|proof of concept
338863|NCT01341704|efficacy
338864|NCT01341691|chronic kidney disease
338865|NCT01341691|K2CG chewing gum
338866|NCT01341691|phosphorus
338867|NCT01341691|saliva
338868|NCT01341678|chronic kidney disease
338869|NCT01341678|phosphorus
338870|NCT01341678|circadian rhythm
338871|NCT01341678|saliva
338872|NCT01341665|hyponatremia
338873|NCT01341665|SIADH
338874|NCT01341665|copeptin
338875|NCT01341639|combination vaccine
338876|NCT01341639|diphtheria
338877|NCT01341639|pertussis
338878|NCT01341639|tetanus
338879|NCT01341639|hepatitis B
338880|NCT01341639|Hep B
338881|NCT01341639|Haemophilus influenzae b
338882|NCT01341639|Hib
338883|NCT01341639|polio
338884|NCT01341639|poliovirus
338885|NCT01341626|delinquency
338886|NCT01341626|drug use
338887|NCT01341626|HIV risk behavior
338888|NCT01341626|economic costs
338889|NCT01341600|Clopidogrel
338890|NCT01341600|Pharmacogenetics
338891|NCT01341600|Platelets
338892|NCT01341600|Healthy Subjects
338893|NCT01341587|SMBG (self monitoring of blood glucose)
338894|NCT01341587|diabetes
338895|NCT01341587|mobile technology
338896|NCT01341574|spatial neglect
338897|NCT01341574|stroke
338898|NCT01341548|Nasal
338899|NCT01341548|Cluster Headache
338900|NCT01341548|Episodic Cluster
338901|NCT01341548|Headache
338902|NCT01341548|Phase 3
338903|NCT01341548|Civamide
338904|NCT01341548|TRPV-1 Receptor
338905|NCT01341509|Surgical Treatment of Insertional Achilles Tendinopathy
338906|NCT01341496|Metastatic Cancer
338907|NCT01341496|Cancer Vaccine
338908|NCT01341496|Immunotherapy
338909|NCT01341496|Chest Metastases
338910|NCT01341496|Sarcoma
338911|NCT01341496|Melanoma
338912|NCT01341483|erectile dysfunction
338913|NCT01341483|internal pudendal artery
338914|NCT01341483|erection
338915|NCT01341483|coronary artery disease
338916|NCT01341483|peripheral atherosclerotic disease
338917|NCT01341431|Parkinson disease
338918|NCT01341431|Bee venom
338919|NCT01341431|Motor fluctuations
338920|NCT01341431|Disease progression
338921|NCT01341418|tibia
338922|NCT01341418|suprapatellar
338923|NCT01341392|Drug-Drug interaction between the CKD-501 and Amlodipine
338924|NCT01341379|Ureagenesis
338925|NCT01341379|Urea cycle
338926|NCT01341379|Inborn errors of metabolism
338927|NCT01341366|Laparoscopic surgery
338928|NCT01341340|Stent
338929|NCT01341340|Infrapopliteal
338930|NCT01341340|Tibial
338931|NCT01341340|Limb Salvage
338932|NCT01341327|Left Main
338933|NCT01341314|joint pain
338934|NCT01341314|stiffness
338935|NCT01341301|allogeneic stem cell transplant
338936|NCT01341301|TJU 2 Step
338937|NCT01341301|HSCT
338938|NCT01341301|Hematopoietic stem cell transplantation
338939|NCT01341275|hepatitis B vaccine
338940|NCT01341275|duration of protection
338941|NCT01341275|adolescent immunization
338942|NCT01341275|anamnestic response
338943|NCT01341275|booster dose
338944|NCT01341275|Immunity to hepatitis B as measured by anti-HBSAg titers
338945|NCT01341262|autologous stem cell transplantation
338946|NCT01341262|thalidomide
338947|NCT01341262|induction therapy
338948|NCT01341236|VLBW
338949|NCT01341236|IUGR
338950|NCT01341236|NIRS
338951|NCT01341236|enteral nutrition
338952|NCT01341236|superior mesenteric artery doppler
338953|NCT01341210|Patients Satisfaction
338954|NCT01341210|Decision Making
338955|NCT01341210|Informed Consent
338956|NCT01341197|Fecal immunochemical test
338957|NCT01341197|Guaiac fecal occult blood test
338958|NCT01341197|Helicobacter pylori stool antigen test
338959|NCT01341197|Mass screening
338960|NCT01341197|Bidirectional endoscopy
338961|NCT01341184|tuberculosis, rifabutin, rifampin, TMC207
338962|NCT01341171|tamoxifen
338963|NCT01341171|aromatase inhibitors
338964|NCT01341171|breast cancer
338965|NCT01341171|platelets
338966|NCT01341158|Malignatn Melanoma
338967|NCT01341145|hypertension
338968|NCT01341145|aerobic exercise
338969|NCT01341145|relaxation
338970|NCT01341145|functional magnetic resonance imaging (fMRI)
338971|NCT01341145|magnetic resonance spectroscopy (MRS)
338972|NCT01341145|brain health
338973|NCT01341132|HCC
338974|NCT01341132|Hepatocellular Carcinoma
338975|NCT01341132|MRI
338976|NCT01341132|Liver
338977|NCT01340157|Fexinidazole
338978|NCT01340157|Phase I
338979|NCT01340157|Bioavailability study
338980|NCT01340157|Food effect
338981|NCT01340157|Human African Trypanosomiasis
338982|NCT01341106|chronic hepatitis B
338983|NCT01341106|liver fibrosis
338984|NCT01341106|treatment with Entecavir
338985|NCT01341080|Balance
338986|NCT01341080|Postural impairment
338987|NCT01341080|Falls
338988|NCT01341080|Parkinson Disease
338989|NCT01341054|mucositis
338990|NCT01341054|chamomilla
338991|NCT01341054|therapeutics
338992|NCT01341028|weight loss
338993|NCT01341028|appetite
338994|NCT01341028|ghrelin
338995|NCT01341028|PYY
338996|NCT01341028|GLP-1
338997|NCT01341028|insulin
338998|NCT01341028|laparoscopic
338999|NCT01341028|Roux-en-Y gastric bypass
339000|NCT01341028|gastric fundus resection
339001|NCT01341002|Postoperative Care
339002|NCT01341002|red blood cell transfusion
339003|NCT01341002|venous oxygen saturation
339004|NCT01340989|women undergoing laparoscopic surgery for: hysterectomy, colpopexy, endometriosis, adhesions or myomas
339005|NCT01340976|Cancer Related Anemia
339006|NCT01340963|Chagas heart disease
339007|NCT01340963|ventricular tachycardia
339008|NCT01340963|atrial fibrillation
339009|NCT01340963|stroke
339010|NCT01340963|cardiac death
339011|NCT01340963|signal averaged electrocardiogram
339012|NCT01340950|Prevention
339013|NCT01340950|Anti-Retroviral Agents
339014|NCT01340950|Neuropsychological Tests
339015|NCT01340937|Diphtheria
339016|NCT01340937|Tetanus
339017|NCT01340937|Whooping Cough (pertussis)
339018|NCT01340937|Poliomyelitis
339019|NCT01340937|Hepatitis B infection
339020|NCT01340937|Haemophilus influenzae type b infection
339021|NCT01340924|Gestational diabetes
339022|NCT01340924|Type 2 diabetes
339023|NCT01340898|meningococcal conjugate vaccine
339024|NCT01340898|serogroups A,C, W-135 or Y
339025|NCT01340898|meningococcal diseases
339026|NCT01340898|Immunogenicity
339027|NCT01340898|Neisseria meningitidis
339028|NCT01340898|co-administration
339029|NCT01340898|routine vaccines
339030|NCT01340885|attention
339031|NCT01340885|mild cognitive impairment
339032|NCT01340885|dementia
339033|NCT01340872|iron deficiency
339034|NCT01340872|anaemia
339035|NCT01340872|inflammatory bowel disease
339036|NCT01340872|ulcerative colitis
339037|NCT01340859|Suicide
339038|NCT01340859|Cognitive Therapy
339039|NCT01340859|Inpatient
339040|NCT01340859|Military
339041|NCT01340846|ketoconazole
339042|NCT01340846|GSK2118436
339043|NCT01340846|warfarin
339044|NCT01340846|gemfibrozil
339045|NCT01340846|oncology
339046|NCT01340846|BRAF inhibitor
339047|NCT01340846|BRAF
339048|NCT01340846|BRAF positive tumor
339049|NCT01340846|Drug Interactions
339050|NCT01340833|GSK2118436
339051|NCT01340833|BRAF inhibitor
339052|NCT01340833|BRAF-mutation positive tumor
339053|NCT01340833|Oncology
339054|NCT01340833|absolute bioavailability
339055|NCT01340833|microtracer
339056|NCT01340781|inpatients
339057|NCT01340781|medical
339058|NCT01340781|polysomnogram
339059|NCT01340781|questionnaires
339060|NCT01340768|Glucose metabolism disorders Metabolic diseases Peptidase inhibitors
339061|NCT01340755|Rectal cancer
339062|NCT01340742|Remote ischemic preconditioning
339063|NCT01340742|Abdominal surgery
339064|NCT01340742|Perioperative complications
339065|NCT01340729|melanoma
339066|NCT01340729|TPI 287
339067|NCT01340729|tumor recurrence
339068|NCT01340729|tumor progression
339069|NCT01340729|novel taxane analog
339070|NCT01340703|optic disc pit
339071|NCT01340703|retinal detachment
339072|NCT01340703|retinoschisis
339073|NCT01340703|vitrectomy
339074|NCT01340703|posterior vitreous detachment
339075|NCT01340690|ADHD
339076|NCT01340690|children
339077|NCT01340690|adolescents
339078|NCT01340690|Polyunsaturated Fatty Acids
339079|NCT01340690|ADHDRS - IV
339080|NCT01340677|Canagliflozin (JNJ-28431754)
339081|NCT01340677|Pharmacokinetic
339082|NCT01340677|Dose proportionality
339083|NCT01340664|Canagliflozin
339084|NCT01340664|Placebo
339085|NCT01340664|Metformin
339086|NCT01340664|Hemoglobin A1c
339087|NCT01340664|Type 2 diabetes mellitus
339088|NCT01340651|myelofibrosis
339089|NCT01340651|myeloproliferative neoplasms
339090|NCT01340651|PMF
339091|NCT01340651|PET-MF
339092|NCT01340651|PPV-MF
339093|NCT01340638|Seal pressure
339094|NCT01340638|Cookgas
339095|NCT01340638|AirQ
339096|NCT01340638|LMA
339097|NCT01340638|supraglottic device
339098|NCT01340625|Healthy Subjects
339099|NCT01340612|large aneurysm
339100|NCT01340612|wide-necked aneurysm
339101|NCT01340612|recurring aneurysm
339102|NCT01340586|PHARMACOKINETIC
339103|NCT01340586|NOS
339104|NCT01340573|Chronic Hepatitis C
339105|NCT01340573|pegylated interferon
339106|NCT01340573|PegIntron Pen
339107|NCT01340573|Ribavirin
339108|NCT01340560|Endometrium, local injury, implantation, pregnancy, in vitro fertilization
339109|NCT01340547|Phase I
339110|NCT01340547|Safety
339111|NCT01340547|PK
339112|NCT01340547|ECG QTc
339113|NCT01340547|Efficacy
339114|NCT01340547|Palifosfamide-tris
339115|NCT01340547|non-randomized
339116|NCT01340534|Surgical wound infection
339117|NCT01340534|Oxygen
339118|NCT01340534|Cesarean
339119|NCT01340521|Pituitary Hormone Response
339120|NCT01340521|Clomiphene Citrate
339121|NCT01340521|Follicle Stimulating Hormone
339122|NCT01340521|Luteinizing Hormone
339123|NCT01340508|Pathological complete response
339124|NCT01340508|Intensity modulated radiotherapy
339125|NCT01340508|Rectal cancer
339126|NCT01340495|Breast Cancer
339127|NCT01340495|Mastectomy
339128|NCT01340482|XLH
339129|NCT01340469|nosocomial infections
339130|NCT01340469|necrotizing enterocolitis
339131|NCT01340469|preterm infants
339132|NCT01340469|ver low birth weight
339133|NCT01340469|probiotics
339134|NCT01340456|4beta-OHcholesterol
339135|NCT01340456|Midazolam
339136|NCT01340456|CYP3A4
339137|NCT01340456|Enzyme induction
339138|NCT01340456|Drug metabolism
339139|NCT01340430|her2 positive breast cancer
339140|NCT01340430|her2 positive non operable breast cancer
339141|NCT01340430|her2 positive locally advanced breast cancer
339142|NCT01340430|neoadjuvant trastuzumab
339143|NCT01340430|pathologic complete response
339144|NCT01340417|melatonin
339145|NCT01340417|preterm
339146|NCT01340417|deficiency
339147|NCT01340417|neuroprotection
339148|NCT01340391|cast, radius fracture
339149|NCT01340378|neonatal surgery
339150|NCT01340378|Blalock-Taussig shunt
339151|NCT01340339|Jaundice
339152|NCT01340339|Hyperbilirubinemia
339153|NCT01340339|Phototherapy and Super-LED Fluorescent lamps
339154|NCT01340326|Post myocardial infarction ventricular remodeling
339155|NCT01340326|valsartan
339156|NCT01340313|caudal block, children, ultrasound, urological surgery
339157|NCT01340300|Colorectal
339158|NCT01340300|Breast
339159|NCT01340300|Insulin
339160|NCT01340300|Exercise
339161|NCT01340287|Plant sterol
339162|NCT01340287|Hypercholesterolemia
339163|NCT01340287|diet
339164|NCT01340287|dairy
339165|NCT01340287|isoprostanes
339166|NCT01340287|Midly hypercholesterolemic subjects
339167|NCT01340274|Community Reinforcement and Family Training
339168|NCT01340274|Concerned Significant Others
339169|NCT01340274|Identified Problem Gambler
339170|NCT01340274|Therapeutics
339171|NCT01340248|food effect
339172|NCT01340248|pharmacokinetics
339173|NCT01340248|healthy male volunteers
339174|NCT01340222|Preterm labour
339175|NCT01340222|monocyte
339176|NCT01340222|lymphocyte
339177|NCT01340222|MCP-1
339178|NCT01340222|Treg Lymphocytes
339179|NCT01340222|biologic markers
339180|NCT01340222|immunology
339181|NCT01340222|HLA-DR
339182|NCT01340222|Th17
339183|NCT01340183|Phase I
339184|NCT01340183|safety
339185|NCT01340183|tolerability
339186|NCT01340183|pharmacokinetics
339187|NCT01340183|AZD5099
339188|NCT01340183|volunteers
339189|NCT01340183|safety of the drug AZD5099
339190|NCT01340183|blood and urine levels of AZD5099
339191|NCT01340183|single intravenous doses
339192|NCT01340183|healthy volunteers
339193|NCT01340144|total knee replacement
339194|NCT01340144|patellar crepitus
339195|NCT01340144|Replacement of knee joint
339196|NCT01340131|CKD-828
339197|NCT01340131|Hypertension
339198|NCT01340131|Primary Hypertension
339199|NCT01340131|Healthy Volunteer
339200|NCT01340131|S-Amlodipine
339201|NCT01340131|Telmisartan
339202|NCT01340131|Amlodipine
339203|NCT01340131|Pharmacokinetic
339204|NCT01340131|Phase 1
339205|NCT01340118|Asthma
339206|NCT01340118|FEF25-75
339207|NCT01340118|exhaled nitric oxide
339208|NCT01340118|inhaled corticosteroid
339209|NCT01340118|children
339210|NCT01340105|Microwave ablation
339211|NCT01340105|Radiofrequency ablation
339212|NCT01340105|Randomised controlled trial
339213|NCT01340092|Family Navigator
339214|NCT01340092|Autistic Disorder
339215|NCT01340092|Early Intervention
339216|NCT01340092|Developmental Disabilities
339217|NCT01340092|Child Development Disorders
339218|NCT01340079|diabetes mellitus, non-insulin dependent
339219|NCT01340066|urinary incontinence
339220|NCT01340066|stress incontinence
339221|NCT01340066|urge incontinence
339222|NCT01340066|mixed incontinence
339223|NCT01340040|Phase I
339224|NCT01340040|cancer
339225|NCT01340040|solid tumours
339226|NCT01340040|advanced solid malignancies
339227|NCT01340040|dose escalation
339228|NCT01340040|Insulin like growth factor
339229|NCT01340040|Japanese
339230|NCT01340027|Overactive bladder (OAB)
339231|NCT01340027|Frequency
339232|NCT01340027|Micturition
339233|NCT01340027|Urgency
339234|NCT01340027|Urinary incontinence
339235|NCT01340027|Urgency incontinence
339236|NCT01340027|YM178
339237|NCT01340014|Glaucoma
339238|NCT01340014|Intraocular pressure
339239|NCT01340014|Tonometry, ocular
339240|NCT01340001|Dementia with Lewy bodies
339241|NCT01340001|Nucleus basalis of Meynert
339242|NCT01340001|Deep brain stimulation
339243|NCT01339988|Stem-cells
339244|NCT01339988|Transplantation
339245|NCT01339988|Busulfex
339246|NCT01339988|Cyclophosphamide
339247|NCT01339988|Total-Body-Ittadiation
339248|NCT01339975|Renal Cell Carcinoma
339249|NCT01339975|Nephrectomy
339250|NCT01339975|Antiangiogenics
339251|NCT01339975|Chemokines
339252|NCT01339975|Prognostic value
339253|NCT01339975|Carcinoma
339254|NCT01339975|Carcinoma, Renal Cell
339255|NCT01339975|Kidney Neoplasms
339256|NCT01339975|Kidney Diseases
339257|NCT01339975|Neoplasms, Glandular and Epithelial
339258|NCT01339975|Neoplasms by Histologic Type
339259|NCT01339975|Neoplasms
339260|NCT01339975|Adenocarcinoma
339261|NCT01339975|Urologic Neoplasms
339262|NCT01339975|Urogenital Neoplasms
339263|NCT01339975|Neoplasms by Site
339264|NCT01339975|Urologic Diseases
339265|NCT01339975|Adjuvants, Immunologic
339266|NCT01339975|Physiological Effects of Drugs
339267|NCT01339975|Pharmacologic Actions
339268|NCT01339975|Biomarkers
339269|NCT01339975|Targeted therapies
339270|NCT01339975|Surgery
339271|NCT01339962|Metastatic renal cell carcinoma
339272|NCT01339949|AMD
339273|NCT01339949|wet AMD
339274|NCT01339949|Macular Degeneration
339275|NCT01339949|wet Age-related Macular Degeneration
339276|NCT01339949|Age-Related Macular Degeneration
339277|NCT01339949|IRay
339278|NCT01339949|radiation
339279|NCT01339949|Oraya
339280|NCT01339949|Oraya Therapeutics, Inc
339281|NCT01339949|Low-voltage stereotactic radiosurgery
339282|NCT01339949|radiosurgery
339283|NCT01339949|x-ray
339284|NCT01339949|Lucentis
339285|NCT01339949|external beam radiation
339286|NCT01339923|Meningococcal disease
339287|NCT01339923|Vaccines
339288|NCT01339923|intercalated administration
339289|NCT01339910|Acute Myelogenous Leukemia
339290|NCT01339910|Myelodysplastic Syndrome
339291|NCT01339897|N6022, GSNORi
339292|NCT01339884|Friedreich ataxia
339293|NCT01339884|Resveratrol
339294|NCT01339884|Frataxin
339295|NCT01339884|Cardiomyopathy
339296|NCT01339884|Oxidative stress
339297|NCT01339871|Pazopanib
339298|NCT01339871|Vorinostat
339299|NCT01339871|Advanced Malignancies
339300|NCT01339845|Cholera vaccine
339301|NCT01339845|Behaviour change intervention
339302|NCT01339845|Cost effectiveness and cost-benefit
339303|NCT01339845|Prevention of cholera
339304|NCT01339845|Control of Cholera
339305|NCT01339845|Vaccination
339306|NCT01339806|mTBI
339307|NCT01339806|Concussion
339308|NCT01339793|corporate social responsibility
339309|NCT01339793|social identity theory
339310|NCT01339793|stakeholder theory
339311|NCT01339793|organizational commitment
339312|NCT01339793|organizational performance
339313|NCT01339767|Autism
339314|NCT01339767|Language Acquisition
339315|NCT01339767|Language Development
339316|NCT01339767|Toddlers
339317|NCT01339754|recurrent pancreatic cancer
339318|NCT01339754|stage IV pancreatic cancer
339319|NCT01339754|adenocarcinoma of the pancreas
339320|NCT01339741|Psoriasis Vulgaris
339321|NCT01339741|Vitamin D Deficiency
339322|NCT01339741|Vitamin D Insufficiency
339323|NCT01339741|Vitamin D Supplement
339324|NCT01339741|Psoriasis Area and Severity Index (PASI Score)
339325|NCT01339741|Dermatologic Life Qualify Index (DLQI)
339326|NCT01339715|Ryodoraku
339327|NCT01339715|Heart Rate Variability
339328|NCT01339715|Traditional medicine
339329|NCT01339715|Autonomic Nervous System
339330|NCT01339715|Acupuncture
339331|NCT01339715|Far Infrared Ray
339332|NCT01339715|CV12 Acupoint
339333|NCT01339702|Traumatic Brain Injury
339334|NCT01339702|TBI
339335|NCT01339702|Head Trauma
339336|NCT01339702|Acute Traumatic Brain Injury
339337|NCT01339702|Trauma, Brain
339338|NCT01339689|PTSD
339339|NCT01339689|Posttraumatic Stress Disorder
339340|NCT01339689|pharmacotherapy
339341|NCT01339689|ganaxolone
339342|NCT01339676|Vitamin D
339343|NCT01339676|Multiple Sclerosis
339344|NCT01339676|MRI
339345|NCT01339676|Randomised Trial
339346|NCT01339676|Finland
339347|NCT01339650|Solid Tumor
339348|NCT01339650|BRCA 1 and BRCA 2 Mutations
339349|NCT01339650|Breast Cancer 1
339350|NCT01339650|Breast Cancer 2
339351|NCT01339650|High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
339352|NCT01339650|Solid Tumors
339353|NCT01339637|Impaired Glucose Tolerance
339354|NCT01339637|Diabetes Risk Factors
339355|NCT01339637|Dark Skin
339356|NCT01339624|analgesia
339357|NCT01339624|renal colic
339358|NCT01339624|ketorolac
339359|NCT01339624|nasal fentanyl
339360|NCT01339624|morphine.
339361|NCT01339624|treatment of acute renal colic
339362|NCT01339611|quality of life
339363|NCT01339611|medical adherence
339364|NCT01339611|warfarin
339365|NCT01339611|Health education
339366|NCT01339572|autologous transplantation
339367|NCT01339572|peripheral stem cell mobilization
339368|NCT01339559|Epilepsy
339369|NCT01339559|Brivaracetam
339370|NCT01339559|Partial Onset Seizures
339371|NCT01339559|Adjunctive treatment
339372|NCT01339546|ecologic
339373|NCT01339546|cross sectional
339374|NCT01339546|trend analysis
339375|NCT01339533|ALI
339376|NCT01339533|ARDS
339377|NCT01339481|Orencia
339378|NCT01339481|Abatacept
339379|NCT01339481|Rheumatoid Arthritis
339380|NCT01339481|Infusion
339381|NCT01339468|living donor liver transplantation
339382|NCT01339468|FK506
339383|NCT01339468|prograf
339384|NCT01339468|advagraf
339385|NCT01339468|Immunosuppressant
339386|NCT01339455|Neuromyelitis Optica
339387|NCT01339455|NMO
339388|NCT01339455|Devic's Disease
339389|NCT01339455|Stem Cell Transplant
339390|NCT01339429|wound
339391|NCT01339429|negative pressure wound therapy
339392|NCT01339429|non-powered negative pressure wound therapy
339393|NCT01339390|Obesity
339394|NCT01339390|Veteran
339395|NCT01339390|Self Care
339396|NCT01339390|Patient Education
339397|NCT01339390|Peer Group
339398|NCT01339377|Ozone
339399|NCT01339377|Oxygen
339400|NCT01339377|Oxygen-Ozone
339401|NCT01339377|AO-1000
339402|NCT01339377|ActiveO
339403|NCT01339377|Herniated Disc
339404|NCT01339377|Disc
339405|NCT01339377|Lumbar
339406|NCT01339351|breast cancer
339407|NCT01339351|social connection
339408|NCT01339325|Laparo-endoscopic single site cholecystectomy
339409|NCT01339325|Quality of Life
339410|NCT01339325|Postoperative Pain
339411|NCT01339325|Cosmetics
339412|NCT01339325|Complication
339413|NCT01339312|Rabies
339414|NCT01339312|Rabies virus
339415|NCT01339312|Purified Vero Rabies Vaccine - Serum Free
339416|NCT01339299|COS
339417|NCT01339299|ART
339418|NCT01339299|Infertility
339419|NCT01339273|TAP block
339420|NCT01339273|Laparoscopic hemicolectomy
339421|NCT01339273|Laparoscopic anterior resection
339422|NCT01339273|laparoscopic colonic resection
339423|NCT01339247|Bioequivalence
339424|NCT01339247|Paroxetine reference/test
339425|NCT01339247|healthy volunteers
339426|NCT01339247|Fed condition
339427|NCT01339234|treadmill exercise
339428|NCT01339234|rehabilitation
339429|NCT01339234|progressive multiple sclerosis
339430|NCT01339234|functional ability
339431|NCT01339234|quality of life
339432|NCT01339234|fatigue
339433|NCT01339221|Observational
339434|NCT01339221|Rotarix™
339435|NCT01339221|post-marketing
339436|NCT01339208|Type 2 Diabetes
339437|NCT01339195|Dementia
339438|NCT01339195|Alzheimer disease
339439|NCT01339195|stroke
339440|NCT01339195|cognitive impairment
339441|NCT01339182|somatropin
339442|NCT01339182|PK
339443|NCT01339182|PD
339444|NCT01339182|male
339445|NCT01339182|pharmacokinetics
339446|NCT01339182|pharmacodynamics
339447|NCT01339182|safety
339448|NCT01339169|YF476
339449|NCT01339169|Hypergastrinaemia
339450|NCT01339169|netazepide
339451|NCT01339169|gastric carcinoids
339452|NCT01339156|Safety
339453|NCT01339156|Tolerability
339454|NCT01339156|Food Effect
339455|NCT01339156|Pharmacokinetics
339456|NCT01339143|Vildagliptin
339457|NCT01339130|Alzheimer disease
339458|NCT01339130|Stroke
339459|NCT01339130|Frontotemporal Lobar Degeneration
339460|NCT01339130|Lewy Body Dementia
339461|NCT01339130|Huntington Disease
339462|NCT01339130|mild cognitive impairment
339463|NCT01339130|vascular injury
339464|NCT01339130|Parkinson's disease
339465|NCT01339117|irritable bowel syndrome
339466|NCT01339117|children
339467|NCT01339117|chronic abdominal pain
339468|NCT01339117|recurrent abdominal pain
339469|NCT01339104|Cardiovascular safety
339470|NCT01339078|Biliary strictures
339471|NCT01339078|liver transplantation
339472|NCT01339065|ketamine
339473|NCT01339065|inflammatory
339474|NCT01339065|pro inflammatory
339475|NCT01339065|pro inflammatory markers IL-6 and IL-1beta
339476|NCT01339052|BKM120
339477|NCT01339052|Brain tumor
339478|NCT01339039|AMD3100
339479|NCT01339039|plerixafor
339480|NCT01339039|Mozobil
339481|NCT01339039|bevacizumab
339482|NCT01339026|Acute coronary syndrome
339483|NCT01339026|Platelet reactivity
339484|NCT01339026|Clopidogrel
339485|NCT01339026|Percutaneous coronary intervention
339486|NCT01339013|Quantification
339487|NCT01339013|ventilatory requirements
339488|NCT01339013|charcoal filter
339489|NCT01339000|Colorectal Cancer
339490|NCT01339000|Breast Cancer
339491|NCT01339000|Immunization
339492|NCT01339000|Immunocompromised Host
339493|NCT01339000|Bladder Cancer
339494|NCT01339000|Colon Cancer
339495|NCT01338987|FLT
339496|NCT01338987|Lupron
339497|NCT01338987|Thymic Renewal
339498|NCT01338987|Stem Cell Transplant
339499|NCT01338987|Acute Lymphocytic Leukemia
339500|NCT01338987|Acute Myelogenous Leukemia
339501|NCT01338987|Myelodyplastic Syndrome
339502|NCT01338974|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
339503|NCT01338974|adult acute myeloid leukemia with del(5q)
339504|NCT01338974|adult acute myeloid leukemia with inv(16)(p13;q22)
339505|NCT01338974|adult acute myeloid leukemia with t(16;16)(p13;q22)
339506|NCT01338974|adult acute myeloid leukemia with t(8;21)(q22;q22)
339507|NCT01338974|recurrent adult acute myeloid leukemia
339508|NCT01338974|untreated adult acute myeloid leukemia
339509|NCT01338974|adult acute minimally differentiated myeloid leukemia (M0)
339510|NCT01338974|adult acute myeloblastic leukemia without maturation (M1)
339511|NCT01338974|adult acute myeloblastic leukemia with maturation (M2)
339512|NCT01338974|adult acute myelomonocytic leukemia (M4)
339513|NCT01338974|adult acute monoblastic leukemia (M5a)
339514|NCT01338974|adult acute monocytic leukemia (M5b)
339515|NCT01338974|adult erythroleukemia (M6a)
339516|NCT01338974|adult pure erythroid leukemia (M6b)
339517|NCT01338974|adult acute megakaryoblastic leukemia (M7)
339518|NCT01338961|Cardiopulmonary Bypass
339519|NCT01338961|Hypothermia
339520|NCT01338961|Normothermia
339521|NCT01338961|Troponin I
339522|NCT01338961|Bleeding
339523|NCT01338935|CW 002
339524|NCT01338935|Phase I trial
339525|NCT01338935|safety
339526|NCT01338935|efficacy
339527|NCT01338935|pharmacokinetics
339528|NCT01338935|estimated dose
339529|NCT01338935|Neuromuscular Blocking Agents
339530|NCT01338935|Treatment Effectiveness
339531|NCT01338935|Drug Antagonism
339532|NCT01338909|prasugrel
339533|NCT01338909|clopidogrel
339534|NCT01338909|primary percutaneous coronary intervention
339535|NCT01338909|high platelet reactivity
339536|NCT01338896|Rotigotine
339537|NCT01338896|Neupro
339538|NCT01338883|HIV-1 Infection
339539|NCT01338883|CCR5-tropic
339540|NCT01338883|Anti-retroviral naive
339541|NCT01338870|Phase 2
339542|NCT01338870|safety and efficacy study with PF-04991532
339543|NCT01338870|Type 2 diabetes
339544|NCT01338857|neurofibromatosis1 (NF1)
339545|NCT01338857|Recurrent or progressive optic pathway gliomas (OPG)
339546|NCT01338857|Recurrent or progressive low-grade glioma
339547|NCT01338857|sorafenib
339548|NCT01338857|low-grade astrocytoma
339549|NCT01338844|Poor oocyte quality
339550|NCT01338844|IVF failure
339551|NCT01338831|prostate cancer,
339552|NCT01338831|breast cancer,
339553|NCT01338831|prolactin,
339554|NCT01338831|prolactin receptor
339555|NCT01338831|uterine leiomyoma
339556|NCT01338818|Attention Deficit /Hyperactivity Disorder,
339557|NCT01338818|hyperactivity
339558|NCT01338805|Partial onset seizure
339559|NCT01338805|seizure frequency
339560|NCT01338805|nervous system diseases
339561|NCT01338805|central nervous system diseases
339562|NCT01338805|CNS
339563|NCT01338805|brain diseases
339564|NCT01338805|neurologic manifestations
339565|NCT01338805|adjunctive treatment
339566|NCT01338805|AEDs
339567|NCT01338805|antiepileptic drug
339568|NCT01338779|Tolerance
339569|NCT01338779|Renal
339570|NCT01338779|Allograft
339571|NCT01338779|B Cell Signature
339572|NCT01338766|spondylolisthesis
339573|NCT01338766|lumbar spinal stenosis
339574|NCT01338753|breast
339575|NCT01338753|cancer
339576|NCT01338753|Pharmacogenomics
339577|NCT01338753|bevacizumab
339578|NCT01338740|Chrohn's disease
339579|NCT01338740|Moderate to severely active Crohn's disease patients
339580|NCT01338714|HBV carrier
339581|NCT01338714|HBV DNA title
339582|NCT01338714|Chinese Medicine
339583|NCT01338714|Liver function
339584|NCT01338714|RHD-1
339585|NCT01338701|TBI
339586|NCT01338701|Headaches
339587|NCT01338701|Military
339588|NCT01338701|Acupuncture
339589|NCT01338701|Walter Reed Army Medical Center
339590|NCT01338701|Fort Belvoir Community Hospital
339591|NCT01338675|Chronic granulomatous disease
339592|NCT01338675|Hematopoietic Stem Cell Transplantation
339593|NCT01338662|Parkinson`s disease
339594|NCT01338649|Parkinson's disease
339595|NCT01338649|Daytime somnolence
339596|NCT01338649|Sleepiness
339597|NCT01338649|Light therapy
339598|NCT01338636|Exercised induced pulmonary arterial hypertension
339599|NCT01338636|Pulmonary hypertension
339600|NCT01338636|ambrisentan
339601|NCT01338636|Advanced cardiopulmonary exercise test
339602|NCT01338623|bioequivalence
339603|NCT01338623|tansulosine
339604|NCT01338610|Ocular discomfort
339605|NCT01338597|thyroidectomy
339606|NCT01338597|invasiveness
339607|NCT01338584|Pelvic floor muscle training
339608|NCT01338584|Post prostatectomy
339609|NCT01338584|Early regaining of urinary continence
339610|NCT01338584|Positive improvement in quality of life
339611|NCT01338571|stool fatty acid
339612|NCT01338532|Hip osteoarthritis
339613|NCT01338532|Exercise
339614|NCT01338532|Patient Education
339615|NCT01338532|Total Hip Replacement
339616|NCT01338506|Military
339617|NCT01338506|Posttraumatic Stress Disorder
339618|NCT01338506|PTSD
339619|NCT01338506|PostTraumatic Stress Disorders
339620|NCT01338506|Combat
339621|NCT01338506|Psychological Treatment
339622|NCT01338506|Psychotherapy
339623|NCT01338506|Trauma
339624|NCT01338506|Posttraumatic Stress
339625|NCT01338506|Prolonged Exposure
339626|NCT01338506|Exposure therapy
339627|NCT01338506|Behavior Therapy
339628|NCT01338506|Cognitive Behavior Therapy
339629|NCT01338506|Stress Disorders
339630|NCT01338506|Drug Abuse
339631|NCT01338506|Drug Dependence
339632|NCT01338506|Alcohol Abuse
339633|NCT01338506|Alcohol Dependence
339634|NCT01338506|Substance Use Disorders
339635|NCT01338506|Alcoholism
339636|NCT01338480|trauma
339637|NCT01338480|surgery
339638|NCT01338480|informed consent
339639|NCT01338467|Glaucoma
339640|NCT01338467|Refractory glaucoma
339641|NCT01338467|Cyclocoagulation
339642|NCT01338467|High Intensity Focused Ultrasound
339643|NCT01338441|Drug induced QT prolongation
339644|NCT01338428|rape
339645|NCT01338428|sexual assault
339646|NCT01338428|intervention
339647|NCT01338428|female university students
339648|NCT01338415|pediatric
339649|NCT01338415|pulmonary arterial hypertension
339650|NCT01338415|bosentan
339651|NCT01338415|Tracleer
339652|NCT01338363|acid suppressing drugs
339653|NCT01338363|pharmacoepidemiology
339654|NCT01338363|children
339655|NCT01338350|safety
339656|NCT01338350|tolerability
339657|NCT01338350|pharmacokinetics
339658|NCT01338350|pharmacodynamics
339659|NCT01338350|AZD5423
339660|NCT01338350|Japanese
339661|NCT01338337|Low risk International Prognostic Scoring System (IPSS) (0 or Int-1)
339662|NCT01338337|Patients who have not responded to previous treatment with erythropoietin (EPO)
339663|NCT01338337|Eastern Cooperative Oncology Group (ECOG) score ≤ 3
339664|NCT01338324|Biomarker
339665|NCT01338324|Pharmacokinetics
339666|NCT01338324|Villous
339667|NCT01338324|Simvastatin
339668|NCT01338324|Celiac disease
339669|NCT01338298|Schizophrenia
339670|NCT01338298|Symptomatic Hyperprolactinemia
339671|NCT01338298|Hormone
339672|NCT01338298|Menstrual
339673|NCT01338285|Industry Hygiene
339674|NCT01338285|Molecular Epidemiology
339675|NCT01338285|Cancer Susceptability
339676|NCT01338285|Genotoxocity
339677|NCT01338285|FISH
339678|NCT01338142|postmenopausal
339679|NCT01338142|women
339680|NCT01338142|absorption
339681|NCT01338142|calcium
339682|NCT01338142|amorphous calcium
339683|NCT01338129|vitamin c
339684|NCT01338129|ascorbic acid
339685|NCT01338129|ankle fracture
339686|NCT01338129|crps
339687|NCT01338129|rds
339688|NCT01338129|crps prevention
339689|NCT01338116|computerized decision support system
339690|NCT01338116|PCR
339691|NCT01338116|antibiotic treatment
339692|NCT01338103|Pemphigus
339693|NCT01338103|Rituximab
339694|NCT01338103|Cylex
339695|NCT01338090|VEGF imaging
339696|NCT01338090|neuroendocrine tumors
339697|NCT01338090|biomarker
339698|NCT01338090|mTOR inhibition
339699|NCT01338077|Alginate
339700|NCT01338077|Gastroesophageal reflux disease
339701|NCT01338064|Silicosis
339702|NCT01338051|Community based participatory research
339703|NCT01338025|HIV
339704|NCT01338025|Bridging
339705|NCT01338025|Strategy
339706|NCT01338012|metastatic castrate resistant prostate cancer
339707|NCT01338012|prostate cancer
339708|NCT01338012|prostate
339709|NCT01338012|immune therapy
339710|NCT01338012|immunotherapy
339711|NCT01338012|vaccine
339712|NCT01338012|dendritic cells
339713|NCT01338012|antigen-presenting cells
339714|NCT01338012|antigen presenting cells
339715|NCT01338012|cancer vaccine
339716|NCT01338012|PSA
339717|NCT01338012|prostatic adenocarcinoma
339718|NCT01337986|Multiple Sclerosis
339719|NCT01337986|Optic Neuritis
339720|NCT01337986|Ampyra
339721|NCT01337986|Dalfampridine
339722|NCT01337986|Fampridine
339723|NCT01337986|Remote Optic Neuritis
339724|NCT01337986|Contrast Sensitivity
339725|NCT01337986|Treatment
339726|NCT01337973|violence
339727|NCT01337973|aggression
339728|NCT01337973|Substance-Related Disorders
339729|NCT01337973|Alcohol-Related Disorders
339730|NCT01337973|Drug-Related Disorders
339731|NCT01337960|Stroke
339732|NCT01337960|Robotics
339733|NCT01337960|Neurorehabilitation
339734|NCT01337947|Type 1 diabetes
339735|NCT01337947|adolescents
339736|NCT01337947|exercise
339737|NCT01337947|vascular function
339738|NCT01337934|Septic shock
339739|NCT01337934|Sepsis
339740|NCT01337934|Albumin
339741|NCT01337934|Lactated Ringer
339742|NCT01337908|depression
339743|NCT01337908|quality of life
339744|NCT01337908|disability
339745|NCT01337895|Dairy
339746|NCT01337895|obesity
339747|NCT01337895|overweight
339748|NCT01337895|weight loss
339749|NCT01337895|adults
339750|NCT01337882|Air Pollution
339751|NCT01337882|Diesel exhaust
339752|NCT01337882|Biodiesel exhaust
339753|NCT01337882|Vascular function
339754|NCT01337882|Fibrinolysis
339755|NCT01337882|Acute vascular and endothelial responses
339756|NCT01337869|Bascom Procedure, Limberg, Pilonidal Disease
339757|NCT01337856|time-effectiveness
339758|NCT01337856|hand hygiene protocols
339759|NCT01337843|Chronic low back pain
339760|NCT01337843|cognitive behavioral pain management
339761|NCT01337843|coping
339762|NCT01337843|mindfulness
339763|NCT01337843|physical activity
339764|NCT01337843|Back Pain Lower Back Chronic
339765|NCT01337830|smoking
339766|NCT01337830|smokeless
339767|NCT01337830|aversion
339768|NCT01337830|nicotine
339769|NCT01337830|nicotine replacement
339770|NCT01337817|smoking
339771|NCT01337817|smokeless
339772|NCT01337817|aversion
339773|NCT01337817|nicotine
339774|NCT01337817|nicotine replacement
339775|NCT01337791|chronic hepatitis B
339776|NCT01337791|hepatitis B virus
339777|NCT01337791|perinatal transmission
339778|NCT01337791|Telbivudine
339779|NCT01337778|gender based violence
339780|NCT01337778|maternal and child health
339781|NCT01337778|women
339782|NCT01337778|India
339783|NCT01337765|BEZ235,
339784|NCT01337765|MEK162
339785|NCT01337765|RAS RAF mutations,
339786|NCT01337765|triple negative breast cancer
339787|NCT01337765|pancreatic cancer,
339788|NCT01337765|NSCLC progressed on EGFR TKI
339789|NCT01337765|PI3K/mTOR inhibitor,
339790|NCT01337765|MEK inhibitor
339791|NCT01337765|Advanced and selected solid tumors
339792|NCT01337752|multiple myeloma
339793|NCT01337752|renal insufficiency
339794|NCT01337752|untreated multiple myeloma
339795|NCT01337739|Hysteroscopic Surgery
339796|NCT01337739|Dexmedetomidine
339797|NCT01337739|Sedation
339798|NCT01337739|Opioids
339799|NCT01337726|Depression
339800|NCT01337726|Heart Failure
339801|NCT01337726|Chronic Obstructive Pulmonary Disease
339802|NCT01337726|Quality of Life
339803|NCT01337726|Functional Impairment
339804|NCT01337713|Anxiety, GAD, Massage
339805|NCT01337700|ASD
339806|NCT01337700|Autism
339807|NCT01337700|Autism Spectrum Disorder
339808|NCT01337700|Asperger Syndrome
339809|NCT01337700|Asperger
339810|NCT01337700|PDD
339811|NCT01337700|PDD-NOS
339812|NCT01337687|Autism
339813|NCT01337687|Autism Spectrum Disorders
339814|NCT01337687|Oxytocin
339815|NCT01337687|Hollander
339816|NCT01337687|ASD
339817|NCT01337687|Asperger Syndrome
339818|NCT01337687|Asperger
339819|NCT01337661|Chronic Obstructive Pulmonary Disease
339820|NCT01337661|COPD
339821|NCT01337661|Acute Exacerbation of COPD
339822|NCT01337661|AECOPD
339823|NCT01337648|Fecal biomarkers
339824|NCT01337648|Radiation biodosimetry
339825|NCT01337648|Total-body irradiation (TBI)
339826|NCT01337648|Hematopoietic stem cell transplantation
339827|NCT01337648|Gene expression profiles
339828|NCT01337648|Fecal metabolites
339829|NCT01337609|Depression
339830|NCT01337609|Irritable Bowel Syndrome
339831|NCT01337609|Probiotic
339832|NCT01337609|Bacillus Coagulans
339833|NCT01337596|pain
339834|NCT01337596|neuropathic pain
339835|NCT01337596|headaches
339836|NCT01337583|HIV Infections
339837|NCT01337583|Anti-HIV agents
339838|NCT01337583|HIV-1
339839|NCT01337570|HIV Infections
339840|NCT01337570|Anti-HIV agents
339841|NCT01337570|HIV-1
339842|NCT01337557|Allergic conjunctivitis
339843|NCT01337544|HAPLOIDENTICAL STEM CELL TRANSPLANTATION
339844|NCT01337544|NK CELL
339845|NCT01337544|IL-15
339846|NCT01337531|Ovarian Response in PCOS
339847|NCT01337531|pregnancy rate in PCOS
339848|NCT01337531|miscarriage rate in PCOS
339849|NCT01337518|Prostate Specific Antigen
339850|NCT01337518|Castration Resistant Prostate Cancer
339851|NCT01337518|Adenocarcinoma
339852|NCT01337518|Androgen Receptor
339853|NCT01337518|Metastases
339854|NCT01337505|INNO-206
339855|NCT01337505|Phase 1
339856|NCT01337505|DOXO-EMCH
339857|NCT01337505|Advanced solid tumors
339858|NCT01337492|Hepatocellular Carcinoma
339859|NCT01337492|Orthotopic Liver Transplant
339860|NCT01337466|Phase I
339861|NCT01337466|FIAU
339862|NCT01337466|Fialuridine
339863|NCT01337466|Biodistribution
339864|NCT01337466|Dosimetry
339865|NCT01337466|Prosthetic
339866|NCT01337466|Joint
339867|NCT01337466|Infection
339868|NCT01337466|PET-CT
339869|NCT01337453|botulinum toxin
339870|NCT01337453|flu like symptoms
339871|NCT01337453|frequency of FLS
339872|NCT01337453|Botox
339873|NCT01337440|Ursodeoxycholic Acid
339874|NCT01337440|sitagliptin
339875|NCT01337440|bile acids
339876|NCT01337440|GLP-1
339877|NCT01337427|multiple sclerosis
339878|NCT01337427|relapsing
339879|NCT01337427|MS
339880|NCT01337427|injectable
339881|NCT01337427|subcutaneous
339882|NCT01337427|SC
339883|NCT01337427|PEGylated
339884|NCT01337427|interferon
339885|NCT01337427|PEG
339886|NCT01337427|OCT
339887|NCT01337427|Optical Coherence Tomography
339888|NCT01337414|age-related macular degeneration
339889|NCT01337414|screening
339890|NCT01337414|monitoring
339891|NCT01337414|diagnosis
339892|NCT01337414|dry or non-neovascular age-related macular degeneration (high risk, intermediate, geographic atrophy or AREDS grade 3/4 AMD)
339893|NCT01337401|Cediranib
339894|NCT01337401|ASPS
339895|NCT01337401|Sarcoma
339896|NCT01337362|Diabetes
339897|NCT01337362|Hypoglycaemia
339898|NCT01337362|EEG
339899|NCT01337362|Thermography
339900|NCT01337362|Hypoglycaemia-associated autonomic failure
339901|NCT01337362|QTc interval
339902|NCT01337362|Hypoglycemic alarm device
339903|NCT01337362|Hormone response
339904|NCT01337349|Pentoxifylline
339905|NCT01337349|Chronic Congestive Heart Failure
339906|NCT01337349|Left Systolic Function
339907|NCT01337349|Biomarkers
339908|NCT01337323|allergic rhinitis, allergies, concomitant medications, allergy symptoms
339909|NCT01337310|Advanced solid tumors
339910|NCT01337297|crack cocaine
339911|NCT01337297|addiction
339912|NCT01337297|tDCS
339913|NCT01337297|ERP
339914|NCT01337297|P300
339915|NCT01337297|attention
339916|NCT01337297|inhibitory control
339917|NCT01337297|working memory
339918|NCT01337271|artificial, ventilation
339919|NCT01337271|mechanical ventilation
339920|NCT01337271|weaning
339921|NCT01337258|cost effectiveness
339922|NCT01337258|dutasteride
339923|NCT01337258|elevated risk population
339924|NCT01337258|Prostate cancer
339925|NCT01337258|prevention
339926|NCT01337245|Envenomation
339927|NCT01337245|Coral Snake
339928|NCT01337245|Antivenom
339929|NCT01337245|Micrurus fulvius
339930|NCT01337232|language development disorders
339931|NCT01337232|learning disorders
339932|NCT01337232|sentences
339933|NCT01337232|syntax
339934|NCT01337232|school-age
339935|NCT01337232|language
339936|NCT01337219|cystic fibrosis
339937|NCT01337219|bioequivalence
339938|NCT01337219|pharmacokinetic
339939|NCT01337219|sputum
339940|NCT01337219|plasma
339941|NCT01337206|Esophageal Stenosis
339942|NCT01337206|Esopageal Strictures
339943|NCT01337206|Esophageal Dysphagia
339944|NCT01337193|stress urinary incontinence
339945|NCT01337193|exercise
339946|NCT01337193|pelvic floor muscles
339947|NCT01337193|biofeedback
339948|NCT01337193|rehabilitative ultrasound imaging
339949|NCT01337180|lung function
339950|NCT01337180|respiratory symptoms
339951|NCT01337180|dust
339952|NCT01337180|inflammation
339953|NCT01337180|prospective
339954|NCT01337167|Diphtheria
339955|NCT01337167|Tetanus
339956|NCT01337167|Whooping Cough (pertussis)
339957|NCT01337167|Poliomyelitis
339958|NCT01337167|Hepatitis B infection
339959|NCT01337167|Haemophilus influenzae type b infection
339960|NCT01337154|NSCLC
339961|NCT01337154|non-small cell lung cancer
339962|NCT01337154|tamibarotene
339963|NCT01337141|Telemedicine
339964|NCT01337141|Type 1 diabetes
339965|NCT01337141|Metabolic control optimisation
339966|NCT01337141|Health care costs
339967|NCT01337141|Intervention study
339968|NCT01337141|Access to internet
339969|NCT01337115|Postoperative pain
339970|NCT01337115|Knee arthroplasty
339971|NCT01337115|Peripheral nerve blocks
339972|NCT01337115|Sciatic nerve block
339973|NCT01337115|Femoral nerve block
339974|NCT01337102|Lung Cancer
339975|NCT01337102|Stage 3b
339976|NCT01337102|Stage 4
339977|NCT01337102|First Line Chemotherapy Treatment
339978|NCT01337102|Quality Of Life
339979|NCT01337102|Palliative Care
339980|NCT01337102|Randomized
339981|NCT01337102|Lung Cancer Scale
339982|NCT01337089|cancer pain
339983|NCT01337089|opioid therapy
339984|NCT01337089|inadequate analgesia
339985|NCT01337089|optimized chronic opioid therapy
339986|NCT01337063|Adverse drug events
339987|NCT01337050|Hepatocellular Carcinoma
339988|NCT01337050|Advanced/Metastatic solid tumors
339989|NCT01337037|video-assisted thoracic surgery
339990|NCT01337037|Lung cancer
339991|NCT01337037|lobectomy
339992|NCT01337024|HRV
339993|NCT01337024|NDO
339994|NCT01337024|BoNT/A,
339995|NCT01337024|adverse effects
339996|NCT01337011|Chronic Ischemic Cardiomyopathy
339997|NCT01336998|necrotizing enterocolitis
339998|NCT01336998|arginine supplementation
339999|NCT01336998|calprotectin
340000|NCT01336985|Chemoembolization
340001|NCT01336985|Hepatic Metastases
340002|NCT01336985|Irinotecan
340003|NCT01336985|Drug Eluding Beads
340004|NCT01336985|Colorectal Cancer
340005|NCT01336985|Liver Cancer
340006|NCT01336985|Hepatic Cancer
340007|NCT01336985|Melanoma
340008|NCT01336959|Acute Kidney Injury
340009|NCT01336959|Cardiopulmonary Bypass
340010|NCT01336959|CABG
340011|NCT01336959|Cardiac Surgery
340012|NCT01336946|lifestyle
340013|NCT01336946|mental disorder
340014|NCT01336907|CNV
340015|NCT01336907|AMD
340016|NCT01336907|Wet-treated CNV
340017|NCT01336894|stage IA non-small cell lung cancer
340018|NCT01336894|stage IB non-small cell lung cancer
340019|NCT01336855|HIV
340020|NCT01336855|Observational
340021|NCT01336855|Pathogenesis
340022|NCT01336855|Immunology
340023|NCT01336855|Virology
340024|NCT01336855|Control
340025|NCT01336855|Healthy control
340026|NCT01336855|Men who have sex with men
340027|NCT01336842|panobinostat
340028|NCT01336842|cisplatin
340029|NCT01336842|pemetrexed
340030|NCT01336842|dose escalation
340031|NCT01336829|Hepatitis C
340032|NCT01336829|HIV
340033|NCT01336829|TMC125IFD1001
340034|NCT01336829|TMC125
340035|NCT01336829|Intelence
340036|NCT01336829|etravirine
340037|NCT01336829|ETR
340038|NCT01336829|TMC278
340039|NCT01336829|telaprevir
340040|NCT01336829|TVR
340041|NCT01336829|VX-950
340042|NCT01336829|healthy volunteers
340043|NCT01336829|crossover
340044|NCT01336816|smoking
340045|NCT01336816|smokeless
340046|NCT01336816|aversion
340047|NCT01336816|nicotine
340048|NCT01336816|nicotine replacement
340049|NCT01336790|Lymphatic disease
340050|NCT01336790|Lymphedema
340051|NCT01336790|Lymphangiomatosis
340052|NCT01336790|Lymphangiectasia
340053|NCT01336790|Protein-losing enteropathy
340054|NCT01336790|Vascular Anomalies
340055|NCT01336777|obesity
340056|NCT01336777|adipocyte differentiation
340057|NCT01336777|inflammation
340058|NCT01336777|insulin resistance
340059|NCT01336777|visceral fat
340060|NCT01336777|regional fat depots
340061|NCT01336764|driving distress
340062|NCT01336764|veterans
340063|NCT01336764|OEF/OIF
340064|NCT01336738|Phase 2
340065|NCT01336738|safety and efficacy study with PF-04991532
340066|NCT01336738|Type 2 diabetes
340067|NCT01336725|Morbid obesity
340068|NCT01336725|Patient education
340069|NCT01336712|CML
340070|NCT01336712|CLL
340071|NCT01336712|AML
340072|NCT01336712|ALL
340073|NCT01336712|MDS
340074|NCT01336712|HD
340075|NCT01336712|NHL
340076|NCT01336712|MFB
340077|NCT01336712|P.vera
340078|NCT01336712|Essential Thrombocytosis
340079|NCT01336699|shigellosis, vaccine, Shigella sonnei, WRSs2, WRSs3
340080|NCT01336673|Glucophage XR
340081|NCT01336673|Tolerability
340082|NCT01336660|Effectiveness
340083|NCT01336660|New Antivenom
340084|NCT01336660|North Africa and Middle East Scorpio Envenomation
340085|NCT01336634|BRAF V600E
340086|NCT01336634|trametinib
340087|NCT01336634|dabrafenib
340088|NCT01336634|GSK2118436
340089|NCT01336634|GSK1120212
340090|NCT01336634|Oncology
340091|NCT01336634|Non-Small Cell Lung Cancer
340092|NCT01336621|Partial-onset seizures
340093|NCT01336621|retigabine IR
340094|NCT01336621|Open Label Extension
340095|NCT01336621|GW582892
340096|NCT01336621|Epilepsy
340097|NCT01336595|total knee arthroplasty
340098|NCT01336595|oxidized zirconium
340099|NCT01336595|genesis II
340100|NCT01336595|femoral component
340101|NCT01336595|cobalt chrome
340102|NCT01336582|suitable candidate
340103|NCT01336582|single agent docetaxel therapy
340104|NCT01336582|Advanced Solid Tumor
340105|NCT01336569|Primary Open-Angle Glaucoma
340106|NCT01336569|Ocular Hypertension
340107|NCT01336569|Pigment Dispersion Glaucoma
340108|NCT01336569|IOP
340109|NCT01336556|Oral appliance
340110|NCT01336556|Continuous positive airway pressure
340111|NCT01336556|Obstructive Sleep Apnea Syndrome
340112|NCT01336556|Snore
340113|NCT01336543|Non small cell lung cancer
340114|NCT01336543|Inoperable Stage III
340115|NCT01336543|Inoperable
340116|NCT01336543|Stage III
340117|NCT01336530|Oesophageal pain
340118|NCT01336530|Radiotherapy
340119|NCT01336530|Combined radio-chemotherapy
340120|NCT01336530|Oesophageal symptoms
340121|NCT01336517|Stroke
340122|NCT01336517|Hemiplegia
340123|NCT01336517|AFO
340124|NCT01336517|Gait
340125|NCT01336478|NK
340126|NCT01336478|natural killer
340127|NCT01336478|immunotherapy
340128|NCT01336478|leukemia
340129|NCT01336478|hematological malignancies
340130|NCT01336478|stem cell transplantation
340131|NCT01336478|adoptive therapy
340132|NCT01336439|Bruxism
340133|NCT01336439|Polysomnography
340134|NCT01336439|Botulinum toxin type A
340135|NCT01336439|Masseter muscle
340136|NCT01336439|Temporal muscle
340137|NCT01336426|Peripheral Artery Disease
340138|NCT01336426|PAD
340139|NCT01336413|brain injuries, traumatic
340140|NCT01336413|pregnenolone
340141|NCT01336413|Veteran
340142|NCT01336413|OEF/OIF
340143|NCT01336413|neurosteroid
340144|NCT01336400|Single cell haplotyping
340145|NCT01336400|Preimplantation genetic diagnosis
340146|NCT01336361|Palliative Care
340147|NCT01336361|Physical Therapy
340148|NCT01336361|Functionally Dependent Elderly
340149|NCT01336348|Prasugrel
340150|NCT01336348|Tirofiban
340151|NCT01336348|Clopidogrel
340152|NCT01336348|glycoprotein IIa/IIIa inhibitors
340153|NCT01336348|P2Y12 blockers
340154|NCT01336335|sleep apnea, obstructive
340155|NCT01336335|sympathetic nerve activity
340156|NCT01336335|treatment
340157|NCT01336322|beta-cell function
340158|NCT01336322|insulin resistance
340159|NCT01336309|Yoga
340160|NCT01336283|COPD
340161|NCT01336283|Exercise Training
340162|NCT01336270|Melanoma
340163|NCT01336270|NK cells
340164|NCT01336270|T lymphocytes
340165|NCT01336270|macrophages
340166|NCT01336257|Decision Support Techniques
340167|NCT01336257|Electronic Health Records
340168|NCT01336257|Reminder Systems
340169|NCT01336257|Early Detection of Cancer
340170|NCT01336257|Mammography
340171|NCT01336257|Women
340172|NCT01336244|Safety
340173|NCT01336244|Tolerability
340174|NCT01336244|Pharmacokinetics
340175|NCT01336231|quality of life
340176|NCT01336231|cognitive functions
340177|NCT01336231|antiangiogenic agents
340178|NCT01336231|kidney cancer
340179|NCT01336231|metastatic
340180|NCT01336218|Phase 1
340181|NCT01336218|healthy volunteers
340182|NCT01336218|Rheumatoid arthritis
340183|NCT01336218|RA
340184|NCT01336218|Fostamatinib
340185|NCT01336218|Rifampicin
340186|NCT01336218|drug-drug interaction
340187|NCT01336218|Pharmacokinetics
340188|NCT01336218|Amount of Rifampicin in blood
340189|NCT01336205|Non-Cancer-Related Pain
340190|NCT01336205|Opioid-Induced Constipation
340191|NCT01336192|Advanced NSCLC
340192|NCT01336192|Maintenance therapy
340193|NCT01336192|Gemcitabine
340194|NCT01336179|gingivitis
340195|NCT01336179|dental plaque
340196|NCT01336179|oral hygiene
340197|NCT01336179|toothbrush
340198|NCT01336179|chewing sticks
340199|NCT01336166|H1N1
340200|NCT01336166|Vaccine
340201|NCT01336166|Immunogenicity
340202|NCT01336166|Safety
340203|NCT01336153|Safety
340204|NCT01336153|Efficacy
340205|NCT01336153|MLC601
340206|NCT01336153|motor recovery
340207|NCT01336140|regadenoson
340208|NCT01336140|chronic kidney disease
340209|NCT01336140|renal failure
340210|NCT01336140|lexiscan
340211|NCT01336140|aminophylline
340212|NCT01336140|SPECT
340213|NCT01336140|Myocardial Perfusion Imaging
340214|NCT01336140|pharmacologic stress test
340215|NCT01336140|Patients with stage IV or V chronic kidney disease being assessed with nuclear stress testing of the heart using the stress agent regadenoson (Lexiscan ®)
340216|NCT01336127|Occupational Therapy
340217|NCT01336127|Parkinson's Disease
340218|NCT01336127|Effectiveness
340219|NCT01336127|RCT
340220|NCT01336127|Activities of daily living
340221|NCT01336127|Participation
340222|NCT01336127|Caregiver's Burden
340223|NCT01336127|Economic evaluation
340224|NCT01336101|PAD
340225|NCT01336101|SFA
340226|NCT01336088|dyskinesia
340227|NCT01336088|Parkinson's disease
340228|NCT01336075|Percutaneous radiofrequency catheter ablation
340229|NCT01336075|Mini invasive thoracoscopic radiofrequency ablation
340230|NCT01336062|advanced
340231|NCT01336062|resistant to prior chemotherapy
340232|NCT01336010|Hepatitis C
340233|NCT01336010|Acute Hepatitis C
340234|NCT01336010|Early chronic Hepatitis C
340235|NCT01335997|Low-density lipoprotein
340236|NCT01335997|LDL
340237|NCT01335997|High-density lipoprotein
340238|NCT01335997|HDL
340239|NCT01335997|Niacin
340240|NCT01335997|Lipid modifying therapy
340241|NCT01335997|Cholesterol
340242|NCT01335997|High cholesterol
340243|NCT01335997|Triglycerides
340244|NCT01335984|telemonitoring
340245|NCT01335984|usual care
340246|NCT01335984|telemedicine
340247|NCT01335984|telehealth
340248|NCT01335984|home care
340249|NCT01335984|Health Care Quality
340250|NCT01335984|Access
340251|NCT01335984|Evaluation
340252|NCT01335971|COPD
340253|NCT01335971|Nrf2
340254|NCT01335971|Sulforaphane
340255|NCT01335945|Cryoablation
340256|NCT01335945|Cryotherapy
340257|NCT01335945|Cryosurgery
340258|NCT01335945|Pancreas
340259|NCT01335945|Pancreatic Cancer
340260|NCT01335945|Celiac Plexus
340261|NCT01335945|Pain
340262|NCT01335945|Abdominal pain
340263|NCT01335932|Acute Lung Injury
340264|NCT01335932|Acute Respiratory Distress Syndrome
340265|NCT01335932|Respiratory Failure
340266|NCT01335932|Cytomegalovirus seropositive
340267|NCT01335932|Infection
340268|NCT01335932|Intravenous Ganciclovir
340269|NCT01335932|Non-immunocompromised
340270|NCT01335932|Valganciclovir
340271|NCT01335919|Hemoglobin
340272|NCT01335919|Monitoring, Physiologic
340273|NCT01335919|Blood Gas Monitoring, Transcutaneous
340274|NCT01335906|Cancer Screening Tests
340275|NCT01335906|Early Diagnosis of Cancer
340276|NCT01335906|Mammography
340277|NCT01335906|Informed Consent
340278|NCT01335906|Consent Forms
340279|NCT01335893|Imaging
340280|NCT01335893|Indocyanine Green
340281|NCT01335893|Lung Cancer
340282|NCT01335893|Lung Neoplasms
340283|NCT01335893|Preliminary Study
340284|NCT01335880|Obesity
340285|NCT01335880|Heart Disease
340286|NCT01335880|Seniors
340287|NCT01335880|Elderly
340288|NCT01335880|Chronic Disease
340289|NCT01335880|Prevention
340290|NCT01335854|Apnea-hypopnea index
340291|NCT01335854|Continuous positive airway pressure
340292|NCT01335854|CPAP adherence
340293|NCT01335828|Echography
340294|NCT01335828|Elastography
340295|NCT01335828|Thyroid nodules
340296|NCT01335828|Needles punction
340297|NCT01335828|Thyroid surgery
340298|NCT01335828|Patients with thyroids nodules
340299|NCT01335802|Abortion, Spontaneous
340300|NCT01335802|Pre-eclampsia
340301|NCT01335802|Gestational hypertension
340302|NCT01335802|Pregnancy Complications
340303|NCT01335802|Subclinical hypothyroidism
340304|NCT01335802|Thyroperoxidase antibodies (TPOab)
340305|NCT01335802|Mitochondrial dysfunction
340306|NCT01335789|marijuana
340307|NCT01335789|substance abuse
340308|NCT01335789|drug abuse
340309|NCT01335789|marijuana dependence
340310|NCT01335789|drug addiction
340311|NCT01335776|Mindfulness-Based Stress Reduction
340312|NCT01335776|Cognitive Behavior Therapy
340313|NCT01335776|Actigraphy
340314|NCT01335776|Noninferiority
340315|NCT01335776|MBSR
340316|NCT01335776|CBT-I
340317|NCT01335763|HbA1c
340318|NCT01335763|Multicentre before-after design
340319|NCT01335763|Glycemic control
340320|NCT01335763|Community pharmacists
340321|NCT01335750|corneal staining
340322|NCT01335698|Pediatric
340323|NCT01335672|Myocardial infarction
340324|NCT01335672|chronic obstructive pulmonary disease
340325|NCT01335672|General Practice Research Database
340326|NCT01335672|Myocardial Ischaemia National Audit Project
340327|NCT01335672|CALIBER
340328|NCT01335659|FFR
340329|NCT01335659|IVUS
340330|NCT01335659|QCA
340331|NCT01335633|MS
340332|NCT01335633|Neuropsychological tests
340333|NCT01335607|HCV
340334|NCT01335607|Hepatitis C Virus
340335|NCT01335594|Sleep apnea, obstructive
340336|NCT01335594|Deglutition Disorders
340337|NCT01335594|Manometry
340338|NCT01335594|Endoscopy
340339|NCT01335568|Hepatocyte
340340|NCT01335568|Scaffold
340341|NCT01335568|Matrix
340342|NCT01335568|Liver cirrhosis
340343|NCT01335568|Liver insufficiency
340344|NCT01335529|HCV infection
340345|NCT01335529|HIV-1 infection
340346|NCT01335503|gluten
340347|NCT01335451|AZD5213
340348|NCT01335451|safety
340349|NCT01335451|pharmacokinetics
340350|NCT01335451|single dose
340351|NCT01335451|repeated dose
340352|NCT01335451|young
340353|NCT01335451|elderly
340354|NCT01335451|Japanese
340355|NCT01335451|healthy subject
340356|NCT01335438|total knee arthroplasty
340357|NCT01335438|cemented
340358|NCT01335438|cementless
340359|NCT01335438|fixation
340360|NCT01335438|posterior stabilized
340361|NCT01335438|cruciate retaining
340362|NCT01335425|Language problems
340363|NCT01335425|childhood epilepsy
340364|NCT01335425|bening (rolandic) epilepsy (of childhood) with centro temporal spikes
340365|NCT01335425|brain maturation
340366|NCT01335425|structral connectivity
340367|NCT01335425|functional connectivity
340368|NCT01335399|Newly Diagnosed
340369|NCT01335399|Previously Untreated
340370|NCT01335373|Vaginal candidiasis
340371|NCT01335373|Bacterial vaginosis (also known as non-specific, or Gardnerellosis, or anaerobic vaginosis)
340372|NCT01335373|Trichomonal vaginitis
340373|NCT01335373|Vaginitis due to mixed infection
340374|NCT01335360|nevirapine
340375|NCT01335360|pharmacokinetics
340376|NCT01335347|Influenza
340377|NCT01335347|pandemic
340378|NCT01335347|avian influenza
340379|NCT01335347|H5N1
340380|NCT01335347|flu
340381|NCT01335334|Effectiveness
340382|NCT01335334|eradication
340383|NCT01335334|Asymptomatic
340384|NCT01335321|viscosupplementation
340385|NCT01335321|intra-articular injection
340386|NCT01335321|hyaluronic acid
340387|NCT01335321|osteoarthritis
340388|NCT01335321|knee
340389|NCT01335308|Pediatric Obesity
340390|NCT01335308|Motivational Interviewing
340391|NCT01335308|Overweight
340392|NCT01335308|Behavior Change
340393|NCT01335295|Flavocoxid
340394|NCT01335295|Duchenne muscular dystrophy
340395|NCT01335295|pilot study
340396|NCT01335256|Phase I, dose escalation, kinase inhibitor, cyclin-dependent kinase inhibitor, target therapy, small molecule
340397|NCT01335243|Orthopedic Procedures
340398|NCT01335243|Spine
340399|NCT01335243|Interbody fusion
340400|NCT01335243|Arthrodesis
340401|NCT01335243|Lumbar Vertebrae
340402|NCT01335243|CT Scan
340403|NCT01335243|Spine balance
340404|NCT01335243|Instrumented fusion
340405|NCT01335243|Posterior fusion
340406|NCT01335243|Degenerative spine
340407|NCT01335243|painful
340408|NCT01335230|HIV
340409|NCT01335230|HCV
340410|NCT01335230|Hepatitis C
340411|NCT01335230|HIV and Hepatitis C coinfection
340412|NCT01335230|HIV/HCV
340413|NCT01335217|Depression
340414|NCT01335217|Major Depressive Disorder (MDD)
340415|NCT01335217|Trigeminal Nerve Stimulation
340416|NCT01335217|Post Traumatic Stress Disorder
340417|NCT01335204|Castration-resistant prostate cancer
340418|NCT01335204|Prostate Cancer
340419|NCT01335204|JEVTANA
340420|NCT01335204|Cabazitaxel
340421|NCT01335204|Bavituximab
340422|NCT01335191|HIV
340423|NCT01335191|vaccine
340424|NCT01335191|lipopeptide
340425|NCT01335191|Tat
340426|NCT01335191|TUTI-16
340427|NCT01335191|THYMON
340428|NCT01335178|Tobacco smoke exposure
340429|NCT01335178|Secondhand smoke exposure
340430|NCT01335178|Passive smoking
340431|NCT01335178|Child health
340432|NCT01335178|Prevention
340433|NCT01335178|Tobacco control
340434|NCT01335178|Motivational Interviewing
340435|NCT01335178|Air quality
340436|NCT01335178|Pilot Study
340437|NCT01335165|PNH
340438|NCT01335152|stress
340439|NCT01335152|depression
340440|NCT01335152|anxiety
340441|NCT01335152|web
340442|NCT01335152|internet
340443|NCT01335152|coping
340444|NCT01335139|sublingual immunotherapy
340445|NCT01335139|subcutaneous immunotherapy
340446|NCT01335126|Artificial tears
340447|NCT01335100|Functional outcome
340448|NCT01335100|Quality of life
340449|NCT01335100|Global Positioning System (GPS)
340450|NCT01335100|Advanced tracking technologies
340451|NCT01335100|Time-space activity.
340452|NCT01335100|walking speed
340453|NCT01335100|distances
340454|NCT01335100|number of walking events and destinations
340455|NCT01335087|sleep apnea
340456|NCT01335087|secondary prevention
340457|NCT01335087|cardiovascular endpoint
340458|NCT01335061|Hemophilia B
340459|NCT01335061|on-demand
340460|NCT01335061|prophylaxis
340461|NCT01335061|nonacog alfa
340462|NCT01335061|BeneFIX
340463|NCT01335061|FIX
340464|NCT01335048|Clopidogrel
340465|NCT01335048|Statins
340466|NCT01335048|Platelet reactivity
340467|NCT01335048|Point-of-care platelet function test
340468|NCT01335035|Iron metabolism,
340469|NCT01335035|Allogenetic Hematopoietic Stem Cell Transplant,
340470|NCT01335035|haematological diseases
340471|NCT01335009|melanoma
340472|NCT01335009|malignant
340473|NCT01335009|metastatic
340474|NCT01334983|cancer
340475|NCT01334983|function
340476|NCT01334983|fatigue
340477|NCT01334983|late stage
340478|NCT01334983|metastases
340479|NCT01334983|quality of life
340480|NCT01334983|functional decline in cancer
340481|NCT01334944|Pain
340482|NCT01334944|Fever
340483|NCT01334931|Exposure to Ionizing Radiation
340484|NCT01334931|Occupational Exposure to Radiation
340485|NCT01334918|Coronary Artery Disease (CAD)
340486|NCT01334918|ischemia
340487|NCT01334918|pharmacologic stress
340488|NCT01334918|regadenoson
340489|NCT01334905|Overactive Bladder
340490|NCT01334905|Urinary incontinence
340491|NCT01334905|YM178
340492|NCT01334905|mirabegron
340493|NCT01334905|Food effect
340494|NCT01334879|radiation
340495|NCT01334879|retinopathy
340496|NCT01334879|anti-VEGF
340497|NCT01334879|eye
340498|NCT01334866|Minimally invasive coronary surgery
340499|NCT01334866|Coronary artery bypass grafting
340500|NCT01334866|MICS CABG
340501|NCT01334840|Cardiovascular risk
340502|NCT01334840|Cholecystokinin
340503|NCT01334840|Gallbladder emptying
340504|NCT01334840|Lipid absorption
340505|NCT01334840|Postprandial triacylglycerols
340506|NCT01334840|Sodium-bicarbonated mineral water
340507|NCT01334827|topical microbicide
340508|NCT01334827|primary prevention
340509|NCT01334827|HIV
340510|NCT01334827|AIDS
340511|NCT01334827|drug delivery systems
340512|NCT01334801|aortic stenosis
340513|NCT01334801|von Willebrand factor
340514|NCT01334801|mitral valve replacement
340515|NCT01334801|aortic valve replacement
340516|NCT01334801|prosthetic valve dysfunction
340517|NCT01334801|brain natriuretic peptide
340518|NCT01334801|mitral valve regurgitation
340519|NCT01334801|aortic valve regurgitation
340520|NCT01334801|hypertrophic cardiomyopathy
340521|NCT01334801|tricuspid insufficiency
340522|NCT01334788|sleep deprivation
340523|NCT01334788|sleep restriction
340524|NCT01334775|Inguinal hernia
340525|NCT01334775|Postoperative pain
340526|NCT01334775|Surgical mesh
340527|NCT01334762|minimal to mild endometriosis
340528|NCT01334762|letrozole
340529|NCT01334762|clomiphene citrate
340530|NCT01334762|IUI
340531|NCT01334749|Stroke
340532|NCT01334749|Dementia
340533|NCT01334749|Dementia, Vascular
340534|NCT01334749|Alzheimer's Disease
340535|NCT01334749|Intracranial Hemorrhage
340536|NCT01334749|Brain Ischemia
340537|NCT01334736|smoking cessation
340538|NCT01334736|contingency management
340539|NCT01334736|spirometry
340540|NCT01334736|lung age
340541|NCT01334723|Benign prostatic hyperplasia, enlarged prostate, 5-alpha-reductase inhibitor, adherence, surgery, acute urinary retention
340542|NCT01334710|Liver cancer
340543|NCT01334697|Cardiotrophin-1
340544|NCT01334697|CT-1
340545|NCT01334684|Type 2 Diabetes Mellitus
340546|NCT01334684|Metformin Efficacy
340547|NCT01334684|Gene Expression Profiles
340548|NCT01334684|Personalized Medicine
340549|NCT01334671|ST-elevation myocardial infarction(STEMI)
340550|NCT01334671|emergency percutaneous coronary intervention(PCI)
340551|NCT01334671|lipitor or Atorvastatin
340552|NCT01334658|Corneal endothelium
340553|NCT01334658|Cataract surgery
340554|NCT01334658|Irrigation solutions intraocular
340555|NCT01334658|Phacoemulsification
340556|NCT01334645|Copeptin
340557|NCT01334645|Troponin
340558|NCT01334645|Diagnosis
340559|NCT01334645|Chest pain
340560|NCT01334645|Acute Coronary Syndrome
340561|NCT01334645|Acute Myocardial Infarction
340562|NCT01334645|Unstable Angina
340563|NCT01334632|Electrophysiological study
340564|NCT01334632|Nerve block
340565|NCT01334632|Analgesia, patient-controlled
340566|NCT01334632|Shoulder surgery
340567|NCT01334619|Anesthetic techniques,regional
340568|NCT01334619|Drug delivery,volume
340569|NCT01334619|Anesthetic, local: ropivacaine
340570|NCT01334606|diabetes
340571|NCT01334606|pen needle
340572|NCT01334606|basal insulin
340573|NCT01334606|long-acting insulin
340574|NCT01334554|African American
340575|NCT01334554|Women
340576|NCT01334554|Metabolic Syndrome
340577|NCT01334554|Endothelial function
340578|NCT01334554|Sildenafil citrate
340579|NCT01334528|Deployment Acquired Mild Traumatic Brain Injury
340580|NCT01334528|Persistent Post-Concussive Symptoms
340581|NCT01334528|Repeated measures
340582|NCT01334502|contiguous stage II adult diffuse large cell lymphoma
340583|NCT01334502|noncontiguous stage II adult diffuse large cell lymphoma
340584|NCT01334502|stage III adult diffuse large cell lymphoma
340585|NCT01334502|stage IV adult diffuse large cell lymphoma
340586|NCT01334489|Monochorionic pregnancy
340587|NCT01334489|Twin to twin transfusion syndrome
340588|NCT01334489|Cervical pessary
340589|NCT01334489|Cervical lenght
340590|NCT01334476|Data Repository
340591|NCT01334476|Facilitate Recruitment of Participants for Ongoing and Future Research
340592|NCT01334450|Improvement of ADAS-COG
340593|NCT01334437|blood test
340594|NCT01334437|ovarian cancer
340595|NCT01334437|Associated Auto Antibodies
340596|NCT01334424|Robot assisted laparoscopic radical prostatectomy
340597|NCT01334424|Hypoperfusion reperfusion injury,
340598|NCT01334424|Propofol
340599|NCT01334424|oxidative stress
340600|NCT01334398|Traumatic Brain Injury
340601|NCT01334372|suicide
340602|NCT01334372|veterans
340603|NCT01334372|assessment
340604|NCT01334372|CAMS
340605|NCT01334359|physical activity
340606|NCT01334359|fitness
340607|NCT01334359|brain health
340608|NCT01334359|cognition
340609|NCT01334359|scholastic achievement
340610|NCT01334359|preadolescent children
340611|NCT01334346|Running
340612|NCT01334346|Footwear
340613|NCT01334346|Injury incidence
340614|NCT01334346|injury risk
340615|NCT01334346|pain
340616|NCT01334333|kidney transplant
340617|NCT01334333|tacrolimus
340618|NCT01334333|medication adherence
340619|NCT01334333|depression
340620|NCT01334333|neuropsychological
340621|NCT01334333|cognition
340622|NCT01334333|Self-efficacy
340623|NCT01334333|everyday problem solving
340624|NCT01334320|oral squamous cell carcinoma
340625|NCT01334320|elective neck dissection
340626|NCT01334320|"watchful waiting"
340627|NCT01334320|survival benefit
340628|NCT01334320|recurrence rate
340629|NCT01334307|Emphysema
340630|NCT01334307|RePneu
340631|NCT01334294|CNV
340632|NCT01334294|AMD
340633|NCT01334281|Panel Reactive Antibody (PRA)
340634|NCT01334281|Sensitization
340635|NCT01334281|Organ Transplant
340636|NCT01334268|In-stent Late Lumen Loss (LLL)
340637|NCT01334268|TARGET VESSEL FAILURE (TVF)
340638|NCT01334268|MYOCARDIAL INFARCTION (MI)
340639|NCT01334268|TARGET VESSEL REVASCULARIZATION (TVR)
340640|NCT01334268|TARGET LESION REVASCULARIZATION (TLR)
340641|NCT01334268|TARGET LESION FAILURE (TLF)
340642|NCT01334268|STENT THROMBOSIS
340643|NCT01334268|RESTENOTIC LESION
340644|NCT01334268|PERCUTANEOUS CORONARY INTERVENTION (PCI)
340645|NCT01334268|REAL-WORLD
340646|NCT01334268|THE RANDOMIZED CONTROLLED TRIAL
340647|NCT01334255|Pigment epithelial detachment
340648|NCT01334255|Exudative age-related macular degeneration
340649|NCT01334255|Polypoidal choroidal vasculopathy
340650|NCT01334242|Pharmacodynamics
340651|NCT01334229|sitagliptin
340652|NCT01334229|diabetes
340653|NCT01334229|apolipoprotein B48 and B100
340654|NCT01334216|smoking
340655|NCT01334216|quitting
340656|NCT01334216|tobacco
340657|NCT01334216|Parental
340658|NCT01334203|Chronic angina
340659|NCT01334203|Angina pectoris
340660|NCT01334203|Coronary artery disease
340661|NCT01334203|Type 2 Diabetes Mellitus
340662|NCT01334203|ETT
340663|NCT01334190|AE adverse event
340664|NCT01334190|AIDS acquired immunodeficiency syndrome
340665|NCT01334190|ALT (SGPT) alanine aminotransferase
340666|NCT01334190|ART antiretroviral therapy
340667|NCT01334190|AST (SGOT) aspartate aminotransferase
340668|NCT01334190|DCF data collection forms
340669|NCT01334190|DMC Data Monitoring Committee
340670|NCT01334190|FDA (U.S.) Food and Drug Administration
340671|NCT01334190|GCP Good Clinical Practice guidelines
340672|NCT01334190|HB sAg Hepatitis B surface antigen
340673|NCT01334190|ICH International Conference of Harmonisation
340674|NCT01334190|IND Investigational New Drug Application
340675|NCT01334190|IRB Institutional Review Board
340676|NCT01334190|IU international units
340677|NCT01334190|mg milligram(s)
340678|NCT01334190|mm3 cubic millimeter(s)
340679|NCT01334190|PCR polymerase chain reaction
340680|NCT01334190|SAE serious adverse event
340681|NCT01334190|µg microgram
340682|NCT01334190|ULN upper limit of the normal range
340683|NCT01334190|WB Western Blot
340684|NCT01334190|post-marketing monitoring
340685|NCT01334190|safety
340686|NCT01334190|efficacy
340687|NCT01334190|acceptability
340688|NCT01334164|substance use disorder
340689|NCT01334164|offenders
340690|NCT01334164|reentry
340691|NCT01334164|HIV risk behavior
340692|NCT01334164|recidivism
340693|NCT01334138|hypertension
340694|NCT01334138|sodium
340695|NCT01334138|diet
340696|NCT01334125|Double Diabetes
340697|NCT01334125|Type 1 diabetes
340698|NCT01334125|Type 2 diabetes
340699|NCT01334125|Obesity
340700|NCT01334125|Acanthosis nigricans
340701|NCT01334125|Diabetes associated autoantibodies
340702|NCT01334112|Hepatocellular Carcinoma
340703|NCT01334112|Advanced Hepatocellular Carcinoma
340704|NCT01334112|Liver Cancer
340705|NCT01334112|Axitinib
340706|NCT01334112|AG-013736
340707|NCT01334086|AML
340708|NCT01334073|Phase I
340709|NCT01334073|Axitinib
340710|NCT01334073|Everolimus
340711|NCT01334073|Maximum tolerated dose (MTD)
340712|NCT01334073|solid tumor
340713|NCT01334073|Renal cell cancer (RCC)
340714|NCT01334073|Pharmacokinetics (PK/PD)
340715|NCT01334021|Genomic Testing
340716|NCT01334021|Genetic Testing
340717|NCT01334021|HER2 Negative
340718|NCT01334021|Primary Invasive Breast Cancer
340719|NCT01334021|Stage I
340720|NCT01334021|Stage II
340721|NCT01334021|Stage III
340722|NCT01334021|Registry
340723|NCT01334021|Biopsy
340724|NCT01334021|Tumor sampling
340725|NCT01334008|Circulating tumor DNA
340726|NCT01334008|Choroidal Melanoma
340727|NCT01333995|Peer counselling
340728|NCT01333995|Infant
340729|NCT01333995|Intervention
340730|NCT01333995|breastfeeding
340731|NCT01333995|complementary feeding
340732|NCT01333995|stunting
340733|NCT01333982|Neonatal Sepsis
340734|NCT01333982|Evaluation
340735|NCT01333982|Bangladesh
340736|NCT01333982|Drying
340737|NCT01333982|Wrapping
340738|NCT01333982|Bathing
340739|NCT01333943|Total Knee Replacement
340740|NCT01333943|Regional Anesthesia
340741|NCT01333943|Quadriceps
340742|NCT01333943|Muscle Strength
340743|NCT01333943|Muscle Strength Dynamometer
340744|NCT01333943|Quadriceps muscle strength after regional anesthesia for TKA
340745|NCT01333930|immunological effects
340746|NCT01333930|Active O2
340747|NCT01333930|strenuous exercise
340748|NCT01333930|procedures
340749|NCT01333930|pharmacodynamic parameters
340750|NCT01333930|blood sampling scheme
340751|NCT01333917|Curcumin
340752|NCT01333917|Colorectal Cancer
340753|NCT01333917|GWAS
340754|NCT01333865|Memantine
340755|NCT01333865|Namenda
340756|NCT01333865|Autism Spectrum Disorders
340757|NCT01333865|Pervasive Developmental Disorders
340758|NCT01333865|Adults
340759|NCT01333852|head and neck cancer
340760|NCT01333852|paclitaxel
340761|NCT01333852|metformin
340762|NCT01333852|squamous cell carcinoma
340763|NCT01333839|CABG surgery
340764|NCT01333839|exercise intervention
340765|NCT01333839|insulin sensitivity
340766|NCT01333839|muscle mass
340767|NCT01333813|immune response
340768|NCT01333813|Engerix-B™Kinder
340769|NCT01333813|Persistence
340770|NCT01333813|challenge dose
340771|NCT01333787|dietary fiber
340772|NCT01333787|clinical trial
340773|NCT01333787|constipation
340774|NCT01333787|children
340775|NCT01333774|Diabetes
340776|NCT01333774|Acarbose
340777|NCT01333774|Diet
340778|NCT01333774|Compliance
340779|NCT01333774|Advising
340780|NCT01333761|right to left cardiac shunt finding
340781|NCT01333748|breast cancer
340782|NCT01333748|ovarian cancer
340783|NCT01333748|BRCA 1 and BRCA 2
340784|NCT01333735|cognitive functions
340785|NCT01333735|quality of life
340786|NCT01333735|breast cancer
340787|NCT01333735|chemotherapy
340788|NCT01333735|ages patients
340789|NCT01333709|locally advanced rectal carcinoma
340790|NCT01333709|Tailored treatment strategy
340791|NCT01333709|MRI volumetry
340792|NCT01333709|Early tumor response
340793|NCT01333696|Squamous cell carcinoma of head and neck
340794|NCT01333696|Pemetrexed
340795|NCT01333683|tinnitus
340796|NCT01333683|hearing loss
340797|NCT01333683|arterial hypertension
340798|NCT01333683|ototoxicity
340799|NCT01333657|sTREM-1
340800|NCT01333657|sepsis
340801|NCT01333657|SIRS
340802|NCT01333657|blood
340803|NCT01333657|urine
340804|NCT01333657|diagnosis
340805|NCT01333657|prognosis
340806|NCT01333644|HIV Infection
340807|NCT01333644|Endothelial function
340808|NCT01333644|Cardiovascular Disease
340809|NCT01333644|Inflammation
340810|NCT01333644|Antiretroviral medication
340811|NCT01333644|Treatment naive
340812|NCT01333644|Treatment experienced
340813|NCT01333631|Locally advanced unresectable pancreatic cancer
340814|NCT01333618|Filter Tilt
340815|NCT01333618|Preventional efficiency
340816|NCT01333618|Günther Tulip filter
340817|NCT01333618|Transfemoral Approach
340818|NCT01333605|Hodgkin lymphoma
340819|NCT01333605|Chemotherapy
340820|NCT01333605|IGEV
340821|NCT01333605|Autologous stem cell transplantation
340822|NCT01333592|Type 2 diabetes
340823|NCT01333592|HbA1c
340824|NCT01333592|Long-term study
340825|NCT01333553|birthmark
340826|NCT01333540|constipation
340827|NCT01333540|opioid induced
340828|NCT01333514|diabetes
340829|NCT01333514|prandial
340830|NCT01333514|insulin
340831|NCT01333514|aspart
340832|NCT01333514|carbohydrate
340833|NCT01333514|inpatient
340834|NCT01333514|novolog
340835|NCT01333501|Multiple sclerosis
340836|NCT01333501|cognitive symptoms
340837|NCT01333501|relapsing-remitting multiple sclerosis (RRMS)
340838|NCT01333501|fingolimod
340839|NCT01333501|Magnetic resonance imaging (MRI)
340840|NCT01333488|Traumatic
340841|NCT01333488|Brain
340842|NCT01333488|Injury
340843|NCT01333475|Targeted Therapy
340844|NCT01333475|KRAS Mutation
340845|NCT01333475|Metastatic Colorectal Cancer
340846|NCT01333475|Colorectal Cancer
340847|NCT01333449|Decitabine
340848|NCT01333449|MDS, myelodysplastic syndrome
340849|NCT01333449|prospective open label, phaseII
340850|NCT01333449|Allogeneic Hematopoietic cell transplant
340851|NCT01333423|Breast Cancer
340852|NCT01333423|Metastatic Triple Negative
340853|NCT01333423|ER/PR/HER2 negative
340854|NCT01333423|Locally advanced
340855|NCT01333423|Stage IV
340856|NCT01333423|Metastatic
340857|NCT01333423|Seliciclib
340858|NCT01333423|Liposomal Doxorubicin
340859|NCT01333423|Doxil
340860|NCT01333423|Doxorubicin Hydrochloride (Liposomal)
340861|NCT01333410|vitiligo
340862|NCT01333410|tacrolimus
340863|NCT01333410|mometasone furoate
340864|NCT01333371|Distal Radius
340865|NCT01333371|Volar locked plating
340866|NCT01333371|Cost Effectiveness
340867|NCT01333371|Randomization
340868|NCT01333371|Outcomes
340869|NCT01333358|Relapsing
340870|NCT01333358|remitting
340871|NCT01333345|Cataract replacement surgery
340872|NCT01333345|implantation
340873|NCT01333345|EC-3 IOL
340874|NCT01333332|Pancreas
340875|NCT01333332|Radiation
340876|NCT01333319|liver transplantation
340877|NCT01333319|acute kidney injury
340878|NCT01333306|tDCS
340879|NCT01333306|cognitive training
340880|NCT01333293|mastocytosis
340881|NCT01333293|omalizumab
340882|NCT01333267|Endocrine System Diseases
340883|NCT01333267|MusculoSkeletal System Disease
340884|NCT01333267|Hormones
340885|NCT01333267|Postmenopausal Women
340886|NCT01333267|Bone metabolism
340887|NCT01333267|Physiologic Properties
340888|NCT01333267|African-Americans
340889|NCT01333254|urinary tract infections
340890|NCT01333254|urinary catheterisation
340891|NCT01333241|Hispanic Americans
340892|NCT01333241|Cardiovascular disease
340893|NCT01333241|Obesity
340894|NCT01333241|Intervention
340895|NCT01333215|Suicide, Attempted
340896|NCT01333215|Cognitive Symptoms
340897|NCT01333202|Fresh lime
340898|NCT01333202|nicotine gum
340899|NCT01333202|smoking cessation
340900|NCT01333202|craving
340901|NCT01333189|total knee arthroplasty
340902|NCT01333189|osteoarthritis
340903|NCT01333189|biomechanics
340904|NCT01333189|gait
340905|NCT01333176|Type 2 Diabetes
340906|NCT01333176|Hb A1c screening for diabetes in aboriginals
340907|NCT01333150|Temporomandibular disorders
340908|NCT01333150|Orofacial pain
340909|NCT01333137|Triple negative breast cancer
340910|NCT01333124|Preoperative chemoradiotherapy with Gemcitabine
340911|NCT01333098|anxiety
340912|NCT01333098|older adult
340913|NCT01333098|memory
340914|NCT01333098|cognitive
340915|NCT01333098|Saint Louis
340916|NCT01333098|treatment
340917|NCT01333098|Non-dementia cognitive impairment in older adults with anxiety disorders.
340918|NCT01333085|stage IV squamous cell carcinoma of the hypopharynx
340919|NCT01333085|stage IV squamous cell carcinoma of the larynx
340920|NCT01333085|stage IV verrucous carcinoma of the larynx
340921|NCT01333085|stage IV squamous cell carcinoma of the lip and oral cavity
340922|NCT01333085|stage IV verrucous carcinoma of the oral cavity
340923|NCT01333085|stage IV squamous cell carcinoma of the oropharynx
340924|NCT01333085|tongue cancer
340925|NCT01333072|Autistic Disorder
340926|NCT01333059|Sedation
340927|NCT01333059|Cycling
340928|NCT01333059|Pediatric
340929|NCT01333046|Hodgkin Lymphoma
340930|NCT01333046|Non-Hodgkin Lymphoma
340931|NCT01333046|CTL
340932|NCT01333033|adenocarcinoma of the gastroesophageal junction
340933|NCT01333033|adenocarcinoma of the esophagus
340934|NCT01333033|stage IB esophageal cancer
340935|NCT01333033|stage IIA esophageal cancer
340936|NCT01333033|stage IIB esophageal cancer
340937|NCT01333033|stage IIIA esophageal cancer
340938|NCT01333033|stage IIIB esophageal cancer
340939|NCT01333033|stage IIIC esophageal cancer
340940|NCT01333020|emulsion
340941|NCT01333020|protein
340942|NCT01333020|cross-linking
340943|NCT01333020|gastric emptying
340944|NCT01332955|Hepatitis C, Chronic
340945|NCT01332955|HIV Infection
340946|NCT01332955|Telaprevir
340947|NCT01332955|Peginterferon alfa-2a
340948|NCT01332955|Ribavirin
340949|NCT01332955|Pharmacokinetic
340950|NCT01332955|Pharmacogenetic
340951|NCT01332955|Previous peginterferon-ribavirin regimen failure
340952|NCT01332942|Anemia
340953|NCT01332929|brain radiation therapy
340954|NCT01332929|Bevacizumab
340955|NCT01332929|brain metastasis
340956|NCT01332929|solid tumor
340957|NCT01332916|No metastatic breast cancer
340958|NCT01332916|cognitive troubles
340959|NCT01332916|adjuvant chemotherapy
340960|NCT01332890|Drug interaction
340961|NCT01332890|revaprazan
340962|NCT01332890|Itopride HCI
340963|NCT01332877|Obesity
340964|NCT01332877|Weight loss
340965|NCT01332877|Ghrelin
340966|NCT01332877|Satiety
340967|NCT01332877|Hunger
340968|NCT01332864|headache
340969|NCT01332864|migraine
340970|NCT01332864|cephalgia
340971|NCT01332864|osteopathic manipulative treatment
340972|NCT01332851|child welfare
340973|NCT01332851|child protective services
340974|NCT01332851|child abuse
340975|NCT01332851|child neglect
340976|NCT01332851|infant
340977|NCT01332851|parenting
340978|NCT01332825|olfaction
340979|NCT01332825|smell dysfunction
340980|NCT01332812|Dexamethasone
340981|NCT01332812|Postoperative cognitive dysfunction
340982|NCT01332812|General Anesthesia
340983|NCT01332812|neuropsychological tests
340984|NCT01332799|cardiovascular disease
340985|NCT01332799|kidney transplantation
340986|NCT01332786|AML
340987|NCT01332760|ergonomics
340988|NCT01332760|workplace
340989|NCT01332760|occupational
340990|NCT01332760|tool
340991|NCT01332760|dental
340992|NCT01332760|dentist
340993|NCT01332747|TC
340994|NCT01332747|TG
340995|NCT01332747|HDL
340996|NCT01332747|LDL
340997|NCT01332747|VLDL
340998|NCT01332734|microcirculation
340999|NCT01332734|SDF
341000|NCT01332734|magnesium sulfate
341001|NCT01332721|TRC105
341002|NCT01332721|CD105
341003|NCT01332721|Endoglin
341004|NCT01332721|Solid Tumors
341005|NCT01332721|Avastin
341006|NCT01332721|Bevacizumab
341007|NCT01332708|high complex carbohydrates
341008|NCT01332708|hypocaloric diet
341009|NCT01332708|cholinergic status
341010|NCT01332708|overweight
341011|NCT01332708|obese
341012|NCT01332695|tremor
341013|NCT01332695|WHIGET
341014|NCT01332695|Fahn Tolosa Marin Scale
341015|NCT01332682|head and neck cancer
341016|NCT01332682|resistance training
341017|NCT01332682|nutrition counseling
341018|NCT01332682|pharyngeal or laryngeal cancer
341019|NCT01332669|hepatocellular carcinoma
341020|NCT01332669|chemoembolization
341021|NCT01332669|drug eluting beads
341022|NCT01332669|HCC
341023|NCT01332669|Liver cancer
341024|NCT01332669|Korea
341025|NCT01332643|Preimplantation Genetic Diagnosis
341026|NCT01332643|recurrent pregnancy loss
341027|NCT01332643|infertility
341028|NCT01332643|genetic screening
341029|NCT01332643|trisomy 21
341030|NCT01332643|Down syndrome
341031|NCT01332630|Breast cancer
341032|NCT01332630|Brain metastases
341033|NCT01332630|TPI 287
341034|NCT01332630|Computed Tomography
341035|NCT01332630|CT
341036|NCT01332630|Magnetic Resonance Imaging
341037|NCT01332630|MRI
341038|NCT01332617|Multiple Myeloma
341039|NCT01332617|Simvastatin
341040|NCT01332617|Zoledronic
341041|NCT01332617|Bortezomib
341042|NCT01332617|Bendamustine
341043|NCT01332617|Methylprednisolone
341044|NCT01332591|STEMI, primary PCI, non-infarct, non-culprit lesion, CABG
341045|NCT01332565|GSK1349572
341046|NCT01332565|pharmacokinetics
341047|NCT01332565|Japanese
341048|NCT01332565|HIV
341049|NCT01332552|pharmacokinetics
341050|NCT01332552|First administration to human
341051|NCT01332552|antiviral activity
341052|NCT01332552|safety
341053|NCT01332552|hepatitis C
341054|NCT01332526|FFT
341055|NCT01332526|inflammation
341056|NCT01332526|lipid metabolism
341057|NCT01332526|hyperuricemia
341058|NCT01332526|Agents Affecting Uric Acid Metabolism
341059|NCT01332513|Healthy Volunteers
341060|NCT01332500|Triptans
341061|NCT01332500|Migraine
341062|NCT01332487|5-alpha-reductase inhibitor
341063|NCT01332487|prostate surgery
341064|NCT01332487|alpha-blocker
341065|NCT01332487|enlarged prostate
341066|NCT01332487|acute urinary retention
341067|NCT01332487|Benign prostatic hyperplasia
341068|NCT01332474|Botox
341069|NCT01332474|JCP
341070|NCT01332448|Xenical
341071|NCT01332448|Alli
341072|NCT01332448|safety
341073|NCT01332448|meta-analysis
341074|NCT01332448|liver-function test
341075|NCT01332448|Roche
341076|NCT01332448|orlistat
341077|NCT01332435|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, early, costs
341078|NCT01332370|Retrospective
341079|NCT01332370|Type 2 Diabetes
341080|NCT01332370|Cost Analysis
341081|NCT01332370|Rosiglitazone
341082|NCT01332370|Sitagliptin
341083|NCT01332357|fluticasone/propionate salmeterol combination
341084|NCT01332357|hospitalization
341085|NCT01332357|emergency department
341086|NCT01332357|asthma
341087|NCT01332344|fluticasone propionate/salmeterol combination
341088|NCT01332344|Asthma
341089|NCT01332344|inhaled corticosteroids
341090|NCT01332344|outcomes
341091|NCT01332331|pulmonary arterial hypertension
341092|NCT01332331|pediatric
341093|NCT01332292|inhalation profiles
341094|NCT01332292|pharmacokinetics
341095|NCT01332292|pharyngometry
341096|NCT01332292|asthma
341097|NCT01332292|pediatric subjects
341098|NCT01332292|GW685698
341099|NCT01332292|Fluticasone furoate
341100|NCT01332292|safety
341101|NCT01332266|Cancer
341102|NCT01332266|head and neck
341103|NCT01332266|squamous cell carcinoma of the head and neck
341104|NCT01332266|phase I
341105|NCT01332266|phase II
341106|NCT01332253|Tonsillectomy, Pediatric
341107|NCT01332240|staging
341108|NCT01332240|endosonography
341109|NCT01332240|lung cancer
341110|NCT01332240|stage III
341111|NCT01332214|Phase 1
341112|NCT01332214|healthy male volunteers
341113|NCT01332214|dose escalation
341114|NCT01332214|pharmacokinetics
341115|NCT01332214|Single Ascending Dose
341116|NCT01332214|AZD2820 Cmax
341117|NCT01332214|tmax
341118|NCT01332214|t1/2λz
341119|NCT01332201|Advagraf
341120|NCT01332201|Heart
341121|NCT01332201|Lung
341122|NCT01332201|Pancreas
341123|NCT01332201|Transplant
341124|NCT01332201|Immunosuppression
341125|NCT01332201|Pharmacokinetics
341126|NCT01332162|Hypertrophic Obstructive Cardiomyopathy (HOCM)
341127|NCT01332162|Pacing
341128|NCT01332149|Diabetic Neuropathies
341129|NCT01332149|Pain
341130|NCT01332149|Efficacy of pregabalin
341131|NCT01332149|Placebo controlled
341132|NCT01332110|Footwear
341133|NCT01332110|Motion Analysis
341134|NCT01332110|Running Injury
341135|NCT01332097|Chronic Obstructive Pulmonary Disease
341136|NCT01332097|Exacerbation
341137|NCT01332097|Pulmonary Inflammation
341138|NCT01332084|SOTI
341139|NCT01332084|tolerance
341140|NCT01332084|desensitization
341141|NCT01332084|challenge test
341142|NCT01332084|HA wheat cereals
341143|NCT01332071|Metformin
341144|NCT01332071|Rosiglitazone
341145|NCT01332071|Healthy volunteers
341146|NCT01332071|Avandamet
341147|NCT01332071|Fed conditions
341148|NCT01332071|Bioequivalence
341149|NCT01332058|Peripheral arterial disease
341150|NCT01332058|Walking
341151|NCT01332058|Motivational Interviewing
341152|NCT01332032|cost effectiveness
341153|NCT01332032|screening mammography
341154|NCT01332032|repeat mammography
341155|NCT01332032|telephone counseling
341156|NCT01332032|computerized reminders
341157|NCT01332032|compliance
341158|NCT01332019|Subcutaneous
341159|NCT01332019|Extension
341160|NCT01332019|Interferon
341161|NCT01332019|MS
341162|NCT01332019|PEGylated
341163|NCT01332019|Injectable
341164|NCT01332019|SC
341165|NCT01332019|PEG
341166|NCT01332019|peginterferon beta-1a
341167|NCT01332019|Relapsing
341168|NCT01331993|Phase 1
341169|NCT01331993|crossover
341170|NCT01331993|bioequivalence
341171|NCT01331993|naproxen
341172|NCT01331993|esomeprazole
341173|NCT01331993|vimovo
341174|NCT01331993|healthy volunteers
341175|NCT01331980|cystic fibrosis
341176|NCT01331980|bone
341177|NCT01331967|pioglitazone
341178|NCT01331967|optical coherence tomography
341179|NCT01331967|microRNA
341180|NCT01331967|neointima
341181|NCT01331967|major adverse cardiovascular event
341182|NCT01331941|AMG 386
341183|NCT01331941|Pharmacokinetic
341184|NCT01331941|Renal Impairment
341185|NCT01331928|Sequential chemotherapy, gastric cancer
341186|NCT01331915|Metastatic Melanoma
341187|NCT01331915|Safety
341188|NCT01331915|Theravac vaccine
341189|NCT01331915|HLA-A2 typing
341190|NCT01331915|Tyrosinase.A2 gene expression
341191|NCT01331902|Adenosine
341192|NCT01331902|Nicorandil
341193|NCT01331902|Fractional Flow Reserve
341194|NCT01331902|Maximal Hyperemia
341195|NCT01331889|transfusion
341196|NCT01331889|liver transplantation
341197|NCT01331889|potassium
341198|NCT01331876|Cognitive and Behavioral Therapy
341199|NCT01331863|Bronchial disease
341200|NCT01331863|Lung cancer surgery
341201|NCT01331863|Aorta/aortic Allograft
341202|NCT01331863|homograft
341203|NCT01331863|Tracheal disease
341204|NCT01331863|Benign
341205|NCT01331863|Malignant
341206|NCT01331824|Bladder Cancer
341207|NCT01331824|Urothelial Cancer
341208|NCT01331824|Chemotherapy
341209|NCT01331824|Second-line
341210|NCT01331824|Metastatic
341211|NCT01331811|HIV
341212|NCT01331811|Tuberculosis
341213|NCT01331811|Diagnosis
341214|NCT01331811|Pediatrics
341215|NCT01331811|Asia
341216|NCT01331811|Africa
341217|NCT01331798|Abdominoplasty
341218|NCT01331785|paracentesis
341219|NCT01331785|ascites
341220|NCT01331785|hypotension
341221|NCT01331772|Breast cancer
341222|NCT01331772|Adapted Physical activity
341223|NCT01331772|Nutrition
341224|NCT01331772|Assessment
341225|NCT01331772|Patient education
341226|NCT01331759|Burnout
341227|NCT01331759|Subthreshold Disorder
341228|NCT01331707|drug-eluting stent
341229|NCT01331707|Zotarolimus
341230|NCT01331707|Everolimus
341231|NCT01331707|all comers population
341232|NCT01331707|target vessel failure
341233|NCT01331707|coronary artery disease
341234|NCT01331681|Diabetic Macular Edema (DME)
341235|NCT01331681|VEGF Trap-Eye
341236|NCT01331681|Best-corrected visual acuity (BCVA)
341237|NCT01331642|Lymphatic Diseases
341238|NCT01331642|Metabolism, Inborn Errors
341239|NCT01331642|Genetic Diseases, Inborn
341240|NCT01331642|Lipidoses
341241|NCT01331642|Lipid Metabolism, Inborn Errors
341242|NCT01331642|Metabolic Diseases
341243|NCT01331642|Lipid Metabolism Disorders
341244|NCT01331629|breast cancer
341245|NCT01331629|fatigue
341246|NCT01331629|quality of life
341247|NCT01331629|art-therapie
341248|NCT01331629|adjuvant radiotherapy
341249|NCT01331616|Prospective study
341250|NCT01331616|Glioblastoma
341251|NCT01331616|Avastin
341252|NCT01331616|Visual Evoked Potential
341253|NCT01331616|Optic neuropathy
341254|NCT01331616|Chemo-radiotherapy
341255|NCT01331603|MDS
341256|NCT01331603|primary myelofibrosis
341257|NCT01331603|low+high risk MDS patients
341258|NCT01331603|patients
341259|NCT01331577|Healthy
341260|NCT01331577|Primary Prevention
341261|NCT01331577|Stress
341262|NCT01331577|Kinesiology
341263|NCT01331577|cognitive behavioural therapy
341264|NCT01331577|Prevention
341265|NCT01331564|Pregnancy
341266|NCT01331564|Postpartum
341267|NCT01331564|Weight gain
341268|NCT01331564|Weight retention
341269|NCT01331564|Behavior
341270|NCT01331564|Electronic Media
341271|NCT01331564|Randomized Clinical Trial
341272|NCT01331551|Inflammatory Bowel disease
341273|NCT01331538|temporomandibular dysfunction
341274|NCT01331538|posture
341275|NCT01331525|Small cell lung cancer
341276|NCT01331525|Chemotherapy
341277|NCT01331525|Immunotherapy
341278|NCT01331525|CTLA-4
341279|NCT01331525|Ipilimumab
341280|NCT01331512|Clinical Geriatrics
341281|NCT01331512|Biomechanics
341282|NCT01331512|Epidemiology
341283|NCT01331512|Decline in Ambulation
341284|NCT01331499|Blood loss
341285|NCT01331499|transfusions
341286|NCT01331499|instrumented spinal fusion
341287|NCT01331486|Prehypertension
341288|NCT01331486|Mild hypertension
341289|NCT01331486|Flow mediated dilation
341290|NCT01331486|Hawthorn
341291|NCT01331473|Carotid Artery
341292|NCT01331473|Stenting
341293|NCT01331473|CAS
341294|NCT01331473|proximal protection
341295|NCT01331460|HIV
341296|NCT01331460|HIV risk
341297|NCT01331460|Sexually Transmitted Diseases
341298|NCT01331460|Drug Use
341299|NCT01331460|Women
341300|NCT01331460|Drug Treatment
341301|NCT01331460|opioids
341302|NCT01331460|injection drug use
341303|NCT01331460|stimulants
341304|NCT01331460|gender-specific treatment
341305|NCT01331395|Infertility
341306|NCT01331395|IVF
341307|NCT01331395|Acupuncture
341308|NCT01331382|Resveratrol
341309|NCT01331382|Piperine
341310|NCT01331382|Cerebral blood flow
341311|NCT01331382|Near- infrared spectroscopy
341312|NCT01331382|Bioavailability
341313|NCT01331369|adherence
341314|NCT01331369|compliance
341315|NCT01331369|persistence
341316|NCT01331369|drop out
341317|NCT01331369|abandon
341318|NCT01331356|Chronic proctalgia
341319|NCT01331356|Botulinum toxin type A
341320|NCT01331356|Ganglion Impar
341321|NCT01331356|Perineal pain
341322|NCT01331356|Pudendal neuralgia
341323|NCT01331356|Refractory chronic proctalgia
341324|NCT01331343|Diabetes
341325|NCT01331343|Glycemic Control
341326|NCT01331343|Continuous Glucose Monitoring
341327|NCT01331330|Depressive Disorder
341328|NCT01331330|Unipolar
341329|NCT01331330|Implantable Stimulation Electrodes
341330|NCT01331317|Cardiovascular disease and mortality
341331|NCT01331317|Plasma NTproBNP
341332|NCT01331317|UAER
341333|NCT01331304|Bipolar disorder
341334|NCT01331304|Comparative effectiveness trial
341335|NCT01331304|Lithium
341336|NCT01331304|Quetiapine
341337|NCT01331291|bosutinib
341338|NCT01331291|SKI-606
341339|NCT01331278|total joint replacement
341340|NCT01331278|knee
341341|NCT01331265|perceived lactose intolerance
341342|NCT01331265|calcium/dairy consumption
341343|NCT01331265|specific health outcomes
341344|NCT01331239|Cushing Disease
341345|NCT01331239|LCI699
341346|NCT01331239|Pituitary Gland
341347|NCT01331239|Adrenocorticotropic Hormone
341348|NCT01331213|Pregabalin
341349|NCT01331213|Irritable Bowel Syndrome
341350|NCT01331213|motor
341351|NCT01331213|sensation
341352|NCT01331213|colon
341353|NCT01331213|human
341354|NCT01331200|ischemic stroke
341355|NCT01331200|tissue plasminogen activator
341356|NCT01331200|early mobilization
341357|NCT01331200|patient safety
341358|NCT01331200|length of stay
341359|NCT01331187|Echocardiography
341360|NCT01331187|Heart failure
341361|NCT01331187|Ultrasonography
341362|NCT01331187|pocket-size device
341363|NCT01331187|Aorta
341364|NCT01331187|Education
341365|NCT01331174|knee
341366|NCT01331174|osteoarthritis
341367|NCT01331174|physical therapy
341368|NCT01331174|pulsed short wave
341369|NCT01331161|shingles vaccine
341370|NCT01331161|immune responses
341371|NCT01331148|sickle cell disease
341372|NCT01331148|vitamin D
341373|NCT01331148|pediatrics
341374|NCT01331148|pain
341375|NCT01331135|pediatrics
341376|NCT01331135|sirolimus
341377|NCT01331135|relapse
341378|NCT01331109|Fibromyalgia
341379|NCT01331109|Pediatric Fibromyalgia
341380|NCT01331109|Adolescent Fibromyalgia
341381|NCT01331109|milnacipran
341382|NCT01331109|Savella
341383|NCT01331109|loss of therapeutic response
341384|NCT01331109|Forest Research Institute
341385|NCT01331109|Pain
341386|NCT01331109|Fatigue
341387|NCT01331109|Serotonin Norepinephrine Reuptake Inhibitors
341388|NCT01331096|thyroid gland resection surgery
341389|NCT01331096|total intravenous anesthesia
341390|NCT01331070|Chronic obstructive pulmonary disease (COPD)
341391|NCT01331057|Bilingualism
341392|NCT01331057|Language
341393|NCT01331057|Evaluation transcultural
341394|NCT01331057|Intra Familial Relationship
341395|NCT01331057|Transmissions mother
341396|NCT01331057|Tongue french
341397|NCT01331057|Language tamil
341398|NCT01331057|Language arabic
341399|NCT01331057|Language soninke
341400|NCT01331057|Language cultural
341401|NCT01331057|Affiliations crossbreeding
341402|NCT01331044|RUTF
341403|NCT01331044|Severe Acute Malnutrition
341404|NCT01331044|Children
341405|NCT01331044|Body composition
341406|NCT01331044|Microbiota
341407|NCT01331044|Short Chain Fatty Acid
341408|NCT01331044|Acceptability of RUTF
341409|NCT01331044|Edema free 15 percent weight gain
341410|NCT01331044|Changes in body composition
341411|NCT01331044|Gut microbiota
341412|NCT01331044|Genome wide association
341413|NCT01331031|temporomandibular disorder
341414|NCT01331031|adolescents
341415|NCT01331005|Macular Edema
341416|NCT01331005|Non steroidal anti-inflammatories
341417|NCT01330992|Circadian rhythms
341418|NCT01330992|Melatonin
341419|NCT01330992|Ocular light exposure
341420|NCT01330992|Darkness Exposure
341421|NCT01330992|Performance
341422|NCT01330992|Alertness
341423|NCT01330979|Intraocular pressure
341424|NCT01330966|surgically unresectable chondrosarcoma
341425|NCT01330953|Anemia
341426|NCT01330940|Kidney stones
341427|NCT01330940|Calcium
341428|NCT01330940|citrate
341429|NCT01330927|VA106483
341430|NCT01330927|Nocturia
341431|NCT01330927|Benign Prostatic Hypertrophy
341432|NCT01330927|BPH
341433|NCT01330927|Elderly
341434|NCT01330927|Males
341435|NCT01330927|Nocturnal voids
341436|NCT01330927|Anti-diuretic
341437|NCT01330914|Obesity, Morbid
341438|NCT01330914|Bariatric Surgery
341439|NCT01330914|Gastric Bypass
341440|NCT01330914|Calcium Metabolism Disorders
341441|NCT01330914|Vitamin D
341442|NCT01330914|Bone Density
341443|NCT01330914|Body Composition
341444|NCT01330914|Weight Loss
341445|NCT01330888|war
341446|NCT01330888|religion
341447|NCT01330888|caregiver
341448|NCT01330888|combat stress disorder
341449|NCT01330862|patient outcomes
341450|NCT01330849|Attention-deficit/hyperactivity disorder
341451|NCT01330849|School
341452|NCT01330849|Behavioral Intervention
341453|NCT01330849|RCT
341454|NCT01330823|pancreatic carcinoma
341455|NCT01330823|L-Carnitine
341456|NCT01330823|quality of life
341457|NCT01330823|survival
341458|NCT01330823|malnutrition
341459|NCT01330823|cancer cachexia
341460|NCT01330823|fatigue
341461|NCT01330810|Pharmacokinetics
341462|NCT01330810|Dietary Supplements
341463|NCT01330810|Curcumin
341464|NCT01330797|Cataract
341465|NCT01330797|Intravitreal
341466|NCT01330797|Ranibizumab
341467|NCT01330797|LOCS III
341468|NCT01330758|Phase I
341469|NCT01330758|Healthy male and non-fertile female volunteers
341470|NCT01330758|Bioavailability
341471|NCT01330758|AZD8931
341472|NCT01330745|cardiopulmonary bypass
341473|NCT01330745|mesenteric
341474|NCT01330745|microcirculatory function
341475|NCT01330732|SPINESCAN®
341476|NCT01330732|kyphosis
341477|NCT01330719|Periodontitis
341478|NCT01330706|Skin Diseases [C17.800]
341479|NCT01330706|Nail Diseases [C17.800.529]
341480|NCT01330706|Nails, Ingrown [C17.800.529.406]
341481|NCT01330693|ADHD
341482|NCT01330693|Atomoxetine
341483|NCT01330693|Biomarker
341484|NCT01330680|coffee
341485|NCT01330680|caffeine
341486|NCT01330680|blood pressure
341487|NCT01330680|nutrigenetics
341488|NCT01330680|gene polymorphisms
341489|NCT01330680|Acute Cardiovascular and Neuropsychologic Effects
341490|NCT01330667|Hyperbilirubinemia
341491|NCT01330667|Breastfeeding
341492|NCT01330667|Limited Formula
341493|NCT01330654|Intermediate risk of adverse cardiac event
341494|NCT01330654|Undergoing laparoscopic surgical procedure
341495|NCT01330654|Age forty to seventy five
341496|NCT01330641|Tendonitis
341497|NCT01330641|Rotator Cuff
341498|NCT01330641|Shoulder
341499|NCT01330641|Injection
341500|NCT01330628|peripheral arterial disease
341501|NCT01330628|in stent restenosis
341502|NCT01330628|peripheral vascular disease
341503|NCT01330615|EMLA
341504|NCT01330615|plantar warts
341505|NCT01330615|cryotherapy
341506|NCT01330589|Percutaneous coronary intervention
341507|NCT01330589|Clopidogrel
341508|NCT01330589|St. John's Wort
341509|NCT01330589|CYP 2C19 loss-of-function allele
341510|NCT01330576|Hypothermia
341511|NCT01330576|cooling
341512|NCT01330576|necrotizing enterocolitis
341513|NCT01330576|NEC
341514|NCT01330576|neonates
341515|NCT01330576|preterm
341516|NCT01330563|Drug-Drug interaction between the CKD-501 and ketoconazole
341517|NCT01330550|High fiber sugar free biscuit
341518|NCT01330550|pre-diabetics
341519|NCT01330537|perceptual development
341520|NCT01330537|topological perception theory
341521|NCT01330537|familiarization/novelty preference method
341522|NCT01330537|Discriminate a disk and a ring (topologically different),
341523|NCT01330537|Discriminate a disk and a triangle (geometrically different)
341524|NCT01330537|Detect a change in the number of holes
341525|NCT01330537|Detect the size of the hole
341526|NCT01330511|Newborn infant
341527|NCT01330511|Congenital hydronephrosis
341528|NCT01330511|Postnatal imaging evaluation
341529|NCT01330511|Diagnostic algorithm
341530|NCT01330498|Longitudinal assessment of biomarkers
341531|NCT01330498|duration of natalizumab
341532|NCT01330498|stratification of risk for PML
341533|NCT01330472|Alprazolam
341534|NCT01330472|Xanax
341535|NCT01330472|Bioequivalence
341536|NCT01330472|Panic disorder with or without agoraphobia.
341537|NCT01330459|Pain during first trimester surgical abortion
341538|NCT01330446|Head and Neck Cancer
341539|NCT01330446|HNC
341540|NCT01330446|Fatigue
341541|NCT01330446|Patient-Reported Fatigue
341542|NCT01330446|Fatigue-Symptom Intervention
341543|NCT01330446|Postoperative Radiation Therapy
341544|NCT01330446|Postoperative Chemoradiation Therapy
341545|NCT01330446|Armodafinil
341546|NCT01330446|Nuvigil
341547|NCT01330446|Placebo
341548|NCT01330446|Sugar Pill
341549|NCT01330446|Questionnaires
341550|NCT01330446|Surveys
341551|NCT01330394|Alcoholism
341552|NCT01330394|Lesch's typology
341553|NCT01330394|tDCS
341554|NCT01330394|ERP
341555|NCT01330394|P300
341556|NCT01330394|FAB
341557|NCT01330394|MMSE
341558|NCT01330394|Cognitive tasks
341559|NCT01330368|Systemic Lupus Erythematosus
341560|NCT01330368|SLE
341561|NCT01330368|Lupus
341562|NCT01330368|children with SLE
341563|NCT01330355|Ocular infections, bacterial
341564|NCT01330329|Obesity
341565|NCT01330329|Weight loss
341566|NCT01330329|Exercise
341567|NCT01330329|Intervention studies
341568|NCT01330303|Bioequivalence
341569|NCT01330303|Healthy volunteers
341570|NCT01330303|tamsulosin hydrochloride
341571|NCT01330303|Fed administration
341572|NCT01330290|Rotigotine
341573|NCT01330290|Neupro®
341574|NCT01330290|Parkinson
341575|NCT01330290|Treatment preference
341576|NCT01330290|Care-giving
341577|NCT01330277|Metabolic Diseases
341578|NCT01330277|Biomarker
341579|NCT01330277|Mucopolysaccharidosis II
341580|NCT01330277|Lysosomal Storage Diseases
341581|NCT01330277|Morbus Hunter
341582|NCT01330277|Mucopolysaccharidoses
341583|NCT01330264|Intracranial Pressure (ICP) Monitoring
341584|NCT01330264|Admission to Intensive Care Unit (ICU)
341585|NCT01330238|Low back pain
341586|NCT01330238|Modic changes
341587|NCT01330238|Vertebral endplate signal changes
341588|NCT01330238|Efficacy
341589|NCT01330238|Zoledronic acid
341590|NCT01330238|Bisphosphonates
341591|NCT01330238|RCT
341592|NCT01330199|Healthy
341593|NCT01330199|Female
341594|NCT01330199|Volunteer
341595|NCT01330160|stroke
341596|NCT01330160|Brain ischemia
341597|NCT01330160|Intracranial hemorrhage
341598|NCT01330160|Dementia, Vascular
341599|NCT01330160|Alzheimer's disease
341600|NCT01330147|HPV
341601|NCT01330147|oral cancer
341602|NCT01330147|oropharyngeal cancer
341603|NCT01330147|tonsillectomy
341604|NCT01330134|procedural
341605|NCT01330121|Adherence with discharge diabetes medications
341606|NCT01330121|Diabeted mellitus type 2 greater than one year
341607|NCT01330121|Patient with provider and prescriptions filled within CCHS
341608|NCT01330108|Pulmonary Arterial Hypertension
341609|NCT01330108|PAH
341610|NCT01330108|WHO Group 1
341611|NCT01330095|Bifidobacterium bifidum
341612|NCT01330095|Very low birth weight infant
341613|NCT01330095|Enteral feeding
341614|NCT01330095|Growth
341615|NCT01330095|amount of enteral feeding
341616|NCT01330082|Photodynamic therapy
341617|NCT01330082|Light-emitting diode
341618|NCT01330082|toluidine blue
341619|NCT01330082|scaling and root planing
341620|NCT01330056|Laryngeal and pharyngeal preservation, survivals
341621|NCT01330043|smoking cessation intervention
341622|NCT01330017|Seasonal allergies
341623|NCT01329991|RA
341624|NCT01329991|Methotrexate
341625|NCT01329978|Hepatitis C
341626|NCT01329978|HCV
341627|NCT01329978|Chronic Hepatitis C
341628|NCT01329965|Cardiovascular disease
341629|NCT01329965|Inflammation
341630|NCT01329965|LPS
341631|NCT01329965|Endotoxin
341632|NCT01329939|Asthma
341633|NCT01329939|Obesity
341634|NCT01329939|Pediatric
341635|NCT01329939|Inflammation
341636|NCT01329939|Leukotriene
341637|NCT01329939|Montelukast
341638|NCT01329926|Parkinson's disease
341639|NCT01329926|Neural stem cells
341640|NCT01329900|Chemotherapy
341641|NCT01329900|Stem Cell Collection
341642|NCT01329900|Ofatumumab
341643|NCT01329900|Arzerra
341644|NCT01329900|Ifosfamide
341645|NCT01329900|Ifex
341646|NCT01329900|Etoposide
341647|NCT01329900|VePesid
341648|NCT01329900|Mesna
341649|NCT01329900|Mesnex
341650|NCT01329900|G-CSF
341651|NCT01329900|Filgrastim
341652|NCT01329900|Neupogen
341653|NCT01329900|Apheresis
341654|NCT01329887|microcirculation
341655|NCT01329887|SDF
341656|NCT01329887|ketanserin
341657|NCT01329887|severe sepsis
341658|NCT01329861|chronic back pain
341659|NCT01329861|internet based treatment
341660|NCT01329861|pain management programme
341661|NCT01329861|cognitive behavioural therapy
341662|NCT01329861|minimal therapist contact
341663|NCT01329848|Accommodation
341664|NCT01329848|Reading
341665|NCT01329848|Autorefraction
341666|NCT01329822|type 2 diabetes
341667|NCT01329822|overweight
341668|NCT01329809|metastatic colorectal cancer
341669|NCT01329809|colon cancer
341670|NCT01329809|liver metastasis
341671|NCT01329809|Pexa-vec
341672|NCT01329809|JX-594
341673|NCT01329796|dysmenorrhea,
341674|NCT01329796|pelvic pain
341675|NCT01329796|dyspareunia
341676|NCT01329796|endometriosis
341677|NCT01329770|Neurodevelopmental disability
341678|NCT01329770|Hyperactivity
341679|NCT01329770|Anxiety
341680|NCT01329770|Cognitive problems
341681|NCT01329770|Behavioural symptoms
341682|NCT01329770|Fragile X syndrome
341683|NCT01329770|Autism
341684|NCT01329770|inherited Genetic condition
341685|NCT01329757|Spinal Cord Injury
341686|NCT01329757|Growth Hormone
341687|NCT01329757|Trauma
341688|NCT01329757|Incomplete
341689|NCT01329757|ASIA
341690|NCT01329744|HIV lipodystrophy
341691|NCT01329731|white spot lesion
341692|NCT01329731|initial caries
341693|NCT01329731|fluoride
341694|NCT01329731|amine fluoride
341695|NCT01329731|orthodontics
341696|NCT01329731|remineralization
341697|NCT01329731|brackets
341698|NCT01329718|Stability of the Septin 9 biomarker
341699|NCT01329718|Epi Pro Colon Test
341700|NCT01329718|CRC
341701|NCT01329692|RYGB
341702|NCT01329692|Intervention
341703|NCT01329692|follow-up
341704|NCT01329692|standard-of-care
341705|NCT01329692|Back on Track program
341706|NCT01329692|poor weight loss
341707|NCT01329692|morbidly obese
341708|NCT01329666|Primary Hyperparathyroidism
341709|NCT01329666|Endocrinology
341710|NCT01329666|Hypercalcemia
341711|NCT01329666|Vitamin D deficiency
341712|NCT01329666|Parathyroid Hormone
341713|NCT01329666|Osteoporosis
341714|NCT01329666|Bone Density
341715|NCT01329666|Vitamin D repletion
341716|NCT01329666|Vitamin D Supplements
341717|NCT01329653|cerebral blood volume
341718|NCT01329653|aging
341719|NCT01329653|exercise
341720|NCT01329640|Metronimic chemotherapy
341721|NCT01329640|Locally Advanced HER2-positive Breast Cancer
341722|NCT01329601|cognitive training
341723|NCT01329601|Alzheimer disease
341724|NCT01329601|tertiary prevention
341725|NCT01329588|Female sex workers
341726|NCT01329588|West Africa
341727|NCT01329588|Presumptive treatment
341728|NCT01329588|Sexually transmitted infections
341729|NCT01329575|endoluminal ultrasound
341730|NCT01329575|Mediastinal LN invasion
341731|NCT01329562|Menstrual migraine
341732|NCT01329562|Menstrually-related migraine
341733|NCT01329562|Treximet
341734|NCT01329562|CGRP
341735|NCT01329562|calcitonin gene-related peptide
341736|NCT01329536|Alzheimer's Disease
341737|NCT01329536|Agitation
341738|NCT01329536|Genetics
341739|NCT01329536|Apolipoprotein
341740|NCT01329536|ApoE4
341741|NCT01329523|Dementia
341742|NCT01329523|Insulin-like growth factor
341743|NCT01329523|IGF
341744|NCT01329523|APO E4
341745|NCT01329523|Genetics
341746|NCT01329510|ADHD
341747|NCT01329510|Adult
341748|NCT01329484|Alzheimer
341749|NCT01329484|Dementia
341750|NCT01329484|Computer
341751|NCT01329484|Cognitive training
341752|NCT01329484|Reminiscence therapy
341753|NCT01329458|FLL
341754|NCT01329458|CEUS
341755|NCT01329458|SonoVue
341756|NCT01329458|HCC
341757|NCT01329458|Liver metastases
341758|NCT01329458|Hemangiomas
341759|NCT01329458|FNH
341760|NCT01329445|Cartilage repair
341761|NCT01329445|Articular cartilage defects
341762|NCT01329432|surfactant
341763|NCT01329432|intubation
341764|NCT01329432|spontaneous breathing
341765|NCT01329432|bronchopulmonary dysplasia
341766|NCT01329406|Osteoarthritis (OA)
341767|NCT01329406|Milnacipran
341768|NCT01329406|Serotonin-norepinephrine reuptake inhibitor (SNRI)
341769|NCT01329406|Knee pain
341770|NCT01329393|Disability
341771|NCT01329393|Social Security
341772|NCT01329393|Representative Payee
341773|NCT01329380|Ankylosing Spondylitis
341774|NCT01329367|EVASYON
341775|NCT01329367|GENOI
341776|NCT01329367|antioxidants
341777|NCT01329367|legume
341778|NCT01329367|fish
341779|NCT01329354|Follicular lymphoma
341780|NCT01329354|Follicular non-Hodgkin´s lymphoma
341781|NCT01329354|Autologous effector lymphocytes
341782|NCT01329354|Cell Therapy
341783|NCT01329354|Maintenance therapy
341784|NCT01329354|Rituximab
341785|NCT01329341|PTSD
341786|NCT01329341|Service Dogs
341787|NCT01329328|whole-body vibration
341788|NCT01329328|radiofrequency
341789|NCT01329328|hormonal status
341790|NCT01329328|muscular strength
341791|NCT01329328|balance
341792|NCT01329276|COPD
341793|NCT01329276|Symbicort
341794|NCT01329276|Turbohaler
341795|NCT01329276|Computational Fluid Dynamics
341796|NCT01329276|Functional Imaging
341797|NCT01329276|Budesonide
341798|NCT01329276|Formoterol
341799|NCT01329263|menthol cigarettes
341800|NCT01329250|Tuberculosis
341801|NCT01329250|Moxifloxacin
341802|NCT01329250|Pharmacokinetics
341803|NCT01329250|Safety
341804|NCT01329237|drug-eluting stent
341805|NCT01329237|coronary endothelial function
341806|NCT01329237|coronary imaging
341807|NCT01329224|acetylsalicylic acid resistance
341808|NCT01329211|Gastroparesis
341809|NCT01329211|Quality of Life
341810|NCT01329198|tourette
341811|NCT01329198|tourette's
341812|NCT01329198|TS
341813|NCT01329198|tourette syndrome
341814|NCT01329198|tourette's syndrome
341815|NCT01329185|EBV Viremia in posttransplant kidney recipients
341816|NCT01329185|CMV viremia in posttransplant kidney recipients
341817|NCT01329172|PUFA
341818|NCT01329172|Cystic Fibrosis
341819|NCT01329172|Nasal brushing
341820|NCT01329172|Mucins
341821|NCT01329172|Mucin production
341822|NCT01329159|High altitude
341823|NCT01329159|respiratory function
341824|NCT01329159|cardiorespiratory health
341825|NCT01329159|indoor pollution
341826|NCT01329146|pulse pressure variation
341827|NCT01329146|preload dependency
341828|NCT01329146|one-lung ventilation
341829|NCT01329146|thoracic surgery
341830|NCT01329133|Deep brain stimulation (DBS)
341831|NCT01329133|Obsessive compulsive disorder
341832|NCT01329133|ventral striatum
341833|NCT01329133|subthalamic nucleus
341834|NCT01329107|Rehabilitation
341835|NCT01329107|Enhanced Recovery
341836|NCT01329107|Health related Qouality of Life
341837|NCT01329107|Patient outcomes
341838|NCT01329094|Severe mental illness
341839|NCT01329094|physical activity
341840|NCT01329094|evaluation
341841|NCT01329081|Rehabilitation
341842|NCT01329081|Strength training
341843|NCT01329081|Long-term effect
341844|NCT01329081|Activity and participation after fast-track knee arthroplasty
341845|NCT01329068|breast cancer
341846|NCT01329042|Potassium sodium citrate
341847|NCT01329042|stone recurrence
341848|NCT01329042|ESWL
341849|NCT01329042|PCNL
341850|NCT01329042|Hypocitraturia
341851|NCT01329042|intervention
341852|NCT01329029|COPD
341853|NCT01329029|Roflumilast
341854|NCT01329029|Daxas
341855|NCT01329016|Pregnancy
341856|NCT01329016|Glyburide
341857|NCT01329016|Metformin
341858|NCT01329016|Pharmacokinetics
341859|NCT01329016|Pharmacodynamics
341860|NCT01329003|Silicosis
341861|NCT01328990|IPTc
341862|NCT01328990|malaria
341863|NCT01328990|children
341864|NCT01328990|pharmacokinetics
341865|NCT01328990|amodiaquiane
341866|NCT01328990|sulfadoxine-pyrimethamine
341867|NCT01328964|pediatric
341868|NCT01328964|asthma
341869|NCT01328964|outcomes
341870|NCT01328964|inhaled cortcosteroids
341871|NCT01328938|Pegfilgrastim
341872|NCT01328938|neutropenia
341873|NCT01328925|Rotavirus
341874|NCT01328925|Viral gastroenteritis
341875|NCT01328925|Gastroenteritis
341876|NCT01328912|ischemic preconditioning
341877|NCT01328912|cardiac surgery
341878|NCT01328912|vascular surgery
341879|NCT01328899|Emphysema
341880|NCT01328899|COPD
341881|NCT01328899|RePneu
341882|NCT01328886|omalizumab
341883|NCT01328886|allergic asthma
341884|NCT01328886|pediatric patients
341885|NCT01328873|Pulmonary infiltrates
341886|NCT01328873|stem cell transplant
341887|NCT01328873|leukemia
341888|NCT01328860|Autologous
341889|NCT01328860|Stem Cells
341890|NCT01328860|Spinal Cord Injury
341891|NCT01328860|Children
341892|NCT01328834|Nephritis, Lupus
341893|NCT01328834|Tacrolimus
341894|NCT01328821|Safety
341895|NCT01328821|Tolerability
341896|NCT01328821|Pharmacokinetics
341897|NCT01328821|Healthy volunteers
341898|NCT01328808|Acetaminophen
341899|NCT01328808|Preterm Infants
341900|NCT01328795|Cardiogoniometry
341901|NCT01328795|Chest Pain Unit
341902|NCT01328795|ST-elevation
341903|NCT01328795|Troponin
341904|NCT01328795|Catheter intervention
341905|NCT01328795|Fast Track
341906|NCT01328782|elbow fracture
341907|NCT01328782|supracondylar elbow fracture
341908|NCT01328782|elbow
341909|NCT01328782|fracture
341910|NCT01328782|pain management
341911|NCT01328782|pediatric
341912|NCT01328769|uric acid
341913|NCT01328769|febuxostat
341914|NCT01328769|hypertension
341915|NCT01328769|intra-renal renin-angiotensin system
341916|NCT01328769|renal plasma flow
341917|NCT01328769|angiotensin II
341918|NCT01328756|ADHD
341919|NCT01328730|significant stenosis (>70% of lumen stenosis)
341920|NCT01328730|epicardial coronary arteries.
341921|NCT01328704|Iron deficiency
341922|NCT01328704|Vitamin D deficiency
341923|NCT01328704|Anemia
341924|NCT01328704|Athletes
341925|NCT01328704|Triathletes
341926|NCT01328704|Triathlon
341927|NCT01328691|Carcinoma, Renal Cell
341928|NCT01328691|thrombus
341929|NCT01328691|body mass index
341930|NCT01328691|grade
341931|NCT01328678|Alopecia Areata
341932|NCT01328678|Vitamin D
341933|NCT01328678|Parathyroid
341934|NCT01328678|Calcium
341935|NCT01328652|LPR
341936|NCT01328652|LTH
341937|NCT01328639|Collaborative care
341938|NCT01328639|Diabetes management
341939|NCT01328639|Depression management
341940|NCT01328639|Primary care
341941|NCT01328626|Chronic Lymphocytic Leukemia
341942|NCT01328626|Maximum Tolerated Dose
341943|NCT01328626|ABT-199
341944|NCT01328626|Safety
341945|NCT01328626|Preliminary Efficacy
341946|NCT01328626|Cancer
341947|NCT01328626|Non-Hodgkin Lymphoma
341948|NCT01328626|Pharmacokinetics
341949|NCT01328613|BDNF
341950|NCT01328613|Homeosis
341951|NCT01328613|Women
341952|NCT01328613|Childbirth
341953|NCT01328613|Major Depressive Disorder
341954|NCT01328600|Placenta
341955|NCT01328600|Pregnancy
341956|NCT01328600|Hypertension
341957|NCT01328600|Supplementation
341958|NCT01328600|Antibody
341959|NCT01328587|Eltrombopag
341960|NCT01328587|Aplastic Anemia
341961|NCT01328587|Aplastic Anemia Treatment
341962|NCT01328587|Moderate Aplastic Anemia
341963|NCT01328587|Moderate Aplastic Anemia Treatment
341964|NCT01328574|Progression-Free Survival
341965|NCT01328574|Carcinoma of the Bladder
341966|NCT01328574|Cancer of the Renal Pelvis
341967|NCT01328574|Ureter Cancer
341968|NCT01328574|Survival
341969|NCT01328574|Bladder Cancer
341970|NCT01328574|Renal Pelvis Cancer
341971|NCT01328574|Urothelial Cancer
341972|NCT01328561|Arginine
341973|NCT01328561|Oxytocin
341974|NCT01328561|Vasopressin
341975|NCT01328561|Placebo
341976|NCT01328561|Analgesia
341977|NCT01328561|Healthy Volunteer
341978|NCT01328561|HV
341979|NCT01328548|varicella-zoster virus
341980|NCT01328548|vaccine
341981|NCT01328548|T-cell
341982|NCT01328548|genes
341983|NCT01328548|frail elderly
341984|NCT01328548|immunosenescence
341985|NCT01328548|immune and genetic correlates of response to zoster vaccine in the elderly
341986|NCT01328509|Zinc
341987|NCT01328496|Hematologic Malignancies
341988|NCT01328496|Umbilical Cord Blood transplantation
341989|NCT01328496|Hematopoietic Cell Transplantation
341990|NCT01328483|Neonates
341991|NCT01328483|Intrapartum Oropharyngeal Suctioning
341992|NCT01328483|Meconium Aspiration Syndrome
341993|NCT01328470|platelet
341994|NCT01328470|cilostazol
341995|NCT01328470|clopidogrel
341996|NCT01328470|chronic kidney disease
341997|NCT01328457|Leishmaniasis, Visceral
341998|NCT01328457|kala-azar
341999|NCT01328457|Paromomycin
342000|NCT01328457|Bangladesh
342001|NCT01328457|Injections, Intramuscular
342002|NCT01328457|Treatment Outcome
342003|NCT01328457|Patient compliance
342004|NCT01328457|Medication adherence
342005|NCT01328457|Drug toxicity
342006|NCT01328431|Tobacco Use Cessation
342007|NCT01328431|Smoking Cessation
342008|NCT01328431|Nicotine Replacement Therapy
342009|NCT01328431|Brief Intervention
342010|NCT01328418|Lengthening
342011|NCT01328392|LPR
342012|NCT01328392|GERD
342013|NCT01328366|Quality of Life
342014|NCT01328366|Psychosocial factors
342015|NCT01328353|triage
342016|NCT01328353|aprn
342017|NCT01328353|telehealth
342018|NCT01328353|CCHCN
342019|NCT01328353|advanced practice nurse
342020|NCT01328353|improve family quality of life
342021|NCT01328353|reduce unplanned use of health care services
342022|NCT01328353|telehealth triage intervention
342023|NCT01328340|muscle power, exercise, aging
342024|NCT01328301|gait
342025|NCT01328301|hemiplegia
342026|NCT01328301|treadmill
342027|NCT01328301|physiotherapy
342028|NCT01328301|rehabilitation
342029|NCT01328288|HIV related adverse events
342030|NCT01328288|Immunological failure
342031|NCT01328288|virological failure
342032|NCT01328288|quality of life
342033|NCT01328288|depression
342034|NCT01328288|genotypic resistance
342035|NCT01328275|HIV related adverse events
342036|NCT01328275|immunological failure
342037|NCT01328275|virological failure
342038|NCT01328275|quality of life
342039|NCT01328275|depression
342040|NCT01328275|genotypic resistance
342041|NCT01328262|Hemoglobins
342042|NCT01328249|Breast Cancer
342043|NCT01328249|HER2-normal Stage I to III invasive breast cancer
342044|NCT01328236|Bortezomib
342045|NCT01328236|PCL
342046|NCT01328223|Hepatocellular carcinoma
342047|NCT01328223|radiotherapy
342048|NCT01328223|sorafenib
342049|NCT01328210|metabolic syndrome
342050|NCT01328210|Phlebotomy
342051|NCT01328210|blood letting
342052|NCT01328210|hypertension
342053|NCT01328210|insulin sensitivity
342054|NCT01328197|Treovance
342055|NCT01328197|aneurysm
342056|NCT01328197|AAA
342057|NCT01328158|Kaletra, Lopinavir (LPV)/Ritonavir (RTV), Human Immunodeficiency Virus (HIV) infection
342058|NCT01328132|Liver
342059|NCT01328132|transplant
342060|NCT01328132|albumin
342061|NCT01328067|MRgFus
342062|NCT01328067|Uterine Fibroids
342063|NCT01328067|Pelvic Pain
342064|NCT01328067|Quality of Life
342065|NCT01328067|Symptomatic Uterine Fibroids
342066|NCT01328054|cancer
342067|NCT01328054|cardiac repolarization
342068|NCT01328054|Holter monitor
342069|NCT01328054|pharmacokinetics
342070|NCT01328054|GW572016
342071|NCT01328054|lapatinib
342072|NCT01328054|QTc interval
342073|NCT01328054|safety
342074|NCT01328054|ECG
342075|NCT01328041|GSK1349572
342076|NCT01328041|resistance to raltegravir or elvitegravir
342077|NCT01328041|Integrase inhibitor
342078|NCT01328041|ART-experienced
342079|NCT01328041|dolutegravir
342080|NCT01328028|Invasive cervical cancer
342081|NCT01328028|Human papillomavirus
342082|NCT01328015|hyperhidrosis
342083|NCT01328015|oxybutynin
342084|NCT01328015|plantar sweating
342085|NCT01328015|compensatory sweating
342086|NCT01328002|Fibromyalgia
342087|NCT01328002|Pediatric Fibromyalgia
342088|NCT01328002|Adolescent Fibromyalgia
342089|NCT01328002|milnacipran
342090|NCT01328002|Savella
342091|NCT01328002|loss of therapeutic response
342092|NCT01328002|Forest Research Institute
342093|NCT01328002|Pain
342094|NCT01328002|Fatigue
342095|NCT01328002|Serotonin Norepinephrine Reuptake Inhibitors
342096|NCT01328002|Randomized Withdrawal
342097|NCT01327989|Solitaire FR Device
342098|NCT01327989|Mechanical Thrombectomy
342099|NCT01327989|Recanalization
342100|NCT01327989|Brain artery recanalization
342101|NCT01327989|Neurovascular intervention
342102|NCT01327989|Interventional Neuroradiology
342103|NCT01327989|STAR
342104|NCT01327989|Acute Ischemic Stroke
342105|NCT01327976|Obesity
342106|NCT01327976|Bariatric surgery
342107|NCT01327976|Excess weight loss
342108|NCT01327976|Vagus nerve
342109|NCT01327976|Vagal blocking
342110|NCT01327976|vBloc Therapy
342111|NCT01327963|Gastroesophageal reflux disease
342112|NCT01327963|GERD
342113|NCT01327963|Heartburn
342114|NCT01327963|Reflux
342115|NCT01327963|Regurgitation
342116|NCT01327963|Hoarseness
342117|NCT01327963|Cough
342118|NCT01327950|Percutaneous treatment
342119|NCT01327950|Superficial Femoral Artery lesions
342120|NCT01327950|EPIC Nitinol Vascular Stent System
342121|NCT01327911|Mactel
342122|NCT01327911|Macular Telangiectasia Type 2
342123|NCT01327898|MSM
342124|NCT01327898|HIV/AIDS
342125|NCT01327898|sexual risk
342126|NCT01327898|substance use
342127|NCT01327872|Idiopathic Thrombocytopenia Purpura(ITP)
342128|NCT01327872|Acute and Chronic Thrombocytopenia Associated with Chronic Liver Disease
342129|NCT01327872|TLD
342130|NCT01327846|Cardiovascular Death
342131|NCT01327846|Myocardial Infarction
342132|NCT01327846|Stroke
342133|NCT01327846|Canakinumab
342134|NCT01327846|IL-1B
342135|NCT01327846|hsCRP
342136|NCT01327820|Oxygen consumption
342137|NCT01327820|Aortic Aneurysm
342138|NCT01327820|Peripheral Arterial Disease
342139|NCT01327807|Registries
342140|NCT01327807|Cystinosis
342141|NCT01327807|Nephropathic Cystinosis
342142|NCT01327807|Renal Fanconi Syndrome
342143|NCT01327807|Cystine
342144|NCT01327807|Kidney
342145|NCT01327807|Rare Diseases
342146|NCT01327794|recurrent pancreatic cancer
342147|NCT01327794|stage III pancreatic cancer
342148|NCT01327794|stage IV pancreatic cancer
342149|NCT01327768|Stroke,
342150|NCT01327768|Stem Cell,
342151|NCT01327768|Olfactory Ensheathing Cells,
342152|NCT01327768|Intracerebral Implantation of Olfactory Ensheathing Cells.
342153|NCT01327755|Selenium
342154|NCT01327755|HIV/ AIDS
342155|NCT01327755|CD4 counts
342156|NCT01327755|Antiretroviral therapy
342157|NCT01327742|Relay
342158|NCT01327742|Thoracic
342159|NCT01327742|Aneurysm
342160|NCT01327729|pegylated interferon
342161|NCT01327729|interferon
342162|NCT01327729|HCV
342163|NCT01327729|genotype 4
342164|NCT01327703|Exocrine Pancreatic Insufficiency
342165|NCT01327703|Cystic Fibrosis
342166|NCT01327703|Steatorrhea
342167|NCT01327703|Malabsorption
342168|NCT01327703|Malnutrition
342169|NCT01327677|pain management
342170|NCT01327677|opioid analgesic therapy
342171|NCT01327677|safety
342172|NCT01327677|craniotomy
342173|NCT01327664|Quiescent uveitis
342174|NCT01327664|intermediate uveitis
342175|NCT01327664|panuveitis
342176|NCT01327664|posterior uveitis
342177|NCT01327664|uveitis
342178|NCT01327651|Drug Administration Schedule
342179|NCT01327651|Nucleoside Reverse Transcriptase Inhibitors
342180|NCT01327651|Pharmacokinetics
342181|NCT01327625|Allogeneic hematopoietic cell transplantation
342182|NCT01327625|Graft versus host disease
342183|NCT01327625|Bronchiolitis obliterans
342184|NCT01327625|Azithromycin
342185|NCT01327625|N-acetylcystein
342186|NCT01327625|Fluticasone
342187|NCT01327625|Inhaled steroid
342188|NCT01327612|AMG 655
342189|NCT01327612|AMG 479
342190|NCT01327612|Apoptosis
342191|NCT01327612|Monoclonal Antibody
342192|NCT01327612|Tumor Necrosis Factor
342193|NCT01327612|Insulin-like Growth Factor
342194|NCT01327612|Bevacizumab
342195|NCT01327612|Modified FOLFOX6
342196|NCT01327612|mFOLFOX6
342197|NCT01327612|FOLFOX
342198|NCT01327612|Lymphoma
342199|NCT01327612|Trail Receptor
342200|NCT01327612|ganitumab
342201|NCT01327612|conatumumab
342202|NCT01327599|Open-angle glaucoma
342203|NCT01327599|Ocular hypertension
342204|NCT01327599|Pigment dispersion glaucoma
342205|NCT01327599|Intraocular pressure
342206|NCT01327586|disability
342207|NCT01327586|substance abuse
342208|NCT01327586|cocaine abuse
342209|NCT01327586|dual diagnosis
342210|NCT01327586|representative payee
342211|NCT01327586|HIV risk reduction
342212|NCT01327573|chronic kidney allograft injury
342213|NCT01327573|complement protein
342214|NCT01327573|eculizumab
342215|NCT01327573|Kidney transplantation
342216|NCT01327560|hemodialysis patients
342217|NCT01327560|sleep quality
342218|NCT01327560|restless legs syndrome
342219|NCT01327560|excessive daytime sleepiness
342220|NCT01327560|sleep apnea syndrome
342221|NCT01327547|HIV coinfection
342222|NCT01327547|maraviroc
342223|NCT01327547|CCR5 blocker
342224|NCT01327547|entry inhibitor
342225|NCT01327547|liver disease
342226|NCT01327547|viral hepatitis
342227|NCT01327534|STEMI
342228|NCT01327534|clopidogrel
342229|NCT01327534|prasugrel
342230|NCT01327534|platelet reactivity index
342231|NCT01327534|ST resolution
342232|NCT01327495|Androgen replacement in men
342233|NCT01327482|Raltegravir
342234|NCT01327482|Pharmacokinetics
342235|NCT01327456|health literacy
342236|NCT01327456|self-management
342237|NCT01327456|inhaler technique
342238|NCT01327443|NAFLD
342239|NCT01327443|NASH
342240|NCT01327443|Weight loss
342241|NCT01327443|Exercise
342242|NCT01327443|NAS scores
342243|NCT01327443|Mitochondrial dysfunction
342244|NCT01327430|glycerophosphates
342245|NCT01327430|sphingomyelins
342246|NCT01327417|Depression
342247|NCT01327404|Depression
342248|NCT01327404|Diabetes Mellitus
342249|NCT01327391|on line hemodiafiltration
342250|NCT01327391|tolerance
342251|NCT01327391|quality of life
342252|NCT01327391|cardiovascular risk
342253|NCT01327391|Hemodialysis patients
342254|NCT01327365|significant coronary artery disease
342255|NCT01327365|PCI
342256|NCT01327365|radial approach
342257|NCT01327365|women
342258|NCT01327365|bifurcation lesion
342259|NCT01327365|ostial lesion
342260|NCT01327365|7 Fr guiding catheter
342261|NCT01327365|percutaneous coronary intervention
342262|NCT01327352|lupus
342263|NCT01327326|Pain modulation
342264|NCT01327326|Experimental pain
342265|NCT01327313|alpha v integrin
342266|NCT01327313|antibody
342267|NCT01327313|solid tumor
342268|NCT01327313|Japanese
342269|NCT01327313|EMD525797
342270|NCT01327300|Irritable Bowel Syndrome
342271|NCT01327300|Irritable Bowel Syndrome Treatment
342272|NCT01327300|Mesalamine
342273|NCT01327300|Anti-inflammatory drugs
342274|NCT01327300|5-ASA drugs
342275|NCT01327300|Apriso ™
342276|NCT01327287|thoracic epidural
342277|NCT01327287|blunt
342278|NCT01327287|blunt thoracic injury
342279|NCT01327274|Pectus excavatum
342280|NCT01327274|Chest wall deformity
342281|NCT01327274|Magnetic Mini-Mover Procedure
342282|NCT01327274|Pectus Severity Index
342283|NCT01327274|pediatric medical device
342284|NCT01327274|magnetic alteration
342285|NCT01327274|sunken chest
342286|NCT01327261|levodopa
342287|NCT01327261|benserazide
342288|NCT01327261|bioequivalence
342289|NCT01327261|pharmacokinetics
342290|NCT01327261|A Single - Dose
342291|NCT01327261|Randomized- Sequence
342292|NCT01327261|Open -Label Crossover Study
342293|NCT01327248|Bronchiolitis obliterans
342294|NCT01327248|HRCT
342295|NCT01327248|Sputum
342296|NCT01327248|Blood
342297|NCT01327248|Inflammation
342298|NCT01327248|adaptive immune system
342299|NCT01327248|innate immune system
342300|NCT01327222|age-related macular degeneration
342301|NCT01327222|bevacizumab
342302|NCT01327196|dementia
342303|NCT01327196|cardiovascular risk
342304|NCT01327196|elderly
342305|NCT01327196|aging
342306|NCT01327196|older 65-100 years
342307|NCT01327157|Facial Paralysis / rehabilitation.
342308|NCT01327157|Dental Occlusion.
342309|NCT01327157|Occlusal Adjustment.
342310|NCT01327157|Malocclusion / therapy.
342311|NCT01327092|Injury
342312|NCT01327092|Injury Prevention
342313|NCT01327092|Cincinnati Home Injury Prevention
342314|NCT01327092|Injury Hazards
342315|NCT01327092|Modifiable Injury Hazards
342316|NCT01327092|CHIP
342317|NCT01327092|Literacy Promotion
342318|NCT01327092|Reduce exposure to injury hazards
342319|NCT01327092|preventable and medically attended injury
342320|NCT01327092|young children
342321|NCT01327079|NICU
342322|NCT01327079|Methadone
342323|NCT01327079|neonates
342324|NCT01327066|QTc
342325|NCT01327066|ECG Effects
342326|NCT01327053|locally advanced basal cell carcinoma,
342327|NCT01327053|metastatic basal cell carcinoma
342328|NCT01327040|light
342329|NCT01327040|melatonin
342330|NCT01327040|circadian
342331|NCT01327040|delayed sleep phase disorder
342332|NCT01327040|circadian light sensitivity
342333|NCT01327040|circadian timing system
342334|NCT01327027|vasopressin
342335|NCT01327027|antisocial
342336|NCT01327027|affiliation
342337|NCT01327014|Hyperlipidemia
342338|NCT01327014|Cholesterol
342339|NCT01327014|Lipids
342340|NCT01327014|Lipoproteins
342341|NCT01327014|XueZhiKang
342342|NCT01327014|Botanical
342343|NCT01327001|Asthma bronchiale, fixed combination
342344|NCT01326988|Spinal anesthesia
342345|NCT01326988|ultrasound
342346|NCT01326988|real-time
342347|NCT01326975|infant, premature
342348|NCT01326975|infant, very low birth weight
342349|NCT01326975|diaphragm
342350|NCT01326975|apnea
342351|NCT01326975|continuous positive airway pressure
342352|NCT01326936|Online education
342353|NCT01326936|Medical education
342354|NCT01326936|Substance abuse training
342355|NCT01326936|Drug abuse training
342356|NCT01326923|Head
342357|NCT01326923|Neck
342358|NCT01326923|Locally advanced
342359|NCT01326923|Squamous Cell
342360|NCT01326923|Hypopharynx
342361|NCT01326923|Larynx
342362|NCT01326923|Oral Cavity
342363|NCT01326923|Base of Tongue
342364|NCT01326923|Tonsil
342365|NCT01326923|Neck lymph node
342366|NCT01326923|Resection
342367|NCT01326910|Eczema
342368|NCT01326884|aortic aneurysm
342369|NCT01326884|iliac aneurysm
342370|NCT01326884|endovascular procedures
342371|NCT01326871|cancer
342372|NCT01326871|immunotherapy
342373|NCT01326871|immunochemotherapy
342374|NCT01326871|combinational therapy
342375|NCT01326871|targeted
342376|NCT01326871|metastatic
342377|NCT01326871|muscle invasive
342378|NCT01326871|interleukin-2
342379|NCT01326871|cisplatin
342380|NCT01326871|gemcitabine
342381|NCT01326871|antitumor
342382|NCT01326871|TCR
342383|NCT01326871|T-cell receptor
342384|NCT01326871|p53
342385|NCT01326871|p53 gene
342386|NCT01326871|p53 tumor supressor protein
342387|NCT01326871|urothelial cancer
342388|NCT01326871|bladder cancer
342389|NCT01326871|renal pelvis cancer
342390|NCT01326871|ureters cancer
342391|NCT01326871|urethra cancer
342392|NCT01326871|HLA-A2 positive
342393|NCT01326871|HLA-A*0201/p53 aa264-272
342394|NCT01326871|HLA complex
342395|NCT01326871|Muscle Invasive or Metastatic
342396|NCT01326858|Ocular discomfort
342397|NCT01326858|AL-4943A Ophthalmic Solution
342398|NCT01326845|Gastrointestinal adverse events,
342399|NCT01326845|myelodysplastic syndrome,
342400|NCT01326845|transfusional iron overload diarrhea,
342401|NCT01326845|constipation abdominal pain,
342402|NCT01326845|vomiting
342403|NCT01326832|THA
342404|NCT01326819|Near infrared spectroscopy
342405|NCT01326819|Skin pigmentation
342406|NCT01326819|Regional oxygen saturation
342407|NCT01326806|Parent-based intervention
342408|NCT01326806|Sexual risk behavior
342409|NCT01326806|Adolescents
342410|NCT01326793|telepsychiatry
342411|NCT01326793|MDD
342412|NCT01326793|Depression
342413|NCT01326793|Major Depressive Disorder
342414|NCT01326793|Skype
342415|NCT01326793|college
342416|NCT01326793|university
342417|NCT01326780|Acne
342418|NCT01326780|Irritation
342419|NCT01326780|Safety
342420|NCT01326780|Sebum
342421|NCT01326741|clonal mast cell disorder
342422|NCT01326741|exercise-induced anaphylaxis
342423|NCT01326741|hypotension
342424|NCT01326728|Relapse
342425|NCT01326728|Hematologic Malignancy
342426|NCT01326728|Allogeneic
342427|NCT01326728|Hematopoietic Stem Cell Transplantation
342428|NCT01326728|Leukemia
342429|NCT01326728|Lymphoma
342430|NCT01326728|Hodgkin Lymphoma
342431|NCT01326715|Multiple Sclerosis
342432|NCT01326715|MRI
342433|NCT01326715|Manganese Enhanced MRI
342434|NCT01326715|Optic Neuritis
342435|NCT01326715|Healthy Volunteer
342436|NCT01326676|Polypill
342437|NCT01326676|Red Heart Pill
342438|NCT01326676|Cardiovascular disease
342439|NCT01326676|Secondary prevention
342440|NCT01326676|carotid intima media thickness
342441|NCT01326663|Veterans
342442|NCT01326663|TBI
342443|NCT01326663|Alcoholism
342444|NCT01326663|Mood
342445|NCT01326650|vitamin D, mortality, event-free survival, heart failure
342446|NCT01326637|primary health care
342447|NCT01326637|aged
342448|NCT01326624|heart failure
342449|NCT01326624|ventricular dysfunction
342450|NCT01326624|sudden death
342451|NCT01326624|sudden cardiac arrest
342452|NCT01326624|ventricular tachycardia
342453|NCT01326624|ventricular fibrillation
342454|NCT01326624|wearable defibrillator
342455|NCT01326611|Chronic lung disease
342456|NCT01326611|Clarithromycin
342457|NCT01326611|Ureaplasma urealyticum
342458|NCT01326598|V Go™
342459|NCT01326598|Type 2 Diabetes
342460|NCT01326598|Insulin
342461|NCT01326598|Oral Anti Hypoglycemic Drugs
342462|NCT01326585|Scleral Buckling
342463|NCT01326585|Dexamethasone
342464|NCT01326585|Post-operative Nausea and Vomiting
342465|NCT01326572|HIV
342466|NCT01326572|Pulmonary disease
342467|NCT01326572|emphysema
342468|NCT01326572|COPD
342469|NCT01326559|induction chemotherapy
342470|NCT01326559|docetaxel
342471|NCT01326559|cisplatin
342472|NCT01326559|fluorouracil
342473|NCT01326559|cetuximab
342474|NCT01326559|intensity-modulated radiotherapy
342475|NCT01326546|Therapeutic HBV Vaccine
342476|NCT01326546|Chronic Hepatitis B
342477|NCT01326546|HBeAg positive
342478|NCT01326533|pre-diabetes
342479|NCT01326533|hydroxychloroquine
342480|NCT01326533|frequently sampled intravenous glucose tolerance testing
342481|NCT01326533|insulin resistance
342482|NCT01326533|insulin secretion
342483|NCT01326533|glucose tolerance
342484|NCT01326507|pulmonary embolism
342485|NCT01326507|Heart-type fatty acid-binding protein
342486|NCT01326507|cardiac biomarkers
342487|NCT01326507|risk stratification
342488|NCT01326494|Upper Respiratory Tract Infection
342489|NCT01326494|Asthma
342490|NCT01326494|URTI induced exacerbation of Asthma
342491|NCT01326481|TRC105
342492|NCT01326481|Breast Cancer
342493|NCT01326481|CD105
342494|NCT01326481|Endoglin
342495|NCT01326481|TRACON Pharma
342496|NCT01326481|Roswell Park Cancer Institute
342497|NCT01326481|Department of Defense
342498|NCT01326468|head and neck cancer
342499|NCT01326468|temsirolimus
342500|NCT01326468|cetuximab
342501|NCT01326468|cisplatin
342502|NCT01326468|radiation therapy
342503|NCT01326455|transradial
342504|NCT01326455|angiogram
342505|NCT01326455|device
342506|NCT01326455|Care of the radial artery post transradial angiogram
342507|NCT01326442|weight loss
342508|NCT01326442|overweight
342509|NCT01326442|body composition
342510|NCT01326442|visceral obesity
342511|NCT01326442|insulin
342512|NCT01326442|glucose tolerance
342513|NCT01326442|cholesterol
342514|NCT01326442|hypertriglyceridemia
342515|NCT01326429|Sodium
342516|NCT01326429|Hyponatremia
342517|NCT01326429|Hypernatremia
342518|NCT01326429|Emergency department
342519|NCT01326416|obesity
342520|NCT01326416|metabolic syndrome
342521|NCT01326416|leucine
342522|NCT01326416|arginine
342523|NCT01326416|physical activity
342524|NCT01326403|proximal
342525|NCT01326403|hip
342526|NCT01326403|fractures
342527|NCT01326338|Diarrhea
342528|NCT01326325|Cancer
342529|NCT01326325|Refractory pain
342530|NCT01326325|Uncontrolled pain
342531|NCT01326325|Ketamine
342532|NCT01326286|Comparative Effectiveness Research
342533|NCT01326286|Prostatectomy
342534|NCT01326286|radiotherapy
342535|NCT01326286|quality of life
342536|NCT01326273|CMV
342537|NCT01326273|cytomegalovirus
342538|NCT01326273|autologous
342539|NCT01326273|leukemia
342540|NCT01326273|hematological malignancies
342541|NCT01326273|stem cell transplantation
342542|NCT01326273|CMV reactivation
342543|NCT01326273|adoptive therapy
342544|NCT01326260|resuscitation
342545|NCT01326260|trauma
342546|NCT01326260|THAM
342547|NCT01326260|colloids
342548|NCT01326260|crystalloids
342549|NCT01326234|Smoking
342550|NCT01326234|Motivation
342551|NCT01326234|Cessation
342552|NCT01326221|Truvada
342553|NCT01326221|tenofovir
342554|NCT01326221|emtricitabine
342555|NCT01326221|Pharmacokinetics
342556|NCT01326221|Healthy Volunteers
342557|NCT01326208|electrical impedance tomography
342558|NCT01326208|positive end-expiratory pressure
342559|NCT01326208|regional ventilation delay index
342560|NCT01326195|HIV Prevention
342561|NCT01326195|Dating Violence
342562|NCT01326195|Females
342563|NCT01326195|Romantic relationships
342564|NCT01326195|Adolescents
342565|NCT01326195|Sexuality
342566|NCT01326195|Underserved youth
342567|NCT01326182|asthma
342568|NCT01326182|depression
342569|NCT01326182|Latino
342570|NCT01326169|Alcohol
342571|NCT01326169|brief intervention
342572|NCT01326169|injuries
342573|NCT01326156|Osteoarthritis
342574|NCT01326156|Knee
342575|NCT01326156|Knee cap
342576|NCT01326156|Patella
342577|NCT01326156|Patellofemoral
342578|NCT01326143|MRD
342579|NCT01326143|Narval
342580|NCT01326143|Oral appliance
342581|NCT01326143|Obstructive Sleep apnea
342582|NCT01326143|OSAH
342583|NCT01326143|OSA treatment
342584|NCT01326130|Integrated care network
342585|NCT01326130|Chronic care model
342586|NCT01326130|Health services research
342587|NCT01326117|gastroparesis
342588|NCT01326117|gastric emptying
342589|NCT01326117|diabetes
342590|NCT01326117|Stomach Diseases
342591|NCT01326117|Gastrointestinal Diseases
342592|NCT01326117|Digestive System Diseases
342593|NCT01326117|Phosphodiesterase Inhibitors
342594|NCT01326117|Neurologic Manifestations
342595|NCT01326117|Paralysis
342596|NCT01326117|Signs and Symptoms
342597|NCT01326117|Pharmacologic Actions
342598|NCT01326104|Medulloblastoma
342599|NCT01326104|Primitive Neuroectodermal Tumor
342600|NCT01326091|Lumbar fusion surgery
342601|NCT01326078|sedation
342602|NCT01326078|children
342603|NCT01326078|leukemia
342604|NCT01326078|bone marrow biopsy
342605|NCT01326013|Stool
342606|NCT01326013|Feces
342607|NCT01326013|Gastrointestinal
342608|NCT01326013|Pathogen
342609|NCT01326013|Panel
342610|NCT01326013|xTAG GPP
342611|NCT01326013|Infectious colitis
342612|NCT01326013|Gastroenteritis
342613|NCT01326013|Detection
342614|NCT01325987|Type 2 diabetes
342615|NCT01325987|Vitamin D deficiency
342616|NCT01325987|Glycemic control
342617|NCT01325974|Malaria
342618|NCT01325974|Plasmodium falciparum
342619|NCT01325974|Diagnosis
342620|NCT01325974|Rapid diagnostic test
342621|NCT01325974|malaria transmission
342622|NCT01325961|prostate, cervical and anal canal cancers with pelvic lymph node irradiation
342623|NCT01325948|COPD
342624|NCT01325935|Coronary Artery Disease
342625|NCT01325935|Coronary Disease
342626|NCT01325935|Myocardial Ischemia
342627|NCT01325935|Heart Disease
342628|NCT01325935|Cardiovascular Disease
342629|NCT01325935|Arteriosclerosis
342630|NCT01325935|Arterial Occlusive Disease
342631|NCT01325935|Vascular Disease
342632|NCT01325935|Clopidogrel
342633|NCT01325935|Platelet Aggregation Inhibitors
342634|NCT01325896|Multiple Mieloma, PEG-Intron
342635|NCT01325870|cardiopulmonary resuscitation
342636|NCT01325818|Coronary Artery Disease
342637|NCT01325818|Coronary Disease
342638|NCT01325818|Dyslipidemia
342639|NCT01325818|Stable Angina Pectoris
342640|NCT01325818|Heart Diseases
342641|NCT01325818|Cardiovascular Diseases
342642|NCT01325818|Arteriosclerosis
342643|NCT01325818|Arterial Occlusive Diseases
342644|NCT01325818|Vascular Diseases Pravastatin
342645|NCT01325818|Rosuvastatin
342646|NCT01325818|Anticholesteremic Agents
342647|NCT01325818|Antilipemic Agents
342648|NCT01325818|Antimetabolites
342649|NCT01325818|Molecular Mechanisms of Pharmacological Action
342650|NCT01325818|Pharmacologic Actions
342651|NCT01325818|Therapeutic Uses
342652|NCT01325818|Hydroxymethylglutaryl-CoA Reductase Inhibitors
342653|NCT01325805|Miscarriage
342654|NCT01325805|Recurrent Pregnancy Loss
342655|NCT01325805|Obesity
342656|NCT01325805|Overweight
342657|NCT01325805|Diet
342658|NCT01325792|Complex ventral incisional hernia repair
342659|NCT01325792|reapproximation of the rectus abdominis muscle
342660|NCT01325792|retrorectus or intraperitoneal placement technique
342661|NCT01325792|mobility for midline fascial closure
342662|NCT01325779|deep venous thrombosis
342663|NCT01325779|DVT
342664|NCT01325779|enoxaparin
342665|NCT01325779|heparin
342666|NCT01325779|surgical intensive care
342667|NCT01325766|Cystic Fibrosis
342668|NCT01325766|Yoga
342669|NCT01325701|PCI-32765
342670|NCT01325701|Lymphoma, B-Cell
342671|NCT01325701|Bruton's Tyrosine Kinase
342672|NCT01325701|Non Hodgkin's Lymphoma
342673|NCT01325701|Germinal Center B-Cell
342674|NCT01325701|Activated B-Cell
342675|NCT01325688|PEP005
342676|NCT01325688|Peplin
342677|NCT01325688|sBCC
342678|NCT01325675|Atrial fibrillation
342679|NCT01325675|Motor activity
342680|NCT01325649|rectal cancer
342681|NCT01325649|MRI
342682|NCT01325649|selective preoperative radiochemotherapy
342683|NCT01325649|involvement of circumferential resection margin
342684|NCT01325649|locoregional recurrence rate
342685|NCT01325636|Allogenic haematopoietic stem cell transplant
342686|NCT01325636|Cytomegalovirus or Adenovirus infection
342687|NCT01325636|Graft versus Host
342688|NCT01325623|Automatic Magnet Mode (AMM)
342689|NCT01325623|Vagal Nerve Stimulation
342690|NCT01325610|vitamin D
342691|NCT01325610|kidney
342692|NCT01325610|renal
342693|NCT01325597|Heart failure
342694|NCT01325597|Electric stimulation
342695|NCT01325597|Breathing exercises
342696|NCT01325571|prograf
342697|NCT01325571|immunosuppressant
342698|NCT01325558|cancer
342699|NCT01325558|tissue factor
342700|NCT01325558|solid tumor
342701|NCT01325558|ovarian cancer
342702|NCT01325558|breast cancer
342703|NCT01325558|non-small cell lung cancer
342704|NCT01325558|colon cancer
342705|NCT01325558|pancreatic cancer
342706|NCT01325558|head and neck cancer
342707|NCT01325558|prostate cancer
342708|NCT01325558|soft-tissue sarcoma
342709|NCT01325558|metastatic
342710|NCT01325558|gemcitabine
342711|NCT01325558|anti-tumor
342712|NCT01325558|venous thromboembolism
342713|NCT01325545|Stroke
342714|NCT01325545|Atrial Fibrillation
342715|NCT01325532|depression
342716|NCT01325532|Major Depressive Disorder
342717|NCT01325532|MDD
342718|NCT01325532|Cranial Electrical Stimulation
342719|NCT01325532|CES
342720|NCT01325506|Prostatectomy
342721|NCT01325493|opioid tolerance
342722|NCT01325493|hyperalgesia
342723|NCT01325493|scoliosis
342724|NCT01325493|pupillometry
342725|NCT01325480|Cardiac Resynchronization Therapy
342726|NCT01325480|Pacing
342727|NCT01325480|His Bundle
342728|NCT01325467|coronary artery disease
342729|NCT01325467|high frequency QRS analysis
342730|NCT01325467|ischemia
342731|NCT01325467|exercise testing
342732|NCT01325467|diagnosis of coronary artery disease
342733|NCT01325454|Pleural effusion
342734|NCT01325454|angiogenic cytokine
342735|NCT01325454|fibrinolytic activity
342736|NCT01325441|BBI608
342737|NCT01325415|Phase 1
342738|NCT01325415|healthy male volunteers
342739|NCT01325415|cross-over study
342740|NCT01325415|NKTR-118
342741|NCT01325402|Radioligand
342742|NCT01325402|Alzheimers disease
342743|NCT01325402|Maximum Diagnostic Mass
342744|NCT01325402|Beta amyloid
342745|NCT01325376|overweight
342746|NCT01325376|obesity
342747|NCT01325363|Schizophrenia
342748|NCT01325363|Novel metaphor
342749|NCT01325298|Keratoconus
342750|NCT01325298|Ectasia
342751|NCT01325298|cross linking
342752|NCT01325298|collagen cross linking
342753|NCT01325298|corneal crosslinking
342754|NCT01325298|corneal diseases
342755|NCT01325298|eye diseases
342756|NCT01325285|Intraocular pressure
342757|NCT01325285|Hypercapnia
342758|NCT01325285|Hyperoxia
342759|NCT01325285|Rebreathing circuit
342760|NCT01325272|otoacoustic emissions in newborns
342761|NCT01325246|ventral hernia
342762|NCT01325246|repair
342763|NCT01325246|clinical
342764|NCT01325246|reoperation
342765|NCT01325233|Astragulus polysaccharides
342766|NCT01325233|Hemorrhagic stroke
342767|NCT01325207|Breast Cancer
342768|NCT01325194|DLBCL
342769|NCT01325194|FL grade 3B
342770|NCT01325194|high risk
342771|NCT01325194|CNS prophylaxis
342772|NCT01325194|chemoimmunotherapy
342773|NCT01325181|Chronic central serous chorioretinopathy
342774|NCT01325181|Ranibizumab
342775|NCT01325181|Photodynamic therapy
342776|NCT01325168|PTSD
342777|NCT01325168|empathy
342778|NCT01325168|oxytocin
342779|NCT01325155|Air Pollution
342780|NCT01325155|particulate matter
342781|NCT01325155|cardiovascular Disease
342782|NCT01325142|Osteonecrosis of the Jaw (ONJ)
342783|NCT01325129|ESIN
342784|NCT01325129|Clavicular Fracture
342785|NCT01325129|Dislocation
342786|NCT01325129|Children
342787|NCT01325129|Adolescents
342788|NCT01325116|STEMI
342789|NCT01325116|Medication Adherence
342790|NCT01325116|Quality Improvement
342791|NCT01325103|Spinal cord injury
342792|NCT01325103|Mesenchymal stem cells
342793|NCT01325103|Bone marrow
342794|NCT01325090|neuropathic pain due to thoracotomy
342795|NCT01325090|Neuropathic Pain Due to Thoracoscopy
342796|NCT01325077|Nurse-based, acute pain service, pediatric, postoperative,
342797|NCT01325077|pain
342798|NCT01325064|Carotid Artery Diseases
342799|NCT01325064|Blood Pressure
342800|NCT01325064|Blood Pressure Monitoring, Ambulatory
342801|NCT01325064|Peripheral Vascular Diseases
342802|NCT01325064|Retinal Vessels
342803|NCT01325051|raltegravir
342804|NCT01325051|pharmacokinetics
342805|NCT01325051|healthy
342806|NCT01325051|male
342807|NCT01325051|volunteers
342808|NCT01325051|gastrointestinal
342809|NCT01325051|tract
342810|NCT01325038|resting metabolic rate
342811|NCT01325025|Metachromatic Leukodystrophy
342812|NCT01325025|Demyelinating Diseases
342813|NCT01325025|Magnetic Resonance Imaging
342814|NCT01325025|Diffusion Tensor Imaging
342815|NCT01325025|Relaxometry
342816|NCT01325025|Spectroscopy
342817|NCT01325025|Longitudinal Studies
342818|NCT01325012|Pain
342819|NCT01325012|Surgery
342820|NCT01325012|Catheter
342821|NCT01325012|Nerve Block
342822|NCT01325012|Popliteal
342823|NCT01325012|Subgluteal
342824|NCT01325012|Sciatic
342825|NCT01325012|UCSD
342826|NCT01325012|Moderate-to-severe pain
342827|NCT01325012|Perineural Catheter
342828|NCT01325012|Orthopedic Surgery
342829|NCT01325012|foot surgery surgery
342830|NCT01325012|sciatic perineural catheter
342831|NCT01325012|age =>18
342832|NCT01324999|Sarcoidosis Associated Pulmonary Hypertension
342833|NCT01324986|extraesophageal symptoms of gastroesophageal reflux disease
342834|NCT01324973|Medical Informatics
342835|NCT01324973|Therapy, Computer-Assisted
342836|NCT01324973|Health Education
342837|NCT01324973|Diet
342838|NCT01324973|Exercise
342839|NCT01324960|IPSS
342840|NCT01324960|High risk
342841|NCT01324960|Azacitidine
342842|NCT01324960|Ceplene
342843|NCT01324947|Myeloma
342844|NCT01324947|Multiple Myeloma
342845|NCT01324947|Relapsed Multiple Myeloma
342846|NCT01324947|Relapsed and Refractory Multiple Myeloma
342847|NCT01324947|Refractory Myeloma
342848|NCT01324947|Resistant Multiple Myeloma
342849|NCT01324947|Treatment-resistant Multiple Myeloma
342850|NCT01324947|Pomalidomide
342851|NCT01324947|Lenalidomide-resistant
342852|NCT01324947|Bortezomib-resistant
342853|NCT01324947|Companion
342854|NCT01324934|acute rejection
342855|NCT01324934|chronic rejection
342856|NCT01324934|subclinical rejection
342857|NCT01324934|renal transplantation
342858|NCT01324934|steroid-free
342859|NCT01324934|kidney transplantation
342860|NCT01324895|Small intestinal bacterial overgrowth syndrome (SIBO)
342861|NCT01324895|bacterial overgrowth syndrome
342862|NCT01324895|Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
342863|NCT01324895|14-Co2 D-Xylose Breath Testing
342864|NCT01324895|Antibiotics
342865|NCT01324895|Prokinteics
342866|NCT01324895|Prokinetic Agents
342867|NCT01324882|colonoscopy
342868|NCT01324869|KH902
342869|NCT01324869|Diabetic macular Edema
342870|NCT01324869|Intravitreal injection
342871|NCT01324869|Multiple injections
342872|NCT01324869|20 patients
342873|NCT01324869|0.5mg/eye/time
342874|NCT01324856|pancreatic cancer
342875|NCT01324856|periampulary cancer
342876|NCT01324856|pancreaticogastro vs pancreaticojejuno anastomosis
342877|NCT01324843|Safety and Tolerability
342878|NCT01324843|Intradermal Electroporation
342879|NCT01324817|Non-Contact
342880|NCT01324817|Radar
342881|NCT01324817|Doppler
342882|NCT01324817|Respiratory
342883|NCT01324817|Respiration
342884|NCT01324817|Breathing
342885|NCT01324817|Rate
342886|NCT01324817|Frequency
342887|NCT01324817|Respiratory Mechanics
342888|NCT01324817|Respiratory Rate Measurement
342889|NCT01324817|Apnea
342890|NCT01324817|Sleep Apnea
342891|NCT01324804|postoperative wound healing
342892|NCT01324778|Edentulism in the Upper Jaw
342893|NCT01324765|Women
342894|NCT01324765|PTSD
342895|NCT01324765|Group Therapy
342896|NCT01324765|Incarceration
342897|NCT01324752|Drug-drug interaction
342898|NCT01324752|Pharmacokinetics
342899|NCT01324752|PA21
342900|NCT01324726|Bacterial colonization
342901|NCT01324726|Extended spectrum beta lactamase producing organisms
342902|NCT01324687|Telemedicine
342903|NCT01324687|Geriatrics
342904|NCT01324674|Common Mental Disorder
342905|NCT01324674|Efficacy of Bach´s flower remedy
342906|NCT01324674|Spiritual well-being
342907|NCT01324648|Guided self-help
342908|NCT01324648|Telephone delivery
342909|NCT01324648|Cognitive behavior therapy
342910|NCT01324648|Bibliotherapy
342911|NCT01324635|glioma
342912|NCT01324635|meningioma
342913|NCT01324635|brain metastasis
342914|NCT01324635|stereotactic
342915|NCT01324635|radiotherapy
342916|NCT01324635|radiosurgery
342917|NCT01324622|Spinal Cord Diseases
342918|NCT01324622|Myelopathy
342919|NCT01324622|Myeloradiculopathy
342920|NCT01324622|Laminectomy
342921|NCT01324622|Laminoplasty
342922|NCT01324609|choroidal nevus
342923|NCT01324609|vitrectomy
342924|NCT01324596|Lymphoma, Large B-Cell, Diffuse
342925|NCT01324596|Bortezomib
342926|NCT01324596|R-CHOP
342927|NCT01324596|Molecular profiling
342928|NCT01324596|Chemotherapy
342929|NCT01324570|Pain
342930|NCT01324570|Opioid
342931|NCT01324570|Analgesia
342932|NCT01324570|Moderate to severe pain
342933|NCT01324557|Continuous glucose monitoring
342934|NCT01324557|CAPD patients
342935|NCT01324557|Insulin pump
342936|NCT01324544|Acute Pain
342937|NCT01324544|Opioid
342938|NCT01324544|Analgesia
342939|NCT01324531|Bankart repair
342940|NCT01324531|remplissage
342941|NCT01324531|Hill-Sachs defect
342942|NCT01324531|shoulder instability
342943|NCT01324531|anterior shoulder instability
342944|NCT01324492|phase Ib,
342945|NCT01324492|RAD001,
342946|NCT01324492|advanced pulmonary neuroendocrine tumor
342947|NCT01324479|Non-small cell lung cancer,
342948|NCT01324479|hepatocellular,
342949|NCT01324479|gastric,
342950|NCT01324479|renal cell,
342951|NCT01324479|c-MET,
342952|NCT01324479|refractory,
342953|NCT01324479|glioblastoma,
342954|NCT01324479|breast,
342955|NCT01324479|nasopharyngeal,
342956|NCT01324479|confirmed evidence of c-MET dysregulation
342957|NCT01324453|Acute Myocardial Infarction
342958|NCT01324453|STEMI
342959|NCT01324453|Post Conditioning
342960|NCT01324453|Primary Percutaneous Coronary Intervention
342961|NCT01324440|Bacterial Vaccines
342962|NCT01324440|Staphylococcus Aureus
342963|NCT01324440|Adjuvanted Vaccine
342964|NCT01324427|Telemedicine
342965|NCT01324427|Virtual Medical Visit
342966|NCT01324427|Quality of Life
342967|NCT01324427|11-022
342968|NCT01324401|Peanut Allergy
342969|NCT01324401|Peanut Hypersensitivity
342970|NCT01324362|FP
342971|NCT01324362|Asthma
342972|NCT01324362|Sont
342973|NCT01324362|FSC
342974|NCT01324362|BHR
342975|NCT01324349|Hepatic
342976|NCT01324349|Topical Hemostat
342977|NCT01324336|ALL
342978|NCT01324336|acute lymphoblastic leukemia
342979|NCT01324336|6-Mercaptopurine
342980|NCT01324336|Pediatric
342981|NCT01324323|ROMI-001
342982|NCT01324323|romi
342983|NCT01324323|Romidepsin
342984|NCT01324323|Istodax
342985|NCT01324323|advanced malignancy
342986|NCT01324323|PK
342987|NCT01324323|pharmacokinetics
342988|NCT01324310|ROMI-001
342989|NCT01324310|romi
342990|NCT01324310|Romidepsin
342991|NCT01324310|Istodax
342992|NCT01324310|advanced malignancy
342993|NCT01324310|PK
342994|NCT01324310|pharmacokinetics
342995|NCT01324297|Diagnostic Techniques and Procedures
342996|NCT01324297|Sensitivity and Specificity
342997|NCT01324297|Skin Tests
342998|NCT01324297|Biological Markers
342999|NCT01324284|Lubiprostone
343000|NCT01324284|Bowel preparation regime
343001|NCT01324271|Tympanostomy tube placement
343002|NCT01324258|pancreatic cancer (combination with gemcitabine)
343003|NCT01324258|Non-small cell lung cancer (combination with gemcitabine)
343004|NCT01324258|solid tumors (single agent)
343005|NCT01324258|MEK inhibitor
343006|NCT01324258|GSK1120212
343007|NCT01324258|biliary cancer (combination with gemcitabine)
343008|NCT01324258|urothelial cancer (combination with gemcitabine)
343009|NCT01324245|Salt
343010|NCT01324245|Balance
343011|NCT01324245|Renin Angiotensin System
343012|NCT01324245|Fenoldopam\blood Pressure
343013|NCT01324245|Sodium
343014|NCT01324219|nursing staff
343015|NCT01324219|residents
343016|NCT01324206|Whole-Body
343017|NCT01324206|Development
343018|NCT01324206|Exposure
343019|NCT01324206|Magnetic
343020|NCT01324206|Resonance
343021|NCT01324180|ALL
343022|NCT01324180|Relapsed
343023|NCT01324180|Refractory
343024|NCT01324167|schizophrenia
343025|NCT01324167|schizoaffective disorder
343026|NCT01324141|Anal Cancer
343027|NCT01324141|Radioprotector
343028|NCT01324141|Topical
343029|NCT01324141|Radiation
343030|NCT01324141|Dermatitis
343031|NCT01324128|PA21
343032|NCT01324128|Phosphate Binder
343033|NCT01324115|unspecified adult solid tumor, protocol specific
343034|NCT01324102|Neoplasms
343035|NCT01324089|Resveratrol
343036|NCT01324089|Piperine
343037|NCT01324076|adult primary hepatocellular carcinoma
343038|NCT01324076|localized unresectable adult primary liver cancer
343039|NCT01324076|advanced adult primary liver cancer
343040|NCT01324063|untreated adult acute myeloid leukemia
343041|NCT01324037|suspected upper extremity deep vein thrombosis
343042|NCT01324037|diagnostic algorithm
343043|NCT01324024|Menopause
343044|NCT01324024|Aging
343045|NCT01324024|Memory
343046|NCT01324024|Women
343047|NCT01323998|enlarged prostate
343048|NCT01323998|Benign prostatic hyperplasia
343049|NCT01323998|alpha-blocker
343050|NCT01323998|5-alpha-reductase inhibitor
343051|NCT01323972|Malaria
343052|NCT01323972|Plasmodium falciparum
343053|NCT01323959|BoostrixTM Polio
343054|NCT01323959|dTpa-IPV
343055|NCT01323959|booster
343056|NCT01323946|H5N1
343057|NCT01323946|influenza infection
343058|NCT01323946|Influenza vaccine GSK1562902A
343059|NCT01323933|Solid tumors
343060|NCT01323933|Oncology
343061|NCT01323933|Cancer
343062|NCT01323920|Stem Cell Transplant
343063|NCT01323920|Allogeneic Transplant
343064|NCT01323920|Donors
343065|NCT01323907|Total Parenteral Nutrition-induced Cholestasis
343066|NCT01323907|Omegaven
343067|NCT01323907|liver disease
343068|NCT01323907|Cholestasis
343069|NCT01323907|Fat emulsions
343070|NCT01323881|theta burst stimulation, stroke, motor, plasticity
343071|NCT01323842|renal colic
343072|NCT01323842|hydronephrosis
343073|NCT01323842|abdominal aortic aneurysm
343074|NCT01323842|ultrasound
343075|NCT01323842|emergency medicine
343076|NCT01323842|urolithiasis
343077|NCT01323829|High Tone Pelvic Floor Dysfunction
343078|NCT01323829|Botulinum toxin type A
343079|NCT01323829|EMG
343080|NCT01323803|Eosinophilic Esophagitis
343081|NCT01323790|Non-Cancer-Related Pain
343082|NCT01323790|Opioid-Induced Constipation
343083|NCT01323764|Hydrocephalus
343084|NCT01323764|CSF shunts
343085|NCT01323764|Normal Pressure Hydrocephalus
343086|NCT01323764|NPH
343087|NCT01323764|ShuntCheck
343088|NCT01323764|Shunt Malfunction
343089|NCT01323764|Suspected shunt malfunction in adult hydrocephalus patients
343090|NCT01323738|Psychoeducation
343091|NCT01323738|Group Control
343092|NCT01323725|Team-based financial incentives
343093|NCT01323725|Smoking cessation
343094|NCT01323712|CKD
343095|NCT01323712|LV mass
343096|NCT01323712|Vitamin D
343097|NCT01323712|LV function
343098|NCT01323699|Parkinson Disease
343099|NCT01323699|Anxiety
343100|NCT01323699|Depression
343101|NCT01323647|IPV
343102|NCT01323647|PoliorixTM
343103|NCT01323647|China
343104|NCT01323608|Thalassemia
343105|NCT01323608|hypercalciuria
343106|NCT01323608|vitamin D
343107|NCT01323608|To conduct a pilot study to determine the effect of various doses of
343108|NCT01323608|vitamin D supplementation on vitamin D stores and their association with calcium excretion
343109|NCT01323595|Pain control
343110|NCT01323595|testicular sperm extraction
343111|NCT01323595|sperm
343112|NCT01323582|Gastroparesis
343113|NCT01323582|Gastroparesis Treatment
343114|NCT01323582|Gastric Emptying
343115|NCT01323582|Prokinetic Agents
343116|NCT01323582|Macrolides
343117|NCT01323582|Erythromycin
343118|NCT01323582|Azithromycin
343119|NCT01323582|Erythromycin Cardiac Side-effects
343120|NCT01323582|Erythromycin drug interactions
343121|NCT01323582|AZI
343122|NCT01323569|Sativex
343123|NCT01323569|Cannabinoids
343124|NCT01323569|Abuse potential
343125|NCT01323569|Addiction
343126|NCT01323556|Panic disorder
343127|NCT01323556|agoraphobia
343128|NCT01323556|panic attacks
343129|NCT01323556|exposure based learning
343130|NCT01323556|interoceptive exposure exercises
343131|NCT01323556|fear augmentation
343132|NCT01323556|in vivo exposure
343133|NCT01323543|Back Pain,
343134|NCT01323543|Back Pains, Low
343135|NCT01323543|Low Back Pains
343136|NCT01323543|Pain, Low Back
343137|NCT01323543|Pains, Low Back
343138|NCT01323543|Lumbago
343139|NCT01323543|Lower Back Pain
343140|NCT01323543|Back Pain, Lower
343141|NCT01323543|Back Pains, Lower
343142|NCT01323543|Lower Back Pains
343143|NCT01323543|Pain, Lower Back
343144|NCT01323543|Pains, Lower Back
343145|NCT01323543|Low Back Ache
343146|NCT01323543|Ache, Low Back
343147|NCT01323543|Aches, Low Back
343148|NCT01323543|Back Ache, Low
343149|NCT01323543|Back Aches, Low
343150|NCT01323543|Low Back Aches
343151|NCT01323543|Low Backache
343152|NCT01323543|Backache, Low
343153|NCT01323543|Backaches, Low
343154|NCT01323543|Low Backaches
343155|NCT01323543|Low Back Pain, Recurrent
343156|NCT01323543|Recurrent Low Back Pain
343157|NCT01323543|Low Back Pain, Postural
343158|NCT01323543|Postural Low Back Pain
343159|NCT01323543|Low Back Pain, Mechanical
343160|NCT01323543|Mechanical Low Back Pain
343161|NCT01323543|Low Back Pain, Posterior Compartment
343162|NCT01323530|metastatic breast cancer
343163|NCT01323517|skin
343164|NCT01323517|DACTINOMYCIN
343165|NCT01323517|MDX-010 (Ipilimumab)
343166|NCT01323517|MELPHALAN
343167|NCT01323517|Isolated Limb Infusion
343168|NCT01323517|10-101
343169|NCT01323504|Stage 5 arteritis
343170|NCT01323504|Stage 6 arteritis
343171|NCT01323504|rutherford classification
343172|NCT01323491|smoking cessation
343173|NCT01323491|nicotine replacement therapy
343174|NCT01323491|routine smokers
343175|NCT01323478|Depressive Disorder
343176|NCT01323478|Depression
343177|NCT01323478|Depressive Disorder, Major
343178|NCT01323478|Mood Disorders
343179|NCT01323478|Mental Disorders
343180|NCT01323478|Behavioural Symptoms
343181|NCT01323465|Sativex
343182|NCT01323465|Cytochrome P450
343183|NCT01323465|Pharmacokinetics
343184|NCT01323465|Cannabinoids
343185|NCT01323465|ketoconazole
343186|NCT01323465|omeprazole
343187|NCT01323465|rifampicin
343188|NCT01323452|entecavir
343189|NCT01323452|hepatitis B
343190|NCT01323439|Patients presenting with an intracranial aneurysm
343191|NCT01323426|urinary incontinence, stress
343192|NCT01323426|autologous
343193|NCT01323413|stroke
343194|NCT01323413|penumbra
343195|NCT01323413|determinants
343196|NCT01323413|CT perfusion
343197|NCT01323400|GIST
343198|NCT01323400|Resistant
343199|NCT01323400|Pazopanib
343200|NCT01323400|Tyrosine kinase inhibitor
343201|NCT01323400|Best supportive care
343202|NCT01323400|Progression-free survival
343203|NCT01323400|Overall survival
343204|NCT01323400|Objective response rate
343205|NCT01323400|Best response
343206|NCT01323400|Tolerance profile
343207|NCT01323374|Fibromyalgia
343208|NCT01323374|FMS
343209|NCT01323374|droxidopa
343210|NCT01323374|pain
343211|NCT01323361|inflammation
343212|NCT01323361|laparoscopy
343213|NCT01323361|hernia
343214|NCT01323361|incisional
343215|NCT01323361|trauma
343216|NCT01323348|Diabetes
343217|NCT01323348|Diabetes Education
343218|NCT01323348|Diabetic Retinopathy
343219|NCT01323348|HbA1c
343220|NCT01323335|Uric Acid
343221|NCT01323335|Rasburicase
343222|NCT01323335|Inflammatory Markers
343223|NCT01323322|Health Disparities
343224|NCT01323322|Diversity
343225|NCT01323322|Socioeconomic Status
343226|NCT01323322|Epidemiology
343227|NCT01323309|Supportive Psychotherapy
343228|NCT01323309|Therapy
343229|NCT01323309|11-021
343230|NCT01323296|Myocardial infarction
343231|NCT01323296|Magnetic resonance
343232|NCT01323296|Nanoparticle
343233|NCT01323296|Iron
343234|NCT01323296|Inflammation
343235|NCT01323283|Omega-3
343236|NCT01323283|physical activity
343237|NCT01323283|children
343238|NCT01323283|obesity
343239|NCT01323283|sedentary
343240|NCT01323283|accelerometry
343241|NCT01323283|BMI
343242|NCT01323283|fatty acids
343243|NCT01323283|inflammatory markers
343244|NCT01323283|intervention
343245|NCT01323283|randomized
343246|NCT01323283|double blind
343247|NCT01323270|Healthy adolescents
343248|NCT01323257|TMC435-TiDP16-C115
343249|NCT01323257|TMC435-C115
343250|NCT01323257|TMC435
343251|NCT01323257|HCV
343252|NCT01323257|Hepatitis C
343253|NCT01323257|Hep C
343254|NCT01323257|healthy volunteers
343255|NCT01323244|TMC435-TiDP16-C213
343256|NCT01323244|TMC435-C213
343257|NCT01323244|TMC435
343258|NCT01323244|HCV
343259|NCT01323244|Hepatitis C
343260|NCT01323231|XY-Zone
343261|NCT01323231|school drop-out risk
343262|NCT01323231|protective factors
343263|NCT01323231|truancy
343264|NCT01323218|Obstructive sleep apnea-hypopnea syndrome
343265|NCT01323218|OSAHS
343266|NCT01323218|Vitamin D
343267|NCT01323205|JNJ-40411813
343268|NCT01323192|Concerta
343269|NCT01323192|Adults
343270|NCT01323192|Attention-Deficit/Hyperactivity Disorder
343271|NCT01323192|ADHD
343272|NCT01323192|Methylphenidate hydrochloride
343273|NCT01323179|Postoperative pain
343274|NCT01323179|Postoperative opioid requirements
343275|NCT01323166|rectal cancer
343276|NCT01323140|hypogonadism, testosterone, transdermal system
343277|NCT01323114|type 2 diabetes mellitus
343278|NCT01323114|non-morbidly obese
343279|NCT01323114|laparoscopic duodenal exclusion
343280|NCT01323088|Childhood obesity
343281|NCT01323088|Visceral fat
343282|NCT01323088|Insulin resistance
343283|NCT01323088|Liver fat
343284|NCT01323088|Skeletal muscle lipid
343285|NCT01323088|Regular exercise
343286|NCT01323062|chemotherapy naive
343287|NCT01323062|stage IV non squamous non small cell lung cancer
343288|NCT01323062|Phase 1b
343289|NCT01323062|Bavituximab
343290|NCT01323062|Chimeric 3G4
343291|NCT01323062|U of North Carolina at Chapel Hill
343292|NCT01323049|extubation strategy
343293|NCT01323010|asthma
343294|NCT01323010|albuterol
343295|NCT01323010|metered dose inhalers
343296|NCT01322984|ASD
343297|NCT01322984|Startle
343298|NCT01322971|Bacterial Vaginosis
343299|NCT01322971|Infertility
343300|NCT01322971|Miscarriage
343301|NCT01322971|Metronidazole
343302|NCT01322958|bedside ultrasound
343303|NCT01322932|Medication Adherence
343304|NCT01322932|HIV Infection
343305|NCT01322932|efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination [Substance Name]
343306|NCT01322932|efavirenz
343307|NCT01322932|emtricitabine
343308|NCT01322932|Patient Satisfaction
343309|NCT01322932|tenofovir disoproxil fumarate
343310|NCT01322919|PresbyLASIK
343311|NCT01322919|Presbyopia
343312|NCT01322919|LASIK
343313|NCT01322919|Supracor
343314|NCT01322919|refractive
343315|NCT01322919|Myopia
343316|NCT01322919|Hyperopia
343317|NCT01322906|ABMLF
343318|NCT01322906|Allogenic Bone marrow Mesenchymal Stem Cells
343319|NCT01322906|Liver Failure
343320|NCT01322906|Transplantation
343321|NCT01322893|Metastatic breast cancer
343322|NCT01322893|Circulating tumour cells
343323|NCT01322893|CTC
343324|NCT01322893|Prognostic factors
343325|NCT01322893|Treatment response
343326|NCT01322880|domestic violence
343327|NCT01322867|bioequivalence study
343328|NCT01322867|alprazolam
343329|NCT01322867|frontal
343330|NCT01322854|IMRT
343331|NCT01322854|Integrated boost
343332|NCT01322854|adjuvant radiotherapy
343333|NCT01322854|breast cancer
343334|NCT01322854|breast conserving surgery
343335|NCT01322841|CHICA
343336|NCT01322841|clinical decision support
343337|NCT01322828|Bicep
343338|NCT01322828|Tendon
343339|NCT01322828|Distal
343340|NCT01322828|Ruptures
343341|NCT01322828|Randomized
343342|NCT01322828|Surgery
343343|NCT01322815|colon cancer
343344|NCT01322815|metastatic
343345|NCT01322815|vaccine
343346|NCT01322802|Ovarian Cancer
343347|NCT01322802|Vaccine
343348|NCT01322802|Stage III
343349|NCT01322802|Stage IV
343350|NCT01322802|Remission
343351|NCT01322789|Diabetes mellitus
343352|NCT01322789|Stem cells
343353|NCT01322789|Autologous stem cell transplantation
343354|NCT01322789|Autoimmune diseases
343355|NCT01322776|Mantle Cell Lymphoma
343356|NCT01322776|Recurrent
343357|NCT01322776|Bortezomib
343358|NCT01322776|Combination Treatment
343359|NCT01322737|resection
343360|NCT01322737|open
343361|NCT01322737|laparoscopic
343362|NCT01322737|benign
343363|NCT01322737|malignant
343364|NCT01322737|disease
343365|NCT01322737|colon
343366|NCT01322737|gastric
343367|NCT01322724|colonoscopy
343368|NCT01322724|colon cancer screening
343369|NCT01322724|patient discomfort scores
343370|NCT01322724|sedation medication requirements
343371|NCT01322724|water insertion method
343372|NCT01322711|Thromboxane
343373|NCT01322711|Aspirin
343374|NCT01322711|Atorvastatin
343375|NCT01322711|Platelet activation
343376|NCT01322711|Thrombin Activation
343377|NCT01322711|Oxidative stress
343378|NCT01322698|ICU
343379|NCT01322685|Tuberculosis
343380|NCT01322685|Lung cancer
343381|NCT01322672|Anesthetic Agents
343382|NCT01322672|POCD
343383|NCT01322672|Delirium
343384|NCT01322672|Cognitive Testing
343385|NCT01322672|Aging
343386|NCT01322672|Surgery
343387|NCT01322672|fMRI
343388|NCT01322672|Diffusion Tensor Imaging
343389|NCT01322672|White Matter
343390|NCT01322659|Mechanical ventilation
343391|NCT01322659|Weaning
343392|NCT01322659|Noninvasive ventilation
343393|NCT01322659|Acute respiratory failure
343394|NCT01322659|Helmet
343395|NCT01322646|ADHD
343396|NCT01322646|Driving
343397|NCT01322646|Behavior modification
343398|NCT01322633|Pantoprazole
343399|NCT01322633|proton pump inhibitor
343400|NCT01322633|gastric cancer
343401|NCT01322633|digestive system cancer
343402|NCT01322633|cancer
343403|NCT01322607|Exercise
343404|NCT01322607|Rehabilitation
343405|NCT01322607|Stroke
343406|NCT01322594|Chronic Obstructive Pulmonary Disease
343407|NCT01322594|COPD
343408|NCT01322581|Plasmodium Falciparum
343409|NCT01322581|Genome-Wide Expression
343410|NCT01322581|Antibody Profiling by Protein Microarray
343411|NCT01322581|Multiplex Cytokine Analysis
343412|NCT01322581|Children and Adults
343413|NCT01322581|Malaria
343414|NCT01322568|Aging
343415|NCT01322568|Gene
343416|NCT01322568|Environment
343417|NCT01322568|Inflammation
343418|NCT01322568|Iceland
343419|NCT01322555|PBR28
343420|NCT01322555|Positron Emission Tomography (PET)
343421|NCT01322555|Propofol
343422|NCT01322555|Autism
343423|NCT01322555|Immune Response
343424|NCT01322555|Autism Spectrum Disorders
343425|NCT01322555|ASD
343426|NCT01322555|Healthy Volunteer
343427|NCT01322555|HV
343428|NCT01322529|nulliparity
343429|NCT01322529|pregnant women
343430|NCT01322529|pregnancy outcomes
343431|NCT01322529|pregnancy complications
343432|NCT01322490|PROSTVAC
343433|NCT01322490|metastatic
343434|NCT01322490|prostate cancer
343435|NCT01322490|castrate-resistant
343436|NCT01322490|vaccine
343437|NCT01322490|immunotherapy
343438|NCT01322490|Phase 3
343439|NCT01322477|Identification of treatment efficacy in patients with advanced HCC by PET/CT F18-FDG
343440|NCT01322464|Sativex
343441|NCT01322464|bio-availability
343442|NCT01322464|cannabinoid
343443|NCT01322464|pharmacokinetics
343444|NCT01322451|Safety
343445|NCT01322451|Tolerability
343446|NCT01322451|Pharmacokinetics
343447|NCT01322438|healthy volunteers
343448|NCT01322438|rifampin
343449|NCT01322438|pharmacokinetics
343450|NCT01322438|single dose
343451|NCT01322412|Adapted physical activity
343452|NCT01322412|breast cancer
343453|NCT01322399|low back pain
343454|NCT01322399|chronic pain
343455|NCT01322399|manual therapy
343456|NCT01322399|Structural Integration
343457|NCT01322386|PSC
343458|NCT01322386|BA
343459|NCT01322373|Alzheimer's disease
343460|NCT01322373|magnetoencephalography
343461|NCT01322373|MEG
343462|NCT01322373|SNI
343463|NCT01322347|End Stage Renal Disease
343464|NCT01322347|Hemodialysis
343465|NCT01322347|SFP
343466|NCT01322347|Hemodialysis-dependent chronic renal failure
343467|NCT01322334|Snoring
343468|NCT01322334|Sleep apnea
343469|NCT01322334|Pharyngeal muscle tone
343470|NCT01322321|ACZ885
343471|NCT01322321|diabetes
343472|NCT01322321|type 1
343473|NCT01322321|C-peptide
343474|NCT01322308|lupus
343475|NCT01322308|HDL particles
343476|NCT01322308|endothelial function
343477|NCT01322308|pioglitazone
343478|NCT01322243|Anxiety
343479|NCT01322243|Metabolic state
343480|NCT01322243|Stress
343481|NCT01322230|Instructional Design
343482|NCT01322230|Online learning module
343483|NCT01322230|Surgical education
343484|NCT01322217|Medication adherence
343485|NCT01322217|Substance use
343486|NCT01322217|Sexual risk behaviors
343487|NCT01322204|codeine, neonates, pediatric pharmacology
343488|NCT01322191|pain, pain management, pediatrics, morphine pharmacokinetics
343489|NCT01322178|cetuximab
343490|NCT01322178|colorectal carcinoma
343491|NCT01322165|Marfan syndrome
343492|NCT01322165|Turner syndrome
343493|NCT01322165|Bicuspid aortic valve
343494|NCT01322165|Ehlers-Danlos Syndrome
343495|NCT01322165|Loeys-Dietz syndrome
343496|NCT01322165|Aneurysm
343497|NCT01322165|Genetic
343498|NCT01322165|aortic
343499|NCT01322165|thoracic
343500|NCT01322165|mutation
343501|NCT01322165|dissection
343502|NCT01322152|metastases
343503|NCT01322152|neoplasm
343504|NCT01322139|Sativex
343505|NCT01322139|Cannabinoid
343506|NCT01322139|Electrocardiogram
343507|NCT01322139|QT interval
343508|NCT01322113|BIPOLAR
343509|NCT01322113|MANIA
343510|NCT01322113|DEPRESSION
343511|NCT01322100|Brain Metastases, CNS Metastases
343512|NCT01322087|Nutrition
343513|NCT01322087|new energy dense food concept
343514|NCT01322074|Acute postoperative pain
343515|NCT01322074|systemic inflammation
343516|NCT01322074|CRP
343517|NCT01322074|IL6
343518|NCT01322061|Gallbladder removal
343519|NCT01322061|acute cholecystitis
343520|NCT01322061|Laparoscopic cholecestectomy
343521|NCT01322048|Sympathetic Hyperactivity
343522|NCT01322048|Traumatic Brain Injury
343523|NCT01322048|Agitation
343524|NCT01322048|Severe TBI
343525|NCT01322048|TBI
343526|NCT01322048|Catecholamines
343527|NCT01322048|Heart rate variability
343528|NCT01322048|Adrenergic alpha-Agonists
343529|NCT01322048|Adrenergic beta-Antagonists
343530|NCT01322048|Cognitive Impairment
343531|NCT01322022|Autism
343532|NCT01322022|Autism Spectrum Disorders
343533|NCT01322022|Sleep Problems
343534|NCT01322022|Sleep Disturbances
343535|NCT01322022|Interventions
343536|NCT01322009|Children
343537|NCT01322009|Brain injury
343538|NCT01322009|Trauma
343539|NCT01321996|PET/CT
343540|NCT01321996|68Ga-DOTANOC
343541|NCT01321996|IPF
343542|NCT01321996|NSIP
343543|NCT01321996|Idiopathic pulmonary fibrosis
343544|NCT01321931|Smoking Cessation
343545|NCT01321931|Nicotine pharmacokinetics
343546|NCT01321892|HRME
343547|NCT01321892|High-resolution microendoscope
343548|NCT01321892|Optical imaging technology
343549|NCT01321892|Non-invasive fluorescence and reflectance imaging
343550|NCT01321892|Upper aerodigestive tract
343551|NCT01321892|Cancer surgery
343552|NCT01321892|Squamous cell carcinoma
343553|NCT01321892|Oral cavity
343554|NCT01321892|Oropharynx
343555|NCT01321892|Larynx
343556|NCT01321892|Hypopharynx
343557|NCT01321892|Squamous cell carcinoma of the oral cavity, oropharynx, larynx, and/or hypopharynx
343558|NCT01321879|Gram Positive Bloodstream Infections
343559|NCT01321879|Sepsis
343560|NCT01321879|Staphylococcus aureus
343561|NCT01321879|Enterococci
343562|NCT01321879|Streptococci
343563|NCT01321879|Pneumococci
343564|NCT01321879|Corynebacterium
343565|NCT01321879|Propionibacterium or Bacillus species
343566|NCT01321879|Telavancin
343567|NCT01321879|Vibativ
343568|NCT01321866|Angioplasty
343569|NCT01321866|cutting balloon
343570|NCT01321853|Home health care
343571|NCT01321853|Medication Management
343572|NCT01321853|Cognitive impairment
343573|NCT01321853|Medication adherence
343574|NCT01321853|Older adults
343575|NCT01321853|Care Coordination management
343576|NCT01321840|Endometriosis
343577|NCT01321840|pain
343578|NCT01321840|sart
343579|NCT01321840|autonomic nervous system
343580|NCT01321840|fMRI
343581|NCT01321840|perfusion
343582|NCT01321840|connectivity
343583|NCT01321840|hypnotherapy
343584|NCT01321840|traditional Chinese medicine
343585|NCT01321827|ABPA
343586|NCT01321814|Hyperacusis
343587|NCT01321814|Personality
343588|NCT01321814|Comorbidity
343589|NCT01321814|Treatment
343590|NCT01321814|Cognitive behavioral therapy
343591|NCT01321801|Pregabalin
343592|NCT01321801|Laparoscopic cholecystectomy
343593|NCT01321801|Postoperative pain
343594|NCT01321801|Opioid consumption
343595|NCT01321788|thromboprophylaxis
343596|NCT01321788|pregnancy
343597|NCT01321788|post-cesarian section
343598|NCT01321762|Prolapse
343599|NCT01321762|Childbirth
343600|NCT01321762|Pregnancy
343601|NCT01321749|ischemic cerebral vascular disease
343602|NCT01321749|stroke secondary prevention
343603|NCT01321749|remote ischemic preconditioning
343604|NCT01321736|dietary fiber
343605|NCT01321736|enteral nutrition
343606|NCT01321736|laxation
343607|NCT01321723|Osteoporosis
343608|NCT01321723|Bone Diseases, Metabolic
343609|NCT01321723|Bone Diseases
343610|NCT01321723|Bone Density Conservation Agents
343611|NCT01321710|sleep hygiene
343612|NCT01321710|actigraphy
343613|NCT01321710|maternal
343614|NCT01321710|infant
343615|NCT01321710|postpartum period
343616|NCT01321710|immunization
343617|NCT01321710|acetaminophen
343618|NCT01321697|Being seen in the Winthrop P. Rockefeller Cancer Institute for vulvar
343619|NCT01321697|cancer requiring lymph node evaluation for the ipsilateral or contralateral
343620|NCT01321697|groin
343621|NCT01321671|pregabalin
343622|NCT01321671|pharmacokinetics
343623|NCT01321671|bioavailability
343624|NCT01321671|bioequivalence
343625|NCT01321658|Geriatric Assessment
343626|NCT01321658|Perioperative Care
343627|NCT01321658|Colorectal Neoplasms
343628|NCT01321658|Frail Elderly
343629|NCT01321645|Acne Vulgaris
343630|NCT01321645|Homoeopathy
343631|NCT01321645|Homeopathy
343632|NCT01321645|Azadirachta Indica
343633|NCT01321632|Acne Vulgaris
343634|NCT01321632|Homoeopathy
343635|NCT01321632|Zingiber officinalis
343636|NCT01321619|Chronic venous insufficiency
343637|NCT01321619|Hemorrhoidal syndrome
343638|NCT01321619|Varicell
343639|NCT01321606|infection
343640|NCT01321606|probiotics
343641|NCT01321567|rabeprazole sodium
343642|NCT01321567|refractory reflux esophagitis
343643|NCT01321541|non-hodgkin lymphoma
343644|NCT01321541|DLBCL
343645|NCT01321541|relapsed
343646|NCT01321541|aggressive NHL
343647|NCT01321541|Diffuse large B-cell lymphoma
343648|NCT01321541|Rituximab
343649|NCT01321541|Rituxan
343650|NCT01321541|Pixantrone
343651|NCT01321541|NHL
343652|NCT01321541|non hodgkin's lymphoma
343653|NCT01321541|de novo DLBCL
343654|NCT01321541|DLBCL transformed from Indolent Lymphoma
343655|NCT01321541|Follicular Grade 3 Lymphoma
343656|NCT01321502|treatment of herpes
343657|NCT01321489|Phase III
343658|NCT01321489|Sildenafil Citrate Tablet Sublingual
343659|NCT01321489|Erectile dysfunction
343660|NCT01321437|Melanoma
343661|NCT01321437|Axitinib
343662|NCT01321437|Anti-angiogenesis
343663|NCT01321437|Neoadjuvant Melanoma
343664|NCT01321424|Dry Eye
343665|NCT01321424|Tear Osmolarity
343666|NCT01321424|Meibomain Gland Disease
343667|NCT01321424|Aqueous Dificiency
343668|NCT01321424|Tear film abnormality
343669|NCT01321411|Respiratory Muscle Blood Flow
343670|NCT01321411|Work of Breathing
343671|NCT01321411|Near Infrared Spectroscopy
343672|NCT01321398|High Frequency Oscillation
343673|NCT01321398|Oscillation
343674|NCT01321398|HFO
343675|NCT01321398|Transpulmonary pressure
343676|NCT01321385|childhood acute myeloid leukemia in remission
343677|NCT01321385|recurrent childhood acute myeloid leukemia
343678|NCT01321385|untreated childhood acute myeloid leukemia and other myeloid malignancies
343679|NCT01321385|childhood acute erythroleukemia (M6)
343680|NCT01321385|childhood acute megakaryocytic leukemia (M7)
343681|NCT01321385|childhood acute monoblastic leukemia (M5a)
343682|NCT01321385|childhood acute monocytic leukemia (M5b)
343683|NCT01321385|childhood acute myeloblastic leukemia with maturation (M2)
343684|NCT01321385|childhood acute myeloblastic leukemia without maturation (M1)
343685|NCT01321385|childhood acute myelomonocytic leukemia (M4)
343686|NCT01321385|childhood acute minimally differentiated myeloid leukemia (M0)
343687|NCT01321346|Relapse
343688|NCT01321346|Lymphoblastic
343689|NCT01321346|Leukemia
343690|NCT01321346|Panobinostat
343691|NCT01321346|LBH589
343692|NCT01321346|Refractory
343693|NCT01321346|Hodgkin's
343694|NCT01321346|Non-Hodgkin's Lymphoma
343695|NCT01321346|Lymphoma
343696|NCT01321346|Myelogenous
343697|NCT01321346|Acute
343698|NCT01321346|Childhood
343699|NCT01321346|Pediatric
343700|NCT01321346|ALL
343701|NCT01321346|AML
343702|NCT01321346|NHL
343703|NCT01321346|HD
343704|NCT01321333|thoracic spinal cord injury
343705|NCT01321333|spinal cord injury thoracic
343706|NCT01321333|sub-acute spinal cord injury
343707|NCT01321333|human neural stem cells
343708|NCT01321333|stem cells
343709|NCT01321333|stem cells transplant
343710|NCT01321333|stem cells transplant spinal cord injury
343711|NCT01321320|ICUAP
343712|NCT01321320|Critical illness
343713|NCT01321320|Muscle wasting
343714|NCT01321320|ICU
343715|NCT01321307|Aphtostomatitis
343716|NCT01321307|Mucositis
343717|NCT01321307|Mouth sores
343718|NCT01321307|Natural
343719|NCT01321307|Herbal
343720|NCT01321281|Osteoarthritis
343721|NCT01321268|orange peel skin
343722|NCT01321268|cellulite
343723|NCT01321255|Myocardial Infarction
343724|NCT01321255|Treatment Adherence
343725|NCT01321242|Resting heart rate
343726|NCT01321242|Stable Angina
343727|NCT01321242|Hypertension
343728|NCT01321242|beta-blockers
343729|NCT01321229|Sleep apnea
343730|NCT01321229|NIHSS scale
343731|NCT01321229|FIM scale
343732|NCT01321229|FUGL-MEYER scale
343733|NCT01321216|rotavirus
343734|NCT01321216|gastroenteritis
343735|NCT01321216|children
343736|NCT01321216|Pediatric
343737|NCT01321216|dehydration
343738|NCT01321216|vaccine
343739|NCT01321203|carbon dioxide insufflation
343740|NCT01321177|Schizophrenia
343741|NCT01321177|Schizoaffective Disorder
343742|NCT01321177|Schizophreniform Disorder
343743|NCT01321177|Brief Psychotic Disorder
343744|NCT01321177|Psychotic Disorder NOS
343745|NCT01321177|First Episode
343746|NCT01321151|Mild Brain Injury
343747|NCT01321151|Concussions
343748|NCT01321151|Resveratrol
343749|NCT01321151|Boxers
343750|NCT01321151|ImPACT
343751|NCT01321151|MRI
343752|NCT01321138|Electrophysiological study
343753|NCT01321138|Nerve block
343754|NCT01321138|Analgesia, Patient-Controlled
343755|NCT01321138|Anterior cruciate ligament
343756|NCT01321125|Antiseptics
343757|NCT01321125|Administration cutaneously
343758|NCT01321125|Chlorine compounds
343759|NCT01321125|Anti-infecting agents, local
343760|NCT01321112|Conversion
343761|NCT01321112|Mycophenolate mofetil
343762|NCT01321112|Calcineurin inhibitors
343763|NCT01321112|Liver transplantation
343764|NCT01321112|Gene expression
343765|NCT01321099|Iron absorption
343766|NCT01321099|Complementary food fortificant
343767|NCT01321099|Young children
343768|NCT01321086|PAD
343769|NCT01321060|severe acute pancreatitis
343770|NCT01321060|acute fluid collection
343771|NCT01321060|catheter drainage
343772|NCT01321060|repeated aspiration
343773|NCT01321047|sedation
343774|NCT01321047|benzodiazepine
343775|NCT01321047|opioid
343776|NCT01321047|propofol
343777|NCT01321034|Lipoprotein (a)
343778|NCT01321034|LPA
343779|NCT01321034|Niacin
343780|NCT01321034|Kringle IV-2 repeats
343781|NCT01321008|NK cell lymphoma-nasal type
343782|NCT01321008|Stage I/II
343783|NCT01321008|Radiation therapy
343784|NCT01321008|XRT
343785|NCT01321008|chemotherapy
343786|NCT01321008|CHOP
343787|NCT01321008|Cyclophosphamide
343788|NCT01321008|Cytoxan
343789|NCT01321008|Neosar
343790|NCT01321008|Adriamycin
343791|NCT01321008|Doxorubicin
343792|NCT01321008|Rubex
343793|NCT01321008|Vincristine
343794|NCT01321008|Oncovin
343795|NCT01321008|Prednisone
343796|NCT01320995|Second degree vaginal tear
343797|NCT01320995|Perineal ultrasound
343798|NCT01320995|Anal incontinence
343799|NCT01320982|Schizophrenia
343800|NCT01320982|schizoaffective disorder
343801|NCT01320969|mindfulness, fear conditioning
343802|NCT01320956|hypnosis
343803|NCT01320956|HYPNOANALGESIA
343804|NCT01320956|surgery
343805|NCT01320956|children
343806|NCT01320956|anxiety
343807|NCT01320956|morphine
343808|NCT01320956|pain
343809|NCT01320956|A-VAS
343810|NCT01320956|orthopaedics
343811|NCT01320956|osteotomy
343812|NCT01320956|tenotomy
343813|NCT01320956|arthrodesis
343814|NCT01320956|spinal column surgery
343815|NCT01320943|stopping oral antiviral therapy
343816|NCT01320943|HBsAg loss
343817|NCT01320943|seroconversion
343818|NCT01320943|restarting oral antiviral therapy
343819|NCT01320930|Effect of Pulmonary rehabilitation.
343820|NCT01320930|Exercise capacity
343821|NCT01320930|Quality of life
343822|NCT01320917|obesity
343823|NCT01320917|contraceptives hormonal
343824|NCT01320917|levonorgestrel-releasing intrauterine device
343825|NCT01320917|cardiovascular risk
343826|NCT01320904|Closed Kinetic Chain
343827|NCT01320904|NMES
343828|NCT01320904|Knee Osteoarthritis
343829|NCT01320891|general anaesthesia for major abdominal surgery
343830|NCT01320878|pulmonary hypertension
343831|NCT01320852|Transplant
343832|NCT01320826|colonoscopy
343833|NCT01320826|primary care physicians
343834|NCT01320826|quality assurance
343835|NCT01320813|da vinci robot
343836|NCT01320813|Thyroidectomy
343837|NCT01320787|Brain
343838|NCT01320787|Adenocarcinoma of the prostate
343839|NCT01320787|Locally advanced breast cancer
343840|NCT01320787|Estrogen receptor
343841|NCT01320787|ER
343842|NCT01320787|Progesterone receptor
343843|NCT01320787|PR
343844|NCT01320787|Negative for ErbB2
343845|NCT01320787|Malignant tumor of the central nervous system
343846|NCT01320787|CNS
343847|NCT01320761|Formulation Comparison
343848|NCT01320748|Abstinence from alcohol
343849|NCT01320748|Substance Abuse and Mental Health Services
343850|NCT01320748|Social Support
343851|NCT01320748|Psychosocial Support Systems
343852|NCT01320748|Psychological support
343853|NCT01320748|Cognitive Support
343854|NCT01320748|Emotional Support
343855|NCT01320748|Mental Support
343856|NCT01320748|Psychosocial Support
343857|NCT01320748|Intervention Studies
343858|NCT01320748|Prevention & control
343859|NCT01320748|Preventive therapy
343860|NCT01320748|Treatment
343861|NCT01320748|Therapy
343862|NCT01320748|Magnetic Resonance Imaging
343863|NCT01320748|fMRI
343864|NCT01320748|Imaging
343865|NCT01320748|Magnetic Resonance Imaging, Functional
343866|NCT01320748|MRI Scans
343867|NCT01320748|MRI, Functional
343868|NCT01320748|Clinical Protocols
343869|NCT01320748|Protocols, Treatment
343870|NCT01320748|Drug Abuse Treatment Center
343871|NCT01320748|Substance Abuse Treatment Center
343872|NCT01320735|Lucrin Depot
343873|NCT01320735|intermittent adjuvant regimen
343874|NCT01320735|advanced prostate cancer
343875|NCT01320735|Leuprorelin
343876|NCT01320722|renin angiotensin system
343877|NCT01320722|vitamin D
343878|NCT01320722|uric acid
343879|NCT01320722|allopurinol
343880|NCT01320722|probenecid
343881|NCT01320722|endothelial function
343882|NCT01320709|Emergency contraception
343883|NCT01320709|Contraception
343884|NCT01320670|pharmacoresistance
343885|NCT01320657|Self-ligating
343886|NCT01320657|orthodontic
343887|NCT01320657|appliance
343888|NCT01320657|expansion
343889|NCT01320657|dental inclination
343890|NCT01320657|Expansion and inclination changes arising with orthodontic treatment
343891|NCT01320644|Uterine prolapse
343892|NCT01320644|vaginal prolapse
343893|NCT01320644|mesh erosion
343894|NCT01320644|urinary incontinence
343895|NCT01320644|bowel symptoms
343896|NCT01320631|uterine prolapse
343897|NCT01320631|vaginal prolapse
343898|NCT01320618|uterine prolapse
343899|NCT01320618|vaginal prolapse
343900|NCT01320618|mesh erosion
343901|NCT01320618|urinary incontinence
343902|NCT01320618|bowel symptoms
343903|NCT01320592|Patient must have histologically or cytologically-confirmed metastatic
343904|NCT01320592|breast cancer
343905|NCT01320592|Any ER, PR or Her2 status is allowed.
343906|NCT01320592|Tumor must express Retinoblastoma (Rb) protein, defined as
343907|NCT01320592|any measurable staining by immunohistochemistry on the invasive tumor component
343908|NCT01320592|<3 prior cyttoxic chemotherapy regimens for metastatic disease.
343909|NCT01320592|Performance status of 0-1 on the ECOG Performance Scale and life expectancy > 3 months.
343910|NCT01320592|Patient must have evaluable disease. Measureable disease is not required.
343911|NCT01320592|The subject has adequate organ function
343912|NCT01320579|atopic dermatitis
343913|NCT01320579|cis-urocanic acid
343914|NCT01320566|Polymeric Lung Volume Reduction (PLVR)
343915|NCT01320566|Bolilogic Lung Volume Reduction (BLVR)
343916|NCT01320566|AeriSeal
343917|NCT01320566|treatment
343918|NCT01320566|device
343919|NCT01320566|breathing
343920|NCT01320566|COPD
343921|NCT01320566|emphysema
343922|NCT01320566|heterogeneous
343923|NCT01320566|homogeneous
343924|NCT01320566|Pathologic Processes
343925|NCT01320566|Respiratory Tract Diseases
343926|NCT01320566|Lung Diseases
343927|NCT01320566|Pulmonary Disease, Chronic Obstructive
343928|NCT01320527|dietary supplement
343929|NCT01320527|cognition
343930|NCT01320527|mood
343931|NCT01320527|Alzheimer's disease
343932|NCT01320527|memory loss
343933|NCT01320501|Lung Cancer
343934|NCT01320488|Breast Cancer
343935|NCT01320475|thoracic epidural analgesia
343936|NCT01320475|epidural opioid
343937|NCT01320475|ketamine
343938|NCT01320475|adverse effect
343939|NCT01320462|Smoking
343940|NCT01320462|quit
343941|NCT01320462|surgery
343942|NCT01320462|anesthesia
343943|NCT01320462|champix
343944|NCT01320449|EPO
343945|NCT01320449|Proteomics
343946|NCT01320449|Carbohydrate metabolism
343947|NCT01320449|Fat metabolism
343948|NCT01320449|Protein metabolism
343949|NCT01320436|Ulcerative colitis
343950|NCT01320436|Curcumin
343951|NCT01320423|Intracerebral Haemorrhage
343952|NCT01320384|ALI
343953|NCT01320371|barbed sutures
343954|NCT01320371|knotted sutures
343955|NCT01320371|total knee arthroplasty
343956|NCT01320371|knee surgery
343957|NCT01320358|Patient compliance
343958|NCT01320358|ECMPS-IEM
343959|NCT01320358|transplantation
343960|NCT01320358|renal maintenance
343961|NCT01320358|Proteus
343962|NCT01320345|Diabetes Mellitus
343963|NCT01320345|Type 1 Diabetes Mellitus
343964|NCT01320345|Retinopathy
343965|NCT01320345|Diabetic Nephropathy
343966|NCT01320345|Fenofibrate
343967|NCT01320332|Ulcerative colitis
343968|NCT01320332|ASP3291
343969|NCT01320293|Moderate to Severe Chronic plaque type psoriasis
343970|NCT01320280|Prostate cancer, BIBW 2992 (Afatinib) , HER inhibitor
343971|NCT01320267|Resectable right colon cancer
343972|NCT01320254|Palliative treatment
343973|NCT01320254|Panitumumab
343974|NCT01320254|Cisplatin
343975|NCT01320254|Cisplatinum
343976|NCT01320254|Gemcitabine
343977|NCT01320254|Vectibix
343978|NCT01320228|Obesity
343979|NCT01320228|orlistat
343980|NCT01320228|fat excretion
343981|NCT01320228|fiber
343982|NCT01320228|dairy calcium
343983|NCT01320215|da Vinci Robot
343984|NCT01320215|uterine prolapse
343985|NCT01320215|vaginal prolapse
343986|NCT01320215|sacrohysteropexy
343987|NCT01320202|End Stage Renal Disease
343988|NCT01320202|Hemodialysis
343989|NCT01320202|SFP
343990|NCT01320202|Hemodialysis-dependent chronic renal failure
343991|NCT01320189|Energy intake
343992|NCT01320189|Protein requirement
343993|NCT01320189|Satiety
343994|NCT01320189|Protein leverage hypothesis
343995|NCT01320150|persistent postsurgical pain (PPP)
343996|NCT01320137|Immunological assay
343997|NCT01320137|Birch allergy
343998|NCT01320124|Contractures
343999|NCT01320124|Total knee arthroplasty
344000|NCT01320124|Tissue bank
344001|NCT01320124|Osteoarthritis
344002|NCT01320124|Gene expressions
344003|NCT01320111|progression free survival
344004|NCT01320111|paclitaxel
344005|NCT01320111|sorafenib
344006|NCT01320111|metastatic breast cancer
344007|NCT01320098|Attention
344008|NCT01320098|Behavior Problems
344009|NCT01320098|Compliance
344010|NCT01320098|Evaluation
344011|NCT01320098|Preschool
344012|NCT01320098|ADHD
344013|NCT01320098|Overactive
344014|NCT01320098|Inattentive
344015|NCT01320098|Attention Deficit Hyperactivity Disorder in Preschoolers
344016|NCT01320085|Metastatic melanoma,
344017|NCT01320085|BRAF-mutant,
344018|NCT01320085|NRAS-mutant
344019|NCT01320072|aspirin
344020|NCT01320072|asthma
344021|NCT01320072|diagnosis
344022|NCT01320072|prostaglandins
344023|NCT01320072|leukotrienes
344024|NCT01320059|18F-Fluoro-PEG6-IPQA
344025|NCT01320059|Radioactive Imaging Solution
344026|NCT01320059|Non-Small Cell Lung Cancer
344027|NCT01320059|Positron Emission Tomography
344028|NCT01320059|PET Scan
344029|NCT01320059|CT
344030|NCT01320059|Computed Tomography
344031|NCT01320046|Urinary Incontinence
344032|NCT01320046|Vulvar pruritus
344033|NCT01320046|Vulvar contact dermatitis
344034|NCT01320033|acne vulgaris
344035|NCT01320033|inflammatory lesions
344036|NCT01320020|Cancer
344037|NCT01320020|Neoplasm
344038|NCT01320020|Carcinoma
344039|NCT01320020|intravenous
344040|NCT01320020|Monoclonal Antibody
344041|NCT01320020|Removab
344042|NCT01319994|glucocorticoid
344043|NCT01319981|Acute Lymphoblastic Leukemia
344044|NCT01319981|ALL
344045|NCT01319981|Lymphoblastic lymphoma
344046|NCT01319981|Cytoxan
344047|NCT01319981|Neosar
344048|NCT01319981|Mesnex
344049|NCT01319981|Liposomal Vincristine
344050|NCT01319981|Vincristine Sulfate Liposomes Injection
344051|NCT01319981|Marqibo
344052|NCT01319981|Dexamethasone
344053|NCT01319981|Adriamycin
344054|NCT01319981|Rubex
344055|NCT01319981|Cytarabine
344056|NCT01319981|Cytosar
344057|NCT01319981|DepoCyt
344058|NCT01319981|Cytosine Arabinosine Hydrochloride
344059|NCT01319981|Imatinib Mesylate
344060|NCT01319981|Gleevec
344061|NCT01319981|ST1571
344062|NCT01319981|NSC-716051
344063|NCT01319981|Filgrastim
344064|NCT01319981|Neupogen
344065|NCT01319968|Postpartum dyspareunia
344066|NCT01319968|Vaginal atrophy
344067|NCT01319955|Pneumonia
344068|NCT01319955|Influenza
344069|NCT01319955|Child
344070|NCT01319955|Respiratory
344071|NCT01319955|Pathogen
344072|NCT01319942|Radiotherapy
344073|NCT01319942|Sorafenib
344074|NCT01319942|Treatment outcome
344075|NCT01319929|Osteoarthritis, knee pain, osteoarthritic knee pain
344076|NCT01319903|sepsis
344077|NCT01319903|inflammation
344078|NCT01319903|complement
344079|NCT01319903|immune system
344080|NCT01319890|all histologic subtypes
344081|NCT01319890|benign
344082|NCT01319890|malignant
344083|NCT01319864|leukemia
344084|NCT01319851|bone marrow transplant
344085|NCT01319851|sickle cell disease
344086|NCT01319851|thalassemia
344087|NCT01319851|Glanzmann thrombasthenia
344088|NCT01319851|Wiskott-Aldrich syndrome
344089|NCT01319851|chronic-granulomatous disease
344090|NCT01319851|severe congenital neutropenia
344091|NCT01319851|leukocyte adhesion deficiency
344092|NCT01319851|Schwachman-Diamond syndrome
344093|NCT01319851|Diamond-Blackfan anemia
344094|NCT01319851|Fanconi anemia
344095|NCT01319851|dyskeratosis-congenita
344096|NCT01319851|Chediak-Higashi syndrome
344097|NCT01319851|severe aplastic anemia
344098|NCT01319838|neuroblastoma
344099|NCT01319838|isotretinoin
344100|NCT01319812|Vascular intervention
344101|NCT01319812|Endovascular
344102|NCT01319812|Peripheral stent
344103|NCT01319799|Embolism
344104|NCT01319799|Nervous system
344105|NCT01319799|Aorta
344106|NCT01319799|Valves
344107|NCT01319799|Ultrasonics
344108|NCT01319786|Hypertension
344109|NCT01319786|Microvascular function
344110|NCT01319760|STEMI
344111|NCT01319747|atrial
344112|NCT01319747|fibrillation
344113|NCT01319747|pvi
344114|NCT01319747|vats
344115|NCT01319747|ablation
344116|NCT01319734|Vitamin C
344117|NCT01319734|Oxidative stress
344118|NCT01319734|Type 2DM
344119|NCT01319721|Amniotic membrane
344120|NCT01319721|Limbal conjunctival autograft
344121|NCT01319721|Limbal
344122|NCT01319721|Conjunctival
344123|NCT01319721|Mitomycin C
344124|NCT01319721|Recurrent pterygium
344125|NCT01319721|Pterygium
344126|NCT01319708|ovarian stimulation
344127|NCT01319708|climiphene citrate
344128|NCT01319708|Gonadotropin-Releasing Hormone agonists/antagonists
344129|NCT01319708|Follicle Stimulating Hormone
344130|NCT01319695|corifollitropin alfa
344131|NCT01319695|FSH ovarian stimulation
344132|NCT01319695|IVF
344133|NCT01319682|Pain
344134|NCT01319682|Preemptive
344135|NCT01319682|Lidocaine
344136|NCT01319682|Intravenous
344137|NCT01319682|Lumbar fusion
344138|NCT01319656|Chronic diseases
344139|NCT01319656|Primary care
344140|NCT01319656|Rehabilitation
344141|NCT01319656|Chronic Care Model
344142|NCT01319656|Patient centered medical home
344143|NCT01319643|Oxygen
344144|NCT01319643|Hyperoxia
344145|NCT01319643|Intensive care unit
344146|NCT01319643|Mortality
344147|NCT01319643|Organ dysfunction
344148|NCT01319643|Postoperative care
344149|NCT01319630|sepsis
344150|NCT01319630|microcirculation
344151|NCT01319630|saline
344152|NCT01319630|crystalloid
344153|NCT01319630|colloid
344154|NCT01319630|albumin
344155|NCT01319630|hydroxyethyl starch
344156|NCT01319578|chronic kidney disease
344157|NCT01319578|phosphorus
344158|NCT01319578|phosphate
344159|NCT01319578|saliva
344160|NCT01319578|K2CG
344161|NCT01319578|medical food
344162|NCT01319578|chitosan
344163|NCT01319565|Young TIL
344164|NCT01319565|Metastatic Melanoma
344165|NCT01319565|Immunotherapy
344166|NCT01319565|Adoptive Cell Therapy
344167|NCT01319565|Skin Cancer
344168|NCT01319552|red blood cells
344169|NCT01319552|transfusion
344170|NCT01319552|storage
344171|NCT01319552|sickle cell disease
344172|NCT01319552|β-thalassemia
344173|NCT01319552|hemoglobin-associated iron
344174|NCT01319526|stage III adult Hodgkin lymphoma
344175|NCT01319526|stage IV adult Hodgkin lymphoma
344176|NCT01319526|HIV infection
344177|NCT01319500|Drug Utilization
344178|NCT01319500|Oral Contraceptives
344179|NCT01319474|Deep vein thrombosis
344180|NCT01319474|Pulmonary embolism
344181|NCT01319474|Ultrasound
344182|NCT01319474|Pregnancy
344183|NCT01319461|Osteoarthritis
344184|NCT01319461|Hyalgan
344185|NCT01319448|Sickle cell disease
344186|NCT01319448|Malaria
344187|NCT01319448|Intermittent Preventive Treatment (IPT)
344188|NCT01319448|prophylaxis
344189|NCT01319435|Ciprofloxacin
344190|NCT01319435|Neonates
344191|NCT01319435|Gram negative infection
344192|NCT01319422|myeloma
344193|NCT01319422|multiple myeloma
344194|NCT01319422|pomalidomide
344195|NCT01319422|immunomodulatory
344196|NCT01319409|Anterior cruciate ligament surgery
344197|NCT01319409|Anterior cruciate ligament reconstruction
344198|NCT01319409|Single bundle anterior cruciate ligament reconstruction
344199|NCT01319409|Double bundle anterior cruciate ligament reconstruction
344200|NCT01319409|Randomized clinical trial
344201|NCT01319396|breathing rate
344202|NCT01319383|HIV-1 Infection
344203|NCT01319383|HIV RNA <50 copies/mL
344204|NCT01319383|Stable ART
344205|NCT01319383|Resting CD4+ T cells
344206|NCT01319383|Leukapheresis
344207|NCT01319383|Vorinostat
344208|NCT01319383|HIV RNA expression
344209|NCT01319383|PK visits
344210|NCT01319331|diabetes
344211|NCT01319331|type 1 diabetes
344212|NCT01319331|AAT
344213|NCT01319331|Alpha-1 Antitrypsin
344214|NCT01319279|Pharmacokinetics
344215|NCT01319279|Hydrocodone
344216|NCT01319279|Extended Release
344217|NCT01319279|Hepatic impairment
344218|NCT01319266|hydrocodone
344219|NCT01319266|extended release
344220|NCT01319266|pharmacokinetics
344221|NCT01319266|renal impairment
344222|NCT01319253|Cystic Fibrosis
344223|NCT01319253|Pseudomonas aeruginosa
344224|NCT01319227|Periprosthetic bone remodeling
344225|NCT01319227|Stress shielding
344226|NCT01319227|Short femoral stem
344227|NCT01319227|Porous Titanium Construct
344228|NCT01319227|Polyethylene wear
344229|NCT01319214|cocaine addiction treatment craving
344230|NCT01319188|Age-related macular degeneration
344231|NCT01319188|ranibizumab
344232|NCT01319188|acute thromboembolic events
344233|NCT01319188|coronary artery disease
344234|NCT01319188|cerebrovascular disease
344235|NCT01319175|hip flexion strength training
344236|NCT01319175|elastic bands
344237|NCT01319175|external resistance
344238|NCT01319162|PCOS
344239|NCT01319149|molecular methods
344240|NCT01319136|new infusion test method
344241|NCT01319136|reference method
344242|NCT01319136|cerebrospinal fluid dynamics
344243|NCT01319123|dressing for venous leg ulcers
344244|NCT01319110|Cardiac Arrest
344245|NCT01319110|Post Cardiac Arrest
344246|NCT01319110|CoQ10
344247|NCT01319110|Ubiquinone
344248|NCT01319110|Post Arrest
344249|NCT01319097|Reduction on local soft tissue edema
344250|NCT01319058|obstructive sleep apnea
344251|NCT01319058|Tonsillectomy
344252|NCT01319058|Tonsillotomy
344253|NCT01319058|Inflammation
344254|NCT01319058|Pain
344255|NCT01319058|Post tonsillectomy bleeding
344256|NCT01319045|Pulmonary Arterial Hypertension
344257|NCT01319045|Congenital Heart Disease
344258|NCT01319045|Eisenmenger's Syndrome
344259|NCT01319045|Prostacyclin
344260|NCT01319045|Iloprost
344261|NCT01319019|lung function
344262|NCT01319019|bronchodilator
344263|NCT01319019|COPD, dose response, dosing interval, efficacy, safety, PD, PK
344264|NCT01319006|relative bioavailability
344265|NCT01318993|GSK1605786A; Inflammatory Bowel Disease; Crohn's disease; long-term treatment; quality of life; CCR9 antagonist
344266|NCT01318980|ADME
344267|NCT01318980|IV radiolabelled
344268|NCT01318980|pharmacokinetics
344269|NCT01318967|Renal blood flow
344270|NCT01318967|Regional renal blood flow
344271|NCT01318967|MRI
344272|NCT01318941|Ophthalmology, age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, ranibizumab
344273|NCT01318941|Ophthalmology
344274|NCT01318941|Age-related macular degeneration
344275|NCT01318941|Diabetic Macular Edema
344276|NCT01318941|Retinal Vein Occlusion
344277|NCT01318941|LUMINOUS
344278|NCT01318941|Ranibizumab
344279|NCT01318928|Periodontitis
344280|NCT01318928|antibiotics
344281|NCT01318928|treatment period
344282|NCT01318928|microbiology
344283|NCT01318915|Kidney transplantation
344284|NCT01318915|Immunosuppression
344285|NCT01318915|Graft rejection
344286|NCT01318915|Graft loss
344287|NCT01318915|Renal transplant
344288|NCT01318915|Transplantation
344289|NCT01318915|kidney disease
344290|NCT01318915|Renal disease
344291|NCT01318915|Organ transplant
344292|NCT01318915|Living donor transplant
344293|NCT01318915|Living-donor
344294|NCT01318889|Dexpanthenol
344295|NCT01318889|Radiotherapy
344296|NCT01318889|chemotherapy
344297|NCT01318889|Mucositis
344298|NCT01318876|influenza
344299|NCT01318876|vaccine safety
344300|NCT01318876|adverse events
344301|NCT01318876|health care workers
344302|NCT01318863|aged matched normal control samples
344303|NCT01318850|schizophrenia
344304|NCT01318850|cognitive remediation
344305|NCT01318850|fMRI
344306|NCT01318837|OABSS
344307|NCT01318837|IPSS
344308|NCT01318837|PPBC
344309|NCT01318837|Solifenacin
344310|NCT01318824|Neonatal Respiratory Failure
344311|NCT01318824|Newborn Infant
344312|NCT01318824|BiPAP
344313|NCT01318824|NIPPV
344314|NCT01318811|Heparin
344315|NCT01318811|CRRT
344316|NCT01318811|Continuous renal replacement therapy
344317|NCT01318811|CVVHD
344318|NCT01318811|Anticoagulation
344319|NCT01318798|Development
344320|NCT01318798|Pre- and intra-operative predictors
344321|NCT01318798|Acute renal failure
344322|NCT01318798|Liver Surgery
344323|NCT01318798|Prediction score
344324|NCT01318798|Validation
344325|NCT01318798|Clinical consequences
344326|NCT01318798|Decision curve analysis
344327|NCT01318798|predictors of acute renal failure after liver resection
344328|NCT01318785|secondary arm-lymphedema
344329|NCT01318785|breast cancer related arm-lymphedema
344330|NCT01318746|change of potassium amount, circadian and day-to-day variability
344331|NCT01318733|Rosacea
344332|NCT01318720|Neck Pain
344333|NCT01318720|Thrust Manipulation
344334|NCT01318720|Non-Thrust Manipulation
344335|NCT01318707|Severe Hemophilia A
344336|NCT01318707|Hemophilia A Patients
344337|NCT01318707|Serum collection vs a method of added FVIII to blood samples
344338|NCT01318694|Chronic hepatitis C
344339|NCT01318694|Cyclophilin inhibitor
344340|NCT01318681|driving, memory, cognition
344341|NCT01318668|fmri smoking vaccination mood
344342|NCT01318655|Phase I
344343|NCT01318655|Japan
344344|NCT01318655|SAD
344345|NCT01318655|MAD
344346|NCT01318642|Adenocarcinoma
344347|NCT01318642|pancreas
344348|NCT01318642|pancreatic cancer
344349|NCT01318642|local
344350|NCT01318642|unresectable
344351|NCT01318642|stage II
344352|NCT01318642|stage III
344353|NCT01318616|hip adduction strength training
344354|NCT01318616|Improvement in adductor strength
344355|NCT01318590|Pancreatitis, Chronic
344356|NCT01318590|Abdominal Pain
344357|NCT01318590|Celiac bloc
344358|NCT01318590|Endosonography
344359|NCT01318564|Type II Diabetes
344360|NCT01318564|Unit dose packaging devices
344361|NCT01318564|Metformin
344362|NCT01318564|Lisinopril
344363|NCT01318564|Enalapril
344364|NCT01318564|Atorvastatin
344365|NCT01318564|Lipitor
344366|NCT01318564|Simvastatin
344367|NCT01318564|Aspirin
344368|NCT01318564|Questionnaires
344369|NCT01318551|Anemia
344370|NCT01318499|cataract
344371|NCT01318499|inflammation
344372|NCT01318499|pain
344373|NCT01318499|inflammatory cells
344374|NCT01318499|aqueous flare
344375|NCT01318473|cancer
344376|NCT01318460|coronary artery disease
344377|NCT01318460|levosimendan
344378|NCT01318460|coronary artery bypass grafting
344379|NCT01318460|cardiac surgery
344380|NCT01318447|Hepatic metastases
344381|NCT01318447|Liver metastases
344382|NCT01318447|Colorectal cancer
344383|NCT01318447|Colorectal adenocarcinoma
344384|NCT01318447|Accuray
344385|NCT01318447|CyberKnife
344386|NCT01318434|Outpatient
344387|NCT01318421|Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)
344388|NCT01318356|Q fever
344389|NCT01318356|Cognitive behavioral therapy
344390|NCT01318356|Doxycycline
344391|NCT01318356|Fatigue
344392|NCT01318356|Coxiella
344393|NCT01318343|Cryolipolysis
344394|NCT01318343|Abdominal Fat
344395|NCT01318343|Adipose Tissue
344396|NCT01318343|Fat Reduction
344397|NCT01318343|Non Invasive
344398|NCT01318304|innate immunity
344399|NCT01318304|HIV
344400|NCT01318304|pregnancy
344401|NCT01318304|vaginal immunity
344402|NCT01318291|IVF
344403|NCT01318291|Drop out
344404|NCT01318278|Hypotension
344405|NCT01318278|Low blood pressure
344406|NCT01318278|Neonate
344407|NCT01318278|Dopamine
344408|NCT01318278|Vasopressin
344409|NCT01318278|Extremely Low Birth Weight Infant
344410|NCT01318265|drug interactions
344411|NCT01318265|ketoconazole
344412|NCT01318265|pharmacokinetics
344413|NCT01318265|human volunteers
344414|NCT01318252|Elevated IOP
344415|NCT01318226|postherpetic neuralgia
344416|NCT01318226|shingles
344417|NCT01318226|analgesia
344418|NCT01318226|neuropathic pain
344419|NCT01318213|VRE
344420|NCT01318213|MRSA
344421|NCT01318200|Primary liver cancer
344422|NCT01318200|Hepatocellular carcinoma
344423|NCT01318200|CyberKnife
344424|NCT01318200|Accuray
344425|NCT01318200|TACE
344426|NCT01318200|Transarterial chemoembolization
344427|NCT01318187|renal colic
344428|NCT01318187|paracetamol
344429|NCT01318187|morphine
344430|NCT01318187|emergency department
344431|NCT01318174|Pulmonary embolism
344432|NCT01318174|Pulmonary Disease, Chronic Obstructive
344433|NCT01318161|Epidural analgesia
344434|NCT01318161|Patient controlled analgesia
344435|NCT01318161|Colorectal cancer
344436|NCT01318161|Morbidity
344437|NCT01318161|Mortality
344438|NCT01318148|Echinocandins
344439|NCT01318148|Caspofungin
344440|NCT01318148|Pharmacokinetics
344441|NCT01318148|Prophylaxis
344442|NCT01318148|Antifungal
344443|NCT01318148|Aspergillosis
344444|NCT01318148|Acute Leucemia
344445|NCT01318135|Diabetes Mellitus - Type 2
344446|NCT01318135|Diabetes Mellitus
344447|NCT01318135|Drug Therapy
344448|NCT01318122|Diabetes Mellitus - Type 2
344449|NCT01318122|Diabetes Mellitus
344450|NCT01318122|Drug Therapy
344451|NCT01318109|Diabetes Mellitus - Type 2
344452|NCT01318109|Diabetes Mellitus
344453|NCT01318109|Drug Therapy
344454|NCT01318096|safety
344455|NCT01318096|efficacy
344456|NCT01318096|raltegravir
344457|NCT01318096|HBV/HIV co-infection
344458|NCT01318083|Diabetes Mellitus - Type 2
344459|NCT01318083|Diabetes Mellitus
344460|NCT01318083|Drug Therapy
344461|NCT01318070|Diabetes Mellitus - Type2
344462|NCT01318070|Diabetes Mellitus
344463|NCT01318070|Drug Therapy
344464|NCT01318057|Pharmacogenetics
344465|NCT01318057|Warfarin
344466|NCT01318057|Personalized Medicine
344467|NCT01318057|Puerto Ricans
344468|NCT01318057|Physiogenomics
344469|NCT01318057|Hispanics
344470|NCT01318057|Anticoagulants
344471|NCT01318057|Cardiovascular
344472|NCT01318057|Deep Vein Thrombosis with or without Pulmonary Embolism
344473|NCT01318057|Cardiac Valvular Replacement
344474|NCT01318044|thiopental
344475|NCT01318044|propofol
344476|NCT01318044|sedation
344477|NCT01318044|MRI
344478|NCT01318031|DDI
344479|NCT01318031|Healthy Volunteers
344480|NCT01318018|depression
344481|NCT01318018|bispectral index
344482|NCT01318018|electroconvulsive therapy
344483|NCT01318018|magnetic seizure therapy
344484|NCT01317992|Medication overuse headache
344485|NCT01317992|ibudilast
344486|NCT01317992|glia
344487|NCT01317940|Leukemia
344488|NCT01317940|ALL
344489|NCT01317940|Vitamin D
344490|NCT01317940|Bone Density
344491|NCT01317940|Body Fat
344492|NCT01317940|Obesity
344493|NCT01317940|Adipose
344494|NCT01317927|belionstat
344495|NCT01317927|warfarin
344496|NCT01317927|hematological malignancy
344497|NCT01317927|solid tumors
344498|NCT01317927|PK/PD study
344499|NCT01317901|follicular lymphoma
344500|NCT01317901|small lymphocytic lymphoma
344501|NCT01317901|marginal zone lymphoma
344502|NCT01317901|non-Hodgkin's lymphoma
344503|NCT01317901|indolent lymphoma
344504|NCT01317888|high grade gliomas of the brain
344505|NCT01317888|anti-body treatment
344506|NCT01317888|survival
344507|NCT01317862|labor induction, transcervical foley catheter, prostaglandin
344508|NCT01317849|folic acid
344509|NCT01317849|B vitamins
344510|NCT01317849|secondary prevention
344511|NCT01317849|stroke
344512|NCT01317849|randomized controlled trial
344513|NCT01317849|homocysteine
344514|NCT01317836|pancreatic cystic lesion
344515|NCT01317836|PET
344516|NCT01317836|PET-CT
344517|NCT01317836|diagnosis
344518|NCT01317823|Multiparas, Bishop score, Cervical length, Cervical ripening
344519|NCT01317810|Overactive Bladder (OAB)
344520|NCT01317810|Observational
344521|NCT01317810|Registry
344522|NCT01317797|Rheumatoid Arthritis
344523|NCT01317797|MT203
344524|NCT01317797|Human IgG1 monoclonal antibody
344525|NCT01317797|GM-CSF monoclonal antibody
344526|NCT01317784|diagnosis screening
344527|NCT01317784|HIV serodiagnosis
344528|NCT01317784|HCV antibodies
344529|NCT01317784|serologic tests
344530|NCT01317784|Bedside testing
344531|NCT01317784|diagnostic test kits
344532|NCT01317784|syphilis serodiagnosis
344533|NCT01317771|Proximal Biceps Pathology
344534|NCT01317758|influenza, vaccine, H5N1
344535|NCT01317745|H5N1, vaccine, influenza
344536|NCT01317732|Energy expenditure, physical activity, accelerometer, magnetometer, monitoring
344537|NCT01317719|Rupture of Distal Bicep Tendon
344538|NCT01317706|Bishop score, Cervical length, Cervical ripening, Labor induction
344539|NCT01317693|LI-ESWT
344540|NCT01317693|Erectile Dysfunction
344541|NCT01317693|ED
344542|NCT01317693|Shock waves
344543|NCT01317693|Therapy
344544|NCT01317680|Erectile Dysfunction
344545|NCT01317680|ED
344546|NCT01317680|PDE5 inhibitors
344547|NCT01317680|LI-ESWT
344548|NCT01317667|Ricin
344549|NCT01317667|RVEc
344550|NCT01317654|Tuberculosis meningitis
344551|NCT01317628|tobacco smoke, intervention program
344552|NCT01317615|Large cell carcinoma,
344553|NCT01317615|Lung cancer,
344554|NCT01317615|Neuroendocrine Tumors,
344555|NCT01317615|RAD001
344556|NCT01317602|Atrial Fibrillation
344557|NCT01317602|AF
344558|NCT01317589|Pain
344559|NCT01317589|Cancer of Head and Neck
344560|NCT01317589|methadone
344561|NCT01317589|Fentanyl
344562|NCT01317576|Magnetic Resonance Spectroscopy
344563|NCT01317576|Exercise
344564|NCT01317563|asthma
344565|NCT01317563|obesity
344566|NCT01317563|nutrition
344567|NCT01317563|antioxidant
344568|NCT01317550|Non-Small Cell Lung Cancer
344569|NCT01317550|NSCLC
344570|NCT01317550|Symptoms
344571|NCT01317550|Concurrent Chemoradiation
344572|NCT01317550|CXRT
344573|NCT01317550|Fatigue
344574|NCT01317550|Pain
344575|NCT01317550|Disturbed Sleep
344576|NCT01317550|Lack of Appetite
344577|NCT01317550|Drowsiness
344578|NCT01317550|Armodafinil
344579|NCT01317550|Nuvigil
344580|NCT01317550|Minocycline
344581|NCT01317550|Dynacin
344582|NCT01317550|Minocin
344583|NCT01317550|Minocin PAC
344584|NCT01317550|Myrac
344585|NCT01317550|Solodyn
344586|NCT01317550|Placebo
344587|NCT01317537|personal health records
344588|NCT01317524|Milk
344589|NCT01317524|Homogenization
344590|NCT01317524|Postprandial hyperlipidemia
344591|NCT01317524|Postprandial inflammation
344592|NCT01317524|Overweight
344593|NCT01317498|ART
344594|NCT01317498|antiretroviral
344595|NCT01317498|treatment
344596|NCT01317498|Vietnam
344597|NCT01317498|Asia
344598|NCT01317498|viral load
344599|NCT01317485|diverticulitis
344600|NCT01317485|perforation
344601|NCT01317485|sigmoidectomy
344602|NCT01317485|sigmoid resection
344603|NCT01317485|lavage
344604|NCT01317485|laparoscopic
344605|NCT01317485|wash-out
344606|NCT01317485|rinsing
344607|NCT01317485|hartmann
344608|NCT01317485|end-colostomy
344609|NCT01317485|primary anastomosis
344610|NCT01317472|laryngopharyngeal reflux, acid reflux, throat reflux
344611|NCT01317459|Self management
344612|NCT01317459|Diabetes type one
344613|NCT01317459|Empowerment
344614|NCT01317459|Intrinsic motivation
344615|NCT01317446|gingivitis index
344616|NCT01317446|plaque index
344617|NCT01317446|discoloration index
344618|NCT01317446|mouth rinse
344619|NCT01317446|amine fluoride/stannous fluoride
344620|NCT01317446|clinical trial
344621|NCT01317433|Metastatic Colorectal Cancer
344622|NCT01317433|K-RAS wild-type
344623|NCT01317433|FOLFIRI
344624|NCT01317433|Cetuximab
344625|NCT01317407|postoperative delirium
344626|NCT01317394|non-albicans candidemia
344627|NCT01317368|Postoperative analgesic treatment
344628|NCT01317368|TAP block
344629|NCT01317368|Prostatectomy
344630|NCT01317368|Double blinded randomized clinical trial
344631|NCT01317355|Cancer
344632|NCT01317355|Symptom burden
344633|NCT01317355|Symptom cluster
344634|NCT01317355|Distress
344635|NCT01317355|Pain
344636|NCT01317355|Fatigue
344637|NCT01317355|Sleep disorder
344638|NCT01317355|HRQoL
344639|NCT01317342|liver transplantation
344640|NCT01317342|machine liver perfusion
344641|NCT01317342|extended criteria liver grafts
344642|NCT01317342|donation after cardiac death
344643|NCT01317342|hypothermic machine liver perfusion
344644|NCT01317342|liver reperfusion injury
344645|NCT01317303|paired associative stimulation
344646|NCT01317303|theta burst stimulation
344647|NCT01317303|transcranial magnetic stimulation
344648|NCT01317303|neuroplasticity
344649|NCT01317303|healthy controls
344650|NCT01317290|Conversion of ALA
344651|NCT01317277|interventions
344652|NCT01317277|technology
344653|NCT01317277|drug abuse
344654|NCT01317277|methamphetamine
344655|NCT01317264|β-glucan
344656|NCT01317264|cholesterol
344657|NCT01317264|bile acids
344658|NCT01317264|blood glucose
344659|NCT01317264|appetite
344660|NCT01317251|Obesity prevention
344661|NCT01317251|appetite regulation
344662|NCT01317251|hyperlipidemia
344663|NCT01317238|Smallpox vaccine efficacy
344664|NCT01317225|Progesterone
344665|NCT01317225|Obstetric labor, premature
344666|NCT01317225|Short cervix
344667|NCT01317212|Glioblastoma multiforme
344668|NCT01317212|Carboplatin
344669|NCT01317212|Convection-enhanced delivery
344670|NCT01317199|Rising psa
344671|NCT01317186|FGF 23
344672|NCT01317186|ADMA
344673|NCT01317186|chronic kidney disease
344674|NCT01317186|Ca-P metabolism disorder
344675|NCT01317173|Chronic kidney disease progression
344676|NCT01317173|FGF 23
344677|NCT01317173|Klotho
344678|NCT01317160|Achilles Tendon
344679|NCT01317160|Immobilization
344680|NCT01317160|Wound Healing
344681|NCT01317160|Intermittent Pneumatic Compression
344682|NCT01317160|Ultrasonography
344683|NCT01317160|Microdialysis
344684|NCT01317147|pharmacokinetics
344685|NCT01317147|serotonin reuptake inhibitors
344686|NCT01317147|gastric bypass
344687|NCT01317147|depression
344688|NCT01317147|bioavailability
344689|NCT01317147|drug absorption
344690|NCT01317147|area under curve
344691|NCT01317134|Pulmonary Arterial Hypertension
344692|NCT01317134|Prognostic factors
344693|NCT01317134|Signal transduction
344694|NCT01317134|Genetics
344695|NCT01317121|Patients with a first episode of schizophrenia
344696|NCT01317121|Subjects at risk for psychosis
344697|NCT01317108|node-negative
344698|NCT01317095|Rigid fixation
344699|NCT01317095|Sternal closure
344700|NCT01317095|Open heart surgery
344701|NCT01317082|Postoperative Nausea & Vomiting.
344702|NCT01317017|Psoriasis
344703|NCT01317004|Multiple sclerosis
344704|NCT01317004|Fingolimod
344705|NCT01317004|Disease Modifying Therapy
344706|NCT01317004|TSQM-9
344707|NCT01316991|chewing gum
344708|NCT01316991|appetite
344709|NCT01316991|hunger
344710|NCT01316991|satiety
344711|NCT01316991|metabolic
344712|NCT01316991|nutrition
344713|NCT01316991|gut peptide hormones
344714|NCT01316991|psychological phenomena and processes
344715|NCT01316965|Postoperative delirium
344716|NCT01316965|elderly
344717|NCT01316965|prevention
344718|NCT01316965|stepped wedge design
344719|NCT01316965|healthcare workers
344720|NCT01316952|carvedilol
344721|NCT01316952|propranolol
344722|NCT01316952|hypersensitivity reactions
344723|NCT01316952|beta- blockers
344724|NCT01316952|Coreg
344725|NCT01316939|Crohn's disease, oral CCR9 antagonist, placebo-controlled, maintenance of remission, 52-week treatment, quality of life
344726|NCT01316926|fast condition
344727|NCT01316926|Paroxetine reference/test
344728|NCT01316926|healthy volunteers
344729|NCT01316926|Bioequivalence
344730|NCT01316913|tiotropium
344731|NCT01316913|long-acting muscarinic antagonist
344732|NCT01316913|COPD
344733|NCT01316913|long-acting beta agonist
344734|NCT01316900|long-acting muscarinic antagonist
344735|NCT01316900|tiotropium
344736|NCT01316900|COPD
344737|NCT01316900|long-acting beta agonist
344738|NCT01316887|Chronic Obstructive Pulmonary Disease
344739|NCT01316887|COPD
344740|NCT01316887|nDPI
344741|NCT01316887|long-acting beta agonist
344742|NCT01316887|long-acting muscarinic antagonist
344743|NCT01316887|tolerability
344744|NCT01316887|safety
344745|NCT01316874|Valrubicin
344746|NCT01316874|CIS
344747|NCT01316874|AD 32, BCG-refractory CIS
344748|NCT01316874|Carcinoma in situ (CIS) previously treated with BCG
344749|NCT01316848|AV-951
344750|NCT01316848|tivozanib
344751|NCT01316848|healthy Subjects
344752|NCT01316848|food Effect
344753|NCT01316848|pharmacokinetics
344754|NCT01316835|retrospective,sitagliptin, glycemia control,real world
344755|NCT01316822|CSF1R
344756|NCT01316822|M-CSF
344757|NCT01316822|CSF-1
344758|NCT01316822|c-FMS
344759|NCT01316822|Tumor-associated macrophage
344760|NCT01316822|Macrophage-Colony Stimulating Factor-1
344761|NCT01316822|Receptor tyrosine kinase inhibitor
344762|NCT01316822|Tumor cell-induced osteolysis
344763|NCT01316809|Brain
344764|NCT01316809|Tumor
344765|NCT01316809|Recurrent
344766|NCT01316809|Surgery
344767|NCT01316809|Radiation
344768|NCT01316809|Glioma
344769|NCT01316809|Brain Tumor
344770|NCT01316809|Glioblastoma Multiforme
344771|NCT01316809|Astrocytoma
344772|NCT01316809|Brainstem Glioma
344773|NCT01316796|Sickle Cell Disease
344774|NCT01316796|Hemolysis
344775|NCT01316796|Anemia
344776|NCT01316796|Nitric Oxide
344777|NCT01316796|Blood Flow
344778|NCT01316796|Leg Ulcer
344779|NCT01316796|Sickle Cell Anemia
344780|NCT01316796|Thalassemia
344781|NCT01316796|Hemolytic Blood Disorder
344782|NCT01316783|Africans
344783|NCT01316783|Obesity
344784|NCT01316783|Diabetes
344785|NCT01316783|Heart Disease
344786|NCT01316783|Genetic
344787|NCT01316783|African Descent
344788|NCT01316783|Cardiovascular Disease
344789|NCT01316770|Xerostomia
344790|NCT01316770|Sj(SqrRoot)(Delta)gren s Syndrome
344791|NCT01316770|Interventional Study
344792|NCT01316770|Sjogren Syndrome
344793|NCT01316770|Dry Mouth
344794|NCT01316744|long-term effects secondary to cancer therapy in adults
344795|NCT01316744|anxiety disorder
344796|NCT01316744|depression
344797|NCT01316744|pain
344798|NCT01316744|unspecified adult solid tumor, protocol specific
344799|NCT01316744|neuropathy
344800|NCT01316744|accelerated phase chronic myelogenous leukemia
344801|NCT01316744|acute undifferentiated leukemia
344802|NCT01316744|adult acute lymphoblastic leukemia in remission
344803|NCT01316744|adult acute myeloid leukemia in remission
344804|NCT01316744|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
344805|NCT01316744|adult acute myeloid leukemia with inv(16)(p13;q22)
344806|NCT01316744|adult acute myeloid leukemia with t(15;17)(q22;q12)
344807|NCT01316744|adult acute myeloid leukemia with t(16;16)(p13;q22)
344808|NCT01316744|adult acute myeloid leukemia with t(8;21)(q22;q22)
344809|NCT01316744|atypical chronic myeloid leukemia, BCR-ABL1 negative
344810|NCT01316744|blastic phase chronic myelogenous leukemia
344811|NCT01316744|chronic myelomonocytic leukemia
344812|NCT01316744|chronic phase chronic myelogenous leukemia
344813|NCT01316744|mast cell leukemia
344814|NCT01316744|meningeal chronic myelogenous leukemia
344815|NCT01316744|progressive hairy cell leukemia, initial treatment
344816|NCT01316744|prolymphocytic leukemia
344817|NCT01316744|recurrent adult acute lymphoblastic leukemia
344818|NCT01316744|recurrent adult acute myeloid leukemia
344819|NCT01316744|recurrent adult T-cell leukemia/lymphoma
344820|NCT01316744|refractory chronic lymphocytic leukemia
344821|NCT01316744|refractory hairy cell leukemia
344822|NCT01316744|relapsing chronic myelogenous leukemia
344823|NCT01316744|secondary acute myeloid leukemia
344824|NCT01316744|stage I adult T-cell leukemia/lymphoma
344825|NCT01316744|stage I chronic lymphocytic leukemia
344826|NCT01316744|stage II adult T-cell leukemia/lymphoma
344827|NCT01316744|stage II chronic lymphocytic leukemia
344828|NCT01316744|stage III adult T-cell leukemia/lymphoma
344829|NCT01316744|stage III chronic lymphocytic leukemia
344830|NCT01316744|stage IV adult T-cell leukemia/lymphoma
344831|NCT01316744|stage IV chronic lymphocytic leukemia
344832|NCT01316744|T-cell large granular lymphocyte leukemia
344833|NCT01316744|AIDS-related diffuse large cell lymphoma
344834|NCT01316744|AIDS-related diffuse mixed cell lymphoma
344835|NCT01316744|AIDS-related diffuse small cleaved cell lymphoma
344836|NCT01316744|AIDS-related immunoblastic large cell lymphoma
344837|NCT01316744|AIDS-related lymphoblastic lymphoma
344838|NCT01316744|AIDS-related peripheral/systemic lymphoma
344839|NCT01316744|AIDS-related primary CNS lymphoma
344840|NCT01316744|AIDS-related small noncleaved cell lymphoma
344841|NCT01316744|HIV-associated Hodgkin lymphoma
344842|NCT01316744|recurrent adult Hodgkin lymphoma
344843|NCT01316744|stage I adult Hodgkin lymphoma
344844|NCT01316744|stage II adult Hodgkin lymphoma
344845|NCT01316744|stage III adult Hodgkin lymphoma
344846|NCT01316744|stage IV adult Hodgkin lymphoma
344847|NCT01316744|anaplastic large cell lymphoma
344848|NCT01316744|angioimmunoblastic T-cell lymphoma
344849|NCT01316744|cutaneous B-cell non-Hodgkin lymphoma
344850|NCT01316744|recurrent cutaneous T-cell non-Hodgkin lymphoma
344851|NCT01316744|stage I cutaneous T-cell non-Hodgkin lymphoma
344852|NCT01316744|stage II cutaneous T-cell non-Hodgkin lymphoma
344853|NCT01316744|stage III cutaneous T-cell non-Hodgkin lymphoma
344854|NCT01316744|stage IV cutaneous T-cell non-Hodgkin lymphoma
344855|NCT01316744|recurrent mycosis fungoides/Sezary syndrome
344856|NCT01316744|stage I mycosis fungoides/Sezary syndrome
344857|NCT01316744|stage II mycosis fungoides/Sezary syndrome
344858|NCT01316744|stage III mycosis fungoides/Sezary syndrome
344859|NCT01316744|stage IV mycosis fungoides/Sezary syndrome
344860|NCT01316744|adult grade III lymphomatoid granulomatosis
344861|NCT01316744|adult nasal type extranodal NK/T-cell lymphoma
344862|NCT01316744|Waldenstrom macroglobulinemia
344863|NCT01316744|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
344864|NCT01316744|nodal marginal zone B-cell lymphoma
344865|NCT01316744|splenic marginal zone lymphoma
344866|NCT01316744|contiguous stage II adult Burkitt lymphoma
344867|NCT01316744|contiguous stage II adult diffuse large cell lymphoma
344868|NCT01316744|contiguous stage II adult diffuse mixed cell lymphoma
344869|NCT01316744|contiguous stage II adult diffuse small cleaved cell lymphoma
344870|NCT01316744|contiguous stage II adult immunoblastic large cell lymphoma
344871|NCT01316744|contiguous stage II adult lymphoblastic lymphoma
344872|NCT01316744|contiguous stage II grade 1 follicular lymphoma
344873|NCT01316744|contiguous stage II grade 2 follicular lymphoma
344874|NCT01316744|contiguous stage II grade 3 follicular lymphoma
344875|NCT01316744|contiguous stage II mantle cell lymphoma
344876|NCT01316744|contiguous stage II marginal zone lymphoma
344877|NCT01316744|contiguous stage II small lymphocytic lymphoma
344878|NCT01316744|stage I adult Burkitt lymphoma
344879|NCT01316744|stage I adult diffuse large cell lymphoma
344880|NCT01316744|stage I adult diffuse mixed cell lymphoma
344881|NCT01316744|stage I adult diffuse small cleaved cell lymphoma
344882|NCT01316744|stage I adult immunoblastic large cell lymphoma
344883|NCT01316744|stage I adult lymphoblastic lymphoma
344884|NCT01316744|stage I grade 1 follicular lymphoma
345109|NCT01316146|T lymphocytes
344885|NCT01316744|stage I grade 2 follicular lymphoma
344886|NCT01316744|stage I grade 3 follicular lymphoma
344887|NCT01316744|stage I mantle cell lymphoma
344888|NCT01316744|stage I marginal zone lymphoma
344889|NCT01316744|stage I small lymphocytic lymphoma
344890|NCT01316744|noncontiguous stage II adult Burkitt lymphoma
344891|NCT01316744|noncontiguous stage II adult diffuse large cell lymphoma
344892|NCT01316744|noncontiguous stage II adult diffuse mixed cell lymphoma
344893|NCT01316744|noncontiguous stage II adult diffuse small cleaved cell lymphoma
344894|NCT01316744|noncontiguous stage II adult immunoblastic large cell lymphoma
344895|NCT01316744|noncontiguous stage II adult lymphoblastic lymphoma
344896|NCT01316744|noncontiguous stage II grade 1 follicular lymphoma
344897|NCT01316744|noncontiguous stage II grade 2 follicular lymphoma
344898|NCT01316744|noncontiguous stage II grade 3 follicular lymphoma
344899|NCT01316744|noncontiguous stage II mantle cell lymphoma
344900|NCT01316744|noncontiguous stage II marginal zone lymphoma
344901|NCT01316744|noncontiguous stage II small lymphocytic lymphoma
344902|NCT01316744|stage III adult Burkitt lymphoma
344903|NCT01316744|stage III adult diffuse large cell lymphoma
344904|NCT01316744|stage III adult diffuse mixed cell lymphoma
344905|NCT01316744|stage III adult diffuse small cleaved cell lymphoma
344906|NCT01316744|stage III adult immunoblastic large cell lymphoma
344907|NCT01316744|stage III adult lymphoblastic lymphoma
344908|NCT01316744|stage III grade 1 follicular lymphoma
344909|NCT01316744|stage III grade 2 follicular lymphoma
344910|NCT01316744|stage III grade 3 follicular lymphoma
344911|NCT01316744|stage III mantle cell lymphoma
344912|NCT01316744|stage III marginal zone lymphoma
344913|NCT01316744|stage III small lymphocytic lymphoma
344914|NCT01316744|stage IV adult Burkitt lymphoma
344915|NCT01316744|stage IV adult diffuse large cell lymphoma
344916|NCT01316744|stage IV adult diffuse mixed cell lymphoma
344917|NCT01316744|stage IV adult diffuse small cleaved cell lymphoma
344918|NCT01316744|stage IV adult immunoblastic large cell lymphoma
344919|NCT01316744|stage IV adult lymphoblastic lymphoma
344920|NCT01316744|stage IV grade 1 follicular lymphoma
344921|NCT01316744|stage IV grade 2 follicular lymphoma
344922|NCT01316744|stage IV grade 3 follicular lymphoma
344923|NCT01316744|stage IV mantle cell lymphoma
344924|NCT01316744|stage IV marginal zone lymphoma
344925|NCT01316744|stage IV small lymphocytic lymphoma
344926|NCT01316744|recurrent adult Burkitt lymphoma
344927|NCT01316744|recurrent adult diffuse large cell lymphoma
344928|NCT01316744|recurrent adult diffuse mixed cell lymphoma
344929|NCT01316744|recurrent adult diffuse small cleaved cell lymphoma
344930|NCT01316744|recurrent adult grade III lymphomatoid granulomatosis
344931|NCT01316744|recurrent adult immunoblastic large cell lymphoma
344932|NCT01316744|recurrent adult lymphoblastic lymphoma
344933|NCT01316744|recurrent grade 1 follicular lymphoma
344934|NCT01316744|recurrent grade 2 follicular lymphoma
344935|NCT01316744|recurrent grade 3 follicular lymphoma
344936|NCT01316744|recurrent mantle cell lymphoma
344937|NCT01316744|recurrent marginal zone lymphoma
344938|NCT01316744|recurrent small lymphocytic lymphoma
344939|NCT01316744|intraocular lymphoma
344940|NCT01316744|primary central nervous system non-Hodgkin lymphoma
344941|NCT01316744|primary central nervous system Hodgkin lymphoma
344942|NCT01316744|post-transplant lymphoproliferative disorder
344943|NCT01316744|chronic eosinophilic leukemia
344944|NCT01316744|chronic neutrophilic leukemia
344945|NCT01316744|primary myelofibrosis
344946|NCT01316744|essential thrombocythemia
344947|NCT01316744|polycythemia vera
344948|NCT01316744|extramedullary plasmacytoma
344949|NCT01316744|isolated plasmacytoma of bone
344950|NCT01316744|stage I multiple myeloma
344951|NCT01316744|stage II multiple myeloma
344952|NCT01316744|stage III multiple myeloma
344953|NCT01316744|primary systemic amyloidosis
344954|NCT01316744|refractory multiple myeloma
344955|NCT01316744|de novo myelodysplastic syndromes
344956|NCT01316744|previously treated myelodysplastic syndromes
344957|NCT01316744|secondary myelodysplastic syndromes
344958|NCT01316744|myelodysplastic/myeloproliferative neoplasm, unclassifiable
344959|NCT01316718|IBS
344960|NCT01316718|diarrhoea
344961|NCT01316679|HCC
344962|NCT01316679|Liver Disease without HCC
344963|NCT01316666|orthostatic hypotension
344964|NCT01316666|Multiple System Atrophy
344965|NCT01316666|Pure Autonomic Failure
344966|NCT01316666|Parkinson's Disease
344967|NCT01316627|Body Dysmorphic Disorder (BDD)
344968|NCT01316627|Cognitive Behavior Therapy (CBT)
344969|NCT01316627|Obsessive Compulsive Disorder (OCD)
344970|NCT01316627|Mirror Retraining
344971|NCT01316627|Crooked Mirror Externalization Therapy
344972|NCT01316614|Fine-Needle Aspiration
344973|NCT01316614|Stylet
344974|NCT01316614|Solid Mass
344975|NCT01316614|Endoscopic Ultrasound (EUS)
344976|NCT01316588|recolonization
344977|NCT01316588|Plastic adhesive drape
344978|NCT01316588|microbial sealant
344979|NCT01316588|SSI
344980|NCT01316588|bacterial growth
344981|NCT01316575|Continuous Positive Airway Pressure
344982|NCT01316575|Postoperative Complications
344983|NCT01316575|Respiratory Insufficiency
344984|NCT01316575|Colorectal Surgery
344985|NCT01316549|fludarabine
344986|NCT01316549|pharmacokinetics
344987|NCT01316549|pediatric
344988|NCT01316549|allogeneic
344989|NCT01316549|hematopoietic cell transplantation
344990|NCT01316536|pain, agitation, music
344991|NCT01316523|Lenalidomide
344992|NCT01316523|Rituximab
344993|NCT01316523|untreated indolent Non-Hodgkin's Lymphoma
344994|NCT01316510|Probiotic
344995|NCT01316510|bifidobacteria
344996|NCT01316510|intestinal motility
344997|NCT01316497|Acute kidney injury
344998|NCT01316497|Ischemic preconditioning
344999|NCT01316497|Congenital heart defects
345000|NCT01316497|Cardiac surgical procedures
345001|NCT01316497|Infant
345002|NCT01316497|Child
345003|NCT01316484|Cognitive Debriefing
345004|NCT01316471|Chronic Pain
345005|NCT01316471|Abdominal Pain
345006|NCT01316471|Headache
345007|NCT01316471|Adolescents
345008|NCT01316471|Internet Interventions
345009|NCT01316471|Behavioral Interventions
345010|NCT01316458|Prostate cancer,
345011|NCT01316458|radical prostatectomy,
345012|NCT01316458|PSA rise
345013|NCT01316445|Electroencephalography
345014|NCT01316445|Benzodiazepines
345015|NCT01316445|Midazolam
345016|NCT01316432|Cenderitide
345017|NCT01316432|CD-NP
345018|NCT01316432|Natriuretic peptide
345019|NCT01316432|Heart failure
345020|NCT01316432|Chronic heart failure
345021|NCT01316432|HF
345022|NCT01316432|CHF
345023|NCT01316406|safety
345024|NCT01316406|efficacy
345025|NCT01316406|treatment
345026|NCT01316406|PPES
345027|NCT01316406|Palmar-Plantar Erythrodysesthesia Syndrome
345028|NCT01316406|Hand-foot syndrome
345029|NCT01316406|capecitabine
345030|NCT01316393|xerostomia, saliva, mucoprotection, oral health
345031|NCT01316367|Health Promotion Education
345032|NCT01316367|Type 2 Diabetes Mellitus
345033|NCT01316367|Cardiovascular Risk Factors
345034|NCT01316367|Spain
345035|NCT01316354|Arabinoxylan
345036|NCT01316354|Beta glucan
345037|NCT01316354|Whole grain
345038|NCT01316354|Dietary fibre
345039|NCT01316354|Metabolic syndrome
345040|NCT01316354|Glycemic index
345041|NCT01316354|Satiety
345042|NCT01316328|toxicity after single shot partial breast irradiation (SSPBI)
345043|NCT01316302|Social Anxiety Disorder
345044|NCT01316302|Social Phobia
345045|NCT01316302|SAD
345046|NCT01316289|tibial fractures
345047|NCT01316289|pilon
345048|NCT01316289|pilon fractures
345049|NCT01316289|tibial plafond
345050|NCT01316289|reduction quality
345051|NCT01316289|anatomical reduction
345052|NCT01316289|functional outcome
345053|NCT01316289|ankle joint
345054|NCT01316276|Cystic Fibrosis
345055|NCT01316276|Respiratory Infections
345056|NCT01316276|Pulmonary Cystic Fibrosis
345057|NCT01316276|CFTR
345058|NCT01316276|Anti-bacterial Agent
345059|NCT01316250|chronic myelogenous leukemia
345060|NCT01316250|nilotinib
345061|NCT01316250|complete cytogenetic response
345062|NCT01316250|imatinib mesylate
345063|NCT01316237|Hepatitis C
345064|NCT01316237|HCV
345065|NCT01316237|HCV RNA
345066|NCT01316237|Polymerase inhibitor
345067|NCT01316237|Treatment naïve
345068|NCT01316237|GS-6620
345069|NCT01316224|Psoriasis
345070|NCT01316224|Incidence
345071|NCT01316224|Quality of Life
345072|NCT01316224|Psoriatic Arthritis
345073|NCT01316224|Prevalence
345074|NCT01316211|Back Pains
345075|NCT01316211|Pain, Back
345076|NCT01316211|Pains, Back
345077|NCT01316211|Backache
345078|NCT01316211|Backaches
345079|NCT01316211|Back Ache
345080|NCT01316211|Ache, Back
345081|NCT01316211|Aches, Back
345082|NCT01316211|Back Aches
345083|NCT01316211|Back Pain without Radiation
345084|NCT01316211|Vertebrogenic Pain Syndrome
345085|NCT01316211|Pain Syndrome, Vertebrogenic
345086|NCT01316211|Pain Syndromes, Vertebrogenic
345087|NCT01316211|Syndrome, Vertebrogenic Pain
345088|NCT01316211|Syndromes, Vertebrogenic Pain
345089|NCT01316211|Vertebrogenic Pain Syndromes
345090|NCT01316211|Back Pain with Radiation
345091|NCT01316211|Stenosis, spinal
345092|NCT01316211|Caudal stenosis
345093|NCT01316211|Spondylopathy
345094|NCT01316211|Spondylopathies
345095|NCT01316211|Low back pain
345096|NCT01316211|Lower back pain
345097|NCT01316198|human study
345098|NCT01316198|AMD
345099|NCT01316198|lutein
345100|NCT01316198|zeaxanthin
345101|NCT01316198|optical density
345102|NCT01316185|Hepatitis D
345103|NCT01316185|HDV
345104|NCT01316185|Hepatitis
345105|NCT01316172|consultation
345106|NCT01316146|Hodgkin's Lymphoma
345107|NCT01316146|Non-Hodgkin's Lymphoma
345108|NCT01316146|Lymphoma
345110|NCT01316133|Tacrolimus
345111|NCT01316133|Prograf
345112|NCT01316133|FK506
345113|NCT01316133|Proteinuria
345114|NCT01316133|Calcineurin inhibitor
345115|NCT01316120|Self-collected vaginal samples
345116|NCT01316120|HPV
345117|NCT01316120|HPV self-obtained sample
345118|NCT01316120|HPV specimen transport medium
345119|NCT01316107|ASP1941
345120|NCT01316107|Diabetes mellitus
345121|NCT01316107|nateglinide
345122|NCT01316107|long-term safety
345123|NCT01316094|Renal impairment
345124|NCT01316094|ASP1941
345125|NCT01316094|Pharmacokinetics
345126|NCT01316081|antioxidant supplementation
345127|NCT01316081|childhood obesity
345128|NCT01316081|hepcidin
345129|NCT01316081|iron status
345130|NCT01316081|oxidative stress
345131|NCT01316081|inflammation
345132|NCT01316068|diabetic nephropathy
345133|NCT01316068|albuminuria
345134|NCT01316068|type 2 diabetes
345135|NCT01316068|sulodexide
345136|NCT01316042|Puberty
345137|NCT01316042|Hormones
345138|NCT01316029|Laying-on-of-hands
345139|NCT01316029|Therapeutic touch
345140|NCT01316029|cross-sectional study
345141|NCT01316029|healing environment
345142|NCT01316029|safety and effectiveness
345143|NCT01316029|optimal condition for the intervention
345144|NCT01316016|obesity
345145|NCT01316016|glucose intolerance
345146|NCT01316016|cholesterol
345147|NCT01316016|blood pressure
345148|NCT01316003|cone outer segment tips line
345149|NCT01316003|Optical coherence tomography
345150|NCT01315990|Phase IV Study
345151|NCT01315990|Metastatic Colorectal Cancer (mCRC
345152|NCT01315990|Cetuximab (Erbitux)
345153|NCT01315990|first-line treatment
345154|NCT01315990|acneiform follicular exanthema
345155|NCT01315990|rash
345156|NCT01315990|vitamin K1
345157|NCT01315977|Type 2 Diabetes Mellitus
345158|NCT01315977|Antioxidant oxidant balance
345159|NCT01315977|Activation of Antioxidant Response Element
345160|NCT01315964|cholesterol
345161|NCT01315964|plant sterols
345162|NCT01315964|atherosclerosis
345163|NCT01315964|arterial stiffness
345164|NCT01315951|Non scalp Seborrheic Dermatitis
345165|NCT01315925|Acute myeloid leukemia
345166|NCT01315925|invasive fungal infection
345167|NCT01315925|Aspergillosis
345168|NCT01315925|candidiasis
345169|NCT01315912|clomiphene citrate
345170|NCT01315912|infertility
345171|NCT01315912|letrozole
345172|NCT01315899|Raynaud's phenomenon
345173|NCT01315899|Systemic sclerosis
345174|NCT01315886|sublingual
345175|NCT01315886|fentanyl
345176|NCT01315886|titration
345177|NCT01315886|conversion
345178|NCT01315886|breakthrough cancer pain
345179|NCT01315886|pain intensity difference
345180|NCT01315886|PID
345181|NCT01315886|Edmonton Symptom Assessment System
345182|NCT01315886|ESAS
345183|NCT01315873|myeloma
345184|NCT01315873|multiple myeloma
345185|NCT01315873|relapsed myeloma
345186|NCT01315873|refractory myeloma
345187|NCT01315860|Low Back Pain
345188|NCT01315860|Pregnancy
345189|NCT01315860|Biomechanics
345190|NCT01315821|Saccharomyces boulardii
345191|NCT01315821|necrotizing enterocolitis
345192|NCT01315795|polycystic liver disease
345193|NCT01315782|Sepsis
345194|NCT01315782|Severe sepsis
345195|NCT01315782|Septic shock
345196|NCT01315782|Alveolar dead space
345197|NCT01315782|Multi-organ failure
345198|NCT01315730|stuttering
345199|NCT01315730|haptic
345200|NCT01315730|feedback
345201|NCT01315730|fluency
345202|NCT01315691|Cystic Fibrosis
345203|NCT01315691|Respiratory Infections
345204|NCT01315691|Pulmonary Cystic Fibrosis
345205|NCT01315691|Amikacin
345206|NCT01315691|Anti-bacterial agents
345207|NCT01315678|Cystic Fibrosis
345208|NCT01315678|Respiratory Infections
345209|NCT01315678|Pulmonary Cystic Fibrosis
345210|NCT01315678|CFTR
345211|NCT01315678|Amikacin
345212|NCT01315678|Anti-bacterial Agents
345213|NCT01315665|broccoli sprouts
345214|NCT01315665|sulforaphane
345215|NCT01315665|triterpenoid
345216|NCT01315665|Nrf2 activation
345217|NCT01315665|cystic fibrosis
345218|NCT01315665|healthy volunteers
345219|NCT01315665|anti-inflammatory
345220|NCT01315652|1 Rheumatoid arthritis
345221|NCT01315652|2 Education
345222|NCT01315652|3 Co-morbidities
345223|NCT01315652|4 Nurse
345224|NCT01315639|Dementia
345225|NCT01315639|Cognitive impairment
345226|NCT01315639|Memory impairment
345227|NCT01315639|Mild Cognitive Impairment
345228|NCT01315639|Cerebrospinal fluid
345229|NCT01315639|Plasma
345230|NCT01315639|Biomarker
345231|NCT01315639|Longitudinal
345232|NCT01315639|Abeta peptide amyloid, saPP alpha
345233|NCT01315639|Oculomotor impairment
345234|NCT01315626|Bronchiectasis
345235|NCT01315626|pulmonary exacerbations
345236|NCT01315626|pulmonary infections
345237|NCT01315574|Glaucoma
345238|NCT01315574|Xalatan
345239|NCT01315574|Travatan Z
345240|NCT01315574|Latanoprost
345241|NCT01315574|Travoprost
345242|NCT01315574|Dry Eye
345243|NCT01315561|acute low back pain
345244|NCT01315561|motion stlye acupuncture treatment
345245|NCT01315561|disability
345246|NCT01315561|MSAT
345247|NCT01315548|Contrast enhanced harmonic endoscopic ultrasound
345248|NCT01315548|Pancreatic adenocarcinoma
345249|NCT01315548|Chronic pancreatitis
345250|NCT01315535|Mandibular Advancement
345251|NCT01315535|Oral Appliance
345252|NCT01315535|TMD
345253|NCT01315522|Stents
345254|NCT01315522|Endoscopy
345255|NCT01315522|Cholangiopancreatography
345256|NCT01315522|Endoscopic Retrograde
345257|NCT01315509|Severe mental illness
345258|NCT01315509|Dental measures
345259|NCT01315509|Resistant depression
345260|NCT01315496|Human Immunoglobulin G
345261|NCT01315496|Sepsis
345262|NCT01315496|Septic shock
345263|NCT01315483|Breast cancer
345264|NCT01315483|survivors
345265|NCT01315483|weight lose
345266|NCT01315483|dietary pattern
345267|NCT01315470|improving pregnancy rate and endometrial thickness
345268|NCT01315457|alemtuzumab, infection, prophylaxis, treatment
345269|NCT01315431|Solid tumor malignancy, excluding lymphoma
345270|NCT01315418|Probiotic - Lactobacillus casei DN-114 001 - dairy product -
345271|NCT01315418|infections - firemen
345272|NCT01315418|Common infectious diseases, occuring in healthy subjects,
345273|NCT01315418|including upper respiratory tract infections (defined as
345274|NCT01315418|rhinopharyngitis, sore throat, sinusitis and otitis)
345275|NCT01315418|lower respiratory tract infections (defined as bronchitis
345276|NCT01315418|pneumopathy and flu and flu-like syndromes)
345277|NCT01315418|gastrointestinal tract infection defined as gastroenteritis
345278|NCT01315405|Emotional facial expression
345279|NCT01315405|Apathy
345280|NCT01315405|Mirror neurons
345281|NCT01315379|Prolonged Exposure
345282|NCT01315379|CBT
345283|NCT01315379|PTSD
345284|NCT01315379|Mild Traumatic Brain Injury
345285|NCT01315379|Post Concussive Syndrome
345286|NCT01315366|Vitamin D
345287|NCT01315366|Elderly
345288|NCT01315366|Cardiovascular profile
345289|NCT01315366|Insulin resistance
345290|NCT01315366|Gene polymorphisms
345291|NCT01315327|Tourette's Disorder, Obsessive-Compulsive Disorder, tics
345292|NCT01315314|Glucose degradation products
345293|NCT01315314|Inflammation
345294|NCT01315314|Endothelial dysfunction
345295|NCT01315314|Soluble adhesion molecules
345296|NCT01315314|Peritoneal dialysis
345297|NCT01315301|Efavirenz
345298|NCT01315301|Rifampicin
345299|NCT01315301|HAART
345300|NCT01315301|Anti Tuberculosis
345301|NCT01315288|Medical decision making
345302|NCT01315288|Asymptomatic Carotid Stenosis
345303|NCT01315275|visual impairment
345304|NCT01315275|macular edema
345305|NCT01315275|ranibizumab
345306|NCT01315275|visual impairment due to macular edema
345307|NCT01315262|Sildenafil 100
345308|NCT01315262|restoring erectile function after radical prostatectomy
345309|NCT01315249|QVA149
345310|NCT01315249|indacaterol
345311|NCT01315249|NVA237
345312|NCT01315249|COPD
345313|NCT01315249|fluticasone/salmeterol
345314|NCT01315210|Fibromyalgia
345315|NCT01315210|Fatigue
345316|NCT01315210|D-Ribose
345317|NCT01315197|Low back Pain
345318|NCT01315184|Interactive Voice Response
345319|NCT01315184|Computer-based Treatment
345320|NCT01315184|Opioid Agonist
345321|NCT01315184|Buprenorphine
345322|NCT01315184|Methadone
345323|NCT01315171|medium chain triglycerides
345324|NCT01315171|hypoglycemia
345325|NCT01315171|cognitive function
345326|NCT01315171|functional MRI
345327|NCT01315158|Obstructive Sleep Apnea
345328|NCT01315158|Body Mass Index
345329|NCT01315132|Myeloablative Hematopoietic Stem Cell Transplant
345330|NCT01315132|Cyclophosphamide tolerization
345331|NCT01315132|2 Step Approach
345332|NCT01315132|Hematological malignancies
345333|NCT01315132|leukemia
345334|NCT01315132|lymphoma
345335|NCT01315132|multiple myeloma
345336|NCT01315132|Hodgkin's Disease
345337|NCT01315093|In Vitro Fertilisation
345338|NCT01315093|poor responders
345339|NCT01315080|mammillary fistula
345340|NCT01315080|triamcinolone
345341|NCT01315080|ultrasound management
345342|NCT01315080|percutaneous treatment
345343|NCT01315067|kidney transplantation
345344|NCT01315067|acute rejection
345345|NCT01315067|diagnosis
345346|NCT01315067|urine analysis
345347|NCT01315067|urinary peptides
345348|NCT01315067|mass spectrometry
345349|NCT01315067|allograft biopsy
345350|NCT01315067|pathology
345351|NCT01315067|diagnostic study
345352|NCT01315054|IDUs
345353|NCT01315054|high risk behaviors
345354|NCT01315054|HIV
345355|NCT01315054|MMT dosage and retention
345356|NCT01315054|psychosocial services
345357|NCT01315028|mania
345358|NCT01315028|hypomania
345359|NCT01315028|bipolar affective disorder
345360|NCT01315028|psychological intervention
345361|NCT01315028|cognitive therapy
345362|NCT01315015|Breast cancer
345363|NCT01315015|Breast neoplasm
345364|NCT01315015|Magnetic Resonance Imaging
345365|NCT01315015|Breast density
345366|NCT01315015|Early detection of cancer
345367|NCT01315015|Cancer screening test
345368|NCT01315015|Secondary prevention
345369|NCT01315002|nicotine
345370|NCT01315002|schizophrenia
345371|NCT01315002|endophenotype
345372|NCT01314976|Children
345373|NCT01314976|parasite
345374|NCT01314976|intestinal
345375|NCT01314976|treatment
345376|NCT01314976|RCT
345377|NCT01314937|preschool-age children
345378|NCT01314937|soil-transmitted helminths
345379|NCT01314937|growth
345380|NCT01314937|development
345381|NCT01314937|deworming
345382|NCT01314924|Hypertension
345383|NCT01314924|Endothelial dysfunction
345384|NCT01314924|Vascular stiffness
345385|NCT01314924|Use of one or two antihypertensive drugs
345386|NCT01314911|H1N1
345387|NCT01314911|Complications
345388|NCT01314911|PCR
345389|NCT01314911|Seasonal Influenza
345390|NCT01314911|Viral Shedding
345391|NCT01314898|Single dose
345392|NCT01314898|cross-over
345393|NCT01314898|active-control
345394|NCT01314898|placebo control
345395|NCT01314898|antimineralocorticoid activity
345396|NCT01314885|Healthy
345397|NCT01314872|Overactive bladder
345398|NCT01314872|MK-4618
345399|NCT01314872|tolterodine
345400|NCT01314859|Nifedipine
345401|NCT01314859|Obstetric Labor
345402|NCT01314859|Premature
345403|NCT01314859|Tocolysis
345404|NCT01314833|Luminal A
345405|NCT01314833|Luminal B
345406|NCT01314833|Her-2 overexpression
345407|NCT01314833|DFS
345408|NCT01314833|DDFS
345409|NCT01314833|OS
345410|NCT01314820|Knee
345411|NCT01314820|Osteoarthritis
345412|NCT01314820|Effusion.
345413|NCT01314807|COPD
345414|NCT01314781|Overactive Bladder
345415|NCT01314781|urinary frequency
345416|NCT01314755|Head and Neck neoplasm
345417|NCT01314755|Nutrition
345418|NCT01314755|Carcinoma
345419|NCT01314755|Infection
345420|NCT01314755|Post-operative
345421|NCT01314755|Surgery
345422|NCT01314755|Immune-enhancing
345423|NCT01314742|neonates
345424|NCT01314742|mechanical ventilation
345425|NCT01314742|oral care
345426|NCT01314742|duration of mechanical ventilation
345427|NCT01314742|feasibility
345428|NCT01314742|ventilator-associated pneumonia
345429|NCT01314729|Orthodontic fixed retainer
345430|NCT01314729|fiber-reinforced-composite retainer
345431|NCT01314729|composite-wire retainer
345432|NCT01314690|obesity
345433|NCT01314690|low calorie diet
345434|NCT01314690|intestinal microbiota
345435|NCT01314690|inflammation (systemic and in adipose tissue)
345436|NCT01314690|fat mass
345437|NCT01314690|Impact of nutritional transition on intestinal microbiota
345438|NCT01314690|relation between food intake, clinical parameters and intestinal microbiota
345439|NCT01314664|Non-Muscle Invasive Bladder Cancer
345440|NCT01314664|CIS
345441|NCT01314664|BCG Refractory
345442|NCT01314651|Migraine Disorders
345443|NCT01314651|Chronic migraine
345444|NCT01314651|Insomnia
345445|NCT01314651|Behavioral sleep management
345446|NCT01314612|Insomnia
345447|NCT01314612|group psychotherapy
345448|NCT01314612|nightmares
345449|NCT01314612|PTSD
345450|NCT01314612|posttraumatic stress disorder
345451|NCT01314612|Veterans
345452|NCT01314612|cognitive-behavioral intervention
345453|NCT01314599|Leukemia
345454|NCT01314599|lurbinectedin
345455|NCT01314599|PM01183
345456|NCT01314599|Pharma Mar
345457|NCT01314599|Acute Leukemia in Relapse and Primary Refractory
345458|NCT01314586|hypercholesterolemia
345459|NCT01314586|postmenopause
345460|NCT01314586|secoisolariciresinol diglucoside
345461|NCT01314586|flaxseed
345462|NCT01314586|lignans
345463|NCT01314586|enterolactone
345464|NCT01314586|enterodiol
345465|NCT01314586|serum cholesterol
345466|NCT01314586|LDL cholesterol
345467|NCT01314573|High intensity exercise training
345468|NCT01314573|Vascular health
345469|NCT01314573|Endothelial function
345470|NCT01314573|Circulating angiogenic cells
345471|NCT01314573|endothelial progenitor cells
345472|NCT01314573|Aerobic capacity
345473|NCT01314573|Arterial stiffness
345474|NCT01314573|Traditional and emerging cardiovascular disease risk factors
345475|NCT01314560|Lowe syndrome
345476|NCT01314560|OCRL
345477|NCT01314560|Haemostasis
345478|NCT01314560|Bleeding Disorders
345479|NCT01314560|Platelet Function Tests
345480|NCT01314547|Environment
345481|NCT01314547|spondylarthritis
345482|NCT01314547|vasculitis
345483|NCT01314547|stress
345484|NCT01314547|life event
345485|NCT01314547|vaccine
345486|NCT01314534|Kabuki syndrome
345487|NCT01314534|Genetic
345488|NCT01314534|CGH-array
345489|NCT01314521|Suicide
345490|NCT01314521|Depression
345491|NCT01314521|Adolescents
345492|NCT01314508|pre-pubertal children
345493|NCT01314508|pre-transplant
345494|NCT01314508|not treated with growth hormone for at least 3 months
345495|NCT01314495|Alopecia Areata
345496|NCT01314482|Neuropathic pain
345497|NCT01314482|Minocycline
345498|NCT01314469|Quality of life in patients with macular edema compared to patients without macular edema.
345499|NCT01314456|Prostate biopsy
345500|NCT01314456|Trans-rectal ultrasound
345501|NCT01314456|Prostate cancer
345502|NCT01314443|smoking cessation
345503|NCT01314443|gamma-tocopherol
345504|NCT01314443|nicotine-replacement therapy
345505|NCT01314443|oxidative stress
345506|NCT01314417|Uveitis
345507|NCT01314417|Macular Edema
345508|NCT01314417|Methotrexate
345509|NCT01314404|Human papillomavirus
345510|NCT01314404|Prevalence
345511|NCT01314404|Knowledge Attitude and Practice
345512|NCT01314404|Willingness to Participate
345513|NCT01314404|Vaccine
345514|NCT01314404|HPV
345515|NCT01314391|stage I Wilms tumor
345516|NCT01314391|stage II Wilms tumor
345517|NCT01314391|stage III Wilms tumor
345518|NCT01314391|stage IV Wilms tumor
345519|NCT01314391|stage V Wilms tumor
345520|NCT01314391|renal failure
345521|NCT01314378|Mindfulness
345522|NCT01314378|Cognitive behavioral therapy
345523|NCT01314378|Smoking
345524|NCT01314378|Impulsivity
345525|NCT01314378|Inhibitory Control
345526|NCT01314326|Optical Coherence Tomography
345527|NCT01314326|Glaucoma
345528|NCT01314326|Advanced Imaging
345529|NCT01314313|SAPIEN XT
345530|NCT01314313|SAPIEN 3
345531|NCT01314313|Transfemoral
345532|NCT01314313|Transapical
345533|NCT01314313|Transaortic
345534|NCT01314313|NovaFlex
345535|NCT01314313|TAVI
345536|NCT01314313|Aortic Stenosis
345537|NCT01314313|THV
345538|NCT01314313|Aortic Valve
345539|NCT01314313|Transcatheter Heart Valve
345540|NCT01314313|tAVR
345541|NCT01314300|Child, adolescent, young adult
345542|NCT01314300|Plaster
345543|NCT01314300|Lidocaine
345544|NCT01314287|Anaesthesia
345545|NCT01314287|pulmonary complications
345546|NCT01314287|Atelectasis
345547|NCT01314274|Epistaxis
345548|NCT01314274|Osler
345549|NCT01314274|Weber
345550|NCT01314274|Rendu
345551|NCT01314274|HHT
345552|NCT01314274|Hereditary haemorrhagic telangiectasia
345553|NCT01314248|airway sealing pressure
345554|NCT01314248|fiberoptic assessment
345555|NCT01314248|ease and time for successful insertion
345556|NCT01314248|incidence of gastric insufflation
345557|NCT01314248|complications were also evaluated
345558|NCT01314235|anticoagulation with ASS
345559|NCT01314235|anticoagulation with clopidogrel
345560|NCT01314209|dexmedetomidine
345561|NCT01314209|pharmacokinetics
345562|NCT01314209|critical illness
345563|NCT01314209|continuous renal replacement therapy
345564|NCT01314196|biceps
345565|NCT01314196|resistance training
345566|NCT01314196|rehabilitation
345567|NCT01314196|impact syndrome
345568|NCT01314183|Knee
345569|NCT01314183|Physical Therapy
345570|NCT01314183|Exercise
345571|NCT01314170|Implant, glaucoma, refractory glaucoma.
345572|NCT01314157|low back pain
345573|NCT01314157|pain
345574|NCT01314157|incapacity
345575|NCT01314157|life quality
345576|NCT01314157|rehabilitation
345577|NCT01314144|axillary clearance
345578|NCT01314144|wound infiltration
345579|NCT01314144|wound infusion
345580|NCT01314144|local anaesthetic wound infusion
345581|NCT01314118|abiraterone acetate
345582|NCT01314118|prednisone
345583|NCT01314118|zytiga
345584|NCT01314092|crohn's disease
345585|NCT01314092|fistula
345586|NCT01314092|complex
345587|NCT01314079|Crohn's fistula
345588|NCT01314079|Autologous adipose derived stem cell
345589|NCT01314053|Daptomycin
345590|NCT01314053|Serious Gram-positive Infections
345591|NCT01314040|Dietary protein
345592|NCT01314040|Biomarkers
345593|NCT01314040|filtration rate
345594|NCT01314040|urinary acid excretion
345595|NCT01314014|Non Hodgkin's Lymphoma
345596|NCT01314014|Lymphoma, Low Grade
345597|NCT01314014|Lymphoma, Intermediate Grade
345598|NCT01314014|Lymphoma, High Grade
345599|NCT01314014|Lymphoma, B Cell
345600|NCT01314001|Tobacco, Smoking, Varenicline, Nicotine Patch
345601|NCT01313988|dose-response study
345602|NCT01313988|blood lipid profile
345603|NCT01313988|plant sterols
345604|NCT01313988|fish oil
345605|NCT01313975|Electrolyte disturbances
345606|NCT01313975|Fluid balance
345607|NCT01313975|subarachnoid hemorrhage
345608|NCT01313975|traumatic brain injury
345609|NCT01313975|Cerebral salt wasting
345610|NCT01313975|SIADH
345611|NCT01313975|Diabetes insipidus
345612|NCT01313962|antiviral
345613|NCT01313962|intranasal
345614|NCT01313962|influenza
345615|NCT01313949|Diabetes
345616|NCT01313949|Peer Support
345617|NCT01313949|Structured Care
345618|NCT01313936|Neuroblastoma
345619|NCT01313936|MIBG
345620|NCT01313936|131I-MIBG
345621|NCT01313936|Irinotecan
345622|NCT01313936|Vincristine
345623|NCT01313936|Resistant
345624|NCT01313936|Relapsed
345625|NCT01313936|Treatment
345626|NCT01313936|UCSF
345627|NCT01313936|Pediatric
345628|NCT01313936|Oncology
345629|NCT01313923|Pemphigus
345630|NCT01313910|HIV
345631|NCT01313910|diarrhea
345632|NCT01313897|Multiple Myeloma
345633|NCT01313832|ventricular septal defect
345634|NCT01313832|remote ischemic preconditioning
345635|NCT01313832|pulmonary hypertension
345636|NCT01313832|infant with ventricular septal defect and pulmonary hypertension
345637|NCT01313819|Freezing
345638|NCT01313806|dementia
345639|NCT01313806|memory loss
345640|NCT01313806|cognitive decline
345641|NCT01313793|Bioequivalence (BE) Study
345642|NCT01313793|Healthy Volunteers
345643|NCT01313780|cancer related pain
345644|NCT01313767|spasticity
345645|NCT01313767|upperlimb
345646|NCT01313767|Botulinum toxin
345647|NCT01313754|Skin closure
345648|NCT01313754|dermabond
345649|NCT01313754|vicryl
345650|NCT01313754|monocryl
345651|NCT01313754|Suburethral sling
345652|NCT01313754|Transobturator Sling
345653|NCT01313754|Pain
345654|NCT01313754|Discomfort
345655|NCT01313754|Skin irritation
345656|NCT01313728|Acne
345657|NCT01313728|Irritation
345658|NCT01313715|Safety
345659|NCT01313715|Immunogenicity
345660|NCT01313715|inactivated EV71 vaccine
345661|NCT01313702|polypill, compliance, cardiovascular disease
345662|NCT01313689|Safety
345663|NCT01313689|Refractory
345664|NCT01313689|Chronic Lymphocytic Leukemia
345665|NCT01313689|Oncology
345666|NCT01313689|Ofatumumab
345667|NCT01313689|Efficacy
345668|NCT01313676|COPD
345669|NCT01313676|Cardiovascular disease
345670|NCT01313676|Novel Dry Powder Inhaler
345671|NCT01313676|Survival
345672|NCT01313663|GW786034
345673|NCT01313663|non-small cell lung cancer
345674|NCT01313663|NSCLC
345675|NCT01313663|pemetrexed
345676|NCT01313663|pazopanib
345677|NCT01313650|long-acting beta agonist
345678|NCT01313650|anticholinergic
345679|NCT01313637|anticholinergic
345680|NCT01313637|long-acting beta agonist
345681|NCT01313598|Patients with solid tumors
345682|NCT01313598|Treatment-refractory
345683|NCT01313585|Primary care
345684|NCT01313585|asthma management
345685|NCT01313585|inhaler device
345686|NCT01313585|maintenance therapy
345687|NCT01313585|reliever therapy
345688|NCT01313585|Easibreathe salbutamol
345689|NCT01313572|Coronary Artery Disease
345690|NCT01313572|Myocardial Perfusion Imaging
345691|NCT01313559|Castrate Resistant
345692|NCT01313559|Chemotherapy Naive
345693|NCT01313559|Prostate Cancer
345694|NCT01313559|SOM230
345695|NCT01313559|Everolimus
345696|NCT01313546|Femoral nerve block
345697|NCT01313546|total knee arthroplasty
345698|NCT01313533|Atherosclerosis of Autologous Vein Bypass Graft
345699|NCT01313507|Primary Immunodeficiency Syndrome
345700|NCT01313507|PID
345701|NCT01313494|COPD
345702|NCT01313494|Roflumilast
345703|NCT01313494|FEV1
345704|NCT01313494|China
345705|NCT01313481|Older persons
345706|NCT01313481|Exercise
345707|NCT01313481|Balance
345708|NCT01313468|NEAT
345709|NCT01313468|maximal oxygen uptake
345710|NCT01313468|stroke volume
345711|NCT01313455|Oligomenorrhea
345712|NCT01313455|Adrenal Hyperplasia
345713|NCT01313455|Obesity
345714|NCT01313455|Hyperandrogenism
345715|NCT01313455|Polycystic Ovarian Syndrome
345716|NCT01313455|PCOS
345717|NCT01313455|Polycystic Ovary
345718|NCT01313455|Healthy Volunteer
345719|NCT01313455|HV
345720|NCT01313442|Tissue Acquisition
345721|NCT01313442|Gastrointestinal Cancer
345722|NCT01313442|Immune Suppressor
345723|NCT01313442|Immune Monitoring
345724|NCT01313442|Samples
345725|NCT01313442|Gastrointestinal Tract Cancer
345726|NCT01313429|Metastatic Cancer
345727|NCT01313429|Cancer Vaccine
345728|NCT01313429|Immunotherapy
345729|NCT01313429|Adjuvant Therapy
345730|NCT01313429|Chest Metastases
345731|NCT01313429|Cancer
345732|NCT01313429|Melanoma
345733|NCT01313429|Lung Cancer
345734|NCT01313429|Sarcoma
345735|NCT01313416|Adjuvant Therapy
345736|NCT01313416|Recombinant Monoclonal Antibody
345737|NCT01313416|Adenocarcinoma of the Pancreas
345738|NCT01313416|Vaccination
345739|NCT01313416|PD-1 Receptor
345740|NCT01313416|Pancreas Cancer
345741|NCT01313416|Pancreatic Cancer
345742|NCT01313403|5-HT1A Receptors
345743|NCT01313403|Major Depression
345744|NCT01313403|PET Imaging
345745|NCT01313403|Depression
345746|NCT01313403|Healthy Volunteer
345747|NCT01313403|HV
345748|NCT01313390|recurrent squamous cell carcinoma of the hypopharynx
345749|NCT01313390|stage III squamous cell carcinoma of the hypopharynx
345750|NCT01313390|stage IV squamous cell carcinoma of the hypopharynx
345751|NCT01313390|stage III squamous cell carcinoma of the larynx
345752|NCT01313390|stage III verrucous carcinoma of the larynx
345753|NCT01313390|stage IV squamous cell carcinoma of the larynx
345754|NCT01313390|stage IV verrucous carcinoma of the larynx
345755|NCT01313390|recurrent squamous cell carcinoma of the larynx
345756|NCT01313390|recurrent verrucous carcinoma of the larynx
345757|NCT01313390|recurrent squamous cell carcinoma of the lip and oral cavity
345758|NCT01313390|stage III squamous cell carcinoma of the lip and oral cavity
345759|NCT01313390|stage IV squamous cell carcinoma of the lip and oral cavity
345760|NCT01313390|recurrent verrucous carcinoma of the oral cavity
345761|NCT01313390|stage III verrucous carcinoma of the oral cavity
345762|NCT01313390|stage IV verrucous carcinoma of the oral cavity
345763|NCT01313390|metastatic squamous neck cancer with occult primary squamous cell carcinoma
345764|NCT01313390|recurrent metastatic squamous neck cancer with occult primary
345765|NCT01313390|recurrent squamous cell carcinoma of the nasopharynx
345766|NCT01313390|stage III squamous cell carcinoma of the nasopharynx
345767|NCT01313390|stage IV squamous cell carcinoma of the nasopharynx
345768|NCT01313390|recurrent squamous cell carcinoma of the oropharynx
345769|NCT01313390|stage III squamous cell carcinoma of the oropharynx
345770|NCT01313390|stage IV squamous cell carcinoma of the oropharynx
345771|NCT01313390|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
345772|NCT01313390|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
345773|NCT01313390|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
345774|NCT01313390|recurrent salivary gland cancer
345775|NCT01313390|salivary gland squamous cell carcinoma
345776|NCT01313390|stage III salivary gland cancer
345777|NCT01313390|stage IV salivary gland cancer
345778|NCT01313390|tongue cancer
345779|NCT01313377|adenocarcinoma of the extrahepatic bile duct
345780|NCT01313377|cholangiocarcinoma of the extrahepatic bile duct
345781|NCT01313377|liver and intrahepatic biliary tract cancer
345782|NCT01313377|localized extrahepatic bile duct cancer
345783|NCT01313377|adenocarcinoma of the gallbladder
345784|NCT01313377|cholangiocarcinoma of the gallbladder
345785|NCT01313377|localized gallbladder cancer
345786|NCT01312740|obesity
345787|NCT01312740|dietary treatment
345788|NCT01312740|high protein diet
345789|NCT01312740|Low glycaemic index
345790|NCT01312740|adipocytes
345791|NCT01312740|fat mass
345792|NCT01312740|systemic inflammatory markers
345793|NCT01312740|improvement of complications
345794|NCT01312740|effect on weight loss
345795|NCT01312727|Tubulointerstitial renal diseases
345796|NCT01312727|Hereditary renal diseases
345797|NCT01312727|Uromodulin
345798|NCT01312727|Renin gene
345799|NCT01312714|Hemodialysis
345800|NCT01312714|Peritoneal dialysis
345801|NCT01312714|Vitamin D Deficiency
345802|NCT01312714|blood pressure
345803|NCT01312714|arterial stiffness
345804|NCT01312714|Heart function
345805|NCT01312714|Renin-angiotensin system
345806|NCT01312714|Calcium
345807|NCT01312714|FGF-23
345808|NCT01312714|Brain natriuretic peptide
345809|NCT01312701|cancer
345810|NCT01312701|immunomonitoring
345811|NCT01312701|CD247 -zeta chain
345812|NCT01312701|chronic inflamation
345813|NCT01312701|anticancertherapy
345814|NCT01312688|Early Goal Directed Hemodunamic Therapy in Sepsis
345815|NCT01312675|severe sepsis
345816|NCT01312675|mechanical ventilation
345817|NCT01312610|orange juice
345818|NCT01312610|cognitive function
345819|NCT01312610|flavonoids
345820|NCT01312610|flavanones
345821|NCT01312597|Flavonoid
345822|NCT01312597|Cognitive performance
345823|NCT01312597|Cognitive function
345824|NCT01312597|Executive function
345825|NCT01312597|fMRI
345826|NCT01312597|Cerebral blood flow
345827|NCT01312597|Acute
345828|NCT01312584|Flavanol
345829|NCT01312584|Cocoa
345830|NCT01312584|Vascular function
345831|NCT01312584|Absorption
345832|NCT01312584|Metabolism
345833|NCT01312584|Alkalisation
345834|NCT01312558|obstructive sleep apnoea/hypopnoea syndrome
345835|NCT01312558|Mediterranean diet
345836|NCT01312558|exercise
345837|NCT01312558|weight loss
345838|NCT01312558|continuous positive airway pressure
345839|NCT01312558|lipid peroxidation
345840|NCT01312545|orbital implant
345841|NCT01312545|evisceration
345842|NCT01312545|economic
345843|NCT01312545|polyethylene
345844|NCT01312545|porous
345845|NCT01312532|Total knee arthroplasty
345846|NCT01312532|Fixed-bearing
345847|NCT01312532|Mobile-bearing
345848|NCT01313325|hippotherapy
345849|NCT01313325|neuromuscular disorders
345850|NCT01313325|balance deficits
345851|NCT01313325|participation
345852|NCT01313286|Diabetes Mellitus, Type 2
345853|NCT01313260|Refractory partial epilepsies
345854|NCT01313247|Paracetamol
345855|NCT01313247|opioids
345856|NCT01313247|cancer pain
345857|NCT01313221|plaque psoriasis
345858|NCT01313221|moderate
345859|NCT01313221|severe
345860|NCT01313221|etanercept
345861|NCT01313221|Enbrel
345862|NCT01313221|topical
345863|NCT01313208|RA
345864|NCT01313208|Enbrel
345865|NCT01313208|DMARD
345866|NCT01313208|Joint Count
345867|NCT01313208|Rheumatoid Arthritis
345868|NCT01313208|Etanercept
345869|NCT01313208|disease modifying anti-rheumatic drug
345870|NCT01313169|Electronic medical record reminders, Panel management
345871|NCT01313156|Metabolic Syndrome, Syndrome X, MetS,
345872|NCT01313156|Type 2 Diabetes
345873|NCT01313143|AOP200704, Esmolol, Pharmacokinetics, Pharmacodynamics
345874|NCT01313130|traumatic brain injury
345875|NCT01313130|post traumatic stress disorder
345876|NCT01313130|Diffusion tensor imaging
345877|NCT01313130|resting state functional connectivity
345878|NCT01313130|genetic factors
345879|NCT01313117|chemotherapy
345880|NCT01313117|peripheral neuropathy
345881|NCT01313117|paclitaxel
345882|NCT01313117|breast cancer
345883|NCT01313078|Ovarian Cancer
345884|NCT01313078|Fallopian Tube Cancer
345885|NCT01313078|Primary Peritoneal Cancer
345886|NCT01313078|Relapsed or Refractory
345887|NCT01313078|Pegaspargase
345888|NCT01313078|Pegylated L-Asparaginase
345889|NCT01313065|VX15/2503
345890|NCT01313065|Semaphorin 4D
345891|NCT01313065|SEMA4D
345892|NCT01313065|CD100
345893|NCT01313065|safety
345894|NCT01313065|tolerability
345895|NCT01313065|pharmacokinetics
345896|NCT01313065|pharmacodynamics
345897|NCT01313065|advanced solid tumors
345898|NCT01313052|Psychotic
345899|NCT01313052|Criminal
345900|NCT01313039|Breast Cancer
345901|NCT01313039|ER-negative
345902|NCT01313039|Allred Score
345903|NCT01313026|Percutaneous nerve evaluation
345904|NCT01313026|Transanal irrigation
345905|NCT01313026|Low anterior resection syndrome
345906|NCT01313000|fat, transfer, autologous fat transfer, bicep
345907|NCT01312948|Obstructive sleep apnea
345908|NCT01312948|OSA
345909|NCT01312948|CPAP
345910|NCT01312948|CPAP mask
345911|NCT01312948|Non-invasive ventilation
345912|NCT01312948|NIV
345913|NCT01312935|Percutaneous Coronary Intervention
345914|NCT01312935|Heparin
345915|NCT01312935|Angioplasty
345916|NCT01312935|LMWH
345917|NCT01312909|smoking cessation in adolescents
345918|NCT01312857|colon
345919|NCT01312857|rectal
345920|NCT01312857|liver
345921|NCT01312857|AMG 954 (Panitumumab)
345922|NCT01312857|DEXAMETHASONE
345923|NCT01312857|FLOXURIDINE
345924|NCT01312857|FLUOROURACIL
345925|NCT01312857|IRINOTECAN (CPT-11) CAMPTOSAR
345926|NCT01312857|LEUCOVORIN
345927|NCT01312857|10-137
345928|NCT01312831|cobalamin
345929|NCT01312831|B12
345930|NCT01312831|homocysteine
345931|NCT01312831|MMA
345932|NCT01312831|holotranscobalamin
345933|NCT01312831|Eligen
345934|NCT01312805|asthma
345935|NCT01312805|clinical decision support
345936|NCT01312805|CHICA
345937|NCT01312792|Severe Pneumonia
345938|NCT01312792|Pneumonia
345939|NCT01312792|ARI
345940|NCT01312792|IMCI
345941|NCT01312792|Modified IMCI
345942|NCT01312792|1st level Health facilities
345943|NCT01312792|Children
345944|NCT01312792|Operational Research
345945|NCT01312792|Bangladesh
345946|NCT01312792|Treatment of Severe Pneumonia
345947|NCT01312779|Mitral Valve Replacement
345948|NCT01312779|23mm CEP
345949|NCT01312779|Magna
345950|NCT01312519|Bone marrow biopsy of iliac crest
345951|NCT01312506|metastatic
345952|NCT01312506|melanoma
345953|NCT01312506|CNS
345954|NCT01312493|Head and neck cancer
345955|NCT01312493|Phase II
345956|NCT01312493|Locally advanced
345957|NCT01312493|Panitumumab
345958|NCT01312493|Vectibix
345959|NCT01312493|Lineberger
345960|NCT01312493|Radiation Therapy
345961|NCT01312493|Intensity modulated radiation therapy (IMRT)
345962|NCT01312493|Stage III to IVB
345963|NCT01312480|Tobacco
345964|NCT01312480|Tobacco Prevention
345965|NCT01312480|Tobacco Cessation
345966|NCT01312480|5A's Model
345967|NCT01312480|Adolescence
345968|NCT01312480|Media Use
345969|NCT01312454|intravitreal injection
345970|NCT01312454|intraocular pressure
345971|NCT01312454|open-angle glaucoma
345972|NCT01312454|ocular hypertension
345973|NCT01312441|Vitamin D
345974|NCT01312441|Ergocalciferol
345975|NCT01312415|total knee arthroplasty
345976|NCT01312415|total knee replacement
345977|NCT01312415|local infiltration analgesia
345978|NCT01312415|intra-articular local anaesthesia
345979|NCT01312415|patients undergoing total knee arthroplasty (total knee replacement)
345980|NCT01312363|Alzheimer's disease
345981|NCT01312363|Rivastigmine
345982|NCT01312363|Patch
345983|NCT01312363|Tolerability
345984|NCT01312350|neoadjuvant chemotherapy
345985|NCT01312350|definitive chemoradiation therapy
345986|NCT01312350|head and neck cancer
345987|NCT01312350|base of tongue
345988|NCT01312350|Locally advanced
345989|NCT01312337|gefitinib
345990|NCT01312337|EGFR mutation negative
345991|NCT01312337|NSCLC
345992|NCT01312324|neoadjuvant chemotherapy
345993|NCT01312324|thymic cancer
345994|NCT01312311|nasopharyngeal cancer
345995|NCT01312311|weekly docetaxel
345996|NCT01312311|cisplatin
345997|NCT01312298|Arthritis
345998|NCT01312298|General anaesthesia
345999|NCT01312298|Spinal anaesthesia
346000|NCT01312285|osteoarthritis
346001|NCT01312285|painful hips
346002|NCT01312272|Schizophrenia
346003|NCT01312272|Social Intelligence
346004|NCT01312272|Perception, Social
346005|NCT01312272|Oxytocin
346006|NCT01312259|Painful Bladder Syndrome
346007|NCT01312259|Interstitial Cystitis
346008|NCT01312259|Pelvic Floor dysfunction
346009|NCT01312259|Fecal incontinence
346010|NCT01312259|Constipation
346011|NCT01312259|Sexual dysfunction
346012|NCT01312259|Dyspareunia
346013|NCT01312259|Vulvodynia
346014|NCT01312246|vessel ligation
346015|NCT01312246|colon resection
346016|NCT01312207|tractional retinoschisis
346017|NCT01312207|traction retinal detachment
346018|NCT01312194|Periapical Periodontitis
346019|NCT01312194|Dental Pulp Necrosis
346020|NCT01312194|Root canal Therapy
346021|NCT01312194|Adolescent
346022|NCT01312181|Technology based intervention
346023|NCT01312181|HIV primary care clinic
346024|NCT01312181|Brief behavioral intervention
346025|NCT01312181|Drug abuse
346026|NCT01312168|Cardiovascular disease
346027|NCT01312168|Continuous positive airway pressure
346028|NCT01312168|Endothelium
346029|NCT01312168|Vascular function
346030|NCT01312168|Inflammation
346031|NCT01312168|Sleep Apnea
346032|NCT01312168|Obstructive
346033|NCT01312155|endotracheal
346034|NCT01312155|intubation
346035|NCT01312155|video
346036|NCT01312155|time
346037|NCT01312129|Alcohol
346038|NCT01312129|Sulfasalazine
346039|NCT01312116|Internet treatment
346040|NCT01312116|GAD
346041|NCT01312116|guided self-help
346042|NCT01312103|Safety Planning
346043|NCT01312090|Weight loss
346044|NCT01312090|brown adipose tissue
346045|NCT01312090|white adipose tissue
346046|NCT01312090|muscle, metabolism
346047|NCT01312090|cold exposure
346048|NCT01312077|total hip arthroplasty
346049|NCT01312077|total hip replacement
346050|NCT01312077|local infiltration analgesia
346051|NCT01312077|wound infusion
346052|NCT01312077|patients undergoing total hip replacement (total hip arthroplasty)
346053|NCT01312064|rituximab
346054|NCT01312064|everolimus
346055|NCT01312038|Eustachian tube
346056|NCT01312038|otitis
346057|NCT01312038|middle-ear pressure
346058|NCT01312038|simethicone
346059|NCT01312012|hepatitis B virus,mother-infant transmission, nucleoside analog,pregnant women
346060|NCT01311999|latent tuberculosis, renal failure, dialysis, interferon-gamma release assay
346061|NCT01311986|atopic dermatitis
346062|NCT01311986|nummular eczema
346063|NCT01311986|chemokines
346064|NCT01311973|Chronic kidney disease, phosphorus, salivary phosphorus
346065|NCT01311960|pterygium
346066|NCT01311960|recurrent pterygium
346067|NCT01311960|bevacizumab
346068|NCT01311960|VEGF
346069|NCT01311960|anti-VEGF
346070|NCT01311947|Chronic hepatitis B
346071|NCT01311947|Peginterferon alfa-2a
346072|NCT01311921|enterovirus 71, host genetics, social, behavior, environmental factors
346073|NCT01311908|Pancreaticoduodenectomy
346074|NCT01311908|Roux-en-Y reconstruction
346075|NCT01311908|Reflux esophagitis
346076|NCT01311895|acute
346077|NCT01311895|pain
346078|NCT01311895|emergency department
346079|NCT01311895|hydromorphone
346080|NCT01311856|Behavioral intervention
346081|NCT01311856|Exercise
346082|NCT01311856|Physical Assessment
346083|NCT01311856|Questionnaire
346084|NCT01311856|Survey
346085|NCT01311856|Telephone counseling
346086|NCT01311856|Internet interventions
346087|NCT01311856|Overweight cancer survivors
346088|NCT01311856|Exercise and weight management program
346089|NCT01311791|Left ventricular augmentation
346090|NCT01311791|Left ventricular restoration
346091|NCT01311765|Postoperative peritonitis
346092|NCT01311765|Intra-abdominal infection
346093|NCT01311765|Surgery
346094|NCT01311765|Laparotomy
346095|NCT01311765|Nosocomial infection
346096|NCT01311765|Antibiotic therapy
346097|NCT01311765|Duration of treatment
346098|NCT01311765|Multidrug resistant bacteria
346099|NCT01311752|human papillomavirus
346100|NCT01311752|follow up
346101|NCT01311739|Pharmacokinetics
346102|NCT01311713|cancer
346103|NCT01311713|tumors
346104|NCT01311713|PARP
346105|NCT01311700|Ischemia
346106|NCT01311700|Reperfusion
346107|NCT01311700|Myocardial infarction
346108|NCT01311700|Beta blockers
346109|NCT01311700|Metoprolol
346110|NCT01311700|Acute myocardial infarction
346111|NCT01311700|Necrosis
346112|NCT01311700|Salvaged Myocardium
346113|NCT01311687|Myeloma
346114|NCT01311687|Multiple Myeloma
346115|NCT01311687|Relapsed Multiple Myeloma
346116|NCT01311687|Relapsed and Refractory Multiple Myeloma
346117|NCT01311687|Refractory Myeloma
346118|NCT01311687|Resistant Multiple Myeloma
346119|NCT01311687|Treatment-resistant Multiple Myeloma
346120|NCT01311687|Pomalidomide
346121|NCT01311687|Lenalidomide-resistant
346122|NCT01311687|Bortezomib-resistant
346123|NCT01311648|recombinant factor VIII
346124|NCT01311648|pediatric use
346125|NCT01311635|Phase 1
346126|NCT01311635|bioavailability study
346127|NCT01311635|AZD1981
346128|NCT01311635|tablets
346129|NCT01311635|To study the relative bioavailability of single dose AZD1981 via three different tablets
346130|NCT01311635|To compare the bioavailability between three different AZD1981 tablets
346131|NCT01311622|drug-drug interaction
346132|NCT01311622|Phase 1
346133|NCT01311622|healthy subjects
346134|NCT01311622|warfarin
346135|NCT01311622|Rheumatoid arthritis
346136|NCT01311622|RA
346137|NCT01311622|fostamatinib open-label
346138|NCT01311622|pharmacokinetics
346139|NCT01311622|pharmacodynamics
346140|NCT01311622|level of Warfarin in the blood
346141|NCT01311609|Systane, Dry Eye
346142|NCT01311596|icons in clinic or office for patients with Autism
346143|NCT01311583|Self-care
346144|NCT01311583|Teach Back
346145|NCT01311557|Tetanus
346146|NCT01311557|Diphtheria
346147|NCT01311557|Pertussis
346148|NCT01311557|Tdap vaccine
346149|NCT01311557|Adacel®
346150|NCT01311531|Fracture
346151|NCT01311531|Radius
346152|NCT01311531|Surgery
346153|NCT01311531|Osteosynthesis
346154|NCT01311518|Thymosin Beta 4
346155|NCT01311518|Thymosin β4 (Tβ4) Injectable Solution
346156|NCT01311518|RGN-352
346157|NCT01311505|bioequivalence; rifampicin
346158|NCT01311492|Alzheimer's Disease
346159|NCT01311492|exercise
346160|NCT01311492|physical activity
346161|NCT01311492|intervention
346162|NCT01311479|Osteopathic Manipulation
346163|NCT01311479|Interstitial Cystitis
346164|NCT01311479|Sacroiliac Joint Dysfunction
346165|NCT01311466|Liver transplantation
346166|NCT01311466|Overall survival
346167|NCT01311440|RCT
346168|NCT01311440|modified Atkins diet
346169|NCT01311440|epilepsy
346170|NCT01311440|adults
346171|NCT01311440|ketogenic diet
346172|NCT01311401|2 diabetes mellitus,Circassians, High fasting glucose
346173|NCT01311388|cancer
346174|NCT01311375|spinal,, bone, cord injury, lipid,antioxidant
346175|NCT01311362|Steady-state
346176|NCT01311362|Ambrisentan
346177|NCT01311362|St. Johns Wort
346178|NCT01311349|Susceptibility of tigecycline
346179|NCT01311349|Drug Resistance, Bacterial
346180|NCT01311336|Pegfilgrastim
346181|NCT01311336|Loratadine
346182|NCT01311336|Myalgia/arthralgia
346183|NCT01311323|Multivessel Coronary Artery Disease
346184|NCT01311323|Left Main Narrowing
346185|NCT01311323|Percutaneous Coronary Intervention
346186|NCT01311323|Coronary Artery Bypass Grafting
346187|NCT01311323|Drug-Eluting Stent
346188|NCT01311310|troponin, open heart surgery, children
346189|NCT01311284|Nasotracheal intubation
346190|NCT01311284|Macintosh laryngoscope
346191|NCT01311284|Airtraq
346192|NCT01311284|McGrath
346193|NCT01311284|Manikin
346194|NCT01311284|airway management
346195|NCT01311271|Stroke
346196|NCT01311271|Cerebrovascular disease
346197|NCT01311271|hemiplegia
346198|NCT01311271|Transcranial magnetic stimulation
346199|NCT01311271|repetitive transcranial magnetic stimulation
346200|NCT01311271|rTMS
346201|NCT01311271|rehabilitation
346202|NCT01311271|Upper Extremity
346203|NCT01311258|AML
346204|NCT01311258|MDS
346205|NCT01311245|Risky drinking
346206|NCT01311245|Brief intervention
346207|NCT01311245|Computer-generated feedback
346208|NCT01311245|Stage-tailored
346209|NCT01311245|Non-stage-tailored
346210|NCT01311232|rituximab, lymphoma, hepatitis B virus
346211|NCT01311206|knee osteoarthritis
346212|NCT01311206|isokinetic knee extensor strength
346213|NCT01311206|quadriceps volume
346214|NCT01311206|symptomatic knee osteoarthritis
346215|NCT01311193|Circadian rhythms
346216|NCT01311193|Sleep-wake cycles
346217|NCT01311193|Melatonin
346218|NCT01311193|Borderline Personality Disorder
346219|NCT01311193|Light therapy
346220|NCT01311167|Dexamethasone
346221|NCT01311167|Sodium
346222|NCT01311154|carriers
346223|NCT01311154|resistant Enterobacteriaceae
346224|NCT01311154|AMR
346225|NCT01311154|antibiotic
346226|NCT01311128|Blood pressure
346227|NCT01311128|Heart rate
346228|NCT01311128|Cardiac output
346229|NCT01311128|Critical care
346230|NCT01311128|Perioperative care
346231|NCT01311102|Pain score
346232|NCT01311102|IUD placement
346233|NCT01311076|Type 1 Diabetes Mellitus
346234|NCT01311076|Insulin
346235|NCT01311076|Glucose
346236|NCT01311076|Drug Therapy
346237|NCT01311050|Metastatic Colorectal Cancer
346238|NCT01311037|Premenopausal Women with Advanced Breast Cancer
346239|NCT01311024|Children
346240|NCT01311024|Pneumococcal Vaccines
346241|NCT01311011|Critical Limb Ischemia
346242|NCT01310998|Schizophrenia
346243|NCT01310998|high intensity exercise
346244|NCT01310998|interval training exercise
346245|NCT01310985|Rectal Cancer
346246|NCT01310972|Adjuvant Colon Cancer
346247|NCT01310959|Aplastic Anemia Marrow Failure Syndrome
346248|NCT01310946|Acute Lymphocytic Leukemia
346249|NCT01310894|Prostatic Disease
346250|NCT01310894|Genital Neoplasm,male
346251|NCT01310894|Urogenital neoplasm
346252|NCT01310894|Genital disease,male
346253|NCT01310894|Male urogenital disease
346254|NCT01310894|Neoplasms
346255|NCT01310894|Neoplasms by site
346256|NCT01310894|Prostatic neoplasm
346257|NCT01310894|Carcinoma
346258|NCT01310881|Neurogenesis
346259|NCT01310881|hippocampal stem cells
346260|NCT01310881|depression
346261|NCT01310881|stroke
346262|NCT01310868|adult giant cell glioblastoma
346263|NCT01310868|adult gliosarcoma
346264|NCT01310868|adult glioblastoma
346265|NCT01310855|adult giant cell glioblastoma
346266|NCT01310855|adult glioblastoma
346267|NCT01310855|adult gliosarcoma
346268|NCT01310855|recurrent adult brain tumor
346269|NCT01310842|Smoker
346270|NCT01310842|Smoking Cessation
346271|NCT01310842|Social Determinants
346272|NCT01310842|Environmental Effects
346273|NCT01310842|Individual-level effects
346274|NCT01310842|Nicotine patch
346275|NCT01310842|Smart Phone
346276|NCT01310842|SP
346277|NCT01310842|Global Positioning System
346278|NCT01310842|GPS
346279|NCT01310842|Questionnaires
346280|NCT01310842|Saliva samples
346281|NCT01310829|Genetic counselor
346282|NCT01310829|Genetic counseling degree program
346283|NCT01310829|Genetic counseling students
346284|NCT01310829|Virtual reality-based intervention
346285|NCT01310829|VR
346286|NCT01310829|Genetic counseling
346287|NCT01310829|hereditary cancers
346288|NCT01310829|Questionnaires
346289|NCT01310829|Physiological measurements
346290|NCT01310829|Skin sensors
346291|NCT01310816|malignant neoplasms of the bone
346292|NCT01310816|bone sarcoma
346293|NCT01310803|Urinary Bladder Neoplasms
346294|NCT01310803|Neoplasms
346295|NCT01310803|Urologic Neoplasms
346296|NCT01310803|Urogenital Neoplasms
346297|NCT01310803|Neoplasms by Site
346298|NCT01310803|Urinary Bladder Diseases
346299|NCT01310803|Urologic Diseases
346300|NCT01310803|TURBT
346301|NCT01310803|Valstar
346302|NCT01310790|septic shock
346303|NCT01310790|lactic acid clearance
346304|NCT01310790|ScVO2
346305|NCT01310777|Open-Angle glaucoma
346306|NCT01310777|Ocular Hypertension
346307|NCT01310777|OAG
346308|NCT01310777|OHT
346309|NCT01310764|Intraocular pressure
346310|NCT01310764|Trabeculectomy
346311|NCT01310764|Mitomycin C
346312|NCT01310764|Bevacizumab
346313|NCT01310738|Visceral leishmaniasis
346314|NCT01310738|Leishmania infantum
346315|NCT01310738|Leishmania chagasi
346316|NCT01310725|CABG
346317|NCT01310725|LIMA
346318|NCT01310725|saphenous vein
346319|NCT01310725|radial artery
346320|NCT01310712|hyperhidrosis
346321|NCT01310712|oxybutynin
346322|NCT01310699|Colonoscopy
346323|NCT01310699|Diagnostic imaging
346324|NCT01310699|Colorectal Neoplasm
346325|NCT01310699|Tandem Colonoscopy
346326|NCT01310699|Flat Polyp
346327|NCT01310699|Nonpolypoid
346328|NCT01310699|Flat and Depressed Lesions
346329|NCT01310699|Primary Prevention
346330|NCT01310699|Endoscopy
346331|NCT01310686|wet AMD anti-VEGF
346332|NCT01310686|Genetic analysis of patients with Wet AMD who have not responded fully to anti-VEGF treatments
346333|NCT01310673|Gout
346334|NCT01310673|Allopurinol
346335|NCT01310673|Acute gout
346336|NCT01310647|estradiol
346337|NCT01310647|testosterone
346338|NCT01310647|combined oral contraceptive
346339|NCT01310647|low responders
346340|NCT01310647|ICSI
346341|NCT01310634|Neonates
346342|NCT01310634|Parenting
346343|NCT01310634|Anxiety
346344|NCT01310634|Depression
346345|NCT01310621|Neonate
346346|NCT01310621|Meconium aspiration syndrome
346347|NCT01310621|surfactant lung lavage
346348|NCT01310608|Atherosclerosis aorta
346349|NCT01310608|A-View
346350|NCT01310608|Distal ascending aorta
346351|NCT01310608|Transoesophageal echocardiography
346352|NCT01310608|CABG
346353|NCT01310608|Cerebral embolisation
346354|NCT01310595|Musculoskeletal manipulations
346355|NCT01310595|Proprioception
346356|NCT01310595|Postural balance
346357|NCT01310582|Sevoflurane
346358|NCT01310582|Desflurane
346359|NCT01310569|PCOS, Skinfold thickness, HOMA-IR
346360|NCT01310556|OGTT
346361|NCT01310556|coronary artery disease
346362|NCT01310543|Teenage pregnancy
346363|NCT01310543|Adolescent
346364|NCT01310543|Sexual health
346365|NCT01310543|Youth development
346366|NCT01310530|Breast Cancer
346367|NCT01310530|Partial Breast
346368|NCT01310530|Proton Beam
346369|NCT01310517|Angiogram
346370|NCT01310517|Injected Contrast
346371|NCT01310517|Heart Function
346372|NCT01310517|contrast dye
346373|NCT01310478|Recombinant human endostatin
346374|NCT01310478|Metastatic colorectal cancer
346375|NCT01310478|DLT
346376|NCT01310478|MTD
346377|NCT01310478|Pharmacokinetics
346378|NCT01310452|diabetes, basal insulin, metformin, liver fat, visceral fat
346379|NCT01310426|Anal Sphincter injury
346380|NCT01310426|Fecal Incontinence
346381|NCT01310413|Influenza
346382|NCT01310413|H5N1
346383|NCT01310413|Pandemic
346384|NCT01310400|Influenza
346385|NCT01310400|Virus
346386|NCT01310400|Vaccination
346387|NCT01310400|Immunisation
346388|NCT01310387|Lung cancer
346389|NCT01310387|Cancer pain
346390|NCT01310387|Opioid
346391|NCT01310374|influenza vaccine
346392|NCT01310374|immune response
346393|NCT01310374|dynamic changes
346394|NCT01310361|Pharyngitis
346395|NCT01310361|Group A β-hemolytic Streptococci
346396|NCT01310361|Exudate
346397|NCT01310361|Erythema Penicillin
346398|NCT01310361|Amoxicillin
346399|NCT01310348|Bone
346400|NCT01310348|Muscle strength
346401|NCT01310348|whole-body vibration
346402|NCT01310335|sclerostin
346403|NCT01310335|whole-body vibration
346404|NCT01310322|Phase I
346405|NCT01310322|Healthy male volunteers
346406|NCT01310322|mild asthmatics
346407|NCT01310322|pharmacokinetics
346408|NCT01310322|Bioavailability and AUC
346409|NCT01310322|Level of AZD5423 in your blood
346410|NCT01310309|Stents
346411|NCT01310309|Drug-eluting Stent
346412|NCT01310309|Angioplasty
346413|NCT01310309|Coronary Artery stenosis
346414|NCT01310309|Coronary Artery Stent Restenosis
346415|NCT01310309|Stent Thrombosis
346416|NCT01310296|Phase 1
346417|NCT01310296|Normal Healthy Volunteers
346418|NCT01310296|Mass Balance
346419|NCT01310296|ADME
346420|NCT01310296|Absolute Bioavailability
346421|NCT01310283|dental caries
346422|NCT01310283|children
346423|NCT01310283|mutans streptococci
346424|NCT01310283|lactobacilli
346425|NCT01310283|cariogenic bacteria
346426|NCT01310244|Phase 1/2
346427|NCT01310244|MTD
346428|NCT01310244|stage IV
346429|NCT01310244|NSCLC
346430|NCT01310244|chemo-naive
346431|NCT01310244|Mixed-cell dose escalation
346432|NCT01310244|lung cancer
346433|NCT01310244|non-small-cell
346434|NCT01310244|phase I
346435|NCT01310244|Belinostat
346436|NCT01310244|Carboplatin
346437|NCT01310244|Paclitaxel
346438|NCT01310244|adenocarcinoma
346439|NCT01310244|PXD-101
346440|NCT01310231|Metastatic Breast Cancer
346441|NCT01310231|Metformin
346442|NCT01310218|orthopedics, carpal tunnel syndrome, postoperative care
346443|NCT01310205|HCV
346444|NCT01310205|Genotype 1
346445|NCT01310205|relapsers
346446|NCT01310205|non cirrhotic
346447|NCT01310205|Chronic Hepatitis C
346448|NCT01310179|gene therapy
346449|NCT01310179|advanced solid tumors
346450|NCT01310179|Head and Neck cancer
346451|NCT01310179|intratumoral therapy
346452|NCT01310166|Multiple sclerosis
346453|NCT01310166|RRMS
346454|NCT01310166|relapsing-remitting
346455|NCT01310166|fingolimod
346456|NCT01310166|biomarkers
346457|NCT01310140|Metabolic Syndrome
346458|NCT01310140|Insulin Resistance
346459|NCT01310140|Massachusetts General Hospital
346460|NCT01310140|Major Depressive Disorder
346461|NCT01310140|Major Depressive Disorder with Psychotic Features
346462|NCT01310140|Cortisol
346463|NCT01310140|Dexamethasone Suppression Test
346464|NCT01310127|NSAID
346465|NCT01310127|Ocular Inflammation
346466|NCT01310127|bromfenac
346467|NCT01310114|Human Placenta-Derived Cells
346468|NCT01310114|Stem cells
346469|NCT01310114|Stroke
346470|NCT01310114|PDA001
346471|NCT01310114|Celgene
346472|NCT01310114|cenplacel-L
346473|NCT01310101|Chronic Lymphocytic Leukemia
346474|NCT01310101|Refractory
346475|NCT01310101|Relapse
346476|NCT01310101|Ofatumumab
346477|NCT01310101|Dexamethasone
346478|NCT01310088|Childhood
346479|NCT01310088|Child
346480|NCT01310088|adolescent
346481|NCT01310088|central blood pressure
346482|NCT01310088|ambulatory blood pressure monitoring
346483|NCT01310088|ABPM
346484|NCT01310088|clinic blood pressure
346485|NCT01310088|pulse wave velocity
346486|NCT01310088|PWV
346487|NCT01310088|Pulse cave analysis
346488|NCT01310088|PWA
346489|NCT01310088|heart rate variability
346490|NCT01310088|HRV
346491|NCT01310088|Echocardiography
346492|NCT01310088|Urine microalbuminuria
346493|NCT01310088|blood samples
346494|NCT01310075|Mastectomy
346495|NCT01310075|Bioprosthetic Mesh
346496|NCT01310075|Breast Reconstruction
346497|NCT01310075|Tissue Expander
346498|NCT01310075|Alloderm
346499|NCT01310075|Surgimend
346500|NCT01310062|hepatocellular carcinoma
346501|NCT01310062|microarray
346502|NCT01310062|gene expression profiling
346503|NCT01310062|biomarkers
346504|NCT01310049|Exploratory study in healthy subjects
346505|NCT01310023|Conditions and diagnoses potentially related to perinatal exposure to antiretroviral medications
346506|NCT01309997|Imatinib
346507|NCT01309997|Rituximab
346508|NCT01309997|Chronic Graft-vs-Host Disease
346509|NCT01309984|Monitored anesthesia care
346510|NCT01309971|Assessment
346511|NCT01309971|Questionable Caries
346512|NCT01309958|Dental Caries
346513|NCT01309958|Intervention
346514|NCT01309958|Non-invasive treatment for early caries
346515|NCT01309919|intrauterine device
346516|NCT01309919|Mirena
346517|NCT01309919|levonorgestrel intrauterine system
346518|NCT01309919|postpartum contraception
346519|NCT01309893|Contact lens
346520|NCT01309880|Contact lens
346521|NCT01309854|Phase 1
346522|NCT01309854|healthy volunteers
346523|NCT01309854|pharmacokinetics
346524|NCT01309854|Rheumatoid arthritis
346525|NCT01309854|RA
346526|NCT01309854|fostamatinib
346527|NCT01309854|pioglitazone
346528|NCT01309854|drug-drug interaction
346529|NCT01309841|Non-Cancer-Related Pain, Opioid-Induced Constipation
346530|NCT01309828|Renal Insufficiency
346531|NCT01309828|Kidney Diseases
346532|NCT01309828|Hypertension
346533|NCT01309828|Drug Therapy
346534|NCT01309815|neoplasms
346535|NCT01309815|existentialism
346536|NCT01309815|existential concerns
346537|NCT01309815|Meaning making
346538|NCT01309815|early palliative phase
346539|NCT01309815|elderly
346540|NCT01309802|botox
346541|NCT01309802|raynaud's
346542|NCT01309802|botulinum toxin
346543|NCT01309802|botulinum toxin A
346544|NCT01309802|raynaud's disease
346545|NCT01309802|raynaud's syndrome
346546|NCT01309802|raynaud's phenomenon
346547|NCT01309802|ischemic digits
346548|NCT01309802|ischemia
346549|NCT01309802|botox treatment
346550|NCT01309802|onabotulinum
346551|NCT01309802|onabotulinum toxin
346552|NCT01309802|onabotulinum toxin type A
346553|NCT01309789|Antibodies, Monoclonal
346554|NCT01309789|Antibody-Drug Conjugate
346555|NCT01309789|Antigens, CD30
346556|NCT01309789|Drug Therapy
346557|NCT01309789|Hematologic Diseases
346558|NCT01309789|Lymphoma
346559|NCT01309789|monomethyl auristatin E
346560|NCT01309789|Lymphoma, Large-Cell, Anaplastic
346561|NCT01309789|Lymphoma, T-cell
346562|NCT01309789|Lymphoma, NK-cell
346563|NCT01309737|Xeljanz
346564|NCT01309737|tofacitinib
346565|NCT01309737|Jak-inhibitor
346566|NCT01309737|oral treatment
346567|NCT01309737|chronic
346568|NCT01309737|severe
346569|NCT01309737|moderate
346570|NCT01309737|Pruritus
346571|NCT01309737|Itch
346572|NCT01309737|DLQI
346573|NCT01309737|treatment
346574|NCT01309737|safety
346575|NCT01309737|efficacy
346576|NCT01309737|CP-690,550
346577|NCT01309737|Plaque Psoriasis
346578|NCT01309737|Psoriasis Vulgaris
346579|NCT01309724|Hypotension
346580|NCT01309724|Fluid
346581|NCT01309711|MRI
346582|NCT01309711|Biomarkers
346583|NCT01309711|Neonatal encephalopathy
346584|NCT01309711|Therapeutic hypothermia
346585|NCT01309698|Drug interaction
346586|NCT01309685|Cognition
346587|NCT01309685|Smoking
346588|NCT01309685|Nicotine
346589|NCT01309685|Varenicline
346590|NCT01309685|Withdrawal
346591|NCT01309672|adenocarcinoma of the prostate
346592|NCT01309672|hormone-resistant prostate cancer
346593|NCT01309672|stage IV prostate cancer
346594|NCT01309672|recurrent prostate cancer
346595|NCT01309659|Anemia
346596|NCT01309659|Unexplained anemia
346597|NCT01309659|elderly
346598|NCT01309659|geriatric
346599|NCT01309659|older adults
346600|NCT01309659|UAE
346601|NCT01309659|over 65
346602|NCT01309659|iron
346603|NCT01309659|pactte
346604|NCT01309659|pactee
346605|NCT01309659|aging
346606|NCT01309659|aged
346607|NCT01309659|old
346608|NCT01309659|older
346609|NCT01309646|Primary vaccination
346610|NCT01309646|combination vaccine
346611|NCT01309646|South Korea
346612|NCT01309633|locally advanced
346613|NCT01309633|metastatic
346614|NCT01309620|zinc, oxidative stress, vascular indices, type 2 diabetes
346615|NCT01309581|depression
346616|NCT01309581|electroconvulsive therapy
346617|NCT01309581|ketamine
346618|NCT01309581|antidepressant
346619|NCT01309555|Growth disorders
346620|NCT01309555|Saizen
346621|NCT01309555|easypod™
346622|NCT01309555|Growth hormone
346623|NCT01309555|Pediatric subject
346624|NCT01309542|major depressive disorder
346625|NCT01309542|desvenlafaxine
346626|NCT01309542|antidepressant
346627|NCT01309529|general thoracic surgery
346628|NCT01309529|epidural analgesia
346629|NCT01309529|postoperative retention of urine
346630|NCT01309529|postoperative urinary tract infection
346631|NCT01309529|catheter associated urinary tract infection
346632|NCT01309516|Postnatal depression
346633|NCT01309516|Maternal depression
346634|NCT01309516|Psychosocial intervention
346635|NCT01309490|high eIF4E expression
346636|NCT01309490|solid tumor cancer
346637|NCT01309477|Refractory Nephrotic Syndrome
346638|NCT01309477|Tacrolimus
346639|NCT01309451|diabetic macular edema
346640|NCT01309451|DME
346641|NCT01309438|Healthy
346642|NCT01309438|Renal Insufficiency
346643|NCT01309438|Rivaroxaban (BAY 59-7939, JNJ-39039039)
346644|NCT01309438|Erythromycin
346645|NCT01309438|Pharmacokinetic
346646|NCT01309438|Pharmacodynamic
346647|NCT01309425|tapentadol
346648|NCT01309425|NUCYNTA
346649|NCT01309425|CG5503
346650|NCT01309425|R331333
346651|NCT01309425|pharmacokinetics
346652|NCT01309425|healthy volunteer
346653|NCT01309412|Relapsed or refractory multiple myeloma
346654|NCT01309412|CNTO 328
346655|NCT01309412|siltuximab
346656|NCT01309412|bortezomib
346657|NCT01309412|dexamethasone
346658|NCT01309399|bone formation rate
346659|NCT01309399|total hip arthroplasty
346660|NCT01309386|Tapentadol
346661|NCT01309386|Tumor related pain
346662|NCT01309386|Opioid
346663|NCT01309386|Cancer related pain
346664|NCT01309386|Morphine
346665|NCT01309373|Schizophrenia
346666|NCT01309373|Schizoaffective Disorder
346667|NCT01309373|Remission
346668|NCT01309373|Psychosocial
346669|NCT01309373|Symtomatic
346670|NCT01309373|Integration
346671|NCT01309373|Schizoaffective
346672|NCT01309373|Adherence
346673|NCT01309360|ultrasound
346674|NCT01309360|methaemoglobin
346675|NCT01309360|prilocaine
346676|NCT01309360|regional anesthesia
346677|NCT01309360|ASA risk groups I-II
346678|NCT01309360|adult outpatients
346679|NCT01309360|surgical spectrum covered procedures
346680|NCT01309360|distal forearm
346681|NCT01309360|hand
346682|NCT01309347|prosthetic socket, residual limb volume fluctuation
346683|NCT01309334|MRI
346684|NCT01309334|PET-scan
346685|NCT01309334|multiple myeloma
346686|NCT01309334|prognosis
346687|NCT01309334|pharmacoeconomic analysis
346688|NCT01309321|Perinatal
346689|NCT01309321|Handwashing
346690|NCT01309321|Neonatal
346691|NCT01309321|Morbidity
346692|NCT01309321|Mortality
346693|NCT01309321|Primiparous
346694|NCT01309321|Health behavior
346695|NCT01309321|Developing countries
346696|NCT01309321|Sepsis
346697|NCT01309321|Omphalitis
346698|NCT01309321|Infectious disease
346699|NCT01309321|Bangladesh
346700|NCT01309308|cervical length
346701|NCT01309308|sweeping the membranes
346702|NCT01309256|distal gastrectomy
346703|NCT01309256|Robotic gastrectomy
346704|NCT01309256|registry
346705|NCT01309256|learning curve
346706|NCT01309256|cost-effectiveness
346707|NCT01309256|quality of life
346708|NCT01309256|acute inflammatory reaction
346709|NCT01309256|Robotic and laparoscopic surgery
346710|NCT01309243|HIV
346711|NCT01309243|HIV-1
346712|NCT01309243|Antiretroviral Treatment-Naïve
346713|NCT01309230|Stage III
346714|NCT01309230|Stage IV
346715|NCT01309230|epithelial ovarian cancer
346716|NCT01309230|ovarian cancer
346717|NCT01309230|Adjuvant
346718|NCT01309230|immunotherapy
346719|NCT01309204|open-angle glaucoma
346720|NCT01309204|ocular hypertension
346721|NCT01309204|OAG
346722|NCT01309204|OHT
346723|NCT01309191|Androgenetic Alopecia
346724|NCT01309191|Minoxidil
346725|NCT01309191|Microarray
346726|NCT01309165|stroke
346727|NCT01309165|cognition
346728|NCT01309165|cognitive strategies
346729|NCT01309165|motor skill acquisition
346730|NCT01309165|participation
346731|NCT01309152|cefazolin
346732|NCT01309152|microdialysis
346733|NCT01309152|morbid obesity
346734|NCT01309152|pharmacokinetics
346735|NCT01309126|Colorectal Cancer
346736|NCT01309126|KRAS Wild Type
346737|NCT01309126|Imprime PGG
346738|NCT01309126|Cetuximab
346739|NCT01309126|Phase 3
346740|NCT01309126|Efficacy
346741|NCT01309126|Safety
346742|NCT01309126|Recurrent or Progressive KRAS Wild Type Colorectal Cancer
346743|NCT01309087|Gene Expression
346744|NCT01309087|Lung Cancer
346745|NCT01309087|Smoking
346746|NCT01309074|Anxiety
346747|NCT01309074|Epilepsy
346748|NCT01309048|bone metastasis
346749|NCT01309048|Patients with bone metastasis
346750|NCT01309035|Prothesis fixation
346751|NCT01309035|Bloodlessness
346752|NCT01309022|Diabetes Mellitus, Type 1
346753|NCT01309022|T1D
346754|NCT01309022|T1DM
346755|NCT01309022|Islets of Langerhans Transplantation
346756|NCT01309022|Pancreatic Islets Transplantation
346757|NCT01309022|Islet Transplant
346758|NCT01309022|Tacrolimus
346759|NCT01309022|Sirolimus
346760|NCT01309022|Mycophenolate mofetil
346761|NCT01309022|Mycophenolic acid
346762|NCT01309009|Infantile Colic
346763|NCT01309009|Tachykinin antagonist
346764|NCT01309009|Nepadutant
346765|NCT01308996|alveolar ridge augmentation
346766|NCT01308996|edentulous ridge
346767|NCT01308996|alveolar ridge defect
346768|NCT01308996|posterior mandible defect
346769|NCT01308996|bone morphogenic protein
346770|NCT01308996|osseointegration
346771|NCT01308983|Prehypertension
346772|NCT01308983|Flow mediated dilation
346773|NCT01308983|Pulse wave velocity
346774|NCT01308983|carotid compliance
346775|NCT01308983|Prehypertension and amiloride
346776|NCT01308944|invasive epithelial ovarian cancer,
346777|NCT01308944|primary peritoneal carcinoma,
346778|NCT01308944|fallopian tube cancer
346779|NCT01308931|Contraception
346780|NCT01308931|IUD
346781|NCT01308931|Essure
346782|NCT01308931|Tubal ligation
346783|NCT01308931|Anti-Mullerian hormone
346784|NCT01308918|Thoracic surgery
346785|NCT01308918|Double lumen tube intubation
346786|NCT01308918|GlideScope
346787|NCT01308918|Stylet
346788|NCT01308905|Neuroblastoma
346789|NCT01308879|Contextualized Feedback System (CFS)
346790|NCT01308879|Mental health outcomes
346791|NCT01308879|Quality improvement
346792|NCT01308879|Feedback
346793|NCT01308879|Clinical trial
346794|NCT01308866|cardiovascular diseases
346795|NCT01308866|patient education
346796|NCT01308866|primary health care
346797|NCT01308866|consumer participation
346798|NCT01308866|decision aids
346799|NCT01308840|Unresectable
346800|NCT01308840|metastatic
346801|NCT01308840|biliary tract
346802|NCT01308840|gallbladder cancer
346803|NCT01308827|Children 28 days to 36 months of age with suspected pneumococcal disease
346804|NCT01308814|Perimenopause
346805|NCT01308814|Menopause
346806|NCT01308814|Depression
346807|NCT01308814|Cardiovascular health
346808|NCT01308801|fibromyalgia
346809|NCT01308801|pain
346810|NCT01308801|repetitive transcranial magnetic stimulation
346811|NCT01308801|rehabilitation exercise
346812|NCT01308801|quality of life
346813|NCT01308788|glaucoma blood flow
346814|NCT01308775|SIS.NET
346815|NCT01308736|tobacco
346816|NCT01308736|nicotine
346817|NCT01308736|cigarette smoking
346818|NCT01308710|endothelial function
346819|NCT01308710|lipids
346820|NCT01308710|pediatrics
346821|NCT01308697|Flail
346822|NCT01308697|Chest
346823|NCT01308671|coronary artery disease
346824|NCT01308671|varenicline
346825|NCT01308671|clopidogrel
346826|NCT01308658|TMC114-C176
346827|NCT01308658|TMC114
346828|NCT01308658|DRV
346829|NCT01308658|HIV
346830|NCT01308658|Healthy volunteers
346831|NCT01308645|SBP Injection
346832|NCT01308645|HCC
346833|NCT01308632|glioblastoma
346834|NCT01308632|temozolamide
346835|NCT01308632|radiotherapy
346836|NCT01308632|TMZ
346837|NCT01308632|irinotecan
346838|NCT01308606|TMC435-TiDP16-C116
346839|NCT01308606|TMC435-C116
346840|NCT01308606|TMC435
346841|NCT01308606|HCV
346842|NCT01308606|Hepatitis C
346843|NCT01308606|Hep C
346844|NCT01308606|healthy volunteers
346845|NCT01308554|TAP block
346846|NCT01308554|Pain
346847|NCT01308554|Obesity
346848|NCT01308554|Surgery
346849|NCT01308554|Laparoscopic gastric bypass
346850|NCT01308528|Venous Thromboembolism
346851|NCT01308515|knee
346852|NCT01308515|osteoarthritis
346853|NCT01308515|joint
346854|NCT01308515|replacement
346855|NCT01308515|knee surgery
346856|NCT01308502|laryngopharyngeal reflux
346857|NCT01308502|LPR
346858|NCT01308502|GERD
346859|NCT01308502|gastroesophageal reflux
346860|NCT01308502|nasopharyngeal probe
346861|NCT01308463|elbow long-term Survivorship
346862|NCT01308463|Study participant Discovery Elbow Multi-center Study who
346863|NCT01308463|consent for the Discovery Elbow Long-term SurvivorshipStudy
346864|NCT01308450|ADHD Normative Control Group
346865|NCT01308424|Herpes Labialis
346866|NCT01308424|Herpes Simplex
346867|NCT01308424|Herpes
346868|NCT01308411|Asthma
346869|NCT01308411|Inhaled Corticosteroids
346870|NCT01308411|Exhaled Nitric oxide
346871|NCT01308411|Airways inflammation
346872|NCT01308411|Step down
346873|NCT01308411|Predicting response
346874|NCT01308372|cardiovascular risk
346875|NCT01308372|France
346876|NCT01308372|General practice
346877|NCT01308372|Primary prevention
346878|NCT01308372|Non treated patients
346879|NCT01308359|fetal movement
346880|NCT01308346|Bioabsorbable
346881|NCT01308346|Coronary Stent
346882|NCT01308346|Everolimus
346883|NCT01308346|drug eluting stents
346884|NCT01308346|stents
346885|NCT01308346|angioplasty
346886|NCT01308346|coronary artery disease
346887|NCT01308346|total coronary occlusion
346888|NCT01308346|coronary artery restenosis
346889|NCT01308346|stent thrombosis
346890|NCT01308346|myocardial ischemia
346891|NCT01308346|coronary artery stenosis
346892|NCT01308307|Non-cycloplegic photorefraction
346893|NCT01308307|cycloplegic refraction,
346894|NCT01308307|Amblyopia
346895|NCT01308294|Melanoma
346896|NCT01308294|Stage II-IV
346897|NCT01308294|Immunotherapy
346898|NCT01308294|Vaccination
346899|NCT01308294|HLA class I and II tumor-specific peptides
346900|NCT01308294|IMP321
346901|NCT01308294|Montanide ISA-51 VG
346902|NCT01308268|STH
346903|NCT01308268|Soil-transmitted Helminthiasis
346904|NCT01308268|mass drug administration
346905|NCT01308229|Bifurcation
346906|NCT01308229|Dedicated
346907|NCT01308229|Drug-eluting stent
346908|NCT01308229|Angioplasty
346909|NCT01308229|Coronary artery disease
346910|NCT01308229|Coronary artery stenosis
346911|NCT01308216|Transcranial Laser Therapy
346912|NCT01308216|Hemiplegia
346913|NCT01308216|Rehabilitation
346914|NCT01308216|Physiotherapy
346915|NCT01308216|Ischemic stroke
346916|NCT01308190|Preoperative chemoradiotherapy
346917|NCT01308190|Transanal endoscopic microsurgery
346918|NCT01308190|Rectal Cancer
346919|NCT01308190|T2-T3s-N0
346920|NCT01308164|Type 1 diabetes
346921|NCT01308164|Insulin Pump Therapy
346922|NCT01308151|CBT, self harm, depression, cultural adaptation, Pakistan
346923|NCT01308138|Physical Activity
346924|NCT01308138|pathology
346925|NCT01308138|Physical Deconditioning
346926|NCT01308125|Stable Angina
346927|NCT01308125|Coronary artery disease
346928|NCT01308125|PCI
346929|NCT01308125|Reperfusion
346930|NCT01308125|Myocardial Infarction
346931|NCT01308125|collateral flow pressure index
346932|NCT01308125|CFpI
346933|NCT01308125|pressure controlled intermittent coronary sinus occlusion
346934|NCT01308125|PICSO
346935|NCT01308112|Iron
346936|NCT01308112|Plasmodium
346937|NCT01308112|Malaria
346938|NCT01308112|Pregnancy
346939|NCT01308112|Kenya
346940|NCT01308099|POTS
346941|NCT01308099|Vascular Endothelial Function
346942|NCT01308086|Cancer
346943|NCT01308086|colorectal cancer
346944|NCT01308086|adjuvant chemotherapy
346945|NCT01308086|capecitabine
346946|NCT01308086|oxaliplatin
346947|NCT01308086|5 fluorouracil
346948|NCT01308060|Canthal lines
346949|NCT01308034|non GIST sarcomas
346950|NCT01308034|sunitinib
346951|NCT01308034|radiotherapy
346952|NCT01308034|dose escalation
346953|NCT01308021|Rhinoconjunctivitis
346954|NCT01308021|Allergy
346955|NCT01308021|Grass pollen
346956|NCT01308021|Hypersensitivity
346957|NCT01308021|Immune system disorder
346958|NCT01308008|Type 2 Diabetes Mellitus
346959|NCT01308008|Mobility Limitation
346960|NCT01307995|GDM
346961|NCT01307995|incretin effect
346962|NCT01307995|gestation
346963|NCT01307995|reversibility
346964|NCT01307982|Gastroesophageal Reflux
346965|NCT01307982|Nervous System Diseases
346966|NCT01307982|Fundoplication
346967|NCT01307982|Enteral Nutrition
346968|NCT01307969|liposomes
346969|NCT01307969|ropivacaine
346970|NCT01307969|dental anesthesia
346971|NCT01307969|dentistry
346972|NCT01307943|MBSR
346973|NCT01307943|adolescent
346974|NCT01307943|mental health
346975|NCT01307930|Echinocandin
346976|NCT01307930|Obesity
346977|NCT01307930|Pharmacokinetics
346978|NCT01307930|Pharmacodynamics
346979|NCT01307930|Fungal infection
346980|NCT01307917|diabetes mellitus
346981|NCT01307917|diabetic nephropathy
346982|NCT01307917|vascular endothelial dysfunction
346983|NCT01307917|flavonoids
346984|NCT01307917|flow-mediated dilation
346985|NCT01307904|Glycemic index
346986|NCT01307904|Dates
346987|NCT01307904|Blood glucose
346988|NCT01307891|Triple negative breast cancer (TNBC)
346989|NCT01307891|Metastatic breast cancer
346990|NCT01307891|Tigatuzumab (CS-1008)
346991|NCT01307891|Abraxane (ABI-007)
346992|NCT01307891|HER-2-neu negative
346993|NCT01307891|ER negative, PR negative
346994|NCT01307865|midface volume loss
346995|NCT01307865|aging of midface
346996|NCT01307865|sculptra
346997|NCT01307865|sculptra aesthetic
346998|NCT01307865|poly-L-lactic acid
346999|NCT01307852|Fiber optic radiation detectors
347000|NCT01307852|Enhanced endorectal balloon
347001|NCT01307852|Radiation treatment
347002|NCT01307852|Radiotherapy
347003|NCT01307852|External beam radiation
347004|NCT01307852|Dosimetry
347005|NCT01307839|labor
347006|NCT01307839|epidural
347007|NCT01307826|massage
347008|NCT01307826|shoulder
347009|NCT01307826|pain
347010|NCT01307826|range of motion
347011|NCT01307826|restricted range of motion
347012|NCT01307813|colon distal
347013|NCT01307813|surgical resection
347014|NCT01307787|exercise
347015|NCT01307787|education
347016|NCT01307787|self-management
347017|NCT01307787|rehabilitation
347018|NCT01307774|parental acceptability of HPV vaccine
347019|NCT01307761|fine needle aspiration; predictor; ultrasonography; thyroid cancer
347020|NCT01307748|aromatherapy
347021|NCT01307748|stress
347022|NCT01307748|older adults
347023|NCT01307748|stress-related change
347024|NCT01307735|myocarditis
347025|NCT01307735|edema
347026|NCT01307735|hyperemia
347027|NCT01307735|fibrosis
347028|NCT01307735|necrosis
347029|NCT01307735|cardiovascular magnetic resonance imaging
347030|NCT01307722|left atrial distensibility
347031|NCT01307722|advanced chronic heart failure
347032|NCT01307722|decompensation
347033|NCT01307722|rehospitalization
347034|NCT01307722|prognosis
347035|NCT01307722|all-cause mortality
347036|NCT01307722|heart failure with hospitalization
347037|NCT01307722|the duration of hospitalization
347038|NCT01307696|Umbilical Hernia Repair
347039|NCT01307696|PVP Mesh
347040|NCT01307683|Pregnancy
347041|NCT01307683|Overweight
347042|NCT01307683|Obese
347043|NCT01307683|Stress
347044|NCT01307683|Mindfulness
347045|NCT01307657|clopidogrel
347046|NCT01307657|platelet
347047|NCT01307657|platelet function test
347048|NCT01307657|healthy
347049|NCT01307657|Platelet function tests
347050|NCT01307644|Overweight
347051|NCT01307644|Obesity
347052|NCT01307644|Rural Health
347053|NCT01307644|Weight Loss
347054|NCT01307644|Weight Maintenance
347055|NCT01307644|Rural Middle Aged and Older Women
347056|NCT01307644|Web Intervention Weight Loss
347057|NCT01307644|Class I, II, & III obese (BMI 28 to 45)
347058|NCT01307605|contiguous stage II grade 1 follicular lymphoma
347059|NCT01307605|contiguous stage II grade 2 follicular lymphoma
347060|NCT01307605|contiguous stage II grade 3 follicular lymphoma
347061|NCT01307605|noncontiguous stage II grade 1 follicular lymphoma
347062|NCT01307605|noncontiguous stage II grade 2 follicular lymphoma
347063|NCT01307605|noncontiguous stage II grade 3 follicular lymphoma
347064|NCT01307605|stage III grade 1 follicular lymphoma
347065|NCT01307605|stage III grade 2 follicular lymphoma
347066|NCT01307605|stage III grade 3 follicular lymphoma
347067|NCT01307605|stage IV grade 1 follicular lymphoma
347068|NCT01307605|stage IV grade 2 follicular lymphoma
347069|NCT01307605|stage IV grade 3 follicular lymphoma
347070|NCT01307592|peripheral T-cell lymphoma
347071|NCT01307592|recurrent adult Burkitt lymphoma
347072|NCT01307592|recurrent adult diffuse large cell lymphoma
347073|NCT01307592|recurrent adult lymphoblastic lymphoma
347074|NCT01307592|recurrent grade 3 follicular lymphoma
347075|NCT01307514|DIABETES
347076|NCT01307514|PHARMACOKINETICS
347077|NCT01307514|PHARMACODYNAMICS
347078|NCT01307514|INSULIN
347079|NCT01307501|Cryoablation
347080|NCT01307501|Cryotherapy
347081|NCT01307501|Cryosurgery
347082|NCT01307501|Metastatic
347083|NCT01307501|Lung
347084|NCT01307501|Pleura
347085|NCT01307501|Tumors
347086|NCT01307488|HIV
347087|NCT01307488|AIDS
347088|NCT01307488|Atazanavir
347089|NCT01307488|Simplification
347090|NCT01307475|Chronic Post-Traumatic Stress Disorder
347091|NCT01307475|Delayed Onset Post-Traumatic Stress Disorder
347092|NCT01307475|Post-Traumatic Neuroses
347093|NCT01307475|Posttraumatic Neuroses
347094|NCT01307475|Post-Traumatic Stress Disorders
347095|NCT01307475|Posttraumatic Stress Disorders
347096|NCT01307475|PTSD
347097|NCT01307475|Post TraumaticStress Disorder
347098|NCT01307475|Endogenous Depression
347099|NCT01307475|Neurotic Depression
347100|NCT01307475|Depressive Syndrome
347101|NCT01307475|Melancholia
347102|NCT01307475|Depressive Neurosis
347103|NCT01307475|Unipolar Depression
347104|NCT01307475|Depressive Symptoms
347105|NCT01307475|Emotional Depression
347106|NCT01307475|Quality of Life
347107|NCT01307449|pneumococcal vaccine
347108|NCT01307449|immune responses
347109|NCT01307436|Hepatitis A Vaccine
347110|NCT01307436|Combined Vaccines
347111|NCT01307436|DTP Vaccine
347112|NCT01307436|MMR Vaccine
347113|NCT01307423|psoriasis
347114|NCT01307423|Arthritis
347115|NCT01307423|Psoriatic Arthritis
347116|NCT01307423|inflammation
347117|NCT01307423|skin condition
347118|NCT01307423|inflammatory cells
347119|NCT01307423|apremilast
347120|NCT01307423|CC-10004
347121|NCT01307423|phosphodiesterase type 4
347122|NCT01307410|Patients with type 2 diabetes and participated in 3B Study
347123|NCT01307384|Total hip Arthroplasty
347124|NCT01307384|Total Hip Replacement (THR)
347125|NCT01307384|Primary Hip Arthroplasty
347126|NCT01307384|THA
347127|NCT01307384|THR
347128|NCT01307371|Bone Marrow Mononuclear cells;
347129|NCT01307371|Diabetes;
347130|NCT01307371|ST-segment Elevation Myocardial Infarction;
347131|NCT01307371|Percutaneous Coronary Intervention;
347132|NCT01307371|Left Ventricular Function
347133|NCT01307332|Multiple Sclerosis
347134|NCT01307332|MS
347135|NCT01307332|Relapsing Remitting Multiple Sclerosis
347136|NCT01307332|RRMS
347137|NCT01307332|Alemtuzumab
347138|NCT01307332|Demyelination
347139|NCT01307332|Remyelination
347140|NCT01307332|Tolerogenic
347141|NCT01307332|T cells
347142|NCT01307332|Demyelinating Autoimmune Diseases, CNS
347143|NCT01307332|Autoimmune Diseases of the Nervous System
347144|NCT01307332|Nervous System Diseases
347145|NCT01307332|Demyelinating Diseases
347146|NCT01307332|Autoimmune Diseases
347147|NCT01307332|Immune System Diseases
347148|NCT01307319|Allergies
347149|NCT01307319|Hayfever
347150|NCT01307306|Thermal injury
347151|NCT01307306|Chemical Burn
347152|NCT01307306|Flame Burn
347153|NCT01307280|Behavioral Weight Management Intervention
347154|NCT01307280|weight loss
347155|NCT01307280|cost-effective analysis
347156|NCT01307280|high blood pressure
347157|NCT01307280|randomized clinical trial
347158|NCT01307280|behavioral interventions
347159|NCT01307280|physical activity
347160|NCT01307280|dietary change
347161|NCT01307280|obesity
347162|NCT01307267|Phase 1
347163|NCT01307267|Non-Hodgkin's Lymphoma
347164|NCT01307267|Advanced malignancies
347165|NCT01307241|Acute lymphoblastic leukemia
347166|NCT01307241|prognostic factor
347167|NCT01307241|pharmacogenetics.
347168|NCT01307228|Knowledge translation
347169|NCT01307228|Policymakers
347170|NCT01307228|Health systems
347171|NCT01307215|TAP block
347172|NCT01307215|incision pain
347173|NCT01307215|total hysterectomy
347174|NCT01307202|knee
347175|NCT01307202|arthroplasty
347176|NCT01307202|postoperative pain
347177|NCT01307202|gabapentin
347178|NCT01307189|Chronic Obstructive Pulmonary Disease (COPD)
347179|NCT01307189|Exercise
347180|NCT01307189|Endurance shuttle walking test
347181|NCT01307189|Bronchodilation
347182|NCT01307189|Tiotropium
347183|NCT01307176|ataxia
347184|NCT01307176|exercise
347185|NCT01307176|training
347186|NCT01307176|cerebellar
347187|NCT01307176|rehabilitation
347188|NCT01307163|saliva
347189|NCT01307163|liver transplantation
347190|NCT01307163|children
347191|NCT01307163|In this prospective study 60 subjects will be examined
347192|NCT01307163|children and adolescents
347193|NCT01307163|after a successful liver transplantation
347194|NCT01307163|informed consent forms signed be the examinees parents
347195|NCT01307150|Atopic Dermatitis
347196|NCT01307150|Dead Sea
347197|NCT01307150|Climatotherapy
347198|NCT01307150|SCORAD
347199|NCT01307124|safety and efficacy
347200|NCT01307124|low dose LPV/r
347201|NCT01307124|standard dose LPV/r
347202|NCT01307124|HIV infected children
347203|NCT01307111|Misoprostol
347204|NCT01307111|IUD insertion
347205|NCT01307111|Nulliparous Women
347206|NCT01307111|Contraception
347207|NCT01307111|Family Planning
347208|NCT01307111|IUD insertion in nulliparous women
347209|NCT01307098|Enzyme Replacement Therapy (ERT)
347210|NCT01307098|Lysosomal Storage Disease
347211|NCT01307098|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
347212|NCT01307098|Acid cholesteryl ester hydrolase deficiency, type 2
347213|NCT01307098|Acid lipase disease
347214|NCT01307098|Cholesterol ester hydrolase deficiency
347215|NCT01307098|LAL Deficiency
347216|NCT01307098|LIPA Deficiency
347217|NCT01307098|Wolman disease
347218|NCT01307085|remote ischemic preconditioning
347219|NCT01307085|lung injury
347220|NCT01307085|pulmonary resection
347221|NCT01307072|periodic examinations, compliance
347222|NCT01307059|Growth disorders
347223|NCT01307059|Saizen
347224|NCT01307059|Easypod
347225|NCT01307059|Growth hormone
347226|NCT01307059|Pediatric subject
347227|NCT01307046|Essential hypertension
347228|NCT01307046|Uncontrolled hypertension
347229|NCT01307046|Antihypertensive agents
347230|NCT01307046|Blood pressure
347231|NCT01307033|Essential hypertension
347232|NCT01307033|Uncontrolled hypertension
347233|NCT01307033|Antihypertensive agents
347234|NCT01307033|Blood pressure
347235|NCT01307020|Moderate to severe pain
347236|NCT01307020|Postoperative pain
347237|NCT01307020|Analgesics
347238|NCT01307020|Dexketoprofen
347239|NCT01307020|Tramadol
347240|NCT01306994|Exercise Test
347241|NCT01306994|Bicycle Ergometry Test
347242|NCT01306994|Stress Test
347243|NCT01306981|Diabetes Mellitus
347244|NCT01306981|Diabetes Complications
347245|NCT01306981|Retinal Diseases
347246|NCT01306981|Endothelial Growth Factors
347247|NCT01306981|Monoclonal Antibodies
347248|NCT01306981|Ranibizumab
347249|NCT01306981|Vitrectomy
347250|NCT01306981|Vitreoretinal Surgery
347251|NCT01306968|mild tramatic brain injury
347252|NCT01306968|mTBI
347253|NCT01306968|hyperbaric oxygen
347254|NCT01306968|post concussive symptoms
347255|NCT01306968|active duty military
347256|NCT01306968|veterans
347257|NCT01306955|retinal vasculitis
347258|NCT01306955|posterior uveitis
347259|NCT01306955|methylprednisolone
347260|NCT01306942|HER2+ metastatic breast cancer
347261|NCT01306942|first line treatment
347262|NCT01306929|Huntington Disease.
347263|NCT01306916|thyroid disease, hyperthyroidism
347264|NCT01306903|Minimizing Cardiopulmonary Bypass MECC damage organ failure
347265|NCT01306877|hemorrhoid
347266|NCT01306877|hemorrhoid stapler
347267|NCT01306864|Endoscopic Hemostasis
347268|NCT01306864|Peptic Ulcer
347269|NCT01306864|Recurrent Bleeding
347270|NCT01306864|Injection Therapy
347271|NCT01306864|Thermal Probe
347272|NCT01306851|fibrin glue
347273|NCT01306851|anastomotic leak
347274|NCT01306851|gastrointestinal high risk anastomosis
347275|NCT01306838|Short bowel syndrome
347276|NCT01306838|Necrotizing enterocolitis
347277|NCT01306838|Small intestine perforation
347278|NCT01306838|Enterostomy
347279|NCT01306838|Intralipid
347280|NCT01306838|Microlipid
347281|NCT01306838|Fish oil
347282|NCT01306825|Daptomycin
347283|NCT01306825|Bone disease,infectious
347284|NCT01306825|Osteomyelitis
347285|NCT01306825|Diabetic foot
347286|NCT01306825|Staphylococcus aureus
347287|NCT01306812|Adolescent
347288|NCT01306812|Alcohol
347289|NCT01306812|Criminology
347290|NCT01306812|Genes
347291|NCT01306812|Environment
347292|NCT01306812|Mono amine Oxidase
347293|NCT01306812|Serotonin
347294|NCT01306812|Social Support
347295|NCT01306799|Barrett's Esophagus
347296|NCT01306799|Erosive Esophagitis
347297|NCT01306799|Proton Pump Inhibitor (PPI)
347298|NCT01306799|Bone
347299|NCT01306799|Bone Density
347300|NCT01306799|GERD
347301|NCT01306799|ulcer prophylaxis
347302|NCT01306773|Influenza A
347303|NCT01306773|convalescent plasma
347304|NCT01306773|death
347305|NCT01306760|depression
347306|NCT01306760|electroconvulsive therapy
347307|NCT01306760|ketamine
347308|NCT01306747|Chronic pain
347309|NCT01306747|Stanford chronic pain self-management programme
347310|NCT01306747|Patient education
347311|NCT01306734|Extracorporeal circulation
347312|NCT01306734|Deep Hypothermic Circulatory Arrest
347313|NCT01306734|aortic aneurism
347314|NCT01306734|neurological injury
347315|NCT01306734|inflammation
347316|NCT01306734|coagulation
347317|NCT01306708|Adhesive Capsulitis
347318|NCT01306708|Shoulder
347319|NCT01306708|SPADI
347320|NCT01306695|Dementia
347321|NCT01306695|Depressive symptoms
347322|NCT01306695|Caregiver Burden
347323|NCT01306695|Hispanic
347324|NCT01306695|Latino
347325|NCT01306695|Intervention
347326|NCT01306695|Geriatric Depression Scale
347327|NCT01306695|Zarit Caregiver Burden Scale
347328|NCT01306656|Endocrinology
347329|NCT01306656|Metabolic Bone Disease
347330|NCT01306656|Primary Hyperparathyroidism
347331|NCT01306656|PHPT
347332|NCT01306656|Vitamin D Deficiency
347333|NCT01306656|Bone Mineral Density
347334|NCT01306656|Hyper-calcemia
347335|NCT01306643|Indolent Non-Hodgkin's Lymphoma
347336|NCT01306643|Non-Hodgkin Lymphoma
347337|NCT01306643|iNHL
347338|NCT01306643|NHL
347339|NCT01306643|CAL-101
347340|NCT01306643|PI3K
347341|NCT01306643|Phosphatidylinositol 3-kinase
347342|NCT01306643|Follicular Lymphoma (FL)
347343|NCT01306643|Small Lymphocytic Lymphoma (SLL)
347344|NCT01306643|Marginal Zone Lymphoma (MZL)
347345|NCT01306630|AV-951
347346|NCT01306630|tivozanib
347347|NCT01306630|capecitabine (Xeloda®)
347348|NCT01306604|Genetic Diseases
347349|NCT01306604|Lipidoses
347350|NCT01306604|Lipid Metabolism
347351|NCT01306604|Lysosomal Storage Diseases
347352|NCT01306604|Metabolic Diseases
347353|NCT01306604|Lipid Metabolism Disorders
347354|NCT01306591|neovascular age-related macular degeneration
347355|NCT01306591|Bevacizumab
347356|NCT01306591|Multicenter Randomized Study
347357|NCT01306578|Guillain Barre syndrome
347358|NCT01306578|IVIG
347359|NCT01306578|Plasma exchange
347360|NCT01306565|Unstable angina
347361|NCT01306565|NSTMI
347362|NCT01306565|Statin
347363|NCT01306565|Atorvastatin
347364|NCT01306552|Tobacco use
347365|NCT01306552|Adolescents
347366|NCT01306552|Primary prevention
347367|NCT01306552|Program effectiveness
347368|NCT01306552|Parental component
347369|NCT01306539|deep brain stimulation
347370|NCT01306539|subthalamic nucleus
347371|NCT01306526|Thin-cap fibroatheroma
347372|NCT01306526|Vulnerable plaque
347373|NCT01306526|Coronary artery disease
347374|NCT01306526|Obstructive sleep apnea
347375|NCT01306526|Intravascular Ultrasound
347376|NCT01306513|emphysema
347377|NCT01306513|lung volume reduction surgery
347378|NCT01306513|mesenchymal stromal cells
347379|NCT01306500|Gastric lavage
347380|NCT01306500|Neonate
347381|NCT01306500|Meconium stained amniotic fluid
347382|NCT01306500|Feeding problems
347383|NCT01306487|macular hole
347384|NCT01306474|CD4/CD25 Tr cell,TNF,IFN-γ,IL-2
347385|NCT01306448|constipation
347386|NCT01306448|gastro
347387|NCT01306448|vibrating capsule
347388|NCT01306448|safety
347389|NCT01306435|Osteoarthritis
347390|NCT01306435|Low Power Laser Therapy
347391|NCT01306435|Exercise
347392|NCT01306435|Knee
347393|NCT01306422|hoodia gordonii
347394|NCT01306422|energy intake
347395|NCT01306422|food intake
347396|NCT01306422|efficacy
347397|NCT01306422|body weight
347398|NCT01306422|functional food
347399|NCT01306422|plant extract
347400|NCT01306422|safety
347401|NCT01306422|steroid glycosides
347402|NCT01306422|tolerability
347403|NCT01306409|anemia
347404|NCT01306409|kidney disease
347405|NCT01306396|NAFLD
347406|NCT01306396|metabolic syndrome
347407|NCT01306396|children
347408|NCT01306396|fructose
347409|NCT01306383|SODIS
347410|NCT01306383|waterborne
347411|NCT01306383|Disease
347412|NCT01306383|Diarrhoea
347413|NCT01306383|dysentery
347414|NCT01306370|primary knee arthroplasty
347415|NCT01306370|fibrin glue
347416|NCT01306370|tranexamic acid
347417|NCT01306370|topic
347418|NCT01306357|Turner's syndrome
347419|NCT01306357|somatropin
347420|NCT01306357|human growth hormone deficiency
347421|NCT01306344|Qualitative Research
347422|NCT01306344|Interview, Psychological
347423|NCT01306344|Patients
347424|NCT01306344|Nurses
347425|NCT01306344|Physicians
347426|NCT01306305|Influenza
347427|NCT01306305|Virus
347428|NCT01306305|Vaccination
347429|NCT01306305|Immunisation
347430|NCT01306292|Pulmonary hypertension
347431|NCT01306292|Right heart Catheterization
347432|NCT01306279|Cystic Fibrosis
347433|NCT01306279|Infection
347434|NCT01306279|Pulmonary exacerbation
347435|NCT01306279|Hypermutators
347436|NCT01306279|Bacterial diversity
347437|NCT01306279|Quorum sensing
347438|NCT01306266|active duty
347439|NCT01306266|blast induced
347440|NCT01306266|headache
347441|NCT01306253|Influenza
347442|NCT01306253|Virus
347443|NCT01306253|Vaccination
347444|NCT01306253|Immunisation
347445|NCT01306240|Infant newborn
347446|NCT01306240|Infant preterm
347447|NCT01306240|Acute respiratory distress syndrome
347448|NCT01306240|surfactant
347449|NCT01306240|Hyaline Membrane disease
347450|NCT01306240|Newborn acute respiratory distress syndrome (ARDS)
347451|NCT01306227|Infant, newborn
347452|NCT01306227|Infant, preterm
347453|NCT01306227|Thyroid
347454|NCT01306227|Outcome
347455|NCT01306227|Newborns less than 32 weeks of gestation
347583|NCT01305798|Biometric Screenings
347456|NCT01306227|TSH < 20 mIU/L and a FT4 < 0.80 ng/dL
347457|NCT01306201|Hospital Setting
347458|NCT01306188|metastatic cancer
347459|NCT01306188|lymphopenia
347460|NCT01306188|T cell receptor diversity
347461|NCT01306149|biochemical parameters
347462|NCT01306149|mineral metabolism
347463|NCT01306149|protein-bound uremic retention solutes
347464|NCT01306149|incident PD patients
347465|NCT01306136|Posttraumatic stress disorder
347466|NCT01306136|Prolonged exposure
347467|NCT01306136|Cognitive behavior therapy
347468|NCT01306123|bioavailability
347469|NCT01306123|pharmacokinetics
347470|NCT01306123|cyanocobalamin
347471|NCT01306123|intranasal
347472|NCT01306123|intramuscular
347473|NCT01306110|Liver fibrosis
347474|NCT01306110|diabetes
347475|NCT01306110|Fibroscan
347476|NCT01306110|Fibrotest
347477|NCT01306110|noninvasive fibrosis biomarkers
347478|NCT01306097|Zinc Supplement
347479|NCT01306097|Diarrhea
347480|NCT01306097|Sever Diarrhea
347481|NCT01306084|Respiratory Infections
347482|NCT01306084|Norovirus
347483|NCT01306084|Adenovirus
347484|NCT01306084|Viral Infection
347485|NCT01306084|Respiratory Viruses
347486|NCT01306071|Cirrhosis
347487|NCT01306071|Natural History
347488|NCT01306071|Hepatitis B
347489|NCT01306058|Hepatocellular Carcinoma
347490|NCT01306058|TRC105
347491|NCT01306058|Sorafenib
347492|NCT01306058|Liver Cancer
347493|NCT01306058|Monoclonal Antibody
347494|NCT01306045|AZD6244
347495|NCT01306045|MK-2206
347496|NCT01306045|Lepatinib
347497|NCT01306045|Erlotinib
347498|NCT01306045|Sunitinib
347499|NCT01306045|Lung Cancer
347500|NCT01306045|Thymic Cancer
347501|NCT01306045|Small Cell Lung Cancer
347502|NCT01306045|Non-Small Cell Lung Cancer
347503|NCT01306032|PARP Inhibitor
347504|NCT01306032|BRCA Mutations
347505|NCT01306032|DNA Damage Repair
347506|NCT01306032|Pharmacodynamics
347507|NCT01306032|Metronomic Cyclophosphamide
347508|NCT01306032|Ovarian Cancer
347509|NCT01306032|Breast Cancer
347510|NCT01306032|Fallopian Tube Cancer
347511|NCT01306032|Peritoneal Cancer
347512|NCT01306019|X-Linked Severe Combined Immunodeficiency (XSCID)
347513|NCT01306019|Gene Transfer
347514|NCT01306019|Peripheral Blood Stem Cells
347515|NCT01306019|Common Gamma Chain (GC), Immune Reconstitution
347516|NCT01306019|Immune Reconstitution
347517|NCT01306019|X-Linked Severe Combined Immunodeficiency
347518|NCT01306019|SCID
347519|NCT01306006|Mortality
347520|NCT01306006|Vaccines
347521|NCT01305954|Breast
347522|NCT01305954|Cancer
347523|NCT01305954|Breast Cancer
347524|NCT01305954|New Diagnosis
347525|NCT01305954|Treatment
347526|NCT01305954|Chemotherapy
347527|NCT01305954|Blood
347528|NCT01305954|Blood Draw
347529|NCT01305954|Lab Draw
347530|NCT01305954|Gene
347531|NCT01305954|Gene Therapy
347532|NCT01305954|Geriatric
347533|NCT01305954|Oncology
347534|NCT01305954|Muss
347535|NCT01305954|UNC
347536|NCT01305954|North Carolina Cancer Hospital
347537|NCT01305954|Initial Treatment
347538|NCT01305954|CBC
347539|NCT01305941|everolimus
347540|NCT01305941|trastuzumab
347541|NCT01305941|vinorelbine
347542|NCT01305941|RAD001
347543|NCT01305941|Breast Cancer
347544|NCT01305941|Herceptin
347545|NCT01305941|Navelbine
347546|NCT01305941|Lineberger Comprehensive Cancer Center
347547|NCT01305941|Brain Metastases
347548|NCT01305915|single-session group
347549|NCT01305915|psychoeducational intervention
347550|NCT01305889|Depression
347551|NCT01305889|Cerebral perfusion
347552|NCT01305889|Brain derived neurotropic factor
347553|NCT01305889|Problem Solving Therapy
347554|NCT01305889|Sertraline
347555|NCT01305876|yoga
347556|NCT01305876|emotional behavioral disorder
347557|NCT01305876|intervention
347558|NCT01305876|school
347559|NCT01305876|meditation
347560|NCT01305876|focus: yoga intervention in students with emotional behavioral disorders in an urban school
347561|NCT01305863|Peripheral Vascular Disease (PVD)
347562|NCT01305850|Aliskiren
347563|NCT01305850|Losartan
347564|NCT01305850|Peritoneal membrane dysfunction
347565|NCT01305837|multiple sclerosis
347566|NCT01305837|methylprednisolone
347567|NCT01305837|osteopontin
347568|NCT01305837|inflammation
347569|NCT01305837|demyelinating
347570|NCT01305824|arteriovenous fistula
347571|NCT01305824|AVF
347572|NCT01305824|hemodialysis
347573|NCT01305824|vascular access
347574|NCT01305824|dialysis
347575|NCT01305824|fistula
347576|NCT01305824|PRT-201
347577|NCT01305824|vonapanitase
347578|NCT01305824|kidney
347579|NCT01305824|renal
347580|NCT01305811|Complex Medical Illness
347581|NCT01305811|Gulf War Illness
347582|NCT01305811|Veteran
347584|NCT01305798|Active Choice
347585|NCT01305798|Behavioral Economics
347586|NCT01305798|Default
347587|NCT01305772|SCCHN
347588|NCT01305772|untreated
347589|NCT01305772|Stage III or IVa-b (M0)
347590|NCT01305759|Total knee arthroplasty
347591|NCT01305759|Total hip arthroplasty
347592|NCT01305759|Peri acetabular osteotomy
347593|NCT01305759|Social class
347594|NCT01305759|Health related quality of life
347595|NCT01305746|SLE
347596|NCT01305746|Lupus
347597|NCT01305746|Lupus Erythematosus, Systemic
347598|NCT01305746|A-623
347599|NCT01305746|Autoimmune Diseases
347600|NCT01305746|Blisibimod
347601|NCT01305733|Pain relief
347602|NCT01305720|mydriatic
347603|NCT01305720|NIRS
347604|NCT01305720|preterm
347605|NCT01305720|eye drops
347606|NCT01305720|cerebral
347607|NCT01305720|mesenteric oxygenation
347608|NCT01305707|Consolidation ECT
347609|NCT01305707|Pharmacotherapy
347610|NCT01305707|Efficacy
347611|NCT01305707|Depression
347612|NCT01305707|Prevention
347613|NCT01305707|Electroconvulsive therapy
347614|NCT01305707|Drug therapy
347615|NCT01305668|COPD
347616|NCT01305668|Emphysema phenotype
347617|NCT01305655|Drug: Glucarpidase
347618|NCT01305642|Postnatal development
347619|NCT01305642|Breast milk fortification
347620|NCT01305642|Composition of breast milk
347621|NCT01305629|HIV
347622|NCT01305629|Medication Adherence
347623|NCT01305629|Substance Use
347624|NCT01305629|Older adults
347625|NCT01305629|Treatment
347626|NCT01305616|Open angle Glaucoma
347627|NCT01305616|Yellow-tinted intraocular lens
347628|NCT01305616|Short-wavelength Automated Perimetry (SWAP)
347629|NCT01305616|Standard Automated Perimetry (SAP)
347630|NCT01305616|cataract
347631|NCT01305590|HIV
347632|NCT01305590|AIDS
347633|NCT01305590|Medication Adherence
347634|NCT01305590|Commitment Devices
347635|NCT01305590|Behavioral Economics
347636|NCT01305564|Pulmonary embolism (PE)
347637|NCT01305564|Deep vein thrombosis (DVT)
347638|NCT01305564|Vena cava
347639|NCT01305564|Vena cava filter
347640|NCT01305564|Inferior vena cava
347641|NCT01305564|Venous thromboembolic disease (VTED)
347642|NCT01305525|SCS
347643|NCT01305525|St. Jude Medical
347644|NCT01305525|Neuromodulation
347645|NCT01305512|Solid
347646|NCT01305512|Tumor
347647|NCT01305512|Taxane
347648|NCT01305499|AML
347649|NCT01305447|smoking cessation
347650|NCT01305447|exercise maintenance
347651|NCT01305447|preventing relapse
347652|NCT01305447|weight gain
347653|NCT01305447|group-mediated cognitive behavioural therapy
347654|NCT01305434|diabetes mellitus type 2
347655|NCT01305434|mulberry leaf extract
347656|NCT01305434|post prandial blood glucose
347657|NCT01305421|ICU
347658|NCT01305421|muscle strength
347659|NCT01305421|mechanical ventilation
347660|NCT01305421|weaning
347661|NCT01305408|Bipolar I Disorder
347662|NCT01305395|Cardiac Allograft Vasculopathy in Heart Transplant
347663|NCT01305382|Cardiac Allograft Vasculopathy
347664|NCT01305369|ASTHMA
347665|NCT01305369|PLATELET RECEPTOR P2Y12
347666|NCT01305369|PRASUGREL
347667|NCT01305369|INFLAMMATION
347668|NCT01305356|degenerative joint disease
347669|NCT01305356|DJD
347670|NCT01305356|joint fusion
347671|NCT01305356|hindfoot
347672|NCT01305356|congenital deformity
347673|NCT01305356|osteoarthritis
347674|NCT01305356|rheumatoid arthritis
347675|NCT01305356|post-traumatic arthritis
347676|NCT01305356|ankylosing spondylitis
347677|NCT01305356|Augment(tm) Injectable Bone Graft
347678|NCT01305356|autologous bone graft
347679|NCT01305356|autogenous bone graft
347680|NCT01305356|beta-TCP
347681|NCT01305356|bovine collagen
347682|NCT01305356|rhPDGF(bb)
347683|NCT01305343|Spinal Deformity
347684|NCT01305343|Scoliosis
347685|NCT01305343|Neurologic complications
347686|NCT01305330|small renal mass
347687|NCT01305330|active surveillance
347688|NCT01305330|kidney mass
347689|NCT01305330|kidney tumour
347690|NCT01305317|Statin
347691|NCT01305291|dietary fiber
347692|NCT01305291|satiety response
347693|NCT01305291|hunger
347694|NCT01305291|CCK
347695|NCT01305291|PYY
347696|NCT01305291|ghrelin
347697|NCT01305291|GIP
347698|NCT01305291|GLP-1
347699|NCT01305278|Balance
347700|NCT01305278|Rehabilitation
347701|NCT01305278|Vestibular
347702|NCT01305265|sore throat
347703|NCT01305265|dysphagia
347704|NCT01305265|hoarseness
347705|NCT01305265|post operative
347706|NCT01305265|endotracheal intubation
347707|NCT01305239|Observational
347708|NCT01305239|epidemiological
347709|NCT01305239|cohort
347710|NCT01305239|cross-sectional
347711|NCT01305239|prospective
347712|NCT01305239|multicenter
347713|NCT01305239|survey
347714|NCT01305239|France.
347715|NCT01305226|THR 100
347716|NCT01305174|Common Iliac Artery and External Iliac Artery
347717|NCT01305161|1Allergy
347718|NCT01305161|2 Neuromuscular blockers
347719|NCT01305148|warfarin
347720|NCT01305148|genetic testing
347721|NCT01305148|personalized medicine
347722|NCT01305148|anti-coagulants
347723|NCT01305148|coumadin
347724|NCT01305135|myelodysplastic syndrome, azacitidine, idarubicin
347725|NCT01305122|Glioma
347726|NCT01305122|Neurocognitive functions
347727|NCT01305096|heart rate variability
347728|NCT01305096|oxygen uptake
347729|NCT01305096|heart rate recovery
347730|NCT01305096|perceived stress
347731|NCT01305096|sleep
347732|NCT01305096|blood pressure
347733|NCT01305096|body mass index
347734|NCT01305096|body weight
347735|NCT01305096|hand grip strength
347736|NCT01305096|sleep quality
347737|NCT01305096|subjective health complaints
347738|NCT01305096|blood lipids
347739|NCT01305096|salivary cortisol
347740|NCT01305096|blood sugar
347741|NCT01305096|HbA1C
347742|NCT01305096|Adiponectin
347743|NCT01305096|Leptin
347744|NCT01305096|Adipolipoproteins
347745|NCT01305096|blood proteins
347746|NCT01305096|cytokines
347747|NCT01305096|insomnia
347748|NCT01305096|sleeplessness
347749|NCT01305096|yoga
347750|NCT01305070|Standard balloon angioplasty
347751|NCT01305070|POBA
347752|NCT01305070|Angioplasty with paclitaxel-eluting balloon
347753|NCT01305070|Superficial femoral artery
347754|NCT01305057|dry skin condition
347755|NCT01305044|tai chi
347756|NCT01305044|elderly cancer survivor
347757|NCT01305044|mind body intervention
347758|NCT01305031|Asphyxia
347759|NCT01305031|Resuscitation
347760|NCT01305031|Room Air
347761|NCT01305018|Branched-chain amino acids
347762|NCT01305018|Leucine
347763|NCT01305018|Muscle damage
347764|NCT01305018|Inflammation
347765|NCT01305018|supplementation
347766|NCT01305018|resistance exercise-induced
347767|NCT01305005|blood flow
347768|NCT01304992|Dietary protein
347769|NCT01304992|Lupin protein
347770|NCT01304992|Cholesterol metabolism
347771|NCT01304992|Protein metabolism
347772|NCT01304992|Hypercholesterolemia
347773|NCT01304992|Protein-enriched drinks
347774|NCT01304979|acupuncture
347775|NCT01304979|auricular acu-therapy
347776|NCT01304979|gua sha therapy
347777|NCT01304979|low back 'spine fusion'
347778|NCT01304979|post surgical pain
347779|NCT01304979|post surgical recovery
347780|NCT01304979|Pain and recovery from 'spine fusion' surgery
347781|NCT01304966|RRP
347782|NCT01304966|HPV
347783|NCT01304953|General anaesthetics
347784|NCT01304953|gynaecological laparoscopy
347785|NCT01304953|anaesthetic i.v.
347786|NCT01304953|propofol
347787|NCT01304953|anaesthetic volatile
347788|NCT01304953|evoflurane
347789|NCT01304953|antiemetics
347790|NCT01304953|reopisetron
347791|NCT01304953|postoperative pain
347792|NCT01304940|Stress
347793|NCT01304940|Stress Disorders, Post-Traumatic
347794|NCT01304940|Stress Disorders, Traumatic
347795|NCT01304927|Reproduction
347796|NCT01304927|Sex hormones
347797|NCT01304927|Glucose metabolism
347798|NCT01304927|Bone metabolism
347799|NCT01304927|Calcium
347800|NCT01304927|Sperm
347801|NCT01304927|testis
347802|NCT01304927|bone
347803|NCT01304927|endocrinology
347804|NCT01304914|Respiratory tract infections
347805|NCT01304914|Gastrointestinal tract infections
347806|NCT01304914|Pediatrics
347807|NCT01304914|Specimen collection
347808|NCT01304901|Acute asthma
347809|NCT01304901|Children
347810|NCT01304901|Montelukast
347811|NCT01304901|Emergency room
347812|NCT01304888|Food consumption
347813|NCT01304875|Fabry disease
347814|NCT01304875|alpha-galactosidase deficiency
347815|NCT01304875|exercise
347816|NCT01304875|pulmonary
347817|NCT01304849|Hodgkin's Lymphoma
347818|NCT01304849|PET CT scan
347819|NCT01304849|Escalated BEACOPP
347820|NCT01304849|ABVD
347821|NCT01304849|Response adapted therapy
347822|NCT01304836|Kidney
347823|NCT01304836|Transplant
347824|NCT01304836|Immunosuppression
347825|NCT01304836|Diabetes Mellitus
347826|NCT01304823|T1R2/T1R3
347827|NCT01304823|gastric emptying
347828|NCT01304823|gut
347829|NCT01304823|lactisole
347830|NCT01304823|nutrient sensing
347831|NCT01304810|NicVAX
347832|NCT01304810|Smoking cessation
347833|NCT01304797|MM302
347834|NCT01304797|Breast Cancer
347835|NCT01304797|Locally advanced/unresectable
347836|NCT01304797|metastatic
347837|NCT01304784|Solid tumors
347838|NCT01304784|Failed at least one line of standard therapy
347839|NCT01304771|Safety
347840|NCT01304771|AKSB
347841|NCT01304771|probiotic
347842|NCT01304771|synbiotic
347843|NCT01304771|enterococcus
347844|NCT01304771|Saccharomyces
347845|NCT01304771|elderly
347846|NCT01304771|influenza
347847|NCT01304771|vaccine
347848|NCT01304771|immune
347849|NCT01304771|response
347850|NCT01304056|Ventilatory physiology
347851|NCT01304043|ovarian tumors
347852|NCT01304043|rare ovarian tumors
347853|NCT01304043|germinal tumors
347854|NCT01304043|sexual cords tumors
347855|NCT01304043|observatory
347856|NCT01304043|forum
347857|NCT01304030|Empathy
347858|NCT01304017|rehabilitation
347859|NCT01304017|stroke
347860|NCT01304017|intervention
347861|NCT01304017|physical activity
347862|NCT01304017|participation
347863|NCT01304004|Obesity
347864|NCT01304004|Yogurt
347865|NCT01304004|Proteins
347866|NCT01304004|Fibres
347867|NCT01304004|Women
347868|NCT01304004|Satiety
347869|NCT01304693|AMD
347870|NCT01304693|Wet AMD
347871|NCT01304693|Exudative
347872|NCT01304693|CNV
347873|NCT01304667|Vulvar cancer
347874|NCT01304667|Radiotherapy
347875|NCT01304667|Chemotherapy
347876|NCT01304654|acute lung injury
347877|NCT01304654|respiratory distress syndrome
347878|NCT01304654|neoplasms
347879|NCT01304654|child
347880|NCT01304641|Dyslipidemia
347881|NCT01304641|Cardiovascular
347882|NCT01304641|Statin
347883|NCT01304628|asthma
347884|NCT01304615|Overweight
347885|NCT01304615|Obesity
347886|NCT01304615|Young Adults
347887|NCT01304615|Energy Density
347888|NCT01304615|Culinary Skills
347889|NCT01304615|Physical Activity
347890|NCT01304615|Consumption of Self-made Meals
347891|NCT01304615|Family History of diabetes
347892|NCT01304602|colorectal cancer
347893|NCT01304602|BKM120
347894|NCT01304602|irinotecan
347895|NCT01304589|provoked vestibulodynia
347896|NCT01304589|vulvodynia
347897|NCT01304589|PVD
347898|NCT01304576|stroke
347899|NCT01304576|parietal lesions
347900|NCT01304550|non-invasive
347901|NCT01304550|hemoglobin
347902|NCT01304524|CIN 2/3 or CIN 3
347903|NCT01304524|Cervical cancer
347904|NCT01304524|Papillomavirus
347905|NCT01304485|Recurrent Prostate Carcinoma
347906|NCT01304485|sodium acetate c11
347907|NCT01304485|PET
347908|NCT01304485|prostate cancer
347909|NCT01304485|rising PSA
347910|NCT01304485|PSA recurrence
347911|NCT01304485|biochemical recurrence
347912|NCT01304472|coronary angioplasty
347913|NCT01304472|clopidogrel resistance
347914|NCT01304472|prasugrel
347915|NCT01304446|Nutritional support
347916|NCT01304446|Cancer
347917|NCT01304446|Malnutrition
347918|NCT01304446|Child
347919|NCT01304446|Adolescent
347920|NCT01304446|pediatric
347921|NCT01304420|Juvenile idiopathic arthritis
347922|NCT01304420|Ultrasonography
347923|NCT01304420|Cartilage
347924|NCT01304420|Cartilage biomarkers
347925|NCT01304420|Bone biomarkers
347926|NCT01304407|Rothmund-Thomson Syndrome
347927|NCT01304407|Calcium absorption
347928|NCT01304407|Bone density
347929|NCT01304394|Parenteral Nutrition
347930|NCT01304394|Multi Chamber Bag
347931|NCT01304381|Heart failure
347932|NCT01304381|Palliative care
347933|NCT01304381|Integrated care
347934|NCT01304368|Hyperthermia, Induced
347935|NCT01304368|Randomized Controlled Trial
347936|NCT01304368|Neck Pain
347937|NCT01304368|Sensory Thresholds
347938|NCT01304368|Pain Measurements
347939|NCT01304355|IBS
347940|NCT01304355|Cognition
347941|NCT01304355|Kynurenine Pathway
347942|NCT01304355|Gastrointestinal
347943|NCT01304342|Propofol
347944|NCT01304342|remifentanil
347945|NCT01304342|fentanyl
347946|NCT01304342|ERCP
347947|NCT01304342|Quality of sedation
347948|NCT01304342|recovery
347949|NCT01304342|satisfaction
347950|NCT01304342|respiratory depression
347951|NCT01304303|solid
347952|NCT01304303|tumor
347953|NCT01304303|taxane
347954|NCT01304303|platinum
347955|NCT01304290|inflammatory process
347956|NCT01304290|hyperglycaemia
347957|NCT01304290|inflammatory cytokine response
347958|NCT01304290|organ survival
347959|NCT01304290|hyperinsulinemic clamp
347960|NCT01304277|Replagal
347961|NCT01304264|glaucoma, ocular, blood flow, fluctuations
347962|NCT01304251|short-term fasting
347963|NCT01304251|adjuvant chemotherapy
347964|NCT01304251|toxicity
347965|NCT01304251|side-effects
347966|NCT01304238|Retrospective evaluation of patients with acute Heparin-induced Thrombocytopenia type II treated with Fondaparinux
347967|NCT01304225|diabetic retinopathy
347968|NCT01304225|photocoagulation
347969|NCT01304225|PASCAL laser
347970|NCT01304212|total knee arthroplasty
347971|NCT01304212|intraarticular infiltration
347972|NCT01304212|femoral block
347973|NCT01304199|Cancer survivor
347974|NCT01304199|Neoplasms
347975|NCT01304199|Treatments
347976|NCT01304199|Physical status
347977|NCT01304199|Psychosocial status
347978|NCT01304199|Survivorship survey
347979|NCT01304199|Survivorship care
347980|NCT01304199|Research
347981|NCT01304199|Cancer patient
347982|NCT01304186|Health literacy
347983|NCT01304186|HIV
347984|NCT01304186|Medication Adherence
347985|NCT01304186|IMB Model
347986|NCT01304173|BCG
347987|NCT01304173|refractory
347988|NCT01304173|NMIBC
347989|NCT01304173|CIS
347990|NCT01304173|non-muscle invasive
347991|NCT01304160|pancreatic cancer
347992|NCT01304160|stereotactic body radiotherapy
347993|NCT01304160|radiation
347994|NCT01304160|gemcitabine
347995|NCT01304160|locally advanced
347996|NCT01304147|ketamine
347997|NCT01304147|depression
347998|NCT01304147|treatment resistance
347999|NCT01304147|intranasal, antidepressant
348000|NCT01304147|glutamate
348001|NCT01304147|NMDA receptor
348002|NCT01304121|Bone tumors
348003|NCT01304121|Bioactive glass
348004|NCT01304121|Autogenous bone grafting
348005|NCT01304121|Allogeneic bone grafting
348006|NCT01304121|PET imaging
348007|NCT01304108|Venous Thromboembolism
348008|NCT01304108|Delivery of Health Care
348009|NCT01304108|Quality Improvement
348010|NCT01304108|Evidence-Based Practice
348011|NCT01304095|Coronary Artery Disease, Angina, Metabolic Syndrome
348012|NCT01304082|pain pH local anesthetics
348013|NCT01304069|Pharmacokinetics
348014|NCT01304069|Pharmacodynamics
348015|NCT01303952|cold agglutinin disease
348016|NCT01303952|hemolysis
348017|NCT01303952|eculizumab
348018|NCT01303952|terminal complement inhibition
348019|NCT01303939|Glaucoma
348020|NCT01303939|MRI Brain Scan
348021|NCT01303939|Voxel-Based Morphometry
348022|NCT01303926|QoL
348023|NCT01303926|EQ5D score
348024|NCT01303926|cisplatin pemetrexed
348025|NCT01303926|carboplatin paclitaxel bevacizumab
348026|NCT01303926|maintenance
348027|NCT01303913|COPD
348028|NCT01303913|Oxygen desaturation
348029|NCT01303913|Walking test
348030|NCT01303900|Haemophilia
348031|NCT01303900|Cardiovascular disease
348032|NCT01303900|Cardiovascular disease risk factors
348033|NCT01303900|Prospective
348034|NCT01303900|QRISK2
348035|NCT01303900|Hypertension
348036|NCT01303900|Hypercholesterolaemia
348037|NCT01303900|Diabetes
348038|NCT01303900|Obesity
348039|NCT01303887|PACIFICO
348040|NCT01303887|Follicular Lymphoma
348041|NCT01303887|Non-Hodgkin's Lymphoma
348042|NCT01303887|Rituximab
348043|NCT01303887|R-CVP
348044|NCT01303887|R-FC
348045|NCT01303887|Older
348046|NCT01303874|Rheumatoid arthritis
348047|NCT01303874|Inflammatory arthritis
348048|NCT01303874|Undifferentiated arthritis
348049|NCT01303874|Etanercept
348050|NCT01303874|Combination Therapy
348051|NCT01303861|Nicotine addiction
348052|NCT01303861|Cigarette smoking
348053|NCT01303861|Smoking cessation
348054|NCT01303861|Zyban
348055|NCT01303861|Chantix
348056|NCT01303861|Nicotine patches
348057|NCT01303861|Nicotrol Inhaler
348058|NCT01303861|varenicline
348059|NCT01303861|bupropion
348060|NCT01303848|Blood lactate
348061|NCT01303848|Lipid transfer proteins
348062|NCT01303848|Lactate
348063|NCT01303848|PLTP
348064|NCT01303848|CETP
348065|NCT01303848|PPARs
348066|NCT01303848|CLOCk
348067|NCT01303848|Bal1
348068|NCT01303835|malignant glioma
348069|NCT01303835|glioblastoma multiforme
348070|NCT01303835|quality of life
348071|NCT01303835|naltrexone
348072|NCT01303809|Perioperative care
348073|NCT01303809|Fast-track
348074|NCT01303809|Enhanced Recovery After Surgery
348075|NCT01303809|ERAS
348076|NCT01303809|Obesity
348077|NCT01303809|Bariatric surgery
348078|NCT01303809|Laparoscopic Sleeve Gastrectomy
348079|NCT01303796|AML
348080|NCT01303783|Nifedipine GITS
348081|NCT01303783|Candesartan
348082|NCT01303783|mild to moderate Hypertension
348083|NCT01303783|Combination therapy
348084|NCT01303770|Multiple Sclerosis
348085|NCT01303770|Cognitive impairment
348086|NCT01303770|Self-management programs
348087|NCT01303770|Occupational Therapy
348088|NCT01303770|Rehabilitation
348089|NCT01303757|obesity
348090|NCT01303731|Spinal anesthesia
348091|NCT01303731|Cesarean section
348092|NCT01303731|Marcaine Spinal 0.5% Heavy minidose
348093|NCT01303731|Fentanyl
348094|NCT01303731|Local Anesthetics
348095|NCT01303718|LV Dysfunction
348096|NCT01303718|Heart Failure
348097|NCT01303705|progressive metastatic prostate cancer
348098|NCT01303705|cancer of the prostate
348099|NCT01303705|prostate cancer
348100|NCT01303692|bone mineral loss
348101|NCT01303692|prostate cancer
348102|NCT01303692|GnRH agonist alone vs. GnRH agonist plus anti-androgen combination
348103|NCT01303679|First line metastatic breast cancer
348104|NCT01303679|Positive estrogen receptors
348105|NCT01303679|Negative HER2 receptors
348106|NCT01303679|At least stable disease after 4 months of paclitaxel-bevcizumab induction chemotheray
348107|NCT01303653|endoscopic tissue closure,
348108|NCT01303653|gastro-gastric fistulas,
348109|NCT01303653|gastrointestinal perforations
348110|NCT01303640|Coronary stent
348111|NCT01303627|Remifentanil
348112|NCT01303627|Laryngeal mask airway removal
348113|NCT01303627|Hemodynamic changing
348114|NCT01303627|Infusion
348115|NCT01303627|Ureterorenoscopy
348116|NCT01303614|hysterosalpingography
348117|NCT01303614|prilocaine
348118|NCT01303614|local anaesthetic
348119|NCT01303614|pain relief
348120|NCT01303614|gynecological pathology
348121|NCT01303601|Olanzapine
348122|NCT01303601|Monotherapy
348123|NCT01303601|bipolar Ⅰ depression
348124|NCT01303588|elderly patients
348125|NCT01303575|Adolescents
348126|NCT01303575|Youth
348127|NCT01303575|Sexual Health
348128|NCT01303575|Sex Education
348129|NCT01303575|Pregnancy Prevention
348130|NCT01303575|Abstinence Education
348131|NCT01303575|HIV
348132|NCT01303575|Human Immunodeficiency Virus
348133|NCT01303575|STI
348134|NCT01303575|Chlamydia
348135|NCT01303575|Gonorrhea
348136|NCT01303575|Sexually Transmitted Infections
348137|NCT01303575|American Indian
348138|NCT01303575|Alaska Native
348139|NCT01303575|Native American
348140|NCT01303575|Internet-Based
348141|NCT01303575|Computer-based Education
348142|NCT01303575|Computer-based learning
348143|NCT01303562|oat
348144|NCT01303562|barley
348145|NCT01303562|whole grain
348146|NCT01303562|bioavailability
348147|NCT01303562|phytochemical
348148|NCT01303549|Liver transplantation
348149|NCT01303549|Hepatic transplant
348150|NCT01303549|Antifungal prophylaxis
348151|NCT01303549|Anidulafungin
348152|NCT01303549|Liposomal Amphotericin B
348153|NCT01303523|LMWH
348154|NCT01303523|heparin
348155|NCT01303523|immobilization
348156|NCT01303523|anticoagulant prophylaxis
348157|NCT01303523|leg injuries
348158|NCT01303523|thromboembolism
348159|NCT01303510|Influenza
348160|NCT01303510|Virus
348161|NCT01303510|Vaccination
348162|NCT01303510|Immunisation
348163|NCT01303497|Angiosarcoma
348164|NCT01303497|Paclitaxel
348165|NCT01303497|bevacizumab
348166|NCT01303471|pain assessment
348167|NCT01303471|anesthesia
348168|NCT01303471|analgesia
348169|NCT01303471|opioid
348170|NCT01303471|HRV
348171|NCT01303471|APV
348172|NCT01303471|autonomic nervous system (ANS)
348173|NCT01303471|pupil size
348174|NCT01303458|community resource
348175|NCT01303458|well-child care visit
348176|NCT01303458|low-income
348177|NCT01303432|Joint discomfort
348178|NCT01303432|Functional Food
348179|NCT01303432|Joint function
348180|NCT01303432|Mobilee
348181|NCT01303419|mammography
348182|NCT01303406|randomized withdrawal
348183|NCT01303406|idebenone
348184|NCT01303406|friedreich's ataxia
348185|NCT01303406|Miconos
348186|NCT01303406|Patient reported outcome
348187|NCT01303406|ICARS
348188|NCT01303393|Patient education. Patient discharge. Needs assessment.
348189|NCT01303380|Hyper IgD syndrome
348190|NCT01303380|canakinumab
348191|NCT01303380|HIDS
348192|NCT01303380|mevalonate kinase deficiency
348193|NCT01303380|MKD
348194|NCT01303367|Dementia
348195|NCT01303367|behavioral and psychological symptoms of dementia
348196|NCT01303354|Epidural, Transforaminal, Steroid Injection, Dexamethasone
348197|NCT01303315|C19 246 300
348198|NCT01303302|C19 246 300
348199|NCT01303289|Total Enteral Nutrition
348200|NCT01303289|Severe insufficient nutrition
348201|NCT01303289|T-Diet plus Standard
348202|NCT01303289|Lipidic profile
348203|NCT01303289|Quality of life
348204|NCT01303276|retinal vein occlusion
348205|NCT01303276|anti-VEGF
348206|NCT01303276|blood flow
348207|NCT01303263|efficiency
348208|NCT01303263|cost-awareness
348209|NCT01303263|hospitals
348210|NCT01303263|graduate medical education
348211|NCT01303250|goal-directed fluid optimization
348212|NCT01303250|hemodynamic optimization
348213|NCT01303250|crystalloid
348214|NCT01303250|colloid
348215|NCT01303237|LA SCCHN
348216|NCT01303237|Cetuximab
348217|NCT01303237|RT
348218|NCT01303237|PMS
348219|NCT01303224|Irritable Bowel Syndrome
348220|NCT01303224|Colon, irritable
348221|NCT01303224|Bowel disease
348222|NCT01303211|Meningococcal serogroup A conjugate vaccine
348223|NCT01303211|Vaccine efficacy
348224|NCT01303211|Serogroup A meningococcal diseases
348225|NCT01303198|CPAP
348226|NCT01303198|APAP
348227|NCT01303198|sleep apnea
348228|NCT01303185|Psoriatic Nail
348229|NCT01303185|Pulsed dye laser
348230|NCT01303159|Cholangiocarcinoma
348231|NCT01303159|Pancreatic Cancer
348232|NCT01303159|Radiofrequency
348233|NCT01303159|Ablation
348234|NCT01303146|Metachromatic Leukodystrophy
348235|NCT01303146|Enzyme replacement therapy
348236|NCT01303146|Allogeneic hematopoietic stem cell transplantation
348237|NCT01303133|beta amyloid, Down Syndrome, Alzheimer's Disease
348238|NCT01303081|Smoking Cessation
348239|NCT01303081|Work-site
348240|NCT01303081|Incentives
348241|NCT01303081|Health Behavior
348242|NCT01303081|Smoking
348243|NCT01303068|CF
348244|NCT01303055|Pancreatic beta Cell
348245|NCT01303055|Diabetes Mellitus, Type 2
348246|NCT01303055|Glucose Metabolism Disorders
348247|NCT01303055|Metabolic Diseases
348248|NCT01303055|Endocrine System Diseases
348249|NCT01303055|Metformin
348250|NCT01303055|Hypoglycemic Agents
348251|NCT01303055|Physiological Effects of Drugs
348252|NCT01303055|Pharmacologic Actions
348253|NCT01303055|hemoglobin A1c protein, human
348254|NCT01303055|Oral Glucose Tolerance Test
348255|NCT01303042|insulin LISPRO
348256|NCT01303042|Insulin therapy
348257|NCT01303042|hemoglobin A1c protein, human
348258|NCT01303042|Blood Glucose Self-Monitoring
348259|NCT01303042|Quality of Life
348260|NCT01303042|Hypoglycemia
348261|NCT01303042|Diabetes Mellitus
348262|NCT01303042|1,5-Anhydroglucitol
348263|NCT01303029|Pancreatic cancer
348264|NCT01303029|gemcitabine
348265|NCT01303029|erlotinib
348266|NCT01303029|capecitabine
348267|NCT01302990|Influenza
348268|NCT01302990|Respiratory disease
348269|NCT01302990|Prevention
348270|NCT01302977|Congenital diaphragmatic hernia
348271|NCT01302977|Fetal anomalies
348272|NCT01302964|Autistic Disorder
348273|NCT01302964|Asperger's Disorder
348274|NCT01302964|Pervasive Developmental Disorder
348275|NCT01302951|pharmacokinetics
348276|NCT01302951|liver resection
348277|NCT01302938|Double-blind
348278|NCT01302938|Placebo-controlled
348279|NCT01302938|frequency
348280|NCT01302938|urgency
348281|NCT01302938|web-based
348282|NCT01302938|incontinence
348283|NCT01302938|methodology
348284|NCT01302938|ediary
348285|NCT01302938|safety
348286|NCT01302938|efficacy
348287|NCT01302938|tolerability ER
348288|NCT01302938|overactive bladder
348289|NCT01302912|ocular adnexal lymphomas
348290|NCT01302886|High risk Smoldering multiple myeloma,
348291|NCT01302886|BHQ880,
348292|NCT01302886|MM
348293|NCT01302873|Tinnitus
348294|NCT01302873|AMPA Receptor antagonist
348295|NCT01302860|Cryopyrin-associated periodic syndromes (CAPS)
348296|NCT01302860|Familial Cold Autoinflammatory Syndrome (FCAS)
348297|NCT01302860|Muckle-Wells Syndrome (MWS) or Neonatal Onset Multisystem Inflammatory Disease (NOMID)
348298|NCT01302860|children
348299|NCT01302860|systemic autoinflammatory disease
348300|NCT01302860|CIAS-1 gene
348301|NCT01302860|NALP-3
348302|NCT01302860|NLRP3
348303|NCT01302860|ACZ885
348304|NCT01302860|Ilaris
348305|NCT01302860|human monoclonal anti-human interleukin-1 beta (IL-beta)
348306|NCT01302860|antibody
348307|NCT01302860|autosomal dominant
348308|NCT01302860|familial autoinflammatory syndrome
348309|NCT01302847|Integrase Inhibitors
348310|NCT01302847|Infant
348311|NCT01302847|Child
348312|NCT01302847|Adolescent
348313|NCT01302834|stage III squamous cell carcinoma of the oropharynx
348314|NCT01302834|stage IV squamous cell carcinoma of the oropharynx
348315|NCT01302834|human papilloma virus infection
348316|NCT01302821|breast - male
348317|NCT01302821|breast - female
348318|NCT01302821|metastatic
348319|NCT01302821|invasive
348320|NCT01302808|recurrent non-small cell lung cancer
348321|NCT01302808|stage IIIB non-small cell lung cancer
348322|NCT01302808|stage IV non-small cell lung cancer
348323|NCT01302808|malignant pleural effusion
348324|NCT01302808|adenocarcinoma of the lung
348325|NCT01302808|adenosquamous cell lung cancer
348326|NCT01302808|bronchoalveolar cell lung cancer
348327|NCT01302808|large cell lung cancer
348328|NCT01302808|squamous cell lung cancer
348329|NCT01302795|Interleukin 1 beta
348330|NCT01302795|Canakinumab
348331|NCT01302795|autoinflammatory syndrome
348332|NCT01302782|Altitude
348333|NCT01302782|Glucose
348334|NCT01302769|Acute Sore Throat
348335|NCT01302769|Ear Acupuncture
348336|NCT01302756|gestational diabetes
348337|NCT01302756|gestational hypertension
348338|NCT01302756|folic acid
348339|NCT01302743|Diabetes
348340|NCT01302743|Metformin
348341|NCT01302743|Cinnamon
348342|NCT01302730|ankylosing spondylitis
348343|NCT01302730|spondylarthritis
348344|NCT01302730|inflammatory back pain
348345|NCT01302730|seronegative
348346|NCT01302717|Left ventricular pacing
348347|NCT01302704|Vitamin D
348348|NCT01302704|Proton Pump Inhibitors
348349|NCT01302691|Essential hypertension
348350|NCT01302691|Uncontrolled hypertension
348351|NCT01302691|Antihypertensive agents
348352|NCT01302691|Blood pressure
348353|NCT01302652|acromegaly
348354|NCT01302652|growth hormone
348355|NCT01302652|growth hormone deficiency
348356|NCT01302626|NSCLC
348357|NCT01302626|SCLC
348358|NCT01302626|lung cancer
348359|NCT01302626|RNA
348360|NCT01302626|DNA
348361|NCT01302626|imaging
348362|NCT01302626|genomics
348363|NCT01302626|proteomics
348364|NCT01302626|predictive model
348365|NCT01302626|prospective study
348366|NCT01302613|rectal cancer
348367|NCT01302574|T1R2/T1R3
348368|NCT01302574|gastric emptying
348369|NCT01302574|gut
348370|NCT01302574|lactisole
348371|NCT01302574|nutrient sensing
348372|NCT01302561|adults
348373|NCT01302561|fiber
348374|NCT01302561|cold
348375|NCT01302561|flu
348376|NCT01302561|immune function
348377|NCT01302561|microbiota
348378|NCT01302548|Abscess
348379|NCT01302548|Wound Irrigation
348380|NCT01302548|Wound Debridement
348381|NCT01302548|Wound Healing
348382|NCT01302548|Incision and drainage
348383|NCT01302548|Chlorhexidine
348384|NCT01302535|Yoga
348385|NCT01302535|Hypertension
348386|NCT01302535|Quality of Life
348387|NCT01302535|Primary Health Care
348388|NCT01302509|Nutritional support.
348389|NCT01302509|Cancer.
348390|NCT01302509|Malnutrition.
348391|NCT01302509|Child.
348392|NCT01302509|Adolescent
348393|NCT01302496|Previously Treated
348394|NCT01302496|Unresectable
348395|NCT01302496|Stage III or IV Melanoma
348396|NCT01302470|biventricular pacing
348397|NCT01302457|Thermal Burn Trauma
348398|NCT01302444|treprostinil
348399|NCT01302444|pulmonary hypertension, tadalafil
348400|NCT01302431|experimental
348401|NCT01302431|intervention
348402|NCT01302431|nurse-led
348403|NCT01302431|nurse specialist
348404|NCT01302431|multiple sclerosis
348405|NCT01302431|support of caregivers
348406|NCT01302418|Respiratory Virus
348407|NCT01302418|Influenza
348408|NCT01302418|RSV
348409|NCT01302418|Parainfluenza
348410|NCT01302418|Metapneumovirus
348411|NCT01302418|Rhinovirus
348412|NCT01302418|Coxsackie virus
348413|NCT01302418|Echo virus
348414|NCT01302418|Adenovirus
348415|NCT01302418|Coronavirus
348416|NCT01302418|Bocavirus
348417|NCT01302405|Advanced solid tumor
348418|NCT01302405|cancer
348419|NCT01302405|phase 1
348420|NCT01302405|pancreatic cancer
348421|NCT01302405|colon cancer
348422|NCT01302405|unresectable neoplastic disease
348423|NCT01302405|Progressive cancer
348424|NCT01302405|metastatic solid tumor
348425|NCT01302379|Obesity
348426|NCT01302379|Survival
348427|NCT01302379|Weight loss
348428|NCT01302379|Metformin
348429|NCT01302379|Biological markers
348430|NCT01302366|multiple myeloma
348431|NCT01302366|myeloma
348432|NCT01302366|asymptomatic myeloma
348433|NCT01302366|smoldering myeloma
348434|NCT01302366|Asymptomatic (smoldering) myeloma
348435|NCT01302353|Phase I trial
348436|NCT01302353|Emulsified Isoflurane
348437|NCT01302353|Health volunteer
348438|NCT01302340|Dementia
348439|NCT01302340|Alzheimer
348440|NCT01302340|Cannabis
348441|NCT01302340|THC
348442|NCT01302340|Behavioral Disturbances
348443|NCT01302340|Neuropsychiatric Inventory
348444|NCT01302327|Wolfram syndrome
348445|NCT01302327|Diabetes mellitus
348446|NCT01302327|Exenatide
348447|NCT01302327|GLP-1 analog
348448|NCT01302327|beta cell function
348449|NCT01302301|endolumenal myotomy, per oral endoscopic myotomy
348450|NCT01302288|endolumenal myotomy, per oral endoscopic myotomy
348451|NCT01302275|neuropathic pain
348452|NCT01302275|oxcarbazepine
348453|NCT01302275|pain mechanism
348454|NCT01302262|Smoking-induced dopamine release
348455|NCT01302262|[11C]-(+)-PHNO PET Study
348456|NCT01302249|Glaucoma
348457|NCT01302249|Intraocular pressure
348458|NCT01302249|Ocular hypertension
348459|NCT01302236|Elderly
348460|NCT01302236|Early stage chronic kidney disease
348461|NCT01302236|Hypertension
348462|NCT01302236|Eplerenone
348463|NCT01302223|burns
348464|NCT01302223|Growth Factors, Combined Defect of
348465|NCT01302223|inflammation
348466|NCT01302223|Cytokine Storm
348467|NCT01302210|MRSA
348468|NCT01302210|Cluster Randomized Trial
348469|NCT01302210|Infection Control Intervention
348470|NCT01302197|Stroke
348471|NCT01302197|Body Composition
348472|NCT01302197|Glucose Tolerance
348473|NCT01302171|dilated cardiomyopathy
348474|NCT01302171|adult stem cells
348475|NCT01302171|bone marrow progenitor cells
348476|NCT01302171|bone marrow stem cells
348477|NCT01302171|autologous
348478|NCT01302171|granulocyte-colony stimulating factor
348479|NCT01302171|intracoronary injection
348480|NCT01302171|left ventricular function
348481|NCT01302171|To determine if patient's own bone marrow derived stem cells can be used to improve cardiac function
348482|NCT01302158|Drug-Drug interaction
348483|NCT01302158|ASP1941
348484|NCT01302158|Glimepiride
348485|NCT01302158|Healthy subjects
348486|NCT01302145|ASP1941
348487|NCT01302145|Drug to drug interaction
348488|NCT01302145|metformin
348489|NCT01302145|pharmacokinetics
348490|NCT01302132|Mass Balance
348491|NCT01302132|ASP1941
348492|NCT01302132|Pharmacokinetics
348493|NCT01302119|Onychomycosis
348494|NCT01302119|nail fungus
348495|NCT01302119|toenail fungus
348496|NCT01302119|fungal nail
348497|NCT01302119|hyperkeratosis
348498|NCT01302119|nail infection
348499|NCT01302119|nail treatment
348500|NCT01302119|toenail infection
348501|NCT01302119|toenail treatment
348502|NCT01302119|foot dermatoses
348503|NCT01302119|fungal culture
348504|NCT01302119|onycholysis
348505|NCT01302119|podiatrist
348506|NCT01302119|podiatry
348507|NCT01302119|subungual
348508|NCT01302119|tinea unguium
348509|NCT01302119|antifungal
348510|NCT01302119|anti-fungal
348511|NCT01302119|dermatologist
348512|NCT01302119|dermatology
348513|NCT01302119|dermatophyte
348514|NCT01302119|distal subungual onychomycosis
348515|NCT01302119|yellow nail
348516|NCT01302119|thick nail
348517|NCT01302119|brittle nail
348518|NCT01302119|crumbling nail
348519|NCT01302119|discolored nail
348520|NCT01302119|weak nail
348521|NCT01302106|Myelodysplastic Syndromes
348522|NCT01302106|Clofarabine
348523|NCT01302106|Low Dose Cytarabine
348524|NCT01302106|Poor risk MDS
348525|NCT01302080|prospective
348526|NCT01302080|cohort
348527|NCT01302080|sertraline
348528|NCT01302080|long-term impact
348529|NCT01302080|cognition
348530|NCT01302080|emotional and physical development
348531|NCT01302080|pubertal maturation
348532|NCT01302054|Bladder Overactive
348533|NCT01302054|Overactive urinary bladder
348534|NCT01302054|Overactive Bladder
348535|NCT01302041|bone turnover
348536|NCT01302041|hormone-naïve
348537|NCT01302041|prostate specific antigen
348538|NCT01302041|Prostate Cancer
348539|NCT01302028|Renal Impairment
348540|NCT01302028|ASP1941
348541|NCT01302028|Pharmacokinetics
348542|NCT01302002|Breast Cancer
348543|NCT01302002|Metformin
348544|NCT01302002|Pre-Surgery
348545|NCT01301989|Sleep
348546|NCT01301989|Children
348547|NCT01301989|Disparities
348548|NCT01301989|Minority
348549|NCT01301989|Urban
348550|NCT01301976|nutritional state
348551|NCT01301976|nutrients intake
348552|NCT01301976|ulcerative colitis
348553|NCT01301950|Arthroplasties, Knee Replacement
348554|NCT01301950|Arthroplasties, Replacement, Knee
348555|NCT01301950|Arthroplasty, Knee Replacement
348556|NCT01301950|Knee Replacement Arthroplasties
348557|NCT01301950|Knee Replacement Arthroplasty
348558|NCT01301950|Knee Replacement, Total
348559|NCT01301950|Replacement Arthroplasties, Knee
348560|NCT01301950|Replacement Arthroplasty, Knee
348561|NCT01301950|Replacement, Total Knee
348562|NCT01301950|Total Knee Replacement
348563|NCT01301937|Mucosal Leishmaniasis
348564|NCT01301937|Leishmania braziliensis
348565|NCT01301937|Meglumine Antimoniate
348566|NCT01301937|Treatment Effectiveness
348567|NCT01301937|Controlled Clinical Trials, Randomized
348568|NCT01301924|Leishmaniasis Cutaneous
348569|NCT01301924|Leishmania braziliensis
348570|NCT01301924|Meglumine Antimoniate
348571|NCT01301924|Treatment Effectiveness
348572|NCT01301924|Controlled Clinical Trials, Randomized
348573|NCT01301911|Breast cancer, Advanced
348574|NCT01301911|Cipatinib
348575|NCT01301911|phase I
348576|NCT01301911|HER2 positive or uncertain advanced breast cancer
348577|NCT01301898|Hunter syndrome
348578|NCT01301898|MPS II
348579|NCT01301898|Idursulfase
348580|NCT01301885|endometriosis
348581|NCT01301885|dysmenorrhea
348582|NCT01301885|infertility
348583|NCT01301885|biomarker
348584|NCT01301885|drug target
348585|NCT01301859|older adults
348586|NCT01301859|adherence
348587|NCT01301859|antidepressant
348588|NCT01301859|depression
348589|NCT01301833|insulin resistance
348590|NCT01301820|maintenance treatment
348591|NCT01301820|Disease free survival
348592|NCT01301807|Relapsed/refractory multiple myeloma
348593|NCT01301807|RRMM
348594|NCT01301807|Carfilzomib
348595|NCT01301807|Panobinostat
348596|NCT01301807|LBH589B
348597|NCT01301794|Hypertriglyceridemia
348598|NCT01301794|Fish oil
348599|NCT01301794|Omega 3 fatty acids
348600|NCT01301768|Dietary Intervention
348601|NCT01301768|Pregnancy Jail
348602|NCT01301768|Iodine Deficiency
348603|NCT01301768|Iodine Nutrition
348604|NCT01301768|Dietary Habits
348605|NCT01301768|Urinary Iodine
348606|NCT01301768|Pregnancy
348607|NCT01301768|Group Education
348608|NCT01301768|Cluster Randomized Trial
348609|NCT01301768|Primary Health Care
348610|NCT01301703|rheumatoid pertussis tetanus
348611|NCT01301690|neck mass
348612|NCT01301690|ultrasound
348613|NCT01301690|FNA
348614|NCT01301690|BMVC
348615|NCT01301664|The bone marrow-derived mesenchymal stem cells (BMMSCs) were obtained from redundant bone marrow from drilling during the joint replacement surgery.
348616|NCT01301664|The synovial-derived mesenchymal stem cells (SMSCs) were isolated from synovial membranes in the joint replacement surgery.
348617|NCT01301664|Cartilage slices were obtained from discard cartilage in the joint replacement surgery.
348618|NCT01301651|Virtual Reality
348619|NCT01301651|Balance
348620|NCT01301651|Parkinson's disease
348621|NCT01301651|Dual Task
348622|NCT01301625|MitraClip
348623|NCT01301625|mitral regurgitation (MR)
348624|NCT01301625|mitral valve insufficiency
348625|NCT01301625|percutaneous mitral valve repair
348626|NCT01301625|congestive heart failure
348627|NCT01301612|carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma
348628|NCT01301599|Benign Prostatic Hyperplasia
348629|NCT01301599|alpha blocker
348630|NCT01301599|5-alpha reductase inhibitor
348631|NCT01301599|combination therapy
348632|NCT01301560|Asymptomatic brain metastasis
348633|NCT01301560|NSCLC
348634|NCT01301560|GKS
348635|NCT01301534|abdominal aortic aneurysm
348636|NCT01301521|Pre-Diabetes
348637|NCT01301521|cinnamon
348638|NCT01301508|atopic dermatitis
348639|NCT01301495|Esophageal Cancer, Malignant, Dysphagia, Esophagus, Cancer
348640|NCT01301482|Acute Sore Throat
348641|NCT01301482|Ear Acupuncture
348642|NCT01301456|Phase 1
348643|NCT01301456|Type 2 Diabetes
348644|NCT01301456|CVX-096
348645|NCT01301443|Age Related Macular Degeneration
348646|NCT01301430|Progressive glioblastoma multiforme
348647|NCT01301430|Recurrent glioblastoma multiforme
348648|NCT01301430|Oncolytic virus
348649|NCT01301417|Compression Anastomosis
348650|NCT01301404|Postoperative nausea and vomiting (PONV)
348651|NCT01301404|Spinal morphine
348652|NCT01301404|Total knee replacement (TKR)
348653|NCT01301404|blood sugar
348654|NCT01301404|carbohydrate drink
348655|NCT01301391|B3 and C malignant thymoma
348656|NCT01301365|autonomic response
348657|NCT01301352|Critical Care
348658|NCT01301352|Intubation, gastrointestinal
348659|NCT01301352|Child
348660|NCT01301352|Infant
348661|NCT01301352|Adolescent
348662|NCT01301352|Continuous positive airway pressure
348663|NCT01301352|Enteral Nutrition
348664|NCT01301339|Pre-Diabetes
348665|NCT01301339|Diabetes
348666|NCT01301339|cardiovascular risks
348667|NCT01301326|retinal arterial macroaneurysm
348668|NCT01301326|laser treatment
348669|NCT01301313|Acute heart failure
348670|NCT01301313|Children
348671|NCT01301313|Levosimendan
348672|NCT01301313|Inotropic treatment
348673|NCT01301274|hyponatremia
348674|NCT01301274|maintenance solutions
348675|NCT01301274|pediatrics
348676|NCT01301261|Sugammadex
348677|NCT01301261|entropy
348678|NCT01301261|bispectral index
348679|NCT01301261|blood pressure
348680|NCT01301261|heart rate
348681|NCT01301261|oxygenation
348682|NCT01301261|end-tidal CO2
348683|NCT01301261|hemodynamics
348684|NCT01301261|general anesthesia
348685|NCT01301248|locally advanced,
348686|NCT01301248|unresectable,
348687|NCT01301248|head and neck squamous cell carcinoma,
348688|NCT01301248|stage III/IV
348689|NCT01301235|Mitochondria
348690|NCT01301222|octreotide
348691|NCT01301222|pancreatic fistula
348692|NCT01301222|soft pancreas
348693|NCT01301222|pancreatoduodenectomy
348694|NCT01301196|sedentary behaviour
348695|NCT01301196|diabetes
348696|NCT01301196|structured education
348697|NCT01301196|18-30 years olds
348698|NCT01301196|family history of T2DM or CVD
348699|NCT01301196|BMI ≥ 25 (≥23 for south Asians)
348700|NCT01301183|Anorexia Nervosa
348701|NCT01301183|Estrogen
348702|NCT01301183|Teenagers
348703|NCT01301183|IGF-1
348704|NCT01301170|Neck pain
348705|NCT01301170|Dry Needling
348706|NCT01301170|Manual Therapy
348707|NCT01301170|Manipulation
348708|NCT01301144|Tuberculosis
348709|NCT01301144|Urea Breath Test
348710|NCT01301118|Transplantation Infection
348711|NCT01301118|Wound of skin
348712|NCT01301118|Burns
348713|NCT01301118|Graft Loss
348714|NCT01301118|Infection
348715|NCT01301105|pain regulation
348716|NCT01301105|social stress
348717|NCT01301105|affect
348718|NCT01301105|attention
348719|NCT01301105|brain
348720|NCT01301105|immune
348721|NCT01301105|endocrine
348722|NCT01301079|Remifentanil
348723|NCT01301079|Hyperalgesia
348724|NCT01301079|Ketamine
348725|NCT01301079|Von Frey's filament
348726|NCT01301079|Algometer
348727|NCT01301079|Interleukines
348728|NCT01301079|Opioid-induced hyperalgesia
348729|NCT01301053|hyperglycemia and increased mortality in the ICU
348730|NCT01301053|hypoglycemia and increased mortality in the ICU
348731|NCT01301053|glucose variability and increased mortality in the ICU
348732|NCT01301053|Continuous Glucose Monitoring (CGM) and hypoglycemia
348733|NCT01301053|hypoglycemia
348734|NCT01301053|reducing ICU mortality
348735|NCT01301040|breast cancer, elderly, early cardiac toxicity
348736|NCT01301027|End stage renal disease
348737|NCT01301027|Hemodialysis
348738|NCT01301027|Pioglitazone
348739|NCT01301027|Adipokines
348740|NCT01301014|accuracy, anterior cruciate ligament, diagnostic value, examination, knee, Lachman test, sensitivity, specificity
348741|NCT01301001|Vulvodynia
348742|NCT01300988|HIV infection
348743|NCT01300988|Neurokinin-1 receptor antagonist
348744|NCT01300988|CCR5 expression
348745|NCT01300988|Treatment Naive
348746|NCT01300975|Leishmaniasis
348747|NCT01300975|intralesional antimony
348748|NCT01300975|cryotherapy
348749|NCT01300962|Xeloda
348750|NCT01300962|Capecitabine
348751|NCT01300962|BKM120
348752|NCT01300962|Lineberger Comprehensive Cancer Center
348753|NCT01300962|Metastatic
348754|NCT01300962|BYL719 Breast Cancer
348755|NCT01300949|Contrast Sensitivity
348756|NCT01300949|Pelli-Robson Test
348757|NCT01300923|Fragile X Syndrome
348758|NCT01300923|Acamprosate
348759|NCT01300910|Adult Males
348760|NCT01300910|Circumcision
348761|NCT01300910|HIV prevention
348762|NCT01300910|Device
348763|NCT01300910|Shang Ring
348764|NCT01300897|cortical function, motor evoked potential responses
348765|NCT01300845|Oxygen mask
348766|NCT01300845|Oxygen cannula
348767|NCT01300845|Humidification
348768|NCT01300845|Oxygen therapy
348769|NCT01300845|Intensive Care Unit
348770|NCT01300832|Surgery
348771|NCT01300832|Deep Vein Thrombosis
348772|NCT01300832|Preoperative
348773|NCT01300819|Rotigotine
348774|NCT01300819|Neupro®
348775|NCT01300819|Non-motor symptoms
348776|NCT01300806|HIV
348777|NCT01300806|harmful substance use
348778|NCT01300793|V-RICE
348779|NCT01300793|Relapsed NHL
348780|NCT01300793|Primary Refractory NHL
348781|NCT01300780|bleaching agent
348782|NCT01300780|tooth bleaching
348783|NCT01300780|sensibility
348784|NCT01300754|Osgood-Schlatter
348785|NCT01300754|Tendinosis
348786|NCT01300754|Apophysitis
348787|NCT01300754|Enthesopathy
348788|NCT01300754|Dextrose.
348789|NCT01300728|Intravenous immunotherapy
348790|NCT01300728|Conversion to Alzheimer Disease
348791|NCT01300715|zygapophysial joint
348792|NCT01300715|facet joint
348793|NCT01300715|low back pain
348794|NCT01300715|radiofrequency
348795|NCT01300715|neurotomy
348796|NCT01300689|HPV
348797|NCT01300689|MSM
348798|NCT01300689|Vaccine
348799|NCT01300689|China
348800|NCT01300676|Tualang honey
348801|NCT01300676|HRT
348802|NCT01300676|safety profiles
348803|NCT01300676|cardiovascular parameters
348804|NCT01300676|hormonal levels
348805|NCT01300676|bone changes
348806|NCT01300676|postmenopausal women
348807|NCT01300650|Heart failure
348808|NCT01300650|Inflammation
348809|NCT01300650|Interleukin-1
348810|NCT01300650|Cardiopulmonary exercise
348811|NCT01300637|schizophrenia
348812|NCT01300637|clozapine
348813|NCT01300637|metabolic dysregulation
348814|NCT01300637|metformin
348815|NCT01300624|Aphasia
348816|NCT01300624|therapy
348817|NCT01300624|treatment
348818|NCT01300624|verbs
348819|NCT01300624|sentences
348820|NCT01300611|Double Cord Blood Transplantation
348821|NCT01300611|Neutrophil Engraftment
348822|NCT01300611|Platelet Engraftment
348823|NCT01300611|Immune Reconstitution
348824|NCT01300611|Mucositis
348825|NCT01300585|Breast
348826|NCT01300585|Cancer
348827|NCT01300559|efficacy
348828|NCT01300559|hemoglobin
348829|NCT01300559|spine
348830|NCT01300546|Frequent migraine
348831|NCT01300546|Migraine transformation
348832|NCT01300546|Migraine
348833|NCT01300546|Treximet
348834|NCT01300546|Naproxen
348835|NCT01300546|Sumatriptan
348836|NCT01300533|Cancer
348837|NCT01300533|Neoplasms
348838|NCT01300533|Solid Tumor
348839|NCT01300533|Ovarian Cancer
348840|NCT01300533|Lung Cancer
348841|NCT01300533|Non-Small Cell Lung Cancer
348842|NCT01300533|Pancreatic Cancer
348843|NCT01300533|Breast Cancer
348844|NCT01300533|Endometrial Cancer
348845|NCT01300533|Melanoma
348846|NCT01300533|Prostate Cancer
348847|NCT01300533|Skin Cancer
348848|NCT01300533|Head and Neck Cancer
348849|NCT01300533|Solid Malignancies
348850|NCT01300520|Fluoroscopy
348851|NCT01300520|Femoral fracture
348852|NCT01300520|Tibial fracture
348853|NCT01300520|Spinal Fusion
348854|NCT01300507|stent thrombosis
348855|NCT01300507|intra coronary imaging
348856|NCT01300507|blood platelet function testing
348857|NCT01300494|bifurcation lesion
348858|NCT01300494|optimal viewing angle
348859|NCT01300494|automated software
348860|NCT01300468|advanced/metastatic solid tumors
348861|NCT01300455|Insomnia
348862|NCT01300455|obstructive sleep apnea
348863|NCT01300455|orexin receptor antagonist
348864|NCT01300442|chronic obstructive pulmonary disease
348865|NCT01300442|diaphragm
348866|NCT01300442|electrical stimulation
348867|NCT01300442|pulmonary rehabilitation
348868|NCT01300429|core biopsy
348869|NCT01300429|Resistance to Crizotinib
348870|NCT01300429|Non-small Cell Lung Cancer
348871|NCT01300429|11-014
348872|NCT01300416|Kidney transplantation
348873|NCT01300416|mycophenolate sodium
348874|NCT01300416|EC-MPS
348875|NCT01300416|Health Related Quality of Life
348876|NCT01300416|GI symptoms
348877|NCT01300416|Immunosuppressants
348878|NCT01300416|HRQL
348879|NCT01300416|PGWB
348880|NCT01300416|GIQLI
348881|NCT01300390|liver transplant
348882|NCT01300390|end-stage liver disease
348883|NCT01300390|cirrhosis
348884|NCT01300377|Post-operative pain
348885|NCT01300377|pain
348886|NCT01300377|pacemaker
348887|NCT01300377|defibrillator
348888|NCT01300377|post-operative narcotic use
348889|NCT01300377|local anesthesia
348890|NCT01300351|Advanced breast cancer
348891|NCT01300351|metastatic breast cancer
348892|NCT01300338|Diabetes
348893|NCT01300325|Bronchiolitis, 3% Hypertonic Saline Solution
348894|NCT01300312|eperisone
348895|NCT01300312|diclofenac
348896|NCT01300312|low back pain
348897|NCT01300299|lung cancer
348898|NCT01300299|radiation
348899|NCT01300299|stereotactic
348900|NCT01300273|Diabetic nephropathy
348901|NCT01300273|Podocyte
348902|NCT01300273|Low Protein Diet
348903|NCT01300273|Ketoanalogs
348904|NCT01300234|tenofovir disoproxil fumarate
348905|NCT01300234|chronic hepatitis B
348906|NCT01300234|adefovir dipivoxil
348907|NCT01300221|Three dimension echocardiography
348908|NCT01300221|Congenital heart disease
348909|NCT01300221|Z-score
348910|NCT01300208|cutaneous lupus erythematosus
348911|NCT01300208|subacute lupus erythematosus
348912|NCT01300208|discoid lupus erythematosus
348913|NCT01300208|lupus
348914|NCT01300195|VATS
348915|NCT01300195|standardized surgery
348916|NCT01300195|persistent pain
348917|NCT01300182|ACLR
348918|NCT01300169|Suicide
348919|NCT01300169|Assessment
348920|NCT01300169|Intervention
348921|NCT01300169|CAMS
348922|NCT01300156|Hodgkin's disease
348923|NCT01300156|lymphoma
348924|NCT01300156|Relapsed
348925|NCT01300156|refractory
348926|NCT01300130|neurological development
348927|NCT01300130|preterm infants
348928|NCT01300130|fatty acid status
348929|NCT01300117|cardiac surgery
348930|NCT01300117|adamts13
348931|NCT01300117|TTP
348932|NCT01300117|extracorporeal circulation
348933|NCT01300117|Heart-Lung Machine
348934|NCT01300104|prostate cancer progression
348935|NCT01300104|active surveillance
348936|NCT01300104|whole grain rye
348937|NCT01300104|exercise
348938|NCT01300104|insulin sensitivity
348939|NCT01300104|quality of life
348940|NCT01300091|Shoulder
348941|NCT01300091|Pain
348942|NCT01300091|Range of Motion
348943|NCT01300091|Disability Evaluation
348944|NCT01300091|Function
348945|NCT01300091|Sick Leave
348946|NCT01300091|Primary Health Care
348947|NCT01300091|Visual Analog Scale
348948|NCT01300091|Visual Analog Pain Scale
348949|NCT01300091|The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form
348950|NCT01300078|Hot Flashes
348951|NCT01300078|Hot Flushes
348952|NCT01300078|Vasomotor Symptoms
348953|NCT01300078|Menopausal Symptoms
348954|NCT01300052|psoriasis
348955|NCT01300039|nephrolithiasis
348956|NCT01300039|urolithiasis
348957|NCT01300039|hyperoxaluria
348958|NCT01300039|Helicobacter pylori
348959|NCT01300026|Low intermediate grade B cell Lymphoma
348960|NCT01300026|Non-cutaneous T-cell NHL
348961|NCT01300026|Mantle Cell Lymphoma
348962|NCT01300026|PI3K delta
348963|NCT01300026|Lymphoid
348964|NCT01300026|NHL
348965|NCT01300026|MCL
348966|NCT01300026|Hematologic
348967|NCT01300026|CLL
348968|NCT01300026|Chronic Lymphocytic Leukemia
348969|NCT01300013|Intravenous
348970|NCT01300013|IV
348971|NCT01300013|Left Ventricular Systolic Dysfunction
348972|NCT01300013|Hospitalized
348973|NCT01300013|Acute heart failure
348974|NCT01300013|Heart failure
348975|NCT01300013|Left ventricular ejection fraction
348976|NCT01300013|pharmacokinetics
348977|NCT01300013|Pharmacodynamics
348978|NCT01300013|Dyspnea
348979|NCT01300013|hospitalization
348980|NCT01300013|In-patient
348981|NCT01300013|Omecamtiv mecarbil
348982|NCT01300013|Double-blind
348983|NCT01300013|Randomized
348984|NCT01300013|Placebo-controlled
348985|NCT01299987|Keywords provided by University Hospital Mannheim:
348986|NCT01299987|Intraoperative Radiotherapy
348987|NCT01299987|Early Breast Cancer
348988|NCT01299987|Elderly Patients
348989|NCT01299974|Family-centered
348990|NCT01299974|teaching
348991|NCT01299974|residents
348992|NCT01299974|family faculty
348993|NCT01299961|Rheumatoid Arthritis
348994|NCT01299961|Subcutaneous Abatacept
348995|NCT01299961|Ultrasound
348996|NCT01299948|HIV
348997|NCT01299948|AIDS
348998|NCT01299948|CD4
348999|NCT01299948|progression
349000|NCT01299948|immune activation
349001|NCT01299935|stress reduction
349002|NCT01299935|Transcendental Meditation technique
349003|NCT01299935|secondary prevention of coronary heart disease
349004|NCT01299922|Lupus nephritis
349005|NCT01299922|Therapy
349006|NCT01299922|Cyclosporin
349007|NCT01299922|Mycophenolic acid
349008|NCT01299909|Mindfulness Training for Smokers
349009|NCT01299909|Smoking
349010|NCT01299909|Smoking cessation
349011|NCT01299909|Addiction
349012|NCT01299909|behavioral intervention
349013|NCT01299909|Nicotine
349014|NCT01299909|Tobacco
349015|NCT01299909|Mindfulness
349016|NCT01299909|Meditation
349017|NCT01299909|MBSR
349018|NCT01299909|Mindfulness Based Stress Reduction
349019|NCT01299909|Mindfulness Based Cognitive Therapy
349020|NCT01299909|MBCT
349021|NCT01299909|Mindfulness Based Relapse Prevention
349022|NCT01299909|MBRP
349023|NCT01299909|Mindfulness Training
349024|NCT01299909|Nicotine Patch
349025|NCT01299909|Quit Line
349026|NCT01299909|Phone counseling
349027|NCT01299909|Freedom from Smoking
349028|NCT01299896|Cigarette Smoking
349029|NCT01299896|Smoking, Tobacco
349030|NCT01299896|Tobacco Smoking
349031|NCT01299896|Smoking Cessation
349032|NCT01299896|Tobacco Dependence
349033|NCT01299883|Cancer
349034|NCT01299883|CVD
349035|NCT01299883|African American
349036|NCT01299883|Health Education Intervention
349037|NCT01299883|Intervention RCT
349038|NCT01299883|Study focus is to examine the influence of health education regarding either CVD or CVD and cancer on health behaviors.
349039|NCT01299857|pemphigus
349040|NCT01299857|Mabthéra (R)
349041|NCT01299857|B lymphocytes
349042|NCT01299857|desmogleines
349043|NCT01299844|Type 2 Diabetes
349044|NCT01299818|central pain
349045|NCT01299818|spine surgey
349046|NCT01299818|outcome
349047|NCT01299818|patients undergo spinal surgery
349048|NCT01299805|Drug Therapy
349049|NCT01299805|pharmacodynamic
349050|NCT01299792|spinal cord injury
349051|NCT01299792|urodynamics
349052|NCT01299792|ultrasound
349053|NCT01299792|neurogenic bladder dysfunction
349054|NCT01299779|hyponatremia
349055|NCT01299779|PEG-SD
349056|NCT01299779|PEG-ELS
349057|NCT01299766|Mild Cognitive Impairment
349058|NCT01299766|Memory
349059|NCT01299727|Recombinant Human Heparan N-Sulfatase (rhHNS)
349060|NCT01299727|Sanfilippo Syndrome Type A (MPS IIIA)
349061|NCT01299727|Lysosomal storage disease (LSD)
349062|NCT01299727|Mucopolysaccharidosis (MPS) III
349063|NCT01299714|Human Papilloma Virus
349064|NCT01299714|vaccine
349065|NCT01299714|stress
349066|NCT01299714|cervical cancer
349067|NCT01299714|GARDASIL
349068|NCT01299701|Advanced or metastatic cancer
349069|NCT01299701|refractory
349070|NCT01299701|core phase
349071|NCT01299701|extension phase
349072|NCT01299701|dose escalation
349073|NCT01299701|standard chemotherapy
349074|NCT01299701|docetaxel
349075|NCT01299701|paclitaxel
349076|NCT01299701|carboplatin
349077|NCT01299701|safety
349078|NCT01299701|tolerability
349079|NCT01299675|MR conditional
349080|NCT01299649|CAD
349081|NCT01299636|PM060184
349082|NCT01299636|Phase I
349083|NCT01299636|Pharma Mar
349084|NCT01299623|breast cancer
349085|NCT01299623|breast cancer prevention
349086|NCT01299623|African American women
349087|NCT01299610|Atopic Dermatitis
349088|NCT01299610|GW870086X
349089|NCT01299610|TIS
349090|NCT01299610|IGA
349091|NCT01299597|repeat dose
349092|NCT01299597|statins
349093|NCT01299597|safety and tolerability
349094|NCT01299597|drug interaction
349095|NCT01299597|sb649868
349096|NCT01299597|healthy male subjects
349097|NCT01299597|pharmacokinetics
349098|NCT01299558|pharmacokinetics
349099|NCT01299558|GW642444
349100|NCT01299558|absolute bioavailability
349101|NCT01299558|healthy subjects
349102|NCT01299558|fluticasone furoate
349103|NCT01299558|GW685698
349104|NCT01299545|Rheumatoid Arthritis
349105|NCT01299545|Anti TNF
349106|NCT01299545|Infliximab
349107|NCT01299545|Methotrexate
349108|NCT01299545|DMARDs
349109|NCT01299545|Gene expression biomarkers
349110|NCT01299519|obesity
349111|NCT01299519|weight loss
349112|NCT01299519|insulin resistance
349113|NCT01299506|soft tissue sarcoma
349114|NCT01299506|trabectedin
349115|NCT01299506|Netherlands
349116|NCT01299493|carcinoma
349117|NCT01299493|colorectal cancer
349118|NCT01299493|community health centers
349119|NCT01299493|cluster-randomized
349120|NCT01299493|health behavior
349121|NCT01299480|Healthy adolescents
349122|NCT01299467|Asthma
349123|NCT01299467|duration of action
349124|NCT01299467|allergen challenge
349125|NCT01299428|CEREBRAL OXYGENATION
349126|NCT01299428|HYPERNATREMİA
349127|NCT01299428|NEWBORN
349128|NCT01299428|NA VALUES
349129|NCT01299415|ASA404,
349130|NCT01299415|Phase I,
349131|NCT01299415|Oncology,
349132|NCT01299415|CYP1A2,
349133|NCT01299415|fluvoxamine,
349134|NCT01299415|drug drug interaction,
349135|NCT01299415|Novartis,
349136|NCT01299415|Antisoma
349137|NCT01299389|Paliperidone palmitate
349138|NCT01299389|Schizophrenia
349139|NCT01299376|Essential hypertension
349140|NCT01299376|Antihypertensive agents
349141|NCT01299376|Blood pressure
349142|NCT01299376|Uncontrolled hypertension
349143|NCT01299363|Prolapse
349144|NCT01299363|Pain with intercourse
349145|NCT01299363|Dyspareunia
349146|NCT01299363|Post operative pain
349147|NCT01299350|Heart failure
349148|NCT01299350|Nt-proBNP
349149|NCT01299324|CHF
349150|NCT01299311|insulin sensitivity
349151|NCT01299285|Absorption
349152|NCT01299285|Distribution
349153|NCT01299285|Metabolism
349154|NCT01299285|Excretion
349155|NCT01299285|Mass balance
349156|NCT01299285|Metabolic profile
349157|NCT01299285|Radiolabeled study
349158|NCT01299285|14C
349159|NCT01299259|Text message reminders
349160|NCT01299259|Pelvic inflammatory disease
349161|NCT01299259|PID
349162|NCT01299259|Primary care follow-up
349163|NCT01299259|Emergency department care
349164|NCT01299259|Discharge instructions
349165|NCT01299246|Diabetic Foot
349166|NCT01299246|non-invasive DFP assessment tools
349167|NCT01299246|early detection of DFP
349168|NCT01299220|Erlotinib
349169|NCT01299220|Acitretin
349170|NCT01299220|Rash
349171|NCT01299220|Dermatology
349172|NCT01299220|Oncology
349173|NCT01299207|Stents
349174|NCT01299207|Drug-Eluting Stents
349175|NCT01299207|Stent Thrombosis
349176|NCT01299207|Bleeding
349177|NCT01299207|Dual-Antiplatelet Therapy
349178|NCT01299194|BRONCHIECTASIS
349179|NCT01299194|PSEUDOMONAS AERUGINOSA
349180|NCT01299194|STATIN
349181|NCT01299194|OUTCOME
349182|NCT01299181|Bronchiectasis
349183|NCT01299181|Outcome
349184|NCT01299181|Statin therapy
349185|NCT01299168|global gene expression
349186|NCT01299168|molecular diagnostic classifiers
349187|NCT01299155|Intraocular Lens
349188|NCT01299155|Presbyopia Correcting IOL
349189|NCT01299142|Influenza
349190|NCT01299142|antibodies
349191|NCT01299142|monoclonal
349192|NCT01299142|virus
349193|NCT01299129|Uveitis
349194|NCT01299129|Cystoid macular edema
349195|NCT01299129|microperimetry
349196|NCT01299129|functional visual acuity
349197|NCT01299129|intravitreal triamcinolone
349198|NCT01299116|AE adverse event
349199|NCT01299116|FDA (U.S.) Food and Drug Administration
349200|NCT01299116|GCP Good Clinical Practice guidelines
349201|NCT01299116|ICH International Conference of Harmonisation
349202|NCT01299116|IRB Institutional Review Board
349203|NCT01299116|IU International units
349204|NCT01299116|mg milligram(s)
349205|NCT01299116|mm3 cubic millimeter(s)
349206|NCT01299116|LARC Long-Acting reversible contraception
349207|NCT01299116|PPCNC Planned Parenthood of North Carolina
349208|NCT01299116|SAE serious adverse event
349209|NCT01299116|SARC Short-Acting reversible contraception
349210|NCT01299116|µg microgram
349211|NCT01299116|ULN upper limit of the normal range
349212|NCT01299103|wrinkle
349213|NCT01299103|rhytide
349214|NCT01299090|wrinkles
349215|NCT01299090|rhytides
349216|NCT01299077|Lumbar disc degenerative disease
349217|NCT01299077|Methycobal
349218|NCT01299064|mindfulness-based intervention
349219|NCT01299064|symptoms reduction
349220|NCT01299064|mental health
349221|NCT01299051|Weight Management
349222|NCT01299051|Employee Health
349223|NCT01299038|Crestor
349224|NCT01299038|TFBP
349225|NCT01299038|rosuvastatin
349226|NCT01299025|balance
349227|NCT01299025|walking
349228|NCT01298999|Barrett's Esophagus
349229|NCT01298999|Esophageal Adenocarcinoma
349230|NCT01298999|GERD
349231|NCT01298999|Acid Reflux
349232|NCT01298986|atrial fibrillation ablation procedures
349233|NCT01298960|Poor Ovarian response in IVF
349234|NCT01298960|Metaphase II oocytes
349235|NCT01298960|Pregnancy Rate
349236|NCT01298960|Growth Hormone
349237|NCT01298947|Photoablative Atherectomy
349238|NCT01298947|Paclitaxel-Coated Balloon
349239|NCT01298947|Instent Femoro-popliteal Obstructions
349240|NCT01298921|Headache
349241|NCT01298921|Cluster Headache
349242|NCT01298921|Oxygen Therapy
349243|NCT01298908|varicose veins, oedema
349244|NCT01298895|optical components
349245|NCT01298895|pseudoexfoliation
349246|NCT01298895|cataract
349247|NCT01298895|LENSTAR® LS 900®
349248|NCT01298882|Type 2 diabetes mellitus
349249|NCT01298882|Overweight
349250|NCT01298882|Obesity
349251|NCT01298869|CKD
349252|NCT01298869|HPV infection
349253|NCT01298869|HPV vaccine
349254|NCT01298869|antibodies titer
349255|NCT01298856|hydrotherapy
349256|NCT01298856|chronic ankle instability
349257|NCT01298856|ankle taping
349258|NCT01298843|Confirmed or Suspected Infections
349259|NCT01298817|Obesity
349260|NCT01298817|Aging
349261|NCT01298817|Soy
349262|NCT01298817|Weight Loss
349263|NCT01298817|Ectopic Fat
349264|NCT01298778|chronic pain post delivery
349265|NCT01298778|postpartum depression
349266|NCT01298778|tailored pain management
349267|NCT01298765|buccal soluble film
349268|NCT01298739|asthma control level , ACQ
349269|NCT01298726|PHARMACEUTICAL SERVICES
349270|NCT01298726|DIABETES MELLITUS
349271|NCT01298713|Hormonoresistance
349272|NCT01298713|tamoxifen
349273|NCT01298713|Previously received anti-aromatase treatment
349274|NCT01298713|mTor inhibitor
349275|NCT01298687|open-angle glaucoma
349276|NCT01298687|ocular hypertension
349277|NCT01298687|divided dose
349278|NCT01298661|Exercise Test
349279|NCT01298661|Reproducibility of Results
349280|NCT01298661|Mortality
349281|NCT01298648|Crohn's Disease
349282|NCT01298635|Primary angle-closure glaucoma
349283|NCT01298635|cataract
349284|NCT01298635|trabeculectomy
349285|NCT01298635|phacotrabeculectomy
349286|NCT01298609|Fibromyalgia
349287|NCT01298609|Occipital Nerve Stimulation
349288|NCT01298570|Metastatic Colorectal Cancer
349289|NCT01298570|K-RAS mutation
349290|NCT01298570|BRAF mutation
349291|NCT01298570|Regorafenib
349292|NCT01298570|BAY 73-4506
349293|NCT01298570|FOLFIRI
349294|NCT01298570|Irinotecan
349295|NCT01298570|5-FU
349296|NCT01298570|Leucovorin
349297|NCT01298570|Placebo
349298|NCT01298570|Phase II
349299|NCT01298570|Multi-Center
349300|NCT01298570|Randomized
349301|NCT01298570|Lineberger
349302|NCT01298570|North Carolina Cancer Hospital
349303|NCT01298570|UNC
349304|NCT01298557|Traumatic brain injury
349305|NCT01298557|Post-concussive symptoms
349306|NCT01298557|Brain imaging
349307|NCT01298557|Neurocognitive testing
349308|NCT01298544|Vaccine
349309|NCT01298544|Prevenar
349310|NCT01298544|Pneumococcal disease
349311|NCT01298531|Etanercept
349312|NCT01298531|Axial Spondyloarthritis
349313|NCT01298531|NSAIDs sparing effect
349314|NCT01298518|multiple dose study in type 2 diabetes patients
349315|NCT01298505|Phase 1 multiple dose safety toleration fexofenadine
349316|NCT01298492|Anti-TNF Refractory
349317|NCT01298492|Immunosuppressant Refractory
349318|NCT01298492|Active Crohn's disease
349319|NCT01298479|volume delivery
349320|NCT01298466|identification
349321|NCT01298466|chronic
349322|NCT01298466|neuropathic
349323|NCT01298466|low back pain
349324|NCT01298466|primary care
349325|NCT01298466|pregabalin
349326|NCT01298414|childhood acute myeloid leukemia/other myeloid malignancies
349327|NCT01298401|adenocarcinoma of the pancreas
349328|NCT01298401|stage IIB pancreatic cancer
349329|NCT01298401|stage III pancreatic cancer
349330|NCT01298388|long-term effects secondary to cancer therapy in children
349331|NCT01298388|cancer survivor
349332|NCT01298388|recurrent childhood acute lymphoblastic leukemia
349333|NCT01298388|untreated childhood acute lymphoblastic leukemia
349334|NCT01298388|T-cell childhood acute lymphoblastic leukemia
349335|NCT01298388|non-T, non-B childhood acute lymphoblastic leukemia
349336|NCT01298388|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
349337|NCT01298388|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
349338|NCT01298388|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
349339|NCT01298388|childhood acute lymphoblastic leukemia in remission
349340|NCT01298375|Metabolic flexibility
349341|NCT01298375|Mitochondrial function
349342|NCT01298375|Human primary myoblasts
349343|NCT01298375|Lipid metabolism
349344|NCT01298336|Mycobacterium Xenopi Pulmonary Infection
349345|NCT01298336|Clarithromycin
349346|NCT01298336|Moxifloxacin
349347|NCT01298323|Medullary Thyroid Cancer
349348|NCT01298323|Locally advanced
349349|NCT01298323|Metastatic
349350|NCT01298323|Vandetanib
349351|NCT01298323|Patient Outreach
349352|NCT01298310|Morton's neuroma, QST measurements
349353|NCT01298297|Buprenorphine, acute pain, analgesia
349354|NCT01298284|Variceal bleeding
349355|NCT01298284|portal hypertension
349356|NCT01298284|hepatocelluar carcinoma
349357|NCT01298284|endoscopic variceal ligation
349358|NCT01298284|non-selective beta-blocker
349359|NCT01298284|rebleeding
349360|NCT01298271|gastric variceal bleeding
349361|NCT01298271|primaryprevention
349362|NCT01298271|cyanoacrylate injection
349363|NCT01298271|non-selective beta-blocker
349364|NCT01298245|diabetes
349365|NCT01298245|diabetic retinopathy
349366|NCT01298245|Chinese
349367|NCT01298245|gene
349368|NCT01298245|associations
349369|NCT01298206|A/H1N1 Influenza
349370|NCT01298206|swine flu
349371|NCT01298206|virus disease
349372|NCT01298206|Avian flu
349373|NCT01298193|Early-stage breast cancer patients
349374|NCT01298180|Prader-Willi Syndrome
349375|NCT01298180|Growth Hormone Deficiency
349376|NCT01298167|Cyanoacrylate
349377|NCT01298167|Fast Absorbing Gut
349378|NCT01298167|Mohs Surgery
349379|NCT01298167|Epidermal closure method
349380|NCT01298154|Food intake
349381|NCT01298154|Blood glucose
349382|NCT01298154|Pulses
349383|NCT01298154|Protein
349384|NCT01298141|Replagal
349385|NCT01298141|Enzyme Replacement Therapy
349386|NCT01298141|agalsidase alfa
349387|NCT01298115|chronic kidney disease
349388|NCT01298115|dialysis
349389|NCT01298115|pre dialysis education
349390|NCT01298115|transplantation
349391|NCT01298115|conservative care
349392|NCT01298102|kidney
349393|NCT01298102|transplantation
349394|NCT01298102|haemodialysis
349395|NCT01298102|vaccination
349396|NCT01298102|influenza H1N1 2009
349397|NCT01298089|Flap
349398|NCT01298089|LASIK
349399|NCT01298089|Corneal
349400|NCT01298076|Diabetes
349401|NCT01298076|Retinopathy
349402|NCT01298076|Macular oedema
349403|NCT01298076|Laser
349404|NCT01298076|Photocoagulation
349405|NCT01298076|Fovea
349406|NCT01298076|Steroid
349407|NCT01298076|Bevacizumab
349408|NCT01298076|Intravitreal
349409|NCT01298037|Immunology, Hepatitis B, HBV
349410|NCT01298024|Achilles tendon rupture
349411|NCT01298024|Non-surgical treatment
349412|NCT01298024|Exercise
349413|NCT01298024|Neuromuscular training
349414|NCT01298011|operable
349415|NCT01298011|pancreas
349416|NCT01298011|Abraxane
349417|NCT01298011|Gemcitabine
349418|NCT01298011|Preoperative
349419|NCT01298011|potentially
349420|NCT01298011|Pancreatic Cancer
349421|NCT01297985|Serious mental illness
349422|NCT01297985|Psychiatric disability
349423|NCT01297985|Mental health peer-led
349424|NCT01297985|Mental illness education
349425|NCT01297985|Illness self-management
349426|NCT01297972|Aplastic Anemia
349427|NCT01297972|Mesenchymal Stem Cells
349428|NCT01297959|Surgical Wound Infection
349429|NCT01297959|Therapeutic Enzyme System
349430|NCT01297959|Singlet Oxygen
349431|NCT01297959|Peroxidase
349432|NCT01297959|Glucose Oxidase
349433|NCT01297959|Colorectal surgery
349434|NCT01297959|Incisional Surgical Site Infections (SSI)
349435|NCT01297959|Anti-infective Agents, Local
349436|NCT01297959|Clinical Trial, Phase III
349437|NCT01297933|parenteral nutrition associated liver disease
349438|NCT01297933|cholestasis
349439|NCT01297933|short bowel syndrome
349440|NCT01297933|Omegaven
349441|NCT01297920|Open-Angle Glaucoma
349442|NCT01297920|Ocular Hypertension
349443|NCT01297920|Brinzolamide
349444|NCT01297920|Brimonidine
349445|NCT01297920|Intraocular pressure
349446|NCT01297907|Crohn's Disease
349447|NCT01297907|Bronchial hyper reactivity
349448|NCT01297907|Fractional exhaled NO
349449|NCT01297907|Methacholine Challenge Test
349450|NCT01297907|Pediatric Crohn's Disease Activity Index
349451|NCT01297907|To determine the frequency of bronchial hyperreactivity in pediatric patients followed and treated for Crohn disease
349452|NCT01297894|A. baumannii
349453|NCT01297894|colistin
349454|NCT01297894|fosfomycin
349455|NCT01297881|Caucasian outpatients
349456|NCT01297881|undiagnosed respiratory symptoms
349457|NCT01297881|dyspnea
349458|NCT01297881|cough
349459|NCT01297881|sputum
349460|NCT01297088|Proof of Mechanism
349461|NCT01297088|Phase I
349462|NCT01297088|Neoplasm
349463|NCT01297088|Inflammation
349464|NCT01297075|Health Services Research
349465|NCT01297075|Chronic Care
349466|NCT01297075|Outreach Visits
349467|NCT01297075|Primary care
349468|NCT01297075|chronic disease management
349469|NCT01297829|ibuprofen
349470|NCT01297829|postoperative narcotics
349471|NCT01297829|visual analog pain scale
349472|NCT01297829|inguinal hernia repair
349473|NCT01297829|umbilical hernia repair
349474|NCT01297790|Cough
349475|NCT01297790|Inhalational cough challenges
349476|NCT01297790|Cough reflex sensitivity
349477|NCT01297790|Chronic cough.
349478|NCT01297777|Mast cell
349479|NCT01297777|Mastocytosis
349480|NCT01297777|Mast cell disease
349481|NCT01297738|diet manipulation
349482|NCT01297738|serotonin
349483|NCT01297738|dopamine
349484|NCT01297738|insulin sensitivity
349485|NCT01297725|Cesarean section
349486|NCT01297725|Cesarean section[*methods]
349487|NCT01297725|Fascia [*surgery]
349488|NCT01297725|Randomized Controlled Trial
349489|NCT01297725|Abdominal Wall [*surgery]
349490|NCT01297725|Pain, postoperative
349491|NCT01297725|Surgical wound infection
349492|NCT01297712|screening colonoscopy
349493|NCT01297712|adenoma
349494|NCT01297712|hyperplastic polyp
349495|NCT01297712|differential diagnosis
349496|NCT01297699|Graves´ orbitopathy
349497|NCT01297699|Graves´ ophthalmopathy
349498|NCT01297699|Thyroid eye disease
349499|NCT01297699|Thyroid-associated ophthalmopathy
349500|NCT01297699|Tocilizumab
349501|NCT01297699|EUGOGO
349502|NCT01297699|CAS
349503|NCT01297686|Chronic plantar fasciitis
349504|NCT01297686|Workplace injury
349505|NCT01297686|Foot and Ankle Disability Index
349506|NCT01297686|Ultrasound measure of disease severity
349507|NCT01297673|vesico-ureteral reflux
349508|NCT01297673|neurogenic bladder dysfunction
349509|NCT01297673|spinal cord injury
349510|NCT01297660|neurogenic detrusor overactivity
349511|NCT01297660|detrusor sphincter dyssynergia
349512|NCT01297660|compliance
349513|NCT01297660|video urodynamic
349514|NCT01297660|spinal cord injury
349515|NCT01297647|urinary tract infection
349516|NCT01297647|urodynamics
349517|NCT01297647|spinal cord injury
349518|NCT01297634|Botulinum toxin type A
349519|NCT01297634|Hyperfunctional forehead lines
349520|NCT01297634|Randomized controlled trial
349521|NCT01297634|Double-blinded trial
349522|NCT01297634|Electromyogram (EMG)
349523|NCT01297634|Electromyographic activity
349524|NCT01297634|Frontal Area
349525|NCT01297621|breast hypertrophy
349526|NCT01297621|physical activity
349527|NCT01297621|sexuality
349528|NCT01297621|patient satisfaction
349529|NCT01297595|relative bioavailability
349530|NCT01297595|pharmacokinetics
349531|NCT01297595|crizotinib
349532|NCT01297595|oral liquid formulation
349533|NCT01297595|formulated capsule
349534|NCT01297582|ONO-6950
349535|NCT01297582|Healthy Adult Subjects
349536|NCT01297569|Diabetic macular edema
349537|NCT01297569|Macular edema
349538|NCT01297569|DME
349539|NCT01297569|Diabetic retinopathy
349540|NCT01297569|Diabetic eye disease
349541|NCT01297569|anti-VEGF
349542|NCT01297569|ranibizumab
349543|NCT01297569|Lucentis
349544|NCT01297556|Irritable Bowel Syndrome
349545|NCT01297543|Induction chemotherapy
349546|NCT01297543|Re-induction chemotherapy
349547|NCT01297543|Consolidation chemotherapy
349548|NCT01297543|Leukemia
349549|NCT01297543|Myelodysplasia
349550|NCT01297530|Phase I
349551|NCT01297530|Dose Escalation
349552|NCT01297530|Hypoxia inducible factor 1 alpha
349553|NCT01297530|Neoplasms
349554|NCT01297517|AOG
349555|NCT01297517|OHT
349556|NCT01297517|Open-Angle Glaucoma
349557|NCT01297517|Ocular Hypertension
349558|NCT01297504|palivizumab
349559|NCT01297504|lower respiratory tract infection
349560|NCT01297504|Respiratory syncytial virus
349561|NCT01297504|usage patterns
349562|NCT01297491|NSCLC
349563|NCT01297491|PI3K
349564|NCT01297465|Ovulation Induction
349565|NCT01297465|Ovarian Stimulation
349566|NCT01297465|Reproductive Technique, Assisted
349567|NCT01297465|Assisted Reproductive Technics
349568|NCT01297465|Assisted Reproductive Technique
349569|NCT01297465|Reproductive Technology, Assisted
349570|NCT01297452|BKM120
349571|NCT01297452|CARBOPLATIN
349572|NCT01297452|TAXOL (PACLITAXEL)
349573|NCT01297452|Chemotherapy
349574|NCT01297452|10-192
349575|NCT01297439|shoulder dystocia,
349576|NCT01297439|Mac Roberts' maneuver,
349577|NCT01297439|pushing maneuver
349578|NCT01297413|allogeneic
349579|NCT01297413|adult
349580|NCT01297413|stem
349581|NCT01297413|cells
349582|NCT01297413|stroke
349583|NCT01297413|ischemic
349584|NCT01297400|Burns, Partial Thickness Burns
349585|NCT01297387|Diabetic Patients
349586|NCT01297387|Critical Limb Ischemia
349587|NCT01297387|Revascularization
349588|NCT01297374|Obesity
349589|NCT01297348|Lybrel
349590|NCT01297348|levonorgestrel
349591|NCT01297348|ethinyl estradiol
349592|NCT01297348|venus thromboembolism (VTE)
349593|NCT01297348|oral contraceptives (OC)
349594|NCT01297348|safety
349595|NCT01297348|database study
349596|NCT01297348|case-control study
349597|NCT01297335|intrathecal
349598|NCT01297335|clonidine
349599|NCT01297335|poorly
349600|NCT01297335|controlled
349601|NCT01297335|hypertension
349602|NCT01297322|vascular closure system
349603|NCT01297322|manual compression
349604|NCT01297322|femoral arteriotomy
349605|NCT01297322|percutaneous endovascular procedures
349606|NCT01297309|PTH 1-84
349607|NCT01297309|Hypoparathyroidism
349608|NCT01297309|Parathyroid Hormone 1-84
349609|NCT01297309|NPSP558
349610|NCT01297296|heart failure
349611|NCT01297296|percutaneous
349612|NCT01297296|interventional cardiology
349613|NCT01297296|apical remodeling
349614|NCT01297296|LV dilatation
349615|NCT01297296|akinesis
349616|NCT01297296|dyskinesis
349617|NCT01297296|myocardial infarction
349618|NCT01297283|Heart failure
349619|NCT01297283|Cardiac resynchronization
349620|NCT01297283|Leadless ECG
349621|NCT01297283|Follow-up
349622|NCT01297244|AV-951
349623|NCT01297244|Tivozanib
349624|NCT01297244|Advanced Renal Cell Carcinoma
349625|NCT01297244|RCC
349626|NCT01297244|Biomarkers
349627|NCT01297231|fibroglandular tissue
349628|NCT01297231|tamoxifen
349629|NCT01297231|MRI
349630|NCT01297231|Background Parenchymal Enhancement
349631|NCT01297231|10-217
349632|NCT01297218|Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood
349633|NCT01297205|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
349634|NCT01297205|Bronchopulmonary dysplasia
349635|NCT01297205|Premature infants
349636|NCT01297192|YM178
349637|NCT01297192|Mirabegron
349638|NCT01297192|DDI
349639|NCT01297192|Phase I
349640|NCT01297192|Solifenacin
349641|NCT01297192|Pharmacokinetics
349642|NCT01297192|Pharmacokinetics of mirabegron
349643|NCT01297179|Pharmacokinetics
349644|NCT01297179|Oral contraceptives
349645|NCT01297179|Drug interactions
349646|NCT01297179|Pharmacokinetics of mirabegron
349647|NCT01297153|Congenital Cataract
349648|NCT01297153|Children younger than 2 years
349649|NCT01297153|Aphakia
349650|NCT01297153|Primary IOL Implantation
349651|NCT01297140|Psychiatry
349652|NCT01297140|Behaviour
349653|NCT01297140|Alzheimer's
349654|NCT01297140|Personality
349655|NCT01297062|Diabetes
349656|NCT01297062|exenatide
349657|NCT01297062|Amylin
349658|NCT01297062|Lilly
349659|NCT01297062|QT interval
349660|NCT01297049|Diabetes
349661|NCT01297049|obesity
349662|NCT01297049|behavior therapy
349663|NCT01297049|self management
349664|NCT01297036|Pharmacokinetics
349665|NCT01297036|Bioequivalence
349666|NCT01297036|Donepezil
349667|NCT01297023|calcium phosphate
349668|NCT01297023|vitamin d3
349669|NCT01297023|bone metabolism
349670|NCT01297023|human study
349671|NCT01297010|Nausea and Vomiting
349672|NCT01297010|Vomiting
349673|NCT01297010|Postoperative
349674|NCT01297010|Anesthesia
349675|NCT01296997|calcium phosphate
349676|NCT01296997|incretins
349677|NCT01296997|human study
349678|NCT01296984|Rectal cancer
349679|NCT01296984|APR
349680|NCT01296958|Taenia solium
349681|NCT01296958|cysticercosis
349682|NCT01296958|neurocysticercosis
349683|NCT01296919|Chronic rhinosinusitis
349684|NCT01296919|Histopathology
349685|NCT01296919|Infundibulum
349686|NCT01296919|Lamina propria
349687|NCT01296919|Uncinate process
349688|NCT01296906|Reminder/recall messages
349689|NCT01296906|reminders
349690|NCT01296906|recall
349691|NCT01296906|immunizations
349692|NCT01296906|immunization information systems
349693|NCT01296906|effectiveness of reminder/recall
349694|NCT01296906|population-based reminder/recall
349695|NCT01296867|Laser ablation algorithms
349696|NCT01296867|Excimer laser
349697|NCT01296867|Refractive correction
349698|NCT01296867|Corneal Asphericity Adjustment
349699|NCT01296854|spa therapy
349700|NCT01296841|telemedicine
349701|NCT01296841|remote consultation
349702|NCT01296841|telehealth
349703|NCT01296841|ehealth
349704|NCT01296841|image archiving
349705|NCT01296841|inflammatory bowel disease
349706|NCT01296815|Kaposi sarcoma
349707|NCT01296815|HIV
349708|NCT01296815|Bevacizumab
349709|NCT01296802|Ecstasy
349710|NCT01296802|MDMA
349711|NCT01296802|Serotonin
349712|NCT01296802|Neurotoxicity
349713|NCT01296802|dexfenfluramine
349714|NCT01296802|Positron emission tomography
349715|NCT01296802|altanserin
349716|NCT01296802|5-HT2A receptor
349717|NCT01296776|exercise
349718|NCT01296776|whole-body electromyostimulation
349719|NCT01296776|bone mineral density
349720|NCT01296776|falls
349721|NCT01296776|physical fitness
349722|NCT01296776|pain
349723|NCT01296763|Irinotecan
349724|NCT01296763|Cisplatin
349725|NCT01296763|Carboplatin
349726|NCT01296763|Mitomycin-C
349727|NCT01296763|Olaparib
349728|NCT01296763|AZD2281
349729|NCT01296711|Rheumatoid arthritis
349730|NCT01296711|CDP6038
349731|NCT01296711|Interleukin-6
349732|NCT01296698|Smoking Cessation
349733|NCT01296698|Tobacco Use Disorder
349734|NCT01296685|cardiovascular surgical procedure
349735|NCT01296672|Finasteride
349736|NCT01296672|Placebo
349737|NCT01296672|Prostate cancer
349738|NCT01296672|Prostate Specific Antigen (PSA)
349739|NCT01296672|Men at intermediate risk of prostate cancer
349740|NCT01296672|Men scheduled for prostate biopsy
349741|NCT01296659|sarcoma
349742|NCT01296659|Ridaforolimus
349743|NCT01296659|soft tissue sarcoma
349744|NCT01296659|unresectable sarcoma
349745|NCT01296646|Alcohol
349746|NCT01296646|Alcoholics
349747|NCT01296646|Substance Abuse
349748|NCT01296646|Alcohol Abuse
349749|NCT01296646|Alcohol Addiction
349750|NCT01296633|health literacy
349751|NCT01296633|patient education
349752|NCT01296633|medication adherence
349753|NCT01296633|patient/provider communication
349754|NCT01296633|Diabetes Mellitus
349755|NCT01296607|Pharmacodynamics
349756|NCT01296607|Pharmacokinetics
349757|NCT01296607|Urocortin 2
349758|NCT01296607|Urocortin 3
349759|NCT01296607|Reproducibility
349760|NCT01296607|Onset/ Offset
349761|NCT01296607|Forearm blood flow
349762|NCT01296607|Plethysmography
349763|NCT01296607|Heart Failure
349764|NCT01296581|Cancer
349765|NCT01296581|Tumors
349766|NCT01296581|VEGFR
349767|NCT01296581|PDGFR
349768|NCT01296568|metastatic solid tumors
349769|NCT01296568|Malignant/M-Neoplasm
349770|NCT01296568|Pancreas NOS
349771|NCT01296568|Absorption
349772|NCT01296568|Distribution
349773|NCT01296568|Metabolism
349774|NCT01296568|Excretion
349775|NCT01296568|Mass balance
349776|NCT01296568|Metabolic profile
349777|NCT01296568|Radiolabeled study
349778|NCT01296516|Women
349779|NCT01296516|Postpartum
349780|NCT01296516|GDM
349781|NCT01296503|Multiple Myeloma
349782|NCT01296503|Treatment
349783|NCT01296503|Maintenance
349784|NCT01296503|Thalidomide
349785|NCT01296490|oxidative stress, physical exercise, fitness level
349786|NCT01296477|Asthma
349787|NCT01296477|ASTHMA IQ tool
349788|NCT01296477|Asthma Control Test (ACT)
349789|NCT01296477|EPR-3 Guidelines, Exacerbations
349790|NCT01296464|Parkinson's Disease
349791|NCT01296464|Motor response
349792|NCT01296464|Wearing-off
349793|NCT01296451|Hepatitis C
349794|NCT01296451|vaccine
349795|NCT01296451|Adenovirus
349796|NCT01296451|MVA
349797|NCT01296451|chronic infection
349798|NCT01296451|interferon
349799|NCT01296451|ribavirin
349800|NCT01296425|Growth disorders
349801|NCT01296425|Saizen
349802|NCT01296425|Easypod
349803|NCT01296425|Growth hormone
349804|NCT01296425|Pediatric subject
349805|NCT01296399|in stent restenosis
349806|NCT01296399|bare metal stent
349807|NCT01296399|drug eluting stent
349808|NCT01296399|de novo lesion
349809|NCT01296373|HIV-1
349810|NCT01296373|immune
349811|NCT01296373|restoration
349812|NCT01296373|observational
349813|NCT01296360|immune response
349814|NCT01296360|IC51-325
349815|NCT01296360|Japanese Encephalitis
349816|NCT01296360|Intercell AG
349817|NCT01296347|Ketamine
349818|NCT01296347|Thoracotomy
349819|NCT01296347|VATS
349820|NCT01296347|Pain
349821|NCT01296334|opioids
349822|NCT01296334|analgesia
349823|NCT01296334|secondary hyperalgesia
349824|NCT01296334|quantitative sensory testing
349825|NCT01296334|inflammatory injury
349826|NCT01296308|Diabetes Mellitus, Type 2
349827|NCT01296308|Diabetic Neuropathy
349828|NCT01296308|Complementary Medicine
349829|NCT01296308|Alternative Medicine
349830|NCT01296308|Integrative Medicine
349831|NCT01296308|Quality of Life
349832|NCT01296308|Quantitative Sensory Testing
349833|NCT01296295|smoking cessation advice
349834|NCT01296295|spirometry
349835|NCT01296295|primary health care
349836|NCT01296269|social cognition
349837|NCT01296269|oxytocin
349838|NCT01296269|vasopressin
349839|NCT01296269|decision making
349840|NCT01296269|social decision making
349841|NCT01296256|Bendamustine
349842|NCT01296256|Conditioning Therapy
349843|NCT01296256|Autologous Stem Cell Transplant
349844|NCT01296256|Aggressive Non Hodgkin's Lymphoma
349845|NCT01296243|Castration-resistant prostate cancer
349846|NCT01296243|Tesetaxel
349847|NCT01296243|Taxanes
349848|NCT01296243|Chemotherapy-naive
349849|NCT01296243|Chemotherapy-exposed
349850|NCT01296243|Progressive, metastatic castration-resistant prostate cancer
349851|NCT01296217|Patients with infiltrant prostatic carcinoma
349852|NCT01296165|Travel
349853|NCT01296165|Spread
349854|NCT01296165|Antibiotic resistance
349855|NCT01296139|Non-Cutaneous Malignancy
349856|NCT01296139|Prostatectomy
349857|NCT01296139|Metastatic Prostate Cancer
349858|NCT01296139|Imaging Study
349859|NCT01296139|Magnetic Resonance Imaging
349860|NCT01296139|Prostate Cancer
349861|NCT01296126|Post Traumatic Stress Disorder (PTSD)
349862|NCT01296126|MRI
349863|NCT01296126|TBI
349864|NCT01296126|Traumatic Brain Injury
349865|NCT01296126|Post Traumatic Stress Disorder
349866|NCT01296126|PTSD
349867|NCT01296100|impaired glucose tolerance
349868|NCT01296100|nutrition
349869|NCT01296100|physical activity
349870|NCT01296087|Asthma
349871|NCT01296087|Mild to Moderate Asthma
349872|NCT01296074|monocyte
349873|NCT01296074|cardiopulmonary bypass
349874|NCT01296074|cardiac surgery
349875|NCT01296061|Dialysis
349876|NCT01296061|Renal Transplantation
349877|NCT01296061|Failure of allograft
349878|NCT01296048|weight
349879|NCT01296048|body fat
349880|NCT01296048|total body water
349881|NCT01296048|bone mass
349882|NCT01296048|muscle mass
349883|NCT01296035|recurrent ovarian cancer
349884|NCT01296035|platinum-refractory ovarian cancer
349885|NCT01296022|Heart rhythm disturbances
349886|NCT01296022|Implantable cardiac defibrillator
349887|NCT01296009|embryonic implantation
349888|NCT01296009|endometrial receptivity
349889|NCT01296009|traditional Chinese medicines
349890|NCT01296009|in vitro fertilization-embryo transfer
349891|NCT01296009|pregnant rate
349892|NCT01295970|Surgery of the brain
349893|NCT01295970|Radiosurgery
349894|NCT01295970|Brain Metastasis
349895|NCT01295944|Chemotherapy
349896|NCT01295944|Brain Tumor
349897|NCT01295944|Spinal Cord Tumor
349898|NCT01295944|Malignancy
349899|NCT01295944|Neurologic
349900|NCT01295931|Near-infrared
349901|NCT01295931|NIR
349902|NCT01295931|Indocyanine green
349903|NCT01295931|ICG
349904|NCT01295931|Melanoma
349905|NCT01295931|Fluorescent dyes
349906|NCT01295931|Lymph nodes
349907|NCT01295931|Experimental camera
349908|NCT01295918|probiotic
349909|NCT01295918|AAD
349910|NCT01295918|Lactobacillus reuteri
349911|NCT01295918|diarrhea
349912|NCT01295892|menopause
349913|NCT01295892|obesity
349914|NCT01295892|capillary
349915|NCT01295892|microcirculation
349916|NCT01295892|estrogen
349917|NCT01295892|Microvascular Function
349918|NCT01295879|Vitamin D insufficiency
349919|NCT01295866|chronic nasal inflammation
349920|NCT01295866|nasal nitric oxide
349921|NCT01295866|atopy
349922|NCT01295827|Melanoma
349923|NCT01295827|Carcinoma
349924|NCT01295827|Cancer
349925|NCT01295827|Advanced cancer
349926|NCT01295827|Metastatic cancer
349927|NCT01295827|Metastatic melanoma
349928|NCT01295827|PD-1
349929|NCT01295827|PD1
349930|NCT01295814|Interstitial cystitis
349931|NCT01295814|Humira
349932|NCT01295814|Adalimumab
349933|NCT01295801|Linezolid
349934|NCT01295801|Vitamin B6
349935|NCT01295801|Linezolid-associated cytopenias
349936|NCT01295775|diabetic retinopathy
349937|NCT01295775|sulodexide
349938|NCT01295775|hard exudates
349939|NCT01295775|microaneurysms
349940|NCT01295775|hemorrhages
349941|NCT01295775|intraretinal microvascular abnormalities
349942|NCT01295762|Children
349943|NCT01295762|Cancer
349944|NCT01295762|Immunomonitoring
349945|NCT01295762|Prognostic/Predictive Factors
349946|NCT01295762|Immunotherapy
349947|NCT01295749|cardiac arrest
349948|NCT01295749|No Flow
349949|NCT01295749|Emergency
349950|NCT01295749|Nurse
349951|NCT01295749|laryngeal Tube
349952|NCT01295736|scleroderma
349953|NCT01295736|digital
349954|NCT01295736|ulcer
349955|NCT01295723|Breast cancer
349956|NCT01295723|Radiation therapy
349957|NCT01295723|Mobetron
349958|NCT01295723|IOERT
349959|NCT01295723|IORT
349960|NCT01295723|Hypofractionated radiation therapy
349961|NCT01295723|Partial breast radiation
349962|NCT01295710|adult acute myeloid leukemia
349963|NCT01295710|adult acute lymphoid leukemia
349964|NCT01295710|adult myelodysplastic syndrome
349965|NCT01295710|allogenic stem cell transplantation
349966|NCT01295710|unrelated donor
349967|NCT01295710|GVHD
349968|NCT01295710|US-ATG-F (Anti-human-T-lymphocyte Immune Globulin, Rabbit)
349969|NCT01295697|Patients with non-CNS or CNS tumors
349970|NCT01295697|Pediatric patients with Relapsed/Refractory Solid Tumors
349971|NCT01295684|cranberry
349972|NCT01295684|cardiovascular
349973|NCT01295684|adhesion
349974|NCT01295684|polyphenol
349975|NCT01295658|cancer
349976|NCT01295658|cancer survivor ship
349977|NCT01295658|psychosocial needs
349978|NCT01295658|cancer experience
349979|NCT01295658|metastatic breast cancer
349980|NCT01295658|multiple myeloma
349981|NCT01295658|chronic myeloid leukemia
349982|NCT01295658|breast cancer
349983|NCT01295658|Prostate
349984|NCT01295658|Colon
349985|NCT01295658|Kidney
349986|NCT01295658|Lung
349987|NCT01295645|Stem Cell Transplant
349988|NCT01295645|Hemorrhagic Cystitis
349989|NCT01295645|Bladder inflammation
349990|NCT01295645|Frequent urination
349991|NCT01295645|Pain
349992|NCT01295645|Polyomavirus hominis type I
349993|NCT01295645|BK virus
349994|NCT01295645|BKV
349995|NCT01295645|Cidofovir
349996|NCT01295645|Vistide
349997|NCT01295632|Recurrent glioblastoma multiforme
349998|NCT01295632|Hormone resistant prostate cancer
349999|NCT01295632|Relapsed ovarian carcinoma
350000|NCT01295632|Refractory ovarian carcinoma
350001|NCT01295632|Refractory breast cancer
350002|NCT01295632|Relapsed breast cancer
350003|NCT01295619|Dura
350004|NCT01295619|Sealant
350005|NCT01295619|Cranial
350006|NCT01295619|Craniotomy
350007|NCT01295619|CSF leakage
350008|NCT01295619|CSF leakage following cranial surgery
350009|NCT01295606|cefazolin
350010|NCT01295606|prophylaxis
350011|NCT01295606|pharmacokinetics
350012|NCT01295606|newborn
350013|NCT01295593|CLL previously treated
350014|NCT01295567|ischemia reperfusion injury
350015|NCT01295567|CABG
350016|NCT01295567|dipyridamole
350017|NCT01295567|HS-troponin-I
350018|NCT01295554|Peripheral arterial disease, MRA
350019|NCT01295541|ICU LOS
350020|NCT01295541|Progressive Mobility
350021|NCT01295541|Deconditioning
350022|NCT01295528|blood pressure
350023|NCT01295528|heart rate
350024|NCT01295515|HIV
350025|NCT01295515|Replication
350026|NCT01295515|Antiretroviral
350027|NCT01295515|Interferon
350028|NCT01295515|Reservoirs
350029|NCT01295476|adult acute lymphoblastic leukemia in remission
350030|NCT01295476|childhood acute lymphoblastic leukemia in remission
350031|NCT01295476|recurrent adult acute lymphoblastic leukemia
350032|NCT01295476|recurrent childhood acute lymphoblastic leukemia
350033|NCT01295476|T-cell adult acute lymphoblastic leukemia
350034|NCT01295476|T-cell childhood acute lymphoblastic leukemia
350035|NCT01295463|sexual dysfunction
350036|NCT01295463|psychosocial effects of cancer and its treatment
350037|NCT01295463|infertility
350038|NCT01295463|colon cancer
350039|NCT01295463|male breast cancer
350040|NCT01295463|breast cancer
350041|NCT01295463|germ cell tumor
350042|NCT01295463|ovarian sarcoma
350043|NCT01295463|uterine sarcoma
350044|NCT01295463|chronic lymphocytic leukemia
350045|NCT01295463|osteosarcoma
350046|NCT01295463|chronic myelogenous leukemia
350047|NCT01295463|non-Hodgkin lymphoma
350048|NCT01295463|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
350049|NCT01295463|adult acute myeloid leukemia with inv(16)(p13;q22)
350050|NCT01295463|adult acute myeloid leukemia with t(15;17)(q22;q12)
350051|NCT01295463|adult acute myeloid leukemia with t(16;16)(p13;q22)
350052|NCT01295463|adult acute myeloid leukemia with t(8;21)(q22;q22)
350053|NCT01295463|mast cell leukemia
350054|NCT01295463|hairy cell leukemia
350055|NCT01295463|prolymphocytic leukemia
350056|NCT01295463|adult acute lymphoblastic leukemia
350057|NCT01295463|adult acute myeloid leukemia
350058|NCT01295463|adult Hodgkin lymphoma
350059|NCT01295463|adult T-cell leukemia/lymphoma
350060|NCT01295463|small intestine lymphoma
350061|NCT01295463|anaplastic large cell lymphoma
350062|NCT01295463|angioimmunoblastic T-cell lymphoma
350063|NCT01295463|mycosis fungoides/Sezary syndrome
350064|NCT01295463|intraocular lymphoma
350065|NCT01295463|primary central nervous system non-Hodgkin lymphoma
350066|NCT01295463|primary central nervous system Hodgkin lymphoma
350067|NCT01295463|noncutaneous extranodal lymphoma
350068|NCT01295463|secondary acute myeloid leukemia
350069|NCT01295463|acute undifferentiated leukemia
350070|NCT01295463|central nervous system leukemia
350071|NCT01295463|T-cell large granular lymphocyte leukemia
350072|NCT01295463|atypical chronic myeloid leukemia, BCR-ABL1 negative
350073|NCT01295463|clear cell sarcoma of the kidney
350074|NCT01295463|Kaposi sarcoma
350075|NCT01295463|adult soft tissue sarcoma
350076|NCT01295463|chronic myelomonocytic leukemia
350077|NCT01295463|secondary central nervous system Hodgkin lymphoma
350078|NCT01295463|cutaneous lymphoma
350079|NCT01295463|adult non-Hodgkin lymphoma
350080|NCT01295450|Phase III
350081|NCT01295450|Apevinat BC
350082|NCT01295450|Lack of appetite
350083|NCT01295437|inguinal hernia, Lichtenstein hernioplasty, chronic pain
350084|NCT01295424|Cardiac Arrest
350085|NCT01295424|Intensive Care Unit
350086|NCT01295424|Emergency Medical Service
350087|NCT01295385|type 2 diabetes
350088|NCT01295385|Cardiovascular diseases
350089|NCT01295385|coronary syndrome have abnormalities of glucidic metabolism
350090|NCT01295372|Schizophrenia
350091|NCT01295372|Antipsychotic
350092|NCT01295372|Risperidone
350093|NCT01295372|Lu 31-130
350094|NCT01295359|Chronic Obstructive Pulmonary Disease
350095|NCT01295359|Walking
350096|NCT01295359|Hospital
350097|NCT01295359|Exercise Tolerance
350098|NCT01295359|Physical Therapy
350099|NCT01295320|Herpes Zoster
350100|NCT01295320|vaccine
350101|NCT01295320|safety
350102|NCT01295320|immunogenicity
350103|NCT01295307|acute myeloid leukemia
350104|NCT01295307|relapsed
350105|NCT01295307|refractory
350106|NCT01295307|Relapsed or refractory AML
350107|NCT01295294|Uterine Hemorrhage
350108|NCT01295294|Contraception
350109|NCT01295294|Contraceptive Methods
350110|NCT01295294|Intrauterine devices
350111|NCT01295294|Mirena
350112|NCT01295268|Vulvar pain
350113|NCT01295268|Vulvodynia
350114|NCT01295268|Vestibulodynia
350115|NCT01295268|Vulvar vestibulitis
350116|NCT01295255|Allergic rhinitis
350117|NCT01295255|Psychological status
350118|NCT01295255|Asthma
350119|NCT01295255|Aeroallergen
350120|NCT01295242|HPV
350121|NCT01295242|Cervical Cancer
350122|NCT01295216|prehypertension
350123|NCT01295216|blood pressure
350124|NCT01295216|mobile technology
350125|NCT01295216|Latin America
350126|NCT01295216|behavioral change
350127|NCT01295216|healthy lifestyles
350128|NCT01295216|mHealth
350129|NCT01295177|wound healing
350130|NCT01295177|diabetes mellitus
350131|NCT01295164|keratoconus, wave-front sensing technology, aberrometer
350132|NCT01295138|Constipation
350133|NCT01295138|Caesarean section
350134|NCT01295138|Abdominal Pain
350135|NCT01295138|Nausea
350136|NCT01295138|Vomiting
350137|NCT01295125|Infected ventral hernia
350138|NCT01295125|Contaminated incisional hernia
350139|NCT01295099|scar formation
350140|NCT01295099|5-FU
350141|NCT01295099|genetic link
350142|NCT01295099|psychological impact
350143|NCT01295099|social impact
350144|NCT01295086|Adenocarcinoma of the gastro-esophageal
350145|NCT01295086|Her2
350146|NCT01295086|Dose finding
350147|NCT01295086|Taxotere (Docetaxel)
350148|NCT01295086|Eloxatin (Oxaliplatin)
350149|NCT01295086|Xeloda (Capecitabine)
350150|NCT01295086|Herceptin (Trastuzumab)
350151|NCT01295073|Trientine
350152|NCT01295073|Cataract surgery
350153|NCT01295073|Macular Edema
350154|NCT01295060|Acromegaly
350155|NCT01295060|Octreotide
350156|NCT01295060|IGF-1
350157|NCT01295060|Growth Hormone
350158|NCT01295060|Implant
350159|NCT01295060|Hydrogel
350160|NCT01295047|Marfan Syndrome
350161|NCT01295047|Large arterial function
350162|NCT01295047|LV function
350163|NCT01295047|atenolol
350164|NCT01295047|perindopril
350165|NCT01295047|verapamil
350166|NCT01295047|central arterial pressure
350167|NCT01295034|HIV
350168|NCT01295034|combination antiretroviral therapy
350169|NCT01295034|vitamin D
350170|NCT01295034|low bone density
350171|NCT01295021|The prevalence of sympathetic overactivity in hypertensive patients.
350172|NCT01295008|Fabry disease
350173|NCT01295008|Male pattern baldness
350174|NCT01295008|Alopecia
350175|NCT01295008|GLA gene mutation
350176|NCT01295008|Alpha-galactosidase A
350177|NCT01294995|short term consumption
350178|NCT01294995|Chinese liquor
350179|NCT01294995|serum lipids
350180|NCT01294995|uric acid
350181|NCT01294995|inflammation biomarkers
350182|NCT01294982|OAB
350183|NCT01294982|Over Active Bladder
350184|NCT01294982|overactive bladder
350185|NCT01294982|Urinary Urge Incontinence
350186|NCT01294982|Urinary Incontinence
350187|NCT01294969|Allergic conjunctivitis
350188|NCT01294956|Dry eye
350189|NCT01294956|artificial tears
350190|NCT01294956|corneal staining
350191|NCT01294943|Intensive Care Units
350192|NCT01294943|Biofilms
350193|NCT01294943|Tongue
350194|NCT01294943|Infection
350195|NCT01294943|Pneumonia/Aspiration
350196|NCT01294930|hip fracture
350197|NCT01294930|mortality
350198|NCT01294930|complications
350199|NCT01294904|Hormone
350200|NCT01294904|Sperm
350201|NCT01294904|Chronic kidney disease
350202|NCT01294891|Rheology
350203|NCT01294891|Sickle cell
350204|NCT01294891|Paroxysmal nocturnal hemoglobinuria
350205|NCT01294891|contrast ultrasound
350206|NCT01294878|anti-IgE treatment
350207|NCT01294878|interstitial cystitis/bladder pain syndrome
350208|NCT01294878|omalizumab
350209|NCT01294865|Sepsis
350210|NCT01294865|late-onset
350211|NCT01294865|suPAR
350212|NCT01294852|prophylactic
350213|NCT01294852|surfactant
350214|NCT01294852|premature
350215|NCT01294852|mechanical ventilation
350216|NCT01294852|mortality
350217|NCT01294852|morbidities
350218|NCT01294839|sinus-node dysfunction
350219|NCT01294839|RVOTs pacing
350220|NCT01294839|RVA pacing
350221|NCT01294826|Colorectal Neoplasms
350222|NCT01294826|Intestinal Neoplasms
350223|NCT01294826|Gastrointestinal Neoplasms
350224|NCT01294826|Digestive System Neoplasms
350225|NCT01294826|Neoplasms by Site
350226|NCT01294826|Neoplasms
350227|NCT01294826|Digestive System Diseases
350228|NCT01294826|Gastrointestinal Diseases
350229|NCT01294826|Colonic Diseases
350230|NCT01294826|Intestinal Diseases
350231|NCT01294826|Rectal Diseases
350232|NCT01294826|Cetuximab
350233|NCT01294826|HSP90 Heat-Shock Proteins
350234|NCT01294826|EGFR protein, human
350235|NCT01294813|Electric Impedance Tomography (EIT)
350236|NCT01294813|Ventilation
350237|NCT01294813|Bronchoscopy
350238|NCT01294813|Lung Impedance
350239|NCT01294813|Recruitment
350240|NCT01294800|Parkinson's disease
350241|NCT01294787|COPD
350242|NCT01294787|QVA149
350243|NCT01294787|tiotropium
350244|NCT01294787|exercise
350245|NCT01294787|exercise tolerance
350246|NCT01294787|combination bronchodilator
350247|NCT01294787|moderate to severe COPD
350248|NCT01294774|Lupus erythematosus
350249|NCT01294774|skin lupus
350250|NCT01294761|HIV-1
350251|NCT01294761|AIDS
350252|NCT01294761|Clinical Trials, Randomized
350253|NCT01294748|Coronary Artery Disease
350254|NCT01294748|Drug-eluting Stent
350255|NCT01294748|Sirolimus
350256|NCT01294735|Temozolomide
350257|NCT01294735|glioblastoma multiforme
350258|NCT01294735|melanoma
350259|NCT01294735|advanced neoplasm
350260|NCT01294722|Rheumatoid Arthritis
350261|NCT01294722|anti-TNF α
350262|NCT01294709|angina pectoris
350263|NCT01294709|coronary artery disease
350264|NCT01294709|calcitonin gene-related peptide
350265|NCT01294709|exercise tolerance,
350266|NCT01294696|Osteoarthritis
350267|NCT01294696|Standard of care
350268|NCT01294683|Low-density lipoprotein
350269|NCT01294683|LDL
350270|NCT01294683|High-density lipoprotein
350271|NCT01294683|HDL
350272|NCT01294683|Niacin
350273|NCT01294683|Lipid modifying therapy
350274|NCT01294683|Cholesterol
350275|NCT01294683|High cholesterol
350276|NCT01294683|Triglycerides
350277|NCT01294683|Mixed Dyslipidemia
350278|NCT01294670|ETOPOSIDE (VP-16)
350279|NCT01294670|SAHA (SUBEROYLANILIDE HYDROXAMIC ACID) (Vorinostat)
350280|NCT01294670|Pediatric
350281|NCT01294670|10-096
350282|NCT01294670|POETIC
350283|NCT01294670|phase II component: the population will be restricted to relapsed/refractory sarcomas.
350284|NCT01294657|Obesity
350285|NCT01294657|Cancer Risk
350286|NCT01294657|African Americans
350287|NCT01294657|Diet
350288|NCT01294657|Physical Activity
350289|NCT01294631|Canagliflozin
350290|NCT01294631|JNJ-28431754
350291|NCT01294631|Hydrochlorothiazide
350292|NCT01294631|Pharmacokinetic
350293|NCT01294631|Pharmacodynamic
350294|NCT01294618|Chronic Myelogenous Leukemia
350295|NCT01294618|nilotinib
350296|NCT01294618|pegylated interferon
350297|NCT01294618|BCR-ABL Philadelphia chromosome
350298|NCT01294618|Hematologic, cytogenetic and molecular response rates and kinetics will be studied in addition to the safety of the combination
350299|NCT01294605|DTPa
350300|NCT01294605|Td
350301|NCT01294605|IPV
350302|NCT01294579|Non-Hodgkin's Lymphoma
350303|NCT01294579|Ofatumumab
350304|NCT01294579|Relapsed
350305|NCT01294579|Rituximab
350306|NCT01294579|Bendamustine
350307|NCT01294566|safety
350308|NCT01294566|motilin agonist
350309|NCT01294566|single dose
350310|NCT01294566|ascending dose
350311|NCT01294566|GSK1322888
350312|NCT01294566|migrating motor complex
350313|NCT01294566|tolerability
350314|NCT01294566|FTIH
350315|NCT01294566|gastric emptying
350316|NCT01294527|Cardiac Resynchronization Therapy
350317|NCT01294527|cardiac pacing
350318|NCT01294527|electrical stimulation
350319|NCT01294527|bi-ventricular pacing
350320|NCT01294514|Respiratory Rate
350321|NCT01294501|Medication administration
350322|NCT01294501|Medication errors
350323|NCT01294501|Health Literacy
350324|NCT01294501|Pediatric Emergency Department
350325|NCT01294501|Web-based education
350326|NCT01294488|PCIT
350327|NCT01294488|Child Maltreatment Prevention
350328|NCT01294488|Practitioner Fidelity
350329|NCT01294462|acute coronary syndrome
350330|NCT01294462|coronary disease
350331|NCT01294462|coronary artery disease
350332|NCT01294436|Phase3
350333|NCT01294436|Clinical trial
350334|NCT01294436|Type 2 Diabetes Mellitus
350335|NCT01294423|Phase3
350336|NCT01294423|Clinical trial
350337|NCT01294423|Type2 Diabetes Mellitus
350338|NCT01294397|Amgen
350339|NCT01294397|Phase 1
350340|NCT01294397|Postmenopausal
350341|NCT01294397|Osteopenia
350342|NCT01294397|Rheumatoid
350343|NCT01294397|Bone Mineral Density
350344|NCT01294397|Arthritis
350345|NCT01294397|Pharmacokinetics
350346|NCT01294397|Osteoporosis
350347|NCT01294371|Lucrin Depot
350348|NCT01294371|genital endometriosis
350349|NCT01294371|6 months therapy
350350|NCT01294358|Pancreatic Cancer
350351|NCT01294358|Regional Therapy
350352|NCT01294358|Selective Arterial Infusion
350353|NCT01294358|Locally Advanced Disease
350354|NCT01294345|Birth Defects
350355|NCT01294345|Genomics
350356|NCT01294345|Congenital Malformations
350357|NCT01294332|Cognition
350358|NCT01294332|TBI
350359|NCT01294332|Mood
350360|NCT01294332|Aerobic Exercise Training
350361|NCT01294332|Cardiorespiratory Fitness
350362|NCT01294332|Traumatic Brain Injury
350363|NCT01294319|Cortical Resistance
350364|NCT01294319|ACTH
350365|NCT01294319|Glucocorticoid
350366|NCT01294319|Mifepristone
350367|NCT01294319|SPIRONOLACTONE
350368|NCT01294319|Exercise
350369|NCT01294319|Hypothalamic-Pituitary-Adrenal Axis
350370|NCT01294319|Healthy Volunteer
350371|NCT01294319|HV
350372|NCT01294280|Stage I Non-Small Cell Lung Cancer
350373|NCT01294280|Stage II Non-Small Cell Lung Cancer
350374|NCT01294267|Ventricular Tachycardia
350375|NCT01294267|Radio Frequency Ablation
350376|NCT01294267|Percutaneous Left Ventricular Assist Device
350377|NCT01294267|Hemodynamic Management
350378|NCT01294267|Interventional Cardiac Procedure
350379|NCT01294267|Mechanical Cardiac Assistance
350380|NCT01294267|Intra-Aortic Balloon Pump
350381|NCT01294267|Coronary Intervention
350382|NCT01294267|Impella 2.5
350383|NCT01294267|Circulation Support system
350384|NCT01294254|wound reepithelialization
350385|NCT01294241|Epidermolysis bullosa
350386|NCT01294241|Wound healing
350387|NCT01294241|Epithelialization
350388|NCT01294215|BAYA1040
350389|NCT01294215|Nifedipine
350390|NCT01294215|Essential hypertension
350391|NCT01294215|Japanese Patients
350392|NCT01294215|Phase III
350393|NCT01294215|combination study
350394|NCT01294215|14024
350395|NCT01294202|GIST
350396|NCT01294202|Gastrointestinal Stromal Tumor
350397|NCT01294202|unresectable
350398|NCT01294202|metastatic
350399|NCT01294202|AT13387
350400|NCT01294202|Astex
350401|NCT01294202|Gleevec
350402|NCT01294202|Imatinib
350403|NCT01294189|end-of-life decisions, critical care, advance directive
350404|NCT01294176|Optic Neuritis
350405|NCT01294176|Lipoic Acid
350406|NCT01294176|Multiple Sclerosis
350407|NCT01294176|Antioxidant
350408|NCT01294176|OCT
350409|NCT01294176|Acute
350410|NCT01294163|Xenon
350411|NCT01294163|Sevoflurane
350412|NCT01294163|Propofol
350413|NCT01294163|Total intravenous anaesthesia
350414|NCT01294163|Anaesthesia
350415|NCT01294163|Coronary artery disease
350416|NCT01294163|Coronary artery bypass graft
350417|NCT01294137|frail
350418|NCT01294137|elderly
350419|NCT01294137|hospitalized
350420|NCT01294137|sleep apnea
350421|NCT01294137|oximetry
350422|NCT01294111|Fatigue
350423|NCT01294111|Quality of life
350424|NCT01294111|Elderly
350425|NCT01294098|Femoral Fractures
350426|NCT01294098|Pediatrics
350427|NCT01294098|Pain, Postoperative
350428|NCT01294072|curcumin
350429|NCT01294072|plant exosomes
350430|NCT01294072|malignant colon tissue
350431|NCT01294059|Fibromyalgia
350432|NCT01294059|Hyperalgesia
350433|NCT01294059|Pain
350434|NCT01294059|Central Sensitization
350435|NCT01294046|Episodic migraine headache
350436|NCT01294020|Transplant
350437|NCT01294020|Liver
350438|NCT01294020|Kidney
350439|NCT01294020|Heart
350440|NCT01294020|Lung
350441|NCT01294020|Immunosuppression
350442|NCT01294020|Advagraf
350443|NCT01294020|Pharmacokinetics
350444|NCT01293994|Chronic Pain, Genetic Variation, Opioid Medications, Pain
350445|NCT01293968|Aphthous Stomatitis
350446|NCT01293968|Ibuprofen
350447|NCT01293968|treatment efficacy
350448|NCT01293955|cartilage
350449|NCT01293955|knee osteoarthritis
350450|NCT01293955|protective effect
350451|NCT01293942|unresectable liver-only metastases in colorectal cancer
350452|NCT01293916|pediatric
350453|NCT01293916|femur
350454|NCT01293916|femoral
350455|NCT01293916|fracture
350456|NCT01293916|spica
350457|NCT01293916|cast
350458|NCT01293916|diaphyseal
350459|NCT01293916|single
350460|NCT01293916|double
350461|NCT01293916|patient age 2 to 6 years old
350462|NCT01293903|Immunomodulation
350463|NCT01293890|adherence
350464|NCT01293890|medication
350465|NCT01293890|exacerbations
350466|NCT01293890|hospital admission
350467|NCT01293877|Laparoscopy
350468|NCT01293877|obesity
350469|NCT01293877|gastric
350470|NCT01293877|restrictive
350471|NCT01293864|structural analysis, diffusible proteins, glycosaminoglycans
350472|NCT01293851|Biomarkers
350473|NCT01293851|Gene Expression
350474|NCT01293851|Neuropathic Pain
350475|NCT01293851|Neurotoxicity
350476|NCT01293851|Chemotherapy
350477|NCT01293851|Peripheral Neuropathic Pain
350478|NCT01293851|Cancer
350479|NCT01293838|Adolescents
350480|NCT01293838|Anxiety Disorder
350481|NCT01293838|Cipralex
350482|NCT01293838|Social Phobia
350483|NCT01293838|Separation Anxiety Disorder
350484|NCT01293838|Panic Disorder
350485|NCT01293838|Generalized Anxiety Disorder
350486|NCT01293838|physiological arousal
350487|NCT01293838|stress response
350488|NCT01293838|salivary cortisol
350489|NCT01293838|salivary alpha-amylase
350490|NCT01293838|heart rate variability
350491|NCT01293799|Randomized
350492|NCT01293799|Peritoneal dialysis
350493|NCT01293799|Peritonitis
350494|NCT01293799|Primary prevention
350495|NCT01293799|Quality control
350496|NCT01293799|Self care
350497|NCT01293799|Kidney failure, chronic
350498|NCT01293786|magnesium
350499|NCT01293786|kidney transplantation
350500|NCT01293786|hypomagnesemia
350501|NCT01293773|Randomized controlled trial
350502|NCT01293773|Drug-eluting Stent
350503|NCT01293773|Multicenter study
350504|NCT01293760|intrauterine device
350505|NCT01293760|contraception
350506|NCT01293747|Estrogen
350507|NCT01293747|Progesterone
350508|NCT01293747|Microspheres
350509|NCT01293747|Menopause
350510|NCT01293747|Pharmacokinetics
350511|NCT01293734|bronchial asthma
350512|NCT01293734|cold type
350513|NCT01293734|heat type
350514|NCT01293734|Asthenia type
350515|NCT01293734|TCM syndrome
350516|NCT01293734|symptoms
350517|NCT01293734|physical signs
350518|NCT01293721|Bone Mineral Density
350519|NCT01293721|Vibration
350520|NCT01293721|Rehabilitation
350521|NCT01293721|Fracture healing rate
350522|NCT01293708|Octogenarians
350523|NCT01293708|HRQOL
350524|NCT01293708|mortality
350525|NCT01293708|prospective observational
350526|NCT01293708|Elderly
350527|NCT01293695|hot flashes
350528|NCT01293695|post menopausal women
350529|NCT01293695|skin conductance monitors
350530|NCT01293695|hypnosis
350531|NCT01293695|hypnotizability
350532|NCT01293669|Type 2 Diabetes
350533|NCT01293669|Type 2 Diabetes Mellitus
350534|NCT01293604|Barley
350535|NCT01293604|Oats
350536|NCT01293604|Whole grains
350537|NCT01293604|Cardiovascular disease
350538|NCT01293604|adults not taking lipid-lowering or glucoregulatory medications.
350539|NCT01293591|Garlic
350540|NCT01293591|Cancer biomarkers
350541|NCT01293591|Gene expression
350542|NCT01293591|Oxidative stress
350543|NCT01293591|DNA damage
350544|NCT01293578|Decision Aids
350545|NCT01293578|Shared Medical Decision Making
350546|NCT01293578|Patient Education
350547|NCT01293578|Endocrine System Diseases
350548|NCT01293578|Glucose Metabolism Disorders
350549|NCT01293578|Metabolic Diseases
350550|NCT01293565|X-Linked Hypohidrotic Ectodermal Dysplasia
350551|NCT01293565|Hypohidrotic Ectodermal Dysplasia
350552|NCT01293565|XLHED
350553|NCT01293565|HED
350554|NCT01293539|Retinoblastoma
350555|NCT01293539|intra-arterial chemotherapy
350556|NCT01293539|angiography
350557|NCT01293526|Heart failure
350558|NCT01293526|echocardiography
350559|NCT01293513|Only patients with Acute or Primary HIV infection will be studied
350560|NCT01293500|SIRS
350561|NCT01293500|shock
350562|NCT01293500|sepsis
350563|NCT01293500|pediatric
350564|NCT01293500|inter-facility transport
350565|NCT01293500|specialized transport
350566|NCT01293500|NIRS monitoring
350567|NCT01293487|Phase 1
350568|NCT01293487|Osteopenia
350569|NCT01293487|RN564
350570|NCT01293448|Esophagectomy
350571|NCT01293448|Barrett's Esophagus
350572|NCT01293435|Community Acquired Pneumonia (CAP)
350573|NCT01293435|Complicated Skin and Skin Structures Infections (cSSSI)
350574|NCT01293435|Complicated Skin and Soft Tissues Infections (cSSTI)
350575|NCT01293435|Antibiotics
350576|NCT01293435|Infection management
350577|NCT01293435|Use of Resources
350578|NCT01293435|MRSA
350579|NCT01293435|PRSP
350580|NCT01293422|PXR, glucose, cholesterol
350581|NCT01293396|insulin aspart 30
350582|NCT01293396|insulin aspart 70
350583|NCT01293396|insulin aspart
350584|NCT01293396|postprandial glucose and lipid metabolism
350585|NCT01293396|consecutive mixed meals
350586|NCT01293344|Cardiovascular diseases
350587|NCT01293344|Controlled nutritional intervention
350588|NCT01293344|Sex differences
350589|NCT01293344|Women
350590|NCT01293344|Men
350591|NCT01293344|Cardiovascular risk
350592|NCT01293344|Lipid profile
350593|NCT01293344|Blood pressure
350594|NCT01293344|Insulin sensitivity
350595|NCT01293344|Inflammatory markers
350596|NCT01293344|Endothelial function
350597|NCT01293344|Oxidative stress
350598|NCT01293331|Dengue Fever Fever Seroprevalence
350599|NCT01293318|Copeptin
350600|NCT01293318|Vasopressin
350601|NCT01293318|antidiuretic hormone (ADH)
350602|NCT01293305|osteoarthritis
350603|NCT01293292|Osteoporosis
350604|NCT01293292|Forsteo
350605|NCT01293292|Teriparatide
350606|NCT01293279|HCV viral genotypes
350607|NCT01293279|host genotypes
350608|NCT01293279|IL28B
350609|NCT01293279|ITPA
350610|NCT01293279|RNA
350611|NCT01293279|China
350612|NCT01293266|Propofol
350613|NCT01293266|Metabolic Acidosis
350614|NCT01293266|Pediatric Cardiology
350615|NCT01293266|Anesthesia
350616|NCT01293227|Wrist Fracture
350617|NCT01293214|limb transplantation
350618|NCT01293214|limb allotransplantation
350619|NCT01293214|hand transplantation
350620|NCT01293214|hand allotransplantation
350621|NCT01293214|hand amputation
350622|NCT01293214|leg transplantation
350623|NCT01293201|SAR
350624|NCT01293201|Seasonal Allergic Rhinitis
350625|NCT01293188|Aortic Valve Replacement
350626|NCT01293188|Bioprosthetic
350627|NCT01293175|whole grains
350628|NCT01293175|polyphenols
350629|NCT01293175|overweight
350630|NCT01293175|bioavailability
350631|NCT01293175|antioxidant status
350632|NCT01293175|inflammation
350633|NCT01293162|Metabolic syndrome
350634|NCT01293162|Cardiovascular risk
350635|NCT01293149|knee, reconstructive surgery
350636|NCT01293149|femoral nerve block
350637|NCT01293136|knee
350638|NCT01293136|reconstructive surgery
350639|NCT01293136|femoral nerve block
350640|NCT01293123|HIV
350641|NCT01293123|raltegravir
350642|NCT01293123|cerebrospinal fluid
350643|NCT01293110|urodynamics
350644|NCT01293110|neurogenic lower urinary tract dysfunction
350645|NCT01293110|neurological disease/injury
350646|NCT01293084|mucociliary clearance
350647|NCT01293084|children
350648|NCT01293084|cystic fibrosis
350649|NCT01293084|hypertonic saline
350650|NCT01293071|Antibiotic rotation
350651|NCT01293071|Cycling
350652|NCT01293071|Mixing
350653|NCT01293071|Gram-negative
350654|NCT01293071|EU
350655|NCT01293071|Multi center
350656|NCT01293071|Multi Centre
350657|NCT01293071|Cluster randomized trial
350658|NCT01293071|Cross over
350659|NCT01293058|opioid
350660|NCT01293058|overdose
350661|NCT01293058|naloxone
350662|NCT01293058|intranasal
350663|NCT01293045|Osteoporosis
350664|NCT01293045|Postmenopausal women
350665|NCT01293045|Functional food
350666|NCT01293045|Hydrolysed collagen
350667|NCT01293045|Bone metabolism
350668|NCT01293045|Bone marker of resorption
350669|NCT01293045|Bone marker of formation
350670|NCT01293032|Estrogen Receptor Positive
350671|NCT01293032|Progesterone Receptor Positive
350672|NCT01293032|HER2/Neu Negative
350673|NCT01293032|Breast Cancer
350674|NCT01293019|Complementary and alternative medicine
350675|NCT01293019|Osteopathic treatment
350676|NCT01293006|Pulmonary Disease, Chronic Obstructive
350677|NCT01292980|sDTI
350678|NCT01292980|Pressure ulcers
350679|NCT01292980|Therapy surfaces
350680|NCT01292980|Mattresses
350681|NCT01292980|Deep Tissue Injury
350682|NCT01292980|pressure ulcer treatment
350683|NCT01292967|Flavanol
350684|NCT01292967|cocoa
350685|NCT01292967|maltitol
350686|NCT01292967|absorption
350687|NCT01292967|metabolism
350688|NCT01292967|chocolate
350689|NCT01292967|food matrix
350690|NCT01292967|bioavailability
350691|NCT01292954|blueberries
350692|NCT01292954|vascular function
350693|NCT01292954|FMD
350694|NCT01292954|Blood pressure
350695|NCT01292954|Laser Doppler
350696|NCT01292954|pharmacokinetics
350697|NCT01292954|absorption
350698|NCT01292954|metabolism
350699|NCT01292954|polyphenols
350700|NCT01292954|flavonoids
350701|NCT01292928|Atherosclerosis, Superficial Femoral Artery (SFA), Proximal Popliteal Artery (PPA), lower extremities, Stenting
350702|NCT01292915|Re-bleeding, NVUGIB
350703|NCT01292889|Seasonal Affective Disorder
350704|NCT01292889|Major Depressive Disorder
350705|NCT01292889|Depression
350706|NCT01292889|Winter Blues
350707|NCT01292876|MTURR
350708|NCT01292876|ECM
350709|NCT01292876|Muscle Loss
350710|NCT01292876|Tendon
350711|NCT01292876|Tendon Repair
350712|NCT01292876|Muscle Repair
350713|NCT01292876|Soft Tissue Repair
350714|NCT01292876|Scaffold
350715|NCT01292876|Extracellular Matrix
350716|NCT01292863|Peritoneal dialysis
350717|NCT01292863|Biocompatible dialysis fluid
350718|NCT01292850|Topical
350719|NCT01292850|Skin
350720|NCT01292850|sterility
350721|NCT01292850|ethylchloride
350722|NCT01292850|ethyl
350723|NCT01292850|chloride
350724|NCT01292850|spray
350725|NCT01292837|Levetiracetam
350726|NCT01292837|Epilepsy
350727|NCT01292837|Generalized tonic-clonic seizures
350728|NCT01292824|Hepatitis C virus
350729|NCT01292824|Entry
350730|NCT01292824|Scavenger receptor-BI
350731|NCT01292824|High density lipoprotein
350732|NCT01292824|Liver transplantation
350733|NCT01292811|Spinal Cord Injury
350734|NCT01292811|Functional Electrical Stimulation
350735|NCT01292811|Hand function
350736|NCT01292811|Tetraplegia
350737|NCT01292798|Diabetes
350738|NCT01292798|Macula
350739|NCT01292798|Edema
350740|NCT01292798|Retina
350741|NCT01292772|breast cancer
350742|NCT01292772|bilateral mastectomy
350743|NCT01292772|immediate breast reconstruction
350744|NCT01292772|locally advanced unilateral breast cancer
350745|NCT01292772|bilateral mastectomy for prophylaxis
350746|NCT01292759|stroke volume
350747|NCT01292759|cardiac output
350748|NCT01292759|validation
350749|NCT01292733|Women with increased risk for developing ovarian cancer
350750|NCT01292733|Women diagnosed with reproductive cancer
350751|NCT01292733|Women with relatives who have had ovarian or breast cancer
350752|NCT01292720|vitamin D deficiency, vitamin D insufficiency, heart failure
350753|NCT01292707|malaria
350754|NCT01292707|rdt
350755|NCT01292707|fever
350756|NCT01292707|treatment
350757|NCT01292694|supine hypertension
350758|NCT01292694|autonomic failure
350759|NCT01292694|angiotensin
350760|NCT01292694|losartan
350761|NCT01292694|captopril
350762|NCT01292681|colorectal cancer
350763|NCT01292681|FDG-PET-CT
350764|NCT01292681|MRS,
350765|NCT01292681|DCE-MRI
350766|NCT01292681|DWI
350767|NCT01292681|colorectal cancer with histologically proven distant metastases
350768|NCT01292642|cognitive behavioral therapy
350769|NCT01292642|nicotine dependence
350770|NCT01292642|cannabis dependence
350771|NCT01292642|smoking cessation
350772|NCT01292642|nicotine replacement therapy
350773|NCT01292629|intraocular lens
350774|NCT01292629|IOL
350775|NCT01292629|cataract
350776|NCT01292629|Hoya
350777|NCT01292629|surgical
350778|NCT01292629|optics
350779|NCT01292629|ocular
350780|NCT01292629|visual acuity
350781|NCT01292577|Schizophrenia
350782|NCT01292577|Schizoaffective Disorder
350783|NCT01292577|Cannabis
350784|NCT01292577|Alcohol
350785|NCT01292577|Substance Misuse
350786|NCT01292577|Cognition
350787|NCT01292577|Psychosocial Treatment
350788|NCT01292577|Cognitive Enhancement Therapy
350789|NCT01292577|Personal Therapy
350790|NCT01292577|Treatment as Usual
350791|NCT01292551|single ventricle physiology
350792|NCT01292551|Fontan procedure
350793|NCT01292525|Withdrawal of Tacrolimus and renal graft
350794|NCT01292525|renal allograft
350795|NCT01292525|stable renal function
350796|NCT01292512|Bereavement management
350797|NCT01292512|Complicated grief
350798|NCT01292499|psychotherapy
350799|NCT01292499|psychoeducation
350800|NCT01292499|depression
350801|NCT01292447|Pain measurement
350802|NCT01292447|Intrauterine devices
350803|NCT01292447|Lidocaine
350804|NCT01292434|Diet
350805|NCT01292434|Obesity
350806|NCT01292434|Child Preschool
350807|NCT01292434|Treatment Outcome
350808|NCT01292434|Body Mass Index
350809|NCT01292434|Intervention Studies
350810|NCT01292434|Randomized Controlled Trial
350811|NCT01292434|Child Day Care Centers
350812|NCT01292434|Schools Nursery
350813|NCT01292434|Child Care
350814|NCT01292408|autophagy
350815|NCT01292408|hydroxychloroquine
350816|NCT01292408|hypoxia
350817|NCT01292408|proven invasive adenocarcinoma of the breast: tumors are found to be ER negative (<10% ER pos cells)
350818|NCT01292395|dietary supplement
350819|NCT01292395|protein metabolism
350820|NCT01292395|bone turnover
350821|NCT01292382|Elderly
350822|NCT01292382|Memory
350823|NCT01292382|Cognition
350824|NCT01292382|Repetitive transcranial magnetic stimulation
350825|NCT01292369|breath test
350826|NCT01292369|colon cancer
350827|NCT01292369|breast cancer
350828|NCT01292343|third molars
350829|NCT01292343|triclosan
350830|NCT01292343|toothpaste
350831|NCT01292343|dry socket
350832|NCT01292343|wound infection
350833|NCT01292330|liver Tumor
350834|NCT01292317|NGAL
350835|NCT01292317|neutrophil gelatinase-associated Lipocalin
350836|NCT01292317|contrast media nephropathy
350837|NCT01292317|CIN
350838|NCT01292317|volume expansion
350839|NCT01292317|acute kidney injury
350840|NCT01292317|contrast media
350841|NCT01292304|Cirrhotic
350842|NCT01292304|Tolvaptan
350843|NCT01292304|v2 receptor antagonist
350844|NCT01292291|stage I prostate cancer
350845|NCT01292291|stage IIA prostate cancer
350846|NCT01292291|stage IIB prostate cancer
350847|NCT01292278|subarachnoid hemorrhage
350848|NCT01292278|cerebral vasospasm
350849|NCT01292278|neuropeptide Y
350850|NCT01292278|spontaneous
350851|NCT01292278|aneurysmal
350852|NCT01292265|Arthritis
350853|NCT01292265|Joint pain
350854|NCT01292265|Inflammation
350855|NCT01292265|Rheumatoid Arthritis
350856|NCT01292239|Hepatitis C, Chronic
350857|NCT01292239|Hepatitis C
350858|NCT01292239|Hepatitis C virus
350859|NCT01292239|Interferon Alfa-2a
350860|NCT01292239|Ribavirin
350861|NCT01292239|Viral RNA
350862|NCT01292213|Chronic cough
350863|NCT01292213|Haemophilus influenzae
350864|NCT01292200|Chinese women
350865|NCT01292200|Mammography
350866|NCT01292200|Breast Cancer
350867|NCT01292187|Osteoporosis
350868|NCT01292187|Osteopenia
350869|NCT01292187|Osteoporosis, Postmenopausal
350870|NCT01292187|Bone Diseases, Metabolic
350871|NCT01292187|Bone Diseases
350872|NCT01292187|Musculoskeletal Diseases
350873|NCT01292187|Salmon calcitonin
350874|NCT01292187|Calcitonin
350875|NCT01292174|HIV prevention
350876|NCT01292161|Hepatitis C
350877|NCT01292161|Silymarin
350878|NCT01292161|Quality of life
350879|NCT01292148|resuscitation, hypothermia
350880|NCT01292135|Lymphoma, B-Cell
350881|NCT01292135|Leukemia, Lymphoid
350882|NCT01292135|Leukemia, B-Cell
350883|NCT01292135|Bruton's Tyrosine Kinase
350884|NCT01292122|Wounds
350885|NCT01292122|Grafts
350886|NCT01292122|Wound Healing
350887|NCT01292122|Cell Therapy
350888|NCT01292122|Split-thickness skin graft donor site wound
350889|NCT01292109|endoscopy
350890|NCT01292109|colonoscopy
350891|NCT01292109|preparation for surgery
350892|NCT01292096|homelessness
350893|NCT01292096|substance use
350894|NCT01292096|frequent hospitalization
350895|NCT01292096|frequent users of health services
350896|NCT01292096|enhanced care management
350897|NCT01292096|coordination services p
350898|NCT01292096|high risk for frequent hospitalization
350899|NCT01292070|Fel d 1 protein, Felis domesticus
350900|NCT01292070|Injections, Intradermal
350901|NCT01292057|Alcohol
350902|NCT01292057|Aripiprazole
350903|NCT01292057|Impulsivity
350904|NCT01292057|Alcoholism
350905|NCT01292057|drinking
350906|NCT01292057|treatment
350907|NCT01292057|craving
350908|NCT01292057|brain imaging
350909|NCT01292057|genetics
350910|NCT01292044|elastography
350911|NCT01292044|cytology
350912|NCT01292031|VAP
350913|NCT01292031|MDR-GNB
350914|NCT01292031|colistin
350915|NCT01292031|meropenem
350916|NCT01292018|Management of dyslipidemia in Type 2 Diabetes Mellitus adult patients in India
350917|NCT01292018|Dyslipidemia control rates in Type 2 diabetic Mellitus patients
350918|NCT01292005|pancreatitis
350919|NCT01292005|pancreatic necrosis
350920|NCT01292005|severe acute pancreatitis (SAP)
350921|NCT01292005|Alcoholic pancreatitis
350922|NCT01292005|gallstone pancreatitis
350923|NCT01291992|Non-convulsive seizures
350924|NCT01291992|Cardiac Surgery
350925|NCT01291992|Postop
350926|NCT01291992|24 hour EEG Monitoring
350927|NCT01291979|Pain
350928|NCT01291979|Preemptive
350929|NCT01291979|Lidocaine
350930|NCT01291979|Intravenous
350931|NCT01291979|Tonsillectomy
350932|NCT01291966|medication errors
350933|NCT01291966|Patient Compliance
350934|NCT01291966|patient safety
350935|NCT01291966|polypharmacy
350936|NCT01291953|atrial fibrillation
350937|NCT01291953|screening
350938|NCT01291953|prevention
350939|NCT01291953|case finding
350940|NCT01291953|primary care
350941|NCT01291927|Periampullary carcinoma
350942|NCT01291927|Pancreas-sparing Duodenectomy
350943|NCT01291927|pancreaticoduodenectomy
350944|NCT01291927|lymphadenectomy
350945|NCT01291914|Osteoarthritis
350946|NCT01291914|knee
350947|NCT01291914|intra-articular
350948|NCT01291914|safety
350949|NCT01291914|efficacy
350950|NCT01291914|pharmacokinetics
350951|NCT01291914|pain
350952|NCT01291901|pain
350953|NCT01291901|cancer
350954|NCT01291901|malignancy
350955|NCT01291901|intractable
350956|NCT01291901|gene therapy
350957|NCT01291901|enkephalin
350958|NCT01291901|opioid
350959|NCT01291875|Type 2 Diabetes mellitus
350960|NCT01291875|Periodontal Disease
350961|NCT01291875|metabolic control
350962|NCT01291875|periodontal treatment
350963|NCT01291875|inflammatory markers
350964|NCT01291849|nasal surgery
350965|NCT01291849|endoscopic sinus surgery
350966|NCT01291849|septoplasty
350967|NCT01291849|Cough
350968|NCT01291836|Acute Kidney Injury (AKI)
350969|NCT01291836|Acute Decompensated Heart Failure (ADHF)
350970|NCT01291836|Neutrophil Gelatinase Associated Lipocalin (NGAL)
350971|NCT01291836|biomarker
350972|NCT01291823|gefitinib
350973|NCT01291823|radiation
350974|NCT01291823|esophageal cancer
350975|NCT01291797|congenital heart disease
350976|NCT01291797|neurodevelopmental outcome
350977|NCT01291797|AEEG
350978|NCT01291797|sleep wake cycles
350979|NCT01291784|monoclonal antibody
350980|NCT01291771|End stage renal disease
350981|NCT01291771|myocardial microvascular disease
350982|NCT01291771|cardiorenal syndrome
350983|NCT01291771|coronary flow reserve
350984|NCT01291771|index of microvascular resistance
350985|NCT01291771|Patients with end stage renal disease scheduled or not for kidney or kidney + pancreatic transplantation
350986|NCT01291758|Persian Gulf War
350987|NCT01291758|Gulf War Syndrome
350988|NCT01291758|GWI
350989|NCT01291758|Gulf War Illness
350990|NCT01291758|Exercise
350991|NCT01291758|Chronic Fatigue
350992|NCT01291758|Fibromyalgia
350993|NCT01291758|Veterans
350994|NCT01291758|Irritable Bowel Syndrome
350995|NCT01291758|Migraine headaches
350996|NCT01291758|Neuropathy
350997|NCT01291719|closed loop glucose control
350998|NCT01291719|intensive care glucose control
350999|NCT01291706|Transcranial Doppler
351000|NCT01291706|Mild and moderate Traumatic Brain Injury
351001|NCT01291706|Neurological deterioration
351002|NCT01291706|Brain CT scan
351003|NCT01291693|Hazardous drinking
351004|NCT01291693|general hospital
351005|NCT01291693|brief intervention
351006|NCT01291693|Motivational Interviewing
351007|NCT01291693|computer-generated feedback
351008|NCT01291693|stage-tailored
351009|NCT01291693|delivery channel
351010|NCT01291680|Pregnancy
351011|NCT01291680|Chronic pain
351012|NCT01291680|Fibromyalgia
351013|NCT01291654|PDA
351014|NCT01291654|Paracetamol
351015|NCT01291654|Indomethacin
351016|NCT01291654|Ibuprofen
351017|NCT01291641|Hyperlipidemias
351018|NCT01291641|Hydroxymethylglutaryl-CoA Reductase Inhibitors
351019|NCT01291641|Probucol
351020|NCT01291641|Cilostazol
351021|NCT01291628|Capecitabine
351022|NCT01291628|Hand and foot syndrome
351023|NCT01291628|Socks
351024|NCT01291628|Copper
351025|NCT01291628|Toxicity
351026|NCT01291602|NXL104
351027|NCT01291602|ceftazidime
351028|NCT01291602|CAZ104
351029|NCT01291602|Healthy Japanese volunteers
351030|NCT01291602|Phase 1
351031|NCT01291602|Single and Multiple Dose Study
351032|NCT01291589|HIV-infected
351033|NCT01291589|MSM
351034|NCT01291589|HIV prevention
351035|NCT01291576|Deep infiltrating endometriosis
351036|NCT01291576|Rectal endometriosis
351037|NCT01291576|Colorectal resection
351038|NCT01291576|Nodule excision
351039|NCT01291576|Rectal shaving
351040|NCT01291576|Functional outcomes
351041|NCT01291576|Constipation
351042|NCT01291563|TMC207TBC1003
351043|NCT01291563|TMC207
351044|NCT01291563|M.Tuberculosis
351045|NCT01291563|TBC
351046|NCT01291563|Moxifloxacin
351047|NCT01291563|ECG
351048|NCT01291563|QT/QTc
351049|NCT01291563|Healthy volunteers
351050|NCT01291550|Detecting volatile biomarkers using breath sample
351051|NCT01291537|Advanced
351052|NCT01291537|Severe form
351053|NCT01291524|pregabalin
351054|NCT01291524|pharmacokinetics
351055|NCT01291524|bioavailability
351056|NCT01291524|bioequivalence
351057|NCT01291511|Schizophrenia
351058|NCT01291511|Mental Disorders
351059|NCT01291511|Antipsychotic Agents
351060|NCT01291511|Iloperdione
351061|NCT01291511|Relapse Prevention
351062|NCT01291498|Primary Parathyroid Adenomas
351063|NCT01291485|HIV
351064|NCT01291485|Medication adherence
351065|NCT01291485|computer-based intervention
351066|NCT01291472|ketorolac
351067|NCT01291472|pain
351068|NCT01291472|pregnancy
351069|NCT01291472|non-pregnant state
351070|NCT01291459|HIV
351071|NCT01291459|naive patients
351072|NCT01291459|maraviroc
351073|NCT01291459|raltegravir
351074|NCT01291446|Intestinal gas production
351075|NCT01291446|Intestinal microbiota
351076|NCT01291407|Combined Modality
351077|NCT01291407|Gastric Cancer
351078|NCT01291407|Radiation Therapy
351079|NCT01291407|S-1
351080|NCT01291394|Growth disorders
351081|NCT01291394|Saizen
351082|NCT01291394|Easypod
351083|NCT01291394|Growth hormone
351084|NCT01291394|Pediatric subject
351085|NCT01291381|allergic rhinitis
351086|NCT01291381|peripheral tolerance
351087|NCT01291381|regulatory T cells
351088|NCT01291381|specific immunotherapy
351089|NCT01291381|Tr1 cells
351090|NCT01291368|Sedation
351091|NCT01291368|Delirium
351092|NCT01291368|PTSD
351093|NCT01291368|Depression
351094|NCT01291368|Anxiety
351095|NCT01291368|HRQoL
351096|NCT01291368|CAM-ICU
351097|NCT01291368|RASS
351098|NCT01291368|SF-36
351099|NCT01291368|ICU-memory tool
351100|NCT01291368|Antipsychotic Agents
351101|NCT01291368|Mobilization
351102|NCT01291368|ICU-nursing
351103|NCT01291368|ICU
351104|NCT01291368|intensive care
351105|NCT01291368|critical care
351106|NCT01291368|critical care nursing
351107|NCT01291355|Maternal position
351108|NCT01291355|Occipitoposterior position
351109|NCT01291355|Labor
351110|NCT01291355|Dystocia
351111|NCT01291355|Fetal presentation Abnormalities
351112|NCT01291342|Pregnancy
351113|NCT01291342|Preeclampsia
351114|NCT01291342|Volatile biomarkers
351115|NCT01291342|Chemical sensors
351116|NCT01291342|Nanomaterials
351117|NCT01291342|Nanosensors
351118|NCT01291342|NA-NOSE
351119|NCT01291329|stem cell
351120|NCT01291329|acute ST-Elevation Myocardial Infarction
351121|NCT01291303|Non invasive ventilation
351122|NCT01291303|acute exacerbation of COPD
351123|NCT01291303|optimized ventilation
351124|NCT01291290|rAAA
351125|NCT01291290|Platelets
351126|NCT01291290|TEG
351127|NCT01291290|Massive bleeding
351128|NCT01291290|Coagulopathy
351129|NCT01291277|gastrointestinal hemorrhage
351130|NCT01291277|esophageal varices
351131|NCT01291277|gastrointestinal endoscopy
351132|NCT01291277|ligation
351133|NCT01291264|Chlamydia trachomatis
351134|NCT01291264|Neisseria gonorrhoeae
351135|NCT01291264|Sexually Transmitted Diseases
351136|NCT01291238|learning disability
351137|NCT01291238|blood lipids
351138|NCT01291238|cardio metabolic risk factors
351139|NCT01291238|upper secondary school for learning disability students
351140|NCT01291238|adolescents
351141|NCT01291238|cardio respiratory fitness
351142|NCT01291238|absorptiometry photos
351143|NCT01291225|playgrounds
351144|NCT01291225|farms
351145|NCT01291225|injury prevention
351146|NCT01291225|safety knowledge, attitudes and practices
351147|NCT01291225|safe play
351148|NCT01291225|rural
351149|NCT01291212|In Vitro Fertilization
351150|NCT01291212|Testosterone
351151|NCT01291212|Ovarian Stimulation
351152|NCT01291212|Luteinizing Hormone
351153|NCT01291199|double-blind placebo controlled cross-over study
351154|NCT01291186|spinal anesthesia
351155|NCT01291186|intrathecal bupivacaine
351156|NCT01291186|median effective dose
351157|NCT01291186|height
351158|NCT01291147|pain
351159|NCT01291147|anaesthetic
351160|NCT01291121|Age related macular degeneration
351161|NCT01291121|Intravitreal ranibizumab
351162|NCT01291121|Intravitreal expansile gas injection
351163|NCT01291082|Breast cancer
351164|NCT01291082|metastasis
351165|NCT01291082|bone
351166|NCT01291082|diffusion MRI
351167|NCT01291069|Fontan
351168|NCT01291069|Tadalafil
351169|NCT01291069|Exercise performance
351170|NCT01291056|Clomiphene citrate
351171|NCT01291056|Mood symptoms
351172|NCT01291056|Infertility
351173|NCT01291056|Superovulation
351174|NCT01291056|Effects of clomiphene on mood
351175|NCT01291043|Shiatsu
351176|NCT01291043|Fibromyalgia
351177|NCT01291043|Pain
351178|NCT01291043|Quality of sleep
351179|NCT01291043|Balance
351180|NCT01291043|Quality of life
351181|NCT01291017|Advanced stage
351182|NCT01290952|off-pump
351183|NCT01290952|bypass
351184|NCT01290952|coronary artery surgery
351185|NCT01290939|adult glioblastoma
351186|NCT01290939|recurrent adult brain tumor
351187|NCT01290939|Cognition Disorders
351188|NCT01290939|functional defects
351189|NCT01290926|advanced chemorefractory colorectal cancer
351190|NCT01290926|sorafenib
351191|NCT01290926|capecitabine
351192|NCT01290926|FDG-PET
351193|NCT01290926|early metabolic response
351194|NCT01290913|peanut allergy
351195|NCT01290913|Xolair
351196|NCT01290900|NXL104
351197|NCT01290900|CAZ104
351198|NCT01290900|Ceftazidime
351199|NCT01290900|CXL104
351200|NCT01290900|Ceftaroline
351201|NCT01290900|Healthy Male Volunteers
351202|NCT01290900|Phase 1
351203|NCT01290900|OT
351204|NCT01290900|Single Dose Study
351205|NCT01290874|Asthma
351206|NCT01290874|Blacks
351207|NCT01290874|LABA
351208|NCT01290874|Tiotropium
351209|NCT01290874|Spiriva
351210|NCT01290874|African American
351211|NCT01290874|Serevent
351212|NCT01290874|salmeterol
351213|NCT01290874|Foradil
351214|NCT01290874|formoterol
351215|NCT01290874|Advair
351216|NCT01290874|Symbicort
351217|NCT01290874|Dulera
351218|NCT01290861|Huntington's Disease
351219|NCT01290861|Cognitive Battery
351220|NCT01290861|Cognitive Testing
351221|NCT01290861|Cognition
351222|NCT01290861|pre-manifest Huntington's Disease
351223|NCT01290848|pediatrics
351224|NCT01290848|Health Promotion Campaign
351225|NCT01290848|Community events
351226|NCT01290835|Stereotactic radiotherapy
351227|NCT01290835|CyberKnife following lumpectomy
351228|NCT01290835|Breast cancer
351229|NCT01290822|Biventricular pacing
351230|NCT01290822|Dilated Cardiomyopathy
351231|NCT01290822|Ischemic Cardiomyopathy
351232|NCT01290822|Congestive heart failure
351233|NCT01290822|Cardiac allograft
351234|NCT01290822|Cardiac surgery
351235|NCT01290822|AVD
351236|NCT01290822|VVD
351237|NCT01290822|LV pacing site
351238|NCT01290822|pacing optimization
351239|NCT01290809|Prophylactic Cranial Irradiation
351240|NCT01290809|lung cancer
351241|NCT01290783|mCRC
351242|NCT01290783|CRC
351243|NCT01290783|colorectal
351244|NCT01290783|irinotecan
351245|NCT01290783|Hyaluronic acid
351246|NCT01290783|Hyaluronan
351247|NCT01290770|obesity
351248|NCT01290770|men
351249|NCT01290770|TFPI
351250|NCT01290770|Lipoprotein(a)
351251|NCT01290770|Lp(a)
351252|NCT01290770|Tissue Factor pathway inhibitor
351253|NCT01290770|aspirin
351254|NCT01290744|leprosy
351255|NCT01290744|ENL
351256|NCT01290744|clofazimine
351257|NCT01290731|Hepatitis C, Chronic
351258|NCT01290731|Hepatitis C virus
351259|NCT01290731|Interferon Alfa-2a
351260|NCT01290731|Ribavirin
351261|NCT01290731|Viral RNA
351262|NCT01290705|Knee
351263|NCT01290705|Anterior Cruciate Ligament
351264|NCT01290705|Pain
351265|NCT01290705|Patella
351266|NCT01290705|Exercise Therapy
351267|NCT01290692|Brain Neoplasms
351268|NCT01290692|Central Nervous System Neoplasms
351269|NCT01290692|Brain Diseases
351270|NCT01290692|Neoplasms
351271|NCT01290692|Nervous System Neoplasms
351272|NCT01290692|Glioblastoma
351273|NCT01290692|Astrocytoma
351274|NCT01290692|Nervous System Diseases
351275|NCT01290692|Central Nervous System Diseases
351276|NCT01290692|Glioma
351277|NCT01290692|Recurrent astrocytoma
351278|NCT01290692|Recurrent glioma
351279|NCT01290692|Cancer vaccine
351280|NCT01290692|Immunotherapy
351281|NCT01290692|Killer T cells
351282|NCT01290692|Activated T cells
351283|NCT01290692|GM-CSF
351284|NCT01290692|Activated lymphocytes
351285|NCT01290679|Hepatitis C
351286|NCT01290679|TMC435
351287|NCT01290679|HCV
351288|NCT01290679|Hep C
351289|NCT01290679|genotype 1
351290|NCT01290601|malaria
351291|NCT01290601|Plasmodium vivax
351292|NCT01290601|adults
351293|NCT01290601|treatment
351294|NCT01290601|tafenoquine
351295|NCT01290562|SBRT
351296|NCT01290562|spinal Metastases
351297|NCT01290562|Paraspinal Metastases
351298|NCT01290562|spinal Metastases and SBRT
351299|NCT01290562|Paraspinal Metastases and SBRT
351300|NCT01290536|Liver metastases
351301|NCT01290510|tendinopathy
351302|NCT01290510|hyaluronan
351303|NCT01290510|tendon
351304|NCT01290510|hyaluronic acid
351305|NCT01290484|Lymphatic malformation, vascular malformation
351306|NCT01290458|Eccentric training
351307|NCT01290458|Free radicals
351308|NCT01290458|Antioxidant supplements
351309|NCT01290458|Training adaptations
351310|NCT01290458|Lipid profile
351311|NCT01290445|varenicline
351312|NCT01290445|smoking
351313|NCT01290445|smoking cessation
351314|NCT01290445|cohort study
351315|NCT01290445|drug safety
351316|NCT01290445|prospective study
351317|NCT01290432|female fertility
351318|NCT01290432|ovarian reserve
351319|NCT01290432|oocyte quality
351320|NCT01290432|oocyte quantity
351321|NCT01290432|antimullerian hormone
351322|NCT01290432|AMH
351323|NCT01290432|dietary supplements
351324|NCT01290432|inofolic plus
351325|NCT01290432|myoinositol
351326|NCT01290432|folic acid
351327|NCT01290419|RSV
351328|NCT01290406|Endometrial cancer,
351329|NCT01290406|uterine cancer,
351330|NCT01290406|PI3K,
351331|NCT01290406|mTOR,
351332|NCT01290406|targeted therapy
351333|NCT01290393|vaccine
351334|NCT01290393|Spontaneous abortions
351335|NCT01290393|Human papillomavirus
351336|NCT01290393|HPV
351337|NCT01290393|Cervarix
351338|NCT01290393|pregnancy
351339|NCT01290380|Solid tumor malignancies,
351340|NCT01290380|simvastatin,
351341|NCT01290380|caffeine,
351342|NCT01290380|omeprazole and diclofenac,
351343|NCT01290380|ASA404,
351344|NCT01290380|PK data
351345|NCT01290367|Chronic Lumbar Back Pain
351346|NCT01290367|Low back pain
351347|NCT01290367|Back pain
351348|NCT01290367|Degenerative Disc Disease
351349|NCT01290367|Injection of Degenerated Lumbar Disc
351350|NCT01290367|Stem Cells
351351|NCT01290367|Adult Stem Cells
351352|NCT01290367|Allogeneic Mesenchymal Precursor cells (MPCs)
351353|NCT01290367|Mesoblast
351354|NCT01290354|Brain penetration
351355|NCT01290354|positron emission tomography
351356|NCT01290354|Lapatinib
351357|NCT01290341|fungal infection
351358|NCT01290341|athlete foot
351359|NCT01290328|anemia
351360|NCT01290328|kidney transplant
351361|NCT01290328|alloimmunity
351362|NCT01290289|Labor
351363|NCT01290289|Epidural
351364|NCT01290289|Combined spinal epidural
351365|NCT01290289|pethidine
351366|NCT01290276|Ondansetron
351367|NCT01290276|Methylphenidate
351368|NCT01290263|Glioblastoma
351369|NCT01290263|GBM
351370|NCT01290263|Brain Tumor
351371|NCT01290263|Glioma
351372|NCT01290237|vancomycin
351373|NCT01290237|loading dose
351374|NCT01290237|pharmacokinetic
351375|NCT01290237|pediatric
351376|NCT01290237|Methicillin-Resistant Staphylococcus aureus (MRSA)
351377|NCT01290237|Serious infection with Gram positive bacteria
351378|NCT01290211|maraviroc
351379|NCT01290211|fosamprenavir
351380|NCT01290211|drug interaction
351381|NCT01290211|pharmacokinetics
351382|NCT01290211|HIV
351383|NCT01290211|AIDS
351384|NCT01290211|CCR5
351385|NCT01290211|protease inhibitor
351386|NCT01290198|epoxy-eicosatrienoic acid
351387|NCT01290198|Laser Doppler
351388|NCT01290198|Endothelium derived hyperpolarizing factor
351389|NCT01290198|cutaneous microcirculation
351390|NCT01290198|post-occlusive hyperaemia
351391|NCT01290198|thermal hyperemia
351392|NCT01290198|intradermal microdialysis
351393|NCT01290198|fluconazole
351394|NCT01290185|Arthroplasty
351395|NCT01290185|Pharmacol Nerve Block
351396|NCT01290172|Liver transplant
351397|NCT01290172|portal hypertension
351398|NCT01290159|tolerance to heat
351399|NCT01290146|Heart Failure
351400|NCT01290146|Levosimendan
351401|NCT01290146|Inotropic agents
351402|NCT01290146|Phosphodiesterase Inhibitors
351403|NCT01290146|Vasodilators
351404|NCT01290146|Diuretics
351405|NCT01290120|Burkitt Lymphoma
351406|NCT01290120|B-ALL
351407|NCT01290120|Adult patients
351408|NCT01290107|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
351409|NCT01290107|childhood acute myeloid leukemia/other myeloid malignancies
351410|NCT01290081|Tuberculosis
351411|NCT01290081|Injecting drug users
351412|NCT01290081|Case management
351413|NCT01290055|yellow fever
351414|NCT01290055|vaccine
351415|NCT01290055|memory T cells
351416|NCT01290029|pediatric
351417|NCT01290029|CKD
351418|NCT01290029|dialysis
351419|NCT01290029|paediatric
351420|NCT01290016|randomized controlled trial
351421|NCT01290016|children
351422|NCT01290016|obesity
351423|NCT01290016|nutrition
351424|NCT01290016|exercise
351425|NCT01290003|Antibacterial agents
351426|NCT01290003|Neonate
351427|NCT01290003|Meconium stained amniotic fluid
351428|NCT01290003|Neonatal sepsis
351429|NCT01289977|Sandfly
351430|NCT01289977|leishmaniasis
351431|NCT01289977|immune response
351432|NCT01289977|individuals age 18-50
351433|NCT01289951|HIV
351434|NCT01289951|VHC
351435|NCT01289951|Advanced hepatic cirrhosis
351436|NCT01289951|Pharmacokinetic
351437|NCT01289951|Raltegravir
351438|NCT01289938|pharmacokinetic
351439|NCT01289938|pharmacogenetic
351440|NCT01289938|Metoclopramide
351441|NCT01289938|Diphenhydramine
351442|NCT01289938|CYP2D6 polymorphisms
351443|NCT01289925|dietary supplement
351444|NCT01289925|selenium
351445|NCT01289925|healthy volunteer
351446|NCT01289925|Johns Hopkins
351447|NCT01289925|older
351448|NCT01289925|aging
351449|NCT01289925|geriatrics
351450|NCT01289925|baltimore
351451|NCT01289925|mineral
351452|NCT01289925|over 70
351453|NCT01289912|Tuberous Sclerosis Complex
351454|NCT01289912|Autism
351455|NCT01289912|Neurocognition
351456|NCT01289912|RAD001
351457|NCT01289912|Everolimus
351458|NCT01289912|Afinitor
351459|NCT01289912|TSC
351460|NCT01289899|BR-A-657
351461|NCT01289899|Fimasartan
351462|NCT01289899|multiple-dose
351463|NCT01289899|pharmacokinetic
351464|NCT01289899|pharmacodynamic
351465|NCT01289899|safety
351466|NCT01289886|single-dose
351467|NCT01289886|pharmacokinetic
351468|NCT01289886|pharmacodynamic
351469|NCT01289886|safety
351470|NCT01289847|Primary Immune Deficiency Disorders
351471|NCT01289847|Common Variable Immunodeficiency
351472|NCT01289847|X-linked agammaglobulinemia
351473|NCT01289847|Hyper-IgM syndrome
351474|NCT01289847|Wiskott-Aldrich Syndrome
351475|NCT01289847|Immunoglobulins
351476|NCT01289847|Bacterial Infections
351477|NCT01289834|RSA
351478|NCT01289834|Bone Cement
351479|NCT01289808|Glucose
351480|NCT01289808|analgesic
351481|NCT01289808|newborns
351482|NCT01289795|Stroke
351483|NCT01289795|Cerebral Infarction
351484|NCT01289795|Cerebrovascular Disorders
351485|NCT01289795|Brain Diseases
351486|NCT01289795|Central Nervous System Diseases
351487|NCT01289782|Hepatitis C
351488|NCT01289782|TMC435
351489|NCT01289782|HCV
351490|NCT01289782|Hep C
351491|NCT01289782|Genotype 1
351492|NCT01289756|pharmacokinetic
351493|NCT01289756|clomiphene
351494|NCT01289756|CYP2D6 polymorphisms
351495|NCT01289756|inhibition of CYP2D6 and CYP3A4
351496|NCT01289743|ankylosing spondylitis
351497|NCT01289743|atanercept
351498|NCT01289743|therapy
351499|NCT01289743|magnetic resonance imaging
351500|NCT01289730|undifferentiated spondyloarthritis
351501|NCT01289730|etanercept
351502|NCT01289730|therapy
351503|NCT01289730|magnetic resonance imaging
351504|NCT01289717|biomarkers
351505|NCT01289717|proteogenomic profiling
351506|NCT01289717|acute rejection
351507|NCT01289717|chronic allograft nephropathy/interstitial fibrosis and tubular atrophy
351508|NCT01289704|Charcot−Marie−Tooth disease,
351509|NCT01289704|CMT1A,
351510|NCT01289704|rehabilitation,
351511|NCT01289704|treadmill,
351512|NCT01289704|stretching,
351513|NCT01289704|proprioception,
351514|NCT01289704|Randomised Controlled Trial.
351515|NCT01289691|One Lung Ventilation
351516|NCT01289691|Atelectasis
351517|NCT01289691|Oxygenation
351518|NCT01289678|acute myelogenous leukemia
351519|NCT01289678|interleukin-2
351520|NCT01289665|lubricating
351521|NCT01289665|gel
351522|NCT01289665|speculum
351523|NCT01289665|Pain, Pelvic
351524|NCT01289665|Examination, Gynecological
351525|NCT01289652|Acute hepatitis C (HCV)
351526|NCT01289652|Human immunodeficiency virus (HIV)
351527|NCT01289639|non-alcoholic fatty liver disease
351528|NCT01289639|non-alcoholic steatohepatitis
351529|NCT01289639|insulin resistance
351530|NCT01289639|pioglitazone
351531|NCT01289639|fenofibrate
351532|NCT01289626|Calciphylaxis, dialysis
351533|NCT01289613|Bispectral Index
351534|NCT01289613|Anesthesia
351535|NCT01289613|Asymmetry
351536|NCT01289587|Diabetes
351537|NCT01289587|Physical activity
351538|NCT01289587|Body composition
351539|NCT01289587|Aerobic fitness
351540|NCT01289587|Metabolic control
351541|NCT01289574|androgen receptor degradation enhancer
351542|NCT01289548|remote ischaemic preconditioning
351543|NCT01289548|kidney transplantation
351544|NCT01289535|Influenza vaccine
351545|NCT01289535|immune response
351546|NCT01289535|elderly
351547|NCT01289522|Squamous cell carcinoma of the head and neck
351548|NCT01289522|recurrent or metastatic
351549|NCT01289522|first line chemotherapy
351550|NCT01289522|cetuximab
351551|NCT01289522|docetaxel
351552|NCT01289522|cisplatin
351553|NCT01289522|antineoplastic agents
351554|NCT01289522|First Line Palliative Treatment
351555|NCT01289496|Ribavirin
351556|NCT01289496|Pegasys
351557|NCT01289496|Hepatitis
351558|NCT01289483|awake fiberoptic intubation (AFI)
351559|NCT01289483|difficult airway
351560|NCT01289483|fospropofol
351561|NCT01289470|NIRS Technology
351562|NCT01289470|Cardiovascular surgery
351563|NCT01289470|valvular surgery with cardiopulmonary bypass
351564|NCT01289457|Acute Myelogenous Leukemia
351565|NCT01289457|AML
351566|NCT01289457|High-Risk Myelodysplastic Syndrome
351567|NCT01289457|MDS
351568|NCT01289457|Relapsed
351569|NCT01289457|Refractory
351570|NCT01289457|Clofarabine
351571|NCT01289457|Clofarex
351572|NCT01289457|Clolar
351573|NCT01289457|Idarubicin
351574|NCT01289457|Idamycin
351575|NCT01289457|Cytarabine
351576|NCT01289457|Ara-C
351577|NCT01289457|Cytosar
351578|NCT01289457|DepoCyt
351579|NCT01289457|Cytosine Arabinosine Hydrochloride
351580|NCT01289444|palliative care
351581|NCT01289444|AIDS
351582|NCT01289444|adolescents
351583|NCT01289444|quality of life
351584|NCT01289444|adherence
351585|NCT01289444|spiritual
351586|NCT01289444|threat appraisal
351587|NCT01289444|treatment congruence
351588|NCT01289444|treatment preferences
351589|NCT01289444|dialysis
351590|NCT01289444|hospitalization
351591|NCT01289444|communication
351592|NCT01289444|family intervention
351593|NCT01289444|Family Centered Advance Care Planning
351594|NCT01289444|decision making
351595|NCT01289444|advance care planning
351596|NCT01289444|end of life
351597|NCT01289418|H1N1
351598|NCT01289418|vaccine safety
351599|NCT01289418|adverse events
351600|NCT01289418|health care workers
351601|NCT01289405|obstructive sleep apnea
351602|NCT01289405|oropharyngeal exercises
351603|NCT01289405|speech therapy
351604|NCT01289392|Obstructive Sleep Apnea
351605|NCT01289392|CPAP
351606|NCT01289392|Oral appliance
351607|NCT01289392|Aerobic exercise
351608|NCT01289392|Resistance training
351609|NCT01289379|pneumoperitoneum
351610|NCT01289379|laparoscopy
351611|NCT01289379|HFJV
351612|NCT01289379|cardiovascular
351613|NCT01289379|Symptomatic
351614|NCT01289353|triple negative
351615|NCT01289353|breast cancer
351616|NCT01289353|adjuvant therapy
351617|NCT01289353|Carboplatin
351618|NCT01289353|chemotherapy
351619|NCT01289353|radiation therapy
351620|NCT01289353|chemo-radiotherapy
351621|NCT01289353|accelerated radiotherapy
351622|NCT01289340|wound healing
351623|NCT01289340|pain
351624|NCT01289340|burn
351625|NCT01289314|total laparoscopic hysterectomy
351626|NCT01289314|laparoscopic supracervical hysterectomy
351627|NCT01289301|renal transplantation
351628|NCT01289301|polyoma BK virus infection
351629|NCT01289301|everolimus
351630|NCT01289301|calcineurin inhibitor
351631|NCT01289301|mTOR inhibitor
351632|NCT01289288|colorectal cancer screening
351633|NCT01289288|Chinese Americans
351634|NCT01289288|patients nonadherent with CRC Screening
351635|NCT01289275|tobacco cessation
351636|NCT01289275|smoking cessation
351637|NCT01289275|telephone
351638|NCT01289275|self-help
351639|NCT01289275|smoking abstinence
351640|NCT01289275|tobacco use disorder
351641|NCT01289275|hospital
351642|NCT01289275|cardiopulmonary diseases
351643|NCT01289275|disparity
351644|NCT01289262|Cesarean section
351645|NCT01289262|Kerr incision
351646|NCT01289262|Purse string suturing in CS
351647|NCT01289262|Continuous locked suturing in CS
351648|NCT01289249|meropenem
351649|NCT01289249|child
351650|NCT01289249|bacterial infection
351651|NCT01289249|treatment evaluation
351652|NCT01289236|Shoulder Pain
351653|NCT01289223|Indolent B-cell NHL, bendamustine, rituximab, progression-free survival
351654|NCT01289210|B cell
351655|NCT01289210|lymphoma
351656|NCT01289184|Occupational Health Hazards
351657|NCT01289184|Air Pollution
351658|NCT01289184|Photocopiers
351659|NCT01289184|Other Specified Personal Exposures
351660|NCT01289184|History Presenting Hazards to Health
351661|NCT01289171|The efficacy, tolerability and safety of 15% glycolic acid lotion for treatment of diffuse flat warts among HIV+ children were investigated
351662|NCT01289158|malonic and methylmalonic aciduria
351663|NCT01289158|malonyl-coenzyme A decarboxylase
351664|NCT01289158|MLYCD
351665|NCT01289145|Action Planning
351666|NCT01289145|Positive Outcome Expectancies
351667|NCT01289145|Randomized Controlled Trial
351668|NCT01289145|Stages of change
351669|NCT01289145|Health behavior
351670|NCT01289145|Motivation
351671|NCT01289132|Drug Therapy
351672|NCT01289119|Type 2 Diabetes Mellitus
351673|NCT01289119|Drug Therapy
351674|NCT01289106|Hepatitis B vaccine
351675|NCT01289106|HIV infection
351676|NCT01289106|Modified HBV vaccine dose
351677|NCT01289106|Modified HBV vaccine schedule
351678|NCT01289093|inguinal hernia
351679|NCT01289093|incisional hernia
351680|NCT01289093|quality of life
351681|NCT01289093|disease-specific
351682|NCT01289080|Schizophrenia
351683|NCT01289080|psychiatric disorders
351684|NCT01289080|renal failure
351685|NCT01289067|Metastatic
351686|NCT01289067|Castration Resistant
351687|NCT01289067|Prostate Cancer
351688|NCT01289054|Female
351689|NCT01289054|Pregnancy
351690|NCT01289054|Hematologic Pregnancy
351691|NCT01289054|Complications
351692|NCT01289054|Registry
351693|NCT01289054|Pregnant Registry
351694|NCT01289054|CML
351695|NCT01289054|GIST
351696|NCT01289054|Gleevec
351697|NCT01289054|Tasigna
351698|NCT01289054|Glivec
351699|NCT01289054|Pregnancy Exposure
351700|NCT01289041|Advanced endometrial cancer
351701|NCT01289041|PI3K pathway
351702|NCT01289041|second-line treatment
351703|NCT01289028|GIST
351704|NCT01289028|Imatinib
351705|NCT01289028|Sunitinib
351706|NCT01289028|Gastrointestinal
351707|NCT01289028|Stromal
351708|NCT01289028|Tumors
351709|NCT01289015|fungal infection
351710|NCT01289015|athlete foot
351711|NCT01288989|Advanced Solid Tumors
351712|NCT01288976|Mitral Valve
351713|NCT01288976|Mitral Regurgitation
351714|NCT01288976|MitraClip
351715|NCT01288976|Mitral Valve Surgery
351716|NCT01288976|Mitral Valve Insufficiency or Mitral Regurgitation
351717|NCT01288963|melanoma
351718|NCT01288963|IL-2
351719|NCT01288963|Aldesleukin
351720|NCT01288950|BCG vaccine
351721|NCT01288950|Vitamin D
351722|NCT01288950|Cholecalciferol
351723|NCT01288950|Tuberculosis
351724|NCT01288937|Milnacipran
351725|NCT01288937|Idiopathic Peripheral Neuropathy
351726|NCT01288937|Diabetic neuropathy
351727|NCT01288937|Neuropathic pain
351728|NCT01288911|Metastatic
351729|NCT01288911|MDV3100
351730|NCT01288911|Prostate
351731|NCT01288911|progressive
351732|NCT01288911|Cancer
351733|NCT01288911|enzalutamide
351734|NCT01288898|ASP1941
351735|NCT01288898|Diabetes Mellitus
351736|NCT01288898|Multiple ascending doses
351737|NCT01288898|Healthy subjects
351738|NCT01288885|ASP1941
351739|NCT01288885|Diabetes Mellitus
351740|NCT01288885|First in Men
351741|NCT01288872|Praziquantal, Schistosomiasis, pregnant women, Philippines
351742|NCT01288859|polyphenols
351743|NCT01288859|curcumin
351744|NCT01288859|bioavailability
351745|NCT01288859|cocoa
351746|NCT01288846|medication list
351747|NCT01288846|changes in medication
351748|NCT01288846|prescription medication
351749|NCT01288833|Colonoscopy
351750|NCT01288833|Diagnostic Imaging
351751|NCT01288833|Colorectal Neoplasm
351752|NCT01288833|Primary Prevention
351753|NCT01288833|Cost and Cost Analysis
351754|NCT01288833|Endoscopy
351755|NCT01288807|Fibromyalgia
351756|NCT01288807|pain
351757|NCT01288794|Cirrhosis
351758|NCT01288794|Uncomplicated ascites
351759|NCT01288794|Refractory ascites
351760|NCT01288794|Chronic albumin treatment
351761|NCT01288781|High Altitude Headache; intra-cranial pressure; hypoxia
351762|NCT01288768|Meniscal injury
351763|NCT01288768|Knee arthroscopy
351764|NCT01288768|Middleaged
351765|NCT01288768|Functional outcome
351766|NCT01288755|TMC278-TiDP6-C153
351767|NCT01288755|TMC278-C153
351768|NCT01288755|TMC278
351769|NCT01288755|HIV
351770|NCT01288742|TMC435-TiDP16-C108
351771|NCT01288742|TMC435-C108
351772|NCT01288742|TMC435
351773|NCT01288742|HPC
351774|NCT01288742|HCV
351775|NCT01288742|Hepatitis C
351776|NCT01288716|ASD
351777|NCT01288716|Autism
351778|NCT01288716|Asperger Syndrome
351779|NCT01288703|urinary incontinence
351780|NCT01288690|Refugees
351781|NCT01288690|Trauma
351782|NCT01288690|Narrative
351783|NCT01288690|Exposure
351784|NCT01288690|Middle East
351785|NCT01288690|Therapy
351786|NCT01288677|Healthy volunteer
351787|NCT01288677|TMC649128HPC1001
351788|NCT01288677|TMC649128
351789|NCT01288677|HCV
351790|NCT01288677|Hepatitis C
351791|NCT01288677|healthy volunteers
351792|NCT01288677|Phase I trial
351793|NCT01288664|Lupus Nephritis
351794|NCT01288664|Tacrolimus
351795|NCT01288664|Induction Phase
351796|NCT01288651|Pulmonary arterial hypertension
351797|NCT01288651|Iron deficiency
351798|NCT01288651|Exercise
351799|NCT01288638|Polycystic Ovary Syndrome
351800|NCT01288638|Metabolic Syndrome
351801|NCT01288638|Pulse
351802|NCT01288638|Lifestyle Intervention
351803|NCT01288638|Aerobic Exercise
351804|NCT01288638|Diet
351805|NCT01288625|Identify whether Cytofos can reduce the incidence and duration of HNC patients' oral mucositis caused by radiotherapy.
351806|NCT01288612|Barrett's Esophagus
351807|NCT01288599|Laparoscopy
351808|NCT01288599|Randomized
351809|NCT01288599|Single port access
351810|NCT01288599|Adnexal disease
351811|NCT01288599|LESS
351812|NCT01288586|Post Traumatic Arthritis
351813|NCT01288586|Rheumatoid Arthritis
351814|NCT01288586|Osteoarthritis
351815|NCT01288560|medical imaging
351816|NCT01288560|heart failure
351817|NCT01288560|morbidity and mortality
351818|NCT01288560|PET/CT,CMR,SPECT, echo, coronary angiography
351819|NCT01288560|knowledge translation
351820|NCT01288560|cost effectiveness
351821|NCT01288560|quality of life
351822|NCT01288560|prospective comparative effectiveness randomized clinical trial
351823|NCT01288547|cognition
351824|NCT01288547|attention
351825|NCT01288547|methylxanthine
351826|NCT01288521|kidney transplantation
351827|NCT01288521|tacrolimus
351828|NCT01288521|P-glycoprotein
351829|NCT01288521|ABCB1
351830|NCT01288521|genotyping
351831|NCT01288482|Methacholine challenge
351832|NCT01288482|nebulizer
351833|NCT01288482|English-Wright
351834|NCT01288482|AeroEclipse II
351835|NCT01288469|10020603
351836|NCT01288456|medical device, space-occupying device
351837|NCT01288430|Heat shock protein 90
351838|NCT01288430|Advanced solid tumors
351839|NCT01288430|Non-small cell lung carcinoma
351840|NCT01288430|Epidermal growth factor receptor
351841|NCT01288430|Tyrosine kinase inhibitor acquired resistance
351842|NCT01288430|Non-small cell lung carcinoma with acquired resistance to erlotinib, gefitinib, afatinib or others.
351843|NCT01288417|HIV infections
351844|NCT01288417|HCV infections
351845|NCT01288417|interaction
351846|NCT01288417|pharmacokinetics
351847|NCT01288417|raltegravir
351848|NCT01288417|boceprevir
351849|NCT01288404|Bevacizumab, impending recurrent pterygium
351850|NCT01288378|fungal infection
351851|NCT01288378|de novo myelodysplastic syndromes
351852|NCT01288378|previously treated myelodysplastic syndromes
351853|NCT01288378|secondary myelodysplastic syndromes
351854|NCT01288378|recurrent adult acute myeloid leukemia
351855|NCT01288378|untreated adult acute myeloid leukemia
351856|NCT01288378|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
351857|NCT01288378|adult acute myeloid leukemia with del(5q)
351858|NCT01288378|adult acute myeloid leukemia with inv(16)(p13;q22)
351859|NCT01288378|adult acute myeloid leukemia with t(15;17)(q22;q12)
351860|NCT01288378|adult acute myeloid leukemia with t(16;16)(p13;q22)
351861|NCT01288378|adult acute myeloid leukemia with t(8;21)(q22;q22)
351862|NCT01288378|secondary acute myeloid leukemia
351863|NCT01288365|heart failure
351864|NCT01288365|preserved ejection fraction
351865|NCT01288352|early treatment
351866|NCT01288352|rhythm control
351867|NCT01288352|atrial fibrillation
351868|NCT01288352|cardiovascular complications
351869|NCT01288313|human milk
351870|NCT01288313|polyunsaturated fatty acids
351871|NCT01288313|linolenic acid
351872|NCT01288313|rapeseed oil
351873|NCT01288287|Certolizumab pegol
351874|NCT01288287|Cimzia®
351875|NCT01288274|Contraception
351876|NCT01288274|Family planning
351877|NCT01288274|Task Shifting
351878|NCT01288274|Community based distribution
351879|NCT01288274|Ethiopia
351880|NCT01288274|DMPA
351881|NCT01288248|Airway
351882|NCT01288248|Airway laryngeal mask
351883|NCT01288248|Endotracheal tube
351884|NCT01288248|Respiration artificial
351885|NCT01288248|Laryngospasm
351886|NCT01288248|Safety of airway laryngeal mask
351887|NCT01288235|proton radiotherapy
351888|NCT01288222|acute myelogenous leukemia
351889|NCT01288222|hematopoietic cell transplantation
351890|NCT01288222|unrelated donor
351891|NCT01288209|Hepatitis C, Chronic
351892|NCT01288209|Hepatitis C
351893|NCT01288209|Hepatitis C virus
351894|NCT01288209|Interferon Alfa-2a
351895|NCT01288209|Ribavirin
351896|NCT01288209|Viral RNA
351897|NCT01288196|CNTO 6785
351898|NCT01288196|Intravenous
351899|NCT01288196|Subcutaneous
351900|NCT01288196|Pharmacokinetics
351901|NCT01288196|Immunogenicity
351902|NCT01288196|Safety
351903|NCT01288196|Tolerability
351904|NCT01288183|tobacco
351905|NCT01288183|smoking
351906|NCT01288183|tDCS
351907|NCT01288183|DLPFC
351908|NCT01288170|cystic fibrosis, bioequivalence, pharmacokinetic, sputum, plasma
351909|NCT01288157|healthy
351910|NCT01288157|adult
351911|NCT01288157|Chinese
351912|NCT01288157|male
351913|NCT01288157|Simponi
351914|NCT01288157|CNTO 148
351915|NCT01288144|Screening
351916|NCT01288144|Gestational diabetes mellitus
351917|NCT01288131|Anti-r-HuEpo antibody
351918|NCT01288131|Anti-r-HuEpo associated PRCA
351919|NCT01288131|Treatment
351920|NCT01288131|Absolute reticulocyte count
351921|NCT01288105|drug-eluting stents
351922|NCT01288105|noncardiac surgery
351923|NCT01288092|Metastatic breast cancer
351924|NCT01288092|HER2 negative
351925|NCT01288092|HR positive
351926|NCT01288092|PI3K pathway
351927|NCT01288092|no more than 2 prior lines of chemotherapy
351928|NCT01288092|Metastatic Breast Cancer(MBC)
351929|NCT01288079|Major Depressive Disorder
351930|NCT01288079|MDD
351931|NCT01288079|Monotherapy
351932|NCT01288079|Inadequate Response to Antidepressant Therapy
351933|NCT01288066|Shoulder
351934|NCT01288066|Total arthroplasty
351935|NCT01288066|Hemiarthroplasty
351936|NCT01288066|Resurfacing
351937|NCT01288066|Glenoid
351938|NCT01288066|Constant score
351939|NCT01288040|stroke
351940|NCT01288040|treadmill
351941|NCT01288040|walking
351942|NCT01288040|hemiparesis
351943|NCT01288040|training
351944|NCT01288014|immune response
351945|NCT01288014|varicella zoster virus (VZV)
351946|NCT01288014|cytokine levels
351947|NCT01288014|immunization
351948|NCT01287975|Stroke Rehabilitation
351949|NCT01287975|Brain Computer Interface
351950|NCT01287975|Upper Limb Rehabilitation
351951|NCT01287975|EEG-based Motor Imagery
351952|NCT01287975|Robotic Rehabilitation
351953|NCT01287975|Haptic Knob
351954|NCT01287962|Apatinib
351955|NCT01287962|Non-small Cell Lung Cancer
351956|NCT01287962|VEGFR TKIs
351957|NCT01287949|Diphtheria
351958|NCT01287949|Tetanus
351959|NCT01287949|Poliomyelitis
351960|NCT01287949|Pertussis (acellular)
351961|NCT01287949|Biological/vaccine
351962|NCT01287936|Chronic Stroke
351963|NCT01287936|Stable Stroke
351964|NCT01287923|Hematology
351965|NCT01287923|Secondary lymphoid organs
351966|NCT01287910|Cardiac
351967|NCT01287910|Angina
351968|NCT01287910|Chest pain
351969|NCT01287897|Crohn's Disease
351970|NCT01287897|safety
351971|NCT01287897|efficacy
351972|NCT01287897|pharmacokinetics
351973|NCT01287897|pharmacodynamics
351974|NCT01287897|Crohn's Disease Activity Index (CDAI)
351975|NCT01287884|ABG
351976|NCT01287884|VBG
351977|NCT01287884|pH
351978|NCT01287884|pCO2
351979|NCT01287871|Cervical Cancer Screening
351980|NCT01287845|Prostate cancer
351981|NCT01287845|Neoplasm
351982|NCT01287845|Diagnostic Imaging
351983|NCT01287845|PET (Positron Emission Tomography) -tracer
351984|NCT01287845|PET-diagnosis
351985|NCT01287832|Methicillin-resistant
351986|NCT01287832|Staphylococcus aureus
351987|NCT01287806|ulinastatin
351988|NCT01287806|inhalation injury
351989|NCT01287780|Humans
351990|NCT01287780|Prostheses and Implants
351991|NCT01287780|Gentamicin administration and dosage
351992|NCT01287780|Surgical sponges
351993|NCT01287780|Treatment outcomes
351994|NCT01287767|Dementia
351995|NCT01287767|Depression
351996|NCT01287767|Burden of care
351997|NCT01287767|Psychosocial intervention
351998|NCT01287767|Family home care
351999|NCT01287702|early feeding
352000|NCT01287702|varices bleeding
352001|NCT01287702|to evaluate impact of early feeding on early rebleeding after ligation of varices
352002|NCT01287689|Non-interventional trial
352003|NCT01287689|immunodeficiency
352004|NCT01287689|outcome study, registry
352005|NCT01287689|long-term outcomes, drug utilization
352006|NCT01287689|effectiveness, treatment patterns
352007|NCT01287689|patient characteristics under real life conditions
352008|NCT01287689|factors for treatment success
352009|NCT01287689|long-term tolerability
352010|NCT01287689|quality of life
352011|NCT01287637|Rectal cancer
352012|NCT01287637|Temporary ileostomy
352013|NCT01287637|Ealy reversal
352014|NCT01287637|Morbidity
352015|NCT01287637|Mortality
352016|NCT01287637|Quality of life
352017|NCT01287637|Economic effect
352018|NCT01287624|triple negative breast cancer
352019|NCT01287624|fine line chemotherapy
352020|NCT01287611|Cesarean section
352021|NCT01287611|Kerr incision
352022|NCT01287611|Purse string suturing in C/S
352023|NCT01287611|Continuous locked suturing in C/S
352024|NCT01287598|Phase I
352025|NCT01287598|Probe substrate
352026|NCT01287598|target therapy
352027|NCT01287598|small molecule
352028|NCT01287598|pharmacokinetics
352029|NCT01287585|Hepatocellular carcinoma
352030|NCT01287585|Arginine
352031|NCT01287585|Arginine deiminase
352032|NCT01287585|ADI-PEG 20
352033|NCT01287572|TcCO2
352034|NCT01287572|sedation
352035|NCT01287572|procedure
352036|NCT01287572|PICU
352037|NCT01287559|NEC
352038|NCT01287559|Premature Infant
352039|NCT01287533|Rheumatoid arthritis
352040|NCT01287533|Glucocorticoid induced osteoporosis
352041|NCT01287533|Vertebral fracture
352042|NCT01287507|VLBW, NEC, Late onset sepsis
352043|NCT01287494|elderly
352044|NCT01287494|care management
352045|NCT01287494|primary care
352046|NCT01287481|Fibromyalgia
352047|NCT01287481|Behavioral interventions
352048|NCT01287481|Psychological interventions
352049|NCT01287468|phytomedicines
352050|NCT01287468|breast cancer
352051|NCT01287468|stromal fibroblasts
352052|NCT01287468|MDSCs
352053|NCT01287468|functional mechanism
352054|NCT01287455|Asthma
352055|NCT01287455|Vitamin D
352056|NCT01287455|airway reactivity
352057|NCT01287455|metacholine challenge test
352058|NCT01287429|Ultrasonography
352059|NCT01287416|Suicide Intervention
352060|NCT01287416|Applied Suicide Intervention Skills Training (ASIST)
352061|NCT01287416|Resilience Retreat
352062|NCT01287416|First Nations
352063|NCT01287416|Suicide Intervention and Response Inventory (SIRI)
352064|NCT01287403|Cereals
352065|NCT01287403|Alkylresorcinols
352066|NCT01287403|Betaine
352067|NCT01287403|Phenolics
352068|NCT01287403|Plasma and urine cereal phytochemicals
352069|NCT01287390|squamous cell carcinoma
352070|NCT01287390|oral cavity
352071|NCT01287390|oropharynx
352072|NCT01287390|hypopharynx
352073|NCT01287390|larynx
352074|NCT01287377|tobacco cessation
352075|NCT01287377|smoking cessation
352076|NCT01287377|nicotine
352077|NCT01287377|counseling
352078|NCT01287377|telephone
352079|NCT01287377|self-help
352080|NCT01287377|smoking abstinence
352081|NCT01287377|tobacco use disorder
352082|NCT01287377|nicotine replacement therapy
352083|NCT01287364|perennial allergic rhinitis
352084|NCT01287364|PAR
352085|NCT01287351|Real-world
352086|NCT01287351|observational
352087|NCT01287351|Fluticasone propionate
352088|NCT01287351|Metred dose inhaler
352089|NCT01287351|Extra-fine hydrofluoroalkane
352090|NCT01287351|Asthma management
352091|NCT01287351|Inhaled corticosteroids
352092|NCT01287351|Beclomethasone dipropionate
352093|NCT01287351|USA
352094|NCT01287325|Chronic obstructive pulmonary disease
352095|NCT01287325|Cough
352096|NCT01287325|DNK333
352097|NCT01287312|We will treat children age 1 month to 20 years with recurrent TEF after surgical failure
352098|NCT01287299|pregnancy
352099|NCT01287299|obesity
352100|NCT01287299|diet glycemic load
352101|NCT01287299|body composition
352102|NCT01287299|body fat
352103|NCT01287299|gestational weight gain
352104|NCT01287299|insulin resistance
352105|NCT01287286|Cancers
352106|NCT01287286|Antrodia cinnamomea
352107|NCT01287286|Chemotherapy
352108|NCT01287286|Gastrointestinal Disorder
352109|NCT01287273|frozen-thawed
352110|NCT01287273|IVF
352111|NCT01287273|incubation
352112|NCT01287273|pregnancy rate
352113|NCT01287273|Pregnancy rate of frozen-thawed embryos of IVF treatments
352114|NCT01287260|BAYA1040_Nifedipine
352115|NCT01287260|Nifedipine
352116|NCT01287260|Essential hypertension
352117|NCT01287260|Japanese Patients
352118|NCT01287260|Phase III
352119|NCT01287260|13176
352120|NCT01287247|Cervical dystonia
352121|NCT01287247|Blepharospasm
352122|NCT01287208|Physical activity
352123|NCT01287208|Accelerometer
352124|NCT01287208|Steps
352125|NCT01287208|Medical residents
352126|NCT01287195|Ulcerative Colitis
352127|NCT01287195|Inflammatory Bowel Disease
352128|NCT01287182|Asymptomatic Myocardial Ischemic patients
352129|NCT01287169|Bisphenol A
352130|NCT01287156|Recruitment
352131|NCT01287156|TBI
352132|NCT01287156|Screening
352133|NCT01287156|Traumatic Brain Injury
352134|NCT01287143|Fever
352135|NCT01287143|Signs and Symptoms
352136|NCT01287143|Febrile Assessment Tool (FAST)
352137|NCT01287130|Antibodies
352138|NCT01287130|Pharmacokinetics
352139|NCT01287130|Kinase Inhibitors
352140|NCT01287130|Colon Cancer
352141|NCT01287130|K-Ras
352142|NCT01287130|Colorectal Cancer
352143|NCT01287130|Solid Tumor
352144|NCT01287104|Leukemia/Lymphoma
352145|NCT01287104|Hematologic Malignacies
352146|NCT01287104|Leukemia
352147|NCT01287104|Lymphoma
352148|NCT01287104|Ewing Sarcoma
352149|NCT01287104|Rhabdomyosarcoma
352150|NCT01287104|Neuroblastoma
352151|NCT01287104|Healthy Donor
352152|NCT01287078|Chronic GVHD of the Lung
352153|NCT01287078|Peripheral Blood Stem Cell Transplant
352154|NCT01287078|Inhaled Cyclosporine
352155|NCT01287078|Graft-Versus-Host Disease
352156|NCT01287078|GVHD
352157|NCT01287078|Bronchiolitis Obliterans
352158|NCT01287078|Lung
352159|NCT01287065|Fluticasone furoate
352160|NCT01287065|Vilanterol
352161|NCT01287065|Efficacy
352162|NCT01287065|FEV1
352163|NCT01287065|FF/VI Inhalation powder
352164|NCT01287052|Migraine
352165|NCT01287052|Pediatric
352166|NCT01287052|Adolescent
352167|NCT01287052|Nitrous Oxide
352168|NCT01287026|MRI Catheterization
352169|NCT01287026|Right Heart Catheterization
352170|NCT01287026|Pulmonary Artery Catheterization
352171|NCT01287026|MRI Safety
352172|NCT01287026|Jugular Vein Catheterization
352173|NCT01287026|Heart Catheterization
352174|NCT01287026|Heart Disease
352175|NCT01287026|Cardiovascular Disease
352176|NCT01287013|Image Guided Procedures
352177|NCT01287013|Xperguide CT
352178|NCT01287013|Electromagnetic Tracking
352179|NCT01287013|Navigation
352180|NCT01287013|Image Guided Procedure
352181|NCT01287013|Cancer
352182|NCT01287013|Granuloma
352183|NCT01287000|Respiratory Health Outcomes
352184|NCT01287000|Petroleum
352185|NCT01287000|Dispersant(s)
352186|NCT01287000|Oil Spill
352187|NCT01287000|Longitudinal Study
352188|NCT01286987|BRCA1 Protein
352189|NCT01286987|BRCA2 Protein
352190|NCT01286961|Bowel preparation
352191|NCT01286961|Polyethylene glycols
352192|NCT01286961|Colonoscopy
352193|NCT01286961|Outpatient
352194|NCT01286948|LNG gel
352195|NCT01286948|oral LNG
352196|NCT01286948|follicle rupture
352197|NCT01286948|intra-vaginal administration
352198|NCT01286948|growth of the leading follicle
352199|NCT01286948|preovulatory peak of serum luteinizing hormone
352200|NCT01286948|characteristics of the cervical mucus
352201|NCT01286948|serum levels of estradiol (E2) and progesterone (P)
352202|NCT01286935|Parkinson's Disease
352203|NCT01286935|PD
352204|NCT01286935|Levodopa
352205|NCT01286935|Patients with idiopathic Parkinson's Disease with motor fluctuations,
352206|NCT01286922|diabetes
352207|NCT01286922|exercise
352208|NCT01286922|insulin resistance
352209|NCT01286922|interval training
352210|NCT01286922|physical activity
352211|NCT01286909|Metabolic
352212|NCT01286896|advanced solid tumors
352213|NCT01286883|stem cell markers
352214|NCT01286883|prognostic markers
352215|NCT01286883|metastatic colorectal cancer
352216|NCT01286883|circulating tumor cells
352217|NCT01286883|tumor microenvironment
352218|NCT01286883|colorectal cancer
352219|NCT01286883|advanced colorectal cancer
352220|NCT01286870|Primary Breast Reconstruction
352221|NCT01286831|Accelerator Mass Spectrometry (AMS)
352222|NCT01286831|Beta-2 agonist
352223|NCT01286831|Absorption, Distribution, Metabolism and Excretion (ADME)
352224|NCT01286831|Radiolabel
352225|NCT01286818|Colon Cancer
352226|NCT01286818|Rectal Cancer
352227|NCT01286766|unresectable
352228|NCT01286766|locally advanced
352229|NCT01286740|HIV-1
352230|NCT01286740|HIV
352231|NCT01286740|Treatment Experienced
352232|NCT01286701|Bioequivalence
352233|NCT01286701|crossover
352234|NCT01286701|Terbinafine hydrochloride
352235|NCT01286701|fed
352236|NCT01286688|Bioequivalence
352237|NCT01286688|crossover
352238|NCT01286688|Terbinafine hydrochloride
352239|NCT01286688|Fasting
352240|NCT01286675|ASCT
352241|NCT01286675|G-CSF
352242|NCT01286662|gardner syndrome
352243|NCT01286662|colorectal carcinoma
352244|NCT01286662|desmoid tumor
352245|NCT01286662|resection
352246|NCT01286662|colon
352247|NCT01286649|Alopecia
352248|NCT01286649|Alopecia, Androgenetic
352249|NCT01286649|Androgenetic Alopecia
352250|NCT01286636|artificial neural network
352251|NCT01286610|vibration
352252|NCT01286610|ICU
352253|NCT01286610|blood pressure
352254|NCT01286610|intracranial pressure
352255|NCT01286610|infection
352256|NCT01286610|indirect calorimetry
352257|NCT01286597|lactose intolerance
352258|NCT01286597|DNA sequencing
352259|NCT01286597|psychosocial factors
352260|NCT01286597|irritable bowel syndrome
352261|NCT01286597|visceral hypersensitivity
352262|NCT01286584|varenicline
352263|NCT01286584|alcohol
352264|NCT01286584|placebo
352265|NCT01286584|smoking cessation
352266|NCT01286545|Ankylosing spondylitis
352267|NCT01286545|Infliximab
352268|NCT01286545|Radiographic progression
352269|NCT01286532|Asthma, Asthma in Children
352270|NCT01286519|pharmacokinetics
352271|NCT01286506|Pulse pressure variation
352272|NCT01286506|Continuous venovenous hemodialysis
352273|NCT01286506|Volume status
352274|NCT01286506|Critical care
352275|NCT01286493|HIV
352276|NCT01286493|booster
352277|NCT01286493|rabies
352278|NCT01286493|immune response
352279|NCT01286480|Health Care Transition
352280|NCT01286480|Adolescent
352281|NCT01286467|PF-04449913
352282|NCT01286467|Hedgehog Inhibitor
352283|NCT01286467|Solid tumor
352284|NCT01286467|Pharmacokinetics
352285|NCT01286467|Safety
352286|NCT01286467|Pharmacodynamics
352287|NCT01286454|BIOAVAILABILITY
352288|NCT01286454|FOOD EFFECT
352289|NCT01286441|Verruca vulgaris
352290|NCT01286428|liver
352291|NCT01286428|cancer
352292|NCT01286428|tumor
352293|NCT01286428|ablation
352294|NCT01286428|Pathfinder
352295|NCT01286415|Posttraumatic Stress Disorder
352296|NCT01286415|Cognitive Processing Therapy
352297|NCT01286415|combat
352298|NCT01286415|military
352299|NCT01286415|CPT
352300|NCT01286415|group therapy
352301|NCT01286402|Smoking cessation during pregnancy
352302|NCT01286402|bupropion
352303|NCT01286389|Mild cognitive impairment
352304|NCT01286389|Dementia
352305|NCT01286389|Obesity
352306|NCT01286389|Overweight
352307|NCT01286389|diet
352308|NCT01286389|caloric restriction
352309|NCT01286389|body composition
352310|NCT01286389|weight loss
352311|NCT01286376|Symbiotics
352312|NCT01286376|Fiber
352313|NCT01286376|Constipation
352314|NCT01286363|Bite force
352315|NCT01286363|Dental occlusion
352316|NCT01286363|Face
352317|NCT01286363|Mastication
352318|NCT01286363|Morphology
352319|NCT01286350|motivational interviewing
352320|NCT01286350|problem solving skills training
352321|NCT01286350|family communication
352322|NCT01286350|social support
352323|NCT01286350|adolescents
352324|NCT01286337|axilla
352325|NCT01286337|surgery
352326|NCT01286337|technique
352327|NCT01286337|bipolar vessel sealing
352328|NCT01286324|Matricaria
352329|NCT01286324|Chamomile
352330|NCT01286324|Herb
352331|NCT01286324|Insomnia
352332|NCT01286311|Health Education
352333|NCT01286311|Health Knowledge, Attitudes, Practice
352334|NCT01286311|Hypolipidemic Agents/therapeutic use
352335|NCT01286311|Patient Education as Topic
352336|NCT01286298|diode laser
352337|NCT01286298|gingival enlargement
352338|NCT01286298|gingival overgrowth
352339|NCT01286298|gingival hyperplasia
352340|NCT01286298|orthodontics
352341|NCT01286285|influenza
352342|NCT01286285|acute respiratory infections
352343|NCT01286285|paediatric
352344|NCT01286285|intensive care units
352345|NCT01286285|epidemiology
352346|NCT01286259|HIV
352347|NCT01286259|HAART suppressed
352348|NCT01286259|Disulfiram
352349|NCT01286259|Antabuse
352350|NCT01286259|Latent reservoir
352351|NCT01286259|Eradication
352352|NCT01286259|Cure
352353|NCT01286246|Progesterone
352354|NCT01286246|Randomized controlled trial
352355|NCT01286233|fatigue
352356|NCT01286233|sleep disorders
352357|NCT01286233|depression
352358|NCT01286233|stage IA breast cancer
352359|NCT01286233|stage IB breast cancer
352360|NCT01286233|stage II breast cancer
352361|NCT01286233|stage IIIA breast cancer
352362|NCT01286207|Migraine headache
352363|NCT01286181|COPD
352364|NCT01286181|Biofeedback
352365|NCT01286181|Dyspnea
352366|NCT01286181|Quality of life
352367|NCT01286181|Stress
352368|NCT01286168|Bilateral breast mastectomy
352369|NCT01286168|Immediate tissue expanders reconstruction
352370|NCT01286155|Barrett's esophagus
352371|NCT01286155|gastroesophageal reflux disease
352372|NCT01286155|GERD
352373|NCT01286142|Prospective, Observational Safety Study
352374|NCT01286116|heart failure
352375|NCT01286116|percutaneous
352376|NCT01286116|interventional cardiology
352377|NCT01286116|apical remodeling
352378|NCT01286116|LV dilatation
352379|NCT01286116|akinesis
352380|NCT01286116|dyskinesis
352381|NCT01286116|myocardial infarction
352382|NCT01286103|Canagliflozin
352383|NCT01286103|Pharmacokinetics
352384|NCT01286103|Pharmacodynamics
352385|NCT01286090|Cisapride (PREPULSID)
352386|NCT01286090|Placebo
352387|NCT01286090|Diabetes mellitus
352388|NCT01286090|Diabetic gastroparesis
352389|NCT01286077|Multiple Myeloma
352390|NCT01286077|bortezomib
352391|NCT01286077|hematology
352392|NCT01286077|bone marrow cancer
352393|NCT01286077|Myeloma-related bone disease
352394|NCT01286077|bone mineral density
352395|NCT01286077|bone markers
352396|NCT01286064|adenocarcinoma,
352397|NCT01286064|colorectal tumors,
352398|NCT01286064|endogenous porphyrins,
352399|NCT01286064|fluorescence,
352400|NCT01286064|tumor markers.
352401|NCT01286051|ovulation induction, GnRH
352402|NCT01286038|platelets
352403|NCT01286025|medical education
352404|NCT01286025|problem-based learning
352405|NCT01286025|interactive tutorial
352406|NCT01286012|End Stage Renal Disease, Hemodialysis, SFP
352407|NCT01285986|Graft patency
352408|NCT01285986|Limb salvage
352409|NCT01285960|Uterine fibroids
352410|NCT01285960|MRgFUS
352411|NCT01285960|ExAblate
352412|NCT01285960|Focused Ultrasound
352413|NCT01285960|Symptomatic uterine fibroids
352414|NCT01285947|pain experience
352415|NCT01285947|energy devices
352416|NCT01285947|Ulthera
352417|NCT01285947|Thermage
352418|NCT01285947|VBeam
352419|NCT01285921|hippocampal
352420|NCT01285921|vestibular test
352421|NCT01285908|Baroreceptor
352422|NCT01285908|Norepinephrine
352423|NCT01285908|Orthostatic Hypotension
352424|NCT01285908|Sympathetic Nervous System
352425|NCT01285908|Blood Pressure
352426|NCT01285895|Lung and heart transplantations
352427|NCT01285895|Mucoviscidosis
352428|NCT01285895|Educational needs
352429|NCT01285882|Lung transplantations
352430|NCT01285882|Representations
352431|NCT01285882|Mucoviscidosis
352432|NCT01285869|Pneumonia
352433|NCT01285869|Intervention Studies
352434|NCT01285869|Aged
352435|NCT01285869|Aged, 80 and over
352436|NCT01285869|Geriatric Assessment
352437|NCT01285856|patients
352438|NCT01285856|illicit consumption of psychotropic agents and alcohol
352439|NCT01285856|buprenorphine
352440|NCT01285856|methadone
352441|NCT01285830|Infants
352442|NCT01285830|Probiotics
352443|NCT01285830|Prevention
352444|NCT01285830|Lactobacillus reuteri
352445|NCT01285830|Eczema
352446|NCT01285830|IgE
352447|NCT01285830|Sensitization
352448|NCT01285830|Microbiota
352449|NCT01285830|Chemokines
352450|NCT01285791|morbid obesity
352451|NCT01285791|intra-abdominal visceral fat
352452|NCT01285791|gastric bypass
352453|NCT01285791|sleeve gastrectomy
352454|NCT01285791|gastric banding
352455|NCT01285791|visceral fat
352456|NCT01285778|Anal squamous cell carcinoma
352457|NCT01285778|panitumumab
352458|NCT01285778|chemoradiation
352459|NCT01285778|anal cancer
352460|NCT01285778|GEMCAD-09-02
352461|NCT01285739|Pulmonary Disease, Chronic Obstructive.
352462|NCT01285739|Tracheostomy.
352463|NCT01285739|Invasive Mechanical Ventilation.
352464|NCT01285739|Non-Invasive Mechanical Ventilation.
352465|NCT01285726|Peritoneal dialysis
352466|NCT01285726|Hydration status
352467|NCT01285726|Residual renal function
352468|NCT01285726|Bioimpedance spectroscopy
352469|NCT01285726|Body composition monitor
352470|NCT01285713|Dehydration
352471|NCT01285713|Gastroenteritis
352472|NCT01285713|Dehydration in Gastroenteritis
352473|NCT01285687|Tonsillectomy
352474|NCT01285687|Post-Operative Pain
352475|NCT01285687|Acupuncture
352476|NCT01285674|cisplatin
352477|NCT01285674|ototoxicity
352478|NCT01285674|intratympanic steroids
352479|NCT01285661|Deep venous thrombosis
352480|NCT01285661|Pulmonary embolism
352481|NCT01285661|Ultrasonography
352482|NCT01285661|D-dimer
352483|NCT01285661|Venous thromboembolism
352484|NCT01285661|Bleeding
352485|NCT01285648|chest tubes,
352486|NCT01285648|Continuous Positive Airway Pressure,
352487|NCT01285648|lung resection, thoracic surgery,
352488|NCT01285648|noninvasive ventilation,
352489|NCT01285648|postoperative
352490|NCT01285622|Surgery; gynecological
352491|NCT01285622|Stroke volume
352492|NCT01285596|Pharmacokinetics
352493|NCT01285596|Cardiography
352494|NCT01285596|Impedance
352495|NCT01285596|Age groups
352496|NCT01285596|Gender Identity
352497|NCT01285583|Amyotrophoc Lateral Sclerosis
352498|NCT01285583|TRO19622
352499|NCT01285583|Olesoxime
352500|NCT01285583|Trophos
352501|NCT01285557|Gastric Cancer , S-1, Phase 3
352502|NCT01285544|statins
352503|NCT01285544|cholesterol
352504|NCT01285544|hypercholesterolemia
352505|NCT01285544|atorvastatin
352506|NCT01285544|Dyslipidemia in cardiovascular disease (KoLipinon)
352507|NCT01285531|lumbar puncture
352508|NCT01285531|Compass
352509|NCT01285531|pressure transducer
352510|NCT01285531|manometry
352511|NCT01285531|The focus of the study is to improve lumbar puncture(LP)success, reduce the number of LP attempts, reduce the number of traumatic attempts.
352512|NCT01285518|Type 2 diabetes
352513|NCT01285518|intravenous
352514|NCT01285518|single dose
352515|NCT01285505|alprazolam
352516|NCT01285505|sublingual
352517|NCT01285505|bioequivalence
352518|NCT01285492|COPD
352519|NCT01285492|QVA149
352520|NCT01285492|NVA237
352521|NCT01285492|indacaterol
352522|NCT01285492|combination bronchodilator
352523|NCT01285479|Fingolimod
352524|NCT01285479|FTY720
352525|NCT01285479|Gilenya
352526|NCT01285479|Multiple sclerosis
352527|NCT01285479|MS
352528|NCT01285479|Safety
352529|NCT01285479|Pregnancy
352530|NCT01285479|Pregnancy outcomes
352531|NCT01285466|Cancer
352532|NCT01285466|BEZ235
352533|NCT01285466|BKM120
352534|NCT01285466|paclitaxel
352535|NCT01285466|trastuzumab
352536|NCT01285453|ASA404,
352537|NCT01285453|vadimezan,
352538|NCT01285453|docetaxel
352539|NCT01285440|breast
352540|NCT01285440|biopsy
352541|NCT01285440|suspicious lesion
352542|NCT01285440|molecular breast imaging
352543|NCT01285427|DNA, sequencing
352544|NCT01285427|Identification and definition of Class I and II Human Leukocyte Antigens (HLA)
352545|NCT01285414|Glioblastoma
352546|NCT01285414|Brain Neoplasms
352547|NCT01285414|Brain Cancer
352548|NCT01285414|Verubulin
352549|NCT01285401|Multiple Sclerosis
352550|NCT01285401|Rebif
352551|NCT01285401|VigantOL® oil
352552|NCT01285401|Vitamin D
352553|NCT01285401|Add-on treatment
352554|NCT01285388|Safety
352555|NCT01285388|Tolerability
352556|NCT01285388|Pharmacokinetic
352557|NCT01285362|Fatty Liver Disease
352558|NCT01285362|Hepatic Steatosis
352559|NCT01285362|Docosahexaenoic Acid
352560|NCT01285362|Eicosapentanoic Acid
352561|NCT01285362|Omega-3 Fatty Acids
352562|NCT01285362|Elevated Transaminases
352563|NCT01285362|Fish oil supplements
352564|NCT01285349|HIV, STI, condom use, drug use,
352565|NCT01285336|Rheumatoid arthritis (RA)
352566|NCT01285336|DNA repair system
352567|NCT01285336|polymorphism
352568|NCT01285336|susceptibility
352569|NCT01285336|copy number variation (CNV)
352570|NCT01285310|Rheumatoid, Arthritis
352571|NCT01285297|Transmyocardial revascularization (TMR)
352572|NCT01285297|Bone marrow aspirate concentrate (BMAC)
352573|NCT01285297|Angina
352574|NCT01285284|Colonoscopy
352575|NCT01285284|Music
352576|NCT01285284|Tolerance
352577|NCT01285284|Pain
352578|NCT01285284|Anxiety
352579|NCT01285284|Dose of sedative drugs administered during the procedure
352580|NCT01285271|xenon
352581|NCT01285271|sevoflurane
352582|NCT01285271|cardiac anesthesia
352583|NCT01285271|CABG
352584|NCT01285271|Bypass surgery
352585|NCT01285258|Peripartum
352586|NCT01285258|hysterectomy
352587|NCT01285258|placenta accreta
352588|NCT01285258|mortality
352589|NCT01285245|insulin sensitivity
352590|NCT01285245|interleukin-1 receptor antagonist
352591|NCT01285245|inflammation
352592|NCT01285245|hyperglycemia-induced insulin resistance
352593|NCT01285219|Granulocyte colony-stimulating factor , recombinant
352594|NCT01285219|Polyethylene glycols
352595|NCT01285219|Neutropenia
352596|NCT01285219|Drug therapy, combination
352597|NCT01285193|hypertension
352598|NCT01285193|high blood pressure
352599|NCT01285193|treatment
352600|NCT01285193|breath control
352601|NCT01285193|breathing exercise
352602|NCT01285193|audio CD
352603|NCT01285180|COPD
352604|NCT01285180|Quality of life
352605|NCT01285180|sociodemographic data
352606|NCT01285180|cost-of-illness data
352607|NCT01285180|roflumilast
352608|NCT01285180|Daxas
352609|NCT01285167|COPD
352610|NCT01285167|Quality of life
352611|NCT01285167|lung function
352612|NCT01285167|spirometry
352613|NCT01285167|roflumilast
352614|NCT01285167|Daxas
352615|NCT01285167|severe COPD
352616|NCT01285154|Hip dysplasia
352617|NCT01285154|Triple Osteotomy
352618|NCT01285154|Femoral Head Coverage
352619|NCT01285154|Femoral Head Medialization
352620|NCT01285141|HIV Infections
352621|NCT01285141|Acquired Immune Deficiency Syndrome
352622|NCT01285115|Generalized anxiety disorder
352623|NCT01285115|Jingji-zhengchong
352624|NCT01285115|Gamisoyosan
352625|NCT01285115|anxiety
352626|NCT01285063|overweight
352627|NCT01285063|obesity
352628|NCT01285063|physical fitness
352629|NCT01285063|kinder garden
352630|NCT01285063|preschool
352631|NCT01285050|HIV
352632|NCT01285050|Human immunodeficiency virus
352633|NCT01285050|Acquired Immune Deficiency Syndrome Virus
352634|NCT01285050|AIDS Virus
352635|NCT01285050|Immunodeficiency Virus, Human
352636|NCT01285050|Virus, Human Immunodeficiency
352637|NCT01285050|Hepatitis C
352638|NCT01285050|Hepatitis C, chronic
352639|NCT01285050|Hepatitis C virus
352640|NCT01285050|Hepatitis C antibodies
352641|NCT01285050|Hepatitis C antigens
352642|NCT01285024|total hip arthroplasty
352643|NCT01285024|transfusion
352644|NCT01285024|hemostat
352645|NCT01285011|arthrodesis
352646|NCT01285011|PIP joint
352647|NCT01284998|forefoot deformities
352648|NCT01284998|basal osteotomy
352649|NCT01284959|cognitive function
352650|NCT01284959|subjective experiences
352651|NCT01284959|neuroleptic-induced deficit syndrome
352652|NCT01284959|paliperidone extended-release
352653|NCT01284959|risperidone
352654|NCT01284946|PCT sporadic or familial
352655|NCT01284946|Skin fragility and bullae lesions
352656|NCT01284946|non-transfusion iron overload
352657|NCT01284933|Stroke
352658|NCT01284933|Ischemic Attack, Transient
352659|NCT01284933|Magnetic Resonance Imaging
352660|NCT01284933|Carotid Arteries
352661|NCT01284933|Carotid Artery Plaque
352662|NCT01284933|Atherosclerosis
352663|NCT01284920|MDV3100
352664|NCT01284920|Response Evaluation Criteria in Solid Tumor (RECIST)
352665|NCT01284920|docetaxel
352666|NCT01284920|PSA level
352667|NCT01284907|Asthma
352668|NCT01284907|Asthma therapy
352669|NCT01284907|Randomized controlled trial
352670|NCT01284907|children
352671|NCT01284894|Dysphagia
352672|NCT01284894|Conventional manometry
352673|NCT01284894|High resolution manometry
352674|NCT01284881|MRA
352675|NCT01284881|compliance
352676|NCT01284881|OSAHS
352677|NCT01284868|Mechanisms of Pharmacological Action
352678|NCT01284868|Pharmacodynamics
352679|NCT01284868|Pharmacokinetics
352680|NCT01284855|neurotoxic envenoming (WHO ICD-10 T63.0)
352681|NCT01284842|sleep-deprivation
352682|NCT01284842|virtual reality
352683|NCT01284842|residency
352684|NCT01284842|performance
352685|NCT01284816|severely obese patients
352686|NCT01284803|patients
352687|NCT01284803|moderate depression
352688|NCT01284777|cancerology
352689|NCT01284777|genetic
352690|NCT01284764|Endoscopy
352691|NCT01284764|Gastrectomy
352692|NCT01284764|Stomach neoplasms
352693|NCT01284738|TM
352694|NCT01284738|TI
352695|NCT01284738|MP
352696|NCT01284712|treatment by bleedings
352697|NCT01284699|Parkinson
352698|NCT01284699|contraindication to Intracerebral electrode implantation
352699|NCT01284699|Gamma Knife radiosurgery
352700|NCT01284686|Pathophysiology
352701|NCT01284686|Parkinson
352702|NCT01284686|neuronal oscillations
352703|NCT01284673|Cord blood stem
352704|NCT01284673|neonatal asphyxia
352705|NCT01284647|Chronic Erosive Gastritis
352706|NCT01284647|Teprenone
352707|NCT01284647|Sucralfate
352708|NCT01284634|Cannabidiol
352709|NCT01284634|Fatty liver
352710|NCT01284634|Diabetes
352711|NCT01284634|Body fat
352712|NCT01284608|Observational
352713|NCT01284608|prospective
352714|NCT01284608|metabolic changes
352715|NCT01284608|metabolic syndrome
352716|NCT01284608|diabetes
352717|NCT01284608|prostatic cancer
352718|NCT01284608|risk fracture
352719|NCT01284595|Radioactive carbon
352720|NCT01284595|Absorption
352721|NCT01284595|Distribution
352722|NCT01284595|Metabolism
352723|NCT01284595|Excretion
352724|NCT01284595|Healthy Volunteers
352725|NCT01284582|CETP
352726|NCT01284582|Vaccine
352727|NCT01284582|Cholesterol
352728|NCT01284582|Inhibition
352729|NCT01284556|partial onset seizures
352730|NCT01284530|Epilepsy
352731|NCT01284530|Pediatrics
352732|NCT01284530|Young Adults
352733|NCT01284517|Bipolar I Depression
352734|NCT01284517|Lurasidone
352735|NCT01284517|Latuda
352736|NCT01284491|Breast reduction
352737|NCT01284491|PlasmaBlade
352738|NCT01284491|Electrosurgery
352739|NCT01284491|PEAK Surgical
352740|NCT01284491|Medtronic Advanced Energy
352741|NCT01284491|Medtronic
352742|NCT01284478|pseudophakic cystoid macular edema, diabetic macular edema, Irvine Gass Syndrome, cataract surgery, ozurdex, dexamethasone
352743|NCT01284465|Type 2 diabetes self-management
352744|NCT01284465|Minority women
352745|NCT01284465|Barriers to diabetes self-management
352746|NCT01284452|Septic shock
352747|NCT01284452|Severe sepsis
352748|NCT01284452|Acute lung injury
352749|NCT01284452|Acute respiratory distress syndrome
352750|NCT01284452|ARDS
352751|NCT01284426|Chronic urticaria
352752|NCT01284426|Natural course
352753|NCT01284426|Remission
352754|NCT01284400|heart failure
352755|NCT01284400|disease management
352756|NCT01284387|Mild to moderate Alzheimer's disease
352757|NCT01284387|immunization
352758|NCT01284387|amyloid imaging
352759|NCT01284387|injection
352760|NCT01284387|vaccine
352761|NCT01284374|HPV Vaccines
352762|NCT01284374|Attitude to Health
352763|NCT01284374|Decision Making
352764|NCT01284374|Qualitative Research
352765|NCT01284361|intermittent catheter
352766|NCT01284361|preference
352767|NCT01284348|Chemotherapy induced anemia
352768|NCT01284348|Non-small cell lung cancer
352769|NCT01284335|Advanced solid tumors
352770|NCT01284335|Unresectable
352771|NCT01284335|Metastatic
352772|NCT01284335|Limited treatment options
352773|NCT01284335|Measurable or nonmeasurable disease
352774|NCT01284309|Intraocular Pressure (IOP)
352775|NCT01284309|YM178
352776|NCT01284283|Arthrosis
352777|NCT01284283|Rheumatoid Arthrosis
352778|NCT01284283|Arthritic joint
352779|NCT01284283|Rheumatoid Arthritis
352780|NCT01284283|Osteoarthritis
352781|NCT01284270|Cardiac MRI
352782|NCT01284270|Plaque
352783|NCT01284257|EC-MPS
352784|NCT01284257|MMF
352785|NCT01284257|kidney transplant
352786|NCT01284257|outcomes
352787|NCT01284257|mycophenolate sodium
352788|NCT01284257|mycophenolic acid (MPA)
352789|NCT01284244|Urinary Incontinence, Stress
352790|NCT01284244|pessary
352791|NCT01284244|conservative management
352792|NCT01284231|MEDI-565, gastrointestinal adenocarcinomas, carcinoembryonic antigen, bispecific T-cell engager
352793|NCT01284205|non-muscle invasive bladder cancer
352794|NCT01284205|superficial bladder cancer
352795|NCT01284192|B-cell Lymphoma
352796|NCT01284192|Advanced Malignancies
352797|NCT01284192|Anaplastic Lymphoma Kinase (ALK)
352798|NCT01284192|ASP3026
352799|NCT01284192|Solid Tumor
352800|NCT01284179|Functional Chest Pain
352801|NCT01284179|Functional GI Disorders
352802|NCT01284179|Home Hypnotherapy
352803|NCT01284153|respiratory gating
352804|NCT01284153|prone radiotherapy
352805|NCT01284153|breast cancer
352806|NCT01284140|Critical illness
352807|NCT01284140|Sleep
352808|NCT01284140|Polysomnography
352809|NCT01284140|Respiratory failure
352810|NCT01284140|Circadian rhythm
352811|NCT01284140|Sedation
352812|NCT01284127|superficial siderosis
352813|NCT01284114|Elderly chronic kidney disease
352814|NCT01284114|Hypertension
352815|NCT01284114|Aliskiren
352816|NCT01284088|Male Circumcision
352817|NCT01284088|HIV Prevention
352818|NCT01284088|Medical Device
352819|NCT01284062|Active Ulcerative Colitis
352820|NCT01284062|Phase 2A
352821|NCT01284062|Double-blind
352822|NCT01284062|Randomized
352823|NCT01284062|PK/PD Biomarker Study
352824|NCT01284049|Home Parenteral Nutrition
352825|NCT01284049|Intralipid 20%®
352826|NCT01284049|OMEGAVEN 10%®
352827|NCT01284049|Liver diseases
352828|NCT01284036|Healthy subject
352829|NCT01284036|safety
352830|NCT01284036|PK study
352831|NCT01284036|healthy volunteers
352832|NCT01284023|near infrared spectroscopy
352833|NCT01284023|acute compartment syndrome
352834|NCT01284010|adult acute lymphoblastic leukemia
352835|NCT01283997|Multiple Myeloma
352836|NCT01283997|Neuropathy
352837|NCT01283997|Peripheral Nerve Function
352838|NCT01283997|Touch Detection Threshold
352839|NCT01283997|Nerve Damage
352840|NCT01283997|Thalidomide
352841|NCT01283997|Bortezomib
352842|NCT01283997|Velcade
352843|NCT01283997|Minocycline
352844|NCT01283997|Dynacin
352845|NCT01283997|Minocin
352846|NCT01283997|Minocin PAC
352847|NCT01283997|Myrac
352848|NCT01283997|Solodyn
352849|NCT01283984|Safety
352850|NCT01283984|tolerability
352851|NCT01283984|healthy
352852|NCT01283984|inhaled
352853|NCT01283984|respiratory disease
352854|NCT01282983|fiber
352855|NCT01282983|orange juice
352856|NCT01282983|digestive symptom
352857|NCT01282944|physical activity in adults 65 or older
352858|NCT01282931|Women
352859|NCT01282931|Stage IV
352860|NCT01282931|Metastatic
352861|NCT01282931|Breast Cancer
352862|NCT01282931|Progressed
352863|NCT01282931|Progression
352864|NCT01282918|ICD
352865|NCT01282918|DF Test
352866|NCT01282918|intra-operative DF testing
352867|NCT01282918|VT
352868|NCT01282892|Visceral fat
352869|NCT01282892|fatty liver
352870|NCT01282892|atherosclerosis
352871|NCT01282892|coronary computed tomography angiography
352872|NCT01283958|Iloprost, Eisenmenger's syndrome
352873|NCT01283945|VEGFRs
352874|NCT01283945|FGFR1
352875|NCT01283945|angiogenesis
352876|NCT01283906|Mucositis
352877|NCT01283906|Head and Neck Cancer
352878|NCT01283906|Squamous Cell Cancer
352879|NCT01283906|Chemotherapy
352880|NCT01283906|Radiation Therapy
352881|NCT01283906|Oral Rinse
352882|NCT01283880|kidney
352883|NCT01283880|transplantation
352884|NCT01283880|metabolic acidosis
352885|NCT01283880|renal tubular acidosis
352886|NCT01283880|nephrocalcinosis
352887|NCT01283815|Laparoscopy
352888|NCT01283815|Drainage
352889|NCT01283815|Appendectomy
352890|NCT01283789|breast
352891|NCT01283789|cancer
352892|NCT01283789|metastatic
352893|NCT01283789|metastasis
352894|NCT01283763|Cervical Intraepithelial Neoplasia, Imiquimod, conization
352895|NCT01283750|care coordination
352896|NCT01283750|dementia care
352897|NCT01283750|intervention
352898|NCT01283750|unmet needs
352899|NCT01283750|community
352900|NCT01283750|older adults
352901|NCT01283750|caregiver
352902|NCT01283737|Osteochondritis Dissecans
352903|NCT01283737|OCD
352904|NCT01283737|Mosaicplasty
352905|NCT01283737|Demineralised Bone Matrix
352906|NCT01283737|DBX
352907|NCT01283737|DBX Putty
352908|NCT01283724|Endometriosis
352909|NCT01283724|DEXA
352910|NCT01283724|Adolescent
352911|NCT01283724|Safety
352912|NCT01283724|Efficacy
352913|NCT01283724|Post-menarche
352914|NCT01283711|wrinkles reduction
352915|NCT01283711|rhytides reduction
352916|NCT01283711|RF treatment
352917|NCT01283698|psoriasis
352918|NCT01283698|topical
352919|NCT01283698|PPT
352920|NCT01283685|Exercise, Physical
352921|NCT01283672|Whole grains
352922|NCT01283672|Barley
352923|NCT01283672|Oats
352924|NCT01283672|Cardiovascular disease
352925|NCT01283672|Postprandial lipid metabolism
352926|NCT01283672|Endothelial function
352927|NCT01283672|Risk of cardiovascular disease in healthy men and women
352928|NCT01283659|computed tomographic angiography
352929|NCT01283659|coronary angiogram
352930|NCT01283659|cost effectiveness
352931|NCT01283659|QoL
352932|NCT01283659|Heart failure
352933|NCT01283659|diagnostic accuracy
352934|NCT01283659|prospective comparative effectiveness randomized clinical trial
352935|NCT01283633|neuromodulation
352936|NCT01283633|remote presence robotics
352937|NCT01283620|stroke
352938|NCT01283620|extremity, upper
352939|NCT01283607|in vitro fertilization
352940|NCT01283607|e-health
352941|NCT01283607|cognitive behavioral therapy
352942|NCT01283607|psychosocial risk profile
352943|NCT01283607|emotional maladjustment
352944|NCT01283568|PMS, climacteric, depression
352945|NCT01283555|Microbicide, Applicator, Safety
352946|NCT01283542|Non-functioning pituitary adenoma,
352947|NCT01283542|pasireotide LAR,
352948|NCT01283542|tumor volume
352949|NCT01283529|Intrathoracal blood volume
352950|NCT01283529|Cardiac output
352951|NCT01283529|Children
352952|NCT01283516|ALK inhibitor,
352953|NCT01283516|NSCLC,
352954|NCT01283516|LDK378,
352955|NCT01283516|ceritinib,
352956|NCT01283516|genetic abnormalities
352957|NCT01283503|PI3K,
352958|NCT01283503|Advanced solid tumor
352959|NCT01283490|topical anesthetic, sonophoresis
352960|NCT01283477|Caesarean Delivery
352961|NCT01283477|Pruritis
352962|NCT01283477|Intrathecal Morphine
352963|NCT01283477|Acupuncture At LI11
352964|NCT01283464|Retinol
352965|NCT01283464|Tretinoin
352966|NCT01283451|near-infrared spectroscopy
352967|NCT01283425|MiniMed Paradigm insulin pump
352968|NCT01283425|insulin Lispro
352969|NCT01283425|Insulin Aspart
352970|NCT01283425|Quick-set infusion set
352971|NCT01283412|Delirium
352972|NCT01283412|Dexmedetomidine
352973|NCT01283412|Adult Patients
352974|NCT01283412|Elective Major Surgery
352975|NCT01283412|General Anesthesia
352976|NCT01283360|MSM
352977|NCT01283360|HIV negative
352978|NCT01283360|microbicide
352979|NCT01283360|prevention
352980|NCT01283347|Parkinson's disease
352981|NCT01283334|Head and Neck Cancer
352982|NCT01283334|Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
352983|NCT01283321|Hemostasis
352984|NCT01283321|Cardiopulmonary bypass (heart-lung machine)
352985|NCT01283321|Fibrinogen
352986|NCT01283321|platelet
352987|NCT01283308|Diabetes Mellitus, Type 2
352988|NCT01283308|India
352989|NCT01283308|Prevention & Control
352990|NCT01283308|Lifestyle Intervention
352991|NCT01283308|Translational Research
352992|NCT01283269|Rehabilitation
352993|NCT01283269|Cognitive Intervention
352994|NCT01283269|Prevention
352995|NCT01283243|ARFI Imaging
352996|NCT01283243|Normal values
352997|NCT01283243|HIV infection
352998|NCT01283230|ARFI imaging
352999|NCT01283230|normal values
353000|NCT01283230|chronic liver disease
353001|NCT01283230|liver donors
353002|NCT01283230|kidney donors
353003|NCT01283191|substance use
353004|NCT01283191|drug use
353005|NCT01283191|drug abuse
353006|NCT01283191|exercise
353007|NCT01283191|physical activity
353008|NCT01283178|squamous cell carcinoma of the paranasal sinus and nasal cavity
353009|NCT01283165|health education
353010|NCT01283165|Polyparasitism
353011|NCT01283165|school based deworming program
353012|NCT01283165|integrated control of parasites
353013|NCT01283152|Hepatic Encephalopathy
353014|NCT01283152|HE
353015|NCT01283152|Cirrhosis
353016|NCT01283152|PSE
353017|NCT01283152|Portosystemic Encephalopathy
353018|NCT01283152|Hepatic coma
353019|NCT01283152|AMS
353020|NCT01283152|Altered mental status
353021|NCT01283152|Complications of cirrhosis
353022|NCT01283152|Chronic liver disease
353023|NCT01283139|SLE
353024|NCT01283139|Systemic Lupus Erythematosus
353025|NCT01283139|Sifalimumab
353026|NCT01283139|MEDI-545
353027|NCT01283126|Hypoglycemia, cognitive function
353028|NCT01283113|Visceral Fat
353029|NCT01283113|Waist Circumference
353030|NCT01283113|Bioelectrical Impedance
353031|NCT01283113|Metabolic Syndrome
353032|NCT01283113|Obesity
353033|NCT01283113|Type 2 Diabetes
353034|NCT01283100|HIV, GSK2248761, GSK1349572, drug interaction, pharmacokinetics
353035|NCT01283087|TNS
353036|NCT01283087|Spinal anesthesia
353037|NCT01283087|Lidocaine
353038|NCT01283048|Kidney Cancer
353039|NCT01283048|Avastin
353040|NCT01283022|Pharmacokinetics
353041|NCT01283022|Misoprostol Vaginal Insert
353042|NCT01283022|Induction of labor
353043|NCT01283022|Cervical Ripening
353044|NCT01283022|Rate of Cesarean section
353045|NCT01283009|Mycoplasma pneumoniae
353046|NCT01282996|Mechanical ventilation
353047|NCT01282996|Postoperative pulmonary complications
353048|NCT01282996|Positive end-expiratory pressure
353049|NCT01282996|Protective lung ventilation
353050|NCT01282996|Alveolar recruitment maneuver
353051|NCT01282996|General anesthesia
353052|NCT01282996|Abdominal surgery
353053|NCT01282879|Itraconazole oral solution
353054|NCT01282879|invasive fungal infections
353055|NCT01282879|prophylaxis
353056|NCT01282879|Graft vs Host Disease
353057|NCT01282879|transplantation
353058|NCT01282853|peptic ulcer
353059|NCT01282853|hemorrhage
353060|NCT01282853|rapid urease test
353061|NCT01282853|urea breath test
353062|NCT01282840|LUTS
353063|NCT01282814|Bioequivalence
353064|NCT01282814|Healthy Subjects
353065|NCT01282801|Bioequivalence
353066|NCT01282801|Healthy Subjects
353067|NCT01282788|infant nutrition
353068|NCT01282788|complementary feeding
353069|NCT01282788|malnutrition
353070|NCT01282788|stunting of growth
353071|NCT01282775|overweight
353072|NCT01282775|obesity
353073|NCT01282775|worksite
353074|NCT01282762|Prevention of Hepatitis B infection.
353075|NCT01282762|End Stage Renal Disease
353076|NCT01282762|Hepatitis B vaccination
353077|NCT01282762|Hepatitis B virus (HBV)
353078|NCT01282749|Overweight
353079|NCT01282749|Obesity
353080|NCT01282749|African American
353081|NCT01282749|Women
353082|NCT01282749|Translational
353083|NCT01282749|Faith based
353084|NCT01282749|Community based participatory research
353085|NCT01282736|eating disorder
353086|NCT01282736|binge eating
353087|NCT01282684|Safety
353088|NCT01282684|Tolerability
353089|NCT01282684|Pharmacokinetics
353090|NCT01282684|PLX5622
353091|NCT01282671|breathing exercises
353092|NCT01282671|cardiac surgery
353093|NCT01282671|lung function
353094|NCT01282671|postoperative complication
353095|NCT01282671|positive expiratory pressure
353096|NCT01282658|CPT-11,pharmacogenomics,colorectal cancer
353097|NCT01282645|Cranial defect
353098|NCT01282645|PSI
353099|NCT01282645|patient specific implant
353100|NCT01282645|PEEK
353101|NCT01282645|polyether ether ketone
353102|NCT01282645|craniectomy
353103|NCT01282645|craniotomy
353104|NCT01282632|depression
353105|NCT01282632|treatment resistant depression
353106|NCT01282632|unipolar
353107|NCT01282632|non- psychotic major depression
353108|NCT01282632|add-on to a serotonin type antidepressants
353109|NCT01282632|risperidone
353110|NCT01282632|olanzapine
353111|NCT01282632|double blind comparison
353112|NCT01282632|randomized
353113|NCT01282606|Chemonucleolysis
353114|NCT01282606|Lumbar Vertebrae
353115|NCT01282606|Hernia
353116|NCT01282593|TEL/ALM1_positive ALL relapses
353117|NCT01282580|Women at high risk of developing breast cancer
353118|NCT01282541|Tearing, Epiphora, Botulinum Toxin A
353119|NCT01282502|rectal cancer
353120|NCT01282502|chemotherapy
353121|NCT01282502|chemoradiation
353122|NCT01282476|DLBCL
353123|NCT01282476|Panobinostat
353124|NCT01282476|LBH589
353125|NCT01282476|LBH-589
353126|NCT01282476|HDAC inhibitor
353127|NCT01282476|DAC inhibitor
353128|NCT01282476|deacetylase inhibitor
353129|NCT01282476|lymphoma
353130|NCT01282463|Carcinoma, Renal Cell
353131|NCT01282450|Radiotherapy
353132|NCT01282450|NSCLC
353133|NCT01282424|indolent Non-Hodgkin Lymphoma
353134|NCT01282424|Non-Hodgkin Lymphoma
353135|NCT01282424|iNHL
353136|NCT01282424|NHL
353137|NCT01282424|GS-1101
353138|NCT01282424|CAL-101
353139|NCT01282424|PI3K
353140|NCT01282424|Phosphatidylinositol 3-kinase
353141|NCT01282424|Follicular Lymphoma (FL)
353142|NCT01282424|Small lymphocytic lymphoma (SLL)
353143|NCT01282424|Lymphoplasmacytoid lymphoma (LPL)
353144|NCT01282424|Marginal zone lymphoma (MZL)
353145|NCT01282372|Ankylosing spondylitis
353146|NCT01282372|Sleep
353147|NCT01282372|Psoriatic arthritis
353148|NCT01282372|Work Productivity
353149|NCT01282372|Rheumatoid Arthritis
353150|NCT01282359|Educational asthma program
353151|NCT01282359|Clusters analysis study
353152|NCT01282359|Asthma Control Test
353153|NCT01282346|Glaucoma shunt
353154|NCT01282346|Ocular implant
353155|NCT01282346|Gold
353156|NCT01282346|Trabeculectomy
353157|NCT01282320|Randomized Controlled Trial
353158|NCT01282320|Clinical Tria
353159|NCT01282320|Postmenopause
353160|NCT01282320|Hot-flashes
353161|NCT01282320|Quality of life
353162|NCT01282320|Physical Fitness
353163|NCT01282307|Guided Self-Determination
353164|NCT01282307|Improving insight
353165|NCT01282307|Autonomy-supportive problem solving intervention
353166|NCT01282307|Evaluate the effects of the method Guided Self-Determination
353167|NCT01282307|Improving insight in patients diagnosed with schizophrenia
353168|NCT01282281|Bipolar Disorder
353169|NCT01282281|Youth
353170|NCT01282281|Adults
353171|NCT01282281|Endocrine-metabolic changes
353172|NCT01282268|fragile X syndrome
353173|NCT01282268|autism spectrum disorder
353174|NCT01282242|acute stroke, IV rt-PA, Activase, Alteplase
353175|NCT01282229|LANAP, Laser dentistry
353176|NCT01282203|General surgery
353177|NCT01282203|General anesthesia
353178|NCT01282203|Inhalation anesthesia
353179|NCT01282203|Sevorane
353180|NCT01282203|Sevoflurane
353181|NCT01282190|dyslipidemia, motivational interview, prevention
353182|NCT01282177|surveillance, safety , tolerability , vaccine
353183|NCT01282164|glucagon stimulation test
353184|NCT01282164|insulin tolerance test
353185|NCT01282164|growth hormone deficiency
353186|NCT01282164|hypothalamic-pituitary disorders
353187|NCT01282151|NSCLC
353188|NCT01282151|Non Squamous cell
353189|NCT01282151|Docetaxel
353190|NCT01282151|Pemetrexed
353191|NCT01282138|Allergic conjunctivitis
353192|NCT01282125|general population
353193|NCT01282125|prevalence
353194|NCT01282125|Norway
353195|NCT01282099|all children entering the PICU eligible for enrollment
353196|NCT01282099|age range: neonate to 16 years
353197|NCT01282086|Sevorane
353198|NCT01282086|Sevoflurane
353199|NCT01282086|General anesthesia
353200|NCT01282086|Inhalation anesthesia
353201|NCT01282086|General surgery
353202|NCT01282073|Idiopathic membranous nephropathy
353203|NCT01282073|Mycophenolate mofetil
353204|NCT01282073|Proteinuria
353205|NCT01282073|Renal function
353206|NCT01282060|HBA1C
353207|NCT01282060|DIABETES-RELATED COMPLICATIONS
353208|NCT01282060|GLYCAEMIC BALANCE
353209|NCT01282047|Lenalidomide
353210|NCT01282047|Kaposi
353211|NCT01282047|HIV
353212|NCT01282047|efficacy
353213|NCT01282047|safety
353214|NCT01282034|CHONDRAL
353215|NCT01282034|OSTEOCHONDRAL
353216|NCT01282021|RBC Antigens
353217|NCT01282021|Molecular Typing
353218|NCT01282021|Ethiopian Sub-Populations
353219|NCT01282021|Immunohematology
353220|NCT01282021|Immune Response
353221|NCT01282008|Online Surveys
353222|NCT01282008|Tobacco Corrective Statements
353223|NCT01282008|Message Testing
353224|NCT01282008|Focus Groups
353225|NCT01281995|Biologic Samples
353226|NCT01281995|Hydrocortisone
353227|NCT01281995|Laboratory Research Specimens
353228|NCT01281995|Glucocorticoids
353229|NCT01281995|Immune Modulation
353230|NCT01281995|Healthy Volunteer
353231|NCT01281995|HV
353232|NCT01281982|Imaging
353233|NCT01281982|Gliomas
353234|NCT01281982|Pet Scan
353235|NCT01281982|Blood Brain Barrier
353236|NCT01281982|P-Glycoprotein
353237|NCT01281982|Brain Tumor
353238|NCT01281982|Glioma
353239|NCT01281982|Glioblastoma Multiforme
353240|NCT01281982|Astrocytoma
353241|NCT01281969|Placebo Controlled
353242|NCT01281969|Obsessive-Compulsive Disorder
353243|NCT01281969|Children and Adolescents
353244|NCT01281969|Intravenous Immunoglobulin
353245|NCT01281969|PANDAS
353246|NCT01281956|Epilepsy
353247|NCT01281956|Drug Trial
353248|NCT01281956|Serotonin
353249|NCT01281956|Serotonin 1A Receptor
353250|NCT01281956|Temporal Lobe Epilepsy
353251|NCT01281956|Partial Epilepsy
353252|NCT01281930|Superficial abscess
353253|NCT01281930|packing material
353254|NCT01281930|wick
353255|NCT01281930|incision and drainage
353256|NCT01281917|velcade
353257|NCT01281917|temsirolimus
353258|NCT01281917|non-hodgkins lymphoma
353259|NCT01281891|Drug: Morphine intrathecal
353260|NCT01281891|Pain: Postoperative
353261|NCT01281891|Surgery: Total hip arthroplasty
353262|NCT01281878|primary hyperoxaluria
353263|NCT01281878|Pyridoxal-phosphate
353264|NCT01281839|Hepatitis C
353265|NCT01281839|TMC435
353266|NCT01281839|HCV
353267|NCT01281839|Hep C
353268|NCT01281839|Genotype 1
353269|NCT01281813|TMC114IFD3001
353270|NCT01281813|TMC114
353271|NCT01281813|HIV
353272|NCT01281813|Darunavir
353273|NCT01281813|PREZISTA
353274|NCT01281787|FAP= post-surgery atrial fibrillation
353275|NCT01281787|ACEI= angiotensin converting enzyme-inhibitors
353276|NCT01281787|ARBs= angiotensin II receptor blockers
353277|NCT01281787|NT-proBNP= brain natriuretic peptide
353278|NCT01281748|acute exacerbation of COPD
353279|NCT01281735|treatment outcome
353280|NCT01281735|side effects
353281|NCT01281735|Protein Kinase Inhibitors
353282|NCT01281735|pediatrics
353283|NCT01281722|healthy adults
353284|NCT01281722|melanoma
353285|NCT01281696|Breast cancer
353286|NCT01281696|CNS metastasis
353287|NCT01281696|Brain metastasis
353288|NCT01281696|Leptomeningeal metastasis
353289|NCT01281696|Bevacizumab
353290|NCT01281696|Etoposide
353291|NCT01281696|Cisplatin
353292|NCT01281670|H reflex; muscle activation; rate of force development; whole body vibration
353293|NCT01281657|Fingolimod
353294|NCT01281657|FTY720
353295|NCT01281657|Relapsing forms of multiple sclerosis
353296|NCT01281657|Multiple sclerosis
353297|NCT01281657|MS
353298|NCT01281657|Safety
353299|NCT01281657|Efficacy
353300|NCT01281644|Keratosis pilaris (KP)
353301|NCT01281631|ALS
353302|NCT01281618|Barrett's esophagus
353303|NCT01281605|Type 2 diabetes
353304|NCT01281605|Basal insulin
353305|NCT01281605|Insulin detemir
353306|NCT01281605|Insulin titration algorithm
353307|NCT01281579|Pharmacokinetics
353308|NCT01281579|Pharmacodynamics
353309|NCT01281579|Canagliflozin
353310|NCT01281566|Cisapride (Prepulsid)
353311|NCT01281566|Feeding intolerance
353312|NCT01281566|Enteral feeding
353313|NCT01281566|Nasogastric tube
353314|NCT01281566|Neonate
353315|NCT01281553|Cisapride (PREPULSID)
353316|NCT01281553|Placebo
353317|NCT01281553|Gastroesophageal Reflux Disease (GERD)
353318|NCT01281553|Gastro-oesophageal Reflux Disease (GORD)
353319|NCT01281540|Cisapride ( PREPULSID )
353320|NCT01281540|Placebo
353321|NCT01281540|Idiopathic
353322|NCT01281540|Stomach Diseases
353323|NCT01281540|Stomach
353324|NCT01281527|Paliperidone palmitate
353325|NCT01281527|Schizophrenia
353326|NCT01281527|Intramuscular injection
353327|NCT01281501|Dyspepsia
353328|NCT01281501|Emergency treatment
353329|NCT01281501|Pantoprazole
353330|NCT01281501|Antacid
353331|NCT01281501|Pain measurement
353332|NCT01281475|Angelman syndrome
353333|NCT01281475|Levodopa
353334|NCT01281475|Carbidopa
353335|NCT01281475|L-dopa
353336|NCT01281462|complicated Urinary Tract Infection
353337|NCT01281462|Acute Pyelonephritis
353338|NCT01281436|childhood
353339|NCT01281436|overweight
353340|NCT01281436|obesity
353341|NCT01281436|Health information technology
353342|NCT01281436|HeartSmartKids
353343|NCT01281436|Motivational Interviewing
353344|NCT01281410|respiratory muscles
353345|NCT01281410|hematopoetic stem cell transplantation
353346|NCT01281410|inspiratory muscle training
353347|NCT01281397|cardiac surgery
353348|NCT01281397|aggregometry
353349|NCT01281397|thromboelastometry
353350|NCT01281397|platelet function
353351|NCT01281397|bleeding
353352|NCT01281397|antiplatelet therapy
353353|NCT01281384|cardiac magnetic resonance imaging
353354|NCT01281384|echocardiography
353355|NCT01281384|heart failure
353356|NCT01281384|imaging
353357|NCT01281384|cost effectiveness
353358|NCT01281384|quality of life
353359|NCT01281384|definitive diagnosis
353360|NCT01281384|prospective comparative effectiveness randomized clinical trial
353361|NCT01281358|Premature infants
353362|NCT01281358|Motor Development
353363|NCT01281345|icu
353364|NCT01281345|candida
353365|NCT01281345|epidemiology
353366|NCT01281345|blood stream infection
353367|NCT01281345|candidemia
353368|NCT01281332|menopause
353369|NCT01281332|hot flash
353370|NCT01281332|quality of life
353371|NCT01281319|preterm labor
353372|NCT01281319|PROM
353373|NCT01281319|mycoplasma
353374|NCT01281319|ureaplasma
353375|NCT01281319|high risk pregnancy
353376|NCT01281306|hypertension
353377|NCT01281306|blood pressure
353378|NCT01281306|LCZ696
353379|NCT01281306|dual-acting
353380|NCT01281306|neprilysin
353381|NCT01281306|nep inhibitor
353382|NCT01281306|vasopeptidase
353383|NCT01281306|angiotensin receptor
353384|NCT01281306|angiotensin receptor neprilysin inhibitor (ARNi)
353385|NCT01281293|V-COMPAS; Vagus Nerve Stimulation Clinical Outcomes;
353386|NCT01281280|PuLsE 2, Drug-resistant Epilepsy Partial-onset Seizures
353387|NCT01281267|facial transplantation
353388|NCT01281267|face transplantation
353389|NCT01281267|composite tissue allotransplantation
353390|NCT01281267|VCA
353391|NCT01281267|composite tissue allograft
353392|NCT01281267|facial allograft
353393|NCT01281254|Fallopian tube cancer
353394|NCT01281254|Primary peritoneal cancer
353395|NCT01281254|AMG386
353396|NCT01281254|Pegylated Liposomal Doxorubicin
353397|NCT01281254|Recurrent epithelial ovarian cancer
353398|NCT01281241|MTWA
353399|NCT01281241|mechanical alternans
353400|NCT01281228|Exenatide
353401|NCT01281228|Type 2 diabetes mellitus
353402|NCT01281228|Incretin hormones
353403|NCT01281228|GLP-1 agonist
353404|NCT01281228|Satiety
353405|NCT01281228|Reward
353406|NCT01281215|Pharmaceutical Education
353407|NCT01281215|Rational Drug Use
353408|NCT01281215|Asthma
353409|NCT01281202|Cocaine
353410|NCT01281202|Cocaine Addiction Treatment
353411|NCT01281202|Cocaine Treatment
353412|NCT01281202|Vigabatrin
353413|NCT01281202|CPP-109
353414|NCT01281202|Catalyst
353415|NCT01281202|National Institute on Drug Abuse
353416|NCT01281189|Amyotrophic Lateral Sclerosis
353417|NCT01281189|ALS
353418|NCT01281189|Motor Neurone Disease
353419|NCT01281137|stage IA breast cancer
353420|NCT01281137|stage IB breast cancer
353421|NCT01281137|stage II breast cancer
353422|NCT01281137|stage IIIA breast cancer
353423|NCT01281098|High Risk Proliferative Diabetic Retinopathy
353424|NCT01281098|Diabetes Mellitus Type I, Type II
353425|NCT01281098|Pegaptanib
353426|NCT01281098|Panretinal Photocoagulation
353427|NCT01281085|Shoulder
353428|NCT01281085|Outcome treatment
353429|NCT01281085|Validation Studies
353430|NCT01281085|Biomechanics
353431|NCT01281033|primary PCI
353432|NCT01281033|ST-segment elevation myocardial infarction
353433|NCT01281033|thrombus aspiration
353434|NCT01281020|Glaucoma
353435|NCT01281020|Adherence
353436|NCT01281020|Fixed combination therapy
353437|NCT01281007|Herpes Simplex Virus
353438|NCT01280994|Lung Disease
353439|NCT01280994|Pulmonary Disease
353440|NCT01280994|Diagnostic Imaging
353441|NCT01280994|MRI
353442|NCT01280981|Menorrhagia
353443|NCT01280981|Heavy Menstrual Bleeding
353444|NCT01280981|Lysteda
353445|NCT01280955|Plerixafor and Allogeneic Myeloablative Stem Cell Transplant
353446|NCT01280942|clinical deterioration
353447|NCT01280942|detection algorithms
353448|NCT01280942|automated warning systems
353449|NCT01280929|High Risk Proliferative Diabetic Retinopathy
353450|NCT01280929|Ranibizumab
353451|NCT01280929|Panretinal Photocoagulation
353452|NCT01280903|Osteoarthritis, Knee
353453|NCT01280903|Hypertension
353454|NCT01280903|Exercise
353455|NCT01280903|Physical activity
353456|NCT01280903|Self Efficacy
353457|NCT01280903|Patient Compliance
353458|NCT01280903|Aged
353459|NCT01280890|Dementia
353460|NCT01280890|Nursing home
353461|NCT01280890|Person-centred Care
353462|NCT01280890|Staff training
353463|NCT01280877|optic neuropathy
353464|NCT01280877|visual field
353465|NCT01280877|electric stimulation
353466|NCT01280877|alternating current
353467|NCT01280877|perimetry
353468|NCT01280851|Living renal donor
353469|NCT01280851|Magnetic Resonance Imaging
353470|NCT01280851|Renal vascular anatomy
353471|NCT01280851|Renal function
353472|NCT01280812|mobile phone
353473|NCT01280812|physical activity
353474|NCT01280812|women
353475|NCT01280812|maintenance
353476|NCT01280812|health promotion
353477|NCT01280812|prevention
353478|NCT01280799|Anorexia Nervosa
353479|NCT01280799|Adolescents
353480|NCT01280799|Family Treatment
353481|NCT01280799|Eating Disorder
353482|NCT01280799|Acceptance and Commitment Therapy
353483|NCT01280786|AML
353484|NCT01280786|leukemia
353485|NCT01280786|relapsed or refractory AML
353486|NCT01280773|weaning, mechanical ventilation
353487|NCT01280747|Prior authorization
353488|NCT01280747|Fibromyalgia
353489|NCT01280747|Painful Diabetic Peripheral Neuropathy
353490|NCT01280747|Policy
353491|NCT01280747|Real World Data
353492|NCT01280734|melatonin
353493|NCT01280734|circadin
353494|NCT01280734|zolpidem
353495|NCT01280734|body sway
353496|NCT01280734|postural instability
353497|NCT01280708|Urology
353498|NCT01280708|Nephrology
353499|NCT01280708|Renal and pancreas transplantation
353500|NCT01280708|Data base
353501|NCT01280708|Epidemiology
353502|NCT01280695|Type 2
353503|NCT01280695|Diabetes Mellitus
353504|NCT01280695|Diabetes
353505|NCT01280695|High blood sugar
353506|NCT01280695|Blood sugar
353507|NCT01280695|Blood glucose
353508|NCT01280695|Glucose
353509|NCT01280682|type 1 diabetes
353510|NCT01280682|age
353511|NCT01280682|course of disease
353512|NCT01280682|autoantibodies
353513|NCT01280682|C-peptide levels
353514|NCT01280669|Non-infectious
353515|NCT01280669|Uveitis
353516|NCT01280669|Panuveitis
353517|NCT01280643|stage IVA colon cancer
353518|NCT01280643|stage IVA rectal cancer
353519|NCT01280643|stage IVB colon cancer
353520|NCT01280643|stage IVB rectal cancer
353521|NCT01280630|ACS: Acute coronary syndrome Retrospective Registry
353522|NCT01280617|Renal Transplant
353523|NCT01280617|Thymoglubulin
353524|NCT01280591|Naproxen sodium
353525|NCT01280591|Diphenhydramine
353526|NCT01280578|Migraine
353527|NCT01280565|non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit
353528|NCT01280552|Glioblastoma Multiforme
353529|NCT01280539|Multiple Sclerosis
353530|NCT01280539|Transcutaneous electrical nerve stimulation
353531|NCT01280539|Cortical Excitability
353532|NCT01280487|ZSTK474
353533|NCT01280487|PI3K inhibitor
353534|NCT01280474|depression during pregnancy
353535|NCT01280474|postpartum depression
353536|NCT01280474|pregnancy outcomes
353537|NCT01280474|newborn development
353538|NCT01280474|paternal psychopathology
353539|NCT01280461|Pneumonia
353540|NCT01280448|Lung Cancer
353541|NCT01280448|Tobacco Smoking
353542|NCT01280448|gene polymorphism
353543|NCT01280435|Online Discourse
353544|NCT01280435|e-Learning
353545|NCT01280435|Biopsy
353546|NCT01280435|Virtual Pathologic Section
353547|NCT01280422|ROCDR
353548|NCT01280396|metabolic
353549|NCT01280396|SGAs
353550|NCT01280396|clozapine
353551|NCT01280383|non-invasive ventilation
353552|NCT01280383|diaphragm
353553|NCT01280383|electrical activity
353554|NCT01280383|neurally adjusted ventilatory assist
353555|NCT01280383|critically ill patients
353556|NCT01280370|Incisional hernia repair
353557|NCT01280357|Fetal Heart Rate (FHR)
353558|NCT01280357|Uterine Activity (UA)
353559|NCT01280357|Labor & Delivery
353560|NCT01280331|Bunionectomy
353561|NCT01280305|schizophrenia
353562|NCT01280305|schizoaffective disorder
353563|NCT01280292|central hypothyroidism, hypopituitarism, eltroxin
353564|NCT01280279|Behavior modification, Behavior therapy, Nocturia, Polyuria, Quality of life
353565|NCT01280266|Pathological Conditions
353566|NCT01280266|Signs and Symptoms
353567|NCT01280266|Blood circulation
353568|NCT01280253|Predictor
353569|NCT01280253|outcome
353570|NCT01280253|biochemical
353571|NCT01280240|anemia
353572|NCT01280240|cancer
353573|NCT01280240|CIA
353574|NCT01280227|Symptom management
353575|NCT01280227|Symptom assessment
353576|NCT01280227|Patient satisfaction
353698|NCT01279681|stage IVB colon cancer
353577|NCT01280227|Patient-provider communication
353578|NCT01280201|Neuroendocrine Tumors
353579|NCT01280201|Pazopanib
353580|NCT01280201|GETNE
353581|NCT01280201|Biomarkers
353582|NCT01280188|Diabetes
353583|NCT01280175|BDP
353584|NCT01280175|Formoterol
353585|NCT01280175|pMDI
353586|NCT01280175|Aerochamber Plus
353587|NCT01280175|Charcoal
353588|NCT01280162|Plasmodium falciparum, Plasmodium vivax
353589|NCT01280149|substance P
353590|NCT01280149|allergic rhinitis
353591|NCT01280149|allergen immunotherapy
353592|NCT01280136|HIV
353593|NCT01280136|Sexually Transmitted Diseases
353594|NCT01280136|Pregnancy Prevention
353595|NCT01280136|Abstinence Education
353596|NCT01280136|Adolescents
353597|NCT01280136|Sexual Health
353598|NCT01280123|Parkinson's Disease
353599|NCT01280123|Biomarkers
353600|NCT01280110|dry eye
353601|NCT01280110|pseudophakia
353602|NCT01280110|cornea
353603|NCT01280110|lubricating drop
353604|NCT01280110|BAK
353605|NCT01280110|blood aqueous barrier
353606|NCT01280110|blood-retina barrier
353607|NCT01280097|Intensive care unit delirium
353608|NCT01280097|Sleep disruption
353609|NCT01280097|Sleep hygiene
353610|NCT01280097|Early mobilization in the Intensive care unit
353611|NCT01280097|Sedative agents and sleep
353612|NCT01280097|Circadian rhythm
353613|NCT01280097|Cognitive disorder
353614|NCT01280097|Electroencephalography (EEG) to measure sleep
353615|NCT01280097|Confusion Assessment Method in the Intensive Care Unit
353616|NCT01280097|Immune function
353617|NCT01280097|REM sleep
353618|NCT01280084|neonate activity
353619|NCT01280084|labour analgesia
353620|NCT01280032|intraoperative radiotherapy
353621|NCT01280032|kyphoplasty
353622|NCT01280032|spinal metastases
353623|NCT01280019|functional residual capacity
353624|NCT01280019|electrical impedance tomography
353625|NCT01280019|inflammatory parameters
353626|NCT01280006|Obstructive Sleep Apnea
353627|NCT01280006|Hypoxia
353628|NCT01280006|Sleep
353629|NCT01280006|Blood Pressure
353630|NCT01280006|Hypertension
353631|NCT01280006|Myocardial Infarction
353632|NCT01280006|Stroke
353633|NCT01280006|Ventilation
353634|NCT01280006|Brain
353635|NCT01280006|Cerebral Blood Flow
353636|NCT01280006|Renal Blood Flow
353637|NCT01279980|ERAS
353638|NCT01279980|Local anaesthetic wound catheter
353639|NCT01279980|Painbuster
353640|NCT01279980|Epidural
353641|NCT01279980|colorectal surgery
353642|NCT01279980|enhanced recovery program
353643|NCT01279967|Pleural Mesothelioma
353644|NCT01279967|ADI-PEG 20
353645|NCT01279928|paediatric and adolescent population
353646|NCT01279928|nailfold capillaroscopy
353647|NCT01279928|laser Doppler flowmetry
353648|NCT01279928|retinal vessel calibre
353649|NCT01279928|retinal vessel fractal analysis
353650|NCT01279928|24 hour Ambulatory Blood Pressure Monitoring
353651|NCT01279915|ASP0456
353652|NCT01279915|Pharmacokinetics
353653|NCT01279915|safety
353654|NCT01279915|tolerability
353655|NCT01279902|diffuse large B-cell lymphoma
353656|NCT01279902|rituximab
353657|NCT01279902|CHOP
353658|NCT01279902|abbreviated therapy
353659|NCT01279889|hypotension
353660|NCT01279889|cesarean delivery
353661|NCT01279889|cardiac output
353662|NCT01279889|blood pressure
353663|NCT01279889|plethysmography variability index
353664|NCT01279863|Pneumonia
353665|NCT01279863|Cough
353666|NCT01279863|Shortness of breath
353667|NCT01279863|VRI
353668|NCT01279850|Lyrica
353669|NCT01279850|Regulatory Post Marketing Commitment Plan
353670|NCT01279850|Safety
353671|NCT01279850|Neuropathic Pain
353672|NCT01279850|Post Marketing Surveillance
353673|NCT01279837|swallowing disorders
353674|NCT01279837|swallowing therapy
353675|NCT01279837|head neck cancer
353676|NCT01279837|oropharyngeal dysphagia
353677|NCT01279824|swallowing, treatment, stroke,rehabilitation
353678|NCT01279811|spinal cord injury, CSF, biomarkers, CSF pressure
353679|NCT01279798|Lung Cancer
353680|NCT01279798|NSCLC
353681|NCT01279798|stage III or IV NSCLC
353682|NCT01279785|Molecular Imaging
353683|NCT01279785|PSMA
353684|NCT01279785|adenocarcinoma
353685|NCT01279785|prostatectomy
353686|NCT01279759|Anterior Cruciate Ligament Reconstruction Predictive Factors
353687|NCT01279759|Function Downstairs walking Step time Symmetry
353688|NCT01279746|DVT Ultrasound compression Hypoxia Pulmonary Emboli
353689|NCT01279746|Occult DVT in hypoxic patients
353690|NCT01279733|microarray
353691|NCT01279720|Adenosine deaminase deficiency
353692|NCT01279720|Gene therapy
353693|NCT01279694|newly-diagnosed multiple myeloma.
353694|NCT01279681|neurotoxicity
353695|NCT01279681|cognitive/functional effects
353696|NCT01279681|stage IVA colon cancer
353697|NCT01279681|stage IVA rectal cancer
353699|NCT01279681|stage IVB rectal cancer
353700|NCT01279681|recurrent colon cancer
353701|NCT01279681|recurrent rectal cancer
353702|NCT01279668|Montelukast
353703|NCT01279668|Persistent cough
353704|NCT01279668|Adults
353705|NCT01279668|Double-blind randomised placebo controlled trial
353706|NCT01279642|Catheterization, Peripheral
353707|NCT01279642|Ultrasonography, Interventional
353708|NCT01279642|Nursing
353709|NCT01279642|Pediatric
353710|NCT01279629|chronic plaque psoriasis
353711|NCT01279629|To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis
353712|NCT01279616|sickle cell
353713|NCT01279616|stem cell transplant
353714|NCT01279603|Cancer
353715|NCT01279590|Hyperlipidemia
353716|NCT01279590|Dyslipidemia
353717|NCT01279590|Metabolic diseases
353718|NCT01279590|Lipid metabolism disorders
353719|NCT01279590|Hyperlipoproteinemia Type IIa
353720|NCT01279590|Hyperlipoproteinemia Type IIb
353721|NCT01279590|Hypercholesterolemia, Autosomal Dominant
353722|NCT01279590|Hypercholesterolemia, Autosomal Dominant, Type B
353723|NCT01279590|Frederickson Type IIa
353724|NCT01279590|Frederickson Type IIb Hyperlipidemia
353725|NCT01279577|Crohn´s disease
353726|NCT01279577|Trichuris suis
353727|NCT01279577|randomized
353728|NCT01279577|placebo
353729|NCT01279577|induction of remission
353730|NCT01279577|porcine whipworm
353731|NCT01279564|Endotracheal intubation and its outcomes
353732|NCT01279538|Kidney Transplantation
353733|NCT01279538|Pharmacokinetics
353734|NCT01279538|Pharmacology
353735|NCT01279538|ASKP1240
353736|NCT01279525|Falls
353737|NCT01279525|Prevention
353738|NCT01279525|Elderly
353739|NCT01279512|Metformin Acarbose pco infertility overweight
353740|NCT01279499|Morbid obesity
353741|NCT01279499|Sevoflurane
353742|NCT01279499|Propofol
353743|NCT01279499|Remifentanyl
353744|NCT01279499|BIS
353745|NCT01279499|Cardiovascular stability
353746|NCT01279499|Recovery scores
353747|NCT01279499|Drug consumption
353748|NCT01279486|Pregnancy,
353749|NCT01279473|Chronic Myelogenous Leukemia
353750|NCT01279473|CML
353751|NCT01279473|Acute Lymphoblastic Leukemia
353752|NCT01279473|Philadelphia Chromosome Positive, ph+ ALL
353753|NCT01279473|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
353754|NCT01279460|chronic kidney disease
353755|NCT01279460|CKD
353756|NCT01279460|pulse wave velocity
353757|NCT01279460|PWV
353758|NCT01279447|infrapatellar nerve
353759|NCT01279447|saphenous nerve
353760|NCT01279447|knee arthroscopy
353761|NCT01279447|nerve block
353762|NCT01279408|Palliative treatment
353763|NCT01279408|advanced non-small cell lung cancer
353764|NCT01279408|Patients with Asymptomatic Centrally Located Advance NSCLC who are palliative
353765|NCT01279395|atherosclerosis
353766|NCT01279395|cholesterol
353767|NCT01279395|cyclooxygenase
353768|NCT01279395|gene expression
353769|NCT01279395|lipid metabolism
353770|NCT01279382|Symptoms
353771|NCT01279382|Psychological status
353772|NCT01279382|Hypnotherapy
353773|NCT01279382|Relaxation training
353774|NCT01279369|Pregnancy
353775|NCT01279369|Trauma
353776|NCT01279369|Placental Abruption
353777|NCT01279369|Fetal fibronectin
353778|NCT01279356|Liver diseases
353779|NCT01279356|Volatile organic compounds
353780|NCT01279356|Inflammation
353781|NCT01279356|Oxidative stress
353782|NCT01279356|non-invasive tests
353783|NCT01279343|labor induction
353784|NCT01279343|foley bulb
353785|NCT01279343|misoprostol
353786|NCT01279330|Colorectal Cancer
353787|NCT01279330|Screening
353788|NCT01279330|General Practitioner
353789|NCT01279330|Fecal Occult Blood Tests
353790|NCT01279304|breast cancer
353791|NCT01279304|locoregional recurrence rate
353792|NCT01279304|neoadjuvant chemotherapy and surgery
353793|NCT01279304|radiotherapy
353794|NCT01279304|risk model
353795|NCT01279304|overall survival
353796|NCT01279304|relapse free survival
353797|NCT01279304|cT1-2cN0-1 breast cancer
353798|NCT01279291|advanced solid tumor
353799|NCT01279291|Ovarian cancer
353800|NCT01279291|Primary peritoneal cancer
353801|NCT01279291|Fallopian tube cancer
353802|NCT01279278|Colorectal Cancer
353803|NCT01279278|Screening
353804|NCT01279278|General Practitioner
353805|NCT01279278|Fecal Occult Blood Tests
353806|NCT01279265|Lactobacillus
353807|NCT01279265|Probiotic
353808|NCT01279265|Crying time
353809|NCT01279265|Fecal microbiota
353810|NCT01279265|Calprotectin
353811|NCT01279265|Colic
353812|NCT01279265|Infant Crying
353813|NCT01279265|Barr Diary
353814|NCT01279265|Breath Hydrogen
353815|NCT01279265|Clinical Design
353816|NCT01279239|Poly Trauma
353817|NCT01279239|Metabonomics
353818|NCT01279239|NMR
353819|NCT01279239|MOF
353820|NCT01279200|letrozole
353821|NCT01279200|ovulation monitoring
353822|NCT01279200|pregnancy rate
353823|NCT01279187|dental
353824|NCT01279187|implant
353825|NCT01279174|Hip, arthrosis
353826|NCT01279161|overweight, obesity, children, insulin, pump therapy, FTO
353827|NCT01279148|biopsy guidance
353828|NCT01279148|tracking device
353829|NCT01279135|IGRT,Postoperative, Cervix, Late toxicity, Bowel
353830|NCT01279109|gestational weight gain
353831|NCT01279096|Acute lymphoblastic leukemia
353832|NCT01279096|relapse
353833|NCT01279096|childhood
353834|NCT01279096|clofarabine
353835|NCT01279070|Schizophrenia
353836|NCT01279070|Cognitive remediation
353837|NCT01279070|Group training
353838|NCT01279070|Executive function
353839|NCT01279070|Social functioning
353840|NCT01279057|Rhinitis, allergic, seasonal, fluticasone furoate, equivalence
353841|NCT01279044|HIV
353842|NCT01279044|MSM
353843|NCT01279044|SUMSM
353844|NCT01279018|Persistent postsurgical pain
353845|NCT01279018|breast cancer
353846|NCT01279018|postmastectomy pain syndrome
353847|NCT01279018|neuropathic pain
353848|NCT01279005|MSM
353849|NCT01279005|focus group
353850|NCT01279005|HIV
353851|NCT01279005|risk-taking
353852|NCT01279005|risk-denial
353853|NCT01279005|signature on inform consent, willing to participate, MSM either HIV positive or negative, age 20-50 years old
353854|NCT01278992|fatigue
353855|NCT01278992|adaptogen
353856|NCT01278992|Rhodiola rosea
353857|NCT01278979|obstetric
353858|NCT01278979|perineal tear
353859|NCT01278979|perineal injury
353860|NCT01278979|diagnosis
353861|NCT01278966|Epilepsy
353862|NCT01278966|Diet
353863|NCT01278966|the Modified Atkins Diet
353864|NCT01278966|Ketogenic diet
353865|NCT01278953|paroxysmal atrial fibrillation
353866|NCT01278953|atrial fibrillation
353867|NCT01278953|radiofrequency ablation
353868|NCT01278953|pulmonary vein isolation
353869|NCT01278953|ablation catheter
353870|NCT01278953|RF
353871|NCT01278953|contact force sensing
353872|NCT01278953|contact force
353873|NCT01278953|contact force assisted ablation
353874|NCT01278927|exercise
353875|NCT01278927|stress management
353876|NCT01278927|post transplant
353877|NCT01278927|physical and emotional relaxation
353878|NCT01278901|helicobacter pylori
353879|NCT01278901|urease test
353880|NCT01278901|13C-UBT
353881|NCT01278901|the focus of the study is to evaluate a possible effect of PPI therapy on Helicobacter pylori diagnostic tests
353882|NCT01278888|Lung cancer
353883|NCT01278888|Pain
353884|NCT01278888|Quality of life
353885|NCT01278888|Economy
353886|NCT01278875|High density lipoproteins
353887|NCT01278875|Acute coronary syndromes
353888|NCT01278875|Cellular cholesterol efflux
353889|NCT01278875|HDL: proteomics
353890|NCT01278875|Nitric Acid production
353891|NCT01278862|Crowns
353892|NCT01278862|posterior teeth
353893|NCT01278862|CAD CAM crowns
353894|NCT01278862|digital veneer system
353895|NCT01278862|Lava
353896|NCT01278862|clinical
353897|NCT01278849|Advanced or metastatic cancer,
353898|NCT01278849|refractory,
353899|NCT01278849|core phase,
353900|NCT01278849|extension phase,
353901|NCT01278849|dose escalation,
353902|NCT01278849|standard chemotherapy,
353903|NCT01278849|pharmacokinetics,
353904|NCT01278849|doctaxel,
353905|NCT01278849|paclitaxel,
353906|NCT01278849|carboplatin,
353907|NCT01278849|safety,
353908|NCT01278849|tolerability,
353909|NCT01278849|hepatic impairment
353910|NCT01278836|Flap
353911|NCT01278836|leg defect
353912|NCT01278836|reconstruction
353913|NCT01278836|tissue
353914|NCT01278823|obesity
353915|NCT01278823|type 2 diabetes
353916|NCT01278810|Icaritin,
353917|NCT01278810|ERa36
353918|NCT01278784|Dry eye syndromes
353919|NCT01278784|Chitosan-N-Acetylcysteine
353920|NCT01278771|CHD
353921|NCT01278758|Advanced or metastatic cancer,
353922|NCT01278758|refractory,
353923|NCT01278758|core phase,
353924|NCT01278758|extension phase,
353925|NCT01278758|dose escalation,
353926|NCT01278758|standard chemotherapy,
353927|NCT01278758|doctaxel,
353928|NCT01278758|paclitaxel,
353929|NCT01278758|carboplatin,
353930|NCT01278758|safety,
353931|NCT01278758|tolerability
353932|NCT01278745|cardiac allograft vasculopathy (CAV)
353933|NCT01278745|prevention
353934|NCT01278745|cardiac transplantation
353935|NCT01278745|rituximab
353936|NCT01278732|arterial hypertension
353937|NCT01278719|Antrochoanal polyp
353938|NCT01278719|Ethmoidal polyp
353939|NCT01278719|Recurrence
353940|NCT01278719|Risk factors
353941|NCT01278719|Environmental factors
353942|NCT01278719|Gene expression
353943|NCT01278719|Micro array
353944|NCT01278719|Mutation
353945|NCT01278693|Renal failure, hemodialysis, dyslipidemia, L-carnitine.
353946|NCT01278680|Behavioral economics
353947|NCT01278680|Incentives
353948|NCT01278680|Health
353949|NCT01278667|ADHD
353950|NCT01278667|Memory
353951|NCT01278667|Social
353952|NCT01278667|Emotion
353953|NCT01278667|Methylphenidate
353954|NCT01278641|Fibromyalgia
353955|NCT01278641|Widespread pain
353956|NCT01278641|Fatigue
353957|NCT01278641|Physical exercise
353958|NCT01278602|Diffuse large B-cell lymphoma
353959|NCT01278602|Chemotherapy
353960|NCT01278602|R-ESHAP
353961|NCT01278602|Autologous stem cell transplantation
353962|NCT01278576|Muscle spasticity
353963|NCT01278576|Stroke
353964|NCT01278576|Botulinum Toxins
353965|NCT01278576|Lower extremity
353966|NCT01278576|Ankle
353967|NCT01278563|Low Glycemic Index Diet
353968|NCT01278537|elderly
353969|NCT01278537|cancer surgery
353970|NCT01278537|quality of life
353971|NCT01278537|empowerment
353972|NCT01278537|shared-decision
353973|NCT01278524|Delirium
353974|NCT01278524|Analgosedation
353975|NCT01278524|ICU
353976|NCT01278524|Pain
353977|NCT01278524|Implementation
353978|NCT01278511|Canadian C-Spine Rule
353979|NCT01278511|Prehospital Emergency Care
353980|NCT01278511|Cervical Spine Injuries
353981|NCT01278511|Cervical Spine Fractures
353982|NCT01278511|Emergency Medicine Undergraduates
353983|NCT01278498|Escitalopram
353984|NCT01278498|Depression
353985|NCT01278498|Stroke
353986|NCT01278485|Diabetes complications
353987|NCT01278472|cholecystectomy
353988|NCT01278472|laparoscopic
353989|NCT01278472|single-port
353990|NCT01278472|gallstones
353991|NCT01278459|endothelial function
353992|NCT01278459|cardiovascular
353993|NCT01278446|Cow's Milk Allergy
353994|NCT01278446|CMA
353995|NCT01278433|Polio
353996|NCT01278433|Poliovirus
353997|NCT01278433|IMOVAX Polio™
353998|NCT01278420|Visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs Six months post cataract surgery
353999|NCT01278407|DLB
354000|NCT01278407|Dementia with Lewy bodies
354001|NCT01278407|Lewy Body Disease
354002|NCT01278407|Dementia
354003|NCT01278407|E2020
354004|NCT01278407|Donepezil
354005|NCT01278407|Aricept
354006|NCT01278394|Onychomycosis
354007|NCT01278394|Fungal Nail
354008|NCT01278381|pancreas, pancreaticoduodenectomy, major complications
354009|NCT01278368|pancreatic cancer, neoadjuvant chemotherapy
354010|NCT01278355|pain
354011|NCT01278355|acupuncture
354012|NCT01278342|Sandostatin LAR
354013|NCT01278342|High Dose
354014|NCT01278342|GH-receptor antagonist
354015|NCT01278342|combination with dopamine-agonist
354016|NCT01278342|acromegalic patients
354017|NCT01278342|octreotide acetate
354018|NCT01278342|Somavert
354019|NCT01278342|Dostinex
354020|NCT01278342|pegvisomant
354021|NCT01278342|cabergoline
354022|NCT01278342|not adequately controlled
354023|NCT01278342|active acromegaly
354024|NCT01278329|Music
354025|NCT01278329|Foetal learning
354026|NCT01278329|Brazelton Neonatal Behavioral Assessment Scale
354027|NCT01278316|PTSD
354028|NCT01278316|TBI
354029|NCT01278316|Cognition
354030|NCT01278316|Cognitive Training
354031|NCT01278303|Coarctation
354032|NCT01278303|Aorta
354033|NCT01278290|Triptorelin acetate
354034|NCT01278290|precocious puberty
354035|NCT01278290|premature thelarche
354036|NCT01278290|GnRH analog
354037|NCT01278290|Diagnostic validation study
354038|NCT01278277|Stargardt disease
354039|NCT01278277|macula
354040|NCT01278277|electroretinogram
354041|NCT01278277|saffron
354042|NCT01278264|Transversus abdominis plane block
354043|NCT01278264|Ultrasound guided
354044|NCT01278264|Abdominoplasty
354045|NCT01277276|Medical tool
354046|NCT01277263|Breast Cancer
354047|NCT01277250|Hospitalized adults
354048|NCT01277250|Tobacco users
354049|NCT01277250|Smokers
354050|NCT01277250|Smoking cessation
354051|NCT01277250|Web-based
354052|NCT01277250|Transition coach
354053|NCT01277237|Non alcoholic fatty liver disease
354054|NCT01277224|physical activity
354055|NCT01277224|obesity
354056|NCT01277224|adiposity
354057|NCT01277224|children
354058|NCT01277224|blood lipids
354059|NCT01277224|blood pressure
354060|NCT01277224|randomized controlled trials
354061|NCT01277211|Contraception
354062|NCT01277211|NuvaRing
354063|NCT01277198|kidney calculi
354064|NCT01277198|ureteral calculi
354065|NCT01277198|cystoscopes
354066|NCT01277198|laparoscopes
354067|NCT01277185|calcium
354068|NCT01277185|healthy
354069|NCT01277185|Mexican-American adolescents
354070|NCT01277185|camp
354071|NCT01277185|girls
354072|NCT01277185|boys
354073|NCT01277185|bone
354074|NCT01277172|DLBCL
354075|NCT01277172|pharmacokinetics
354076|NCT01277172|pharmacodynamics
354077|NCT01277172|Rituximab
354078|NCT01277172|LymphomaLymphoma
354079|NCT01277172|Non-HodgkinLymphoma
354080|NCT01277172|B-CellLymphoma
354081|NCT01277172|Large B-Cell
354082|NCT01277172|Disorders Lymphatic Diseases
354083|NCT01277172|Immunoproliferative Disorders
354084|NCT01277172|Antineoplastic Agents
354085|NCT01277172|Adverse Effects
354086|NCT01277159|Analgesia
354087|NCT01277159|Duration
354088|NCT01277159|Popliteal Fossa Nerve Block
354089|NCT01277159|Dexamethasone
354090|NCT01277159|Buprenorphine
354091|NCT01277159|Additives
354092|NCT01277159|Ankle surgery
354093|NCT01277146|Phase 1
354094|NCT01277146|dose escalation
354095|NCT01277146|histologically confirmed
354096|NCT01277146|malignancy metastatic
354097|NCT01277107|PSG
354098|NCT01277107|LPS
354099|NCT01277107|TST
354100|NCT01277107|WASO
354101|NCT01277107|Subjects With Insomnia characterized by both Difficulty in Falling Asleep and Staying Asleep
354102|NCT01277081|Paracetamol
354103|NCT01277081|Common cold
354104|NCT01278238|Hypotension
354105|NCT01278238|Caesarean section
354106|NCT01278238|Spinal anaesthesia
354107|NCT01278238|Lower limb compression / wrapping
354108|NCT01278238|Phenylephrine
354109|NCT01278225|Neurofeedback
354110|NCT01278225|Neural Function
354111|NCT01278225|Neuromodulation
354112|NCT01278225|Chemotherapy-Induced Neuropathic Pain
354113|NCT01278225|Electroencephalogram
354114|NCT01278225|EEG
354115|NCT01278225|Biofeedback
354116|NCT01278225|BF
354117|NCT01278225|Quality of Life
354118|NCT01278225|QOL
354119|NCT01278225|Pain Quality Assessment Scale
354120|NCT01278225|PQAS
354121|NCT01278225|Brief Symptom Inventory
354122|NCT01278225|BSI
354123|NCT01278225|Sleep Disturbances
354124|NCT01278225|Fatigue
354125|NCT01278225|Questionnaires
354126|NCT01278212|breast cancer
354127|NCT01278212|breast neoplasm
354128|NCT01278212|breast tumor
354129|NCT01278212|radiotherapy
354130|NCT01278212|radiation
354131|NCT01278212|accelerated
354132|NCT01278212|lumpectomy
354133|NCT01278199|Bronchial Artery Embolization
354134|NCT01278199|Non-severe Hemoptysis
354135|NCT01278199|Bleeding mild-to-moderate abundance
354136|NCT01278199|Volume ranging from 100 ml to 200 ml
354137|NCT01278186|Coronary stenosis
354138|NCT01278186|Bifurcation
354139|NCT01278186|Drug-eluting balloon
354140|NCT01278186|Drug-eluting stent
354141|NCT01278186|Angiographic follow-up
354142|NCT01278186|Late Lumen Loss
354143|NCT01278186|Restenosis
354144|NCT01278173|Vigabatrin-associated vision change
354145|NCT01278173|Adult refractory complex partial seizures
354146|NCT01278173|CPS
354147|NCT01278173|Epilepsy
354148|NCT01278173|Seizures
354149|NCT01278173|Brain diseases
354150|NCT01278173|Central Nervous System Diseases
354151|NCT01278173|Nervous System Diseases
354152|NCT01278173|Neurologic Manifestations
354153|NCT01278173|Enzyme Inhibitors
354154|NCT01278173|GABA Agents
354155|NCT01278147|cancer
354156|NCT01278147|fatigue program education
354157|NCT01278121|Obesity
354158|NCT01278121|Diabetes Mellitus, Type 2
354159|NCT01278121|Cardiovascular diseases
354160|NCT01278108|Safety
354161|NCT01278108|Tolerability
354162|NCT01278108|Pharmacokinetics
354163|NCT01278095|Safety
354164|NCT01278095|Tolerability
354165|NCT01278095|Pharmacokinetics
354166|NCT01278082|Randomized
354167|NCT01278082|double-blind
354168|NCT01278082|Placebo-controlled
354169|NCT01278082|budesonide
354170|NCT01278082|collagenous colitis
354171|NCT01278082|acute treatment
354172|NCT01278082|maintaining remission
354173|NCT01278069|Acute myeloid Leukemia
354174|NCT01278069|Myeloid Sarcoma
354175|NCT01278069|Extramedullary Acute myeloid Leukemia
354176|NCT01278069|18FDG-PET-CT
354177|NCT01278056|Non-alcoholic steatohepatitis (NASH) and increased iron storage / disturbed distribution
354178|NCT01278043|Antiplatelet
354179|NCT01278043|Percutaneous Coronary Intervention
354180|NCT01278043|Coronary artery disease
354181|NCT01278043|Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention
354182|NCT01278017|nontyphoidal salmonellae
354183|NCT01278017|enterocolitis
354184|NCT01278017|ceftriaxone
354185|NCT01278004|Adult cancer patients with chemotherapy-induced painful peripheral neuropathy
354186|NCT01277991|Bioequivalence
354187|NCT01277991|healthy volunteer study
354188|NCT01277991|Rheumatoid Arthritis
354189|NCT01277978|Caesarean section
354190|NCT01277978|Cardiovascular effects
354191|NCT01277978|Postpartum hemorrhage
354192|NCT01277978|Carbetocin
354193|NCT01277978|Oxytocin
354194|NCT01277965|Algorithm basal insulin
354195|NCT01277965|physical activity
354196|NCT01277965|Type 1 diabetes
354197|NCT01277965|Insulin pump treatment
354198|NCT01277952|Traumatic Brain Injury
354199|NCT01277952|DBS
354200|NCT01277926|Breast Cancer
354201|NCT01277926|Hormone Receptor Positive, Advanced Breast Cancer
354202|NCT01277913|diabetes
354203|NCT01277913|vitamin D
354204|NCT01277913|bone density
354205|NCT01277913|children
354206|NCT01277887|Smoking
354207|NCT01277887|Nicotine
354208|NCT01277887|Nicotine polacrilex
354209|NCT01277887|Nicotine replacement
354210|NCT01277861|Desflurane, Fentanyl, Airway responses
354211|NCT01277848|PLAC1
354212|NCT01277848|pregnant
354213|NCT01277848|first prenatal visit
354214|NCT01277848|pre-eclampsia
354215|NCT01277835|video-assisted
354216|NCT01277835|thoracic surgery
354217|NCT01277835|VATS
354218|NCT01277835|lidocaine infusion
354219|NCT01277835|VATS procedures
354220|NCT01277822|Hypertension
354221|NCT01277822|Uncontrolled hypertension
354222|NCT01277822|High blood pressure
354223|NCT01277822|Uncontrolled high blood pressure
354224|NCT01277822|Untreated high blood pressure
354225|NCT01277822|Untreated hypertension
354226|NCT01277822|Essential hypertension
354227|NCT01277809|Long term care
354228|NCT01277809|Aging
354229|NCT01277809|Accidental Falls
354230|NCT01277809|Muscle Weakness
354231|NCT01277809|Gait
354232|NCT01277809|Physical Fitness
354233|NCT01277809|Muscle Strength
354234|NCT01277809|Postural Balance
354235|NCT01277809|Activities of Daily Living
354236|NCT01277809|Body Weight
354237|NCT01277809|Blood Pressure
354238|NCT01277809|Depression
354239|NCT01277809|Behavior
354240|NCT01277809|Dementia
354241|NCT01277770|Thymoglobulin
354242|NCT01277770|Kidney Transplant Recipients
354243|NCT01277770|Steroid-Free
354244|NCT01277770|Immunosuppression
354245|NCT01277744|Desmoplastic small round cell tumor
354246|NCT01277744|DSRCT
354247|NCT01277744|Hyperthermic peritoneal perfusion
354248|NCT01277744|HIPEC
354249|NCT01277744|Complete abdominal tumor excision
354250|NCT01277744|Extensive abdominal disease
354251|NCT01277744|Non-carcinoma tumors
354252|NCT01277744|Abdominal cavity
354253|NCT01277744|Cisplatin
354254|NCT01277744|Platinol-AQ
354255|NCT01277744|Platinol
354256|NCT01277744|CDDP
354257|NCT01277744|Diffuse peritoneal tumor
354258|NCT01277744|Retroperitoneal tumor
354259|NCT01277744|Ovarian germ cell
354260|NCT01277744|Wilms' tumor
354261|NCT01277705|Booster vaccination
354262|NCT01277692|First administration to human, safety, pharmacokinetics, healthy subjects, antiviral activity, hepatitis C patients
354263|NCT01277679|lung water measures
354264|NCT01277679|pulmonary edema
354265|NCT01277679|MRI
354266|NCT01277679|heart failure
354267|NCT01277666|Crohn's disease
354268|NCT01277666|capsule
354269|NCT01277666|GSK1605786A
354270|NCT01277666|quality of life
354271|NCT01277666|inflammatory bowel disease
354272|NCT01277666|oral therapy
354273|NCT01277653|Hepatocellular carcinoma
354274|NCT01277640|male tolerance
354275|NCT01277640|HIV-1
354276|NCT01277640|microbicide
354277|NCT01277640|The study will assess the safety and tolerability of dapivirine when applied topically to the penis of healthy, HIV-uninfected, adult males, both circumcised
354278|NCT01277640|and uncircumcised
354279|NCT01277627|HCV
354280|NCT01277627|HIV
354281|NCT01277627|Nevirapine
354282|NCT01277627|HCV viral load
354283|NCT01277627|Efavirenz
354284|NCT01277627|Protease inhibitors
354285|NCT01277614|lifestyle
354286|NCT01277614|diet
354287|NCT01277614|exercise
354288|NCT01277601|Chronic Hepatitis B
354289|NCT01277601|Hep B
354290|NCT01277601|Non cirrhotic
354291|NCT01277601|Tenofovir disoproxil fumarate (TDF)
354292|NCT01277601|Peginterferon α-2a (Peg-IFN)
354293|NCT01277588|fetal scalp sampling
354294|NCT01277588|experience questionnaire
354295|NCT01277575|stroke
354296|NCT01277575|aphasia
354297|NCT01277575|language
354298|NCT01277562|Breast Cancer
354299|NCT01277562|Prostate Cancer
354300|NCT01277562|Osteopenia
354301|NCT01277562|Osteoporosis
354302|NCT01277562|Secondary causes of bone loss
354303|NCT01277549|Leukapheresis
354304|NCT01277549|Hematopoetic Stem Cell Mobilization
354305|NCT01277510|dialysis
354306|NCT01277510|sensipar
354307|NCT01277510|mimpara
354308|NCT01277510|hemodialysis
354309|NCT01277510|peritoneal dialysis
354310|NCT01277510|renal
354311|NCT01277510|parathyroid hormone
354312|NCT01277510|pediatric
354313|NCT01277497|Chronic kidney disease
354314|NCT01277497|Phosphate binder
354315|NCT01277497|Sevelamer carbonate
354316|NCT01277497|Calcium acetate
354317|NCT01277497|Vascular calcification
354318|NCT01277497|Endothelial Dysfunction
354319|NCT01277484|decitabine
354320|NCT01277484|dose
354321|NCT01277484|schedule
354322|NCT01277484|safety
354323|NCT01277484|allogeneic stem cell transplantation
354324|NCT01277471|meal frequency
354325|NCT01277471|type two diabetes
354326|NCT01277458|HIV
354327|NCT01277458|MSM
354328|NCT01277458|Ethnicity
354329|NCT01277445|gut microbiome
354330|NCT01277445|prebiotics
354331|NCT01277445|immunological status
354332|NCT01277445|fructans
354333|NCT01277432|Diabetes
354334|NCT01277432|Depression
354335|NCT01277406|Colorectal Carcinoma
354336|NCT01277406|Resminostat
354337|NCT01277406|HDAC
354338|NCT01277406|4SC-201
354339|NCT01277406|Phase I
354340|NCT01277406|Phase II
354341|NCT01277393|Enteral nutrition feeding
354342|NCT01277380|H1N1 Influenza virus
354343|NCT01277380|swine flu
354344|NCT01277380|Real Time RT-PCR
354345|NCT01277367|Obesity
354346|NCT01277367|Sedentary
354347|NCT01277367|Physical activity
354348|NCT01277367|exercise
354349|NCT01277367|incentives
354350|NCT01277354|Cognitive Processing Therapy (CPT)
354351|NCT01277315|ALS
354352|NCT01277315|Anakinra
354353|NCT01277315|Kineret
354354|NCT01277315|Progressive Muscular Atrophy
354355|NCT01277315|PMA
354356|NCT01277315|Safety Trial
354357|NCT01277315|Tolerability Trial
354358|NCT01277289|dexamethasone
354359|NCT01277289|ery-dex
354360|NCT01277289|Chron's disease
354361|NCT01277289|CD
354362|NCT01277068|obese patients
354363|NCT01277068|TRL
354364|NCT01277068|the bariatric surgery
354365|NCT01277042|Safety
354366|NCT01277042|HPV vaccine
354367|NCT01277042|Immune response
354368|NCT01277042|Human papillomavirus
354369|NCT01277042|China
354370|NCT01277016|Amyloidosis
354371|NCT01277016|Bortezomib
354372|NCT01276977|Migraine
354373|NCT01276977|Acute Migraine
354374|NCT01276977|Headache
354375|NCT01276964|menses
354376|NCT01276964|quantitative determination of menstrual losses
354377|NCT01276964|kinetic definition of menses
354378|NCT01276951|Cocoa
354379|NCT01276951|Chocolate
354380|NCT01276951|Endothelial disfunction
354381|NCT01276951|Cardiovascular disease
354382|NCT01276951|Blood Pressure
354383|NCT01276951|Hypertension
354384|NCT01276938|Breast cancer
354385|NCT01276938|Intra Operative Radiation Therapy
354386|NCT01276938|Toxicity
354387|NCT01276925|Hip arthroplasty
354388|NCT01276925|Peripheral nervous blockade
354389|NCT01276925|Postoperative
354390|NCT01276925|Pain
354391|NCT01276925|Ropivacaine
354392|NCT01276899|Breast Cancer
354393|NCT01276899|Triple negative breast cancer
354394|NCT01276899|ERnegative, PRnegative and Her2negative
354395|NCT01276899|Taxanes
354396|NCT01276899|Metastases
354397|NCT01276899|Biomarkers
354398|NCT01276899|Resistance
354399|NCT01276899|Biobanking
354400|NCT01276899|Breast cancer with unresectable metastases to the liver
354401|NCT01276899|Breast cancer with unresectable metastases to the skin
354402|NCT01276899|Breast cancer with unresectable metastases to the lymph node
354403|NCT01276899|Neoadjuvant chemotherapy
354404|NCT01276886|Left sided acute diverticulitis diagnosed clinically by the presence of abdominal pain, leukocytosis (>11x109) and/or fever >38°C, confirmed by imaging.
354405|NCT01276886|CT criteria: localized thickening (≥4 mm) of the colonic wall and signs of inflammation of the pericolic fat, abscess and/or extraluminal air and/or contrast.
354406|NCT01276886|US criteria: bowel wall thickening (>4 mm), diverticular inflammation, pericolic fat edema, intramural or pericolic inflammatory mass, intramural fistula.
354407|NCT01276886|WSCE criteria: segmental luminal narrowing and a tethered mucosa with or without a mass effect or extravasation of contrast and/or extraluminal air.
354408|NCT01276873|Artificial Respiration
354409|NCT01276873|Suction
354410|NCT01276873|Pain
354411|NCT01276873|Nursing
354412|NCT01276873|Neonatology
354413|NCT01276860|Obstructive Sleep Apnea
354414|NCT01276860|Pediatric Obstructive Sleep Apnea
354415|NCT01276860|OSA
354416|NCT01276860|PVT
354417|NCT01276860|Psychomotor Vigilance Testing
354418|NCT01276860|Psychomotor Vigilance Task
354419|NCT01276847|psoriasis
354420|NCT01276847|Ustekinumab
354421|NCT01276847|Stelara
354422|NCT01276847|Etanercept
354423|NCT01276847|Enbrel
354424|NCT01276821|Bronchiolitis
354425|NCT01276821|L-Epinephrine
354426|NCT01276821|3% Hypertonic Saline
354427|NCT01276821|Clinical Severity Score
354428|NCT01276808|Magnetic navigation, percutaneous coronary intervention
354429|NCT01276769|Triple Negative Breast Cancer
354430|NCT01276769|Neoadjuvant chemotherapy
354431|NCT01276769|Platinum
354432|NCT01276730|Advanced cervical cancer
354433|NCT01276730|India
354434|NCT01276691|Vascular function
354435|NCT01276691|Inflammation
354436|NCT01276691|Oxidative stress
354437|NCT01276691|Hemostatic balance
354438|NCT01276691|Aspirin
354439|NCT01276691|Firefighting
354440|NCT01276678|CAD
354441|NCT01276665|Bladder cancer
354442|NCT01276665|urinary diversion
354443|NCT01276665|Postoperative Complications
354444|NCT01276665|Fluid Therapy
354445|NCT01276665|Norepinephrine
354446|NCT01276652|Polysomnography
354447|NCT01276652|Circadian rhythmicity
354448|NCT01276639|Xeljanz
354449|NCT01276639|tofacitinib
354450|NCT01276639|chronic
354451|NCT01276639|Pruritus
354452|NCT01276639|Itch
354453|NCT01276639|DLQI
354454|NCT01276639|severe
354455|NCT01276639|moderate
354456|NCT01276639|treatment
354457|NCT01276639|safety
354458|NCT01276639|efficacy
354459|NCT01276639|CP-690,550
354460|NCT01276639|Plaque Psoriasis
354461|NCT01276639|Psoriasis Vulgaris
354462|NCT01276639|Jax-inhibitor
354463|NCT01276639|Oral Treatment
354464|NCT01276613|Resectable Adenocarcinoma of the Pancreas
354465|NCT01276613|Gemcitabine
354466|NCT01276613|Gemcitabine Hydrochloride
354467|NCT01276613|Gemzar
354468|NCT01276587|sickle cell disease
354469|NCT01276587|children
354470|NCT01276587|vitamin D
354471|NCT01276587|safety
354472|NCT01276574|PET/CT
354473|NCT01276574|Ovarian cancer
354474|NCT01276574|HE4
354475|NCT01276561|laparoscopy
354476|NCT01276561|splenectomy
354477|NCT01276561|single site
354478|NCT01276561|trial
354479|NCT01276522|Schnitzler syndrome
354480|NCT01276522|IL-1 beta
354481|NCT01276522|Canakinumab
354482|NCT01276522|Ilaris
354483|NCT01276522|Treatment
354484|NCT01276522|Efficacy
354485|NCT01276522|Safety
354486|NCT01276509|Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)
354487|NCT01276483|GIST
354488|NCT01276483|Response Monitoring
354489|NCT01276483|Functional Magnetic Imaging
354490|NCT01276483|Positron Emission Tomography
354491|NCT01276483|Computer Tomography
354492|NCT01276470|Adult and Pediatric Autoimmune Disease
354493|NCT01276470|Antibody
354494|NCT01276470|Autoimmune Diseases
354495|NCT01276470|Autoimmunity Pathogenesis
354496|NCT01276470|Environmental Risk Factors
354497|NCT01276470|Myositis
354498|NCT01276457|immunosuppression
354499|NCT01276457|kidney transplantation
354500|NCT01276457|everolimus
354501|NCT01276457|safety
354502|NCT01276444|valve repair
354503|NCT01276444|postoperative period
354504|NCT01276444|goal-directed therapy
354505|NCT01276444|pulmonary artery catheter
354506|NCT01276444|transpulmonary thermodilution
354507|NCT01276444|central venous oxygen saturation
354508|NCT01276392|regional and systemical anticoagulation
354509|NCT01276392|continuous renal replacement therapy
354510|NCT01276392|multiplate
354511|NCT01276392|rotational thrombelastometry
354512|NCT01276379|colorectal cancer
354513|NCT01276379|advanced
354514|NCT01276379|metastatic
354515|NCT01276379|KRAS
354516|NCT01276379|biomarkers (BRAF, IGF1P/MMp7,PI3K-PTEN)
354517|NCT01276379|cetuximab
354518|NCT01276366|Heel lance
354519|NCT01276366|Premature
354520|NCT01276366|Breast milk
354521|NCT01276353|Alzheimer Disease
354522|NCT01276353|Dementia
354523|NCT01276353|Delirium
354524|NCT01276353|Amnestic
354525|NCT01276353|Cognitive Disorders
354526|NCT01276353|Donepezil
354527|NCT01276353|Brain Diseases
354528|NCT01276353|Central Nervous System Diseases
354529|NCT01276353|Nervous System Diseases
354530|NCT01276353|Tauopathies
354531|NCT01276353|Neurodegenerative Diseases
354532|NCT01276353|Mental Disorders
354533|NCT01276353|Cholinesterase Inhibitors
354534|NCT01276353|Enzy
354535|NCT01276340|Urinary Incontinence
354536|NCT01276340|Urinary stress incontinence
354537|NCT01276340|Urinary urge incontinence
354538|NCT01276340|Women
354539|NCT01276340|electrical stimulation
354540|NCT01276340|KEAT stimulator
354541|NCT01276340|quality of life
354542|NCT01276314|SCAR
354543|NCT01276314|anti-TNF-a
354544|NCT01276275|Acute coronary syndrome, thienopyridine, epidemiology
354545|NCT01276262|Phase 1, healthy female volunteers, oral contraceptive, pharmacokinetics, Rheumatoid arthritis, RA, fostamatinib
354546|NCT01276249|Aptus Endosystem
354547|NCT01276249|EndoStaple
354548|NCT01276249|Endograft
354549|NCT01276249|Stent Graft
354550|NCT01276249|Abdominal Aortic Aneurysm
354551|NCT01276249|Heli-FX
354552|NCT01276249|EndoAnchor
354553|NCT01276236|Kaposi's Sarcoma
354554|NCT01276236|Maraviroc
354555|NCT01276236|CCR5
354556|NCT01276236|HIV
354557|NCT01276223|Dry eye
354558|NCT01276223|ocular discomfort
354559|NCT01276197|hypertension
354560|NCT01276197|healthcare disparities
354561|NCT01276197|minority health
354562|NCT01276197|health behavior
354563|NCT01276184|HPV Vaccine
354564|NCT01276184|HPV vaccination
354565|NCT01276184|SMS
354566|NCT01276184|Text Message
354567|NCT01276184|Gardasil
354568|NCT01276145|pudendal artery disease
354569|NCT01276145|erectile dysfunction
354570|NCT01276145|coronary angiography
354571|NCT01276145|coronary disease
354572|NCT01276145|cardiac
354573|NCT01276132|percutaneous coronary artery intervention
354574|NCT01276132|coronary disease
354575|NCT01276119|CDP6038
354576|NCT01276119|single-dose
354577|NCT01276119|pharmacokinetics
354578|NCT01276119|healthy subjects
354579|NCT01276106|AC-201
354580|NCT01276106|Interleukin 1 inhibitor
354581|NCT01276093|Atrial fibrillation
354582|NCT01276093|PVI ablation
354583|NCT01276093|Elderly patients
354584|NCT01276093|Efficacy
354585|NCT01276041|MAB 2C4 (PERTUZUMAB)
354586|NCT01276041|MAB HER 2 (HERCEPTIN) (TRASTUZUMAB)
354587|NCT01276041|TAXOL (PACLITAXEL)
354588|NCT01276041|10-142
354589|NCT01276041|Stage IV HER2 (+) breast cancer
354590|NCT01276028|Acupuncture
354591|NCT01276028|Hot Flashes
354592|NCT01276028|Menopause
354593|NCT01276028|Vasomotor Symptoms
354594|NCT01276015|BoNT-A-botulinum neurotoxin type A
354595|NCT01276015|CMAP-compound muscle action potential
354596|NCT01276015|CP-cerebral palsy
354597|NCT01276015|LG-lateral gastrocnemius
354598|NCT01276015|MG-medial gastrocnemius
354599|NCT01276015|TA-tibialis anterior
354600|NCT01276015|PROMS-passive range of movement
354601|NCT01276015|MAS-modified Ashworth scale
354602|NCT01276015|EVGS-Edinburgh visual gait scale
354603|NCT01276015|GMF-CS-gross motor function classification system
354604|NCT01276002|disrupted duct
354605|NCT01276002|pancreatic pseudocysts
354606|NCT01275976|C1-esterase inhibitor
354607|NCT01275976|Systemic inflammation
354608|NCT01275976|Sepsis
354609|NCT01275976|Trauma
354610|NCT01275976|Multiple Organ Dysfunction Syndrome
354611|NCT01275976|Cytokines
354612|NCT01275963|Echocardiography
354613|NCT01275963|Strain imaging
354614|NCT01275963|Ventricular Dysfunction
354615|NCT01275963|Cardiomyopathy
354616|NCT01275963|Longitudinal left ventricular function
354617|NCT01275950|Tobacco vendor
354618|NCT01275950|students
354619|NCT01275950|knowledge
354620|NCT01275950|attitude
354621|NCT01275950|practice
354622|NCT01275950|direct advertisements
354623|NCT01275950|surrogate advertisements
354624|NCT01275924|Syndesmosis
354625|NCT01275924|Injury
354626|NCT01275924|Ankle
354627|NCT01275924|Fracture
354628|NCT01275898|NIRS
354629|NCT01275898|cerebral oxygenation
354630|NCT01275885|cholecalciferol
354631|NCT01275885|infant
354632|NCT01275885|bone mineral density
354633|NCT01275872|guided imagery
354634|NCT01275872|progressive muscle relaxation
354635|NCT01275872|complimentary and alternative medicine
354636|NCT01275872|quality of life
354637|NCT01275872|stress
354638|NCT01275872|pain
354639|NCT01275872|anxiety
354640|NCT01275859|Neoadjuvant
354641|NCT01275859|Letrozole
354642|NCT01275859|Lapatinib
354643|NCT01275859|Postmenopausal
354644|NCT01275846|heart failure
354645|NCT01275846|congestive heart failure
354646|NCT01275846|telemedicine
354647|NCT01275833|Implantable cardioverter-defibrillator (ICD) indicated patients
354648|NCT01275833|First Degree AV block.
354649|NCT01275820|diabetes, insulin, blood sugar
354650|NCT01275807|climacteric, climacteric syndrome
354651|NCT01275794|Type 2 Diabetes
354652|NCT01275781|Phase 1
354653|NCT01275781|healthy male volunteers
354654|NCT01275781|radioactivity
354655|NCT01275781|excretion
354656|NCT01275781|metabolism
354657|NCT01275781|AZD9742
354658|NCT01275781|amount of radioactive AZD9742 in urine, feces, and vomitus (if appropriate)
354659|NCT01275768|radio-frequency ablation
354660|NCT01275768|Malignant jaundice
354661|NCT01275755|opioid therapy
354662|NCT01275755|constipation
354663|NCT01275755|chronic noncancer pain
354664|NCT01275755|mu opioid receptor antagonist
354665|NCT01275755|ADL5945
354666|NCT01275755|Opioid Induced Constipation
354667|NCT01275742|Heart failure
354668|NCT01275742|Depression
354669|NCT01275742|Depressive symptoms
354670|NCT01275742|Cognitive therapy
354671|NCT01275742|Hospitalization
354672|NCT01275742|Quality of life
354673|NCT01275729|Renal Replacement Therapy
354674|NCT01275729|Diuretics
354675|NCT01275729|Biomarkers
354676|NCT01275729|Renal Insufficiency
354677|NCT01275729|Furosemide
354678|NCT01275729|Therapeutic Uses
354679|NCT01275729|Physiological Effects of Drugs
354680|NCT01275729|Biological Markers
354681|NCT01275716|Patient Education
354682|NCT01275716|coronary artery disease
354683|NCT01275716|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications.
354684|NCT01275703|To determine the utility of a noninvasive method of measuring cardiac output during exercise testing in patients with PH
354685|NCT01275690|cardiac
354686|NCT01275690|pulmonary hypertension
354687|NCT01275690|To determine the accuracy of a noninvasive method of measuring cardiac output as compared to the standard invasive approach in patients with PH
354688|NCT01275651|adenocarcinoma of the prostate
354689|NCT01275651|recurrent prostate cancer
354690|NCT01275638|cortisol, prednisolone, adrenal insufficiency, sepsis
354691|NCT01275625|maraviroc
354692|NCT01275625|naive
354693|NCT01275625|hiv
354694|NCT01275625|zidovudine
354695|NCT01275625|lamivudine
354696|NCT01275625|combivir
354697|NCT01275625|Clade A
354698|NCT01275612|Mesenchymal Stromal Cells
354699|NCT01275612|Solid tumors
354700|NCT01275612|Cisplatin therapy
354701|NCT01275612|Acute kidney injury
354702|NCT01275586|NF1
354703|NCT01275586|plexiform neurofibromas
354704|NCT01275586|nilotinib
354705|NCT01275586|Tasigna
354706|NCT01275573|Repetitive Transcranial Magnetic Stimulation
354707|NCT01275573|pain threshold
354708|NCT01275573|Parkinson's disease
354709|NCT01275573|Pain threshold in Parkinson's disease
354710|NCT01275547|Patient controlled analgesia
354711|NCT01275547|Morphine
354712|NCT01275547|S-Ketamine intranasal
354713|NCT01275547|Midazolam intranasal
354714|NCT01275534|Stem cell transplantation
354715|NCT01275534|Symptom experience
354716|NCT01275534|Late effects
354717|NCT01275534|Self-management
354718|NCT01275508|Subjects with active Crohn's disease
354719|NCT01275508|Safety and tolerability of FITC-Adalimumab
354720|NCT01275508|Intestinal topical application
354721|NCT01275495|Stroke
354722|NCT01275495|Family Caregivers
354723|NCT01275495|Cerebrovascular Accident
354724|NCT01275495|Carers
354725|NCT01275495|Care Givers
354726|NCT01275495|Depression
354727|NCT01275495|Life change events
354728|NCT01275495|Family health
354729|NCT01275495|Quality of life
354730|NCT01275495|Cost
354731|NCT01275495|Intervention studies
354732|NCT01275495|Clinical trial
354733|NCT01275482|Latent Myofascial trigger point.
354734|NCT01275482|Transverse friction massage
354735|NCT01275482|Local twitch response
354736|NCT01275482|Effectiveness
354737|NCT01275469|Impaired Glucose tolerance
354738|NCT01275469|OGTT
354739|NCT01275469|PPARs
354740|NCT01275456|allergen provocation
354741|NCT01275456|environmental challenge
354742|NCT01275456|allergen chamber
354743|NCT01275456|house dust mite
354744|NCT01275456|immunotherapy
354745|NCT01275443|HIV
354746|NCT01275430|central venous catheters
354747|NCT01275430|peripherally inserted central catheters (PICC_
354748|NCT01275430|Electrocardiography (ECG)
354749|NCT01275430|intravascular ECG
354750|NCT01275430|Tip Positioning System
354751|NCT01275417|Acupuncture
354752|NCT01275404|Erectile Dysfunction
354753|NCT01275404|focus group
354754|NCT01275404|Quality of Life
354755|NCT01275404|10-204
354756|NCT01275391|Tobacco use
354757|NCT01275391|Alcohol abuse
354758|NCT01275391|Drug abuse
354759|NCT01275391|Substance use
354760|NCT01275391|Prevention
354761|NCT01275391|Brief intervention
354762|NCT01275391|Screening
354763|NCT01275391|Adolescents
354764|NCT01275365|Mobility Limitation
354765|NCT01275365|Low Protein Intake
354766|NCT01275365|Older Men
354767|NCT01275365|Testosterone
354768|NCT01275352|left ventricular hypertrophy
354769|NCT01275352|heart failure
354770|NCT01275339|Aortic valve stenosis
354771|NCT01275339|Tadalafil
354772|NCT01275339|Phosphodiesterase inhibitors
354773|NCT01275339|Hypertension, pulmonary
354774|NCT01275339|Hypertrophy, left ventricular
354775|NCT01275326|Indoor Air Quality
354776|NCT01275326|Infectious Aerosols
354777|NCT01275313|Pressure ulcers
354778|NCT01275313|wheelchairs
354779|NCT01275313|wheelchair functional capacity
354780|NCT01275313|custom-fitted wheelchair
354781|NCT01275287|Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
354782|NCT01275287|Complement Activation
354783|NCT01275274|ANCA
354784|NCT01275274|Vasculitis
354785|NCT01275274|Pauci-immune vasculitis
354786|NCT01275261|Stroke
354787|NCT01275261|Urinary Tract Infection
354788|NCT01275248|OCD
354789|NCT01275248|Obsessive Compulsive Disorder
354790|NCT01275222|GIST
354791|NCT01275222|everolimus
354792|NCT01275222|mTOR
354793|NCT01275222|Imatinib resistant
354794|NCT01275222|Imatinib-refractory/resistant gastrointestinal stromal tumors
354795|NCT01275209|HCD122
354796|NCT01275209|Lucatumumab
354797|NCT01275209|CD40
354798|NCT01275209|Follicular Lymphoma
354799|NCT01275209|Non-Hodgkin's Lymphoma
354800|NCT01275209|Antibody
354801|NCT01275196|Newly diagnosed,
354802|NCT01275196|Ph+ chronic myeloid leukemia,
354803|NCT01275196|CML-CP
354804|NCT01275183|HNSCC
354805|NCT01275183|SCC
354806|NCT01275183|head and neck
354807|NCT01275183|squamous cell
354808|NCT01275183|nasopharyngeal
354809|NCT01275157|Absorption
354810|NCT01275157|Distribution
354811|NCT01275157|Metabolism
354812|NCT01275157|Excretion
354813|NCT01275157|Mass balance
354814|NCT01275157|Metabolic profile
354815|NCT01275157|Radiolabeled study
354816|NCT01275157|14C
354817|NCT01275131|Insulin analog
354818|NCT01275131|Type 1 diabetes mellitus
354819|NCT01275131|Pharmacokinetic
354820|NCT01275131|Glucodynamic
354821|NCT01275131|Phase 1
354822|NCT01275092|robotic-assisted PCI
354823|NCT01275092|coronary intervention
354824|NCT01275092|CorPath PRECISE
354825|NCT01275092|PCI
354826|NCT01275079|tonsillectomy
354827|NCT01275079|nasalance
354828|NCT01275079|tonsil volume
354829|NCT01275079|Thai
354830|NCT01275079|adult
354831|NCT01275066|Mucopolysaccharidosis IV type A
354832|NCT01275066|MPS IV Type A
354833|NCT01275066|Mucopolysaccharidosis IVA
354834|NCT01275066|MPS IVA
354835|NCT01275066|Morquio A Syndrome
354836|NCT01275066|Lysosomal Storage Disorder
354837|NCT01275066|LSD
354838|NCT01275066|N-acetylgalactosamine-6-sulfatase
354839|NCT01275066|N-acetylgalactosamine-6-sulfate sulfatase
354840|NCT01275066|galactose-6-sulfatase
354841|NCT01275066|GALNS
354842|NCT01275066|enzyme replacement therapy
354843|NCT01275066|ERT
354844|NCT01275053|Leptin
354845|NCT01275053|In Vivo
354846|NCT01275053|Diabetic
354847|NCT01275053|Obese
354848|NCT01275053|Lean
354849|NCT01275040|diabetes
354850|NCT01275040|mobile screening
354851|NCT01275040|complications
354852|NCT01275040|primary care
354853|NCT01275040|specialised care
354854|NCT01275040|quality of care
354855|NCT01275027|diabetes
354856|NCT01275027|blood sugar
354857|NCT01275027|insulin
354858|NCT01275027|nutritional supplement
354859|NCT01275027|nutraceutical
354860|NCT01275014|TMJ
354861|NCT01275014|corticosteroids
354862|NCT01275014|osteoarthritis
354863|NCT01275014|arthrocentesis
354864|NCT01275014|pain
354865|NCT01275001|brain
354866|NCT01275001|brain development
354867|NCT01275001|MRI
354868|NCT01275001|preschool children
354869|NCT01275001|cortical mantle thickness
354870|NCT01275001|hippocampal volume
354871|NCT01274988|Opiate dependence
354872|NCT01274988|Deep brain stimulation
354873|NCT01274988|Nucleus accumbens
354874|NCT01274949|LI-ESWT
354875|NCT01274949|Erectile Dysfunction
354876|NCT01274949|Radical Prostatectomy
354877|NCT01274949|Non PDE5 inhibitor responders
354878|NCT01274949|Shock wave
354879|NCT01274923|Erectile dysfunction
354880|NCT01274923|Low Intensity Shock Wave
354881|NCT01274910|Fish Oil
354882|NCT01274910|Knee
354883|NCT01274910|Analgetics
354884|NCT01274897|Meningococcal
354885|NCT01274897|ACWY-CRM
354886|NCT01274897|Conjugate Vaccine
354887|NCT01274897|Meningitis
354888|NCT01274897|Adolescents
354889|NCT01274897|Persistence
354890|NCT01274897|Adults
354891|NCT01274884|Acromioclavicular
354892|NCT01274884|Injury
354893|NCT01274884|Dislocation
354894|NCT01274884|Surgery
354895|NCT01274871|Thoracotomy
354896|NCT01274871|Chronic Pain
354897|NCT01274871|persistent post-surgical pain
354898|NCT01274858|persistent pain
354899|NCT01274858|neuropathic pain
354900|NCT01274858|Thoracotomy
354901|NCT01274858|Chronic Pain
354902|NCT01274845|Meconium aspiration syndrome
354903|NCT01274845|Heliox
354904|NCT01274845|Mechanical ventilation
354905|NCT01274845|Newborn
354906|NCT01274832|Parkinson
354907|NCT01274832|DBS of STN
354908|NCT01274832|PD
354909|NCT01274832|Deep Brain stimulation of STN
354910|NCT01274832|Early treatment
354911|NCT01274819|delirium
354912|NCT01274819|confusion
354913|NCT01274806|breast cancer
354914|NCT01274806|physical therapy
354915|NCT01274806|massage
354916|NCT01274806|core stability
354917|NCT01274793|functional constipation
354918|NCT01274793|functional diarrhea
354919|NCT01274793|acupuncture
354920|NCT01274754|neuroprotection
354921|NCT01274754|erythromycin
354922|NCT01274754|neurocognitive assessment
354923|NCT01274741|Posttraumatic stress disorder
354924|NCT01274741|Substance use disorder
354925|NCT01274741|Treatment efficacy
354926|NCT01274741|Randomized trial
354927|NCT01274728|Acute myocardial infarction
354928|NCT01274728|Primary percutaneous coronary intervention
354929|NCT01274728|Drug-eluting balloon
354930|NCT01274728|Bivalirudin
354931|NCT01274715|Behavioral health coaching
354932|NCT01274715|Diabetes
354933|NCT01274715|Emotional health
354934|NCT01274702|History of
354935|NCT01274702|Patients
354936|NCT01274702|acute
354937|NCT01274689|lagophthalmos
354938|NCT01274689|parotis tumor
354939|NCT01274689|m. orbicularis oculi paresis
354940|NCT01274676|stenting
354941|NCT01274676|carotid plaque
354942|NCT01274676|stenosis
354943|NCT01274676|angioplasty
354944|NCT01274663|Single Ascending Dose
354945|NCT01274663|Phase 1
354946|NCT01274663|Safety and Tolerability
354947|NCT01274663|PK
354948|NCT01274663|Healthy Subjects
354949|NCT01274637|postpartum
354950|NCT01274637|low molecular weight heparin
354951|NCT01274637|venous thromboembolism
354952|NCT01274637|prophylaxis
354953|NCT01274637|Dalteparin Sodium
354954|NCT01274624|Colorectal
354955|NCT01274624|Cancer
354956|NCT01274624|REOLYSIN®
354957|NCT01274624|Chemotherapy
354958|NCT01274624|FOLFIRI
354959|NCT01274624|Reovirus
354960|NCT01274624|Oncolytic virus
354961|NCT01274624|Fluorouracil
354962|NCT01274624|Irinotecan
354963|NCT01274624|Leucovorin
354964|NCT01274624|Bevacizumab
354965|NCT01274611|sweating
354966|NCT01274611|sweat
354967|NCT01274611|underarm
354968|NCT01274611|axillary
354969|NCT01274611|hyperhidrosis
354970|NCT01274611|botox
354971|NCT01274611|liposuction
354972|NCT01274611|suction-curettage
354973|NCT01274611|suction
354974|NCT01274611|curettage
354975|NCT01274598|Probiotics
354976|NCT01274598|Safety
354977|NCT01274598|Elderly
354978|NCT01274598|Lactobacillus
354979|NCT01274598|LGG
354980|NCT01274559|MK-0524A/ER
354981|NCT01274559|Hypercholesterolemia
354982|NCT01274559|Dyslipidemia
354983|NCT01274559|Niacin
354984|NCT01274559|Laropiprant
354985|NCT01274533|ATLL
354986|NCT01274520|ECD liver transplant allografts
354987|NCT01274520|Hypothermic machine perfusion
354988|NCT01274520|Cold storage preservation
354989|NCT01274520|liver transplant
354990|NCT01274520|portable bypass system
354991|NCT01274520|machine perfusion preservation
354992|NCT01274520|extended criteria liver
354993|NCT01274507|Asthma
354994|NCT01274507|Pulmonary Disease, Chronic Obstructive
354995|NCT01274507|Healthy
354996|NCT01274507|Longitudinal Study
354997|NCT01274507|Bronchoscopy
354998|NCT01274494|Hypertension
354999|NCT01274481|Acute Respiratory Distress Syndrome
355000|NCT01274481|Acute Lung Injury
355001|NCT01274481|pulmonary hypertension
355002|NCT01274481|oxygenation
355003|NCT01274481|lung mechanics
355004|NCT01274481|gas exchange
355005|NCT01274455|Gene therapy
355006|NCT01274455|pancreatic carcinoma
355007|NCT01274455|gemcitabine
355008|NCT01274455|endoscopic ultrasound
355009|NCT01274442|dental implant
355010|NCT01274429|Peanut allergy
355011|NCT01274429|Immunotherapy
355012|NCT01274429|OIT
355013|NCT01274416|Anorexia Nervosa
355014|NCT01274416|Eating Disorder
355015|NCT01274416|Treatment
355016|NCT01274416|Acceptance and Commitment Therapy
355017|NCT01274416|Separated Family Treatment
355018|NCT01274403|Multiple Myeloma
355019|NCT01274403|Elderly patients
355020|NCT01274390|Cardiac Surgery
355021|NCT01274390|Red Blood Cell
355022|NCT01274390|Transfusion
355023|NCT01274390|Oxygen Saturation
355024|NCT01274390|Microvascular Flow
355025|NCT01274377|nonmyeloablative allogeneic stem cell transplantation
355026|NCT01274377|cytomegalovirus
355027|NCT01274377|donor lymphocyte infusions
355028|NCT01274377|cytotoxic T lymphocyte
355029|NCT01274364|Diabetes
355030|NCT01274364|Structured Care
355031|NCT01274351|First line treatment
355032|NCT01274351|newly diagnosed
355033|NCT01274351|Philadelphia chromosome positive
355034|NCT01274351|Chronic Myelogenous Leukemia
355035|NCT01274351|Ph+
355036|NCT01274351|CML-CP
355037|NCT01274351|major molecular response
355038|NCT01274351|Social risk
355039|NCT01274325|asthma
355040|NCT01274312|Somato-sensory reflex arch
355041|NCT01274312|Spinal cord injury
355042|NCT01274312|Xiao Procedure
355043|NCT01274299|Infants
355044|NCT01274299|morphometry
355045|NCT01274299|face
355046|NCT01274299|3D
355047|NCT01274286|hospital accreditation
355048|NCT01274286|patient-centered
355049|NCT01274286|healthcare quality index
355050|NCT01274286|documentary analysis
355051|NCT01274286|meta analysis
355052|NCT01274273|Bevacizumab
355053|NCT01274273|interleukin-2
355054|NCT01274273|interferon-alpha
355055|NCT01274260|child
355056|NCT01274260|infant
355057|NCT01274260|lung injury
355058|NCT01274260|inflammation
355059|NCT01274260|pneumonia
355060|NCT01274260|ventilator
355061|NCT01274247|Tongue-tie
355062|NCT01274247|Ankyloglossia
355187|NCT01273714|recurrent goiter
355063|NCT01274234|EPC capturing sirolimus eluting COMBO stent
355064|NCT01274234|Optical coherence tomography (OCT)
355065|NCT01274234|Early neointimal healing and stent coverage
355066|NCT01274234|Late neointimal thickness, neointimal area, and lumen loss
355067|NCT01274208|Gaucher disease, Hepatitis C , Glucocerebroside immunity
355068|NCT01274195|Hematopoietic stem cell transplantation
355069|NCT01274156|Erectile dysfunction
355070|NCT01274156|Low Intensity Shock Wave
355071|NCT01274143|Colorectal
355072|NCT01274143|Cancer
355073|NCT01274143|Colon
355074|NCT01274143|Rectal
355075|NCT01274143|Behavioral Intervention
355076|NCT01274143|Screening
355077|NCT01274143|Motivational Interviewing
355078|NCT01274143|Extended Parallel Process Model
355079|NCT01274143|Implementation Intentions
355080|NCT01274143|Family CARE
355081|NCT01274117|Chronic renal failure
355082|NCT01274117|Basilic vein transposition fistula
355083|NCT01274104|statin-related myalgia
355084|NCT01274104|high cholesterol
355085|NCT01274091|Gene-diet interaction
355086|NCT01274091|PPARgamma gene
355087|NCT01274091|Pro12Ala
355088|NCT01274091|Fatty acids
355089|NCT01274091|Dietary modification
355090|NCT01274091|Insulin sensitivity
355091|NCT01274091|Glucose metabolism
355092|NCT01274078|inflammation
355093|NCT01274078|lipids
355094|NCT01274078|CRP
355095|NCT01274065|psychiatry
355096|NCT01274065|psychiatric illness
355097|NCT01274065|developmental disability
355098|NCT01274065|mental health
355099|NCT01274065|medication burden
355100|NCT01274052|Gestational diabetes mellitus
355101|NCT01274052|Meal test
355102|NCT01274052|Incretin hormones
355103|NCT01274052|Glucagon-like peptide-1 (GLP-1)
355104|NCT01274052|Glucose-dependent insulinotropic polypeptide
355105|NCT01274052|Insulin
355106|NCT01274052|C-peptide
355107|NCT01274052|Glucagon
355108|NCT01274026|phenylketonuria
355109|NCT01274026|PKU
355110|NCT01274026|phenylalanine
355111|NCT01274026|neurotransmitters
355112|NCT01274026|gene
355113|NCT01274026|Kuvan
355114|NCT01274026|sapropterin
355115|NCT01274013|Hepatitis C
355116|NCT01274013|Chronic Hepatitis C
355117|NCT01274013|Vitamin D
355118|NCT01274013|Vitamin D deficiency
355119|NCT01274000|diarrhea
355120|NCT01274000|IBS
355121|NCT01274000|Colonic disease
355122|NCT01274000|YM060
355123|NCT01274000|Ramosetron
355124|NCT01273974|intradermal influenza vaccine
355125|NCT01273974|hemodialysis patients
355126|NCT01273935|Aspirin, Acute Cerebrovascular Ischemia, Platelet Function
355127|NCT01273922|NDV-3
355128|NCT01273922|vaccine
355129|NCT01273922|Staphylococcus aureus
355130|NCT01273922|MRSA
355131|NCT01273922|Candida
355132|NCT01273909|Breast Cancer
355133|NCT01273909|BRACA1/2 Genotype
355134|NCT01273909|Acquired Lymphedema
355135|NCT01273909|Congenital Lymphedema
355136|NCT01273896|STA-9090
355137|NCT01273896|advanced breast cancer
355138|NCT01273896|10-145
355139|NCT01273883|hearing
355140|NCT01273883|magnesium
355141|NCT01273870|hemodialysis
355142|NCT01273870|high-flux-dialyzer
355143|NCT01273870|performance
355144|NCT01273870|blood compatibility
355145|NCT01273857|Cardiac progenitor cells
355146|NCT01273857|Cell therapy
355147|NCT01273857|Hypoplastic Left Heart Syndrome
355148|NCT01273857|Single Ventricle
355149|NCT01273857|Norwood
355150|NCT01273857|Sano modification
355151|NCT01273857|Glenn
355152|NCT01273857|Fontan
355153|NCT01273844|hematopoietic stem cell transplantation
355154|NCT01273844|amyloidosis
355155|NCT01273844|Bortezomib
355156|NCT01273831|intraocular pressure, anesthesia,cisatracurium,atracurium.
355157|NCT01273818|inguinal hernia
355158|NCT01273818|infection prophylaxis
355159|NCT01273818|topical gentamicin
355160|NCT01273805|metastatic pancreatic cancer
355161|NCT01273805|hydroxychloroquine
355162|NCT01273779|sepsis
355163|NCT01273779|talactoferrin
355164|NCT01273779|lactoferrin
355165|NCT01273779|recombinant human lactoferrin
355166|NCT01273753|End-stage renal disease
355167|NCT01273753|Hemodialysis
355168|NCT01273753|Bioimpedance analysis
355169|NCT01273753|Blood volume monitoring
355170|NCT01273740|PTFE bypass
355171|NCT01273740|femoro-popliteal
355172|NCT01273740|femoro-crural
355173|NCT01273740|popliteal arteries
355174|NCT01273740|crural arteries
355175|NCT01273740|external support
355176|NCT01273740|crtical limb ischemia
355177|NCT01273727|epiretinal membrane
355178|NCT01273727|macular pucker
355179|NCT01273727|cellophane maculopathy
355180|NCT01273727|macular edema
355181|NCT01273727|retinal edema
355182|NCT01273727|ozurdex
355183|NCT01273727|dexamethasone
355184|NCT01273727|intravitreal implant
355185|NCT01273714|benign thyroid disease
355186|NCT01273714|incidental thyroid cancer
355188|NCT01273714|revision thyroid surgery
355189|NCT01273701|amphetamine
355190|NCT01273701|methamphetamine
355191|NCT01273701|psychosocial intervention
355192|NCT01273701|contingency management
355193|NCT01273701|slow prosecution
355194|NCT01273701|substance use disorder
355195|NCT01273688|pain
355196|NCT01273688|elbow
355197|NCT01273688|tendinopathy
355198|NCT01273675|Hypertension
355199|NCT01273675|Primary disease
355200|NCT01273662|HCC
355201|NCT01273649|muscle activation
355202|NCT01273649|ACL reconstruction
355203|NCT01273649|cryotherapy
355204|NCT01273649|TENS
355205|NCT01273636|Endometrial hyperplasia
355206|NCT01273636|Hysterectomy
355207|NCT01273636|Endometrial carcinoma
355208|NCT01273623|PAD, Peripheral Arterial Disease, Calcium, Atherectomy, Jetstream
355209|NCT01273610|Breast Neoplasms
355210|NCT01273610|HER2 protein, human
355211|NCT01273610|Geriatric Health Services
355212|NCT01273610|Antineoplastic Agents, Combined
355213|NCT01273610|Geriatric Assessment
355214|NCT01273610|Pharmacokinetics
355215|NCT01273610|Toxicity
355216|NCT01273610|Patient Adherence
355217|NCT01273597|Parathyroid hormone,Kidney failure, chronic,Hyperparathyroidism, secondary
355218|NCT01273584|Metformin, obese, pregnancy, gestational diabetes
355219|NCT01273571|Canagliflozin
355220|NCT01273571|Metformin (GLUCOPHAGE IR)
355221|NCT01273571|Pharmacokinetics
355222|NCT01273571|Pharmacodynamics
355223|NCT01273558|Canagliflozin
355224|NCT01273558|Renal threshold for glucose
355225|NCT01273558|Pharmacodynamics
355226|NCT01273545|Dapoxetine hydrochloride (PRILIGY)
355227|NCT01273545|Premature ejaculation
355228|NCT01273532|tapentadol
355229|NCT01273532|NUCYNTA
355230|NCT01273532|CG5503
355231|NCT01273532|R331333
355232|NCT01273532|pharmacokinetics
355233|NCT01273532|healthy volunteer
355234|NCT01273519|Ankylosing
355235|NCT01273519|Rheumatoid
355236|NCT01273519|Antibodies
355237|NCT01273519|Arthritis
355238|NCT01273519|Pain
355239|NCT01273519|Antirheumatic Agents
355240|NCT01273519|Psoriatic
355241|NCT01273519|Spondylitis
355242|NCT01273519|Monoclonals
355243|NCT01273506|tapentadol
355244|NCT01273506|NUCYNTA
355245|NCT01273506|CG5503
355246|NCT01273506|R331333
355247|NCT01273506|pharmacokinetics
355248|NCT01273506|healthy volunteer
355249|NCT01273493|Trabectedin, YONDELIS
355250|NCT01273493|Antineoplastic Agents
355251|NCT01273493|Solid tumors
355252|NCT01273493|Locally advanced or metastatic disease
355253|NCT01273493|Chemotherapy
355254|NCT01273493|Pharmacokinetics
355255|NCT01273493|Hepatic Dysfunction
355256|NCT01273480|Trabectedin, YONDELIS
355257|NCT01273480|Rifampin (RIFADIN)
355258|NCT01273480|Antineoplastic Agents
355259|NCT01273480|Solid tumors
355260|NCT01273480|Locally advanced or metastatic disease
355261|NCT01273480|Chemotherapy
355262|NCT01273480|Pharmacokinetics
355263|NCT01273467|Ischemic Cerebral Infarction
355264|NCT01273467|Stroke
355265|NCT01273467|CNTO0007
355266|NCT01273467|42037788
355267|NCT01273454|Open-label
355268|NCT01273454|Non-interventional
355269|NCT01273454|OROS hydromorphone
355270|NCT01273454|Korean cancer patients
355271|NCT01273415|hormone receptor-positive breast cancer
355272|NCT01273415|nomogram
355273|NCT01273415|Ki67
355274|NCT01273415|Effects of Chemotherapy
355275|NCT01273402|colorectal cancer
355276|NCT01273402|TF2 (Recombinant, humanized Tri-Fab bsMAb composed of 2 humanized MN-14 anti-CEA Fab x and one 679 anti-HSG Fab)
355277|NCT01273402|IMP288 (DOTA-di-HSG hapten-peptide for 111In/90Y labeling)
355278|NCT01273389|Lupus nephritis
355279|NCT01273389|CNTO 136
355280|NCT01273389|Sirukumab
355281|NCT01273389|Kidney diseases
355282|NCT01273389|Proteinuria
355283|NCT01273389|Glomerulonephritis
355284|NCT01273376|MDD
355285|NCT01273376|Depression
355286|NCT01273376|Major Depression
355287|NCT01273363|Asthma
355288|NCT01273363|Asthma in Children
355289|NCT01273350|internal carotid artery
355290|NCT01273350|common carotid artery
355291|NCT01273350|bruit
355292|NCT01273350|tia
355293|NCT01273337|Stroke
355294|NCT01273337|Ischemia
355295|NCT01273337|Ischemic Stroke
355296|NCT01273337|Middle Cerebral Artery
355297|NCT01273337|MCA
355298|NCT01273337|Stem Cells
355299|NCT01273337|Stem Cell
355300|NCT01273337|Autologous Bone Marrow
355301|NCT01273337|Ipsilateral MCA
355302|NCT01273324|Osteoarthritis
355303|NCT01273311|Brain Aging
355304|NCT01273311|Diabetes
355305|NCT01273311|Aging
355306|NCT01273311|Obesity
355307|NCT01273311|CARDIA
355308|NCT01273298|chronic obstructive pulmonary disease
355309|NCT01273298|exercise
355310|NCT01273298|dynamic hyperinflation
355311|NCT01273298|cardioselective beta blockers
355312|NCT01273272|Cognitive Behavior Therapy
355313|NCT01273272|Early dementia, Alzheimer type
355314|NCT01273259|Hypertension, pulmonary
355315|NCT01273259|DHEA
355316|NCT01273259|six-minute walk test
355317|NCT01273259|pulmonary arterial pressure
355318|NCT01273220|Epidemiology
355319|NCT01273220|Epidemiologic Survey
355320|NCT01273220|Alcohol
355321|NCT01273207|Peripheral Blood Stem Cell Transplant
355322|NCT01273207|Inhaled Cyclosporine
355323|NCT01273207|Graft-Versus-Host Disease
355324|NCT01273207|Bone Marrow Transplant
355325|NCT01273207|Lung Transplantation
355326|NCT01273207|Bronchiolitis Obliterans
355327|NCT01273207|Graft Versus Host Disease
355328|NCT01273194|Palliative Care
355329|NCT01273194|Survey
355330|NCT01273194|Quality of Life
355331|NCT01273194|Attitudes
355332|NCT01273194|Pediatric Cancer
355333|NCT01273181|Immunotherapy
355334|NCT01273181|Gene Therapy
355335|NCT01273181|Metastatic Cancer
355336|NCT01273181|Clinical Response
355337|NCT01273181|Metastatic Melanoma
355338|NCT01273181|Metastatic Renal Cell Cancer
355339|NCT01273168|Pharmacokinetics
355340|NCT01273168|Advanced Cancer
355341|NCT01273168|Cytochrome P 450
355342|NCT01273168|Selective Estrogen Receptor Modulator
355343|NCT01273168|Tamoxifen Metabolite
355344|NCT01273168|Gynecologic Cancer
355345|NCT01273168|Breast Cancer
355346|NCT01273168|Desmoid Tumor
355347|NCT01273168|Endometrial Cancer
355348|NCT01273168|Ovarian Cancer
355349|NCT01273168|Uterine Cancer
355350|NCT01273168|Fallopian Tube Cancer
355351|NCT01273168|Peritoneal Cancer
355352|NCT01273155|Histone Deacetylase Inhibitor
355353|NCT01273155|Liver Dysfunction
355354|NCT01273155|Pharmacokinetics
355355|NCT01273155|UGT1A1 Polymorphisms
355356|NCT01273155|Solid Tumor
355357|NCT01273155|Cancer
355358|NCT01273155|Lymphoma
355359|NCT01273142|Human Immunodeficiency Virus, liver toxicity, hapatitis co-infection
355360|NCT01273129|Neurosurgery
355361|NCT01273129|Childhood Epilepsy
355362|NCT01273129|Epilepsy
355363|NCT01273129|Frontal Lobe Epilepsy
355364|NCT01273129|Temporal Lobe Epilepsy
355365|NCT01273116|frailty
355366|NCT01273116|integrated care
355367|NCT01273116|hospital
355368|NCT01273116|geriatrics
355369|NCT01273116|hospital-wide intervention
355370|NCT01273090|unspecified childhood solid tumor, protocol specific
355371|NCT01273090|recurrent childhood anaplastic large cell lymphoma
355372|NCT01273090|recurrent childhood grade III lymphomatoid granulomatosis
355373|NCT01273090|recurrent childhood large cell lymphoma
355374|NCT01273090|recurrent childhood lymphoblastic lymphoma
355375|NCT01273090|recurrent childhood small noncleaved cell lymphoma
355376|NCT01273090|recurrent/refractory childhood Hodgkin lymphoma
355377|NCT01273090|recurrent childhood brain stem glioma
355378|NCT01273090|recurrent childhood anaplastic astrocytoma
355379|NCT01273090|recurrent childhood anaplastic oligoastrocytoma
355380|NCT01273090|recurrent childhood anaplastic oligodendroglioma
355381|NCT01273090|recurrent childhood cerebellar astrocytoma
355382|NCT01273090|recurrent childhood cerebral astrocytoma
355383|NCT01273090|recurrent childhood diffuse astrocytoma
355384|NCT01273090|recurrent childhood fibrillary astrocytoma
355385|NCT01273090|recurrent childhood gemistocytic astrocytoma
355386|NCT01273090|recurrent childhood giant cell glioblastoma
355387|NCT01273090|recurrent childhood glioblastoma
355388|NCT01273090|recurrent childhood gliomatosis cerebri
355389|NCT01273090|recurrent childhood gliosarcoma
355390|NCT01273090|recurrent childhood oligoastrocytoma
355391|NCT01273090|recurrent childhood oligodendroglioma
355392|NCT01273090|recurrent childhood pilocytic astrocytoma
355393|NCT01273090|recurrent childhood pilomyxoid astrocytoma
355394|NCT01273090|recurrent childhood pleomorphic xanthoastrocytoma
355395|NCT01273090|recurrent childhood protoplasmic astrocytoma
355396|NCT01273090|recurrent childhood subependymal giant cell astrocytoma
355397|NCT01273090|recurrent childhood visual pathway and hypothalamic glioma
355398|NCT01273090|recurrent childhood visual pathway glioma
355399|NCT01273090|childhood pineal parenchymal tumor
355400|NCT01273090|recurrent childhood central nervous system embryonal tumor
355401|NCT01273090|childhood central nervous system choriocarcinoma
355402|NCT01273090|childhood central nervous system germ cell tumor
355403|NCT01273090|childhood central nervous system germinoma
355404|NCT01273090|childhood central nervous system mixed germ cell tumor
355405|NCT01273090|childhood central nervous system teratoma
355406|NCT01273090|childhood central nervous system yolk sac tumor
355407|NCT01273090|recurrent childhood pineoblastoma
355408|NCT01273090|childhood diffuse large cell lymphoma
355409|NCT01273090|childhood nasal type extranodal NK/T-cell lymphoma
355410|NCT01273090|childhood nodular lymphocyte predominant Hodgkin lymphoma
355411|NCT01273090|angioimmunoblastic T-cell lymphoma
355412|NCT01273090|childhood Burkitt lymphoma
355413|NCT01273090|childhood grade III lymphomatoid granulomatosis
355414|NCT01273090|childhood immunoblastic large cell lymphoma
355415|NCT01273090|cutaneous B-cell non-Hodgkin lymphoma
355416|NCT01273090|hepatosplenic T-cell lymphoma
355417|NCT01273090|intraocular lymphoma
355418|NCT01273090|noncutaneous extranodal lymphoma
355419|NCT01273090|peripheral T-cell lymphoma
355420|NCT01273090|post-transplant lymphoproliferative disorder
355421|NCT01273090|recurrent cutaneous T-cell non-Hodgkin lymphoma
355422|NCT01273090|recurrent mycosis fungoides/Sezary syndrome
355423|NCT01273090|small intestine lymphoma
355424|NCT01273077|Rotavirus
355425|NCT01273077|Rotarix
355426|NCT01273064|HCV
355427|NCT01273064|Null Responders
355428|NCT01273051|Rectal Cancer
355429|NCT01273051|Radiochemotherapy
355430|NCT01273051|TEM
355431|NCT01273051|Organ preservation
355432|NCT01273025|pharmacokinetic
355433|NCT01273025|lime powder regimen
355434|NCT01273025|kidney stone
355435|NCT01273025|Oxidative stress
355436|NCT01273012|probiotic
355437|NCT01273012|cost-effectiveness
355438|NCT01273012|diarrhea
355439|NCT01273012|children
355440|NCT01273012|Sum of the monetary cost of the hospitalization
355441|NCT01272999|Acute otitis media
355442|NCT01272999|Prevnar 13
355443|NCT01272999|Streptococcus pneumoniae
355444|NCT01272986|Determination of the level of oxidised LDL by measuring the level of IgG in Blood
355445|NCT01272960|Contraception
355446|NCT01272960|Postnatal care
355447|NCT01272947|Blunt soft tissue injury/contusion
355448|NCT01272934|Ankle Sprain, soft tissue injury
355449|NCT01272895|OCT images
355450|NCT01272895|Stent strut coverage
355451|NCT01272895|Endothelialization
355452|NCT01272895|Neointimal thickness, area and hyperplasia
355453|NCT01272895|Stent malapposition
355454|NCT01272830|total joint arthroplasty
355455|NCT01272830|synovitis
355456|NCT01272830|ALVAL
355457|NCT01272830|osteolysis
355458|NCT01272830|periprosthetic metallosis
355459|NCT01272817|Nonmyeloablative transplant
355460|NCT01272817|Allogeneic transplant
355461|NCT01272817|Transplant
355462|NCT01272804|Pharmacokinetics PK Pharmacodynamics PD T2DM Phase 1 Type 2 diabetes mellitus safety and tolerability
355463|NCT01272791|metastatic stage IV pancreatic cancer
355464|NCT01272765|obesity
355465|NCT01272765|weight loss
355466|NCT01272765|weight management
355467|NCT01272765|anti-psychotic medication
355468|NCT01272765|Zyprexa
355469|NCT01272765|Seroquel
355470|NCT01272765|Risperdal
355471|NCT01272752|obesity
355472|NCT01272752|weight loss
355473|NCT01272752|weight management
355474|NCT01272752|anti-psychotic medication
355475|NCT01272752|nutriceutical
355476|NCT01272739|obesity
355477|NCT01272739|weight loss
355478|NCT01272739|weight management
355479|NCT01272739|overweight
355480|NCT01272739|nutriceutical
355481|NCT01272687|Parkinson Disease
355482|NCT01272687|Parkinsonian Disorders
355483|NCT01272687|Brain Diseases
355484|NCT01272687|Central Nervous System Diseases
355485|NCT01272687|Nervous System Diseases
355486|NCT01272687|Neurodegenerative Diseases
355487|NCT01272661|breastfeeding
355488|NCT01272661|low-income
355489|NCT01272661|high-risk
355490|NCT01272661|African-American
355491|NCT01272661|health disparity
355492|NCT01272648|Rehabilitation
355493|NCT01272648|Coping
355494|NCT01272648|Prostate cancer
355495|NCT01272648|Nursing
355496|NCT01272648|Physiotherapy
355497|NCT01272648|Pelvic floor exercises
355498|NCT01272648|Motivational Interviewing
355499|NCT01272635|Asthma
355500|NCT01272635|Wheezing
355501|NCT01272635|Respiratory Tract Illness
355502|NCT01272635|Azythromycin
355503|NCT01272635|Prednisolone
355504|NCT01272635|Preschool-age
355505|NCT01272622|Quality of life
355506|NCT01272622|Endocrinology
355507|NCT01272622|Oncology
355508|NCT01272622|Hypothalamus
355509|NCT01272622|Irradiation
355510|NCT01272622|Neurosurgery
355511|NCT01272622|Pediatric Brain tumors
355512|NCT01272622|Randomized trial
355513|NCT01272596|Multiple Sclerosis
355514|NCT01272596|Visual Contrast Acuity
355515|NCT01272596|Visual Contrast Sensitivity
355516|NCT01272596|Sloan Charts
355517|NCT01272583|Type 1 diabetes
355518|NCT01272583|DPP-4 inhibitor
355519|NCT01272583|Glucagon
355520|NCT01272570|breast
355521|NCT01272570|oral
355522|NCT01272570|cancer
355523|NCT01272557|HCC
355524|NCT01272544|Dental caries
355525|NCT01272544|Epidemiology
355526|NCT01272544|Gingivitis
355527|NCT01272544|Oral health
355528|NCT01272531|pharmacogenetics
355529|NCT01272531|bipolar disorders
355530|NCT01272531|affective disorders
355531|NCT01272531|mood disorders
355532|NCT01272531|pharmacologic actions
355533|NCT01272531|psychotropic drugs
355534|NCT01272531|antimanic agents
355535|NCT01272531|antidepressant agents
355536|NCT01272531|lithium
355537|NCT01272531|lithium carbonate
355538|NCT01272531|Lithobid
355539|NCT01272531|Eskalith
355540|NCT01272531|divalproex
355541|NCT01272531|divalproex sodium
355542|NCT01272531|Depakote
355543|NCT01272531|valproate
355544|NCT01272518|mood disorder chaos theory heart rate variability mania bipolar disorder
355545|NCT01272479|hemodialysis
355546|NCT01272479|hepatitis C
355547|NCT01272479|inflammation
355548|NCT01272479|iron stores
355549|NCT01272479|prohepcidin
355550|NCT01272466|multiple myeloma
355551|NCT01272466|vaccination
355552|NCT01272466|antiapoptotic proteins
355553|NCT01272466|proteasome inhibition
355554|NCT01272453|coronary artery disease
355555|NCT01272453|CT scan
355556|NCT01272453|coronary angiography
355557|NCT01272453|chest pain
355558|NCT01272453|aortic aneurysm
355559|NCT01272453|pulmonary embolism
355560|NCT01272440|PEG-asparaginase
355561|NCT01272440|children
355562|NCT01272440|pharmacokinetics
355563|NCT01272440|antibodies
355564|NCT01272440|acute lymphoblastic leukaemia
355565|NCT01272440|adverse effects
355566|NCT01272414|Eyelid retraction
355567|NCT01272414|Botulinum Toxins
355568|NCT01272388|Aortic valve stenosis
355569|NCT01272388|Tadalafil
355570|NCT01272388|Phosphodiesterase inhibitors
355571|NCT01272388|Hypertension, pulmonary
355572|NCT01272388|Hypertrophy, left ventricular
355573|NCT01272362|Indacaterol
355574|NCT01272362|COPD
355575|NCT01272362|LABA
355576|NCT01272362|Reversibility
355577|NCT01272349|spinal cord injury
355578|NCT01272349|walking
355579|NCT01272349|low oxygen
355580|NCT01272349|air
355581|NCT01272349|strength
355582|NCT01272336|spinal cord injury, low oxygen, strength, motor control
355583|NCT01272323|Cat allergy
355584|NCT01272323|Rhinoconjunctivitis
355585|NCT01272310|Chronic Hepatitis C
355586|NCT01272310|Combination Therapy
355587|NCT01272310|Hydroxychloroquine
355588|NCT01272310|Pegylated Interferon Alpha-2a
355589|NCT01272310|Ribavirin
355590|NCT01272310|Chronic Hepatitis C Genotype 1 infected adult subjects
355591|NCT01272297|LI-ESWT
355592|NCT01272297|Erectile Dysfunction
355593|NCT01272297|Non PDE5 inhibitor responders
355594|NCT01272297|Shock wave
355595|NCT01272284|Female
355596|NCT01272284|Stress urinary incontinence
355597|NCT01272284|Mini sling
355598|NCT01272284|Single incision sling
355599|NCT01272284|Urinary incontinence
355600|NCT01272284|Mixed urinary incontinence
355601|NCT01272284|Additional relevant MeSH terms:
355602|NCT01272284|Stress
355603|NCT01272284|Urinary Incontinence, Stress
355604|NCT01272284|Pathological Processes
355605|NCT01272284|Urination Disorders
355606|NCT01272284|Urological Disorders
355607|NCT01272284|Urological Manifestations
355608|NCT01272284|Signs and Symptoms
355609|NCT01272271|Contact lens
355610|NCT01272271|Infection
355611|NCT01272271|Cornea
355612|NCT01272245|Acute Myelogenous Leukemia
355613|NCT01272245|AML
355614|NCT01272245|High-Risk Myelodysplastic Syndrome
355615|NCT01272245|MDS
355616|NCT01272245|Omacetaxine
355617|NCT01272245|Cytarabine
355618|NCT01272245|ARA-C
355619|NCT01272245|Cytosar
355620|NCT01272245|DepoCyt
355621|NCT01272245|Cytosine Arabinosine Hydrochloride
355622|NCT01272180|Safety
355623|NCT01272180|Immunogenicity
355624|NCT01272180|Vaccine
355625|NCT01272180|Meningococcal
355626|NCT01272180|Seroresponse
355627|NCT01272167|Post-menopausal women
355628|NCT01272167|Grapefruit juice
355629|NCT01272167|Naringin
355630|NCT01272167|Vascular protection
355631|NCT01272167|Bone metabolism
355632|NCT01272154|Cerebellum
355633|NCT01272154|Cortical plasticity
355634|NCT01272154|Sensorimotor adaptation
355635|NCT01272154|Dystonia
355636|NCT01272154|Cerebral Palsy
355637|NCT01272154|Transcranial Magnetic Stimulation
355638|NCT01272154|and
355639|NCT01272141|Metastatic breast cancer
355640|NCT01272141|Triple negative breast cancer
355641|NCT01272141|Estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer
355642|NCT01272115|Climacteric stage
355643|NCT01272115|Integrative health care model
355644|NCT01272115|Empowerment approach
355645|NCT01272115|Primary care services
355646|NCT01272076|Age Related Macular Degeneration
355647|NCT01272076|Geographic Atrophy
355648|NCT01272076|Imaging
355649|NCT01272076|OCT
355650|NCT01272063|Drusen
355651|NCT01272063|Dry AMD
355652|NCT01272063|OCT
355653|NCT01272063|Imaging
355654|NCT01272050|adenocarcinoma of the prostate
355655|NCT01272050|recurrent prostate cancer
355656|NCT01272050|stage IIA prostate cancer
355657|NCT01272050|stage IIB prostate cancer
355658|NCT01272050|stage III prostate cancer
355659|NCT01272024|clinical trial
355660|NCT01272024|symptom education
355661|NCT01272024|advanced cancer
355662|NCT01272011|Respiration
355663|NCT01272011|Spinal cord injuries
355664|NCT01272011|Walking recovery
355665|NCT01271998|antibiotic
355666|NCT01271998|healthy subjects
355667|NCT01271998|pharmacokinetics
355668|NCT01271985|Cardiovascular Diseases
355669|NCT01271985|Drug Combinations
355670|NCT01271985|prevention and control
355671|NCT01271985|Aspirin
355672|NCT01271985|Antihypertensive Agents
355673|NCT01271985|Antilipemic Agents
355674|NCT01271959|Ovarian
355675|NCT01271959|Fallopian Tube
355676|NCT01271959|Peritoneal
355677|NCT01271959|Uterine Neoplasms
355678|NCT01271959|Vulva
355679|NCT01271959|Endometrial
355680|NCT01271959|Cervical
355681|NCT01271959|Lung
355682|NCT01271959|Carcinoid
355683|NCT01271959|Sarcoma
355684|NCT01271959|Mesothelioma
355685|NCT01271959|Adenocarcinoma
355686|NCT01271959|Colorectal
355687|NCT01271959|Breast
355688|NCT01271959|Assay
355689|NCT01271959|Chemotherapy
355690|NCT01271959|Recurrent
355691|NCT01271959|Refractory
355692|NCT01271959|Persistent
355693|NCT01271959|Chemoresponse
355694|NCT01271933|fibromyalgia
355695|NCT01271933|pain
355696|NCT01271933|pregabalin
355697|NCT01271933|Lyrica
355698|NCT01271920|Trastuzumab-refractory
355699|NCT01271920|advanced HER2-positive breast cancer,
355700|NCT01271920|Hsp90,
355701|NCT01271920|2nd or 3rd line treatment
355702|NCT01271907|Skin Cancer
355703|NCT01271907|Malignancy
355704|NCT01271907|Immunotherapy
355705|NCT01271907|Melanoma Peptides
355706|NCT01271907|Melanoma
355707|NCT01271907|Metastatic Melanoma
355708|NCT01271894|HIV
355709|NCT01271894|efavirenz
355710|NCT01271894|pharmacokinetic
355711|NCT01271881|Hemodialysis
355712|NCT01271881|Fistula
355713|NCT01271881|Angiograph
355714|NCT01271881|Angiogram
355715|NCT01271881|Adult patients who are currently receiving hemodialysis treatment via an AV vascular graft or fistula located in the upper extremity
355716|NCT01271868|Recombinant Factor IX
355717|NCT01271829|Avocados
355718|NCT01271829|Satiety
355719|NCT01271829|Feeding study
355720|NCT01271816|genetics
355721|NCT01271816|sudden death
355722|NCT01271816|monitoring
355723|NCT01271816|loop recorder
355724|NCT01271816|cardiomyopathy
355725|NCT01271790|Hepatitis C
355726|NCT01271790|HCV
355727|NCT01271790|Rapid Virologic Response
355728|NCT01271790|Sustained Virologic Response
355729|NCT01271790|Direct Acting Antiviral
355730|NCT01271790|Combination Therapy
355731|NCT01271790|HCV RNA
355732|NCT01271790|Polymerase inhibitor
355733|NCT01271790|Protease inhibitor
355734|NCT01271790|Treatment naïve
355735|NCT01271790|GS-9190
355736|NCT01271790|GS-9451
355737|NCT01271777|Pre-diabetes
355738|NCT01271777|Clamp technique
355739|NCT01271777|PPARs
355740|NCT01271777|Insulin resistance
355741|NCT01271751|Atherogenic-dyslipidaemia
355742|NCT01271751|PPARs
355743|NCT01271738|Breast Cancer
355744|NCT01271738|Tumors or cancer of the human breast
355745|NCT01271738|Breast Tumors
355746|NCT01271738|Cancer of Breast
355747|NCT01271738|Cancer of the Breast
355748|NCT01271738|Human Mammary Carcinoma
355749|NCT01271738|Neoplasms, Breast
355750|NCT01271712|Gastrointestinal stromal cancer
355751|NCT01271712|GIST
355752|NCT01271712|multikinase inhibitor
355753|NCT01271699|Fabry Disease
355754|NCT01271699|Fabry´s Disease
355755|NCT01271699|Anderson-Fabry Disease
355756|NCT01271699|Multiple Sclerosis
355757|NCT01271660|muscle cramp
355758|NCT01271660|liver cirrhosis
355759|NCT01271660|pregabalin
355760|NCT01271647|osteopenia,chinese herb
355761|NCT01271634|cross-transmission
355762|NCT01271634|offending vessel
355763|NCT01271621|Airtraq, Intraocular pressure
355764|NCT01271608|Accident prevention
355765|NCT01271608|Blood-borne pathogens
355766|NCT01271608|Protective devices.
355767|NCT01271608|Needlestick injuries
355768|NCT01271608|Injections subcutaneous
355769|NCT01271608|Injections intradermal
355770|NCT01271595|acupuncture
355771|NCT01271595|autonomic nervous system
355772|NCT01271595|seasonal allergic rhinitis
355773|NCT01271582|Colorecatal cancer
355774|NCT01271582|Gastric cancer
355775|NCT01271582|Irinotecan
355776|NCT01271582|UGT1A1
355777|NCT01271582|Neutropenia
355778|NCT01271556|COPD
355779|NCT01271556|LABA
355780|NCT01271556|salmeterol
355781|NCT01271543|Comparison of hemodynamic
355782|NCT01271543|endotracheal intubation
355783|NCT01271543|changes induced by
355784|NCT01271543|performed
355785|NCT01271543|the aid of the SOS
355786|NCT01271543|as compared to the Macintosh Laryngoscope
355787|NCT01271530|Late Effects of Polio
355788|NCT01271530|Cardiovascular Fitness
355789|NCT01271530|Fatigue
355790|NCT01271530|Energy cost of Walking
355791|NCT01271530|Pain
355792|NCT01271517|Basal insulin
355793|NCT01271517|long acting insulin analogs
355794|NCT01271517|metabolic control
355795|NCT01271517|HbA1c
355796|NCT01271517|C-peptide
355797|NCT01271517|IGF-I
355798|NCT01271517|GH
355799|NCT01271517|IGFBP
355800|NCT01271504|Cancer
355801|NCT01271504|liver
355802|NCT01271504|hepatocellular carcinoma
355803|NCT01271504|phase I
355804|NCT01271504|phase II
355805|NCT01271491|Pediatric
355806|NCT01271478|inflammation
355807|NCT01271478|telmisartan
355808|NCT01271478|captopril
355809|NCT01271478|hemodialysis
355810|NCT01271426|Polypoidal Choroidal Vasculopathy
355811|NCT01271426|Ranibizumab
355812|NCT01271400|Infertility treatments
355813|NCT01271400|Frozen embryo transfers (FET).
355814|NCT01271400|IVF.
355815|NCT01271400|ART.
355816|NCT01271400|Cryopreservation
355817|NCT01271400|Slow-Freeze
355818|NCT01271400|Freeze / thaw survival rates
355819|NCT01271400|Blastocyst formation
355820|NCT01271400|Pregnancy
355821|NCT01271387|Liver disease
355822|NCT01271387|pharmacokinetics
355823|NCT01271374|African American
355824|NCT01271374|Hypertension
355825|NCT01271374|Cardiometabolic Syndrome
355826|NCT01271361|thrombus aspiration
355827|NCT01271361|Drug-Eluting Stent
355828|NCT01271361|optical frequency domain imaging (OFDI)
355829|NCT01271335|CTO
355830|NCT01271335|Angioplasty
355831|NCT01271335|PCI
355832|NCT01271322|PET
355833|NCT01271322|response evaluation
355834|NCT01271322|neoadjuvant
355835|NCT01271322|radiochemotherapy
355836|NCT01271322|adenocarcinoma of the esophagogastric junction
355837|NCT01271322|esophageal carcinoma
355838|NCT01271322|evaluation of preoperative (radio)-chemotherapy in patients with adenocarcinomas of the oesophagogastric junction
355839|NCT01271296|Addison Disease
355840|NCT01271296|Pharmacokinetics
355841|NCT01271296|Hormone Replacement Therapy
355842|NCT01271296|cortisone acetate
355843|NCT01271296|Quality of Life
355844|NCT01271270|Age-Related Macular Degeneration (AMD)
355845|NCT01271270|Palomid 529
355846|NCT01271270|Age Related Macular Degeneration
355847|NCT01271270|AMD
355848|NCT01271257|misoprostol, pharmacokinetics
355849|NCT01271231|periodontal treatment, diabetes, glycemia, glycated hemoglobin
355850|NCT01271205|pneumonia
355851|NCT01271205|RDW
355852|NCT01271205|mortality
355853|NCT01271205|prognostic factor
355854|NCT01271192|local recurrent rectal cancer
355855|NCT01271192|surgical resection
355856|NCT01271192|adjuvant therapy
355857|NCT01271179|orthotopic liver transplantation
355858|NCT01271179|preservation solution
355859|NCT01271179|peribiliary plexus
355860|NCT01271179|nonanastomotic biliary strictures
355861|NCT01271179|primary non-function
355862|NCT01271166|Colorectal,
355863|NCT01271166|Cancer
355864|NCT01271153|Septic shock
355865|NCT01271127|radiation therapy
355866|NCT01271127|coronary artery disease
355867|NCT01271127|Hodgkin Lymphoma
355868|NCT01271101|Non-ST-elevated acute coronary syndromes (NSTE-ACS)
355869|NCT01271101|anticoagulation
355870|NCT01271088|ototoxicity
355871|NCT01271088|aminoglycoside
355872|NCT01271088|vancomycine
355873|NCT01271088|peritoneal dialysis
355874|NCT01271088|peritonitis
355875|NCT01271075|urticaria
355876|NCT01271075|bilastine
355877|NCT01271062|Resolvment of Diabetes Mellitus, Type 2
355878|NCT01271062|gastric bypass
355879|NCT01271036|Lubricating Agents
355880|NCT01271036|Personal Lubricant
355881|NCT01270984|Imatinib mesylate
355882|NCT01270984|Pharmacokinetics
355883|NCT01270984|Healthy volunteers
355884|NCT01270971|Onychomycosis
355885|NCT01270971|nail fungus
355886|NCT01270971|toenail fungus
355887|NCT01270971|fungal nail
355888|NCT01270971|hyperkeratosis
355889|NCT01270971|nail infection
355890|NCT01270971|nail treatment
355891|NCT01270971|toenail infection
355892|NCT01270971|toenail treatment
355893|NCT01270971|foot dermatoses
355894|NCT01270971|fungal culture
355895|NCT01270971|onycholysis
355896|NCT01270971|podiatrist
355897|NCT01270971|podiatry
355898|NCT01270971|subungual
355899|NCT01270971|tinea unguium
355900|NCT01270971|antifungal
355901|NCT01270971|anti-fungal
355902|NCT01270971|dermatologist
355903|NCT01270971|dermatology
355904|NCT01270971|dermatophyte
355905|NCT01270971|distal subungual onychomycosis
355906|NCT01270971|yellow nail
355907|NCT01270971|thick nail
355908|NCT01270971|brittle nail
355909|NCT01270971|crumbling nail
355910|NCT01270971|discolored nail
355911|NCT01270971|weak nail
355912|NCT01270958|AVY-REG00108VN
355913|NCT01270906|Neoplasms
355914|NCT01270906|Cancer
355915|NCT01270906|Tumors
355916|NCT01270906|Administration
355917|NCT01270906|oral
355918|NCT01270906|CHIR258
355919|NCT01270906|CHIR-258
355920|NCT01270906|CHIR 258
355921|NCT01270906|TKI258
355922|NCT01270906|TKI-258
355923|NCT01270906|TKI 258
355924|NCT01270906|dose finding
355925|NCT01270893|Gastrointestinal stromal tumor
355926|NCT01270893|GIST
355927|NCT01270893|Nilotinib
355928|NCT01270893|AMN107
355929|NCT01270893|Tasigna
355930|NCT01270867|Ischemia
355931|NCT01270867|Stroke
355932|NCT01270867|Ischemic Stroke
355933|NCT01270867|Mechanical Thrombectomy
355934|NCT01270867|Brain
355935|NCT01270867|Brain clot
355936|NCT01270867|Cerebrovascular disease
355937|NCT01270867|Recanalization
355938|NCT01270867|Revascularization
355939|NCT01270854|Normal saline
355940|NCT01270854|Plasmalyte
355941|NCT01270854|Intravenous fluid
355942|NCT01270854|Traumatic injury
355943|NCT01270854|Fluid resuscitation
355944|NCT01270828|Control Release Pregabalin in Post Herpetic Neuralgia
355945|NCT01270815|pregabalin
355946|NCT01270815|pharmacokinetics
355947|NCT01270815|bioavailability
355948|NCT01270815|bioequivalence
355949|NCT01270802|Endothelial function
355950|NCT01270802|Vitamin D
355951|NCT01270802|Efavirenz
355952|NCT01270802|Raltegravir
355953|NCT01270789|beta-cell function
355954|NCT01270789|GLP-1 analogue
355955|NCT01270789|diabetes
355956|NCT01270776|Randomized Controlled Trial
355957|NCT01270776|Chlorhexidine
355958|NCT01270776|Infant, Premature
355959|NCT01270763|Obesity
355960|NCT01270763|physical fitness
355961|NCT01270763|cholesterol levels
355962|NCT01270763|genetics
355963|NCT01270763|weight loss
355964|NCT01270750|ENDOTHELIN RECEPTOR ANTAGONIST
355965|NCT01270750|BOSENTAN
355966|NCT01270750|SECONDARY PULMONARY HYPERTENSION
355967|NCT01270750|RHEUMATOID FEVER
355968|NCT01270750|CONGESTIVE HEART FAILURE
355969|NCT01270750|SECONDARY PULMONARY HYPERTENSION DUE TO MITRAL STENOSIS
355970|NCT01270711|compliance study
355971|NCT01270711|effectiveness study
355972|NCT01270711|hyperprolactinemia
355973|NCT01270711|Parkinson's disease
355974|NCT01270711|retrospective cohort study
355975|NCT01270698|colorectal cancer
355976|NCT01270672|MDMA
355977|NCT01270672|carvedilol
355978|NCT01270672|norepinephrine
355979|NCT01270672|alpha - beta receptor
355980|NCT01270672|Ecstasy
355981|NCT01270672|stimulant
355982|NCT01270659|Fentanyl buccal tablet
355983|NCT01270646|Cardiac insufficiency
355984|NCT01270646|Invasive procedure
355985|NCT01270646|Heart Failure
355986|NCT01270646|Noninvasive procedure
355987|NCT01270646|Congestive Heart Failure
355988|NCT01270646|Mapping
355989|NCT01270646|Cardiac resynchronisation therapy
355990|NCT01270646|Open study
355991|NCT01270646|Cardiac Pacings, Artificial
355992|NCT01270646|Hemodynamics
355993|NCT01270620|elderly obese
355994|NCT01270581|transient tachypnea of the newborn
355995|NCT01270581|high flow nasal cannula
355996|NCT01270581|bubble nasal
355997|NCT01270581|continuous positive airway pressure
355998|NCT01270568|positive psychology
355999|NCT01270568|cardiovascular disease
356000|NCT01270542|Traction Retinal Detachment (PDR)
356001|NCT01270542|Proliferative Diabetic Retinopathy (PDR)
356002|NCT01270529|Physical Activity
356003|NCT01270529|Physical Performance
356004|NCT01270529|Physical Functioning
356005|NCT01270529|CKD
356006|NCT01270529|ESRD
356007|NCT01270529|Transplant Recipients
356008|NCT01270516|diaphragm
356009|NCT01270516|limb muscle
356010|NCT01270516|EPA
356011|NCT01270516|HMB
356012|NCT01270516|ICU patients
356013|NCT01270503|Meningitis
356014|NCT01270503|Meningococcal disease
356015|NCT01270503|Menactra®
356016|NCT01270490|candidemia
356017|NCT01270490|candida sepsis
356018|NCT01270490|invasive fungal disease
356019|NCT01270477|Frost injury
356020|NCT01270451|Weight maintenance
356021|NCT01270451|Group counseling
356022|NCT01270451|Prevention of diseases
356023|NCT01270425|systemic sclerosis
356024|NCT01270425|hashimoto thyroiditis
356025|NCT01270425|thyroid nodules
356026|NCT01270412|Osteoarthritis
356027|NCT01270412|PRP
356028|NCT01270412|PRGF
356029|NCT01270412|Hyaluronic acid
356030|NCT01270386|NSCLC
356031|NCT01270386|apatinib
356032|NCT01270386|phase II
356033|NCT01270386|lung
356034|NCT01270386|cancer
356035|NCT01270373|neoadjuvant therapy
356036|NCT01270373|drug therapy
356037|NCT01270321|Thyroid Cancer
356038|NCT01270308|Bioequivalence
356039|NCT01270308|two way crossover
356040|NCT01270295|Receptor for advanced glycation end products (RAGE)
356041|NCT01270295|Soluble RAGE (sRAGE)
356042|NCT01270295|Endogenous secretory RAGE (esRAGE)
356043|NCT01270295|High-mobility group box-1 protein (HMGB-1)
356044|NCT01270295|Extracellular newly-identified RAGE-binding protein (EN-RAGE or S100A12)
356045|NCT01270295|Advanced glycation endproducts (AGEs)
356046|NCT01270295|Pentosidine
356047|NCT01270295|N--carboxymethyllysine
356048|NCT01270295|Acute lung injury (ALI)
356049|NCT01270295|Acute respiratory distress syndrome (ARDS)
356050|NCT01270295|Alveolar epithelium
356051|NCT01270295|Mechanical ventilation
356052|NCT01270295|Intensive Care Unit (ICU)
356053|NCT01270269|Asthenia
356054|NCT01270269|Muscle Weakness
356055|NCT01270269|Brain Injuries
356056|NCT01270269|Critical Illness
356057|NCT01270269|Critical Illness Myoneuropathy
356058|NCT01270269|Rehabilitation
356059|NCT01270269|Sepsis
356060|NCT01270269|Respiratory Failure
356061|NCT01270269|Delirium
356062|NCT01270269|Over-sedation
356063|NCT01270269|Immobility
356064|NCT01270269|Aging
356065|NCT01270269|Signs and Symptoms
356066|NCT01270269|Muscular Diseases
356067|NCT01270269|Musculoskeletal Diseases
356068|NCT01270269|Neuromuscular Manifestations
356069|NCT01270269|Neurologic Manifestations
356070|NCT01270269|Pathologic Processes
356071|NCT01270269|Brain Diseases
356072|NCT01270269|Central Nervous System Diseases
356073|NCT01270269|Craniocerebral Trauma
356074|NCT01270269|Trauma, Nervous System
356075|NCT01270269|Wounds and Injuries
356076|NCT01270269|Disorders of Environmental Origin
356077|NCT01270256|allergy
356078|NCT01270230|HIV Prevention Intervention
356079|NCT01270230|African American Men who have Sex with Men
356080|NCT01270217|Automobile driving
356081|NCT01270217|Driving under the influence
356082|NCT01270217|Interview, psychological
356083|NCT01270217|Brief intervention
356084|NCT01270217|Brief motivational interview
356085|NCT01270204|Dysphagia
356086|NCT01270204|Swallowing Problems
356087|NCT01270204|Dynamic Fluoroscopic Swallow Study
356088|NCT01270204|Aspiration
356089|NCT01270204|Regurgitation
356090|NCT01270204|Acid Reflux
356091|NCT01270191|Exenatide, Beta-Cell Function, Glycemic Control
356092|NCT01270191|in Newly Diagnosed Type 2 Diabetic Patients
356093|NCT01270165|lamivudine
356094|NCT01270165|telbivudine
356095|NCT01270165|adefovir
356096|NCT01270165|lamivudine resistance
356097|NCT01270152|ascorbic acid
356098|NCT01270152|catheterization central venous
356099|NCT01270152|nursing care
356100|NCT01270139|nanoparticles
356101|NCT01270139|mesenchymal stem cell
356102|NCT01270139|plasmonics
356103|NCT01270139|atherosclerosis
356104|NCT01270139|IVUS
356105|NCT01270139|stenting
356106|NCT01270126|optic neuropathy
356107|NCT01270126|alternating current stimulation
356108|NCT01270126|vision recovery
356109|NCT01270126|restoration
356110|NCT01270126|plasticity
356111|NCT01270087|Rheumatoid arthritis, cardiovascular disease, adalimumab
356112|NCT01270074|double blind placebo controlled randomised clinical trial
356113|NCT01270074|azithromycin
356114|NCT01270074|infant
356115|NCT01270074|pediatric
356116|NCT01270074|cystic fibrosis
356117|NCT01270074|bronchiectasis
356118|NCT01270061|HIV testing
356119|NCT01270061|black Africans
356120|NCT01270061|immigrants
356121|NCT01270061|health screening
356122|NCT01270048|Hwa-byung, Bunsimgi-eum(Fenxinqiyin)
356123|NCT01269996|type 2 diabetes mellitus
356124|NCT01269996|JUBILEE Study
356125|NCT01269996|Janumet
356126|NCT01269996|Lantus
356127|NCT01269983|low back pain
356128|NCT01269983|fascial manipulation
356129|NCT01269983|physioterapy
356130|NCT01269983|physical activity
356131|NCT01269957|halitosis
356132|NCT01269957|pediatric dentistry
356133|NCT01269957|mouth breathing
356134|NCT01269944|osteoarthritis
356135|NCT01269944|knee
356136|NCT01269944|high wedge tibial osteotomy
356137|NCT01269944|dGEMRIC
356138|NCT01269931|endobronchial ultrasound
356139|NCT01269931|bronchoscopy
356140|NCT01269931|education
356141|NCT01269931|interventional bronchoscopy
356142|NCT01269931|simulation
356143|NCT01269918|Craniotomy, pain relief
356144|NCT01269918|Adult solid neoplasm
356145|NCT01269892|diarrhea, lactose, milk, weight, acute.
356146|NCT01269879|epicondylitis
356147|NCT01269879|pain
356148|NCT01269879|tendon
356149|NCT01269866|Lupus Pain
356150|NCT01269866|Lupus
356151|NCT01269866|Pain
356152|NCT01269866|Systemic Lupus Erythematosus
356153|NCT01269866|Duloxetine
356154|NCT01269866|Cymbalta
356155|NCT01269853|GBM
356156|NCT01269853|AA
356157|NCT01269853|AO
356158|NCT01269853|Brain
356159|NCT01269853|Tumors
356160|NCT01269853|Malignant
356161|NCT01269853|Glioblastoma
356162|NCT01269853|Multiforme
356163|NCT01269853|Anaplastic
356164|NCT01269853|Astrocytoma
356165|NCT01269827|inflammation
356166|NCT01269827|pentoxifylline
356167|NCT01269827|hemodialysis
356168|NCT01269814|Gastrointestinal bleeding
356169|NCT01269814|Emergency endoscopy
356170|NCT01269814|Rockall Risk Scoring System
356171|NCT01269801|BOTOX
356172|NCT01269801|JUVEDERM
356173|NCT01269801|Prospective
356174|NCT01269801|Open Label
356175|NCT01269801|Randomized
356176|NCT01269801|Crossover Study
356177|NCT01269788|non-erosive reflux disease
356178|NCT01269788|heartburn
356179|NCT01269788|functional
356180|NCT01269788|Antidepressive Agents, Second-Generation
356181|NCT01269788|Proton Pump Inhibitors
356182|NCT01269762|Red yeast rice
356183|NCT01269762|Lovastatin
356184|NCT01269762|Drug-drug interaction
356185|NCT01269762|Pharmacokinetics
356186|NCT01269749|Hyperthyroidism
356187|NCT01269749|Antithyroid drugs
356188|NCT01269749|Cancer
356189|NCT01269749|Dosimetry
356190|NCT01269749|Children
356191|NCT01269736|electrocardiographic monitoring
356192|NCT01269736|arrhythmia
356193|NCT01269736|myocardial ischemia
356194|NCT01269723|Smoking
356195|NCT01269723|influenza
356196|NCT01269723|influenza vaccine
356197|NCT01269710|Second Generation Antipsychotics
356198|NCT01269710|Schizophrenia
356199|NCT01269710|Schizoaffective
356200|NCT01269710|Schizophreniform
356201|NCT01269710|Psychosis NOS
356202|NCT01269710|Mood Disorders
356203|NCT01269710|Weight
356204|NCT01269710|Autism
356205|NCT01269697|AMD
356206|NCT01269697|food supplementation
356207|NCT01269697|macular pigments
356208|NCT01269697|luthéine
356209|NCT01269697|zéaxanthine
356210|NCT01269697|visual acuity
356211|NCT01269697|prevention
356212|NCT01269697|genetique risk
356213|NCT01269684|Kidney
356214|NCT01269684|renal
356215|NCT01269684|transplantation
356216|NCT01269684|tacrolimus
356217|NCT01269684|everolimus
356218|NCT01269684|stable allograft recipients
356219|NCT01269671|Functional Abdominal Pain
356220|NCT01269671|Irritable Bowel Syndrome
356221|NCT01269671|IBS
356222|NCT01269671|Functional Dyspepsia
356223|NCT01269671|Melatonin
356224|NCT01269671|Simethicone
356225|NCT01269671|Peppermint Oil
356226|NCT01269671|mentharil
356227|NCT01269671|functional bowel disorders
356228|NCT01269671|quality of life
356229|NCT01269645|Cancer
356230|NCT01269645|Clinical trials
356231|NCT01269632|teenagers to adult transition
356232|NCT01269632|comparison
356233|NCT01269619|back pain
356234|NCT01269619|posture
356235|NCT01269619|lumbar support
356236|NCT01269619|dynamic support
356237|NCT01269593|PET Scan
356238|NCT01269593|124I-PUH71
356239|NCT01269593|10-139
356240|NCT01269567|RectalNeoplasms
356241|NCT01269567|Colorectal Neoplasms
356242|NCT01269567|Intestinal Neoplasms
356243|NCT01269567|Gastrointestinal Neoplasms
356244|NCT01269567|Digestive System Neoplasms
356245|NCT01269567|Neoplasms by Site
356246|NCT01269567|Digestive System Diseases
356247|NCT01269567|Gastrointestinal Diseases
356248|NCT01269567|Intestinal Diseases
356249|NCT01269567|Rectal Diseases
356250|NCT01269554|diarrhea
356251|NCT01269554|Guinea-Bissau
356252|NCT01269554|Finland
356253|NCT01269554|Children
356254|NCT01269554|Adults
356255|NCT01269554|Intestinal pathogens
356256|NCT01269554|Bacteria
356257|NCT01269554|Virus
356258|NCT01269554|Parasites
356259|NCT01269528|Palivizumab
356260|NCT01269528|Airway Hyperreactivity
356261|NCT01269528|EBC
356262|NCT01269528|MCT
356263|NCT01269515|Cox-2 inhibitor
356264|NCT01269515|HIV
356265|NCT01269515|immune activation
356266|NCT01269515|immune modulating
356267|NCT01269515|progression markers
356268|NCT01269515|vaccine
356269|NCT01269489|quality of life
356270|NCT01269489|general Slovenian population
356271|NCT01269489|EORTC QLQ C30
356272|NCT01269463|Attention deficit
356273|NCT01269463|Hyperactivity
356274|NCT01269463|Impulsivity
356275|NCT01269463|Inattention
356276|NCT01269450|second trimester vaginal bleeding
356277|NCT01269450|late abortion
356278|NCT01269450|preterm birth
356279|NCT01269450|progesterone
356280|NCT01269437|mild to moderate asthma
356281|NCT01269424|adult giant cell glioblastoma
356282|NCT01269424|adult glioblastoma
356283|NCT01269424|adult gliosarcoma
356284|NCT01269385|Imprime PGG
356285|NCT01269372|polyps
356286|NCT01269372|capsule endoscopy
356287|NCT01269372|colonoscopy
356288|NCT01269346|Locally recurrent
356289|NCT01269346|metastatic HER2Positive breast cancer
356290|NCT01269307|Anesthesia
356291|NCT01269307|Pain
356292|NCT01269307|Procedural sedation
356293|NCT01269307|Airway/Anesthesia/Analgesia
356294|NCT01269294|Hepatitis C
356295|NCT01269294|TMC435-TiDP16-C117
356296|NCT01269294|TMC435-C117
356297|NCT01269294|TMC435
356298|NCT01269294|HCV
356299|NCT01269294|Moxifloxacin
356300|NCT01269294|ECG
356301|NCT01269294|QT
356302|NCT01269294|QTc
356303|NCT01269281|Bioequivalence
356304|NCT01269281|two way crossover
356305|NCT01269242|coronary restenosis
356306|NCT01269242|angioplasty
356307|NCT01269242|stent
356308|NCT01269242|MCP-1/CCL2
356309|NCT01269242|MCP-3/CCL7
356310|NCT01269203|multiple myeloma
356311|NCT01269203|MM
356312|NCT01269203|maintenance therapy
356313|NCT01269203|lenalidomide
356314|NCT01269203|bone marrow transplantation
356315|NCT01269203|auto-HSCT
356316|NCT01269203|Autologous Hematopoietic Stem Cell Transplantation
356317|NCT01269203|NF-kB inhibition
356318|NCT01269203|reducing symptoms
356319|NCT01269203|maintenance chemotherapy
356320|NCT01269203|inflammatory cytokines
356321|NCT01269203|nuclear factor kappa B
356322|NCT01269203|NF-kB
356323|NCT01269203|interleukin
356324|NCT01269203|IL-6
356325|NCT01269203|tumor necrosis factor
356326|NCT01269203|TNF-a
356327|NCT01269203|NF-kB activation levels
356328|NCT01269190|oral mucosa in vivo
356329|NCT01269190|Wide-Field In Vivo Imaging
356330|NCT01269190|High Resolution In Vivo Imaging
356331|NCT01269190|Oral Neoplasia
356332|NCT01269190|Topical Fluorescent Dyes
356333|NCT01269190|contrast dye
356334|NCT01269190|oral dysplasia
356335|NCT01269190|Proflavine
356336|NCT01269190|oral lesions
356337|NCT01269190|surgical resection
356338|NCT01269190|High Resolution Microendoscope
356339|NCT01269190|HRME
356340|NCT01269190|Identafi 3000
356341|NCT01269190|Multispectral Digital Microscope
356342|NCT01269190|MDM
356343|NCT01269190|Portable Screening System
356344|NCT01269190|PS2
356345|NCT01269177|ACPE
356346|NCT01269177|Acute respiratory failure
356347|NCT01269177|Non invasive ventilation
356348|NCT01269177|acute cardiogenic pulmonary edema
356349|NCT01269164|Face Transplant
356350|NCT01269164|Facial Transplantation
356351|NCT01269164|Composite Facial Allograft Transplantation
356352|NCT01269151|Age-Related Macular Degeneration
356353|NCT01269151|Retinal Function
356354|NCT01269151|multifocal-ERG
356355|NCT01269151|Electroretinography
356356|NCT01269151|microperimetry
356357|NCT01269151|Lucentis
356358|NCT01269151|Ranibizumab
356359|NCT01269151|longterm effects
356360|NCT01269151|best corrected visual acuity
356361|NCT01269151|BCVA
356362|NCT01269138|Inherited Factor VII deficiency
356363|NCT01269138|Inhibitor development in Factor VII deficiency
356364|NCT01269138|Bleeding in Factor VII Deficiency
356365|NCT01269138|Surgery in Factor VII deficiency
356366|NCT01269138|Prophylaxis in Factor VII Deficiency
356367|NCT01269125|cytokines
356368|NCT01269125|endometriosis
356369|NCT01269125|fertilization rate
356370|NCT01269125|follicular fluid
356371|NCT01269125|pregnancy rate
356372|NCT01269099|hypokalemia
356373|NCT01269099|intravenous patient controlled analgesia
356374|NCT01269086|Primary Heath Care
356375|NCT01269086|Preventive Medicine
356376|NCT01269086|Adolescent Health Services
356377|NCT01269086|Spouses
356378|NCT01269086|Family
356379|NCT01269086|Family Practice
356380|NCT01269073|Obstructive Sleep Apnea
356381|NCT01269060|Colorectal Cancer, laparoscopic surgery
356382|NCT01269047|type 1 diabetes
356383|NCT01269047|Symlin
356384|NCT01269047|Byetta
356385|NCT01269047|CGMS iPro
356386|NCT01269034|Type 1 diabetes Milletus
356387|NCT01269034|diabetes
356388|NCT01269034|healthy controls
356389|NCT01269034|exenatide
356390|NCT01269034|byetta
356391|NCT01269021|MMF treatment IgA Nephropathy (IgAN)
356392|NCT01269008|Closed loop
356393|NCT01269008|type 1 diabetes
356394|NCT01269008|Symlin
356395|NCT01269008|Byetta
356396|NCT01269008|diabetes
356397|NCT01269008|insulin
356398|NCT01269008|insulin pump
356399|NCT01268995|NODAT
356400|NCT01268995|kidney transplantation
356401|NCT01268995|beta cell function
356402|NCT01268995|insulin
356403|NCT01268995|Tacrolimus
356404|NCT01268995|Cyclosporine A
356405|NCT01268982|socket preservation
356406|NCT01268982|alveolar ridge augmentation
356407|NCT01268969|pilonidal disease PND
356408|NCT01268943|rectal neoplasms
356409|NCT01268943|aged
356410|NCT01268943|radiotherapy
356411|NCT01268943|drug therapy
356412|NCT01268943|dose-escalation
356413|NCT01268943|capecitabine
356414|NCT01268930|ovarian reserve
356415|NCT01268930|endometrioma excision
356416|NCT01268930|hemostatic matrix
356417|NCT01268930|bipolar electrocoagulation
356418|NCT01268930|thermal injury
356419|NCT01268917|coronary artery disease
356420|NCT01268917|off-pump coronary artery bypass
356421|NCT01268917|aspirin
356422|NCT01268891|Azilect
356423|NCT01268891|Motor fluctuations
356424|NCT01268891|Parkinson´s Disease
356425|NCT01268891|Rasagiline
356426|NCT01268878|effect of febrile neutropenia resulting chemotherapy by TPF
356427|NCT01268865|Acoustic Radiation Force Impulse (ARFI)
356428|NCT01268865|Virtual Touch Quantification (VTQ)
356429|NCT01268865|liver stiffness measurement (LSM)
356430|NCT01268865|liver fibrosis
356431|NCT01268865|cirrhosis
356432|NCT01268865|hepatitis B
356433|NCT01268865|hepatitis C
356434|NCT01268839|TMC278, rilpivirine, efavirenz, healthy volunteer
356435|NCT01268800|AML
356436|NCT01268800|Induction
356437|NCT01268761|Ovarian hyperstimulation syndrome (OHSS)
356438|NCT01268761|GnRH antagonist
356439|NCT01268761|Ascitis.
356440|NCT01268748|single site surgery
356441|NCT01268748|laparoscopic surgery
356442|NCT01268748|pain
356443|NCT01268748|nausea
356444|NCT01268735|Dysfunctional Tear Syndrome
356445|NCT01268735|Dry Eye
356446|NCT01268735|LIPCOF
356447|NCT01268735|Hydroxypropyl-guar
356448|NCT01268722|Nitinol Stent
356449|NCT01268722|Balloon angioplasty
356450|NCT01268722|Chronic total occlusions
356451|NCT01268722|Femoropopliteal
356452|NCT01268696|diabetes
356453|NCT01268696|obesity
356454|NCT01268696|hypertension
356455|NCT01268696|dyslipidemia
356456|NCT01268683|Ischemic stroke
356457|NCT01268657|PTSD
356458|NCT01268657|Fear of Falling
356459|NCT01268657|Older Adults
356460|NCT01268657|Injurious Falls
356461|NCT01268657|Exposure Therapy
356462|NCT01268644|Type 1 Diabetes Mellitus
356463|NCT01268631|Fibromyalgia
356464|NCT01268631|Pain modulation
356465|NCT01268618|IBS
356466|NCT01268618|Diarrhea
356467|NCT01268618|Dyspepsia
356468|NCT01268605|Dental caries
356469|NCT01268605|Resin based composite
356470|NCT01268605|Hypersensitivity
356471|NCT01268605|Teeth
356472|NCT01268605|Dentistry
356473|NCT01268605|Practice-based research network
356474|NCT01268592|fertility preservation
356475|NCT01268592|oocyte cryopreservation
356476|NCT01268592|vitrification
356477|NCT01268592|egg freezing
356478|NCT01268592|fertility preservation in female cancer patients
356479|NCT01268579|ribavirin
356480|NCT01268579|VIRAZOLE
356481|NCT01268579|tonsil
356482|NCT01268579|base of tongue
356483|NCT01268579|squamous cell carcinoma
356484|NCT01268579|10-218
356485|NCT01268566|Glioblastoma
356486|NCT01268553|pulmonary arterial hypertension
356487|NCT01268553|inhaled prostacyclin
356488|NCT01268540|intraocular lens
356489|NCT01268540|IOL
356490|NCT01268540|cataract
356491|NCT01268540|refractive astigmatism
356492|NCT01268540|Aspheric
356493|NCT01268540|Toric
356494|NCT01268540|Hoya
356495|NCT01268540|Surgical
356496|NCT01268540|Optics
356497|NCT01268540|visual acuity
356498|NCT01268527|Psoriasis vulgaris
356499|NCT01268514|Complex
356500|NCT01268514|Abdominal Wall Reconstruction
356501|NCT01268514|AWR
356502|NCT01268514|Hernia
356503|NCT01268475|Bronchiectasis
356504|NCT01268475|Quality of Life
356505|NCT01268475|Respiratory Function Tests
356506|NCT01268475|Exercise Test
356507|NCT01268449|Tinnitus
356508|NCT01268449|Low power laser
356509|NCT01268423|Percutaneous tracheostomy
356510|NCT01268423|Swallowing dysfunction
356511|NCT01268423|Mechanical ventilation
356512|NCT01268423|Intensive Care
356513|NCT01268410|Acute respiratory failure
356514|NCT01268410|Acute lung injury
356515|NCT01268410|Acute respiratory distress syndrome
356516|NCT01268410|Mechanical Ventilation
356517|NCT01268410|Non-Invasive Ventilation
356518|NCT01268397|elderly
356519|NCT01268397|wrist fracture
356520|NCT01268397|fracture of the distal radius
356521|NCT01268397|volar plate
356522|NCT01268397|plaster cast
356523|NCT01268384|pancreatic cancer
356524|NCT01268384|neoadjuvant chemotherapy
356525|NCT01268384|gemcitabine
356526|NCT01268384|capecitabine
356527|NCT01268371|Coronary artery disease
356528|NCT01268371|Stent
356529|NCT01268345|blood glucose
356530|NCT01268332|Placebo IVR as a delivery method
356531|NCT01268319|Myocardial Infarction
356532|NCT01268319|percutaneous coronary intervention
356533|NCT01268319|embolization
356534|NCT01268319|necrotic core
356535|NCT01268319|vulnerable plaque
356536|NCT01268319|coronary plaque rupture
356537|NCT01268306|contact lens
356538|NCT01268306|corneal staining
356539|NCT01268306|fluorescein staining
356540|NCT01268306|preservatives
356541|NCT01268306|keratitis
356542|NCT01268306|punctate keratopathy
356543|NCT01268306|superficial punctate keratopathy
356544|NCT01268306|SPK
356545|NCT01268293|Cancer
356546|NCT01268254|wine
356547|NCT01268254|aging
356548|NCT01268254|atherosclerosis
356549|NCT01268254|telomere
356550|NCT01268254|tomography
356551|NCT01268254|coronary vessels
356552|NCT01268241|Fabry Disease
356553|NCT01268241|Fabry´s Disease
356554|NCT01268241|Anderson-Fabry Disease
356555|NCT01268228|intracoronary ECG
356556|NCT01268228|coronary bifurcation stenosis
356557|NCT01268228|side branch compromise
356558|NCT01268228|Periprocedural myonecrosis during coronary bifurcation lesion stenting assessed with ic ECG
356559|NCT01268215|Bronchopulmonary Dysplasia
356560|NCT01268215|Budesonide
356561|NCT01268215|Infasurf
356562|NCT01268202|cutaneous radioinduced fibrosis
356563|NCT01268189|burn wound
356564|NCT01268189|management with oxygen
356565|NCT01268176|Vitamin D
356566|NCT01268176|vitamin D deficiency
356567|NCT01268176|vitamin D absorption
356568|NCT01268163|Docetaxel
356569|NCT01268163|Phase I
356570|NCT01268163|Pharmacokinetic
356571|NCT01268163|Bioequivalence
356572|NCT01268137|MDD
356573|NCT01268137|DBS
356574|NCT01268124|Japanese
356575|NCT01268111|vitamin D deficiency, insulin sensitivity
356576|NCT01268098|Hypoparathyroidism, rhPTH[1-84], NPSP558
356577|NCT01268085|Radiation Safety
356578|NCT01268085|Computerized Physician Order Entry
356579|NCT01268085|Decision Support
356580|NCT01268085|Cat Scans
356581|NCT01268072|COPD
356582|NCT01268059|Non-small cell lung cancer
356583|NCT01268059|NSCLC
356584|NCT01268046|aging
356585|NCT01268046|postmenopausal women
356586|NCT01268046|estrogen
356587|NCT01268046|memory
356588|NCT01268033|rituximab
356589|NCT01268033|idiopathic nephrotic syndrome
356590|NCT01268033|minimal change disease
356591|NCT01268033|focal and segmental glomerulosclerosis
356592|NCT01268020|Alzheimer
356593|NCT01268020|AD
356594|NCT01267994|Steroid
356595|NCT01267994|Steroid-Resistant
356596|NCT01267994|Autoimmune Inner Ear Disease
356597|NCT01267994|Immune Mediated Hearing Loss
356598|NCT01267994|Sudden Sensorineural Hearing Loss
356599|NCT01267994|Meniere's Disease
356600|NCT01267994|Autoimmune
356601|NCT01267994|Hearing
356602|NCT01267981|Small bowel
356603|NCT01267981|video-capsule endoscopy
356604|NCT01267981|gastrointestinal bleeding
356605|NCT01267981|polyethylene glycol
356606|NCT01267968|pharmacokinetics
356607|NCT01267968|bronchoalveolar lavage
356608|NCT01267968|GSK2251052
356609|NCT01267968|pulmonary
356610|NCT01267968|healthy volunteer
356611|NCT01267968|antimicrobial
356612|NCT01267942|Adenotonsillectomy.
356613|NCT01267929|Children with cerebral palsy
356614|NCT01267929|Gross Motor Function Measure
356615|NCT01267929|Imitative learning
356616|NCT01267929|Mirror neuron
356617|NCT01267929|Action observation
356618|NCT01267929|Conventional physical therapy
356619|NCT01267916|intrinsic positive end-expiratory pressure
356620|NCT01267916|obesity
356621|NCT01267916|ventilator setting
356622|NCT01267916|respiratory rate
356623|NCT01267903|Vaccines Adverse Reaction
356624|NCT01267890|ethics
356625|NCT01267890|law
356626|NCT01267890|surrogate
356627|NCT01267890|conflict
356628|NCT01267877|U.S. Preventive Services Task Force
356629|NCT01267877|Patient attitude
356630|NCT01267877|Mammogram
356631|NCT01267877|Guideline
356632|NCT01267864|migraine
356633|NCT01267864|emergency
356634|NCT01267864|metoclopramide
356635|NCT01267864|ketorolac
356636|NCT01267864|valproate
356637|NCT01267851|gynecologic disease
356638|NCT01267838|Coronary artery disease
356639|NCT01267838|Restenosis
356640|NCT01267838|Stent thrombosis
356641|NCT01267825|Disc herniation
356642|NCT01267825|Lumbosacral radiculopathy
356643|NCT01267825|Corticosteroids
356644|NCT01267786|Oxidotic stress
356645|NCT01267773|depression
356646|NCT01267773|conduct problems
356647|NCT01267760|dialysis
356648|NCT01267760|hemodialysis
356649|NCT01267760|Effect of recycled low-volume dialysate on dialysis efficacy
356650|NCT01267747|Atrial fibrillation
356651|NCT01267747|Atrial Flutter
356652|NCT01267747|Primary Aldosteronism
356653|NCT01267747|Aldosterone Producing Adenoma
356654|NCT01267734|Everolimus
356655|NCT01267734|Zotarolimus
356656|NCT01267734|Cilostazol
356657|NCT01267734|Clopidogrel
356658|NCT01267721|heart surgery
356659|NCT01267695|Gastrointestinal Stromal Tumor
356660|NCT01267695|Imatinib mesylate
356661|NCT01267695|Perioperative therapy
356662|NCT01267682|Delirium
356663|NCT01267682|Dementia
356664|NCT01267682|Non-pharmacological Intervention
356665|NCT01267682|Post-acute care
356666|NCT01267669|Variceal bleeding
356667|NCT01267669|Endoscopic therapy
356668|NCT01267669|Band ligation
356669|NCT01267669|Somatostatin
356670|NCT01267669|Vasoactive drugs
356671|NCT01267669|Octreotide
356672|NCT01267643|Alefacept
356673|NCT01267643|Amevive
356674|NCT01267643|Aplastic Anemia
356675|NCT01267643|Moderate to Severe Aplastic Anemia
356676|NCT01267630|Delirium of Mixed Origin
356677|NCT01267630|Subacute Delirium
356678|NCT01267630|Mental Disorders, Organic
356679|NCT01267630|Organic Brain Syndrome, Nonpsychotic
356680|NCT01267630|Organic Mental Disorders
356681|NCT01267630|Organic Mental Disorders, Psychotic
356682|NCT01267630|Psychoses, Traumatic
356683|NCT01267630|Cognition Disorder
356684|NCT01267630|Confusion state
356685|NCT01267630|Disorientation
356686|NCT01267617|hemodialysis
356687|NCT01267617|hypotension
356688|NCT01267617|circulatory stress
356689|NCT01267617|photo-plethysmography
356690|NCT01267578|Epitope peptide, CTL, Esophageal cancer, Vaccination
356691|NCT01267565|ventilator-acquired pneumonia
356692|NCT01267565|prevention
356693|NCT01267565|amylase
356694|NCT01267565|tracheal aspiration
356695|NCT01267565|microaspiration
356696|NCT01267552|Breast cancer
356697|NCT01267552|Surgery
356698|NCT01267552|Complications
356699|NCT01267552|Drainage
356700|NCT01267552|Seroma
356701|NCT01267539|Suan Zao Ren Tang, climacteric, PSQI, WHOQOL-BREF
356702|NCT01267526|Growth disorders
356703|NCT01267526|Saizen
356704|NCT01267526|Easypod
356705|NCT01267526|Growth hormone
356706|NCT01267526|Pediatric subject
356707|NCT01267513|oxygen saturation
356708|NCT01267513|pulse rate
356709|NCT01267513|tachycardia
356710|NCT01267513|bradycardia
356711|NCT01267513|hypoxia
356712|NCT01267487|Heparin
356713|NCT01267487|Protamine
356714|NCT01267487|Cardiopulmonary Bypass
356715|NCT01267487|Titration
356716|NCT01267474|School children
356717|NCT01267474|Sugar intake
356718|NCT01267474|Nutritional education program
356719|NCT01267461|To asses the biological actions of insulin analogs in primary tumor cells
356720|NCT01267448|Diabetes Mellitus Type2.
356721|NCT01267448|Severe Hyperglycemia - blood glucose levels >300mg/dl.
356722|NCT01267435|Arthroscopy, Anterior Cruciate Ligament, Tibial Tunnel.
356723|NCT01267422|Leber's Hereditary Optic Neuropathy,11778 LHON mutation,
356724|NCT01267422|rAAV2-ND4,triamcinolone acetonide
356725|NCT01267409|Mapping the emotional territories of the STN
356726|NCT01267409|Identifying the emotional spectral signature of the STN single unit activity
356727|NCT01267409|Manipulating emotional processing of PD patients by high and low frequency stimulation
356728|NCT01267409|Affecting long-term emotional states of the PD patients
356729|NCT01267396|Bioequivalence
356730|NCT01267396|Sertraline
356731|NCT01267396|crossover
356732|NCT01267383|Bioequivalence
356733|NCT01267383|Sertraline
356734|NCT01267383|crossover
356735|NCT01267370|clinical trial
356736|NCT01267370|dietary fiber
356737|NCT01267370|constipation
356738|NCT01267370|children
356739|NCT01267357|Serous Papillary Endometrial Cancer
356740|NCT01267357|Endometrioid endometrial cancer
356741|NCT01267357|biomarkers
356742|NCT01267357|P16
356743|NCT01267357|P53
356744|NCT01267357|Prognosis
356745|NCT01267344|biliary tract cancer
356746|NCT01267344|BTC
356747|NCT01267344|cetuximaba
356748|NCT01267331|Old Myocardial Infarction
356749|NCT01267331|Stem Cell Therapy
356750|NCT01267331|Coronary Artery Bypass Grafting
356751|NCT01267331|Coronary Artery Disease
356752|NCT01267318|Gastric juice
356753|NCT01267318|Stomach
356754|NCT01267318|GI
356755|NCT01267318|Gastric juice samples with presence of blood.
356756|NCT01267305|esophagectomy
356757|NCT01267305|lung resection
356758|NCT01267305|venous thromboembolism
356759|NCT01267305|low molecular weight heparin
356760|NCT01267305|chest drainage
356761|NCT01267305|TEG
356762|NCT01267292|cocaine dependence
356763|NCT01267292|psychopharmacology
356764|NCT01267292|attentional bias
356765|NCT01267292|risky decision making
356766|NCT01267292|buspirone
356767|NCT01267292|methylphenidate
356768|NCT01267227|Hyperlipidemia
356769|NCT01267227|Cholesterol
356770|NCT01267227|Blood Pressure
356771|NCT01267227|Oxidative Stress
356772|NCT01267227|Pterostilbene
356773|NCT01267227|Blueberry
356774|NCT01267227|Grape Extract
356775|NCT01267201|Single dose bioavailability study of methylprednisolone powder for oral suspension (4mg/mL) versus methylprednisolone tablet (32 mg)
356776|NCT01267162|CHB
356777|NCT01267149|superficial vertical perioral lines
356778|NCT01267149|superficial horizontal and lateral canthal lines
356779|NCT01267149|correct moderate to severe facial wrinkles and folds
356780|NCT01267136|Tonsillectomy
356781|NCT01267136|Pain
356782|NCT01267136|Pediatric
356783|NCT01267136|Opioids
356784|NCT01267136|Tramadol
356785|NCT01267136|Codeine
356786|NCT01267097|Pediatric Obesity
356787|NCT01267097|Treatment
356788|NCT01267097|Cognitive Behavioural Therapy
356789|NCT01267097|Psychoeducation
356790|NCT01267097|Canada
356791|NCT01267084|Trabectedin (YONDELIS)
356792|NCT01267084|Ketoconazole
356793|NCT01267084|Antineoplastic Agents
356794|NCT01267084|Solid tumors
356795|NCT01267084|Locally advanced or metastatic disease
356796|NCT01267084|Chemotherapy
356797|NCT01267084|Pharmacokinetics
356798|NCT01267071|Entero-test
356799|NCT01267071|Phase I
356800|NCT01267071|GSK962040
356801|NCT01267071|i.v. microtracer
356802|NCT01267071|radioactivity
356803|NCT01267071|pharmacokinetics
356804|NCT01267071|healthy volunteer
356805|NCT01267058|Booster vaccination
356806|NCT01267045|Persian Gulf Syndrome
356807|NCT01267045|Pain
356808|NCT01267045|Fatigue
356809|NCT01267045|Attention
356810|NCT01267045|Meditation
356811|NCT01267019|social cognition
356812|NCT01267019|training intervention
356813|NCT01266993|Persistence
356814|NCT01266993|Conjugate vaccine
356815|NCT01266993|Safety
356816|NCT01266993|Immunogenicity
356817|NCT01266993|Meningococcal vaccine
356818|NCT01266980|cortisol
356819|NCT01266980|renal impairment
356820|NCT01266980|serum potassium
356821|NCT01266980|pharmacokinetics
356822|NCT01266980|Fluticasone furoate
356823|NCT01266980|heart rate
356824|NCT01266967|GSK2118436
356825|NCT01266967|Metastatic melanoma to the brain
356826|NCT01266967|Brain metastases
356827|NCT01266967|Braf mutation
356828|NCT01266967|Brain neoplasm
356829|NCT01266967|BRAF inhibitor
356830|NCT01266954|Cancer
356831|NCT01266954|18F FDG
356832|NCT01266954|PK
356833|NCT01266954|PET
356834|NCT01266954|Positron Emission Tomography
356835|NCT01266954|PD
356836|NCT01266954|AKT Inhibitor
356837|NCT01266954|GSK2141795
356838|NCT01266941|pharmacokinetics
356839|NCT01266941|hepatic impairment
356840|NCT01266941|heart rate
356841|NCT01266941|serum potassium
356842|NCT01266941|serum cortisol
356843|NCT01266941|GW642444M
356844|NCT01266941|Fluticasone furoate (GW685698)
356845|NCT01266915|SCLE
356846|NCT01266915|CLE
356847|NCT01266915|DLE
356848|NCT01266902|HIV-1 Infection
356849|NCT01266902|HIV-1
356850|NCT01266902|HIV
356851|NCT01266902|TMC278-TiDP6-C222
356852|NCT01266902|TMC278-C222
356853|NCT01266902|TMC278
356854|NCT01266902|Rilpivirine
356855|NCT01266889|preterm infant,cerebral oxygenation, intracranial haemorrhagia
356856|NCT01266863|Hospital-acquired pneumonia
356857|NCT01266863|E test
356858|NCT01266863|Antibiogram
356859|NCT01266863|Bronchoalveolar lavage
356860|NCT01266850|vaccine, rotavirus, gastroenteritis, infants
356861|NCT01266837|metastatic renal cell carcinoma
356862|NCT01266837|biomarker
356863|NCT01266837|Everolimus
356864|NCT01266824|Pain
356865|NCT01266824|Retinopathy of Prematurity
356866|NCT01266824|Neonates
356867|NCT01266811|dexamethasone
356868|NCT01266811|Siltuximab
356869|NCT01266811|CNTO 328
356870|NCT01266811|IL-6
356871|NCT01266811|Monoclonal Antibody
356872|NCT01266811|Multiple Myeloma
356873|NCT01266811|Relapsed or Refractory
356874|NCT01266811|Velcade
356875|NCT01266811|bortezomib
356876|NCT01266798|Health literacy, participation
356877|NCT01266785|crohn's
356878|NCT01266785|Infliximab
356879|NCT01266785|Inflammatory bowel disease
356880|NCT01266785|digestive tract
356881|NCT01266785|Interleukin
356882|NCT01266772|asthma; children; montelukast; treatment; exacerbation
356883|NCT01266759|Menorrhagia
356884|NCT01266759|Vaginal ring
356885|NCT01266759|Norethisterone Acetate
356886|NCT01266746|gas tamponade,
356887|NCT01266746|macular hole,
356888|NCT01266746|macular hole retinal detachment,
356889|NCT01266746|optical coherence tomography
356890|NCT01266733|fibromyalgia, non pharmacological intervention
356891|NCT01266720|pancreatic cancer
356892|NCT01266720|peptide vaccine
356893|NCT01266720|VEGFR
356894|NCT01266720|gemcitabine
356895|NCT01266707|Hepatocellular carcinoma
356896|NCT01266707|peptide vaccine
356897|NCT01266707|VEGFR
356898|NCT01266694|Pericardial effusion
356899|NCT01266694|Cardiac surgery
356900|NCT01266694|Tamponade
356901|NCT01266694|colchicine
356902|NCT01266668|Diffuse large B cell lymphoma
356903|NCT01266668|Breast
356904|NCT01266668|Rituximab
356905|NCT01266642|Breast cancer
356906|NCT01266642|Early invasive breast cancer
356907|NCT01266642|Ductal carcinoma in situ of the breast
356908|NCT01266642|Tis
356909|NCT01266642|T1
356910|NCT01266642|T2
356911|NCT01266642|N0
356912|NCT01266642|N1mic
356913|NCT01266642|N1a
356914|NCT01266642|Lumpectomy
356915|NCT01266642|Hypofractionated whole breast irradiation
356916|NCT01266642|HF-WBI
356917|NCT01266642|Conventionally fractionated whole breast irradiation
356918|NCT01266642|CF-WBI
356919|NCT01266642|Radiation therapy
356920|NCT01266642|Radiotherapy
356921|NCT01266629|small bowel
356922|NCT01266616|Interleukin-12
356923|NCT01266616|Electroporation
356924|NCT01266616|HIV Therapeutic Vaccine
356925|NCT01266603|Metastatic Melanoma
356926|NCT01266603|Unresectable Melanoma
356927|NCT01266603|HDIL-2
356928|NCT01266603|Interleukin-2
356929|NCT01266603|IL-2
356930|NCT01266603|Aldesleukin
356931|NCT01266603|Proleukin
356932|NCT01266603|recMAGE-A3 + AS15
356933|NCT01266603|ASCI
356934|NCT01266603|recMAGE-A3
356935|NCT01266603|Recombinant MAGE-A3 protein
356936|NCT01266603|recMAGE-A3 + AS15 ASCI
356937|NCT01266603|MAGE-A3
356938|NCT01266603|MAGE-A3 ASCI
356939|NCT01266577|Brain Metabolism
356940|NCT01266577|Neurochemistry
356941|NCT01266577|Magnetic Resonance Imaging
356942|NCT01266577|Mental Illness
356943|NCT01266577|Magnetic Resonance Spectroscopy
356944|NCT01266577|Healthy Volunteer
356945|NCT01266577|HV
356946|NCT01266551|Antireflux procedure
356947|NCT01266551|Gastroesophageal reflux
356948|NCT01266551|Infant sleep position
356949|NCT01266551|pH monitoring
356950|NCT01266499|Klebsiella , pneumonia, carbapenem-hydrolyzing lactamase, carbapenem-resistant Klebsiella (KPC), eradication,
356951|NCT01266486|Breast cancer
356952|NCT01266486|Pharmacodynamics
356953|NCT01266486|AMPK
356954|NCT01266486|PET Scan
356955|NCT01266473|Adults
356956|NCT01266434|moderate persistent asthma
356957|NCT01266434|Inhaled corticosteroids
356958|NCT01266421|DNG
356959|NCT01266421|Anemia
356960|NCT01266421|Depression
356961|NCT01266408|Drospirenone
356962|NCT01266408|Dienogest
356963|NCT01266408|Metafolin
356964|NCT01266408|Folic acid
356965|NCT01266408|Safety
356966|NCT01266395|morning symptoms COPD
356967|NCT01266369|mastocytosis
356968|NCT01266369|D816V
356969|NCT01266369|handicaps
356970|NCT01266356|Minor Traumatic Brain Injury
356971|NCT01266356|Translation
356972|NCT01266343|Glaucoma
356973|NCT01266343|anterior chamber paracentesis
356974|NCT01266343|conventional Mannitol infusion
356975|NCT01266330|dairy
356976|NCT01266330|inflammation
356977|NCT01266330|reactive oxygen species
356978|NCT01266330|oxidative stress
356979|NCT01266330|body composition
356980|NCT01266291|Tuberous sclerosis
356981|NCT01266291|TS
356982|NCT01266291|Seizures
356983|NCT01266278|shoulder injuries
356984|NCT01266265|pulmonary arterial hypertension
356985|NCT01266265|PAH
356986|NCT01266265|treprostinil sodium
356987|NCT01266265|Tyvaso
356988|NCT01266265|inhalation
356989|NCT01266265|Ventavis
356990|NCT01266265|iloprost
356991|NCT01266265|prostacyclin
356992|NCT01266265|epoprostenol sodium
356993|NCT01266265|Flolan
356994|NCT01266265|Veletri
356995|NCT01266265|subcutaneous and intravenous prostacyclin analogue
356996|NCT01266265|Remodulin
356997|NCT01266265|oral ERA
356998|NCT01266265|bosentan
356999|NCT01266265|Tracleer
357000|NCT01266265|ambrisentan
357001|NCT01266265|Letairis
357002|NCT01266265|oral PDE5 inhibitors
357003|NCT01266265|sildenafil
357004|NCT01266265|Revatio
357005|NCT01266265|tadalafil
357006|NCT01266265|Adcirca
357007|NCT01266265|Opsumit
357008|NCT01266265|macitentan
357009|NCT01266265|Adempas
357010|NCT01266265|riociguat
357011|NCT01266265|Orenitram
357012|NCT01266265|oral treprostinil
357013|NCT01266252|neonates
357014|NCT01266252|single organ respiratory failure
357015|NCT01266239|Bifurcation lesion, drug-eluting stent, symmetric expansion
357016|NCT01266226|Rotator cuff tears
357017|NCT01266226|ACP
357018|NCT01266213|fulvestrant
357019|NCT01266213|anastrozole
357020|NCT01266213|goserelin
357021|NCT01266213|tamoxifen
357022|NCT01266213|premenopausal
357023|NCT01266213|hormone receptor positive
357024|NCT01266200|microcirculation
357025|NCT01266200|vertebral fracture
357026|NCT01266200|inflammation
357027|NCT01266200|minimal-invasive surgery
357028|NCT01266187|FOLFOX
357029|NCT01266187|liver metastasis
357030|NCT01266187|cetuximab
357031|NCT01266174|CIAS
357032|NCT01266174|Cognition
357033|NCT01266174|Schizophrenia
357034|NCT01266174|Eltoprazine
357035|NCT01266161|dental pain
357036|NCT01266161|multiple dose
357037|NCT01266161|ibuprofen
357038|NCT01266161|third molar extraction
357039|NCT01266135|Interstitial Lung Disease
357040|NCT01266135|Usual Interstitial Pneumonia
357041|NCT01266135|Fibrosis,
357042|NCT01266135|Pulmonary Fibrosis,
357043|NCT01266135|Respiratory Disease,
357044|NCT01266135|Interstitial Lung Disease,
357045|NCT01266135|Biological Therapy,
357046|NCT01266135|Therapeutic Uses,
357047|NCT01266122|HIV
357048|NCT01266122|Psychosocial problems
357049|NCT01266122|MSM
357050|NCT01266122|India
357051|NCT01266109|Substance Use
357052|NCT01266109|Delinquency
357053|NCT01266109|Juvenile Drug Court
357054|NCT01266109|Contingency Management
357055|NCT01266109|Family Engagement
357056|NCT01266096|124I-cRGDY-PEG-dots
357057|NCT01266096|Pet scan
357058|NCT01266096|10-155
357059|NCT01266096|melanoma
357060|NCT01266096|brain
357061|NCT01266083|MONTANIDE ISA 51
357062|NCT01266083|WT1 PEPTIDE SPECIFIC T CELLS
357063|NCT01266083|vaccine
357064|NCT01266083|10-143
357065|NCT01266070|VHL
357066|NCT01266070|Hemangioblastoma
357067|NCT01266070|Tumor of the central nervous system
357068|NCT01266070|TKI258
357069|NCT01266057|Advanced Malignancies
357070|NCT01266057|Metastatic cancers
357071|NCT01266057|Sirolimus
357072|NCT01266057|Hydroxychloroquine
357073|NCT01266057|Vorinostat
357074|NCT01266057|Plaquenil
357075|NCT01266057|Rapamune
357076|NCT01266057|Saha
357077|NCT01266057|Suberoylanilide Hydroxamic Acid
357078|NCT01266057|MSK-390
357079|NCT01266057|Zolinza
357080|NCT01266044|Radiation-induced xerostomia
357081|NCT01266044|Acupuncture
357082|NCT01266044|Oropharyngeal cancer
357083|NCT01266044|Radiation Therapy
357084|NCT01266044|IMRT
357085|NCT01266044|Dry mouth
357086|NCT01266031|Glioblastoma Multiforme
357087|NCT01266018|small cell lung cancer
357088|NCT01266018|SCLC
357089|NCT01266018|ADI-PEG 20
357090|NCT01266018|arginine deiminase pegylated
357091|NCT01266005|HBe Ag(-) Chronic Hepatitis B
357092|NCT01265992|Secondary hyperparathyroidism
357093|NCT01265992|Mineral and Bone Disorder (CKD-MBD)
357094|NCT01265992|Chronic Kidney Disease
357095|NCT01265979|advanced
357096|NCT01265979|metastatic
357097|NCT01265979|gastro-intestinal
357098|NCT01265979|stromal
357099|NCT01265979|GIST
357100|NCT01265979|regorafenib
357101|NCT01265966|Moderate Sedation
357102|NCT01265966|Sedation, Deep
357103|NCT01265953|cancer prevention
357104|NCT01265953|isothiocyanate
357105|NCT01265953|sulforaphane
357106|NCT01265940|bladder cancer
357107|NCT01265940|urothelial cancer
357108|NCT01265940|metastatic urothelial cancer
357109|NCT01265940|advanced urothelial cancer
357110|NCT01265927|Breast Cancer
357111|NCT01265927|Breast Tumors
357112|NCT01265927|Cancer of Breast
357113|NCT01265927|Cancer of the Breast
357114|NCT01265927|Genes, HER-2
357115|NCT01265927|Genes, HER2
357116|NCT01265901|Metastatic Renal Cell Carcinoma
357117|NCT01265901|First line
357118|NCT01265901|Eligible for sunitinib
357119|NCT01265888|PAH
357120|NCT01265888|PH IPF
357121|NCT01265875|Chronic Pancreatitis
357122|NCT01265862|Tracheal intubation
357123|NCT01265862|Supraglottic airway devices
357124|NCT01265862|Patients undergoing general anesthesia
357125|NCT01265836|Dyslipidemia Treatment and Cardiovascular Outcomes
357126|NCT01265823|Humira
357127|NCT01265823|Adalimumab
357128|NCT01265823|Plaque Psoriasis
357129|NCT01265810|oral mucositis
357130|NCT01265810|targeted therapy
357131|NCT01265810|Caphosol
357132|NCT01265810|management
357133|NCT01265771|Arrhythmia
357134|NCT01265771|Children
357135|NCT01265758|Atrial fibrillation
357136|NCT01265758|Cardiac arrhythmia
357137|NCT01265758|ECG
357138|NCT01265758|Telemonitoring
357139|NCT01265758|Telemetry
357140|NCT01265758|Holter
357141|NCT01265745|Phase I
357142|NCT01265732|Phase 1
357143|NCT01265732|relative bioavailability
357144|NCT01265732|healthy volunteers
357145|NCT01265732|pharmacokinetics
357146|NCT01265732|suspension
357147|NCT01265732|dispersion
357148|NCT01265719|Prospective
357149|NCT01265719|non-interventional
357150|NCT01265719|longitudinal
357151|NCT01265719|cohort study
357152|NCT01265706|Hydroxymethylglutaryl-CoA Reductase Inhibitors
357153|NCT01265680|Blood Transfusion
357154|NCT01265680|Heart surgery
357155|NCT01265680|Erythropoietin
357156|NCT01265680|HRE
357157|NCT01265667|Psoriasis
357158|NCT01265667|Plaque psoriasis
357159|NCT01265654|Advanced Breast Cancer
357160|NCT01265654|Hormonal Treatment
357161|NCT01265615|chronic allograft nephropathy
357162|NCT01265615|stem-progenitor cells
357163|NCT01265615|cardiorenal syndrome
357164|NCT01265615|calcitriol
357165|NCT01265615|paricalcitol
357166|NCT01265615|cholecalciferol
357167|NCT01265615|cardiac repair
357168|NCT01265615|renal repair
357169|NCT01265602|Actinic Keratosis
357170|NCT01265602|AK
357171|NCT01265602|NMSC
357172|NCT01265589|RDS
357173|NCT01265589|Infant, newborn
357174|NCT01265589|Vitamin A
357175|NCT01265589|Surfactant
357176|NCT01265563|silymarin
357177|NCT01265563|glutathione
357178|NCT01265563|diabetic nephropathies
357179|NCT01265563|oxidative stress
357180|NCT01265563|N-acetylcysteine
357181|NCT01265563|protein tholation
357182|NCT01265537|Transplant
357183|NCT01265537|Tacrolimus
357184|NCT01265537|Diabetes after transplant
357185|NCT01265537|Acute rejection prevention
357186|NCT01265537|New onset diabetes after transplant
357187|NCT01265511|Hepatitis C
357188|NCT01265511|SCY-635
357189|NCT01265511|Ribavirin
357190|NCT01265511|Interferon
357191|NCT01265498|Farnesoid X Receptor
357192|NCT01265498|FXR
357193|NCT01265498|Nonalcoholic fatty liver disease
357194|NCT01265498|Nonalcoholic steatohepatitis
357195|NCT01265498|NAFLD
357196|NCT01265498|NASH
357197|NCT01265498|obeticholic acid
357198|NCT01265472|Translocator Protein
357199|NCT01265472|Basal Cell Carcinoma
357200|NCT01265472|Squamous Cell Carcinoma
357201|NCT01265472|Malignancy
357202|NCT01265446|Sore throat, upper respiratory tract infection, lozenge with lidocaine and cetylpyridinium chloride.
357203|NCT01265433|GM-CSF
357204|NCT01265433|MONTANIDE ISA 51
357205|NCT01265433|WT1 PEPTIDE SPECIFIC T CELLS
357206|NCT01265433|Vaccine
357207|NCT01265433|10-134
357208|NCT01265420|Dupuytren
357209|NCT01265420|Dupuytren's Disease
357210|NCT01265407|Children
357211|NCT01265407|Hemoglobinopathies
357212|NCT01265407|Epidemiology
357213|NCT01265407|Malaria
357214|NCT01265394|Amyloid
357215|NCT01265394|Magnetic resonance imaging
357216|NCT01265394|Positron Emission Tomography
357217|NCT01265394|Standard uptake value ratios
357218|NCT01265394|Healthy Subjects
357219|NCT01265381|Cohort
357220|NCT01265381|Radiation
357221|NCT01265381|Thyroid Cancer
357222|NCT01265368|Advanced Renal Cell Carcinoma
357223|NCT01265368|Tumor Vaccine
357224|NCT01265368|Cell-based Therapy
357225|NCT01265342|Bronchial Spasm
357226|NCT01265342|Respiratory Tract Infections
357227|NCT01265342|Viral wheezing
357228|NCT01265342|Child, Preschool
357229|NCT01265342|Beclomethasone
357230|NCT01265342|Italy
357231|NCT01265342|Physicians, Primary Care
357232|NCT01265342|Pediatrics
357233|NCT01265316|Cardiac arrest, CPR, pediatric
357234|NCT01265303|ablation, cardiac arrhythmia, atrial fibrillation, telemonitoring, telemetry
357235|NCT01265290|Cardiac arrhythmia
357236|NCT01265290|Cardiogenic syncope
357237|NCT01265290|Pediatrics
357238|NCT01265290|Children
357239|NCT01265277|sudden infant death syndrome
357240|NCT01265277|SIDS
357241|NCT01265277|infant
357242|NCT01265277|licensed day care
357243|NCT01265277|sleep patterns
357244|NCT01265277|stress levels
357245|NCT01265264|Gout
357246|NCT01265264|hyperuricemia
357247|NCT01265264|arthritis
357248|NCT01265264|joint diseases
357249|NCT01265264|allopurinol
357250|NCT01265251|Normal Pressure Hydrocephalus
357251|NCT01265251|Neuropsychological Test
357252|NCT01265251|Assessment of cognitive disorders/dementia
357253|NCT01265251|Neuropsychological assessment
357254|NCT01265238|Spastic equinovarus foot
357255|NCT01265238|Stroke
357256|NCT01265238|Neurotomy
357257|NCT01265238|Tendon surgery
357258|NCT01265225|breast cancer stages 0-II
357259|NCT01265199|AML
357260|NCT01265186|Sedation
357261|NCT01265186|BIS
357262|NCT01265186|aEEG
357263|NCT01265186|Neonatal Pain and Sedation Scale
357264|NCT01265186|neonate
357265|NCT01265186|newborn
357266|NCT01265173|SBP
357267|NCT01265173|liver cirrhosis
357268|NCT01265173|antibiotics
357269|NCT01265134|the elders
357270|NCT01265134|falling
357271|NCT01265134|loss balance
357272|NCT01265121|Acromegaly
357273|NCT01265121|Insulin resistance
357274|NCT01265121|Euglycemic Clamp
357275|NCT01265121|Somatostatin analogues
357276|NCT01265095|VRE
357277|NCT01265069|Helicobacter pylori
357278|NCT01265069|concomitant therapy
357279|NCT01265069|high dose dual therapy
357280|NCT01265069|antibiotic resistance
357281|NCT01265043|oral health
357282|NCT01265043|oral hygiene
357283|NCT01265043|bacteria
357284|NCT01265043|quality of life
357285|NCT01265043|Clinical oral health in patients following acute stroke
357286|NCT01265043|Oral opportunistic pathogens in patients following acute stroke
357287|NCT01265043|Oral health-related quality of life in patients following acute stroke
357288|NCT01265030|Desmoid Tumor
357289|NCT01265030|Sirolimus
357290|NCT01265030|Surgically-Resectable Desmoid Tumor
357291|NCT01265017|type 1 diabetes
357292|NCT01265017|pregnancy
357293|NCT01265017|insulin requirement
357294|NCT01265004|Functional outcome
357295|NCT01264991|Sham
357296|NCT01264991|Meniscus tear
357297|NCT01264991|Meniscectomy
357298|NCT01264978|COPD
357299|NCT01264978|Rehabilitation
357300|NCT01264978|Neuromuscular stimulation
357301|NCT01264978|Quadriceps muscle
357302|NCT01264978|Magnetic stimulation
357303|NCT01264965|Pain
357304|NCT01264965|Analgesia
357305|NCT01264965|Cognitive impairment
357306|NCT01264965|Randomized controlled trial
357307|NCT01264965|Physical function
357308|NCT01264952|Liver metastases of colorectal cancer
357309|NCT01264952|Bleomycin
357310|NCT01264952|Electrochemotherapy
357311|NCT01264900|Psychotherapy
357312|NCT01264900|Cognitive Behavioral Therapy
357313|NCT01264900|Aggression
357314|NCT01264900|fMRI
357315|NCT01264900|Behavioral Intervention
357316|NCT01264887|analgesia
357317|NCT01264887|analgesics
357318|NCT01264887|chronic pain
357319|NCT01264887|tumour related pain
357320|NCT01264887|chronic malignant tumor-related pain
357321|NCT01264861|Evaluate dopamine and serotonin activity in the brain at 3 doses of Safinamide
357322|NCT01264848|multiple sclerosis
357323|NCT01264848|venous insufficiency
357324|NCT01264822|Rabeprazole Sodium
357325|NCT01264822|Helicobacter pylori
357326|NCT01264822|stomach neoplasms
357327|NCT01264809|diabetes
357328|NCT01264796|Korean American, type 2 diabetes, cuturally tailored
357329|NCT01264770|Rheumatoid Arthritis
357330|NCT01264770|OSKIRA
357331|NCT01264770|fostamatinib
357332|NCT01264757|pedometer
357333|NCT01264757|accelerometer
357334|NCT01264757|moderate-to-vigorous physical activity
357335|NCT01264757|adult
357336|NCT01264757|randomized trial
357337|NCT01264744|Bladder cancer
357338|NCT01264744|Chromosomal aberrations
357339|NCT01264744|FISH
357340|NCT01264744|Urine sample
357341|NCT01264731|melanoma
357342|NCT01264731|peptide vaccine
357343|NCT01264731|aldara
357344|NCT01264731|imiquimod
357345|NCT01264731|immunotherapy
357346|NCT01264718|minority health
357347|NCT01264718|child
357348|NCT01264718|Medicaid
357349|NCT01264705|Cirrhosis
357350|NCT01264705|GI Cancer
357351|NCT01264705|Hepatitis
357352|NCT01264705|Oncology
357353|NCT01264679|Iron deficiency anemia, Feraheme, ferumoxytol, CKD, pediatric, dialysis-dependent, pediatric nondialysis-dependent
357354|NCT01264666|Chinese tea flavor liquor
357355|NCT01264666|postprandial
357356|NCT01264666|uric acid
357357|NCT01264666|high-sensitive C-reactive protein
357358|NCT01264653|cataract
357359|NCT01264640|Brain-derived neurotrophic factor (BDNF)
357360|NCT01264640|Platelets
357361|NCT01264640|Aspirin
357362|NCT01264640|Clopidogrel
357363|NCT01264627|Hypertension
357364|NCT01264627|Blood pressure
357365|NCT01264627|Breathing
357366|NCT01264627|PetCO2
357367|NCT01264627|Stress
357368|NCT01264614|exercise
357369|NCT01264614|neuropsychological
357370|NCT01264614|dementia
357371|NCT01264614|Alzheimer's Disease
357372|NCT01264614|mild cognitive impairment
357373|NCT01264614|strength
357374|NCT01264614|MCI
357375|NCT01264614|AD
357376|NCT01264614|EEG
357377|NCT01264614|neurophysiological
357378|NCT01264614|growth factor
357379|NCT01264614|cognitive decline
357380|NCT01264614|executive function
357381|NCT01264601|Anaphylaxis to Egg
357382|NCT01264601|Severe Egg Allergy
357383|NCT01264575|spinal anesthesia
357384|NCT01264575|intrathecal bupivacaine
357385|NCT01264575|epinephrine
357386|NCT01264575|ED50
357387|NCT01264575|ED95
357388|NCT01264562|chemotherapy, adjuvant
357389|NCT01264562|adverse effects
357390|NCT01264562|breast neoplasms
357391|NCT01264562|cognition disorders
357392|NCT01264562|Stress Disorders, post-traumatic
357393|NCT01264562|cortisol
357394|NCT01264549|ischemic stroke
357395|NCT01264549|stroke-associated infections
357396|NCT01264549|biomarkers
357397|NCT01264549|PCT
357398|NCT01264549|immune and infection parameters
357399|NCT01264536|lactoferrin
357400|NCT01264536|sepsis
357401|NCT01264536|neonates
357402|NCT01264536|prevention
357403|NCT01264536|infections
357404|NCT01264523|chrononutrition
357405|NCT01264523|moderately high protein
357406|NCT01264523|glycemic index
357407|NCT01264523|type-2 diabetes
357408|NCT01264523|overweight
357409|NCT01264523|obesity
357410|NCT01264523|weight management
357411|NCT01264510|conductive hearing loss
357412|NCT01264510|mixed hearing loss
357413|NCT01264510|unilateral deafness
357414|NCT01264510|implanted with Baha
357415|NCT01264510|conductive or mixed hearing loss implanted with a Baha or
357416|NCT01264510|unilateral deafness implanted with a Baha
357417|NCT01264484|Advantage
357418|NCT01264484|Non-interventional
357419|NCT01264484|Post market release study
357420|NCT01264484|Germany
357421|NCT01264484|Treated with Advantage prosthetic heart valve
357422|NCT01264471|Gulf War Syndrome
357423|NCT01264471|Gulf War Illness
357424|NCT01264471|Mitochondrial defects
357425|NCT01264471|Mitochondrial disorders
357426|NCT01264471|Persian Gulf Syndrome
357427|NCT01264445|HIV
357428|NCT01264328|Head and neck cancer, panitumumab, TTCC-2009-03
357429|NCT01264315|Lenalidomide
357430|NCT01264315|Tandem Autologous-Allogeneic Transplant
357431|NCT01264302|Bioequivalence
357432|NCT01264302|Finasteride
357433|NCT01264302|crossover
357434|NCT01264289|Bioequivalence
357435|NCT01264289|Finasteride
357436|NCT01264289|crossover
357437|NCT01264276|ROP
357438|NCT01264276|Retinopathy of Prematurity
357439|NCT01264276|Telemedicine
357440|NCT01264263|cIMT
357441|NCT01264263|hs CRP (C-reactive protein)
357442|NCT01264263|DM (Diabetic Mellitus)
357443|NCT01264263|Korea
357444|NCT01264263|Corelation between cIMT (carotid intima media thickness)
357445|NCT01264263|Cardio Vascular risk in Diabetic Mellitus
357446|NCT01264250|Safety
357447|NCT01264250|Tolerability
357448|NCT01264250|pharmacokinetics
357449|NCT01264250|drug metabolism
357450|NCT01264237|Postherpetic neuralgia
357451|NCT01264237|Neuropathic pain
357452|NCT01264237|Etoricoxib
357453|NCT01264211|Efficacy of Diacerein
357454|NCT01264211|Safety of Diacerein
357455|NCT01264211|Carry-over effect of Diacerein
357456|NCT01264172|Functional outcome
357457|NCT01264172|Microcirculation
357458|NCT01264172|Inflammatory response
357459|NCT01264159|Developing acute heart failure
357460|NCT01264146|hyperbaric oxygen therapy
357461|NCT01264146|calcaneal fracture
357462|NCT01264146|calcaneal plating
357463|NCT01264146|wound infection
357464|NCT01264146|microcirculation
357465|NCT01264120|Obesity
357466|NCT01264120|Bariatric surgery
357467|NCT01264120|Health Psychology
357468|NCT01264081|Lapatinib
357469|NCT01264081|Melanoma
357470|NCT01264081|ERBB4 Mutation
357471|NCT01264081|Malignant Melanoma
357472|NCT01264081|Skin Cancer
357473|NCT01264068|Suan-Tsao-Jen-Tang ,Jia-Wey-Shiau-Yau-San,metabolomics,menopause
357474|NCT01264055|Rare Diseases of Airways
357475|NCT01264055|Bronchiectasis
357476|NCT01264055|Idiopathic Bronchiectasis
357477|NCT01264055|Chronic Cough
357478|NCT01264055|Nontuberculous Mycobacteriam Infection
357479|NCT01264042|Iron Supplementation,
357480|NCT01264042|week 24 to 28 at study day
357481|NCT01264029|Well-Being
357482|NCT01264029|Tai Chi
357483|NCT01264029|Obesity
357484|NCT01264029|Mindfulness
357485|NCT01264029|Meditation
357486|NCT01264029|Overweight
357487|NCT01264003|inguinal hernia, antibiotic, prophylaxis
357488|NCT01263990|hemodynamic monitoring systems
357489|NCT01263990|stroke volume
357490|NCT01263977|septic shock
357491|NCT01263977|goal directed volume therapy
357492|NCT01263977|outcome
357493|NCT01263964|ischemic stroke
357494|NCT01263964|troponin elevation
357495|NCT01263964|transient apical ballooning
357496|NCT01263964|acute coronary syndrome
357497|NCT01263964|troponin elevation,
357498|NCT01263964|culprit lesion on coronary angiogram,
357499|NCT01263964|troponin elevation and stroke localisation (temporal lobe?)
357500|NCT01263951|Differentiated metastatic thyroid cancer
357501|NCT01263938|HIV
357502|NCT01263938|monocytes
357503|NCT01263938|CD16+
357504|NCT01263938|statins
357505|NCT01263938|mcp1
357506|NCT01263938|inflammation
357507|NCT01263925|Alprostadil
357508|NCT01263925|Prostaglandin E1
357509|NCT01263925|Prostavasin®
357510|NCT01263925|PAOD
357511|NCT01263912|Polyunsaturated fatty acids
357512|NCT01263912|Cognitive development
357513|NCT01263912|Growth
357514|NCT01263912|Infection
357515|NCT01263899|Lymphoid malignancies
357516|NCT01263899|Hodgkin lymphoma
357517|NCT01263899|Mantle Cell Lymphoma
357518|NCT01263899|Indolent Lymphoma
357519|NCT01263899|SB1518
357520|NCT01263847|Dietary Supplement: Galactooligosaccharide
357521|NCT01263834|Trabeculectomy
357522|NCT01263834|bevacizumab
357523|NCT01263834|intraocular pressure
357524|NCT01263821|glioma
357525|NCT01263821|biologic imaging
357526|NCT01263821|magnetic resonance spectroscopy
357527|NCT01263821|magnetic resonance imaging
357528|NCT01263821|perfusion imaging
357529|NCT01263821|diffusion imaging
357530|NCT01263821|functional magnetic resonance imaging
357531|NCT01263821|radiation therapy
357532|NCT01263821|intensity modulated radiation therapy
357533|NCT01263808|Indacaterol
357534|NCT01263808|Moxifloxacin
357535|NCT01263782|Non-Small Cell Lung Cancer
357536|NCT01263782|NSCLL
357537|NCT01263782|Nonsquamous cell
357538|NCT01263782|Metastatic disease
357539|NCT01263782|Cixutumumab
357540|NCT01263782|IMC-A12
357541|NCT01263782|Carboplatin
357542|NCT01263782|Paraplatin
357543|NCT01263782|Pemetrexed
357544|NCT01263782|LY231514
357545|NCT01263782|Alimta
357546|NCT01263782|MTA
357547|NCT01263782|Multitargeted Antifolate
357548|NCT01263782|NSC-698037
357549|NCT01263782|Bevacizumab
357550|NCT01263782|Avastin
357551|NCT01263782|Anti-VEGF monoclonal antibody
357552|NCT01263782|rhuMAb-VEGF
357553|NCT01263769|Locally advanced clear cell renal cell carcinoma
357554|NCT01263769|AG-013736
357555|NCT01263769|Axitinib
357556|NCT01263769|Radical nephrectomy
357557|NCT01263756|Driving
357558|NCT01263756|Autism Spectrum Disorders
357559|NCT01263756|ASD
357560|NCT01263756|Attention Deficits
357561|NCT01263756|Adults
357562|NCT01263756|Adolescents
357563|NCT01263756|Pervasive Developmental Disorders
357564|NCT01263743|Stage 1 hypertension
357565|NCT01263717|HIV
357566|NCT01263717|lipodystrophy
357567|NCT01263717|tesamorelin
357568|NCT01263717|Egrifta
357569|NCT01263717|growth hormone releasing hormone
357570|NCT01263691|AVA
357571|NCT01263691|AV7909
357572|NCT01263691|Anthrax vaccine
357573|NCT01263678|Decisional Conflict
357574|NCT01263678|Coaching
357575|NCT01263678|Decisional Regret
357576|NCT01263665|stent-graft
357577|NCT01263665|superficial femoral artery
357578|NCT01263665|SFA
357579|NCT01263665|peripheral artery disease
357580|NCT01263665|PAD
357581|NCT01263652|Pain
357582|NCT01263652|intramuscular
357583|NCT01263652|oral
357584|NCT01263652|spine
357585|NCT01263652|preference
357586|NCT01263639|patient satisfaction
357587|NCT01263639|patient-physician relationship
357588|NCT01263639|orthopaedic trauma
357589|NCT01263626|Cough
357590|NCT01263626|Chronic Cough
357591|NCT01263626|Reflux
357592|NCT01263600|Hepatitis B
357593|NCT01263600|HBV
357594|NCT01263600|Pediatric
357595|NCT01263587|Hepatitis B
357596|NCT01263587|HBV
357597|NCT01263587|Cohort Study
357598|NCT01263574|Catheter related infections prevention/control
357599|NCT01263574|Anti infective agents
357600|NCT01263574|Catheter related infections prevention
357601|NCT01263561|glaucoma
357602|NCT01263561|filtration surgery
357603|NCT01263561|trabeculectomy
357604|NCT01263561|ExPRESS shunt
357605|NCT01263522|primary prevention
357606|NCT01263522|endurance
357607|NCT01263522|cardiovascular risk factors
357608|NCT01263522|training
357609|NCT01263522|exercise
357610|NCT01263522|non-responder
357611|NCT01263509|Diabetes Mellitus - Type 2
357612|NCT01263509|Diabetes Mellitus
357613|NCT01263509|Drug Therapy
357614|NCT01263496|Diabetes Mellitus - Type 2
357615|NCT01263496|Diabetes Mellitus
357616|NCT01263496|Drug Therapy
357617|NCT01263483|Diabetes Mellitus - Type 2
357618|NCT01263483|Diabetes Mellitus
357619|NCT01263483|Drug Therapy
357620|NCT01263470|Diabetes Mellitus - Type 2
357621|NCT01263470|Diabetes Mellitus
357622|NCT01263470|Drug Therapy
357623|NCT01263457|Growth disorders
357624|NCT01263457|Saizen
357625|NCT01263457|EasypodTM
357626|NCT01263457|Growth hormone
357627|NCT01263457|Pediatric subject
357628|NCT01263444|AZARGA®
357629|NCT01263444|Open angle glaucoma
357630|NCT01263444|Prostaglandin Therapy
357631|NCT01263431|Hemorrhoidectomy, haemorrhoidal dearterialisation, anopexy
357632|NCT01263418|Follicular Lymphoma
357633|NCT01263418|Marginal Zone Lymphoma
357634|NCT01263418|Non-Hodgkins Lymphoma
357635|NCT01263418|Elderly
357636|NCT01263418|Newly Diagnosed
357637|NCT01263418|Lineberger Comprehensive Cancer Center
357638|NCT01263418|University of North Carolina
357639|NCT01263418|Ofatumumab
357640|NCT01263418|Arzerra
357641|NCT01263418|Phase 2
357642|NCT01263418|Geriatric
357643|NCT01263418|Lymphoma
357644|NCT01263405|Sarcoma
357645|NCT01263392|Neurogenic bladder
357646|NCT01263392|Spina bifida
357647|NCT01263392|Intermittent catheterization
357648|NCT01263392|Urinary tract infections
357649|NCT01263379|gene transfer
357650|NCT01263366|Radiodermatitis
357651|NCT01263366|Prevention
357652|NCT01263366|Radiotherapy
357653|NCT01263366|Breast
357654|NCT01263366|Radiation Dermatitis
357655|NCT01263353|Carcinoid tumor,
357656|NCT01263353|Gastroenteropancreatic Neuroendocrine Tumors,
357657|NCT01263353|Pulmonary Neuroendocrine Tumors,
357658|NCT01263353|pasireotide LAR,
357659|NCT01263353|SOM230 LAR,
357660|NCT01263353|everolimus,
357661|NCT01263353|RAD001,
357662|NCT01263353|Advanced Neuroendocrine Tumor,
357663|NCT01263353|Gastroenteropancreatic System
357664|NCT01263340|COPD
357665|NCT01263340|observational study
357666|NCT01263340|prevalence
357667|NCT01263340|characterisation
357668|NCT01263327|human papillomavirus vaccine
357669|NCT01263314|Hypertension
357670|NCT01263301|subclavian steal
357671|NCT01263301|carotid duplex
357672|NCT01263301|subclavian stenosis
357673|NCT01263301|hemodialysis with vascular access in the upper limbs
357674|NCT01263301|the focus of this study is to see if duplex can be used as an tool to differentiate the different causes of subclavian steal syndromes
357675|NCT01263275|depression
357676|NCT01263275|direct current stimulation
357677|NCT01263275|alternative electrode montage
357678|NCT01263262|Surgical site infection
357679|NCT01263262|Corneal toxicity
357680|NCT01263262|Ototoxicity
357681|NCT01263262|Povidone-iodine
357682|NCT01263262|Chlorhexidine-alcohol
357683|NCT01263249|Femoral
357684|NCT01263249|Nerve Block
357685|NCT01263249|Anterior
357686|NCT01263249|Posterior
357687|NCT01263249|Continuous Infusion
357688|NCT01263249|Perineural Catheter
357689|NCT01263249|Volunteer
357690|NCT01263249|Lower Extremity Nerve Blocks
357691|NCT01263236|Depression
357692|NCT01263210|Recurrent acute otitis media
357693|NCT01263210|Conjugate pneumococcal vaccine
357694|NCT01263210|Ventilation tube treatment
357695|NCT01263210|Nasopharyngeal flora
357696|NCT01263184|shoulder
357697|NCT01263184|strength
357698|NCT01263184|quality of life
357699|NCT01263171|adenocarcinoma of the rectum
357700|NCT01263171|stage IIIB rectal cancer
357701|NCT01263171|stage IIIC rectal cancer
357702|NCT01263158|randomised controlled trial
357703|NCT01263158|nulliparous women
357704|NCT01263158|slow labour progress
357705|NCT01263158|prolonged labour
357706|NCT01263158|oxytocin augmentation
357707|NCT01263158|operative delivery
357708|NCT01263158|childbirth experience
357709|NCT01263132|Polyneuropathy
357710|NCT01263132|Diabetes Mellitus
357711|NCT01263132|Diabetic peripheral neuropathy
357712|NCT01263080|mirtazapine
357713|NCT01263080|folic acid
357714|NCT01263080|schizophrenia
357715|NCT01263067|Posttraumatic Stress Disorder
357716|NCT01263067|PTSD
357717|NCT01263067|Car Accident
357718|NCT01263067|Auto Accident
357719|NCT01263067|Lifespan Integration
357720|NCT01263054|Back Pain
357721|NCT01263054|Low Back Pain
357722|NCT01263054|Discogenic Back Pain
357723|NCT01263041|Glutamine, NEC, L-arginine,Preterm,Sepsis
357724|NCT01263015|GSK1349572
357725|NCT01263015|Abacavir/Lamivudine
357726|NCT01263015|Treatment-naive
357727|NCT01263015|HIV Infection
357728|NCT01263015|Dolutegravir
357729|NCT01263015|integrase inhibitor
357730|NCT01263015|Atripla
357731|NCT01262989|Bioequivalence
357732|NCT01262989|Tamsulosin
357733|NCT01262989|Healthy volunteers
357734|NCT01262989|Fast conditions
357735|NCT01262976|Tuberculosis vaccine
357736|NCT01262963|GSK2118436
357737|NCT01262963|BRAF inhibitor
357738|NCT01262963|BRAF positive tumor
357739|NCT01262963|ADME
357740|NCT01262963|Oncology
357741|NCT01262937|confocal, biliary, esophagus
357742|NCT01262924|Booster vaccination
357743|NCT01262898|13 C oral breath test
357744|NCT01262898|pharmacokinetics
357745|NCT01262898|symptoms
357746|NCT01262898|tolerability
357747|NCT01262898|gut motility
357748|NCT01262898|repeat dose
357749|NCT01262898|pharmacodynamics
357750|NCT01262898|GSK962040
357751|NCT01262898|phase II
357752|NCT01262898|Type I and II Diabetes mellitus
357753|NCT01262898|gastric emptying
357754|NCT01262898|gastroparesis
357755|NCT01262885|pharmacokinetics
357756|NCT01262885|tolerability
357757|NCT01262885|single dose
357758|NCT01262885|antibiotics
357759|NCT01262885|repeat dose
357760|NCT01262885|GSK2251052
357761|NCT01262885|safety
357762|NCT01262872|Haemophilus influenzae
357763|NCT01262872|Streptococcus pneumoniae
357764|NCT01262872|The Gambia
357765|NCT01262872|immunogenicity
357766|NCT01262872|nasopharyngeal carriage
357767|NCT01262872|infants
357768|NCT01262872|safety
357769|NCT01262872|Pneumococcal vaccine
357770|NCT01262872|children
357771|NCT01262846|HIV
357772|NCT01262846|Flu vaccination
357773|NCT01262846|HIV infected individuals
357774|NCT01262846|Fluzone SD
357775|NCT01262846|Fluzone HD
357776|NCT01262820|Pazopanib
357777|NCT01262820|Non Squamous Non Small Cell Lung Cancer
357778|NCT01262820|After Progress on first line therapy
357779|NCT01262820|Using Bevacizumab
357780|NCT01262807|fracture
357781|NCT01262807|radius
357782|NCT01262807|adult
357783|NCT01262807|range of motion
357784|NCT01262794|Healthy volunteers
357785|NCT01262794|Japanese
357786|NCT01262781|neonatal adiposity
357787|NCT01262781|metabolic syndrome
357788|NCT01262781|fructose
357789|NCT01262781|maternal diet
357790|NCT01262768|Nutrition
357791|NCT01262768|Obesity
357792|NCT01262768|Parent
357793|NCT01262768|Portion Size Estimation
357794|NCT01262768|Accuracy
357795|NCT01262755|GERD
357796|NCT01262755|IBS
357797|NCT01262755|Minority
357798|NCT01262742|pregnancy
357799|NCT01262742|postpartum hemorrhage
357800|NCT01262742|Cesarean delivery
357801|NCT01262742|carbetocin
357802|NCT01262729|xenon inhalation
357803|NCT01262729|therapeutical hypothermia
357804|NCT01262729|patients after cardiopulmonary resuscitation
357805|NCT01262729|efficacy
357806|NCT01262729|safety
357807|NCT01262716|Chest wall progression breast cancer
357808|NCT01262716|PDT
357809|NCT01262716|Photofrin
357810|NCT01262716|Photosensitizer
357811|NCT01262690|First-in-human (FIH)
357812|NCT01262690|Single Ascending Dose (SAD) Study
357813|NCT01262690|TAM-163
357814|NCT01262690|PF-05230901
357815|NCT01262690|Cachexia
357816|NCT01262677|Partial epilepsy
357817|NCT01262677|partial seizures
357818|NCT01262677|epilepsy
357819|NCT01262677|seizures
357820|NCT01262677|adjunctive therapy
357821|NCT01262677|intervention
357822|NCT01262677|controlled-release
357823|NCT01262677|placebo-controlled
357824|NCT01262677|seizure
357825|NCT01262664|Advanced prostate cancer
357826|NCT01262664|Castrate-Resistant Prostate Cancer
357827|NCT01262664|Prohibitin-TP01
357828|NCT01262651|Cancer pain
357829|NCT01262651|Opioid therapy
357830|NCT01262651|Inadequate analgesia
357831|NCT01262651|Optimized chronic opioid therapy
357832|NCT01262625|stable angina
357833|NCT01262625|recurrent chest pain
357834|NCT01262625|chest pain
357835|NCT01262625|angina equivalent
357836|NCT01262625|diagnosis
357837|NCT01262625|coronary artery disease
357838|NCT01262612|cediranib
357839|NCT01262612|malignant ascites
357840|NCT01262612|malignant pleural effusion
357841|NCT01262599|Breast and abdomen morbidities after TRAM flap surgery
357842|NCT01262599|TRAM flap surgery
357843|NCT01262599|Post-mastectomy breast reconstructive surgery
357844|NCT01262586|Type II Diabetes Mellitus
357845|NCT01262586|Vildagliptin
357846|NCT01262586|Glimepiride
357847|NCT01262586|Continuous glucose monitoring
357848|NCT01262560|pain
357849|NCT01262560|dysphagia
357850|NCT01262560|recurrent non-small cell lung cancer
357851|NCT01262560|stage IA non-small cell lung cancer
357852|NCT01262560|stage IB non-small cell lung cancer
357853|NCT01262560|stage IIA non-small cell lung cancer
357854|NCT01262560|stage IIB non-small cell lung cancer
357855|NCT01262560|stage IIIA non-small cell lung cancer
357856|NCT01262560|stage IIIB non-small cell lung cancer
357857|NCT01262560|extensive stage small cell lung cancer
357858|NCT01262560|limited stage small cell lung cancer
357859|NCT01262560|recurrent small cell lung cancer
357860|NCT01262560|esophagitis
357861|NCT01262534|Psoriasis
357862|NCT01262534|comorbidities, associated treatment, quality of life
357863|NCT01262521|Dietary nitrate
357864|NCT01262508|autonomic nervous system
357865|NCT01261507|lung neoplasm nodule image processing computer-assisted
357866|NCT01261494|Diabetes Mellitus, Type 2
357867|NCT01261494|Glucose Metabolism Disorders
357868|NCT01261494|Metabolic Diseases
357869|NCT01261494|Cardiovascular Diseases
357870|NCT01261494|PPARs
357871|NCT01261494|OGTT
357872|NCT01262482|adenocarcinoma
357873|NCT01262482|gastric
357874|NCT01262482|gastroesophageal junction
357875|NCT01262482|Relapsed
357876|NCT01262482|sorafenib
357877|NCT01262482|oxaliplatin
357878|NCT01262443|Atrial flutter
357879|NCT01262430|Osteoarthritis
357880|NCT01262417|colorectal cancer
357881|NCT01262417|two stage surgery for the resection of hepatic metastases
357882|NCT01262417|resorbable barrier membrane
357883|NCT01262417|abdominal and peri-hepatic adhesion
357884|NCT01262391|Overactive bladder
357885|NCT01262391|Pediatric
357886|NCT01262391|Pharmacokinetics
357887|NCT01262391|Single-dose
357888|NCT01262391|Solifenacin suspension
357889|NCT01262365|Lupus
357890|NCT01262365|Monoclonal antibody
357891|NCT01262365|B-Cell immunotherapy
357892|NCT01262365|Epratuzumab
357893|NCT01262339|Primary focal hyperhidrosis
357894|NCT01262339|interdermal injections
357895|NCT01262339|iontophoresis
357896|NCT01262339|BTX-A
357897|NCT01262300|Immunosenescence
357898|NCT01262300|Shingles
357899|NCT01262300|Vitamin D
357900|NCT01262300|Varicella Zoster Virus
357901|NCT01262300|Vaccine
357902|NCT01262300|Immune Response
357903|NCT01262300|Geriatrics
357904|NCT01262287|Randomized Trial
357905|NCT01262287|Medication for Heavy Drinking
357906|NCT01262287|Dutasteride Treatment
357907|NCT01262261|opioid dependence
357908|NCT01262261|opioid addiction
357909|NCT01262261|buprenorphine
357910|NCT01262261|implant
357911|NCT01262261|methadone
357912|NCT01262261|heroin
357913|NCT01262261|suboxone
357914|NCT01262261|opioid pain medication
357915|NCT01262261|opioid withdrawal
357916|NCT01262248|small colorectal polyps
357917|NCT01262248|narrow band imaging
357918|NCT01262248|vascularization
357919|NCT01262248|computer-based classification
357920|NCT01262235|Solid tumor
357921|NCT01262235|Non-Hodgkin's Lymphoma
357922|NCT01262235|Hodgkin's Disease
357923|NCT01262235|Neuroendocrine tumors (NET)
357924|NCT01262235|Adrenocortical carcinoma (ACC)
357925|NCT01262235|Carcinoid
357926|NCT01262222|Predictive Value For Postoperative Cardiac Events
357927|NCT01262222|Endothelial Dysfunction
357928|NCT01262222|10-206
357929|NCT01262209|Vision loss
357930|NCT01262209|Chronic glaucoma
357931|NCT01262209|Low vision rehabilitation
357932|NCT01262196|Trauma
357933|NCT01262196|Hemorrhage
357934|NCT01262196|Hemorrhagic shock
357935|NCT01262196|Lactic acidosis
357936|NCT01262196|Oxygen carriers
357937|NCT01262196|Oxygen therapeutics
357938|NCT01262196|Hemoglobin solutions
357939|NCT01262196|Red cell substitutes
357940|NCT01262196|PEG-hemoglobin
357941|NCT01262183|oesophagus cancer
357942|NCT01262183|chemoradiotherapy
357943|NCT01262183|panitumumab
357944|NCT01262183|irresectable
357945|NCT01262170|dietary supplement
357946|NCT01262170|nutraceutical
357947|NCT01262157|Erectile dysfunction
357948|NCT01262157|PDE5 Inhibitor
357949|NCT01262157|Low intensity shock wave therapy.
357950|NCT01262144|Cervical Cancer
357951|NCT01262144|PET CT
357952|NCT01262144|SUV Max
357953|NCT01262131|Fibromyalgia
357954|NCT01262131|Pain associated with Fibromyalgia
357955|NCT01262118|Cholesterol metabolism
357956|NCT01262118|Cholesterol flux
357957|NCT01262118|Rheumatoid Arthritis
357958|NCT01262118|Tasocitinib
357959|NCT01262118|CP-690
357960|NCT01262118|550
357961|NCT01262105|CFU
357962|NCT01262105|surgery site
357963|NCT01262092|opioid dependent
357964|NCT01262092|detoxification
357965|NCT01262092|buprenorphine
357966|NCT01262092|suboxone
357967|NCT01262092|opiate
357968|NCT01262079|influenza
357969|NCT01262079|healthy volunteer
357970|NCT01262079|immunity
357971|NCT01262079|antibody
357972|NCT01262079|blood sample
357973|NCT01262066|hypertension
357974|NCT01262066|stress reduction
357975|NCT01262053|Computerized Physician Order Entry
357976|NCT01262053|CPOE
357977|NCT01262053|Wrong Patient
357978|NCT01262053|Juxtaposition
357979|NCT01262053|Patient Safety
357980|NCT01262053|Medical Errors
357981|NCT01262040|NBI
357982|NCT01262040|ENDOMETRIUM
357983|NCT01262040|FALLOPIAN TUBE
357984|NCT01262040|OVARY
357985|NCT01262040|PERITONEUM
357986|NCT01262040|Surgery
357987|NCT01262040|Lung
357988|NCT01262040|Pancreatic
357989|NCT01262040|Esophageal
357990|NCT01262040|thorascopic
357991|NCT01262040|laparoscopic
357992|NCT01262040|robotic
357993|NCT01262040|10-180
357994|NCT01262027|Metastatic inflammatory breast cancer
357995|NCT01262027|Stage IV disease
357996|NCT01262027|HER2-negative
357997|NCT01262027|Dovitinib
357998|NCT01262027|TKI258
357999|NCT01262014|platinum
358000|NCT01262014|resistant
358001|NCT01262014|advanced
358002|NCT01262014|ovarian
358003|NCT01262014|cancer
358004|NCT01261975|Ocular Surgery
358005|NCT01261975|Intraocular Lens
358006|NCT01261962|Humoral immunity
358007|NCT01261962|Neutrophil function
358008|NCT01261962|Gene expression
358009|NCT01261949|Tinnitus
358010|NCT01261949|chronic subjective tinnitus
358011|NCT01261949|transcranial magnetic stimulation
358012|NCT01261949|sensation disorders
358013|NCT01261949|hearing disorders
358014|NCT01261936|Menorrhagia
358015|NCT01261936|Congenital Bleeding Disorders(CBDs)
358016|NCT01261936|Diagnosis and treatment of menorrhagia in CBDs
358017|NCT01261897|Adductor-Canal-Blockade
358018|NCT01261897|postoperative pain
358019|NCT01261897|US-guided nerve block
358020|NCT01261897|total knee arthroplasty
358021|NCT01261884|Pregnancy
358022|NCT01261884|Exercise
358023|NCT01261884|Hypertension
358024|NCT01261884|Preeclampsia
358025|NCT01261884|Resistance exercise
358026|NCT01261858|Sternal closure
358027|NCT01261858|Coronary artery bypass grafting
358028|NCT01261858|Biologic bone cement
358029|NCT01261845|Delivery of Health Care
358030|NCT01261845|Equity in Health Services
358031|NCT01261845|Ethnic Groups
358032|NCT01261845|Health Services Research
358033|NCT01261845|Health Surveys
358034|NCT01261845|Immigration
358035|NCT01261845|Referral and Consultation
358036|NCT01261845|Resource Allocation
358037|NCT01261845|Social Justice
358038|NCT01261845|Vulnerable Populations
358039|NCT01261832|Acute Myocardial Infarction
358040|NCT01261832|Percutaneous coronary intervention
358041|NCT01261819|cystoscopy, minimally invasive hysterectomy
358042|NCT01261793|Lupus
358043|NCT01261793|Monoclonal antibody
358044|NCT01261793|B-Cell immunotherapy
358045|NCT01261793|Epratuzumab
358046|NCT01261780|neuropathy,paraneoplastic
358047|NCT01261780|paraneoplastic peripheral neuropathy
358048|NCT01261780|pain
358049|NCT01261780|hyperalgesia
358050|NCT01261754|Metastatic Prostate Adenocarcinoma
358051|NCT01261728|Gemcitabine
358052|NCT01261728|Cisplatin
358053|NCT01261728|Bladder
358054|NCT01261728|radical nephroureterectomy
358055|NCT01261728|ureterectomy
358056|NCT01261728|10-208
358057|NCT01261702|Magnesium sulphate
358058|NCT01261702|Post Pulmonary Resection
358059|NCT01261702|Pain
358060|NCT01261689|Epidural analgesia
358061|NCT01261689|Instrumental delivery
358062|NCT01261689|Maternal outcome
358063|NCT01261689|Neonatal outcome
358064|NCT01261676|caesarean section
358065|NCT01261676|labour, obstetric
358066|NCT01261676|implementation guidelines
358067|NCT01261676|quality indicators
358068|NCT01261650|widespread chronic pain, transcranial direct current stimulation, fibromyalgia
358069|NCT01261637|cesarean, pain, transversus abdominus plane block
358070|NCT01261624|poly JIA
358071|NCT01261598|Positron-Emission Tomography
358072|NCT01261598|PET Scan
358073|NCT01261598|Non-Small-Cell Lung Carcinoma
358074|NCT01261598|Radiation Oncology
358075|NCT01261598|SUV
358076|NCT01261585|Positron-Emission Tomography
358077|NCT01261585|PET Scan
358078|NCT01261585|FDG
358079|NCT01261585|FLT
358080|NCT01261585|FMISO
358081|NCT01261585|Non-Small-Cell Lung Carcinoma
358082|NCT01261585|chemo-Radiation Oncology
358083|NCT01261585|SUV
358084|NCT01261572|ASP3550
358085|NCT01261572|Degarelix
358086|NCT01261572|Prostate cancer
358087|NCT01261572|Prostatic neoplasms
358088|NCT01261559|Computed tomography
358089|NCT01261559|Radiation dose
358090|NCT01261559|Dose reduction
358091|NCT01261559|Breast displacement
358092|NCT01261559|Chrysalis device
358093|NCT01261559|Image quality
358094|NCT01261546|pleural effusion, empyema, corticoids, dexamethasone
358095|NCT01261533|vitreous body substitute
358096|NCT01261533|foldable capsular vitreous body
358097|NCT01261481|Bioavailability
358098|NCT01261468|Chronic pain
358099|NCT01261468|Electric Stimulation Therapy
358100|NCT01261468|Neurologic Examination
358101|NCT01261442|distal symmetric polyneuropathy
358102|NCT01261442|diabetic peripheral neuropathy
358103|NCT01261442|posterior tibial nerve
358104|NCT01261442|regional anesthesia
358105|NCT01261442|nerve conduction study
358106|NCT01261429|Pigmented villonodular synovitis
358107|NCT01261429|tenosynovial giant cell tumour
358108|NCT01261429|nilotinib
358109|NCT01261416|seizures
358110|NCT01261416|epilepsy
358111|NCT01261416|neonatal
358112|NCT01261416|levetiracetam
358113|NCT01261403|Human Placenta-Derived Cells
358114|NCT01261390|Sleep Apnea
358115|NCT01261390|Heart Disease
358116|NCT01261390|Risk factors for heart disease
358117|NCT01261377|COPD, obstructive sleep apnea, OSA, BPAP, CPAP
358118|NCT01261364|GeneSight
358119|NCT01261364|Assurex
358120|NCT01261364|AssureRx
358121|NCT01261351|Pre eclampsia
358122|NCT01261351|Endogenous thrombin potential
358123|NCT01261338|PCBs
358124|NCT01261338|Olestra
358125|NCT01261325|Epilepsy
358126|NCT01261325|Brivaracetam
358127|NCT01261325|Partial Onset Seizures
358128|NCT01261325|Adjunctive treatment
358129|NCT01261312|SGI-110
358130|NCT01261312|DNA Hypomethylating Agent
358131|NCT01261312|Intermediate 1, Intermediate 2, CMML or High Risk MDS
358132|NCT01261312|AML
358133|NCT01261299|Phase 0 Clinical trial
358134|NCT01261299|Human microdosing trial
358135|NCT01261299|Drug resistance, neoplasm
358136|NCT01261299|Carcinoma, Non-small cell lung
358137|NCT01261299|Urinary Bladder Neoplasm
358138|NCT01261299|Individualized Medicine
358139|NCT01261299|Carboplatin
358140|NCT01261299|Carboplatin-DNA adducts
358141|NCT01261286|inflammation
358142|NCT01261286|receptor downregulation
358143|NCT01261286|reduced response
358144|NCT01261286|calcium channels
358145|NCT01261286|PK-PD relationship
358146|NCT01261273|PCI
358147|NCT01261273|observational registry
358148|NCT01261260|uridine
358149|NCT01261260|gamma-amino butyric acid
358150|NCT01261260|Magnetic Resonance Imaging
358151|NCT01261260|Magnetic Resonance Spectroscopy
358152|NCT01261260|Proton Echo-Planar Spectroscopic Imaging
358153|NCT01261234|Carotid Artery Disease
358154|NCT01261234|Carotid Artery Stenting
358155|NCT01261234|In stent restenosis
358156|NCT01261234|Cardiovascular event
358157|NCT01261234|Intima Media Thickness
358158|NCT01261208|HIV, AIDS, Helicobacter pylori
358159|NCT01261182|Malnutrition
358160|NCT01261182|School feeding
358161|NCT01261182|Infant nutrition
358162|NCT01261182|Mother's nutrition
358163|NCT01261182|Fortified food
358164|NCT01261182|Anemia
358165|NCT01261182|Cluster randomized controlled trials
358166|NCT01261182|Effectiveness
358167|NCT01261182|Impact evaluation studies
358168|NCT01261182|Uganda
358169|NCT01261169|Mycophenolate sodium (Myfortic®)
358170|NCT01261169|Corticosteroid-refractory autoimmune Uveitis
358171|NCT01261130|Human Hookworm Vaccine Initiative
358172|NCT01261130|HHVI
358173|NCT01261130|Human Hookworm
358174|NCT01261130|Hookworm
358175|NCT01261130|Hookworm Disease
358176|NCT01261130|N. americanus
358177|NCT01261130|Soil-transmitted helminth infection
358178|NCT01261130|Intestinal blood loss
358179|NCT01261130|Iron deficiency anemia
358180|NCT01261117|Patent ductus arteriosis
358181|NCT01261117|İbuprofen
358182|NCT01261117|Extremely Low Birth Weigh infant
358183|NCT01261104|hearing loss
358184|NCT01261104|handicap
358185|NCT01261104|counseling
358186|NCT01261091|Neurocritical Care
358187|NCT01261091|Ischemic Stroke
358188|NCT01261091|Intracerebral Hemorrhage
358189|NCT01261091|Subarachnoid Hemorrhage
358190|NCT01261091|Tracheostomy
358191|NCT01261091|Tracheotomy
358192|NCT01261091|Percutaneous Dilatative Tracheostomy
358193|NCT01261091|Weaning
358194|NCT01261091|Ventilation
358195|NCT01261078|intrathecal epinephrine
358196|NCT01261078|duration of anesthesia
358197|NCT01261078|quality of anesthesia
358198|NCT01261078|intrathecal fentanyl
358199|NCT01261065|beta blockers
358200|NCT01261065|heart failure
358201|NCT01261065|contractility
358202|NCT01261065|remodeling
358203|NCT01261052|glucose sensors
358204|NCT01261052|artificial pancreas
358205|NCT01261052|Diabetes Mellitus
358206|NCT01261013|Keratoconus
358207|NCT01261013|intrastromal corneal ring segment
358208|NCT01261013|To evaluate the visual and refractive outcomes of intrastromal corneal ring segment in keratoconic eyes at different stages
358209|NCT01261000|Acromegaly
358210|NCT01260987|Moderate to severe actinic keratoses
358211|NCT01260987|Difficult to treat nodular basal cell carcinomas
358212|NCT01260974|Invasive fungal infections
358213|NCT01260974|Liver Transplantation
358214|NCT01260974|Organ Transplantation
358215|NCT01260974|Mycoses
358216|NCT01260974|Fungus Diseases
358217|NCT01260974|Antifungal Agents
358218|NCT01260974|Invasive Mycosis
358219|NCT01260948|Bioequivalence
358220|NCT01260948|Healthy Subjects
358221|NCT01260935|GERD
358222|NCT01260935|laparoscopic surgery
358223|NCT01260935|gastroesophageal
358224|NCT01260935|reflux
358225|NCT01260922|Bioequivalence
358226|NCT01260922|Healthy Subjects
358227|NCT01260896|Bioequivalence
358228|NCT01260896|Healthy Subjects
358229|NCT01260883|ketorolac pharmacokinetics
358230|NCT01260883|ketorolac stereo-isomers
358231|NCT01260883|infants
358232|NCT01260883|postoperative analgesia
358233|NCT01260883|safety
358234|NCT01260857|Spirinolactone
358235|NCT01260857|Hydroflumethiazide
358236|NCT01260857|Hypertension
358237|NCT01260857|Filipinos
358238|NCT01260857|Diabetes mellitus
358239|NCT01260857|Proteinuria
358240|NCT01260831|Bedside PEWS
358241|NCT01260831|Intensive Care
358242|NCT01260818|Tranexamic Acid
358243|NCT01260805|bioequivalence
358244|NCT01260805|study
358245|NCT01260805|ethinylestradiol
358246|NCT01260805|gestodene
358247|NCT01260740|Traumatic Brain Injury
358248|NCT01260740|Explicit Learning
358249|NCT01260740|Primary Motor Cortex
358250|NCT01260740|Dorsolateral Prefrontal Cortex
358251|NCT01260740|Implicit Learning
358252|NCT01260740|Healthy Volunteer
358253|NCT01260740|HV
358254|NCT01260727|HIV Preventive Vaccine
358255|NCT01260675|phase 1 study
358256|NCT01260675|volunteers
358257|NCT01260662|Deep Procedural Sedation
358258|NCT01260662|Propofol
358259|NCT01260662|Ketamine
358260|NCT01260662|Emergency Department
358261|NCT01260662|Monitoring
358262|NCT01260662|Capnography
358263|NCT01260662|Procedural Sedation in the Emergency Department
358264|NCT01260649|Electroconvulsive treatment
358265|NCT01260649|ketamine
358266|NCT01260649|Major Depression
358267|NCT01260649|Treatment-resistant Major Depressive Disorder
358268|NCT01260623|asthma
358269|NCT01260623|pharmacokinetics
358270|NCT01260623|prednisone
358271|NCT01260623|prednisolone
358272|NCT01260623|asthma exacerbation
358273|NCT01260623|pharmacokinetic profile
358274|NCT01260610|Hepatitis B, Tenofovir, Telbivudine
358275|NCT01260597|smoking
358276|NCT01260597|quit line re-enrollment and IVR systems
358277|NCT01260584|thienopyridine
358278|NCT01260584|antiplatelet
358279|NCT01260584|prasugrel
358280|NCT01260584|clopidogrel
358281|NCT01260571|blackheads and pimples
358282|NCT01260571|Acne vulgaris grade II
358283|NCT01260532|Autoimmune thyroid disease
358284|NCT01260506|Relapsed Glioblastoma Multiforme, GBM
358285|NCT01260493|very frail
358286|NCT01260493|case manager
358287|NCT01260493|integrated care
358288|NCT01260493|multiprofessional
358289|NCT01260493|intervention
358290|NCT01260480|Carcinoma, non-small-cell lung
358291|NCT01260480|Head and neck neoplasms
358292|NCT01260480|Diagnostic imaging
358293|NCT01260467|recurrent
358294|NCT01260454|Qutenza
358295|NCT01260454|Capsaicin
358296|NCT01260454|Remodulin
358297|NCT01260454|Treprostinil
358298|NCT01260428|hypoxia
358299|NCT01260428|O2 diffusion and convection
358300|NCT01260428|cardiac output
358301|NCT01260428|PEEP
358302|NCT01260428|Effects of hypoxia
358303|NCT01260415|colorectal cancer
358304|NCT01260415|liver metastases
358305|NCT01260415|panitumumab
358306|NCT01260415|FOLFOX
358307|NCT01260415|Colorectal cancer with liver metastases
358308|NCT01260402|heart failure
358309|NCT01260402|Cardiomyopathy, dilated
358310|NCT01260402|Coronary disease
358311|NCT01260402|Cardiac Pacing, Artificial
358312|NCT01260402|cardiac resynchronization therapy
358313|NCT01260402|Hemodynamics
358314|NCT01260402|Randomized Controlled Trials
358315|NCT01260402|Open Study
358316|NCT01260389|Chronic Obstructive Pulmonary Disease
358317|NCT01260389|COPD
358318|NCT01260376|VLDL-TG
358319|NCT01260376|Metabolism
358320|NCT01260376|Exercise
358321|NCT01260376|Free Fatty Acids
358322|NCT01260350|PSI-7977
358323|NCT01260350|Sofosbuvir
358324|NCT01260350|GS-7977
358325|NCT01260350|GS-5885
358326|NCT01260350|GS-9669
358327|NCT01260350|FDC
358328|NCT01260350|ribavirin
358329|NCT01260350|RBV
358330|NCT01260350|Pegylated Interferon
358331|NCT01260350|PEG-IFN
358332|NCT01260350|Chronic Hepatitis C Infection
358333|NCT01260350|HCV
358334|NCT01260350|Hepatitis
358335|NCT01260350|Genotype 1
358336|NCT01260350|Genotype 2
358337|NCT01260350|Genotype 3
358338|NCT01260350|GT 1
358339|NCT01260350|GT 2
358340|NCT01260350|GT 3
358341|NCT01260350|Hemophilia
358342|NCT01260337|Weight loss
358343|NCT01260337|Type 2 Diabetes
358344|NCT01260337|Behavior Modification
358345|NCT01260337|portion control
358346|NCT01260324|Phosphodiesterase type 5 inhibitors
358347|NCT01260324|non-arteritic anterior ischemic optic neuropathy
358348|NCT01260324|descriptive epidemiology study
358349|NCT01260311|Observational
358350|NCT01260298|MC1 VASER VASERShape
358351|NCT01260272|Cardiovascular
358352|NCT01260272|Risk Factors
358353|NCT01260272|Cardiovascular Disease
358354|NCT01260272|Glucose
358355|NCT01260272|Blood Pressure
358356|NCT01260272|BMI
358357|NCT01260272|Weight
358358|NCT01260272|Waist Circumference
358359|NCT01260259|Pediatric
358360|NCT01260259|Cardiac
358361|NCT01260259|Surgery
358362|NCT01260259|Cardiopulmonary
358363|NCT01260259|Bypass
358364|NCT01260259|Myocardial
358365|NCT01260259|Kidney
358366|NCT01260259|Lung
358367|NCT01260259|Injury
358368|NCT01260233|smoking cessation
358369|NCT01260233|complications
358370|NCT01260233|cigarettes
358371|NCT01260233|preoperative
358372|NCT01260233|perioperative
358373|NCT01260233|surgery
358374|NCT01260233|education
358375|NCT01260233|nicotine replacement therapy
358376|NCT01260207|Acute Coronary Syndrome
358377|NCT01260207|Interactive Voice Response Technology
358378|NCT01260207|Best Practice Guidelines
358379|NCT01260207|Compliance
358380|NCT01260207|Health Care Utilization
358381|NCT01260168|Cancer
358382|NCT01260168|Colorectal Cancer
358383|NCT01260168|Neoplasm
358384|NCT01260168|Colorectal Neoplasm
358385|NCT01260168|Intestinal Neoplasms
358386|NCT01260168|Gastrointestinal Neoplasms
358387|NCT01260168|Digestive System Neoplasms
358388|NCT01260168|Neoplasms by Site
358389|NCT01260168|Neoplasms
358390|NCT01260168|Digestive System Diseases
358391|NCT01260168|Gastrointestinal Diseases
358392|NCT01260168|Colonic Diseases
358393|NCT01260168|Intestinal Diseases
358394|NCT01260168|Rectal Diseases
358395|NCT01260129|BPH
358396|NCT01260129|silodosin
358397|NCT01260116|Efficacy,safety,ziprasidone,depressive symptoms ,schizophrenia
358398|NCT01260103|Optic pathway glioma, recurrent
358399|NCT01260103|Optic pathway glioma, progressive
358400|NCT01260103|Temozolomide
358401|NCT01260103|Temodar
358402|NCT01260103|TMZ
358403|NCT01260103|Antineoplastons
358404|NCT01260103|ANP therapy
358405|NCT01260103|Atengenal (A10)
358406|NCT01260103|Astugenal (AS2-1)
358407|NCT01260090|Minimally conscious states
358408|NCT01260090|Persistently vegetative states
358409|NCT01260090|Traumatic brain injury
358410|NCT01260064|Appendicitis
358411|NCT01260064|Open appendectomy
358412|NCT01260064|Laparoscopic appendectomy
358413|NCT01260064|Endoclip
358414|NCT01260064|Intracorporeal suture
358415|NCT01260064|Quality-of-life
358416|NCT01260038|Non Small Cell Lung Cancer
358417|NCT01260038|observational study
358418|NCT01260038|EGFR mutation analysis
358419|NCT01260038|EGFR mutation status
358420|NCT01260038|testing turn around time
358421|NCT01260025|Tolerability
358422|NCT01260025|Pharmacokinetics
358423|NCT01260025|Endostatin
358424|NCT01260025|antiangiogenesis
358425|NCT01260025|cancer
358426|NCT01260012|Schistosoma mansoni
358427|NCT01260012|Schistosomiasis
358428|NCT01260012|periportal fibrosis
358429|NCT01260012|antioxidant
358430|NCT01260012|fibrosis reversal
358431|NCT01259999|malnutrition
358432|NCT01259999|oleic-acid
358433|NCT01259999|micronutrient supplement
358434|NCT01259999|old peoples home
358435|NCT01259986|Vitiligo
358436|NCT01259986|Laser
358437|NCT01259986|Segmental vitiligo
358438|NCT01259986|Acral vitiligo
358439|NCT01259973|Pharmacogenetics
358440|NCT01259973|Antipsychotics
358441|NCT01259973|Extrapyramidal Symptoms
358442|NCT01259947|headache
358443|NCT01259947|migraine
358444|NCT01259947|medicinal plant
358445|NCT01259947|essential oil
358446|NCT01259947|phytotherapy
358447|NCT01259934|Randomized Phase III trial
358448|NCT01259934|Adjuvant therapy
358449|NCT01259934|Interferon
358450|NCT01259934|Melanoma
358451|NCT01259921|EEG biofeedback
358452|NCT01259921|neurofeedback
358453|NCT01259921|PTSD
358454|NCT01259921|Affect Regulation
358455|NCT01259921|Chronic Trauma
358456|NCT01259908|laparoscopic aortic surgery
358457|NCT01259908|aorto-iliac occlusive disease
358458|NCT01259882|Pharmacokinetics Safety Tolerability Pharmacodynamics
358459|NCT01259856|Polycythemia vera
358460|NCT01259856|Essential thrombocythemia
358461|NCT01259856|Hydroxyurea
358462|NCT01259856|PEGASYS
358463|NCT01259856|Pegylated Interferon Alfa-2a
358464|NCT01259843|Acute aortic syndrome
358465|NCT01259830|fast-track
358466|NCT01259830|colon or rectal surgery
358467|NCT01259830|pain relief
358468|NCT01259817|Polycythemia Vera
358469|NCT01259817|Essential Thrombocythemia
358470|NCT01259817|Hydroxyurea Resistant
358471|NCT01259817|Abdominal Vein Thrombosis
358472|NCT01259817|PEGASYS
358473|NCT01259804|peanut
358474|NCT01259804|food allergy
358475|NCT01259804|anaphylaxis
358476|NCT01259804|immunotherapy
358477|NCT01259778|Growth disorders
358478|NCT01259778|Saizen
358479|NCT01259778|easypod™
358480|NCT01259778|Growth hormone
358481|NCT01259778|Pediatric subject
358482|NCT01259765|llama antibody
358483|NCT01259765|rotavirus diarrhoea
358484|NCT01259765|children
358485|NCT01259752|Trauma
358486|NCT01259752|ankle sprain
358487|NCT01259752|emergency
358488|NCT01259752|compression stocking
358489|NCT01259739|trained cyclists
358490|NCT01259739|no medications
358491|NCT01259739|no diseases
358492|NCT01259739|non-smokers
358493|NCT01259726|Diarrhea
358494|NCT01259726|Clostridium difficile
358495|NCT01259726|Clostridium infections
358496|NCT01259726|Signs and Symptoms Digestive
358497|NCT01259726|Bacterial Infections
358498|NCT01259726|Pharmacologic Actions
358499|NCT01259713|Ambisome
358500|NCT01259713|ALL
358501|NCT01259713|invasive fungal infection
358502|NCT01259713|prophylaxis
358503|NCT01259713|liposomal amphotericin B
358504|NCT01259713|Invasive fungal infection prophylaxis
358505|NCT01259700|High blood pressure
358506|NCT01259700|Primary care
358507|NCT01259700|Cardiovascular disease prevention
358508|NCT01259700|Salt reduction
358509|NCT01259687|Electrocardiogram
358510|NCT01259687|Arterial line waveform
358511|NCT01259687|Cardiac output
358512|NCT01259674|Pediatric
358513|NCT01259674|children
358514|NCT01259674|acute cough
358515|NCT01259674|treatment
358516|NCT01259674|syrup
358517|NCT01259674|protective natural extracts
358518|NCT01259661|physical activity
358519|NCT01259661|metabolic syndrome
358520|NCT01259661|postmenopausal women
358521|NCT01259661|exercise training
358522|NCT01259648|remifentanil
358523|NCT01259648|anesthesia induction
358524|NCT01259648|reactional tachycardia
358525|NCT01259635|Parkinson's disease
358526|NCT01259635|freezing of gait
358527|NCT01259609|Diabetic Macular Edema
358528|NCT01259609|Ciliary Body
358529|NCT01259609|Ultrasound Biomicroscopy
358530|NCT01259609|Vitrectomy
358531|NCT01259596|anxiety
358532|NCT01259596|rural
358533|NCT01259596|elderly
358534|NCT01259544|CP-Chronic Pancreatitis
358535|NCT01259544|DPT-Di peptide breath test
358536|NCT01259544|ePFT- Endoscopic pancreatic function test
358537|NCT01259531|strong
358538|NCT01259531|silodosin
358539|NCT01259531|benign prostatic hyperplasia
358540|NCT01259531|BPH
358541|NCT01259531|lower urinary tract symptoms associated with severe BPH
358542|NCT01259505|no number
358543|NCT01259492|Attention Deficit /Hyperactivity Disorder, hyperactivity
358544|NCT01259479|Solid Tumors
358545|NCT01259479|Maximum Tolerated Dose
358546|NCT01259479|Parmacokinetics
358547|NCT01259479|Pharmacogenomics
358548|NCT01259479|Satraplatin
358549|NCT01259479|Cancer
358550|NCT01259479|Solid Tumor
358551|NCT01259479|Brain Tumor
358552|NCT01259466|Smoking cessation
358553|NCT01259466|Overweight
358554|NCT01259466|Obesity
358555|NCT01259466|Internet treatment
358556|NCT01259453|Hepatitis B vaccination
358557|NCT01259453|Syringe exchange programs
358558|NCT01259453|Injection drug users
358559|NCT01259453|Hepatitis B prevention through vaccination
358560|NCT01259440|Telemedicine
358561|NCT01259440|continuous positive airway pressure
358562|NCT01259440|treatment adherence
358563|NCT01259427|Mental Disorders
358564|NCT01259427|Psychotic Disorders
358565|NCT01259427|Schizophrenia
358566|NCT01259427|Stigmatization
358567|NCT01259427|Mood Disorders
358568|NCT01259427|Schizophrenia and Disorders with Psychotic Feature
358569|NCT01259414|Carcinoma,Hepatocellular
358570|NCT01259414|Liver Neoplasms
358571|NCT01259414|Survival analysis
358572|NCT01259414|treatment outcome
358573|NCT01259414|administration drugs
358574|NCT01259414|Chemoembolization,
358575|NCT01259414|TACE
358576|NCT01259414|polyvinyl alcohol
358577|NCT01259414|water-soluble contrast mesium
358578|NCT01259414|iopamidol
358579|NCT01259414|lipiodol
358580|NCT01259414|distilled water
358581|NCT01259401|Sleep
358582|NCT01259401|Rehabilitation
358583|NCT01259401|Behavior therapy
358584|NCT01259401|Insomnia
358585|NCT01259388|Multiple sclerosis
358586|NCT01259388|Lithium
358587|NCT01259349|cataract,
358588|NCT01259349|phacoemulsification,
358589|NCT01259349|one percent ultrasound
358590|NCT01259349|endothelial cell density
358591|NCT01259336|Itraconazole
358592|NCT01259336|chronic cavitary pulmonary aspergillosis
358593|NCT01259336|Aspergillosis
358594|NCT01259336|fungal ball
358595|NCT01259336|mycetoma
358596|NCT01259336|efficacy
358597|NCT01259336|safety
358598|NCT01259310|fertility
358599|NCT01259310|women
358600|NCT01259310|epilepsy
358601|NCT01259310|pregnancy
358602|NCT01259310|seizures
358603|NCT01259310|seizure frequency
358604|NCT01259310|ovulation
358605|NCT01259310|menstruation
358606|NCT01259310|hormones
358607|NCT01259310|progesterone
358608|NCT01259297|Aliskiren
358609|NCT01259297|Elderly
358610|NCT01259297|Major Cardiovascular Events
358611|NCT01259297|Effect of aliskiren-based regimen on major CV events (composite of CV death, non-fatal MI, non-fatal stroke and significant heart failure) in the elderly
358612|NCT01259284|Breast cancer
358613|NCT01259284|Colorectal cancer
358614|NCT01259284|Genitourinary cancer
358615|NCT01259284|Head and neck cancers
358616|NCT01259284|Lung cancer
358617|NCT01259284|Melanoma
358618|NCT01259284|Sarcoma
358619|NCT01259284|Atorvastatin
358620|NCT01259284|Lipitor
358621|NCT01259284|Fish Oil supplement
358622|NCT01259284|Placebo
358623|NCT01259258|varicocele, methylene blue, varicocelectomy, hydrocele,
358624|NCT01259245|Chronic obstructive pulmonary disease COPD
358625|NCT01259245|pulmonary rehabilitation program PRP
358626|NCT01259245|Tai chi
358627|NCT01259219|HIV
358628|NCT01259219|Completion of TB treamtment
358629|NCT01259206|Calcaneal Spur, Diabetic Obese Patients
358630|NCT01259193|Hepatocellular Carcinoma
358631|NCT01259193|Sorafenib
358632|NCT01259193|Zoledronic Acid
358633|NCT01259193|toxic reaction
358634|NCT01259180|acupuncture
358635|NCT01259167|JOBA, Low Back Pain, Physical Exercise
358636|NCT01259141|macrolide- resistant Mycoplasma pneumoniae,
358637|NCT01259141|Mycoplasm pneumonia antibiotic therapy
358638|NCT01259115|Healthy subjects
358639|NCT01259115|Opioid
358640|NCT01259115|Transdermal
358641|NCT01259102|Healthy subjects
358642|NCT01259102|Opioid
358643|NCT01259102|Transdermal
358644|NCT01259089|Adenocarcinoma of the Lung
358645|NCT01259089|Non-small Cell Lung Cancer
358646|NCT01259063|GEMCITABINE
358647|NCT01259063|RAD001(EVEROLIMUS)
358648|NCT01259063|urinary
358649|NCT01259063|BCG-Refractory
358650|NCT01259063|Intravesical
358651|NCT01259063|10-165
358652|NCT01259050|ALS treatment
358653|NCT01259050|Zinc
358654|NCT01259050|Copper
358655|NCT01259050|BMAA
358656|NCT01259050|ALS
358657|NCT01259037|Elastography
358658|NCT01259037|Cutaneous
358659|NCT01259037|Imaging
358660|NCT01259024|hepatocellular carcinoma
358661|NCT01259024|chemoembolization
358662|NCT01259024|transarterial chemoembolization
358663|NCT01259024|liver cancer
358664|NCT01259024|doxorubicin
358665|NCT01259024|drug-eluting beads
358666|NCT01259024|LC Bead
358667|NCT01259011|end stage renal disease
358668|NCT01259011|dialysis
358669|NCT01259011|end of life decision making
358670|NCT01259011|surrogate psychological morbidities
358671|NCT01258985|Knee
358672|NCT01258985|Knee osteoarthritis
358673|NCT01258985|osteoarthritis
358674|NCT01258985|Knee pain
358675|NCT01258985|Tai Chi
358676|NCT01258985|Physical Therapy
358677|NCT01258985|mind-body exercise
358678|NCT01258972|Bifurcation lesions
358679|NCT01258959|Ultrasound, retrobulbar, parabulbar, ophthalmic surgery.
358680|NCT01258946|epicardial adipose pcos
358681|NCT01258933|Leukemia
358682|NCT01258933|Chronic Lymphocytic Leukemia
358683|NCT01258933|CLL
358684|NCT01258933|Lymphoma
358685|NCT01258933|Small Lymphocytic Lymphoma
358686|NCT01258933|SLL
358687|NCT01258933|Ofatumumab
358688|NCT01258920|Schizophrenia
358689|NCT01258920|Paliperidone palmitate
358690|NCT01258920|Intramascular Injection
358691|NCT01258907|BI-204
358692|NCT01258868|Mesothelioma
358693|NCT01258868|Esophageal Cancer
358694|NCT01258868|Lung Cancer
358695|NCT01258868|Thoracic Malignancies
358696|NCT01258868|Tumor Cell Vaccine
358697|NCT01258842|Influenza
358698|NCT01258842|Prevention
358699|NCT01258842|Probiotic
358700|NCT01258829|Heart Failure Cardiac Resynchronisation Therapy
358701|NCT01258816|Acute Myeloid Leukaemia (AML)
358702|NCT01258816|Pharmacokinetics
358703|NCT01258816|Elacytarabine
358704|NCT01258816|CP-4055
358705|NCT01258803|asthma
358706|NCT01258803|children
358707|NCT01258803|persistent
358708|NCT01258790|TS
358709|NCT01258790|tics
358710|NCT01258790|tourette
358711|NCT01258777|Healthy volunteers
358712|NCT01258777|Japanese male
358713|NCT01258777|Caucasian male
358714|NCT01258777|Simponi
358715|NCT01258764|hypertension
358716|NCT01258764|Blood Pressure control
358717|NCT01258764|hypertension treatment
358718|NCT01258764|antihypertensive
358719|NCT01258764|N of 1 study
358720|NCT01258751|Healthy Volunteers
358721|NCT01258738|Early ankylosing spondylitis (SpA) study; efficacy and safety and health out comes
358722|NCT01258725|amnioinfusion, severe idiopahic oligohydramnios
358723|NCT01258673|Fimasartan
358724|NCT01258673|Fimasartan/Hydrochlorothiazide combination
358725|NCT01258647|infant nutrition
358726|NCT01258647|complementary feeding
358727|NCT01258647|malnutrition
358728|NCT01258647|stunting of growth
358729|NCT01258634|Osteosarcoma
358730|NCT01258634|Surgically Resectable High Grade Osteosarcoma
358731|NCT01258634|Lung Metastases Only
358732|NCT01258621|distal pancreatectomy, laparoscopy, learning curve
358733|NCT01258608|advanced hepatocellular carcinoma
358734|NCT01258608|Mapatumumab
358735|NCT01258608|HGS1012
358736|NCT01258608|sorafenib
358737|NCT01258595|Influenza
358738|NCT01258595|Trivalent Inactivated Influenza Vaccine
358739|NCT01258595|High-Dose Trivalent Inactivated Influenza Vaccine
358740|NCT01258595|Influenza vaccines
358741|NCT01258582|HIV
358742|NCT01258582|Testing
358743|NCT01258582|HIV Seronegativity
358744|NCT01258569|laparoscopic
358745|NCT01258569|colon
358746|NCT01258569|resection
358747|NCT01258569|Entereg
358748|NCT01258543|Global osteopathic evaluation
358749|NCT01258543|Non-specific back pain
358750|NCT01258543|Inter-examiner reliability
358751|NCT01258530|influenza, bioequivalence, oseltamivir, Tamiflu, over-encapsulation
358752|NCT01258517|RDS
358753|NCT01258517|surfactant
358754|NCT01258517|cerebral oxygenation
358755|NCT01258517|near infrared spectroscopy
358756|NCT01258504|Steady-state
358757|NCT01258504|Bosentan
358758|NCT01258504|St. Johns Wort
358759|NCT01258478|NSCLC, rehabilitation, CPET, lung resection
358760|NCT01258465|Communication
358761|NCT01258465|Pivotal Response Training
358762|NCT01258465|Picture Exchange Communication System
358763|NCT01258439|HIV
358764|NCT01258439|cardiovascular disease
358765|NCT01258439|post prandial lipids
358766|NCT01258439|ritonavir
358767|NCT01258439|darunavir
358768|NCT01258439|raltegravir
358769|NCT01258439|arterial stiffness
358770|NCT01258439|tonometry
358771|NCT01257191|Vehicle Emissions
358772|NCT01257191|Diesel Exhaust
358773|NCT01257165|Automobile driving
358774|NCT01257165|Zopiclone
358775|NCT01257165|Drug safety
358776|NCT01257165|Traffic accidents
358777|NCT01257139|To evaluate a geriatric scale designed to help with treatment
358778|NCT01257139|allocation to dual-agent therapy based on platinum or to
358779|NCT01257139|single-agent chemotherapy in elderly subjects with advancedstage
358780|NCT01257139|NSCLC, based on the time to failure in the two arms
358781|NCT01257126|Upper respiratory tract infections
358782|NCT01257126|diclofenac potassium
358783|NCT01257126|nimesulide
358784|NCT01257126|fever
358785|NCT01257126|pain
358786|NCT01257113|shoulder pain
358787|NCT01257113|shoulder impingement
358788|NCT01257113|rotatorcuff pathology
358789|NCT01257113|supervised exercise
358790|NCT01257113|homebased exercise
358791|NCT01257100|Nasopharyngeal Carcinoma
358792|NCT01257100|Epstein-Barr Virus
358793|NCT01257100|NPC
358794|NCT01257087|Type 2 Diabetes Mellitus
358795|NCT01257087|Obesity
358796|NCT01257087|Bariatric Surgery
358797|NCT01257087|Glycaemic control
358798|NCT01257087|Microvascular complications
358799|NCT01257087|Intensive
358800|NCT01257087|Conservative
358801|NCT01257074|Herpes Simplex
358802|NCT01257061|Dermatitis
358803|NCT01257061|Dermatitis, Atopic
358804|NCT01257048|Oxygen enhanced magnetic resonance imaging
358805|NCT01257048|chronic obstructive pulmonary disease
358806|NCT01257048|method evaluation
358807|NCT01257035|Rectum cancer
358808|NCT01257035|FAZA
358809|NCT01257035|18F-FAZA-PET/CT
358810|NCT01257035|Radiotherapy
358811|NCT01257035|Chemoradiotherapy
358812|NCT01257022|Prevention
358813|NCT01257022|HIV
358814|NCT01257022|Substance use
358815|NCT01257022|Hispanic
358816|NCT01257022|Adolescents
358817|NCT01257022|Unsafe sexual behavior
358818|NCT01257022|Behavioral intervention
358819|NCT01257009|sympathetic activity
358820|NCT01257009|chronic kidney disease
358821|NCT01257009|atorvastatin
358822|NCT01257009|lipitor
358823|NCT01258413|Cervical Cancer
358824|NCT01258413|Radical hysterectomy, Laparoscopic
358825|NCT01258413|Overall survival
358826|NCT01258413|Disease-free five-years survival
358827|NCT01258374|Pharmacokinetics, raltegravir, darunavir, NRTI sparing regimen
358828|NCT01258361|preoperative fasting
358829|NCT01258296|Postoperative pain
358830|NCT01258296|Breast reconstruction
358831|NCT01258296|Abdominal flap breast reconstruction
358832|NCT01258257|Aneurysm
358833|NCT01258257|Subarachnoid hemorrhage
358834|NCT01258257|Lumbar drain
358835|NCT01258257|Cerebral vasospasm
358836|NCT01258257|Cerebral Ventricles
358837|NCT01258257|Cerebrospinal Fluid
358838|NCT01258257|Prospective Studies
358839|NCT01258257|Drainage/methods*
358840|NCT01258257|Humans
358841|NCT01258257|Subarachnoid Hemorrhage/cerebrospinal fluid*
358842|NCT01258257|Subarachnoid Hemorrhage/complications*
358843|NCT01258257|Subarachnoid Space/surgery*
358844|NCT01258257|Vasospasm, Intracranial/etiology
358845|NCT01258257|Vasospasm, Intracranial/surgery*
358846|NCT01258244|Out-of-Hospital Cardiac Arrest, OHCA
358847|NCT01258205|Amgen
358848|NCT01258205|AMG 139
358849|NCT01258205|Crohn's Disease
358850|NCT01258192|esophageal squamous cell carcinoma
358851|NCT01258192|neoadjuvant chemotherapy
358852|NCT01258192|albumin-bound paclitaxel
358853|NCT01258192|cisplatin
358854|NCT01258153|Infantile Colic
358855|NCT01258153|tachykinin antagonist
358856|NCT01258153|Nepadutant
358857|NCT01258140|CT angiography
358858|NCT01258140|radiation dose
358859|NCT01258140|contrast medium
358860|NCT01258127|Pemetrexed
358861|NCT01258127|Vinorelbine
358862|NCT01258127|Carboplatin
358863|NCT01258114|Overweight
358864|NCT01258114|Obesity
358865|NCT01258114|Balneotherapy
358866|NCT01258114|Spa Therapy
358867|NCT01258114|balneology
358868|NCT01258114|hydrotherapy
358869|NCT01258114|SF 12
358870|NCT01258114|Nutritional counselling
358871|NCT01258114|Zelen double consent
358872|NCT01258114|Lifestyle modification program
358873|NCT01258114|IMC
358874|NCT01258088|psoriasis
358875|NCT01258075|type 2 diabetes mellitus
358876|NCT01258075|blood glucose
358877|NCT01258075|anti-diabetic
358878|NCT01258075|bile acid sequestrant
358879|NCT01258075|colesevelam HCl
358880|NCT01258075|oral suspension
358881|NCT01258075|pediatric
358882|NCT01258075|add-on therapy
358883|NCT01258075|add-on to metformin
358884|NCT01258075|metformin
358885|NCT01258075|adolescent
358886|NCT01258075|lipid
358887|NCT01258049|Plasmodium infections
358888|NCT01258049|Remittent fever
358889|NCT01258049|Artemether
358890|NCT01258049|Artemesinins
358891|NCT01258049|Quinine
358892|NCT01258049|Malaria
358893|NCT01258049|Protozoan infections
358894|NCT01258049|sublingual drug delivery
358895|NCT01258049|Parasitic disease
358896|NCT01258049|Antiprotozoan agents
358897|NCT01258036|Bone microarchitecture
358898|NCT01258036|Bone mineral density
358899|NCT01258036|Bone markers
358900|NCT01258036|hereditary determinism
358901|NCT01258010|Red blood cell transfusion
358902|NCT01258010|Neurosurgery
358903|NCT01258010|Orthopedic surgery
358904|NCT01258010|Tranexamic acid
358905|NCT01258010|Surgical blood loss
358906|NCT01257997|No specific experimental conditions
358907|NCT01257971|Cholesterol
358908|NCT01257971|HMG-CoA reductase inhibitor
358909|NCT01257971|cardiovascular risk
358910|NCT01257971|LDLl
358911|NCT01256983|Sleep quality
358912|NCT01256983|Daytime Sleepiness
358913|NCT01256944|PCOS
358914|NCT01256944|DM
358915|NCT01256944|Hypertension
358916|NCT01256944|CVD
358917|NCT01256931|2009 H1N1 influenza vaccine, organ transplant patients,
358918|NCT01256931|booster with Fluarix
358919|NCT01256918|cataract
358920|NCT01256918|phacoemulsification
358921|NCT01256918|phacochop
358922|NCT01256918|phacotip
358923|NCT01255228|obesity
358924|NCT01255228|body composition
358925|NCT01255228|adipocyte-derived cytokine
358926|NCT01255228|low glycemic index
358927|NCT01255215|malaria
358928|NCT01255215|children
358929|NCT01255202|preeclampsia
358930|NCT01255202|toxemia
358931|NCT01255202|twin
358932|NCT01255202|pregnancy
358933|NCT01255202|pp13
358934|NCT01255202|prediction
358935|NCT01255202|kongo red
358936|NCT01255189|NIRS
358937|NCT01255176|Infant
358938|NCT01255176|Physical Therapy
358939|NCT01255163|Alzheimer's
358940|NCT01255163|Memory
358941|NCT01255163|Diabetes
358942|NCT01255163|Placebo
358943|NCT01255163|Alzheimer Disease
358944|NCT01255150|Genetic Ancestry Analysis
358945|NCT01255150|Molecular Profiling
358946|NCT01255150|Smoking Status
358947|NCT01255150|Wood Smoke Exposure
358948|NCT01255150|EGFR Mutation Analysis
358949|NCT01255150|Non Small Cell Lung Cancer
358950|NCT01255137|Selective VEGF Inhibitor
358951|NCT01255137|Clinical Activity
358952|NCT01255137|Response Rate
358953|NCT01255137|Measurable Disease
358954|NCT01255137|Biological Markers
358955|NCT01255137|Adrenocortical Cancer
358956|NCT01255111|Chronic respiratory failure
358957|NCT01255111|Noninvasive ventilation
358958|NCT01255111|Patient-ventilator interactions
358959|NCT01255111|Sleep
358960|NCT01255111|Sleep fragmentation
358961|NCT01254123|Glucagon Like Peptide-1
358962|NCT01254123|Exenatide
358963|NCT01254123|myocardial infarction
358964|NCT01254123|MRI
358965|NCT01254123|PCI
358966|NCT01254084|Herbal medicine; Type 2 diabetes; Gynostemma pentaphyllum Tea; Insulin sensitivity;
358967|NCT01254071|GI198745
358968|NCT01254071|Tamsulosin hydrochloride
358969|NCT01254071|Dutasteride
358970|NCT01254071|food effect
358971|NCT01254071|healthy male subjects
358972|NCT01254071|north-east Asian ancestry
358973|NCT01254071|Bioequivalence
358974|NCT01254071|cross-over design
358975|NCT01254071|Pilot bioequivalence
358976|NCT01257958|Vitamin D, 19 nor Vitamin D, Multiple Sclerosis
358977|NCT01257932|Breast Cancer
358978|NCT01257906|acne
358979|NCT01257906|Ziana
358980|NCT01257906|clindamycin
358981|NCT01257906|tretinoin
358982|NCT01257893|migraine
358983|NCT01257893|chronic migraine
358984|NCT01257893|migraine with aura
358985|NCT01257893|migraine without aura
358986|NCT01257893|aspirin
358987|NCT01257893|platelets
358988|NCT01257880|Migraine
358989|NCT01257880|Migraine with Aura
358990|NCT01257880|Aura
358991|NCT01257880|Patent Foramen Ovale
358992|NCT01257880|Platelets
358993|NCT01257880|Sleep Apnea
358994|NCT01257880|Cognitive Function
358995|NCT01257867|Brain-derived neurotrophic factor
358996|NCT01257867|Oxidative stress
358997|NCT01257867|Neurogenesis
358998|NCT01257867|Lithium
358999|NCT01257867|Lithia water
359000|NCT01257854|busulfan
359001|NCT01257854|pharmacogenetic
359002|NCT01257854|pharmacokinetic
359003|NCT01257854|toxicity
359004|NCT01257854|survival
359005|NCT01257841|Fasting
359006|NCT01257841|Gut hormones
359007|NCT01257841|Inflammatory Cytokines
359008|NCT01257815|Diabetes mellitus
359009|NCT01257815|Diabetic retinopathy
359010|NCT01257815|Macular oedema
359011|NCT01257815|Visual acuity
359012|NCT01257789|laparoscopic gastric bypass
359013|NCT01257789|learning curve
359014|NCT01257789|complications
359015|NCT01257789|operative time
359016|NCT01257776|Critical Limb Ischemia (CLI)
359017|NCT01257776|Diabetes
359018|NCT01257776|Mesenchymal Stem Cells
359019|NCT01257776|Regenerative Therapy
359020|NCT01257763|needles/adverse effects
359021|NCT01257763|administration, cutaneous
359022|NCT01257763|erythema
359023|NCT01257763|pain measurement
359024|NCT01257763|Safety
359025|NCT01257763|Microstructure Transdermal System
359026|NCT01257750|corneal neovascularization
359027|NCT01257750|pazopanib
359028|NCT01257750|votrient
359029|NCT01257750|rosacea
359030|NCT01257737|Urea Cycle Disorders
359031|NCT01257737|GT4P
359032|NCT01257737|HPN-100
359033|NCT01257737|Sodium Phenylbutyrate
359034|NCT01257737|Glyceryl tri-(4-phenylbutyrate)
359035|NCT01257737|Phenylbutyrate
359036|NCT01257737|Hyperion
359037|NCT01257737|Buphenyl
359038|NCT01257737|hyperammonemia
359039|NCT01257724|Knowledge translation
359040|NCT01257724|Community based organizations
359041|NCT01257724|HIV/AIDS
359042|NCT01257711|Gastric Cancer
359043|NCT01257711|Gastrectomy
359044|NCT01257711|Billroth 2
359045|NCT01257711|Roux-en-Y
359046|NCT01257698|Vitrectomy
359047|NCT01257698|Gas bubble
359048|NCT01257698|Retinal detachment
359049|NCT01257698|Macular hole
359050|NCT01257698|Aqueous suppressant
359051|NCT01257672|acute gastroenteritis
359052|NCT01257672|vomiting
359053|NCT01257672|ondansetron
359054|NCT01257672|domperidon
359055|NCT01257672|symptomatic treatment
359056|NCT01257659|Rectocele
359057|NCT01257659|Trans anal STARR resection
359058|NCT01257659|Transvaginal repair
359059|NCT01257633|da Vinci surgical robot
359060|NCT01257633|laryngeal cancer
359061|NCT01257620|Inflammatory Bowel Disease
359062|NCT01257620|Coeliac Disease
359063|NCT01257594|Gliomas
359064|NCT01257594|Erlotinib
359065|NCT01257594|Glioblastoma
359066|NCT01257594|GBM
359067|NCT01257594|Gliosarcoma
359068|NCT01257594|Glioma
359069|NCT01257581|ALS
359070|NCT01257581|Lou Gehrig's Disease
359071|NCT01257581|Amyotrophic Lateral Sclerosis
359072|NCT01257581|Creatine
359073|NCT01257581|Tamoxifen
359074|NCT01257581|Selection Design
359075|NCT01257542|randomized
359076|NCT01257542|parallel
359077|NCT01257542|double-blind
359078|NCT01257542|placebo-controlled
359079|NCT01257542|cough
359080|NCT01257542|efficacy
359081|NCT01257542|safety
359082|NCT01257542|dextromethorphan
359083|NCT01257529|pregabalin
359084|NCT01257529|pharmacokinetics
359085|NCT01257529|bioavailability
359086|NCT01257529|bioequivalence
359087|NCT01257516|pregabalin
359088|NCT01257516|pharmacokinetics
359089|NCT01257516|bioavailability
359090|NCT01257516|bioequivalence
359091|NCT01257503|children
359092|NCT01257503|upper respiratory tract infections
359093|NCT01257503|homeopathy
359094|NCT01257477|Diarrhea
359095|NCT01257477|IBS
359096|NCT01257477|Irritable Bowel Syndrome
359097|NCT01257464|CFRD
359098|NCT01257464|sitagliptin
359099|NCT01257464|cystic fibrosis-related diabetes
359100|NCT01257464|incretins
359101|NCT01257464|hyperglycemia
359102|NCT01257464|GIP
359103|NCT01257464|GLP-1
359104|NCT01257451|Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients
359105|NCT01257412|Phase III
359106|NCT01257412|Type 2 Diabetes Mellitus
359107|NCT01257412|inadequate glycaemic control
359108|NCT01257360|RAS-Wildtype
359109|NCT01257360|Radiotherapy
359110|NCT01257360|Neoadjuvant treatment
359111|NCT01257347|Medication adherence
359112|NCT01257347|clinical inertia
359113|NCT01257347|treatment intensification
359114|NCT01257347|quality of care
359115|NCT01257334|type 2 diabetes
359116|NCT01257308|lung cancer
359117|NCT01257295|dietary fiber
359118|NCT01257295|energy intake
359119|NCT01257295|appetite
359120|NCT01257295|satiety hormones
359121|NCT01257295|glucose
359122|NCT01257295|gastric emptying
359123|NCT01257269|Thrombotic thrombocytopenic purpura
359124|NCT01257269|ADAMTS13
359125|NCT01257269|Von Willebrand factor
359126|NCT01257269|Von Willebrand factor cleaving protease
359127|NCT01257269|Thrombocytopenia
359128|NCT01257269|Hemolytic anemia
359129|NCT01257256|infertile patients
359130|NCT01257243|cough
359131|NCT01257243|symptoms
359132|NCT01257243|cold
359133|NCT01257243|flu
359134|NCT01256879|cimetidine
359135|NCT01256879|pharmacokinetics
359136|NCT01256879|formulation
359137|NCT01256866|Dexmedetomidine
359138|NCT01256866|Midazolam
359139|NCT01256866|Sedation
359140|NCT01256866|Mechanical ventilation
359141|NCT01256866|Critically ill patients
359142|NCT01256853|histologically confirmed EBV+ NPC patients
359143|NCT01256827|age-related macular degeneration
359144|NCT01256827|ranibizumab
359145|NCT01256827|geographic atrophy
359146|NCT01256827|ANCHOR Study
359147|NCT01256827|MARINA Study
359148|NCT01256814|HIV/AIDS
359149|NCT01256814|Adult
359150|NCT01256814|Behavioral Intervention
359151|NCT01256814|Sleep
359152|NCT01256814|Physical Activity
359153|NCT01256801|Metastatic Breast Neoplasms
359154|NCT01256801|Gene Expression Profiling
359155|NCT01256801|immunotherapy
359156|NCT01256788|viscosupplementation
359157|NCT01256788|meniscus tear
359158|NCT01256788|degenerative joint disease
359159|NCT01256775|atherosclerosis
359160|NCT01256775|carotid intima-media thickness
359161|NCT01256775|intermittent claudication
359162|NCT01256775|Nitric Oxide / NO
359163|NCT01256762|imetelstat
359164|NCT01256762|imetelstat sodium
359165|NCT01256762|GRN163L
359166|NCT01256762|telomerase inhibitor
359167|NCT01256762|telomerase inhibition
359168|NCT01256762|metastatic breast cancer
359169|NCT01256762|locally recurrent breast cancer
359170|NCT01256762|Bevacizumab
359171|NCT01256762|Paclitaxel
359172|NCT01256762|Avastin
359173|NCT01256762|Taxol
359174|NCT01256762|HER-2-negative
359175|NCT01256762|First-Line Chemotherapy
359176|NCT01256762|Second-Line Chemotherapy
359177|NCT01256723|drug eluting stent (DES)
359178|NCT01256723|unprotected left main coronary artery (ULMCA)
359179|NCT01256684|Vulvar/vaginal atrophy
359180|NCT01256684|Atrophic Vaginitis
359181|NCT01256684|Dehydroepiandrosterone
359182|NCT01256684|DHEA
359183|NCT01256684|Prasterone
359184|NCT01256684|Vaginorm
359185|NCT01256684|Menopause
359186|NCT01256671|Vulvar/Vaginal Atrophy
359187|NCT01256671|Atrophic Vaginitis
359188|NCT01256671|Dehydroepiandrosterone
359189|NCT01256671|DHEA
359190|NCT01256671|Prasterone
359191|NCT01256671|Vaginorm
359192|NCT01256671|Menopause
359193|NCT01256658|P. falciparum
359194|NCT01256658|malaria
359195|NCT01256658|asymptomatic carriers
359196|NCT01256658|bed-nets
359197|NCT01256658|ITN-insecticide-treated net
359198|NCT01256658|idiopathic trigeminal neuralgia
359199|NCT01256658|RDT-Rapid diagnostic test
359200|NCT01256645|weaning
359201|NCT01256645|mechanical ventilation
359202|NCT01256645|blood transfusion
359203|NCT01256645|spontaneous breathing trials
359204|NCT01256619|Marvelon
359205|NCT01256619|PMS
359206|NCT01256619|serum Lipids
359207|NCT01256593|Lyrica
359208|NCT01256593|Regulatory Post Marketing Commitment Plan
359209|NCT01256593|Safety
359210|NCT01256593|Neuropathic Pain
359211|NCT01256593|Post Marketing Surveillance
359212|NCT01256554|Stereotactic Radiosurgery
359213|NCT01256554|SSRS
359214|NCT01256554|Radiation
359215|NCT01256554|Radiotherapy
359216|NCT01256554|Metastatic Epidural Spinal Cord Compression
359217|NCT01256554|MESCC
359218|NCT01256528|Invasive breast carcinoma
359219|NCT01256528|Breast reconstruction
359220|NCT01256528|Mastectomy
359221|NCT01256528|Breast cancer
359222|NCT01256528|Delayed-delayed breast reconstruction
359223|NCT01256528|Post-mastectomy radiation therapy
359224|NCT01256515|Healthy adults aged 50 or older
359225|NCT01256489|KPro
359226|NCT01256489|Keratoprosthesis
359227|NCT01256489|Stevens-Johnson Syndrome
359228|NCT01256489|Infliximab
359229|NCT01256489|Corneal Blindness
359230|NCT01256450|buccal soluble film
359231|NCT01256450|enriched enrollment
359232|NCT01256450|randomized withdrawal
359233|NCT01256437|Acneiform eruption
359234|NCT01256437|papulopustular
359235|NCT01256437|EGFR
359236|NCT01256437|cetuximab
359237|NCT01256437|erlotinib
359238|NCT01256437|gefitinib
359239|NCT01256437|panitumumab
359240|NCT01256437|eruption secondary to treatment with either cetuximab
359241|NCT01256424|CIN
359242|NCT01256411|hypertension
359243|NCT01256411|blood pressure
359244|NCT01256411|LCZ696
359245|NCT01256411|dual-acting
359246|NCT01256411|neprilysin
359247|NCT01256411|nep inhibitor
359248|NCT01256411|vasopeptidase
359249|NCT01256411|angiotensin receptor
359250|NCT01256411|angiotensin receptor neprilysin inhibitor (ARNi)
359251|NCT01256372|Cardiac surgery
359252|NCT01256372|Acute kidney injury
359253|NCT01256346|Premature
359254|NCT01256346|baby
359255|NCT01256346|heart rate
359256|NCT01256346|resuscitation
359257|NCT01256307|Obstructive Sleep Apnea/Hypopnea Syndrome
359258|NCT01256307|Exercise training program
359259|NCT01256307|Inflammation
359260|NCT01256307|Oxidative Stress
359261|NCT01256307|Insulin resistance
359262|NCT01256294|Renal transplant
359263|NCT01256294|kidney transplant
359264|NCT01256294|immunosuppressive therapy
359265|NCT01256294|anti-rejection medication
359266|NCT01256294|pharmacokinetics
359267|NCT01256294|tacrolimus
359268|NCT01256281|Sickle Cell Disease
359269|NCT01256281|Pain
359270|NCT01256281|Vasoocclusion
359271|NCT01256281|Nerve Block
359272|NCT01256281|Regional Anesthesia
359273|NCT01256268|metastatic
359274|NCT01256268|recurrent
359275|NCT01256268|Solid Cancer
359276|NCT01256255|transplant
359277|NCT01256255|influenza infection
359278|NCT01256242|tendon
359279|NCT01256242|shoulder
359280|NCT01256242|rotator cuff
359281|NCT01256242|Glenohumeral
359282|NCT01256229|deafness
359283|NCT01256229|hearing loss
359284|NCT01256229|developmental delay
359285|NCT01256229|mental retardation
359286|NCT01256216|Arthritis
359287|NCT01256216|Osteoarthritis
359288|NCT01256216|Arthroplasty
359289|NCT01256203|PDT
359290|NCT01256203|Porfimer sodium
359291|NCT01256203|Phototoxicity
359292|NCT01256203|Sunscreen
359293|NCT01256177|Bipolar Depression
359294|NCT01256177|Mental disease,
359295|NCT01256164|fibrin sealants
359296|NCT01256164|hemostatics
359297|NCT01256164|time to hemostasis
359298|NCT01256151|Bioequivalence
359299|NCT01256151|sublingual
359300|NCT01256151|alprazolam
359301|NCT01256151|pharmacokinetics
359302|NCT01256138|Allogene MSCs
359303|NCT01256138|transplantation
359304|NCT01256138|chronic liver diseases
359305|NCT01256138|portal vein
359306|NCT01256125|allogene MSCs
359307|NCT01256125|transplantation
359308|NCT01256125|chronic liver diseases
359309|NCT01256125|peripheral vein
359310|NCT01256112|obesity
359311|NCT01256112|behavioral intervention
359312|NCT01256112|family based
359313|NCT01256112|weight loss
359314|NCT01256099|Self-help treatment
359315|NCT01256099|Internet treatment
359316|NCT01256099|CBT
359317|NCT01256099|Prevention
359318|NCT01256099|Comorbidity
359319|NCT01256060|Autism Spectrum disorder
359320|NCT01256060|Oxytocin
359321|NCT01256060|Clinical Trial
359322|NCT01256060|Children
359323|NCT01256060|Pharmacology
359324|NCT01256047|immunonutrition
359325|NCT01256047|hepatectomy
359326|NCT01256047|Th1
359327|NCT01256047|Th2
359328|NCT01256034|immunonutrition
359329|NCT01256034|pancreaticoduodenectomy
359330|NCT01256034|Th1
359331|NCT01256034|Th2
359332|NCT01256008|Breast Cancer
359333|NCT01256008|Depression
359334|NCT01256008|Anxiety
359335|NCT01256008|Cognitive-Behavioral Therapy
359336|NCT01255995|PXF
359337|NCT01255982|Bipolar depression
359338|NCT01255982|subsyndromal symptoms
359339|NCT01255982|functioning
359340|NCT01255982|cognitive function
359341|NCT01255969|Dialysis
359342|NCT01255969|Physical exercise
359343|NCT01255969|Clinical Trial
359344|NCT01255969|Quality of Life
359345|NCT01255969|Performance
359346|NCT01255969|Fitness
359347|NCT01255969|Cardiovascular Mortality
359348|NCT01255969|Vascular access
359349|NCT01255956|restenosis
359350|NCT01255956|ISR
359351|NCT01255956|in-stent restenosis
359352|NCT01255956|drug eluting stent
359353|NCT01255956|rapamycin eluting stent
359354|NCT01255956|paclitaxel eluting balloon catheter
359355|NCT01255943|MRSA
359356|NCT01255943|bloodstream infections
359357|NCT01255943|hemodialysis
359358|NCT01255280|Crystal methamphetamine abuse
359359|NCT01255280|Crystal methamphetamine dependence
359360|NCT01255280|Sexual risk behavior
359361|NCT01255280|Men who have sex with men (MSM)
359362|NCT01255280|Behavioral activation
359363|NCT01255267|Acute coronary syndrome and chronic coronary artery disease patients
359364|NCT01255254|he effect of gingival scaling on Metabolic control
359365|NCT01255241|Lower Limbs Deformities
359366|NCT01255241|kinetics
359367|NCT01255241|kinematics
359368|NCT01255241|gait
359369|NCT01255241|energy expenditure
359370|NCT01255930|Pregnant Women
359371|NCT01255930|Sonographic Textures
359372|NCT01255917|Tio identify role of NGF in pain in CP
359373|NCT01255917|Identify biomarkers related to progression of CP
359374|NCT01255891|high risk localized adenocarcinoma of the prostate
359375|NCT01255878|Sleep bruxism
359376|NCT01255878|Gabapentine
359377|NCT01255878|Occlusal splint
359378|NCT01255878|Polysomnography
359379|NCT01255865|Thermometry
359380|NCT01255865|Deep Tissue Temperature
359381|NCT01255865|Core Temperature
359382|NCT01255865|Body Temperature
359383|NCT01255865|Rectal Temperature
359384|NCT01255865|Oral Temperature
359385|NCT01255852|atorvastatin
359386|NCT01255852|intracranial artery stenting
359387|NCT01255852|restenosis
359388|NCT01255839|double-balloon
359389|NCT01255839|balloon catheter
359390|NCT01255839|prostaglandin
359391|NCT01255839|minprostin
359392|NCT01255839|induction of labour
359393|NCT01255839|fetal outcome
359394|NCT01255826|Preterm
359395|NCT01255826|Neonates
359396|NCT01255826|Delivery room
359397|NCT01255826|Resuscitation
359398|NCT01255826|Ventilation
359399|NCT01255826|Neopuff
359400|NCT01255826|CPAP
359401|NCT01255813|Chronic Cluster Headache
359527|NCT01255007|Primovist
359402|NCT01255787|Major Depressive Disorder
359403|NCT01255787|Depression
359404|NCT01255787|Melancholia
359405|NCT01255787|Drug Therapy
359406|NCT01255774|subfoveal CNV
359407|NCT01255774|Wet (Exudative) AMD
359408|NCT01255774|macular degeneration
359409|NCT01255761|Certolizumab Pegol
359410|NCT01255761|Cimzia
359411|NCT01255761|Rheumatoid Arthritis
359412|NCT01255761|CDAI
359413|NCT01255761|RAPID3
359414|NCT01255748|cancer, proton, radiation
359415|NCT01255735|pediatrics
359416|NCT01255735|voice
359417|NCT01255735|voice therapy
359418|NCT01255735|vocal therapy
359419|NCT01255735|hoarseness
359420|NCT01255722|iodinated contrast media, coronary artery disease
359421|NCT01255709|Asthma
359422|NCT01255709|shortness of breath
359423|NCT01255709|wheezing
359424|NCT01255696|Celiac Disease
359425|NCT01255696|Coeliac Disease
359426|NCT01255696|Celiac Sprue
359427|NCT01255696|Keliakia Disease
359428|NCT01255683|Chronic
359429|NCT01255683|Sinusitis
359430|NCT01255683|Steroid
359431|NCT01255683|treatment
359432|NCT01255670|Peritonsillar Abscess
359433|NCT01255670|Quinsy
359434|NCT01255670|Penicillin
359435|NCT01255670|Metronidazole
359436|NCT01255670|Recurrence
359437|NCT01255605|Intermittent preventive treatment with sulfadoxin-pyrimethamine
359438|NCT01255605|in Bobo-Dioulasso peri-urban areas, 5 years after its implementation
359439|NCT01255605|Burkina Faso.
359440|NCT01255592|Bronchiectasis
359441|NCT01255592|Neutrophil
359442|NCT01255592|Respiratory disease
359443|NCT01255592|Sputum
359444|NCT01255579|asthma
359445|NCT01255579|small airways
359446|NCT01255579|inhaled corticosteroids
359447|NCT01255540|Coronary heart disease in patients over
359448|NCT01255540|80 years of age.
359449|NCT01255488|Search engine
359450|NCT01255488|Clinical decision-making
359451|NCT01255488|Research abstracts
359452|NCT01255488|Full-text manuscripts
359453|NCT01255488|Family Nurse Practitioners
359454|NCT01255462|AMD,
359455|NCT01255462|ARMD,
359456|NCT01255462|Age-related Macular Degeneration,
359457|NCT01255462|Eye Disease,
359458|NCT01255462|Wet AMD,
359459|NCT01255462|Neovascular AMD,
359460|NCT01255462|Choroidal Neovascular Membrane,
359461|NCT01255462|Choroidal Neovascularization,
359462|NCT01255462|Drusen,
359463|NCT01255462|Geographic Atrophy,
359464|NCT01255462|Complement,
359465|NCT01255462|C5,
359466|NCT01255462|Antibody
359467|NCT01255449|Forced oscillation technique
359468|NCT01255449|Respiratory input impedance
359469|NCT01255449|Allogeneic hematopoietic stem cell transplantation
359470|NCT01255449|Obliterative bronchiolitis
359471|NCT01255423|Ankle sprain, soft tissue injury
359472|NCT01255397|male infertility
359473|NCT01255397|natural cycle IVF
359474|NCT01255397|in-vitro fertilization
359475|NCT01255397|intrauterine inseminatio
359476|NCT01255371|HIV
359477|NCT01255371|Second line antiretroviral treatment
359478|NCT01255371|Sub saharian Africa
359479|NCT01255371|Generic
359480|NCT01255358|Ataxia Teleangiectasia
359481|NCT01255358|AT
359482|NCT01255358|Ery-Dex
359483|NCT01255358|Dexamethasone
359484|NCT01255358|Dexamethasone sodium phosphate
359485|NCT01255345|Physiotherapy
359486|NCT01255345|Multidisciplinary Pain Centers
359487|NCT01255345|Pain measurements
359488|NCT01255345|Physical activity
359489|NCT01255345|Quality of life
359490|NCT01255332|ITP
359491|NCT01255319|MDS
359492|NCT01255306|Rhegmatogenous retinal detachment
359493|NCT01255306|Pars plana vitrectomy
359494|NCT01255306|Silicone oil
359495|NCT01255306|Retinal nerve fibre layer
359496|NCT01255293|Retinal detachment
359497|NCT01255293|Proliferative vitreoretinopathy
359498|NCT01255293|Diabetic retinopathy
359499|NCT01255293|Vitrectomy
359500|NCT01255293|Silicone oil
359501|NCT01255085|Obesity
359502|NCT01255085|Food intake regulation
359503|NCT01255085|blood glucose regulation
359504|NCT01255085|protein
359505|NCT01255085|fiber
359506|NCT01255085|pulses
359507|NCT01255085|yellow peas
359508|NCT01255072|TMS
359509|NCT01255072|elderly
359510|NCT01255072|depression
359511|NCT01255072|neuronavegation
359512|NCT01255072|neurocognition
359513|NCT01255059|Genome-wide association studies(GWAS)
359514|NCT01255059|Single nucleotide polymorphism(SNP)
359515|NCT01255059|Lung cancer
359516|NCT01255033|perioperative surgery
359517|NCT01255033|regional oxygenation
359518|NCT01255033|hypoxemia
359519|NCT01255033|brain hypoxemia
359520|NCT01255033|spectroscopy, near-infrared
359521|NCT01255020|α-Keto Acid
359522|NCT01255020|Restricted Protein Diet
359523|NCT01255020|Residual Renal Function
359524|NCT01255007|Colorectal
359525|NCT01255007|liver
359526|NCT01255007|metastases
359528|NCT01255007|MRI
359529|NCT01255007|CT
359530|NCT01255007|cancer
359531|NCT01255007|resection
359532|NCT01255007|MDCT
359533|NCT01255007|Diffusion
359534|NCT01255007|Weighted
359535|NCT01255007|3T
359536|NCT01254994|hepatitis B
359537|NCT01254994|acute on chronic liver failure (ACHBLF)
359538|NCT01254994|entecavir
359539|NCT01254994|treatment
359540|NCT01254994|predicting
359541|NCT01254981|Percutaneous coronary intervention
359542|NCT01254981|DES
359543|NCT01254981|Angina pectoris
359544|NCT01254981|Stent
359545|NCT01254968|blood flow in the middle cerebral artery of brain
359546|NCT01254955|2009 H1N1 influenza vaccine, organ transplant patients
359547|NCT01254942|exercise
359548|NCT01254942|hip fractures
359549|NCT01254942|rehabilitation
359550|NCT01254942|aged
359551|NCT01254942|aged 80 and over
359552|NCT01254929|Cancer
359553|NCT01254929|Bone metastases
359554|NCT01254916|Chronic Rhinosinusitis
359555|NCT01254916|Sinonasal Outcome test 22
359556|NCT01254903|Stereotactic Radiosurgery
359557|NCT01254903|Radiation
359558|NCT01254903|Radiotherapy
359559|NCT01254903|Metastatic Epidural Spinal Cord Compression
359560|NCT01254903|MESCC
359561|NCT01254890|Relapsed Acute Leukemia
359562|NCT01254890|Chronic Myelomonocytic Leukemia
359563|NCT01254890|CMML
359564|NCT01254890|Myelodysplastic Syndrome
359565|NCT01254890|MDS
359566|NCT01254890|Acute myeloid leukemia
359567|NCT01254890|AML
359568|NCT01254890|5-azacitidine
359569|NCT01254890|Azacitidine
359570|NCT01254890|5-aza
359571|NCT01254890|Vidaza
359572|NCT01254890|5-AZC
359573|NCT01254890|AZA-CR
359574|NCT01254890|Ladakamycin
359575|NCT01254890|NSC-102816
359576|NCT01254890|Sorafenib
359577|NCT01254890|Nexavar
359578|NCT01254890|BAY43-9006
359579|NCT01254877|HIV
359580|NCT01254864|Castrate resistant prostate cancer
359581|NCT01254864|Adenocarcinoma of the prostate
359582|NCT01254864|Sunitinib Malate
359583|NCT01254864|SUO11248
359584|NCT01254864|Sutent
359585|NCT01254864|BMS-354825
359586|NCT01254864|Sprycel
359587|NCT01254851|discharge criteria, gynecologic surgery, post-op ambulation
359588|NCT01254825|Adductor Canal Block (ACB)
359589|NCT01254825|Diagnostic Knee Arthroscopy
359590|NCT01254825|Saphenous nerve
359591|NCT01254825|Pain
359592|NCT01254825|Ultrasound block
359593|NCT01254812|pulmonary function
359594|NCT01254812|BD-TAP-block
359595|NCT01254786|VATS
359596|NCT01254786|one lung ventilation
359597|NCT01254786|continuous positive pressure ventilation
359598|NCT01254786|high frequency positive pressure ventilation
359599|NCT01254721|Acute bipolar mania
359600|NCT01254721|Seroquel XR
359601|NCT01254721|Seroquel XR plus lithium
359602|NCT01254721|Quetiapine fumarate
359603|NCT01254695|Idiopathic Fecal Incontinence
359604|NCT01254695|Fecal Incontinence
359605|NCT01254695|Sacral Nerve Stimulation
359606|NCT01254695|Sacral Nerve Neuromodulation
359607|NCT01254682|wrist
359608|NCT01254682|joint
359609|NCT01254682|arthroscopy
359610|NCT01254682|hyaluronan
359611|NCT01254682|hyaluronic acid
359612|NCT01254682|Necessity of Arthroscopic surgery
359613|NCT01254669|Haitian girls, African American girls
359614|NCT01254669|Brief Negotiated Interview
359615|NCT01254669|cognitive behavioral intervention
359616|NCT01254669|HPV vaccine
359617|NCT01254669|cervical cancer
359618|NCT01254643|Papillomavirus vaccines
359619|NCT01254643|Uterine cervical cancer
359620|NCT01254643|Human Papilloma Virus infections
359621|NCT01254630|Herpes zoster
359622|NCT01254630|vaccine
359623|NCT01254630|solid tumor malignancy
359624|NCT01254630|hematologic malignancy
359625|NCT01254630|immunocompromised
359626|NCT01254630|herpes-zoster-related complications
359627|NCT01254604|Tafluprost
359628|NCT01254604|Glaucoma
359629|NCT01254604|Ocular Hypertension
359630|NCT01254604|Timolol
359631|NCT01254604|Eye Disorder
359632|NCT01254604|Preservative-Free
359633|NCT01254604|Prostaglandin Analogue
359634|NCT01254591|stage IA non-small cell lung cancer
359635|NCT01254591|stage IB non-small cell lung cancer
359636|NCT01254591|stage IIA non-small cell lung cancer
359637|NCT01254591|stage IIB non-small cell lung cancer
359638|NCT01254591|stage IIIA non-small cell lung cancer
359639|NCT01254591|stage I colon cancer
359640|NCT01254591|stage IIA colon cancer
359641|NCT01254591|stage IIB colon cancer
359642|NCT01254591|stage IIC colon cancer
359643|NCT01254591|stage IIIA colon cancer
359644|NCT01254591|stage I rectal cancer
359645|NCT01254591|stage IIA rectal cancer
359646|NCT01254591|stage IIB rectal cancer
359647|NCT01254591|stage IIC rectal cancer
359648|NCT01254591|stage IIIA rectal cancer
359649|NCT01254591|stage IA breast cancer
359650|NCT01254591|stage IB breast cancer
359651|NCT01254591|stage II breast cancer
359652|NCT01254591|stage IIIA breast cancer
359653|NCT01254591|stage IIIB breast cancer
359654|NCT01254591|stage I esophageal cancer
359655|NCT01254591|stage II esophageal cancer
359656|NCT01254591|stage III esophageal cancer
359657|NCT01254591|stage I hypopharyngeal cancer
359658|NCT01254591|stage II hypopharyngeal cancer
359659|NCT01254591|stage III hypopharyngeal cancer
359660|NCT01254591|stage I laryngeal cancer
359661|NCT01254591|stage II laryngeal cancer
359662|NCT01254591|stage III laryngeal cancer
359663|NCT01254591|stage I lip and oral cavity cancer
359664|NCT01254591|stage II lip and oral cavity cancer
359665|NCT01254591|stage III lip and oral cavity cancer
359666|NCT01254591|stage I nasopharyngeal cancer
359667|NCT01254591|stage II nasopharyngeal cancer
359668|NCT01254591|stage III nasopharyngeal cancer
359669|NCT01254591|stage I oropharyngeal cancer
359670|NCT01254591|stage II oropharyngeal cancer
359671|NCT01254591|stage III oropharyngeal cancer
359672|NCT01254591|stage I paranasal sinus and nasal cavity cancer
359673|NCT01254591|stage II paranasal sinus and nasal cavity cancer
359674|NCT01254591|stage III paranasal sinus and nasal cavity cancer
359675|NCT01254591|stage I salivary gland cancer
359676|NCT01254591|stage II salivary gland cancer
359677|NCT01254591|stage III salivary gland cancer
359678|NCT01254591|tongue cancer
359679|NCT01254565|Clinical Trial, Phase 2
359680|NCT01254565|Renal Dialysis
359681|NCT01254565|Secondary Hyperparathyroidism
359682|NCT01254565|Parathyroid hormone
359683|NCT01254539|Amyotrophic Lateral Sclerosis
359684|NCT01254539|Bone marrow
359685|NCT01254539|Stem cells
359686|NCT01254539|Autologous
359687|NCT01254539|Safety
359688|NCT01254513|Metastatic Prostate cancer
359689|NCT01254513|Elderly patients
359690|NCT01254513|Vulnerable and Frail (SIOG classification)
359691|NCT01254513|castration-resistant
359692|NCT01254500|patients with brain lesions
359693|NCT01254474|Depolarization, tissue
359694|NCT01254474|Repolarization, tissue
359695|NCT01254474|Cardiac Arrhythmias
359696|NCT01254474|Action potentials, monophasic
359697|NCT01254474|Mapping, Catheter
359698|NCT01254474|Cardiac activation
359699|NCT01254461|Phase 1
359700|NCT01254461|Drug-Drug interaction
359701|NCT01254461|pravastatin
359702|NCT01254461|AZD1981
359703|NCT01254461|The pharmacokinetics resulting from AZD1981 and pravastatin interaction
359704|NCT01254461|The effects of taking a combination of AZD1981 and pravastatin
359705|NCT01254448|Alzheimer's Disease
359706|NCT01254435|Colonoscopy
359707|NCT01254435|Positioning in colonoscopy
359708|NCT01254435|Quality control
359709|NCT01254422|Dengue fever
359710|NCT01254422|Dengue hemorrhagic fever
359711|NCT01254422|CYD dengue vaccine
359712|NCT01254409|pulmonary, fibrosis
359713|NCT01254396|Bioavailability Food Effect Oral Dissolving Tablet (ODT)
359714|NCT01254383|Bioequivalence Oral Dissolving Tablet
359715|NCT01254357|Burns
359716|NCT01254357|Trauma
359717|NCT01254357|Outcomes
359718|NCT01254357|Quality of Life
359719|NCT01254344|Colorectal surgery
359720|NCT01254318|hematological malignancy
359721|NCT01254318|fungal infection
359722|NCT01254318|leukemia
359723|NCT01254305|Depression
359724|NCT01254305|Fatigue
359725|NCT01254305|Major Depressive Disorder
359726|NCT01254266|morbid obesity
359727|NCT01254266|adolescents
359728|NCT01254266|inpatient treatment
359729|NCT01254253|percutaneous coronary intervention
359730|NCT01254253|chronic total occlusion
359731|NCT01254253|coronary angiography
359732|NCT01254253|single photon emission CT
359733|NCT01254253|Multislice coronary CT angiography
359734|NCT01254227|Cardiac iron overload,
359735|NCT01254227|deferasirox,
359736|NCT01254227|deferoxamine
359737|NCT01254214|Mindfulness
359738|NCT01254214|Quality of life
359739|NCT01254214|Transplantation
359740|NCT01254214|Renal disease
359741|NCT01254188|Chronic myeloid leukemia,
359742|NCT01254188|CML,
359743|NCT01254188|nilotinib,
359744|NCT01254188|myelogenous,
359745|NCT01254188|Philadelphia chromosome
359746|NCT01254162|Oily Skin
359747|NCT01254162|Sebum
359748|NCT01254032|CAT
359749|NCT01254032|COPD
359750|NCT01254019|Duchenne Muscular Dystrophy
359751|NCT01254019|DMD
359752|NCT01254019|968
359753|NCT01254019|GSK
359754|NCT01254019|Duchenne
359755|NCT01253993|Disruptive Behavior Disorders, Substance abuse,
359756|NCT01253993|Iowa Gambling Task, Decision Making.
359757|NCT01253980|pneumonitis
359758|NCT01253980|paraffin
359759|NCT01253980|kerosene
359760|NCT01253967|Gastroenteritis
359761|NCT01253967|Hospital surveillance
359762|NCT01253967|Rotavirus gastroenteritis
359763|NCT01253954|invasive candida infection
359764|NCT01253941|COPD, Intensive Resistive Breathing, Cytokine IL6,
359765|NCT01253928|body composition
359766|NCT01253928|insulin sensitivity
359767|NCT01253928|protein metabolism
359768|NCT01253928|pioglitazone
359769|NCT01253889|Functional echocardiography
359770|NCT01253889|oral glucose
359771|NCT01253889|neonatal stress
359772|NCT01253863|Clinical Examination, Accuracy, Hand, Tendon, Injury.
359773|NCT01253850|hiv
359774|NCT01253850|antiretroviral
359775|NCT01253850|adherence
359776|NCT01253850|adolescent
359777|NCT01253837|L19
359778|NCT01253837|antibody
359779|NCT01253837|monoclonal
359780|NCT01253837|tumor targeting
359781|NCT01253837|TNFa
359782|NCT01253837|colorectal cancer
359783|NCT01253837|Phase I: Patients with relapsed or refractory locally advanced or metastatic solid tumors not amenable to standard systemic therapy.
359784|NCT01253837|Phase II: Patients with relapsed or refractory locally advanced or metastatic colorectal cancer not amenable to standard systemic therapy.
359785|NCT01253824|NPC-01
359786|NCT01253824|IKH-01
359787|NCT01253824|Pharmacodynamics
359788|NCT01253824|Norethisterone
359789|NCT01253824|Ethinyl Estradiol
359790|NCT01253824|Estradiol
359791|NCT01253824|Progesterone
359792|NCT01253824|FSH
359793|NCT01253824|LH
359794|NCT01253798|exercise
359795|NCT01253798|hydrotherapy
359796|NCT01253759|Transpupillary thermotherapy
359797|NCT01253759|Choroidal melanoma
359798|NCT01253759|ICG-Photodynamic therapy
359799|NCT01253746|NTD
359800|NCT01253746|open NTD
359801|NCT01253746|spina bifida
359802|NCT01253746|anencephaly
359803|NCT01253746|closed NTD
359804|NCT01253746|lipomeningocele
359805|NCT01253746|tethered cord.
359806|NCT01253733|Cystic Fibrosis
359807|NCT01253733|Inflammatory Bowel Disease
359808|NCT01253733|Type 1 Diabetes
359809|NCT01253733|Chronic Disease Management
359810|NCT01253733|SMS
359811|NCT01253733|Text messages
359812|NCT01253733|Internet
359813|NCT01253733|Healthcare Interactions
359814|NCT01253720|obesity
359815|NCT01253720|text messages
359816|NCT01253720|internet
359817|NCT01253720|cancer
359818|NCT01253720|overweight
359819|NCT01253707|Solid Tumors
359820|NCT01253707|C-met inhibitor
359821|NCT01253694|Diabetes
359822|NCT01253694|edema
359823|NCT01253694|ranibizumab
359824|NCT01253694|bevacizumab
359825|NCT01253694|refractory
359826|NCT01253681|AMG 386
359827|NCT01253681|Ovarian Cancer
359828|NCT01253655|Healthy Volunteers
359829|NCT01253629|Fragile X Syndrome
359830|NCT01253629|Martin-Bell Syndrome
359831|NCT01253629|Genetic Diseases
359832|NCT01253629|X-Linked
359833|NCT01253603|Asthma
359834|NCT01253590|atrial fibrillation
359835|NCT01253590|ECG monitor
359836|NCT01253590|Blood pressure device
359837|NCT01253590|Remote Cardiac Monitoring
359838|NCT01253551|VX-950HEP1001
359839|NCT01253551|hepatitis
359840|NCT01253551|telaprevir
359841|NCT01253551|raltegravir
359842|NCT01253551|crossover
359843|NCT01253551|healthy volunteers
359844|NCT01253551|VX-950.
359845|NCT01253538|Mother-to-Child Transmission of HIV
359846|NCT01253538|HAART
359847|NCT01253525|Adenocarcinoma
359848|NCT01253525|Gastroesophageal Junction
359849|NCT01253512|Ischemic Stroke
359850|NCT01253512|Thrombolysis
359851|NCT01253486|expressive writing
359852|NCT01253486|cardiac rehabilitation
359853|NCT01253473|COPD
359854|NCT01253460|Chronic Lymphocytic Leukemia
359855|NCT01253460|CLL
359856|NCT01253460|Small Lymphocytic Lymphoma
359857|NCT01253460|SLL
359858|NCT01253460|Cyclophosphamide
359859|NCT01253460|Rituximab
359860|NCT01253460|Sapacitabine
359861|NCT01253460|Cytoxan
359862|NCT01253460|Neosar
359863|NCT01253460|Rituxan
359864|NCT01253434|Transdermal Administration
359865|NCT01253421|MDD
359866|NCT01253421|Major Depressive Disorder
359867|NCT01253421|Amisulpride
359868|NCT01253408|anandamide
359869|NCT01253408|cannabinoid
359870|NCT01253408|fatty acid amide hydrolase
359871|NCT01253408|gastric
359872|NCT01253408|motility
359873|NCT01253408|small bowel
359874|NCT01253395|Exercise
359875|NCT01253395|Pain
359876|NCT01253369|pazopanib
359877|NCT01253317|Rett Syndrome
359878|NCT01253317|IGF-1
359879|NCT01253317|Increlex
359880|NCT01253317|Mecasermin
359881|NCT01253317|IGF1
359882|NCT01253317|MECP2
359883|NCT01253317|RTT
359884|NCT01253252|Abdominal Aortic Aneurysm
359885|NCT01253252|Prosthesis
359886|NCT01253252|Fluorodeoxyglucose F18
359887|NCT01253252|Positron-emission Tomography
359888|NCT01253252|Spiral computed tomography
359889|NCT01253252|Biological markers
359890|NCT01253239|Visual outcomes
359891|NCT01253239|Patient satisfaction
359892|NCT01253213|Prostate cancer
359893|NCT01253213|Ultrasound molecular imaging
359894|NCT01253213|Contrast agent
359895|NCT01253213|BR55
359896|NCT01253213|VEGFR2
359897|NCT01253200|Type 1 Atrial Flutter
359898|NCT01253200|Typical Atrial Flutter
359899|NCT01253200|Arrhythmias, Cardiac
359900|NCT01253200|Heart Diseases
359901|NCT01253200|Cardiovascular Diseases
359902|NCT01253161|advanced
359903|NCT01253161|metastatic
359904|NCT01253161|unresectable
359905|NCT01253161|carcinoma
359906|NCT01253161|gastrointestinal tract
359907|NCT01253161|lungs
359908|NCT01253161|colon
359909|NCT01253161|liver
359910|NCT01253161|rectum
359911|NCT01253161|small intestine
359912|NCT01253161|stomach
359913|NCT01253161|pancreatic
359914|NCT01253148|Liver
359915|NCT01253148|Bile Duct
359916|NCT01253135|Fibrin, white petrolatum, wound healing
359917|NCT01253096|Interleukin
359918|NCT01253096|IL2
359919|NCT01253096|monoclonal
359920|NCT01253096|antibody
359921|NCT01253096|cytokine
359922|NCT01253096|metastatic
359923|NCT01253096|melanoma
359924|NCT01253096|tumor targeting
359925|NCT01253096|intratumoral
359926|NCT01253096|Malignant melanoma with presence of injectable soft-tissue metastases either in clinical stage III or stage IV without visceral metastases.
359927|NCT01253083|Mobility
359928|NCT01253083|Developmental Delay
359929|NCT01253083|Cerebral Palsy
359930|NCT01253083|Early Walking
359931|NCT01253083|Postural Control
359932|NCT01253057|cleaning staff
359933|NCT01253057|antineoplastic agents
359934|NCT01253044|OEF/OIF
359935|NCT01253044|Veterans
359936|NCT01253044|Psychotherapy
359937|NCT01253031|hearing loss
359938|NCT01253031|aging
359939|NCT01253031|short term memory
359940|NCT01253031|attentional blink
359941|NCT01253018|stroke
359942|NCT01253018|robotics
359943|NCT01253018|upper extremity rehabilitation
359944|NCT01252992|Extrapulmonary
359945|NCT01252992|Tuberculosis
359946|NCT01252992|Paradoxical reaction
359947|NCT01252992|Risk factors
359948|NCT01252992|Incidence
359949|NCT01252992|CT scan
359950|NCT01252992|Natural history
359951|NCT01252992|Immune system phenomena
359952|NCT01252992|Immune markers
359953|NCT01252992|Gene Expression Profiling
359954|NCT01252979|MELAS
359955|NCT01252979|Ketones
359956|NCT01252979|Medium Chain Triglycerides
359957|NCT01252979|MCT oil
359958|NCT01252979|Mitochondrial Disorder
359959|NCT01252979|Heteroplasmy
359960|NCT01252979|3243AG
359961|NCT01252979|Subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent.
359962|NCT01252979|Subject is willing and able to comply with all trial requirements.
359963|NCT01252979|Subject harbors the 3243 A>G mtDNA mutation at a level detectable in blood.
359964|NCT01252979|Female subjects of child-bearing potential must not be pregnant.
359965|NCT01252979|Subjects must not have Diabetes Mellitus.
359966|NCT01252966|Tobacco
359967|NCT01252966|Smoking
359968|NCT01252966|Cognition
359969|NCT01252966|Behavioral Training
359970|NCT01252966|Relapse
359971|NCT01252953|vascular disease
359972|NCT01252953|lipids
359973|NCT01252953|cholesteryl ester transfer protein (CETP) inhibition
359974|NCT01252953|anacetrapib
359975|NCT01252940|HIV-1
359976|NCT01252940|HIV
359977|NCT01252940|Treatment Experienced
359978|NCT01252914|Open angle
359979|NCT01252914|Glaucoma
359980|NCT01252914|Surgery
359981|NCT01252914|Ocular Hypertension
359982|NCT01252914|Eye Diseases
359983|NCT01252901|WT1
359984|NCT01252901|Wilms Tumor
359985|NCT01252901|Denys-Drash Syndrome
359986|NCT01252901|Nephrotic Syndrome
359987|NCT01252901|Proteinuria
359988|NCT01252888|Open angle
359989|NCT01252888|Glaucoma
359990|NCT01252888|Surgery
359991|NCT01252888|Glaucoma Open-Angle
359992|NCT01252888|Ocular Hypertension
359993|NCT01252888|Eye Diseases
359994|NCT01252875|LDL-C
359995|NCT01252875|Cholesterol
359996|NCT01252875|Stroke
359997|NCT01252875|Transient ischemic attack
359998|NCT01252875|Statin
359999|NCT01252875|Lipid lowering therapy
360000|NCT01252862|Open angle
360001|NCT01252862|Glaucoma
360002|NCT01252862|Surgery
360003|NCT01252862|Ocular Hypertension
360004|NCT01252862|eye diseases
360005|NCT01252849|Open angle
360006|NCT01252849|Glaucoma
360007|NCT01252849|surgery
360008|NCT01252849|Glaucoma, Open-Angle
360009|NCT01252849|Ocular Hypertension
360010|NCT01252849|Eye Diseases
360011|NCT01252823|Hemodialysis
360012|NCT01252823|Cardiac Arrhythmia
360013|NCT01252823|Cardiac Death
360014|NCT01252823|Implantable Loop Recorder
360015|NCT01252810|CATH Catheterization
360016|NCT01252810|CI-AKI Contrast-induced acute kidney injury
360017|NCT01252810|DM Diabetes mellitus
360018|NCT01252810|eGFR Estimated glomerular filtration rate
360019|NCT01252810|MDRD Modification of Diet in Renal Disease
360020|NCT01252810|NYHA New York Heart Association
360021|NCT01252810|PCI Percutaneous coronary intervention
360022|NCT01252810|SCr Serum creatinine
360023|NCT01252797|brain metastases
360024|NCT01252784|higher risk MDS
360025|NCT01252771|phosphorus
360026|NCT01252771|dialysis
360027|NCT01252771|PhosLo
360028|NCT01252732|ABSSSI
360029|NCT01252732|Skin Infection
360030|NCT01252732|Abscess
360031|NCT01252719|ABSSSI
360032|NCT01252719|Skin Infection
360033|NCT01252719|Abscess
360034|NCT01252706|brief intervention
360035|NCT01252706|alcohol
360036|NCT01252706|nicotine
360037|NCT01252706|drug abuse
360038|NCT01252654|Lasik
360039|NCT01252654|Femtosecond Laser
360040|NCT01252654|Visumax
360041|NCT01252654|IntraLase
360042|NCT01252654|Myopia
360043|NCT01252654|Myopic Patients undergoing LASIK
360044|NCT01252641|HIV
360045|NCT01252628|CRC
360046|NCT01252628|SCCHN
360047|NCT01252628|PX-866
360048|NCT01252628|Cetuximab
360049|NCT01252628|ERBITUX
360050|NCT01252628|Colon
360051|NCT01252628|Head and Neck
360052|NCT01252628|Colorectal cancer
360053|NCT01252628|Squamous cell carcinoma
360054|NCT01252628|PI-3K
360055|NCT01252628|PI3 kinase
360056|NCT01252628|PI3K
360057|NCT01252615|ICD
360058|NCT01252615|HF
360059|NCT01252615|cardiac arrest
360060|NCT01252615|VF
360061|NCT01252615|cardiac arrhythmias
360062|NCT01252602|breastfeeding, EPDS, prenatal depression
360063|NCT01252589|Chronic Myeloid Leukemia
360064|NCT01252589|Quality of Life
360065|NCT01252589|Symptoms
360066|NCT01252589|Patient-Reported outcomes
360067|NCT01252589|Questionnaire
360068|NCT01252576|FSFI
360069|NCT01252576|female sexual function
360070|NCT01252576|italian validation
360071|NCT01252563|ENTER10
360072|NCT01252563|Hypertension
360073|NCT01252563|Japanese
360074|NCT01252563|Norvasc 10mg
360075|NCT01252563|Post Marketing surveillance
360076|NCT01252550|IBS
360077|NCT01252550|GI
360078|NCT01252550|QOL
360079|NCT01252550|Pathophysiology
360080|NCT01252550|Gut microbiota
360081|NCT01252550|Danone
360082|NCT01252550|Activia
360083|NCT01252550|Probiotics
360084|NCT01252537|HIV
360085|NCT01252537|Tuberculosis
360086|NCT01252537|Immunosuppression
360087|NCT01252537|ART
360088|NCT01252537|Ethiopia
360089|NCT01252537|Primary health care
360090|NCT01252524|diabetes mellitus
360091|NCT01252524|fiber
360092|NCT01252524|glycemic control
360093|NCT01252524|calcium polycarbophil
360094|NCT01252511|Malabsorption after RYGB
360095|NCT01252511|Fat Malabsorption and maldigestion
360096|NCT01252511|Obesity surgery
360097|NCT01252511|Bariatric surgery
360098|NCT01252498|Cancer of the head and neck
360099|NCT01252498|Radiotherapy
360100|NCT01252498|Prostaglandins
360101|NCT01252485|AML
360102|NCT01252485|Registry study
360103|NCT01252485|Biology and Outcome
360104|NCT01252485|Higher Risk MDS
360105|NCT01252472|Flomax
360106|NCT01252472|Floppy iris Syndrome
360107|NCT01252472|Tamsulosin
360108|NCT01252459|AA-PET
360109|NCT01252459|T1-Gd-MRI
360110|NCT01252459|re-irradiation
360111|NCT01252459|recurrent glioma
360112|NCT01252446|ICD 10
360113|NCT01252446|Attention-Deficit-Hyperactivity-Disorder (ADHD)
360114|NCT01252446|Comorbidity
360115|NCT01252446|Social-demographic profile
360116|NCT01252420|Distal Vein Thrombosis
360117|NCT01252420|Proximal Vein Thrombosis
360118|NCT01252420|Pulmonary Embolism
360119|NCT01252420|Post-thrombotic syndrome
360120|NCT01252420|Limited duration treatment
360121|NCT01252407|Transcutaneous electrical nerve stimulation
360122|NCT01252407|Sympathetic nervous system
360123|NCT01252407|Parasympathetic nervous system
360124|NCT01252407|heart rate
360125|NCT01252342|Oxytocin
360126|NCT01252342|Intramyometrial
360127|NCT01252329|high risk cutaneous squamous cell carcinoma
360128|NCT01252329|selective neck dissection
360129|NCT01252329|elective lymph node management
360130|NCT01252329|clinical nodal observation
360131|NCT01252303|Obesity, weight loss, meal replacements
360132|NCT01252264|biorepository
360133|NCT01252264|genetics
360134|NCT01252264|craniofacial
360135|NCT01252264|cleft lip
360136|NCT01252264|cleft palate
360137|NCT01252251|PASIREOTIDE (SOM230)
360138|NCT01252251|RAD001 (EVEROLIMUS)
360139|NCT01252251|eye
360140|NCT01252251|10-123
360141|NCT01252225|Chronic Cough
360142|NCT01252225|Lidocaine
360143|NCT01252212|HIV, antiretroviral, adherence, SMS, cell phone
360144|NCT01252199|Shigamabs
360145|NCT01252199|Monoclonal
360146|NCT01252199|Antibodies
360147|NCT01252199|Shiga
360148|NCT01252199|Toxin
360149|NCT01252199|E.coli
360150|NCT01252199|HUS
360151|NCT01252199|Bloody
360152|NCT01252199|Diarrhea
360153|NCT01252186|Contraception
360154|NCT01252186|Hemostasis
360155|NCT01252186|Blood Coagulation
360156|NCT01252173|endotracheal
360157|NCT01252173|intubation
360158|NCT01252173|tracheal
360159|NCT01252173|pressure
360160|NCT01252173|cufflator
360161|NCT01252160|Neuralgia, Postherpetic
360162|NCT01252160|QUTENZA
360163|NCT01252134|Soft Contact lens
360164|NCT01252134|Multi-purpose solution
360165|NCT01252134|Wettability
360166|NCT01252121|Dry Eye
360167|NCT01252121|Ocular Retention Time
360168|NCT01252108|Helicobacter pylori
360169|NCT01252108|peptic ulcer disease
360170|NCT01252108|stomach ulcers
360171|NCT01252108|gastric cancer
360172|NCT01252095|PG545
360173|NCT01252095|Phase I
360174|NCT01252095|Progen
360175|NCT01252095|antimetastatic
360176|NCT01252095|antiangiogenic
360177|NCT01252095|advanced cancer patients
360178|NCT01252095|solid tumors
360179|NCT01252095|solid tumours
360180|NCT01252082|metabolic control
360181|NCT01252082|fasting plasma glucose
360182|NCT01252082|glycated hemoglobin
360183|NCT01252043|cholestasis
360184|NCT01252043|children
360185|NCT01252030|CAD, physical activity, rehabilitation, prevention
360186|NCT01252004|Left ventricular ballooning
360187|NCT01251978|Choroidal melanoma
360188|NCT01251978|Ranibizumab
360189|NCT01251978|Transpupillary Thermotherapy
360190|NCT01251978|CSTIP
360191|NCT01251978|Indocyanine Green
360192|NCT01251965|Relapsed Acute Leukemia
360193|NCT01251965|Acute myeloid leukemia
360194|NCT01251965|AML
360195|NCT01251965|Acute lymphocytic leukemia
360196|NCT01251965|ALL
360197|NCT01251965|Ruxolitinib
360198|NCT01251965|Jakafi
360199|NCT01251965|INC424
360200|NCT01251965|INCB018424
360201|NCT01251926|Bevacizumab
360202|NCT01251926|Camptothecin
360203|NCT01251926|EZN-2208
360204|NCT01251926|Anti-Angiogenesis
360205|NCT01251926|Advanced Cancer
360206|NCT01251926|Cancer
360207|NCT01251926|Solid Tumor
360208|NCT01251913|Tissue Harvest
360209|NCT01251913|Hospice
360210|NCT01251913|Autopsy
360211|NCT01251913|Crainiotomy
360212|NCT01251913|Brain Tumor
360213|NCT01251913|Glioma
360214|NCT01251913|Astrocytoma
360215|NCT01251900|Triple Negative Disease
360216|NCT01251900|BRCA1
360217|NCT01251900|BRCA2
360218|NCT01251900|Hispanic/Latino
360219|NCT01251900|Breast Cancer
360220|NCT01251887|Lipids
360221|NCT01251887|Obesity
360222|NCT01251887|Omega-3 Fatty Acids
360223|NCT01251887|Overweight
360224|NCT01251848|Sitaxentan
360225|NCT01251848|ritonavir
360226|NCT01251848|drug interaction
360227|NCT01251848|pharmacokinetics
360228|NCT01251835|Sitaxsentan
360229|NCT01251835|Rifampin
360230|NCT01251835|Drug Interaction
360231|NCT01251835|Pharmacokinetics
360232|NCT01251809|Asparaginase
360233|NCT01251809|ALL
360234|NCT01251783|term babies
360235|NCT01251770|Hyponatremia
360236|NCT01251770|Water-Electrolyte Imbalance
360237|NCT01251757|diabetes
360238|NCT01251757|cardiovascular disease
360239|NCT01251757|randomized clinical trial
360240|NCT01251757|medication adherence
360241|NCT01251757|health information technology
360242|NCT01251757|adult
360243|NCT01251757|telephone calls
360244|NCT01251757|IVR
360245|NCT01251744|Pregnancy
360246|NCT01251744|Congenital
360247|NCT01251744|Cytomegalovirus infection
360248|NCT01251718|Donepezil hydrochloride
360249|NCT01251718|Alzheimer's Disease
360250|NCT01251705|Cornea
360251|NCT01251705|SL OCT
360252|NCT01251705|Spectral OCT Cornea modul
360253|NCT01251705|ultrasound pachymetry
360254|NCT01251705|Pentacam
360255|NCT01251692|Corneal erosions
360256|NCT01251692|PTK
360257|NCT01251679|handwashing
360258|NCT01251679|masks
360259|NCT01251679|infectious disease transmission
360260|NCT01251666|Colorectal cancer
360261|NCT01251666|Screening
360262|NCT01251666|Average-risk population
360263|NCT01251666|faecal occult blood tests
360264|NCT01251640|pancreatic cancer,
360265|NCT01251640|MEK-inhibitor
360266|NCT01251627|Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Decitabine
360267|NCT01251614|Randomized
360268|NCT01251614|Double-blind
360269|NCT01251614|Chronic plaque psoriasis
360270|NCT01251614|Pediatric
360271|NCT01251588|Cartilage legions,
360272|NCT01251588|Symptomatic focal cartilage defects,
360273|NCT01251588|Microfracture,
360274|NCT01251588|MACI,
360275|NCT01251588|Autologous chondrocyte,
360276|NCT01251588|Trochlea
360277|NCT01251549|ReWalk
360278|NCT01251549|Paraplegia
360279|NCT01251549|Spinal Cord Injuries (SCI)
360280|NCT01251536|colorectal cancer
360281|NCT01251536|K-Ras wildtype
360282|NCT01251536|first line metastatic
360283|NCT01251536|standard cetuximab + FOLFIRI
360284|NCT01251536|dose escalation cetuximab
360285|NCT01251523|Asthma
360286|NCT01251471|major depressive disorder
360287|NCT01251471|MDD
360288|NCT01251471|imaging genetics
360289|NCT01251471|pharmacoMRI
360290|NCT01251432|otitis media
360291|NCT01251432|Eustachian tube
360292|NCT01251432|allergy
360293|NCT01251432|gastroesophageal reflux
360294|NCT01251432|tympanostomy tube
360295|NCT01251419|Generic Medication
360296|NCT01251419|Brand Name Medication
360297|NCT01251419|Conversion Rates
360298|NCT01251419|Social Proximity
360299|NCT01251419|Behavioral Economics
360300|NCT01251406|Stable
360301|NCT01251406|Chronic Heart Failure
360302|NCT01251406|Systolic
360303|NCT01251393|Cocaine
360304|NCT01251393|crack
360305|NCT01251393|treatment
360306|NCT01251393|dependence
360307|NCT01251393|biperiden
360308|NCT01251341|inflammation
360309|NCT01251341|immune system
360310|NCT01251341|cytokines
360311|NCT01251341|meditation
360312|NCT01251341|compassion
360313|NCT01251341|attention
360314|NCT01251315|Glutathione
360315|NCT01251315|Antioxidant
360316|NCT01251315|Free radical
360317|NCT01251315|Oxidative stress
360318|NCT01251315|N-Acetyl Cysteine
360319|NCT01251315|Glutathione precursor
360320|NCT01251302|Coronary Artery Disease
360321|NCT01251302|Angina
360322|NCT01251302|Molecular Genetics
360323|NCT01251302|Atherosclerosis
360324|NCT01251263|headaches
360325|NCT01251263|migraines
360326|NCT01251263|breakthrough bleeding
360327|NCT01251263|breakthrough spotting
360328|NCT01251263|menstrually associated migraines
360329|NCT01251263|breakthrough bleeding or breakthrough spotting
360330|NCT01251224|asthma
360331|NCT01251224|mouse allergen
360332|NCT01251224|environmental intervention
360333|NCT01251211|BOTULINUM TOXIN
360334|NCT01251211|NEUROPATHIC PAIN
360335|NCT01251211|RANDOMIZED CONTROLLED TRIAL
360336|NCT01251185|Extracorporeal Shockwave Therapy
360337|NCT01251185|Heart Failure
360338|NCT01251185|Congestive Heart Failure
360339|NCT01251185|Non-invasive
360340|NCT01251185|Device Trial
360341|NCT01251185|NYHA (New York Heart Association)
360342|NCT01251185|Ischemic cardiomyopathy
360343|NCT01251185|Ischemia
360344|NCT01251185|Myocardial contractility
360345|NCT01251159|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
360346|NCT01251159|adult acute myeloid leukemia with del(5q)
360347|NCT01251159|adult acute myeloid leukemia with inv(16)(p13;q22)
360348|NCT01251159|adult acute myeloid leukemia with t(16;16)(p13;q22)
360349|NCT01251159|adult acute myeloid leukemia with t(8;21)(q22;q22)
360350|NCT01251159|untreated adult acute myeloid leukemia
360351|NCT01251159|adult acute minimally differentiated myeloid leukemia (M0)
360352|NCT01251159|adult acute myeloblastic leukemia with maturation (M2)
360353|NCT01251159|adult acute myeloblastic leukemia without maturation (M1)
360354|NCT01251159|adult acute myelomonocytic leukemia (M4)
360355|NCT01251159|adult acute monoblastic leukemia (M5a)
360356|NCT01251159|adult acute monocytic leukemia (M5b)
360357|NCT01251159|adult erythroleukemia (M6a)
360358|NCT01251159|adult pure erythroid leukemia (M6b)
360359|NCT01251159|adult acute megakaryoblastic leukemia (M7)
360360|NCT01251146|Hypertension
360361|NCT01251146|Bisoprolol
360362|NCT01251146|Atenolol
360363|NCT01251133|Communicable Diseases
360364|NCT01251133|Infection
360365|NCT01251133|Influenza
360366|NCT01251133|Orthomyxoviridae Infections
360367|NCT01251133|RNA Virus Infections
360368|NCT01251133|Virus Diseases
360369|NCT01251133|Respiratory Tract Infections
360370|NCT01251133|Respiratory Tract Diseases
360371|NCT01251107|Hodgkin lymphoma
360372|NCT01251107|ABVD
360373|NCT01251107|BEACOPP
360374|NCT01251107|Salvage high dose chemotherapy
360375|NCT01251094|Dementia
360376|NCT01251094|Parkinson's
360377|NCT01251094|impairment
360378|NCT01251094|Dementia Registry for Parkinson's Disease
360379|NCT01251081|high volume hemofiltration
360380|NCT01251081|sepsis
360381|NCT01251081|acute kidney injury
360382|NCT01251081|survival
360383|NCT01251068|anemic preterms, cerebral oxygenation,somatic oxygenation, blood transfusion
360384|NCT01251055|N-methyl-D-aspartate receptor
360385|NCT01251055|glycine transporter
360386|NCT01251055|schizophrenia
360387|NCT01251016|Type 2 diabetes mellitus
360388|NCT01251016|Y-Roux gastric bypass
360389|NCT01251016|Gut hormones
360390|NCT01251016|Gene expression
360391|NCT01251016|Surgery
360392|NCT01251003|Traumatic Brain Injury
360393|NCT01251003|TBI
360394|NCT01251003|Pediatric
360395|NCT01251003|Chronic
360396|NCT01250990|Niacin
360397|NCT01250990|HDL
360398|NCT01250990|Reverse cholesterol transport
360399|NCT01250977|Non-treatment seeking smokers, reporting consumption of at least
360400|NCT01250977|10 cigarettes per day for at least the past 6 months
360401|NCT01250951|Iron Overload
360402|NCT01250951|hemotranfusion
360403|NCT01250951|deferasirox
360404|NCT01250951|ferritin
360405|NCT01250951|Rare anemia
360406|NCT01250951|Transfusional Iron Overload
360407|NCT01250938|autism
360408|NCT01250938|autism spectrum disorders
360409|NCT01250938|pervasive developmental disorders
360410|NCT01250938|intervention
360411|NCT01250938|low-income
360412|NCT01250938|underserved populations
360413|NCT01250938|underrepresented populations
360414|NCT01250925|Contact lens
360415|NCT01250925|Lens care
360416|NCT01250912|Ablation
360417|NCT01250912|Arrythmia
360418|NCT01250912|Imaging
360419|NCT01250899|HIV
360420|NCT01250899|Vitamin D
360421|NCT01250899|HAART
360422|NCT01250860|Manual therapy
360423|NCT01250860|DoboMed exercise
360424|NCT01250860|Spirometric test
360425|NCT01250847|ARMS
360426|NCT01250847|Ultra High Risk
360427|NCT01250847|Quetiapine
360428|NCT01250847|Verbal memory
360429|NCT01250821|Infertility
360430|NCT01250821|Anovulation
360431|NCT01250821|Ovulation induction
360432|NCT01250795|Prevention
360433|NCT01250782|Glutamine, trauma patients, infections, mortality
360434|NCT01250769|dental
360435|NCT01250769|dentist
360436|NCT01250769|plaque
360437|NCT01250769|IP Cleaning
360438|NCT01250756|vaccine
360439|NCT01250756|pneumococcal conjugate
360440|NCT01250743|genotype 1
360441|NCT01250730|PK profile in Japanese healthy male volunteers
360442|NCT01250717|prostatectomy
360443|NCT01250717|docetaxel
360444|NCT01250704|Neuromyotonia, Isaac's syndrome; Peripheral nerve hyperexcitability; Myokymia; Potassium channelopathy
360445|NCT01250691|pneumonia
360446|NCT01250691|ICU
360447|NCT01250691|isolation room
360448|NCT01250691|clinical epidemiology
360449|NCT01250691|infection control
360450|NCT01250678|multiple sclerosis
360451|NCT01250678|cognitive impairment
360452|NCT01250678|natalizumab
360453|NCT01250678|SDMT
360454|NCT01250665|multiple sclerosis
360455|NCT01250665|cognitive impairment
360456|NCT01250665|interferon-beta 1b
360457|NCT01250665|corpus callosum index
360458|NCT01250652|Chronic urticaria
360459|NCT01250652|Urticaria
360460|NCT01250652|Antihistamine
360461|NCT01250639|Type 2 Diabetes Mellitus
360462|NCT01250639|non-aboriginal Taiwanese
360463|NCT01250639|Genome-wide association study
360464|NCT01250626|Inulin
360465|NCT01250626|childhood GFR formula
360466|NCT01250587|Open label
360467|NCT01250587|dose-finding Phase 1 study
360468|NCT01250574|CD64
360469|NCT01250574|Procalcitonin
360470|NCT01250561|gabapentin
360471|NCT01250561|valacyclovir
360472|NCT01250561|phn
360473|NCT01250561|shingles
360474|NCT01250548|Rheumatoid arthritis
360475|NCT01250548|RA
360476|NCT01250548|Active rheumatoid arthritis
360477|NCT01250535|Drug drug interactions
360478|NCT01250535|Warfarin
360479|NCT01250535|Anticoagulants
360480|NCT01250535|Lovastatin
360481|NCT01250535|Statins
360482|NCT01250535|CYP4F2
360483|NCT01250535|Vitamin K
360484|NCT01250509|Obesity
360485|NCT01250509|Mindfulness based stress reduction
360486|NCT01250509|Mindful eating
360487|NCT01250509|Stress
360488|NCT01250509|Overnutrition
360489|NCT01250509|Nutrition Disorders
360490|NCT01250509|Overweight
360491|NCT01250509|Body Weight
360492|NCT01250509|Signs and Symptoms
360493|NCT01250496|regadenoson
360494|NCT01250496|lexiscan
360495|NCT01250496|aminophylline
360496|NCT01250496|SPECT
360497|NCT01250496|Myocardial Perfusion Imaging
360498|NCT01250496|pharmacologic stress test
360499|NCT01250483|prostate
360500|NCT01250483|prostate-specific antigen
360501|NCT01250483|benign prostatic hyperplasia
360502|NCT01250483|adrenergic alpha-Antagonists
360503|NCT01250444|Inspiratory Muscle Training
360504|NCT01250444|Hypertension
360505|NCT01250444|Breathing Exercises
360506|NCT01250444|Cardiac Rehabilitation
360507|NCT01250418|Bispectral Index
360508|NCT01250418|Ketamine
360509|NCT01250392|Active choice
360510|NCT01250392|Nurse visits
360511|NCT01250392|Behavioral economics
360512|NCT01250366|Safety and Pharmacokinetics
360513|NCT01250353|ocular surface reconstruction
360514|NCT01250353|conjunctival healing
360515|NCT01250353|pterygium
360516|NCT01250353|latex biomembrane
360517|NCT01250353|pterygium surgery
360518|NCT01250340|Diabetes
360519|NCT01250340|Isoprostanes
360520|NCT01250340|Thromboxane
360521|NCT01250340|Aspirin
360522|NCT01250327|right ventricular outflow tract
360523|NCT01250327|endovascular valve insertion
360524|NCT01250327|economic evaluation
360525|NCT01250327|valved stent
360526|NCT01250314|osteoporosis
360527|NCT01250314|men
360528|NCT01250314|bone micro-architecture
360529|NCT01250314|bone markers
360530|NCT01250301|Smoking Cessation
360531|NCT01250301|Tobacco Dependence
360532|NCT01250301|De-nicotinised cigarettes
360533|NCT01250288|Health Information Technology
360534|NCT01250288|Health Records, Personal
360535|NCT01250288|Hospital Information Systems
360536|NCT01250288|Patient Access to Records
360537|NCT01250288|Medical Records
360538|NCT01250288|Medical Record Systems, Computerized
360539|NCT01250275|Canola Oil
360540|NCT01250275|Peripheral Arterial Disease
360541|NCT01250275|Peripheral Vascular Disease
360542|NCT01250275|PAD
360543|NCT01250262|low back pain
360544|NCT01250262|obese
360545|NCT01250262|fear avoidance
360546|NCT01250262|disability and low back pain
360547|NCT01250262|chronic low back pain in obese older adults
360548|NCT01250249|To compare Safety and Reactogenecity of BCG vaccine of Green Signal Biopharma Private Limited with BCG vaccine of serum institute of India limited
360549|NCT01250236|brimonidine
360550|NCT01250236|alpha-2 adrenoceptor
360551|NCT01250236|cornea
360552|NCT01250236|corneal thickness
360553|NCT01250223|Lymphoma, Follicular
360554|NCT01250223|Prognosis
360555|NCT01250223|Progression-Free Survival
360556|NCT01250223|Outcome
360557|NCT01250223|International Cooperation
360558|NCT01250223|Data Collection
360559|NCT01250223|Prospective studies
360560|NCT01250223|Rare Diseases
360561|NCT01250210|contraception
360562|NCT01250210|pregnancy prevention
360563|NCT01250197|Normal Volunteers
360564|NCT01250184|Myofascial pain
360565|NCT01250184|Trigger points.
360566|NCT01250184|Lidocaine injection.
360567|NCT01250184|Physical therapy
360568|NCT01250171|Dry eye
360569|NCT01250171|IL17/ IL-1β
360570|NCT01250171|Biologic
360571|NCT01250158|Liver Percutaneous Isolated Localized Perfusion
360572|NCT01250158|PILP
360573|NCT01250158|Isolated Hepatic Perfusion
360574|NCT01250158|IHP
360575|NCT01250158|Liver metastases
360576|NCT01250158|Unresectable liver metastases of different etiologies
360577|NCT01250132|Traumatic brain injury
360578|NCT01250132|Paediatrics
360579|NCT01250132|Hypopituitarism
360580|NCT01250106|probiotics
360581|NCT01250106|prevention
360582|NCT01250106|dietary intervention
360583|NCT01250106|insulin resistance
360584|NCT01250106|obesity
360585|NCT01250106|type 2 diabetes
360586|NCT01250015|colorectal cancer
360587|NCT01250015|consent
360588|NCT01250015|screening
360589|NCT01250002|Pain
360590|NCT01250002|MQOR 40
360591|NCT01250002|Lidocaine
360592|NCT01250002|Gynecologic
360593|NCT01250002|Surgery
360594|NCT01250002|Laparoscopic
360595|NCT01249989|Physical Activity
360596|NCT01249989|Sedentary Lifestyle
360597|NCT01249989|Diet
360598|NCT01249989|Health Behavior
360599|NCT01249976|blood culture
360600|NCT01249976|central venous catheter
360601|NCT01249976|acridine orange leucocyte cytospin test
360602|NCT01249976|semi-quantitative skin culture
360603|NCT01249963|acute pancreatitis
360604|NCT01249963|enteral nutrition
360605|NCT01249963|nutritional status
360606|NCT01249963|pancreas
360607|NCT01249963|T-Diet plus Atémpero
360608|NCT01249950|Morbid obesity
360609|NCT01249950|teenagers
360610|NCT01249950|co-morbidities
360611|NCT01249950|bariatric surgery
360612|NCT01249950|epidemiology
360613|NCT01249937|Macular Degeneration
360614|NCT01249937|Age-related macular degeneration
360615|NCT01249937|Anti-inflammatory
360616|NCT01249937|Anti-vascular endothelial growth factor (Anti-VEGF)
360617|NCT01249937|Lucentis
360618|NCT01249937|Ranibizumab
360619|NCT01249937|Kenalog
360620|NCT01249937|Triamcinolone Acetonide
360621|NCT01249937|Vision loss
360622|NCT01249924|Obstructive sleep apnea (OSA), continuous positive airway pressure(CPAP), surgery, anesthesia
360623|NCT01249911|Infants
360624|NCT01249898|Fracture in the Scaphoid fractures
360625|NCT01249885|pacifier sucking
360626|NCT01249885|children
360627|NCT01249885|occlusion
360628|NCT01249885|drooling
360629|NCT01249872|open gastric by-pass
360630|NCT01249872|super morbidly obese patients
360631|NCT01249872|postoperative thoracic epidural analgesia
360632|NCT01249872|different drug regimens (morphine and levobupivacaine)
360633|NCT01249872|Lung function tests
360634|NCT01249872|Postoperative Bowel recovery
360635|NCT01249872|Postoperative Ambulation
360636|NCT01249859|stomach disease
360637|NCT01249859|signet ring cell carcinoma
360638|NCT01249859|chemotherapy
360639|NCT01249859|Prognostic
360640|NCT01249833|Influenza
360641|NCT01249833|Cognition
360642|NCT01249833|Attention
360643|NCT01249833|Simple Reaction Time
360644|NCT01249833|Alertness
360645|NCT01249833|Calmness
360646|NCT01249833|Contentment
360647|NCT01249833|Mood
360648|NCT01249820|anidulafungin
360649|NCT01249820|antifungal prophylaxis
360650|NCT01249820|allogeneic haematopoietic stem cell transplant
360651|NCT01249820|myeloablative chemotherapy
360652|NCT01249820|AML-MDS
360653|NCT01249820|pharmacokinetics
360654|NCT01249807|Cancer Screening
360655|NCT01249807|health service utilization model
360656|NCT01249807|quality of health life
360657|NCT01249794|NIV
360658|NCT01249794|non invasive ventilation
360659|NCT01249794|cardiac surgery
360660|NCT01249794|continuous positive airway pressure
360661|NCT01249768|Prospective study
360662|NCT01249768|diagnostic accuracy
360663|NCT01249768|CSF
360664|NCT01249768|MRI
360665|NCT01249742|diabetes mellitus
360666|NCT01249742|adolescent
360667|NCT01249742|online intervention
360668|NCT01249742|psychosocial
360669|NCT01249742|quality of life
360670|NCT01249729|Magnetic Resonance Imaging, 3D reconstructed image
360671|NCT01249716|follow-up home visit
360672|NCT01249716|Geriatric Disorder
360673|NCT01249716|rehabilitation
360674|NCT01249690|Bortezomib,Thalidomide,bone metabolites
360675|NCT01249677|type 2 diabetes
360676|NCT01249677|first phase insulin secretion
360677|NCT01249677|beta-cell rest
360678|NCT01249677|basal insulin
360679|NCT01249664|sham-controlled
360680|NCT01249664|pathologic myopia
360681|NCT01249664|mCNV
360682|NCT01249664|choroidal neovascularization
360683|NCT01249664|intravitreal injection
360684|NCT01249664|vision loss
360685|NCT01249664|macular damage
360686|NCT01249651|Patients, Single
360687|NCT01249638|Bevacizumab
360688|NCT01249638|Capecitabine
360689|NCT01249638|Irinotecan
360690|NCT01249638|mCRC
360691|NCT01249625|Influenza
360692|NCT01249625|H1N1
360693|NCT01249625|Respiratory protection
360694|NCT01249625|N95 respirator
360695|NCT01249625|Medical mask
360696|NCT01249625|Personal protective equipment
360697|NCT01249625|Facial protective equipment
360698|NCT01249625|Pandemic planning
360699|NCT01249612|Knee joint icing
360700|NCT01249612|knee-extension strength
360701|NCT01249599|Takotsubo Syndrome
360702|NCT01249599|apical balooning syndrome
360703|NCT01249599|stress-cardiomyopathy
360704|NCT01249599|endothelial function
360705|NCT01249599|sympathetic nervous activity
360706|NCT01249599|platelet adhesion
360707|NCT01249599|arterial compliance
360708|NCT01249573|fascia therapy
360709|NCT01249573|transcutaneous fibrolysis
360710|NCT01249573|acute ankle distortion
360711|NCT01249495|leg ulcer
360712|NCT01249495|wound therapy
360713|NCT01249495|Pro-inflammatory interleukins
360714|NCT01249482|Helicobacter pylori
360715|NCT01249482|reflux
360716|NCT01249482|acid rebound
360717|NCT01249391|Hand
360718|NCT01249391|osteoarthritis
360719|NCT01249391|splint
360720|NCT01249391|pain
360721|NCT01249391|deformity
360722|NCT01249391|function
360723|NCT01249378|Nutrition
360724|NCT01249378|Lipid
360725|NCT01249378|Digestion
360726|NCT01249378|Endotoxemia
360727|NCT01249378|Inflammation
360728|NCT01249378|Metabolism
360729|NCT01249378|Stable Isotope
360730|NCT01249378|Obesity
360731|NCT01249365|medically significant conditions
360732|NCT01249365|cervical neoplasia
360733|NCT01249365|serious adverse events (SAEs)
360734|NCT01249365|HPV vaccine
360735|NCT01249352|Esophageal Cancer
360736|NCT01249352|Nimotuzumab
360737|NCT01249352|EF024
360738|NCT01249352|EF024-201
360739|NCT01249339|smokeless tobacco
360740|NCT01249339|Nicotine
360741|NCT01249339|Cadmium
360742|NCT01249339|lead
360743|NCT01249339|Tobacco Specific Nitrosamines
360744|NCT01249326|Morbid obesity,
360745|NCT01249326|Bariatric surgery, by-pass, sleeve gastrectomy,
360746|NCT01249326|Nitrogen balance,
360747|NCT01249326|Protein requirement,
360748|NCT01249326|Weight loss
360749|NCT01249326|Muscle wasting, muscle disability
360750|NCT01249313|Risk
360751|NCT01249313|outcome
360752|NCT01249300|Dysphagia caused by cerebral vascular accidents
360753|NCT01249287|stroke
360754|NCT01249287|stem cell
360755|NCT01249274|cocaine abuse
360756|NCT01249274|cocaine dependence
360757|NCT01249274|postpartum period
360758|NCT01249261|Postmenopausal Women
360759|NCT01249261|Osteoporosis
360760|NCT01249248|Heart rate variability
360761|NCT01249248|Autonomic dysfunction
360762|NCT01249248|Exercise
360763|NCT01249248|Sports
360764|NCT01249248|Competition
360765|NCT01249248|Athletes
360766|NCT01249209|obesity
360767|NCT01249209|adults
360768|NCT01249209|lifestyle intervention
360769|NCT01249209|effect after two years treatment for lifestyle change - morbid obesity adults
360770|NCT01249183|Diphtheria
360771|NCT01249183|Tetanus
360772|NCT01249183|Pertussis (acellular, component)
360773|NCT01249183|Diphteria
360774|NCT01249183|Biological / vaccine
360775|NCT01249170|Communication skills
360776|NCT01249157|MRI
360777|NCT01249157|PEM
360778|NCT01249157|10-189
360779|NCT01249144|Intraocular Lens (IOL)
360780|NCT01249144|Quarter Diopter
360781|NCT01249144|Biaspheric
360782|NCT01249105|MK-2206
360783|NCT01249105|GBM
360784|NCT01249092|biliary cirrhosis
360785|NCT01249066|AMP-activated protein kinase
360786|NCT01249066|lung adenocarcinomas
360787|NCT01249066|Prognosis
360788|NCT01249066|Observation study
360789|NCT01249053|OPA1
360790|NCT01249053|lung adenocarcinomas
360791|NCT01249053|Prognosis
360792|NCT01249053|Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma
360793|NCT01249040|Frozen shoulder
360794|NCT01249040|pain scale
360795|NCT01249040|range of motion(ROM)
360796|NCT01249040|muscle strength
360797|NCT01249040|shoulder arthrography
360798|NCT01249027|Drug eluting stents
360799|NCT01249027|Stents
360800|NCT01249027|China
360801|NCT01249027|DES
360802|NCT01249027|XIENCE V EECSS
360803|NCT01249001|pediatrics
360804|NCT01249001|nausea
360805|NCT01249001|vomiting
360806|NCT01249001|chemotherapy
360807|NCT01249001|antiemetic
360808|NCT01248988|Pneumococcal vaccine
360809|NCT01248988|Safety
360810|NCT01248988|Synflorix
360811|NCT01248988|Pneumococcal diseases
360812|NCT01248975|asthma
360813|NCT01248975|GSK2190915
360814|NCT01248962|BEVACIZUMAB (AVASTIN)
360815|NCT01248962|CARBOPLATIN
360816|NCT01248962|DEXAMETHASONE
360817|NCT01248962|GEMCITABINE
360818|NCT01248962|LIPODOX(LIPOSOMAL DOXORUBICIN)
360819|NCT01248962|MONTELUKAST (SINGULAR)
360820|NCT01248962|TAXOL (PACLITAXEL
360821|NCT01248962|Fallopian Tubes
360822|NCT01248962|10-184
360823|NCT01248949|Advanced solid tumors
360824|NCT01248949|Advanced recurrent ovarian tumors
360825|NCT01248949|MEDI3617
360826|NCT01248949|Ang2
360827|NCT01248949|Ovarian cancer
360828|NCT01248949|Malignant glioma
360829|NCT01248923|relapsed multiple myeloma
360830|NCT01248923|plasma cell dyscrasia
360831|NCT01248923|plasmacytoma
360832|NCT01248923|kinesin spindle protein
360833|NCT01248923|anti-mitotic
360834|NCT01248884|combination vaccine
360835|NCT01248884|Primary vaccination
360836|NCT01248871|renal
360837|NCT01248871|transplantation
360838|NCT01248871|Volatile
360839|NCT01248871|anesthetic
360840|NCT01248845|Mechanical ventilation
360841|NCT01248845|Electrical diaphragmatic activity
360842|NCT01248832|tobacco cessation
360843|NCT01248832|smoking cessation
360844|NCT01248832|telephone
360845|NCT01248832|self-help
360846|NCT01248832|smoking abstinence
360847|NCT01248832|tobacco use disorder
360848|NCT01248832|disparity
360849|NCT01248819|Laparoscopic Cholecystectomy
360850|NCT01248819|Nebulization
360851|NCT01248819|Ropivacaine
360852|NCT01248806|Lung nodule
360853|NCT01248806|Screening
360854|NCT01248806|Spiral low - dose computed tomography
360855|NCT01248806|Lung cancer
360856|NCT01248793|Ankylosing Sponylitis, injection, golimumab, simponi
360857|NCT01248780|Rheumatoid Arthritis
360858|NCT01248780|injection
360859|NCT01248780|golimumab
360860|NCT01248780|simponi
360861|NCT01248767|Pathological gambling
360862|NCT01248767|"at risk gambling"
360863|NCT01248767|cohort
360864|NCT01248767|cognitive distortions
360865|NCT01248767|impulsivity
360866|NCT01248767|psychiatric comorbidities
360867|NCT01248767|gambling trajectory
360868|NCT01248767|gambling practice evolution
360869|NCT01248767|addiction
360870|NCT01248754|Neurosurgery
360871|NCT01248754|Neuronavigation
360872|NCT01248754|Positron emission tomography
360873|NCT01248754|FDOPA
360874|NCT01248741|prostate cancer
360875|NCT01248741|interstitial radiation,
360876|NCT01248741|brachytherapy
360877|NCT01248728|Autism Spectrum Disorder
360878|NCT01248728|Clinical Trial
360879|NCT01248728|Omega-3 Fatty Acids
360880|NCT01248728|Toddlers
360881|NCT01248715|pneumonia, bacterial
360882|NCT01248715|pneumonia, viral
360883|NCT01248715|respiratory tract infections
360884|NCT01248715|oseltamivir, therapeutic use
360885|NCT01248702|Myocardial Infarction
360886|NCT01248702|Heart Failure
360887|NCT01248702|Sudden Cardiac Death
360888|NCT01248702|Critical Pathways
360889|NCT01248676|cancer radiation patient education
360890|NCT01248663|pancreatic cancer
360891|NCT01248663|pylorus-preserving pancreaticoduodenectomy
360892|NCT01248663|delayed gastric emptying
360893|NCT01248663|reconstruction
360894|NCT01248650|Safety evaluation
360895|NCT01248650|Pharmacokinetic analysis
360896|NCT01248637|pancreas
360897|NCT01248637|pancreatic cancer
360898|NCT01248637|pancreatic tumor
360899|NCT01248637|pimonidazole
360900|NCT01248637|hypoxia
360901|NCT01248637|whipple's resection
360902|NCT01248624|Palliative Care
360903|NCT01248624|Quality of Life
360904|NCT01248624|Satisfaction with Care
360905|NCT01248611|pain
360906|NCT01248611|adverse effects
360907|NCT01248611|safety
360908|NCT01248611|feasibility
360909|NCT01248585|Symptom Control
360910|NCT01248572|Cataract
360911|NCT01248572|Biaspheric intraocular lens
360912|NCT01248572|Uniplanar intraocular lens
360913|NCT01248572|Effective lens position
360914|NCT01248546|Breast cancer
360915|NCT01248546|Computer-aided detection
360916|NCT01248546|Mammography screening
360917|NCT01248546|Digital breast tomosynthesis
360918|NCT01248533|Abdominal aortic aneurysm, atherosclerosis
360919|NCT01248520|Pregnancy
360920|NCT01248520|Influenza Vaccination
360921|NCT01248507|COPD
360922|NCT01248481|Acarbose/Glucobay®
360923|NCT01248481|Basal insulin
360924|NCT01248481|PPG (Postprandial Glycaemia)
360925|NCT01248468|Pain, Migraine
360926|NCT01248455|Monoclonal Antibody
360927|NCT01248455|NK Cell Mediated Killing
360928|NCT01248455|Response Rate
360929|NCT01248455|Pharmacokinetics
360930|NCT01248455|Biological Activity
360931|NCT01248455|Smoldering Multiple Myeloma
360932|NCT01248455|SMM
360933|NCT01248442|Vitamin D Deficiency
360934|NCT01248442|Autoimmune disease
360935|NCT01248442|Diabetes
360936|NCT01248429|thyrosine kinase inhibitor
360937|NCT01248429|phosphokinase creatinin
360938|NCT01248429|myalgia
360939|NCT01248416|Aromatase
360940|NCT01248416|Growth
360941|NCT01248416|Letrozole
360942|NCT01248416|Anastrozole
360943|NCT01248416|GH
360944|NCT01248416|Children
360945|NCT01248416|Puberty
360946|NCT01248403|RAD001
360947|NCT01248403|Paclitaxel
360948|NCT01248403|gastric cancer
360949|NCT01248403|advanced gastric or esophagogastric junction cancer
360950|NCT01248390|traumatic brain injury
360951|NCT01248390|post-concussion
360952|NCT01248377|Cephalosporins
360953|NCT01248377|Drug hypersensitivity
360954|NCT01248351|aspirin, clopidogrel, pharmacodynamics, platelet transfusion
360955|NCT01248299|Chemotherapy
360956|NCT01248299|Best Supportive Care
360957|NCT01248286|Diabetes
360958|NCT01248286|Prediabetes
360959|NCT01248286|Prevention
360960|NCT01248286|Whole grain
360961|NCT01248286|Advanced glycation end products
360962|NCT01248286|Insulin sensitivity
360963|NCT01248273|GLOBO H-KLH CONJUGATE
360964|NCT01248273|MUC-1 KLH
360965|NCT01248273|QS-21
360966|NCT01248273|TF(C)-KLH
360967|NCT01248273|TN(C)-KLH
360968|NCT01248273|Immunization
360969|NCT01248273|Vaccine
360970|NCT01248273|09-184
360971|NCT01248260|Fetal body size
360972|NCT01248260|Fetal brain size
360973|NCT01248260|Folic acid
360974|NCT01248247|Non small cell lung cancer
360975|NCT01248247|Biopsy accessible tumor
360976|NCT01248247|Stage IIIB non small cell lung cancer
360977|NCT01248247|Stage IV non small cell lung cancer
360978|NCT01248234|elderly
360979|NCT01248234|hypertensive
360980|NCT01248234|anesthesia
360981|NCT01248221|Breath test
360982|NCT01248221|Dyspepsia
360983|NCT01248221|Gastric Emptying
360984|NCT01248221|Gastroparesis
360985|NCT01248208|egg allergy
360986|NCT01248208|influenza vaccine
360987|NCT01248195|Schizophrenia
360988|NCT01248195|Schizophreniform disorder
360989|NCT01248195|Schizoaffective disorder
360990|NCT01248195|Imaging
360991|NCT01248195|Prognosis
360992|NCT01248195|Treatment guidelines
360993|NCT01248195|Pharmacogenetics
360994|NCT01248182|acetabular fracture
360995|NCT01248182|pelvic ring injury
360996|NCT01248143|Green Tea
360997|NCT01248143|Fermented papaya preparation
360998|NCT01248143|Diabetes
360999|NCT01248143|Cardiovascular diseases
361000|NCT01248143|Atherosclerotic plaques
361001|NCT01248143|Glucose
361002|NCT01248143|Dietary supplements and functional foods
361003|NCT01248130|Omega-3 Fatty Acid
361004|NCT01248130|Autism Spectrum Disorders
361005|NCT01248130|Pervasive Developmental Disorders
361006|NCT01248130|Children
361007|NCT01248130|Cognitive Functioning
361008|NCT01248117|PCV
361009|NCT01248117|polypoidal
361010|NCT01248117|choroidal
361011|NCT01248117|vasculopathy
361012|NCT01248104|Cardiac Surgery
361013|NCT01248104|Antifibrinolytic agents
361014|NCT01248104|Blood transfusion
361015|NCT01248104|epsilon aminocaproic acid
361016|NCT01248104|tranexamic acid
361017|NCT01248091|IUD, Insertion, Decrease, Pain
361018|NCT01248078|elective cesarean section
361019|NCT01248078|antibiotic prophylaxis
361020|NCT01248078|cefazoline
361021|NCT01248078|wound infection
361022|NCT01248065|Asthma
361023|NCT01248065|Vitamin D
361024|NCT01248065|Corticosteroids
361025|NCT01248065|Treatment failure
361026|NCT01248039|Muscle strength, functional performance, joint replacement
361027|NCT01248026|Cardiovascular disease
361028|NCT01248026|Buttermilk
361029|NCT01248026|Blood lipids
361030|NCT01248026|Cholesterol absorption
361031|NCT01248026|Cholesterol synthesis
361032|NCT01248000|Hodgkin lymphoma
361033|NCT01248000|FDG-PET
361034|NCT01248000|prognostic factor
361035|NCT01248000|clinical trial
361036|NCT01247987|IVF, assisted reproduction, embryo transfer
361037|NCT01247974|Coronary Artery Bypass Grafting
361038|NCT01247974|New Onset Postoperative Atrial Fibrillation
361039|NCT01247948|pedicle screw of fixation operation
361040|NCT01247948|spine surgery
361041|NCT01247948|navigation assisted
361042|NCT01247935|Pain
361043|NCT01247935|Acupuncture
361044|NCT01247935|Transcutaneous electrical nerve stimulation
361045|NCT01247935|Colonoscopy
361046|NCT01247922|Pediatric Ependymoma
361047|NCT01247922|Ependymoma
361048|NCT01247922|Erlotinib
361049|NCT01247922|Tarceva
361050|NCT01247883|Phase 1
361051|NCT01247883|relative bioavailability
361052|NCT01247883|healthy volunteers
361053|NCT01247883|pharmacokinetics
361054|NCT01247883|solution
361055|NCT01247883|tablet
361056|NCT01247870|Chronic obstructive pulmonary disease, COPD, metformin
361057|NCT01247857|Laparoscopic Cholecystectomy
361058|NCT01247857|Nebulization
361059|NCT01247857|Ropivacaine
361060|NCT01247844|adult Males
361061|NCT01247844|circumcision
361062|NCT01247844|HIV prevention
361063|NCT01247844|device
361064|NCT01247831|glaucoma, selective laser trabeculoplasty, ocular rigidity
361065|NCT01247805|Bioequivalence
361066|NCT01247805|Powder for oral suspention
361067|NCT01247792|sepsis
361068|NCT01247792|organ failure
361069|NCT01247792|end-of-life decisions
361070|NCT01247792|patient-centered communication
361071|NCT01247779|gynecology
361072|NCT01247779|oncology
361073|NCT01247779|coelioscopy
361074|NCT01247779|robot
361075|NCT01247779|morbidity
361076|NCT01247727|Heart rate variability
361077|NCT01247727|extracorporeal membrane oxygenation
361078|NCT01247714|T-Diet plus Diabet NP
361079|NCT01247714|Diabetic
361080|NCT01247714|Enteral Nutrition
361081|NCT01247714|Glycaemic response
361082|NCT01247714|Metabolic Syndrome
361083|NCT01247714|Insulin resistance
361084|NCT01247714|Lipidic profile
361085|NCT01247701|UCB
361086|NCT01247701|Umbilical Cord Blood
361087|NCT01247701|Transplant
361088|NCT01247701|Umbilical Cord Blood Transplant
361089|NCT01247701|Cord Blood Stem Cell Transplantation
361090|NCT01247701|Pediatric
361091|NCT01247701|Myeloid Hematological Malignancies
361092|NCT01247701|Busulfan
361093|NCT01247701|Cytoxan
361094|NCT01247701|Cyclophosphamide
361095|NCT01247701|Fludarabine
361096|NCT01247688|Lymphoid
361097|NCT01247688|hematologic malignancy
361098|NCT01247688|UCB
361099|NCT01247688|Umbilical Cord Blood Transplant
361100|NCT01247688|Total Body Irradiation
361101|NCT01247688|Cytoxan
361102|NCT01247688|Cyclophosphamide
361103|NCT01247688|Fludarabine
361104|NCT01247662|Autism spectrum disorder
361105|NCT01247662|Social Responsiveness Scale
361106|NCT01247662|Childhood Asperger's Syndrome Test
361107|NCT01247662|Adult Autism Spectrum Quotient
361108|NCT01247662|psychometric
361109|NCT01247649|Continuous glucose monitoring system
361110|NCT01247649|Non invasive
361111|NCT01247649|Type 1 diabetes
361112|NCT01247649|Dielectric spectroscopy
361113|NCT01247636|HLRQ
361114|NCT01247636|Elderly
361115|NCT01247636|Balance
361116|NCT01247636|Mobility
361117|NCT01247636|Fear of falling
361118|NCT01247623|Non-resectable, advanced malignant melanoma.
361119|NCT01247597|Thyroid Cancer
361120|NCT01247597|Germline DICER1 Mutation
361121|NCT01247597|MicroRNA Biogenesis
361122|NCT01247597|Pleuropulmonary Blastoma
361123|NCT01247597|PPB
361124|NCT01247584|childhood acute myeloid leukemia/other myeloid malignancies
361125|NCT01247584|childhood acute erythroleukemia (M6)
361126|NCT01247584|childhood acute megakaryocytic leukemia (M7)
361127|NCT01247584|childhood acute monoblastic leukemia (M5a)
361128|NCT01247584|childhood acute monocytic leukemia (M5b)
361129|NCT01247584|childhood acute myeloblastic leukemia without maturation (M1)
361130|NCT01247584|childhood acute myelomonocytic leukemia (M4)
361131|NCT01247584|childhood acute myeloblastic leukemia with maturation (M2)
361132|NCT01247558|Metanx®
361133|NCT01247558|diabetes
361134|NCT01247558|neuropathy
361135|NCT01247558|peripheral neurological disorder
361136|NCT01247558|peripheral circulation disorder
361137|NCT01247558|folic acid
361138|NCT01247558|folate
361139|NCT01247558|L-methylfolate
361140|NCT01247558|vitamin B6
361141|NCT01247558|Pyridoxal 5'-phosphate
361142|NCT01247558|vitamin B12
361143|NCT01247558|methylcobalamin
361144|NCT01247545|Remote ischemic preconditioning
361145|NCT01247545|Coronary artery bypass graft surgery
361146|NCT01247545|Cardioprotection
361147|NCT01247545|Clinical Outcomes
361148|NCT01247532|Cancer
361149|NCT01247532|Fatigue
361150|NCT01247532|Mindfulness
361151|NCT01247532|Meditation
361152|NCT01247532|Neoplasms
361153|NCT01247506|microRNA
361154|NCT01247493|fludarabine
361155|NCT01247493|AML
361156|NCT01247493|Efficacy
361157|NCT01247493|tolerability
361158|NCT01247454|CVD
361159|NCT01247454|primary prevention
361160|NCT01247454|ASA
361161|NCT01247454|physician behavioral change
361162|NCT01247454|Patient behavioral change
361163|NCT01247441|All breast cancer patients who were diagnosed or managed in NUH will be included into this registry
361164|NCT01247428|Coronary Artery Disease
361165|NCT01247428|Drug-eluting Stent
361166|NCT01247428|Sirolimus
361167|NCT01247415|anaphylaxis
361168|NCT01247415|allergy
361169|NCT01247415|IgE mediated
361170|NCT01247415|ORS
361171|NCT01247415|oculorespiratory syndrome
361172|NCT01247415|Allergic-like reactions
361173|NCT01247415|H1N1
361174|NCT01247415|Arepanrix
361175|NCT01247402|peripheral arterial disease
361176|NCT01247402|in-stent restenosis
361177|NCT01247402|drug eluting balloon
361178|NCT01247389|laparoscopy
361179|NCT01247389|colon resection
361180|NCT01247389|incisional hernia
361181|NCT01247376|inflammation
361182|NCT01247376|arthroscopy
361183|NCT01247376|knee
361184|NCT01247376|microdialysis
361185|NCT01247363|Diabetes glucokinase safety
361186|NCT01247311|Vitamin D
361187|NCT01247311|pulse wave velocity
361188|NCT01247298|Hepatocellular Carcinoma, HCC, TACE, Radiation Induced Liver Disease (RILD), SBRT
361189|NCT01247285|Bioequivalence
361190|NCT01247285|Healthy Subjects
361191|NCT01247272|Bioequivalence
361192|NCT01247272|Healthy Subjects
361193|NCT01247259|allergic rhinitis
361194|NCT01247259|immunotherapy
361195|NCT01247259|sublingual
361196|NCT01247246|Oral Mucositis
361197|NCT01247246|Head and Neck
361198|NCT01247246|Head and Neck Neoplasms
361199|NCT01247246|Mucositis
361200|NCT01247246|Stomatitis
361201|NCT01247246|Neoplasms by Site
361202|NCT01247246|Neoplasms
361203|NCT01247246|Gastroenteritis
361204|NCT01247246|Gastrointestinal Diseases
361205|NCT01247246|Digestive System Diseases
361206|NCT01247246|Mouth Diseases
361207|NCT01247246|Stomatognathic Diseases
361208|NCT01247246|SCV-07
361209|NCT01247233|breast cancer
361210|NCT01247233|Accelerated Partial Breast Irradiation
361211|NCT01247233|invasive cancer
361212|NCT01247233|Hypofractionated Irradiation
361213|NCT01247233|Lumpectomy
361214|NCT01247220|Macular Edema
361215|NCT01247220|Branch retinal vein occlusion
361216|NCT01247220|Ranibizumab
361217|NCT01247207|Duchenne muscular dystrophy
361218|NCT01247207|Becker muscular dystrophy
361219|NCT01247207|Nonsense mutation
361220|NCT01247207|Premature stop codon
361221|NCT01247207|DMD
361222|NCT01247207|BMD
361223|NCT01247207|nmDBMD
361224|NCT01247207|DBMD
361225|NCT01247207|Ataluren
361226|NCT01247207|PTC124
361227|NCT01247194|hepatitis C
361228|NCT01247194|NS5A
361229|NCT01247194|HCV RNA
361230|NCT01247181|compliance
361231|NCT01247181|observance
361232|NCT01247181|mobile phone
361233|NCT01247181|SMS
361234|NCT01247181|text message
361235|NCT01247181|ARV
361236|NCT01247181|HAART
361237|NCT01247181|AIDS
361238|NCT01247168|Refractory
361239|NCT01247168|Solid tumors
361240|NCT01247168|Cancer
361241|NCT01245751|Shingles
361242|NCT01245751|Vaccine
361243|NCT01245712|Adenocarcinoma of the breast
361244|NCT01245712|Lumpectomy
361245|NCT01245712|Stage 0 breast cancer
361246|NCT01245712|Stage I breast cancer
361247|NCT01245712|Stage II breast cancer
361248|NCT01245712|Accelerated partial breast irradiation
361249|NCT01245712|APBI
361250|NCT01245699|Cardiac arrest, CPR, quality improvement
361251|NCT01245686|Diet interventions
361252|NCT01245686|Physical activity interventions
361253|NCT01245686|Medication adherence
361254|NCT01245686|Tailored interventions
361255|NCT01245673|Advanced Disease
361256|NCT01245673|MAGE-A3 Immunizations with Hiltonol
361257|NCT01245673|Vaccine-Primed Autologous T-Cells
361258|NCT01245673|Lenalidomide Maintenance
361259|NCT01245660|Phase 0
361260|NCT01245660|Bladder carcinoma
361261|NCT01245660|egf pathway
361262|NCT01245660|infiltrative bladder carcinoma
361263|NCT01245660|cystectomy
361264|NCT01245660|LAPATINIB
361265|NCT01245647|women
361266|NCT01245647|HIV
361267|NCT01245647|alcohol
361268|NCT01245647|medication
361269|NCT01245647|adherence
361270|NCT01245647|acceptability
361271|NCT01245621|palliative care
361272|NCT01245621|end of life care
361273|NCT01245621|quality of life
361274|NCT01245621|caregivers
361275|NCT01245608|Atorvastatin
361276|NCT01245608|Aspirin
361277|NCT01245608|nonalcoholic steatohepatitis
361278|NCT01245608|nonalcoholic fatty liver disease
361279|NCT01245608|antihypertensive agents
361280|NCT01245595|Acute Kidney Injury (AKI)
361281|NCT01245595|Cardiopulmonary bypass (CPB)
361282|NCT01247142|invasive pulmonary aspergillosis
361283|NCT01247142|exhaled breath condensate
361284|NCT01247129|Superficial inferior epigastric artery flap, delay phenomenon
361285|NCT01247103|healthy volunteers
361286|NCT01247103|safety
361287|NCT01247103|tolerability
361288|NCT01247090|hypertension
361289|NCT01247090|end stage renal disease
361290|NCT01247090|vasopressin
361291|NCT01247090|Arginine Vasopressin
361292|NCT01247090|AVP
361293|NCT01247090|Pitressin®
361294|NCT01247077|selenium
361295|NCT01247077|neuropsychological testing
361296|NCT01247077|autoantibodies
361297|NCT01247064|Bronchiolitis
361298|NCT01247064|Hypertonic Saline
361299|NCT01247051|priming
361300|NCT01247051|cardiac surgery
361301|NCT01247051|cardio pulmonary bypass
361302|NCT01247051|precoating
361303|NCT01246999|Influenza
361304|NCT01246999|A/California/7/2009-like (2009 H1N1)
361305|NCT01246999|A/Perth/16/2009-like (H3N2)
361306|NCT01246999|B/Brisbane/60/2008-like (B/Victoria lineage)
361307|NCT01246973|Oral Curcumin
361308|NCT01246973|Radiation Dermatitis
361309|NCT01246973|Breast Cancer Patients
361310|NCT01246960|cancer
361311|NCT01246960|stomach
361312|NCT01246960|esophagus
361313|NCT01246960|gastroesophageal
361314|NCT01246947|Moderate Tricuspid Valve Regurgitation
361315|NCT01246947|Tricuspid Valve Repair
361316|NCT01246947|Mitral Value Surgery
361317|NCT01246921|Vitiligo, repigmentation, satisfaction
361318|NCT01246908|TRD
361319|NCT01246895|Cartilage repair
361320|NCT01246895|Cartilage
361321|NCT01246895|Knee
361322|NCT01246895|Knee Injuries
361323|NCT01246895|Knee Pain
361324|NCT01246895|Microfracture
361325|NCT01246895|Bone Marrow Stimulation
361326|NCT01246895|Arthroscopy
361327|NCT01246882|Stroke, gait, walking, disability
361328|NCT01246882|wireless inertial sensing
361329|NCT01246882|mobile health
361330|NCT01246869|brain, cancer,glioblastoma multiforme, meningioma, glioma
361331|NCT01246856|Cardiotoxicity
361332|NCT01246856|Breast cancer treatment
361333|NCT01246856|MIBG scintigraphy
361334|NCT01246856|Strain Echocardiography
361335|NCT01246856|patients who have been treated with TAC one year previously
361336|NCT01246843|sunitinib
361337|NCT01246843|sorafenib
361338|NCT01246843|cognitive functioning
361339|NCT01246817|Carcinoma, Renal Cell
361340|NCT01246817|temsirolimus
361341|NCT01246817|FLT-PET
361342|NCT01246817|FDG-PET
361343|NCT01246817|Adult patients with metastatic RCC (any histology and any MSKCC prognostic score), with documented
361344|NCT01246817|progressive disease after more than two prior systemic treatments with any of the following: cytokines (±
361345|NCT01246817|chemotherapy), sunitinib, sorafenib, or bevacizumab (± IFN).
361346|NCT01246804|HIV infections
361347|NCT01246804|interaction
361348|NCT01246804|pharmacokinetics
361349|NCT01246791|NPC-01
361350|NCT01246791|Pharmacokinetics
361351|NCT01246791|Healthy female volunteer
361352|NCT01246791|Norethisterone
361353|NCT01246791|Ethinyl Estradiol
361354|NCT01246765|Atypical Antipsychotics and pregnancy
361355|NCT01246765|Pregnancy
361356|NCT01246765|Medication use during pregnancy
361357|NCT01246752|AML, Leukemia
361358|NCT01246752|Acute Myeloid Leukemia
361359|NCT01246752|HSCT
361360|NCT01246752|Stem Cell Transplantation
361361|NCT01246752|Tx
361362|NCT01246752|Chemotherapy
361363|NCT01246739|mild hypercortisolism
361364|NCT01246739|adrenal tumour
361365|NCT01246739|surgical procedures, elective
361366|NCT01246739|indication
361367|NCT01246726|cancer, breast, radiotherapy, boost
361368|NCT01246713|acetaminophen
361369|NCT01246713|excipients
361370|NCT01246700|Parkinson's disease
361371|NCT01246700|Randomized single-blind crossover trial
361372|NCT01246700|Sensory Attention Focused Exercise
361373|NCT01246674|function, hip muscle strength, hip replacement, hip pain,
361374|NCT01246609|acid base balance
361375|NCT01246609|Percutaneous Lithotripsy
361376|NCT01246583|Multi Site
361377|NCT01246583|Randomized
361378|NCT01246583|Placebo Controlled
361379|NCT01246583|Double Blind
361380|NCT01246583|Parallel Group
361381|NCT01246583|chronic plaque psoriasis
361382|NCT01246583|topical treatment
361383|NCT01246583|skin diseases
361384|NCT01246583|papulosquamous
361385|NCT01246570|exercise
361386|NCT01246570|heart
361387|NCT01246570|coronary disease
361388|NCT01246570|rehabilitation
361389|NCT01246557|Patients with Chronic Lymphatic Leukemia relapsing or resistant to treatment
361390|NCT01246544|Patient Safety
361391|NCT01246544|The Helsinki Declaration on Patient Safety in Anaesthesiology
361392|NCT01246544|Helsinki Declaration on Patient Safety
361393|NCT01246544|European Board of Anaesthesiology (EBA)
361394|NCT01246544|European Society of Anaesthesiology (ESA)
361395|NCT01246531|Urolithiasis
361396|NCT01246531|Renal calculi
361397|NCT01246531|Aging
361398|NCT01246531|Osteoporosis
361399|NCT01246518|distal subungual onychomycosis
361400|NCT01246466|Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation, Ablation, catheter ablation
361401|NCT01246427|Adjuvant hormonal therapy
361402|NCT01246427|Homeopathic treatment
361403|NCT01246427|Hot flashes
361404|NCT01246427|Quality of life
361405|NCT01246427|Hot flash score
361406|NCT01246414|Asthma
361407|NCT01246414|Exhaled breath condensates
361408|NCT01246414|Cytokines
361409|NCT01246388|Fibrosis
361410|NCT01246388|Steatosis
361411|NCT01246388|Liver biopsy
361412|NCT01246388|Elastography
361413|NCT01246388|MRI
361414|NCT01246349|Motivational Interviewing
361415|NCT01246349|Child and Adolescent Self-Efficacy
361416|NCT01246349|Health Behaviours
361417|NCT01246336|Parkinson's disease, Parkinsonism
361418|NCT01246336|Biomarkers
361419|NCT01246336|Exhaled breath
361420|NCT01246336|Nanothechnology
361421|NCT01246323|Visual analogue scale
361422|NCT01246323|pain level
361423|NCT01246323|analgesia
361424|NCT01246323|combined anesthesia
361425|NCT01246284|Alopecia areata
361426|NCT01246284|Intralesional
361427|NCT01246284|Triamcinolone acetonide
361428|NCT01246284|Concentration
361429|NCT01246258|primary ciliary dyskinesia
361430|NCT01246258|otolith
361431|NCT01246258|vestibular tests
361432|NCT01245530|Alzheimer disease
361433|NCT01246245|PIN SITE INFECTION AFTER EXTERNAL FIXATION
361434|NCT01246219|Idiopathic Short stature
361435|NCT01246219|Self Image
361436|NCT01246219|GH therapy
361437|NCT01246219|Psychological distress
361438|NCT01246206|● Non-Hodgkin lymphoma,
361439|NCT01246206|● Hodgkin disease,
361440|NCT01246206|● Acute Myelogenous or Acute Lymphocytic Leukemia
361441|NCT01246206|● Myelodysplastic Syndromes,
361442|NCT01246206|● Chronic Myelogenous Leukemia
361443|NCT01246206|● Multiple Myeloma
361444|NCT01246206|● Chronic Lymphocytic Leukemia
361445|NCT01246206|● Myelofibrosis and other myeloproliferative disorders;
361446|NCT01246193|CKD-828
361447|NCT01246193|Hypertension
361448|NCT01246193|Primary Hypertension
361449|NCT01246193|Healthy Volunteer
361450|NCT01246193|S-Amlodipine
361451|NCT01246193|Telmisartan
361452|NCT01246193|Amlodipine
361453|NCT01246193|Pharmacokinetic
361454|NCT01246193|Phase 1
361455|NCT01246180|Skin, microcirculation; ASIC, pressure ulcer
361456|NCT01246167|Proximal humerus fracture
361457|NCT01246167|conservative
361458|NCT01246167|locking plate
361459|NCT01246167|Philos
361460|NCT01246167|Hemiprosthesis
361461|NCT01246154|ASTHMA
361462|NCT01246141|tricuspid valve regurgitation
361463|NCT01246141|replacement
361464|NCT01246141|repair
361465|NCT01246141|outcomes
361466|NCT01246128|Nicotinic Acetylcholine Receptors
361467|NCT01246128|Schizophrenia Smokers
361468|NCT01246128|PET Imaging
361469|NCT01246102|Targeted Therapy
361470|NCT01246102|HER2 Positive Cancer
361471|NCT01246102|Cancer
361472|NCT01246102|Solid Tumor
361473|NCT01246102|Breast Cancer
361474|NCT01246089|Ranibizumab
361475|NCT01246089|Myopia
361476|NCT01246089|Complications
361477|NCT01246089|Neovascularization
361478|NCT01246089|OCT
361479|NCT01246050|Heart Failure
361480|NCT01246050|Outcome Assessment
361481|NCT01246050|Congestive Heart Failure
361482|NCT01246037|Pulmonary Arterial Hypertension
361483|NCT01246037|Beta-blocker
361484|NCT01246037|Adrenergic Receptor Antagonist
361485|NCT01245998|Thrombophlebitis
361486|NCT01245998|Venous thrombosis
361487|NCT01245998|Pulmonary embolism
361488|NCT01245998|Anticoagulants
361489|NCT01245998|Low-Molecular-Weight Heparin
361490|NCT01245985|SCCHN
361491|NCT01245985|squamous cell carcinoma of the head and neck
361492|NCT01245985|oropharyngeal carcinoma
361493|NCT01245985|hypopharyngeal carcinoma
361494|NCT01245985|laryngeal carcinoma
361495|NCT01245972|pulsed dye laser
361496|NCT01245972|PDL
361497|NCT01245972|basal cell carcinoma
361498|NCT01245972|squamous cell carcinoma
361499|NCT01245972|BCC
361500|NCT01245972|SCC
361501|NCT01245972|594nM laser
361502|NCT01245959|Nasopharyngeal carcinoma
361503|NCT01245959|Concurrent chemoradiotherapy
361504|NCT01245959|Induction chemotherapy
361505|NCT01245959|Clinical trial
361506|NCT01245946|Acne moderate
361507|NCT01245946|Photodynamic Therapy
361508|NCT01245946|Topical retinoids
361509|NCT01245946|Antimicrobial agents
361510|NCT01245933|COPD
361511|NCT01245933|register
361512|NCT01245933|comorbidities
361513|NCT01245933|systemic inflammation
361514|NCT01245920|Dental implant
361515|NCT01245920|Alveolar bone
361516|NCT01245920|Clinical attachment Level
361517|NCT01245907|Hot flashes
361518|NCT01245907|Menopause
361519|NCT01245907|HRQoL
361520|NCT01245907|Applied relaxation
361521|NCT01245907|Insomnia
361522|NCT01245907|Women's knowledge
361523|NCT01245894|Index of microcirculatory resistance
361524|NCT01245894|Fractional Flow Reserve
361525|NCT01245881|controlled trial
361526|NCT01245881|fractional photothermolysis
361527|NCT01245881|laser surgery
361528|NCT01245881|melasma
361529|NCT01245881|pigment disorder
361530|NCT01245868|Spinal anaesthesia
361531|NCT01245868|Bupivacaine
361532|NCT01245868|Lidocaine
361533|NCT01245868|Duration of blockade
361534|NCT01245855|Prostaglandin E1
361535|NCT01245855|percutaneous coronary intervention
361536|NCT01245855|Cardiac troponin T
361537|NCT01245855|Creatine kinase-MB
361538|NCT01245829|Cross Infection
361539|NCT01245829|Nosocomial Infection
361540|NCT01245829|Healthcare Acquired Infection
361541|NCT01245829|Hospital Paperwork
361542|NCT01245829|Observation Charts
361543|NCT01245829|Critical Care
361544|NCT01245829|Contamination
361545|NCT01245816|colon polyps
361546|NCT01245803|rosuvastatin
361547|NCT01245803|angioplasty
361548|NCT01245803|acute coronary syndrome
361549|NCT01245790|Phase 1
361550|NCT01245790|healthy volunteers
361551|NCT01245790|volunteers with renal impairment
361552|NCT01245790|pharmacokinetics
361553|NCT01245790|Rheumatoid arthritis
361554|NCT01245790|RA
361555|NCT01245790|fostamatinib
361556|NCT01245790|Patients
361557|NCT01245777|RLS
361558|NCT01245777|Pregnancy
361559|NCT01245777|Iron Deficiency
361560|NCT01245777|Anaemia
361561|NCT01245764|Cervical cancer
361562|NCT01245764|vulvar cancer
361563|NCT01245764|vaginal cancer
361564|NCT01245764|genital warts
361565|NCT01245764|human papillomavirus
361566|NCT01245517|hyperphosphatemia or malnutrition
361567|NCT01245478|Surgical Procedures, Elective
361568|NCT01245452|Rheumatoid arthritis
361569|NCT01245452|Tocilizumab
361570|NCT01245452|Cardiorespiratory endurance
361571|NCT01245426|Asthma
361572|NCT01245426|GW870086
361573|NCT01245426|Efficacy
361574|NCT01245426|FEV1
361575|NCT01245413|Stoma
361576|NCT01245413|adhesive
361577|NCT01245413|warm
361578|NCT01245413|moist
361579|NCT01245413|cycling
361580|NCT01245413|men
361581|NCT01245413|peel-value
361582|NCT01245413|healthy men 50-70 years old
361583|NCT01245413|men with colostoma, above 18 years
361584|NCT01245400|Z-Lig
361585|NCT01245400|allograft
361586|NCT01245400|ACL
361587|NCT01245400|Anterior Cruciate Ligament
361588|NCT01245400|ACLR
361589|NCT01245400|Anterior Cruciate Ligament Reconstruction
361590|NCT01245400|EU
361591|NCT01245400|European Union
361592|NCT01245400|S. Africa
361593|NCT01245400|Reconstruction of ruptured anterior cruciate ligaments
361594|NCT01245387|prospective
361595|NCT01245387|observational
361596|NCT01245387|Phase 4
361597|NCT01245387|non-interventional
361598|NCT01245387|open-label
361599|NCT01245361|Undifferentiated Arthritis
361600|NCT01245361|Rheumatoid Arthritis
361601|NCT01245361|Infliximab
361602|NCT01245348|Schizophrenia
361603|NCT01245348|Bipolar Disorder
361604|NCT01245348|atypical antipsychotic
361605|NCT01245348|adherence
361606|NCT01245348|cost effectiveness
361607|NCT01245348|pharmacogenetics
361608|NCT01245348|mental illness
361609|NCT01245348|SULT4A1
361610|NCT01245335|CLI
361611|NCT01245335|Critical Limb Ischemia
361612|NCT01245335|PAOD
361613|NCT01245335|Peripheral Arterial Disease
361614|NCT01245335|Stem Cells
361615|NCT01245335|Limb amputation
361616|NCT01245335|Leg ulcers
361617|NCT01245322|treatment, lactobacilli
361618|NCT01245296|Umbilical cord
361619|NCT01245296|cord clamping
361620|NCT01245296|iron
361621|NCT01245296|Ferritin
361622|NCT01245296|newborn
361623|NCT01245296|jaundice
361624|NCT01245296|infant
361625|NCT01245296|development
361626|NCT01245296|infections
361627|NCT01245283|knee
361628|NCT01245283|osteoarthritis
361629|NCT01245283|pain
361630|NCT01245283|function
361631|NCT01245283|impairment
361632|NCT01245270|anthocyanin
361633|NCT01245270|blaeberries
361634|NCT01245270|bilberries
361635|NCT01245270|blueberries
361636|NCT01245270|mirtoselect
361637|NCT01245270|glucose AUC
361638|NCT01245257|Inflammation
361639|NCT01245257|Urea Synthesis
361640|NCT01245257|Catabolism
361641|NCT01245257|Nitrogen balance
361642|NCT01245231|childhood acute myeloid leukemia/other myeloid malignancies
361643|NCT01245179|sickle cell anemia
361644|NCT01245179|sickle cell thalassemia
361645|NCT01245179|HDAC inhibitor
361646|NCT01245179|hemoglobin F
361647|NCT01245179|sickle beta thalassemia
361648|NCT01245179|Fetal Hemoglobin
361649|NCT01245153|Urinary incontinence, Pelvic floor muscle training
361650|NCT01245140|Palmo-Plantar Pustolosis
361651|NCT01245127|Schnitzler syndrome
361652|NCT01245101|HIV raltegravir intensification replication activation
361653|NCT01245088|Crohn's disease
361654|NCT01245088|chondroitin sulfate
361655|NCT01245062|MEK inhibitor
361656|NCT01245062|Cancer
361657|NCT01245062|Metastatic Melanoma
361658|NCT01245062|BRAF mutant metastatic melanoma
361659|NCT01245062|GSK1120212
361660|NCT01245049|MMR
361661|NCT01245049|dTpa-IPV
361662|NCT01245049|Boostrix Polio
361663|NCT01245049|Repevax
361664|NCT01245049|Priorix
361665|NCT01245036|Sarcoidosis
361666|NCT01245036|Tuberculosis
361667|NCT01245010|Metabolic Syndrome
361668|NCT01245010|Water
361669|NCT01245010|Obesity
361670|NCT01245010|Clinical trial
361671|NCT01245010|Prevention
361672|NCT01244997|Partial edentulism
361673|NCT01244997|Bone atrophy
361674|NCT01244997|Bone healing
361675|NCT01244984|asthma
361676|NCT01244984|Fluticasone furoate
361677|NCT01244984|GW642444
361678|NCT01244958|Active rheumatoid arthritis
361679|NCT01244958|leflunomide
361680|NCT01244958|rituximab
361681|NCT01244958|inadequate clinical response to leflunomide
361682|NCT01244945|Functional Constipation
361683|NCT01244945|Functional Foods
361684|NCT01244945|Probiotics
361685|NCT01244945|Lactobacillus reuteri
361686|NCT01244906|Chronic Myelogenous Leukemia
361687|NCT01244906|Acute Myelogenous Leukemia
361688|NCT01244906|Myelodysplastic Syndrome
361689|NCT01244906|Myelofibrosis
361690|NCT01244906|Acute Lymphocytic Leukemia
361691|NCT01244906|Acute Lymphoblastic Lymphoma
361692|NCT01244906|Chronic Lymphocytic Leukemia
361693|NCT01244906|Prolymphocytic Leukemia
361694|NCT01244906|Low-grade non-Hodgkin's Lymphoma
361695|NCT01244906|Mantle Cell Lymphoma
361696|NCT01244906|Hodgkin Lymphoma
361697|NCT01244906|Myeloma
361698|NCT01244880|PF-02545920
361699|NCT01244880|ketamine
361700|NCT01244880|fMRI
361701|NCT01244880|associative Learning
361702|NCT01244854|chronic mental disorders
361703|NCT01244854|cardiovascular disease
361704|NCT01244854|behavior change
361705|NCT01244841|ST elevation acute myocardial infarction
361706|NCT01244841|Primary percutaneous coronary intervention
361707|NCT01244841|Discharge
361708|NCT01244841|Health status
361709|NCT01244841|Quality of care
361710|NCT01244815|Bi-polar I disorder
361711|NCT01244815|antipsychotic
361712|NCT01244815|serotonin
361713|NCT01244815|dopamine
361714|NCT01244815|noradrenalin
361715|NCT01244815|histamine
361716|NCT01244815|pediatric
361717|NCT01244802|yellow fever vaccine
361718|NCT01244789|endometrial cancer
361719|NCT01244789|chemotherapy
361720|NCT01244789|carboplatin
361721|NCT01244789|paclitaxel
361722|NCT01244789|Stage 1 & 2
361723|NCT01244789|node-negative
361724|NCT01244789|intermediate risk
361725|NCT01244789|high risk
361726|NCT01244763|Kidney
361727|NCT01244763|Chronic Kidney Disease
361728|NCT01244763|CKD
361729|NCT01244763|Renal
361730|NCT01244763|Anemia
361731|NCT01244763|Oral anemia treatment
361732|NCT01244763|Hemoglobin levels
361733|NCT01244763|Erythropoietin
361734|NCT01244763|Blood count
361735|NCT01244763|Predialysis
361736|NCT01244763|Pre-dialysis
361737|NCT01244763|Hb
361738|NCT01244763|Non-dialysis
361739|NCT01244750|Chronic Phase - Chronic Myeloid Leukemia
361740|NCT01244737|Brain neoplasms
361741|NCT01244737|Children
361742|NCT01244737|Positron-Emission Tomography
361743|NCT01244737|18F-FLT
361744|NCT01244711|Major Depression
361745|NCT01244711|Generalized Anxiety Disorder
361746|NCT01244711|Benzodiazepine
361747|NCT01244711|Quetiapine
361748|NCT01244698|Surgical Site Infection, Breast Reconstruction, Antibiotics
361749|NCT01244685|bowel resection
361750|NCT01244685|Deltex CardioQ Probe
361751|NCT01244685|fluid management
361752|NCT01244672|Hemorrhoids
361753|NCT01244672|THD
361754|NCT01244672|Ferguson
361755|NCT01244659|Tacrolimus
361756|NCT01244659|Immunosuppressive Agents
361757|NCT01244659|Kidney transplantation
361758|NCT01244646|Diabetes Mellitus
361759|NCT01244646|Type 2
361760|NCT01244646|DMT2
361761|NCT01244646|T2DM
361762|NCT01244646|metformin
361763|NCT01244646|sulfonylurea
361764|NCT01244646|hypoglycemia
361765|NCT01244646|weight
361766|NCT01244646|quality of life
361767|NCT01244646|compliance
361768|NCT01244633|Tourette's
361769|NCT01244633|Ecopipam
361770|NCT01244633|Dopamine receptors
361771|NCT01244633|Efficacy
361772|NCT01244633|Safety
361773|NCT01244633|Adults
361774|NCT01244620|A pharmacokinetic drug-drug interaction study between sitaxsentan and tadalafil and between sitaxsentan and sildenafil at the steady-state
361775|NCT01244594|Spinal Cord Injury
361776|NCT01244594|Cycling
361777|NCT01244594|Functional Electrical Stimulation
361778|NCT01244581|middle ear effusion
361779|NCT01244581|amoxicillin-clavulanate
361780|NCT01244581|tympanometry
361781|NCT01244568|Prostate Cancer
361782|NCT01244568|Decision support interventions (DESI)
361783|NCT01244568|Comparative Effectiveness Research (CER)
361784|NCT01244542|Schizophrenia
361785|NCT01244542|DSM IV criteria
361786|NCT01244542|Pain insensitivity
361787|NCT01244542|Painful perception
361788|NCT01244542|Opioid receptors
361789|NCT01244490|ADHD
361790|NCT01244477|Stress Disorders, Post Traumatic
361791|NCT01244477|Trust
361792|NCT01244477|functional Magnetic Resonance Imaging (fMRI)
361793|NCT01244464|Poliomyelitis
361794|NCT01244464|IMOVAX POLIO™
361795|NCT01244464|Polio
361796|NCT01244451|CLL
361797|NCT01244451|relapsed
361798|NCT01244451|refractory
361799|NCT01244451|Bendamustine
361800|NCT01244451|Ofatumumab
361801|NCT01244438|endometrial cancer
361802|NCT01244438|FGFR2 mutations
361803|NCT01244412|Fundus photography
361804|NCT01244399|inositol
361805|NCT01244399|caffeine
361806|NCT01244399|NTDs
361807|NCT01244386|Computed tomography
361808|NCT01244386|Iterative reconstruction
361809|NCT01244386|Automatic tube current modulation
361810|NCT01244386|Crohn's disease
361811|NCT01244386|Inflammatory bowel disease
361812|NCT01244386|Radiation dose optimization
361813|NCT01244386|C reactive protein
361814|NCT01244373|Best-corrected visual acuity
361815|NCT01244373|posterior capsule opacification
361816|NCT01244373|QUATRIX® Aspheric Evolutive pre-loaded
361817|NCT01244360|resveratrol
361818|NCT01244360|insulin
361819|NCT01244360|inflammation
361820|NCT01244360|cognition
361821|NCT01244360|metabolism
361822|NCT01244347|folic acid
361823|NCT01244347|malformations
361824|NCT01244347|prevention
361825|NCT01244334|cataract surgery, vision, corneal edema, retinal thickness
361826|NCT01244321|End stage heart failure
361827|NCT01244321|heart transplantation
361828|NCT01244321|Ventricular assist device
361829|NCT01244321|Patients with end stage heart failure
361830|NCT01244321|awaiting heart transplantation
361831|NCT01244308|Phrenic nerve stimulation
361832|NCT01244308|LV pacing configuration
361833|NCT01244308|CRT
361834|NCT01244308|Cardiac resynchronisation therapy
361835|NCT01244308|Heart failure
361836|NCT01244295|Grief
361837|NCT01244295|Bereavement
361838|NCT01244295|Psychotherapy
361839|NCT01244295|Randomized controlled trial
361840|NCT01244295|Treatment study
361841|NCT01244282|brain imaging
361842|NCT01244269|Parkinson's disease
361843|NCT01244269|Methylphenidate
361844|NCT01244269|Non motor symptoms
361845|NCT01244269|Postural control
361846|NCT01244243|stroke
361847|NCT01244243|rehabilitation
361848|NCT01244204|vitamin D deficiency
361849|NCT01244204|tuberculin sin test
361850|NCT01244204|immunity
361851|NCT01244204|tuberculosis
361852|NCT01244191|Non squamous, non-small-cell lung cancer
361853|NCT01244191|Epidermal growth factor receptor, wild type
361854|NCT01244191|c-Met inhibitor
361855|NCT01244178|Sepsis
361856|NCT01244178|Insulin
361857|NCT01244139|BIIB033
361858|NCT01244139|Multiple Sclerosis
361859|NCT01244139|anti-LINGO-1 antibody
361860|NCT01244139|Relapsing Remitting MS
361861|NCT01244139|remyelination
361862|NCT01244139|myelin repair
361863|NCT01244139|Multiple ascending dose
361864|NCT01244139|Secondary progessive MS
361865|NCT01244126|otitis media
361866|NCT01244126|recurrent ear infections (otitis media)
361867|NCT01244100|Food-effects PK study in healthy subjects.
361868|NCT01244087|Inquiry-based stress reduction
361869|NCT01244087|Quality of life
361870|NCT01244087|breast cancer
361871|NCT01244048|n3 LC-PUFA, yoghurt, inflammatory markers
361872|NCT01244035|High blood pressure
361873|NCT01244022|Colorectal cancer
361874|NCT01244022|Surgical stress response
361875|NCT01244022|interleukins
361876|NCT01244009|Poly (ADP-ribose) polymerase (PARP) inhibitor
361877|NCT01243996|Patent ductus arteriosus, ibuprofen, preterm infants
361878|NCT01243970|Spinal anaesthesia
361879|NCT01243970|phenylephrine
361880|NCT01243970|ephedrine
361881|NCT01243970|ECG changes
361882|NCT01243970|Caesarean delivery
361883|NCT01243970|Myocardial ischaemia
361884|NCT01243970|Cardiac output
361885|NCT01243970|hypotension
361886|NCT01243944|INCB018424
361887|NCT01243931|Phototherapeutic keratectomy
361888|NCT01243931|Optical coherence tomography
361889|NCT01243931|Corneal opacity
361890|NCT01243918|Acute respiratory failure
361891|NCT01243918|Oxygen therapy delivery systems
361892|NCT01243918|Non invasive ventilation
361893|NCT01243918|High concentration mask
361894|NCT01243918|Hypoxemic pneumonia
361895|NCT01243879|fasting
361896|NCT01243879|starvation
361897|NCT01243879|calorie restriction
361898|NCT01243879|fMRI
361899|NCT01243840|Central aortic pressure
361900|NCT01243840|Aortic pulse wave velocity
361901|NCT01243840|Aortic PWV using a single pressure recording
361902|NCT01243840|Vascular aging
361903|NCT01243840|Left ventricular hypertrophy
361904|NCT01243840|Left ventricular diastolic function
361905|NCT01243827|Hypertension, carvedilol, bisoprolol, central pulse pressure, pulse pressure amplification, reflection magnitude, LV mass index, LV diastolic function
361906|NCT01243814|hyaluronate
361907|NCT01243814|hyaluronic acid
361908|NCT01243814|viscosupplementation
361909|NCT01243801|chronic pain
361910|NCT01243801|persistent postsurgical pain
361911|NCT01243801|hyperalgesia
361912|NCT01243801|ketamine
361913|NCT01243801|quantitative sensory testing
361914|NCT01243788|COPD
361915|NCT01243788|Seretide
361916|NCT01243788|Combivent
361917|NCT01243788|effect and safety
361918|NCT01243788|Twelve weeks
361919|NCT01243775|NSCLC
361920|NCT01243762|Colorectal cancer
361921|NCT01243762|Solid tumors
361922|NCT01243762|Ovarian cancer
361923|NCT01243762|Fallopian tube cancer
361924|NCT01243762|Primary peritoneal cancer
361925|NCT01243749|Target Vessel Revascularization (TVR)
361926|NCT01243749|Target Lesion Revascularization (TLR)
361927|NCT01243749|Myocardial Infarction (MI)
361928|NCT01243749|Target Vessel Failure (TVF)
361929|NCT01243749|Target Lesion Failure (TLF)
361930|NCT01243749|Stent Thrombosis
361931|NCT01243749|Restenotic Lesion
361932|NCT01243749|Percutaneous Coronary Intervention (PCI)
361933|NCT01243749|Real-world
361934|NCT01243736|anemic
361935|NCT01243736|bleeding
361936|NCT01243736|blood in stool
361937|NCT01243736|abdomen pain
361938|NCT01243736|Gastrointestinal bleeding
361939|NCT01243736|capsule endoscopy (CE)
361940|NCT01243723|Dyschesia treatment
361941|NCT01243723|Inconfort related to dyschesia
361942|NCT01243723|Quality of life
361943|NCT01243723|Bowel function index
361944|NCT01243697|Desogestrel
361945|NCT01243697|Chemosensitivity
361946|NCT01243684|Spinal cord
361947|NCT01243684|cervical spondylosis
361948|NCT01243684|myelopathy
361949|NCT01243671|Behçet's, intestinal
361950|NCT01243658|Oxytocin
361951|NCT01243658|BPD
361952|NCT01243658|Borderline
361953|NCT01243632|malignant pleural mesothelioma
361954|NCT01243632|chemotherapy
361955|NCT01243632|gemcitabine
361956|NCT01243632|cisplatin
361957|NCT01243632|long infusion
361958|NCT01243619|PET
361959|NCT01243619|CT
361960|NCT01243619|radiotherapy
361961|NCT01243606|Anxiety
361962|NCT01243606|Depression
361963|NCT01243606|Obsessive Compulsive Disorder
361964|NCT01243606|Panic Disorder
361965|NCT01243606|Generalized Anxiety Disorder
361966|NCT01243606|Social Anxiety Disorder
361967|NCT01243606|Transdiagnostic Treatment
361968|NCT01243606|CBT
361969|NCT01243593|pediatrics
361970|NCT01243593|anesthesia
361971|NCT01243593|pyeloplasty
361972|NCT01243593|Transversus Abdominis Plane Block
361973|NCT01243593|Regional Anesthesia
361974|NCT01243580|PK and safety
361975|NCT01243580|Pharmacokinetic profile (PK) and safety
361976|NCT01243554|Exercise training
361977|NCT01243554|Pregnancy
361978|NCT01243554|Obesity
361979|NCT01243528|Malnutrition
361980|NCT01243528|Infection
361981|NCT01243528|Neurological
361982|NCT01243515|Central Venous Pressure
361983|NCT01243515|Kidney Diseases
361984|NCT01243515|Chronic Kidney Disease
361985|NCT01243515|Healthy Subjects
361986|NCT01243515|Non-Invasive Monitor
361987|NCT01243489|CML
361988|NCT01243489|compliance
361989|NCT01243489|compliance supporting measures
361990|NCT01243489|complete cytogenetic response
361991|NCT01243489|mayor molecular remission
361992|NCT01243489|Philadelphia chromosome
361993|NCT01243489|BCR-ABL
361994|NCT01243489|Imatinib
361995|NCT01243489|tyrosine kinase inhibitor
361996|NCT01243489|smart blister
361997|NCT01243476|myelodysplastic syndrome
361998|NCT01243476|5q deletion
361999|NCT01243476|anemia
362000|NCT01243476|lenalidomide
362001|NCT01243476|red blood cells transfusion
362002|NCT01243437|plague, ciprofloxacin
362003|NCT01243411|Peyronie's Disease, penile plaque, penile curvature
362004|NCT01243398|adenocarcinoma of the gastroesophageal junction
362005|NCT01243398|adenocarcinoma of the esophagus
362006|NCT01243398|squamous cell carcinoma of the esophagus
362007|NCT01243398|recurrent esophageal cancer
362008|NCT01243398|stage IA esophageal cancer
362009|NCT01243398|stage IB esophageal cancer
362010|NCT01243398|stage IIA esophageal cancer
362011|NCT01243398|stage IIB esophageal cancer
362012|NCT01243398|stage IIIA esophageal cancer
362013|NCT01243398|stage IIIB esophageal cancer
362014|NCT01243398|stage IIIC esophageal cancer
362015|NCT01243398|stage IV esophageal cancer
362016|NCT01243385|adenocarcinoma of the prostate
362017|NCT01243385|hormone-resistant prostate cancer
362018|NCT01243385|stage III prostate cancer
362019|NCT01243385|stage IV prostate cancer
362020|NCT01243385|recurrent prostate cancer
362021|NCT01243372|recurrent colon cancer
362022|NCT01243372|stage IIIA colon cancer
362023|NCT01243372|stage IIIB colon cancer
362024|NCT01243372|stage IIIC colon cancer
362025|NCT01243372|stage IVA colon cancer
362026|NCT01243372|stage IVB colon cancer
362027|NCT01243372|recurrent rectal cancer
362028|NCT01243372|stage III rectal cancer
362029|NCT01243372|stage IV rectal cancer
362030|NCT01243346|Gastrointestinal Stromal Tumor
362031|NCT01243346|PDGFR Inhibitor
362032|NCT01243346|Crenolanib (CP-868,596)
362033|NCT01243333|cancer, imaging
362034|NCT01243281|hepatitis B
362035|NCT01243281|HBeAg
362036|NCT01243281|pegylated interferon
362037|NCT01243281|entecavir
362038|NCT01243255|hypercholesterolemia
362039|NCT01243255|low density lipoprotein
362040|NCT01243255|undertreatment of hypercholesterolemia
362041|NCT01243242|ADHD,Adults,MG01CI,METADOXINE
362042|NCT01243216|Pregnancy
362043|NCT01243216|Labor
362044|NCT01243216|Epidural Analgesia
362045|NCT01243216|Epidural Anesthesia
362046|NCT01243216|Spinal Anesthesia
362047|NCT01243216|Ultrasound
362048|NCT01243216|Neuraxial Analgesia
362049|NCT01243216|Neuraxial Anesthesia
362050|NCT01243216|Cesarean delivery
362051|NCT01243203|Smoking, surgery, Anesthesia, quit
362052|NCT01243190|leukemia
362053|NCT01243190|small lymphocytic leukemia
362054|NCT01243190|SLL
362055|NCT01243190|CLL
362056|NCT01243190|ofatumumab
362057|NCT01243190|untreated
362058|NCT01243190|early stage
362059|NCT01243190|high-risk
362060|NCT01243177|Lacosamide
362061|NCT01243177|Vimpat®
362062|NCT01243177|Epilepsy
362063|NCT01243177|Monotherapy
362064|NCT01243177|Velocity
362065|NCT01243164|confidence
362066|NCT01243164|wheelchair performance
362067|NCT01243151|Hypercholesterolemia
362068|NCT01243151|Dyslipidemia
362069|NCT01243151|LDL
362070|NCT01243151|High Cholesterol
362071|NCT01243151|Japanese Volunteers
362072|NCT01243151|PF-04950615
362073|NCT01243151|RN316
362074|NCT01243138|Cross-sectional
362075|NCT01243138|epidemiological study
362076|NCT01243138|to evaluate the prevalence of CV risk factors in patients attending general practice in AfME region
362077|NCT01243125|Blockage
362078|NCT01243125|Encrustation
362079|NCT01243125|Catheter
362080|NCT01243125|Spinal Cord Injury
362081|NCT01243125|SCI
362082|NCT01243086|Macular Degeneration
362083|NCT01243086|Age-related macular degeneration
362084|NCT01243086|Anti-inflammatory
362085|NCT01243086|Anti-vascular endothelial growth factor (Anti-VEGF)
362086|NCT01243086|Lucentis
362087|NCT01243086|Ranibizumab
362088|NCT01243086|OZURDEX
362089|NCT01243086|Dexamethasone
362090|NCT01243086|Vision loss
362091|NCT01243073|imetelstat
362092|NCT01243073|imetelstat sodium
362093|NCT01243073|GRN163L
362094|NCT01243073|telomerase inhibitor
362095|NCT01243073|telomerase
362096|NCT01243073|essential thrombocytosis
362097|NCT01243073|essential thrombocythemia
362098|NCT01243073|ET
362099|NCT01243073|polycythemia vera
362100|NCT01243073|PV
362101|NCT01243060|Sleep Aid
362102|NCT01243047|Second line treatment for metastatic colorectal cancer
362103|NCT01243008|Lyme disease
362104|NCT01243008|Borreliosis
362105|NCT01243008|Azithromycin
362106|NCT01242982|5. metacarpal fracture/fractures
362107|NCT01242982|subcapital
362108|NCT01242982|shaft
362109|NCT01242982|closed
362110|NCT01242956|stroke
362111|NCT01242956|video-based training
362112|NCT01242956|rehabilitation
362113|NCT01242943|I131
362114|NCT01242943|L19
362115|NCT01242943|antibody
362116|NCT01242943|monoclonal
362117|NCT01242943|tumour targeting
362118|NCT01242943|radioimmunotherapy
362119|NCT01242943|cancer
362120|NCT01242930|imetelstat
362121|NCT01242930|imetelstat sodium
362122|NCT01242930|GRN163L
362123|NCT01242930|telomerase inhibitor
362124|NCT01242930|telomerase inhibition
362125|NCT01242930|multiple myeloma
362126|NCT01242930|myeloma
362127|NCT01242930|myeloma progenitor cells
362128|NCT01242904|dialysis solutions
362129|NCT01242904|renal replacement therapy
362130|NCT01242904|peritoneal dialysis
362131|NCT01242904|bimodal solution
362132|NCT01242904|glucose sparing therapy
362133|NCT01242891|Ventricular Assist Device
362134|NCT01242891|Pediatric Ventricular Assist Device
362135|NCT01242878|HbSS
362136|NCT01242878|Sickle cell anemia
362137|NCT01242878|HbSC
362138|NCT01242878|HbSbetathalassemia
362139|NCT01242878|Hemoglobinopathy
362140|NCT01242878|Hemoglobinopathies
362141|NCT01242865|Stress
362142|NCT01242865|Anxiety
362143|NCT01242865|Resilience
362144|NCT01242865|Mindfulness
362145|NCT01242865|Quality of Life
362146|NCT01242865|Stress Management
362147|NCT01242852|Hysteroscopy
362148|NCT01242852|infertility
362149|NCT01242852|subfertility
362150|NCT01242852|intrauterine abnormalities
362151|NCT01242852|intracavitary pathology
362152|NCT01242852|IVF
362153|NCT01242852|ICSI
362154|NCT01242852|in vitro fertilization
362155|NCT01242852|intracytoplasmic sperm injection
362156|NCT01242839|CACICOL20
362157|NCT01242813|TNF-receptor associated periodic syndrome
362158|NCT01242813|fevers
362159|NCT01242813|rashes
362160|NCT01242813|musculoskeletal and abdominal pain
362161|NCT01242813|periorbital edema
362162|NCT01242813|TNFR1
362163|NCT01242800|male breast cancer
362164|NCT01242800|stage IV breast cancer
362165|NCT01242787|Chronic hepatitis B
362166|NCT01242787|LB80380
362167|NCT01242787|treatment-naive
362168|NCT01242787|entecavir
362169|NCT01242787|Extension
362170|NCT01242774|AML
362171|NCT01242774|bone marrow
362172|NCT01242774|abnormal blast cells of myeloid
362173|NCT01242774|acute leukemia
362174|NCT01242774|cytogenetic abnormalities
362175|NCT01242774|HDACi
362176|NCT01242761|Accuracy of diagnostic ultrasound based in community or as part of a specialist hospital-based service
362177|NCT01242735|Obsessive Compulsive Disorder
362178|NCT01242735|OCD
362179|NCT01242735|Exercise
362180|NCT01242735|Aerobic Exercise
362181|NCT01242722|Heart failure
362182|NCT01242722|auto threshold
362183|NCT01242722|pacing
362184|NCT01242722|CRT-D recipients
362185|NCT01242722|Left Ventricular (LV) evoked response signals
362186|NCT01242696|Drug Eluting Stents
362187|NCT01242696|Observational
362188|NCT01242696|All-Comers
362189|NCT01242657|Tobacco Use Cessation
362190|NCT01242657|Youth Tobacco Use
362191|NCT01242657|Physical Activity
362192|NCT01242657|Smoking Cessation Intervention
362193|NCT01242618|nasal cartilage diseases
362194|NCT01242605|unresectable
362195|NCT01242605|advanced
362196|NCT01242566|Temozolomide
362197|NCT01242566|Elderly
362198|NCT01242566|Glioblastoma
362199|NCT01242566|Karnofsky performance score (KPS)
362200|NCT01242540|Pain
362201|NCT01242540|Functional Magnetic Resonance Imaging
362202|NCT01242527|dyslipidemia
362203|NCT01242527|hyperlipidemia
362204|NCT01242527|omega-3 carboxylic acid
362205|NCT01242514|Rheumatoid Arthritis
362206|NCT01242514|OSKIRA
362207|NCT01242514|Fostamatinib
362208|NCT01242501|Prevention
362209|NCT01242501|Counseling
362210|NCT01242501|Behavioral interventions
362211|NCT01242501|HIV risk reduction
362212|NCT01242488|Rheumatoid Arthritis
362213|NCT01242488|CDP6038
362214|NCT01242488|Interleukin-6
362215|NCT01242488|Tocilizumab
362216|NCT01242475|tuberculosis
362217|NCT01242475|rdESAT-6
362218|NCT01242475|CFP-10
362219|NCT01242475|skin test
362220|NCT01242475|diagnostic test
362221|NCT01242462|Conventional mechanical ventilation
362222|NCT01242462|Mid-frequency ventilation
362223|NCT01242462|Respiratory Distress Syndrome
362224|NCT01242462|Preterm Newborn Infant
362225|NCT01242462|Mean Airway Pressure
362226|NCT01242462|Mean Arterial Pressure
362227|NCT01242462|Mean Peak Inspiratory Pressure
362228|NCT01242449|Breast cancer
362229|NCT01242449|Metastatic
362230|NCT01242449|HER2 positive
362231|NCT01242449|vinorelbine
362232|NCT01242436|Ovarian Cancer
362233|NCT01242436|Peritoneal Metastasis
362234|NCT01242436|Whole body diffusion MRI
362235|NCT01242436|therapy
362236|NCT01242423|musculoskeletal shockwave therapy
362237|NCT01242410|Short cervix
362238|NCT01242410|Preterm birth
362239|NCT01242410|Cervical pessary
362240|NCT01242410|Twins
362241|NCT01242371|Schizophrenia
362242|NCT01242371|Schizoaffective
362243|NCT01242371|Probiotic supplements
362244|NCT01242371|Gliadin
362245|NCT01242371|Casein
362246|NCT01242358|hypoxaemia - capnography - integrated pulmonary index - PEG
362247|NCT01242345|Hypoxemia
362248|NCT01242345|Capnography
362249|NCT01242345|Integrated pulmonary index
362250|NCT01242345|Sedation
362251|NCT01242345|Propofol
362252|NCT01242345|Safety
362253|NCT01242332|perioperative
362254|NCT01242332|pregabalin
362255|NCT01242332|arthroscopic anterior cruciate ligament reconstruction
362256|NCT01242332|postoperative pain management
362257|NCT01242319|quality improvement
362258|NCT01242319|implementation trials
362259|NCT01242319|cholesterol guidelines
362260|NCT01242319|patient activation
362261|NCT01242306|endothelial dysfunction acetylcholine bms ses
362262|NCT01242280|Acute variceal bleeding
362263|NCT01242280|Massive bleeding
362264|NCT01242280|Liver Cirrhosis
362265|NCT01242280|Esophageal tamponade
362266|NCT01242280|Esophageal stent
362267|NCT01242267|multiple myeloma
362268|NCT01242267|transplant
362269|NCT01242267|Multiple myeloma patients undergoing transplant
362270|NCT01242254|KH902
362271|NCT01242254|age-related macular degeneration
362272|NCT01242254|choroidal neovascularization
362273|NCT01242254|intravitreal injection
362274|NCT01242254|multiple injections
362275|NCT01242241|Propofol
362276|NCT01242241|Childhood obesity
362277|NCT01242241|Pharmacodynamics
362278|NCT01242228|ASP1941
362279|NCT01242228|Diabetes mellitus
362280|NCT01242228|Dipeptidyl peptidase-4 inhibitor
362281|NCT01242228|DPP-4 inhibitor
362282|NCT01242228|long-term safety
362283|NCT01242215|ASP1941
362284|NCT01242215|Diabetes mellitus
362285|NCT01242215|sulfonylurea
362286|NCT01242202|ASP1941
362287|NCT01242202|Diabetes mellitus
362288|NCT01242202|alpha glucosidase inhibitor
362289|NCT01242202|long-term safety
362290|NCT01242150|Acute Respiratory Failure
362291|NCT01242150|Continuous Positive Airway Pressure
362292|NCT01242150|Infants
362293|NCT01242150|Helmet
362294|NCT01242111|Mucopolysaccharidosis IV type A
362295|NCT01242111|MPS IV Type A
362296|NCT01242111|Mucopolysaccharidosis IVA
362297|NCT01242111|MPS IVA
362298|NCT01242111|Morquio A Syndrome
362299|NCT01242111|Lysosomal Storage Disorder
362300|NCT01242111|LSD
362301|NCT01242111|N-acetylgalactosamine-6-sulfatase
362302|NCT01242111|N-acetylgalactosamine-6-sulfate sulfatase
362303|NCT01242111|galactose-6-sulfatase
362304|NCT01242111|GALNS
362305|NCT01242111|enzyme replacement therapy
362306|NCT01242111|ERT
362307|NCT01242098|Asthma
362308|NCT01242098|Combination therapy
362309|NCT01242098|Primary care management
362310|NCT01242098|Switch
362311|NCT01242098|ICS/LABA
362312|NCT01242098|Fostair
362313|NCT01242098|Seretide
362314|NCT01242085|alignment
362315|NCT01242072|malignancy
362316|NCT01242072|etoposide and carboplatin
362317|NCT01242072|non small cell lung cancer
362318|NCT01242072|small cell lung cancer
362319|NCT01242072|testicular cancer
362320|NCT01242072|thymoma
362321|NCT01242072|ovarian cancer
362322|NCT01242072|osteosarcoma
362323|NCT01242059|Obesity
362324|NCT01242059|Food intake regulation
362325|NCT01242059|blood glucose regulation
362326|NCT01242059|protein
362327|NCT01242059|fiber
362328|NCT01242059|pulses
362329|NCT01242059|yellow peas
362330|NCT01242046|female sexual arousal
362331|NCT01242033|red raspberries
362332|NCT01242033|post-prandial
362333|NCT01242033|oxidative stress
362334|NCT01242033|antioxidants
362335|NCT01242033|polyphenols
362336|NCT01242033|vitamin C
362337|NCT01242033|acute dietary intervention
362338|NCT01242007|Myotonic dystrophy
362339|NCT01242007|Steinert's disease
362340|NCT01241981|Breast
362341|NCT01241981|Cancer
362342|NCT01241981|Digital
362343|NCT01241981|Mammography
362344|NCT01241981|Tomosynthesis
362345|NCT01241968|Extracorporeal Shockwave Therapy
362346|NCT01241968|Myocardial Ischemia
362347|NCT01241968|Refractory Angina
362348|NCT01241955|CPR
362349|NCT01241942|Lung Transplant
362350|NCT01241942|Emphysema
362351|NCT01241942|Chronic Obstructive Pulmonary Disease (COPD)
362352|NCT01241942|Cystic Fibrosis
362353|NCT01241942|Pulmonary Fibrosis
362354|NCT01241942|Bronchiectasis
362355|NCT01241942|Sarcoidosis
362356|NCT01241942|Pulmonary Hypertension
362357|NCT01241942|Alpha-1 Antitrypsin Deficiency
362358|NCT01241929|advanced cancer
362359|NCT01241916|elbow, splint
362360|NCT01241903|Platelet activation
362361|NCT01241903|platelet leukocyte aggregates
362362|NCT01241890|Cystic Fibrosis
362363|NCT01241890|Children
362364|NCT01241890|Exhaled Breath Condensate
362365|NCT01241890|Non-invasive Inflammatory Markers
362366|NCT01241890|Volatile Organic Compounds
362367|NCT01241890|Home monitoring
362368|NCT01241890|Quality of life
362369|NCT01241838|Heart failure
362370|NCT01241838|Left ventricular hypertrophy
362371|NCT01241838|Diastolic dysfunction
362372|NCT01241825|capsule endoscopy
362373|NCT01241825|chewing gum
362374|NCT01241825|small bowel transit time
362375|NCT01241812|knee
362376|NCT01241812|osteoarthritis
362377|NCT01241799|endoscopic ultrasound guided fine needle aspiration (EUS-FNA)
362378|NCT01241799|pancreatic biopsy
362379|NCT01241799|randomized
362380|NCT01241799|single blind
362381|NCT01241799|fine needle aspiration (FNA) adequacy
362382|NCT01241799|fine needle aspiration (FNA) accuracy
362383|NCT01241786|chronic lymphocytic leukemia (CLL)
362384|NCT01241786|small lymphocytic lymphoma (SLL)
362385|NCT01241773|TMC435-TiDP16-C123
362386|NCT01241773|TMC435-C123
362387|NCT01241773|TMC435
362388|NCT01241773|HCV
362389|NCT01241773|Hepatitis C
362390|NCT01241760|Genotype 1 chronic hepatitis C
362391|NCT01241760|VX-950-C211
362392|NCT01241760|VX-950
362393|NCT01241760|IL28B
362394|NCT01241760|Telaprevir
362395|NCT01241760|Hepatitis C
362396|NCT01241760|BID
362397|NCT01241760|Q8h
362398|NCT01241760|SOC
362399|NCT01241734|Diffuse Large B cell Lymphoma
362400|NCT01241721|Breast Diseases
362401|NCT01241721|Breast Neoplasms
362402|NCT01241721|Neoplasms
362403|NCT01241695|Oral nutritional supplement, diabetes mellitus type 2, glycaemic control
362404|NCT01241695|Oral nutritional supplement (Food for special medical purposes)
362405|NCT01241682|Mesothelioma
362406|NCT01241682|Dendritic cells
362407|NCT01241682|Cyclophosphamide
362408|NCT01241682|Tumor lysate-loaded
362409|NCT01241682|Immunotherapy
362410|NCT01241656|Prostate cancer
362411|NCT01241656|Decision support intervention (DESI)
362412|NCT01241656|Shared medical appointments (SMA)
362413|NCT01241656|Comparative effectiveness research (CER)
362414|NCT01241643|interleukin-7
362415|NCT01241643|immune-based therapies
362416|NCT01241643|HIV
362417|NCT01241643|infectious disease
362418|NCT01241643|immune non-responders
362419|NCT01241630|Somato-sensory reflex arch
362420|NCT01241630|Spinal cord injury
362421|NCT01241630|Xiao Procedure
362422|NCT01241617|Lung disease
362423|NCT01241617|Lobectomy
362424|NCT01241617|Pulmonary resection
362425|NCT01241591|CP-690,550
362426|NCT01241591|Etanercept
362427|NCT01241591|Moderate
362428|NCT01241591|Severe
362429|NCT01241591|Chronic
362430|NCT01241591|Plaque
362431|NCT01241591|Psoriasis
362432|NCT01241591|Efficacy
362433|NCT01241591|Safety
362434|NCT01241591|Tofacitinib
362435|NCT01241591|Xeljanz
362436|NCT01241591|OPT Compare
362437|NCT01241591|OPT
362438|NCT01241591|head-to-head
362439|NCT01241591|non-inferiority
362440|NCT01241591|Psoriasis vulgaris
362441|NCT01241591|short-term
362442|NCT01241591|Itch
362443|NCT01241591|Pruritus
362444|NCT01241591|Plaque psoriasis
362445|NCT01241591|DLQI
362446|NCT01241578|Obesity
362447|NCT01241578|Behavior Therapy
362448|NCT01241578|Lifestyle
362449|NCT01241578|Technology
362450|NCT01241578|Cellular Phone
362451|NCT01241565|lung cancer
362452|NCT01241565|lobectomy
362453|NCT01241565|wedge resection
362454|NCT01241552|Clostridium difficile
362455|NCT01241552|recurrent Clostridium difficile
362456|NCT01241552|vancomycin
362457|NCT01241552|metronidazole
362458|NCT01241552|monoclonal antibody
362459|NCT01241552|Clostridium difficile infection (CDI)
362460|NCT01241526|COPD
362461|NCT01241526|COMET
362462|NCT01241526|Disease management
362463|NCT01241513|glutathione
362464|NCT01241513|redox status
362465|NCT01241513|carotid body chemosensitivity
362466|NCT01241513|ventilation
362467|NCT01241500|Myelodysplastic syndromes
362468|NCT01241500|MDS
362469|NCT01241487|Hypertension, Valsartan/Amlodipine,
362470|NCT01241461|Advanced Cancer
362471|NCT01241461|Metastatic Cancer
362472|NCT01241461|p70s6 inhibitor
362473|NCT01241448|Type 2 Diabetes Mellitus
362474|NCT01241422|Asthma
362475|NCT01241422|Mild asthma
362476|NCT01241422|Singulair
362477|NCT01241422|JNJ 40929837
362478|NCT01241422|Montelukast
362479|NCT01241409|Healthy
362480|NCT01241409|Sprinkle Capsule Formulation
362481|NCT01241409|Rabeprazole sodium
362482|NCT01241409|Pharmacokinetics
362483|NCT01241409|Bioequivalence
362484|NCT01241409|Safety
362485|NCT01241396|Multiple Myeloma
362486|NCT01241396|observational
362487|NCT01241396|survey
362488|NCT01241396|non-interventional
362489|NCT01241396|international
362490|NCT01241396|epidemiology
362491|NCT01241396|treatment
362492|NCT01241396|routine clinical practice
362493|NCT01241396|retrospective
362494|NCT01241396|prospective
362495|NCT01241383|Scleroderma renal crisis
362496|NCT01241383|angiotensin converting enzyme inhibitors
362497|NCT01241383|bosentan
362498|NCT01241383|endothelin receptor antagonist
362499|NCT01241370|Retinal endothelia dysfunction
362500|NCT01241370|Type 2 diabetes mellitus
362501|NCT01241370|Insulin-resistance
362502|NCT01241370|micro-lightguide spectrophotometry
362503|NCT01241370|laserdopplerfluxmetry
362504|NCT01241357|Iron
362505|NCT01241357|Iron overload
362506|NCT01241357|Hepatic iron concentration
362507|NCT01241357|High-temperature superconductivity
362508|NCT01241357|Magnetic susceptibility
362509|NCT01241357|Susceptometer
362510|NCT01241344|Adv
362511|NCT01241344|Hematopoeitic Stem cell Transplant
362512|NCT01241344|HSCT
362513|NCT01241331|moderate to severe facial acne vulgaris
362514|NCT01241318|neonate
362515|NCT01241318|omphalitis
362516|NCT01241318|neonatal mortality
362517|NCT01241318|maternal health
362518|NCT01241318|umbilical cord infection
362519|NCT01241305|Vasculitis
362520|NCT01241305|CSS
362521|NCT01241305|EGPA
362522|NCT01241305|GCA
362523|NCT01241305|GPA
362524|NCT01241305|WG
362525|NCT01241305|MPA
362526|NCT01241305|PAN
362527|NCT01241305|TAK
362528|NCT01241279|cataract surgery
362529|NCT01241279|intraocular lens
362530|NCT01241266|Peptic Ulcer Bleeding
362531|NCT01241266|high risk
362532|NCT01241266|None-Interventional Study
362533|NCT01241266|he proportion of peptic ulcer bleeding patients who are at high risk (Forrest Ia-IIb)
362534|NCT01241253|legumes
362535|NCT01241253|glycemic response
362536|NCT01241253|glucose
362537|NCT01241253|type 2 diabetes mellitus
362538|NCT01241227|liver fibrosis
362539|NCT01241227|survival
362540|NCT01241227|transient elastography
362541|NCT01241214|Seasonal allergic rhinitis
362542|NCT01241214|SAR
362543|NCT01241214|Allergic rhinitis
362544|NCT01241214|Allergies
362545|NCT01241201|intestinal health
362546|NCT01241201|probiotics
362547|NCT01241201|inflammation
362548|NCT01241201|biomarkers
362549|NCT01241188|tuberculosis
362550|NCT01241188|rdESAT-6
362551|NCT01241188|CFP-10
362552|NCT01241188|skin test
362553|NCT01241188|diagnostic test
362554|NCT01241175|IOP
362555|NCT01241175|ophthalmic anesthesia
362556|NCT01241175|magnesium sulfate
362557|NCT01241162|Neuroblastoma
362558|NCT01241162|Ewings sarcoma
362559|NCT01241162|osteogenic sarcoma
362560|NCT01241162|rhabdomyosarcoma
362561|NCT01241162|synovial sarcoma
362562|NCT01241162|high-risk
362563|NCT01241162|relapsed
362564|NCT01241162|children
362565|NCT01241149|Nissen fundoplication
362566|NCT01241149|non-acid reflux disease
362567|NCT01241149|anti-reflux surgery
362568|NCT01241136|pilonidal disease, cystectomy, recurrence
362569|NCT01241123|return of bowel function, post-operative, colon surgery
362570|NCT01241110|PID, Ofloxacin, Azitromicine, Metronidazole
362571|NCT01241097|endothelial function
362572|NCT01241097|statins
362573|NCT01241097|ezetimibe
362574|NCT01241097|pleiotropism
362575|NCT01241084|asthmatic children
362576|NCT01241071|Lumbar region
362577|NCT01241071|Pain
362578|NCT01241071|Fascia
362579|NCT01241071|Electromyography
362580|NCT01241071|Goniometry
362581|NCT01241058|pediatrics, crohn's disease, disease course, therapy
362582|NCT01241032|DA-8159
362583|NCT01241032|Udenafil
362584|NCT01241032|Alcohol
362585|NCT01241019|asphyxia neonatorum, hypothermia, neuroprotection
362586|NCT01241006|Relapse
362587|NCT01241006|Corticosteroids
362588|NCT01240993|parenting intervention
362589|NCT01240993|mother-child relations
362590|NCT01240993|substance abuse
362591|NCT01240993|attachment
362592|NCT01240993|child development
362593|NCT01240967|Phase 1
362594|NCT01240967|healthy volunteers
362595|NCT01240967|volunteers with renal impairment
362596|NCT01240967|pharmacokinetics
362597|NCT01240967|TC-5214
362598|NCT01240954|Rhinitis
362599|NCT01240954|Allergic
362600|NCT01240954|Immunotherapy
362601|NCT01240915|safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis
362602|NCT01240902|Valvular Heart Disease
362603|NCT01240902|Critical Aortic Stenosis
362604|NCT01240902|Severe Aortic Stenosis
362605|NCT01240902|High Risk
362606|NCT01240902|Aortic Valve Replacement
362607|NCT01240889|Ragweed allergies
362608|NCT01240889|acoustic rhinometry
362609|NCT01240889|nasal allergen challenge
362610|NCT01240876|Sciatica
362611|NCT01240876|Pain
362612|NCT01240863|osteoarthritis
362613|NCT01240863|low back pain
362614|NCT01240863|Moderate to Severe Pain
362615|NCT01240850|Retroperitoneal fibrosis
362616|NCT01240850|Inflammatory aneurysms
362617|NCT01240850|Methotrexate
362618|NCT01240850|Prednisone
362619|NCT01240850|Aorta
362620|NCT01240837|glycaemic index
362621|NCT01240837|arenga pinnata sugar
362622|NCT01240837|palm sugar
362623|NCT01240837|diabetes
362624|NCT01240824|bladder cancer
362625|NCT01240824|urothelial carcinoma
362626|NCT01240824|transitional cell carcinoma bladder
362627|NCT01240824|ureter
362628|NCT01240811|intrauterine device
362629|NCT01240811|IUD
362630|NCT01240811|levonorgestrel
362631|NCT01240811|copper
362632|NCT01240811|CD4
362633|NCT01240811|CCR5
362634|NCT01240811|microflora
362635|NCT01240798|Depression
362636|NCT01240798|Anxiety
362637|NCT01240798|Coronary disease
362638|NCT01240785|gestational diabetes
362639|NCT01240785|metformin
362640|NCT01240785|insulin
362641|NCT01240772|Haemorrhoids, Surgery, Cost-effectiveness, Morbidity, Risk assessment,RCT, Stapled haemorrhoidopexy, Doppler-guided, Haemorrhoidal artery ligation, Outcome
362642|NCT01240759|Type 2 Diabetes Mellitus
362643|NCT01240759|Metformin
362644|NCT01240746|Influenza
362645|NCT01240746|Quadrivalent Influenza Vaccine
362646|NCT01240746|Trivalent Influenza Vaccine
362647|NCT01240746|Influenza viruses
362648|NCT01240746|Fluzone®
362649|NCT01240720|I131
362650|NCT01240720|F16
362651|NCT01240720|antibody
362652|NCT01240720|monoclonal
362653|NCT01240720|tumor targeting
362654|NCT01240720|radioimmunotherapy
362655|NCT01240720|lymphoma, breast and lung cancer
362656|NCT01240720|Patients with different cancer types
362657|NCT01240694|Lupus
362658|NCT01240694|SLE
362659|NCT01240681|Locally Advanced Breast Cancer (LABC)
362660|NCT01240681|neoadjuvant chemotherapy
362661|NCT01240681|Fluorothymidine Positron Emission Tomography (FLT PET)
362662|NCT01240681|Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI)
362663|NCT01240681|tumor response
362664|NCT01240681|mastectomy
362665|NCT01240668|Hyponatremia
362666|NCT01240668|Euvolemia
362667|NCT01240668|Hypervolemia
362668|NCT01240668|Euvolemic
362669|NCT01240668|Hypervolemic
362670|NCT01240655|LCL161
362671|NCT01240655|solid tumors
362672|NCT01240655|paclitaxel
362673|NCT01240642|Advanced or metastatic cancer
362674|NCT01240642|refractory
362675|NCT01240642|core phase
362676|NCT01240642|extension phase
362677|NCT01240642|dose escalation
362678|NCT01240642|standard chemotherapy
362679|NCT01240642|doctaxel
362680|NCT01240642|paclitaxel
362681|NCT01240642|carboplatin
362682|NCT01240642|safety
362683|NCT01240642|tolerability
362684|NCT01240616|Nicotine
362685|NCT01240616|Mecamylamine
362686|NCT01240616|Attention
362687|NCT01240616|fMRI
362688|NCT01240616|Default Network
362689|NCT01240616|Healthy Volunteer
362690|NCT01240616|HV
362691|NCT01240603|Artemisinin
362692|NCT01240603|Malaria
362693|NCT01240603|Drug Resistance
362694|NCT01240603|Hemoglobin E
362695|NCT01240590|Anaplastic Thyroid Cancer
362696|NCT01240590|Crolibulin
362697|NCT01240590|Solid Tumors
362698|NCT01240590|ATC
362699|NCT01240577|IPdR
362700|NCT01240577|Pharmacokinetics
362701|NCT01240577|Early Phase I
362702|NCT01240577|Cancer
362703|NCT01240577|Solid Tumor
362704|NCT01240577|Lymphoma
362705|NCT01240551|Imaging
362706|NCT01240551|Bone Metastasis
362707|NCT01240551|Bone Scan
362708|NCT01240551|Radiopharmaceutical
362709|NCT01240551|Pet Scan
362710|NCT01240551|Prostate Cancer
362711|NCT01240525|graft versus host disease
362712|NCT01240525|recurrent grade 1 follicular lymphoma
362713|NCT01240525|recurrent grade 2 follicular lymphoma
362714|NCT01240525|recurrent small lymphocytic lymphoma
362715|NCT01240525|stage III small lymphocytic lymphoma
362716|NCT01240525|stage IV small lymphocytic lymphoma
362717|NCT01240525|Waldenstrom macroglobulinemia
362718|NCT01240525|stage III grade 1 follicular lymphoma
362719|NCT01240525|stage III grade 2 follicular lymphoma
362720|NCT01240525|stage IV grade 1 follicular lymphoma
362721|NCT01240525|stage IV grade 2 follicular lymphoma
362722|NCT01240525|stage III chronic lymphocytic leukemia
362723|NCT01240525|stage IV chronic lymphocytic leukemia
362724|NCT01240525|refractory chronic lymphocytic leukemia
362725|NCT01240525|Non-Hodgkin's lymphoma
362726|NCT01240525|Hodgkin's lymphoma
362727|NCT01240525|Chronic (Pro-)lymphocytic leukaemia
362728|NCT01240525|Plasma cell myeloma
362729|NCT01240525|Acute myeloid leukaemia
362730|NCT01240525|Acute lymphoblastic leukaemia
362731|NCT01240525|Myelodysplastic syndrome
362732|NCT01240525|Chronic myelomonocytic leukaemia
362733|NCT01240499|Weight management
362734|NCT01240499|New weight paradigm
362735|NCT01240499|Overweight women
362736|NCT01240499|Eating behaviors
362737|NCT01240499|Appetite ratings
362738|NCT01240499|Blood lipids
362739|NCT01240486|IRIS
362740|NCT01240486|HIV
362741|NCT01240486|Immune
362742|NCT01240486|Reconstitution
362743|NCT01240486|Inflammatory
362744|NCT01240486|Syndrome
362745|NCT01240473|kala azar
362746|NCT01240473|visceral leishmaniasis
362747|NCT01240473|diagnosis
362748|NCT01240473|drug resistance
362749|NCT01240473|Therapeutics
362750|NCT01240473|Capacity Building
362751|NCT01240447|NSCLC
362752|NCT01240447|lung cancer, small-cell
362753|NCT01240447|advanced lung cancer
362754|NCT01240434|trocar hernia closure laparoscopy
362755|NCT01240421|Metastatic breast cancer with no other treatment options
362756|NCT01240395|Multiple chemical sensitivities
362757|NCT01240395|MCS
362758|NCT01240395|Mindfulness-based cognitive therapy
362759|NCT01240395|MBCT
362760|NCT01240369|VEGFC
362761|NCT01240369|CTTN
362762|NCT01240369|miR326
362763|NCT01240369|ESCC
362764|NCT01240369|NSCLC
362765|NCT01240356|transcranial doppler
362766|NCT01240356|sonothrombolysis
362767|NCT01240356|ultrasound
362768|NCT01240356|stroke
362769|NCT01240343|Biobank
362770|NCT01240343|Genetics
362771|NCT01240330|Deep Vein Thrombosis
362772|NCT01240330|Effects of compression therapy
362773|NCT01240330|Peak Flow Velocity
362774|NCT01240317|expert system
362775|NCT01240317|decision support system
362776|NCT01240317|human patient simulator
362777|NCT01240317|anesthesia
362778|NCT01240291|glutamine
362779|NCT01240291|trauma
362780|NCT01240291|alanyl-glutamine
362781|NCT01240265|Vitamin D deficiency
362782|NCT01240265|Rickets
362783|NCT01240265|Infant
362784|NCT01240265|Nutrition
362785|NCT01240252|diabetes
362786|NCT01240252|insulin resistance
362787|NCT01240239|Pre anesthesia consultation
362788|NCT01240239|telemedicine
362789|NCT01240213|Vitamin D
362790|NCT01240213|lifestyle intervention
362791|NCT01240213|postmenopausal women
362792|NCT01240200|diabetes
362793|NCT01240200|elderly
362794|NCT01240200|insulin injections
362795|NCT01240187|epilepsy
362796|NCT01240174|Antibiotic
362797|NCT01240174|Antimicrobial
362798|NCT01240174|Prescribing
362799|NCT01240174|Cough
362800|NCT01240174|Acute Bronchitis
362801|NCT01240161|Glioblastoma multiforme
362802|NCT01240161|FLT
362803|NCT01240161|PET
362804|NCT01240148|Allodynia
362805|NCT01240148|hyperalgesia
362806|NCT01240148|paresthesia
362807|NCT01240135|Contact Lens Wear
362808|NCT01240135|Contact Lens Solution
362809|NCT01240135|Multi-purpose disinfecting solution
362810|NCT01240135|Myopia
362811|NCT01240122|Corneal staining and comfort evaluation in normal, habitual contact lens wearers.
362812|NCT01240096|Functional dyspepsia
362813|NCT01240096|Weight loss
362814|NCT01240096|Mirtazapine
362815|NCT01240083|Depression
362816|NCT01240083|Transcranial magnetic stimulation
362817|NCT01240083|Thetaburst Stimulation
362818|NCT01240083|Alternative treatment methods
362819|NCT01240070|diabetes,
362820|NCT01240070|cardiovascular
362821|NCT01240070|risk factor
362822|NCT01240070|cardiovascular event
362823|NCT01240070|intervention
362824|NCT01240057|Isolated Congenital Diaphragmatic Hernia
362825|NCT01240057|Fetal Surgery
362826|NCT01240057|Pulmonary Hypoplasia
362827|NCT01240044|Newborn Pain
362828|NCT01240044|Respiratory Physiotherapy
362829|NCT01240044|Neonatal intensive care unit
362830|NCT01240031|Malnutrition
362831|NCT01240031|Nutritional Risk
362832|NCT01240031|Intake
362833|NCT01240031|Food sensory
362834|NCT01240031|Nutritional therapy
362835|NCT01240031|Energy
362836|NCT01240031|Protein
362837|NCT01240031|Handgrip strength
362838|NCT01240031|Reaction time
362839|NCT01240031|Quality of Life
362840|NCT01239979|coronary artery disease
362841|NCT01239966|Acute Respiratory Distress syndrome
362842|NCT01239966|Acute renal Failure
362843|NCT01239953|In-stent restenosis
362844|NCT01239953|Drug-eluting balloon
362845|NCT01239953|Drug-eluting stent
362846|NCT01239953|Angiography
362847|NCT01239953|Minimal lumen diameter
362848|NCT01239940|In-stent restenosis
362849|NCT01239940|Drug-eluting balloon
362850|NCT01239940|Drug-eluting stent
362851|NCT01239940|Angiography
362852|NCT01239940|Minimal lumen diameter
362853|NCT01239927|diverticulitis
362854|NCT01239927|hartmann
362855|NCT01239927|anastomosis
362856|NCT01239914|drug eluting stent
362857|NCT01239914|coronary artery disease
362858|NCT01239914|Korean registry
362859|NCT01239901|sickle cell disease
362860|NCT01239901|sickle cell anemia
362861|NCT01239901|sickled cells
362862|NCT01239901|blood vessel
362863|NCT01239901|iron overload
362864|NCT01239888|Depression
362865|NCT01239888|Treatment resistant depression
362866|NCT01239888|Oxytocin
362867|NCT01239888|Estrogen Modulators
362868|NCT01239888|HPA axis
362869|NCT01239888|Mental Disorders
362870|NCT01239888|Estrogens
362871|NCT01239888|Tibolone
362872|NCT01239888|Estrogen Receptor Modulators
362873|NCT01239888|Androgens
362874|NCT01239888|Hormones
362875|NCT01239888|Hormone Substitutes
362876|NCT01239888|Physiological Effects of Drugs
362877|NCT01239888|Pharmacologic Actions
362878|NCT01239888|Hormone Antagonists
362879|NCT01239888|Bone Density Conservation Agents
362880|NCT01239888|Estrogen Antagonists
362881|NCT01239862|pulmonary, silicosis, chronic and accelerated silicosis, autologous transplantation
362882|NCT01239862|bone marrow cells, stem cells, cell therapy
362883|NCT01239849|Diabetes Mellitus, Hypercholesterolemia
362884|NCT01239836|urinary incontinence, self-management, cost, self-efficacy, continence promotion
362885|NCT01239823|osteoarthritis
362886|NCT01239823|whole body vibration
362887|NCT01239823|mobility
362888|NCT01239823|rehabilitation
362889|NCT01239810|hyaluronic acid
362890|NCT01239810|cartilage
362891|NCT01239810|T2 mapping
362892|NCT01239810|quantitative
362893|NCT01239810|MRI
362894|NCT01239810|volume
362895|NCT01239784|pediatrics
362896|NCT01239784|Heart Defects
362897|NCT01239784|Neurodevelopmental deficit
362898|NCT01239784|Neurodevelopmental Rehabilitation
362899|NCT01239771|Safety
362900|NCT01239771|tolerability
362901|NCT01239771|healthy
362902|NCT01239771|stable disease
362903|NCT01239771|oral
362904|NCT01239771|tablet
362905|NCT01239745|Hormone adjuvant treatment of early breast cancer with aromatase inhibitors following 2-3 years of tamoxifen
362906|NCT01239719|Allergic dermatitis
362907|NCT01239693|Stunting
362908|NCT01239693|Growth failure
362909|NCT01239693|Malnutrition
362910|NCT01239693|Lipid based nutrient supplement
362911|NCT01239693|LNS
362912|NCT01239693|Prevention
362913|NCT01239693|Malawi
362914|NCT01239693|Sub-Saharan Africa
362915|NCT01239693|Dietary supplementation
362916|NCT01239693|Efficacy
362917|NCT01239693|Pregnancy
362918|NCT01239693|Infancy
362919|NCT01239693|Newborn
362920|NCT01239680|hemorrhagic shock
362921|NCT01239680|glutamine
362922|NCT01239680|trauma resuscitation
362923|NCT01239680|department of defense
362924|NCT01239680|trauma
362925|NCT01239667|Health related quality of Life, Self Care behavior, activities of daily living
362926|NCT01239654|acute
362927|NCT01239654|coronary
362928|NCT01239654|syndrome
362929|NCT01239654|everolimus
362930|NCT01239654|zotarolimus
362931|NCT01239654|optical
362932|NCT01239654|coherence
362933|NCT01239654|tomography
362934|NCT01239641|Uterine Fibroids
362935|NCT01239641|Myoectomy
362936|NCT01239641|High Intensity Focused Ultrasound
362937|NCT01239641|ablation
362938|NCT01239602|changes in cortical excitability in subjects with chronic stroke after stem cell therapy
362939|NCT01239589|Patients admitted as for an acute bipolar manic episode
362940|NCT01239589|Description of management patterns and hospital stay in patients admitted for acute bipolar manic episode and treated with either quetiapine IR or quetiapine XR
362941|NCT01239563|kidney transplantation
362942|NCT01239563|donation after cardiac death
362943|NCT01239563|ischemia-reperfusion injury
362944|NCT01239563|thymoglobulin
362945|NCT01239563|steroid avoidance
362946|NCT01239563|lymphocyte
362947|NCT01239550|Insulin
362948|NCT01239550|Detemir
362949|NCT01239550|Dopamine, brain,neurotransmitter
362950|NCT01239550|Diabetes
362951|NCT01239550|Obesity
362952|NCT01239550|Neurotransmitters
362953|NCT01239524|breast reconstruction, latissimus dorsi flap, thoracodorsal nerve, skeletal muscle disuse, breast MRI
362954|NCT01239485|Pediatric refractory or relapsed acute leukemia
362955|NCT01239472|chronic allograft nephropathy
362956|NCT01239472|cytokines
362957|NCT01239472|kidney transplant
362958|NCT01239472|calcineurin inhibitors withdrawn
362959|NCT01239446|Hodgkin lymphoma
362960|NCT01239446|mediastinal irradiation
362961|NCT01239446|Coronary Artery Disease
362962|NCT01239394|NHL
362963|NCT01239394|ofatumumab
362964|NCT01239381|proton radiation
362965|NCT01239381|stereotactic body radiotherapy
362966|NCT01239381|SBRT
362967|NCT01239368|Multiple Myeloma
362968|NCT01239368|High Risk
362969|NCT01239368|Newly Diagnosed
362970|NCT01239368|Adoptive Immunotherapy
362971|NCT01239368|Autologous
362972|NCT01239329|Complex multiple disabilities
362973|NCT01239329|Malnutrition
362974|NCT01239277|muscle
362975|NCT01239277|FSR
362976|NCT01239277|protein
362977|NCT01239277|carbohydrate
362978|NCT01239277|leucine
362979|NCT01239251|GlowCap
362980|NCT01239251|adjuvant endocrine therapy
362981|NCT01239238|asthma
362982|NCT01239238|children
362983|NCT01239238|home monitoring
362984|NCT01239238|exhaled breath condensate
362985|NCT01239238|non-invasive inflammatory markers
362986|NCT01239238|volatile organic compounds
362987|NCT01239225|Patients undergoing coronary angiography
362988|NCT01239212|seizures
362989|NCT01239212|neonate
362990|NCT01239212|levetiracetam
362991|NCT01239212|Epilepsy
362992|NCT01239212|central nervous system diseases
362993|NCT01239212|anticonvulsants
362994|NCT01239199|Infants
362995|NCT01239199|Exhaled Nitric Oxide
362996|NCT01239199|Asthma
362997|NCT01239199|Tobacco smoke exposure
362998|NCT01239199|environment
362999|NCT01239186|methylation
363000|NCT01239186|micro array
363001|NCT01239186|locus H19
363002|NCT01239186|male infertility
363003|NCT01239173|Posttraumatic stress disorder
363004|NCT01239173|functional Magnetic Resonance Imaging
363005|NCT01239173|Amygdala
363006|NCT01239173|emotion regulation
363007|NCT01239173|memory
363008|NCT01239160|lymphedema
363009|NCT01239160|pneumatic compression device
363010|NCT01239160|randomised clinical trial
363011|NCT01239160|volume reduction
363012|NCT01239147|weight maintenance
363013|NCT01239134|Malignant melanoma
363014|NCT01239134|Metastatic
363015|NCT01239134|Unresectable
363016|NCT01239134|Stage III or Stage IV
363017|NCT01239134|Solid tumor
363018|NCT01239121|drug toxicity
363019|NCT01239121|drug interactions
363020|NCT01239121|electronic health records
363021|NCT01239121|medical errors
363022|NCT01239043|Meningitis
363023|NCT01239043|Meningococcal Meningitis
363024|NCT01239043|Meningococcal Infections
363025|NCT01239043|Menactra®
363026|NCT01239043|Menomune®
363027|NCT01239043|Meningococcal vaccine
363028|NCT01239030|inattention
363029|NCT01239030|impulsivity
363030|NCT01239030|hyperactivity
363031|NCT01239030|ADHD
363032|NCT01239004|dyslipidemia
363033|NCT01239004|hyperlipidemia
363034|NCT01239004|hyperglycemia
363035|NCT01239004|impaired fasting glucose
363036|NCT01238978|Diabetes mellitus, vildagliptin, hypoglycemia, elderly
363037|NCT01238952|solid tumors
363038|NCT01238952|breast cancer
363039|NCT01238952|triple negative breast cancer
363040|NCT01238952|HER2 negative
363041|NCT01238952|ER negative
363042|NCT01238952|PR negative
363043|NCT01238939|solid tumors
363044|NCT01238939|colorectal cancer
363045|NCT01238926|Oxidative stress
363046|NCT01238926|Parkinson's disease
363047|NCT01238926|Homocysteine
363048|NCT01238926|Glutathione
363049|NCT01238926|B vitamins
363050|NCT01238887|Satiety
363051|NCT01238887|Food Intake
363052|NCT01238887|Weight Loss
363053|NCT01238887|Oxidative Stress
363054|NCT01238887|botanicals
363055|NCT01238887|Garcinia Cambogia-derived hydroxycitric acid
363056|NCT01238861|Asthma
363057|NCT01238861|Benralizumab
363058|NCT01238861|MEDI-563
363059|NCT01238848|Hypertonic
363060|NCT01238848|Saline
363061|NCT01238848|Bronchiolitis
363062|NCT01238848|Efficacy
363063|NCT01238835|Sapien XT Valve
363064|NCT01238835|Valvular Heart Disease
363065|NCT01238835|Aortic Stenosis
363066|NCT01238835|Heart Valve Therapy
363067|NCT01238835|Transapical
363068|NCT01238835|Transcatheter
363069|NCT01238809|Compliance
363070|NCT01238809|France
363071|NCT01238796|telavancin
363072|NCT01238796|Pharmacokinetics
363073|NCT01238796|Severe renal disease
363074|NCT01238796|VIBATIV®
363075|NCT01238796|ASP9809
363076|NCT01238770|Ovarian cancer
363077|NCT01238757|Prospective Studies
363078|NCT01238757|Humans, pediatric
363079|NCT01238757|Positive-Pressure Respiration/methods*
363080|NCT01238757|Respiration, Artificial/methods*
363081|NCT01238757|Intensive Care
363082|NCT01238757|Intensive Care Units/statistics & numerical data*
363083|NCT01238757|Respiration, Artificial/statistics & numerical data*
363084|NCT01238757|Patients/statistics & numerical data*
363085|NCT01238757|Prevalence
363086|NCT01238757|Respiratory Muscles/innervation
363087|NCT01238757|Child
363088|NCT01238757|Child, Preschool
363089|NCT01238757|Infant
363090|NCT01238757|Infant, Newborn
363091|NCT01238757|Intensive Care Units, Pediatric
363092|NCT01238757|Respiratory Rate*
363093|NCT01238731|Valve replacement
363094|NCT01238731|pulmonary hypertension
363095|NCT01238731|long term follow up
363096|NCT01238718|lidocaine
363097|NCT01238718|anesthetic depth
363098|NCT01238718|hemodynamics
363099|NCT01238718|rapid sequence induction
363100|NCT01238718|BIS
363101|NCT01238705|Hypertension
363102|NCT01238705|Antihypertensive Agents
363103|NCT01238705|Combination
363104|NCT01238705|Sexual Dysfunction
363105|NCT01238705|Oxidative Stress
363106|NCT01238692|Diffuse large B cell lymphoma
363107|NCT01238692|DLBCL
363108|NCT01238692|Relapsed B-cell lymphoma
363109|NCT01238692|Refractory B-cell lymphoma
363110|NCT01238692|B-cell Lymphoma
363111|NCT01238692|Panobinostat
363112|NCT01238692|LBH589
363113|NCT01238692|Rituximab
363114|NCT01238692|Histone Deacetylase Inhibitors
363115|NCT01238679|safety
363116|NCT01238679|tolerability
363117|NCT01238679|pharmacokinetics
363118|NCT01238679|healthy volunteers
363119|NCT01238666|liver
363120|NCT01238666|cancer
363121|NCT01238666|tumor
363122|NCT01238666|ablation
363123|NCT01238666|Pathfinder
363124|NCT01238653|liver
363125|NCT01238653|cancer
363126|NCT01238653|tumor
363127|NCT01238653|Pathfinder
363128|NCT01238640|Smoking Cessation
363129|NCT01238640|Nicotine
363130|NCT01238627|Smoking Cessation
363131|NCT01238627|Nicotine pharmacokinetics
363132|NCT01238614|maternal depression
363133|NCT01238614|clinical decision support
363134|NCT01238601|Breast augmentation
363135|NCT01238575|Pervasive Developmental Disorders
363136|NCT01238575|PDD
363137|NCT01238575|PDD-NOS
363138|NCT01238575|Autistic Disorder
363139|NCT01238575|Autism
363140|NCT01238575|Asperger's Disorder
363141|NCT01238575|Hyperactivity
363142|NCT01238575|Attention Deficit Hyperactivity Disorder
363143|NCT01238575|ADHD
363144|NCT01238575|Medication
363145|NCT01238575|Drug
363146|NCT01238575|Guanfacine
363147|NCT01238575|Intuniv
363148|NCT01238575|Placebo
363149|NCT01238575|Methylphenidate
363150|NCT01238562|cancer patient
363151|NCT01238562|chemotherapy
363152|NCT01238562|carboplatin
363153|NCT01238562|taxol
363154|NCT01238562|cyclophosphamide
363155|NCT01238562|pharmorubicin
363156|NCT01238549|Spinal Cord Injuries
363157|NCT01238549|Quality of Life
363158|NCT01238536|Epidural Steroid Injection
363159|NCT01238536|Low Back Pain
363160|NCT01238536|Spinal Stenosis
363161|NCT01238536|Elderly
363162|NCT01238523|tibia
363163|NCT01238523|shaft
363164|NCT01238523|fracture
363165|NCT01238523|children
363166|NCT01238497|SAPIEN XT™
363167|NCT01238497|Transfemoral
363168|NCT01238497|NovaFlex
363169|NCT01238497|NovaFlex+
363170|NCT01238497|NF
363171|NCT01238497|NF+
363172|NCT01238497|Transapical
363173|NCT01238497|Transaortic
363174|NCT01238497|Ascendra2
363175|NCT01238497|Ascendra+
363176|NCT01238497|Asc+
363177|NCT01238497|aortic stenosis
363178|NCT01238497|aortic valve
363179|NCT01238497|Transcatheter Heart Valve
363180|NCT01238497|THV
363181|NCT01238484|Ankle Equinus
363182|NCT01238484|Ankle contracture
363183|NCT01238484|Diabetes Mellitus
363184|NCT01238484|Dynasplint
363185|NCT01238484|AFD
363186|NCT01238471|retinopathy of prematurity
363187|NCT01238471|Propranolol
363188|NCT01238471|Vascular endothelial growth factor
363189|NCT01238471|premature infant
363190|NCT01238458|[18F]AV-45 PET amyloid binding imaging
363191|NCT01238458|Alzheimer's disease
363192|NCT01238458|mild cognitive impartment,
363193|NCT01238445|Pediatric
363194|NCT01238432|Pediatric
363195|NCT01238432|Polymorphism, Genetic
363196|NCT01238432|Adrenergic beta-Agonists
363197|NCT01238406|Type 1 diabetes
363198|NCT01238406|Closed loop
363199|NCT01238406|Artificial Pancreas
363200|NCT01238380|Monogenic diabetes
363201|NCT01238380|HNF1A
363202|NCT01238380|HNF4A
363203|NCT01238380|GCK
363204|NCT01238380|genetic testing
363205|NCT01238380|health economic model
363206|NCT01238354|Weight Loss
363207|NCT01238354|Social support
363208|NCT01238341|Pancreatobiliary disease in patients with altered gastric anatomy.
363209|NCT01238328|Mucopolysaccharidosis
363210|NCT01238328|HSCT
363211|NCT01238315|Batten's disease
363212|NCT01238315|INCL
363213|NCT01238315|LINCL
363214|NCT01238315|Neuronal Ceroid Lipofuscinosis
363215|NCT01238315|NCL
363216|NCT01238289|peer education
363217|NCT01238289|diabetes
363218|NCT01238289|randomized
363219|NCT01238289|trial
363220|NCT01238276|soft tissue infection
363221|NCT01238276|wound infection
363222|NCT01238276|cellulitis
363223|NCT01238276|foot ulcer
363224|NCT01238276|Diabetes
363225|NCT01238276|antibiotics
363226|NCT01238276|cefazolin
363227|NCT01238276|cephazolin
363228|NCT01238276|Ancef
363229|NCT01238276|Kefzol
363230|NCT01238276|subcutaneous fluid administration
363231|NCT01238276|ultrasound
363232|NCT01238276|MRSA
363233|NCT01238276|Methicillin-resistant Staphylococcus aureus
363234|NCT01238263|Atopic dermatitis, autologous serum skin testing, IgE autoantibodies
363235|NCT01238250|16p11.2
363236|NCT01238250|16p11.2 del
363237|NCT01238250|16p11.2 deletion
363238|NCT01238250|16p11.2 dup
363239|NCT01238250|16p11.2 duplication
363240|NCT01238250|chromosome 16
363241|NCT01238250|chromosome 16p
363242|NCT01238250|chromosome 16p11
363243|NCT01238250|chromosome 16p11.2
363244|NCT01238250|1q21.1
363245|NCT01238250|1q21.1 del
363246|NCT01238250|1q21.1 deletion
363247|NCT01238250|1q21.1 dup
363248|NCT01238250|1q21.1 duplication
363249|NCT01238250|chromosome 1
363250|NCT01238250|chromosome 1q
363251|NCT01238250|chromosome 1q21
363252|NCT01238250|chromosome 1q21.1
363253|NCT01238250|genetic mutation
363254|NCT01238250|genetic variant
363255|NCT01238250|gene variant
363256|NCT01238250|autism
363257|NCT01238250|ADNP
363258|NCT01238250|ANKRD1
363259|NCT01238250|ARID1B
363260|NCT01238250|ASXL3
363261|NCT01238250|BAF105
363262|NCT01238250|BAF180
363263|NCT01238250|BAF190
363264|NCT01238250|BAF35
363265|NCT01238250|BAF35b
363266|NCT01238250|BCL11A
363267|NCT01238250|CHD2
363268|NCT01238250|CHD8
363269|NCT01238250|CTNNB1
363270|NCT01238250|CUL3
363271|NCT01238250|DST
363272|NCT01238250|DYRK1A
363273|NCT01238250|FOXP1
363274|NCT01238250|GRIN2B
363275|NCT01238250|KDM6B
363276|NCT01238250|KMT2E
363277|NCT01238250|MBD5
363278|NCT01238250|MED13L
363279|NCT01238250|PTEN
363280|NCT01238250|REST
363281|NCT01238250|SCN2A
363282|NCT01238250|SMARCC1
363283|NCT01238250|SMARCC2
363284|NCT01238250|SYNGAP1
363285|NCT01238250|HIVEP2
363286|NCT01238250|HNRNPH2
363287|NCT01238250|PPP2R5D
363288|NCT01238237|Glioblastoma Multiforme
363289|NCT01238237|Anaplastic Astrocytoma
363290|NCT01238237|High Grade Glial Neoplasms
363291|NCT01238237|Brain Tumor
363292|NCT01238237|EGFR
363293|NCT01238237|Epidermal Growth Factor Receptor
363294|NCT01238237|EGFRvIII
363295|NCT01238224|Insulin resistance
363296|NCT01238224|Phosphodiesterase-5 inhibition
363297|NCT01238224|Microdialysis
363298|NCT01238224|Type 2 diabetes
363299|NCT01238224|Endothelial dysfunction
363300|NCT01238224|Oral hypoglycaemic agents
363301|NCT01238185|oral leukoplakia
363302|NCT01238172|stage I prostate cancer
363303|NCT01238172|stage IIB prostate cancer
363304|NCT01238172|stage IIA prostate cancer
363305|NCT01238172|adenocarcinoma of the prostate
363306|NCT01238159|Natural killer cell
363307|NCT01238159|T cell
363308|NCT01238159|Lymphoma
363309|NCT01238159|Radiation
363310|NCT01238159|Chemotherapy
363311|NCT01238120|Cancer
363312|NCT01238120|Cognitive difficulties
363313|NCT01238107|Cachexia
363314|NCT01238107|Cancer
363315|NCT01238094|colorectal cancer
363316|NCT01238094|simvastatin
363317|NCT01238094|second-line chemotherapy
363318|NCT01238081|Cystic fibrosis
363319|NCT01238055|advanced gastric cancer
363320|NCT01238055|sunitinib
363321|NCT01238055|docetaxel
363322|NCT01238055|fluoropyrimidine platinum based chemotherapy
363323|NCT01238029|Dose finding study
363324|NCT01238029|Combination
363325|NCT01237990|liver
363326|NCT01237990|cancer
363327|NCT01237990|tumor
363328|NCT01237951|Autologous Hematopoietic-Cell Support
363329|NCT01237951|Stem Cell Transplant
363330|NCT01237951|Busulfan
363331|NCT01237951|Myleran
363332|NCT01237951|Busulfex
363333|NCT01237951|Gemcitabine
363334|NCT01237951|Gemzar
363335|NCT01237951|Melphalan
363336|NCT01237951|Alkeran
363337|NCT01237951|Decadron
363338|NCT01237951|Dexamethasone
363339|NCT01237951|G-CSF
363340|NCT01237951|Filgrastim
363341|NCT01237951|Neupogen
363342|NCT01237925|Sunburn
363343|NCT01237925|Dexchlorpheniramine
363344|NCT01237925|Gel
363345|NCT01237925|Cream
363346|NCT01237899|Kidney
363347|NCT01237899|Renal
363348|NCT01237886|spontaneous breathing trial
363349|NCT01237886|heart rate variability
363350|NCT01237886|respiratory rate variability
363351|NCT01237873|Aliskiren
363352|NCT01237873|Amlodipine
363353|NCT01237873|Essential hypertension
363354|NCT01237873|Long term
363355|NCT01237860|Foot drop
363356|NCT01237860|Thigh muscle weakness
363357|NCT01237860|Upper Motor Neuron injury or disease
363358|NCT01237847|inflammatory bowel disease
363359|NCT01237847|IBD
363360|NCT01237847|Crohn's disease
363361|NCT01237847|ulcerative colitis
363362|NCT01237847|adolescent
363363|NCT01237808|AML
363364|NCT01237808|NPM1 Mutation
363365|NCT01237808|elderly patients (>60 years)
363366|NCT01237808|unfit for intensive chemotherapy
363367|NCT01237795|Chloramine T
363368|NCT01237795|Complete Denture
363369|NCT01237795|Dental Plaque Index
363370|NCT01237795|Dentifrice
363371|NCT01237795|Denture Bases
363372|NCT01237795|Denture Cleansers
363373|NCT01237795|Edentulous Mouth
363374|NCT01237795|Fluorosurfactant
363375|NCT01237795|Oral Health
363376|NCT01237795|Toothpaste
363377|NCT01237782|Candida
363378|NCT01237782|Complete Denture
363379|NCT01237782|Dental Plaque Index
363380|NCT01237782|Denture Bases
363381|NCT01237782|Denture Cleansers
363382|NCT01237782|Edentulous Mouth
363383|NCT01237782|Mutans Streptococci
363384|NCT01237782|Oral Health
363385|NCT01237782|Propolis
363386|NCT01237782|Streptococcus mutans
363387|NCT01237769|vitamin D
363388|NCT01237769|Metabolic syndrome
363389|NCT01237769|Hypertension
363390|NCT01237769|Dyslipidemia
363391|NCT01237769|Dysglycemia
363392|NCT01237769|Inflammation
363393|NCT01237756|pediatric anesthesia
363394|NCT01237756|endotracheal tube
363395|NCT01237756|electrical impedance tomography
363396|NCT01237756|misplacement
363397|NCT01237756|endobronchial
363398|NCT01237743|Embolism
363399|NCT01237743|Nervous system
363400|NCT01237743|Aorta
363401|NCT01237743|Valves
363402|NCT01237743|Ultrasonics
363403|NCT01237730|percutaneous endoscopic gastrostomy
363404|NCT01237730|peristomal wound infection
363405|NCT01237730|prophylactic antibiotics
363406|NCT01237717|hypertension
363407|NCT01237691|drug use
363408|NCT01237691|drug arrests
363409|NCT01237691|incarceration
363410|NCT01237678|Immunogen
363411|NCT01237678|Lung
363412|NCT01237678|Small Cell Lung Cancer
363413|NCT01237678|Carboplatin
363414|NCT01237678|ADC
363415|NCT01237665|locally resectable advanced adenocarcinoma of the rectum
363416|NCT01237652|Isolated Systolic Hypertension
363417|NCT01237652|Perioperative Myocardial Ischemia
363418|NCT01237652|Perioperative Cardiovascular adverse events
363419|NCT01237639|Red Cells
363420|NCT01237639|Transfusion
363421|NCT01237639|Trigger
363422|NCT01237639|Threshold
363423|NCT01237639|Hematopoietic Stem cell Transplantation
363424|NCT01237626|Driving
363425|NCT01237626|Aging
363426|NCT01237626|Older drivers
363427|NCT01237626|Medical Fitness to drive
363428|NCT01237626|Health Status
363429|NCT01237626|At-fault collisions
363430|NCT01237613|Achilles
363431|NCT01237613|Rupture
363432|NCT01237613|Tendon
363433|NCT01237613|Artelon
363434|NCT01237600|Ocular surface damage
363435|NCT01237600|Limbal deficiency
363436|NCT01237600|Cultivated corneal epithelial stem cell transplantation
363437|NCT01237587|Adolescents
363438|NCT01237587|Juvenile Primary Fibromyalgia Syndrome
363439|NCT01237574|Liver Diseases
363440|NCT01237574|Alcoholic
363441|NCT01237574|Metabolic Diseases
363442|NCT01237574|cohort
363443|NCT01237574|liver disease
363444|NCT01237561|Chronic Obstructive Pulmonary Disease
363445|NCT01237561|COPD Guidelines
363446|NCT01237561|Patient Activation
363447|NCT01237561|Lung Age
363448|NCT01237548|water pipe smoking
363449|NCT01237548|acute effect
363450|NCT01237548|Endothelial
363451|NCT01237548|healthy adults who smoke narghile
363452|NCT01237535|Unexplained infertility
363453|NCT01237535|Insemination
363454|NCT01237535|Luteal phase support
363455|NCT01237535|Ovarian stimulation
363456|NCT01237522|Diabetes Mellitus, Type 2
363457|NCT01237522|Metabolic Clearance Rate
363458|NCT01237522|Pharmacokinetics
363459|NCT01237522|Pharmacogenetics
363460|NCT01237509|EEG
363461|NCT01237509|Sleep
363462|NCT01237509|device
363463|NCT01237509|diabetes
363464|NCT01237509|hypoglycemia
363465|NCT01237483|reirradiation with Erbitux
363466|NCT01237483|HNSCC
363467|NCT01237483|local recurrent inoperable Squamous Cell Cancer of the Head and Neck
363468|NCT01237470|inguinal hernia
363469|NCT01237470|hernia recurrence
363470|NCT01237470|no mesh techniques
363471|NCT01237470|Desarda technique
363472|NCT01237444|Lopinavir/ritonavir plus 3TC as a dual therapy regimen.
363473|NCT01237431|Water drinking
363474|NCT01237431|osmoreceptors
363475|NCT01237431|autonomic failure
363476|NCT01237431|syncope
363477|NCT01237431|blood pressure
363478|NCT01237431|liver transplant
363479|NCT01237405|osteoarthritis
363480|NCT01237405|nuclear medicine
363481|NCT01237405|macrophages
363482|NCT01237392|wound debridement
363483|NCT01237392|requiring debridement
363484|NCT01237366|HIV/AIDS
363485|NCT01237366|Methamphetamine
363486|NCT01237366|Trauma
363487|NCT01237340|Adult Growth Hormone Deficiency (AGHD)
363488|NCT01237340|immunogenicity
363489|NCT01237340|growth hormone
363490|NCT01237340|antibodies
363491|NCT01237340|GH biomarkers
363492|NCT01237340|IGF-I
363493|NCT01237327|Metastatic Breast Cancer
363494|NCT01237327|Advanced
363495|NCT01237327|Postmenopausal
363496|NCT01237327|Exemestane vs Megestrol
363497|NCT01237314|type 2 diabetes
363498|NCT01237314|metformin
363499|NCT01237314|glargine
363500|NCT01237314|exenatide
363501|NCT01237314|glycemic impact of food
363502|NCT01237314|continuous glucose monitoring
363503|NCT01237301|Type 2 Diabetes
363504|NCT01237301|Continuous Glucose Monitoring
363505|NCT01237275|Pharmacogenomics
363506|NCT01237275|Prediction of Antidepressant Response
363507|NCT01237275|Depressed Patients
363508|NCT01237262|psoriasis
363509|NCT01237262|immune infiltrate
363510|NCT01237262|dendritic cells
363511|NCT01237262|cytokine expression
363512|NCT01237249|Multiple Myeloma
363513|NCT01237249|Velcade
363514|NCT01237249|Revlimid
363515|NCT01237236|Advanced solid tumor
363516|NCT01237236|lymphoma
363517|NCT01237223|Aliskiren
363518|NCT01237223|Amlodipine
363519|NCT01237223|Essential hypertension
363520|NCT01237210|Parkinson's Disease
363521|NCT01237210|PD
363522|NCT01237210|magnetic resonance spectroscopy
363523|NCT01237184|initial dental implant stability
363524|NCT01237184|maxillary sinus proximity
363525|NCT01237184|bicortical fixation
363526|NCT01237171|Brachytherapy
363527|NCT01237171|Lung Brachytherapy
363528|NCT01237171|NSCLC
363529|NCT01237171|Sub-lobar resection
363530|NCT01237158|GAD1,
363531|NCT01237158|GAD67,
363532|NCT01237158|bipolar,
363533|NCT01237158|GABA,
363534|NCT01237158|Glutamate,
363535|NCT01237158|Reelin,
363536|NCT01237158|Rln,
363537|NCT01237158|Spectroscopy
363538|NCT01237158|euthymic bipolar I patients
363539|NCT01237145|pigeon
363540|NCT01237145|bird fancier
363541|NCT01237145|extrinsic allergic alveolitis
363542|NCT01237145|BAL
363543|NCT01237145|broncho-alveolar lavage
363544|NCT01237145|elispot
363545|NCT01237145|antigen
363546|NCT01237106|PCOS
363547|NCT01237106|IVM
363548|NCT01237106|Polycystic ovarian syndrome
363549|NCT01237106|In Vitro Maturation
363550|NCT01237106|IVF
363551|NCT01237093|Fish Diet
363552|NCT01237093|Meat Diet
363553|NCT01237093|Biomarkers
363554|NCT01237093|Stable Isotopes
363555|NCT01237093|Dietary Intake
363556|NCT01237067|PARP inhibitor, womens's cancers, relapsed, recurrent
363557|NCT01237067|Ovarian, breast, endometrial, cervical
363558|NCT01237067|Carboplatin
363559|NCT01237067|BRCA 1 and BRCA 2
363560|NCT01237067|Breast Cancer
363561|NCT01237067|Ovarian Cancer
363562|NCT01237067|Uterine Cancer
363563|NCT01237067|Cervical Cancer
363564|NCT01237067|Peritoneal Cancer
363565|NCT01237067|Endometrial Cancer
363566|NCT01237067|Fallopian Tube Cancer
363567|NCT01237054|18-FDG PET/CT
363568|NCT01237054|Abnormal Plasma Cells
363569|NCT01237054|Serum Free Light-Chain Abnormality
363570|NCT01237054|Serum M-Protein
363571|NCT01237054|DCE-MRI
363572|NCT01237054|Multiple Myeloma
363573|NCT01237054|Smoldering Multiple Myeloma
363574|NCT01237054|SMM
363575|NCT01237054|MM
363576|NCT01237041|Child
363577|NCT01237041|Body Fat
363578|NCT01237041|Niacin
363579|NCT01237041|Growth Hormone
363580|NCT01237041|Obesity
363581|NCT01237041|Growth Hormones
363582|NCT01237041|Short Stature
363583|NCT01237041|Children
363584|NCT01237015|Neonate
363585|NCT01237015|Oral feeding
363586|NCT01237015|Nasal CPAP
363587|NCT01237015|Sucking
363588|NCT01237015|Swallowing
363589|NCT01237015|Breathing
363590|NCT01237002|Liver ischemia; Pringle time
363591|NCT01236989|anatomical resection
363592|NCT01236989|non-anatomical resection
363593|NCT01236989|IOUS-guided finger compression
363594|NCT01236963|Clinical trial
363595|NCT01236963|Prevention mouthrinse
363596|NCT01236963|Dental Floss
363597|NCT01236950|Clinical Trial
363598|NCT01236950|Prevention Mouthrinse
363599|NCT01236937|CT, lung nodule biopsy, Respiration Gated, Lung Cancer
363600|NCT01236911|Calcium , TBI,complications, days in hospital
363601|NCT01236898|N-acetylneuraminic acid,
363602|NCT01236898|pharmacokinetics
363603|NCT01236898|hIBM
363604|NCT01236872|Nitrate
363605|NCT01236872|Nitrite
363606|NCT01236872|Vegetable
363607|NCT01236872|Aortic stiffness
363608|NCT01236859|Gabapentin
363609|NCT01236859|prophylaxis
363610|NCT01236859|incidence of pruritus
363611|NCT01236859|intrathecal morphine
363612|NCT01236846|Vitamin D fortification
363613|NCT01236846|Yogurt Drink
363614|NCT01236846|Efficacy
363615|NCT01236833|Lactated Ringer's Solution
363616|NCT01236833|Isotonic Solution
363617|NCT01236833|Intestinal Disease
363618|NCT01236833|Feeding Intolerance
363619|NCT01236833|Necrotizing Enterocolitis
363620|NCT01236833|Newborn
363621|NCT01236833|Premature Infant
363622|NCT01236820|L5
363623|NCT01236820|LDL
363624|NCT01236820|Cardiovascular disease
363625|NCT01236820|Chronic kidney disease
363626|NCT01236820|Hemodialysis
363627|NCT01236807|Adenosine
363628|NCT01236807|Magnetic Resonance Imaging
363629|NCT01236807|MR perfusion
363630|NCT01236807|Fractional Flow Reserve, Myocardial
363631|NCT01236807|FFR
363632|NCT01236807|Pressure wire
363633|NCT01236807|Coronary Disease
363634|NCT01236807|Heart Diseases
363635|NCT01236807|Cardiovascular Diseases
363636|NCT01236807|Arteriosclerosis
363637|NCT01236781|breast cancer
363638|NCT01236781|screening
363639|NCT01236781|diagnostics
363640|NCT01236781|diagnosis
363641|NCT01236781|high-risk
363642|NCT01236781|breast neoplasms
363643|NCT01236781|digital mammography
363644|NCT01236781|mammography
363645|NCT01236781|tomosynthesis
363646|NCT01236781|dense breasts
363647|NCT01236781|radiation dose
363648|NCT01236781|comparison
363649|NCT01236781|Hologic
363650|NCT01236781|Pennsylvania
363651|NCT01236781|Philadelphia
363652|NCT01236781|breast study
363653|NCT01236781|mammo
363654|NCT01236781|tomo
363655|NCT01236781|mammary
363656|NCT01236768|Contraceptive
363657|NCT01236755|children
363658|NCT01236755|corneal reshaping
363659|NCT01236755|myopia
363660|NCT01236755|myopia progression
363661|NCT01236755|orthokeratology
363662|NCT01236742|children
363663|NCT01236742|corneal reshaping
363664|NCT01236742|myopia
363665|NCT01236742|myopia progression
363666|NCT01236742|orthokeratology
363667|NCT01236729|knee replacement
363668|NCT01236729|disability
363669|NCT01236729|older people
363670|NCT01236716|squamous cell carcinoma of lung
363671|NCT01236716|Albumin bound paclitaxel
363672|NCT01236716|chemotherapy
363673|NCT01236703|SIRS
363674|NCT01236703|Sepsis
363675|NCT01236703|hematological infection score
363676|NCT01236690|Transcatheter arterial embolization
363677|NCT01236690|Cinobufacin injection
363678|NCT01236690|hepatoma
363679|NCT01236677|Pathogen
363680|NCT01236664|memory training
363681|NCT01236664|mnemonics
363682|NCT01236664|cognition
363683|NCT01236664|work
363684|NCT01236638|Primary Myelofibrosis
363685|NCT01236638|Post-Polycythemia Vera
363686|NCT01236638|Post-Essential Thrombocythemia
363687|NCT01236638|CYT387
363688|NCT01236625|Tissue Adhesions
363689|NCT01236625|Adhesiolysis
363690|NCT01236625|Inadvertent enterotomy
363691|NCT01236625|Prospective cohort study
363692|NCT01236625|Quality of life
363693|NCT01236612|Plasmodium
363694|NCT01236612|falciparum
363695|NCT01236612|malaria
363696|NCT01236612|chloroquine
363697|NCT01236612|immunity
363698|NCT01236599|preterm infant, thermoregulation, polyethylene bag
363699|NCT01236586|Maximum Tolerated Dose
363700|NCT01236586|Toxicity
363701|NCT01236586|Pharmacokinetics
363702|NCT01236586|NOTCH Signaling Pathway
363703|NCT01236586|Expression of JAGGED 1 and 2
363704|NCT01236586|Cancer
363705|NCT01236586|Solid Tumor
363706|NCT01236586|Brain Tumor
363707|NCT01236586|Wilms Tumor
363708|NCT01236586|Osteosarcoma
363709|NCT01236586|Lymphoma
363710|NCT01236573|Gene Therapy
363711|NCT01236573|Immunotherapy
363712|NCT01236573|Adoptive Cell Therapy
363713|NCT01236573|Metastatic Melanoma
363714|NCT01236534|Multiple Sclerosis
363715|NCT01236534|Constipation
363716|NCT01236534|Multiple Sclerosis Associated Constipation
363717|NCT01236521|Back pain
363718|NCT01236521|Care Management
363719|NCT01236521|Pain
363720|NCT01236521|Patient outcomes
363721|NCT01236521|Patient-center Care
363722|NCT01236521|Primary care
363723|NCT01236508|White Matter Hyperintensity
363724|NCT01236508|Stroke
363725|NCT01236508|Carotid Artery Plaque Inflammation
363726|NCT01236508|FDG PET
363727|NCT01236508|MRI
363728|NCT01236508|TIA
363729|NCT01236495|thoracotomy
363730|NCT01236495|postoperative pain
363731|NCT01236495|spinal morphine
363732|NCT01236482|Pregnancy
363733|NCT01236482|Postpartum hemorrhage
363734|NCT01236482|Uterine tone
363735|NCT01236482|Oxytocin
363736|NCT01236482|Ergometrine
363737|NCT01236482|Pharmacokinetic-pharmacodynamic analysis
363738|NCT01236469|Aortic Valve
363739|NCT01236456|chronic inflammatory demyelinating polyneuropathy
363740|NCT01236456|cyclophosphamide
363741|NCT01236456|autoimmune
363742|NCT01236430|Hyperlipidemia
363743|NCT01236430|statin
363744|NCT01236430|Ezetimibe
363745|NCT01236430|Zetia
363746|NCT01236430|Atorvastatin
363747|NCT01236430|Lipitor
363748|NCT01236391|Pharmacyclics
363749|NCT01236391|Mantle
363750|NCT01236391|Mantle Cell
363751|NCT01236391|Lymphoma
363752|NCT01236391|Non-Hodgkins
363753|NCT01236391|Bortezomib
363754|NCT01236391|Velcade
363755|NCT01236391|Naive
363756|NCT01236391|PCYC
363757|NCT01236378|Organ Transplants
363758|NCT01236378|Anti-Rejection Therapy
363759|NCT01236378|Pharmacokinetics
363760|NCT01236365|Type 1 diabetes
363761|NCT01236365|Children
363762|NCT01236365|Statins
363763|NCT01236365|Hypercholesterolemia
363764|NCT01236365|Lipoproteins
363765|NCT01236365|C reactive protein
363766|NCT01236365|Continuous glucose monitors
363767|NCT01236365|Adolescence
363768|NCT01236365|Abdominal magnetic resonance imaging
363769|NCT01236365|Toll like receptors
363770|NCT01236365|Receptors of advanced glycation end products
363771|NCT01236365|Nutrition
363772|NCT01236352|Advanced Cancer, Various, NOS
363773|NCT01236313|TEE
363774|NCT01236313|Cardiac Surgery
363775|NCT01236313|Pulse Pressure
363776|NCT01236300|Pancreatic cysts
363777|NCT01236274|Myocardial Infarction
363778|NCT01236274|Antipsychotic agents
363779|NCT01236274|Self-controlled case series method
363780|NCT01236274|General Practice Research Database
363781|NCT01236274|Myocardial Ischaemia National Audit Project
363782|NCT01236274|CALIBER
363783|NCT01236261|Fungemia, fungal infection, susceptibility, antifungal
363784|NCT01236248|drugs
363785|NCT01236248|youth
363786|NCT01236248|parent
363787|NCT01236248|computer
363788|NCT01236248|prevention
363789|NCT01236222|commuter cycling
363790|NCT01236222|fitness
363791|NCT01236222|metabolic syndrome
363792|NCT01236222|children
363793|NCT01236196|pain
363794|NCT01236196|chronic pain
363795|NCT01236196|cognitive therapy
363796|NCT01236196|telehealth
363797|NCT01236183|manual skill
363798|NCT01236183|anesthesia residents
363799|NCT01236170|Amputees
363800|NCT01236170|spinal cord injuries
363801|NCT01236170|quality of life
363802|NCT01236170|satisfaction
363803|NCT01236170|healthcare disparities
363804|NCT01236170|wheelchairs
363805|NCT01236157|Cardiology
363806|NCT01236144|Myeloid
363807|NCT01236144|Leukaemia
363808|NCT01236144|Acute
363809|NCT01236144|Myelodysplastic
363810|NCT01236144|Pilot
363811|NCT01236144|Cardiff
363812|NCT01236144|Haematology
363813|NCT01236144|Burnett
363814|NCT01236144|AC220
363815|NCT01236144|Plerixafor
363816|NCT01236144|Ganetespib
363817|NCT01236092|resolution of low back pain
363818|NCT01236092|show measurable improvement in disc measurement
363819|NCT01236092|conservative therapy vs. surgery in resolving low back pain
363820|NCT01236066|Rotavirus Gastroenteritis
363821|NCT01236066|Rotarix
363822|NCT01236066|RotaTeq
363823|NCT01236066|Gastroenteritis
363824|NCT01236053|renal cancer
363825|NCT01236053|pancreatic cancer
363826|NCT01236053|epidemiology
363827|NCT01236053|renal cell carcinoma
363828|NCT01236053|nervous system cancer
363829|NCT01236053|lung cancer
363830|NCT01236053|breast cancer
363831|NCT01236053|case-control
363832|NCT01236053|GPRD
363833|NCT01236053|Gapabentin
363834|NCT01236053|cancer
363835|NCT01236053|anal cancer
363836|NCT01236053|bone and joint cancer
363837|NCT01236053|renal pelvis cancer
363838|NCT01236053|penis cancer
363839|NCT01236053|stomach cancer
363840|NCT01236053|bladder cancer
363841|NCT01236040|H5N1
363842|NCT01236040|Influenza
363843|NCT01236040|Pandemic
363844|NCT01236001|Lacosamide
363845|NCT01236001|Vimpat®
363846|NCT01235975|Neisseria meningitidis
363847|NCT01235975|Meningococcal Vaccines
363848|NCT01235975|serogroups A,C, W-135 or Y
363849|NCT01235975|meningococcal diseases
363850|NCT01235975|meningococcal conjugate vaccine
363851|NCT01235975|Immunogenicity
363852|NCT01235962|anti-angiogenic agent
363853|NCT01235962|renal cell carcinoma
363854|NCT01235962|pazopanib
363855|NCT01235962|adjuvant therapy
363856|NCT01235962|VEGFR inhibitor
363857|NCT01235949|Pneumococcal vaccine
363858|NCT01235949|Immunogenicity
363859|NCT01235949|Safety
363860|NCT01235949|Fever
363861|NCT01235949|Primary vaccination
363862|NCT01235949|Booster vaccination
363863|NCT01235949|Pneumococcal disease
363864|NCT01235949|Prophylactic antipyretic
363865|NCT01235936|anemia
363866|NCT01235936|chronic kidney disease
363867|NCT01235936|CKD
363868|NCT01235936|chronic renal insufficiency
363869|NCT01235936|renal impairment
363870|NCT01235936|erythropoietin
363871|NCT01235936|safety
363872|NCT01235936|efficacy
363873|NCT01235936|tolerability
363874|NCT01235936|pharmacokinetics
363875|NCT01235923|anemia
363876|NCT01235923|transfusions
363877|NCT01235923|erythropoiesis
363878|NCT01235923|neonate
363879|NCT01235923|preterm
363880|NCT01235910|Hypertension
363881|NCT01235910|Cardiac transplantation
363882|NCT01235910|Aliskiren
363883|NCT01235910|Cyclosporine
363884|NCT01235897|Neoplasms
363885|NCT01235897|Paclitaxel
363886|NCT01235897|Trastuzumab
363887|NCT01235884|gaseous colic, regurgitation and of constipation
363888|NCT01235871|Safety
363889|NCT01235871|Tolerability
363890|NCT01235871|SB1578
363891|NCT01235858|Epidural analgesia
363892|NCT01235858|Epidural anesthesia labor
363893|NCT01235858|Aseptic technique
363894|NCT01235858|gown
363895|NCT01235858|no gown
363896|NCT01235832|cholesterol
363897|NCT01235832|triglycerides
363898|NCT01235832|low-density lipoprotein
363899|NCT01235832|high-density lipoprotein
363900|NCT01235832|reverse cholesterol transport
363901|NCT01235819|type 1 diabetes
363902|NCT01235819|exenatide
363903|NCT01235819|sitagliptin
363904|NCT01235806|scaphoid
363905|NCT01235806|MRI
363906|NCT01235806|ESAOTE
363907|NCT01235793|Relapsed
363908|NCT01235793|Refractory
363909|NCT01235793|Primary Central Nervous System B-cell Lymphoma
363910|NCT01235793|Autologous Stem Cell Transplant
363911|NCT01235793|Temozolomide
363912|NCT01235793|B-Cell Lymphoma
363913|NCT01235793|RBEAM
363914|NCT01235793|Conditioning Regimen
363915|NCT01235780|corneal hysteresis, ocular response analyzer
363916|NCT01235767|birth weight
363917|NCT01235767|prematurity
363918|NCT01235767|gestational age
363919|NCT01235767|low birth weight
363920|NCT01235767|pregnancy
363921|NCT01235767|nutrition
363922|NCT01235767|Vietnam
363923|NCT01235754|testosterone
363924|NCT01235754|hypoactive sexual desire disorder
363925|NCT01235754|menopause
363926|NCT01235741|Pramlintide
363927|NCT01235741|Metreleptin
363928|NCT01235741|Obesity
363929|NCT01235741|Amylin
363930|NCT01235741|Takeda
363931|NCT01235715|osteoarthritis
363932|NCT01235715|total knee replacement
363933|NCT01235702|high blood pressure, hypertension, African Americans, perceived stress
363934|NCT01235689|Efficacy and Safety of two treatment algorithms in Subjects with Moderate to Severe Crohn's Disease
363935|NCT01235676|obesity
363936|NCT01235676|lifestyle
363937|NCT01235676|pregnancy
363938|NCT01235676|newborn infant
363939|NCT01235663|obesity, insulin resistance
363940|NCT01235637|COMFORT B score
363941|NCT01235637|Bis score
363942|NCT01235624|Autosomal dominant retinitis pigmentosa
363943|NCT01235624|Rare disease
363944|NCT01235624|Genetics
363945|NCT01235598|Cimzia®
363946|NCT01235598|CDP870
363947|NCT01235598|CZP
363948|NCT01235598|Certolizumab Pegol
363949|NCT01235598|Rheumatoid Arthritis
363950|NCT01235598|MRI
363951|NCT01235572|Acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
363952|NCT01235572|Adult acute eosinophilic leukemia
363953|NCT01235572|Adult acute basophilic leukemia
363954|NCT01235572|De
363955|NCT01235572|novo myelodysplastic syndromes
363956|NCT01235572|Secondary myelodysplastic syndromes
363957|NCT01235572|Untreated adult acute myeloid leukemia
363958|NCT01235546|Pregnancy
363959|NCT01235546|Cesarean section
363960|NCT01235546|Antibiotic
363961|NCT01235546|Infections
363962|NCT01235533|late-life depression
363963|NCT01235533|recurrence of depression
363964|NCT01235533|cognition
363965|NCT01235533|N-3 polyunsaturated fatty acids
363966|NCT01235481|pulmonary rehabilitation
363967|NCT01235481|exercise therapy
363968|NCT01235481|chronic lung disease
363969|NCT01235481|self-efficacy
363970|NCT01235468|umbilical cord blood
363971|NCT01235468|ex vivo expansion
363972|NCT01235468|engraftment
363973|NCT01235468|GVHD
363974|NCT01235455|Multiple Sclerosis
363975|NCT01235455|Adherence
363976|NCT01235455|Interferon beta-1b
363977|NCT01235455|Coping styles
363978|NCT01235442|Psoriasis
363979|NCT01235442|Topical
363980|NCT01235442|etanercept
363981|NCT01235442|clobetasol propionate
363982|NCT01235429|Diabetes
363983|NCT01235429|Behavioral intervention
363984|NCT01235429|diabetes self-management
363985|NCT01235429|Native Hawaiians
363986|NCT01235429|health disparities
363987|NCT01235403|Epilepsy treatment.
363988|NCT01235403|Anti-epileptic drugs
363989|NCT01235403|Seizures
363990|NCT01235390|Postmenopausal women
363991|NCT01235390|walnuts
363992|NCT01235377|prescribing patterns
363993|NCT01235377|thiazide
363994|NCT01235377|chlorthalidone
363995|NCT01235377|hydrochlorothiazide
363996|NCT01235377|target dose
363997|NCT01235377|cluster randomized trial
363998|NCT01235364|Foley catheter
363999|NCT01235364|induction
364000|NCT01235364|labour
364001|NCT01235364|skin conductance
364002|NCT01235364|visual analogue scale
364003|NCT01235364|mechanical method
364004|NCT01235351|Myocardial infarction
364005|NCT01235351|Percutaneous coronary intervention
364006|NCT01235351|Clopidogrel
364007|NCT01235351|Genetics
364008|NCT01235351|Platelet Function
364009|NCT01235325|vitamin K
364010|NCT01235325|supplementation
364011|NCT01235325|bone health indices
364012|NCT01235325|adult
364013|NCT01235325|Crohn's disease
364014|NCT01235286|remote ischemic preconditioning, free flap, microcirculation
364015|NCT01235260|REGRANEX (becaplermin)
364016|NCT01235260|Platelet-derived growth factor BB
364017|NCT01235260|Cancer
364018|NCT01235260|Cancer incidence
364019|NCT01235260|Cancer mortality
364020|NCT01235260|Lower Extremity Diabetic Neuropathic Ulcer
364021|NCT01235234|Dry eye disease
364022|NCT01235234|KCS
364023|NCT01235234|Aqueous Deficient Dry Eye
364024|NCT01235208|Overweight
364025|NCT01235208|Obesity
364026|NCT01235208|Metabolic syndrome
364027|NCT01235208|Diet
364028|NCT01235208|Carbohydrate
364029|NCT01235208|Low glycemic index
364030|NCT01235208|Eurodiet
364031|NCT01235195|bioequivalence study
364032|NCT01235195|sertraline 50 mg
364033|NCT01235195|capsules vs tablets
364034|NCT01235182|acute dyspnea
364035|NCT01235182|prehospital emergency setting
364036|NCT01235182|differential diagnosis
364037|NCT01235182|ultrasound
364038|NCT01235182|NT-proBNP
364039|NCT01235156|Premature ventricular contraction
364040|NCT01235156|Frequent premature ventricular contraction, with or without a short array of non-sustained ventricular tachycardia
364041|NCT01235143|incidence
364042|NCT01235143|emergence agitation
364043|NCT01235143|sevoflurane
364044|NCT01235143|desflurane
364045|NCT01235143|ambulatory pediatric surgery
364046|NCT01235117|chronic myelomonocytic leukemia
364047|NCT01235091|HIV prevention
364048|NCT01235091|substance abuse
364049|NCT01235091|high risk behaviors
364050|NCT01235091|peer intervention
364051|NCT01235065|airway management
364052|NCT01235065|trauma
364053|NCT01235065|intubation
364054|NCT01235052|Head and neck neoplasms
364055|NCT01235052|Positron Emission Tomography
364056|NCT01235052|F18 fluoromisonidazole
364057|NCT01235026|Obesity
364058|NCT01235026|Type-2 Diabetes
364059|NCT01235026|Metabolic syndrome
364060|NCT01235026|Low grade inflammation
364061|NCT01235026|Metabolic endotoxinemia
364062|NCT01235026|Insulin resistance
364063|NCT01235026|Lipopolysaccharide
364064|NCT01235026|LPS-binding protein
364065|NCT01235026|sCD14
364066|NCT01235026|Synbiotic
364067|NCT01235026|Oligofructose
364068|NCT01235026|Bifidobacterium animalis subsp. lactis Bb12
364069|NCT01235026|probiotic
364070|NCT01235026|Prebiotic
364071|NCT01235013|HIV-1 infection
364072|NCT01235013|Maraviroc
364073|NCT01235013|CD4 lymphocyte count
364074|NCT01235000|Influenza vaccines
364075|NCT01235000|Infant
364076|NCT01235000|Dose-Response relationship, immunologic
364077|NCT01235000|Prime-boost response
364078|NCT01234987|Cancer
364079|NCT01234987|Breast Cancer
364080|NCT01234987|Colon cancer
364081|NCT01234987|Lung Cancer
364082|NCT01234974|multiple myeloma
364083|NCT01234948|Halitosis
364084|NCT01234948|VSC
364085|NCT01234948|Periodontitis
364086|NCT01234948|Gingivitis
364087|NCT01234948|Putative periodontal pathogens
364088|NCT01234948|Real-time PCR
364089|NCT01234909|Missed immunizations
364090|NCT01234896|Smoking Cessation, Nicotine pharmacokinetics
364091|NCT01234883|dehydration
364092|NCT01234883|gastroenteritis
364093|NCT01234870|Myocardial Perfusion Imaging
364094|NCT01234870|Magnetic Resonance Imaging
364095|NCT01234857|mTOR
364096|NCT01234857|breast cancer
364097|NCT01234857|estrogen receptor positive
364098|NCT01234844|pet-therapy
364099|NCT01234844|guinea-pigs
364100|NCT01234844|rehabilitation
364101|NCT01234844|elderly
364102|NCT01234831|MRSA
364103|NCT01234831|colonization
364104|NCT01234831|nucleic acid amplification
364105|NCT01234831|chromogenic agar
364106|NCT01234818|Endometrial hyperplasia
364107|NCT01234818|LNG-IUS
364108|NCT01234792|Smoking Cessation, Nicotine pharmacokinetics
364109|NCT01234753|Adults with CHD
364110|NCT01234753|GUCH
364111|NCT01234753|Congenital heart disease
364112|NCT01234753|Computer-based education
364113|NCT01234753|Nursing
364114|NCT01234740|Los Angeles
364115|NCT01234727|diabetes, SMBG, glucose testing systems, accuracy
364116|NCT01234714|Fatty Liver
364117|NCT01234714|Liver
364118|NCT01234714|Magnetic Resonance Imaging
364119|NCT01234714|Surgery
364120|NCT01234701|Liver
364121|NCT01234701|Neoplasms
364122|NCT01234701|Magnetic Resonance Imaging
364123|NCT01234701|Surgery
364124|NCT01234701|Pathology
364125|NCT01234688|Exercise Tolerance
364126|NCT01234688|Physical Endurance
364127|NCT01234675|Fibromyalgia
364128|NCT01234675|Sleep disorders
364129|NCT01234675|Forest Laboratories
364130|NCT01234675|Milnacipran
364131|NCT01234662|Elective cesarean sections
364256|NCT01234194|Pain
364132|NCT01234662|Postoperative pain level
364133|NCT01234662|Spinal anesthesia
364134|NCT01234662|Combined spinal epidural anesthesia
364135|NCT01234662|Epidural catheter
364136|NCT01234649|gestational diabetes mellitus
364137|NCT01234649|type 2 diabetes mellitus
364138|NCT01234649|metabolic dysfunction
364139|NCT01234649|impaired fasting glucose
364140|NCT01234649|impaired glucose tolerance
364141|NCT01234649|incretin mimetic
364142|NCT01234636|Platelets
364143|NCT01234636|Platelet aggregation
364144|NCT01234636|Platelet activation
364145|NCT01234636|Platelet function
364146|NCT01234636|Light transmission aggregometry
364147|NCT01234636|Flow cytometry
364148|NCT01234636|Platelet function analyzer-100 (PFA-100)
364149|NCT01234636|Linoleic acid, conjugated
364150|NCT01234636|cis9, trans11 conjugated linoleic acid
364151|NCT01234636|dietary supplement
364152|NCT01234636|short-term intervention
364153|NCT01234623|Umbilical cord serum, eyedrops, GVHD, SS-I, corneal healing
364154|NCT01234610|Exercise
364155|NCT01234610|Aortic aneurysm
364156|NCT01234610|Feasibility
364157|NCT01234610|Vascular disease
364158|NCT01234571|Pulmonary hypertension
364159|NCT01234571|Remodulin (Treprostenil sodium)
364160|NCT01234571|End-stage renal disease
364161|NCT01234571|Hemo-dialysis
364162|NCT01234558|depression
364163|NCT01234558|NMDA antagonist
364164|NCT01234558|treatment resistant
364165|NCT01234519|ureter cancer
364166|NCT01234519|renal pelvis cancer
364167|NCT01234519|bladder cancer
364168|NCT01234519|urethra
364169|NCT01234506|long term care
364170|NCT01234506|lignans
364171|NCT01234506|oxidative stress
364172|NCT01234506|inflammation
364173|NCT01234506|aging
364174|NCT01234506|dementia
364175|NCT01234506|postural balance
364176|NCT01234506|depression
364177|NCT01234506|muscle weakness
364178|NCT01234506|quality of life
364179|NCT01234506|pain
364180|NCT01234493|ankle; fracture; syndesmosis;
364181|NCT01234467|Diffuse Large B-Cell Lymphoma
364182|NCT01234467|Elderly
364183|NCT01234467|Newly Diagnosed
364184|NCT01234467|Lineberger Comprehensive Cancer Center
364185|NCT01234467|University of North Carolina
364186|NCT01234467|Bendamustine
364187|NCT01234467|Rituximab
364188|NCT01234467|Rituxan
364189|NCT01234467|Treanda
364190|NCT01234467|Phase 2
364191|NCT01234467|Geriatric
364192|NCT01234467|Lymphoma
364193|NCT01234428|laparoscopy
364194|NCT01234428|adjustable gastric banding
364195|NCT01234428|morbid obesity
364196|NCT01234428|esophageal motility
364197|NCT01234428|esophageal dilatation
364198|NCT01234415|nasal
364199|NCT01234415|septum
364200|NCT01234415|reconstruction
364201|NCT01234402|Breast Cancer
364202|NCT01234363|Renal allograft
364203|NCT01234363|kidney
364204|NCT01234363|fibrosis
364205|NCT01234363|elastography
364206|NCT01234363|elasticity
364207|NCT01234337|Breast Cancer
364208|NCT01234337|HER2-neu
364209|NCT01234324|Stomach Neoplasms
364210|NCT01234324|Gastroesophageal Junction Neoplasms
364211|NCT01234324|gastric cancer
364212|NCT01234324|cancer of the gastroesophageal junction
364213|NCT01234285|sepsis
364214|NCT01234285|septic shock
364215|NCT01234285|anticoagulation
364216|NCT01234285|intensive care unit
364217|NCT01234272|patients with
364218|NCT01234272|undergoing
364219|NCT01234272|gastrectomy
364220|NCT01234259|Wrinkles
364221|NCT01234259|rhytides
364222|NCT01234259|Cellulite
364223|NCT01234259|circumference reduction
364224|NCT01234246|Colorectal cancer
364225|NCT01234246|Sexual function
364226|NCT01234246|Sexual dysfunction
364227|NCT01234246|Quality of (sexual) life
364228|NCT01234246|Partners
364229|NCT01234246|Body image
364230|NCT01234246|Anxiety (state and trait)
364231|NCT01234246|Depressive symptoms
364232|NCT01234246|Personality
364233|NCT01234233|hypothermia, accidental
364234|NCT01234233|prewarming
364235|NCT01234233|body temperature monitoring
364236|NCT01234233|preoperative warming
364237|NCT01234233|sublingual temperature assessment
364238|NCT01234233|tympanic temperature assessment
364239|NCT01234220|Aldosterone
364240|NCT01234220|Primary Aldosteronism
364241|NCT01234220|Aldosterone Producing Adenoma (APA)
364242|NCT01234220|Idiopathic Adrenal Hyperplasia (IHA)
364243|NCT01234220|Adrenal Venous Sampling
364244|NCT01234207|Progressive addition lenses
364245|NCT01234207|Customized free-form
364246|NCT01234207|Presbyopia
364247|NCT01234207|Bifocals
364248|NCT01234207|Subjective assessment
364249|NCT01234207|Visual performance
364250|NCT01234207|Visual acuity
364251|NCT01234207|Amsler grid
364252|NCT01234194|Composite Variability Index
364253|NCT01234194|Bispectral Index
364254|NCT01234194|Electromyography
364255|NCT01234194|Nociception
364257|NCT01234155|Exercise
364258|NCT01234155|Diabetes
364259|NCT01234155|Obesity
364260|NCT01234155|Insulin Sensitivity
364261|NCT01234155|Insulin Secretion
364262|NCT01234155|Beta-cell Function
364263|NCT01234155|Glycemic Control
364264|NCT01234155|GIP
364265|NCT01234155|GLP-1
364266|NCT01234142|varenicline transdermal percutaneous transcutaneous transdermal delivery system patch
364267|NCT01234129|multiple myeloma
364268|NCT01234129|stem cell transplant
364269|NCT01234129|zoledronic acid
364270|NCT01234116|Post exposure prophylaxis
364271|NCT01234116|Health Care Workers
364272|NCT01234103|sexually transmitted infection
364273|NCT01234103|sexual risk
364274|NCT01234103|HIV
364275|NCT01234103|young adults
364276|NCT01234103|cognitive-behavioral intervention
364277|NCT01234090|Aphasia
364278|NCT01234090|Quality of Life
364279|NCT01234077|scheduled for a polysomnogram (overnight sleep study)
364280|NCT01234064|Symptomatic Venous Thromboembolism
364281|NCT01234064|Graduated Compression Stockings
364282|NCT01234064|Randomized Controlled Trial
364283|NCT01234064|Noncardiac Surgery
364284|NCT01234038|Non-small cell lung cancer
364285|NCT01234025|Castrate-Resistant Prostate Cancer
364286|NCT01234012|melanoma
364287|NCT01234012|breast cancer
364288|NCT01234012|ovarian cancer
364289|NCT01234012|prostate cancer
364290|NCT01234012|esophageal cancer
364291|NCT01234012|uterine cancer
364292|NCT01234012|sarcoma
364293|NCT01234012|NY-ESO-1
364294|NCT01233999|Scleroderma
364295|NCT01233999|Raynaud's Syndrome
364296|NCT01233986|Acute Ischemic Stroke
364297|NCT01233986|Atherosclerosis
364298|NCT01233986|Apolipoprotein B48
364299|NCT01233973|nursing home
364300|NCT01233973|advance care planning
364301|NCT01233960|Crohn's Disease
364302|NCT01233960|Adult Stem Cell Therapy
364303|NCT01233960|inflammation of the gastrointestinal tract
364304|NCT01233934|Insect bites
364305|NCT01233934|Dexchlorpheniramine
364306|NCT01233934|Gel
364307|NCT01233934|Cream
364308|NCT01233882|Renal impairment
364309|NCT01233882|healthy volunteers
364310|NCT01233869|Bosutinib
364311|NCT01233869|Autosomal Dominant Polycystic Kidney Disease
364312|NCT01233856|ADHD
364313|NCT01233843|induction chemotherapy
364314|NCT01233843|followed by irradiation and concurrent Erbitux, or radiochemotherapy
364315|NCT01233830|safety, tolerability, pharmacokinetics, AZD2423, Japanese
364316|NCT01233817|Spinal muscular atrophy
364317|NCT01233817|Neuromuscular disorder
364318|NCT01233817|Progressive strength training
364319|NCT01233817|Children
364320|NCT01233804|influenza vaccination rates
364321|NCT01233791|high tone pelvic floor dysfunction
364322|NCT01233791|levator pain
364323|NCT01233791|dyspareunia
364324|NCT01233778|Cardiovascular disease
364325|NCT01233778|Omega-3 fatty acids
364326|NCT01233778|Inflammation
364327|NCT01233778|Endothelial function
364328|NCT01233778|Canola oil
364329|NCT01233765|Periodontitis
364330|NCT01233765|Neutrophil
364331|NCT01233765|Inflammation
364332|NCT01233752|systemic morphine analgesia
364333|NCT01233752|pharmacogenetics
364334|NCT01233752|pharmacokinetics
364335|NCT01233739|rhizarthrosis
364336|NCT01233739|Chondroitin sulfate
364337|NCT01233739|Placebo
364338|NCT01233726|Critical illness
364339|NCT01233726|Hyperglycemia
364340|NCT01233726|Mechanical Ventilation
364341|NCT01233726|Enteral nutrition
364342|NCT01233726|T-Diet plus Diabet IR
364343|NCT01233726|Malnutrition
364344|NCT01233726|Insulin resistance
364345|NCT01233726|Metabolic stress
364346|NCT01233713|Emergency Surgery
364347|NCT01233713|Bowel perforation
364348|NCT01233713|Diverticulitis
364349|NCT01233713|Neoplasms
364350|NCT01233713|Postoperative Complications
364351|NCT01233713|Randomized Controlled Trial
364352|NCT01233700|living donation
364353|NCT01233700|organ donation
364354|NCT01233700|psychological adaptation
364355|NCT01233700|mental health
364356|NCT01233700|physical well-being
364357|NCT01233700|interpersonal relations
364358|NCT01233700|quality of life
364359|NCT01233700|psychosocial factors
364360|NCT01233687|Recurrent
364361|NCT01233687|progressive
364362|NCT01233687|advanced
364363|NCT01233648|heart failure
364364|NCT01233648|CRT-D
364365|NCT01233609|retinitis pigmentosa
364366|NCT01233609|valproic acid
364367|NCT01233609|visual field
364368|NCT01233596|congenital nasolacrimal duct obstruction
364369|NCT01233596|monocanalicular intubation
364370|NCT01233596|bicanalicular intubation
364371|NCT01233596|complications
364372|NCT01233583|Regulatory T-cells, psoriasis, IL-10.
364373|NCT01233570|Cutaneous Crohns Disease
364374|NCT01233570|Topical Tacrolimus
364375|NCT01233570|Protopic
364376|NCT01233570|Metastatic Crohns Disease
364377|NCT01233570|Pyoderma Gangrenosum
364378|NCT01233570|Granulomatous chelitis
364379|NCT01233570|Oral crohns disease
364380|NCT01233570|Perianal crohns disease
364381|NCT01233544|Colorectal carcinoma
364382|NCT01233544|Liver metastases
364383|NCT01233544|Stereotactic body radiation therapy
364384|NCT01233544|Radiofrequency ablation
364385|NCT01233518|CCTA Coronary Artery Disease CAD
364386|NCT01233492|adult glioblastoma
364387|NCT01233492|adult giant cell glioblastoma
364388|NCT01233492|adult gliosarcoma
364389|NCT01233479|untreated childhood medulloblastoma
364390|NCT01233479|untreated childhood cerebellar astrocytoma
364391|NCT01233479|untreated childhood cerebral astrocytoma
364392|NCT01233479|untreated childhood brain stem glioma
364393|NCT01233479|childhood medulloepithelioma
364394|NCT01233479|childhood infratentorial ependymoma
364395|NCT01233479|newly diagnosed childhood ependymoma
364396|NCT01233479|childhood atypical teratoid/rhabdoid tumor
364397|NCT01233414|Pervasive Developmental Disorder
364398|NCT01233414|Autism
364399|NCT01233414|Children
364400|NCT01233414|Behavior Therapy
364401|NCT01233414|Aggression
364402|NCT01233414|Tantrums
364403|NCT01233414|Noncompliance
364404|NCT01233401|Pertussis, Vaccination, Adult
364405|NCT01233375|cancer
364406|NCT01233375|metastatic
364407|NCT01233375|pancreatic
364408|NCT01233375|pancreas
364409|NCT01233375|adenocarcinoma
364410|NCT01233375|gemcitabine
364411|NCT01233375|human equilibrative nucleoside transporter-1 (hENT1)
364412|NCT01233375|CO-1.01
364413|NCT01233375|CO-101
364414|NCT01233375|CO101
364415|NCT01233375|Stage 4
364416|NCT01233375|Stage IV
364417|NCT01233375|Gemcitabine-Refractory
364418|NCT01233375|Second-Line Therapy
364419|NCT01233362|Cholera
364420|NCT01233362|Vaccine
364421|NCT01233362|Kolkata
364422|NCT01233362|West Bengal
364423|NCT01233362|India
364424|NCT01233362|Immunogenicity
364425|NCT01233362|Vaccination Schedules
364426|NCT01233349|overweight
364427|NCT01233349|obesity
364428|NCT01233349|weight loss
364429|NCT01233349|body fat
364430|NCT01233349|waist circumference
364431|NCT01233349|satiety
364432|NCT01233336|ACS,
364433|NCT01233336|HGF,
364434|NCT01233336|myocardial infarction
364435|NCT01233336|markers of myocardial injury
364436|NCT01233336|acute coronary syndrome (ACS)
364437|NCT01233336|prognostic factors in patients with ACS
364438|NCT01233323|Phrenic nerve stimulation
364439|NCT01233323|Cardiac Resynchronization Therapy
364440|NCT01233323|Heart Failure
364441|NCT01233323|Heart Diseases
364442|NCT01233310|Crohn's Disease
364443|NCT01233297|wheeze
364444|NCT01233297|infections
364445|NCT01233271|algorithm
364446|NCT01233271|tight glycemic control
364447|NCT01233271|glucose control
364448|NCT01233271|intensive care
364449|NCT01233271|insulin
364450|NCT01233271|ICU
364451|NCT01233258|Haemophilia treatment
364452|NCT01233258|rFVIII
364453|NCT01233245|Multiple Sclerosis
364454|NCT01233245|Adherence
364455|NCT01233245|Interferon beta-1b
364456|NCT01233245|Coping Styles
364457|NCT01233232|Chronic Obstructive Pulmonary Disease, Neutrophil, Respiratory Disease
364458|NCT01233219|systemic morphine analgesia
364459|NCT01233219|pharmacogenetics
364460|NCT01233219|pharmacokinetics
364461|NCT01233206|PCOS
364462|NCT01233206|Polycystic ovary syndrome
364463|NCT01233206|Cancelled cycles
364464|NCT01233206|OHSS
364465|NCT01233206|Infertility
364466|NCT01233193|Home blood pressure measurement
364467|NCT01233193|Pharmaceutical Services
364468|NCT01233193|Medication adherence
364469|NCT01233193|hypertension management
364470|NCT01233193|Blood Pressure
364471|NCT01233180|neck pain
364472|NCT01233180|massage
364473|NCT01233180|hyperthermia, induced
364474|NCT01233180|touch perception
364475|NCT01233180|randomized controlled trial
364476|NCT01233167|dual antiplatelet therapy
364477|NCT01233167|sirolimus drug-eluting stent
364478|NCT01233167|major adverse cardiac events
364479|NCT01233167|bleeding
364480|NCT01233141|peripheral artery disease stage IV (Fontaine's classification) or stage 5 and 6 (Rutherford's classification
364481|NCT01233102|liver Cirrhosis
364482|NCT01233102|Mesenchymal stem cells
364483|NCT01233102|Hepatic artery infusion
364484|NCT01233102|Intravenous infusion
364485|NCT01233089|Myopia
364486|NCT01233089|contact lenses
364487|NCT01233089|children
364488|NCT01233063|behavior change
364489|NCT01233063|physical activity
364490|NCT01233063|nutrition
364491|NCT01233063|fruits and vegetables
364492|NCT01233063|saturated fat
364493|NCT01233063|trans fat
364494|NCT01233063|added sugars
364495|NCT01233063|email
364496|NCT01233063|web
364497|NCT01233063|obesity
364498|NCT01233063|aging
364499|NCT01233050|undergoing elective colon and /or rectal surgical procedures involving an abdominal incision
364500|NCT01233024|Adult
364501|NCT01233024|Women
364502|NCT01233024|Dietary Fiber
364503|NCT01233024|Satiety Response
364504|NCT01233024|Food Intake
364505|NCT01233011|Intubating laryngeal airway
364506|NCT01233011|Pediatric
364507|NCT01233011|Observational study
364508|NCT01232998|Patient Satisfaction
364509|NCT01232985|Atopic Dermatitis
364510|NCT01232985|Pruritus
364511|NCT01232972|vitrification
364512|NCT01232972|egg freezing
364513|NCT01232972|oocyte cryopreservation
364514|NCT01232972|female fertility potential
364515|NCT01232972|fertility preservation
364516|NCT01232972|Fertility preservation, female
364517|NCT01232959|Gallbladder removal
364518|NCT01232946|Diabetes
364519|NCT01232946|Myocardial metabolism
364520|NCT01232933|PICC
364521|NCT01232920|uveitis
364522|NCT01232920|antimetabolite
364523|NCT01232920|immunosuppressive
364524|NCT01232920|clinical trial
364525|NCT01232907|Spinal Cord Injury (SCI)
364526|NCT01232894|indacaterol
364527|NCT01232894|COPD
364528|NCT01232894|Long-acting beta2-agonist (LABA)
364529|NCT01232868|Innate immunity
364530|NCT01232868|Adaptive immunity
364531|NCT01232868|Slu shot
364532|NCT01232868|Elderly
364533|NCT01232855|adult acute myeloid leukemia with t(15;17)(q22;q12)
364534|NCT01232855|adult acute promyelocytic leukemia (M3)
364535|NCT01232855|childhood acute promyelocytic leukemia (M3)
364536|NCT01232855|adult acute myeloid leukemia in remission
364537|NCT01232855|untreated adult acute myeloid leukemia
364538|NCT01232855|childhood acute myeloid leukemia in remission
364539|NCT01232855|untreated childhood acute myeloid leukemia and other myeloid malignancies
364540|NCT01232842|adult acute myeloid leukemia
364541|NCT01232842|childhood acute myeloid leukemia/other myeloid malignancies
364542|NCT01232803|Rectal Microbicides
364543|NCT01232803|Tenofovir
364544|NCT01232803|Rectal use
364545|NCT01232803|Rectal mucosal damage
364546|NCT01232790|Schizophrenia
364547|NCT01232790|working memory
364548|NCT01232790|N-Acetylcysteine
364549|NCT01232777|Retinopathy of Prematurity
364550|NCT01232777|Bevacizumab
364551|NCT01232777|Avastin
364552|NCT01232777|Vascular Endothelial Growth Factor
364553|NCT01232751|health
364554|NCT01232751|women
364555|NCT01232725|BSID III
364556|NCT01232725|Human Milk
364557|NCT01232725|Donor Human Milk
364558|NCT01232725|Preterm infant
364559|NCT01232725|Breastfeeding
364560|NCT01232712|MUC1
364561|NCT01232712|ImMucin
364562|NCT01232712|Vaccine
364563|NCT01232712|Multiple Myeloma
364564|NCT01232699|obesity
364565|NCT01232699|weight loss
364566|NCT01232699|internet treatment
364567|NCT01232699|motivational interviewing
364568|NCT01232686|Communicable Diseases
364569|NCT01232686|Epidemiology
364570|NCT01232686|Population surveillance
364571|NCT01232686|Computerized Medical Record
364572|NCT01232686|Data collection
364573|NCT01232673|Critical Limb Ischemia
364574|NCT01232673|Bone-Marrow Aspiration Concentrate
364575|NCT01232673|Diabetes Mellitus
364576|NCT01232673|Major Amputation
364577|NCT01232647|osteoporosis
364578|NCT01232647|vitamin K
364579|NCT01232647|BONE MINERAL DENSITY
364580|NCT01232647|BIOCHEMICAL MARKERS OF BONE TURNOVER
364581|NCT01232634|pediatrics
364582|NCT01232634|haemophilia
364583|NCT01232634|ultrasound
364584|NCT01232634|MRI
364585|NCT01232634|arthropathy
364586|NCT01232608|Coronary Artery Disease
364587|NCT01232608|Atherosclerosis.
364588|NCT01232608|Diabetes Mellitus, type 2
364589|NCT01232608|Exercise
364590|NCT01232608|HbA1c
364591|NCT01232608|Carotid Atherosclerotic Disease
364592|NCT01232608|Inflammation
364593|NCT01232595|Clostridium difficile,
364594|NCT01232595|C. difficile,
364595|NCT01232595|CDI,
364596|NCT01232595|Clostridium difficile-associated disease,
364597|NCT01232595|CDAD,
364598|NCT01232595|pseudomembranous colitis,
364599|NCT01232595|PMC,
364600|NCT01232595|antibiotic-associated diarrhea
364601|NCT01232582|Lower back pain, Facets joints Osteoarthritis
364602|NCT01232556|inotuzumab ozogamicin
364603|NCT01232556|aggressive Non-Hodgkin lymphoma
364604|NCT01232556|diffuse large b-cell lymphoma
364605|NCT01232556|relapsed/refractory lymphoma
364606|NCT01232543|Atopic Dermatitis
364607|NCT01232530|Malria, ACT, Safety, Efficacy, pregarnancy
364608|NCT01232504|Allo-HSCT
364609|NCT01232504|rhGM-CSF
364610|NCT01232504|Systemic fungal infection (SFI)
364611|NCT01232478|Cystic Fibrosis
364612|NCT01232478|Adherence
364613|NCT01232478|Problem-Solving
364614|NCT01232478|Adolescents
364615|NCT01232478|Education
364616|NCT01232478|Skills Remediation
364617|NCT01232465|sperm DNA integrity
364618|NCT01232465|Toluidine blue assay (TBA)
364619|NCT01232465|IVF outcome
364620|NCT01232452|lung cancer
364621|NCT01232452|advanced
364622|NCT01232452|non-small cell
364623|NCT01232413|Thorough QT (TQT)
364624|NCT01232413|ASP1941
364625|NCT01232400|subarachnoid hemorrhage
364626|NCT01232400|esmolol
364627|NCT01232400|cardiac function
364628|NCT01232400|cardiac electrophysiology
364629|NCT01232387|Fetomaternal hemorrhage
364630|NCT01232387|neonatal anemia
364631|NCT01232387|perinatal epidemiology
364632|NCT01232387|Kleihauer-Betke
364633|NCT01232387|flow cytometry
364634|NCT01232374|Nimotuzumab
364635|NCT01232374|local advanced esophageal squamous cell carcinoma
364636|NCT01232374|chemo-irradiation
364637|NCT01232361|ADHD
364638|NCT01232361|HIV
364639|NCT01232361|Pharmacokinetics
364640|NCT01232348|bronchial asthma
364641|NCT01232348|Symbicort
364642|NCT01232335|bronchial asthma
364643|NCT01232335|Symbicort
364644|NCT01232335|long term use,
364645|NCT01232322|bronchial asthma
364646|NCT01232322|Pulmicort Respules
364647|NCT01232322|long term use
364648|NCT01232322|pediatrics
364649|NCT01232309|Arterial Health
364650|NCT01232309|Fiber
364651|NCT01232309|Chitin-glucan
364652|NCT01232309|oxidized LDL
364653|NCT01232296|Hepatocellular Carcinoma
364654|NCT01232296|HCC
364655|NCT01232296|Liver cancer
364656|NCT01232296|Child Pugh A
364657|NCT01232296|HCC Stage C
364658|NCT01232257|Chronic kidney disease
364659|NCT01232257|Chronic kidney failure
364660|NCT01232257|End stage kidney disease
364661|NCT01232257|End stage renal disease
364662|NCT01232257|Hydrogen sulfide
364663|NCT01232257|N-acetylcysteine
364664|NCT01232257|Acetylcysteine
364665|NCT01232244|Incretin hormones
364666|NCT01232244|Glucagon
364667|NCT01232244|Satiety
364668|NCT01232244|Hunger
364669|NCT01232244|Energy expenditure
364670|NCT01232231|methicillin-resistant Staphylococcus aureus
364671|NCT01232231|decolonization
364672|NCT01232231|random allocation
364673|NCT01232231|outpatient
364674|NCT01232218|Cerebral Vascular Accident
364675|NCT01232218|Stroke
364676|NCT01232218|Hemiplegic
364677|NCT01232218|Shoulder pain
364678|NCT01232218|range of motion
364679|NCT01232218|scapula
364680|NCT01232218|mobilization
364681|NCT01232205|antioxidant supplementation
364682|NCT01232205|preeclampsia
364683|NCT01232153|chest tube
364684|NCT01232153|preoxygenation
364685|NCT01232153|NIV
364686|NCT01232153|out-of-hospital
364687|NCT01232153|patients needing tracheal chest tube managed by Medical Mobile Emergency rescue services
364688|NCT01232140|COPD
364689|NCT01232140|exacerbation
364690|NCT01232140|antibiotic treatment
364691|NCT01232140|CRP
364692|NCT01232140|sputum
364693|NCT01232140|inflammation
364694|NCT01232101|covered, uncovered, palliative treatment, stent
364695|NCT01232088|drug labelling
364696|NCT01232088|standardized drug syringe labelling
364697|NCT01232088|European ICU
364698|NCT01232075|Letrozole ,Clomiphene citrate , IUI,unexplained infertility
364699|NCT01232062|breast neoplasm
364700|NCT01232062|Neoplasm Metastasis
364701|NCT01232062|Drug Therapy
364702|NCT01232049|healthy volunteers
364703|NCT01232036|healthy volunteers
364704|NCT01232023|Indobufen
364705|NCT01232023|healthy volunteers
364706|NCT01232010|SK-3530
364707|NCT01232010|renal impairment
364708|NCT01232010|healthy volunteers
364709|NCT01231997|Udenafil
364710|NCT01231997|DA-8159
364711|NCT01231997|renal impairment
364712|NCT01231997|healthy volunteers
364713|NCT01231984|diabetes
364714|NCT01231984|obesity
364715|NCT01231984|hypoglycemia
364716|NCT01231984|hyperglycemia
364717|NCT01231984|pen needle
364718|NCT01231971|amyloid
364719|NCT01231971|plaques
364720|NCT01231971|neuroimaging
364721|NCT01231971|biomarkers
364722|NCT01231971|cognition disorder
364723|NCT01231971|early detection
364724|NCT01231971|Amnestic MCI
364725|NCT01231971|pre-dementia
364726|NCT01231971|dementia
364727|NCT01231971|Alzheimer's disease
364728|NCT01231971|tau
364729|NCT01231958|Puerto Rican; CVD; Hispanic; health disparities; allostatic load; diet
364730|NCT01231945|Cervical Cancer
364731|NCT01231945|Human Papilloma Virus (HPV)
364732|NCT01231945|Cervical Intraepithelial Neoplasia (CIN)
364733|NCT01231932|Fatigue
364734|NCT01231932|Cancer
364735|NCT01231932|Cancer Therapy
364736|NCT01231932|Cancer Treatment
364737|NCT01231932|Gene Expression Patterns
364738|NCT01231893|human, spinal cord injury, olfactory ensheathing cells, transplantation
364739|NCT01231880|Malaria
364740|NCT01231867|Coronary Heart Disease
364741|NCT01231867|Acute Coronary Syndrome
364742|NCT01231867|Drug interactions
364743|NCT01231867|Clopidogrel
364744|NCT01231867|Proton Pump Inhibitors
364745|NCT01231867|Gastrointestinal Hemorrhage
364746|NCT01231854|atopic hand dermatitis
364747|NCT01231854|Chronic hand dermatitis
364748|NCT01231828|sleep
364749|NCT01231828|cirrhosis
364750|NCT01231828|encephalopathy
364751|NCT01231828|simulated driving
364752|NCT01231828|sleep disorders
364753|NCT01231815|Heart transplantation
364754|NCT01231789|cardiac surgery
364755|NCT01231789|RIPC
364756|NCT01231789|brain injury
364757|NCT01231776|cardiopulmonary bypass
364758|NCT01231776|sleep
364759|NCT01231776|acupuncture
364760|NCT01231763|HIV prevention
364761|NCT01231763|Vaginal film
364762|NCT01231763|Microbicide
364763|NCT01231763|Administration, intravaginal
364764|NCT01231737|Prophylasy
364765|NCT01231737|recurrent urinary tract infection
364766|NCT01231737|prulifloxacin
364767|NCT01231737|phosphomycin
364768|NCT01231711|depression
364769|NCT01231711|post traumatic stress syndrome
364770|NCT01231711|functional status
364771|NCT01231711|veteran
364772|NCT01231711|military
364773|NCT01231711|stigma
364774|NCT01231711|mental health self-efficacy
364775|NCT01231698|septic shock
364776|NCT01231698|esmolol
364777|NCT01231698|tachycardia
364778|NCT01231698|betablockers
364779|NCT01231685|Liver fibrosis
364780|NCT01231685|HIV
364781|NCT01231685|Hepatitis C Virus
364782|NCT01231685|Coinfection
364783|NCT01231659|RAD001 (Everolimus)
364784|NCT01231659|Letrozole
364785|NCT01231659|Breast cancer
364786|NCT01231659|Metastatic Breast cancer
364787|NCT01231659|Estrogen receptor positive
364788|NCT01231659|Failure of Tamoxifen
364789|NCT01231659|Anastrozole or Examestane
364790|NCT01231646|Folate Receptor Autoantibodies
364791|NCT01231646|Epilepsy
364792|NCT01231646|Psychiatric conditions
364793|NCT01231633|Macular Edema
364794|NCT01231633|Central Retinal Vein Occlusion
364795|NCT01231620|Seasonal Influenza
364796|NCT01231620|Pandemic
364797|NCT01231620|Orthomyxoviridae Infections
364798|NCT01231620|Influenza
364799|NCT01231620|Influenza A Virus, H1N1 Subtype
364800|NCT01231620|Enzyme Inhibitors
364801|NCT01231620|Influenza, seasonal
364802|NCT01231620|Respiratory Tract Diseases
364803|NCT01231620|Zanamivir
364804|NCT01231620|Pharmacologic Actions
364805|NCT01231620|Antiviral Agents
364806|NCT01231620|Anti-Infective Agents
364807|NCT01231620|H1N1
364808|NCT01231620|Neuraminidase inhibitor
364809|NCT01231620|Influenza B virus
364810|NCT01231594|BRAF Inhibitor
364811|NCT01231594|Cancer
364812|NCT01231594|Safety
364813|NCT01231594|GSK2118436
364814|NCT01231594|BRAF mutation positive tumors
364815|NCT01231568|particle size
364816|NCT01231568|food effect; high fat meal
364817|NCT01231568|GSK2118436
364818|NCT01231568|pharmacokinetic
364819|NCT01231568|BRAF inhibitor
364820|NCT01231568|BRAF positive tumor
364821|NCT01231555|antiretroviral
364822|NCT01231555|HAART
364823|NCT01231555|NNRTI
364824|NCT01231555|emtricitabine
364825|NCT01231555|Sexually Transmitted Disease
364826|NCT01231555|antiretroviral therapy (ART)-naive adults
364827|NCT01231555|Immunologic Deficiency Syndrome
364828|NCT01231555|tenofovir
364829|NCT01231555|abacavir
364830|NCT01231555|Retroviridae Infections
364831|NCT01231555|GSK2248761
364832|NCT01231555|lamivudine
364833|NCT01231555|Acquired ImmunoDeficiency Syndrome (AIDS)
364834|NCT01231555|HIV infection
364835|NCT01231555|efavirenz
364836|NCT01231542|GSK1349572
364837|NCT01231542|pharmacokinetics
364838|NCT01231542|dolutegravir
364839|NCT01231542|integrase
364840|NCT01231542|rifabutin
364841|NCT01231542|rifampin
364842|NCT01231516|ART-experienced
364843|NCT01231516|Integrase inhibitor
364844|NCT01231516|Raltegravir
364845|NCT01231516|GSK1349572
364846|NCT01231516|Integrase inhibitor naive
364847|NCT01231503|Africa
364848|NCT01231503|malaria vaccine
364849|NCT01231503|schedule
364850|NCT01231503|EPI
364851|NCT01231503|Plasmodium falciparum
364852|NCT01231477|anaesthetic techniques, inhalation
364853|NCT01231477|sevoflurane
364854|NCT01231477|Cytokines
364855|NCT01231477|Immune response
364856|NCT01231464|safety
364857|NCT01231464|efficacy
364858|NCT01231464|placebo
364859|NCT01231464|allergic rhinitis
364860|NCT01231464|fluticasone furoate
364861|NCT01231451|HIV Infection
364862|NCT01231438|Renal failure stage 3B
364863|NCT01231425|Back pain
364864|NCT01231425|cervicalgia
364865|NCT01231425|dorsalgia
364866|NCT01231425|lumbalgia
364867|NCT01231425|acupuncture
364868|NCT01231386|Female Breast Cancer
364869|NCT01231386|miRNA expression
364870|NCT01231386|Neoadjuvant/Adjuvant Treatment
364871|NCT01231386|Locally and Inflammatory Breast Cancer
364872|NCT01231373|varicose veins
364873|NCT01231360|claudication
364874|NCT01231360|peripheral artery disease
364875|NCT01231360|PAD
364876|NCT01231347|pancreas
364877|NCT01231347|gemcitabine
364878|NCT01231347|metastatic
364879|NCT01231347|jaundice
364880|NCT01231321|Adalimumab added to inadequate standard anti-rheumatic therapy in patients with active Rheumatoid Arthritis
364881|NCT01231256|Quality of life
364882|NCT01231256|preventive health consultation
364883|NCT01231256|General practice
364884|NCT01231256|resources
364885|NCT01231256|life style
364886|NCT01231243|tooth bleaching, bleaching agent, hydrogen peroxide
364887|NCT01231230|asthma, corticosteroids, bronchodilator, airway blood flow
364888|NCT01231204|Breast Cancer
364889|NCT01231204|Mastectomy
364890|NCT01231204|UCSD
364891|NCT01231204|Surgery
364892|NCT01231204|PVB Catheter
364893|NCT01231204|Paravertebral Catheter
364894|NCT01231204|Breast Pain
364895|NCT01231204|Mastectomy Pain
364896|NCT01231204|Postoperative Pain
364897|NCT01231139|Brain Injury
364898|NCT01231139|Temperature
364899|NCT01231139|Paracetamol
364900|NCT01231139|Phase 2
364901|NCT01231139|TBI
364902|NCT01231126|Induced labor
364903|NCT01231126|Misoprostol
364904|NCT01231126|Postpartum blood
364905|NCT01231126|Erythrocyte indices
364906|NCT01231126|Vaginal delivery
364907|NCT01231113|malaria,
364908|NCT01231113|pregnancy,
364909|NCT01231113|dihydroartemisinin-piperaquine,
364910|NCT01231113|efficacy,
364911|NCT01231113|safety,
364912|NCT01231113|Ghana
364913|NCT01231087|energy expenditure
364914|NCT01231087|morbid obesity
364915|NCT01231087|bariatric surgery
364916|NCT01231087|nutritional follow-up
364917|NCT01231074|obesity
364918|NCT01231074|weight gain
364919|NCT01231074|metformin
364920|NCT01231074|psychotropic drugs
364921|NCT01231061|spine metastasis
364922|NCT01231061|SBRT
364923|NCT01231061|Radiosurgery
364924|NCT01231035|acute cardiac syndrome
364925|NCT01231035|stent thrombosis
364926|NCT01231035|platelet function
364927|NCT01231035|antiplatelet therapy
364928|NCT01231022|breast neoplasm
364929|NCT01231022|Neoplasm Metastasis
364930|NCT01231022|Stem Cells
364931|NCT01231022|Drug-Induced Liver Injury
364932|NCT01230996|cervical adenocarcinoma
364933|NCT01230996|cervical adenosquamous cell carcinoma
364934|NCT01230996|cervical squamous cell carcinoma
364935|NCT01230996|stage IB cervical cancer
364936|NCT01230996|stage IIA cervical cancer
364937|NCT01230996|stage IIB cervical cancer
364938|NCT01230996|stage III cervical cancer
364939|NCT01230996|stage IVA cervical cancer
364940|NCT01230983|stage III childhood lymphoblastic lymphoma
364941|NCT01230983|stage IV childhood lymphoblastic lymphoma
364942|NCT01230983|untreated childhood acute lymphoblastic leukemia
364943|NCT01230983|T-cell childhood acute lymphoblastic leukemia
364944|NCT01230983|cardiac toxicity
364945|NCT01230957|Clostridium difficile infection
364946|NCT01230957|Diarrhea
364947|NCT01230957|Pseudomembranous colitis
364948|NCT01230957|Clostridium Difficile Toxoid Vaccine
364949|NCT01230957|ACAM-CDIFF™ vaccine
364950|NCT01230944|GERD
364951|NCT01230944|LNF
364952|NCT01230944|CNF
364953|NCT01230944|Laparoscopic Nissen fundoplication
364954|NCT01230944|Open Nissen fundoplication
364955|NCT01230944|Antireflux surgery
364956|NCT01230931|Acetabulum
364957|NCT01230931|Fracture
364958|NCT01230931|Hemostatis
364959|NCT01230931|Vitagel
364960|NCT01230931|Fibrin sealant
364961|NCT01230918|Hypertrophic Cardiomyopathy
364962|NCT01230918|Acute Coronary Syndrome
364963|NCT01230918|Myocardial Fibrosis
364964|NCT01230918|Fibrogenesis
364965|NCT01230918|Intimal Hyperplasia
364966|NCT01230918|Sudden Death
364967|NCT01230918|avB3 Integrin Expression
364968|NCT01230905|Androgen Suppression Therapy
364969|NCT01230905|Hormonal Toxicity
364970|NCT01230905|Quantitative PET
364971|NCT01230905|Myocardial blood flow
364972|NCT01230905|Coronary blood flow reserve
364973|NCT01230905|Endothelial dysfunction
364974|NCT01230905|Coronary Artery Disease
364975|NCT01230879|Aging lung
364976|NCT01230879|Airway remodeling
364977|NCT01230879|Airway segmentation
364978|NCT01230879|Chest CT
364979|NCT01230866|Proton Radiation Prostate Cancer
364980|NCT01230840|fiber
364981|NCT01230840|calcium
364982|NCT01230840|magnesium
364983|NCT01230827|Juvenile Idiopathic Arthritis
364984|NCT01230827|golimumab
364985|NCT01230827|juvenile arthritis
364986|NCT01230827|GO KIDS
364987|NCT01230827|anti TNF alpha medications
364988|NCT01230827|juvenile psoriatic arthritis
364989|NCT01230814|Bacterial vaginosis, metronidazole, miconazole, vulvovaginal candidiasis, trichomonas vaginalis, women, Kenya
364990|NCT01230788|ALL
364991|NCT01230788|Leukemia
364992|NCT01230788|Rituximab
364993|NCT01230788|Pediatrics
364994|NCT01230762|Dapoxetine, Orgasmic disorder
364995|NCT01230762|Premature ejaculation
364996|NCT01230762|Sexual dysfunction
364997|NCT01230762|Sexual intercourse
364998|NCT01230762|Ejaculation
364999|NCT01230762|Erectile Dysfunction
365000|NCT01230749|Diabetes Mellitus, Type 2
365001|NCT01230749|Diabetes Mellitus
365002|NCT01230749|Hyperglycemia
365003|NCT01230749|JNJ-41443532
365004|NCT01230749|Pioglitazone
365005|NCT01230749|Placebo
365006|NCT01230697|Advanced
365007|NCT01230697|hepatocarcinoma
365008|NCT01230684|CEUS, Abdominal Aortic Aneurysm, Endoleaks
365009|NCT01230658|prophylactic enoxaparin
365010|NCT01230658|Roux en Y gastric bypass surgery
365011|NCT01230632|assisted reproduction technology
365012|NCT01230632|Metabolic risk factors
365013|NCT01230632|In Vitro Fertilisation
365014|NCT01230606|Percutaneous Intervention
365015|NCT01230606|Percutaneous Coronary Intervention
365016|NCT01230606|Catheterization
365017|NCT01230606|Coronary Catheterization
365018|NCT01230606|Same day Discharge
365019|NCT01230606|Next Day Discharge
365020|NCT01230606|Patient Satisfaction
365021|NCT01230606|Multi-Center
365022|NCT01230606|Randomized
365023|NCT01230606|Low-risk PCI
365024|NCT01230606|BlindedClosure device
365025|NCT01230606|Vascular closure device
365026|NCT01230580|Protease Inhibitors
365027|NCT01230580|RNA virus infections
365028|NCT01230580|Virus diseases
365029|NCT01230580|Sexually Transmitted Diseases viral
365030|NCT01230580|Immune system diseases
365031|NCT01230580|Anti-infective Agents
365032|NCT01230580|Drug resistance
365033|NCT01230567|Problem wounds
365034|NCT01230567|Non healing wounds
365035|NCT01230567|BCC
365036|NCT01230567|SCC
365037|NCT01230567|Vasculitis
365038|NCT01230554|contact lens
365039|NCT01230541|Semen characteristics
365040|NCT01230541|Erectile Dysfunction
365041|NCT01230515|Oncology Pain Management in outpatient hospice setting
365042|NCT01230502|immunosuppression
365043|NCT01230502|anti-rejection
365044|NCT01230502|immune tolerance
365045|NCT01230476|Locally advanced nasopharyngeal carcinoma
365046|NCT01230476|Neoadjuvant chemotherapy
365047|NCT01230476|Chemoradiation
365048|NCT01230476|Cetuximab
365049|NCT01230463|Pain, Postoperative
365050|NCT01230463|Ketorolac
365051|NCT01230463|Anti-Inflammatory Agents, Non-Steroidal
365052|NCT01230463|Intraoperative Care
365053|NCT01230450|urodynamic urinary incontinence, sub-urethral tape
365054|NCT01230437|montelukast
365055|NCT01230437|asthma
365056|NCT01230437|allergic rhinitis
365057|NCT01230437|nasal epithelial cells
365058|NCT01230437|inflammatory mediators
365059|NCT01230424|OA
365060|NCT01230424|Knee arthritis
365061|NCT01230424|MRI
365062|NCT01230424|Steroid
365063|NCT01230411|Episodic migraine
365064|NCT01230385|lersivirine
365065|NCT01230385|UK-453
365066|NCT01230385|061
365067|NCT01230385|safety
365068|NCT01230385|tolerability
365069|NCT01230385|pharmacokinetics
365070|NCT01230385|HIV
365071|NCT01230385|non-nucleoside reverse transcriptase inhibitor
365072|NCT01230385|NNRTI
365073|NCT01230359|Autism
365074|NCT01230359|Children
365075|NCT01230359|ASD
365076|NCT01230359|Vitamin B6
365077|NCT01230359|Magnesium
365078|NCT01230320|Cost estimates
365079|NCT01230320|Complete Denture
365080|NCT01230320|Dental Economics
365081|NCT01230320|Dental Impression Technique
365082|NCT01230320|Denture Retention
365083|NCT01230320|Edentulous
365084|NCT01230320|Edentulism
365085|NCT01230320|Oral Health-Related Quality of Life
365086|NCT01230320|Patient Acceptance of Health Care
365087|NCT01230320|Patient Satisfaction
365088|NCT01230320|Quality of Health Care
365089|NCT01230320|Quality of Life
365090|NCT01230307|Vitamin D
365091|NCT01230307|Systolic failure
365092|NCT01230307|Genomics
365093|NCT01230307|Biomarkers
365094|NCT01230307|Exercise
365095|NCT01230307|Quality of Life
365096|NCT01230294|echocardiography of the right heart
365097|NCT01230294|3D 4D echocardiography
365098|NCT01230294|strain measurement
365099|NCT01230294|chronic heart failure
365100|NCT01230294|pulmonary hypertension
365101|NCT01230281|C3G
365102|NCT01230281|Oxidative stress
365103|NCT01230281|Antioxidant
365104|NCT01230281|Black bean
365105|NCT01230268|C3G
365106|NCT01230268|Oxidative stress
365107|NCT01230268|Antioxidant
365108|NCT01230268|Mulberry
365109|NCT01230255|intra-abdominal pressure
365110|NCT01230255|intra-abdominal hypertension
365111|NCT01230255|abdominal compartment syndrome
365112|NCT01230255|open abdomen
365113|NCT01230255|percutaneous
365114|NCT01230242|Mirena
365115|NCT01230242|postplacental intrauterine device
365116|NCT01230242|postpartum insertion
365117|NCT01230229|Intermittent claudication
365118|NCT01230229|Superficial femoral artery
365119|NCT01230229|Stenting
365120|NCT01230229|Medical treatment
365121|NCT01230229|Quality of life
365122|NCT01230216|coronary artery disease
365123|NCT01230216|hypertension
365124|NCT01230190|infants
365125|NCT01230190|adaptive immunology
365126|NCT01230190|atopic dermatitis
365127|NCT01230190|probiotics
365128|NCT01230151|Deep Brain Stimulation
365129|NCT01230151|DBS
365130|NCT01230151|Parkinson's disease
365131|NCT01230151|PD
365132|NCT01230151|Patients who have a preexisting Deep Brain Stimulation (DBS) system for the treatment of Parkinson's disease (PD)
365133|NCT01230125|Inflammation
365134|NCT01230125|Pain
365135|NCT01230125|Ocular surgery
365136|NCT01230099|Critical Illness
365137|NCT01230099|Mechanical Ventilation
365138|NCT01230099|Palliative Care
365139|NCT01230099|Caregivers
365140|NCT01230086|ICD
365141|NCT01230086|DFT-testing
365142|NCT01230073|ICD
365143|NCT01230073|Home-Monitoring
365144|NCT01230073|Quality of life
365145|NCT01230060|ocular surgery
365146|NCT01230060|phacoemulsification
365147|NCT01230047|depression
365148|NCT01230047|anxiety
365149|NCT01230047|psychoeducation
365150|NCT01230047|self-help
365151|NCT01230047|psychosocial
365152|NCT01230034|Imidapril, Ramipril, Hypertension, Type 2 diabetes mellitus, Microalbuminuria
365153|NCT01230008|primary mediastinal lymphoma
365154|NCT01230008|radiotherapy
365155|NCT01230008|chemotherapy
365156|NCT01230008|rituximab
365157|NCT01229969|falls, balance problems, gaming systems, balance assessments
365158|NCT01229956|childhood acute myeloid leukemia in remission
365159|NCT01229956|recurrent childhood acute myeloid leukemia
365160|NCT01229956|untreated childhood acute myeloid leukemia and other myeloid malignancies
365161|NCT01229930|cervical adenocarcinoma
365162|NCT01229930|cervical adenosquamous cell carcinoma
365163|NCT01229930|cervical squamous cell carcinoma
365164|NCT01229930|recurrent cervical cancer
365165|NCT01229930|stage IVB cervical cancer
365166|NCT01229930|stage IVA cervical cancer
365167|NCT01229891|vitamin D fortification
365168|NCT01229891|yogurt drink
365169|NCT01229891|type 2 diabetes
365170|NCT01229891|efficacy
365171|NCT01229852|Fibromyalgia
365172|NCT01229852|Transcranial Magnetic Stimulation
365173|NCT01229852|Pain
365174|NCT01229839|Carcinoma,Hepatocellular
365175|NCT01229839|Liver Neoplasms
365176|NCT01229839|Therapeutic
365177|NCT01229839|Chemoembolization,
365178|NCT01229839|TACE
365179|NCT01229839|pharmacokinetics
365180|NCT01229839|Iodized Oil/administration & dosage
365181|NCT01229839|polyvinyl alcohol
365182|NCT01229839|Humans
365183|NCT01229826|Uterine fibroids
365184|NCT01229826|Uterine leiomyomas
365185|NCT01229826|MR Elastography
365186|NCT01229826|MRI (Magnetic Resonance Imaging)
365187|NCT01229826|Symptomatic Uterine Fibroids
365188|NCT01229813|Untreated
365189|NCT01229813|First line
365190|NCT01229813|Chemotherapy
365191|NCT01229813|Maintenance treatment
365192|NCT01229813|KRAS wt
365193|NCT01229813|KRAS mutated
365194|NCT01229813|Anti-angiogenetic treatment
365195|NCT01229813|Metronomic capecitabine
365196|NCT01229813|bevacizumab
365197|NCT01229813|erlotinib
365198|NCT01229813|Translational research
365199|NCT01229800|Polyethylene Glycol, Sodium Phosphate, Bowel preparation, Efficacy
365200|NCT01229787|asthma
365201|NCT01229787|allergies
365202|NCT01229787|obesity
365203|NCT01229761|HIV
365204|NCT01229761|Trimethoprim-Sulfamethoxazole Combination
365205|NCT01229761|Breast Feeding
365206|NCT01229761|Infant Mortality
365207|NCT01229761|Morbidity
365208|NCT01229761|Botswana
365209|NCT01229761|Africa
365210|NCT01229761|Infectious disease transmission, vertical
365211|NCT01229761|adverse drug event
365212|NCT01229735|levetiracetam
365213|NCT01229735|topiramate
365214|NCT01229735|epilepsy
365215|NCT01229735|partial seizures
365216|NCT01229722|adherence
365217|NCT01229722|reminders
365218|NCT01229722|text messages
365219|NCT01229722|SMS
365220|NCT01229722|mHealth
365221|NCT01229709|Tinnitus
365222|NCT01229709|Mindfulness
365223|NCT01229709|MBSR
365224|NCT01229709|Mindfulness Based Stress Reduction
365225|NCT01229709|MBTR
365226|NCT01229696|Popliteal
365227|NCT01229696|UCSD
365228|NCT01229696|Postoperative pain
365229|NCT01229696|Foot surgery
365230|NCT01229696|Ankle surgery
365231|NCT01229696|Popliteal Catheter
365232|NCT01229696|Popliteal Nerve Block
365233|NCT01229696|Lower extremity surgery
365234|NCT01229696|Bifurcation
365235|NCT01229696|Catheter Insertion Site
365236|NCT01229683|UCSD
365237|NCT01229683|Perineural Nerve Block
365238|NCT01229683|Shoulder Surgery
365239|NCT01229683|Pain
365240|NCT01229683|Grip Strength
365241|NCT01229683|Sensation
365242|NCT01229683|Interscalene Nerve Block
365243|NCT01229670|Heart failure
365244|NCT01229670|Hemorheology
365245|NCT01229670|Atherothrombosis
365246|NCT01229670|Angiogenesis
365247|NCT01229657|Reopening of macular hole;
365248|NCT01229657|Visual acuity;
365249|NCT01229657|Phacoemulsification cataract surgery;
365250|NCT01229657|Vitrectomy
365251|NCT01229644|Glioma
365252|NCT01229644|Brain Cancer
365253|NCT01229644|Recurrent glioma
365254|NCT01229644|Low grade glioma
365255|NCT01229644|PDGFR Inhibitor
365256|NCT01229644|Crenolanib (CP-868,596)
365257|NCT01229644|Neo-adjuvant Therapy
365258|NCT01229631|Periodontitis
365259|NCT01229631|Dietary supplementation
365260|NCT01229618|Prostate Cancer
365261|NCT01229592|infection
365262|NCT01229592|catheter
365263|NCT01229592|bacteriaemia
365264|NCT01229592|ethanol
365265|NCT01229579|poliomyelitis
365266|NCT01229579|OPV
365267|NCT01229579|zinc supplement
365268|NCT01229579|diarrhea
365269|NCT01229579|placebo
365270|NCT01229579|double blind randomized control trial
365271|NCT01229579|elemental zinc
365272|NCT01229579|seroconversion
365273|NCT01229579|bOPV
365274|NCT01229579|infants
365275|NCT01229579|immunity
365276|NCT01229527|Colonoscopy
365277|NCT01229527|Remifentanil
365278|NCT01229527|Sedation
365279|NCT01229514|Children
365280|NCT01229514|before
365281|NCT01229514|the age of 2 years
365282|NCT01229475|Atrial fibrillation
365283|NCT01229475|recurrence
365284|NCT01229475|repeat procedure
365285|NCT01229475|linear ablation
365286|NCT01229475|stepwise approach
365287|NCT01229449|Dental pain
365288|NCT01229449|Ibuprofen
365289|NCT01229449|Acetaminophen
365290|NCT01229449|Nurofen Plus®
365291|NCT01229449|Panadeine® Extra
365292|NCT01229436|Dupuytren's
365293|NCT01229436|treatment
365294|NCT01229436|injection
365295|NCT01229436|recovery
365296|NCT01229436|health care resources
365297|NCT01229397|Influenza
365298|NCT01229397|Virus
365299|NCT01229397|Vaccination
365300|NCT01229397|Immunisation
365301|NCT01229371|Influenza
365302|NCT01229371|Virus
365303|NCT01229371|Vaccination
365304|NCT01229371|Immunisation
365305|NCT01229358|vascular surgery
365306|NCT01229358|wound infection
365307|NCT01229358|wound complication
365308|NCT01229332|Motor fluctuations levodopa pharmacokinetics carbidopa solution continuous
365309|NCT01229319|actinic keratosis, keratocytic lesion, keratoses, cryotherapy, imiquimod
365310|NCT01229293|Mechanical muscle function
365311|NCT01229293|Muscle strength
365312|NCT01229293|Hip replacement
365313|NCT01229293|Osteoarthritis
365314|NCT01229293|Hip arthroplasty
365315|NCT01229280|Bioequivalence
365316|NCT01229280|Darifenacin
365317|NCT01229280|Healthy volunteers
365318|NCT01229280|Postprandial
365319|NCT01229267|Herpes zoster
365320|NCT01229267|vaccine
365321|NCT01229267|herpes zoster-related complications
365322|NCT01229267|immunocompromised
365323|NCT01229267|autologous hematopoietic cell transplants
365324|NCT01229254|Betrixaban
365325|NCT01229254|MK-4448
365326|NCT01229254|nonvalvular atrial fibrillation
365327|NCT01229241|local anesthetic
365328|NCT01229241|epidural
365329|NCT01229241|pharmacokinetics
365330|NCT01229241|plasmatic concentration
365331|NCT01229241|epidural continuous infusion
365332|NCT01229202|trabeculectomy
365333|NCT01229202|glaucoma surgery
365334|NCT01229202|bevacizumab
365335|NCT01229202|Vascular Endothelial Growth Inhibitor
365336|NCT01229202|glaucoma
365337|NCT01229189|Vitamin D
365338|NCT01229189|Effectiveness
365339|NCT01229189|Pregnant women and their neonates
365340|NCT01229163|Motivational Incentive
365341|NCT01229163|Automation
365342|NCT01229163|Contingency Management
365343|NCT01229163|Counseling Adherance
365344|NCT01229150|Kinase Signal Transduction Pathway
365345|NCT01229150|Tumor Mutational Analysis
365346|NCT01229150|Tissue Immunohistochemistry
365347|NCT01229150|MIB-1 (Ki-67) Rate
365348|NCT01229150|PERK Level
365349|NCT01229150|Lung Cancer
365350|NCT01229150|Non-Small Cell Lung Cancer
365351|NCT01229124|childhood acute myeloid leukemia/other myeloid malignancies
365352|NCT01229085|Psoriasis, mometasone, salicylic acid.
365353|NCT01229072|Safety
365354|NCT01229072|Non-inferiority
365355|NCT01229059|FFA
365356|NCT01229059|insulin resistance
365357|NCT01229059|mitochondria
365358|NCT01229046|presumed sepsis
365359|NCT01229033|Atrial fibrillation
365360|NCT01229033|ablation
365361|NCT01229033|atrial flutter
365362|NCT01229020|Emphysema
365363|NCT01229020|COPD
365364|NCT01229020|lung sounds
365365|NCT01229020|vibration response imaging
365366|NCT01229007|Hemophilia A
365367|NCT01229007|Children
365368|NCT01228994|smoking cessation treatment
365369|NCT01228994|baclofen
365370|NCT01228994|Smoking cessation counselling
365371|NCT01228968|obesity
365372|NCT01228942|ovarian cancer
365373|NCT01228942|fallopian tube cancer
365374|NCT01228942|primary peritoneal cancer
365375|NCT01228929|Dry Eye
365376|NCT01228929|Non-invasive instruments
365377|NCT01228929|MGD
365378|NCT01228929|Environment
365379|NCT01228929|Thermal Imaging
365380|NCT01228916|tobacco
365381|NCT01228916|smoking
365382|NCT01228916|secondhand smoke
365383|NCT01228903|uric acid kidney disease endothelial dysfunction
365384|NCT01228851|Parkinson's Disease
365385|NCT01228851|Rehabilitation
365386|NCT01228851|Balance
365387|NCT01228851|Exercise
365388|NCT01228851|Parkinson's disease with balance deficits
365389|NCT01228851|H&Y 2.5-3
365390|NCT01228838|postherpetic neuralgia
365391|NCT01228838|PHN
365392|NCT01228838|capsaicin
365393|NCT01228838|herpes zoster
365394|NCT01228838|shingles
365395|NCT01228838|analgesics
365396|NCT01228838|neuropathy
365397|NCT01228825|Cardiac surgery
365398|NCT01228825|Cardiopulmonary bypass
365399|NCT01228825|Antibiotic prophylaxis
365400|NCT01228825|Cefuroxime
365401|NCT01228812|Rheumatoid arthritis, physical activity
365402|NCT01228799|trabeculectomy,
365403|NCT01228799|canaloplasty,
365404|NCT01228799|glaucoma surgery
365405|NCT01228799|non-penetrating surgery
365406|NCT01228786|VDR, CaSR, PTH, Cyclin D1, Ki67, PCNA
365407|NCT01228773|Cancer Survivors, Fatigue, web-based, tailored program
365408|NCT01228760|Castration-Resistant Prostate Cancer
365409|NCT01228760|ASG-5ME
365410|NCT01228760|Pharmacokinetics of ASG-5ME
365411|NCT01228747|Levetiracetam
365412|NCT01228747|epilepsy
365413|NCT01228747|generalized tonic-clonic
365414|NCT01228734|Metastatic colorectal cancer
365415|NCT01228734|RAS wild type
365416|NCT01228734|Cetuximab
365417|NCT01228734|First line treatment
365418|NCT01228734|First occurrence of metastatic colorectal cancer in Chinese subjects with RAS wildtype
365419|NCT01228734|status
365420|NCT01228708|Implementation strategy
365421|NCT01228708|Chronic disease management programme
365422|NCT01228708|COPD
365423|NCT01228695|steroids
365424|NCT01228695|patients treated with systemic steroids
365425|NCT01228682|Sodium
365426|NCT01228682|SIADH
365427|NCT01228682|Hyponatremia
365428|NCT01228682|Vasopressin
365429|NCT01228682|Salt
365430|NCT01228682|Water
365431|NCT01228656|Psoriasis
365432|NCT01228643|Pancreatic enzymes.
365433|NCT01228643|To evaluate the efficacy of drugs in chronic renal failure
365434|NCT01228630|rhinitis, loratadine, coated pill
365435|NCT01228617|Smoking Cessation
365436|NCT01228617|Nicotine pharmacokinetics
365437|NCT01228604|open label
365438|NCT01228604|Ritalin®
365439|NCT01228604|ADHD
365440|NCT01228578|Multivitamins
365441|NCT01228578|HIV/AIDS
365442|NCT01228578|Immune reconstitution
365443|NCT01228578|Weight Gain
365444|NCT01228578|Quality of Life
365445|NCT01228565|Head and neck carcinoma treated by radiotherapy plus erbitux
365446|NCT01228552|Acute Migraine Treatment
365447|NCT01228552|Migraine Treatment
365448|NCT01228552|Migraine
365449|NCT01228552|Headache
365450|NCT01228552|Treatment
365451|NCT01228539|PTSD
365452|NCT01228539|Anger
365453|NCT01228539|Aggression
365454|NCT01228539|Military
365455|NCT01228487|Oxidative Dysbalance
365456|NCT01228487|Oxidative Stress
365457|NCT01228487|Biomarker
365458|NCT01228461|Hodgkin Lymphoma Survivors
365459|NCT01228461|Adolescent and Young Adults
365460|NCT01228448|external beam proton radiotherapy
365461|NCT01228448|PET
365462|NCT01228435|NSCLC
365463|NCT01228435|IPI-504
365464|NCT01228435|ALK translocation
365465|NCT01228435|Hsp90 inhibitor
365466|NCT01228422|Will be studied 24 subjects divided Research and 2 parallel groups
365467|NCT01228422|The treatment is a dose of 3MUI of alpha interferon 2nd
365468|NCT01228422|There will be collection of blood at times: 0, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours.
365469|NCT01228422|The volunteers will be hospitalized 24 hours.
365470|NCT01228422|Will be measured labels the AUC, Tmax, Cmax, neopterin and beta2-microglobulin
365471|NCT01228409|Psoriasis
365472|NCT01228409|phototherapy
365473|NCT01228409|soriatane
365474|NCT01228409|acitretin
365475|NCT01228409|retinoid-related adverse events
365476|NCT01228396|bladder
365477|NCT01228396|optic neuritis
365478|NCT01228396|secondary progressive multiple sclerosis
365479|NCT01228396|AIMSPRO
365480|NCT01228396|hyperimmune caprine serum
365481|NCT01228396|hyperimmune goat serum
365482|NCT01228383|Monoclonal antibody
365483|NCT01228383|Rabies
365484|NCT01228383|Post-exposure prophylaxis
365485|NCT01228370|sildosin
365486|NCT01228370|neurogenic bladder
365487|NCT01228370|voiding dysfunction
365488|NCT01228357|Pharmacogenomics
365489|NCT01228357|Depressed Patients
365490|NCT01228344|Artemether-lumefantrine
365491|NCT01228344|demographics
365492|NCT01228344|malaria
365493|NCT01228331|childhood acute lymphoblastic leukemia
365494|NCT01228331|untreated childhood acute lymphoblastic leukemia
365495|NCT01228318|HAART
365496|NCT01228318|Antiresorptive drugs
365497|NCT01228318|HIV/AIDS
365498|NCT01228318|Bone loss
365499|NCT01228305|ventricular septal defect
365500|NCT01228305|atrioventricular septal defect
365501|NCT01228305|oxidative stress
365502|NCT01228305|cardiopulmonary bypass
365503|NCT01228305|acetaminophen
365504|NCT01228305|hemolysis
365505|NCT01228305|acute kidney injury
365506|NCT01228305|Congenital heart disease undergoing cardiopulmonary bypass
365507|NCT01228292|Anticoagulation
365508|NCT01228292|Intensive Care Medicine
365509|NCT01228292|Hemodialysis
365510|NCT01228292|Critical Ill Patients
365511|NCT01228279|Peritoneal Dialysis
365512|NCT01228279|Dialysis Solutions
365513|NCT01228279|Artificial Kidney
365514|NCT01228279|Renal Replacement Therapy
365515|NCT01228279|Renal Dialysis
365516|NCT01228279|Sympathetic Nervous System
365517|NCT01228279|Leptin
365518|NCT01228279|Icodextrin
365519|NCT01228266|Multiple Sclerosis
365520|NCT01228240|Diabetes mellitus, type 2, Metformin, Generic, Efficacy
365521|NCT01228227|Myonecrosis
365522|NCT01228227|Percutaneous Angioplasty
365523|NCT01228227|Myocardial Infarction
365524|NCT01228188|FTMH
365525|NCT01228188|PPV
365526|NCT01228188|inverted ILM repositioning
365527|NCT01228149|glaucoma
365528|NCT01228149|trabeculectomy
365529|NCT01228149|intraocular pressure
365530|NCT01228136|Adenotonsillectomy
365531|NCT01228136|Tranexamic acid
365532|NCT01228136|Blood loss
365533|NCT01228136|Postoperative hemorrhage
365534|NCT01228084|sulforaphane
365535|NCT01228084|broccoli sprout extract (BSE)
365536|NCT01228084|prostate cancer
365537|NCT01228084|recurrent prostate cancer
365538|NCT01228084|phase II
365539|NCT01228071|testosterone deficiency
365540|NCT01228071|hypogonadism
365541|NCT01228058|Trauma
365542|NCT01228058|Coagulopathy
365543|NCT01228058|Coagulopathy in adult trauma patients
365544|NCT01228045|Patients with histologically proved adenocarcinoma of advanced gastric cancer
365545|NCT01228019|Usual practice re-examination
365546|NCT01228006|Reduction of stress and fatigue
365547|NCT01227993|Central Serous Chorioretinopathy
365548|NCT01227993|Finasteride
365549|NCT01227993|Proscar
365550|NCT01227993|Retinal Eye Disease
365551|NCT01227980|Addiction
365552|NCT01227980|Alcohol
365553|NCT01227980|Alcohol Treatment
365554|NCT01227980|Alcoholics
365555|NCT01227980|Alcohol Dependence
365556|NCT01227980|Anxiety Disorder
365557|NCT01227980|Alcoholism
365558|NCT01227967|Adaptive Design
365559|NCT01227967|At Risk
365560|NCT01227967|H1N1
365561|NCT01227967|Synergy
365562|NCT01227967|TCAD
365563|NCT01227954|cognitive/functional effects
365564|NCT01227954|tumors metastatic to brain
365565|NCT01227954|unspecified adult solid tumor, protocol specific
365566|NCT01227941|advanced solid tumors
365567|NCT01227941|ovarian cancer
365568|NCT01227941|pegylated liposomal doxorubicin
365569|NCT01227941|Doxil
365570|NCT01227941|Caelyx
365571|NCT01227928|tyrosine kinase inhibitors
365572|NCT01227928|Primary Peritoneal Carcinoma
365573|NCT01227928|primary peritoneal cancer
365574|NCT01227928|ovarian cancer
365575|NCT01227928|Fallopian Tube Cancer
365576|NCT01227928|gynecologic cancer
365577|NCT01227928|anti-angiogenesis
365578|NCT01227928|pazopanib
365579|NCT01227915|SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
365580|NCT01227902|Seizures
365581|NCT01227902|retigabine IR
365582|NCT01227902|GW582892
365583|NCT01227902|Epilepsy
365584|NCT01227902|Open label, flexible dose
365585|NCT01227902|Partial-onset seizures
365586|NCT01227889|Metastatic melanoma
365587|NCT01227889|melanoma
365588|NCT01227889|BRAF mutant
365589|NCT01227889|Advanced melanoma
365590|NCT01227876|Control of postoperative inflammation in cataract surgery by phacoemulsification
365591|NCT01227863|SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
365592|NCT01227850|Leptin
365593|NCT01227850|IGF1
365594|NCT01227850|Refeeding Index
365595|NCT01227850|Hypophosphataemia
365596|NCT01227850|Primary focus of the study was to detemine whether the 'Refeeding Index', could reliably predict,that the refeeding syndrome would occur
365597|NCT01227837|omega 3
365598|NCT01227837|CRT_AICD
365599|NCT01227837|congestive heart failure
365600|NCT01227837|CHF
365601|NCT01227824|integrase inhibitor
365602|NCT01227824|HIV Infection
365603|NCT01227824|raltegravir
365604|NCT01227824|GSK1349572
365605|NCT01227811|Darifenacin
365606|NCT01227811|Bioequivalence
365607|NCT01227811|Healthy volunteers
365608|NCT01227811|Postprandial
365609|NCT01227798|influenza A, H1N1
365610|NCT01227772|gastric cancer vaccine
365611|NCT01227772|OTSGC-A24
365612|NCT01227772|A Phase I/IIa study
365613|NCT01227772|HLA-A24-positive
365614|NCT01227746|Advanced gastro-intestinal stromal tumors
365615|NCT01227720|Smoking Cessation, Nicotine pharmacokinetics
365616|NCT01227694|Cell therapy
365617|NCT01227694|Regenerative therapy
365618|NCT01227694|Advance therapy
365619|NCT01227694|Bone marrow
365620|NCT01227694|Mesenchymal stem cell
365621|NCT01227694|Autologous
365622|NCT01227694|Interventional clinical trial
365623|NCT01227694|Osteoarthrosis
365624|NCT01227694|Osteoarthritis
365625|NCT01227694|Knee
365626|NCT01227655|Parkinson
365627|NCT01227655|PD
365628|NCT01227655|Wearing-off
365629|NCT01227655|Levodopa/DDCI
365630|NCT01227642|Prostate Cancer
365631|NCT01227642|Prostate brachytherapy
365632|NCT01227642|Ultrasound treatment planning
365633|NCT01227616|Iron deficiency anemia (IDA), Feraheme, ferumoxytol, chronic kidney disease (CKD), hemodialysis, magnetic resonance imaging (MRI)
365634|NCT01227603|Bioequivalence
365635|NCT01227603|Nifedipine
365636|NCT01227603|Candesartan
365637|NCT01227603|FDC
365638|NCT01227590|Herbal medicine
365639|NCT01227590|African Potato
365640|NCT01227590|Hypoxis obtusa
365641|NCT01227590|Drug interaction
365642|NCT01227590|HIV Infections
365643|NCT01227590|Acquired Immunodeficiency Syndrome
365644|NCT01227590|Healthy Subjects
365645|NCT01227590|Anti-retroviral Agents
365646|NCT01227590|Lopinavir
365647|NCT01227590|Ritonavir
365648|NCT01227577|CML
365649|NCT01227577|Chronic Myelogenous Leukemia
365650|NCT01227577|Leukemia
365651|NCT01227577|CML-CP
365652|NCT01227577|Nilotinib
365653|NCT01227564|Early Alzheimer's disease
365654|NCT01227564|active immunization
365655|NCT01227564|amyloid imaging
365656|NCT01227551|Melanoma
365657|NCT01227551|CALM
365658|NCT01227538|Beta cell reserve, urinary C peptide
365659|NCT01227512|Hyponatremia
365660|NCT01227512|Dilutional Hyponatremia
365661|NCT01227512|Euvolemic Hyponatremia
365662|NCT01227512|Hypervolemic Hyponatremia
365663|NCT01227512|Fluid Restriction
365664|NCT01227512|Tolvaptan
365665|NCT01227486|Intubation, intratracheal
365666|NCT01227486|Ultrasonography
365667|NCT01227486|Auscultation
365668|NCT01227486|Capnography
365669|NCT01227486|Obesity
365670|NCT01227473|prediabetes
365671|NCT01227473|African Americans
365672|NCT01227473|mindfulness
365673|NCT01227473|behavioral
365674|NCT01227473|diabetes
365675|NCT01227460|Type 1 diabetes, Sitagliptin
365676|NCT01227434|Glioblastoma
365677|NCT01227434|Gliosarcoma
365678|NCT01227434|Anaplastic astrocytoma
365679|NCT01227434|Malignant astrocytoma NOS
365680|NCT01227434|Malignant glioma
365681|NCT01227434|GBM
365682|NCT01227421|influenza
365683|NCT01227408|Patients with confirmed breast cancer for neoadjuvant chemotherapy
365684|NCT01227395|HIV
365685|NCT01227395|Post Marketing Surveillance
365686|NCT01227369|Bisphosphonates
365687|NCT01227369|OPSAT-Q
365688|NCT01227356|Chronic myeloid leukemia, imatinib, interferon
365689|NCT01227343|Gender differences
365690|NCT01227343|nicotine
365691|NCT01227343|cigarette smoking habits
365692|NCT01227343|behavior changes
365693|NCT01227317|Dyspnea
365694|NCT01227317|Mortality
365695|NCT01227291|Glaucoma
365696|NCT01227291|IOP
365697|NCT01227291|siRNAs
365698|NCT01227291|RNAi
365699|NCT01227291|beta inhibitor
365700|NCT01227278|Benralizumab
365701|NCT01227278|MEDI-563
365702|NCT01227278|Pulmonary Disease, Chronic Obstructive
365703|NCT01227226|Dry eye
365704|NCT01227187|Hemodialysis
365705|NCT01227187|Anticoagulation
365706|NCT01227187|Xigris
365707|NCT01227187|PTT
365708|NCT01227174|propofol only
365709|NCT01227174|safety and efficacy
365710|NCT01227161|ASA I-II children between the age 0-7
365711|NCT01227161|general anesthesia
365712|NCT01227148|critical care, glycemic control, insulin, nitrogen balance
365713|NCT01227135|chronic phase chronic myelogenous leukemia
365714|NCT01227135|chronic myelogenous leukemia, BCR-ABL1 positive
365715|NCT01227122|NGAL plasmatic level
365716|NCT01227122|Preoperative KIDNEY FAILURE, CHRONIC
365717|NCT01227122|Postoperative KIDNEY FAILURE, ACUTE
365718|NCT01227122|Cardiac Surgery Procedures
365719|NCT01227109|Infections
365720|NCT01227109|Cancer
365721|NCT01227109|Procalcitonin
365722|NCT01227109|C reactive protein
365723|NCT01227096|electroacupuncture pediatric cardioprotection
365724|NCT01227083|AQLQ and cAQOL
365848|NCT01226589|MRS
365849|NCT01226589|Treatment response
365725|NCT01227070|Asthma, hospitalization, children, exhaled nitric oxide, lung function, breath condensate, cysteinyl leukotrienes
365726|NCT01227057|exposure therapy
365727|NCT01227057|case management
365728|NCT01227057|older adults
365729|NCT01227057|cognitive rehabilitation
365730|NCT01227044|Substance Abuse Counseling
365731|NCT01227044|Adherence (medication)
365732|NCT01227044|Alcohol Abuse
365733|NCT01227044|Highly Active Antiretroviral Therapy (HAART)
365734|NCT01227044|Naltrexone
365735|NCT01227044|Vivitrol
365736|NCT01227044|HIV
365737|NCT01227031|Genetic susceptibility of androgenetic alopecia
365738|NCT01227031|Genetic difference in Finasteride response
365739|NCT01227005|Transfusion
365740|NCT01227005|Whole Blood
365741|NCT01227005|Trauma
365742|NCT01227005|Coagulopathy
365743|NCT01227005|Component Therapy
365744|NCT01227005|Civilian
365745|NCT01227005|Military
365746|NCT01226992|Clostridium difficile
365747|NCT01226992|Fecal Transplant
365748|NCT01226992|Recurrent Diarrhea
365749|NCT01226992|Abdominal distension/bloating
365750|NCT01226992|Fever
365751|NCT01226979|rectal cancer
365752|NCT01226979|high dose endorectal brachytherapy
365753|NCT01226953|Haemophilus influenzae type b (Hib)
365754|NCT01226953|Vaccine
365755|NCT01226953|Anti-PRP antibody
365756|NCT01226914|EVICEL, Fibrin Sealant, Thyroidectomy
365757|NCT01226901|Poly (ADP-ribose) polymerase (PARP) inhibitor
365758|NCT01226901|tumor
365759|NCT01226901|cancer
365760|NCT01226888|brown adipose tissue
365761|NCT01226888|androgen deprivation therapy
365762|NCT01226875|SWL
365763|NCT01226875|kidney stones
365764|NCT01226875|renal calculi
365765|NCT01226862|Stroke
365766|NCT01226862|Telemedicine
365767|NCT01226862|Telestroke
365768|NCT01226849|diffuse large B-cell lymphoma relapse refractory
365769|NCT01226836|Pulmonary Rehabilitation
365770|NCT01226823|cholestasis
365771|NCT01226823|pregnancy
365772|NCT01226823|ursodeoxycholic acid
365773|NCT01226823|ICP
365774|NCT01226797|Chronic HCV infection
365775|NCT01226797|raised ALT
365776|NCT01226797|transaminitis
365777|NCT01226797|HCV infection
365778|NCT01226771|hepatitis V virus
365779|NCT01226771|genotype 1
365780|NCT01226771|ribavirin
365781|NCT01226771|interferon
365782|NCT01226771|Alternative ribavirin dosing
365783|NCT01226758|Safety
365784|NCT01226758|Tolerability
365785|NCT01226758|Efficacy
365786|NCT01226758|Influenza
365787|NCT01226758|Flu
365788|NCT01226758|Virus
365789|NCT01226758|Vaccine
365790|NCT01226745|Multiple sclerosis
365791|NCT01226745|ONO-4641
365792|NCT01226745|MSC2430913A
365793|NCT01226745|Efficacy
365794|NCT01226732|Solid tumor
365795|NCT01226732|Capecitabine
365796|NCT01226732|Hsp90 inhibitor AUY922
365797|NCT01226719|liver-only metastatic KRAS wild-type colorectal cancer
365798|NCT01226719|Panitumumab
365799|NCT01226719|Oxaliplatin
365800|NCT01226719|Irinotecan
365801|NCT01226719|Leucovorin
365802|NCT01226719|5-Fluorouracil
365803|NCT01226706|Urinary incontinence, urge
365804|NCT01226706|detrusor hyperreflexia
365805|NCT01226706|detrusor instability
365806|NCT01226706|non-neurogenic
365807|NCT01226706|Female Urogenital Diseases and Pregnancy Complications
365808|NCT01226706|Female Urogenital Diseases
365809|NCT01226706|Urologic Diseases
365810|NCT01226706|Urination Disorders
365811|NCT01226706|Urinary Incontinence
365812|NCT01226693|pharmacokinetic
365813|NCT01226693|single dose bioequivalence study
365814|NCT01226693|balanced incomplete block design
365815|NCT01226693|PH-797804
365816|NCT01226693|P38 kinase inhibitor
365817|NCT01226680|Dry Eye
365818|NCT01226680|Schirmer test
365819|NCT01226680|corneal staining
365820|NCT01226680|OSDI
365821|NCT01226680|OCI
365822|NCT01226667|fibromyalgia
365823|NCT01226667|lyrica
365824|NCT01226667|pregabalin
365825|NCT01226654|Quantitative Imaging of Multiple Sclerosis
365826|NCT01226641|Obstructive Sleep Apnea Syndrome
365827|NCT01226641|SCORE
365828|NCT01226641|Telemedicine
365829|NCT01226641|Arterial blood pressure
365830|NCT01226641|Daily physical activity
365831|NCT01226628|Macular degeneration
365832|NCT01226628|Age-related macular degeneration
365833|NCT01226628|Cell therapy
365834|NCT01226628|CNTO 2476
365835|NCT01226628|Human umbilical tissue-derived cells
365836|NCT01226628|hUTC
365837|NCT01226628|Geographic Atrophy
365838|NCT01226628|Subretinal
365839|NCT01226628|Visual Acuity
365840|NCT01226615|Chondroitin sulphate
365841|NCT01226615|Knee osteoarthritis
365842|NCT01226615|Functional Magnetic Resonance Imaging
365843|NCT01226602|Ticagrelor
365844|NCT01226602|Healthy
365845|NCT01226602|Coronary flow velocity
365846|NCT01226602|Adenosine
365847|NCT01226589|Cancer cancer
365850|NCT01226589|Histologically confirmed diagnosed Breast cancer.
365851|NCT01226589|Patient is 18 years or older.
365852|NCT01226589|Karnofsky performance score is equal to or greater than 70.
365853|NCT01226589|No previously irradiated or recurrent breast.
365854|NCT01226589|No contraindication to MRS/MRI.
365855|NCT01226576|MRgFUS
365856|NCT01226576|Prostate Cancer
365857|NCT01226576|Low-Intermediate Risk Prostate Cancer
365858|NCT01226576|Localized Prostate Cancer
365859|NCT01226576|InSightec
365860|NCT01226576|ExAblate
365861|NCT01226563|STEMI
365862|NCT01226563|Acute Myocardial Infarction
365863|NCT01226563|Congestive Heart Failure
365864|NCT01226563|Left Ventricular Remodeling
365865|NCT01226563|Devices, Medical
365866|NCT01226550|hyperthermic intraoperative peritoneal chemotherapy (HIPEC)
365867|NCT01226550|Irinotecan
365868|NCT01226550|Pharmacokinetics
365869|NCT01226550|peritoneal carcinomatosis (PC)
365870|NCT01226537|Taurine,Diabetes mellitus,oxidative stress,glycemic control
365871|NCT01226498|Blood Transfusion, Autologous
365872|NCT01226498|Blood Preservation/adverse effects
365873|NCT01226498|Blood Transfusion/adverse effects
365874|NCT01226498|Endothelium, Vascular/physiopathology
365875|NCT01226498|Inflammation Mediators
365876|NCT01226485|Cancer
365877|NCT01226485|Terminal
365878|NCT01226485|Solid Tumor
365879|NCT01226485|End Stage
365880|NCT01226485|Metastatic
365881|NCT01226472|PTCL
365882|NCT01226472|CTCL
365883|NCT01226472|MF
365884|NCT01226472|SS
365885|NCT01226459|Female Pattern Baldness
365886|NCT01226433|AE adverse event
365887|NCT01226433|AIDS acquired immunodeficiency syndrome
365888|NCT01226433|ALT (SGPT) alanine aminotransferase
365889|NCT01226433|ART antiretroviral therapy
365890|NCT01226433|AST (SGOT) aspartate aminotransferase
365891|NCT01226433|DCF data collection forms
365892|NCT01226433|DMC Data Monitoring Committee
365893|NCT01226433|FDA (U.S.) Food and Drug Administration
365894|NCT01226433|GCP Good Clinical Practice guidelines
365895|NCT01226433|HB sAg Hepatitis B surface antigen
365896|NCT01226433|ICH International Conference of Harmonisation
365897|NCT01226433|IND Investigational New Drug Application
365898|NCT01226433|IRB Institutional Review Board
365899|NCT01226433|IU International units
365900|NCT01226433|mg milligram(s)
365901|NCT01226433|mm3 cubic millimeter(s)
365902|NCT01226433|PCR polymerase chain reaction
365903|NCT01226433|SAE serious adverse event
365904|NCT01226433|µg microgram
365905|NCT01226433|ULN upper limit of the normal range
365906|NCT01226433|WB Western Blot
365907|NCT01226420|GVHD
365908|NCT01226420|Alefacept
365909|NCT01226420|Amevive
365910|NCT01226407|Solid Tumour
365911|NCT01226394|peritoneal carcinomatosis
365912|NCT01226394|HIPEC
365913|NCT01226394|controlled clinical trial
365914|NCT01226381|Paracetamol and setrons
365915|NCT01226381|No disease, healthy volunteers
365916|NCT01226368|HIV, HPV, cervical-vaginal smear
365917|NCT01226342|Chronic obstructive pulmonary disease
365918|NCT01226329|Minority Groups
365919|NCT01226329|Decision Making
365920|NCT01226329|Patient Participation
365921|NCT01226329|Mental Health Services
365922|NCT01226329|retention
365923|NCT01226329|attendance
365924|NCT01226329|patient activation
365925|NCT01226329|Hispanic Americans
365926|NCT01226329|patient-provider communication
365927|NCT01226316|Advanced solid malignancy,PIK3CA mutated,AKT1 mutated, PTEN mutation, PTEN alteration, metastatic,ER+,breast,ovarian,endometrial,AZD5363,AKT inhibitor,
365928|NCT01226290|uterine fibroid RF ablation
365929|NCT01226290|intrauterine ultrasound
365930|NCT01226290|VizAblate
365931|NCT01226264|Uterine cervical cancer
365932|NCT01226264|diffusion-weighted MRI
365933|NCT01226264|recurrence
365934|NCT01226251|oral malodour
365935|NCT01226251|halitosis
365936|NCT01226251|Subjects consulting a bad breath clinic
365937|NCT01226225|Patients with recent coronary event
365938|NCT01226212|Older people
365939|NCT01226212|Synbiotic
365940|NCT01226212|Prebiotic
365941|NCT01226212|Probiotic
365942|NCT01226212|Bacteria
365943|NCT01226212|Immune
365944|NCT01226186|Knee replacement
365945|NCT01226186|Pain control
365946|NCT01226186|Self medication
365947|NCT01226173|Prospective screening of blood donors.
365948|NCT01226147|Lupus Nephritis
365949|NCT01226147|SLE
365950|NCT01226147|retinoid
365951|NCT01226147|tamibarotene
365952|NCT01226134|Functional Dyspepsia
365953|NCT01226134|Itopride
365954|NCT01226134|Gastric Emptying
365955|NCT01226134|Gastric Accommodation
365956|NCT01226134|Dyspeptic Symptoms
365957|NCT01226121|dupuytren
365958|NCT01226121|dupuytren's
365959|NCT01226095|Osteoarthritis
365960|NCT01226095|Pain
365961|NCT01226095|Morning stiffness
365962|NCT01226069|superficial phlebitis
365963|NCT01226069|cannula-related vein inflammation
365964|NCT01226069|Glycerine magnesium sulphate
365965|NCT01226069|Hirudoid cream
365966|NCT01226069|Nursing
365967|NCT01226056|advanced solid tumors
365968|NCT01226056|Sorafenib (Nexavar®)
365969|NCT01226056|RAD001 (everolimus)
365970|NCT01226056|tumor molecular targets
365971|NCT01226030|Advanced Solid Tumors
365972|NCT01226017|Oxytocin
365973|NCT01226017|Animal Assisted therapy
365974|NCT01226017|Farm animals
365975|NCT01226017|Healthy nursing students
365976|NCT01226004|radiosurgery
365977|NCT01226004|prostate
365978|NCT01226004|cancer
365979|NCT01226004|early
365980|NCT01226004|intermediate
365981|NCT01226004|CyberKnife
365982|NCT01225991|Pain, Fatigue, Geriatric, Rheumatoid Arthritis, Milnacipran
365983|NCT01225978|Genetic Information
365984|NCT01225978|Variant Updates
365985|NCT01225978|Information Technology
365986|NCT01225978|Hypertrophic Cardiomyopathy
365987|NCT01225978|Hearing Loss
365988|NCT01225978|Oncology
365989|NCT01225965|Particulate Matter induced inflammation of the lung
365990|NCT01225952|phacoemulsification
365991|NCT01225952|intraocular lens
365992|NCT01225939|Type 2 diabetes mellitus
365993|NCT01225939|Healthy
365994|NCT01225926|Intraocular Lens
365995|NCT01225926|Toric
365996|NCT01225913|asthma
365997|NCT01225913|lung function
365998|NCT01225913|inflammation
365999|NCT01225874|untreated childhood acute lymphoblastic leukemia
366000|NCT01225874|B-cell childhood acute lymphoblastic leukemia
366001|NCT01225874|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
366002|NCT01225809|AD01 follow-up extension
366003|NCT01225796|Bicarbonate
366004|NCT01225796|Chronic allograft nephropathy
366005|NCT01225796|Urinary TGF-beta
366006|NCT01225796|Urinary acid excretion
366007|NCT01225770|green tea
366008|NCT01225770|gargling
366009|NCT01225770|prophylaxis
366010|NCT01225770|influenza
366011|NCT01225770|Respiratory Tract Infections
366012|NCT01225770|high school students
366013|NCT01225757|Echocardiography
366014|NCT01225757|HIPEC
366015|NCT01225692|Brain Injury
366016|NCT01225692|Head Trauma
366017|NCT01225692|Trauma Systems
366018|NCT01225692|Head Injury Guideline
366019|NCT01225692|Time to Tertiary Care
366020|NCT01225679|Congenital Central Hypoventilation Syndrome
366021|NCT01225679|Phox2B gene
366022|NCT01225679|invasive ventilation
366023|NCT01225679|genetics
366024|NCT01225679|late-onset
366025|NCT01225679|sleep
366026|NCT01225679|central sleep apnea
366027|NCT01225666|MOD-4023
366028|NCT01225666|Growth Hormone Deficient Adults
366029|NCT01225666|Phase II
366030|NCT01225653|Latanoprost
366031|NCT01225653|vasodilation
366032|NCT01225653|diabetic retinopathy
366033|NCT01225640|Tuberculosis
366034|NCT01225640|EBA
366035|NCT01225640|WBA
366036|NCT01225627|Chronic disease management
366037|NCT01225627|Chronic obstructive pulmonary disease
366038|NCT01225627|Discharge planning
366039|NCT01225627|Discharge coordinator
366040|NCT01225614|Home ventilation
366041|NCT01225614|Myotonic dystrophy type 1 (DM1)
366042|NCT01225575|large cartilage defects
366043|NCT01225575|knee joint
366044|NCT01225575|femoral condyle, tibia, trochlear, retropatellar
366045|NCT01225562|Heart attack
366046|NCT01225562|Heart Disease
366047|NCT01225562|Acute coronary syndrome
366048|NCT01225562|ACS
366049|NCT01225562|Cardiovascular Disease
366050|NCT01225549|Allergen Challenge
366051|NCT01225549|Asthma
366052|NCT01225549|Inhaled selective glucocorticoid receptor agonist (iSEGRA)
366053|NCT01225536|BRAF mutations
366054|NCT01225510|recurrent glioblastoma multiforme (GBM)
366055|NCT01225510|CVX-060
366056|NCT01225510|PF-04856884
366057|NCT01225510|phase 2
366058|NCT01225510|open-label
366059|NCT01225510|bevacizumab
366060|NCT01225510|anti-angiogenic
366061|NCT01225497|Randomized
366062|NCT01225497|Pilot study
366063|NCT01225497|VISA-A
366064|NCT01225497|VAS
366065|NCT01225484|Knee arthroplasty, perioperative analgesia
366066|NCT01225471|novel epitope peptide
366067|NCT01225471|CTL
366068|NCT01225471|advanced prostate cancer
366069|NCT01225458|Elderly patients
366070|NCT01225458|renal insufficiency
366071|NCT01225458|systematized gerontologic evaluation
366072|NCT01225419|Plerixafor
366073|NCT01225419|Hematopoietic Stem Cell Transplant mobilization
366074|NCT01225419|children
366075|NCT01225406|Third line ARV therapy
366076|NCT01225406|HIV RNA
366077|NCT01225406|Absolute CD4+ T cell count
366078|NCT01225406|serious adverse events (SAEs)
366079|NCT01225406|Drug resistance
366080|NCT01225380|Hepatitis C
366081|NCT01225380|HCV
366082|NCT01225380|Rapid Virologic Response
366083|NCT01225380|Sustained Virologic Response
366084|NCT01225380|Direct Acting Antiviral
366085|NCT01225380|Combination Therapy
366086|NCT01225380|HCV RNA
366087|NCT01225380|Polymerase inhibitor
366088|NCT01225380|Protease inhibitor
366089|NCT01225380|Treatment naïve
366090|NCT01225380|GS-9190
366091|NCT01225380|GS-9256
366092|NCT01225354|Cheek
366093|NCT01225354|Cheek flattening
366094|NCT01225354|Malar deficiency
366095|NCT01225354|Filler
366096|NCT01225341|HSV-1
366097|NCT01225341|Herpes labialis
366098|NCT01225341|Cold sores
366099|NCT01225341|Fever blisters
366100|NCT01225289|Multiple Sclerosis
366101|NCT01225289|Vitamin A
366102|NCT01225289|CD4-Positive T-Lymphocytes
366103|NCT01225289|Th1 Cells
366104|NCT01225289|Th2 Cells
366105|NCT01225276|CIDP
366106|NCT01225276|IVIG
366107|NCT01225263|Migraine disorders
366108|NCT01225263|Headache
366109|NCT01225263|Simvastatin
366110|NCT01225263|Vitamin D
366111|NCT01225250|Caudal septal extension graft
366112|NCT01225250|Primary rhinoplasty
366113|NCT01225250|Secondary rhinoplasty
366114|NCT01225237|diarrhea
366115|NCT01225237|IBS
366116|NCT01225237|Colonic disease
366117|NCT01225237|YM060
366118|NCT01225224|ASP015K
366119|NCT01225224|Ethnic difference
366120|NCT01225198|Vitamins
366121|NCT01225198|Minerals
366122|NCT01225185|neurological complications
366123|NCT01225185|brain blood flow autoregulation
366124|NCT01225159|tight glycemic control
366125|NCT01225159|cardiac surgery
366126|NCT01225146|Ischemic
366127|NCT01225146|Central
366128|NCT01225146|Retinal
366129|NCT01225146|Vein
366130|NCT01225146|Occlusion
366131|NCT01225146|Ranibizumab
366132|NCT01225146|Lucentis
366133|NCT01225146|CRVO
366134|NCT01225146|ISCRVO
366135|NCT01225133|Osteoarthritis, Osteoarthrosis, Arthritis, Arthrosis
366136|NCT01225107|Burns
366137|NCT01225107|Infections
366138|NCT01225107|Cranberry
366139|NCT01225094|AAA
366140|NCT01225094|abdominal aortic aneurysm
366141|NCT01225094|acute kidney injury
366142|NCT01225094|ischemia-reperfusion
366143|NCT01225081|ASP1941
366144|NCT01225081|Diabetes mellitus
366145|NCT01225081|pioglitazone
366146|NCT01225042|infectious diarrhea
366147|NCT01225042|probiotics
366148|NCT01225042|prevention
366149|NCT01225042|dietary intervention
366150|NCT01225042|E. coli infection
366151|NCT01225042|intestinal infection
366152|NCT01225042|intestinal resistance
366153|NCT01225029|premature birth
366154|NCT01225029|late preterm birth
366155|NCT01225029|respiratory distress of the newborn
366156|NCT01225029|Transient tachypnea of the newborn
366157|NCT01225003|gliomas
366158|NCT01225003|magnetic resonance
366159|NCT01225003|diffusion kurtosis imaging
366160|NCT01225003|MR spectroscopy
366161|NCT01225003|grading
366162|NCT01224990|gastro-intestinal tumor
366163|NCT01224990|accurate staging
366164|NCT01224990|whole-body diffusion weighted MRI
366165|NCT01224990|non-invasive
366166|NCT01224925|carious exposure
366167|NCT01224925|pulp capping
366168|NCT01224925|MTA
366169|NCT01224925|Dycal
366170|NCT01224912|Insomnia
366171|NCT01224912|Intervention
366172|NCT01224912|Self-help
366173|NCT01224912|Internet
366174|NCT01224899|Heart Failure
366175|NCT01224899|Sympathetic Nervous System
366176|NCT01224899|Sympathectomy
366177|NCT01224899|Adrenergic beta-Antagonists
366178|NCT01224899|Ventricular Dysfunction, Left
366179|NCT01224886|Aging
366180|NCT01224886|Insulin resistance
366181|NCT01224886|Ectopic lipids
366182|NCT01224886|Obesity
366183|NCT01224886|Exercise
366184|NCT01224886|Physical activity
366185|NCT01224886|Oxidative capacity
366186|NCT01224886|Diabetes
366187|NCT01224886|Metabolic syndrome
366188|NCT01224873|breast cancer
366189|NCT01224873|bone metastasis
366190|NCT01224873|comparison of diagnostic methods
366191|NCT01224873|bone scintigraphy
366192|NCT01224873|fluoride PET/CT
366193|NCT01224873|FDG-PET/CT
366194|NCT01224860|Telmisartan
366195|NCT01224860|Losartan
366196|NCT01224860|Renal transplant
366197|NCT01224847|AMD
366198|NCT01224847|Intravitreal Injection
366199|NCT01224847|Anesthesia
366200|NCT01224834|Ragweed, allergy, sublingual immunotherapy
366201|NCT01224821|iodine I 131 tositumomab
366202|NCT01224821|anti-B1 Antibody
366203|NCT01224821|Bexxar
366204|NCT01224821|radioimmunotherapy
366205|NCT01224821|tositumomab
366206|NCT01224808|von Willebrand Disease
366207|NCT01224795|uncomplicated influenza
366208|NCT01224782|Zemplar capsules
366209|NCT01224782|Chronic kidney disease (CKD) stage 3 or 4
366210|NCT01224782|Secondary hyperparathyroidism (SHPT)
366211|NCT01224782|Postmarketing observational study (PMOS)
366212|NCT01224756|Tonsillitis
366213|NCT01224756|Pharyngitis
366214|NCT01224756|Sore Throat
366215|NCT01224756|Drug Therapy
366216|NCT01224717|Osteoporosis
366217|NCT01224704|Hypertonic Saline Infusion
366218|NCT01224704|Water Deprivation
366219|NCT01224704|Thirst
366220|NCT01224704|Water/Electrolytes Homeostasis
366221|NCT01224704|Obesity
366222|NCT01224691|Respiratory Syncytial Virus
366223|NCT01224691|TGF Beta
366224|NCT01224691|RSV
366225|NCT01224691|Asthma
366226|NCT01224691|Healthy Volunteer
366227|NCT01224678|breast cancer
366228|NCT01224665|stage II bladder cancer
366229|NCT01224665|stage III bladder cancer
366230|NCT01224665|transitional cell carcinoma of the bladder
366231|NCT01224652|gastric cancer
366232|NCT01224652|paclitaxel
366233|NCT01224652|irinotecan
366234|NCT01224639|dengue fever
366235|NCT01224639|live attenuated tetravalent dengue vaccine
366236|NCT01224639|DENVax
366237|NCT01224626|VRE
366238|NCT01224626|Japanese
366239|NCT01224626|Post Marketing Surveillance
366240|NCT01224600|lower limbs
366241|NCT01224600|Arterial Diseases
366242|NCT01224587|Imaging technique
366243|NCT01224587|gastric transport through the gut
366244|NCT01224574|atrial fribrillation, cardiovascular events, aging, D-dimer
366245|NCT01224561|Thinness
366246|NCT01224561|Leanness
366247|NCT01224561|healthy volunteers
366248|NCT01224561|Lipid metabolism disorder
366249|NCT01224548|vegan
366250|NCT01224548|diet
366251|NCT01224548|diabetes
366252|NCT01224548|overweight
366253|NCT01224548|workplace
366254|NCT01224548|nutrition
366255|NCT01224548|diabetes and/or overweight
366256|NCT01224535|Complementary foods
366257|NCT01224535|Amaranth
366258|NCT01224535|Food Based approaches
366259|NCT01224535|Iron Deficiency anemia
366260|NCT01224535|Arid Areas
366261|NCT01224535|Africa
366262|NCT01224522|Randomized Controlled Trial
366263|NCT01224522|Total Knee Arthroplasty
366264|NCT01224522|Patient Matched Cutting Blocks
366265|NCT01224509|Cervix
366266|NCT01224509|EP3 receptors
366267|NCT01224509|Mifepristone
366268|NCT01224509|Prostaglandin
366269|NCT01224509|Receptors
366270|NCT01224509|Steroids
366271|NCT01224496|Chronic cytopenic haematological diseases
366272|NCT01224496|Chinese herbal concoction
366273|NCT01224496|Supportive management
366274|NCT01224444|colon polyps
366275|NCT01224444|adenoma resection
366276|NCT01224444|colon cancer screening
366277|NCT01224444|colonoscopy
366278|NCT01224431|pain
366279|NCT01224431|lidocaine
366280|NCT01224431|lumbar puncture
366281|NCT01224431|j-tip
366282|NCT01224418|Tacrolimus
366283|NCT01224418|Prograf
366284|NCT01224418|Calcinurin inhibitor
366285|NCT01224418|Rheumatoid arthritis(RA)
366286|NCT01224392|colorectal cancer
366287|NCT01224392|colorectal neoplasms
366288|NCT01224392|radiotherapy
366289|NCT01224392|chemoradiotherapy
366290|NCT01224392|T3-4 rectal cancer
366291|NCT01224379|Lumbar spine
366292|NCT01224379|fusion
366293|NCT01224379|adjacent instability
366294|NCT01224379|topping-off.
366295|NCT01224366|Add-on to insulin
366296|NCT01224327|Liver cirrhosis
366297|NCT01224327|Radiology
366298|NCT01224327|Mesenchymal Stem Cells
366299|NCT01224327|Umbilical Cord
366300|NCT01224314|Haemodynamics
366301|NCT01224314|Hypotension
366302|NCT01224314|Potassium
366303|NCT01224314|Haemodialysis
366304|NCT01224314|Dialysis fluids
366305|NCT01224301|seasonal influenza vaccine
366306|NCT01224301|school-based clinics
366307|NCT01224301|economic analysis of school based influenza vaccine delivery
366308|NCT01224301|pediatric influenza vaccine rates
366309|NCT01224301|Influenza vaccine information for parents
366310|NCT01224288|RCC
366311|NCT01224288|Kidney cancer
366312|NCT01224288|Metastatic renal cell carcinoma
366313|NCT01224288|mRCC
366314|NCT01224288|Dynamic contrast enhanced CT
366315|NCT01224288|DCE-CT
366316|NCT01224288|Tumor perfusion
366317|NCT01224275|group based care
366318|NCT01224275|antenatal care
366319|NCT01224275|parents satisfaction
366320|NCT01224275|Antenatal care´s organization and patient satisfaction
366321|NCT01224262|influenza vaccine
366322|NCT01224262|seasonal influenza
366323|NCT01224262|novel vaccine
366324|NCT01224262|flu
366325|NCT01224249|Selenium
366326|NCT01224249|Selenoprotein P
366327|NCT01224249|Fish
366328|NCT01224249|Shellfish
366329|NCT01224249|Bioavailability
366330|NCT01224223|asthma
366331|NCT01224210|portopulmonary hypertension
366332|NCT01224210|portal hypertension
366333|NCT01224210|esophageal or gastric varices
366334|NCT01224210|right heart catheterization
366335|NCT01224210|transpulmonary gradient
366336|NCT01224210|Endothelin Receptor Antagonist
366337|NCT01224210|Ambrisentan
366338|NCT01224210|Letairis
366339|NCT01224210|pulmonary hemodynamics
366340|NCT01224197|TMC435HPC1004
366341|NCT01224197|TMC435
366342|NCT01224197|HCV
366343|NCT01224197|Hepatitis C
366344|NCT01224197|Healthy Chinese volunteer
366345|NCT01224184|HIV
366346|NCT01224184|Sexually Transmitted Diseases
366347|NCT01224184|Substance Abuse Detection
366348|NCT01224184|Randomized Controlled Trial
366349|NCT01224132|Atopic dermatitis, probiotic, SCORAD index, prick tests, cytokines
366350|NCT01224119|foot ankle arthritis bone graft
366351|NCT01224054|Tolerance alimentary
366352|NCT01224054|Morbid obesity
366353|NCT01224054|Type 2 Diabetes Mellitus
366354|NCT01224041|Tacrolimus
366355|NCT01224041|Prograf
366356|NCT01224041|Calcinurin inhibitor
366357|NCT01224041|Rheumatoid arthritis (RA)
366358|NCT01224028|Tacrolimus
366359|NCT01224028|Prograf
366360|NCT01224028|Calcinurin inhibitor
366361|NCT01224028|Albuminurea
366362|NCT01224028|Proteinurea
366363|NCT01224028|FK506
366364|NCT01224002|Cross-Sectional
366365|NCT01224002|Observational
366366|NCT01224002|Comparative
366367|NCT01224002|Retrospective
366368|NCT01224002|Feasibility
366369|NCT01224002|Dental Decay
366370|NCT01224002|Drug Abuse
366371|NCT01224002|Survey
366372|NCT01223989|overweight
366373|NCT01223989|obesity
366374|NCT01223989|bread
366375|NCT01223989|hypocaloric diet
366376|NCT01223976|latent tuberculosis psoriasis arthritis TST QTF
366377|NCT01223976|Screening of latent tuberculosis in psoriasis
366378|NCT01223963|Macrolane
366379|NCT01223963|Retrospective
366380|NCT01223924|cancer
366381|NCT01223898|CML,
366382|NCT01223898|nilotinib,
366383|NCT01223898|midazolam
366384|NCT01223859|Radiofrequency, ablation, RFA, RFTA, RFITT, soft palate.
366385|NCT01223833|breast cancer
366386|NCT01223833|postmenopausal
366387|NCT01223833|aromatase inhibitors
366388|NCT01223833|tamoxifen
366389|NCT01223833|arthralgia
366390|NCT01223833|IGF-I
366391|NCT01223833|BMI
366392|NCT01223833|grip strength
366393|NCT01223807|COPD, diaphragm, rehabilitation
366394|NCT01223794|Fall
366395|NCT01223794|all in surgical & Medical in-patient
366396|NCT01223781|Freezing
366397|NCT01223781|biofeedback
366398|NCT01223781|motor learning
366399|NCT01223781|freezing of gait in PD
366400|NCT01223755|Autosomal dominant polycystic kidney disease
366401|NCT01223755|Sirolimus
366402|NCT01223755|Renal insufficiency
366403|NCT01223729|Acetyl-L-carnitine;
366404|NCT01223729|Minimal hepatic encephalopathy;
366405|NCT01223729|Quality of life;
366406|NCT01223729|Depression.
366407|NCT01223716|amblyopia treatment
366408|NCT01223716|neural plasticity
366409|NCT01223716|perceptual learning
366410|NCT01223716|vision therapy
366411|NCT01223716|spatial vision
366412|NCT01223716|video games
366413|NCT01223716|occlusion therapy
366414|NCT01223703|n-3 PUFAs
366415|NCT01223703|Heart Failure
366416|NCT01223703|Dilated cardiomyopathy
366417|NCT01223703|Ejection Fraction
366418|NCT01223703|Exercise Capacity
366419|NCT01223690|sepsis
366420|NCT01223690|infection
366421|NCT01223690|bacteremia
366422|NCT01223690|clarithromycin
366423|NCT01223664|ABMSC
366424|NCT01223664|Allogenic bone marrow mesenchymal stem cells
366425|NCT01223664|Liver cirrhosis
366426|NCT01223664|Transplantation
366427|NCT01223651|Diabetes Mellitus, Type 1
366428|NCT01223651|Continuous Glucose Monitoring System
366429|NCT01223651|Accuracy
366430|NCT01223651|Altitude
366431|NCT01223638|Congenital hypothyroidism(CH)
366432|NCT01223638|Hearing loss among children with CH
366433|NCT01223612|Diabetes Mellitus
366434|NCT01223612|Diabetes Complications
366435|NCT01223612|Retinal Diseases
366436|NCT01223612|Edema
366437|NCT01223612|Endothelial Growth Factors
366438|NCT01223612|Monoclonal Antibodies
366439|NCT01223612|Ranibizumab
366440|NCT01223612|Laser therapy
366441|NCT01223599|pilonidal disease
366442|NCT01223599|natal cleft
366443|NCT01223599|limberg flap
366444|NCT01223560|Artificial pancreas
366445|NCT01223560|Model predictive control
366446|NCT01223560|Virtual patient
366447|NCT01223547|Carbohydrate counting
366448|NCT01223547|Insulin bolus calculation
366449|NCT01223534|Tuberculosis
366450|NCT01223534|Latent tuberculosis infection
366451|NCT01223534|Tuberculin skin test
366452|NCT01223534|Interferon-gamma release assays
366453|NCT01223534|Contact-tracing study
366454|NCT01223521|Contraception
366455|NCT01223521|Abortion
366456|NCT01223521|First trimester
366457|NCT01223521|Intrauterine device
366458|NCT01223482|Miscarriage
366459|NCT01223482|Karyotyping
366460|NCT01223482|Genetic testing
366461|NCT01223469|Atrial Fibrillation
366462|NCT01223469|Supraventricular Tachycardia
366463|NCT01223469|Contact Force
366464|NCT01223469|RF Ablation
366465|NCT01223469|Radiofrequency
366466|NCT01223469|Pulmonary Vein Isolation
366467|NCT01223469|Paroxysmal Atrial Fibrillation
366468|NCT01223456|Saxagliptin
366469|NCT01223456|type 2 diabetes
366470|NCT01223456|clinical practice
366471|NCT01223443|Coronary Artery Bypass Grafting
366472|NCT01223443|Drug Eluting Stent
366473|NCT01223443|Saphenous Vein Graft
366474|NCT01223430|septic shock
366475|NCT01223430|shock reversal
366476|NCT01223430|ICU
366477|NCT01223430|traditional Chinese medicine
366478|NCT01223404|nicotine
366479|NCT01223404|mecamylamine
366480|NCT01223404|attention
366481|NCT01223404|default network
366482|NCT01223404|fMRI
366483|NCT01223391|orthostatic
366484|NCT01223391|abdominal compression
366485|NCT01223365|Chronic Pain
366486|NCT01223352|pulmonary arterial hypertension
366487|NCT01223352|children
366488|NCT01223352|pediatric
366489|NCT01223352|bosentan
366490|NCT01223339|Ertugliflozin
366491|NCT01223339|Japanese and Western population
366492|NCT01223339|pharmacokinetics
366493|NCT01223339|pharmacodynamics
366494|NCT01223326|Acetylcysteine
366495|NCT01223313|Contraception
366496|NCT01223313|Woman's Condom
366497|NCT01223313|Female Condom
366498|NCT01223313|Condom
366499|NCT01223287|NICHD Neonatal Research Network
366500|NCT01223287|Extremely Low Birth Weight (ELBW)
366501|NCT01223287|Very Low Birth Weight (VLBW)
366502|NCT01223287|Prematurity
366503|NCT01223287|Mechanical ventilation
366504|NCT01223287|Chronic Lung Disease (CLD)
366505|NCT01223274|NICHD Neonatal Research Network
366506|NCT01223274|Extremely Low Birth Weight (ELBW)
366507|NCT01223274|Very Low Birth Weight (VLBW)
366508|NCT01223274|Prematurity
366509|NCT01223274|Mechanical ventilation
366510|NCT01223274|Positive-Pressure Ventilation
366511|NCT01223274|Surfactant
366512|NCT01223274|Intubation
366513|NCT01223274|Pulse oximetry
366514|NCT01223274|Oxygen saturation
366515|NCT01223261|NICHD Neonatal Research Network
366516|NCT01223261|Very Low Birth Weight (VLBW)
366517|NCT01223261|Extremely Low Birth Weight (ELBW)
366518|NCT01223261|Prematurity
366519|NCT01223261|Laparotomy
366520|NCT01223261|Drainage
366521|NCT01223261|Isolated intestinal perforation
366522|NCT01223261|Focal intestinal performation
366523|NCT01223248|radiation
366524|NCT01223248|Hypofractionated Image- Guided
366525|NCT01223248|IGIMRT
366526|NCT01223248|RT
366527|NCT01223248|10-154
366528|NCT01223235|FALLOPIAN TUBE
366529|NCT01223235|OVARY
366530|NCT01223235|PERITONEUM
366531|NCT01223235|BEVACIZUMAB (AVASTIN)
366532|NCT01223235|GLOBO H-KLH CONJUGATE
366533|NCT01223235|MUC-1 KLH
366534|NCT01223235|OPT-821
366535|NCT01223235|TF (C) - KLH
366536|NCT01223235|TN(C)-KLH
366537|NCT01223235|10-099
366538|NCT01223222|Uncomplicated skin infections
366539|NCT01223222|Impetigo
366540|NCT01223222|Gram-negative
366541|NCT01223222|Diagnosis of uncomplicated, Gram-positive, skin infection. This may include patients with mild eczema/dermatoses such as atopic dermatitis.
366542|NCT01223222|Gram-positive organisms which in the opinion of the investigator are causative for infection of the lesion(s),
366543|NCT01223209|Cancer
366544|NCT01223209|Carcinoma
366545|NCT01223209|Curative surgery
366546|NCT01223209|Curative surgery for carcinoma at least three months and not more than 5 years prior to treatment start
366547|NCT01223196|Type 2 Diabetes, Thiazolidinediones, TIMP-3, TACE, TNF-a,
366548|NCT01223196|insulin resistance
366549|NCT01223183|cystic fibrosis
366550|NCT01223183|nuclear medicine
366551|NCT01223183|aerosol
366552|NCT01223183|nebulizer
366553|NCT01223170|Tailoring
366554|NCT01223170|Cardiac rehabilitation
366555|NCT01223170|Internet based intervention
366556|NCT01223170|Exercise
366557|NCT01223170|Cardiovascular Disease rehabilitation
366558|NCT01223157|obesity
366559|NCT01223157|endocannabinoids
366560|NCT01223144|Cognition
366561|NCT01223144|orbitofrontal cortex
366562|NCT01223144|Iowa Gambling Task
366563|NCT01223144|facial emotion recognition
366564|NCT01223118|Oocyte
366565|NCT01223118|vitrification
366566|NCT01223118|IVF
366567|NCT01223118|PGD
366568|NCT01223118|embryo biopsy
366569|NCT01223105|slow freeze
366570|NCT01223105|cryopreservation
366571|NCT01223105|vitrification
366572|NCT01223105|oocyte preservation
366573|NCT01223092|IVF
366574|NCT01223092|infertility
366575|NCT01223092|DNA
366576|NCT01223079|r-hFSH
366577|NCT01223079|r-hLH
366578|NCT01223066|Macrolane
366579|NCT01223053|Sprain
366580|NCT01223053|Strain
366581|NCT01223053|Pain
366582|NCT01223053|Ankle Pain
366583|NCT01223053|Knee Pain
366584|NCT01223053|Wrist Pain
366585|NCT01223053|Hand Pain
366586|NCT01223027|Dovitinib
366587|NCT01223027|TKI
366588|NCT01223027|Renal cell cancer
366589|NCT01223027|RCC
366590|NCT01223027|mRCC
366591|NCT01223014|Radioactive
366592|NCT01223014|ADME
366593|NCT01223014|Neuropathic pain
366594|NCT01223001|Depression
366595|NCT01223001|Traumatic brain injury
366596|NCT01223001|Duloxetine
366597|NCT01223001|Cymbalta
366598|NCT01223001|impaired cognitive function
366599|NCT01222975|risperidone fasting study
366600|NCT01222936|LBH581
366601|NCT01222936|Panobinostat
366602|NCT01222936|Small Cell Lung Carcinoma
366603|NCT01222923|Risperidone fed study
366604|NCT01222910|Valacyclovir hydrochloride fasting study
366605|NCT01222897|Valacyclovir hydrochloride fed study
366606|NCT01222871|Treatment
366607|NCT01222858|Obesity
366608|NCT01222858|Primary Care
366609|NCT01222858|Internet
366610|NCT01222858|Technology
366611|NCT01222858|Behavior Modification
366612|NCT01222819|Febrile neutropenia
366613|NCT01222819|growth factors
366614|NCT01222819|leukemia
366615|NCT01222806|Functional Magnetic Resonance Imaging (fMRI)
366616|NCT01222806|Cocaine
366617|NCT01222806|Cue-Induced Craving
366618|NCT01222806|Repetitive TMS (rTMS)
366619|NCT01222806|Cocaine Craving
366620|NCT01222793|High Weight Gain Liability (HWLA)
366621|NCT01222793|Antipsychotic
366622|NCT01222793|Obesity
366623|NCT01222793|Low Weight Gain
366624|NCT01222793|Schizophrenia
366625|NCT01222793|Food Craving
366626|NCT01222780|Hematologic Malignancies
366627|NCT01222780|Vincristine Sulfate
366628|NCT01222780|Maximum Tolerated Dose
366629|NCT01222780|Pharmacokinetics
366630|NCT01222780|Solid Tumors
366631|NCT01222780|Cancer
366632|NCT01222780|Pediatrics
366633|NCT01222780|Sarcoma
366634|NCT01222780|Wilms Tumor
366635|NCT01222780|Leukemia
366636|NCT01222780|Lymphoma
366637|NCT01222780|Brain Tumor
366638|NCT01222767|EFT
366639|NCT01222767|PNET
366640|NCT01222767|EOE
366641|NCT01222754|Newly Diagnosed
366642|NCT01222754|DIPG
366643|NCT01222754|CC 5013
366644|NCT01222754|Radiation Therapy
366645|NCT01222754|Lenalidomide
366646|NCT01222754|XRT
366647|NCT01222754|Brain Tumor
366648|NCT01222754|Glioma
366649|NCT01222754|Pediatrics
366650|NCT01222741|AIRE- Autoimmune Regulator Gene
366651|NCT01222741|APECED- Autoimmune Polyendocrinopathy-Candidiasis Ectodermal Dystrophy
366652|NCT01222741|CGD- Chronic Granulomatous Disease
366653|NCT01222741|CMC- Chronic Mucocutaneous Candidiasis
366654|NCT01222728|PET Imaging
366655|NCT01222728|Vestibular Schwannoma
366656|NCT01222728|Neurofibromatosis
366657|NCT01222728|Neurofibromatosis Type 2
366658|NCT01222728|NF2
366659|NCT01222702|CDIFF
366660|NCT01222702|CDI
366661|NCT01222702|CDAD
366662|NCT01222702|Clostridium difficile infection
366663|NCT01222676|transitional cell carcinoma of the bladder
366664|NCT01222676|stage II bladder cancer
366665|NCT01222676|stage III bladder cancer
366666|NCT01222676|stage IV bladder cancer
366667|NCT01222663|peritonitis
366668|NCT01222663|septic shock
366669|NCT01222663|hemoperfusion
366670|NCT01222663|Polymyxin B
366671|NCT01222663|endotoxin
366672|NCT01222650|Benign Prostatic Hyperplasia
366673|NCT01222650|I-PSS
366674|NCT01222650|α1A-AR antagonist
366675|NCT01222637|advanced solid cancers
366676|NCT01222637|metastatic solid cancers
366677|NCT01222624|advanced solid malignancies
366678|NCT01222611|HIV
366679|NCT01222611|HCV
366680|NCT01222611|HIV/HCV
366681|NCT01222611|Coinfection
366682|NCT01222611|Fosamprenavir
366683|NCT01222585|Metronidazole
366684|NCT01222585|Neonate
366685|NCT01222585|Premature
366686|NCT01222585|Sepsis
366687|NCT01222585|Necrotizing enterocolitis
366688|NCT01222572|radiation therapy
366689|NCT01222572|stereotactic radiotherapy
366690|NCT01222572|stereotactic boost
366691|NCT01222559|Cartilage defects
366692|NCT01222559|Knee joint
366693|NCT01222559|Femoral Condyle
366694|NCT01222507|tinnitus
366695|NCT01222507|cognition
366696|NCT01222507|brain processing speed
366697|NCT01222507|Brain Fitness Program
366698|NCT01222507|Posit Science
366699|NCT01222494|Child Psychiatry
366700|NCT01222494|Obesity
366701|NCT01222494|Antipsychotic
366702|NCT01222481|Head and Neck Cancer
366703|NCT01222481|Functional Status
366704|NCT01222481|Cognitive Status
366705|NCT01222481|Neurocognitive Assessments
366706|NCT01222481|Performance-based Assessments
366707|NCT01222481|Cancer
366708|NCT01222481|Function
366709|NCT01222481|Cognition
366710|NCT01222481|Quality of Life
366711|NCT01222468|Spasticity, Spinal Cord Injury
366712|NCT01222455|Phase 1
366713|NCT01222455|Healthy volunteers
366714|NCT01222455|Volunteers with hepatic impairment
366715|NCT01222455|Pharmacokinetics
366716|NCT01222455|Fostamatinib
366717|NCT01222442|Respiratory disease
366718|NCT01222442|Bronchiolitis
366719|NCT01222442|Emphysema
366720|NCT01222442|Lung disease causing persistent narrowing of the airways
366721|NCT01222390|Breast Cancer Reconstruction
366722|NCT01222390|Tissue Expander
366723|NCT01222390|3-D Camera
366724|NCT01222390|Breast Reconstruction
366725|NCT01222390|Crescentric
366726|NCT01222390|Expander Profile
366727|NCT01222390|Fill-Volume
366728|NCT01222390|Lower Pole
366729|NCT01222390|Upper Pole
366730|NCT01222390|Acellular Dermis
366731|NCT01222390|3-D Imaging
366732|NCT01222364|NICHD Neonatal Research Network
366733|NCT01222364|Extremely Low Birth Weight (ELBW)
366734|NCT01222364|Very Low Birth Weight (VLBW)
366735|NCT01222364|Prematurity
366736|NCT01222351|Alzheimer's disease
366737|NCT01222351|Positron emission tomography
366738|NCT01222351|Biomarker
366739|NCT01222351|Plasma Aβ
366740|NCT01222351|Brain amyloid plaque load
366741|NCT01222338|Mycobacterium
366742|NCT01222338|MDR-TB
366743|NCT01222338|XDR-TB
366744|NCT01222338|HIV
366745|NCT01222338|HCV
366746|NCT01222325|kidney calculi
366747|NCT01222325|urolithiasis
366748|NCT01222325|urologic surgical procedures
366749|NCT01222325|extracorporeal shockwave lithotripsy
366750|NCT01222312|advanced NSCLC
366751|NCT01222312|oxaliplatin
366752|NCT01222312|cisplatin
366753|NCT01222312|docetaxel
366754|NCT01222312|locally advanced or metastatic non small cell lung cancer (stage IIIB-IV)
366755|NCT01222286|Smoldering Multiple Myeloma
366756|NCT01222273|cystic fibrosis
366757|NCT01222273|Allergic bronchopulmonary aspergillosis
366758|NCT01222273|A. fumigatus
366759|NCT01222273|Immune response
366760|NCT01222260|Amyloidosis
366761|NCT01222260|Dexamethasone
366762|NCT01222260|Bendamustine
366763|NCT01222260|Relapsed AL Amyloidosis
366764|NCT01222247|Betamethasone
366765|NCT01222247|Celestone
366766|NCT01222247|Steroids
366767|NCT01222247|Perinatology
366768|NCT01222221|adult gliosarcoma
366769|NCT01222221|adult giant cell glioblastoma
366770|NCT01222221|adult glioblastoma
366771|NCT01222208|Bowel resection
366772|NCT01222195|Myelodysplastic Syndrome
366773|NCT01222195|Red cell transfusion independence
366774|NCT01222195|Darbepoetin alfa
366775|NCT01222195|Lenalidomide
366776|NCT01222195|CC-5013
366777|NCT01222195|Revlimid
366778|NCT01222195|Aranesp
366779|NCT01222195|Erythropoietin
366780|NCT01222195|Erythropoiesis Stimulating Protein
366781|NCT01222182|low density lipoprotein (LDL) cholesterol
366782|NCT01222182|statin
366783|NCT01222182|dose equivalent
366784|NCT01222182|Hypercholesterolemia (defined by LDL guidelines)
366785|NCT01222169|Anesthesia
366786|NCT01222169|Children
366787|NCT01222169|Larynx
366788|NCT01222156|Cardiac arrhythmias
366789|NCT01222156|Catheter ablation
366790|NCT01222156|Electrophysiology
366791|NCT01222156|Magnetic
366792|NCT01222156|Mapping
366793|NCT01222156|Remote navigation
366794|NCT01222143|AML
366795|NCT01222143|NOVE-HiDAC
366796|NCT01222143|Nilotinib
366797|NCT01222130|HIV
366798|NCT01222130|Infant infection
366799|NCT01222130|Diagnosis
366800|NCT01222130|Non-virological algorithm
366801|NCT01222117|Acute Limb Ischemia
366802|NCT01222104|vascular closure
366803|NCT01222104|Angio-Seal
366804|NCT01222104|Interventional radiology
366805|NCT01222104|femoral artery
366806|NCT01222078|newly diagnosed type 1 diabetes mellitus
366807|NCT01222078|re-treatment
366808|NCT01222078|intravenous otelixizumab
366809|NCT01222078|beta-cell preservation
366810|NCT01222065|Glaucoma
366811|NCT01222065|Neurotubules
366812|NCT01222065|Birefringence
366813|NCT01222065|Retinal Nerve Fiber Layer (RNFL)
366814|NCT01222052|high risk breast cancer
366815|NCT01222052|low risk breast cancer
366816|NCT01222052|uPA
366817|NCT01222052|urokinase-type plasminogen activator
366818|NCT01222052|PAI
366819|NCT01222052|plasminogen activator inhibitor-type
366820|NCT01222039|Graft versus host disease
366821|NCT01222039|Mesenchymal stem cell
366822|NCT01222039|Allogeneic mesenchymal stem cell
366823|NCT01222039|Adipose tissue
366824|NCT01222039|Allotransplant
366825|NCT01222039|Allogenic
366826|NCT01222039|Mesenchymal Stem Cells
366827|NCT01222039|Immune System Diseases
366828|NCT01222039|Chronic
366829|NCT01222039|Expanded
366830|NCT01222026|Primary Hyperparathyroidism
366831|NCT01222026|Osteopenia
366832|NCT01222026|Osteoporosis
366833|NCT01221987|Human papillomavirus
366834|NCT01221987|neoplasia
366835|NCT01221974|Hydrosalpinx or infertility
366836|NCT01221961|Major spine surgery
366837|NCT01221961|Hemoglobin
366838|NCT01221961|Blood transfusion
366839|NCT01221948|Deep Brain Stimulation
366840|NCT01221948|Parkinson's Disease
366841|NCT01221935|retrospective chart review study
366842|NCT01221935|desvenlafaxine utilization
366843|NCT01221935|psychiatrists and primary care physicians
366844|NCT01221935|treatment of major depressive disorder
366845|NCT01221909|bleeding
366846|NCT01221909|dacryocystorhinostomy
366847|NCT01221909|operative duration
366848|NCT01221896|Localization of a parathyroid adenoma in patients with primary hyperparathyroidism.
366849|NCT01221883|Posttraumatic Stress
366850|NCT01221883|Prevention
366851|NCT01221883|Diazepam
366852|NCT01221870|Metastatic breast cancer
366853|NCT01221870|First-line therapy
366854|NCT01221870|Tesetaxel
366855|NCT01221870|Oral taxane
366856|NCT01221857|Double Umbilical Cord Blood Stem Cell Transplantation
366857|NCT01221857|Hematological Malignancies
366858|NCT01221857|HLA Mismatched Donors
366859|NCT01221857|Cord Blood Transplantation
366860|NCT01221844|Lactoferrin
366861|NCT01221844|Pregnancy
366862|NCT01221844|Hereditary Thrombophilia
366863|NCT01221844|Iron deficiency
366864|NCT01221844|Iron deficiency anemia
366865|NCT01221818|Inflammatory Bowel Disease
366866|NCT01221805|deep venous thrombosis
366867|NCT01221805|pulmonary embolism
366868|NCT01221805|venous thromboembolism
366869|NCT01221805|D-dimer
366870|NCT01221805|Wells score
366871|NCT01221805|Wells clinical pretest probability
366872|NCT01221792|PTSD
366873|NCT01221792|Anxiety
366874|NCT01221792|Trauma
366875|NCT01221792|Assault
366876|NCT01221792|Victim
366877|NCT01221792|Witness
366878|NCT01221792|Post Traumatic Stress Disorder
366879|NCT01221792|Combat veteran
366880|NCT01221792|Flashbacks
366881|NCT01221792|Nightmares
366882|NCT01221792|Sleep Disturbance
366883|NCT01221792|Hyperarousal
366884|NCT01221792|Numbness
366885|NCT01221792|Avoidance
366886|NCT01221779|Intensive language therapy
366887|NCT01221779|Anomia
366888|NCT01221779|Magnetic Resonance Imaging
366889|NCT01221766|adnexal
366890|NCT01221766|hair and nail
366891|NCT01221766|chronic graft vs host disease
366892|NCT01221766|children
366893|NCT01221753|SSCHN
366894|NCT01221753|HPV
366895|NCT01221753|IMRT
366896|NCT01221740|To show that patients with greater pain sensitivity
366897|NCT01221740|will show greater improvement in their symptoms
366898|NCT01221740|(self-reported pain intensity, mood, sleep, and
366899|NCT01221740|quality of life) than those with lower pain
366900|NCT01221740|sensitivity, based on QST, after taking milnacipran.
366901|NCT01221740|To compare outcome differences
366902|NCT01221740|(pain intensity, mood, activity interference,
366903|NCT01221740|sleep, and side effects) with those patients
366904|NCT01221740|who are either taking or not taking opioids for
366905|NCT01221740|their pain 10 weeks after being prescribed milnacipran.
366906|NCT01221740|To show that patients who are older, male,
366907|NCT01221740|with more medical comorbidities, greater disability,
366908|NCT01221740|and longer pain duration will report less improvement
366909|NCT01221740|(pain, mood, sleep, health-related quality of life)
366910|NCT01221740|and treatment satisfaction while taking milnacipran
366911|NCT01221740|compared with others without such characteristics.
366912|NCT01221740|identify patients back or neck pain
366913|NCT01221740|greater 6 months
366914|NCT01221740|QST
366915|NCT01221740|10 weeks
366916|NCT01221740|milnacipran
366917|NCT01221740|pain intensity
366918|NCT01221740|mood
366919|NCT01221740|activity
366920|NCT01221740|interference
366921|NCT01221740|sleep
366922|NCT01221740|side effects
366923|NCT01221740|age
366924|NCT01221740|gender
366925|NCT01221740|medical comorbidities
366926|NCT01221740|pain diagnosis
366927|NCT01221740|pain duration
366928|NCT01221740|disability status
366929|NCT01221727|Amgen
366930|NCT01221727|Phase 1
366931|NCT01221727|Postmenopausal
366932|NCT01221727|Osteoporosis
366933|NCT01221714|nutritional supplements
366934|NCT01221714|supplements
366935|NCT01221714|vitamins
366936|NCT01221714|omega-3
366937|NCT01221714|Amerisciences
366938|NCT01221714|Carlos Montesinos
366939|NCT01221701|depression
366940|NCT01221701|psychological treatments
366941|NCT01221701|Cognitive Behavioral Therapy
366942|NCT01221701|child social/emotional functioning
366943|NCT01221701|parenting
366944|NCT01221701|home visitation
366945|NCT01221688|Sentinel lymph node biopsy (SLNB)
366946|NCT01221688|large operable breast cancer
366947|NCT01221688|neoadjuvant chemotherapy
366948|NCT01221688|patients with large operable breast cancer after neoadjuvant chemotherapy (NAC)
366949|NCT01221675|Small Cell Lung Cancer or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
366950|NCT01221675|Radio Immunotherapy
366951|NCT01221675|Lutetium
367079|NCT01221025|elderly patients;
366952|NCT01221675|patient ≥ 18 years of age with CEA-positive SCLC in partial response
366953|NCT01221675|or who failed at least two lines of standard radiation and/or chemotherapy
366954|NCT01221675|or Patients with histologic diagnosis of NSCLC
366955|NCT01221662|Siwu tang
366956|NCT01221662|brain hypoperfusion
366957|NCT01221662|cognition function
366958|NCT01221623|Peyronie's Disease
366959|NCT01221623|penile plaque
366960|NCT01221623|penile curvature
366961|NCT01221610|Stenosis
366962|NCT01221610|Occlusions
366963|NCT01221610|SFA
366964|NCT01221610|PTA
366965|NCT01221610|POBA
366966|NCT01221610|DRB
366967|NCT01221597|Peyronie's Disease
366968|NCT01221597|penile plaque
366969|NCT01221597|penile curvature
366970|NCT01221584|Dyslipidaemia
366971|NCT01221584|LDL-C goals
366972|NCT01221584|guidelines
366973|NCT01221571|Phase I
366974|NCT01221571|Dose escalation
366975|NCT01221571|AFM 13
366976|NCT01221571|Natural killer cell
366977|NCT01221545|Diabetes Mellitus
366978|NCT01221519|Phase I
366979|NCT01221519|Bioavailability
366980|NCT01221519|Type 2 Diabetes Mellitus
366981|NCT01221519|Diabetic treatment
366982|NCT01221519|Metformin
366983|NCT01221519|High blood sugar
366984|NCT01221506|unresectable
366985|NCT01221506|metastatic
366986|NCT01221506|clear cell renal carcinoma
366987|NCT01221493|solitary pulmonary nodules
366988|NCT01221493|transbronchial lung biopsy
366989|NCT01221493|endobronchial ultrasound
366990|NCT01221454|ABMSC
366991|NCT01221454|Allogenic bone marrow mesenchymal stem cells
366992|NCT01221454|Liver Failure
366993|NCT01221454|Transplantation
366994|NCT01221441|Cartilage
366995|NCT01221441|Knee
366996|NCT01221441|Osteoarthritis
366997|NCT01221428|Ulcerative colitis
366998|NCT01221428|Mesenchymal Stem Cells
366999|NCT01221428|Umbilical Cord
367000|NCT01221389|hemorrhage
367001|NCT01221389|plasma
367002|NCT01221389|coagulopathy
367003|NCT01221389|trauma
367004|NCT01221363|Life style disease
367005|NCT01221363|Obesity
367006|NCT01221363|Sedentary behaviour
367007|NCT01221363|Cardiovascular biomarkers
367008|NCT01221350|Asthma
367009|NCT01221350|Allergic rhinitis
367010|NCT01221350|Respiratory disease
367011|NCT01221350|Allergy
367012|NCT01221350|Lipoic acid
367013|NCT01221350|Thioctic acid
367014|NCT01221350|Antioxidant
367015|NCT01221350|Oxidative stress
367016|NCT01221311|stenosis
367017|NCT01221311|bile duct
367018|NCT01221311|chronic pancreatitis
367019|NCT01221311|postoperative
367020|NCT01221311|post-liver transplant
367021|NCT01221285|Cockroach
367022|NCT01221285|Immunotherapy
367023|NCT01221285|Subcutaneous immunotherapy
367024|NCT01221285|Inner city asthma
367025|NCT01221272|SPECT MPI
367026|NCT01221246|Acute Middle Cerebral Artery Ischemic Stroke within 18 hours
367027|NCT01221207|diabetic foot ulcers
367028|NCT01221207|casting
367029|NCT01221207|wound care
367030|NCT01221194|diabetes
367031|NCT01221194|foot ulcer prevention
367032|NCT01221194|therapeutic stockings
367033|NCT01221181|Dense deposit disease
367034|NCT01221181|C3 nephropathy
367035|NCT01221181|Eculizumab
367036|NCT01221168|prostate
367037|NCT01221168|cancer
367038|NCT01221168|genetic
367039|NCT01221168|epidemiology
367040|NCT01221168|susceptibility
367041|NCT01221155|Musculoskeletal
367042|NCT01221142|Hypothermia, ICH
367043|NCT01221129|zinc
367044|NCT01221129|reticulocyte
367045|NCT01221129|PBMC
367046|NCT01221129|whole blood
367047|NCT01221129|transcriptome
367048|NCT01221129|microarray
367049|NCT01221116|coronary artery disease,
367050|NCT01221116|aortic stenosis,
367051|NCT01221116|heart failure
367052|NCT01221103|Dexamethasone
367053|NCT01221103|Ofatumumab
367054|NCT01221103|Bendamustine
367055|NCT01221103|Lymphoma, Mantle-Cell
367056|NCT01221103|Non-Hodgkin lymphoma
367057|NCT01221090|Type 2 diabetes
367058|NCT01221090|Health disparities
367059|NCT01221090|Central Texas
367060|NCT01221090|PDA
367061|NCT01221090|CDSMP
367062|NCT01221077|NSCLC
367063|NCT01221077|Non-small cell lung cancer
367064|NCT01221077|OSI-906
367065|NCT01221077|IGF-IR
367066|NCT01221077|Tarceva
367067|NCT01221077|Erlotinib
367068|NCT01221077|Epidermal Growth Factor Receptor
367069|NCT01221077|EGFR
367070|NCT01221077|Chemonaive
367071|NCT01221077|Activating mutations
367072|NCT01221064|Breast cancer
367073|NCT01221064|Axillary clearance
367074|NCT01221064|lymphorrhoea
367075|NCT01221051|third stage of labor,oxytocics, postpartum hemorrhage,
367076|NCT01221025|Parecoxib;
367077|NCT01221025|emergence delirium;
367078|NCT01221025|postoperative pain;
367080|NCT01221025|abdominal surgery
367081|NCT01221025|Parecoxib on emergence agitation and postoperative pain
367082|NCT01220999|Clinical trial
367083|NCT01220999|CS-1008 mAb
367084|NCT01220999|monoclonal antibody CS-1008
367085|NCT01220999|Positron-Emission Tomography
367086|NCT01220999|Pharmacokinetics
367087|NCT01220999|Pharmacodynamics
367088|NCT01220999|apoptosis
367089|NCT01220999|caspases
367090|NCT01220986|Liver regeneration
367091|NCT01220986|Innate immune response
367092|NCT01220973|stage IV prostate cancer
367093|NCT01220973|stage III prostate cancer
367094|NCT01220973|recurrent prostate cancer
367095|NCT01220973|stage IIB prostate cancer
367096|NCT01220973|stage IIA prostate cancer
367097|NCT01220960|art therapy
367098|NCT01220960|breast cancer
367099|NCT01220960|women
367100|NCT01220960|young women
367101|NCT01220960|older women
367102|NCT01220960|quality of life
367103|NCT01220960|meaning making
367104|NCT01220960|support group
367105|NCT01220960|art making
367106|NCT01220960|art symbols
367107|NCT01220908|LVRS (Lung Volume Reduction Surgery)
367108|NCT01220908|LVRC (Lung Volume Reduction Coil)
367109|NCT01220908|Emphysema
367110|NCT01220908|coil
367111|NCT01220908|RePneu
367112|NCT01220895|Adoptive cellular therapy
367113|NCT01220895|Hematopoietic Stem Cell Transplantation
367114|NCT01220882|Slipped capital femoral epiphysis
367115|NCT01220856|Islet transplantation
367116|NCT01220856|Type 1 diabetes mellitus
367117|NCT01220843|chronic renal failure
367118|NCT01220843|FGF23
367119|NCT01220843|Sevelamer carbonate
367120|NCT01220830|Multiple sclerosis
367121|NCT01220830|RFQMR
367122|NCT01220830|Cytotron
367123|NCT01220830|EDSS
367124|NCT01220830|QOL assessment with FAMS
367125|NCT01220817|prostate
367126|NCT01220817|cancer
367127|NCT01220817|psa
367128|NCT01220817|psadt
367129|NCT01220817|pomegranate
367130|NCT01220817|POMx
367131|NCT01220791|methylprednisolone
367132|NCT01220791|IVF
367133|NCT01220791|progesterone
367134|NCT01220791|corticosteroid
367135|NCT01220791|late follicular phase
367136|NCT01220791|pregnancy rates
367137|NCT01220765|hypoxemia
367138|NCT01220765|capnography
367139|NCT01220765|sedation
367140|NCT01220752|IMRT
367141|NCT01220752|carbon ion therapy
367142|NCT01220752|paranasal sinus
367143|NCT01220752|nasal cavity
367144|NCT01220752|adenocarcinoma
367145|NCT01220752|squamous cell carcinoma
367146|NCT01220739|ischemic stroke
367147|NCT01220739|transcranial laser
367148|NCT01220739|tissue plasminogen activator
367149|NCT01220739|therapy
367150|NCT01220726|OAB
367151|NCT01220713|Traumatic Brain Injury
367152|NCT01220713|Veterans
367153|NCT01220713|Hyperbaric Oxygen Treatment
367154|NCT01220713|OEF/OIF
367155|NCT01220713|Post-Concussive Symptoms
367156|NCT01220713|Blast Exposure
367157|NCT01220687|Prematurity
367158|NCT01220687|Oxygen exposure
367159|NCT01220687|Nitric Oxide
367160|NCT01220674|neuropsychological assessment
367161|NCT01220674|cognitive impairment
367162|NCT01220674|computer-aided diagnostic tool
367163|NCT01220661|Colorectal Surgery
367164|NCT01220661|Surgical Wound Infection
367165|NCT01220661|Laparoscopy
367166|NCT01220661|Anti-Bacterial Agents
367167|NCT01220648|Chronic myeloid leukemia
367168|NCT01220648|interferon alfa
367169|NCT01220648|nilotinib
367170|NCT01220648|combination
367171|NCT01220648|CML
367172|NCT01220648|Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP) after switch from previous CML treatment
367173|NCT01220635|Depressive Symptoms
367174|NCT01220635|Depression prevention
367175|NCT01220635|Adolescents
367176|NCT01220635|School-Based Services
367177|NCT01220635|Health Behavior
367178|NCT01220622|Stroke
367179|NCT01220622|Mild cognitive impairment
367180|NCT01220622|Nimodipine
367181|NCT01220583|stage I salivary gland cancer
367182|NCT01220583|stage II salivary gland cancer
367183|NCT01220583|stage III salivary gland cancer
367184|NCT01220583|high-grade salivary gland mucoepidermoid carcinoma
367185|NCT01220583|salivary gland adenocarcinoma
367186|NCT01220583|stage IVA salivary gland cancer
367187|NCT01220583|stage IVB salivary gland cancer
367188|NCT01220583|stage IVC salivary gland cancer
367189|NCT01220570|breast cancer
367190|NCT01220570|ridaforolimus
367191|NCT01220570|ridaforolimus/dalotuzumab combination therapy
367192|NCT01220557|Diabetes mellitus, education, self management
367193|NCT01220531|DiGeorge Anomaly
367194|NCT01220531|Thymus Transplantation
367195|NCT01220531|DiGeorge Syndrome
367196|NCT01220531|Athymia
367197|NCT01220531|Low T cell numbers
367198|NCT01220531|Immunoreconstitution
367199|NCT01220531|Immunodeficiency
367200|NCT01220531|Complete DiGeorge
367201|NCT01220531|Typical DiGeorge
367202|NCT01220531|Atypical DiGeorge
367203|NCT01220531|Complete DiGeorge Anomaly
367204|NCT01220505|scoliosis
367205|NCT01220505|kyphosis
367206|NCT01220505|spinal deformity
367207|NCT01220505|curvature
367208|NCT01220505|lordosis
367209|NCT01220492|liver cirrhosis
367210|NCT01220492|mesenchymal stem cells
367211|NCT01220492|ascites
367212|NCT01220492|serum albumin
367213|NCT01220479|Type 1 Diabetes, Bone mineral density, Growth
367214|NCT01220479|Cardiovascular diseases, Exercise, Training,
367215|NCT01220479|Child, Adolescent
367216|NCT01220440|ADHD
367217|NCT01220440|Children
367218|NCT01220440|Methylphenidate
367219|NCT01220440|Dextroamphetamine
367220|NCT01220440|Placebo
367221|NCT01220440|Crossover
367222|NCT01220440|Double Blind
367223|NCT01220440|Neuropsychological tests
367224|NCT01220440|Behavioural Questionnaires
367225|NCT01220427|high-risk prostate cancer
367226|NCT01220427|radical prostatectomy
367227|NCT01220427|micro-RNA
367228|NCT01220401|Nightmare
367229|NCT01220401|PTSD
367230|NCT01220401|Posttraumatic stress disorder
367231|NCT01220401|Suicide
367232|NCT01220401|Exposure Relaxation Rescription Therapy
367233|NCT01220401|Sleep
367234|NCT01220388|Aldosterone
367235|NCT01220388|L-lysine
367236|NCT01220388|Cortisol
367237|NCT01220388|Adrenal glands
367238|NCT01220375|Mobilization of autologous peripheral blood progenitor cells PBPC
367239|NCT01220375|Autologous stem cell mobilization
367240|NCT01220375|Multiple Myeloma
367241|NCT01220375|Plerixafor
367242|NCT01220362|Analgesia, Epidural
367243|NCT01220362|Urodynamics
367244|NCT01220362|Urinary Retention
367245|NCT01220284|solid tumors
367246|NCT01220284|oral treatment
367247|NCT01220284|platinum compound
367248|NCT01220284|vinca alkaloid
367249|NCT01220284|drug combination
367250|NCT01220271|Glioma
367251|NCT01220271|Glioblastoma
367252|NCT01220245|endoluminal
367253|NCT01220245|surgical
367254|NCT01220245|bypass
367255|NCT01220245|patency
367256|NCT01220245|quality of life
367257|NCT01220245|multicentre
367258|NCT01220245|RCT
367259|NCT01220245|superficial femoral artery
367260|NCT01220245|vascular patency
367261|NCT01220232|Lersivirine
367262|NCT01220232|UK-453
367263|NCT01220232|061
367264|NCT01220232|NNRTI
367265|NCT01220232|Abacavir
367266|NCT01220232|Lamivudine
367267|NCT01220232|Combivir
367268|NCT01220232|Pharmacokinetics
367269|NCT01220232|Drug Interaction
367270|NCT01220232|HIV
367271|NCT01220232|AIDS
367272|NCT01220219|pregabalin
367273|NCT01220219|pharmacokinetics
367274|NCT01220219|bioavailability
367275|NCT01220219|bioequivalence
367276|NCT01220206|ED
367277|NCT01220206|POMx
367278|NCT01220206|Pomegranate
367279|NCT01220206|Erectile dysfunction
367280|NCT01220180|epilepsy
367281|NCT01220180|neuropathic pain
367282|NCT01220180|fibromyalgia
367283|NCT01220180|post-market surveillance
367284|NCT01220180|prospective observational
367285|NCT01220154|ovarian
367286|NCT01220154|cancer
367287|NCT01220154|fallopian tube
367288|NCT01220154|peritoneal
367289|NCT01220154|intraperitoneal
367290|NCT01220154|bevacizumab
367291|NCT01220154|carboplatin
367292|NCT01220154|paclitaxel
367293|NCT01220154|chemo-naive
367294|NCT01220128|WT1
367295|NCT01220128|neoadjuvant
367296|NCT01220128|tumor antigen
367297|NCT01220128|immunotherapy
367298|NCT01220128|breast cancer
367299|NCT01220128|adult
367300|NCT01220115|sickle cell disease
367301|NCT01220115|iron over load
367302|NCT01220102|acne
367303|NCT01220102|Epiduo
367304|NCT01220102|adapalene/ benzoyl peroxide
367305|NCT01220089|obesity
367306|NCT01220089|weight loss
367307|NCT01220076|Tamoxifen,
367308|NCT01220076|Breat Cancer
367309|NCT01220076|Pharmacogenetic
367310|NCT01220076|non metastatic breast cancer, HR +
367311|NCT01220063|RSHF
367312|NCT01220063|Irinotecan
367313|NCT01220063|Colorectal Cancer
367314|NCT01220063|metastases
367315|NCT01220050|Paricalcitol
367316|NCT01220050|Renal transplant
367317|NCT01220050|Secondary Hyperparathyroidism
367318|NCT01220011|Fetoscopic Laser surgery
367319|NCT01220011|Stage 1 Twin - twin transfusion syndrome
367320|NCT01219998|Postoperative Complications
367321|NCT01219998|Acute Kidney Failure
367322|NCT01219998|Peritoneal Dialysis
367323|NCT01219998|NGAL
367324|NCT01219985|positron emission tomography / computed tomography
367325|NCT01219985|18F-fluoro-2-deoxyglucose
367326|NCT01219985|liver neoplasm
367327|NCT01219985|respiratory motion
367328|NCT01219972|Bone marrow transplant
367329|NCT01219972|Pulmonary complications
367330|NCT01219959|ESRD
367331|NCT01219959|Diabetes
367332|NCT01219959|CAPD
367333|NCT01219946|Chronic Obstructive Pulmonary Disease, symptoms
367334|NCT01219920|Metastatic colorectal cancer
367335|NCT01219920|Phase III
367336|NCT01219920|FOLFOXIRI
367337|NCT01219920|FOLFIRI
367338|NCT01219894|Coronary Disease
367339|NCT01219894|Stent
367340|NCT01219894|Healing
367341|NCT01219894|Anti-platelet therapy
367342|NCT01219881|desflurane
367343|NCT01219881|sevoflurane
367344|NCT01219855|Parathyroid Diseases
367345|NCT01219855|Renal Insufficiency
367346|NCT01219855|Kidney Failure, Chronic
367347|NCT01219855|Hyperparathyroidism, Secondary
367348|NCT01219855|Vitamin D
367349|NCT01219855|Hyperparathyroidism
367350|NCT01219855|Kidney Diseases
367351|NCT01219855|Kidney Failure
367352|NCT01219855|Renal Insufficiency, Chronic
367353|NCT01219842|Intermittent claudication
367354|NCT01219842|Health Related Quality of Life
367355|NCT01219842|Walking performance
367356|NCT01219842|Daily walking capacity
367357|NCT01219829|Pancreatic intraepithelial neoplasia (PanIN)
367358|NCT01219829|Pancreatic Cancer
367359|NCT01219829|Recurrence of pancreatic cancer
367360|NCT01219829|Field Effect
367361|NCT01219829|Genetic mutations in pancreatic cancer
367362|NCT01219816|efficacy of Chemo-immunotherapy
367363|NCT01219803|Dose-Response Relationship, type 2 diabetes,TCM
367364|NCT01219790|Patients with painful vertebral metastases with a prostate cancer with an indication of analgesic treatment.
367365|NCT01219777|bevacizumab
367366|NCT01219777|paclitaxel
367367|NCT01219777|carboplatin
367368|NCT01219777|ovarian
367369|NCT01219777|cancer
367370|NCT01219777|fallopian tube
367371|NCT01219777|primary peritoneal
367372|NCT01219764|Helicobacter pylori infection
367373|NCT01219764|quadruple therapy
367374|NCT01219764|Amoxicillin
367375|NCT01219764|Metronidazole
367376|NCT01219764|Clarithromycin
367377|NCT01219764|Rabeprazole
367378|NCT01219738|Asthma, airway blood flow, budesonide, glucocorticosteroid.
367379|NCT01219725|Body composition
367380|NCT01219725|Endothelial function
367381|NCT01219725|Lipoprotein profile
367382|NCT01219725|Inflammatory markers
367383|NCT01219725|Aerobic capacity
367384|NCT01219725|Thrombotic markers
367385|NCT01219725|Arterial stiffness
367386|NCT01219725|Cardiac function
367387|NCT01219725|Traditional and emerging cardiovascular disease risk factors
367388|NCT01219712|NT-proBNP
367389|NCT01219712|non-cardiac surgery
367390|NCT01219712|left ventricular dysfunction
367391|NCT01219712|cardiac complications
367392|NCT01219699|advanced solid tumors
367393|NCT01219699|mutation
367394|NCT01219699|amplification
367395|NCT01219699|wild type
367396|NCT01219699|PIK3CA gene
367397|NCT01219699|dose-escalation
367398|NCT01219699|estrogen receptor positive breast cancer
367399|NCT01219686|unipolar depression, escitalopram, pindolol
367400|NCT01219673|Epithelial carcinoma
367401|NCT01219673|Oropharynx
367402|NCT01219673|Larynx
367403|NCT01219673|Symptom-management
367404|NCT01219673|Chemoradiation
367405|NCT01219673|Placebo
367406|NCT01219673|Armodafinil
367407|NCT01219673|Nuvigil
367408|NCT01219673|Bupropion
367409|NCT01219673|Wellbutrin
367410|NCT01219673|Wellbutrin SR
367411|NCT01219673|Zyban
367412|NCT01219673|Minocycline
367413|NCT01219673|Dynacin
367414|NCT01219673|Minocin
367415|NCT01219673|Minocin PAC
367416|NCT01219673|Myrac
367417|NCT01219673|Solodyn
367418|NCT01219660|sleep
367419|NCT01219660|apnea
367420|NCT01219647|Multiple Sclerosis
367421|NCT01219647|Exercise
367422|NCT01219647|Cognition
367423|NCT01219621|Symphony DR 2550,
367424|NCT01219621|Dual Chamber Pacemaker,
367425|NCT01219621|Sorin,
367426|NCT01219621|Ela Medical,
367427|NCT01219621|DDD Mode,
367428|NCT01219621|AAIsafeR2 mode,
367429|NCT01219621|AV-Conduction,
367430|NCT01219621|Reducing Ventricular Pacing,
367431|NCT01219621|Congestive Heart Failure,
367432|NCT01219621|Cardiac Function,
367433|NCT01219621|Atrial Arrhythmia,
367434|NCT01219621|Atrial Fibrillation,
367435|NCT01219621|Atrial and Ventricular Hemodynamics,
367436|NCT01219621|Long AV-delays.
367437|NCT01219621|Ventricular Function,
367438|NCT01219621|Implantation,
367439|NCT01219595|Urinary Tract Infection
367440|NCT01219595|UTI
367441|NCT01219582|Diabetes Mellitus Type-2
367442|NCT01219582|Acarbose
367443|NCT01219582|Metformin
367444|NCT01219582|Drug Therapy, Combination
367445|NCT01219569|blindness
367446|NCT01219569|ischemic optic neuropathy
367447|NCT01219556|Hypertension
367448|NCT01219556|Antihypertensive Agents
367449|NCT01219556|Drug Therapy, Combination
367450|NCT01219556|Olmesartan Medoxomil
367451|NCT01219556|Hydrochlorothiazide
367452|NCT01219543|Advanced solid malignancies
367453|NCT01219543|Child-Pugh A to B7 advanced hepatocellular carcinoma
367454|NCT01219543|EGFR and/or ROS mutant NSCLC
367455|NCT01219543|Non-smokers with lung metastasis
367456|NCT01219543|Gastric cancer
367457|NCT01219543|Solid tumour
367458|NCT01219543|AZD1480
367459|NCT01219543|JAK1/JAK2 kinase inhibitor
367460|NCT01219530|gestational carrier
367461|NCT01219530|intended parent
367462|NCT01219517|IVF
367463|NCT01219517|embryo biopsy
367464|NCT01219517|DNA fingerprinting
367465|NCT01219517|SNP
367466|NCT01219504|PGD
367467|NCT01219504|IVF
367468|NCT01219491|egg donor
367469|NCT01219491|recipients
367470|NCT01219491|donor characteristics
367471|NCT01219478|To investigate the relationship between retinal thickness (RT) and metabolic risks (MRs) in patients without retinal lesion
367472|NCT01219465|Diabetes Mellitus
367473|NCT01219465|Diabetes Mellitus, Type 1
367474|NCT01219465|mesenchymal stem cells
367475|NCT01219465|Umbilical cord
367476|NCT01219452|Dilated Cardiomyopathy
367477|NCT01219452|Umbilical cord
367478|NCT01219452|Mesenchymal stem cells
367479|NCT01219452|Children
367480|NCT01219439|discarded pathological specimens
367481|NCT01219439|discarded media
367482|NCT01219439|IVF
367483|NCT01219426|Gambling
367484|NCT01219426|cognitive distortions
367485|NCT01219426|assessment tool
367486|NCT01219426|validation
367487|NCT01219426|French
367488|NCT01219413|aliskiren
367489|NCT01219413|renin inhibitor
367490|NCT01219413|proteinuria
367491|NCT01219413|chronic kidney diseases
367492|NCT01219413|ACE inhibitor
367493|NCT01219400|DPP-4
367494|NCT01219400|GLP-1
367495|NCT01219400|Glucagon
367496|NCT01219400|Catecholamines
367497|NCT01219400|Counterregulation
367498|NCT01219400|Insulin-treatment
367499|NCT01219400|Type 2 diabetes
367500|NCT01219387|AMH
367501|NCT01219387|inhibin B
367502|NCT01219387|infertility
367503|NCT01219374|egg donor
367504|NCT01219361|Donated embryos
367505|NCT01219348|IDO enzyme
367506|NCT01219348|Vaccination trial
367507|NCT01219348|Immunotherapy
367508|NCT01219348|NSCLC, stage III_IV
367509|NCT01219348|Indeolamine 2,3 dioxygenase = IDO
367510|NCT01219335|IVF
367511|NCT01219322|general endotracheal anesthesia
367512|NCT01219322|ASA I or II
367513|NCT01219309|Attention-deficit/hyperactivity disorder
367514|NCT01219309|Omega 3/6 fatty acids
367515|NCT01219309|Developmental coordination disorder
367516|NCT01219309|Reading/writing difficulties.
367517|NCT01219296|infertility
367518|NCT01219296|IVF
367519|NCT01219283|PGD
367520|NCT01219283|IVF
367521|NCT01219270|Radiocontrast media,
367522|NCT01219270|hyponatremia
367523|NCT01219257|SpA
367524|NCT01219257|Anti-TNF alpha treatment
367525|NCT01219257|Ultrasonography
367526|NCT01219257|Synovitis
367527|NCT01219257|Enthesitis
367528|NCT01219244|memory
367529|NCT01219244|diet
367530|NCT01219244|elderly
367531|NCT01219244|cognition
367532|NCT01219244|prevention
367533|NCT01219244|lifestyle
367534|NCT01219231|Exercise
367535|NCT01219231|elderly
367536|NCT01219231|cognition
367537|NCT01219231|prevention
367538|NCT01219231|cognitive decline
367539|NCT01219231|Lifestyle
367540|NCT01219218|Extracorporeal Shockwave Therapy
367541|NCT01219218|Myocardial Ischemia
367542|NCT01219218|Refractory Angina
367543|NCT01219205|macular edema secondary to retinal benous occlusion
367544|NCT01219179|Extremely Low Birth Weight Infants
367545|NCT01219179|Hypernatremia
367546|NCT01219179|Enteral Sterile Water Feeds
367547|NCT01219153|Letrozole ,IVF, poor responders , GnRH antagonist
367548|NCT01219140|POMx
367549|NCT01219140|Osteopenia
367550|NCT01219140|postmenopausal women
367551|NCT01219140|Pomegranate
367552|NCT01219127|Hyperbaric oxygen therapy
367553|NCT01219114|Daptomycin
367554|NCT01219114|endocarditis
367555|NCT01219114|complicated skin and skin structure infection
367556|NCT01219101|Ethinyl estradiol
367557|NCT01219101|Polycystic ovary syndrome
367558|NCT01219101|Intrauterine insemination
367559|NCT01219049|Diet
367560|NCT01219049|Fibromyalgia
367561|NCT01219049|Pain
367562|NCT01219049|Drug
367563|NCT01219049|Amino-acid
367564|NCT01219049|Fatigue
367565|NCT01219036|Asthma
367566|NCT01219036|Non-adherence
367567|NCT01219036|Fractional exhaled nitric oxide
367568|NCT01219023|Hand foot syndrome
367569|NCT01219023|Palmar Plantar Erythrodysesthesia
367570|NCT01219023|chemotherapy
367571|NCT01219023|Sunitinib
367572|NCT01219023|Capecitebine
367573|NCT01219023|Sildenafil
367574|NCT01219010|Monoclonal Gammopathy of Undetermined Significance
367575|NCT01219010|Smoldering Multiple Myeloma
367576|NCT01219010|Indolent Multiple Myeloma
367577|NCT01219010|QT
367578|NCT01219010|Siltuximab
367579|NCT01219010|CNTO 328
367580|NCT01219010|IL-6
367581|NCT01219010|Monoclonal Antibody
367582|NCT01218997|Alcoholism
367583|NCT01218997|Alcohol dependence
367584|NCT01218984|Opiate Dependence
367585|NCT01218971|Alcohol Dependence
367586|NCT01218958|Alcoholism
367587|NCT01218932|primaquine
367588|NCT01218932|chloroquine
367589|NCT01218932|pharmacokinetic
367590|NCT01218932|interactions
367591|NCT01218906|Dengue Fever Fever Dengue Infection
367592|NCT01218867|Clinical Response
367593|NCT01218867|Metastatic Cancer
367594|NCT01218867|Immunotherapy
367595|NCT01218867|Adoptive Cell Therapy
367596|NCT01218867|Metastatic Melanoma
367597|NCT01218854|Biopsy
367598|NCT01218854|Surgical Navigation
367599|NCT01218854|Image-guided Therapy
367600|NCT01218854|CT- Guided Biopsy
367601|NCT01218854|Cancer
367602|NCT01218841|Fish oil
367603|NCT01218841|Omega-3 fatty acids
367604|NCT01218841|Parenteral lipid emulsions
367605|NCT01218841|Immune response
367606|NCT01218841|Surgery
367607|NCT01218828|Contrast
367608|NCT01218828|nephropathy
367609|NCT01218828|cardiac catheterization
367610|NCT01218828|angiography
367611|NCT01218828|percutaneous coronary intervention is
367612|NCT01218802|HIV
367613|NCT01218802|Heart Disease
367614|NCT01218802|Bone Density
367615|NCT01218789|Blindness
367616|NCT01218789|Eye Diseases
367617|NCT01218789|Nap Disorders
367618|NCT01218789|Circadian Rhythm Disorders
367619|NCT01218789|Sleep disorders
367620|NCT01218789|Circadian Rhythm Sleep Disorders
367621|NCT01218789|Dyssomnias
367622|NCT01218789|Nervous System Diseases
367623|NCT01218776|Acute Coronary Syndrome, Eastern Europe, Therapies
367624|NCT01218763|Cardiac Event recorder
367625|NCT01218763|Sensitivity
367626|NCT01218763|Efficacy
367627|NCT01218750|DDME, ppV, ILM peeling, bevacizumab injection
367628|NCT01218685|Immunocompromised patients
367629|NCT01218685|Safety of pandemic influenza A (H1N1)vaccine
367630|NCT01218685|Immunogenicity of pandemic influenza A (H1N1)vaccine
367631|NCT01218672|BPH
367632|NCT01218672|Benign Prostatic Hyperplasia
367633|NCT01218659|Fabry Disease
367634|NCT01218646|Influenza
367635|NCT01218646|Quadrivalent Inactivated Influenza Vaccine
367636|NCT01218646|Trivalent Inactivated Influenza Vaccine
367637|NCT01218646|Influenza viruses
367638|NCT01218607|Heart Septal Defects, Atrial
367639|NCT01218607|Pulmonary Circulation
367640|NCT01218607|Ventricular Function, Right
367641|NCT01218607|Echocardiography, Stress
367642|NCT01218607|Ergometry
367643|NCT01218607|Tissue Doppler Imaging
367644|NCT01218594|Stage III
367645|NCT01218594|Unresectable
367646|NCT01218594|Non-small cell lung cancer
367647|NCT01218581|Adenomyosis, letrozole, GnRH-a
367648|NCT01218555|kidney cancer
367649|NCT01218555|adenoidcystic cancer
367650|NCT01218542|Secondary brain malignancies
367651|NCT01218542|RapidArc
367652|NCT01218542|Volumetric modulated arc therapy
367653|NCT01218529|Brain metastases from lung and breast tumors
367654|NCT01218490|surgery
367655|NCT01218490|ovarian cancer
367656|NCT01218490|lymphadectomy
367657|NCT01218477|Leukemia
367658|NCT01218477|(Chronic Myeloid Leukemia-Chronic Phase and Advanced)
367659|NCT01218464|Liver Failure
367660|NCT01218464|Mesenchymal Stem Cells
367661|NCT01218464|Model for End-Stage Liver Disease
367662|NCT01218464|Ascite
367663|NCT01218464|Serum Albumin
367664|NCT01218425|dopamine
367665|NCT01218425|EEG
367666|NCT01218425|episodic memory
367667|NCT01218425|contingent negative variation
367668|NCT01218425|response preparation
367669|NCT01218425|levodopa
367670|NCT01218425|methylphenidate
367671|NCT01218412|Physical Activity
367672|NCT01218412|Motivational Interviewing
367673|NCT01218412|Web-based
367674|NCT01218412|Physician Referral
367675|NCT01218399|Asthma
367676|NCT01218386|ICSI
367677|NCT01218386|GnRH antagonists
367678|NCT01218386|planning
367679|NCT01218373|older people
367680|NCT01218373|living independently at home
367681|NCT01218360|Crohn's disease
367682|NCT01218360|standard-of-care
367683|NCT01218360|Crohn Disease
367684|NCT01218360|Active Crohn's Disease
367685|NCT01218347|OATP1B1
367686|NCT01218347|rosuvastatin
367687|NCT01218321|antiepileptic drugs
367688|NCT01218321|mitochondria
367689|NCT01218308|Influenza
367690|NCT01218295|COPD
367691|NCT01218295|inspiratory muscles training
367692|NCT01218282|COPD
367693|NCT01218282|home exercise training
367694|NCT01218269|anastomoses
367695|NCT01218256|diabetes mellitus
367696|NCT01218256|type 2 diabetes
367697|NCT01218256|T2DM
367698|NCT01218256|resistance training
367699|NCT01218256|hypertrophy training
367700|NCT01218256|endurance training
367701|NCT01218243|Acupuncture
367702|NCT01218243|Mild and moderate BPH
367703|NCT01218230|Pegaptanib, myopic CNVM, intravitreal anti-VEGF
367704|NCT01218217|TB
367705|NCT01218217|Tuberculosis
367706|NCT01218217|EBA
367707|NCT01218217|Pulmonary
367708|NCT01218217|Early Bactericidal Activity
367709|NCT01218204|Dyslipidemia
367710|NCT01218204|Tolerability
367711|NCT01218204|Safety
367712|NCT01218204|Ezetimibe
367713|NCT01218204|Pharmacokinetics
367714|NCT01218204|Lipids
367715|NCT01218204|Statin
367716|NCT01218204|Atorvastatin
367717|NCT01218204|Pharmacodynamics
367718|NCT01218204|GSK1292263
367719|NCT01218191|subarachnoid hemorrhage
367720|NCT01218191|scintigraphy
367721|NCT01218191|neurocardiogenic injury
367722|NCT01218178|acute myocardial infarction
367723|NCT01218178|acute kidney injury
367724|NCT01218178|contrast induced nephropathy
367725|NCT01218178|primary PCI
367726|NCT01218178|sodium-bicarbonate
367727|NCT01218178|N-acetylcysteine
367728|NCT01218165|Healthy Eldery People
367729|NCT01218152|NF1
367730|NCT01218152|MPNST
367731|NCT01218152|plasma
367732|NCT01218152|microarray CGH
367733|NCT01218139|neurofibroma
367734|NCT01218139|MPNST
367735|NCT01218139|array CGH
367736|NCT01218139|sequencing
367737|NCT01218113|Human Immunodeficiency Virus (HIV)-1
367738|NCT01218113|safety
367739|NCT01218113|vaccine
367740|NCT01218113|immunogenicity
367741|NCT01218113|reactogenicity
367742|NCT01218113|HIV infection
367743|NCT01218087|Positional Head Shape Deformity
367744|NCT01218074|bleeding
367745|NCT01218074|blood sparing procedure
367746|NCT01218074|desmopressin
367747|NCT01218074|aggregometry
367748|NCT01218074|thromboelastography
367749|NCT01218061|Pre-diabetes
367750|NCT01218061|Type 2 diabetes
367751|NCT01218061|Biomarkers
367752|NCT01218061|Cohort
367753|NCT01218061|Diabetes Risk Score
367754|NCT01218048|Carcinoma
367755|NCT01218048|Head and Neck
367756|NCT01218048|Cetuximab
367757|NCT01218048|Locally Advanced Head and Neck Squamous Cell Carcinoma
367758|NCT01218035|Hip osteoarthritis
367759|NCT01218035|Bisphophonate therapy
367760|NCT01218035|Zoledronic acid
367761|NCT01218035|Radiostereometric analysis
367762|NCT01218035|Osteoporosis
367763|NCT01218009|asthma
367764|NCT01218009|dry powder inhaler
367765|NCT01218009|short-acting beta2-agonist
367766|NCT01218009|SABA
367767|NCT01218009|bronchoconstriction
367768|NCT01218009|bronchodilation
367769|NCT01218009|bronchodilator
367770|NCT01218009|metered dose inhaler
367771|NCT01217996|working memory intervention
367772|NCT01217996|memory impairment
367773|NCT01217996|cognitive late effects
367774|NCT01217996|Childhood Cancer Survivors
367775|NCT01217970|methamphetamine
367776|NCT01217970|dependence
367777|NCT01217970|stimulant
367778|NCT01217970|amphetamine
367779|NCT01217970|los angeles
367780|NCT01217970|meth
367781|NCT01217970|speed
367782|NCT01217970|crank
367783|NCT01217970|abuse
367784|NCT01217957|Drug therapy
367785|NCT01217944|Pathologic myopia
367786|NCT01217944|PM
367787|NCT01217944|choroidal neovascularization
367788|NCT01217944|CNV
367789|NCT01217944|ranibizumab
367790|NCT01217944|verteporfin PDT
367791|NCT01217931|Renal Cell Carcinoma
367792|NCT01217931|Metastatic Renal Cell Carcinoma
367793|NCT01217931|Clear cell component
367794|NCT01217931|RCC
367795|NCT01217931|Bevacizumab
367796|NCT01217931|Everolimus
367797|NCT01217931|Pazopanib
367798|NCT01217931|GW786034
367799|NCT01217931|Avastin
367800|NCT01217931|Anti-VEGF monoclonal antibody
367801|NCT01217931|rhuMAb-VEGF
367802|NCT01217931|Afinitor
367803|NCT01217931|RAD001
367804|NCT01217918|PH-797804
367805|NCT01217918|Japanese
367806|NCT01217918|Phase 1
367807|NCT01217918|multiple dose study
367808|NCT01217905|Phase 1
367809|NCT01217905|Type 2 diabetes
367810|NCT01217905|obesity
367811|NCT01217905|Japanese healthy volunteer
367812|NCT01217905|AZD7687
367813|NCT01217892|Type 2 diabetes
367814|NCT01217892|metformin treated
367815|NCT01217892|inadequate control
367816|NCT01217892|metformin treatment alone
367817|NCT01217879|Cough
367818|NCT01217879|Telmisartan
367819|NCT01217879|Bradykinin
367820|NCT01217879|Tolerability
367821|NCT01217866|laparoscopic
367822|NCT01217866|vaginal
367823|NCT01217866|hysterectomy
367824|NCT01217840|Adolescents, Vitamin D
367825|NCT01217788|Generalized Social Phobia
367826|NCT01217788|Social Anxiety Disorder
367827|NCT01217788|Social Phobia
367828|NCT01217788|Phobic Disorders
367829|NCT01217788|Phobias
367830|NCT01217775|PMDD, Premenstrual, Dysphoria, Mood Swings, Bloating.
367831|NCT01217762|Oraya
367832|NCT01217762|Oraya Therapeutics, Inc.
367833|NCT01217762|low voltage stereotactic radiosurgery
367834|NCT01217762|radiosurgery
367835|NCT01217762|radiotherapy
367836|NCT01217762|IRay
367837|NCT01217762|AMD
367838|NCT01217762|Macular Degeneration
367839|NCT01217762|Wet AMD
367840|NCT01217762|xray
367841|NCT01217762|radiation
367842|NCT01217762|x ray
367843|NCT01217762|external beam radiation
367844|NCT01217762|Ranibizumab
367845|NCT01217762|Lucentis
367846|NCT01217723|Acute leukemia (myeloid,lymphoid,or biphenotypic)
367847|NCT01217723|Chronic myeloid leukemia
367848|NCT01217723|Chronic lymphocytic leukemia
367849|NCT01217723|Lymphoma
367850|NCT01217723|Myelodysplastic syndrome
367851|NCT01217723|Myeloproliferative disorder
367852|NCT01217710|Chronic Obstructive Pulmonary Disease
367853|NCT01217710|Physical Activity
367854|NCT01217710|Self Management
367855|NCT01217710|Exercise
367856|NCT01217710|Technology
367857|NCT01217710|Motivational Interviewing
367858|NCT01217697|Metastatic Castration-Resistant Prostate Cancer (CRPC)
367859|NCT01217697|Abiraterone Acetate
367860|NCT01217671|Pulmonary, Emphysema
367861|NCT01217671|Alpha-1 Antitrypsin Deficiency
367862|NCT01217658|Randomized Trial
367863|NCT01217658|Infant Colic
367864|NCT01217658|Abusive Head Trauma
367865|NCT01217658|Shaken Baby Syndrome
367866|NCT01217645|Major depression disorder
367867|NCT01217632|Connective tissue growth factor (CTGF)
367868|NCT01217632|human IgG1 monoclonal antibody
367869|NCT01217619|neoadjuvant treatment
367870|NCT01217593|mastectomy
367871|NCT01217593|breast cancer
367872|NCT01217593|breast surgery
367873|NCT01217580|c-section
367874|NCT01217580|cesarean section
367875|NCT01217580|TAP block
367876|NCT01217580|pain
367877|NCT01217580|pain after delivery
367878|NCT01217580|pain after C-section
367879|NCT01217580|pain after C-section delivery
367880|NCT01217580|pain after cesarean delivery
367881|NCT01217580|pain after cesarean
367882|NCT01217567|cicatrix
367883|NCT01217567|cesarean section
367884|NCT01217567|sutures
367885|NCT01217567|surgical staples
367886|NCT01217567|postoperative pain
367887|NCT01217567|Infection
367888|NCT01217554|Low Back Pain
367889|NCT01217554|Disability
367890|NCT01217554|Kinematic measures
367891|NCT01217541|Dementia
367892|NCT01217541|BPSD
367893|NCT01217541|Quality of Life
367894|NCT01217541|Person-centred care
367895|NCT01217541|Job satisfaction
367896|NCT01217541|Nursing home
367897|NCT01217541|Primary care
367898|NCT01217528|ICD
367899|NCT01217528|CRTD
367900|NCT01217528|Sudden cardiac death
367901|NCT01217528|Device settings
367902|NCT01217528|Patients who received ICD/CRTD for primary prevention of sudden cardiac death
367903|NCT01217502|Aged
367904|NCT01217502|Homes for the aged
367905|NCT01217502|Self management
367906|NCT01217502|Personal autonomy
367907|NCT01217502|Disease management
367908|NCT01217502|Self efficacy
367909|NCT01217502|Participation
367910|NCT01217489|breast
367911|NCT01217489|cancer
367912|NCT01217489|diagnosis
367913|NCT01217489|electrical
367914|NCT01217489|non-invasive
367915|NCT01217489|mammography
367916|NCT01217476|Diabetic foot
367917|NCT01217476|Neuropathic
367918|NCT01217476|Wound
367919|NCT01217476|Growth factor
367920|NCT01217463|Diabetic foot
367921|NCT01217463|Neuropathic
367922|NCT01217463|Wound
367923|NCT01217463|Growth factor
367924|NCT01217424|psychosocial effects of cancer and its treatment
367925|NCT01217424|pain
367926|NCT01217424|unspecified adult solid tumor, protocol specific
367927|NCT01217398|ciliary body and choroid melanoma, medium/large size
367928|NCT01217398|ciliary body and choroid melanoma, small size
367929|NCT01217398|iris melanoma
367930|NCT01217398|metastatic intraocular melanoma
367931|NCT01217398|stage IV intraocular melanoma
367932|NCT01217385|stage IIIA breast cancer
367933|NCT01217385|stage IIIB breast cancer
367934|NCT01217385|stage IIIC breast cancer
367935|NCT01217372|Recurrent idiopathic calcium oxalate nephrolithiasis.
367936|NCT01217333|Telephones
367937|NCT01217333|Community-Based Participatory Research
367938|NCT01217333|Participation, Patient
367939|NCT01217333|Rural health services
367940|NCT01217320|rheumatology
367941|NCT01217320|creatine supplementation
367942|NCT01217320|quality of life
367943|NCT01217320|strength
367944|NCT01217320|juvenile systemic lupus erythematosus
367945|NCT01217320|juvenile dermatomyositis
367946|NCT01217307|Metformin
367947|NCT01217307|ST elevation myocardial infarction (STEMI)
367948|NCT01217307|Coronary artery disease
367949|NCT01217307|Heart failure
367950|NCT01217307|Diabetes
367951|NCT01217294|anaesthetic techniques, regional
367952|NCT01217294|analgesia, post-operative
367953|NCT01217294|fascia iliaca compartment block
367954|NCT01217294|ultrasound guided
367955|NCT01217294|surgery, orthopaedic
367956|NCT01217281|CKD, Renal, Chronic Kidney Disease, Periodontitis, Perio
367957|NCT01217255|Hemophilia
367958|NCT01217255|Burden of Illness
367959|NCT01217255|Pediatric
367960|NCT01217255|Quality of Life
367961|NCT01217255|Disability
367962|NCT01217255|Participation
367963|NCT01217242|cerebral palsy
367964|NCT01217242|walking activity
367965|NCT01217242|physical activity
367966|NCT01217242|participation
367967|NCT01217242|activity performance
367968|NCT01217242|activity capacity
367969|NCT01217229|Hodgkin Lymphoma
367970|NCT01217216|Breast Cancer
367971|NCT01217216|Weight loss
367972|NCT01217216|Group Intervention
367973|NCT01217216|Telephone Intervention
367974|NCT01217177|Cervical cancer,
367975|NCT01217177|radiotherapy,
367976|NCT01217177|chemotherapy,
367977|NCT01217177|rad001,
367978|NCT01217177|everolimus
367979|NCT01217164|nutrition
367980|NCT01217164|very low birth weight
367981|NCT01217164|premature
367982|NCT01217151|Hemodynamic Monitoring
367983|NCT01217151|Goal-Directed Therapy
367984|NCT01217138|Anaphylaxis, autoinjector, design, epinephrine
367985|NCT01217125|tuberousclerosis, angiomyolipoma, rapamycin
367986|NCT01217112|Dyslipidemias
367987|NCT01217112|Diabetes
367988|NCT01217112|Liver Fat
367989|NCT01217112|Body Fat
367990|NCT01217099|refractory mycoplasma pneumoniae pneumonia
367991|NCT01217060|Adenocarcinoma
367992|NCT01217060|Squamous cell carcinoma
367993|NCT01217060|Thoracic esophagus
367994|NCT01217060|Gastroesophageal junction
367995|NCT01217060|Chemoradiotherapy
367996|NCT01217060|Esophagectomy
367997|NCT01217060|5-Fluorouracil
367998|NCT01217060|Docetaxel
367999|NCT01217060|Radiation
368000|NCT01217060|Radiotherapy
368001|NCT01217060|XRT
368002|NCT01217060|IMRT
368003|NCT01217060|Taxotere
368004|NCT01217060|Adrucil
368005|NCT01217060|Efudex
368006|NCT01217060|Dexamethasone
368007|NCT01217060|Decadron
368008|NCT01217047|Spinal cord injury
368009|NCT01217047|Functional electrical stimulation
368010|NCT01217047|Rehabilitation
368011|NCT01217047|Growth factors
368012|NCT01217047|Cytokines
368013|NCT01217034|Transcatheter arterial chemoembolization
368014|NCT01217034|TACE
368015|NCT01217034|sorafenib
368016|NCT01217034|Time to untreatable progression
368017|NCT01217034|TTUP
368018|NCT01217008|Spinal Cord Injury
368019|NCT01217008|GRNOPC1
368020|NCT01216995|Heart Attack
368021|NCT01216995|Regenerative Cells
368022|NCT01216995|Stem Cells
368023|NCT01216982|Mood Disorders
368024|NCT01216982|Depression
368025|NCT01216982|Combat Disorders
368026|NCT01216982|Stress Disorders
368027|NCT01216982|Fatty Acids, Omega-3
368028|NCT01216982|Military Personnel
368029|NCT01216982|Docosahexaenoic Acids/*therapeutic use
368030|NCT01216982|Eicosapentaenoic Acid/*therapeutic use
368031|NCT01216956|extended release nicotinic acid
368032|NCT01216956|non esterified fatty acid (NEFA)
368033|NCT01216956|insulin resistance
368034|NCT01216956|Cholesteryl ester transfer protein (CETP)
368035|NCT01216956|High density lipoprotein cholesterol
368036|NCT01216891|Schizophrenia
368037|NCT01216891|Schizoaffective Disorder
368038|NCT01216891|Schizophreniform Disorder
368039|NCT01216891|Delusional Disorder
368040|NCT01216891|Psychosis
368041|NCT01216891|First episode
368042|NCT01216865|Diabetic foot
368043|NCT01216865|critical limb ischemia
368044|NCT01216865|mesenchymal stem cells
368045|NCT01216865|umbilical cord
368046|NCT01216813|esophageal cancer
368047|NCT01216813|gastric cancer
368048|NCT01216813|cervical cancer
368049|NCT01216813|fallopian tube cancer
368050|NCT01216813|ovarian epithelial cancer
368051|NCT01216813|ovarian germ cell tumor
368052|NCT01216813|ovarian sarcoma
368053|NCT01216813|ovarian stromal cancer
368054|NCT01216813|endometrial cancer
368055|NCT01216813|uterine sarcoma
368056|NCT01216813|vaginal cancer
368057|NCT01216813|vulvar cancer
368058|NCT01216813|adenocarcinoma of the gastroesophageal junction
368059|NCT01216800|ototoxicity
368060|NCT01216800|radiation toxicity
368061|NCT01216800|stage I salivary gland cancer
368062|NCT01216800|stage II salivary gland cancer
368063|NCT01216800|stage III salivary gland cancer
368064|NCT01216761|Bacteremia
368065|NCT01216761|Blood culture
368066|NCT01216761|Contamination
368067|NCT01216761|Antiseptic agents
368068|NCT01216748|airway blood flow
368069|NCT01216748|albuterol
368070|NCT01216748|acidosis
368071|NCT01216748|alkalosis
368072|NCT01216735|smokers
368073|NCT01216735|inhaled corticosteroids
368074|NCT01216735|brachial flow
368075|NCT01216735|airway blood flow
368076|NCT01216735|albuterol
368077|NCT01216735|spirometry
368078|NCT01216735|endothelial dysfunction
368079|NCT01216722|Muscle Wasting
368080|NCT01216722|Strengthening
368081|NCT01216722|Liver Disease
368082|NCT01216722|Transplant
368083|NCT01216709|Infant
368084|NCT01216709|Dietary Supplements
368085|NCT01216709|Food, Fortified
368086|NCT01216709|Iron Absorption
368087|NCT01216696|ipilimumab
368088|NCT01216696|melanoma
368089|NCT01216696|NY-ESO-1
368090|NCT01216683|contiguous stage II grade 1 follicular lymphoma
368091|NCT01216683|contiguous stage II grade 2 follicular lymphoma
368092|NCT01216683|contiguous stage II grade 3 follicular lymphoma
368093|NCT01216683|noncontiguous stage II grade 1 follicular lymphoma
368094|NCT01216683|noncontiguous stage II grade 2 follicular lymphoma
368095|NCT01216683|noncontiguous stage II grade 3 follicular lymphoma
368096|NCT01216683|stage III grade 1 follicular lymphoma
368097|NCT01216683|stage III grade 2 follicular lymphoma
368098|NCT01216683|stage III grade 3 follicular lymphoma
368099|NCT01216683|stage IV grade 1 follicular lymphoma
368100|NCT01216683|stage IV grade 2 follicular lymphoma
368101|NCT01216683|stage IV grade 3 follicular lymphoma
368102|NCT01216670|Reveal® XT
368103|NCT01216670|Acute Heart Failure
368104|NCT01216670|Low Ejection Fraction
368105|NCT01216670|Reveal® XT implanted
368106|NCT01216657|melanoma
368107|NCT01216657|sunitinib
368108|NCT01216644|gastric cancer
368109|NCT01216644|perioperative
368110|NCT01216644|FLOT
368111|NCT01216644|ECF
368112|NCT01216644|pathological complete remission
368113|NCT01216644|locally advanced resectable adenocarcinoma of the esophagogastric juction or the stomach
368114|NCT01216631|seronegative
368115|NCT01216631|oligoarthritis
368116|NCT01216631|infliximab
368117|NCT01216631|intraarticular
368118|NCT01216618|MiniMed paradigm insulin pumps
368119|NCT01216618|insulin Lispro
368120|NCT01216618|Insulin Asprt.
368121|NCT01216592|COPD
368122|NCT01216592|Airway inflammation
368123|NCT01216592|Symptoms
368124|NCT01216592|Lung function
368125|NCT01216592|Correlation
368126|NCT01216553|Bronchiolitis
368127|NCT01216553|Infants
368128|NCT01216553|Nebulized Inhalation
368129|NCT01216553|RSV
368130|NCT01216553|Oxygen
368131|NCT01216540|vancomycin
368132|NCT01216540|nephrotoxicity
368133|NCT01216540|length of stay
368134|NCT01216540|costs
368135|NCT01216527|Stage IIB or III squamous cell esophageal carcinoma.
368136|NCT01216514|chronic inflammatory bowel diseases
368137|NCT01216514|crohn disease
368138|NCT01216514|hemorrhagic rectocolitis
368139|NCT01216514|immunological markers
368140|NCT01216514|serological markers
368141|NCT01216514|ANCA
368142|NCT01216514|ASCA
368143|NCT01216488|Forearm surgery
368144|NCT01216488|Hand surgery
368145|NCT01216488|Anesthesia
368146|NCT01216462|Acute Coronary Syndrome
368147|NCT01216449|Citalopram
368148|NCT01216449|Functional Magnetic Resonance Imaging
368149|NCT01216449|fMRI
368150|NCT01216449|Pharmacokinetics
368151|NCT01216449|Pharmacodynamics
368152|NCT01216449|Amygdala
368153|NCT01216449|Elderly
368154|NCT01216436|melanoma
368155|NCT01216436|immunotherapy
368156|NCT01216436|dendritic cell
368157|NCT01216436|GITR-ligand
368158|NCT01216436|CTLA-4
368159|NCT01216423|Patent Foramen Ovale
368160|NCT01216423|Pulmonary embolism
368161|NCT01216423|Stroke
368162|NCT01216410|Nausea
368163|NCT01216410|Vomiting
368164|NCT01216371|carcinoma
368165|NCT01216371|metastases
368166|NCT01216371|renal
368167|NCT01216371|lung
368168|NCT01216358|Headache
368169|NCT01216358|Contraception
368170|NCT01216319|Biodesign
368171|NCT01216319|Nipple Reconstruction
368172|NCT01216319|Breast Cancer
368173|NCT01216319|Mastectomy
368174|NCT01216306|Obesity
368175|NCT01216306|Physical Activity
368176|NCT01216306|Sedentary Activity
368177|NCT01216306|Television viewing
368178|NCT01216306|Latino
368179|NCT01216306|Hispanic
368180|NCT01216306|Preschool
368181|NCT01216306|School
368182|NCT01216306|Head Start
368183|NCT01216293|Drug Therapy
368184|NCT01216280|Natura-alpha
368185|NCT01216280|ulcerative colitis
368186|NCT01216280|cytokines
368187|NCT01216280|Th1
368188|NCT01216280|Th17
368189|NCT01216267|chromogranin A
368190|NCT01216267|neuroendocrine
368191|NCT01216267|carcinoid
368192|NCT01216267|Proton Pump Inhibitor
368193|NCT01216254|breast cancer
368194|NCT01216254|stage 2
368195|NCT01216254|breast conserving therapy
368196|NCT01216254|sentinel lymph node dissection
368197|NCT01216254|high frequency electrocoagulation
368198|NCT01216202|Rectal cancer
368199|NCT01216202|Preoperative radiotherapy
368200|NCT01216202|Pelvic surgery
368201|NCT01216202|Sexual function
368202|NCT01216202|Wellbeing
368203|NCT01216202|Hormone levels
368204|NCT01216202|Spermatogenesis
368205|NCT01216189|Rectal cancer
368206|NCT01216189|Preoperative radiotherapy
368207|NCT01216189|Pelvic surgery
368208|NCT01216189|Sexual function
368209|NCT01216189|Wellbeing
368210|NCT01216189|Hormone levels
368211|NCT01216176|Breast Cancer
368212|NCT01216176|Postmenopausal
368213|NCT01216176|Metastatic Phase I ONLY
368214|NCT01216176|AZD0530
368215|NCT01216176|Anastrozole
368216|NCT01216176|Phase I for metastatic disease
368217|NCT01216176|Phase II for newly diagnosed breast cancer
368218|NCT01216176|Pharmacokinetic
368219|NCT01216176|PK
368220|NCT01216176|Hormone Receptor
368221|NCT01216176|Estrogen Receptor
368222|NCT01216176|Progesterone Receptor
368223|NCT01216176|ER+
368224|NCT01216176|PR+
368225|NCT01216176|HER negative
368226|NCT01216176|Aromatase Inhibitors
368227|NCT01216163|Pain following third molar extraction (wisdom tooth)
368228|NCT01216150|antifibrinolytic drug
368229|NCT01216150|coronary surgery
368230|NCT01216150|hemorrhage
368231|NCT01216150|aspirin
368232|NCT01216150|clopidogrel
368233|NCT01216137|Multiple Sclerosis
368234|NCT01216137|Fatigue
368235|NCT01216137|Balance
368236|NCT01216137|Upright Postural Control
368237|NCT01216137|Dizziness
368238|NCT01216124|triple negative local advanced breast cancer(TNLABC),neoadjuvant chemotherapy
368239|NCT01216111|triple negative breast cancer，local recurrence,distant metastasis
368240|NCT01216098|Intrapartum
368241|NCT01216098|Clinical trial
368242|NCT01216098|Perinatal
368243|NCT01216098|Doula
368244|NCT01216098|VBAC
368245|NCT01216098|Perinatal Outcomes
368246|NCT01216072|Relapsing Forms of Multiple Sclerosis
368247|NCT01216072|Disease Modifying Therapy
368248|NCT01216072|fingolimod
368249|NCT01216072|Patient Reported Outcomes
368250|NCT01216059|adherence
368251|NCT01216059|text message
368252|NCT01216059|reminder
368253|NCT01216059|adolescents
368254|NCT01216033|Breast cancer
368255|NCT01216033|Diagnostics
368256|NCT01216033|HER2
368257|NCT01216033|Imaging
368258|NCT01216033|Metastases
368259|NCT01216033|SPECT
368260|NCT01216033|Imaging of metastases
368261|NCT01216020|Head and Neck Cancer
368262|NCT01216020|Radiotherapy
368263|NCT01216020|Cetuximab
368264|NCT01216020|Cisplatin
368265|NCT01216007|Plasma
368266|NCT01216007|bupivacaine
368267|NCT01216007|concentration
368268|NCT01216007|caudal
368269|NCT01216007|epidural
368270|NCT01216007|TIVA
368271|NCT01216007|Inhalational
368272|NCT01216007|anesthesia
368273|NCT01216007|Caudal epidural
368274|NCT01215981|influenza vaccine
368275|NCT01215955|Type 2 Diabetes
368276|NCT01215955|Insulin
368277|NCT01215955|Algorithms
368278|NCT01215955|Blood glucose levels
368279|NCT01215942|Rheumatoid Arthritis
368280|NCT01215929|methamphetamine withdrawal
368281|NCT01215929|mood
368282|NCT01215929|retention
368283|NCT01215929|sleep
368284|NCT01215916|Solid tumors
368285|NCT01215890|Crohn's disease
368286|NCT01215890|Low bone mineral density
368287|NCT01215890|inflammatory bowel disease
368288|NCT01215890|bisphosphonate
368289|NCT01215877|Bladder cancer
368290|NCT01215877|Previously treated patients
368291|NCT01215877|Tesetaxel
368292|NCT01215877|Oral taxane
368293|NCT01215864|metastatic tumors
368294|NCT01215864|refractory tumors
368295|NCT01215864|recurrent tumors
368296|NCT01215851|Tuberculosis
368297|NCT01215851|EBA
368298|NCT01215851|TMC207
368299|NCT01215851|pretomanid
368300|NCT01215851|Early Bactericidal Activity
368301|NCT01215851|Pulmonary Tuberculosis
368302|NCT01215851|PA-824
368303|NCT01215851|bedaquiline
368304|NCT01215851|pyrazinamide
368305|NCT01215851|moxifloxacin
368306|NCT01215851|ethambutol
368307|NCT01215851|rifafour
368308|NCT01215838|HCC
368309|NCT01215838|hepatocellular carcinoma
368310|NCT01215838|Eovist
368311|NCT01215838|MR
368312|NCT01215838|MRI
368313|NCT01215838|magnetic resonance
368314|NCT01215825|Chronic obstructive pulmonary disease
368315|NCT01215825|systemic steroid
368316|NCT01215799|Hormone Refractory Prostate Cancer
368317|NCT01215799|HRPC
368318|NCT01215760|peripheral nerve injury
368319|NCT01215760|sensory reeducation
368320|NCT01215760|brain plasticity
368321|NCT01215760|training with a mirror
368322|NCT01215760|rehabilitation
368323|NCT01215747|Kiacta for AA amyloidosis
368324|NCT01215721|Incontinence
368325|NCT01215721|Robotic Prostatectomy
368326|NCT01215721|Prostate Cancer
368327|NCT01215708|Kidney calculi
368328|NCT01215708|Lithotripsy
368329|NCT01215708|Calcium channel blockers
368330|NCT01215708|Adrenergic alpha-antagonists.
368331|NCT01215695|Intubation, Endotracheal
368332|NCT01215695|Endotracheal Intubation, adverse events
368333|NCT01215682|infections
368334|NCT01215682|immune system
368335|NCT01215682|vitamin D
368336|NCT01215682|sport
368337|NCT01215682|children
368338|NCT01215669|Influenza
368339|NCT01215669|Influenza Virus Vaccines
368340|NCT01215669|Intradermal Injections
368341|NCT01215643|Chronic hepatitis C genotype 2
368342|NCT01215643|Chronic hepatitis C genotype 3
368343|NCT01215643|Cyclophilin inhibitor
368344|NCT01215630|Veins
368345|NCT01215630|Exercise tests
368346|NCT01215630|maximal oxygen uptake
368347|NCT01215630|VO2max
368348|NCT01215617|Randomized controlled study
368349|NCT01215617|Exercise training
368350|NCT01215617|Lung function
368351|NCT01215617|Heart function
368352|NCT01215604|elderly patients
368353|NCT01215604|acute infection
368354|NCT01215604|translation initiation factors
368355|NCT01215604|eIF4E
368356|NCT01215604|eIF4G
368357|NCT01215591|Neonatal
368358|NCT01215591|Nasal CPAP
368359|NCT01215591|Randomized controlled trial
368360|NCT01215591|Weaning
368361|NCT01215578|Neuroendocrine Tumors
368362|NCT01215578|Neuroectodermal Tumors
368363|NCT01215578|Neoplasms, Germ Cell and Embryonal
368364|NCT01215578|Neoplasms by Histologic Type
368365|NCT01215578|Neoplasms
368366|NCT01215578|Neoplasms, Glandular and Epithelial
368367|NCT01215578|Neoplasms, Nerve Tissue
368368|NCT01215578|Pancreatic Neoplasms
368369|NCT01215578|Digestive System Neoplasms
368370|NCT01215578|Neoplasms by Site
368371|NCT01215578|Endocrine Gland Neoplasms
368372|NCT01215578|Adenoma, Islet Cell
368373|NCT01215578|Adenocarcinoma
368374|NCT01215578|Carcinoma
368375|NCT01215578|Adenoma
368376|NCT01215578|Digestive System Diseases
368377|NCT01215578|Pancreatic Diseases
368378|NCT01215578|Endocrine System Diseases
368379|NCT01215578|Sunitinib
368380|NCT01215578|Antineoplastic Agents
368381|NCT01215578|Therapeutic Uses
368382|NCT01215578|Pharmacologic Actions
368383|NCT01215578|Angiogenesis Inhibitors
368384|NCT01215578|Angiogenesis Modulating Agents
368385|NCT01215578|Growth Substances
368386|NCT01215578|Physiological Effects of Drugs
368387|NCT01215578|Growth Inhibitors
368388|NCT01215565|Carcinoma, Hepatocellular
368389|NCT01215565|Carcinoma
368390|NCT01215565|Fibrosis
368391|NCT01215565|Liver Neoplasms
368392|NCT01215565|Pathologic Processes
368393|NCT01215565|Digestive System Neoplasms
368394|NCT01215565|Neoplasms by Site
368395|NCT01215565|Neoplasms
368396|NCT01215565|Liver Diseases
368397|NCT01215565|Adenocarcinoma
368398|NCT01215565|Neoplasms, Glandular and Epithelial
368399|NCT01215565|Neoplasms by Histologic Type
368400|NCT01215565|Sunitinib
368401|NCT01215565|Antineoplastic Agents
368402|NCT01215565|Therapeutic Uses
368403|NCT01215565|Pharmacologic Actions
368404|NCT01215565|Angiogenesis Inhibitors
368405|NCT01215565|Angiogenesis Modulating Agents
368406|NCT01215565|Growth Substances
368407|NCT01215565|Physiological Effects of Drugs
368408|NCT01215565|Growth Inhibitors
368409|NCT01215500|solid tumor cancer
368410|NCT01215500|epithelial carcinoma
368411|NCT01215487|CML Predictive Study
368412|NCT01215461|Neonatal mortality
368413|NCT01215461|Preterm birth
368414|NCT01215461|Low gestational age
368415|NCT01215461|VLBW
368416|NCT01215448|Fatigue
368417|NCT01215448|Quality of life
368418|NCT01215448|Lifestyle
368419|NCT01215448|Complementary medicine
368420|NCT01215422|Surgical procedures
368421|NCT01215422|Intubation
368422|NCT01215422|Anesthesiologist
368423|NCT01215422|Laryngoscope
368424|NCT01215422|Videolaryngoscope
368425|NCT01215409|Levitra
368426|NCT01215409|Erectile dysfunction
368427|NCT01215409|Taiwan
368428|NCT01215396|Branched Chain Amino Acids
368429|NCT01215396|Mental Performance
368430|NCT01215396|Muscular Performance
368431|NCT01215396|Central Fatigue Theory
368432|NCT01215383|HDL
368433|NCT01215383|psychiatric patients
368434|NCT01215383|psychiatric patients before and during antipsychotic therapy
368435|NCT01215357|Pathological Gambling
368436|NCT01215357|ecopipam
368437|NCT01215357|Dopamine
368438|NCT01215331|Gestational Diabetes Mellitus
368439|NCT01215331|Treatment
368440|NCT01215331|Insulin
368441|NCT01215331|Metformin
368442|NCT01215331|Glyburide
368443|NCT01215305|Gastroesophageal Reflux Disease, extraesophageal symptoms
368444|NCT01215292|testosterone
368445|NCT01215292|acyline
368446|NCT01215292|ketoconazole
368447|NCT01215292|dutasteride
368448|NCT01215292|anastrazole
368449|NCT01215292|Intratesticular hormone concentration
368450|NCT01215279|Respiratory disease
368451|NCT01215279|Chronic Obstructive Pulmonary Disease
368452|NCT01215266|Bladder cancer
368453|NCT01215266|Chemotherapy
368454|NCT01215266|Urothelium cancer
368455|NCT01215253|Sudden Death
368456|NCT01215253|Ranolazine
368457|NCT01215253|Heart failure
368458|NCT01215253|Ventricular tachycardia
368459|NCT01215253|Ventricular fibrillation
368460|NCT01215253|Implantable cardioverter-defibrillator
368461|NCT01215214|metabolite profiles
368462|NCT01215214|pharmacokinetics
368463|NCT01215214|CYP3A
368464|NCT01215214|metabolomics
368465|NCT01215201|Periodontal maintenance
368466|NCT01215201|≥5mm probing depth
368467|NCT01215201|bleeding on probing and/or suppuration
368468|NCT01215188|Invasive pneumococcal disease
368469|NCT01215188|Pneumonia
368470|NCT01215188|Pneumococcal conjugate vaccine
368471|NCT01215175|Pneumococcal disease
368472|NCT01215149|HIV
368473|NCT01215084|Human Volunteers
368474|NCT01215071|Lymphadenectomy
368475|NCT01215071|Extension
368476|NCT01215071|Bladder cancer
368477|NCT01215058|Compliance, France
368478|NCT01215058|Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID
368479|NCT01215045|AcrySof ReSTOR Aspheric +4
368480|NCT01215032|castration-resistant prostate cancer
368481|NCT01215032|insulin levels
368482|NCT01215032|metformin
368483|NCT01215019|traumatic brain injury
368484|NCT01214993|GSK1349572
368485|NCT01214993|para-aminohippurate
368486|NCT01214993|iohexol
368487|NCT01214980|Low-frequency ultrasound
368488|NCT01214980|Wound healing
368489|NCT01214980|Split thickness wound healing
368490|NCT01214980|Skin graft donor site healing
368491|NCT01214967|risk factors for maternal depression
368492|NCT01214954|Total Hip Replacement
368493|NCT01214954|Rehabilitation
368494|NCT01214954|Resistance training
368495|NCT01214928|vitamin D
368496|NCT01214928|cholecalciferol
368497|NCT01214928|hemodialysis
368498|NCT01214928|randomized controlled trial
368499|NCT01214928|pilot
368500|NCT01214889|Diphtheria
368501|NCT01214889|Tetanus
368502|NCT01214889|Pertussis
368503|NCT01214889|Haemophilus influenzae type B
368504|NCT01214889|Poliomyelitis
368505|NCT01214889|PENTAXIM™
368506|NCT01214889|TETRAXIM™
368507|NCT01214863|Toric Intraocular Lens (IOL)
368508|NCT01214850|Meningococcal vaccines
368509|NCT01214850|Meningococcal B
368510|NCT01214850|Meningococcal ACWY serogroups
368511|NCT01214837|Meningococcal
368512|NCT01214837|ACWY
368513|NCT01214837|Conjugate Vaccine
368514|NCT01214837|Meningitis
368515|NCT01214837|Infants
368516|NCT01214837|Persistence
368517|NCT01214824|Diabetes
368518|NCT01214824|Continuous Glucose Monitoring
368519|NCT01214811|The change in signs of inflammation/local infection
368520|NCT01214811|To evaluate the comfort, conformability,
368521|NCT01214811|Pain during wear
368522|NCT01214798|sesamoid displacement,
368523|NCT01214798|metacarpophalangeal joint,
368524|NCT01214798|radial condylar ridge of the metacarpal head.
368525|NCT01214772|pregnancy
368526|NCT01214772|heparin
368527|NCT01214772|fertilization
368528|NCT01214759|HIV
368529|NCT01214759|prevention
368530|NCT01214759|prophylaxis
368531|NCT01214759|Raltegravir
368532|NCT01214759|Truvada
368533|NCT01214746|Statin
368534|NCT01214746|L-NMMA
368535|NCT01214746|Healthy subjects
368536|NCT01214746|Nephrology
368537|NCT01214707|Exercise/No active Treatment
368538|NCT01214694|TBI
368539|NCT01214694|intracranial edema
368540|NCT01214694|brain edema
368541|NCT01214694|craniocerebral trauma
368542|NCT01214694|head injury
368543|NCT01214694|brain hemorrhage, traumatic
368544|NCT01214694|subdural hematoma
368545|NCT01214694|brain concussion
368546|NCT01214694|head injuries, closed
368547|NCT01214694|epidural hematoma
368548|NCT01214694|extra-axial hemorrhage
368549|NCT01214694|cortical contusion
368550|NCT01214694|Additional relevant MeSH terms:
368551|NCT01214694|Nervous System Diseases
368552|NCT01214694|Wounds and Injuries
368553|NCT01214694|Disorders of Environmental Origin
368554|NCT01214694|Central Nervous System Diseases
368555|NCT01214694|Trauma, Nervous System
368556|NCT01214694|Brain Diseases
368557|NCT01214694|Brain Injuries
368558|NCT01214681|Biomarkers
368559|NCT01214681|Colorectal cancer
368560|NCT01214681|Resistant starch
368561|NCT01214681|Polydextrose
368562|NCT01214681|Non-digestible carbohydrate
368563|NCT01214655|Acute Myelogenous Leukemia
368564|NCT01214655|Acute Lymphoblastic Leukemia
368565|NCT01214655|Chronic Myelogenous Leukemia,Blast Crisis
368566|NCT01214642|Advanced Cancer
368567|NCT01214642|Cancer
368568|NCT01214629|Advanced Cancer
368569|NCT01214629|Metastatic Cancer
368570|NCT01214629|Cancer
368571|NCT01214603|Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute
368572|NCT01214603|Leukemia, Leukemia
368573|NCT01214577|PEP005
368574|NCT01214577|Peplin
368575|NCT01214577|Photo-damage
368576|NCT01214564|PEP005
368577|NCT01214564|Peplin
368578|NCT01214564|Seborrhoeic Keratosis
368579|NCT01214538|Vaccine pneumococcal natural history Acute otitis media
368580|NCT01214525|Meatal stenosis
368581|NCT01214525|Meatotomy
368582|NCT01214525|Uroflow
368583|NCT01214525|Postvoid residual
368584|NCT01214499|Refractory angina
368585|NCT01214499|Transmyocardial revascularization
368586|NCT01214499|Stem cells
368587|NCT01214499|Diffuse coronary disease not amenable to percutaneous coronary intervention, and angina, despite proper medical treatment
368588|NCT01214486|HIV
368589|NCT01214486|RAL
368590|NCT01214486|Raltegravir
368591|NCT01214486|Isentress
368592|NCT01214486|Pharmacokinetics
368593|NCT01214473|Clinical sepsis
368594|NCT01214473|Pneumonia
368595|NCT01214473|Diarrhea
368596|NCT01214473|Probiotics
368597|NCT01214473|Synbiotics
368598|NCT01214460|MET
368599|NCT01214447|Hemodialysis
368600|NCT01214447|Inflammation
368601|NCT01214447|Malnutrition
368602|NCT01214447|Phase Angle
368603|NCT01214434|Cradle Cap
368604|NCT01214434|Infantile seborrheic Dermatitis
368605|NCT01214421|Kidney Disease
368606|NCT01214421|ADPKD
368607|NCT01214421|Autosomal Dominant Polycystic Kidney Disease
368608|NCT01214421|Adult Polycystic Kidney Disease
368609|NCT01214395|haemodialysis
368610|NCT01214395|peritoneal dialysis
368611|NCT01214382|Gastric Bypass
368612|NCT01214382|Bariatric Surgery
368613|NCT01214382|Sertraline
368614|NCT01214382|Zoloft
368615|NCT01214382|Pharmacokinetic
368616|NCT01214369|intraosseous injection
368617|NCT01214369|X-tip
368618|NCT01214369|PDL injection
368619|NCT01214369|Supplementary Injection
368620|NCT01214356|diabetes
368621|NCT01214356|kidney disease
368622|NCT01214356|vitamin D
368623|NCT01214343|sorafenib
368624|NCT01214343|Hepatic intraarterial infusion chemotherapy
368625|NCT01214343|HAIC
368626|NCT01214343|Low dose FP
368627|NCT01214343|cisplatin
368628|NCT01214343|fluorouracil
368629|NCT01214330|cervical cancer
368630|NCT01214317|multiple sclerosis
368631|NCT01214317|mitoxantrone
368632|NCT01214317|plasmapheresis
368633|NCT01214317|induction therapy
368634|NCT01214304|Colposcopy
368635|NCT01214291|fractures
368636|NCT01214291|prostate cancer
368637|NCT01214291|androgen deprivation therapy
368638|NCT01214278|bioavailability
368639|NCT01214278|marine n-3 fatty acids
368640|NCT01214278|EPA
368641|NCT01214278|DHA
368642|NCT01214252|Repair of patients' abdominal wall defects
368643|NCT01214187|idiopathic pulmonary fibrosis
368644|NCT01214187|IPF
368645|NCT01214187|pulmonary fibrosis
368646|NCT01214187|carbon monoxide
368647|NCT01214174|cataract
368648|NCT01214174|inflammation
368649|NCT01214161|IUD
368650|NCT01214161|Lidocaine gel
368651|NCT01214135|Mental disorder
368652|NCT01214135|antipsychotic treatment
368653|NCT01214122|Phase 1
368654|NCT01214122|Drug-Drug interaction
368655|NCT01214122|warfarin
368656|NCT01214122|AZD9668
368657|NCT01214122|resulting from AZD9668 and Warfarin interaction
368658|NCT01214122|pharmacokinetics
368659|NCT01214122|pharmacodynamics
368660|NCT01214096|Chronic Heart failure
368661|NCT01214096|rhNRG-1
368662|NCT01214096|MRI
368663|NCT01214083|N-acetylcysteine
368664|NCT01214083|naltrexone
368665|NCT01214070|Visual Perception
368666|NCT01214070|Vision, Ocular
368667|NCT01214070|Neuronal Plasticity
368668|NCT01214057|chronic rhinosinusitis
368669|NCT01214057|endoscopic sinus surgery
368670|NCT01214057|TIVA
368671|NCT01214057|surgical field visualization
368672|NCT01214031|Confocal laser endomicroscope
368673|NCT01214031|Adenomatous polyps
368674|NCT01214031|Colonoscopy
368675|NCT01214005|nicotine
368676|NCT01214005|reinforcement
368677|NCT01214005|craving
368678|NCT01214005|relapse
368679|NCT01213966|Acute uncomplicated Plasmodium Falciparum malaria
368680|NCT01213966|Blood stage Plasmodium Vivax malaria
368681|NCT01213953|Vertebral disc, mesenchymal stem cell.
368682|NCT01213914|Burns
368683|NCT01213914|Hemofiltration
368684|NCT01213914|Vasopressins
368685|NCT01213914|Kidney Failure Acute
368686|NCT01213914|Shock, Septic
368687|NCT01213901|Insulin absorption
368688|NCT01213901|Insulin injection technique
368689|NCT01213888|Diabetic retinopathy
368690|NCT01213888|pan-retinal photocoagulation
368691|NCT01213888|macular edema
368692|NCT01213875|heart failure
368693|NCT01213875|nursing
368694|NCT01213875|home based intervention
368695|NCT01213875|cost
368696|NCT01213875|efficacy
368697|NCT01213862|Home Based education
368698|NCT01213862|Knowledge of Disease
368699|NCT01213862|Self-Care Skills
368700|NCT01213862|Quality of Life
368701|NCT01213862|Heart Failure
368702|NCT01213862|Randomized Clinical Trial
368703|NCT01213836|Stable schizophrenia
368704|NCT01213836|cognitive functioning
368705|NCT01213823|invasive candidiasis
368706|NCT01213823|candidemia
368707|NCT01213823|severe hepatic injury
368708|NCT01213823|echinocandins
368709|NCT01213823|anidulafungin
368710|NCT01213823|caspofungin
368711|NCT01213823|micafungin
368712|NCT01213810|HIV
368713|NCT01213810|VZV (Varicella zoster Virus)
368714|NCT01213810|vaccine
368715|NCT01213810|T cell
368716|NCT01213810|immunogenicity
368717|NCT01213810|safety
368718|NCT01213797|Suicide
368719|NCT01213771|Preoperative
368720|NCT01213771|Intervention
368721|NCT01213771|Support
368722|NCT01213771|Care
368723|NCT01213758|liver function
368724|NCT01213758|galactose
368725|NCT01213758|18-F-deoxy-galactose
368726|NCT01213758|PET/CT
368727|NCT01213758|stereotactic body radiation therapy
368728|NCT01213758|SBRT
368729|NCT01213745|lung
368730|NCT01213745|cancer
368731|NCT01213745|quality of life
368732|NCT01213732|L19, antibody, monoclonal, tumor targeting, TNFa, ILP, melanoma
368733|NCT01213719|betaine, creatine, strength
368734|NCT01213706|airway blood flow
368735|NCT01213706|albuterol
368736|NCT01213706|Whole Body Periodic Acceleration (WBPA)
368737|NCT01213706|Nitric Oxide
368738|NCT01213706|Endothelial Dysfunction
368739|NCT01213693|COPD
368740|NCT01213693|Bacteria
368741|NCT01213693|Virus
368742|NCT01213693|Inhaled Corticosteroids
368743|NCT01213680|Inflammatory Bowel Disease, IBD
368744|NCT01213654|Lung cancer
368745|NCT01213654|VATS Lobectomy
368746|NCT01213641|Cryopyrin-associated periodic syndromes(CAPS)
368747|NCT01213641|CIAS1 protein
368748|NCT01213641|NLRP3 protein
368749|NCT01213641|human cryopyrin protein
368750|NCT01213641|Familial Cold Autoinflammatory Syndrome(FCAS)
368751|NCT01213641|Muckle-Wells Syndrome(MWS)
368752|NCT01213641|Neonatal Onset Multisystem Inflammatory disease(NOMID)
368753|NCT01213641|NALP3
368754|NCT01213641|canakinumab
368755|NCT01213641|Interleukin-1(IL-1)
368756|NCT01213628|abdominal surgery
368757|NCT01213628|hypothermia
368758|NCT01213628|wound desiccation
368759|NCT01213628|warming
368760|NCT01213602|Trauma patients
368761|NCT01213589|descending
368762|NCT01213589|thoracic
368763|NCT01213589|aortic
368764|NCT01213589|dissection
368765|NCT01213589|Valiant
368766|NCT01213589|Medtronic
368767|NCT01213589|Type B
368768|NCT01213589|VIRTUE
368769|NCT01213589|stent
368770|NCT01213576|Lymphatic filariasis
368771|NCT01213576|microfilaria
368772|NCT01213576|Albendazole
368773|NCT01213576|ivermectin
368774|NCT01213576|human immunodeficiency
368775|NCT01213563|Diabetes Mellitus, Type 2
368776|NCT01213537|Heart failure
368777|NCT01213524|nicotine
368778|NCT01213524|craving
368779|NCT01213524|dual-diagnosis
368780|NCT01213524|comorbidity
368781|NCT01213511|coronary artery disease; coronary artery bypass grafting; cardiopulmonary bypass; minimal extracorporeal circulation
368782|NCT01213498|Nephrology
368783|NCT01213498|Atorvastatin
368784|NCT01213498|L-NMMA
368785|NCT01213498|NO
368786|NCT01213472|ASCI
368787|NCT01213472|melanoma
368788|NCT01213472|tumor antigen
368789|NCT01213472|unresectable
368790|NCT01213472|progressive
368791|NCT01213472|NY-ESO-1
368792|NCT01213472|adult
368793|NCT01213472|cancer-testis antigen
368794|NCT01213472|Immunotherapy
368795|NCT01213459|Human papillomavirus
368796|NCT01213446|Von Willebrand Disease
368797|NCT01213420|Donor sites after wound closure
368798|NCT01213407|Dendritic cell
368799|NCT01213407|Cancer vaccine
368800|NCT01213407|Anti-tumor immune therapy
368801|NCT01213407|Interleukine-12
368802|NCT01213407|Individualised autologous therapy
368803|NCT01213407|Brain cancer
368804|NCT01213407|Temozolomide
368805|NCT01213407|Radiotherapy
368806|NCT01213407|Irradiation
368807|NCT01213407|High-grade glioma
368808|NCT01213407|Advanced therapy medicinal product ATMP
368809|NCT01213407|Somatic cell therapy
368810|NCT01213407|Leukocyte apheresis
368811|NCT01213407|Neurosurgery
368812|NCT01213407|Neurooncology
368813|NCT01213407|Neurology
368814|NCT01213407|Immunology
368815|NCT01213407|Tumor immunology
368816|NCT01213407|Transfusion medicine
368817|NCT01213407|Monocyte
368818|NCT01213407|Killer cell
368819|NCT01213407|Cytotoxic T-cell
368820|NCT01213407|Cytotoxic T-lymphocyte
368821|NCT01213394|Framingham score
368822|NCT01213394|kidney transplant
368823|NCT01213394|immunosuppression
368824|NCT01213394|cardiovascular disease
368825|NCT01213394|CellCept
368826|NCT01213394|mycophenolate mofetil
368827|NCT01213355|Randomized
368828|NCT01213355|double-blind
368829|NCT01213355|placebo-controlled
368830|NCT01213355|5-way crossover
368831|NCT01213355|single oral administrations of PF 05212377
368832|NCT01213355|scopolamine induced deficits in healthy subjects
368833|NCT01213342|dry eye disease
368834|NCT01213316|HIV
368835|NCT01213316|antiretroviral
368836|NCT01213316|human immunodeficiency virus
368837|NCT01213316|Raltegravir
368838|NCT01213316|Adults with HIV-1 infection
368839|NCT01213303|cardiovascular risk
368840|NCT01213303|metabolic syndrome
368841|NCT01213303|fatty acids
368842|NCT01213303|oxysterols
368843|NCT01213303|antioxidants
368844|NCT01213303|oxidative stress
368845|NCT01213290|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
368846|NCT01213290|Stylet
368847|NCT01213277|Diabetes Mellitus
368848|NCT01213277|HbA1c
368849|NCT01213277|Glycation Rate
368850|NCT01213277|Fructosamine
368851|NCT01213264|neuromuscular blockade, NMBA, sugammadex, Bridion, TOF,
368852|NCT01213238|Liver metastasis
368853|NCT01213238|hepatic arterial infusion
368854|NCT01213238|HAI
368855|NCT01213238|Eloxatin
368856|NCT01213238|Xeloda
368857|NCT01213238|Avastin
368858|NCT01213238|Anti-VEGF monoclonal antibody
368859|NCT01213238|rhuMAb-VEGF
368860|NCT01213238|Oxaliplatin
368861|NCT01213238|Capecitabine
368862|NCT01213238|Bevacizumab
368863|NCT01213225|Elderly
368864|NCT01213225|Hospitalization
368865|NCT01213225|Geriatrics
368866|NCT01213225|Mortality
368867|NCT01213225|Readmission
368868|NCT01213225|Length of Stay
368869|NCT01213212|Caloric restriction
368870|NCT01213212|type 2 diabetes
368871|NCT01213212|abdominal obesity
368872|NCT01213212|renal disease
368873|NCT01213186|stem cell
368874|NCT01213186|hiv
368875|NCT01213186|CD4
368876|NCT01213186|immune activation
368877|NCT01213173|angina pectoris
368878|NCT01213173|chest pain
368879|NCT01213173|heart rate
368880|NCT01213160|Phase I
368881|NCT01213160|cancer
368882|NCT01213160|solid tumours
368883|NCT01213160|advanced solid malignancies
368884|NCT01213160|dose escalation
368885|NCT01213160|FGFR TKI
368886|NCT01213160|Japanese
368887|NCT01213147|Pregnancy
368888|NCT01213147|Clomiphene Citrate
368889|NCT01213147|Fertilization
368890|NCT01213147|Buserelin
368891|NCT01213134|Medical Education
368892|NCT01213134|Resident Training
368893|NCT01213134|Portfolio
368894|NCT01213121|bipolar depression
368895|NCT01213121|heart rate variability
368896|NCT01213121|cardio-respiratory coupling
368897|NCT01213121|electroencephalography
368898|NCT01213108|Örebro prevention program
368899|NCT01213108|Youth drinking
368900|NCT01213095|Lymphoma
368901|NCT01213095|B-Cell
368902|NCT01213095|Marginal Zone
368903|NCT01213095|Rituximab
368904|NCT01213082|Exudative Age-related Macular Degeneration
368905|NCT01213082|Proton beam irradiation
368906|NCT01213082|ranibizumab
368907|NCT01213082|bevacizumab
368908|NCT01213082|anti-VEGF therapy
368909|NCT01213056|Mindfulness Based Cognitive Therapy
368910|NCT01213056|Chronic Headache Pain
368911|NCT01213056|Randomized Controlled Trial.
368912|NCT01213043|emphysema
368913|NCT01213043|alpha 1-antitrypsin
368914|NCT01213043|alpha 1-antitrypsin deficiency (AATD)
368915|NCT01213043|alpha 1-proteinase inhibitor (Alpha-1 PI)
368916|NCT01213030|HX4
368917|NCT01213030|[F-18]HX4
368918|NCT01213030|FMISO
368919|NCT01213030|[F-18]FMISO
368920|NCT01213030|Solitary Tumor
368921|NCT01213030|Hypoxia
368922|NCT01213017|Certolizumab pegol
368923|NCT01213017|Magnetic Resonance Imaging
368924|NCT01213017|Rheumatoid Arthritis
368925|NCT01213017|RAPID 3
368926|NCT01213004|gastro-esophageal junction
368927|NCT01213004|lung
368928|NCT01213004|abdominal
368929|NCT01213004|cone-beam CT (CBCT)
368930|NCT01213004|10-146
368931|NCT01212991|Progressive Metastatic Prostate Cancer
368932|NCT01212978|Aging
368933|NCT01212978|Endothelium,Vascular
368934|NCT01212978|Arterial Remodeling
368935|NCT01212978|Ventricular Vascular Coupling
368936|NCT01212978|Nitric Oxide
368937|NCT01212978|Walking
368938|NCT01212978|Software
368939|NCT01212965|Selenium
368940|NCT01212965|Lymphatic Malformations
368941|NCT01212965|Adolescents
368942|NCT01212939|Dead pulps and open root ends
368943|NCT01212939|Patients who have teeth with dead pulp and open root ends
368944|NCT01212900|Atherosclerosis
368945|NCT01212900|Cardiovascular Disease
368946|NCT01212900|Cardiac MRI
368947|NCT01212900|Cardiac CT
368948|NCT01212900|Cholesterol
369066|NCT01212523|propofol
368949|NCT01212887|unspecified adult solid tumor, protocol specific
368950|NCT01212887|recurrent colon cancer
368951|NCT01212887|stage IIIA colon cancer
368952|NCT01212887|stage IIIB colon cancer
368953|NCT01212887|stage IIIC colon cancer
368954|NCT01212887|stage IV colon cancer
368955|NCT01212887|stage IVB colon cancer
368956|NCT01212887|recurrent rectal cancer
368957|NCT01212887|stage IIIA rectal cancer
368958|NCT01212887|stage IIIB rectal cancer
368959|NCT01212887|stage IIIC rectal cancer
368960|NCT01212887|stage IVA rectal cancer
368961|NCT01212887|stage IVB rectal cancer
368962|NCT01212887|recurrent gastric cancer
368963|NCT01212887|stage IV gastric cancer
368964|NCT01212887|recurrent pancreatic cancer
368965|NCT01212887|stage III pancreatic cancer
368966|NCT01212887|stage IV pancreatic cancer
368967|NCT01212887|recurrent breast cancer
368968|NCT01212887|stage IIIC breast cancer
368969|NCT01212887|stage IV breast cancer
368970|NCT01212887|extensive stage small cell lung cancer
368971|NCT01212887|recurrent non-small cell lung cancer
368972|NCT01212887|recurrent small cell lung cancer
368973|NCT01212887|stage IIIA non-small cell lung cancer
368974|NCT01212887|stage IIIB non-small cell lung cancer
368975|NCT01212887|stage IV non-small cell lung cancer
368976|NCT01212887|recurrent ovarian epithelial cancer
368977|NCT01212887|recurrent ovarian germ cell tumor
368978|NCT01212887|stage IIIA ovarian epithelial cancer
368979|NCT01212887|stage IIIA ovarian germ cell tumor
368980|NCT01212887|stage IIIB ovarian epithelial cancer
368981|NCT01212887|stage IIIB ovarian germ cell tumor
368982|NCT01212887|stage IIIC ovarian epithelial cancer
368983|NCT01212887|stage IIIC ovarian germ cell tumor
368984|NCT01212887|stage IV ovarian epithelial cancer
368985|NCT01212887|stage IV ovarian germ cell tumor
368986|NCT01212848|Transcranial Magnetic Stimulation
368987|NCT01212848|Suicidal ideation
368988|NCT01212835|Obesity
368989|NCT01212835|gastroesophageal reflux disease
368990|NCT01212835|Morbid obesity
368991|NCT01212835|esophagitis
368992|NCT01212835|GERD
368993|NCT01212835|silastic ring
368994|NCT01212835|Gastric bypass
368995|NCT01212796|allogeneic stem cell transplantation
368996|NCT01212783|depression
368997|NCT01212783|psychological treatments
368998|NCT01212783|Cognitive Behavioral Therapy
368999|NCT01212783|child development
369000|NCT01212783|parenting
369001|NCT01212783|home visitation
369002|NCT01212770|Psoriatic Arthritis
369003|NCT01212770|Psoriasis
369004|NCT01212770|Arthritis
369005|NCT01212770|inflammation
369006|NCT01212770|skin condition
369007|NCT01212770|inflammatory cells
369008|NCT01212770|apremilast
369009|NCT01212770|CC-10004
369010|NCT01212770|phosphodiesterase type 4
369011|NCT01212757|Psoriasis
369012|NCT01212757|Arthritis
369013|NCT01212757|Psoriatic Arthritis
369014|NCT01212757|inflammation
369015|NCT01212757|skin condition
369016|NCT01212757|inflammatory cells
369017|NCT01212757|apremilast
369018|NCT01212757|CC-10004
369019|NCT01212757|phosphodiesterase type 4
369020|NCT01212744|PEG PAL; PKU; injection;
369021|NCT01212731|Patients with malignancies of the skull base or patients with low grade glioma who require radiotherapy.
369022|NCT01212718|Colorectal Cancer
369023|NCT01212718|non resectable metastasis
369024|NCT01212718|reference lesion
369025|NCT01212718|biopsy
369026|NCT01212718|thymidylate synthase quantitation
369027|NCT01212679|nerve growth factor
369028|NCT01212679|traumatic brain injury
369029|NCT01212679|intranasal
369030|NCT01212679|prognosis
369031|NCT01212679|neurological function
369032|NCT01212666|Adductor Canal Block (ACB)
369033|NCT01212666|Anterior Cruciate Ligament (ACL) Reconstruction
369034|NCT01212666|Saphenous nerve
369035|NCT01212666|Pain
369036|NCT01212666|Ultrasound block
369037|NCT01212653|Ankylosing Spondylitis
369038|NCT01212653|Golimumab
369039|NCT01212653|Simponi
369040|NCT01212653|Anti-TNF alpha
369041|NCT01212653|EPCs
369042|NCT01212653|Vascular stiffness
369043|NCT01212640|Transfusion, distress
369044|NCT01212627|Non-Small Cell Lung Cancer
369045|NCT01212601|safety
369046|NCT01212601|efficacy
369047|NCT01212601|Chinese patients
369048|NCT01212601|practice
369049|NCT01212588|BPD
369050|NCT01212588|Borderline
369051|NCT01212588|personality disorder
369052|NCT01212588|mifepristone
369053|NCT01212575|Mental disorder
369054|NCT01212575|Antipsychotic treatment
369055|NCT01212562|basal cell carcinoma
369056|NCT01212562|cryosurgery
369057|NCT01212562|imiquimod
369058|NCT01212562|immunocryosurgery
369059|NCT01212549|basal cell carcinoma
369060|NCT01212549|cryosurgery
369061|NCT01212549|imiquimod
369062|NCT01212549|immunocryosurgery
369063|NCT01212536|children
369064|NCT01212536|intubation
369065|NCT01212536|laryngoscope
369067|NCT01212523|isoflurane
369068|NCT01212523|pulmonary hypertension
369069|NCT01212523|congenital heart disease
369070|NCT01212510|metastatic colorectal cancer
369071|NCT01212510|circulating tumor markers
369072|NCT01212510|circulating tumor cell
369073|NCT01212510|circulating tumor DNA
369074|NCT01212510|marker's kinetic
369075|NCT01212497|mindfulness
369076|NCT01212497|meditation
369077|NCT01212497|training
369078|NCT01212497|coaching
369079|NCT01212497|virtual coach
369080|NCT01212471|Sign and symptoms of dry eye disease
369081|NCT01212458|gesunde Probanden
369082|NCT01212432|Gram positive infection and CRRT
369083|NCT01212406|Organ rejection
369084|NCT01212406|Lung transplantation
369085|NCT01212406|Bronchiolitis Obliterans
369086|NCT01212406|Vitamin D
369087|NCT01212406|Prevention
369088|NCT01212393|venous thromboembolism disease
369089|NCT01212393|emergency
369090|NCT01212393|prevention
369091|NCT01212393|thromboprophylaxis
369092|NCT01212393|medical
369093|NCT01212393|hosptitalization
369094|NCT01212393|health care risks
369095|NCT01212380|Chronic Lymphocytic Leukemia
369096|NCT01212380|Small Lymphocytic Lymphoma
369097|NCT01212380|Prolymphocytic Leukemia
369098|NCT01212367|Gene transfer
369099|NCT01212367|Immunology
369100|NCT01212367|Cancer
369101|NCT01212354|intensity modulated radiotherapy
369102|NCT01212354|selective dose escalation
369103|NCT01212354|hypoxia
369104|NCT01212354|head cancer
369105|NCT01212354|neck cancer
369106|NCT01212341|Allogenetic NK cells
369107|NCT01212341|Lymphomas
369108|NCT01212341|Solid tumors
369109|NCT01212328|T2DM
369110|NCT01212328|Decision support software
369111|NCT01212328|care coordinator
369112|NCT01212315|Wound infection
369113|NCT01212315|SSI
369114|NCT01212315|Suture
369115|NCT01212302|Clopidogrel
369116|NCT01212302|ASA
369117|NCT01212302|Low Response
369118|NCT01212302|Resistance
369119|NCT01212263|PCOS
369120|NCT01212263|Clomiphene resistance
369121|NCT01212263|ovulation induction
369122|NCT01212263|low dose uFSH
369123|NCT01212263|uFSH step-up protocol
369124|NCT01212237|glioma
369125|NCT01212237|meningioma
369126|NCT01212237|anaplastic astrocytoma
369127|NCT01212211|Hyponatremia; Sodium level
369128|NCT01212211|Falls
369129|NCT01212211|Gait
369130|NCT01212211|elderly
369131|NCT01212185|oxytocin
369132|NCT01212185|alcohol withdrawal
369133|NCT01212185|lorazepam
369134|NCT01212185|alcoholism
369135|NCT01212185|intranasal administration
369136|NCT01212185|CIWA-Ar
369137|NCT01212172|Hair removal
369138|NCT01212172|Laser
369139|NCT01212172|Diode laser
369140|NCT01212159|Internet based monitoring system
369141|NCT01212146|Artichokes
369142|NCT01212146|Constipation
369143|NCT01212146|Functional Foods
369144|NCT01212146|Prebiotics
369145|NCT01212146|Probiotics
369146|NCT01212120|Diabetic foot
369147|NCT01212107|Advanced cancer
369148|NCT01212107|Metastatic cancer
369149|NCT01212107|Oncology
369150|NCT01212094|Rituximab
369151|NCT01212094|Multiple Sclerosis
369152|NCT01212094|Intrathecal
369153|NCT01212094|MS
369154|NCT01212094|Secondary-Progressive Multiple Sclerosis
369155|NCT01212094|SP-MS
369156|NCT01212081|Virtual Reality
369157|NCT01212081|Schizophrenia
369158|NCT01212081|Cannabis
369159|NCT01212081|Assessment
369160|NCT01212081|Craving
369161|NCT01212068|MEG
369162|NCT01212068|Epilepsy
369163|NCT01212068|Brain Imaging
369164|NCT01212068|Brain Scan
369165|NCT01212068|Auditory Processing
369166|NCT01212068|Auditory Perceptual Disorder
369167|NCT01212055|PBSC Collection
369168|NCT01212055|Immunodeficiency
369169|NCT01212055|Spectra Apheresis System
369170|NCT01212055|Stem Cell Mobilization
369171|NCT01212055|Leukapheresis
369172|NCT01212042|Pneumonia
369173|NCT01212042|Pulmonary Pathogens
369174|NCT01212042|HIV
369175|NCT01212042|Immunocompromised Host
369176|NCT01212042|Respiratory Infection
369177|NCT01212042|Mycobacteria
369178|NCT01212029|Near Infrared
369179|NCT01212029|Optical Imaging
369180|NCT01212029|Brain Imaging
369181|NCT01212029|Healthy Volunteer
369182|NCT01212029|HV
369183|NCT01212016|Eosinophilic Esophagitis
369184|NCT01212016|Eosinophilic Gastroenteritis
369185|NCT01212016|Peanut Allergy
369186|NCT01212016|T Cell
369187|NCT01212016|IgE
369188|NCT01212016|Food Allergy
369189|NCT01212003|Mycobacterium Tuberculosis
369190|NCT01212003|Active Tuberculosis
369191|NCT01212003|Latent Tuberculosis
369192|NCT01212003|Tuberculosis
369193|NCT01212003|TB
369194|NCT01211990|Pediatric
369195|NCT01211990|Children
369196|NCT01211990|Cancer
369197|NCT01211990|Bone Marrow Transplant
369198|NCT01211977|Muckle Wells Syndrome
369199|NCT01211977|Autoinflammatory
369200|NCT01211977|Interleukin-1
369201|NCT01211951|Dry eye syndromes
369202|NCT01211951|Corneal diseases
369203|NCT01211951|Conjunctival diseases
369204|NCT01211938|phase II/III
369205|NCT01211938|upper aerodigestive tract carcinoma
369206|NCT01211938|re irradiation
369207|NCT01211938|Recurrent or second upper aerodigestive tract carcinoma
369208|NCT01211925|unreconstructable peripheral arterial disease
369209|NCT01211912|Fetal movement
369210|NCT01211912|Fetal breathing
369211|NCT01211912|Acetaminophen
369212|NCT01211899|polymorphism,
369213|NCT01211899|plasminogen activator inhibitor,
369214|NCT01211899|disseminated intravascular coagulation,
369215|NCT01211886|Brain natriuretic peptide
369216|NCT01211886|Cardio-renal syndrome
369217|NCT01211873|CNS
369218|NCT01211873|Contrast Agent
369219|NCT01211873|MRI
369220|NCT01211873|Dotarem
369221|NCT01211873|Magnevist
369222|NCT01211860|DCCR
369223|NCT01211860|Diazoxide Chonline Controlled-Release Tablet = DCCR
369224|NCT01211860|Hypertriglyceridemia
369225|NCT01211860|Triglycerides
369226|NCT01211860|Pharmacokinetics
369227|NCT01211847|triglycerides
369228|NCT01211847|Apo B
369229|NCT01211847|non-HDL
369230|NCT01211847|statin
369231|NCT01211847|fenofibrate
369232|NCT01211795|Migraine
369233|NCT01211795|Prevention
369234|NCT01211795|Treatment
369235|NCT01211795|Ketoprofen
369236|NCT01211795|Trigeminal nerve
369237|NCT01211782|Alzheimer's disease
369238|NCT01211782|AD
369239|NCT01211782|AC-1204
369240|NCT01211782|ketogenic
369241|NCT01211782|ketosis
369242|NCT01211769|PUFAs
369243|NCT01211769|Alcoholism
369244|NCT01211769|Treatment
369245|NCT01211769|Effectiveness
369246|NCT01211743|SILS
369247|NCT01211743|Oxidative Stress
369248|NCT01211743|8-epiPGF2a
369249|NCT01211743|SILS vs standard laparoscopic cholecystectomy
369250|NCT01211730|Liver
369251|NCT01211730|transplantation
369252|NCT01211730|Glucose
369253|NCT01211730|Hyperglycemia
369254|NCT01211730|Insulin
369255|NCT01211730|Rejection
369256|NCT01211730|Hypoglycemia
369257|NCT01211717|Branched Chained Amino Acids
369258|NCT01211717|Delayed Onset Muscle Soreness
369259|NCT01211717|Diabetes
369260|NCT01211717|Muscle Damage
369261|NCT01211704|Bipolar, Alcoholism
369262|NCT01211691|Hematologic
369263|NCT01211691|Leukemia
369264|NCT01211691|Malignancies
369265|NCT01211691|Myeloproliferative Neoplasms
369266|NCT01211665|IVMP
369267|NCT01211665|corticosteroids
369268|NCT01211665|IRIS
369269|NCT01211665|Progressive Multifocal Leukoencephalopathy
369270|NCT01211665|Immune reconstitution inflammatory syndrome
369271|NCT01211665|PML
369272|NCT01211652|Compliance
369273|NCT01211652|France
369274|NCT01211652|Self-administered questionnaire to patients
369275|NCT01211613|Manipulation
369276|NCT01211613|Chiropractic
369277|NCT01211613|Low Back Pain
369278|NCT01211600|Staples
369279|NCT01211600|Sutures
369280|NCT01211600|Wound infections
369281|NCT01211600|Cosmesis
369282|NCT01211600|Aesthetic appearance of skin incision
369283|NCT01211587|Parkinson's Disease
369284|NCT01211587|Cognition
369285|NCT01211587|Safinamide
369286|NCT01211587|Phase 2
369287|NCT01211587|Non-demented patients
369288|NCT01211587|Levodopa
369289|NCT01211587|Dopamine agonist
369290|NCT01211535|Soft contact lenses
369291|NCT01211535|Multi-purpose Solution
369292|NCT01211522|Delirium
369293|NCT01211522|Intensive care
369294|NCT01211522|Mechanical ventilation
369295|NCT01211522|Antipsychotic
369296|NCT01211522|Haloperidol
369297|NCT01211522|Ziprasidone
369298|NCT01211522|Randomized
369299|NCT01211522|Placebo
369300|NCT01211522|Sepsis
369301|NCT01211522|Sedation
369302|NCT01211522|Long-term cognitive impairment
369303|NCT01211509|montelukast
369304|NCT01211509|cysteinyl leukotriene
369305|NCT01211509|lung transplantation
369306|NCT01211509|bronchiolitis obliterans syndrome
369307|NCT01211496|functional testing
369308|NCT01211496|resistance training
369309|NCT01211496|velocity training
369310|NCT01211496|elderly
369311|NCT01211496|geriatric
369312|NCT01211496|knee
369313|NCT01211496|leg
369314|NCT01211496|leg strength
369315|NCT01211483|Lung cancer
369316|NCT01211470|MRSA
369317|NCT01211470|ABSSSI
369318|NCT01211470|Staphylococcus aureus
369319|NCT01211444|Obstructive Sleep Apnea
369320|NCT01211444|OSA
369321|NCT01211444|Hypoglossal nerve stimulation
369322|NCT01211444|Sleep apnea
369323|NCT01211431|cesarean section
369324|NCT01211431|pain
369325|NCT01211431|ropivacain
369326|NCT01211431|diclofena
369327|NCT01211431|morphine
369328|NCT01211405|MDMA
369329|NCT01211405|Psychotherapy
369330|NCT01211405|Veterans
369331|NCT01211405|Posttraumatic Stress Disorder
369332|NCT01211379|colorectal cancer screening
369333|NCT01211379|primary care
369334|NCT01211379|health disparities
369335|NCT01211366|cell saver
369336|NCT01211366|allogeneic RBCs
369337|NCT01211366|washed cells
369338|NCT01211366|PRBC transfusion
369339|NCT01211353|Alcohol
369340|NCT01211353|Brief Intervention
369341|NCT01211353|Personalized Feedback
369342|NCT01211353|Veterans
369343|NCT01211340|Hospice
369344|NCT01211340|Caregivers
369345|NCT01211340|Interdisciplinary Team
369346|NCT01211340|Pain management
369347|NCT01211314|hypertension
369348|NCT01211314|Fixed combination
369349|NCT01211314|lercanidipine
369350|NCT01211314|enalapril
369351|NCT01211314|Blood Pressure Monitoring, Ambulatory
369352|NCT01211301|obesity
369353|NCT01211301|overweight
369354|NCT01211301|weight loss
369355|NCT01211301|randomized controlled trial
369356|NCT01211301|Medifast
369357|NCT01211288|HIV
369358|NCT01211288|Implant
369359|NCT01211288|Crown
369360|NCT01211275|mesothelioma
369361|NCT01211275|chemotherapy
369362|NCT01211275|translational research
369363|NCT01211275|axitinib
369364|NCT01211262|Melanoma
369365|NCT01211262|Phase I
369366|NCT01211262|Biologic
369367|NCT01211249|Methotrexate-refractory
369368|NCT01211223|Chronic periodontitis
369369|NCT01211223|Metronidazole plus Amoxicillin
369370|NCT01211223|Mechanical periodontal therapy
369371|NCT01211223|Scaling and Root Planning
369372|NCT01211223|Periodontal treatment
369373|NCT01211210|rectal cancer
369374|NCT01211210|neoadjuvant therapy
369375|NCT01211210|oxaliplatin
369376|NCT01211210|radiation
369377|NCT01211184|Hip surgery
369378|NCT01211184|Metabolism
369379|NCT01211184|Glucose
369380|NCT01211184|Body fluids
369381|NCT01211184|Complications
369382|NCT01211171|Cough
369383|NCT01211171|Telmisartan
369384|NCT01211171|Bradykinin
369385|NCT01211171|Tolerability
369386|NCT01211158|emergency department
369387|NCT01211158|procedural sedation
369388|NCT01211158|ketofol
369389|NCT01211158|ketamine
369390|NCT01211158|propofol
369391|NCT01211158|conscious sedation
369392|NCT01211145|Migraine
369393|NCT01211145|Headache
369394|NCT01211145|Pain
369395|NCT01211145|Efficacy
369396|NCT01211145|Adolescents
369397|NCT01211132|Colon polyps
369398|NCT01211132|Adenoma detection
369399|NCT01211132|Cap
369400|NCT01211132|Standard
369401|NCT01211132|Colon Cancer
369402|NCT01211106|Treatment
369403|NCT01211106|PTSD
369404|NCT01211106|Addiction
369405|NCT01211093|vibration
369406|NCT01211093|muscle
369407|NCT01211093|cerebrovascular accident
369408|NCT01211093|exercise
369409|NCT01211093|rehabilitation
369410|NCT01211080|infancy hemangioma
369411|NCT01211080|propranolol
369412|NCT01211080|study design
369413|NCT01211080|side effects
369414|NCT01211080|safety
369415|NCT01211067|Inguinal hernia
369416|NCT01211067|Inguinal ring
369417|NCT01211067|Histology
369418|NCT01211067|Hernioplasty
369419|NCT01211067|Lichtenstein
369420|NCT01211041|Candida albicans, fungemia , prognostic factor
369421|NCT01211028|Critical leg ischemia
369422|NCT01211028|Adipose derived Stroma/Stem Cells
369423|NCT01211028|Autologous
369424|NCT01211028|Angiogenesis
369425|NCT01211002|Radiotherapy
369426|NCT01211002|rh-endostatin
369427|NCT01211002|chemotherapy
369428|NCT01211002|NSCLC
369429|NCT01210976|levosimendan
369430|NCT01210976|CABG
369431|NCT01210976|AVR
369432|NCT01210950|distraction
369433|NCT01210950|osteogenesis
369434|NCT01210950|limb length discrepancy
369435|NCT01210950|callus
369436|NCT01210937|Internal Carotid Artery Stenosis
369437|NCT01210937|Carotid Endarterectomy
369438|NCT01210937|Stroke
369439|NCT01210937|Cerebrovascular
369440|NCT01210937|Atherosclerosis
369441|NCT01210924|children
369442|NCT01210924|Acquired Immunodeficiency Syndrome
369443|NCT01210924|antiretroviral therapy
369444|NCT01210924|China
369445|NCT01210924|Mortality
369446|NCT01210911|pancreatic cancer
369447|NCT01210911|metformin
369448|NCT01210911|MAPK pathway
369449|NCT01210911|PI3K/Akt pathway
369450|NCT01210911|gemcitabine
369451|NCT01210898|Influenza
369452|NCT01210898|Trivalent
369453|NCT01210898|Adjuvanted
369454|NCT01210898|Vaccine
369455|NCT01210898|Children
369456|NCT01210885|Meningococcal Disease
369457|NCT01210885|Vaccines
369458|NCT01210885|Adolescents
369459|NCT01210872|stage I squamous cell carcinoma of the lip and oral cavity
369460|NCT01210872|stage II squamous cell carcinoma of the lip and oral cavity
369461|NCT01210872|stage III squamous cell carcinoma of the lip and oral cavity
369462|NCT01210872|stage I lymphoepithelioma of the oropharynx
369463|NCT01210872|stage II lymphoepithelioma of the oropharynx
369464|NCT01210872|stage III lymphoepithelioma of the oropharynx
369465|NCT01210872|stage I squamous cell carcinoma of the oropharynx
369466|NCT01210872|stage II squamous cell carcinoma of the oropharynx
369467|NCT01210872|stage III squamous cell carcinoma of the oropharynx
369468|NCT01210872|stage I lymphoepithelioma of the nasopharynx
369469|NCT01210872|stage II lymphoepithelioma of the nasopharynx
369470|NCT01210872|stage III lymphoepithelioma of the nasopharynx
369471|NCT01210872|stage I squamous cell carcinoma of the nasopharynx
369472|NCT01210872|stage II squamous cell carcinoma of the nasopharynx
369473|NCT01210872|stage III squamous cell carcinoma of the nasopharynx
369474|NCT01210872|stage I squamous cell carcinoma of the hypopharynx
369475|NCT01210872|stage II squamous cell carcinoma of the hypopharynx
369476|NCT01210872|stage III squamous cell carcinoma of the hypopharynx
369477|NCT01210872|stage I squamous cell carcinoma of the larynx
369478|NCT01210872|stage II squamous cell carcinoma of the larynx
369479|NCT01210872|stage III squamous cell carcinoma of the larynx
369480|NCT01210872|stage I verrucous carcinoma of the larynx
369481|NCT01210872|stage II verrucous carcinoma of the larynx
369482|NCT01210872|stage III verrucous carcinoma of the larynx
369483|NCT01210872|tongue cancer
369484|NCT01210859|detrusitol
369485|NCT01210859|overactive
369486|NCT01210859|bladder
369487|NCT01210859|ureteral
369488|NCT01210859|stents
369489|NCT01210846|AV-951
369490|NCT01210846|tivozanib
369491|NCT01210846|QTc
369492|NCT01210846|advanced solid tumors
369493|NCT01210846|pharmacokinetics
369494|NCT01210833|Finger Fractures
369495|NCT01210833|Tendon Injuries
369496|NCT01210833|Soft Tissue Injuries
369497|NCT01210781|All indication for deep brain stimulation (DBS)
369498|NCT01210768|Phase II
369499|NCT01210768|Pegylated Liposomal Doxorubicin
369500|NCT01210768|Adjuvant Chemotherapy
369501|NCT01210768|Breast Cancer
369502|NCT01210755|Antithrombotics
369503|NCT01210755|Haemostatics
369504|NCT01210755|Antidote
369505|NCT01210729|stroke
369506|NCT01210729|mechanical recanalization
369507|NCT01210729|self-expanding stent
369508|NCT01210729|Solitaire
369509|NCT01210716|Therapeutic plasma exchange
369510|NCT01210716|Autoimmune diseases
369511|NCT01210716|Kidney transplant
369512|NCT01210716|Hematologic disorders
369513|NCT01210716|Monoclonal gammopathy
369514|NCT01210716|Neurologic disorders
369515|NCT01210703|Acoustic Pharyngometry
369516|NCT01210703|CPAP
369517|NCT01210703|Obstructive Sleep Apnea Syndrome
369518|NCT01210690|Levetiracetam
369519|NCT01210690|Keppra® Oral Solution
369520|NCT01210690|Keppra® in Children
369521|NCT01210677|Cardiac Sarcoidosis
369522|NCT01210677|Sarcoidosis
369523|NCT01210664|Diabetes
369524|NCT01210664|Treg
369525|NCT01210651|Yoga
369526|NCT01210651|Major Depression
369527|NCT01210651|Self-Efficacy
369528|NCT01210651|Self-Esteem
369529|NCT01210651|Hatha yoga
369530|NCT01210651|mind-body therapies
369531|NCT01210651|depression
369532|NCT01210625|Constipation
369533|NCT01210599|Back Pain
369534|NCT01210599|Bisphosphonate
369535|NCT01210599|Pamidronate
369536|NCT01210599|Bone Pain
369537|NCT01210573|Heart Failure
369538|NCT01210573|Heart-Assist Devices
369539|NCT01210573|Left Ventricular Assist Device
369540|NCT01210560|Kidney Disease
369541|NCT01210560|Polycystic Kidney Disease
369542|NCT01210521|Asthmatic Patients
369543|NCT01210521|Vitamin D
369544|NCT01210521|Steroid Resistant Asthmatic Patients
369545|NCT01210521|cholecalciferol
369546|NCT01210508|Cancer patients with metastases to the spinal column
369547|NCT01210495|Hepatocellular Carcinoma
369548|NCT01210482|Torisel
369549|NCT01210482|Regulatory Post Marketing Commitment Plan
369550|NCT01210469|elderly
369551|NCT01210469|postural balance
369552|NCT01210469|musculoskeletal equilibrium
369553|NCT01210469|posture
369554|NCT01210469|muscle strength
369555|NCT01210469|muscle stretching exercises
369556|NCT01210456|Chronic Kidney Disease
369557|NCT01210456|Contrast Media
369558|NCT01210456|Acute Kidney Injury
369559|NCT01210456|N-Acetylcysteine
369560|NCT01210456|Bicarbonate
369561|NCT01210443|sitaxentan sodium pulmonary hypertension
369562|NCT01210430|Postural Tachycardia Syndrome
369563|NCT01210430|Orthostatic Intolerance
369564|NCT01210430|Reactive Oxygen Species
369565|NCT01210430|Oxidative Stress
369566|NCT01210430|Angiotensin II
369567|NCT01210430|Nitric Oxide
369568|NCT01210430|Blood Flow
369569|NCT01210430|POTS
369570|NCT01210430|Ascorbic Acid
369571|NCT01210430|Vitamin C
369572|NCT01210430|Losartan
369573|NCT01210417|Trauma
369574|NCT01210417|Hypovolemia
369575|NCT01210417|Hemorrhage
369576|NCT01210417|Out of hospital trauma
369577|NCT01210404|Drug interaction with methadone.
369578|NCT01210378|NSCLC
369579|NCT01210378|Nitroglycerin
369580|NCT01210378|Tumour perfusion
369581|NCT01210378|Hypoxia
369582|NCT01210378|Toxicity
369583|NCT01210378|Phase II
369584|NCT01210378|HX4
369585|NCT01210365|CHF functional class II
369586|NCT01210365|Patients with CHF
369587|NCT01210365|Patients with CHF functional class II (NYHA) of any etiology
369588|NCT01210352|surgical pain
369589|NCT01210352|acute pain
369590|NCT01210352|Acute Post Surgical Pain
369591|NCT01210339|phase 1
369592|NCT01210339|cross-over
369593|NCT01210339|drug-drug Interaction
369594|NCT01210339|esomeprazole
369595|NCT01210339|acetylsalicylic acid
369596|NCT01210339|clopidogrel
369597|NCT01210339|healthy volunteers
369598|NCT01210339|cardiovascular disease
369599|NCT01210339|patients with acid associated gastrointestinal symptoms
369600|NCT01210326|TESE
369601|NCT01210326|TESA
369602|NCT01210326|non obstructive
369603|NCT01210326|azoospermi
369604|NCT01210313|physical activity
369605|NCT01210300|caesarean section
369606|NCT01210300|vaginal birth after caesarean section
369607|NCT01210300|repeat caesarean section
369608|NCT01210300|childbirth expectation
369609|NCT01210300|childbirth experience
369610|NCT01210287|hepatitis B virus reactivation
369611|NCT01210287|HBsAg negative
369612|NCT01210287|HBcAb positive
369613|NCT01210287|lymphoma
369614|NCT01210287|rituximab
369615|NCT01210261|OSA
369616|NCT01210261|CPAP
369617|NCT01210261|APAP
369618|NCT01210261|SPAP
369619|NCT01210261|Obstructive Sleep Apnea
369620|NCT01210261|Sleep Apnea
369621|NCT01210235|colorectal cancer screening
369622|NCT01210235|preventive health
369623|NCT01210235|primary care
369624|NCT01210209|Ewing sarcoma
369625|NCT01210209|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
369626|NCT01210196|Fabry
369627|NCT01210183|Dextrose
369628|NCT01210183|Cartilage
369629|NCT01210183|Regeneration
369630|NCT01210170|asthma,
369631|NCT01210170|inhaled corticosteroids,
369632|NCT01210170|airway blood flow,
369633|NCT01210170|mometasone,
369634|NCT01210170|albuterol
369635|NCT01210170|spirometry
369636|NCT01210144|Infertility
369637|NCT01210144|Gonal-f
369638|NCT01210144|gene expression
369639|NCT01210144|Assisted Reproductive Technologies
369640|NCT01210144|Follitropin alfa
369641|NCT01210144|endometrium
369642|NCT01210131|Toxicity
369643|NCT01210131|Progression
369644|NCT01210131|Survival
369645|NCT01210131|SCLC
369646|NCT01210118|Pregnancy
369647|NCT01210118|Smoking cessation
369648|NCT01210118|Cognitive-Behavioural interventions
369649|NCT01210105|intubation
369650|NCT01210105|video laryngoscopes
369651|NCT01210079|opioid-induced hyperalgesia
369652|NCT01210079|methadone
369653|NCT01210079|gabapentin
369654|NCT01210079|opioid addiction
369655|NCT01210066|inflammation
369656|NCT01210066|opioid-induced hyperalgesia
369657|NCT01210066|bupenorphine
369658|NCT01210066|prescription opioid abuse
369659|NCT01210053|Non-Small Cell Lung Cancer
369660|NCT01210040|Pregnancy
369661|NCT01210040|Iron deficiency
369662|NCT01210040|Iron supplementation
369663|NCT01210040|Burkina Faso
369664|NCT01210014|Recurrent aphthous stomatitis
369665|NCT01210014|treatment
369666|NCT01210014|zinc sulphate
369667|NCT01209975|blood flow
369668|NCT01209975|glaucoma
369669|NCT01209975|SLT
369670|NCT01209936|Body Fat
369671|NCT01209936|Total body water
369672|NCT01209923|Percent body fat
369673|NCT01209923|Body Composition
369674|NCT01209923|Stayhealthy
369675|NCT01209897|Smoking
369676|NCT01209871|Lymphoplasmacytic Lymphoma
369677|NCT01209871|Recombinant DNA
369678|NCT01209871|Fusion DNA Vaccine
369679|NCT01209871|Waldenström macroglobulinemia
369680|NCT01209858|epilepsy
369681|NCT01209845|depression
369682|NCT01209845|suicide ideation
369683|NCT01209845|emergency department
369684|NCT01209845|ketamine
369685|NCT01209832|Metastatic Tumors
369686|NCT01209832|Lymphoma
369687|NCT01209819|Bone Mineral Density
369688|NCT01209819|Adults
369689|NCT01209780|seasonal influenza, vaccine
369690|NCT01209767|Cellulite
369691|NCT01209767|Cryolipolysis
369692|NCT01209767|Zeltiq
369693|NCT01209767|Subcision
369694|NCT01209754|Pregnancy
369695|NCT01209754|Chemoprophylactic Exposure
369696|NCT01209754|Mother
369697|NCT01209754|Infant
369698|NCT01209754|malformations
369699|NCT01209754|HIV
369700|NCT01209728|insomnia
369701|NCT01209728|insomniacs
369702|NCT01209728|simulated driving
369703|NCT01209728|alcohol
369704|NCT01209728|ethanol
369705|NCT01209715|airway blood flow,
369706|NCT01209715|COPD,
369707|NCT01209715|endothelial dysfunction
369708|NCT01209715|inhaled corticosteroids
369709|NCT01209676|melanoma, with advanced unresectable
369710|NCT01209663|General Surgery
369711|NCT01209663|Emergency treatment
369712|NCT01209663|Postoperative care
369713|NCT01209663|Intermediate care unit
369714|NCT01209663|High dependency unit
369715|NCT01209663|Mortality
369716|NCT01209637|stable coronary artery disease
369717|NCT01209637|significant coronary stenosis
369718|NCT01209624|prospective
369719|NCT01209624|non-interventional
369720|NCT01209624|observational
369721|NCT01209624|multi-center
369722|NCT01209624|long-term
369723|NCT01209598|soft tissue
369724|NCT01209598|Palbociclib (PD0332991)
369725|NCT01209598|10-094
369726|NCT01209572|energy expenditure
369727|NCT01209572|heart rate
369728|NCT01209572|accelerometry
369729|NCT01209572|body temperature
369730|NCT01209572|heat flow galvanic response of skin
369731|NCT01209546|Bronchiectasis
369732|NCT01209546|Pulmonary function
369733|NCT01209546|Respiratory muscle strength
369734|NCT01209546|Respiratory secretions
369735|NCT01209533|Asthma
369736|NCT01209520|Lung Cancer
369737|NCT01209520|Non-Small Cell Lung Carcinoma
369738|NCT01209520|NSCLC
369739|NCT01209520|Methylation Analysis
369740|NCT01209520|Hypermethylation
369741|NCT01209520|Targeted Genes
369742|NCT01209520|Tumorigenesis
369743|NCT01209520|Tumor Supressor Genes
369744|NCT01209507|Adrenal suppression
369745|NCT01209507|Chemotherapy fatigue
369746|NCT01209507|Quality of life
369747|NCT01209494|sudden cardiac death
369748|NCT01209494|implantable cardioverter defibrillator
369749|NCT01209494|ventricular arrhythmias
369750|NCT01209494|genetic syndromes
369751|NCT01209494|calcium metabolism
369752|NCT01209494|ventricular repolarization
369753|NCT01209494|ECG
369754|NCT01209494|T wave
369755|NCT01209494|programmed electrical stimulation
369756|NCT01209494|alternans
369757|NCT01209494|late potentials
369758|NCT01209494|risk stratification
369759|NCT01209481|fruits
369760|NCT01209481|vegetables
369761|NCT01209481|primary health care
369762|NCT01209481|nutritional education
369763|NCT01209455|Acetylcysteine
369764|NCT01209455|Adverse effects
369765|NCT01209455|Acetaminophen
369766|NCT01209455|Anaphylactoid reactions
369767|NCT01209442|Glioblastoma
369768|NCT01209442|Multiforme
369769|NCT01209429|Calorie restriction
369770|NCT01209429|GH/IGF-I axis
369771|NCT01209429|STATb5
369772|NCT01209429|SIRT1
369773|NCT01209429|Intracellular signaling peptides and proteins
369774|NCT01209429|Fasting
369775|NCT01209429|Growth hormone
369776|NCT01209429|IGF-1
369777|NCT01209416|ghrelin
369778|NCT01209416|metabolism
369779|NCT01209416|type 2 diabetes
369780|NCT01209416|insulin resistance
369781|NCT01209403|Dialysis
369782|NCT01209403|Malnutrition
369783|NCT01209403|Insulin-Like Growth Factor I
369784|NCT01209403|Insulin-Like Growth Factor Binding Protein 1
369785|NCT01209403|Inflammation
369786|NCT01209390|osteochondral
369787|NCT01209390|regenerative
369788|NCT01209390|repair
369789|NCT01209390|cartilage lesion
369790|NCT01209377|standard
369791|NCT01209377|fixed
369792|NCT01209377|no focus
369793|NCT01209377|EMDR treatment with bilateral stimulation via eye movement
369794|NCT01209377|EMDR treatment with fixed eyes
369795|NCT01209377|Trauma exposition without external stimulus
369796|NCT01209364|comparative
369797|NCT01209364|randomized
369798|NCT01209364|double-blind
369799|NCT01209364|non-inferior
369800|NCT01209364|knee OA
369801|NCT01209351|Pharmacokinetics
369802|NCT01209351|Pharmacodynamics
369803|NCT01209351|teduglutide
369804|NCT01209325|human papilloma virus infection
369805|NCT01209325|anal cancer
369806|NCT01209325|penile cancer
369807|NCT01209325|HIV infection
369808|NCT01209299|recurrent melanoma
369809|NCT01209299|stage IIIC melanoma
369810|NCT01209299|stage IV melanoma
369811|NCT01209286|Blinatumomab
369812|NCT01209286|B-ALL
369813|NCT01209286|adult ALL
369814|NCT01209286|relapsed ALL
369815|NCT01209286|refractory ALL
369816|NCT01209286|Leukemia
369817|NCT01209286|ALL
369818|NCT01209286|Lymphatic diseases
369819|NCT01209286|Lymphoproliferative disorders
369820|NCT01209286|bispecific antibody
369821|NCT01209286|anti-CD19
369822|NCT01209286|Immunotherapeutic treatment
369823|NCT01209273|Quality of Life
369824|NCT01209273|Automated Peritoneal Dialysis
369825|NCT01209273|Continuous Ambulatory Peritoneal Dialysis
369826|NCT01209273|End Stage Renal Disease
369827|NCT01209260|Transseptal Puncture
369828|NCT01209260|Radiofrequency Energy
369829|NCT01209260|Left Atrium Access
369830|NCT01209260|Left Atrial Catheterization
369831|NCT01209260|Ablation
369832|NCT01209260|Transseptal Catheterization
369833|NCT01209260|Electrocautery
369834|NCT01209260|Catheter Ablation
369835|NCT01209260|Atrial Fibrillation
369836|NCT01209247|Fluoroquinolone -resistance
369837|NCT01209247|Commensal flora
369838|NCT01209247|Emergence of resistance
369839|NCT01209234|Methicillin-resistant Staphylococcus aureus
369840|NCT01209234|MRSA
369841|NCT01209195|Ovarian cancer
369842|NCT01209195|HER-2 negative breast cancer
369843|NCT01209195|Breast cancer
369844|NCT01209195|Fallopian tube cancer
369845|NCT01209169|Kidney Renal
369846|NCT01209117|formulation
369847|NCT01209117|bioavailability
369848|NCT01209117|pharmacokinetics
369849|NCT01209117|GSK2248761
369850|NCT01209104|omeprazole
369851|NCT01209104|proton pump inhibitor
369852|NCT01209104|COPD
369853|NCT01209104|CXCR2 inhibitor
369854|NCT01209104|bioavailability
369855|NCT01209104|food-effect
369856|NCT01209078|methicillin-resistant Staphylococcus aureus
369857|NCT01209078|linezolid
369858|NCT01209078|repeat dose
369859|NCT01209078|GSK1322322
369860|NCT01209065|integrase
369861|NCT01209065|fosamprenavir
369862|NCT01209065|ritonavir
369863|NCT01209065|GSK1349572
369864|NCT01209052|COPD
369865|NCT01209052|CXCR2 inhibitor
369866|NCT01209039|Schizophrenia
369867|NCT01209039|PET
369868|NCT01209026|Fluticasone furoate (GW685698)
369869|NCT01209026|moxifloxacin
369870|NCT01209026|QTc
369871|NCT01209026|GW642444
369872|NCT01209026|pharmacokinetics
369873|NCT01209013|PDT
369874|NCT01209013|porfimer sodium
369875|NCT01209013|BE
369876|NCT01209000|Focal and Segmental Glomerulosclerosis
369877|NCT01209000|Focal & Segmental Glomerulosclerosis
369878|NCT01209000|Focal Segmental Glomerulosclerosis
369879|NCT01209000|FSGS
369880|NCT01209000|Minimal change disease
369881|NCT01209000|MCD
369882|NCT01209000|Membranous Nephropathy
369883|NCT01209000|MN
369884|NCT01209000|Nephrotic Syndrome
369885|NCT01209000|Neph Syndrome
369886|NCT01209000|NEPTUNE
369887|NCT01209000|NephCure
369888|NCT01209000|Halpin
369889|NCT01208974|Breast Cancer
369890|NCT01208974|Nipple Area Complex
369891|NCT01208974|Mastectomy
369892|NCT01208974|Radiation Therapy
369893|NCT01208974|Nipple-Sparing
369894|NCT01208974|Breast Reconstruction
369895|NCT01208961|Eicosapentaenoic Acid
369896|NCT01208961|Docosahexaenoic Acid
369897|NCT01208961|Hypertriglyceridemia
369898|NCT01208961|Omega-3 acid ethyl esters
369899|NCT01208961|Omega-3 carboxylic acids
369900|NCT01208961|Epanova
369901|NCT01208961|Lovaza
369902|NCT01208961|bioavailability
369903|NCT01208961|pharmacokinetics
369904|NCT01208961|low-fat meal
369905|NCT01208961|high-fat meal
369906|NCT01208948|macular edema
369907|NCT01208948|diabetes mellitus
369908|NCT01208948|prevention alpha lipoic acid
369909|NCT01208935|Randomized
369910|NCT01208935|Double blind
369911|NCT01208935|double-dummy
369912|NCT01208935|placebo-controlled
369913|NCT01208896|Allogeneic hematopoietic stem cell transplantation
369914|NCT01208896|Reduced-intensity conditioning
369915|NCT01208896|Chemosensitive relapsed follicular lymphoma
369916|NCT01208883|Primary non-operated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx.
369917|NCT01208831|Advanced tumors
369918|NCT01208831|hedgehog
369919|NCT01208831|smoothened inhibitor
369920|NCT01208792|Auto antibodies
369921|NCT01208792|Target antigens
369922|NCT01208792|2D-immunoblot
369923|NCT01208792|Reactive oxygen species
369924|NCT01208792|Pulmonary arterial hypertension
369925|NCT01208792|Systemic sclerosis
369926|NCT01208792|Human immunodeficiency virus infection
369927|NCT01208792|Porto pulmonary hypertension
369928|NCT01208792|Congenital heart defect
369929|NCT01208792|Systemic lupus erythematosus
369930|NCT01208792|Mixed connective tissue disease
369931|NCT01208792|Sjögren's syndrome
369932|NCT01208779|Compliance
369933|NCT01208779|HR+ breast cancer
369934|NCT01208779|epidemiology
369935|NCT01208766|Multiple Myeloma (Kahler's disease)
369936|NCT01208753|Safety
369937|NCT01208753|Tolerability
369938|NCT01208753|Pharmacokinetics
369939|NCT01208740|Gonadotropins
369940|NCT01208740|infertility
369941|NCT01208740|IVF
369942|NCT01208740|metformin
369943|NCT01208740|PCOS
369944|NCT01208740|poor prognosis
369945|NCT01208740|poor responder
369946|NCT01208727|Myocardial infarction
369947|NCT01208727|Postconditioning
369948|NCT01208727|Microvascular obstruction
369949|NCT01208727|No reflow
369950|NCT01208727|MRI
369951|NCT01208714|Renal artery stenosis
369952|NCT01208714|Atherosclerosis
369953|NCT01208714|Arterial hypertension
369954|NCT01208714|Percutaneous renal angioplasty
369955|NCT01208714|Stenting
369956|NCT01208701|Atorvastatin
369957|NCT01208701|L-NMMA
369958|NCT01208701|NO
369959|NCT01208701|Nephrology
369960|NCT01208701|Diabetes Mellitus
369961|NCT01208688|Spinal Cord Injuries
369962|NCT01208662|Lenalidomide
369963|NCT01208662|Bortezomib
369964|NCT01208662|Dexamethasone
369965|NCT01208662|Stem Cell Transplant
369966|NCT01208662|Myeloma
369967|NCT01208662|Multiple Myeloma
369968|NCT01208649|exenatide
369969|NCT01208649|hepatic steatosis
369970|NCT01208649|insulin resistance
369971|NCT01208649|insulin sensitizers
369972|NCT01208649|nonalcoholic fatty liver disease
369973|NCT01208649|- GLP1-Analog
369974|NCT01208636|Vitamin D deficiency
369975|NCT01208636|Sun
369976|NCT01208636|Genetics
369977|NCT01207609|Obesity
369978|NCT01207609|Morbid Obesity
369979|NCT01207609|Bariatric Surgery
369980|NCT01207609|Laparoscopic Gastric Plication
369981|NCT01207596|Pain
369982|NCT01207596|Neuropathy
369983|NCT01207596|Neuropathic Pain
369984|NCT01207596|Hydromorphone
369985|NCT01207583|vaccine
369986|NCT01207583|infant
369987|NCT01207583|healthy subjects
369988|NCT01207570|flexibility
369989|NCT01207570|muscle
369990|NCT01207570|stretching
369991|NCT01207570|cerebral palsy
369992|NCT01207570|developmental
369993|NCT01208584|functional MRI,primary motor cortex,spinal cord injury
369994|NCT01208571|Harmful use
369995|NCT01208571|Hazardous use
369996|NCT01208571|Dependence
369997|NCT01208558|Blood pressure
369998|NCT01208558|Cereals
369999|NCT01208558|Diet Therapy
370000|NCT01208558|Dietary carbohydrates
370001|NCT01208558|Dietary fiber
370002|NCT01208558|Exercise Therapy
370003|NCT01208558|Food
370004|NCT01208558|Glucose intolerance
370005|NCT01208558|Lifestyle
370006|NCT01208558|Physiotherapy
370007|NCT01208558|Stroke
370008|NCT01208558|TIA
370009|NCT01208558|Waist circumference
370010|NCT01208558|Weight loss
370011|NCT01208545|taxol
370012|NCT01208545|vincristine
370013|NCT01208545|oxaliplatin
370014|NCT01208545|chemotherapy
370015|NCT01208545|nerve degeneration
370016|NCT01208545|nerve conduction
370017|NCT01208545|cancer
370018|NCT01208545|nerve conduction studies
370019|NCT01208519|Drug resistance, Microbial
370020|NCT01208519|Methicillin-Resistant Staphylococcus aureus
370021|NCT01208519|ESBL
370022|NCT01208519|Colonisation
370023|NCT01208519|Screening
370024|NCT01208519|Gram-negative
370025|NCT01208493|prematurity
370026|NCT01208493|enteral feeding
370027|NCT01208493|proteins
370028|NCT01208493|formula
370029|NCT01208480|stage II breast cancer
370030|NCT01208480|stage IIIA breast cancer
370031|NCT01208480|stage IIIB breast cancer
370032|NCT01208480|stage IIIC breast cancer
370033|NCT01208480|triple-negative breast cancer
370034|NCT01208428|Depression
370035|NCT01208415|Zenith aortoiliac aneurysm
370036|NCT01208415|iliac aneurysm
370037|NCT01208415|branch
370038|NCT01208415|connections
370039|NCT01208415|endovascular graft
370040|NCT01208415|graft-iliac bifurcation
370041|NCT01208415|Aneurysm
370042|NCT01208415|Vascular Diseases
370043|NCT01208415|Cardiovascular Diseases
370044|NCT01208363|Iron fortification
370045|NCT01208363|polyphenols
370046|NCT01208363|NaFeEDTA
370047|NCT01208363|cowpea
370048|NCT01208363|school feeding program
370049|NCT01208350|Weight Loss
370050|NCT01208350|Motivation
370051|NCT01208350|Workplace
370052|NCT01208350|Web platform
370053|NCT01208337|Rejection
370054|NCT01208324|Cognitive difficulties
370055|NCT01208324|memory impairment
370056|NCT01208324|mood changes
370057|NCT01208324|brain activation
370058|NCT01208311|Alcoholic cirrhosis
370059|NCT01208311|hepatitis c cirrhosis
370060|NCT01208311|cirrhosis
370061|NCT01208298|Cold Sore Patch
370062|NCT01208272|Body Mass Index
370063|NCT01208272|Bulimia/therapy
370064|NCT01208272|Comorbidity
370065|NCT01208272|Interpersonal Relations
370066|NCT01208272|Psychotherapy/methods
370067|NCT01208259|Body Mass Index
370068|NCT01208259|Bulimia/therapy
370069|NCT01208259|Comorbidity
370070|NCT01208259|Interpersonal Relations
370071|NCT01208259|Psychotherapy/methods
370072|NCT01208233|Phase 2 Ischemic stroke Safety and efficacy
370073|NCT01208220|Collagenase Santyl
370074|NCT01208220|Enzymatic debridement
370075|NCT01208220|maintenance debridement
370076|NCT01208220|VAC
370077|NCT01208220|NPWT
370078|NCT01208194|Advanced colorectal carcinoma
370079|NCT01208194|Maintenance therapy
370080|NCT01208194|Immunomodulator
370081|NCT01208168|toenail fungus
370082|NCT01208168|onychomycosis
370083|NCT01208168|nail infection
370084|NCT01208155|Phase 1
370085|NCT01208155|Healthy
370086|NCT01208155|pharmacokinetics
370087|NCT01208155|Fostamatinib
370088|NCT01208142|toe walker
370089|NCT01208142|Pediatric toe walking
370090|NCT01208142|ankle flexion
370091|NCT01208129|toenail fungus
370092|NCT01208129|onychomycosis
370093|NCT01208129|nail infection
370094|NCT01208116|Atherosclerosis
370095|NCT01208116|Prognosis
370096|NCT01208116|Flow-mediated dilatation
370097|NCT01208116|Brachial-ankle pulse wave velocity
370098|NCT01208116|Carotid Intimal-Medial Thickness
370099|NCT01208116|coronary artery calcification score
370100|NCT01208116|Ankle-brachial index
370101|NCT01208103|Cancer
370102|NCT01208103|Small bowel
370103|NCT01208103|Ampulla of Vater
370104|NCT01208103|CAPOX Chemotherapy
370105|NCT01208103|Bevacizumab
370106|NCT01208103|Capecitabine
370107|NCT01208103|Oxaliplatin
370108|NCT01208103|Xeloda
370109|NCT01208103|Eloxatin
370110|NCT01208103|Avastin
370111|NCT01208103|Anti-VEGF monoclonal antibody
370112|NCT01208103|rhuMab-VEGF
370113|NCT01208090|psoriasis
370114|NCT01208090|chronic plaque psoriasis
370115|NCT01208090|Moderate to severe chronic plaque psoriasis
370116|NCT01208077|ED hemodynamic profiles
370117|NCT01208077|patients treated under current clinical standards
370118|NCT01208077|Acute CHF
370119|NCT01208077|Stroke syndromes
370120|NCT01208077|Systemic infection
370121|NCT01208064|adenocarcinoma of the lung
370122|NCT01208064|adenosquamous cell lung cancer
370123|NCT01208064|bronchoalveolar cell lung cancer
370124|NCT01208064|large cell lung cancer
370125|NCT01208064|recurrent non-small cell lung cancer
370126|NCT01208064|stage IIIB non-small cell lung cancer
370127|NCT01208064|stage IV non-small cell lung cancer
370128|NCT01208025|Plaque
370129|NCT01208025|Imaging
370130|NCT01208012|Diabetes Mellitus treatment Metformin
370131|NCT01207999|Human papillomavirus
370132|NCT01207960|dental phobia
370133|NCT01207960|psychotherapy
370134|NCT01207960|eye movement desensitization and reprocessing - EMDR
370135|NCT01207960|efficacy
370136|NCT01207960|wait-list control
370137|NCT01207947|Vardenafil
370138|NCT01207947|Erectile dysfunction
370139|NCT01207947|Phosphodiesterase Inhibitors
370140|NCT01207947|Combination use with alpha-blockers
370141|NCT01207934|diabetes
370142|NCT01207934|obesity
370143|NCT01207908|DMD
370144|NCT01207908|Duchenne Muscular Dystrophy
370145|NCT01207908|Insulin like growth factor
370146|NCT01207908|6 minute walk test
370147|NCT01207869|Bronchopulmonary dysplasia (BPD)
370148|NCT01207869|Extremely premature infant
370149|NCT01207869|Mesenchymal stem cells (MSCs)
370150|NCT01207869|umbilical cord
370151|NCT01207856|Multiple sclerosis
370152|NCT01207856|functional MRI
370153|NCT01207856|cognitive rehabilitation
370154|NCT01207856|ecological evaluation
370155|NCT01207856|neuroplasticity
370156|NCT01207843|Computed tomography
370157|NCT01207830|Obesity
370158|NCT01207817|a light flash in each eye for a total of 48 measurements
370159|NCT01207804|Obesity
370160|NCT01207791|drug abuse
370161|NCT01207791|emergency department
370162|NCT01207791|brief intervention
370163|NCT01207791|motivational interviewing
370164|NCT01207791|SBIRT
370165|NCT01207778|brain
370166|NCT01207778|development
370167|NCT01207778|erythropoietin
370168|NCT01207778|neuroprotection
370169|NCT01207778|MRI
370170|NCT01207765|Multiple Myeloma
370171|NCT01207765|Zevalin
370172|NCT01207752|dry eye, meibomian gland dysfunction, tear film break up time
370173|NCT01207739|Prolonged antibiotic treatment in Lyme disease
370174|NCT01207739|Doxycycline
370175|NCT01207739|Clarithromycin
370176|NCT01207739|Hydroxychloroquine
370177|NCT01207700|post discharge intervention
370178|NCT01207700|adherence
370179|NCT01207700|compliance
370180|NCT01207700|community health worker
370181|NCT01207674|Pathological gambling
370182|NCT01207674|"at risk gambling"
370183|NCT01207674|gambling practice evolution
370184|NCT01207674|psychiatric comorbidities
370185|NCT01207674|gambling trajectory
370186|NCT01207674|cognitive distortions
370187|NCT01207674|ADHD
370188|NCT01207674|addiction
370189|NCT01207674|recourse to care
370190|NCT01207661|Mesenchymal cells
370191|NCT01207661|osteoarthritis
370192|NCT01207661|intra articular injection
370193|NCT01207648|Interferon beta 1a
370194|NCT01207648|Autoimmune Diseases
370195|NCT01207648|Demyelinating Diseases
370196|NCT01207648|Immune System Diseases
370197|NCT01207648|Immunologic Factors
370198|NCT01207648|Nervous System Diseases
370199|NCT01207648|Physiological Effects of Drugs
370200|NCT01207648|Demyelinating Autoimmune Diseases, CNS
370201|NCT01207648|Autoimmune Diseases of the Nervous System
370202|NCT01207648|Retrospective Cohort Study
370203|NCT01207635|Cancer
370204|NCT01207635|Arimidex
370205|NCT01207557|Healthcare personnel
370206|NCT01207557|influenza
370207|NCT01207557|immunization
370208|NCT01207557|flu
370209|NCT01207557|vaccine
370210|NCT01207544|motor
370211|NCT01207544|balance
370212|NCT01207544|developmental
370213|NCT01207544|physiotherapy
370214|NCT01207531|sepsis
370215|NCT01207531|miRNA
370216|NCT01207518|influenza
370217|NCT01207518|immunization
370218|NCT01207518|healthcare personnel
370219|NCT01207505|bipolar disorder
370220|NCT01207505|depression
370221|NCT01207505|mania
370222|NCT01207505|emotion regulation
370223|NCT01207505|dialectical behavior therapy
370224|NCT01207505|group therapy
370225|NCT01207505|mindfulness
370226|NCT01207492|nilotinib
370227|NCT01207453|Arthritis, Rheumatoid
370228|NCT01207453|Milnacipran
370229|NCT01207453|Pain
370230|NCT01207440|CML
370231|NCT01207440|ALL
370232|NCT01207440|PH
370233|NCT01207440|ponatinib
370234|NCT01207440|Ph+ALL
370235|NCT01207440|T315I mutation
370236|NCT01207440|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
370237|NCT01207427|opioid therapy
370238|NCT01207427|constipation
370239|NCT01207427|chronic noncancer pain
370240|NCT01207427|mu opioid receptor antagonist
370241|NCT01207427|ADL5945
370242|NCT01207414|Schizophrenia
370243|NCT01207414|iloperidone
370244|NCT01207414|switch
370245|NCT01207414|gradual switch
370246|NCT01207414|immediate switch
370247|NCT01207401|intrauterine device
370248|NCT01207401|local anesthetic
370249|NCT01207388|Blinatumomab
370250|NCT01207388|MRD
370251|NCT01207388|B-ALL
370252|NCT01207388|Minimal residual disease
370253|NCT01207388|adult ALL
370254|NCT01207388|Leukemia
370255|NCT01207388|ALL
370256|NCT01207388|Lymphatic diseases
370257|NCT01207388|Lymphoproliferative disorders
370258|NCT01207388|bispecific antibody
370259|NCT01207388|anti-CD19
370260|NCT01207388|Immunotherapeutic treatment
370261|NCT01207375|memory
370262|NCT01207375|learning
370263|NCT01207375|Traumatic Brain Injury
370264|NCT01207375|cognition
370265|NCT01207375|treatment
370266|NCT01207375|therapy
370267|NCT01207349|Type 2 diabetes
370268|NCT01207349|Secondary prevention
370269|NCT01207349|Physical activity
370270|NCT01207349|Nutritional education
370271|NCT01207349|HbA1c
370272|NCT01207349|Reunion island
370273|NCT01207349|diabetic patients, both female and male, age >=18 years, able to practise a physical activity, in Saint Pierre (GHSR) and Saint Denis (CHD)
370274|NCT01207336|stroke
370275|NCT01207336|rehabilitation
370276|NCT01207336|transcranial direct current stimulation
370277|NCT01207336|nerve stimulation
370278|NCT01207310|smoking
370279|NCT01207310|smoking of 10 cigarettes per day
370280|NCT01207297|Lupus nephritis
370281|NCT01207297|tacrolimus
370282|NCT01207297|cyclophosphamide
370283|NCT01207271|depression
370284|NCT01207271|community mental health
370285|NCT01207271|treatment
370286|NCT01207271|psychotherapy
370287|NCT01207271|mediators
370288|NCT01207258|Motivational Interviewing
370289|NCT01207258|Brief Intervention
370290|NCT01207258|Intimate Partner Violence
370291|NCT01207258|Domestic Violence
370292|NCT01207258|Alcohol Abuse
370293|NCT01207245|Cystic fibrosis
370294|NCT01207245|Tobramycin
370295|NCT01207245|Pharmacokinetics
370296|NCT01207245|Toxicity
370297|NCT01207232|seasonal influenza
370298|NCT01207232|behavioral economics
370299|NCT01207232|implementation intentions
370300|NCT01207232|planning prompt
370301|NCT01207232|nudge
370302|NCT01207219|psychosis
370303|NCT01207219|yoga
370304|NCT01207219|aerobic exercise
370305|NCT01207219|memory
370306|NCT01207219|attention
370307|NCT01207219|neuro cognition
370308|NCT01207206|Patient suffering from severe cancer pain despite the opioid treatment
370309|NCT01207206|Opiate tolerance suspected on the basis of rapid escalation in opiate dose
370310|NCT01207206|Severe opiate side effects
370311|NCT01207193|bone cyst bone defect mesenchymal cell
370312|NCT01207180|emergency medicine
370313|NCT01207180|primary care physicians
370314|NCT01207141|Liver Transplantation
370315|NCT01207141|Thymoglobulin
370316|NCT01207141|Rejection
370317|NCT01207102|Breast cancer
370318|NCT01207102|Triple negative
370319|NCT01207089|Safety
370320|NCT01207089|tolerability
370321|NCT01207089|PK
370322|NCT01207089|healthy
370323|NCT01207089|overweight
370324|NCT01207089|obese
370325|NCT01207076|CD45+ disease
370326|NCT01207063|Radiotherapy
370327|NCT01207063|NSCLC
370328|NCT01207063|Stage II-III non-small cell lung cancer
370329|NCT01207050|sleep disorders
370330|NCT01207050|traumatic brain injury
370331|NCT01207024|knee arthrosis
370332|NCT01207024|obesity
370333|NCT01207024|MRI
370334|NCT01207024|bariatric surgery
370335|NCT01206998|preterm labor
370336|NCT01206998|progesterone
370337|NCT01206998|tocolysis
370338|NCT01206998|cervical length
370339|NCT01206985|Paracetamol
370340|NCT01206985|per-oral mucosa PMB
370341|NCT01206985|No disease, healthy volunteers
370342|NCT01206972|venous thromboembolism
370343|NCT01206972|prevention
370344|NCT01206972|orthopaedic surgery
370345|NCT01206959|BP
370346|NCT01206946|Respiratory distress
370347|NCT01206946|Antenatal steroids
370348|NCT01206946|late preterm
370349|NCT01206933|HIV/HCV Coinfection
370350|NCT01206933|Tat Protein
370351|NCT01206933|HCV
370352|NCT01206920|HIV
370353|NCT01206920|AIDS
370354|NCT01206920|Co-morbidities
370355|NCT01206907|sickle cell anemia
370356|NCT01206907|juvenile rheumatoid arthritis
370357|NCT01206907|burn victim
370358|NCT01206907|cancer
370359|NCT01206907|Chronic pain of malignant or non-malignant etiology
370360|NCT01206894|lung cancer
370361|NCT01206894|chest wall invasion
370362|NCT01206894|transthoracic ultrasound
370363|NCT01206881|breast cancer
370364|NCT01206881|neoadjuvant
370365|NCT01206881|liposomal doxorubicin
370366|NCT01206881|PET scan
370367|NCT01206868|kidney, transplantation, surgery, complications, lymphocele, fluid collections.
370368|NCT01206855|MIST Therapy
370369|NCT01206842|functional capacity
370370|NCT01206842|training
370371|NCT01206842|neurocognition
370372|NCT01206829|Hearing Impaired Persons
370373|NCT01206829|Tinnitus
370374|NCT01206829|Life Change Events
370375|NCT01206829|Adaptation, Psychological
370376|NCT01206829|Rehabilitation, Vocational
370377|NCT01206829|Cognitive Therapy
370378|NCT01206829|Avoidance Learning
370379|NCT01206829|Escape Reaction
370380|NCT01206803|ovarian stimulation
370381|NCT01206803|recombinant FSH
370382|NCT01206803|GnRH-antagonist
370383|NCT01206803|corifollitropin alfa
370384|NCT01206790|PTSD
370385|NCT01206790|Narrative Exposure Therapy
370386|NCT01206790|torture victims
370387|NCT01206790|immune system
370388|NCT01206777|Hypersensitivity Reactions
370389|NCT01206777|B-cell malignancies
370390|NCT01206764|RCC,
370391|NCT01206764|mTOR pathway,
370392|NCT01206764|angiogenesis,
370393|NCT01206764|PFS,
370394|NCT01206764|partial response [PR] + complete response [CR])
370395|NCT01206764|metastatic recurrent renal cell carcinoma
370396|NCT01206764|metastatic unresectable renal cell carcinoma
370397|NCT01206725|Diabetes type 2
370398|NCT01206725|exercise
370399|NCT01206725|tissue Doppler velocity
370400|NCT01206712|Diabetes Mellitus Type 2
370401|NCT01206712|insulin glargine
370402|NCT01206712|Metformin
370403|NCT01206686|seasonal influenza
370404|NCT01206686|behavioral economics
370405|NCT01206686|nudge
370406|NCT01206686|implementations intentions
370407|NCT01206686|vaccination
370408|NCT01206621|dyspnea
370409|NCT01206621|COPD
370410|NCT01206621|CHF
370411|NCT01206621|asthma
370412|NCT01206608|Breast augmentation
370413|NCT01206608|Pain
370414|NCT01206608|Analgesia
370415|NCT01206595|Postoperative Pain
370416|NCT01206595|Bunionectomy
370417|NCT01206595|Analgesia
370418|NCT01206569|glomerulonephritis
370419|NCT01206569|systemic lupus erythematosus
370420|NCT01206556|HUMAN PAPILLOMA VIRUS
370421|NCT01206556|HPV
370422|NCT01206543|Craniopharyngioma
370423|NCT01206543|Surgery
370424|NCT01206543|Intraoperative imaging
370425|NCT01206543|Rate of total removal
370426|NCT01206530|histologically documented
370427|NCT01206530|advanced
370428|NCT01206530|metastatic
370429|NCT01206530|adenocarcinoma
370430|NCT01206530|colon
370431|NCT01206530|rectum
370432|NCT01206517|asenapine
370433|NCT01206517|pediatric schizophrenia
370434|NCT01206517|bipolar I disorder
370435|NCT01206504|West Nile virus
370436|NCT01206504|WNV
370437|NCT01206504|Encephalitis
370438|NCT01206504|Meningitis
370439|NCT01206504|Acute Flaccid Paralysis
370440|NCT01206504|Monoclonal Antibody
370441|NCT01206504|WNND
370442|NCT01206504|West Nile Neuroinvasive Disease
370443|NCT01206504|Accidental Exposure to West Nile Virus
370444|NCT01206452|Atrial Fibrillation; Ablation
370445|NCT01206426|Urothelial, cancer, cisplatin, neoadjuvant, chemotherapy, germline
370446|NCT01206413|overweight; treatment; women
370447|NCT01206400|eugonadal, testosterone
370448|NCT01206374|Vitiligo Vulgaris
370449|NCT01206361|Real world
370450|NCT01206361|observational
370451|NCT01206361|retrospective
370452|NCT01206361|database analysis
370453|NCT01206348|Acne
370454|NCT01206335|Cancer Cachexia
370455|NCT01206335|Anorexia
370456|NCT01206335|Advanced Malignancies
370457|NCT01206335|Weight Loss
370458|NCT01206335|Fatigue
370459|NCT01206335|Karnofsky
370460|NCT01206335|C-Reactive Protein
370461|NCT01206335|Simmonds Functional Assessment
370462|NCT01206322|diabetes, blood flow, brain perfusion, cognitive function
370463|NCT01206309|Graft vs Host Disease
370464|NCT01206309|Allogeneic Hematopoietic Cell Transplantation
370465|NCT01206309|Bone Marrow Transplantation
370466|NCT01206309|Peripheral Blood Stem Cell Transplantation
370467|NCT01206309|Umbilical Cord Blood Stem Cell Transplantation
370468|NCT01206296|Adjuvant
370469|NCT01206296|Intraperitoneal
370470|NCT01206296|Gemcitabine
370471|NCT01206296|Pancreas
370472|NCT01206296|Adenocarcinoma
370473|NCT01206283|traumatic brain injury
370474|NCT01206283|subarachnoid hemorrhage
370475|NCT01206283|secondary brain ischemia
370476|NCT01206283|microdialysis
370477|NCT01206283|modified Lund concept
370478|NCT01206283|cerebral perfusion pressure
370479|NCT01206283|intracranial pressure
370480|NCT01206270|Klinefelter
370481|NCT01206270|Leydig
370482|NCT01206270|Testicular Tumor
370483|NCT01206270|LH
370484|NCT01206270|Infertility
370485|NCT01206257|Survey
370486|NCT01206257|Angiography
370487|NCT01206257|ADR
370488|NCT01206257|Image quality
370489|NCT01206244|dry eye
370490|NCT01206244|tear meniscus
370491|NCT01206244|tear osmolarity
370492|NCT01206231|Standard daily practice in managing patients with hypercholesterolemia
370493|NCT01206218|Gastric Cancer, BRCA1
370494|NCT01206205|De novo Multiple Myeloma
370495|NCT01206205|Bortezomib
370496|NCT01206205|Lenalidomide
370497|NCT01206205|induction therapy
370498|NCT01206205|consolidation therapy
370499|NCT01206205|maintenance therapy
370500|NCT01206205|High dose therapy
370501|NCT01206205|frontline therapy including new drugs and high dose therapy
370502|NCT01206192|Intimate Terrorism
370503|NCT01206192|Situational couple violence
370504|NCT01206192|Mental health
370505|NCT01206192|Chinese
370506|NCT01206192|Women
370507|NCT01206179|nonunion fracture bone formation pain relief
370508|NCT01206166|Randomized trial
370509|NCT01206166|Parental nutrition
370510|NCT01206166|Enteral nutrition
370511|NCT01206166|Intensive care unit
370512|NCT01206166|BMI < 25 or ≥ 35
370513|NCT01206114|2009 H1N1 influenza
370514|NCT01206114|vaccination
370515|NCT01206114|pandemic
370516|NCT01206114|effectiveness
370517|NCT01206075|Beta Thalassemia Major
370518|NCT01206075|Hematopoietic Stem Cell Mobilization
370519|NCT01206075|Gene Transfer Techniques
370520|NCT01206062|blood pressure
370521|NCT01206062|antihypertensive
370522|NCT01206062|systolic
370523|NCT01206062|diastolic
370524|NCT01206062|heart failure
370525|NCT01206062|myocardial infarction
370526|NCT01206062|stroke
370527|NCT01206062|chronic kidney disease
370528|NCT01206062|dementia
370529|NCT01206062|cognitive decline
370530|NCT01206049|Cholangiocarcinoma
370531|NCT01206049|Inoperable
370532|NCT01206049|KRAS mutation
370533|NCT01206049|Biological treatment
370534|NCT01206049|Combination chemotherapy
370535|NCT01206049|Monoclonal antibody
370536|NCT01206036|castration
370537|NCT01206036|prostate cancer
370538|NCT01206036|castration resistant prostate cancer
370539|NCT01206036|PSA
370540|NCT01206036|Docetaxel
370541|NCT01206036|Temsirolimus
370542|NCT01206036|disease progression free survival
370543|NCT01206036|DPFS
370544|NCT01206036|dose escalation
370545|NCT01206023|Multiple Sclerosis
370546|NCT01206023|Breath
370547|NCT01206023|Diagnosis
370548|NCT01206023|Discrimination MS/healthy subj. via exhaled breath samples
370549|NCT01206010|Tobacco Dependence
370550|NCT01206010|Smoking cessation
370551|NCT01206010|Varenicline
370552|NCT01206010|Tailored dosing
370553|NCT01205997|magnesium
370554|NCT01205997|fentanyl
370555|NCT01205997|intrathecal
370556|NCT01205997|pain
370557|NCT01205984|Chronic rhinosinusitis
370558|NCT01205984|Computed tomography scan
370559|NCT01205984|Methylprednisolone
370560|NCT01205958|Cervical pain
370561|NCT01205958|Neck pain
370562|NCT01205958|western medicine
370563|NCT01205958|oriental medicine
370564|NCT01205958|acupuncture
370565|NCT01205958|needle
370566|NCT01205945|Aortic aneurysm, abdominal
370567|NCT01205945|Screening
370568|NCT01205945|Mortality
370569|NCT01205932|venous thromboembolism
370570|NCT01205932|prevention
370571|NCT01205932|othopaedic surgery
370572|NCT01205919|Tinnitus
370573|NCT01205919|Internet Training
370574|NCT01205919|Cognitive-Behavior Therapy
370575|NCT01205919|CBT
370576|NCT01205906|Tinnitus
370577|NCT01205906|Internet Training
370578|NCT01205906|Cognitive-Behavior Therapy
370579|NCT01205906|CBT
370580|NCT01205880|combination treatment
370581|NCT01205880|topical corticosteroid
370582|NCT01205880|vitamin D analogue
370583|NCT01205880|clobex
370584|NCT01205880|vectical
370585|NCT01205880|clobetasol
370586|NCT01205880|calcitriol
370587|NCT01205867|Butyrylcholinesterase deficiency
370588|NCT01205867|tolerability
370589|NCT01205867|safety
370590|NCT01205867|AZD8848
370591|NCT01205867|pharmacokinetics
370592|NCT01205867|pharmacodynamics
370593|NCT01205867|BChE deficient subjects and matched control subject
370594|NCT01205854|rheumatoid arthritis
370595|NCT01205854|ultrasonography
370596|NCT01205854|remission
370597|NCT01205854|imaging remission
370598|NCT01205854|tight control
370599|NCT01205854|treat to target
370600|NCT01205841|Ottawa Ankle and Foot Rules
370601|NCT01205841|Buffalo Rule
370602|NCT01205841|Bernese Ankle Rules
370603|NCT01205841|Low Risk Exam
370604|NCT01205841|Malleolar Zone Algorithm
370605|NCT01205841|Clinical decision rule
370606|NCT01205841|Ankle injury
370607|NCT01205841|Ankle sprain
370608|NCT01205841|Inversion trauma
370609|NCT01205828|liver cancer
370610|NCT01205828|hepatocellular
370611|NCT01205828|temozolomide
370612|NCT01205828|veliparib
370613|NCT01205802|patency, hepatic venous congestion, liver transplantation
370614|NCT01205789|Drug eluting stents
370615|NCT01205789|Stents
370616|NCT01205789|Angioplasty
370617|NCT01205789|Left Main Coronary Artery Disease
370618|NCT01205776|Drug eluting stents
370619|NCT01205776|Stents
370620|NCT01205776|Unprotected Left Main Coronary Artery Disease
370621|NCT01205776|Coronary artery bypass graft surgery
370622|NCT01205737|DLBCL
370623|NCT01205737|pharmacokinetics
370624|NCT01205737|pharmacodynamics
370625|NCT01205711|recurrent colon cancer
370626|NCT01205711|stage IV colon cancer
370627|NCT01205711|recurrent rectal cancer
370628|NCT01205711|stage IV rectal cancer
370629|NCT01205672|Endometrium
370630|NCT01205672|Gynecologic malignancy
370631|NCT01205672|Endometrial adenocarcinoma
370632|NCT01205672|Insulin/glucose metabolism
370633|NCT01205672|Metformin
370634|NCT01204684|dendritic cells
370635|NCT01204684|glioma
370636|NCT01204684|vaccine
370637|NCT01204684|glioma of WHO Grade III or IV
370638|NCT01204671|influenza infection
370639|NCT01204671|GSK Biologicals influenza vaccine GSK2321138A
370640|NCT01204658|Haemophilus influenzae
370641|NCT01204658|Streptococcus pneumoniae
370642|NCT01204658|immunogenicity
370643|NCT01204658|Pneumococcal vaccine
370644|NCT01204658|infants
370645|NCT01204658|safety
370646|NCT01204619|peritoneal dialysis
370647|NCT01205646|prostate cancer
370648|NCT01205646|metastatic
370649|NCT01205646|zoledronate
370650|NCT01205646|zometa
370651|NCT01205633|neurodegenerative disease
370652|NCT01205633|neurovascular disease
370653|NCT01205633|fatigue
370654|NCT01205633|Hubbard Foundation
370655|NCT01205633|angioplasty
370656|NCT01205620|CABG
370657|NCT01205607|traumatic brain injury
370658|NCT01205594|CABG surgery
370659|NCT01205581|Fluzone
370660|NCT01205581|Trivalent Influenza Vaccine
370661|NCT01205555|intra uterine insemination
370662|NCT01205529|Atrial Fibrillation
370663|NCT01205529|ST elevation
370664|NCT01205529|Genotype
370665|NCT01205503|chemobrain
370666|NCT01205503|Oxidative Stress
370667|NCT01205503|Mesna
370668|NCT01205477|Anserine bursitis
370669|NCT01205464|Persistent symptoms
370670|NCT01205464|Doxycycline
370671|NCT01205464|Placebo
370672|NCT01205464|Neuroborreliosis
370673|NCT01205451|GSK1358820
370674|NCT01205451|upper limb
370675|NCT01205451|spasticity
370676|NCT01205451|post-stroke
370677|NCT01205438|SLE
370678|NCT01205438|Systemic Lupus Erythematosis
370679|NCT01205438|Lupus
370680|NCT01205438|autoimmune disease
370681|NCT01205438|LY2127399
370682|NCT01205438|Immune System Disease
370683|NCT01205425|Computed coronary angiography
370684|NCT01205425|Stent implantation
370685|NCT01205425|IVUS
370686|NCT01205386|CTO
370687|NCT01205386|peripheral artery occlusive disease
370688|NCT01205386|PAOD
370689|NCT01205386|SFA
370690|NCT01205386|superficial femoral artery
370691|NCT01205360|Analgesia, labour;
370692|NCT01205360|Analgesic techniques, epidural;
370693|NCT01205360|Drug delivery, intermittent bolus;
370694|NCT01205360|Anesthetics local, Bupivacaine;
370695|NCT01205360|Analgesics opioid, Fentanyl;
370696|NCT01205347|Statin
370697|NCT01205347|Myocardial infarction
370698|NCT01205347|Insulin sensitivity
370699|NCT01205334|Glioblastoma multiforme
370700|NCT01205334|GBM
370701|NCT01205334|Brain Cancer
370702|NCT01205334|CTL
370703|NCT01205321|Neoplasm
370704|NCT01205321|PET/CT diagnosis
370705|NCT01205321|PET tracer
370706|NCT01205308|Plant stanols
370707|NCT01205308|type 1 diabetes
370708|NCT01205308|sterol metabolism
370709|NCT01205308|cholesterol
370710|NCT01205295|hip
370711|NCT01205295|shoulder
370712|NCT01205295|mental disorders
370713|NCT01205295|anxiety
370714|NCT01205295|concern
370715|NCT01205295|efficacy of treatment
370716|NCT01205282|ASD
370717|NCT01205269|Chronic Obstructive Pulmonary Disease (COPD)
370718|NCT01205269|safety
370719|NCT01205269|inhalation
370720|NCT01205269|long-acting muscarinic receptor antagonist (LAMA)
370721|NCT01205256|Methadone pharmacokinetics in adolescents
370722|NCT01205243|Abacavir
370723|NCT01205243|post-marketing surveillance
370724|NCT01205230|Esomeprazole
370725|NCT01205230|Pharmacogenetics
370726|NCT01205230|Pharmacokinetics
370727|NCT01205230|Ketoconazole
370728|NCT01205230|Pazopanib
370729|NCT01205230|Drug Interaction
370730|NCT01205230|Safety
370731|NCT01205230|Solid Tumors
370732|NCT01205217|lapatinib
370733|NCT01205217|epirubicin
370734|NCT01205217|cyclophosphamide
370735|NCT01205217|trastuzumab
370736|NCT01205217|paclitaxel
370737|NCT01205217|neoadjuvant therapy
370738|NCT01205217|Breast Cancer
370739|NCT01205204|Clonidine
370740|NCT01205204|Fentanyl
370741|NCT01205204|Bupivacaine
370742|NCT01205204|Spinal Anesthesia
370743|NCT01205204|Lower Segment Caesarian Section
370744|NCT01205191|Cognitive behavioural therapy
370745|NCT01205191|Anxiety
370746|NCT01205191|Primary care
370747|NCT01205191|Effectiveness trial
370748|NCT01205191|Cell-phone supported therapy
370749|NCT01205152|Hypophosphatasia
370750|NCT01205152|HPP
370751|NCT01205152|Bone Disease
370752|NCT01205152|Soft Bones
370753|NCT01205152|Low Alkaline Phosphatase
370754|NCT01205152|genetic metabolic disorder
370755|NCT01205152|alkaline phosphatase
370756|NCT01205152|tissue non-specific alkaline phosphatase
370757|NCT01205152|rickets
370758|NCT01205152|osteomalacia
370759|NCT01205139|TMC435-TiDP16-C114
370760|NCT01205139|TMC435-C114
370761|NCT01205139|TMC435
370762|NCT01205139|HCV
370763|NCT01205139|Hepatitis C
370764|NCT01205126|Pain
370765|NCT01205126|Hydromorphone hydrochloride
370766|NCT01205126|Oxycodone hydrochloride
370767|NCT01205100|Gastrointestinal Diseases
370768|NCT01205100|Irritable Bowel Syndrome
370769|NCT01205100|Behavioral Research
370770|NCT01205100|Biofeedback
370771|NCT01205074|Patients with chronic liver disease and cirrhosis
370772|NCT01205035|Idiopathic Parafoveal Telangiectasia
370773|NCT01205035|Macular Telangiectasia
370774|NCT01205035|Macula Lutea/pathology
370775|NCT01205035|Retinal Diseases/pathology
370776|NCT01205035|Retinal Pigments/metabolism
370777|NCT01205035|Telangiectasis/metabolism
370778|NCT01205035|Telangiectasis/pathology
370779|NCT01205009|in-vitro fertilization
370780|NCT01205009|poor responders
370781|NCT01205009|human chorionic gonadotropin
370782|NCT01205009|Fertility Agents, Female
370783|NCT01204996|monoclonal antibody
370784|NCT01204996|solid tumor
370785|NCT01204996|chemotherapy
370786|NCT01204996|standard of care
370787|NCT01204983|very low birth weight infant
370788|NCT01204983|donor human milk
370789|NCT01204970|Confocal Laser Scanning Microendoscopy
370790|NCT01204970|Small airways
370791|NCT01204970|COPD
370792|NCT01204970|Lung transplantation
370793|NCT01204957|Homocysteine
370794|NCT01204957|Insulin-like growth factor
370795|NCT01204957|Insulin-like growth factor binding protein
370796|NCT01204957|Serum estrogen
370797|NCT01204957|Urinary phytoestrogens
370798|NCT01204957|Thyroid hormones
370799|NCT01204931|reflux
370800|NCT01204931|gastroesophageal reflux disease
370801|NCT01204931|GERD
370802|NCT01204918|MDD
370803|NCT01204918|Depression
370804|NCT01204918|Treatment refractory
370805|NCT01204918|Glutamate
370806|NCT01204918|Riluzole
370807|NCT01204918|Major depressive disorder
370808|NCT01204918|psychopharmacology
370809|NCT01204918|rilutek
370810|NCT01204905|HIV-1
370811|NCT01204905|CD4
370812|NCT01204905|Viral Load
370813|NCT01204905|Human Immunodeficiency Virus (HIV)
370814|NCT01204866|Allergic-Like Reaction
370815|NCT01204866|Selected Formulation Components
370816|NCT01204853|sitaxentan sodium hypertension
370817|NCT01204840|in vitro fertilization
370818|NCT01204840|IVF
370819|NCT01204840|poor responder
370820|NCT01204840|growth hormone
370821|NCT01204840|Poor responders to in vitro fertilization treatments
370822|NCT01204827|Patients with chronic HBeAg negative hepatitis B virus infection treated with Sebivo (Telbivudine)
370823|NCT01204814|HIV
370824|NCT01204814|Drug resistance
370825|NCT01204814|mutations
370826|NCT01204814|ARV's
370827|NCT01204801|Cancer
370828|NCT01204801|Breast Cancer
370829|NCT01204801|Breast Tumor
370830|NCT01204801|Breast Neoplasm
370831|NCT01204801|Neoplasms by Site
370832|NCT01204801|Neoplasms
370833|NCT01204801|Breast Diseases
370834|NCT01204801|Breast Conserving Surgery
370835|NCT01204801|Breast Conservation
370836|NCT01204801|Partial Mastectomy
370837|NCT01204801|Lumpectomy
370838|NCT01204801|Mastectomy
370839|NCT01204801|Surgery
370840|NCT01204801|Neoadjuvant Therapy
370841|NCT01204801|Primary Therapy
370842|NCT01204801|Neoadjuvant Systemic Therapy
370843|NCT01204801|Thermotherapy
370844|NCT01204801|Fever Therapy
370845|NCT01204801|Hot Temperature
370846|NCT01204801|Hyperthermia
370847|NCT01204801|Hyperthermia, Therapeutic
370848|NCT01204801|Hyperthermia, Local
370849|NCT01204801|Hyperthermia, Induced
370850|NCT01204801|Therapeutic Hyperthermia
370851|NCT01204801|Microwave
370852|NCT01204801|Focused Microwave
370853|NCT01204801|Focused Microwave Thermotherapy
370854|NCT01204801|Minimally Invasive
370855|NCT01204801|Doxorubicin
370856|NCT01204801|Epirubicin
370857|NCT01204801|Epidoxirubicin
370858|NCT01204801|Immunosuppresive Agent
370859|NCT01204801|Immunologic Factors
370860|NCT01204801|Physiological Effects of Drugs
370861|NCT01204801|Chemotherapy
370862|NCT01204801|Drug Therapy
370863|NCT01204801|Pharmalogic Actions
370864|NCT01204801|Antirheumatic Agents
370865|NCT01204801|Therapeutic Uses
370866|NCT01204801|Antineoplastic Agents, Alkylating
370867|NCT01204801|Alkylating Agents
370868|NCT01204801|Molecular Mechanisms of Pharmacological Action
370869|NCT01204801|Antineoplastic Agents
370870|NCT01204801|Myeloblative Agonists
370871|NCT01204801|Antibiotics, Antineoplastic
370872|NCT01204801|Anthracycline Agents
370873|NCT01204788|Acute myelogenous leukemia
370874|NCT01204788|AML
370875|NCT01204788|Undifferentiated and bi-phenotypic leukemia
370876|NCT01204788|High-risk myelodysplastic syndrome
370877|NCT01204788|Chronic myelogenous leukemia
370878|NCT01204788|Infection
370879|NCT01204788|Radiated Prophylactic White Cell Transfusions
370880|NCT01204788|Therapeutic Radiated White Cell Transfusion
370881|NCT01204788|prophylactic antibiotics
370882|NCT01204749|AMGEN
370883|NCT01204749|AMG 386
370884|NCT01204749|Angiogenesis Inhibitors
370885|NCT01204749|Fallopian Tube Cancer
370886|NCT01204749|Primary Peritoneal Cancer
370887|NCT01204749|Paclitaxel
370888|NCT01204749|Ovarian Cancer
370889|NCT01204749|TRINOVA-1
370890|NCT01204736|tendon transfer
370891|NCT01204736|elbow
370892|NCT01204723|Marijuana Abuse
370893|NCT01204723|Nicotine Dependence
370894|NCT01204723|Nicotine Withdrawal
370895|NCT01204723|neurokinin Receptor
370896|NCT01204723|NK1 Receptor antagonist
370897|NCT01204723|Substance P
370898|NCT01204723|Recurrence
370899|NCT01204723|Substance Withdrawal Syndrome
370900|NCT01204723|Substance-Related Disorders
370901|NCT01204723|Disorders of Environmental Origin
370902|NCT01204723|Mental Disorders
370903|NCT01204723|Disease Attributes
370904|NCT01204723|Pathologic Processes
370905|NCT01204723|Tetrahydrocannabinol
370906|NCT01204723|Therapeutic Uses
370907|NCT01204723|Psychotropic Drugs
370908|NCT01204723|Analgesics, Non-Narcotic
370909|NCT01204723|Analgesics
370910|NCT01204723|Sensory System Agents
370911|NCT01204723|Peripheral Nervous System Agents
370912|NCT01204723|Neurotransmitter Agents
370913|NCT01204723|Molecular Mechanisms of Pharmacological Action
370914|NCT01204723|Narcotic Antagonists
370915|NCT01204723|cannabis
370916|NCT01204710|Prostate Cancer
370917|NCT01204567|HLRQ
370918|NCT01204567|elderly
370919|NCT01204567|aerobic fitness
370920|NCT01204567|cognitive capacity
370921|NCT01204554|perforator flaps
370922|NCT01204541|Non-exudative age-related macular degeneration
370923|NCT01204528|Dysfunction in CKD
370924|NCT01204515|IBS
370925|NCT01204515|irritable bowel syndrome
370926|NCT01204515|abdominal pain
370927|NCT01204515|urgency
370928|NCT01204515|bloating
370929|NCT01204515|diarrhea
370930|NCT01204515|constipation
370931|NCT01204502|Gene therapy
370932|NCT01204502|Haploidentical
370933|NCT01204502|Bone marrow transplant
370934|NCT01204502|Graft versus host disease
370935|NCT01204502|haploidentical stem cell transplantation
370936|NCT01204502|T-cell suicide gene therapy
370937|NCT01204450|recurrent childhood brain tumor
370938|NCT01204450|recurrent childhood rhabdomyosarcoma
370939|NCT01204450|recurrent childhood soft tissue sarcoma
370940|NCT01204450|recurrent childhood supratentorial primitive neuroectodermal tumor
370941|NCT01204450|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
370942|NCT01204450|recurrent neuroblastoma
370943|NCT01204450|recurrent osteosarcoma
370944|NCT01204450|unspecified childhood solid tumor, protocol specific
370945|NCT01204437|adjuvant chemotherapy
370946|NCT01204437|primary carcinoma
370947|NCT01204437|elderly non frail patients
370948|NCT01204437|EC
370949|NCT01204437|CMF
370950|NCT01204437|Capecitabine
370951|NCT01204437|Nab-Paclitaxel
370952|NCT01204424|minimal invasive
370953|NCT01204424|sinus floor augmentation
370954|NCT01204424|sinuslift
370955|NCT01204424|dental implants
370956|NCT01204411|Efficacy
370957|NCT01204411|Safety
370958|NCT01204411|Artesunate-amodiaquine
370959|NCT01204411|Malaria
370960|NCT01204411|Plasmodium falciparum
370961|NCT01204411|Malnutrition
370962|NCT01204385|Non-typeable Haemophilus Influenzae
370963|NCT01204385|Acute Otitis Media
370964|NCT01204385|Streptococcus Pneumoniae
370965|NCT01204385|etiology
370966|NCT01204372|Metastatic pancreatic adenocarcinoma
370967|NCT01204372|First-line chemotherapy
370968|NCT01204372|Combination chemotherapy
370969|NCT01204372|Targeted agents
370970|NCT01204346|adolescents
370971|NCT01204346|MBT
370972|NCT01204346|depression
370973|NCT01204346|emerging personality disorder
370974|NCT01204333|Cerebral venous and sinus thrombosis
370975|NCT01204333|Cerebral venous thrombosis
370976|NCT01204333|Sinus Thrombosis, Intracranial
370977|NCT01204333|Endovascular thrombolysis
370978|NCT01204333|Thrombolysis
370979|NCT01204333|Thrombectomy
370980|NCT01204320|Restenosis
370981|NCT01204320|POBA
370982|NCT01204320|Stenting
370983|NCT01204320|Paclitaxel
370984|NCT01204281|Proportional Assist Ventilation plus
370985|NCT01204281|Acute respiratory failure
370986|NCT01204281|Mechanical ventilation
370987|NCT01204268|cerebral ischemia
370988|NCT01204268|sevoflurane preconditioning
370989|NCT01204268|intracranial aneurysm surgery
370990|NCT01204255|healthy, no evidence of disease
370991|NCT01204242|Breast Cancer
370992|NCT01204229|Alcohol Consumption
370993|NCT01204229|Social Anxiety
370994|NCT01204229|Depression
370995|NCT01204229|Brief Intervention
370996|NCT01204229|Motivational Interviewing
370997|NCT01204229|Cognitive Behavioral Therapy
370998|NCT01204229|Sub-Clinical Social Anxiety
370999|NCT01204229|Sub-Clinical Depression
371000|NCT01204216|Hemoglobin A1c
371001|NCT01204216|HbA1c
371002|NCT01204216|glycated serum proteins
371003|NCT01204216|fructosamine
371004|NCT01204216|glycated albumin
371005|NCT01204216|glycation gap
371006|NCT01204203|mesothelioma
371007|NCT01204203|zoledronic acid
371008|NCT01204203|zometa
371009|NCT01204203|bisphosphonate therapy
371010|NCT01204203|CT scan
371011|NCT01204203|PET scan
371012|NCT01204190|Administration
371013|NCT01204190|Cutaneous
371014|NCT01204177|Hepatocellular carcinoma (HCC)
371015|NCT01204177|MEK inhibitor
371016|NCT01204177|Sorafenib
371017|NCT01204177|Disease control rate (DCR)
371018|NCT01204177|Safety
371019|NCT01204164|AML
371020|NCT01204164|ALL
371021|NCT01204164|MDS
371022|NCT01204164|CML in blast crisis
371023|NCT01204164|Multiple Myeloma
371024|NCT01204164|Carfilzomib refractory
371025|NCT01204138|RA, treatment, TNF, cytokines
371026|NCT01204112|Drug-Drug Interaction
371027|NCT01204112|Tasocitinib (CP-690
371028|NCT01204112|550)
371029|NCT01204112|Rifampin
371030|NCT01204112|Healthy Volunteers
371031|NCT01204099|PX-866
371032|NCT01204099|Non small cell lung cancer
371033|NCT01204099|solid tumors
371034|NCT01204099|Squamous cell cancer of the head and neck
371035|NCT01204099|docetaxel
371036|NCT01204099|NSCLC
371037|NCT01204099|taxotere
371038|NCT01204099|SCCHN
371039|NCT01204099|PI-3K
371040|NCT01204099|PI3 kinase
371041|NCT01204099|PI3K
371042|NCT01204086|Major Depressive Disorder
371043|NCT01204086|Antidepressants
371044|NCT01204086|Pharmacogenetics
371045|NCT01204086|venlafaxine
371046|NCT01204086|fluoxetine
371047|NCT01204060|Nasal Allergen Lipopolysaccharide Inflammation Asthma
371048|NCT01204034|COPD
371049|NCT01204034|Formoterol
371050|NCT01204034|Beclomethasone Dipropionate
371051|NCT01204034|Computational Fluid Dynamics
371052|NCT01204034|Functional Imaging
371053|NCT01204034|Central and Peripheral Airways
371054|NCT01204034|BODE index
371055|NCT01204034|COPD Assessment Test (CAT)
371056|NCT01204034|Borg CR10 scale
371057|NCT01204021|Stress
371058|NCT01204021|loneliness
371059|NCT01204021|social isolation
371060|NCT01204021|autonomic activity
371061|NCT01204021|inflammation
371062|NCT01204021|Perceived social isolation
371063|NCT01204021|Chronic stress
371064|NCT01203982|CIMT
371065|NCT01203982|IVUS-VH
371066|NCT01203982|Coronary artery disease
371067|NCT01203956|AutoAdjust
371068|NCT01203956|SmartFlex
371069|NCT01203956|Apnea Hypopnea Index
371070|NCT01203956|Patient reported outcomes
371071|NCT01203943|Idiopathic Pulmonary Fibrosis
371072|NCT01203943|Pulmonary Fibrosis
371073|NCT01203943|Fibrosis
371074|NCT01203943|Interstitial Lung Disease
371075|NCT01203943|Lung Diseases, Interstitial
371076|NCT01203943|CC-930
371077|NCT01203930|CLL
371078|NCT01203930|SLL
371079|NCT01203930|GS-1101
371080|NCT01203930|CAL-101
371081|NCT01203930|Phosphatidylinositol 3-kinase (PI3K)
371082|NCT01203930|Rituximab
371083|NCT01203930|Rituxan
371084|NCT01203917|Gefitinib
371085|NCT01203917|EGFR TKI
371086|NCT01203917|efficacy
371087|NCT01203917|Caucasian patients
371088|NCT01203917|EGFR mutation positive advanced NSCLC
371089|NCT01203917|safety
371090|NCT01203904|bronchial asthma, Pulmicort, long term use, pediatrics
371091|NCT01203891|SPECT
371092|NCT01203891|Imaging
371093|NCT01203891|Healthy brain
371094|NCT01203891|regional cerebral blood flow
371095|NCT01203878|Imiquimod
371096|NCT01203878|Photodynamic therapy
371097|NCT01203878|Actinic keratoses
371098|NCT01203878|Sequential therapy
371099|NCT01203878|Therapeutic uses
371100|NCT01203865|Fibromyalgia
371101|NCT01203865|Fatigue
371102|NCT01203852|hypertension
371103|NCT01203852|antihypertensive drug
371104|NCT01203852|pharmacogenetics
371105|NCT01203852|genetics
371106|NCT01203852|blood pressure
371107|NCT01203852|glucose
371108|NCT01203839|stage 1 breast cancer
371109|NCT01203839|invasive ductal breast
371110|NCT01203839|Partial Breast Irradiation (PBI)
371111|NCT01203839|radiation
371112|NCT01203839|10-114
371113|NCT01203826|Hypophosphatasia
371114|NCT01203826|HPP
371115|NCT01203826|Bone Disease
371116|NCT01203826|Soft Bones
371117|NCT01203826|Low Alkaline Phosphatase
371118|NCT01203826|genetic metabolic disorder
371119|NCT01203826|alkaline phosphatase
371120|NCT01203826|tissue non-specific alkaline phosphatase
371121|NCT01203826|rickets
371122|NCT01203826|osteomalacia
371123|NCT01203813|Chronic kidney disease
371124|NCT01203813|Quality improvement
371125|NCT01203813|Self management support
371126|NCT01203813|Electronic health records
371127|NCT01203813|Clinical decision support
371128|NCT01203813|Electronic reminders
371129|NCT01203813|Patient outreach
371130|NCT01203787|Hepatocellular Carcinoma
371131|NCT01203787|HCC
371132|NCT01203787|Liver Cancer
371133|NCT01203774|Diabetes
371134|NCT01203761|loneliness
371135|NCT01203735|Non-small-cell lung cancer
371136|NCT01203735|Valproic acid
371137|NCT01203735|Chemotherapy
371138|NCT01203735|Radiotherapy
371139|NCT01203722|Reduced intensity
371140|NCT01203722|partially HLA mismatched allogeneic BMT
371141|NCT01203722|Acute leukemias
371142|NCT01203722|Chronic leukemias
371143|NCT01203722|Myelodysplasia
371144|NCT01203722|Lymphomas
371145|NCT01203722|Unrelated or non-first-degree related donors
371146|NCT01203709|lupus
371147|NCT01203709|nephritis
371148|NCT01203709|glomerulonephritis
371149|NCT01203709|nephropathy
371150|NCT01203709|refractory
371151|NCT01203696|Clopidogrel
371152|NCT01203696|Platelet reactivity
371153|NCT01203696|Amlodipine
371154|NCT01203683|depression
371155|NCT01203670|Glomerular filtration rate (GFR)
371156|NCT01203670|Aspartate Amino Transferase (ASAT)
371157|NCT01203670|Alanine Amino transferase (ALAT)
371158|NCT01203670|gamma Glutamyl transpeptidase (gamma GT)
371159|NCT01203670|Lipase
371160|NCT01203670|Amylase
371161|NCT01203657|exercise
371162|NCT01203657|physical activity
371163|NCT01203657|tai chi
371164|NCT01203644|Postoperative pain
371165|NCT01203644|Analgesia
371166|NCT01203618|Resectable, non-functioning pituitary adenoma
371167|NCT01203618|Pituitary tumor
371168|NCT01203618|Pituitary adenoma
371169|NCT01203618|Pituitary macroadenoma
371170|NCT01203605|Operative surgical procedures
371171|NCT01203605|mortality
371172|NCT01203605|adverse effects
371173|NCT01203605|Postoperative complications
371174|NCT01203605|Epidemiological Study
371175|NCT01203592|Congenital myasthenic syndrome
371176|NCT01203592|Albuterol
371177|NCT01203592|Neuromuscular transmission
371178|NCT01203579|CDT-Lung,CT scan,lung cancer detection
371179|NCT01203566|Single incision laparoscopic surgery
371180|NCT01203566|Single site access laparoscopic surgery
371181|NCT01203566|SILS
371182|NCT01203566|Single-port access
371183|NCT01203566|Laparoendoscopic single site surgery
371184|NCT01203566|Appendectomy
371185|NCT01203553|Incisional hernias
371186|NCT01203553|Prophylaxis
371187|NCT01203553|Preperitoneal mesh
371188|NCT01203527|H1N1 influenza
371189|NCT01203527|Swine flu
371190|NCT01203527|Oseltamivir
371191|NCT01203527|Tamiflu
371192|NCT01203527|Pregnancy
371193|NCT01203514|NICHD Neonatal Research Network
371194|NCT01203514|Extremely Low Birth Weight (ELBW)
371195|NCT01203514|Prematurity
371196|NCT01203514|Erythrocyte transfusions
371197|NCT01203514|Erythropoietin (Epo)
371198|NCT01203514|Blood loss
371199|NCT01203514|Phlebotomy
371200|NCT01203501|NICHD Neonatal Research Network
371201|NCT01203501|Extremely Low Birth Weight (ELBW)
371202|NCT01203501|Prematurity
371203|NCT01203501|Antenatal Magnesium sulfate
371204|NCT01203488|NICHD Neonatal Research Network
371205|NCT01203488|Extremely Low Birth Weight (ELBW)
371206|NCT01203488|Prematurity
371207|NCT01203488|Vitamin A
371208|NCT01203488|Chronic Lung Disease
371209|NCT01203475|NICHD Neonatal Research Network
371210|NCT01203475|Extremely Low Birth Weight (ELBW)
371211|NCT01203475|Prematurity
371212|NCT01203475|Growth Curve
371213|NCT01203475|Head Circumference
371214|NCT01203475|Length
371215|NCT01203449|NICHD Neonatal Research Network
371216|NCT01203449|Extremely Low Birth Weight (ELBW)
371217|NCT01203449|Prematurity
371218|NCT01203449|Gestational Age
371219|NCT01203436|NICHD Neonatal Research Network
371220|NCT01203436|Very Low Birth Weight (VLBW)
371221|NCT01203436|Extremely Low Birth Weight (ELBW)
371222|NCT01203436|Prematurity
371223|NCT01203423|NICHD Neonatal Research Network
371224|NCT01203423|Extremely Low Birth Weight (ELBW)
371225|NCT01203423|Prematurity
371226|NCT01203423|Persistent Pulmonary Hypertension of Newborn (PPHN)
371227|NCT01203410|NICHD Neonatal Research Network
371228|NCT01203410|Term infant
371229|NCT01203410|Hyperbilirubinemia
371230|NCT01203397|SUPERFICIAL VARICOSE VEINS
371231|NCT01203371|naftopidil
371232|NCT01203371|symptoms of lower urinary tract
371233|NCT01203371|benign prostate hyperplasia
371234|NCT01203371|LUTS
371235|NCT01203358|NICHD Neonatal Research Network
371236|NCT01203358|Extremely Low Birth Weight (ELBW)
371237|NCT01203358|Prematurity
371238|NCT01203358|Respiratory distress syndrome
371239|NCT01203358|Surfactant
371240|NCT01203345|NICHD Neonatal Research Network
371241|NCT01203345|Extremely Low Birth Weight (ELBW)
371242|NCT01203345|Prematurity
371243|NCT01203345|Septicemia
371244|NCT01203345|Meningitis
371245|NCT01203345|Urinary tract infection
371246|NCT01203345|Immune globulin
371247|NCT01203332|HIV testing
371248|NCT01203332|Latino
371249|NCT01203332|Latina
371250|NCT01203332|Men who have sex with men
371251|NCT01203319|immunogenicity
371252|NCT01203319|safety
371253|NCT01203319|recombinant hepatitis B vaccine
371254|NCT01203319|nonresponders
371255|NCT01203306|bevacizumab
371256|NCT01203306|somatostatin analogue
371257|NCT01203306|metronomic capecitabine
371258|NCT01203306|neuroendocrine tumors
371259|NCT01203280|icing
371260|NCT01203280|boxer
371261|NCT01203280|balance
371262|NCT01203280|neck range of motion
371263|NCT01203280|neck isometric strength
371264|NCT01203280|balance performance
371265|NCT01203267|Breast Neoplasms
371266|NCT01203267|Neoadjuvant
371267|NCT01203267|Chemotherapy
371268|NCT01203267|Paclitaxel
371269|NCT01203267|Carboplatin
371270|NCT01203267|Pathological Complete Remission
371271|NCT01203254|Colesevelam
371272|NCT01203254|IBD
371273|NCT01203254|Bile Acid Malabsorption
371274|NCT01203254|Crohns disease
371275|NCT01203228|Reduced Intensity conditioning
371276|NCT01203228|Myeloablative conditionig
371277|NCT01203228|Allogeneic stem cell transplantation
371278|NCT01203228|MUD
371279|NCT01203215|exercise
371280|NCT01203215|physical activity
371281|NCT01203215|women
371282|NCT01203215|community
371283|NCT01203202|PE
371284|NCT01203202|IELT
371285|NCT01203202|DCIT
371286|NCT01203189|dandruff, flaky scalp
371287|NCT01203176|Endometrial polyp
371288|NCT01203176|Endometrial carcinoma
371289|NCT01203176|Endometrial hyperplasia
371290|NCT01203176|Postmenopausal symptomatic women
371291|NCT01203176|Postmenopausal asymptomatic women
371292|NCT01203163|PDT
371293|NCT01203163|porfimer sodium
371294|NCT01203163|esophageal cancer
371295|NCT01203163|NSCLC
371296|NCT01203163|HGD in BE
371297|NCT01203137|tricuspid regurgitation, severe
371298|NCT01203124|Intranasal
371299|NCT01203124|Biomarker
371300|NCT01203124|Healthy
371301|NCT01203124|Effect of different doses and dosing regimens of AZD8848 on biomarkers
371302|NCT01203124|Effect different doses and dosing frequency of AZD8848 on biomarkers
371303|NCT01203098|prevention
371304|NCT01203098|venous thromboembolism
371305|NCT01203098|edoxaban
371306|NCT01203098|anticoagulants
371307|NCT01203072|prevention
371308|NCT01203072|venous thromboembolism
371309|NCT01203072|edoxaban
371310|NCT01203072|factor Xa
371311|NCT01203046|DURATION OF THERAPY
371312|NCT01203046|PENETRATING ABDOMINAL TRAUMA
371313|NCT01203033|acute myeloid leukemia
371314|NCT01203033|single cell network profiling
371315|NCT01203033|AML
371316|NCT01203033|SCNP
371317|NCT01203020|Hodgkin's
371318|NCT01203020|non-Hodgkin's
371319|NCT01203020|lymphomas
371320|NCT01203020|allogeneic hematopoietic progenitor cell transplant
371321|NCT01203020|HPCT
371322|NCT01203020|busulfex
371323|NCT01203020|fludarabine
371324|NCT01203020|reduced-toxicity conditioning
371325|NCT01203020|reduced-intensity conditioning
371326|NCT01202994|Alzheimer's disease
371327|NCT01202994|Mild cognitive impairment
371328|NCT01202994|PET
371329|NCT01202994|Practice effects
371330|NCT01202981|glistenings
371331|NCT01202981|contrast sensitivity
371332|NCT01202981|visual quality
371333|NCT01202981|straylight
371334|NCT01202981|AcrySof IOL
371335|NCT01202968|intubation electric stimulation deglutition disorder
371336|NCT01202955|Smoking, Abstinence
371337|NCT01202929|High Resolution Manometry
371338|NCT01202929|achalasia
371339|NCT01202929|dysphagia
371340|NCT01202929|GERD
371341|NCT01202929|chest pain
371342|NCT01202929|Post fundoplication
371343|NCT01202916|children with congenital heart disease
371344|NCT01202903|omalizumab
371345|NCT01202903|asthma
371346|NCT01202903|immunoglobulin E
371347|NCT01202903|IgE
371348|NCT01202890|lenalidomide
371349|NCT01202890|revlimid
371350|NCT01202890|liposomal doxorubicin
371351|NCT01202890|doxil
371352|NCT01202890|bevacizumab
371353|NCT01202890|avastin
371354|NCT01202890|platinum resistant ovarian cancer
371355|NCT01202890|ovarian cancer
371356|NCT01202877|Myelodysplastic Syndrome
371357|NCT01202877|MDS
371358|NCT01202877|Refractory acute leukemias
371359|NCT01202877|Relapsed acute leukemia
371360|NCT01202877|Acute myeloid leukemia
371361|NCT01202877|AML
371362|NCT01202877|5-Azacytidine
371363|NCT01202877|Azacitidine
371364|NCT01202877|5-aza
371365|NCT01202877|Vidaza
371366|NCT01202877|5-AZC
371367|NCT01202877|AZA-CR
371368|NCT01202877|Ladakamycin
371369|NCT01202877|NSC-102816
371370|NCT01202877|PKC412
371371|NCT01202864|Intracerebral Hemorrhage
371372|NCT01202864|ICH
371373|NCT01202864|Stroke
371374|NCT01202864|Cerebrovascular accident
371375|NCT01202851|radiotherapy
371376|NCT01202851|radiation therapy
371377|NCT01202851|stretching
371378|NCT01202851|relaxation
371379|NCT01202851|quality of life
371380|NCT01202851|QOL
371381|NCT01202851|fatigue
371382|NCT01202851|sleep disturbances
371383|NCT01202851|mental health
371384|NCT01202851|cost-effectiveness analysis
371385|NCT01202851|work productivity
371386|NCT01202851|home productivity
371387|NCT01202851|cortisol rhythmicity
371388|NCT01202838|Cranial bone reconstruction, composite
371389|NCT01202825|HCV genotype 1 infected patients
371390|NCT01202825|TMC647055HPC1001
371391|NCT01202825|TMC647055
371392|NCT01202825|HPC
371393|NCT01202825|Hepatitis C
371394|NCT01202825|Healthy volunteers
371395|NCT01202825|TMC435
371396|NCT01202812|Sickle Cell Anemia
371397|NCT01202812|Sickle Cell Disease
371398|NCT01202812|Hemoglobin SS Disease
371399|NCT01202812|Hemoglobin S beta-0 Thalassemia
371400|NCT01202812|Inflammation
371401|NCT01202812|Quality of Life
371402|NCT01202812|Sickle Thalassemia
371403|NCT01202812|C-Reative Protein
371404|NCT01202812|Hemolytic Anemia
371405|NCT01202812|Hemostasis
371406|NCT01202812|Biomarkers
371407|NCT01202812|Coagulation
371408|NCT01202812|Omega-3 Fatty Acids
371409|NCT01202812|Eicosapentaenoic Acid
371410|NCT01202812|Docosahexaenoic Acid
371411|NCT01202812|Fish Oils
371412|NCT01202812|Drug: Placebo
371413|NCT01202812|Drug: LOVAZA
371414|NCT01202799|Pharmacokinetics
371415|NCT01202799|Healthy volunteers
371416|NCT01202799|PENNSAID
371417|NCT01202799|Topical NSAID
371418|NCT01202799|Diclofenac
371419|NCT01202786|Cancer of Unknown Primary Site (CUP)
371420|NCT01202773|Rheumatoid Arthritis
371421|NCT01202760|Rheumatoid Arthritis
371422|NCT01202734|CONCERTA
371423|NCT01202734|Methylphenidate HCl
371424|NCT01202734|Pharmacokinetic
371425|NCT01202734|Safety
371426|NCT01202734|Adult
371427|NCT01202734|Men
371428|NCT01202734|Male
371429|NCT01202721|Congenital
371430|NCT01202721|Aortic Valve
371431|NCT01202721|Bicuspid
371432|NCT01202721|Aortopathy
371433|NCT01202721|bicuspid aortic valve aortopathy
371434|NCT01202682|Healthy subject exercise study
371435|NCT01202656|Fertility Agents, Female
371436|NCT01202656|In vitro fertilization
371437|NCT01202643|Thin Endometrium
371438|NCT01202643|Asherman's Syndrome
371439|NCT01202643|Endometrial Scarring
371440|NCT01202630|Clostridium difficile
371441|NCT01202630|diarrhea
371442|NCT01202617|Seroquel XR
371443|NCT01202617|schizophrenia
371444|NCT01202617|relapse prevention
371445|NCT01202604|Bipolar disorder I and II
371446|NCT01202604|mood event
371447|NCT01202604|manic or depressive
371448|NCT01202604|Greece
371449|NCT01202591|Breast Cancer
371450|NCT01202591|ER+
371451|NCT01202591|FGFR1
371452|NCT01202591|Exemestane
371453|NCT01202591|AZD4547
371454|NCT01202591|Fulvestrant
371455|NCT01202565|Post-marketing observational study (PMOS) Protocol
371456|NCT01202565|Moderate to Severe Plaque Psoriasis
371457|NCT01202565|Treatment of Scalp and Nail Affection
371458|NCT01202565|Effectiveness of Adalimumab (HUMIRA®)
371459|NCT01202552|influenza
371460|NCT01202552|aged
371461|NCT01202552|intradermal injection
371462|NCT01202526|Insulin resistance
371463|NCT01202526|Gastric bypass
371464|NCT01202513|Vitiligo
371465|NCT01202513|Repigmentation
371466|NCT01202487|Laceration
371467|NCT01202487|Lacerations
371468|NCT01202487|LET
371469|NCT01202487|Lidocaine Epinephrine Tetracaine
371470|NCT01202487|LAT
371471|NCT01202487|Lidocaine Adrenaline Tetracaine
371472|NCT01202487|Tissue Adhesive
371473|NCT01202487|Skin Glue
371474|NCT01202487|Pre-Treatment with LET
371475|NCT01202487|Pre-Treatment with LAT
371476|NCT01202487|Pre-Treatment with Lidocaine Epinephrine Tetracaine
371477|NCT01202487|Pre-Treatment with Lidocaine Adrenaline Tetracaine
371478|NCT01202487|Use of LET with Skin Glue
371479|NCT01202487|Use of LET with Tissue Adhesive
371480|NCT01202487|Histoacryl
371481|NCT01202461|Diabetic macular edema
371482|NCT01202461|Combination therapy for DME
371483|NCT01202461|DME
371484|NCT01202448|Diffuse large B cell lymphoma
371485|NCT01202448|central nervous system
371486|NCT01202448|prognosis
371487|NCT01202435|pregabalin
371488|NCT01202435|pharmacokinetics
371489|NCT01202435|bioavailability
371490|NCT01202435|bioequivalence
371491|NCT01202422|pregabalin
371492|NCT01202422|pharmacokinetics
371493|NCT01202422|bioavailability
371494|NCT01202422|bioequivalence
371495|NCT01202409|Ampulla of Vater
371496|NCT01202409|Adenocarcinoma of the small bowel
371497|NCT01202409|Metastatic
371498|NCT01202409|Kirsten rat sarcoma
371499|NCT01202409|KRAS
371500|NCT01202409|Capecitabine
371501|NCT01202409|Xeloda
371502|NCT01202409|Oxaliplatin
371503|NCT01202409|Eloxatin
371504|NCT01202409|CAPOX
371505|NCT01202409|Panitumumab
371506|NCT01202409|Vectibix
371507|NCT01202396|pouch
371508|NCT01202396|pouchitis
371509|NCT01202396|ulcerative colitis
371510|NCT01202396|microbiota
371511|NCT01202396|defensins
371512|NCT01202396|epithelial integrity
371513|NCT01202370|Cancer
371514|NCT01202370|Tumors
371515|NCT01202357|Psychotic Disorders
371516|NCT01202357|Psychosis
371517|NCT01202344|Angioplasty
371518|NCT01202344|Stenosis
371519|NCT01202344|Restenosis
371520|NCT01202344|Elastic Recoil
371521|NCT01202344|cheduled for percutaneous dilation of a peripheral artery
371522|NCT01202344|Target lesion in native artery
371523|NCT01202344|Baseline lumen diameter greater than 4 mm
371524|NCT01202331|Bacterial Infections
371525|NCT01202331|Chlamydia Infections
371526|NCT01202331|Eye Diseases
371527|NCT01202318|Cerebrovascular Accident
371528|NCT01202318|Stroke,Acute
371529|NCT01202305|HIV
371530|NCT01202305|HIV persistence
371531|NCT01202305|Lymph node fibrosis
371532|NCT01202292|overweight
371533|NCT01202292|obesity
371534|NCT01202292|motivational intervention
371535|NCT01202279|Acute Upper Respiratory Track Infection Who Seek Treatment
371536|NCT01202266|Multiple Ascending Dose
371537|NCT01202266|Phase 1
371538|NCT01202266|Safety and Tolerability
371539|NCT01202266|PK
371540|NCT01202266|Healthy Subjects
371541|NCT01202253|Ecalta
371542|NCT01202253|Eraxis
371543|NCT01202253|Candida
371544|NCT01202253|Candidemia
371545|NCT01202253|Systemic Candidiasis
371546|NCT01202253|ICU
371547|NCT01202253|Intensive Care Unit
371548|NCT01202253|Critical Care Unit
371549|NCT01202240|Drug-Drug Interaction
371550|NCT01202240|Healthy Volunteers
371551|NCT01202240|Tasocitinib (CP-690
371552|NCT01202240|550)
371553|NCT01202240|Ketoconazole
371554|NCT01202227|Central Nervous System Diseases
371555|NCT01202227|Therapeutic Uses
371556|NCT01202227|Wounds and Injuries
371557|NCT01202227|Trauma
371558|NCT01202227|Nervous System
371559|NCT01202227|pregabalin
371560|NCT01202188|QVA149, COPD, combination bronchodilator, indacaterol, glycopyrronium bromide
371561|NCT01202175|Genetic risk of hypertension
371562|NCT01202162|Induction
371563|NCT01202162|Coughing
371564|NCT01202162|Anesthesia
371565|NCT01202149|eczema
371566|NCT01202149|elidel
371567|NCT01202149|non-medicated device
371568|NCT01202149|hylatopic plus
371569|NCT01202149|pimecrolimus
371570|NCT01202149|bilateral comparison study
371571|NCT01202149|topical therapy
371572|NCT01202136|pancreatic cyst
371573|NCT01202136|IPMN
371574|NCT01202136|PAN INs
371575|NCT01202136|Pancreatic cancer
371576|NCT01202136|pancreatic neoplasia
371577|NCT01202071|Rabeprazole
371578|NCT01202071|proton pump inhibitor
371579|NCT01202071|pharmacokinetics
371580|NCT01202071|pharmacodynamics
371581|NCT01202071|healthy adult male Japanese subjects
371582|NCT01202058|Coronary artery disease
371583|NCT01202058|Drug-eluting stents
371584|NCT01202058|Reservoir technology
371585|NCT01202045|Echocardiography, Stress
371586|NCT01202045|right heart catheterization
371587|NCT01202032|Metastatic renal cell carcinoma
371588|NCT01202032|Advanced solid tumors
371589|NCT01202032|Dose escalation
371590|NCT01202032|Association Pazopanib-Bevacizumab
371591|NCT01202019|cardiovascular risk
371592|NCT01202019|exercise
371593|NCT01202019|post-exercise diet supplementation
371594|NCT01202006|Heart failure
371595|NCT01202006|Diagnosis
371596|NCT01202006|Treatment
371597|NCT01202006|Primary care
371598|NCT01201993|syncope
371599|NCT01201993|evaluation
371600|NCT01201993|recurrence
371601|NCT01201993|morbidity
371602|NCT01201980|essential arterial hypertension
371603|NCT01201980|calcium antagonist
371604|NCT01201967|Collaborative care
371605|NCT01201967|Cardiovascular disease
371606|NCT01201967|Depression
371607|NCT01201967|Anxiety
371608|NCT01201954|pain
371609|NCT01201954|sucrose
371610|NCT01201954|newborn
371611|NCT01201954|mechanical ventilation
371612|NCT01201876|Dental Caries
371613|NCT01201876|Assessments
371614|NCT01201876|dental materials
371615|NCT01201863|Testosterone
371616|NCT01201863|Traumatic Brain Injury
371617|NCT01201863|Hypogonadism
371618|NCT01201863|Endocrine Dysfunction
371619|NCT01201863|Low Testosterone in men with new Traumatic Brain Injury
371620|NCT01201850|radiation necrosis
371621|NCT01201850|Bevacizumab (Avastin®)
371622|NCT01201850|Central Nervous System Tumors
371623|NCT01201837|Acute coronary syndrome
371624|NCT01201837|HDL mimetic
371625|NCT01201837|ApoA-I
371626|NCT01201824|lung cancer
371627|NCT01201824|intracavitary ultrasound
371628|NCT01201824|pulmonary nodules
371629|NCT01201824|VATS procedures
371630|NCT01201811|Myelodysplastic Syndromes
371631|NCT01201811|Taiwan
371632|NCT01201811|Azacitidine
371633|NCT01201811|Vidaza
371634|NCT01201811|Celgene
371635|NCT01201811|Pathologic Processes
371636|NCT01201811|Neoplasms
371637|NCT01201811|Bone Marrow Diseases
371638|NCT01201811|Hematologic Diseases
371639|NCT01201811|Antineoplastic Agents
371640|NCT01201811|Antimetabolites, Antineoplastic
371641|NCT01201811|Antimetabolites
371642|NCT01201811|Molecular Mechanisms of Pharmacological Action
371643|NCT01201811|Pharmacologic Actions
371644|NCT01201811|Therapeutic Uses
371645|NCT01201811|Enzyme inhibitors
371646|NCT01201785|diabetes mellitus, coronary artery disease, aspirin therapy
371647|NCT01201772|coronary artery disease
371648|NCT01201772|percutaneous coronary revascularization
371649|NCT01201772|prasugrel therapy
371650|NCT01201759|cardiovascular risk
371651|NCT01201746|Non-surgical periodontal therapy
371652|NCT01201746|Coronary heart disease (CHD)
371653|NCT01201746|periodontal Disease
371654|NCT01201746|hsCRP
371655|NCT01201746|Fibrinogen
371656|NCT01201746|WBCs
371657|NCT01201720|cirrhosis
371658|NCT01201720|cirrhotic patients with acute on chronic liver failure
371659|NCT01201707|Multiple Sclerosis
371660|NCT01201707|Angioplasty
371661|NCT01201707|Vein
371662|NCT01201694|Advanced malignancies
371663|NCT01201694|Surface-controlled water soluble curcumin
371664|NCT01201694|Turmeric
371665|NCT01201694|Dietary supplements
371666|NCT01201681|Post-operative pain
371667|NCT01201681|intra-operative pain
371668|NCT01201681|root canal therapy
371669|NCT01201681|feasibility
371670|NCT01201681|post-surgical persistent pain
371671|NCT01201668|post-operative pain
371672|NCT01201668|root canal therapy
371673|NCT01201668|feasibility
371674|NCT01201668|post-surgical persistent pain
371675|NCT01201655|Posthepatitic cirrhosis;
371676|NCT01201655|Hepatocarcinogenesis;
371677|NCT01201655|Splenectomy;
371678|NCT01201642|Bell's palsy
371679|NCT01201642|Prednisolone
371680|NCT01201642|acupuncture
371681|NCT01201629|Ischemic Strokes
371682|NCT01201629|t DC stimulation
371683|NCT01201629|Functional recovery
371684|NCT01201616|Cognitive function
371685|NCT01201616|mood
371686|NCT01201616|women
371687|NCT01201616|high fat diet
371688|NCT01201616|high carbohydrate diet
371689|NCT01201603|Women
371690|NCT01201603|Orange Juice
371691|NCT01201603|Insulin Resistance
371692|NCT01201603|Obesity
371693|NCT01201590|Insulin resistance
371694|NCT01201590|obesity
371695|NCT01201590|cocoa
371696|NCT01201590|women
371697|NCT01201577|Quorum sensing
371698|NCT01201577|Prebiotics
371699|NCT01201577|Probiotics
371700|NCT01201577|Sepsis
371701|NCT01201564|umbilical hernia,
371702|NCT01201564|wound complications,
371703|NCT01201564|mesh repair, IPOM,
371704|NCT01201564|quality of life,
371705|NCT01201564|sublay mesh repair,
371706|NCT01201564|recurrence rate
371707|NCT01201551|Alphagan
371708|NCT01201551|Xalatan
371709|NCT01201551|corneal temperature
371710|NCT01201551|primary vascular dysregulation
371711|NCT01201512|TMJD pain
371712|NCT01201512|feasibility
371713|NCT01201486|Ultrasound
371714|NCT01201486|Pregnancy
371715|NCT01201486|Fetal heart defects
371716|NCT01201486|Color doppler
371717|NCT01201473|effect of participation
371718|NCT01201473|effect of association
371719|NCT01201460|glucose testing
371720|NCT01201447|Assessment
371721|NCT01201447|Questionable Caries
371722|NCT01201434|cystic fibrosis
371723|NCT01201434|probiotics
371724|NCT01201434|pulmonary
371725|NCT01201434|infections
371726|NCT01201421|patient satisfaction
371727|NCT01201421|assessments
371728|NCT01201421|dental caries
371729|NCT01201421|dental materials
371730|NCT01201408|Dental Caries
371731|NCT01201408|Assessments
371732|NCT01201408|dental materials
371733|NCT01201395|Dental Caries
371734|NCT01201395|Assessment
371735|NCT01201395|dental materials
371736|NCT01201382|Depression
371737|NCT01201382|Prevention
371738|NCT01201382|Adolescents
371739|NCT01201369|Percutaneous Coronary Intervention
371740|NCT01201369|Coronary Artery Stenosis
371741|NCT01201369|Acute Myocardial Infarction
371742|NCT01201369|Coronary Artery Stent
371743|NCT01201369|Optical Coherence Tomography
371744|NCT01201356|Fingolimod
371745|NCT01201356|FTY720
371746|NCT01201356|Relapsing forms of MS
371747|NCT01201356|Multiple Sclerosis
371748|NCT01201356|Efficacy
371749|NCT01201343|Multiple sclerosis, relapsing, remitting
371750|NCT01201343|Interferon-beta
371751|NCT01201330|ONJ
371752|NCT01201317|Analgesic effect
371753|NCT01201304|Anxiety sensitivity
371754|NCT01201304|Panic
371755|NCT01201291|TBI
371756|NCT01201291|Normobaric hyperoxia
371757|NCT01201291|Outcome
371758|NCT01201291|GOS
371759|NCT01201291|GOSE
371760|NCT01201278|intranasal insulin
371761|NCT01201252|children
371762|NCT01201252|gastroenteritis
371763|NCT01201252|Rotavirus
371764|NCT01201239|raltegravir
371765|NCT01201239|HIV-1
371766|NCT01201239|drug resistance
371767|NCT01201226|Primordial ovarian follicles
371768|NCT01201226|PTEN
371769|NCT01201226|PI3K activating peptide
371770|NCT01201226|Low ovarian reserve
371771|NCT01201226|Gonadotrophins
371772|NCT01201213|Bupivacaine
371773|NCT01201213|levobupivacaine
371774|NCT01201213|ropivacaine
371775|NCT01201200|Obstructive Sleep Apnea
371776|NCT01201200|Right Ventricular Function
371777|NCT01201200|Pulmonary Hypertension
371778|NCT01201187|ADHD(Attention Deficit Hyperactivity Disorder)
371779|NCT01201174|Hemolysis in Patients with Hereditary Spherocytosis
371780|NCT01201174|with documented family history of HS.
371781|NCT01201174|spherocyte morphology,
371782|NCT01201174|splenomegaly and non-immune mediated hemolysis.
371783|NCT01201161|Diabetic Retinopathy
371784|NCT01201161|Retinal detachment
371785|NCT01201161|Vitreous Hemorrhage
371786|NCT01201161|Preoperative Ranibizumab
371787|NCT01201161|pars plana vitrectomy
371788|NCT01201148|depression
371789|NCT01201148|transcranial direct current stimulation (tDCS)
371790|NCT01201148|random noise stimulation
371791|NCT01201148|oscillatory tDCS
371792|NCT01201148|intermittent tDCS
371793|NCT01201122|Pediatric
371794|NCT01201122|Ulcerative colitis
371795|NCT01201122|5-ASA
371796|NCT01201122|Mesalamine
371797|NCT01201122|Dosing
371798|NCT01201109|Carpal tunnel syndrome
371799|NCT01201109|Entrapment neuropathies
371800|NCT01201109|Diabetes
371801|NCT01201096|neuroendocrine tumor
371802|NCT01201096|liver metastasis
371803|NCT01201096|peptide receptor therapy
371804|NCT01201096|gastro-entero-pancreatic system
371805|NCT01201057|SPL7013
371806|NCT01201057|VivaGel
371807|NCT01201057|bacterial vaginosis
371808|NCT01201057|BV
371809|NCT01201044|BAI
371810|NCT01201044|3DCRT
371811|NCT01201031|for the active surveillance of VRE colinization and infection
371812|NCT01201018|Tumor
371813|NCT01201018|cancer
371814|NCT01201018|metastasis
371815|NCT01200992|Urinary Bladder Neoplasms
371816|NCT01200992|Neoplasms
371817|NCT01200992|Urologic Neoplasms
371818|NCT01200992|Urogenital Neoplasms
371819|NCT01200992|Neoplasms by Site
371820|NCT01200992|Urinary Bladder Diseases
371821|NCT01200992|Urologic Diseases
371822|NCT01200992|Mycobacterial cell wall DNA complex
371823|NCT01200992|Intravesical drug administration
371824|NCT01200979|Cytokine
371825|NCT01200979|Lymphocyte
371826|NCT01200979|Toll-Like Receptor
371827|NCT01200979|NK Cell
371828|NCT01200979|Innate Immunity
371829|NCT01200979|Pregnancy
371830|NCT01200979|Immune Function
371831|NCT01200966|Essential Tremor
371832|NCT01200966|Transcranial Magnetic Stimulation (TMS)
371833|NCT01200966|Ethanol
371834|NCT01200966|Alcohol
371835|NCT01200966|Alcohol Clamp
371836|NCT01200966|ET
371837|NCT01200953|Select Agents
371838|NCT01200953|Biosafety
371839|NCT01200953|Bioterrorism
371840|NCT01200953|SCSU (Special Clinical Studies Unit)
371841|NCT01200953|Infectious Disease
371842|NCT01200953|Bioterrorism-Related Illness
371843|NCT01200940|GLP-1
371844|NCT01200940|Glucose Tolerance
371845|NCT01200940|Gut Hormones
371846|NCT01200940|Gastric Bypass
371847|NCT01200940|Roux-en-Y
371848|NCT01200940|Bariatric Surgery
371849|NCT01200927|infant
371850|NCT01200927|sitting
371851|NCT01200927|postural control
371852|NCT01200914|Hemodialysis
371853|NCT01200914|Fistula
371854|NCT01200914|Angiograph
371855|NCT01200914|Angiogram
371856|NCT01200901|depression
371857|NCT01200901|healthy
371858|NCT01200875|PRP
371859|NCT01200875|platelet rich plasma
371860|NCT01200875|platelet
371861|NCT01200875|growth hormone
371862|NCT01200875|tendonitis
371863|NCT01200875|tendinosis
371864|NCT01200875|tendinopathy
371865|NCT01200875|enthesopathy
371866|NCT01200875|muscle
371867|NCT01200875|sport
371868|NCT01200875|tendon
371869|NCT01200862|Obese
371870|NCT01200862|obesity
371871|NCT01200862|hypogonadism
371872|NCT01200862|hypogonadotropic
371873|NCT01200862|hyperestrogenemic
371874|NCT01200862|testosterone
371875|NCT01200862|hypogonadal
371876|NCT01200836|Statins
371877|NCT01200836|Immune Modulation
371878|NCT01200836|Healthy Volunteer
371879|NCT01200823|Laboratory Research
371880|NCT01200823|Biologic Samples
371881|NCT01200823|Tissue Collection
371882|NCT01200823|Tissue Procurement
371883|NCT01200771|FDG-PET/CT
371884|NCT01200771|FUO
371885|NCT01200771|Chronic Inflammatory syndrome
371886|NCT01200771|Fever of unknown origin
371887|NCT01200745|neck pain
371888|NCT01200745|capsaicin
371889|NCT01200745|dermal patch
371890|NCT01200732|Tadalafil
371891|NCT01200732|phosphodiesterase-5 inhibitor
371892|NCT01200732|Eisenmenger syndrome
371893|NCT01200719|brain electrical stimulation
371894|NCT01200719|sub-acute post-stroke
371895|NCT01200719|rehabilitation
371896|NCT01200706|children aged under 5 years
371897|NCT01200706|Non-severe
371898|NCT01200693|Angioplasty, Transluminal, Percutaneous Coronary
371899|NCT01200693|Drug-Eluting Stents
371900|NCT01200680|Sporadic Chordoma
371901|NCT01200680|Pediatric and Adult
371902|NCT01200680|Gene Identification
371903|NCT01200680|Rare Bone Cancer
371904|NCT01200680|All Chordoma Sites
371905|NCT01200680|Bone Cancer
371906|NCT01200654|Population pharmacokinetics
371907|NCT01200654|Linezolid
371908|NCT01200654|Monolix
371909|NCT01200654|nonlinear mixed effects models
371910|NCT01200641|melatonin
371911|NCT01200641|gabapentin
371912|NCT01200641|anxiety
371913|NCT01200641|pain
371914|NCT01200641|retrobulbar block
371915|NCT01200628|posttraumatic stress disorder
371916|NCT01200628|acute PTSD
371917|NCT01200628|PTSD
371918|NCT01200628|motor vehicle accident
371919|NCT01200615|nocebo side-effects SSRI informed consent
371920|NCT01200589|Randomized trial
371921|NCT01200589|Ofatumumab
371922|NCT01200589|Rituximab
371923|NCT01200589|Indolent B-Cell Non Hodgkin Lymphoma
371924|NCT01200576|CRF: Case Report Form
371925|NCT01200576|DM: Data Management
371926|NCT01200576|FHI: FHI (formerly known as Family Health International)
371927|NCT01200576|IRB: Institutional Review Board
371928|NCT01200576|IUD: Intra-uterine Device
371929|NCT01200576|LTPM: Long-term and Permanent Contraceptive Methods
371930|NCT01200576|MSI: Marie Stopes International
371931|NCT01200576|MSM: Marie Stopes Madagascar
371932|NCT01200576|PHSC: Protection of Human Subjects Committee
371933|NCT01200576|PI: Principal Investigator
371934|NCT01200576|SAE: Serious Adverse Event
371935|NCT01200576|Sino-Implant (II)
371936|NCT01200576|SOP: Standard Operating Procedure
371937|NCT01200576|Zarin
371938|NCT01200563|MIST Therapy
371939|NCT01200563|Negative Pressure Wound Therapy
371940|NCT01200563|Wound care in long-term acute care hospital
371941|NCT01200563|Wound care in skilled nursing facility setting
371942|NCT01200550|Gastroesophageal reflux disease
371943|NCT01200550|GERD Impact Scale
371944|NCT01200537|IVF
371945|NCT01200537|poor responders
371946|NCT01200537|follicle synchrony
371947|NCT01200537|IVF response
371948|NCT01200537|estrogen
371949|NCT01200537|estradiol (E2)
371950|NCT01200537|oral contraceptive pill (OCP)
371951|NCT01200537|birth control pill (BCP)
371952|NCT01200524|Analgesic effect
371953|NCT01200498|Primary Polycythemia Vera
371954|NCT01200498|Post Polycythemia Vera
371955|NCT01200498|Post Essential Thrombocythemia Myelofibrosis
371956|NCT01200498|SB939
371957|NCT01200498|PMF
371958|NCT01200498|post-PV MF
371959|NCT01200498|post-ET MF
371960|NCT01200485|Supportive Care
371961|NCT01200485|Recombinant urate oxidase
371962|NCT01200485|Chemotherapy
371963|NCT01200485|Tumor Lysis Syndrome (TLS)
371964|NCT01200485|Hematologic malignancies
371965|NCT01200485|Acute myeloid leukemia
371966|NCT01200472|EHOA
371967|NCT01200459|Obesity
371968|NCT01200459|Weight Loss
371969|NCT01200459|Healthy Lifestyle
371970|NCT01200459|Social
371971|NCT01200459|Mobile
371972|NCT01200459|Facebook
371973|NCT01200459|Text Messages
371974|NCT01200446|Asthma
371975|NCT01200446|Exercise-Induced Bronchoconstriction
371976|NCT01200446|Inflammation
371977|NCT01200446|Airway
371978|NCT01200446|Fish Oil
371979|NCT01200446|Docosahexaenoic Acid
371980|NCT01200446|DHA
371981|NCT01200433|dexmedetomidine
371982|NCT01200433|propofol
371983|NCT01200433|cerebral blood flow
371984|NCT01200433|brain oxygenation
371985|NCT01200420|Antisense
371986|NCT01200420|miR-122 antagonist
371987|NCT01200420|host factor
371988|NCT01200420|CHC
371989|NCT01200407|Hypertension
371990|NCT01200407|fixed drug combination
371991|NCT01200407|Filipinos
371992|NCT01200407|Amlodipine
371993|NCT01200407|Olmesartan medoxomil
371994|NCT01200407|uncontrolled hypertension
371995|NCT01200407|difficult to treat hypertension
371996|NCT01200394|Diabetic nephropathy
371997|NCT01200394|chronic kidney disease
371998|NCT01200394|PF-00489791
371999|NCT01200394|phosphodiesterase
372000|NCT01200394|PDE5
372001|NCT01200381|ICD
372002|NCT01200381|CRTD
372003|NCT01200381|Remote care
372004|NCT01200381|Remote monitoring
372005|NCT01200381|Heart failure
372006|NCT01200368|vaccine
372007|NCT01200368|pneumococcal conjugate
372008|NCT01200355|MICAFUNGIN
372009|NCT01200355|POSACONAZOLE
372010|NCT01200355|antifungal
372011|NCT01200355|prolonged neutropenia
372012|NCT01200355|10-038
372013|NCT01200342|Uveal melanoma
372014|NCT01200342|Carboplatin
372015|NCT01200342|Genasense
372016|NCT01200342|Paclitaxel
372017|NCT01200342|oblimersen
372018|NCT01200342|GCP
372019|NCT01200329|Hodgkin's disease
372020|NCT01200329|Relapsed
372021|NCT01200329|Refractory
372022|NCT01200329|High-dose chemotherapy
372023|NCT01200329|Busulfan
372024|NCT01200329|Gemcitabine
372025|NCT01200329|Melphalan
372026|NCT01200316|Colon Cancer
372027|NCT01200316|Abdominal Surgery
372028|NCT01200316|Stress
372029|NCT01200316|Rocking Motion
372030|NCT01200316|Salivary Cortisol
372031|NCT01200316|Postoperative Ileus
372032|NCT01200303|colon cancer
372033|NCT01200303|adenomatous colonic polyps
372034|NCT01200303|colon screening
372035|NCT01200303|CT Colonography (Virtual Colonoscopy)
372036|NCT01200303|Computer Aided Detection
372037|NCT01200303|Electronic Cleansing
372038|NCT01200290|end stage renal disease
372039|NCT01200290|end stage kidney disease
372040|NCT01200290|ESRD
372041|NCT01200290|Uremia
372042|NCT01200290|Renal Dialysis
372043|NCT01200277|osteoporosis
372044|NCT01200277|vertebral fracture
372045|NCT01200277|vertebroplasty
372046|NCT01200277|percutaneous
372047|NCT01200238|STA9090
372048|NCT01200238|STA-9090
372049|NCT01200238|HSP90
372050|NCT01200212|Palliative Therapy
372051|NCT01200212|bevacizimab
372052|NCT01200212|Avastin
372053|NCT01200212|Xeloda
372054|NCT01200212|metastatic breast cancer
372055|NCT01200212|Progression Free Survival
372056|NCT01200212|Time to Progression
372057|NCT01200212|Overall survival
372058|NCT01200173|Probiotic - Lactobacillus casei DN-114 001 - dairy
372059|NCT01200173|product - infections - children
372060|NCT01200160|Low-Density Lipoprotein Cholesterol
372061|NCT01200160|Hypertriglyceridemia
372062|NCT01200160|Latin America
372063|NCT01200160|Cardiovascular Diseases
372064|NCT01200160|Cholesterol
372065|NCT01200160|Sedentary Lifestyle
372066|NCT01200160|High-Density Lipoprotein Cholesterol
372067|NCT01200134|glioma patients : anaplasic glioma (grade III) and GBM (grade IV)
372068|NCT01200121|Symptomatic malignant ascites due to advanced-stage gastrointestinal cancers
372069|NCT01200108|Severe Asthma, requiring chronic oral steroid use
372070|NCT01200082|chronic hepatitis C/B
372071|NCT01200082|alcoholic liver disease
372072|NCT01200082|primary biliary cirrhosis
372073|NCT01200082|primary sclerosing cholangitis
372074|NCT01200082|progressive familial intrahepatic cholestasis
372075|NCT01200069|depression,myalgia
372076|NCT01200056|Volumetric virtual histology intravascular ultrasound.
372077|NCT01200056|Statin-naive patient.
372078|NCT01200056|Varying doses atorvastatin.
372079|NCT01200056|Clinical outcomes.
372080|NCT01200043|Childhood obesity
372081|NCT01200043|metabolic syndrome
372082|NCT01200043|insulin resistance
372083|NCT01200043|intrahepatic fat
372084|NCT01200043|hypertension
372085|NCT01200030|Sitting balance
372086|NCT01200030|Stroke
372087|NCT01200017|T cell depleted
372088|NCT01200017|Matched unrelated donors
372089|NCT01200017|Haplocompatible donors
372090|NCT01200017|Graft vs Host Disease
372091|NCT01200017|Hemoglobinopathies
372092|NCT01200017|Leukemia
372093|NCT01200017|Leukemia, Lymphoid
372094|NCT01200017|Precursor Cell Lymphoblastic Leukemia-Lymphoma
372095|NCT01200017|Leukemia, Myeloid, Acute
372096|NCT01200017|Leukemia, Myeloid
372097|NCT01200017|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
372098|NCT01200017|Lymphoma
372099|NCT01200017|Myelodysplastic Syndromes
372100|NCT01200017|Preleukemia
372101|NCT01200017|Osteopetrosis
372102|NCT01200017|Pancytopenia
372103|NCT01200017|Immune System Diseases
372104|NCT01200017|Hematologic Diseases
372105|NCT01200017|Genetic Diseases, Inborn
372106|NCT01200017|Neoplasms by Histologic Type
372107|NCT01200017|Neoplasms
372108|NCT01200017|Lymphoproliferative Disorders
372109|NCT01200017|Lymphatic Diseases
372110|NCT01200017|Immunoproliferative Disorders
372111|NCT01200017|Myeloproliferative Disorders
372112|NCT01200017|Bone Marrow Diseases
372113|NCT01200017|Precancerous Conditions
372114|NCT01200017|Osteosclerosis
372115|NCT01200017|Osteochondrodysplasias
372116|NCT01200017|Bone Diseases, Developmental
372117|NCT01200017|Bone Diseases
372118|NCT01200017|Musculoskeletal Diseases
372119|NCT01200017|Severe acquired and congenital cytopenias
372120|NCT01200017|White and red blood cell abnormalities
372121|NCT01200004|Advanced solid tumor
372122|NCT01200004|Azacitidine
372123|NCT01200004|Grifola frondosa
372124|NCT01200004|Basidiomycete fungus
372125|NCT01200004|Lenalidomide
372126|NCT01199978|radiation
372127|NCT01199978|fractionated proton radiation
372128|NCT01199952|contraception
372129|NCT01199939|Human Immunodeficiency Virus
372130|NCT01199939|HIV
372131|NCT01199939|Etravirine
372132|NCT01199939|Darunavir
372133|NCT01199939|Prezista
372134|NCT01199939|Intelence
372135|NCT01199939|Ritonavir
372136|NCT01199939|INROADS
372137|NCT01199926|25-hydroxyvitamin D
372138|NCT01199926|Parathyroid hormone
372139|NCT01199926|Lean mass
372140|NCT01199926|Muscular strength
372141|NCT01199926|Glucose tolerance
372142|NCT01199913|problems with thinking after surgery;
372143|NCT01199900|Healthy People
372144|NCT01199900|Glucocorticoids
372145|NCT01199900|Prednisone
372146|NCT01199887|safety, biologic effects, IPF, autoimmune
372147|NCT01199874|Rotavirus
372148|NCT01199874|Rotavirus vaccine
372149|NCT01199874|Dosing schedule
372150|NCT01199874|Immunogenicity
372151|NCT01199874|Breast feeding
372152|NCT01199874|Pakistan
372153|NCT01199861|Relapsing multiple sclerosis
372154|NCT01199861|MS
372155|NCT01199861|Immune response
372156|NCT01199848|nutrition
372157|NCT01199848|polyphenolic
372158|NCT01199848|strawberry
372159|NCT01199848|insulin resistance
372160|NCT01199848|metabolic syndrome
372161|NCT01199835|obesity
372162|NCT01199835|metabolic syndrome
372163|NCT01199835|fecal fat excretion
372164|NCT01199835|fecal calcium
372165|NCT01199835|weight loss
372166|NCT01199835|appetite regulation
372167|NCT01199835|intestinal micro flora
372168|NCT01199835|lipid profile
372169|NCT01199835|energy balance
372170|NCT01199783|Diabetic Foot,MRSA,
372171|NCT01199783|Complicated skin and skin structure infections
372172|NCT01199783|Antimicrobial therapy
372173|NCT01199783|Daptomycin
372174|NCT01199770|pasta
372175|NCT01199770|appetite
372176|NCT01199770|hunger
372177|NCT01199770|satiety
372178|NCT01199770|nutrition
372179|NCT01199770|metabolic
372180|NCT01199770|gut peptide hormones
372181|NCT01199770|psychological phenomena and processes
372182|NCT01199757|ocular symptoms
372183|NCT01199757|nasal symptoms
372184|NCT01199757|Allergic Rhinitis
372185|NCT01199757|Symptom Free Days
372186|NCT01199757|Quality of Life
372187|NCT01199744|Influenza
372188|NCT01199744|Relenza®
372189|NCT01199744|SSMP
372190|NCT01199731|raltegravir
372191|NCT01199731|NNRTI
372192|NCT01199731|ritonavir
372193|NCT01199731|darunavir
372194|NCT01199731|HIV
372195|NCT01199731|GSK2248761
372196|NCT01199731|antiretroviral
372197|NCT01199731|HIV Infection
372198|NCT01199731|HAART
372199|NCT01199718|Multiple myeloma
372200|NCT01199718|Plasmacytoma
372201|NCT01199705|Immune globulin subcutaneous
372202|NCT01199705|SCIG
372203|NCT01199705|Primary immunodeficiency
372204|NCT01199705|PID
372205|NCT01199679|Gastroesophageal Reflux Disease
372206|NCT01199679|Heartburn
372207|NCT01199679|Regurgitation
372208|NCT01199679|Dyspepsia
372209|NCT01199666|Underimmunization, text message, vaccination
372210|NCT01199666|Underimmunization
372211|NCT01199653|clavicle fractures
372212|NCT01199653|midshaft
372213|NCT01199653|dislocated
372214|NCT01199653|operative treatment
372215|NCT01199653|conservative treatment
372216|NCT01199653|non-operative treatment
372217|NCT01199653|randomized controlled trial
372218|NCT01199653|bone plates
372219|NCT01199627|total hip replacement
372220|NCT01199627|tranexamic acid
372221|NCT01199614|Hypoparathyroidism
372222|NCT01199614|Hypopara
372223|NCT01199614|HPTH
372224|NCT01199614|Hypocalcemia
372225|NCT01199614|Hypercalciuria
372226|NCT01199614|PTH
372227|NCT01199614|PTH(1-84)
372228|NCT01199588|VLU
372229|NCT01199588|Venous Leg Ulcers
372230|NCT01199588|Ulcers
372231|NCT01199588|chronic wounds
372232|NCT01199588|wounds
372233|NCT01199588|Nexagon
372234|NCT01199588|CoDa
372235|NCT01199575|Chronic Lymphocytic Leukemia
372236|NCT01199575|CLL
372237|NCT01199575|Relapsed or Refractory
372238|NCT01199575|previously treated
372239|NCT01199536|Helicobacter-positive duodenal ulcer
372240|NCT01199523|YM178
372241|NCT01199523|Mirabegron
372242|NCT01199523|QT
372243|NCT01199497|cough, acute rhinitis, nasal congestion, common cold, nasal symptoms, children.
372244|NCT01199497|Nasal congestion and non-productive cough, with or without associate other nasal and extranasal symptoms.
372245|NCT01199484|Cow's milk allergy
372246|NCT01199484|food allergy
372247|NCT01199484|oral desensitization
372248|NCT01199484|randomized trial
372249|NCT01199484|specific oral tolerance induction.
372250|NCT01199471|Sevoflurane
372251|NCT01199471|Physician's Practice Patterns
372252|NCT01199471|Economics, Pharmaceutical
372253|NCT01199471|Chinese
372254|NCT01199458|Lower Esophageal Sphincter
372255|NCT01199458|Barrier pressure
372256|NCT01199445|vitamin A deficiency
372257|NCT01199432|Primary Breast Cancer
372258|NCT01199419|multivessel coronary artery disease
372259|NCT01199419|drug-eluting stent
372260|NCT01199419|CABG
372261|NCT01199419|cost-effectiveness
372262|NCT01199406|gallstone
372263|NCT01199406|gallbladder
372264|NCT01199406|cholecystectomy
372265|NCT01199406|laparoscopic
372266|NCT01199406|pain
372267|NCT01199393|breast neoplasm
372268|NCT01199393|drug therapy
372269|NCT01199393|polymorphism
372270|NCT01199393|gene
372271|NCT01199380|Smoking, Smoking Cessation
372272|NCT01199367|advanced or metastatic breast cancer
372273|NCT01199354|Invasive breast carcinoma
372274|NCT01199341|Phase 1
372275|NCT01199341|Drug-Drug interaction
372276|NCT01199341|warfarin
372277|NCT01199341|AZD1981
372278|NCT01199328|Nexium
372279|NCT01199328|aspirin
372280|NCT01199328|peptic ulcers
372281|NCT01199328|pharmacodynamic (PD)
372282|NCT01199328|Esomoeprazole
372283|NCT01199315|safety
372284|NCT01199315|tolerability
372285|NCT01199315|AZD1446
372286|NCT01199315|AD
372287|NCT01199315|ADHD
372288|NCT01199315|Japanese
372289|NCT01199302|Amgen
372290|NCT01199302|Crohn's
372291|NCT01199302|Inflammatory Bowel Disease
372292|NCT01199302|IBD
372293|NCT01199302|Irritable Bowel Syndrome
372294|NCT01199302|IBS
372295|NCT01199302|Inflammation
372296|NCT01199302|bowel
372297|NCT01199302|colon
372298|NCT01199302|gastrointestinal
372299|NCT01199289|Amgen
372300|NCT01199289|chronic inflammatory disease
372301|NCT01199289|wheezing
372302|NCT01199276|Delirium
372303|NCT01199276|Hip Fracture
372304|NCT01199276|Elderly
372305|NCT01199237|Reflex, Pharyngeal
372306|NCT01199237|Anesthetics, Inhalation
372307|NCT01199224|Solid Tumors
372308|NCT01199224|veliparib
372309|NCT01199224|refractory
372310|NCT01199224|relapsed
372311|NCT01199211|hypertrophy, exercise, HDL, lipids, cholesterol
372312|NCT01199198|Hyponatremia
372313|NCT01199198|Serum sodium
372314|NCT01199198|Tolvaptan
372315|NCT01199198|Placebo
372316|NCT01199172|Student teachers with normal or mildly disordered voices
372317|NCT01199159|misoprostol
372318|NCT01199159|hysterectomy
372319|NCT01199159|operative blood loss
372320|NCT01199159|total abdominal hysterectomy
372321|NCT01199146|Abiraterone acetate
372322|NCT01199120|Omega-3
372323|NCT01199120|Cognition
372324|NCT01199120|Malnourishment
372325|NCT01199107|PTSD
372326|NCT01199107|Anxiety
372327|NCT01199107|Behavior Therapy
372328|NCT01199107|Prolonged Exposure
372329|NCT01199107|Exercise
372330|NCT01199107|Wellness
372331|NCT01199107|Posttraumatic
372332|NCT01199107|Stress
372333|NCT01199094|low density lipoprotein receptor 5
372334|NCT01199094|high bone mass
372335|NCT01199094|autosomal dominant osteopetrosis type I
372336|NCT01199094|bone turnover markers
372337|NCT01199068|PPAR gamma agonist
372338|NCT01199068|Tumor
372339|NCT01199068|Cancer
372340|NCT01199068|Antineoplastic Agent
372341|NCT01199068|Respiratory Tract Neoplasms
372342|NCT01199068|Erlotinib
372343|NCT01199068|Protein Kinase Inhibitors
372344|NCT01199068|Neoplasms
372345|NCT01199055|PPAR gamma agonist
372346|NCT01199055|Tumor
372347|NCT01199055|Cancer
372348|NCT01199055|Antineoplastic Agent
372349|NCT01199055|Respiratory Tract Neoplasms
372350|NCT01199055|Carboplatin
372351|NCT01199055|Paclitaxel
372352|NCT01199055|Neoplasms
372353|NCT01199029|Healthy People
372354|NCT01199029|Glucocorticoids
372355|NCT01199029|Prednisone
372356|NCT01199016|Acute otitis media
372357|NCT01199016|Prevnar 13
372358|NCT01199016|Streptococcus pneumoniae
372359|NCT01199016|nasopharyngeal colonization.
372360|NCT01198977|multiple sclerosis
372361|NCT01198977|Fatigue
372362|NCT01198977|exercise
372363|NCT01198977|telemedicine
372364|NCT01198977|motivational interviewing
372365|NCT01198977|counseling
372366|NCT01198977|depression
372367|NCT01198977|physical activity
372368|NCT01198964|ECoG
372369|NCT01198964|Epilepsy
372370|NCT01198964|cortical
372371|NCT01198964|stimulation
372372|NCT01198964|Electrocorticography
372373|NCT01198964|electrodes
372374|NCT01198964|mapping
372375|NCT01198938|Cardiac surgery, delirium, melatonin
372376|NCT01198925|Infectious disease
372377|NCT01198925|piperacillin
372378|NCT01198925|continuous infusion
372379|NCT01198925|extended infusion
372380|NCT01198912|rhinosinusitis
372381|NCT01198912|doxycycline
372382|NCT01198912|Chronic rhinosinusitis with or without nasal polyps
372383|NCT01198899|Fabry-Anderson disease
372384|NCT01198899|gen mutation
372385|NCT01198899|left ventricular hypertrophy
372386|NCT01198886|Mobility disability
372387|NCT01198886|Older adults
372388|NCT01198886|Physical activity
372389|NCT01198886|Nutritional status
372390|NCT01198860|HBsAg
372391|NCT01198847|child overweight
372392|NCT01198847|child obesity
372393|NCT01198847|prevention
372394|NCT01198847|targeted intervention
372395|NCT01198847|development of overweight
372396|NCT01198834|ankle sprains
372397|NCT01198821|pancreas
372398|NCT01198821|adenocarcinoma
372399|NCT01198821|metastatic
372400|NCT01198821|unresectable
372401|NCT01198808|Bladder cancer
372402|NCT01198808|chemotherapy
372403|NCT01198808|T cells
372404|NCT01198808|Immunotherapy
372405|NCT01198808|Tumor-specific immunity in bladder cancer
372406|NCT01198795|depression
372407|NCT01198795|major depressive disorder
372408|NCT01198795|escitalopram
372409|NCT01198795|Lexapro
372410|NCT01198795|pediatric
372411|NCT01198769|Human rotavirus vaccine
372412|NCT01198756|Influenza
372413|NCT01198743|Genetics modifications
372414|NCT01198743|colorectal cancer
372415|NCT01198743|prognosis aim
372416|NCT01198743|DNA
372417|NCT01198743|Plasma
372418|NCT01198730|DM
372419|NCT01198730|CAD
372420|NCT01198730|Meal tolerance test
372421|NCT01198730|Acarbose
372422|NCT01198704|Hepatocellular carcinoma
372423|NCT01198704|Cirrhosis
372424|NCT01198704|Transplantation
372425|NCT01198691|metallic staples
372426|NCT01198691|absorbable staples
372427|NCT01198691|Cesarean Delivery
372428|NCT01198665|RAD001
372429|NCT01198665|chemotherpy
372430|NCT01198665|T cell lymphoma
372555|NCT01198106|scopolamine
372431|NCT01198626|community-acquired bacterial pneumonia
372432|NCT01198626|CABP
372433|NCT01198626|CAP
372434|NCT01198626|pneumonia
372435|NCT01198626|pneumonia, bacterial
372436|NCT01198626|bacterial infections
372437|NCT01198626|anti-bacterial agents
372438|NCT01198626|anti-infective agents
372439|NCT01198626|lung disease, interstitial
372440|NCT01198626|respiratory tract diseases
372441|NCT01198626|respiratory tract infections
372442|NCT01198626|community-acquired infections
372443|NCT01198613|Ragweed allergy
372444|NCT01198613|Rhinoconjunctivitis
372445|NCT01198613|Exposure chamber
372446|NCT01198613|Immunotherapy
372447|NCT01198613|ToleroMune Ragweed
372448|NCT01198587|Diarrhea
372449|NCT01198587|Gastroenteritis
372450|NCT01198587|Zinc Supplementation
372451|NCT01198574|anemia
372452|NCT01198574|iron supplementation
372453|NCT01198574|sub-clinical inflammation
372454|NCT01198574|adolescents
372455|NCT01198561|repetitive Transcranial Magnetic Stimulation
372456|NCT01198561|Major Depressive Disorder
372457|NCT01198522|Interleukin, IL2, Gemcitabine, monoclonal, antibody, cytokine, tumour targeting, dose finding, fusion protein, Pancreatic cancer,
372458|NCT01198522|L19
372459|NCT01198509|rheumatoid arthritis
372460|NCT01198509|psoriatic arthritis
372461|NCT01198509|periodontitis
372462|NCT01198509|microbiota
372463|NCT01198509|microbiome
372464|NCT01198509|vancomycin
372465|NCT01198509|doxycycline
372466|NCT01198509|T cell
372467|NCT01198509|Th17
372468|NCT01198496|hypertension
372469|NCT01198496|stroke
372470|NCT01198496|blood pressure
372471|NCT01198483|refraction
372472|NCT01198483|refractive error
372473|NCT01198483|combined surgery
372474|NCT01198483|microincision
372475|NCT01198483|smallincision
372476|NCT01198483|cataract surgery
372477|NCT01198483|vitrectomy
372478|NCT01198470|Low back pain
372479|NCT01198470|Leg pain
372480|NCT01198470|Discogenic pain
372481|NCT01198470|Degenerative Disc Disease (DDD)
372482|NCT01198470|Herniated disc
372483|NCT01198470|Radiculopathy
372484|NCT01198457|Clodronate
372485|NCT01198457|Compliance
372486|NCT01198444|Contraception
372487|NCT01198444|Compliance
372488|NCT01198431|Appetite regulation
372489|NCT01198431|Physical activity
372490|NCT01198431|Energy balance
372491|NCT01198418|STI
372492|NCT01198418|MSM
372493|NCT01198418|HIV
372494|NCT01198418|Prevention
372495|NCT01198418|Men having sex with men
372496|NCT01198405|coronary artery disease
372497|NCT01198405|enhanced external counterpulsation
372498|NCT01198392|gastric cancer
372499|NCT01198379|aspirin
372500|NCT01198379|aspirin resistance
372501|NCT01198379|hemodialysis
372502|NCT01198379|cardiovascular
372503|NCT01198379|Prevalence of aspirin resistance, cardiovascular events, and safety profile
372504|NCT01198366|Tuberculosis
372505|NCT01198366|Vaccine
372506|NCT01198366|Immunogenicity
372507|NCT01198366|Prevention of Tuberculosis
372508|NCT01198353|Schizophrenia
372509|NCT01198353|Schizoaffective Disorder
372510|NCT01198353|Ziprasidone
372511|NCT01198353|Switch
372512|NCT01198353|Metabolic syndrome
372513|NCT01198327|RVO
372514|NCT01198327|CRVO
372515|NCT01198327|BRVO
372516|NCT01198327|Horizon
372517|NCT01198327|Bravo
372518|NCT01198327|Cruise
372519|NCT01198314|long term
372520|NCT01198314|stable
372521|NCT01198314|recipients
372522|NCT01198301|Metastatic Breast Neoplasms
372523|NCT01198301|Gene Expression Profiling
372524|NCT01198301|Drug Therapy
372525|NCT01198288|COPD
372526|NCT01198288|Respiratory Physiotherapy
372527|NCT01198275|PUFA atrial fibrillation
372528|NCT01198262|polymerase chain reaction
372529|NCT01198236|hematological malignancy
372530|NCT01198236|previous proven or probable invasive fungal infection
372531|NCT01198223|denture stomatitis
372532|NCT01198223|nystatin
372533|NCT01198223|garlic
372534|NCT01198210|pain
372535|NCT01198210|tonsillectomy
372536|NCT01198210|peritonsillar infiltration
372537|NCT01198210|postoperative pain
372538|NCT01198197|Nociceptin/Orphanin FQ Peptide (NOP)
372539|NCT01198197|PET Imaging
372540|NCT01198197|Brain Imaging
372541|NCT01198197|Healthy Volunteer
372542|NCT01198197|HV
372543|NCT01198145|diarrhea
372544|NCT01198145|gastrointestinal complications
372545|NCT01198145|unspecified adult solid tumor, protocol specific
372546|NCT01198132|Multiple Sclerosis Relapsing-Remitting
372547|NCT01198132|Relapsing Multiple Sclerosis (RMS)
372548|NCT01198132|Rebif
372549|NCT01198132|Vitamin D3
372550|NCT01198132|Cholecalciferol
372551|NCT01198119|oral cavity tumor
372552|NCT01198119|narrow band imaging
372553|NCT01198119|subclinical cancer lesion
372554|NCT01198106|simulator sickness
372556|NCT01198106|cinnarizine
372557|NCT01198093|Alzheimer's disease
372558|NCT01198093|Mild Cognitive Impairment
372559|NCT01198093|cohort study
372560|NCT01198080|Avascular osteonecrosis,CD133+,core decompression
372561|NCT01198067|Waldenstrom Macroglobulinemia
372562|NCT01198067|B-cell lymphoproliferative disorder
372563|NCT01198067|Bone marrow
372564|NCT01198067|Lymphoplasmacytic cells
372565|NCT01198067|Monoclonal gammopathy
372566|NCT01198067|Pomalidomide
372567|NCT01198067|Actimid
372568|NCT01198067|CC-4047
372569|NCT01198054|AML
372570|NCT01198054|Lenalidomide
372571|NCT01198028|Squamous cell carcinoma of the skin
372572|NCT01198028|Cutaneous squamous cell carcinoma
372573|NCT01198028|CSCC
372574|NCT01198028|epidermal growth factor receptor
372575|NCT01198028|EGFR
372576|NCT01198028|tyrosine kinase inhibitor
372577|NCT01198028|recurrent
372578|NCT01198028|Erlotinib
372579|NCT01198028|Erlotinib hydrochloride
372580|NCT01198028|OSI-774
372581|NCT01198028|Tarceva
372582|NCT01198015|Rett syndrome
372583|NCT01198015|Nutritional status
372584|NCT01198015|Creatine metabolism
372585|NCT01198002|Rheumatoid Arthritis
372586|NCT01197989|pustulosis
372587|NCT01197989|soles
372588|NCT01197989|teflon
372589|NCT01197976|psoriasis
372590|NCT01197976|soles
372591|NCT01197976|teflon
372592|NCT01197963|Type 2 diabetes mellitus
372593|NCT01197950|acupuncture
372594|NCT01197950|labour
372595|NCT01197950|pain
372596|NCT01197950|pain relief
372597|NCT01197950|complementary
372598|NCT01197924|child cancer brain
372599|NCT01197898|Diabetic
372600|NCT01197898|Foot
372601|NCT01197898|Ulcers
372602|NCT01197898|Wounds
372603|NCT01197833|varicose veins
372604|NCT01197833|Great saphenous vein
372605|NCT01197833|varicosities
372606|NCT01197820|HIFU
372607|NCT01197820|mobile organs
372608|NCT01197820|thermometry
372609|NCT01197820|MR
372610|NCT01197820|liver
372611|NCT01197820|kidney
372612|NCT01197820|cancer
372613|NCT01197820|Liver tumors, kidney carcinoma
372614|NCT01197807|Suctioning
372615|NCT01197807|Wiping
372616|NCT01197807|Neonate
372617|NCT01197807|Resuscitation
372618|NCT01197794|Efficacy
372619|NCT01197794|safety
372620|NCT01197794|tolerability
372621|NCT01197794|dose finding
372622|NCT01197794|asthma patients
372623|NCT01197781|Phase I
372624|NCT01197781|FosD
372625|NCT01197781|fostamatinib disodium
372626|NCT01197781|verapamil
372627|NCT01197781|healthy volunteers
372628|NCT01197755|Rheumatoid Arthritis
372629|NCT01197742|Diabetes
372630|NCT01197742|STEMI
372631|NCT01197742|NSTEMI
372632|NCT01197742|Myocardial infarction
372633|NCT01197729|Myocardial infarction
372634|NCT01197729|ST-Elevation myocardial infarction
372635|NCT01197729|Non-ST-Elevation myocardial infarction
372636|NCT01197729|Register
372637|NCT01197729|CARDS
372638|NCT01197716|Chest Pain Unit
372639|NCT01197716|Myocardial infarction
372640|NCT01197716|Register
372641|NCT01197716|Admission to a Chest Pain Unit for any reason
372642|NCT01197703|Clinical Practice Cardiac CT
372643|NCT01197703|Clinical Implications Coronary CT Angiography
372644|NCT01197703|Radiation Exposure of Coronary CT Angiography
372645|NCT01197703|Registry
372646|NCT01197690|Bronchial asthma
372647|NCT01197690|level of control of asthma
372648|NCT01197690|fractional exhaled nitric oxide (FeNO)
372649|NCT01197690|asthma control test (ACT)
372650|NCT01197677|CMR
372651|NCT01197677|Register
372652|NCT01197677|CAD
372653|NCT01197677|myocard scarring
372654|NCT01197651|Aorta
372655|NCT01197651|Aorta-Stent-Graft
372656|NCT01197651|Surgical operation
372657|NCT01197651|Aortic dissection
372658|NCT01197638|Cardiac arrhythmia
372659|NCT01197638|Catheter ablation
372660|NCT01197638|Register
372661|NCT01197625|Vaccination treatment, dendritic cells
372662|NCT01197599|Healthy Control
372663|NCT01197586|surfactant protein B
372664|NCT01197586|differential diagnostics
372665|NCT01197560|Diffuse Large B-Cell Lymphoma
372666|NCT01197560|Non Hodgkin's Lymphoma
372667|NCT01197560|relapsed
372668|NCT01197560|refractory
372669|NCT01197560|relapsed/refractory
372670|NCT01197560|DLBCL
372671|NCT01197560|Diffuse Large B Cell Lymphoma
372672|NCT01197547|Menorrhagia
372673|NCT01197534|Rheumatoid Arthritis
372674|NCT01197521|Rheumatoid Arthritis
372675|NCT01197508|Major Depressive Disorder, MDD, Depression
372676|NCT01197482|asthma
372677|NCT01197482|inhalation
372678|NCT01197469|Secondary Pulmonary Hypertension
372679|NCT01197456|Breast cancer
372680|NCT01197456|Ovarian insufficiency
372681|NCT01197456|Ovarian failure
372682|NCT01197456|Reproduction
372683|NCT01197443|obesity
372684|NCT01197443|overweight
372685|NCT01197443|overweight children
372686|NCT01197443|overweight parents
372687|NCT01197443|families with overweight child
372688|NCT01197443|body mass index
372689|NCT01197443|BMI
372690|NCT01197443|weight
372691|NCT01197443|childhood obesity
372692|NCT01197443|diet
372693|NCT01197443|treatment
372694|NCT01197443|parent modeling
372695|NCT01197443|traffic light diet
372696|NCT01197443|stop light diet
372697|NCT01197430|volleyball
372698|NCT01197430|neck vertical stability training
372699|NCT01197430|eye-hand coordination
372700|NCT01197417|Sickle Cell Disease
372701|NCT01197417|Magnesium Sulfate
372702|NCT01197417|Pediatric
372703|NCT01197404|HIV Prevention
372704|NCT01197378|cystinosis
372705|NCT01197378|cysteamine
372706|NCT01197378|inheritable disease
372707|NCT01197378|orphan disease
372708|NCT01197378|CTNS protein, human
372709|NCT01197378|metabolic disease
372710|NCT01197378|nephropathic cystinosis
372711|NCT01197365|Acidified milk
372712|NCT01197365|Beta-palmitate
372713|NCT01197365|Bifidobacteria
372714|NCT01197365|Infant formula
372715|NCT01197365|Galacto-oligosaccharides
372716|NCT01197365|Growth
372717|NCT01197365|Infants
372718|NCT01197365|Prebiotics
372719|NCT01197352|Alcohol
372720|NCT01197352|Abuse
372721|NCT01197352|Drinking
372722|NCT01197352|Behavior
372723|NCT01197352|Text
372724|NCT01197352|Computer
372725|NCT01197339|acute phonotrauma
372726|NCT01197339|computer modeling
372727|NCT01197339|resonant voice
372728|NCT01197339|breathy voice
372729|NCT01197339|voice rest
372730|NCT01197339|relaxation
372731|NCT01197326|patient deterioration
372732|NCT01197326|unplanned ICU admissions
372733|NCT01197326|rapid response teams
372734|NCT01197313|chronic heart failure (CHF); anxiety and depression; quality of life (QOL); exercise
372735|NCT01197300|Osteoporosis, children and adolescents, zoledronic acid, chronic inflammation, Duchenne muscular dystrophy, glucocorticoids
372736|NCT01197287|Chronic obstructive pulmonary disease
372737|NCT01197274|allergy
372738|NCT01197274|skin prick test
372739|NCT01197274|mite sensitivity
372740|NCT01197261|Severe pain
372741|NCT01197261|Bladder Pain Syndrome
372742|NCT01197261|Interstitial Cystitis
372743|NCT01197261|Painful Bladder Syndrome
372744|NCT01197261|Severe pain due to Bladder Pain Syndrome/Interstitial Cystitis/Painful Bladder Syndrome
372745|NCT01197248|cystocele
372746|NCT01197248|voiding
372747|NCT01197248|dysfunction
372748|NCT01197235|darbepoetin, chronic kidney disease, coronary angiography
372749|NCT01197222|Laparoscopic
372750|NCT01197222|EndoClear
372751|NCT01197222|Lens Cleaning Device
372752|NCT01197209|Prostate Cancer
372753|NCT01197209|Prostatectomy
372754|NCT01197209|Postectomy
372755|NCT01197209|Oncology
372756|NCT01197209|REIC
372757|NCT01197209|Dikkoff
372758|NCT01197209|Apoptosis
372759|NCT01197196|Migraine
372760|NCT01197196|Obesity
372761|NCT01197196|Weight loss
372762|NCT01197196|Lifestyle
372763|NCT01197196|Behavior
372764|NCT01197183|Hypothyroidism
372765|NCT01197183|Thyroid hormones
372766|NCT01197170|Hormonal therapies
372767|NCT01197170|Estrogen receptor
372768|NCT01197170|Progesterone receptor
372769|NCT01197170|Hormone blockade
372770|NCT01197170|Hormone-positive tumors
372771|NCT01197170|Advanced cancer
372772|NCT01197170|Metastatic cancer
372773|NCT01197170|Avastin
372774|NCT01197170|Anti-VEGF monoclonal antibody
372775|NCT01197170|rhuMAB-VEGF
372776|NCT01197170|Afinitor
372777|NCT01197170|RAD001
372778|NCT01197170|Nexavar
372779|NCT01197170|BAY43-9006
372780|NCT01197170|OSI-774
372781|NCT01197170|Tarceva
372782|NCT01197157|chronic hepatitis C
372783|NCT01197157|genotype 4
372784|NCT01197157|treatment naive patients
372785|NCT01197157|Egypt
372786|NCT01197144|TNF
372787|NCT01197144|functional Magnetic Resonance Imaging
372788|NCT01197144|Autonomic
372789|NCT01197144|Vagus
372790|NCT01197144|adalimumab
372791|NCT01197131|autism
372792|NCT01197131|autism spectrum disorder
372793|NCT01197131|steroids
372794|NCT01197131|steroid metabolites
372795|NCT01197131|urinary steroid metabolites
372796|NCT01197131|hormone formation
372797|NCT01197131|androgen precursor
372798|NCT01197118|gastric cancer
372799|NCT01197118|sequence chemoradiotherapy
372800|NCT01197118|OLF regimen
372801|NCT01197118|survival rate
372802|NCT01197105|gingivitis
372803|NCT01197105|schinus terebinthifolius
372804|NCT01197105|natural products
372805|NCT01197092|Diabetes
372806|NCT01197079|HPV
372807|NCT01197079|Vaccine
372808|NCT01197079|Vaccine utilization
372809|NCT01197079|Disease awareness
372810|NCT01197053|Peanut Allergy
372811|NCT01197053|Food Allergy
372812|NCT01197053|Epicutaneous Immunotherapy (EPIT)
372813|NCT01197053|Food Challenge
372814|NCT01197040|Minimal Change Nephrotic Syndrome
372815|NCT01197040|Complete remission
372816|NCT01197040|Myfortic
372817|NCT01197040|Minimal Change Disease
372818|NCT01197014|Amlodipine, Losartan
372819|NCT01197001|Amlodipine, Losartan
372820|NCT01196988|GSK Biologicals influenza vaccine GSK2321138A
372821|NCT01196988|influenza infection
372822|NCT01196975|Influenza
372823|NCT01196962|central venous catheter
372824|NCT01196962|complications
372825|NCT01196962|internal jugular vein
372826|NCT01196962|randomized trial
372827|NCT01196962|subclavian vein
372828|NCT01196949|Ankle
372829|NCT01196949|Chronic
372830|NCT01196949|Instability
372831|NCT01196949|Manipulative
372832|NCT01196949|Rehabilitative
372833|NCT01196949|Manipulation
372834|NCT01196949|Rehabilitation
372835|NCT01196936|Cancer survivors
372836|NCT01196936|Low Dose Tamoxifen
372837|NCT01196936|Breast Cancer Risk Reduction
372838|NCT01196897|Atrial fibrillation
372839|NCT01196897|Stroke
372840|NCT01196897|Warfarin
372841|NCT01196897|Coumadin
372842|NCT01196897|TIA
372843|NCT01196897|Trans Ischemic Attack
372844|NCT01196884|Patients with primary Immune Thrombocytopenia (ITP)
372845|NCT01196871|Fabry disease
372846|NCT01196871|drug drug interaction
372847|NCT01196845|adipose tissue
372848|NCT01196845|obese patients
372849|NCT01196845|inflammation
372850|NCT01196845|oxidative stress
372851|NCT01196845|sleep apnea syndrome
372852|NCT01196806|Non-Invasive Blood Pressure(NIBP)
372853|NCT01196793|Feverish illness in children
372854|NCT01196767|Sternotomy
372855|NCT01196767|Pain
372856|NCT01196767|Respiratory function
372857|NCT01196767|Opiates
372858|NCT01196767|Patient-controlled
372859|NCT01196767|Scheduled cardiac surgery under general anaesthesia without any locoregional anaesthesia protocol other than this presently studied
372860|NCT01196754|Pharmacokinetics
372861|NCT01196754|Sevoflurane
372862|NCT01196754|Fluorides
372863|NCT01196754|Sedation
372864|NCT01196754|Adult patients with a predicted sedation more than 48 h
372865|NCT01196754|Stable respiratory and hemodynamic conditions for SBT
372866|NCT01196754|Consent of patients
372867|NCT01196754|Arterial line
372868|NCT01196715|Quality of Life
372869|NCT01196715|Erythroid response
372870|NCT01196715|disease progression
372871|NCT01196715|survival
372872|NCT01196715|Overall erythroid response at 24 weeks
372873|NCT01196715|Quality of life at 24 weeks
372874|NCT01196715|Quality of life at 12, 36 and 52 weeks
372875|NCT01196715|Overall erythroid response at 12 and 52 weeks
372876|NCT01196715|Incidence of disease progression
372877|NCT01196715|Overall Survival
372878|NCT01196702|common variable immunodeficiency
372879|NCT01196702|granulomatous disease
372880|NCT01196702|crohns disease
372881|NCT01196702|bronchiectasis
372882|NCT01196702|immunoglobulin replacement or treatment
372883|NCT01196702|B-cell immunophenotyping
372884|NCT01196689|Pharmacokinetics AZD1981
372885|NCT01196689|Asthma
372886|NCT01196676|AZD4451
372887|NCT01196676|Bipolar
372888|NCT01196676|depression
372889|NCT01196663|TMS
372890|NCT01196637|thoracic outlet syndrome
372891|NCT01196637|brachial plexopathy
372892|NCT01196637|ultrasonography
372893|NCT01196624|PTSD
372894|NCT01196624|FLASHBACKS
372895|NCT01196624|TMS
372896|NCT01196624|EXPOSURE
372897|NCT01196611|Voice disorders
372898|NCT01196611|Voice
372899|NCT01196598|pelvic floor
372900|NCT01196598|pelvic organ prolapse
372901|NCT01196585|Pleura
372902|NCT01196585|biopsy
372903|NCT01196585|diagnosis
372904|NCT01196585|CT
372905|NCT01196585|ultrasonography
372906|NCT01196572|stricture
372907|NCT01196572|urethra
372908|NCT01196572|laser
372909|NCT01196572|urethrotomy
372910|NCT01196572|holmium
372911|NCT01196572|bladder outlet obstruction
372912|NCT01196559|ovarian cancer
372913|NCT01196546|Type 2 Diabetes Mellitus
372914|NCT01196546|vildagliptin
372915|NCT01196546|metformin
372916|NCT01196533|Non Invasive, Invasive, optical, light source, color image sensor,
372917|NCT01196533|, Hemodynamic, Arterial Systolic, Arterial Diastolic, MAP, PA Systolic,
372918|NCT01196533|PA Diastolic, Heart rate, Stroke volume, CBC, WBC, RBC, Hgb, HCT ,Iron.
372919|NCT01196533|PLT, PH, PCO2, PO2, HCO3, SaO2 , Na, K, Cl, CO2, Bun, Cr, Gluc, HGB (A1C),
372920|NCT01196533|TBiLi, LDL, HDL.
372921|NCT01196520|Burkitt Lymphoma
372922|NCT01196520|Epstein-Barr Virus
372923|NCT01196520|Malaria
372924|NCT01196494|Obstructive left-sided colonic cancer
372925|NCT01196494|Colorectal stent
372926|NCT01196494|Intraoperative colon lavage
372927|NCT01196494|Lavage
372928|NCT01196494|Stent
372929|NCT01196468|HIV
372930|NCT01196468|Testing
372931|NCT01196468|Targeted
372932|NCT01196468|Indicator
372933|NCT01196468|Diseases
372934|NCT01196468|Anal dysplasia
372935|NCT01196468|Cervical dysplasia
372936|NCT01196468|STI
372937|NCT01196468|Lymphoma
372938|NCT01196468|Seborrhoeic dermatitis
372939|NCT01196468|Exanthema
372940|NCT01196468|Thrombocytpaenia
372941|NCT01196468|Lymphopaenia
372942|NCT01196468|Hypergammaglobulinaemia
372943|NCT01196455|Metastatic breast cancer patients
372944|NCT01196403|transitional cell carcinoma of the bladder
372945|NCT01196403|squamous cell carcinoma of the bladder
372946|NCT01196403|adenocarcinoma of the bladder
372947|NCT01196403|stage I bladder cancer
372948|NCT01196403|stage II bladder cancer
372949|NCT01196403|stage III bladder cancer
372950|NCT01196377|Asthma
372951|NCT01196377|Acute asthma
372952|NCT01196377|Pediatrics
372953|NCT01196364|Girls
372954|NCT01196351|boys
372955|NCT01196351|obesity
372956|NCT01196351|physical activity
372957|NCT01196351|exercise
372958|NCT01196338|Ankle fracture
372959|NCT01196338|Return to work
372960|NCT01196338|Return to function
372961|NCT01196338|Rehabilitation
372962|NCT01196338|Weight-bearing
372963|NCT01196325|Diabetes
372964|NCT01196325|Diabetic Macular Edema
372965|NCT01196325|Laser
372966|NCT01196325|Anti-VEGF
372967|NCT01196325|Morphology
372968|NCT01196325|Blood Flow
372969|NCT01196325|Vision
372970|NCT01196312|anxiety sensitivity
372971|NCT01196312|heroin
372972|NCT01196299|diffusion tensor imaging
372973|NCT01196299|magnetic resonance spectroscopy
372974|NCT01196299|traumatic brain injury
372975|NCT01196299|Metabolite changes
372976|NCT01196299|Cerebral perfusion
372977|NCT01196299|Hemorrhagic burden
372978|NCT01196286|First-episode psychosis
372979|NCT01196286|cognitive remediation
372980|NCT01196286|family psychoeducation
372981|NCT01196273|Cardiac Diseases,
372982|NCT01196273|HIV-Infection,
372983|NCT01196273|AIDS,
372984|NCT01196273|Antiretroviral Therapy,
372985|NCT01196273|Cardiovascular Medication,
372986|NCT01196273|Risk Factors,
372987|NCT01196273|coronary heart disease,
372988|NCT01196273|heart failure,
372989|NCT01196273|metabolic syndrome
372990|NCT01196260|efficiency
372991|NCT01196260|capecitabine
372992|NCT01196260|oxaliplatin
372993|NCT01196260|colorectal cancer
372994|NCT01196247|pancreatic cancer
372995|NCT01196247|molecular profiling
372996|NCT01196247|SU2C
372997|NCT01196247|Second line therapy
372998|NCT01196247|Stage 4
372999|NCT01196208|Disease, Hodgkin
373000|NCT01196208|Lymphoma
373001|NCT01196208|Monomethylauristatin E
373002|NCT01196208|Lymphoma, Large-Cell, Anaplastic
373003|NCT01196208|Lymphoma, T-Cell, Cutaneous
373004|NCT01196208|Lymphoma, Non-Hodgkin
373005|NCT01196208|Antibodies, Monoclonal
373006|NCT01196208|Antibody-Drug Conjugate
373007|NCT01196208|Antigens, CD30
373008|NCT01196208|Hematologic Diseases
373009|NCT01196208|Immunotherapy
373010|NCT01196195|antiretroviral therapy
373011|NCT01196195|child
373012|NCT01196195|HIV-1
373013|NCT01196169|daptomycin
373014|NCT01196169|vancomycin
373015|NCT01196169|perioperative
373016|NCT01196169|prophylaxis
373017|NCT01196169|arthroplasty
373018|NCT01196169|prosthesis
373019|NCT01196169|preoperative
373020|NCT01196156|Infant, Small for Gestational Age
373021|NCT01196156|Dwarfism Pituitary
373022|NCT01196156|Saizen
373023|NCT01196156|Somatropin; Growth Hormone
373024|NCT01196156|Insulin resistance
373025|NCT01196143|Ovulation induction
373026|NCT01196143|Intrauterine insemination
373027|NCT01196143|Gonal-f
373028|NCT01196143|Controlled ovarian stimulation
373029|NCT01196143|Female infertility
373030|NCT01196130|Metastatic colorectal cancer
373031|NCT01196130|CRC
373032|NCT01196130|Colorectal adenocarcinoma
373033|NCT01196130|Biomarker determination
373034|NCT01196130|Tumor tissue
373035|NCT01196130|Treatment protocols
373036|NCT01196117|automatic positive airway pressure (APAP)
373037|NCT01196117|continuous positive airway pressure (CPAP)
373038|NCT01196117|Salivary Cortisol
373039|NCT01196117|Apnea
373040|NCT01196117|Sleep Apnea and/or any Sleep Disordered Breathing
373041|NCT01196091|Lupus
373042|NCT01196091|SLE
373043|NCT01196091|Systemic Lupus Erythematosis
373044|NCT01196091|autoimmune disease
373045|NCT01196091|LY2127399
373046|NCT01196091|Immune system disease
373047|NCT01196026|Influenza
373048|NCT01196026|H1N1
373049|NCT01196026|Fluarix
373050|NCT01196026|Pandemrix
373051|NCT01195987|Hepatitis C
373052|NCT01195987|Arthritis
373053|NCT01195974|oral contraceptive, drug interaction, pharmacokinetics
373054|NCT01195961|Direct Current Stimulation
373055|NCT01195961|Learning
373056|NCT01195961|Cognitive Enhancement
373057|NCT01195961|Cognitive Tasks
373058|NCT01195961|Cognitive Training
373059|NCT01195961|Developmental Dyscalculia
373060|NCT01195961|Learning Disability
373061|NCT01195961|Cognition Disorder
373062|NCT01195948|Uveitis
373063|NCT01195948|Oral Tolerance
373064|NCT01195922|Head and Neck Squamous Cell Carcinoma
373065|NCT01195922|Oral Cancer
373066|NCT01195922|mTOR Inhibitors
373067|NCT01195922|Targeted Therapies
373068|NCT01195922|Signal Transduction Inhibitors
373069|NCT01195922|Head and Neck Cancer
373070|NCT01195922|Squamous Cell Carcinoma
373071|NCT01195922|Tongue Cancer
373072|NCT01195883|IV fluid
373073|NCT01195883|recovery
373074|NCT01195883|goal directed fluid replacement
373075|NCT01195883|improved patient recovery
373076|NCT01195870|Multiple sclerosis
373077|NCT01195870|Rebif
373078|NCT01195870|Interferon beta-1a
373079|NCT01195857|Multiple sclerosis
373080|NCT01195857|Rebif
373081|NCT01195857|Interferon beta-1a
373082|NCT01195844|Pediatric gastroenteritis, rotavirus infection
373083|NCT01195818|Albuminuria, hyperfiltration, RAS inhibitors, ADMA
373084|NCT01195805|Blood pressure, PWV, HRV, PWV, potassium
373085|NCT01195792|Opioid receptors
373086|NCT01195792|Body weight
373087|NCT01195792|Over-eating behaviour
373088|NCT01195792|Obesity
373089|NCT01195792|Fat mass
373090|NCT01195779|immunogenicity
373091|NCT01195779|safety
373092|NCT01195779|Influenza
373093|NCT01195779|children
373094|NCT01195779|vaccine
373095|NCT01195766|Hodgkin
373096|NCT01195766|Ofatumumab
373097|NCT01195766|Lymphoma
373098|NCT01195753|Urea cycle Disorders
373099|NCT01195740|Suicide Ideation
373100|NCT01195740|Depression
373101|NCT01195740|Family Conflict
373102|NCT01195701|female sexual dysfunction
373103|NCT01195701|anorgasmia
373104|NCT01195701|clitoral complex
373105|NCT01195701|pelvic MRI
373106|NCT01195701|testosterone
373107|NCT01195662|Diabetes Mellitus, Type 2
373108|NCT01195662|Diabetes Mellitus
373109|NCT01195662|Endocrine System Diseases
373110|NCT01195662|Glucose Metabolism Disorders
373111|NCT01195662|Metabolic Diseases
373112|NCT01195662|Angiotensin Receptor Inhibitors
373113|NCT01195662|Angiotensin-Converting Enzyme Inhibitors
373114|NCT01195662|Antihypertensive Agents
373115|NCT01195662|Cardiovascular Agents
373116|NCT01195662|Pharmacological Actions
373117|NCT01195636|Pain from Shingles, PHN, Postherpetic Neuralgia
373118|NCT01195623|varicose veins
373119|NCT01195623|venous insufficiency
373120|NCT01195623|surgery
373121|NCT01195623|duplex
373122|NCT01195623|recurrence
373123|NCT01195597|electronic cigarette
373124|NCT01195597|ENDD
373125|NCT01195597|nicotine
373126|NCT01195597|smoking cessation
373127|NCT01195597|smoking reduction
373128|NCT01195584|complication rate in 3 cohorts (BMI < 25, > 25 and > 30)
373129|NCT01195558|Non-24
373130|NCT01195558|N24HSWD
373131|NCT01195558|Blindness
373132|NCT01195558|Sleep
373133|NCT01195558|Wake
373134|NCT01195558|Circadian Rhythm
373135|NCT01195558|Nap
373136|NCT01195545|Veritas® Collagen Matrix, Hiatal hernia
373137|NCT01195532|hypoglycemic drug
373138|NCT01195519|peritoneal dialysis
373139|NCT01195519|hemodialysis patients
373140|NCT01195506|We Will Collect the Bone Marrow Specimens From AML Patients
373141|NCT01195493|Chronic periodontitis
373142|NCT01195480|Immunotherapy
373143|NCT01195480|Gene Therapy
373144|NCT01195480|Paediatric
373145|NCT01195480|B cell Acute Lymphoblastic Leukaemia
373146|NCT01195441|Preeclampsia
373147|NCT01195441|Doppler ultrasound
373148|NCT01195441|First trimester
373149|NCT01195441|Acetylsalicylic acid
373150|NCT01195402|COPD
373151|NCT01195402|pulmonary rehabilitation
373152|NCT01195389|dementia
373153|NCT01195389|memory loss
373154|NCT01195389|cognitive decline
373155|NCT01195376|PI3K
373156|NCT01195376|mTOR
373157|NCT01195376|Advanced solid tumor
373158|NCT01195363|bipolar disorder, mania, depression
373159|NCT01195350|Ischemic Stroke
373160|NCT01195350|Hemorrhagic Stroke
373161|NCT01195350|Blood pressure
373162|NCT01195350|Intensive care
373163|NCT01195337|Sedentary minority adult
373164|NCT01195337|Psychosocial factors
373165|NCT01195337|Environmental factors
373166|NCT01195337|Obesity
373167|NCT01195337|Physical Activity
373168|NCT01195337|PA
373169|NCT01195337|Cancer Risk
373170|NCT01195337|African Americans
373171|NCT01195337|Latino
373172|NCT01195324|Canagliflozin (JNJ-28431754)
373173|NCT01195324|Warfarin
373174|NCT01195324|Pharmacokinetic
373175|NCT01195324|Pharmacodynamic
373176|NCT01195324|Prothrombin time (PT)
373177|NCT01195324|International normalized ratio (INR)
373178|NCT01195311|Refractory, Advanced malignancies
373179|NCT01195298|metastatic breast cancer
373180|NCT01195298|elderly patients
373181|NCT01195298|chemoimmunotherapy
373182|NCT01195298|Triple negative metastatic breast cancer
373183|NCT01195285|Laparoscopic cholecystectomy
373184|NCT01195285|Quality of life
373185|NCT01195285|Biliary Cholic
373186|NCT01195285|Chronic Cholecystitis
373187|NCT01195285|Symptomatic Cholelithiasis
373188|NCT01195259|rosiglitazone
373189|NCT01195259|ADOPT
373190|NCT01195259|metformin
373191|NCT01195259|malignancy
373192|NCT01195259|RECORD
373193|NCT01195246|end stage renal failure
373194|NCT01195246|renal failure
373195|NCT01195246|kidney failure
373196|NCT01195246|kidney failure, chronic
373197|NCT01195246|chronic kidney failure
373198|NCT01195246|hepatitis B virus (HBV) vaccine
373199|NCT01195246|hepatitis B vaccine
373200|NCT01195246|hepatitis B
373201|NCT01195246|hepatitis
373202|NCT01195246|HBV
373203|NCT01195246|prevention and control
373204|NCT01195246|dialysis
373205|NCT01195233|Xerostomia
373206|NCT01195233|Radiotherapy of head and neck
373207|NCT01195233|BioXtra
373208|NCT01195220|STI screening
373209|NCT01195220|Emergency Department
373210|NCT01195220|Chlamydia
373211|NCT01195220|Gonorrhea
373212|NCT01195220|HIV
373213|NCT01195220|behavior
373214|NCT01195220|teenagers
373215|NCT01195220|intervention
373216|NCT01195207|CNTO 3157
373217|NCT01195207|healthy volunteers
373218|NCT01195207|asthma
373219|NCT01195194|T-cell lymphocyte allo-recognition
373220|NCT01195194|CNI-free immunosuppressive regimen
373221|NCT01195194|Enzyme-linked immunospot (ELISPOT)
373222|NCT01195181|peginterferon alfa 2a and 2b type
373223|NCT01195181|ribavirin
373224|NCT01195181|chronic hepatitis C
373225|NCT01195181|antiviral therapy cost/efficacy
373226|NCT01195181|viral kinetics
373227|NCT01195168|PCOS
373228|NCT01195155|PCOS
373229|NCT01195142|PCOS
373230|NCT01195129|Stent
373231|NCT01195129|cerebral aneursym
373232|NCT01195129|neurology
373233|NCT01195129|radiology
373234|NCT01195116|Post-operative pain management
373235|NCT01195116|Pain Management
373236|NCT01195116|Painful bladder syndrome
373237|NCT01195116|frequency and urgency
373238|NCT01195116|Dexmedetomidine
373239|NCT01195116|hydrodistension
373240|NCT01195103|Procedural sedation
373241|NCT01195103|Regional Anesthesia block
373242|NCT01195103|Orthopedic surgery
373243|NCT01195103|Lusedra
373244|NCT01195103|Fospropofol disodium
373245|NCT01195103|Midazolam
373246|NCT01195090|sitagliptin
373247|NCT01195090|pioglitazone
373248|NCT01195090|type 2 diabetes
373249|NCT01195077|HIV
373250|NCT01195077|Dietary intervention
373251|NCT01195077|Algae
373252|NCT01195077|HIV progression
373253|NCT01195077|Algae specific kind
373254|NCT01195064|COPD patients
373255|NCT01195064|OSAS patients
373256|NCT01195064|cardiovascular surgery
373257|NCT01195064|Endothelial function
373258|NCT01195051|Medication Reconciliation
373259|NCT01195051|Inpatient
373260|NCT01195051|Electronic Medical Records
373261|NCT01195038|Avian influenza, H5N1, pandemic, recombinant HA vaccine
373262|NCT01195025|Blood volume
373263|NCT01195025|blood coagulation
373264|NCT01195025|volume kinetics
373265|NCT01195012|child
373266|NCT01195012|primary care
373267|NCT01195012|treatment
373268|NCT01195012|parenting
373269|NCT01195012|lifestyle behaviors
373270|NCT01194999|OAB
373271|NCT01194999|Urinary Bladder, Overactive
373272|NCT01194999|Overactive Bladder Syndrome
373273|NCT01194999|VESIcare
373274|NCT01194999|Urgency
373275|NCT01194999|Nocturia
373276|NCT01194999|Frequency
373277|NCT01194999|Urge Urinary Incontinence
373278|NCT01194999|UUI
373279|NCT01194999|Pubovaginal Sling
373280|NCT01194999|PVS
373281|NCT01194999|Incontinence
373282|NCT01194986|Receptor binding
373283|NCT01194986|Histamine H3 receptor
373284|NCT01194986|binding
373285|NCT01194986|radioligand
373286|NCT01194973|Atypical Hemolytic-Uremic Syndrome
373287|NCT01194960|cancer of prostate
373288|NCT01194960|cancer of the prostate
373289|NCT01194960|neoplasms prostate
373290|NCT01194960|neoplasms prostatic
373291|NCT01194960|prostate cancer
373292|NCT01194960|prostate neoplasms
373293|NCT01194960|prostatic cancer
373294|NCT01194960|prostate specific antigen
373295|NCT01194960|prostatic hyperplasia
373296|NCT01194947|banal-appearing nevi
373297|NCT01194947|NEVUS
373298|NCT01194934|Stem Cell Transplantation
373299|NCT01194934|SDF-1
373300|NCT01194934|L-oligonucleotide Aptamer
373301|NCT01194934|Spiegelmer
373302|NCT01194934|Hematopoietic Stem Cells
373303|NCT01194908|Breast Cancer
373304|NCT01194908|Breast Tumors
373305|NCT01194908|Breast Neoplasms
373306|NCT01194895|esophagectomy
373307|NCT01194895|acute lung injury
373308|NCT01194895|protective ventilation
373309|NCT01194869|Breast Cancer
373310|NCT01194856|HIV
373311|NCT01194856|Lipoatrophy
373312|NCT01194856|mitochondrial dysfunction
373313|NCT01194817|total knee arthroplasty
373314|NCT01194817|total knee replacement
373315|NCT01194817|cementless TKA
373316|NCT01194817|high flexion
373317|NCT01194817|trabecular metal
373318|NCT01194804|Hemolytic Paroxysmal Nocturnal Hemoglobinuria
373319|NCT01194804|Eculizumab
373320|NCT01194804|PNH
373321|NCT01194791|Amyloidosis
373322|NCT01194791|Lenalidomide
373323|NCT01194141|Barth syndrome
373324|NCT01194141|cardiomyopathy
373325|NCT01194141|mitochondria
373326|NCT01194141|cardiolipin
373327|NCT01194128|caregivers,
373328|NCT01194128|institutionalization,
373329|NCT01194128|dementia patients,
373330|NCT01194128|bereavement,
373331|NCT01194128|grief
373332|NCT01194128|complicated grief
373333|NCT01194115|surgical site infection
373334|NCT01194115|obesity
373335|NCT01194115|pregnancy
373336|NCT01194115|cesarean section
373337|NCT01194115|cesarean delivery
373338|NCT01194102|Stroke
373339|NCT01194102|Exercise
373340|NCT01194102|Physical function
373341|NCT01194102|Community program
373342|NCT01194102|Patient education
373343|NCT01194102|Self-management
373344|NCT01194089|Nicotine
373345|NCT01194089|Postoperative pain
373346|NCT01194089|Bariatric surgery
373347|NCT01194076|cognitive behavior therapy
373348|NCT01194076|exposure and response prevention
373349|NCT01194076|pediatric
373350|NCT01194076|obsessive compulsive disorder
373351|NCT01194076|child
373352|NCT01194076|anxiety
373353|NCT01194076|intensive
373354|NCT01194076|OCD
373355|NCT01194076|CBT
373356|NCT01194063|short bowel syndrome
373357|NCT01194063|parenteral nutrition associated liver disease
373358|NCT01194063|pediatric
373359|NCT01194037|Hepatitis C
373360|NCT01194037|HCV
373361|NCT01194037|Interferon
373362|NCT01194037|Hanferon
373363|NCT01194024|Inhalation Injury, Smoke
373364|NCT01194024|Inhalation Injury, Acute
373365|NCT01194011|Health care quality, information openness, health care information website
373366|NCT01194713|Alzheimer Disease
373367|NCT01194713|Cerebrospinal fluid
373368|NCT01194713|Sleep
373369|NCT01194713|Abeta
373370|NCT01194700|lung bioavailability
373371|NCT01194700|asthma
373372|NCT01194700|seretide
373373|NCT01194700|Spacer
373374|NCT01194687|Estrogens
373375|NCT01194687|Fecal Microbiome
373376|NCT01194687|Fecal Occult Blood
373377|NCT01194674|Microplasmin
373378|NCT01194674|Macular Edema
373379|NCT01194674|Uveitis
373380|NCT01194661|Inhibitory Control
373381|NCT01194661|Executive Function
373382|NCT01194661|fMRI
373383|NCT01194661|TMS
373384|NCT01194661|TBI
373385|NCT01194661|Traumatic Brain Injury
373386|NCT01194661|Healthy Volunteer
373387|NCT01194661|HV
373388|NCT01194648|urinary incontinence
373389|NCT01194648|male erectile disorder
373390|NCT01194648|therapy-related toxicity
373391|NCT01194648|stage I prostate cancer
373392|NCT01194648|stage IIB prostate cancer
373393|NCT01194648|stage IIA prostate cancer
373394|NCT01194635|stage IV squamous cell carcinoma of the lip and oral cavity
373395|NCT01194635|stage IV verrucous carcinoma of the oral cavity
373396|NCT01194635|stage IV squamous cell carcinoma of the nasopharynx
373397|NCT01194635|stage IV squamous cell carcinoma of the oropharynx
373398|NCT01194635|stage IV squamous cell carcinoma of the hypopharynx
373399|NCT01194635|stage IV squamous cell carcinoma of the larynx
373400|NCT01194635|stage IV verrucous carcinoma of the larynx
373401|NCT01194609|Low dose radiation
373402|NCT01194609|Adoptive immune cell therapy
373403|NCT01194609|Cervical cancer
373404|NCT01194609|Pilot study
373405|NCT01194596|smoking cessation advice
373406|NCT01194596|spirometry
373407|NCT01194596|primary health care
373408|NCT01194583|electronic cigarette
373409|NCT01194583|nicotine
373410|NCT01194583|smoking cessation
373411|NCT01194583|smoking reduction
373412|NCT01194557|history of fever
373413|NCT01194557|measured fever
373414|NCT01194557|appropriate treatment
373415|NCT01194557|appropriate referral
373416|NCT01194531|Preimplantation Gentic Screening
373417|NCT01194531|PGS
373418|NCT01194531|In Vitro Fertilization
373419|NCT01194531|IVF
373420|NCT01194531|Preimplantation Genetic Diagnosis
373421|NCT01194531|PGD
373422|NCT01194518|Life experience
373423|NCT01194518|Life style
373424|NCT01194518|Health behavior
373425|NCT01194518|Mixed method
373426|NCT01194505|anterior cruciate ligament reconstruction
373427|NCT01194505|obturator nerve block
373428|NCT01194505|sciatic nerve block
373429|NCT01194505|femoral nerve block
373430|NCT01194505|posterior lumbar plexus block
373431|NCT01194505|ultrasound guided nerve block
373432|NCT01194492|plasma albumin
373433|NCT01194492|inflammatory reaction
373434|NCT01194492|systemic inflammatory response syndrome
373435|NCT01194479|type 1 diabetes
373436|NCT01194479|hypoglycemia
373437|NCT01194479|formoterol
373438|NCT01194466|Head and Neck Cancer
373439|NCT01194466|Oral Cancer
373440|NCT01194466|Laryngeal Cancer
373441|NCT01194466|Oropharyngeal Cancer
373442|NCT01194466|Transcutaneous Electrical Nerve Stimulation (TENS)
373443|NCT01194466|Oral Mucositis
373444|NCT01194466|Pain
373445|NCT01194466|Function
373446|NCT01194466|TENS
373447|NCT01194466|Functional Pain
373448|NCT01194466|Non-pharamcologic
373449|NCT01194466|Quality of Life
373450|NCT01194427|Preoperative
373451|NCT01194427|Neoadjuvant
373452|NCT01194388|Patients presenting with an intracranial aneurysm
373453|NCT01194362|aortic valve disease
373454|NCT01194362|gene expression
373455|NCT01194349|S. pneumoniae
373456|NCT01194349|thrombocytosis
373457|NCT01194349|pediatric patients
373458|NCT01194349|The study aimed to understand the diagnostic value of thrombocytosis in children with S. pneumoniae infection
373459|NCT01194336|Central nervous system
373460|NCT01194336|Cholinesterase
373461|NCT01194336|Neurocognitive performance testing
373462|NCT01194323|esophageal erosion
373463|NCT01194323|abnormal pH monitoring
373464|NCT01194310|glaucoma
373465|NCT01194310|cataract
373466|NCT01194297|influenza
373467|NCT01194297|premature infant
373468|NCT01194297|very low birth weight infant
373469|NCT01194297|immunization
373470|NCT01194297|vaccine
373471|NCT01194271|Hormone Ablation
373472|NCT01194271|Prostate adenocarcinoma
373473|NCT01194271|Radical prostatectomy
373474|NCT01194271|Leuprolide Acetate
373475|NCT01194271|Lupron Depot
373476|NCT01194271|Ipilimumab
373477|NCT01194271|BMS-734016
373478|NCT01194271|MDX010
373479|NCT01194258|Type 2 diabetes
373480|NCT01194245|Type 1 diabetes
373481|NCT01194232|Cystic Fibrosis
373482|NCT01194232|CF
373483|NCT01194232|CMRI
373484|NCT01194232|vascularization
373485|NCT01194232|perfusion
373486|NCT01194219|Plaque Psoriasis
373487|NCT01194193|Cancer
373488|NCT01194193|Advanced solid tumours
373489|NCT01194193|lymphomas
373490|NCT01194193|dose escalation
373491|NCT01194193|preliminary anti-tumour activity
373492|NCT01194193|Tor kinase inhibitor
373493|NCT01194193|oral administration
373494|NCT01194193|intermittent dosing
373495|NCT01194180|Mycobacterium tuberculosis
373496|NCT01194180|BCG
373497|NCT01194180|MVA85A
373498|NCT01194167|Platelet refractory thrombocytopenia
373499|NCT01193972|Smoking cessation
373500|NCT01193972|Smoking
373501|NCT01193972|Tobacco
373502|NCT01193946|Protein requirement
373503|NCT01193946|Elderly women
373504|NCT01193946|Indicator amino acid oxidation
373505|NCT01193933|adult ALL
373506|NCT01193933|Ph-negative
373507|NCT01193933|dexamethasone
373508|NCT01193933|L-asparaginase
373509|NCT01193920|Group B streptococcus
373510|NCT01193920|GBS
373511|NCT01193920|Vaccine
373512|NCT01193920|Prevention of group B streptococcus infection
373513|NCT01193907|Typhoid fever
373514|NCT01193907|Glycoconjugate vaccine
373515|NCT01193907|Vi polysaccharide
373516|NCT01193907|Immunogenicity
373517|NCT01193894|IBD
373518|NCT01193894|UC
373519|NCT01193894|Profermin
373520|NCT01193894|Fresubin
373521|NCT01193894|Probiotics
373522|NCT01193894|Dietetic
373523|NCT01193855|stage IIB prostate cancer
373524|NCT01193855|stage IIA prostate cancer
373525|NCT01193816|restlessness during mechanical ventilation weaning
373526|NCT01193803|Prosthetic Joint Infections
373527|NCT01193803|Vertebral Osteomyelitis
373528|NCT01193803|Septic arthritis
373529|NCT01193803|Molecular methods
373530|NCT01193790|chronic tonsillitis
373531|NCT01193790|radio-frequency coblation
373532|NCT01193790|radio-frequency coblation in chronic tonsillitis treatment
373533|NCT01193777|Carnitine
373534|NCT01193777|Shock
373535|NCT01193777|Sepsis
373536|NCT01193764|acne
373537|NCT01193764|cocoa
373538|NCT01193764|chocolate
373539|NCT01193764|gelatin
373540|NCT01193764|pustule
373541|NCT01193764|comedones
373542|NCT01193764|papules
373543|NCT01193764|pustules
373544|NCT01193751|Birth Asphyxia
373545|NCT01193751|Newborn's Resuscitation
373546|NCT01193751|Death
373547|NCT01193751|Neurodevelopmental Impairment
373548|NCT01193738|osteopathy
373549|NCT01193725|Combat Disorders
373550|NCT01193725|Exposure Therapy
373551|NCT01193725|Army Personnel
373552|NCT01193712|Electrophysiologic Techniques, Cardiac
373553|NCT01193660|umbilical cord blood
373554|NCT01193660|stem cell
373555|NCT01193660|cerebral palsy
373556|NCT01193634|ICD VR 9250, DR 9550 and CRT 9750 - PARADYM RF ICD
373557|NCT01193621|early evaluation
373558|NCT01193621|pharmacokinetics
373559|NCT01193621|pharmacodynamics
373560|NCT01193621|Biodistribution
373561|NCT01193621|D2-receptor occupancy
373562|NCT01193608|Randomized
373563|NCT01193608|Safety Study
373564|NCT01193608|Adaptive
373565|NCT01193608|Double Blind
373566|NCT01193582|Prevenar
373567|NCT01193582|catch-up
373568|NCT01193582|pneumococcal
373569|NCT01193582|pneumonia
373570|NCT01193556|Tonsillectomy
373571|NCT01193556|PlasmaBlade
373572|NCT01193556|Electrosurgery
373573|NCT01193556|PEAK Surgical
373574|NCT01193556|Medtronic Advanced Energy
373575|NCT01193556|Medtronic
373576|NCT01193530|Sleep Disturbances
373577|NCT01193530|Depression
373578|NCT01193530|Anxiety
373579|NCT01193530|Fatigue
373580|NCT01193530|Quality of life
373581|NCT01193517|Refractory metastatic colorectal cancer
373582|NCT01193517|CRC
373583|NCT01193517|colorectal adenocarcinoma with metastatic disease
373584|NCT01193517|Azacitidine
373585|NCT01193517|5-Azacytidine
373586|NCT01193517|5-aza
373587|NCT01193517|Vidaza
373588|NCT01193517|5-AZC
373589|NCT01193517|AZA-CR
373590|NCT01193517|Ladakamycin
373591|NCT01193517|NSC-102816
373592|NCT01193517|Capecitabine
373593|NCT01193517|Oxaliplatin
373594|NCT01193517|CAPOX
373595|NCT01193517|Xeloda
373596|NCT01193517|Eloxatin
373597|NCT01193517|Hypermethylation
373598|NCT01193517|CpG island methylator phenotype
373599|NCT01193504|Prevention of Retinal Thickening and CME Following Phacoemulsification
373600|NCT01193504|Pseudophakia following cataract surgery
373601|NCT01193491|Phase 1
373602|NCT01193491|AML
373603|NCT01193491|CML
373604|NCT01193491|MPD
373605|NCT01193491|Client Proteins
373606|NCT01193491|Hsp90
373607|NCT01193478|Hepatitis C
373608|NCT01193478|HCV RNA
373609|NCT01193478|multiple ascending dose
373610|NCT01193478|NS5A
373611|NCT01193478|GS-5885
373612|NCT01193478|chronic genotype 1 HCV infection
373613|NCT01193465|Humidity
373614|NCT01193465|Temperature
373615|NCT01193465|Low Flow Anesthesia
373616|NCT01193452|elderly patients
373617|NCT01193452|advanced colorectal cancer
373618|NCT01193452|chemotherapy
373619|NCT01193452|S-1
373620|NCT01193452|5-fluorouracil
373621|NCT01193452|leucovorin
373622|NCT01193439|thoracoscopy
373623|NCT01193439|pleural diseases
373624|NCT01193439|complications
373625|NCT01193439|safety
373626|NCT01193426|Hepatic
373627|NCT01193426|cirrhosis
373628|NCT01193426|IL-6
373629|NCT01193426|IL-8
373630|NCT01193426|Leptine
373631|NCT01193413|acute pancreatitis
373632|NCT01193413|Drainage
373633|NCT01193413|Pancreatic surgery
373634|NCT01193413|Biological Markers/analysis
373635|NCT01193413|Infection diagnosis
373636|NCT01193413|ROC Curve
373637|NCT01193413|Sensitivity and Specificity
373638|NCT01193413|Endoscopic ultrasonography
373639|NCT01193400|Acute myelogenous leukemia
373640|NCT01193400|Clofarabine
373641|NCT01193400|Cytarabine
373642|NCT01193374|Childhood Obesity
373643|NCT01193374|Primary Care
373644|NCT01193374|Counseling
373645|NCT01193374|Screening
373646|NCT01193348|Atypical Hemolytic-Uremic Syndrome
373647|NCT01193335|13-valent pneumococcal conjugate vaccine
373648|NCT01193335|premature
373649|NCT01193335|immunization
373650|NCT01193335|safety.
373651|NCT01193296|Diabetes mellitus, vildagliptin, continuous glucose monitoring
373652|NCT01193283|Aplastic Anemia
373653|NCT01193283|Immunosuppression
373654|NCT01193283|T-Cells
373655|NCT01193283|Hematopoiesis
373656|NCT01193283|Autoimmunity
373657|NCT01193283|Severe Aplastic Anemia
373658|NCT01193270|NICHD Neonatal Research Network
373659|NCT01193270|Intraventricular Hemorrhage (IVH)
373660|NCT01193270|Very Low Birth Weight (VLBW)
373661|NCT01193270|Extremely Low Birth Weight (ELBW)
373662|NCT01193270|Prematurity
373663|NCT01193231|Laser Vision Correction
373664|NCT01193231|Photorefractive Keratectomy
373665|NCT01193231|PRK
373666|NCT01193231|Nearsighted
373667|NCT01193231|Myopia
373668|NCT01193205|Borderline Personality Disorder
373669|NCT01193205|Skills Training
373670|NCT01193205|Dialectical Behavior Therapy
373671|NCT01193205|Suicidal and parasuicidal behavior
373672|NCT01193192|Neevo
373673|NCT01193192|Neevo DHA
373674|NCT01193192|L-methylfolate
373675|NCT01193192|anemia during pregnancy
373676|NCT01193192|folic acid
373677|NCT01193192|vitamin B12
373678|NCT01193192|prenatal vitamins
373679|NCT01193192|hemoglobin
373680|NCT01193192|iron deficiency
373681|NCT01193192|Pregnancy
373682|NCT01193166|Schizophrenia
373683|NCT01193166|Risperidone
373684|NCT01193166|Risperdal
373685|NCT01193166|Paliperidone palmitate
373686|NCT01193166|Aripiprazole
373687|NCT01193166|Haloperidol
373688|NCT01193166|Olanzapine
373689|NCT01193166|Paliperidone
373690|NCT01193166|Perphenazine
373691|NCT01193166|Quetiapine
373692|NCT01193153|schizoaffective disorder
373693|NCT01193153|paliperidone palmitate
373694|NCT01193153|INVEGA SUSTENNA
373695|NCT01193153|schizoaffective disorder relapse prevention
373696|NCT01193140|veliparib
373697|NCT01193140|relapsed and refractory tumors
373698|NCT01193140|Temodar
373699|NCT01193140|temozolomide
373700|NCT01193140|ABT-888
373701|NCT01193140|Solid Tumors
373702|NCT01193114|substance abuse
373703|NCT01193114|homeless mothers
373704|NCT01193101|hypertension
373705|NCT01193101|blood pressure
373706|NCT01193101|LCZ696
373707|NCT01193101|dual-acting
373708|NCT01193101|neprilysin
373709|NCT01193101|nep inhibitor
373710|NCT01193101|vasopeptidase
373711|NCT01193101|angiotensin receptor
373712|NCT01193101|ARNi
373713|NCT01193101|Essential hypertension
373714|NCT01193088|CMT
373715|NCT01193088|CMT1A
373716|NCT01193075|Charcot Marie Tooth disease
373717|NCT01193075|CMT
373718|NCT01193075|HMSN
373719|NCT01193075|HMN
373720|NCT01193075|HSN
373721|NCT01193075|CMT1
373722|NCT01193075|CMT2
373723|NCT01193062|healthy volunteers
373724|NCT01193062|pharmacokinetics-pharmacodynamics
373725|NCT01193062|cerebrospinal fluid
373726|NCT01193062|serial sampling
373727|NCT01193049|Nasal Allergen Challenge, Inhaled Allergen Challenge, Asthma
373728|NCT01193036|Psychosocial
373729|NCT01193036|Skin Problems
373730|NCT01193036|Supportive Care
373731|NCT01193036|Melanoma
373732|NCT01193036|Questionnaire
373733|NCT01193023|Prospective Studies
373734|NCT01193023|Humans, pediatric
373735|NCT01193023|Positive-Pressure Respiration/methods*
373736|NCT01193023|Respiration, Artificial/methods*
373737|NCT01193023|Intensive Care
373738|NCT01193023|Intensive Care Units/statistics & numerical data*
373739|NCT01193023|Respiration, Artificial/statistics & numerical data*
373740|NCT01193023|Patients/statistics & numerical data*
373741|NCT01193023|Prevalence
373742|NCT01193023|Respiratory Muscles/innervation
373743|NCT01192997|Meningitis
373744|NCT01192997|Meningococci
373745|NCT01192997|Meningitis C
373746|NCT01192997|Meningitis A
373747|NCT01192997|Meningitis W135
373748|NCT01192997|Meningitis Y
373749|NCT01192997|Antibody
373750|NCT01192971|hcc, apatinib, phase II, cancer
373751|NCT01192958|swine flu
373752|NCT01192958|novel h1n1v
373753|NCT01192958|novel h1n1
373754|NCT01192958|h1n1
373755|NCT01192945|Azacitidin
373756|NCT01192945|Vidaza
373757|NCT01192945|Piaza
373758|NCT01192945|myelodysplastic syndrome
373759|NCT01192945|MDS
373760|NCT01192945|chronic myelomonocytic leukemia
373761|NCT01192945|CMML
373762|NCT01192945|acute myeloid leukemia
373763|NCT01192945|AML
373764|NCT01192945|daily routine
373765|NCT01192945|concomitant antiemetic therapy
373766|NCT01192945|germany
373767|NCT01192945|non-interventional study
373768|NCT01192919|bronchial carcinoma
373769|NCT01192919|registry
373770|NCT01192919|real life treatment
373771|NCT01192919|cohort study
373772|NCT01192919|NSCLC
373773|NCT01192919|SCLC
373774|NCT01192919|Germany
373775|NCT01192854|Clevudine
373776|NCT01192854|efficacy
373777|NCT01192854|safety
373778|NCT01192854|chronic hepatitis B
373779|NCT01192841|physician uniform
373780|NCT01192841|MRSA
373781|NCT01192841|bacterial contamination
373782|NCT01192828|cystathionine beta-synthase (CBS)
373783|NCT01192802|albendazole
373784|NCT01192802|ascaris
373785|NCT01192802|trichiurus
373786|NCT01192802|hookworms
373787|NCT01192789|Severe pneumonia
373788|NCT01192789|Pneumonia
373789|NCT01192789|Lady health workers
373790|NCT01192789|Amoxicillin
373791|NCT01192789|Treatment failure
373792|NCT01192789|Injectable Antibiotics
373793|NCT01192789|Referral treatment
373794|NCT01192789|Health Facility
373795|NCT01192789|Under five children
373796|NCT01192789|home based management
373797|NCT01192789|community case management
373798|NCT01192776|NICHD Neonatal Research Network
373799|NCT01192776|Hypoxic-ischemic encephalopathy (HIE)
373800|NCT01192776|Hypothermia
373801|NCT01192776|Neonatal depression
373802|NCT01192776|Perinatal asphyxia
373803|NCT01192776|Fetal acidosis
373804|NCT01192750|recurrent metastatic squamous neck cancer with occult primary
373805|NCT01192750|recurrent squamous cell carcinoma of the hypopharynx
373806|NCT01192750|recurrent squamous cell carcinoma of the larynx
373807|NCT01192750|recurrent squamous cell carcinoma of the lip and oral cavity
373808|NCT01192750|recurrent squamous cell carcinoma of the nasopharynx
373809|NCT01192750|recurrent squamous cell carcinoma of the oropharynx
373810|NCT01192750|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
373811|NCT01192750|stage IV squamous cell carcinoma of the hypopharynx
373812|NCT01192750|stage IV squamous cell carcinoma of the larynx
373813|NCT01192750|stage IV squamous cell carcinoma of the lip and oral cavity
373814|NCT01192750|stage IV squamous cell carcinoma of the nasopharynx
373815|NCT01192750|stage IV squamous cell carcinoma of the oropharynx
373816|NCT01192750|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
373817|NCT01192750|recurrent verrucous carcinoma of the larynx
373818|NCT01192750|recurrent verrucous carcinoma of the oral cavity
373819|NCT01192750|stage IV verrucous carcinoma of the larynx
373820|NCT01192750|stage IV verrucous carcinoma of the oral cavity
373821|NCT01192750|recurrent salivary gland cancer
373822|NCT01192750|salivary gland squamous cell carcinoma
373823|NCT01192737|pandemic
373824|NCT01192737|A/H1N1
373825|NCT01192737|pregnancy
373826|NCT01192737|cohort
373827|NCT01192737|vaccine
373828|NCT01192737|Influenza and Pregnancy
373829|NCT01192724|Antiplatelet
373830|NCT01192724|Coronary artery diseae
373831|NCT01192724|Percutaneous coronary intervention
373832|NCT01192711|diabetes
373833|NCT01192711|telemedicine
373834|NCT01192711|self monitoring blood glucose
373835|NCT01192698|hepatitis c
373836|NCT01192698|liver transplant
373837|NCT01192698|hepatitis C after liver transplant
373838|NCT01192685|Depression
373839|NCT01192685|Depressed
373840|NCT01192685|TMS
373841|NCT01192685|Transcranial Magnetic Stimulation
373842|NCT01192646|maternal health
373843|NCT01192646|birth preparedness
373844|NCT01192646|cost effectiveness
373845|NCT01192646|male involvement
373846|NCT01192646|delivery at hospital
373847|NCT01192646|complication readiness
373848|NCT01192646|Health seeking behavior in pregnancy, labour and pregnancy complication
373849|NCT01192633|Sarcoma
373850|NCT01192633|gemcitabine
373851|NCT01192633|vincristine
373852|NCT01192633|cisplatin
373853|NCT01192633|chemotherapy
373854|NCT01192620|Pediatric Appendicitis
373855|NCT01192620|Pathway
373856|NCT01192594|symptom management
373857|NCT01192594|empowerment
373858|NCT01192594|medication adherence
373859|NCT01192594|recovery
373860|NCT01192594|schizophrenia
373861|NCT01192594|post-psychotic adjustment process
373862|NCT01192594|psychological adjustment
373863|NCT01192594|psychiatric case managers
373864|NCT01192594|psychosis
373865|NCT01192594|insight
373866|NCT01192594|cognitive function
373867|NCT01192581|brain hypoperfusion
373868|NCT01192581|Vuloven
373869|NCT01192581|computed tomography perfusion
373870|NCT01192555|Neuroblastoma
373871|NCT01192555|Chemotherapy
373872|NCT01192555|Pediatrics
373873|NCT01192555|Cytoxan
373874|NCT01192555|immunotherapy
373875|NCT01192555|vaccine
373876|NCT01192529|Senile
373877|NCT01192529|Dementia
373878|NCT01192529|Neurodegenerative
373879|NCT01192529|Supressi
373880|NCT01192529|Specific diet
373881|NCT01192529|Cognitive Status
373882|NCT01192529|Memory
373883|NCT01192529|Malnutrition
373884|NCT01192529|Parkinson
373885|NCT01192529|Alzheimer
373886|NCT01192516|Osteoarthritis
373887|NCT01192516|Activity Pacing
373888|NCT01192503|Restless Legs Syndrome
373889|NCT01192503|rasagiline
373890|NCT01192503|futility
373891|NCT01192477|Air pollution
373892|NCT01192477|Ozone
373893|NCT01192477|Health effects of ozone exposure
373894|NCT01192464|Hodgkin's Lymphoma
373895|NCT01192464|Non-Hodgkin's Lymphoma
373896|NCT01192438|prostate
373897|NCT01192438|cancer
373898|NCT01192438|ablation
373899|NCT01192438|laser-induced
373900|NCT01192438|focal therapy
373901|NCT01192425|PNH clone cells
373902|NCT01192425|Aplastic Anemia
373903|NCT01192425|AA
373904|NCT01192425|Myelodysplastic Syndromes
373905|NCT01192425|MDS
373906|NCT01192425|bone marrow failure syndromes
373907|NCT01192425|FLAER
373908|NCT01192425|Paroxysmal Nocturnal Hemoglobinuria
373909|NCT01192412|hypertension
373910|NCT01192412|pregnancy
373911|NCT01192412|antihypertensive therapy
373912|NCT01192412|perinatal outcome
373913|NCT01192412|maternal outcome
373914|NCT01192412|Non-severe, non-proteinuric pre-existing or gestational hypertension in pregnancy
373915|NCT01192399|Hemolytic Paroxysmal Nocturnal Hemoglobinuria
373916|NCT01192399|Eculizumab
373917|NCT01192399|PNH
373918|NCT01192399|Japan
373919|NCT01192360|pediatrics
373920|NCT01192360|Heart Disease
373921|NCT01192360|Cystic Fibrosis
373922|NCT01192360|Severe Asthma
373923|NCT01192360|Magnetic Resonance Imaging
373924|NCT01192334|knee osteoarthritis arthroplasty postural balance
373925|NCT01192321|intraocular lens
373926|NCT01192321|Toric
373927|NCT01192308|Breast cancer
373928|NCT01192308|Tamoxifen
373929|NCT01192308|Pharmacokinetics
373930|NCT01192308|Pharmacogenetics
373931|NCT01192308|CYP2D6
373932|NCT01192295|Malignant pain
373933|NCT01192295|Nonmalignant pain
373934|NCT01192295|Pediatric
373935|NCT01192295|Opioid
373936|NCT01192295|Moderate to severe malignant or nonmalignant pain
373937|NCT01192282|Female Genital Warts
373938|NCT01192282|HPV Typing
373939|NCT01192282|HIV Status
373940|NCT01192282|Treatment Modalities and Recurrence
373941|NCT01192282|Socio-economic Burdens
373942|NCT01192269|cheek cells
373943|NCT01192269|phospholipids
373944|NCT01192269|fatty acids
373945|NCT01192269|docosahexaenoic acid
373946|NCT01192269|Buccal Cheek cells
373947|NCT01192269|non invasive fatty acid status marker
373948|NCT01192256|smoking
373949|NCT01192256|cessation
373950|NCT01192256|mortality
373951|NCT01192256|quality of life
373952|NCT01192243|Objective response rate
373953|NCT01192243|Time to Progression
373954|NCT01192243|Quality of Live
373955|NCT01192230|Objective response rate
373956|NCT01192230|Disease control rate
373957|NCT01192230|Disease free survival
373958|NCT01192230|Overall survival
373959|NCT01192230|Quality of Live
373960|NCT01192230|Nonsmall cell lung cancer
373961|NCT01192230|toxicity
373962|NCT01192217|video-assisted thoracic surgery
373963|NCT01192217|axillary mini-thoracotomy
373964|NCT01192217|bullectomy
373965|NCT01192204|FBR, OSCC, chemoprevention
373966|NCT01192191|GW642444
373967|NCT01192191|COPD
373968|NCT01192191|Fluticasone Furoate
373969|NCT01192178|pediatric
373970|NCT01192178|exacerbation
373971|NCT01192178|viral induced exacerbation
373972|NCT01192178|asthma
373973|NCT01192165|Taxotere
373974|NCT01192165|Cisplatin
373975|NCT01192165|Carboplatin
373976|NCT01192165|Trametinib
373977|NCT01192165|GSK1120212
373978|NCT01192165|Tarceva
373979|NCT01192165|KRAS
373980|NCT01192165|Pemetrexed
373981|NCT01192165|MEK inhibitor
373982|NCT01192165|nab-Paclitaxel
373983|NCT01192165|Docetaxel
373984|NCT01192165|Alimta
373985|NCT01192165|Abraxane
373986|NCT01192165|Erlotinib
373987|NCT01192113|Mecobalamin
373988|NCT01192113|peripheral neuropathy
373989|NCT01192113|diabetic neuropathy
373990|NCT01192100|Protein-rich breakfast
373991|NCT01192100|Breakfast Skipping
373992|NCT01192100|Adolescents
373993|NCT01192100|Obesity
373994|NCT01192100|Increased dietary protein
373995|NCT01192100|Breakfast
373996|NCT01192100|fMRI
373997|NCT01192100|Ghrelin
373998|NCT01192100|PYY
373999|NCT01192087|adenoid cystic carcinoma
374000|NCT01192087|carbon ion therapy
374001|NCT01192087|IMRT (intensity-modulated therapy)
374002|NCT01192087|radioimmunotherapy
374003|NCT01192087|Cetuximab
374004|NCT01192074|Obstetric
374005|NCT01192074|Analgesia
374006|NCT01192074|Anesthesia
374007|NCT01192074|Obstetric Anesthesia
374008|NCT01192074|Obstetric Analgesia
374009|NCT01192074|ultrasound
374010|NCT01192074|ultrasonography
374011|NCT01192074|epidural analgesia
374012|NCT01192074|epidural anesthesia
374013|NCT01192074|spinal anesthesia
374014|NCT01192074|neuraxial anesthesia
374015|NCT01192074|neuraxial analgesia
374016|NCT01192074|pregnancy
374017|NCT01192074|labor
374018|NCT01192074|cesarean delivery
374019|NCT01192074|cesarean section
374020|NCT01192061|autonomic nervous system
374021|NCT01192061|heart rate variability
374022|NCT01192061|blood pressure variability
374023|NCT01192061|retrobulbar hemodynamics
374024|NCT01192061|vascular dysregulation
374025|NCT01192048|Congenital Heart Disease
374026|NCT01192048|birth defect
374027|NCT01192048|genetics
374028|NCT01192048|gene
374029|NCT01192048|DNA
374030|NCT01192048|direct sequencing
374031|NCT01192048|microarray
374032|NCT01192048|single nucleotide polymorphism
374033|NCT01192048|whole genome array comparative genomic hybridization
374034|NCT01192048|chromosomal copy number change
374035|NCT01192048|nucleotide sequence variation
374036|NCT01192048|exome sequencing
374037|NCT01192048|whole exome sequencing
374038|NCT01192035|Africa, Western
374039|NCT01192035|Antiretroviral Therapy, Highly Active
374040|NCT01192022|Liver resection
374041|NCT01192022|Liver transplantation
374042|NCT01192022|Liver surgery
374043|NCT01192022|Secondary hemostasis
374044|NCT01192009|Leucine
374045|NCT01192009|Skeletal Muscle Disuse
374046|NCT01192009|Atrophy
374047|NCT01192009|Proteolysis
374048|NCT01191996|SPMS
374049|NCT01191996|PPMS
374050|NCT01191996|MS
374051|NCT01191996|Multiple Sclerosis
374052|NCT01191970|epidural
374053|NCT01191970|beta-endorphins
374054|NCT01191970|breast-feeding
374055|NCT01191970|colostrum
374056|NCT01191970|feeding
374057|NCT01191957|Acute Myeloid Leukemia
374058|NCT01191957|Allogeneic hematopoietic stem cell transplantation
374059|NCT01191918|acetylcholinesterase inhibitor
374060|NCT01191918|donepezil
374061|NCT01191918|bipolar disorder
374062|NCT01191918|mania
374063|NCT01191918|lithium
374064|NCT01191892|metastatic transitional cell cancer of the renal pelvis and ureter
374065|NCT01191892|regional transitional cell cancer of the renal pelvis and ureter
374066|NCT01191892|transitional cell carcinoma of the bladder
374067|NCT01191892|stage III bladder cancer
374068|NCT01191892|stage IV bladder cancer
374069|NCT01191892|anterior urethral cancer
374070|NCT01191892|posterior urethral cancer
374071|NCT01191892|urethral cancer associated with invasive bladder cancer
374072|NCT01191892|ureter cancer
374073|NCT01191866|diabetes mellitus
374074|NCT01191866|psychosocial
374075|NCT01191866|metabolic control
374076|NCT01191866|quality of life questionnaires
374077|NCT01191866|children
374078|NCT01191866|adolescents
374079|NCT01191853|Post Swine Flu Blood Samples
374080|NCT01191853|Biologic Samples
374081|NCT01191853|Laboratory Research Samples
374082|NCT01191853|Swine Flu
374083|NCT01191853|Immunization
374084|NCT01191853|Healthy Volunteer
374085|NCT01191853|HV
374086|NCT01191840|staphylococci
374087|NCT01191814|pancreatic cancer
374088|NCT01191814|obstructive jaundice
374089|NCT01191814|Obstructive jaundice secondary to pancreatic cancer
374090|NCT01191801|Leukemia
374091|NCT01191801|Acute Myeloid Leukemia
374092|NCT01191801|Hematologic
374093|NCT01191801|Hematologic diseases
374094|NCT01191801|Blood
374095|NCT01191801|Cancer
374096|NCT01191801|Malignancy
374097|NCT01191801|Vosaroxin
374098|NCT01191801|Cytarabine
374099|NCT01191801|First Relapsed AML
374100|NCT01191801|Refractory AML
374101|NCT01191801|VALOR
374102|NCT01191801|Sunesis
374103|NCT01191801|Voreloxin
374104|NCT01191801|SNS-595
374105|NCT01191788|Depression
374106|NCT01191788|Substance Use
374107|NCT01191788|Group Cognitive Behavioral Therapy
374108|NCT01191775|Oligonucleotide
374109|NCT01191775|DNAi
374110|NCT01191775|Oncology
374111|NCT01191775|Antineoplastic agent
374112|NCT01191775|Lymphoma
374113|NCT01191775|PNT2258
374114|NCT01191762|secondary hyperparathyroidism
374115|NCT01191762|phosphate
374116|NCT01191762|calcium
374117|NCT01191762|chronic kidney disease
374118|NCT01191749|Hematologic Disorder
374119|NCT01191749|Aplastic Anemia
374120|NCT01191749|T - Cell Large Granular Lymphocytic Leukemia
374121|NCT01191749|T-LGL
374122|NCT01191749|Myelodysplastic Syndrome
374123|NCT01191749|Chronic Lymphocytic Leukemia
374124|NCT01191749|CLL
374125|NCT01191749|Chemotherapy
374126|NCT01191749|Alemtuzumab
374127|NCT01191736|hands only
374128|NCT01191736|CPR
374129|NCT01191736|resuscitation
374130|NCT01191736|cardiac arrest
374131|NCT01191736|Education of general public regarding resuscitation methods
374132|NCT01191723|Healthy Volunteers
374133|NCT01191710|progesterone
374134|NCT01191697|HER2 positive
374135|NCT01191671|Child Development
374136|NCT01191671|Child
374137|NCT01191671|Daycare centers
374138|NCT01191671|Language
374139|NCT01191645|Lower esophageal sphincter pressure
374140|NCT01191645|Esophageal motility
374141|NCT01191645|Remifentanil
374142|NCT01191645|Metoclopramide
374143|NCT01191645|Naloxone
374144|NCT01191645|High resolution solid state manometry
374145|NCT01191632|T cell
374146|NCT01191632|surgery
374147|NCT01191632|radiation
374148|NCT01191619|McIvor retractor
374149|NCT01191619|Proseal laryngeal mask airway
374150|NCT01191606|pressure controlled
374151|NCT01191606|volume controlled
374152|NCT01191606|arterial oxygenation
374153|NCT01191606|one lung ventilation
374154|NCT01191593|Adductor-Canal-Blockade
374155|NCT01191593|postoperative pain
374156|NCT01191593|US-guided nerve block
374157|NCT01191593|revision knee arthroplasty
374158|NCT01191567|acute wounds
374159|NCT01191567|postoperative wounds
374160|NCT01191541|ara-c
374161|NCT01191541|As2O3
374162|NCT01191541|pediatric
374163|NCT01191541|acute
374164|NCT01191528|Adult
374165|NCT01191528|Post
374166|NCT01191528|operative
374167|NCT01191528|oximetry
374168|NCT01191528|capnometry
374169|NCT01191528|Integrated
374170|NCT01191528|Pulmonary
374171|NCT01191528|Index
374172|NCT01191528|End-tidal
374173|NCT01191528|Monitoring Respiratory status
374174|NCT01191528|post-operative
374175|NCT01191515|Previous Cataract patients
374176|NCT01191515|Monofocal IOL implant
374177|NCT01191515|Evaluation
374178|NCT01191502|Patients who have had binocular implantation of the Tecnis Multifocal IOL or the Crystalens™ HD Accommodating IOL.
374179|NCT01191476|Sevoflurane
374180|NCT01191476|Propofol
374181|NCT01191476|Economics
374182|NCT01191476|Pharmaceutical
374183|NCT01191476|Chinese
374184|NCT01191450|chlortalidone
374185|NCT01191450|amiloride
374186|NCT01191450|arterial hypertension
374187|NCT01191424|Asthma
374188|NCT01191424|PK
374189|NCT01191424|Adolescents
374190|NCT01191424|Adults
374191|NCT01191411|colorectal neoplasms
374192|NCT01191411|screening
374193|NCT01191398|Hypersalivation
374194|NCT01191398|Conscious Sedation
374195|NCT01191398|Procedural Sedation
374196|NCT01191398|Ketamine
374197|NCT01191398|Atropine
374198|NCT01191398|Glycopyrrolate
374199|NCT01191385|HCC
374200|NCT01191385|Liver cancer
374201|NCT01191385|Cancer of liver
374202|NCT01191385|Cancer, liver
374203|NCT01191385|Hepatic cancer
374204|NCT01191385|Cancer, hepatic
374205|NCT01191385|Carcinoma, hepatocellular
374206|NCT01191372|Hemophilia A
374207|NCT01191372|Hemophilia B
374208|NCT01191372|pharmacokinetics
374209|NCT01191372|pharmacodynamics
374210|NCT01191372|Tissue Factor Pathway Inhibitor
374211|NCT01191333|Mood Disorder
374212|NCT01191333|Depression
374213|NCT01191333|stress disorder, post-traumatic
374214|NCT01191333|Depressive Disorder
374215|NCT01191333|Stress Disorders, Traumatic
374216|NCT01191333|substance related disorders
374217|NCT01191333|Transcranial Magnetic Stimulation, repetitive
374218|NCT01191333|transcranial magnetic stimulation
374219|NCT01191333|Veterans
374220|NCT01191333|mental health
374221|NCT01191320|Adult onset hypogonadotropic hypogonadism
374222|NCT01191307|Primary dystonia
374223|NCT01191307|Epilepsy
374224|NCT01191307|Hydrocephalus
374225|NCT01191307|Bladder Control
374226|NCT01191307|Deaf or Hearing Impaired
374227|NCT01191294|Melanoma
374228|NCT01191294|Simulation Training
374229|NCT01191294|Medical Students
374230|NCT01191281|food habits
374231|NCT01191281|nutrition requirements
374232|NCT01191281|antiretroviral therapy
374233|NCT01191255|ESRD
374234|NCT01191255|end-stage renal disease
374235|NCT01191255|dialysis
374236|NCT01191255|hemodialysis
374237|NCT01191255|peritoneal dialysis
374238|NCT01191255|hemodialysis (HD)
374239|NCT01191255|peritoneal dialysis (PD)
374240|NCT01191255|chronic renal insufficiency
374241|NCT01191255|phosphate binder
374242|NCT01191255|kidney failure
374243|NCT01191255|renal failure
374244|NCT01191242|methadone
374245|NCT01191242|genetic
374246|NCT01191203|Acceptability and Adherence to methods
374247|NCT01191190|Leukemia
374248|NCT01191190|Chronic leukemia
374249|NCT01191190|Chronic Lymphocytic Leukemia
374250|NCT01191190|Relapsed
374251|NCT01191190|Refractory
374252|NCT01191177|oral fish oil
374253|NCT01191177|Lovaza
374254|NCT01191177|Omega-3-acid supplementation
374255|NCT01191177|Faster normalization of ALT with oral fish oil
374256|NCT01191177|Faster normalization of liver function test with oral fish oil
374257|NCT01191177|Increased growth with oral fish oil
374258|NCT01191164|Brachytherapy, Partial Breast Irradiation, Breast Seed Implant, Palladium Seeds
374259|NCT01191151|Orthopedic surgery
374260|NCT01191151|sports medicine
374261|NCT01191138|Delayed Gastric emptying
374262|NCT01191138|Gastric emptying scintigraphy
374263|NCT01191138|Pancreatic fistula
374264|NCT01191138|Pancreatic Neoplasms
374265|NCT01191138|Whipple Operation
374266|NCT01191086|Epilepsy
374267|NCT01191086|partial onset seizure
374268|NCT01191086|adjunctive therapy
374269|NCT01191073|edentulous
374270|NCT01191060|Progression free survival prolongation
374271|NCT01191060|Disease Progression
374272|NCT01191060|Overall survival
374273|NCT01191021|breath
374274|NCT01191021|propofol
374275|NCT01191021|general anesthesia
374276|NCT01191008|Xalacom Regulatory post marketing commitment plan safety
374277|NCT01190995|Pain
374278|NCT01190995|Neonate
374279|NCT01190995|Procedure
374280|NCT01190995|Neurobehavioural outcome
374281|NCT01190969|Elderly
374282|NCT01190969|malnutrition
374283|NCT01190969|nutritional supplement
374284|NCT01190943|localized osteosarcoma
374285|NCT01190943|metastatic osteosarcoma
374286|NCT01190943|recurrent osteosarcoma
374287|NCT01190917|Autism
374288|NCT01190917|Autism Spectrum Disorder
374289|NCT01190917|Disorder
374290|NCT01190917|Autistic
374291|NCT01190917|Asperger Syndrome
374292|NCT01190917|social skills group
374293|NCT01190917|behavioral intervention
374294|NCT01190917|Imaging, Magnetic Resonance
374295|NCT01190917|fMRI
374296|NCT01190917|Functional MRI
374297|NCT01190917|MRI, Functional
374298|NCT01190917|Magnetic Resonance Imaging
374299|NCT01190917|Functional
374300|NCT01190904|Androgen deficiency
374301|NCT01190904|Erectile dysfunction
374302|NCT01190904|Coronary Artery Disease
374303|NCT01190904|Coronary Revascularization
374304|NCT01190904|Diabetes mellitus
374305|NCT01190904|MI
374306|NCT01190904|Stroke
374307|NCT01190904|MACCE
374308|NCT01190904|DM
374309|NCT01190904|ED
374310|NCT01190904|CAD
374311|NCT01190904|Development of predictive cardiovascular/cerebrovascular AE
374312|NCT01190891|Rotator cuff tendonitis
374313|NCT01190891|Shoulder pain
374314|NCT01190891|Shoulder impingement
374315|NCT01190839|Crohn's Disease
374316|NCT01190839|Inflammatory Bowel Disease
374317|NCT01190839|infliximab
374318|NCT01190839|TNF-alpha
374319|NCT01190826|Stable moderate asthma
374320|NCT01190813|amblyopia, levodopa
374321|NCT01190800|Alzheimer's Disease
374322|NCT01190800|Capacity assessment
374323|NCT01190800|Decision-making assessment
374324|NCT01190800|Capacity to consent to treatment
374325|NCT01190800|Capacity to vote
374326|NCT01190800|Capacity to appoint a proxy
374327|NCT01190787|Multiple Myeloma
374328|NCT01190787|Elderly Patients
374329|NCT01190787|Diagnosis
374330|NCT01190787|Velcade subcutaneous
374331|NCT01190787|Prednisone
374332|NCT01190787|Melphalan
374333|NCT01190787|Cyclophosphamide
374334|NCT01190774|dental anxiety
374335|NCT01190774|state anxiety
374336|NCT01190774|randomised control trial
374337|NCT01190774|psychological intervention
374338|NCT01190761|Bioequivalence
374339|NCT01190761|Galantamine
374340|NCT01190761|Reminyl
374341|NCT01190761|Galantamine hydrobromide
374342|NCT01190761|Healthy subjects
374343|NCT01190748|Bioequivalence
374344|NCT01190748|Galantamine
374345|NCT01190748|Reminyl
374346|NCT01190748|Galantamine hydrobromide
374347|NCT01190748|Healthy subjects
374348|NCT01190735|Caffeine
374349|NCT01190735|Parkinson's Disease
374350|NCT01190735|Parkinson Disease
374351|NCT01190735|Parkinsonian Disorders
374352|NCT01190735|Basal Ganglia Diseases
374353|NCT01190735|Brain Diseases
374354|NCT01190735|Central Nervous System Diseases
374355|NCT01190735|Nervous System Diseases
374356|NCT01190735|Movement Disorders
374357|NCT01190735|Neurodegenerative Diseases
374358|NCT01190735|Caffeine citrate
374359|NCT01190735|Molecular Mechanisms of Pharmacological Action
374360|NCT01190735|Pharmacologic Actions
374361|NCT01190735|Central Nervous System Stimulants
374362|NCT01190735|Physiological Effects of Drugs
374363|NCT01190735|Central Nervous System Agents
374364|NCT01190735|Therapeutic Uses
374365|NCT01190722|Day case surgery
374366|NCT01190722|postoperative pain
374367|NCT01190722|NSAIDs
374368|NCT01190722|Coxibs
374369|NCT01190709|Close Fracture
374370|NCT01190709|Tibia
374371|NCT01190709|Unreamed Intramedullary Nailing
374372|NCT01190709|Dynamic Compression Plate
374373|NCT01190696|Spica Cast
374374|NCT01190696|TEN
374375|NCT01190696|Femoral Shaft Fracture
374376|NCT01190696|Children
374377|NCT01190670|ASP015K
374378|NCT01190670|tacrolimus
374379|NCT01190670|healthy volunteers
374380|NCT01190657|Teprenone
374381|NCT01190657|safety
374382|NCT01190657|efficacy
374383|NCT01190657|acute gastric lesion
374384|NCT01190657|chronic gastritis
374385|NCT01190644|Red Blood Cell Mass
374386|NCT01190644|Plasma Volume
374387|NCT01190644|Solid Tumors
374388|NCT01190631|intraocular lens
374389|NCT01190631|cataracts
374390|NCT01190631|total residual spherical aberration
374391|NCT01190631|high order aberrations
374392|NCT01190605|HIV
374393|NCT01190605|postpartum
374394|NCT01190605|postpartum entry into HIV care
374395|NCT01190592|Resistance training
374396|NCT01190592|Body Composition
374397|NCT01190592|Cardiovascular Risk factors
374398|NCT01190592|Dairy
374399|NCT01190579|Coronary Artery Disease
374400|NCT01190579|Chest Pain
374401|NCT01190579|Computed Tomography
374402|NCT01190566|Magnetic Resonance Imaging, Functional
374403|NCT01190566|Tomography, Positron-Emission
374404|NCT01190566|chemotherapy
374405|NCT01190553|amantadine
374406|NCT01190553|parkinson disease
374407|NCT01190553|dyskinesia
374408|NCT01190540|On site support services.
374409|NCT01190540|mid level health professionals.
374410|NCT01190540|cost effectiveness.
374411|NCT01190540|infectious disease.
374412|NCT01190540|capacity building.
374413|NCT01190514|DVS SR
374414|NCT01190514|healthy
374415|NCT01190514|Bioequivalence study
374416|NCT01190501|blood pressure
374417|NCT01190501|antihypertensive treatments
374418|NCT01190488|End of life decision making
374419|NCT01190488|End of life decision aid
374420|NCT01190488|Palliative care decision making
374421|NCT01190488|Palliative care decision aid
374422|NCT01190488|Advanced care planning
374423|NCT01190488|Decision Aid
374424|NCT01190475|Endometriosis
374425|NCT01190475|Infertility
374426|NCT01190475|Pain
374427|NCT01190475|Vaginal Diseases
374428|NCT01190475|Uterine Diseases
374429|NCT01190462|recurrent colon cancer
374430|NCT01190462|stage III colon cancer
374431|NCT01190462|stage IV colon cancer
374432|NCT01190462|recurrent rectal cancer
374433|NCT01190462|stage III rectal cancer
374434|NCT01190462|stage IV rectal cancer
374435|NCT01190449|stage III grade 1 follicular lymphoma
374436|NCT01190449|stage III grade 2 follicular lymphoma
374437|NCT01190449|stage III grade 3 follicular lymphoma
374438|NCT01190449|stage IV grade 1 follicular lymphoma
374439|NCT01190449|stage IV grade 2 follicular lymphoma
374440|NCT01190449|stage IV grade 3 follicular lymphoma
374441|NCT01190449|contiguous stage II grade 1 follicular lymphoma
374442|NCT01190449|contiguous stage II grade 2 follicular lymphoma
374443|NCT01190449|contiguous stage II grade 3 follicular lymphoma
374444|NCT01190449|noncontiguous stage II grade 1 follicular lymphoma
374445|NCT01190449|noncontiguous stage II grade 2 follicular lymphoma
374446|NCT01190449|noncontiguous stage II grade 3 follicular lymphoma
374447|NCT01190436|Hypertension
374448|NCT01190436|Diabetes Mellitus
374449|NCT01190436|Bisoprolol
374450|NCT01190423|AN
374451|NCT01190410|Certolizumab Pegol
374452|NCT01190410|Cimzia®
374453|NCT01190410|Crohn's Disease
374454|NCT01190410|Children and Adolescents with Crohn's Disease
374455|NCT01190397|Warming goggles
374456|NCT01190384|Metabolic Syndrome
374457|NCT01190384|Inflammation
374458|NCT01190384|Antioxidants
374459|NCT01190384|Satiety
374460|NCT01190384|Fiber
374461|NCT01190371|Artemisinin tolerance
374462|NCT01190345|breast cancer
374463|NCT01190332|common bile duct stones
374464|NCT01190319|blood pressure
374465|NCT01190319|strawberry
374466|NCT01190319|fruit phenolics
374467|NCT01190319|LDL oxidation
374468|NCT01190319|Flow mediated dilation (FMD)
374469|NCT01190254|Asenapine
374470|NCT01190254|adolescents
374471|NCT01190254|schizophrenia
374472|NCT01190254|phase IIIb
374473|NCT01190254|placebo-controlled
374474|NCT01190241|targeted therapy
374475|NCT01190241|individualized medicine
374476|NCT01190241|tyrosine kinase inhibitor
374477|NCT01190241|kinome profiling
374478|NCT01190241|Metastasized
374479|NCT01190228|Japanese Encephalitis
374480|NCT01190228|Japanese encephalitis chimeric virus vaccine
374481|NCT01190228|Varicella
374482|NCT01190228|Varicella vaccine
374483|NCT01190215|Influenza
374484|NCT01190215|Pandemrix
374485|NCT01190215|H1N1
374486|NCT01190215|Fluarix
374487|NCT01190202|Malaria
374488|NCT01190202|Plasmodium falciparum
374489|NCT01190189|Serious adverse events (SAEs)
374490|NCT01190189|HPV vaccine
374491|NCT01190189|Medically significant conditions
374492|NCT01190189|Cervical neoplasia
374493|NCT01190176|HPV
374494|NCT01190176|HPV vaccine
374495|NCT01190176|Cervical neoplasia
374496|NCT01190176|Human papillomavirus
374497|NCT01190176|Papillomavirus
374498|NCT01190176|Cervical cancer
374499|NCT01190176|Human papillomavirus (HPV) type 16/18 infections
374500|NCT01190163|Vaginal Birth delivery within 24 hours and C-section rate
374501|NCT01190150|Cyclic Heavy Menstrual Bleed
374502|NCT01190150|Menorraghia
374503|NCT01190137|Optimal vitamin D status
374504|NCT01190137|25-hydroxy vitamin D
374505|NCT01190137|Rickets and bone mineralization
374506|NCT01190137|Breast fed infants
374507|NCT01190137|Cholecalciferol and ergocalciferol
374508|NCT01190124|HIV infections
374509|NCT01190124|HIV-1
374510|NCT01190124|HIV-2
374511|NCT01190124|Acquired Immunodeficiency Syndrome
374512|NCT01190124|AIDS
374513|NCT01190124|Anti-Retroviral Agents
374514|NCT01190124|Raltegravir
374515|NCT01190124|Integrase Inhibitors
374516|NCT01190124|multiple-experienced HIV infected patients
374517|NCT01190111|interleukin-7
374518|NCT01190111|immune-based therapy
374519|NCT01190111|HIV
374520|NCT01190111|viral disease
374521|NCT01190098|Partial epilepsy
374522|NCT01190098|Excessive daytime sleepiness
374523|NCT01190098|Epworth Sleepiness Scale
374524|NCT01190098|Maintenance of Wakefulness Test
374525|NCT01190085|alcoholism
374526|NCT01190085|ghrelin
374527|NCT01190085|craving
374528|NCT01190072|Blood lipids
374529|NCT01190072|percutaneous coronary intervention
374530|NCT01190072|lipid lowering treatment
374531|NCT01190059|Lung
374532|NCT01190059|Transplantation
374533|NCT01190059|Lung Transplantation
374534|NCT01190059|Transplantation Lung
374535|NCT01190046|elderly
374536|NCT01190046|muscle
374537|NCT01190046|disuse
374538|NCT01190046|osteoarthritis
374539|NCT01190046|exercise
374540|NCT01189994|Fibromyalgia
374541|NCT01189994|Acupuncture
374542|NCT01189994|Randomized Controlled Trial
374543|NCT01189994|Pain
374544|NCT01189994|Quality of Life
374545|NCT01189968|Phase 1,
374546|NCT01189968|dose escalation,
374547|NCT01189968|histologically
374548|NCT01189968|confirmed
374549|NCT01189968|malignancy
374550|NCT01189968|metastatic
374551|NCT01189955|thyroidectomy
374552|NCT01189955|harmonic
374553|NCT01189955|RLN
374554|NCT01189942|Phase 1
374555|NCT01189942|dose escalation
374556|NCT01189942|histologically
374557|NCT01189942|confirmed
374558|NCT01189942|malignancy
374559|NCT01189942|metastatic
374560|NCT01189929|Phase 1,
374561|NCT01189929|dose escalation,
374562|NCT01189929|histologically
374563|NCT01189929|cytologically
374564|NCT01189929|confirmed
374565|NCT01189929|malignancy
374566|NCT01189929|metastatic
374567|NCT01189890|Type 2 Diabetes Mellitus, Hemoglobin A1C, glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), dipeptidyl peptidase 4 inhibitor (DPP-4)
374568|NCT01189877|Direct pO2 Measurements
374569|NCT01189877|10-121
374570|NCT01189851|breast
374571|NCT01189851|IORT
374572|NCT01189851|electronic brachytherapy
374573|NCT01189838|Cancer
374574|NCT01189838|cysteine-rich 61
374575|NCT01189838|prognosis
374576|NCT01189838|transitional cell carcinoma
374577|NCT01189825|Physiological
374578|NCT01189825|Antidepressive Agents
374579|NCT01189812|hopelessness
374580|NCT01189812|alone
374581|NCT01189812|sad
374582|NCT01189812|troubled
374583|NCT01189812|depression
374584|NCT01189799|Co-occurring Disorders
374585|NCT01189799|Depression
374586|NCT01189799|Substance Dependence
374587|NCT01189799|Motivational Therapy
374588|NCT01189799|Aftercare
374589|NCT01189799|Cognitive Behavioral Therapy
374590|NCT01189786|Haploidentical Stem Cell Transplant
374591|NCT01189786|CD34+ Selection
374592|NCT01189786|CliniMACS CD34 Reagent system
374593|NCT01189773|pain control
374594|NCT01189773|limb trauma
374595|NCT01189734|common bile duct stones
374596|NCT01189734|laparoscopic common bile duct exploration
374597|NCT01189734|intraoperative ercp
374598|NCT01189734|Preoperatively diagnosed common bile duct stones
374599|NCT01189721|remifentanil
374600|NCT01189721|hyperalgesia
374601|NCT01189708|Abdominal aortic aneurysm
374602|NCT01189708|Abdominal hernia
374603|NCT01189695|HIV or AIDS
374604|NCT01189695|Lopinavir
374605|NCT01189695|Ritonavir
374606|NCT01189695|Anti-Retroviral Agents
374607|NCT01189695|treatment failure
374608|NCT01189695|treatment experienced
374609|NCT01189695|NNRTI failure
374610|NCT01189695|monotherapy
374611|NCT01189682|catheter
374612|NCT01189682|dressing
374613|NCT01189682|chlorhexidine
374614|NCT01189682|Patient admitted in ICU with a CVC or art. catheter
374615|NCT01189669|PCOS
374616|NCT01189656|Chronic hepatitis B patients
374617|NCT01189643|BEVACIZUMAB (AVASTIN)
374618|NCT01189643|IRINOTECAN (CPT-11) CAMPTOSAR
374619|NCT01189643|TEMOZOLOMIDE
374620|NCT01189643|DSRCT
374621|NCT01189643|10-091
374622|NCT01189630|"Real World Electronic Database with clinical information"
374623|NCT01189630|related to Implantable Cardiac devices.
374624|NCT01189617|Personal Lubricant
374625|NCT01189604|propofol endoscopy sedation
374626|NCT01189578|Recreational
374627|NCT01189578|cocaine
374628|NCT01189578|fMRI
374629|NCT01189578|neuroimaging
374630|NCT01189578|craving
374631|NCT01189578|impulsivity
374632|NCT01189565|Total Hip Replacement/Revision
374633|NCT01189526|Branch retinal vein occlusion
374634|NCT01189526|macular edema
374635|NCT01189526|intravitreal injection
374636|NCT01189526|ranibizumab
374637|NCT01189513|Recurrent Glioblastoma
374638|NCT01189513|Gliosarcoma
374639|NCT01189513|SCH 900105
374640|NCT01189500|Pharmacokinetic
374641|NCT01189500|safety and tolerability
374642|NCT01189500|genetic testing
374643|NCT01189500|CYP 2D6
374644|NCT01189487|ampicillin sodium/sulbactam sodium
374645|NCT01189487|Unasyn-S
374646|NCT01189487|community acquired pneumonia
374647|NCT01189487|bacterial pneumonia
374648|NCT01189474|Meibomian Gland Dysfunction
374649|NCT01189461|pegaptanib sodium
374650|NCT01189461|diabetic macular edema
374651|NCT01189448|Congenital Toxoplasmosis,
374652|NCT01189448|Pregnancy,
374653|NCT01189448|prenatal diagnosis,
374654|NCT01189448|mother-to-child transmission,
374655|NCT01189448|prevention,
374656|NCT01189448|spiramycine,
374657|NCT01189448|pyrimethamine-sulfadiazine
374658|NCT01189435|OSI-774, TARCEVA (ERLOTINIB)
374659|NCT01189435|Lung
374660|NCT01189435|recurrent
374661|NCT01189435|10-097
374662|NCT01189435|Gefitinib
374663|NCT01189422|Type 1 Diabetes Mellitus
374664|NCT01189422|T1DM
374665|NCT01189409|Constipation
374666|NCT01189409|Opioids
374667|NCT01189409|Cancer
374668|NCT01189409|Polyethylene glycol
374669|NCT01189409|Sennosides
374670|NCT01189409|Opioid Therapy
374671|NCT01189396|asthma
374672|NCT01189396|bronchospasm
374673|NCT01189396|COPD
374674|NCT01189396|reversibility
374675|NCT01189396|efficacy
374676|NCT01189383|Melanoma
374677|NCT01189383|Vaccine
374678|NCT01189383|Dendritic Cell
374679|NCT01189383|Immune response
374680|NCT01189383|Safety
374681|NCT01189383|Efficacy
374682|NCT01189370|carcinoma, renal cell
374683|NCT01189370|kidney
374684|NCT01189370|cancer
374685|NCT01189357|meniscal transplant
374686|NCT01189344|Obesity
374687|NCT01189344|LT4
374688|NCT01189344|Absorption
374689|NCT01189344|Thyroid function
374690|NCT01189331|Coronary artery disease
374691|NCT01189331|CT
374692|NCT01189331|Computational flow dynamics
374693|NCT01189305|Drug Abuse
374694|NCT01189305|Female Patients
374695|NCT01189292|postoperative nausea and vomitus
374696|NCT01189292|PONV
374697|NCT01189292|thyroid surgery
374698|NCT01189253|stage III adult soft tissue sarcoma
374699|NCT01189253|stage IV adult soft tissue sarcoma
374700|NCT01189253|adult alveolar soft-part sarcoma
374701|NCT01189253|adult angiosarcoma
374702|NCT01189253|adult desmoplastic small round cell tumor
374703|NCT01189253|adult epithelioid sarcoma
374704|NCT01189253|adult extraskeletal chondrosarcoma
374705|NCT01189253|adult extraskeletal osteosarcoma
374706|NCT01189253|adult fibrosarcoma
374707|NCT01189253|adult leiomyosarcoma
374708|NCT01189253|adult malignant fibrous histiocytoma
374709|NCT01189253|adult malignant hemangiopericytoma
374710|NCT01189253|adult malignant mesenchymoma
374711|NCT01189253|adult neurofibrosarcoma
374712|NCT01189253|adult synovial sarcoma
374713|NCT01189227|stage IV colon cancer
374714|NCT01189227|adenocarcinoma of the colon
374715|NCT01189227|stage IV rectal cancer
374716|NCT01189227|adenocarcinoma of the rectum
374717|NCT01189227|liver metastases
374718|NCT01189162|Primary treatment of RDS and treatment of RDS post extubation
374719|NCT01189136|Voiding dysfunction
374720|NCT01189123|influenza
374721|NCT01189123|vaccine
374722|NCT01189123|cell mediated immunity
374723|NCT01189123|elderly
374724|NCT01189123|high dose influenza vaccine
374725|NCT01189110|smoking cessation
374726|NCT01189110|veterans
374727|NCT01189110|auriculotherapy
374728|NCT01189084|Alzheimer's disease
374729|NCT01189084|amyloid beta
374730|NCT01189084|vaccine
374731|NCT01189071|Stents [E07.695.750]
374732|NCT01189071|Darifenacin (C101207)
374733|NCT01189071|Kidney calculi
374734|NCT01189058|Perinatal stroke
374735|NCT01189058|Periventricular venous infarction
374736|NCT01189058|Presumed perinatal stroke
374737|NCT01189058|Neonatal stroke
374738|NCT01189058|Arterial ischemic stroke
374739|NCT01189058|Fetal stroke
374740|NCT01189058|Transcranial magnetic stimulation
374741|NCT01189058|Constraint-induced movement therapy
374742|NCT01189058|CIMT
374743|NCT01189058|Cerebral palsy
374744|NCT01189058|Congenital hemiplegia
374745|NCT01189058|Hemiplegic cerebral palsy
374746|NCT01189058|Neuroplasticity
374747|NCT01189058|Developmental plasticity
374748|NCT01189045|Stroke
374749|NCT01189045|Exercise
374750|NCT01189045|Rehabilitation
374751|NCT01189045|Risk factors
374752|NCT01189019|ranibizumab
374753|NCT01189019|Wet macular degeneration
374754|NCT01189019|macular degeneration
374755|NCT01189019|PED
374756|NCT01189019|Retinal Pigment Epithelial Detachment
374757|NCT01188967|Drugs, Investigational
374758|NCT01188967|Nicotine Dependence
374759|NCT01188967|Therapies for Relapse to Nicotine
374760|NCT01188967|Relapse Prevention
374761|NCT01188967|Smoking Cessation
374762|NCT01188967|Nicotine Cessation Therapies
374763|NCT01188954|Seroma
374764|NCT01188954|Doxycycline
374765|NCT01188954|Cardiopulmonary By-Pass
374766|NCT01188954|Femoral Artery/Vein Cannulation
374767|NCT01188954|Prevent Seroma Formation
374768|NCT01188915|Hodgkin disease
374769|NCT01188915|Breast cancer
374770|NCT01188889|Chronic Myeloid Leukemia
374771|NCT01188876|carboplatin
374772|NCT01188876|recurrent
374773|NCT01188876|platinum sensitive
374774|NCT01188876|pralatrexate
374775|NCT01188850|CIN 2 or 3
374776|NCT01188850|cervical cancer
374777|NCT01188850|Human Papillomavirus (HPV)
374778|NCT01188837|Osteoarthritis, Knee
374779|NCT01188837|Manipulation Therapy
374780|NCT01188811|Multiple Sclerosis
374781|NCT01188811|Multiple sclerosis, chronic progressive
374782|NCT01188811|Neuroprotective agents
374783|NCT01188811|Magnetic resonance imaging
374784|NCT01188811|Optical coherence tomography
374785|NCT01188811|Gait
374786|NCT01188811|Thioctic acid
374787|NCT01188811|Alpha-lipoic acid
374788|NCT01188798|Allogeneic Bone Marrow Transplantation
374789|NCT01188798|Graft versus host disease
374790|NCT01188798|Tacrolimus
374791|NCT01188798|Sirolimus
374792|NCT01188798|Methotrexate
374793|NCT01188798|Pentostatin
374794|NCT01188785|siRNA
374795|NCT01188785|RNA interference (RNAi)
374796|NCT01188785|Cancer
374797|NCT01188785|Pancreatic ductal adenocarcinoma
374798|NCT01188785|Pancreatic cancer
374799|NCT01188785|Solid tumor
374800|NCT01188785|Operable pancreatic ductal adenocarcinoma
374801|NCT01188785|Non operable pancreatic ductal adenocarcinoma
374802|NCT01188772|Hepatitis C Virus
374803|NCT01188772|HCV
374804|NCT01188772|hepatitis
374805|NCT01188772|Genotype 1
374806|NCT01188772|Genotype 2
374807|NCT01188772|Genotype 3
374808|NCT01188759|Aspergillosis
374809|NCT01188759|Combination Therapy
374810|NCT01188759|Voriconazole
374811|NCT01188759|Anidulafungin
374812|NCT01188746|catheter
374813|NCT01188746|palliative
374814|NCT01188746|quality of life
374815|NCT01188746|10-059
374816|NCT01188733|portal hypertension
374817|NCT01188733|varices
374818|NCT01188733|cirrhosis
374819|NCT01188733|octreotide
374820|NCT01188733|somatostatin analog
374821|NCT01188733|Child Pugh Class A,B
374822|NCT01188707|Non small cell lung cancer
374823|NCT01188707|Belinostat
374824|NCT01188707|Erlotinib
374825|NCT01188707|HDAC inhibitor
374826|NCT01188707|Phase I/II
374827|NCT01188681|CLL
374828|NCT01188681|TRU-016
374829|NCT01188681|chronic lymphocytic leukemia
374830|NCT01188681|relapsed CLL
374831|NCT01188681|bendamustine
374832|NCT01188668|Pharmacokinetic
374833|NCT01188668|safety and tolerability
374834|NCT01188668|genetic testing
374835|NCT01188668|CYP 2D6 and CYP 3A4
374836|NCT01188655|Ankylosing Spondylitis
374837|NCT01188642|childhood obesity
374838|NCT01188642|adipocytokines
374839|NCT01188642|physical exercise
374840|NCT01188642|nutrition education
374841|NCT01188629|Preventive Care
374842|NCT01188629|Medication Management
374843|NCT01188629|Electronic Medical Records
374844|NCT01188629|Automated Telephone System
374845|NCT01188616|Childhood Obesity
374846|NCT01188616|Obesity Intervention
374847|NCT01188590|Post operative Respiratory insufficiency
374848|NCT01188577|asthma
374849|NCT01188577|bronchospasm
374850|NCT01188577|wheezing
374851|NCT01188577|shortness of breath
374852|NCT01188564|Hereditary Angioedema
374853|NCT01188564|HAE
374854|NCT01188564|Angioedema
374855|NCT01188564|Recombinant C1 Inhibitor
374856|NCT01188564|rhC1INH
374857|NCT01188551|myringotomy
374858|NCT01188551|pressure equalization tubes
374859|NCT01188538|P. acnes, Acne vulgaris
374860|NCT01188525|pharmacokinetics
374861|NCT01188525|enzymes
374862|NCT01188525|metabolism prediction
374863|NCT01188512|Live nasal vaccine for prevention of pertussis
374864|NCT01188473|Status Asthmaticus
374865|NCT01188473|Noninvasive Positive Pressure Ventilation
374866|NCT01188473|Asthma in Children
374867|NCT01188460|Insomnia
374868|NCT01188460|Chronic pain
374869|NCT01188447|cervical-spine injuries
374870|NCT01188447|cervical-spine fractures
374871|NCT01188447|spinal cord injury
374872|NCT01188447|neck injury
374873|NCT01188447|Canadian C-Spine Rule
374874|NCT01188447|paramedics
374875|NCT01188447|emergency medical services
374876|NCT01188434|Methamphetamine
374877|NCT01188434|Substance Abuse
374878|NCT01188434|Child Neglect
374879|NCT01188434|Child Welfare
374880|NCT01188434|Evidence Based Practice
374881|NCT01188382|Intracranial pressure
374882|NCT01188382|resistance
374883|NCT01188382|CSF outflow
374884|NCT01188382|elderly
374885|NCT01188382|reference value
374886|NCT01188369|levosimendan
374887|NCT01188369|heart failure
374888|NCT01188369|inotropics
374889|NCT01188369|diastolic dysfunction
374890|NCT01188369|left ventricular hypertrophy
374891|NCT01188369|aortic valve stenosis
374892|NCT01188356|Reply
374893|NCT01188356|Symphony
374894|NCT01188356|Atrial arrhythmias
374895|NCT01188356|V pacing
374896|NCT01188356|Evaluate the incidence and evolution over-time of co-morbidities
374897|NCT01188343|Japanese Encephalitis
374898|NCT01188343|Japanese encephalitis chimeric virus vaccine
374899|NCT01188343|Measles
374900|NCT01188343|Mumps
374901|NCT01188343|Rubella
374902|NCT01188330|acute myeloid leukemia
374903|NCT01188291|Optical Coherence Tomography
374904|NCT01188291|Retinal Nerve Fiber Layer Thickness
374905|NCT01188291|Obstructive Sleep Apnea
374906|NCT01188291|Hypopnea syndrome
374907|NCT01188291|Glaucoma
374908|NCT01188252|Phase I
374909|NCT01188252|Dose escalation
374910|NCT01188252|Kinase inhibitor
374911|NCT01188252|Cyclin-dependent kinases
374912|NCT01188239|electronic cigarette
374913|NCT01188239|nicotine
374914|NCT01188239|smoking cessation
374915|NCT01188239|smoking reduction
374916|NCT01188187|custirsen sodium
374917|NCT01188187|prostate cancer
374918|NCT01188187|overall survival
374919|NCT01188187|Metastatic Castrate Resistant Prostate Cancer
374920|NCT01188174|AML
374921|NCT01188174|primary induction failure
374922|NCT01188161|Posturography
374923|NCT01188161|Balance
374924|NCT01188161|Falls
374925|NCT01188161|Gyroscope
374926|NCT01188161|Rotational Chair
374927|NCT01188161|Vestibular
374928|NCT01188161|Movement Disorders
374929|NCT01188135|depression
374930|NCT01188135|interactive voice messaging
374931|NCT01188135|patient persistence with antidepressant medication treatment
374932|NCT01188122|VAP
374933|NCT01188109|Pancreatic Neoplasms
374934|NCT01188109|Pancreatic cancer
374935|NCT01188096|glioma
374936|NCT01188096|pediatrics
374937|NCT01188096|cancer
374938|NCT01188096|brain tumor
374939|NCT01188083|NASH
374940|NCT01188083|non-alcoholic fatty-liver disease
374941|NCT01188083|Hispanic
374942|NCT01188083|overweight
374943|NCT01188070|Behavioral/Social
374944|NCT01188070|Cardiology
374945|NCT01188070|Clinical Laboratory Methods
374946|NCT01188070|Congestive Heart Failure
374947|NCT01188070|Heart Disease
374948|NCT01188070|Knowledge Dissemination
374949|NCT01188070|Lipids
374950|NCT01188070|Nursing
374951|NCT01188070|Health Promotion
374952|NCT01188070|Alzheimer's Disease/Dementia
374953|NCT01188057|Bioequivalence
374954|NCT01188057|ALPRAZOLAM
374955|NCT01188057|Healthy subjects
374956|NCT01188044|Motor activity
374957|NCT01188044|Infant
374958|NCT01188044|Validation studies
374959|NCT01188044|Malawi
374960|NCT01188044|Sub-Saharan Africa
374961|NCT01188031|Bioequivalence
374962|NCT01188031|ALPRAZOLAM
374963|NCT01188031|Healthy subjects
374964|NCT01188018|Smoking
374965|NCT01188018|Smoking Cessation
374966|NCT01188018|Nicotine Dependence
374967|NCT01188018|Tobacco Use Cessation
374968|NCT01188018|Health Education
374969|NCT01188018|Patient Education
374970|NCT01188005|OSAS
374971|NCT01188005|Sleep Apnoea
374972|NCT01188005|IL6
374973|NCT01188005|TNFα
374974|NCT01188005|Oxidative Stress
374975|NCT01188005|Antioxidants
374976|NCT01187992|Atorvastatin
374977|NCT01187992|Acute coronary syndrome
374978|NCT01187992|Advanced coronary artery disease
374979|NCT01187979|Cash incentive
374980|NCT01187979|HIV prevention
374981|NCT01187979|Adolescents
374982|NCT01187979|South Africa
374983|NCT01187979|HIV
374984|NCT01187966|Parkinson's Disease
374985|NCT01187966|PD
374986|NCT01187966|Levodopa
374987|NCT01187966|Patients with idiopathic Parkinson's disease with motor fluctuations
374988|NCT01187953|Tacrolimus
374989|NCT01187953|Acute Rejection
374990|NCT01187953|Kidney
374991|NCT01187940|Autism Spectrum Disorder;
374992|NCT01187940|Psychoeducation
374993|NCT01187914|Paroxysmal Atrial Fibrillation
374994|NCT01187914|Radio-frequency Ablation
374995|NCT01187914|Ablation
374996|NCT01187914|Open irrigation cooled-tip
374997|NCT01187901|Familial Adenomatous Polyposis
374998|NCT01187901|Attenuated Familial Polyposis
374999|NCT01187888|PSP
375000|NCT01187888|Progressive Supranuclear Palsy
375001|NCT01187888|Rasagiline
375002|NCT01187888|Azilect
375003|NCT01187888|PROSPERA
375004|NCT01187875|satiety, dietary fiber
375005|NCT01187823|Chronic heart failure
375006|NCT01187823|Central sleep apnea
375007|NCT01187823|Obstructive sleep apnea
375008|NCT01187823|Adaptive servo ventilation
375009|NCT01187810|leukemia,lymphoma
375010|NCT01187758|antibiotic use
375011|NCT01187758|antibiotic prescription
375012|NCT01187758|antibiotic resistant S. pneumoniae
375013|NCT01187758|MRSA
375014|NCT01187745|renal calculi
375015|NCT01187732|skin damage
375016|NCT01187732|intertrigo
375017|NCT01187732|dermatitis
375018|NCT01187732|erythema
375019|NCT01187732|aggression
375020|NCT01187732|body Wipes
375021|NCT01187732|soaps
375022|NCT01187732|no rinse
375023|NCT01187732|cost effectiveness
375024|NCT01187732|nursing home residents
375025|NCT01187732|nurse
375026|NCT01187719|HIV
375027|NCT01187719|pregnancy
375028|NCT01187719|phenytoin
375029|NCT01187719|ARV prophylaxis
375030|NCT01187719|nevirapine
375031|NCT01187706|gynecological cancer survivors
375032|NCT01187706|quality of life
375033|NCT01187680|Tissue adhesions
375034|NCT01187680|Laparoscopy
375035|NCT01187667|delirium
375036|NCT01187667|prevention
375037|NCT01187667|critical care
375038|NCT01187667|haloperidol
375039|NCT01187654|myocardial infarction
375040|NCT01187654|bone marrow stem cell
375041|NCT01187654|AC133
375042|NCT01187654|mono nuclear cell
375043|NCT01187641|cancer, colon, MRI scan
375044|NCT01187628|Long-term study in Chronic Kidney Disease
375045|NCT01187628|Lanthanum Carbonate
375046|NCT01187615|Nonsquamous Non-small cell lung cancer
375047|NCT01187615|Phase I
375048|NCT01187576|Physical activity
375049|NCT01187576|Hypertension
375050|NCT01187576|Diabetes mellitus
375051|NCT01187576|Motivational interviewing
375052|NCT01187563|Rheumatoid arthritis, tocilizumab
375053|NCT01187550|Dwarfism, pituitary
375054|NCT01187550|Growth hormone
375055|NCT01187537|Knee Replacement
375056|NCT01187537|Analgesia
375057|NCT01187537|Analgesics
375058|NCT01187537|Nerve blocks
375059|NCT01187537|Recovery of functions
375060|NCT01187537|Post operative analgesia
375061|NCT01187524|Patient Registry
375062|NCT01187524|FMR1 Gene
375063|NCT01187524|Fragile X Syndrome
375064|NCT01187524|Primary Ovarian Insufficiency
375065|NCT01187524|Premature Ovarian Failure
375066|NCT01187524|Premature Ovarian Insufficiency
375067|NCT01187511|Addiction
375068|NCT01187511|Alcohol Dependence
375069|NCT01187511|Anxiety
375070|NCT01187511|CRH Antagonist
375071|NCT01187511|Stress Induced Craving
375072|NCT01187498|Overactive bladder
375073|NCT01187498|Behavioral treatment
375074|NCT01187498|Drug therapy
375075|NCT01187498|Lower urinary tract symptoms
375076|NCT01187498|Urinary incontinence
375077|NCT01187498|Clinical trial
375078|NCT01187485|Androderm®
375079|NCT01187485|Testosterone
375080|NCT01187485|refractory
375081|NCT01187485|prostate
375082|NCT01187485|cancer
375083|NCT01187485|"Patients with hormone refractory prostate cancer will be treated with a daily testosterone patch Androderm® applied every 24 hours to the skin"
375084|NCT01187472|Head
375085|NCT01187472|neck
375086|NCT01187472|cancer
375087|NCT01187472|advanced
375088|NCT01187472|oral cavity
375089|NCT01187472|lip
375090|NCT01187472|larynx
375091|NCT01187459|Vitamin D
375092|NCT01187459|Crohn's Disease
375093|NCT01187459|Dose Response
375094|NCT01187446|Cutaneous T-cell Lymphoma
375095|NCT01187433|Dengue
375096|NCT01187433|Dengue hemorrhagic fever
375097|NCT01187433|CYD Dengue Vaccines
375098|NCT01187420|Cerebral vasospasm
375099|NCT01187420|delayed cerebral ischemia (DCI)
375100|NCT01187420|subarachnoid hemorrhage (SAH) patients
375101|NCT01187394|Frozen Plasma
375102|NCT01187394|Fresh Frozen Plasma
375103|NCT01187394|Cardiac Surgery
375104|NCT01187394|Bleeding
375105|NCT01187394|Knowledge Translation
375106|NCT01187368|heart failure
375107|NCT01187368|LVAS
375108|NCT01187368|LVAD
375109|NCT01187368|bridge-to-transplant
375110|NCT01187368|rotary pump
375111|NCT01187355|Symptomatic, Contact lens care
375112|NCT01187355|Multi-purpose solution
375113|NCT01187342|Stroke
375114|NCT01187329|Hyperglycemia
375115|NCT01187329|open heart surgery
375116|NCT01187329|bypass
375117|NCT01187316|Facial Pain
375118|NCT01187316|Temporomandibular Joint Disorders
375119|NCT01187316|Transcutaneous Electric Nerve Stimulation
375120|NCT01187316|Adolescent
375121|NCT01187290|Preoperative chemoradiotherapy
375122|NCT01187290|stage IIIA, N2
375123|NCT01187277|stroke
375124|NCT01187277|rehabilitation
375125|NCT01187277|gait training
375126|NCT01187277|robot-assisted therapy
375127|NCT01187251|tinnitus
375128|NCT01187251|mp3 players
375129|NCT01187251|noise induced hearing loss
375130|NCT01187251|high frequencies audiometry
375131|NCT01187251|acoustic otoemissions
375132|NCT01187238|Nasopharyngeal carcinoma
375133|NCT01187238|Stage II
375134|NCT01187238|Intensity-modulated radiotherapy
375135|NCT01187238|Concurrent chemoradiotherapy
375136|NCT01187238|Cisplatin
375137|NCT01187225|Cardiac surgical procedures
375138|NCT01187225|Fibrinogen
375139|NCT01187225|Bleeding
375140|NCT01187225|Cryoprecipitate
375141|NCT01187212|First line chemotherapy in advanced gastric cancer
375142|NCT01187199|Metastatic cancer
375143|NCT01187199|Chemotherapy
375144|NCT01187199|Avastin
375145|NCT01187199|Carboplatin
375146|NCT01187199|Paclitaxel
375147|NCT01187199|Sorafenib
375148|NCT01187199|Temsirolimus
375149|NCT01187186|Liver disease
375150|NCT01187186|ASP1941
375151|NCT01187160|Obstructive sleep apnea
375152|NCT01187147|Asthma, green tea, antioxidants
375153|NCT01187134|sepsis
375154|NCT01187134|shock, septic
375654|NCT01185171|Larynx
375155|NCT01187134|quality assurance, health care
375156|NCT01187134|quality control
375157|NCT01187134|Survival Rate
375158|NCT01187134|Follow-Up Studies
375159|NCT01187134|Anti-Infective Agents/*therapeutic use
375160|NCT01187121|Graduated Sanctions
375161|NCT01187121|Probationary failure
375162|NCT01187121|recidivism
375163|NCT01187121|drug relapse
375164|NCT01187121|criminal justice
375165|NCT01187108|Cobalt
375166|NCT01187108|Excessive Erythrocytosis
375167|NCT01187108|Monge's Disease
375168|NCT01187108|Acetazolamide
375169|NCT01187108|N-acetylcysteine
375170|NCT01187108|Altitude Sickness
375171|NCT01187108|Chronic Mountain Sickness
375172|NCT01187095|Involuntary childlessness
375173|NCT01187095|Infertility
375174|NCT01187095|IVF
375175|NCT01187095|EWI
375176|NCT01187095|Couples in IVF treatment
375177|NCT01187095|Psychosocial intervention
375178|NCT01187082|overactive bladder
375179|NCT01187082|women
375180|NCT01187082|bladder training
375181|NCT01187082|groups
375182|NCT01187069|Motivation
375183|NCT01187069|patients with type 2 diabetes
375184|NCT01187069|practice nurses
375185|NCT01187069|general practice
375186|NCT01187069|Self-determination Theory
375187|NCT01187056|Shared decision-making
375188|NCT01187056|Risk information
375189|NCT01187056|Decision aids
375190|NCT01187043|Liver Function
375191|NCT01187043|Steady State Exposure
375192|NCT01187030|Frozen Plasma
375193|NCT01187030|Fresh Frozen Plasma
375194|NCT01187030|Prothrombin Complex Concentrates
375195|NCT01187030|RAND UCLA
375196|NCT01187030|Modified Delphi Methodology
375197|NCT01187030|Expert Panel
375198|NCT01187030|Appropriateness Rating
375199|NCT01187017|Severe Aplastic Anemia
375200|NCT01187017|Aplastic Anemia
375201|NCT01187017|Immunosuppression
375202|NCT01187017|Immunosuppressive Therapy
375203|NCT01187017|T-Cells
375204|NCT01186965|Diabetes
375205|NCT01186965|Second Life
375206|NCT01186965|virtual community
375207|NCT01186965|diabetes education
375208|NCT01186965|diabetes support group
375209|NCT01186952|overweight
375210|NCT01186952|obesity
375211|NCT01186952|type 2 diabetes
375212|NCT01186952|caloric restriction
375213|NCT01186952|exercise program
375214|NCT01186952|epicardial fat
375215|NCT01186939|Myelodysplastic Syndromes
375216|NCT01186939|MDS
375217|NCT01186926|Obstructive sleep apnea
375218|NCT01186926|OSA
375219|NCT01186926|hypoglossal nerve stimulation
375220|NCT01186926|sleep apnea
375221|NCT01186900|skin abscess
375222|NCT01186900|needle aspiration
375223|NCT01186900|incision and drainage
375224|NCT01186887|primary ACL reconstruction with a hamstring graft
375225|NCT01186861|NSCLC
375226|NCT01186861|Erlotinib
375227|NCT01186861|OSI-906
375228|NCT01186861|Placebo
375229|NCT01186861|Platinum-based chemotherapy
375230|NCT01186848|Stretch marks
375231|NCT01186848|Striae distensae
375232|NCT01186809|hematologic malignancies (excluding Chronic Myeloid Leukemia)
375233|NCT01186796|Women
375234|NCT01186796|Fulvestrant Study
375235|NCT01186796|Post Menopausal Women
375236|NCT01186796|Hormones
375237|NCT01186796|Healthy Adult Women
375238|NCT01186783|heart rate
375239|NCT01186783|multiple organ dysfunction syndrome
375240|NCT01186783|ivabradine
375241|NCT01186783|sepsis
375242|NCT01186783|cardiogenic shock
375243|NCT01186770|Treatment of Opioid-Induced Constipation in Subjects with Chronic, Non-Malignant Pain
375244|NCT01186744|OPT Retreatment
375245|NCT01186744|OPT
375246|NCT01186744|chronic
375247|NCT01186744|moderate
375248|NCT01186744|severe
375249|NCT01186744|treatment
375250|NCT01186744|safety
375251|NCT01186744|treatment withdrawal
375252|NCT01186744|retreatment
375253|NCT01186744|retreatment withdrawal
375254|NCT01186744|CP-690,550
375255|NCT01186744|Psoriasis Vulgaris
375256|NCT01186744|Plaque Psoriasis
375257|NCT01186744|tofacitinib
375258|NCT01186744|Xeljanz
375259|NCT01186744|nail psoriasis
375260|NCT01186744|Jak-inhibitor
375261|NCT01186744|oral treatment
375262|NCT01186744|Pruritus
375263|NCT01186744|Itch
375264|NCT01186744|DLQI
375265|NCT01186744|rebound
375266|NCT01186744|intermittent
375267|NCT01186744|retreat
375268|NCT01186731|SPARC (secreted protein acid rich in cysteine)
375269|NCT01186731|serum Carbohydrate Antigen CA 19-9
375270|NCT01186718|Cervical, motions, kinematics
375271|NCT01186705|MK-2206
375272|NCT01186705|colon
375273|NCT01186705|rectal
375274|NCT01186705|10-068
375275|NCT01186666|Atherosclerosis
375276|NCT01186666|Vulnerable plaque
375277|NCT01186666|Intravascular ultrasound
375278|NCT01186666|Virtual histology
375279|NCT01186666|Fluorodeoxyglucose
375655|NCT01185171|Lip
375280|NCT01186666|Positron emission tomography
375281|NCT01186666|Multidetector computed tomography
375282|NCT01186640|T-PLL
375283|NCT01186640|Polychemotherapy
375284|NCT01186640|Alemtuzumab
375285|NCT01186640|Efficacy
375286|NCT01186627|Neurodevelopmental Impairment
375287|NCT01186627|Intraventricular hemorrhage
375288|NCT01186627|Retinopathy of prematurity
375289|NCT01186627|Mortality
375290|NCT01186627|Apgar Score
375291|NCT01186614|cardiac arrest
375292|NCT01186614|ECMO
375293|NCT01186614|hypothermia
375294|NCT01186614|automated CPR
375295|NCT01186614|coronary intervention
375296|NCT01186601|Prostatic Neoplasms
375297|NCT01186601|Colorectal Neoplasms
375298|NCT01186601|Head and Neck Neoplasms
375299|NCT01186601|Melanoma
375300|NCT01186601|Neoplasm Metastasis
375301|NCT01186588|Canagliflozin
375302|NCT01186588|JNJ-28431754
375303|NCT01186588|Liver diseases
375304|NCT01186588|Hepatic impairment
375305|NCT01186588|Pharmacokinetic
375306|NCT01186588|Normal hepatic function
375307|NCT01186575|HIV Infections
375308|NCT01186575|Acquired Immunodeficiency Syndrome
375309|NCT01186575|Circumcision, Male
375310|NCT01186575|Coitus
375311|NCT01186575|Patient Compliance
375312|NCT01186575|Cellular Phone
375313|NCT01186562|Pancreatitis
375314|NCT01186562|Pancreatectomy
375315|NCT01186562|Islet autotransplant
375316|NCT01186562|Sitagliptin
375317|NCT01186562|Diabetes
375318|NCT01186549|propofol
375319|NCT01186549|ephedrine
375320|NCT01186549|pain
375321|NCT01186536|Whey Protein
375322|NCT01186536|Soy Protein
375323|NCT01186536|Resistance training
375324|NCT01186536|Weight Management
375325|NCT01186523|Obesity
375326|NCT01186523|Weight Management
375327|NCT01186523|Physical Activity
375328|NCT01186497|Healthy
375329|NCT01186497|Rabeprazole sodium
375330|NCT01186497|Rabeprazole sprinkle capsule granule formulation
375331|NCT01186497|Pharmacokinetics
375332|NCT01186497|Bioavailability
375333|NCT01186497|Safety
375334|NCT01186497|Adult
375335|NCT01186484|Castration-resistant prostate cancer
375336|NCT01186484|Abiraterone acetate
375337|NCT01186484|JNJ-212082
375338|NCT01186471|Symptomatic treatment
375339|NCT01186471|Cognition
375340|NCT01186471|Cognitive deficits
375341|NCT01186471|Schizophrenia
375342|NCT01186445|Acute Myocardial Infarction
375343|NCT01186445|Cardioprotective effect
375344|NCT01186445|Pharmacological postconditioning
375345|NCT01186445|Morphine Chlorhydrate
375346|NCT01186445|Cardiac MRI
375347|NCT01186419|Beta-thalassemia
375348|NCT01186419|Sickle cell anemia
375349|NCT01186419|Transfusional iron overload
375350|NCT01186419|Iron overload
375351|NCT01186419|Iron chelation
375352|NCT01186406|glioblastoma multiforme
375353|NCT01186406|gliosarcoma
375354|NCT01186406|malignant glioma
375355|NCT01186406|glioma
375356|NCT01186406|Gliadel
375357|NCT01186406|carmustine wafers
375358|NCT01186406|Avastin
375359|NCT01186406|bevacizumab
375360|NCT01186406|Temodar
375361|NCT01186406|temozolomide
375362|NCT01186406|Pro00025180
375363|NCT01186406|Desjardins
375364|NCT01186406|Duke
375365|NCT01186406|Preston Robert Tisch Brain Tumor Center
375366|NCT01186393|Weight Loss
375367|NCT01186393|Potatoes
375368|NCT01186393|Dietary Meetings
375369|NCT01186393|Glycemic Control
375370|NCT01186380|TEE
375371|NCT01186380|Transesophageal
375372|NCT01186380|Transducer
375373|NCT01186380|Esophagus
375374|NCT01186380|Ease of passage and during transitioning into and down the esophagus to complete a normal TEE study
375375|NCT01186367|breast cancer
375376|NCT01186367|Linear Versus Nonlinear Aerobic Training
375377|NCT01186367|15-147
375378|NCT01186354|Type 2 diabetes
375379|NCT01186354|health literacy
375380|NCT01186354|genetic literacy
375381|NCT01186354|genetic risk
375382|NCT01186341|Chronic Pain
375383|NCT01186328|Relapse
375384|NCT01186328|T cell
375385|NCT01186328|Lymphoblastic
375386|NCT01186328|Leukemia
375387|NCT01186328|EZN3042
375388|NCT01186328|Refractory
375389|NCT01186328|Precursor B
375390|NCT01186328|Pre B cell
375391|NCT01186328|Survivan
375392|NCT01186328|Acute
375393|NCT01186328|Childhood
375394|NCT01186328|Pediatric
375395|NCT01186315|Addiction
375396|NCT01186315|Posttraumatic Stress
375397|NCT01186315|substance abuse and posttraumatic stress
375398|NCT01186302|medical abortion
375399|NCT01186302|Nepal
375400|NCT01186302|midlevel providers
375401|NCT01186289|Neurocognitive Dysfunction
375402|NCT01186263|liver metastases
375403|NCT01186263|MAA
375404|NCT01186263|B20
375405|NCT01186263|SIR spheres
375406|NCT01186263|SPECT
375407|NCT01186263|intra-hepatic distribution
375408|NCT01186250|cardiac allograft vasculopathy
375409|NCT01186250|pioglitazone
375410|NCT01186250|insulin resistance
375411|NCT01186250|heart transplant
375412|NCT01186237|Colon/Rectal Cancer Rectal Cancer
375413|NCT01186237|Quality of Life
375414|NCT01186211|knee, joint
375415|NCT01186198|Coronary Dilatation Catheter
375416|NCT01186198|Balloon Dilatation Catheter
375417|NCT01186198|Predilatation Balloon
375418|NCT01186198|Angioplasty
375419|NCT01186198|Myocardial Ischemia
375420|NCT01186198|Coronary Stenosis
375421|NCT01186198|PCI
375422|NCT01186198|PTCA
375423|NCT01186198|CTO
375424|NCT01186185|sudden
375425|NCT01186185|sensorineural
375426|NCT01186185|hearing loss
375427|NCT01186185|fludrocortisone
375428|NCT01186185|mineralocorticoid
375429|NCT01186185|steroid
375430|NCT01186172|ethanol
375431|NCT01186172|lock therapy
375432|NCT01186172|vascular access
375433|NCT01186172|central venous catheter
375434|NCT01186172|sepsis
375435|NCT01186159|COX-2
375436|NCT01186159|PMNL
375437|NCT01186159|pain
375438|NCT01186159|macrophages
375439|NCT01186159|NSAIDs
375440|NCT01186146|coronary disease
375441|NCT01186146|stents
375442|NCT01186146|antiplatelet drugs
375443|NCT01186146|drug-eluting stents
375444|NCT01186133|coronary disease
375445|NCT01186133|drug eluting stent
375446|NCT01186120|coronary disease
375447|NCT01186120|stent
375448|NCT01186107|coronary disease
375449|NCT01186107|stent
375450|NCT01186094|Coronary Artery Disease
375451|NCT01186094|Stent
375452|NCT01186081|Rectal cancer
375453|NCT01186081|Preoperative CCRT
375454|NCT01186081|Postoperative CCRT
375455|NCT01186081|Capecitabine
375456|NCT01186068|Rosacea, erythema
375457|NCT01186055|Smoking Relapse
375458|NCT01186055|Nicotine Abstinence
375459|NCT01186042|HIV
375460|NCT01186042|Aging
375461|NCT01186042|Neuropsychological function
375462|NCT01186042|Activity
375463|NCT01186042|Sleep patterns
375464|NCT01186042|Frailty
375465|NCT01186042|Emotional well-being
375466|NCT01186042|Sexual health
375467|NCT01186029|Looking at adding drug to already established treatment regimen for
375468|NCT01186029|Nausea and Vomiting
375469|NCT01186016|Genetic Education
375470|NCT01186016|Smoking Cessation
375471|NCT01186016|Quitting Smoking
375472|NCT01186016|Standard Smoking Cessation Program
375473|NCT01186016|Genetic Education for Smoking Cessation
375474|NCT01186003|Diabetes
375475|NCT01185977|Major Depressive Disorder
375476|NCT01185977|Fluoxetine
375477|NCT01185977|QEEG
375478|NCT01185977|cordance
375479|NCT01185977|ATR
375480|NCT01185964|Sarcoma, Soft Tissue
375481|NCT01185964|Advanced Soft Tissue Sarcoma
375482|NCT01185951|Achilles Tendon
375483|NCT01185951|Patella
375484|NCT01185951|Allergy
375485|NCT01185951|Necrosis
375486|NCT01185951|Infection
375487|NCT01185938|statin
375488|NCT01185938|CIN
375489|NCT01185938|periprocedural damage
375490|NCT01185925|PDE5-inhibition
375491|NCT01185925|exercise ventilation
375492|NCT01185925|heart failure
375493|NCT01185925|sildenafil
375494|NCT01185925|pulmonary hemodynamics
375495|NCT01185912|Cardiac MRI
375496|NCT01185912|Cardiac ultrasound
375497|NCT01185912|Cardiac surgery
375498|NCT01185899|heart attack
375499|NCT01185899|acute myocardial infarction
375500|NCT01185899|STEMI
375501|NCT01185899|NSTEMI
375502|NCT01185899|Unstable Angina
375503|NCT01185899|suspected acute coronary syndrome
375504|NCT01185899|Non-ischemic chest pain
375505|NCT01185886|untreated childhood acute lymphoblastic leukemia
375506|NCT01185886|L1 childhood acute lymphoblastic leukemia
375507|NCT01185886|L2 childhood acute lymphoblastic leukemia
375508|NCT01185886|B-cell childhood acute lymphoblastic leukemia
375509|NCT01185886|T-cell childhood acute lymphoblastic leukemia
375510|NCT01185886|stage I childhood lymphoblastic lymphoma
375511|NCT01185886|stage II childhood lymphoblastic lymphoma
375512|NCT01185886|stage III childhood lymphoblastic lymphoma
375513|NCT01185886|stage IV childhood lymphoblastic lymphoma
375514|NCT01185886|Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia
375515|NCT01185821|Multiple Sclerosis
375516|NCT01185821|Relapsing remitting Multiple Sclerosis
375517|NCT01185821|Demyelinating Autoimmune Diseases
375518|NCT01185808|sinusitis
375519|NCT01185808|chronic sinusitis with polyps
375520|NCT01185795|yogurt
375521|NCT01185795|probiotic
375522|NCT01185795|cholesterol
375523|NCT01185782|Infertility
375524|NCT01185782|Ovulation induction
375525|NCT01185782|Gonalef® (Follitropin alfa)
375526|NCT01185782|Purified pituitary gonadotropin (Fertinorm-P®)
375527|NCT01185782|gonadotropin
375528|NCT01185782|Reproductive technologies, assisted
375529|NCT01185782|Polycystic ovary syndrome
375530|NCT01185769|Vitamin E
375531|NCT01185769|Absorption
375532|NCT01185756|Heart failure
375533|NCT01185756|Sudden death
375534|NCT01185756|Implantable Cardioverter Defibrillator
375535|NCT01185756|MIBG scintigraphy
375536|NCT01185743|healthy volunteers
375537|NCT01185743|antipsychotics
375538|NCT01185743|gene expression
375539|NCT01185730|Pulmonary hypertension
375540|NCT01185730|Prognostic factors
375541|NCT01185730|Idiopathic pulmonary hypertension
375542|NCT01185730|Family pulmonary hypertension
375543|NCT01185730|use anorectics
375544|NCT01185704|Cetrorelix acetate; follitropin alfa; human chorionic-gonadotropin alfa; follicular maturation; pregnancy; ovarian stimulation
375545|NCT01185678|Contraception
375546|NCT01185678|Compliance
375547|NCT01185665|FBSS
375548|NCT01185652|Smoking
375549|NCT01185652|airflow obstruction
375550|NCT01185652|pulmonary function tests
375551|NCT01185639|lung cancer
375552|NCT01185639|metastatic
375553|NCT01185639|SBRT
375554|NCT01185639|Stereotactic body radiation therapy
375555|NCT01185639|liver
375556|NCT01185639|spine
375557|NCT01185639|adrenal
375558|NCT01185639|bone cancer
375559|NCT01185639|Spinal Column
375560|NCT01185626|patients
375561|NCT01185600|transfusion complications
375562|NCT01185600|washed RBC
375563|NCT01185600|microparticles
375564|NCT01185600|storage lesion
375565|NCT01185587|SCN5A protein
375566|NCT01185587|voltage-gated Na+ channel
375567|NCT01185561|Diabetes
375568|NCT01185561|SWEEP
375569|NCT01185561|Dysphoria
375570|NCT01185548|Advanced or Metastatic Solid Tumors or Lymphoma
375571|NCT01185535|topical anesthesia
375572|NCT01185535|tracheal intubation
375573|NCT01185535|difficult airway
375574|NCT01185509|HER2 negative
375575|NCT01185509|HER2 positive
375576|NCT01185496|diabetes mellitus
375577|NCT01185483|Endoscopic submucosal dissection
375578|NCT01185483|Submucosal tumor
375579|NCT01185483|Minimal invasive
375580|NCT01185483|Gastroscopy
375581|NCT01185470|Chronic pain
375582|NCT01185470|Morphine Sufate
375583|NCT01185470|Intrathecal
375584|NCT01185470|Implantable drug delivery pumps
375585|NCT01185457|Shoulder surgery
375586|NCT01185457|Beach chair position
375587|NCT01185457|Interscalene block
375588|NCT01185457|HRV
375589|NCT01185457|Autonomic nervous system
375590|NCT01185444|Knee Balance
375591|NCT01185444|Hyaluronate
375592|NCT01185444|Osteoarthritis
375593|NCT01185444|Viscosupplementation
375594|NCT01185431|Ficus Carica
375595|NCT01185431|Functional Constipation
375596|NCT01185431|Dietary Supplement
375597|NCT01185431|Fig Paste
375598|NCT01185405|Voriconazole
375599|NCT01185405|Therapeutic drug monitoring
375600|NCT01185405|Intensive care unit
375601|NCT01185392|Cardiac Resynchronisation Therapy in Heart Failure
375602|NCT01185379|Docosahexaenoic acid
375603|NCT01185379|omega 3
375604|NCT01185379|cerebral blood flow
375605|NCT01185379|Near Infrared spectroscopy
375606|NCT01185379|cognitive function
375607|NCT01185379|mood
375608|NCT01185366|Advanced non-clear cell renal cell cancer (RCC)
375609|NCT01185366|Clear-cell renal cell carcinoma
375610|NCT01185366|Collecting duct carcinoma
375611|NCT01185366|Translocation carcinoma
375612|NCT01185366|Chromophobe
375613|NCT01185366|Everolimus
375614|NCT01185366|Sunitinib
375615|NCT01185366|Afinitor
375616|NCT01185366|RAD001
375617|NCT01185366|Sunitinib Malate
375618|NCT01185366|SUO11248
375619|NCT01185366|Sutent
375620|NCT01185366|ESPN
375621|NCT01185353|Rheumatoid Arthritis
375622|NCT01185353|RA
375623|NCT01185340|Depression
375624|NCT01185340|MDD
375625|NCT01185327|Regurgitation
375626|NCT01185327|Infants to Israeli Ethiopian-origin mothers
375627|NCT01185314|NSCLC, EGFR mutation
375628|NCT01185301|Arthritis
375629|NCT01185301|Erosion
375630|NCT01185301|Humira
375631|NCT01185301|Adalimumab
375632|NCT01185301|Injection
375633|NCT01185301|Rheumatoid
375634|NCT01185301|Methotrexate
375635|NCT01185288|Rheumatoid Arthritis
375636|NCT01185262|Recurrent and refractory chronic lymphocytic leukemia
375637|NCT01185249|CHF
375638|NCT01185249|congestive heart failure
375639|NCT01185236|Diabetes mellitus
375640|NCT01185223|Valganciclovir
375641|NCT01185223|Ganciclovir
375642|NCT01185223|Antiviral Drug
375643|NCT01185223|CMV disease
375644|NCT01185197|Minimal Change Nephrotic Syndrome
375645|NCT01185197|Corticosteroid
375646|NCT01185197|Mycophenolate
375647|NCT01185197|Remission
375648|NCT01185197|Safety
375649|NCT01185184|Relative bioavailability
375650|NCT01185184|controlled release
375651|NCT01185184|Phase 1
375652|NCT01185184|CP-690
375653|NCT01185184|550
375656|NCT01185171|Oral Cavity and Pharynx
375657|NCT01185158|Larynx
375658|NCT01185158|Lip
375659|NCT01185158|Oral Cavity and Pharynx
375660|NCT01185145|breast-conservation
375661|NCT01185145|accelerated partial breast irradiation
375662|NCT01185145|APBI
375663|NCT01185145|IMRT
375664|NCT01185145|Intensity modulated radiotherapy
375665|NCT01185145|breast brachytherapy
375666|NCT01185145|lumpectomy
375667|NCT01185145|early stage breast cancer
375668|NCT01185145|DCIS
375669|NCT01185145|Mammosite
375670|NCT01185132|breast-conservation
375671|NCT01185132|adjuvant radiotherapy
375672|NCT01185132|breast cancer
375673|NCT01185132|early-stage breast cancer
375674|NCT01185132|DCIS
375675|NCT01185132|lumpectomy
375676|NCT01185132|accelerated partial breast irradiation
375677|NCT01185132|APBI
375678|NCT01185132|three dimensional conformal external radiotherapy
375679|NCT01185132|intensity modulated radiotherapy
375680|NCT01185132|3D CRT
375681|NCT01185132|IMRT
375682|NCT01185119|glucose uptake and metabolism in brain
375683|NCT01185093|Cells
375684|NCT01185093|Prevention
375685|NCT01185093|Cancer education
375686|NCT01185093|Nutrition
375687|NCT01185093|Healthy living
375688|NCT01185093|Physical activity
375689|NCT01185093|Dangers of tobacco
375690|NCT01185093|Sun protection
375691|NCT01185080|AZD8848
375692|NCT01185080|allergic rhinitis
375693|NCT01185080|efficacy
375694|NCT01185080|tolerability
375695|NCT01185080|safety
375696|NCT01185080|nasal symptoms
375697|NCT01185067|Hypertension
375698|NCT01185067|Endothelial function
375699|NCT01185067|Antioxidants
375700|NCT01185067|Oxidative stress
375701|NCT01185067|Grapes
375702|NCT01185067|Polyphenols
375703|NCT01185067|Resveratrol
375704|NCT01185067|Quercetin
375705|NCT01185067|Anthocyanins
375706|NCT01185067|Flavanols
375707|NCT01185067|Flavonols
375708|NCT01185067|Congestive heart failure
375709|NCT01185067|Heart failure with normal ejection fraction
375710|NCT01185067|Heart failure with preserved systolic function
375711|NCT01185067|HFNEF
375712|NCT01185067|HFPSF
375713|NCT01185067|HFPEF
375714|NCT01185067|DHF
375715|NCT01185054|Pediatrics
375716|NCT01185054|Gastroenteritis
375717|NCT01185054|Oral Rehydration
375718|NCT01185054|Electrolyte Maintenance Solution
375719|NCT01185041|Arterial Stiffness
375720|NCT01185041|Wave Reflection
375721|NCT01185041|Watermelon Supplementation
375722|NCT01185041|Aortic Blood Pressure
375723|NCT01185041|Obesity
375724|NCT01185028|Chronic HCV
375725|NCT01185028|HCV Treatment Nonresponders
375726|NCT01185028|HCV Treatment Relapsers
375727|NCT01185028|HIV-HCV Co-Infection
375728|NCT01185028|Nitazoxanide
375729|NCT01185028|Hepatitis C
375730|NCT01185015|Angina Pectoris, Coronary disease
375731|NCT01185002|CE
375732|NCT01185002|colonoscopy
375733|NCT01185002|colon
375734|NCT01185002|Eligable for colon evaluation
375735|NCT01184976|H5N1
375736|NCT01184976|Avian Influenza
375737|NCT01184976|DNA Vaccine
375738|NCT01184976|Electroporation
375739|NCT01184976|Intramuscular (IM) Injection
375740|NCT01184963|PCOS
375741|NCT01184963|High protein diet
375742|NCT01184924|Arthritis
375743|NCT01184924|Tai Chi
375744|NCT01184911|Malaria
375745|NCT01184911|Pregnancy
375746|NCT01184898|AML
375747|NCT01184898|mTOR
375748|NCT01184898|rapamycin
375749|NCT01184885|hyperCVAD
375750|NCT01184885|rapamycin
375751|NCT01184885|lymphoid malignancies
375752|NCT01184885|lymphoblastic leukemia
375753|NCT01184885|B and T cell
375754|NCT01184885|philadelphia chromosome negative
375755|NCT01184885|burkitt lymphoma
375756|NCT01184885|burkitt-type lymphoma
375757|NCT01184885|lymphoblastic lymphoma
375758|NCT01184885|mantle cell lymphoma
375759|NCT01184885|adult t cell leukemia
375760|NCT01184885|adult t cell lymphoma
375761|NCT01184872|Skin infection
375762|NCT01184872|Daptomycin
375763|NCT01184872|Elderly
375764|NCT01184872|Gram positive
375765|NCT01184872|Complicated skin and soft tissue infections
375766|NCT01184859|nocturia
375767|NCT01184859|bladder function
375768|NCT01184846|Chronic inflammatory demyelinating polyneuropathy
375769|NCT01184846|CIDP
375770|NCT01184833|Multiple sclerosis
375771|NCT01184833|Interferon beta-1b
375772|NCT01184833|Compliance to treatment
375773|NCT01184833|Premature treatment discontinuation
375774|NCT01184820|Pharmacokinetics
375775|NCT01184820|Safety
375776|NCT01184807|Advanced solid tumor
375777|NCT01184794|Analgesia laparoscopy
375778|NCT01184768|type 2 diabetes
375779|NCT01184768|HbA1c
375780|NCT01184768|vitamin D
375781|NCT01184768|diagnosis
375782|NCT01184755|Device-guided breathing
375783|NCT01184755|hypertension
375784|NCT01184755|behavioral intervention
375785|NCT01184755|stress reduction
375786|NCT01184755|HRV biofeedback
375787|NCT01184729|aerobic capacity
375788|NCT01184716|Vitamin D status (serum 25-hydroxyvitamin D)
375789|NCT01184703|Diabetes Mellitus, Type 1
375790|NCT01184703|Glycemic Index Diet
375791|NCT01184703|HbA1c
375792|NCT01184703|Lipids
375793|NCT01184690|double-balloon endoscopy
375794|NCT01184690|diagnostic yield
375795|NCT01184664|Smoking cessation
375796|NCT01184664|Tobacco dependence
375797|NCT01184664|Varenicline
375798|NCT01184664|Nicotine Replacement Therapy
375799|NCT01184664|Combination therapy
375800|NCT01184651|Congenital Adrenal Hyperplasia
375801|NCT01184651|CAH
375802|NCT01184651|sex differences
375803|NCT01184651|adolescence
375804|NCT01184651|androgen
375805|NCT01184651|behavior
375806|NCT01184651|gender development
375807|NCT01184638|Cognitive Disorders
375808|NCT01184638|General anesthesia
375809|NCT01184638|Sevoflurane
375810|NCT01184638|Propofol
375811|NCT01184638|Memory
375812|NCT01184625|Myositis
375813|NCT01184625|Physical exercise
375814|NCT01184625|Disability
375815|NCT01184612|Inmates with heavy use of alcohol or drugs
375816|NCT01184599|Aliskiren
375817|NCT01184599|Albuminuria
375818|NCT01184599|Angiotensinogen
375819|NCT01184599|collagen type IV
375820|NCT01184599|Transforming Growth Factor beta
375821|NCT01184599|aldosterone
375822|NCT01184599|renin
375823|NCT01184599|prorenin receptor
375824|NCT01184599|des-angiotensin I renin substrate
375825|NCT01184599|oxidative stress
375826|NCT01184599|advanced glycosylation end-product receptor
375827|NCT01184599|N,N-dimethylarginine
375828|NCT01184586|function
375829|NCT01184586|DASH
375830|NCT01184586|MHQ
375831|NCT01184586|pain
375832|NCT01184586|strength
375833|NCT01184573|chronic pancreatitis
375834|NCT01184573|breath test
375835|NCT01184573|bicarbonate
375836|NCT01184560|obesity
375837|NCT01184534|Lung Biopsy
375838|NCT01184534|Multimedia patient education tool
375839|NCT01184534|Multimedia Education Tool
375840|NCT01184534|Computed tomography guided lung biopsy
375841|NCT01184534|Computerized Tomography
375842|NCT01184534|CT
375843|NCT01184534|Questionnaire
375844|NCT01184534|Lung nodules
375845|NCT01184508|classic with aura
375846|NCT01184508|common without aura
375847|NCT01184508|migraine
375848|NCT01184508|headache
375849|NCT01184495|Erythropoietin
375850|NCT01184495|Chronic renal failure
375851|NCT01184495|Hemodialysis
375852|NCT01184495|Anemia
375853|NCT01184482|recurrent colorectal cancer
375854|NCT01184482|recurrent head and neck cancer
375855|NCT01184482|recurrent lung cancer
375856|NCT01184482|cetuximab
375857|NCT01184482|lapatinib
375858|NCT01184456|AIDS
375859|NCT01184456|Acquired Immunodeficiency Syndrome
375860|NCT01184456|HIV
375861|NCT01184456|Human Immunodeficiency Virus
375862|NCT01184443|Anorexia Nervosa
375863|NCT01184443|Eating Disorder Not Otherwise Specified
375864|NCT01184443|Olanzapine
375865|NCT01184443|Pediatric
375866|NCT01184430|advanced hemodynamic monitoring
375867|NCT01184430|goal-directed therapy
375868|NCT01184430|cardiac surgery
375869|NCT01184430|hemodynamic monitoring
375870|NCT01184404|Congenital heart disease
375871|NCT01184404|Cardiac surgery
375872|NCT01184404|Bosentan
375873|NCT01184378|infant formula
375874|NCT01184378|dairy fat
375875|NCT01184378|soluble milk protein
375876|NCT01184365|fatigue
375877|NCT01184365|energy management
375878|NCT01184365|spinal cord injury
375879|NCT01184365|self-efficacy
375880|NCT01184365|environment
375881|NCT01184339|Staphylococcus
375882|NCT01184339|aureus
375883|NCT01184339|methicillin
375884|NCT01184339|resistant
375885|NCT01184339|MRSA
375886|NCT01184339|MSSA
375887|NCT01184339|Blood Culture
375888|NCT01184339|diagnostic
375889|NCT01184326|RAD001
375890|NCT01184326|pazopanib
375891|NCT01184326|everolimus
375892|NCT01184326|advanced cancer
375893|NCT01184313|aortic valve surgery
375894|NCT01184313|CPB
375895|NCT01184313|lung injury
375896|NCT01184300|CYP2C19*2
375897|NCT01184300|Pharmacogenomics
375898|NCT01184300|Clopidogrel
375899|NCT01184300|Prasugrel
375900|NCT01184300|Percutaneous Coronary Intervention
375901|NCT01184287|Non Small Cell Lung Cancer, NSCLC, Lung Cancer
375902|NCT01184287|Previously untreated Non-Squamous, Non-Small Cell Lung Cancer
375903|NCT01184235|Circadian Disorders
375904|NCT01184235|Autism Spectrum Disorders
375905|NCT01184235|Mood Disorders
375906|NCT01184235|Executive Functioning
375907|NCT01184235|Pediatric Mood Disorders
375908|NCT01184196|knee replacement
375909|NCT01184196|knee arthroplasty
375910|NCT01184196|total knee replacement
375911|NCT01184196|arthroplasty, knee replacement
375912|NCT01184183|Patch for Carotid Endarterectomy
375913|NCT01184170|obesity
375914|NCT01184170|metabolism
375915|NCT01184170|cardiovascular metabolic syndrome
375916|NCT01184144|Endometriosis
375917|NCT01184144|Peritoneal fluid
375918|NCT01184144|Cytokines
375919|NCT01184144|Peroxisome Proliferator-Activated Receptors
375920|NCT01184131|Mentor Training
375921|NCT01184131|Randomized trial of mentoring effectiveness
375922|NCT01184131|Mentoring clinical researchers
375923|NCT01184118|asthma
375924|NCT01184118|sleep apnea
375925|NCT01184092|Bioequivalence
375926|NCT01184092|healthy volunteer study
375927|NCT01184092|Rheumatoid Arthritis
375928|NCT01184079|human papillomavirus vaccine L1, type 6,11,16,18
375929|NCT01184079|HPV Vaccines
375930|NCT01184079|HPV L1 vaccine, quadrivalent 6,11,16,18
375931|NCT01184066|Chemotherapy
375932|NCT01184066|Patient Adherence
375933|NCT01184066|African Americans
375934|NCT01184066|Cancer Survivor
375935|NCT01184066|Decision Making
375936|NCT01184066|Communication
375937|NCT01184066|Quality of Life
375938|NCT01184066|Social Support
375939|NCT01184066|Patient Education
375940|NCT01184053|endometrial
375941|NCT01184053|carcinoma
375942|NCT01184053|recurrent
375943|NCT01184053|metastatic
375944|NCT01184053|Trisenox
375945|NCT01184053|arsenic trioxide
375946|NCT01184053|Phase II
375947|NCT01184053|VEGF
375948|NCT01184053|gynecology
375949|NCT01184053|Lineberger
375950|NCT01184053|UNC
375951|NCT01184027|head and neck cancer
375952|NCT01184027|surgery
375953|NCT01184027|nutrition
375954|NCT01184014|corticosteroid
375955|NCT01184014|hyperglycemia
375956|NCT01184014|hospital
375957|NCT01184014|corticosteroid induced hyperglycemia in the hospital
375958|NCT01184001|Healthy subjects
375959|NCT01184001|Food Effect Study
375960|NCT01183962|CAD
375961|NCT01183962|Vitamin D
375962|NCT01183962|CVD
375963|NCT01183949|Neoplasms
375964|NCT01183949|Neoplasms, Plasma Cell
375965|NCT01183949|Neoplasms by Histologic Type
375966|NCT01183949|Hemostatic Disorders
375967|NCT01183949|Paraproteinemias
375968|NCT01183949|Blood Protein Disorders
375969|NCT01183949|Hematologic Diseases
375970|NCT01183949|Hemorrhagic Disorders
375971|NCT01183949|Lymphoproliferative Disorders
375972|NCT01183949|Immunoproliferative Disorders
375973|NCT01183949|Immune System Diseases
375974|NCT01183949|Bortezomib
375975|NCT01183949|Antineoplastic Agents
375976|NCT01183936|Melanoma/mortality/pathology/*surgery
375977|NCT01183936|Randomized Controlled Trials as Topic
375978|NCT01183936|Survival
375979|NCT01183936|Disease-Free Survival
375980|NCT01183923|asthma
375981|NCT01183923|dietary interventions
375982|NCT01183923|mouse allergy
375983|NCT01183910|PURPURA
375984|NCT01183910|SENILE PURPURA
375985|NCT01183910|BATEMAN'S PURPURA
375986|NCT01183897|GM-CSF
375987|NCT01183897|MAB 3F8
375988|NCT01183897|RETINOIC ACID (CIS-9 & 13)
375989|NCT01183897|09-161
375990|NCT01183884|GM-CSF
375991|NCT01183884|MAB 3F8
375992|NCT01183884|RETINOIC ACID (CIS-9 & 13)
375993|NCT01183884|09-160
375994|NCT01183871|Cerebral oxygenation
375995|NCT01183871|thoracotomy
375996|NCT01183871|lung resection
375997|NCT01183871|pulmonary dysfunction
375998|NCT01183845|Crohn Disease
375999|NCT01183845|Crohn's Disease Endoscopy Index of Severity
376000|NCT01183845|Colon Capsule Endoscopy
376001|NCT01183845|Crohn's Disease located in colon and/or ileum
376002|NCT01183832|Breast cancer
376003|NCT01183832|radiotherapy
376004|NCT01183832|hormonotherapy
376005|NCT01183819|cognitive function
376006|NCT01183819|fMRI
376007|NCT01183819|apoE
376008|NCT01183819|inflammatory markers
376009|NCT01183819|exercise
376010|NCT01183819|cognitive intervention
376011|NCT01183819|Space Fortress
376012|NCT01183806|Alzheimer's disease
376013|NCT01183806|Exercise
376014|NCT01183806|Rivastigmine
376015|NCT01183806|Quality of life
376016|NCT01183793|Gastrointestinal Tract [A03.556]
376017|NCT01183780|second line
376018|NCT01183780|metastatic colorectal cancer
376019|NCT01183780|FOLFIRI
376020|NCT01183780|ramucirumab
376021|NCT01183780|CRC
376022|NCT01183780|mCRC
376023|NCT01183767|Duchenne Muscular Dystrophy
376024|NCT01183767|Epigallocatechin-Gallate
376025|NCT01183767|Green tea extract
376026|NCT01183754|coronary disease
376027|NCT01183754|platelet reactivity
376028|NCT01183754|drug-eluting stent
376029|NCT01183741|Hypertension
376030|NCT01183741|Hypotension
376031|NCT01183741|Blood pressure
376032|NCT01183728|Knee degenerative disease
376033|NCT01183728|osteoarthritis
376034|NCT01183728|gonarthrosis
376035|NCT01183728|stem cell
376036|NCT01183728|cellular therapy
376037|NCT01183728|regenerative therapy
376038|NCT01183728|Mesenchymal stem cells
376039|NCT01183728|Bone marrow
376040|NCT01183728|musculoskeletal Diseases
376041|NCT01183715|Single Ascending Dose
376042|NCT01183715|Phase 1
376043|NCT01183715|Safety and Tolerability
376044|NCT01183715|PK
376045|NCT01183715|Healthy Subjects
376046|NCT01183702|LASIK vs. non-LASIK
376047|NCT01183663|Lenalidomide
376048|NCT01183663|Bevacizumab
376049|NCT01183663|Sorafenib
376050|NCT01183663|Temsirolimus
376051|NCT01183663|5-Fluorouracil
376052|NCT01183663|Leucovorin
376053|NCT01183663|Oxaliplatin
376054|NCT01183663|Avastin
376055|NCT01183663|Anti-VEGF monoclonal antibody
376056|NCT01183663|rhuMAB-VEGF
376057|NCT01183663|CC-5013
376058|NCT01183663|Revlimid
376059|NCT01183663|Nexavar
376060|NCT01183663|BAY 43-90006
376061|NCT01183663|Metastatic cancer
376062|NCT01183663|Metastatic colorectal cancer
376063|NCT01183663|Advanced solid tumors
376064|NCT01183663|Hematologic malignancies
376065|NCT01183663|Colon cancer
376066|NCT01183663|Advanced colorectal cancer
376067|NCT01183663|Breast cancer
376068|NCT01183663|Pancreatic cancer
376069|NCT01183663|Gastric cancer
376070|NCT01183663|Advanced renal cell carcinoma
376071|NCT01183663|Prostate cancer
376072|NCT01183663|Melanoma
376073|NCT01183663|Unresectable hepatocellular carcinoma
376074|NCT01183663|Renal cell carcinoma
376075|NCT01183663|Metastatic breast cancer
376076|NCT01183663|Glioblastoma
376077|NCT01183663|Multiple myeloma
376078|NCT01183637|Cartilage
376079|NCT01183637|Knee
376080|NCT01183637|Osteochondral
376081|NCT01183624|Osteoarthritis
376082|NCT01183624|Pain
376083|NCT01183624|Herbal medicine
376084|NCT01183624|Topical administration
376085|NCT01183611|safety
376086|NCT01183611|immunogenicity
376087|NCT01183611|HBV vaccine
376088|NCT01183611|perinatal transmission
376089|NCT01183572|multivitamins
376090|NCT01183572|folate
376091|NCT01183572|iron
376092|NCT01183572|periconception
376093|NCT01183546|rehabilitation
376094|NCT01183546|spinal cord injury
376095|NCT01183546|wheelchairs
376096|NCT01183533|Wake-Up Stroke
376097|NCT01183533|Ischemic stroke
376098|NCT01183533|ischemic stroke patients who wake-up with their symptoms
376099|NCT01183481|nausea
376100|NCT01183481|vomiting
376101|NCT01183481|antiemetics
376102|NCT01183481|radiotherapy
376103|NCT01183481|Radiation-induced nausea and vomiting
376104|NCT01183468|Diabetes Mellitus, Type 1 (new-onset)
376105|NCT01183468|Diabetes Mellitus, Insulin-Dependent (new-onset)
376106|NCT01183468|new-onset T1DM
376107|NCT01183468|new-onset T1D
376108|NCT01183468|Diabetes Mellitus, Juvenile-Onset
376109|NCT01183468|Diabetes, Autoimmune
376110|NCT01183468|Aralast NP
376111|NCT01183468|Alpha-1 Antitrypsin
376112|NCT01183468|AAT
376113|NCT01183455|Diabetes Mellitus, Type 1 (new-onset)
376114|NCT01183455|T1DM (new-onset)
376115|NCT01183455|T1D (new-onset)
376116|NCT01183455|Diabetes, Autoimmune
376117|NCT01183455|Alpha1-Proteinase Inhibitor
376118|NCT01183455|Alpha-1 Antitrypsin
376119|NCT01183455|AAT
376120|NCT01183442|endothelial function
376121|NCT01183442|insulin sensitivity
376122|NCT01183429|MAB 3F8
376123|NCT01183429|RETINOIC ACID (CIS-9 & 13)
376124|NCT01183429|Bone Marrow
376125|NCT01183429|09-159
376126|NCT01183416|GM-CSF
376127|NCT01183416|MAB 3F8
376128|NCT01183416|RETINOIC ACID (CIS-9 & 13)
376129|NCT01183416|09-158
376130|NCT01183403|stricture
376131|NCT01183403|anti-TNF
376132|NCT01183403|ileal Crohn'Disease
376133|NCT01183403|patients with ileal Crohn's disease complicated by
376134|NCT01183403|symptomatic stricture after failure of corticosteroids
376135|NCT01183403|and/or immunosuppressives
376136|NCT01183390|Bioequivalence
376137|NCT01183390|Healthy Subjects
376138|NCT01183377|Female Athlete Triad syndrom
376139|NCT01183377|Eating disorder
376140|NCT01183377|osteoprosis
376141|NCT01183364|solid tumor malignancies
376142|NCT01183364|tumor
376143|NCT01183364|cancer
376144|NCT01183364|STA-9090
376145|NCT01183364|ganetespib
376146|NCT01183364|HSP90 inhibitor
376147|NCT01183351|Dementia
376148|NCT01183351|Agitation
376149|NCT01183351|Challenging behaviour
376150|NCT01183351|Behavioural and psychological symptoms in dementia (BPSD)
376151|NCT01183338|SpO2
376152|NCT01183338|Oxygen saturation
376153|NCT01183325|Umbilical and small ventral hernias less than 3cm diameter
376154|NCT01183312|Hypersomnia
376155|NCT01183312|Primary Hypersomnia
376156|NCT01183312|Idiopathic Hypersomnia
376157|NCT01183312|Narcolepsy without Cataplexy
376158|NCT01183312|Flumazenil
376159|NCT01183299|bone metabolism
376160|NCT01183299|salt intake
376161|NCT01183299|acid base balance
376162|NCT01183299|bed rest
376163|NCT01183260|revision total hip arthroplasty
376164|NCT01183260|bone mineral density
376165|NCT01183260|trabecular metal
376166|NCT01183260|DEXA
376167|NCT01183247|Everolimus,
376168|NCT01183247|rapamycin,
376169|NCT01183247|prednisone,
376170|NCT01183247|tacrolimus,
376171|NCT01183247|MMF,
376172|NCT01183247|steroid-free,
376173|NCT01183247|protocol biopsy
376174|NCT01183182|Lung nodule
376175|NCT01183182|Lung lesion
376176|NCT01183169|Chronic hepatitis C
376177|NCT01183169|Cyclophilin inhibitor
376178|NCT01183156|Colorectal Cancer
376179|NCT01183156|Screening
376180|NCT01183156|Colonoscopy
376181|NCT01183156|Attendance
376182|NCT01183156|Participation
376183|NCT01183143|Infertility
376184|NCT01183143|Ovulation induction
376185|NCT01183143|Gonal-F
376186|NCT01183143|Follitropin alpha
376187|NCT01183143|Controlled ovarian stimulation.
376188|NCT01183130|opiate dependence
376189|NCT01183130|compliance monitoring
376190|NCT01183130|substitution treatment
376191|NCT01183104|Type 2 Diabetes
376192|NCT01183104|Sitagliptin
376193|NCT01183104|Glimepiride
376194|NCT01183104|Elderly patients
376195|NCT01183104|Japanese
376196|NCT01183091|Atrial fibrillation
376197|NCT01183091|Ablation
376198|NCT01183078|efficacy
376199|NCT01183078|drill placement
376200|NCT01183078|nail placement
376201|NCT01183078|radiation
376202|NCT01183078|Operative time
376203|NCT01183078|Reduction in exposure to radiation
376204|NCT01183078|Accuracy for nail placement
376205|NCT01183065|Pralatrexate
376206|NCT01183065|Vitamin B12
376207|NCT01183065|Folic Acid
376208|NCT01183065|10-112
376209|NCT01183052|COPD
376210|NCT01183052|exercise tolerance
376211|NCT01183052|oxidative stress
376212|NCT01183039|Sedentary
376213|NCT01183000|Formation of adhesions assessed at subsequent cs
376214|NCT01182987|Quality improvement
376215|NCT01182987|Quality of care
376216|NCT01182987|Health care utilization
376217|NCT01182987|Behavioral change
376218|NCT01182974|fever in severe sepsis
376219|NCT01182961|Gait
376220|NCT01182961|Falls
376221|NCT01182961|Virtual reality
376222|NCT01182948|aerobic training
376223|NCT01182948|resistance training
376224|NCT01182948|type 2 diabetes
376225|NCT01182948|therapy
376226|NCT01182935|vitamin D
376227|NCT01182935|triglycerides
376228|NCT01182935|type 2 diabetes
376229|NCT01182922|Attendance
376230|NCT01182922|Colorectal cancer
376231|NCT01182922|Screening
376232|NCT01182922|Invitation letter
376233|NCT01182909|NPC
376234|NCT01182909|Environmental and Genetic
376235|NCT01182909|evaluate putative environmental exposures and NPC
376236|NCT01182909|assess the effect of genetic factors
376237|NCT01182909|investigate gene-environment interactions
376238|NCT01182909|examine the natural history of EBV infection
376239|NCT01182883|Maximum Tolerated Dose
376240|NCT01182883|Dose Escalation
376241|NCT01182883|Pharmacokinetics
376242|NCT01182883|Antitumor Activity
376243|NCT01182883|Biologic Activity
376244|NCT01182870|vitamin D
376245|NCT01182870|influenza
376246|NCT01182870|prevention
376247|NCT01182857|Quality of Life
376248|NCT01182857|Gene Therapy
376249|NCT01182857|ADA-SCID
376250|NCT01182857|SCID-ADA
376251|NCT01182857|Severe Combined Immunodeficiency
376252|NCT01182844|metabolic syndrome, probiotic
376253|NCT01182831|carcinoma pancreas
376254|NCT01182831|percutaneous celiac plexus neurolysis
376255|NCT01182831|endosonography guided celiac plexus neurolysis
376256|NCT01182818|Cerebrovascular Accident
376257|NCT01182818|Cerebrovascular Accident, Acute
376258|NCT01182818|Fabry Disease
376259|NCT01182818|Fabry´s Disease
376260|NCT01182818|Anderson-Fabry Disease
376261|NCT01182818|CVA (Cerebrovascular Accident)
376262|NCT01182818|Stroke, Acute
376263|NCT01182818|Cerebral Stroke
376264|NCT01182792|Endothelial Function
376265|NCT01182792|Chronic Hypoxia
376266|NCT01182792|Oxidative Stress
376267|NCT01182779|base of skull chordoma
376268|NCT01182779|radiation
376269|NCT01182779|carbon ions
376270|NCT01182779|protons
376271|NCT01182766|alcohol
376272|NCT01182766|alcoholism
376273|NCT01182766|nicotine
376274|NCT01182766|cigarette
376275|NCT01182753|Chondrosarcoma
376276|NCT01182753|Radiation
376277|NCT01182753|carbon ion
376278|NCT01182727|schizophrenia
376279|NCT01182727|salsalate
376280|NCT01182727|obesity
376281|NCT01182714|Hysterectomy
376282|NCT01182714|Catheterisation
376283|NCT01182701|Type 2 Diabetes
376284|NCT01182701|Asian Pacific Islanders
376285|NCT01182701|Cognitive behavioral intervention
376286|NCT01182688|utilization of Procalcitonin in the cardiac setting
376287|NCT01182675|SCID
376288|NCT01182675|Transplant
376289|NCT01182675|Alemtuzumab
376290|NCT01182675|Plerixafor
376291|NCT01182662|Bone Marrow Disease
376292|NCT01182662|Aplastic Anemia
376293|NCT01182662|Umbilical Cord/placenta-Derived MSC
376294|NCT01182662|Transplantation
376295|NCT01182649|Drug Eluting Stents
376296|NCT01182649|Everolimus Eluting Stent
376297|NCT01182649|Coronary Angioplasty
376298|NCT01182636|Bioequivalence
376299|NCT01182636|Acne Vulgaris
376300|NCT01182623|FICE
376301|NCT01182623|Chromoendoscopy
376302|NCT01182623|Colonic polyps
376303|NCT01182623|Adenomas
376304|NCT01182623|Hyperplastic polyps
376305|NCT01182597|Oral PPI treatment has similar benefit as proton pump inhibitor infusion in patient with bleeding ulcers after combined endoscopic hemostasis
376306|NCT01182571|Heart Transplantation
376307|NCT01182571|Symptom Distress
376308|NCT01182571|Fatigue
376309|NCT01182571|Depression
376310|NCT01182571|Quality Of Life.
376311|NCT01182558|Muscle
376312|NCT01182558|Activation
376313|NCT01182558|Effect
376314|NCT01182558|Compound muscle action potential
376315|NCT01182545|Anaesthesia
376316|NCT01182545|laparoscopic cholecystectomy
376317|NCT01182545|CO2 insufflation
376318|NCT01182545|hemodynamic
376319|NCT01182545|hyperventilation
376320|NCT01182532|Mild type of hand, foot and mouth disease
376321|NCT01182532|Traditional Chinese Medicine
376322|NCT01182532|Effectiveness
376323|NCT01182532|Safety
376324|NCT01182519|lung inflammation
376325|NCT01182519|lung metastases
376326|NCT01182519|10-115
376327|NCT01182506|Cogmed Working Memory Training (CWMT)
376328|NCT01182506|cognitive
376329|NCT01182506|10-105
376330|NCT01182506|Breast cancer survivor
376331|NCT01182493|Diabetes Mellitus
376332|NCT01182493|MDI
376333|NCT01182493|pump therapy
376334|NCT01182467|Inflammatory bowel disease, PET scan, Crohn's disease
376335|NCT01182454|blood pressure
376336|NCT01182441|atrial fibrillation
376337|NCT01182441|stroke
376338|NCT01182441|TIA
376339|NCT01182441|trans ischemic attack
376340|NCT01182441|warfarin
376341|NCT01182441|Coumadin
376342|NCT01182428|Stents
376343|NCT01182428|Angioplasty
376344|NCT01182428|Total coronary occlusions
376345|NCT01182428|Coronary restenosis
376346|NCT01182428|Stent thrombosis
376347|NCT01182428|Everolimus
376348|NCT01182415|CNS involvement
376349|NCT01182402|opiate dependence
376350|NCT01182402|substitution treatment
376351|NCT01182402|unsupervised dosing
376352|NCT01182402|monitoring
376353|NCT01182389|Ventricular Tachycardia
376354|NCT01182389|Implantable Cardioverter Defibrillator
376355|NCT01182389|Catheter Ablation
376356|NCT01182389|Robotic
376357|NCT01182376|Multaq
376358|NCT01182376|dronedarone
376359|NCT01182376|Atrial Fibrillation
376360|NCT01182363|maternal depression
376361|NCT01182363|prematurity
376362|NCT01182363|early intervention
376363|NCT01182363|developmental delay
376364|NCT01182350|Molecularly Determined Treatment
376365|NCT01182324|Expectations
376366|NCT01182324|Duchenne Muscular Dystrophy
376367|NCT01182324|Clinical Trial
376368|NCT01182324|Motivations
376369|NCT01182311|Hepatitis B Virus
376370|NCT01182311|Hepatitis B Vaccine
376371|NCT01182311|Immunity
376372|NCT01182311|B-Cell Response
376373|NCT01182311|T-Cell Response
376374|NCT01182311|Hepatitis B Immunity
376375|NCT01182311|Hepatitis B Virus Vaccine
376376|NCT01182298|Latino
376377|NCT01182298|HCV
376378|NCT01182298|pegIFN
376379|NCT01182298|Viral Kinetics
376380|NCT01182298|IL-28 Haplotype
376381|NCT01182285|Depakote
376382|NCT01182285|Poorly Differentiated Thyroid Cancer
376383|NCT01182285|RAI Uptake
376384|NCT01182285|Thyrogen
376385|NCT01182272|adult primary hepatocellular carcinoma
376386|NCT01182272|localized resectable adult primary liver cancer
376387|NCT01182246|adenocarcinoma
376388|NCT01182246|Pancreatic cancer
376389|NCT01182233|Multiple Myeloma
376390|NCT01182233|Autologous Hematopoietic Stem Cell Transplant
376391|NCT01182233|Total Skeletal Irradiation
376392|NCT01182233|High dose chemotherapy
376393|NCT01182220|epidural
376394|NCT01182220|labor pain
376395|NCT01182220|ultrasound
376396|NCT01182207|Bioequivalence
376397|NCT01182207|Healthy Subjects
376398|NCT01182194|Bioequivalence
376399|NCT01182194|Healthy Subjects
376400|NCT01182181|Healthy Subjects
376401|NCT01182181|Bioequivalence
376402|NCT01182168|CISPLATIN
376403|NCT01182168|GEMCITABINE
376404|NCT01182168|RAD001 (EVEROLIMUS)
376405|NCT01182168|10-106
376532|NCT01181674|Metformin
376406|NCT01182155|Lung Cancer Non-Small Cell Cancer (NSCLC)
376407|NCT01182155|Lung Cancer Small Cell Lung Cancer (SCLC)
376408|NCT01182129|Nicotine Polacrilex chewing gum versus Swedish Snus
376409|NCT01182116|J pouch
376410|NCT01182116|colorectal
376411|NCT01182116|rectal cancer
376412|NCT01182116|coloplasty
376413|NCT01182103|Major depression
376414|NCT01182103|BDNF
376415|NCT01182103|DNA methylation
376416|NCT01182103|Histone modification
376417|NCT01182090|pelvic organ prolapse
376418|NCT01182090|colposacropexy
376419|NCT01182090|surgery
376420|NCT01182077|ASP015K
376421|NCT01182077|midazolam
376422|NCT01182077|healthy volunteers
376423|NCT01182064|Heart injuries
376424|NCT01182064|Posttraumatic myocardial infarction
376425|NCT01182064|Echocardiography
376426|NCT01182064|Coronary angiography
376427|NCT01182051|headache
376428|NCT01182051|anxiety
376429|NCT01182051|pediatric headache and anxiety
376430|NCT01182038|birth seat
376431|NCT01182038|childbirth
376432|NCT01182038|instrumental delivery
376433|NCT01182038|upright position
376434|NCT01182025|Mild type of hand, foot and mouth disease
376435|NCT01182025|Xiyanping Injection
376436|NCT01182025|Effectiveness
376437|NCT01182025|Safety
376438|NCT01182012|Cardiovascular risk factor
376439|NCT01182012|Severe mental illness
376440|NCT01182012|Drug appropriateness
376441|NCT01182012|Drug compliance
376442|NCT01182012|Lifestyle counseling
376443|NCT01181999|diffuse large B-cell lymphoma
376444|NCT01181999|elderly patients
376445|NCT01181999|rituximab augmentation
376446|NCT01181986|Type 2 diabetes mellitus, Impaired glucose tolerance
376447|NCT01181973|Relative bioavailability
376448|NCT01181973|pegvisomant
376449|NCT01181960|Risperidone long acting injectable
376450|NCT01181960|Risperdal Consta
376451|NCT01181960|Paliperidone Palmitate
376452|NCT01181960|Invega Sustenna
376453|NCT01181947|Stent graft
376454|NCT01181947|thoracic aorta
376455|NCT01181947|dissection
376456|NCT01181947|aneurysm
376457|NCT01181947|TEVAR
376458|NCT01181947|VALIANT
376459|NCT01181947|CAPTIVIA
376460|NCT01181947|endovascular
376461|NCT01181934|symptomatic treatment
376462|NCT01181934|cognition
376463|NCT01181934|cognitive deficits
376464|NCT01181934|Schizophrenia
376465|NCT01181921|Alzheimer Disease
376466|NCT01181921|Dementia
376467|NCT01181921|Sleep Disorders
376468|NCT01181921|Galantamine
376469|NCT01181921|Reminyl
376470|NCT01181908|alcohol
376471|NCT01181908|drug interaction
376472|NCT01181908|pharmacodynamic
376473|NCT01181895|asthma
376474|NCT01181882|Cardiovascular Disease
376475|NCT01181882|Aspirin Resistance
376476|NCT01181882|Diabetes Mellitus, Type 2
376477|NCT01181882|Platelet Function
376478|NCT01181882|Omega-3 Fatty Acids
376479|NCT01181882|Aspirin
376480|NCT01181882|Lysophospholipids
376481|NCT01181882|Lysophosphatidic Acid
376482|NCT01181882|Lysophosphatidylcholine
376483|NCT01181869|respiratory failure
376484|NCT01181869|oxygen
376485|NCT01181869|sleep apnoea
376486|NCT01181869|ventilation
376487|NCT01181856|Vaccine
376488|NCT01181856|MVA 85A
376489|NCT01181843|postoperative pain management
376490|NCT01181843|respiratory depression
376491|NCT01181843|capnography
376492|NCT01181843|duramorph
376493|NCT01181830|magnesium
376494|NCT01181830|metabolic syndrome
376495|NCT01181830|diabetes
376496|NCT01181830|family history
376497|NCT01181817|FBSS
376498|NCT01181817|at least one prior spinal surgery
376499|NCT01181804|boceprevir
376500|NCT01181804|hepatitis C
376501|NCT01181804|bioequivalence
376502|NCT01181804|SCH 503034
376503|NCT01181791|probiotics
376504|NCT01181791|premature infants
376505|NCT01181791|feeding tolerance
376506|NCT01181778|hormonal contraceptive methods
376507|NCT01181778|combined hormonal contraceptive methods
376508|NCT01181778|physician counseling
376509|NCT01181765|Crohn's Disease
376510|NCT01181765|infliximab
376511|NCT01181765|capsule endoscopy
376512|NCT01181752|proficiency
376513|NCT01181752|eye drop instillation
376514|NCT01181752|postoperative cataract surgery
376515|NCT01181752|Ghana
376516|NCT01181739|Colonoscopy
376517|NCT01181739|Virtual Colonoscopy
376518|NCT01181739|Colonography
376519|NCT01181739|Colorectal Cancer
376520|NCT01181739|Colonic Polyps
376521|NCT01181739|Screening
376522|NCT01181726|Bioequivalence
376523|NCT01181726|Healthy Subjects
376524|NCT01181687|COMFORT behavioral scale
376525|NCT01181687|pain assessment scale
376526|NCT01181687|child
376527|NCT01181687|validity
376528|NCT01181687|reliability
376529|NCT01181674|Diabetes
376530|NCT01181674|Insulin
376531|NCT01181674|Glargine
376533|NCT01181674|Acarbose
376534|NCT01181674|Diet
376535|NCT01181674|Exercise
376536|NCT01181674|Lifestyle
376537|NCT01181661|Cigarette
376538|NCT01181661|Smoking
376539|NCT01181661|Nicotine
376540|NCT01181661|Contingency Management
376541|NCT01181661|Voucher Reinforcement
376542|NCT01181661|Smoking Abstinence
376543|NCT01181661|Internet
376544|NCT01181661|Internet-based Treatment
376545|NCT01181661|Group Contingencies
376546|NCT01181648|Survivor
376547|NCT01181648|Human Papillomavirus (HPV)
376548|NCT01181648|Quality of Life
376549|NCT01181648|Surviving Oropharynx Cancer
376550|NCT01181648|10-111
376551|NCT01181596|neonates and infants, from the 23-week gestational (0.5 kg)
376552|NCT01181596|up to a 6 month old born at term (7 kg), for whom the PIV,
376553|NCT01181596|PAC, UAC, UVC or PICC catheter insertion is medically
376554|NCT01181596|indicated.
376555|NCT01181570|psoriasis
376556|NCT01181570|adalimumab
376557|NCT01181570|obstructive sleep apnea
376558|NCT01181570|obesity
376559|NCT01181557|quality of life
376560|NCT01181544|Anticoagulation
376561|NCT01181544|Heparin
376562|NCT01181544|Hemodialysis
376563|NCT01181544|Dialysis
376564|NCT01181544|Renal Dialysis
376565|NCT01181531|Secondary Hyperthyroidism
376566|NCT01181531|Hemodialysis
376567|NCT01181531|Parathyroid
376568|NCT01181531|PARADIGM
376569|NCT01181518|Tamoxifen
376570|NCT01181518|Pharmacogenomics
376571|NCT01181518|Breast cancer
376572|NCT01181505|HNF4a
376573|NCT01181505|CYP2D6
376574|NCT01181505|Toterodine
376575|NCT01181505|Genetic polymorphism
376576|NCT01181492|gene polymorphism
376577|NCT01181492|CYP3A4
376578|NCT01181492|fentanyl
376579|NCT01181492|HPLC
376580|NCT01181492|Analgesics
376581|NCT01181479|Contraceptive
376582|NCT01181466|PLVR
376583|NCT01181466|BLVR
376584|NCT01181466|AeriSeal
376585|NCT01181466|treatment
376586|NCT01181466|device
376587|NCT01181466|breathing
376588|NCT01181466|COPD
376589|NCT01181466|emphysema
376590|NCT01181466|polymeric lung volume reduction
376591|NCT01181466|biologic lung volume reduction
376592|NCT01181466|heterogeneous
376593|NCT01181466|homogeneous
376594|NCT01181466|Pathologic Processes
376595|NCT01181466|Respiratory Tract Diseases
376596|NCT01181466|Lung Diseases
376597|NCT01181466|Pulmonary Disease, Chronic Obstructive
376598|NCT01181453|Diabetic foot ulcer
376599|NCT01181453|Randomized trial
376600|NCT01181453|Clinical trial
376601|NCT01181453|Dermagraft
376602|NCT01181453|Standard care
376603|NCT01181440|Diabetic foot ulcer
376604|NCT01181440|Randomized trial
376605|NCT01181440|Clinical trial
376606|NCT01181440|Dermagraft
376607|NCT01181440|Conventional care
376608|NCT01181414|Permanent Atrial Fibrillation
376609|NCT01181414|Resynchronization therapy
376610|NCT01181414|Ablation
376611|NCT01181401|induction chemotherapy
376612|NCT01181401|radiotherapy
376613|NCT01181401|locally advanced head neck tumor
376614|NCT01181401|toxicity
376615|NCT01181401|LA SCCHN
376616|NCT01181401|Unresectable squamous cell cancer of the head and neck,
376617|NCT01181401|Stage IV (UICC)
376618|NCT01181375|cervical cancer
376619|NCT01181375|assay
376620|NCT01181375|hypoxia
376621|NCT01181362|Endoscopy
376622|NCT01181362|Head and Neck region
376623|NCT01181362|Scope
376624|NCT01181349|neuromuscular blockade; general anesthesia
376625|NCT01181336|Safety
376626|NCT01181336|Tolerability
376627|NCT01181336|Immunogenicity
376628|NCT01181336|Influenza
376629|NCT01181336|Virus
376630|NCT01181336|Vaccine
376631|NCT01181323|influenza, vaccine, breastfeeding, post-partum women, infant, LAIV, TIV, parent protocol
376632|NCT01181310|dementia, cognitive impairment, neurodegeneration, Alzheimer's, acetylcholine, AchE
376633|NCT01181297|Confirmed milk allergy
376634|NCT01181284|Pulmonary Arterial Hypertension (PAH)
376635|NCT01181271|Lymphoma
376636|NCT01181271|non-hodgkins lymphoma
376637|NCT01181271|Hodgkin's lymphoma
376638|NCT01181271|Hodgkin's disease
376639|NCT01181271|stem cell transplant
376640|NCT01181271|High-risk diffuse large B cell
376641|NCT01181271|Transformed low grade lymphoma
376642|NCT01181271|T-cell non-Hodgkin's lymphoma
376643|NCT01181271|Mantle cell lymphoma at any time in therapy
376644|NCT01181271|"Double-hit lymphoma"
376645|NCT01181258|related HLA-haploidentical donor
376646|NCT01181245|Pancreatic Cancer
376647|NCT01181232|insomnia
376648|NCT01181232|zolpidem
376649|NCT01181206|Surgical site infections
376650|NCT01181206|Covering the abdominal wound edge in laparotomies
376651|NCT01181193|glioblastoma multiforme
376652|NCT01181193|chemoradiotherapy
376653|NCT01181193|vitamin D
376654|NCT01181180|Ageing
376655|NCT01181180|Balance control
376656|NCT01181180|Falls
376657|NCT01181180|dehydration
376658|NCT01181167|Anticoagulants
376659|NCT01181167|Venous thromboembolism
376660|NCT01181167|Thromboembolism
376661|NCT01181167|Thrombosis
376662|NCT01181167|enoxaparin sodium
376663|NCT01181167|Embolism
376664|NCT01181167|Deep vein thrombosis
376665|NCT01181167|DU-176b
376666|NCT01181167|edoxaban
376667|NCT01181167|factor Xa
376668|NCT01181167|total hip arthroplasty
376669|NCT01181154|Auto-Immune
376670|NCT01181154|Hemolytic
376671|NCT01181154|Anemia
376672|NCT01181154|AHA
376673|NCT01181154|AIHA
376674|NCT01181154|Rituximab
376675|NCT01181141|Anticoagulants
376676|NCT01181141|Enoxaparin sodium
376677|NCT01181141|venous thromboembolism.
376678|NCT01181141|thromboembolism
376679|NCT01181141|Thrombosis
376680|NCT01181141|deep vein thrombosis
376681|NCT01181141|DU-176b
376682|NCT01181141|Edoxaban
376683|NCT01181141|factor Xa
376684|NCT01181141|hip fracture surgery
376685|NCT01181141|embolism
376686|NCT01181115|Chinese Patients
376687|NCT01181115|Relapsing MS
376688|NCT01181115|Safety
376689|NCT01181115|Avonex
376690|NCT01181115|Tolerability
376691|NCT01181115|Gadolinium
376692|NCT01181115|Interferon Beta 1a
376693|NCT01181102|anticoagulant
376694|NCT01181102|venus thromboembolism
376695|NCT01181102|thrombosis
376696|NCT01181102|thromboembolism
376697|NCT01181102|embolism and thrombosis
376698|NCT01181102|deep vein thrombosis
376699|NCT01181102|DU-176b
376700|NCT01181102|Edoxaban
376701|NCT01181102|factor Xa
376702|NCT01181102|total knee arthroplasty
376703|NCT01181102|Enoxaparin sodium
376704|NCT01181076|Stem cell transplantation
376705|NCT01181076|Individualized Nutrition
376706|NCT01181076|Quality of life
376707|NCT01181076|Oral Mucositis
376708|NCT01181076|Adult
376709|NCT01181063|Asthma
376710|NCT01181063|Easyhaler
376711|NCT01181037|Displaced subcapital femoral fracture
376712|NCT01181037|Bbipolar H.A.
376713|NCT01181037|CRIF with Ttrochanteric Antegrade Nail
376714|NCT01180972|Obesity, diabetes, hispanic, physical activity, nutrition
376715|NCT01180959|Advanced Liver Cancer
376716|NCT01180959|primary neoplasm of the liver
376717|NCT01180959|Erlotinib
376718|NCT01180959|Bevacizumab
376719|NCT01180959|Hepatocellular Carcinoma
376720|NCT01180959|HCC
376721|NCT01180959|Avastin
376722|NCT01180959|Anti-VEGF monoclonal antibody
376723|NCT01180959|rhuMAb-VEGF
376724|NCT01180959|OSI-774
376725|NCT01180959|Tarceva
376726|NCT01180946|FGF23
376727|NCT01180946|FGF-23
376728|NCT01180946|vitamin D
376729|NCT01180946|vitamin D deficiency
376730|NCT01180946|insulin resistance
376731|NCT01180946|Healthy volunteers
376732|NCT01180933|docosahexaenoic acid
376733|NCT01180933|folate
376734|NCT01180933|neurological development
376735|NCT01180933|allergies
376736|NCT01180933|long term consequences for the offspring
376737|NCT01180933|allergy risk
376738|NCT01180920|Dental
376739|NCT01180920|Periodontal
376740|NCT01180920|Surgery
376741|NCT01180920|Gums
376742|NCT01180907|18F-FAC
376743|NCT01180907|imaging
376744|NCT01180907|cancer
376745|NCT01180907|inflammation
376746|NCT01180907|PET
376747|NCT01180894|Trauma
376748|NCT01180894|Anemia
376749|NCT01180894|Iron
376750|NCT01180894|Erythropoeisis
376751|NCT01180881|Proton Radiation
376752|NCT01180881|CNS tumors
376753|NCT01180881|Brain Tumors
376754|NCT01180881|Neurobehavioral functioning
376755|NCT01180868|imaging probe
376756|NCT01180868|cancer
376757|NCT01180868|inflammatory tissue
376758|NCT01180868|inflammatory diseases
376759|NCT01180855|Melatonin
376760|NCT01180855|Cognitive Behavior Therapy
376761|NCT01180842|CF
376762|NCT01180816|GBM
376763|NCT01180816|AA
376764|NCT01180816|AO
376765|NCT01180816|Brain
376766|NCT01180816|Tumors
376767|NCT01180816|Malignant
376768|NCT01180816|Glioblastoma
376769|NCT01180816|Multiforme
376770|NCT01180816|Anaplastic
376771|NCT01180816|Astrocytoma
376772|NCT01180803|COPD - long term oxygenotherapy
376773|NCT01180803|COPD patients with respiratory failure
376774|NCT01180790|HCV
376775|NCT01180790|Hepatitis C Genotype 1
376776|NCT01180764|hypertriglyceridemia
376777|NCT01180764|omega-3 acid ethyl esters
376778|NCT01180764|high-density lipoproteins
376779|NCT01180764|fish oil
376780|NCT01180751|Positron Emission Tomography
376781|NCT01180751|Fluorodeoxyglucose
376782|NCT01180751|FDG (18F-Fluorodeoxyglucose)
376783|NCT01180751|Oncology
376784|NCT01180751|Neurology
376785|NCT01180738|chronic stroke
376786|NCT01180738|walking training
376787|NCT01180738|rehabilitation
376788|NCT01180738|body weight supported treadmill training
376789|NCT01180738|physical therapy
376790|NCT01180738|balance
376791|NCT01180725|To investigate and compare the effects of dried plums and psyllium on the overall relief of constipation symptoms
376792|NCT01180725|To investigate and compare the taste of dried plums and psyllium
376793|NCT01180725|To investigate and compare the quality of life of dried plums and psyllium
376794|NCT01180712|anthocyanin
376795|NCT01180712|blaeberries
376796|NCT01180712|bilberries
376797|NCT01180712|blueberries
376798|NCT01180712|mirtoselect
376799|NCT01180712|type 2 diabetes
376800|NCT01180712|insulin resistance
376801|NCT01180712|Adipose tissue
376802|NCT01180712|inflammation
376803|NCT01180699|adult solid organ transplant patients
376804|NCT01180686|low back pain
376805|NCT01180686|chiropractic
376806|NCT01180686|manipulation
376807|NCT01180673|Hypertension
376808|NCT01180673|Older Adults
376809|NCT01180673|Motivational Interviewing
376810|NCT01180673|Lifestyle Counseling
376811|NCT01180673|Senior Centers
376812|NCT01180660|Gastric Surgery
376813|NCT01180660|Pain
376814|NCT01180660|Recovery
376815|NCT01180660|Laparoscopic Surgery
376816|NCT01180647|Extended-release naltrexone
376817|NCT01180647|Prisoners
376818|NCT01180647|Opioid addiction prevention
376819|NCT01180647|Medication Treatment Alternatives
376820|NCT01180647|Prevention of Relapse to Opioid Addiction
376821|NCT01180621|vaccine
376822|NCT01180621|Seasonal Influenza Vaccine
376823|NCT01180621|Influenza Vaccine
376824|NCT01180621|Vaccine Safety
376825|NCT01180621|Vaccine Immunogenicity
376826|NCT01180621|Fluviral 2010-2011
376827|NCT01180608|neuropathic pain
376828|NCT01180608|Diabetic Polyneuropathy
376829|NCT01180595|osteoarthritis
376830|NCT01180595|arthroplasty
376831|NCT01180595|knee joint
376832|NCT01180595|radiography
376833|NCT01180595|surgery
376834|NCT01180595|Bone Density
376835|NCT01180595|Outcome Assessment (Health Care)
376836|NCT01180582|knee
376837|NCT01180582|arthroplasty
376838|NCT01180582|RSA
376839|NCT01180582|migration
376840|NCT01180582|micromotion
376841|NCT01180582|osteoarthritis
376842|NCT01180569|Lenalidomide
376843|NCT01180569|10-022
376844|NCT01180556|childhood
376845|NCT01180556|abdominal pain
376846|NCT01180556|probiotics
376847|NCT01180517|Angioplasty Balloon
376848|NCT01180504|ovarian cancer
376849|NCT01180504|whole-abdominal radiotherapy
376850|NCT01180504|consolidation treatment
376851|NCT01180504|helical tomotherapy
376852|NCT01180491|Discoloured and deformed nails resulting from onychomycosis
376853|NCT01180478|Bladder Cancer
376854|NCT01180478|Urothelial carcinoma
376855|NCT01180478|Stage pTa or pT1
376856|NCT01180478|NMIBC Ta/T1
376857|NCT01180478|Narrow Band Imaging
376858|NCT01180478|White Light Cystoscopy
376859|NCT01180478|Transurethral resection
376860|NCT01180478|Superficial bladder tumor
376861|NCT01180478|Positive urine cytology
376862|NCT01180465|Treatment of abdominal adiposity
376863|NCT01180452|Crohn disease
376864|NCT01180452|dysplasia
376865|NCT01180452|adenocarcinoma
376866|NCT01180452|endoscopy
376867|NCT01180452|jejunum
376868|NCT01180452|ileum
376869|NCT01180439|Non-invasive ventilation
376870|NCT01180439|Chronic Obstructive Pulmonary Disease
376871|NCT01180439|Patient-ventilator synchronisation
376872|NCT01180439|Sleep study
376873|NCT01180439|Polysomnography
376874|NCT01180426|Relapse Refractory Acute Myeloid Leukemia
376875|NCT01180413|Inward eutrophic remodelling
376876|NCT01180400|Major Depressive Disorder
376877|NCT01180400|MDD
376878|NCT01180400|Depression
376879|NCT01180400|Safety
376880|NCT01180400|add-on therapy
376881|NCT01180374|Cannabis
376882|NCT01180374|Marijuana
376883|NCT01180374|Cannabidiol
376884|NCT01180374|CBD
376885|NCT01180374|THC
376886|NCT01180374|Psychotic Disorders
376887|NCT01180361|rheumatoid arthritis
376888|NCT01180361|systemic lupus erythematosus
376889|NCT01180361|atherosclerosis
376890|NCT01180361|adenosine
376891|NCT01180348|Wrinkles, glabellar, facial.
376892|NCT01180335|Genomic driven chemotherapy
376893|NCT01180322|azacitidine
376894|NCT01180322|Acute myeloid Leukemia (AML)
376895|NCT01180309|Tongue frenum
376896|NCT01180309|Lingual frenum
376897|NCT01180309|Audio Phonology
376898|NCT01180309|Speech disorders
376899|NCT01180296|Preterm birth, prevention, progesterone, oral
376900|NCT01180283|Erectile dysfunction
376901|NCT01180283|Lodenafil carbonate
376902|NCT01180283|Diabetes
376903|NCT01180270|Cervical dystonia
376904|NCT01180270|torticollis spasmodicus
376905|NCT01180270|botulinum toxin
376906|NCT01180270|Subjective visual vertical (SVV)
376907|NCT01180270|SVV
376908|NCT01180270|static graviceptive function
376909|NCT01180244|fibromyalgia
376910|NCT01180244|noninvasive
376911|NCT01180244|electrical
376912|NCT01180244|cortical
376913|NCT01180244|stimulation
376914|NCT01180244|pain
376915|NCT01180244|brain
376916|NCT01180244|tender point
376917|NCT01180231|Overweight or obese young adults (18 to 30 years old) with no previous history of cardiovascular disease/psychiatric illness, and not on medications
376918|NCT01180218|myocardial revascularization
376919|NCT01180218|myocardial infarction
376920|NCT01180205|FMD
376921|NCT01180205|hypertension
376922|NCT01180205|Telmisartan
376923|NCT01180205|Amlodipine
376924|NCT01180192|blood loss
376925|NCT01180192|oxygen inhalation
376926|NCT01180179|H. pylori-negative idiopathic peptic ulcers
376927|NCT01180179|Recurrent ulcer bleeding
376928|NCT01180166|Gastric cancer
376929|NCT01180166|concurrent chemoradiotherapy
376930|NCT01180166|target therapy
376931|NCT01180153|40 S-1/L-OHP
376932|NCT01180153|biliary tract
376933|NCT01180153|ampullary carcinoma
376934|NCT01180140|Seamguard
376935|NCT01180140|staple-line reinforcement
376936|NCT01180140|leak
376937|NCT01180140|bleeding
376938|NCT01180127|flavonol
376939|NCT01180127|exercise
376940|NCT01180127|dentate gyrus
376941|NCT01180127|cerebral blood volume
376942|NCT01180127|dentate gyrus CBV
376943|NCT01180114|economic empowerment model,
376944|NCT01180114|orphaned children and youth,
376945|NCT01180114|Uganda,
376946|NCT01180114|sub-Saharan Africa
376947|NCT01180101|Obesity
376948|NCT01180101|Chronic Kidney Disease
376949|NCT01180088|LIVER TUMOURS
376950|NCT01180062|Latanoprost subconjunctival insert
376951|NCT01180049|Mantle Cell Lymphoma
376952|NCT01180049|non-Hodgkin lymphoma (NHL)
376953|NCT01180049|temsirolimus
376954|NCT01180036|Membranous Nephropathy
376955|NCT01180023|GBS
376956|NCT01180023|Membrane sweeping
376957|NCT01180010|Hodgkin's Lymphoma
376958|NCT01180010|Lung Cancer
376959|NCT01180010|Lung Nodule
376960|NCT01180010|CT scan
376961|NCT01179971|n-3 fatty acids
376962|NCT01179971|n-6 fatty acids
376963|NCT01179971|anti-inflammatory action
376964|NCT01179971|clinical trial
376965|NCT01179971|randomized double-blinded
376966|NCT01179971|incorporation of fatty acids
376967|NCT01179958|cognitive function
376968|NCT01179958|fMRI
376969|NCT01179958|apoE
376970|NCT01179958|inflammatory markers
376971|NCT01179958|exercise
376972|NCT01179945|diabetes
376973|NCT01179945|benzoic acid
376974|NCT01179945|benzoate
376975|NCT01179945|soda
376976|NCT01179945|soft drink
376977|NCT01179945|preservative
376978|NCT01179945|blood sugar
376979|NCT01179932|Pilot
376980|NCT01179932|Charting
376981|NCT01179932|Anesthesia Record
376982|NCT01179932|Cardiac surgical operating room
376983|NCT01179932|Cardiac surgical intensive care unit
376984|NCT01179932|Electrophysiology lab
376985|NCT01179919|Oseltamivir
376986|NCT01179919|Obesity
376987|NCT01179919|Influenza
376988|NCT01179919|Pharmacokinetics in Obesity
376989|NCT01179906|CKD
376990|NCT01179893|Myasthenia Gravis
376991|NCT01179893|IVIG
376992|NCT01179893|PLEX
376993|NCT01179880|Dermatitis
376994|NCT01179880|Atopic
376995|NCT01179867|Medication reconciliation
376996|NCT01179867|Adverse drug events
376997|NCT01179867|Hospital readmission
376998|NCT01179867|Medication management
376999|NCT01179841|Autism Spectrum Disorder
377000|NCT01179841|language
377001|NCT01179841|social
377002|NCT01179841|toddlers
377003|NCT01179828|Quantitative sensory testing
377004|NCT01179828|Drug efficacy
377005|NCT01179828|Low back pain syndrome
377006|NCT01179828|Imipramine
377007|NCT01179828|Oxycodone
377008|NCT01179828|Clobazam
377009|NCT01179828|Tolterodine
377010|NCT01179815|Diabetes mellitus, Type 1
377011|NCT01179815|Diabetes mellitus, Type 2
377012|NCT01179815|Cohort Studies
377013|NCT01179789|Healthy Elderly People
377014|NCT01179776|ST-eleveation
377015|NCT01179776|Myocardial infarct
377016|NCT01179776|Percutaneous coronary intervention
377017|NCT01179776|Myocardial infarct STEMI patients
377018|NCT01179763|Amblyopia
377019|NCT01179763|Retinal layer thickness
377020|NCT01179750|Ultrasonic coagulating shears in gastrectomy
377021|NCT01179737|Pulmonary Arterial Hypertension
377022|NCT01179737|Nilotinib
377023|NCT01179737|6MWD
377024|NCT01179737|Pulmonary Hypertension
377025|NCT01179711|accommodative esotropia
377026|NCT01179698|computer-assisted surgery
377027|NCT01179698|bone tumor
377028|NCT01179698|We will evaluate whether computer-assisted surgery
377029|NCT01179698|will be feasible and safe for bone tumor resection
377030|NCT01179672|Diabetic Peripheral Neuropathic Pain
377031|NCT01179659|Single dose crossover BE study
377032|NCT01179646|Bioequivalency
377033|NCT01179620|Hemodialysis, Certoparin
377034|NCT01179581|Safety
377035|NCT01179581|Tolerability
377036|NCT01179581|Pharmacokinetics
377037|NCT01179568|Grief
377038|NCT01179568|Bereavement
377039|NCT01179568|Psychotherapy
377040|NCT01179568|Medication
377041|NCT01179568|Treatment study
377042|NCT01179555|Diabetic Complications
377043|NCT01179555|Intervention Studies
377044|NCT01179555|African Americans
377045|NCT01179555|Vision Screening
377046|NCT01179555|Vision, Low
377047|NCT01179555|Geriatric Assessment
377048|NCT01179555|Outcomes Assessment
377049|NCT01179555|Cultural Characteristics
377050|NCT01179555|Cultural Competency
377051|NCT01179542|iugr pet eIF4E Translation Initiation Factor
377052|NCT01179542|4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
377053|NCT01179529|Atopic dermatitis (atopic eczema)
377054|NCT01179516|Major Depressive Disorder
377055|NCT01179516|Depression
377056|NCT01179516|Drug Therapy
377057|NCT01179503|vitamin D
377058|NCT01179503|physical performance
377059|NCT01179490|Multiple Myeloma
377060|NCT01179477|Left heart pacing lead
377061|NCT01179477|Cardiac resynchronization therapy (CRT)
377062|NCT01179477|Heart failure
377063|NCT01179425|marijuana
377064|NCT01179425|dependence
377065|NCT01179425|cognition
377066|NCT01179425|stress
377067|NCT01179386|methylphenidate
377068|NCT01179386|ADHD
377069|NCT01179386|driving
377070|NCT01179386|simulator
377071|NCT01179386|pressure
377072|NCT01179386|adolescent
377073|NCT01179360|Locally advanced
377074|NCT01179360|HNSCC
377075|NCT01179334|Pulmonary Hypertension
377076|NCT01179334|Riociguat
377077|NCT01179334|Blood Pressure
377078|NCT01179308|regional analgesia
377079|NCT01179308|routine general anesthesia
377080|NCT01179308|immune system response
377081|NCT01179308|lung cancer (stage 1-3)
377082|NCT01179295|MEK inhibitor
377083|NCT01179295|BAY86-9766
377084|NCT01179295|RDEA 119
377085|NCT01179295|Solid tumor
377086|NCT01179282|DUST MITE ALLERGIES
377087|NCT01179269|Non-small cell lung cancer
377088|NCT01179269|Pazopanib
377089|NCT01179269|Stage IIIB/IV non small cell lung cancer
377090|NCT01179256|ASTHMA
377091|NCT01179243|microcirculatory alterations
377092|NCT01179243|SDF imaging
377093|NCT01179230|CAD
377094|NCT01179230|chest pain
377095|NCT01179230|acute coronary syndrome
377096|NCT01179230|Myocardial perfusion imaging
377097|NCT01179217|Sickle Cell Anemia
377098|NCT01179217|Sickle Cell Pain Crises
377099|NCT01179217|Painful Crises
377100|NCT01179217|Sickle Cell Pain
377101|NCT01179217|Vaso-occlusive Crises
377102|NCT01179191|chronic pain
377103|NCT01179191|Embeda
377104|NCT01179191|opioid
377105|NCT01179191|moderate pain
377106|NCT01179191|severe pain
377107|NCT01179191|conversion
377108|NCT01179191|converting
377109|NCT01179191|switching
377110|NCT01179191|morphine
377111|NCT01179191|aberrant behavior
377112|NCT01179191|Pain (DT) + Chronic Disease (DT)
377113|NCT01179152|asthma, september epidemic, children, preventive
377114|NCT01179139|CRS
377115|NCT01179126|myocardial infarction
377116|NCT01179126|primary angioplasty
377117|NCT01179126|multivessel disease
377118|NCT01179126|stress echocardiography
377119|NCT01179113|Laminectomy
377120|NCT01179113|Esmolol Infusion
377121|NCT01179113|Quality of recovery
377122|NCT01179113|beta-blockers
377123|NCT01179113|Pain management
377124|NCT01179113|Postoperative pain
377125|NCT01179113|Opioid requirements
377126|NCT01179113|Intraoperative esmolol infusion
377127|NCT01179113|Return to normal activities of daily living
377128|NCT01179100|elderly
377129|NCT01179100|general anesthesia
377130|NCT01179100|lidocaine infusion
377131|NCT01179100|lidocaine
377132|NCT01179100|local anesthetic
377133|NCT01179100|pain management
377134|NCT01179100|cognitive function
377135|NCT01179087|sleep disordered breathing
377136|NCT01179087|lung transplantation
377137|NCT01179074|palliation inoperable oesophageal cancer
377138|NCT01179061|Apelin
377139|NCT01179061|Heart failure
377140|NCT01179061|Pulmonary artery pressure
377141|NCT01179061|Inotropic
377142|NCT01179061|Diuretic
377143|NCT01179035|Post-release, community health
377144|NCT01179022|Bacteremia
377145|NCT01179022|Argon Plasma Coagulation
377146|NCT01179022|Endobronchial Lesions
377147|NCT01179009|depression
377148|NCT01178983|work related musculoskeletal disorders (WRMSD) among computer operators
377149|NCT01178957|Type 1 diabetes
377150|NCT01178957|Very-Low-Density-Lipoprotein(VLDL)
377151|NCT01178957|Hyperglycemia
377152|NCT01178931|IVF
377153|NCT01178931|luteal phase support
377154|NCT01178931|oral progesterone
377155|NCT01178931|vaginal progesterone
377156|NCT01178931|pregnancy rate
377157|NCT01178931|safety
377158|NCT01178931|tolerability
377159|NCT01178918|Influenza H1N1
377160|NCT01178918|Vaccine
377161|NCT01178918|Adjuvant
377162|NCT01178918|T Lymphocytes
377163|NCT01178918|Non-specific response
377164|NCT01178918|Interleukin-2
377165|NCT01178918|Non-specific T cell responce
377166|NCT01178905|Postnatal CMV infection of preterm infants
377167|NCT01178905|breast milk
377168|NCT01178892|Hot Flashes
377169|NCT01178892|Menopause
377170|NCT01178892|Vasomotor symptoms
377171|NCT01178892|Yoga
377172|NCT01178892|Exercise
377173|NCT01178892|Omega-3
377174|NCT01178892|Fish oil
377175|NCT01178879|Telehealth
377176|NCT01178879|nurse consultation
377177|NCT01178879|outpatient clinic
377178|NCT01178866|thoracic surgery
377179|NCT01178866|myocardial revascularization
377180|NCT01178866|left ventricular dysfunction
377181|NCT01178866|tissue perfusion
377182|NCT01178866|prognosis
377183|NCT01178853|Healthy Volunteers
377184|NCT01178840|female condom
377185|NCT01178840|condom
377186|NCT01178840|clinical failure
377187|NCT01178840|prostate-specific antigen
377188|NCT01178840|semen exposure
377189|NCT01178840|acceptability
377190|NCT01178840|Prevention of semen exposure
377191|NCT01178801|liver cancer
377192|NCT01178801|data mining
377193|NCT01178801|knowledge discovering
377194|NCT01178801|The clinical data of the patients with liver cancer.
377195|NCT01178788|Progestagens
377196|NCT01178788|Tertiary Prophylaxis
377197|NCT01178788|Micronized Progesterone
377198|NCT01178788|17 alpha hydroxy P
377199|NCT01178788|Preterm Delivery
377200|NCT01178788|Cervical shortening
377201|NCT01178775|fatigue
377202|NCT01178775|meaning
377203|NCT01178775|education
377204|NCT01178775|walking program
377205|NCT01178762|Oral Azithromycin
377206|NCT01178762|Chlamydial Conjunctivitis
377207|NCT01178749|Hepatitis C
377208|NCT01178749|Interferon
377209|NCT01178749|Symptom Distress
377210|NCT01178749|Quality of Life
377211|NCT01178736|neoplasms
377212|NCT01178723|breakfast size
377213|NCT01178723|blood glucose balance
377214|NCT01178723|hormonal profile
377215|NCT01178723|appetite hormones
377216|NCT01178723|adipokines
377217|NCT01178723|pro-inflammatory cytokines
377218|NCT01178684|ENFD
377219|NCT01178684|epidermal nerve fiber density
377220|NCT01178684|HIV
377221|NCT01178684|HIV-infection
377222|NCT01178671|PTSD
377223|NCT01178671|trauma
377224|NCT01178671|anxiety disorder
377225|NCT01178671|medication
377226|NCT01178671|sertraline
377227|NCT01178671|mirtazapine
377228|NCT01178671|pharmacotherapy
377229|NCT01178632|Herbal
377230|NCT01178632|Phytotherapy
377231|NCT01178632|Passiflora
377232|NCT01178632|Valeriana
377233|NCT01178632|Anxiety
377234|NCT01178619|IUGR fetuses
377235|NCT01178619|symmetrical IUGR
377236|NCT01178619|asymmetrical IUGR
377237|NCT01178606|echogenic halo around lateral fetal ventricles
377238|NCT01178593|IBS
377239|NCT01178593|RCT
377240|NCT01178593|psychology
377241|NCT01178593|hypnosis
377242|NCT01178593|psychotherapy
377243|NCT01178593|group therapy
377244|NCT01178580|fibrinolytic activity
377245|NCT01178580|Community acquired pneumonia (CAP)
377246|NCT01178580|Pleural effusion
377247|NCT01178567|laparoscopic sleeve gastrectomy
377248|NCT01178567|Gastrectomy
377249|NCT01178567|Pulmonary Complications
377250|NCT01178554|anxiety disorders
377251|NCT01178554|depression
377252|NCT01178554|depressive disorders
377253|NCT01178554|disruptive behavioral problems
377254|NCT01178554|conduct problems
377255|NCT01178541|ventricles
377256|NCT01178541|fetal
377257|NCT01178541|brain
377258|NCT01178541|asymmetry
377259|NCT01178528|heart failure
377260|NCT01178528|heart rate
377261|NCT01178528|ivabradine
377262|NCT01178528|carvedilol
377263|NCT01178515|epidemiological risk
377264|NCT01178515|diet
377265|NCT01178515|fat intake
377266|NCT01178450|Renal transplant
377267|NCT01178450|Hypercalcemia
377268|NCT01178437|seizure disorder,
377269|NCT01178437|seizures,
377270|NCT01178437|convulsions,
377271|NCT01178437|grand mal,
377272|NCT01178437|petit mal,
377273|NCT01178437|absence seizures,
377274|NCT01178437|repeated seizures,
377275|NCT01178437|children's seizures,
377276|NCT01178437|secondary epilepsy,
377277|NCT01178437|symptomatic epilepsy,
377278|NCT01178437|generalized seizures,
377279|NCT01178437|partial seizure,
377280|NCT01178437|focal seizure,
377281|NCT01178437|partial complex seizure,
377282|NCT01178437|anticonvulsant medication
377283|NCT01178424|Unipolar depression
377284|NCT01178424|Mindfulness based cognitive therapy
377285|NCT01178424|Cognitive behavioural Therapy
377286|NCT01178424|Functional magnetic resonance imaging
377287|NCT01178424|Relapse
377288|NCT01178424|Depressive relapse
377289|NCT01178424|Dysphoric
377290|NCT01178424|Cognitive reactivity
377291|NCT01178424|Serotonin transporter gene
377292|NCT01178411|hepatocellular carcinoma
377293|NCT01178411|renal cell carcinoma
377294|NCT01178411|melanoma
377295|NCT01178411|non-small cell lung cancer
377296|NCT01178411|breast cancer
377297|NCT01178411|ovarian cancer
377298|NCT01178411|MiT tumors
377299|NCT01178398|fish
377300|NCT01178398|pregnancy
377301|NCT01178398|nutrition
377302|NCT01178398|mercury
377303|NCT01178398|focus group
377304|NCT01178398|omega-3 fatty acid
377305|NCT01178398|docosahexaenoic acid (DHA)
377306|NCT01178385|Autism
377307|NCT01178385|Asperger's Syndrome
377308|NCT01178385|Treatment
377309|NCT01178385|Cognitive-behavioral therapy
377310|NCT01178385|Anxiety
377311|NCT01178385|Children
377312|NCT01178385|Therapy
377313|NCT01178372|hepatic encephalopathy
377314|NCT01178372|lactulose
377315|NCT01178372|probiotics
377316|NCT01178359|cardiac arrest
377317|NCT01178359|ventricular fibrillation
377318|NCT01178359|nitrite
377319|NCT01178346|Pharmacoeconomic
377320|NCT01178346|Quality of Life
377321|NCT01178346|Health Outcomes
377322|NCT01178346|Smoking
377323|NCT01178346|NicVAX
377324|NCT01178346|Smoking vaccine
377325|NCT01178346|Smoking cessation
377326|NCT01178333|Thrombocytopenia
377327|NCT01178333|Heparin
377328|NCT01178320|Magnetic Resonance Imaging
377329|NCT01178320|Atherosclerotic Plaque
377330|NCT01178320|Lipid Lowering Therapy
377331|NCT01178307|GI cancers
377332|NCT01178307|GIST
377333|NCT01178307|Symptom Severity
377334|NCT01178307|Quality of Life
377335|NCT01178307|Questionnaire
377336|NCT01178307|M.D. Anderson Symptom Inventory
377337|NCT01178307|MDASI-GIST
377338|NCT01178307|patient-reported outcomes
377339|NCT01178294|hemophilia A
377340|NCT01178294|haemophilia A
377341|NCT01178294|blood coagulation disorders
377342|NCT01178294|hemorrhagic disorders
377343|NCT01178294|coagulation protein disorder
377344|NCT01178294|hematologic diseases
377345|NCT01178294|Acquired Hemophilia A
377346|NCT01178281|Myelofibrosis
377347|NCT01178281|Post-polycythemia vera myelofibrosis
377348|NCT01178281|Post-essential thrombocythemia myelofibrosis
377349|NCT01178281|RBC-transfusion-dependence
377350|NCT01178281|Primary Myelofibrosis
377351|NCT01178268|Drug eluting stents
377352|NCT01178268|Stents
377353|NCT01178268|Angioplasty
377354|NCT01178255|depression
377355|NCT01178255|homoeopathy
377356|NCT01178242|Labial mucous membrane
377357|NCT01178242|symblepharon
377358|NCT01178242|dry eye
377359|NCT01178242|Stevens -Johnson syndrome
377360|NCT01178242|salivary gland
377361|NCT01178242|ocular surface disease
377362|NCT01178242|transplantation
377363|NCT01178229|Sleep bruxism
377364|NCT01178229|Airway remodeling
377365|NCT01178229|Physical therapy modalities
377366|NCT01178229|Child preschool.
377367|NCT01178216|Kidney transplant
377368|NCT01178216|highly sensitized
377369|NCT01178203|Endodontics
377370|NCT01178203|pain
377371|NCT01178203|visual analogue scale
377372|NCT01178203|NSAIDs
377373|NCT01178190|narrow band imaging
377374|NCT01178190|malignant lesion
377375|NCT01178190|lung cancer
377376|NCT01178190|NBI
377377|NCT01178177|Invasive pulmonary aspergillosis
377378|NCT01178177|Solid organ transplantation
377379|NCT01178177|Hematologic disease
377380|NCT01178164|chronic pains
377381|NCT01178164|unknown aetiology
377382|NCT01178151|Peutz-Jeghers syndrome
377383|NCT01178151|mTOR inhibition
377384|NCT01178151|cancer
377385|NCT01178138|substance abuse
377386|NCT01178125|Pregnancy Prevention
377387|NCT01178125|Oral Contraceptives
377388|NCT01178112|Metastasis
377389|NCT01178112|Carboplatin
377390|NCT01178112|Trientine
377391|NCT01178112|Chemotherapy
377392|NCT01178073|Pulmonary Arterial Hypertension
377393|NCT01178073|Ambrisentan
377394|NCT01178073|Sponsor Rest of World: GSK
377395|NCT01178073|Tadalafil
377396|NCT01178073|PAH
377397|NCT01178073|Sponsor US: Gilead
377398|NCT01178060|Stroke
377399|NCT01178060|Risk
377400|NCT01178060|Communication
377401|NCT01178060|Cardiovascular Disease Knowledge
377402|NCT01178060|Improve Risk Communication
377403|NCT01178034|Warfarin
377404|NCT01178034|Dose
377405|NCT01178034|Pharmacogenetic
377406|NCT01178034|INR
377407|NCT01178021|malaria
377408|NCT01178021|vivax
377409|NCT01178021|relapse
377410|NCT01178008|Insomnia
377411|NCT01178008|Post-partum Depression
377412|NCT01178008|Electroacupuncture
377413|NCT01178008|Acupuncture
377414|NCT01178008|Randomized Clinical Trial
377415|NCT01178008|Traditional Chinese Medicine
377416|NCT01177982|pregnancy, opioid, cocaine, alcohol, benzodiazepines, neonate
377417|NCT01177969|Autism
377418|NCT01177969|Anxiety
377419|NCT01177969|Asperger's Syndrome
377420|NCT01177969|Cognitive-behavioral therapy
377421|NCT01177969|Treatment
377422|NCT01177969|Obsessive-compulsive disorder
377423|NCT01177969|Fears
377424|NCT01177956|Recurrent and/or metastatic squamous cell carcinoma of the head and neck
377425|NCT01177956|1st-line
377426|NCT01177956|Cetuximab
377427|NCT01177956|Chemotherapy
377428|NCT01177956|EMR 62241 -055
377429|NCT01177956|Merck KGaA
377430|NCT01177956|Recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
377431|NCT01177215|Algorithm
377432|NCT01177215|Treatment Protocol
377433|NCT01177215|Thoracic Drainage Device
377434|NCT01177202|HAC1, H1N1
377435|NCT01177189|Oxidative Stress
377436|NCT01177189|Free radicals
377437|NCT01177189|Aging
377438|NCT01177176|Cigarette smoking
377439|NCT01177176|Tobacco smoking
377440|NCT01177163|Type 2 diabetes mellitus
377441|NCT01177163|Canagliflozin
377442|NCT01177163|JNJ-28431754
377443|NCT01177163|Insulin
377444|NCT01177163|Pharmacokinetic
377445|NCT01177163|Pharmacodynamic
377446|NCT01177163|SGLT-1
377447|NCT01177150|Sodium-Glucose Transporter 2
377448|NCT01177150|Canagliflozin
377449|NCT01177150|Pharmacodynamic
377450|NCT01177150|Pharmacokinetic
377451|NCT01177150|Safety
377452|NCT01177150|Tolerability
377453|NCT01177137|tinnitus
377454|NCT01177137|tinnitus retraining therapy
377455|NCT01177137|standard of care
377456|NCT01177137|directive counseling
377457|NCT01177137|sound therapy
377458|NCT01177137|tinnitus questionnaire
377459|NCT01177137|tinnitus handicap inventory
377460|NCT01177124|Breast cancer
377461|NCT01177124|Survivors
377462|NCT01177124|Mindfulness-Based Stress Reduction (MBSR)
377463|NCT01177124|Symptoms
377464|NCT01177124|Immune markers
377465|NCT01177085|obesity
377466|NCT01177085|weight
377467|NCT01177085|weight-loss
377468|NCT01177085|mushroom
377469|NCT01177085|oxidative
377470|NCT01177085|stress
377471|NCT01177085|immune
377472|NCT01177085|function
377473|NCT01177085|inflammation
377474|NCT01177865|adenocarcinoma of the prostate
377475|NCT01177865|stage I prostate cancer
377476|NCT01177865|stage IIB prostate cancer
377477|NCT01177865|stage IIA prostate cancer
377478|NCT01177865|stage III prostate cancer
377479|NCT01177852|cough, acute rhinitis, common cold, nasal symptoms, children.
377480|NCT01177852|Acute inflammation upper airway
377481|NCT01177826|Hospitalized
377482|NCT01177826|Rotavirus
377483|NCT01177826|Children
377484|NCT01177826|effectiveness
377485|NCT01177826|Gastroenteritis
377486|NCT01177800|Psoriasis
377487|NCT01177800|Infliximab
377488|NCT01177800|Remicade
377489|NCT01177787|cryolipolysis fat zeltiq thigh Korean women
377490|NCT01177774|functional connectivity MRI
377491|NCT01177774|brain volumetry
377492|NCT01177774|negative reinforcement
377493|NCT01177774|OCD
377494|NCT01177774|ADHD
377495|NCT01177761|Osteoporosis
377496|NCT01177761|exercise
377497|NCT01177761|fractures
377498|NCT01177761|Bone Mineral Density
377499|NCT01177761|CHD-risk
377500|NCT01177748|Stroke
377501|NCT01177748|Cardiac Monitoring
377502|NCT01177735|Pomalidomide
377503|NCT01177735|multiple myeloma
377504|NCT01177735|relapsed
377505|NCT01177722|Diphtheria
377506|NCT01177722|Tetanus
377507|NCT01177722|Whooping cough
377508|NCT01177722|Hepatitis B
377509|NCT01177722|Poliomyelitis
377510|NCT01177722|Diphtheria-Tetanus-acellular Pertussis Vaccines
377511|NCT01177709|schizophrenia
377512|NCT01177709|antipsychotics
377513|NCT01177709|obesity
377514|NCT01177709|diabetes
377515|NCT01177696|caregivers
377516|NCT01177696|Family Health
377517|NCT01177696|Psychotherapeutic
377518|NCT01177696|Primary Health Care
377519|NCT01177670|Adiana Permanent Contraception System
377520|NCT01177670|women seeking permanent sterilization.
377521|NCT01177631|Carcinoma, hepatocellular
377522|NCT01177631|Portal vein
377523|NCT01177631|Proteomics
377524|NCT01177618|Chronic Obstructive Pulmonary Disease
377525|NCT01177618|COPD
377526|NCT01177618|Emphysema
377527|NCT01177618|Chronic Bronchitis
377528|NCT01177618|Genetics
377529|NCT01177618|Association Studies
377530|NCT01177579|Bariatric surgery, copper deficiency, biomarkers
377531|NCT01177566|Atopic dermatitis
377532|NCT01177566|Elidel
377533|NCT01177566|pimecrolimus cream 1%
377534|NCT01177566|Eletone
377535|NCT01177566|medical device cream
377536|NCT01177566|topical calcineurin inhibitor
377537|NCT01177553|Intrauterine Growth Retardation in Monochorionic Twins
377538|NCT01177527|Waldenstrom
377539|NCT01177527|myeloma
377540|NCT01177527|smoldering
377541|NCT01177527|lymphoma
377542|NCT01177527|MGUS
377543|NCT01177527|distinct B-cell lymphoproliferative disorder
377544|NCT01177514|Refractive surgery
377545|NCT01177514|PRK
377546|NCT01177514|PAIN
377547|NCT01177514|Gabapentin
377548|NCT01177501|Ovarian cancer
377549|NCT01177501|Topotecan
377550|NCT01177501|Carboplatine
377551|NCT01177501|Higt dose chemotherapy
377552|NCT01177488|Military
377553|NCT01177488|Health Service Delivery
377554|NCT01177488|Behavioral Symptoms
377555|NCT01177488|Telepsychology
377556|NCT01177488|Behavioral Activation
377557|NCT01177488|Exposure Therapy
377558|NCT01177488|Veterans
377559|NCT01177488|Telemedicine
377560|NCT01177475|kidney-transplant recipients
377561|NCT01177462|coordinate system
377562|NCT01177462|normal
377563|NCT01177449|prolotherapy
377564|NCT01177436|prostate cancer
377565|NCT01177436|benign prostatic hypertrophy
377566|NCT01177423|restorative odontology
377567|NCT01177423|Patients cared in restorative odontology department
377568|NCT01177410|IBS
377569|NCT01177410|Diarrhea
377570|NCT01177410|IBS-D
377571|NCT01177410|Irritable Bowel Syndrome
377572|NCT01177410|Abdominal pain
377573|NCT01177410|Bloating
377574|NCT01177397|Advanced solid malignant neoplasms,Non-Hodgkin Lymphoma,
377575|NCT01177397|Multiple Myeloma
377576|NCT01177384|Type 2 diabetes mellitus
377577|NCT01177384|T2DM
377578|NCT01177358|Scar
377579|NCT01177358|Botox
377580|NCT01177332|FFA
377581|NCT01177332|Liver
377582|NCT01177332|steatosis
377583|NCT01177332|exercise
377584|NCT01177319|Parkinson's Disease
377585|NCT01177319|Glutathione
377586|NCT01177306|ADHD, working memory
377587|NCT01177293|biological availability
377588|NCT01177293|bioavailability
377589|NCT01177293|amlodipine
377590|NCT01177293|orally disintegrating tablet
377591|NCT01177293|ODT
377592|NCT01177293|tablets
377593|NCT01177280|retrospective chronic low back pain
377594|NCT01177267|retrospective database analysis in osteoarthritis patients
377595|NCT01177254|retrospective chronic low back pain
377596|NCT01177241|retrospective chronic low back pain
377597|NCT01177072|PTSD
377598|NCT01177059|Gene Therapy
377599|NCT01177059|Anti-HIV-1 Ribozyme
377600|NCT01177059|OZ1
377601|NCT01177059|HIV-1 Infections
377602|NCT01177046|Women receiving labour epidural for most recent delivery
377603|NCT01177007|Gastrointestinal Diseases
377604|NCT01177007|Colonic Diseases
377605|NCT01177007|Intestinal Diseases
377606|NCT01177007|Rectal Diseases
377607|NCT01177007|Neoplastic Processes
377608|NCT01177007|Pathologic Processes
377609|NCT01177007|Neuroendocrine Tumors
377610|NCT01177007|Neuroectodermal Tumors
377611|NCT01177007|Neoplasms, Germ Cell and Embryonal
377612|NCT01177007|Adenocarcinoma
377613|NCT01177007|Neoplasms, Nerve Tissue
377614|NCT01177007|Liver Diseases
377615|NCT01177007|Neoplasms
377616|NCT01177007|Carcinoma
377617|NCT01177007|Colorectal Neoplasms
377618|NCT01177007|Neoplasm Metastasis
377619|NCT01177007|Carcinoma, Neuroendocrine
377620|NCT01177007|Liver Neoplasms
377621|NCT01177007|Neoplasms, Glandular and Epithelial
377622|NCT01177007|Neoplasms by Histologic Type
377623|NCT01177007|Intestinal Neoplasms
377624|NCT01177007|Gastrointestinal Neoplasms
377625|NCT01177007|Digestive System Neoplasms
377626|NCT01177007|Neoplasms by Site
377627|NCT01177007|Digestive System Diseases
377628|NCT01176994|Patients with skin lesions that are treated by dermatologists with destructive modalities without histological evaluation.
377629|NCT01176981|pediatrics
377630|NCT01176981|Osteosarcoma
377631|NCT01176981|Methotrexate
377632|NCT01176981|Outpatient
377633|NCT01176968|Eplerenone
377634|NCT01176968|myocardial infarction
377635|NCT01176968|mortality
377636|NCT01176968|morbidity
377637|NCT01176955|Acne
377638|NCT01176955|Acne vulgaris
377639|NCT01176955|Adherence
377640|NCT01176955|Compliance
377641|NCT01176955|MEMS
377642|NCT01176955|Benzoyl peroxide
377643|NCT01176929|Suicide, Attempted
377644|NCT01176929|prevention suicidal act
377645|NCT01176929|telephone contact
377646|NCT01176929|professional coordination
377647|NCT01176916|breast cancer
377648|NCT01176916|Aromasin
377649|NCT01176916|adjuvant chemotherapy
377650|NCT01176916|endocrine therapy
377651|NCT01176890|truncal vagotomy
377652|NCT01176890|GLP-1
377653|NCT01176890|gastric emptying
377654|NCT01176890|appetite
377655|NCT01176890|food intake
377656|NCT01176864|Small-Bowel Disorders
377657|NCT01176864|Double-balloon enteroscopy
377658|NCT01176864|Single-balloon enteroscopy
377659|NCT01176851|None (study in healthy volunteers)
377660|NCT01176838|Breast Cancer Quality of Life Survey
377661|NCT01176825|bipolar disorder
377662|NCT01176825|cognitive behavior therapy
377663|NCT01176825|alcohol abuse
377664|NCT01176825|drug abuse
377665|NCT01176825|high risk behaviors
377666|NCT01176825|medication adherence
377667|NCT01176825|psychosocial functioning
377668|NCT01176812|Facialwasting
377669|NCT01176812|Juvederm
377670|NCT01176812|Restylane
377671|NCT01176799|Breast cancer patients with measurable primary breast cancer tumor.
377672|NCT01176786|infection
377673|NCT01176786|tissue expander
377674|NCT01176786|breast implant
377675|NCT01176786|breast reconstruction
377676|NCT01176786|Infections rates
377677|NCT01176760|vagotomy
377678|NCT01176760|vagus
377679|NCT01176760|GLP-1
377680|NCT01176760|Insulin secretion
377681|NCT01176734|Pulsatile Tinnitus
377682|NCT01176734|Ringing-Buzzing-Tinnitus
377683|NCT01176734|Spontaneous Oto-Acoustic Emission Tinnitus
377684|NCT01176734|Tensor Palatini Induced Tinnitus
377685|NCT01176734|Tensor Tympani Induced Tinnitus
377686|NCT01176734|Tinnitus of Vascular Origin
377687|NCT01176734|Tinnitus, Clicking
377688|NCT01176734|Tinnitus, Leudet
377689|NCT01176734|Tinnitus, Leudet's
377690|NCT01176734|Tinnitus, Noise Induced
377691|NCT01176734|Tinnitus, Objective
377692|NCT01176734|Tinnitus, Spontaneous Oto-Acoustic Emission
377693|NCT01176734|Tinnitus, Subjective
377694|NCT01176734|Tinnitus, Tensor Palatini Induced
377695|NCT01176734|Tinnitus, Tensor Tympani Induced
377696|NCT01176734|Vascular Origin Tinnitus
377697|NCT01176721|schizophrenic disorders
377698|NCT01176721|psychosis
377699|NCT01176721|psychotic
377700|NCT01176721|dementia
377701|NCT01176721|delusional
377702|NCT01176721|delusions
377703|NCT01176721|hallucinations
377704|NCT01176721|residual-type schizophrenia
377705|NCT01176721|illusions
377706|NCT01176721|split mind
377707|NCT01176721|mental health disorder
377708|NCT01176721|schizoid
377709|NCT01176721|paranoid-type schizophrenia
377710|NCT01176721|disorganized-type schizophrenia
377711|NCT01176721|undifferentiated-type schizophrenia
377712|NCT01176721|catatonic-type schizophrenia
377713|NCT01176721|mental illness
377714|NCT01176721|tardive dyskinesia
377715|NCT01176721|neuroleptic malignant syndrome
377716|NCT01176721|NMS
377717|NCT01176721|antipsychotics
377718|NCT01176721|atypical antipsychotics
377719|NCT01176721|psychosocial treatments
377720|NCT01176721|rehabilitation
377721|NCT01176708|liver transplantation
377722|NCT01176708|kidney transplanted
377723|NCT01176708|glucagon-like peptide-1
377724|NCT01176708|insulin secretion
377725|NCT01176708|vagotomy
377726|NCT01176682|NSAID-treated patients
377727|NCT01176682|gastrointestinal events
377728|NCT01176682|Non-steroid anti-inflammatory drug (NSAID)
377729|NCT01176682|Gastrointestinal events (GI events)
377730|NCT01176682|Proton Pump Inhibitors (PPI)
377731|NCT01176669|Apatinib
377732|NCT01176669|Triple-Negative Breast Cancer
377733|NCT01176669|Metastatic Breast Cancer
377734|NCT01176669|ER/PR Negative
377735|NCT01176669|Her2/Neu Negative
377736|NCT01176656|Type 2 Diabetes Mellitus
377737|NCT01176656|Hypoglycemia
377738|NCT01176643|SLE
377739|NCT01176643|Yoga
377740|NCT01176630|metabolic syndrome, ESRD patient
377741|NCT01176617|Atrial Fibrillation
377742|NCT01176617|A-Fib
377743|NCT01176617|AF
377744|NCT01176617|Persistent
377745|NCT01176617|Permanent
377746|NCT01176617|Pulmonary Vein isolation
377747|NCT01176617|Ablation
377748|NCT01176604|Hepatocellular carcinoma (HCC) of the liver
377749|NCT01176604|Hepatocellular cancer
377750|NCT01176604|Hepatocellular carcinoma
377751|NCT01176604|Liver cancer
377752|NCT01176604|HCC
377753|NCT01176604|Humanitarian Device Exemption
377754|NCT01176604|Liver Diseases
377755|NCT01176604|(HDE)
377756|NCT01176604|Radioactive
377757|NCT01176604|TheraSphere
377758|NCT01176591|Cocaine and alcohol dependence (CAD)
377759|NCT01176565|Acute hypertensive response
377760|NCT01176565|intracerebral hemorrhage
377761|NCT01176565|blood pressure
377762|NCT01176565|outcome
377763|NCT01176565|nicardipine
377764|NCT01176552|Kidney Cancer
377765|NCT01176552|Renal cell carcinoma
377766|NCT01176552|High risk
377767|NCT01176552|Adjuvant therapy
377768|NCT01176526|Coping
377769|NCT01176526|Quality of Life
377770|NCT01176526|Prostate Cancer
377771|NCT01176513|Prostate Cancer
377772|NCT01176513|MRI
377773|NCT01176513|PET
377774|NCT01176513|GE-148 (18F)
377775|NCT01176500|PET Imaging
377776|NCT01176500|(18F)Fluciclatide
377777|NCT01176500|Anti-Angiogenic Therapies
377778|NCT01176500|Solid Tumors
377779|NCT01176487|recurrent non-small cell lung cancer
377780|NCT01176487|recurrent small cell lung cancer
377781|NCT01176487|extensive stage small cell lung cancer
377782|NCT01176487|stage IIIA non-small cell lung cancer
377783|NCT01176487|stage IIIB non-small cell lung cancer
377784|NCT01176487|stage IV non-small cell lung cancer
377785|NCT01176474|stage IV melanoma
377786|NCT01176474|stage IIIC melanoma
377787|NCT01176461|recurrent melanoma
377788|NCT01176461|stage IIIA melanoma
377789|NCT01176461|stage IIIB melanoma
377790|NCT01176461|stage IIIC melanoma
377791|NCT01176461|stage IV melanoma
377792|NCT01176448|Cicatrix
377793|NCT01176448|Dermabrasion
377794|NCT01176448|Coagulation, Laser
377795|NCT01176435|Levodopa
377796|NCT01176435|Albinism
377797|NCT01176435|Vision
377798|NCT01176422|AML
377799|NCT01176422|MDS
377800|NCT01176396|Dental Caries
377801|NCT01176396|Preventive Dentistry
377802|NCT01176396|Dental Prophylaxis
377803|NCT01176396|Dental Care
377804|NCT01176383|Nicotine addiction
377805|NCT01176383|Behaviour
377806|NCT01176383|Gene test
377807|NCT01176383|Lung cancer
377808|NCT01176383|Lifetime risk of lung cancer in smokers
377809|NCT01176370|Heart Failure
377810|NCT01176370|Device
377811|NCT01176370|Implantable
377812|NCT01176370|Active
377813|NCT01176370|Class III and Class IV
377814|NCT01176370|Counterpulsation
377815|NCT01176357|Coronary artery disease (CAD)
377816|NCT01176357|atherosclerosis
377817|NCT01176357|mediastinal adipose tissue
377818|NCT01176357|adiponectin, inflammatory mediators
377819|NCT01176344|Vitamin D supplementation
377820|NCT01176344|Osteoarthritis
377821|NCT01176344|Knee
377822|NCT01176344|Randomised clinical trial (RCT)
377823|NCT01176344|Cartilage
377824|NCT01176344|MRI
377825|NCT01176318|cough
377826|NCT01176318|exacerbation
377827|NCT01176318|quality of life
377828|NCT01176305|Thromboembolic event
377829|NCT01176292|total knee replacement
377830|NCT01176292|high flexion
377831|NCT01176292|range of motion
377832|NCT01176292|rotating platform
377833|NCT01176292|TKA
377834|NCT01176279|Critical illness
377835|NCT01176279|Hyperglycemia
377836|NCT01176279|Catheters, Indwelling
377837|NCT01176279|Intensive care unit
377838|NCT01176266|Hypophosphatasia
377839|NCT01176266|HPP
377840|NCT01176266|Bone Disease
377841|NCT01176266|Soft Bones
377842|NCT01176266|Low Alkaline Phosphatase
377843|NCT01176266|genetic metabolic disorder
377844|NCT01176266|alkaline phosphatase
377845|NCT01176266|tissue-specific alkaline phosphatase (TNSALP)
377846|NCT01176266|rickets
377847|NCT01176266|osteomalacia
377848|NCT01176253|Type I DM
377849|NCT01176240|lightheadedness
377850|NCT01176240|unsteadiness
377851|NCT01176240|dizziness
377852|NCT01176240|weak
377853|NCT01176240|fatigue
377854|NCT01176240|concentration
377855|NCT01176240|head & neck pain
377856|NCT01176240|standing/walking for a short time
377857|NCT01176240|standing/walking for a long time
377858|NCT01176240|Neurogenic Orthostatic Hypotension
377859|NCT01176240|falls
377860|NCT01176240|NOH
377861|NCT01176240|Parkinson's disease
377862|NCT01176240|weakness
377863|NCT01176227|bloating
377864|NCT01176227|constipation
377865|NCT01176227|diarrhea
377866|NCT01176227|gas
377867|NCT01176227|mucous
377868|NCT01176227|cramping
377869|NCT01176214|supratentorial intracerebral hemorrhage
377870|NCT01176214|tracheostomy
377871|NCT01176214|sedation
377872|NCT01176214|weaning
377873|NCT01176201|SLV337
377874|NCT01176201|Diabetes
377875|NCT01176201|Relative bioavailability
377876|NCT01176201|ADME
377877|NCT01176188|Pediatric Intensive Care Unit
377878|NCT01176188|Environmental Stressors
377879|NCT01176188|Sleep
377880|NCT01176188|Psychological Outcomes
377881|NCT01176188|Pediatrics
377882|NCT01176175|Progesterone
377883|NCT01176175|Microspheres
377884|NCT01176175|postmenopausal
377885|NCT01176175|Luteal phase support
377886|NCT01176162|Non Invasive measurement
377887|NCT01176162|Preterm infants
377888|NCT01176162|Aldosterone resistance
377889|NCT01176149|Diabetes
377890|NCT01176149|Self monitoring blood glucose
377891|NCT01176136|ADHD
377892|NCT01176136|School-Based
377893|NCT01176136|Organizational Skills
377894|NCT01176136|Homework
377895|NCT01176136|Time Management
377896|NCT01176123|Cognitive behavioral therapy
377897|NCT01176123|Insomnia
377898|NCT01176123|Traumatic Stress
377899|NCT01176110|hypothermia
377900|NCT01176110|minimal invasive valve replacement
377901|NCT01176097|First in man study evaluating AZD5658 in Type 2 Diabetics.
377902|NCT01176097|Effect of fasting
377903|NCT01176097|Safety
377904|NCT01176097|Tolerability
377905|NCT01176084|low carbohydrate diet
377906|NCT01176084|obesity
377907|NCT01176084|moderate exercise
377908|NCT01176084|men
377909|NCT01176071|galactomannan
377910|NCT01176071|beta-D-glucan
377911|NCT01176071|aspergillosis
377912|NCT01176071|outcome
377913|NCT01176058|Phase 3b
377914|NCT01176058|Efficacy and Safety evaluation of Anidulafungin
377915|NCT01176058|ICC
377916|NCT01176045|Dry Eye Disease
377917|NCT01176045|Osmolarity
377918|NCT01176045|Refractive Surgery
377919|NCT01176045|Lasik
377920|NCT01176045|TearLab
377921|NCT01176032|Aliskiren
377922|NCT01176032|hypertension
377923|NCT01176032|concentric LVH
377924|NCT01176032|LV remodeling
377925|NCT01176032|LVMI
377926|NCT01176032|biomarkers
377927|NCT01176032|PICP
377928|NCT01176032|CT-1
377929|NCT01176032|MMP-1
377930|NCT01176032|TIMP-1
377931|NCT01176032|AnxA5
377932|NCT01176032|Aldosterone
377933|NCT01176032|Essential hypertension with concentric left ventricle hypertrophy
377934|NCT01176019|Amniocentesis
377935|NCT01176019|Chorionic Villus Sampling
377936|NCT01176019|First trimester screening
377937|NCT01176019|Down syndrome
377938|NCT01176006|DOCK8
377939|NCT01176006|Molluscum
377940|NCT01176006|Transplant
377941|NCT01176006|Immunodeficiency
377942|NCT01175993|Motor Training
377943|NCT01175993|Post-Traumatic Stress Disorder (PTSD)
377944|NCT01175993|Balance
377945|NCT01175967|psychosocial effects of cancer and its treatment
377946|NCT01175967|perioperative/postoperative complications
377947|NCT01175967|stage III ovarian epithelial cancer
377948|NCT01175967|stage IV ovarian epithelial cancer
377949|NCT01175954|Partial Epilepsy
377950|NCT01175928|Diabetic polyneuropathy
377951|NCT01175928|Pneumatic Compression Device
377952|NCT01175915|Mild type of hand, foot and mouth disease
377953|NCT01175915|Reduning Injection
377954|NCT01175915|Effectiveness
377955|NCT01175915|Safety
377956|NCT01175902|Normal tension glaucoma
377957|NCT01175876|MMSE
377958|NCT01175876|NSE
377959|NCT01175876|S100B
377960|NCT01175876|hsCRP
377961|NCT01175876|DWI-MRI
377962|NCT01175863|intravascular ultrasound
377963|NCT01175863|fractional flow reserve
377964|NCT01175824|Metabolic Diseases
377965|NCT01175824|Diabetes Mellitus, Type 2
377966|NCT01175824|Glargine
377967|NCT01175824|Diabetes Mellitus
377968|NCT01175824|Insulin LISPRO
377969|NCT01175824|Insulin
377970|NCT01175811|Metabolic Diseases
377971|NCT01175811|Diabetes Mellitus, Type 2
377972|NCT01175811|Glargine
377973|NCT01175811|Diabetes Mellitus
377974|NCT01175811|Insulin LISPRO
377975|NCT01175811|Insulin
377976|NCT01175798|Vitamin D deficiency
377977|NCT01175798|End-stage renal disease
377978|NCT01175798|Immunity
377979|NCT01175772|Ovary
377980|NCT01175772|Carcinoma
377981|NCT01175772|Maintenance
377982|NCT01175772|Metronomic
377983|NCT01175772|Chemotherapy
377984|NCT01175772|Time to Progression
377985|NCT01175772|overall survival
377986|NCT01175759|Unexplained Recurrent Pregnancy Loss
377987|NCT01175759|Recurrent Abortions
377988|NCT01175759|Recurrent Miscarriages
377989|NCT01175759|Hormones
377990|NCT01175759|Skin tests
377991|NCT01175759|Allergen
377992|NCT01175759|Immunotherapy
377993|NCT01175759|Hypersensitivity
377994|NCT01175759|Skin reaction
377995|NCT01175746|healthy adult patients
377996|NCT01175746|ASA class I
377997|NCT01175746|hypotensive anesthesia
377998|NCT01175733|Panitumumab
377999|NCT01175733|Chemoradiation
378000|NCT01175733|Pancreatic cancer
378001|NCT01175733|Locally advanced
378002|NCT01175733|Inoperable
378003|NCT01175720|gingival recession
378004|NCT01175720|acellular dermal matrix graft
378005|NCT01175720|root coverage
378006|NCT01175694|Brachytherapy
378007|NCT01175694|APBI
378008|NCT01175694|dose modification
378009|NCT01175694|local recurrences
378010|NCT01175694|side effects
378011|NCT01175694|cosmetic result
378012|NCT01175681|rheumatic heart disease
378013|NCT01175681|degenerated heart valve disease
378014|NCT01175681|heart valve prolapse
378015|NCT01175655|Mesenchymal stromal cells
378016|NCT01175655|Bronchiolitis obliterans
378017|NCT01175655|Lung transplant
378018|NCT01175642|Schizophrenia
378019|NCT01175642|Psychosis
378020|NCT01175642|Schizoaffective Disorder
378021|NCT01175629|Stress Disorders, Post-Traumatic
378022|NCT01175629|Depression
378023|NCT01175629|Diabetes
378024|NCT01175629|Cardiovascular Disease
378025|NCT01175629|Depressive Disorder
378026|NCT01175629|Behavioral Symptoms
378027|NCT01175629|Metabolic Diseases
378028|NCT01175629|Mental Disorders
378029|NCT01175629|Anxiety Disorders
378030|NCT01175616|Depression
378031|NCT01175616|Adults
378032|NCT01175603|depression, African American, home visiting, prevention
378033|NCT01175577|mixed carotenes
378034|NCT01175564|TC-5214
378035|NCT01175564|safety
378036|NCT01175564|pharmacokinetics
378037|NCT01175564|single dose
378038|NCT01175564|repeated dose
378039|NCT01175564|Japanese
378040|NCT01175564|healthy subjects
378041|NCT01175551|Preterm Birth
378042|NCT01175551|Cervix
378043|NCT01175551|Cervical Shortening
378044|NCT01175551|Cervical remodeling
378045|NCT01175551|PTB
378046|NCT01175538|Hepatic encephalopathy
378047|NCT01175538|Lactulose
378048|NCT01175499|laryngoscopy
378049|NCT01175499|Laryngoscopic Surgery
378050|NCT01175499|laryngoscopes
378051|NCT01175499|upper aerodigestive tract lesions
378052|NCT01175499|endoscopy
378053|NCT01175499|biopsy
378054|NCT01175486|thiazolidinediones
378055|NCT01175486|diabetes
378056|NCT01175486|retinopathy
378057|NCT01175486|nephropathy
378058|NCT01175460|esophageal Cancer
378059|NCT01175460|radiation
378060|NCT01175460|s-1
378061|NCT01175460|nedaplatin
378062|NCT01175447|S-1
378063|NCT01175447|radiation
378064|NCT01175447|esophageal Cancer
378065|NCT01175434|Asthma
378066|NCT01175421|snoring
378067|NCT01175421|sleep apnea
378068|NCT01175421|sleep study
378069|NCT01175421|cardiovascular outcomes
378070|NCT01175408|Remote Blood Glucose Monitoring System,
378071|NCT01175408|Continuous Glucose Monitoring System,
378072|NCT01175408|Self Monitoring Blood Glucose,
378073|NCT01175408|Strip Counting,
378074|NCT01175408|Type 2 Diabetes
378075|NCT01175395|Choroidal neovascular membranes
378076|NCT01175395|CNV
378077|NCT01175395|AMD
378078|NCT01175395|Age-relate Macular Degeneration
378079|NCT01175395|CNVM
378080|NCT01175395|subfoveal
378081|NCT01175382|Male Urogenital Diseases
378082|NCT01175382|Urinary Bladder, overactive
378083|NCT01175382|Behavioral Medicine
378084|NCT01175382|Drug Therapy
378085|NCT01175369|Asthma
378086|NCT01175330|Omega-3 fatty acid
378087|NCT01175330|Ischemic Heart Disease
378088|NCT01175330|Atrial Fibrillation
378089|NCT01175330|Subcutaneous cardiac monitoring
378090|NCT01175317|Hemodynamic optimization
378091|NCT01175317|Enhanced recovery after surgery
378092|NCT01175317|Goal-directed fluid
378093|NCT01175304|sleep
378094|NCT01175304|sleep apnea
378095|NCT01175304|work
378096|NCT01175304|sleep habits
378097|NCT01175304|sleepiness
378098|NCT01175291|colon
378099|NCT01175291|rectum
378100|NCT01175291|colorectal
378101|NCT01175291|metastatic
378102|NCT01175291|adenocarcinoma
378103|NCT01175278|vertebral
378104|NCT01175278|compression
378105|NCT01175278|fracture
378106|NCT01175278|VCF
378107|NCT01175278|kyphoplasty
378108|NCT01175278|spine
378109|NCT01175265|clinically stable
378110|NCT01175265|COPD (GOLD-classification I-IV)
378111|NCT01175265|COPD
378112|NCT01175265|breathing retraining
378113|NCT01175265|pulmonary rehabilitation
378114|NCT01175265|cardiac autonomic function
378115|NCT01175265|quality of life
378116|NCT01175265|exercise capacity
378117|NCT01175265|pulmonary function
378118|NCT01175252|Gastroenteritis
378119|NCT01175239|X-linked severe combined immunodeficiency, gene therapy
378120|NCT01175239|Patients will be enrolled following diagnosis and referral to Great Ormond Street Immunology Service.
378121|NCT01175226|Human rhinovirus
378122|NCT01175226|Aviragen Therapeutics, Inc.
378123|NCT01175226|Aviragen Therapeutics
378124|NCT01175226|Aviragen
378125|NCT01175187|evron
378126|NCT01175174|asthma
378127|NCT01175174|preschool children
378128|NCT01175174|adenosine provocation test
378129|NCT01175174|metacholine provocation test
378130|NCT01175174|pediatric emergency department
378131|NCT01175161|Postpartum Contraception
378132|NCT01175161|Intrauterine device
378133|NCT01175161|feasibility
378134|NCT01175161|IUD
378135|NCT01175161|Immediate postpartum IUD
378136|NCT01175148|HSCT
378137|NCT01175148|HPC
378138|NCT01175148|HCT
378139|NCT01175148|BMT
378140|NCT01175148|lipitor
378141|NCT01175148|atorvastatin
378142|NCT01175148|HMG-CoA Reductase Inhibitor
378143|NCT01175148|Hematopoietic stem cell transplant
378144|NCT01175148|allogeneic transplant
378145|NCT01175148|GVHD
378146|NCT01175148|graft-versus-host-disease
378147|NCT01175148|Graft vs Host Disease
378148|NCT01175135|schizophrenia
378149|NCT01175135|acute exacerbation
378150|NCT01175135|inpatient
378151|NCT01175109|Chordoma
378152|NCT01175096|neuroendocrine tumors
378153|NCT01175096|carcinoid tumor
378154|NCT01175096|RAD001 (everolimus, Afinitor®)
378155|NCT01175083|Catch-up vaccination
378156|NCT01175083|Pneumococcal vaccine
378157|NCT01175083|Sickle cell disease
378158|NCT01175083|Booster vaccination
378159|NCT01175083|Safety
378160|NCT01175083|Immunogenicity
378161|NCT01175083|Pneumococcal disease
378162|NCT01175070|diabetic macular oedema
378163|NCT01175070|ischaemia
378164|NCT01175070|anti VEGF
378165|NCT01175070|pegaptanib
378166|NCT01175070|Ischaemic diabetic macular oedema
378167|NCT01175057|feasibility
378168|NCT01175057|compliance
378169|NCT01175057|telemedical home monitoring
378170|NCT01175057|post stationary rehabilitation
378171|NCT01175057|patients with myocardial infarction
378172|NCT01175044|Revision
378173|NCT01175044|Knee
378174|NCT01175044|Arthroplasty
378175|NCT01175044|Betadine
378176|NCT01175044|Lavage
378177|NCT01175044|Infection
378178|NCT01175018|Acute myocardial infarction
378179|NCT01175018|Heart Failure
378180|NCT01175018|Cardiac Remodeling
378181|NCT01175005|Fever
378182|NCT01175005|Central venous catheter
378183|NCT01175005|Procalcitonin
378184|NCT01175005|Fever with a central venous catheter
378185|NCT01174992|Fibrin sealant
378186|NCT01174992|CSF leak
378187|NCT01174979|Morbus Meniere
378188|NCT01174979|Sudden hearing loss
378189|NCT01174979|Blast injury
378190|NCT01174979|Presbyacusis
378191|NCT01174979|Chron. Otitis Media
378192|NCT01174966|oxygen challenge test
378193|NCT01174966|shock
378194|NCT01174966|mortality
378195|NCT01174966|Oxygen Delivery Index
378196|NCT01174966|cardiac output index
378197|NCT01174953|prostate cancer
378198|NCT01174940|myelogenous leukemia
378199|NCT01174940|lymphocytic leukemia
378200|NCT01174940|lymphoblastic leukemia
378201|NCT01174940|myelodysplastic syndrome
378202|NCT01174940|non-Hodgkin's lymphoma
378203|NCT01174940|Hodgkin's disease
378204|NCT01174927|Substance use disorder
378205|NCT01174927|Stress
378206|NCT01174901|cephalalgia
378207|NCT01174901|copeptins
378208|NCT01174901|biomarkers
378209|NCT01174901|headache
378210|NCT01174901|C-terminal provasopression
378211|NCT01174901|physiological stress response
378212|NCT01174888|Acute Myeloid Leukemia
378213|NCT01174888|AML
378214|NCT01174875|Epigenetics
378215|NCT01174875|Development
378216|NCT01174875|Metabolic
378217|NCT01174875|Neurodevelopment
378218|NCT01174862|aspirin
378219|NCT01174862|aspirin responsiveness
378220|NCT01174862|long-term outcome
378221|NCT01174862|CABG
378222|NCT01174849|otitis media
378223|NCT01174849|pneumococcal vaccines
378224|NCT01174849|randomised controlled trial
378225|NCT01174849|high-risk children
378226|NCT01174849|indigenous
378227|NCT01174849|Australia
378228|NCT01174836|CT utilization
378229|NCT01174836|physician attitudes
378230|NCT01174810|Parkinson's Disease
378231|NCT01174810|PD
378232|NCT01174810|Moderate Parkinson's Disease
378233|NCT01174784|Chronic Total Occlusions
378234|NCT01174784|Superficial Femoral Artery
378235|NCT01174784|Popliteal Artery
378236|NCT01174771|Transcranial magnetic stimulation
378237|NCT01174771|Cortical excitability
378238|NCT01174771|parkinsonism
378239|NCT01174771|Progressive Supranuclear Palsy
378240|NCT01174771|Corticobasal Degeneration
378241|NCT01174771|PSP
378242|NCT01174771|CBD
378243|NCT01174771|CBGD
378244|NCT01174758|balance
378245|NCT01174758|mobility
378246|NCT01174758|ON/OFF Levodopa
378247|NCT01174732|asthma
378248|NCT01174732|bronchospasm
378249|NCT01174732|COPD
378250|NCT01174732|chronic respiratory disease
378251|NCT01174719|Hydroxyethylstarch
378252|NCT01174719|Humanalbumin
378253|NCT01174719|Ringer Lactate
378254|NCT01174719|patients undergoing cardiac surgery
378255|NCT01174706|infections
378256|NCT01174706|flu
378257|NCT01174706|abdominal pain
378258|NCT01174706|chest pain
378259|NCT01174706|cold
378260|NCT01174706|fever
378261|NCT01174706|different acute care conditions
378262|NCT01174693|prospective
378263|NCT01174693|randomized
378264|NCT01174693|open label
378265|NCT01174693|multi-center
378266|NCT01174693|double-blind for CYP2C19 genotypes
378267|NCT01174680|cardiogoniometry
378268|NCT01174680|stable angina pectoris patients
378269|NCT01174667|Myofascial pain
378270|NCT01174667|Trigger points
378271|NCT01174641|unilateral neglect
378272|NCT01174641|TMS intervention
378273|NCT01174628|Exercise Tolerance
378274|NCT01174628|Venous Thrombosis
378275|NCT01174628|Pulmonary Embolism
378276|NCT01174628|Quality of Life (QOL)
378277|NCT01174615|Blood/bone marrow collection, hematologic diseases, leukemia
378278|NCT01174589|Lower limb strength training
378279|NCT01174589|Randomized clinical trial
378280|NCT01174589|Patients with Hip fracture
378281|NCT01174589|6 vs. 12 weeks physical strength training
378282|NCT01174576|coffee
378283|NCT01174576|appetite
378284|NCT01174576|energy intake
378285|NCT01174576|inflammation
378286|NCT01174576|cortisol
378287|NCT01174576|glucose
378288|NCT01174576|randomized controlled trial
378289|NCT01174550|chest pain
378290|NCT01174550|coronary artery disease
378291|NCT01174550|CAD
378292|NCT01174537|NDV
378293|NCT01174537|Metastatic
378294|NCT01174537|Refractory
378295|NCT01174537|Cancer
378296|NCT01174537|Progression-free
378297|NCT01174537|survival
378298|NCT01174537|recurrent
378299|NCT01174524|Quality of life
378300|NCT01174524|Menopause
378301|NCT01174524|Contraception
378302|NCT01174511|ATOPIC DERMATITIS
378303|NCT01174511|A-1 COOL CREAM
378304|NCT01174498|discomfort
378305|NCT01174498|distress
378306|NCT01174498|hurt
378307|NCT01174498|sting
378308|NCT01174485|Liposuction
378309|NCT01174485|exercise
378310|NCT01174485|metabolism
378311|NCT01174485|adiposity
378312|NCT01174472|Dialysis access
378313|NCT01174472|angioplasty
378314|NCT01174472|drug eluting balloon
378315|NCT01174433|Bifurcation coronary artery disease
378316|NCT01174433|Percutaneous coronary intervention
378317|NCT01174433|Tryton Stent
378318|NCT01174420|ologen
378319|NCT01174420|Mitomycin-C
378320|NCT01174420|Collagen Matrix
378321|NCT01174420|trabeculectomy
378322|NCT01174420|glaucoma
378323|NCT01174420|filtering surgery
378324|NCT01174394|Acupuncture
378325|NCT01174394|Post Stroke Depression
378326|NCT01174394|Depressive Disorder
378327|NCT01174394|Cardiovascular Accident
378328|NCT01174394|Stroke
378329|NCT01174394|Apoplexy
378330|NCT01174394|CVA
378331|NCT01174381|Non communicable disease
378332|NCT01174381|Lifestyle Modification
378333|NCT01174381|Community Based organization
378334|NCT01174381|community based study
378335|NCT01174342|Intraocular pressure
378336|NCT01174342|Ocular tonometry
378337|NCT01174342|Obstetric delivery
378338|NCT01174316|Acute exacerbation
378339|NCT01174316|Respiratory insufficiency
378340|NCT01174316|Respiratory failure
378341|NCT01174316|Hypercapnia
378342|NCT01174316|Hypoventilation
378343|NCT01174316|Sleep
378344|NCT01174316|Hypoxia
378345|NCT01174316|Titration
378346|NCT01174316|Non Invasive Ventilation
378347|NCT01174290|subsyndromal delirium
378348|NCT01174290|delirium
378349|NCT01174290|haloperidol
378350|NCT01174290|antipsychotic
378351|NCT01174290|randomized controlled trial
378352|NCT01174290|placebo-controlled
378353|NCT01174290|intensive care unit
378354|NCT01174290|critical care
378355|NCT01174290|subsyndromal delirium in the intensive care unit
378356|NCT01174277|chronic graft versus host disease
378357|NCT01174277|transplant
378358|NCT01174277|stem cell
378359|NCT01174251|general anesthesia
378360|NCT01174251|electrocardiography
378361|NCT01174251|long QT syndrome, acquired
378362|NCT01174238|Melanoma
378363|NCT01174238|Axitinib
378364|NCT01174238|Carboplatin
378365|NCT01174238|Paclitaxel
378366|NCT01174225|Copper IUD
378367|NCT01174225|Nova T 200
378368|NCT01174225|Flexi T 380
378369|NCT01174225|expulsion
378370|NCT01174225|contraception satisfaction
378371|NCT01174225|post-abortion contraception
378372|NCT01174212|revision
378373|NCT01174212|infection
378374|NCT01174212|knee
378375|NCT01174212|hip
378376|NCT01174212|replacement
378377|NCT01174212|antibiotics
378378|NCT01174173|Angina
378379|NCT01174173|Right Ventricular Ischemia
378380|NCT01174173|Pulmonary Arterial Hypertension
378381|NCT01174173|Pulmonary Hypertension
378382|NCT01174160|Atrial Fibrillation
378383|NCT01174121|Digestive Tract Cancers
378384|NCT01174121|Breast Cancer
378385|NCT01174121|Cell Therapy
378386|NCT01174121|Ovarian/Endometrial Cancer
378387|NCT01174121|Urothelial Cancers
378388|NCT01174108|Myelodysplastic Syndrome (MDS)
378389|NCT01174108|Severe Aplastic Anemia
378390|NCT01174108|Pure Red Cell Aplasia
378391|NCT01174108|Paroxysmal Nocturnal Hemoglobinuria (PNH)
378392|NCT01174108|Miltenyi CD34 Reagent System
378393|NCT01174108|Allogeneic Stem Cell Transplant
378394|NCT01174095|Diffuse Coronary Artery Disease
378395|NCT01174095|Ischemic Myocardium
378396|NCT01174095|Ischemia
378397|NCT01174082|Multiple Myeloma
378398|NCT01174082|Vaccine
378399|NCT01174082|Lymphocyte Infusion
378400|NCT01174069|NOTES
378401|NCT01174069|cholecystectomy
378402|NCT01174069|endoscopic
378403|NCT01174056|Lung inflammation
378404|NCT01174056|positron emission tomography
378405|NCT01174056|fluorodeoxyglucose
378406|NCT01174056|rosiglitazone
378407|NCT01174056|zileuton
378408|NCT01174056|lung anti-inflammatory therapy
378409|NCT01174043|Leukemia, Myelomonocytic, Acute
378410|NCT01174043|Erlotinib
378411|NCT01174017|prostate cancer
378412|NCT01174017|Iodine 125 brachytherapy
378413|NCT01174017|seed migration
378414|NCT01174017|seed migration in the first month after brachytherapy
378415|NCT01173991|carbohydrate counting
378416|NCT01173991|continuous subcutaneous insulin infusion
378417|NCT01173991|type 1 diabetes mellitus
378418|NCT01173978|Incretin hormones
378419|NCT01173978|Glucagon
378420|NCT01173978|Insulin/c-peptide
378421|NCT01173978|Plasma glucose
378422|NCT01173978|Insulin resistance
378423|NCT01173978|Deteriorated glucose homeostasis
378424|NCT01173978|Inactivity
378425|NCT01173939|Hypercholesterolemia with concomitant type 2 diabetes and hypertension
378426|NCT01173913|oral docetaxel
378427|NCT01173913|ModraDoc
378428|NCT01173913|pharmacokinetics
378429|NCT01173913|safety
378430|NCT01173913|MTD
378431|NCT01173913|DLT
378432|NCT01173900|human papillomavirus
378433|NCT01173900|vaccine
378434|NCT01173900|school girls
378435|NCT01173900|Tanzania
378436|NCT01173900|acceptability
378437|NCT01173900|vaccine coverage
378438|NCT01173900|Cervical cancer prevention
378439|NCT01173874|Cognition
378440|NCT01173874|Function
378441|NCT01173874|Attention
378442|NCT01173874|Vigilance
378443|NCT01173874|Verbal Memory
378444|NCT01173874|Visual Memory
378445|NCT01173874|Processing Speed
378446|NCT01173874|Problem Solving
378447|NCT01173874|Social Cognition
378448|NCT01173848|CKD
378449|NCT01173848|Vitamin D
378450|NCT01173835|Adolescent tobacco use
378451|NCT01173835|Tobacco Free and Win
378452|NCT01173835|Incentive-based intervention
378453|NCT01173835|Contingency Management
378454|NCT01173835|Smoking Prevention
378455|NCT01173835|Smoking cessation
378456|NCT01173822|cardiopulmonary bypass
378457|NCT01173822|hemorrhage
378458|NCT01173822|trials
378459|NCT01173822|surgery
378460|NCT01173809|AF
378461|NCT01173809|Catheter Ablation
378462|NCT01173809|Recurrence of AF
378463|NCT01173809|Amiodarone
378464|NCT01173783|Heart failure
378465|NCT01173783|Cardiac insufficiency
378466|NCT01173783|Implantable Cardioverter/Defibrillator
378467|NCT01173783|Cardiac Resynchronization therapy
378468|NCT01173783|ICD
378469|NCT01173783|CRT
378470|NCT01173783|Register
378471|NCT01173757|Healthy Volunteers
378472|NCT01173744|Intertrochanteric femoral fractures - unstable
378473|NCT01173731|Parkinson Disease
378474|NCT01173731|L-dopa
378475|NCT01173731|Levodopa
378476|NCT01173731|Dyskinesia
378477|NCT01173731|involuntary movement
378478|NCT01173731|motor complication
378479|NCT01173718|Hemodialysis
378480|NCT01173718|Vascular Graft
378481|NCT01173705|Obesity
378482|NCT01173705|Insulin Resistance
378483|NCT01173705|Inflammation
378484|NCT01173692|Oropharynx Cancer
378485|NCT01173692|Radiation Therapy
378486|NCT01173692|XRT
378487|NCT01173692|Radiotherapy
378488|NCT01173692|Minocycline
378489|NCT01173692|Symptoms
378490|NCT01173692|Head and Neck
378491|NCT01173679|CLL
378492|NCT01173679|fludarabine
378493|NCT01173679|rituximab
378494|NCT01173679|dasatinib
378495|NCT01173679|refractory
378496|NCT01173679|relapsed
378497|NCT01173666|RAS
378498|NCT01173666|LVMI
378499|NCT01173666|Renal revascularization
378500|NCT01173653|smoking
378501|NCT01173653|smoking cessation
378502|NCT01173653|health behavior
378503|NCT01173640|drug interactions
378504|NCT01173640|midazolam
378505|NCT01173640|cytochrome P450
378506|NCT01173640|resveratrol
378507|NCT01173640|pharmacokinetics
378508|NCT01173627|Bioequivalence
378509|NCT01173627|Fentanyl
378510|NCT01173588|bowel function
378511|NCT01173588|functional foods
378512|NCT01173562|Healthy volunteers
378513|NCT01173562|Parasitic Diseases
378514|NCT01173562|Mebendazole (VERMOX)
378515|NCT01173562|Anthelmintics
378516|NCT01173562|Antiparasitic Agents
378517|NCT01173562|Soil-transmitted helminth (STH) infections
378518|NCT01173562|Pediatric
378519|NCT01173549|Canagliflozin
378520|NCT01173549|Pharmacodynamic
378521|NCT01173549|Glucose absorption
378522|NCT01173549|Glucose metabolism
378523|NCT01173523|Hsp90 Inhibitor
378524|NCT01173523|relapsed
378525|NCT01173523|refractory
378526|NCT01173510|HIV
378527|NCT01173510|AIDS
378528|NCT01173510|Atripla
378529|NCT01173510|Truvada
378530|NCT01173510|Raltegravir
378531|NCT01173510|Human Immunodeficiency Virus
378532|NCT01173510|Acquired Immune Deficiency Syndrome Virus
378533|NCT01173497|Triple negative breast cancer
378534|NCT01173497|Brain metastasis
378535|NCT01173497|BSI-201
378536|NCT01173497|iniparib
378537|NCT01173484|Idiopathic gastroparesis
378538|NCT01173484|Vomiting
378539|NCT01173484|Dyspepsia
378540|NCT01173484|GERD
378541|NCT01173471|Raised intraocular pressure
378542|NCT01173458|cancer
378543|NCT01173458|lung
378544|NCT01173458|small cell
378545|NCT01173445|cancer
378546|NCT01173445|kidney
378547|NCT01173445|renal cell
378548|NCT01173445|tumor cells
378549|NCT01173445|circulating tumor cells
378550|NCT01173445|circulating endothelial cells
378551|NCT01173432|obstructive sleep apnea
378552|NCT01173432|metabolic dysfunction
378553|NCT01173432|metabolic syndrome
378554|NCT01173432|adipocyte fatty acid binding protein
378555|NCT01173419|Great Saphenous Vein
378556|NCT01173406|Continuous Positive Airway Pressure treatment
378557|NCT01173406|Adherence
378558|NCT01173406|Education
378559|NCT01173393|out of hospital cardiac arrest
378560|NCT01173393|OHCA
378561|NCT01173393|EMS
378562|NCT01173393|Emergency medical System
378563|NCT01173393|non-VF
378564|NCT01173393|non-ventricular fibrillation
378565|NCT01173380|Soy
378566|NCT01173380|Equol
378567|NCT01173380|Metabolic syndrome
378568|NCT01173380|Endothelial function
378569|NCT01173367|Fever
378570|NCT01173367|ICU
378571|NCT01173367|Acetaminophen
378572|NCT01173367|Inflammatory mediators
378573|NCT01173367|Safety
378574|NCT01173354|COPD
378575|NCT01173354|Protein metabolism
378576|NCT01173354|Essential amino acid intake
378577|NCT01173328|exercise tolerance
378578|NCT01173328|dynamic hyperinflation
378579|NCT01173328|respiratory mechanics
378580|NCT01173315|Type 2 diabetes
378581|NCT01173315|micronutrients
378582|NCT01173315|nephropathy
378583|NCT01173315|neuropathy
378584|NCT01173302|Rabies
378585|NCT01173302|Anti-rabies antibody
378586|NCT01173302|Persistence
378587|NCT01173289|Thyroid Carcinoma
378588|NCT01173289|External Beam Radiotherapy
378589|NCT01173276|Acquired Immune Deficiency Syndrome
378590|NCT01173276|Assisted Reproductive Technology
378591|NCT01173276|Fertility
378592|NCT01173276|HIV
378593|NCT01173276|HIV Discordant
378594|NCT01173276|Infertility
378595|NCT01173276|Intrauterine Insemination
378596|NCT01173276|Sexually Transmitted Diseases
378597|NCT01173276|Sperm Washing
378598|NCT01173263|breathing machine
378599|NCT01173263|mechanical ventilator
378600|NCT01173250|total proctocolectomy with ileal pouch anal anastomosis with and without ileostomy
378601|NCT01173237|tracheal intubation
378602|NCT01173237|proseal laryngeal mask airway
378603|NCT01173237|neonate
378604|NCT01173237|surfactant
378605|NCT01173237|respiratory distress syndrome
378606|NCT01173224|influenza, DAS181, antiviral
378607|NCT01173211|pregnant, women, influenza, vaccine
378608|NCT01173198|LOW TO MODERATE MYOPIC PATIENTS
378609|NCT01173172|Boron neutron capture therapy (BNCT)
378610|NCT01173172|Head and neck cancer
378611|NCT01173172|toxicities
378612|NCT01173172|response rate
378613|NCT01173159|Parenteral Nutrition
378614|NCT01173159|Cholestasis
378615|NCT01173146|Primary prostate cancer undergoing prostatectomy
378616|NCT01173133|Free Flap
378617|NCT01173133|Surgery
378618|NCT01173133|Ischemia
378619|NCT01173133|Outcome
378620|NCT01173133|Reconstructive Plastic Surgery
378621|NCT01173133|Monitoring
378622|NCT01173094|Critical limb ischemia
378623|NCT01173094|Diabetes Mellitus
378624|NCT01173094|Diabetes foot
378625|NCT01173081|Jones fracture
378626|NCT01173081|fifth metatarsal fracture
378627|NCT01173081|teriparatide
378628|NCT01173081|fracture healing
378629|NCT01173068|Ertapenem
378630|NCT01173068|Clinical outcome
378631|NCT01173068|Complicated Urinary Tract Infections
378632|NCT01173042|Overweight
378633|NCT01173042|Obese
378634|NCT01173029|Systemic arterial hypertension
378635|NCT01173029|Hypertension Resistant to Conventional Therapy
378636|NCT01173029|Genetic polymorphisms
378637|NCT01173029|Renin-angiotensin-aldosterone system genetic polymorphism
378638|NCT01173029|Risk markers
378639|NCT01173029|Adverse events
378640|NCT01173029|Acute myocardial infarction
378641|NCT01173029|Stroke
378642|NCT01173016|mucopolysaccharide IH (MPS IH)
378643|NCT01173003|Medical abortion
378644|NCT01173003|mifepristone
378645|NCT01173003|misoprostol
378646|NCT01173003|Tunisia
378647|NCT01172990|ST Depression
378648|NCT01172977|Diabetes mellitus
378649|NCT01172977|Stroke
378650|NCT01172964|Los Angeles
378651|NCT01172951|Post-prandial
378652|NCT01172951|Nutrigenomic
378653|NCT01172951|Test meal
378654|NCT01172951|Oral glucose tolerance test
378655|NCT01172951|Oral lipid tolerance test
378656|NCT01172938|Psoriatic Arthritis
378657|NCT01172938|Psoriasis
378658|NCT01172938|Arthritis
378659|NCT01172938|inflammation
378660|NCT01172938|skin condition
378661|NCT01172938|inflammatory cells
378662|NCT01172938|apremilast
378663|NCT01172938|CC-10004
378664|NCT01172938|phosphodiesterase type 4
378665|NCT01172925|NSCLC
378666|NCT01172925|dyspnea
378667|NCT01172925|phase II
378668|NCT01172925|crossover
378669|NCT01172925|tiotropium
378670|NCT01172912|recurrent extragonadal germ cell tumor
378671|NCT01172912|recurrent extragonadal non-seminomatous germ cell tumor
378672|NCT01172912|recurrent malignant testicular germ cell tumor
378673|NCT01172912|stage IV extragonadal non-seminomatous germ cell tumor
378674|NCT01172912|stage III malignant testicular germ cell tumor
378675|NCT01172912|recurrent extragonadal seminoma
378676|NCT01172912|stage IV extragonadal seminoma
378677|NCT01172912|testicular mature teratoma
378678|NCT01172912|adult central nervous system germ cell tumor
378679|NCT01172912|testicular immature teratoma
378680|NCT01172899|Bariatric Surgery
378681|NCT01172899|Adolescent
378682|NCT01172886|Metabolic Syndrome obesity visceral adiposity breast cancer
378683|NCT01172873|OCD
378684|NCT01172873|DCS
378685|NCT01172873|D-cycloserine
378686|NCT01172873|CBT
378687|NCT01172873|E/RP
378688|NCT01172873|exposure response prevention
378689|NCT01172860|Inoperable
378690|NCT01172860|Colorectal
378691|NCT01172860|Endoscopic
378692|NCT01172860|Electroporation
378693|NCT01172860|Outpatient
378694|NCT01172834|Nurses
378695|NCT01172795|Whiplash associated disorder
378696|NCT01172795|chronic pain
378697|NCT01172795|neural inhibition
378698|NCT01172795|neuropsychological tests
378699|NCT01172769|HNSCC
378700|NCT01172756|Pulmonary Hypertension
378701|NCT01172756|Left ventricular dysfunction
378702|NCT01172743|Diabetes Mellitus
378703|NCT01172743|Diabetes
378704|NCT01172743|Type-2
378705|NCT01172743|Adult Onset
378706|NCT01172730|Post operative pain
378707|NCT01172730|thoracic epidural
378708|NCT01172730|acute pain
378709|NCT01172730|Ultrasound scanning of the thoracic spine
378710|NCT01172717|Carcinoid
378711|NCT01172717|Carcinoid syndrome
378712|NCT01172704|Motivational Interviewing
378713|NCT01172704|Serious Mental Illness
378714|NCT01172704|HIV/AIDS
378715|NCT01172704|HIV Testing
378716|NCT01172691|Liver transplant
378717|NCT01172665|Celiac Disease
378718|NCT01172652|Bipolar disorder
378719|NCT01172652|Anxiety
378720|NCT01172652|Panic
378721|NCT01172652|GAD
378722|NCT01172652|Generalized Anxiety Disorder
378723|NCT01172639|CoBRA
378724|NCT01172626|epilepsy
378725|NCT01172626|valproate sodium
378726|NCT01172626|metabolic enzymes
378727|NCT01172626|adverse effects
378728|NCT01172626|systemic adverse effects
378729|NCT01172613|allergic rhinitis
378730|NCT01172613|concentration of diagnostic reagent
378731|NCT01172613|allergen extract, house dust mites (Dp)
378732|NCT01172613|skin prick test
378733|NCT01172613|nasal allergen provocation test
378734|NCT01172600|radiating back pain
378735|NCT01172600|epidural block
378736|NCT01172600|steroid
378737|NCT01172600|recurrent low back pain
378738|NCT01172600|Lumbar Epidural Steroid Block with 3 injections
378739|NCT01172587|Cognitive Behavioral Therapy
378740|NCT01172587|Couples Treatment
378741|NCT01172587|Alcohol Use
378742|NCT01172587|Effects on Youth
378743|NCT01172574|Osteoporosis
378744|NCT01172574|Pain
378745|NCT01172574|Kyphosis
378746|NCT01172574|Posture
378747|NCT01172574|Exercise therapy
378748|NCT01172548|Resected GIST
378749|NCT01172548|primary GIST
378750|NCT01172548|tumor recurrence
378751|NCT01172548|KIT receptor
378752|NCT01172548|KIT positive
378753|NCT01172548|advanced GIST
378754|NCT01172548|minimal toxicity
378755|NCT01172548|GIST
378756|NCT01172535|Lopinavir/ritonavir
378757|NCT01172535|Pediatric dosing
378758|NCT01172535|World Health Organization
378759|NCT01172522|Under eye dark circles
378760|NCT01172522|Under eye puffiness
378761|NCT01172509|plasticity
378762|NCT01172509|excitatory
378763|NCT01172509|inhibitory
378764|NCT01172509|synaptic plasticity
378765|NCT01172509|R-Baclofen
378766|NCT01172509|TMS
378767|NCT01172509|transcranial magnetic stimulation
378768|NCT01172509|biomarker
378769|NCT01172509|autism
378770|NCT01172483|primary care
378771|NCT01172483|physical and aquatic exercises
378772|NCT01172483|promotion physical activity
378773|NCT01172483|chronic disorders
378774|NCT01172470|Recurrent head and neck cancer
378775|NCT01172470|larynx, lip, oral cavity and pharynx
378776|NCT01172457|low back pain
378777|NCT01172457|failed back surgery syndrome (FBSS)
378778|NCT01172457|epidural fibrosis
378779|NCT01172457|ozone therapy
378780|NCT01172457|oxygen therapy
378781|NCT01172457|epiduroscopy
378782|NCT01172457|spinal endoscopy
378783|NCT01172444|Mild to Moderate Ulcerative Proctitis
378784|NCT01172431|hypertension
378785|NCT01172431|renal insufficiency
378786|NCT01172431|indapamide
378787|NCT01172431|hydrochlorothiazide
378788|NCT01172418|adult
378789|NCT01172418|primary kidney transplant recipient
378790|NCT01172405|Headache
378791|NCT01172405|Migraine
378792|NCT01172405|Ibuprofen
378793|NCT01172405|Caffeine
378794|NCT01172366|Open label, single dose, pharmacokinetic study
378795|NCT01172353|contras-induced nephropathy
378796|NCT01172340|behavioral
378797|NCT01172340|diet
378798|NCT01172340|exercise
378799|NCT01172314|NSCLC
378800|NCT01172314|Weight loss
378801|NCT01172314|protein metabolism
378802|NCT01172314|essential amino acid intake
378803|NCT01172301|CF
378804|NCT01172301|protein metabolism
378805|NCT01172301|essential amino acid intake
378806|NCT01172288|Tic disorders,
378807|NCT01172288|Tourette syndrome
378808|NCT01172288|Chronic Tic Disorders
378809|NCT01172275|Obsessive-Compulsive Disorder
378810|NCT01172275|OCD
378811|NCT01172262|Tinnitus
378812|NCT01172262|MRI
378813|NCT01172262|fMRI
378814|NCT01172262|task based MRI
378815|NCT01172262|Otolaryngology
378816|NCT01172249|Osteoarthritis
378817|NCT01172249|Knee
378818|NCT01172249|Glucosamine
378819|NCT01172249|Chondroitin
378820|NCT01172223|HER2-positive
378821|NCT01172223|early breast cancer
378822|NCT01172197|local anesthetic
378823|NCT01172197|levobupivacaine
378824|NCT01172197|ropivacaine
378825|NCT01172197|femoral perineural block
378826|NCT01172184|Left atrial distensibility
378827|NCT01172184|Left ventricular filling pressure
378828|NCT01172184|Severe mitral regurgitation
378829|NCT01172184|Prognosis
378830|NCT01172184|Post-operation (mitral valve replacement or valvuloplasty) atrial fibrillation
378831|NCT01172171|Ischemia-reperfusion injury
378832|NCT01172171|Acute Myocardial Infarction
378833|NCT01172171|Intracoronary melatonin
378834|NCT01172158|forgotten ureteral stents, SMS Reminder
378835|NCT01172145|apathy
378836|NCT01172145|Alzheimer's disease
378837|NCT01172145|activities of daily living performance
378838|NCT01172145|caregiver burden
378839|NCT01172132|Leukemia
378840|NCT01172132|Lymphoma
378841|NCT01172132|Bone-Marrow Transplant
378842|NCT01172132|Neutropenia
378843|NCT01172132|Acute respiratory failure
378844|NCT01172132|Mechanical ventilation
378845|NCT01172132|Post ICU burden
378846|NCT01172132|ICU triage
378847|NCT01172132|Dialysis
378848|NCT01172132|Septic shock
378849|NCT01172119|Coronary Disease, Coronary Stenosis, Angioplasty, Coronary restenosis, Drug Eluting Stent
378850|NCT01172106|Postpartum psychosis
378851|NCT01172106|Perceived social support
378852|NCT01172106|Family psychoeducation
378853|NCT01172093|obstructive sleep apnea
378854|NCT01172093|prevalence
378855|NCT01172093|diabetes mellitus
378856|NCT01172093|Chinese
378857|NCT01172080|colonoscopy
378858|NCT01172080|adherence
378859|NCT01172080|reminders
378860|NCT01172080|quality
378861|NCT01172067|CRT
378862|NCT01172067|heart failure
378863|NCT01172067|optimization
378864|NCT01172067|Timing cycle optimization methods
378865|NCT01172054|influenza vaccine recombinant
378866|NCT01172028|stage IIIA non-small cell lung cancer
378867|NCT01172028|stage IIIB non-small cell lung cancer
378868|NCT01172028|stage IV non-small cell lung cancer
378869|NCT01172028|recurrent non-small cell lung cancer
378870|NCT01172028|male breast cancer
378871|NCT01172028|stage IIIA breast cancer
378872|NCT01172028|stage IIIB breast cancer
378873|NCT01172028|stage IIIC breast cancer
378874|NCT01172028|stage IV breast cancer
378875|NCT01172028|recurrent breast cancer
378876|NCT01172028|stage III prostate cancer
378877|NCT01172028|stage IV prostate cancer
378878|NCT01172028|recurrent prostate cancer
378879|NCT01172028|stage III esophageal cancer
378880|NCT01172028|stage IV esophageal cancer
378881|NCT01172028|recurrent esophageal cancer
378882|NCT01172028|recurrent adenoid cystic carcinoma of the oral cavity
378883|NCT01172028|recurrent mucoepidermoid carcinoma of the oral cavity
378884|NCT01172028|stage III adenoid cystic carcinoma of the oral cavity
378885|NCT01172028|stage III mucoepidermoid carcinoma of the oral cavity
378886|NCT01172028|stage IV adenoid cystic carcinoma of the oral cavity
378887|NCT01172028|stage IV mucoepidermoid carcinoma of the oral cavity
378888|NCT01172028|recurrent basal cell carcinoma of the lip
378889|NCT01172028|stage III basal cell carcinoma of the lip
379001|NCT01171703|Diabetes
378890|NCT01172028|stage IV basal cell carcinoma of the lip
378891|NCT01172028|recurrent lymphoepithelioma of the nasopharynx
378892|NCT01172028|stage III lymphoepithelioma of the nasopharynx
378893|NCT01172028|stage IV lymphoepithelioma of the nasopharynx
378894|NCT01172028|recurrent lymphoepithelioma of the oropharynx
378895|NCT01172028|stage III lymphoepithelioma of the oropharynx
378896|NCT01172028|stage IV lymphoepithelioma of the oropharynx
378897|NCT01172028|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
378898|NCT01172028|recurrent inverted papilloma of the paranasal sinus and nasal cavity
378899|NCT01172028|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
378900|NCT01172028|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
378901|NCT01172028|stage III inverted papilloma of the paranasal sinus and nasal cavity
378902|NCT01172028|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
378903|NCT01172028|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
378904|NCT01172028|stage IV inverted papilloma of the paranasal sinus and nasal cavity
378905|NCT01172028|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
378906|NCT01172028|recurrent salivary gland cancer
378907|NCT01172028|stage III salivary gland cancer
378908|NCT01172028|stage IV salivary gland cancer
378909|NCT01172028|stage III ovarian epithelial cancer
378910|NCT01172028|stage IV ovarian epithelial cancer
378911|NCT01172028|recurrent ovarian epithelial cancer
378912|NCT01172028|stage III ovarian germ cell tumor
378913|NCT01172028|stage IV ovarian germ cell tumor
378914|NCT01172028|recurrent ovarian germ cell tumor
378915|NCT01172028|stage III gastric cancer
378916|NCT01172028|stage IV gastric cancer
378917|NCT01172028|recurrent gastric cancer
378918|NCT01172028|recurrent hypopharyngeal cancer
378919|NCT01172028|stage III hypopharyngeal cancer
378920|NCT01172028|stage IV hypopharyngeal cancer
378921|NCT01172028|recurrent laryngeal cancer
378922|NCT01172028|stage III laryngeal cancer
378923|NCT01172028|stage IV laryngeal cancer
378924|NCT01172002|Lupus Nephritis
378925|NCT01172002|Leflunomide
378926|NCT01172002|Azathioprine
378927|NCT01171989|booster vaccination
378928|NCT01171989|combined vaccine
378929|NCT01171976|DME
378930|NCT01171976|Diabetic macula edema
378931|NCT01171976|RETAIN
378932|NCT01171976|ranibizumab
378933|NCT01171963|Liquid human retrovirus vaccine
378934|NCT01171950|Thoratec Corporation
378935|NCT01171937|ages 8-16
378936|NCT01171937|Repetitive Behaviors
378937|NCT01171924|Head and Neck Cancer
378938|NCT01171924|Liver Cancer
378939|NCT01171924|Breast Cancer
378940|NCT01171924|Gastric Cancer
378941|NCT01171924|Non-Small Cell Lung Cancer
378942|NCT01171924|EGFR
378943|NCT01171924|HDAC
378944|NCT01171924|Her2
378945|NCT01171924|CUDC-101
378946|NCT01171911|Endothelial shear stress
378947|NCT01171911|Calcium channel blocker
378948|NCT01171898|Non-Metastatic
378949|NCT01171898|Rising PSA
378950|NCT01171898|Castration-Resistant
378951|NCT01171898|Treatment-Naive
378952|NCT01171898|Post-abiraterone
378953|NCT01171885|Superficial cervical block
378954|NCT01171885|Thyroidectomy
378955|NCT01171885|Pain
378956|NCT01171872|Inflammatory Bowel Disease
378957|NCT01171872|Inflammatory Bowel Disease (IBD)
378958|NCT01171872|Crohn's Disease
378959|NCT01171872|Ulcerative Colitis
378960|NCT01171872|Indeterminate Colitis
378961|NCT01171872|IBD
378962|NCT01171872|CD
378963|NCT01171872|UC
378964|NCT01171872|IC
378965|NCT01171859|amyloidosis
378966|NCT01171859|transthyretin
378967|NCT01171859|doxycycline
378968|NCT01171859|Tauroursodeoxycholic acid
378969|NCT01171846|prevention
378970|NCT01171846|pelvic floor muscle training
378971|NCT01171846|prolapse symptoms
378972|NCT01171846|urinary symptoms
378973|NCT01171846|sexual function
378974|NCT01171846|randomised controlled trial
378975|NCT01171833|Anesthetic induction
378976|NCT01171833|Desflurane
378977|NCT01171833|Isoflurane
378978|NCT01171833|Sevoflurane
378979|NCT01171833|Ventilation
378980|NCT01171820|drug eluting stents
378981|NCT01171820|stents
378982|NCT01171820|Angioplasty
378983|NCT01171820|coronary artery disease
378984|NCT01171820|total coronary occlusion
378985|NCT01171820|coronary artery restenosis
378986|NCT01171820|stent thrombosis
378987|NCT01171820|vascular disease
378988|NCT01171820|myocardial ischemia
378989|NCT01171820|coronary artery stenosis
378990|NCT01171807|Ulcerative colitis
378991|NCT01171807|Steroid-dependency
378992|NCT01171807|Steroid adverse events
378993|NCT01171807|Erythrocytes
378994|NCT01171768|Vascular endothelial growth factor
378995|NCT01171768|angiopoietin-2
378996|NCT01171729|Prostate cancer
378997|NCT01171729|PSA
378998|NCT01171729|Hormone refractory prostatic cancer
378999|NCT01171716|overweight, protein intake, satiety, eating, meal patterns
379000|NCT01171703|Critical limb ischemia
379002|NCT01171703|Femoropopliteal artery bypass
379003|NCT01171703|Stent
379004|NCT01171690|Hypoparathyroidism
379005|NCT01171677|addiction
379006|NCT01171677|exercise
379007|NCT01171677|cognitive function
379008|NCT01171677|mood
379009|NCT01171677|self efficacy
379010|NCT01171664|Phase 2
379011|NCT01171664|SAR
379012|NCT01171664|STAHIST
379013|NCT01171651|Vaccinia
379014|NCT01171651|Vaccinia Virus
379015|NCT01171651|JX-594
379016|NCT01171651|Jennerex
379017|NCT01171651|Primary Hepatocellular Carcinoma
379018|NCT01171651|Primary Liver Cancer
379019|NCT01171651|Liver Cancer
379020|NCT01171651|Sorafenib
379021|NCT01171651|Nexavar
379022|NCT01171651|Pexa-Vec
379023|NCT01171638|near infrared spectroscopy
379024|NCT01171638|compartment syndrome
379025|NCT01171638|fasciotomy
379026|NCT01171638|INVOS
379027|NCT01171625|PERIMOUNT, Aortic valve replacement/regurgitation
379028|NCT01171612|Coronary Stent
379029|NCT01171612|BMS stent
379030|NCT01171612|DES stent
379031|NCT01171612|Date of stent implantation
379032|NCT01171612|cardiac event
379033|NCT01171612|neurovascular event
379034|NCT01171612|Bleeding
379035|NCT01171612|transfusion
379036|NCT01171599|Weight Loss
379037|NCT01171599|Obesity
379038|NCT01171599|Overweight
379039|NCT01171599|Physical Activity
379040|NCT01171599|Nutrition
379041|NCT01171599|Youth
379042|NCT01171599|Adolescent
379043|NCT01171599|Technology
379044|NCT01171586|Obesity
379045|NCT01171586|overweight
379046|NCT01171586|weight loss
379047|NCT01171586|weight maintenance
379048|NCT01171586|SMS
379049|NCT01171586|technology
379050|NCT01171586|cell phone
379051|NCT01171586|physical activity
379052|NCT01171586|nutrition
379053|NCT01171573|Polymyositis
379054|NCT01171573|Dermatomyositis
379055|NCT01171573|Inclusion Body Myositis
379056|NCT01171560|EZ Blocker
379057|NCT01171560|Double-lumen Tube
379058|NCT01171560|Airway
379059|NCT01171560|thoracic surgery
379060|NCT01171560|time for intubation
379061|NCT01171560|blind insertion
379062|NCT01171560|conditions of surgery
379063|NCT01171560|postoperative sore throat
379064|NCT01171560|postoperative hoarseness
379065|NCT01171547|pharmacokinetics
379066|NCT01171508|Circadian Rhythm Disorders
379067|NCT01171508|Breast Neoplasms Surgery
379068|NCT01171508|Sleep
379069|NCT01171508|Heart Rate
379070|NCT01171495|HIV/AIDS
379071|NCT01171495|Nutrition Therapy
379072|NCT01171495|Dietary Supplement
379073|NCT01171495|Antioxidant
379074|NCT01171495|Immunity
379075|NCT01171495|CD4 count
379076|NCT01171495|Anthropometry
379077|NCT01171495|Body Mass Index
379078|NCT01171469|Brain tumor
379079|NCT01171469|Immunotherapy
379080|NCT01171469|Glioma
379081|NCT01171456|GDM
379082|NCT01171456|Gestational Diabetes
379083|NCT01171456|Diabetes
379084|NCT01171456|Pregnancy
379085|NCT01171430|multiple myeloma
379086|NCT01171430|Autologous Stem Cell Transplantation
379087|NCT01171417|Fulvestrant
379088|NCT01171417|Exemestane
379089|NCT01171417|postmenopausal patients
379090|NCT01171417|advanced HR+ breast cancer
379091|NCT01171417|Hormone Receptor positive
379092|NCT01171417|advanced breast cancer
379093|NCT01171404|Acute coronary syndrome
379094|NCT01171404|heart attack
379095|NCT01171404|myocardial infarction
379096|NCT01171404|ACS long-tem follow up
379097|NCT01171404|antithrombotic management
379098|NCT01171404|quality of life
379099|NCT01171404|Antithrombotic
379100|NCT01171391|Nocturia
379101|NCT01171391|Pharmacokinetics
379102|NCT01171391|Pharmacodynamics
379103|NCT01171391|Water-loading
379104|NCT01171391|Females
379105|NCT01171378|Richter's Syndrome
379106|NCT01171378|High-grade transformation in patients with B cell chronic lymphocytic leukemia
379107|NCT01171378|Feasibility
379108|NCT01171378|Ofatumumab Induction and maintenance
379109|NCT01171378|CHOP
379110|NCT01171378|CHOP-0
379111|NCT01171378|CHOP-OR
379112|NCT01171378|Non Hodgkin's lymphoma
379113|NCT01171365|Ciclesonide
379114|NCT01171365|Asthma
379115|NCT01171365|Therapeutic Uses
379116|NCT01171365|Pulmonary Eosinophilia
379117|NCT01171365|Nitric Oxide
379118|NCT01171365|Lung Diseases
379119|NCT01171365|Respiratory Tract Diseases
379120|NCT01171352|hemodialysis
379121|NCT01171352|dialysis
379122|NCT01171352|hypotension
379123|NCT01171352|CritLine
379124|NCT01171352|PiCCO
379125|NCT01171352|Thermodilution
379126|NCT01171352|CVVHDF
379127|NCT01171352|IHD
379128|NCT01171339|elderly
379129|NCT01171339|multimorbidity
379130|NCT01171339|polypharmacy
379131|NCT01171339|multimedication
379132|NCT01171339|medication appropriateness
379133|NCT01171339|medication appropriateness index
379134|NCT01171339|cluster-randomised controlled trial
379135|NCT01171339|pragmatic trial
379136|NCT01171326|topical
379137|NCT01171326|minocycline
379138|NCT01171326|foam
379139|NCT01171326|phase II
379140|NCT01171326|impetigo
379141|NCT01171300|staged T3-4 N0 and T1-4N1-2
379142|NCT01171300|adenocarcinoma of the rectum
379143|NCT01171300|rectum
379144|NCT01171287|Automobile Driving
379145|NCT01171287|Fracture Fixation/instrumentation
379146|NCT01171287|Lower Extremity
379147|NCT01171287|Orthopedic Fixation Devices
379148|NCT01171287|Orthopedic Procedures
379149|NCT01171287|Reaction Time
379150|NCT01171287|Task Performance and Analysis
379151|NCT01171287|Time Factors
379152|NCT01171274|neck pain
379153|NCT01171274|yoga
379154|NCT01171274|proprioception
379155|NCT01171274|sensory thresholds
379156|NCT01171274|randomized controlled trial
379157|NCT01171261|Physical Activity
379158|NCT01171261|Sedentary Behavior
379159|NCT01171261|Video Games
379160|NCT01171261|Exergames
379161|NCT01171248|nocturnal blood pressure dip
379162|NCT01171248|complications
379163|NCT01171248|ambulatory blood pressure
379164|NCT01171235|Laryngeal Neoplasms
379165|NCT01171235|Pharyngeal Neoplasms
379166|NCT01171222|soccer
379167|NCT01171222|prevention
379168|NCT01171222|veteran athletes
379169|NCT01171222|exercise
379170|NCT01171222|Cardiovascular
379171|NCT01171209|MS
379172|NCT01171196|Sleep Apnea
379173|NCT01171196|Questionnaire
379174|NCT01171183|cocaine dependence
379175|NCT01171183|cocaine withdrawal
379176|NCT01171170|non small cell lung cancer
379177|NCT01171170|stage IV
379178|NCT01171170|nitroglycerin
379179|NCT01171170|carboplatin
379180|NCT01171170|paclitaxel
379181|NCT01171170|bevacizumab
379182|NCT01171157|vaccine effectiveness
379183|NCT01171157|Influenza-like illness
379184|NCT01171157|elderly
379185|NCT01171157|Influenza
379186|NCT01171131|TBI
379187|NCT01171131|Brain Injury
379188|NCT01171118|Breathing
379189|NCT01171118|Sedation
379190|NCT01171105|AZD5213 Phase 1
379191|NCT01171105|Safety
379192|NCT01171105|tolerability
379193|NCT01171092|stem cell
379194|NCT01171092|transplant
379195|NCT01171092|myeloma
379196|NCT01171092|lymphoma
379197|NCT01171092|BMT
379198|NCT01171092|autologous
379199|NCT01171079|postoperative adhesion after thyroidectomy
379200|NCT01170026|substance use
379201|NCT01170026|adolescents
379202|NCT01170026|intervention
379203|NCT01170026|truancy
379204|NCT01170026|sexual risk behavior
379205|NCT01170013|substance use
379206|NCT01170013|adolescents
379207|NCT01170013|initiation
379208|NCT01169987|Multicenter study
379209|NCT01169974|Microcirculation
379210|NCT01169974|laser flowmetry
379211|NCT01169974|Skin
379212|NCT01169974|Physiology
379213|NCT01171053|Cognitive behavior therapy
379214|NCT01171053|Internet
379215|NCT01171053|Cost-effectiveness
379216|NCT01171053|Irritable bowel syndrome
379217|NCT01171040|left atrial distensibility
379218|NCT01171040|mortality
379219|NCT01171040|heart failure
379220|NCT01171040|atrial fibrillation
379221|NCT01171040|stroke
379222|NCT01171040|prognosis
379223|NCT01171027|Cholecystectomy
379224|NCT01171027|NOTES
379225|NCT01171027|Transvaginal
379226|NCT01171027|Transgastric
379227|NCT01171027|Natural orifice
379228|NCT01171027|Gallbladder removal
379229|NCT01170988|patients scheduled for bypass grafting
379230|NCT01170975|Advanced solid tumors
379231|NCT01170949|urticaria
379232|NCT01170936|Urticarial vasculitis
379233|NCT01170936|anti-IL1ß therapy
379234|NCT01170923|non small cell lung cancer
379235|NCT01170923|FDG PET
379236|NCT01170910|Chronic renal failure
379237|NCT01170910|Transplantation
379238|NCT01170910|Marginal kidney graft
379239|NCT01170910|Pulsatile perfusion machine
379240|NCT01170897|PEGPH20
379241|NCT01170897|PEGylated Recombinant Human Hyaluronidase
379242|NCT01170897|Metastatic or Locally Advanced Solid Tumors
379243|NCT01170845|Esophagectomy
379244|NCT01170845|Postoperative respiratory complications
379245|NCT01170845|neutrophil elastase inhibitor
379246|NCT01170819|Cervical ripening
379247|NCT01170819|Induction of labor
379248|NCT01170819|Prostaglandins
379249|NCT01170819|Mechanical methods
379250|NCT01170819|Balloon catheter
379251|NCT01170806|Intestinal lipase
379252|NCT01170806|Orlistat
379253|NCT01170806|fecal fat
379254|NCT01170806|obesity
379255|NCT01170793|education, quality of life
379256|NCT01170780|Inguinal hernia
379257|NCT01170780|Transabdominal preperitoneal hernia repair
379258|NCT01170780|TAPP
379259|NCT01170780|Dexamethasone
379260|NCT01170780|Pain
379261|NCT01170767|Age-related Macular Degeneration
379262|NCT01170767|Bevacizumab
379263|NCT01170767|Ranibizumab
379264|NCT01170754|PEG-3350, polyethylene glycol, colonoscopy
379265|NCT01170728|Male Sling
379266|NCT01170728|Fixation
379267|NCT01170728|Stress Urinary Incontinence
379268|NCT01170728|Urinary incontinence
379269|NCT01170715|Psoriasis
379270|NCT01170715|Co morbidities
379271|NCT01170715|Inflammation
379272|NCT01170702|Cesarean Delivery
379273|NCT01170702|Ropivicaine
379274|NCT01170702|TAP block
379275|NCT01170689|Schizophrenia
379276|NCT01170689|inpatient
379277|NCT01170689|obesity
379278|NCT01170689|prevalence
379279|NCT01170676|asthma
379280|NCT01170676|smoking
379281|NCT01170676|teens
379282|NCT01170663|Metastatic Adenocarcinoma
379283|NCT01170663|Gastric Adenocarcinoma
379284|NCT01170663|Gastroesophageal Junction Adenocarcinoma
379285|NCT01170650|cancer
379286|NCT01170650|ovarian
379287|NCT01170650|platinum-resistant
379288|NCT01170650|Phase III
379289|NCT01170650|EC145
379290|NCT01170650|EC20
379291|NCT01170624|PhD
379292|NCT01170624|EGM
379293|NCT01170624|CRT-D
379294|NCT01170624|The study will particularly focus on a new-based diagnostic feature, called PhD-Clinical Status (PhD)
379295|NCT01170598|acute myeloid leukemia
379296|NCT01170598|AML
379297|NCT01170598|chemotherapy
379298|NCT01170598|exercise
379299|NCT01170598|quality of life
379300|NCT01170598|cancer-related fatigue
379301|NCT01170598|elderly
379302|NCT01170598|physical fitness
379303|NCT01170598|muscular strength
379304|NCT01170598|Feasibility
379305|NCT01170598|Efficacy
379306|NCT01170598|Safety
379307|NCT01170546|anterior cruciate ligament
379308|NCT01170546|agility
379309|NCT01170546|knee stability
379310|NCT01170546|hamstring
379311|NCT01170546|knee internal rotator
379312|NCT01170533|proton pump inhibitor
379313|NCT01170533|clopidogrel
379314|NCT01170533|platelet function
379315|NCT01170520|adolescent resistant depression
379316|NCT01170520|repetitive transcranial magnetic stimulation
379317|NCT01170520|treatment of resistant adolescent depression
379318|NCT01170507|vitamin D3, 25 OH vitamin D3 level
379319|NCT01170494|vitamin D2, vitamin D3, 25 Oh vitamin D2, 25 Oh vitamin D3
379320|NCT01170481|anterior and intermediate uveitis
379321|NCT01170481|papilloedema
379322|NCT01170468|Prediabetics
379323|NCT01170468|DM
379324|NCT01170468|vitamin D
379325|NCT01170455|nasal
379326|NCT01170455|intubation
379327|NCT01170455|direct laryngoscope
379328|NCT01170455|blind
379329|NCT01170455|normal airway
379330|NCT01170429|Cough Variant Asthma
379331|NCT01170429|Procaterol Hydrochloride
379332|NCT01170416|Ventricular Tachycardia
379333|NCT01170416|Body Surface Mapping
379334|NCT01170403|coronary heart disease
379335|NCT01170403|Multidetector row cardiac computed tomography
379336|NCT01170403|type 2 diabetes
379337|NCT01170403|metabolic syndrome
379338|NCT01170390|Obesity
379339|NCT01170390|Body weight
379340|NCT01170390|Oral contraception
379341|NCT01170390|Efficacy
379342|NCT01170377|Intravenous sedation
379343|NCT01170377|Dental treatment
379344|NCT01170377|Mental retardation
379345|NCT01170377|Antiepileptic drug
379346|NCT01170377|Valproate
379347|NCT01170377|Propofol
379348|NCT01170364|Obesity
379349|NCT01170364|sibutramine
379350|NCT01170364|eating behavior
379351|NCT01170351|autoimmune hepatitis
379352|NCT01170351|corticosteroids
379353|NCT01170351|cysclosporine-A
379354|NCT01170351|treatment
379355|NCT01170351|treatment-naive
379356|NCT01170351|induction of remossion
379357|NCT01170351|efficacy
379358|NCT01170351|tolerability
379359|NCT01170338|smoking
379360|NCT01170338|tobacco abuse
379361|NCT01170325|Valproic Acid
379362|NCT01170325|Divalproex
379363|NCT01170325|Autism
379364|NCT01170325|EEG
379365|NCT01170325|Electroencephalogram (EEG)
379366|NCT01170325|Depakote
379367|NCT01170312|Arthroscopic repair
379368|NCT01170312|Rotator cuff
379369|NCT01170312|Platelet rich plasma
379370|NCT01170312|Randomized
379371|NCT01170312|Pilot
379372|NCT01170299|radiation toxicity
379373|NCT01170299|gastrointestinal complications
379374|NCT01170299|cervical cancer
379375|NCT01170299|fallopian tube cancer
379376|NCT01170299|ovarian epithelial cancer
379377|NCT01170299|ovarian germ cell tumor
379378|NCT01170299|ovarian sarcoma
379379|NCT01170299|ovarian stromal cancer
379380|NCT01170299|uterine sarcoma
379381|NCT01170299|bladder cancer
379382|NCT01170299|colon cancer
379383|NCT01170299|rectal cancer
379384|NCT01170299|anal cancer
379385|NCT01170286|Food allergy
379386|NCT01170286|Immediate hypersensitivity
379387|NCT01170286|Whole peanut extract
379388|NCT01170286|Allergenic product
379389|NCT01170286|Specific Immunotherapy
379390|NCT01170286|Epicutaneous Immunotherapy (EPIT)
379391|NCT01170286|Safety
379392|NCT01170273|aged
379393|NCT01170273|vitamin d deficiency
379394|NCT01170247|Procedural Sedation
379395|NCT01170234|Exhaled nitric oxide
379396|NCT01170234|Eosinophilic esophagitis
379397|NCT01170221|ABSSSI
379398|NCT01170221|Tedizolid Phosphate
379399|NCT01170221|TR-701
379400|NCT01170221|Acute Bacterial Skin and Skin Structure Infections
379401|NCT01170208|insulin
379402|NCT01170208|dosage software
379403|NCT01170195|Postmenopausal
379404|NCT01170195|licorice
379405|NCT01170195|vaginal complaints
379406|NCT01170156|deep sedation
379407|NCT01170156|respiratory resuscitation
379408|NCT01170156|Hi-Lo Evac tube
379409|NCT01170156|suctioning manoeuvre
379410|NCT01170143|IIB-IIIB Breast Cancer
379411|NCT01170143|Her2 positive
379412|NCT01170130|Cataract
379413|NCT01170130|Mydriasis
379414|NCT01170130|Lidocaine
379415|NCT01170117|Eating Disorders
379416|NCT01170117|Anorexia Nervosa
379417|NCT01170104|Hepatocellular Carcinoma
379418|NCT01170104|Sorafenib
379419|NCT01170104|TACE
379420|NCT01170104|locally, advanced Hepatocellular Carcinoma
379421|NCT01170078|chronic renal failure requiring hemodialysis
379422|NCT01170052|Relapsed Mantle Cell Lymphoma
379423|NCT01170052|Refractory Mantle Cell Lymphoma
379424|NCT01170052|Non-Hodgkins Lymphoma
379425|NCT01170052|Temsirolimus
379426|NCT01170052|Bendamustine
379427|NCT01170052|Phase 1/2
379428|NCT01170039|Constipation
379429|NCT01170039|Diabetes
379430|NCT01170039|Lubiprostone
379431|NCT01170039|Amitiza
379432|NCT01170039|African Americans
379433|NCT01169961|IRON OVERLOAD IN HEMODIALYSIS PATIENTS
379434|NCT01169948|Coronary disease
379435|NCT01169948|Coronary artery bypass
379436|NCT01169948|Cardiac surgery
379437|NCT01169948|Computed tomography
379438|NCT01169948|Coronary angiography
379439|NCT01169935|MRI
379440|NCT01169935|SPIO
379441|NCT01169935|Healthy Volunteer
379442|NCT01169909|Pterygium
379443|NCT01169896|Impact of ventricular pacing on the incidence of VT/VF episodes for each models
379444|NCT01169883|adherence
379445|NCT01169883|asthma
379446|NCT01169883|pediatrics
379447|NCT01169883|behavioral intervention
379448|NCT01169883|inner city
379449|NCT01169870|metastatic
379450|NCT01169857|Proliferative lupus nephritis
379451|NCT01169857|WHO class III/IV/V lupus nephritis
379452|NCT01169857|Proteinuria
379453|NCT01169857|Hematuria
379454|NCT01169857|Velcade
379455|NCT01169857|SLE
379456|NCT01169857|Bortezomib
379457|NCT01169857|Proteasome inhibitor
379458|NCT01169844|Psoriatic arthritis
379459|NCT01169844|IgG1K monoclonal antibody
379460|NCT01169844|Interleukin -17A neutralizing
379461|NCT01169792|Tamoxifen
379462|NCT01169792|Cytochrome P-450 CYP2D6
379463|NCT01169792|Polymorphism
379464|NCT01169792|Single nucleotide
379465|NCT01169792|Antineoplastic Agents, Hormonal
379466|NCT01169753|Chronic Myeloid Leukemia
379467|NCT01169753|CML
379468|NCT01169753|Nuvigil
379469|NCT01169753|Armodafinil
379470|NCT01169753|Fatigue
379471|NCT01169740|Hyperbilirubinemia
379472|NCT01169740|Neonatal
379473|NCT01169740|Serum bilirubin
379474|NCT01169740|Transcutaneous bilirubin
379475|NCT01169740|Skin color
379476|NCT01169727|COPD and CCQ score
379477|NCT01169727|Changes in PEF,overall CCQ score
379478|NCT01169714|multiple dose
379479|NCT01169714|healthy volunteer
379480|NCT01169714|healthy elderly volunteer
379481|NCT01169714|safety
379482|NCT01169714|pharmacokinetic
379483|NCT01169701|Renal transplant, everolimus, cardiovascular profile, CNI-free immunosuppression, left ventricular hypertrophy, biopsy proved acute rejection (BPAR)
379484|NCT01169688|Cataract Surgery
379485|NCT01169688|Pupillary Dilation
379486|NCT01169649|MK-2206
379487|NCT01169649|Neuroendocrine Tumors
379488|NCT01169649|10-067
379489|NCT01169636|Chemotherapy
379490|NCT01169636|Panobinostat
379491|NCT01169636|Ifosfamide
379492|NCT01169636|Mesna
379493|NCT01169636|Etoposide
379494|NCT01169636|Carboplatin
379495|NCT01169636|Pegfilgrastim
379496|NCT01169636|ICE
379497|NCT01169623|Supportive leadership behaviour
379498|NCT01169623|Nurse Performance
379499|NCT01169623|Educational Intervention
379500|NCT01169610|Alcohol
379501|NCT01169610|Smoking
379502|NCT01169597|polymyalgia rheumatica
379503|NCT01169597|prednisone
379504|NCT01169597|clinical examination
379505|NCT01169597|remission
379506|NCT01169597|ultrasonography
379507|NCT01169584|Phase I
379508|NCT01169584|advanced metastatic pediatric solid tumors
379509|NCT01169584|pediatric
379510|NCT01169584|vaccinia virus
379511|NCT01169584|oncolytic virus
379512|NCT01169584|neuroblastoma
379513|NCT01169584|rhabdomyosarcoma
379514|NCT01169584|lymphoma
379515|NCT01169584|Wilm's tumor
379516|NCT01169584|Ewing's sarcoma
379517|NCT01169584|osteosarcoma
379518|NCT01169584|non-rhabdomyosarcoma soft tissue sarcomas
379519|NCT01169584|malignant peripheral nerve sheath tumors
379520|NCT01169584|Pexa-Vec
379521|NCT01169571|Initially intubated
379522|NCT01169571|Mechanically ventilated
379523|NCT01169571|Post-surgical
379524|NCT01169545|any type of cancer
379525|NCT01169519|Hypoplastic left heart syndrome
379526|NCT01169519|Hypoplastic right heart syndrome
379527|NCT01169519|Superior cavopulmonary anastomosis
379528|NCT01169519|Total cavopulmonary anastomosis
379529|NCT01169519|Children with single ventricle anatomy
379530|NCT01169506|blood gas analysis
379531|NCT01169506|ventilatory insufficiency
379532|NCT01169493|Heart Failure
379533|NCT01169493|Right Bundle-Branch Block
379534|NCT01169493|Cardiac Resynchronization Therapy
379535|NCT01169480|Massage
379536|NCT01169480|Therapist, Massage
379537|NCT01169480|DASS
379538|NCT01169480|Depression
379539|NCT01169480|Anxiety, State
379540|NCT01169480|Anxiety, Trait
379541|NCT01169480|Stress
379542|NCT01169480|Touch
379543|NCT01169480|Therapeutic Relationship
379544|NCT01169454|Cerebral Spinal Fluid
379545|NCT01169454|Ventriculostomy
379546|NCT01169454|Subarachnoid hemorrhage
379547|NCT01169454|Vasospasm
379548|NCT01169454|Human Subjects
379549|NCT01169441|ICD leads
379550|NCT01169441|Removal
379551|NCT01169441|Extraction
379552|NCT01169441|Ventricular leads
379553|NCT01169441|Extract
379554|NCT01169441|laser
379555|NCT01169441|Observe the lead with x-ray during movement and collect information on current ways of removing an ICD lead.
379556|NCT01169428|Mindfulness-Based Weight Loss Maintenance
379557|NCT01169428|prevention of weight regain
379558|NCT01169428|Obesity
379559|NCT01169415|Randomized
379560|NCT01169415|Dexamethasone
379561|NCT01169415|Abbreviated
379562|NCT01169415|Protracted
379563|NCT01169415|Post-operatively
379564|NCT01169402|extracorporeal membrane oxygenation
379565|NCT01169402|ECMO
379566|NCT01169402|extracorporeal life support
379567|NCT01169402|fluconazole
379568|NCT01169402|diflucan
379569|NCT01169402|pharmacokinetics
379570|NCT01169402|pharmacodynamics
379571|NCT01169376|disseminated neuroblastoma
379572|NCT01169376|localized resectable neuroblastoma
379573|NCT01169376|localized unresectable neuroblastoma
379574|NCT01169376|regional neuroblastoma
379575|NCT01169376|stage 4S neuroblastoma
379576|NCT01169363|adult acute myeloid leukemia in remission
379577|NCT01169363|recurrent adult acute myeloid leukemia
379578|NCT01169363|adult erythroleukemia (M6a)
379579|NCT01169363|adult pure erythroid leukemia (M6b)
379580|NCT01169363|adult acute megakaryoblastic leukemia (M7)
379581|NCT01169363|adult acute minimally differentiated myeloid leukemia (M0)
379582|NCT01169363|adult acute monoblastic leukemia (M5a)
379583|NCT01169363|adult acute monocytic leukemia (M5b)
379584|NCT01169363|adult acute myeloblastic leukemia with maturation (M2)
379585|NCT01169363|adult acute myeloblastic leukemia without maturation (M1)
379586|NCT01169363|adult acute myelomonocytic leukemia (M4)
379587|NCT01169363|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
379588|NCT01169363|adult acute myeloid leukemia with del(5q)
379589|NCT01169363|adult acute myeloid leukemia with inv(16)(p13;q22)
379590|NCT01169363|adult acute myeloid leukemia with t(16;16)(p13;q22)
379591|NCT01169363|adult acute myeloid leukemia with t(8;21)(q22;q22)
379592|NCT01169324|Parkinson's disease
379593|NCT01169324|Tremor
379594|NCT01169324|Dystonia
379595|NCT01169324|DBS
379596|NCT01169324|Sleep
379597|NCT01169311|Hemorrhoids
379598|NCT01169311|Hemorrhoid
379599|NCT01169311|grade II, III, IV
379600|NCT01169298|Adult T-cell Leukemia-Lymphoma
379601|NCT01169298|Peripheral T-cell Lymphoma
379602|NCT01169298|PTCL
379603|NCT01169298|HTLV-1
379604|NCT01169285|Burn Department Nursing Staff
379605|NCT01169272|ICD CRT 9770 - PARADYM RF ICD - SonR atrial lead
379606|NCT01169259|vitamin D3
379607|NCT01169259|omega-3 fatty acids
379608|NCT01169259|fish oil
379609|NCT01169259|cardiovascular disease
379610|NCT01169259|cancer
379611|NCT01169259|primary prevention
379612|NCT01169246|ATP,CRT, ICD PARADYM
379613|NCT01169233|Sleep
379614|NCT01169233|Alertness
379615|NCT01169233|fatigue
379616|NCT01169233|performance
379617|NCT01169233|spaceflight
379618|NCT01169233|isolation
379619|NCT01169233|light
379620|NCT01169233|Sleep , alertness and performance during a simulated spaceflight mission
379621|NCT01169220|Colonoscopy
379622|NCT01169220|Bowel preparation
379623|NCT01169207|Inflammatory Bowel Disease
379624|NCT01169207|Crohn's Disease
379625|NCT01169207|Ulcerative Colitis
379626|NCT01169207|Indeterminate Colitis
379627|NCT01169207|IBD
379628|NCT01169207|CD
379629|NCT01169207|UC
379630|NCT01169207|IC
379631|NCT01169194|Inflammatory Bowel Disease
379632|NCT01169194|Crohn's Disease
379633|NCT01169194|Ulcerative Colitis
379634|NCT01169194|Indeterminate Colitis
379635|NCT01169194|IBD
379636|NCT01169194|African American IBD
379637|NCT01169194|African American CD
379638|NCT01169194|African American UC
379639|NCT01169194|Black IBD
379640|NCT01169194|Black CD
379641|NCT01169194|Black UC
379642|NCT01169194|African American Inflammatory Bowel Disease
379643|NCT01169194|African American Crohn's Disease
379644|NCT01169194|African American Ulcerative Colitis
379645|NCT01169194|Black Inflammatory Bowel Disease
379646|NCT01169194|Black Crohn's Disease
379647|NCT01169194|Black Ulcerative Colitis
379648|NCT01169181|Stroke
379649|NCT01169181|Cerebrovascular Accident
379650|NCT01169181|Plegia
379651|NCT01169181|Upper Extremity
379652|NCT01169181|rTMS
379653|NCT01169181|tDCS
379654|NCT01169168|fibrinogen
379655|NCT01169168|SIRS
379656|NCT01169168|sepsis
379657|NCT01169168|liver disease
379658|NCT01169168|chronic liver disease
379659|NCT01169168|septic shock
379660|NCT01169155|Smoke inhalation injury
379661|NCT01169155|Burns
379662|NCT01169155|Injuries
379663|NCT01169142|Vitamin D
379664|NCT01169142|Schizophrenia
379665|NCT01169142|Severely Mentally Ill
379666|NCT01169129|brain metastases
379667|NCT01169129|radiosurgery
379668|NCT01169129|neurosurgery
379669|NCT01169129|surgery
379670|NCT01169129|radiotherapy
379671|NCT01169129|resectable brain metastases
379672|NCT01169116|radiotherapy
379673|NCT01169116|radiation oncology
379674|NCT01169116|brain metastasis
379675|NCT01169116|metastases
379676|NCT01169116|radiosurgery
379677|NCT01169116|neurosurgery
379678|NCT01169116|hypofractionation
379679|NCT01169116|stereotaxy
379680|NCT01169103|Obesity
379681|NCT01169103|Adolescent
379682|NCT01169103|Insulin resistance
379683|NCT01169103|Growth hormone
379684|NCT01169103|Visceral fat
379685|NCT01169103|Adolescent obesity
379686|NCT01169077|malaria, plasmodium falciparum, electroporation
379687|NCT01169064|Wound infection prevention
379688|NCT01169064|Silver-containing surgical dressing
379689|NCT01169064|Cesarean delivery infection prevention
379690|NCT01169051|Esophagectomy
379691|NCT01169051|Pulmonary wedge resection
379692|NCT01169051|Pulmonary lobectomy
379693|NCT01169051|Pulmonary pneumonectomy
379694|NCT01169051|Thoracic Surgery
379695|NCT01169051|Lung Cancer
379696|NCT01169051|Esophageal Cancer
379697|NCT01169038|sarcoidosis
379698|NCT01169038|mycobacteria
379699|NCT01169038|lung
379700|NCT01169038|pulmonary
379701|NCT01169038|radiographic improvement
379702|NCT01169025|Analgesia
379703|NCT01169025|Pain
379704|NCT01169012|Myelodysplastic syndrome
379705|NCT01169012|Acute Myeloid Leukemia
379706|NCT01169012|Acute Lymphoblastic Leukemia
379707|NCT01169012|Chronic myelomonocytic leukemia
379708|NCT01169012|Clofarabine
379709|NCT01169012|Clolar
379710|NCT01169012|University of North Carolina at Chapel Hill
379711|NCT01169012|Lineberger Comprehensive Cancer Center
379712|NCT01168999|low back pain
379713|NCT01168999|spinal manipulation
379714|NCT01168999|manual therapy
379715|NCT01168999|placebo
379716|NCT01168986|neck pain
379717|NCT01168986|manual therapy
379718|NCT01168986|exercise
379719|NCT01168973|second line
379720|NCT01168973|non small cell lung cancer
379721|NCT01168973|NSCLC
379722|NCT01168973|phase 3
379723|NCT01168973|ramucirumab
379724|NCT01168973|lung cancer
379725|NCT01168973|docetaxel
379726|NCT01168973|taxotere
379727|NCT01168947|sodium
379728|NCT01168947|hypertension
379729|NCT01168947|fluid overload
379730|NCT01168947|hemodialysis
379731|NCT01168947|dialysate
379732|NCT01168947|interdialytic weight gain
379733|NCT01168947|intradialytic hypotension
379734|NCT01168934|healthy volunteers
379735|NCT01168934|crizotinib
379736|NCT01168934|absolute bioavailability
379737|NCT01168934|pharmacokinetics
379738|NCT01168921|Chronic Lymphocytic Leukemia
379739|NCT01168921|CLL
379740|NCT01168921|Thrombocytopenia
379741|NCT01168921|Small lymphocytic lymphoma
379742|NCT01168921|SLL
379743|NCT01168921|Eltrombopag
379744|NCT01168921|Promacta
379745|NCT01168921|thrombopoietin (TPO)-receptor agonist
379746|NCT01168921|platelets
379747|NCT01168908|Clinical trial
379748|NCT01168908|Revatio
379749|NCT01168908|Sildenafil
379750|NCT01168908|Muscular Dystrophy
379751|NCT01168908|Duchenne
379752|NCT01168908|Becker
379753|NCT01168908|Adult
379754|NCT01168908|Adolescent
379755|NCT01168895|75 mg dose strength
379756|NCT01168895|Safety
379757|NCT01168895|Pharmacokinetics
379758|NCT01168882|RGB-286638
379759|NCT01168882|Hematological Malignancies
379760|NCT01168869|Manifestation
379761|NCT01168869|Coronary Heart Disease
379762|NCT01168869|Myocardial infarction
379763|NCT01168869|Angina pectoris
379764|NCT01168869|Unheralded
379765|NCT01168869|General Practice Research Database
379766|NCT01168869|Myocardial Ischaemia National Audit Project
379767|NCT01168869|CALIBER
379768|NCT01168817|Combination Drug Therapy
379769|NCT01168817|Phosphodiesterase inhibitors
379770|NCT01168804|multiple myeloma
379771|NCT01168804|bendamustine
379772|NCT01168804|bortezomib
379773|NCT01168804|dexamethasone
379774|NCT01168791|Metastatic
379775|NCT01168791|Front line
379776|NCT01168765|Physical Activity, Mexican-American, Obesity, Diabetes, Nutrition, Border Health
379777|NCT01168752|Cancer
379778|NCT01168752|solid tumour
379779|NCT01168752|lymphoma
379780|NCT01168752|dose-escalation
379781|NCT01168752|Hsp90 inhibitor
379782|NCT01168739|thermotolerance
379783|NCT01168739|heat acclimation
379784|NCT01168739|quercetin
379785|NCT01168739|exertional heat illness
379786|NCT01168739|gastrointestinal barrier permeability
379787|NCT01168713|Adults with Community-Acquired Bacterial Pneumonia
379788|NCT01168700|Metabolic syndrome, Aged Garlic Extract, Insulin, inflammation, endothelium.
379789|NCT01168687|keppra
379790|NCT01168687|levetiracetam
379791|NCT01168687|alcoholism
379792|NCT01168687|genetics
379793|NCT01168687|subjective report
379794|NCT01168674|Major Depressive Disorder
379795|NCT01168674|MDD
379796|NCT01168674|Bipolar Disorder
379797|NCT01168674|BD
379798|NCT01168674|Depression
379799|NCT01168674|Major Depressive Disorder with Bipolar features
379800|NCT01168661|Stress
379801|NCT01168661|Burnout
379802|NCT01168661|Anxiety
379803|NCT01168661|Depression
379804|NCT01168648|Yoga
379805|NCT01168648|Stress
379806|NCT01168648|Stress management
379807|NCT01168648|Hypothalamus-pituitary-adrenal axis
379808|NCT01168635|Asthma
379809|NCT01168635|Spirometry
379810|NCT01168635|Pediatric
379811|NCT01168635|Primary Health Care
379812|NCT01168635|Education, Distance
379813|NCT01168609|Left atrial distensibility
379814|NCT01168609|left ventricular filling pressure
379815|NCT01168609|tissue Doppler
379816|NCT01168609|prognosis
379817|NCT01168609|acute myocardial infarction
379818|NCT01168596|Parkinson's Disease
379819|NCT01168596|Fatigue
379820|NCT01168570|familial Mediterranean fever
379821|NCT01168570|amyloidosis AA
379822|NCT01168570|serum amyloid A
379823|NCT01168570|renal failure
379824|NCT01168570|nephrotic syndrome
379825|NCT01168557|electric impedance tomography
379826|NCT01168557|stress-echocardiography
379827|NCT01168557|ventilation
379828|NCT01168557|perfusion
379829|NCT01168544|Vitamin D
379830|NCT01168544|Colecalciferol
379831|NCT01168544|Nursing home
379832|NCT01168544|Loading dose
379833|NCT01168531|patients undergoing lumbar spinal surgery
379834|NCT01168518|Evaluate the Sorin Group new passive- and active- fixation pacing leads
379835|NCT01168492|pediatric
379836|NCT01168492|gastroscopy
379837|NCT01168492|colonoscopy
379838|NCT01168492|sedation
379839|NCT01168492|ketamine
379840|NCT01168479|prostate cancer
379841|NCT01168479|external beam radiotherapy
379842|NCT01168479|dose escalation
379843|NCT01168479|dose painting
379844|NCT01168479|95Gy in 35 fractions
379845|NCT01168479|MRI
379846|NCT01168479|FLAME
379847|NCT01168466|Frontotemporal Lobar Degeneration
379848|NCT01168466|EEG Biofeedback
379849|NCT01168466|Cerebral oxygenation biofeedback
379850|NCT01168466|Peak Alpha Rhythm Biofeedback
379851|NCT01168466|Frontotemporal Dementia
379852|NCT01168453|jugular vein
379853|NCT01168453|anatomy
379854|NCT01168453|ultrasonography
379855|NCT01168440|von Hippel-Lindau
379856|NCT01168440|VHL
379857|NCT01168440|sunitinib
379858|NCT01168401|Prevention of acute gastroenteritis due to infection with noroviruses
379859|NCT01168388|Dystonia
379860|NCT01168388|Hemifacial spasm
379861|NCT01168388|Cervical dystonia
379862|NCT01168388|Blepharospasm
379863|NCT01168362|coronary artery disease
379864|NCT01168362|cardiovascular risk
379865|NCT01168362|pericardial fat
379866|NCT01168336|betahistine olanzapine weight sleepiness
379867|NCT01168336|olanzapine induced weight gain and sleepiness
379868|NCT01168323|Medical Education
379869|NCT01168323|Educational Technology
379870|NCT01168323|Clinical Practice Guideline
379871|NCT01168323|Prostate specific antigen
379872|NCT01168310|Pulmonary, Obstructive, lungs, COPD
379873|NCT01168297|Obesity
379874|NCT01168297|Type 2 Diabetes Mellitus
379875|NCT01168297|Genetics
379876|NCT01168297|Energy Expenditure
379877|NCT01168297|Physical Activity
379878|NCT01168284|Autism Spectrum Disorders
379879|NCT01168271|Observational
379880|NCT01168271|Newborns
379881|NCT01168271|Hospitalized
379882|NCT01168271|Febrile
379883|NCT01168271|Resistance
379884|NCT01168258|Diabetic Retinopathy
379885|NCT01168258|Diabetes
379886|NCT01168258|Single Nucleotide Polymorphism (SNP)
379887|NCT01168258|Diabetic Macular Edema
379888|NCT01168245|Alzheimer Disease
379889|NCT01168245|Dementia
379890|NCT01168245|Brain Diseases
379891|NCT01168245|Central Nervous System Diseases
379892|NCT01168245|Nervous System Disease
379893|NCT01168245|Cognitive Training
379894|NCT01168245|Cortical Reorganization
379895|NCT01168245|Brain Plasticity
379896|NCT01168193|surgery
379897|NCT01168193|post operative
379898|NCT01168193|complications
379899|NCT01168193|length of stay
379900|NCT01168180|Traditional Thai Massage
379901|NCT01168180|Scapulocostal Syndrome
379902|NCT01168167|Antiretroviral Therapy, Highly Active
379903|NCT01168167|MK 0518
379904|NCT01168167|HIV-1 DNA species
379905|NCT01168167|viral slope
379906|NCT01168167|Ribonucleic Acid
379907|NCT01168167|DNA, Complementary
379908|NCT01168154|Diverticula
379909|NCT01168154|Diverticular disease
379910|NCT01168154|Diverticulitis
379911|NCT01168154|Probiotics
379912|NCT01168141|Castrate-resistant prostate cancer with bone metastasis
379913|NCT01168128|Enteral Nutrition
379914|NCT01168128|Parenteral Nutrition
379915|NCT01168128|Critically ill
379916|NCT01168128|Nutrition Therapy
379917|NCT01168128|Nutrition Support
379918|NCT01168128|Practice Guidelines as Topic
379919|NCT01168128|Guideline Adherence
379920|NCT01168128|Quality Assurance, Health Care
379921|NCT01168128|Nutrition Surveys
379922|NCT01168128|Questionnaires
379923|NCT01168063|Helicobacter pylori
379924|NCT01168063|Diagnostic molecular testing
379925|NCT01168063|Antibiotic resistance
379926|NCT01168063|Treatment protocols
379927|NCT01168050|Malignant Skin Melanoma T0
379928|NCT01168050|stage III unresectable melanomas,
379929|NCT01168050|or stage IV melanomas with c-KIT mutation
379930|NCT01168050|or amplification.
379931|NCT01168037|Aorta
379932|NCT01168037|Aneurysm
379933|NCT01168037|endovascular
379934|NCT01168037|stent-graft
379935|NCT01168024|Acute Kidney Injury
379936|NCT01168024|Iodinated Contrast Agent Retrieval
379937|NCT01168024|Coronary Sinus Cannulation
379938|NCT01167985|antibacterial polyethyleneimine nanoparticles
379939|NCT01167985|quaternary ammonium
379940|NCT01167985|dental
379941|NCT01167985|Endodotnic
379942|NCT01167985|pulp
379943|NCT01167985|bacteria
379944|NCT01167985|Root canal sealer
379945|NCT01167985|temporary filling
379946|NCT01167985|provisional restoration
379947|NCT01167972|M + mutation
379948|NCT01167972|Non Small Cell Lung Cancer adenocarcinoma
379949|NCT01167972|To determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma
379950|NCT01167959|Obesity
379951|NCT01167959|Diabetes
379952|NCT01167959|Bariatric surgery
379953|NCT01167946|Alopecia Areata
379954|NCT01167946|Alopecia totalis
379955|NCT01167946|Alopecia Universalis
379956|NCT01167946|Ophiasic alopecia
379957|NCT01167946|Oral Pulse steroid
379958|NCT01167946|Methylprednisolone
379959|NCT01167933|Bioequivalence
379960|NCT01167933|Crossover
379961|NCT01167933|Simvastatin
379962|NCT01167920|High Blood Pressure
379963|NCT01167920|Hypertension
379964|NCT01167920|Home Blood Pressure Measurements
379965|NCT01167920|Wireless communication of measurements
379966|NCT01167920|Wireless communication of blood pressure measurements
379967|NCT01167907|ankle
379968|NCT01167907|arthrodesis
379969|NCT01167907|internal fixation
379970|NCT01167907|bi/tri malleolar fracture
379971|NCT01167894|Bioequivalence
379972|NCT01167894|Crossover
379973|NCT01167894|Simvastatin
379974|NCT01167868|fostamatinib disodium
379975|NCT01167868|FosD
379976|NCT01167868|Japanese
379977|NCT01167868|Healthy volunteers
379978|NCT01167868|Phase 1
379979|NCT01167868|Single and Multiple Ascending Dose Study
379980|NCT01167868|Healthy Japanese volunteers
379981|NCT01167868|Healthy White volunteers
379982|NCT01167855|Pediatric Asthma
379983|NCT01167855|Low-income
379984|NCT01167855|Arkansas Delta Region
379985|NCT01167829|Experimental
379986|NCT01167829|Acyline plus 27 oral testosterone pills
379987|NCT01167829|taken 3x/day
379988|NCT01167803|Bariatric surgery
379989|NCT01167803|Anesthesia
379990|NCT01167790|Precancerous lesions of the oral mucosa
379991|NCT01167790|Fluorescence visualization
379992|NCT01167777|CT
379993|NCT01167777|GC
379994|NCT01167777|NG
379995|NCT01167777|chlamydia
379996|NCT01167777|gonorrhoeae
379997|NCT01167764|hemoptysis
379998|NCT01167764|recurrence
379999|NCT01167751|Myocardial infarction
380000|NCT01167751|Bone marrow stem cells
380001|NCT01167751|AC133
380002|NCT01167738|adenocarcinoma of the pancreas
380003|NCT01167738|stage IV pancreatic cancer
380004|NCT01167725|mucinous adenocarcinoma of the colon
380005|NCT01167725|stage III colon cancer
380006|NCT01167725|stage IV colon cancer
380007|NCT01167699|Oxycodone/naloxone
380008|NCT01167699|patient preference
380009|NCT01167699|WHO step I/II
380010|NCT01167699|Moderate to severe non-malignant pain
380011|NCT01167686|Respiratory infection
380012|NCT01167686|Viral infection
380013|NCT01167686|Food supplement
380014|NCT01167686|Goldtrain Plus (GT+)
380015|NCT01167673|irritable bowel syndrome
380016|NCT01167673|selenium
380017|NCT01167673|curcumin
380018|NCT01167673|green tea
380019|NCT01167660|Coagulation tests
380020|NCT01167660|Neonates
380021|NCT01167660|Non invasive
380022|NCT01167647|Tuberculosis, culture, bronchoscopy
380023|NCT01167634|Weight Loss
380024|NCT01167634|Motivation
380025|NCT01167634|Contracts
380026|NCT01167621|Refractory Acute Respiratory Distress Syndrome
380027|NCT01167621|Indexed Extra-vascular Lung Water
380028|NCT01167621|HFO-ventilation
380029|NCT01167608|Parkinson's disease
380030|NCT01167608|Depression
380031|NCT01167608|Anxiety
380032|NCT01167608|Treatment
380033|NCT01167595|Critically ill
380034|NCT01167595|Nutrition therapy
380035|NCT01167595|Enteral nutrition
380036|NCT01167582|blood transfusion
380037|NCT01167582|red blood cell transfusion
380038|NCT01167582|myocardial infarction
380039|NCT01167582|acute coronary syndrome
380040|NCT01167582|anemia
380041|NCT01167569|Free Radicals
380042|NCT01167569|Ascorbic Acid
380043|NCT01167569|Cardiac Surgery
380044|NCT01167569|Prevention of Reperfusion Injury
380045|NCT01167556|Family intervention
380046|NCT01167556|Recent-onset schizophrenia
380047|NCT01167556|Motivational Interviewing
380048|NCT01167556|Cannabis use
380049|NCT01167530|Everolimus
380050|NCT01167530|Radiotherapy
380051|NCT01167530|Chemotherapy
380052|NCT01167517|Breast milk
380053|NCT01167517|Feeding
380054|NCT01167517|Prematurity
380055|NCT01167517|Low birth weight infant
380056|NCT01167517|Low maternal breast milk feeding
380057|NCT01167504|saliva
380058|NCT01167504|food
380059|NCT01167504|sensory
380060|NCT01167504|oral health
380061|NCT01167504|film
380062|NCT01167504|pellicle
380063|NCT01167491|Wegener
380064|NCT01167491|CD4+ T cells
380065|NCT01167491|DAP12
380066|NCT01167491|NKG2D
380067|NCT01167478|Exercise
380068|NCT01167478|Caffeine
380069|NCT01167478|Reserve
380070|NCT01167465|Diaper Dermatitis
380071|NCT01167465|Diaper Rash
380072|NCT01167465|Erythema
380073|NCT01167452|Obesity
380074|NCT01167452|Pharmacokinetics
380075|NCT01167452|MRSA
380076|NCT01167452|Tuberculosis
380077|NCT01167452|PCP
380078|NCT01167439|OPMD, dysphagia
380079|NCT01167439|Dysphagia severity
380080|NCT01167439|Nutritional state
380081|NCT01167439|Speech quality
380082|NCT01167439|Upper esophageal sphincter myotomy
380083|NCT01167426|Relapsing Remitting Multiple Sclerosis
380084|NCT01167426|RRMS
380085|NCT01167426|Clinically Isolated Syndrome
380086|NCT01167426|CIS
380087|NCT01167426|Copaxone
380088|NCT01167426|glatiramer acetate
380089|NCT01167426|Autoject 2
380090|NCT01167400|exercise
380091|NCT01167400|executive function
380092|NCT01167400|older adults
380093|NCT01167387|carbohydrate
380094|NCT01167387|glucose metabolism
380095|NCT01167387|surgery, outcome
380096|NCT01167387|major elective surgery
380097|NCT01167387|urology
380098|NCT01167387|hyperglicemia
380099|NCT01167374|HCC
380100|NCT01167361|upper respiratory tract infection
380101|NCT01167361|lower respiratory tract infection
380102|NCT01167348|auricular acupressure
380103|NCT01167348|obesity
380104|NCT01167348|schizophrenia
380105|NCT01167348|body weight
380106|NCT01167335|partial onset seizure
380107|NCT01167335|seizure frequency
380108|NCT01167335|nervous system diseases
380109|NCT01167335|central nervous system diseases
380110|NCT01167335|CNS
380111|NCT01167335|brain diseases
380112|NCT01167335|neurologic manifestations
380113|NCT01167335|adjunctive treatment
380114|NCT01167335|AEDs
380115|NCT01167335|antiepileptic drug
380360|NCT01166282|arthritis
380116|NCT01167322|NPC-07, 5-ALA, photodynamic diagnosis, pharmacokinetics
380117|NCT01167309|Safety and tolerability of LEO 27847
380118|NCT01167296|Intrauterine adhesion
380119|NCT01167296|Cook balloon uterine stent
380120|NCT01167283|COPD
380121|NCT01167270|Infant Diet
380122|NCT01167270|Toddler Diet
380123|NCT01167270|Responsive Feeding
380124|NCT01167270|Infant Temperament
380125|NCT01167270|Parent competency
380126|NCT01167270|Childhood Obesity prevention
380127|NCT01167270|Rapid infant weight gain
380128|NCT01167257|Overactive bladder
380129|NCT01167257|Detrusor overactivity
380130|NCT01167257|Liposome
380131|NCT01167257|Botulinum toxin A
380132|NCT01167231|Diabetes
380133|NCT01167231|Acarbose
380134|NCT01167218|verify now assay for hematological disorders
380135|NCT01167205|Healthy adults with BMI over 25.0 kg/m2
380136|NCT01167179|head and neck cancer
380137|NCT01167179|nurse-led care
380138|NCT01167179|follow-up care
380139|NCT01167179|professional-patient relations
380140|NCT01167179|psychosocial adjustment
380141|NCT01167179|quasi-experimental
380142|NCT01167179|prospective
380143|NCT01167179|quality of life
380144|NCT01167166|Acute Myelocytic Leukemia
380145|NCT01167166|Acute Lymphocytic Leukemia
380146|NCT01167166|Myeloproliferative Disease
380147|NCT01167166|Myelofibrosis
380148|NCT01167166|Essential thrombocythemia
380149|NCT01167166|Polycythemia vera
380150|NCT01167166|Chronic Myeloid Leukemia
380151|NCT01167153|Hypertension
380152|NCT01167153|Valsartan Amlodipine single pill combination
380153|NCT01167153|BP control
380154|NCT01167153|ABPM
380155|NCT01167153|Hypertensive patients not adequately controlled by mono antihypertensive drugs
380156|NCT01167127|Oxycodone/naloxone
380157|NCT01167127|pain relief
380158|NCT01167127|bowel function
380159|NCT01167127|moderate to severe non-malignant pain
380160|NCT01167114|STA-9090
380161|NCT01167101|Rebamipide
380162|NCT01167101|gastric ulcer
380163|NCT01167101|healing rate
380164|NCT01167101|iatrogenic gastric ulcer after endoscopic submucosal dissection
380165|NCT01167088|Double-blind
380166|NCT01167088|Placebo-controlled
380167|NCT01167088|Non-alcoholic fatty liver disease
380168|NCT01167088|NAFLD
380169|NCT01167075|critically ill
380170|NCT01167075|sepsis
380171|NCT01167075|antioxidants
380172|NCT01167075|enteral nutrition
380173|NCT01167075|SIRS (APACHE score 10-30)
380174|NCT01167075|enteral feeding within 48 h of admission
380175|NCT01167049|gastric cancer with liver metastasis
380176|NCT01167036|Myofascial pain syndrome
380177|NCT01167036|Trigger points, Myofascial
380178|NCT01167036|Chiropractic
380179|NCT01167036|Massage
380180|NCT01167036|Musculoskeletal manipulation
380181|NCT01167023|Sickle Cell Disease
380182|NCT01167023|Sickle Cell Anemia
380183|NCT01167023|Adult
380184|NCT01166997|Pulmonary embolism
380185|NCT01166997|Pulmonary thromboembolism
380186|NCT01166997|anticoagulation
380187|NCT01166997|thrombolysis
380188|NCT01166997|ultrasound accelerated thrombolysis
380189|NCT01166984|sepsis
380190|NCT01166984|septic shock
380191|NCT01166971|presbyopia
380192|NCT01166971|intraocular lens
380193|NCT01166945|Child
380194|NCT01166945|Child, preschool
380195|NCT01166945|Sinusitis
380196|NCT01166945|Antimicrobial agents
380197|NCT01166932|pneumonia
380198|NCT01166932|children
380199|NCT01166932|antibiotics
380200|NCT01166906|pain blocking
380201|NCT01166893|burn wound
380202|NCT01166880|assessment
380203|NCT01166867|assessment
380204|NCT01166854|muscle and bone disease
380205|NCT01166841|minimally invasive cardiac surgery
380206|NCT01166841|cardiac surgery
380207|NCT01166841|near infrared spectroscopy
380208|NCT01166841|mitral valve repair
380209|NCT01166841|mitral valve replacement
380210|NCT01166828|Spinal cord injury
380211|NCT01166828|telehealth
380212|NCT01166828|pressure ulcers
380213|NCT01166828|quality of life
380214|NCT01166815|diarrhea morbidity
380215|NCT01166815|malaria incidence
380216|NCT01166815|zinc supplementation
380217|NCT01166802|questionnaire development
380218|NCT01166802|hypervigilance
380219|NCT01166802|pain sensitivity
380220|NCT01166789|IBS
380221|NCT01166789|pain threshold
380222|NCT01166789|constipation
380223|NCT01166776|Wharton's jelly
380224|NCT01166776|umbilical cord
380225|NCT01166776|decellularization
380226|NCT01166763|breast atypia
380227|NCT01166763|high risk for breast cancer
380228|NCT01166763|random periareolar fine needle aspiration
380229|NCT01166763|RPFNA
380230|NCT01166763|breast epithelial hyperplasia
380231|NCT01166763|ki-67
380232|NCT01166763|chemoprevention
380233|NCT01166763|vitamin D3
380234|NCT01166763|Additional relevant MeSH terms:
380235|NCT01166763|Molecular Mechanisms of Pharmacological Action
380236|NCT01166763|Physiological Effects of Drugs
380237|NCT01166763|Breast Neoplasms
380238|NCT01166763|Pharmacologic Actions
380239|NCT01166763|Hyperplasia
380240|NCT01166763|high risk for development of breast cancer
380241|NCT01166763|Neoplasms
380242|NCT01166763|Neoplasms by Site
380243|NCT01166763|Pathologic Processes
380244|NCT01166763|Antirheumatic Agents
380245|NCT01166763|Breast Diseases
380246|NCT01166737|Ovarian Cancer
380247|NCT01166737|Cancer of the fallopian tube
380248|NCT01166737|Primary peritoneal cancer
380249|NCT01166737|Recurrent disease
380250|NCT01166737|Platinum-sensitive
380251|NCT01166737|Surgery
380252|NCT01166737|Chemotherapy
380253|NCT01166737|Quality of Life
380254|NCT01166737|First recurrence of platinum sensitive:
380255|NCT01166737|Fallopian Tube Cancer
380256|NCT01166737|or Ovarian Cancer
380257|NCT01166737|or Peritoneal Cavity Cancer
380258|NCT01166724|Kidney transplant
380259|NCT01166698|Safety
380260|NCT01166698|tolerability
380261|NCT01166698|healthy
380262|NCT01166698|inhalation
380263|NCT01166685|coronary artery disease
380264|NCT01166685|drug-eluting stent
380265|NCT01166685|anti-thrombotic therapy
380266|NCT01166685|bare-metal stent
380267|NCT01166685|long-term outcome
380268|NCT01166672|obese women (BMI greater than or equal to 30), do not already have a diagnosis of lymphedema, who are done
380269|NCT01166672|with surgery, chemotherapy, and radiation therapy, and who were diagnosed with breast cancer within the
380270|NCT01166672|past 2 years will be invited to participate.
380271|NCT01166659|Glaucoma
380272|NCT01166659|Glaucoma device
380273|NCT01166659|Glaucoma surgery
380274|NCT01166659|Intraocular pressure
380275|NCT01166633|Hydroxymethylglutaryl-CoA Reductase Inhibitors
380276|NCT01166633|hyperlipidemia
380277|NCT01166594|Glaucoma
380278|NCT01166594|Elevated Intraocular Pressure (IOP)
380279|NCT01166594|Optic Neuropathy
380280|NCT01166594|Bleb Failure
380281|NCT01166594|Avastin (Bevacizumab)
380282|NCT01166581|early stage breast cancer
380283|NCT01166581|preoperative breast MRI
380284|NCT01166581|mastectomy
380285|NCT01166568|Presbyopia
380286|NCT01166568|Reading Vision
380287|NCT01166568|Near Vision
380288|NCT01166555|Safety and tolerability
380289|NCT01166555|Pharmacokinetics
380290|NCT01166555|PF-04236921
380291|NCT01166555|Rheumatoid Arthritis
380292|NCT01166542|carcinoma
380293|NCT01166542|squamous cell
380294|NCT01166542|head
380295|NCT01166542|neck
380296|NCT01166542|REOLYSIN (Reovirus Type 3 Dearing)
380297|NCT01166542|chemotherapy
380298|NCT01166542|Carboplatin
380299|NCT01166542|Paclitaxel
380300|NCT01166542|metastatic
380301|NCT01166542|recurrent
380302|NCT01166516|Prolonged air leak
380303|NCT01166516|lobectomy
380304|NCT01166516|segmentectomy
380305|NCT01166516|lung volume reduction surgery (LVRS)
380306|NCT01166503|pediatrics
380307|NCT01166503|Esotropia
380308|NCT01166503|Surgery
380309|NCT01166490|Monomethyl auristatin E (MMAE)
380310|NCT01166490|Immunotherapy
380311|NCT01166490|AGS-5 Antigen
380312|NCT01166490|SLC44A4 Antigen
380313|NCT01166490|Gastric Neoplasms
380314|NCT01166490|Pancreatic Neoplasms
380315|NCT01166490|Antibody-Drug Conjugate
380316|NCT01166490|Antibodies, Monoclonal
380317|NCT01166490|Drug Therapy
380318|NCT01166464|tobacco
380319|NCT01166464|smoking
380320|NCT01166464|text message
380321|NCT01166464|therapy
380322|NCT01166451|iron deficiency anemia
380323|NCT01166451|cognitive development
380324|NCT01166451|motor development
380325|NCT01166438|incontinence
380326|NCT01166438|overactive bladder
380327|NCT01166438|botox
380328|NCT01166438|anticholinergic
380329|NCT01166399|Fecal Incontinence,
380330|NCT01166399|bowel incontinence,
380331|NCT01166399|pelvic floor disorder
380332|NCT01166386|rehabilitation
380333|NCT01166386|brain injury
380334|NCT01166373|prolapse
380335|NCT01166373|urinary incontinence
380336|NCT01166373|uterosacral vaginal vault ligament suspension
380337|NCT01166373|sacrospinous ligament fixation
380338|NCT01166373|behavioral therapy
380339|NCT01166373|pelvic muscle training
380340|NCT01166360|Risk prediction
380341|NCT01166360|Euroscore
380342|NCT01166360|GDF-15
380343|NCT01166360|hsTnT
380344|NCT01166360|cardiac surgery
380345|NCT01166334|Smoking
380346|NCT01166334|Smoke
380347|NCT01166334|Cigarette
380348|NCT01166334|Cessation
380349|NCT01166334|Quit
380350|NCT01166334|Online
380351|NCT01166334|Web
380352|NCT01166334|Stop
380353|NCT01166321|Atypical Meningioma
380354|NCT01166308|Recurrent Glioma
380355|NCT01166282|inflammatory back pain
380356|NCT01166282|ankylosing spondylitis
380357|NCT01166282|sacroiliitis
380358|NCT01166282|Juvenile Idiopathic Arthritis
380359|NCT01166282|enthesitis
380361|NCT01166269|grass-pollen allergy
380362|NCT01166256|respiratory failure
380363|NCT01166243|Hemostasis
380364|NCT01166217|Single Dose Study in Healthy Subjects
380365|NCT01166204|Radiotherapy
380366|NCT01166204|NSCLC
380367|NCT01166191|Radiotherapy
380368|NCT01166191|SCLC
380369|NCT01166178|Multiple Sclerosis
380370|NCT01166178|Osteoporosis
380371|NCT01166178|Zoledronic Acid
380372|NCT01166165|Hypertension
380373|NCT01166165|blood pressure
380374|NCT01166165|vitamin d
380375|NCT01166165|winter
380376|NCT01166165|cholecalciferol
380377|NCT01166165|arterial stiffness
380378|NCT01166165|renin
380379|NCT01166165|angiotensin
380380|NCT01166165|aldosterone
380381|NCT01166165|calcium
380382|NCT01166152|autistic spectrum disorders
380383|NCT01166152|developmental disorders
380384|NCT01166139|Systemic Sclerosis
380385|NCT01166113|Pomalidomide
380386|NCT01166113|Relapsed/Refractory to Lenalidomide
380387|NCT01166100|Bioequivalence
380388|NCT01166100|Crossover
380389|NCT01166100|Fluoxetine Hydrochloride
380390|NCT01166087|Bioequivalence
380391|NCT01166087|Crossover
380392|NCT01166087|Fluoxetine Hydrochloride
380393|NCT01166061|Grass Allergy
380394|NCT01166061|Immunotherapy
380395|NCT01166061|Rhinoconjunctivitis
380396|NCT01166061|ToleroMune Grass
380397|NCT01166048|Chronic Low Back Pain
380398|NCT01166048|Radicular component
380399|NCT01166048|neuropathic pain
380400|NCT01166048|duloxetine
380401|NCT01166048|CLBP
380402|NCT01166035|Solid tumors
380403|NCT01166035|Lenalidomide
380404|NCT01166035|Cetuximab
380405|NCT01166035|Colorectal Cancer
380406|NCT01166035|Non-Small Cell Lung Cancer
380407|NCT01166035|Head and Neck Cancer
380408|NCT01166022|Spinal Muscular Atrophy
380409|NCT01166022|Exercise
380410|NCT01166022|Conditioning
380411|NCT01166022|Strengthening
380412|NCT01166009|Data Collection
380413|NCT01166009|CIBMTR
380414|NCT01166009|NMDP
380415|NCT01166009|Stem Cell Transplantation
380416|NCT01165996|previously treated myelodysplastic syndromes
380417|NCT01165996|secondary myelodysplastic syndromes
380418|NCT01165970|enamel
380419|NCT01165970|dentin
380420|NCT01165970|saliva substitute
380421|NCT01165970|demineralization
380422|NCT01165970|remineralization
380423|NCT01165957|Knee replacement
380424|NCT01165957|Mobile and fixed bearings
380425|NCT01165957|Volumetric wear
380426|NCT01165957|Micro-CT analysis
380427|NCT01165957|Articular and backside wear
380428|NCT01165944|Post transplant diabetes mellitus
380429|NCT01165931|Coronary artery disease
380430|NCT01165905|cancer
380431|NCT01165905|solid malignancy
380432|NCT01165905|tumor
380433|NCT01165905|malignant neoplasm
380434|NCT01165905|histologically confirmed solid malignancy
380435|NCT01165892|Pulmonary embolism
380436|NCT01165892|contrast agent
380437|NCT01165879|Pregnancy
380438|NCT01165879|Term
380439|NCT01165879|Preterm
380440|NCT01165879|Uterine Contractions
380441|NCT01165866|Ondansetron
380442|NCT01165866|Metoclopramide
380443|NCT01165866|Gastroenteritis
380444|NCT01165840|Obesity
380445|NCT01165840|Pharmacokinetics
380446|NCT01165840|Dapsone
380447|NCT01165840|Leprosy
380448|NCT01165840|Tuberculosis
380449|NCT01165827|Aortic Valve Insufficiency
380450|NCT01165827|Aortic Valve Stenosis
380451|NCT01165827|Aortic Valve Valvuloplasty
380452|NCT01165827|Aortic valve Replacement
380453|NCT01165827|Aortic valve Intervention
380454|NCT01165814|Pain control after cesarean section
380455|NCT01165801|AMD
380456|NCT01165801|Cataract surgery
380457|NCT01165801|Size of AMD
380458|NCT01165801|Influence of cataract surgery on AMD Size
380459|NCT01165788|Blood and Marrow Transplant (BMT)
380460|NCT01165736|pharmacokinetics
380461|NCT01165736|safety
380462|NCT01165736|tolerability
380463|NCT01165736|Chronic Pain
380464|NCT01165723|safety
380465|NCT01165723|tolerability
380466|NCT01165723|pharmacokinetics
380467|NCT01165723|pharmacodynamics
380468|NCT01165723|chronic pain
380469|NCT01165710|Irregular heart beat
380470|NCT01165697|Fabry Disease
380471|NCT01165697|vascular disease
380472|NCT01165697|storage endotheliopathy
380473|NCT01165671|Primary Glioblastoma
380474|NCT01165658|non-small cell lung cancer
380475|NCT01165658|NSCLC
380476|NCT01165658|small cell lung cancer
380477|NCT01165658|SCLC
380478|NCT01165658|carcinoid
380479|NCT01165658|thymic cancer
380480|NCT01165658|lung cancer
380481|NCT01165658|radiation therapy
380482|NCT01165658|radiotherapy
380483|NCT01165658|proton therapy
380484|NCT01165645|recurrent adult Hodgkin lymphoma
380485|NCT01165554|Amyloid
380486|NCT01165554|PET-Positron Emission Tomography
380487|NCT01165554|SUVR-Standard uptake value ratios
380488|NCT01165502|MAD study CM3.1-AC100
380489|NCT01165502|Healthy men, age 18 - 50
380490|NCT01165489|Laryngomalacia
380491|NCT01165489|Congenital Anomalies
380492|NCT01165489|Associated Health Problems
380493|NCT01165476|treprostinil
380494|NCT01165476|bioavailability
380495|NCT01165476|bioequivalence
380496|NCT01165463|Aging
380497|NCT01165463|Healthy
380498|NCT01165450|persistent epithelial defect
380499|NCT01165450|cornea
380500|NCT01165437|Peripheral
380501|NCT01165437|Arterial
380502|NCT01165437|Vascular
380503|NCT01165411|Central Catheterization
380504|NCT01165411|Central Line
380505|NCT01165411|Database
380506|NCT01165411|Registry
380507|NCT01165411|Registries
380508|NCT01165398|Education
380509|NCT01165398|central lines
380510|NCT01165398|infections
380511|NCT01165398|complications
380512|NCT01165398|Bundles
380513|NCT01165385|Relapsed or refractory solid tumors
380514|NCT01165385|Pazopanib
380515|NCT01165385|Cisplatin
380516|NCT01165372|Malaria
380517|NCT01165372|Drug resistance
380518|NCT01165346|liver cancer
380519|NCT01165346|hepatocellular carcinoma
380520|NCT01165333|Paediatric oncology
380521|NCT01165333|Cilengitide
380522|NCT01165333|Glioma
380523|NCT01165307|Menorrhagia
380524|NCT01165307|Endometrial ablation
380525|NCT01165307|Heavy menstrual bleeding
380526|NCT01165294|Ketamine
380527|NCT01165281|Pain
380528|NCT01165281|R331333 (JNS024ER, CG5503), tapentadol (NUCYNTA)
380529|NCT01165281|Opioid analgesic
380530|NCT01165281|Oxycodone CR (OXYCONTIN CR)
380531|NCT01165281|Chronic malignant tumor related cancer pain
380532|NCT01165255|congenital malformation
380533|NCT01165255|cardiovascular malformation
380534|NCT01165255|cardiovascular defect
380535|NCT01165255|antidepressants
380536|NCT01165255|pregnancy
380537|NCT01165255|first trimester
380538|NCT01165255|Bupropion
380539|NCT01165255|prevalence
380540|NCT01165242|Neisseria meningitidis
380541|NCT01165242|Adult
380542|NCT01165242|Adolescent
380543|NCT01165242|Safety
380544|NCT01165242|Vaccines, conjugate
380545|NCT01165242|Meningococcal vaccines
380546|NCT01165242|Immunogenicity
380547|NCT01165229|Immunogenicity
380548|NCT01165229|Subjects 70 years and older
380549|NCT01165229|Efficacy
380550|NCT01165229|Herpes Zoster
380551|NCT01165229|Safety
380552|NCT01165229|Adults
380553|NCT01165229|Vaccine
380554|NCT01165203|HIV
380555|NCT01165203|immunogenicity
380556|NCT01165203|Herpes Zoster
380557|NCT01165203|safety
380558|NCT01165203|vaccine
380559|NCT01165177|subjects 50 years and older
380560|NCT01165177|vaccine
380561|NCT01165177|immunogenicity
380562|NCT01165177|efficacy
380563|NCT01165177|Herpes Zoster
380564|NCT01165177|safety
380565|NCT01165164|Dry eye
380566|NCT01165164|artificial tears
380567|NCT01165151|obesity
380568|NCT01165151|weight loss
380569|NCT01165151|group size
380570|NCT01165138|GW642444
380571|NCT01165138|Vilanterol
380572|NCT01165138|Asthma
380573|NCT01165138|Fluticasone Furoate
380574|NCT01165125|pharmacodynamics
380575|NCT01165125|drug interaction
380576|NCT01165125|ketoconazole
380577|NCT01165125|pharmacokinetics
380578|NCT01165125|Fluticasone furoate
380579|NCT01165125|GW642444
380580|NCT01165099|acupuncture
380581|NCT01165099|induced labour
380582|NCT01165099|labour outcome
380583|NCT01165099|nulliparae
380584|NCT01165099|pain-relief
380585|NCT01165099|epidural during labour
380586|NCT01165073|Cirrhosis
380587|NCT01165073|Malnutrition
380588|NCT01165073|Enteral nutrition
380589|NCT01165060|X-ALD
380590|NCT01165060|AMN
380591|NCT01165060|adrenomyeloneuropathy phenotype
380592|NCT01164995|MK-1775
380593|NCT01164995|Carboplatin
380594|NCT01164995|epithelial ovarian cancer
380595|NCT01164995|p53
380596|NCT01164956|methylphenidate
380597|NCT01164956|fatigue
380598|NCT01164917|Lupus
380599|NCT01164917|Discoid Lupus
380600|NCT01164917|Cutaneous Lupus
380601|NCT01164904|Inflammatory Bowel Disease
380602|NCT01164904|Amgen
380603|NCT01164878|Cholestasis
380604|NCT01164878|Liver damage
380605|NCT01164878|Parenteral Nutrition
380606|NCT01164878|Aggressive Nutrition
380607|NCT01164878|Preterm
380608|NCT01164878|Extreme low birth weight infant
380609|NCT01164878|Parenteral Nutrition Associated Cholestasis
380610|NCT01164865|Soft Contact lens
380611|NCT01164865|Multi-Purpose Solution
380612|NCT01164865|Hydrogen Peroxide
380613|NCT01164839|coronary artery
380614|NCT01164839|CT angiography
380615|NCT01164839|image quality
380616|NCT01164839|multicenter trial
380617|NCT01164826|Bioequivalence
380618|NCT01164826|Crossover
380619|NCT01164826|Nabumetone
380620|NCT01164813|Bioequivalence
380621|NCT01164813|Crossover
380622|NCT01164813|Nabumetone
380623|NCT01164800|Bioequivalence
380624|NCT01164800|Crossover
380625|NCT01164800|Trandolapril
380626|NCT01164787|Bioequivalence
380627|NCT01164787|Crossover
380628|NCT01164787|Trandolapril
380629|NCT01164774|Bioavailability
380630|NCT01164774|Crossover
380631|NCT01164774|Ramipril
380632|NCT01164761|Bioavailability
380633|NCT01164761|Crossover
380634|NCT01164761|Ramipril
380635|NCT01164722|anal cancer
380636|NCT01164722|HIV infection
380637|NCT01164722|human papilloma virus infection
380638|NCT01164722|neoplasm of uncertain malignant potential
380639|NCT01164722|high-grade squamous intraepithelial lesion
380640|NCT01164709|refractory multiple myeloma
380641|NCT01164709|recurrent adult acute myeloid leukemia
380642|NCT01164709|recurrent adult acute lymphoblastic leukemia
380643|NCT01164709|recurrent adult diffuse large cell lymphoma
380644|NCT01164709|recurrent adult Hodgkin lymphoma
380645|NCT01164709|recurrent mantle cell lymphoma
380646|NCT01164709|recurrent adult T-cell leukemia/lymphoma
380647|NCT01164709|adult nasal type extranodal NK/T-cell lymphoma
380648|NCT01164709|angioimmunoblastic T-cell lymphoma
380649|NCT01164709|peripheral T-cell lymphoma
380650|NCT01164709|T-cell large granular lymphocyte leukemia
380651|NCT01164709|anaplastic large cell lymphoma
380652|NCT01164709|recurrent grade 3 follicular lymphoma
380653|NCT01164709|recurrent cutaneous T-cell non-Hodgkin lymphoma
380654|NCT01164709|recurrent mycosis fungoides/Sezary syndrome
380655|NCT01164709|aggressive NK-cell leukemia
380656|NCT01164709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
380657|NCT01164709|adult acute myeloid leukemia with inv(16)(p13;q22)
380658|NCT01164709|adult acute myeloid leukemia with t(15;17)(q22;q12)
380659|NCT01164709|adult acute myeloid leukemia with t(16;16)(p13;q22)
380660|NCT01164709|adult acute myeloid leukemia with t(8;21)(q22;q22)
380661|NCT01164709|secondary acute myeloid leukemia
380662|NCT01164709|stage III adult diffuse large cell lymphoma
380663|NCT01164709|stage IV adult diffuse large cell lymphoma
380664|NCT01164709|stage III adult Hodgkin lymphoma
380665|NCT01164709|stage IV adult Hodgkin lymphoma
380666|NCT01164709|stage III mantle cell lymphoma
380667|NCT01164709|stage IV mantle cell lymphoma
380668|NCT01164709|stage III adult T-cell leukemia/lymphoma
380669|NCT01164709|stage IV adult T-cell leukemia/lymphoma
380670|NCT01164709|stage III grade 3 follicular lymphoma
380671|NCT01164709|stage IV grade 3 follicular lymphoma
380672|NCT01164709|stage III mycosis fungoides/Sezary syndrome
380673|NCT01164709|stage IV mycosis fungoides/Sezary syndrome
380674|NCT01164709|stage III cutaneous T-cell non-Hodgkin lymphoma
380675|NCT01164709|stage IV cutaneous T-cell non-Hodgkin lymphoma
380676|NCT01164709|prolymphocytic leukemia
380677|NCT01164696|Quality of Life, Health Care Costs
380678|NCT01164683|sleep apnea
380679|NCT01164683|adherence
380680|NCT01164657|upright position
380681|NCT01164657|birth position
380682|NCT01164657|childbirth
380683|NCT01164657|instrumental deliveries
380684|NCT01164657|primiparous
380685|NCT01164644|ecchymosis
380686|NCT01164644|bruising
380687|NCT01164644|rhinoplasty
380688|NCT01164644|nose job
380689|NCT01164644|arnica
380690|NCT01164644|arnica montana
380691|NCT01164631|Sleep Apnea Syndrome
380692|NCT01164631|Orthodontics
380693|NCT01164631|Tonsillectomy
380694|NCT01164631|Child
380695|NCT01164618|pediatrics
380696|NCT01164618|Remote ischemic preconditioning
380697|NCT01164605|NRTI-regimen
380698|NCT01164605|Raltegravir
380699|NCT01164605|Elvitegravir
380700|NCT01164605|HIV-1 integrase inhibitor
380701|NCT01164605|Fat Waste
380702|NCT01164592|Heart failure (HF)
380703|NCT01164592|Sleep disordered breathing (SDB)
380704|NCT01164592|Cheyne Stokes Respiration (CSR)
380705|NCT01164592|Adaptive Servoventilation (ASV)
380706|NCT01164579|Early Rheumatoid Arthritis
380707|NCT01164579|Joint Structure
380708|NCT01164579|Magnetic Resonance Imaging
380709|NCT01164579|Janus Kinase (JAK) Inhibitor
380710|NCT01164579|Tasocitinib
380711|NCT01164579|Tofacitinib
380712|NCT01164553|influenza, pediatric, vaccine
380713|NCT01164540|Deep venous thrombosis
380714|NCT01164540|Pulmonary embolism
380715|NCT01164540|rosuvastatin treatment
380716|NCT01164514|bacterial sepsis, septicemia, vaccine
380717|NCT01164449|algorithm
380718|NCT01164449|tight glycemic control
380719|NCT01164449|glucose control
380720|NCT01164449|intensive care
380721|NCT01164449|insulin
380722|NCT01164449|ICU
380723|NCT01164423|algorithm
380724|NCT01164423|tight glycemic control
380725|NCT01164423|glucose control
380726|NCT01164423|intensive care
380727|NCT01164423|insulin
380728|NCT01164423|ICU
380729|NCT01164397|Hypercholesterolemia
380730|NCT01164397|Statins
380731|NCT01164371|coronary disease
380732|NCT01164371|cardiovascular disease
380733|NCT01164371|cardiovascular risk
380734|NCT01164371|cardiovascular risk management
380735|NCT01164371|primary care
380736|NCT01164371|angina
380737|NCT01164371|stable angina
380738|NCT01164371|angina pectoris
380739|NCT01164371|acute coronary syndrome
380740|NCT01164371|coronary death
380741|NCT01164371|unheralded acute coronary syndrome
380742|NCT01164371|unheralded coronary death
380743|NCT01164371|gender differences
380744|NCT01164371|sex differences
380745|NCT01164371|myocardial infarction
380746|NCT01164371|ST elevation myocardial infarction
380747|NCT01164371|non ST elevation myocardial infarction
380748|NCT01164371|STEMI
380749|NCT01164371|nSTEMI
380750|NCT01164371|unstable angina
380751|NCT01164358|Presbyopia
380752|NCT01164358|INTRACOR
380753|NCT01164358|patient satisfaction
380754|NCT01164358|long term
380755|NCT01164345|non-Hodgkin's lymphoma
380756|NCT01164345|Hodgkin's lymphoma
380757|NCT01164345|stem cell mobilization
380758|NCT01164345|autologous stem cell transplantation
380759|NCT01164319|Atrial fibrillation
380760|NCT01164319|Percutaneous continous monitoring
380761|NCT01164319|ablation
380762|NCT01164306|LifeSkills Training
380763|NCT01164306|Tobacco prevention
380764|NCT01164306|Tobacco cessation
380765|NCT01164306|Healthy lifestyles
380766|NCT01164306|Tobacco control
380767|NCT01164293|Atopy patch test
380768|NCT01164254|Exposure Assessment
380769|NCT01164254|Web-Based Dietary Assessment
380770|NCT01164254|Web-Based Physical Activity Assessment
380771|NCT01164241|Eczema
380772|NCT01164241|Allergy
380773|NCT01164241|Immunodeficiency
380774|NCT01164241|Netherton's Syndrome
380775|NCT01164241|Piebaldism
380776|NCT01164228|recurrent renal cell cancer
380777|NCT01164228|stage IV renal cell cancer
380778|NCT01164228|clear cell renal cell carcinoma
380779|NCT01164228|papillary renal cell carcinoma
380780|NCT01164228|clear cell sarcoma of the kidney
380781|NCT01164215|neutropenia
380782|NCT01164215|diarrhea
380783|NCT01164215|stage I colon cancer
380784|NCT01164215|stage II colon cancer
380785|NCT01164215|stage III colon cancer
380786|NCT01164215|stage IV colon cancer
380787|NCT01164215|recurrent colon cancer
380788|NCT01164215|stage I rectal cancer
380789|NCT01164215|stage II rectal cancer
380790|NCT01164215|stage III rectal cancer
380791|NCT01164215|stage IV rectal cancer
380792|NCT01164215|recurrent rectal cancer
380793|NCT01164202|adult primary hepatocellular carcinoma
380794|NCT01164202|localized unresectable adult primary liver cancer
380795|NCT01164202|advanced adult primary liver cancer
380796|NCT01164189|adult anaplastic astrocytoma
380797|NCT01164189|adult diffuse astrocytoma
380798|NCT01164189|adult pilocytic astrocytoma
380799|NCT01164189|adult pineal gland astrocytoma
380800|NCT01164189|adult subependymal giant cell astrocytoma
380801|NCT01164189|adult oligodendroglioma
380802|NCT01164189|adult anaplastic oligodendroglioma
380803|NCT01164189|recurrent adult brain tumor
380804|NCT01164189|adult giant cell glioblastoma
380805|NCT01164189|adult glioblastoma
380806|NCT01164189|adult gliosarcoma
380807|NCT01164189|adult mixed glioma
380808|NCT01164176|anaplastic thyroid cancer
380809|NCT01164176|insular thyroid cancer
380810|NCT01164176|recurrent thyroid cancer
380811|NCT01164176|stage III follicular thyroid cancer
380812|NCT01164176|stage III papillary thyroid cancer
380813|NCT01164176|stage IV follicular thyroid cancer
380814|NCT01164176|stage IV papillary thyroid cancer
380815|NCT01164176|thyroid gland medullary carcinoma
380816|NCT01164163|unspecified childhood solid tumor, protocol specific
380817|NCT01164163|recurrent childhood acute lymphoblastic leukemia
380818|NCT01164163|recurrent childhood acute myeloid leukemia
380819|NCT01164163|refractory chronic lymphocytic leukemia
380820|NCT01164163|relapsing chronic myelogenous leukemia
380821|NCT01164163|childhood myelodysplastic syndromes
380822|NCT01164163|previously treated myelodysplastic syndromes
380823|NCT01164163|atypical chronic myeloid leukemia, BCR-ABL1 negative
380824|NCT01164163|chronic myelomonocytic leukemia
380825|NCT01164163|juvenile myelomonocytic leukemia
380826|NCT01164163|myelodysplastic/myeloproliferative neoplasm, unclassifiable
380827|NCT01164163|polycythemia vera
380828|NCT01164163|essential thrombocythemia
380829|NCT01164163|childhood acute promyelocytic leukemia (M3)
380830|NCT01164163|acute myeloid leukemia/transient myeloproliferative disorder
380831|NCT01164163|primary myelofibrosis
380832|NCT01164150|gastrointestinal complications
380833|NCT01164150|urinary complications
380834|NCT01164150|radiation toxicity
380835|NCT01164150|recurrent endometrial carcinoma
380836|NCT01164150|endometrial adenocarcinoma
380837|NCT01164150|stage IA endometrial carcinoma
380838|NCT01164150|stage IB endometrial carcinoma
380839|NCT01164150|stage II endometrial carcinoma
380840|NCT01164150|stage IIIA endometrial carcinoma
381460|NCT01161485|Methamphetamine
380841|NCT01164150|stage IIIB endometrial carcinoma
380842|NCT01164150|stage IIIC endometrial carcinoma
380843|NCT01164137|Adverse Drug Events
380844|NCT01164137|Medication Reconciliation
380845|NCT01164137|Pharmacist-led Intervention
380846|NCT01164124|extremely low birth weight
380847|NCT01164124|probiotics
380848|NCT01164124|growth
380849|NCT01164124|nutrition
380850|NCT01164124|premature infants
380851|NCT01164124|growth in extremely low birth weight infants
380852|NCT01164111|osteoarthritis
380853|NCT01164111|hip arthroplasty
380854|NCT01164111|resistance training
380855|NCT01164111|preoperative training
380856|NCT01164085|Inflammation
380857|NCT01164085|Macular Edema
380858|NCT01164072|electronic cigarette
380859|NCT01164072|nicotine
380860|NCT01164072|smoking cessation
380861|NCT01164072|smoking reduction
380862|NCT01164059|Schizophrenia
380863|NCT01164059|atypical antipsychotic drugs
380864|NCT01164059|conventional antipsychotic drugs
380865|NCT01164059|olanzapine
380866|NCT01164059|quetiapine
380867|NCT01164059|aripiprazole
380868|NCT01164059|haloperidol
380869|NCT01164059|flupentixol
380870|NCT01164046|anticoagulants
380871|NCT01164046|Heparin, Low-Molecular-Weight
380872|NCT01164046|4-Hydroxycoumarins
380873|NCT01164046|recurrent venous thrombosis
380874|NCT01164020|cognition
380875|NCT01164020|supplementation creatine
380876|NCT01164020|resistance training
380877|NCT01164020|aging
380878|NCT01163994|erythema migrans
380879|NCT01163994|Lyme borreliosis
380880|NCT01163994|ceftriaxone treatment
380881|NCT01163994|doxycycline treatment
380882|NCT01163994|outcome
380883|NCT01163994|subjective symptoms
380884|NCT01163981|duplex Ultrasound
380885|NCT01163981|Haemodialysis
380886|NCT01163981|Vascular Access
380887|NCT01163968|Weight reduction
380888|NCT01163968|Cardiac revascularization
380889|NCT01163968|Percutaneous Coronary Intervention
380890|NCT01163968|Cardiac Rehabilitation
380891|NCT01163968|Rural
380892|NCT01163955|Posture analysis
380893|NCT01163955|Video gaming
380894|NCT01163955|Forward Head Position
380895|NCT01163955|Rounded Shoulder Position
380896|NCT01163955|Spine Posture
380897|NCT01163929|breast cancer
380898|NCT01163929|HER2 positive
380899|NCT01163929|Phase II
380900|NCT01163929|RAD001
380901|NCT01163929|paclitaxel
380902|NCT01163929|trastuzumab
380903|NCT01163929|everolimus
380904|NCT01163916|Rheumatoid Arthritis
380905|NCT01163916|Psoriatic Arthritis
380906|NCT01163916|Ankylosing Spondylitis
380907|NCT01163903|Advanced solid tumours
380908|NCT01163903|Pantoprazole
380909|NCT01163903|Doxorubicin
380910|NCT01163903|PANTO IV
380911|NCT01163903|Adriamycin
380912|NCT01163903|no standard treatment options
380913|NCT01163903|dose-escalation schedule
380914|NCT01163903|Phase I
380915|NCT01163903|single-centre
380916|NCT01163903|open label
380917|NCT01163903|dose finding
380918|NCT01163903|recommended phase II dose
380919|NCT01163903|proton pump inhibitor
380920|NCT01163903|advanced cancer
380921|NCT01163903|anthracycline
380922|NCT01163903|gastric acid secretion
380923|NCT01163890|Depression
380924|NCT01163890|Work Performance and Productivity
380925|NCT01163890|Worksite Intervention
380926|NCT01163877|iron absorption
380927|NCT01163877|iron utilization
380928|NCT01163877|malaria
380929|NCT01163877|helminth
380930|NCT01163877|Ivory Coast
380931|NCT01163877|Acute symptomatic uncomplicated falciparum malaria
380932|NCT01163877|Asymptomatic falciparum malaria
380933|NCT01163877|Moderate to heavy hookworm infection
380934|NCT01163877|Heavy Schistosoma haematobium infection
380935|NCT01163864|smoking
380936|NCT01163864|smoking relapse
380937|NCT01163864|smoking cessation
380938|NCT01163864|pregnancy
380939|NCT01163864|smoking cessation in pregnant women
380940|NCT01163851|Hypercholesterolemia
380941|NCT01163851|Dyslipidemia
380942|NCT01163851|LDL
380943|NCT01163851|Cholesterol
380944|NCT01163851|High Cholesterol
380945|NCT01163851|PF-04950615
380946|NCT01163851|RN316
380947|NCT01163838|Hypercholesterolemia
380948|NCT01163838|Dyslipidemia
380949|NCT01163838|LDL
380950|NCT01163838|Cholesterol
380951|NCT01163838|High Cholesterol
380952|NCT01163812|D2 lymph node dissection
380953|NCT01163799|Kidney
380954|NCT01163799|Transplant
380955|NCT01163799|Northwestern
380956|NCT01163799|Calcineurin Inhibitor
380957|NCT01163799|Corticosteroids
380958|NCT01163799|Steroid avoidance
380959|NCT01163786|Bortezomib GVHD Bronchiolitis Obliterans
380960|NCT01163773|Cardiovascular disease
380961|NCT01163773|Milk
380962|NCT01163773|Metabolic syndrome
380963|NCT01163773|Blood lipids
380964|NCT01163773|Menopausal women
380965|NCT01163734|Heart Failure with Preserved Ejection Fraction (HFpEF)
380966|NCT01163734|Coronary Artery Disease (CAD)
380967|NCT01163721|Type 2 diabetes mellitus
380968|NCT01163721|T2DM
380969|NCT01163721|Ranolazine
380970|NCT01163721|Ranexa
380971|NCT01163721|HbA1c
380972|NCT01163695|economic empowerment model, orphans, sub-Saharan Africa
380973|NCT01163682|Taxane induced neuropathy
380974|NCT01163669|hyperparathyroidism
380975|NCT01163656|Neonate
380976|NCT01163656|Laryngoscopes
380977|NCT01163630|open label, randomized
380978|NCT01163630|single-center
380979|NCT01163630|2-way crossover
380980|NCT01163630|food interaction study
380981|NCT01163617|Rheumatoid
380982|NCT01163617|Arthritis
380983|NCT01163604|Argatroban
380984|NCT01163604|intracranial artery stenting
380985|NCT01163604|extracranial artery stenting
380986|NCT01163604|occlusion
380987|NCT01163604|restenosis
380988|NCT01163591|Diabetes
380989|NCT01163591|Nephropathy
380990|NCT01163591|Screening
380991|NCT01163578|Transplantation
380992|NCT01163578|Rejection
380993|NCT01163565|Thyroidectomy
380994|NCT01163552|pleural metastases
380995|NCT01163513|ethnicity
380996|NCT01163513|prognosis
380997|NCT01163474|Telemedicine
380998|NCT01163474|Surgery, Cardiac
380999|NCT01163448|Prostate
381000|NCT01163448|Radiation
381001|NCT01163448|Radical prostatectomy
381002|NCT01163448|09-013
381003|NCT01163435|Helicobacter pylori
381004|NCT01163435|antibiotic resistance
381005|NCT01163435|high dose dual therapy
381006|NCT01163435|sequential therapy
381007|NCT01163435|clarithromycin-based triple therapy
381008|NCT01163435|levofloxacin-based triple therapy
381009|NCT01163422|Right ventricular failure
381010|NCT01163422|Pacemaker
381011|NCT01163422|Cardiac resynchronization therapy
381012|NCT01163422|Pulmonary hypertension
381013|NCT01163409|juvenile fibromyalgia
381014|NCT01163409|acupuncture
381015|NCT01163409|exercise training
381016|NCT01163383|Refractory Neuroblastoma
381017|NCT01163383|Recurrent Neuroblastoma
381018|NCT01163383|Neuroblastoma
381019|NCT01163383|stage IV neuroblastoma
381020|NCT01163383|metastatic pheochromocytoma
381021|NCT01163383|paraganglioma
381022|NCT01163370|creatine supplementation
381023|NCT01163370|resistance training
381024|NCT01163370|osteopenia
381025|NCT01163370|osteoporosis
381026|NCT01163370|bone mineral density
381027|NCT01163344|Gait, balance, Parkinson's Disease
381028|NCT01163331|Parkinson's Disease, voice quality, vocal strength, voice loudness
381029|NCT01163318|Rheumatoid Arthritis
381030|NCT01163305|Identifying an early indicator of drug efficacy
381031|NCT01163292|Rheumatoid Arthritis
381032|NCT01163279|Age-related changes
381033|NCT01163266|Major Depressive Disorder
381034|NCT01163266|Depression
381035|NCT01163266|Melancholia
381036|NCT01163266|Drug Therapy
381037|NCT01163253|chronic
381038|NCT01163253|severe
381039|NCT01163253|treatment
381040|NCT01163253|safety
381041|NCT01163253|CP-690
381042|NCT01163253|550
381043|NCT01163253|Plaque Psoriasis
381044|NCT01163253|Psoriasis Vulgaris
381045|NCT01163253|Xeljanz
381046|NCT01163253|Tofacitinib
381047|NCT01163240|hepatitis B
381048|NCT01163240|HBV
381049|NCT01163240|chronic hepatitis B
381050|NCT01163240|pediatric
381051|NCT01163227|Hallucinations,
381052|NCT01163227|psychotic,
381053|NCT01163227|delusions,
381054|NCT01163227|cognitive deficits
381055|NCT01163188|very low birthweight/ very preterm children
381056|NCT01163188|Bavarian Longitudinal Study (BLS)
381057|NCT01163188|Quality of life and social adjustment in adulthood
381058|NCT01163175|Cardiovascular disease
381059|NCT01163175|Trans fatty acids
381060|NCT01163175|Ruminant
381061|NCT01163175|Blood lipids
381062|NCT01163162|Chronic Kidney Disease
381063|NCT01163162|Vitamin D
381064|NCT01163149|Hypophosphatasia
381065|NCT01163149|HPP
381066|NCT01163149|Bone Disease
381067|NCT01163149|Soft Bones
381068|NCT01163149|Low Alkaline Phosphatase
381069|NCT01163149|genetic metabolic disorder
381070|NCT01163149|alkaline phosphatase
381071|NCT01163149|tissue-specific alkaline phosphatase (TNSALP)
381072|NCT01163149|rickets
381073|NCT01163149|osteomalacia
381074|NCT01163136|Parental decision making
381075|NCT01163136|Decision Making in Serious Pediatric Illness (DSPI)
381076|NCT01163136|palliative care decision making
381077|NCT01163123|Subclinical infection of Japanese encephalitis virus
381078|NCT01163045|neurostimulation
381079|NCT01163045|intraoperative neuromonitoring
381080|NCT01163045|recurrent laryngeal nerve
381081|NCT01163045|palsy of recurrent laryngeal nerve
381082|NCT01163045|RCT
381083|NCT01163032|Blindness
381084|NCT01163032|Eye Diseases
381085|NCT01163032|Nap Disorders
381086|NCT01163032|Circadian Rhythm Disorders
381087|NCT01163032|Sleep disorders
381088|NCT01163032|Circadian Rhythm Sleep Disorders
381089|NCT01163032|Dyssomnias
381090|NCT01163032|Nervous System Diseases
381091|NCT01163019|Chest pain
381092|NCT01163019|acute coronary syndrome
381093|NCT01163019|Emergency department
381094|NCT01163019|speckle tracking imaging
381095|NCT01163019|2D strain
381096|NCT01163019|Echocardiography
381097|NCT01162993|Electric stimulation therapy
381098|NCT01162993|Diabetic Neuropathies
381099|NCT01162980|ACE inhibitors
381100|NCT01162980|ARBs
381101|NCT01162954|Eye drop, Dry eye
381102|NCT01162941|ITP
381103|NCT01162928|critically ill, mechanically ventilated patients requiring enteral and parenteral nutritional support
381104|NCT01162915|Spinal Cord Injury
381105|NCT01162889|pharmacokinetics
381106|NCT01162889|Crohn's disease
381107|NCT01162876|Diabetes, Type 2
381108|NCT01162863|IBSC
381109|NCT01162863|irritable bowel syndrome
381110|NCT01162863|constipation
381111|NCT01162850|Melasma
381112|NCT01162837|Acne
381113|NCT01162824|Endothelial Dysfunction
381114|NCT01162824|Microvascular dysfunction
381115|NCT01162824|Coronary artery spasm
381116|NCT01162824|Inflammation
381117|NCT01162824|CD4+CD28null T cells
381118|NCT01162824|Myocardial ischemia
381119|NCT01162824|Early atherosclerosis
381120|NCT01162811|Visualization
381121|NCT01162811|relaxation
381122|NCT01162811|self hypnotic relaxation
381123|NCT01162811|hypnosis
381124|NCT01162811|invasive medical procedures
381125|NCT01162811|atrial fibrillation
381126|NCT01162811|ablation
381127|NCT01162811|catheter ablation
381128|NCT01162811|pain
381129|NCT01162811|anxiety
381130|NCT01162798|infant formula
381131|NCT01162798|premature infants
381132|NCT01162798|Growth and Development
381133|NCT01162785|BCG Refractory Superficial Bladder Cancer
381134|NCT01162785|SCH 721015
381135|NCT01162785|Syn3
381136|NCT01162785|novel excipient
381137|NCT01162785|interferon -alpha-2b
381138|NCT01162785|Intravesical
381139|NCT01162785|urine IFNa
381140|NCT01162785|transitional cell carcinoma of the bladder
381141|NCT01162785|superficial non-muscle invasive tumor
381142|NCT01162759|hypertension, intervention
381143|NCT01162733|Vancomycin
381144|NCT01162733|Therapeutic Levels
381145|NCT01162733|Infectious Disease
381146|NCT01162733|Recommendations
381147|NCT01162720|Primary knee replacement
381148|NCT01162720|Unilateral knee replacement
381149|NCT01162694|Remote Blood Glucose Monitoring System,
381150|NCT01162694|Continuous Glucose Monitoring System,
381151|NCT01162694|Type 2 Diabetes
381152|NCT01162681|SLE
381153|NCT01162681|Lupus
381154|NCT01162681|Lupus Erythematosus, Systemic
381155|NCT01162681|Autoimmune Diseases
381156|NCT01162681|A-623
381157|NCT01162681|Blisibimod
381158|NCT01162668|bariatric surgery
381159|NCT01162668|obesity
381160|NCT01162668|outcomes
381161|NCT01162655|Insomnia
381162|NCT01162655|Cognitive-Behavioral Therapy
381163|NCT01162655|Internet
381164|NCT01162655|Telehealth
381165|NCT01162642|Healthy moderately heavy smokers
381166|NCT01162629|bounded saddles
381167|NCT01162629|missing teeth
381168|NCT01162629|dental implants
381169|NCT01162629|Tooth, Nonvital
381170|NCT01162616|iron absorption
381171|NCT01162616|polyphenols
381172|NCT01162616|sodium iron EDTA
381173|NCT01162616|sorghum
381174|NCT01162590|Human Rotavirus vaccine
381175|NCT01162577|Weight
381176|NCT01162577|Smoking
381177|NCT01162577|Quitline
381178|NCT01162551|Leukemia
381179|NCT01162551|Non-Hodgkin's Lymphoma
381180|NCT01162538|Raltegravir, non B subtype, naive patients
381181|NCT01162525|Fecal Incontinence
381182|NCT01162525|Fecal Urge Incontinence
381183|NCT01162525|Percutaneous tibial nerve stimulation
381184|NCT01162512|physical activity
381185|NCT01162512|obesity
381186|NCT01162512|adolescents
381187|NCT01162512|telephone
381188|NCT01162512|BMI
381189|NCT01162512|body mass index
381190|NCT01162499|Post prandial hypoglycemia
381191|NCT01162499|hypoglycemia
381192|NCT01162499|Nissen fundoplication
381193|NCT01162499|Dumping
381194|NCT01162486|Anti-infective agents
381195|NCT01162486|Anti-bacterial agents
381196|NCT01162486|Rifampin
381197|NCT01162486|Rifapentine
381198|NCT01162486|Midazolam
381199|NCT01162486|Molecular mechanisms of pharmacological action
381200|NCT01162486|Antitubercular agents
381201|NCT01162486|Pharmacologic actions
381202|NCT01162473|Food hypersensitivity
381203|NCT01162473|Milk hypersensitivity
381204|NCT01162473|Milk allergy
381205|NCT01162473|Food allergy
381206|NCT01162447|BMP- 4 and 7, polycystic ovarian syndrome
381207|NCT01162434|Treatment resistant depression
381208|NCT01162434|Deep brain stimulation
381209|NCT01162434|Brain volumetric analysis
381210|NCT01162421|Rheumatoid Arthritis
381211|NCT01162421|Anti-Inflammatory
381212|NCT01162421|Biological Therapy
381213|NCT01162421|adalimumab
381214|NCT01162421|Disease-Modifying Antirheumatic Drugs
381215|NCT01162421|Antirheumatic Agents
381216|NCT01162421|Agents
381217|NCT01162408|ICU
381218|NCT01162395|Prostate Cancer
381219|NCT01162395|Tumour
381220|NCT01162395|Castration Resistant
381221|NCT01162395|Prostate Androgen Receptor Down Regulator
381222|NCT01162395|Metastatic
381223|NCT01162382|transcranial magnetic stimulation
381224|NCT01162382|TMS
381225|NCT01162382|rTMS
381226|NCT01162382|depression
381227|NCT01162382|fcMRI
381228|NCT01162382|EEG
381229|NCT01162369|Delirium, diagnosis, elderly, hospitalization
381230|NCT01162356|Vitrectomy
381231|NCT01162356|Glaucoma
381232|NCT01162356|Macula
381233|NCT01162356|Optic nerve
381234|NCT01162356|OCT
381235|NCT01162343|Delirium, diagnosis, elderly, hospitalization
381236|NCT01162330|Screening
381237|NCT01162330|Congenital Cytomegalovirus
381238|NCT01162330|CMV
381239|NCT01162330|Hearing loss
381240|NCT01162317|Acupuncture
381241|NCT01162317|Sleep
381242|NCT01162317|Traumatic brain injury
381243|NCT01162304|Chronic Pain
381244|NCT01162304|This clinical trial will compare immediate-release (IR)
381245|NCT01162304|oxycodone and extended-release (ER) oxycodone in the
381246|NCT01162304|management of chronic pain
381247|NCT01162291|intramuscular
381248|NCT01162291|distribution
381249|NCT01162291|NaCl
381250|NCT01162291|botulinum toxin
381251|NCT01162291|muscle
381252|NCT01162291|volume
381253|NCT01162291|movement
381254|NCT01162291|biceps brachii
381255|NCT01162291|primary distribution of intramuscular NaCl representative for primary distribution of intramuscular botulinum toxin
381256|NCT01162291|shift from extracellular to intracellular viewed by DTI technology
381257|NCT01162291|effect of volume
381258|NCT01162291|effect of muscle movement
381259|NCT01162278|liver metastases
381260|NCT01162278|Stereotactic Body Radiation Therapy
381261|NCT01162265|Tuberculosis
381262|NCT01162265|IGRA
381263|NCT01162265|latent
381264|NCT01162252|psoriasis
381265|NCT01162252|mindfulness
381266|NCT01162252|MBSR
381267|NCT01162252|stress
381268|NCT01162252|living well
381269|NCT01162239|smoking
381270|NCT01162239|tobacco
381271|NCT01162239|nicotine
381272|NCT01162239|smoking cessation
381273|NCT01162226|gait
381274|NCT01162226|movement disorders
381275|NCT01162226|balance
381276|NCT01162226|function
381277|NCT01162213|Postmenopausal Women
381278|NCT01162213|Healthy Males
381279|NCT01162213|Cardiovascular
381280|NCT01162213|Flavanols
381281|NCT01162187|secondary prevention
381282|NCT01162187|aspirin
381283|NCT01162187|beta blocker
381284|NCT01162187|ACE inhibitor
381285|NCT01162187|statin
381286|NCT01162187|acute coronary syndrome
381287|NCT01162187|myocardial infarction
381288|NCT01162187|unstable angina
381289|NCT01162187|trends
381290|NCT01162174|Flavanols
381291|NCT01162174|cardiovascular
381292|NCT01162161|sphingolipid
381293|NCT01162161|ceramide
381294|NCT01162161|sphingomyelinase
381295|NCT01162148|inspiratory muscle training
381296|NCT01162148|pulmonary rehabilitation
381297|NCT01162135|Digoxin
381298|NCT01162135|Recurrent Prostate Cancer
381299|NCT01162135|Prostate Specific Antigen
381300|NCT01162122|Elderly
381301|NCT01162122|Influenza
381302|NCT01162122|Immunogenicity
381303|NCT01162122|Safety
381304|NCT01162122|Adjuvant
381305|NCT01162122|Adjuvanted
381306|NCT01162122|Adjuvants
381307|NCT01162122|Vaccines
381308|NCT01162109|Zinc
381309|NCT01162109|sepsis
381310|NCT01162109|critical illness
381311|NCT01162109|mechanical ventilation
381312|NCT01162109|ICU
381313|NCT01162096|Reduced Intensity Haploidentical Transplant
381314|NCT01162083|Exercise Physiology
381315|NCT01162083|Cardiopulmonary Interaction
381316|NCT01162083|Heart Failure
381317|NCT01162070|Uveitis
381318|NCT01162070|etiological diagnosis
381319|NCT01162070|standardized strategy
381320|NCT01161069|phase 1
381321|NCT01161069|healthy young adult volunteers
381322|NCT01161069|healthy elderly adult volunteers
381323|NCT01161043|diabetes
381324|NCT01161043|glucose
381325|NCT01161043|sensor
381326|NCT01161017|migraine patients
381327|NCT01160991|schizophrenia
381328|NCT01160991|olanzapine
381329|NCT01160991|atypical antipsychotic drugs
381330|NCT01160991|amisulpride
381331|NCT01160991|diabetes
381332|NCT01160991|insulin resistance
381333|NCT01160991|insulin secretion
381334|NCT01160991|glucose
381592|NCT01160783|Autistic Disorder
381335|NCT01160991|euglycemic hyperinsulinemic clamp
381336|NCT01160991|hyperglycemic clamp
381337|NCT01160978|Transplantation
381338|NCT01160978|Simvastatin treatment
381339|NCT01160978|Ischemia-reperfusion injury
381340|NCT01160978|Lung failure
381341|NCT01160965|epidural top-up
381342|NCT01160965|emergency Caesarean section
381343|NCT01160952|primary prophylaxis
381344|NCT01160952|itraconazole
381345|NCT01160952|stem cell transplantation
381346|NCT01160939|Exercise
381347|NCT01160939|heart failure
381348|NCT01160939|rehabilitation
381349|NCT01160926|rectal cancer
381350|NCT01160926|capecitabine
381351|NCT01160926|radiotherapy
381352|NCT01160926|AZD6244
381353|NCT01160926|MEK inhibitor
381354|NCT01160926|AZD2171
381355|NCT01160926|Cediranib
381356|NCT01160926|VEGFR inhibitor
381357|NCT01160926|FLT-PET (fluoro-l-pyrimidine positron emission tomography)
381358|NCT01160926|DCE-MRI (dynamic contrast enhanced magnetic resonance imaging)
381359|NCT01160900|cardiovascular diseases
381360|NCT01160900|heart disease
381361|NCT01160900|hemorrhage
381362|NCT01160900|coronary angioplasty
381363|NCT01160900|drug eluting stents
381364|NCT01160874|Attention Deficit Disorder / Hyperactivity (ADHD)
381365|NCT01160874|Cognition
381366|NCT01160874|Sleepiness
381367|NCT01160874|Driving
381368|NCT01162057|Hemodialysis
381369|NCT01162057|Hearing
381370|NCT01162057|Hemodialysis patients
381371|NCT01162044|PTSD
381372|NCT01162044|prevention
381373|NCT01162005|Primary Nephrotic syndrome
381374|NCT01161992|Primary Sclerosing Cholangitis
381375|NCT01161992|PSC
381376|NCT01161992|Cholestatic Liver Disease
381377|NCT01161953|Primary Biliary Cirrhosis
381378|NCT01161953|PBC
381379|NCT01161953|Cholestatic Liver Disease
381380|NCT01161940|Bioavailability
381381|NCT01161940|Nizatidine
381382|NCT01161940|Crossover
381383|NCT01161927|Bioavailability
381384|NCT01161927|Nizatidine
381385|NCT01161927|Crossover
381386|NCT01161914|Type I Gaucher
381387|NCT01161901|ARDS
381388|NCT01161901|Plasmatic biomarkers
381389|NCT01161901|Lung Morphology
381390|NCT01161901|Mechanical ventilation
381391|NCT01161901|CT scan
381392|NCT01161862|Closed-loop
381393|NCT01161862|Artificial pancreas
381394|NCT01161862|Bi-hormonal
381395|NCT01161862|Insulin
381396|NCT01161862|Glucagon
381397|NCT01161862|Diabetes mellitus type 1
381398|NCT01161849|lactate
381399|NCT01161849|urgent surgery
381400|NCT01161849|major surgery
381401|NCT01161849|surgical complications
381402|NCT01161849|possum
381403|NCT01161849|sapsII
381404|NCT01161849|relaparotomy
381405|NCT01161810|Burn
381406|NCT01161810|Rehabilitation
381407|NCT01161797|1,5-Anhydroglucitol
381408|NCT01161784|Functional constipation
381409|NCT01161784|Probiotic
381410|NCT01161784|Probiotic microorganism
381411|NCT01161784|Lactobacillus casei Shirota (LcS)
381412|NCT01161758|physical therapy
381413|NCT01161758|pain threshold
381414|NCT01161758|electromyography
381415|NCT01161758|musculoskeletal manipulation
381416|NCT01161758|neck muscles
381417|NCT01161745|sepsis
381418|NCT01161732|aortic stenosis
381419|NCT01161732|surgery, survival
381420|NCT01161719|ADHD
381421|NCT01161719|Parent training
381422|NCT01161719|Videoconference
381423|NCT01161706|vegetable juice
381424|NCT01161706|cardiovascular
381425|NCT01161706|blood pressure
381426|NCT01161693|Cesarean section
381427|NCT01161693|spinal anesthesia
381428|NCT01161693|CSE
381429|NCT01161693|ramped up position
381430|NCT01161693|TROOP pillow
381431|NCT01161693|elevation pillow
381432|NCT01161693|maternal comfort
381433|NCT01161693|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
381434|NCT01161680|Cross sectional and Longitudinal Observational study
381435|NCT01161641|Protein Losing Enteropathy
381436|NCT01161628|Chronic Graft versus Host Disease
381437|NCT01161628|allogeneic stem cell transplant
381438|NCT01161615|tendonitis and/or bursitis of the shoulder
381439|NCT01161615|acute tendonitis and/or bursitis of the shoulder
381440|NCT01161602|Symptoms of Gastroesophageal Reflux Disease (GERD)
381441|NCT01161589|sensing
381442|NCT01161589|S-ICD
381443|NCT01161589|ICD
381444|NCT01161589|CRT D
381445|NCT01161576|Batten Disease
381446|NCT01161576|Late Infantile Neuronal Lipofuscinosis
381447|NCT01161576|gene transfer
381448|NCT01161563|palliative treatment
381449|NCT01161563|prostate cancer
381450|NCT01161511|CLL
381451|NCT01161511|SLL
381452|NCT01161511|CD19
381453|NCT01161498|squamous cell
381454|NCT01161498|OncoVEX^GM-CSF
381455|NCT01161498|Oncovex
381456|NCT01161498|chemoradiation
381457|NCT01161498|Cisplatin
381458|NCT01161485|HIV Infections
381459|NCT01161485|Treatment
381461|NCT01161459|Idiopathic Membranous Nephropathy
381462|NCT01161459|Treatment
381463|NCT01161459|FK506
381464|NCT01161459|Tripterygium wilfordii
381465|NCT01161446|HIV
381466|NCT01161446|Home testing
381467|NCT01161446|Self-testing
381468|NCT01161446|HIV Infections/diagnosis
381469|NCT01161446|HIV Infections/prevention and control
381470|NCT01161446|AIDS Serodiagnosis
381471|NCT01161446|Oral fluids
381472|NCT01161446|Homosexuality, Male
381473|NCT01161446|Sexually transmitted diseases
381474|NCT01161446|Sexual behavior
381475|NCT01161433|Asthma
381476|NCT01161433|Spirometry
381477|NCT01161433|Pediatric
381478|NCT01161433|Primary Health Care
381479|NCT01161433|Education, Distance
381480|NCT01161420|tongue
381481|NCT01161420|surgery
381482|NCT01161420|neurostimulation
381483|NCT01161420|hypoglossal nerve
381484|NCT01161420|upper airway stimulation
381485|NCT01161381|OSAHS
381486|NCT01161381|nonlinear analysis
381487|NCT01161381|polysomnography
381488|NCT01161381|biosignal analysis
381489|NCT01161381|DFA
381490|NCT01161381|APEN
381491|NCT01161381|LLE
381492|NCT01161368|Metastatic Breast Cancer
381493|NCT01161355|Safety
381494|NCT01161355|tolerability
381495|NCT01161355|healthy
381496|NCT01161355|microdose
381497|NCT01161342|Malnutrition
381498|NCT01161342|Aged
381499|NCT01161342|Aged 80 and over
381500|NCT01161342|Prevalence
381501|NCT01161342|Mortality
381502|NCT01161329|stroke
381503|NCT01161329|physical activity
381504|NCT01161329|balance
381505|NCT01161329|muscle-strength
381506|NCT01161316|metastatic colorectal cancer
381507|NCT01161316|wild-type KRAS tumours
381508|NCT01161316|cetuximab
381509|NCT01161316|mFOLFOX-6
381510|NCT01161303|Asthma
381511|NCT01161303|TNF alpha
381512|NCT01161303|epithelial cell culture
381513|NCT01161290|Telemedicine
381514|NCT01161290|Internet
381515|NCT01161290|Dyspnea
381516|NCT01161290|Self care
381517|NCT01161290|Breathing Exercises
381518|NCT01161290|Real-Time Systems
381519|NCT01161277|Aripiprazole
381520|NCT01161277|Haloperidol
381521|NCT01161277|Ventral striatum
381522|NCT01161277|Reward
381523|NCT01161277|fMRI
381524|NCT01161264|Elderly
381525|NCT01161264|Influenza
381526|NCT01161264|Immunogenicity
381527|NCT01161264|Safety
381528|NCT01161264|Influenza vaccine
381529|NCT01161251|Atrial Fibrillation
381530|NCT01161251|ABI
381531|NCT01161251|PAD
381532|NCT01161251|Registry
381533|NCT01161251|Italian
381534|NCT01161225|Adolescents
381535|NCT01161225|Peer leader program
381536|NCT01161225|asthma camp
381537|NCT01161225|asthma control
381538|NCT01161225|quality of life
381539|NCT01161225|self-efficacy
381540|NCT01161225|knowledge
381541|NCT01161225|attitudes
381542|NCT01161225|barrier perceptions
381543|NCT01161212|body mass index
381544|NCT01161212|health-related quality of life
381545|NCT01161212|physical education
381546|NCT01161212|children
381547|NCT01161212|cluster randomized controlled trial
381548|NCT01161212|prevention
381549|NCT01161212|Child
381550|NCT01161212|French
381551|NCT01161212|Schoolchildren
381552|NCT01161199|HIV
381553|NCT01161199|latent reservoir
381554|NCT01161199|functional cure
381555|NCT01161199|leukapheresis
381556|NCT01161186|pancreas
381557|NCT01161186|cancer
381558|NCT01161186|abraxane
381559|NCT01161186|metastatic
381560|NCT01161186|gemcitabine
381561|NCT01161186|capecitabine
381562|NCT01161186|adenocarcinoma
381563|NCT01161160|H1N1
381564|NCT01161160|Influenza
381565|NCT01161160|Pandemic
381566|NCT01161160|GSK Bio's influenza vaccines GSK2340274A and GSK234072A
381567|NCT01161121|Fractional flow reserve
381568|NCT01161121|adenosine
381569|NCT01161121|regadenoson
381570|NCT01161108|Pediatrics
381571|NCT01161108|Epilepsy
381572|NCT01161108|Insomnia
381573|NCT01161108|Melatonin
381574|NCT01161095|Intrauterine Device
381575|NCT01161095|Postpartum contraception
381576|NCT01161095|Long-acting reversible contraception
381577|NCT01160848|Moderate to severe Acne Vulgaris
381578|NCT01160835|total knee arthroplasty
381579|NCT01160835|minimally invasive
381580|NCT01160835|quadriceps-sparing
381581|NCT01160835|Quadriceps-sparing total knee arthroplasty
381582|NCT01160822|Osteo arthritis
381583|NCT01160822|pain control
381584|NCT01160822|intra- articular injections
381585|NCT01160822|Knee OA
381586|NCT01160809|Malaria
381587|NCT01160809|Mosquito repellent
381588|NCT01160809|LLINs
381589|NCT01160783|Autism
381590|NCT01160783|Asperger's Syndrome
381591|NCT01160783|Asperger Syndrome
381593|NCT01160783|Autism Spectrum Disorder
381594|NCT01160783|Pervasive Developmental Disorders
381595|NCT01160783|PDD-NOS
381596|NCT01160783|Child Development Disorders, Pervasive
381597|NCT01160783|Pervasive Developmental Disorder-Not Otherwise Specified
381598|NCT01160770|Lennox-Gastaut Syndrome (LGS)
381599|NCT01160770|Epilepsy
381600|NCT01160770|Drop Seizures
381601|NCT01160770|Clobazam
381602|NCT01160744|Lung neoplasms
381603|NCT01160744|Lung cancer
381604|NCT01160744|Non-small Cell Lung Cancer
381605|NCT01160744|pemetrexed
381606|NCT01160744|ALIMTA®
381607|NCT01160744|squamous
381608|NCT01160744|nonsquamous
381609|NCT01160731|extensive stage small cell lung cancer
381610|NCT01160718|estrogen receptor-positive breast cancer
381611|NCT01160718|HER2-positive breast cancer
381612|NCT01160718|HER2-negative breast cancer
381613|NCT01160718|progesterone receptor-positive breast cancer
381614|NCT01160718|recurrent breast cancer
381615|NCT01160718|stage IIIA breast cancer
381616|NCT01160718|stage IIIB breast cancer
381617|NCT01160718|stage IIIC breast cancer
381618|NCT01160718|stage IV breast cancer
381619|NCT01160705|adenocarcinoma of the prostate
381620|NCT01160705|recurrent prostate cancer
381621|NCT01160705|stage III prostate cancer
381622|NCT01160705|stage IV prostate cancer
381623|NCT01160705|bone metastases
381624|NCT01160705|liver metastases
381625|NCT01160705|lung metastases
381626|NCT01160705|hormone-resistant prostate cancer
381627|NCT01160692|Memory
381628|NCT01160692|Cognitive Function
381629|NCT01160692|Elderly
381630|NCT01160692|Gingko
381631|NCT01160692|Age Associated Memory Impairment (AAMI)
381632|NCT01160679|anhedonic features in patients with schizophrenia
381633|NCT01160666|Belimumab
381634|NCT01160666|Sjögren's syndrome
381635|NCT01160666|Sjögren disease
381636|NCT01160653|stroke
381637|NCT01160653|Gait training
381638|NCT01160653|Cognitive Training
381639|NCT01160640|PID
381640|NCT01160640|Pelvic Inflammatory Disease
381641|NCT01160627|CIN STEMI
381642|NCT01160614|Pediatric
381643|NCT01160614|Post-operative
381644|NCT01160614|Nonsurgical
381645|NCT01160614|patients
381646|NCT01160614|Opioid
381647|NCT01160601|NSCLC
381648|NCT01160601|lung cancer
381649|NCT01160601|non small cell lung cancer
381650|NCT01160601|bavituximab
381651|NCT01160601|monoclonal antibody
381652|NCT01160588|Anxiety
381653|NCT01160588|Social Phobia
381654|NCT01160588|Social Anxiety
381655|NCT01160588|Generalized Anxiety
381656|NCT01160588|Separation Anxiety
381657|NCT01160575|Counseling
381658|NCT01160575|Epidemiology
381659|NCT01160575|HIV
381660|NCT01160575|AIDS
381661|NCT01160575|Prevention
381662|NCT01160562|Prevalence
381663|NCT01160562|Incidence
381664|NCT01160562|Children
381665|NCT01160562|Adults
381666|NCT01160562|Global Positioning system
381667|NCT01160549|Pregnancy
381668|NCT01160549|Hormones
381669|NCT01160549|Mongolia
381670|NCT01160549|Asian
381671|NCT01160549|Breast Cancer
381672|NCT01160536|Hypertrophic Cardiomyopathy (HCM)
381673|NCT01160536|Genetic Testing
381674|NCT01160523|Podoconiosis
381675|NCT01160523|Genetic Education
381676|NCT01160523|Primary Prevention
381677|NCT01160523|Ethiopa
381678|NCT01160523|Youth
381679|NCT01160510|Breast
381680|NCT01160510|Mammographic Density
381681|NCT01160484|multiple myeloma
381682|NCT01160484|refractory
381683|NCT01160484|relapsed
381684|NCT01160484|bortezomib
381685|NCT01160484|doxil
381686|NCT01160471|Heart Failure
381687|NCT01160471|Computed Tomography
381688|NCT01160471|Ultrasound
381689|NCT01160471|Fibrosis
381690|NCT01160471|Biomarker
381691|NCT01160458|Monoclonal Antibody
381692|NCT01160458|Pleural Mesothelioma
381693|NCT01160458|Peritoneal Mesothelioma
381694|NCT01160445|Metastatic Melanoma
381695|NCT01160445|Metastatic Kidney Cancer
381696|NCT01160445|Clinical Performance
381697|NCT01160445|Tumor Regression
381698|NCT01160445|Toxicity
381699|NCT01160432|opiate dependence
381700|NCT01160432|methadone
381701|NCT01160432|naloxone
381702|NCT01160432|withdrawal symptom
381703|NCT01160432|substitution treatment
381704|NCT01160406|silent paroxysmal atrial fibrillation
381705|NCT01160406|stroke
381706|NCT01160406|tele ECG
381707|NCT01160393|Atrial fibrillation
381708|NCT01160393|Cardiac surgery
381709|NCT01160393|Prevention
381710|NCT01160393|Conventional bypass system
381711|NCT01160393|Miniaturized bypass system
381712|NCT01160393|Arrhythmia
381713|NCT01160393|The Incidence of atrial fibrillation after cardiac surgery
381714|NCT01160380|cancer related fatigue
381715|NCT01160380|fatigue
381716|NCT01160380|multiple myeloma
381717|NCT01160380|cancer
381718|NCT01160380|quality of life
381719|NCT01160354|Leukemia
381720|NCT01160354|AML
381721|NCT01160354|Clofarabine
381722|NCT01160354|Plerixafor
381723|NCT01160354|elderly patients
381724|NCT01160354|previously untreated
381725|NCT01160354|unfavorable prognostic factors
381726|NCT01160341|Metabolic syndrome
381727|NCT01160341|Hypogonadism
381728|NCT01160341|Testosterone
381729|NCT01160328|Regional Fat Storage
381730|NCT01160328|Fat Oxidation
381731|NCT01160328|Testosterone
381732|NCT01160328|Male
381733|NCT01160315|ovarian failure, chemotherapy, lymphoma, GnRH agonist
381734|NCT01160302|cancer
381735|NCT01160276|renal graft
381736|NCT01160276|colchicine
381737|NCT01160276|drug interaction
381738|NCT01160276|cyclosporine
381739|NCT01160276|tacrolimus
381740|NCT01160276|renal transplantation
381741|NCT01160276|renal transplant
381742|NCT01160276|ABCB1
381743|NCT01160276|CYP3A5
381744|NCT01160276|SLCO1B1
381745|NCT01160263|ALS
381746|NCT01160263|serotonin
381747|NCT01160263|dopamine
381748|NCT01160237|H1N1
381749|NCT01160237|Pandemrix
381750|NCT01160237|Fluarix
381751|NCT01160237|Influenza
381752|NCT01160224|Asthma
381753|NCT01160224|CCR3 receptor antagonists
381754|NCT01160224|GW766944
381755|NCT01160211|1st line MBC
381756|NCT01160211|MBC
381757|NCT01160211|hormone receptor positive
381758|NCT01160211|lapatinib
381759|NCT01160211|trastuzumab
381760|NCT01160211|HER2 positive
381761|NCT01160211|aromatase inhibitor
381762|NCT01160172|vaccine
381763|NCT01160172|young adults
381764|NCT01160172|Staphylococcus aureus
381765|NCT01160159|Venous thrombosis
381766|NCT01160159|Women
381767|NCT01160159|Vasodilatation endothelium-dependent
381768|NCT01160159|IMT
381769|NCT01160159|Arterial stiffness
381770|NCT01160159|Arterial compliance
381771|NCT01160159|Capillary density
381772|NCT01160146|Obestiy
381773|NCT01160146|Over weight
381774|NCT01160146|referral patterns
381775|NCT01160146|Continuing Medical Education
381776|NCT01160133|Systane
381777|NCT01160133|Refresh Tears
381778|NCT01160133|Dry Eye
381779|NCT01160133|Moderate to Severe Dry Eye
381780|NCT01160120|fixed dose combinations
381781|NCT01160120|tenofovir
381782|NCT01160120|lamivudine
381783|NCT01160120|efavirenz
381784|NCT01160120|therapeutic drug levels
381785|NCT01160120|safety and efficacy
381786|NCT01160120|HIV
381787|NCT01160120|To evaluation new formulations of FDC of TDF/3TC/EFV
381788|NCT01160107|Diagnosis
381789|NCT01160107|Elderly Patients
381790|NCT01160107|Imids
381791|NCT01160107|Chemotherapy
381792|NCT01160094|Trastuzumab
381793|NCT01160094|Metastatic Breast Cancer
381794|NCT01160094|Breast Cancer
381795|NCT01160094|Observational Study
381796|NCT01160094|Lapatinib
381797|NCT01160003|ACTH stimulation test
381798|NCT01160003|Pharmacokinetics
381799|NCT01160003|Nebules
381800|NCT01160003|Cortisol
381801|NCT01159990|HIV Preventive Vaccine
381802|NCT01159990|HIV Seronegativity
381803|NCT01159964|PRAME
381804|NCT01159964|Non-Small Cell Lung Cancer
381805|NCT01159964|Antigen-Specific Cancer Immunotherapeutic (ASCI)
381806|NCT01159964|PRAME-positive stage IB, II or IIIA Non-Small Cell Lung Cancer patients after complete surgical resection
381807|NCT01159912|fluticasone propionate
381808|NCT01159912|Fluticasone furoate
381809|NCT01159899|Osteoarthritis
381810|NCT01159899|knee arthritis
381811|NCT01159899|Knee arthrosis
381812|NCT01159899|articular cartilage defects
381813|NCT01159899|osteochondral defects
381814|NCT01159899|mesenchymal stem cells
381815|NCT01159899|stem cells
381816|NCT01159899|cellules souches,
381817|NCT01159899|genou
381818|NCT01159899|arthrose genou
381819|NCT01159899|PRP platelet rich plasma
381820|NCT01159899|thérapie cellulaire
381821|NCT01159899|implantation cellules souches mésenchymateuses
381822|NCT01159899|régénération cartilage
381823|NCT01159899|cicatrisation ménisque
381824|NCT01159899|ligament
381825|NCT01159899|plasma riche plaquettaire
381826|NCT01159899|platelet rich plasma
381827|NCT01159899|stem cell
381828|NCT01159899|regrowt cartilage
381829|NCT01159899|cellules souches
381830|NCT01159899|PRP
381831|NCT01159886|Tuberculosis
381832|NCT01159886|IBD
381833|NCT01159886|endoscopy
381834|NCT01159860|seborrheic keratoses
381835|NCT01159860|cryosurgery
381836|NCT01159860|curettage
381837|NCT01159847|sitagliptin
381838|NCT01159847|LADA
381839|NCT01159847|C-Peptide
381840|NCT01159847|Flow Cytometry
381841|NCT01159847|ELISPOT
381842|NCT01159834|HPV infection
381843|NCT01159834|Cervical cancer
381844|NCT01159834|HPV vaccine
381845|NCT01159821|31001074
381846|NCT01159821|Paroxetine
381847|NCT01159821|CYP2D6 inhibitor
381848|NCT01159808|Safety and Pharmacokinetics
381849|NCT01159795|Respiratory Syncytial Virus
381850|NCT01159795|Infant
381851|NCT01159795|Interferon
381852|NCT01159769|Allergic conjunctivitis
381853|NCT01159756|Travacom
381854|NCT01159756|Glaucoma
381855|NCT01159756|Travoprost
381856|NCT01159756|Timolol
381857|NCT01159743|lipodystrophy
381858|NCT01159743|Lipoatrophy
381859|NCT01159743|antiretroviral treatment
381860|NCT01159704|HIV infection
381861|NCT01159704|Intervention
381862|NCT01159704|Risk-reduction
381863|NCT01159704|Injection drug users
381864|NCT01159691|Rotigotine
381865|NCT01159691|Neupro®
381866|NCT01159691|Parkinson's disease
381867|NCT01159691|Gastrointestinal
381868|NCT01159691|Switch from oral therapy to patch
381869|NCT01159652|sleep
381870|NCT01159652|memory
381871|NCT01159652|hypnotics
381872|NCT01159652|zaleplon
381873|NCT01159652|zolpidem
381874|NCT01159652|Sonata
381875|NCT01159652|Ambien
381876|NCT01159652|Hypnotics and Sedatives
381877|NCT01159652|Polysomnography
381878|NCT01159652|Monitoring, sleep
381879|NCT01159639|aspirin resistance
381880|NCT01159639|coronary artery bypass grafting
381881|NCT01159639|multiple electrode aggregometry
381882|NCT01159639|multiplate
381883|NCT01159626|Phase1
381884|NCT01159626|Pharmacokinetics
381885|NCT01159626|Healthy Male
381886|NCT01159626|Japanese
381887|NCT01159626|Schizophrenia
381888|NCT01159613|SVR
381889|NCT01159613|Cholesterol level
381890|NCT01159613|fibrosis score
381891|NCT01159613|HDL
381892|NCT01159535|substance use
381893|NCT01159535|addiction
381894|NCT01159535|meditation
381895|NCT01159535|mindfulness
381896|NCT01159535|relapse prevention
381897|NCT01159522|Advanced Solid Tumors Who Have Failed Standard Therapy
381898|NCT01159509|hypertrophic pyloric stenosis
381899|NCT01159509|sodium intake
381900|NCT01159509|Healthy children with no chronic diseases
381901|NCT01159509|Status post HPS
381902|NCT01159483|safety
381903|NCT01159483|tolerability
381904|NCT01159483|pharmacokinetics
381905|NCT01159470|CRP velocity
381906|NCT01159457|Celiac Disease
381907|NCT01159457|Hepatitis B vaccination
381908|NCT01159444|noninvasive ventilation
381909|NCT01159444|ventilator software
381910|NCT01159444|ventilator settings
381911|NCT01159444|domiciliary ventilation
381912|NCT01159431|partial seizures
381913|NCT01159431|poorly controlled epilepsy
381914|NCT01159431|intractable epilepsy
381915|NCT01159431|treatment resistant epilepsy
381916|NCT01159431|Trigeminal Nerve
381917|NCT01159431|Trigeminal Nerve Stimulation
381918|NCT01159418|solid tumors
381919|NCT01159418|Panobinostat
381920|NCT01159418|histone deacetylase inhibitors
381921|NCT01159392|brain injury
381922|NCT01159392|mechanical ventilation
381923|NCT01159392|acute lung injury
381924|NCT01159392|lung recruitment
381925|NCT01159379|IgE-mediated allergy
381926|NCT01159379|Beta-lactams
381927|NCT01159379|Ertapenem
381928|NCT01159379|Cross-reactivity
381929|NCT01159379|Immediate-type skin tests
381930|NCT01159379|Intravenous tolerance tests
381931|NCT01159366|myocardial infarction
381932|NCT01159366|coronary occlusion
381933|NCT01159366|myocardial revascularization
381934|NCT01159366|collaterals
381935|NCT01159366|prognosis
381936|NCT01159327|Sorafenib (nexavar)
381937|NCT01159327|ED-SCLC
381938|NCT01159327|Maintenance
381939|NCT01159327|Extensive Disease Small cell lung cancer
381940|NCT01159314|glaucoma
381941|NCT01159314|Baerveldt Implants
381942|NCT01159288|Advanced unresectable non small cell lung cancer
381943|NCT01159288|Responding or stabilized after induction chemotherapy
381944|NCT01159275|lopinavir/ritonavir
381945|NCT01159275|pharmacokinetics
381946|NCT01159275|HIV-1 infected adults
381947|NCT01159275|aim to investigate the lower dose of boosted lopinavir in Thais and to compare the levels of lopinavir/ritonavir from Abbot and GPO
381948|NCT01159262|Initially intubated and mechanically ventilated neonates
381949|NCT01159249|Vildagliptin, Type 2 Diabetes, HbA1c, Fasting Plasma Glucose, Long-Term Safety
381950|NCT01159236|Gene signatures
381951|NCT01159236|HER-2 normal stage I-III breast cancer
381952|NCT01159236|Estrogen Receptor
381953|NCT01159236|ER-positive
381954|NCT01159236|ER-negative
381955|NCT01159236|RCB categories II-III
381956|NCT01159236|Neoadjuvant Chemotherapy
381957|NCT01159236|adjuvant systemic therapy
381958|NCT01159236|molecular testing
381959|NCT01159236|Fluorouracil
381960|NCT01159236|5-fluorouracil
381961|NCT01159236|5-FU
381962|NCT01159236|Doxorubicin
381963|NCT01159236|Adriamycin
381964|NCT01159236|Rubex
381965|NCT01159236|Epirubicin
381966|NCT01159236|Ellence
381967|NCT01159236|Cyclophosphamide
381968|NCT01159236|Cytoxan
381969|NCT01159236|Neosar
381970|NCT01159236|Bevacizumab
381971|NCT01159236|Avastin
381972|NCT01159236|Anti-VEGF monoclonal
381973|NCT01159236|rhu-MAb-VEGF
381974|NCT01159223|atazanavir / ritonavir
381975|NCT01159223|low dose
381976|NCT01159223|noninferiority
381977|NCT01159223|safety and efficacy
381978|NCT01159223|efficacy and safety of lower dose atazanavir/ritonavir in suppressed HIV-infected adults
381979|NCT01159197|sleep disturbance
381980|NCT01159197|cognitive behavioral therapy
381981|NCT01159197|inflammation
381982|NCT01159197|oxidative stress
381983|NCT01159197|hemodialysis
381984|NCT01159184|stress
381985|NCT01159184|coping methods
381986|NCT01159184|social support
381987|NCT01159184|diabetes mellitus
381988|NCT01159145|Healthy volunteer
381989|NCT01159145|Japanese males
381990|NCT01159145|homo-EM/hetero-EM/PM
381991|NCT01159132|pharmacokinetics
381992|NCT01159132|low dose raltegravir
381993|NCT01159132|HIV
381994|NCT01159132|To study the pharmacokinetics profile of low dose raltegravir (RAL) (400mg OD and 800mg OD) and standard dose of 400mg BID in Thai HIV-infected patients.
381995|NCT01159119|Chronic Abdominal Pain
381996|NCT01159119|Exocrine Pancreatic Insufficiency
381997|NCT01159106|Positive Pressure Ventilation
381998|NCT01159106|Neurally Adjusted Ventilatory Assist
381999|NCT01159106|Patient/ventilator Asynchrony
382000|NCT01159106|Pediatric patient
382001|NCT01159106|Infant
382002|NCT01159093|Clinical Decision Support Systems
382003|NCT01159080|immunosuppression control in kidney transplantation
382004|NCT01159067|hematopoietic stem cell transplant, iron overload, deferasirox, labile plasma iron
382005|NCT01159041|Depression, children, adolescent, family
382006|NCT01159028|Liposomal Grb-2 treatment of CML, AML, CLL, MDS
382007|NCT01159028|Liposomal Grb-2 with LDAC for AML
382008|NCT01159002|Endoscopy, Video Capsule
382009|NCT01159002|Motility, Gastrointestinal
382010|NCT01158989|Critical care
382011|NCT01158989|Endoscopy, Video Capsule
382012|NCT01158989|Nutrition, Enteral
382013|NCT01158937|meropenem
382014|NCT01158937|cystic fibrosis
382015|NCT01158937|extended infusion
382016|NCT01158937|pharmacokinetic
382017|NCT01158911|kidney disease
382018|NCT01158911|uric acid
382019|NCT01158911|outcomes
382020|NCT01158911|cardiovascular
382021|NCT01158911|mortality
382022|NCT01158911|kidney failure
382023|NCT01158911|Uric Acid levels in patients with Chronic Kidney Disease
382024|NCT01158898|Mild to moderate asthma
382025|NCT01158898|Allergen inhalation challenge
382026|NCT01158885|relapsed
382027|NCT01158885|relapse
382028|NCT01158885|refractory
382029|NCT01158885|Minimal Residual disease
382030|NCT01158885|MRD
382031|NCT01158885|MRD positive
382032|NCT01158885|MRD+
382033|NCT01158885|ALL
382034|NCT01158885|Acute lymphoblastic leukemia
382035|NCT01158885|AML
382036|NCT01158885|Acute myelogenous leukemia
382037|NCT01158885|Relapsed AML
382038|NCT01158859|Anesthesia, General
382039|NCT01158859|Propofol
382040|NCT01158859|Pregabalin
382041|NCT01158859|Preoperative care
382042|NCT01158859|Laparoscopic surgery
382043|NCT01158846|STEMI
382044|NCT01158846|Primary PCI
382045|NCT01158846|anticoagulants
382046|NCT01158846|antiplatelets
382047|NCT01158833|Cerebral palsy
382048|NCT01158833|diplegia
382049|NCT01158833|gait
382050|NCT01158833|classification
382051|NCT01158820|bronchoscopy
382052|NCT01158807|Hereditary Hemorrhagic Telangiectasia
382053|NCT01158807|Cerebral arteriovenous malformations
382054|NCT01158794|Iron overload
382055|NCT01158794|Blood Transfusion
382056|NCT01158781|TBI
382057|NCT01158781|motor learning
382058|NCT01158781|robotics
382059|NCT01158781|Functional electrical stimulation
382060|NCT01158768|domestic violence in childhood/adolescence
382061|NCT01158768|comorbidities
382062|NCT01158768|climactery
382063|NCT01158768|domestic violence against women
382064|NCT01158768|trauma questionnaire
382065|NCT01158768|Violence
382066|NCT01158755|Meningitis, tuberculous
382067|NCT01158755|Intensified Regimen
382068|NCT01158755|PK/PD and tolerability
382069|NCT01158755|Outcome
382070|NCT01158742|Glomerular Filtration Rate
382071|NCT01158729|Antithrombin III
382072|NCT01158729|Postoperative Hemorrhage
382073|NCT01158729|Cardiopulmonary Bypass
382074|NCT01158729|Pediatrics
382075|NCT01158729|Blood Transfusion
382076|NCT01158716|percutaneous coronary intervention
382077|NCT01158716|remote ischemic preconditioning
382078|NCT01158703|aspirin
382079|NCT01158703|clopidogrel
382080|NCT01158703|coronary artery bypass graft
382081|NCT01158703|Plavix
382082|NCT01158690|Intimate partner violence
382083|NCT01158677|meniscectomy
382084|NCT01158664|dental implants
382085|NCT01158664|different tread pitch design
382086|NCT01158651|NF1
382087|NCT01158651|low-grade glioma
382088|NCT01158651|progressive
382089|NCT01158651|children
382090|NCT01158651|Participants studied have NF Type 1 and a low grade glioma that has either not responded to one or more standard treatments.
382091|NCT01158638|Physical Activity Enhancement
382092|NCT01158599|Japanese Encephalitis
382093|NCT01158599|Vaccination
382094|NCT01158599|Ixiaro
382095|NCT01158599|elderly population
382096|NCT01158586|post total knee replacement
382097|NCT01158586|patient control
382098|NCT01158586|epidural analgesia
382099|NCT01158573|Asthma
382100|NCT01158573|Obesity
382101|NCT01158560|upper respiratory tract infections
382102|NCT01158560|rhinovirus infections
382103|NCT01158560|vitamin D
382104|NCT01158534|recurrent renal cell cancer
382105|NCT01158508|cerebral aneurysm
382106|NCT01158508|cerebral vasospasm
382107|NCT01158508|subarachnoid hemorrhage
382108|NCT01158508|remote ischemic preconditioning
382109|NCT01158456|smoking
382110|NCT01158456|lung cancer
382111|NCT01158456|ethnic racial differences
382112|NCT01158456|tobacco specific nitrosamines
382113|NCT01158456|metabolism of carcinogens
382114|NCT01158443|HIV+
382115|NCT01158443|fatigue
382116|NCT01158443|return to work
382117|NCT01158430|Hypochondriasis
382118|NCT01158430|Acceptance and Commitment Therapy
382119|NCT01158430|ACT
382120|NCT01158417|Type 2 Diabetes
382121|NCT01158417|Obesity
382122|NCT01158417|Insulin Resistance
382123|NCT01158417|Resveratrol
382124|NCT01158417|Inflammation
382125|NCT01158404|Metastatic Cancer
382126|NCT01158404|Solid Tumors
382127|NCT01158391|Premature Birth
382128|NCT01158378|Adherus Dural Sealant
382129|NCT01158378|Adherus AutoSpray Dural Sealant
382130|NCT01158352|Growth
382131|NCT01158352|Low weight
382132|NCT01158352|Low height
382133|NCT01158352|Nutritional Formula
382134|NCT01158339|Low back pain
382135|NCT01158339|Cognitive behavioural therapy
382136|NCT01158339|Group therapy
382137|NCT01158339|Exposure in session
382138|NCT01158326|reducing symptoms
382139|NCT01158326|events
382140|NCT01158326|Common Cold
382141|NCT01158326|flu syndrome
382142|NCT01158326|Symptomatic treatment of the Common Cold and Flu syndrome
382143|NCT01158300|recurrent childhood malignant germ cell tumor
382144|NCT01158300|recurrent childhood brain stem glioma
382145|NCT01158300|recurrent childhood brain tumor
382146|NCT01158300|recurrent childhood central nervous system embryonal tumor
382147|NCT01158300|recurrent childhood cerebellar astrocytoma
382148|NCT01158300|recurrent childhood cerebral astrocytoma
382149|NCT01158300|recurrent childhood ependymoma
382150|NCT01158300|recurrent childhood medulloblastoma
382151|NCT01158300|recurrent childhood pineoblastoma
382152|NCT01158300|recurrent childhood rhabdomyosarcoma
382153|NCT01158300|recurrent childhood spinal cord neoplasm
382154|NCT01158300|recurrent childhood subependymal giant cell astrocytoma
382155|NCT01158300|recurrent childhood visual pathway and hypothalamic glioma
382156|NCT01158300|recurrent childhood visual pathway glioma
382157|NCT01158300|childhood central nervous system choriocarcinoma
382158|NCT01158300|childhood central nervous system germ cell tumor
382159|NCT01158300|childhood central nervous system germinoma
382160|NCT01158300|childhood central nervous system mixed germ cell tumor
382161|NCT01158300|childhood central nervous system teratoma
382162|NCT01158300|childhood central nervous system yolk sac tumor
382163|NCT01158300|childhood astrocytoma
382164|NCT01158300|childhood medulloepithelioma
382165|NCT01158300|childhood meningioma
382166|NCT01158300|childhood mixed glioma
382167|NCT01158300|childhood oligodendroglioma
382168|NCT01158300|childhood pineal parenchymal tumor
382169|NCT01158287|adenocarcinoma of the esophagus
382170|NCT01158287|recurrent esophageal cancer
382171|NCT01158287|recurrent gastric cancer
382172|NCT01158287|adenocarcinoma of the stomach
382173|NCT01158261|hemostasis
382174|NCT01158248|cervical adenocarcinoma
382175|NCT01158248|cervical adenosquamous cell carcinoma
382176|NCT01158248|cervical small cell carcinoma
382177|NCT01158248|stage IB cervical cancer
382178|NCT01158248|stage IIA cervical cancer
382179|NCT01158248|stage IIB cervical cancer
382180|NCT01158248|stage III cervical cancer
382181|NCT01158248|cervical squamous cell carcinoma
382182|NCT01158235|MRSA
382183|NCT01158235|nose
382184|NCT01158196|laser
382185|NCT01158196|keloid
382186|NCT01158196|scar
382187|NCT01158183|Outcomes
382188|NCT01158183|real world and web tool
382189|NCT01158183|electronic data capture
382190|NCT01158170|nonsmall cell lung cancer
382191|NCT01158170|brain metastasis
382192|NCT01158170|prophylactic cranial irradiation
382193|NCT01158144|Non-small cell lung cancer
382194|NCT01158144|Locally advanced
382195|NCT01158144|Radiotherapy
382196|NCT01158144|Concomitant Chemotherapy
382197|NCT01158144|Endostar
382198|NCT01158131|Gestational diabetes mellitus (GDM) in the most recent pregnancy
382199|NCT01158118|Precursor Cell Lymphoblastic Leukemia-Lymphoma
382200|NCT01158118|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
382201|NCT01158105|Steroid refractory chronic graft vs host disease (cGVHD)
382202|NCT01158105|Bortezomib
382203|NCT01158105|Velcade
382204|NCT01158079|Liver
382205|NCT01158079|Solid Tumors
382206|NCT01158079|Advanced Solid Tumors with Liver Involvement
382207|NCT01158066|NAFLD
382208|NCT01158066|Calcium score
382209|NCT01158066|Liver Fat
382210|NCT01158066|Visceral fat
382211|NCT01158066|excessive visceral fat
382212|NCT01158066|excessive liver fat accumulation
382213|NCT01158066|Biomarkers of insulin resistance (HOMA), inflammation (CRP) and (MDA-Paraoxonase)
382214|NCT01158040|Maternal intrapartum glycemic control
382215|NCT01158040|Pregestational diabetes
382216|NCT01158014|pterygium
382217|NCT01158014|conjunctival graft
382218|NCT01158014|recurrence
382219|NCT01158014|primary pterygium
382220|NCT01158001|Posttraumatic stress disorders
382221|NCT01158001|Telemedicine
382222|NCT01158001|Psychotherapy
382223|NCT01158001|Neuropsychological test
382224|NCT01158001|Depression
382225|NCT01157988|bulky diffuse large B cell lymphoma
382226|NCT01157988|90Y-ibritumomab tiuxetan
382227|NCT01157988|clinical response
382228|NCT01157988|Safety and toxicity
382229|NCT01157962|Sentinel Concept
382230|NCT01157962|Lymphadenectomy
382231|NCT01157962|Early Stage Cervical Cancer
382232|NCT01157962|Overall Survive
382233|NCT01157962|Improvement Therapy
382234|NCT01157936|hypertension
382235|NCT01157936|hyperuricemia
382236|NCT01157936|metabolic syndrome
382237|NCT01157923|Type 1 diabetes
382238|NCT01157923|Insulin Pump Therapy
382239|NCT01157910|Ear infection
382240|NCT01157910|Chronic
382241|NCT01157897|Malaria
382242|NCT01157897|Plasmodium Vivax
382243|NCT01157897|Vaccine
382244|NCT01157884|body composition
382245|NCT01157884|obesity
382246|NCT01157884|kidney transplantation
382247|NCT01157858|liver cyst
382248|NCT01157832|water pipe smoking acute effect
382249|NCT01157819|swimmer's ear
382250|NCT01157819|ear drops
382251|NCT01157819|ear foam
382252|NCT01157819|otic foam
382253|NCT01157819|ear infection
382254|NCT01157819|ear pain
382255|NCT01157819|ear inflammation
382256|NCT01157806|rectal cancer
382257|NCT01157806|unresectable synchronous metastases
382258|NCT01157806|pelvic radiochemotherapy
382259|NCT01157793|Dwarfism
382260|NCT01157793|Growth hormone deficiency
382261|NCT01157793|Growth hormone
382262|NCT01157780|Fish oil
382263|NCT01157767|exercise
382264|NCT01157767|lymphedema
382265|NCT01157767|post-operative chemotherapy
382266|NCT01157767|post-operative radiation
382267|NCT01157767|10-062
382268|NCT01157754|Infertility patients requiring IVF
382269|NCT01157754|good prognosis
382270|NCT01157741|Community based follow up, severely underweight children
382271|NCT01157728|Multiple sclerosis
382272|NCT01157728|Cognitive impairment
382273|NCT01157715|KH902
382274|NCT01157715|age-related macular degeneration (AMD)
382275|NCT01157715|choroidal neovascularization (CNV)
382276|NCT01157715|intravitreal injection
382277|NCT01157715|best corrected visual acuity (BCVA)
382278|NCT01157715|central retinal thickness
382279|NCT01157689|malaria
382280|NCT01157689|children
382281|NCT01157689|Guinea-Bissau
382282|NCT01157689|artemether
382283|NCT01157689|lumefantrine
382284|NCT01157689|effectiveness
382285|NCT01157676|open cystectomy
382286|NCT01157676|robotic assisted radical cystectomy
382287|NCT01157676|bladder cancer
382288|NCT01157663|Functional ankle instability
382289|NCT01157650|Fistulizing Crohn's disease
382290|NCT01157650|stem cells implant
382291|NCT01157624|hypoxia or hypercarbia during surgery under the drape
382292|NCT01157611|online based mentoring program,
382293|NCT01157611|type 1 diabetes,
382294|NCT01157611|blood glucose,
382295|NCT01157611|satisfaction score
382296|NCT01157598|gastric adenoma
382297|NCT01157598|early gastric cancer
382298|NCT01157572|Aortic valve insufficiency
382299|NCT01157572|Beta-blocker
382300|NCT01157533|Vancomycin
382301|NCT01157533|Pharmacokinetic testing
382302|NCT01157533|PK
382303|NCT01156545|BIBW 2992
382304|NCT01156545|Simvastatin
382305|NCT01156545|NSCLC
382306|NCT01156545|advanced stage
382307|NCT01156545|previously treated patients
382308|NCT01156545|non-adenocarcinoma
382309|NCT01156532|adalimumab therapy
382310|NCT01156532|Psoriasis
382311|NCT01156532|observational study
382312|NCT01156519|Infra-clinic cortisol adenoma
382313|NCT01156519|Salivary cortisol
382314|NCT01156519|Obesity
382315|NCT01156506|quality of life
382316|NCT01156506|patient education
382317|NCT01156506|rehabilitation
382318|NCT01156506|focus group interview
382319|NCT01156493|feeding intolerance
382320|NCT01156493|prematurity
382321|NCT01156480|necrotizing enterocolitis
382322|NCT01156480|NEC
382323|NCT01156480|premature
382324|NCT01156480|hydrocortisone
382325|NCT01156480|steroids
382326|NCT01156480|anti-inflammatory
382327|NCT01156467|Neurally adjusted ventilatory assist NAVA
382328|NCT01156467|Premature infant
382329|NCT01156467|Edi-signal
382330|NCT01156454|sentinel lymph node dissection
382331|NCT01156454|radiology
382332|NCT01156454|X-ray identification of nodes in a surgical specimen
382333|NCT01156441|Myocardial Infarction
382334|NCT01156441|Mitral Regurgitation
382335|NCT01156441|Percutaneous Coronary Intervention
382336|NCT01156428|Nephritic syndrome
382337|NCT01156428|Nephrotic syndrome
382338|NCT01156428|Proteinuria
382339|NCT01156428|Acute kidney injury
382340|NCT01156428|Chronic kidney disease
382341|NCT01156428|Lupus nephritis
382342|NCT01156415|agomelatine
382343|NCT01156415|Major Depressive Disorder
382344|NCT01156415|MDD
382345|NCT01156415|depression
382346|NCT01156402|Obesity
382347|NCT01156402|Pediatric Obesity
382348|NCT01156389|malaria
382349|NCT01156389|artemisinin-based combination therapy
382350|NCT01156350|Neuroblastoma - Haplo HSCT - Reduced Intensity Conditioning - immunotherapy NK
382351|NCT01156337|Heart failure III NYHA class
382352|NCT01156337|Furosemide
382353|NCT01156337|Sodium
382354|NCT01156337|water restriction
382355|NCT01156337|decompensated heart failure
382356|NCT01156337|Hypertonic saline solution
382357|NCT01156337|Moderate sodium restriction
382358|NCT01156324|IVF
382359|NCT01156324|Stress management
382360|NCT01156311|BG00012
382361|NCT01156311|MS
382362|NCT01156311|RRMS
382363|NCT01157507|Botulinum A toxin
382364|NCT01157507|Painful Bladder Syndrome (PBS)
382365|NCT01157507|Bladder overdistention
382366|NCT01157494|cerebral palsy
382367|NCT01157494|hemiplegia
382368|NCT01157494|upper limb
382369|NCT01157494|assessment
382370|NCT01157494|classification system
382371|NCT01157481|Diastolic Heart Failure
382372|NCT01157481|Heart failure with preserved ejection fraction
382373|NCT01157481|nifedipine
382374|NCT01157468|Systemic Lupus Erythematosus in Martinique
382375|NCT01157468|Hydrolase and DNase activities
382376|NCT01157455|Stent
382377|NCT01157455|Coronary artery diseases
382378|NCT01157442|prevention of maternal to child transmission of HIV
382379|NCT01157442|mhealth
382380|NCT01157442|access to antenatal care
382381|NCT01157442|pregnancy
382382|NCT01157429|Cognitive Behavior Therapy
382383|NCT01157429|Children
382384|NCT01157429|Adolescents
382385|NCT01157429|Pharmacotherapy
382386|NCT01157416|Cognitive Behavior Therapy
382387|NCT01157416|Children
382388|NCT01157416|Pharmacotherapy
382389|NCT01157403|mesenchymal stem cells
382390|NCT01157390|Term-infant
382391|NCT01157390|sn-2 palmitic acid
382392|NCT01157390|infant formula
382393|NCT01157351|Schizophrenia
382394|NCT01157351|Risperidone
382395|NCT01157351|Risperdal
382396|NCT01157351|Paliperidone palmitate
382397|NCT01157351|Aripiprazole
382398|NCT01157351|Haloperidol
382399|NCT01157351|Olanzapine
382400|NCT01157351|Paliperidone
382401|NCT01157351|Perphenazine
382402|NCT01157351|Quetiapine
382403|NCT01157338|Catheter
382404|NCT01157338|coronary artery disease
382405|NCT01157338|embolus
382406|NCT01157338|stroke
382407|NCT01157338|retinal emboli
382408|NCT01157325|Epidural analgesia
382409|NCT01157325|Latent analgesia
382410|NCT01157325|Active analgesia
382411|NCT01157325|Cesarean section
382412|NCT01157312|Polycystic ovary syndrome
382413|NCT01157312|clomiphene citrate
382414|NCT01157312|minimal stimulation
382415|NCT01157312|infertility treatment
382416|NCT01157299|Hemodynamics
382417|NCT01157299|Pediatric Intensive Care Unit
382418|NCT01157299|Low cardiac output
382419|NCT01157299|Thermodilution
382420|NCT01157299|Stroke volume
382421|NCT01157299|Global end-diastolic volume
382422|NCT01157299|Fluid responsiveness
382423|NCT01157299|Passive leg raising
382424|NCT01157299|Infant
382425|NCT01157286|OBSTRUCTIVE SLEEP APNEA LARINGECTOMY CPAP
382426|NCT01157273|Behavior
382427|NCT01157273|Anxiety
382428|NCT01157273|Communication
382429|NCT01157273|Voice
382430|NCT01157260|Indoxyl sulfate
382431|NCT01157260|AST-120
382432|NCT01157247|Anesthetic techniques
382433|NCT01157247|regional, spinal
382434|NCT01157247|Pain
382435|NCT01157247|lumbar puncture
382436|NCT01157247|Analgesia, local
382437|NCT01157247|Analgesia, intravenous
382438|NCT01157234|Hypertension
382439|NCT01157234|Kidney transplantation
382440|NCT01157234|Renal function
382441|NCT01157234|Nitric Oxide
382442|NCT01157234|Nebivolol
382443|NCT01157208|chronic pain
382444|NCT01157208|headache
382445|NCT01157208|nutrition
382446|NCT01157208|inflammation
382447|NCT01157208|complementary medicine
382448|NCT01157195|stroke
382449|NCT01157195|chronic
382450|NCT01157195|arm
382451|NCT01157195|rehabilitation
382452|NCT01157195|tele-health
382453|NCT01157182|Healthy
382454|NCT01157182|Bioequivalence
382455|NCT01157182|Post-Menopausal
382456|NCT01157169|Bioequivalence
382457|NCT01157169|Healthy
382458|NCT01157130|Breast Cancer
382459|NCT01157130|Exercise
382460|NCT01157130|CRP
382461|NCT01157130|C-reactive protein
382462|NCT01157130|BMI
382463|NCT01157130|Nevada Cancer Institute
382464|NCT01157130|Rehabilitation
382465|NCT01157130|Prescriptive exercise
382466|NCT01157130|Physical Activity
382467|NCT01157130|DEXA
382468|NCT01157130|Obesity
382469|NCT01157130|lifestyle intervention
382470|NCT01157130|Early Stage Breast Cancer Patients (stage 0-III)
382471|NCT01157117|food allergy
382472|NCT01157104|HCV
382473|NCT01157104|Hepatitis C
382474|NCT01157078|Major Depressive Disorder
382475|NCT01157078|MDD
382476|NCT01157078|Depression
382477|NCT01157078|Safety
382478|NCT01157078|add-on therapy
382479|NCT01157065|Wet AMD
382480|NCT01157065|Intravitreal Injection
382481|NCT01157065|Macular Degeneration
382482|NCT01157065|VEGF treatment
382483|NCT01157052|magnesium
382484|NCT01157052|calcium
382485|NCT01157052|adverse effects
382486|NCT01157052|kinetics, drug
382487|NCT01157039|glutamine
382488|NCT01157039|oxaliplatin
382489|NCT01157039|adverse effects
382490|NCT01157026|Breast cancer
382491|NCT01157026|Tocotrienol-rich fraction with tamoxifen
382492|NCT01157013|Positron Emission Tomography
382493|NCT01157013|Hepatocellular carcinoma
382494|NCT01157013|Liver Cancer
382495|NCT01157013|Sorafenib
382496|NCT01157013|Response Evaluation
382497|NCT01157000|Canagliflozin
382498|NCT01157000|Pharmacokinetic
382499|NCT01157000|Bioavailability
382500|NCT01156974|care management
382501|NCT01156974|chronic disease
382502|NCT01156974|outpatient
382503|NCT01156948|misoprostol
382504|NCT01156948|nulliparous
382505|NCT01156948|hysteroscopy
382506|NCT01156935|Neoplasm
382507|NCT01156935|Laugh-Yoga
382508|NCT01156935|Mood
382509|NCT01156935|Quality of life
382510|NCT01156922|Chronic fatigue syndrome
382511|NCT01156922|CFS
382512|NCT01156922|Myalgic encephalomyelitis
382513|NCT01156922|Rituximab
382514|NCT01156922|B-cell depletion
382515|NCT01156909|Chronic fatigue syndrome
382516|NCT01156909|CFS
382517|NCT01156909|Myalgic encephalomyelitis
382518|NCT01156909|Rituximab
382519|NCT01156909|B-cell depletion
382520|NCT01156896|Non-transferrin-bound iron
382521|NCT01156896|Iron stable isotopes
382522|NCT01156896|Iron deficiency
382523|NCT01156896|Malaria
382524|NCT01156896|Iron supplementation
382525|NCT01156896|Iron fortification
382526|NCT01156883|B-cell adult acute lymphoblastic leukemia
382527|NCT01156883|recurrent adult acute lymphoblastic leukemia
382528|NCT01156883|T-cell adult acute lymphoblastic leukemia
382529|NCT01156883|untreated adult acute lymphoblastic leukemia
382530|NCT01156844|Indacaterol
382531|NCT01156844|Asthma
382532|NCT01156844|Bronchodilation
382533|NCT01156844|Beta-agonist
382534|NCT01156831|Esophageal cancer
382535|NCT01156831|PET-CT planning
382536|NCT01156818|Wheeze measurements
382537|NCT01156805|Children
382538|NCT01156805|School-based program
382539|NCT01156805|Obesity
382540|NCT01156792|asthma
382541|NCT01156792|GSK2190915
382542|NCT01156779|SR-Exenatide
382543|NCT01156766|Fracture
382544|NCT01156766|Radius
382545|NCT01156766|Osteosynthesis
382546|NCT01156766|Metaphyseal
382547|NCT01156766|Pinning
382548|NCT01156766|Locking anterior plate
382549|NCT01156753|CR011-vcMMAE
382550|NCT01156753|locally advanced breast cancer
382551|NCT01156753|metastatic breast cancer
382552|NCT01156753|breast cancer
382553|NCT01156753|CDX-011
382554|NCT01156753|GPNMB
382555|NCT01156753|Targeted treatment for breast cancer
382556|NCT01156753|Locally advanced or metastatic breast cancer
382557|NCT01156740|streptococcal pharyngitis
382558|NCT01156740|randomized clinical trial
382559|NCT01156740|amoxicillin
382560|NCT01156740|intramuscular benzathine penicillin G.
382561|NCT01156727|OEF/OIF
382562|NCT01156727|Mental Health
382563|NCT01156727|Veterans
382564|NCT01156714|Parkinson's Disease
382565|NCT01156714|Treadmill Training
382566|NCT01156714|Exercise
382567|NCT01156714|Cognitive Training
382568|NCT01156714|Executive Function
382569|NCT01156714|Dual Task
382570|NCT01156701|Influenza
382571|NCT01156701|Zanamivir
382572|NCT01156701|Influenza prophylaxis
382573|NCT01156701|Relenza
382574|NCT01156688|medical abortion for pregnancy of less than 9 weeks gestation
382575|NCT01156675|Back pain
382576|NCT01156675|Pain
382577|NCT01156675|Spinal Diseases
382578|NCT01156675|Spinal Stenosis
382579|NCT01156675|Lumbar Vertebrae
382580|NCT01156675|Spinal Canal
382581|NCT01156662|Thrombus aspiration
382582|NCT01156662|Percutaneous coronary intervention
382583|NCT01156649|Obstructive sleep apnea
382584|NCT01156649|neurocognitive function
382585|NCT01156649|cognition
382586|NCT01156649|pediatrics
382587|NCT01156649|children
382588|NCT01156649|continuous positive airway pressure therapy
382589|NCT01156649|sham treatment
382590|NCT01156649|randomized clinical trial
382591|NCT01156649|behavior
382592|NCT01156649|treatment
382593|NCT01156636|Diastolic Heart Failure
382594|NCT01156636|Pulmonary Hypertension
382595|NCT01156623|EBUS-TBNA
382596|NCT01156623|NSCLC
382597|NCT01156623|Mediastinal lymph node
382598|NCT01156623|tuberculosis
382599|NCT01156610|Smoking
382600|NCT01156610|Smoking Cessation
382601|NCT01156610|Electronic Health Record
382602|NCT01156610|Telephone
382603|NCT01156597|diabetes
382604|NCT01156597|dyslipidemia
382605|NCT01156597|pioglitazone
382606|NCT01156597|HDL-Cholesterol
382607|NCT01156597|Reverse cholesterol transport
382608|NCT01156584|glioma
382609|NCT01156584|glioblastoma
382610|NCT01156584|glioblastoma multiforme
382611|NCT01156584|Grade IV astrocytoma
382612|NCT01156584|brain cancer
382613|NCT01156584|recurrent glioblastoma
382614|NCT01156584|GBM
382615|NCT01156584|AA
382616|NCT01156584|AOD
382617|NCT01156584|anaplastic astrocytoma
382618|NCT01156584|anaplastic oligodendroglioma
382619|NCT01156584|anaplastic oligoastrocytoma
382620|NCT01156584|malignant glioma
382621|NCT01156584|high grade glioma
382622|NCT01156272|Isolated aortic valve replacement
382623|NCT01156272|heart valve
382624|NCT01156259|B cell cll/lymphoma, human
382625|NCT01156246|Healthy volunteers
382626|NCT01156246|Dapagliflozin
382627|NCT01156246|Diabetes Type 2
382628|NCT01156246|Food interaction
382629|NCT01156233|evaluating precision of tube tip position with two methods
382630|NCT01156220|gender, diuretics, furosemide, aminohippuric acid
382631|NCT01156207|To establish the coupling between components of arterial load ( and components of LV myocardial deformations at baseline and 6 months after randomization.
382632|NCT01156207|To establish the role of EPCs on modulation of the components of arterial load and LV myocardial deformations and their coupling.
382633|NCT01156194|third stage, labor, postpartum hemorrhage, homeopathy, arnica, bellis perennis
382634|NCT01156181|Cervical mucus, Embryo transfer, ICSI cycle, Pregnancy rate
382635|NCT01156168|male breast cancer
382636|NCT01156168|stage IV breast cancer
382637|NCT01156168|recurrent breast cancer
382638|NCT01156155|rheumatoid arthritis
382639|NCT01156155|osteoarthritis
382640|NCT01156155|periodontal disease
382641|NCT01156142|oral complications of radiation therapy
382642|NCT01156142|mucositis
382643|NCT01156142|pain
382644|NCT01156142|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
382645|NCT01156142|recurrent squamous cell carcinoma of the hypopharynx
382646|NCT01156142|squamous cell carcinoma of the hypopharynx
382647|NCT01156142|recurrent squamous cell carcinoma of the larynx
382648|NCT01156142|recurrent verrucous carcinoma of the larynx
382649|NCT01156142|squamous cell carcinoma of the larynx
382650|NCT01156142|verrucous carcinoma of the larynx
382651|NCT01156142|recurrent adenoid cystic carcinoma of the oral cavity
382652|NCT01156142|recurrent mucoepidermoid carcinoma of the oral cavity
382653|NCT01156142|recurrent verrucous carcinoma of the oral cavity
382654|NCT01156142|adenoid cystic carcinoma of the oral cavity
382655|NCT01156142|mucoepidermoid carcinoma of the oral cavity
382656|NCT01156142|verrucous carcinoma of the oral cavity
382657|NCT01156142|squamous cell carcinoma of the lip and oral cavity
382658|NCT01156142|recurrent basal cell carcinoma of the lip
382659|NCT01156142|recurrent squamous cell carcinoma of the lip and oral cavity
382660|NCT01156142|basal cell carcinoma of the lip
382661|NCT01156142|metastatic squamous neck cancer with occult primary squamous cell carcinoma
382662|NCT01156142|recurrent metastatic squamous neck cancer with occult primary
382663|NCT01156142|untreated metastatic squamous neck cancer with occult primary
382664|NCT01156142|recurrent lymphoepithelioma of the nasopharynx
382665|NCT01156142|recurrent squamous cell carcinoma of the nasopharynx
382666|NCT01156142|lymphoepithelioma of the nasopharynx
382667|NCT01156142|squamous cell carcinoma of the nasopharynx
382668|NCT01156142|recurrent lymphoepithelioma of the oropharynx
382669|NCT01156142|recurrent squamous cell carcinoma of the oropharynx
382670|NCT01156142|lymphoepithelioma of the oropharynx
382671|NCT01156142|squamous cell carcinoma of the oropharynx
382672|NCT01156142|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
382673|NCT01156142|recurrent inverted papilloma of the paranasal sinus and nasal cavity
382674|NCT01156142|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
382675|NCT01156142|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
382676|NCT01156142|esthesioneuroblastoma of the paranasal sinus and nasal cavity
382677|NCT01156142|inverted papilloma of the paranasal sinus and nasal cavity
382678|NCT01156142|midline lethal granuloma of the paranasal sinus and nasal cavity
382679|NCT01156142|squamous cell carcinoma of the paranasal sinus and nasal cavity
382680|NCT01156142|high-grade salivary gland mucoepidermoid carcinoma
382681|NCT01156142|low-grade salivary gland mucoepidermoid carcinoma
382682|NCT01156142|recurrent salivary gland cancer
382683|NCT01156142|salivary gland acinic cell tumor
382684|NCT01156142|salivary gland adenocarcinoma
382685|NCT01156142|salivary gland adenoid cystic carcinoma
382686|NCT01156142|salivary gland anaplastic carcinoma
382687|NCT01156142|salivary gland malignant mixed cell type tumor
382688|NCT01156142|salivary gland poorly differentiated carcinoma
382689|NCT01156142|salivary gland squamous cell carcinoma
382690|NCT01156142|salivary gland cancer
382691|NCT01156142|tongue cancer
382692|NCT01156129|liver transplant
382693|NCT01156129|liver resection
382694|NCT01156116|CPAP
382695|NCT01156116|diabetes
382696|NCT01156116|sleep apnea
382697|NCT01156103|obesity
382698|NCT01156103|minority
382699|NCT01156103|child
382700|NCT01156103|physical fitness
382701|NCT01156103|school
382702|NCT01156103|physical activity
382703|NCT01156090|vectibix
382704|NCT01156077|antibiotic
382705|NCT01156077|Adolescents receiving antibiotics
382706|NCT01156064|Endoscopy
382707|NCT01156064|Confocal laser endomicroscopy
382708|NCT01156064|Digestive Diseases
382709|NCT01156051|ADHD
382710|NCT01156051|ADD
382711|NCT01156051|sleep disturbance
382712|NCT01156038|Atopy patch test
382713|NCT01156025|GV550
382714|NCT01156025|Acute adenoviral keratoconjunctivitis
382715|NCT01155986|analgesic
382716|NCT01155986|analgesics
382717|NCT01155986|pain
382718|NCT01155986|chronic pain
382719|NCT01155986|localized pain
382720|NCT01155986|focal pain
382721|NCT01155986|neuropathic pain
382722|NCT01155986|postoperative pain
382723|NCT01155986|topical analgesia
382724|NCT01155973|Hypertension.
382725|NCT01155973|Cardiovascular risk.
382726|NCT01155973|Monitoring.
382727|NCT01155973|Primary health care.
382728|NCT01155973|Randomised controlled trial.
382729|NCT01155973|Cluster analysis
382730|NCT01155960|Bioavailability
382731|NCT01155960|Anastrozole
382732|NCT01155960|Crossover
382733|NCT01155947|Bioavailability
382734|NCT01155947|Anastrozole
382735|NCT01155947|Crossover
382736|NCT01155934|Bioavailability
382737|NCT01155934|Crossover
382738|NCT01155934|Risperidone
382739|NCT01155921|Bioavailability
382740|NCT01155921|Crossover
382741|NCT01155921|Risperidone
382742|NCT01155908|Bioavailability
382743|NCT01155908|10 mg Amlodipine besylate/20 mg benazepril hydrochloride capsules
382744|NCT01155908|Crossover
382745|NCT01155895|Bioavailability
382746|NCT01155895|10 mg Amlopdipine besylate /20 mg Benazepril Hydrochloride
382747|NCT01155895|Crossover
382748|NCT01155869|alcohol dependence
382749|NCT01155869|homelessness
382750|NCT01155869|naltrexone
382751|NCT01155856|telemedicine
382752|NCT01155856|COPD
382753|NCT01155830|inflammatory cytokines
382754|NCT01155830|extracorporeal membrane oxygenation
382755|NCT01155830|ECMO
382756|NCT01155804|preparation of the delivery
382757|NCT01155804|lumbago
382758|NCT01155804|anxiety
382759|NCT01155804|urinary incontinence
382760|NCT01155778|Sanfilippo Syndrome Type A (MPS IIIA)
382761|NCT01155778|Recombinant Human Heparan N-Sulfatase (rhHNS)
382762|NCT01155778|Lysosomal Storage Disease (LSD)
382763|NCT01155778|Intrathecal Drug Delivery Device (IDDD)
382764|NCT01155765|Clopidogrel Resistance
382765|NCT01155765|prasugrel
382766|NCT01155765|Hemodialysis
382767|NCT01155752|sinusitis
382768|NCT01155752|cystic fibrosis
382769|NCT01155752|therapy
382770|NCT01155713|Neoplasms
382771|NCT01155713|Cancer
382772|NCT01155713|Tumors
382773|NCT01155713|Administration, oral
382774|NCT01155713|Capsules
382775|NCT01155713|CHIR258, CHIR-258, CHIR 258, TKI258, TKI-258, TKI 258,
382776|NCT01155713|Bioavailability,
382777|NCT01155713|Food
382778|NCT01155700|omalizumab
382779|NCT01155700|allergic asthma
382780|NCT01155700|pediatric patients
382781|NCT01155687|afghanistan
382782|NCT01155687|depression
382783|NCT01155687|anxiety
382784|NCT01155687|social stress
382785|NCT01155687|counseling
382786|NCT01155687|medication
382787|NCT01155687|psychotherapy
382788|NCT01155687|mental health
382789|NCT01155674|Innate immunity
382790|NCT01155674|Neutrophils
382791|NCT01155674|Band forms
382792|NCT01155648|Mechanical ventilation
382793|NCT01155648|Chest physiotherapy
382794|NCT01155648|Chest wall compression
382795|NCT01155635|Myocardial infarction
382796|NCT01155635|Adrenergic beta-Antagonists
382797|NCT01155635|Percutaneous coronary intervention
382798|NCT01155622|Hypothermia, induced
382799|NCT01155622|Cardiac arrest
382800|NCT01155622|Disability evaluation
382801|NCT01155622|Cardiac arrhythmia
382802|NCT01155622|Ventricular function
382803|NCT01155622|Internal cooling
382804|NCT01155622|Out-of-hospital cardiac arrest
382805|NCT01155622|Post-cardiac arrest syndrome
382806|NCT01155596|Acute respiratory failure patients in medical ICUs.
382807|NCT01155570|Psoriasis
382808|NCT01155557|Tension-Type Headache
382809|NCT01155557|Strength Capacity
382810|NCT01155557|Neck and Shoulder
382811|NCT01155544|Aripiprazole
382812|NCT01155544|Psychotic experiences
382813|NCT01155544|Substance abuse
382814|NCT01155544|Substance dependence
382815|NCT01155544|Craving
382816|NCT01155544|Mood
382817|NCT01155544|Substance use
382818|NCT01155531|Obesity
382819|NCT01155531|Overweight
382820|NCT01155531|Sertraline
382821|NCT01155531|Telenzepine
382822|NCT01155531|Decrease appetite
382823|NCT01155531|Reduce appetite
382824|NCT01155531|Lose weight
382825|NCT01155518|hypogonadism
382826|NCT01155518|diabetes
382827|NCT01155518|spermatogenesis
382828|NCT01155518|insulin resistance
382829|NCT01155492|lipopolysaccharides
382830|NCT01155492|etiology
382831|NCT01155492|inflammation
382832|NCT01155492|colonic bacteria
382833|NCT01155492|intestinal permeability
382834|NCT01155466|Idiopathic Parkinson Disease
382835|NCT01155466|Idiopathic Parkinson's Disease
382836|NCT01155453|BKM120
382837|NCT01155453|RAS RAF mutations,
382838|NCT01155453|triple negative breast cancer,
382839|NCT01155453|pancreatic cancer,
382840|NCT01155453|PI3K inhibitor,
382841|NCT01155453|MEK inhibitor
382842|NCT01155440|60 patients scheduled to have a colorectal surgery
382843|NCT01155440|recruit at Montreal General Hospital
382844|NCT01155401|acute upper gastrointestinal bleeding
382845|NCT01155401|patients with drug-induced upper gastrointestinal bleeding
382846|NCT01155401|routine management
382847|NCT01155388|Iron deficiency anemia
382848|NCT01155388|Feraheme
382849|NCT01155388|ferumoxytol
382850|NCT01155388|CKD
382851|NCT01155388|pediatric
382852|NCT01155388|nondialysis-dependent
382853|NCT01155388|The treatment of iron deficiency anemia in pediatric subjects with nondialysis dependent chronic kidney disease
382854|NCT01155375|Iron deficiency anemia
382855|NCT01155375|Feraheme
382856|NCT01155375|ferumoxytol
382857|NCT01155375|CKD
382858|NCT01155375|pediatric
382859|NCT01155375|dialysis-dependent
382860|NCT01155375|non-dialysis dependent
382861|NCT01155375|The treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease.
382862|NCT01155362|Human Placenta-Derived Cells for the Treatment of Moderate-to-Severe Crohn's Disease
382863|NCT01155349|brain fitness
382864|NCT01155349|cognitive training
382865|NCT01155349|cognitive intervention
382866|NCT01155349|speed of processing training
382867|NCT01155349|Parkinson's disease
382868|NCT01155336|Acute Coronary Syndrome
382869|NCT01155336|Fish Oils
382870|NCT01155336|Platelet Function Tests
382871|NCT01155336|Cardiac Electrophysiology
382872|NCT01155310|Exacerbation of COPD
382873|NCT01155310|Helium/Oxygen
382874|NCT01155310|ICU
382875|NCT01155310|Non-Invasive Ventilation
382876|NCT01155310|Patient with known or suspected COPD
382877|NCT01155310|patient Admitted in an ICU
382878|NCT01155310|Patient presenting current exacerbation of COPD
382879|NCT01155297|Quality of Life
382880|NCT01155297|Biological Markers
382881|NCT01155297|Renal Insufficiency
382882|NCT01155297|Resistance Training
382883|NCT01155297|Exercise
382884|NCT01155297|Chronic Kidney Failure
382885|NCT01155284|diabetes
382886|NCT01155284|HGB A1C
382887|NCT01155284|Beta Cell Regeneration
382888|NCT01155245|osteoporosis
382889|NCT01155245|HR-pQCT
382890|NCT01155245|PTH
382891|NCT01155232|osteoporosis
382892|NCT01155232|Forteo
382893|NCT01155232|Parathyroid hormone
382894|NCT01155232|HR-pQCT
382895|NCT01155219|Bilateral Glaucoma
382896|NCT01155219|Bilateral ocular hypertension
382897|NCT01155219|Bilateral primary open angle glaucoma
382898|NCT01155219|Bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day)
382899|NCT01155219|With local intolerance signs in at least one eye
382900|NCT01155206|glucagon,
382901|NCT01155206|high physiological dose and basal dose of glucagon
382902|NCT01155206|hepatic lipoprotein production,
382903|NCT01155206|free fatty acid
382904|NCT01155206|intestinal lipoprotein production
382905|NCT01155206|particle
382906|NCT01155206|glucagon affects production of fat in intestine and liver.
382907|NCT01155193|Children
382908|NCT01155193|Pre-term infants
382909|NCT01155193|Congenital heart disease
382910|NCT01155193|Infection
382911|NCT01155193|Respiratory syncytial virus
382912|NCT01155167|radial artery spasm
382913|NCT01155154|wounds and lacerations
382914|NCT01155154|hand
382915|NCT01155154|infection
382916|NCT01155154|Antibiotics
382917|NCT01155154|antibacterial agents
382918|NCT01155128|physical activity
382919|NCT01155128|exercise
382920|NCT01155128|sedentarism
382921|NCT01155128|chronic renal disease
382922|NCT01155128|failure renal chronic
382923|NCT01155128|proteinuria
382924|NCT01155128|progression
382925|NCT01155128|Renal Protective Effects of Exercise
382926|NCT01155128|quality of life changes with exercise in CKD
382927|NCT01155128|Endothelial progenitor cells in CKD
382928|NCT01155128|Chronic Kidney Disease and Ankle Brachial Index
382929|NCT01155115|pediatrics
382930|NCT01155115|CF
382931|NCT01155115|PCD
382932|NCT01155115|exacerbation
382933|NCT01155115|inflammatory markers
382934|NCT01155115|induced sputum
382935|NCT01155063|Exemestane
382936|NCT01155063|Adjuvant Treatment In Postmenopausal Women
382937|NCT01155063|Estrogen Receptor Positive Early Breast Cancer
382938|NCT01155063|Tamoxifen
382939|NCT01155050|overweight
382940|NCT01155050|obese
382941|NCT01155050|type II diabetes
382942|NCT01155050|hypertension
382943|NCT01155037|HIV, influenza A H1N1, vaccine
382944|NCT01155024|Lower extremity amputation
382945|NCT01155024|Prosthetic Sockets
382946|NCT01155024|Direct Manufactured (DM)
382947|NCT01155011|Older adults
382948|NCT01155011|physical activity
382949|NCT01155011|sedentary
382950|NCT01155011|retirement communities
382951|NCT01155011|advocacy
382952|NCT01155011|built environment
382953|NCT01155011|peer mentoring
382954|NCT01155011|walkability
382955|NCT01154998|non-specific interstitial pneumonia
382956|NCT01154985|omega-3 fatty acids
382957|NCT01154985|alanine transaminase
382958|NCT01154985|triglycerides
382959|NCT01154985|lipids
382960|NCT01154985|EPA
382961|NCT01154985|ethyl-EPA
382962|NCT01154985|ethyl icosapentate
382963|NCT01154985|Non Alcoholic steatohepatitis
382964|NCT01154985|Non Alcoholic fatty liver disease
382965|NCT01154985|fatty acids
382966|NCT01154972|breast
382967|NCT01154972|cancer
382968|NCT01154972|sentinel lymph node
382969|NCT01154959|Pulmonary TB
382970|NCT01154959|Immune response
382971|NCT01154959|ATT
382972|NCT01154959|Immune responses in pulmonary tuberculosis
382973|NCT01154959|Predictors for relapse
382974|NCT01154946|detrusor after-contraction
382975|NCT01154946|urodynamic
382976|NCT01154946|LUTS
382977|NCT01154946|urinary bladder, overactive
382978|NCT01154946|bladder dysfunction
382979|NCT01154933|type 2 diabetes
382980|NCT01154933|obesity
382981|NCT01154920|Head and Neck Cancer
382982|NCT01154920|HNSCC
382983|NCT01154920|Paclitaxel
382984|NCT01154920|Carboplatin
382985|NCT01154920|Cetuximab
382986|NCT01154920|Docetaxel
382987|NCT01154920|Taxotere
382988|NCT01154920|Cisplatin
382989|NCT01154920|Platinol-AQ
382990|NCT01154920|Platinol
382991|NCT01154920|CDDP
382992|NCT01154920|Fluorouracil
382993|NCT01154920|5-FU
382994|NCT01154920|Adrucil
382995|NCT01154920|Efudex
382996|NCT01154920|chemotherapy
382997|NCT01154920|radiation
382998|NCT01154920|Chemoradiotherapy
382999|NCT01154907|Uro-genital schistosomiasis
383000|NCT01154907|Female
383001|NCT01154907|South Africa
383002|NCT01154907|Rural
383003|NCT01154907|Sexually transmitted diseases
383004|NCT01154894|arachidonic acid
383005|NCT01154894|autism spectrum disorders
383006|NCT01154894|social interaction
383007|NCT01154894|randomized controlled trial
383008|NCT01154894|DHA
383009|NCT01154855|Periodontal disease
383010|NCT01154855|Gum disease
383011|NCT01154855|Dental
383012|NCT01154855|Inflammation
383013|NCT01154855|Microorganisms
383014|NCT01154855|Bacteria
383015|NCT01154842|FGF-23
383016|NCT01154842|Dialysis
383017|NCT01154842|plasma FGF-23 levels
383018|NCT01154842|echocardiography
383019|NCT01154829|dopamine
383020|NCT01154829|first episode
383021|NCT01154829|reward
383022|NCT01154829|cognition
383023|NCT01154829|MRI
383024|NCT01154829|fMRI
383025|NCT01154829|PPI
383026|NCT01154829|P300
383027|NCT01154829|P50 gating
383028|NCT01154829|endophenotypes
383029|NCT01154803|Supplementation
383030|NCT01154803|RUTF
383031|NCT01154803|Micronutrients
383032|NCT01154803|Plumpynut
383033|NCT01154803|Mixme
383034|NCT01154803|sprinkles
383035|NCT01154803|convalescence
383036|NCT01154803|weight
383037|NCT01154803|morbidity
383038|NCT01154790|healthy volunteers
383039|NCT01154777|Neurofeedback
383040|NCT01154777|Braintraining
383041|NCT01154777|Autism
383042|NCT01154777|Mild
383043|NCT01154777|Moderate
383044|NCT01154777|Mild to Moderate Autism
383045|NCT01154764|healthy male volunteers
383046|NCT01154751|Femoral artery stenosis
383047|NCT01154751|Peripheral vascular Disease
383048|NCT01154725|Patient education
383049|NCT01154725|Health-Related Quality of Life
383050|NCT01154725|patients with stomas
383051|NCT01154725|stomatherapy
383052|NCT01154725|health economics
383053|NCT01154712|Gambling
383054|NCT01154712|Deep TMS
383055|NCT01154712|addiction
383056|NCT01154712|Brain stimulation
383057|NCT01154699|Asthma
383058|NCT01154699|Nocturnal Asthma
383059|NCT01154699|Lung volumes
383060|NCT01154699|Deep inspiration
383061|NCT01154699|Obstructive sleep apnea
383062|NCT01154660|any operation that required for general anesthesia
383063|NCT01154634|Pharmacodynamic effect
383064|NCT01154634|Reflux inhibition
383065|NCT01154621|Phase I
383066|NCT01154621|Double-blind
383067|NCT01154621|Randomized
383068|NCT01154621|Placebo-controlled study
383069|NCT01154621|Safety and tolerability of single intravenous dose of AZD9742 in healthy elderly volunteers
383070|NCT01154608|Protein absorption in pancreatitis
383071|NCT01154608|Protein metabolism in pancreatitis
383072|NCT01154595|moderate acute malnutrition, prevention, Lipid-based supplement
383073|NCT01154582|ingestive behavior
383074|NCT01154569|drug absorption
383075|NCT01154569|azithromycin
383076|NCT01154569|obesity
383077|NCT01154569|bariatric surgery
383078|NCT01154556|Antiretroviral therapy experienced
383079|NCT01154556|failed NNRTI regime
383080|NCT01154543|Recurrent genital Herpes Simplex Virus
383081|NCT01154530|Gastroscopy
383082|NCT01154530|Bacteria
383083|NCT01154530|Chlorhexidine
383084|NCT01154530|General surgery
383085|NCT01154504|adrenomedullin
383086|NCT01154504|heart failure
383087|NCT01154504|ultrafiltration
383088|NCT01154504|hemofiltration
383089|NCT01154491|hip fractures
383090|NCT01154491|blood substitutes
383091|NCT01154491|blood transfusion
383092|NCT01154491|intravenous infusion
383093|NCT01154491|erythropoietin, recombinant
383094|NCT01154491|frail elderly
383095|NCT01154478|polyphenols omega-3 postprandial lipemia adipose tissue
383096|NCT01154465|Central venous catheterization
383097|NCT01154465|Obese
383098|NCT01154465|Ultrasound guidance
383099|NCT01154465|Jugular
383100|NCT01154465|Randomized
383101|NCT01154465|Intensive Care Unit
383102|NCT01154439|secondary acute myeloid leukemia
383103|NCT01154439|untreated adult acute myeloid leukemia
383104|NCT01154439|adult acute basophilic leukemia
383105|NCT01154439|adult acute eosinophilic leukemia
383106|NCT01154439|adult erythroleukemia (M6a)
383107|NCT01154439|adult pure erythroid leukemia (M6b)
383108|NCT01154439|adult acute megakaryoblastic leukemia (M7)
383109|NCT01154439|adult acute minimally differentiated myeloid leukemia (M0)
383110|NCT01154439|adult acute monoblastic leukemia (M5a)
383111|NCT01154439|adult acute monocytic leukemia (M5b)
383112|NCT01154439|adult acute myeloblastic leukemia with maturation (M2)
383113|NCT01154439|adult acute myeloblastic leukemia without maturation (M1)
383114|NCT01154439|adult acute myelomonocytic leukemia (M4)
383115|NCT01154439|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
383116|NCT01154439|adult acute myeloid leukemia with inv(16)(p13;q22)
383117|NCT01154439|adult acute myeloid leukemia with t(16;16)(p13;q22)
383118|NCT01154439|adult acute myeloid leukemia with t(8;21)(q22;q22)
383119|NCT01154400|casein protein
383120|NCT01154400|whey protein
383121|NCT01154400|hydrolysates
383122|NCT01154400|leucine
383123|NCT01154400|protein metabolism
383124|NCT01154400|COPD
383125|NCT01154387|Kidney
383126|NCT01154387|Renal
383127|NCT01154387|Transplant
383128|NCT01154387|Kidney Transplant
383129|NCT01154387|Kidney Failure
383130|NCT01154387|Induction
383131|NCT01154387|Monoclonal
383132|NCT01154387|Antibody
383133|NCT01154387|T cell
383134|NCT01154387|Anti-rejection
383135|NCT01154387|Immunosuppression
383136|NCT01154374|Diabetic Foot Ulcers (DFUs)
383137|NCT01154361|ACE inhibitor induced angioedema
383138|NCT01154361|Bradykinin
383139|NCT01154361|Non-itching edema
383140|NCT01154361|Non-allergic angioedema
383141|NCT01154361|Quincke edema
383142|NCT01154361|Drug induced angioedema
383143|NCT01154361|Bradykinin B2 receptor antagonist
383144|NCT01154361|Icatibant
383145|NCT01154361|HOE 140
383146|NCT01154348|Metformin
383147|NCT01154335|refractory metastatic colorectal cancer
383148|NCT01154309|Depression
383149|NCT01154309|Substance Use
383150|NCT01154309|Group Cognitive Behavioral Therapy
383151|NCT01154296|HIV
383152|NCT01154296|Rapid Testing
383153|NCT01154296|Counseling
383154|NCT01154296|STD
383155|NCT01154296|U.S.
383156|NCT01154270|cancer of the salivary glands
383157|NCT01154270|radiation
383158|NCT01154270|carbon ion therapy
383159|NCT01154257|Dental plaque
383160|NCT01154257|Gingivitis
383161|NCT01154244|Insulin resistance
383162|NCT01154244|Insulin deficiency
383163|NCT01154244|HOMA-IR
383164|NCT01154244|Drug naive
383165|NCT01154244|Diabetes mellitus, type II
383166|NCT01154231|BeneFIX Regulatory Post Marketing Commitment Plan
383167|NCT01154218|bioequivalence
383168|NCT01154218|food effect
383169|NCT01154218|pharmacokinetics
383170|NCT01154218|crizotinib
383171|NCT01154192|PCOS
383172|NCT01154192|oligomenorrhea
383173|NCT01154192|irregular menses
383174|NCT01154192|hyperandrogenemia
383175|NCT01154192|elevated testosterone
383176|NCT01154192|adolescents
383177|NCT01154192|androgens
383178|NCT01154192|ovary
383179|NCT01154192|LH
383180|NCT01154179|permissive underfeeding
383181|NCT01154179|hypocaloric feeding
383182|NCT01154179|artificial nutrition
383183|NCT01154140|open label
383184|NCT01154140|randomized Phase 3
383185|NCT01154140|first line treatment
383186|NCT01154140|non squamous lung cancer
383187|NCT01154140|ALK translocation event positive
383188|NCT01154127|NVA237
383189|NCT01154127|COPD
383190|NCT01154127|bronchodilator
383191|NCT01154127|exercise endurance
383192|NCT01154114|healthy volunteer
383193|NCT01154114|hepatic impairment
383194|NCT01154114|darapladib
383195|NCT01154114|atherosclerosis
383196|NCT01154088|Adolescent
383197|NCT01154088|Vaccine, conjugate
383198|NCT01154088|Adult
383199|NCT01154088|Neisseria meningitidis
383200|NCT01154088|Immunogenicity
383201|NCT01154088|Meningococcal vaccine
383202|NCT01154088|Safety
383203|NCT01154075|Liver transplant
383204|NCT01154075|Adherence
383205|NCT01154075|Compliance
383206|NCT01154075|Tacrolimus
383207|NCT01154062|age-related macular degeneration
383208|NCT01154062|pazopanib
383209|NCT01154062|choroidal neovascularization
383210|NCT01154062|GW786034
383211|NCT01154049|Schistosomiasis
383212|NCT01154049|Vaccine
383213|NCT01154049|sm14
383214|NCT01154023|Sleep Initiation and Maintenance Disorders
383215|NCT01154023|Behavior Therapy
383216|NCT01154010|PEMF
383217|NCT01154010|iritis
383218|NCT01154010|anterior uveitis
383219|NCT01153958|Vaginosis, Bacterial
383220|NCT01153958|Colposeptine
383221|NCT01153958|Metronidazole
383222|NCT01153945|Hypothyroid and non hypothyroid
383223|NCT01153932|968
383224|NCT01153932|muscular dystrophy
383225|NCT01153932|duchenne
383226|NCT01153932|DMD
383227|NCT01153906|autoimmune diseases
383228|NCT01153906|HPV vaccine
383229|NCT01153906|papillomavirus
383230|NCT01153906|human papillomavirus
383231|NCT01153906|HPV
383232|NCT01153893|Pneumococcal disease
383233|NCT01153893|Pneumococcal vaccine
383234|NCT01153893|Catch-up vaccination
383235|NCT01153893|Immunogenicity
383236|NCT01153893|Booster vaccination
383237|NCT01153893|Safety
383238|NCT01153880|Altabax
383239|NCT01153880|United States
383240|NCT01153880|topical
383241|NCT01153880|Mupirocin
383242|NCT01153880|Retapamulin
383243|NCT01153880|Bactroban
383244|NCT01153867|Schema Focused Therapy
383245|NCT01153867|Chronic Depression
383246|NCT01153867|Mechanisms of Change
383247|NCT01153854|acute diarrhea
383248|NCT01153854|Acute diarrhea (three or more watery or semi-watery bowel movements for at least one day lasting no more than 5 days before being admitted)
383249|NCT01153841|Pneumococcal vaccine
383250|NCT01153828|Altargo
383251|NCT01153828|Bactroban
383252|NCT01153828|Fucidin
383253|NCT01153828|Fusidic acid
383254|NCT01153828|Mupirocin
383255|NCT01153828|topical
383256|NCT01153828|Retapamulin
383257|NCT01153828|United Kingdom
383258|NCT01153815|efficacy
383259|NCT01153815|Spasticity, Post-Stroke
383260|NCT01153815|safety
383261|NCT01153815|Botulinum toxin type A
383262|NCT01153815|placebo
383263|NCT01153815|spasticity
383264|NCT01153802|Positron Emission Tomography
383265|NCT01153802|serotonin
383266|NCT01153802|inhibitor of the neurotransmitters
383267|NCT01153802|safety of single oral doses
383268|NCT01153802|norepinephrine
383269|NCT01153802|dopamine
383270|NCT01153789|Vergence-accommodation evaluation
383271|NCT01153789|Vergence and postural control
383272|NCT01153789|Dynamic visual acuity
383273|NCT01153776|Arterial switch operation,
383274|NCT01153776|Transposition of the great arteries,
383275|NCT01153776|Congenital heart diseases
383276|NCT01153776|CT coronary angiography,
383277|NCT01153763|Metastatic melanoma
383278|NCT01153763|BRAF mutant
383279|NCT01153763|Melanoma
383280|NCT01153763|BRAF mutant metastatic melanoma
383281|NCT01153750|cholangiocellular carcinoma
383282|NCT01153750|bile duct cancer
383283|NCT01153737|Neck pain
383284|NCT01153737|Primary Health Care
383285|NCT01153737|Manual Therapy
383286|NCT01153737|TENS
383287|NCT01153685|Fluviral®Influenza
383288|NCT01153659|rabeprazole
383289|NCT01153659|esomeprazole
383290|NCT01153659|h. pylori-negative
383291|NCT01153659|nocturnal acid breakthrough
383292|NCT01153659|intragastric pH, PK/PD
383293|NCT01153659|effect on gastric pH in healthy, H. pylori-Negative subjects
383294|NCT01153646|HIV
383295|NCT01153646|Gene Transfer
383296|NCT01153646|T-Cell Immunotherapy
383297|NCT01153646|HIV-1 infected patients who have failed anti-retroviral therapy
383298|NCT01153620|Acute traumatic wounds
383299|NCT01153607|Alzheimer's disease
383300|NCT01153607|Diagnostic imaging
383301|NCT01153607|PET diagnosis
383302|NCT01153607|PET tracer
383303|NCT01153594|Substance Use Disorders
383304|NCT01153594|Relapse
383305|NCT01153594|Recovery
383306|NCT01153594|Disease Management
383307|NCT01153594|Long term outcomes
383308|NCT01153594|Addiction Treatment
383309|NCT01153568|Vitamin D
383310|NCT01153568|osteoporosis
383311|NCT01153568|african american women
383312|NCT01153529|PTSD
383313|NCT01153516|Type 2 diabetes
383314|NCT01153516|Bariatric surgery
383315|NCT01153516|Obesity
383316|NCT01153516|Weight loss
383317|NCT01153503|Postoperative pain, TAP block, Hysterectomy
383318|NCT01153490|Quetiapine
383319|NCT01153490|Psychotic experiences
383320|NCT01153490|Cannabis dependence
383321|NCT01153490|Craving
383322|NCT01153490|Mood
383323|NCT01153490|Substance use
383324|NCT01153451|Pending tests
383325|NCT01153451|Discharge
383326|NCT01153451|Awareness
383327|NCT01153451|Care transitions
383328|NCT01153438|Diabetes
383329|NCT01153438|Obesity
383330|NCT01153438|Bariatric surgery
383331|NCT01153438|Gut hormones
383332|NCT01153438|Glucagon like peptide 1
383333|NCT01153438|Insulin
383334|NCT01153425|Osteoporosis
383335|NCT01153425|Osteopenia
383336|NCT01153425|Fracture Risk
383337|NCT01153425|teriparatide or Forteo
383338|NCT01153425|zoledronic acid or Reclast
383339|NCT01153399|Non Small Cell Lung Cancer
383340|NCT01153399|EGFR mutations
383341|NCT01153386|Pulmonary arterial hypertension
383342|NCT01153386|Treprostinil
383343|NCT01153386|Pharmacokinetics
383344|NCT01153373|Detection of tobacco, alcohol, and drug use.
383345|NCT01153347|Major Depressive Disorder
383346|NCT01153347|MDD
383347|NCT01153347|Depression
383348|NCT01153347|Safety
383349|NCT01153347|add-on therapy
383350|NCT01153321|Respiratory disease
383351|NCT01153321|chronic obstructive pulmonary disease
383352|NCT01153308|Morbid Obesity
383353|NCT01153308|Obesity
383354|NCT01153308|Weight Loss
383355|NCT01153308|Bariatric Surgery
383356|NCT01153295|IBS
383357|NCT01153295|Irritable bowel syndrome
383358|NCT01153295|diagnosis
383359|NCT01153295|safety
383360|NCT01153295|Health related quality of life
383361|NCT01153282|Breast Cancer patients
383362|NCT01153269|Human Immunodeficiency Virus
383363|NCT01153269|Co-infection with Hepatitis B or Hepatitis C
383364|NCT01153269|Tolerability
383365|NCT01153269|Effectiveness
383366|NCT01153243|inflammatory markers
383367|NCT01153230|PQ
383368|NCT01153217|Tenofovir
383369|NCT01153217|HIV-infection
383370|NCT01153217|BMD
383371|NCT01153217|Osteoporosis
383372|NCT01153217|Osteopenia
383373|NCT01153204|Erectile Dysfunction
383374|NCT01153204|Group Psychotherapy
383375|NCT01153204|Sildenafil [Substance Name]
383376|NCT01153204|Patient Satisfaction
383377|NCT01153204|Efficacy
383378|NCT01153204|Randomized Controlled Trial [Publication Type]
383379|NCT01153191|colorectal surgery
383380|NCT01153165|Refractory
383381|NCT01153165|Asthma
383382|NCT01153165|Depression
383383|NCT01153152|wisdom teeth
383384|NCT01153152|acute pulpitis
383385|NCT01153152|extraction
383386|NCT01153152|pain
383387|NCT01153152|Pain Following Removal of Wisdom Teeth with Acute Pulpitis
383388|NCT01153139|Transcranial Magnetic Stimulation
383389|NCT01153139|Depression
383390|NCT01153139|Theta Burst Stimulation
383391|NCT01153126|Diagnostic Imaging
383392|NCT01153126|Breast Screening
383393|NCT01153126|Breast Cancer
383394|NCT01153126|To be eligible for the study, subjects must:
383395|NCT01153126|Be females at least 18 years of age,
383396|NCT01153126|Have had their screening mammogram performed at the UW Breast Center,
383397|NCT01153126|Be able to read and write English at the 6th grade level (as shown by their, ability to understand the informed consent),
383398|NCT01153126|Have access to a computer with internet capability.
383399|NCT01153113|adenocarcinoma of the prostate
383400|NCT01153113|metastatic prostate adenocarcinoma, Stage (T1-4, N+, M0) or (T1-4, N0-3, M+)
383401|NCT01153113|rising PSA levels while maintained on LHRH analogues
383402|NCT01153100|Diabetes
383403|NCT01153074|Bronchopleural fistula
383404|NCT01153074|Bronchoscopy
383405|NCT01153048|Intensification of Education
383406|NCT01153048|learning nest methodology
383407|NCT01153048|peer educators
383408|NCT01153048|type 2 diabetes
383409|NCT01153048|Mali
383410|NCT01153048|the focus of this study is on the intensification of education on the treatment of type 2 diabetes
383411|NCT01153035|Breast Conservation Therapy
383412|NCT01153035|Lumpectomy
383413|NCT01153035|Radiofrequency Ablation
383414|NCT01153035|Radiation
383415|NCT01153022|Musculoskeletal manipulations
383416|NCT01153022|Muscle spasticity
383417|NCT01153009|Major Depressive Disorder
383418|NCT01153009|Depression
383419|NCT01153009|Melancholia
383420|NCT01153009|Drug Therapy
383421|NCT01152996|Depression
383422|NCT01152996|Melancholia
383423|NCT01152996|Paraphrenia
383424|NCT01152996|Drug Therapy
383425|NCT01152983|Finger sticks
383426|NCT01152983|Rapid Ring
383427|NCT01152983|Finger sticks method of obtaining blood for diagnostic testing
383428|NCT01152957|diabetes
383429|NCT01152957|cardiovascular
383430|NCT01152957|chronic
383431|NCT01152957|Community Health Workers
383432|NCT01152957|behavioral
383433|NCT01152957|social
383434|NCT01152957|diet
383435|NCT01152957|exercise
383436|NCT01152957|patient
383437|NCT01152957|cholesterol
383438|NCT01152957|A1C
383439|NCT01152957|glucose
383440|NCT01152944|Symptomatic intracranial atherosclerotic disease enrolled in the medical arm of SAMMPRIS
383441|NCT01152931|Antioxidants
383442|NCT01152931|Micronutrients
383443|NCT01152931|Malaria
383444|NCT01152931|focus is to determine the effect of antioxidant micronutrients in malaria
383445|NCT01152918|HIV Prevention
383446|NCT01152918|HIV Treatment
383447|NCT01152918|HIV Test and Treat Model of Prevention
383448|NCT01152918|ART for Prevention
383449|NCT01152918|Prevention for HIV Positives
383450|NCT01152918|Financial Incentives
383451|NCT01152918|Computer-delivered risk-reduction counseling
383452|NCT01152905|Neuromuscular blockade
383453|NCT01152905|Neuromuscular blocking agents
383454|NCT01152905|Atracurium
383455|NCT01152905|Nitrous oxide
383456|NCT01152892|end stage renal disease
383457|NCT01152892|chronic kidney disease
383458|NCT01152892|cardiovascular event
383459|NCT01152892|sudden cardiac death
383460|NCT01152892|autonomic function
383461|NCT01152879|Parenteral Nutrition
383462|NCT01152879|Quality of Life
383463|NCT01152866|Multifollicular stimulation
383464|NCT01152866|Pregnancy
383465|NCT01152866|Reproductive Techniques, Assisted
383466|NCT01152866|Fertilization in Vitro
383467|NCT01152866|Infertility
383468|NCT01152853|advanced gastric cancer
383469|NCT01152853|HER2
383470|NCT01152853|PF00299804
383471|NCT01152840|Adenoid cystic carcinoma
383472|NCT01152840|RAD001
383473|NCT01152827|Pheochromocytoma
383474|NCT01152827|extra-adrenal paraganglioma
383475|NCT01152827|non-functioning carcinoid
383476|NCT01152827|RAD001
383477|NCT01152814|Seasonal influenza
383478|NCT01152814|Vaccine
383479|NCT01152801|mRCC,
383480|NCT01152801|everolimus,
383481|NCT01152801|mTOR,
383482|NCT01152801|intolerant of VEGF-therapies
383483|NCT01152775|partnered surgical decision-making
383484|NCT01152775|impact of multimedia-based teaching
383485|NCT01152775|patient education
383486|NCT01152775|understanding and retention by patients
383487|NCT01152762|Physiotherapy, COPD, effectiveness, primary care
383488|NCT01152749|Smoking Cessation
383489|NCT01152749|Nicotine pharmacokinetics
383490|NCT01152736|Smoking Cessation, Nicotine pharmacokinetics
383491|NCT01152723|Smoking Cessation, Nicotine pharmacokinetics
383492|NCT01152710|capecitabine
383493|NCT01152710|chemoradiation
383494|NCT01152710|rectal cancer
383495|NCT01152710|phase II study
383496|NCT01152697|nonadherence
383497|NCT01152697|noncompliance
383498|NCT01152697|homeless
383499|NCT01152697|schizophrenia
383500|NCT01152697|schizoaffective
383501|NCT01152684|CAM
383502|NCT01152684|HIV-Positive
383503|NCT01152684|Latinos
383504|NCT01152684|US-Mexico Border region
383505|NCT01152684|San Diego-Tijuana
383506|NCT01152684|Identify the nature and extent of complementary and alternative medicine use among HIV-positive Latinos in the US-Mexico border region
383507|NCT01152658|Partial supraspinatus tear
383508|NCT01152658|partial tear ssp per echo
383509|NCT01152645|Advanced/recurrent gastric cancer
383510|NCT01152632|acupuncture
383511|NCT01152632|migraine
383512|NCT01152632|specific acupoints
383513|NCT01152632|brain network
383514|NCT01152580|melatonin
383515|NCT01152580|menopause
383516|NCT01152580|perimenopause
383517|NCT01152580|sleep
383518|NCT01152580|osteoporosis
383519|NCT01152580|osteopenia
383520|NCT01152580|anxiety
383521|NCT01152580|depression
383522|NCT01152580|hypertension
383523|NCT01152567|Hypertension
383524|NCT01152567|ACE
383525|NCT01152567|ARB
383526|NCT01152567|real life data
383527|NCT01152567|CVD
383528|NCT01152567|cost effectiveness
383529|NCT01152554|Major Depressive Disorder
383530|NCT01152554|MDD
383531|NCT01152554|Depression
383532|NCT01152554|Safety
383533|NCT01152554|add-on therapy
383534|NCT01152541|Keratoconus
383535|NCT01152541|Corneal Ectasia
383536|NCT01152541|Collagen Crosslinking
383537|NCT01152541|Riboflavin
383538|NCT01152528|bacterial vaginosis
383539|NCT01152528|screening
383540|NCT01152528|abortion
383541|NCT01152528|preterm delivery
383542|NCT01152515|safety and efficacy of maintaining a remifentanil infusion during extubation in propofol-remifentanil sedated patients after surgery
383543|NCT01152502|Post operative conditions, paracetamol metabolites
383544|NCT01152489|Pain
383545|NCT01152476|healthy pediatric patients undergoing tonsillectomy and adenoidectomy
383546|NCT01152463|thoracic ultrasound (US)
383547|NCT01152463|post-op care
383548|NCT01152463|pneumothorax
383549|NCT01152463|pleural effusion
383550|NCT01152424|Acute eosinophilic pneumonia
383551|NCT01152424|Exhaled nitric oxide
383552|NCT01152411|Renal Failure
383553|NCT01152411|Chronic Kidney Disease
383554|NCT01152411|Chronic Renal Failure
383555|NCT01152398|Breast cancer
383556|NCT01152398|Vaccine
383557|NCT01152398|Metastatic
383558|NCT01152398|HER-2-positive
383559|NCT01152398|Phase I
383560|NCT01152398|HER-2 Positive Breast Cancer
383561|NCT01152385|Type 2 diabetes mellitus
383562|NCT01152385|Japanese
383563|NCT01152385|phase 2
383564|NCT01152385|AZD1656
383565|NCT01152385|efficacy
383566|NCT01152385|dose regimen
383567|NCT01152385|pharmacokinetics
383568|NCT01152359|obesity
383569|NCT01152359|diet, low carbohydrate
383570|NCT01152359|diet, fat-restricted
383571|NCT01152359|food preferences
383572|NCT01152359|quality of life
383573|NCT01152359|patient compliance
383574|NCT01152346|Bioequivalence
383575|NCT01152346|Myelodysplastic Syndrome
383576|NCT01152346|MDS
383577|NCT01152346|Azacitidine
383578|NCT01152320|Asthma
383579|NCT01152320|Spirometry
383580|NCT01152320|Pediatric
383581|NCT01152320|Primary Health Care
383582|NCT01152320|Education, Distance
383583|NCT01152307|Depression
383584|NCT01152307|Depressive disorder
383585|NCT01152307|Decision Making
383586|NCT01152307|Decision Aids
383587|NCT01152307|Decision Quality Instrument
383588|NCT01152294|Menopause
383589|NCT01152294|Decision making
383590|NCT01152294|Decision aids
383591|NCT01152294|Decision quality instrument
383592|NCT01152281|retention
383593|NCT01152281|attrition
383594|NCT01152281|empowering
383595|NCT01152281|reactance
383596|NCT01152281|motivational
383597|NCT01152281|goals
383598|NCT01152281|Basic control
383599|NCT01152281|Control with stories of people with AIDS
383600|NCT01152281|Instrumental
383601|NCT01152281|Instrumental and Empowering
383602|NCT01152268|sperm banking
383603|NCT01152268|Adolescent males
383604|NCT01152268|Infertility
383605|NCT01152268|Adolescents diagnosed with cancer
383606|NCT01152255|Treatment of HIV-1 Infection
383607|NCT01152242|Insulin
383608|NCT01152203|Bendamustine
383609|NCT01152203|Bevacizumab
383610|NCT01152177|Heading Health Plan Implementation
383611|NCT01152177|General Practice
383612|NCT01152177|Point of care testing
383613|NCT01152177|education
383614|NCT01152164|quality of life
383615|NCT01152164|rectal cancer
383616|NCT01152151|Heading Health Plan Implementation
383617|NCT01152151|General Practice
383618|NCT01152151|Point of care testing
383619|NCT01152151|education
383620|NCT01152138|Acute myocardial infarction
383621|NCT01152138|Closed cell stent
383622|NCT01152138|Open cell stent
383623|NCT01152138|primary percutaneous coronary intervention
383624|NCT01152125|Osteoarthritis
383625|NCT01152125|stem cell implantation
383626|NCT01152125|bone marrow
383627|NCT01152125|autologous
383628|NCT01152112|morcellator
383629|NCT01152112|hysteroscope
383630|NCT01152112|myomectomy
383631|NCT01152112|polypectomy
383632|NCT01152112|uterine fibroids
383633|NCT01152112|uterine polyps
383634|NCT01152112|office
383635|NCT01152112|cost
383636|NCT01152112|local anesthetic
383637|NCT01152112|cervical block
383638|NCT01152112|pain management
383639|NCT01152099|Postmastectomy
383640|NCT01152086|Physical activity
383641|NCT01152086|mountain hiking
383642|NCT01152086|exercise
383643|NCT01152086|training program
383644|NCT01152086|hopelessness
383645|NCT01152086|chronic suicidality
383646|NCT01152086|depression
383647|NCT01152086|suicide attempt
383648|NCT01152086|suicide
383649|NCT01152073|Cholesterol
383650|NCT01152073|Statin
383651|NCT01152073|Nutraceuticals
383652|NCT01152073|Niacin
383653|NCT01152073|Hyperlipidemia
383654|NCT01152073|Liquid
383655|NCT01152060|remission of proteinuria
383656|NCT01152060|HBVe-antigen
383657|NCT01152047|oxytocin
383658|NCT01152047|satiety
383659|NCT01152047|dyspepsia
383660|NCT01152034|Bipolar disorder
383661|NCT01152034|psychosocial intervention
383662|NCT01152034|group therapy
383663|NCT01152034|relapse prevention
383664|NCT01152034|parasuicide
383665|NCT01152034|Recurrence
383666|NCT01152034|hospitalization
383667|NCT01152034|Medication adherence
383668|NCT01152034|Self-Injurious Behavior
383669|NCT01152034|Quality of Life
383670|NCT01152021|dexmedetomidine
383671|NCT01152021|propofol
383672|NCT01152021|sedation
383673|NCT01152021|MRI
383674|NCT01152021|scanning
383675|NCT01152021|pediatric
383676|NCT01152021|children
383677|NCT01152021|Magnetic Resonance Imaging
383678|NCT01152008|Microcirculation
383679|NCT01152008|laser flowmetry
383680|NCT01152008|Skin
383681|NCT01152008|Physiology
383682|NCT01151995|Clinical Trial Monitoring
383683|NCT01151995|Effectiveness of remote monitoring
383684|NCT01151995|Efficiency of remote monitoring
383685|NCT01151995|Costs of remote monitoring
383686|NCT01151982|Depression
383687|NCT01151982|Primary prevention.
383688|NCT01151982|Primary health care.
383689|NCT01151982|Randomised controlled trial.
383690|NCT01151969|Health Service Misuse
383691|NCT01151969|Overutilization of Health Services
383692|NCT01151969|Primary Health Care
383693|NCT01151969|Cost Effectiveness
383694|NCT01151969|Quality of life
383695|NCT01151969|Randomised Controlled Trial
383696|NCT01151969|Multilevel analysis
383697|NCT01151956|observational study
383698|NCT01151956|actinic keratosis
383699|NCT01151956|imiquimod
383700|NCT01151943|cesarean section
383701|NCT01151943|continuous wound infiltration
383702|NCT01151943|transversus abdominis plane block
383703|NCT01151930|Advanced solid tumor failed with standard therapy
383704|NCT01151917|Bilio-pancreatic diversion
383705|NCT01151917|morbid obesity
383706|NCT01151917|insulin resistance
383707|NCT01151917|proteomics
383708|NCT01151891|Pedal puncture wounds
383709|NCT01151891|Infection in pedal puncture wounds
383710|NCT01151891|Diabetes education and pedal puncture wounds
383711|NCT01151878|constipation
383712|NCT01151878|children
383713|NCT01151865|Delirium
383714|NCT01151865|Intensive Care Unit
383715|NCT01151865|Dexmedetomidine
383716|NCT01151852|Imatinib
383717|NCT01151852|Re-challenge
383718|NCT01151839|Esophagus
383719|NCT01151839|squamous cell carcinoma
383720|NCT01151839|neoadjuvant chemoradiation
383721|NCT01151826|Lung transplantation
383722|NCT01151826|Primary Graft Dysfunction
383723|NCT01151826|Extravascular Lung Water
383724|NCT01151826|Receptor for Advanced Glycation Endproducts (RAGE)
383725|NCT01151826|Intercellular Adhesion Molecule-1 (ICAM-1)
383726|NCT01151800|ACS
383727|NCT01151800|Interactive Voice Response Technology
383728|NCT01151800|Best Practice Guidelines
383729|NCT01151800|Health Care Utilization
383730|NCT01151800|Outcome Assessment
383731|NCT01151787|migraine
383732|NCT01151735|Angioedema
383733|NCT01151735|Hereditary Diseases
383734|NCT01151735|Orphan Disease
383735|NCT01151735|HAE
383736|NCT01151709|Gout
383737|NCT01151709|Chronic condition management
383738|NCT01151709|Gout management
383739|NCT01151696|Pain
383740|NCT01151696|morphine
383741|NCT01151696|hydroxyzine
383742|NCT01151696|acute pain
383743|NCT01151696|traumatic pain
383744|NCT01151696|anxiety
383745|NCT01151696|post trauma stress
383746|NCT01151696|post trauma anxiety
383747|NCT01151696|post trauma disorders
383748|NCT01151683|hypertension
383749|NCT01151683|endothelial dysfunction
383750|NCT01151670|radiation therapy
383751|NCT01151670|cognitive dysfunction
383752|NCT01151670|brain tumor
383753|NCT01151670|memory problems
383754|NCT01151670|short term memory loss
383755|NCT01151657|IBS
383756|NCT01151657|Irritable bowel syndrome
383757|NCT01151657|Probiotics
383758|NCT01151657|Treatment
383759|NCT01151657|Adequate relief
383760|NCT01151644|H1N1 VACCINE
383761|NCT01151644|INFLUENZA
383762|NCT01151644|RHEUMATIC DISEASES
383763|NCT01151644|ANTI-H1N1 IMMUNIZATION
383764|NCT01151592|Iron deficiency anemia in Chronic Kidney Disease Patients
383765|NCT01151579|Tachycardia
383766|NCT01151579|tachyarrhythmias
383767|NCT01151579|bronchodilator therapy
383768|NCT01151579|Critically ill patients
383769|NCT01151566|Ultrasound
383770|NCT01151566|Contrast enhanced Ultrasound (CEUS)
383771|NCT01151566|Nephrotoxicity
383772|NCT01151566|CT contrast agents
383773|NCT01151553|Cardiology
383774|NCT01151553|Cardiomyopathy
383775|NCT01151553|Cardiovascular Disease
383776|NCT01151553|Cardiac Resynchronization Therapy (CRT)
383777|NCT01151540|Epilepsy
383778|NCT01151540|Seizures
383779|NCT01151514|No referral
383780|NCT01151514|Late referral
383781|NCT01151514|Acute kidney injury
383782|NCT01151514|Intensive care unit
383783|NCT01151514|In-hospital mortality
383784|NCT01151514|Renal outcome
383785|NCT01151514|Requirement for renal replacement therapy
383786|NCT01151514|Length of hospital stay
383787|NCT01151514|Impact
383788|NCT01151514|Incidence
383789|NCT01151501|acute hypoxemic respiratory failure
383790|NCT01151501|intermittent positive-pressure ventilation
383791|NCT01151501|noninvasive positive pressure ventilation
383792|NCT01151501|ventilator weaning
383793|NCT01151475|liver cirrhosis
383794|NCT01151475|hepatic encephalopathy
383795|NCT01151475|ammonia
383796|NCT01151475|cerebral blood flow
383797|NCT01151462|Postnatal HCMV infection in very preterm infants
383798|NCT01151462|Neurodevelopmental disabilities
383799|NCT01151462|Hearing loss
383800|NCT01151462|Mental retardation
383801|NCT01151462|Microcephaly
383802|NCT01151462|Chorioretinitis
383803|NCT01151462|Growth
383804|NCT01151436|Facial wrinkle correction
383805|NCT01151410|Pediatric hypertension
383806|NCT01151410|primary hypertension
383807|NCT01151410|secondary
383808|NCT01151410|hypertension
383809|NCT01151397|SVR
383810|NCT01151397|VITAMIN D
383811|NCT01151397|Hepatitis C
383812|NCT01151397|Genotype 2,3
383813|NCT01151397|Naive
383814|NCT01151397|RVR
383815|NCT01151384|Cancer Patients
383816|NCT01151358|radioimmunotherapy
383817|NCT01151358|follicular non-Hodgkin´s lymphoma
383818|NCT01151358|FDG-PET
383819|NCT01151358|prognostic factors
383820|NCT01151358|multicenter study
383821|NCT01151345|diltiazem
383822|NCT01151345|angiotrofin
383823|NCT01151345|bioequivalence
383824|NCT01151293|Type D personality
383825|NCT01151293|diabetes
383826|NCT01151293|medical compliance
383827|NCT01151293|HbA1c
383828|NCT01151293|complication
383829|NCT01151293|mortality
383830|NCT01151293|T2DM
383831|NCT01151267|Isocapnic hyperpnoea (IH)
383832|NCT01151267|Anesthesia
383833|NCT01151267|Accelerate elimination of inhalation agents
383834|NCT01151267|Recovery from anesthesia
383835|NCT01151254|Cardiac Surgery
383836|NCT01151254|Sedation
383837|NCT01151254|Intensive care
383838|NCT01151254|Volatile anesthesia
383839|NCT01151254|Intravenous anesthesia
383840|NCT01151254|Pre and post conditioning after cardiac surgery
383841|NCT01151241|elbow surgery
383842|NCT01151241|infraclavicular nerve block
383843|NCT01151241|continuous passive motion
383844|NCT01151241|ultrasound guided regional anesthesia
383845|NCT01151241|early discharge
383846|NCT01151228|gastroscopy
383847|NCT01151228|ultrasound
383848|NCT01151228|stomach volume
383849|NCT01151228|patients having gastroscopy
383850|NCT01151215|Cancer
383851|NCT01151215|tumour
383852|NCT01151215|breast cancer
383853|NCT01151215|metastatic
383854|NCT01151215|secondary
383855|NCT01151215|locally advanced
383856|NCT01151202|acute upper respiratory tract infection, chronic inflamatory bronchitis
383857|NCT01151189|HIV
383858|NCT01151189|Tuberculosis
383859|NCT01151189|Vaccine
383860|NCT01151176|Intensive Insulin Therapy
383861|NCT01151176|Glucose control
383862|NCT01151176|Acute Coronary Syndrome
383863|NCT01151176|Intensive Care
383864|NCT01151163|Fibromyalgia, Peripheral arterial tonometry, sleep
383865|NCT01151111|Parkinson's disease
383866|NCT01151111|Relaxation
383867|NCT01151111|Visual imagery
383868|NCT01151111|Motor fluctuations
383869|NCT01151111|Treatment
383870|NCT01151098|Chronic nonmalignant pain
383871|NCT01151098|Opioid
383872|NCT01151098|Transdermal
383873|NCT01151098|Butrans (BTDS)
383874|NCT01151085|Systemic Mycosis
383875|NCT01151085|Aspergillus infection
383876|NCT01151085|Candidiasis
383877|NCT01151085|Cryptococcal infections
383878|NCT01151085|Japanese
383879|NCT01151085|voriconazole
383880|NCT01151085|VFEND
383881|NCT01151085|Regulatory Post Marketing Commitment Plan.
383882|NCT01151059|seasonal influenza
383883|NCT01151059|vaccine
383884|NCT01151046|Breast Cancer
383885|NCT01151046|Her2 negative
383886|NCT01151046|Estrogen Receptor Positive
383887|NCT01151046|Progesterone Receptor Positive
383888|NCT01151046|MM-121
383889|NCT01151046|Exemestane
383890|NCT01151046|Postmenopausal Women
383891|NCT01151033|ProNOVA XR Polymer Free Drug Eluting Coronary Stent System
383892|NCT01151033|DES
383893|NCT01151033|stent
383894|NCT01151033|coronary artery lesions
383895|NCT01151033|ProNOVA
383896|NCT01151033|stent implantation
383897|NCT01151020|Aortic Aneurysm
383898|NCT01151020|Aneurysm
383899|NCT01151020|Vascular Prosthesis
383900|NCT01151020|Vascular Disease
383901|NCT01151020|Blood Vessel Prosthesis Implantation
383902|NCT01151007|Kras mutation
383903|NCT01151007|colorectal carcinoma
383904|NCT01151007|Martinique
383905|NCT01150994|Suicide screening among ED patients
383906|NCT01150955|Resveratrol
383907|NCT01150955|Diabetes
383908|NCT01150955|SIRT1
383909|NCT01150955|STAT5
383910|NCT01150955|IGF-I
383911|NCT01150955|Growth hormone
383912|NCT01150955|NAFLD
383913|NCT01150955|Longevity
383914|NCT01150955|Substrate metabolism
383915|NCT01150955|Calorie restriction
383916|NCT01150942|JEV
383917|NCT01150942|vero cell
383918|NCT01150929|Knee arthroplasty
383919|NCT01150929|RSA
383920|NCT01150929|DXA
383921|NCT01150929|Gait analysis
383922|NCT01150929|Motion analysis
383923|NCT01150916|natriuretic peptide
383924|NCT01150916|heart failure
383925|NCT01150916|ascites
383926|NCT01150916|liver cirrhosis
383927|NCT01150903|erectile dysfunction
383928|NCT01150903|phosphodiesterase inhibitor
383929|NCT01150903|cardiovascular diseases
383930|NCT01150890|Ileal Crohn's Disease
383931|NCT01150890|Ileo-colonic Crohn's Disease
383932|NCT01150890|Colonic Chron's Disease
383933|NCT01150877|Vitamin D
383934|NCT01150877|Vitamin D3
383935|NCT01150877|colon cancer
383936|NCT01150877|rectal cancer
383937|NCT01150877|Cholecalciferol
383938|NCT01150864|Hot water humidifier, Passive heat and moisture exchangers
383939|NCT01150838|intubation of children without neuromuscular blockade
383940|NCT01150825|STEMI
383941|NCT01150825|NSTEMI
383942|NCT01150825|acute ischemia
383943|NCT01150825|non-invasive diagnosis
383944|NCT01150825|elevated troponin
383945|NCT01150812|First time in man
383946|NCT01150812|healthy
383947|NCT01150812|thrombin inhibitor
383948|NCT01150786|inflammation
383949|NCT01150786|oxidative stress
383950|NCT01150786|selenium
383951|NCT01150786|hemodialysis
383952|NCT01150760|GI recovery after bowel resection
383953|NCT01150760|morbidity after bowel resection
383954|NCT01150760|mortality
383955|NCT01150760|readmission
383956|NCT01150760|length of stay
383957|NCT01150734|differences of Muscle evoked potentials (MEP) in psychiatric illnesses
383958|NCT01150734|differences in neuromodulation
383959|NCT01150734|normalization of neuromodulation after pharmacological treatment
383960|NCT01150721|Atypical Mycobacterium Infection
383961|NCT01150721|Microbial Tests
383962|NCT01150721|Molecular Tests
383963|NCT01150721|Inflammation
383964|NCT01150721|Respiratory Secretions
383965|NCT01150708|Syringomyelia
383966|NCT01150708|Magnetic Resonance Imaging
383967|NCT01150708|Natural History Study
383968|NCT01150708|Neurological Examination
383969|NCT01150695|vaccine, Francisella tularensis, Tularemia, rabbit fever, parent protocol
383970|NCT01150682|endometrial adenocarcinoma
383971|NCT01150682|stage II endometrial carcinoma
383972|NCT01150682|stage III endometrial carcinoma
383973|NCT01150682|stage IV endometrial carcinoma
383974|NCT01150682|endometrial adenosquamous cell carcinoma
383975|NCT01150682|endometrial clear cell carcinoma
383976|NCT01150682|endometrial papillary serous carcinoma
383977|NCT01150656|childhood acute myeloid leukemia/other myeloid malignancies
383978|NCT01150643|stage III grade 1 follicular lymphoma
383979|NCT01150643|stage III grade 2 follicular lymphoma
383980|NCT01150643|stage IV grade 1 follicular lymphoma
383981|NCT01150643|stage IV grade 2 follicular lymphoma
383982|NCT01150630|adenocarcinoma of the pancreas
383983|NCT01150630|stage I pancreatic cancer
383984|NCT01150630|stage II pancreatic cancer
383985|NCT01150617|Type 2 diabetes mellitus
383986|NCT01150617|Normoglycemia
383987|NCT01150617|Peripheral angioplasty
383988|NCT01150604|Cognitive Behavioral Therapy
383989|NCT01150604|Mood Management
383990|NCT01150604|Self-help
383991|NCT01150604|Internet
383992|NCT01150578|Echocardiography, 2D
383993|NCT01150578|speckle tracking
383994|NCT01150578|Lexiscan
383995|NCT01150578|regadenoson
383996|NCT01150578|Myocardial ischemia
383997|NCT01150578|Myocardial perfusion imaging
383998|NCT01150578|cost and cost analysis
383999|NCT01150578|Cardiac-Gated SPECT Imaging
384000|NCT01150578|Echocardiography
384001|NCT01150552|Serology
384002|NCT01150552|Poultry
384003|NCT01150552|H5N1 virus
384004|NCT01150552|HPAI virus
384005|NCT01150526|Acute Exercise
384006|NCT01150526|Muscle Inflammation
384007|NCT01150526|CaHMB
384008|NCT01150526|HMB Free Acid Gel
384009|NCT01150526|Healthy Subjects
384010|NCT01150513|TRIPLE-NEGATIVE
384011|NCT01150513|BREAST CANCER
384012|NCT01150500|Medtronic
384013|NCT01150500|Japan
384014|NCT01150500|Arterial Occlusive Diseases
384015|NCT01150500|Myocardial Ischemia
384016|NCT01150500|Cardiovascular Diseases
384017|NCT01150500|Coronary Artery Disease
384018|NCT01150500|Small Vessel Stent
384019|NCT01150487|kidney transplant
384020|NCT01150474|Belladonna
384021|NCT01150474|Morphine
384022|NCT01150474|Suppositories
384023|NCT01150474|Vaginal
384024|NCT01150474|Surgery
384025|NCT01150474|Postoperative
384026|NCT01150474|Pain
384027|NCT01150461|Hypertrophic nonobstructive cardiomyopathy
384028|NCT01150448|Paliperidone palmitate
384029|NCT01150448|paliperidone ER (INVEGA)
384030|NCT01150448|R092670PSY1008
384031|NCT01150448|Risperidone
384032|NCT01150448|Risperdal (RISPERDAL CONSTA)
384033|NCT01150448|Pharmacokinetics
384034|NCT01150422|medical abortion
384035|NCT01150409|Sepsis
384036|NCT01150409|hydrocortisone
384037|NCT01150396|extremely premature infant
384038|NCT01150396|outcome
384039|NCT01150396|follow-up
384040|NCT01150383|Lung Diseases, Obstructive
384041|NCT01150383|Respiratory Tract Diseases
384042|NCT01150383|Lung Diseases
384043|NCT01150383|Respiration Disorders
384044|NCT01150383|Pulmonary Disease, Chronic Obstructive
384045|NCT01150383|COPD
384046|NCT01150383|Chronic Obstructive Lung Disease
384047|NCT01150383|Chronic Obstructive Airway Disease
384048|NCT01150383|Chronic Airflow Obstruction
384049|NCT01150383|oxygen
384050|NCT01150383|oxygen supplementation
384051|NCT01150370|male circumcision
384052|NCT01150370|HIV
384053|NCT01150370|Rwanda
384054|NCT01150370|HIV Seronegativity
384055|NCT01150357|Pediatric hypertension
384056|NCT01150357|primary hypertension
384057|NCT01150357|secondary hypertension
384058|NCT01150344|Multicentric study
384059|NCT01150344|Antimalarial
384060|NCT01150344|P. falciparum
384061|NCT01150344|Efficacy
384062|NCT01150344|Failures
384063|NCT01150344|Malarone
384064|NCT01150344|RIAMET
384065|NCT01150331|status epilepticus
384066|NCT01150331|generalised convulsive status epilepticus
384067|NCT01150331|first line treatments
384068|NCT01150331|double-blind randomized controlled trial
384069|NCT01150331|prehospital treatment
384070|NCT01150318|Male
384071|NCT01150318|Infertility
384072|NCT01150318|Radioisotopes Therapy
384073|NCT01150318|Follicular thyroid cancer
384074|NCT01150305|Autosomal dominant inheritance
384075|NCT01150305|Mutation
384076|NCT01150305|Prevalence
384077|NCT01150292|DHA supplementation
384078|NCT01150292|Type 2 diabetic patient
384079|NCT01150292|Platelet function
384080|NCT01150279|medical abortion
384081|NCT01150279|Medical Abortion Follow Up Care
384082|NCT01150266|stroke
384083|NCT01150266|ischemia
384084|NCT01150266|thrombolysis
384085|NCT01150266|thrombolytics
384086|NCT01150266|tPA
384087|NCT01150266|rt-PA
384088|NCT01150266|t-PA
384089|NCT01150266|Activase®
384090|NCT01150266|Alteplase
384091|NCT01150266|wake-up stroke
384092|NCT01150266|waking onset stroke
384093|NCT01150266|sleep
384094|NCT01150240|Primary Immunodeficiency Disease
384095|NCT01149174|intravesical chemotherapy
384096|NCT01149174|early single instillation
384097|NCT01149174|mitomycin-C
384098|NCT01149174|electromotive drug administration
384099|NCT01149161|neck dissection
384100|NCT01149161|sentinel lymph node
384101|NCT01149161|Carcinoma
384102|NCT01149161|Papillary
384103|NCT01149161|thyroid
384104|NCT01149161|dissection
384105|NCT01149148|Aortic Surgeries
384106|NCT01149148|Deep Hypothermic Circulatory Arrest
384107|NCT01149135|Seasonal Affective Disorder
384108|NCT01149135|phototherapy
384109|NCT01149135|circadian rhythms
384110|NCT01149135|blue enriched light
384111|NCT01149135|melanopsin
384112|NCT01149135|low intensity
384113|NCT01149122|unresectable, metastatic biliary tract carcinoma
384114|NCT01149122|Gemcitabine/Oxaliplatin (GEMOX)
384115|NCT01149122|Erlotinib
384116|NCT01149109|MGMT promotor status
384117|NCT01149109|overall survival
384118|NCT01150214|atrial fibrillation
384119|NCT01150214|af
384120|NCT01150214|magnetic resonance imaging
384121|NCT01150214|mri
384122|NCT01150214|left atrium
384123|NCT01150214|fibrosis
384124|NCT01150214|structural remodeling
384125|NCT01150201|CKD
384126|NCT01150201|proteinuria
384127|NCT01150201|eGFR
384128|NCT01150201|Progression of chronic kidney disease
384129|NCT01150188|aging
384130|NCT01150188|lipid metabolism
384131|NCT01150188|very low density lipoproteins
384132|NCT01150188|amino acids
384133|NCT01150188|dietary supplements
384134|NCT01150175|END-HF
384135|NCT01150149|Influenza
384136|NCT01150149|Humans
384137|NCT01150149|Experimental
384138|NCT01150149|Challenge
384139|NCT01150136|choline
384140|NCT01150136|cystic fibrosis
384141|NCT01150136|methyl metabolism
384142|NCT01150136|oxidative stress
384143|NCT01150123|Group B streptococcus
384144|NCT01150123|GBS
384145|NCT01150123|Vaccine
384146|NCT01150123|Group B streptococcus (GBS) disease
384147|NCT01150110|Temporomandibular disorders
384148|NCT01150110|occlusal splints
384149|NCT01150110|electromyography
384150|NCT01150110|TMD (muscle and joint dysfunction)
384151|NCT01150110|masseteres e anterior temporalis muscles.
384152|NCT01150097|Liver transplantation
384153|NCT01150097|Everolimus
384154|NCT01150097|Calcineurin inhibitors
384155|NCT01150097|Tacrolimus
384156|NCT01150097|Renal function
384157|NCT01150097|Progression of HCV related allograft fibrosis
384158|NCT01150084|increasing physical activity in sedentary employees
384159|NCT01150071|extremely premature infant
384160|NCT01150071|follow-up
384161|NCT01150071|behavior
384162|NCT01150071|growth
384163|NCT01150071|mental health
384164|NCT01150071|lung function
384165|NCT01150071|spirometry
384166|NCT01150071|muscle mass
384167|NCT01150071|bone density
384168|NCT01150071|magnetic Resonance imaging
384169|NCT01150058|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
384170|NCT01150058|adult acute myeloid leukemia with del(5q)
384171|NCT01150058|adult acute myeloid leukemia with inv(16)(p13;q22)
384172|NCT01150058|adult acute myeloid leukemia with t(15;17)(q22;q12)
384173|NCT01150058|adult acute myeloid leukemia with t(16;16)(p13;q22)
384174|NCT01150058|adult acute myeloid leukemia with t(8;21)(q22;q22)
384175|NCT01150058|childhood acute myeloid leukemia/other myeloid malignancies
384176|NCT01150058|adult acute myeloid leukemia
384177|NCT01150045|adenocarcinoma of the colon
384178|NCT01150045|stage III colon cancer
384179|NCT01150032|Osteoporosis
384180|NCT01150032|Fracture
384181|NCT01150032|Bone microarchitecture
384182|NCT01150019|atherosclerosis
384183|NCT01150019|vascular inflammation
384184|NCT01150019|resistin
384185|NCT01150019|adiponectin
384186|NCT01150019|18FDG-PET
384187|NCT01150006|atherosclerosis
384188|NCT01150006|vascular inflammation
384189|NCT01150006|adipocyte fatty acid binding protein
384190|NCT01150006|adiponectin
384191|NCT01150006|leptin
384192|NCT01150006|18FDG-PET
384193|NCT01149993|living donation
384194|NCT01149993|kidney transplantation
384195|NCT01149993|delayed graft function
384196|NCT01149993|ischemia reperfusion injury
384197|NCT01149980|Bioequivalence
384198|NCT01149980|Crossover
384199|NCT01149980|Citalopram
384200|NCT01149967|Bioequivalence
384201|NCT01149967|Citalopram
384202|NCT01149967|Crossover
384203|NCT01149954|Bioequivalence
384204|NCT01149954|Crossover
384205|NCT01149954|Ibuprofen
384206|NCT01149941|Bioequivalence
384207|NCT01149941|Crossover
384208|NCT01149941|Ibuprofen
384209|NCT01149928|Fetal lung fluid
384210|NCT01149928|Pulmonary adaptation
384211|NCT01149928|Transient tachypnea of the newborn
384212|NCT01149928|Epinephrine
384213|NCT01149928|Stress hormones
384214|NCT01149915|Advanced Leukemias
384215|NCT01149915|Relapsed/Refractory Leukemias
384216|NCT01149915|AML
384217|NCT01149915|ALL
384218|NCT01149915|CML
384219|NCT01149915|MDS
384220|NCT01149915|CLL
384221|NCT01149915|MF
384222|NCT01149915|Evofosfamide
384223|NCT01149863|Autologous Transplantation
384224|NCT01149850|adult giant cell glioblastoma
384225|NCT01149850|adult glioblastoma
384226|NCT01149850|adult gliosarcoma
384227|NCT01149837|HTLV
384228|NCT01149837|HTLV I
384229|NCT01149837|HTLV II
384230|NCT01149837|HTLV Type I and/or HTLV Type II antibody
384231|NCT01149824|Salvia divinorum
384232|NCT01149824|Salvinorin A
384233|NCT01149811|Dyskinesia
384234|NCT01149798|metastatic breast cancer
384235|NCT01149798|combined chemotherapy
384236|NCT01149785|crizotinib
384237|NCT01149785|healthy volunteers
384238|NCT01149785|ketoconazole
384239|NCT01149785|pharmacokinetics
384240|NCT01149785|single dose
384241|NCT01149772|Chronic Obstructive Pulmonary Disease
384242|NCT01149772|Heart Failure
384243|NCT01149772|Anxiety
384244|NCT01149772|Depression
384245|NCT01149759|Atopic Dermatitis
384246|NCT01149759|Eczema
384247|NCT01149720|Relative bioavailability
384248|NCT01149720|ARQ 197
384249|NCT01149707|PUR 0110
384250|NCT01149707|PUR 0110 Rectal Enema
384251|NCT01149707|Distal Ulcerative Colitis
384252|NCT01149707|Left-Sided Ulcerative Colitis
384253|NCT01149707|Mild
384254|NCT01149707|Moderate
384255|NCT01149694|PurGenesis Technologies Inc.
384256|NCT01149694|PUR 0110 rectal enema
384257|NCT01149694|Ulcerative colitis
384258|NCT01149694|Distal
384259|NCT01149694|Normal healthy volunteers
384260|NCT01149681|Aplidin
384261|NCT01149681|Plitidepsin
384262|NCT01149681|Myelofibrosis
384263|NCT01149681|Pharma Mar
384264|NCT01149668|PCI-24781
384265|NCT01149668|Lymphoma
384266|NCT01149668|Non-Hodgkin's
384267|NCT01149668|Hodgkin Disease
384268|NCT01149668|Multiple Myeloma
384269|NCT01149668|Leukemia
384270|NCT01149668|Lymphocytic
384271|NCT01149668|Chronic
384272|NCT01149655|Adolescent
384273|NCT01149655|Schizophrenia
384274|NCT01149629|Droxidopa
384275|NCT01149629|Randomized
384276|NCT01149629|Crossover
384277|NCT01149629|Open Label
384278|NCT01149629|Bioequivalence
384279|NCT01149629|Fed Fast
384280|NCT01149629|TID
384281|NCT01149603|failing Fontan
384282|NCT01149603|single-ventricle
384283|NCT01149603|destination therapy
384284|NCT01149603|HeartMate II
384285|NCT01149603|HMII
384286|NCT01149603|cardiac congenital anomaly
384287|NCT01149603|ventricular assist device
384288|NCT01149603|VAD
384289|NCT01149590|Angina
384290|NCT01149590|Coronary Heart Disease
384291|NCT01149590|Computed Tomography
384292|NCT01149590|Angiogram
384293|NCT01149590|Coronary Artery Calcium Score
384294|NCT01149590|Chest Pain
384295|NCT01149590|Angina Pectoris due to Coronary Heart Disease
384296|NCT01149577|Olanzapine
384297|NCT01149577|Schizophrenia
384298|NCT01149577|Polysomnography
384299|NCT01149577|Slow wave sleep
384300|NCT01149551|Schizophrenia
384301|NCT01149551|Bipolar disorder
384302|NCT01149551|Genetic research
384303|NCT01149538|FASD
384304|NCT01149538|FAS
384305|NCT01149538|Alcohol
384306|NCT01149538|Prenatal Alcohol
384307|NCT01149525|Multiple Sclerosis/complications
384308|NCT01149525|Fatigue Syndrome
384309|NCT01149525|Chronic/drug therapy
384310|NCT01149486|Bioequivalence
384311|NCT01149486|Healthy Subjects
384312|NCT01149473|Bioequivalence
384313|NCT01149473|Healthy Subjects
384314|NCT01149447|cryptogenic stroke
384315|NCT01149447|percutaneous closure of PFO
384316|NCT01149447|follow-up exams
384317|NCT01149434|Low grade endocrine tumors
384318|NCT01149434|ovarian cancers
384319|NCT01149434|K-RAS mutant colon cancers
384320|NCT01149421|Type 2 Diabetes
384321|NCT01149421|Diabetes
384322|NCT01149421|Ambulatory Blood Pressure Monitoring
384323|NCT01149421|ABPM
384324|NCT01149421|Blood Pressure
384325|NCT01149421|Heart Rate
384326|NCT01149408|AML
384327|NCT01149408|Decitabine
384328|NCT01149408|Acute Myeloid Leukemia
384329|NCT01149408|Elderly Patients
384330|NCT01149408|Cancer
384331|NCT01149395|Heartburn
384332|NCT01149395|Gastroesophageal Reflux Disease
384333|NCT01149382|flu shot
384334|NCT01149382|islet cell transplant recipients
384335|NCT01149369|gastroparesis
384336|NCT01149369|nausea
384337|NCT01149369|vomiting
384338|NCT01149343|PRAME
384339|NCT01149343|Cancer immunotherapeutic
384340|NCT01149343|Malignant melanoma
384341|NCT01149343|ASCI (Antigen-Specific Cancer Immunotherapeutic)
384342|NCT01149330|Adapalene
384343|NCT01149330|Benzoyl Peroxide
384344|NCT01149330|Acne Vulgaris
384345|NCT01149317|acupuncture
384346|NCT01149317|health services research
384347|NCT01149317|chronic pain
384348|NCT01149317|health disparities
384349|NCT01149304|brachytherapy
384350|NCT01149304|liver metastases
384351|NCT01149304|irradiation
384352|NCT01149304|radiation induced liver disease
384353|NCT01149304|dosimetry
384354|NCT01149291|high sensitivity C-reactive protein (hsCRP)
384355|NCT01149291|cardiorenal
384356|NCT01149291|end stage renal disease (ESRD)
384357|NCT01149291|Secondary hyperparathyroidism (SHPT)
384358|NCT01149291|dialysis
384359|NCT01149291|paricalcitol
384360|NCT01149291|osteodystrophy
384361|NCT01149291|selective Vitamin D receptor activators (sVDRA)
384362|NCT01149291|chronic kidney disease
384363|NCT01149252|Psoriasis
384364|NCT01149226|pediatric patients
384365|NCT01149226|ASA physical status I or II
384366|NCT01149226|aged between 1-5 yrs
384367|NCT01149213|Major depressive disorder
384368|NCT01149213|follow-up
384369|NCT01149213|relapse
384370|NCT01149213|remission
384371|NCT01149213|transcranial direct current stimulation
384372|NCT01149200|Irritable Bowel Syndrome
384373|NCT01149200|IBS-C
384374|NCT01149070|Infertility
384375|NCT01149070|Controlled ovarian stimulation
384376|NCT01149070|Reproductive techniques, assisted
384377|NCT01149070|Sperm injections, intracytoplasmic
384378|NCT01149070|Gonal-f
384379|NCT01149070|Ovitrelle
384380|NCT01149044|Acute Coronary Syndrome
384381|NCT01149044|PCI
384382|NCT01149044|Percutaneous Coronary Intervention
384383|NCT01149044|STEMI
384384|NCT01149044|Thrombectomy
384385|NCT01149031|Provoked Vestibulodynia
384386|NCT01149031|Low Level Laser Therapy
384387|NCT01149018|Fibromyalgia
384388|NCT01149018|Tetrahydrocannabinol
384389|NCT01149018|Chronic Widespread Pain
384390|NCT01149005|Normal Glucose Tolerance Test
384391|NCT01149005|Mixed Meal Tolerance Test
384392|NCT01149005|Cystic Fibrosis
384393|NCT01149005|Pulmonary Exacerbation
384394|NCT01149005|Impaired Glucose Tolerance Test
384395|NCT01149005|Insulin Therapy
384396|NCT01148979|Major Depressive Disorder
384397|NCT01148979|Cognitive Impairment
384398|NCT01148979|Partial Response
384399|NCT01148979|Residual Symptoms
384400|NCT01148940|sickle cell trait
384401|NCT01148940|thrombosis
384402|NCT01148940|D-Dimer
384403|NCT01148914|Inflammatory biomarkers
384404|NCT01148914|Atrial fibrillation
384405|NCT01148914|Catheter ablation
384406|NCT01148914|To assess if pre-ablation levels of inflammatory biomarkers serve as independent predictors of procedure outcome
384407|NCT01148914|To evaluate the inflammatory activation following catheter ablation and examine its predictive role in procedure success
384408|NCT01148914|To determine if a change in the baseline level of biomarkers at 3-months follow-up has any correlation with long-term outcome
384409|NCT01148914|To study the association of certain biomarkers with specific types of AF (paroxysmal or persistent or long standing persistent)
384410|NCT01148901|Ankylosing spondylitis
384411|NCT01148901|Hip arthritis
384412|NCT01148901|Infliximab
384413|NCT01148888|pediatrics
384414|NCT01148888|Anaesthesia
384415|NCT01148888|Scoliosis
384416|NCT01148888|Magnesium
384417|NCT01148875|breast cancer screening
384418|NCT01148875|mammography adherence
384419|NCT01148875|non-adherent
384420|NCT01148849|HER2 positive
384421|NCT01148849|breast cancer
384422|NCT01148849|gastric cancer
384423|NCT01148836|Coenzyme Q-10
384424|NCT01148836|Pulmonary Arterial Hypertension
384425|NCT01148836|Pulmonary Arterial Hypertension Class I (Venice 2003)
384426|NCT01148823|breast
384427|NCT01148823|plastic surgery
384428|NCT01148823|bandages
384429|NCT01148823|surgical site infection
384430|NCT01148823|skin colonization
384431|NCT01148810|Inflammatory muscle disease
384432|NCT01148810|Muscle weakness
384433|NCT01148810|Myositis
384434|NCT01148797|FMF, Colchicine resistant
384435|NCT01148797|Colchicine intolerant
384436|NCT01148797|Flare rate
384437|NCT01148797|Canakinumab
384438|NCT01148784|anterior cruciate ligament tear
384439|NCT01148784|ACL
384440|NCT01148784|ligament
384441|NCT01148784|knee
384442|NCT01148784|allograft
384443|NCT01148771|Pharmacokinetics
384444|NCT01148771|Safety
384445|NCT01148732|Endotracheal tube
384446|NCT01148732|ultrasonography
384447|NCT01148719|Heart Failure
384448|NCT01148719|Chronic Obstructive Pulmonary Disease
384449|NCT01148719|Dyspnea
384450|NCT01148719|Elderly
384451|NCT01148719|Diagnosis
384452|NCT01148719|Primary health care
384453|NCT01148706|thorax
384454|NCT01148706|abdomen
384455|NCT01148693|Cholangitis; Cholangiopancreatography, Endoscopic Retrograde; stents; cholestasis
384456|NCT01148680|Islet Cell Transplantation
384457|NCT01148680|Metabolic Diseases
384458|NCT01148680|Endocrine System Diseases
384459|NCT01148667|atopic dermatitis
384460|NCT01148667|barrier function
384461|NCT01148667|gut
384462|NCT01148667|probiotics
384463|NCT01148667|skin
384464|NCT01148654|preterm birth
384465|NCT01148654|preterm labor
384466|NCT01148654|PTB
384467|NCT01148654|PTL
384468|NCT01148641|Lipid-based supplements
384469|NCT01148641|LNS
384470|NCT01148641|Acceptability
384471|NCT01148641|Infant nutrition
384472|NCT01148641|Guatemala
384473|NCT01148641|Malnutrition
384474|NCT01148602|Acute stroke
384475|NCT01148602|Emergency departments
384476|NCT01148602|Quality Improvement
384477|NCT01148602|Improved Processes
384478|NCT01148602|tPA
384479|NCT01148602|door-to-needle
384480|NCT01148602|door-to-treatment
384481|NCT01148576|hepatic steatosis, chronic hepatitis B, entecavir
384482|NCT01148563|congestive heart failure
384483|NCT01148563|systolic
384484|NCT01148563|chronic disease
384485|NCT01148563|heart failure
384486|NCT01148550|neonatal acute liver failure
384487|NCT01148550|late-onset liver failure
384488|NCT01148550|cholestasis,
384489|NCT01148550|fatty liver,
384490|NCT01148550|liver dysfunction,
384491|NCT01148550|cirrhosis
384492|NCT01148537|Healthy subjects
384493|NCT01148537|Opioid
384494|NCT01148537|Transdermal
384495|NCT01148524|Meningococcal disease
384496|NCT01148524|Vaccines
384497|NCT01148524|Adolescents
384498|NCT01148511|Macula degeneration
384499|NCT01148511|Ranibizumab
384500|NCT01148511|Choroidal neovascularisation
384501|NCT01148511|Treat and extend
384502|NCT01148511|Treat and observe
384503|NCT01148485|- Staphylococcus aureus Carriage among Athletes
384504|NCT01148472|Depressive disorder, major
384505|NCT01148472|Randomized controlled trials
384506|NCT01148472|Antidepressive agents
384507|NCT01148459|schedule
384508|NCT01148459|Africa
384509|NCT01148459|Plasmodium falciparum
384510|NCT01148459|malaria vaccine
384511|NCT01148459|EPI
384512|NCT01148459|HIV
384513|NCT01148446|DLBCL
384514|NCT01148446|R-CHOP
384515|NCT01148446|R-CEOP
384516|NCT01148446|Elderly patients
384517|NCT01148407|breast cancer
384518|NCT01148407|platelets
384519|NCT01148407|metastatic cancer
384520|NCT01148407|malignancy
384521|NCT01148394|Colorectal surgery
384522|NCT01148394|multimodal rehabilitation
384523|NCT01148394|fast track
384524|NCT01148394|early feeding
384525|NCT01148381|Genotype
384526|NCT01148381|Phenotype
384527|NCT01148381|Characterization
384528|NCT01148368|fimasartan
384529|NCT01148368|renal impairment
384530|NCT01148368|hypertension
384531|NCT01148355|Craving
384532|NCT01148355|Moods
384533|NCT01148355|Adolescents
384534|NCT01148355|Nicotine
384535|NCT01148355|Reinforcement
384536|NCT01148342|Ecstacy
384537|NCT01148342|fMRI
384538|NCT01148342|Alternative Matrices
384539|NCT01148342|Cognitive Training
384540|NCT01148342|Brain Imaging
384541|NCT01148329|Coronary stenting
384542|NCT01148329|Drug-eluting stent
384543|NCT01148329|Post-market surveillance study
384544|NCT01148329|Promus Element stent
384545|NCT01148316|Developmental Psychiatry
384546|NCT01148316|Sequential Randomized Clinical Trial
384547|NCT01148316|Obsessive-Compulsive Disorder D009771
384548|NCT01148303|Headache
384549|NCT01148303|Fasting
384550|NCT01148303|Fasting Headache
384551|NCT01148303|Ramadan
384552|NCT01148303|Ramadan Headache
384553|NCT01148303|Yom Kippur
384554|NCT01148303|Yom Kippur Headache
384555|NCT01148290|bulking agent
384556|NCT01148290|emivulvectomy
384557|NCT01148290|radical vulvectomy
384558|NCT01148290|TVT
384559|NCT01148290|urinary incontinence
384560|NCT01148290|vulvar cancer
384561|NCT01148277|Endoscopies
384562|NCT01148277|Liver diseases
384563|NCT01148277|Propofol
384564|NCT01148277|Midazolam and remifentanyl
384565|NCT01148264|break-through
384566|NCT01148264|emesis
384567|NCT01148264|break through emesis after prophylaxis with dexamethasone, 5-HT 3RA and aprepitant
384568|NCT01148238|Autoimmune diabetes
384569|NCT01148238|LADA
384570|NCT01148238|T-reg
384571|NCT01148238|cytokine
384572|NCT01148225|Non-infectious Uveitis
384573|NCT01148225|Active Uveitis
384574|NCT01148225|Posterior-Uveitis
384575|NCT01148225|Uveitis
384576|NCT01148225|Pan-uveitis
384577|NCT01148225|Intermediate-Uveitis
384578|NCT01148199|biliary anastomotic stricture
384579|NCT01148199|orthotopic liver transplantation
384580|NCT01148199|ERCP
384581|NCT01148186|Polypharmacy
384582|NCT01148186|Benzodiazepine use
384583|NCT01148186|Oxybutynin use
384584|NCT01148186|cognition disorders/drug therapy
384585|NCT01148186|incontinence
384586|NCT01148173|CNS relapse
384587|NCT01148173|aggressive lymphoma
384588|NCT01148173|HD-ASCT
384589|NCT01148160|voriconazole
384590|NCT01148160|invasive pulmonary aspergillosis
384591|NCT01148160|hematologic malignancy
384592|NCT01148160|therapeutic drug monitoring
384593|NCT01148160|genetic polymorphism
384594|NCT01148160|efficacy
384595|NCT01148160|safety
384596|NCT01148147|Adenosine
384597|NCT01148147|randomized trial
384598|NCT01148147|periprocedural myocardial necrosis
384599|NCT01148147|elective coronary angioplasty
384600|NCT01148108|NHL
384601|NCT01148108|Non-Hodgkins Lymphoma
384602|NCT01148108|Lymphoma
384603|NCT01148108|Mantle Cell
384604|NCT01148108|Diffuse Large B Cell
384605|NCT01148108|Multiple Myeloma
384606|NCT01148108|Telcyta
384607|NCT01148108|canfosfamide
384608|NCT01148108|TLK286
384609|NCT01148108|Prodrug
384610|NCT01148108|Enzyme activated drug
384611|NCT01148108|Glutathione Transferase P1-1 activated drug
384612|NCT01148108|GSTp1-1 activated drug
384613|NCT01148108|Glutathione Transferase activated drug
384614|NCT01148108|Glutathione
384615|NCT01148108|Glutathione analong
384616|NCT01148095|AZD2516
384617|NCT01148095|Phase 1
384618|NCT01148095|Healthy volunteer
384619|NCT01148095|pharmacokinetics
384620|NCT01148095|safety
384621|NCT01148095|tolerability
384622|NCT01148095|Multiple ascending doses
384623|NCT01148082|Carcinomas (including Squamous Cell and Adenocarcinoma)
384624|NCT01148069|IMRT-IGRT
384625|NCT01148069|radiotherapy toxicity
384626|NCT01148069|seminal vesicles
384627|NCT01148056|IMRT
384628|NCT01148056|radiation therapy
384629|NCT01148017|Meningococcal
384630|NCT01148017|ACWY
384631|NCT01148017|Conjugate Vaccine
384632|NCT01148017|Meningitis
384633|NCT01148017|Children
384634|NCT01148017|Persistence
384635|NCT01148017|Booster dose
384636|NCT01148004|HIV
384637|NCT01148004|Hypertriglyceridemia
384638|NCT01148004|Protease Inhibitors
384639|NCT01148004|Healthy Volunteer
384640|NCT01148004|HV
384641|NCT01147991|Epstein-Barr virus infection
384642|NCT01147991|stage I nasopharyngeal cancer
384643|NCT01147991|stage II nasopharyngeal cancer
384644|NCT01147991|stage I adult Hodgkin lymphoma
384645|NCT01147991|stage II adult Hodgkin lymphoma
384646|NCT01147991|post-transplant lymphoproliferative disorder
384647|NCT01147991|stage I gastric cancer
384648|NCT01147991|stage II gastric cancer
384649|NCT01147991|adult nasal type extranodal NK/T-cell lymphoma
384650|NCT01147991|angioimmunoblastic T-cell lymphoma
384651|NCT01147991|stage I adult Burkitt lymphoma
384652|NCT01147991|contiguous stage II adult Burkitt lymphoma
384653|NCT01147991|contiguous stage II adult immunoblastic large cell lymphoma
384654|NCT01147991|stage I adult immunoblastic large cell lymphoma
384655|NCT01147978|ICU
384656|NCT01147978|Anxiety
384657|NCT01147978|Depression
384658|NCT01147978|PTSD
384659|NCT01147965|Colon Cancer
384660|NCT01147965|Lung Cancer
384661|NCT01147965|Breast Cancer
384662|NCT01147965|CEA
384663|NCT01147952|angina
384664|NCT01147952|gene expression
384665|NCT01147952|depression
384666|NCT01147952|anxiety
384667|NCT01147939|Acute Myeloid Leukaemia
384668|NCT01147939|AML
384669|NCT01147939|Haematology
384670|NCT01147939|Investigator's Choice
384671|NCT01147939|Elacytarabine
384672|NCT01147939|Refractory or relapsed AML
384673|NCT01147939|Phase III
384674|NCT01147939|Randomized
384675|NCT01147939|CLAVELA
384676|NCT01147939|CP4055-306
384677|NCT01147939|Elacyt
384678|NCT01147926|Constipation
384679|NCT01147926|Male
384680|NCT01147913|Major Depression
384681|NCT01147913|Depression
384682|NCT01147913|Anxiety
384683|NCT01147913|Dysthymia
384684|NCT01147900|Immune persistence
384685|NCT01147900|Boostrix
384686|NCT01147900|dTpa booster study
384687|NCT01147887|26489112
384688|NCT01147887|Omeprazole
384689|NCT01147887|Tolbutamide
384690|NCT01147874|non-therapeutic
384691|NCT01147874|interventional
384692|NCT01147861|T2DM
384693|NCT01147861|Pharmacodynamics
384694|NCT01147861|GSK256073
384695|NCT01147848|Salmeterol
384696|NCT01147848|fluticasone furoate
384697|NCT01147848|Vilanterol
384698|NCT01147848|fluticasone propionate
384699|NCT01147848|GW642444
384700|NCT01147835|Herbal lollipops
384701|NCT01147835|Asthma
384702|NCT01147835|Dental Caries
384703|NCT01147835|Streptococcus mutans levels
384704|NCT01147835|DMFT/dmft scores
384705|NCT01147822|SUTENT
384706|NCT01147822|GW76034
384707|NCT01147822|Sunitinib
384708|NCT01147822|Renal cell carcinoma
384709|NCT01147822|Pazopanib
384710|NCT01147809|Solid Tumor
384711|NCT01147809|Eltrombopag
384712|NCT01147809|chemotherapy-induced thrombocytopenia
384713|NCT01147809|Thrombocytopenia
384714|NCT01147796|Thrombus
384715|NCT01147796|computed tomography
384716|NCT01147796|Transoesophageal echocardiography
384717|NCT01147770|progesterone
384718|NCT01147770|antagonist
384719|NCT01147770|rec FSH
384720|NCT01147770|IVF
384721|NCT01147770|pregnancy
384722|NCT01147757|pediatric patients (ASA physical status I or II) aged between
384723|NCT01147744|Efficacy
384724|NCT01147744|Asthma
384725|NCT01147744|Safety
384726|NCT01147744|Fluticasone Propionate
384727|NCT01147744|FLAP
384728|NCT01147744|Beta-agonists
384729|NCT01147744|GSK2190915
384730|NCT01147744|Montelukast
384731|NCT01147744|Placebo
384732|NCT01147744|FLAIR
384733|NCT01147731|pharmacokinetics
384734|NCT01147731|albiglutide
384735|NCT01147731|warfarin
384736|NCT01147731|Healthy volunteers
384737|NCT01147718|pharmacokinetics
384738|NCT01147718|albiglutide
384739|NCT01147718|Healthy volunteer
384740|NCT01147718|digoxin
384741|NCT01147705|Peripheral arterial disease
384742|NCT01147705|Allopurinol
384743|NCT01147692|albiglutide
384744|NCT01147692|simvastatin
384745|NCT01147692|healthy volunteers
384746|NCT01147692|pharmacokinetics
384747|NCT01147679|Frontotemporal dementia
384748|NCT01147679|Alzheimer's disease
384749|NCT01147679|Young-Onset
384750|NCT01147679|Frontotemporal degeneration
384751|NCT01147679|control
384752|NCT01147679|social
384753|NCT01147679|behavior
384754|NCT01147679|observation
384755|NCT01147679|emotion
384756|NCT01147679|morality
384757|NCT01147679|dementia
384758|NCT01147679|brain
384759|NCT01147679|relationships
384760|NCT01147679|caregiver
384761|NCT01147679|MRI
384762|NCT01147679|neurology
384763|NCT01147666|Kidney
384764|NCT01147666|End Stage Renal Disease
384765|NCT01147666|ESRD
384766|NCT01147666|Chronic Kidney Disease
384767|NCT01147666|CKD
384768|NCT01147666|Renal
384769|NCT01147666|Anemia
384770|NCT01147666|Oral anemia treatment
384771|NCT01147666|Hemoglobin levels
384772|NCT01147666|Blood count
384773|NCT01147666|Erythropoietin
384774|NCT01147666|Hemodialysis
384775|NCT01147666|Normoresponder
384776|NCT01147666|Hyporesponder
384777|NCT01147653|Cerebral Palsy
384778|NCT01147653|CP
384779|NCT01147653|Spastic Cerebral Palsy
384780|NCT01147653|Cord Blood
384781|NCT01147653|Umbilical Cord Blood
384782|NCT01147653|Autologous Cord Blood
384783|NCT01147627|diabetes mellitus, type 2
384784|NCT01147627|newly diagnosed
384785|NCT01147627|exenatide
384786|NCT01147627|premixed insulin analog
384787|NCT01147627|thiazolidinedione
384788|NCT01147627|β-cell function
384789|NCT01147627|glycemic control
384790|NCT01147614|Child
384791|NCT01147614|adolescent
384792|NCT01147614|anxiety
384793|NCT01147614|depression
384794|NCT01147614|internalizing
384795|NCT01147614|cognitive behavioral therapy
384796|NCT01147614|pediatric primary care
384797|NCT01147601|topical 0.5% Timolol
384798|NCT01147601|infantile hemangioma (IH)
384799|NCT01147588|open label
384800|NCT01147588|randomized
384801|NCT01147588|4-treatment
384802|NCT01147588|3-period
384803|NCT01147588|crossover
384804|NCT01147588|interaction study
384805|NCT01147588|Safety
384806|NCT01147588|tolerability
384807|NCT01147588|pharmacokinetics
384808|NCT01147588|pharmacodynamics
384809|NCT01147575|Rett Syndrome, Randomized, Methylation
384810|NCT01147562|Lung cancer
384811|NCT01147562|Biopsy
384812|NCT01147562|Biomarker
384813|NCT01147562|Tissue Collection
384814|NCT01147549|ADME
384815|NCT01147523|nonalcoholic fatty liver disease
384816|NCT01147523|nonalcoholic steatohepatitis
384817|NCT01147523|adipokines
384818|NCT01147523|spironolactone
384819|NCT01147523|vitamin E
384820|NCT01147523|adiponectin
384821|NCT01147523|visfatin
384822|NCT01147523|leptin
384823|NCT01147523|resistin
384824|NCT01147523|TNF-alpha
384825|NCT01147523|IL-6
384826|NCT01147523|IL-1
384827|NCT01147510|asthma control in elderly patients
384828|NCT01147510|age 60-75
384829|NCT01147497|IUD insertion
384830|NCT01147497|nulliparous women
384831|NCT01147497|contraception
384832|NCT01147497|family planning
384833|NCT01147497|IUD insertion in nulliparous women
384834|NCT01147484|Breast Cancer
384835|NCT01147471|flail chest
384836|NCT01147471|rib fixation
384837|NCT01147458|Cross-over
384838|NCT01147458|safety
384839|NCT01147458|efficacy
384840|NCT01147458|tolerability
384841|NCT01147458|osteoarthritis
384842|NCT01147458|knee
384843|NCT01147458|pain
384844|NCT01147445|Enterotoxigenic Escherichia coli, vaccine
384845|NCT01147432|Healthy male volunteers
384846|NCT01147432|capsaicin challenge
384847|NCT01147432|safety
384848|NCT01147432|toleration
384849|NCT01147419|critical limb ischemia
384850|NCT01147419|peripheral artery occlusive disease
384851|NCT01147419|femoropopliteal artery bypass
384852|NCT01147419|Stent
384853|NCT01147367|exercise
384854|NCT01147367|breast cancer
384855|NCT01147367|physical activity
384856|NCT01147367|fatigue
384857|NCT01147367|sleep dysfunction
384858|NCT01147367|cytokines
384859|NCT01147367|muscle strength
384860|NCT01147367|inflammation
384861|NCT01147354|Hemodialysis
384862|NCT01147354|oxidative stress
384863|NCT01147354|selenium
384864|NCT01147354|inflammation
384865|NCT01147341|rheumatoid arthritis
384866|NCT01147341|anti-TNF therapy
384867|NCT01147328|Health information technology
384868|NCT01147328|Health information exchange
384869|NCT01147328|Virtual health record
384870|NCT01147328|Health care utilization
384871|NCT01147315|mandibular osteoradionecrosis
384872|NCT01147315|hybrid bone substitution
384873|NCT01147315|calcium-phosphate ceramic biomaterial
384874|NCT01147315|autologous bone marrow
384875|NCT01147289|lumbar sciatic pain
384876|NCT01147289|moderate to severe lumbar sciatic pain within the last three days
384877|NCT01147276|DPP-4
384878|NCT01147276|GLP-1
384879|NCT01147276|Glucagon
384880|NCT01147276|Catecholamines
384881|NCT01147276|Counterregulation
384882|NCT01147276|Type 1 diabetes
384883|NCT01147263|Fibromyalgia
384884|NCT01147263|Autonomic dysfunction
384885|NCT01147263|Tachycardia
384886|NCT01147263|Palpitations
384887|NCT01147224|Asthma
384888|NCT01147224|Allergy
384889|NCT01147224|Ciclesonide
384890|NCT01147224|Alvesco
384891|NCT01147224|Inhaled steroids
384892|NCT01147211|dose defining
384893|NCT01147211|MK-2206
384894|NCT01147211|NSCLC With EGFR Mutation
384895|NCT01147211|NSCLC
384896|NCT01147198|Moderate
384897|NCT01147198|Wasting
384898|NCT01147198|Malnutrition
384899|NCT01147198|Ready to Use Food
384900|NCT01147198|Fortified Blended Flour
384901|NCT01147185|Spinal Cord Injuries, Locomotor training, Dose-Response
384902|NCT01147172|Nasolabial Folds
384903|NCT01147172|Cosmetic
384904|NCT01147172|Injectable Dermal Filler
384905|NCT01147172|Hyaluronic Acid with Lidocaine
384906|NCT01147146|transurethral surgery
384907|NCT01147133|Platelet aggregation
384908|NCT01147133|Generic
384909|NCT01147133|Clopidogrel
384910|NCT01147133|Comparison
384911|NCT01147133|VASP-PRI
384912|NCT01147107|HIV/HCV co-infection
384913|NCT01147107|Antiretroviral therapy
384914|NCT01147081|Influenza vaccine
384915|NCT01147081|Vaccine
384916|NCT01147068|Influenza
384917|NCT01147055|crizotinib
384918|NCT01147055|healthy volunteers
384919|NCT01147055|rifampin
384920|NCT01147055|pharmacokinetics
384921|NCT01147055|single dose
384922|NCT01147042|NADPH Oxidase
384923|NCT01147042|CGD
384924|NCT01147042|Gene Mutation
384925|NCT01147042|Superoxide by Phagocytes
384926|NCT01147042|IFN-Gamma
384927|NCT01147042|Chronic Granulomatous Disease
384928|NCT01147029|unspecified adult solid tumor, protocol specific
384929|NCT01147016|estrogen receptor-negative breast cancer
384930|NCT01147016|HER2-negative breast cancer
384931|NCT01147016|male breast cancer
384932|NCT01147016|progesterone receptor-negative breast cancer
384933|NCT01147016|recurrent breast cancer
384934|NCT01147016|stage IIA breast cancer
384935|NCT01147016|stage IIB breast cancer
384936|NCT01147016|stage IIIA breast cancer
384937|NCT01147016|stage IIIB breast cancer
384938|NCT01147016|triple-negative breast cancer
384939|NCT01147003|Seizure frequency
384940|NCT01147003|nervous system diseases
384941|NCT01147003|brain diseases
384942|NCT01147003|neurologic manifestations
384943|NCT01147003|adjunctive treatment
384944|NCT01147003|AEDs
384945|NCT01147003|antiepileptic drug
384946|NCT01146990|17P Efficacy Trial Follow up
384947|NCT01146977|CBF(+)
384948|NCT01146964|Age related cataract
384949|NCT01146964|Phacoemulsification
384950|NCT01146964|Manual super small incision cataract surgery
384951|NCT01146951|Epilepsy
384952|NCT01146951|Seizures
384953|NCT01146938|fimasartan
384954|NCT01146938|hepatic impairment
384955|NCT01146925|Acute Kidney Injury
384956|NCT01146925|Contrast-Induced Nephropathy
384957|NCT01146925|Labile Iron
384958|NCT01146925|Iron Chelation
384959|NCT01146925|Deferiprone
384960|NCT01146912|Influenza, text message, vaccination
384961|NCT01146899|influenza, vaccine, clinical decision support
384962|NCT01146860|BNO 1016, acute rhinosinusitis
384963|NCT01146847|algorithm
384964|NCT01146847|tight glycemic control
384965|NCT01146847|glucose control
384966|NCT01146847|intensive care
384967|NCT01146847|insulin
384968|NCT01146847|ICU
384969|NCT01146808|Vaccination
384970|NCT01146808|Immunocompromised Host
384971|NCT01146808|Antiviral Agents
384972|NCT01146808|Drug Resistance, Viral
384973|NCT01146808|Resource Allocation
384974|NCT01146769|Cancer of rectum
384975|NCT01146769|Physiotherapy
384976|NCT01146756|MEK inhibitor
384977|NCT01146756|thoracic radiotherapy
384978|NCT01146756|lung cancer
384979|NCT01146743|EUS-guided transmural cholecystostomy
384980|NCT01146730|Anxiety
384981|NCT01146730|Depression
384982|NCT01146730|Vocational Rehabilitation
384983|NCT01146730|Common Mental Disorders
384984|NCT01146730|Mental Health Problems
384985|NCT01146730|Work Related Therapy
384986|NCT01146717|Mild Cognitive Impairment
384987|NCT01146717|Exercise
384988|NCT01146704|Obesity
384989|NCT01146691|Organizational models
384990|NCT01146691|Intensive care units
384991|NCT01146691|Physicians
384992|NCT01146691|Staffing and scheduling
384993|NCT01146691|Burnout, professional
384994|NCT01146691|Job satisfaction
384995|NCT01146691|Education, medical
384996|NCT01146691|Patient satisfaction
384997|NCT01146665|alcohol consumption
384998|NCT01146665|personalized assessment feedback
384999|NCT01146665|youth
385000|NCT01146665|emergency department
385001|NCT01146639|EVAR DynaCT
385002|NCT01146626|Vitamin D
385003|NCT01146626|Hepatitis C
385004|NCT01146626|Genotype2,3
385005|NCT01146626|SVR
385006|NCT01146626|Naive
385007|NCT01146626|RVR rate
385008|NCT01146626|EVR rate
385009|NCT01146626|SVR rate
385010|NCT01146613|Alcohol
385011|NCT01146613|Alcohol abuse
385012|NCT01146613|Alcoholism
385013|NCT01146613|Alcohol Dependence
385014|NCT01146613|Varenicline
385015|NCT01146613|Drinking
385016|NCT01146600|Primary hypersomnia
385017|NCT01146600|CNS hypersomnia
385018|NCT01146600|hypersomnia
385019|NCT01146600|idiopathic hypersomnia
385020|NCT01146600|narcolepsy without cataplexy
385021|NCT01146600|clarithromycin
385022|NCT01146587|Stroke
385023|NCT01146587|Robotics
385024|NCT01146587|Gait
385025|NCT01146587|Rehabilitation
385026|NCT01146574|End-Stage Renal Disease
385027|NCT01146574|Anemia
385028|NCT01146574|Hemodialysis
385029|NCT01146574|Renal Anemia
385030|NCT01146574|ESRD
385031|NCT01146548|Fluoxetine effect
385032|NCT01146548|Multiple System Atrophy
385033|NCT01146548|MSA
385034|NCT01146535|interferon-alpha
385035|NCT01146535|oseltamivir
385036|NCT01146535|drug therapy, combination
385037|NCT01146535|influenza
385038|NCT01146535|therapies, investigational
385039|NCT01146522|Familial hyperchylomicronemia
385040|NCT01146522|Lipoprotein lipase deficiency
385041|NCT01146522|Hyperlipoproteinemia
385042|NCT01146522|Triglycerides
385043|NCT01146522|Hypertriglyceridemia
385044|NCT01146522|LCQ908
385045|NCT01146522|Hyperlipoproteinemia associated with lipoprotein lipase deficiency
385046|NCT01146509|migraine
385047|NCT01146509|headache
385048|NCT01146496|Pesticide poisoning
385049|NCT01146496|Suicide
385050|NCT01146496|Unintentional poisoning
385051|NCT01146496|Prevention
385052|NCT01146496|Cluster randomised controlled trial
385053|NCT01146457|Obstetric anesthesia
385054|NCT01146457|labor analgesia
385055|NCT01146457|morphine
385056|NCT01146457|epidural analgesia
385057|NCT01146444|Sunscreening Agents
385058|NCT01146418|Reproductive Techniques, Assisted
385059|NCT01146418|Follicle Stimulating Hormone, Human
385060|NCT01146418|Fertilization In Vitro
385061|NCT01146405|Laparoscopic
385062|NCT01146392|Epidemiological
385063|NCT01146392|COPD health care
385064|NCT01146392|treatment in primary care
385065|NCT01146379|stroke
385066|NCT01146379|upper extremity
385067|NCT01146379|paresis
385068|NCT01146379|function
385069|NCT01146379|translational research
385070|NCT01146366|Early stage lung cancer
385071|NCT01146366|Cervical mediastinoscopy
385072|NCT01146366|Observational study
385073|NCT01146366|clinical stage T2N0M0 and select T1N0M0 (suvMAX on FDG-PET of >/=10)
385074|NCT01146353|peramivir
385075|NCT01146353|CVVH
385076|NCT01146353|CRRT
385077|NCT01146353|CVVHD
385078|NCT01146353|influenza
385079|NCT01146353|sieving coefficient
385080|NCT01146353|clearance
385081|NCT01146340|Prostatic Neoplasms
385082|NCT01146340|Radiotherapy
385083|NCT01146340|Hypofractionation
385084|NCT01146340|Low and Intermediate Risk Prostate Cancer
385085|NCT01146327|Multiple Dose Study in Overweight Healthy Subjects
385086|NCT01146327|body weight
385087|NCT01146314|family-focused intervention
385088|NCT01146314|pediatric obesity
385089|NCT01146314|diabetes prevention
385090|NCT01146301|Platelet Aggregation Inhibitors
385091|NCT01146301|Coronary Artery Bypass Grafting
385092|NCT01146288|obesity
385093|NCT01146288|acetazolamide
385094|NCT01146288|furosemide
385095|NCT01146275|Patients who participated in pilot study (31GB0601) and performed breast augmentation with previous formulation of Macrolane
385096|NCT01146262|Antitumoral immune response after autologous dendritic cells vaccination
385097|NCT01146249|Multisensorial integration
385098|NCT01146249|Postural control
385099|NCT01146249|Visual reliance
385100|NCT01146236|Surgical
385101|NCT01146236|Infection
385102|NCT01146236|Post-operative
385103|NCT01146236|Sutures
385104|NCT01146236|Staples
385105|NCT01146197|Hypokalemia
385106|NCT01146197|Hypomagnesemia
385107|NCT01146197|Salt loosing nephropathy
385108|NCT01146184|Cholelithiasis
385109|NCT01146184|Single Incision
385110|NCT01146184|Flexible Endoscope
385111|NCT01146184|Ethicon Manually Articulating Device
385112|NCT01146184|Pain
385113|NCT01146158|Axillary dissection
385114|NCT01146145|postoperative
385115|NCT01146145|pain
385116|NCT01146145|analgesia
385117|NCT01146145|morphine
385118|NCT01146145|titration
385119|NCT01146145|ketamine
385120|NCT01146132|Nutrition
385121|NCT01146132|Physical activity
385122|NCT01146132|Cerebrovascular disease
385123|NCT01146132|wine consumption
385124|NCT01146132|BMI
385125|NCT01146132|Pulse transit time
385126|NCT01146132|transcranial Doppler sonography
385127|NCT01146119|HAI
385128|NCT01146119|Influenza
385129|NCT01146119|prime
385130|NCT01146119|boost
385131|NCT01146119|immune response
385132|NCT01146119|seroconversion
385133|NCT01146119|universal
385134|NCT01146119|vaccine
385135|NCT01146080|drug eluting stent
385136|NCT01146080|everolimus eluting stent
385137|NCT01146080|optical coherence tomography
385138|NCT01146080|intravascular ultrasound
385139|NCT01146067|Bioequivalence
385140|NCT01146041|Bioequivalence
385141|NCT01146015|Influenza
385142|NCT01146015|Vaccine
385143|NCT01146015|CHMP criteria
385144|NCT01146002|Attention-deficit/hyperactivity disorder, primarily inattentive or combined type.
385145|NCT01145989|Relapsed or Refractory Multiple Myeloma
385146|NCT01145976|aplastic anemia, fludarabine, cyclophosphamide, thymoglobulin
385147|NCT01145963|pasta
385148|NCT01145963|appetite
385149|NCT01145963|hunger
385150|NCT01145963|satiation
385151|NCT01145963|nutrition
385152|NCT01145963|Psychological Phenomena and Processes
385153|NCT01145950|Etanercept
385154|NCT01145950|Enbrel
385155|NCT01145950|healthy volunteers
385156|NCT01145937|Keratoconus
385157|NCT01145937|Corneal grafting
385158|NCT01145937|Corneal transplantation
385159|NCT01145937|Anterior Lamellar Keratoplasty
385160|NCT01145924|bronchoscopy
385161|NCT01145924|endobronchial ultrasound
385162|NCT01145924|transbronchial needle aspiration
385163|NCT01145924|lung cancer
385164|NCT01145924|staging
385165|NCT01145911|Glaucoma
385166|NCT01145911|Blood Flow
385167|NCT01145911|Progression
385168|NCT01145898|Glaucoma
385169|NCT01145898|Cosopt
385170|NCT01145898|blood flow
385171|NCT01145898|progression
385172|NCT01145872|Mindfulness
385173|NCT01145872|clinical trial
385174|NCT01145872|intervention
385175|NCT01145872|prevention
385176|NCT01145859|Venous Thrombosis
385177|NCT01145859|Pediatrics
385178|NCT01145833|obesity
385179|NCT01145833|guided self help treatment
385180|NCT01145833|treatment method
385181|NCT01145833|overweight
385182|NCT01145833|overweight children and parents
385183|NCT01145833|families with overweight child
385184|NCT01145833|efficacy
385185|NCT01145833|body mass index
385186|NCT01145833|weight
385187|NCT01145820|third molar
385188|NCT01145820|trauma
385189|NCT01145820|pain
385190|NCT01145820|wound healing
385191|NCT01145820|post operative morbidity
385192|NCT01145820|acute trauma
385193|NCT01145820|short-term wound healing
385194|NCT01145807|Distal Subungual Toenail Onychomycosis
385195|NCT01145794|SHS
385196|NCT01145781|ectocervical CIN lesions
385197|NCT01145768|Double-blind
385198|NCT01145768|randomized
385199|NCT01145768|placebo-controlled
385200|NCT01145768|parallel-group study
385201|NCT01145768|Safety
385202|NCT01145768|pharmacokinetics
385203|NCT01145755|Depression
385204|NCT01145742|Type 2 diabetes
385205|NCT01145742|Hypertension
385206|NCT01145742|Health services research
385207|NCT01145742|Health disparities
385208|NCT01145742|Behavior change
385209|NCT01145729|Biomarker feedback
385210|NCT01145729|Smoking cessation
385211|NCT01145729|Childhood secondhand smoke exposure
385212|NCT01145716|TFCC injuries
385213|NCT01145716|Distal radius fractures
385214|NCT01145703|Body Composition
385215|NCT01145703|Cardiovascular Risk
385216|NCT01145703|Cognitive Function
385217|NCT01145690|cognitive behaviour therapy
385218|NCT01145677|Alcohol dependence
385219|NCT01145677|Alcoholism
385220|NCT01145677|Topiramate
385221|NCT01145664|Chinese medicines
385222|NCT01145664|Severe hand-foot-mouth diseases
385223|NCT01145664|effectiveness
385224|NCT01145664|safety
385225|NCT01145638|cancer
385226|NCT01145638|chemotherapy induced anaemia
385227|NCT01145638|iron
385228|NCT01145638|Patients with non-myeloid malignancies and Chemotherapy Induced Anaemia (CIA)
385229|NCT01145638|CIA
385230|NCT01145625|Female Pattern Baldness
385231|NCT01145612|Aortic dilation
385232|NCT01145612|Marfan syndrome
385233|NCT01145612|Losartan
385234|NCT01145612|Atenolol
385235|NCT01145573|calcium
385236|NCT01145573|vitamin D
385237|NCT01145573|bone
385238|NCT01145573|pregnancy
385239|NCT01145560|severe sepsis
385240|NCT01145560|TNF neutralisation
385241|NCT01145560|septic shock patients
385242|NCT01145547|glycemic index
385243|NCT01145547|Diabetes Mellitus
385244|NCT01145547|continuous glucose monitoring
385245|NCT01145534|diabetes,
385246|NCT01145534|medicinal plants,
385247|NCT01145534|glucose
385248|NCT01145482|Memory Disorders
385249|NCT01145482|Alzheimer's Disease
385250|NCT01145469|stage I chronic lymphocytic leukemia
385251|NCT01145469|stage II chronic lymphocytic leukemia
385252|NCT01145469|stage III chronic lymphocytic leukemia
385253|NCT01145469|stage IV chronic lymphocytic leukemia
385254|NCT01145469|B-cell chronic lymphocytic leukemia
385255|NCT01145443|Organizational models
385256|NCT01145443|Intensive care units
385257|NCT01145443|Physicians
385258|NCT01145443|Staffing and scheduling
385259|NCT01145443|Burnout, professional
385260|NCT01145443|Job satisfaction
385261|NCT01145417|peripheral neuropathic pain
385262|NCT01145417|pregabalin
385263|NCT01145417|safety
385264|NCT01145404|Her2 Gastro Gastric Esophageal Cancer
385265|NCT01145391|hypertension
385266|NCT01145391|blood pressure
385267|NCT01145391|primary care
385268|NCT01145391|patient centered medical home
385269|NCT01145391|health information technology
385270|NCT01145391|clinical inertia
385271|NCT01144351|MS
385272|NCT01144351|SPMS
385273|NCT01144351|RRMS
385274|NCT01144351|Relapsing Forms of Secondary Progressive Multiple Sclerosis (SPMS)
385275|NCT01144351|or Relapsing-Remitting Multiple Sclerosis (RRMS)
385276|NCT01144338|exenatide once weekly
385277|NCT01144338|cardiovascular
385278|NCT01144338|Bydureon
385279|NCT01144338|Amylin
385280|NCT01144325|Minimally Invasive Esophagectomy
385281|NCT01144312|LDLT
385282|NCT01144299|Influenza
385283|NCT01144286|VVC
385284|NCT01144286|candidiasis
385285|NCT01144286|vaginal candidiasis
385286|NCT01144260|CLL
385287|NCT01144260|leukemia
385288|NCT01144260|chronic lymphocytic leukemia
385289|NCT01144247|Recurrent Grade III or Grade IV Gliomas
385290|NCT01144247|anaplastic astrocytoma
385291|NCT01144247|anaplastic oligodendroglioma
385292|NCT01144247|anaplastic mixed glioma
385293|NCT01144247|glioblastoma multiforme
385294|NCT01144247|biotherapy
385295|NCT01144247|malignant meningioma
385296|NCT01144234|Prevention of mother-to-child transmission of HIV-1
385297|NCT01144221|Chronic Ischemic Heart Disease
385298|NCT01144208|Radius fracture
385299|NCT01144208|Adverse effects
385300|NCT01144208|Wrist
385301|NCT01144208|Postoperative complications
385302|NCT01144208|Colles' fracture
385303|NCT01144208|Intraoperative complications
385304|NCT01144208|Osteoporosis
385305|NCT01144208|Dual-energy x-ray absorptiometry (DXA)
385306|NCT01144208|Bone Density
385307|NCT01145365|Crohns
385308|NCT01145365|Fistula
385309|NCT01145365|Perianal Abscess
385310|NCT01145365|Perianal
385311|NCT01145352|Enbrel-JIA
385312|NCT01145326|venipuncture
385313|NCT01145326|phlebotomy
385314|NCT01145326|pain perception
385315|NCT01145300|COPD
385316|NCT01145300|Inflammation
385317|NCT01145300|Small airways
385318|NCT01145287|Celiac disease
385319|NCT01145287|Gluten-free diet
385320|NCT01145287|Screen-detected
385321|NCT01145287|Asymptomatic
385322|NCT01145287|Quality of life
385323|NCT01145287|Self-perceived health
385324|NCT01145287|Healthcare resource utilization
385325|NCT01145274|allopurinol
385326|NCT01145274|chronic kidney diseae
385327|NCT01145261|Anxiety,
385328|NCT01145261|Emotional Regulation
385329|NCT01145248|Cholangiocellular Carcinoma
385330|NCT01145235|Breast augmentation with Macrolane
385331|NCT01145222|CNS 7056
385332|NCT01145222|Procedural Sedation
385333|NCT01145222|Colonoscopy
385334|NCT01145209|Arzerra
385335|NCT01145209|Chemoimmunotherapy
385336|NCT01145209|CLL (Chronic Lymphocytic Leukemia)
385337|NCT01145209|SLL
385338|NCT01145209|Small Lymphocytic Lymphoma (SLL)
385339|NCT01145196|Retinal Disease
385340|NCT01145196|Plaquenil-Induced
385341|NCT01145183|Cocaine Dependence
385342|NCT01145183|Substance Related Disorders
385343|NCT01145183|genotype
385344|NCT01145170|brainstem gliomas
385345|NCT01145170|pediatric patients
385346|NCT01145157|knee
385347|NCT01145157|arthroplasty
385348|NCT01145144|Dehydroepiandrosterone
385349|NCT01145144|DHEA
385350|NCT01145144|IVF outcome
385351|NCT01145144|long protocol IVF
385352|NCT01145144|poor-responder
385353|NCT01145144|recombinant LH
385354|NCT01145144|embryo quality
385355|NCT01145144|pregnancy rate
385356|NCT01145144|live birth rate
385357|NCT01145144|poor response to ovarian stimulation
385358|NCT01145131|muscle
385359|NCT01145131|FSR
385360|NCT01145131|protein
385361|NCT01145131|meat
385362|NCT01145118|Plantar Fasciitis
385363|NCT01145118|Physiotherapy
385364|NCT01145105|Low back pain
385365|NCT01145105|Sciatica
385366|NCT01145105|Pain
385367|NCT01145105|Physiotherapy
385368|NCT01145092|type 2 diabetes
385369|NCT01145092|exercise training
385370|NCT01145092|ATP-synthesis
385371|NCT01145092|intramyocellular lipids
385372|NCT01145092|hepatocellular lipids
385373|NCT01145092|first degree relatives of T2DM patients
385374|NCT01145066|diabetes
385375|NCT01145066|metabolic syndrome
385376|NCT01145066|inflammation
385377|NCT01145066|botanical oils
385378|NCT01145040|Overt primary hypothyroidism
385379|NCT01145040|Overt primary hyperthyroidism
385380|NCT01145040|Thyrotropic feedback control
385381|NCT01145040|Mathematical modelling
385382|NCT01145040|Nonlinear modelling
385383|NCT01145040|Thyroid
385384|NCT01145040|Pituitary
385385|NCT01145040|Physiological cybernetics
385386|NCT01145040|Full-dose levothyroxine substitution therapy
385387|NCT01145040|Syndrome T
385388|NCT01145027|Capillary recruitment
385389|NCT01145027|Cephalic Phase of Insulin Secretion
385390|NCT01145027|Dietary Intake
385391|NCT01145001|smoking
385392|NCT01145001|adolescents
385393|NCT01145001|contingency management
385394|NCT01145001|nicotine replacement therapy
385395|NCT01144988|Recurrent Malignant Glioma
385396|NCT01144988|Bevacizumab / Irinotecan
385397|NCT01144988|Functional MR Imaging
385398|NCT01144988|Metabolic Imaging (FET/FLT-PET)
385399|NCT01144975|Diabetes
385400|NCT01144975|Type 2
385401|NCT01144975|Mellitus
385402|NCT01144962|Crohn's Disease
385403|NCT01144962|Fistula
385404|NCT01144962|Mesenchymal Stem Cell
385405|NCT01144962|Mesenchymal Stromal Cell
385406|NCT01144962|MSC
385407|NCT01144962|IBD
385408|NCT01144949|ureteral calculi
385409|NCT01144949|renal colic
385410|NCT01144949|ureteral stones
385411|NCT01144949|kidney stones
385412|NCT01144949|medical expulsive therapy
385413|NCT01144923|epidural steroid injection
385414|NCT01144923|neck pain
385415|NCT01144923|pharmacotherapy
385416|NCT01144923|radiculopathy
385417|NCT01144910|asthma
385418|NCT01144910|preschool child
385419|NCT01144910|bronchial hyperresponsiveness
385420|NCT01144910|methacholine challenge test
385421|NCT01144910|atopy
385422|NCT01144897|Castrate resistant
385423|NCT01144897|Prostate cancer
385424|NCT01144897|Docetaxel
385425|NCT01144897|Taxotere
385426|NCT01144897|PET Acetate
385427|NCT01144884|Neck pain
385428|NCT01144884|education
385429|NCT01144884|exercise
385430|NCT01144884|clinical prediction rule
385431|NCT01144871|adolescent
385432|NCT01144871|reproductive health
385433|NCT01144871|parents
385434|NCT01144871|STIs
385435|NCT01144871|confidentiality
385436|NCT01144871|Examine parental knowledge/attitudes of confidential health services/STI care for adolescents.
385437|NCT01144871|Examine how parental knowledge/attitudes affects parent's behavioral intentions to support adolescent's access to confidential care.
385438|NCT01144871|Identify key mechanisms to form an intervention to parents knowledge/skills to facilitate teen's access to confidential STI services.
385439|NCT01144858|atrial fibrillation
385440|NCT01144858|ablation catheter
385441|NCT01144858|left atrial appendage peak emptying velocity
385442|NCT01144858|tool for predicting successful catheter ablation
385443|NCT01144845|Thoracotomy
385444|NCT01144845|Thoracic Surgery
385445|NCT01144845|Thoracic Surgical Procedures
385446|NCT01144845|Thoracic Surgery, Video-Assisted
385447|NCT01144845|Lung Neoplasms
385448|NCT01144845|Thoracic Nerves
385449|NCT01144832|visceral hypersensitivity
385450|NCT01144832|mast cells
385451|NCT01144819|STEMI
385452|NCT01144819|Acute myocardial infarction
385453|NCT01144819|Antiplatelet therapy
385454|NCT01144819|aspirin
385455|NCT01144819|clopidogrel
385456|NCT01144819|VerifyNow aggregometry
385457|NCT01144819|Multiplate aggregometry
385458|NCT01144806|SAM
385459|NCT01144806|RUTF
385460|NCT01144806|BIA
385461|NCT01144806|D2O
385462|NCT01144806|Children with severe malnutrition
385463|NCT01144741|rehabilitation
385464|NCT01144741|surgery
385465|NCT01144741|therapy
385466|NCT01144715|Stroke Rehabilitation
385467|NCT01144715|Home rehabilitation
385468|NCT01144715|robotic therapy
385469|NCT01144702|malaria
385470|NCT01144702|Plasmodium falciparum
385471|NCT01144702|artesunate and mefloquine combination (ASMQ)
385472|NCT01144702|treatment
385473|NCT01144702|Juruá Valley
385474|NCT01144702|Brazil
385475|NCT01144702|multidrug resistance 1 gene of Plasmodium falciparum -Pfmdr1
385476|NCT01144689|mindfulness
385477|NCT01144689|smoking
385478|NCT01144689|stress
385479|NCT01144663|Infants
385480|NCT01144663|conjugate vaccine
385481|NCT01144663|immunogenicity
385482|NCT01144663|meningococcal vaccine
385483|NCT01144663|non-inferiority
385484|NCT01144663|co-administration
385485|NCT01144650|Dapsone
385486|NCT01144650|Cerebrovascular Accident, Acute
385487|NCT01144650|Neuroprotection
385488|NCT01144624|TNF neutralisation
385489|NCT01144611|valve replacement
385490|NCT01144611|CABG
385491|NCT01144611|SIRTS
385492|NCT01144611|Combined aortic valve replacement and CABG surgery
385493|NCT01144598|Rheumatoid Arthritis
385494|NCT01144598|Disease-Modifying Anti-Rheumatic Drug
385495|NCT01144598|Work Limitation
385496|NCT01144585|RIPC
385497|NCT01144585|lung protection
385498|NCT01144585|ischemic reperfusion injury
385499|NCT01144585|cardiopulmonary bypass
385500|NCT01144572|Quality of Life
385501|NCT01144572|postmenopausal HR(+)
385502|NCT01144572|Early Breast Cancer
385503|NCT01144572|adjuvant AI treatment
385504|NCT01144572|Quality of Life in Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
385505|NCT01144559|Femoral
385506|NCT01144559|Nerve Block
385507|NCT01144559|Bolus
385508|NCT01144559|Continuous Infusion
385509|NCT01144559|UCSD
385510|NCT01144559|Perineural Catheter
385511|NCT01144559|Volunteer
385512|NCT01144559|lower extremity nerve blocks
385513|NCT01144546|Passive leg raising
385514|NCT01144546|FloTrac/Vigileo
385515|NCT01144546|Anesthesia hypotension
385516|NCT01144507|Cystic Fibrosis
385517|NCT01144507|Pancreatic insufficiency
385518|NCT01144494|Aqueous Humor Dynamics
385519|NCT01144494|Aqueous Humor Dynamics and Circadian Rhythms
385520|NCT01144481|bone metastasis
385521|NCT01144481|breast cancer
385522|NCT01144481|skeletal related event
385523|NCT01144481|HR-pQCT
385524|NCT01144481|VFA
385525|NCT01144468|breast cancer prevention
385526|NCT01144468|osteoporosis
385527|NCT01144455|Locally Advanced Unresectable Pancreatic Adenocarcinoma
385528|NCT01144455|Metastatic Pancreatic Adenocarcinoma
385529|NCT01144455|Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
385530|NCT01144442|recurrent ovarian cancer
385531|NCT01144442|recurrent fallopian tube cancer
385532|NCT01144442|recurrent peritoneal carcinoma
385533|NCT01144429|Allergic Rhinitis +- intermittent asthma
385534|NCT01144429|Allergic Rhinoconjunctivitis +- intermittent asthma
385535|NCT01144429|Specific Immunotherapy
385536|NCT01144416|Reproductive Techniques, Assisted
385537|NCT01144416|Follicle Stimulating Hormone, Human
385538|NCT01144416|Fertilization In Vitro
385539|NCT01144390|heroin dependence
385540|NCT01144390|community-based
385541|NCT01144390|MMT
385542|NCT01144377|osteoporosis
385543|NCT01144182|heart failure
385544|NCT01144182|quality of life
385545|NCT01144182|readmissions
385546|NCT01144169|Renal cell carcinoma
385547|NCT01144169|Hydroxychloroquine
385548|NCT01144169|Nephrectomy
385549|NCT01144169|Autophagy
385550|NCT01144156|Crohn's disease
385551|NCT01144156|Small bowel
385552|NCT01144156|Mucosal healing
385553|NCT01144156|Capsule endoscopy
385554|NCT01144156|Adalimumab
385555|NCT01144156|Small bowel Crohn's disease
385556|NCT01144143|Mild to moderate osteoarthritis of the knee
385557|NCT01144117|Progressive Multiple Sclerosis
385558|NCT01144091|diabetes mellitus
385559|NCT01144091|creatinin level
385560|NCT01144091|contrast induced nephropathy
385561|NCT01144091|prevention contrast induced nephropathy in high risk patients
385562|NCT01144078|Adiposity
385563|NCT01144078|Exercise training
385564|NCT01144078|Older adults
385565|NCT01144065|Myocardial infarction
385566|NCT01144065|Cortisol
385567|NCT01144065|Testosterone
385568|NCT01144052|Natalizumab
385569|NCT01144052|Interferon-beta 1b
385570|NCT01144052|De-escalation
385571|NCT01144052|Ticino
385572|NCT01144026|HIV
385573|NCT01144026|vaccine
385574|NCT01144026|lipopeptide
385575|NCT01144026|Tat
385576|NCT01144026|TUTI-16
385577|NCT01144026|THYMON
385578|NCT01144000|Prosthetic joint infection
385579|NCT01144000|daptomycin
385580|NCT01144000|staphylococcus
385581|NCT01143987|hyperparathyroidism
385582|NCT01143987|pulse wave velocity
385583|NCT01143987|end-stage renal disease
385584|NCT01143987|arterial stiffness
385585|NCT01143974|progress free survival
385586|NCT01143974|response rate
385587|NCT01143974|safety
385588|NCT01143961|Positive pressure ventilation
385589|NCT01143961|Electrical impedance tomography
385590|NCT01143948|Diabetes
385591|NCT01143948|Cirrhosis
385592|NCT01143948|Insulin
385593|NCT01143948|Inpatient
385594|NCT01143935|Liver volume estimation
385595|NCT01143935|Indian population
385596|NCT01143922|Intraoperative ultrasound
385597|NCT01143922|GI tract malignancies
385598|NCT01143922|modality
385599|NCT01143922|ultrasound
385600|NCT01143922|staging modality
385601|NCT01143909|Fresh frozen plasma
385602|NCT01143909|Coagulopathy
385603|NCT01143909|Intensive care
385604|NCT01143909|Adverse effects
385605|NCT01143909|Lung injury
385606|NCT01143896|Hepatitis C
385607|NCT01143896|Depression
385608|NCT01143896|Collaborative care
385609|NCT01143896|Antiviral treatment
385610|NCT01143883|All patients undergoing a colorectal resection
385611|NCT01143883|surgical site infections
385612|NCT01143844|Oncofertility
385613|NCT01143844|Fertility
385614|NCT01143844|Late effects
385615|NCT01143844|cancer
385616|NCT01143844|chemotherapy
385617|NCT01143844|radiation therapy
385618|NCT01143844|survivor
385619|NCT01143844|ovarian reserve
385620|NCT01143844|premature ovarian failure
385621|NCT01143844|early menopause
385622|NCT01143844|healthy volunteers
385623|NCT01143844|perimenopause
385624|NCT01143844|middle age
385625|NCT01143844|pediatric survivors
385626|NCT01143844|healthy women
385627|NCT01143831|Vitamin K
385628|NCT01143831|Thrombosis
385629|NCT01143818|Male hypogonadism
385630|NCT01143805|Absolute Bioavailability
385631|NCT01143805|Rheumatoid Arthritis
385632|NCT01143792|Substance abuse
385633|NCT01143792|Homelessness
385634|NCT01143792|HIV risk behavior
385635|NCT01143779|Advanced Malignancy
385636|NCT01143779|FLT-PET Scan
385637|NCT01143779|[F-18]-fluoro-L-thymidine
385638|NCT01143779|FLT
385639|NCT01143779|Positron emission tomography
385640|NCT01143779|PET
385641|NCT01143779|Imaging Biomarker
385642|NCT01143779|Temsirolimus
385643|NCT01143779|Topotecan
385644|NCT01143779|Bortezomib
385645|NCT01143766|Sedation
385646|NCT01143766|Gabapentin
385647|NCT01143766|ERCP
385648|NCT01143766|Endoscopy
385649|NCT01143675|Humerus fractures
385650|NCT01143675|Tomography, x-ray computed
385651|NCT01143675|Bone and bones
385652|NCT01143675|Orthopedic fixation devices
385653|NCT01143675|Surgery
385654|NCT01143675|Postoperative complications
385655|NCT01143675|Osteoporosis
385656|NCT01143675|Intraoperative complications
385657|NCT01143675|Bone density
385658|NCT01143675|Radiography, dual-energy scanned projection
385659|NCT01143662|peginterferon
385660|NCT01143662|interferon
385661|NCT01143662|Pegasys
385662|NCT01143662|HBV
385663|NCT01143662|Hepatitis B
385664|NCT01143662|HBeAg positive
385665|NCT01143649|Stroke
385666|NCT01143649|Transcranial direct current stimulation
385667|NCT01143649|Motor function
385668|NCT01143636|Transcranial direct current stimulation
385669|NCT01143636|Chronic Pelvic Pain
385670|NCT01143623|antibiotic
385671|NCT01143623|diarrhea
385672|NCT01143623|probiotic
385673|NCT01143610|Root coverage
385674|NCT01143610|Graft
385675|NCT01143610|Soft tissue
385676|NCT01143610|Periodontal regeneration
385677|NCT01143597|task-specific training
385678|NCT01143597|arm and hand function
385679|NCT01143597|corticomotor plasticity
385680|NCT01143597|individuals with motor-incomplete spinal cord injury
385681|NCT01143584|Prolactin
385682|NCT01143584|Cabergoline
385683|NCT01143584|Macroadenomas
385684|NCT01143584|escalation
385685|NCT01143571|Microbiome
385686|NCT01143571|Samples
385687|NCT01143558|Borrelia Burgdorferi
385688|NCT01143558|Xenodiagnosis
385689|NCT01143558|Ticks
385690|NCT01143558|Skin Biopsy
385691|NCT01143558|Lyme Disease
385692|NCT01143545|Cancer Vaccine
385693|NCT01143545|Immunotherapy
385694|NCT01143545|Adjuvant Therapy
385695|NCT01143545|Surgical Intervention
385696|NCT01143545|Lung Cancer
385697|NCT01143545|Esophageal Cancer
385698|NCT01143545|Thymic Carcinoma
385699|NCT01143545|Malignant Pleural Mesothelioma
385700|NCT01143532|African-Americans
385701|NCT01143532|MYH9
385702|NCT01143532|Chronic Kidney Disease
385703|NCT01143532|Focal Segmental Glomerulosclerosis
385704|NCT01143532|Proteinuria
385705|NCT01143532|Kidney Disease
385706|NCT01143532|Kidney Transplant
385707|NCT01143532|African-American
385708|NCT01143519|p53
385709|NCT01143519|Inflammatory Response
385710|NCT01143519|Gene Association
385711|NCT01143519|Nutlin
385712|NCT01143519|Doxorubicin
385713|NCT01143519|Healthy Volunteer
385714|NCT01143519|HV
385715|NCT01143506|Sense of Agency
385716|NCT01143506|Ulnar Nerve Block
385717|NCT01143506|Healthy Volunteer
385718|NCT01143506|fMRI
385719|NCT01143506|EEG
385720|NCT01143493|Genetic Polymorphism
385721|NCT01143493|Glucocorticoid
385722|NCT01143493|Health Volunteer
385723|NCT01143493|HV
385724|NCT01143480|Endotoxin
385725|NCT01143480|Cytokines
385726|NCT01143480|Gene Association
385727|NCT01143480|Inflammatory Response
385728|NCT01143480|Healthy Volunteer
385729|NCT01143480|HV
385730|NCT01143467|Fatigue
385731|NCT01143467|Mitochondria
385732|NCT01143467|Mitochondrial Abnormality
385733|NCT01143467|Oxidative Stress
385734|NCT01143467|Gene Expression
385735|NCT01143467|Prostate Cancer
385736|NCT01143454|Cardiac Disease
385737|NCT01143454|iPS Cells
385738|NCT01143454|Cardiac Risk Factors
385739|NCT01143454|Cardiac Disease Discovery
385740|NCT01143454|Heart Disease
385741|NCT01143454|Heart Disease Risk
385742|NCT01143441|Multiple Sclerosis
385743|NCT01143441|Daclizumab
385744|NCT01143428|Motor Neuron Disease
385745|NCT01143428|Primary Lateral Sclerosis
385746|NCT01143428|Oxidative Stress
385747|NCT01143428|Physiology
385748|NCT01143428|PLS
385749|NCT01143389|Keratoconus
385750|NCT01143389|Ectasia
385751|NCT01143389|cross linking
385752|NCT01143389|collagen cross linking
385753|NCT01143376|Obesity
385754|NCT01143376|exercise
385755|NCT01143376|body composition
385756|NCT01143376|insulin sensitivity
385757|NCT01143376|appetite
385758|NCT01143376|food intake
385759|NCT01143363|Obesity
385760|NCT01143363|exercise
385761|NCT01143363|appetite
385762|NCT01143363|hunger
385763|NCT01143363|satiety
385764|NCT01143363|food intake
385765|NCT01143337|Rheumatoid Arthritis
385766|NCT01143324|Single or double level instrumented fusion
385767|NCT01143324|Degenerative lumbar spine
385768|NCT01143324|PLIF
385769|NCT01143324|TLIF
385770|NCT01143324|MAST procedure
385771|NCT01143285|Active nutritional and dietary management
385772|NCT01143285|Metastatic colorectal cancer
385773|NCT01143285|Non surgical metastatic colorectal cancer
385774|NCT01143272|antibiotic
385775|NCT01143272|associated
385776|NCT01143272|diarrhoea
385777|NCT01143272|saccharomyces boulardii
385778|NCT01143272|Antibiotic-associated diarrhoea (AAD)
385779|NCT01143272|Clostridium difficile-associated-diarrhoea (CDAD)
385780|NCT01143259|Ileus
385781|NCT01143259|Post operative ileus
385782|NCT01143246|Hepatorenal syndrome
385783|NCT01143246|Renal failure
385784|NCT01143246|Cirrhosis
385785|NCT01143246|Alcoholic hepatitis
385786|NCT01143246|Ascites
385787|NCT01143220|Cardiac Resynchronization Therapy
385788|NCT01143220|Heart Failure
385789|NCT01143220|Pathologic Processes
385790|NCT01143220|Heart Diseases
385791|NCT01143220|Tachycardia
385792|NCT01143220|Cardiovascular Diseases
385793|NCT01143220|Ventricular Flutter
385794|NCT01143220|Tachycardia, Ventricular
385795|NCT01143220|Ventricular Fibrillation
385796|NCT01143220|Arrhythmias, Cardiac
385797|NCT01143220|Ease of Use
385798|NCT01143207|AE adverse event
385799|NCT01143207|DCF data collection forms
385800|NCT01143207|DMC Data Monitoring Committee
385801|NCT01143207|FDA U.S.) Food and Drug Administration
385802|NCT01143207|GCP Good Clinical Practice guidelines
385803|NCT01143207|ICH International Conference of Harmonisation
385804|NCT01143207|IND Investigational New Drug Application
385805|NCT01143207|IRB Institutional Review Board
385806|NCT01143207|IU International units
385807|NCT01143207|mg milligram(s)
385808|NCT01143207|SAE serious adverse event
385809|NCT01143207|µg microgram
385810|NCT01143207|ULN upper limit of the normal range
385811|NCT01143194|Attention
385812|NCT01143194|Vigilance
385813|NCT01143194|Concentration
385814|NCT01143194|Memory
385815|NCT01143194|Healthy Volunteer
385816|NCT01143181|CMV, ADV, HSV, VAVC, VARV
385817|NCT01143181|life threatening
385818|NCT01143168|stem cells;
385819|NCT01143168|diabetes mellitus;
385820|NCT01143168|treatment.
385821|NCT01143155|Pneumonia
385822|NCT01143155|Community-acquired pneumonia
385823|NCT01143155|Healthcare-associated pneumonia
385824|NCT01143155|Failure
385825|NCT01143155|Cardiovascular events
385826|NCT01143155|Outcome
385827|NCT01143142|Human papillomavirus
385828|NCT01143142|HPV
385829|NCT01143142|Prevention
385830|NCT01143142|Tailoring
385831|NCT01143142|Persuasive communication
385832|NCT01143142|Adolescent
385833|NCT01143129|Atrial fibrillation
385834|NCT01143129|Cardiac surgery
385835|NCT01143129|Cardiopulmonary bypass
385836|NCT01143129|New-onset
385837|NCT01142076|adiposity
385838|NCT01142063|Neratinib
385839|NCT01142050|stem cells;
385840|NCT01142050|diabetes mellitus;
385841|NCT01142050|treatment.
385842|NCT01142037|Healthy volunteer
385843|NCT01142024|contrast medium induced nephropathy
385844|NCT01142024|polymorphism of oxidative stress genes
385845|NCT01142024|antioxidant prevention
385846|NCT01142011|Waldenstroms
385847|NCT01142011|Belimumab
385848|NCT01142011|anti Blys
385849|NCT01142011|monoclonal antibody
385850|NCT01141985|cataract
385851|NCT01141985|cornea
385852|NCT01141985|keratoplasty
385853|NCT01141972|Vitamin D
385854|NCT01141972|Obesity
385855|NCT01141972|Menopause
385856|NCT01141972|Hot Flashes
385857|NCT01141959|hematopoietic stem cell transplantation
385858|NCT01141959|cyclophosphamide
385859|NCT01141959|fludarabine
385860|NCT01141959|mycophenolate mofetil
385861|NCT01141959|mycophenolic acid
385862|NCT01141959|biomarkers
385863|NCT01141946|lung cancer
385864|NCT01141946|pleural effusion
385865|NCT01141946|post-op care
385866|NCT01141946|diaphragmatic ultrasound
385867|NCT01141933|Creating meaning
385868|NCT01141933|Therapy
385869|NCT01141933|Cancer
385870|NCT01141933|Oncology
385871|NCT01141933|Existential
385872|NCT01141933|Spirituality
385873|NCT01141933|Quality of life
385874|NCT01141933|QOL
385875|NCT01141933|Psycho-oncology
385876|NCT01141933|French-canadian
385877|NCT01141933|Cognitive therapy
385878|NCT01141933|Existentialism
385879|NCT01141920|treatment retention
385880|NCT01141920|methadone maintenance
385881|NCT01141920|treatment induction
385882|NCT01141920|Retention in methadone maintenance treatment
385883|NCT01141907|heart failure
385884|NCT01141907|self care
385885|NCT01141907|decision support
385886|NCT01141907|telemonitoring
385887|NCT01141907|navigator
385888|NCT01141894|Proximal Femoral Fracture
385889|NCT01141881|Tissue Plasminogen activator,
385890|NCT01141881|Clinically significant macular edema,
385891|NCT01141881|Refractory Diabetic macular edema ,
385892|NCT01141881|posterior vitreous detachment
385893|NCT01141868|insomnia
385894|NCT01141868|breast cancer survivor
385895|NCT01141868|Internet intervention
385896|NCT01143103|Respiratory therapy in neurologic disorder
385897|NCT01143090|Schizophrenia
385898|NCT01143090|Lurasidone
385899|NCT01143090|Latuda
385900|NCT01143077|Lurasidone
385901|NCT01143077|Schizophrenia
385902|NCT01143077|Latuda
385903|NCT01143064|Brain Injury
385904|NCT01143064|Trauma
385905|NCT01143051|Asthma
385906|NCT01143051|Pharmacokinetics
385907|NCT01143051|Epinephrine
385908|NCT01143051|Bronchodilator
385909|NCT01143051|metered dose inhaler
385910|NCT01143038|ITP
385911|NCT01143025|Laparoscopic Cholecystectomy
385912|NCT01143025|Nebulization
385913|NCT01143025|Ropivacaine
385914|NCT01143012|Group eczema education
385915|NCT01142986|Methadone
385916|NCT01142986|Syringe exchange
385917|NCT01142986|Treatment retention
385918|NCT01142986|Voucher incentives
385919|NCT01142947|Inhaled corticosteroids
385920|NCT01142947|Asthma
385921|NCT01142947|Pharmacogenomics
385922|NCT01142947|Genome wide association study
385923|NCT01142947|Admixture mapping
385924|NCT01142947|Continental population groups
385925|NCT01142934|Catheter-related bloodstream infections
385926|NCT01142934|Chlorhexidine
385927|NCT01142934|Transparent dressings
385928|NCT01142921|Stent Occlusion
385929|NCT01142921|Biliary Bleeding
385930|NCT01142921|Biliary Perforation
385931|NCT01142908|Cardiovascular Disease
385932|NCT01142908|Hypertension
385933|NCT01142908|Diabetes
385934|NCT01142908|Hyperlipidemia
385935|NCT01142908|Adherence
385936|NCT01142882|adolescent HIV prevention
385937|NCT01142882|web-based interventions
385938|NCT01142882|adolescent substance abuse treatment
385939|NCT01142882|comparative effectiveness research
385940|NCT01142882|HIV prevention
385941|NCT01142882|hepatitis prevention
385942|NCT01142882|STI prevention
385943|NCT01142869|Carcinoma, Squamous Cell
385944|NCT01142869|Erbitux
385945|NCT01142869|Neoplasms, Squamous Cell
385946|NCT01142843|clinical trial
385947|NCT01142843|mouthwash
385948|NCT01142843|green propolis
385949|NCT01142843|dental plaque
385950|NCT01142843|gingivitis
385951|NCT01142830|Craniotomy
385952|NCT01142830|Pain
385953|NCT01142830|Children
385954|NCT01142817|HIV
385955|NCT01142817|Women
385956|NCT01142817|Menopause
385957|NCT01142817|Dyslipidemia
385958|NCT01142817|Bone Mineral Density
385959|NCT01142804|Walking programs
385960|NCT01142804|Physical Activity
385961|NCT01142804|Behavior Modification
385962|NCT01142804|Social Support
385963|NCT01142791|Uterine fibroids
385964|NCT01142791|MRgFUS
385965|NCT01142791|ExAblate
385966|NCT01142791|Focused Ultrasound
385967|NCT01142791|Symptomatic uterine fibroids
385968|NCT01142765|Vaccine
385969|NCT01142765|Safety
385970|NCT01142765|Immunogenicity
385971|NCT01142765|Protection
385972|NCT01142765|Sporozoite challenge
385973|NCT01142713|Small Bowel Radiotherapy Dose
385974|NCT01142713|This is a prospective non-randomized open study to evaluate the impact of patient's positioning and use of belly board in rectal radiotherapy
385975|NCT01142687|Resting energy expenditure (REE)
385976|NCT01142687|metabolic rate
385977|NCT01142674|Lymphoma, T-Cell, Peripheral
385978|NCT01142674|Prognosis
385979|NCT01142674|Outcome
385980|NCT01142674|International Cooperation
385981|NCT01142674|Biological Characteristics
385982|NCT01142674|Heterogeneity
385983|NCT01142674|Rare Diseases
385984|NCT01142661|Advanced breast cancer refractory to all commercially available therapies
385985|NCT01142648|Electroencephalogram
385986|NCT01142648|Electromyogram
385987|NCT01142648|Entropy Index
385988|NCT01142648|Bispectral Index
385989|NCT01142648|Reversal of neuromuscular blockade
385990|NCT01142635|Electroencephalogram
385991|NCT01142635|Electromyogram
385992|NCT01142635|Entropy Index
385993|NCT01142635|Bispectral Index
385994|NCT01142635|Neuromuscular blockade; rocuronium
385995|NCT01142635|Propofol
385996|NCT01142635|Intubation
385997|NCT01142622|Ovarian Cysts
385998|NCT01142622|Nebulization
385999|NCT01142622|Ropivacaine
386000|NCT01142609|Web based videoconferencing
386001|NCT01142609|methadone
386002|NCT01142609|substance abuse counseling
386003|NCT01142583|Multiple sclerosis
386004|NCT01142583|Expanded Disability Status Scale
386005|NCT01142583|Multiple Sclerosis, Relapsing-Remitting
386006|NCT01142570|Mechanical Ventilation
386007|NCT01142557|Multiple sclerosis
386008|NCT01142557|Rebif
386009|NCT01142557|Interferon-beta
386010|NCT01142544|acute lung injury
386011|NCT01142544|incidence
386012|NCT01142544|lung damage
386013|NCT01142544|PaO2/FiO2 ratio
386014|NCT01142518|Interferon beta-1a
386015|NCT01142518|Multiple Sclerosis
386016|NCT01142505|wheeze
386017|NCT01142505|preschool
386018|NCT01142505|leukotriene
386019|NCT01142505|montelukast
386020|NCT01142505|5-lipoxygenase
386021|NCT01142492|Interferon beta
386022|NCT01142492|Multiple Sclerosis
386023|NCT01142479|Breast Cancer
386024|NCT01142479|Radiotherapy
386025|NCT01142479|Chinese herbal medicine
386026|NCT01142479|TPE-1
386027|NCT01142479|Leukopenia
386028|NCT01142466|Multiple sclerosis
386029|NCT01142466|Expanded Disability Status Scale
386030|NCT01142466|Multiple Sclerosis, Relapsing-Remitting
386031|NCT01142466|Rebif
386032|NCT01142466|Beta-1, interferon
386033|NCT01142453|Multiple sclerosis
386034|NCT01142453|Rebif
386035|NCT01142453|Interferon
386036|NCT01142414|stage III squamous cell carcinoma of the hypopharynx
386037|NCT01142414|stage IV squamous cell carcinoma of the hypopharynx
386038|NCT01142414|stage III squamous cell carcinoma of the larynx
386039|NCT01142414|stage IV squamous cell carcinoma of the larynx
386040|NCT01142414|stage III squamous cell carcinoma of the lip and oral cavity
386041|NCT01142414|stage IV squamous cell carcinoma of the lip and oral cavity
386042|NCT01142414|stage III squamous cell carcinoma of the oropharynx
386043|NCT01142414|stage IV squamous cell carcinoma of the oropharynx
386044|NCT01142414|tongue cancer
386045|NCT01142375|AML
386046|NCT01142362|H5N1
386047|NCT01142362|Avian Influenza
386048|NCT01142362|DNA Vaccine
386049|NCT01142362|Intramuscular (IM) Injection
386050|NCT01142362|Electroporation
386051|NCT01142362|Healthy Adults
386052|NCT01142349|Arthritis
386053|NCT01142349|Group Program
386054|NCT01142349|Pain
386055|NCT01142349|Insomnia
386056|NCT01142349|Pain dysfunction and sleep disturbance among older adults with osteoarthritis.
386057|NCT01142336|Alzheimer's Disease
386058|NCT01142336|Prevention
386059|NCT01142336|Spinal Fluid
386060|NCT01142336|Biomarkers
386061|NCT01142336|Simvastatin
386062|NCT01142297|dental implant
386063|NCT01142297|implant stabilization
386064|NCT01142297|type 2 diabetes
386065|NCT01142297|glycated hemoglobin 8.0-12.0%
386066|NCT01142284|Biomarker
386067|NCT01142284|Endothelial Function
386068|NCT01142284|Peripheral Artery Disease
386069|NCT01142284|Coronary Artery Disease
386070|NCT01142284|Flow Mediated Dilation
386071|NCT01142284|Cilostazol
386072|NCT01142284|Probucol
386073|NCT01142271|Distal gastrectomy
386074|NCT01142271|Reconstruction
386075|NCT01142271|Reflux
386076|NCT01142271|subtotal gastrectomy
386077|NCT01142258|Sleep Disturbances
386078|NCT01142258|Alzheimer disease
386079|NCT01142258|Insomnia
386080|NCT01142258|Trazodone
386081|NCT01142258|Treatment
386082|NCT01142245|ulcer bleeding
386083|NCT01142245|endoscopic therapy
386084|NCT01142232|autologous stem cell transplantation
386085|NCT01142219|sickle cell disease
386086|NCT01142219|L-arginine
386087|NCT01142219|hemolysis
386088|NCT01142219|nitric oxide
386089|NCT01142219|pulmonary arterial hypertension
386090|NCT01142206|Obesity
386091|NCT01142206|Weight Loss
386092|NCT01142206|Leisure-time activities
386093|NCT01142206|Physical Activity
386094|NCT01142206|Television watching
386095|NCT01142206|Dietary Intake
386096|NCT01142206|Energy
386097|NCT01142206|Behavioral
386098|NCT01142206|Healthy Eating
386099|NCT01142193|Epilepsy
386100|NCT01142193|partial onset seizure
386101|NCT01142193|adjunctive therapy
386102|NCT01142180|Bleeding peptic ulcer
386103|NCT01142180|Active bleeding
386104|NCT01142180|Trans-arterial angiographic embolization
386105|NCT01142167|Ultra-thin colonoscope
386106|NCT01142154|Cockayne Syndrome
386107|NCT01142154|Ageing
386108|NCT01142154|pediatrics
386109|NCT01142154|Pharmacokinetics
386110|NCT01142154|Prodarsan
386111|NCT01142154|Dwarfism
386112|NCT01142154|Genetic disease, inborn
386113|NCT01142154|DNA Repair-Deficiency Disorders
386114|NCT01142154|Tolerability
386115|NCT01142154|Safety
386116|NCT01142102|Bladder
386117|NCT01142102|Radiotherapy
386118|NCT01142102|Online
386119|NCT01142102|Adaptive
386120|NCT01142089|traveler's
386121|NCT01142089|diarrhea
386122|NCT01141855|Cardiovascular Diseases
386123|NCT01141855|Peripheral Vascular Diseases
386124|NCT01141855|Cerebrovascular Stroke
386125|NCT01141855|Lung Diseases, Obstructive
386126|NCT01141855|Asthma
386127|NCT01141855|Tobacco Use Disorder
386128|NCT01141855|Smoking
386129|NCT01141855|Smoking Cessation
386130|NCT01141842|lung cancer
386131|NCT01141842|exhalation analysis
386132|NCT01141842|chronic obstructive pulmonary disease
386133|NCT01141842|cancer screening test
386134|NCT01141829|NADPH oxidase
386135|NCT01141816|renal cell carcinoma
386136|NCT01141816|radiofrequency ablation
386137|NCT01141816|contrast enhanced ultrasound
386138|NCT01141816|monitoring
386139|NCT01141816|follow up
386140|NCT01141803|Apple
386141|NCT01141803|Apple pomace
386142|NCT01141803|Metabolomics
386143|NCT01141803|Gene expression
386144|NCT01141803|Lipid metabolism
386145|NCT01141803|Prevention
386146|NCT01141803|Antiinflammatory effect
386147|NCT01141790|Glasgow Coma Scale
386148|NCT01141790|Glasgow Outcome Scale
386149|NCT01141790|Ethics
386150|NCT01141777|Spirulina platensis
386151|NCT01141777|Insulin resistance
386152|NCT01141777|HIV/AIDS
386153|NCT01141777|HAART
386154|NCT01141777|Soya beans
386155|NCT01141764|pediatrics
386156|NCT01141764|Epilepsy
386157|NCT01141764|Deep Brain Stimulation
386158|NCT01141764|Positron Emission Tomography
386159|NCT01141751|Multiple sclerosis
386160|NCT01141751|Expanded Disability Status Scale
386161|NCT01141751|Multiple Sclerosis, Relapsing-Remitting; Rebif
386162|NCT01141751|Beta-1, interferon
386163|NCT01141738|stroke
386164|NCT01141738|caregiver
386165|NCT01141738|depression
386166|NCT01141738|mediators
386167|NCT01141738|problem-solving
386168|NCT01141712|HIV
386169|NCT01141712|B-cell Lymphoma
386170|NCT01141712|Burkitt's Lymphoma
386171|NCT01141712|Follicular Lymphoma
386172|NCT01141712|Hodgkin's Lymphoma
386173|NCT01141699|women health behaviors
386174|NCT01141686|lung cancer
386175|NCT01141673|FLT3-ITD
386176|NCT01141673|acute myeloid leukemia
386177|NCT01141673|FLT3
386178|NCT01141673|D835
386179|NCT01141647|Adult
386180|NCT01141647|Depression
386181|NCT01141647|Supported Employment
386182|NCT01141647|Health Service
386183|NCT01141647|Humans
386184|NCT01141647|Outcomes
386185|NCT01141647|Quality of Life
386186|NCT01141647|Veterans/rh (rehabilitation)
386187|NCT01141647|Workplace
386188|NCT01141647|Spinal Cord Injuries
386189|NCT01141634|Attention Deficit Hyperactivity Disorder
386190|NCT01141634|Attention Deficit Disorder
386191|NCT01141634|ADHD
386192|NCT01141634|ADD
386193|NCT01141634|Homeopathy
386194|NCT01141621|HS
386195|NCT01141621|congenital hemolytic anemia
386196|NCT01141621|splenectomy
386197|NCT01141621|quality of life
386198|NCT01141556|selenium
386199|NCT01141556|clinical outcome
386200|NCT01141556|heart surgery
386201|NCT01141543|Plerixafor injection
386202|NCT01141530|Identify novel genes and predict putative proteins in breast cancer.
386203|NCT01141530|Find biomarkers that can be used for early detection, diagnosis, and prognosis.
386204|NCT01141517|adolescent quit-smoking program.
386205|NCT01141504|Supplemental ATP
386206|NCT01141504|Muscle Work Performed
386207|NCT01141504|Muscle Fatigue
386208|NCT01141491|Sarcoma
386209|NCT01141491|Metastatic
386210|NCT01141491|Vaccine
386211|NCT01141491|Adjuvant
386212|NCT01141478|Carcinoma, Hepatocellular
386213|NCT01141478|Proton Beam Radiotherapy
386214|NCT01141478|Sorafenib
386215|NCT01141465|Primary care
386216|NCT01141465|Asthma management
386217|NCT01141465|Combined therapy
386218|NCT01141465|Real-world
386219|NCT01141465|Effectiveness
386220|NCT01141465|Control
386221|NCT01141465|Exacerbations
386222|NCT01141452|chronic obstructive pulmonary disease
386223|NCT01141452|inhaled corticosteroid
386224|NCT01141452|increase
386225|NCT01141452|initiate
386226|NCT01141452|exacerbations
386227|NCT01141452|treatment success
386228|NCT01141439|Primary care
386229|NCT01141439|Asthma management
386230|NCT01141439|Inhaled corticosteroids
386231|NCT01141439|Beclomethasone dipropionate
386232|NCT01141439|Fluticasone propionate
386233|NCT01141439|Metred dose inhaler
386234|NCT01141439|Extra-fine hydrofluoroalkane
386235|NCT01141439|Chlorofluorocarbon
386236|NCT01141426|depression
386237|NCT01141426|treatment-resistance
386238|NCT01141426|psychodynamic psychotherapy
386239|NCT01141426|Treatment refractory depression
386240|NCT01141374|Stress
386241|NCT01141361|Claudication
386242|NCT01141361|Artery
386243|NCT01141361|Ambulatory technique
386244|NCT01141361|GPS
386245|NCT01141335|shrinkage
386246|NCT01141335|postoperative pain and discomfort
386247|NCT01141322|drug-induced liver injury
386248|NCT01141322|hepatitis, toxic
386249|NCT01141322|ursodeoxycholic acid
386250|NCT01141309|Everolimus
386251|NCT01141309|Sorafenib
386252|NCT01141309|Thyroid
386253|NCT01141309|10-060
386254|NCT01141283|Osteoarthritis
386255|NCT01141283|Opioid
386256|NCT01141283|Transdermal
386257|NCT01141270|recombinant human follicle stimulating hormone
386258|NCT01141270|pharmacokinetics
386259|NCT01141270|bioequivalence
386260|NCT01141257|Angiocal®; PRS-050-PEG40; Solid tumor; Phase I
386261|NCT01141231|hypopharyngeal cancer
386262|NCT01141231|laryngeal cancer
386263|NCT01141231|lip and oral cavity cancer
386264|NCT01141231|nasopharyngeal cancer
386265|NCT01141231|oropharyngeal cancer
386266|NCT01141231|paranasal sinus and nasal cavity cancer
386267|NCT01141231|salivary gland cancer
386268|NCT01141231|radiation toxicity
386269|NCT01141231|xerostomia
386270|NCT01141231|long-term effects of cancer treatment
386271|NCT01141231|oral complications of radiation therapy
386272|NCT01141218|non-small cell lung cancer
386273|NCT01141205|AIDS vaccines
386274|NCT01141205|HIV-1 vaccine
386275|NCT01141205|Therapeutic vaccine
386276|NCT01141205|Cellular immunity
386277|NCT01141192|vitamin D status
386278|NCT01141192|25-OH D
386279|NCT01141192|ionized calcium
386280|NCT01141192|fasting glucose
386281|NCT01141192|hemoglobin A1c
386282|NCT01141192|fasting insulin
386283|NCT01141192|glucose metabolism
386284|NCT01141192|HOMA index
386285|NCT01141192|blood lipids
386286|NCT01141192|type 2 diabetes
386287|NCT01141192|PTH
386288|NCT01141192|adiposity
386289|NCT01141192|body fat percentage
386290|NCT01141192|dual energy x-ray absorptiometry
386291|NCT01141192|pulse wave velocity
386292|NCT01141192|arterial stiffness
386293|NCT01141192|flow-mediated dilation
386294|NCT01141192|African American
386295|NCT01141192|inflammatory markers
386296|NCT01141166|ELDERLY
386297|NCT01141166|NUTRITION
386298|NCT01141153|atrial fibrillation
386299|NCT01141153|Coronary Stent implantation
386300|NCT01141153|Low-moderate risk of stroke
386301|NCT01141153|dual antiplatelet therapy
386302|NCT01141153|anticoagulation
386303|NCT01141127|tranexamic acid in pediatric surgery
386304|NCT01141127|fibrinolysis and paediatric cardiac surgery
386305|NCT01141114|community health centers
386306|NCT01141114|colorectal cancer screening
386307|NCT01141114|urban health
386308|NCT01141101|Methicillin-resistant Staphylococcus aureus
386309|NCT01141101|Neonatal
386310|NCT01141101|Vertical transmission
386311|NCT01141101|Horizontal transmission
386312|NCT01141101|MRSA colonization in enrolled infants
386313|NCT01141101|MRSA colonization obtained from maternal source
386314|NCT01141101|MRSA colonization obtained from source other that mother
386315|NCT01141062|Uterine Fibroids
386316|NCT01141049|Alcohol Withdrawal
386317|NCT01141049|Reducing Alcohol Consumption
386318|NCT01141049|Promoting abstinence in alcohol-dependent patients
386319|NCT01141049|Gabapentin
386320|NCT01141036|Propofol
386321|NCT01141036|Midazolam
386322|NCT01141036|sedation
386323|NCT01141036|cirrhosis
386324|NCT01141036|endoscopy
386325|NCT01141036|recovery time
386326|NCT01141036|efficacy and safety of sedation
386327|NCT01141036|patient satisfaction
386328|NCT01141036|return to baseline function
386329|NCT01141036|saturation of oxygen
386330|NCT01141023|Parkinson
386331|NCT01141023|Bio-markers
386332|NCT01141023|Neurodegenerative disorder
386333|NCT01141023|Imaging
386334|NCT01141023|Prodromal
386335|NCT01141010|Linguistic
386336|NCT01141010|Stress response
386337|NCT01141010|Corticosteroid
386338|NCT01141010|Cesarean section
386339|NCT01141010|Anxiety
386340|NCT01141010|Depression
386341|NCT01141010|Maternal psychosis
386342|NCT01140997|HCV
386343|NCT01140997|CHC
386344|NCT01140997|Hepatitis C, Chronic
386345|NCT01140997|Liver Diseases
386346|NCT01140997|Hepatitis, Chronic
386347|NCT01140997|Hepatitis, Viral, Human
386348|NCT01140997|Hepadnaviridae Infections
386349|NCT01140997|Antiviral Agents
386350|NCT01140997|Virus Diseases
386351|NCT01140997|Peginterferon alfa
386352|NCT01140984|acute graft versus host disease
386353|NCT01140984|intra arterial steroid infusion
386354|NCT01140984|steroid resistant acute hepatic graft versus host disease
386355|NCT01140971|Balloon dilatation,
386356|NCT01140971|misoprostol,
386357|NCT01140971|cervical ripening,
386358|NCT01140971|obstetric labor,
386359|NCT01140971|labor induced.
386360|NCT01140958|lung cancer
386361|NCT01140958|pharmacoeconomics
386362|NCT01140958|new agents
386363|NCT01140932|Retina
386364|NCT01140932|Electroretinography
386365|NCT01140932|Diabetes Mellitus
386366|NCT01140932|Glucose Intolerance
386367|NCT01140932|Physiology
386368|NCT01140906|Major depressive disorder
386369|NCT01140906|Placebo-controlled
386370|NCT01140906|Active reference
386371|NCT01140906|Multicenter study
386372|NCT01140906|Randomised study
386373|NCT01140906|Acute treatment
386374|NCT01140893|Type 2 diabetes
386375|NCT01140893|CSII
386376|NCT01140893|Exenatide
386377|NCT01140893|Double Blind Placebo Controlled Study
386378|NCT01140880|Methamphetamine
386379|NCT01140880|Amphetamine
386380|NCT01140880|Cocaine
386381|NCT01140880|HIV
386382|NCT01140880|Post-exposure prophylaxis
386383|NCT01140880|HIV seronegativity
386384|NCT01140854|hypertension
386385|NCT01140854|hypotension
386386|NCT01140854|cognitive
386387|NCT01140854|neurocognitive
386388|NCT01140854|cognitive dysfunction
386389|NCT01140854|postoperative cognitive dysfunction (POCD)
386390|NCT01140854|neuropsychometric
386391|NCT01140841|Dyskinesia
386392|NCT01140828|Arthritis
386393|NCT01140828|Bone pain
386394|NCT01140828|dyspepsia
386395|NCT01140815|Total Knee Arthroplasty
386396|NCT01140815|Bicompartmental Knee Arthroplasty
386397|NCT01140802|First degree relatives
386398|NCT01140802|Crohn's disease
386399|NCT01140802|Ulcerative colitis
386400|NCT01140802|Healthy control
386401|NCT01140776|metastasis
386402|NCT01140776|molecular pathology
386403|NCT01140763|metastasis
386404|NCT01140750|Heart Rate Variability
386405|NCT01140750|Temperature Curve Complexity
386406|NCT01140750|Autonomic Dysfunction
386407|NCT01140750|Prolonged Mechanical Ventilation
386408|NCT01140750|Failure to Wean
386409|NCT01140737|advanced soft tissue sarcoma
386410|NCT01140724|pain
386411|NCT01140724|genes
386412|NCT01140724|morphine
386413|NCT01140724|respiratory depression
386414|NCT01140724|tonsillectomy
386415|NCT01140724|children
386416|NCT01140724|Opioid adverse effects
386417|NCT01140724|Pharmacogenetics of morphine
386418|NCT01140724|Pharmacokinetics of morphine
386419|NCT01140724|Personalizing analgesia
386420|NCT01140685|mucus-stimulated (induced sputum)
386421|NCT01140685|lung disease (asthma, COPD, ILD and OLD)
386422|NCT01140685|HO-1 (heme oxigenase-1)
386423|NCT01140685|oxidative stress
386424|NCT01140685|CO (carbon monoxide)
386425|NCT01140685|The oxidative stress in lung diseases
386426|NCT01140672|Healthy volunteers
386427|NCT01140672|pharmacokinetics
386428|NCT01140672|safety
386429|NCT01140672|tolerability
386430|NCT01140672|multiple dosing
386431|NCT01140672|Diabetic Nephropathies
386432|NCT01140659|Hyperhidrosis
386433|NCT01140659|Thoracic sympathectomy
386434|NCT01140659|Objective measurement of sweat
386435|NCT01140646|Hot flashes, dietary supplements, symptom management
386436|NCT01140633|HIV/AIDS
386437|NCT01140633|pediatric
386438|NCT01140633|wireless adherence monitoring
386439|NCT01140633|HIV Infections
386440|NCT01140620|NMDA receptor antagonism
386441|NCT01140620|cognitive processes
386442|NCT01140620|healthy volunteers
386443|NCT01140620|dopamine antagonist
386444|NCT01140620|schizophrenia
386445|NCT01140568|glioma
386446|NCT01140568|PDGFR
386447|NCT01140568|kinase
386448|NCT01140568|inhibitor
386449|NCT01140568|malignant
386450|NCT01140568|nilotinib
386451|NCT01140542|Diabetes Mellitus Type 2
386452|NCT01140542|Roflumilast
386453|NCT01140529|Dexmedetomidine
386454|NCT01140516|Antenatal
386455|NCT01140490|Hemodialysis
386456|NCT01140490|Sub-total Parathyroidectomy
386457|NCT01140464|Adolescents
386458|NCT01140438|Latent autoimmune diabetes
386459|NCT01140438|adults
386460|NCT01140438|Beta cell rest
386461|NCT01140438|Insulin secretion
386462|NCT01140425|PF-00232798
386463|NCT01140425|CCR5
386464|NCT01140425|QT
386465|NCT01140425|QTc
386466|NCT01140425|pharmacokinetics
386467|NCT01140412|maraviroc
386468|NCT01140412|fosamprenavir
386469|NCT01140412|drug interaction
386470|NCT01140412|pharmacokinetics
386471|NCT01140412|HIV
386472|NCT01140412|AIDS
386473|NCT01140412|CCR5
386474|NCT01140412|protease inhibitor
386475|NCT01140399|1 Acute Decompensated Heart Failure
386476|NCT01140399|2 Cardiorenal Syndrome
386477|NCT01140399|3 Ultrafiltration
386478|NCT01140399|4 Dopamine
386479|NCT01140386|venous thromboembolism
386480|NCT01140386|duplex ultrasound
386481|NCT01140386|pediatric population
386482|NCT01140386|Vascular lab duplex ultrasound database
386483|NCT01140386|Inpatient hospital admission/discharge ICD-9 database
386484|NCT01140386|PTSF pediatric trauma database
386485|NCT01140373|Prostate
386486|NCT01140373|Autologous T Cells
386608|NCT01139814|AVNRT
386487|NCT01140373|Castrate Metastatic Prostate Cancer
386488|NCT01140373|cyclophosphamide
386489|NCT01140373|09-036
386490|NCT01140360|Neurofibromas
386491|NCT01140347|Hepatocellular carcinoma (HCC)
386492|NCT01140347|recombinant human immunoglobulin G
386493|NCT01140347|subclass 1 (IgG1) monoclonal antibody (MAb)
386494|NCT01140347|Hepatocellular Carcinoma (HCC) following First-Line Therapy With Sorafenib
386495|NCT01140334|Psychiatric adherence
386496|NCT01140334|Voucher incentives
386497|NCT01140334|Methadone treatment
386498|NCT01140321|Thalassemia
386499|NCT01140321|Neridronate
386500|NCT01140321|Osteopenia
386501|NCT01140321|Osteoporosis
386502|NCT01140308|Statin Myopathy
386503|NCT01140308|CoEnzyme Q10
386504|NCT01140308|CoQ10
386505|NCT01140308|Statin Myalgia
386506|NCT01140295|Preparation
386507|NCT01140295|Pediatric
386508|NCT01140295|Colonoscopy
386509|NCT01140282|cancer survivor
386510|NCT01140269|Burn
386511|NCT01140269|Sepsis
386512|NCT01140269|Infection
386513|NCT01140256|Zinc
386514|NCT01140256|SGA
386515|NCT01140256|AGA
386516|NCT01140256|stable isotope
386517|NCT01140243|fat formulation
386518|NCT01140230|rotator cuff tear
386519|NCT01140230|rotator cuff repair
386520|NCT01140230|age
386521|NCT01140230|timing to surgery
386522|NCT01140217|contraception
386523|NCT01140217|pregnancy
386524|NCT01140204|stent
386525|NCT01140204|contrast media
386526|NCT01140204|paclitaxel
386527|NCT01140204|stent implantation
386528|NCT01140191|leishmaniasis
386529|NCT01140191|cutaneous
386530|NCT01140191|WR 279,396
386531|NCT01140191|paromomycin
386532|NCT01140191|gentamicin
386533|NCT01140191|pharmacokinetics
386534|NCT01140191|safety
386535|NCT01140191|efficacy
386536|NCT01140191|military
386537|NCT01140178|Photodynamic Therapy
386538|NCT01140178|Oral dysplasia
386539|NCT01140178|oral cavity carcinoma
386540|NCT01140178|oropharynx carcinoma.
386541|NCT01140152|intestinal transplantation
386542|NCT01140152|rejection
386543|NCT01140152|proteomics
386544|NCT01140152|innate immunity
386545|NCT01140126|HIV-1, CD4, antibody, immunotherapy
386546|NCT01140113|hemoconcentration
386547|NCT01140113|ultrafiltration
386548|NCT01140113|coronary artery disease
386549|NCT01140087|Face Transplant
386550|NCT01140087|Composite Tissue Allograft
386551|NCT01140087|Facial Allotransplantation
386552|NCT01140074|acute diarrhoea, children
386553|NCT01140048|Asthma
386554|NCT01140035|Insulin
386555|NCT01140035|Deceased donors
386556|NCT01140035|Renal Allograft Function
386557|NCT01140035|Transplanted Allograft Outcomes
386558|NCT01140022|Chlamydia, Screening, young women, kiosk, computer module
386559|NCT01140009|Vaccine
386560|NCT01140009|Seasonal Influenza vaccine
386561|NCT01140009|Influenza vaccine
386562|NCT01140009|Vaccine safety
386563|NCT01140009|Vaccine immunogenicity
386564|NCT01140009|Fluviral 2010/11
386565|NCT01139983|osteosarcoma
386566|NCT01139944|recurrent non-small cell lung cancer
386567|NCT01139944|stage I non-small cell lung cancer
386568|NCT01139944|stage II non-small cell lung cancer
386569|NCT01139944|squamous cell lung cancer
386570|NCT01139931|childhood acute myeloid leukemia/other myeloid malignancies
386571|NCT01139918|psoriatic arthritis
386572|NCT01139918|psoriasis
386573|NCT01139918|Quality of life
386574|NCT01139905|Lopinavir/ritonavir
386575|NCT01139905|pharmacokinetic
386576|NCT01139905|low dose
386577|NCT01139905|HIV-infected children
386578|NCT01139905|pharmacokinetics of low-dose lopinavir/ritonavir in HIV-1 infected Thai children.
386579|NCT01139892|Unruptured aneurysm
386580|NCT01139892|endovascular treatment
386581|NCT01139892|surgical treatment
386582|NCT01139892|randomized
386583|NCT01139892|intracranial aneurysm
386584|NCT01139879|Pressure Ulcer treatment Mattresses
386585|NCT01139879|Home Care
386586|NCT01139879|Extended Care
386587|NCT01139879|Wound measurements
386588|NCT01139866|Long-term Safety
386589|NCT01139866|Shoulder Surgery
386590|NCT01139866|bupivacaine
386591|NCT01139853|pyloric stenosis
386592|NCT01139853|nasogastric tube
386593|NCT01139853|pyloromyotomy
386594|NCT01139840|vitamin D2
386595|NCT01139840|vitamin D3
386596|NCT01139840|ergocalciferol
386597|NCT01139840|cholecalciferol
386598|NCT01139840|vitamin D status
386599|NCT01139840|To determine relative potency of vitamins D2 and D3 under conditions of continuous administration
386600|NCT01139840|To determine change in vitamin D content of subcutaneous fat after 12 weeks' administration
386601|NCT01139827|atherosclerosis
386602|NCT01139827|inflammation
386603|NCT01139827|hsCRP
386604|NCT01139827|Framingham risk score
386605|NCT01139827|positron emission tomography
386606|NCT01139827|inflammation in FDG-PET
386607|NCT01139814|atrial flutter
386609|NCT01139814|right sided accessory pathway
386610|NCT01139814|ventricular tachycardia
386611|NCT01139814|Patients who have one or more standard indications for a right-sided diagnostic electrophysiology procedure.
386612|NCT01139801|Cervical Ripening
386613|NCT01139801|Rate of Cesearean Section
386614|NCT01139788|Cancer
386615|NCT01139775|solid tumors
386616|NCT01139775|Mesothelioma
386617|NCT01139775|Carcinoma
386618|NCT01139762|Benign Prostatic Hyperplasia (BPH)
386619|NCT01139762|Enlarged Prostate
386620|NCT01139749|oral isotretinoin
386621|NCT01139749|sebaceous secretion
386622|NCT01139749|seborrhea
386623|NCT01139749|seborrheic dermatitis
386624|NCT01139749|quality of life
386625|NCT01139749|Malassezia
386626|NCT01139736|Irritable bowel syndrome
386627|NCT01139736|IBS
386628|NCT01139736|probiotics
386629|NCT01139736|rectal sensitivity
386630|NCT01139736|gut flora
386631|NCT01139736|gut bacteria
386632|NCT01139710|SARCOIDOSIS
386633|NCT01139710|PULMONARY HYPERTENSION
386634|NCT01139710|outpatients clinic at Meir medical center
386635|NCT01139697|Heart failure
386636|NCT01139697|Cortisol
386637|NCT01139697|Testosterone
386638|NCT01139684|Exercise test
386639|NCT01139671|Remifentanil
386640|NCT01139671|Sufentanil
386641|NCT01139671|Surgical removal of three to four wisdom teeth
386642|NCT01139671|General anaesthesia
386643|NCT01139671|Ambulatory oral surgery
386644|NCT01139671|Target Controlled Infusion (TCI)
386645|NCT01139671|Opioid induced hyperalgesia
386646|NCT01139671|Postoperative nausea and vomiting
386647|NCT01139671|Postoperative Morphine consumption
386648|NCT01139671|Under General anaesthesia
386649|NCT01139671|In Ambulatory surgery
386650|NCT01139645|Calcium
386651|NCT01139645|bone
386652|NCT01139645|metabolism
386653|NCT01139645|Proton Pump Inhibitors
386654|NCT01139645|Rabeprazole
386655|NCT01139645|Esomeprazole
386656|NCT01139645|Lanzoprazole
386657|NCT01139645|Vitamin D
386658|NCT01139645|bone and bones
386659|NCT01139632|NAFLD
386660|NCT01139632|lP-pla2
386661|NCT01139632|Coronary Arthery Disease
386662|NCT01139619|Biopsy Mapping
386663|NCT01139619|Non small cell lung cancer
386664|NCT01139619|NSCLC
386665|NCT01139619|Lung cancer diagnosis
386666|NCT01139619|Retrospective
386667|NCT01139619|Inoperable Non Small Cell Lung Cancer
386668|NCT01139593|IVF
386669|NCT01139593|ICSI
386670|NCT01139593|gonadotropin
386671|NCT01139593|am dose
386672|NCT01139593|pm dose
386673|NCT01139593|pregnancy
386674|NCT01139593|implantation
386675|NCT01139593|live birth
386676|NCT01139580|Plaque Psoriasis
386677|NCT01139580|Psoriasis
386678|NCT01139567|Diabetic Wounds
386679|NCT01139567|Hyperbaric Oxygen
386680|NCT01139567|Laser Speckle Imaging
386681|NCT01139567|Hyperbaric Oxygenation
386682|NCT01139528|Fracture
386683|NCT01139528|5th metacarpal bone
386684|NCT01139528|Bouquet pinning
386685|NCT01139528|Fractures of the neck of the 5th metacarpal bone
386686|NCT01139515|pharmacokinetic
386687|NCT01139515|eletriptan
386688|NCT01139515|Korean
386689|NCT01139515|crossover
386690|NCT01139502|schizophrenia spectrum disorders
386691|NCT01139502|work rehabilitation
386692|NCT01139502|cognitive therapy
386693|NCT01139502|cognitive training
386694|NCT01139502|Adaptation to work
386695|NCT01139502|Work as a treatment factor
386696|NCT01139489|Procalcitonin
386697|NCT01139489|antibiotic therapy
386698|NCT01139489|antibiotics
386699|NCT01139489|sepsis
386700|NCT01139489|infections
386701|NCT01139489|biomarker
386702|NCT01139476|Multiple Myeloma
386703|NCT01139476|MGUS
386704|NCT01139476|Leukemia
386705|NCT01139476|Biorepository
386706|NCT01139463|antipsychotics
386707|NCT01139463|lactates
386708|NCT01139463|side effects
386709|NCT01139450|Atopic Dermatitis
386710|NCT01139437|Vaccine
386711|NCT01139437|HPIV2
386712|NCT01139437|Infants
386713|NCT01139424|surgical leak
386714|NCT01139424|endoscopic suturing
386715|NCT01139424|Anastomotic leakage
386716|NCT01139424|esophageal or gastric resection
386717|NCT01139398|Cholesterol
386718|NCT01139398|LDL-cholesterol
386719|NCT01139398|Coronary artery disease
386720|NCT01139398|Red yeast rice
386721|NCT01139398|Plants extract
386722|NCT01139398|Cholesterol excess.
386723|NCT01139372|Dry eye, artificial tears
386724|NCT01139359|Lymphoma
386725|NCT01139359|Darinaparsin
386726|NCT01139359|CHOP
386727|NCT01139359|Frontline
386728|NCT01139359|PTCL
386729|NCT01139359|B-cell
386730|NCT01139346|carcinoma
386731|NCT01139346|sarcoma
386732|NCT01139346|metastatic
386733|NCT01139346|solid tumor
386852|NCT01138852|cefuroxime
386734|NCT01139333|childhood acute myeloid leukemia/other myeloid malignancies
386735|NCT01139320|untreated childhood acute myeloid leukemia and other myeloid malignancies
386736|NCT01139307|adult acute megakaryoblastic leukemia (M7)
386737|NCT01139307|childhood acute megakaryocytic leukemia (M7)
386738|NCT01139307|recurrent adult acute myeloid leukemia
386739|NCT01139307|recurrent childhood acute myeloid leukemia
386740|NCT01139307|untreated adult acute myeloid leukemia
386741|NCT01139307|untreated childhood acute myeloid leukemia and other myeloid malignancies
386742|NCT01139294|cardiac output
386743|NCT01139294|dehydration
386744|NCT01139294|pediatrics
386745|NCT01139281|Ear protection
386746|NCT01139281|Ginkgo Biloba Extract
386747|NCT01139281|Distortion-product otoacoustic emission
386748|NCT01139281|Ototoxicity
386749|NCT01139281|Cisplatin
386750|NCT01139268|embryo viability
386751|NCT01139242|CRC screening status
386752|NCT01139242|physical activity level
386753|NCT01139242|fruit and vegetable consumption
386754|NCT01139242|Early Detection of Cancer
386755|NCT01139242|Colorectal Cancer (CRC) screening status
386756|NCT01139229|Esophagogastrostomy
386757|NCT01139229|Circular everted anastomosis
386758|NCT01139229|Side-side anastomosis
386759|NCT01139229|Randomized clinical trial
386760|NCT01139216|Digestive system diseases
386761|NCT01139216|Gastrointestinal diseases
386762|NCT01139216|Intestinal diseases
386763|NCT01139216|Colonic inertia
386764|NCT01139203|HBV recurrence
386765|NCT01139203|entecavir
386766|NCT01139190|NSAID-induced gastroduodenal ulcerations or erosion
386767|NCT01139177|Peripheral vascular disease - SFA and popliteal arteries.
386768|NCT01139164|high-risk hematological malignancies
386769|NCT01139151|Advanced Hematologic Malignancies
386770|NCT01139151|4'-Thio-araC
386771|NCT01139151|Thiarabine
386772|NCT01139151|4'-thio-â-D-arabinofuranosylcytosine
386773|NCT01139151|deoxycytidine nucleoside analog
386774|NCT01139151|poor-risk myelodysplasia
386775|NCT01139151|MDS
386776|NCT01139151|refractory anemia
386777|NCT01139151|Excess blasts
386778|NCT01139151|RAEB-1
386779|NCT01139151|RAEB-2
386780|NCT01139151|Chronic myelomonocytic leukemia
386781|NCT01139151|CMML
386782|NCT01139151|Relapsed/refractory leukemia
386783|NCT01139151|Acute non-lymphocytic leukemia
386784|NCT01139151|AML
386785|NCT01139151|Acute lymphocytic leukemia
386786|NCT01139151|ALL
386787|NCT01139151|Chronic lymphocytic leukemia
386788|NCT01139151|CLL
386789|NCT01139151|Chronic myelogenous leukemia
386790|NCT01139151|CML
386791|NCT01139151|blast crisis
386792|NCT01139138|Colorectal Cancer
386793|NCT01139138|Colorectal Carcinoma
386794|NCT01139138|Colorectal Tumors
386795|NCT01139138|Neoplasms, Colorectal
386796|NCT01139112|Necrotizing Fasciitis, Klebsiella Pneumoniae
386797|NCT01139086|chronic heart failure
386798|NCT01139086|isokinetic test
386799|NCT01139086|near-infrared spectroscopy
386800|NCT01139086|laser Doppler flowmetry
386801|NCT01139086|endothelial function
386802|NCT01139073|Halitosis
386803|NCT01139060|chronic or recurrent depression
386804|NCT01139021|Children
386805|NCT01139021|Meningococcal disease
386806|NCT01139021|Prevention
386807|NCT01139021|Vaccination
386808|NCT01138995|Poststroke/CVA hemiparesis
386809|NCT01138995|Drop Foot
386810|NCT01138995|Gait Disorders, Neurological
386811|NCT01138995|Gait, Drop foot
386812|NCT01138982|Youth mentoring
386813|NCT01138982|Effectiveness
386814|NCT01138982|Sweden
386815|NCT01138982|low-risk youth
386816|NCT01138969|proton pump inhibitor
386817|NCT01138969|peptic ulcer
386818|NCT01138969|clopidogrel
386819|NCT01138969|prevention
386820|NCT01138956|Visceral leishmaniasis
386821|NCT01138956|N-acetylcysteine
386822|NCT01138956|Antimony
386823|NCT01138956|Immune response
386824|NCT01138943|Chlorhexidine mouthrinse
386825|NCT01138943|Plaque control
386826|NCT01138930|Polycystic Ovary Syndrome
386827|NCT01138930|Obesity
386828|NCT01138904|gastric cancer
386829|NCT01138904|oxaliplatin
386830|NCT01138904|irinotecan
386831|NCT01138904|sequential treatment
386832|NCT01138891|Breast implants
386833|NCT01138891|capsular contraction
386834|NCT01138891|sonication
386835|NCT01138891|biofilm
386836|NCT01138891|Complications
386837|NCT01138891|surgery
386838|NCT01138878|HIV
386839|NCT01138878|testing
386840|NCT01138878|non traditional settings
386841|NCT01138878|acceptability
386842|NCT01138878|feasibility
386843|NCT01138865|Obstructive sleep apnea
386844|NCT01138865|Cytokine levels
386845|NCT01138865|Insulin resistance
386846|NCT01138865|Hypertension
386847|NCT01138865|Dyslipidemia
386848|NCT01138865|Albumin-creatinine ratio
386849|NCT01138865|Continuous positive airway pressure (CPAP)
386850|NCT01138852|post-cesarean infections
386851|NCT01138852|ampicillin-sulbactam
386853|NCT01138852|cesarean
386854|NCT01138839|HELLP 1
386855|NCT01138839|Dexamethasone
386856|NCT01138839|Clinical trial
386857|NCT01138826|biological availability
386858|NCT01138826|bioavailability
386859|NCT01138826|amlodipine
386860|NCT01138826|orally disintegrating tablet
386861|NCT01138826|ODT
386862|NCT01138826|tablets
386863|NCT01138813|magnetic resonance spectroscopy (MRS)
386864|NCT01138813|lactate editing
386865|NCT01138813|metabolite content
386866|NCT01138813|glioma
386867|NCT01138774|Obesity
386868|NCT01138774|Calorie restriction
386869|NCT01138774|Eicosapentaenoic acid (EPA)
386870|NCT01138774|Lipoic acid
386871|NCT01138774|Weight loss
386872|NCT01138774|Insulin sensitivity
386873|NCT01138774|Lipid metabolism
386874|NCT01138774|Adipokines
386875|NCT01138774|Inflammation
386876|NCT01138774|Oxidative stress
386877|NCT01138774|Adipose tissue gene profile
386878|NCT01138774|Metabolomic profile
386879|NCT01138761|pediatric atopic dermatitis
386880|NCT01138761|EASI
386881|NCT01138761|REALM-SF
386882|NCT01138761|nurse instruction
386883|NCT01138761|health literacy
386884|NCT01138748|inoperable early stage non-small cell lung cancer
386885|NCT01138748|radiation therapy
386886|NCT01138722|early stage non-small cell lung cancer
386887|NCT01138722|hypofractionated radiation therapy
386888|NCT01138696|ACL
386889|NCT01138683|Acute decompensated heart failure
386890|NCT01138683|ultrafiltration
386891|NCT01138683|diuretics
386892|NCT01138683|AKI
386893|NCT01138657|inflammation of uvea
386894|NCT01138644|Atrial Fibrillation
386895|NCT01138644|Atrial Flutter
386896|NCT01138631|IVF, Infertility, embryo selection, embryoscope, time-lapse
386897|NCT01138618|Clozapine
386898|NCT01138618|hematological monitoring
386899|NCT01138618|CHEMPAQ
386900|NCT01138618|Granulocytes
386901|NCT01138618|WBC
386902|NCT01138605|TMC114
386903|NCT01138605|TMC114-TiDP29-C232
386904|NCT01138605|TMC114-C232
386905|NCT01138605|Darunavir
386906|NCT01138605|PREZISTA
386907|NCT01138579|FBTA05
386908|NCT01138579|CD20
386909|NCT01138579|CLL
386910|NCT01138579|NHL
386911|NCT01138579|DLI
386912|NCT01138579|allogeneic transplantation
386913|NCT01138579|CD20 positive chronic lymphocytic leukemia (CLL)
386914|NCT01138579|low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantation with active disease
386915|NCT01138566|community-onset urinary tract infections caused by Enterobacteriaceae
386916|NCT01138553|biomarker
386917|NCT01138553|breast cancer
386918|NCT01138553|antiprogesterone
386919|NCT01138540|VAP
386920|NCT01138527|multi-parametric MRI approach
386921|NCT01138475|PTH
386922|NCT01138475|Gastric bypass surgery
386923|NCT01138475|vitamin D
386924|NCT01138475|paricalcitol
386925|NCT01138462|Methicillin-Resistant Staphylococcus aureus
386926|NCT01138462|Decolonisation
386927|NCT01138462|Nursing homes
386928|NCT01138462|Infection Control
386929|NCT01138449|Vitamin A
386930|NCT01138449|Neonatal mortality
386931|NCT01138449|Infant mortality
386932|NCT01138436|Venous Leg Ulcers, VLU
386933|NCT01138423|Hypertension
386934|NCT01138423|Metabolic Syndrome X
386935|NCT01138423|Obesity
386936|NCT01138423|Adiposity
386937|NCT01138423|Clinical trial
386938|NCT01138410|Immunotherapy
386939|NCT01138410|Melanoma
386940|NCT01138410|Gene therapy
386941|NCT01138410|DNA plasmid
386942|NCT01138410|Cancer vaccine
386943|NCT01138410|Electroporation
386944|NCT01138410|CTL response
386945|NCT01138397|Influenza
386946|NCT01138397|Influenza vaccine
386947|NCT01138397|Influenza virus
386948|NCT01138397|Intradermal
386949|NCT01138384|Breast Cancer
386950|NCT01138371|LDL apheresis
386951|NCT01138371|Familial hypercholesterolemia
386952|NCT01138371|Inflammatory markers
386953|NCT01138371|Hyperlipidemia
386954|NCT01138371|Cardiovascular disease
386955|NCT01138358|dyspnea
386956|NCT01138358|lung metastases
386957|NCT01138358|recurrent non-small cell lung cancer
386958|NCT01138358|recurrent small cell lung cancer
386959|NCT01138358|extensive stage small cell lung cancer
386960|NCT01138358|stage IIIA non-small cell lung cancer
386961|NCT01138358|stage IIIB non-small cell lung cancer
386962|NCT01138358|stage IV non-small cell lung cancer
386963|NCT01138345|cancer survivor
386964|NCT01138345|stage I breast cancer
386965|NCT01138345|stage II breast cancer
386966|NCT01138345|stage IIIA breast cancer
386967|NCT01138345|stage IIIB breast cancer
386968|NCT01138345|stage IIIC breast cancer
386969|NCT01138332|childhood acute myeloid leukemia/other myeloid malignancies
386970|NCT01138319|adult acute myeloid leukemia
386971|NCT01138319|childhood acute myeloid leukemia/other myeloid malignancies
386972|NCT01138306|childhood acute myeloid leukemia/other myeloid malignancies
386973|NCT01138293|differences between patients´ self-assessment and objective perception of physical activity and eating habits
386974|NCT01138280|biofilm formation
386975|NCT01138280|proinflammatory cytokines
386976|NCT01138280|high sensitive c reactive protein
386977|NCT01138280|cardiovascular events
386978|NCT01138280|overall mortality
386979|NCT01138280|hemodialysis
386980|NCT01138267|pharmacogenomics
386981|NCT01138267|ATV
386982|NCT01138267|EFV
386983|NCT01138267|pharmacogenomics of ATV and EFV
386984|NCT01138254|flow,echocardiography,far infrared therapy,nitric oxide
386985|NCT01138241|HIV
386986|NCT01138241|Chronic kidney disease
386987|NCT01138241|Glomerular Filtration Rate (GFR)
386988|NCT01138241|Tenofovir
386989|NCT01138241|Serum creatinine (sCr)
386990|NCT01138241|24 hr urine creatinine clearance
386991|NCT01138241|Serum Cystatin C[40]
386992|NCT01138241|Modification of Diet in Renal Disease (MDRD)
386993|NCT01138241|Cockcroft Gault Equation
386994|NCT01138241|Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
386995|NCT01138241|99mTc-diethylenetriaminepentaacetic acid (Tc-99m DTPA) scan
386996|NCT01138241|Validate which renal function assessments can accurately detect GFR and assess the effect of TDF concentration on renal function
386997|NCT01138228|intravenous cannulation
386998|NCT01138228|vein identification
386999|NCT01138228|vascular identification
387000|NCT01138228|vein cannulation
387001|NCT01138215|varicella-zoster virus vaccine
387002|NCT01138215|varicella-zoster virus antibody
387003|NCT01138215|immunogenicity
387004|NCT01138215|safety and efficacy
387005|NCT01138215|HIV-infected children
387006|NCT01138215|Assess protective VZV Antibody
387007|NCT01138215|Adverse events from VZV vaccine
387008|NCT01138202|pharmacokinetics
387009|NCT01138202|safety
387010|NCT01138202|efficacy
387011|NCT01138202|Lopinavir/ritonavir
387012|NCT01138202|HIV/TB
387013|NCT01138202|rifampicin containing anti-tuberculosis therapy
387014|NCT01138202|Pharmacokinetics and safety of Lopinavir/ritonavir with rifampicin containing anti-tuberculosis therapy
387015|NCT01138189|Wavefront-guided LASIK.
387016|NCT01138189|Wavefront-optimized LASIK.
387017|NCT01138189|Custom LASIK
387018|NCT01138176|Neonatal encephalopathy
387019|NCT01138176|Therapeutic hypothermia
387020|NCT01138176|Phase changing material
387021|NCT01138176|MR imaging
387022|NCT01138163|NSCLC
387023|NCT01138163|second-line
387024|NCT01138163|lung cancer
387025|NCT01138163|non small cell lung cancer
387026|NCT01138163|bavituximab
387027|NCT01138163|monoclonal antibody
387028|NCT01138150|migraine, headache, sumatriptan, naproxen sodium
387029|NCT01138137|ovarian cancer
387030|NCT01138137|epithelial ovarian cancer
387031|NCT01138137|peritoneal cancer
387032|NCT01138124|renal cell carcinoma
387033|NCT01138124|epidemiology
387034|NCT01138124|pancreatic cancer
387035|NCT01138124|renal cancer
387036|NCT01138124|renal pelvis cancer
387037|NCT01138124|GPRD
387038|NCT01138124|case-control
387039|NCT01138124|Gapabentin
387040|NCT01138111|Florbetaben
387041|NCT01138111|Amyloid beta-protein
387042|NCT01138111|MCI
387043|NCT01138111|Alzheimer's disease
387044|NCT01138098|Persistence
387045|NCT01138098|challenge dose
387046|NCT01138098|Engerix-B
387047|NCT01138098|immune response
387048|NCT01138085|Triple negative breast cancer
387049|NCT01138085|BRAF wild-type melanoma
387050|NCT01138085|Solid tumors
387051|NCT01138085|Endometrial Cancer
387052|NCT01138085|Oncology
387053|NCT01138085|GSK2141795
387054|NCT01138085|AKT Inhibitor
387055|NCT01138085|GSK1120212
387056|NCT01138072|GSK2248761, atorvastatin, rosuvastatin, simvastatin, drug interaction, pharmacokinetics
387057|NCT01138059|Acute ischemic stroke with unclear onset time
387058|NCT01138046|advanced/metastatic breast cancer
387059|NCT01138046|lapatinib
387060|NCT01138046|ErbB2
387061|NCT01138046|ErbB2-overexpressing
387062|NCT01138046|pharmacokinetics
387063|NCT01138046|dual kinase inhibitor
387064|NCT01138046|HER-2/neu
387065|NCT01138046|EGFR
387066|NCT01138046|ErbB1
387067|NCT01138033|pharmacodynamics
387068|NCT01138033|cancer
387069|NCT01138033|focal adhesion kinase inhibitor
387070|NCT01138033|pharmacokinetics
387071|NCT01138033|solid tumors
387072|NCT01138033|Phase 1
387073|NCT01138020|Rehabilitation Outcome
387074|NCT01138020|Cognitive treatment
387075|NCT01138020|TBI
387076|NCT01138007|Bupropion
387077|NCT01138007|323U66 Sustained Release (SR)
387078|NCT01138007|MDD (Major Depressive Disorder)
387079|NCT01138007|IVRS HAM-D
387080|NCT01138007|IDS-SR
387081|NCT01138007|MADRS
387082|NCT01137994|ErbB2
387083|NCT01137994|Trastuzumab
387084|NCT01137994|p95HER2
387085|NCT01137994|Metastatic Breast Cancer
387086|NCT01137994|HER2
387087|NCT01137994|Lapatinib
387088|NCT01137981|Combivir (Zidovudine+Lamivudine)
387089|NCT01137981|Antiretrovirals
387090|NCT01137981|ARV
387091|NCT01137981|HAART
387092|NCT01137981|Maraviroc
387093|NCT01137981|Delavirdine
387094|NCT01137981|Lamivudine
387095|NCT01137981|Antiretroviral Pregnancy Registry
387096|NCT01137981|Fosamprenavir
387097|NCT01137981|APR
387098|NCT01137981|Zidovudine
387099|NCT01137981|pregnancy registry
387100|NCT01137981|Amprenavir
387101|NCT01137981|HIV
387102|NCT01137981|Trizivir (Abacavir+Lamivudine+Zidovudine)
387103|NCT01137981|Epzicom (Abacavir+Lamivudine)
387104|NCT01137968|imetelstat
387105|NCT01137968|imetelstat sodium
387106|NCT01137968|GRN163L
387107|NCT01137968|telomerase inhibitor
387108|NCT01137968|telomerase inhibition
387109|NCT01137968|maintenance therapy
387110|NCT01137968|non-small cell lung cancer
387111|NCT01137968|relapsed non-small cell lung cancer
387112|NCT01137968|advanced non-small cell lung cancer
387113|NCT01137968|NSCLC, cancer stem cells
387114|NCT01137968|Bevacizumab
387115|NCT01137968|post induction chemotherapy
387116|NCT01137955|Gastrointestinal Symptom Rating Scale (GSRS)
387117|NCT01137955|Poorly responsive
387118|NCT01137955|Refractory
387119|NCT01137955|Small intestine bacterial overgrowth
387120|NCT01137955|Breath test
387121|NCT01137942|helicobacter pylori
387122|NCT01137942|eradication failure
387123|NCT01137929|Vesicoureteral reflux
387124|NCT01137929|Kidney
387125|NCT01137929|Renal Scar
387126|NCT01137929|Urinary tract infection
387127|NCT01137903|Diabetic foot
387128|NCT01137903|Osteomyelitis
387129|NCT01137903|Diabetic foot ulcers
387130|NCT01137903|Foot infections
387131|NCT01137890|cocaine
387132|NCT01137890|addiction
387133|NCT01137890|drug dependence
387134|NCT01137890|anticonvulsant
387135|NCT01137890|zonisamide
387136|NCT01137890|drug self-administration
387137|NCT01137890|nicotine withdrawal
387138|NCT01137890|neurocognition
387139|NCT01137864|Emergency wards
387140|NCT01137864|Hospitalization
387141|NCT01137864|Adults
387142|NCT01137864|Antimicrobial therapy
387143|NCT01137825|cognitive/functional effects
387144|NCT01137825|unspecified adult solid tumor, protocol specific
387145|NCT01137825|accelerated phase chronic myelogenous leukemia
387146|NCT01137825|acute undifferentiated leukemia
387147|NCT01137825|adult acute lymphoblastic leukemia in remission
387148|NCT01137825|adult acute myeloid leukemia in remission
387149|NCT01137825|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
387150|NCT01137825|adult acute myeloid leukemia with inv(16)(p13;q22)
387151|NCT01137825|adult acute myeloid leukemia with t(15;17)(q22;q12)
387152|NCT01137825|adult acute myeloid leukemia with t(16;16)(p13;q22)
387153|NCT01137825|adult acute myeloid leukemia with t(8;21)(q22;q22)
387154|NCT01137825|atypical chronic myeloid leukemia, BCR-ABL negative
387155|NCT01137825|blastic phase chronic myelogenous leukemia
387156|NCT01137825|chronic myelomonocytic leukemia
387157|NCT01137825|chronic phase chronic myelogenous leukemia
387158|NCT01137825|mast cell leukemia
387159|NCT01137825|meningeal chronic myelogenous leukemia
387160|NCT01137825|progressive hairy cell leukemia, initial treatment
387161|NCT01137825|prolymphocytic leukemia
387162|NCT01137825|recurrent adult acute lymphoblastic leukemia
387163|NCT01137825|recurrent adult acute myeloid leukemia
387164|NCT01137825|recurrent adult T-cell leukemia/lymphoma
387165|NCT01137825|refractory chronic lymphocytic leukemia
387166|NCT01137825|refractory hairy cell leukemia
387167|NCT01137825|relapsing chronic myelogenous leukemia
387168|NCT01137825|secondary acute myeloid leukemia
387169|NCT01137825|stage 0 chronic lymphocytic leukemia
387170|NCT01137825|stage I adult T-cell leukemia/lymphoma
387171|NCT01137825|stage I chronic lymphocytic leukemia
387172|NCT01137825|stage II adult T-cell leukemia/lymphoma
387173|NCT01137825|stage II chronic lymphocytic leukemia
387174|NCT01137825|stage III adult T-cell leukemia/lymphoma
387175|NCT01137825|stage III chronic lymphocytic leukemia
387176|NCT01137825|stage IV adult T-cell leukemia/lymphoma
387177|NCT01137825|stage IV chronic lymphocytic leukemia
387178|NCT01137825|T-cell large granular lymphocyte leukemia
387179|NCT01137825|untreated adult acute lymphoblastic leukemia
387180|NCT01137825|untreated adult acute myeloid leukemia
387181|NCT01137825|untreated hairy cell leukemia
387182|NCT01137825|recurrent adult Hodgkin lymphoma
387183|NCT01137825|stage I adult Hodgkin lymphoma
387184|NCT01137825|stage II adult Hodgkin lymphoma
387185|NCT01137825|stage III adult Hodgkin lymphoma
387186|NCT01137825|stage IV adult Hodgkin lymphoma
387187|NCT01137825|anaplastic large cell lymphoma
387188|NCT01137825|angioimmunoblastic T-cell lymphoma
387189|NCT01137825|cutaneous B-cell non-Hodgkin lymphoma
387190|NCT01137825|recurrent cutaneous T-cell non-Hodgkin lymphoma
387191|NCT01137825|stage I cutaneous T-cell non-Hodgkin lymphoma
387192|NCT01137825|stage II cutaneous T-cell non-Hodgkin lymphoma
387193|NCT01137825|stage III cutaneous T-cell non-Hodgkin lymphoma
387194|NCT01137825|stage IV cutaneous T-cell non-Hodgkin lymphoma
387195|NCT01137825|recurrent mycosis fungoides/Sezary syndrome
387196|NCT01137825|stage I mycosis fungoides/Sezary syndrome
387197|NCT01137825|stage II mycosis fungoides/Sezary syndrome
387198|NCT01137825|stage III mycosis fungoides/Sezary syndrome
387199|NCT01137825|stage IV mycosis fungoides/Sezary syndrome
387200|NCT01137825|adult grade III lymphomatoid granulomatosis
387201|NCT01137825|adult nasal type extranodal NK/T-cell lymphoma
387202|NCT01137825|Waldenstrom macroglobulinemia
387203|NCT01137825|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
387204|NCT01137825|nodal marginal zone B-cell lymphoma
387205|NCT01137825|splenic marginal zone lymphoma
387206|NCT01137825|contiguous stage II adult Burkitt lymphoma
387207|NCT01137825|contiguous stage II adult diffuse large cell lymphoma
387208|NCT01137825|contiguous stage II adult diffuse mixed cell lymphoma
387209|NCT01137825|contiguous stage II adult diffuse small cleaved cell lymphoma
387210|NCT01137825|contiguous stage II adult immunoblastic large cell lymphoma
387211|NCT01137825|contiguous stage II adult lymphoblastic lymphoma
387212|NCT01137825|contiguous stage II grade 1 follicular lymphoma
387213|NCT01137825|contiguous stage II grade 2 follicular lymphoma
387214|NCT01137825|contiguous stage II grade 3 follicular lymphoma
387215|NCT01137825|contiguous stage II mantle cell lymphoma
387216|NCT01137825|contiguous stage II marginal zone lymphoma
387217|NCT01137825|contiguous stage II small lymphocytic lymphoma
387218|NCT01137825|stage I adult Burkitt lymphoma
387219|NCT01137825|stage I adult diffuse large cell lymphoma
387220|NCT01137825|stage I adult diffuse mixed cell lymphoma
387221|NCT01137825|stage I adult diffuse small cleaved cell lymphoma
387222|NCT01137825|stage I adult immunoblastic large cell lymphoma
387223|NCT01137825|stage I adult lymphoblastic lymphoma
387224|NCT01137825|stage I grade 1 follicular lymphoma
387225|NCT01137825|stage I grade 2 follicular lymphoma
387226|NCT01137825|stage I grade 3 follicular lymphoma
387227|NCT01137825|stage I mantle cell lymphoma
387228|NCT01137825|stage I marginal zone lymphoma
387229|NCT01137825|stage I small lymphocytic lymphoma
387230|NCT01137825|noncontiguous stage II adult Burkitt lymphoma
387231|NCT01137825|noncontiguous stage II adult diffuse large cell lymphoma
387232|NCT01137825|noncontiguous stage II adult diffuse mixed cell lymphoma
387233|NCT01137825|noncontiguous stage II adult diffuse small cleaved cell lymphoma
387234|NCT01137825|noncontiguous stage II adult immunoblastic large cell lymphoma
387235|NCT01137825|noncontiguous stage II adult lymphoblastic lymphoma
387236|NCT01137825|noncontiguous stage II grade 1 follicular lymphoma
387237|NCT01137825|noncontiguous stage II grade 2 follicular lymphoma
387238|NCT01137825|noncontiguous stage II grade 3 follicular lymphoma
387239|NCT01137825|noncontiguous stage II mantle cell lymphoma
387240|NCT01137825|noncontiguous stage II marginal zone lymphoma
387241|NCT01137825|noncontiguous stage II small lymphocytic lymphoma
387242|NCT01137825|stage III adult Burkitt lymphoma
387243|NCT01137825|stage III adult diffuse large cell lymphoma
387244|NCT01137825|stage III adult diffuse mixed cell lymphoma
387245|NCT01137825|stage III adult diffuse small cleaved cell lymphoma
387246|NCT01137825|stage III adult immunoblastic large cell lymphoma
387247|NCT01137825|stage III adult lymphoblastic lymphoma
387248|NCT01137825|stage III grade 1 follicular lymphoma
387249|NCT01137825|stage III grade 2 follicular lymphoma
387250|NCT01137825|stage III grade 3 follicular lymphoma
387251|NCT01137825|stage III mantle cell lymphoma
387252|NCT01137825|stage III marginal zone lymphoma
387253|NCT01137825|stage III small lymphocytic lymphoma
387254|NCT01137825|stage IV adult Burkitt lymphoma
387255|NCT01137825|stage IV adult diffuse large cell lymphoma
387256|NCT01137825|stage IV adult diffuse mixed cell lymphoma
387257|NCT01137825|stage IV adult diffuse small cleaved cell lymphoma
387258|NCT01137825|stage IV adult immunoblastic large cell lymphoma
387259|NCT01137825|stage IV adult lymphoblastic lymphoma
387260|NCT01137825|stage IV grade 1 follicular lymphoma
387261|NCT01137825|stage IV grade 2 follicular lymphoma
387262|NCT01137825|stage IV grade 3 follicular lymphoma
387263|NCT01137825|stage IV mantle cell lymphoma
387264|NCT01137825|stage IV marginal zone lymphoma
387265|NCT01137825|stage IV small lymphocytic lymphoma
387266|NCT01137825|recurrent adult Burkitt lymphoma
387267|NCT01137825|recurrent adult diffuse large cell lymphoma
387268|NCT01137825|recurrent adult diffuse mixed cell lymphoma
387269|NCT01137825|recurrent adult diffuse small cleaved cell lymphoma
387270|NCT01137825|recurrent adult grade III lymphomatoid granulomatosis
387271|NCT01137825|recurrent adult immunoblastic large cell lymphoma
387272|NCT01137825|recurrent adult lymphoblastic lymphoma
387273|NCT01137825|recurrent grade 1 follicular lymphoma
387274|NCT01137825|recurrent grade 2 follicular lymphoma
387275|NCT01137825|recurrent grade 3 follicular lymphoma
387276|NCT01137825|recurrent mantle cell lymphoma
387277|NCT01137825|recurrent marginal zone lymphoma
387278|NCT01137825|recurrent small lymphocytic lymphoma
387279|NCT01137825|intraocular lymphoma
387280|NCT01137825|post-transplant lymphoproliferative disorder
387281|NCT01137825|chronic eosinophilic leukemia
387282|NCT01137825|chronic neutrophilic leukemia
387283|NCT01137825|primary myelofibrosis
387284|NCT01137825|essential thrombocythemia
387285|NCT01137825|polycythemia vera
387286|NCT01137825|extramedullary plasmacytoma
387287|NCT01137825|isolated plasmacytoma of bone
387288|NCT01137825|stage I multiple myeloma
387289|NCT01137825|stage II multiple myeloma
387290|NCT01137825|stage III multiple myeloma
387291|NCT01137825|primary systemic amyloidosis
387292|NCT01137825|refractory multiple myeloma
387293|NCT01137825|de novo myelodysplastic syndromes
387294|NCT01137825|previously treated myelodysplastic syndromes
387295|NCT01137825|secondary myelodysplastic syndromes
387296|NCT01137825|myelodysplastic/myeloproliferative neoplasm, unclassifiable
387297|NCT01137812|Canagliflozin
387298|NCT01137812|Sitagliptin (Januvia)
387299|NCT01137812|Metformin
387300|NCT01137812|Sulphonylurea
387301|NCT01137812|Hemoglobin A1c
387302|NCT01137812|Type 2 diabetes mellitus
387303|NCT01137799|symptomatic treatment
387304|NCT01137799|cognition
387305|NCT01137799|cognitive deficits
387306|NCT01137799|schizophrenia
387307|NCT01137799|Alzheimer's Disease
387308|NCT01137773|SAH (Subarachnoid Hemorrhage)
387309|NCT01137773|Brain Hemorrhage
387310|NCT01137773|Traumatic Brain Injury
387311|NCT01137773|SAH
387312|NCT01137773|ICH
387313|NCT01137760|adults
387314|NCT01137760|fiber
387315|NCT01137760|cold
387316|NCT01137760|flu
387317|NCT01137760|stress
387318|NCT01137760|microbiota
387319|NCT01137747|carfilzomib
387320|NCT01137747|acute myeloid leukemia
387321|NCT01137747|acute lymphoblastic leukemia
387322|NCT01137747|phase I
387323|NCT01137734|Heart Diseases
387324|NCT01137734|Heart Valve Diseases
387325|NCT01137734|Cardiovascular Diseases
387326|NCT01137721|magnetic resonance imaging
387327|NCT01137721|sickle cell disease
387328|NCT01137721|hydroxyurea therapy
387329|NCT01137708|drug interactions
387330|NCT01137708|CYP3A
387331|NCT01137708|oral contraceptive
387332|NCT01137708|anti-rheumatic agents
387333|NCT01137695|pramlintide
387334|NCT01137695|glucose
387335|NCT01137695|type 2 diabetes mellitus
387336|NCT01137695|amylin
387337|NCT01137682|Acromegaly
387338|NCT01137682|hormone disorder
387339|NCT01137682|growth hormone
387340|NCT01137682|insulin like growth factor-1
387341|NCT01137682|pituitary tumor
387342|NCT01137669|immunocompromised,parent protocol,shingles,varicella-zoster virus,ZOSTAVAX®
387343|NCT01137656|Blood storage
387344|NCT01137656|Blood transfusion
387345|NCT01137656|Aged blood
387346|NCT01137656|Blood Forearm
387347|NCT01137656|Storage lesion in blood
387348|NCT01137643|accelerated phase chronic myelogenous leukemia
387349|NCT01137643|acute undifferentiated leukemia
387350|NCT01137643|adult acute lymphoblastic leukemia in remission
387351|NCT01137643|adult acute myeloid leukemia in remission
387352|NCT01137643|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
387353|NCT01137643|adult acute myeloid leukemia with inv(16)(p13;q22)
387354|NCT01137643|adult acute myeloid leukemia with t(15;17)(q22;q12)
387355|NCT01137643|adult acute myeloid leukemia with t(16;16)(p13;q22)
387356|NCT01137643|adult acute myeloid leukemia with t(8;21)(q22;q22)
387357|NCT01137643|atypical chronic myeloid leukemia, BCR-ABL negative
387358|NCT01137643|blastic phase chronic myelogenous leukemia
387359|NCT01137643|mast cell leukemia
387360|NCT01137643|meningeal chronic myelogenous leukemia
387361|NCT01137643|progressive hairy cell leukemia, initial treatment
387362|NCT01137643|prolymphocytic leukemia
387363|NCT01137643|recurrent adult acute lymphoblastic leukemia
387364|NCT01137643|recurrent adult acute myeloid leukemia
387365|NCT01137643|recurrent adult T-cell leukemia/lymphoma
387366|NCT01137643|refractory chronic lymphocytic leukemia
387367|NCT01137643|refractory hairy cell leukemia
387368|NCT01137643|relapsing chronic myelogenous leukemia
387369|NCT01137643|secondary acute myeloid leukemia
387370|NCT01137643|stage 0 chronic lymphocytic leukemia
387371|NCT01137643|stage I adult T-cell leukemia/lymphoma
387372|NCT01137643|stage I chronic lymphocytic leukemia
387373|NCT01137643|stage II adult T-cell leukemia/lymphoma
387374|NCT01137643|stage II chronic lymphocytic leukemia
387375|NCT01137643|stage III adult T-cell leukemia/lymphoma
387376|NCT01137643|stage III chronic lymphocytic leukemia
387377|NCT01137643|stage IV adult T-cell leukemia/lymphoma
387378|NCT01137643|stage IV chronic lymphocytic leukemia
387379|NCT01137643|T-cell large granular lymphocyte leukemia
387380|NCT01137643|untreated adult acute lymphoblastic leukemia
387381|NCT01137643|untreated adult acute myeloid leukemia
387382|NCT01137643|untreated hairy cell leukemia
387383|NCT01137643|recurrent adult Hodgkin lymphoma
387384|NCT01137643|stage I adult Hodgkin lymphoma
387385|NCT01137643|stage II adult Hodgkin lymphoma
387386|NCT01137643|stage III adult Hodgkin lymphoma
387387|NCT01137643|stage IV adult Hodgkin lymphoma
387388|NCT01137643|anaplastic large cell lymphoma
387389|NCT01137643|angioimmunoblastic T-cell lymphoma
387390|NCT01137643|cutaneous B-cell non-Hodgkin lymphoma
387391|NCT01137643|recurrent cutaneous T-cell non-Hodgkin lymphoma
387392|NCT01137643|stage I cutaneous T-cell non-Hodgkin lymphoma
387393|NCT01137643|stage II cutaneous T-cell non-Hodgkin lymphoma
387394|NCT01137643|stage III cutaneous T-cell non-Hodgkin lymphoma
387605|NCT01137032|Psoriasis
387395|NCT01137643|stage IV cutaneous T-cell non-Hodgkin lymphoma
387396|NCT01137643|recurrent mycosis fungoides/Sezary syndrome
387397|NCT01137643|stage I mycosis fungoides/Sezary syndrome
387398|NCT01137643|stage II mycosis fungoides/Sezary syndrome
387399|NCT01137643|stage III mycosis fungoides/Sezary syndrome
387400|NCT01137643|stage IV mycosis fungoides/Sezary syndrome
387401|NCT01137643|adult grade III lymphomatoid granulomatosis
387402|NCT01137643|adult nasal type extranodal NK/T-cell lymphoma
387403|NCT01137643|Waldenstrom macroglobulinemia
387404|NCT01137643|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
387405|NCT01137643|nodal marginal zone B-cell lymphoma
387406|NCT01137643|splenic marginal zone lymphoma
387407|NCT01137643|contiguous stage II adult Burkitt lymphoma
387408|NCT01137643|contiguous stage II adult diffuse large cell lymphoma
387409|NCT01137643|contiguous stage II adult diffuse mixed cell lymphoma
387410|NCT01137643|contiguous stage II adult diffuse small cleaved cell lymphoma
387411|NCT01137643|contiguous stage II adult immunoblastic large cell lymphoma
387412|NCT01137643|contiguous stage II adult lymphoblastic lymphoma
387413|NCT01137643|contiguous stage II grade 1 follicular lymphoma
387414|NCT01137643|contiguous stage II grade 2 follicular lymphoma
387415|NCT01137643|contiguous stage II grade 3 follicular lymphoma
387416|NCT01137643|contiguous stage II mantle cell lymphoma
387417|NCT01137643|contiguous stage II marginal zone lymphoma
387418|NCT01137643|contiguous stage II small lymphocytic lymphoma
387419|NCT01137643|stage I adult Burkitt lymphoma
387420|NCT01137643|stage I adult diffuse large cell lymphoma
387421|NCT01137643|stage I adult diffuse mixed cell lymphoma
387422|NCT01137643|stage I adult diffuse small cleaved cell lymphoma
387423|NCT01137643|stage I adult immunoblastic large cell lymphoma
387424|NCT01137643|stage I adult lymphoblastic lymphoma
387425|NCT01137643|stage I grade 1 follicular lymphoma
387426|NCT01137643|stage I grade 2 follicular lymphoma
387427|NCT01137643|stage I grade 3 follicular lymphoma
387428|NCT01137643|stage I mantle cell lymphoma
387429|NCT01137643|stage I marginal zone lymphoma
387430|NCT01137643|stage I small lymphocytic lymphoma
387431|NCT01137643|noncontiguous stage II adult Burkitt lymphoma
387432|NCT01137643|noncontiguous stage II adult diffuse large cell lymphoma
387433|NCT01137643|noncontiguous stage II adult diffuse mixed cell lymphoma
387434|NCT01137643|noncontiguous stage II adult diffuse small cleaved cell lymphoma
387435|NCT01137643|noncontiguous stage II adult immunoblastic large cell lymphoma
387436|NCT01137643|noncontiguous stage II adult lymphoblastic lymphoma
387437|NCT01137643|noncontiguous stage II grade 1 follicular lymphoma
387438|NCT01137643|noncontiguous stage II grade 2 follicular lymphoma
387439|NCT01137643|noncontiguous stage II grade 3 follicular lymphoma
387440|NCT01137643|noncontiguous stage II mantle cell lymphoma
387441|NCT01137643|noncontiguous stage II marginal zone lymphoma
387442|NCT01137643|noncontiguous stage II small lymphocytic lymphoma
387443|NCT01137643|stage III adult Burkitt lymphoma
387444|NCT01137643|stage III adult diffuse large cell lymphoma
387445|NCT01137643|stage III adult diffuse mixed cell lymphoma
387446|NCT01137643|stage III adult diffuse small cleaved cell lymphoma
387447|NCT01137643|stage III adult immunoblastic large cell lymphoma
387448|NCT01137643|stage III adult lymphoblastic lymphoma
387449|NCT01137643|stage III grade 1 follicular lymphoma
387450|NCT01137643|stage III grade 2 follicular lymphoma
387451|NCT01137643|stage III grade 3 follicular lymphoma
387452|NCT01137643|stage III mantle cell lymphoma
387453|NCT01137643|stage III marginal zone lymphoma
387454|NCT01137643|stage III small lymphocytic lymphoma
387455|NCT01137643|stage IV adult Burkitt lymphoma
387456|NCT01137643|stage IV adult diffuse large cell lymphoma
387457|NCT01137643|stage IV adult diffuse mixed cell lymphoma
387458|NCT01137643|stage IV adult diffuse small cleaved cell lymphoma
387459|NCT01137643|stage IV adult immunoblastic large cell lymphoma
387460|NCT01137643|stage IV adult lymphoblastic lymphoma
387461|NCT01137643|stage IV grade 1 follicular lymphoma
387462|NCT01137643|stage IV grade 2 follicular lymphoma
387463|NCT01137643|stage IV grade 3 follicular lymphoma
387464|NCT01137643|stage IV mantle cell lymphoma
387465|NCT01137643|stage IV marginal zone lymphoma
387466|NCT01137643|stage IV small lymphocytic lymphoma
387467|NCT01137643|recurrent adult Burkitt lymphoma
387468|NCT01137643|recurrent adult diffuse large cell lymphoma
387469|NCT01137643|recurrent adult diffuse mixed cell lymphoma
387470|NCT01137643|recurrent adult diffuse small cleaved cell lymphoma
387471|NCT01137643|recurrent adult grade III lymphomatoid granulomatosis
387472|NCT01137643|recurrent adult immunoblastic large cell lymphoma
387473|NCT01137643|recurrent adult lymphoblastic lymphoma
387474|NCT01137643|recurrent grade 1 follicular lymphoma
387475|NCT01137643|recurrent grade 2 follicular lymphoma
387476|NCT01137643|recurrent grade 3 follicular lymphoma
387477|NCT01137643|recurrent mantle cell lymphoma
387478|NCT01137643|recurrent marginal zone lymphoma
387479|NCT01137643|recurrent small lymphocytic lymphoma
387480|NCT01137643|intraocular lymphoma
387481|NCT01137643|post-transplant lymphoproliferative disorder
387482|NCT01137643|chronic eosinophilic leukemia
387483|NCT01137643|chronic neutrophilic leukemia
387484|NCT01137643|primary myelofibrosis
387485|NCT01137643|essential thrombocythemia
387486|NCT01137643|polycythemia vera
387487|NCT01137643|extramedullary plasmacytoma
387488|NCT01137643|isolated plasmacytoma of bone
387489|NCT01137643|stage I multiple myeloma
387490|NCT01137643|stage II multiple myeloma
387491|NCT01137643|stage III multiple myeloma
387492|NCT01137643|primary systemic amyloidosis
387493|NCT01137643|refractory multiple myeloma
387494|NCT01137643|de novo myelodysplastic syndromes
387495|NCT01137643|previously treated myelodysplastic syndromes
387496|NCT01137643|secondary myelodysplastic syndromes
387497|NCT01137643|myelodysplastic/myeloproliferative neoplasm, unclassifiable
387498|NCT01137643|aplastic anemia
387499|NCT01137630|seborrhoeic dermatitis
387500|NCT01137630|scalp
387501|NCT01137630|K40a
387502|NCT01137630|K40b
387503|NCT01137591|Acetaminophen
387504|NCT01137591|Acetylcysteine
387505|NCT01137591|Antidotes
387506|NCT01137565|Amgen
387507|NCT01137565|Adolescent
387508|NCT01137565|Safety
387509|NCT01137552|First-In-Human
387510|NCT01137552|Dose Escalation
387511|NCT01137552|Dose Expansion
387512|NCT01137552|Advance Solid Tumors
387513|NCT01137552|Anti-Angiopoietin
387514|NCT01137552|Advance Malignancy
387515|NCT01137552|Cancer
387516|NCT01137552|Oncology
387517|NCT01137552|Oncology Patients
387518|NCT01137552|Phase 1
387519|NCT01137552|Clinical Trial
387520|NCT01137552|Tumors
387521|NCT01137552|Solid Tumors
387522|NCT01137552|Angiogenesis Inhibitors
387523|NCT01137539|urinary incontinence
387524|NCT01137539|stress urinary incontinence
387525|NCT01137539|mid-urethral slings
387526|NCT01137539|Tension-free vaginal taping
387527|NCT01137539|TVT
387528|NCT01137513|Chest Pain
387529|NCT01137513|Acute coronary syndrome
387530|NCT01137513|AMI
387531|NCT01137487|mechanical ventilation
387532|NCT01137487|enteral nutrition
387533|NCT01137487|Ventilation-Associated Pneumonia
387534|NCT01137487|residual gastric volume measurement
387535|NCT01137487|vomiting
387536|NCT01137487|gastro-oesophageal reflux
387537|NCT01137487|early enteral nutrition
387538|NCT01137487|Intensive care unit
387539|NCT01137487|Enteral Feeding
387540|NCT01137474|Diabetes Mellitus, Type 2
387541|NCT01137474|Diabetes Mellitus
387542|NCT01137474|Endocrine System Diseases
387543|NCT01137474|Glucose Metabolism Disorders
387544|NCT01137474|Metabolic Diseases
387545|NCT01137474|Angiotensin Receptor Antagonists
387546|NCT01137474|Angiotensin-Converting Enzyme Inhibitors
387547|NCT01137474|Hypoglycemic Agents
387548|NCT01137474|Pharmacologic Actions
387549|NCT01137474|Physiological Effects of Drugs
387550|NCT01137461|Female infertility with indication of oocyte reception
387551|NCT01137448|Psoriasis
387552|NCT01137448|Obesity
387553|NCT01137435|Adacel
387554|NCT01137435|Diphtheria
387555|NCT01137435|Tetanus
387556|NCT01137435|Pertussis
387557|NCT01137383|Hepatitis C
387558|NCT01137331|seborrhoeic eczema
387559|NCT01137331|scalp
387560|NCT01137331|dandruff
387561|NCT01137331|K301
387562|NCT01137331|K40
387563|NCT01137318|ADHD
387564|NCT01137318|Impairment
387565|NCT01137318|Treatment
387566|NCT01137318|Cognitive Remediation
387567|NCT01137318|Behavioral Parent Training
387568|NCT01137305|Virtual reality
387569|NCT01137305|surgical training
387570|NCT01137305|Health Care [N]
387571|NCT01137292|observational study
387572|NCT01137292|voriconazole
387573|NCT01137292|high-risk patients
387574|NCT01137266|chronic pain osteo-arthritis in one or both knees, adults
387575|NCT01137253|Nitric Oxide
387576|NCT01137253|Autonomic Nervous System
387577|NCT01137240|subjects suffering from mitochondrial disorders with one or more gastrointestinal symptoms would be the focus of the study
387578|NCT01137227|Physical activity
387579|NCT01137227|Epidemiology
387580|NCT01137227|Questionnaire
387581|NCT01137227|Cross-sectional study
387582|NCT01137214|complex sleep apnea
387583|NCT01137201|Small bowel obstruction
387584|NCT01137201|Laparoscopic gastric bypass
387585|NCT01137201|Internal Hernia
387586|NCT01137201|Mesenteric defect
387587|NCT01137201|Morbid obesity
387588|NCT01137175|Rickettsioses
387589|NCT01137175|Scrub Typhus
387590|NCT01137175|Q fever
387591|NCT01137175|Typhus fever
387592|NCT01137175|Spotted fever
387593|NCT01137175|Rickettsioses reported cases
387594|NCT01137149|Adolescent Depression
387595|NCT01137149|Treatment of depression in adolescents
387596|NCT01137149|Behavioral activation treatment for depressed adolescents
387597|NCT01137123|esophageal squamous cell carcinoma
387598|NCT01137110|Subarachnoid Hemorrhage
387599|NCT01137110|Seizure Prophylaxis
387600|NCT01137110|Levetiracetam
387601|NCT01137045|rabies vaccine
387602|NCT01137045|vero cells
387603|NCT01137045|serology
387604|NCT01137045|safety
387606|NCT01137032|Atopic Dermatitis
387607|NCT01137019|Drug-eluting stents
387608|NCT01137019|Tomography, Optical Coherence
387609|NCT01137006|Melanoma
387610|NCT01137006|Phase I
387611|NCT01137006|antibody
387612|NCT01137006|melanin
387613|NCT01137006|tyrosinase related protein 1
387614|NCT01137006|glycoprotein
387615|NCT01137006|20D7S
387616|NCT01136993|Stroke
387617|NCT01136993|Thrombolysis
387618|NCT01136993|Telestroke
387619|NCT01136980|GERD
387620|NCT01136980|Esophagitis
387621|NCT01136980|Fundoplication
387622|NCT01136980|Anti-reflux surgery
387623|NCT01136980|PPI dependent
387624|NCT01136928|Antiretroviral therapy
387625|NCT01136928|American ginseng
387626|NCT01136928|Efavirenz
387627|NCT01136928|Cytochrome P450 enzymes
387628|NCT01136928|Complementary and Alternative Medicine
387629|NCT01136928|Herbal
387630|NCT01136928|Pharmacikinetics
387631|NCT01136928|Healthy volunteers
387632|NCT01136902|Diabetes Mellitus
387633|NCT01136902|Retinal Vessels
387634|NCT01136902|Physiology
387635|NCT01136889|PFMT
387636|NCT01136889|Vaginal pessary
387637|NCT01136889|Pelvic Organ Prolapse
387638|NCT01136863|hypertension
387639|NCT01136863|felodipine
387640|NCT01136863|moderate to high risk patients
387641|NCT01136850|Plasmodium falciparum
387642|NCT01136850|Plasmodium vivax
387643|NCT01136850|azithromycin
387644|NCT01136850|sulphadoxine pyrimethamine
387645|NCT01136850|low birth weight
387646|NCT01136850|haemoglobin
387647|NCT01136850|Chlamydia trachomatis
387648|NCT01136850|Neisseria gonorrhoeae
387649|NCT01136850|Treponema pallidum
387650|NCT01136824|Sarcoma
387651|NCT01136824|questionnaire
387652|NCT01136824|doxorubicin plus ifosfamide (AI)
387653|NCT01136798|slow wave sleep
387654|NCT01136798|effect of exenatide therapy on sleep in patients with type 2 diabetes
387655|NCT01136759|Prevention
387656|NCT01136759|Microbicide
387657|NCT01136759|Mother-to-Child-Transmission
387658|NCT01136759|Pregnancy
387659|NCT01136746|Hyperglycemia
387660|NCT01136746|Diabetes
387661|NCT01136746|Hospital
387662|NCT01136746|Diabetic
387663|NCT01136733|Unresectable advanced or metastatic renal cell carcinoma
387664|NCT01136681|Anonymised Electronic Cohort
387665|NCT01136681|Record Linkage
387666|NCT01136681|Routine Data
387667|NCT01136681|Environment
387668|NCT01136681|Childhood Obesity
387669|NCT01136681|Low birth weight
387670|NCT01136681|Premature birth
387671|NCT01136668|pediatrics
387672|NCT01136668|Transversus Abdominis Plane Block
387673|NCT01136668|Ostomy Surgery
387674|NCT01136668|Anesthesia
387675|NCT01136668|Regional Anesthetic
387676|NCT01136655|asthmatic children
387677|NCT01136655|Symbicort
387678|NCT01136655|Foradil
387679|NCT01136642|Nicotine
387680|NCT01136642|Nicotine Nasal Spray
387681|NCT01136642|Attention
387682|NCT01136642|Smoking
387683|NCT01136629|Hyper-pigmented spots
387684|NCT01136629|Lentigines
387685|NCT01136629|Mealsma
387686|NCT01136629|RNA extraction
387687|NCT01136629|Isolation of Keratinocytes
387688|NCT01136629|Isolation of Melanocytes
387689|NCT01136616|Nasal fracture
387690|NCT01136616|Nasal buttresses
387691|NCT01136616|Septal deviation
387692|NCT01136616|Nasal morphology
387693|NCT01136616|CT Scan
387694|NCT01136603|Abdominal wall defects
387695|NCT01136603|Inflammation reactions
387696|NCT01136603|Amount of tissue ingrowth
387697|NCT01136603|Adhesion formation
387698|NCT01136603|Shrinkage profiles of the implant
387699|NCT01136590|Spinal deformity correction
387700|NCT01136590|Surgical bleeding
387701|NCT01136590|Transfusion practice
387702|NCT01136590|Spinal Fusion
387703|NCT01136590|Antifibrinolytic Agents
387704|NCT01136590|Hemorrhage
387705|NCT01136590|Blood Transfusion
387706|NCT01136577|Jaundice
387707|NCT01136577|Hyperbilirubinemia
387708|NCT01136577|Phototherapy
387709|NCT01136577|term newborn
387710|NCT01136577|LED
387711|NCT01136577|Fluorescent lamps
387712|NCT01136564|paricalcitol
387713|NCT01136564|vitamin d
387714|NCT01136564|kidney disease
387715|NCT01136564|renin
387716|NCT01136564|proteinuria
387717|NCT01136551|Pharmacokinetic profile of controlled release formulation of Huperzine A
387718|NCT01136551|Bioequivalence of Huperzine A IR formulation and CR formulation
387719|NCT01136538|Bioequivalence
387720|NCT01136538|Crossover
387721|NCT01136538|Valacyclovir Hydrochloride
387722|NCT01136525|Bioequivalence
387723|NCT01136525|Crossover
387724|NCT01136525|Valacyclovir Hydrochloride
387725|NCT01136512|metformin
387726|NCT01136512|vitamin B12
387727|NCT01136512|type 2 diabetes
387728|NCT01136512|methylmalonic acid
387729|NCT01136512|deficiency
387730|NCT01136499|Sarcoma
387731|NCT01136499|Safety
387732|NCT01136499|Efficacy
387733|NCT01136499|PANOBINOSTAT
387734|NCT01136486|head trauma; traumatic brain injury
387735|NCT01136473|congenital cataract
387736|NCT01136473|aphakic
387737|NCT01136473|pseudophakic glaucoma
387738|NCT01136473|pediatric patients
387739|NCT01136460|Primary congenital glaucoma
387740|NCT01136460|neonatal
387741|NCT01136460|Genotype correlation
387742|NCT01136460|Phenotype correlation
387743|NCT01136447|Brachial plexus
387744|NCT01136447|Ultrasound
387745|NCT01136421|COPD exacerbation
387746|NCT01136421|Magnesium sulfate
387747|NCT01136421|Ipratropium bromide
387748|NCT01136421|Emergency departement
387749|NCT01136395|Kidney Transplantation
387750|NCT01136395|Rituximab
387751|NCT01136395|Living Donor
387752|NCT01136395|ABO Incompatible Transplantation
387753|NCT01136395|Immunology
387754|NCT01136395|CMV
387755|NCT01136395|EBV
387756|NCT01136395|Polyomavirus
387757|NCT01136382|asthma, children, budesonide pMDI
387758|NCT01136369|metastasis
387759|NCT01136369|molecular pathology
387760|NCT01136356|opioid pharmacology
387761|NCT01136356|buprenorphine
387762|NCT01136356|morphine
387763|NCT01136356|withdrawal
387764|NCT01136356|human research
387765|NCT01136343|women
387766|NCT01136343|middle age
387767|NCT01136343|risk factor
387768|NCT01136330|Myotonic dystrophy
387769|NCT01136330|Prognosis
387770|NCT01136330|Sudden death
387771|NCT01136330|Respiratory failure
387772|NCT01136304|Gaucher disease
387773|NCT01136304|Imiglucerase
387774|NCT01136304|Cerezyme
387775|NCT01136304|Severity score
387776|NCT01136291|pregnancy
387777|NCT01136291|obesity
387778|NCT01136291|physical exercise
387779|NCT01136291|quality of life
387780|NCT01136278|MDMA
387781|NCT01136278|norepinephrine
387782|NCT01136278|alpha2 receptor
387783|NCT01136278|Ecstasy
387784|NCT01136278|stimulant
387785|NCT01136265|dual-time PET/CT
387786|NCT01136265|sentinel node
387787|NCT01136239|COPD
387788|NCT01136239|N-acetylcysteine
387789|NCT01136239|airtrapping
387790|NCT01136239|airway resistance
387791|NCT01136239|antioxidant
387792|NCT01136226|Prostate Cancer
387793|NCT01136200|Surgical and medical wards
387794|NCT01136200|Adults
387795|NCT01136200|Antimicrobial therapy
387796|NCT01136187|Myocardial infarction
387797|NCT01136187|Primary percutaneous coronary intervention
387798|NCT01136187|Radial
387799|NCT01136187|Bleeding
387800|NCT01136161|LTBI (Latent Tuberculosis Infection)
387801|NCT01136161|TB (Tuberculosis)
387802|NCT01136161|Vaccine
387803|NCT01136148|Mental Health
387804|NCT01136148|Aged
387805|NCT01136148|Hospitals, general
387806|NCT01136148|Dementia
387807|NCT01136148|Delirium
387808|NCT01136148|Dementia and confusion
387809|NCT01136135|Heart transplant rejection
387810|NCT01136135|cardiac MRI
387811|NCT01136135|diagnosis
387812|NCT01136096|diabetes
387813|NCT01136096|physical activity
387814|NCT01136096|adiponectin
387815|NCT01136096|metabolic risks
387816|NCT01136096|exercise
387817|NCT01136096|primary prevention
387818|NCT01136083|Tumor
387819|NCT01136083|Angiogenesis
387820|NCT01136083|Exercise training
387821|NCT01136083|VEGF
387822|NCT01136083|Myostatin
387823|NCT01136070|Psychological Functioning in Burn Patients
387824|NCT01136044|tensor fasciae latae
387825|NCT01136044|septocutaneous perforators
387826|NCT01136031|advanced gastric cancer
387827|NCT01136031|1st-line failure
387828|NCT01136005|receptor, epidermal growth factor
387829|NCT01136005|skin toxicity
387830|NCT01136005|quality of life
387831|NCT01136005|adherence
387832|NCT01135966|COPD
387833|NCT01135966|Whole Body Vibration training
387834|NCT01135966|Conventional resistance training
387835|NCT01135953|Brain excitation
387836|NCT01135953|transcranial Direct Stimulation
387837|NCT01135953|administration pattern
387838|NCT01135940|neuromuscular scoliosis
387839|NCT01135940|dermabond
387840|NCT01135940|infection
387841|NCT01135940|wound closure
387842|NCT01135914|DME
387843|NCT01135914|visual impairment
387844|NCT01135914|diabetes
387845|NCT01135914|macular edema
387846|NCT01135914|diabetic macular edema
387847|NCT01135914|ranibizumab
387848|NCT01135914|laser
387849|NCT01135914|photocoagulation
387850|NCT01135914|retinopathy
387851|NCT01135914|retina
387852|NCT01135901|prevention
387853|NCT01135901|public health
387854|NCT01135901|community health services
387855|NCT01135901|Norway
387856|NCT01135888|hypohidrotic ectodermal dysplasia
387857|NCT01135888|exertional hyperthermia
387858|NCT01135888|cooling device
387859|NCT01135875|GBM
387860|NCT01135875|Brain Tumor
387861|NCT01135875|Brain Neoplasm
387862|NCT01135875|Control
387863|NCT01135875|Normal Control
387864|NCT01135875|Volunteer
387865|NCT01135836|Shoulder pain
387866|NCT01135836|Gynecologic laparoscopic surgery
387867|NCT01135836|Nausea
387868|NCT01135836|Vomiting
387869|NCT01135836|Abdominal fullness
387870|NCT01135810|healthy subjects
387871|NCT01135771|glucose monitoring
387872|NCT01135771|diabetes
387873|NCT01135771|glucose monitoring in patients with diabetes
387874|NCT01135758|depression, ketamine, fMRI
387875|NCT01135732|late development cholangiocarcinoma
387876|NCT01135719|Myopia
387877|NCT01135719|Hyperopia
387878|NCT01135719|Astigmatism
387879|NCT01135719|PRK
387880|NCT01135719|LASIK
387881|NCT01135706|Pulmonary Hypertension
387882|NCT01135706|Fractal dimension
387883|NCT01135693|Section 136
387884|NCT01135693|Mental Health Act 1983
387885|NCT01135693|Police
387886|NCT01135693|Detention
387887|NCT01135693|Failure of community care
387888|NCT01135667|clopidogrel
387889|NCT01135667|prasugrel
387890|NCT01135667|low responder
387891|NCT01135667|multiplate
387892|NCT01135667|verify now
387893|NCT01135654|alcohol dependence
387894|NCT01135654|unhealthy drinking
387895|NCT01135654|SBIRT
387896|NCT01135641|Adult patients (≥18 years)
387897|NCT01135641|first allogeneic stem cell transplantation
387898|NCT01135641|first episode of chronic GVHD requiring systemic immunosuppressive therapy
387899|NCT01135628|Hepatic cirrhosis
387900|NCT01135628|Minimal hepatic encephalopathy
387901|NCT01135628|Hyperproteic and fiber-rich diet
387902|NCT01135628|Lactobacillus reuteri
387903|NCT01135628|Psychometric Hepatic Encephalopathy Score (PHES)
387904|NCT01135628|Critical Flicker Frequency (CFF)
387905|NCT01135615|FGF-23, endothelial dysfunction, sevelamer
387906|NCT01135602|Alcohol dependence
387907|NCT01135602|Alcoholism
387908|NCT01135602|Topiramate
387909|NCT01135589|pediatric
387910|NCT01135589|adolescent
387911|NCT01135589|micafungin
387912|NCT01135576|Ferric pyrophosphate
387913|NCT01135576|Fortification
387914|NCT01135576|Fruit juice
387915|NCT01135576|Functional food
387916|NCT01135576|Bioavailability
387917|NCT01135576|iron status
387918|NCT01135576|Women
387919|NCT01135576|iron-deficiency anemia
387920|NCT01135563|pediatrics
387921|NCT01135563|Solid Tumors
387922|NCT01135563|CNS Tumors
387923|NCT01135563|Vinblastine
387924|NCT01135563|Sirolimus
387925|NCT01135563|Recurrent
387926|NCT01135563|Refractory
387927|NCT01135550|Pediatrics
387928|NCT01135550|Vomiting
387929|NCT01135550|Headache
387930|NCT01135550|Radiation Therapy
387931|NCT01135537|allogeneic hematopoietic stem cell transplantation
387932|NCT01135537|pharmacokinetics
387933|NCT01135537|pediatrics
387934|NCT01135524|Osteoarthritis
387935|NCT01135524|Opioid
387936|NCT01135524|Transdermal
387937|NCT01135511|Dry eye
387938|NCT01135472|NEXIUM
387939|NCT01135472|HEALTHY VOLUNTEERS
387940|NCT01135472|BLOOD DRAW
387941|NCT01135472|to measure gastrin levels in healthy volunteers while taking nexium
387942|NCT01135459|Lupus
387943|NCT01135433|ASP1941
387944|NCT01135433|Diabetes mellitus
387945|NCT01135433|Metformin
387946|NCT01135407|Parkinson's disease
387947|NCT01135407|Deep brain stimulation
387948|NCT01135407|Subthalamic nucleus
387949|NCT01135407|Levodopa
387950|NCT01135407|Selective visual attention
387951|NCT01135407|Basal ganglia diseases
387952|NCT01135394|Pioglitazone
387953|NCT01135394|Type 2 diabetes
387954|NCT01135394|Insulin sensitivity
387955|NCT01135394|Healthy adults
387956|NCT01135394|Thiazolidinediones
387957|NCT01135394|Pharmacogenetics
387958|NCT01135381|care transitions
387959|NCT01135381|information technology
387960|NCT01135368|GERD
387961|NCT01135368|Gastroesophageal Reflux Disease
387962|NCT01135368|Drug Therapy
387963|NCT01135329|Lymphoma
387964|NCT01135329|Hodgkin's lymphoma
387965|NCT01135329|Non hodgkin's lymphoma
387966|NCT01135329|Leukemia
387967|NCT01135329|Acute myeloid leukemia (AML)
387968|NCT01135329|Acute lymphoblastic leukemia(ALL)
387969|NCT01135329|Chronic myeloid leukemia (CML)
387970|NCT01135329|Chronic Myelomonocytic (CMML)
387971|NCT01135329|Myelodysplastic syndrome (MDS)
387972|NCT01135329|High-risk acute leukemia in first remission
387973|NCT01135329|Relapsed leukemia in remission
387974|NCT01135329|Cyclophosphamide
387975|NCT01135329|High-dose cyclophosphamide
387976|NCT01135329|Fludarabine
387977|NCT01135329|Busulfan
387978|NCT01135329|Allogeneic
387979|NCT01135329|Nonmyeloablative
387980|NCT01135329|Reduced intensity
387981|NCT01135329|Haploidentical
387982|NCT01135329|Bone marrow transplant (BMT)
387983|NCT01135316|NSF, Ablavar, Kidney Disease, Magnetic Resonance Imaging (MRI),
387984|NCT01135303|Sleep Apnea Syndromes
387985|NCT01135303|Polysomnography
387986|NCT01135303|Holter ECG
387987|NCT01135303|Thoracic impedance
387988|NCT01135303|Heart rate variability
387989|NCT01135290|The management of post-treatment symptoms for subjects that had either a medium grade chemical peel or fractional resurfacing
387990|NCT01135251|Neuropathic pain
387991|NCT01135251|AIDS
387992|NCT01135251|Dimiracetam
387993|NCT01135251|Treatment related painful neuropathy in AIDS patients
387994|NCT01135238|adrenalectomy
387995|NCT01135238|metastasis
387996|NCT01135238|morbidity
387997|NCT01135238|mortality
387998|NCT01135238|survival
387999|NCT01135225|Drug-eluting stent
388000|NCT01135225|Percutaneous coronary intervention
388001|NCT01135225|Stent implantation
388002|NCT01135225|Evolution Stent System
388003|NCT01135225|Biodegradable polymer coating
388004|NCT01135225|Feasibility study
388005|NCT01135212|Hypertension
388006|NCT01135212|ARB
388007|NCT01135212|Fimasartan
388008|NCT01135173|Smoking Cessation, Waterpipe
388009|NCT01135160|weight bearing
388010|NCT01135160|pain
388011|NCT01135160|total hip arthroplasty
388012|NCT01135160|total knee arthroplasty
388013|NCT01135160|weight bearing after TKA or THA
388014|NCT01135108|Analgesics. Non-narcotic / therapeutic use
388015|NCT01135108|Spinal Cord Injuries
388016|NCT01135108|Pain
388017|NCT01135108|Pain measurement / drug effect
388018|NCT01135108|Pain postoperative / drug therapy
388019|NCT01135095|Myocardial perfusion
388020|NCT01135095|Low radiation dose
388021|NCT01135095|Single photon emission computed tomography
388022|NCT01135082|immunogenicity
388023|NCT01135082|safety
388024|NCT01135082|Pneumococcal conjugate vaccine
388025|NCT01135082|HIV infected children
388026|NCT01135082|objective of this study is to assess the safety and immunogenicity of a 7 - valent PCV vaccine among HIV - infected compared with HIV - exposed children
388027|NCT01135056|Hepatocellular Carcinoma
388028|NCT01135056|Randomized
388029|NCT01135056|Open-label
388030|NCT01135056|Multi-Centre
388031|NCT01135056|Phase III
388032|NCT01135056|Sorafenib
388033|NCT01135056|SIR-Spheres
388034|NCT01135043|acceptable sputum
388035|NCT01135043|AFB culture
388036|NCT01135043|pulmonary tuberculosis
388037|NCT01135030|total knee arthroplasty
388038|NCT01135004|pneumothorax
388039|NCT01135004|thoracoscopy
388040|NCT01135004|pathogenesis
388041|NCT01135004|blebs
388042|NCT01135004|surgery
388043|NCT01134991|rosacea
388044|NCT01134991|topical
388045|NCT01134991|minocycline
388046|NCT01134991|foam
388047|NCT01134991|phase II
388048|NCT01134978|repeated measures design
388049|NCT01134978|random assignment to groups
388050|NCT01134952|sirolimus
388051|NCT01134952|everolimus
388052|NCT01134952|mycophenolic acid
388053|NCT01134952|hepatitis C virus
388054|NCT01134952|tacrolimus
388055|NCT01134952|viral load
388056|NCT01134926|Retained products of conception
388057|NCT01134926|residua
388058|NCT01134926|misoprostol
388059|NCT01134926|expectant management
388060|NCT01134913|ACS
388061|NCT01134913|Acute Coronary Syndrome
388062|NCT01134913|Emergency Department
388063|NCT01134900|Medication Errors
388064|NCT01134900|Adverse Drug Events
388065|NCT01134900|Decision Support Systems, Clinical
388066|NCT01134887|hypertension
388067|NCT01134887|physician-patient relations
388068|NCT01134887|communication
388069|NCT01134861|stage II non-small cell lung cancer
388070|NCT01134861|stage IIIA non-small cell lung cancer
388071|NCT01134861|stage IIIB non-small cell lung cancer
388072|NCT01134848|Bile ducts
388073|NCT01134848|Sphincter of Oddi
388074|NCT01134848|Pancreatic ducts
388075|NCT01134822|Idiopathic Pulmonary Fibrosis
388076|NCT01134822|IPF
388077|NCT01134822|Lung Fibrosis
388078|NCT01134822|Biomarkers
388079|NCT01134809|Major abdominal surgery
388080|NCT01134770|Prenatal Substance Use
388081|NCT01134770|Cocaine
388082|NCT01134770|Cigarette Smoking
388083|NCT01134770|Mothers
388084|NCT01134770|Pregnant women
388085|NCT01134770|Smoking Mothers
388086|NCT01134757|EAR
388087|NCT01134757|LAR
388088|NCT01134757|BHR
388089|NCT01134757|house dust mite
388090|NCT01134757|alternaria
388091|NCT01134744|CXray
388092|NCT01134731|depression
388093|NCT01134731|suicidality
388094|NCT01134731|Major Depressive Disorder, current episode, with suicidality
388095|NCT01134718|TMC435-TiDP16-C119
388096|NCT01134718|TMC435-C119
388097|NCT01134718|TMC435
388098|NCT01134718|Protease inhibitor
388099|NCT01134718|HCV
388100|NCT01134718|Hepatitis C
388101|NCT01134718|Bioavailability
388223|NCT01134146|Radical Pleurectomy
388102|NCT01134692|Patients with cirrhosis who have large esophageal varices with No history of upper GI bleeding in the past
388103|NCT01134679|Drug Eluting Stent
388104|NCT01134679|Clopidogrel
388105|NCT01134679|Aspirin
388106|NCT01134666|Colorectal neoplasms
388107|NCT01134666|Intestinal neoplasms
388108|NCT01134666|Neoplasms
388109|NCT01134666|cetuximab
388110|NCT01134666|Erbitux
388111|NCT01134653|Acute ankle sprain in children and young adults
388112|NCT01134640|metastatic colorectal cancer
388113|NCT01134640|mCRC
388114|NCT01134640|post marketing surveillance
388115|NCT01134640|Erbitux
388116|NCT01134640|Cetuximab
388117|NCT01134640|KRAS
388118|NCT01134627|Multiple Sclerosis, Relapsing-Remitting
388119|NCT01134627|Interferon-β
388120|NCT01134627|Rebif®
388121|NCT01134627|Minocycline
388122|NCT01134601|Rectal Cancer
388123|NCT01134601|Radiation Therapy
388124|NCT01134601|Capecitabine
388125|NCT01134601|AZD6244
388126|NCT01134575|Relapsed
388127|NCT01134575|Refractory
388128|NCT01134575|Acute Lymphoblastic Leukemia
388129|NCT01134575|ALL
388130|NCT01134575|Burkitt's lymphoma
388131|NCT01134575|Lymphoblastic lymphoma
388132|NCT01134575|CMC-544
388133|NCT01134575|Inotuzumab Ozogamycin
388134|NCT01134575|Rituxan
388135|NCT01134575|Rituximab
388136|NCT01134562|Clinical Trial, Phase 1
388137|NCT01134562|Renal Dialysis
388138|NCT01134562|Secondary Hyperparathyroidism
388139|NCT01134562|Parathyroid hormone
388140|NCT01134549|Phase 1 Clinical Trials
388141|NCT01134536|Pain, Postoperative
388142|NCT01134536|Postoperative Pain
388143|NCT01134536|Tapentadol
388144|NCT01134536|NUCYNTA
388145|NCT01134536|CG5503
388146|NCT01134536|R331333
388147|NCT01134536|Pharmacokinetics
388148|NCT01134536|Postsurgical pain
388149|NCT01134536|Children
388150|NCT01134536|Adolescents
388151|NCT01134523|positive lymph node
388152|NCT01134510|Kidney transplantation
388153|NCT01134484|autologous stem cell transplantation
388154|NCT01134484|complete remission
388155|NCT01134484|bortezomib
388156|NCT01134484|thalidomide
388157|NCT01134484|progression free survival
388158|NCT01134484|induction and consolidation therapy
388159|NCT01134458|cardiovascular disease
388160|NCT01134445|Arthroplasty
388161|NCT01134445|Replacement
388162|NCT01134445|Hip
388163|NCT01134445|Conservative
388164|NCT01134445|Anatomic
388165|NCT01134445|Cementless
388166|NCT01134432|autoimmune hemolytic anemia
388167|NCT01134432|hemolytic anemia
388168|NCT01134432|Rituximab
388169|NCT01134432|Treatment of autoimmune hemolytic anemia
388170|NCT01134432|warm antibody dependant autoimmune hemolytic anemia
388171|NCT01134419|Patient Safety
388172|NCT01134419|Medical Errors
388173|NCT01134419|Handoff
388174|NCT01134419|Sign-out
388175|NCT01134419|Resident
388176|NCT01134419|Intern
388177|NCT01134419|Graduate Medical Education
388178|NCT01134406|Osteoarthritis
388179|NCT01134406|knee
388180|NCT01134380|Percutaneous coronary intervention
388181|NCT01134380|Acute coronary syndrome
388182|NCT01134380|Dual antiplatelet therapy
388183|NCT01134380|clopidogrel/prasugrel
388184|NCT01134380|genotyping
388185|NCT01134380|stent
388186|NCT01134380|compliance
388187|NCT01134367|gastroesophageal reflux disease (GERD)
388188|NCT01134354|Validation study
388189|NCT01134354|Outcome Measures
388190|NCT01134354|Patient Outcomes Assessment
388191|NCT01134354|Patient expectations
388192|NCT01134354|Physician patient relationship
388193|NCT01134341|Relapsed
388194|NCT01134341|Refractory
388195|NCT01134315|Evaluating incidence of hypercalcemia in pediatric patients
388196|NCT01134302|Hybrid
388197|NCT01134302|Norwood
388198|NCT01134302|congenital heart disease
388199|NCT01134302|single ventricle
388200|NCT01134289|complex regional pain syndrome
388201|NCT01134289|lumbar sympathetic blockade
388202|NCT01134289|photoplethysmography
388203|NCT01134289|diagnostic lumbar sympathetic blockade
388204|NCT01134263|Dengue Fever
388205|NCT01134263|Dengue Hemorrhagic Fever
388206|NCT01134263|CYD Dengue Vaccine
388207|NCT01134263|Lot Consistency
388208|NCT01134250|Interleukin, IL2, F16, monoclonal, antibody, cytokine Paclitaxel, breast cancer,solid tumour
388209|NCT01134250|metastatic melanoma, non-small cell lung cancer (NSCLC)
388210|NCT01134237|non-surgical rate
388211|NCT01134198|Cocaine Dependence
388212|NCT01134185|Two groups of 8 hepatically impaired subjects, one group of 8 matched healthy subjects
388213|NCT01134172|Sociodemographic
388214|NCT01134172|Ethnicity
388215|NCT01134172|Work-related
388216|NCT01134172|Health system
388217|NCT01134172|QOL
388218|NCT01134172|Questionnaires
388219|NCT01134172|10-071
388220|NCT01134146|Intensity Modulated Radiotherapy
388221|NCT01134146|IMRT
388222|NCT01134146|Malignant Pleural Mesothelioma
388224|NCT01134146|Decortication
388225|NCT01134146|PD
388226|NCT01134146|pleurectomy
388227|NCT01134146|lung surgery
388228|NCT01134146|pleura
388229|NCT01134094|Undisplaced
388230|NCT01134094|Ankle Fracture
388231|NCT01134094|Weber B
388232|NCT01134081|gum
388233|NCT01134081|recession
388234|NCT01134068|D-dimer
388235|NCT01134068|Pulmonary embolism
388236|NCT01134068|Diagnostic strategy
388237|NCT01134068|Safety of ruling PE with and age-adjusted DD cut-off
388238|NCT01134055|ranibizumab
388239|NCT01134055|wet AMD
388240|NCT01134055|MD7110852
388241|NCT01134055|age related macular degeneration
388242|NCT01134055|age-related macular degeneration
388243|NCT01134055|macular degeneration
388244|NCT01134055|pazopanib
388245|NCT01134042|Fluticasone propionate
388246|NCT01134042|asthma
388247|NCT01134042|vilanterol
388248|NCT01134042|GW642444
388249|NCT01134042|Fluticasone furoate
388250|NCT01134029|obesity
388251|NCT01134029|weight management and cardiovascular risk factors
388252|NCT01134016|Lung cancer
388253|NCT01134016|NSCLC
388254|NCT01133028|Attention Deficit Hyperactivity Disorder (ADHD)
388255|NCT01133015|FFR
388256|NCT01133015|IVUS
388257|NCT01133015|MLA
388258|NCT01132989|Patients with cutaneous T cell lymphoma
388259|NCT01132976|Personality disorders
388260|NCT01132976|Personal Concerns Inventory
388261|NCT01132976|Non completion
388262|NCT01132937|Diffusion/Perfusion-MRI
388263|NCT01132937|Magnetic Resonance Imaging (MRI)
388264|NCT01132937|Traumatic Brain Injury
388265|NCT01132937|Brain Imaging
388266|NCT01132937|Brain Injuries
388267|NCT01132937|TBI
388268|NCT01132924|Early Pregnancy
388269|NCT01132924|Gestational Age
388270|NCT01132924|Fecundability
388271|NCT01132924|Ovulation
388272|NCT01132924|Recall
388273|NCT01132911|Solid Tumors
388274|NCT01132911|Maximum Tolerated Dose
388275|NCT01132911|Lymphoma
388276|NCT01132911|Dose Escalation
388277|NCT01132911|Pharmacokinetics
388278|NCT01132911|Pediatric Cancer
388279|NCT01132911|Solid Tumor
388280|NCT01132911|Sarcoma
388281|NCT01132911|Wilms Tumor
388282|NCT01132911|Neuroblastoma
388283|NCT01132898|Traumatic Brain Injury
388284|NCT01132898|Biomarkers
388285|NCT01132898|Magnetic Resonance Imaging (MRI)
388286|NCT01132898|DTI
388287|NCT01132898|Functional Capacity
388288|NCT01132898|TBI
388289|NCT01132885|MRI
388290|NCT01132885|Children
388291|NCT01132885|Williams Syndrome
388292|NCT01132885|Phenotype
388293|NCT01132885|Brain
388294|NCT01132885|Healthy Volunteer
388295|NCT01132885|HV
388296|NCT01132872|Serotonin 1A Receptor
388297|NCT01132872|Positron Emission Tomograhy (PET)
388298|NCT01132872|Dosimetry
388299|NCT01132872|Healthy Volunteer
388300|NCT01132872|HV
388301|NCT01132859|Specimen Collection
388302|NCT01132859|Mucosal Immunity
388303|NCT01132859|Immune Responses
388304|NCT01132859|Immunity
388305|NCT01132859|Vaccines
388306|NCT01132859|Healthy Volunteer
388307|NCT01132859|HV
388308|NCT01132833|thromboembolism
388309|NCT01132833|stage I multiple myeloma
388310|NCT01132833|stage II multiple myeloma
388311|NCT01132833|stage III multiple myeloma
388312|NCT01132807|stage I adult Hodgkin lymphoma
388313|NCT01132807|stage II adult Hodgkin lymphoma
388314|NCT01132794|Pain relief and sedation condition
388315|NCT01132781|rhinosinusitis
388316|NCT01132781|asthma
388317|NCT01132781|allergic rhinitis
388318|NCT01132781|theophylline
388319|NCT01132755|gastric
388320|NCT01132755|pancreas
388321|NCT01132755|laparoscopy
388322|NCT01132755|peritoneal lavage
388323|NCT01132755|10-011
388324|NCT01132755|gastric and pancreatic cancer
388325|NCT01134003|Gynecare Prolift
388326|NCT01134003|Pelvic organ prolapse
388327|NCT01134003|forming a large database of women who have recieve Gynecare prolift system
388328|NCT01133964|Dairy proteins
388329|NCT01133964|Appetite regulation
388330|NCT01133964|Energy expenditure
388331|NCT01133951|Helicobacter Infections
388332|NCT01133951|Helicobacter pylori
388333|NCT01133951|Drug Therapy
388334|NCT01133951|Precancerous Conditions
388335|NCT01133951|Stomach Neoplasms
388336|NCT01133951|Incidence
388337|NCT01133925|Coronary Artery Disease
388338|NCT01133925|Percutaneous Coronary Intervention
388339|NCT01133925|Drug Eluting Stent
388340|NCT01133925|Optical Coherence Tomography
388341|NCT01133925|Thrombosi
388342|NCT01133925|Long lesions in native vessels requiring overlap
388343|NCT01133912|Patients with HER2 Positive Operable Breast Cancer
388344|NCT01133899|strength, anaerobic performance, recovery, ergogenic
388345|NCT01133860|inherited thrombocytopenia
388346|NCT01133860|MYH9 mutations
388347|NCT01133860|eltrombopag
388348|NCT01133834|meningococcal disease
388349|NCT01133834|cytokines
388350|NCT01133821|Bipolar II Disorder
388351|NCT01133821|Bipolar II Depression
388352|NCT01133821|Psychotherapy
388353|NCT01133821|IPSRT
388354|NCT01133821|Seroquel
388355|NCT01133821|Quetiapine
388356|NCT01133821|Placebo
388357|NCT01133821|Sugar Pill
388358|NCT01133808|diarrhea
388359|NCT01133808|childhood
388360|NCT01133808|rotavirus
388361|NCT01133808|vaccine
388362|NCT01133808|Nicaragua
388363|NCT01133795|cirrhosis
388364|NCT01133795|renal failure
388365|NCT01133795|hepatorenal syndrome
388366|NCT01133795|albumine
388367|NCT01133795|midodrine
388368|NCT01133769|Clavicle fracture
388369|NCT01133769|fixation
388370|NCT01133769|polytrauma
388371|NCT01133769|Clavicle fracture patients with chest injury
388372|NCT01133743|Lenalidomide
388373|NCT01133743|Dexamethasone
388374|NCT01133743|Immunomodulatory Drugs(IMiD™)
388375|NCT01133743|Thalidomide analogues
388376|NCT01133730|supraclavicular nerve block
388377|NCT01133730|regional anesthesia
388378|NCT01133730|transversalis fascia plane block
388379|NCT01133730|ultrasound guided
388380|NCT01133730|opioid consumption
388381|NCT01133730|iliac crest bone harvest
388382|NCT01133730|hand surgery
388383|NCT01133730|wrist surgery
388384|NCT01133730|Upper limb surgery combined with iliac crest bone harvest.
388385|NCT01133717|Sleep Apnea
388386|NCT01133717|Cerebrovascular Reactivity
388387|NCT01133704|asymptomatic metastatic hormone-refractory prostate cancer
388388|NCT01133691|gastric emptying
388389|NCT01133691|children
388390|NCT01133691|gastric fluid volume
388391|NCT01133691|preoperative fasting
388392|NCT01133678|Squamous Cell Carcinoma
388393|NCT01133665|Head and Neck, Squamous Cell
388394|NCT01133665|Recurrent or metastatic squamous cell or undifferentiated carcinoma of the head and neck that is not amenable to curative therapy
388395|NCT01133652|Venipuncture
388396|NCT01133652|Randomized Controlled Trial
388397|NCT01133652|Intravenous access
388398|NCT01133652|Children
388399|NCT01133652|Pediatric Emergency Department
388400|NCT01133652|Peripheral intravenous catheterization
388401|NCT01133652|Catheterization, Peripheral Phlebotomy
388402|NCT01133587|Schizophrenia
388403|NCT01133587|bipolar disorder
388404|NCT01133587|Long term care
388405|NCT01133587|patient admission
388406|NCT01133574|Healthy volunteers
388407|NCT01133574|SLV354
388408|NCT01133574|Phase I
388409|NCT01133574|SRDT
388410|NCT01133561|psoriasis
388411|NCT01133561|insulin resistance
388412|NCT01133561|metabolic syndrome
388413|NCT01133561|pioglitazone
388414|NCT01133561|randomized control trial
388415|NCT01133548|testosterone, hypogonadal, males
388416|NCT01133522|AMG145
388417|NCT01133522|Multiple Dose
388418|NCT01133522|Statin
388419|NCT01133522|Ascending
388420|NCT01133496|Bioequivalence
388421|NCT01133496|Alendronate Sodium
388422|NCT01133496|crossover
388423|NCT01133483|Bioequivalence
388424|NCT01133483|Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride
388425|NCT01133470|Bioequivalence
388426|NCT01133470|Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride
388427|NCT01133457|Bioequivalence,Finasteride,Crossover
388428|NCT01133444|Bioequivalence,Finasteride,Crossover
388429|NCT01133431|CKD-501
388430|NCT01133431|Glimepiride
388431|NCT01133431|Placebo
388432|NCT01133431|Healthy male volunteer
388433|NCT01133431|Pharmacokinetic
388434|NCT01133431|Metabolite
388435|NCT01133392|insulin
388436|NCT01133392|lispro
388437|NCT01133366|ISIS301012
388438|NCT01133366|antisense
388439|NCT01133366|ApoB (Apolipoprotein B)
388440|NCT01133366|LDL (low density lipoprotein)
388441|NCT01133366|mipomersen
388442|NCT01133340|RADIOTHERAPY
388443|NCT01133340|CT simulation
388444|NCT01133340|MRI simulation
388445|NCT01133340|Endoscopic clip placement
388446|NCT01133340|Rectal cancer
388447|NCT01133340|Accuracy of MRI Simulation for target delineation and planning
388448|NCT01133327|Carotid Artery Stenting
388449|NCT01133327|High Risk patient
388450|NCT01133327|Carotid artery stenosis
388451|NCT01133327|stroke
388452|NCT01133327|Carotid artery disease
388453|NCT01133327|ASTI study
388454|NCT01133327|Adapt Carotid Stent system
388455|NCT01133327|FilterWire EZ Embolic Protection System
388456|NCT01133301|Borderline Personality Disorder
388457|NCT01133301|Dissociation
388458|NCT01133301|Naltrexone
388459|NCT01133249|total hip
388460|NCT01133236|Salt restriction
388461|NCT01133236|Fluid restriction
388462|NCT01133236|Congestion
388463|NCT01133236|Heart Failure
388464|NCT01133223|Stroke, mecanical thrombectomy
388465|NCT01133210|hypertriglyceridemia
388466|NCT01133210|triglyceride
388467|NCT01133210|cholesterol
388468|NCT01133210|Maraviroc
388469|NCT01133197|thumb
388470|NCT01133197|arthritis
388471|NCT01133197|Impact of thumb arthritis on health
388472|NCT01133184|HBV transmission PreS1/PreS2/S HBV vaccine
388473|NCT01133171|Cardiovascular Disease
388474|NCT01133171|Stroke
388475|NCT01133158|Follicular non-Hodgkin's lymphoma in relapse or refractory to standard first-line immunochemotherapy
388476|NCT01133145|composite tissue allotransplantation
388477|NCT01133145|hand transplantation
388478|NCT01133145|knee transplantation
388479|NCT01133145|face transplantation
388480|NCT01133132|Colon cancer patients who have completed treatment
388481|NCT01133119|cardiac catheterization
388482|NCT01133119|local anesthetic
388483|NCT01133119|pain experienced post-operatively
388484|NCT01133119|pediatric patients
388485|NCT01133106|stroke recovery
388486|NCT01133106|quality of life
388487|NCT01133093|Cardiovascular risk factors
388488|NCT01133093|Nutritional assessment
388489|NCT01133093|Epidemiology
388490|NCT01133067|lung cancer
388491|NCT01133067|followup
388492|NCT01133067|physical follow up
388493|NCT01133067|telephonic followup
388494|NCT01133054|Coronary Vessel Anomalies
388495|NCT01132742|Malnutrition
388496|NCT01132742|children
388497|NCT01132742|Hospital Stay
388498|NCT01132742|Screening Tools
388499|NCT01132742|Anthropometry
388500|NCT01132690|gaucher disease
388501|NCT01132690|pediatric
388502|NCT01132677|OA of Knee
388503|NCT01132677|Osteoarthritis of Knee
388504|NCT01132677|Viscosupplementation and Osteoarthritis
388505|NCT01132677|Viscosupplementation and OA
388506|NCT01132677|Hyaluronic Acid
388507|NCT01132677|Corticosteroid injection versus hyaluronic acid
388508|NCT01132677|Synvisc One and Knee OA
388509|NCT01132677|viscosupplementation and knee pain
388510|NCT01132677|knee Pain from OA
388511|NCT01132664|HER2
388512|NCT01132664|BKM120
388513|NCT01132664|PIK3
388514|NCT01132664|metastatic breast cancer
388515|NCT01132664|brain metastases
388516|NCT01132664|Herceptin
388517|NCT01132664|trastuzumab
388518|NCT01132664|capecitabine
388519|NCT01132664|open-label
388520|NCT01132664|maximum tolerated dose
388521|NCT01132664|Phase I/Phase ll
388522|NCT01132651|eczema
388523|NCT01132651|itch
388524|NCT01132651|pruritus
388525|NCT01132651|head
388526|NCT01132651|neck
388527|NCT01132638|Gastroesophageal
388528|NCT01132638|Pantoprazole
388529|NCT01132638|erosive
388530|NCT01132638|Erosive GERD grades A-D, acc. to Los Angeles classification
388531|NCT01132625|HSP90
388532|NCT01132625|molecular chaperone
388533|NCT01132625|advanced solid tumors
388534|NCT01132625|Japan
388535|NCT01132612|Chronic plaque-type psoriasis
388536|NCT01132612|AIN457
388537|NCT01132612|dermatology
388538|NCT01132612|Moderate to severe chronic plaque-type psoriasis
388539|NCT01132599|stage IV prostate cancer
388540|NCT01132560|ductal breast carcinoma in situ
388541|NCT01132547|cachexia
388542|NCT01132547|weight changes
388543|NCT01132547|nausea and vomiting
388544|NCT01132547|alveolar childhood rhabdomyosarcoma
388545|NCT01132547|anaplastic osteosarcoma
388546|NCT01132547|childhood alveolar soft-part sarcoma
388547|NCT01132547|childhood angiosarcoma
388548|NCT01132547|childhood epithelioid sarcoma
388549|NCT01132547|childhood fibrosarcoma
388550|NCT01132547|childhood gliosarcoma
388551|NCT01132547|childhood leiomyosarcoma
388552|NCT01132547|childhood liposarcoma
388553|NCT01132547|childhood neurofibrosarcoma
388554|NCT01132547|childhood synovial sarcoma
388555|NCT01132547|chondrosarcoma
388556|NCT01132547|chondrosarcomatous osteosarcoma
388557|NCT01132547|clear cell sarcoma of the kidney
388558|NCT01132547|embryonal childhood rhabdomyosarcoma
388559|NCT01132547|embryonal-botryoid childhood rhabdomyosarcoma
388560|NCT01132547|endometrial stromal sarcoma
388561|NCT01132547|extraosseous Ewing sarcoma
388562|NCT01132547|peripheral primitive neuroectodermal tumor
388563|NCT01132547|fibrosarcomatous osteosarcoma
388564|NCT01132547|localized Ewing sarcoma
388565|NCT01132547|localized osteosarcoma
388566|NCT01132547|mast cell sarcoma
388567|NCT01132547|metastatic childhood soft tissue sarcoma
388568|NCT01132547|metastatic Ewing sarcoma
388569|NCT01132547|metastatic osteosarcoma
388570|NCT01132547|mixed childhood rhabdomyosarcoma
388571|NCT01132547|mixed osteosarcoma
388572|NCT01132547|nonmetastatic childhood soft tissue sarcoma
388573|NCT01132547|osteoblastic osteosarcoma
388574|NCT01132547|ovarian carcinosarcoma
388575|NCT01132547|ovarian sarcoma
388576|NCT01132547|pleomorphic childhood rhabdomyosarcoma
388577|NCT01132547|previously treated childhood rhabdomyosarcoma
388578|NCT01132547|previously untreated childhood rhabdomyosarcoma
388579|NCT01132547|recurrent adult soft tissue sarcoma
388580|NCT01132547|recurrent childhood gliosarcoma
388581|NCT01132547|recurrent childhood rhabdomyosarcoma
388582|NCT01132547|recurrent childhood soft tissue sarcoma
388583|NCT01132547|recurrent Ewing sarcoma
388584|NCT01132547|recurrent osteosarcoma
388585|NCT01132547|recurrent uterine sarcoma
388586|NCT01132547|small intestine leiomyosarcoma
388587|NCT01132547|stage I uterine sarcoma
388588|NCT01132547|stage II uterine sarcoma
388589|NCT01132547|stage III uterine sarcoma
388590|NCT01132547|stage IV uterine sarcoma
388591|NCT01132547|telangiectatic osteosarcoma
388592|NCT01132547|untreated childhood gliosarcoma
388593|NCT01132547|uterine carcinosarcoma
388594|NCT01132547|uterine leiomyosarcoma
388595|NCT01132547|localized resectable neuroblastoma
388596|NCT01132547|localized unresectable neuroblastoma
388597|NCT01132547|recurrent neuroblastoma
388598|NCT01132547|regional neuroblastoma
388599|NCT01132547|stage 4S neuroblastoma
388600|NCT01132547|recurrent Wilms tumor
388601|NCT01132547|childhood kidney tumors
388602|NCT01132547|stage III Wilms tumor
388603|NCT01132547|stage IV Wilms tumor
388604|NCT01132547|childhood hepatoblastoma
388605|NCT01132547|childhood extracranial germ cell tumor
388606|NCT01132547|childhood extragonadal germ cell tumor
388607|NCT01132547|childhood gonadal germ cell tumor
388608|NCT01132547|childhood malignant ovarian germ cell tumor
388609|NCT01132547|childhood malignant testicular germ cell tumor
388610|NCT01132547|recurrent childhood malignant germ cell tumor
388611|NCT01132547|recurrent extragonadal germ cell tumor
388612|NCT01132547|recurrent extragonadal non-seminomatous germ cell tumor
388613|NCT01132547|recurrent malignant testicular germ cell tumor
388614|NCT01132547|recurrent ovarian germ cell tumor
388615|NCT01132547|stage III extragonadal non-seminomatous germ cell tumor
388616|NCT01132547|stage III malignant testicular germ cell tumor
388617|NCT01132547|stage IIIA ovarian germ cell tumor
388618|NCT01132547|stage IIIB ovarian germ cell tumor
388619|NCT01132547|stage IIIC ovarian germ cell tumor
388620|NCT01132547|stage IV extragonadal non-seminomatous germ cell tumor
388621|NCT01132547|stage IV ovarian germ cell tumor
388622|NCT01132547|recurrent childhood medulloblastoma
388623|NCT01132547|untreated childhood medulloblastoma
388624|NCT01132547|childhood ependymoblastoma
388625|NCT01132547|childhood infratentorial ependymoma
388626|NCT01132547|newly diagnosed childhood ependymoma
388627|NCT01132547|recurrent childhood ependymoma
388628|NCT01132547|recurrent childhood subependymal giant cell astrocytoma
388629|NCT01132547|untreated childhood subependymal giant cell astrocytoma
388630|NCT01132547|peripheral primitive neuroectodermal tumor of the kidney
388631|NCT01132547|childhood supratentorial primitive neuroectodermal tumor
388632|NCT01132547|recurrent childhood brain stem glioma
388633|NCT01132547|recurrent childhood brain tumor
388634|NCT01132547|untreated childhood brain stem glioma
388635|NCT01132547|recurrent childhood anaplastic astrocytoma
388636|NCT01132547|recurrent childhood anaplastic oligoastrocytoma
388637|NCT01132547|recurrent childhood anaplastic oligodendroglioma
388638|NCT01132547|stage I childhood anaplastic large cell lymphoma
388639|NCT01132547|stage II childhood anaplastic large cell lymphoma
388640|NCT01132547|stage III childhood anaplastic large cell lymphoma
388641|NCT01132547|stage IV childhood anaplastic large cell lymphoma
388642|NCT01132547|untreated childhood anaplastic astrocytoma
388643|NCT01132547|untreated childhood anaplastic oligoastrocytoma
388644|NCT01132547|untreated childhood anaplastic oligodendroglioma
388645|NCT01132547|childhood high-grade cerebellar astrocytoma
388646|NCT01132547|childhood low-grade cerebellar astrocytoma
388647|NCT01132547|recurrent childhood astrocytoma
388648|NCT01132547|other tumor of glial origin
388649|NCT01132547|recurrent childhood cerebellar astrocytoma
388650|NCT01132547|recurrent childhood cerebral astrocytoma
388651|NCT01132547|recurrent childhood diffuse astrocytoma
388652|NCT01132547|recurrent childhood fibrillary astrocytoma
388653|NCT01132547|recurrent childhood gemistocytic astrocytoma
388654|NCT01132547|recurrent childhood oligoastrocytoma
388655|NCT01132547|recurrent childhood pilocytic astrocytoma
388656|NCT01132547|recurrent childhood pilomyxoid astrocytoma
388657|NCT01132547|recurrent childhood pleomorphic xanthoastrocytoma
388658|NCT01132547|recurrent childhood protoplasmic astrocytoma
388659|NCT01132547|untreated childhood cerebellar astrocytoma
388660|NCT01132547|untreated childhood cerebral astrocytoma
388661|NCT01132547|untreated childhood diffuse astrocytoma
388662|NCT01132547|untreated childhood fibrillary astrocytoma
388663|NCT01132547|untreated childhood gemistocytic astrocytoma
388664|NCT01132547|untreated childhood oligoastrocytoma
388665|NCT01132547|untreated childhood pilocytic astrocytoma
388666|NCT01132547|untreated childhood pilomyxoid astrocytoma
388667|NCT01132547|untreated childhood pleomorphic xanthoastrocytoma
388668|NCT01132547|untreated childhood protoplasmic astrocytoma
388669|NCT01132547|recurrent childhood gliomatosis cerebri
388670|NCT01132547|recurrent childhood oligodendroglioma
388671|NCT01132547|recurrent childhood visual pathway
388672|NCT01132547|hypothalamic glioma
388673|NCT01132547|recurrent childhood visual pathway glioma
388674|NCT01132547|untreated childhood gliomatosis cerebri
388675|NCT01132547|untreated childhood oligodendroglioma
388676|NCT01132547|untreated childhood visual pathway
388677|NCT01132547|untreated childhood visual pathway glioma
388678|NCT01132547|recurrent childhood giant cell glioblastoma
388679|NCT01132547|recurrent childhood glioblastoma
388680|NCT01132547|untreated childhood giant cell glioblastoma
388681|NCT01132547|untreated childhood glioblastoma
388682|NCT01132547|childhood choroid plexus tumor
388683|NCT01132547|childhood grade I meningioma
388684|NCT01132547|childhood grade II meningioma
388685|NCT01132547|childhood grade III meningioma
388686|NCT01132547|minimally differentiated myeloid leukemia (M0)
388687|NCT01132547|myeloblastic leukemia with maturation (M2)
388688|NCT01132547|myeloblastic leukemia without maturation (M1)
388689|NCT01132547|childhood acute myelomonocytic leukemia (M4)
388690|NCT01132547|childhood acute promyelocytic leukemia (M3)
388691|NCT01132547|recurrent childhood acute myeloid leukemia
388692|NCT01132547|untreated childhood acute myeloid leukemia
388693|NCT01132547|other myeloid malignancies
388694|NCT01132547|childhood acute monoblastic leukemia (M5a)
388695|NCT01132547|childhood acute monocytic leukemia (M5b)
388696|NCT01132547|childhood acute erythroleukemia (M6)
388697|NCT01132547|childhood acute megakaryocytic leukemia (M7)
388698|NCT01132547|unspecified childhood solid tumor
388699|NCT01132534|OGD
388700|NCT01132534|NBI
388701|NCT01132534|AFI
388702|NCT01132534|Videoendoscopy
388703|NCT01132534|Narrow Band Imaging
388704|NCT01132534|Autofluorescence Imaging
388705|NCT01132521|ulinastatin
388706|NCT01132521|severe acute pancreatitis
388707|NCT01132508|Tibial plateau fracture
388708|NCT01132508|Orthopaedic Trauma Association (OTA) B2 B3 C3
388709|NCT01132508|Bone Void
388710|NCT01132495|Stable angina
388711|NCT01132495|angina pectoris
388712|NCT01132495|PCI
388713|NCT01132495|FAME
388714|NCT01132495|FAME II
388715|NCT01132495|FFR
388716|NCT01132495|Fractional Flow Reserve
388717|NCT01132495|Pressure wire
388718|NCT01132482|Cystic fibrosis
388719|NCT01132482|CFTR
388720|NCT01132482|Phosphodiesterase inhibitor
388721|NCT01132482|Nasal potential difference
388722|NCT01132482|Sweat test
388723|NCT01132456|TARGET VESSEL REVASCULARIZATION (TVR)
388724|NCT01132456|MYOCARDIAL INFARCTION (MI)
388725|NCT01132456|TARGET VESSEL FAILURE (TVF)
388726|NCT01132456|TARGET LESION REVASCULARIZATION (TLR)
388727|NCT01132456|TARGET LESION FAILURE (TLF)
388728|NCT01132456|STENT THROMBOSIS
388729|NCT01132456|RESTENOTIC LESION
388730|NCT01132456|PERCUTANEOUS CORONARY INTERVENTION (PCI)
388731|NCT01132456|LONG LESION
388732|NCT01132456|DUAL VESSEL
388733|NCT01132430|ADHERENCE
388734|NCT01132430|ASTHMA CONTROL
388735|NCT01132430|ASTHMA QUALITY OF LIFE
388736|NCT01132430|MOTIVATIONAL INTERVIEWING
388737|NCT01132417|Tigecycline, MDR
388738|NCT01132417|Patient infected with multidrug resistance bacteria
388739|NCT01132391|anal fissure
388740|NCT01132391|nitroglycerin
388741|NCT01132391|medical treatment
388742|NCT01132378|Total knee arthroplasty
388743|NCT01132365|knee arthroplasty
388744|NCT01132352|Bioavailability
388745|NCT01132352|Crossover
388746|NCT01132352|Levetiracetam
388747|NCT01132339|Adverse reactions to Gadolinium-based contrast agents.
388748|NCT01132339|Adverse reactions to Iodine-basedcontrast agents.
388749|NCT01132326|Symptomatic NOH
388750|NCT01132287|Contact lens wear
388751|NCT01132287|lubricant eye drops
388752|NCT01132274|Supraventricular arrhythmia catheter ablation
388753|NCT01132248|schistosomiasis, schistosoma haematobium
388754|NCT01132222|Bioequivalence
388755|NCT01132222|Crossover
388756|NCT01132222|Ibuprofen and Pseudoephedrine
388757|NCT01132209|surgery
388758|NCT01132209|incisional hernia
388759|NCT01132209|woundinfection
388760|NCT01132209|burst abdomen
388761|NCT01132209|pain
388762|NCT01132196|Bioequivalence
388763|NCT01132196|Crossover
388764|NCT01132196|Divalproex Sodium
388765|NCT01132170|Bioequivalence
388766|NCT01132170|Crossover
388767|NCT01132170|Divalproex Sodium
388768|NCT01132157|Healthy Kidney Donors and Their Recipients with End Stage Renal Disease
388769|NCT01132144|Reproductive Techniques
388770|NCT01132144|Embryo Implantation
388771|NCT01132144|Endometrium
388772|NCT01132144|Ultrasonography
388773|NCT01132131|Urinary tract infection
388774|NCT01132131|Cystitis
388775|NCT01132131|Bacteruria
388776|NCT01132118|rheumatoid arthritis
388777|NCT01132118|insulin resistance
388778|NCT01132118|hydroxychloroquine
388779|NCT01132118|cholesterol
388780|NCT01132092|Evoked Potentials, Adult, Hearing Loss
388781|NCT01132079|atopic dermatitis
388782|NCT01132079|barrier function
388783|NCT01132079|pimecrolimus
388784|NCT01132066|swallowing
388785|NCT01132066|stroke
388786|NCT01132053|JCV
388787|NCT01132040|Bioequivalence
388788|NCT01132040|Crossover
388789|NCT01132040|Primidone
388790|NCT01132027|Bioavailability, crossover, tacrolimus
388791|NCT01132014|Subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer,
388792|NCT01132014|from whom solid tumor or ascites have been harvested and are available and
388793|NCT01132014|sufficient for tumorlysate preparation;and whose largest tumor nodule is 4.5
388794|NCT01132014|cm. Subjects may have undergone chemotherapy or other therapy following
388795|NCT01132014|tumor harvesting and prior to enrollment.
388796|NCT01131988|Bioavailability, crossover, tacrolimus
388797|NCT01131975|Bioequivalence
388798|NCT01131975|Crossover
388799|NCT01131975|Lamotrigine (chewable, dispersible)
388800|NCT01131962|esophageal varices
388801|NCT01131962|hematemesis
388802|NCT01131962|endoscopy
388803|NCT01131949|Bioequivalence
388804|NCT01131949|Crossover
388805|NCT01131949|Lamotrigine (chewable, dispersible)
388806|NCT01131936|Bioequivalence
388807|NCT01131936|Amlodipine Besylate
388808|NCT01131923|Bioequivalence
388809|NCT01131923|Amlodipine Besylate
388810|NCT01131910|Rheumatoid arthritis
388811|NCT01131910|TBE-vaccine
388812|NCT01131910|Immunosuppression
388813|NCT01131897|Bioavailability
388814|NCT01131897|Crossover
388815|NCT01131897|Levetiracetam
388816|NCT01131884|ASIA A or ASIA B Spinal Cord Injury
388817|NCT01131871|obesity
388818|NCT01131871|overweight
388819|NCT01131832|Cholesterol, Plant sterols, Non-response, SNPs,
388820|NCT01131819|Trans-tibial Amputation
388821|NCT01131806|chronic obstructive pulmonary disease
388822|NCT01131806|lung function change FEV1 FVC
388823|NCT01131806|acute exacerbation
388824|NCT01131806|life quality questionnaire
388825|NCT01131793|Coronary Artery Chronic Total Occlusion In-Stent
388826|NCT01131780|Bioequivalence
388827|NCT01131780|Crossover
388828|NCT01131780|Ibuprofen and Pseudoephedrine
388829|NCT01131767|Bioequivalence
388830|NCT01131767|Crossover
388831|NCT01131767|Naproxen Sodium and Pseudoephedrine Hydrochloride
388832|NCT01131754|Peripheral venous catheter complications
388833|NCT01131754|PVC occlusion
388834|NCT01131754|PVC phlebitis
388835|NCT01131741|anesthesia, general
388836|NCT01131741|blood pressure
388837|NCT01131741|epinephrine
388838|NCT01131741|heart rate
388839|NCT01131741|injections, intravenous
388840|NCT01131728|Bioequivalence
388841|NCT01131728|Crossover
388842|NCT01131728|Naproxen Sodium and Pseudoephedrine Hydrochloride
388843|NCT01131715|Qualitetive interview
388844|NCT01131715|Coronary heart disease (CHD)
388845|NCT01131715|Patient experience
388846|NCT01131715|Patient perception
388847|NCT01131702|Bioequivalence
388848|NCT01131702|Crossover
388849|NCT01131702|Ranitidine
388850|NCT01131689|metastatic HCC
388851|NCT01131663|Infants, aerosol, acceptance, face mask, drug delivery
388852|NCT01131650|Prevalence of diabetic retinopathy
388853|NCT01131650|Diabetes
388854|NCT01131650|Retinopathy
388855|NCT01131650|Prevalence
388856|NCT01131650|Population
388857|NCT01131637|chronic heart failure
388858|NCT01131637|rhNRG-1
388859|NCT01131637|mortality
388860|NCT01131624|Iron deficiency
388861|NCT01131611|Spinal Stenosis
388862|NCT01131611|Rehabilitation
388863|NCT01131611|Physical Therapy (specialty)
388864|NCT01131611|Cognitive Behavior Therapy
388865|NCT01131611|Behavioral Research
388866|NCT01131598|ALI
388867|NCT01131598|SDRA
388868|NCT01131585|Diabetic macular edema
388869|NCT01131585|DME
388870|NCT01131585|Proliferative diabetic retinopathy
388871|NCT01131585|PDR
388872|NCT01131585|ranibizumab
388873|NCT01131585|laser
388874|NCT01131559|bipolar disorder
388875|NCT01131559|manic depression
388876|NCT01131559|depression
388877|NCT01131559|Bipolar I or II
388878|NCT01131546|Essential Hypertension
388879|NCT01131546|Levamlodipine Besylate
388880|NCT01131546|Amlodipine Maleate
388881|NCT01131520|SBIRT
388882|NCT01131520|Drug abuse
388883|NCT01131507|Exocrine Pancreatic Insufficiency
388884|NCT01131507|Infants with CF
388885|NCT01131494|Parkinson's disease
388886|NCT01131494|Dysphagia
388887|NCT01131494|Treatment
388888|NCT01131481|cataracts,glistenings,intraocular lenses.
388889|NCT01131468|ototoxicity
388890|NCT01131468|aminoglycoside
388891|NCT01131468|vancomycine
388892|NCT01131468|peritoneal dialysis
388893|NCT01131468|peritonitis
388894|NCT01131442|immune
388895|NCT01131429|mutation analysis
388896|NCT01131429|first-line
388897|NCT01131429|second-line
388898|NCT01131429|targeted therapy
388899|NCT01131403|IL-1α, skin care; baby wet wipes; full-term newborn; skin barrier function
388900|NCT01131377|mechanical ventilation weaning phase patients with metabolic alkalosis
388901|NCT01131364|Interleukin
388902|NCT01131364|IL2
388903|NCT01131364|F16
388904|NCT01131364|monoclonal
388905|NCT01131364|antibody
388906|NCT01131364|cytokine
388907|NCT01131364|doxorubicin
388908|NCT01131364|breast cancer
388909|NCT01131364|solid tumour
388910|NCT01131364|Phase I: Advanced Solid Tumour Patients
388911|NCT01131364|Phase II: Breast Cancer Patients Amenable to anthracyclin Therapy
388912|NCT01131351|MDR-TB
388913|NCT01131351|Dose Escalation
388914|NCT01131351|Phase II
388915|NCT01131351|Open Label
388916|NCT01131351|Non Controlled
388917|NCT01131351|Pulmonary Multidrug-Resistant Tuberculosis (MDR TB)
388918|NCT01131325|Philadelphia chromosome positive
388919|NCT01131325|Ph+
388920|NCT01131325|chronic myelogenous leukemia chronic phase
388921|NCT01131325|CML-CP
388922|NCT01131325|low imatinib trough levels
388923|NCT01131312|Cervix
388924|NCT01131312|CIN
388925|NCT01131312|HPV
388926|NCT01131312|Triage
388927|NCT01131312|ASCUS/LSIL
388928|NCT01131312|Pap Smear
388929|NCT01131312|HPV Test
388930|NCT01131299|HDL
388931|NCT01131299|Cholesterol
388932|NCT01131299|Lipoproteins
388933|NCT01131299|Serum Lipids
388934|NCT01131299|Alpha-Cyclodextrin
388935|NCT01131299|Atherosclerosis
388936|NCT01131299|Heart Disease
388937|NCT01131273|buprenorphine injecting
388938|NCT01131273|opiate dependence
388939|NCT01131273|HIV risk
388940|NCT01131273|treatment outcome
388941|NCT01131273|opiate dependence with buprenorphine injecting
388942|NCT01131260|STAN
388943|NCT01131260|Fetal monitoring
388944|NCT01131260|Fetal acidosis
388945|NCT01131260|Fetal heart rate monitoring
388946|NCT01131260|Perinatology
388947|NCT01131247|CLL
388948|NCT01131247|bendamustine
388949|NCT01131247|ofatumumab
388950|NCT01131247|blood cancer
388951|NCT01131247|leukemia
388952|NCT01131247|lymphoma
388953|NCT01131247|lymphocyte
388954|NCT01131247|refractory
388955|NCT01131247|Advanced
388956|NCT01131247|relapsed
388957|NCT01131247|hematologic
388958|NCT01131247|hematology
388959|NCT01131247|antibody
388960|NCT01131247|non-Hodgkin lymphoma
388961|NCT01131247|small lymphocytic lymphoma
388962|NCT01131247|nevada cancer institute
388963|NCT01131247|cephalon
388964|NCT01131247|Glaxosmithkline
388965|NCT01131221|contiguous stage II grade 1 follicular lymphoma
388966|NCT01131221|contiguous stage II grade 2 follicular lymphoma
388967|NCT01131221|contiguous stage II grade 3 follicular lymphoma
388968|NCT01131221|noncontiguous stage II grade 1 follicular lymphoma
388969|NCT01131221|noncontiguous stage II grade 2 follicular lymphoma
388970|NCT01131221|noncontiguous stage II grade 3 follicular lymphoma
388971|NCT01131221|stage III grade 1 follicular lymphoma
388972|NCT01131221|stage III grade 2 follicular lymphoma
388973|NCT01131221|stage III grade 3 follicular lymphoma
388974|NCT01131221|stage IV grade 1 follicular lymphoma
388975|NCT01131221|stage IV grade 2 follicular lymphoma
388976|NCT01131221|stage IV grade 3 follicular lymphoma
388977|NCT01131208|contiguous stage II adult diffuse large cell lymphoma
388978|NCT01131208|noncontiguous stage II adult diffuse large cell lymphoma
388979|NCT01131208|recurrent adult diffuse large cell lymphoma
388980|NCT01131208|stage I adult diffuse large cell lymphoma
388981|NCT01131208|stage III adult diffuse large cell lymphoma
388982|NCT01131208|stage IV adult diffuse large cell lymphoma
388983|NCT01131195|HER2-negative breast cancer
388984|NCT01131195|recurrent breast cancer
388985|NCT01131195|stage IIIB breast cancer
388986|NCT01131195|stage IIIC breast cancer
388987|NCT01131195|stage IV breast cancer
388988|NCT01131169|Myeloma
388989|NCT01131169|Busulfan
388990|NCT01131169|Melphalan
388991|NCT01131169|Fludarabine
388992|NCT01131169|T-Cell
388993|NCT01131169|Stem Cell Transplantation
388994|NCT01131169|10-051
388995|NCT01131156|postpartum
388996|NCT01131156|smoking
388997|NCT01131156|relapse
388998|NCT01131156|breastfeeding
388999|NCT01131143|Urban community centers
389000|NCT01131143|Obesity
389001|NCT01131143|Obesity counseling
389002|NCT01131143|Low-cost intervention
389003|NCT01131130|Contact lens
389004|NCT01131117|healthy
389005|NCT01131117|women
389006|NCT01131117|pregnancy
389007|NCT01131104|NAION
389008|NCT01131065|Hepatitis B
389009|NCT01131065|HBV
389010|NCT01131065|Orthotopic liver transplantation
389011|NCT01131065|Liver transplantation
389012|NCT01131065|Recurrence
389013|NCT01131065|Reinfection
389014|NCT01131065|Protective titers
389015|NCT01131065|HBsAb
389016|NCT01131065|Hepatitis B virus immune globulin
389017|NCT01131065|Niuliva
389018|NCT01131052|elderly populations
389019|NCT01131052|diabetes
389020|NCT01131039|Ovarian Cancer
389021|NCT01131026|Helicobacter pylori
389022|NCT01131026|levofloxacin
389023|NCT01131026|amoxicillin
389024|NCT01131026|lansoprazole
389025|NCT01131026|efficacy
389026|NCT01131026|safety
389027|NCT01131026|triple therapy
389028|NCT01130987|resident
389029|NCT01130987|intern
389030|NCT01130987|patient safety
389031|NCT01130987|medical error
389032|NCT01130987|time motion
389033|NCT01130987|handoff
389034|NCT01130987|sign-out
389035|NCT01130987|Resident Workflow
389036|NCT01130987|Resident Communications
389037|NCT01130961|Advanced NSCLC
389038|NCT01130961|Gefitinib
389039|NCT01130961|Thai patient
389040|NCT01130948|hypoxia
389041|NCT01130948|altitude
389042|NCT01130948|sleep
389043|NCT01130948|sleep apnea
389044|NCT01130948|periodic breathing
389045|NCT01130948|vigilance
389046|NCT01130948|psychomotor
389047|NCT01130948|endothelial function
389048|NCT01130935|GERD
389049|NCT01130935|gastric and duodenal ulcers
389050|NCT01130935|NSAID therapy
389051|NCT01130922|Roux-and-Y gastric bypass surgery
389052|NCT01130922|stable body weight
389053|NCT01130909|Healthy
389054|NCT01130909|Effect of a single dose on gamma-band qEEG
389055|NCT01130896|MRI, pacemakers, Defibrillator
389056|NCT01130883|acute tracheitis
389057|NCT01130883|acute tracheobronchitis or acute bronchitis
389058|NCT01130883|acute exacerbation of chronic bronchitis
389059|NCT01130883|mild community-acquired pneumonia
389060|NCT01130870|Fecal incontinence
389061|NCT01130870|Sacral nerve stimulation
389062|NCT01130870|Quality of life
389063|NCT01130870|DR15.9 Incontinentia alva
389064|NCT01130818|Safety
389065|NCT01130818|Tolerability
389066|NCT01130818|Pharmacokinetics
389067|NCT01130818|Bioavailability (solid vs solution, fasting vs fed)
389068|NCT01130818|Young healthy subjects
389069|NCT01130818|Elderly healthy subjects
389070|NCT01130805|gastric cancer pazopanib capecitabine, oxaliplatin
389071|NCT01130805|Metastatic or recurrent gastric cancer
389072|NCT01130792|rotavirus
389073|NCT01130792|cryptosporidium
389074|NCT01130792|probiotics
389075|NCT01130792|intestinal function
389076|NCT01130792|immune response
389077|NCT01130779|Non-small Cell Lung Cancer
389078|NCT01130779|Erlotinib
389079|NCT01130779|brain metastasis
389080|NCT01130766|Non-small Cell Lung Cancer
389081|NCT01130766|Asymptomatic brain metastasis
389082|NCT01130766|Stereotactic radiosurgery (SRS)
389083|NCT01130740|Osteoarthritis
389084|NCT01130740|Exercise
389085|NCT01130740|Diet
389086|NCT01130740|Coping Skills
389087|NCT01130740|Education, Medical
389088|NCT01130727|diabetes mellitus
389089|NCT01130727|diabetic nephropathy
389090|NCT01130727|hypertension
389091|NCT01130727|green tea
389092|NCT01130727|cocoa
389093|NCT01130727|polyphenol
389094|NCT01130727|nitric oxide
389095|NCT01130714|inflammation
389096|NCT01130714|chemotherapy
389097|NCT01130714|lung cancer
389098|NCT01130701|Pancreatic Cancer
389099|NCT01130701|Neoadjuvant
389100|NCT01130701|Panitumumab
389101|NCT01130701|Capecitabine
389102|NCT01130688|Leukemia
389103|NCT01130688|Zileuton
389104|NCT01130688|myeloproliferative neoplasm
389105|NCT01130662|acute myeloid leukemia
389106|NCT01130662|AML
389107|NCT01130662|Relapsed AML
389108|NCT01130662|Refractory AML
389109|NCT01130649|Epilepsy
389110|NCT01130649|Tracking
389111|NCT01130649|Electronic diary
389112|NCT01130636|oseltamivir carboxylate
389113|NCT01130636|oseltamivir phosphate
389114|NCT01130636|Tamiflu pharmacokinetics in lactating women with influenza
389115|NCT01130623|VEGF Inhibitor
389116|NCT01130623|Maximum Tolerated Dose
389117|NCT01130623|Dose Escalation
389118|NCT01130623|Pharmacokinetics
389119|NCT01130623|Antitumor Activity
389120|NCT01130623|Pediatric Cancer
389121|NCT01130623|Solid Tumor
389122|NCT01130623|Sarcoma
389123|NCT01130623|Neuroblastoma
389124|NCT01130623|Wilms Tumor
389125|NCT01130623|Osteosarcoma
389126|NCT01130623|Brain Tumor
389127|NCT01130610|preoperative period
389128|NCT01130610|preoperative care
389129|NCT01130610|anesthesia
389130|NCT01130610|program evaluation
389131|NCT01130597|HF
389132|NCT01130597|Heart failure
389133|NCT01130597|hyperkalemia
389134|NCT01130597|chronic kidney disease
389135|NCT01130597|prevention of hyperkalemia in heart failure participants
389136|NCT01130584|Cancer Patients
389137|NCT01130558|type 2 diabetes mellitus
389138|NCT01130558|basal-bolus insulin
389139|NCT01130558|insulin ordering
389140|NCT01130545|Magnetic Resonance Imaging
389141|NCT01130545|Gadolinium
389142|NCT01130545|Healthy Volunteer
389143|NCT01130545|HV
389144|NCT01130532|Erectile Dysfunction
389145|NCT01130532|ED
389146|NCT01130532|Impotence
389147|NCT01130519|Advanced HLRCC
389148|NCT01130519|Sporadic Papillary Renal Cell Cancer
389149|NCT01130519|Papillary Kidney Cancer
389150|NCT01130519|Bevacizumab
389151|NCT01130519|Erlotinib
389152|NCT01130519|Kidney Cancer
389153|NCT01130519|Renal Cell Cancer
389154|NCT01130519|Hereditary Leiomyomatosis and Renal Cell Cancer
389155|NCT01130519|HLRCC
389156|NCT01130467|Attention Deficit Disorders with Hyperactivity
389157|NCT01130467|Attention Deficit Disorder
389158|NCT01130467|Event related potential
389159|NCT01130454|Unfavorable effect of environmental factors, stressors
389160|NCT01130441|adolescent behavior
389161|NCT01130441|harm reduction
389162|NCT01130428|Mechanical stimulation
389163|NCT01130428|Vibration platform
389164|NCT01130428|Bone metabolism
389165|NCT01130428|ATP release
389166|NCT01130415|Sacral neuromodulation
389167|NCT01130415|Screening
389168|NCT01130415|Percutaneous nerve evaluation
389169|NCT01130415|Tined lead
389170|NCT01130402|age
389171|NCT01130402|lymphadenopathy
389172|NCT01130402|fine needle aspiration
389173|NCT01130402|sonography
389174|NCT01130389|ONJ
389175|NCT01130376|Immune based therapy
389176|NCT01130376|Therapeutic vaccination
389177|NCT01130376|cytokine therapy
389178|NCT01130376|HIV therapeutic vaccine
389179|NCT01130363|Proton Pump Inhibitor
389180|NCT01130363|Gastric carcinoid tumors
389181|NCT01130363|Gastric cancer
389182|NCT01130363|Fundic Gland Polyps
389183|NCT01130324|VIBATIV
389184|NCT01130324|telavancin
389185|NCT01130324|Pregnancy
389186|NCT01130324|Registry
389187|NCT01130298|testosterone, replacement, therapy
389188|NCT01130285|Lung Cancer
389189|NCT01130272|Irritable bowel syndrome with diarrhea
389190|NCT01130272|Irritable bowel syndrome
389191|NCT01130272|Diarrhea predominant irritable bowel syndrome
389192|NCT01130272|Colonic diseases
389193|NCT01130272|Colonic diseases, functional
389194|NCT01130272|Digestive system disease
389195|NCT01130272|Gastrointestinal disease
389196|NCT01130272|Intestinal disease
389197|NCT01130272|Colonic pseudo-obstruction
389198|NCT01130272|Diarrhea
389199|NCT01130272|Signs and Symptoms, Digestive
389200|NCT01130259|mTNBC
389201|NCT01130259|triple negative breast cancer
389202|NCT01130259|metastatic triple negative breast cancer
389203|NCT01130259|metastatic breast cancer that is ER-, PR-, and HER2-negative
389204|NCT01130233|rectal cancer
389205|NCT01130220|Brain Tumor
389206|NCT01130220|Brain Neoplasm
389207|NCT01130207|Obesity
389208|NCT01130207|Diabetes
389209|NCT01130207|Periodontal disease
389210|NCT01130194|follicular lymphoma
389211|NCT01130194|radioimmunotherapy
389212|NCT01130194|rituximab
389213|NCT01130194|C-MOPP-R
389214|NCT01130194|autologous transplant
389215|NCT01130155|Antimalarials
389216|NCT01130155|Diagnosis
389217|NCT01130155|Access to treatment
389218|NCT01130155|Quality of care
389219|NCT01130129|Flavonoids
389220|NCT01130129|Platelets
389221|NCT01130103|PTSD
389222|NCT01130103|anxiety disorders
389223|NCT01130103|trauma
389224|NCT01130077|Pediatric glioma
389225|NCT01130077|Vaccine therapy
389226|NCT01130064|Asthma
389227|NCT01130064|QAX576
389228|NCT01130051|bioavailability
389229|NCT01130038|Characteristic of play
389230|NCT01130038|DCD
389231|NCT01130038|children
389232|NCT01130038|Typical Development
389233|NCT01130038|Whether there are any differences in the issue of Characteristic of play between Children with DCD and Children with Typical Development
389234|NCT01130012|Gestational diabetes mellitus
389235|NCT01130012|Lifestyle intervention
389236|NCT01130012|Oral glucose tolerance test
389237|NCT01130012|Insulin treatment
389238|NCT01130012|Pregnancy outcomes
389239|NCT01129999|smoking cessation, CBT, hypnotherapy
389240|NCT01129986|venous ulcer Dermastream
389241|NCT01129973|speech and language
389242|NCT01129973|phonoaudiology
389243|NCT01129973|marketing
389244|NCT01129960|Diabetic Neuropathic Pain
389245|NCT01129934|Low Back Pain,
389246|NCT01129934|Emergency medicine,
389247|NCT01129934|Promethazine,
389248|NCT01129934|Morphine,
389249|NCT01129934|Pain relief
389250|NCT01129921|Lumbar Spine Stenosis
389251|NCT01129921|Decompression
389252|NCT01129908|oral health in children with celiac disease
389253|NCT01129882|Schizophrenia
389254|NCT01129869|Survey
389255|NCT01129869|Perception
389256|NCT01129869|Perception of Clinical Research Participation
389257|NCT01129869|Research Participant Perception
389258|NCT01129856|Dry eye
389259|NCT01129856|Keratoconjunctivitis sicca
389260|NCT01129856|Iontophoresis
389261|NCT01129856|Ophthalmic drug delivery
389262|NCT01129856|EGP-437
389263|NCT01129856|Dexamethasone phosphate
389264|NCT01129843|anemia
389265|NCT01129843|iron deficiency
389266|NCT01129843|nutritional
389267|NCT01129843|iron supplementation
389268|NCT01129843|cluster randomized control trial
389269|NCT01129830|ovarian reserve
389270|NCT01129830|FSH
389271|NCT01129830|anti-mullerian hormone
389272|NCT01129830|estradiol
389273|NCT01129830|oocyte
389274|NCT01129830|IVF
389275|NCT01129830|embryo transfer
389276|NCT01129817|Cognitive Functional Therapy
389277|NCT01129817|Manual Therapy and Exercise
389278|NCT01129817|Chronic Low Back Pain
389279|NCT01129817|Randomized Controlled Trial
389280|NCT01129817|Subclassification
389281|NCT01129804|Alcohol dependence
389282|NCT01129804|Network Support
389283|NCT01129804|Cognitive-behavioral treatment
389284|NCT01129804|Relapse prevention
389285|NCT01129804|Consequences of drinking
389286|NCT01129804|Social network development
389287|NCT01129765|Nasal suction
389288|NCT01129765|Nasal aspiration
389289|NCT01129765|Nasal saline irrigation
389290|NCT01129765|Nasal lavage
389291|NCT01129739|Bone Marrow Disease
389292|NCT01129739|MDS-RA
389293|NCT01129739|MDS-RARS
389294|NCT01129739|Umbilical Cord/placenta-Derived MSC
389295|NCT01129739|Transplant
389296|NCT01129726|Transillumination-guided
389297|NCT01129726|Fiberoptic Intubation
389298|NCT01129726|time
389299|NCT01129726|success rate
389300|NCT01129726|intubation
389301|NCT01129713|GERD
389302|NCT01129713|Acid Reflux
389303|NCT01129713|Heartburn
389304|NCT01129713|Regurgitation
389305|NCT01129713|Indigestion
389306|NCT01129700|rectal cancer, short-course, chemoradiotherapy
389307|NCT01129648|Hyperuricemia, gout
389308|NCT01129635|Heart failure
389309|NCT01129635|Cardiac resynchronization therapy
389310|NCT01129635|Regional left ventricular dyssynchrony
389311|NCT01129635|CRT
389312|NCT01129622|Letrozole
389313|NCT01129622|Breast MRI
389314|NCT01129622|Postmenopausal women
389315|NCT01129609|Post-approval observation of patients being treated according to the indications for use for the Talent Converter Stent Graft
389316|NCT01129583|Botulinum Toxin
389317|NCT01129583|Elbow Stiffness
389318|NCT01129544|Severe combined immunodeficiency
389319|NCT01129544|SCID
389320|NCT01129544|XSCID
389321|NCT01129544|SCID-X1
389322|NCT01129518|meningococcal serogroup C
389323|NCT01129518|vaccine
389324|NCT01129518|conjugate
389325|NCT01129505|pregnancy
389326|NCT01129505|intervention
389327|NCT01129505|exercise
389328|NCT01129505|nutrition
389329|NCT01129505|infants
389330|NCT01129492|Autoimmune Thyroiditis, Laser, Therapy, Thyroid, Ultrasound
389331|NCT01129479|Aphasia
389332|NCT01129479|treatment
389333|NCT01129479|cholinesterase inhibitor
389334|NCT01129479|stroke
389335|NCT01129453|Salmonella
389336|NCT01129453|Vaccine
389337|NCT01129440|Children
389338|NCT01129440|Fluoride varnish
389339|NCT01129440|Glass ionomer sealant
389340|NCT01129440|Prevention
389341|NCT01129401|methamphetamine
389342|NCT01129401|men who have sex with men
389343|NCT01129401|HIV/AIDS
389344|NCT01129362|Pertussis
389345|NCT01129362|Whooping Cough
389346|NCT01129362|Pertussis Vaccine
389347|NCT01129349|Solid Tumors
389348|NCT01129336|HER2-negative
389349|NCT01129336|HER2
389350|NCT01129336|Metastatic breast cancer
389351|NCT01129336|First Line breast cancer
389352|NCT01129336|Second Line breast cancer
389353|NCT01129336|Breast cancer
389354|NCT01129336|Metastatic
389355|NCT01129336|Stage IV breast cancer
389356|NCT01129336|Progression free survival
389357|NCT01129336|PFS
389358|NCT01129336|Circulating Tumor Cells
389359|NCT01129336|CTCs
389360|NCT01129336|Zoledronic acid
389361|NCT01129336|HER2-negative metastatic breast cancer patients without bone metastasis
389362|NCT01129323|Anemia, Severe, Aplastic, Reduced-Intensity, Allogeneic, Stem, Cell, Transplantation
389363|NCT01129310|irinotecan
389364|NCT01129310|capecitabine
389365|NCT01129310|oxaliplatin
389366|NCT01129310|health-related quality of life
389367|NCT01129310|gastroesophageal(GE) junction adenocarcinoma
389368|NCT01129297|Obesity
389369|NCT01129297|surgery
389370|NCT01129297|genetic expression
389371|NCT01129297|collection of samples
389372|NCT01129284|Treatment Resistance
389373|NCT01129284|Nephrotic Syndrome
389374|NCT01129284|Focal Segmental Glomerulosclerosis
389375|NCT01129284|lipoid nephrosis
389376|NCT01129284|Membranous nephropathy
389377|NCT01129284|IgA nephropathy
389378|NCT01129284|proteinuria
389379|NCT01129258|phase 1
389380|NCT01129258|safety and tolerability
389381|NCT01129258|pharmacokinetics
389382|NCT01129258|PK
389383|NCT01129258|pharmacodynamics
389384|NCT01129258|PD
389385|NCT01129258|type 2 diabetes mellitus
389386|NCT01129245|Celebrex
389387|NCT01129245|prostoglandin inhibitor
389388|NCT01129245|ovulation
389389|NCT01129245|emergency contraception
389390|NCT01129232|insulin
389391|NCT01129219|Strength
389392|NCT01129219|Function
389393|NCT01129219|Mobility
389394|NCT01129206|Gastroesophageal Cancer
389395|NCT01129206|Gastroesophageal Carcinoma
389396|NCT01129206|Adenocarcinoma
389397|NCT01129180|T-Cell Lymphoma
389398|NCT01129167|Pancreatic adenocarcinoma
389399|NCT01129167|Local invasion by pancreatic adenocarcinoma
389400|NCT01129167|Recurrence of pancreatic cancer
389401|NCT01129167|Surgical resection of pancreatic cancer
389402|NCT01129154|Squamous cell carcinoma
389403|NCT01129141|Tinnitus
389404|NCT01129141|Traumatic Brain Injury Counseling
389405|NCT01129141|Counseling
389406|NCT01129141|Education
389407|NCT01129141|Evaluation studies
389408|NCT01129141|Quality of health care
389409|NCT01129128|Echinacea
389410|NCT01129128|immune modulation
389411|NCT01129128|prevention
389412|NCT01129089|Acceptability
389413|NCT01129089|Lipid-based nutrient supplements
389414|NCT01129089|Micronutrient powder
389415|NCT01129089|Malnutrition
389416|NCT01129076|Thalassemia Major
389417|NCT01129076|Stigma
389418|NCT01129076|Singapore
389419|NCT01129076|Qualitative
389420|NCT01129037|Oncology
389421|NCT01129024|Splenectomy
389422|NCT01129024|Low Platelet Count
389423|NCT01129024|Thrombopoiesis
389424|NCT01129024|Thrombocytopaenia
389425|NCT01129024|Idiopathic Thrombocytopenic Purpura
389426|NCT01129024|Immune Thrombocytopenia (ITP)
389427|NCT01129024|Thrombotic Thrombocytopenic Purpura (ITP)
389428|NCT01129024|Hematologic Disease
389429|NCT01129024|Auto-immune Thrombocytopenic Purpura
389430|NCT01129024|S-888711
389431|NCT01129024|Blood Platelet Disorders
389432|NCT01129024|Relapsed Persistent or Chronic ITP
389433|NCT01129024|ITP
389434|NCT01129011|NSAID
389435|NCT01129011|gastric ulcers
389436|NCT01129011|Vimovo
389437|NCT01129011|Esomeprazole
389438|NCT01129011|Naproxen
389439|NCT01128998|Sorafenib
389440|NCT01128998|S1
389441|NCT01128998|Advanced Solid Tumors
389442|NCT01128998|RD
389443|NCT01128998|MTD
389444|NCT01128998|DLT
389445|NCT01128998|PK
389446|NCT01128998|PG
389447|NCT01128998|Biomarker
389448|NCT01128985|Canagliflozin
389449|NCT01128985|Placebo
389450|NCT01128985|Type 2 diabetes mellitus
389451|NCT01128985|Pharmacokinetic
389452|NCT01128985|Pharmacodynamic
389453|NCT01128972|enamel erosion
389454|NCT01128972|tooth remineralization
389455|NCT01128972|tooth erosion
389456|NCT01128959|Epilepsy
389457|NCT01128959|Intravenous Carbamazepine
389458|NCT01128959|Oral Carbamazepine
389459|NCT01128946|Enamel remineralization
389460|NCT01128946|Fluoride
389461|NCT01128946|caries
389462|NCT01128933|Fractional flow reserve
389463|NCT01128933|Revascularization
389464|NCT01128933|Prognosis
389465|NCT01128933|Hemodynamics
389466|NCT01128933|Hypertension
389467|NCT01128920|bacterial infections
389468|NCT01128920|skin infections
389469|NCT01128920|HIV
389470|NCT01128920|Hepatitis C
389471|NCT01128920|risk reduction intervention
389472|NCT01128907|Invasive Aspergillosis in neutropenic patients
389473|NCT01128894|GSK716155
389474|NCT01128894|liraglutide
389475|NCT01128894|albiglutide
389476|NCT01128894|open-label
389477|NCT01128868|Reverse oblique intertrochanteric fractures
389478|NCT01128868|Reverse oblique subtrochanteric fractures
389479|NCT01128855|Duchenne
389480|NCT01128855|Duchenne Muscular Dystrophy
389481|NCT01128855|DMD
389482|NCT01128855|968
389483|NCT01128842|Neratinib
389484|NCT01128842|Capecitabine
389485|NCT01128842|Combination
389486|NCT01128842|Solid Tumor
389487|NCT01128829|obesity
389488|NCT01128829|diabetes
389489|NCT01128829|artificial sweeteners
389490|NCT01128816|obstructive sleep apnea
389491|NCT01128816|central sleep apnea
389492|NCT01128816|heart failure
389493|NCT01128816|congestive heart failure
389494|NCT01128816|adaptive servo ventilation
389495|NCT01128816|ASV
389496|NCT01128803|Hepatocellular carcinoma
389497|NCT01128803|immunotherapy
389498|NCT01128803|alpha foetoprotein
389499|NCT01128803|dendritic cells
389500|NCT01128790|exercise
389501|NCT01128790|remote ischemic preconditioning
389502|NCT01128790|heart failure
389503|NCT01128790|left ventricular dysfunction
389504|NCT01128777|depression
389505|NCT01128777|anxiety
389506|NCT01128777|family conflict
389507|NCT01128777|behavior problems
389508|NCT01128751|Cognition
389509|NCT01128751|Neuroprotection
389510|NCT01128751|Cardiopulmonary bypass
389511|NCT01128751|Aortic valve replacement
389512|NCT01128751|Micro-emboli
389513|NCT01128738|Neuromuscular Agents
389514|NCT01128738|Botulinum Toxin Type A
389515|NCT01128738|Sweating
389516|NCT01128738|Sweat Gland Disease
389517|NCT01128738|Axillary Hyperhidrosis
389518|NCT01128738|Skin Disease
389519|NCT01128699|Ahmed valve
389520|NCT01128699|Neovascular Glaucoma
389521|NCT01128699|Uveitic glaucoma
389522|NCT01128699|Failed glaucoma
389523|NCT01128699|VEGF-A
389524|NCT01128699|Intraocular pressure
389525|NCT01128699|Subconjunctival Avastin
389526|NCT01128686|retrospective
389527|NCT01128686|naïve Chronic Hepatitis B (CHB) patients
389528|NCT01128686|cohort study
389529|NCT01128686|lamivudine
389530|NCT01128673|Hypoxic Ischemic encephalopathy
389531|NCT01128673|Magnet resonance imaging
389532|NCT01128673|Selective Head cooling
389533|NCT01128673|Therapeutic hypothermia
389534|NCT01128660|Prescription, General practitioner, Pharmacy
389535|NCT01128634|Verapamil
389536|NCT01128634|Anticholinergic, β2 agonist
389537|NCT01128634|P-GP
389538|NCT01128634|LABA
389539|NCT01128634|Muscarinic Receptor Antagonist
389540|NCT01128634|LAMA
389541|NCT01128621|Pharmacokinetics
389542|NCT01128621|Glucose
389543|NCT01128621|Safety
389544|NCT01128621|Male
389545|NCT01128621|Female
389546|NCT01128621|Metformin
389547|NCT01128621|Pharmacodynamics
389548|NCT01128621|Tolerability
389549|NCT01128621|Type II Diabetes
389550|NCT01128608|GERD
389551|NCT01128608|Heartburn
389552|NCT01128608|Acid Reflux
389553|NCT01128595|allergen challenge
389554|NCT01128595|early asthmatic response
389555|NCT01128595|mild asthma
389556|NCT01128595|late asthmatic response
389557|NCT01128582|GERD
389558|NCT01128582|Insomnia
389559|NCT01128582|Acid Reflux
389560|NCT01128582|Heartburn
389561|NCT01128569|mild asthma
389562|NCT01128569|allergen challenge
389563|NCT01128569|early asthmatic response
389564|NCT01128556|allergic conjunctivitis
389565|NCT01128556|histamine skin testing
389566|NCT01128543|lapatinib
389567|NCT01128543|breast cancer
389568|NCT01128530|cSSSI
389569|NCT01128530|complicated skin and skin structure infections
389570|NCT01128530|acute bacterial skin and skin structure infections
389571|NCT01128530|abscess
389572|NCT01128530|cellulitis
389573|NCT01128530|bacterial infections
389574|NCT01128530|anti-bacterial agents
389575|NCT01128530|anti-infective agents
389576|NCT01128530|skin diseases, infectious
389577|NCT01128530|skin diseases
389578|NCT01128530|wound infection
389579|NCT01128517|Maternal education
389580|NCT01128517|Complementary food
389581|NCT01128517|Infant growth
389582|NCT01128478|Acute pancreatitis
389583|NCT01128478|Enteral nutrition
389584|NCT01128478|Pancreas rest
389585|NCT01128465|propofol
389586|NCT01128465|awake craniotomy
389587|NCT01128465|patients requiring an awake craniotomy for brain tumor/lesion resection
389588|NCT01128452|Treatment-Resistant Depression
389589|NCT01128439|Pneumococcal conjugate vaccine
389590|NCT01128426|Pneumococcal conjugate vaccine
389591|NCT01128413|Shock
389592|NCT01128413|Resuscitation
389593|NCT01128413|Hemodynamics
389594|NCT01128413|Emergencies
389595|NCT01128413|Critical Care
389596|NCT01128413|Lactic Acid
389597|NCT01128413|Plasma volume
389598|NCT01128400|obesity
389599|NCT01128400|orlistat
389600|NCT01128400|taste perception
389601|NCT01128387|esophageal cancer
389602|NCT01128387|Locally advanced esophageal cancer
389603|NCT01128374|Periodontal disease
389604|NCT01128374|Nonsurgical therapy
389605|NCT01128374|Type 2 Diabetes Mellitus
389606|NCT01128374|Bacterial burden
389607|NCT01128374|Gene polymorphisms
389608|NCT01128348|asthma
389609|NCT01128348|adherence
389610|NCT01128348|quality of life
389611|NCT01128348|health literacy
389612|NCT01128348|health disparities
389613|NCT01128335|Liver transplantation
389614|NCT01128335|HCV-negative recipient
389615|NCT01128335|deceased donor
389616|NCT01128335|sotrastaurin
389617|NCT01128335|oran transplantation
389618|NCT01128335|tacrolimus
389619|NCT01128322|CKD-828
389620|NCT01128322|Hypertension
389621|NCT01128322|Primary Hypertension
389622|NCT01128322|S-Amlodipine
389623|NCT01128322|Telmisartan
389624|NCT01128322|Amlodipine
389625|NCT01128322|Factorial
389626|NCT01128322|Phase 2
389627|NCT01128296|high risk stage IIb or III adenocarcinoma of the pancreas
389628|NCT01128283|Sepsis
389629|NCT01128283|organ failure
389630|NCT01128283|cytokines
389631|NCT01128283|clotting factors
389632|NCT01128270|Dichloroacetate
389633|NCT01128270|Chloral Hydrate
389634|NCT01128270|Metabolism
389635|NCT01128244|oral contraceptives
389636|NCT01128244|Vitamin B6
389637|NCT01128244|birth control pills
389638|NCT01128244|amino acids
389639|NCT01128244|Vitamin B6 deficiency
389640|NCT01128244|Vitamin B6 deficiency in women on oral contraceptives
389641|NCT01128218|Brain Neoplasms
389642|NCT01128218|5-ALA
389643|NCT01128218|Aminolevulinic acid
389644|NCT01128218|Fluorescence
389645|NCT01128218|Gliomas
389646|NCT01128218|Glioblastoma
389647|NCT01128218|Surgery
389648|NCT01128205|diabetes
389649|NCT01128205|cardiovascular risk factors
389650|NCT01128205|blood pressure
389651|NCT01128205|blood lipid
389652|NCT01128205|blood glucose
389653|NCT01128166|Heart Failure
389654|NCT01128166|Decompensation
389655|NCT01128166|Cardiac Resynchronization Therapy
389656|NCT01128153|Type 2 Diabetes
389657|NCT01128153|Inadequate Glycaemic Control
389658|NCT01128153|Saxagliptin
389659|NCT01128153|Metformin
389660|NCT01128153|Sulfonylurea
389661|NCT01128153|Triple Oral Therapy
389662|NCT01128140|motivational enhancement therapy
389663|NCT01128127|knowledge translation
389664|NCT01128127|prescription
389665|NCT01128127|primary care
389666|NCT01128127|NSAID
389667|NCT01128127|PPI
389668|NCT01128127|Gastrointestinal damage
389669|NCT01128127|Inappropriate prescription
389670|NCT01128114|Acute bipolar mania
389671|NCT01128114|Seroquel XR
389672|NCT01128114|Quetiapine fumarate
389673|NCT01128114|Add-on therapy
389674|NCT01128101|spironolactone
389675|NCT01128101|chronic kidney disease
389676|NCT01128101|dialysis
389677|NCT01128101|LHV
389678|NCT01128088|Enhanced recovery program in laparoscopic surgery
389679|NCT01128075|RebiSmart
389680|NCT01128075|Rebif
389681|NCT01128075|Adherence
389682|NCT01128075|Multidose
389683|NCT01128075|Relapsing Multiple Sclerosis
389684|NCT01128075|RMS
389685|NCT01128062|Canthaxanthin retinopathy
389686|NCT01128049|Aqueous deficient dry eye (ADDE)
389687|NCT01128049|Meibomium Gland Dysfunction (MGD)
389688|NCT01128049|Normal/Control (Non Dry Eye)
389689|NCT01128036|Congestive Heart failure
389690|NCT01128036|Cardiomyopathy
389691|NCT01128023|myocardial perfusion imaging
389692|NCT01128023|rubidium-82
389693|NCT01128023|medical isotope production
389694|NCT01128023|Positron emission tomography
389695|NCT01128023|clinically useful
389696|NCT01127984|pacemaker
389697|NCT01127984|pocket haematoma
389698|NCT01127984|antiplatelet therapy
389699|NCT01127984|fibrin glue
389700|NCT01127971|patients
389701|NCT01127971|receiving
389702|NCT01127971|irradiation
389703|NCT01127971|device
389704|NCT01127971|External Beam
389705|NCT01127958|In-stent restenosis
389706|NCT01127958|Minimal lumen diameter
389707|NCT01127958|Drug eluting balloon
389708|NCT01127958|Drug eluting stent
389709|NCT01127932|Cognitive Behavioral Therapy
389710|NCT01127919|Exercise
389711|NCT01127919|Activity
389712|NCT01127919|Adherence
389713|NCT01127919|Genetics
389714|NCT01127906|Healthy Volunteers
389715|NCT01127906|cross-over
389716|NCT01127906|randomized
389717|NCT01127906|placebo and active controlled
389718|NCT01127906|heat pain
389719|NCT01127906|UVB-Induced pain model
389720|NCT01127893|Musculoskeletal Diseases
389721|NCT01127893|Joint Diseases
389722|NCT01127893|Arthritis
389723|NCT01127893|Rheumatic Diseases
389724|NCT01127880|Traumatic Hemopneumothorax
389725|NCT01127880|Thoracotomy
389726|NCT01127880|Antibiotics
389727|NCT01127854|kidney stone
389728|NCT01127854|urolithiasis
389729|NCT01127854|calcium oxalate kidney stone
389730|NCT01127854|calcium oxalate stone
389731|NCT01127854|calcium oxalate
389732|NCT01127828|IBS (Irritable Bowel Syndrome)
389733|NCT01127828|Probiotic yoghurt
389734|NCT01127828|Symptom severity
389735|NCT01127815|Peritoneal washing cytology
389736|NCT01127815|pancreatic cancer
389737|NCT01127815|peritoneal metastasis
389738|NCT01127815|anoikis
389739|NCT01127815|to determine the relationship between PWC results and clinicopathologic parameters of pancreatic cancers
389740|NCT01127815|to identify the predictive value of PWC and postoperative drainage cytology on the peritoneal recurrence or outcomes
389741|NCT01127815|to dissect the molecular mechanism of peritoneal recurrence, especially on the PWC-inducing peritoneal seeding process.
389742|NCT01127802|CABG
389743|NCT01127802|functional status
389744|NCT01127802|symptoms distress
389745|NCT01127802|quality of life
389746|NCT01127802|the trajectory of functional status
389747|NCT01127802|the changes of symptoms distress
389748|NCT01127802|the changes of quality of life
389749|NCT01127776|patient after bi-trimalleolar fracture of ankle
389750|NCT01127763|metastatic
389751|NCT01127763|breast
389752|NCT01127763|cancer
389753|NCT01127750|Relapsing multiple sclerosis
389754|NCT01127750|MS
389755|NCT01127750|safety
389756|NCT01127750|tolerability
389757|NCT01127750|health outcomes
389758|NCT01127737|SCCs
389759|NCT01127737|Squamous Cell Carcinoma
389760|NCT01127737|Skin Self Exam
389761|NCT01127737|SSE
389762|NCT01127737|Organ Transplant
389763|NCT01127737|Performance of SSE with our written educational intervention
389764|NCT01127737|Time after organ transplantation to deliver intervention
389765|NCT01127737|Evaluate internation information
389766|NCT01127724|Vitamin B12
389767|NCT01127724|Aphthous stomatitis
389768|NCT01127724|Cobalamin
389769|NCT01127724|Doses
389770|NCT01127685|weight bearing
389771|NCT01127685|acl
389772|NCT01127672|plantar fasciitis
389773|NCT01127672|PRP
389774|NCT01127672|platelet rich plasma
389775|NCT01127659|diabetes
389776|NCT01127659|hypogonadism
389777|NCT01127659|obesity
389778|NCT01127659|testosterone
389779|NCT01127659|insulin sensitivity
389780|NCT01127659|inflammation
389781|NCT01127620|Allergic Rhinoconjunctivitis
389782|NCT01127620|Persistent allergic rhinitis
389783|NCT01127620|Hay fever
389784|NCT01127620|Allergic Rhinitis
389785|NCT01127620|Sneezing
389786|NCT01127620|Nasal congestion
389787|NCT01127620|Rhinorrhea
389788|NCT01127620|Nasal itching
389789|NCT01127620|Ocular itching
389790|NCT01127620|Ocular tearing
389791|NCT01127620|Antihistamine
389792|NCT01127607|parenting
389793|NCT01127594|Melanoma
389794|NCT01127581|Misoprostol vaginal insert
389795|NCT01127581|Dinoprostone vaginal insert
389796|NCT01127581|Cervidil
389797|NCT01127581|Cervical ripening
389798|NCT01127581|Induction of labor
389799|NCT01127581|Rate of cesarean section
389800|NCT01127568|Post-Traumatic Stress Disorders
389801|NCT01127568|Posttraumatic Stress Disorders
389802|NCT01127568|PTSD
389803|NCT01127568|Stress Disorder, Post Traumatic
389804|NCT01127568|Stress Disorders, Posttraumatic
389805|NCT01127568|Chronic Post Traumatic Stress Disorder
389806|NCT01127555|Biliary Tract Cancer
389807|NCT01127555|Salvage therapy
389808|NCT01127555|FOLFOX
389809|NCT01127516|Susceptibility testing
389810|NCT01127516|Antimicrobial stewardship
389811|NCT01127503|Patients with velocardiofacial syndrome and psychosis
389812|NCT01127477|Hypovolemia, surgical blood loss
389813|NCT01127464|HIV-1
389814|NCT01127464|HIV preventative vaccine
389815|NCT01127464|Healthy Volunteers
389816|NCT01127451|Neoplasms
389817|NCT01127438|Monitored anesthesia care sedation
389818|NCT01127425|nursing hours
389819|NCT01127425|length of hospital stay
389820|NCT01127425|reconvalescence
389821|NCT01127425|colorectal surgery
389822|NCT01127425|laparoscopic
389823|NCT01127425|sigmoid neoplasms
389824|NCT01127412|overweight
389825|NCT01127412|physical activity
389826|NCT01127412|infancy
389827|NCT01127412|body composition
389828|NCT01127412|motor development
389829|NCT01127412|motor activity
389830|NCT01127373|Breast
389831|NCT01127373|Radiation
389832|NCT01127373|Multi-Beam Intensity-Modulated Radiation
389833|NCT01127373|post mastectomy
389834|NCT01127373|post partial mastectomy
389835|NCT01127373|node-positive breast cancer
389836|NCT01127373|10-025
389837|NCT01127360|Anti-VEGF
389838|NCT01127360|Ranibizumab
389839|NCT01127360|Bevacizumab
389840|NCT01127360|exudative
389841|NCT01127360|macular degeneration
389842|NCT01127334|Dyssynchrony
389843|NCT01127334|Cardiac resynchronization therapy
389844|NCT01127321|Systemic lupus erythematosus
389845|NCT01127321|SLE
389846|NCT01127321|MEDI-570
389847|NCT01127308|Absorption
389848|NCT01127308|Distribution
389849|NCT01127308|Metabolism
389850|NCT01127308|and Excretion
389851|NCT01127308|Mass Balance
389852|NCT01127308|Metabolic Profile
389853|NCT01127308|Radiolabel Study
389854|NCT01127295|Pharmacokinetics
389855|NCT01127295|Pharmacogenetic
389856|NCT01127295|tamoxifen
389857|NCT01127295|anti-aromatases
389858|NCT01127295|breast cancer
389859|NCT01127295|pharmacodynamy
389860|NCT01127295|Observance
389861|NCT01127282|influenza
389862|NCT01127282|vitamin
389863|NCT01127282|improvement of symptom
389864|NCT01127243|Hysterectomy
389865|NCT01127243|laparoscopy
389866|NCT01127243|day-case surgery
389867|NCT01127243|quality of life
389868|NCT01127243|Ambulatory Surgical Procedures
389869|NCT01127230|ADRC
389870|NCT01127230|adipocyte derived regenerative cells
389871|NCT01127230|stem cells
389872|NCT01127230|liposuction
389873|NCT01127230|Cytori
389874|NCT01127230|Celution
389875|NCT01127230|Lipoaspirate is obtained from patients who have opted for liposuction and consent to donate the lipoasirate for this study, which would otherwise be discarded.
389876|NCT01127217|amlodipine
389877|NCT01127217|losartan
389878|NCT01127217|hypertension
389879|NCT01127217|stage 2
389880|NCT01127204|HIV
389881|NCT01127204|Antiretroviral therapy
389882|NCT01127204|Infant
389883|NCT01127204|Sub Saharian Africa
389884|NCT01127191|military exercises
389885|NCT01127191|neuromuscular fatigue
389886|NCT01127191|physiological responses
389887|NCT01127191|biomechanical responses
389888|NCT01127191|simulated military effort
389889|NCT01127191|high load carriage
389890|NCT01127191|Healthy voluntary
389891|NCT01127152|Noradrenalin relays
389892|NCT01127152|Automatic relays
389893|NCT01127152|Manual relays
389894|NCT01127152|Hypotension
389895|NCT01127152|Intensive care unit
389896|NCT01127139|Essential hypertension
389897|NCT01127113|Myocardial infarction
389898|NCT01127113|Magnetic resonance imaging
389899|NCT01127113|Nanoparticles
389900|NCT01127113|Mononuclear cells
389901|NCT01127113|Cell tracking
389902|NCT01127100|neuropathic pain
389903|NCT01127100|gabapentin
389904|NCT01127100|transdermal fentanyl matrix
389905|NCT01127100|multicenter
389906|NCT01127100|non-inferiority trial
389907|NCT01127087|Hyperoxaluria
389908|NCT01127087|Oxazyme
389909|NCT01127087|oxalate
389910|NCT01127087|enteric hyperoxaluria
389911|NCT01127074|metastatic breast cancer
389912|NCT01127074|breast cancer stage IV
389913|NCT01127074|vaccination
389914|NCT01127074|CD80
389915|NCT01127074|immunotherapy
389916|NCT01127061|Hypertrophic Cardiomyopathy
389917|NCT01127061|Exercise
389918|NCT01127061|Oxygen consumption
389919|NCT01127048|bronchitis
389920|NCT01127048|coughing
389921|NCT01127048|children
389922|NCT01127048|Ivy
389923|NCT01127048|Hedera helix L.
389924|NCT01127035|allergic rhinitis
389925|NCT01127035|alternaria alternata
389926|NCT01127035|symptom score
389927|NCT01127022|Pregnancy
389928|NCT01127022|Lactation
389929|NCT01127022|Choline
389930|NCT01127022|Cognition
389931|NCT01127022|Biomarkers
389932|NCT01126996|MenC conjugate vaccine
389933|NCT01126996|Healthy children previously vaccinated against MenC
389934|NCT01126970|reduced calorie diet
389935|NCT01126970|orlistat
389936|NCT01126970|velneperit
389937|NCT01126944|heart failure
389938|NCT01126944|resynchronization
389939|NCT01126944|left ventricular assist device
389940|NCT01126931|Crohn disease
389941|NCT01126931|Involuntary weight loss in cancer
389942|NCT01126931|IgA nephropathy
389943|NCT01126931|Depression with reduced appetite
389944|NCT01126918|Eating Disorders
389945|NCT01126918|Obesity
389946|NCT01126918|Body Dissatisfaction
389947|NCT01126918|Female
389948|NCT01126905|Reticulated Haemoglobin Equivalent
389949|NCT01126905|Functional Iron Deficiency
389950|NCT01126905|Response to therapy
389951|NCT01126905|Iron deficiency
389952|NCT01126892|Advanced Disease,
389953|NCT01126892|Resistance,
389954|NCT01126892|Intolerance
389955|NCT01126866|advanced colorectal carcinoma
389956|NCT01126866|CRC
389957|NCT01126866|UICC Stages IV
389958|NCT01126866|liver and/or lung only metastases
389959|NCT01126853|Immunization
389960|NCT01126853|Immunity
389961|NCT01126853|Prevention
389962|NCT01126840|Lynch Syndrome
389963|NCT01126840|Families
389964|NCT01126840|Quality of life
389965|NCT01126840|QOL
389966|NCT01126840|First-degree relatives
389967|NCT01126840|Questionnaire
389968|NCT01126840|Interview
389969|NCT01126827|Bipolar Disorder
389970|NCT01126827|Mood Disorders
389971|NCT01126827|Residual Symptoms
389972|NCT01126827|Depression
389973|NCT01126827|Mania
389974|NCT01126827|Hypomania
389975|NCT01126827|Bipolar
389976|NCT01126827|Bipolar I
389977|NCT01126827|Bipolar II
389978|NCT01126814|Gleevec
389979|NCT01126814|c-kit
389980|NCT01126814|aml
389981|NCT01126775|Systematic prevention, stroke, vascular dementia, silent strokes, cerebral microangiopathy.
389982|NCT01126762|Docosahexaenoic acid
389983|NCT01126762|fish
389984|NCT01126762|pregnancy
389985|NCT01126762|methylmercury
389986|NCT01126762|n-3 polyunsaturated fatty acid
389987|NCT01126749|Locally Advanced or Metastatic Bladder Cancer, including other transitional cell cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)
389988|NCT01126736|neoplams
389989|NCT01126736|lung neoplasms
389990|NCT01126736|Stage IIIB
389991|NCT01126736|IV Nonsquamous Non Small Cell Lung Cancer
389992|NCT01126710|infiltration
389993|NCT01126710|extravasation
389994|NCT01126710|optical monitoring
389995|NCT01126697|Cardiac
389996|NCT01126697|Muscular Dystrophy
389997|NCT01126697|Randomized
389998|NCT01126684|essential hypertension
389999|NCT01126671|vitamin D
390000|NCT01126658|pressure-volume curve
390001|NCT01126658|intracranial pressure
390002|NCT01126658|volume pressure response
390003|NCT01126658|pressure-volume relationship
390004|NCT01126658|mathematical model
390005|NCT01126645|Liver
390006|NCT01126645|HCC
390007|NCT01126632|Colonoscopy
390008|NCT01126619|Psoriasis
390009|NCT01126567|Phase 1 Clinical Trials, Cerebrospinal Fluid, Biomarker
390010|NCT01126554|Prognostic value
390011|NCT01126528|Vitamin D
390012|NCT01126528|cholecalciferol
390013|NCT01126528|Micronutrients
390014|NCT01126528|Developing countries
390015|NCT01126528|Bangladesh
390016|NCT01126528|Infant, Newborn
390017|NCT01126528|Reproductive Health
390018|NCT01126528|Infant, Newborn, Diseases
390019|NCT01126528|Perinatology
390020|NCT01126528|Immunology
390021|NCT01126528|cathelicidin
390022|NCT01126528|Maternal Nutrition Physiology
390023|NCT01126515|brain injury
390024|NCT01126515|sequelae
390025|NCT01126515|stroke
390026|NCT01126515|anoxia
390027|NCT01126515|trauma
390028|NCT01126476|Adults with non-CNS recurrent tumors who have been previously irradiated
390029|NCT01126476|and have a tumor recurrence in or near prior radiation fields
390030|NCT01126463|Hepatocellular carcinomas
390031|NCT01126463|lipiodol
390032|NCT01126463|rhenium
390033|NCT01126463|Non operable Hepatocellular carcinomas
390034|NCT01126450|recurrent colon cancer
390035|NCT01126450|recurrent rectal cancer
390036|NCT01126424|Anti-muscarinics
390037|NCT01126424|Anti-cholinergics
390038|NCT01126424|Cognition
390039|NCT01126424|Solifenacin
390040|NCT01126411|pulmonary hypertension
390041|NCT01126411|autoantibodies
390042|NCT01126411|immunoadsorption
390043|NCT01126411|immunoglobulin substitution
390044|NCT01126411|right ventricular function
390045|NCT01126385|Spinal Diseases
390046|NCT01126385|Bone strength
390047|NCT01126385|Transpedicular fixation
390048|NCT01126385|Dorsal instrumentation
390049|NCT01126385|DensiProbe
390050|NCT01126372|Prostaglandin-dependent Congenital Heart Disease
390051|NCT01126372|Prematurity
390052|NCT01126372|Feeding intolerances
390053|NCT01126372|Necrotizing Enterocolitis
390054|NCT01126372|Regional Oxygen Saturation
390055|NCT01126372|Near Infrared Spectroscopy
390056|NCT01126372|Somanetics INVOS Oxyalert
390057|NCT01126359|Wound Vacuum Assisted Dressings
390058|NCT01126359|Lidocaine
390059|NCT01126359|Dressing change
390060|NCT01126359|Pain management
390061|NCT01126359|palliative care
390062|NCT01126333|Nephrotoxicity, Kidney Transplantation, Graft Survival
390063|NCT01126333|Kidney transplant survival.
390064|NCT01126320|VAP
390065|NCT01126307|refractory epilepsy- greater than 4 seizures in 2 month baseline period
390066|NCT01126294|lumbar laminectomy, melatonin, perioperative, pain, anxiety, analgesia, VAS score
390067|NCT01126268|Eczema
390068|NCT01126268|Atopic dermatitis
390069|NCT01126268|Infection
390070|NCT01126268|Impetigo
390071|NCT01126268|Folliculitis
390072|NCT01126255|vulvar lichen sclerosus
390073|NCT01126255|progesterone
390074|NCT01126255|clobetasol
390075|NCT01126255|randomized controlled trial
390076|NCT01126242|Ankle
390077|NCT01126242|ligament injuries
390078|NCT01126242|non-surgical treatment
390079|NCT01126242|tape
390080|NCT01126242|brace
390081|NCT01126242|orthotic device
390082|NCT01126242|bandage
390083|NCT01126242|cost-effectiveness
390084|NCT01126242|randomized trial
390085|NCT01126229|Resveratrol
390086|NCT01126229|Grape
390087|NCT01126229|Aging
390088|NCT01126229|functional MRI (fMRI)
390089|NCT01126229|Anti-Aging therapeutic
390090|NCT01126229|Oxidative Stress
390091|NCT01126229|Functional Performance
390092|NCT01126216|Radiochemotherapy
390093|NCT01126216|head and neck cancer
390094|NCT01126216|Paclitaxel
390095|NCT01126216|Cisplatin
390096|NCT01126216|5-FU
390097|NCT01126203|Pseudoexfoliation
390098|NCT01126203|Glaucoma
390099|NCT01126203|Ocular Hypertension
390100|NCT01126203|SLT
390101|NCT01126203|Selective Laser Trabeculoplasy (SLT)
390102|NCT01126203|Argon Laser Trabeculoplasty (ALT)
390103|NCT01126177|asthma
390104|NCT01126164|parents
390105|NCT01126164|peer
390106|NCT01126164|basics
390107|NCT01126164|college student drinking
390108|NCT01126151|drinking
390109|NCT01126151|alcohol consequences
390110|NCT01126138|unresectable
390111|NCT01126138|locally advanced
390112|NCT01126138|metastatic
390113|NCT01126138|breast cancer
390114|NCT01126125|iodine
390115|NCT01126125|infant
390116|NCT01126125|breastfeeding
390117|NCT01126125|deficiency
390118|NCT01126112|advanced colorectal cancer; K-RAS; panitumumab
390119|NCT01126112|advanced Wild Type K-RAS colorectal cancer
390120|NCT01126099|double-blind
390121|NCT01126099|treatment
390122|NCT01126099|prazosin
390123|NCT01126099|Disruptive behaviors in Alzheimer's Disease
390124|NCT01126073|niacin/laropiprant
390125|NCT01126073|endothelial function
390126|NCT01126060|Neck dissection
390127|NCT01126047|Lung Diseases
390128|NCT01126034|Metoclopramide
390129|NCT01126034|Randomized Controlled Trial
390130|NCT01126021|Senior citizens
390131|NCT01126021|mental acuity
390132|NCT01126021|memory
390133|NCT01126008|locally advanced Squamous cell carcinoma
390134|NCT01125995|limited disease
390135|NCT01125969|diabetes
390136|NCT01125969|glucose
390137|NCT01125969|peer mentor
390138|NCT01125969|incentives
390139|NCT01125969|behavioral economics
390140|NCT01125969|cost-effectiveness
390141|NCT01125956|Diabetes
390142|NCT01125956|Diabetes mellitus
390143|NCT01125956|HbA1c
390144|NCT01125930|rosacea
390145|NCT01125930|tretinoin
390146|NCT01125930|atralin
390147|NCT01125917|Low back pain
390148|NCT01125917|Opioid
390149|NCT01125917|Transdermal
390150|NCT01125904|Crizotinib
390151|NCT01125891|gemcitabine hydrochloride
390152|NCT01125891|Gemzar
390153|NCT01125891|ON 01910.Na
390154|NCT01125878|satiety
390155|NCT01125878|appetite
390156|NCT01125878|fiber
390157|NCT01125878|starch
390158|NCT01125878|nutrition
390159|NCT01125865|Malignant hilar stricture
390160|NCT01125852|Peptic ulcer hemorrhage
390161|NCT01125852|Peptic ulcer bleeding
390162|NCT01125852|Angiographic embolization
390163|NCT01125852|Arterial embolization
390164|NCT01125852|Angiography
390165|NCT01125839|osteomyelitis
390166|NCT01125839|16S rRNA
390167|NCT01125839|spine
390168|NCT01125839|Magnetic resonance imaging
390169|NCT01125800|Recurrent,
390170|NCT01125800|refractory,
390171|NCT01125800|medulloblastoma,
390172|NCT01125800|rhabdomyosarcoma,
390173|NCT01125800|neuroblastoma,
390174|NCT01125800|hepatoblastoma,
390175|NCT01125800|astrocytoma,
390176|NCT01125800|children,
390177|NCT01125800|pediatric,
390178|NCT01125800|hedgehog pathway inhibitor, adult
390179|NCT01125787|CLL
390180|NCT01125787|bendamustine
390181|NCT01125787|ofatumumab
390182|NCT01125787|blood cancer
390183|NCT01125787|leukemia
390184|NCT01125787|lymphocyte
390185|NCT01125787|hematology
390186|NCT01125787|non-Hodgkin lymphoma
390187|NCT01125787|small lymphocytic lymphoma
390188|NCT01125787|nevada cancer institute
390189|NCT01125787|cephalon
390190|NCT01125787|Glaxosmithkline
390191|NCT01125774|Menstrually related migraine
390192|NCT01125774|migraine
390193|NCT01125774|Premenstrual migraine
390194|NCT01125761|Allergic dermatitis
390195|NCT01125722|Urinary Incontinence
390196|NCT01125722|Overactive Bladder
390197|NCT01125722|Frequency
390198|NCT01125722|Urgency
390199|NCT01125709|Neuromuscular disease
390200|NCT01125709|Duchenne
390201|NCT01125709|Muscular Dystrophy
390202|NCT01125709|DMD
390203|NCT01125709|Strength assessment
390204|NCT01125709|CINRG Quantitative Measurement System
390205|NCT01125709|CQMS
390206|NCT01125709|Hand Held Myometry
390207|NCT01125709|HHM
390208|NCT01125696|mother-to-child transmission
390209|NCT01125696|HIV
390210|NCT01125696|Hepatitis B
390211|NCT01125696|Pregnant women
390212|NCT01125696|Tenofovir
390213|NCT01125696|Infants
390214|NCT01125683|Phase II
390215|NCT01125683|Alzheimer's disease
390216|NCT01125683|EEG
390217|NCT01125683|cognition
390218|NCT01125683|pharmacodynamic
390219|NCT01125670|YM150
390220|NCT01125670|Food effect
390221|NCT01125657|YM150
390222|NCT01125657|bioequivalence study
390223|NCT01125644|necrotic pulmonary infections
390224|NCT01125631|Alzheimer's disease
390225|NCT01125631|amyloid
390226|NCT01125631|antibody
390227|NCT01125631|Japanese
390228|NCT01125618|child mortality
390229|NCT01125618|intervention
390230|NCT01125618|Poverty
390231|NCT01125618|Africa
390232|NCT01125618|Millennium Development Goal
390233|NCT01125618|Millennium Development Goals
390234|NCT01125605|PASCONAL
390235|NCT01125605|nervousness
390236|NCT01125605|nervosity
390237|NCT01125605|sleep disorder
390238|NCT01125592|assess the ability of the IonCleanse machine to remove heavy metals through the feet
390239|NCT01125579|nervousness
390240|NCT01125579|restlessness
390241|NCT01125579|depression
390242|NCT01125579|affective disorder
390243|NCT01125540|Allergic conjunctivitis
390244|NCT01125527|Haemophilus influenzae type b (Hib)
390245|NCT01125527|Vaccine
390246|NCT01125527|Anti PRP antibody
390247|NCT01125514|Heart failure,
390248|NCT01125514|aliskiren,
390249|NCT01125514|furosemide,
390250|NCT01125514|diuretic efficacy,
390251|NCT01125514|interaction
390252|NCT01125488|Maintenance therapy
390253|NCT01125488|LNG-IUS
390254|NCT01125488|recurrence,endometriosis
390255|NCT01125488|Recurrence
390256|NCT01125475|Relapsing Remitting Multiple Sclerosis
390257|NCT01125475|RebiSmart
390258|NCT01125475|Rebif
390259|NCT01125475|Adherence
390260|NCT01125462|Ovulation Induction
390261|NCT01125462|Infertility
390262|NCT01125462|Gonal-f
390263|NCT01125462|FertiQoL
390264|NCT01125462|Quality of Life
390265|NCT01125449|ascorbic acid
390266|NCT01125449|vitamin C
390267|NCT01125449|antioxidants
390268|NCT01125449|vitamins
390269|NCT01125423|Female
390270|NCT01125423|age 18 to 70
390271|NCT01125410|Fluomizin
390272|NCT01125410|Dequalinium chloride
390273|NCT01125410|Bacterial vaginosis
390274|NCT01125410|vaginal therapy
390275|NCT01125397|bariatric surgery
390276|NCT01125397|behavioral weight management
390277|NCT01125397|psychosocial outcomes following bariatric surgery
390278|NCT01125371|Hazardous alcohol use
390279|NCT01125371|Binge drinking
390280|NCT01125371|High risk sexual behaviors
390281|NCT01125371|HIV risk reduction
390282|NCT01125345|hydrophobic acrylic
390283|NCT01125345|PCO
390284|NCT01125345|posterior capsule opacification
390285|NCT01125345|hydrophilic acrylic IO
390286|NCT01125306|Drug consumption
390287|NCT01125306|The Xal-Ease device
390288|NCT01125306|Patient's compliance
390289|NCT01125306|Using a novel Pfizer-Pharmacia device to facilitate the Xalatan/Xalacom instillation and to avoid loss of eye drops
390290|NCT01125293|everolimus
390291|NCT01125293|rituximab
390292|NCT01125293|bortezomib
390293|NCT01125293|RAD001
390294|NCT01125293|Rituxan
390295|NCT01125293|Velcade
390296|NCT01125280|Small bowel occlusion
390297|NCT01125280|Conservative treatment for small bowel occlusion
390298|NCT01125280|Surgical treatment for small bowel occlusion
390299|NCT01125280|Small bowel resection
390300|NCT01125280|Score of severity of small bowel occlusion
390301|NCT01125267|medication adherence
390302|NCT01125267|schizophrenia
390303|NCT01125267|Mexican American
390304|NCT01125267|multifamily groups
390305|NCT01125254|thalassemia major
390306|NCT01125254|calcium channel blockade
390307|NCT01125254|magnetic resonance imaging
390308|NCT01125241|wuling capsule
390309|NCT01125241|epilepsy
390310|NCT01125241|depression
390311|NCT01125241|superiority clinical research
390312|NCT01125228|AIDS
390313|NCT01125228|Antiretroviral
390314|NCT01125228|Kaposi's Sarcoma
390315|NCT01125215|Painful diabetic neuropathy
390316|NCT01125215|Capsaicin
390317|NCT01125215|Nanoparticle
390318|NCT01125215|Quantitative Sensory Testing
390319|NCT01125202|Intervention studies
390320|NCT01125202|Computers, handheld
390321|NCT01125202|Randomized controlled trial
390322|NCT01125202|Sodium, dietary
390323|NCT01125176|CLL
390324|NCT01125163|very low birth weight infants
390325|NCT01125163|anemia
390326|NCT01125163|iron supplementation
390327|NCT01125150|diffuse reflectance spectroscopy
390328|NCT01125137|Keloid
390329|NCT01125137|MMP
390330|NCT01125137|Matrix metalloproteinase
390331|NCT01125137|dermatology
390332|NCT01125124|Pleurodesis
390333|NCT01125124|Malignant pleural effusion
390334|NCT01125124|Silver Nitrate
390335|NCT01125124|Pain
390336|NCT01125098|COPD
390337|NCT01125098|PRO-CT
390338|NCT01125098|antibiotics
390339|NCT01125085|I131
390340|NCT01125085|L19
390341|NCT01125085|antibody
390342|NCT01125085|monoclonal
390343|NCT01125085|multiple brain metastasis
390344|NCT01125085|tumor targeting
390345|NCT01125085|radioimmunotherapy
390346|NCT01125085|Patients with brain metastases of solid tumors (>1), who are not amenable for surgical excision or stereotactic radiosurgery.
390347|NCT01125072|chest pain
390348|NCT01125072|echocardiography
390349|NCT01125072|strain imaging
390350|NCT01125059|hydromorphone
390351|NCT01125059|lumbar posterior spinal fusion
390352|NCT01125059|lumbosacral spondylosis
390353|NCT01125059|Spinal Fusion
390354|NCT01125033|Dialysis, Restless legs syndrome, Ascorbic acid, Vitamin E
390355|NCT01125007|Dental plaque
390356|NCT01125007|Gingival abrasion
390357|NCT01125007|toothbrushing
390358|NCT01124994|Barrett's oesophagus
390359|NCT01124994|High grade intraepithelial neoplasia (HGIEN)
390360|NCT01124981|Fibrinogen concentrate
390361|NCT01124981|Coagulopathy
390362|NCT01124968|User-Computer Interface
390363|NCT01124968|Office Visits
390364|NCT01124968|Primary Health Care
390365|NCT01124968|Patient Satisfaction
390366|NCT01124968|Job Satisfaction
390367|NCT01124968|Health Services Research
390368|NCT01124955|treatment
390369|NCT01124955|acupuncture
390370|NCT01124955|spine
390371|NCT01124929|Intestinal tuberculosis
390372|NCT01124929|Tuberculous peritonitis
390373|NCT01124929|Abdominal tuberculosis
390374|NCT01124916|incontinence
390375|NCT01124916|prolapse
390376|NCT01124916|Abdominal sacrocolpopexy
390377|NCT01124903|dehydration
390378|NCT01124903|hypohydration
390379|NCT01124903|diagnostic accuracy
390380|NCT01124903|biological variation
390381|NCT01124903|hydration assessment
390382|NCT01124903|body mass
390383|NCT01124903|osmolality
390384|NCT01124903|plasma
390385|NCT01124903|saliva
390386|NCT01124903|urine
390387|NCT01124890|acute myocardial infarction
390388|NCT01124890|thrombolysis
390389|NCT01124890|percutaneous coronary interention
390390|NCT01124877|Children and Adolescents with Bipolar I Disorder (manic or mixed)
390514|NCT01124435|toxicity
390391|NCT01124864|Non-small-cell lung cancer
390392|NCT01124864|HSP90
390393|NCT01124864|2nd to 3rd line treatment
390394|NCT01124851|Sleep disorder
390395|NCT01124838|Uveitis
390396|NCT01124825|Anesthesia induction and maintenance
390397|NCT01124825|Surgery
390398|NCT01124812|I131
390399|NCT01124812|L19
390400|NCT01124812|antibody
390401|NCT01124812|monoclonal
390402|NCT01124812|NSCLC
390403|NCT01124812|lung
390404|NCT01124812|tumor targeting
390405|NCT01124812|radioimmunotherapy
390406|NCT01124812|Patients with newly diagnosed inoperable, locally-advanced (stage III) NSCLC
390407|NCT01124799|Hepatitis C virus
390408|NCT01124799|TMC435-TiDP16-C125
390409|NCT01124799|TMC435-C125
390410|NCT01124799|TMC435
390411|NCT01124799|TMC435350
390412|NCT01124799|protease inhibitor
390413|NCT01124799|HCV
390414|NCT01124799|Hepatitis C
390415|NCT01124799|photosensitivity
390416|NCT01124799|phototoxicity
390417|NCT01124786|cancer
390418|NCT01124786|metastatic
390419|NCT01124786|pancreatic
390420|NCT01124786|pancreas
390421|NCT01124786|adenocarcinoma
390422|NCT01124786|gemcitabine
390423|NCT01124786|human equilibrative nucleoside transporter-1 (hENT1)
390424|NCT01124786|CO-1.01
390425|NCT01124786|CO-101
390426|NCT01124786|CO101
390427|NCT01124786|Stage 4
390428|NCT01124786|Stage IV
390429|NCT01124773|cognition
390430|NCT01124773|memory
390431|NCT01124773|hormone therapy
390432|NCT01124760|open label
390433|NCT01124760|2-consecutive-group
390434|NCT01124760|2-period
390435|NCT01124760|1-sequence crossover study
390436|NCT01124747|ASP1585
390437|NCT01124747|Healthy Volunteers
390438|NCT01124734|metastatic melanoma
390439|NCT01124721|Cognitive training
390440|NCT01124708|ADHD
390441|NCT01124708|Attention Deficit Hyperactive Disorder
390442|NCT01124695|estrogen receptor-positive breast cancer
390443|NCT01124695|male breast cancer
390444|NCT01124695|progesterone receptor-positive breast cancer
390445|NCT01124695|recurrent breast cancer
390446|NCT01124695|stage IV breast cancer
390447|NCT01124682|adenocarcinoma of the bladder
390448|NCT01124682|squamous cell carcinoma of the bladder
390449|NCT01124682|transitional cell carcinoma of the bladder
390450|NCT01124682|recurrent bladder cancer
390451|NCT01124682|stage II bladder cancer
390452|NCT01124682|stage III bladder cancer
390453|NCT01124682|stage IV bladder cancer
390454|NCT01124669|recurrent non-small cell lung cancer
390455|NCT01124669|stage IIIB non-small cell lung cancer
390456|NCT01124669|stage IV non-small cell lung cancer
390457|NCT01124656|angiotensin II receptor blocker
390458|NCT01124656|thiazolidinediones
390459|NCT01124656|combination
390460|NCT01124656|Actos
390461|NCT01124656|HbA1c
390462|NCT01124656|Type 2 diabetes
390463|NCT01124656|Drug Therapy
390464|NCT01124656|Hypertension
390465|NCT01124643|Replagal
390466|NCT01124643|Agalsidase alfa
390467|NCT01124643|Alpha-Galactosidase
390468|NCT01124643|Enzyme Replacement Therapy
390469|NCT01124617|Chronic pain
390470|NCT01124617|Diabetic Neuropathic Pain
390471|NCT01124617|Neuralgia, Postherpetic
390472|NCT01124617|Tapentadol hydrochloride extended-release
390473|NCT01124617|JNS024ER
390474|NCT01124617|Placebo
390475|NCT01124604|Pain
390476|NCT01124604|Low Back Pain
390477|NCT01124604|Back Pain
390478|NCT01124604|Osteoarthritis, Knee
390479|NCT01124604|Tapentadol
390480|NCT01124604|Tapentadol Hydrochloride Extended Release
390481|NCT01124578|Ventilators, Mechanical
390482|NCT01124565|Lateral Canthal Lines
390483|NCT01124565|Crow's Feet
390484|NCT01124565|Facial Wrinkles
390485|NCT01124552|Lateral Canthal Lines
390486|NCT01124552|Crow's Feet Wrinkles
390487|NCT01124552|Facial Wrinkles
390488|NCT01124539|Adult Patients
390489|NCT01124539|Recurrence of Glioblastoma Multiforme
390490|NCT01124539|Recurrence of GBM
390491|NCT01124539|Gliosarcoma
390492|NCT01124526|R F C treatment in patients with Non Hodgkin Lymphoma
390493|NCT01124513|Melanin Index
390494|NCT01124513|Fitzpatrick Skin Phototype
390495|NCT01124513|Videodermoscopy
390496|NCT01124513|Spectrophotometry
390497|NCT01124500|methylphenidate
390498|NCT01124500|transdermal patch
390499|NCT01124500|placebo
390500|NCT01124500|fatigue
390501|NCT01124500|10-020
390502|NCT01124487|fat
390503|NCT01124487|inflammation
390504|NCT01124487|lipids
390505|NCT01124487|total cholesterol
390506|NCT01124487|Triglycerides
390507|NCT01124487|insulin sensitivity
390508|NCT01124461|Malignant Brain Tumors
390509|NCT01124461|Cancer of the Brain
390510|NCT01124435|Carboplatin plus Celecoxib
390511|NCT01124435|Pre-treated Recurrent Ovarian Cancer Patients
390512|NCT01124435|The antitumor activity and potential adverse effects
390513|NCT01124435|tumor response rate
390515|NCT01124435|progression free survival
390516|NCT01124435|duration of response
390517|NCT01124435|quality of life
390518|NCT01124422|endurance shuttle walk test
390519|NCT01124422|chronic obstructive pulmonary disease
390520|NCT01124422|fluticasone propionate
390521|NCT01124422|dyspnea
390522|NCT01124422|exercise endurance time
390523|NCT01124422|tiotropium
390524|NCT01124422|salmeterol
390525|NCT01124422|exercise inspiratory capacity
390526|NCT01124422|quality of life
390527|NCT01124409|IGRT
390528|NCT01124409|3DCRT
390529|NCT01124409|EPID
390530|NCT01124409|CBCT
390531|NCT01124409|HNSCC
390532|NCT01124383|Glycine absorption
390533|NCT01124383|Operative hysteroscopy
390534|NCT01124383|Endometrial resection
390535|NCT01124383|General anesthesia
390536|NCT01124383|Local anesthesia
390537|NCT01124370|Sleep Disordered Breathing
390538|NCT01124370|Cheyne Stokes Respiration
390539|NCT01124370|Periodic Breathing
390540|NCT01124370|Sleep Apnea
390541|NCT01124370|Central Sleep Apnea
390542|NCT01124357|Heavy menstrual bleeding
390543|NCT01124357|menorrhagia
390544|NCT01124357|ThermachoiceTM
390545|NCT01124357|NovaSureTM
390546|NCT01124357|Endometrail Ablation
390547|NCT01124331|prospective meta-analysis
390548|NCT01124331|preterm infant
390549|NCT01124331|pulse oximetry
390550|NCT01124331|oxygen saturation
390551|NCT01124318|Lactofiltrum
390552|NCT01124318|atopic dermatitis
390553|NCT01124318|itching
390554|NCT01124318|Dermatological Index of Life Quality
390555|NCT01124318|SCORAD
390556|NCT01124318|Behavioral Rating Scores
390557|NCT01124305|Total Knee Arthroplasty
390558|NCT01124305|Instrumentation
390559|NCT01124292|Disability
390560|NCT01124292|Quadriplegia
390561|NCT01124292|Paralysis
390562|NCT01124292|Assistive technology
390563|NCT01124292|Quality of life
390564|NCT01124292|Computer access
390565|NCT01124292|Wheeled mobility
390566|NCT01124279|Amgen
390567|NCT01124279|Healthy
390568|NCT01124279|Adult
390569|NCT01124266|polyp
390570|NCT01124266|adenoma
390571|NCT01124266|screening
390572|NCT01124266|colonoscopy
390573|NCT01124266|diagnosis
390574|NCT01124253|adjuvant therapy
390575|NCT01124253|non-small cell lung cancer
390576|NCT01124253|vinorelbine
390577|NCT01124253|cisplatin
390578|NCT01124253|recombinant human endostatin
390579|NCT01124253|endostar
390580|NCT01124240|Glioblastoma Multiforme
390581|NCT01124227|Congestive Heart Failure
390582|NCT01124227|Peritoneal Dialysis
390583|NCT01124227|Symptomatic improvement
390584|NCT01124227|Renal function
390585|NCT01124214|Barrett's
390586|NCT01124214|BE
390587|NCT01124214|esophageal cancer
390588|NCT01124214|esophageal dysplasia
390589|NCT01124201|low back pain
390590|NCT01124201|clinical trial
390591|NCT01124201|stabilization
390592|NCT01124201|muscle stretching exercises
390593|NCT01124201|exercise therapy
390594|NCT01124188|Geriatric psychiatry
390595|NCT01124188|Aged
390596|NCT01124188|Elderly
390597|NCT01124188|Venlafaxine
390598|NCT01124188|Self efficacy
390599|NCT01124188|Pain
390600|NCT01124188|Psychotherapy
390601|NCT01124188|Effexor
390602|NCT01124175|Bioequivalence
390603|NCT01124175|Healthy Subjects
390604|NCT01124162|Bioequivalence
390605|NCT01124162|Healthy Subjects
390606|NCT01124136|Chronic Heart Failure
390607|NCT01124136|Neurostimulation
390608|NCT01124123|Pharmacokinetics
390609|NCT01124123|Oral bioavailability
390610|NCT01124123|absorption
390611|NCT01124123|AUC
390612|NCT01124123|Bioequivalence
390613|NCT01124123|Bioavailability study
390614|NCT01124110|Operating Engineers
390615|NCT01124110|Smoking Cessation
390616|NCT01124097|post herpetic neuralgia
390617|NCT01124071|Korean Diet
390618|NCT01124058|restarting warfarin
390619|NCT01124058|time to therapeutic INR
390620|NCT01124045|Pediatric
390621|NCT01124045|Cataracts
390622|NCT01124045|Inflammation
390623|NCT01124045|Durezol
390624|NCT01124045|Pred Forte
390625|NCT01124045|Difluprednate
390626|NCT01124045|Prednisolone
390627|NCT01124019|Women undergoing screening mammography will be chosen if they are between the ages of 40 and 65.
390628|NCT01123993|Thai traditional music
390629|NCT01123993|dementia
390630|NCT01123993|Cognitive function
390631|NCT01123993|behavioural problem
390632|NCT01123993|sleep quality
390633|NCT01123993|psychological health
390634|NCT01123993|quality of sleep
390635|NCT01123967|nicotine replacement therapy
390636|NCT01123967|smoking cessation
390637|NCT01123967|tobacco dependent
390638|NCT01123954|Seasonal influenza
390639|NCT01123954|Vaccine
390640|NCT01123941|Typhoid fever
390641|NCT01123941|Glycoconjugate vaccine
390642|NCT01123941|Carrier protein
390643|NCT01123941|Immunogenicity
390644|NCT01123928|cataract
390645|NCT01123928|counseling
390646|NCT01123928|surgical uptake
390647|NCT01123928|follow-up
390648|NCT01123915|HIV
390649|NCT01123915|Therapeutic
390650|NCT01123915|Immunotherapy
390651|NCT01123915|Acquired Immunodeficiency Syndrome
390652|NCT01123915|Virus Diseases
390653|NCT01123915|Lentivirus Infections
390654|NCT01123915|Human Immunodeficiency Virus
390655|NCT01123902|Breathlessness
390656|NCT01123902|Dyspnea
390657|NCT01123902|Hand-held fan
390658|NCT01123902|Palliative Care
390659|NCT01123889|subacromial impingement
390660|NCT01123889|partial thickness rotator cuff
390661|NCT01123889|PRP
390662|NCT01123889|platelet rich plasma
390663|NCT01123876|Gastric Cancer
390664|NCT01123863|Neuro cognitive deficits;
390665|NCT01123863|Brigance pre-school screen;
390666|NCT01123850|CopiOs
390667|NCT01123850|Degenerative spondylolisthesis,
390668|NCT01123850|stenosis with instability, or
390669|NCT01123850|degenerative disc disease as diagnosed by radicular signs and/or imaging studies
390670|NCT01123824|healthy subjects
390671|NCT01123811|adenocarcinoma
390672|NCT01123811|gastric cancer
390673|NCT01123811|esophagogastric junction cancer
390674|NCT01123798|near infrared spectroscopy
390675|NCT01123798|lower extremity injury
390676|NCT01123785|glaucoma
390677|NCT01123785|ocular hypertension
390678|NCT01123785|adenosine agonist
390679|NCT01123785|eye drop
390680|NCT01123785|primary open angle glaucoma
390681|NCT01123772|adenosine agonist
390682|NCT01123772|eye drop
390683|NCT01123772|elderly volunteer
390684|NCT01123772|older healthy volunteer
390685|NCT01123759|Fish
390686|NCT01123759|mercury
390687|NCT01123759|omega-3 fatty acids
390688|NCT01123759|infant
390689|NCT01123759|brain development
390690|NCT01123759|pregnancy
390691|NCT01123759|nursing mother
390692|NCT01123759|dietary recommendations
390693|NCT01123759|Hair mercury
390694|NCT01123759|Blood mercury
390695|NCT01123759|Recommendations for pregnant or nursing women
390696|NCT01123759|Infant brain health
390697|NCT01123746|Seizure
390698|NCT01123746|electrolyte
390699|NCT01123746|risk factor
390700|NCT01123733|Baby-friendly hospitals
390701|NCT01123733|Non baby-friendly hospitals
390702|NCT01123733|Breastfeeding
390703|NCT01123733|Ten steps for successful breastfeeding
390704|NCT01123707|Major Depressive Disorder
390705|NCT01123707|MDD
390706|NCT01123707|Depression
390707|NCT01123694|xeroderma pigmentosum
390708|NCT01123694|quality of life
390709|NCT01123694|DLQI
390710|NCT01123694|CDLQI
390711|NCT01123681|Respiration, Artificial
390712|NCT01123681|Pneumonia, Ventilator-Associated
390713|NCT01123681|Critical Illness
390714|NCT01123668|Smoking
390715|NCT01123668|ADHD
390716|NCT01123668|Nicotine
390717|NCT01123668|Methylphenidate
390718|NCT01123668|function Magnetic Resonance Imaging
390719|NCT01123668|Neurobiological basis of abstinence-induced deficits in response inhibition
390720|NCT01123642|post-traumatic stress disorder
390721|NCT01123642|depressive disorder
390722|NCT01123642|alcoholism
390723|NCT01123642|Longitudinal studies
390724|NCT01123642|readjustment
390725|NCT01123616|surgical site infection
390726|NCT01123616|elective colorectal surgery
390727|NCT01123616|level of surgical site infection
390728|NCT01123616|complication of surgical site infection
390729|NCT01123616|type of changed bandage
390730|NCT01123616|frequency of bandage changing
390731|NCT01123603|frequency
390732|NCT01123603|women
390733|NCT01123603|fibroids
390734|NCT01123603|uterine artery embolization
390735|NCT01123603|myomectomy
390736|NCT01123603|hysterectomy
390737|NCT01123590|Thymoma
390738|NCT01123590|Autoimmune diseases
390739|NCT01123590|Immunodeficiency
390740|NCT01123577|Self Blood Pressure Monitoring
390741|NCT01123577|SBPM
390742|NCT01123577|Randomized Control Trial
390743|NCT01123577|Hypertension (HTN)
390744|NCT01123577|Cardiovascular Disease (CVD)
390745|NCT01123577|HTN
390746|NCT01123577|CVD
390747|NCT01123564|macular edema secondary to retinal vein occlusion
390748|NCT01123551|Nebulized morphine
390749|NCT01123551|Intravenous morphine
390750|NCT01123551|Post traumatic
390751|NCT01123551|Pain
390752|NCT01123551|Emergency department
390753|NCT01123512|Vertebral Compression Fracture
390754|NCT01123512|Kyphoplasty
390755|NCT01123512|Spine
390756|NCT01123512|Vertebral Body Compression Fracture
390757|NCT01123512|Back Pain
390758|NCT01123499|G-CSF
390759|NCT01123499|Plerixafor
390760|NCT01123499|Normal Volunteer
390761|NCT01123499|Apheresis
390762|NCT01123499|Healthy Volunteer
390763|NCT01123499|HV
390764|NCT01123486|Intravenous opioids
390765|NCT01123486|Patient Controlled Analgesia
390766|NCT01123486|volunteer pharmacokinetic-pharmacodynamic study
390767|NCT01123473|adenocarcinoma of the gastroesophageal junction
390768|NCT01123473|adenocarcinoma of the stomach
390769|NCT01123473|stage IIIA gastric cancer
390770|NCT01123473|stage IIIB gastric cancer
390771|NCT01123473|stage IIIC gastric cancer
390772|NCT01123473|stage IV gastric cancer
390773|NCT01123460|non-small cell lung cancer
390774|NCT01123434|prostate cancer
390775|NCT01123434|adjuvant
390776|NCT01123434|hormonal
390777|NCT01123421|osteoporosis
390778|NCT01123421|fracture risk
390779|NCT01123421|aging
390780|NCT01123421|tibia
390781|NCT01123421|sonometer
390782|NCT01123421|ultrasound
390783|NCT01123421|BMD
390784|NCT01123421|bone mineral density
390785|NCT01123421|DXA
390786|NCT01123421|3D-HRpQT
390787|NCT01123421|waveform profiles
390788|NCT01123408|schizophrenia
390789|NCT01123408|aggression
390790|NCT01123408|clozapine
390791|NCT01123408|olanzapine
390792|NCT01123395|bioavailability
390793|NCT01123382|Stroke
390794|NCT01123382|Shoulder pain
390795|NCT01123382|Electrical stimulation
390796|NCT01123382|Neuromuscular stimulation
390797|NCT01123382|Intramuscular stimulation
390798|NCT01123369|Sickle Cell Disease
390799|NCT01123356|Relapsed chronic lymphocytic leukemia
390800|NCT01123343|limbal relaxing incision
390801|NCT01123343|LRI
390802|NCT01123343|capsulorhexis
390803|NCT01123343|surgical guidance
390804|NCT01123343|3d visualization
390805|NCT01123317|Schizophrenia
390806|NCT01123317|PET
390807|NCT01123317|Oxytocin
390808|NCT01123304|melanoma
390809|NCT01123291|follow-up coronary angiography
390810|NCT01123278|Adiponectin
390811|NCT01123278|Resistin
390812|NCT01123278|Adipocytes
390813|NCT01123278|Testosterone
390814|NCT01123278|Aging
390815|NCT01123278|HOMA-IR
390816|NCT01123278|Insulin
390817|NCT01123278|Hypogonadism
390818|NCT01123278|Metabolic Syndrome
390819|NCT01123278|Obesity
390820|NCT01123278|Erectile Dysfunction
390821|NCT01123265|PsA
390822|NCT01123265|methotrexate
390823|NCT01123265|Anti-TNF
390824|NCT01123265|TNF
390825|NCT01123265|DC-Stamp
390826|NCT01123252|Lactobacillus casei
390827|NCT01123239|Healthcare Disparities
390828|NCT01123213|pelvic organ prolapse
390829|NCT01123213|pessary fitting
390830|NCT01123187|diabetes type 1
390831|NCT01123187|kidney transplantation
390832|NCT01123187|islet
390833|NCT01123187|hypoglycemia
390834|NCT01123174|Suicide
390835|NCT01123174|case management algorithm
390836|NCT01123174|suicidal behaviors
390837|NCT01123174|prevention of suicide
390838|NCT01123161|Hypothermia
390839|NCT01123161|Molecular Mechanisms of Pharmacological Action
390840|NCT01123161|Cerebral Infarction
390841|NCT01123161|Hematologic Agents
390842|NCT01123161|Stroke
390843|NCT01123161|Nervous System Diseases
390844|NCT01123161|Vascular Diseases
390845|NCT01123161|Tissue Plasminogen Activator
390846|NCT01123161|Central Nervous System Diseases
390847|NCT01123161|Fibrinolytic Agents
390848|NCT01123161|Cardiovascular Agents
390849|NCT01123161|Body Temperature Changes
390850|NCT01123161|Brain Diseases
390851|NCT01123161|Cerebrovascular Disorders
390852|NCT01123161|Pharmacologic Actions
390853|NCT01123161|Signs and Symptoms
390854|NCT01123161|Fibrin Modulating Agents
390855|NCT01123161|Therapeutic Uses
390856|NCT01123161|Brain Ischemia
390857|NCT01123161|Cardiovascular Diseases
390858|NCT01123161|Brain Infarction
390859|NCT01123161|Plasminogen
390860|NCT01123161|cooling
390861|NCT01123161|tPA
390862|NCT01123161|thrombolysis
390863|NCT01123148|Brain computer interface
390864|NCT01123148|wheelchair control
390865|NCT01123135|urodynamic stress incontinence
390866|NCT01123135|postmenopausal women
390867|NCT01123109|nulliparous women
390868|NCT01123096|Stress urinary incontinence
390869|NCT01123083|new onset type 1 diabetes
390870|NCT01123083|juvenile diabetes
390871|NCT01123083|T1DM
390872|NCT01123083|Type 1 diabetes
390873|NCT01123057|keratoconus
390874|NCT01123057|collagen cross-linking
390875|NCT01123057|LASIK ectasia
390876|NCT01123057|keratoconus,lasik ectasia
390877|NCT01123018|Memory Loss
390878|NCT01122992|Limbal relaxing incision
390879|NCT01122992|Astigmatic correction
390880|NCT01122992|Phacoemulsification surgery
390881|NCT01122992|Chinese eyes
390882|NCT01122966|trabeculectomy
390883|NCT01122953|Bioequivalence
390884|NCT01122953|EPAMIN
390885|NCT01122953|PHENYTOIN
390886|NCT01122940|Bioequivalence
390887|NCT01122940|Phenytoin
390888|NCT01122940|Epamin
390889|NCT01122927|schizophrenia
390890|NCT01122927|adolescent
390891|NCT01122927|bipolar
390892|NCT01122914|Kineret
390893|NCT01122914|Anakinra
390894|NCT01122914|Atopic Dermatitis
390895|NCT01122914|Eczema
390896|NCT01122914|Allergic Disease
390897|NCT01122862|tooth plaque
390898|NCT01122849|trouble with sleep
390899|NCT01122849|night time nasal congestion
390900|NCT01122836|Massage
390901|NCT01122836|Chronic Neck Pain
390902|NCT01122836|Dosing Study
390903|NCT01122823|Chronic Disease Self-Management Program (CDSMP)
390904|NCT01122810|Diagnostic accuracy of coronary angiography
390905|NCT01122810|Transplant heart patients
390906|NCT01122810|X-Ray and contrast agent exposure
390907|NCT01122810|Coronary stenosis
390908|NCT01122797|PNPLA3
390909|NCT01122797|fibrosis
390910|NCT01122797|cirrhosis
390911|NCT01122797|alcoholic liver disease
390912|NCT01122784|Plague
390913|NCT01122784|Vaccine
390914|NCT01122771|visceral leishmaniasis
390915|NCT01122771|phase III
390916|NCT01122771|randomised ccontrolled trial
390917|NCT01122771|Bangladesh
390918|NCT01122771|Combination treatment
390919|NCT01122771|Ambisome
390920|NCT01122771|miltefosine
390921|NCT01122771|paromomycin
390922|NCT01122758|Cohort
390923|NCT01122758|COPD
390924|NCT01122758|Natural history
390925|NCT01122758|Phenotyping
390926|NCT01122758|Smoking
390927|NCT01122745|continuous block
390928|NCT01122745|single shot
390929|NCT01122745|interscalene
390930|NCT01122745|rotator cuff surgery
390931|NCT01122732|nerve block
390932|NCT01122732|continuous catheter
390933|NCT01122732|shoulder surgery
390934|NCT01122732|pain control after total shoulder arthroplasty
390935|NCT01122719|Optima
390936|NCT01122719|Tacrolimus
390937|NCT01122719|Drug eluting stent
390938|NCT01122706|tai ji
390939|NCT01122706|psychosocial stress
390940|NCT01122706|primary prevention
390941|NCT01122706|Trier Social Stress Test
390942|NCT01122706|salivary cortisol
390943|NCT01122706|salivary alpha amylase
390944|NCT01122706|heart rate variability
390945|NCT01122706|stress management
390946|NCT01122693|Regional Anesthesia
390947|NCT01122693|Pain Medicine
390948|NCT01122693|Ultrasound
390949|NCT01122693|Nerve Blocks
390950|NCT01122667|Renal Insufficiency
390951|NCT01122641|Insulin resistance
390952|NCT01122641|incretins
390953|NCT01122641|DPP4 inhibitors
390954|NCT01122641|vildagliptin
390955|NCT01122641|microcirculation
390956|NCT01122628|Distal Radial Fracture
390957|NCT01122628|Volar Locking Plate
390958|NCT01122615|Kidney
390959|NCT01122615|metastatic renal cell carcinoma
390960|NCT01122615|RCC
390961|NCT01122615|Sunitinib
390962|NCT01122615|Sunitinib Malate
390963|NCT01122615|Sutent
390964|NCT01122615|Temsirolimus
390965|NCT01122615|Torisel
390966|NCT01122602|Aspirin
390967|NCT01122589|Smoking Abstinence
390968|NCT01122589|Smoking Cessation
390969|NCT01122576|Intra Ocular Lens
390970|NCT01122576|Ocular surgery
390971|NCT01122576|Phacoemulsification
390972|NCT01122563|OABSS
390973|NCT01122563|IPSS
390974|NCT01122563|PPBC
390975|NCT01122563|3-day micturition diary
390976|NCT01122563|Solifenacin
390977|NCT01122550|OABSS
390978|NCT01122550|IPSS
390979|NCT01122550|PPBC
390980|NCT01122550|3-day micturition diary
390981|NCT01122537|Meningitis
390982|NCT01122537|infection
390983|NCT01122537|cerebrospinal fluid
390984|NCT01122537|procalcitonin
390985|NCT01122537|adenosine deaminase
390986|NCT01122524|Trisomy 21
390987|NCT01122472|lenalidomide (Revlimid)
390988|NCT01122472|diffuse large B-cell lymphoma
390989|NCT01122472|phase III study
390990|NCT01122472|after R-CHOP
390991|NCT01122472|Maintenance treatment
390992|NCT01122472|Maintenance
390993|NCT01122459|Perioperative intravenous fluids
390994|NCT01122446|Alum-GAD
390995|NCT01122446|Type 1 diabetes
390996|NCT01122446|prevention
390997|NCT01122446|immune tolerance
390998|NCT01122446|glucose tolerance
390999|NCT01122446|glutamate decarboxylase autoantibodies
391000|NCT01122433|difficult airway
391001|NCT01122433|indirect laryngoscopy
391002|NCT01122433|C-MAC video laryngoscope
391003|NCT01122420|Obesity
391004|NCT01122394|stroke
391005|NCT01122394|recurrence
391006|NCT01122394|blood pressure
391007|NCT01122394|prevention
391008|NCT01122381|headache, migraine
391009|NCT01122381|depression
391010|NCT01122381|disability evaluation
391011|NCT01122381|weight gain
391012|NCT01122368|Micafungin
391013|NCT01122368|mycoses
391014|NCT01122368|invasive fungal infection
391015|NCT01122368|intra-abdominal surgery
391016|NCT01122368|intra-abdominal infection
391017|NCT01122342|Testosterone
391018|NCT01122342|Vaginal administration
391019|NCT01122342|Aromatase inhibitors
391020|NCT01122329|dementia
391021|NCT01122316|Heart Failure
391022|NCT01122316|Diabetes
391023|NCT01122316|Metformin
391024|NCT01122303|Autologous serum eye drops
391025|NCT01122303|EGF
391026|NCT01122303|TGF-β1
391027|NCT01122303|TGF-β2
391028|NCT01122303|Fibronectin
391029|NCT01122303|Stevens-Johnson syndrome
391030|NCT01122303|Dry eye
391031|NCT01122290|Emotional eating
391032|NCT01122290|Eating in the absence of hunger
391033|NCT01122290|emotion induction
391034|NCT01122277|Volume therapy
391035|NCT01122277|Fluid therapy
391036|NCT01122277|Patients in ICU
391037|NCT01122264|Erectile Dysfunction
391038|NCT01122251|hypertension
391039|NCT01122251|lercanidipine
391040|NCT01122251|valsartan
391041|NCT01122238|Smoking
391042|NCT01122238|Smoking Cessation
391043|NCT01122238|Motivation
391044|NCT01122238|Nicotine Dependence
391045|NCT01122225|septic shock
391046|NCT01122225|medical intensive care
391047|NCT01122212|intracerebral hemorrhage
391048|NCT01122212|ct scans
391049|NCT01122212|protein s100
391050|NCT01122212|inpatient treatment
391051|NCT01122186|Medication Adherence
391052|NCT01122186|Methamphetamine Use
391053|NCT01122186|Sexual Risk
391054|NCT01122186|Poly-substance Use
391055|NCT01122186|HIV
391056|NCT01122186|Treatment
391057|NCT01122186|Motivational Interviewing
391058|NCT01122186|Cognitive Behavioral Skills Training
391059|NCT01122186|Men Who Have Sex With Men
391060|NCT01122173|Atrial Fibrillation
391061|NCT01122173|Robotic Control
391062|NCT01122173|Remote Control
391063|NCT01122160|anthocyanin
391064|NCT01122160|omeprazole
391065|NCT01122160|Prilosec
391066|NCT01122160|gastric pH
391067|NCT01122160|proton pump inhibitor
391068|NCT01122160|PPI
391069|NCT01122160|nutrition
391070|NCT01122147|Aphthous stomatitis; Herbal medicines; Matricaria Chamomilla
391071|NCT01122134|severe
391072|NCT01122134|malaria
391073|NCT01122134|artesunate
391074|NCT01122134|intravenous
391075|NCT01122121|Drug Therapy
391076|NCT01122121|Radiotherapy
391077|NCT01122108|Bile Acid Sequestrant
391078|NCT01122108|Resin
391079|NCT01122108|Lipids
391080|NCT01122108|Glucose
391081|NCT01122108|Cholesterol
391082|NCT01122108|Diabetes Mellitus
391083|NCT01122108|Bile Acid Sequestrant Acceptability Scale
391084|NCT01122095|Psoriasis
391085|NCT01122095|Cardiovascular risk
391086|NCT01122082|energy intake
391087|NCT01122082|energy expenditure
391088|NCT01122082|macronutrient selection
391089|NCT01122056|Multiple Sclerosis
391090|NCT01122056|b1b-interferon
391091|NCT01122056|Fatigue
391092|NCT01122056|Exercise
391093|NCT01122043|Endoglide
391094|NCT01122043|Endothelial Keratoplasty
391095|NCT01122043|Donor Insertion
391096|NCT01122043|DSAEK
391097|NCT01122043|Corneal Transplant
391098|NCT01122043|Patients with Bullous Keratopathy
391099|NCT01122030|Chronic pain
391100|NCT01122030|Opioid physical dependence
391101|NCT01121991|Infertility
391102|NCT01121991|Ovarian Stimulation
391103|NCT01121991|Luveris
391104|NCT01121991|Lutropin alpha
391105|NCT01121991|Controlled ovarian stimulation
391106|NCT01121991|Reproductive techniques, assisted
391107|NCT01121978|macular tractional maculopathy
391108|NCT01121978|pathologic myopia
391109|NCT01121965|macular hole
391110|NCT01121965|impending macular hole
391111|NCT01121965|stage 1 macular hole
391112|NCT01121952|Ankle joint
391113|NCT01121952|Talo-crural joint
391114|NCT01121952|Vertical jump
391115|NCT01121952|Chiropractic manipulation (HVLA)
391116|NCT01121952|ROM
391117|NCT01121952|Proprioception
391118|NCT01121952|Pain
391119|NCT01121939|advanced neuroendocrine
391120|NCT01121939|Gastrointestinal
391121|NCT01121939|Bevacizumab
391122|NCT01121939|Avastin
391123|NCT01121939|Pertuzumab
391124|NCT01121939|Omnitarg
391125|NCT01121939|2C4
391126|NCT01121939|Sandostatin
391127|NCT01121939|Octreotide
391128|NCT01121926|Healthy subjects
391129|NCT01121926|Bioavailability
391130|NCT01121926|Pharmacokinetics
391131|NCT01121926|Trazodone
391132|NCT01121926|Steady-state
391133|NCT01121913|Healthy subjects
391134|NCT01121900|Healthy subjects
391135|NCT01121887|smoking cessation
391136|NCT01121887|telephone counselling
391137|NCT01121887|motivational interviewing
391138|NCT01121887|treatment integrity
391139|NCT01121887|Tobacco Smoking
391140|NCT01121874|CMC arthritis
391141|NCT01121874|thumb carpometacarpal arthritis
391142|NCT01121874|basal joint arthritis
391143|NCT01121874|thumb CMC arthritis
391144|NCT01121861|efficacy
391145|NCT01121861|safety
391146|NCT01121861|predictability
391147|NCT01121861|stability
391148|NCT01121861|toric IOL
391149|NCT01121861|refractive astigmatism
391150|NCT01121861|phacoemulsification
391151|NCT01121822|Influenza
391152|NCT01121822|Influenza vaccine
391153|NCT01121822|Influenza virus
391154|NCT01121822|Intramuscular
391155|NCT01121809|Raltegravir
391156|NCT01121809|etravirine
391157|NCT01121809|pharmacokinetics
391158|NCT01121809|intracellular
391159|NCT01121757|relapsed
391160|NCT01121757|refractory
391161|NCT01121757|lymphoma
391162|NCT01121757|follicular
391163|NCT01121757|marginal zone
391164|NCT01121744|Coronary Artery Disease
391165|NCT01121744|Drug Eluting Stents (DES)
391166|NCT01121744|Pharmacokinetic (PK)
391167|NCT01121731|Chronic Hepatitis C Viral Infection
391168|NCT01121731|Interferon alfa-5
391169|NCT01121731|Interferon
391170|NCT01121718|lymph node
391171|NCT01121705|genotype 3
391172|NCT01121705|Combination treatment
391173|NCT01121705|Short treatment
391174|NCT01121692|Couples
391175|NCT01121692|Alcohol use
391176|NCT01121692|HIV risk
391177|NCT01121692|Outreach
391178|NCT01121679|Older patients
391179|NCT01121679|Aged, 80 and Over
391180|NCT01121679|Cardiology
391181|NCT01121666|Assisted reproductive treatment
391182|NCT01121666|Superovulation
391183|NCT01121666|Follitropin alfa
391184|NCT01121666|r-hFSH
391185|NCT01121666|AFOLIA
391186|NCT01121653|Neuropathic pain, magnesium
391187|NCT01121640|Ovarian Cancer
391188|NCT01121640|Screening
391189|NCT01121640|Biomarkers
391190|NCT01121627|Computerized Cognitive training
391191|NCT01121627|Quality of life
391192|NCT01121627|Gait Function
391193|NCT01121627|Executive Function
391194|NCT01121614|Harmonic scalpel
391195|NCT01121614|ultrasonic scalpel
391196|NCT01121614|LOTUS
391197|NCT01121614|LigaSure
391198|NCT01121614|vessel sealing
391199|NCT01121614|burst pressure
391200|NCT01121614|collateral damage
391201|NCT01121588|neoplasm malignant
391202|NCT01121588|lymphoma
391203|NCT01121588|neuroblastoma
391204|NCT01121588|Crizotinib
391205|NCT01121588|anaplastic lymphoma kinase
391206|NCT01121588|ALK
391207|NCT01121575|Phase 1 acquired resistance to erlotinib or gefitinib cMET inhibitor EGFR inhibitor panHER inhibitor combination trial Crizotinib
391208|NCT01121562|Neuroendocrine tumors
391209|NCT01121549|Prospective
391210|NCT01121549|non-comparative
391211|NCT01121549|NIS
391212|NCT01121549|600
391213|NCT01121549|postmenopausal
391214|NCT01121549|hormone-receptor
391215|NCT01121549|positive
391216|NCT01121549|EBC
391217|NCT01121549|tamoxifen
391218|NCT01121549|current medical practice.
391219|NCT01121536|Bipolar I Disorder
391220|NCT01121523|Prematurity
391221|NCT01121523|massage
391222|NCT01121523|stress
391223|NCT01121523|parenting
391224|NCT01121523|infancy
391225|NCT01121523|sleep
391226|NCT01121523|intervention
391227|NCT01121510|vascular closure device
391228|NCT01121497|Sedation
391229|NCT01121497|Cognitive decline
391230|NCT01121497|Physostigmine
391231|NCT01121497|Colonoscopy
391232|NCT01121471|diabetes
391233|NCT01121471|conjugated linoleic acid
391234|NCT01121458|pulmonary artery
391235|NCT01121458|vascular resistance
391236|NCT01121445|Sleep apnea
391237|NCT01121445|CPAP
391238|NCT01121445|Saline irrigation
391239|NCT01121419|Neuroblastoma
391240|NCT01121419|IMP3
391241|NCT01121419|Prognosis
391242|NCT01121380|Healthy
391243|NCT01121380|Volunteers
391244|NCT01121367|emphysema; pulmonary fibrosis;chemokine;sputum
391245|NCT01121354|Cefazolin
391246|NCT01121354|Caphalosporin
391247|NCT01121354|antibiotic
391248|NCT01121354|gram positive
391249|NCT01121354|Infection control
391250|NCT01121341|Endoscopic vein harvesting
391251|NCT01121341|Saphenous vein
391252|NCT01121341|Conventional vein harvesting
391253|NCT01121328|Preterm neonates.
391254|NCT01121328|Autologous cord blood transfusion.
391255|NCT01121315|Epidemiological
391256|NCT01121315|Diabetes
391257|NCT01121315|Glucose Lowering Drug Treatment in Primary care
391258|NCT01121315|CVD
391259|NCT01121302|AZD5213
391260|NCT01121302|Phase 1
391261|NCT01121302|Safety
391262|NCT01121263|coronary arteriosclerosis
391263|NCT01121263|coronary heart disease
391264|NCT01121263|coronary artery bypass
391265|NCT01121263|coronary artery bypass, off-pump
391266|NCT01121263|coronary angiography
391267|NCT01121263|drug-eluting stents
391268|NCT01121250|Combat disorders
391269|NCT01121250|Spouses
391270|NCT01121250|Support
391271|NCT01121250|Military personnel
391272|NCT01121237|chronic kidney disease
391273|NCT01121237|end-stage renal disease
391274|NCT01121237|renal anaemia
391275|NCT01121237|epoetin alfa
391276|NCT01121224|Saphenous vein graft
391277|NCT01121224|Percutaneous coronary intervention
391278|NCT01121224|Stents
391279|NCT01121211|Testosterone
391280|NCT01121211|Hormones
391281|NCT01121211|Mental Health
391282|NCT01121198|Food effect
391283|NCT01121185|Hepatitis C virus (HCV)
391284|NCT01121185|Liver transplantation
391285|NCT01121185|Human Monoclonal Antibody
391286|NCT01121146|Osteolysis
391287|NCT01121146|Polyethylene
391288|NCT01121146|Crosslinked Polyethylene
391289|NCT01121146|Total Hip Replacement
391290|NCT01121146|CT
391291|NCT01121120|Lymphoma, Non-Hodgkin
391292|NCT01121120|Hodgkin Disease
391293|NCT01121120|Multiple myeloma
391294|NCT01121120|Peripheral Blood Stem Cell Transplant
391295|NCT01121120|Autologous Peripheral Blood Stem Cell Transplant
391296|NCT01121120|Limited re-infusion of CD34+ cells
391297|NCT01121107|Heart Failure
391298|NCT01121107|Decompensated Heart Failure
391299|NCT01121107|Acute Decompensated Heart Failure
391300|NCT01121107|Hemodynamic Monitoring
391301|NCT01121107|Implantable Pressure Monitor
391302|NCT01121107|Left Atrial Pressure Monitoring
391303|NCT01121094|Liver, spleen , T2* , MRI, fetus
391304|NCT01121081|Male or female subjects
391305|NCT01121081|≥18 to ≤75 years of age
391306|NCT01121081|who have a diagnosis of plaque or guttate psoriasis
391307|NCT01121068|IGRA
391308|NCT01121068|variability
391309|NCT01121068|Long-term variability of IGRA
391310|NCT01121055|Fiberoptic Bronchoscopy
391311|NCT01121055|Patient
391312|NCT01121055|Satisfaction
391313|NCT01121055|Lorazepam
391314|NCT01121016|NAEB, chronic cough, montelukast, induced sputum
391315|NCT01121003|Fructose
391316|NCT01121003|VLDL-triglycerides
391317|NCT01121003|de novo lipogenesis
391318|NCT01121003|Human metabolism
391319|NCT01120990|Blood pressure measuring devices
391320|NCT01120990|Essential Hypertension
391321|NCT01120990|Automated blood pressure measurement
391322|NCT01120951|Respiratory rate R8 Anaxsys
391323|NCT01120938|AIrways, Patency, Infant death
391324|NCT01120925|Cirrhotic
391325|NCT01120925|Stem Cells
391326|NCT01120925|Bone marrow stem cells
391327|NCT01120925|Decompensate Cirrhotic Patients
391328|NCT01120912|oral insulin
391329|NCT01120899|Diabetic Macular Edema
391330|NCT01120899|Microglia
391331|NCT01120899|Minocycline
391332|NCT01120899|Diabetes
391333|NCT01120886|Ion channelopathy,
391334|NCT01120886|Still birth
391335|NCT01120886|Sudden death
391336|NCT01120873|Hyperglycemia
391337|NCT01120873|dyslipidemia
391338|NCT01120873|Hypertension
391339|NCT01120873|Obesity
391340|NCT01120860|Cognitive Aging
391341|NCT01120860|Apolipoproteins E
391342|NCT01120860|Magnetic Resonance Imaging
391343|NCT01120834|diffuse large b cell lymphoma
391344|NCT01120821|PV
391345|NCT01120769|Myocardial Infarction
391346|NCT01120769|Percutaneous Coronary Intervention
391347|NCT01120769|Acetaminophen
391348|NCT01120769|Lipid Peroxidation
391349|NCT01120756|executive dysfunction
391350|NCT01120756|brain injury
391351|NCT01120756|attention
391352|NCT01120756|rehabilitation
391353|NCT01120756|fMRI
391354|NCT01120743|liver failure
391355|NCT01120743|cytokines
391356|NCT01120743|hemodynamic instability
391357|NCT01120717|QVA149
391358|NCT01120717|COPD
391359|NCT01120717|combination bronchodilator
391360|NCT01120704|Smoking
391361|NCT01120704|Smoking Cessation
391362|NCT01120704|Adherence
391363|NCT01120704|Nicotine
391364|NCT01120704|Motivation
391365|NCT01120691|QVA149
391366|NCT01120691|NVA237
391367|NCT01120691|COPD
391368|NCT01120691|exacerbation
391369|NCT01120691|combination bronchodilator
391370|NCT01120678|cytokines
391371|NCT01120678|late-onset neonatal sepsis
391372|NCT01120678|neonatal sepsis
391373|NCT01120678|diagnosis of sepsis
391374|NCT01120678|bacteremia
391375|NCT01120678|blood culture
391376|NCT01120678|clinical sepsis
391377|NCT01120665|women's health
391378|NCT01120665|hormone replacement therapy
391379|NCT01120665|exercise
391380|NCT01120613|Nocturnal Hypertension
391381|NCT01120613|Nondipping
391382|NCT01120613|Renal Transplant
391383|NCT01120613|Chronotherapy
391384|NCT01120587|Deglutition
391385|NCT01120587|Fluoroscopy
391386|NCT01120574|Nocturnal hypercapnic response to oxygen
391387|NCT01120574|Home mechanical ventilation
391388|NCT01120574|COPD
391389|NCT01120561|TDM-1 EAP
391390|NCT01120561|T-DM1 EAP
391391|NCT01120561|TDM1 EAP
391392|NCT01120561|Trastuzumab-MCC-DM1 EAP
391393|NCT01120561|Trastuzumab emtansine
391394|NCT01120561|EAP
391395|NCT01120561|T-PAS
391396|NCT01120548|CARDIAC REHABILITATION
391397|NCT01120548|Nocturnal Ventilation
391398|NCT01120548|Apnea hypopnea index is > 15/h
391399|NCT01120535|Vena Cava
391400|NCT01120535|Vena Cava Filter
391401|NCT01120535|Pulmonary Embolism
391402|NCT01120535|Venous Thromboembolism
391403|NCT01120535|Risk of Pulmonary Embolism
391404|NCT01120522|Vena Cava
391405|NCT01120522|Vena Cava Filter
391406|NCT01120522|Pulmonary Embolism
391407|NCT01120522|Venous Thromboembolism
391408|NCT01120522|Risk of Pulmonary Embolism
391409|NCT01120509|Vena Cava
391410|NCT01120509|Vena Cava Filter
391411|NCT01120509|Pulmonary Embolism
391412|NCT01120509|Venous Thromboembolism
391413|NCT01120509|Risk of Pulmonary Embolism
391414|NCT01120496|Hypertonic saline solution, bronchiolitis, RSV
391415|NCT01120483|mortality
391416|NCT01120483|functional status
391417|NCT01120470|Castration Resistant
391418|NCT01120470|Prostate Cancer
391419|NCT01120470|OGX-427
391420|NCT01120444|Diabetes
391421|NCT01120444|Insulin
391422|NCT01120444|Blood Glucose
391423|NCT01120431|dehydration
391424|NCT01120431|fluid therapy
391425|NCT01120431|hyaluronoglucosaminidase
391426|NCT01120431|hyaluronidase
391427|NCT01120431|hypodermoclysis
391428|NCT01120431|clysis
391429|NCT01120431|subcutaneous hydration
391430|NCT01120431|subcutaneous rehydration
391431|NCT01120431|hyaluronan
391432|NCT01120431|rHuPH20
391433|NCT01120431|pediatric
391434|NCT01120431|ORT
391435|NCT01120418|Endothelial cell density
391436|NCT01120418|screening
391437|NCT01120405|Xenon
391438|NCT01120405|Cardiac safety
391439|NCT01120405|Cardiovascular risk
391440|NCT01120405|Non cardiac surgery
391441|NCT01120405|Atherosclerotic vascular surgery
391442|NCT01120392|Parkinson's disease
391443|NCT01120392|Physical therapy
391444|NCT01120392|Virtual Reality
391445|NCT01120392|Quality of life
391446|NCT01120392|Motor performance
391447|NCT01120379|drug eluting stents
391448|NCT01120379|Stents
391449|NCT01120379|Angioplasty
391450|NCT01120379|Stent thrombosis
391451|NCT01120353|Childhood cancer
391452|NCT01120353|Young Children
391453|NCT01120353|Adults
391454|NCT01120301|stroke
391455|NCT01120288|Anti-Angiogenesis
391456|NCT01120288|Targeted Therapy
391457|NCT01120288|HIF
391458|NCT01120288|Antisense
391459|NCT01120288|VEGF
391460|NCT01120288|Cancer
391461|NCT01120288|Solid Tumor
391462|NCT01120288|Liver Metastasis
391463|NCT01120262|recurrent prostate cancer
391464|NCT01120262|stage IV prostate cancer
391465|NCT01120249|stage I renal cell cancer
391466|NCT01120249|stage II renal cell cancer
391467|NCT01120249|stage III renal cell cancer
391468|NCT01120249|clear cell renal cell carcinoma
391469|NCT01120249|papillary renal cell carcinoma
391470|NCT01120210|Heart Failure
391471|NCT01120210|Cardiac Failure
391472|NCT01120197|randomized controlled trial
391473|NCT01120197|osteoporosis
391474|NCT01120197|moderate-intensity circuit exercises
391475|NCT01120197|balance
391476|NCT01120197|health-related quality of life
391477|NCT01120171|Breast cancer
391478|NCT01120171|Elderly
391479|NCT01120171|Chemotherapy
391480|NCT01120171|Cardiotoxicity
391481|NCT01120158|Breast cancer
391482|NCT01120158|Elderly
391483|NCT01120158|Chemotherapy
391484|NCT01120158|Anti-angiogenesis therapy
391485|NCT01120145|Malaria
391486|NCT01120145|Pregnancy
391487|NCT01120145|Sulphadoxine-pyrimethamine
391488|NCT01120106|levosimendan
391489|NCT01120106|pediatric cardiac surgery
391490|NCT01120106|low cardiac output syndrome
391491|NCT01120106|transposition of the great arteries
391492|NCT01120093|COPD
391493|NCT01120080|Smoking
391494|NCT01120080|Tobacco
391495|NCT01120080|Drinking
391496|NCT01120067|Psychology
391497|NCT01120067|Pain
391498|NCT01120067|Veterans
391499|NCT01120067|Stress Disorders, Post-Traumatic
391500|NCT01120054|Traumatic Brain Injury
391501|NCT01120054|Homelessness
391502|NCT01120015|OA
391503|NCT01120015|knee
391504|NCT01120002|mild to moderate Alzheimer's Disease
391505|NCT01119989|hepatic fat content
391506|NCT01119989|hepatic de novo lipogenesis
391507|NCT01119963|Preterm delivery
391508|NCT01119950|COPD
391509|NCT01119937|COPD
391510|NCT01119937|NVA237
391511|NCT01119924|Mirtazapine
391512|NCT01119924|Smilon
391513|NCT01119924|Depression
391514|NCT01119924|Pain
391515|NCT01119911|Blood sampling
391516|NCT01119911|Venipuncture
391517|NCT01119911|Peripheral venous catheter
391518|NCT01119911|Complete blood count
391519|NCT01119911|Basic chemistry
391520|NCT01119911|Hemolysis
391521|NCT01119911|Peripheral venous catheter replaces venipuncture.
391522|NCT01119911|Peripheral venous catheter blood sampling reduces pain.
391523|NCT01119898|Osteoarthritis
391524|NCT01119898|Arthritis
391525|NCT01119898|NSAIDs
391526|NCT01119898|Topical NSAID
391527|NCT01119898|Diclofenac
391528|NCT01119898|PENNSAID
391529|NCT01119885|chronic pain
391530|NCT01119885|fentanyl matrix
391531|NCT01119885|arthritis
391532|NCT01119885|osteoarthritis
391533|NCT01119872|Positive-Pressure Respiration
391534|NCT01119872|Respiration, Artificial
391535|NCT01119846|Tolerability
391536|NCT01119846|Pharmacokinetics
391537|NCT01119846|Safety
391538|NCT01119846|Pharmacodynamics
391539|NCT01119846|Glucose
391540|NCT01119833|Sickle Cell Disease
391541|NCT01119820|elective obstetric or gynecologic surgery
391542|NCT01119807|Intraosseous infusion
391543|NCT01119807|Emergency Medical Services
391544|NCT01119794|B-cell small lymphocytic lymphoma
391545|NCT01119794|marginal zone lymphoma
391546|NCT01119794|follicular lymphoma
391547|NCT01119794|mantle cell lymphoma
391548|NCT01119794|Waldenström macroglobulinemia.
391549|NCT01119794|Low Grade B cell Non-Hodgkins Lymphoma
391550|NCT01119768|GI
391551|NCT01119768|Nexium
391552|NCT01119768|Phase IV
391553|NCT01119768|Co-diagnosed NERD
391554|NCT01119755|TREATMENT OF HYPERTENSION
391555|NCT01119742|Tinea Pedis
391556|NCT01119742|Interdigital
391557|NCT01119729|Cardiac Diseases • HIV-Infection • AIDS • Antiretroviral Therapy
391558|NCT01119716|Atrial Fibrillation
391559|NCT01119716|Afib
391560|NCT01119716|cardioversion
391561|NCT01119716|normal sinus rhythm
391562|NCT01119716|arrhythmia
391563|NCT01119716|AF
391564|NCT01119703|Vaccine Hyporesponse
391565|NCT01119690|Dietary
391566|NCT01119690|Cross-Over Study
391567|NCT01119690|Lipids
391568|NCT01119690|Rapeseed oil
391569|NCT01119690|Butter
391570|NCT01119690|Milk Fat
391571|NCT01119690|Unsaturated Fat
391572|NCT01119690|Saturated Fat
391573|NCT01119690|Oxidized LDL
391574|NCT01119690|Platelet Function
391575|NCT01119690|Arterial Elasticity
391576|NCT01119664|Adult subjects with malignant pleural mesothelioma who present for first (front) line or second line chemotherapy,
391577|NCT01119651|Healthy Volunteer Subjects
391578|NCT01119638|Alzheimer's disease
391579|NCT01119638|BPSD
391580|NCT01119638|escitalopram
391581|NCT01119638|Risperidone
391582|NCT01119638|Agitation
391583|NCT01119638|Psychosis
391584|NCT01119638|Dementia
391585|NCT01119638|Elderly
391586|NCT01119625|safety
391587|NCT01119625|Streptococcus pneumoniae
391588|NCT01119625|immunogenicity
391589|NCT01119625|Pneumococcal conjugate vaccine
391590|NCT01119625|Haemophilus influenzae
391591|NCT01119612|Malaria
391592|NCT01119612|Iron
391593|NCT01119612|Pregnancy
391594|NCT01119612|Anemia
391595|NCT01119612|Birth Weight
391596|NCT01119586|B-cell adult acute lymphoblastic leukemia
391597|NCT01119586|B-cell childhood acute lymphoblastic leukemia
391598|NCT01119586|untreated adult acute lymphoblastic leukemia
391599|NCT01119586|untreated childhood acute lymphoblastic leukemia
391600|NCT01119573|stage I endometrial carcinoma
391601|NCT01119573|stage III endometrial carcinoma
391602|NCT01119547|Musculoskeletal Diseases
391603|NCT01119547|Osteoarthritis
391604|NCT01119547|Joint Diseases
391605|NCT01119547|Arthritis
391606|NCT01119547|Rheumatic Diseases
391607|NCT01119534|Cough treatment
391608|NCT01119521|South Africa,tuberculosis,vaccine
391609|NCT01119508|Advanced
391610|NCT01119508|Inoperable
391611|NCT01119508|Melanoma
391612|NCT01119508|Ipilimumab
391613|NCT01119508|MDX010
391614|NCT01119508|BMS-734016
391615|NCT01119508|Temozolomide
391616|NCT01119508|Temodar
391617|NCT01119508|TMZ
391618|NCT01119508|skin
391619|NCT01119508|mucosal
391620|NCT01119482|Serogroup A meningococcal vaccine
391621|NCT01119482|meningococcal carriage
391622|NCT01119482|incidence
391623|NCT01119482|prevalence
391624|NCT01119469|Hypochondriasis
391625|NCT01119469|Health Anxiety
391626|NCT01119469|randomized controlled trial
391627|NCT01119469|Cognitive Therapy
391628|NCT01119469|Exposure Therapy
391629|NCT01119456|Tumors
391630|NCT01119456|Macrophage stimulating 1 receptor, human
391631|NCT01119456|RON protein
391632|NCT01119456|RON receptor protein tyrosine kinase
391633|NCT01119430|major depression
391634|NCT01119430|DU 125530
391635|NCT01119430|Treatment depression
391636|NCT01119430|Latency antidepressant
391637|NCT01119417|supine Hypertension
391638|NCT01119417|autonomic failure
391639|NCT01119417|BQ123
391640|NCT01119417|BQ-123
391641|NCT01119417|endothelin
391642|NCT01119404|Metabolic Syndrome
391643|NCT01119404|Coronary Heart Disease
391644|NCT01119404|Erectile Dysfunction
391645|NCT01119404|Arterial Elasticity
391646|NCT01119404|Oxidized Low Density Lipoprotein
391647|NCT01119404|Cardiovascular Diseases
391648|NCT01119404|Risk Assessment
391649|NCT01119404|Endothelial Dysfunction
391650|NCT01119404|Diabetes Mellitus
391651|NCT01119404|Surrogate Markers
391652|NCT01119404|Risk Factors
391653|NCT01119391|IVF
391654|NCT01119391|Lifestyle habits
391655|NCT01119378|Post menopausal
391656|NCT01119378|Vitamin D sufficiency
391657|NCT01119378|Calcium absorption efficiency
391658|NCT01119378|Dual isotope technique
391659|NCT01119365|Healthy controls
391660|NCT01119352|Safety
391661|NCT01119352|tolerability
391662|NCT01119352|PK
391663|NCT01119352|healthy
391664|NCT01119352|overweight
391665|NCT01119352|obese
391666|NCT01119339|psoriasis
391667|NCT01119339|topical
391668|NCT01119339|psoriasis plaques test
391669|NCT01119326|scar prevention
391670|NCT01119326|healing
391671|NCT01119326|tissue
391672|NCT01119326|AFT
391673|NCT01119326|scar analysis
391674|NCT01119300|Venous Thromboembolism (VTE)
391675|NCT01119300|Atrial Fibrillation (AF)
391676|NCT01119287|Conjunctivitis
391677|NCT01119287|ocular allergy
391678|NCT01119261|Venous thromboembolism (VTE)
391679|NCT01119261|Atrial fibrillation (AF)
391680|NCT01119248|Children MRI General Anesthesia
391681|NCT01119235|Pharmacokinetics
391682|NCT01119235|tablet performance
391683|NCT01119235|healthy volunteers
391684|NCT01119235|open label
391685|NCT01119222|Cold pain methodology
391686|NCT01119222|Healthy male volunteers
391687|NCT01119222|gabapentin
391688|NCT01119222|Diphenhydramine
391689|NCT01119222|morphine
391690|NCT01119209|Hip fracture
391691|NCT01119209|intertrochanteric
391692|NCT01119196|Peritoneal Dialysis
391693|NCT01119196|Insulin resistance
391694|NCT01119183|Patient understanding and counseling
391695|NCT01119170|nutrition
391696|NCT01119170|infant formula
391697|NCT01119170|probiotics
391698|NCT01119157|influenza vaccine
391699|NCT01119157|cellular immune response
391700|NCT01119157|humoral immune response
391701|NCT01119144|Orbital
391702|NCT01119144|fractures
391703|NCT01119144|enophthalmos
391704|NCT01119144|diplopia
391705|NCT01119144|eye
391706|NCT01119131|Vitamin D
391707|NCT01119131|Parkinson disease
391708|NCT01119131|accidental falls
391709|NCT01119118|Metastatic
391710|NCT01119118|castrate-resistant prostate cancer
391711|NCT01119118|bone metastasis
391712|NCT01119105|acute bacterial skin and skin structure infection
391713|NCT01119105|bacteria
391714|NCT01119092|Ankle Sprain
391715|NCT01119092|Joint Mobilization
391716|NCT01119092|Manual Therapy
391717|NCT01119092|Range of Motion
391718|NCT01119079|labor pain
391719|NCT01119079|epidural
391720|NCT01119066|Leukemia
391721|NCT01119066|Multiple Myeloma
391722|NCT01119066|radiation
391723|NCT01119066|Thiotepa
391724|NCT01119066|cyclophosphamide
391725|NCT01119066|fludarabine
391726|NCT01119066|Clofarabine
391727|NCT01119066|CliniMACS device
391728|NCT01119066|GCSF
391729|NCT01119066|10-050
391730|NCT01119053|VNS
391731|NCT01119053|Depression
391732|NCT01119053|Personality-Disorder
391733|NCT01119053|Stimulation
391734|NCT01119040|Dislodged PEG tube
391735|NCT01119040|NOTES
391736|NCT01119027|Laparoscopic Colectomy
391737|NCT01119027|Colorectal Skills Training
391738|NCT01119014|Aripiprazole
391739|NCT01119014|Quetiapine
391740|NCT01119014|Psychosis
391741|NCT01119014|Child
391742|NCT01119014|Adolescent
391743|NCT01118988|Peer Support
391744|NCT01118988|Social Support
391745|NCT01118988|Chronic Pain
391746|NCT01118988|Behavioral Interventions for Pain
391747|NCT01118988|Adolescents
391748|NCT01118988|Children
391749|NCT01118988|Pediatric
391750|NCT01118988|Mentorship
391751|NCT01118988|Complementary and Alternative Medicine
391752|NCT01118988|CAM
391753|NCT01118988|Pain
391754|NCT01118988|Pain Management
391755|NCT01118988|Behavioral
391756|NCT01118975|lapatinib ditosylate
391757|NCT01118975|Zolinza (vorinostat)
391758|NCT01118975|Cancer Stem Cells
391759|NCT01118962|Primary Generalized Tonic-Clonic (PGTC) Seizures
391760|NCT01118962|Absence Seizures
391761|NCT01118962|Myoclonic Seizures
391762|NCT01118962|Idiopathic Generalized Epilepsy (IGE)
391763|NCT01118949|Primary Generalized Tonic-Clonic (PGTC) Seizures
391764|NCT01118949|Absence Seizures
391765|NCT01118949|Myoclonic Seizures
391766|NCT01118949|Idiopathic Generalized Epilepsy (IGE)
391767|NCT01118936|Chronic Obstructive Pulmonary Disease
391768|NCT01118936|Daily magnesium supplement
391769|NCT01118936|EQ-5D
391770|NCT01118923|Bronchial challenge test
391771|NCT01118923|Hyperreactivity
391772|NCT01118923|PD20 for metacholine
391773|NCT01118923|Daily magnesium supplement
391774|NCT01118910|Intertrigo
391775|NCT01118910|Vusion
391776|NCT01118897|Gall bladder
391777|NCT01118897|Pancreatic cancers
391778|NCT01118897|Tomotherapy
391779|NCT01118884|Midazolam
391780|NCT01118884|Nitrous oxide
391781|NCT01118884|Behaviour management
391782|NCT01118871|Treatment experienced
391783|NCT01118858|CYP2D6
391784|NCT01118858|CYP3A4
391785|NCT01118858|cytochrome P450
391786|NCT01118858|children
391787|NCT01118858|pediatrics
391788|NCT01118858|dextromethorphan
391789|NCT01118858|phenotype
391790|NCT01118858|genotype
391791|NCT01118845|Non-Hodgkin's lymphoma
391792|NCT01118845|Lymphoma, Large B-Cell
391793|NCT01118845|Diffuse, Mantle cell lymphoma, Lymphoma
391794|NCT01118845|Follicular, Lymphoma
391795|NCT01118845|Large B-Cell, Diffuse
391796|NCT01118832|Thermography
391797|NCT01118819|Phase I
391798|NCT01118819|Metastatic Disease
391799|NCT01118819|Solid Tumor
391800|NCT01118819|Malignancy
391801|NCT01118819|Metastases
391802|NCT01118819|Clinical trial
391803|NCT01118819|Hypoxia
391804|NCT01118819|Necrosis
391805|NCT01118780|GAD
391806|NCT01118780|Generalized Anxiety Disorder
391807|NCT01118780|Anxiety
391808|NCT01118767|Adherence
391809|NCT01118767|Appointment
391810|NCT01118767|Cell Phone
391811|NCT01118767|Cellular Phone
391812|NCT01118767|Clinic
391813|NCT01118767|Computers
391814|NCT01118767|Controlled Clinical Trials, Randomized
391815|NCT01118767|HIV/AIDS
391816|NCT01118767|Health Informatics
391817|NCT01118767|Health behavior
391818|NCT01118767|Information Technology
391819|NCT01118767|Internet
391820|NCT01118767|Intervention
391821|NCT01118767|Medication
391822|NCT01118767|Patient Satisfaction
391823|NCT01118767|Patient Self-Report
391824|NCT01118767|Patients
391825|NCT01118767|Peru
391826|NCT01118767|Phone
391827|NCT01118767|Public Health
391828|NCT01118767|Public Health Informatics
391829|NCT01118767|Randomized
391830|NCT01118767|Randomized Controlled Clinical Trials
391831|NCT01118767|Randomized Controlled Trials
391832|NCT01118767|Research
391833|NCT01118767|Secondary Prevention
391834|NCT01118767|Self-Report
391835|NCT01118767|Sex Behavior
391836|NCT01118767|Sexual Behavior
391837|NCT01118767|Sexually Transmitted Diseases
391838|NCT01118767|Sexually Transmitted Infection
391839|NCT01118767|Survey Instrument
391840|NCT01118767|Surveys
391841|NCT01118767|Telephone
391842|NCT01118767|Telephone, Cellular
391843|NCT01118767|Text
391844|NCT01118767|Unprotected Sex
391845|NCT01118767|Viral Load result
391846|NCT01118767|Vulnerable Populations
391847|NCT01118767|WWW
391848|NCT01118767|anti-retroviral therapy
391849|NCT01118767|consumer informatics
391850|NCT01118767|evidence base
391851|NCT01118767|follow-up
391852|NCT01118767|medication adherence
391853|NCT01118767|medication compliance
391854|NCT01118767|randomization
391855|NCT01118767|randomized controlled study
391856|NCT01118767|randomized trial
391857|NCT01118767|randomly assigned
391858|NCT01118767|safer sex
391859|NCT01118767|treatment adherence
391860|NCT01118767|user centered design
391861|NCT01118767|web
391862|NCT01118767|world wide web
391863|NCT01118754|Santen
391864|NCT01118754|Dry
391865|NCT01118754|Eye
391866|NCT01118741|Rising PSA
391867|NCT01118741|Recurrent Non Metastatic Prostate Cancer
391868|NCT01118715|distal radius fracture
391869|NCT01118715|post-traumatic carpal tunnel syndrome
391870|NCT01118715|complex regional pain syndrome
391871|NCT01118715|compression glove
391872|NCT01118715|edema glove
391873|NCT01118702|Pharmacokinetic
391874|NCT01118702|Methylphenidate
391875|NCT01118702|Novo-methylphenidate ER-C
391876|NCT01118702|Ritalin-SR
391877|NCT01118702|CONCERTA
391878|NCT01118702|Plasma profile
391879|NCT01118676|locally advanced non small cell lung cancer (NSCLC), locally advanced, Phase I, Cilengitide, concomitant radiochemotherapy
391880|NCT01118663|Acetaminophen overdose; induced hepatotoxicity, liver injury
391881|NCT01118650|Inattention
391882|NCT01118650|Hyperactivity
391883|NCT01118650|Impulsivity
391884|NCT01118637|trichotillomania
391885|NCT01118637|self-help
391886|NCT01118637|web-based
391887|NCT01118637|habit reversal
391888|NCT01118637|behavior therapy
391889|NCT01118624|Female
391890|NCT01118624|Advanced
391891|NCT01118624|Metastatic
391892|NCT01118611|unspecified adult solid tumor, protocol specific
391893|NCT01118598|PCOS
391894|NCT01118585|GERD
391895|NCT01118585|Esophagitis
391896|NCT01118585|Fundoplication
391897|NCT01118585|Anti-reflux surgery
391898|NCT01118585|PPI dependent
391899|NCT01118572|Celecoxib
391900|NCT01118572|Celecox
391901|NCT01118572|Pain
391902|NCT01118572|Surgery
391903|NCT01118572|NSAIDs
391904|NCT01118559|YM150
391905|NCT01118559|Food effect
391906|NCT01118559|Healthy volunteer
391907|NCT01118546|aspirin
391908|NCT01118546|coronary artery disease
391909|NCT01118546|hypersensitivity
391910|NCT01118546|Platelet aggregation
391911|NCT01118533|Intubation
391912|NCT01118533|Sore throat
391913|NCT01118533|Blades
391914|NCT01118533|Laryngoscopy
391915|NCT01118533|Morbidity
391916|NCT01118520|abdominal aortic aneurysm
391917|NCT01118520|ACE Inhibition
391918|NCT01118507|Trisomy of chromosome 21 diagnosis
391919|NCT01118507|first trimester of pregnancy
391920|NCT01118507|maternal blood
391921|NCT01118507|High output shotgun sequencing
391922|NCT01118494|CKD
391923|NCT01118494|RAS
391924|NCT01118494|AGT
391925|NCT01118481|Coronary stenosis
391926|NCT01118481|Wave intensity analysis
391927|NCT01118481|Instantaneous Flow Reserve
391928|NCT01118481|iFR
391929|NCT01118481|Fractional Flow Reserve
391930|NCT01118468|Competitive Flow
391931|NCT01118468|Coronary artery bypass
391932|NCT01118468|Wave Intensity Analysis
391933|NCT01118442|Aortic Stenosis
391934|NCT01118442|Coronary Flow
391935|NCT01118442|Wave Intensity Analysis
391936|NCT01118429|hyperhidrosis
391937|NCT01118429|axillary
391938|NCT01118429|osmidrosis
391939|NCT01118429|oxybutynin
391940|NCT01118416|sexual risk
391941|NCT01118416|substance use
391942|NCT01118416|HIV
391943|NCT01118416|prevention
391944|NCT01118416|intervention
391945|NCT01118416|Motivational Enhancement Therapy
391946|NCT01118416|young men who have sex with men
391947|NCT01118403|Ventilator associated pneumonia
391948|NCT01118403|Coma
391949|NCT01118403|Brain Injuries
391950|NCT01118403|Intensive care units
391951|NCT01118403|antibiotic prophylaxis
391952|NCT01118390|telangiectasias
391953|NCT01118390|leg
391954|NCT01118390|sclerotherapy
391955|NCT01118390|laser
391956|NCT01118390|glycose
391957|NCT01118364|Social circumstances
391958|NCT01118325|Stable Coronary Artery Disease
391959|NCT01118325|Platelet Aggregation
391960|NCT01118312|Asthma
391961|NCT01118312|Rhinitis
391962|NCT01118312|Sinusitis
391963|NCT01118312|Chronic
391964|NCT01118312|ACRC
391965|NCT01118312|STAN
391966|NCT01118312|Nasal steroid
391967|NCT01118312|Mometasone
391968|NCT01118312|Nasal spray
391969|NCT01118286|Hypertension
391970|NCT01118286|Drug therapy, combination
391971|NCT01118273|Naproxen sodium
391972|NCT01118273|Diphenhydramine
391973|NCT01118273|Drugs, Investigational
391974|NCT01118260|prostata hyperplasia
391975|NCT01118260|transurethral resection
391976|NCT01118260|TIVA
391977|NCT01118260|spinal anaesthesia
391978|NCT01118247|Uncemented THA
391979|NCT01118247|alumina-on-alumina
391980|NCT01118247|survival
391981|NCT01118247|HHS
391982|NCT01118247|Patient satisfaction
391983|NCT01118234|CLL
391984|NCT01118234|Rituximab
391985|NCT01118234|Maintenance
391986|NCT01118221|oxidant stress
391987|NCT01118221|exercise
391988|NCT01118208|Medication adherence
391989|NCT01118208|Accidental overdose
391990|NCT01118208|Deliberate overdose
391991|NCT01118208|Suicide, attempted
391992|NCT01118182|Traumatic Brain Injury
391993|NCT01118182|Veterans
391994|NCT01118182|Psychiatric Disorders
391995|NCT01118182|Suicide
391996|NCT01118169|Personal values
391997|NCT01118169|Suicidal thoughts
391998|NCT01118156|Suicide Nomenclature
391999|NCT01118130|Genetics
392000|NCT01118130|genomics
392001|NCT01118130|Multiple Sclerosis
392002|NCT01118130|beta-interferons
392003|NCT01118117|atherosclerotic stenosis
392004|NCT01118117|occlusions
392005|NCT01118117|Superficial Femoral Artery
392006|NCT01118117|SFA
392007|NCT01118091|Immunotherapy
392008|NCT01118091|Metastatic Melanoma
392009|NCT01118091|Randomized
392010|NCT01118091|Cell Therapy
392011|NCT01118091|Skin Cancer
392012|NCT01118091|Melanoma
392013|NCT01118065|anaplastic thyroid cancer
392014|NCT01118065|recurrent thyroid cancer
392015|NCT01118065|stage III follicular thyroid cancer
392016|NCT01118065|stage III papillary thyroid cancer
392017|NCT01118065|stage IV follicular thyroid cancer
392018|NCT01118065|stage IV papillary thyroid cancer
392019|NCT01118065|thyroid gland medullary carcinoma
392020|NCT01118039|localized transitional cell cancer of the renal pelvis and ureter
392021|NCT01118039|metastatic transitional cell cancer of the renal pelvis and ureter
392022|NCT01118039|recurrent transitional cell cancer of the renal pelvis and ureter
392023|NCT01118039|transitional cell carcinoma of the bladder
392024|NCT01118039|distal urethral cancer
392025|NCT01118039|proximal urethral cancer
392026|NCT01118039|recurrent urethral cancer
392027|NCT01118039|recurrent bladder cancer
392028|NCT01118039|stage IV bladder cancer
392029|NCT01118039|stage III bladder cancer
392030|NCT01118039|urethral cancer associated with invasive bladder cancer
392031|NCT01118039|stage III urethral cancer
392032|NCT01118039|stage IV urethral cancer
392033|NCT01118026|stage I adult Hodgkin lymphoma
392034|NCT01118026|stage II adult Hodgkin lymphoma
392035|NCT01118026|adult favorable prognosis Hodgkin lymphoma
392036|NCT01118026|adult lymphocyte depletion Hodgkin lymphoma
392037|NCT01118026|adult lymphocyte predominant Hodgkin lymphoma
392038|NCT01118026|adult mixed cellularity Hodgkin lymphoma
392039|NCT01118026|adult nodular sclerosis Hodgkin lymphoma
392040|NCT01118026|adult unfavorable prognosis Hodgkin lymphoma
392041|NCT01118013|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
392042|NCT01118013|adult acute myeloid leukemia with inv(16)(p13;q22)
392043|NCT01118013|adult acute myeloid leukemia with t(15;17)(q22;q12)
392044|NCT01118013|adult acute myeloid leukemia with t(16;16)(p13;q22)
392045|NCT01118013|adult acute myeloid leukemia with t(8;21)(q22;q22)
392046|NCT01118013|juvenile myelomonocytic leukemia
392047|NCT01118013|prolymphocytic leukemia
392048|NCT01118013|recurrent adult acute myeloid leukemia
392049|NCT01118013|recurrent adult T-cell leukemia/lymphoma
392050|NCT01118013|recurrent childhood acute myeloid leukemia
392051|NCT01118013|refractory chronic lymphocytic leukemia
392052|NCT01118013|recurrent adult Hodgkin lymphoma
392053|NCT01118013|recurrent adult Burkitt lymphoma
392054|NCT01118013|recurrent adult diffuse large cell lymphoma
392055|NCT01118013|recurrent adult diffuse mixed cell lymphoma
392056|NCT01118013|recurrent adult diffuse small cleaved cell lymphoma
392057|NCT01118013|recurrent adult grade III lymphomatoid granulomatosis
392058|NCT01118013|recurrent adult immunoblastic large cell lymphoma
392059|NCT01118013|recurrent adult lymphoblastic lymphoma
392060|NCT01118013|recurrent childhood grade III lymphomatoid granulomatosis
392061|NCT01118013|recurrent childhood large cell lymphoma
392062|NCT01118013|recurrent childhood lymphoblastic lymphoma
392063|NCT01118013|recurrent childhood small noncleaved cell lymphoma
392064|NCT01118013|recurrent cutaneous T-cell non-Hodgkin lymphoma
392065|NCT01118013|recurrent mycosis fungoides/Sezary syndrome
392066|NCT01118013|recurrent grade 1 follicular lymphoma
392067|NCT01118013|recurrent grade 2 follicular lymphoma
392068|NCT01118013|recurrent grade 3 follicular lymphoma
392069|NCT01118013|recurrent mantle cell lymphoma
392070|NCT01118013|recurrent marginal zone lymphoma
392071|NCT01118013|recurrent small lymphocytic lymphoma
392072|NCT01118013|recurrent/refractory childhood Hodgkin lymphoma
392073|NCT01118013|childhood diffuse large cell lymphoma
392074|NCT01118013|childhood grade III lymphomatoid granulomatosis
392075|NCT01118013|childhood immunoblastic large cell lymphoma
392076|NCT01118013|childhood nasal type extranodal NK/T-cell lymphoma
392077|NCT01118013|post-transplant lymphoproliferative disorder
392078|NCT01118013|stage I multiple myeloma
392079|NCT01118013|stage II multiple myeloma
392080|NCT01118013|stage III multiple myeloma
392081|NCT01118013|refractory multiple myeloma
392082|NCT01118013|de novo myelodysplastic syndromes
392083|NCT01118013|previously treated myelodysplastic syndromes
392084|NCT01118013|secondary myelodysplastic syndromes
392085|NCT01118013|childhood myelodysplastic syndromes
392086|NCT01118013|recurrent childhood anaplastic large cell lymphoma
392087|NCT01118013|adult acute myelomonocytic leukemia (M4)
392088|NCT01118013|childhood acute myelomonocytic leukemia (M4)
392089|NCT01118013|adult acute minimally differentiated myeloid leukemia (M0)
392090|NCT01118013|childhood acute minimally differentiated myeloid leukemia (M0)
392091|NCT01118013|adult acute myeloblastic leukemia without maturation (M1)
392092|NCT01118013|childhood acute myeloblastic leukemia without maturation (M1)
392093|NCT01118013|adult acute myeloblastic leukemia with maturation (M2)
392094|NCT01118013|childhood acute myeloblastic leukemia with maturation (M2)
392095|NCT01118013|adult acute promyelocytic leukemia (M3)
392096|NCT01118013|childhood acute promyelocytic leukemia (M3)
392097|NCT01118013|adult acute monoblastic leukemia (M5a)
392098|NCT01118013|adult acute monocytic leukemia (M5b)
392099|NCT01118013|childhood acute monoblastic leukemia (M5a)
392100|NCT01118013|childhood acute monocytic leukemia (M5b)
392101|NCT01118013|adult erythroleukemia (M6a)
392102|NCT01118013|adult pure erythroid leukemia (M6b)
392103|NCT01118013|childhood acute erythroleukemia (M6)
392104|NCT01118013|adult acute megakaryoblastic leukemia (M7)
392105|NCT01118013|childhood acute megakaryocytic leukemia (M7)
392106|NCT01118013|childhood Burkitt lymphoma
392107|NCT01118013|atypical chronic myeloid leukemia, BCR-ABL1 negative
392108|NCT01118013|chronic myelomonocytic leukemia
392109|NCT01118013|cutaneous B-cell non-Hodgkin lymphoma
392110|NCT01118013|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
392111|NCT01118013|nodal marginal zone B-cell lymphoma
392112|NCT01118013|splenic marginal zone lymphoma
392113|NCT01118013|myelodysplastic/myeloproliferative neoplasm, unclassifiable
392114|NCT01118000|ischemic preconditioning,serum proteins,human
392115|NCT01117987|Pulmonary arterial hypertension, imatinib, 6MWD, pulmonary hypertension
392116|NCT01117961|Excessive gestational weight gain
392117|NCT01117935|IMRT
392118|NCT01117935|prostate cancer
392119|NCT01117935|radiation therapy
392120|NCT01117935|external beam
392121|NCT01117935|recurrent prostate cancer
392122|NCT01117922|preterm birth
392123|NCT01117922|interconceptional intervention
392124|NCT01117922|pregnancy outcomes
392125|NCT01117909|ankle sprain
392126|NCT01117909|athletic injury
392127|NCT01117909|arthritis
392128|NCT01117896|CPR
392129|NCT01117896|Rescuer fatigue
392130|NCT01117896|Chest Compression effectiveness
392131|NCT01117883|Perfusion pressures
392132|NCT01117883|central venous pressure
392133|NCT01117883|cardiac output
392134|NCT01117883|CPR
392135|NCT01117883|cardiac arrest
392136|NCT01117883|Leaning
392137|NCT01117883|incomplete release
392138|NCT01117870|chronic
392139|NCT01117870|pain
392140|NCT01117870|lumbar
392141|NCT01117870|Radicular
392142|NCT01117831|Diabetes mellitus
392143|NCT01117805|Asthma
392144|NCT01117779|kidney tumors
392145|NCT01117779|renal tumors
392146|NCT01117779|renal cell carcinoma
392147|NCT01117779|kidney lesions
392148|NCT01117779|renal lesions
392149|NCT01117779|cryoablation
392150|NCT01117779|cryotherapy
392151|NCT01117779|cryosurgery
392152|NCT01117766|Methodology
392153|NCT01117766|Quantitative Sensory Testing
392154|NCT01117766|Neuropathies Pain
392155|NCT01117766|Pregabalin
392156|NCT01117740|Malignant Pleural Effusions
392157|NCT01117740|MPE
392158|NCT01117740|Lungs
392159|NCT01117740|Quality of Life
392160|NCT01117740|M. D. Anderson Symptom Inventory
392161|NCT01117740|MDASI
392162|NCT01117740|Indwelling Pleural Catheters
392163|NCT01117740|Thoracoscopic Pleurodesis
392164|NCT01117740|Symptom burden
392165|NCT01117740|Pleurodesis efficacy
392166|NCT01117740|Complications
392167|NCT01117740|Health care resource utilization
392168|NCT01117714|Lung cancer
392169|NCT01117714|Lung neoplasm
392170|NCT01117714|Pulmonary cancer
392171|NCT01117714|Pulmonary neoplasm
392172|NCT01117714|Lung cancer staging
392173|NCT01117688|Ureteroscopy
392174|NCT01117675|Telemedicine
392175|NCT01117675|Home care
392176|NCT01117675|Chronic HIV infection
392177|NCT01117675|HIV-infected patients
392178|NCT01117662|transplantation
392179|NCT01117662|acute rejection
392180|NCT01117662|kidney
392181|NCT01117649|PVR
392182|NCT01117649|HES 130
392183|NCT01117649|pancreatic head
392184|NCT01117649|goal-directed
392185|NCT01117649|intraoperative PVR in elective surgery of the pancreatic head
392186|NCT01117636|Aspirin
392187|NCT01117623|Oncology patients with advanced disease
392188|NCT01117623|BAY73-4506
392189|NCT01117610|pain
392190|NCT01117610|preemptive
392191|NCT01117610|postoperative
392192|NCT01117610|epidural injection
392193|NCT01117610|laminectomy
392194|NCT01117597|Healthy subjects
392195|NCT01117584|Type 2 diabetes
392196|NCT01117584|diabetes
392197|NCT01117584|ASP1941
392198|NCT01117584|metformin
392199|NCT01117571|knee
392200|NCT01117571|osteoarthritis
392201|NCT01117571|unicompartmental
392202|NCT01117571|arthroplasty
392203|NCT01117558|PCOS,
392204|NCT01117558|DM,
392205|NCT01117558|Hypertension,
392206|NCT01117558|CVD
392207|NCT01117545|veterans,
392208|NCT01117545|PTSD,
392209|NCT01117545|EFT (Emotional Freedom Techniques),
392210|NCT01117545|depression,
392211|NCT01117545|anxiety
392212|NCT01117532|students,
392213|NCT01117532|depression,
392214|NCT01117532|group therapy,
392215|NCT01117532|EFT (Emotional Freedom Techniques),
392216|NCT01117532|energy psychology
392217|NCT01117519|fluid and volume management
392218|NCT01117519|acid-base balance
392219|NCT01117519|goal-directed therapy
392220|NCT01117519|transoesophageal doppler
392221|NCT01117506|Angina
392222|NCT01117506|Myocardial Ischemia
392223|NCT01117506|Molecular Genetics
392224|NCT01117506|Atherosclerosis
392225|NCT01117480|Moderate Rheumatoid Arthritis
392226|NCT01117480|Rheumatoid Arthritis
392227|NCT01117480|Severe Rheumatoid Arthritis
392228|NCT01117480|Adalimumab
392229|NCT01117480|Clinical Effectiveness
392230|NCT01117467|Simulation
392231|NCT01117467|Learning
392232|NCT01117467|Medical Students
392233|NCT01117467|Empathy
392234|NCT01117467|Anxiety
392235|NCT01117454|Catecholaminergic Polymorphic Ventricular Tachycardia
392236|NCT01117454|implantable cardioverter-defibrillator
392237|NCT01117454|flecainide
392238|NCT01117428|Advanced solid tumors
392239|NCT01117428|Metastatic colorectal Cancer
392240|NCT01117415|Gall Bladder
392241|NCT01117415|Cholecystectomy
392242|NCT01117402|recurrent carcinoma cervix
392243|NCT01117402|Vault carcinoma
392244|NCT01117402|Tomotherapy
392245|NCT01117402|Brachytherapy
392246|NCT01117389|Human Papillomavirus Vaccination
392247|NCT01117389|Childhood cancer survivors
392248|NCT01117389|cervical cancer
392249|NCT01117389|sexually transmitted infection
392250|NCT01117376|Gastroparesis
392251|NCT01117376|Erythromycin
392252|NCT01117376|Methylnaltrexone
392253|NCT01117376|ICU
392254|NCT01117363|Appetite whole grain
392255|NCT01117337|Hernia, laparoscopic, recurrence, pain, inguinal
392256|NCT01117324|Bone density
392257|NCT01117324|infant of diabetic mother
392258|NCT01117324|large birth weight
392259|NCT01117311|Vagus
392260|NCT01117311|Diabetes
392261|NCT01117311|Obesity
392262|NCT01117298|Raynaud's phenomenon
392263|NCT01117298|ischemic ulcers
392264|NCT01117298|digital ulcers
392265|NCT01117298|digital infarcts
392266|NCT01117298|gangrene
392267|NCT01117298|vasodilators
392268|NCT01117298|endothelial dysfunction
392269|NCT01117298|scleroderma
392270|NCT01117285|Occupational Therapy
392271|NCT01117285|Evidence-Based Practice
392272|NCT01117285|Continuing Education
392273|NCT01117285|utilization
392274|NCT01117285|Guideline
392275|NCT01117285|Dementia
392276|NCT01117285|Guideline implementation
392277|NCT01117272|PCOS
392278|NCT01117272|hyperprolactinemia
392279|NCT01117272|obesity
392280|NCT01117272|hyperandrogenic
392281|NCT01117246|bone metastasis
392282|NCT01117246|pain palliation
392283|NCT01117233|Healthy volunteers
392284|NCT01117233|PK
392285|NCT01117233|PD
392286|NCT01117233|safety and toleration
392287|NCT01117220|pediatric
392288|NCT01117220|bipolar
392289|NCT01117181|Alzheimer's disease
392290|NCT01117181|Apathy
392291|NCT01117181|Methylphenidate
392292|NCT01117181|Dopaminergic agents
392293|NCT01117181|Apathy Evaluation Scale
392294|NCT01117181|Dementia
392295|NCT01117168|Children's Oncology Group
392296|NCT01117168|Pediatric Oncology
392297|NCT01117168|Pediatric Cancer
392298|NCT01117168|Registration
392299|NCT01117168|Leukemia
392300|NCT01117168|Brain Tumor
392301|NCT01117168|Sarcoma
392302|NCT01117155|Brain Tumor
392303|NCT01117155|Imaging
392304|NCT01117155|FLT
392305|NCT01117155|FDG
392306|NCT01117155|Spectroscopy
392307|NCT01117155|Glioma
392308|NCT01117155|Glioblastoma Multiforme
392309|NCT01117155|Astrocytoma
392310|NCT01117142|CLL
392311|NCT01117142|MBL
392312|NCT01117142|SLL
392313|NCT01117142|MCL
392314|NCT01117142|Growth
392315|NCT01117142|Development
392316|NCT01117142|Aging
392317|NCT01117142|Chronic Lymphocytic Leukemia
392318|NCT01117142|Monoclonal B-Cell Lymphocytosis
392319|NCT01117142|Small Lymphocytic Lymphoma
392320|NCT01117142|Mantle Cell Lymphoma
392321|NCT01117142|Healthy Volunteer
392322|NCT01117142|HV
392323|NCT01117103|Type 2 diabetes
392324|NCT01117103|Diabetes Mellitus
392325|NCT01117103|Glucophage
392326|NCT01117103|Metformin
392327|NCT01117090|Feasibility
392328|NCT01117090|SynchroMed II
392329|NCT01117090|Intrathecal catheter
392330|NCT01117090|Baclofen
392331|NCT01117077|liver transplantation
392332|NCT01117077|aspergillus infection
392333|NCT01117077|interleukin-17
392334|NCT01117077|Treg cell
392335|NCT01117077|immune tolerance
392336|NCT01117064|Sleep Apnea
392337|NCT01117064|OSA
392338|NCT01117064|CPAP
392339|NCT01117051|Opioid induced constipation/prucalopride chronic non-cancer pain
392340|NCT01117051|Subjects with chronic non-cancer pain suffering from OIC
392341|NCT01117038|ED
392342|NCT01117038|Erectile Dysfunction
392343|NCT01117025|Resistant hypertension
392344|NCT01117025|Atrial Fibrillation
392345|NCT01117025|Percutaneous renal denervation
392346|NCT01116986|Smoking
392347|NCT01116986|Smoking Cessation
392348|NCT01116986|Nicotine
392349|NCT01116973|CVP monitoring compared with peripheral monitoring
392350|NCT01116960|P4P
392351|NCT01116960|anonomyous responses from each group will be compared to asses the attitude
392352|NCT01116947|Hypoalbuminemia
392353|NCT01116947|Hyperphosphatemia
392354|NCT01116947|Phosphorus
392355|NCT01116947|Protein
392356|NCT01116947|CKD
392357|NCT01116947|Dialysis
392358|NCT01116947|Meals
392359|NCT01116947|Lanthanum
392360|NCT01116947|End-Stage Renal Disease (ESRD)
392361|NCT01116947|Dietary Protein Intake (DPI)
392362|NCT01116947|Dietary Phosphorus Binding (DPB)
392363|NCT01116947|Protein-Energy Wasting (PEW)
392364|NCT01116947|Sources of Dietary Phosphorus
392365|NCT01116934|blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma
392366|NCT01116921|neonatal respiratory distress syndrome
392367|NCT01116921|surfactant
392368|NCT01116921|laryngeal mask airway
392369|NCT01116908|Diarrhea
392370|NCT01116908|Water
392371|NCT01116908|Household Water Treatment
392372|NCT01116908|HIV
392373|NCT01116908|Infant Health
392374|NCT01116895|Psoriasis Vulgaris
392375|NCT01116895|Systemic
392376|NCT01116895|Anti-psoriatic
392377|NCT01116882|PCI
392378|NCT01116882|heart disease
392379|NCT01116882|ischemic heart disease
392380|NCT01116869|MBC
392381|NCT01116869|Healthy
392382|NCT01116869|Benign disease
392383|NCT01116869|Confirmed metastatic breast cancer patient with at least one measurable solid tumor according to the RECIST guideline
392384|NCT01116869|Medical examinations detect no breast benign and malignant tumors
392385|NCT01116869|Benign Breast Disease
392386|NCT01116869|Pathology diagnosed breast benign tumor disease
392387|NCT01116856|Exercise
392388|NCT01116856|Training
392389|NCT01116856|Obesity
392390|NCT01116856|Overweight
392391|NCT01116856|Body composition
392392|NCT01116856|Lipidic profile
392393|NCT01116856|Nutrition
392394|NCT01116856|Polymorphisms
392395|NCT01116843|Oral cavity cancer
392396|NCT01116843|No prior treatment
392397|NCT01116817|Long-term Lopinavir/ritonavir monotherapy
392398|NCT01116817|neurocognitive performance
392399|NCT01116817|ultrasensitive CSF-viraemia
392400|NCT01116804|Primary liver cancer
392401|NCT01116791|cytoreductive surgery
392402|NCT01116791|peritoneal chemotherapy
392403|NCT01116791|cisplatin
392404|NCT01116791|cancer
392405|NCT01116791|gastric
392406|NCT01116791|biliary
392407|NCT01116791|pancreas
392408|NCT01116791|peritoneal metastases
392409|NCT01116791|liver metastases
392410|NCT01116791|peritoneal carcinomatosis from upper gastrointestinal cancer
392411|NCT01116778|perennial allergic rhinitis
392412|NCT01116778|probiotics
392413|NCT01116778|Lactobacillus paracasei GMNL-32 (eN-Lac®)
392414|NCT01116778|efficacy and safety
392415|NCT01116765|preterm infants born between 26 to 29 weeks of gestation age.
392416|NCT01116752|Intensive Care
392417|NCT01116752|Critical care
392418|NCT01116752|Glycemic Control
392419|NCT01116752|Hypoglycemia
392420|NCT01116752|Hyperglycemia
392421|NCT01116752|Insulin treatment
392422|NCT01116752|Organ Function
392423|NCT01116752|PELOD
392424|NCT01116752|Outcomes
392425|NCT01116752|Pediatrics
392426|NCT01116713|Mastectomy
392427|NCT01116713|Breast cancer
392428|NCT01116713|Postoperative pain
392429|NCT01116713|Postoperative nausea and vomiting
392430|NCT01116700|Epilepsy
392431|NCT01116700|Dexmedetomidine
392432|NCT01116700|Seizure
392433|NCT01116674|Intensive critical care, glycemic control, hypoglycemia, hyperglycemia , insulin treatment, intensive care outcomes, pediatrics
392434|NCT01116661|glioma
392435|NCT01116661|high grade glioma, low grade glioma
392436|NCT01116635|chemoembolization
392437|NCT01116635|drug eluting microsphere
392438|NCT01116635|hepato
392439|NCT01116635|embolotherapy
392440|NCT01116635|downstage
392441|NCT01116622|Aerodigestive
392442|NCT01116622|Targretin
392443|NCT01116622|Tarceva
392444|NCT01116609|Phenylalanine
392445|NCT01116609|Palmitate
392446|NCT01116609|hyperinsulinemic-euglycemic-clamp
392447|NCT01116609|Effects of epinephrine in healthy volunteers
392448|NCT01116596|Glutathione
392449|NCT01116596|Paracetamol
392450|NCT01116596|elderly people
392451|NCT01116583|Gabapentin
392452|NCT01116583|Thoracotomy
392453|NCT01116583|Pain, Postoperative
392454|NCT01116583|Analgesia
392455|NCT01116583|Recovery of Function
392456|NCT01116583|Quality of Life
392457|NCT01116570|Muscular Dystrophy
392458|NCT01116570|Facioscapulohumeral
392459|NCT01116570|Physical training
392460|NCT01116570|Exercise
392461|NCT01116557|radiofrequency
392462|NCT01116557|ablation
392463|NCT01116557|atrial fibrillation
392464|NCT01116557|CARTO
392465|NCT01116557|THERMOCOOL
392466|NCT01116557|LASSO
392467|NCT01116557|PVAC
392468|NCT01116544|AMES device
392469|NCT01116544|Cerebrovascular Accident
392470|NCT01116544|Chronic Stroke
392471|NCT01116544|Rehabilitation
392472|NCT01116544|Upper Extremity
392473|NCT01116544|Biofeedback
392474|NCT01116531|Pharmacokinetics
392475|NCT01116531|Pharmacodynamics
392476|NCT01116531|Interaction
392477|NCT01116531|tramadol
392478|NCT01116531|duloxetine
392479|NCT01116531|pregabalin
392480|NCT01116505|Celiac disease
392481|NCT01116505|Endomysial antibodies
392482|NCT01116505|Gluten-free diet
392483|NCT01116505|Screen-detected
392484|NCT01116505|Asymptomatic
392485|NCT01116505|Bone mineral density
392486|NCT01116492|SILS
392487|NCT01116492|Inflammatory reaction
392488|NCT01116492|a-defensins
392489|NCT01116492|SILS vs standard laparoscopic cholecystectomy
392490|NCT01116479|Anaemia, transfusion, cancer, chemotherapy, Quality of life
392491|NCT01116453|dysmenorrhea
392492|NCT01116453|acupuncture
392493|NCT01116453|randomized controlled trial
392494|NCT01116440|Menstrual pain
392495|NCT01116440|Refractory endometriosis
392496|NCT01116440|Pelvic pain
392497|NCT01116427|MS
392498|NCT01116427|multiple sclerosis
392499|NCT01116427|relapsing-remitting multiple sclerosis
392500|NCT01116427|RRMS
392501|NCT01116401|Hot Flashes
392502|NCT01116401|Sleep disturbance
392503|NCT01116401|Lupron
392504|NCT01116401|Menopause
392505|NCT01116388|Autism
392506|NCT01116388|Gastrointestinal Disorders
392507|NCT01116388|Food Allergy
392508|NCT01116388|Gluten free, casein free diet
392509|NCT01116388|Diarrhea
392510|NCT01116388|Constipation
392511|NCT01116388|Reflux
392512|NCT01116388|Abdominal pain
392513|NCT01116388|Pain after eating
392514|NCT01116388|Self injurious behavior
392515|NCT01116375|Obesity
392516|NCT01116375|OSA
392517|NCT01116375|PAP therapy
392518|NCT01116362|ulna
392519|NCT01116362|median
392520|NCT01116362|repair
392521|NCT01116362|primary
392522|NCT01116349|humeral diaphysis fracture
392523|NCT01116349|plate and screws for humeral diaphysis fracture
392524|NCT01116349|nailing for humerus diaphysis fracture
392525|NCT01116349|Hanging Support System
392526|NCT01116336|Pre-cancerous conditions
392527|NCT01116336|Head and neck tumors
392528|NCT01116336|Cancer of head and neck
392529|NCT01116323|Adverse events
392530|NCT01116323|Adverse effects
392531|NCT01116323|Emergency Service, Hospital
392532|NCT01116323|Emergency department
392533|NCT01116323|Crowding
392534|NCT01116310|Hot flushes
392535|NCT01116310|Hot flashes
392536|NCT01116310|menopause
392537|NCT01116310|postmenopause
392538|NCT01116310|Soy isoflavones
392539|NCT01116310|Red clover
392540|NCT01116310|Equol
392541|NCT01116297|breast reconstruction
392542|NCT01116297|breast cancer
392543|NCT01116297|near infrared imaging
392544|NCT01116284|Weight Loss
392545|NCT01116284|Obesity
392546|NCT01116284|Gastric Bypass
392547|NCT01116271|colorectal
392548|NCT01116271|second line therapy
392549|NCT01116271|K-ras or B-raf mutations
392550|NCT01116271|response rate
392551|NCT01116271|Progression Free Survival
392552|NCT01116258|Safety
392553|NCT01116245|Cervical Intraepithelial Neoplasia Stage 2/3
392554|NCT01116232|graft versus host disease
392555|NCT01116232|accelerated phase chronic myelogenous leukemia
392556|NCT01116232|adult acute lymphoblastic leukemia in remission
392557|NCT01116232|adult acute myeloid leukemia in remission
392558|NCT01116232|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
392559|NCT01116232|adult acute myeloid leukemia with inv(16)(p13;q22)
392560|NCT01116232|adult acute myeloid leukemia with t(15;17)(q22;q12)
392561|NCT01116232|adult acute myeloid leukemia with t(16;16)(p13;q22)
392562|NCT01116232|adult acute myeloid leukemia with t(8;21)(q22;q22)
392563|NCT01116232|atypical chronic myeloid leukemia, BCR-ABL negative
392564|NCT01116232|blastic phase chronic myelogenous leukemia
392565|NCT01116232|chronic myelomonocytic leukemia
392566|NCT01116232|chronic phase chronic myelogenous leukemia
392567|NCT01116232|meningeal chronic myelogenous leukemia
392568|NCT01116232|progressive hairy cell leukemia, initial treatment
392569|NCT01116232|prolymphocytic leukemia
392570|NCT01116232|recurrent adult acute lymphoblastic leukemia
392571|NCT01116232|recurrent adult acute myeloid leukemia
392572|NCT01116232|recurrent adult T-cell leukemia/lymphoma
392573|NCT01116232|refractory chronic lymphocytic leukemia
392574|NCT01116232|refractory hairy cell leukemia
392575|NCT01116232|relapsing chronic myelogenous leukemia
392576|NCT01116232|stage I adult T-cell leukemia/lymphoma
392577|NCT01116232|stage I chronic lymphocytic leukemia
392578|NCT01116232|stage II adult T-cell leukemia/lymphoma
392579|NCT01116232|stage II chronic lymphocytic leukemia
392580|NCT01116232|stage III adult T-cell leukemia/lymphoma
392581|NCT01116232|stage III chronic lymphocytic leukemia
392582|NCT01116232|stage IV adult T-cell leukemia/lymphoma
392583|NCT01116232|stage IV chronic lymphocytic leukemia
392584|NCT01116232|T-cell large granular lymphocyte leukemia
392585|NCT01116232|untreated adult acute lymphoblastic leukemia
392586|NCT01116232|untreated adult acute myeloid leukemia
392587|NCT01116232|untreated hairy cell leukemia
392588|NCT01116232|recurrent adult Hodgkin lymphoma
392589|NCT01116232|stage I adult Hodgkin lymphoma
392590|NCT01116232|stage II adult Hodgkin lymphoma
392591|NCT01116232|stage III adult Hodgkin lymphoma
392592|NCT01116232|stage IV adult Hodgkin lymphoma
392593|NCT01116232|anaplastic large cell lymphoma
392594|NCT01116232|angioimmunoblastic T-cell lymphoma
392595|NCT01116232|cutaneous B-cell non-Hodgkin lymphoma
392596|NCT01116232|recurrent cutaneous T-cell non-Hodgkin lymphoma
392597|NCT01116232|stage I cutaneous T-cell non-Hodgkin lymphoma
392598|NCT01116232|stage II cutaneous T-cell non-Hodgkin lymphoma
392599|NCT01116232|stage III cutaneous T-cell non-Hodgkin lymphoma
392600|NCT01116232|stage IV cutaneous T-cell non-Hodgkin lymphoma
392601|NCT01116232|recurrent mycosis fungoides/Sezary syndrome
392602|NCT01116232|stage I mycosis fungoides/Sezary syndrome
392603|NCT01116232|stage II mycosis fungoides/Sezary syndrome
392604|NCT01116232|stage III mycosis fungoides/Sezary syndrome
392605|NCT01116232|stage IV mycosis fungoides/Sezary syndrome
392606|NCT01116232|adult grade III lymphomatoid granulomatosis
392607|NCT01116232|adult nasal type extranodal NK/T-cell lymphoma
392608|NCT01116232|Waldenstrom macroglobulinemia
392609|NCT01116232|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
392610|NCT01116232|nodal marginal zone B-cell lymphoma
392611|NCT01116232|splenic marginal zone lymphoma
392612|NCT01116232|contiguous stage II adult Burkitt lymphoma
392613|NCT01116232|contiguous stage II adult diffuse large cell lymphoma
392614|NCT01116232|contiguous stage II adult diffuse mixed cell lymphoma
392615|NCT01116232|contiguous stage II adult diffuse small cleaved cell lymphoma
392616|NCT01116232|contiguous stage II adult immunoblastic large cell lymphoma
392617|NCT01116232|contiguous stage II adult lymphoblastic lymphoma
392618|NCT01116232|contiguous stage II grade 1 follicular lymphoma
392619|NCT01116232|contiguous stage II grade 2 follicular lymphoma
392620|NCT01116232|contiguous stage II grade 3 follicular lymphoma
392621|NCT01116232|contiguous stage II mantle cell lymphoma
392622|NCT01116232|contiguous stage II marginal zone lymphoma
392623|NCT01116232|contiguous stage II small lymphocytic lymphoma
392624|NCT01116232|stage I adult Burkitt lymphoma
392625|NCT01116232|stage I adult diffuse large cell lymphoma
392626|NCT01116232|stage I adult diffuse mixed cell lymphoma
392627|NCT01116232|stage I adult diffuse small cleaved cell lymphoma
392628|NCT01116232|stage I adult immunoblastic large cell lymphoma
392629|NCT01116232|stage I adult lymphoblastic lymphoma
392630|NCT01116232|stage I grade 1 follicular lymphoma
392631|NCT01116232|stage I grade 2 follicular lymphoma
392632|NCT01116232|stage I grade 3 follicular lymphoma
392633|NCT01116232|stage I mantle cell lymphoma
392634|NCT01116232|stage I marginal zone lymphoma
392635|NCT01116232|stage I small lymphocytic lymphoma
392636|NCT01116232|noncontiguous stage II adult Burkitt lymphoma
392637|NCT01116232|noncontiguous stage II adult diffuse large cell lymphoma
392638|NCT01116232|noncontiguous stage II adult diffuse mixed cell lymphoma
392639|NCT01116232|noncontiguous stage II adult diffuse small cleaved cell lymphoma
392640|NCT01116232|noncontiguous stage II adult immunoblastic large cell lymphoma
392641|NCT01116232|noncontiguous stage II adult lymphoblastic lymphoma
392642|NCT01116232|noncontiguous stage II grade 1 follicular lymphoma
392643|NCT01116232|noncontiguous stage II grade 2 follicular lymphoma
392644|NCT01116232|noncontiguous stage II grade 3 follicular lymphoma
392645|NCT01116232|noncontiguous stage II mantle cell lymphoma
392646|NCT01116232|noncontiguous stage II marginal zone lymphoma
392647|NCT01116232|noncontiguous stage II small lymphocytic lymphoma
392648|NCT01116232|stage III adult Burkitt lymphoma
392649|NCT01116232|stage III adult diffuse large cell lymphoma
392650|NCT01116232|stage III adult diffuse mixed cell lymphoma
392651|NCT01116232|stage III adult diffuse small cleaved cell lymphoma
392652|NCT01116232|stage III adult immunoblastic large cell lymphoma
392653|NCT01116232|stage III adult lymphoblastic lymphoma
392654|NCT01116232|stage III grade 1 follicular lymphoma
392655|NCT01116232|stage III grade 2 follicular lymphoma
392656|NCT01116232|stage III grade 3 follicular lymphoma
392657|NCT01116232|stage III mantle cell lymphoma
392658|NCT01116232|stage III marginal zone lymphoma
392659|NCT01116232|stage III small lymphocytic lymphoma
392660|NCT01116232|stage IV adult Burkitt lymphoma
392661|NCT01116232|stage IV adult diffuse large cell lymphoma
392662|NCT01116232|stage IV adult diffuse mixed cell lymphoma
392663|NCT01116232|stage IV adult diffuse small cleaved cell lymphoma
392664|NCT01116232|stage IV adult immunoblastic large cell lymphoma
392665|NCT01116232|stage IV adult lymphoblastic lymphoma
392666|NCT01116232|stage IV grade 1 follicular lymphoma
392667|NCT01116232|stage IV grade 2 follicular lymphoma
392668|NCT01116232|stage IV grade 3 follicular lymphoma
392669|NCT01116232|stage IV mantle cell lymphoma
392670|NCT01116232|stage IV marginal zone lymphoma
392671|NCT01116232|stage IV small lymphocytic lymphoma
392672|NCT01116232|recurrent adult Burkitt lymphoma
392673|NCT01116232|recurrent adult diffuse large cell lymphoma
392674|NCT01116232|recurrent adult diffuse mixed cell lymphoma
392675|NCT01116232|recurrent adult diffuse small cleaved cell lymphoma
392676|NCT01116232|recurrent adult grade III lymphomatoid granulomatosis
392677|NCT01116232|recurrent adult immunoblastic large cell lymphoma
392678|NCT01116232|recurrent adult lymphoblastic lymphoma
392679|NCT01116232|recurrent grade 1 follicular lymphoma
392680|NCT01116232|recurrent grade 2 follicular lymphoma
392681|NCT01116232|recurrent grade 3 follicular lymphoma
392682|NCT01116232|recurrent mantle cell lymphoma
392683|NCT01116232|recurrent marginal zone lymphoma
392684|NCT01116232|recurrent small lymphocytic lymphoma
392685|NCT01116232|intraocular lymphoma
392686|NCT01116232|post-transplant lymphoproliferative disorder
392687|NCT01116232|chronic eosinophilic leukemia
392688|NCT01116232|chronic neutrophilic leukemia
392689|NCT01116232|primary myelofibrosis
392690|NCT01116232|stage I multiple myeloma
392691|NCT01116232|stage II multiple myeloma
392692|NCT01116232|stage III multiple myeloma
392693|NCT01116232|refractory multiple myeloma
392694|NCT01116232|de novo myelodysplastic syndromes
392695|NCT01116232|previously treated myelodysplastic syndromes
392696|NCT01116232|myelodysplastic/myeloproliferative neoplasm, unclassifiable
392697|NCT01116219|adenocarcinoma of the lung
392698|NCT01116219|bronchoalveolar cell lung cancer
392699|NCT01116219|large cell lung cancer
392700|NCT01116219|stage IV non-small cell lung cancer
392701|NCT01116219|recurrent non-small cell lung cancer
392702|NCT01116206|Constipation
392703|NCT01116206|Prucalopride
392704|NCT01116206|Resolor
392705|NCT01116193|antileukemic therapy
392706|NCT01116193|lymphoblastic leukemia
392707|NCT01116193|lenalidomide
392708|NCT01116193|dexamethasone
392709|NCT01116180|Type 1 diabetes
392710|NCT01116180|Hypoglycaemia
392711|NCT01116180|genetic susceptibility
392712|NCT01116180|Renin angiotensin system activity
392713|NCT01116167|Polycystic Ovary Syndrome
392714|NCT01116141|rheumatoid arthritis
392715|NCT01116141|MTX
392716|NCT01116141|CH-405
392717|NCT01116141|antifolates
392718|NCT01116128|relapsed/refractory myeloma patients
392719|NCT01116128|Progression free survival
392720|NCT01116128|Overall survival
392721|NCT01116128|dasatinib
392722|NCT01116115|Term Infants
392723|NCT01116115|Intestine flora
392724|NCT01116115|Stool characteristics
392725|NCT01116102|dehydration
392726|NCT01116102|fluid therapy
392727|NCT01116102|hyaluronoglucosaminidase
392728|NCT01116102|hyaluronidase
392729|NCT01116102|hypodermoclysis
392730|NCT01116102|clysis
392731|NCT01116102|subcutaneous hydration
392732|NCT01116102|subcutaneous rehydration
392733|NCT01116102|hyaluronan
392734|NCT01116102|rHuPH20
392735|NCT01116089|Cystic fibrosis, tobramycin,nebulizer, PK
392736|NCT01116063|COPD, Pulmonary hypertension
392737|NCT01116037|Diseased Heart Valve, Replacement, Aortic, Stentless
392738|NCT01116024|Diseased Heart Valve, Replacement, Aortic
392739|NCT01116011|Phase I
392740|NCT01116011|Japanese Healthy volunteer
392741|NCT01115998|cerebral palsy
392742|NCT01115998|wheelchair
392743|NCT01115998|disabled children
392744|NCT01115985|ASP1585
392745|NCT01115985|Drug-drug interaction
392746|NCT01115985|Atorvastatin
392747|NCT01115985|Healthy volunteer
392748|NCT01115972|ASP1585
392749|NCT01115972|Drug-drug interaction
392750|NCT01115972|valsartan
392751|NCT01115972|Healthy volunteer
392752|NCT01115946|ASP1585
392753|NCT01115946|Drug-drug interaction
392754|NCT01115946|enalapril
392755|NCT01115946|Healthy volunteer
392756|NCT01115933|drug eluting stents
392757|NCT01115933|small vessel
392758|NCT01115933|Stents
392759|NCT01115933|Everolimus
392760|NCT01115933|Angioplasty
392761|NCT01115920|Drug Safety
392762|NCT01115920|Clinical Trial, Phase I
392763|NCT01115920|Nontherapeutic Human Experimentation
392764|NCT01115920|Heading Pharmacokinetics
392765|NCT01115920|Phase I Safety and Tolerability
392766|NCT01115907|Aortic
392767|NCT01115907|Valve replacement
392768|NCT01115894|problem drinking
392769|NCT01115894|alcohol
392770|NCT01115881|To examine the relationship between signal strength and macular thickness measured by stratus OCT
392771|NCT01115855|Double-blind
392772|NCT01115855|eplerenone
392773|NCT01115855|Japanese
392774|NCT01115842|Vitamin D
392775|NCT01115842|Acute coronary syndrome
392776|NCT01115842|inflammatory cytokines
392777|NCT01115803|Advanced Cancer
392778|NCT01115803|Metastatic Cancer
392779|NCT01115803|Non-Small Cell Lung Cancer
392780|NCT01115803|Renal Cell Carcinoma
392781|NCT01115803|Neuroendocrine Tumors
392782|NCT01115777|Pediatric patients
392783|NCT01115777|treated with
392784|NCT01115777|radiation therapy
392785|NCT01115777|for brain tumors
392786|NCT01115777|and non-CNS malignancies
392787|NCT01115764|diastolic dysfunction
392788|NCT01115751|Advanced Cancer
392789|NCT01115751|Metastatic Cancer
392790|NCT01115751|Solid Tumors
392791|NCT01115738|Plavix, Effient
392792|NCT01115725|Follitropin alfa
392793|NCT01115725|Fertilization in vitro
392794|NCT01115725|Intracytoplasmic sperm injection
392795|NCT01115725|Reproductive techniques, assisted
392796|NCT01115712|Healthy Volunteers
392797|NCT01115699|Depression
392798|NCT01115699|rTMS
392799|NCT01115660|stroke
392800|NCT01115660|patient education
392801|NCT01115660|medication adherence
392802|NCT01115647|Malnutrition
392803|NCT01115647|Nutritional intervention
392804|NCT01115647|Behavioural intervention
392805|NCT01115647|Burkina Faso
392806|NCT01115647|Cluster randomize trial
392807|NCT01115634|Fibroblast
392808|NCT01115634|Cell transplantation
392809|NCT01115634|Facial deformities
392810|NCT01115608|Preventive Health Services
392811|NCT01115595|Allergic rhinitis
392812|NCT01115595|Allergen injection immunotherapy
392813|NCT01115595|Efficacy
392814|NCT01115582|Inborn Errors
392815|NCT01115582|Bile Acid
392816|NCT01115582|Pediatrics
392817|NCT01115582|Liver Disease
392818|NCT01115569|chronic pain
392819|NCT01115504|Thiamine
392820|NCT01115504|heart failure
392821|NCT01115478|Malaria
392822|NCT01115478|Low birth weight
392823|NCT01115478|Anemia
392824|NCT01115478|Perinatal mortality
392825|NCT01115478|Vitamin A
392826|NCT01115478|Zinc
392827|NCT01115465|Stress Urinary Incontinence
392828|NCT01115465|silicone elastomer
392829|NCT01115452|potassium nitrate
392830|NCT01115452|tooth sensitivity
392831|NCT01115452|dentin sensitivity
392832|NCT01115439|falciparum malaria
392833|NCT01115439|artemisinin combination treatments
392834|NCT01115413|teenage
392835|NCT01115413|pregnancy
392836|NCT01115413|obstetrical risk
392837|NCT01115400|Abdominal Wall Hernia
392838|NCT01115400|quality of life
392839|NCT01115387|Age-related macular degeneration
392840|NCT01115387|AMD
392841|NCT01115387|Genetic risk
392842|NCT01115387|Environmental risk factors
392843|NCT01115387|Complex genetic disorder
392844|NCT01115387|Age-related maculopathy
392845|NCT01115387|Risk modeling
392846|NCT01115387|Smoking
392847|NCT01115387|Light exposure
392848|NCT01115387|Sleep apnea
392849|NCT01115387|Fundus Photography
392850|NCT01115387|Macula
392851|NCT01115387|Drusen
392852|NCT01115387|Wet AMD
392853|NCT01115387|Dry AMD
392854|NCT01115387|Geographic atrophy
392855|NCT01115387|Vitamins & supplements
392856|NCT01115361|family planning
392857|NCT01115361|postpartum
392858|NCT01115361|immunization
392859|NCT01115361|integration
392860|NCT01115361|Contraceptive behavior
392861|NCT01115335|neonatal male circumcision
392862|NCT01115335|Gomco
392863|NCT01115335|Plastibell
392864|NCT01115335|Mogen
392865|NCT01115335|Safety
392866|NCT01115335|Uptake
392867|NCT01115335|Acceptability
392868|NCT01115335|Feasibility
392869|NCT01115335|Zambia
392870|NCT01115322|Healthy volunteer study
392871|NCT01115322|phototoxicity
392872|NCT01115309|Sinusitis
392873|NCT01115296|Helicobacter Pylori
392874|NCT01115296|gastritis
392875|NCT01115296|Probiotics
392876|NCT01115296|Lactobacillus Reuteri
392877|NCT01115283|amblyopia treatment
392878|NCT01115283|neural plasticity
392879|NCT01115283|perceptual learning
392880|NCT01115283|vision therapy
392881|NCT01115283|spatial vision
392882|NCT01115283|video games
392883|NCT01115283|occlusion therapy
392884|NCT01115270|Normal Pressure Hydrocephalus
392885|NCT01115257|severe proliferative diabetic retinopathy
392886|NCT01115257|vitrectomy
392887|NCT01115257|panretinalphotocoagulation
392888|NCT01115244|Dermatitis herpetiformis
392889|NCT01115244|Dapsone
392890|NCT01115231|Age-Related Macular Degeneration
392891|NCT01115231|Age-Related Maculopathies
392892|NCT01115231|Age-Related Maculopathy
392893|NCT01115231|Macular Dystrophy
392894|NCT01115231|Maculopathies, Age-Related
392895|NCT01115231|Maculopathy, Age-Related
392896|NCT01115218|Glaucoma
392897|NCT01115205|Exercise, Walking, Type 2 diabetes, Therapy
392898|NCT01115179|propofol
392899|NCT01115179|inflammation
392900|NCT01115179|perioperative
392901|NCT01115179|lipids
392902|NCT01115179|Apolipoprotein A-I
392903|NCT01115166|blood volume
392904|NCT01115153|Acute appendicitis
392905|NCT01115153|Antibiotic prophylaxis
392906|NCT01115153|Wound infection
392907|NCT01115153|Nosocomial infection
392908|NCT01115140|Folate
392909|NCT01115140|Metformin
392910|NCT01115140|PCOS
392911|NCT01115140|Pregnancy
392912|NCT01115140|Trophoblastic invasion
392913|NCT01115140|Uterine artery velocimetry
392914|NCT01115127|pre-menopause
392915|NCT01115127|melatonin
392916|NCT01115127|myo-inositol
392917|NCT01115101|pain after cesarean
392918|NCT01115101|visual analog scale
392919|NCT01115101|oxycodon
392920|NCT01115101|piritramid
392921|NCT01115075|Leptin
392922|NCT01115075|Changes in leptin may precede the
392923|NCT01115075|phasing of oscillations of dietary fat intake
392924|NCT01115062|Pain
392925|NCT01115062|Children
392926|NCT01115062|Local anesthetics
392927|NCT01115036|glioblastoma
392928|NCT01115036|recurrent
392929|NCT01115036|surgical resection
392930|NCT01115023|iron deficiency anemia
392931|NCT01115023|dietary intervention
392932|NCT01115023|To evaluate a cheap and sustainable dietary intervention to improve the iron status of the entire family of the index case of non-severe iron deficiency anemia.
392933|NCT01115010|intubation rate
392934|NCT01115010|intubation time
392935|NCT01115010|stiffening device
392936|NCT01115010|stiffening wire
392937|NCT01114997|Lidocaine Infusion
392938|NCT01114997|Esmolol Infusion
392939|NCT01114997|Anesthetic adjuvant
392940|NCT01114997|Abdominal surgery
392941|NCT01114997|Pain management
392942|NCT01114997|Hemodynamic stability
392943|NCT01114997|Perioperative outcomes
392944|NCT01114984|Pain management
392945|NCT01114984|Radical mastectomy
392946|NCT01114984|Breast surgery
392947|NCT01114984|post-operative pain
392948|NCT01114971|Labetalol
392949|NCT01114971|Esmolol
392950|NCT01114971|Fentanyl
392951|NCT01114971|Anesthetic adjuvant
392952|NCT01114971|Ambulatory surgery
392953|NCT01114971|Outpatient surgery
392954|NCT01114971|Pain management
392955|NCT01114971|Hemodynamic stability
392956|NCT01114971|Perioperative outcomes
392957|NCT01114958|Lung cancer
392958|NCT01114958|Non-small cell lung cancer
392959|NCT01114958|Small-cell lung cancer
392960|NCT01114958|Lung metastases
392961|NCT01114958|Metastatic cancer
392962|NCT01114958|Stage IIIA
392963|NCT01114958|Stage IIIB
392964|NCT01114958|Stage III
392965|NCT01114958|Stage 3
392966|NCT01114945|Direct Laryngoscopy
392967|NCT01114945|Video-Mac
392968|NCT01114945|GlideScope
392969|NCT01114945|McGrath
392970|NCT01114945|Laryngoscopy
392971|NCT01114945|Bariatrics
392972|NCT01114945|Glottic view
392973|NCT01114945|Airway intubating devices
392974|NCT01114945|Tracheal intubation
392975|NCT01114932|pre-oxygenation
392976|NCT01114932|body mass index
392977|NCT01114932|end-tidal O2
392978|NCT01114932|anesthesia induction
392979|NCT01114919|Problem drinking
392980|NCT01114919|Alcohol dependence
392981|NCT01114919|Alcohol abuse
392982|NCT01114919|Internet based intervention
392983|NCT01114919|Treatment
392984|NCT01114919|Alcohol Use Disorders Identification Test
392985|NCT01114906|Asthma
392986|NCT01114906|Resource use
392987|NCT01114880|ankylosing spondylitis
392988|NCT01114880|China
392989|NCT01114867|ultrasound
392990|NCT01114867|penis length
392991|NCT01114867|corpus cavernosum
392992|NCT01114867|length of fetal penis and fetal corpus cavernosum
392993|NCT01114841|Healthy Volunteer Subjects
392994|NCT01114828|Cirrhosis
392995|NCT01114828|ascites
392996|NCT01114828|Tolvaptan
392997|NCT01114828|OPC-41061
392998|NCT01114815|CADASIL
392999|NCT01114815|cerebral
393000|NCT01114815|autosomal dominant
393001|NCT01114815|arteriopathy
393002|NCT01114815|subcortical infarcts
393003|NCT01114815|leukoencephalopathy
393004|NCT01114802|Cancer survivors
393005|NCT01114802|Anxiety
393006|NCT01114802|Depression
393007|NCT01114802|Technology Assisted
393008|NCT01114802|Internet
393009|NCT01114789|chronic renal failure
393010|NCT01114789|hemodialysis
393011|NCT01114789|obesity
393012|NCT01114789|proteolysis
393013|NCT01114763|Metabolic Syndrome
393014|NCT01114763|Oxidized Low Density Lipoprotein
393015|NCT01114763|Arterial Elasticity
393016|NCT01114763|Diabetes Mellitus
393017|NCT01114763|Cardiovascular Diseases
393018|NCT01114750|blood glucose
393019|NCT01114750|blood insulin
393020|NCT01114750|dextran
393021|NCT01114750|diabetes
393022|NCT01114750|hyperglycemia
393023|NCT01114750|hypoglycemia
393024|NCT01114750|oral delivery
393025|NCT01114750|portal delivery
393026|NCT01114737|Phenylketonuria
393027|NCT01114737|PKU
393028|NCT01114737|Kuvan
393029|NCT01114737|Sapropterin dihydrochloride
393030|NCT01114737|Neuropsychiatric disorder
393031|NCT01114737|ADHD
393032|NCT01114724|Thoracic dissection
393033|NCT01114724|Endovascular aortic repair
393034|NCT01114711|Menstrual Migraine
393035|NCT01114711|Frova
393036|NCT01114711|Imaging
393037|NCT01114711|fMRI
393038|NCT01114711|Pain
393039|NCT01114698|Depression
393040|NCT01114698|Major Depressive Disorder
393041|NCT01114698|Venlafaxine XR (EFFEXOR XR)
393042|NCT01114698|26489112
393043|NCT01114698|JNJ26489112
393044|NCT01114672|Pruritis in hemodialysis patients
393045|NCT01114672|25-Vitamin D in chronic kidney disease
393046|NCT01114646|Hemiarthroplasty
393047|NCT01114646|Cemented
393048|NCT01114646|Press Fit
393049|NCT01114646|Mortality
393050|NCT01114646|Morbidity
393051|NCT01114646|Functional Status
393052|NCT01114646|Displaced femoral neck fracture
393053|NCT01114633|PCOS
393054|NCT01114633|Acne
393055|NCT01114633|Hirsutism
393056|NCT01114620|elderly
393057|NCT01114620|post-marketing
393058|NCT01114620|H1N1
393059|NCT01114620|Clinical trial
393060|NCT01114620|pandemic influenza
393061|NCT01114607|relative bioavailability
393062|NCT01114607|GSK1605786
393063|NCT01114607|CCR9 receptor antagonist
393064|NCT01114594|Chronic Kidney Disease (CKD)
393065|NCT01114594|Autosomal Dominant Polycystic Kidney Disease (ADPKD)
393066|NCT01114581|Acute Respiratory Infection
393067|NCT01114581|Mucociliary
393068|NCT01114581|Cough Clearance
393069|NCT01114581|Guaifenesin
393070|NCT01114568|Relative Bioavailability
393071|NCT01114568|Pharmacokinetics
393072|NCT01114568|Pharmacodynamics
393073|NCT01114555|Bevacizumab
393074|NCT01114555|Irinotecan
393075|NCT01114555|Temozolomide
393076|NCT01114555|10-015
393077|NCT01114529|de novo renal allograft recipients
393078|NCT01114529|renal allograft function
393079|NCT01114529|CNI-free regimen
393080|NCT01114516|cervical insufficiency
393081|NCT01114503|GSK2136525
393082|NCT01114503|Pharmacodynamics
393083|NCT01114503|Safety
393084|NCT01114503|Otelixizumab
393085|NCT01114503|Thyroid eye disease
393086|NCT01114503|Graves' ophthalmopathy
393087|NCT01114503|Repeat dose
393088|NCT01114503|Intravenous infusion
393089|NCT01114503|Tolerability
393090|NCT01114503|EUGOGO
393091|NCT01114490|Hepatic Insufficiency
393092|NCT01114477|Transcranial magnetic stimulation
393093|NCT01114477|TMS
393094|NCT01114477|Observational study
393095|NCT01114477|Major Depression
393096|NCT01114464|Breast cancer
393097|NCT01114464|Ovarian reserve
393098|NCT01114464|Anti-Mullerian Hormone (AMH)
393099|NCT01114464|Chemotherapy
393100|NCT01114451|Cesarean delivery
393101|NCT01114451|Obesity
393102|NCT01114451|Skin staples
393103|NCT01114451|Wound complications
393104|NCT01114425|tolerability of post exposure to HIV infection prophylaxis
393105|NCT01114412|focus groups
393106|NCT01114412|overactive bladder
393107|NCT01114412|bladder sensations
393108|NCT01114399|Cardiovascular Disease
393109|NCT01114399|Cardiovascular Disease risk (mild to moderate)
393110|NCT01114399|Cholesterol
393111|NCT01114399|Ambulatory blood pressure
393112|NCT01114399|Arterial Stiffness
393113|NCT01114386|Smoking
393114|NCT01114386|Dyspnea
393115|NCT01114386|Cough
393116|NCT01114386|Exercise
393117|NCT01114373|Melatonin
393118|NCT01114373|Hypertension
393119|NCT01114373|Blood Pressure
393120|NCT01114373|Cardiovascular
393121|NCT01114373|Sleep
393122|NCT01114373|Nighttime
393123|NCT01114373|Nocturnal
393124|NCT01114373|Catecholamines
393125|NCT01114373|Sympathetic Nervous System
393126|NCT01114373|Endothelial Function
393127|NCT01114373|African American
393128|NCT01114360|Melatonin
393129|NCT01114360|Hypertension
393130|NCT01114360|Blood Pressure
393131|NCT01114360|Cardiovascular
393132|NCT01114360|Sleep
393133|NCT01114360|Nighttime
393134|NCT01114360|Nocturnal
393135|NCT01114360|Catecholamines
393136|NCT01114360|Sympathetic Nervous System
393137|NCT01114360|Endothelial function
393138|NCT01114360|African American
393139|NCT01114321|Idiopathic Parkinson's disease
393140|NCT01114321|Glucose intolerance
393141|NCT01114321|Diabetes
393142|NCT01114321|OGTT
393143|NCT01114321|Patient with an Idiopathic Parkinson's disease
393144|NCT01114308|opioid dependence
393145|NCT01114308|opioid addiction
393146|NCT01114308|buprenorphine
393147|NCT01114308|implant
393148|NCT01114308|methadone
393149|NCT01114308|heroin
393150|NCT01114308|suboxone
393151|NCT01114308|opioid pain medication
393152|NCT01114308|opioid withdrawal
393153|NCT01114295|overt
393154|NCT01114295|obscure
393155|NCT01114295|gastrointestinal
393156|NCT01114295|bleeding
393157|NCT01114295|hemorrhage
393158|NCT01114269|Coronary Artery Disease
393159|NCT01114269|Sudden Cardiac Death
393160|NCT01114269|Myocardial Infarction
393161|NCT01114269|Percutaneous coronary intervention
393162|NCT01114269|Implantable Cardiac Defibrillator
393163|NCT01114230|Advanced Renal Cell Carcinoma
393164|NCT01114230|Advanced Kidney Cancer
393165|NCT01114230|AGS-16M8F
393166|NCT01114217|Iron deficiency anemia
393167|NCT01114217|Feraheme
393168|NCT01114217|ferumoxytol
393169|NCT01114217|AUB
393170|NCT01114217|cancer
393171|NCT01114217|GI disorders
393172|NCT01114217|postpartum anemia
393173|NCT01114217|The treatment of iron deficiency anemia (IDA)
393174|NCT01114204|Iron deficiency anemia
393175|NCT01114204|Feraheme
393176|NCT01114204|ferumoxytol
393177|NCT01114204|iron sucrose
393178|NCT01114204|Venofer
393179|NCT01114204|AUB
393180|NCT01114204|cancer
393181|NCT01114204|GI disorders
393182|NCT01114204|postpartum anemia
393183|NCT01114204|The treatment of iron deficiency anemia (IDA)
393184|NCT01114178|questionnaire
393185|NCT01114178|peripheral artery disease
393186|NCT01114178|exercise
393187|NCT01114165|Neutropenia
393188|NCT01114165|Febrile Neutropenia
393189|NCT01114165|Sepsis
393190|NCT01114165|Polymerase Chain Reaction
393191|NCT01114152|AZD9742
393192|NCT01114152|Japanese Healthy Volunteers
393193|NCT01114152|Phase I
393194|NCT01114152|Single and Multiple Ascending Dose
393195|NCT01114139|Iron deficiency anemia
393196|NCT01114139|Feraheme
393197|NCT01114139|ferumoxytol
393198|NCT01114139|AUB
393199|NCT01114139|cancer
393200|NCT01114139|GI disorders
393201|NCT01114139|postpartum anemia
393202|NCT01114139|The treatment of iron deficiency anemia (IDA)
393203|NCT01114126|Neu-P11
393204|NCT01114126|Insomnia
393205|NCT01114126|PSG
393206|NCT01114126|safety
393207|NCT01114113|IBS-D
393208|NCT01114113|Post meal Diarrhea
393209|NCT01114113|Trigger meals
393210|NCT01114100|chest pain
393211|NCT01114100|panic attacks
393212|NCT01114100|palpitations
393213|NCT01114100|depression
393214|NCT01114100|panic disorder
393215|NCT01114100|depressive disorder
393216|NCT01114100|non cardiac chest pain
393217|NCT01114087|Spermatogenesis
393218|NCT01114087|Inhibitors of tyrosine kinase
393219|NCT01114087|Fragmentation of the spermatic DNA
393220|NCT01114074|Thrombosis
393221|NCT01114074|Blood coagulation
393222|NCT01114074|Perfusion flow experiments
393223|NCT01114074|Factor XII
393224|NCT01114074|Factor XI
393225|NCT01114074|Prekallikrein
393226|NCT01114074|High molecular weight kininogen
393227|NCT01114061|diabetes
393228|NCT01114061|postprandial glucose level
393229|NCT01114061|insulin pharmacodynamics
393230|NCT01114061|Insulin Pharmacokinetics
393231|NCT01114048|age under 65
393232|NCT01114048|Previous untreated
393233|NCT01114035|intestinal epithelial dysplasia
393234|NCT01114035|characterization phenotypic
393235|NCT01114035|genetic study
393236|NCT01114035|"or  tufting enteropathy "
393237|NCT01114022|Acute respiratory failure
393238|NCT01114009|recruitment maneuvers
393239|NCT01114009|ARDS
393240|NCT01114009|lung protective strategy
393241|NCT01114009|ARDS, Human
393242|NCT01113996|Obesity
393243|NCT01113996|Gastric by-pass
393244|NCT01113996|Body composition
393245|NCT01113996|Nutrition
393246|NCT01113996|Physical activity
393247|NCT01113983|SAPIEN XT Valve, Cardiovascular Disease, Valvular Heart Disease, Aortic Stenosis, Heart Valve Therapy, Transapical, Transcatheter, Transfemoral
393248|NCT01113970|breast cancer
393249|NCT01113970|Indibulin
393250|NCT01113970|unresectable, locally advanced breast cancer
393251|NCT01113957|Ovarian Cancer
393252|NCT01113931|Chlamydia
393253|NCT01113918|Obesity,
393254|NCT01113918|PCOS,
393255|NCT01113918|HA,
393256|NCT01113918|CVD
393257|NCT01113905|Fatigue
393258|NCT01113905|Breast Cancer
393259|NCT01113879|rehabilitation
393260|NCT01113879|aphasia
393261|NCT01113879|exercise
393262|NCT01113879|fMRI
393263|NCT01113879|BDNF
393264|NCT01113853|asthma
393265|NCT01113853|exhaled nitric oxide
393266|NCT01113853|lung function
393267|NCT01113840|elderly
393268|NCT01113840|heart failure
393269|NCT01113840|exercise
393270|NCT01113840|diastolic dysfunction
393271|NCT01113827|Olive
393272|NCT01113827|antioxidant
393273|NCT01113827|exercise
393274|NCT01113827|inflammation
393275|NCT01113827|recovery
393276|NCT01113827|Healthy men
393277|NCT01113801|Chronic Kidney Disease
393278|NCT01113801|Diabetic Kidney Disease
393279|NCT01113801|End-Stage Renal Disease
393280|NCT01113801|Transforming Growth Factor beta 1 Monoclonal Antibody
393281|NCT01113801|Type 1 Diabetes
393282|NCT01113801|Type 2 Diabetes
393283|NCT01113788|atrial flutter, tricuspid isthmus, ablation
393284|NCT01113775|pulmonary embolism
393285|NCT01113775|computed tomography
393286|NCT01113762|Arthroplasty, Replacement, Hip
393287|NCT01113762|Bone Density
393288|NCT01113762|Rehabilitation
393289|NCT01113762|T-Lymphocytes
393290|NCT01113762|Chromium Alloys
393291|NCT01113749|Dementia
393292|NCT01113749|Nutrition
393293|NCT01113749|Feeding
393294|NCT01113736|Ileostomy
393295|NCT01113736|Stenosis
393296|NCT01113736|Surgical Wound Dehiscence
393297|NCT01113736|Peritoneal
393298|NCT01113736|Colorectal Surgery
393299|NCT01113723|C-MAC
393300|NCT01113723|Fiberoptic bronchoscope
393301|NCT01113723|Laryngoscopy
393302|NCT01113723|Cervical spine injury
393303|NCT01113723|Glottic view
393304|NCT01113723|Tracheal intubation
393305|NCT01113710|Rotigotine
393306|NCT01113710|Neupro®
393307|NCT01113710|Restless Legs Syndrome
393308|NCT01113697|allergen challenge
393309|NCT01113697|blood draw
393310|NCT01113697|gene expression analysis
393311|NCT01113697|protein analysis
393312|NCT01113697|genetics
393313|NCT01113671|Diabetes Mellitus type 2
393314|NCT01113671|Haptoglobin phenotype
393315|NCT01113671|Vitamin E
393316|NCT01113658|negative pressure wound therapy
393317|NCT01113658|NPWT
393318|NCT01113658|Spiracur
393319|NCT01113658|SNaP Wound Care System
393320|NCT01113645|Decompressive craniectomy
393321|NCT01113645|Cranioplasty
393322|NCT01113645|Cerebral blood flow
393323|NCT01113645|Cerebral hemodynamic
393324|NCT01113645|Neurological-cognitive test GOS, FAB, MMSE,
393325|NCT01113645|Transcranial Doppler
393326|NCT01113632|Chronic Lymphocytic Leukemia
393327|NCT01113632|Small Lymphocytic Lymphoma
393328|NCT01113632|Ofatumumab
393329|NCT01113619|lactose maldigestion
393330|NCT01113619|dairy intolerance
393331|NCT01113619|intolerance to milk
393332|NCT01113619|intolerance to dairy
393333|NCT01113619|milk intolerance
393334|NCT01113619|GI disorder
393335|NCT01113619|lactose metabolism
393336|NCT01113619|GI symptoms after dairy ingestion
393337|NCT01113606|Moderate to severe facial photo damage
393338|NCT01113606|Periocular or perioral fine wrinkles
393339|NCT01113593|COPD
393340|NCT01113567|Hepatic Encephalopathy
393341|NCT01113567|Liver Cirrhosis
393342|NCT01113567|Disaccharides
393343|NCT01113567|Lactose
393344|NCT01113567|Quality of Life
393345|NCT01113541|Ziprasidone
393346|NCT01113541|Bipolar Disorder
393347|NCT01113541|Metabolic Syndrome
393348|NCT01113528|Bone allograft
393349|NCT01113528|IL-1
393350|NCT01113528|IL-10
393351|NCT01113528|periodontal regeneration
393352|NCT01113528|omega-3
393353|NCT01113528|aspirin
393354|NCT01113515|Diabetic foot ulcer
393355|NCT01113515|Diabetic wound
393356|NCT01113515|chronic non healing ulcer
393357|NCT01113476|Advanced Malignancies
393358|NCT01113476|Nab-paclitaxel
393359|NCT01113476|Gemcitabine
393360|NCT01113476|Bevacizumab
393361|NCT01113463|Brain Tumor
393362|NCT01113463|Central Nervous System
393363|NCT01113463|CNS
393364|NCT01113463|Glioblastoma Multiforme
393365|NCT01113463|GBM
393366|NCT01113463|TPI 287
393367|NCT01113463|Radiation Therapy
393368|NCT01113463|Temozolomide
393369|NCT01113463|Chemotherapy
393370|NCT01113463|taxanes
393371|NCT01113450|hearing, newborn, screening
393372|NCT01113437|Bronchial Asthma
393373|NCT01113437|Allergy
393374|NCT01113424|Smoking Cessation
393375|NCT01113424|Nicotine pharmacokinetics
393376|NCT01113411|humerus fracture
393377|NCT01113411|locked plate
393378|NCT01113398|glioblastoma multiforme
393379|NCT01113398|gliosarcoma
393380|NCT01113398|malignant glioma
393381|NCT01113398|glioma
393382|NCT01113398|Avastin
393383|NCT01113398|bevacizumab
393384|NCT01113398|AMG 102
393385|NCT01113398|rilotumumab
393386|NCT01113398|recurrent
393387|NCT01113398|Duke
393388|NCT01113398|Pro00022491
393389|NCT01113385|Nephrotic syndrome
393390|NCT01113385|Focal Segmental glomerulosclerosis
393391|NCT01113385|FSGS
393392|NCT01113385|Minimal change
393393|NCT01113385|Steroid resistant
393394|NCT01113385|Pediatric
393395|NCT01113385|Proteinuria
393396|NCT01113385|Galactose
393397|NCT01113385|FSPF
393398|NCT01113372|Coronary, Disease
393399|NCT01113359|HCMV infection
393400|NCT01113359|Hypertension
393401|NCT01113359|The Potential Link Between HCMV Infection and Essential Hypertension
393402|NCT01113346|enterosorbent
393403|NCT01113346|sorbent
393404|NCT01113346|gastrointestinal decontamination
393405|NCT01113346|viral diarrhea
393406|NCT01113346|rotavirus
393407|NCT01113346|Filtrum
393408|NCT01113346|Filtrum-STI
393409|NCT01113346|lignin
393410|NCT01113320|Safinamide - Parkinson's disease - Levodopa induced dyskinesia
393411|NCT01113320|Advanced idiopathic PD patients treated with L-dopa and suffering from temporally predictable L-dopa induced peak-dose dyskinesia.
393412|NCT01113307|Chronic ulcers
393413|NCT01113307|pressure ulcers
393414|NCT01113307|venous ulcers
393415|NCT01113307|diabetic foot ulcers
393416|NCT01113307|post operative ulcers
393417|NCT01113307|hard to heal ulcers
393418|NCT01113281|Tuberculosis
393419|NCT01113281|Vaccine
393420|NCT01113281|Live Vaccine
393421|NCT01113281|rBCG
393422|NCT01113268|Patient collection
393423|NCT01113268|Cardiac remodelling
393424|NCT01113268|Echography
393425|NCT01113268|Magnetic Resonance Imaging
393426|NCT01113268|Gene polymorphisms
393427|NCT01113268|Biomarkers
393428|NCT01113255|VENTILATORS
393429|NCT01113255|BENCH EVALUATION
393430|NCT01113255|MECHANICAL VENTILATION
393431|NCT01113242|Parkinson Disease Dementia
393432|NCT01113242|Observational
393433|NCT01113242|Case control
393434|NCT01113242|Neuropsychological assessment
393435|NCT01113229|Post Partum Haemorrhage,
393436|NCT01113229|oxytocin,
393437|NCT01113229|misoprostol,
393438|NCT01113229|prevention,
393439|NCT01113229|delivery.
393440|NCT01113216|CF
393441|NCT01113216|CFRD
393442|NCT01113216|Diabetes
393443|NCT01113216|Genetic Modifiers
393444|NCT01113203|resistance training
393445|NCT01113203|blood pressure
393446|NCT01113203|hemodynamics
393447|NCT01113203|autonomic
393448|NCT01113203|Elderly Subjects
393449|NCT01113177|Mandibular growth temporomandibular arthritis
393450|NCT01113164|ondansetron
393451|NCT01113164|sertraline
393452|NCT01113164|lab studies
393453|NCT01113164|alcoholism
393454|NCT01113164|alcohol dependence
393455|NCT01113151|Steroid-resistant
393456|NCT01113151|Severe asthmatics
393457|NCT01113151|Annual symptoms
393458|NCT01113151|Daily magnesium supplement
393459|NCT01113151|ACT (asthma control test)
393460|NCT01113138|Clearance
393461|NCT01113138|Half-life
393462|NCT01113138|Absorption fraction
393463|NCT01113138|Pharmacokinetics
393464|NCT01113125|hypertrophic scar
393465|NCT01113125|keloid
393466|NCT01113125|central venous catheter
393467|NCT01113125|children
393468|NCT01113125|cancer
393469|NCT01113112|Ovarian Neoplasms
393470|NCT01113086|Parkinson
393471|NCT01113086|Transcranial direct current stimulation
393472|NCT01113086|Motor function
393473|NCT01113086|Cognitive function
393474|NCT01113086|Affective function
393475|NCT01113073|pulse pressure variation
393476|NCT01113073|hemodynamic monitoring
393477|NCT01113073|fluid responsiveness
393478|NCT01113073|mechanical ventilation
393479|NCT01113073|fluid therapy
393480|NCT01113060|Coronary Artery Disease
393481|NCT01113060|Aspirin
393482|NCT01113060|Secondary Prevention
393483|NCT01113047|Hypertension
393484|NCT01113047|Aliskiren
393485|NCT01113047|Amlodipine
393486|NCT01113034|Asthma
393487|NCT01113034|Bronchiectasis
393488|NCT01113008|Myocardial Reperfusion Injury/mortality
393489|NCT01113008|Coronary angioplasty
393490|NCT01113008|Reperfusion
393491|NCT01113008|Myocardial Reperfusion Injury/prevention & control
393492|NCT01112995|Probiotic
393493|NCT01112995|Lactobacillus
393494|NCT01112995|Antibiotic resistance
393495|NCT01112982|Gout
393496|NCT01112982|Synovial pannus
393497|NCT01112982|Magnetic resonance imaging
393498|NCT01112969|Internet-based supportive coaching
393499|NCT01112969|guided self-help
393500|NCT01112969|Caregivers
393501|NCT01112969|Brain Injury
393502|NCT01112969|Caregiver Burden
393503|NCT01112969|Coping
393504|NCT01112969|Stress
393505|NCT01112969|Depression
393506|NCT01112956|HSV-2
393507|NCT01112956|HSV-1
393508|NCT01112956|Sensitivity
393509|NCT01112956|Specificity
393510|NCT01112956|Testing algorithm
393511|NCT01112956|Test evaluation
393512|NCT01112943|Acupuncture, Pulmonary Rehabilitation, Inflammation, COPD
393513|NCT01112930|essential fatty acids
393514|NCT01112930|DHA
393515|NCT01112930|preschool children
393516|NCT01112930|docosahexanoic acid (DHA)
393517|NCT01112904|essential fatty acids
393518|NCT01112904|DHA status
393519|NCT01112904|preschool children
393520|NCT01112904|gestation
393521|NCT01112891|Vitamin D
393522|NCT01112891|Infant
393523|NCT01112891|Lactation
393524|NCT01112891|Dose-Response
393525|NCT01112878|Shoulder arthroscopy
393526|NCT01112878|Knee arthroscopy
393527|NCT01112878|Clonidine
393528|NCT01112878|Gabapentin
393529|NCT01112878|Pain management
393530|NCT01112878|Ambulatory surgery
393531|NCT01112878|Perioperative outcome
393532|NCT01112878|Analgesia
393533|NCT01112865|Growth Hormone Deficiency
393534|NCT01112865|Somatropin
393535|NCT01112865|Injection Pen
393536|NCT01112865|Medical Device
393537|NCT01112865|Cross Over Study
393538|NCT01112865|Preference
393539|NCT01112865|Convenience
393540|NCT01112865|Children
393541|NCT01112865|Dyads
393542|NCT01112865|Adults
393543|NCT01112852|control of bleed
393544|NCT01112839|Overweight
393545|NCT01112839|Obese
393546|NCT01112839|Breast cancer survivors
393547|NCT01112839|Weight loss
393548|NCT01112839|Exercise
393549|NCT01112839|Physical activity
393550|NCT01112826|triple-negative breast cancer
393551|NCT01112826|metronomic chemotherapy
393552|NCT01112826|capecitabine (xeloda)
393553|NCT01112813|Stroke
393554|NCT01112813|lithium
393555|NCT01112813|MRI
393556|NCT01112813|gray matter
393557|NCT01112800|Anthracycline
393558|NCT01112800|Cardiac Muscle Injury
393559|NCT01112800|Doxorubicin
393560|NCT01112800|Doppler Imaging
393561|NCT01112800|Intermediate non-rhabdomyosarcoma soft tissue sarcomas
393562|NCT01112800|High-risk non-rhabdomyosarcoma soft tissue sarcomas
393684|NCT01112189|Breast Cancer
393563|NCT01112787|Healthy Volunteer Subjects
393564|NCT01112774|Transcranial direct current stimulation
393565|NCT01112774|Spinal cord injury
393566|NCT01112774|Chronic pain
393567|NCT01112774|Brain excitability
393568|NCT01112761|Athletes
393569|NCT01112761|Multiple Concussions
393570|NCT01112761|Transcranial Stimulation
393571|NCT01112748|Focal neuropathic pain
393572|NCT01112735|Abdominoplasty
393573|NCT01112735|Flap adherence in subjects undergoing abdominoplasty to eliminate dead space and reduce seroma/hematoma formation
393574|NCT01112722|honeybee toxin
393575|NCT01112722|Apitox
393576|NCT01112722|pain
393577|NCT01112722|inflammation
393578|NCT01112722|osteoarthritis
393579|NCT01112722|Apitoxin
393580|NCT01112709|Diabetes
393581|NCT01112709|Prediabetes
393582|NCT01112709|Resistance training
393583|NCT01112709|behavior
393584|NCT01112709|behavioral change theory
393585|NCT01112696|diabetes
393586|NCT01112696|glucose sensor
393587|NCT01112696|CGM
393588|NCT01112683|Down syndrome
393589|NCT01112683|Trisomy 21
393590|NCT01112683|Pattern Recognition Memory (PRM)
393591|NCT01112683|Paired Associates Learning (PAL)
393592|NCT01112683|California Verbal Learning Test (CVLT)
393593|NCT01112683|Test of Reception of Grammar (TROG-II)
393594|NCT01112683|Peabody Picture Vocabulary Test (PPVT-III)
393595|NCT01112683|Scales of Independent Behavior revised (SIB-R)
393596|NCT01112670|Healthy volunteers
393597|NCT01112657|Multiple Sclerosis
393598|NCT01112657|Clinical isolated syndrome
393599|NCT01112657|Demyelination
393600|NCT01112631|NSCLC,
393601|NCT01112631|PORT,
393602|NCT01112631|Quality of Life,
393603|NCT01112631|Pulmonary function after RT
393604|NCT01112618|Infertility
393605|NCT01112618|Reproductive technologies, Assisted
393606|NCT01112618|r-hFSH
393607|NCT01112618|r-hLH
393608|NCT01112618|Pergoveris
393609|NCT01112605|achilles tendon
393610|NCT01112605|sural nerve
393611|NCT01112605|distance
393612|NCT01112605|US
393613|NCT01112605|ultrasound
393614|NCT01112605|Distance between Sural nerve and the Achilles tendon
393615|NCT01112592|NETs
393616|NCT01112592|Infections
393617|NCT01112592|Neutrophil function
393618|NCT01112553|Acute Migraine
393619|NCT01112553|Treximet
393620|NCT01112553|Imaging
393621|NCT01112553|fMRI
393622|NCT01112553|Pain
393623|NCT01112553|Heat Stimulus
393624|NCT01112540|to evaluate the anal. efficacy of IV morph. vs. place. for elderly presenting to the ED with UAP and determine if it has an impact on diag. accu. and phy. exam
393625|NCT01112527|PF-00299804
393626|NCT01112514|ICG
393627|NCT01112514|indocyanine green
393628|NCT01112501|Diagnosis
393629|NCT01112501|Dementia
393630|NCT01112501|Imaging
393631|NCT01112488|stroke
393632|NCT01112488|patient engagement programme
393633|NCT01112488|community rehabilitation
393634|NCT01112488|new carer
393635|NCT01112462|Nasal congestion, Headache
393636|NCT01112449|selenium
393637|NCT01112449|oxidative stress
393638|NCT01112449|prostate cancer
393639|NCT01112449|PSA
393640|NCT01112449|glucose
393641|NCT01112436|Pain
393642|NCT01112436|preemptive
393643|NCT01112436|Postoperative
393644|NCT01112436|delirium
393645|NCT01112410|Bronchiectasis
393646|NCT01112410|Hypertonic saline
393647|NCT01112397|Jak2
393648|NCT01112397|cancer
393649|NCT01112397|jak 1
393650|NCT01112397|stat 3
393651|NCT01112397|Phase 1
393652|NCT01112371|scars after abdominal Caesarean section
393653|NCT01112358|Lutropin alfa
393654|NCT01112358|Fertilization in vitro
393655|NCT01112358|Intracytoplasmic sperm injection
393656|NCT01112358|Reproductive techniques, assisted
393657|NCT01112345|Multiple Sclerosis, Relapsing-Remitting
393658|NCT01112345|Interferon-beta
393659|NCT01112319|COLD HOT or Electrotherapy treatment
393660|NCT01112306|Open-label
393661|NCT01112306|PAH
393662|NCT01112306|Pulmonary Arterial Hypertension
393663|NCT01112293|Subjects who have pleural malignant mesothelioma
393664|NCT01112280|Colorectal neoplasm
393665|NCT01112280|Colonoscopy
393666|NCT01112280|chromoendoscopy
393667|NCT01112280|cap-assisted colonoscopy
393668|NCT01112267|Chronic low back pain
393669|NCT01112267|Tramadol Hydrochloride (HCl)
393670|NCT01112267|acetaminophen
393671|NCT01112254|Ductal Carcinoma In Situ (DCIS) breast cancer
393672|NCT01112241|Obliterative bronchiolitis
393673|NCT01112241|Bronchodilator responsiveness
393674|NCT01112241|Partial forced expiratory flow
393675|NCT01112241|Lung volumes
393676|NCT01112215|SLE
393677|NCT01112215|non-renal manifestations
393678|NCT01112202|direct thrombin inhibitors
393679|NCT01112202|Dabigatran
393680|NCT01112202|Coagulation parameters
393681|NCT01112189|Lymphedema
393682|NCT01112189|Stem cells
393683|NCT01112189|Mastectomy
393685|NCT01112176|Strain
393686|NCT01112176|Ejection fraction
393687|NCT01112176|Diastolic function
393688|NCT01112163|ischemic heart disease
393689|NCT01112150|Edema
393690|NCT01112150|Heart failure
393691|NCT01112150|Pulmonary hypertension
393692|NCT01112150|Edema in legs
393693|NCT01112124|Typical
393694|NCT01112124|Development
393695|NCT01112124|Microwave
393696|NCT01112124|Children
393697|NCT01112124|Behavior
393698|NCT01112085|Diabetic macular edema
393699|NCT01112085|Ranibizumab
393700|NCT01112072|keratoconus
393701|NCT01112072|corneal ectasia
393702|NCT01112072|collagen crosslinking
393703|NCT01112072|riboflavin
393704|NCT01112072|cornea
393705|NCT01112072|ultraviolet
393706|NCT01112059|cystic fibrosis
393707|NCT01112046|Early colorectal neoplasms
393708|NCT01112033|biliverdin reductase
393709|NCT01112033|BLVRA
393710|NCT01112033|hepatitis C
393711|NCT01112033|HCV
393712|NCT01112033|peripheral blood mononuclear cells
393713|NCT01112033|PBMC
393714|NCT01112033|liver
393715|NCT01112033|genetic polymorphisms
393716|NCT01112020|Chlorhexidine digluconate (CHG)
393717|NCT01112020|Biopatch Protective Disk
393718|NCT01112020|Tegaderm CHG IV (intravenous) Securement Dressing
393719|NCT01112020|parachloroaniline (PCA)
393720|NCT01112020|No condition being studied.
393721|NCT01112020|Assessing components of CHG-containing dressings after use.
393722|NCT01112007|Insulin Resistance
393723|NCT01112007|Hypertension
393724|NCT01112007|Blood pressure
393725|NCT01112007|Aldosterone
393726|NCT01112007|Renin
393727|NCT01111994|hyperpigmentation
393728|NCT01111981|alopecia
393729|NCT01111981|CCCA - Central Centrifugal Cicatricial Alopecia
393730|NCT01111968|vaccine
393731|NCT01111968|pandemic influenza A
393732|NCT01111968|adjuvant
393733|NCT01111968|safety
393734|NCT01111942|head and neck cancer
393735|NCT01111942|chemotherapy
393736|NCT01111942|radiation
393737|NCT01111929|Emergency contraception
393738|NCT01111929|pregnancy during breastfeeding
393739|NCT01111929|Lactational amenorrhea Method
393740|NCT01111929|unplanned pregnancy
393741|NCT01111877|ear tubes
393742|NCT01111877|ear drainage
393743|NCT01111877|ear infection
393744|NCT01111877|ear drops
393745|NCT01111877|tympanostomy tubes
393746|NCT01111877|Pediatric patients
393747|NCT01111851|NK1-receptor occupancy
393748|NCT01111838|STA-9090
393749|NCT01111838|colon
393750|NCT01111838|rectal
393751|NCT01111838|10-029
393752|NCT01111825|HKI-272 (NERATINIB)
393753|NCT01111825|TEMSIROLIMUS (CCI-779)
393754|NCT01111825|HER2-Amplified
393755|NCT01111825|Triple-negative
393756|NCT01111825|invasive adenocarcinoma
393757|NCT01111825|10-005
393758|NCT01111812|overweight
393759|NCT01111812|obese
393760|NCT01111812|children
393761|NCT01111812|weighing
393762|NCT01111812|weight
393763|NCT01111799|endometrial biopsy
393764|NCT01111799|implantation
393765|NCT01111799|uterine receptivity
393766|NCT01111799|infertility
393767|NCT01111799|controled ovarian hyperstimulation
393768|NCT01111799|intra uterine insemination
393769|NCT01111786|scleroderma
393770|NCT01111786|skin
393771|NCT01111786|tightness
393772|NCT01111786|durometer
393773|NCT01111773|Patellar tendonitis
393774|NCT01111760|cardiovascular disease
393775|NCT01111760|heart CT scan
393776|NCT01111760|CT scan
393777|NCT01111760|pulmonary embolisms
393778|NCT01111760|aortography
393779|NCT01111747|platelet-rich plasma
393780|NCT01111747|patellar ligament
393781|NCT01111747|regeneration
393782|NCT01111747|growth substances
393783|NCT01111734|self harm
393784|NCT01111734|self injury
393785|NCT01111734|self mutilation
393786|NCT01111734|N-Acetylcysteine
393787|NCT01111734|adolescents
393788|NCT01111734|impulse control disorder
393789|NCT01111734|borderline personality disorder
393790|NCT01111734|fMRI
393791|NCT01111721|Sexually Transmitted Diseases
393792|NCT01111721|HIV Infections
393793|NCT01111721|Genital Diseases, Female
393794|NCT01111721|Acquired Immunodeficiency Syndrome
393795|NCT01111721|Risk Reduction Behavior
393796|NCT01111721|HIV prevention
393797|NCT01111695|wound healing
393798|NCT01111695|granulation tissue
393799|NCT01111695|Varicose Ulcer
393800|NCT01111682|traumatic brain injury
393801|NCT01111682|hypertonic saline therapy
393802|NCT01111682|intracranial pressure
393803|NCT01111669|Functional Endoscopic Sinus Surgery
393804|NCT01111669|Tranexamic Acid
393805|NCT01111656|Multi-center
393806|NCT01111656|randomized
393807|NCT01111656|prospective
393808|NCT01111656|parallel-group
393809|NCT01111656|rater-blinded
393810|NCT01111656|RR-MS
393811|NCT01111630|chronic renal failure
393812|NCT01111630|Anaemia
393813|NCT01111604|Colonic Neoplasms
393814|NCT01111604|Rectal Neoplasms
393815|NCT01111604|Adenocarcinoma
393816|NCT01111604|Antibodies, Monoclonal
393817|NCT01111591|Cyclooxygenase-2 inhibitor (Celecoxib)
393818|NCT01111591|Extrahepatic bile duct cancer
393819|NCT01111591|Pancreas cancer
393820|NCT01111565|Major Depressive Disorder
393821|NCT01111565|MDD
393822|NCT01111565|Depression
393823|NCT01111552|Major Depressive Disorder
393824|NCT01111552|MDD
393825|NCT01111552|Depression
393826|NCT01111539|Major Depressive Disorder
393827|NCT01111539|MDD
393828|NCT01111539|Depression
393829|NCT01111526|Graft versus host disease
393830|NCT01111526|GVHD
393831|NCT01111526|allogeneic transplant
393832|NCT01111526|acute GVHD
393833|NCT01111526|chronic GVHD
393834|NCT01111513|knee surgery
393835|NCT01111513|total knee arthroplasty
393836|NCT01111513|total knee replacement
393837|NCT01111513|ropivacaine
393838|NCT01111513|femoral nerve block
393839|NCT01111487|COPD
393840|NCT01111487|Electromyography
393841|NCT01111487|Inspiratory muscles
393842|NCT01111474|dentin hypersensitivity
393843|NCT01111474|cyanoacrylate
393844|NCT01111474|laser
393845|NCT01111461|Advanced Endometrial Cancer
393846|NCT01111448|Myelodysplastic Syndromes of all IPSS subgroups
393847|NCT01111422|Antioxidant
393848|NCT01111422|Epithelial to Mesenchymal Transition
393849|NCT01111422|peritoneal fibrosis
393850|NCT01111422|Peritoneal Dialysis, Continuous Ambulatory
393851|NCT01111396|ALL
393852|NCT01111396|GMALL 2003
393853|NCT01111396|Chemotherapy
393854|NCT01111396|Hippocampus
393855|NCT01111383|cystic fibrosis
393856|NCT01111383|P. aeruginosa
393857|NCT01111383|tobramycin
393858|NCT01111370|diabetes mellitus requiring insulin
393859|NCT01111357|Rheumatoid Arthritis
393860|NCT01111357|Rheumatoid Arthritis according to ACR criteria of diagnosis
393861|NCT01111344|Dietary supplement
393862|NCT01111344|Anogenital warts
393863|NCT01111344|Viusid
393864|NCT01111344|Glizigen
393865|NCT01111305|Filariasis
393866|NCT01111305|Post-Treatment Reactions
393867|NCT01111305|Monoclonal Antibody
393868|NCT01111305|Loa Loa
393869|NCT01111305|Loiasis
393870|NCT01111266|in vivo KUF
393871|NCT01111266|ß2M
393872|NCT01111266|leptin
393873|NCT01111253|multicenter randomized, open label, clinical trial
393874|NCT01111253|acute uncomplicated (mild) diverticulitis
393875|NCT01111253|treatment strategies
393876|NCT01111253|management of diverticulitis
393877|NCT01111253|antibiotics
393878|NCT01111253|observation and supportive care
393879|NCT01111253|cost analysis
393880|NCT01111253|economic evaluation
393881|NCT01111240|Humira
393882|NCT01111240|Long-term safety and effectiveness
393883|NCT01111240|Psoriatic Arthritis
393884|NCT01111227|cytokines
393885|NCT01111227|propofol
393886|NCT01111227|isoflurane
393887|NCT01111227|flow cytometry
393888|NCT01111227|Types of General Anesthesia
393889|NCT01111214|Invasive Pneumococcal Disease (IPD)
393890|NCT01111214|pneumococcal serotypes
393891|NCT01111201|Autologous Bone Marrow Transplant
393892|NCT01111201|Breast
393893|NCT01111201|Lymphoma
393894|NCT01111201|International travel
393895|NCT01111201|questionnaire
393896|NCT01111201|Hematopoietic Stem Cell Transplant (HSCT) recipients
393897|NCT01111175|Locally recurrent breast cancer
393898|NCT01111162|HIV
393899|NCT01111162|H1N1 vaccination
393900|NCT01111162|HIV infected individuals
393901|NCT01111149|Schizophrenia
393902|NCT01111149|Smoking cessation
393903|NCT01111149|Varenicline
393904|NCT01111149|Bupropion
393905|NCT01111136|Urticaria
393906|NCT01111136|Hives
393907|NCT01111136|Stress
393908|NCT01111123|plaque psoriasis
393909|NCT01111123|lac-hydrin
393910|NCT01111123|ammonium lactate
393911|NCT01111123|Ultravate
393912|NCT01111123|halobetasol propionate
393913|NCT01111123|weekend only application
393914|NCT01111123|topical therapy
393915|NCT01111123|topical corticosteroid
393916|NCT01111123|class I steroid
393917|NCT01111097|Brain tumors, Glioblastoma and DCA
393918|NCT01111097|Brain tumor,Glioblastoma recurrent
393919|NCT01111084|Ovulation induction
393920|NCT01111084|Ovarian Hyperstimulation Syndrome
393921|NCT01111084|Pregnancy
393922|NCT01111084|Fertility
393923|NCT01111071|hospital variation
393924|NCT01111071|30 day mortality
393925|NCT01111071|in hospital mortality
393926|NCT01111071|acute coronary syndrome
393927|NCT01111071|myocardial infarction
393928|NCT01111071|unstable angina
393929|NCT01111071|hospital performance
393930|NCT01111071|trends
393931|NCT01111058|Squamous Cell Cancer
393932|NCT01111032|Treadmill
393933|NCT01111032|Exercise
393934|NCT01111032|Cancer
393935|NCT01111032|Validity
393936|NCT01111032|Reliability
393937|NCT01111019|Hypochondroplasia
393938|NCT01111019|Skeletal dysplasia
393939|NCT01111019|Growth
393940|NCT01111019|Growth Hormone
393941|NCT01111019|Recombinant-human Growth Hormone
393942|NCT01111006|Electronic toilet
393943|NCT01111006|Bidet
393944|NCT01111006|Anorectal resting pressure
393945|NCT01110993|Multiple Sclerosis, Interferon-beta 1-a
393946|NCT01110980|Head and Neck neoplasms
393947|NCT01110980|Radiotherapy
393948|NCT01110980|Diet counselling
393949|NCT01110980|Swallow therapy
393950|NCT01110980|Food intake
393951|NCT01110941|S-1
393952|NCT01110941|leucovorin
393953|NCT01110941|oxaliplatin
393954|NCT01110941|colorectal cancer
393955|NCT01110941|SOL
393956|NCT01110941|unresectable or recurrent colorectal cancer
393957|NCT01110902|Agomelatine
393958|NCT01110902|Major Depressive Disorder
393959|NCT01110902|MDD
393960|NCT01110902|depression
393961|NCT01110889|Agomelatine
393962|NCT01110889|Major Depressive Disorder
393963|NCT01110889|MDD
393964|NCT01110889|depression
393965|NCT01110876|Recurrent Glioblastoma Multiforme
393966|NCT01110876|GBM
393967|NCT01110876|Brain
393968|NCT01110876|Central Nervous Center
393969|NCT01110876|Malignant glioma
393970|NCT01110876|Glioblastoma multiforme
393971|NCT01110876|Gliosarcoma
393972|NCT01110876|Anaplastic astrocytoma
393973|NCT01110876|Anaplastic oligodendroglioma
393974|NCT01110876|Anaplastic oligoastrocytoma
393975|NCT01110876|Vorinostat
393976|NCT01110876|SAHA
393977|NCT01110876|Suberoylanilide Hydroxamic Acid
393978|NCT01110876|MSK-390
393979|NCT01110876|Zolinza
393980|NCT01110876|Erlotinib
393981|NCT01110876|Erlotinib Hydrochloride
393982|NCT01110876|OSI-774
393983|NCT01110876|Tarceva
393984|NCT01110876|Temozolomide
393985|NCT01110876|Temodar
393986|NCT01110863|Chronic Lymphocytic Leukemia
393987|NCT01110850|Chronic Lymphocytic Leukemia
393988|NCT01110837|Allergic rhinitis
393989|NCT01110837|Allergen
393990|NCT01110824|Prevention
393991|NCT01110824|ventricular dysfunction
393992|NCT01110824|chemotherapy
393993|NCT01110824|acute myeloid leukemia
393994|NCT01110824|precursor-cell lymphoblastic leukemia
393995|NCT01110824|multiple myeloma
393996|NCT01110824|lymphoma
393997|NCT01110824|ejection fraction
393998|NCT01110824|Autologous hematopoietic stem cell transplantation
393999|NCT01110811|GERD
394000|NCT01110811|Esophagitis
394001|NCT01110811|Fundoplication
394002|NCT01110811|Anti-reflux surgery
394003|NCT01110811|PPI dependent
394004|NCT01110798|perioperative/postoperative complications
394005|NCT01110798|gastrointestinal complications
394006|NCT01110798|adenocarcinoma of the rectum
394007|NCT01110798|stage I rectal cancer
394008|NCT01110798|stage II rectal cancer
394009|NCT01110798|stage III rectal cancer
394010|NCT01110785|recurrent colon cancer
394011|NCT01110785|stage III colon cancer
394012|NCT01110785|stage IV colon cancer
394013|NCT01110785|recurrent rectal cancer
394014|NCT01110785|stage III rectal cancer
394015|NCT01110785|stage IV rectal cancer
394016|NCT01110772|Surgical site infection
394017|NCT01110772|Skin preparation
394018|NCT01110772|Cost analysis
394019|NCT01110759|pain management
394020|NCT01110759|ambulatory surgery
394021|NCT01110759|opioid
394022|NCT01110759|local anesthesia
394023|NCT01110759|hand surgery
394024|NCT01110759|postoperative pain
394025|NCT01110733|Non-Hodgkins Lymphoma
394026|NCT01110733|Non-Hodgkin's Lymphoma
394027|NCT01110733|Lymphoma
394028|NCT01110707|Reproductive technology, Assisted
394029|NCT01110707|Recombinant human follicle stimulating hormone (r-hFSH)
394030|NCT01110707|Recombinant leutinizing hormone (r-hLH)
394031|NCT01110707|Ovulation induction
394032|NCT01110707|Infertility
394033|NCT01110694|Idiopathic pulmonary fibrosis
394034|NCT01110694|Interstitial lung disease
394035|NCT01110694|Prognosis
394036|NCT01110694|Biomarkers
394037|NCT01110694|Mortality
394038|NCT01110694|Acute exacerbations
394039|NCT01110668|Unresectable
394040|NCT01110668|metastatic gastrointestinal stromal tumor
394041|NCT01110668|disease progression
394042|NCT01110668|progression-free survival
394043|NCT01110655|Exercise-associated hyponatremia
394044|NCT01110655|Randomized treatment trial
394045|NCT01110655|Endurance runners
394046|NCT01110629|Chronic kidney disease not on dialysis
394047|NCT01110629|Lanthanum carbonate
394048|NCT01110616|EEG Standardization
394049|NCT01110603|Cancer
394050|NCT01110603|Advanced Solid Tumors
394051|NCT01110590|Erectile Dysfunction
394052|NCT01110577|MRI
394053|NCT01110577|Hepatic Steatosis Study
394054|NCT01110564|Chronic Obstructive Pulmonary Disease
394055|NCT01110564|daily symptom variability
394302|NCT01109537|Glutamate
394056|NCT01110564|effects of symptom on morning activities
394057|NCT01110551|Dengue, vaccine, flavivirus
394058|NCT01110525|Phase I
394059|NCT01110525|Drug-drug interaction
394060|NCT01110525|Oral contraceptives
394061|NCT01110525|AZD 1981
394062|NCT01110512|Improvement of CVI parameters
394063|NCT01110447|Hepatic Encephalopathy, probiotics
394064|NCT01110421|Doripenem
394065|NCT01110421|Child, Hospitalized
394066|NCT01110421|Cefepime
394067|NCT01110421|Infusions, Intravenous
394068|NCT01110421|Severe community acquired pneumonia
394069|NCT01110421|Nosocomial pneumonia
394070|NCT01110421|Ventilator associated pneumonia
394071|NCT01110408|Antibiotic
394072|NCT01110408|Child, Hospitalized
394073|NCT01110408|Complicated Urinary Tract Infection
394074|NCT01110408|Pyelonephritis
394075|NCT01110408|Doripenem
394076|NCT01110408|Cefepime
394077|NCT01110382|Anti-Infective Agents
394078|NCT01110382|Doripenem
394079|NCT01110382|Meropenem
394080|NCT01110382|Child, Hospitalized
394081|NCT01110382|Complicated Intra-Abdominal Infections
394082|NCT01110369|sarcopenia
394083|NCT01110369|frail elderly
394084|NCT01110369|protein drink
394085|NCT01110369|resistance exercise
394086|NCT01110369|Skeletal muscle mass
394087|NCT01110369|muscle mass in elderly
394088|NCT01110343|parent stress
394089|NCT01110343|parent coping
394090|NCT01110343|parent anxiety
394091|NCT01110343|parent health
394092|NCT01110343|parent depression
394093|NCT01110330|Tinea Pedis
394094|NCT01110330|Ketoconazole (NIZORAL)
394095|NCT01110330|Antifungal Agents
394096|NCT01110330|Miconazole (DAKTARIN)
394097|NCT01110317|Paliperidone palmitate
394098|NCT01110317|R092670PSY1001
394099|NCT01110317|Pharmacokinetics
394100|NCT01110317|Risperdal (CONSTA)
394101|NCT01110317|Risperidone, Paliperidone
394102|NCT01110304|acromio-clavicular joint dislocation
394103|NCT01110304|type III acromio-clavicular joint dislocation
394104|NCT01110304|joint dislocation
394105|NCT01110304|clavicle hook plate
394106|NCT01110291|docetaxel toxicity
394107|NCT01110291|CYP3A activity
394108|NCT01110291|CYP3A5
394109|NCT01110291|MDR1
394110|NCT01110291|peroral midazolam
394111|NCT01110278|Urge Urinary Incontinence
394112|NCT01110278|Magnetic Resonance Imaging
394113|NCT01110278|Diffusion Tensor Imaging
394114|NCT01110278|Brain Connectivity
394115|NCT01110278|Bladder Control
394116|NCT01110278|fMRI
394117|NCT01110252|Chronic Obstructive Pulmonary Disease
394118|NCT01110252|Emphysema
394119|NCT01110252|Cell therapy
394120|NCT01110252|Bone marrow mononuclear cells
394121|NCT01110252|stem cells
394122|NCT01110239|limb preconditioning
394123|NCT01110239|remote preconditioning
394124|NCT01110239|ischemic preconditioning
394125|NCT01110226|non small cell lung cancer
394126|NCT01110226|small cell lung cancer
394127|NCT01110226|Platinum Responsive
394128|NCT01110226|solid tumor malignancies
394129|NCT01110213|Aging
394130|NCT01110213|physical activity
394131|NCT01110213|diet
394132|NCT01110213|goal setting
394133|NCT01110200|Hospitalization
394134|NCT01110200|Exacerbations of COPD
394135|NCT01110200|Chronic Obstructive Pulmonary Disease (COPD)
394136|NCT01110187|Lacosamide
394137|NCT01110187|Fosphenytoin
394138|NCT01110187|traumatic brain injury
394139|NCT01110187|Glasgow coma scale
394140|NCT01110187|Disability Rating Scale
394141|NCT01110187|Resource Utilization Questionnaire
394142|NCT01110187|Continuous EEG
394143|NCT01110187|seizures
394144|NCT01110161|Abdominal Fat
394145|NCT01110161|Visceral Fat
394146|NCT01110161|Subcutaneous Fat
394147|NCT01110161|Dual-energy x-ray absorptiometry
394148|NCT01110161|DXA
394149|NCT01110161|Computed Tomography
394150|NCT01110161|CT
394151|NCT01110161|Body Mass Index
394152|NCT01110161|Body composition
394153|NCT01110161|Percent fat
394154|NCT01110161|Waist circumference
394155|NCT01110161|Hip circumference
394156|NCT01110148|skin biopsy
394157|NCT01110148|informed consent
394158|NCT01110148|patient education
394159|NCT01110148|video education
394160|NCT01110148|patients requiring skin biopsies
394161|NCT01110122|Muscle recovery
394162|NCT01110122|Intermittent exercise
394163|NCT01110122|Whey protein
394164|NCT01110122|Soccer
394165|NCT01110109|Adult
394166|NCT01110109|Surgery
394167|NCT01110109|Endotracheal Tube
394168|NCT01110109|Ventilator
394169|NCT01110109|Pneumonia
394170|NCT01110109|Suctioning
394171|NCT01110096|Obesity
394172|NCT01110096|Child
394173|NCT01110096|Parent
394174|NCT01110096|Family
394175|NCT01110083|Phase 1
394176|NCT01110083|advanced solid tumors
394177|NCT01110083|refractory to standard therapy
394300|NCT01109537|Restless Legs Syndrome (RLS)
394301|NCT01109537|GABA
394178|NCT01110083|Patients with solid tumors, either refractory to standard therapy or for which no effective standard therapy is available
394179|NCT01110070|articular
394180|NCT01110070|cartilage
394181|NCT01110070|microfracture
394182|NCT01110070|knee pain
394183|NCT01110070|cartilage repair
394184|NCT01110070|Subjects with an articular cartilage defect in the knee.
394185|NCT01110057|p38 kinase inhibitor
394186|NCT01110057|male and female
394187|NCT01110057|patients
394188|NCT01110044|Neonatal vaccination
394189|NCT01110031|Chronic lymphocytic leukemia
394190|NCT01110031|Cardiac Repolarization (QTc)
394191|NCT01110018|Tolerability
394192|NCT01110018|COPD
394193|NCT01110018|Safety
394194|NCT01110018|Muscarinic receptor (mAChR) antagonist
394195|NCT01110018|GSK573719
394196|NCT01110018|Healthy subjects
394197|NCT01110018|Pharmacokinetics
394198|NCT01110018|IV study
394199|NCT01110005|D5LR
394200|NCT01110005|glucose containing IV solution
394201|NCT01110005|LR
394202|NCT01110005|non glucose IV solution
394203|NCT01109992|coronary artery disease
394204|NCT01109992|exercise
394205|NCT01109992|regadenoson
394206|NCT01109992|positron emission tomography
394207|NCT01109979|Cardiovascular, vascular
394208|NCT01109966|Allergy
394209|NCT01109966|Cow's Milk
394210|NCT01109966|Infants
394211|NCT01109966|Food Allergy
394212|NCT01109953|Lung
394213|NCT01109953|PET/CT scan
394214|NCT01109953|10-054
394215|NCT01109940|Ankylosing spondylitis
394216|NCT01109940|IgG1K monoclonal antibody
394217|NCT01109940|Interleukin -17A neutralizing
394218|NCT01109914|Renal transplantation
394219|NCT01109914|Immunosuppression
394220|NCT01109914|ETEC
394221|NCT01109914|Dukoral
394222|NCT01109914|Vaccination
394223|NCT01109914|Immunity, Humoral
394224|NCT01109901|Cubital tunnel,subcutaneous transposition,submuscular
394225|NCT01109862|Femoral neck fractures
394226|NCT01109862|Hip fractures
394227|NCT01109862|Elderly
394228|NCT01109862|Total hip arthroplasty
394229|NCT01109862|Bipolar hemiarthroplasty
394230|NCT01109849|ADHD
394231|NCT01109849|growth
394232|NCT01109849|BMI
394233|NCT01109849|stimulant medication
394234|NCT01109836|prevention
394235|NCT01109836|cognitive decline
394236|NCT01109836|post-stroke dementia
394237|NCT01109836|life-style intervention
394238|NCT01109836|vascular risk factors
394239|NCT01109836|polyintervention
394240|NCT01109836|multifactorial treatment
394241|NCT01109823|Patients hospitalized at Intensive Care Unit treated with levofloxacin IV
394242|NCT01109784|coronary angioplasty
394243|NCT01109784|clopidogrel resistance
394244|NCT01109784|prasugrel
394245|NCT01109771|Ventral hernia
394246|NCT01109758|Fenofibrate
394247|NCT01109758|Gene Expression
394248|NCT01109758|DNA methylation
394249|NCT01109745|Asthma
394250|NCT01109745|health-related quality of life
394251|NCT01109745|patient-centred care
394252|NCT01109719|Protocol
394253|NCT01109719|Critical pathway
394254|NCT01109719|Intensive care units
394255|NCT01109706|Acute coronary syndrome
394256|NCT01109706|PCSK9
394257|NCT01109706|cardiovascular safety
394258|NCT01109667|Thromboplastin, Prothrombin, Diagnostic Reagent Kits, International Normalized Ratio, Laboratory Tests.
394259|NCT01109654|Fertilization in Vitro
394260|NCT01109654|Reproductive Techniques, Assisted
394261|NCT01109654|Follicle Stimulating Hormone
394262|NCT01109654|Cetrotide
394263|NCT01109654|Gonal-f
394264|NCT01109628|sarcopenia
394265|NCT01109628|frail elderly
394266|NCT01109628|protein drink
394267|NCT01109628|skeletal muscle mass
394268|NCT01109628|muscle mass in elderly
394269|NCT01109615|Colorectal cancer
394270|NCT01109615|Metastatic colorectal cancer
394271|NCT01109615|Treatment resistant
394272|NCT01109615|Chemotherapy refractory
394273|NCT01109615|KRAS mutation
394274|NCT01109602|Stroke
394275|NCT01109602|accidental falls
394276|NCT01109602|Yoga
394277|NCT01109602|Blood pressure
394278|NCT01109602|Range of Motion
394279|NCT01109602|Rehabilitation
394280|NCT01109602|Exercise
394281|NCT01109602|balance
394282|NCT01109602|quality of life
394283|NCT01109602|mobility
394284|NCT01109589|antibiotics
394285|NCT01109589|prescriptions
394286|NCT01109589|pregnancy
394287|NCT01109589|children
394288|NCT01109576|deafness-blindness
394289|NCT01109576|pilot study
394290|NCT01109576|self management education
394291|NCT01109576|dual sensory loss
394292|NCT01109576|rehabilitation
394293|NCT01109576|peer support groups
394294|NCT01109576|age related
394295|NCT01109563|cannabis use disorder
394296|NCT01109563|marijuana
394297|NCT01109563|motivational enhancement treatment
394298|NCT01109563|cognitive behavioral treatment
394299|NCT01109563|continuing care
394303|NCT01109537|Magnetic Resonance Spectroscopy
394304|NCT01109498|LPLD
394305|NCT01109498|Lipoprotein Lipase Deficiency
394306|NCT01109498|Chylomicronaemia
394307|NCT01109498|Genetherapy
394308|NCT01109498|AAV
394309|NCT01109498|Alipogene Tiparvovec
394310|NCT01109498|AMT-011
394311|NCT01109498|Lipoprotein Lipase
394312|NCT01109485|Allergic conjunctivitis
394313|NCT01109459|preschool
394314|NCT01109459|screening
394315|NCT01109459|cluster randomized
394316|NCT01109459|physician practice patterns
394317|NCT01109459|behavior
394318|NCT01109459|knowledge
394319|NCT01109459|attitudes
394320|NCT01109459|guideline adherence
394321|NCT01109446|Lateral Epicondylitis
394322|NCT01109446|Tennis Elbow
394323|NCT01109446|Epicondylitis Lateralis
394324|NCT01109433|Behcet's Disease
394325|NCT01109433|Intermediate Uveitis
394326|NCT01109433|Uveitis
394327|NCT01109433|Immunogenetics
394328|NCT01109420|Thyroid Malignancy
394329|NCT01109420|Hereditary Thyroid Cancer
394330|NCT01109420|Inherited Thyroid Cancer
394331|NCT01109420|Thyroid Cancer
394332|NCT01109407|Plasma Cell Neoplasm
394333|NCT01109407|Natural History
394334|NCT01109407|Translational Studies
394335|NCT01109407|Gene Expression Profiling
394336|NCT01109407|Protein Markers
394337|NCT01109407|Smoldering Myeloma
394338|NCT01109407|SMM
394339|NCT01109407|Monoclonal Gammopathy of Undetermined Significance
394340|NCT01109407|MGUS
394341|NCT01109394|Genomics
394342|NCT01109394|Proteomics
394343|NCT01109394|Tissue Repository
394344|NCT01109394|Omics
394345|NCT01109394|Cell Lines
394346|NCT01109394|Pediatric Cancer
394347|NCT01109394|Solid Tumor
394348|NCT01109394|Sarcoma
394349|NCT01109394|Kidney Cancer
394350|NCT01109394|Neuroblastoma
394351|NCT01109381|bacterial infections
394352|NCT01109381|anti-infective agents
394353|NCT01109381|gastrointestinal agents
394354|NCT01109381|antibacterial agents
394355|NCT01109381|omeprazole
394356|NCT01109381|lauric acid
394357|NCT01109381|n-acetylcysteine
394358|NCT01109381|helicobacter infections
394359|NCT01109381|helicobacter pylori
394360|NCT01109381|non-antibiotic treatment
394361|NCT01109368|Autosomal Dominant Familial Hypercholesterolemia
394362|NCT01109355|PEEP
394363|NCT01109355|Patients with hemorrhage stroke under mechanical ventilation
394364|NCT01109342|HIV Prevention
394365|NCT01109342|Vaccine
394366|NCT01109342|Recombinant Adenovirus-5
394367|NCT01109342|HIV Preventative Vaccine
394368|NCT01109329|Vaccine
394369|NCT01109303|ankle fracture with syndesmotic ligament rupture
394370|NCT01109303|ankle syndesmosis rupture
394371|NCT01109264|Chronic Lymphocytic Leukemia
394372|NCT01109264|Bendamustine Hydrochloride
394373|NCT01109264|Chlorambucil
394374|NCT01109238|Refractory Neuroblastoma
394375|NCT01109238|Relapsed Neuroblastoma
394376|NCT01109225|aldosterone
394377|NCT01109212|Type 2-Diabetic Nephrophaty
394378|NCT01109212|bindarit
394379|NCT01109212|albuminuria
394380|NCT01109212|MCP-1
394381|NCT01109199|viscous
394382|NCT01109199|fibre
394383|NCT01109199|polysaccharide
394384|NCT01109199|appetite
394385|NCT01109199|hunger
394386|NCT01109199|satiety
394387|NCT01109199|weight management
394388|NCT01109186|patient with a kidney transplantation since less than 30 days
394389|NCT01109160|azithromycin
394390|NCT01109160|lymphocytic bronchitis or bronchiolitis
394391|NCT01109160|lung transplantation
394392|NCT01109160|acute allograft rejection
394393|NCT01109160|chronic allograft rejection
394394|NCT01109160|bronchiolitis obliterans syndrome
394395|NCT01109147|Schizophrenic Disorders
394396|NCT01109147|Schizophrenia
394397|NCT01109147|Affect
394398|NCT01109147|Emotional Blunting
394399|NCT01109134|primary angioplasty
394400|NCT01109134|tirofiban
394401|NCT01109134|microcirculation
394402|NCT01109121|Moderate to severe gout
394403|NCT01109121|Hyperuricemia
394404|NCT01109108|pneumococcal vaccine
394405|NCT01109108|nasopharyngeal carriage
394406|NCT01109095|Glioblastoma Multiforme (GBM)
394407|NCT01109095|HER2
394408|NCT01109095|CMV
394409|NCT01109095|Brain Cancer
394410|NCT01109095|Autologous HER2.CAR CMV-specific cytotoxic CTL
394411|NCT01109095|CMV-specific cytotoxic CTL
394412|NCT01109082|Scoliosis
394413|NCT01109082|gait
394414|NCT01109082|posture
394415|NCT01109082|balance
394416|NCT01109069|PCI-32765
394417|NCT01109069|Lymphoma, B-Cell
394418|NCT01109069|Leukemia, Lymphoid
394419|NCT01109069|Leukemia, B-Cell
394420|NCT01109069|Bruton's Tyrosine Kinase
394421|NCT01109043|Hypertension
394422|NCT01109043|Bisoprolol
394423|NCT01109043|Antihypertensive drugs
394424|NCT01109043|Blood pressure
394425|NCT01109043|Quality of life
394426|NCT01109043|Diabetes
394427|NCT01109043|Ketohexokinase
394428|NCT01109030|Major depressive disorder
394429|NCT01109030|pioglitazone
394430|NCT01109030|double blind
394431|NCT01109030|placebo controlled
394432|NCT01109004|Symptomatic Multiple Myeloma
394433|NCT01109004|Lenalidomide
394434|NCT01109004|Anti-Myeloma Agents
394435|NCT01109004|Hematologic Disorders
394436|NCT01109004|Maintenance Therapy
394437|NCT01109004|Progression
394438|NCT01109004|Autologous Transplant
394439|NCT01109004|RVD Consolidation
394440|NCT01108991|Chronic obstructive pulmonary disease
394441|NCT01108991|Randomized controlled trial
394442|NCT01108991|Self-management support
394443|NCT01108991|Physical activity
394444|NCT01108978|Type 2 Diabetes Mellitus
394445|NCT01108978|Cardiovascular Disease
394446|NCT01108978|hypercholesterolemia
394447|NCT01108965|Hydrocephalus
394448|NCT01108965|Shunt Dysfunction
394449|NCT01108965|Shunt Flow
394450|NCT01108952|Chemotherapy
394451|NCT01108952|Memory
394452|NCT01108952|Methotrexate
394453|NCT01108952|Glucocorticoids
394454|NCT01108952|Trauma
394455|NCT01108952|pediatric oncology
394456|NCT01108952|traumatization
394457|NCT01108939|Malaria, Iron absorption, Iron utilization, Benin
394458|NCT01108913|COPD
394459|NCT01108900|Erectile Dysfunction udenafil sildenafil treatment satisfaction
394460|NCT01108887|Multiple Sclerosis, Relapsing-Remitting
394461|NCT01108887|RebiSmart
394462|NCT01108887|Rebif
394463|NCT01108887|Interferon beta-1a
394464|NCT01108874|Cesarean section
394465|NCT01108874|Hypotension
394466|NCT01108874|Metaraminol
394467|NCT01108874|Vasoconstrictor Agents
394468|NCT01108874|Adult
394469|NCT01108874|Female
394470|NCT01108874|Pregnancy
394471|NCT01108874|Anesthesia, Obstetrical/adverse effects
394472|NCT01108874|Anesthesia,Spinal
394473|NCT01108874|Blood Pressure/drug effects
394474|NCT01108874|Nausea
394475|NCT01108874|Vomiting
394476|NCT01108861|Peripheral Vascular Disease
394477|NCT01108861|In-stent restenosis
394478|NCT01108861|Endoprosthesis
394479|NCT01108861|Plain old balloon angioplasty
394480|NCT01108848|C1-esterase Inhibitor
394481|NCT01108848|Hereditary angioedema
394482|NCT01108848|Acute HAE attack
394483|NCT01108835|COPD
394484|NCT01108835|Comprehensive care
394485|NCT01108783|Rhinitis
394486|NCT01108783|Allergic
394487|NCT01108783|Seasonal
394488|NCT01108783|Hay Fever
394489|NCT01108783|Pollen Allergy
394490|NCT01108783|Pollinosis
394491|NCT01108783|Rhinoconjunctivitis
394492|NCT01108783|Sneezing
394493|NCT01108783|Nasal itching
394494|NCT01108783|Nasal Congestion
394495|NCT01108783|Rhinorrhea
394496|NCT01108783|Ocular itching
394497|NCT01108783|Ocular redness
394498|NCT01108783|Tearing
394499|NCT01108770|HED
394500|NCT01108770|XLHED
394501|NCT01108770|Hypohidrotic Ectodermal Dysplasia
394502|NCT01108757|catheter
394503|NCT01108757|urinary tract infection
394504|NCT01108744|clinical trial
394505|NCT01108744|mannitol
394506|NCT01108744|intracranial pressure (ICP)
394507|NCT01108744|hypertonic saline
394508|NCT01108744|cerebral edema
394509|NCT01108744|traumatic brain injury (TBI)
394510|NCT01108718|Mattress
394511|NCT01108718|Tempur-Pedic
394512|NCT01108718|Fibromyalgia
394513|NCT01108718|Sleep patterns
394514|NCT01108692|atrial fibrillation
394515|NCT01108692|supraventricular arrhythmia
394516|NCT01108692|antithrombotic treatment
394517|NCT01108692|antiarrhythmic drugs
394518|NCT01108692|medical reaction time
394519|NCT01108692|telecardiology
394520|NCT01108692|early detection
394521|NCT01108692|holters memories
394522|NCT01108692|Pacemaker
394523|NCT01108666|Adult subjects with a confirmed diagnosis of Stage IIIA or IIIB NSCLC, with adequate bone marrow, liver and renal function.
394524|NCT01108653|Cardiovascular diseases
394525|NCT01108653|Heart diseases
394526|NCT01108653|Myocardial infarction
394527|NCT01108653|Rehabilitation
394528|NCT01108653|Health Economy
394529|NCT01108653|Randomized controlled trials
394530|NCT01108653|Non ST Elevation Myocardial Infarction (NSTEMI)
394531|NCT01108653|Cost analysis
394532|NCT01108653|Sick-leave
394533|NCT01108653|Quality of Life
394534|NCT01108614|Methadone maintenance treatment
394535|NCT01108614|drug users
394536|NCT01108614|heroin
394537|NCT01108614|HIV
394538|NCT01108614|HCV
394539|NCT01108614|Syphilis
394540|NCT01108614|HSV-2
394541|NCT01108601|Ringer's
394542|NCT01108601|lactate
394543|NCT01108601|cisplatin
394544|NCT01108601|ototoxicity
394545|NCT01108601|hearing loss
394546|NCT01108575|Mechanical ventilation
394547|NCT01108575|mechanical ventilation weaning
394548|NCT01108575|inspiratory muscle strength training
394672|NCT01107912|Platelet function
394673|NCT01107899|Acute Coronary Syndromes
394549|NCT01108575|Patients admitted to a surgical intensive care unit who are expected to receive mechanical ventilation for more than three days.
394550|NCT01108562|postoperative pain management
394551|NCT01108549|Fibromyalgia
394552|NCT01108549|Chronic Fatigue Syndrome
394553|NCT01108549|D-ribose
394554|NCT01108549|fatigue
394555|NCT01108536|prosthetics
394556|NCT01108536|socket comfort
394557|NCT01108536|amputation stump
394558|NCT01108536|amputee rehabilitation
394559|NCT01108523|Moisture Associated Skin Damage
394560|NCT01108510|Treatment Naive
394561|NCT01108510|HIV 1 Infected
394562|NCT01108484|Cancer survivors, exercise, diet, emotional support
394563|NCT01108471|cesarean section; hemoglobin; postpartum hemorrhage;
394564|NCT01108445|cancer
394565|NCT01108445|kidney cancer
394566|NCT01108445|sutent
394567|NCT01108445|everolimus
394568|NCT01108445|renal cancer
394569|NCT01108445|papillary renal cell
394570|NCT01108445|chromophobe renal cell
394571|NCT01108445|papillary
394572|NCT01108445|chromophobe
394573|NCT01108432|Tobacco cessation counseling
394574|NCT01108419|healthy adults
394575|NCT01108406|Hearing Loss
394576|NCT01108406|Unilateral Hearing Loss
394577|NCT01108406|Single Sided Deafness
394578|NCT01108393|Obsessive Compulsive Disorder
394579|NCT01108393|Agomelatine
394580|NCT01108380|Liver cirrhosis
394581|NCT01108380|liver regeneration
394582|NCT01108380|liver volume
394583|NCT01108380|liver function
394584|NCT01108380|hepatocellular carcinoma, extensive
394585|NCT01108380|hepatectomy
394586|NCT01108328|viscous
394587|NCT01108328|fibre
394588|NCT01108328|polysaccharide
394589|NCT01108328|blood glucose
394590|NCT01108328|postprandial
394591|NCT01108328|appetite
394592|NCT01108328|hunger
394593|NCT01108328|satiety
394594|NCT01108315|Patient Reported Outcomes (PRO)
394595|NCT01108315|Web-based
394596|NCT01108315|Phone-based
394597|NCT01108315|Breast Cancer
394598|NCT01108302|uterotonic
394599|NCT01108302|oxytocin
394600|NCT01108302|randomized trial
394601|NCT01108302|India
394602|NCT01108302|community
394603|NCT01108302|hemorrhage
394604|NCT01108289|hemorrhage
394605|NCT01108289|uterotonic
394606|NCT01108289|oxytocin
394607|NCT01108289|blood loss
394608|NCT01108289|community
394609|NCT01108289|Ghana
394610|NCT01108289|randomized trial
394611|NCT01108237|Arthroplasties, Knee Replacement
394612|NCT01108237|Arthroplasties, Replacement, Knee
394613|NCT01108237|Arthroplasty, Knee Replacement
394614|NCT01108237|Knee Replacement Arthroplasties
394615|NCT01108237|Knee Replacement Arthroplasty
394616|NCT01108237|Knee Replacement, Total
394617|NCT01108237|Replacement Arthroplasties, Knee
394618|NCT01108237|Replacement Arthroplasty, Knee
394619|NCT01108237|Replacement, Total Knee
394620|NCT01108237|Total Knee Replacement
394621|NCT01108224|Quality of life
394622|NCT01108224|Coping
394623|NCT01108224|Social relations
394624|NCT01108224|Survival
394625|NCT01108224|Psychotherapy
394626|NCT01108211|Adolescent Idiopathic Scoliosis
394627|NCT01108211|AIS
394628|NCT01108211|Vibration Therapy
394629|NCT01108211|Low bone mass
394630|NCT01108211|osteopenia
394631|NCT01108198|phimosis,
394632|NCT01108198|non-retractable foreskin
394633|NCT01108198|topical steroids
394634|NCT01108198|children
394635|NCT01108185|treatment with Klacid®SR
394636|NCT01108185|tracheitis
394637|NCT01108185|tracheobronchitis
394638|NCT01108185|bronchitis
394639|NCT01108185|chronic bronchitis
394640|NCT01108185|community-acquired pneumonia
394641|NCT01108133|Posttraumatic Stress Disorder
394642|NCT01108133|Traumatic Memories
394643|NCT01108133|fMRI
394644|NCT01108120|diabetic foot ulcer
394645|NCT01108120|artery mini-pump
394646|NCT01108120|continuous infusion of urokinase
394647|NCT01108120|femoral artery
394648|NCT01108107|Colon cancer
394649|NCT01108107|Neoadjuvant treatment
394650|NCT01108107|KRAS mutation
394651|NCT01108107|BRAF mutation
394652|NCT01108107|PIK3CA mutation
394653|NCT01108107|Possibly avoid chemotherapy after operation
394654|NCT01108081|Sleep apnea
394655|NCT01108081|Sleep symptoms
394656|NCT01108081|Quality of Life
394657|NCT01108068|Osteoporosis-pseudoglioma syndrome, OPPG, LRP5 mutation
394658|NCT01108029|Parkinson's disease
394659|NCT01108029|Freezing of Gait
394660|NCT01108029|Memantine
394661|NCT01108029|NMDA receptor
394662|NCT01108029|glutamate
394663|NCT01108029|No Dementia
394664|NCT01107964|Dry Eye Syndrome
394665|NCT01107964|Recent Diagnosis of Dry Eye Syndrome
394666|NCT01107951|Rituximab
394667|NCT01107951|Dexamethasone
394668|NCT01107951|Low-dose
394669|NCT01107951|ITP
394670|NCT01107938|GERD
394671|NCT01107925|Platelet function
394674|NCT01107899|Angina
394675|NCT01107899|Platelet Function
394676|NCT01107899|Coronary Angiography
394677|NCT01107899|Clinical Symptoms of Angina
394678|NCT01107899|Positive Stress Test
394679|NCT01107886|Risk of cardiovascular disease and death in patients with type 2 diabetes mellitus
394680|NCT01107873|Twenty (ASA status I) unpremedicated children, ages 1 to 5 yr old
394681|NCT01107847|electrical impedance tomography
394682|NCT01107847|EIT
394683|NCT01107847|acute lung injury
394684|NCT01107847|regional lung opening pressure
394685|NCT01107847|regional lung closing pressure
394686|NCT01107834|HIV
394687|NCT01107834|heart function
394688|NCT01107834|HAART
394689|NCT01107834|in utero
394690|NCT01107834|children
394691|NCT01107821|Pressure sores grade III and IV
394692|NCT01107821|Traumatic wounds with considerable soft tissue loss
394693|NCT01107821|Wounds after necrotizing fasciitis
394694|NCT01107821|Abdominal wounds
394695|NCT01107808|Adolescents
394696|NCT01107808|African American
394697|NCT01107808|Female
394698|NCT01107782|sildenafil
394699|NCT01107782|FGR
394700|NCT01107743|Hypertension
394701|NCT01107743|Angina pectoris
394702|NCT01107743|Hypercholesterolemia
394703|NCT01107743|Familial hypercholesterolemia
394704|NCT01107743|Japanese
394705|NCT01107743|caduet
394706|NCT01107743|Regulatory Post Marketing Commitment Plan
394707|NCT01107730|Atrial fibrillation
394708|NCT01107730|Cardiac valve repair
394709|NCT01107730|Aneurysm repair
394710|NCT01107730|CABG
394711|NCT01107730|On-pump
394712|NCT01107730|Cardiac surgery
394713|NCT01107730|Vitamin C
394714|NCT01107717|type 2 diabetes
394715|NCT01107717|new onset
394716|NCT01107717|combination therapy
394717|NCT01107717|new onset type 2 diabetes
394718|NCT01107704|Intensive Care Units
394719|NCT01107704|Surrogates
394720|NCT01107704|Family Members
394721|NCT01107704|Physicians
394722|NCT01107704|Critically Ill
394723|NCT01107704|Depression
394724|NCT01107704|Anxiety
394725|NCT01107704|Emotional
394726|NCT01107704|Support
394727|NCT01107704|Multi-faceted communication
394728|NCT01107704|Grief
394729|NCT01107704|Prognosis
394730|NCT01107704|Family Support Counselor
394731|NCT01107691|resistance and weight loss training
394732|NCT01107678|YMCA; Preventative child obesity
394733|NCT01107665|pazopanib
394734|NCT01107665|paclitaxel
394735|NCT01107665|melanoma
394736|NCT01107639|stage IIB esophageal cancer
394737|NCT01107639|adenocarcinoma of the esophagus
394738|NCT01107639|adenocarcinoma of the gastroesophageal junction
394739|NCT01107639|squamous cell carcinoma of the esophagus
394740|NCT01107639|stage IIIA esophageal cancer
394741|NCT01107639|stage IIIB esophageal cancer
394742|NCT01107639|stage IIIC esophageal cancer
394743|NCT01107626|recurrent non-small cell lung cancer
394744|NCT01107626|stage IIIB non-small cell lung cancer
394745|NCT01107626|stage IV non-small cell lung cancer
394746|NCT01107626|adenocarcinoma of the lung
394747|NCT01107626|bronchoalveolar cell lung cancer
394748|NCT01107626|large cell lung cancer
394749|NCT01107613|opinion leader
394750|NCT01107613|COPD
394751|NCT01107613|Emergency Department
394752|NCT01107613|relapse
394753|NCT01107613|follow-up
394754|NCT01107613|evidence-based guidelines
394755|NCT01107613|Exacerbation of COPD
394756|NCT01107600|Dental Implants, Single-Tooth
394757|NCT01107600|Bone Regeneration
394758|NCT01107600|Dental Restoration
394759|NCT01107600|Socket preservation
394760|NCT01107587|Human rotavirus vaccine
394761|NCT01107574|Chronic Pain, tenderpoints, insomnia, mood disorder, fatigue
394762|NCT01107561|cricothyroidotomy
394763|NCT01107561|intubation
394764|NCT01107561|airway
394765|NCT01107561|emergency medicine
394766|NCT01107561|education
394767|NCT01107535|Synagis (palivizumab) immunoprophylaxis
394768|NCT01107535|Respiratory syncytial virus infection
394769|NCT01107535|Preterm infants
394770|NCT01107509|Renal cell carcinoma
394771|NCT01107509|Metastatic
394772|NCT01107509|everolimus
394773|NCT01107509|neo-adjuvant
394774|NCT01107509|biomarkers
394775|NCT01107509|nephrectomy
394776|NCT01107509|Locally advanced clear cell renal carcinoma
394777|NCT01107509|Metastatic clear cell renal carcinoma
394778|NCT01107509|Clear Cell Renal Carcinoma
394779|NCT01107483|endotoxaemia
394780|NCT01107470|Infertility IVF ART
394781|NCT01107457|Moderate
394782|NCT01107457|Severe
394783|NCT01107457|Plaque
394784|NCT01107457|Chronic
394785|NCT01107431|glucose
394786|NCT01107431|insulin
394787|NCT01107431|L-arabinose
394788|NCT01107431|Chromium
394789|NCT01107366|lupiae techinque
394790|NCT01107366|aortic aneurism
394791|NCT01107366|aortic dissection
394792|NCT01107327|cancer
394793|NCT01107301|ADHD
394794|NCT01107288|Aged
394795|NCT01107288|Balance
394796|NCT01107288|Dual-task
394797|NCT01107288|Exercise
394798|NCT01107288|Falls
394799|NCT01107288|Gait
394800|NCT01107288|Music
394801|NCT01107275|Rabies
394802|NCT01107275|PCECV
394803|NCT01107275|pre-exposure immunization
394804|NCT01107275|intradermal
394805|NCT01107275|children
394806|NCT01107262|H5N1 Subtype
394807|NCT01107262|Avian viruses
394808|NCT01107262|Highly pathogenic avian influenza (HPAI)
394809|NCT01107249|esophageal
394810|NCT01107249|stenting
394811|NCT01107249|perforations
394812|NCT01107249|gastric
394813|NCT01107249|esophageal stenting
394814|NCT01107236|Healthy subjects
394815|NCT01107223|Antibiotic
394816|NCT01107223|Prescribing behaviour
394817|NCT01107223|Guidelines
394818|NCT01107223|Respiratory tract infections
394819|NCT01107223|Non-antibiotic prescription
394820|NCT01107210|stroke
394821|NCT01107210|physical fitness
394822|NCT01107210|evolution
394823|NCT01107210|determinants
394824|NCT01107197|Pressure ulcers
394825|NCT01107197|Healing
394826|NCT01107197|Malnutrition
394827|NCT01107197|Nutritional support
394828|NCT01107197|Micronutrients
394829|NCT01107184|Remote ischemic conditioning
394830|NCT01107184|CABG surgery
394831|NCT01107184|Atrial fibrillation
394832|NCT01107184|Coronary Artery Bypass
394833|NCT01107184|Ischemic Preconditioning
394834|NCT01107171|Tang-min-ling pills;
394835|NCT01107171|overweight type 2 diabetes mellitus;
394836|NCT01107171|blood glucose
394837|NCT01107171|Traditional Chinese Medicine
394838|NCT01107171|Clinical Trial
394839|NCT01107171|Intervention Studies
394840|NCT01107145|Plasmodium
394841|NCT01107145|Vivax
394842|NCT01107145|Malaria
394843|NCT01107145|Pregnancy
394844|NCT01107145|Brazil
394845|NCT01107145|Treatment
394846|NCT01107119|Frail elderly
394847|NCT01107119|Chronic illness
394848|NCT01107119|Integrated care model
394849|NCT01107119|Clinical pathways
394850|NCT01107119|Home care services
394851|NCT01107106|Contraceptive Methods
394852|NCT01107106|Female Contraception
394853|NCT01107080|breast cancer
394854|NCT01107080|breast carcinoma in situ
394855|NCT01107080|ductal breast carcinoma in situ
394856|NCT01107080|invasive carcinoma
394857|NCT01107080|invasive ductal carcinoma
394858|NCT01107080|invasive lobular carcinoma
394859|NCT01107067|hypogonadism
394860|NCT01107067|paraoxonase
394861|NCT01107067|Hipogonadism
394862|NCT01107054|QTC
394863|NCT01107041|Depression
394864|NCT01107041|Technology Assisted
394865|NCT01107041|Mobile Phone
394866|NCT01107028|Idiopathic pulmonary fibrosis
394867|NCT01107028|Dyspnea
394868|NCT01107028|Functional capacity
394869|NCT01107028|Quality of life
394870|NCT01107015|Diabetes
394871|NCT01107015|Glucose control
394872|NCT01107015|Diabetes monitoring
394873|NCT01107015|Care management
394874|NCT01107015|Electronic communication
394875|NCT01107015|Mobile phone technology
394876|NCT01107015|Self care
394877|NCT01107002|infertility
394878|NCT01107002|Embryo transfer
394879|NCT01106976|PET
394880|NCT01106976|acetylcholine
394881|NCT01106963|knee
394882|NCT01106963|tibial fractures
394883|NCT01106963|pain
394884|NCT01106963|osteosynthesis
394885|NCT01106963|intramedullary nailing
394886|NCT01106950|acute myelogenous leukemia
394887|NCT01106950|primary acute myelogenous leukemia
394888|NCT01106950|secondary acute myelogenous leukemia
394889|NCT01106950|relapsed acute myelogenous leukemia
394890|NCT01106924|Probiotics, Weight control, Body composition
394891|NCT01106911|digital breast tomosynthesis
394892|NCT01106911|baseline screening mammography
394893|NCT01106911|recall rates
394894|NCT01106885|Diabetes
394895|NCT01106885|Depression
394896|NCT01106885|Telephone Care Management
394897|NCT01106885|Medication Care Management (MCM)
394898|NCT01106885|Cognitive Behavioral Therapy (CBT)
394899|NCT01106872|Sarcoma
394900|NCT01106872|Soft Tissue Sarcoma
394901|NCT01106872|Locally Advanced Sarcoma
394902|NCT01106872|Unresectable Sarcoma
394903|NCT01106872|Metastatic Sarcoma
394904|NCT01106872|Valproic Acid
394905|NCT01106872|Bevacizumab
394906|NCT01106872|Histone Deacetylase Inhibitor
394907|NCT01106859|insomnia
394908|NCT01106846|Ketamine
394909|NCT01106846|Anesthesia
394910|NCT01106846|Pain
394911|NCT01106846|Outpatient surgery
394912|NCT01106833|Chronic Graft-versus-Host Disease (cGVHD)
394913|NCT01106794|diffuse intrinsic pontine glioma
394914|NCT01106794|DIPG
394915|NCT01106794|childhood brainstem glioma
394916|NCT01106794|pediatric brainstem glioma
394917|NCT01106794|brainstem glioma
394918|NCT01106794|BSG
394919|NCT01106781|EGFR mutation test
394920|NCT01106781|NSCLC
394921|NCT01106781|Non-Interventional Study
394922|NCT01106781|EGFR mutation status
394923|NCT01106768|oral health needs
394924|NCT01106768|children
394925|NCT01106768|attention deficit disorder with or without hyperactivity
394926|NCT01106755|kinematic
394927|NCT01106755|hemiparesis
394928|NCT01106755|gait
394929|NCT01106755|Body weight support
394930|NCT01106755|Functional electrical stimulation
394931|NCT01106742|Inflammatory
394932|NCT01106742|AbM
394933|NCT01106742|IBD
394934|NCT01106729|Flavonoids
394935|NCT01106729|Anthocyanin
394936|NCT01106729|Cyanidin 3 glucoside
394937|NCT01106729|Acute feeding trial
394938|NCT01106729|Stable isotope
394939|NCT01106729|Metabolism
394940|NCT01106729|Clearance
394941|NCT01106729|Bioavailability
394942|NCT01106729|Pharmacokinetics
394943|NCT01106716|Lidocaine
394944|NCT01106716|Lignocaine
394945|NCT01106716|Analgesics. Non-narcotic / therapeutic use
394946|NCT01106716|Neuralgia, Postherpetic
394947|NCT01106716|Pain
394948|NCT01106716|Pain measurement / drug effect
394949|NCT01106716|Pain postoperative / drug therapy
394950|NCT01106716|PHN
394951|NCT01106703|atopy, IgE
394952|NCT01106690|Canagliflozin
394953|NCT01106690|Placebo
394954|NCT01106690|Sitagliptin (Januvia)
394955|NCT01106690|Metformin
394956|NCT01106690|Pioglitazone (Actos)
394957|NCT01106690|Hemoglobin A1c
394958|NCT01106690|Type 2 diabetes mellitus
394959|NCT01106677|Type 2 diabetes mellitus
394960|NCT01106677|Canagliflozin
394961|NCT01106677|Placebo
394962|NCT01106677|Sitagliptin
394963|NCT01106677|Januvia
394964|NCT01106677|Metformin Immediate Release (IR)
394965|NCT01106677|Hemoglobin A1c
394966|NCT01106664|ONO-7746
394967|NCT01106664|Healthy adult subjects
394968|NCT01106651|Canagliflozin
394969|NCT01106651|Placebo
394970|NCT01106651|Hemoglobin A1c
394971|NCT01106651|Bone
394972|NCT01106651|Type 2 diabetes mellitus
394973|NCT01106638|HIV
394974|NCT01106638|AIDS
394975|NCT01106638|Smoking
394976|NCT01106638|Tobacco
394977|NCT01106638|Cessation
394978|NCT01106638|Tobacco use in persons living with HIV/AIDS
394979|NCT01106625|Canagliflozin
394980|NCT01106625|Placebo
394981|NCT01106625|Metformin
394982|NCT01106625|Sulphonylurea
394983|NCT01106625|Hemoglobin A1c
394984|NCT01106625|Type 2 diabetes mellitus
394985|NCT01106612|randomized controlled trial
394986|NCT01106612|controlled clinical trial
394987|NCT01106612|comparative effectiveness research
394988|NCT01106612|chest pain
394989|NCT01106612|angina pectoris
394990|NCT01106612|non-invasive cardiac imaging
394991|NCT01106612|nuclear stress testing
394992|NCT01106612|coronary CT angiography
394993|NCT01106612|coronary catheterization
394994|NCT01106612|coronary revascularization
394995|NCT01106586|HIV 1 Infection
394996|NCT01106586|Treatment Naive
394997|NCT01106573|Diabetes Mellitus
394998|NCT01106573|Arteriosclerosis
394999|NCT01106573|Intima media thickness
395000|NCT01106573|arterial stiffness
395001|NCT01106573|pulsewave velocity
395002|NCT01106573|fibulin-1
395003|NCT01106547|abdominal hysterectomy
395004|NCT01106547|glucocorticoids
395005|NCT01106547|rehabilitation
395006|NCT01106547|postoperative pain
395007|NCT01106547|analgetics
395008|NCT01106534|drug eluting stents
395009|NCT01106534|Stents
395010|NCT01106534|Angioplasty
395011|NCT01106534|Stent thrombosis
395012|NCT01106534|antiplatelet treatment
395013|NCT01106521|Infiltrating ductal carcinoma
395014|NCT01106521|Brachytherapy
395015|NCT01106508|Advanced solid tumors
395016|NCT01106508|recurrent or refractory medulloblastoma
395017|NCT01106508|locally advanced or metastatic basal cell carcinoma
395018|NCT01106508|hedgehog pathway inhibitor
395019|NCT01106495|atherosclerosis, endothelial, vascular, counterpulsation
395020|NCT01106482|TBE
395021|NCT01106482|Tick Borne Encephalitis
395022|NCT01106469|Healthy Volunteers
395023|NCT01106469|Healthy
395024|NCT01106469|JNJ-41443532
395025|NCT01106469|Pharmacokinetics
395026|NCT01106443|Indeterminate thyroid nodule
395027|NCT01106443|fine needle aspirate biopsy
395028|NCT01106443|thyroidectomy
395029|NCT01106443|central lymph node dissection
395030|NCT01106430|ADHD
395031|NCT01106417|Cervical Degenerative Disc Disease
395032|NCT01106417|Degenerative Spondylolisthesis
395033|NCT01106417|Spinal Stenosis
395034|NCT01106417|Stem cells
395035|NCT01106417|Adult Stem Cells
395036|NCT01106417|Anterior cervical discectomy and Fusion (ACDF)
395037|NCT01106417|Anterior Cervical Plate Fixation
395038|NCT01106391|Abdominal aortic aneurysm
395039|NCT01106391|AAA
395040|NCT01106391|Safety
395041|NCT01106391|Performance
395042|NCT01106391|Stent graft system
395043|NCT01106391|First in Human
395044|NCT01106391|Endovascular repair
395045|NCT01106378|Coronary artery disease
395046|NCT01106378|drug-eluting stents
395047|NCT01106378|sirolimus-eluting coronary stents
395048|NCT01106365|multiple sclerosis
395049|NCT01106365|fatigue
395050|NCT01106365|depressivity
395051|NCT01106365|repetitive deep transcranial magnetic stimulation
395052|NCT01106352|The target population is patients with bone metastasis from castration-resistant prostate cancer intended for treatment with docetaxel
395053|NCT01106339|humans
395054|NCT01106339|patients
395055|NCT01106339|somatoform disorders
395056|NCT01106339|fibromyalgia
395057|NCT01106339|myofascial pain syndrome diffuse
395058|NCT01106339|depression
395059|NCT01106339|chronic fatigue syndrome
395060|NCT01106339|inflammation
395061|NCT01106339|inflammatory response
395062|NCT01106339|biomarkers
395063|NCT01106339|cytokines
395064|NCT01106339|cell surface markers
395065|NCT01106339|functional polymorphisms
395066|NCT01106326|Asthma
395067|NCT01106248|tumor
395068|NCT01105468|Breath gas analysis
395069|NCT01105468|Volatile components in exhaled breath
395070|NCT01106209|premature infants
395071|NCT01106209|polymorphonuclear leukocytes
395072|NCT01106209|PMNs
395073|NCT01106209|neutrophil extracellular traps
395074|NCT01106209|NET formation
395075|NCT01106209|necrotizing enterocolitis
395076|NCT01106196|Influenza, Human
395077|NCT01106196|Influenza, Human/complications
395078|NCT01106196|Myocardial infarction/etiology
395079|NCT01106196|Cardiovascular Diseases/mortality
395080|NCT01106157|Autoimmune, Diabetes Mellitus, Glucose Metabolism
395081|NCT01106079|Early psoriatic arthritis
395082|NCT01106079|Tight control
395083|NCT01106079|Intensive management
395084|NCT01106053|Binge eating disorder
395085|NCT01106053|Food craving
395086|NCT01106053|Obesity
395087|NCT01106053|Pramipexole
395088|NCT01106053|Mirapex
395089|NCT01106053|Binge
395090|NCT01106040|Lymphoseek
395091|NCT01106040|Breast Cancer
395092|NCT01106040|Melanoma
395093|NCT01106040|Experimental
395094|NCT01106014|pulmonary arterial hypertension
395095|NCT01106014|PAH
395096|NCT01106001|total hip arthroplasty
395097|NCT01106001|periarticular injection
395098|NCT01106001|pain
395099|NCT01105988|GBM
395100|NCT01105988|PET scans
395101|NCT01105988|MRI scans
395102|NCT01105975|Dyslipidemias
395103|NCT01105975|Mixed dyslipidemia
395104|NCT01105975|Hypercholesterolemia
395105|NCT01105975|Atherosclerosis
395106|NCT01105975|Atorvastatin
395107|NCT01105975|Simvastatin
395108|NCT01105975|Rosuvastatin
395109|NCT01105975|Metabolic Diseases
395110|NCT01105975|Antilipemic Agents
395111|NCT01105975|Enzyme Inhibitors
395112|NCT01105975|Anticholesteremic Agents
395113|NCT01105975|Cholesteryl Ester Transfer Protein Inhibitors
395114|NCT01105975|Cholesteryl Ester
395115|NCT01105975|Lipid Metabolism Disorders
395116|NCT01105962|traumatic
395117|NCT01105962|brain
395118|NCT01105962|injury
395119|NCT01105962|post-traumatic
395120|NCT01105962|stress
395121|NCT01105962|hyperbaric
395122|NCT01105962|oxygen
395123|NCT01105962|HBOT
395124|NCT01105962|TBI
395125|NCT01105962|PTSD
395126|NCT01105949|nasal patency
395127|NCT01105949|acoustic rhinometry
395128|NCT01105949|nasal strip
395129|NCT01105936|pain
395130|NCT01105936|paracetamol
395131|NCT01105936|Blood-Oxygen-Level-Dependent functional magnetic resonance imaging
395132|NCT01105936|osteoarthritis
395133|NCT01105910|Dry Eye, Post Menopausal dry eye
395134|NCT01105897|endometriosis
395135|NCT01105897|deep endometriosis
395136|NCT01105897|surgery
395137|NCT01105897|laparoscopy
395138|NCT01105897|chronic pain
395139|NCT01105897|quality of life
395140|NCT01105897|sexual function
395141|NCT01105897|complications
395142|NCT01105897|recurrence
395143|NCT01105884|Wound healing, type 2 diabetes, diabetic foot ulcers, different dressings
395144|NCT01105871|Pain relief
395145|NCT01105858|Diabetes Mellitus
395146|NCT01105858|Obesity
395147|NCT01105858|Diabetic Complications
395148|NCT01105858|Genetics
395149|NCT01105858|Molecular Profiling
395150|NCT01105845|Motor Learning
395151|NCT01105845|Genetic Analysis
395152|NCT01105845|BDNF
395153|NCT01105845|Parkinson Disease
395154|NCT01105845|Movement Disorders
395155|NCT01105845|Dystonia
395156|NCT01105845|Healthy Volunteer
395157|NCT01105845|HV
395158|NCT01105832|Teriparatide
395159|NCT01105832|fracture healing
395160|NCT01105832|proximal humeral fractures
395161|NCT01105819|Probiotics
395162|NCT01105819|Lactobacillus plantarum 299
395163|NCT01105819|Ventilator-associated pneumonia VAP
395164|NCT01105819|Chlorhexidine
395165|NCT01105819|Tracheal secretions
395166|NCT01105819|Oropharyngeal secretions
395167|NCT01105806|advance directive
395168|NCT01105806|CPR Intervention
395169|NCT01105806|Video
395170|NCT01105806|Narrative
395171|NCT01105806|10-043
395172|NCT01105793|cyclic mastalgia
395173|NCT01105793|cyclic breast pain
395174|NCT01105793|fibrocystic breast disease
395175|NCT01105780|Healthy Volunteers
395176|NCT01105780|Healthy
395177|NCT01105780|Japanese
395178|NCT01105780|Pharmacokinetics
395179|NCT01105780|JNJ-41443532
395180|NCT01105767|Staphylococcus aureus
395181|NCT01105767|MRSA Skin Infection
395182|NCT01105767|Staphylococcal Skin Infections
395183|NCT01105767|Chlorhexidine gluconate
395184|NCT01105741|Crohn's disease
395185|NCT01105741|Adalimumab
395186|NCT01105741|Metabolome
395187|NCT01105728|Gastric subepitelial mass
395188|NCT01105728|Endoscopic full thickness resection
395189|NCT01105715|Rheumatoid Arthritis
395190|NCT01105715|cLDL
395191|NCT01105715|Cardiovascular disease
395192|NCT01105702|brain tumor
395193|NCT01105702|brain cancer
395194|NCT01105702|glioma
395195|NCT01105689|Urine Calcium to Creatinine Ratio
395196|NCT01105689|Hypocalciuria
395197|NCT01105689|Infants
395198|NCT01105689|Toddlers
395199|NCT01105676|vascular malformation
395200|NCT01105676|vascular anomalies
395201|NCT01105676|abnormalities of growth
395202|NCT01105676|overgrowth
395203|NCT01105676|subjects with vascular malformations abnormalities of growth.
395204|NCT01105663|sedated
395205|NCT01105663|intubated
395206|NCT01105663|mechanically ventilated
395207|NCT01105663|pediatric
395208|NCT01105663|lung injury
395209|NCT01105650|recurrent ovarian cancer
395210|NCT01105650|recurrent fallopian tube cancer
395211|NCT01105650|recurrent primary peritoneal cancer
395212|NCT01105650|refractory ovarian cancer
395213|NCT01105650|refractory fallopian tube cancer
395214|NCT01105650|refractory peritoneal cancer
395215|NCT01105650|metastatic breast cancer
395216|NCT01105637|burn injuries
395217|NCT01105637|exercise
395218|NCT01105611|HIV
395219|NCT01105611|Hepatitis C
395220|NCT01105611|Co-infection
395221|NCT01105611|Intravenous drug users
395222|NCT01105611|Treatment-naïve
395223|NCT01105611|Methadone
395224|NCT01105585|Cataracts
395225|NCT01105585|aspheric
395226|NCT01105585|IOL
395227|NCT01105585|ocular aberrations
395228|NCT01105572|Congestive Heart Failure
395229|NCT01105559|Diphtheria
395230|NCT01105559|Tetanus
395231|NCT01105559|Whooping cough
395232|NCT01105559|Hepatitis B
395233|NCT01105559|Poliomyelitis
395234|NCT01105559|Diphtheria-Tetanus-acellular Pertussis Vaccines
395235|NCT01105546|hemophilia A
395236|NCT01105546|inhibitors
395237|NCT01105546|prophylaxis
395238|NCT01105546|immune tolerance induction
395239|NCT01105533|VGEF inhibitor
395240|NCT01105533|Anti angiogenesis
395241|NCT01105533|Advanced Solid Tumors
395242|NCT01105520|Intraspinal processes (tumor or vascular malformation AVM)
395243|NCT01105507|Canakinumab
395244|NCT01105507|Cryopyrin-associated periodic syndromes
395245|NCT01105507|Familial Cold Autoinflammatory Syndrome (FCAS)
395246|NCT01105507|Familial Cold Urticaria (FCU)
395247|NCT01105507|Muckle-Wells Syndrome (MWS)
395248|NCT01105507|Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
395249|NCT01105507|Chronic Infantile Neurological
395250|NCT01105507|Cutaneous
395251|NCT01105507|Articular Syndrome (CINCA)
395252|NCT01105507|Treatment of patients diagnosed with CAPS (Cryopyrin associated periodic syndrome)
395253|NCT01105481|treatment-resistant schizophrenia
395254|NCT01105481|clozapine
395255|NCT01105481|amisulpride
395256|NCT01105455|Randomized clinical trial
395257|NCT01105455|Gestational diabetes
395258|NCT01105455|Carbohydrates
395259|NCT01105455|Glycemic index
395260|NCT01105442|Post-operative pain treatment
395261|NCT01105442|Fast-track colonic surgery patients
395262|NCT01105442|Surgery
395263|NCT01105416|Pediatric Emergency Department
395264|NCT01105416|Parental monitoring
395265|NCT01105416|Adolescent
395266|NCT01105416|Parents
395267|NCT01105416|Communication
395268|NCT01105416|Alcohol Drinking
395269|NCT01105403|Hematopoietic stem cells
395270|NCT01105403|Mobilisation
395271|NCT01105403|Autologous transplantation
395272|NCT01105364|recurrent renal cell cancer
395273|NCT01105364|stage IV renal cell cancer
395274|NCT01105364|liver metastases
395275|NCT01105351|Folate
395276|NCT01105351|MTHFR
395277|NCT01105351|Homocysteine
395278|NCT01105338|prostate cancer
395279|NCT01105325|acute coronary syndrome
395280|NCT01105325|treatment compliance
395281|NCT01105325|cardiac intensive care unit
395282|NCT01105325|secondary prevention
395283|NCT01105325|cardiac intensive care unit (CIC)
395284|NCT01105325|compliance
395285|NCT01105325|intensive care
395286|NCT01105312|male breast cancer
395287|NCT01105312|estrogen receptor-negative breast cancer
395288|NCT01105312|estrogen receptor-positive breast cancer
395289|NCT01105312|HER2-negative breast cancer
395290|NCT01105312|HER2-positive breast cancer
395291|NCT01105312|progesterone receptor-negative breast cancer
395292|NCT01105312|progesterone receptor-positive breast cancer
395293|NCT01105312|triple-negative breast cancer
395294|NCT01105312|recurrent breast cancer
395295|NCT01105312|stage IV breast cancer
395296|NCT01105299|bioequivalence
395297|NCT01105299|anastrozole
395298|NCT01105299|Healthy subjects
395299|NCT01105299|Antineoplastic Agents
395300|NCT01105299|Therapeutic Uses
395301|NCT01105299|Enzyme Inhibitors
395302|NCT01105273|Aplastic anemia
395303|NCT01105273|Fludarabine
395304|NCT01105273|CD3±CD19 depletion
395305|NCT01105273|Haploidentical hematopoietic stem cell transplantation
395306|NCT01105260|early reconditioning program
395307|NCT01105260|spinal cord injury
395308|NCT01105260|early rehabilitation
395309|NCT01105260|wheelchair
395310|NCT01105247|PCI-32765
395311|NCT01105247|Lymphoma, B-Cell
395312|NCT01105247|Leukemia, Lymphoid
395313|NCT01105247|Leukemia, B-Cell
395314|NCT01105247|Bruton's Tyrosine Kinase
395315|NCT01105234|Healthy volunteers
395316|NCT01105221|Acupuncture
395317|NCT01105221|Dry eye
395318|NCT01105221|Artificial tear drop
395319|NCT01105221|Mixed method approach
395320|NCT01105221|Qualitative study
395321|NCT01105221|Cost effectiveness analysis
395322|NCT01105221|Tear cytokine analysis
395323|NCT01105195|DuraPrep
395324|NCT01105195|ChloraPrep
395325|NCT01105195|Lumbar Spine
395326|NCT01105182|Radiofrequency Ablation
395327|NCT01105169|Personalized prevention
395328|NCT01105169|Colorectal cancer
395329|NCT01105169|Investigational Nutrigenetic Studies
395330|NCT01105169|Magnesium
395331|NCT01105169|Gene polymorphism
395332|NCT01105156|Gastric band
395333|NCT01105156|Questionnaire
395334|NCT01105156|Post operative management
395335|NCT01105156|Adjustment
395336|NCT01105143|weight loss
395337|NCT01105143|muscle mass
395338|NCT01105130|radiation toxicity
395339|NCT01105130|male erectile disorder
395340|NCT01105130|prostate cancer
395341|NCT01105117|Pulmonary Arterial Hypertension
395342|NCT01105117|PAH
395343|NCT01105117|EPITOME-1
395344|NCT01105091|Pulmonary Arterial Hypertension
395345|NCT01105091|PAH
395346|NCT01105091|EPITOME-1
395347|NCT01105078|cardiopulmonary bypass flow rate outcome tissue perfusion oxygenation l/min/m2
395348|NCT01105065|Normal Pressure Glaucoma
395349|NCT01105052|Insomnia
395350|NCT01105052|Co-morbid
395351|NCT01105052|CBT
395352|NCT01105052|Self-help
395353|NCT01105052|Bibliotherapy
395354|NCT01105039|Pain pattern
395355|NCT01105039|overall pain
395356|NCT01105039|incisional pain
395357|NCT01105039|shoulder pain
395358|NCT01105039|visceral pain
395359|NCT01105026|alveolar ridge preservation, bioactive glass, tooth extraction, graft material
395360|NCT01105013|fungal infections
395361|NCT01105013|tinea
395362|NCT01105013|tonaftato
395363|NCT01105000|HPV
395364|NCT01105000|HPV vaccine
395365|NCT01104987|Ankylosing spondylitis
395366|NCT01104987|spondarthritis
395367|NCT01104987|Osteoporosis
395368|NCT01104987|Bone mineral density
395369|NCT01104987|Dual energy x-ray absorptiometry
395370|NCT01104987|Quantitative computed tomography
395371|NCT01104974|HIV
395372|NCT01104974|HIV providers
395373|NCT01104974|Infectious Disease
395374|NCT01104974|HIV and pregnancy
395375|NCT01104961|Bacterial infection
395376|NCT01104961|Loss of epithelial cells
395377|NCT01104922|Re-irradiation with Fractionated Stereotactic Radiosurgery for Head and Neck
395378|NCT01104909|Dry weight
395379|NCT01104909|Blood Pressure
395380|NCT01104909|Chronic Kidney disease
395381|NCT01104896|Cigarette
395382|NCT01104896|tobacco
395383|NCT01104896|mechanical ventilation
395384|NCT01104896|nicotine
395385|NCT01104883|Adductor-Canal-Blockade
395386|NCT01104883|postoperative pain
395387|NCT01104883|US-guided nerve block
395388|NCT01104883|total knee arthroplasty
395389|NCT01104857|Respiratory muscle
395390|NCT01104857|Myosin
395391|NCT01104857|Mechanical ventilation
395392|NCT01104844|dental pain
395393|NCT01104844|Analgesia
395394|NCT01104831|Tibial Plateau Fracture
395395|NCT01104831|AO/OTA 41
395396|NCT01104818|Sibling relationship quality
395397|NCT01104818|Foster Care
395398|NCT01104818|Parent Management Training
395399|NCT01104818|Mental health outcomes
395400|NCT01104805|Drug Abuse
395401|NCT01104805|Substance Abuse
395402|NCT01104805|Substance Use Disorder
395403|NCT01104805|Addiction
395404|NCT01104805|Behavioral Treatment
395405|NCT01104792|Schizophrenia
395406|NCT01104792|Acute Schizophrenia
395407|NCT01104792|Psychotropic Drugs
395408|NCT01104792|Antipsychotic Agents
395409|NCT01104792|Mental Disorders
395410|NCT01104792|Dopamine Agents
395411|NCT01104792|Central Nervous System Agents
395412|NCT01104779|Schizophrenia
395413|NCT01104779|Acute Schizophrenia
395414|NCT01104779|Psychotropic Drugs
395415|NCT01104779|Antipsychotic Agents
395416|NCT01104779|Mental Disorders
395417|NCT01104779|Dopamine Agents
395418|NCT01104779|Central Nervous System Agents
395419|NCT01104766|Schizophrenia
395420|NCT01104766|Acute Schizophrenia
395421|NCT01104766|Psychotropic Drugs
395422|NCT01104766|Aripiprazole
395423|NCT01104766|Antipsychotic Agents
395424|NCT01104766|Mental Disorders
395425|NCT01104766|Dopamine Agents
395426|NCT01104766|Central Nervous System Agents
395427|NCT01104727|SINGLE PORT SURGERY
395428|NCT01104727|LAPAROSCOPY, CHOLECYSTECTOMY
395429|NCT01104701|Exenatide
395430|NCT01104701|Amylin
395431|NCT01104701|Lilly
395432|NCT01104701|Byetta
395433|NCT01104701|Exenatide Once Weekly
395434|NCT01104688|Abdominal Aortic Aneurysm
395435|NCT01104688|Wall Stress
395436|NCT01104688|Shear Stress
395437|NCT01104688|Inflammation
395438|NCT01104688|Magnetic Resonance Imaging
395439|NCT01104675|ovarian
395440|NCT01104675|platinum resistant ovarian cancer
395441|NCT01104649|Spinocerebellar ataxia
395442|NCT01104649|Friedreich ataxia
395443|NCT01104623|ADHD
395444|NCT01104597|Healthy Asian Indians and Caucasians
395445|NCT01104584|Breast Cancer
395446|NCT01104584|Gadobutrol-enhanced MRI
395447|NCT01104584|Mammography
395448|NCT01104584|Diagnostic Imaging
395449|NCT01104571|HER2-positive breast cancer
395450|NCT01104571|stage IA breast cancer
395451|NCT01104571|stage IB breast cancer
395452|NCT01104571|stage II breast cancer
395453|NCT01104571|stage IIIA breast cancer
395454|NCT01104571|estrogen receptor-negative breast cancer
395455|NCT01104571|estrogen receptor-positive breast cancer
395456|NCT01104558|Bisoprolol
395457|NCT01104558|Chronic Heart failure
395458|NCT01104532|ASP1941
395459|NCT01104532|Januvia
395460|NCT01104532|sitagliptin
395461|NCT01104480|Relapsing Polychondritis
395462|NCT01104480|Unremitting
395463|NCT01104480|Inflammation
395464|NCT01104480|IL6
395465|NCT01104467|Acute Ischemic Stroke
395466|NCT01104467|Desmoteplase
395467|NCT01104467|Japan
395468|NCT01104467|Safety
395469|NCT01104467|Stroke
395470|NCT01104467|Tolerability
395471|NCT01104454|healthy pregnant women
395472|NCT01104441|critical limb ischaemia
395473|NCT01104441|Aspirin resistance
395474|NCT01104428|Hench-schonlein purpura
395475|NCT01104428|Renal damage
395476|NCT01104428|Relapse
395477|NCT01104428|End event
395478|NCT01104428|TCM syndrome
395479|NCT01104415|Carcinoid syndrome
395480|NCT01104402|telemedicine
395481|NCT01104402|spirometer
395482|NCT01104402|CF
395483|NCT01104402|pulmonary
395484|NCT01104402|home monitoring
395485|NCT01104376|Cytochrome P450
395486|NCT01104376|CYP2B6
395487|NCT01104376|Voriconazole
395488|NCT01104376|Efavirenz
395489|NCT01104376|Pharmacokinetics
395490|NCT01104376|Drug-Interactions
395491|NCT01104376|Pharmacogenetics
395492|NCT01104376|Healthy volunteers
395493|NCT01104363|Dental implants
395494|NCT01104350|Bladder
395495|NCT01104350|Radiotherapy
395496|NCT01104350|Gemcitabine
395497|NCT01104350|Chemotherapy
395498|NCT01104350|10-031
395499|NCT01104337|paracetamol
395500|NCT01104337|warfarin
395501|NCT01104337|drug interaction
395502|NCT01104337|pathogenic mechanism
395503|NCT01104324|bone health
395504|NCT01104324|Osteonecrosis
395505|NCT01104324|acute lymphoblastic leukemia
395506|NCT01104311|Blood Pressure
395507|NCT01104311|Atherosclerosis
395508|NCT01104311|Brain Ischemia
395509|NCT01104298|metastatic STS
395510|NCT01104298|Trabectedin
395511|NCT01104298|doxorrubicin
395512|NCT01104298|soft tissue sarcoma
395513|NCT01104298|non operable sarcoma
395514|NCT01104272|Ultrasound Treatment of Subcutaneous Adipose Tissue
395515|NCT01104246|Hypogonadism
395516|NCT01104246|Testosterone
395517|NCT01104246|Hormone replacement therapy
395518|NCT01104233|Video-assisted Thoracoscopic Surgery
395519|NCT01104233|Soft spreading
395520|NCT01104233|LAP Protector
395521|NCT01104220|NAFLD
395522|NCT01104220|Obesity
395523|NCT01104220|Metabolic syndrome
395524|NCT01104207|tinnitus
395525|NCT01104207|TMS
395526|NCT01104207|transcranial magnetic stimulation
395527|NCT01104194|depression
395528|NCT01104194|cognition
395529|NCT01104194|heart rate variability
395530|NCT01104194|omega-3 fatty acids
395531|NCT01104194|Depression (in remission) (vulnerability to depression)
395532|NCT01104181|Anal HPV
395533|NCT01104181|Anal Dysplasia
395534|NCT01104181|Ana Cancer
395535|NCT01104168|diabetes
395536|NCT01104168|elderly
395537|NCT01104168|nursing home resident
395538|NCT01104155|NSCLC
395539|NCT01104129|Pancreatic Cancer
395540|NCT01104129|Intraductal Papillary Mucinous Neoplasm (IPMN)
395541|NCT01104129|Stool-based digital melt curve (DMC) assay
395542|NCT01104129|Surgical resection for pancreatic cancer
395543|NCT01104129|Hereditary Pancreatic Cancer Syndrome
395544|NCT01104129|Genetic mutations linked to pancreatic cancer
395545|NCT01104116|Pancreatic Cancer
395546|NCT01104116|Intraductal Papillary Mucinous Neoplasm
395547|NCT01104116|Pre-cancerous pancreatic lesion
395548|NCT01104116|PET Scan
395549|NCT01104116|Pancreatic Cancer Screening
395550|NCT01104103|Catheterization, Peripheral
395551|NCT01104103|Disposable Equipment
395552|NCT01104103|Emergency Medical Technicians
395553|NCT01104103|Emergency Nursing
395554|NCT01104090|C-MAC
395555|NCT01104090|direct laryngoscopy
395556|NCT01104090|indirect laryngoscopy
395557|NCT01104090|to determine the safety and efficacy of the C-MAC
395558|NCT01104077|Pancreatic Cancer
395559|NCT01104077|Family History
395560|NCT01104077|Pre-cancerous lesion
395561|NCT01104077|Intraductal Papillary Mucinous Neoplasm (IPMN)
395562|NCT01104077|Intraductal Papillary Mucinous Neoplasm
395563|NCT01104064|Stroke
395564|NCT01104038|physical activity
395565|NCT01104038|cardiometabolic risk
395566|NCT01104038|children
395567|NCT01104025|hemophagocytic lymphohistiocytosis
395568|NCT01104025|hybrid immunotherapy
395569|NCT01104025|dexamethasone
395570|NCT01104025|Etoposide
395571|NCT01104025|ATG,rabbit
395572|NCT01103999|spleen
395573|NCT01103986|health literacy
395574|NCT01103986|consumer health information
395575|NCT01103986|patient education as topics/methods
395576|NCT01103986|patient participation
395577|NCT01103973|IVF, Mind/Body
395578|NCT01103947|Anesthesia induction
395579|NCT01103947|Facemask
395580|NCT01103947|surgery
395581|NCT01103921|sugar
395582|NCT01103921|fructose
395583|NCT01103921|glucose
395584|NCT01103921|HFCS
395585|NCT01103921|metabolism
395586|NCT01103908|cardiac output
395587|NCT01103908|cardiopulmonary bypass
395588|NCT01103908|ultrasound dilution
395589|NCT01103895|cardiac output
395590|NCT01103895|cardiopulmonary bypass
395591|NCT01103895|ultrasound dilution
395592|NCT01103856|HIV
395593|NCT01103856|adherence to care
395594|NCT01103856|retention in care
395595|NCT01103856|patient navigation
395596|NCT01103843|Coronary artery disease
395597|NCT01103843|clopidogrel
395598|NCT01103843|prasugrel
395599|NCT01103843|Verify Now
395600|NCT01103843|PRU measurements
395601|NCT01103843|Drug eluting stents (EDS)
395602|NCT01103843|P2Y12
395603|NCT01103843|Platelet reactivity
395604|NCT01103830|P. falciparum Malaria, Eurartesim, ACT
395605|NCT01103817|Type 1 Diabetes
395606|NCT01103817|Adolescents and Young Adults
395607|NCT01103817|Vitamin D
395608|NCT01103817|Cardiovascular Disease
395609|NCT01103804|GerdQ questionnaire
395610|NCT01103778|Chronic kidney disease
395611|NCT01103778|IgA nephropathy
395612|NCT01103778|Velcade®
395613|NCT01103778|Proteinuria
395614|NCT01103778|Bortezomib
395615|NCT01103778|Proteasome inhibitor
395616|NCT01103765|Post-dilatation
395617|NCT01103765|noncompliant balloon
395618|NCT01103765|optimal stent deployment of drug-eluting stent
395619|NCT01103765|Intravascular ultrasound (IVUS)
395620|NCT01103765|Optimal stent deployment defined by intravascular ultrasound analysis
395621|NCT01103739|pharmacokinetics
395622|NCT01103739|drug-drug interaction
395623|NCT01103726|FDG-PET
395624|NCT01103726|regional cerebral glucose metabolism
395625|NCT01103726|striatum
395626|NCT01103726|PDE10 inhibitor
395627|NCT01103713|P. falciparum malaria
395628|NCT01103713|asymptomatic parasitemia
395629|NCT01103713|parasitological clearance
395630|NCT01103713|Intermittent Preventive Treatment of Falciparum Malaria in Pregnant Women (IPTp)
395631|NCT01102725|Colon Surgery
395632|NCT01102725|Rectal Surgery
395633|NCT01102725|Colorectal Surgery
395634|NCT01103700|Quality of dying and death of terminal cancer patients
395635|NCT01103687|HIV Preventive Vaccine
395636|NCT01103674|Paroxysmal Atrial Fibrillation
395637|NCT01103674|AF
395638|NCT01103674|Atrial Fibrillation
395639|NCT01103674|RF ablation
395640|NCT01103661|Longstanding Persistent Atrial Fibrillation
395641|NCT01103661|AF
395642|NCT01103661|Chronic AF
395643|NCT01103661|RF Ablation
395644|NCT01103661|nContact Surgical
395645|NCT01103661|Therapy Cool Path Ablation Catheter
395646|NCT01103661|St. Jude Medical
395647|NCT01103648|Prediabetes
395648|NCT01103648|Statin
395649|NCT01103648|Ezetimibe
395650|NCT01103648|Pleiotropic effects
395651|NCT01103648|Cardiometabolic risk
395652|NCT01103622|Diabetes
395653|NCT01103622|Type 2
395654|NCT01103622|Digoxin
395655|NCT01103622|drug-drug interaction
395656|NCT01103609|Diabetes
395657|NCT01103609|Type 2
395658|NCT01103609|Warfarin
395659|NCT01103609|drug-drug interaction
395660|NCT01103596|Evaluation of the impact of Kaletra on antiretroviral resistance
395661|NCT01103570|Laparoscopic cholecystectomy
395662|NCT01103570|Intra-operative cholangiography
395663|NCT01103557|Papillary thyroid carcinoma with neck metastasis
395664|NCT01103557|neck dissection
395665|NCT01103544|TCCU
395666|NCT01103544|advanced TCCU
395667|NCT01103544|metastatic TCCU
395668|NCT01103544|transitional cell carcinoma of the urothelium
395669|NCT01103544|advanced transitional cell carcinoma of the urothelium
395670|NCT01103544|metastatic transitional cell carcinoma of the urothelium
395671|NCT01103544|Cisplatinum failure
395672|NCT01103544|Vinflunine
395673|NCT01103544|Javlor
395674|NCT01103544|daily routine
395675|NCT01103544|concomitant antiemetic treatment
395676|NCT01103544|concomitant antiobstipative treatment
395677|NCT01103544|concomitant antiobstipative diet
395678|NCT01103544|patient compliance
395679|NCT01103544|quality of life
395680|NCT01103544|non-interventional study
395681|NCT01103544|Germany
395682|NCT01103544|Advanced / metastatic TCCU after Cisplatinum-failure
395683|NCT01103531|Methamphetamine
395684|NCT01103531|Methamphetamine Dependence
395685|NCT01103531|Methamphetamine Treatment
395686|NCT01103531|Aerobic Exercise
395687|NCT01103531|Resistance Exercise
395688|NCT01103531|Brain Imaging
395689|NCT01103531|D2 and D3 receptor availability
395690|NCT01103518|Menstrual irregularity
395691|NCT01103518|Menstruation disturbances
395692|NCT01103518|Hyperandrogenism
395693|NCT01103505|AMD
395694|NCT01103505|CNV
395695|NCT01103492|prostate cancer
395696|NCT01103492|endometrial cancer
395697|NCT01103492|radiation proctitis
395698|NCT01103492|pelvic radiotherapy
395699|NCT01103492|rectal bleeding
395700|NCT01103479|Early Detection of Cancer
395701|NCT01103479|Colorectal Cancer Screening
395702|NCT01103466|Ileostomy base plate
395703|NCT01103453|MCI
395704|NCT01103453|Executive Function
395705|NCT01103453|ADL
395706|NCT01103453|Virtual Supermarket
395707|NCT01103440|Major Adverse Cardiovascular Event
395708|NCT01103440|MACE
395709|NCT01103440|Death
395710|NCT01103440|MI
395711|NCT01103440|CK MB greater 3x Normal
395712|NCT01103440|Urgent Revascularization
395713|NCT01103440|Stent Thrombosis
395714|NCT01103440|Bleeding
395715|NCT01103427|smoking cessation
395716|NCT01103427|telemedicine
395717|NCT01103427|smoking
395718|NCT01103427|prevention intervention
395719|NCT01103427|internet-based
395720|NCT01103427|text messages
395721|NCT01103427|behavioral
395722|NCT01103414|Diabetes
395723|NCT01103388|Rituximab
395724|NCT01103388|Rituxan
395725|NCT01103388|Lymphoma
395726|NCT01103388|High dose chemotherapy
395727|NCT01103388|Autologous transplantation
395728|NCT01103388|Autologous stem cell transplant
395729|NCT01103388|ASCT
395730|NCT01103336|Patients with chronic renal failure undergoing coronary angiography
395731|NCT01103323|Metastatic Colorectal Cancer
395732|NCT01103310|Neoplasm
395733|NCT01103310|PET/CT diagnosis
395734|NCT01103310|PET tracer
395735|NCT01103297|Distal radius fracture
395736|NCT01103297|Double row plate
395737|NCT01103297|Volar approach
395738|NCT01103297|DVR plate
395739|NCT01103297|Postoperative complications [MeSH]
395740|NCT01103284|beta-cells
395741|NCT01103284|autoimmune
395742|NCT01103284|Diabetes
395743|NCT01103284|immunomodulation
395744|NCT01103271|depression
395745|NCT01103271|placebo effect
395746|NCT01103271|complementary therapies
395747|NCT01103271|alternative therapies
395748|NCT01103258|Incompetence of the great saphenous vein.
395749|NCT01103245|Glucose
395750|NCT01103245|Insulin
395751|NCT01103232|Cross education
395752|NCT01103232|Muscle training
395753|NCT01103219|VLBW
395754|NCT01103219|nutrition
395755|NCT01103219|vitamin A
395756|NCT01103219|long-chain unsaturated fatty acids
395757|NCT01103219|growth
395758|NCT01103219|cognitive functions
395759|NCT01103219|Very low birth weight infants (birth weight below 1,500 grams).
395760|NCT01103206|Parathyroid hormone
395761|NCT01103206|Cinacalcet
395762|NCT01103206|Primary hyperparathyroidism
395763|NCT01103206|Diagnosis
395764|NCT01103193|ASA class I/II patients, with surgery under general anesthesia
395765|NCT01103180|Selective Serotonin Reuptake Inhibitor
395766|NCT01103180|Escitalopram
395767|NCT01103180|Borderline Personality Disorder
395768|NCT01103180|Major Depressive Disorder
395769|NCT01103180|Self-harm
395770|NCT01103167|body composition
395771|NCT01103167|blood pressure
395772|NCT01103167|hemodialysis
395773|NCT01103154|beta blocker
395774|NCT01103154|variceal rebleeding
395775|NCT01103154|efficacy and safety in reducing variceal rebleeding
395776|NCT01103141|Vascular Surgical Procedures
395777|NCT01103141|Angioplasty
395778|NCT01103141|Radiology, Interventional
395779|NCT01103128|Pancreatic Cancer
395780|NCT01103128|Pre-neoplastic lesions
395781|NCT01103128|Breast and Ovarian Cancer Syndrome
395782|NCT01103128|BRCA1/2
395783|NCT01103128|Mouse model for pancreatic cancer
395784|NCT01103115|Adolescent Idiopathic Scoliosis
395785|NCT01103115|AIS
395786|NCT01103115|low bone mass
395787|NCT01103115|osteopenia
395788|NCT01103115|bone health
395789|NCT01103115|bone density
395790|NCT01103102|Gingivitis
395791|NCT01103102|Biological Markers
395792|NCT01103089|NSCLC
395793|NCT01103089|EGFR
395794|NCT01103089|gefitinib
395795|NCT01103089|observational
395796|NCT01103076|Immune dysfunction
395797|NCT01103076|Hemodialysis
395798|NCT01103076|HBV
395799|NCT01103076|Vaccination
395800|NCT01103076|Immune response
395801|NCT01103063|P. falciparum malaria
395802|NCT01103063|IPTp
395803|NCT01103050|Allergic inflammation
395804|NCT01103050|Seasonal rhinitis
395805|NCT01103037|Mild
395806|NCT01103037|Moderate
395807|NCT01103037|Asthma
395808|NCT01103024|Active uveitis
395809|NCT01103024|intermediate uveitis
395810|NCT01103024|panuveitis
395811|NCT01103024|posterior uveitis
395812|NCT01103024|uveitis
395813|NCT01102998|Sleep complaints
395814|NCT01102998|Brain Tumor Survivors
395815|NCT01102985|exercise
395816|NCT01102985|physical activity
395817|NCT01102985|intervention
395818|NCT01102985|cancer survivor
395819|NCT01102972|HIV-1
395820|NCT01102972|HIV
395821|NCT01102959|EDUCATION
395822|NCT01102959|DIABETES MELLITUS
395823|NCT01102959|ADOLESCENT
395824|NCT01102959|DIABETIC DIET
395825|NCT01102946|proliferative diabetic retinopathy
395826|NCT01102946|retinal neovascularization
395827|NCT01102946|Angiogenesis Inhibitors
395828|NCT01102946|ranibizumab
395829|NCT01102946|laser
395830|NCT01102920|Obstructive sleep apnea
395831|NCT01102920|Obesity
395832|NCT01102920|Behavioural medicine
395833|NCT01102920|Physical therapy
395834|NCT01102920|Health behaviour change
395835|NCT01102920|Physical activity
395836|NCT01102920|Eating habits
395837|NCT01102907|Appetite
395838|NCT01102907|Satiety
395839|NCT01102907|Gastric Emptying Time
395840|NCT01102907|Food Intake
395841|NCT01102907|Food Form
395842|NCT01102881|Healthy adults
395843|NCT01102829|Knee Joint
395844|NCT01102829|Arthroplasty
395845|NCT01102829|Replacement
395846|NCT01102829|Knee
395847|NCT01102816|hemodialysis
395848|NCT01102816|end-stage renal disease
395849|NCT01102816|pain
395850|NCT01102816|acupuncture
395851|NCT01102803|Phobias
395852|NCT01102803|Anxiety Disorders
395853|NCT01102803|D-Cycloserine
395854|NCT01102803|Phobic Disorders
395855|NCT01102803|Mental Disorders
395856|NCT01102803|Heights
395857|NCT01102803|Acrophobia
395858|NCT01102790|HIT
395859|NCT01102777|internet
395860|NCT01102777|walking
395861|NCT01102764|Anxiety Disorders: PTSD
395862|NCT01102764|Prolong Exposure (PE)
395863|NCT01102764|Telemedicine
395864|NCT01102764|cost effectiveness
395865|NCT01102764|deployment related problems
395866|NCT01102764|mental health care delivery
395867|NCT01102751|fibroblast growth factor 23
395868|NCT01102751|Osteomalacia
395869|NCT01102751|vitamin D
395870|NCT01102712|Emphysema
395871|NCT01102712|COPD
395872|NCT01102712|Lung Volume Reduction
395873|NCT01102712|BTVA
395874|NCT01102699|Diabetes
395875|NCT01102699|stem cells
395876|NCT01102699|bone marrow
395877|NCT01102699|mobilization
395878|NCT01102686|Late-onset GM2-gangliosidosis
395879|NCT01102686|pyrimethamine
395880|NCT01102673|phase 1
395881|NCT01102673|safety and tolerability
395882|NCT01102673|PK
395883|NCT01102673|T2DM
395884|NCT01102673|type 2 diabetes mellitus
395885|NCT01102660|Knee osteoarthritis
395886|NCT01102660|clinical trial
395887|NCT01102660|cross-over
395888|NCT01102621|hearing loss
395889|NCT01102621|head and neck cancer
395890|NCT01102621|radiotherapy
395891|NCT01102621|hearing complaint
395892|NCT01102621|Hearing loss due to the exposure of radiotherapy
395893|NCT01102608|sarcoma
395894|NCT01102608|ifosfamide
395895|NCT01102595|Unresectable/inoperable glioblastomas
395896|NCT01102582|Parkinson's disease dementia, neuropsychiatric symptoms
395897|NCT01102569|Hereditary pancreatic cancer
395898|NCT01102569|Breast and Ovarian Cancer Syndrome
395899|NCT01102569|BRCA1/2
395900|NCT01102569|Ashkenazi Jewish patients
395901|NCT01102556|Pancreatic Cancer
395902|NCT01102556|Pre-Neoplastic Lesions
395903|NCT01102556|Pancreatic Cancer Surgery
395904|NCT01102556|High-Risk for Pancreatic Cancer
395905|NCT01102556|Tissue and Blood Bank for Pancreatic Cancer
395906|NCT01102556|Pancreatic Cancer Questionnaire
395907|NCT01102543|pulmonary surfactant
395908|NCT01102543|Respiratory distress syndrome
395909|NCT01102543|Newborn
395910|NCT01102543|prophylaxis
395911|NCT01102517|NSCLC
395912|NCT01102517|Clinical
395913|NCT01102517|Early-stage
395914|NCT01102504|carotid atheroma
395915|NCT01102504|plaque vulnerability
395916|NCT01102504|stroke risk
395917|NCT01102491|postoperative nausea and vomiting
395918|NCT01102439|Clopidogrel
395919|NCT01102439|Aspirin
395920|NCT01102439|Interaction
395921|NCT01102426|Multiple Myeloma
395922|NCT01102426|Aplidin
395923|NCT01102426|plitidepsin
395924|NCT01102426|dexamethasone
395925|NCT01102400|cancer
395926|NCT01102400|tumor
395927|NCT01102400|hepatocellular carcinoma
395928|NCT01102387|Candida infections in intertriginous areas
395929|NCT01102374|Vitamin D
395930|NCT01102374|Respiratory Infection
395931|NCT01102374|Nursing Home Residents
395932|NCT01102374|Geriatrics
395933|NCT01102374|Immunosenescence
395934|NCT01102374|Prevention
395935|NCT01102348|Critically Ill
395936|NCT01102348|Nutrition Therapy
395937|NCT01102348|Enteral Nutrition
395938|NCT01102335|hepatitis B virus
395939|NCT01102335|Antiviral Agents
395940|NCT01102335|Liver Neoplasms
395941|NCT01102335|Drug Toxicity
395942|NCT01102335|Survival
395943|NCT01102322|Acute respiratory distress syndrome
395944|NCT01102309|cerebrovascular accident
395945|NCT01102309|hemiparesis
395946|NCT01102309|recovery of function
395947|NCT01102309|rehabilitation
395948|NCT01102309|robotics
395949|NCT01102309|subacute therapy
395950|NCT01102309|training
395951|NCT01102296|hepatitis A vaccine
395952|NCT01102296|male homosexual
395953|NCT01102296|HIV infection
395954|NCT01102296|male homosexuals who are seronegative for hepatitis A virus
395955|NCT01102283|Colonic obstruction
395956|NCT01102270|Obstructive sleep apnea
395957|NCT01102270|Arousal threshold
395958|NCT01102270|Sedative medication
395959|NCT01102270|upper airway
395960|NCT01102257|Dry Eye Disease
395961|NCT01102257|DED
395962|NCT01102257|Keratoconjunctivitis Sicca
395963|NCT01102257|Omega-3
395964|NCT01102244|blepharitis
395965|NCT01102244|moderate to severe chronic blepharitis
395966|NCT01102218|Anemia, ESRD
395967|NCT01102192|Myasthenia gravis
395968|NCT01102192|Thymoma
395969|NCT01102192|T-cells
395970|NCT01102192|Thymectomy
395971|NCT01102166|This study was conducted in healthy subjects
395972|NCT01102153|sudden cardiac arrest
395973|NCT01102153|Hypothermia
395974|NCT01102153|Coolgard
395975|NCT01102153|arctic sun
395976|NCT01102153|neurological outcome
395977|NCT01102153|neuron specific enolase
395978|NCT01102140|Cardiomyopathy
395979|NCT01102140|Heart Failure
395980|NCT01102127|elastography
395981|NCT01102127|thyroid nodule
395982|NCT01102127|fine-needle aspiration
395983|NCT01102114|Smoking Cessation
395984|NCT01102114|NicVAX
395985|NCT01102114|Smoking Vaccine
395986|NCT01102114|Smoking Abstinence
395987|NCT01102114|Smoking
395988|NCT01102114|Tobacco Cessation
395989|NCT01102101|Remifentanil
395990|NCT01102101|Hyperalgesia
395991|NCT01102101|Zoster
395992|NCT01102101|Postherpetic neuralgia
395993|NCT01102088|Cancer
395994|NCT01102088|Gastroesophageal
395995|NCT01102088|Simultaneous Integrated Boost
395996|NCT01102088|SIB
395997|NCT01102088|5-Fluorouracil
395998|NCT01102088|5-FU
395999|NCT01102088|Adrucil
396000|NCT01102088|Efudex
396001|NCT01102088|Docetaxel
396002|NCT01102088|Taxotere
396003|NCT01102088|Radiation
396004|NCT01102088|chemoradiation
396005|NCT01102075|Obesity
396006|NCT01102075|Electroacupuncture
396007|NCT01102075|Sham electroacupuncture
396008|NCT01102075|Waist circumference
396009|NCT01102075|Thickness of subcutaneous fat
396010|NCT01102036|Transit time
396011|NCT01102036|constipation
396012|NCT01102036|gut regularity
396013|NCT01102036|defecation frequency
396014|NCT01102036|Colonic transit time
396015|NCT01102010|Blood transfusion
396016|NCT01102010|Hip fracture
396017|NCT01102010|Elderly
396018|NCT01102010|Geriatrics
396019|NCT01102010|Hospitalization
396020|NCT01102010|Frail elderly
396021|NCT01101997|Lipolysis
396022|NCT01101997|Cryolipolysis
396023|NCT01101997|Fat Reduction
396024|NCT01101971|Education, Medical
396025|NCT01101971|Students, Medical
396026|NCT01101971|Gynecology
396027|NCT01101971|Physical Examination
396028|NCT01101971|Computer-Assisted Instruction
396029|NCT01101945|diabetes
396030|NCT01101945|DPP4 inhibitor
396031|NCT01101945|dutogliptin
396032|NCT01101945|PHX1149
396033|NCT01101932|Safety
396034|NCT01101932|Tolerability
396035|NCT01101932|Pharmacokinetics/Pharmacodynamics
396036|NCT01101932|Rheumatoid Arthritis
396037|NCT01101932|healthy volunteers
396038|NCT01101919|Rheumatoid Arthritis
396039|NCT01101906|OSI-906
396040|NCT01101906|HCC
396041|NCT01101906|Hepatocellular Carcinoma
396042|NCT01101893|GSK2248761, raltegravir, drug interaction, pharmacokinetics
396043|NCT01101867|diabetes
396044|NCT01101867|glucose
396045|NCT01101867|hospital
396046|NCT01101854|gene expression in wounds
396047|NCT01101854|healing wounds
396048|NCT01101854|non-healing wounds
396049|NCT01101854|punch biopsy
396050|NCT01101841|Vasomotor Symptoms
396051|NCT01101841|Menopause
396052|NCT01101841|Hot Flashes
396053|NCT01101841|Perimenopause
396054|NCT01101841|Nonhormonal therapies
396055|NCT01101841|Climacteric symptoms
396056|NCT01101841|Mesafem
396057|NCT01101841|Low-Dose Mesylate salt of Paroxetine (LDMP)
396058|NCT01101815|Viral Loads
396059|NCT01101815|Naltrexone
396060|NCT01101815|HIV Risk
396061|NCT01101815|Substance Abuse
396062|NCT01101802|SLE
396063|NCT01101802|Atherosclerosis
396064|NCT01101802|Endothelial function
396065|NCT01101802|Mycophenolate mofetil
396066|NCT01101789|surgical wound infection
396067|NCT01101789|triclosan-coated suture
396068|NCT01101776|Multiple Sclerosis, relapsing
396069|NCT01101776|Rebif New Formulation
396070|NCT01101776|Interferon beta-1a
396071|NCT01101750|Gardasil
396072|NCT01101750|HPV
396073|NCT01101750|transplant
396074|NCT01101750|adolescent
396075|NCT01101750|prevention
396076|NCT01101750|vaccine
396077|NCT01101750|immunogenicity
396078|NCT01101750|vaccination
396079|NCT01101737|Hypertension, clinical trial, nurse-led clinic, primary care
396080|NCT01101724|mild traumatic brain injury
396081|NCT01101724|Concussion
396082|NCT01101724|postconcussive syndrome
396083|NCT01101698|Vitamin K
396084|NCT01101698|chronic kidney disease
396085|NCT01101698|coronary artery calcification
396086|NCT01101698|intima media thickness
396087|NCT01101685|non-dysphoric
396088|NCT01101685|Dysphoric
396089|NCT01101672|Single port laparoscopic colectomy
396090|NCT01101659|Activity of JNJ-40411813
396091|NCT01101659|Challenge study
396092|NCT01101646|Rabeprazole sodium
396093|NCT01101646|Pharmacokinetics
396094|NCT01101646|Biological Availability
396095|NCT01101646|Safety
396096|NCT01101646|Adult
396097|NCT01101633|Appetite
396098|NCT01101633|Energy intake
396099|NCT01101633|gastric emptying
396100|NCT01101633|well being
396101|NCT01101633|Body weight
396102|NCT01101607|Pediatrics
396103|NCT01101607|Distal Forearm fractures
396104|NCT01101607|Pediatric Emergency Medicine
396105|NCT01101607|Pediatric Orthopedics
396106|NCT01101594|Treatment
396107|NCT01101594|Multiple Myeloma
396108|NCT01101594|Relapsed, refractory multiple myeloma
396109|NCT01101581|Diffuse Large cell NHL
396110|NCT01101581|Mantle cell NHL
396111|NCT01101581|Lymphoblastic lymphoma
396112|NCT01101581|Diffuse mixed cell lymphoma
396113|NCT01101581|Diffuse large cell lymphoma
396114|NCT01101581|large noncleaved cell lymphoma
396115|NCT01101568|GSK1292263, rosuvastatin, simvastatin, pharmacokinetics, drug interaction
396116|NCT01101555|Rheumatoid arthritis
396117|NCT01101555|repeat dose
396118|NCT01101555|pharmacodynamics
396119|NCT01101555|pharmacokinetics
396120|NCT01101555|subcutaneous
396121|NCT01101555|safety
396122|NCT01101555|Otelixizumab
396123|NCT01101555|long term follow up
396124|NCT01101555|tolerability
396125|NCT01101542|Post-marketing surveillance
396126|NCT01101542|Human papillomavirus
396127|NCT01101542|Korea
396128|NCT01101542|Safety
396129|NCT01101542|Prescribing Information
396130|NCT01101529|Chemotherapy-induced nausea and vomiting CINV
396131|NCT01101503|Newly diagnosed type 2 diabetes
396132|NCT01101503|Endothelial dysfunction
396133|NCT01101503|Intensive therapy
396134|NCT01101503|Metabolic Memorial Effect
396135|NCT01101490|To compare the change of cerebral oxygen saturation and blood flow between right and left side in lateral decubitus position during nephrectomy
396136|NCT01101477|Target-controlled infusion,
396137|NCT01101477|bronchoscopy,
396138|NCT01101477|sedation,
396139|NCT01101477|propofol
396140|NCT01101438|stage I breast cancer
396141|NCT01101438|stage II breast cancer
396142|NCT01101438|stage IIIA breast cancer
396143|NCT01101438|stage IIIC breast cancer
396144|NCT01101438|male breast cancer
396145|NCT01101438|HER2-negative breast cancer
396146|NCT01101438|estrogen receptor-positive breast cancer
396147|NCT01101438|HER2-positive breast cancer
396148|NCT01101438|progesterone receptor-positive breast cancer
396149|NCT01101425|male
396150|NCT01101425|breast cancer
396151|NCT01101412|infection
396152|NCT01101412|unspecified adult solid tumor, protocol specific
396153|NCT01101412|accelerated phase chronic myelogenous leukemia
396154|NCT01101412|acute undifferentiated leukemia
396155|NCT01101412|adult acute lymphoblastic leukemia in remission
396156|NCT01101412|adult acute myeloid leukemia in remission
396157|NCT01101412|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
396158|NCT01101412|adult acute myeloid leukemia with inv(16)(p13;q22)
396159|NCT01101412|adult acute myeloid leukemia with t(15;17)(q22;q12)
396160|NCT01101412|adult acute myeloid leukemia with t(16;16)(p13;q22)
396161|NCT01101412|adult acute myeloid leukemia with t(8;21)(q22;q22)
396162|NCT01101412|atypical chronic myeloid leukemia, BCR-ABL negative
396163|NCT01101412|blastic phase chronic myelogenous leukemia
396164|NCT01101412|chronic myelomonocytic leukemia
396165|NCT01101412|chronic phase chronic myelogenous leukemia
396166|NCT01101412|mast cell leukemia
396167|NCT01101412|meningeal chronic myelogenous leukemia
396168|NCT01101412|progressive hairy cell leukemia, initial treatment
396169|NCT01101412|prolymphocytic leukemia
396170|NCT01101412|recurrent adult acute lymphoblastic leukemia
396171|NCT01101412|recurrent adult acute myeloid leukemia
396172|NCT01101412|recurrent adult T-cell leukemia/lymphoma
396173|NCT01101412|refractory chronic lymphocytic leukemia
396174|NCT01101412|refractory hairy cell leukemia
396175|NCT01101412|relapsing chronic myelogenous leukemia
396176|NCT01101412|secondary acute myeloid leukemia
396177|NCT01101412|stage 0 chronic lymphocytic leukemia
396178|NCT01101412|stage I adult T-cell leukemia/lymphoma
396179|NCT01101412|stage I chronic lymphocytic leukemia
396180|NCT01101412|stage II adult T-cell leukemia/lymphoma
396181|NCT01101412|stage II chronic lymphocytic leukemia
396182|NCT01101412|stage III adult T-cell leukemia/lymphoma
396183|NCT01101412|stage III chronic lymphocytic leukemia
396184|NCT01101412|stage IV adult T-cell leukemia/lymphoma
396185|NCT01101412|stage IV chronic lymphocytic leukemia
396186|NCT01101412|T-cell large granular lymphocyte leukemia
396187|NCT01101412|untreated adult acute lymphoblastic leukemia
396188|NCT01101412|untreated adult acute myeloid leukemia
396189|NCT01101412|untreated hairy cell leukemia
396190|NCT01101412|recurrent adult Hodgkin lymphoma
396191|NCT01101412|stage I adult Hodgkin lymphoma
396192|NCT01101412|stage II adult Hodgkin lymphoma
396193|NCT01101412|stage III adult Hodgkin lymphoma
396194|NCT01101412|stage IV adult Hodgkin lymphoma
396195|NCT01101412|anaplastic large cell lymphoma
396196|NCT01101412|angioimmunoblastic T-cell lymphoma
396197|NCT01101412|cutaneous B-cell non-Hodgkin lymphoma
396198|NCT01101412|recurrent cutaneous T-cell non-Hodgkin lymphoma
396199|NCT01101412|stage I cutaneous T-cell non-Hodgkin lymphoma
396200|NCT01101412|stage II cutaneous T-cell non-Hodgkin lymphoma
396201|NCT01101412|stage III cutaneous T-cell non-Hodgkin lymphoma
396202|NCT01101412|stage IV cutaneous T-cell non-Hodgkin lymphoma
396203|NCT01101412|recurrent mycosis fungoides/Sezary syndrome
396204|NCT01101412|stage I mycosis fungoides/Sezary syndrome
396205|NCT01101412|stage II mycosis fungoides/Sezary syndrome
396206|NCT01101412|stage III mycosis fungoides/Sezary syndrome
396207|NCT01101412|stage IV mycosis fungoides/Sezary syndrome
396208|NCT01101412|adult grade III lymphomatoid granulomatosis
396209|NCT01101412|adult nasal type extranodal NK/T-cell lymphoma
396210|NCT01101412|Waldenstrom macroglobulinemia
396211|NCT01101412|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
396212|NCT01101412|nodal marginal zone B-cell lymphoma
396213|NCT01101412|splenic marginal zone lymphoma
396214|NCT01101412|contiguous stage II adult Burkitt lymphoma
396215|NCT01101412|contiguous stage II adult diffuse large cell lymphoma
396216|NCT01101412|contiguous stage II adult diffuse mixed cell lymphoma
396217|NCT01101412|contiguous stage II adult diffuse small cleaved cell lymphoma
396218|NCT01101412|contiguous stage II adult immunoblastic large cell lymphoma
396219|NCT01101412|contiguous stage II adult lymphoblastic lymphoma
396220|NCT01101412|contiguous stage II grade 1 follicular lymphoma
396221|NCT01101412|contiguous stage II grade 2 follicular lymphoma
396222|NCT01101412|contiguous stage II grade 3 follicular lymphoma
396223|NCT01101412|contiguous stage II mantle cell lymphoma
396224|NCT01101412|contiguous stage II marginal zone lymphoma
396225|NCT01101412|contiguous stage II small lymphocytic lymphoma
396226|NCT01101412|stage I adult Burkitt lymphoma
396227|NCT01101412|stage I adult diffuse large cell lymphoma
396228|NCT01101412|stage I adult diffuse mixed cell lymphoma
396229|NCT01101412|stage I adult diffuse small cleaved cell lymphoma
396230|NCT01101412|stage I adult immunoblastic large cell lymphoma
396231|NCT01101412|stage I adult lymphoblastic lymphoma
396232|NCT01101412|stage I grade 1 follicular lymphoma
396233|NCT01101412|stage I grade 2 follicular lymphoma
396234|NCT01101412|stage I grade 3 follicular lymphoma
396235|NCT01101412|stage I mantle cell lymphoma
396236|NCT01101412|stage I marginal zone lymphoma
396237|NCT01101412|stage I small lymphocytic lymphoma
396238|NCT01101412|noncontiguous stage II adult Burkitt lymphoma
396239|NCT01101412|noncontiguous stage II adult diffuse large cell lymphoma
396240|NCT01101412|noncontiguous stage II adult diffuse mixed cell lymphoma
396241|NCT01101412|noncontiguous stage II adult diffuse small cleaved cell lymphoma
396242|NCT01101412|noncontiguous stage II adult immunoblastic large cell lymphoma
396243|NCT01101412|noncontiguous stage II adult lymphoblastic lymphoma
396244|NCT01101412|noncontiguous stage II grade 1 follicular lymphoma
396245|NCT01101412|noncontiguous stage II grade 2 follicular lymphoma
396246|NCT01101412|noncontiguous stage II grade 3 follicular lymphoma
396247|NCT01101412|noncontiguous stage II mantle cell lymphoma
396248|NCT01101412|noncontiguous stage II marginal zone lymphoma
396249|NCT01101412|noncontiguous stage II small lymphocytic lymphoma
396250|NCT01101412|stage III adult Burkitt lymphoma
396251|NCT01101412|stage III adult diffuse large cell lymphoma
396252|NCT01101412|stage III adult diffuse mixed cell lymphoma
396253|NCT01101412|stage III adult diffuse small cleaved cell lymphoma
396254|NCT01101412|stage III adult immunoblastic large cell lymphoma
396255|NCT01101412|stage III adult lymphoblastic lymphoma
396256|NCT01101412|stage III grade 1 follicular lymphoma
396257|NCT01101412|stage III grade 2 follicular lymphoma
396258|NCT01101412|stage III grade 3 follicular lymphoma
396259|NCT01101412|stage III mantle cell lymphoma
396260|NCT01101412|stage III marginal zone lymphoma
396261|NCT01101412|stage III small lymphocytic lymphoma
396262|NCT01101412|stage IV adult Burkitt lymphoma
396263|NCT01101412|stage IV adult diffuse large cell lymphoma
396264|NCT01101412|stage IV adult diffuse mixed cell lymphoma
396265|NCT01101412|stage IV adult diffuse small cleaved cell lymphoma
396266|NCT01101412|stage IV adult immunoblastic large cell lymphoma
396267|NCT01101412|stage IV adult lymphoblastic lymphoma
396268|NCT01101412|stage IV grade 1 follicular lymphoma
396269|NCT01101412|stage IV grade 2 follicular lymphoma
396270|NCT01101412|stage IV grade 3 follicular lymphoma
396271|NCT01101412|stage IV mantle cell lymphoma
396272|NCT01101412|stage IV marginal zone lymphoma
396273|NCT01101412|stage IV small lymphocytic lymphoma
396274|NCT01101412|recurrent adult Burkitt lymphoma
396275|NCT01101412|recurrent adult diffuse large cell lymphoma
396276|NCT01101412|recurrent adult diffuse mixed cell lymphoma
396277|NCT01101412|recurrent adult diffuse small cleaved cell lymphoma
396278|NCT01101412|recurrent adult grade III lymphomatoid granulomatosis
396279|NCT01101412|recurrent adult immunoblastic large cell lymphoma
396280|NCT01101412|recurrent adult lymphoblastic lymphoma
396281|NCT01101412|recurrent grade 1 follicular lymphoma
396282|NCT01101412|recurrent grade 2 follicular lymphoma
396283|NCT01101412|recurrent grade 3 follicular lymphoma
396284|NCT01101412|recurrent mantle cell lymphoma
396285|NCT01101412|recurrent marginal zone lymphoma
396286|NCT01101412|recurrent small lymphocytic lymphoma
396287|NCT01101412|intraocular lymphoma
396288|NCT01101412|post-transplant lymphoproliferative disorder
396289|NCT01101412|chronic eosinophilic leukemia
396290|NCT01101412|chronic neutrophilic leukemia
396291|NCT01101412|primary myelofibrosis
396292|NCT01101412|essential thrombocythemia
396293|NCT01101412|polycythemia vera
396294|NCT01101412|extramedullary plasmacytoma
396295|NCT01101412|isolated plasmacytoma of bone
396296|NCT01101412|stage I multiple myeloma
396297|NCT01101412|stage II multiple myeloma
396298|NCT01101412|stage III multiple myeloma
396299|NCT01101412|primary systemic amyloidosis
396300|NCT01101412|refractory multiple myeloma
396301|NCT01101412|de novo myelodysplastic syndromes
396302|NCT01101412|previously treated myelodysplastic syndromes
396303|NCT01101412|secondary myelodysplastic syndromes
396304|NCT01101412|myelodysplastic/myeloproliferative neoplasm, unclassifiable
396305|NCT01101399|Anemia
396306|NCT01101399|Lymphoproliferative Disorders
396307|NCT01101399|Chemotherapy
396308|NCT01101399|ferric carboxymaltose
396309|NCT01101399|iron
396310|NCT01101386|Voriconazole
396311|NCT01101386|SBECD
396312|NCT01101386|pharmacokinetics
396313|NCT01101386|Renal Failure
396314|NCT01101373|Limbic surgery
396315|NCT01101373|Stereotactic surgery
396316|NCT01101373|Major Depressive Disorder: Treatment Refractory
396317|NCT01101360|port wine stains
396318|NCT01101360|radiofrequency
396319|NCT01101360|Pulse Dye Laser
396320|NCT01101334|NSCLC
396321|NCT01101321|Healthy subjects
396322|NCT01101321|Opioid
396323|NCT01101321|Healthy volunteers
396324|NCT01101308|Healthy subjects
396325|NCT01101308|Opioid
396326|NCT01101308|Healthy volunteers
396327|NCT01101295|Immune Thrombocytopenia
396328|NCT01101295|Rituximab
396329|NCT01101295|side effects
396330|NCT01101295|tolerance
396331|NCT01101295|safety
396332|NCT01101295|splenectomy
396333|NCT01101295|serum sickness
396334|NCT01101282|PEP
396335|NCT01101282|exacerbation
396336|NCT01101282|physiotherapy
396337|NCT01101282|airway clearance
396338|NCT01101282|sputum
396339|NCT01101282|physical Therapy modalities
396340|NCT01101269|Diabetic nephropathy
396341|NCT01101243|Vitamin D
396342|NCT01101243|UVB
396343|NCT01101243|Frequency
396344|NCT01101243|Body surface area
396345|NCT01101243|Dose-Response
396346|NCT01101230|Cardiovascular disease
396347|NCT01101230|cholesterol
396348|NCT01101230|low-density
396349|NCT01101230|lipoprotein
396350|NCT01101230|high-density lipoprotein
396351|NCT01101230|triglycerides
396352|NCT01101217|hemocystein zinc renal failure
396353|NCT01101191|Healthy subjects
396354|NCT01101191|Opioid
396355|NCT01101191|Healthy volunteers
396356|NCT01101178|Healthy subjects
396357|NCT01101178|Opioid
396358|NCT01101178|Healthy volunteers
396359|NCT01101165|Healthy subjects
396360|NCT01101165|Opioid
396361|NCT01101165|Healthy volunteers
396362|NCT01101152|Antidepressant
396363|NCT01101152|healthy volunteers
396364|NCT01101152|desvenlafaxine succinate
396365|NCT01101152|norepinephrine reuptake
396366|NCT01101152|serotonin reuptake
396367|NCT01101152|tyramine test
396368|NCT01101126|Chronic obstructive pulmonary disease (COPD)
396369|NCT01101126|Asthma
396370|NCT01101113|peritoneal dialysis
396371|NCT01101100|Psoriasis
396372|NCT01101087|Dialysis
396373|NCT01101074|Swine Flu A (H1N1) vaccine
396374|NCT01101074|Adjuvanted flu egg derived
396375|NCT01101074|Novel influenza A (H1N1): a new flu virus of swine origin
396376|NCT01101061|Amgen
396377|NCT01101061|Phase 1
396378|NCT01101061|Postmenopausal
396379|NCT01101061|Japanese
396380|NCT01101048|Amgen
396381|NCT01101048|Phase 1b
396382|NCT01101048|Postmenopausal
396383|NCT01101048|Bone Mineral Density
396384|NCT01101035|cardiovascular outcomes
396385|NCT01101035|heart attack
396386|NCT01101035|stroke
396387|NCT01101035|Drug Therapy
396388|NCT01101035|physiology
396389|NCT01101035|Hyperuricemia
396390|NCT01101035|Uric Acid
396391|NCT01101009|Sevikar®
396392|NCT01101009|Central Arterial Blood Pressure
396393|NCT01100996|enteral nutrition
396394|NCT01100996|endotoxemia
396395|NCT01100996|innate immunity
396396|NCT01100996|nutritional anti-inflammatory pathway
396397|NCT01100996|intestinal damage
396398|NCT01100970|Caesarean section
396399|NCT01100970|cortisol
396400|NCT01100970|stress
396401|NCT01100970|unipolar electric needle
396402|NCT01100970|bipolar electric needle
396403|NCT01100944|Gene Expression
396404|NCT01100944|HDAC Class I and II enzymes
396405|NCT01100944|Thymoma
396406|NCT01100944|Chemotherapy
396407|NCT01100944|Hydroxamic Acid Deacetylase Inhibitor
396408|NCT01100944|Thymic Cancer
396409|NCT01100931|NSCLC
396410|NCT01100931|Solid Tumors
396411|NCT01100931|YM155
396412|NCT01100931|Survivin
396413|NCT01100931|Non Small-Cell Lung Cancer
396414|NCT01100931|Solid Tumor
396415|NCT01100918|Cardiac resynchronisation therapy
396416|NCT01100918|Tissue Doppler Imaging
396417|NCT01100918|Dyssynchrony
396418|NCT01100905|Iron
396419|NCT01100905|Iron status
396420|NCT01100905|Iron deficiency
396421|NCT01100905|Iron deficiency anemia
396422|NCT01100892|Pediatrics
396423|NCT01100892|Pancreas
396424|NCT01100879|Anemia
396425|NCT01100879|Lymphoproliferative Disorders
396426|NCT01100879|Chemotherapy
396427|NCT01100879|ferric carboxymaltose
396428|NCT01100879|iron
396429|NCT01100866|clinically localized Prostate Cancer
396430|NCT01100866|low and intermediate risk for relapse
396431|NCT01100866|candidates for radical prostatectomy
396432|NCT01100853|amphetamine dependence
396433|NCT01100853|amphetamine injection
396434|NCT01100853|VIVITROL/VIVITROL placebo
396435|NCT01100853|amphetamine craving
396436|NCT01100827|EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC
396437|NCT01100827|The association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.
396438|NCT01100801|advanced
396439|NCT01100801|metastatic
396440|NCT01100775|Galantamine
396441|NCT01100775|Schizophrenia
396442|NCT01100775|working memory
396443|NCT01100775|cognitive
396444|NCT01100762|Parkinson's Disease
396445|NCT01100762|Cranial Electric Stimulation
396446|NCT01100762|Gait
396447|NCT01100749|Hepatitis C
396448|NCT01100749|Genotype 3
396449|NCT01100749|Demographics
396450|NCT01100749|Genetics
396451|NCT01100749|Metabolic status
396452|NCT01100736|Forearm Blood Flow
396453|NCT01100736|Vasodilation
396454|NCT01100736|Vasoconstriction
396455|NCT01100736|Endothelin System
396456|NCT01100736|Endothelin-1
396457|NCT01100736|Endothelin-3
396458|NCT01100736|Endothelin antagonists
396459|NCT01100736|Bosentan
396460|NCT01100736|Sitaxsentan
396461|NCT01100736|Endothelin
396462|NCT01100736|Regional Blood Flow
396463|NCT01100723|secondary hyperparathyroidism
396464|NCT01100723|calcium
396465|NCT01100723|phosphorus
396466|NCT01100723|ESRD
396467|NCT01100723|CKD
396468|NCT01100723|mineral disorder
396469|NCT01100710|Age Gender left ventricular mass high sensitive Troponin T
396470|NCT01100697|prenatal diagnosis
396471|NCT01100697|ultrasound
396472|NCT01100697|outcome
396473|NCT01100697|spina bifida
396474|NCT01100697|neural tube defect
396475|NCT01100684|diarrhea predominant irritable bowel syndrome
396476|NCT01100671|atherosclerosis
396477|NCT01100671|vascular inflammation
396478|NCT01100671|MDCT
396479|NCT01100671|18FDG-PET
396480|NCT01100606|Exocrine Pancreatic Insufficiency
396481|NCT01100606|Infants with CF
396482|NCT01100593|Ultrasound
396483|NCT01100593|IV catheters
396484|NCT01100593|Extravasation
396485|NCT01100580|Low-salt diet
396486|NCT01100580|calciuria
396487|NCT01100580|blood pressure
396488|NCT01100580|nephrolithiasis
396489|NCT01100580|hypertension
396490|NCT01100580|BMI
396491|NCT01100580|urinary stone risk factors
396492|NCT01100567|skeletal health
396493|NCT01100567|bone turnover
396494|NCT01100567|bone geometry
396495|NCT01100567|malnutrition
396496|NCT01100541|Therapeutic Hyperthermia
396497|NCT01100541|Thermotherapy
396498|NCT01100541|Polymers
396499|NCT01100541|Castor Oil
396500|NCT01100515|intoxication
396501|NCT01100515|carbon monoxide
396502|NCT01100515|adults
396503|NCT01100515|domestic accident
396504|NCT01100515|acute domestic carbon monoxide poisoning
396505|NCT01100502|Antigens, CD30
396506|NCT01100502|Antibody-Drug Conjugate
396507|NCT01100502|Antibodies, Monoclonal
396508|NCT01100502|Disease, Hodgkin
396509|NCT01100502|Drug Therapy
396510|NCT01100502|Hematologic Diseases
396511|NCT01100502|Immunotherapy
396512|NCT01100502|Lymphoma
396513|NCT01100502|Monomethylauristatin E
396514|NCT01100476|Closure Device
396515|NCT01100476|endovascular procedures
396516|NCT01100476|sealing femoral arterial access
396517|NCT01100476|Mynx M5
396518|NCT01100463|HFS, Hand-Foot Syndrome, Capecitabine, Breast Cancer
396519|NCT01100450|bariatric surgery
396520|NCT01100450|class III obesity
396521|NCT01100450|resistance training
396522|NCT01100450|strength
396523|NCT01100450|fitness
396524|NCT01100437|opioid
396525|NCT01100437|morphine
396526|NCT01100437|naltrexone
396527|NCT01100437|withdrawal signs
396528|NCT01100437|withdrawal symptoms
396529|NCT01100424|Contact lenses
396530|NCT01100424|Contact lens solution
396531|NCT01100424|Corneal staining
396532|NCT01100411|Contact lenses, myopia, lens geometry
396533|NCT01100398|Fatty liver disease
396534|NCT01100385|Healthy adults
396535|NCT01100372|recurrent ovarian epithelial cancer
396536|NCT01100372|recurrent fallopian tube cancer
396537|NCT01100372|recurrent primary peritoneal cavity cancer
396538|NCT01100359|endometrial clear cell carcinoma
396539|NCT01100359|recurrent endometrial carcinoma
396540|NCT01100359|stage IIIA endometrial carcinoma
396541|NCT01100359|stage IIIB endometrial carcinoma
396542|NCT01100359|stage IIIC endometrial carcinoma
396543|NCT01100359|stage IVA endometrial carcinoma
396544|NCT01100359|stage IVB endometrial carcinoma
396545|NCT01100346|Ovulation induction
396546|NCT01100346|Intrauterine insemination
396547|NCT01100346|Gonal-f
396548|NCT01100346|Controlled ovarian stimulation
396549|NCT01100346|Infertility
396550|NCT01100333|Infertility
396551|NCT01100333|Reproductive technologies, Assisted
396552|NCT01100333|r-hFSH
396553|NCT01100333|Gonal-f
396554|NCT01100320|Healthy subjects
396555|NCT01100320|Opioid
396556|NCT01100307|diabetic macular edema
396557|NCT01100307|Macugen
396558|NCT01100307|sham-controlled study
396559|NCT01100294|Influenza
396560|NCT01100294|Pandemic vaccine
396561|NCT01100294|Seasonal vaccine
396562|NCT01100294|Prevention
396563|NCT01100294|Influenza vaccine
396564|NCT01100294|Influenza in humans
396565|NCT01100294|Pandemic influenza in humans
396566|NCT01100294|Influenza vaccine for children
396567|NCT01100281|prefrontal cortex
396568|NCT01100268|Hoarding
396569|NCT01100255|OCD
396570|NCT01100242|Renal Cell Carcinoma
396571|NCT01100242|metastatic renal cell cancer
396572|NCT01100242|kidney cancer
396573|NCT01100216|smokeless tobacco
396574|NCT01100216|nicotine
396575|NCT01100216|snus
396576|NCT01100216|snuff
396577|NCT01100216|chewing tobacco
396578|NCT01100216|oral tobacco
396579|NCT01100203|aldosterone receptor inhibition
396580|NCT01100203|arterial stiffness
396581|NCT01100203|ambulatory arterial stiffness index
396582|NCT01100177|Patients with non resectable Glioblastoma who have only a
396583|NCT01100177|biopsy as surgical treatment
396584|NCT01100164|INSOMNIA
396585|NCT01100164|FOR THE TREATMENT OF INSOMNIA
396586|NCT01100151|Opioid-induced constipation
396587|NCT01100151|RDC-1036
396588|NCT01100151|ALKS 37
396589|NCT01100125|Diabetes
396590|NCT01100125|Sitagliptin
396591|NCT01100125|insulin
396592|NCT01100125|C-peptide
396593|NCT01100112|ulcerative colitis
396594|NCT01100112|Budesonide
396595|NCT01100099|Celiac disease.
396596|NCT01100099|Food intolerance.
396597|NCT01100099|Gluten intolerance without celiac disease.
396598|NCT01100086|Healthy subjects
396599|NCT01100086|Opioid
396600|NCT01100060|Azithromycin
396601|NCT01100060|chloroquine
396602|NCT01100060|microsphere
396603|NCT01100060|pharmacokinetics
396604|NCT01100060|bioavailability
396605|NCT01100047|Phase I
396606|NCT01100047|Japanese healthy volunteer
396607|NCT01100047|AZD5069
396608|NCT01100034|pediatric psoriasis
396609|NCT01100034|etanercept
396610|NCT01100034|PASS
396611|NCT01100034|safety
396612|NCT01100034|effectiveness
396613|NCT01100008|Pulmonary arterial hypertension
396614|NCT01100008|cardiac MRI (magnetic resonance imaging)
396615|NCT01100008|severity
396616|NCT01100008|prognosis
396617|NCT01099995|domestic accident
396618|NCT01099995|coma
396619|NCT01099995|carbon monoxide
396620|NCT01099995|intoxication
396621|NCT01099995|acute domestic carbon monoxide poisoning
396622|NCT01099982|Congestive Heart Failure
396623|NCT01099982|Left Ventricular Assist Device
396624|NCT01099982|LVAD
396625|NCT01099982|Myocardium
396626|NCT01099982|Remodeling
396627|NCT01099982|Microvasculature
396628|NCT01099982|Fibrosis
396629|NCT01099982|Cardiac Transplant
396630|NCT01099969|Endotrol Endotracheal tube
396631|NCT01099969|Regular endotracheal tube
396632|NCT01099969|glide rite stylet
396633|NCT01099969|McGarth video laryngoscope
396634|NCT01099969|Glidescope
396635|NCT01099969|comparison of endotrol endotracheal tube to regular endotracheal tube with video laryngoscopes Glidescope and McGrath
396636|NCT01099956|type 1 diabetes
396637|NCT01099956|children
396638|NCT01099956|low grade inflammation
396639|NCT01099956|cytokine
396640|NCT01099956|CRP
396641|NCT01099930|immunoablation
396642|NCT01099930|stem cell transplantation
396643|NCT01099917|MDS
396644|NCT01099917|Maitake
396645|NCT01099917|mushroom
396646|NCT01099917|09-094
396647|NCT01099878|Cycling Exercise
396648|NCT01099878|Functional Electrical Stimulation
396649|NCT01099878|Stroke
396650|NCT01099852|dengue
396651|NCT01099852|fever
396652|NCT01099852|dengue hemorrhagic fever
396653|NCT01099852|dengue virus
396654|NCT01099852|Chikungunya virus
396655|NCT01099852|Zika Virus
396656|NCT01099852|Joint pain
396657|NCT01099839|ASP1941
396658|NCT01099839|Miglitol
396659|NCT01099826|colorectal cancer screening
396660|NCT01099826|tailored education
396661|NCT01099826|motivational interview
396662|NCT01099826|patient education
396663|NCT01099813|Critical Illness
396664|NCT01099813|Sepsis
396665|NCT01099813|Duration
396666|NCT01099813|Severity of Illness Scores
396667|NCT01099813|Trajectory
396668|NCT01099800|asthma
396669|NCT01099800|health disparities
396670|NCT01099800|illness representations
396671|NCT01099800|CAM
396672|NCT01099800|Latino
396673|NCT01099748|Drug interaction
396674|NCT01099748|pharmacokinetics
396675|NCT01099748|lersivirine
396676|NCT01099748|methadone
396677|NCT01099735|Bariatric Surgery
396678|NCT01099735|Sleep Apnea
396679|NCT01099735|Gastroesophageal Reflux Disease
396680|NCT01099735|GERD
396681|NCT01099722|moderate to severe persistent reversible asthma
396682|NCT01099709|healthy subjects
396683|NCT01099709|opioid
396684|NCT01099696|abdominal discomfort and bloating
396685|NCT01099644|Peritoneum
396686|NCT01099644|Desmoplastic Small Round Cell Tumors
396687|NCT01099644|Intraperitoneal Radioimmunotherapy
396688|NCT01099644|131 I-8H9
396689|NCT01099644|09-090
396690|NCT01099631|Salmonella typhimurium
396691|NCT01099631|unresectable hepatic cancer
396692|NCT01099631|attenuated Salmonella typhimurium
396693|NCT01099631|IL-2
396694|NCT01099605|hemorrhoidectomy
396695|NCT01099605|pain management
396696|NCT01099579|HIV, Pediatric
396697|NCT01099566|human endotoxemia
396698|NCT01099566|tissue factor induced coagulation
396699|NCT01099566|platelet activation
396700|NCT01099566|thienopyridines
396701|NCT01099553|Educational video
396702|NCT01099553|colonoscopy
396703|NCT01099553|bowel preparation
396704|NCT01099553|Bowel preparation for colonoscopy
396705|NCT01099540|neuroendocrine tumor
396706|NCT01099527|gastric cancer
396707|NCT01099527|refractory
396708|NCT01099527|metastatic
396709|NCT01099501|Mechanical Ventilation
396710|NCT01099488|Immunological assays
396711|NCT01099475|liver surgery
396712|NCT01099475|pringle manoeuvre
396713|NCT01099475|hepatocellular damage
396714|NCT01099475|surgical complications
396715|NCT01099475|patients requiring liver surgery
396716|NCT01099462|fever
396717|NCT01099462|Ibuprofen
396718|NCT01099449|neurotoxicity
396719|NCT01099449|neuropathy
396720|NCT01099449|chemotherapeutic agent toxicity
396721|NCT01099449|stage II colon cancer
396722|NCT01099449|stage III colon cancer
396723|NCT01099449|stage IV colon cancer
396724|NCT01099449|stage II rectal cancer
396725|NCT01099449|stage III rectal cancer
396726|NCT01099449|stage IV rectal cancer
396727|NCT01099449|adenocarcinoma of the colon
396728|NCT01099449|adenocarcinoma of the rectum
396729|NCT01099436|HER2-negative breast cancer
396730|NCT01099436|stage II breast cancer
396731|NCT01099436|stage IIIA breast cancer
396732|NCT01099436|stage IIIB breast cancer
396733|NCT01099436|stage IIIC breast cancer
396734|NCT01099423|clear cell renal cell carcinoma
396735|NCT01099423|stage IV renal cell cancer
396736|NCT01099410|macrophages, alveolar
396737|NCT01099410|monocytes
396738|NCT01099410|Receptor Protein-Tyrosine Kinases
396739|NCT01099410|Humans
396740|NCT01099410|Phagocytosis
396741|NCT01099410|Lung
396742|NCT01099410|in vitro
396743|NCT01099397|Glucose
396744|NCT01099397|Glucose Tolerance Test
396745|NCT01099397|Insulin Resistance
396746|NCT01099397|Metabolic adverse effects
396747|NCT01099397|Hypertension
396748|NCT01099397|Beta-blocker
396749|NCT01099397|Atenolol
396750|NCT01099397|Diuretic
396751|NCT01099397|Hydrochlorothiazide
396752|NCT01099397|Blood pressure
396753|NCT01099371|Knee
396754|NCT01099371|Osteoarthritis
396755|NCT01099371|Exercise
396756|NCT01099358|Cancer of Head
396757|NCT01099358|Cancer of Head and Neck
396758|NCT01099358|Cancer of Neck
396759|NCT01099358|Cancer of the Head
396760|NCT01099358|Cancer of the Head and Neck
396761|NCT01099358|Cancer of the Neck
396762|NCT01099358|Head and Neck Cancer
396763|NCT01099358|Head Cancer
396764|NCT01099358|Head Neoplasms
396765|NCT01099358|Head, Neck Neoplasms
396766|NCT01099358|Neck Cancer
396767|NCT01099358|Neck Neoplasms
396768|NCT01099358|Solid Neoplasm
396769|NCT01099358|Carcinoma
396770|NCT01099358|Sarcoma
396771|NCT01099345|OAB
396772|NCT01099345|Nocturia
396773|NCT01099345|Bladder function
396774|NCT01099345|cystometry
396775|NCT01099345|polysomnography
396776|NCT01099332|Alzheimer's disease
396777|NCT01099332|Mild Cognitive Impairment
396778|NCT01099332|Copper metabolism
396779|NCT01099332|Zinc metabolism
396780|NCT01099332|Ceruloplasmin
396781|NCT01099319|Dietary supplement
396782|NCT01099319|Renalof
396783|NCT01099319|gallstones
396784|NCT01099319|elderly
396785|NCT01099293|Hepatic Encephalopathy
396786|NCT01099293|Psychometric Hepatic Encephalopathy Score
396787|NCT01099293|Critical Flicker Frequency
396788|NCT01099293|Cerebrovascular Reactivity
396789|NCT01099293|Endotoxemia
396790|NCT01099293|Transcranial Doppler
396791|NCT01099293|Liver Cirrhosis
396792|NCT01099280|induction of labor in term
396793|NCT01099280|premature rupture of membranes
396794|NCT01099280|dinoprostone
396795|NCT01099280|oxytocin
396796|NCT01099267|MDS
396797|NCT01099254|CVP
396798|NCT01099254|US
396799|NCT01099254|Trendelenburg position
396800|NCT01099254|Ultrasound
396801|NCT01099254|Head Down Tilt
396802|NCT01099241|CVP
396803|NCT01099241|US
396804|NCT01099241|Ultrasonography
396805|NCT01099228|Neuroendocrine Tumor
396806|NCT01099228|Imaging
396807|NCT01099215|peripheral artery disease
396808|NCT01099215|percutaneous transluminal angioplasty
396809|NCT01099215|stent
396810|NCT01099215|balloon/stent
396811|NCT01099215|superficial femoral artery
396812|NCT01099202|Procrit
396813|NCT01099202|Acute Lymphocytic Leukemia
396814|NCT01099202|Lymphoblastic Lymphoma
396815|NCT01099202|Burkitt's
396816|NCT01099202|Chemotherapy
396817|NCT01099202|Hyper-CVAD
396818|NCT01099202|augmented BFM
396819|NCT01099202|Epoetin alfa
396820|NCT01099202|Epogen
396821|NCT01099202|Erythropoietin
396822|NCT01099189|Histology
396823|NCT01099189|Compliance
396824|NCT01099189|Dialysis
396825|NCT01099189|Arteriovenous access fistula
396826|NCT01099189|vein
396827|NCT01099176|hyperlipidemia
396828|NCT01099176|impaired fasting glycemia
396829|NCT01099176|adipokines
396830|NCT01099176|atorvastatin
396831|NCT01099176|fenofibrate
396832|NCT01099163|Diabetes mellitus
396833|NCT01099163|CLA
396834|NCT01099163|Antioxidant
396835|NCT01099163|Glycemic control
396836|NCT01099150|Platelets
396837|NCT01099150|Platelet aggregation
396838|NCT01099150|Platelet activation
396839|NCT01099150|Platelet function
396840|NCT01099150|Light transmission aggregometry
396841|NCT01099150|Platelet Function Analyzer-100 (PFA-100)
396842|NCT01099150|P-selectin
396843|NCT01099150|Fibrinogen receptor
396844|NCT01099150|Glycoprotein IIb-IIIa
396845|NCT01099150|Chocolate
396846|NCT01099150|Cocoa
396847|NCT01099150|Flavan-3-ols
396848|NCT01099150|Procyanidins
396849|NCT01099137|Diabetes
396850|NCT01099137|Vildagliptin
396851|NCT01099137|insulin
396852|NCT01099137|C-peptide
396853|NCT01099124|M2ES
396854|NCT01099124|NSCLC
396855|NCT01099124|Phase I Trial
396856|NCT01099124|Advanced NSCLC
396857|NCT01099124|Recurrent NSCLC
396858|NCT01099111|IBS
396859|NCT01099111|UC
396860|NCT01099111|CD
396861|NCT01099111|CRAP/CRC
396862|NCT01099098|People who have fibrosis or nodules in their upper lobe of the lung
396863|NCT01099085|gastric cancer, unresectable/metastatic
396864|NCT01099072|ADHD
396865|NCT01099072|carnitine
396866|NCT01099072|methylphenidate
396867|NCT01099059|Attention-deficit/hyperactivity disorder
396868|NCT01099059|Clinical Trial
396869|NCT01099059|Amantadine
396870|NCT01099059|Methylphenidate
396871|NCT01099046|Meniere's disease
396872|NCT01099046|stress management
396873|NCT01099046|vasopressin
396874|NCT01099046|V2 receptor
396875|NCT01099046|water intake
396876|NCT01099046|tympanic tubing
396877|NCT01099046|regular sleep under dark
396878|NCT01099033|hiatal hernia
396879|NCT01099033|paraesophageal hernia
396880|NCT01099033|biologic mesh
396881|NCT01099033|MMPs
396882|NCT01099033|Hiatal/Paraesophageal hernia
396883|NCT01099020|Subjects receiving large volumes of Radiation
396884|NCT01099007|Women
396885|NCT01099007|Menopause
396886|NCT01099007|Cardiovascular Disease
396887|NCT01099007|Physical Activity
396888|NCT01099007|Weight Loss
396889|NCT01098994|Type 1 diabetes
396890|NCT01098994|Haptoglobin genotype
396891|NCT01098994|HDL function
396892|NCT01098994|Heart disease
396893|NCT01098994|Feasibility of clinical trial
396894|NCT01098955|Cancer
396895|NCT01098955|Smoking Cessation Treatment
396896|NCT01098955|Acceptance and Commitment Therapy
396897|NCT01098955|ACT Theory
396898|NCT01098955|Motivational and Behavioral Counseling
396899|NCT01098955|MBC
396900|NCT01098955|abstinence
396901|NCT01098955|Varenicline
396902|NCT01098955|Chantix
396903|NCT01098942|bariatric surgery
396904|NCT01098929|genes
396905|NCT01098929|genetic
396906|NCT01098929|chromosome
396907|NCT01098929|chromosome microarray
396908|NCT01098916|hospital at home
396909|NCT01098916|radiology at home
396910|NCT01098916|frail elderly
396911|NCT01098903|sunitinib
396912|NCT01098903|cancer
396913|NCT01098903|pharmacogenomics
396914|NCT01098903|pharmacokinetics
396915|NCT01098903|Patients who have a malignancy and are going to be treated with sunitinib
396916|NCT01098903|doseindividualism
396917|NCT01098877|Phase1
396918|NCT01098877|pharmacokinetics
396919|NCT01098877|safety
396920|NCT01098877|toleration
396921|NCT01098877|pharmacodynamics
396922|NCT01098864|Behavior
396923|NCT01098864|Impulsivity
396924|NCT01098864|Transcranial Magnetic Stimulation
396925|NCT01098851|Obstructive Sleep Apnea
396926|NCT01098851|Pulse Oximetry
396927|NCT01098838|Cancer
396928|NCT01098838|adults
396929|NCT01098838|solid tumor
396930|NCT01098838|apoptosis
396931|NCT01098838|programmed cell death
396932|NCT01098838|LCL161
396933|NCT01098825|vaccine hesitancy
396934|NCT01098825|vaccine refusal
396935|NCT01098812|Cataract, Intraocular lens
396936|NCT01098799|Urotensin II,Chronic renal disease
396937|NCT01098786|Influenza A
396938|NCT01098786|H1N1 subtype
396939|NCT01098786|Vaccine
396940|NCT01098786|Adjuvant
396941|NCT01098786|Cell culture
396942|NCT01098773|Weaning from mechanical ventilation
396943|NCT01098773|BNP
396944|NCT01098773|Lung ultrasound
396945|NCT01098773|Echocardiography
396946|NCT01098760|Sorafenib
396947|NCT01098760|Hepatocellular Carcinoma (HCC)
396948|NCT01098747|Pain following third molar extraction
396949|NCT01098734|non-steroid
396950|NCT01098734|anti-inflammatory
396951|NCT01098734|skin disease
396952|NCT01098734|topical cream
396953|NCT01098734|small molecule
396954|NCT01098734|atopic dermatitis
396955|NCT01098734|eczema
396956|NCT01098721|plaque psoriasis
396957|NCT01098721|skin diseases
396958|NCT01098721|anti-inflammatory
396959|NCT01098721|non-steroid
396960|NCT01098721|topical cream
396961|NCT01098708|DMD
396962|NCT01098708|non ambulatory
396963|NCT01098695|parenting interventions
396964|NCT01098695|Family Check-Up
396965|NCT01098695|Early Intervention
396966|NCT01098695|Self-Regulation
396967|NCT01098669|cancer survivor
396968|NCT01098669|lymphedema
396969|NCT01098669|head and neck cancer
396970|NCT01098656|stage III mycosis fungoides/Sezary syndrome
396971|NCT01098656|stage IV mycosis fungoides/Sezary syndrome
396972|NCT01098656|stage II mycosis fungoides/Sezary syndrome
396973|NCT01098656|stage II cutaneous T-cell non-Hodgkin lymphoma
396974|NCT01098656|stage III cutaneous T-cell non-Hodgkin lymphoma
396975|NCT01098656|stage IV cutaneous T-cell non-Hodgkin lymphoma
396976|NCT01098643|unspecified adult solid tumor, protocol specific
396977|NCT01098617|endoscopic sphincterotomy
396978|NCT01098617|hemorrhage
396979|NCT01098617|nonsteroidal antiinflammatory agents
396980|NCT01098617|antiaggregants
396981|NCT01098617|anticoagulants
396982|NCT01098617|Endoscopic biliary sphincterotomy induced bleeding
396983|NCT01098591|meta-analysis
396984|NCT01098591|stem cell
396985|NCT01098591|cardiac
396986|NCT01098591|remodeling
396987|NCT01098591|MESS
396988|NCT01098578|Posterior Epistaxis
396989|NCT01098552|Prostate Cancer
396990|NCT01098539|sitagliptin
396991|NCT01098539|albiglutide
396992|NCT01098539|renal impairment
396993|NCT01098526|GSK1349572
396994|NCT01098526|efavirenz
396995|NCT01098526|integrase
396996|NCT01098526|pharmacokinetics
396997|NCT01098513|HIV
396998|NCT01098513|healthy
396999|NCT01098513|GSK1349572
397000|NCT01098500|Liver function
397001|NCT01098500|Tyrosine Kinase Inhibitor
397002|NCT01098487|Immune (idiopathic) thrombocytopenic purpura (ITP)
397003|NCT01098487|bone marrow fibers
397004|NCT01098487|eltrombopag olamine
397005|NCT01098487|thrombopoietin receptor agonist
397006|NCT01098474|Tuberculosis vaccine
397007|NCT01098461|dose-ranging
397008|NCT01098461|pharmacokinetics
397009|NCT01098461|GSK716155
397010|NCT01098461|Japan
397011|NCT01098461|albiglutide
397012|NCT01098448|Amoxicillin
397013|NCT01098448|antibiotics
397014|NCT01098448|chronic periodontitis
397015|NCT01098448|local drug delivery
397016|NCT01098448|metronidazol
397017|NCT01098448|randomized controlled trial
397018|NCT01098448|subgingival scaling
397019|NCT01098448|surgery
397020|NCT01098448|tetracycline
397021|NCT01098448|moderate to advanced chronic periodontitis
397022|NCT01098435|Binge eating disorder
397023|NCT01098435|RDC-0313
397024|NCT01098422|liver
397025|NCT01098422|colorectal
397026|NCT01098422|metastasis
397027|NCT01098422|carcinoma
397028|NCT01098422|Yttrium-90
397029|NCT01098422|microspheres
397030|NCT01098409|sodium nitrite
397031|NCT01098409|coronary artery bypass surgery
397032|NCT01098409|cardioprotection
397033|NCT01098409|myocardial injury
397034|NCT01098396|parkinson disease
397035|NCT01098396|gait
397036|NCT01098383|Autism
397037|NCT01098357|rhPDGF, diabetic foot ulcer,
397038|NCT01098344|stage III pancreatic cancer
397039|NCT01098344|stage IV pancreatic cancer
397040|NCT01098344|duct cell adenocarcinoma of the pancreas
397041|NCT01098331|stage I prostate cancer
397042|NCT01098331|stage IIB prostate cancer
397043|NCT01098331|stage IIA prostate cancer
397044|NCT01098318|Depression
397045|NCT01098318|Antidepressant Therapy
397046|NCT01098318|Herbal Treatment
397047|NCT01098318|Rhodiola rosea
397048|NCT01098318|Alternative Therapy
397049|NCT01098305|nicotine smokeless tobacco chewing tobacco varenicline
397050|NCT01098292|Fibromyalgia
397051|NCT01098292|Irritable Bowel Syndrome
397052|NCT01098292|Chronic Fatigue Syndrome
397053|NCT01098292|Interstitial Cystitis
397054|NCT01098292|Chronic Prostatitis
397055|NCT01098292|Urological Chronic Pelvic Pain
397056|NCT01098292|Painful Bladder Syndrome
397057|NCT01098279|Interstitial Cystitis
397058|NCT01098279|Chronic Prostatitis
397059|NCT01098279|Urological Chronic Pelvic Pain
397060|NCT01098279|Painful Bladder Syndrome
397061|NCT01098266|MPM
397062|NCT01098266|NGR-hTNF
397063|NCT01098266|NGR-hTNF plus BIC
397064|NCT01098266|Randomized double-blind phase III study
397065|NCT01098253|adherence
397066|NCT01098253|diabetes mellitus
397067|NCT01098253|depression
397068|NCT01098253|primary health care
397069|NCT01098240|Antidepressant Augmentation
397070|NCT01098227|RSV Bronchiolitis
397071|NCT01098227|Lower Respiratory Viral infection
397072|NCT01098227|Exhaled Nitric Oxide
397073|NCT01098214|Normal pregnancy
397074|NCT01098214|Amniotic fluid
397075|NCT01098214|Cytokines
397076|NCT01098214|Biomarkers
397077|NCT01098201|Certolizumab
397078|NCT01098201|TNF
397079|NCT01098201|RA
397080|NCT01098201|Cizmia
397081|NCT01098175|laparotomy
397082|NCT01098175|thoracotomy
397083|NCT01098175|peritoneal conditioning
397084|NCT01098175|humidification
397085|NCT01098175|temperature control
397086|NCT01098162|Lacosamide
397087|NCT01098162|Vimpat®
397088|NCT01098162|Epilepsy
397089|NCT01098162|Partial-Onset Seizures
397090|NCT01098162|Adjunctive therapy
397091|NCT01098149|Haemodialysis treatment tolerance
397092|NCT01098149|acetate free biofiltration
397093|NCT01098149|frequency of hypotensive events during dialysis
397094|NCT01098149|nurse intervention during dialysis
397095|NCT01098136|Pelvic girdle pain
397096|NCT01098136|Chiropractic
397097|NCT01098136|Single-blinded
397098|NCT01098136|Outcome study
397099|NCT01098084|Decitabine, chronic myelomonocytic leukemia
397100|NCT01098058|Adult attention deficit hyperactivity disorder
397101|NCT01098058|cognitive-behavioural therapy
397102|NCT01098058|randomised controlled trial
397103|NCT01098045|HIV
397104|NCT01098045|fat redistribution
397105|NCT01098045|brown adipose tissue
397106|NCT01098045|PET
397107|NCT01098032|Contrast media
397108|NCT01098032|Kidney
397109|NCT01098032|Complication
397110|NCT01098019|Notalgia paresthetica
397111|NCT01098019|Xeomin
397112|NCT01098019|Botulinum Toxin A
397113|NCT01098019|Pruritus
397114|NCT01098019|Upper Back
397115|NCT01098019|Hyperpigmentation
397116|NCT01098006|Immunological assays
397117|NCT01098006|Chronic hepatitis B
397118|NCT01097980|trazodone
397119|NCT01097980|SSRI
397120|NCT01097980|sexual dysfunction
397121|NCT01097980|5-HT2A polymorphism
397122|NCT01097967|Sleep disordered breathing
397123|NCT01097967|Continuous Positive Airway Pressure
397124|NCT01097967|Sleep apnoea
397125|NCT01097967|Markers of atherosclerosis
397126|NCT01097954|Exercise induced asthma
397127|NCT01097954|Exercise induced bronchospasm
397128|NCT01097954|exhaled Nitric Oxide
397129|NCT01097941|Influenza
397130|NCT01097941|H1N1
397131|NCT01097915|PROP taste sensitivity
397132|NCT01097915|Gustin (CAVI) polymorphism
397133|NCT01097915|Salivary zinc
397134|NCT01097915|BMI
397135|NCT01097915|Electrophysiological recording from the tongue
397136|NCT01097889|United Nations World Food Programme
397137|NCT01097889|blended food (CSB)
397138|NCT01097889|ready-to-use supplementary foods (RUSF)
397139|NCT01097889|Plumpy®
397140|NCT01097876|healthy volunteer
397141|NCT01097876|pharmacokinetic
397142|NCT01097876|safety
397143|NCT01097850|hand foot skin syndrome
397144|NCT01097850|palmar plantar erythrodysesthesia
397145|NCT01097850|doxorubicin
397146|NCT01097850|capecitabine
397147|NCT01097837|Epilepsy
397148|NCT01097837|Contraceptive
397149|NCT01097837|Birth Control
397150|NCT01097837|Seizure
397151|NCT01097837|This study is looking at the use of different birth control measures in women with epilepsy.
397152|NCT01097811|Hepatic Encephalopathy
397153|NCT01097811|Hypertension, Portal
397154|NCT01097811|Liver Cirrhosis
397155|NCT01097811|Bacterial Overgrowth Syndrome
397156|NCT01097798|muscle injury
397157|NCT01097772|abdominal
397158|NCT01097772|aortic
397159|NCT01097772|aneurysm
397160|NCT01097759|hemorrhoids
397161|NCT01097759|prolapsed
397162|NCT01097759|hemorrhoidectomy
397163|NCT01097759|Hemorrhoidopexy
397164|NCT01097759|LigaSure
397165|NCT01097759|Stapled
397166|NCT01097746|Cancer
397167|NCT01097746|Fallopian Tube
397168|NCT01097746|Ovary
397169|NCT01097746|Peritoneum
397170|NCT01097746|Epithelial ovarian
397171|NCT01097746|Paclitaxel
397172|NCT01097746|Carboplatin
397173|NCT01097746|Bevacizumab
397174|NCT01097746|Taxol
397175|NCT01097746|Avastin
397176|NCT01097746|Paraplatin
397177|NCT01097746|Carcinoma
397178|NCT01097746|Surgery
397179|NCT01097720|Valproate
397180|NCT01097720|Lamotrigine
397181|NCT01097720|Carbamazepine
397182|NCT01097720|Anticonvulsant
397183|NCT01097720|Antiepileptic
397184|NCT01097720|Teratogen
397185|NCT01097720|Autism
397186|NCT01097720|Developmental Delay
397187|NCT01097694|cKIT inhibition in Asthma
397188|NCT01097694|Efficacy of Imatinib in severe resistent asthma.
397189|NCT01097681|ASP1941
397190|NCT01097681|Diabetes mellitus
397191|NCT01097681|Urinary glucose excretion
397192|NCT01097668|Multiple sclerosis
397193|NCT01097668|Immunomodulation
397194|NCT01097668|Phase 1
397195|NCT01097655|Tolerability
397196|NCT01097655|Viral load
397197|NCT01097655|Human immunodeficiency Virus
397198|NCT01097655|Effectiveness
397199|NCT01097655|Treatment-naïve
397200|NCT01097655|Tablets
397201|NCT01097655|Infection
397202|NCT01097655|Non Nucleoside Reverse Transcriptase Inhibitor
397203|NCT01096615|Allergic rhinitis-Probiotic Lactobacillus paracasei LP-33-
397204|NCT01096602|Dendritic Cell/AML vaccine
397205|NCT01096602|CT-011
397206|NCT01096589|lymphoedema
397207|NCT01096589|lymphedema
397208|NCT01096563|Phase I
397209|NCT01096563|Japanese healthy volunteer
397210|NCT01096563|AZD9164
397211|NCT01097603|Non-Invasive Blood Pressure
397212|NCT01097590|ulcerative colitis
397213|NCT01097590|leukapheresis treatment
397214|NCT01097577|photorefractive keratectomy
397215|NCT01097577|excimer laser
397216|NCT01097577|PRK
397217|NCT01097577|pain, postoperative
397218|NCT01097577|pregabalin
397219|NCT01097564|Genetic
397220|NCT01097564|Cerebral angiopathy
397221|NCT01097564|Retinal angiopathy
397222|NCT01097564|COL4A1 gene
397223|NCT01097564|Infantile Cerebral Palsy
397224|NCT01097564|Congenital porencephaly
397225|NCT01097564|Congenital cataract
397226|NCT01097564|Leukoencephalopathy
397227|NCT01097564|COL4A1 gene related cerebra-retinal angiopathy
397228|NCT01097551|Type 1 diabetes mellitus
397229|NCT01097551|Diabetic retinopathy
397230|NCT01097551|Pathogenesis
397231|NCT01097551|Dynamic Vessel Analyser
397232|NCT01097551|Endothelial dysfunction
397233|NCT01097538|exercise
397234|NCT01097538|rehabilitation
397235|NCT01097538|progressive multiple sclerosis
397236|NCT01097538|functional ability
397237|NCT01097538|fatigue
397238|NCT01097538|quality of life
397239|NCT01097512|AS703569
397240|NCT01097512|MSC1992371A
397241|NCT01097512|Aurora kinase inhibitor
397242|NCT01097512|Cancer treatable with gemcitabine
397243|NCT01097499|Dental implant initial stability
397244|NCT01097499|Initial bone resorption post implant placement
397245|NCT01097499|Analgesia effect of LED intervention
397246|NCT01097486|Cervical Degenerative Disc Disease
397247|NCT01097486|Degenerative Spondylolisthesis
397248|NCT01097486|Spinal Stenosis
397249|NCT01097486|Stem cells
397250|NCT01097486|Adult Stem Cells
397251|NCT01097486|Anterior cervical discectomy and Fusion (ACDF)
397252|NCT01097486|Cervical Allograft Spacer
397253|NCT01097486|Anterior Cervical Plate Fixation
397254|NCT01097460|HER2/HER3
397255|NCT01097460|Bispecific Antibody
397256|NCT01097460|Breast Cancer
397257|NCT01097460|Advanced Breast Cancer
397258|NCT01097460|Metastatic Breast Cancer
397259|NCT01097460|HER2 Positive Breast Cancer
397260|NCT01097460|Trastuzumab
397261|NCT01097460|Herceptin
397262|NCT01097447|Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration
397263|NCT01097395|ribavirin
397264|NCT01097395|pharmacokinetics
397265|NCT01097395|Hepatitis C virus
397266|NCT01097343|Clopidogrel pharmacogenomics study
397267|NCT01097343|Performing genetic study looking at clopidogrel resistance
397268|NCT01097330|Defibrillators, Implantable
397269|NCT01097330|Tachycardia, Ventricular
397270|NCT01097330|Catheter Ablation
397271|NCT01097330|Amiodarone
397272|NCT01097317|chemotherapeutic agent toxicity
397273|NCT01097317|musculoskeletal complications
397274|NCT01097317|fatigue
397275|NCT01097317|stage I non-small cell lung cancer
397276|NCT01097317|stage II non-small cell lung cancer
397277|NCT01097317|stage IIIA non-small cell lung cancer
397278|NCT01097317|stage IIIB non-small cell lung cancer
397279|NCT01097317|stage IV non-small cell lung cancer
397280|NCT01097317|recurrent non-small cell lung cancer
397281|NCT01097278|breast cancer
397282|NCT01097278|ductal breast carcinoma in situ
397283|NCT01097278|lobular breast carcinoma in situ
397284|NCT01097278|BRCA1 mutation carrier
397285|NCT01097278|BRCA2 mutation carrier
397286|NCT01097265|stage I colon cancer
397287|NCT01097265|stage II colon cancer
397288|NCT01097252|Cervical Neoplasm
397289|NCT01097252|chemoradiation
397290|NCT01097252|compliance
397291|NCT01097252|toxicity
397292|NCT01097239|High Intensity Focused Ultrasound
397293|NCT01097239|HIFU
397294|NCT01097239|Rectal Cancer
397295|NCT01097239|Sonablate 500
397296|NCT01097239|Transrectal
397297|NCT01097226|Dietary intervention
397298|NCT01097226|bioavailability
397299|NCT01097226|Healthy volunteers
397300|NCT01097200|sacrocolpopexy
397301|NCT01097200|meshes
397302|NCT01097200|sacrospinous ligament
397303|NCT01097174|Glaucoma
397304|NCT01097174|Glaucoma device
397305|NCT01097174|Glaucoma surgery
397306|NCT01097174|Intraocular pressure
397307|NCT01097161|Stuttering
397308|NCT01097161|Apraxia of speech
397309|NCT01097161|Motor control
397310|NCT01097161|Prosody
397311|NCT01097161|Pitch range
397312|NCT01097161|Speech rate
397313|NCT01097161|fluency disorders
397314|NCT01097148|Obese
397315|NCT01097148|Atracurium
397316|NCT01097148|Cefazolin
397317|NCT01097148|Morfine
397318|NCT01097148|Nadroparin
397319|NCT01097122|bone
397320|NCT01097122|motor neuron excitability
397321|NCT01097122|forearm vibration
397322|NCT01097122|mechanical loading
397323|NCT01097122|muscle electrical activity
397324|NCT01097109|Effect of Somatic Dysfunctions of Pelvis
397325|NCT01097109|Effect of Somatic Dysfunctions of Sacrum
397326|NCT01097109|Effect of Somatic Dysfunctions of Lower Lumbar Spine
397327|NCT01097109|Weight-Bearing
397328|NCT01097096|Active immunization
397329|NCT01097096|Alzheimer disease
397330|NCT01097096|Antibody
397331|NCT01097096|Central Nervous System Diseases
397332|NCT01097096|Neurodegenerative diseases
397333|NCT01097096|Vaccine
397334|NCT01097083|Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
397335|NCT01097083|Patients who are unfit for standard therapy
397336|NCT01097044|Erythropoietic Protoporphyria
397337|NCT01097044|EPP
397338|NCT01097044|Afamelanotide
397339|NCT01097031|blood pressure
397340|NCT01097031|pediatric
397341|NCT01097031|nursing
397342|NCT01097031|maintenance arterial catheter
397343|NCT01097005|Mycobacterium Infections, Atypical
397344|NCT01096992|Chronic lymphocytic leukemia
397345|NCT01096992|CLL
397346|NCT01096992|Bendamustine
397347|NCT01096992|Fludarabine
397348|NCT01096992|Fludara
397349|NCT01096992|Fludarabine Phosphate
397350|NCT01096992|Rituximab
397351|NCT01096992|Rituxan
397352|NCT01096979|Subcutaneous Adipose Tissue Reduction
397353|NCT01096966|chronic low back pain
397354|NCT01096953|Attention Deficit Hyperactivity Disorder
397355|NCT01096953|ADHD
397356|NCT01096953|attention deficit
397357|NCT01096940|Type 2 Diabetes Mellitus
397358|NCT01096940|Glucose lowering
397359|NCT01096927|Lower Abdominal Pain
397360|NCT01096927|Right Iliac Fossa Pain
397361|NCT01096927|Acute Appendicitis
397362|NCT01096927|Antibiotic Therapy
397363|NCT01096927|Conservative Management
397364|NCT01096927|Appendectomy
397365|NCT01096927|Recurrence
397366|NCT01096927|Length of hospital stay
397367|NCT01096927|Sick leave time
397368|NCT01096927|Short and Long Term Abdominal pain evaluation
397369|NCT01096888|WIC
397370|NCT01096888|Weight loss
397371|NCT01096888|Overweight
397372|NCT01096888|Post Partum
397373|NCT01096888|Internet based weight loss intervention for Mothers in the WIC program.
397374|NCT01096875|Endothelial progenitor cells
397375|NCT01096875|Atorvastatin
397376|NCT01096875|Coronary surgery
397377|NCT01096862|Psoriasis
397378|NCT01096862|ASP015K
397379|NCT01096849|urinary tract infection
397380|NCT01096849|UTI
397381|NCT01096849|cUTI
397382|NCT01096849|pyelonephritis
397383|NCT01096849|AP
397384|NCT01096849|ACHN-490
397385|NCT01096836|resistance exercise
397386|NCT01096836|body mass index
397387|NCT01096836|hypertrophy
397388|NCT01096836|endothelial function
397389|NCT01096836|blood lipids
397390|NCT01096823|Rheumatoid Arthritis
397391|NCT01096823|Yoga
397392|NCT01096823|Adolescents
397393|NCT01096823|Young Adults
397394|NCT01096810|Asymptomatic
397395|NCT01096784|insulin-like growth factor
397396|NCT01096784|ROP
397397|NCT01096784|IGF-I
397398|NCT01096784|BPD
397399|NCT01096784|bronchopulmonary dysplasia
397400|NCT01096784|retinopathy of prematurity
397401|NCT01096771|ARDS
397402|NCT01096771|Parenteral
397403|NCT01096771|Pharmaconutrition
397404|NCT01096758|PKU
397405|NCT01096758|phenylketonuria
397406|NCT01096758|adult
397407|NCT01096758|patient
397408|NCT01096758|development
397409|NCT01096758|nutritional deficiencies
397410|NCT01096758|neurological outcome
397411|NCT01096758|psychological and neurological development
397412|NCT01096758|comparison with healthy adults
397413|NCT01096758|longitudinal development
397414|NCT01096758|quality of life
397415|NCT01096745|Gemcitabine
397416|NCT01096745|Cisplatin
397417|NCT01096745|S-1
397418|NCT01096745|bile duct cancer
397419|NCT01096732|Pancreatic
397420|NCT01096732|adenocarcinoma
397421|NCT01096732|cancer
397422|NCT01096719|Weight
397423|NCT01096719|Dietary intake
397424|NCT01096719|Energy Density
397425|NCT01096719|Behavioral
397426|NCT01096719|Satiety
397427|NCT01096719|Deprivation
397428|NCT01096719|Hunger
397429|NCT01096719|Fruit
397430|NCT01096719|Vegetable
397431|NCT01096706|Urocortin 2
397432|NCT01096706|Urocortin 3
397433|NCT01096706|Nitric Oxide
397434|NCT01096706|Plethysmography
397435|NCT01096706|Forearm blood flow
397436|NCT01096706|Vascular
397437|NCT01096706|Heart failure
397438|NCT01096706|endothelium
397439|NCT01096706|Cyclo-oxygenase pathway
397440|NCT01096706|EDHF
397441|NCT01096693|Urocortin 2
397442|NCT01096693|Urocortin 3
397443|NCT01096693|Astressin 2B
397444|NCT01096693|forearm blood flow
397445|NCT01096693|plethysmography
397446|NCT01096693|vascular
397447|NCT01096693|heart failure
397448|NCT01096667|type 2 diabetes
397449|NCT01096667|hypertension
397450|NCT01096667|ambulatory blood pressure monitoring
397451|NCT01096654|endocrine hypertension
397452|NCT01096654|primary hyperaldosteronism
397453|NCT01096654|aldosterone
397454|NCT01096654|aldosterone-producing adenoma
397455|NCT01096654|bilateral adrenal hyperplasia
397456|NCT01096654|computed tomography
397457|NCT01096654|adrenal vein sampling
397458|NCT01096641|Fatigued disease-free Cancer Patients
397459|NCT01096641|cancer treatment finished > one year and < ten years ago
397460|NCT01096628|adolescent
397461|NCT01096628|low back pain
397462|NCT01096628|chiropractic
397463|NCT01096628|exercise
397464|NCT01096550|opioid dependence
397465|NCT01096550|outpatient treatment
397466|NCT01096550|intensive outpatient treatment
397467|NCT01096537|incidence
397468|NCT01096537|young workers
397469|NCT01096537|occupations at risk
397470|NCT01096537|public health
397471|NCT01096537|epidemiology
397472|NCT01096537|polymorphisms
397473|NCT01096537|gentic
397474|NCT01096524|Kneehab
397475|NCT01096524|NMES
397476|NCT01096524|Total Knee Arthroplasty
397477|NCT01096524|Total Knee Replacement
397478|NCT01096524|TKA
397479|NCT01096524|Disuse atrophy
397480|NCT01096524|muscle hypertrophy
397481|NCT01096524|TKR
397482|NCT01096524|Atrophy Prevention
397483|NCT01096511|Moxifloxacin,
397484|NCT01096511|cIAI
397485|NCT01096511|non-interventional
397486|NCT01096472|Tinea pedis
397487|NCT01096459|spina
397488|NCT01096459|bifida
397489|NCT01096459|restore
397490|NCT01096459|urinary
397491|NCT01096459|function
397492|NCT01096459|nerve
397493|NCT01096459|reroute
397494|NCT01096433|Sleep apnea
397495|NCT01096433|CPAP
397496|NCT01096433|Prostaglandins
397497|NCT01096433|Circadian variations
397498|NCT01096420|chronic migraine
397499|NCT01096420|acupuncture
397500|NCT01096420|Topiramate
397501|NCT01096420|Randomized trial
397502|NCT01096407|pain
397503|NCT01096407|arthralgia
397504|NCT01096407|unspecified adult solid tumor, protocol specific
397505|NCT01096394|stage III ovarian epithelial cancer
397506|NCT01096394|stage IV ovarian epithelial cancer
397507|NCT01096381|cardiovascular complications
397508|NCT01096381|stage I breast cancer
397509|NCT01096381|stage II breast cancer
397510|NCT01096381|stage IIIA breast cancer
397511|NCT01096381|stage IIIB breast cancer
397512|NCT01096381|stage IIIC breast cancer
397513|NCT01096381|stage IV breast cancer
397514|NCT01096381|stage I colon cancer
397515|NCT01096381|stage II colon cancer
397516|NCT01096381|stage III colon cancer
397517|NCT01096381|stage IV colon cancer
397518|NCT01096381|stage I rectal cancer
397519|NCT01096381|stage II rectal cancer
397520|NCT01096381|stage III rectal cancer
397521|NCT01096381|stage IV rectal cancer
397522|NCT01096381|stage I non-small cell lung cancer
397523|NCT01096381|stage II non-small cell lung cancer
397524|NCT01096381|stage IIIA non-small cell lung cancer
397525|NCT01096381|stage IIIB non-small cell lung cancer
397526|NCT01096381|stage IV non-small cell lung cancer
397527|NCT01096381|unspecified adult solid tumor, protocol specific
397528|NCT01096381|recurrent squamous cell carcinoma of the hypopharynx
397529|NCT01096381|stage IV squamous cell carcinoma of the hypopharynx
397530|NCT01096381|recurrent squamous cell carcinoma of the larynx
397531|NCT01096381|stage IV squamous cell carcinoma of the larynx
397532|NCT01096381|recurrent verrucous carcinoma of the larynx
397533|NCT01096381|stage IV verrucous carcinoma of the larynx
397534|NCT01096381|recurrent adenoid cystic carcinoma of the oral cavity
397535|NCT01096381|recurrent mucoepidermoid carcinoma of the oral cavity
397536|NCT01096381|recurrent verrucous carcinoma of the oral cavity
397537|NCT01096381|stage IV adenoid cystic carcinoma of the oral cavity
397538|NCT01096381|stage IV mucoepidermoid carcinoma of the oral cavity
397539|NCT01096381|stage IV verrucous carcinoma of the oral cavity
397540|NCT01096381|recurrent basal cell carcinoma of the lip
397541|NCT01096381|recurrent squamous cell carcinoma of the lip and oral cavity
397542|NCT01096381|stage IV basal cell carcinoma of the lip
397543|NCT01096381|stage IV squamous cell carcinoma of the lip and oral cavity
397544|NCT01096381|metastatic squamous neck cancer with occult primary squamous cell carcinoma
397545|NCT01096381|recurrent metastatic squamous neck cancer with occult primary
397546|NCT01096381|untreated metastatic squamous neck cancer with occult primary
397547|NCT01096381|recurrent lymphoepithelioma of the nasopharynx
397548|NCT01096381|recurrent squamous cell carcinoma of the nasopharynx
397549|NCT01096381|stage IV lymphoepithelioma of the nasopharynx
397550|NCT01096381|stage IV squamous cell carcinoma of the nasopharynx
397551|NCT01096381|recurrent lymphoepithelioma of the oropharynx
397552|NCT01096381|recurrent squamous cell carcinoma of the oropharynx
397553|NCT01096381|stage IV lymphoepithelioma of the oropharynx
397554|NCT01096381|stage IV squamous cell carcinoma of the oropharynx
397555|NCT01096381|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
397556|NCT01096381|recurrent inverted papilloma of the paranasal sinus and nasal cavity
397557|NCT01096381|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
397558|NCT01096381|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
397559|NCT01096381|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
397676|NCT01095913|Indocyanine green
397560|NCT01096381|stage IV inverted papilloma of the paranasal sinus and nasal cavity
397561|NCT01096381|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
397562|NCT01096381|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
397563|NCT01096381|stage II ovarian epithelial cancer
397564|NCT01096381|stage III ovarian epithelial cancer
397565|NCT01096381|stage IV ovarian epithelial cancer
397566|NCT01096381|fallopian tube cancer
397567|NCT01096381|peritoneal cavity cancer
397568|NCT01096329|postmenopausal
397569|NCT01096329|hormone replacement therapy
397570|NCT01096316|mood disorders
397571|NCT01096316|depressive disorder
397572|NCT01096316|women
397573|NCT01096316|depression
397574|NCT01096303|COPD
397575|NCT01096303|pulmonary function
397576|NCT01096303|tobacco and marihuana smoking
397577|NCT01096290|constipation
397578|NCT01096290|lubiprostone
397579|NCT01096290|healthy volunteers
397580|NCT01096264|Arterial stiffness
397581|NCT01096264|Pulse wave velocity
397582|NCT01096264|Ultrafastecho
397583|NCT01096264|Supersonic shear imaging
397584|NCT01096251|Obesity
397585|NCT01096251|Binge Eating Disorder
397586|NCT01096251|Cognitive Behavioural Therapy
397587|NCT01096251|Brief Strategic Therapy
397588|NCT01096251|Telepsychology
397589|NCT01096238|The immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in adults after half a year will be analyzed and discussed.
397590|NCT01096225|the antibody response
397591|NCT01096225|T-cell response
397592|NCT01096225|S-OIV
397593|NCT01096225|vaccine
397594|NCT01096225|Immunogenicity assessment
397595|NCT01096212|Efficacy
397596|NCT01096212|Minimum alveolar concentration
397597|NCT01096212|Safety
397598|NCT01096212|Sevoflurane
397599|NCT01096199|The purpose of the study is to evaluate the safety and feasibility of combining TS-1/CDDP with RAD001. Primary
397600|NCT01096199|Objectives
397601|NCT01096199|To determine the MTD/recommended phase II dose of TS-1/CDDP/RAD001 combination —To determine
397602|NCT01096199|the safety of TS-1/CDDP/RAD001 combination Secondary Objectives —To preliminarily describe any clinical activity in
397603|NCT01096199|platinum refractory disease
397604|NCT01096199|To assess to effect of concurrent TS-1/CDDP on RAD001 pharmacokinetics —To explore
397605|NCT01096199|the relationship of tumour biomarkers and treatment response
397606|NCT01096186|motor Symptoms
397607|NCT01096186|efficacy
397608|NCT01096186|IPX066
397609|NCT01096186|Parkinson's Disease
397610|NCT01096173|Sputum
397611|NCT01096173|chronic obstructive pulmonary disease
397612|NCT01096160|Hypertension
397613|NCT01096147|FBSS
397614|NCT01096147|chronic pain
397615|NCT01096147|leg pain
397616|NCT01096147|low back pain
397617|NCT01096147|spinal cord stimulation
397618|NCT01096121|Angiotensin-converting enzyme inhibitors (ACE)
397619|NCT01096121|Renal disease
397620|NCT01096121|Microalbuminemia
397621|NCT01096108|Smoking cessation
397622|NCT01096108|Quit smoking
397623|NCT01096108|Quit & Win
397624|NCT01096095|SCA
397625|NCT01096095|Spinocerebellar Ataxia
397626|NCT01096095|Sodium Phenylbutyrate
397627|NCT01096095|Machado-Joseph Disease
397628|NCT01096095|Treatment
397629|NCT01096082|spinocerebellar ataxia
397630|NCT01096082|Treatment
397631|NCT01096082|Lithium carbonate
397632|NCT01096069|Rituximab, rheumatoid arthritis, CD55, CD59
397633|NCT01096056|Children
397634|NCT01096056|Influenza
397635|NCT01096056|Safety
397636|NCT01096056|Immunogenicity
397637|NCT01096056|Vaccine
397638|NCT01096043|Heart Failure
397639|NCT01096043|ADHF
397640|NCT01096030|Regorafenib
397641|NCT01096030|Advanced
397642|NCT01096030|Refractory solid tumors
397643|NCT01096017|Terbutaline
397644|NCT01096017|Turbuhaler
397645|NCT01096017|Efficacy
397646|NCT01096017|Asthma
397647|NCT01096017|Japanese
397648|NCT01096017|salbutamol
397649|NCT01096017|Bricanyl
397650|NCT01096004|Pharmacodynamic method evaluation
397651|NCT01095991|Type 2 Diabetes Mellitus, Sitagliptin
397652|NCT01095978|Klacid SR
397653|NCT01095978|Clarithromycin
397654|NCT01095978|Respiratory tract infections
397655|NCT01095978|Bronchitis
397656|NCT01095978|Pneumonia
397657|NCT01095965|Nutrition education intervention
397658|NCT01095965|Type 2 diabetes mellitus
397659|NCT01095952|atrial fibrillation
397660|NCT01095952|inappropriate shock
397661|NCT01095952|AV-node stimulation
397662|NCT01095952|ventricular arrhythmia
397663|NCT01095939|Renal function consecutive to pre-eclampsia
397664|NCT01095926|pharmacokinetic
397665|NCT01095926|doxorubicin
397666|NCT01095926|cancer
397667|NCT01095926|troponin
397668|NCT01095926|natriuretic peptide
397669|NCT01095926|cardiotoxicity
397670|NCT01095926|anthracyclines
397671|NCT01095926|Ewing
397672|NCT01095926|ALL
397673|NCT01095913|Near-Infrared Imaging
397674|NCT01095913|Fluorescent Dyes
397675|NCT01095913|Lymph Node Mapping
397677|NCT01095913|IC-Green
397678|NCT01095913|nonradioactive optical imaging
397679|NCT01095913|fluorescent contrast agent
397680|NCT01095913|ICG
397681|NCT01095913|lymph nodes
397682|NCT01095913|axillary nodal dissection
397683|NCT01095900|Pain after treatment
397684|NCT01095900|healing of fissure after treatment
397685|NCT01095900|continence scores after treatment
397686|NCT01095887|ABO incompatibility
397687|NCT01095887|living donor kidney transplant
397688|NCT01095887|kidney transplant
397689|NCT01095887|ABO blood type incompatible
397690|NCT01095874|myelodysplasia
397691|NCT01095874|allogeneic hematopoietic stem cell transplantation
397692|NCT01095874|Survival
397693|NCT01095874|Transplantation
397694|NCT01095861|endotracheal tube
397695|NCT01095848|vaccine
397696|NCT01095848|cancer
397697|NCT01095848|ovarian
397698|NCT01095848|breast
397699|NCT01095848|prostate
397700|NCT01095848|tumor
397701|NCT01095848|Immunotherapy
397702|NCT01095822|Diabetes
397703|NCT01095822|Hypertension
397704|NCT01095822|Platelets
397705|NCT01095822|Hemostasis
397706|NCT01095822|Aliskiren
397707|NCT01095822|Valsartan
397708|NCT01095796|Treatment Naive
397709|NCT01095796|HIV 1 Infected
397710|NCT01095783|low back pain
397711|NCT01095783|physiotherapy
397712|NCT01095783|hemodialysis
397713|NCT01095783|end-stage renal disease
397714|NCT01095770|Atrial Fibrillation
397715|NCT01095770|Atrial Fibrillation Ablation
397716|NCT01095770|Atrial Fibrillation monitoring
397717|NCT01095770|Ablation Frontiers
397718|NCT01095770|Reveal XT
397719|NCT01095770|LASSO
397720|NCT01095757|Myeloma
397721|NCT01095757|Lymphoma
397722|NCT01095757|Stem cell transplantation
397723|NCT01095744|PIB imaging,
397724|NCT01095744|brain atrophy
397725|NCT01095744|cognitive impairment
397726|NCT01095744|Pet imaging
397727|NCT01095744|Alzheimer's disease
397728|NCT01095744|amyloid protein
397729|NCT01095731|aneurysm
397730|NCT01095731|aneurysmal
397731|NCT01095731|subarachnoid
397732|NCT01095731|hemorrhage
397733|NCT01095731|haemorrhage
397734|NCT01095731|neuroprotection
397735|NCT01095731|3-aminopropanal
397736|NCT01095731|3AP
397737|NCT01095731|polyamine oxidase
397738|NCT01095731|spermine
397739|NCT01095731|spermidine
397740|NCT01095731|vasospasm
397741|NCT01095731|cerebral ischemia
397742|NCT01095731|neurosurgery
397743|NCT01095731|neurological intensive care unit
397744|NCT01095731|NICU
397745|NCT01095731|Tiopronin
397746|NCT01095731|Thiola
397747|NCT01095731|FDA
397748|NCT01095731|Thiopronin
397749|NCT01095731|Thiosol
397750|NCT01095731|Tioglis
397751|NCT01095731|Acadione
397752|NCT01095731|Capen
397753|NCT01095731|Captimer
397754|NCT01095731|Epatiol
397755|NCT01095731|Vincol
397756|NCT01095731|Mucolysin
397757|NCT01095731|Sutilan
397758|NCT01095731|Meprin
397759|NCT01095731|Thiolpropionamidoacetic acid
397760|NCT01095731|Mercaptopropionyl glycine
397761|NCT01095731|2 MPG
397762|NCT01095705|Hypnosis
397763|NCT01095705|Transesophageal Echocardiography
397764|NCT01095705|Efficiency of Hypnosis
397765|NCT01095692|Occult stress Incontinence,
397766|NCT01095692|Pelvic Organ Prolapse,
397767|NCT01095692|Prevention of stress urinary incontinence,
397768|NCT01095692|Postoperative incontinence,
397769|NCT01095692|Sub-urethral tape
397770|NCT01095679|CHEYNE Stokes respiration
397771|NCT01095679|Periodic ventilation
397772|NCT01095679|baclofen
397773|NCT01095679|hypoxia
397774|NCT01095679|healthy subject
397775|NCT01095640|acne
397776|NCT01095640|adapalene
397777|NCT01095640|Differin
397778|NCT01095614|Women
397779|NCT01095614|Hormonal status
397780|NCT01095614|Exercise
397781|NCT01095614|Substrate utilization
397782|NCT01095614|Women Hormonal Status (with oral contraception or without any contraception)
397783|NCT01095601|avanafil
397784|NCT01095601|absoprion
397785|NCT01095601|bioavailability
397786|NCT01095601|food effect
397787|NCT01095601|dose-proportionality
397788|NCT01095601|TA-1790
397789|NCT01095601|Pharmacokinetics of avanafil
397790|NCT01095588|ED
397791|NCT01095575|Epidural
397792|NCT01095575|Morphine
397793|NCT01095575|Preoperative
397794|NCT01095575|Postoperative
397795|NCT01095575|Analgesia
397796|NCT01095575|Tolerance
397797|NCT01095575|Preoperative, Postoperative Analgesia
397798|NCT01095549|ankle-brachial index (ABI)
397799|NCT01095549|brachial-ankle pulse wave velocity (baPWV)
397800|NCT01095549|far infrared therapy (FIR)
397801|NCT01095549|hemodialysis (HD)
397802|NCT01095549|peripheral artery disease (PAD)
397803|NCT01095549|Peripheral artery disease in hemodialysis
397804|NCT01095536|laparoscopic cholecystectomy, elective
397805|NCT01095536|anesthesia, general
397806|NCT01095536|shoulder pain
397807|NCT01095536|nausea
397808|NCT01095536|vomiting
397809|NCT01095536|laparoscopic cholecystectomy
397810|NCT01095536|general anesthesia
397811|NCT01095523|Colon Cancer
397812|NCT01095523|Rectal Cancer
397813|NCT01095523|Peritoneal Perfusion
397814|NCT01095523|Metastatic Cancer
397815|NCT01095523|Recurrence
397816|NCT01095523|Colorectal Cancer
397817|NCT01095510|HAE
397818|NCT01095510|CINRYZE
397819|NCT01095510|C1 INH
397820|NCT01095510|C1 inhibitor
397821|NCT01095510|Pediatric
397822|NCT01095510|PK/PD
397823|NCT01095497|HAE
397824|NCT01095497|C1 inhibitor (C1INH)
397825|NCT01095497|Subcutaneous
397826|NCT01095484|Rotigotine
397827|NCT01095484|Neupro®
397828|NCT01095471|7 valent Pneumococcal conjugate vaccine
397829|NCT01095471|13 valent Pneumococcal conjugate vaccine
397830|NCT01095471|PCV13
397831|NCT01095471|PCV7
397832|NCT01095458|Obesity
397833|NCT01095458|Phone vs Clinical methods
397834|NCT01095445|hepatitis C
397835|NCT01095445|genotype 3
397836|NCT01095445|end of treatment response
397837|NCT01095445|relapse rate
397838|NCT01095445|rapid virologic response
397839|NCT01095445|complete early virologic response
397840|NCT01095432|Colonoscopy
397841|NCT01095432|Flexible Sigmoidoscopy
397842|NCT01095419|massage therapy
397843|NCT01095419|sleep quality
397844|NCT01095419|coronary artery bypass grafting surgery
397845|NCT01095419|Patients after Coronary Artery Bypass Graft Surgery
397846|NCT01095406|Weaning
397847|NCT01095406|closed loop
397848|NCT01095406|mechanical ventilation
397849|NCT01095406|children
397850|NCT01095393|Certolizumab Pegol
397851|NCT01095393|CZP
397852|NCT01095393|Cimzia®
397853|NCT01095393|NDB
397854|NCT01095393|registry
397855|NCT01095380|task-specific training
397856|NCT01095380|walking
397857|NCT01095380|locomotion
397858|NCT01095380|function
397859|NCT01095380|body weight support
397860|NCT01095380|Individuals with motor-incomplete spinal cord injury
397861|NCT01095367|Adhesion barrier sheets
397862|NCT01095367|ovarian cancer
397863|NCT01095367|Advanced stage epithelial ovarian cancer
397864|NCT01095354|pediatric
397865|NCT01095354|lung ventilation inhomogeneity
397866|NCT01095341|hyperthyroidism
397867|NCT01095341|tertiary hyperparathyroidism
397868|NCT01095341|palpation thyroiditis
397869|NCT01095341|parathyroidectomy
397870|NCT01095341|thyroglobulin
397871|NCT01095341|rate of postoperative hyperthyroidism
397872|NCT01095328|Q fever
397873|NCT01095328|Pregnancy
397874|NCT01095328|Screening
397875|NCT01095328|Cost-effectiveness
397876|NCT01095289|electromyography
397877|NCT01095289|laryngeal neoplasms
397878|NCT01095289|masticatory muscles
397879|NCT01095276|Mechanical Ventilation
397880|NCT01095276|Extubation
397881|NCT01095276|dornase alpha
397882|NCT01095276|oxygenation
397883|NCT01095276|chest x ray
397884|NCT01095250|Active uveitis
397885|NCT01095250|intermediate uveitis
397886|NCT01095250|panuveitis
397887|NCT01095250|posterior uveitis
397888|NCT01095250|uveitis
397889|NCT01095237|Peripheral Arterial Disease
397890|NCT01095237|Peripheral Vascular Disease
397891|NCT01095237|PAD
397892|NCT01095237|vascular prosthesis
397893|NCT01095237|revascularization
397894|NCT01095237|patency
397895|NCT01095237|blood vessel
397896|NCT01095237|Rutherford
397897|NCT01095237|ABI
397898|NCT01095237|Ankle Brachial Index
397899|NCT01095237|Vascular Graft
397900|NCT01095237|Carbothane
397901|NCT01095237|ProEndoTecc
397902|NCT01095237|implantation
397903|NCT01095224|HIV Preventive Vaccine
397904|NCT01095211|folic acid
397905|NCT01095211|homocysteine
397906|NCT01095211|MMSE scores
397907|NCT01095211|methyl malonic acid
397908|NCT01095211|betaine
397909|NCT01095198|vaginal self collection
397910|NCT01095198|human papillomavirus (hpv)
397911|NCT01095198|cervical intraepithelial neoplasia
397912|NCT01095172|Immunosuppression
397913|NCT01095172|Rituximab
397914|NCT01095172|B cell
397915|NCT01095159|TVTO
397916|NCT01095159|TVTSecur
397917|NCT01095159|Mini sling
397918|NCT01095159|stress urinary incontinence
397919|NCT01095146|MAS
397920|NCT01095146|Hemophagocytosis
397921|NCT01095146|Reactive HLH
397922|NCT01095146|Macrophage activation syndrome
397923|NCT01095146|Systemic onset juvenile idiopathic arthritis
397924|NCT01095146|SoJIA
397925|NCT01095146|JIA
397926|NCT01095133|Gastroesophageal reflux disease
397927|NCT01095133|Heartburn
398045|NCT01094626|Synthetic human secretin
398046|NCT01094613|Crohn's Disease
397928|NCT01095107|Determining whether adjustments in the amounts of fat grams within the current inpatient protocol meal plans will lead to a change in the hospital stay duration
397929|NCT01095107|Alter their recovery by affecting vital signs
397930|NCT01095107|Rate of weight change or need for supplemental feeds/medications
397931|NCT01095107|Effect gastrointestinal symptoms (bloating, gastroesophageal reflux, constipation, diarrhea, abdominal pain
397932|NCT01095107|And/or effect their perceived body image or cause any changes in their mood.
397933|NCT01095094|adult brain tumor
397934|NCT01095094|adult anaplastic astrocytoma
397935|NCT01095094|adult anaplastic ependymoma
397936|NCT01095094|adult anaplastic oligodendroglioma
397937|NCT01095094|adult brain stem glioma
397938|NCT01095094|adult giant cell glioblastoma
397939|NCT01095094|adult glioblastoma
397940|NCT01095094|adult gliosarcoma
397941|NCT01095094|adult mixed glioma
397942|NCT01095094|recurrent adult brain tumor
397943|NCT01095042|HRV
397944|NCT01095042|emotion
397945|NCT01095042|cognition
397946|NCT01095042|stress
397947|NCT01095042|cortisol
397948|NCT01095042|Autonomic nervous system
397949|NCT01095029|Positron emission tomography (PET)
397950|NCT01095029|Idiopathic Faecal Incontinence
397951|NCT01095029|Bilateral Sacral Nerve Stimulation
397952|NCT01095029|Sacral Nerve Stimulation
397953|NCT01095029|Sacral Nervemodulation
397954|NCT01094990|crossover; double blinded; intrathecal chemotherapy; dexamethasone; ketamine;vomiting
397955|NCT01094977|Blood Loss and Transfusion
397956|NCT01094977|Craniosynostoses
397957|NCT01094977|Tranexamic Acid
397958|NCT01094977|Children
397959|NCT01094964|recurrent bladder cancer
397960|NCT01094964|stage 0 bladder cancer
397961|NCT01094964|stage I bladder cancer
397962|NCT01094964|adenocarcinoma of the bladder
397963|NCT01094964|squamous cell carcinoma of the bladder
397964|NCT01094951|Depression
397965|NCT01094938|Aortic aneurysm repair
397966|NCT01094925|Cesarean section
397967|NCT01094925|Gabapentin
397968|NCT01094912|Cancer pain
397969|NCT01094899|diabetes
397970|NCT01094899|osteopenia
397971|NCT01094899|neuropathy
397972|NCT01094899|foot
397973|NCT01094899|AGE
397974|NCT01094886|Total Hip Replacement
397975|NCT01094886|Total Knee Replacement
397976|NCT01094886|Hip Implant
397977|NCT01094886|Knee Implant
397978|NCT01094886|Joint Prosthesis
397979|NCT01094886|Orthopedic Surgery
397980|NCT01094886|Rivaroxaban
397981|NCT01094886|Xarelto
397982|NCT01094886|Blood Clot
397983|NCT01094873|Hepatitis C
397984|NCT01094873|HCV
397985|NCT01094873|Adenovirus
397986|NCT01094873|Vaccine
397987|NCT01094860|Relapsed/Refractory Lymphoid Malignancies
397988|NCT01094860|Chronic lymphocytic leukemia
397989|NCT01094860|CLL
397990|NCT01094860|Small lymphocytic lymphoma
397991|NCT01094860|SLL
397992|NCT01094860|B-prolymphocytic leukemia
397993|NCT01094860|Follicular lymphoma
397994|NCT01094860|Mantle cell lymphoma
397995|NCT01094860|Lymphoplasmacytoid lymphoma
397996|NCT01094860|Marginal zone lymphoma
397997|NCT01094860|T-cell prolymphocytic leukemia
397998|NCT01094860|large granular lymphocyte leukemia
397999|NCT01094860|mycosis fungoides
398000|NCT01094860|Sezary syndrome
398001|NCT01094860|peripheral T-cell lymphoma
398002|NCT01094860|Chemotherapy
398003|NCT01094860|Monoclonal antibody therapy
398004|NCT01094860|T-cell or B-cell acute lymphoblastic leukemia (ALL)
398005|NCT01094860|Continuous Infusion Nelarabine
398006|NCT01094860|Arranon
398007|NCT01094821|Healthy volunteers
398008|NCT01094821|ATI-7505
398009|NCT01094821|Scintigraphy
398010|NCT01094821|Gastrointestinal transit
398011|NCT01094808|pregabalin
398012|NCT01094808|motor
398013|NCT01094808|sensation
398014|NCT01094808|colon
398015|NCT01094808|pain
398016|NCT01094808|gas
398017|NCT01094782|Pain
398018|NCT01094782|Pain management
398019|NCT01094756|Obesity
398020|NCT01094717|psoriasis
398021|NCT01094717|excimer
398022|NCT01094717|acitretin
398023|NCT01094717|tazarotene
398024|NCT01094704|cystic fibrosis
398025|NCT01094704|mucociliary clearance
398026|NCT01094704|hypertonic saline
398027|NCT01094678|Peripheral Aterial Disease (PAD)
398028|NCT01094678|Peripheral Vascular Disease
398029|NCT01094678|Drug-Eluting Stent
398030|NCT01094678|Drug-Coated Stent
398031|NCT01094678|Vascular Diseases
398032|NCT01094678|Cardiovascular Diseases
398033|NCT01094652|Adolescent
398034|NCT01094652|Whole grain
398035|NCT01094652|Digestive health
398036|NCT01094652|Dietary fiber
398037|NCT01094652|Grain
398038|NCT01094652|Microbiota
398039|NCT01094652|Inflammation
398040|NCT01094652|Mucosal Immunity
398041|NCT01094626|Pancreatic adenocarcinoma
398042|NCT01094626|Intraductal papillary mucinous neoplasm
398043|NCT01094626|Imaging techniques
398044|NCT01094626|Pancreatic surgical resection
398047|NCT01094613|Delayed Release
398048|NCT01094613|Targeted Ileal Delivery
398049|NCT01094600|Pancreatic cancer
398050|NCT01094600|Pancreatic resection
398051|NCT01094600|Synthetic human secretin
398052|NCT01094600|Secretin-enhanced MRCP
398053|NCT01094600|Endoscopic pancreatic function test
398054|NCT01094600|Pancreatic exocrine insufficiency
398055|NCT01094561|Family history of pancreatic cancer
398056|NCT01094561|Pancreatic adenocarcinoma
398057|NCT01094561|Imaging techniques
398058|NCT01094561|Synthetic human secretin
398059|NCT01094561|Pancreatic abnormalities
398060|NCT01094561|Early detection and prevention
398061|NCT01094548|L-BLP25 liposome
398062|NCT01094548|Multiple myeloma
398063|NCT01094535|Pancreatic adenocarcinoma
398064|NCT01094535|Synthetic human secretin
398065|NCT01094535|Secretin-enhanced MRCP
398066|NCT01094535|Pancreatic insufficiency
398067|NCT01094535|Endoscopic Pancreatic Function Test (ePFT)
398068|NCT01094535|Endocrine pancreatic function test
398069|NCT01094535|Exocrine pancreatic function test
398070|NCT01094496|bladder cancer
398071|NCT01094496|immunotherapy
398072|NCT01094496|cystectomy
398073|NCT01094496|cancer vaccine
398074|NCT01094496|human chorionic gonadotropin
398075|NCT01094496|hCG
398076|NCT01094496|urogenital neoplasms
398077|NCT01094496|urinary bladder neoplasms
398078|NCT01094496|muscle invasive
398079|NCT01094496|non-metastatic
398080|NCT01094496|transitional cell (urothelial) bladder cancer
398081|NCT01094483|Thromboxane B2
398082|NCT01094470|gait
398083|NCT01094470|ambulation
398084|NCT01094470|kinematics
398085|NCT01094457|antiplatelet therapy
398086|NCT01094457|clopidogrel low responsiveness
398087|NCT01094457|acute coronary syndromes
398088|NCT01094457|percutaneous coronary intervention
398089|NCT01094457|cilostazol
398090|NCT01094444|Vitamin K3 lotion
398091|NCT01094444|Cetuximab induced folliculitis
398092|NCT01094431|Fever
398093|NCT01094431|Etiology
398094|NCT01094431|Children under five years of age
398095|NCT01094431|IMCI
398096|NCT01094418|polyneuropathy
398097|NCT01094418|Nerve conduction study
398098|NCT01094418|Impaired glucose tolerance test
398099|NCT01094418|Diabetes mellitus
398100|NCT01094405|NPC with persistent, recurrent or metastatic disease patients
398101|NCT01094392|ALL
398102|NCT01094392|PEG-asparaginase
398103|NCT01094392|prolonged treatment
398104|NCT01094392|Thrombosis
398105|NCT01094392|Central venous line
398106|NCT01094392|Echocardiography
398107|NCT01094379|cholecystectomy
398108|NCT01094379|laparoscopic
398109|NCT01094379|pain
398110|NCT01094379|single incision
398111|NCT01094366|Paracervical Block
398112|NCT01094366|pain control
398113|NCT01094366|abortion
398114|NCT01094353|Urodynamic Stress urinary incontinence
398115|NCT01094353|Minisling
398116|NCT01094353|Ophira™
398117|NCT01094353|Unitape™
398118|NCT01094327|focal segmental glomerulosclerosis
398119|NCT01093352|Alveolar-decortication
398120|NCT01093352|Corticotomy assisted orthodontics
398121|NCT01093352|Palatally impacted canine
398122|NCT01093352|Surgical exposure of canines
398123|NCT01093352|Velocity of tooth movement
398124|NCT01093339|GERD
398125|NCT01093339|SLEEP DEPRIVATION
398126|NCT01093339|APPETITE REGULATION
398127|NCT01093339|GHRELIN
398128|NCT01093339|LEPTIN
398129|NCT01093274|colonoscopy
398130|NCT01093274|Cathartics
398131|NCT01093274|Sodium picosulfate
398132|NCT01093274|Polyethylene Glycol
398133|NCT01093261|trauma
398134|NCT01093261|trauma brain injury
398135|NCT01093261|multiple trauma
398136|NCT01093261|head trauma
398137|NCT01093261|hydrocortisone
398138|NCT01093261|fludrocortisone
398139|NCT01093261|glucocorticoid insufficiency related to ICU
398140|NCT01093261|adrenal Insufficiency
398141|NCT01093261|pneumonia
398142|NCT01093261|intensive care unit
398143|NCT01093261|shock
398144|NCT01093261|neurological recovery
398145|NCT01093235|cardiac toxicity
398146|NCT01093235|perioperative/postoperative complications
398147|NCT01093235|HER2-negative breast cancer
398148|NCT01093235|male breast cancer
398149|NCT01093235|estrogen receptor-negative breast cancer
398150|NCT01093235|estrogen receptor-positive breast cancer
398151|NCT01093235|progesterone receptor-negative breast cancer
398152|NCT01093235|progesterone receptor-positive breast cancer
398153|NCT01093235|stage II breast cancer
398154|NCT01093235|stage IIIA breast cancer
398155|NCT01093235|stage IIIB breast cancer
398156|NCT01093235|inflammatory breast cancer
398157|NCT01093209|Carpal Tunnel Syndrome
398158|NCT01093209|Interferential laser therapy
398159|NCT01093209|Low-level laser therapy
398160|NCT01093209|Neuropathic pain
398161|NCT01093209|Median nerve compression
398162|NCT01093196|Multiple Myeloma
398163|NCT01093196|Elderly Patients
398164|NCT01093196|Diagnosis
398165|NCT01093196|Lenalidomide
398166|NCT01093196|Prednisone
398167|NCT01093196|Melphalan
398168|NCT01093196|Dexamethasone
398169|NCT01093196|Cyclophosphamide
398170|NCT01093157|Kidney disease, Glomerulonephritis
398171|NCT01093144|Delivery mode
398172|NCT01093144|pelvic measurement
398173|NCT01093131|Contrast induced nephropathy
398174|NCT01093131|Percutaneous transluminal coronary angioplasty
398175|NCT01093131|chronic kidney disease
398176|NCT01093131|Prevention
398177|NCT01093131|Equivalence
398178|NCT01093118|Distal subungual onychomycosis
398179|NCT01093105|Leukodystrophy, Globoid Cell
398180|NCT01093105|Classic Globoid Cell Leukodystrophy
398181|NCT01093105|Early-Onset Globoid Cell Leukodystrophy
398182|NCT01093105|Globoid Cell Leukodystrophy
398183|NCT01093105|Globoid Cell Leukoencephalopathy
398184|NCT01093105|Infantile Globoid Cell Leukodystrophy
398185|NCT01093105|Late-Onset Globoid Cell Leukodystrophy
398186|NCT01093105|Leukodystrophy, Globoid Cell, Classic
398187|NCT01093105|Leukodystrophy, Globoid Cell, Early-Onset
398188|NCT01093105|Leukodystrophy, Globoid Cell, Infantile
398189|NCT01093105|Leukodystrophy, Globoid Cell, Late-Onset
398190|NCT01093105|Psychosine
398191|NCT01093105|galactosylsphingosine (psychosine) beta-galactosidase
398192|NCT01093105|Psychosine-UDP galactosyltransferase
398193|NCT01093105|Krabbe Disease
398194|NCT01093105|Krabbe Leukodystrophy
398195|NCT01093105|Krabbe's Disease
398196|NCT01093105|Krabbe's Leukodystrophy
398197|NCT01093079|Renal tumor, RCC, Partial nephrectomy, Laparoscopy
398198|NCT01094301|electrical stimulation
398199|NCT01094301|neurostimulation
398200|NCT01094301|neuromodulation
398201|NCT01094301|shoulder pain
398202|NCT01094301|post-stroke shoulder pain
398203|NCT01094301|hemiplegic shoulder pain
398204|NCT01094275|drug resistance
398205|NCT01094275|gene polymorphism
398206|NCT01094262|Osteoarthritis pain of the knee
398207|NCT01094262|Osteoarthritis
398208|NCT01094262|Osteoarthritis, Knee
398209|NCT01094262|Pain
398210|NCT01094262|Arthralgia
398211|NCT01094262|Joint Pain
398212|NCT01094262|JNJ-42160443
398213|NCT01094249|Paliperidone ER
398214|NCT01094249|INVEGA
398215|NCT01094249|Divalproex sodium
398216|NCT01094249|Depakote ER
398217|NCT01094249|Valproic acid
398218|NCT01094249|Pharmacokinetics
398219|NCT01094249|R076477BIM1004
398220|NCT01094236|behavior management
398221|NCT01094236|academic performance
398222|NCT01094236|playground supervision
398223|NCT01094236|harm reduction
398224|NCT01094236|Behavioral Research
398225|NCT01094223|Stimulant
398226|NCT01094223|Addiction
398227|NCT01094223|Mindfulness
398228|NCT01094223|Treatment
398229|NCT01094210|Anti-erosion dental benefits
398230|NCT01094197|Transfusion-associated microchimerism
398231|NCT01094197|Injuries
398232|NCT01094197|Leukocytes
398233|NCT01094171|poliomyelitis
398234|NCT01094171|diphtheria
398235|NCT01094171|Primary immunization
398236|NCT01094171|pertussis
398237|NCT01094171|Children
398238|NCT01094171|tetanus
398239|NCT01094158|NAFLD
398240|NCT01094158|NASH
398241|NCT01094158|Fatty Liver
398242|NCT01094158|Metabolic Syndrome
398243|NCT01094158|Endothelial Dysfunction
398244|NCT01094158|Insulin Resistance
398245|NCT01094158|Liver Fat
398246|NCT01094145|(light to moderate)
398247|NCT01094132|cervical cancer
398248|NCT01094132|cervical intraepithelial neoplasia grade 1
398249|NCT01094132|cervical intraepithelial neoplasia grade 2
398250|NCT01094132|cervical intraepithelial neoplasia grade 3
398251|NCT01094132|Nonmalignant Condition
398252|NCT01094119|heated blanket
398253|NCT01094119|heated pad
398254|NCT01094106|postoperative pain
398255|NCT01094106|infiltration analgesia
398256|NCT01094106|ropivacaine
398257|NCT01094106|Caesarean Section
398258|NCT01094093|Amgen
398259|NCT01094093|AMG 139
398260|NCT01094080|fully formula fed
398261|NCT01094080|fully breast fed
398262|NCT01094041|Gluten
398263|NCT01094041|Diarrhea or diarrhea predominant irritable bowel syndrome
398264|NCT01094041|Colonic permeability
398265|NCT01094041|Small bowel permeability
398266|NCT01094041|Colonic inflammatory response
398267|NCT01094041|Small bowel inflammatory response
398268|NCT01094028|Blood loss in the third and fourth stage of labor and the duration of third stage of labor
398269|NCT01094015|hysteroscopy
398270|NCT01094015|local anaesthetic
398271|NCT01094015|pain relief
398272|NCT01094015|gynecological pathology
398273|NCT01094002|OCCUPATIONAL THERAPY
398274|NCT01094002|RANDOMISED CLINICAL TRIAL
398275|NCT01094002|AGED
398276|NCT01094002|PATIENT CARE
398277|NCT01093976|Skin Picking
398278|NCT01093976|OCD
398279|NCT01093976|Trichotillomania
398280|NCT01093976|Pathological Skin Picking
398281|NCT01093950|anthropometric
398282|NCT01093950|white light scanner
398283|NCT01093950|extraction profiles
398284|NCT01093950|Body lipodystrophy
398285|NCT01093937|Bipolar disorder
398286|NCT01093937|Bipolar-I
398287|NCT01093937|Varenicline
398288|NCT01093937|Champix
398289|NCT01093937|Chantix
398290|NCT01093937|Nicotine
398291|NCT01093937|Nicotinic receptor
398292|NCT01093937|Nicotinic receptor dysregulation
398293|NCT01093937|Dopamine
398294|NCT01093937|Acetylcholine
398295|NCT01093937|Cigarette
398296|NCT01093937|Smoking
398297|NCT01093937|Tobacco
398298|NCT01093937|Dependence
398299|NCT01093937|Neuropsychological function
398300|NCT01093924|Behavioral weight loss maintenance intervention
398301|NCT01093924|Weight loss
398302|NCT01093924|Weight loss maintenance
398303|NCT01093911|Lupus
398304|NCT01093911|SLE
398305|NCT01093859|acetylcholinesterase
398306|NCT01093846|uveitis
398307|NCT01093833|Diabetes
398308|NCT01093833|Type 1 diabetes
398309|NCT01093833|Type 2 diabetes
398310|NCT01093833|Diabetes mellitus
398311|NCT01093833|Blood glucose
398312|NCT01093833|Continuous blood glucose monitoring
398313|NCT01093833|CGM
398314|NCT01093820|acute myocardial infarction
398315|NCT01093820|continuous erythropoetin receptor activator
398316|NCT01093820|Mircera
398317|NCT01093820|hemoglobin kinetics
398318|NCT01093807|Hypertension
398319|NCT01093807|Lercanidipine
398320|NCT01093807|Calcium antagonist
398321|NCT01093807|Enalapril
398322|NCT01093794|Type 2 Diabetes
398323|NCT01093781|membranous nephropathy aliskiren proteinuria, glomerulonephritis
398324|NCT01093768|Oxytocin
398325|NCT01093768|Vasopressin
398326|NCT01093768|Autism
398327|NCT01093768|Amygdala
398328|NCT01093768|Social Cognition
398329|NCT01093768|Autism Spectrum Disorders
398330|NCT01093768|ASD
398331|NCT01093768|Healthy Volunteer
398332|NCT01093768|HV
398333|NCT01093755|Barrett's Esophagus
398334|NCT01093755|Radiofrequency ablation
398335|NCT01093755|Patients post-radiofrequency ablation for Barrett's Esophagus.
398336|NCT01093742|Healthy
398337|NCT01093729|Exendin-4
398338|NCT01093716|Alcohol dependence
398339|NCT01093716|Craving
398340|NCT01093716|rTMS
398341|NCT01093716|Dorsolateral prefrontal cortex
398342|NCT01093703|kidney transplantation
398343|NCT01093703|hypertension
398344|NCT01093703|chronotherapy
398345|NCT01093703|graft function
398346|NCT01093703|circadian pattern
398347|NCT01093690|chemotherapy induced nausea and vomiting, metoclopramide
398348|NCT01093612|HER2-positive breast cancer
398349|NCT01093599|Smoking
398350|NCT01093599|Smoking cessation
398351|NCT01093599|Nicotine
398352|NCT01093599|Tobacco
398353|NCT01093599|Mindfulness
398354|NCT01093599|Meditation
398355|NCT01093599|MBSR
398356|NCT01093599|Mindfulness Training
398357|NCT01093599|Behavioral Intervention
398358|NCT01093599|Nicotine Patch
398359|NCT01093599|Quit Line
398360|NCT01093599|Phone counseling
398361|NCT01093573|Untreated myelodysplastic syndromes
398362|NCT01093560|metabolic syndrome
398363|NCT01093560|premenopausal women
398364|NCT01093560|fat feeding
398365|NCT01093534|Overactive Bladder
398366|NCT01093534|Detrusor Overactivity
398367|NCT01093534|Bladder wall thickness
398368|NCT01093534|Urinary Nerve Growth Factor
398369|NCT01093534|Solifenacin
398370|NCT01093534|Vesicare
398371|NCT01093521|IV Gallium
398372|NCT01093521|Gallium
398373|NCT01093521|Ganite
398374|NCT01093521|Cystic Fibrosis
398375|NCT01093521|Gallium Infusion
398376|NCT01093495|Nasal Continuous positive Airway pressure
398377|NCT01093495|Nasal Cannula
398378|NCT01093495|CPAP
398379|NCT01093495|Premature
398380|NCT01093495|RDS
398381|NCT01093495|HMD
398382|NCT01093495|NICU
398383|NCT01093482|mechanical ventilation
398384|NCT01093482|epidemiology
398385|NCT01093482|outcomes
398386|NCT01093482|mortality
398387|NCT01093482|weaning
398388|NCT01093482|sedation
398389|NCT01093482|non-invasive positive pressure ventilation
398390|NCT01093469|Atopic Dermatitis
398391|NCT01093469|Wake Forest
398392|NCT01093469|Dermatology
398393|NCT01093469|Skin
398394|NCT01093469|Over-the-counter
398395|NCT01093469|Moisturizer
398396|NCT01093469|Children
398397|NCT01093456|diurnal variation
398398|NCT01093456|peritoneal dialysis
398399|NCT01093456|uremic retention solutes
398400|NCT01093456|phosphorous
398401|NCT01093456|indoxyl sulfate
398402|NCT01093456|p-cresol sulfate
398403|NCT01093443|IVF
398404|NCT01093443|ICSI
398405|NCT01093443|GnRH antagonist
398406|NCT01093443|pretreatment
398407|NCT01093430|Gynecological surgery
398408|NCT01093430|laparoscopic ports
398409|NCT01093430|neuropathy
398410|NCT01093417|Vitamin D
398411|NCT01093417|Human Immunodeficiency Virus (HIV)
398412|NCT01093417|Complementary Therapies
398413|NCT01093404|Heart disease
398414|NCT01093404|Myocardial infarction
398415|NCT01093404|Angioplasty
398416|NCT01093404|Thrombus aspiration
398417|NCT01093391|coronary artery
398418|NCT01093391|thrombosis
398419|NCT01093391|stent
398420|NCT01093378|Infertility
398421|NCT01093378|Obesity
398422|NCT01093378|Dietary intake
398423|NCT01093378|Fertility
398424|NCT01093378|nutrition
398425|NCT01093378|diet
398426|NCT01093378|weight
398427|NCT01093365|Schizophrenia
398428|NCT01093365|Schizoaffective Disorder
398429|NCT01093365|Varenicline
398430|NCT01093365|Champix
398431|NCT01093365|Chantix
398432|NCT01093365|Nicotine
398433|NCT01093365|Nicotinic receptor
398434|NCT01093365|Dopamine
398435|NCT01093365|Acetylcholine
398436|NCT01093365|Cigarette
398437|NCT01093365|Smoking
398438|NCT01093365|Tobacco
398439|NCT01093365|Executive function
398440|NCT01093365|Working memory
398441|NCT01093365|Verbal memory
398442|NCT01093365|Cognitive function
398443|NCT01093365|Neuropsychological function
398444|NCT01093066|urothelial carcinoma
398445|NCT01093066|TURB
398446|NCT01093066|chemotherapy
398447|NCT01093053|Mind-Body Therapies
398448|NCT01093027|Essential Tremor
398449|NCT01093027|Cooling
398450|NCT01093027|Temperature
398451|NCT01093027|Patients with Essential Tremor involving the upper limbs with at least moderate tremor.
398452|NCT01093014|Quadriceps Muscle
398453|NCT01093014|RNA, Messenger
398454|NCT01093014|Hypertrophy
398455|NCT01093014|Electric Stimulation Therapy
398456|NCT01093001|Reduce Tricuspid Regurgitation
398457|NCT01093001|Reduce Right Ventricular pacing
398458|NCT01093001|Lead position
398459|NCT01093001|Lead size
398460|NCT01092988|Uterine Fibroids
398461|NCT01092988|Bleeding
398462|NCT01092988|Pain
398463|NCT01092988|Quality of life
398464|NCT01092988|MR guided focused ultrasound
398465|NCT01092975|radiotherapy
398466|NCT01092962|Children
398467|NCT01092962|Mycophenolate mofetil
398468|NCT01092962|Cyclophosphamide
398469|NCT01092962|Idiopathic nephrotic steroid sensitive syndrome
398470|NCT01092949|Placenta
398471|NCT01092949|perfusion
398472|NCT01092949|MRI
398473|NCT01092949|spin tagging
398474|NCT01092949|Gadolinium
398475|NCT01092949|placental insufficiency
398476|NCT01092949|urinary tract, sexual organs and pregnancy conditions
398477|NCT01092936|Comparative fit index
398478|NCT01092936|Movement Disorders' Society
398479|NCT01092936|Unified Parkinson's Disease Rating Scale
398480|NCT01092923|Nitrous Oxide
398481|NCT01092923|washin
398482|NCT01092923|washout
398483|NCT01092923|second gas effect
398484|NCT01092923|sevoflurane
398485|NCT01092923|induction
398486|NCT01092923|emergence
398487|NCT01092910|Sensorineural
398488|NCT01092910|Hearing Loss
398489|NCT01092884|melasma
398490|NCT01092884|sunscreen
398491|NCT01092884|polypodium leucotomos
398492|NCT01092858|Testosterone undecanoate
398493|NCT01092858|Hypogonadism
398494|NCT01092845|Double-Blind
398495|NCT01092845|Randomized
398496|NCT01092845|Placebo-Controlled
398497|NCT01092845|2-Way Crossover
398498|NCT01092845|Polysomnographic Endpoints
398499|NCT01092832|Invasive Candidiasis Candidemia Esophageal Candidiasis
398500|NCT01092819|acute ischemic stroke, large vessel occlusion, natural history, functional outcome
398501|NCT01092806|tacrolimus
398502|NCT01092806|pharmacokinetics
398503|NCT01092806|formulations
398504|NCT01092806|once daily
398505|NCT01092806|twice daily
398506|NCT01092806|renal transplant recipients
398507|NCT01092806|Kidney transplantation
398508|NCT01092793|Fish oil
398509|NCT01092793|Krill
398510|NCT01092793|CAD
398511|NCT01092767|Thoracic Aneurysm
398512|NCT01092767|Thoracic Transection
398513|NCT01092767|Endovascular Aortic Repair
398514|NCT01092754|brain, spine, liver, MRI, Pediatric
398515|NCT01092741|Leukemia
398516|NCT01092741|Gleevec
398517|NCT01092741|STI571
398518|NCT01092741|CML
398519|NCT01092741|Chronic Myelogenous Leukemia
398520|NCT01092728|Acral lentiginous melanoma
398521|NCT01092728|Mucosal melanoma
398522|NCT01092728|Chronic sun-damaged melanoma
398523|NCT01092728|Surgically removed tumor
398524|NCT01092728|biopsied
398525|NCT01092728|Sprycel
398526|NCT01092728|Dasatinib
398527|NCT01092715|Neck pain
398528|NCT01092715|Spinal manipulation
398529|NCT01092715|Massage
398530|NCT01092702|Tobacco Dependence
398531|NCT01092702|Smoking
398532|NCT01092702|Tobacco Cessation
398533|NCT01092689|heterocyclic amines
398534|NCT01092689|PhIP
398535|NCT01092689|Meat
398536|NCT01092689|pancreas neoplasms
398537|NCT01092676|Pediatrics
398538|NCT01092676|Emergency
398539|NCT01092663|Colesevelam
398540|NCT01092663|type 2 diabetes
398541|NCT01092663|sitagliptin
398542|NCT01092663|glucose metabolism
398543|NCT01092650|Tobacco toxicants
398544|NCT01092650|Polycyclic aromatic hydrocarbons
398545|NCT01092650|Smoking
398546|NCT01092624|voiding dysfunction
398547|NCT01092624|defecatory dysfunction
398548|NCT01092624|vaginal bulge symptoms
398549|NCT01092611|HIV-infected subjects
398550|NCT01092611|long-term follow-up study
398551|NCT01092611|HIV therapeutic vaccine
398552|NCT01092572|cystic fibrosis
398553|NCT01092572|adult cystic fibrosis
398554|NCT01092559|Diagnostic Techniques and Procedures
398555|NCT01092546|Amyloid
398556|NCT01092546|Normal pressure hydrocephalus (NPH)
398557|NCT01092546|Positron Emission Tomography (PET)
398558|NCT01092546|Standard uptake value ratios (SUVR)
398559|NCT01092520|Gabapentin
398560|NCT01092520|Burn Injuries in Children
398561|NCT01092520|pruritus
398562|NCT01092507|Encephalitis
398563|NCT01092507|Japanese Encephalitis
398564|NCT01092507|Japanese Encephalitis Vaccines
398565|NCT01092507|Infant
398566|NCT01092494|Endometrioma recurrence
398567|NCT01092494|oral contraceptives
398568|NCT01092494|gonadotropin-releasing hormone agonist
398569|NCT01092481|Adjuvant FOLFOX or CAPOX Therapy
398570|NCT01092481|Stage II/III Colon Cancer
398571|NCT01092481|Adjuvant Therapy
398572|NCT01092468|cancer
398573|NCT01092468|reconstruction
398574|NCT01092468|free flap
398575|NCT01092468|surgery
398576|NCT01092455|End Stage Renal Disease
398577|NCT01092455|Renal Dialysis
398578|NCT01092455|Hemodialysis therapy
398579|NCT01092455|Heparin
398580|NCT01092455|Citrasate
398581|NCT01092455|Anticoagulant
398582|NCT01092442|Pulmonary Valve
398583|NCT01092442|Right Ventricular Outflow Tract Reconstruction
398584|NCT01092442|Ross Procedure
398585|NCT01092429|CAD
398586|NCT01092416|CAD
398587|NCT01092416|Severely calcified lesion
398588|NCT01092390|randomized trial
398589|NCT01092390|omega three fatty acids
398590|NCT01092364|Young adults
398591|NCT01092351|urinary tract infection
398592|NCT01092351|nitrofurantoin
398593|NCT01092338|Human Immunodeficiency Virus
398594|NCT01092338|Acquired Immune Deficiency Syndrome
398595|NCT01092338|Vitamin D
398596|NCT01092338|HIV
398597|NCT01092338|Complementary therapies
398598|NCT01092325|Heart Failure
398599|NCT01092312|knee
398600|NCT01092312|arthroplasty
398601|NCT01092299|Phase I
398602|NCT01092299|Relative bioavailability
398603|NCT01092299|Pharmacokinetic study
398604|NCT01092299|AZD1446
398605|NCT01092299|healthy volunteers
398606|NCT01092286|Knee injury
398607|NCT01092286|ankle sprain
398608|NCT01092286|anterior cruciate ligament
398609|NCT01092286|adolescent
398610|NCT01092286|soccer
398611|NCT01092286|basketball
398612|NCT01092286|prevention
398613|NCT01092273|Glaucoma and Ocular Hypertension
398614|NCT01092260|Glomerular Filtration Rate
398615|NCT01092260|Kidney disease
398616|NCT01092260|Child
398617|NCT01092260|Iohexol
398618|NCT01092260|Cystatin C
398619|NCT01092260|Measurement of kidney function in children
398620|NCT01092247|Patients with malignant tumors
398621|NCT01092234|Observational units
398622|NCT01092234|Length of stay (LOS)
398623|NCT01092234|Readmission
398624|NCT01092221|mania, allopurinol, add-on treatment
398625|NCT01092208|Autism
398626|NCT01092208|iPS Cells
398627|NCT01092208|Fibroblasts
398628|NCT01092208|Gene Networks
398629|NCT01092208|Tuberous Sclerosis
398630|NCT01092208|Healthy Volunteer
398631|NCT01092208|HV
398632|NCT01092195|Women's Health
398633|NCT01092195|Genital Precancer
398634|NCT01092195|Stem Cell Donor
398635|NCT01092195|Cervical Cytology
398636|NCT01092195|Healthy Volunteers
398637|NCT01092195|Stem Cell Transplant
398638|NCT01092195|Healthy Volunteer
398639|NCT01092195|HV
398640|NCT01092182|Microarray
398641|NCT01092182|Toxicity
398642|NCT01092182|Therapeutic Index
398643|NCT01092182|HIV Positive
398644|NCT01092182|HIV Negative
398645|NCT01092182|Lymphoma
398646|NCT01092182|Burkitt Lymphoma
398647|NCT01092182|Diffuse Large B-Cell Lymphoma
398648|NCT01092182|HIV Infections
398649|NCT01092156|Nipple pain during lactation
398650|NCT01092130|Heart failure
398651|NCT01092130|Vitamin D
398652|NCT01092130|Plasma renin activity
398653|NCT01092130|Renin angiotensin system
398654|NCT01092117|abdominal
398655|NCT01092117|aortic
398656|NCT01092117|aneurysm
398657|NCT01092091|Neoplasm
398658|NCT01092091|Hepatocellular Carcinoma
398659|NCT01092078|hypertension
398660|NCT01092078|colon cancer screening
398661|NCT01092078|african american
398662|NCT01092078|men
398663|NCT01092078|motivational interviewing
398664|NCT01092078|patient navigation
398665|NCT01092065|Parkinson's Disease
398666|NCT01092065|Dyskinesia
398667|NCT01092065|Drug-induced
398668|NCT01092065|Levodopa
398669|NCT01092065|L-dopa
398670|NCT01092052|Phase I study
398671|NCT01092052|Advanced/Metastatic Solid Tumors
398672|NCT01092052|Cdc7 kinase inhibitor
398673|NCT01092039|Common Cold
398674|NCT01092039|Cold Virus
398675|NCT01092039|Feeling sick
398676|NCT01092039|Influenza
398677|NCT01092000|Health Promotion, Dietary Guidelines, Physical Activity Guidelines
398678|NCT01091987|Insomnia
398679|NCT01091974|Insomnia
398680|NCT01091974|Fatigue
398681|NCT01091974|QOL
398682|NCT01091974|CBT
398683|NCT01091974|Breast cancer
398684|NCT01091974|Survivors
398685|NCT01091974|Chemotherapy
398686|NCT01091961|ACE inhibitor
398687|NCT01091961|ARB
398688|NCT01091961|Non-cardiac surgery
398689|NCT01091961|Perioperative
398690|NCT01091961|Preoperative
398691|NCT01091961|Hypotension
398692|NCT01091961|Congestive heart failure
398693|NCT01091961|Hypertension
398694|NCT01091961|Angiotensin-Converting Enzyme Inhibitors
398695|NCT01091961|Angiotensin II Type 1 Receptor Blockers
398696|NCT01091961|Perioperative Care
398697|NCT01091948|elective general surgery
398698|NCT01091948|orotracheal intubation
398699|NCT01091948|Patients would be eligible for inclusion if they were at least 18 years old and scheduled for elective surgery requiring orotracheal intubation.
398700|NCT01091935|Lidocaine,Intravenous Infusions,Neuropathic Pain,Side Effects
398701|NCT01091922|flavonoids
398702|NCT01091922|flavanols
398703|NCT01091922|bacteria
398704|NCT01091909|type 2 diabetes
398705|NCT01091909|wound healing
398706|NCT01091909|neutrophil count
398707|NCT01091909|dental extraction
398708|NCT01091896|bevacizumab
398709|NCT01091896|vitreous hemorrhage
398710|NCT01091896|diabetes mellitus
398711|NCT01091883|Bone cancer
398712|NCT01091883|Bone Metastases
398713|NCT01091883|pain palliation
398714|NCT01091883|metastasis
398715|NCT01091883|breast cancer
398716|NCT01091883|lung cancer
398717|NCT01091883|prostate cancer
398718|NCT01091883|cancer related pain
398719|NCT01091883|tumors
398720|NCT01091870|Aneurysm
398721|NCT01091870|Vasospasm
398722|NCT01091870|sildenafil
398723|NCT01091870|Viagra
398724|NCT01091857|Exercise
398725|NCT01091857|Transdisciplinary
398726|NCT01091857|Physiology
398727|NCT01091857|Mood
398728|NCT01091857|Motivation
398729|NCT01091844|voiding trial, urinary retention, catheterization
398730|NCT01091844|Urinary retention after gynecologic surgery
398731|NCT01091831|Multiple Myeloma
398732|NCT01091831|Lenalidomide
398733|NCT01091831|High dose melphalan
398734|NCT01091831|Mobilization
398735|NCT01091831|CD 34
398736|NCT01091831|Newly Diagnosed patients
398737|NCT01091818|To see if sedation with dexmedetomidine results in faster emergence after end of intensive care treatment in children
398738|NCT01091818|treatment
398739|NCT01091792|GBM
398740|NCT01091792|Grade IV
398741|NCT01091792|glioma
398742|NCT01091779|Male patients scheduled to have spinal anaesthesia for TURP
398743|NCT01091766|local anaesthetics toxicity
398744|NCT01091766|heart arrhythmia
398745|NCT01091766|heart rate
398746|NCT01091766|heart conduction
398747|NCT01091766|regional anaesthesia
398748|NCT01091766|paediatric anaesthesia
398749|NCT01091766|cardio-vascular system
398750|NCT01091766|prevention
398751|NCT01091753|Non-dipper HTN patient
398752|NCT01091740|Drug eluting stent
398753|NCT01091740|Tomography, optical coherence
398754|NCT01091727|Neurogenic
398755|NCT01091727|Detrusor
398756|NCT01091727|Overactive
398757|NCT01091727|Overactivity
398758|NCT01091727|Bladder
398759|NCT01091727|Spinal
398760|NCT01091727|Cord
398761|NCT01091727|Injury
398762|NCT01091701|Ischemic Cerebral Stroke
398763|NCT01091688|neonatal
398764|NCT01091688|discharge planning
398765|NCT01091688|health transition
398766|NCT01091688|educational needs assessment
398767|NCT01091688|Intensive care, neonatal
398768|NCT01091675|ankylosing spondylitis
398769|NCT01091675|biologic therapies
398770|NCT01091675|ASAS
398771|NCT01091675|ASASBIO
398772|NCT01091675|etoricoxib
398773|NCT01091675|NSAIDs
398774|NCT01091675|COX-2 Inhibitor
398775|NCT01091675|ARCOXIA 90 mg
398776|NCT01091675|BASDAI Bath Ankylosing Spondylitis Disease Activity Index
398777|NCT01091662|Seizures
398778|NCT01091662|Epilepsy
398779|NCT01091662|Anticonvulsant
398780|NCT01091662|Monotherapy
398781|NCT01091662|Historical control
398782|NCT01091649|Pharmacokinetics, Safety
398783|NCT01091623|improvement of exercise capacity in patients with COPD
398784|NCT01091610|retrospective study
398785|NCT01091610|wounds and injuries/epidemiology
398786|NCT01091610|emergency medical technicians
398787|NCT01091610|human
398788|NCT01091610|emergency medical services
398789|NCT01091610|ambulance
398790|NCT01091610|health personnel
398791|NCT01091610|emergency medicine
398792|NCT01091610|risk factors
398793|NCT01091571|Adenosine
398794|NCT01091571|Endotoxin
398795|NCT01091571|Innate Immunity
398796|NCT01091571|Dipyridamole
398797|NCT01091558|ulcerative colitis
398798|NCT01091558|colon cancer
398799|NCT01091558|endoscopy
398800|NCT01091558|screening
398801|NCT01091545|breast cancer
398802|NCT01091545|screening
398803|NCT01091545|sensitivity
398804|NCT01091545|tomosynthesis
398805|NCT01091519|Non-interventional study fesoterodine educational materials
398806|NCT01091506|L-methylfolate
398807|NCT01091506|Deplin
398808|NCT01091506|schizophrenia
398809|NCT01091506|folate
398810|NCT01091506|folic acid
398811|NCT01091506|homocysteine
398812|NCT01091506|methionine
398813|NCT01091506|MTHFR genotype
398814|NCT01091506|C677T mutation
398815|NCT01091506|vitamin B6
398816|NCT01091506|vitamin B12
398817|NCT01091506|psychotic symptoms
398818|NCT01091506|MTHFR C677T Polymorphism
398819|NCT01091493|COPD
398820|NCT01091480|Hypertrophic cardiomyopathy
398821|NCT01091480|Observatory
398822|NCT01091480|LVH
398823|NCT01091467|Heart Failure
398824|NCT01091467|Ejection Fraction
398825|NCT01091467|Echocardiography
398826|NCT01091454|stage IV breast cancer
398827|NCT01091454|triple-negative breast cancer
398828|NCT01091454|male breast cancer
398829|NCT01091441|therapeutic education
398830|NCT01091428|RECIST: Response Evaluation Criteria in Solid Tumors
398831|NCT01091428|OC: Ovarian Cancer
398832|NCT01091428|GCIG: Gynecologic Cancer Intergroup
398833|NCT01091428|Breast carcinoma (Phase 1)
398834|NCT01091402|autologous serum skin test, IL-18
398835|NCT01091389|Atrial Fibrillation
398836|NCT01091389|Totally Thoracoscopic PV isolation
398837|NCT01091376|Non-small cell lung cancer
398838|NCT01091376|EGFR-TKI
398839|NCT01091376|Erlotinib
398840|NCT01091376|Radiotherapy
398841|NCT01091363|smoking cessation
398842|NCT01091363|tobacco dependence treatment
398843|NCT01091363|cultural adaptation
398844|NCT01091363|Asian Americans
398845|NCT01091324|CKD, proteinuria, dextromethorphan, silymarin
398846|NCT01091324|patients with 15 ml<eGFR< 60ml and 0.5 g/day<proteinuria<3g/day
398847|NCT01091311|Meibomian Gland Dysfunction
398848|NCT01091298|Safety of vaccine
398849|NCT01091272|healthy volunteer
398850|NCT01091272|safety
398851|NCT01091272|pharmacokinetic
398852|NCT01091259|antibody therapy
398853|NCT01091259|chemotherapy
398854|NCT01091259|biologic therapy
398855|NCT01091259|combination therapy
398856|NCT01091233|Critically ill patients
398857|NCT01091233|liver cirrhosis
398858|NCT01091233|ascites requiring Paracentesis
398859|NCT01091220|certolizumab pegol
398860|NCT01091220|Cimzia®
398861|NCT01091220|healthy male volunteers
398862|NCT01091220|sperm
398863|NCT01091207|Sorafenib
398864|NCT01091207|GIST
398865|NCT01091207|Refractory
398866|NCT01091207|advanced GIST failed after both imatinib and sunitinib
398867|NCT01091194|Heart Transplantation
398868|NCT01091194|Aerobic Exercise
398869|NCT01091194|Exercise, Physical
398870|NCT01091194|Exercise Test
398871|NCT01091194|Treadmill Test
398872|NCT01091194|VO2 peak
398873|NCT01091194|Muscle Strength
398874|NCT01091194|Quality of Life
398875|NCT01091194|Reinnervation
398876|NCT01091194|Heart Rate
398877|NCT01091194|Myocardial Function
398878|NCT01091181|Caesarean
398879|NCT01091155|Colon Anastomosis
398880|NCT01091155|Rectum Anastomosis
398881|NCT01091155|Intestine
398882|NCT01091155|Colorectal Surgery
398883|NCT01091155|Colorectal Anastomosis
398884|NCT01091129|hyperhidrosis
398885|NCT01091116|Injections, Intra-Articular
398886|NCT01091090|Smoking cessation
398887|NCT01091090|Nicotine dependence
398888|NCT01091090|Chronic pain
398889|NCT01091077|dietary supplement
398890|NCT01091051|Ustekinumab, Palmo-Plantar, Pustular Psoriasis, Pustulosis
398891|NCT01091038|Adverse drug events
398892|NCT01091038|medical errors
398893|NCT01091038|computerized physician order entry
398894|NCT01091038|clinical decision support
398895|NCT01091025|Adults
398896|NCT01091025|Cystic Fibrosis Related Diabetes
398897|NCT01091025|Screening
398898|NCT01091025|Oral glucose tolerance test
398899|NCT01091025|Royal Brompton & Harefield Foundation Trust
398900|NCT01090999|COPD
398901|NCT01090999|Pulmonary Rehabilitation
398902|NCT01090986|Restrictive pulmonary disease with hypercapnic chronic respiratory failure.
398903|NCT01090986|COPD patients who need NIV hypercapnic chronic respiratory failure.
398904|NCT01090973|relapsed
398905|NCT01090973|refractory
398906|NCT01090973|CLL
398907|NCT01090973|chronic lymphocytic leukemia
398908|NCT01090973|MCL
398909|NCT01090973|mantle cell lymphoma
398910|NCT01090934|Diagnosis
398911|NCT01090934|Partial Epilepsy
398912|NCT01090921|Multiple Myeloma
398913|NCT01090921|Bortezomib
398914|NCT01090921|Newly diagnosed
398915|NCT01090921|Newly diagnosed Multiple Myeloma
398916|NCT01090895|Percutaneous Coronary Intervention
398917|NCT01090895|Vitamin C
398918|NCT01090895|Biomarkers
398919|NCT01090895|Magnetic Risonance
398920|NCT01090882|Local anaesthetic
398921|NCT01090882|Laparoscopic cholecystectomy
398922|NCT01090882|Pain scores
398923|NCT01090882|Bupivocaine
398924|NCT01090882|Day case surgery
398925|NCT01090856|Bifurcations
398926|NCT01090856|Drug eluting-stents
398927|NCT01090856|Provisional stenting
398928|NCT01090843|Obscure digestive bleeding (ODB)
398929|NCT01090843|Chronic anaemia of unknown origin
398930|NCT01090843|Chronic diarrhoea
398931|NCT01090830|Non small cell lung cancer
398932|NCT01090830|Belinostat
398933|NCT01090830|carboplatin
398934|NCT01090830|Paclitaxel
398935|NCT01090830|Bevacizumab
398936|NCT01090830|chemotherapy
398937|NCT01090830|Maximum Tolerated Dose
398938|NCT01090830|Neoplasms, Pulmonary
398939|NCT01090830|Lung Cancer
398940|NCT01090830|Event Free Survival
398941|NCT01090830|Disease free survival
398942|NCT01090830|Progression Free Survival
398943|NCT01090830|Histone Deacetylase Inhibitors
398944|NCT01090830|Treatment Efficacy
398945|NCT01090817|mesenchymal stromal cells
398946|NCT01090817|ileitis
398947|NCT01090817|colitis
398948|NCT01090804|BreatheMAX breathing device
398949|NCT01090804|Secretion clearance
398950|NCT01090804|Ventilatory dependence
398951|NCT01090804|Intubated patients
398952|NCT01090791|critically ill patient
398953|NCT01090778|growth hormone deficiency
398954|NCT01090778|circadian variation
398955|NCT01090765|Prostate
398956|NCT01090765|Tumor
398957|NCT01090765|Cancer
398958|NCT01090765|Hormone
398959|NCT01090765|Androgen
398960|NCT01090765|Prostate Cancer
398961|NCT01090752|diabetes
398962|NCT01090752|blood pressure
398963|NCT01090752|pioglitazone
398964|NCT01090752|sodium
398965|NCT01090752|insulin resistance, renal function, sodium, pioglitazone
398966|NCT01090739|Fecal incontinence
398967|NCT01090739|Accidental bowel leakage
398968|NCT01090739|Failure conservative therapy
398969|NCT01090739|Women
398970|NCT01090739|Class III medical device
398971|NCT01090739|Surgical mesh
398972|NCT01090700|TMC435-TiDP16-C112
398973|NCT01090700|TMC435-C112
398974|NCT01090700|TMC435
398975|NCT01090700|HCV
398976|NCT01090700|Hepatitis C
398977|NCT01090687|breast cancer, CT scans, mammography
398978|NCT01090674|Diaphragmatic force
398979|NCT01090674|mobility
398980|NCT01090661|antisense
398981|NCT01090661|ApoB (Apolipoprotein B)
398982|NCT01090661|LDL (low density lipoprotein)
398983|NCT01090661|thorough QT
398984|NCT01090648|TMC125HIV1083
398985|NCT01090648|TMC125
398986|NCT01090648|HIV
398987|NCT01090648|Etravirine
398988|NCT01090648|ETR
398989|NCT01090648|Intelence
398990|NCT01090648|HIV Infections
398991|NCT01090635|Cervical Intraepithelial Neoplasia
398992|NCT01090609|Coronary Stent
398993|NCT01090609|Cobalt-Chromium coronary stent
398994|NCT01090583|Cytokines
398995|NCT01090583|Pregnancy
398996|NCT01090583|Cesarean
398997|NCT01090544|COPD
398998|NCT01090544|TNI
398999|NCT01090544|PaCO2
399000|NCT01090492|Raynaud's phenomenon
399001|NCT01090492|vasospasm
399002|NCT01090492|scleroderma
399003|NCT01090492|systemic sclerosis
399004|NCT01090492|CREST
399005|NCT01090492|phosphodiesterase inhibitor
399006|NCT01090479|Surgical site infections
399007|NCT01090479|Chlorhexidine
399008|NCT01090479|Shoulder surgery
399009|NCT01090466|transitional cell carcinoma of the bladder
399010|NCT01090466|recurrent bladder cancer
399011|NCT01090466|recurrent urethral cancer
399012|NCT01090466|recurrent transitional cell cancer of the renal pelvis and ureter
399013|NCT01090466|stage IV bladder cancer
399014|NCT01090466|metastatic transitional cell cancer of the renal pelvis and ureter
399015|NCT01090466|regional transitional cell cancer of the renal pelvis and ureter
399016|NCT01090466|distal urethral cancer
399017|NCT01090466|proximal urethral cancer
399018|NCT01090466|urethral cancer associated with invasive bladder cancer
399019|NCT01090466|stage IV urethral cancer
399020|NCT01090440|GSK1144814
399021|NCT01090440|pharmacokinetics
399022|NCT01090440|effect of food
399023|NCT01090440|depressive disorder
399024|NCT01090440|schizophrenia
399025|NCT01090440|healthy subjects
399026|NCT01090427|Ustekinumab
399027|NCT01090427|Injection
399028|NCT01090427|CNTO 1275
399029|NCT01090427|Stelara
399030|NCT01090427|Pediatric psoriasis
399031|NCT01090427|Adolescents
399032|NCT01090414|Idelalisib
399033|NCT01090414|Chronic lymphocytic leukemia (CLL)
399034|NCT01090414|Non-Hodgkin lymphoma (NHL)
399035|NCT01090414|Phosphatidylinositol 3-kinase (PI3K)
399036|NCT01090388|Cross-sectional survey
399037|NCT01090388|Health-related quality of life
399038|NCT01090388|Symptom management
399039|NCT01090375|osteoarthritis
399040|NCT01090375|biochemical markers
399041|NCT01090375|cartilage
399042|NCT01090375|inflammation
399043|NCT01090375|microdialysis
399044|NCT01090362|Atrial fibrillation
399045|NCT01090362|Anticoagulation
399046|NCT01090362|Stroke
399047|NCT01090362|Stroke prevention
399048|NCT01090362|Health Economics
399049|NCT01090349|ICD, CRTD, Remote Care
399050|NCT01090336|platelet aggregation inhibition
399051|NCT01090336|prasugrel
399052|NCT01090336|clopidogrel
399053|NCT01090336|ACS
399054|NCT01090323|Deferasirox
399055|NCT01090323|ICL670A
399056|NCT01090323|Iron chelators
399057|NCT01090323|Sickle Cell Disease
399058|NCT01090323|Transfusional Hemosiderosis
399059|NCT01090310|Quiescent uveitis
399060|NCT01090310|intermediate uveitis
399061|NCT01090310|panuveitis
399062|NCT01090310|posterior uveitis
399063|NCT01090310|uveitis
399064|NCT01090310|NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database.
399065|NCT01090310|Avoid acronyms, abbreviations and trade names.
399066|NCT01090310|Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases
399067|NCT01090310|Psoriasis, inflammatory skin disease, scaly patches
399068|NCT01090297|Obstructive Sleep Apnea Syndrome
399069|NCT01090297|Blood pressure
399070|NCT01090297|Continuous Positive Airway Pressure
399071|NCT01090284|Inguinal hernia
399072|NCT01090284|Immune system
399073|NCT01090284|Cytokines
399074|NCT01090284|Prosthetic repair
399075|NCT01090284|Oxidative Stress
399076|NCT01090271|Subacromial impingement syndrome
399077|NCT01090271|Muscle Strength
399078|NCT01090271|Resistance Training
399079|NCT01090258|cardiac surgery
399080|NCT01090258|mechanical ventilation
399081|NCT01090258|automation
399082|NCT01090258|weaning
399083|NCT01090245|contingency management
399084|NCT01090245|substance abuse treatment
399085|NCT01090245|criminal justice populations
399086|NCT01090245|substance abuse treatment retention
399087|NCT01090245|HIV prevention in criminal justice settings
399088|NCT01090245|voucher based reinforcement therapy
399089|NCT01090245|Parole treatment admission for substance abusing parolees
399090|NCT01090245|Parole treatment retention for substance abusing parolees
399091|NCT01090245|HIV testing and counseling for substance abusing parolees
399092|NCT01090219|Inguinal Hernia
399093|NCT01090219|contraction of two different meshes in the repair of inguinal hernias in men
399094|NCT01090206|Hemophilia
399095|NCT01090206|Vitamin D
399096|NCT01090193|Obstructive jaundice
399097|NCT01090193|kidney histopathology
399098|NCT01090193|lactulose
399099|NCT01090180|PTSD
399100|NCT01090180|combat
399101|NCT01090180|stress disorders
399102|NCT01090180|veteran
399103|NCT01090154|Ulcerative colitis
399104|NCT01090154|UC
399105|NCT01090154|Inflammatory Bowel Disease
399106|NCT01090141|Micafungin
399107|NCT01090141|Body Weight
399108|NCT01090141|Anti-Infective Agents
399109|NCT01090141|Signs and Symptoms
399110|NCT01090141|Mycoses
399111|NCT01090141|Therapeutic Uses
399112|NCT01090141|Antifungal Agents
399113|NCT01090141|Overnutrition
399114|NCT01090141|Pharmacologic Actions
399115|NCT01090076|Pressure Ulcer Wound
399116|NCT01090076|Specialized Amino Acid Mixture
399117|NCT01090063|Palmar Plantar Psoriasis
399118|NCT01090050|Chronic Migraine
399119|NCT01090050|Migraine
399120|NCT01090050|Treximet
399121|NCT01090050|naproxen
399122|NCT01090050|sumatriptan
399123|NCT01090037|ESRD
399124|NCT01090037|Chronic Renal Failure
399125|NCT01090037|Prostaglandin
399126|NCT01090037|Prostacyclin
399127|NCT01090037|Asian Multinational Study
399128|NCT01089998|Neoplasm
399129|NCT01089998|PET/CT diagnosis
399130|NCT01089998|PET tracer
399131|NCT01089998|Inflammation
399132|NCT01089972|radial artery
399133|NCT01089972|ulnar artery
399134|NCT01089972|catheterization
399135|NCT01089972|regional blood flow
399136|NCT01089959|Acid re-flux,GERD
399137|NCT01089959|sleep related arousals due to GERD
399138|NCT01089959|Treatment of acid reflux during sleep in patients with GERD.
399139|NCT01089946|Mobilization
399140|NCT01089946|Hip arthroplasty
399141|NCT01089946|cardiovascular
399142|NCT01089933|Anesthesia
399143|NCT01089933|Local Anesthetics
399144|NCT01089933|Analgesia
399145|NCT01089933|Quality of life
399146|NCT01089933|Paravertebral blocks
399147|NCT01089933|Arm morbidity
399148|NCT01089907|genomic
399149|NCT01089907|childhood
399150|NCT01089907|acute lymphoblastic leukemia
399151|NCT01089894|18F-FLT
399152|NCT01089894|PET
399153|NCT01089894|non-small cell lung cancer
399154|NCT01089894|cell proliferation
399155|NCT01089894|therapeutic response
399156|NCT01089894|18F-3'-fluoro-3'-deoxy-L-thymidine (18F-FLT)
399157|NCT01089881|prostate cancer
399158|NCT01089881|18F-fluorocholine
399159|NCT01089881|PET
399160|NCT01089881|recurrence
399161|NCT01089881|metastases
399162|NCT01089868|Glioblastoma multiforme
399163|NCT01089868|Microsurgery
399164|NCT01089868|Stereotactic biopsy
399165|NCT01089868|Radiochemotherapy
399166|NCT01089868|Temodar
399167|NCT01089868|FET PET
399168|NCT01089868|Molecular imaging
399169|NCT01089855|Neuropathic Pain
399170|NCT01089855|Brief Pain Inventory
399171|NCT01089855|DN4 questionnaire
399172|NCT01089855|ElectroCardioGram
399173|NCT01089842|Secondary Prevention
399174|NCT01089842|Health Promotion
399175|NCT01089842|Behavioral Medicine
399176|NCT01089842|Exercise Therapy
399177|NCT01089829|CKD
399178|NCT01089829|Foot Ulceration
399179|NCT01089829|Diabetes
399180|NCT01089816|Influenza infections
399181|NCT01089816|Orthomyxoviridae infections
399182|NCT01089816|Influenza Human
399183|NCT01089803|laryngectomy
399184|NCT01089803|larynx
399185|NCT01089803|hypopharynx
399186|NCT01089764|breast neoplasm
399187|NCT01089764|breast cancer
399188|NCT01089764|behavioral intervention
399189|NCT01089764|online support
399190|NCT01089764|relationship distress
399191|NCT01089764|dyadic coping
399192|NCT01089738|mulitple dose
399193|NCT01089738|pharmacokinetics
399194|NCT01089738|safety
399195|NCT01089738|healthy elderly volunteers
399196|NCT01089725|safety
399197|NCT01089725|efficacy
399198|NCT01089725|parallel group
399199|NCT01089725|double-blind
399200|NCT01089725|multicenter
399201|NCT01089725|injection
399202|NCT01089725|infusion
399203|NCT01089725|osteoarthritis
399204|NCT01089725|bridging
399205|NCT01089725|subcutaneous
399206|NCT01089725|intravenous
399207|NCT01089725|tanezumab
399208|NCT01089712|Infection
399209|NCT01089712|Cardiac Surgery
399210|NCT01089712|Post Operative Cardiac Surgery Infection
399211|NCT01089712|Management Practices
399212|NCT01089699|breast cancer
399213|NCT01089699|support groups
399214|NCT01089699|Primary diagnosis of breast cancer within the past three years.
399215|NCT01089686|Chronic Cerebrospinal Venous Insufficiency
399216|NCT01089673|retrospective data collection
399217|NCT01089660|Influenza
399218|NCT01089660|Pandemic Flu
399219|NCT01089660|Swine-origin Influenza
399220|NCT01089660|Inactivated split-virion vaccine
399221|NCT01089647|OSA
399222|NCT01089647|Medical treatment
399223|NCT01089634|LV measurement
399224|NCT01089634|CRT
399225|NCT01089634|Concerto
399226|NCT01089634|LVCM
399227|NCT01089634|LV threshold
399228|NCT01089634|new CRT
399229|NCT01089608|Azyter in patients affected by chronic blepharitis.
399230|NCT01089595|Imatinib Resistance
399231|NCT01089595|GIST
399232|NCT01089595|Advanced Disease
399233|NCT01089595|Nilotinib
399234|NCT01089582|non-interventional
399235|NCT01089582|mild to moderate Alzheimer's
399236|NCT01089582|ARICEPT.
399237|NCT01089569|diabetes
399238|NCT01089569|continuous glucose monitoring
399239|NCT01089569|exenatide
399240|NCT01089569|insulin glargine
399241|NCT01089543|dyspepsia
399242|NCT01089543|rabeprazole
399243|NCT01089543|Japan
399244|NCT01089530|Fibrinogen
399245|NCT01089530|Cholesterol
399246|NCT01089530|Cardiovascular risk factors
399247|NCT01089530|Primary prevention
399248|NCT01089530|High levels fibrinogen
399249|NCT01089530|High plasma fibrinogen
399250|NCT01089504|phenobarbital
399251|NCT01089504|neonate
399252|NCT01089504|antiepileptic drugs
399253|NCT01089504|neurodevelopmental outcome
399254|NCT01089504|seizure
399255|NCT01089491|Low back pain
399256|NCT01089491|Epiduroscopy
399257|NCT01089491|Cytology
399258|NCT01089491|Electrical stimulation
399259|NCT01089478|Back pain
399260|NCT01089478|Low back pain
399261|NCT01089478|Cytology
399262|NCT01089478|Epiduroscopy
399263|NCT01089478|Pain
399264|NCT01089478|Radiculopathy
399265|NCT01089465|Bed bugs
399266|NCT01089465|Cimex
399267|NCT01089465|insects
399268|NCT01089465|bites
399269|NCT01089452|Mild to moderate hypertension
399270|NCT01089439|Nitric oxide
399271|NCT01089426|Pediatric patients with Parenteral Nutrition (PN) induced Liver Injury
399272|NCT01089400|influenza
399273|NCT01089400|H1N1
399274|NCT01089400|lymphocytes
399275|NCT01089400|T cell
399276|NCT01089400|CD4
399277|NCT01089400|CD8
399278|NCT01089400|cytokine
399279|NCT01089400|serology
399280|NCT01089400|broncho-alveolar lavage
399281|NCT01089400|acute respiratory distress syndrome
399282|NCT01089400|ventilation
399283|NCT01089400|intensive care unit
399284|NCT01089387|radical prostatectomy
399285|NCT01089374|Phyllodes
399286|NCT01089361|systemic inflammatory syndrome
399287|NCT01089361|sepsis syndrome
399288|NCT01089361|septic shock
399289|NCT01089361|Cytokine
399290|NCT01089361|Ketamine
399291|NCT01089348|Vaginosis, Bacterial
399292|NCT01089348|Prebiotics
399293|NCT01089348|Lactofiltrum
399294|NCT01089348|Therapy
399295|NCT01089335|Sentinel node
399296|NCT01089335|Thyroid cancer
399297|NCT01089335|Thyroid neoplasia
399298|NCT01089335|Follicular neoplasia
399299|NCT01089322|SEVERE ASTHMA
399300|NCT01089322|RISK FACTORS
399301|NCT01089322|CHARACTERIZATION
399302|NCT01089322|CLINICAL CONTROL
399303|NCT01089322|INFLAMMATORY MARKERS
399304|NCT01089322|SEVERE
399305|NCT01089322|CONTROL
399306|NCT01089309|Aldosterone Blockade
399307|NCT01089309|Arterial elasticity
399308|NCT01089309|Glycemic control
399309|NCT01089296|Infants born preterm
399310|NCT01089296|Early physiotherapy intervention
399311|NCT01089296|Motor development
399312|NCT01089296|Parental participation
399313|NCT01089296|Parental competency
399314|NCT01089283|parkinson
399315|NCT01089283|fdg pet-ct
399316|NCT01089283|i123 dat scan
399317|NCT01089283|LRRK2
399318|NCT01089283|GBA
399319|NCT01089283|parkinson patients with known genetic characteristic
399320|NCT01089270|Parkinson
399321|NCT01089270|fdg pet-ct
399322|NCT01089270|i123 dat scan
399323|NCT01089270|first degree relatives of diagnosed Parkinson patients
399324|NCT01089270|with no clinical evidence of movement disorders
399325|NCT01089257|Cardiovascular risks
399326|NCT01089257|Oxidative stress
399327|NCT01089257|Systemic inflammation
399328|NCT01089257|Endothelial function
399329|NCT01089257|Peripheral Arterial Tone
399330|NCT01089257|Positive Airway Pressure
399331|NCT01089244|Low grade glioma
399332|NCT01089244|Astrocytoma
399333|NCT01089244|Molecular imaging
399334|NCT01089244|FET PET
399335|NCT01089244|Therapy monitoring
399336|NCT01089244|Temodar
399337|NCT01089231|Hyperlipidemia
399338|NCT01089231|coronary heart disease
399339|NCT01089231|gene expression
399340|NCT01089231|fish oil
399341|NCT01089231|DHA, EPA
399342|NCT01089218|bronchoscopy
399343|NCT01089218|post-bronchoscopy fever
399344|NCT01089218|pneumonia
399345|NCT01089218|cytokines
399346|NCT01089218|amoxicillin/clavulanate
399347|NCT01089218|prophylaxis
399348|NCT01089153|human blood, urine and fecal samples
399349|NCT01089140|pediatrics
399350|NCT01089140|scoliosis
399351|NCT01089140|tranexamic acid
399352|NCT01089140|Investigating non-idiopathic scoliosis
399353|NCT01089127|Indacaterol
399354|NCT01089127|COPD
399355|NCT01089127|salmeterol
399356|NCT01089114|Cardiac Imaging
399357|NCT01089114|MR Spectroscopy
399358|NCT01089114|HIV
399359|NCT01089114|Lipid Metabolism
399360|NCT01089114|HIV Infection
399361|NCT01089114|Cardiovascular Disease
399362|NCT01089114|HIV Infections
399363|NCT01089088|recurrent urethral cancer
399364|NCT01089088|recurrent transitional cell cancer of the renal pelvis and ureter
399365|NCT01089088|metastatic transitional cell cancer of the renal pelvis and ureter
399366|NCT01089088|regional transitional cell cancer of the renal pelvis and ureter
399367|NCT01089088|posterior urethral cancer
399368|NCT01089088|urethral cancer associated with invasive bladder cancer
399369|NCT01089088|transitional cell carcinoma of the bladder
399370|NCT01089088|stage IV bladder cancer
399371|NCT01089088|recurrent bladder cancer
399372|NCT01089088|anterior urethral cancer
399373|NCT01089075|neuropsychological effects of hydrocortisone replacement
399374|NCT01089062|Healthy volunteers
399375|NCT01089049|Urinary Estrogen Metabolites
399376|NCT01089049|2-OH Estrone
399377|NCT01089049|16-alpha-OH Estrone
399378|NCT01089049|Urinary 2/16a Estrogen Metabolite Ratio
399379|NCT01089036|ECMO
399380|NCT01089036|cardiogenic shock
399381|NCT01089036|ROS
399382|NCT01089036|GPx
399383|NCT01089036|cytokines
399384|NCT01088997|Persistent pulmonary hypertension of newborn
399385|NCT01088997|PPHN
399386|NCT01088997|Persistent pulmonary hypertension
399387|NCT01088997|Pulmonary hypertension
399759|NCT01087541|Safety
399388|NCT01088997|Pulmonary hypertension of newborn
399389|NCT01088958|Kenya
399390|NCT01088958|Child Nutrition Disorders
399391|NCT01088958|Social marketing
399392|NCT01088945|Infant, Premature, Diseases
399393|NCT01088932|Safety in Healthy Volunteers
399394|NCT01088919|ASP1941
399395|NCT01088919|Actos
399396|NCT01088919|pioglitazone hydrochloride
399397|NCT01088906|Phalcis
399398|NCT01088906|BRCA1
399399|NCT01088906|RAP80
399400|NCT01088906|TS
399401|NCT01088906|First line
399402|NCT01088906|Non-squamous
399403|NCT01088893|everolimus
399404|NCT01088893|neoadjuvant
399405|NCT01088893|m-TOR inhibitor
399406|NCT01088880|Familial Mediterranean Fever
399407|NCT01088880|canakinumab
399408|NCT01088880|colchicine resistance
399409|NCT01088867|Pain
399410|NCT01088867|Acupuncture
399411|NCT01088867|DNIC
399412|NCT01088867|Electroacupuncture
399413|NCT01088828|MRI, clubfoot, CTEV, Congenital Talipes Equinovarus
399414|NCT01088815|Adenocarcinoma
399415|NCT01088815|Hedgehog
399416|NCT01088815|Neoplasms
399417|NCT01088815|Digestive System Diseases
399418|NCT01088815|Neoplasms by Site
399419|NCT01088815|Digestive System Neoplasms
399420|NCT01088815|Neoplasms by Histologic Type
399421|NCT01088815|Pancreatic Neoplasms
399422|NCT01088815|Pancreatic Diseases
399423|NCT01088815|Carcinoma
399424|NCT01088802|Squamous Cell Carcinoma
399425|NCT01088802|Oropharynx
399426|NCT01088789|Adenocarcinoma
399427|NCT01088789|Cyclophosphamide
399428|NCT01088789|Immunotherapy
399429|NCT01088789|Neo-Adjuvant
399430|NCT01088789|Pancreatic tumor vaccine
399431|NCT01088789|GM-CSF
399432|NCT01088789|Randomize
399433|NCT01088776|CKD
399434|NCT01088776|hypertriglyceridemia
399435|NCT01088776|Fatty Acid Supplementation
399436|NCT01088776|Children
399437|NCT01088776|Omega-3
399438|NCT01088750|childhood nodular lymphocyte predominant Hodgkin lymphoma
399439|NCT01088750|stage I childhood Hodgkin lymphoma
399440|NCT01088750|stage II childhood Hodgkin lymphoma
399441|NCT01088737|Lentigo maligna
399442|NCT01088737|melanoma
399443|NCT01088737|imiquimod
399444|NCT01088737|prevention
399445|NCT01088711|Type 2 diabetes (T2D)
399446|NCT01088698|psoriasis
399447|NCT01088698|golimumab
399448|NCT01088698|TNF-alpha inhibition
399449|NCT01088698|phototherapy
399450|NCT01088698|311-nm
399451|NCT01088672|Stroke
399452|NCT01088672|Ischemic
399453|NCT01088672|Thrombus
399454|NCT01088672|Embolectomy
399455|NCT01088672|Thrombectomy
399456|NCT01088672|Concentric
399457|NCT01088672|Embolus
399458|NCT01088672|Mechanical
399459|NCT01088672|Trevo
399460|NCT01088646|capsule endoscopy
399461|NCT01088646|small bowel disease
399462|NCT01088646|inflammatory bowel disease
399463|NCT01088646|Subjects indicated for EGD endoscopy
399464|NCT01088633|COPD
399465|NCT01088620|NSCLC
399466|NCT01088620|Stage IIIb or IV
399467|NCT01088620|Nonsquamous
399468|NCT01088620|KRAS-Wildtype
399469|NCT01088607|Primary sclerosing cholangitis
399470|NCT01088607|Autoimmune hepatitis
399471|NCT01088607|Cholestatic liver disease
399472|NCT01088607|Cirrhosis
399473|NCT01088607|Children
399474|NCT01088607|Primary Sclerosing Cholangitis/Autoimmune Hepatitis Overlap
399475|NCT01088594|urinary sodium excretion
399476|NCT01088594|Pioglitazone
399477|NCT01088594|Rosiglitazone
399478|NCT01088594|Methodological study
399479|NCT01088581|hepatocellular carcinoma
399480|NCT01088581|hepatic arterial infusion chemotherapy
399481|NCT01088581|5-fluorouracil
399482|NCT01088581|cisplatin
399483|NCT01088581|adjuvant chemotherapy
399484|NCT01088581|hepatectomy
399485|NCT01088568|Keratomileusis, laser in situ
399486|NCT01088568|Phakic Intraocular Lenses
399487|NCT01088568|myopia
399488|NCT01088568|astigmatism
399489|NCT01088568|Implantable Collamer Lens, Toric
399490|NCT01088555|nephrolithiasis
399491|NCT01088555|calcium stones
399492|NCT01088555|kidney stones
399493|NCT01088555|hypercalciuria
399494|NCT01088555|sodium thiosulfate
399495|NCT01088555|Calcium containing kidney stones
399496|NCT01088542|substance use
399497|NCT01088542|delinquency
399498|NCT01088542|risky sexual behavior
399499|NCT01088542|risk factors
399500|NCT01088542|protective factors
399501|NCT01088542|prevention
399502|NCT01088542|community coalitions
399503|NCT01088542|systems transformation
399504|NCT01088542|violence
399505|NCT01088529|Neoadjuvant Prostate Cancer
399506|NCT01088529|Abiraterone Acetate
399507|NCT01088529|LHRHa
399508|NCT01088529|high risk prostate cancer
399509|NCT01088529|Radical prostatectomy
399510|NCT01088529|Prednisone
399511|NCT01088529|Luteinizing Hormone-Releasing Hormone
399512|NCT01088529|LHRH analogue
399513|NCT01088516|Human Immunodeficiency Virus
399514|NCT01088516|Vertical Transmission
399515|NCT01088516|Pregnancy
399516|NCT01088516|Breastfeeding
399517|NCT01088516|Prevention of mother to child transmission
399518|NCT01088516|HAART
399519|NCT01088516|Aluvia
399520|NCT01088516|Lopinavir
399521|NCT01088516|Africa
399522|NCT01088516|Infectious Disease Transmission, Vertical
399523|NCT01088490|Hydrogen sulfide
399524|NCT01088490|critically ill
399525|NCT01088490|mortality
399526|NCT01088477|Acquired anti-hormonal resistant breast cancer
399527|NCT01088464|Human Immunoglobulin Gamma-1 (IgG1)
399528|NCT01088464|Monoclonal Antibody (MAb)
399529|NCT01088464|Epidermal Growth Factor Receptor (EGFR)
399530|NCT01088464|Advanced Solid Tumors
399531|NCT01088451|Diabetes Mellitus, Type 1
399532|NCT01088451|Prandial Glycemia
399533|NCT01088451|Rapid Acting Insulin Analogue
399534|NCT01088451|Human Insulin
399535|NCT01088438|medical education
399536|NCT01088438|decision making
399537|NCT01088438|diagnostic error
399538|NCT01088438|contextualization
399539|NCT01088425|vitrification
399540|NCT01088425|2PN oocyte
399541|NCT01088425|maternal and infant health
399542|NCT01088425|embryo survival, clinical pregnancy rate
399543|NCT01088425|mode of delivery
399544|NCT01088425|injury during delivery
399545|NCT01088425|infant development
399546|NCT01088425|infant morbidity
399547|NCT01088425|slow- rate freezing
399548|NCT01088347|TRAIL
399549|NCT01088347|TRM1
399550|NCT01088347|advanced cervical cancer
399551|NCT01088347|mapatumumab
399552|NCT01088347|Uterine cervical neoplasm
399553|NCT01088347|Radiotherapy
399554|NCT01088347|Cisplatin
399555|NCT01088334|Idiopathic venous thromboembolism
399556|NCT01088334|Malignancy
399557|NCT01088334|screening
399558|NCT01088295|Metabolic
399559|NCT01088295|HIV
399560|NCT01088295|Fat accumulation
399561|NCT01088295|AIDS
399562|NCT01088295|Metabolic abnormalities in HIV infection
399563|NCT01088295|HIV Infections
399564|NCT01088282|Diffractive multifocal IOL
399565|NCT01088269|Blood Pressure Measurement
399566|NCT01088269|Atrial Fibrillation
399567|NCT01088269|Blood pressure measurement in atrial fibrillation
399568|NCT01088269|Atrial Fibrillation diagnosis
399569|NCT01088256|CRPS
399570|NCT01088256|Morbus Sudeck
399571|NCT01088256|Causalgia
399572|NCT01088256|Etoricoxib
399573|NCT01088256|Polyneuropathy
399574|NCT01088256|post herpetic neuralgia
399575|NCT01088256|peripheral nerve injury
399576|NCT01088256|radiculopathy
399577|NCT01088256|Nervenverletzung
399578|NCT01088256|postherpetische Neuralgie
399579|NCT01088256|COX-2-Inhibitor
399580|NCT01088243|Berylliosis
399581|NCT01088243|Beryllium Disease
399582|NCT01088230|hemiparesis
399583|NCT01088230|robotics
399584|NCT01088230|stroke
399585|NCT01088230|Botox®
399586|NCT01088230|rehabilitation
399587|NCT01088230|wrist spasticity
399588|NCT01088217|Idiopathic Pulmonary Fibrosis
399589|NCT01088217|Familial Pulmonary Fibrosis
399590|NCT01088217|Idiopathic Interstitial Pneumonia
399591|NCT01088217|Familial Interstitial Pneumonia
399592|NCT01088217|Pulmonary Fibrosis
399593|NCT01088191|Acute Anterior Cruciate Ligament Injury
399594|NCT01088191|Anterior Cruciate Ligament Reconstruction
399595|NCT01088191|Adult Stem Cells
399596|NCT01088191|Mesenchymal precursor cells
399597|NCT01088178|Long-Acting Reversible Contraception
399598|NCT01088178|Contraceptive Agents
399599|NCT01088178|Therapeutic Uses
399600|NCT01088178|Contraceptive Agents, Female
399601|NCT01088178|Reproductive Control Agents
399602|NCT01088178|Pharmacologic Actions
399603|NCT01088178|Levonorgestrel
399604|NCT01088165|Psoriasis
399605|NCT01088165|Cardiovascular Diseases
399606|NCT01088165|Diabetes Mellitus, Type 2
399607|NCT01088165|Adalimumab
399608|NCT01088165|Fumaric acid esters
399609|NCT01088152|Celiac disease
399610|NCT01088152|Education
399611|NCT01088152|Sweden
399612|NCT01088152|Gluten-free diet
399613|NCT01088139|Nutritional support
399614|NCT01088139|Rehabilitation outcomes
399615|NCT01088113|Tai Chi
399616|NCT01088113|Qigong
399617|NCT01088113|Heart rate variability
399618|NCT01088113|Near Infrared Spectroscopy
399619|NCT01088113|blood pressure
399620|NCT01088100|POCD
399621|NCT01088100|clock-gene genotypes
399622|NCT01088100|HPER3
399623|NCT01088074|Total Knee Replacement
399624|NCT01088074|Closure Methods
399625|NCT01088048|CLL
399626|NCT01088048|non-Hodgkin lymphoma (NHL)
399627|NCT01088048|mantle cell lymphoma (MCL)
399628|NCT01088048|phosphatidylinositol 3-kinase
399629|NCT01088048|bendamustine
399630|NCT01088048|CD20 mAb
399631|NCT01088048|rituximab
399632|NCT01088048|CAL-101
399633|NCT01088048|Ofatumumab
399634|NCT01088048|indolent non-Hodgkin lymphoma (iNHL)
399635|NCT01088048|fludarabine
399636|NCT01088048|everolimus
399637|NCT01088048|bortezomib
399638|NCT01088048|chlorambucil
399639|NCT01088048|lenalidomide
399640|NCT01088035|Childhood ependymoma
399641|NCT01088035|Ependymoma
399642|NCT01088035|Survivin
399643|NCT01088022|the complete response (CR) rate defined as the number of patients with no emetic episodes and no rescue medication in the first 120 hours post-chemotherapy
399644|NCT01088009|chronic hepatitis B
399645|NCT01087996|Chronic Ischemic Left Ventricular
399646|NCT01087983|Metastatic cancer
399647|NCT01087983|Lapatinib
399648|NCT01087983|Tykerb
399649|NCT01087983|Metformin
399650|NCT01087983|Glucophage
399651|NCT01087983|Sirolimus
399652|NCT01087983|Rapamune
399653|NCT01087970|Pharynx
399654|NCT01087970|Larynx
399655|NCT01087970|Nose
399656|NCT01087970|Parathyroid
399657|NCT01087931|Local anesthetic
399658|NCT01087931|Iliac crest bone harvest
399659|NCT01087931|Patients undergoing spine surgery that require use of iliac crest bone autograft
399660|NCT01087918|ASIA C and D
399661|NCT01087905|Smoking
399662|NCT01087905|Smoking cessation
399663|NCT01087905|Medication adherence
399664|NCT01087879|oral glucose tolerance test
399665|NCT01087879|hormonal contraception
399666|NCT01087879|androgens
399667|NCT01087879|crp
399668|NCT01087866|Gestational diabetes mellitus
399669|NCT01087866|treatment
399670|NCT01087866|metformin
399671|NCT01087853|Fluid Therapy
399672|NCT01087853|Water Electrolyte Imbalance
399673|NCT01087853|Acid Base Imbalance
399674|NCT01087853|Renal Circulation
399675|NCT01087853|Magnetic Resonance Imaging
399676|NCT01087840|HIV
399677|NCT01087840|nonoccupational
399678|NCT01087840|postexposure
399679|NCT01087840|prophylaxis
399680|NCT01087840|HIV Seronegativity
399681|NCT01087827|oscillometric blood pressure
399682|NCT01087827|cuff site
399683|NCT01087827|forearm blood pressure
399684|NCT01087827|upper arm blood pressure
399685|NCT01087827|anthropometric measurements
399686|NCT01087827|tonometry
399687|NCT01087827|site of blood pressure measurement
399688|NCT01087827|measurement accuracy
399689|NCT01087814|efavirenz
399690|NCT01087814|Sustiva
399691|NCT01087814|pharmacokinetics
399692|NCT01087801|Genetic End Marker
399693|NCT01087788|Certolizumab Pegol
399694|NCT01087788|Cimzia
399695|NCT01087762|Certolizumab Pegol
399696|NCT01087762|Cimzia
399697|NCT01087736|PTSD
399698|NCT01087736|Alcohol abuse
399699|NCT01087736|Alcoholism
399700|NCT01087736|Topiramate
399701|NCT01087736|Stress Disorder, Post Traumatic
399702|NCT01087736|Chronic Post-Traumatic Stress Disorder
399703|NCT01087723|EUROMAX
399704|NCT01087723|STEMI
399705|NCT01087723|STE-ACS
399706|NCT01087723|UFH
399707|NCT01087723|bivalirudin
399708|NCT01087723|PCI
399709|NCT01087723|ambulance study
399710|NCT01087723|STE-MI participants
399711|NCT01087697|bladder cancer
399712|NCT01087697|radical cystectomy
399713|NCT01087697|incontinent urinary diversion
399714|NCT01087684|Glaucoma
399715|NCT01087684|laser trabeculoplasty
399716|NCT01087684|intraocular pressure
399717|NCT01087632|Metabolic Syndrome Insulin-resistance Endothelial Function
399718|NCT01087619|Hyperparathyroidism, primary
399719|NCT01087619|Aged 66 years or older
399720|NCT01087619|Mild hypercalcaemia
399721|NCT01087619|Surgical Procedures, Elective
399722|NCT01087619|Indication
399723|NCT01087619|Osteoporosis
399724|NCT01087619|Cognitive function
399725|NCT01087619|Atherosclerosis
399726|NCT01087619|Follow-up
399727|NCT01087619|Randomized trial
399728|NCT01087593|estrogen
399729|NCT01087593|substitution
399730|NCT01087593|pain
399731|NCT01087593|hormonal levels
399732|NCT01087593|quantitative sensory testing
399733|NCT01087580|Prostate Cancer
399734|NCT01087580|non metastatic prostate cancer
399735|NCT01087580|oligometastatic prostate cancer
399736|NCT01087567|diabetes
399737|NCT01087567|insulin
399738|NCT01087567|rescue therapy
399739|NCT01087554|Advanced Cancer
399740|NCT01087554|Sirolimus
399741|NCT01087554|Rapamune
399742|NCT01087554|mTOR Inhibitor
399743|NCT01087554|Histone Deacetylase Inhibitor
399744|NCT01087554|Vorinostat
399745|NCT01087554|SAHA
399746|NCT01087554|Suberoylanilide Hydroxamic Acid
399747|NCT01087554|MSK-390
399748|NCT01087554|Zolinza
399749|NCT01087554|Everolimus
399750|NCT01087554|Afinitor
399751|NCT01087554|Zortress
399752|NCT01087554|RAD001
399753|NCT01087554|Temsirolimus
399754|NCT01087554|CCI-779
399755|NCT01087554|Torisel
399756|NCT01087541|Patient's Safety
399757|NCT01087541|Diabetes mellitus
399758|NCT01087541|Public Health for professionals
399760|NCT01087541|Public health
399761|NCT01087528|Colonic Diseases
399762|NCT01087528|bowel diseases
399763|NCT01087528|large bowel diseases
399764|NCT01087489|pain
399765|NCT01087489|discomfort
399766|NCT01087489|anesthetic drugs
399767|NCT01087489|topical drug administration
399768|NCT01087489|injections, intraocular
399769|NCT01087489|lidocaine
399770|NCT01087489|intraocular pressure
399771|NCT01087489|keratopathy
399772|NCT01087476|oral mucositis
399773|NCT01087476|chemotherapy
399774|NCT01087476|acute leukemia
399775|NCT01087476|salivary flow.
399776|NCT01087450|Erythropoietin
399777|NCT01087450|Sepsis
399778|NCT01087450|Septic shock
399779|NCT01087450|Orthogonal Polarization Spectroscopy
399780|NCT01087450|Severe sepsis or Septic shock
399781|NCT01087437|Distraction osteogenesis
399782|NCT01087424|Diffuse Large B-Cell Lymphoma
399783|NCT01087411|accelerometry
399784|NCT01087411|physical activity
399785|NCT01087411|obesity
399786|NCT01087411|children
399787|NCT01087411|cardiovascular risk markers
399788|NCT01087411|metabolic risk markers
399789|NCT01087411|DXA
399790|NCT01087411|obesity prevention
399791|NCT01087411|omega 3
399792|NCT01087411|fish liver oil
399793|NCT01087411|motivational interviewing
399794|NCT01087398|Osteopetrosis
399795|NCT01087398|HSCT
399796|NCT01087385|peripheral arterial occlusive disease
399797|NCT01087385|mortality
399798|NCT01087385|cardiovascular events
399799|NCT01087385|amputation
399800|NCT01087385|peripheral arterial revascularization
399801|NCT01087372|Stress hyperglycemia
399802|NCT01087372|Incretins
399803|NCT01087372|GLP-1
399804|NCT01087372|GIP
399805|NCT01087372|glucoregulatory hormones
399806|NCT01087346|Parents
399807|NCT01087346|Obesity
399808|NCT01087346|Family History
399809|NCT01087346|Healthy Volunteer
399810|NCT01087346|HV
399811|NCT01087333|Cytotoxicity Assay
399812|NCT01087333|Neutralizing Antibodies
399813|NCT01087333|Apheresis
399814|NCT01087333|Flow Cytometry
399815|NCT01087333|Hemolytic Uremic Syndrome (HUS)
399816|NCT01087333|Leukemia
399817|NCT01087333|Lymphoma
399818|NCT01087333|Hairy Cell Leukemia
399819|NCT01087333|Chronic Lymphocytic Leukemia
399820|NCT01087333|Non-Hodgkin Lymphoma
399821|NCT01087333|Cutaneous T Cell Lymphoma
399822|NCT01087333|Adult T Cell Lymphoma
399823|NCT01087320|Genetic Counseling
399824|NCT01087320|Genetic Disorders
399825|NCT01087320|Genetic Testing
399826|NCT01087320|Genetic/Genomic Researchers
399827|NCT01087320|Human Genetic Variation
399828|NCT01087320|Congenital Disorders
399829|NCT01087320|Inherited Diseases
399830|NCT01087307|Biospecimen
399831|NCT01087307|Registry
399832|NCT01087307|Assay Development
399833|NCT01087307|Assay Validation
399834|NCT01087307|Specimen Collection
399835|NCT01087294|CD19
399836|NCT01087294|Chimeric-Antigen-Receptor
399837|NCT01087294|Gene Therapy
399838|NCT01087294|Adoptive T Cell Therapy
399839|NCT01087294|Allogeneic Stem Cell Transplantation
399840|NCT01087294|B Cell Cancer
399841|NCT01087294|Allogenic Stem Cell Transplant
399842|NCT01087281|Visual Attention
399843|NCT01087281|Visual Cortex
399844|NCT01087281|Focal Lesions
399845|NCT01087281|Neurological Disorder
399846|NCT01087281|Functional Magnetic Resonance Imaging (fMRI)
399847|NCT01087281|Focal Brain Lesion
399848|NCT01087281|Healthy Volunteer
399849|NCT01087281|HV
399850|NCT01087268|gastrointestinal complications
399851|NCT01087268|radiation toxicity
399852|NCT01087268|long-term effects secondary to cancer therapy in adults
399853|NCT01087268|stage I rectal cancer
399854|NCT01087268|stage II rectal cancer
399855|NCT01087268|stage III rectal cancer
399856|NCT01087268|stage I prostate cancer
399857|NCT01087268|stage IIB prostate cancer
399858|NCT01087268|stage IIA prostate cancer
399859|NCT01087268|stage III prostate cancer
399860|NCT01087268|stage IV prostate cancer
399861|NCT01087268|stage I bladder cancer
399862|NCT01087268|stage II bladder cancer
399863|NCT01087268|stage III bladder cancer
399864|NCT01087268|stage IV bladder cancer
399865|NCT01087268|stage IA cervical cancer
399866|NCT01087268|stage IB cervical cancer
399867|NCT01087268|stage IIA cervical cancer
399868|NCT01087268|stage IIB cervical cancer
399869|NCT01087268|stage III cervical cancer
399870|NCT01087268|stage I vaginal cancer
399871|NCT01087268|stage II vaginal cancer
399872|NCT01087268|stage III vaginal cancer
399873|NCT01087268|stage I malignant testicular germ cell tumor
399874|NCT01087268|stage II malignant testicular germ cell tumor
399875|NCT01087268|stage III malignant testicular germ cell tumor
399876|NCT01087268|stage I endometrial carcinoma
399877|NCT01087268|stage II endometrial carcinoma
399878|NCT01087268|stage III endometrial carcinoma
399879|NCT01087268|stage I uterine sarcoma
399880|NCT01087268|stage II uterine sarcoma
399881|NCT01087268|stage III uterine sarcoma
399882|NCT01087268|stage IA ovarian epithelial cancer
399883|NCT01087268|stage IB ovarian epithelial cancer
399884|NCT01087268|stage IC ovarian epithelial cancer
399885|NCT01087268|stage IIA ovarian epithelial cancer
399886|NCT01087268|stage IIB ovarian epithelial cancer
399887|NCT01087268|stage IIC ovarian epithelial cancer
399888|NCT01087268|stage IIIA ovarian epithelial cancer
399889|NCT01087268|stage IIIB ovarian epithelial cancer
399890|NCT01087268|stage IIIC ovarian epithelial cancer
399891|NCT01087268|stage IA ovarian germ cell tumor
399892|NCT01087268|stage IB ovarian germ cell tumor
399893|NCT01087268|stage IC ovarian germ cell tumor
399894|NCT01087268|stage IIA ovarian germ cell tumor
399895|NCT01087268|stage IIB ovarian germ cell tumor
399896|NCT01087268|stage IIC ovarian germ cell tumor
399897|NCT01087268|stage IIIA ovarian germ cell tumor
399898|NCT01087268|stage IIIB ovarian germ cell tumor
399899|NCT01087268|stage IIIC ovarian germ cell tumor
399900|NCT01087255|Caregiver-based interventions
399901|NCT01087255|Chronic Kidney Disease
399902|NCT01087255|Medication Adherence
399903|NCT01087242|Tang-min Lin pills
399904|NCT01087242|type 2 diabetes
399905|NCT01087242|liver and stomach heat retention
399906|NCT01087242|Evaluate the safety and efficacy of Tang-min Lin pills
399907|NCT01087203|diabetic peripheral neuropathy
399908|NCT01087203|tanezumab
399909|NCT01087203|diabetic neuropathies
399910|NCT01087203|diabetic polyneuropathy
399911|NCT01087203|diabetic neuropathy painful
399912|NCT01087190|kidney
399913|NCT01087190|transplantation
399914|NCT01087190|tuberculosis
399915|NCT01087190|ELISPOT
399916|NCT01087190|isoniazid
399917|NCT01087177|Smoking
399918|NCT01087177|Tobacco
399919|NCT01087177|Pediatrics
399920|NCT01087164|Vaccine acceptance
399921|NCT01087164|human papillomavirus
399922|NCT01087164|brief messages
399923|NCT01087164|social compliance
399924|NCT01087164|Message sidedness
399925|NCT01087151|Rituxan
399926|NCT01087151|Apoptosis
399927|NCT01087151|BCl-2
399928|NCT01087138|bone health
399929|NCT01087138|bone density
399930|NCT01087138|bone mass
399931|NCT01087112|MIP
399932|NCT01087112|RCT
399933|NCT01087112|postnatal depression
399934|NCT01087112|Mother-child relationship
399935|NCT01087086|Metabolic syndrome
399936|NCT01087086|Oxidative stress
399937|NCT01087086|Proinflammatory state
399938|NCT01087086|Insulin resistance
399939|NCT01087086|Hypertension
399940|NCT01087086|Dyslipidemia
399941|NCT01087086|Mediterranean diet
399942|NCT01087086|Glycemic index
399943|NCT01087086|Hypocaloric diet
399944|NCT01087086|Hyperproteic diet
399945|NCT01087086|Macronutrient distribution
399946|NCT01087086|Antioxidant capacity of the diet
399947|NCT01087086|Crononutrition
399948|NCT01087086|Dietary and psychological support
399949|NCT01087086|Waist circumference
399950|NCT01087073|Healthcare Disparities
399951|NCT01087073|Health Care Quality Improvement
399952|NCT01087073|Shared Decision-Making
399953|NCT01087073|Patient Education
399954|NCT01087073|Patient Activation
399955|NCT01087073|Community Outreach
399956|NCT01087073|Provider Training
399957|NCT01087047|Pregnancy
399958|NCT01087047|Upper airways
399959|NCT01087047|Acoustic reflection method
399960|NCT01087034|Infantile scoliosis
399961|NCT01087034|bracing
399962|NCT01087034|acoustic reflection method
399963|NCT01087034|EOS™
399964|NCT01087034|noninvasive
399965|NCT01087034|upper airways
399966|NCT01087034|thoracic penetration index
399967|NCT01087034|Idiopathic juvenile evolutive thoracic scoliosis
399968|NCT01087008|Multiple Myeloma
399969|NCT01087008|Zoledronic acid
399970|NCT01086995|extubation
399971|NCT01086995|weaning
399972|NCT01086995|mechanical ventilation
399973|NCT01086969|Meningococcal Infection
399974|NCT01086969|Meningitis, Bacterial
399975|NCT01086969|Menactra®
399976|NCT01086956|patients of prostatic cancer aged more than 65 years
399977|NCT01086917|Malaria Challenge
399978|NCT01086917|Plasmodium falciparum
399979|NCT01086917|Controlled human malaria infection
399980|NCT01086917|PfSPZ Challenge
399981|NCT01086904|renal transplantation
399982|NCT01086904|immunosuppression
399983|NCT01086904|inflenza A (H1N1)
399984|NCT01086904|vaccine
399985|NCT01086878|Antiretroviral Therapy, Highly Active
399986|NCT01086878|Trimethoprim-Sulfamethoxazole Combination
399987|NCT01086878|anemia
399988|NCT01086878|neutropenia
399989|NCT01086878|safety
399990|NCT01086878|hematologic toxicity
399991|NCT01086865|inappetence
399992|NCT01086865|apetiviton BC
399993|NCT01086852|Factor X deficiency
399994|NCT01086852|surgery
399995|NCT01086852|Factor X deficiency subjects requiring surgery
399996|NCT01086839|Cystic Fibrosis
399997|NCT01086839|chronic rhinosinusitis
399998|NCT01086813|Safety
399999|NCT01086813|Tolerability
400000|NCT01086813|Pharmacokinetics
400001|NCT01086813|Sedation
400002|NCT01086787|Heart failure
400003|NCT01086787|Bone marrow
400004|NCT01086787|Bone marrow mononuclear cells
400005|NCT01086787|Surgery
400006|NCT01086787|Orthopedic surgery
400007|NCT01086787|Cardiac surgery
400008|NCT01086774|Dry eye
400009|NCT01086774|Tear Film Stability
400010|NCT01086735|hematological malignancy
400011|NCT01086735|allogeneic hematopoietic stem cell transplantation
400012|NCT01086735|donor lymphocyte infusion
400013|NCT01086735|antitumor immunotherapy
400014|NCT01086735|graft-versus-tumor effect
400015|NCT01086735|gene therapy
400016|NCT01086735|relapse
400017|NCT01086735|adult
400018|NCT01086709|Human Papillomavirus
400019|NCT01086709|Vaccine
400020|NCT01086709|Crossover
400021|NCT01086709|Hepatitis A
400022|NCT01086709|Hepatitis B
400023|NCT01086696|PET Imaging
400024|NCT01086696|F-18 Paclitaxel (FPAC)
400025|NCT01086696|Breast Cancer
400026|NCT01086696|Lung Cancer
400027|NCT01086696|Renal and Adrenal Cancers
400028|NCT01086696|Kidney Cancer
400029|NCT01086696|Adrenal Cancer
400030|NCT01086683|neoplasms
400031|NCT01086683|rehabilitation
400032|NCT01086683|intervention
400033|NCT01086683|quality of life
400034|NCT01086683|lifestyle
400035|NCT01086670|Coordination
400036|NCT01086670|Neuroimaging
400037|NCT01086670|Motion Analysis
400038|NCT01086670|Locomotor
400039|NCT01086670|Cerebral Palsy
400040|NCT01086670|Pediatrics
400041|NCT01086657|Bird Flu
400042|NCT01086657|Avian Influenza
400043|NCT01086657|Healthy
400044|NCT01086657|Immunity
400045|NCT01086657|Prevention
400046|NCT01086657|Healthy Volunteer
400047|NCT01086657|HV
400048|NCT01086631|Autoimmune Retinopathy
400049|NCT01086631|RITUXAN
400050|NCT01086631|Rituximab
400051|NCT01086631|Immunosuppression
400052|NCT01086618|stage IV colon cancer
400053|NCT01086618|stage IV rectal cancer
400054|NCT01086605|HER2-negative breast cancer
400055|NCT01086605|male breast cancer
400056|NCT01086605|recurrent breast cancer
400057|NCT01086605|stage IV breast cancer
400058|NCT01086605|stage IIIC breast cancer
400059|NCT01086592|Aged
400060|NCT01086592|Strength
400061|NCT01086592|Balance
400062|NCT01086592|Electrotherapy
400063|NCT01086592|Quality of life
400064|NCT01086579|paclitaxel PTCA drug-eluting balloon
400065|NCT01086579|provisional spot stenting
400066|NCT01086579|coronary artery disease
400067|NCT01086579|Late Lumen Loss
400068|NCT01086579|Minimal lumen diameter
400069|NCT01086579|coronary artery disease in a small vessel
400070|NCT01086566|Influenza, H5N1, avian influenza, parent protocol
400071|NCT01086553|Crohn´s disease
400072|NCT01086553|budesonide
400073|NCT01086553|induction of remission
400074|NCT01086540|Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
400075|NCT01086540|Autoimmune Disease
400076|NCT01086540|Systemic Scleroderma
400077|NCT01086540|Pulmonary Arterial Hypertension
400078|NCT01086527|Pharmacogenetics
400079|NCT01086527|Singulair
400080|NCT01086527|montelukast
400081|NCT01086527|Leukotriene Antagonists
400082|NCT01086527|Anti-Asthmatic Agents
400083|NCT01086527|Intestinal Absorption
400084|NCT01086527|pharmacokinetics
400085|NCT01086527|absorption
400086|NCT01086527|biochemical transport
400087|NCT01086527|Membrane Transport Proteins
400088|NCT01086514|Breast
400089|NCT01086514|mammography
400090|NCT01086514|MRI
400091|NCT01086514|Digital Mammography
400092|NCT01086514|10-024
400093|NCT01086501|open, non-interventional
400094|NCT01086488|recurrent or persistent Nasopharyngeal Carcinoma
400095|NCT01086488|treatment of patients with squamous cell carcinoma of the head and neck
400096|NCT01086488|Foscan-PDT
400097|NCT01086488|Brachytherapy
400098|NCT01086475|Autism Spectrum Disorder
400099|NCT01086475|D-cycloserine
400100|NCT01086475|Social Skills Training
400101|NCT01086462|GSK2239633
400102|NCT01086462|RADIOLABEL
400103|NCT01086462|PHARMACOKINETICS
400104|NCT01086462|INTRAVENOUS
400105|NCT01086462|MICRODOSE
400106|NCT01086449|safety
400107|NCT01086449|Japanese
400108|NCT01086449|Herpes Zoster
400109|NCT01086449|immunogenicity
400110|NCT01086449|Herpes Zoster in healthy ethnic Japanese adults
400111|NCT01086449|Vaccine
400112|NCT01086436|Human Rotavirus vaccine
400113|NCT01086423|Infanrix-IPV+Hib
400114|NCT01086410|HPA axis
400115|NCT01086397|pneumococcal pneumonia
400116|NCT01086397|community-acquired pneumonia
400117|NCT01086371|Multiple Sclerosis
400118|NCT01086371|gait
400119|NCT01086358|productivity
400120|NCT01086358|migraine
400121|NCT01086358|Treximet
400122|NCT01086358|triptan
400123|NCT01086345|adult giant cell glioblastoma
400124|NCT01086345|adult gliosarcoma
400125|NCT01086345|recurrent adult brain tumor
400126|NCT01086332|radiotherapy
400127|NCT01086332|gemcitabine
400128|NCT01086332|nelfinavir
400129|NCT01086332|neoplasms
400130|NCT01086241|Tomography
400131|NCT01086241|Mammography
400132|NCT01086241|Breast Neoplasms
400133|NCT01086241|Prevention and Control
400134|NCT01086228|Drug eluting stents
400135|NCT01086228|Stents
400136|NCT01086228|Angioplasty
400137|NCT01086202|irreparable rotator cuff tears
400138|NCT01086163|Omacor
400139|NCT01086163|Simvastatin
400140|NCT01086163|Aspirin
400141|NCT01086163|Platelet activity
400142|NCT01086163|Coronary artery disease
400143|NCT01086137|salivary biomarker
400144|NCT01086137|metabolic syndrome
400145|NCT01086137|prediabetes
400146|NCT01086137|diabetes hypertension
400147|NCT01086124|echocardiography
400148|NCT01086124|ST elevation myocardial infarction
400149|NCT01086124|Heart failure
400150|NCT01086124|Coronary artery disease
400151|NCT01086124|Cardiovascular diseases
400152|NCT01086111|type 2 diabetes
400153|NCT01086111|gastric bypass
400154|NCT01086111|sleeve gastrectomy
400155|NCT01086111|clamp study
400156|NCT01086111|weight loss surgery
400157|NCT01086098|Pacemakers
400158|NCT01086098|Survival
400159|NCT01086059|Autoimmune diseases
400160|NCT01086059|adalimumab
400161|NCT01086059|pregnancy
400162|NCT01086059|birth defects
400163|NCT01086059|TNF
400164|NCT01086059|Tumor necrosis factor
400165|NCT01086046|platelet
400166|NCT01086046|thrombozyme
400167|NCT01086046|ASD
400168|NCT01086046|Heparin
400169|NCT01086046|Enoxaparin
400170|NCT01086033|Evaluation of safety and efficacy
400171|NCT01086033|Adalimumab treatment
400172|NCT01086033|Rheumatoid Arthritis
400173|NCT01086020|IVUS
400174|NCT01086020|coronary plaque
400175|NCT01086020|regression
400176|NCT01086007|Groin hernia
400177|NCT01086007|chronic pain
400178|NCT01086007|Persistent postoperative pain
400179|NCT01086007|Laparoscopic inguinal herniotomy
400180|NCT01086007|Sexual dysfunction
400181|NCT01085994|antibiotics
400182|NCT01085994|resistance
400183|NCT01085994|bio-marker
400184|NCT01085994|procalcitonin
400185|NCT01085994|algorithm
400186|NCT01085994|critically ill
400187|NCT01085981|quantitative assessment of the effects of a topically
400188|NCT01085981|applied vasodilating cream to the clitoris using doppler
400189|NCT01085981|flow plethysmography
400190|NCT01085968|Parkinson's disease
400191|NCT01085968|Cognitive deficits
400192|NCT01085968|fMRI
400193|NCT01085968|neuro rehabilitation
400194|NCT01085968|Age Matched Controls
400195|NCT01085955|peripartum
400196|NCT01085955|cardiomyopathy
400197|NCT01085955|post pregnancy
400198|NCT01085955|myocardial recovery
400199|NCT01085955|pregnant women with peripartum cardiomyopathy
400200|NCT01085942|rotator cuff tear
400201|NCT01085942|asymptomatic
400202|NCT01085942|natural course
400203|NCT01085942|tear characteristics
400204|NCT01085942|Asymptomatic rotator cuff tears
400205|NCT01085942|Natural course of rotator cuff tears
400206|NCT01085929|abscess
400207|NCT01085929|infection
400208|NCT01085929|ultrasound guidance
400209|NCT01085929|incision and drainage
400210|NCT01085929|needle aspiration
400211|NCT01085929|skin
400212|NCT01085929|ultrasound
400213|NCT01085916|prevalence of asthma and Rhinitis symptoms among secondary school students in Saudi Arabia
400214|NCT01085903|Spatial Neglect
400215|NCT01085903|Dysphagia
400216|NCT01085903|Arousal
400217|NCT01085903|Modafinil
400218|NCT01085903|Stroke
400219|NCT01085890|Blood Pressure
400220|NCT01085890|Life Style
400221|NCT01085890|Body Mass Index
400222|NCT01085890|Obesity, Abdominal
400223|NCT01085890|Blood Chemical Analysis
400224|NCT01085864|Lung Nodules
400225|NCT01085864|A need exists for non-invasive testing to aid in clinical decision-making for CT scan detected lung nodules of indeterminate etiology.
400226|NCT01085851|Sunburn
400227|NCT01085851|Dexchlorpheniramine
400228|NCT01085851|Lotion
400229|NCT01085851|Cream
400230|NCT01085838|Erlotinib
400231|NCT01085838|myelodysplastic syndrome
400232|NCT01085825|induced abortion
400233|NCT01085825|termination of pregnancy
400234|NCT01085825|manual vacuum aspiration
400235|NCT01085825|electric vacuum aspiration
400236|NCT01085799|Educational activities
400237|NCT01085799|Cluster-randomized controlled trial
400238|NCT01085799|Albendazole
400239|NCT01085799|Deworming
400240|NCT01085799|School-age children
400241|NCT01085799|Peru
400242|NCT01085799|Ascaris lumbricoides
400243|NCT01085799|Trichuris trichiura
400244|NCT01085799|Hookworm
400245|NCT01085799|STH infections
400246|NCT01085799|Intestinal helminth infections
400247|NCT01085786|Helicobacter pylori infection
400248|NCT01085773|HbA1c
400249|NCT01085773|Type 2 Diabetes
400250|NCT01085773|Lifestyle changes
400251|NCT01085773|Exercise
400252|NCT01085747|Chronic pancreatitis
400253|NCT01085747|Biliary stricture
400254|NCT01085747|Endoscopic treatment
400255|NCT01085747|SEMS
400256|NCT01085721|allergic rhinitis
400257|NCT01085721|viral infections of the upper respiratory tract
400258|NCT01085721|dexchlorpheniramine
400259|NCT01085721|pseudoephedrine
400260|NCT01085721|guaifenesin
400261|NCT01085708|Rabeprazole
400262|NCT01085708|Japan
400263|NCT01085708|healthy Japanese male
400264|NCT01085695|Rabeprazole
400265|NCT01085695|Japan
400266|NCT01085695|healthy Japanese male
400267|NCT01085682|Diabetes prevention
400268|NCT01085682|Lifestyle modification
400269|NCT01085682|Obesity
400270|NCT01085682|Impaired glucose tolerance
400271|NCT01085682|Diet
400272|NCT01085682|Physical activity
400273|NCT01085669|Infection rate of VEPTR-Implants
400274|NCT01085669|VEPTR. Vertical Expandable
400275|NCT01085669|Prosthetic Titanium Rib
400276|NCT01085643|IBS
400277|NCT01085643|Lubiprostone
400278|NCT01085643|Small Bowel
400279|NCT01085643|High Resolution Manometry
400280|NCT01085643|Delayed Intestinal Transit
400281|NCT01085630|epithelial mesothelioma
400282|NCT01085630|sarcomatous mesothelioma
400283|NCT01085630|stage II malignant mesothelioma
400284|NCT01085630|stage III malignant mesothelioma
400285|NCT01085630|stage IV malignant mesothelioma
400286|NCT01085617|oral complications
400287|NCT01085617|mucositis
400288|NCT01085617|untreated adult acute lymphoblastic leukemia
400289|NCT01085617|B-cell adult acute lymphoblastic leukemia
400290|NCT01085617|T-cell adult acute lymphoblastic leukemia
400291|NCT01085617|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
400292|NCT01085604|low back pain
400293|NCT01085604|clinical instability
400294|NCT01085604|neuromuscular control
400295|NCT01085604|core stabilization
400296|NCT01085604|physical therapy
400297|NCT01085591|CDI
400298|NCT01085591|Clostridium difficile Infection
400299|NCT01085591|Diarrhea
400300|NCT01085578|healthy male volunteers
400301|NCT01085578|fasted and fed state
400302|NCT01085565|Bone cancer
400303|NCT01085565|Bone Metastases
400304|NCT01085565|pain palliation
400305|NCT01085565|metastasis
400306|NCT01085565|breast cancer
400307|NCT01085565|lung cancer
400308|NCT01085565|prostate cancer
400309|NCT01085565|cancer related pain
400310|NCT01085565|tumors
400311|NCT01085552|NeoRecormon®
400312|NCT01085552|Caucasian
400313|NCT01085552|Japanese
400314|NCT01085552|Bioequivalence
400315|NCT01085552|Ethnic
400316|NCT01085539|neonatal intensive care
400317|NCT01085539|infant pulse oximetry
400318|NCT01085526|basophil activity
400319|NCT01085526|plasma cells
400320|NCT01085526|IgE
400321|NCT01085526|IgG1
400322|NCT01085526|IgG4
400323|NCT01085526|mast cells
400324|NCT01085526|IgE receptor
400325|NCT01085526|allergic rhinoconjunctivitis
400326|NCT01085526|grass pollen allergy
400327|NCT01085513|intestinal abnormalities
400328|NCT01085500|laparoscopic
400329|NCT01085500|totally extraperitoneal inguinal hernia repair
400330|NCT01085487|Menorrhagia
400331|NCT01085474|Asthma
400332|NCT01085474|Pharmaceutical intervention
400333|NCT01085474|Effect of a pharmaceutical intervention on the level of control of the asthmatic patient
400334|NCT01085448|low back pain
400335|NCT01085448|core stabilization
400336|NCT01085448|physical therapy
400337|NCT01085435|ICD
400338|NCT01085435|defibrillator
400339|NCT01085422|Prostate Cancer
400340|NCT01085409|experienced utility
400341|NCT01085409|decision utility
400342|NCT01085409|subjective well-being
400343|NCT01085409|experience sampling method
400344|NCT01085409|day reconstruction method
400345|NCT01085409|Quality of life
400346|NCT01085396|Fiber Optic
400347|NCT01085396|Melanoma
400348|NCT01085396|UV Exposure
400349|NCT01085383|Antipsychotic
400350|NCT01085383|hyperprolactinemia
400351|NCT01085383|hypogonadism
400352|NCT01085383|aripiprazole
400353|NCT01085370|posttraumatic stress
400354|NCT01085370|prevention
400355|NCT01085370|children
400356|NCT01085370|acute stress disorder due to burn injury or injuries associated with road traffic accidents
400357|NCT01085357|Glaucoma
400358|NCT01085357|Glaucoma device
400359|NCT01085357|Glaucoma surgery
400360|NCT01085357|Intraocular pressure
400361|NCT01085344|hemophilia, prophylaxis, cost effectiveness
400362|NCT01085331|Mek Inhibitor
400363|NCT01085331|Metastatic Colorectal Cancer
400364|NCT01085331|K-Ras Mutation
400365|NCT01085331|Phase II
400485|NCT01084785|genomics
400366|NCT01085331|Second line K-Ras mutated metastatic colorectal cancer
400367|NCT01085305|Behavior problems
400368|NCT01085305|Parent-Child Interaction
400369|NCT01085305|Locus of control
400370|NCT01085305|Psychiatric symptoms
400371|NCT01085305|Depressive symptoms
400372|NCT01085305|Attachment
400373|NCT01085279|fractional laser
400374|NCT01085279|melasma
400375|NCT01085279|topical bleaching
400376|NCT01085253|Parkinson's
400377|NCT01085253|supranuclear palsy
400378|NCT01085253|substantia nigra
400379|NCT01085253|sub thalamic nucleus
400380|NCT01085253|MRI
400381|NCT01085227|Parkinson's disease
400382|NCT01085227|LRRK2
400383|NCT01085227|asymptomatic carriers
400384|NCT01085201|lexiscan
400385|NCT01085175|Heart Failure,
400386|NCT01085175|PET Imaging,
400387|NCT01085175|Implantable Cardioverter-Defibrillator,
400388|NCT01085175|Sudden Cardiac Death
400389|NCT01085162|Coronary Artery Disease
400390|NCT01085162|PET imaging
400391|NCT01085162|SPECT imaging
400392|NCT01085149|simvastatin
400393|NCT01085149|alveolar bone
400394|NCT01085149|tooth extraction
400395|NCT01085149|remodeling
400396|NCT01085149|alveolar bone remodeling
400397|NCT01085123|Migraine
400398|NCT01085123|ZOMIG® Rapimelt
400399|NCT01085110|Groin hernia
400400|NCT01085110|Chronic pain
400401|NCT01085110|QST
400402|NCT01085110|Quantitative sensory testing
400403|NCT01085110|Persistent postoperative pain
400404|NCT01085110|Laparoscopic inguinal herniotomy
400405|NCT01085110|Postherniotomy Pain after laparoscopic inguinal herniotomy
400406|NCT01085110|laparoscopic inguinal hernia repair
400407|NCT01085097|Systemic Lupus Erythematosus (SLE)
400408|NCT01085097|Lupus Nephritis
400409|NCT01085097|Laquinimod
400410|NCT01085084|Systemic Lupus Erythematosus (SLE)
400411|NCT01085084|Lupus Arthritis
400412|NCT01085084|Laquinimod
400413|NCT01085071|intensive care unit
400414|NCT01085071|potassium
400415|NCT01085071|atrial fibrillation
400416|NCT01085071|cardiac surgery
400417|NCT01085071|Critically ill patients post CABG and/or valvular surgery
400418|NCT01085071|Critically ill patients not post CABG and/or valvular surgery
400419|NCT01085071|coronary artery bypass graft
400420|NCT01085058|Lymphoproliferative diseases (Hodgkin's disease, non-Hodgkin's lymphomas, multiple myelomas) and high-dose therapy
400421|NCT01085045|COPD
400422|NCT01085032|Smoking Cessation
400423|NCT01085032|Substance Withdrawal Syndrome
400424|NCT01085032|Depression
400425|NCT01085019|Endothelial function
400426|NCT01085019|Cardiovascular risk factors
400427|NCT01085019|Spices
400428|NCT01085019|Herbs
400429|NCT01085019|Antioxidant
400430|NCT01085006|cesarean delivery
400431|NCT01085006|Tranexamic acid
400432|NCT01085006|hemorrhage
400433|NCT01085006|Spinal analgesia
400434|NCT01085006|1-the amount of hemorrhage during cesarean delivery
400435|NCT01085006|2-the amount of hemorrhage in the first 2 hours of cesarean delivery
400436|NCT01085006|3-the amount of hemorrhage in the first 24 hour after cesarean delivery
400437|NCT01084993|Coronary artery stenting, transradial, intracoronary
400438|NCT01084980|minimal change disease
400439|NCT01084980|tacrolimus
400440|NCT01084980|corticosteroid
400441|NCT01084967|obesity
400442|NCT01084967|metabolic syndrome
400443|NCT01084967|genetic risk markers
400444|NCT01084967|copy number variation
400445|NCT01084954|HIV validation helicase-dependent amplification
400446|NCT01084941|pregnancy
400447|NCT01084941|weight gain
400448|NCT01084941|obesity
400449|NCT01084941|pregnancy and weight gain
400450|NCT01084928|diabetes
400451|NCT01084928|obesity
400452|NCT01084928|pre-diabetes
400453|NCT01084928|South Asian
400454|NCT01084915|Weight loss after SAGB VC band placement
400455|NCT01084902|POAG
400456|NCT01084902|OH
400457|NCT01084902|Xalatan
400458|NCT01084902|Azopt
400459|NCT01084902|Primary Open Angle Study
400460|NCT01084889|polypropylene mesh
400461|NCT01084889|Prolapse
400462|NCT01084889|Cystocele
400463|NCT01084889|Surgical Mesh
400464|NCT01084876|Herceptin
400465|NCT01084876|metastatic breast cancer
400466|NCT01084876|CT-P6
400467|NCT01084863|Herceptin
400468|NCT01084863|Her 2-positive
400469|NCT01084863|metastatic breast cancer
400470|NCT01084863|CT-P6
400471|NCT01084850|Corneal endothelium
400472|NCT01084850|diabetes mellitus
400473|NCT01084850|corneal thickness
400474|NCT01084837|Multiple myeloma
400475|NCT01084837|Renal failure
400476|NCT01084824|Warts
400477|NCT01084824|Verruca vulgaris
400478|NCT01084824|Liquid Nitrogen
400479|NCT01084824|Cantharidin
400480|NCT01084824|combination treatment
400481|NCT01084798|Multiple sclerosis
400482|NCT01084798|Expanded Disability Status Scale
400483|NCT01084798|Sclerosis
400484|NCT01084785|Cancer
400486|NCT01084785|proteomics
400487|NCT01084746|Colorectal Cancer Screening
400488|NCT01084746|Computer Interactive Intervention
400489|NCT01084746|Predictors
400490|NCT01084746|Cost Effective Analysis
400491|NCT01084746|Transtheoretical Model
400492|NCT01084707|Smoking Cessation, Nicotine pharmacokinetics
400493|NCT01084694|HSCT
400494|NCT01084694|Caregiver
400495|NCT01084694|Caregiver Burden
400496|NCT01084694|Allogeneic Transplant
400497|NCT01084694|Autologous Transplant
400498|NCT01084694|Hematopoietic Stem Cell Transplantation
400499|NCT01084681|SILK flow diverter, intracranial stents, intracranial aneurysms
400500|NCT01084668|moderate to severe chronic plaque psoriasis
400501|NCT01084668|adalimumab
400502|NCT01084668|Psoriasis Area and Severity Index (PASI)
400503|NCT01084668|Disease Life Quality Index (DLQI)
400504|NCT01084668|Nail Psoriasis Severity Index (NAPSI)
400505|NCT01084668|biologic disease modifying anti-rheumatic drug (BDMARD)
400506|NCT01084668|antibodies
400507|NCT01084668|monoclonals
400508|NCT01084642|Survey
400509|NCT01084642|Sexual Health Issues
400510|NCT01084642|10-034
400511|NCT01084629|Barrett's Esophagus
400512|NCT01084629|Surveillance
400513|NCT01084603|Smoking Cessation
400514|NCT01084603|Nicotine pharmacokinetics
400515|NCT01084590|Prevention
400516|NCT01084590|Obesity
400517|NCT01084590|Safety
400518|NCT01084590|Unhealthy weight gain
400519|NCT01084590|Injury prevention
400520|NCT01084564|Cost-effectiveness analysis
400521|NCT01084564|Colombia
400522|NCT01084538|paricalcitol iv
400523|NCT01084538|vitamin D
400524|NCT01084538|secondary hyperparathyroidism
400525|NCT01084538|hemodialysis
400526|NCT01084525|Meniere's Disease
400527|NCT01084525|Vertigo
400528|NCT01084525|Definitive vertigo
400529|NCT01084525|Vertigo episodes
400530|NCT01084525|Vertigo frequency
400531|NCT01084525|Tinnitus
400532|NCT01084525|Hearing loss
400533|NCT01084525|Aural Fullness
400534|NCT01084512|kinematic analysis,
400535|NCT01084512|three-compartment model,
400536|NCT01084512|chest wall motion,
400537|NCT01084512|spinal cord injury.
400538|NCT01084499|Healthy Subjects
400539|NCT01084486|nonalcoholic fatty liver disease
400540|NCT01084486|Pulse wave velocity
400541|NCT01084486|augmentation index
400542|NCT01084486|metformin
400543|NCT01084473|Dexmedetomidine
400544|NCT01084473|gastric emptying
400545|NCT01084473|oro-cecal transit time
400546|NCT01084473|Sedation in intensive care
400547|NCT01084473|Gastrointestinal effects of sedation
400548|NCT01084460|Gastrointestinal stromal tumor,endoscopic ultrasound,submucosal tumor
400549|NCT01084447|obesity
400550|NCT01084447|gastroplasty
400551|NCT01084447|respiratory muscle training
400552|NCT01084447|muscle strength
400553|NCT01084447|physical therapy
400554|NCT01084421|Adolescents
400555|NCT01084421|Parents
400556|NCT01084421|Computer Based
400557|NCT01084421|Latino
400558|NCT01084421|Sexual Communication
400559|NCT01084408|de-novo
400560|NCT01084408|coronary stenoses
400561|NCT01084408|PEPCAD
400562|NCT01084408|DEBonly
400563|NCT01084408|Paclitaxel
400564|NCT01084395|Parent
400565|NCT01084395|Adolescent
400566|NCT01084395|Mexico
400567|NCT01084395|Safer Sex Communication
400568|NCT01084395|Randomized Controlled Trial
400569|NCT01084395|HIV/AIDS
400570|NCT01084395|STD
400571|NCT01084395|Sexual Behavior
400572|NCT01084382|Arthrospira platensis
400573|NCT01084382|female HIV patient
400574|NCT01084382|Yaounde
400575|NCT01084382|Redox potential
400576|NCT01084382|Life quality
400577|NCT01084382|female patient infected by HIV in Yaounde: Cameroon
400578|NCT01084369|Type 2 diabetes
400579|NCT01084369|Hypogonadism
400580|NCT01084369|Testosterone
400581|NCT01084369|Endothelial dysfunction
400582|NCT01084356|CZT
400583|NCT01084356|sentinel node
400584|NCT01084356|osseous processes
400585|NCT01084343|vaccination
400586|NCT01084343|prophylaxis
400587|NCT01084330|gastric cancer
400588|NCT01084330|metastatic gastric cancer
400589|NCT01084330|advanced gastric cancer
400590|NCT01084317|asthma
400591|NCT01084317|children
400592|NCT01084317|delay in asthma diagnosis
400593|NCT01084304|Pregnancy
400594|NCT01084304|Ovulation tests
400595|NCT01084304|stress
400596|NCT01084304|Wishing to become pregnant
400597|NCT01084291|Vaccine
400598|NCT01084291|Dengue Hemorrhagic Fever
400599|NCT01084265|Hypogonadism
400600|NCT01084265|Recombinant human follicle stimulating hormone (r-hFSH)
400601|NCT01084265|Recombinant leutinizing hormone (r-hLH)
400602|NCT01084239|acute chest pain
400603|NCT01084239|emergency department
400604|NCT01084239|cardiac computed tomography
400605|NCT01084226|Rye fiber
400606|NCT01084226|Alkylresorcinols
400607|NCT01084226|Plant sterols
400608|NCT01084226|Cholesterol
400609|NCT01084226|Antioxidant
400610|NCT01084226|Effects of plant sterols in rye bread on serum lipids
400611|NCT01084226|Effects of alkylresorcinols in rye fiber on LDL particles
400612|NCT01084213|Low birth weight
400613|NCT01084213|Placenta malaria
400614|NCT01084213|Anaemia
400615|NCT01084213|Intermittent preventive treatment
400616|NCT01084213|Intermittent screening and treatment
400617|NCT01084213|Rapid diagnostic test
400618|NCT01084200|Postoperative pain
400619|NCT01084200|Sevoflurane
400620|NCT01084200|Propofol
400621|NCT01084200|Female
400622|NCT01084200|Elective gynaecological surgery
400623|NCT01084200|Laparoscopic and hysteroscopic surgery
400624|NCT01084200|Female patients
400625|NCT01084200|Undergoing elective laparoscopic and hysteroscopic surgery
400626|NCT01084187|erectile dysfunction
400627|NCT01084187|arterial hypertension
400628|NCT01084187|flow mediated vasodilation
400629|NCT01084187|endothelial dysfunction
400630|NCT01084187|carotid intima media thickness
400631|NCT01084187|vardenafil
400632|NCT01084174|Peanut Allergy
400633|NCT01084135|Clinical trial
400634|NCT01084135|Down syndrome
400635|NCT01084135|adolescents
400636|NCT01084135|cognitive
400637|NCT01084135|rivastigmine
400638|NCT01084122|Intravenous iron sucrose
400639|NCT01084122|Anemia
400640|NCT01084122|Transfusion
400641|NCT01084109|Complementary feeding
400642|NCT01084109|Infant growth
400643|NCT01084109|Developing countries
400644|NCT01084096|Antenatal Corticosteroids, Preterm Birth, Diffusion
400645|NCT01084083|human papilloma virus infection
400646|NCT01084083|stage III squamous cell carcinoma of the oropharynx
400647|NCT01084083|stage IV squamous cell carcinoma of the oropharynx
400648|NCT01084083|tongue cancer
400649|NCT01084070|early feeding
400650|NCT01084070|postoperative care
400651|NCT01084070|emergency surgery
400652|NCT01084018|acute postoperative pain
400653|NCT01084018|nursing intervention
400654|NCT01083992|NAFLD
400655|NCT01083992|Galvus
400656|NCT01083992|vitamin D
400657|NCT01083966|Vestibular
400658|NCT01083966|Schwannoma
400659|NCT01083966|earing-loss
400660|NCT01083966|brain-tumor
400661|NCT01083966|Acoustic
400662|NCT01083966|Neuroma
400663|NCT01083953|end tidal concentration
400664|NCT01083927|Pterygium
400665|NCT01083914|extracorporeal circulation, off-pump CABG
400666|NCT01083888|Pharmacokinetics
400667|NCT01083888|Safety and tolerability
400668|NCT01083888|Plasma concentration
400669|NCT01083888|ASP1517
400670|NCT01083888|FG-4592
400671|NCT01083875|Radiation
400672|NCT01083875|mucositis
400673|NCT01083875|head and neck carcinoma
400674|NCT01083875|oral rinse
400675|NCT01083875|amlexanox
400676|NCT01083875|MuGard
400677|NCT01083862|Health literacy
400678|NCT01083862|patient education
400679|NCT01083862|health behaviors
400680|NCT01083862|chronic disease management
400681|NCT01083862|shared decision-making
400682|NCT01083862|patient-centered decision making
400683|NCT01083849|Observational study
400684|NCT01083849|Paricalcitol
400685|NCT01083849|Treatment of Hyperparathyroidism
400686|NCT01083849|Chronic kidney disease stage 3, 4 and 5 (CKD stage 3, 4 and 5)
400687|NCT01083849|Chronic Kidney Disease
400688|NCT01083849|Zemplar
400689|NCT01083849|sHPT
400690|NCT01083849|Secondary
400691|NCT01083823|Mental health telemetry
400692|NCT01083823|Mood telemetry
400693|NCT01083823|Mood
400694|NCT01083823|Bipolar disorder
400695|NCT01083823|Affective instability
400696|NCT01083823|Cyclothymia
400697|NCT01083823|Electronic diaries
400698|NCT01083823|Mood diaries
400699|NCT01083823|Mood swings
400700|NCT01083810|Human Immunodeficiency Virus
400701|NCT01083810|Infection
400702|NCT01083810|Kaletra
400703|NCT01083810|Resistance
400704|NCT01083810|Mutations
400705|NCT01083810|alternative Therapy regimen
400706|NCT01083797|Sedation
400707|NCT01083797|Electroencephalography
400708|NCT01083797|Dexmedetomidine
400709|NCT01083797|Chloral hydrate
400710|NCT01083784|Cardiac arrest
400711|NCT01083784|Prophylactic anticonvulsant
400712|NCT01083719|Glioblastoma
400713|NCT01083719|FDG-PET
400714|NCT01083719|MRI
400715|NCT01083693|Monoclonals
400716|NCT01083693|Antibodies
400717|NCT01083693|Ankylosing Spondylitis
400718|NCT01083693|Antirheumatic Agents
400719|NCT01083693|Quality of Life
400720|NCT01083693|Adalimumab
400721|NCT01083693|rheumatoid arthritis
400722|NCT01083693|psoriatic arthritis
400723|NCT01083680|Routine clinical setting
400724|NCT01083680|Long-term efficacy and safety
400725|NCT01083680|Crohn's Disease
400726|NCT01083680|Humira
400727|NCT01083667|ALS
400728|NCT01083667|Familial ALS
400729|NCT01083667|SOD1 Gene Mutation
400730|NCT01083654|Smoking
400731|NCT01083654|Smoking cessation
400732|NCT01083641|Breast Cancer
400733|NCT01083615|CRPC patients with cancer related pain
400734|NCT01083615|CRPC
400735|NCT01083615|HRPC
400736|NCT01083602|Multiple Myeloma
400737|NCT01083602|Relapsed Multiple Myeloma
400738|NCT01083602|Refractory Multiple Myeloma
400739|NCT01083589|Lung Cancer
400740|NCT01083589|Metastatic NSCLC
400741|NCT01083589|Tumor
400742|NCT01083589|Imatinib Mesylate
400743|NCT01083589|Gleevec
400744|NCT01083589|Docetaxel
400745|NCT01083589|Taxotere
400746|NCT01083576|leishmaniasis
400747|NCT01083576|cutaneous
400748|NCT01083576|WR 279,396
400749|NCT01083576|paromomycin
400750|NCT01083576|gentamicin
400751|NCT01083576|pharmacokinetics
400752|NCT01083576|safety
400753|NCT01083576|efficacy
400754|NCT01083563|TNF
400755|NCT01083563|CD20
400756|NCT01083563|RA
400757|NCT01083550|thyroid carcinoma
400758|NCT01083550|thyroid cancer
400759|NCT01083550|therapeutic radioisotopes
400760|NCT01083550|radioactive iodine
400761|NCT01083537|malignant bowel obstruction
400762|NCT01083537|ovarian cancer
400763|NCT01083537|Peritoneal cancer
400764|NCT01083537|Fallopian Tube cancer
400765|NCT01083524|Pulmonary arterial hypertension
400766|NCT01083524|Pulmonary hypertension
400767|NCT01083524|Dichloroacetate
400768|NCT01083524|Dichloroacetate Sodium
400769|NCT01083524|DCA
400770|NCT01083511|Influenza
400771|NCT01083511|Influenza A
400772|NCT01083511|Influenza B
400773|NCT01083511|Swine Influenza A/H1N1
400774|NCT01083511|Respiratory Virus
400775|NCT01083498|Becker's nevus
400776|NCT01083498|ablative fractional laser therapy
400777|NCT01083498|randomized controlled trial
400778|NCT01083498|split-lesion design
400779|NCT01083485|Oxycodone
400780|NCT01083485|Naloxone
400781|NCT01083485|Postoperative pain
400782|NCT01083485|Arthroplasty
400783|NCT01083485|Efficacy
400784|NCT01083472|dehiscence
400785|NCT01083472|laparotomy
400786|NCT01083472|Hernia repair
400787|NCT01083472|surgical wound
400788|NCT01083472|surgical mesh
400789|NCT01083446|Encephalopathy
400790|NCT01083446|Cirrhotics
400791|NCT01083433|Continuous Glucose Monitor
400792|NCT01083433|Adherence
400793|NCT01083433|Adolescents
400794|NCT01083433|Diabetes Education
400795|NCT01083420|Oral lichen planus
400796|NCT01083420|Minocycline
400797|NCT01083420|Dexamethasone
400798|NCT01083407|Oral care.
400799|NCT01083407|Chlorhexidine.
400800|NCT01083407|Pediatric Nursing
400801|NCT01083407|Intensive Care
400802|NCT01083407|Nosocomial infection
400803|NCT01083407|Pneumonia
400804|NCT01083407|Oropharyngeal colonization
400805|NCT01083407|Tracheal colonization
400806|NCT01083394|PTA
400807|NCT01083394|paclitaxel
400808|NCT01083394|restenosis
400809|NCT01083381|Schizophrenia treatment MS14 randomized clinical trial
400810|NCT01083368|adenocarcinoma of the prostate
400811|NCT01083368|hormone-resistant prostate cancer
400812|NCT01083368|recurrent prostate cancer
400813|NCT01083368|stage IV prostate cancer
400814|NCT01083355|Variable ventilation
400815|NCT01083355|Pressure regulated volume control ventilation
400816|NCT01083355|Airway pressure release ventilation
400817|NCT01083342|primary CNS lymphoma
400818|NCT01083342|MTX: Methotrexate,Leucovorin
400819|NCT01083342|MVD: Methotrexate,Vincristine,Dexamethasone
400820|NCT01083342|VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
400821|NCT01083342|Newly diagnosed primary CNS lymphoma patients
400822|NCT01083329|nicotinic acid
400823|NCT01083329|lipolysis
400824|NCT01083329|training program
400825|NCT01083329|adipose tissue inflammation
400826|NCT01083329|obese
400827|NCT01083316|Amyloid
400828|NCT01083316|Amyloidosis
400829|NCT01083316|AL Amyloidosis
400830|NCT01083316|Primary Amyloidosis
400831|NCT01083316|Stem Cell Transplant
400832|NCT01083303|energy expenditure
400833|NCT01083303|hypothermia
400834|NCT01083303|body temperature
400835|NCT01083303|weaning
400836|NCT01083303|preterm infants
400837|NCT01083290|spironolactone
400838|NCT01083290|linearity of pharmacokinetics
400839|NCT01083290|Healthy volunteers
400840|NCT01083277|oxygenation
400841|NCT01083277|ventilation
400842|NCT01083277|tidal volume
400843|NCT01083277|patterns of breathing
400844|NCT01083277|variable ventilation
400845|NCT01083277|mechanical ventilation
400846|NCT01083264|Pharmacokinetics
400847|NCT01083251|HBV
400848|NCT01083251|VITAMIN D
400849|NCT01083251|PEGITERFERON
400850|NCT01083251|Telbivudine
400851|NCT01083238|pharmacokinetics
400852|NCT01083238|fasting or after a high fat meal
400853|NCT01083238|adult
400854|NCT01083238|elderly adult
400855|NCT01083238|COPD
400856|NCT01083212|Type 2 Diabetes Mellitus
400857|NCT01083212|Gemfibrozil
400858|NCT01083199|Prostate Cancer
400859|NCT01083199|Radical Prostatectomy
400860|NCT01083199|Vesico-Urethral Anastomosis
400861|NCT01083186|Secondary Hyperparathyroidism
400862|NCT01083186|Chronic Kidney Failure
400863|NCT01083173|Postmarketing Drug Surveillance
400864|NCT01083173|HIV-1 infection
400865|NCT01083173|Kaletra
400866|NCT01083160|Rheumatoid Arthritis
400867|NCT01083160|Anti-TNF
400868|NCT01083160|Adalimumab
400869|NCT01083160|Infliximab
400870|NCT01083160|Etanercept
400871|NCT01083147|Intermediate AMD
400872|NCT01083134|CAD
400873|NCT01083121|Postmarketing Drug Surveillance
400874|NCT01083108|Behavioral Weight Loss Treatment
400875|NCT01083108|Bariatric Surgery
400876|NCT01083108|Diabetes Type II
400877|NCT01083108|Obesity
400878|NCT01083108|Adult
400879|NCT01083108|Type 2 Diabetes
400880|NCT01083095|Malaria
400881|NCT01083095|Sporozoite
400882|NCT01083095|Challenge Model
400883|NCT01083095|Plasmodium vivax
400884|NCT01083095|Human Volunteers
400885|NCT01083082|lifestyles
400886|NCT01083082|diet
400887|NCT01083082|exercise
400888|NCT01083082|central blood pressure
400889|NCT01083082|arterial stiffness
400890|NCT01083082|endothelial dysfunction
400891|NCT01083082|Healthy people
400892|NCT01083069|Sudden cardiac arrest
400893|NCT01083069|hypothermia
400894|NCT01083069|neurological outcome
400895|NCT01083056|retina
400896|NCT01083056|gliosis
400897|NCT01083056|macula
400898|NCT01083056|membrane
400899|NCT01083056|ILM
400900|NCT01083043|Glycemic Variability
400901|NCT01083043|Endothelial Dysfunction
400902|NCT01083030|pAVK
400903|NCT01083030|PTA
400904|NCT01083030|drug coated balloon
400905|NCT01083004|dye
400906|NCT01083004|internal limiting membrane
400907|NCT01083004|macular hole
400908|NCT01083004|macular pucker
400909|NCT01082978|Quality of Life
400910|NCT01082978|Health Care Quality and Safety
400911|NCT01082978|Randomized controlled trial
400912|NCT01082965|ASL MRI
400913|NCT01082965|perfusion
400914|NCT01082965|cognition
400915|NCT01082965|donepezil
400916|NCT01082965|alzheimer's disease
400917|NCT01082965|translational medicine
400918|NCT01082939|Chronic lymphocytic leukemia
400919|NCT01082939|Refractory CLL
400920|NCT01082939|CFAR
400921|NCT01082939|Alemtuzumab
400922|NCT01082939|Campath-1H
400923|NCT01082939|Campath
400924|NCT01082939|Cyclophosphamide
400925|NCT01082939|Cytoxan
400926|NCT01082939|Neosar
400927|NCT01082939|Fludarabine
400928|NCT01082939|Fludara
400929|NCT01082939|Fludarabine Phosphate
400930|NCT01082939|Rituximab
400931|NCT01082939|Rituxan
400932|NCT01082939|CLL
400933|NCT01082926|adult anaplastic astrocytoma
400934|NCT01082926|adult anaplastic ependymoma
400935|NCT01082926|adult anaplastic meningioma
400936|NCT01082926|adult anaplastic oligodendroglioma
400937|NCT01082926|adult brain stem glioma
400938|NCT01082926|adult ependymoblastoma
400939|NCT01082926|adult giant cell glioblastoma
400940|NCT01082926|adult glioblastoma
400941|NCT01082926|adult gliosarcoma
400942|NCT01082926|adult grade III meningioma
400943|NCT01082926|adult meningeal hemangiopericytoma
400944|NCT01082926|adult mixed glioma
400945|NCT01082926|adult pineal gland astrocytoma
400946|NCT01082926|recurrent adult brain tumor
400947|NCT01082926|Los Angeles
400948|NCT01082900|Transient Tachypnea of the Newborn
400949|NCT01082900|Elective Cesarean section
400950|NCT01082900|Late preterm
400951|NCT01082900|CPAP
400952|NCT01082900|Delivery Room
400953|NCT01082887|Immunotherapy TIL (Tumor Infiltrating Lymphocytes)
400954|NCT01082887|Intra-tumoral injection
400955|NCT01082887|Interferon gamma-adenovirus(Ad-IFNg)
400956|NCT01082887|Metastatic melanoma
400957|NCT01082887|A stage IIIc/IV metastatic melanoma with nodal relapse
400958|NCT01082887|in transit metastasis
400959|NCT01082887|cutaneous unresectable metastases
400960|NCT01082887|visceral metastases
400961|NCT01082874|Randomized Controlled Trial
400962|NCT01082874|Blinded
400963|NCT01082874|Clonidine
400964|NCT01082874|acetyl-salicylic acid (ASA)
400965|NCT01082874|Perioperative vascular complications
400966|NCT01082874|Noncardiac surgery
400967|NCT01082861|1998 female birth cohort eligible for HPV vaccination in 2011 within the Dutch NIP
400968|NCT01082835|Chinese herbs
400969|NCT01082822|cell sheet PDLSC periodontitis
400970|NCT01082809|advanced biliary tract carcinoma
400971|NCT01082809|Sunitinib
400972|NCT01082783|stroke-induced immunodepression
400973|NCT01082783|acute media infarct
400974|NCT01082783|acute intracerebral bleeding
400975|NCT01082783|leucocytes
400976|NCT01082783|autoaggressive T-cells
400977|NCT01082783|acute media infarct or acute intracerebral bleeding
400978|NCT01082757|Colorectal neoplasms
400979|NCT01082757|metastasis
400980|NCT01082757|colorectal cancer
400981|NCT01082744|Paravertebral Block
400982|NCT01082744|Regional Anesthesia
400983|NCT01082744|Anesthetics Local
400984|NCT01082744|Ropivacaine
400985|NCT01082744|Sufentanil
400986|NCT01082744|Pain Postoperative
400987|NCT01082744|Chronic Pain
400988|NCT01082744|Thoracic Surgery Video-Assisted.
400989|NCT01082731|Malaria
400990|NCT01082731|Plasmodium falciparum
400991|NCT01082731|Treatment
400992|NCT01082731|Brazil
400993|NCT01082718|Malaria
400994|NCT01082718|Pregnancy
400995|NCT01082718|Pharmacokinetics
400996|NCT01082718|Brazil
400997|NCT01082705|malaria
400998|NCT01082705|treatment
400999|NCT01082705|artemisinin combination therapy
401000|NCT01082705|Tanzania
401001|NCT01082705|P. falciparum malaria in children age 6-59 months
401002|NCT01082692|HIV Infection
401003|NCT01082692|DNA vaccine
401004|NCT01082692|Electroporation
401005|NCT01082692|HIV therapeutic vaccine
401006|NCT01082679|opioid dependent
401007|NCT01082679|methadone
401008|NCT01082679|Suboxone
401009|NCT01082679|buprenorphine
401010|NCT01082666|Cuff pressure
401011|NCT01082666|microaspiration
401012|NCT01082666|pepsin
401013|NCT01082666|VAP
401014|NCT01082666|Mechanical ventilation
401015|NCT01082653|ALS
401016|NCT01082653|Lou Gehrig's Disease
401017|NCT01082640|Gout
401018|NCT01082640|physiology
401019|NCT01082640|Hyperuricemia
401020|NCT01082640|Uric Acid
401021|NCT01082640|Drug Therapy
401022|NCT01082627|Somatostatin small bowel obstruction
401023|NCT01082601|Catheter Ablation
401024|NCT01082601|Atrial Fibrillation
401025|NCT01082601|Congestive heart failure
401026|NCT01082588|schizophrenia
401027|NCT01082588|pravastatin
401028|NCT01082588|inflammation
401029|NCT01082588|cognition
401030|NCT01082588|antipsychotics
401031|NCT01082588|cholesterol
401032|NCT01082575|Post Op Patients
401033|NCT01082575|Continuous Pulse Oximetry Monitoring
401034|NCT01082575|Major Surgery
401035|NCT01082549|Patients with Previously Untreated Advanced Squamous Cell Lung Cancer
401036|NCT01082536|Pediatrics
401037|NCT01082536|Congenital heart disease
401038|NCT01082536|NIRS
401039|NCT01082536|Brain oxygenation
401040|NCT01082510|UFT
401041|NCT01082510|BCG
401042|NCT01082497|Mindfulness
401043|NCT01082497|Stress
401044|NCT01082497|Burnout
401045|NCT01082497|Ward atmosphere
401046|NCT01082497|Stress and burnout among staff, psychosocial atmosphere at the ward
401047|NCT01082484|Healthy volunteers
401048|NCT01082484|iontophoresis
401049|NCT01082471|Morphine 6-glucuronide
401050|NCT01082471|Morphine
401051|NCT01082471|Patient Controlled Analgesia
401052|NCT01082471|Post Operative Nausea and Vomiting
401053|NCT01082458|Patients scheduled to undergo thyroidectomy
401054|NCT01082445|stage C
401055|NCT01082445|grade 0 (Texas University)
401056|NCT01082432|thumb
401057|NCT01082432|Ulnar collateral ligament
401058|NCT01082432|superimposed electrical stimulation
401059|NCT01082432|stiffness
401060|NCT01082432|adhesions
401061|NCT01082419|Liver stiffness measurement
401062|NCT01082419|ARFI
401063|NCT01082419|fibrosis
401064|NCT01082419|hepatopathy
401065|NCT01082393|vitiligo
401066|NCT01082380|radiolabeled
401067|NCT01082380|healthy volunteers
401068|NCT01082367|Tobramycin Inhalation solution
401069|NCT01082367|Cystic fibrosis
401070|NCT01082367|Lung disease
401071|NCT01082367|anti-bacterial agents
401072|NCT01082354|Infant, Low birth weight
401073|NCT01082354|Infant, Low birth height
401074|NCT01082354|Infant, Small for Gestational Age
401075|NCT01082341|GCP Good Clinical Practice
401076|NCT01082341|IFAT Indirect Immunofluorescence antibody test
401077|NCT01082341|MFA Membrane Feeding Assay
401078|NCT01082341|N Number (typically refers to subjects)
401079|NCT01082341|RBC Red Blood Cells
401080|NCT01082341|SOP Standard Operating Procedure
401081|NCT01082341|TBS Thick blood smear
401082|NCT01082341|P. Vivax
401083|NCT01082341|irradiated sporozoite vaccination.
401084|NCT01082328|Phenylketonuria (PKU)
401085|NCT01082328|Hyperphenylalaninemia (HPA)
401086|NCT01082328|Kuvan®
401087|NCT01082328|Sapropterin dihydrochloride
401088|NCT01082328|Kuvan responder
401089|NCT01082328|Tetrahydrobiopterin (BH4)
401090|NCT01082315|Colorectal cancer
401091|NCT01082315|Neoplasm metastasis
401092|NCT01082315|Cetuximab
401093|NCT01082315|Erbitux
401094|NCT01082315|EGFR
401095|NCT01082302|green tea extract
401096|NCT01082302|Polyphenon E
401097|NCT01082302|Pharmacokinetics
401098|NCT01082289|Lurasidone
401099|NCT01082289|Schizophrenia
401100|NCT01082289|Latuda
401223|NCT01081808|Antineoplastic Agents
401101|NCT01082276|Rifampin DDI with Lurasidone HCl
401102|NCT01082263|DDI study between Midazolam and Lurasidone HCl
401103|NCT01082263|Male and Female
401104|NCT01082250|Bioequivalence
401105|NCT01082250|Male/Female Patient
401106|NCT01082250|Reference/Test Formulation
401107|NCT01082250|Schizophrenia Patients
401108|NCT01082237|Major Depressive Disorder
401109|NCT01082237|EEG
401110|NCT01082237|SSRI
401111|NCT01082224|adult primary hepatocellular carcinoma
401112|NCT01082224|localized unresectable adult primary liver cancer
401113|NCT01082224|recurrent adult primary liver cancer
401114|NCT01082211|invasive ductal breast carcinoma
401115|NCT01082211|medullary ductal breast carcinoma with lymphocytic infiltrate
401116|NCT01082211|invasive lobular breast carcinoma
401117|NCT01082211|tubular ductal breast carcinoma
401118|NCT01082211|mucinous ductal breast carcinoma
401119|NCT01082211|ductal breast carcinoma in situ
401120|NCT01082211|lobular breast carcinoma in situ
401121|NCT01082211|recurrent breast cancer
401122|NCT01082198|stage III melanoma
401123|NCT01082185|abdominal
401124|NCT01082185|aortic
401125|NCT01082185|aneurysm
401126|NCT01082185|AAA
401127|NCT01082172|thoracic
401128|NCT01082172|aortic
401129|NCT01082172|aneurysm
401130|NCT01082172|TAA
401131|NCT01082159|Spinal Stenosis
401132|NCT01082159|Lumbar Spinal Stenosis
401133|NCT01082146|pharmacokinetics, lurasidone
401134|NCT01082133|Fanconi Anemia
401135|NCT01082120|Type 2 Diabetes Mellitus
401136|NCT01082120|Pioglitazone
401137|NCT01082094|Ischemic heart failure
401138|NCT01082094|Congestive heart failure
401139|NCT01082094|Stromal cell-derived factor 1
401140|NCT01082094|SDF-1
401141|NCT01082094|Gene therapy
401142|NCT01082081|paracetamol
401143|NCT01082081|dental pain
401144|NCT01082081|Post-surgical dental pain
401145|NCT01082068|HER2 negative
401146|NCT01082068|Hormone Receptor Positive
401147|NCT01082068|Breast Neoplasms
401148|NCT01082055|Cardiac
401149|NCT01082055|Dysrhythmia
401150|NCT01082055|Safety
401151|NCT01082042|Balance, postural
401152|NCT01082042|Aged, over 70
401153|NCT01082042|Exercise
401154|NCT01082042|Accidental falls
401155|NCT01082016|Sleep
401156|NCT01082016|Critical Illness
401157|NCT01082016|Sleep promotion during recovery form illness
401158|NCT01082003|Capsular contractures in breast cancer patients
401159|NCT01081977|Delayed cord clamping
401160|NCT01081977|Ferritin
401161|NCT01081977|Hemoglobin
401162|NCT01081977|Neonatal anemia
401163|NCT01081977|Postpartum haemorrhage
401164|NCT01081977|Neonatal jaundice
401165|NCT01081964|pneumonia
401166|NCT01081964|Community acquired pneumonia of moderate severity
401167|NCT01081951|Poly(ADP ribose)
401168|NCT01081951|polymerisation (PARP)
401169|NCT01081951|Platinum sensitive
401170|NCT01081951|Advanced Serous Ovarian cancer
401171|NCT01081951|olaparib
401172|NCT01081951|PARP inhibitors
401173|NCT01081951|Platinum Sensitive Advanced Serous Ovarian Cancer
401174|NCT01081925|Congestive Heart Failure
401175|NCT01081925|Cardiac Failure
401176|NCT01081912|chronic pain
401177|NCT01081912|back pain
401178|NCT01081899|dying patients
401179|NCT01081899|cancer
401180|NCT01081899|hospital
401181|NCT01081899|Liverpool Care Pathways
401182|NCT01081886|Total knee arthroplasty
401183|NCT01081886|PlasmaBlade
401184|NCT01081886|Electrosurgery
401185|NCT01081886|PEAK Surgical
401186|NCT01081886|Medtronic Advanced Energy
401187|NCT01081886|Medtronic
401188|NCT01081873|Multicenter study
401189|NCT01081860|Carpal tunnel syndrome
401190|NCT01081860|CTS
401191|NCT01081860|Skinstiffness
401192|NCT01081860|Jointstiffness
401193|NCT01081847|Malaria
401194|NCT01081847|Synthetic peptides
401195|NCT01081847|Plasmodium vivax
401196|NCT01081847|Human volunteers
401197|NCT01081834|Diabetes Mellitus, Type 2
401198|NCT01081834|Canagliflozin
401199|NCT01081834|Placebo
401200|NCT01081834|Hemoglobin A1c
401201|NCT01081834|Type 2 diabetes mellitus
401202|NCT01081821|JNJ 39758979
401203|NCT01081821|Japanese descent
401204|NCT01081808|PhaseI
401205|NCT01081808|Solid Tumor
401206|NCT01081808|biomarkers
401207|NCT01081808|T cell
401208|NCT01081808|Cetuximab
401209|NCT01081808|Epidermal Growth Factor Receptor
401210|NCT01081808|Aldesleukin
401211|NCT01081808|Lymphocytes
401212|NCT01081808|Autologous
401213|NCT01081808|Recurrent
401214|NCT01081808|Refractory
401215|NCT01081808|Metastatic
401216|NCT01081808|Immunotherapy
401217|NCT01081808|Antibodies
401218|NCT01081808|Neoplasms by Site
401219|NCT01081808|Anti-Retroviral Agents
401220|NCT01081808|Therapeutic Uses
401221|NCT01081808|Anti-Infective Agents
401222|NCT01081808|Neoplasms by Histologic Type
401224|NCT01081808|Antiviral Agents
401225|NCT01081808|Pharmacologic Actions
401226|NCT01081808|Carcinoma
401227|NCT01081808|Neoplasms
401228|NCT01081795|Topiramate
401229|NCT01081795|Migraine
401230|NCT01081782|Multiple Sclerosis
401231|NCT01081782|ONO-4641
401232|NCT01081769|Schizophrenia
401233|NCT01081769|paliperidone palmitate
401234|NCT01081769|Invega
401235|NCT01081769|Intramuscular injection
401236|NCT01081769|Oral antipsychotics
401237|NCT01081769|Relapse
401238|NCT01081756|Reproductive technology; Assisted
401239|NCT01081756|recombinant human chorionic hormone (r-hCG)
401240|NCT01081743|Alzheimer
401241|NCT01081743|Dementia
401242|NCT01081743|Mild to moderately severe
401243|NCT01081743|New diagnosis
401244|NCT01081743|Prevention of behavioural problems
401245|NCT01081730|psoriasis
401246|NCT01081730|ustekinumab
401247|NCT01081730|anti-TNF biologics
401248|NCT01081730|non-anti-TNF biologics
401249|NCT01081730|systemic non-biological treatments
401250|NCT01081717|Rheumatoid arthritis
401251|NCT01081717|psoriatic arthritis
401252|NCT01081717|ankylosing spondylitis
401253|NCT01081717|golimumab
401254|NCT01081717|anti-TNF biologics
401255|NCT01081717|non-anti-TNF biologics
401256|NCT01081717|non-biological treatments
401257|NCT01081704|Healthy volunteer
401258|NCT01081704|Chinese male
401259|NCT01081704|Stelara
401260|NCT01081691|CNTO 5825
401261|NCT01081691|Safety
401262|NCT01081691|Phase I
401263|NCT01081691|Healthy adults
401264|NCT01081691|Healthy Atopic adults
401265|NCT01081678|AMG 785
401266|NCT01081678|Proximal Femur
401267|NCT01081678|Fracture Healing
401268|NCT01081678|Hip Fracture
401269|NCT01081665|Chronic Kidney Failure
401270|NCT01081665|Secondary Hyperparathyroidism
401271|NCT01081665|Paricalcitol IV treatment
401272|NCT01081665|Safety and efficacy assessment
401273|NCT01081652|Fertilisation, In vitro
401274|NCT01081652|Embryo transfer
401275|NCT01081652|progesterone
401276|NCT01081652|Reproductive technologies, Assisted
401277|NCT01081639|Follitropin alfa
401278|NCT01081639|Follitropin beta
401279|NCT01081639|Fertilization, in vitro
401280|NCT01081639|Intracytoplasmic sperm injection
401281|NCT01081639|Assisted reproductive techniques
401282|NCT01081639|Polycystic ovary syndrome
401283|NCT01081626|Infertility
401284|NCT01081626|Ovulation induction
401285|NCT01081626|Gonal-f
401286|NCT01081626|Follitropin alpha
401287|NCT01081626|Polycystic ovarian syndrome
401288|NCT01081626|Anovulatory infertility
401289|NCT01081613|heat shock protein
401290|NCT01081613|breast cancer
401291|NCT01081613|PET imaging
401292|NCT01081613|bevacizumab
401293|NCT01081600|Heat shock protein
401294|NCT01081600|breast cancer
401295|NCT01081600|PET imaging
401296|NCT01081600|trastuzumab
401297|NCT01081587|Non MeSH terms:
401298|NCT01081587|Children
401299|NCT01081587|Malnutrition
401300|NCT01081587|Computer Clinical Decision Support System
401301|NCT01081587|Cluster randomized trial
401302|NCT01081587|Healthcare workers
401303|NCT01081587|Guideline adherence
401304|NCT01081587|Patient safety
401305|NCT01081587|MeSH terms:
401306|NCT01081587|Nutrition Surveys
401307|NCT01081587|Secondary Prevention
401308|NCT01081587|Pediatrics
401309|NCT01081587|Child Care
401310|NCT01081587|Health Personnel
401311|NCT01081587|Reminder Systems
401312|NCT01081587|Intervention Studies
401313|NCT01081587|Quality of Health Care
401314|NCT01081574|Allergic Rhinitis
401315|NCT01081574|Seasonal Allergic Rhinitis
401316|NCT01081574|Perennial Allergic Rhinitis
401317|NCT01081574|Urticaria
401318|NCT01081574|Chronic Idiopathic Urticaria
401319|NCT01081574|Allergy
401320|NCT01081574|Sneezing
401321|NCT01081574|Nasal Itching
401322|NCT01081574|Rhinorrhea
401323|NCT01081574|Nasal Congestion
401324|NCT01081574|Wheals
401325|NCT01081574|Hives
401326|NCT01081574|Skin itching
401327|NCT01081574|Flare
401328|NCT01081574|Erythema
401329|NCT01081535|Pediatric patients (6 months-5 years) scheduled elective ureteroneocystostomy
401330|NCT01081509|adherence
401331|NCT01081509|early breast cancer
401332|NCT01081509|Arimidex
401333|NCT01081509|Therapy adherence
401334|NCT01081496|EGFR mutation, Non-small cell lung carcinoma, Spain
401335|NCT01081496|Evaluate the prevalence of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC
401336|NCT01081483|Healthy Volunteers
401337|NCT01081483|HCV Infections
401338|NCT01081457|Parkinson's disease
401339|NCT01081457|deep brain stimulation
401340|NCT01081457|GI motility
401341|NCT01081444|repetitive transcranial stimulation
401342|NCT01081431|Myelodysplastic Syndromes
401343|NCT01081431|MDS
401344|NCT01081431|deletion 5q
401345|NCT01081431|del 5q
401346|NCT01081431|IPSS
401347|NCT01081431|low risk
401348|NCT01081431|intermediate-1 risk
401349|NCT01081431|GMIHO
401350|NCT01081431|ClinAssess
401351|NCT01081431|Germing
401352|NCT01081431|Düsseldorf
401353|NCT01081431|MDS-LE-MON-5
401354|NCT01081431|Lenalidomide
401355|NCT01081431|Revlimid
401356|NCT01081418|Schizophrenia, assertive community treatment, quetiapine
401357|NCT01081405|ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
401358|NCT01081405|TOTAL LYMPHOID IRRADIATION
401359|NCT01081405|ANTI-THYMOCYTE GLOBULIN
401360|NCT01081392|LPS
401361|NCT01081392|endotoxin
401362|NCT01081392|inflammatory markers
401363|NCT01081392|healthy volunteers
401364|NCT01081392|neutrophils in sputum
401365|NCT01081379|Cytomegalovirus Infections
401366|NCT01081379|Pregnancy
401367|NCT01081379|T-Lymphocytes
401368|NCT01081379|Transmission
401369|NCT01081353|Aspirin
401370|NCT01081353|Acetylsalicylic Acid
401371|NCT01081340|gestational weight gain
401372|NCT01081340|postpartum weight loss
401373|NCT01081340|breastfeeding
401374|NCT01081340|overfeeding
401375|NCT01081327|Atrial Fibrillation
401376|NCT01081327|Warfarin
401377|NCT01081327|Safety
401378|NCT01081301|hope
401379|NCT01081301|quality of life
401380|NCT01081301|caregivers
401381|NCT01081288|Breast cancer
401382|NCT01081288|Breast screening
401383|NCT01081288|Mammography
401384|NCT01081288|Routine screening programme
401385|NCT01081275|Multiple Sclerosis
401386|NCT01081275|MS
401387|NCT01081275|CI Therapy
401388|NCT01081275|CIMT
401389|NCT01081275|Constraint-Induced Movement Therapy
401390|NCT01081275|Complementary and Alternative Medicine
401391|NCT01081275|CAM
401392|NCT01081275|Physical Therapy
401393|NCT01081275|Occupational Therapy
401394|NCT01081275|Relaxation
401395|NCT01081275|Exercise
401396|NCT01081275|Massage
401397|NCT01081275|Yoga
401398|NCT01081275|Pool Therapy
401399|NCT01081275|Aquatherapy
401400|NCT01081275|Aquatic Therapy
401401|NCT01081249|psychotherapy
401402|NCT01081236|liver cirrhosis
401403|NCT01081236|intestinal permeability
401404|NCT01081236|microbiota
401405|NCT01081236|complications
401406|NCT01081223|Brain Neoplasms
401407|NCT01081223|Central Nervous System Neoplasms
401408|NCT01081223|Brain Diseases
401409|NCT01081223|Neoplasms
401410|NCT01081223|Nervous System Neoplasms
401411|NCT01081223|Glioblastoma
401412|NCT01081223|Astrocytoma
401413|NCT01081223|Nervous System Diseases
401414|NCT01081223|Central Nervous System Diseases
401415|NCT01081223|Glioma
401416|NCT01081223|Recurrent astrocytoma
401417|NCT01081223|Recurrent glioma
401418|NCT01081223|Cancer vaccine
401419|NCT01081223|Immunotherapy
401420|NCT01081223|Killer T cells
401421|NCT01081223|Activated T cells
401422|NCT01081223|GM-CSF
401423|NCT01081223|Low dose IL-2
401424|NCT01081223|Activated lymphocytes
401425|NCT01081210|Echocardiography
401426|NCT01081210|Heart failure
401427|NCT01081210|Kidney
401428|NCT01081210|Lung
401429|NCT01081210|Aorta
401430|NCT01081197|heart failure
401431|NCT01081197|liver
401432|NCT01081197|depression
401433|NCT01081197|neuropathy
401434|NCT01081184|primary Sjögren syndrome
401435|NCT01081184|neurotrophins
401436|NCT01081184|B cell
401437|NCT01081184|sicca syndrome
401438|NCT01081184|T cell
401439|NCT01081119|adolescent
401440|NCT01081119|middle school
401441|NCT01081119|prevention
401442|NCT01081119|alcohol
401443|NCT01081119|cigarettes
401444|NCT01081119|marijuana
401445|NCT01081106|Breast Cancer
401446|NCT01081093|Hypertrophic Cardiomyopathy Diastolic Ventricular Interaction
401447|NCT01081093|Biventricular Pacemaker cardiac surgery aortic valve replacement
401448|NCT01081080|cardiac
401449|NCT01081080|muscle
401450|NCT01081080|pediatric
401451|NCT01081080|dystrophy
401452|NCT01081054|Diverticulitis
401453|NCT01081054|Not complicated diverticulitis
401454|NCT01081028|Multiple Myeloma
401455|NCT01081028|MM
401456|NCT01081028|disease registry
401457|NCT01081028|Connect®
401458|NCT01081015|Chronic Lymphocytic Leukemia
401459|NCT01081015|CLL
401460|NCT01081015|disease registry
401461|NCT01081015|Connect™
401462|NCT01081002|Propofol
401463|NCT01081002|Conscious sedation
401464|NCT01081002|Topical pharyngeal anesthesia
401465|NCT01081002|Anesthetics, Local
401466|NCT01081002|Gastrointestinal Endoscopy
401467|NCT01080989|solomon islands
401468|NCT01080989|malaria
401469|NCT01080989|flavivirus
401470|NCT01080989|alphavirus
401471|NCT01080989|parasite
401472|NCT01080989|leptospirosis
401473|NCT01080963|Prophylaxis
401474|NCT01080963|Antibiotic
401475|NCT01080963|Sternotomy
401476|NCT01080963|Heart-Lung Machine
401477|NCT01080950|zinc
401478|NCT01080950|sepsis
401479|NCT01080950|fever
401480|NCT01080950|vitamin d
401481|NCT01080937|acute heart failure
401482|NCT01080911|Spinal morphine
401483|NCT01080911|Vaginal hysterectomy
401484|NCT01080898|Age - Related Macular Degeneration
401485|NCT01080898|Optical Coherence Tomography
401486|NCT01080898|Choroidal neovascularization
401487|NCT01080898|FLORESCEIN Angiography
401488|NCT01080898|Fundus photographs
401489|NCT01080885|Prevention
401490|NCT01080885|Prevention of unhealthy weight gain
401491|NCT01080872|acute coronary syndrome
401492|NCT01080872|coronary flow reserve
401493|NCT01080872|OCT
401494|NCT01080872|healing
401495|NCT01080872|drug eluting stent
401496|NCT01080859|titanium
401497|NCT01080859|everolimus
401498|NCT01080859|oct
401499|NCT01080859|acute coronary syndrome
401500|NCT01080859|stent
401501|NCT01080859|pci
401502|NCT01080859|stenting
401503|NCT01080846|Primary postpartum hemorrhage
401504|NCT01080846|PPH
401505|NCT01080846|uterine atony
401506|NCT01080846|high fever
401507|NCT01080846|hyperpyrexia
401508|NCT01080833|EMS
401509|NCT01080833|ERCP
401510|NCT01080833|Training
401511|NCT01080833|Trainees
401512|NCT01080820|Healthy adult volunteers
401513|NCT01080820|Pharmacokinetics
401514|NCT01080794|Parkinson's Disease
401515|NCT01080794|Depression
401516|NCT01080794|Transcranial Magnetic Stimulation
401517|NCT01080781|Cardiomyopathy
401518|NCT01080781|Ephrin-B1 expression
401519|NCT01080781|cell-cell junctions
401520|NCT01080781|heart rate variability
401521|NCT01080781|right appendage
401522|NCT01080768|Pedal edema
401523|NCT01080768|hypertension
401524|NCT01080768|aliskiren
401525|NCT01080768|amlodipine
401526|NCT01080755|Adult Growth Hormone Deficiency
401527|NCT01080755|Pituitary
401528|NCT01080755|Saizen
401529|NCT01080755|Somatropin
401530|NCT01080755|Growth Hormone
401531|NCT01080742|Hypertension
401532|NCT01080742|Lodoz
401533|NCT01080742|Bisoprolol
401534|NCT01080742|Hydrochlorothiazide
401535|NCT01080729|Ovulation induction
401536|NCT01080729|Ovarian Hyperstimulation Syndrome
401537|NCT01080729|Multifollicular stimulation
401538|NCT01080729|Pregnancy
401539|NCT01080729|Sperm injections, intracytoplasmic
401540|NCT01080729|Fertility
401541|NCT01080703|Lung Transplant
401542|NCT01080703|Quadriceps Strength
401543|NCT01080703|Quality of Life
401544|NCT01080703|Patients with pulmonary disease awaiting lung transplant.
401545|NCT01080690|endosonography, right side abdominal pain
401546|NCT01080690|Endosonography (diagnostic value in right side abdominal pain)
401547|NCT01080664|AS703569
401548|NCT01080664|Aurora Kinase Inhibitor
401549|NCT01080664|Haematological malignancies
401550|NCT01080638|abciximab
401551|NCT01080638|Myocardial Infarction
401552|NCT01080638|angioplasty
401553|NCT01080638|Platelet
401554|NCT01080625|postreperfusion syndrome
401555|NCT01080625|phenylephrine
401556|NCT01080625|epinephrine
401557|NCT01080625|liver transplantation
401558|NCT01080612|pregabalin
401559|NCT01080612|pharmacokinetics
401560|NCT01080612|bioavailability
401561|NCT01080599|obturator nerve block in TURB
401562|NCT01080586|Bioequivalence study in healthy volunteers
401563|NCT01080573|Multiple sclerosis
401564|NCT01080573|Rebif
401565|NCT01080573|Interferon beta-1a
401566|NCT01080560|Bioequivalence study in healthy volunteers
401567|NCT01080534|Bioequivalence study in healthy volunteers
401568|NCT01080508|pressure pattern
401569|NCT01080508|esophageal and tracheal ventilation.
401570|NCT01080508|esophageal intubation.
401571|NCT01080495|left ventricular function
401572|NCT01080495|radial strain
401573|NCT01080495|fractional shortening
401574|NCT01080495|fractional area change
401575|NCT01080482|Bioequivalence study in healthy volunteers
401576|NCT01080469|Bioequivalence study in healthy volunteers
401577|NCT01080456|Bioequivalence study in healthy volunteers
401578|NCT01080443|Bioequivalence study in healthy volunteers
401579|NCT01080430|vestibular
401580|NCT01080430|vertigo
401581|NCT01080430|rehabilitation
401582|NCT01080430|rotation
401583|NCT01080430|balance
401584|NCT01080417|Bioequivalence study in healthy volunteers
401585|NCT01080404|Obstructive sleep apnea
401586|NCT01080404|Obesity
401587|NCT01080404|Metabolism
401588|NCT01080404|Bariatric surgery
401589|NCT01080404|CPAP
401590|NCT01080391|Multiple Myeloma
401591|NCT01080352|Prostate cancer
401592|NCT01080352|palliative care
401593|NCT01080352|antioxidants
401594|NCT01080352|ascorbic acid
401595|NCT01080352|rna expression
401596|NCT01080339|insulin resistance
401597|NCT01080339|cardiovascular risk
401598|NCT01080339|physical activity
401599|NCT01080339|child
401600|NCT01080326|ulcer repair surgery
401601|NCT01080326|transluminal omental patch
401602|NCT01080300|Hot Flushes
401603|NCT01080300|Vasomotor Symptoms
401604|NCT01080300|Menopausal Hot Flashes
401605|NCT01080287|autonomic
401606|NCT01080287|orthostatic
401607|NCT01080287|syncope
401608|NCT01080287|biopsy
401609|NCT01080287|prevalence of autonomic dysfunction in migraineurs with orthostatic intolerance
401610|NCT01080287|characterize autonomic findings utilizing neurocardiac testing, neurophysiological testing and skin biopsies to analyze autonomic fibers in the dermis
401611|NCT01080274|ergometry
401612|NCT01080274|vitamin d
401613|NCT01080274|zinc
401614|NCT01080261|Atherosclerosis
401615|NCT01080261|Coronary Artery Disease
401616|NCT01080248|Pancreas
401617|NCT01080235|quality improvement
401618|NCT01080235|geriatric care
401619|NCT01080235|residency training
401620|NCT01080222|VX-950
401621|NCT01080196|Falling risk
401622|NCT01080196|muscle conditioning
401623|NCT01080196|whole muscle volume
401624|NCT01080196|isometric strength and concentric power
401625|NCT01080196|Incidence in falls following a 3 month multi-component fall reduction exercise program
401626|NCT01080183|Health-related quality of life
401627|NCT01080183|physical activity
401628|NCT01080170|Aromatase Inhibitor
401629|NCT01080170|Anastrazole
401630|NCT01080170|Arimidex
401631|NCT01080170|Heart disease
401632|NCT01080170|Lipids
401633|NCT01080170|Body composition
401634|NCT01080170|Breast cancer.
401635|NCT01080157|Diabetes
401636|NCT01080157|Diabetes Screening
401637|NCT01080157|Experimental Medical Device
401638|NCT01080144|Cirrhosis
401639|NCT01080144|TIPS (Transjugular intrahepatic portosystemic shunt)
401640|NCT01080144|Encephalopathy
401641|NCT01080131|Frequent flares
401642|NCT01080131|Gout
401643|NCT01080131|Anti-interleukin-1β monoclonal antibody
401644|NCT01080118|Teaching
401645|NCT01080118|Video Scope
401646|NCT01080118|Intubation
401647|NCT01080105|Depression Prevention
401648|NCT01080105|Prevention
401649|NCT01080105|Major Depressive Disorder
401650|NCT01080105|Internet
401651|NCT01080105|Technology Assisted
401652|NCT01080092|smokers
401653|NCT01080079|Onychomycosis
401654|NCT01080066|Carcinoma
401655|NCT01080066|Squamous cell
401656|NCT01080066|Erbitux
401657|NCT01080066|cetuximab
401658|NCT01080066|Head
401659|NCT01080066|Neck
401660|NCT01080053|Multiple Sclerosis, Relapsing Remitting
401661|NCT01080053|Sexual dysfunction
401662|NCT01080040|Multiple Sclerosis, Relapsing Remitting
401663|NCT01080040|Quality of life
401664|NCT01080027|Multiple sclerosis
401665|NCT01080027|Relapsing remitting
401666|NCT01080027|Rebif
401667|NCT01080014|Relapsing-remitting multiple sclerosis (RRMS)
401668|NCT01080014|primary progressive multiple sclerosis (PPMS)
401669|NCT01080014|secondary progressive multiple sclerosis (SPMS)
401670|NCT01080014|Multiple Sclerosis Functional Composite (MSFC)
401671|NCT01080014|Expanded Disability Status Scale (EDSS)
401672|NCT01080001|Multiple sclerosis
401673|NCT01080001|Multiple sclerosis, Relapsing-remitting
401674|NCT01080001|Expanded Disability Status Scale
401675|NCT01080001|Fatigue
401676|NCT01080001|Hamilton Depression Inventory
401677|NCT01080001|Depression
401678|NCT01079988|Psoriasis
401679|NCT01079988|Discontinuation of efalizumab
401680|NCT01079988|Managing inflammatory recurrence
401681|NCT01079975|Multiple sclerosis
401682|NCT01079975|Depression
401683|NCT01079962|Bisoprolol
401684|NCT01079962|Atenolol
401685|NCT01079962|Hypertension
401686|NCT01079962|Blood pressure
401687|NCT01079949|Infertility
401688|NCT01079949|Ovulation induction
401689|NCT01079949|Luveris
401690|NCT01079949|Lutropin alfa
401691|NCT01079949|Controlled ovarian stimulation
401692|NCT01079949|Reproductive technologies, Assisted
401693|NCT01079936|Multiple Myeloma
401694|NCT01079936|Lenalidomide
401695|NCT01079936|Revlimid
401696|NCT01079936|Melphalan
401697|NCT01079936|Alkeran
401698|NCT01079936|Autologous stem cell transplantation
401699|NCT01079936|High-dose chemotherapy
401700|NCT01079923|healthy volunteers
401701|NCT01079923|healthy subjects
401702|NCT01079923|vitamin D
401703|NCT01079923|cholecalciferol
401704|NCT01079923|vitamin D3
401705|NCT01079923|total vitamin D
401706|NCT01079910|Plaque
401707|NCT01079910|Toothpaste
401708|NCT01079910|Gingivitis
401709|NCT01079897|Atopic dermatitis
401710|NCT01079897|Ectoine
401711|NCT01079897|Treatment
401712|NCT01079897|Atopiclair
401713|NCT01079897|Medical device
401714|NCT01079871|Sjogren's Syndrome
401715|NCT01079871|Dry Eye
401837|NCT01079286|Akt inhibition
401716|NCT01079858|Meibomian Gland Dysfunction
401717|NCT01079858|Dry Eye
401718|NCT01079845|Diet
401719|NCT01079845|Nutrition
401720|NCT01079845|Adolescent
401721|NCT01079845|Young Adult
401722|NCT01079845|Overweight
401723|NCT01079845|Obesity
401724|NCT01079793|adenocarcinoma of the prostate
401725|NCT01079793|stage III prostate cancer
401726|NCT01079780|mucinous adenocarcinoma of the colon
401727|NCT01079780|recurrent colon cancer
401728|NCT01079780|signet ring adenocarcinoma of the colon
401729|NCT01079780|stage III colon cancer
401730|NCT01079780|stage IV colon cancer
401731|NCT01079780|mucinous adenocarcinoma of the rectum
401732|NCT01079780|recurrent rectal cancer
401733|NCT01079780|signet ring adenocarcinoma of the rectum
401734|NCT01079780|stage III rectal cancer
401735|NCT01079780|stage IV rectal cancer
401736|NCT01079767|adult primary hepatocellular carcinoma
401737|NCT01079767|advanced adult primary liver cancer
401738|NCT01079767|localized unresectable adult primary liver cancer
401739|NCT01079767|recurrent adult primary liver cancer
401740|NCT01079754|Spinal morphine 0.05 mg
401741|NCT01079754|Spinal morphine
401742|NCT01079741|Melanoma
401743|NCT01079741|Skin Cancer
401744|NCT01079741|Adjuvant Therapy
401745|NCT01079741|Oncogenesis
401746|NCT01079741|LAGE
401747|NCT01079741|Cancer Immunity
401748|NCT01079741|Neoplasms
401749|NCT01079741|Immunogenicity
401750|NCT01079741|Vaccine
401751|NCT01079741|Immunotherapy
401752|NCT01079728|ischemic stroke
401753|NCT01079728|stroke-associated pneumonia
401754|NCT01079728|prediction
401755|NCT01079728|immune and infection parameters
401756|NCT01079715|Newborn
401757|NCT01079715|Retinal Diseases
401758|NCT01079715|Angiogenesis Modulating Agents
401759|NCT01079715|Adrenergic beta-Antagonists
401760|NCT01079689|basic science
401761|NCT01079689|healthy volunteers
401762|NCT01079650|children
401763|NCT01079637|Sella and Barrete Stage 0 1 or 2
401764|NCT01079624|Incretin hormones
401765|NCT01079624|Glucose-insulinotropic peptide
401766|NCT01079624|Glucagon-like peptide-1
401767|NCT01079624|Gastric emptying
401768|NCT01079624|Appetite
401769|NCT01079624|Glucose disposal
401770|NCT01079624|Gut hormones
401771|NCT01079598|IPV
401772|NCT01079598|RadioFrequency
401773|NCT01079598|QOL
401774|NCT01079572|osteoarthritis
401775|NCT01079572|arthroplasty
401776|NCT01079572|web-based
401777|NCT01079572|electronic follow-up
401778|NCT01079559|total knee arthroplasty
401779|NCT01079559|infection
401780|NCT01079559|antibiotic bone cement
401781|NCT01079546|HPV, Israel, Squamous cell carcinoma of head and neck
401782|NCT01079533|Colorectal Neoplasms
401783|NCT01079533|Mass Screening
401784|NCT01079533|Patient Compliance
401785|NCT01079533|Intervention Studies
401786|NCT01079533|Clinical Trial
401787|NCT01079520|Cancer
401788|NCT01079520|Lung Cancer
401789|NCT01079520|Ultrasound
401790|NCT01079520|Surgery
401791|NCT01079507|single nucleotide polymorphism
401792|NCT01079507|adult acute lymphoblastic leukemia
401793|NCT01079494|Uncontrolled blood pressure
401794|NCT01079481|Relapsed or Refractory Small Cell Lung Cancer
401795|NCT01079481|Paclitaxel
401796|NCT01079481|Everolimus
401797|NCT01079468|Transient cognitive decline following orthopaedic surgery
401798|NCT01079455|Coxarthrosis
401799|NCT01079455|Hip
401800|NCT01079455|Infiltration
401801|NCT01079455|Hyaluronic Acid
401802|NCT01079455|Corticosterone
401803|NCT01079442|postoperative ileus after colonic resections
401804|NCT01079429|Monoclonal gammopathy of undetermined significance
401805|NCT01079429|MGUS
401806|NCT01079429|Smoldering myeloma
401807|NCT01079429|SMM
401808|NCT01079429|Multiple myeloma
401809|NCT01079416|Esophageal Capsule Endoscopy, Screening
401810|NCT01079390|acupuncture
401811|NCT01079390|osteoarthritis
401812|NCT01079390|fMRI
401813|NCT01079377|Adolescents
401814|NCT01079377|Bariatric Surgery
401815|NCT01079377|Psychological Symptoms
401816|NCT01079377|Cognitive Behavioral Therapy
401817|NCT01079377|Telemedicine
401818|NCT01079377|Longitudinal
401819|NCT01079351|Epilepsy
401820|NCT01079351|Intravenous Carbamazepine
401821|NCT01079351|Oral Carbamazepine
401822|NCT01079338|sensitivity to caffeine
401823|NCT01079325|Diabetic neuropathy
401824|NCT01079325|Diabetes Type 1 or 2
401825|NCT01079325|Moderately severe sensorimotor diabetic polyneuropathy
401826|NCT01079312|ERCP
401827|NCT01079312|patient-controlled sedation
401828|NCT01079312|propofol
401829|NCT01079312|remifentanil
401830|NCT01079312|sedation level
401831|NCT01079299|venous ulcer
401832|NCT01079299|secondary lymphedema
401833|NCT01079299|chronic lower leg ulceration
401834|NCT01079286|mTOR inhibition
401835|NCT01079286|advanced malignancies
401836|NCT01079286|pharmacokinetics
401838|NCT01079286|Advanced malignancies, including metastatic renal cell cancer
401839|NCT01079273|Influenza
401840|NCT01079273|Vaccines
401841|NCT01079273|A/H1N1
401842|NCT01079273|Influenza Vaccines
401843|NCT01079260|Malnourished
401844|NCT01079260|Elderly
401845|NCT01079260|Nutrition support
401846|NCT01079247|Burn
401847|NCT01079247|Transfusion
401848|NCT01079247|blood
401849|NCT01079247|hemoglobin
401850|NCT01079221|exercise
401851|NCT01079221|Knee extensor
401852|NCT01079208|infant formula, synbiotics, probiotics, nutrition
401853|NCT01079195|Effectiveness and tolerability of Tarka
401854|NCT01079195|Hypertensive patients
401855|NCT01079195|Diabetes mellitus
401856|NCT01079195|Observational study
401857|NCT01079182|Daily practice
401858|NCT01079182|Humira
401859|NCT01079182|Efficacy
401860|NCT01079182|Safety
401861|NCT01079182|Ankylosing spondylitis
401862|NCT01079169|urinary tract infection
401863|NCT01079169|prevention
401864|NCT01079169|rehabilitation
401865|NCT01079169|spinal cord injury
401866|NCT01079143|De Novo renal transplantation
401867|NCT01079130|Indacaterol
401868|NCT01079130|asthma
401869|NCT01079130|salmeterol
401870|NCT01079117|Opiate
401871|NCT01079117|Methadone
401872|NCT01079117|Slow Release Oral Morphine (SORM)
401873|NCT01079117|Sevre-Long™
401874|NCT01079104|Liver failure
401875|NCT01079104|Hepatic insufficiency
401876|NCT01079104|Artificial liver
401877|NCT01079104|Albumin dialysis
401878|NCT01079091|Liver failure
401879|NCT01079091|Hepatic insufficiency
401880|NCT01079091|Liver Cirrhosis
401881|NCT01079091|Artificial liver
401882|NCT01079091|Albumin dialysis
401883|NCT01079078|Acetaminophen fed study
401884|NCT01079065|Famotidine tablets fasting study
401885|NCT01079052|Famotidine tablets fed study
401886|NCT01079026|biomarker
401887|NCT01079026|epidural steroid
401888|NCT01079026|radiculopathy
401889|NCT01079026|hnp
401890|NCT01079000|asthma
401891|NCT01079000|exacerbation
401892|NCT01079000|emergency department
401893|NCT01079000|relapse
401894|NCT01078987|Nephrogenic Fibrosing Dermopathy (NFD)
401895|NCT01078987|Nephrogenic Systemic Fibrosis (NSF)
401896|NCT01078974|WM
401897|NCT01078974|pomalidomide
401898|NCT01078974|dexamethasone
401899|NCT01078974|rituximab
401900|NCT01078961|bortezomib
401901|NCT01078961|sorafenib
401902|NCT01078961|advanced melanoma
401903|NCT01078948|tDCS
401904|NCT01078948|transcranial direct current stimulation
401905|NCT01078948|major depression
401906|NCT01078948|double-blind
401907|NCT01078948|randomized
401908|NCT01078948|placebo-controlled
401909|NCT01078948|treatment
401910|NCT01078935|Crohn's disease activity index
401911|NCT01078935|CDAI
401912|NCT01078922|ofatumumab diffuse B cell non hodgkins lymphoma DLBCL
401913|NCT01078922|refractory DLBCL
401914|NCT01078922|relapsed DLBCL
401915|NCT01078909|Cardiovascular disease
401916|NCT01078909|Inflammation
401917|NCT01078909|Fish Oil
401918|NCT01078909|Omega-3 Fatty Acids
401919|NCT01078909|LPS
401920|NCT01078909|Endotoxin
401921|NCT01078883|Lung cancer
401922|NCT01078883|Respiratory muscle strength
401923|NCT01078883|Dyspnea
401924|NCT01078883|Functional capacity
401925|NCT01078870|Negative symptom
401926|NCT01078857|Chronic kidney disease
401927|NCT01078857|Small-fiber neuropathy
401928|NCT01078857|Skin biopsy
401929|NCT01078857|Contact heat evoked potential
401930|NCT01078857|Autonomic neuropathy
401931|NCT01078857|Neuropathy in late stage chronic kidney disease
401932|NCT01078844|Autism
401933|NCT01078844|Asperger's Disorder
401934|NCT01078844|Pervasive Developmental Disorder NOS
401935|NCT01078844|Adult
401936|NCT01078844|Memantine
401937|NCT01078818|Cardiac surgery
401938|NCT01078818|Extracorporeal circulation
401939|NCT01078818|Anaemia
401940|NCT01078818|Intravenous iron
401941|NCT01078818|Oral Iron
401942|NCT01078779|Influenza
401943|NCT01078779|Prevention
401944|NCT01078779|Chloroquine
401945|NCT01078779|Randomised controlled trial
401946|NCT01078779|Respiratory virus infection
401947|NCT01078766|cerebral palsy
401948|NCT01078740|cystic fibrosis
401949|NCT01078740|cystic fibrosis transmembrane conductance regulator
401950|NCT01078740|biomarkers
401951|NCT01078740|Intestinal Current Measurement
401952|NCT01078727|Thermal Stimulation
401953|NCT01078727|Upper Extremity
401954|NCT01078727|Motor Recovery
401955|NCT01078727|Stroke
401956|NCT01078714|Autism
401957|NCT01078714|Bumetanide
401958|NCT01078714|GABA
401959|NCT01078714|NKCC1
401960|NCT01078701|live attenuated flu vaccines
401961|NCT01078701|Influenza A (H1N1)
401962|NCT01078701|intranasal application
401963|NCT01078701|replication-deficient influenza virus
401964|NCT01078688|Limitations of activities
401965|NCT01078688|persistent asthma
401966|NCT01078688|general practitioner
401967|NCT01078688|frequency of limitations of activities
401968|NCT01078688|depending on gender and age-group
401969|NCT01078675|Familial Hypercholesterolaemia
401970|NCT01078675|pediatric
401971|NCT01078662|olaparib
401972|NCT01078662|PARP inhibitors
401973|NCT01078662|genetic BRCA1 mutation
401974|NCT01078662|BRCA2 mutation
401975|NCT01078662|solid tumour refractory
401976|NCT01078649|cancer
401977|NCT01078649|solid tumors
401978|NCT01078649|lymphoma
401979|NCT01078649|smac mimetic
401980|NCT01078649|IAP inhibitor
401981|NCT01078649|Phase I
401982|NCT01078649|Dose escalation
401983|NCT01078636|amyloid
401984|NCT01078636|plaques
401985|NCT01078636|imaging
401986|NCT01078636|early detection
401987|NCT01078636|Amnestic MCI
401988|NCT01078636|pre-dementia
401989|NCT01078623|Bronchitis
401990|NCT01078623|Chronic
401991|NCT01078623|Emphysema
401992|NCT01078610|Psoriatic Arthritis
401993|NCT01078610|Long-term Observation
401994|NCT01078610|Humira
401995|NCT01078610|Safety
401996|NCT01078610|Effectiveness
401997|NCT01078610|Quality of Life
401998|NCT01078610|Work Productivity
401999|NCT01078597|anti-MCV
402000|NCT01078597|anti-CCP
402001|NCT01078597|Biomarkers
402002|NCT01078597|Rheumatoid Arthritis
402003|NCT01078584|Uncontrolled hypertension
402004|NCT01078584|trandolapril
402005|NCT01078571|Rheumatoid Arthritis
402006|NCT01078571|Biologic
402007|NCT01078571|Tumor Necrosis Factors blockers agents Monoclonal antibody
402008|NCT01078558|Multicenter study
402009|NCT01078545|Prostate cancer
402010|NCT01078545|Lower urinary tract symptoms
402011|NCT01078545|Hormonotherapy
402012|NCT01078545|LHRH analogue
402013|NCT01078545|Androgen deprivation therapy (ADT)
402014|NCT01078532|medically complex diseases that increase cardiovascular risk
402015|NCT01078519|Fever
402016|NCT01078519|anesthesia
402017|NCT01078519|Labor
402018|NCT01078506|Chinese
402019|NCT01078506|intracranial aneurysm
402020|NCT01078506|magnetic resonance imaging
402021|NCT01078493|Platelet rich plasma
402022|NCT01078493|PRP
402023|NCT01078493|wrinkles
402024|NCT01078493|MyCells®
402025|NCT01078493|CREATE
402026|NCT01078493|Life Source Medical Centre
402027|NCT01078493|Dr Tan Kok leong
402028|NCT01078480|Fracture
402029|NCT01078480|Collar bone
402030|NCT01078467|Wound Healing
402031|NCT01078467|Oral Wounds
402032|NCT01078467|Cutaneous Wounds
402033|NCT01078467|Gene Array Analysis
402034|NCT01078467|Proteomic Analysis
402035|NCT01078467|Healthy Volunteer
402036|NCT01078467|HV
402037|NCT01078454|Melphalan
402038|NCT01078454|Dexamethasone
402039|NCT01078454|Bortezomib
402040|NCT01078454|Systemic Light-chain (AL) Amyloidosis
402041|NCT01078441|Bortezomib
402042|NCT01078441|Liposomal Doxorubicin
402043|NCT01078441|Dexamethasone
402044|NCT01078441|Cyclophosphamide
402045|NCT01078441|refractory multiple myeloma
402046|NCT01078428|Hypertrophic scars
402047|NCT01078428|Topical silicone gel
402048|NCT01078428|Scar thickness
402049|NCT01078428|Scar Color
402050|NCT01078428|Scar pliability
402051|NCT01078428|Scar appearance
402052|NCT01078415|HCC
402053|NCT01078415|Hepatocellular Carcinoma
402054|NCT01078415|Early Stage
402055|NCT01078415|Prospective
402056|NCT01078415|Multicenter
402057|NCT01078415|Irreversible Electroporation (IRE)
402058|NCT01078415|Electroporation
402059|NCT01078415|Low Energy Direct Current
402060|NCT01078415|LEDC
402061|NCT01078415|Nonthermal ablation
402062|NCT01078415|NTIRE (nonthermal IRE)
402063|NCT01078415|Ablation
402064|NCT01078415|Soft Tissue
402065|NCT01078402|Treatment compliance and tolerability of Humira in patients
402066|NCT01078402|Eastern European countries
402067|NCT01078402|Rheumatoid Arthritis
402068|NCT01078402|Psoriatic Arthritis
402069|NCT01078402|Adalimumab
402070|NCT01078402|Ankylosing Spondylitis
402071|NCT01078402|Evaluation of clinical outcome
402072|NCT01078389|Gout
402073|NCT01078389|Hyperuricemia
402074|NCT01078389|Uric Acid
402075|NCT01078389|Drug Therapy
402076|NCT01078376|Pediatrics
402077|NCT01078376|Blood Pressure, High
402078|NCT01078376|Drug Therapy
402079|NCT01078363|Heart Transplantation
402080|NCT01078350|Lymphoma
402081|NCT01078350|Hodgkin Disease
402082|NCT01078311|Patients with advanced hepatocellular cancer
402083|NCT01078298|smoking
402084|NCT01078298|smoking cessation
402085|NCT01078298|smoking cessation in depressed subjects
402086|NCT01078285|Integrated program on adherence using counseling
402201|NCT01077635|HIV
402087|NCT01078285|support services including cost-sharing where appropriate and educational materials mailed monthly.
402088|NCT01078272|Coronary Atherosclerosis
402089|NCT01078272|Percutaneous Coronary Intervention
402090|NCT01078272|Coronary Stenting
402091|NCT01078272|Coronary Stenosis
402092|NCT01078272|Remote Ischemic Preconditioning
402093|NCT01078246|HIV
402094|NCT01078233|HIV
402095|NCT01078233|antiretroviral treatment
402096|NCT01078233|HIV Cohort
402097|NCT01078233|Treatment
402098|NCT01078220|Human Papillomavirus (HPV)
402099|NCT01078194|Weight regain
402100|NCT01078194|Weight loss failure
402101|NCT01078194|Gastric bypass
402102|NCT01078181|gastric bypass
402103|NCT01078181|banded gastric bypass
402104|NCT01078181|weight loss
402105|NCT01078181|weight regain
402106|NCT01078181|bariatric surgery
402107|NCT01078168|Alzheimer`s Disease
402108|NCT01078155|Bone mineral density
402109|NCT01078155|Bone turnover markers
402110|NCT01078155|Rheumatoid arthritis
402111|NCT01078155|Osteoporosis
402112|NCT01078142|temsirolimus
402113|NCT01078142|bendamustine
402114|NCT01078142|rituximab
402115|NCT01078142|mantle cell lymphoma
402116|NCT01078142|follicular lymphoma
402117|NCT01078129|cognitive deficits
402118|NCT01078116|Rheumatoid Arthritis
402119|NCT01078116|Adalimumab treatment
402120|NCT01078116|Evaluation of the patients' Health Related Quality of Life
402121|NCT01078116|Cost of the disease management
402122|NCT01078103|Diabetes Mellitus
402123|NCT01078103|cornea endothelium
402124|NCT01078103|cell loss
402125|NCT01078103|cataract surgery
402126|NCT01078090|Safety
402127|NCT01078090|Rheumatoid Arthritis
402128|NCT01078090|Effectiveness
402129|NCT01078077|healthy females ages twentyfive through sixty
402130|NCT01078064|Gastroesophageal reflux disease, gastric motility
402131|NCT01078051|chronic total occlusion
402132|NCT01078051|stent
402133|NCT01078051|medical therapy
402134|NCT01078038|Coronary Artery Disease
402135|NCT01078038|Stent
402136|NCT01078025|transvaginal access for cholecystectomy
402137|NCT01077999|chemoradiation
402138|NCT01077999|panitumumab
402139|NCT01077999|esophageal cancer
402140|NCT01077999|Resectable squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastro esophageal junction
402141|NCT01077986|mTOR inhibition
402142|NCT01077986|EGFR inhibition
402143|NCT01077986|pancreatic cancer
402144|NCT01077986|pharmacodynamics
402145|NCT01077973|Headache
402146|NCT01077960|Serostim
402147|NCT01077960|HARS
402148|NCT01077947|low back pain
402149|NCT01077947|spinal fusion
402150|NCT01077947|Primarily axial low back pain
402151|NCT01077934|All Patients admitted to Grady Memorial Hospital with Unilateral Lower leg injury at risk for compartment syndrome
402152|NCT01077921|sickle
402153|NCT01077921|adhesion
402154|NCT01077921|propranolol
402155|NCT01077908|Adoptive cellular therapy
402156|NCT01077908|Hematopoietic Stem Cell Transplantation
402157|NCT01077895|Critically ill patients with positive fluid balance, IAH and AKI requiring RRT
402158|NCT01077882|Moderate and severe psoriasis and atopic dermatitis
402159|NCT01077869|oropharynx and lymph node metastases from an unknown primary tumor
402160|NCT01077856|congenital anomaly
402161|NCT01077856|pregnancy
402162|NCT01077856|GARDASIL®
402163|NCT01077856|Nordic
402164|NCT01077856|population-based
402165|NCT01077843|Ankylosing Spondylitis
402166|NCT01077830|New Incidence of Cancer
402167|NCT01077791|Schizophrenia
402168|NCT01077791|social cognition
402169|NCT01077791|theory of mind
402170|NCT01077791|cognitive therapy
402171|NCT01077791|therapeutic trial
402172|NCT01077791|magnetoencephalography (MEG)
402173|NCT01077778|Magnetic Resonance Imaging/methods
402174|NCT01077778|Magnetic Resonance Angiography
402175|NCT01077778|Perfusion Imaging
402176|NCT01077778|Pulmonary Embolism/diagnosis
402177|NCT01077765|HIV-associated Lipodystrophy
402178|NCT01077765|Polyacrylamide hydrogel
402179|NCT01077752|Pain, postoperative
402180|NCT01077752|Local infiltration
402181|NCT01077752|Hyperalgesia, postoperative
402182|NCT01077752|Local anesthetic, ropivacaine, lidocaine
402183|NCT01077752|Colorectal laparoscopic surgery
402184|NCT01077752|Pain management after colorectal laparoscopic surgery
402185|NCT01077687|schizophrenia
402186|NCT01077687|genome-wide association study (GWAS)
402187|NCT01077687|single-nucleotide polymorphisms (SNPs)
402188|NCT01077687|Han Chinese population
402189|NCT01077687|trio families
402190|NCT01077687|Schizophrenia with trio families
402191|NCT01077674|Electroencephalogram
402192|NCT01077674|Entropy
402193|NCT01077674|BIS
402194|NCT01077674|Sevoflurane
402195|NCT01077661|Nebivolol
402196|NCT01077661|PMS (post-marketing surveillance)
402197|NCT01077648|Breast Cancer
402198|NCT01077648|Treatment
402199|NCT01077648|Brain metastases
402200|NCT01077648|ErbB2 expression
402202|NCT01077635|Antiretroviral therapy
402203|NCT01077635|protease inbitor
402204|NCT01077635|fosamprenavir
402205|NCT01077635|paediatrics
402206|NCT01077609|Intranasal steroids
402207|NCT01077609|beclometasone diproprionate
402208|NCT01077609|steroid-related outcomes
402209|NCT01077596|Carcinogenicity
402210|NCT01077596|Case control
402211|NCT01077596|Bupropion
402212|NCT01077583|Pregnancy test
402213|NCT01077583|Wishing to become pregnant
402214|NCT01077557|Combivir (Zidovudine+Lamivudine)
402215|NCT01077557|Trizivir (Abacavir+Lamivudine+Zidovudine)
402216|NCT01077557|Zidovudine
402217|NCT01077557|Epzicom (Abacavir+Lamivudine)
402218|NCT01077557|Fracture
402219|NCT01077557|Amprenavir
402220|NCT01077557|human immunodeficiency virus (HIV) infection
402221|NCT01077557|antiretroviral (ARV) therapy
402222|NCT01077557|Lamivudine
402223|NCT01077557|incidence
402224|NCT01077557|Abacavir
402225|NCT01077557|risk
402226|NCT01077557|Fosamprenavir
402227|NCT01077544|Chronic Myeloid Leukemia
402228|NCT01077544|Acute Lymphoblastic Leukemia
402229|NCT01077544|Ph+ CML
402230|NCT01077544|Ph+ ALL
402231|NCT01077544|pediatric
402232|NCT01077544|nilotinib
402233|NCT01077544|imatinib
402234|NCT01077544|chronic phase
402235|NCT01077544|accelerated phase
402236|NCT01077544|newly diagnosed Ph+ CML
402237|NCT01077544|dasatinib
402238|NCT01077531|Rheumatoid arthritis
402239|NCT01077531|intravenous infusion
402240|NCT01077531|long-term followup
402241|NCT01077518|Refractory
402242|NCT01077518|Safety
402243|NCT01077518|Efficacy
402244|NCT01077518|Rituximab refractory
402245|NCT01077518|Oncology
402246|NCT01077505|pharmacokinetics
402247|NCT01077505|GSK716155
402248|NCT01077505|Brevicon
402249|NCT01077505|albiglutide
402250|NCT01077505|healthy female volunteers
402251|NCT01077505|oral contraceptive
402252|NCT01077492|lung cancer
402253|NCT01077492|mediastinal lymph nodes
402254|NCT01077492|TBNA
402255|NCT01077492|staging lung cancer
402256|NCT01077479|body fat mass gain
402257|NCT01077479|Insulin resistance
402258|NCT01077466|Primary Progressive Multiple Sclerosis
402259|NCT01077466|Secondary Progressive Multiple Sclerosis
402260|NCT01077466|Natalizumab
402261|NCT01077466|Treatment
402262|NCT01077466|Safety
402263|NCT01077466|Efficacy
402264|NCT01077466|Cerebrospinal fluid
402265|NCT01077466|Osteopontin
402266|NCT01077440|cancer survivor
402267|NCT01077440|stage III adult Burkitt lymphoma
402268|NCT01077440|stage III adult diffuse large cell lymphoma
402269|NCT01077440|stage III adult diffuse mixed cell lymphoma
402270|NCT01077440|stage III adult diffuse small cleaved cell lymphoma
402271|NCT01077440|stage III adult Hodgkin lymphoma
402272|NCT01077440|stage III adult immunoblastic large cell lymphoma
402273|NCT01077440|stage III adult lymphoblastic lymphoma
402274|NCT01077440|stage III grade 1 follicular lymphoma
402275|NCT01077440|stage III grade 2 follicular lymphoma
402276|NCT01077440|stage III grade 3 follicular lymphoma
402277|NCT01077440|stage III mantle cell lymphoma
402278|NCT01077440|stage III marginal zone lymphoma
402279|NCT01077440|stage III small lymphocytic lymphoma
402280|NCT01077440|stage IV adult Burkitt lymphoma
402281|NCT01077440|stage IV adult diffuse large cell lymphoma
402282|NCT01077440|stage IV adult diffuse mixed cell lymphoma
402283|NCT01077440|stage IV adult diffuse small cleaved cell lymphoma
402284|NCT01077440|stage IV adult Hodgkin lymphoma
402285|NCT01077440|stage IV adult immunoblastic large cell lymphoma
402286|NCT01077440|stage IV adult lymphoblastic lymphoma
402287|NCT01077440|stage IV grade 1 follicular lymphoma
402288|NCT01077440|stage IV grade 2 follicular lymphoma
402289|NCT01077440|stage IV grade 3 follicular lymphoma
402290|NCT01077440|stage IV mantle cell lymphoma
402291|NCT01077440|stage IV marginal zone lymphoma
402292|NCT01077440|stage IV small lymphocytic lymphoma
402293|NCT01077440|recurrent adult Burkitt lymphoma
402294|NCT01077440|recurrent adult diffuse large cell lymphoma
402295|NCT01077440|recurrent adult diffuse mixed cell lymphoma
402296|NCT01077440|recurrent adult diffuse small cleaved cell lymphoma
402297|NCT01077440|recurrent adult Hodgkin lymphoma
402298|NCT01077440|recurrent adult immunoblastic large cell lymphoma
402299|NCT01077440|recurrent adult lymphoblastic lymphoma
402300|NCT01077440|recurrent cutaneous T-cell non-Hodgkin lymphoma
402301|NCT01077440|recurrent grade 1 follicular lymphoma
402302|NCT01077440|recurrent grade 2 follicular lymphoma
402303|NCT01077440|recurrent grade 3 follicular lymphoma
402304|NCT01077440|recurrent mantle cell lymphoma
402305|NCT01077440|recurrent marginal zone lymphoma
402306|NCT01077440|recurrent small lymphocytic lymphoma
402307|NCT01077440|recurrent mycosis fungoides/Sezary syndrome
402308|NCT01077440|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
402309|NCT01077440|nodal marginal zone B-cell lymphoma
402310|NCT01077440|splenic marginal zone lymphoma
402419|NCT01077245|Metronidazole
402311|NCT01077440|noncontiguous stage II adult Burkitt lymphoma
402312|NCT01077440|noncontiguous stage II adult diffuse large cell lymphoma
402313|NCT01077440|noncontiguous stage II adult diffuse mixed cell lymphoma
402314|NCT01077440|noncontiguous stage II adult diffuse small cleaved cell lymphoma
402315|NCT01077440|noncontiguous stage II adult immunoblastic large cell lymphoma
402316|NCT01077440|noncontiguous stage II adult lymphoblastic lymphoma
402317|NCT01077440|noncontiguous stage II grade 1 follicular lymphoma
402318|NCT01077440|noncontiguous stage II grade 2 follicular lymphoma
402319|NCT01077440|noncontiguous stage II grade 3 follicular lymphoma
402320|NCT01077440|noncontiguous stage II mantle cell lymphoma
402321|NCT01077440|noncontiguous stage II marginal zone lymphoma
402322|NCT01077440|noncontiguous stage II small lymphocytic lymphoma
402323|NCT01077440|accelerated phase chronic myelogenous leukemia
402324|NCT01077440|adult acute lymphoblastic leukemia in remission
402325|NCT01077440|adult acute myeloid leukemia in remission
402326|NCT01077440|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
402327|NCT01077440|adult acute myeloid leukemia with inv(16)(p13;q22)
402328|NCT01077440|adult acute myeloid leukemia with t(15;17)(q22;q12)
402329|NCT01077440|adult acute myeloid leukemia with t(16;16)(p13;q22)
402330|NCT01077440|adult acute myeloid leukemia with t(8;21)(q22;q22)
402331|NCT01077440|atypical chronic myeloid leukemia, BCR-ABL negative
402332|NCT01077440|blastic phase chronic myelogenous leukemia
402333|NCT01077440|chronic myelomonocytic leukemia
402334|NCT01077440|chronic phase chronic myelogenous leukemia
402335|NCT01077440|recurrent adult acute lymphoblastic leukemia
402336|NCT01077440|recurrent adult acute myeloid leukemia
402337|NCT01077440|refractory chronic lymphocytic leukemia
402338|NCT01077440|refractory hairy cell leukemia
402339|NCT01077440|relapsing chronic myelogenous leukemia
402340|NCT01077440|secondary acute myeloid leukemia
402341|NCT01077440|stage III chronic lymphocytic leukemia
402342|NCT01077440|stage IV chronic lymphocytic leukemia
402343|NCT01077440|chronic eosinophilic leukemia
402344|NCT01077440|primary myelofibrosis
402345|NCT01077440|chronic neutrophilic leukemia
402346|NCT01077440|de novo myelodysplastic syndromes
402347|NCT01077440|disseminated neuroblastoma
402348|NCT01077440|myelodysplastic/myeloproliferative neoplasm, unclassifiable
402349|NCT01077440|previously treated myelodysplastic syndromes
402350|NCT01077440|recurrent neuroblastoma
402351|NCT01077440|recurrent malignant testicular germ cell tumor
402352|NCT01077440|secondary myelodysplastic syndromes
402353|NCT01077440|stage I multiple myeloma
402354|NCT01077440|stage II multiple myeloma
402355|NCT01077440|stage III multiple myeloma
402356|NCT01077440|stage III malignant testicular germ cell tumor
402357|NCT01077440|refractory multiple myeloma
402358|NCT01077427|pancreatic cancer
402359|NCT01077427|adjuvant treatment
402360|NCT01077427|hyperthermia
402361|NCT01077414|Psychosocial Functioning
402362|NCT01077414|Psychosocial Stress
402363|NCT01077414|Palliative Care
402364|NCT01077414|Spirituality
402365|NCT01077414|Cancer
402366|NCT01077401|Diabetic
402367|NCT01077401|edema
402368|NCT01077401|DME
402369|NCT01077388|CVD
402370|NCT01077388|uncontrolled HTN
402371|NCT01077375|Milnacipran
402372|NCT01077375|Duloxetine
402373|NCT01077375|Switch
402374|NCT01077375|Forest Research Institute
402375|NCT01077362|Ustekinumab
402376|NCT01077362|CNTO 1275
402377|NCT01077362|Stelara
402378|NCT01077362|Psoriatic Arthritis
402379|NCT01077362|Psoriasis
402380|NCT01077362|TNF alpha
402381|NCT01077349|Cardiac surgery
402382|NCT01077349|Shock
402383|NCT01077349|Continuous Veno-Venous Haemofiltration
402384|NCT01077349|Continuous Renal Replacement Therapy
402385|NCT01077349|Renal Insufficiency
402386|NCT01077349|Acute
402387|NCT01077336|susceptibility testing
402388|NCT01077323|pancreatitis
402389|NCT01077323|exenatide
402390|NCT01077323|Byetta
402391|NCT01077323|Amylin
402392|NCT01077323|Lilly
402393|NCT01077310|HIV
402394|NCT01077310|Acquired Immunodeficiency Syndrome
402395|NCT01077310|Alcohol dependence
402396|NCT01077310|CD4
402397|NCT01077310|HIV-1 RNA
402398|NCT01077310|Alcohol treatment outcomes
402399|NCT01077284|Kidney Calculi
402400|NCT01077284|Kidney Stones
402401|NCT01077284|Nephrolithiasis
402402|NCT01077284|Drug Therapy
402403|NCT01077284|Uric Acid
402404|NCT01077271|Premature infants
402405|NCT01077271|Respiratory Syncytial Virus (RSV)
402406|NCT01077271|Compliance
402407|NCT01077271|Palivizumab
402408|NCT01077258|Safety
402409|NCT01077258|Long-term observation
402410|NCT01077258|Routine Clinical Setting
402411|NCT01077258|Rheumatoid Arthritis
402412|NCT01077258|Effectiveness
402413|NCT01077245|Clostridium difficile
402414|NCT01077245|Clostridium Infections
402415|NCT01077245|Gram-Positive Bacterial Infections
402416|NCT01077245|Bacterial Infections
402417|NCT01077245|Anti-Infective Agents
402418|NCT01077245|Clostridium butyricum
402420|NCT01077245|Vancomycin
402421|NCT01077245|Gastrointestinal Diseases
402422|NCT01077245|Physiological Effects of Drugs
402423|NCT01077245|Colonic Diseases
402424|NCT01077245|Enterocolitis, Pseudomembranous
402425|NCT01077245|Intestinal Diseases
402426|NCT01077245|Enterocolitis
402427|NCT01077245|Pharmacologic Actions
402428|NCT01077245|Digestive System Diseases
402429|NCT01077245|Therapeutic Uses
402430|NCT01077245|Gastroenteritis
402431|NCT01077245|Colitis
402432|NCT01077245|Diarrhea
402433|NCT01077245|Probiotics
402434|NCT01077245|Gastrointestinal Agents
402435|NCT01077232|Moderate to Severe Plaque Psoriasis
402436|NCT01077232|Safety
402437|NCT01077232|Efficacy
402438|NCT01077232|Humira
402439|NCT01077232|Work Productivity
402440|NCT01077219|healthy female
402441|NCT01077206|Aneurysm
402442|NCT01077206|statin
402443|NCT01077206|subarachnoid hemorrhage
402444|NCT01077193|Bariatric
402445|NCT01077193|Obesity
402446|NCT01077167|Omecamtiv mecarbil
402447|NCT01077167|pharmacokinetics
402448|NCT01077154|Early Stage Breast Cancer
402449|NCT01077154|Bone Metastasis
402450|NCT01077154|Adjuvant treatment
402451|NCT01077154|Neoadjuvant treatment
402452|NCT01077154|Denosumab
402453|NCT01077154|Stage II breast cancer
402454|NCT01077154|Stage III breast cancer
402455|NCT01077154|Stage IIA breast cancer
402456|NCT01077154|Stage IIB breast cancer
402457|NCT01077154|Stage IIIA breast cancer
402458|NCT01077154|Stage IIIB breast cancer
402459|NCT01077154|Stage IIIC breast cancer
402460|NCT01077154|Early breast cancer
402461|NCT01077154|Breast Tumors
402462|NCT01077154|Breast Neoplasms
402463|NCT01077128|Psoriasis
402464|NCT01077128|Quality of life
402465|NCT01077115|Cholecystectomy
402466|NCT01077115|Cholecystitis
402467|NCT01077115|Laparoscopy
402468|NCT01077115|Cholelithiasis
402469|NCT01077115|Operative trauma
402470|NCT01077102|COPD
402471|NCT01077102|eccentric exercise training
402472|NCT01077102|cycle ergometer
402473|NCT01077102|muscle function
402474|NCT01077089|traumatic brain injury
402475|NCT01077089|In-hospital transport
402476|NCT01077076|Gastric Acid
402477|NCT01077076|Human Experimentation
402478|NCT01077063|Pleurx catheter
402479|NCT01077063|malignant ascites
402480|NCT01077024|Stimulant treatment
402481|NCT01077024|Smoking Cessation
402482|NCT01077011|Dry eye
402483|NCT01077011|artificial tears
402484|NCT01076998|Dry eye
402485|NCT01076998|artificial tears
402486|NCT01076985|Human Immunodeficiency Virus
402487|NCT01076972|Human Immunodeficiency Virus
402488|NCT01076959|Rheumatoid Arthritis
402489|NCT01076946|ballooning
402490|NCT01076946|TLVBS
402491|NCT01076933|Borderline Personality Disorder
402492|NCT01076933|Transcranial Magnetic Stimulation
402493|NCT01076933|Neuropsychological Test
402494|NCT01076933|Randomised Control Trial
402495|NCT01076907|colonoscopy
402496|NCT01076907|polyps
402497|NCT01076894|pain
402498|NCT01076894|thoracotomy
402499|NCT01076894|pulmonary function
402500|NCT01076894|epidural anesthesia
402501|NCT01076894|intercostal nerve block
402502|NCT01076868|vivax
402503|NCT01076868|malaria
402504|NCT01076868|relapse
402505|NCT01076842|Diabetes
402506|NCT01076829|MDA
402507|NCT01076829|Spice
402508|NCT01076816|Patients with single-organ failure in need of mechanical ventilation
402509|NCT01076803|Malignant intestinal obstruction in inoperable patients
402510|NCT01076790|Nociception
402511|NCT01076790|Dexmedetomidine
402512|NCT01076790|Electroencephalogram
402513|NCT01076790|Electromyogram
402514|NCT01076790|Entropy Index
402515|NCT01076790|Bispectral Index
402516|NCT01076790|Electrocardiogram
402517|NCT01076790|Plethysmogram
402518|NCT01076790|Heart
402519|NCT01076790|Heart rate
402520|NCT01076790|Heart rate variability
402521|NCT01076790|Surgery
402522|NCT01076777|Panic disorder
402523|NCT01076777|Physical exercise
402524|NCT01076777|Cognitive-behavioral therapy
402525|NCT01076777|Manualized
402526|NCT01076725|ProSeal LMA
402527|NCT01076725|standard insertion
402528|NCT01076725|rotational insertion
402529|NCT01076699|abdominal pain
402530|NCT01076699|bloating
402531|NCT01076699|diarrhea
402532|NCT01076699|irritable bowel
402533|NCT01076686|Augmentation mammoplasty
402534|NCT01076686|Breast augmentation
402535|NCT01076686|Postoperative pain
402536|NCT01076686|Analgesia
402537|NCT01076660|Ischemic cardiomyopathy
402538|NCT01076660|Nonischemic cardiomyopathy
402539|NCT01076660|Implantable cardioverter defibrillator
402540|NCT01076660|Sudden Cardiac Death
402541|NCT01076660|Ventricular tachycardia
402542|NCT01076660|Ventricular fibrillation
402543|NCT01076608|primary care patients
402544|NCT01076595|Multiple sclerosis
402545|NCT01076595|BetaPlus program
402546|NCT01076595|Recurrent/remittent multiple sclerosis patients
402547|NCT01076595|Adherence to treatment regimen
402548|NCT01076582|hormone withdrawal associated symptoms
402549|NCT01076504|SCLC
402550|NCT01076504|Amrubicin
402551|NCT01076504|Carboplatin
402552|NCT01076504|Pegfilgrastim
402553|NCT01076504|Neulasta
402554|NCT01076478|Symmetric Diabetic Polyneuropathy
402555|NCT01076465|Heart failure
402556|NCT01076465|Elderly
402557|NCT01076465|Disease management
402558|NCT01076452|Parkinson's Disease
402559|NCT01076452|levo-dopa
402560|NCT01076452|tremor
402561|NCT01076452|dyskinesia
402562|NCT01076452|subthalamic nucleus
402563|NCT01076452|globus pallidus
402564|NCT01076426|probiotic
402565|NCT01076426|peritoneal dialysis
402566|NCT01076426|peritonitis
402567|NCT01076426|nutrition status
402568|NCT01076413|gait
402569|NCT01076413|exercise
402570|NCT01076413|skill-based
402571|NCT01076413|aerobic
402572|NCT01076387|Bladder
402573|NCT01076387|Cystectomy
402574|NCT01076387|Robotic
402575|NCT01076387|Open Radical
402576|NCT01076387|10-016
402577|NCT01076374|pacemaker
402578|NCT01076361|Epicardial
402579|NCT01076361|Pacing Lead
402580|NCT01076348|Epicardial
402581|NCT01076348|Pacing Lead
402582|NCT01076335|Neoadjuvant Hormonal Therapy
402583|NCT01076335|Docetaxel
402584|NCT01076335|Taxotere
402585|NCT01076335|Chemotherapy
402586|NCT01076335|Radical Prostatectomy
402587|NCT01076335|Node-positive Prostate Cancer
402588|NCT01076335|Androgen-dependent prostate cancer
402589|NCT01076335|Lymph node metastases
402590|NCT01076309|cataract surgery
402591|NCT01076309|tamsulosin
402592|NCT01076309|endothelium cell
402593|NCT01076283|baclofen
402594|NCT01076283|alcoholism
402595|NCT01076283|urge
402596|NCT01076283|craving
402597|NCT01076283|alcohol drinking
402598|NCT01076283|biobehavioral mechanisms of baclofen in alcoholism
402599|NCT01076257|brain damage
402600|NCT01076257|constraint induced movement therapy
402601|NCT01076257|kinematic
402602|NCT01076257|function
402603|NCT01076257|outcome
402604|NCT01076257|Quality of life
402605|NCT01076218|Continuous Glucose Monitoring
402606|NCT01076218|Accuracy
402607|NCT01076218|Continuous Glucose Error-Grid Analysis
402608|NCT01076205|Work Productivity
402609|NCT01076205|Long-term Observation
402610|NCT01076205|Humira
402611|NCT01076205|Quality of Life
402612|NCT01076205|Rheumatoid Arthritis
402613|NCT01076192|Moderate Psoriasis
402614|NCT01076192|Psoriasis
402615|NCT01076192|Severe Psoriasis
402616|NCT01076192|Adalimumab
402617|NCT01076192|Effectiveness
402618|NCT01076192|Safety
402619|NCT01076192|Clinical practice
402620|NCT01076179|Infection
402621|NCT01076179|Rilpivirine
402622|NCT01076179|CCR5 antagonists
402623|NCT01076179|Etravirine
402624|NCT01076179|Human Immunodeficiency Virus
402625|NCT01076179|Maraviroc
402626|NCT01076179|Safety and efficacy
402627|NCT01076179|Non nucleoside reverse transcriptase inhibitors (NNRTIs)
402628|NCT01076179|Integrase inhibitors
402629|NCT01076179|Raltegravir
402630|NCT01076179|Kaletra
402631|NCT01076166|Post-marketing observational study
402632|NCT01076166|Lower respiratory tract infections
402633|NCT01076166|Klacid Granules for Oral Suspension
402634|NCT01076153|Post-marketing observational study
402635|NCT01076153|Upper or lower respiratory tract infection
402636|NCT01076153|Klacid MR
402637|NCT01076140|Hypertension as a result of bevacizumab therapy
402638|NCT01076101|SLE
402639|NCT01076101|sister
402640|NCT01076101|autoimmune disease
402641|NCT01076075|Type 2 Diabetes Mellitus
402642|NCT01076062|Pregnancy Maintenance
402643|NCT01076062|Labor, Induced
402644|NCT01076062|spontaneous labor
402645|NCT01076062|cesarean delivery
402646|NCT01076036|ischemia
402647|NCT01076036|stent
402648|NCT01076023|Diabetes
402649|NCT01076023|Cardiovascular disease
402650|NCT01076023|Observational study
402651|NCT01076023|China
402652|NCT01075997|Diabetes Mellitus
402653|NCT01075984|Antifungal Agents pharmacokinetics
402654|NCT01075984|Mycoses prevention and control
402655|NCT01075971|Buprenorphine tablet
402656|NCT01075971|Fast dissolving tablet
402657|NCT01075971|Opioid dependant patients
402658|NCT01075958|n-3 PUFAs
402659|NCT01075958|Fish oil
402660|NCT01075958|Cognitive function
402661|NCT01075958|Healthy young adults
402662|NCT01075945|antimalarials
402663|NCT01075945|ACTs
402664|NCT01075945|Piperaquine
402665|NCT01075945|uncomplicated
402666|NCT01075932|cerebral blood flow
402667|NCT01075932|NIRS
402668|NCT01075932|n-3 PUFAs
402669|NCT01075932|fish oil
402670|NCT01075932|cognitive function
402671|NCT01075919|n-3 PUFAs
402672|NCT01075919|Cognitive function
402673|NCT01075919|Healthy young adults
402674|NCT01075919|Fish oil
402675|NCT01075919|Mood
402676|NCT01075906|pharmacokinetics
402677|NCT01075893|Colorectal cancer
402678|NCT01075893|Stem cells
402679|NCT01075893|Ulcerative colitis
402680|NCT01075893|Polyps
402681|NCT01075880|Multiple Sclerosis, Relapsing-Remitting
402682|NCT01075880|Rebif
402683|NCT01075880|Interferon beta-1a
402684|NCT01075854|Gonal-F
402685|NCT01075854|Multifollicular stimulation
402686|NCT01075854|Pregnancy
402687|NCT01075854|Ovarian hyperstimulation
402688|NCT01075854|In vitro fertilization
402689|NCT01075854|Intracytoplasmic sperm injection
402690|NCT01075854|Infertility
402691|NCT01075841|Head and neck neoplasms
402692|NCT01075841|Carcinoma, squamous cell
402693|NCT01075841|Cetuximab
402694|NCT01075828|Head and Neck Neoplasms
402695|NCT01075828|Neoplasms, Squamous Cell
402696|NCT01075828|Cetuximab
402697|NCT01075815|Infertility
402698|NCT01075815|Ovulation induction
402699|NCT01075815|Luveris
402700|NCT01075815|Controlled ovarian stimulation
402701|NCT01075815|Reproductive technologies, assisted
402702|NCT01075802|Breast cancer
402703|NCT01075802|Tamoxifen
402704|NCT01075802|Endoxifen
402705|NCT01075802|polymorphism of CYP2D6
402706|NCT01075789|Pain
402707|NCT01075789|Discomfort
402708|NCT01075789|Insertion
402709|NCT01075789|Nasogastric tube
402710|NCT01075763|Alzheimer's
402711|NCT01075763|Dementia
402712|NCT01075763|Interferon beta-1a
402713|NCT01075763|Rebif
402714|NCT01075750|hyperkalaemia
402715|NCT01075750|metabolic acidosis
402716|NCT01075750|renal transplantation
402717|NCT01075750|normal saline
402718|NCT01075750|elomel isoton
402719|NCT01075750|fluid management in renal transplantation
402720|NCT01075737|Multiple sclerosis
402721|NCT01075737|Sclerosis
402722|NCT01075737|Quality of life
402723|NCT01075724|Perioperative Hypothermia Prevention
402724|NCT01075724|Accidental Perioperative Hypothermia
402725|NCT01075711|Arthritis, Rheumatoid
402726|NCT01075711|Prednisone
402727|NCT01075698|Type 2 Diabetes
402728|NCT01075698|Cerebrovascular disease
402729|NCT01075698|Coronary Artery Disease
402730|NCT01075698|Chronic Kidney Disease
402731|NCT01075698|Peripheral Artery Disease
402732|NCT01075672|OCD
402733|NCT01075672|BDD
402734|NCT01075672|Tourette syndrome
402735|NCT01075672|trichotillomania
402736|NCT01075672|Compulsive Skin Picking
402737|NCT01075672|panic disorder
402738|NCT01075672|social phobia
402739|NCT01075672|generalized anxiety disorder
402740|NCT01075672|depression
402741|NCT01075672|PTSD
402742|NCT01075672|ADHD
402743|NCT01075672|eating disorder
402744|NCT01075672|Specific Phobia
402745|NCT01075659|Smoking Cessation
402746|NCT01075659|VAS
402747|NCT01075659|Urges to smoke
402748|NCT01075646|postoperative pain
402749|NCT01075646|wound infusion
402750|NCT01075646|local anesthesia
402751|NCT01075633|FOBT
402752|NCT01075633|colonoscopy
402753|NCT01075633|familiar risk
402754|NCT01075633|colorectal cancer
402755|NCT01075633|advanced adenoma
402756|NCT01075620|rotating platform
402757|NCT01075620|posterior stabilized
402758|NCT01075620|non-posterior stabilized
402759|NCT01075607|Lymph fluid collection
402760|NCT01075594|Dyslipidemia
402761|NCT01075594|Target cholesterol
402762|NCT01075594|Undertreatment
402763|NCT01075581|Hemodynamic instability
402764|NCT01075581|Hemostasis
402765|NCT01075555|adult primary hepatocellular carcinoma
402766|NCT01075555|localized unresectable adult primary liver cancer
402767|NCT01075555|advanced adult primary liver cancer
402768|NCT01075555|recurrent adult primary liver cancer
402769|NCT01075542|Corneal astigmatism
402770|NCT01075542|Intraocular lens
402771|NCT01075529|major depressive disorder, fluoxetine, Hamilton Rating Scale for Depression (HAM-D-17)
402772|NCT01075516|Remote Monitoring
402773|NCT01075516|ICD patients
402774|NCT01075516|EQ-5D questionnaire
402775|NCT01075516|remote follow up
402776|NCT01075503|Supraclavicular
402777|NCT01075503|Interscalene
402778|NCT01075503|Infraclavicular
402779|NCT01075503|Brachial plexus block
402780|NCT01075503|Ropivacaine
402781|NCT01075490|spinal anesthesia
402782|NCT01075490|neonates
402783|NCT01075490|clonidine
402784|NCT01075490|post operative apnea
402785|NCT01075464|Solid Tumor
402786|NCT01075451|Staphylococcus aureus
402787|NCT01075451|Antimicrobial Stewardship
402788|NCT01075451|Antibacterial resistance
402789|NCT01075451|Vancomycin
402790|NCT01075438|ataxia telangiectasia
402791|NCT01075438|Pneumococcal Vaccines
402792|NCT01075425|leukemia
402793|NCT01075425|acute leukemia
402794|NCT01075425|chronic myelogenous leukemia
402795|NCT01075425|myelodysplastic syndrome
402796|NCT01075425|relapsed acute leukemia
402797|NCT01075425|refractory acute leukemia
402798|NCT01075425|belinostat
402799|NCT01075425|bortezomib
402800|NCT01075425|Velcade
402801|NCT01075425|PXD-101
402802|NCT01075412|Positron-Emission Tomography
402803|NCT01075412|Radiotherapy, Intensity-Modulated
402804|NCT01075399|[F 18]HX4
402805|NCT01075399|HX4
402806|NCT01075399|Hypoxia
402807|NCT01075399|Head/Neck Cancer
402808|NCT01075399|Lung Cancer
402809|NCT01075399|Liver Cancer
402810|NCT01075399|Rectal Cancer
402811|NCT01075399|Cervical Cancer
402812|NCT01075399|HIF1 alpha
402813|NCT01075399|CAIX
402814|NCT01075386|Hysterectomy
402815|NCT01075386|Endometrial cancer
402816|NCT01075386|Benign
402817|NCT01075386|Endocrine system
402818|NCT01075386|Tissue collection
402819|NCT01075373|early stage schizophrenia
402820|NCT01075373|drug naïve schizophrenia
402821|NCT01075373|treatment response
402822|NCT01075373|Aripiprazole
402823|NCT01075373|pharmacogenetics
402824|NCT01075373|Disrupted-in-Schizophrenia 1 gene (DISC1)
402825|NCT01075373|Neuregulin 1 gene (NRG1)
402826|NCT01075373|Dopamine receptor type 2 gene (DRD2)
402827|NCT01075373|Catechol-O-Methyltransferase gene (COMT)
402828|NCT01075373|neurocognitive function
402829|NCT01075373|event-related evoked potential (ERP)
402830|NCT01075373|Niacin skin test
402831|NCT01075373|plasma neurotransmitter level
402832|NCT01075373|plasma cytokine level
402833|NCT01075373|plasma signaling protein level
402834|NCT01075373|AKT1 protein level in the peripheral lymphocytes
402835|NCT01075373|16-45 y/o
402836|NCT01075373|without mental retardation or epilepsy
402837|NCT01075360|Neuroblastoma, MYCN, AHR
402838|NCT01075347|autoserum
402839|NCT01075347|ocular surgery
402840|NCT01075347|corneal epithelium healing
402841|NCT01075334|sperm
402842|NCT01075334|male infertility
402843|NCT01075334|Carnitine
402844|NCT01075334|food supplementation
402845|NCT01075334|insemination
402846|NCT01075308|hormone-resistant prostate cancer
402847|NCT01075308|recurrent prostate cancer
402848|NCT01075308|stage IV prostate cancer
402849|NCT01075308|stage III prostate cancer
402850|NCT01075308|adenocarcinoma of the prostate
402851|NCT01075295|Schizophreniform Disorder
402852|NCT01075295|Schizophrenia, Schizoaffective disorder
402853|NCT01075295|Bipolar I Disorder
402854|NCT01075295|Bipolar II Disorder
402855|NCT01075295|Major Depressive Disorder with Psychotic Features,
402856|NCT01075295|Substance-Induced Psychoses
402857|NCT01075295|Psychosis Not Otherwise Specified
402858|NCT01075295|antipsychotic
402859|NCT01075295|weight gain
402860|NCT01075295|body mass index
402861|NCT01075295|BMI
402862|NCT01075295|waist circumference
402863|NCT01075295|WC
402864|NCT01075295|coronary heart disease
402865|NCT01075295|CHD
402866|NCT01075269|robotic thyroidectomy, comparative study, cosmetic result, postoperative neck discomfort, swallowing symptom
402867|NCT01075269|Robotic thyroidectomy, cosmetic effect, postoperative distress, surgical outcome
402868|NCT01075256|sensitivity
402869|NCT01075256|occlusion
402870|NCT01075243|dental pain
402871|NCT01075243|paracetamol
402872|NCT01075243|Post-surgical dental pain
402873|NCT01075230|PRP, TKA, pain scale, hemoglobin, hematocrit, narcotics
402874|NCT01075217|Peripheral arterial occlusive disease (PAOD)
402875|NCT01075204|Respiratory Tract Infection
402876|NCT01075204|Clarithromycin
402877|NCT01075204|Recovery
402878|NCT01075191|Viral load
402879|NCT01075191|Resistance
402880|NCT01075191|Double protease inhibitors
402881|NCT01075191|Mutations
402882|NCT01075191|Immune system
402883|NCT01075191|Infection
402884|NCT01075191|Nucleoside Reverse Transcriptase Inhibitors-free
402885|NCT01075191|Human Immunodeficiency Virus
402886|NCT01075178|Infection
402887|NCT01075178|Arrhythmia
402888|NCT01075178|Death
402889|NCT01075178|Palivizumab
402890|NCT01075178|Safety
402891|NCT01075178|Hemodynamically Significant Congenital Heart Disease
402892|NCT01075178|Pediatric
402893|NCT01075178|Observational
402894|NCT01075165|silicone
402895|NCT01075165|burn scar
402896|NCT01075165|hypertrophic scar
402897|NCT01075165|keloid
402898|NCT01075165|scar assessment
402899|NCT01075165|abnormal scarring
402900|NCT01075165|Burn patients
402901|NCT01075152|cryptococcal meningitis
402902|NCT01075152|cryptococcus
402903|NCT01075152|cryptococcosis
402904|NCT01075152|HIV
402905|NCT01075152|AIDS
402906|NCT01075152|strategy
402907|NCT01075139|Motivational interviewing
402908|NCT01075139|Physical activity
402909|NCT01075139|Diet
402910|NCT01075126|bipolar affective disorder
402911|NCT01075126|African American
402912|NCT01075126|antimanic
402913|NCT01075126|lithium
402914|NCT01075126|depakote
402915|NCT01075113|adult primary hepatocellular carcinoma
402916|NCT01075113|advanced adult primary liver cancer
402917|NCT01075113|recurrent adult primary liver cancer
402918|NCT01075100|metastatic
402919|NCT01075100|breast
402920|NCT01075100|cancer
402921|NCT01075087|TAP Block
402922|NCT01075087|Pain
402923|NCT01075087|Obesity
402924|NCT01075087|Surgery
402925|NCT01075087|Laparoscopic Banding
402926|NCT01075074|Pain
402927|NCT01075074|TAP block
402928|NCT01075074|Laparoscopic
402929|NCT01075074|Gynecologic
402930|NCT01075061|Congenital mirror movement, physiopathology, imaging, transcranial magnetic stimulation, candidate gene
402931|NCT01075048|Colorectal cancer
402932|NCT01075048|wild-type KRAS
402933|NCT01075048|irinotecan
402934|NCT01075048|cetuximab
402935|NCT01075048|second-line therapy
402936|NCT01075035|Traumatic Brain Injury
402937|NCT01075035|TBI
402938|NCT01075035|Military
402939|NCT01075035|Imaging
402940|NCT01075035|MEG
402941|NCT01075035|PET/CT
402942|NCT01075035|MRI
402943|NCT01075035|fMRI
402944|NCT01075035|DTI
402945|NCT01075035|SANIC
402946|NCT01075035|veteran
402947|NCT01075009|Antibiotics
402948|NCT01075009|Resistance
402949|NCT01075009|Epidemiology
402950|NCT01075009|Gram-negative bacteria
402951|NCT01075009|Epidemiology of antibiotic use
402952|NCT01074996|Pancreatic cancer
402953|NCT01074996|S-1
402954|NCT01074996|S-1 plus Leucovorin
402955|NCT01074996|second-line therapy
402956|NCT01074983|Prehospital, Oxygen, Trauma, Hypoxemia
402957|NCT01074970|PARP inhibition + breast cancer
402958|NCT01074970|breast cancer
402959|NCT01074970|PARP inhibitor
402960|NCT01074970|Triple negative
402961|NCT01074944|Gaucher disease
402962|NCT01074944|Genz-112638
402963|NCT01074944|beta-glucosidase
402964|NCT01074944|acid β-glucosidase
402965|NCT01074944|glucocerebrosidase
402966|NCT01074944|glucosylceramide
402967|NCT01074944|D-glucosyl-N-acylsphingosine glucohydrolase
402968|NCT01074944|substrate reduction therapy
402969|NCT01074931|Lopinavir/ritonavir
402970|NCT01074918|Pre-hypertension
402971|NCT01074918|Hypertension
402972|NCT01074905|vivax malaria
402973|NCT01074905|artesunate
402974|NCT01074905|chloroquine
402975|NCT01074905|primaquine
402976|NCT01074905|relapse
402977|NCT01074892|endometrial hyperplasia treatment MPA per os LNG-IUD
402978|NCT01074879|Elderly
402979|NCT01074879|protein consumption
402980|NCT01074879|resistance exercise
402981|NCT01074879|muscle mass
402982|NCT01074866|Mechanical ventilation
402983|NCT01074866|Non invasive Ventilation
402984|NCT01074866|Patient-ventilator interaction
402985|NCT01074866|Pressure support
402986|NCT01074866|Neurally adjusted ventilatory assist
402987|NCT01074840|Food Hypersensitivity
402988|NCT01074840|Hypersensitivity
402989|NCT01074840|Immune System Diseases
402990|NCT01074840|Hypersensitivity, Immediate
402991|NCT01074840|Peanut Hypersensitivity
402992|NCT01074840|Food Allergy
402993|NCT01074827|Multiple Sclerosis
402994|NCT01074827|Walking ability
402995|NCT01074827|Strength
402996|NCT01074827|Balance
402997|NCT01074827|Treadmill walking
402998|NCT01074814|Metastatic Breast Cancer
402999|NCT01074814|Molecular profiling
403000|NCT01074801|Closed-loop systems
403001|NCT01074801|day-and-night glucose control
403002|NCT01074788|rehabilitation
403003|NCT01074788|mind body therapy
403004|NCT01074788|integrative medicine
403005|NCT01074775|innate immunity
403006|NCT01074775|mycobacterium bovis
403007|NCT01074775|mucosal immunity
403008|NCT01074775|adaptive immunity
403009|NCT01074775|genomics
403010|NCT01074762|Diabetes mellitus
403011|NCT01074762|Quality of health care
403012|NCT01074762|Health services research
403013|NCT01074749|AF
403014|NCT01074749|Automatic Mode Switch
403015|NCT01074749|FFRW
403016|NCT01074749|paroxysmal AF
403017|NCT01074736|influenza A/H5N1
403018|NCT01074736|host genetic susceptibility
403019|NCT01074736|genotyping
403020|NCT01074723|b-cryptoxanthin
403021|NCT01074723|cholesterol
403022|NCT01074723|bone markers
403023|NCT01074723|Osteoporosis
403024|NCT01074723|cardiovascular risk
403025|NCT01074723|post-menopausal women
403026|NCT01074697|Randomized Controlled Trial
403027|NCT01074697|Serotonin Agonists
403028|NCT01074697|Dexamethasone
403029|NCT01074697|Receptors, Neurokinin-1
403030|NCT01074697|Radiotherapy
403031|NCT01074697|Cisplatin
403032|NCT01074697|Prevention & control
403033|NCT01074684|diagnosis
403034|NCT01074684|nodules
403035|NCT01074684|fine needle aspiration
403036|NCT01074658|Advance
403037|NCT01074658|Medtronic CoreValve System
403038|NCT01074658|International
403039|NCT01074658|Interventional
403040|NCT01074658|Post Market Study
403041|NCT01074645|Acute-on -chronic liver failure
403042|NCT01074645|Reactivation of hepatitis B
403043|NCT01074645|Spontaneous reactivation of chronic hepatitis B presenting as to acute-on-chronic liver failure
403044|NCT01074606|Cataract
403045|NCT01074593|PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUG INTERFERON BETA-1A
403046|NCT01074580|Crohn's disease
403047|NCT01074580|sonography
403048|NCT01074580|contrast enhanced ultrasound
403049|NCT01074554|sarcoidosis
403050|NCT01074554|mycobacteria
403051|NCT01074554|cutaneous lesions
403052|NCT01074541|Vitamin D
403053|NCT01074541|UVB
403054|NCT01074541|Dose-Response
403055|NCT01074541|UV intensity
403056|NCT01074541|Skin cancer
403057|NCT01074528|cancer patients
403058|NCT01074528|relatives or partners of cancer patients
403059|NCT01074515|COPD
403060|NCT01074515|Depression
403061|NCT01074515|Inflammation
403062|NCT01074515|Genetics
403063|NCT01074515|Functioning
403064|NCT01074515|Dyspnea
403065|NCT01074515|Physical activity
403066|NCT01074502|acne
403067|NCT01074489|GDM
403068|NCT01074489|Gestational Diabetes
403069|NCT01074489|GTT
403070|NCT01074489|CGMS
403071|NCT01074476|Knee osteoarthritis
403072|NCT01074476|glucosamine
403073|NCT01074476|synovial fluid
403074|NCT01074476|viscosity
403075|NCT01074476|viscoelasticity
403076|NCT01074476|WOMAC
403077|NCT01074463|Bioequivalence
403078|NCT01074463|Healthy Subjects
403079|NCT01074450|Bioequivalence
403080|NCT01074450|Healthy Subjects
403081|NCT01074424|stage IIB cervical cancer
403082|NCT01074424|stage III cervical cancer
403083|NCT01074424|stage IVA cervical cancer
403084|NCT01074424|cervical adenocarcinoma
403085|NCT01074424|cervical adenosquamous cell carcinoma
403086|NCT01074424|cervical squamous cell carcinoma
403087|NCT01074398|recurrent ovarian epithelial cancer
403088|NCT01074398|stage III ovarian epithelial cancer
403089|NCT01074398|stage IV ovarian epithelial cancer
403090|NCT01074398|fallopian tube cancer
403091|NCT01074398|peritoneal cavity cancer
403092|NCT01074385|Stage IV Colorectal Cancer
403093|NCT01074359|A3243G Mitochondrial DNA Point Mutation
403094|NCT01074346|Multiple sclerosis
403095|NCT01074346|Interferon-beta 1-a
403096|NCT01074333|Colorectal cancer
403097|NCT01074333|Metastasis
403098|NCT01074333|Cetuximab
403099|NCT01074333|Erbitux
403100|NCT01074333|Epidermal growth factor receptor
403101|NCT01074320|breast cancer
403102|NCT01074320|aromatase inhibitors
403103|NCT01074320|musculoskeletal symptoms
403104|NCT01074307|Systolic heart failure
403105|NCT01074307|Bisoprolol
403106|NCT01074307|Concor
403107|NCT01074307|Echocardiogram
403108|NCT01074294|Inattention
403109|NCT01074294|Hyperactivity
403110|NCT01074294|Impulsivity
403111|NCT01074294|Distractibility
403112|NCT01074294|Procrastination
403113|NCT01074294|Disorganized
403114|NCT01074294|ADHD
403115|NCT01074281|Hypertension
403116|NCT01074281|Isolated systolic hypertonia
403117|NCT01074281|Eneas
403118|NCT01074255|Nausea
403119|NCT01074255|Vomiting
403120|NCT01074255|Chemotherapy
403121|NCT01074255|Post-chemotherapy
403122|NCT01074242|Gastroenteritis rotavirus
403123|NCT01074229|Pain
403124|NCT01074229|Post Operative
403125|NCT01074229|Opioids
403126|NCT01074229|Laparoscopic
403127|NCT01074229|Surgery
403128|NCT01074229|Hysterectomy
403129|NCT01074216|Vitamin D
403130|NCT01074216|Vitamin D3
403131|NCT01074216|colon cancer
403132|NCT01074216|rectum cancer
403133|NCT01074216|Cholecalciferol
403134|NCT01074216|09-143
403135|NCT01074203|nitazoxanide
403136|NCT01074203|liver transplantation
403137|NCT01074203|HCV recurrence
403138|NCT01074190|Epidural Labor Analgesia
403139|NCT01074190|Pain
403140|NCT01074190|Infant
403141|NCT01074190|Breastfeeding
403142|NCT01074177|BIBW 2992
403143|NCT01074177|NSCLC
403144|NCT01074164|eczema
403145|NCT01074164|atopic dermatitis
403146|NCT01074164|itch
403147|NCT01074164|pruritus
403148|NCT01074164|acupressure
403149|NCT01074164|acupuncture
403150|NCT01074151|Pregnancy
403151|NCT01074151|pregnant
403152|NCT01074151|Cymbalta
403153|NCT01074151|Pregnancy Outcomes
403154|NCT01074138|CPRC
403155|NCT01074125|Hyperphosphatemia
403156|NCT01074125|ESRD
403157|NCT01074125|Dialysis
403158|NCT01074125|End Stage Renal Disease
403159|NCT01074125|Phosphorus
403160|NCT01074125|Renal
403161|NCT01074125|Kidney
403162|NCT01074112|Ultrasound
403163|NCT01074112|Prehospital
403164|NCT01074112|Trauma
403165|NCT01074112|EMS
403166|NCT01074112|Paramedics
403167|NCT01074112|Sonography
403168|NCT01074112|Ultrasonography
403169|NCT01074112|Ambulance
403170|NCT01074112|FAST
403171|NCT01074112|EFAST
403172|NCT01074086|RAD 001 in relapsed AML
403173|NCT01074073|Lithium DDI with Lurasidone HCl
403174|NCT01074073|Male/Female, Schizophrenia Patients
403175|NCT01074047|Acute Myeloid Leukemia
403176|NCT01074047|Cytarabine
403177|NCT01074047|Vidaza
403178|NCT01074047|azacitidine
403179|NCT01074047|Intensive Chemotherapy
403180|NCT01074047|Low Dose Cytarabine
403181|NCT01074047|Celgene
403182|NCT01074021|Nimotuzumab
403183|NCT01074021|Nasopharyngeal cancer
403184|NCT01074021|chemoradiation
403185|NCT01073995|Radiculopathy
403186|NCT01073995|Sciatica
403187|NCT01073995|Lumbar Disc Herniation
403188|NCT01073995|Surgical Alternative
403189|NCT01073982|pain
403190|NCT01073982|inflammation
403191|NCT01073982|osteoarthritis
403192|NCT01073969|prebiotic study
403193|NCT01073969|modulating colonic bacteria
403194|NCT01073956|Subacromial Impingement Syndrome
403195|NCT01073956|Shoulder Pain
403196|NCT01073956|Physical therapy
403197|NCT01073956|Electrotherapy
403198|NCT01073956|Ultrasonic therapy
403199|NCT01073956|Medium-wave 448 kHz therapy
403200|NCT01073943|Bowel Preparation
403201|NCT01073943|Colonoscopy
403202|NCT01073930|Bowel Preparation
403203|NCT01073930|Colonoscopy
403204|NCT01073917|Ventilation
403205|NCT01073917|General Anesthesia
403206|NCT01073917|electrical impedance tomography
403207|NCT01073917|pressure support
403208|NCT01073917|spontaneous breathing
403209|NCT01073917|laryngeal mask
403210|NCT01073917|Patients who are scheduled for elective knee or ankle surgery
403211|NCT01073891|Pharmacokinetics
403212|NCT01073891|Bioavailability
403213|NCT01073891|Food effect
403214|NCT01073891|Oral liquid formulation
403215|NCT01073878|Urinary Urge Incontinence
403216|NCT01073878|Urinary Stress Incontinence
403217|NCT01073878|Urinary Mixed Incontinence
403218|NCT01073865|ZOLADEX
403219|NCT01073865|Pre-menopausal
403220|NCT01073865|Oestrogen Receptor
403221|NCT01073865|Advanced Breast Cancer
403222|NCT01073865|Progression Free Survival
403223|NCT01073852|Chronic Urticaria
403224|NCT01073852|Hives
403225|NCT01073852|Hydroxychloroquine
403226|NCT01073813|Minocycline
403227|NCT01073813|Retinal nerve fibre layer thickness
403228|NCT01073813|Macular volume
403229|NCT01073813|Visual outcomes
403230|NCT01073800|atorvastatin
403231|NCT01073800|vascular occlusion
403232|NCT01073800|myocardial infarction
403233|NCT01073800|stroke
403234|NCT01073800|renal failure
403235|NCT01073800|critically ill
403236|NCT01073800|Vascular occlusive events among the critically ill
403237|NCT01073787|migraine
403238|NCT01073787|headache
403239|NCT01073787|pediatric
403240|NCT01073787|children
403241|NCT01073787|Emergency Department
403242|NCT01073774|breast cancer couples coping
403243|NCT01073748|Asthma
403244|NCT01073748|Acetaminophen
403245|NCT01073748|paracetamol
403246|NCT01073748|FeNO
403247|NCT01073748|Spirometry
403248|NCT01073748|Lung function
403249|NCT01073735|Needs assessment
403250|NCT01073735|Health-related needs
403251|NCT01073735|Childhood cancer survivors
403252|NCT01073722|thoracic surgery
403253|NCT01073722|one-lung ventilation
403254|NCT01073722|double lumen tube
403255|NCT01073722|endobronchial blocker
403256|NCT01073709|Acetaminophen fasting study
403257|NCT01073696|Sancuso
403258|NCT01073696|granisetron
403259|NCT01073696|Pharmacokinetics
403260|NCT01073683|TPF
403261|NCT01073683|INDUCTION CHEMOTHERAPY
403262|NCT01073683|LARYNX PRESERVATION
403263|NCT01073683|SUPACRICOID LARYNGECTOMY
403264|NCT01073683|Stage 3 and 4 larynx cancer
403265|NCT01073670|NSAIDs
403266|NCT01073670|bleeding
403267|NCT01073670|thromboelastography
403268|NCT01073670|cardiac surgery
403269|NCT01073670|Indomethacin
403270|NCT01073670|acetaminophen
403271|NCT01073657|Rehabilitation
403272|NCT01073644|imatinib resistant or intolerant
403273|NCT01073631|voriconazole
403274|NCT01073631|Korea
403275|NCT01073631|invasive fungal infection
403276|NCT01073618|voriconazole
403277|NCT01073618|Korea
403278|NCT01073618|invasive fungal infection
403279|NCT01073605|Short height
403280|NCT01073605|intra-uterine growth retardation
403281|NCT01073605|Genotonorm
403282|NCT01073605|continuous treatment
403283|NCT01073605|intermittent treatment
403284|NCT01073592|HMP
403285|NCT01073592|CNV
403286|NCT01073592|AMD
403287|NCT01073592|PHP
403288|NCT01073592|HPHP
403289|NCT01073592|FORESEE HOME
403290|NCT01073579|Cryptogenic Infantile Spasms
403291|NCT01073579|Cryptogenic West Syndrome
403292|NCT01073579|Hypsarrhythmia
403293|NCT01073579|Infantile Spasms
403294|NCT01073579|Symptomatic Infantile Spasms
403295|NCT01073579|Symptomatic West Syndrome
403296|NCT01073579|West Syndrome
403297|NCT01073579|Refractory Complex Partial Seizures
403298|NCT01073579|Complex Partial Epilepsy
403299|NCT01073579|Complex Partial Seizure Disorder
403300|NCT01073579|Cryptogenic Partial Complex Epilepsy
403301|NCT01073579|Disorder, Complex Partial Seizures
403302|NCT01073579|Epilepsy, Cryptogenic, Partial Complex
403303|NCT01073579|Epilepsy, Psychic Equivalent
403304|NCT01073579|Epilepsy, Psychomotor
403305|NCT01073579|Epilepsy, Symptomatic, Partial Complex
403306|NCT01073579|Partial Complex Epilepsy, Cryptogenic
403307|NCT01073579|Partial Complex Epilepsy, Symptomatic
403308|NCT01073579|Seizure Disorder, Complex Partial
403309|NCT01073579|Symptomatic Partial Complex Epilepsy
403310|NCT01073566|Autoimmune Diseases
403311|NCT01073566|Diabetes Mellitus
403312|NCT01073566|Endocrine System Diseases
403313|NCT01073566|Glucose Metabolism Disorders
403314|NCT01073566|Immune System Diseases
403315|NCT01073566|Insulin
403316|NCT01073566|Metabolic Diseases
403317|NCT01073527|Child, preschool
403318|NCT01073527|Pediatric emergency department
403319|NCT01073514|Malignant biliary obstruction (MBO)
403320|NCT01073501|UREMIC PRURITUS
403321|NCT01073501|PREGABALIN
403322|NCT01073501|UP
403323|NCT01073488|Pregnancy
403324|NCT01073488|Maternal child health
403325|NCT01073488|Developing countries
403326|NCT01073488|Stillbirth
403327|NCT01073488|Neonatal mortality
403328|NCT01073488|Maternal mortality
403329|NCT01073488|Community intervention
403330|NCT01073488|Community mobilization
403331|NCT01073488|Home-based Life Saving Skills
403332|NCT01073475|Pregnancy
403333|NCT01073475|Maternal mortality
403334|NCT01073475|Neonatal mortality
403335|NCT01073475|Stillbirth
403336|NCT01073475|Maternal Near Miss
403337|NCT01073475|Maternal Cause of Death
403338|NCT01073475|Neonatal Cause of Death
403339|NCT01073462|Secondary Hyperparathyroidism (sHPT)
403340|NCT01073462|Paricalcitol
403341|NCT01073462|Chronic kidney disease stage 5 (CKD stage 5)
403342|NCT01073449|Cardiac devices
403343|NCT01073449|In-Hospital Follow-up
403344|NCT01073449|Analytical
403345|NCT01073436|diagnosis of Ph+) CML in chronic phase.
403346|NCT01073436|prior therapy with interferon-alpha for at least 2 years, and achieved at least a partial cytogenetic response
403347|NCT01073436|receiving a TKI (imatinib mesylate, dasatinib, nilotinib)
403348|NCT01073436|WBC ≤ 10 x 109/L.
403349|NCT01073436|Platelet count < 450,000 x 109/L.
403350|NCT01073436|No blasts or promyelocytes in peripheral blood.
403351|NCT01073436|No evidence of disease-related symptoms and extramedullary disease
403352|NCT01073436|complete cytogenetic response (CCyR) on a TKI for a minimum of 1 yr
403353|NCT01073436|major molecular remission on a TKI for a minimum of 1 yr
403354|NCT01073436|18 years of age or older
403355|NCT01073436|ECOG performance status of 0-2 (Appendix 13.1)
403356|NCT01073436|Informed Consent
403357|NCT01073423|HIV
403358|NCT01073423|sleep
403359|NCT01073423|insomnia
403360|NCT01073423|yoga
403361|NCT01073423|music
403362|NCT01073397|Menopause
403363|NCT01073397|Hot Flashes
403364|NCT01073397|Vasomotor symptoms
403365|NCT01073397|Yoga
403366|NCT01073371|Liposome
403367|NCT01073371|Prilocaine
403368|NCT01073371|Dental anesthesia
403369|NCT01073358|resectable hepatic metastases of colorectal cancer
403370|NCT01073345|Patients undergoing elective hepatic resection
403371|NCT01073319|Methamphetamine
403372|NCT01073319|Rivastigmine
403373|NCT01073306|Vaccine
403374|NCT01073306|Dengue Hemorrhagic Fever
403375|NCT01073280|Cerebral and subarachnoid biopsy
403376|NCT01073280|flexible endoscopy
403377|NCT01073280|Patients with neurological findings without diagnosis.
403378|NCT01073267|Stage IB-IIIA Mycosis fungoides
403379|NCT01073267|Total Skin Electron Beam Therapy
403380|NCT01073267|TSEBT
403381|NCT01073241|benign prostatic hyperplasia
403382|NCT01073241|Transurethral Resection of Prostate
403383|NCT01073241|transurethral enucleation of prostate
403384|NCT01073228|Alzheimer's disease
403385|NCT01073228|Central Nervous System diseases
403386|NCT01073228|Cognition
403387|NCT01073215|Adolescents
403388|NCT01073215|Obesity
403389|NCT01073215|Weight Management
403390|NCT01073215|Family-based Lifestyle Modification
403391|NCT01073189|Acute kidney injury
403392|NCT01073189|Fenoldopam mesylate
403393|NCT01073189|Benephit catheter
403394|NCT01073176|ADHD
403395|NCT01073176|Executive function
403396|NCT01073176|Preschool children
403397|NCT01073176|Treatment
403398|NCT01073176|Memory
403399|NCT01073176|Attention
403400|NCT01073176|Training
403401|NCT01073176|Cognitive enhancement
403402|NCT01073150|Tea Tree Oil
403403|NCT01073150|Chronic Blepharitis
403404|NCT01073137|diabetes
403405|NCT01073072|bovine pericardium bioprosthesis
403406|NCT01073072|contamination
403407|NCT01073072|hernia repair
403408|NCT01073072|abdominal wall reconstruction
403409|NCT01073072|Tutomesh
403410|NCT01073072|Tutopatch
403411|NCT01073072|Potentially Contaminated Hernia Repair
403412|NCT01073072|Potentially Contaminated Abdominal Wall Reconstruction
403413|NCT01073059|valproic acid
403414|NCT01073059|ertapenem
403415|NCT01073046|Naso-Gastric/Jejunal Tube
403416|NCT01073046|Sub-total Gastrectomy
403417|NCT01073046|Gastric Cancer
403418|NCT01073046|Decompression
403419|NCT01073046|Discomfort
403420|NCT01073046|Complications
403421|NCT01073033|pregnancy
403422|NCT01073033|lactation
403423|NCT01073033|oral supplement
403424|NCT01073033|probiotics
403425|NCT01073033|early infections
403426|NCT01073020|Type 2 Diabetes Mellitus
403427|NCT01073020|Obesity
403428|NCT01073020|Lifestyle
403429|NCT01073020|Bariatric Surgery
403430|NCT01073020|Laparoscopic Adjustable Gastric Band
403431|NCT01073020|Laparoscopic Roux-en-Y Gastric Bypass
403432|NCT01073007|Acute Stroke
403433|NCT01073007|tissue plasminogen activator
403434|NCT01073007|simvastatin
403435|NCT01072994|Myocardium
403436|NCT01072994|Phospholipid
403437|NCT01072994|Fish oil
403438|NCT01072994|Cardiolipin
403439|NCT01072994|Transplantation
403440|NCT01072981|Pancreatic Cancer
403441|NCT01072981|Vaccine Therapy
403442|NCT01072968|Multicenter
403443|NCT01072968|Randomized
403444|NCT01072968|Double-blind
403445|NCT01072968|Efficacy and safety study
403446|NCT01072968|BF2.649 versus placebo
403447|NCT01072968|Patients suffering from Obstructive Sleep Apnea
403448|NCT01072968|Complaining from Excessive Daytime Sleepiness
403449|NCT01072968|Refusing nasal Continuous Positive Airway Pressure
403450|NCT01072942|Chronic Obstructive
403451|NCT01072942|Phase I
403452|NCT01072942|Pharmacokinetics
403453|NCT01072942|Microbiology
403454|NCT01072929|Bipolar I Disorder
403455|NCT01072916|Colon, Irritable
403456|NCT01072916|Microbiota
403457|NCT01072903|inflammation
403458|NCT01072903|colon, irritable
403459|NCT01072903|Colonic Diseases, Functional
403460|NCT01072903|Irritable Bowel Syndrome
403461|NCT01072890|Temsirolimus, Pazopanib
403462|NCT01072877|Varicose Veins
403463|NCT01072864|Postmenopausal
403464|NCT01072851|colorectal cancer screening
403465|NCT01072851|multimedia education
403466|NCT01072851|print education
403467|NCT01072851|culturally competent
403468|NCT01072838|breast cancer
403469|NCT01072838|APBI
403470|NCT01072838|brachytherapy
403471|NCT01072838|Contura
403472|NCT01072812|Alzheimer's
403473|NCT01072812|Amnestic Mild Cognitive Impairment
403474|NCT01072812|Pharmacokinetics
403475|NCT01072812|Pharmacodynamics
403476|NCT01072812|Biomarkers
403477|NCT01072799|A (H1N1)
403478|NCT01072786|Dengue Virus
403479|NCT01072786|Dengue Fever
403480|NCT01072786|Dengue Vaccine
403481|NCT01072786|Dengue Hemorrhagic Fever
403482|NCT01072786|Dengue Shock Syndrome
403483|NCT01072760|Mallet finger
403484|NCT01072760|extensor tendon
403485|NCT01072760|Kirschner wire
403486|NCT01072760|Fracture Fixation
403487|NCT01072734|Lupus
403488|NCT01072734|CXCR4 on leucocytes of patients with SLE
403489|NCT01072734|Influenza vaccine
403490|NCT01072721|Liver
403491|NCT01072721|Fibrosis
403492|NCT01072721|Elastometry
403493|NCT01072721|FIBROSCANN
403494|NCT01072721|Children
403495|NCT01072708|Cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors
403496|NCT01072695|Hepatitis C
403497|NCT01072695|HCV
403498|NCT01072695|GS-9256
403499|NCT01072695|GS-9190
403500|NCT01072695|Genotype 1
403501|NCT01072682|Acute Renal Failure
403502|NCT01072682|Acute tubular necrosis
403503|NCT01072682|Continuous Renal Replacement Therapy
403504|NCT01072682|Selective cytopheretic device
403505|NCT01072669|Ambrisentan increases digital micro-vascular flow (measured by LDPI) in patients with Raynaud's phenomenon (RP) and digital ischemia secondary to SSc.
403506|NCT01072643|Sedation
403507|NCT01072643|Pulmonary Hypertension
403508|NCT01072643|Pediatric
403509|NCT01072643|Cardiac Catheterization
403510|NCT01072643|Pulmonary Vascular Resistance
403511|NCT01072630|Bipolar I Disorder
403512|NCT01072604|Aspirin
403513|NCT01072604|Acetylsalicylic Acid
403514|NCT01072591|anti-NGF
403515|NCT01072591|OA
403516|NCT01072591|pain
403517|NCT01072578|Healthy volunteers
403518|NCT01072578|Inhibition of glucose re-absorption
403519|NCT01072578|diabetes
403520|NCT01072578|dapagliflozin
403521|NCT01072565|Type 2 Diabetes
403522|NCT01072565|A1c
403523|NCT01072565|Continuous Glucose Monitoring
403524|NCT01072565|Blood Glucose
403525|NCT01072552|recurrent wheezing
403526|NCT01072552|asthma
403527|NCT01072552|preterm infants
403528|NCT01072552|palivizumab
403529|NCT01072552|atopic diseases
403530|NCT01072539|infection
403531|NCT01072539|Tygacil
403532|NCT01072539|PMS
403533|NCT01072526|Dry Eye Syndromes
403534|NCT01072526|Lacrimal Apparatus Diseases
403535|NCT01072513|Semen Analysis, Prostate Cancer, Proton Radiation
403536|NCT01072500|Aging
403537|NCT01072500|Physical Activity
403538|NCT01072500|Exercise
403539|NCT01072500|Sedentary Lifestyle
403540|NCT01072500|Mobility
403541|NCT01072500|Disability
403542|NCT01072500|Falls
403543|NCT01072500|Cost effectiveness
403544|NCT01072500|Behavioral counseling
403545|NCT01072487|Safety
403546|NCT01072487|Sedation
403547|NCT01072487|Gastrointestinal endoscopy
403548|NCT01072487|Colonoscopy
403549|NCT01072474|Safety
403550|NCT01072474|Sedation
403551|NCT01072474|Gastrointestinal endoscopy
403552|NCT01072474|Colonoscopy
403553|NCT01072461|Cerebrovascular Accident
403554|NCT01072461|Robotics
403555|NCT01072461|Virtual Reality
403556|NCT01072461|Rehabilitation
403557|NCT01072461|Neuroplasticity
403558|NCT01072448|COPD
403559|NCT01072448|indacaterol
403560|NCT01072435|ERCP
403561|NCT01072435|patient-controlled sedation
403562|NCT01072435|target-controlled infusion
403563|NCT01072435|propofol
403564|NCT01072435|Sedation with propofol for ERCP
403565|NCT01072435|Endoscopic Retrograde Cholangiopancreatography
403566|NCT01072422|Smoking
403567|NCT01072422|Pulmonary Disease, Chronic Obstructive
403568|NCT01072422|Questionnaires
403569|NCT01072422|Nurses
403570|NCT01072422|Primary Health Care
403571|NCT01072409|Speech perception ability in the CI alone condition
403572|NCT01072383|chronic plaque psoriasis
403573|NCT01072383|psoriasis vulgaris
403574|NCT01072383|autoimmune disease
403575|NCT01072370|Umbilical Cord Blood
403576|NCT01072370|Stem Cells
403577|NCT01072370|Autologous Blood Transfusion
403578|NCT01072370|Cerebral Palsy
403579|NCT01072357|High-Risk Corneal Transplantation
403580|NCT01072357|Penetrating Keratoplasty
403581|NCT01072357|Neovascularization
403582|NCT01072357|Corneal Blood Vessels
403583|NCT01072357|Avastin
403584|NCT01072357|Bevacizumab
403585|NCT01072357|Corneal Graft
403586|NCT01072344|Anxiety
403587|NCT01072344|Chamomile
403588|NCT01072344|Herbal Remedy
403589|NCT01072344|Complementary and Alternative Medicine
403590|NCT01072331|insulin resistance
403591|NCT01072318|Breast cancer
403592|NCT01072318|extended adjuvant hormonal therapy
403593|NCT01072318|letrozole
403594|NCT01072318|Toremifene
403595|NCT01072305|fluid restriction
403596|NCT01072305|fluid therapy
403597|NCT01072305|intraoperative care
403598|NCT01072279|Malnutrition;
403599|NCT01072279|Infant nutrition;
403600|NCT01072279|Fortified food
403601|NCT01072279|Linear growth
403602|NCT01072279|Cluster randomized controlled trials
403603|NCT01072279|Effectiveness
403604|NCT01072279|Impact evaluation studies
403605|NCT01072279|Burundi
403606|NCT01072279|Guatemala
403607|NCT01072266|Refractory, Advanced malignancies
403608|NCT01072227|Non-typeable Haemophilus Influenzae
403609|NCT01072227|Acute Otitis Media
403610|NCT01072227|Streptococcus Pneumoniae
403611|NCT01072227|Etiology
403612|NCT01072214|Pazopanib
403613|NCT01072214|Tolerability
403614|NCT01072214|Pharmacokinetics
403615|NCT01072214|GW786034
403616|NCT01072214|Safety
403617|NCT01072175|drug-drug interaction
403618|NCT01072175|BRAF inhibitor
403619|NCT01072175|expansion cohorts
403620|NCT01072175|melanoma
403621|NCT01072175|dose escalation
403622|NCT01072175|MEK inhibitor
403623|NCT01072162|healthy
403624|NCT01072162|powder for suspension
403625|NCT01072162|tablets
403626|NCT01072162|bioavailibility
403627|NCT01072162|eltrombopag
403628|NCT01072149|COPD
403629|NCT01072149|Safety
403630|NCT01072149|FEV1
403631|NCT01072149|Efficacy
403632|NCT01072136|mucopurulent cervicitis, chlamydia, gonorrhea, women
403633|NCT01072110|Patients with diarrhea
403634|NCT01072097|PCOS
403635|NCT01072097|Atorvastatin
403636|NCT01072097|Androgens
403637|NCT01072097|Glucose metabolism
403638|NCT01072097|Inflammatory markers
403639|NCT01072084|food allergy
403640|NCT01072084|confocal laser endoscope
403641|NCT01072084|diagnosis
403642|NCT01072084|Diagnosis of food allergy
403643|NCT01072071|abdominal compartment syndrome
403644|NCT01072071|intra-abdominal pressure
403645|NCT01072071|furosemide
403646|NCT01072071|fluid balance
403647|NCT01072058|Infliximab
403648|NCT01072058|Adalimumab
403649|NCT01072058|Etanercept
403650|NCT01072058|Heart failure
403651|NCT01072058|Diastolic disfunction
403652|NCT01072058|TNF blocker
403653|NCT01072058|Anti-TNF
403654|NCT01072058|Echocardiography
403655|NCT01072058|Tissue doppler imaging
403656|NCT01072058|Brain Natriuretic Peptide
403657|NCT01072058|NT-proBNP
403658|NCT01072045|Hemangioma
403659|NCT01072045|Proliferative hemangioma
403660|NCT01072045|Treatment
403661|NCT01072045|Propranolol
403662|NCT01072045|Corticosteroid
403663|NCT01072032|EEG
403664|NCT01072032|Robotics (ankle)
403665|NCT01072032|Motor-learning
403666|NCT01072032|Brain Plasticity
403667|NCT01072006|TBI (Traumatic Brain Injury)
403668|NCT01072006|PTSD
403669|NCT01072006|fMRI
403670|NCT01072006|attention
403671|NCT01071993|prevention
403672|NCT01071993|nephropathy
403673|NCT01071967|Community Health Nursing
403674|NCT01071967|Nursing Care Management
403675|NCT01071967|Aged
403676|NCT01071967|Aged, 80 and over
403677|NCT01071967|Health Services for the Aged
403678|NCT01071967|Geriatric Nursing
403679|NCT01071967|Geriatric Assessment
403680|NCT01071967|Longevity
403681|NCT01071967|Mortality
403682|NCT01071954|Immune thrombocytopenic Purpura
403683|NCT01071954|Pediatric
403684|NCT01071954|Thrombocytopenia
403685|NCT01071941|rRp450
403686|NCT01071941|Herpes virus
403687|NCT01071941|Gene therapy
403688|NCT01071928|Advanced Urothelial Carcinoma
403689|NCT01071902|ear tubes
403690|NCT01071902|ear drainage
403691|NCT01071902|ear infection
403692|NCT01071902|ear drops
403693|NCT01071902|acute otitis media
403694|NCT01071889|Healthy Volunteers
403695|NCT01071876|Sleep disorder
403696|NCT01071876|obstructive sleep apnea
403697|NCT01071876|excessive daytime sleepiness
403698|NCT01071876|patients with OSA treated by CPAP presenting EDS
403699|NCT01071850|Type 2 diabetes
403700|NCT01071850|diabetes
403701|NCT01071850|ASP1941
403702|NCT01071850|Metformin
403703|NCT01071837|Glioblastoma Multiforme
403704|NCT01071824|size
403705|NCT01071824|limb
403706|NCT01071824|transverse coloplasty pouch
403707|NCT01071824|rectal resection
403708|NCT01071824|mesorectal excision
403709|NCT01071824|treatment outcome
403710|NCT01071811|Randomized controlled trial
403711|NCT01071811|Pedometer
403712|NCT01071811|Physical activity
403713|NCT01071811|Health measurement
403714|NCT01071811|Self-rated health
403715|NCT01071811|Stress
403716|NCT01071811|Sleep quality
403717|NCT01071785|Metabolic Syndrome
403718|NCT01071785|diet
403719|NCT01071785|fiber
403720|NCT01071785|Serum lipids
403721|NCT01071785|Albuminuria
403722|NCT01071759|Pregnancy
403723|NCT01071759|anemia
403724|NCT01071759|Helicobacter pylori
403725|NCT01071759|Hemoglobin
403726|NCT01071759|Iron
403727|NCT01071759|Ferritin
403728|NCT01071720|Healthy subjects
403729|NCT01071707|IPF
403730|NCT01071707|Idiopathic Pulmonary Fibrosis
403731|NCT01071694|Multiple Sclerosis,
403732|NCT01071694|Relapsing-Remitting,
403733|NCT01071694|Interferon beta-1b,
403734|NCT01071694|Quality of life
403735|NCT01071681|Arterial hypertension
403736|NCT01071668|onset of labor
403737|NCT01071668|metabolomics
403738|NCT01071668|vaginal secretions
403739|NCT01071668|urine
403740|NCT01071668|blood
403741|NCT01071655|colorectal cancer
403742|NCT01071655|Bevacizumab
403743|NCT01071655|Oxaliplatin
403744|NCT01071655|Irinotecan
403745|NCT01071655|5FU
403746|NCT01071655|capecitabine
403747|NCT01071642|Change in eGFR from baseline to 72 hours following the exposure to the contrast.
403748|NCT01071642|Rate of eGFR decrease>25% from the baseline
403749|NCT01071642|Length of hospitalization.
403750|NCT01071642|Requirement of unplanned therapy for elevated blood pressure
403751|NCT01071629|interval training
403752|NCT01071629|strength training
403753|NCT01071629|exercise capacity
403754|NCT01071629|chronic heart failure
403755|NCT01071629|Cardiac rehabilitation
403756|NCT01071616|Cannabinoids
403757|NCT01071616|Oral Fluid
403758|NCT01071616|Pharmacokinetics
403759|NCT01071616|Stability
403760|NCT01071616|Smoked Cannabis
403761|NCT01071603|Biomarkers
403762|NCT01071603|Extrapulmonary TB
403763|NCT01071603|NTM
403764|NCT01071603|HRCT
403765|NCT01071603|MDRTB
403766|NCT01071603|Tuberculosis
403767|NCT01071590|Parkinson's Disease
403768|NCT01071590|Sensory Input
403769|NCT01071590|Gait
403770|NCT01071590|Imagery
403771|NCT01071590|Parkinson Disease
403772|NCT01071590|PD
403773|NCT01071577|Bone Marrow Stromal Cells
403774|NCT01071577|Mesenchymal Stem Cells
403775|NCT01071577|Immune Modulation
403776|NCT01071577|Tissue Regeneration
403777|NCT01071577|Bone Marrow
403778|NCT01071577|Healthy Volunteer
403779|NCT01071577|HV
403780|NCT01071551|Children
403781|NCT01071551|Obesity
403782|NCT01071551|Lifestyle
403783|NCT01071551|LSES
403784|NCT01071551|Caries
403785|NCT01071538|Depressive Disorder, Major
403786|NCT01071538|Late-Life Depression
403787|NCT01071538|Geriatrics
403788|NCT01071538|Buprenorphine
403789|NCT01071512|MRI
403790|NCT01071512|OCT
403791|NCT01071512|Tysabri
403792|NCT01071512|Multiple Sclerosis
403793|NCT01071512|cognition
403794|NCT01071499|pharmacokinetics
403795|NCT01071499|pharmacogenetics
403796|NCT01071499|morphine
403797|NCT01071499|children
403798|NCT01071486|Busulfan
403799|NCT01071486|Glutathione S-transferase
403800|NCT01071486|Genetic polymorphism
403801|NCT01071486|HVOD
403802|NCT01071486|GVHD
403803|NCT01071473|Childhood cancer
403804|NCT01071473|Anthracyclines
403805|NCT01071473|Cardiomyopathy
403806|NCT01071460|PAD
403807|NCT01071447|Rheumatic diseases
403808|NCT01071447|Biologic treatment
403809|NCT01071447|Nurse-led
403810|NCT01071421|Sleep apnea syndrome
403811|NCT01071421|community acquired pneumonia
403812|NCT01071421|prevalence
403813|NCT01071408|chronic care model
403814|NCT01071408|stroke prevention
403815|NCT01071408|health services research
403816|NCT01071395|Parkinson's disease
403817|NCT01071395|Dyskinesia
403818|NCT01071395|Dyskinesia Rating Scales
403819|NCT01071395|Amantadine
403820|NCT01071395|Placebo
403821|NCT01071382|Aeromedical Evacuation
403822|NCT01071382|Repatriation
403823|NCT01071356|methamphetamine
403824|NCT01071356|motivational interviewing
403825|NCT01071343|muscular atrophy
403826|NCT01071343|recovery of function
403827|NCT01071343|rehabilitation
403828|NCT01071343|Intensive care unit
403829|NCT01071304|Relapsed or refractory advanced cancer, metastatic cancer, locally advanced cancer
403830|NCT01071278|Lipid metabolism disorder
403831|NCT01071252|Moderate to severe chronic plaque-type psoriasis
403832|NCT01071252|AIN457
403833|NCT01071252|dermatology
403834|NCT01071239|Fanconi Anemia
403835|NCT01071239|Hematopoietic stem cell transplant
403836|NCT01071226|Malignant and non-malignant diseases
403837|NCT01071226|Hematopoietic stem cell transplant
403838|NCT01071226|Peripheral blood progenitor cell transplant
403839|NCT01071226|CliniMACS device
403840|NCT01071226|T cell depletion
403841|NCT01071200|Reproductive Techniques, Assisted
403842|NCT01071200|Recombinant human follicle stimulating hormone (r-hFSH)
403843|NCT01071200|Recombinant leutinizing hormone (r-hLH)
403844|NCT01071187|alcohol dependence
403845|NCT01071187|addiction
403846|NCT01071187|alcohol
403847|NCT01071187|relapse prevention
403848|NCT01071174|HIV infections
403849|NCT01071174|Anti-HIV agents
403850|NCT01071174|HIV-1
403851|NCT01071161|chronic cough
403852|NCT01071161|COPD
403853|NCT01071161|Azithromycin
403854|NCT01071161|Zithromax
403855|NCT01071161|LCQ
403856|NCT01071148|Infertility
403857|NCT01071148|Gonal-f
403858|NCT01071148|Pergoveris
403859|NCT01071148|Luveris
403860|NCT01071122|Central blood pressure
403861|NCT01071122|Nifedipine
403862|NCT01071122|Valsartan
403863|NCT01071109|Therapeutic massage
403864|NCT01071109|massage
403865|NCT01071109|inflammation
403866|NCT01071109|fatigue
403867|NCT01071109|insomnia
403868|NCT01071109|radiation therapy
403869|NCT01071109|breast cancer
403870|NCT01071109|Breast Cancer patients receiving radiation therapy
403871|NCT01071096|Botox
403872|NCT01071096|OnabotulinumtoxinA
403873|NCT01071096|Chronic Migraine
403874|NCT01071096|Calcitonin Gene-Related Peptide
403875|NCT01071096|Saliva
403876|NCT01071083|MS
403877|NCT01071070|Chronic Kidney Disease
403878|NCT01071070|Secondary hyperparathyroidism
403879|NCT01071057|opioid-induced pruritus
403880|NCT01071057|naloxone
403881|NCT01071044|Chronic Fatigue Syndrome
403882|NCT01071031|Safety
403883|NCT01071031|Tolerability
403884|NCT01071031|Immunogenicity
403885|NCT01071031|Human Immunodeficiency Virus
403886|NCT01071031|HIV-1
403887|NCT01071031|Vaccine
403888|NCT01071031|CD4
403889|NCT01071031|Viral Load
403890|NCT01071031|HIV
403891|NCT01071018|locally advanced or metastatic solid tumors
403892|NCT01071005|Decrease serum levels of luteinizing hormone, FSH and Testosterone
403893|NCT01070966|Atherosclerosis
403894|NCT01070953|Hypercholesterolemia
403895|NCT01070940|L-NMMA
403896|NCT01070940|blood pressure
403897|NCT01070940|arterial stiffness
403898|NCT01070940|pulse wave velocity
403899|NCT01070940|augmentation index
403900|NCT01070940|dose-response
403901|NCT01070940|healthy subjects
403902|NCT01070940|GFR
403903|NCT01070914|Cilia
403904|NCT01070914|Phenotyping
403905|NCT01070914|Diagnosis
403906|NCT01070914|Nitric Oxide
403907|NCT01070914|Bronchiectasis
403908|NCT01070888|Asthma
403909|NCT01070888|Exercise Induced Asthma
403910|NCT01070875|Antithrombotic prophylaxis
403911|NCT01070862|multiple myeloma, treatment, first line
403912|NCT01070849|exercise
403913|NCT01070849|physical activity
403914|NCT01070836|JCV
403915|NCT01070836|Sample Collection
403916|NCT01070836|PML
403917|NCT01070836|Antibody
403918|NCT01070823|Sample Collection
403919|NCT01070823|JCV
403920|NCT01070823|PML
403921|NCT01070810|Septic Shock
403922|NCT01070810|Sepsis
403923|NCT01070797|Epstein-Barr virus
403924|NCT01070797|CTL
403925|NCT01070797|cytotoxic T Lymphocytes
403926|NCT01070797|CMV
403927|NCT01070797|Adenovirus Infection
403928|NCT01070797|viral infection
403929|NCT01070797|hematopoietic stem cell transplantation
403930|NCT01070784|Symbicort
403931|NCT01070784|Safety
403932|NCT01070784|Efficacy
403933|NCT01070784|COPD
403934|NCT01070784|Japanese
403935|NCT01070771|Pressure wire
403936|NCT01070771|Fractional flow reserve
403937|NCT01070758|Congenital hyperinsulinism
403938|NCT01070758|Somatostatin analog
403939|NCT01070758|Lanreotide autogel
403940|NCT01070758|Hypoglycemia
403941|NCT01070745|PDA
403942|NCT01070745|Indomethacin
403943|NCT01070745|Ibuprofen
403944|NCT01070732|Fever
403945|NCT01070732|Infectious diseases
403946|NCT01070732|Neoplasia
403947|NCT01070732|Pain
403948|NCT01070732|cholecystectomy
403949|NCT01070732|Colectomy
403950|NCT01070719|Multiple Sclerosis, relapsing forms
403951|NCT01070706|Patients with HER2- stage II/III breast cancer
403952|NCT01070693|Inguinal hernia
403953|NCT01070693|Open mesh repair
403954|NCT01070693|Long term outcome
403955|NCT01070693|Recurrence
403956|NCT01070693|Discomfort
403957|NCT01070680|ERCP
403958|NCT01070680|dexmedetomidine
403959|NCT01070680|propofol
403960|NCT01070680|patient-controlled sedation
403961|NCT01070680|Chronic Alcoholic pancreatitis
403962|NCT01070667|PAF
403963|NCT01070667|AF
403964|NCT01070667|Dronedarone
403965|NCT01070667|AF Burden
403966|NCT01070667|AFB
403967|NCT01070667|PPM
403968|NCT01070667|Permanent Pacemaker
403969|NCT01070667|Atrial Fibrillation Burden in Paroxysmal Atrial Fibrillation
403970|NCT01070654|ARDS
403971|NCT01070654|Recruitment Manoeuvres
403972|NCT01070654|PEEP
403973|NCT01070654|Cytokines
403974|NCT01070654|Respiratory Insufficiency
403975|NCT01070641|CARVEDILOL
403976|NCT01070641|VARICEAL BAND LIGATION
403977|NCT01070641|PRIMARY PROPHYLAXIS
403978|NCT01070628|Pharmacokinetic
403979|NCT01070602|IFIS
403980|NCT01070589|Obesity
403981|NCT01070589|Growth hormone secretion
403982|NCT01070589|Anaerobic exercise
403983|NCT01070576|non union
403984|NCT01070576|fracture
403985|NCT01070576|healing
403986|NCT01070576|arginine
403987|NCT01070576|NO
403988|NCT01070563|Brain death
403989|NCT01070563|CT angiography
403990|NCT01070563|Ultrasonography, doppler, transcranial
403991|NCT01070537|Otolaryngology
403992|NCT01070537|Equipment and Supplies
403993|NCT01070537|Intubation
403994|NCT01070511|Muscular Dystrophy
403995|NCT01070511|Tadalafil
403996|NCT01070498|peanut hypersensitivity
403997|NCT01070498|tree nut hypersensitivity
403998|NCT01070498|allergy
403999|NCT01070498|Trichuris suis
404000|NCT01070498|hygiene hypothesis
404001|NCT01070498|treatment
404002|NCT01070498|clinical trial
404003|NCT01070498|food/adverse effect
404004|NCT01070498|peanut allergy (mild to moderate)
404005|NCT01070498|tree nut allergy (mild to moderate)
404006|NCT01070472|labor induction at term using a titrated oral misoprostol solution
404007|NCT01070459|Stroke aerobic exercise daily functioning rehabilitation
404008|NCT01070446|choline
404009|NCT01070446|cystic fibrosis
404010|NCT01070446|methyl metabolism
404011|NCT01070446|fatty acids
404012|NCT01070446|oxidative stress
404013|NCT01070446|pulmonary function
404014|NCT01070433|Diabetic Foot Ulcers (DFUs)
404015|NCT01070420|Adenosine
404016|NCT01070420|Fractional flow reserve, Hyperemia
404017|NCT01070420|Fractional Flow Reserve, Myocardial
404018|NCT01070407|Hepatitis C virus
404019|NCT01070407|HCV
404020|NCT01070407|Adenovirus
404021|NCT01070407|Vaccine
404022|NCT01070394|ADHD
404023|NCT01070394|Lisdexamfetamine Dimesylate
404024|NCT01070394|Amphetamine
404025|NCT01070368|skin test
404026|NCT01070368|open wheat challenge
404027|NCT01070355|Colorectal Neoplasms
404028|NCT01070355|Fish Oils
404029|NCT01070355|Fatty Acids, Omega-3
404030|NCT01070355|Eicosapentaenoic Acid
404031|NCT01070355|Liver Metastases
404032|NCT01070355|Randomised Controlled Trial
404033|NCT01070316|Epilepsy
404034|NCT01070316|Tuberous Sclerosis Complex
404035|NCT01070316|Everolimus
404036|NCT01070316|RAD001
404037|NCT01070316|Mammalian Target of Rapamycin (MTOR)
404038|NCT01070303|HUMIRA
404039|NCT01070303|adalimumab
404040|NCT01070303|Inflammatory Bowel Disease
404041|NCT01070290|gastric carcinoma
404042|NCT01070290|Locally Advanced or Metastatic Gastric Cancer
404043|NCT01070277|chronic diarrhea
404044|NCT01070277|travelers
404045|NCT01070277|Parasites
404046|NCT01070277|albendazole
404047|NCT01070277|tinidazole
404048|NCT01070264|Osteoarthritis
404049|NCT01070238|Isomaltulose
404050|NCT01070238|Slow Released Carbohydrates
404051|NCT01070238|Postprandial Glucose Metabolism
404052|NCT01070238|Type 2 diabetes
404053|NCT01070212|human, chewing, appetite,
404054|NCT01070199|obese, liquid, solid, fitness, humans, appetite
404055|NCT01070186|nephrectomy
404056|NCT01070186|T1b
404057|NCT01070186|T2
404058|NCT01070186|T3
404059|NCT01070186|T4
404060|NCT01070186|N1
404061|NCT01070186|Kidney Cancer
404062|NCT01070173|Ghrelin
404063|NCT01070173|short stature
404064|NCT01070173|failure to thrive
404065|NCT01070160|Polycystic Ovarian Syndrome (PCOS)
404066|NCT01070160|Metformin
404067|NCT01070160|Endometrin
404068|NCT01070147|asthma
404069|NCT01070147|emergency medicine
404070|NCT01070147|medical informatics
404071|NCT01070147|computerized reminder systems
404072|NCT01070121|Rheumatoid Arthritis
404073|NCT01070121|RA
404074|NCT01070121|Autoimmune Disease
404075|NCT01070121|Muscular Skeletal Disease
404076|NCT01070108|Preemption, ketamine, escalating, dose, pain, analgesia
404077|NCT01070082|adult ICU patients
404078|NCT01070082|procedural pain
404079|NCT01070082|pain intensity
404080|NCT01070082|pain distress
404081|NCT01070082|pain behaviors
404082|NCT01070082|pain
404083|NCT01070082|ICU procedures
404084|NCT01070069|Percutaneous
404085|NCT01070069|Preclose
404086|NCT01070069|Endologix
404087|NCT01070069|Abbott Vascular
404088|NCT01070069|Endovascular
404089|NCT01070069|PEVAR
404090|NCT01070069|Stent graft
404091|NCT01070069|Suture mediated closure devices
404092|NCT01070056|Blood Pressure
404093|NCT01070056|Lifestyle Changes
404094|NCT01070056|African American
404095|NCT01070043|Hypertension
404096|NCT01070043|valsartan
404097|NCT01070043|amlodipine
404098|NCT01070043|high blood pressure
404099|NCT01070030|Stage II Hypertension, Aliskiren, Amlodipine, Hydrochlorothiazide
404100|NCT01070017|Peru
404101|NCT01070017|DOT
404102|NCT01070017|HIV
404103|NCT01070017|AIDS
404104|NCT01070017|Community based
404105|NCT01070017|social capital
404106|NCT01070004|sleepiness
404107|NCT01070004|driving
404108|NCT01070004|countermeasures
404109|NCT01070004|coffee
404110|NCT01070004|blue light exposure
404111|NCT01070004|physical activity
404112|NCT01069991|Asthma
404113|NCT01069991|Adolescents
404114|NCT01069991|Patient Education
404115|NCT01069991|Schools
404116|NCT01069965|Type 2
404117|NCT01069952|Deep Brain Stimulation
404118|NCT01069952|Treatment Refractory
404119|NCT01069952|Neurosurgery
404120|NCT01069952|Implantable Neurostimulator (INS)
404121|NCT01069952|Internal Capsule
404122|NCT01069939|Gastric ulcer
404123|NCT01069939|Duodenal ulcer
404124|NCT01069939|Low-dose aspirin
404125|NCT01069926|Diabetes
404126|NCT01069913|Healthy Volunteer
404127|NCT01069900|Intra-abdominal infection
404128|NCT01069900|Pediatric infection
404129|NCT01069887|febrile events
404130|NCT01069887|invasive fungal infections
404131|NCT01069887|hematological patients
404132|NCT01069874|Bone Density Conservation Agents
404133|NCT01069874|Cholecalciferol
404134|NCT01069874|Communicable Diseases
404135|NCT01069874|Growth Substances
404136|NCT01069874|Housing for the Elderly
404137|NCT01069874|Infection
404138|NCT01069874|Micronutrients
404139|NCT01069874|Pharmacologic Actions
404140|NCT01069874|Physiological Effects of Drugs
404141|NCT01069874|Respiratory Tract Diseases
404142|NCT01069874|Vitamins
404143|NCT01069874|Respiratory Tract Infections/prevention & control*
404144|NCT01069874|Vitamin D
404145|NCT01069861|PPHN
404146|NCT01069861|neonates
404147|NCT01069861|sildanefil IV
404148|NCT01069835|Non small cell lung cancer
404149|NCT01069835|EGFR mutation
404150|NCT01069835|NSCLC
404151|NCT01069822|Midazolam
404152|NCT01069822|Pharmacokinetics
404153|NCT01069796|triple negative
404154|NCT01069796|metastatic
404155|NCT01069796|breast cancer
404156|NCT01069796|First line chemotherapy
404157|NCT01069783|dyslipidemia
404158|NCT01069783|cholesterol
404159|NCT01069783|LDL
404160|NCT01069770|Neoadjuvant Therapy
404161|NCT01069770|Sunitinib
404162|NCT01069770|Clear Cell Renal Cell Carcinoma
404163|NCT01069770|Metastasis
404164|NCT01069757|Advanced/recurrent non-small-cell lung cancer
404165|NCT01069705|Tobramycin Inhalation Powder
404166|NCT01069705|Cystic fibrosis
404167|NCT01069705|Lung diseases
404168|NCT01069705|Anti-Bacterial Agents
404169|NCT01069705|Treatment of pulmonary infections with P. aeruginosa in cystic fibrosis patients
404170|NCT01069692|Chronic Kidney Disease
404171|NCT01069692|Hemodialysis
404172|NCT01069692|Hyperphosphatemia
404173|NCT01069692|Hyperphosphatemia patients with chronic kidney disease on 3x/week hemodialysis
404174|NCT01069666|atopic dermatitis
404175|NCT01069666|Thai pediatricians
404176|NCT01069653|CDCA1
404177|NCT01069653|KIF20A
404178|NCT01069653|lung cancer
404179|NCT01069653|vaccine
404180|NCT01069653|HLA-A*2402
404181|NCT01069640|URLC10
404182|NCT01069640|lung cancer
404183|NCT01069640|vaccine
404184|NCT01069640|HLA-A*0201
404185|NCT01069640|HLA-A*0206
404186|NCT01069614|Equipment and supplies
404187|NCT01069601|solid organ transplantation
404188|NCT01069601|bone marrow transplantation
404189|NCT01069601|adults
404190|NCT01069601|adults with solid organ transplantation
404191|NCT01069601|adults with bone marrow transplantation
404192|NCT01069588|bioabsorbable screw
404193|NCT01069588|acl reconstruction
404194|NCT01069575|URLC10
404195|NCT01069575|CDCA1
404196|NCT01069575|KIF20A
404197|NCT01069575|lung cancer
404198|NCT01069575|vaccine
404199|NCT01069575|HLA-A*2402
404200|NCT01069562|closed loop control of anesthesia
404201|NCT01069562|isoflurane
404202|NCT01069562|open heart surgery
404203|NCT01069549|Type 2 Diabetes Mellitus
404204|NCT01069549|Diabetic Nephropathy
404205|NCT01069549|Angiotensin II type 1 receptor gene polymorphism
404206|NCT01069549|Acetyl coA carboxylase beta gene polymorphism.
404207|NCT01069536|metoclopramide
404208|NCT01069536|akathisia
404209|NCT01069536|nausea
404210|NCT01069536|vomiting
404211|NCT01069536|antiemetic
404212|NCT01069536|improvement of nausea
404213|NCT01069523|Attention Deficit Disorder with Hyperactivity
404214|NCT01069523|Guanfacine
404215|NCT01069523|Event Related Potentials
404216|NCT01069497|Infection control
404217|NCT01069497|Urinary Tract Infections
404218|NCT01069497|Respiratory Tract Infections
404219|NCT01069484|Randomized controlled trial
404220|NCT01069484|Post partum pelvic floor muscle training
404221|NCT01069484|Urinary incontinence
404222|NCT01069484|Pelvic floor dysfunction
404223|NCT01069484|Pelvic floor muscle injury
404224|NCT01069484|Pelvic floor muscle strength
404225|NCT01069484|Pelvic floor muscle morphology
404226|NCT01069471|S.dysenteriae
404227|NCT01069471|Healthy volunteers
404228|NCT01069471|Conjugate vaccine
404229|NCT01069471|Safety
404230|NCT01069471|Immunogenicity
404231|NCT01069471|Dose scaling
404232|NCT01069458|Dietary intervention
404233|NCT01069458|Smoking cessation
404234|NCT01069458|Body weight
404235|NCT01069445|diet
404236|NCT01069445|probiotics
404237|NCT01069445|inflammaging
404238|NCT01069445|oxidative stress
404239|NCT01069445|gut microbiota
404240|NCT01069445|food complements
404241|NCT01069432|Chronic Lymphocytic Leukemia
404242|NCT01069432|CLL
404243|NCT01069432|Normal Volunteers
404244|NCT01069419|Certolizumab Pegol
404245|NCT01069419|Cimzia
404246|NCT01069406|notch
404247|NCT01069406|uterine
404248|NCT01069406|first
404249|NCT01069406|bleeding
404250|NCT01069380|resting metabolic rate
404251|NCT01069380|bed ridden, vegetative
404252|NCT01069380|low conscious
404253|NCT01069380|minimal conscious state
404254|NCT01069380|immobilized
404255|NCT01069380|resting energy expenditure
404256|NCT01069367|Influenza A
404257|NCT01069367|H1N1 subtype
404258|NCT01069367|Children/adolescent
404259|NCT01069367|Vaccine
404260|NCT01069367|Adjuvant
404261|NCT01069367|Cell culture
404262|NCT01069341|Rubeosis
404263|NCT01069341|Neovascularization of iris
404264|NCT01069341|Proliferative diabetic retinopathy
404265|NCT01069341|PDR
404266|NCT01069341|Cataract
404267|NCT01069328|Lung
404268|NCT01069328|cancer
404269|NCT01069328|NSCLC
404270|NCT01069315|open wound
404271|NCT01069315|solution
404272|NCT01069315|pressure
404273|NCT01069315|randomized
404274|NCT01069302|Coronary artery disease
404275|NCT01069289|Symbicort
404276|NCT01069289|Oxis
404277|NCT01069289|Chronic Obstructive Pulmonary Disease
404278|NCT01069289|COPD
404279|NCT01069289|Efficacy
404280|NCT01069276|Stroke
404281|NCT01069276|prehospital ultrasound
404282|NCT01069263|Interstitial cystitis
404283|NCT01069263|Painful bladder syndrome
404284|NCT01069263|Chronic pelvic pain
404285|NCT01069263|DMSO
404286|NCT01069263|Hyperbaric oxygen therapy
404287|NCT01069250|dynamic cerebrovascular autoregulation
404288|NCT01069250|static cerebrovascular autoregulation
404289|NCT01069250|acute brain injury
404290|NCT01069250|transcranial Doppler ultrasound
404291|NCT01069250|critical care
404292|NCT01069237|contact lens wear
404293|NCT01069237|multi-purpose solution
404294|NCT01069237|corneal staining
404295|NCT01069224|rotator cuff
404296|NCT01069224|synovial fluid
404297|NCT01069224|proinflammatory cytokines
404298|NCT01069211|Breast cancer, Letrozole
404299|NCT01069211|postmenopause
404300|NCT01069211|hormone receptor positive breast cancer
404301|NCT01069198|Visceral leishmaniasis
404302|NCT01069198|Kala-azar
404303|NCT01069198|Bangladesh
404304|NCT01069198|Malnutrition
404305|NCT01069198|Asymptomatic
404306|NCT01069198|Albendazole
404307|NCT01069198|Iron
404308|NCT01069198|Zinc
404309|NCT01069198|Vitamin A
404310|NCT01069185|Unplanned extubation
404311|NCT01069185|Length of stay in PICU
404312|NCT01069185|Length of mechanical ventilation
404313|NCT01069172|Cataract
404314|NCT01069172|Surgery, cataract extraction
404315|NCT01069172|Optical devices, laser
404316|NCT01069159|Traumatic memory
404317|NCT01069159|Traumatic memories
404318|NCT01069159|Traumatic memories and associated symptoms
404319|NCT01069159|Posttraumatic Stress Disorder
404320|NCT01069159|PTSD
404321|NCT01069146|sepsis,
404322|NCT01069146|septic shock,
404323|NCT01069146|therapeutic hypothermia
404324|NCT01069133|minimal hepatic encephalopathy
404325|NCT01069133|cirrhosis
404326|NCT01069133|complications
404327|NCT01069120|Uterine Fibroids
404328|NCT01069107|community hospital
404329|NCT01069107|alternative acute admissions
404330|NCT01069094|Uterine fibroids
404331|NCT01069081|Metastasis Breast Cancer
404332|NCT01069081|Proton Pump Inhibitor
404333|NCT01069081|Chemotherapy
404334|NCT01069081|Phase II study
404335|NCT01069081|TTP
404336|NCT01069068|To evaluate the effect of advancing Jaw on airway dimension
404337|NCT01069055|inguinal hernia
404338|NCT01069055|surgery
404339|NCT01069055|general anesthesia
404340|NCT01069055|analgesia
404341|NCT01069055|pre-emptive
404342|NCT01069055|SF36
404343|NCT01069042|Rho kinase activity
404344|NCT01069042|Heart failure
404345|NCT01069042|ACE inhibitor
404346|NCT01069042|LVEF change
404347|NCT01069042|Rho kinase activity change
404348|NCT01069029|Macular Hole
404349|NCT01069029|Cataract surgery
404350|NCT01069029|Vitreoretinal surgery
404351|NCT01069029|Combined surgery
404352|NCT01069029|Idiopathic
404353|NCT01069016|Fecal Incontinence
404354|NCT01069016|Colorectal surgery
404355|NCT01069016|Sacral nerve stimulation
404356|NCT01069016|Pudendal nerve stimulation
404357|NCT01069003|Heart Disease
404358|NCT01069003|Cardiovascular Disease
404359|NCT01069003|Platelet Aggregation Inhibitors
404360|NCT01069003|Dual Antiplatelet Therapy
404361|NCT01069003|Clopidogrel
404362|NCT01069003|Prasugrel
404363|NCT01069003|Vascular Disease
404364|NCT01069003|Myocardial Ischemia
404365|NCT01068990|pneumonia
404366|NCT01068951|type 1 diabetes
404367|NCT01068951|mesenchymal stem cells
404368|NCT01068951|intervention
404369|NCT01068938|visual field
404370|NCT01068938|perimetry
404371|NCT01068938|glaucoma progression
404372|NCT01068938|grid
404373|NCT01068938|POAG and glaucoma suspects with prostaglandin monotherapy
404374|NCT01068925|healthy volunteer
404375|NCT01068925|pharmacokinetics
404376|NCT01068925|HIV, GSK1349572, tipranavir, ritonavir, drug interaction
404377|NCT01068912|Influenza
404378|NCT01068899|healthy adults
404379|NCT01068899|healthy children
404380|NCT01068886|Pancreaticoduodenectomy
404381|NCT01068873|HIV
404382|NCT01068873|Protease Inhibitor
404383|NCT01068873|CCR5 Co-receptor Antagonist
404384|NCT01068873|treatment naive
404385|NCT01068860|Type 2 Diabetes Mellitus
404386|NCT01068860|canakinumab
404387|NCT01068860|Pre diabetic
404388|NCT01068860|glucose intolerant
404389|NCT01068860|oral anti diabetic medication
404390|NCT01068860|insulin treatment
404391|NCT01068860|metabolic syndrome
404392|NCT01068847|Opioid dependence
404393|NCT01068847|methadone
404394|NCT01068847|opioid
404395|NCT01068834|Adherence
404396|NCT01068834|Statins
404397|NCT01068834|Kinesin-like protein 6
404398|NCT01068821|Slide
404399|NCT01068821|Trendelenburg's position
404400|NCT01068821|Postoperative
404401|NCT01068821|neurologic complaints
404402|NCT01068808|Nonallergic rhinitis
404403|NCT01068808|Allergic rhinitis
404404|NCT01068808|Development
404405|NCT01068795|placental syndrome
404406|NCT01068795|maternal thromboembolic event
404407|NCT01068795|enoxaparin
404408|NCT01068795|anti-factor Xa
404409|NCT01068782|Glioblastoma
404410|NCT01068782|Glioma
404411|NCT01068782|Brain Cancer
404412|NCT01068782|Brain Tumor
404413|NCT01068782|Astrocytoma
404414|NCT01068769|regorafenib
404415|NCT01068769|GIST
404416|NCT01068691|aortic dissection
404417|NCT01068691|ambulatory blood pressure
404418|NCT01068691|obstructive sleep apnea syndrome
404419|NCT01068691|patients undergoing surgery for a dissection of the thoracic aorta
404420|NCT01068613|COPD
404421|NCT01068613|Long acting muscarinic antagonist
404422|NCT01068600|COPD
404423|NCT01068600|Indacaterol
404424|NCT01068587|recurrent non-small cell lung cancer
404425|NCT01068587|stage IIIA non-small cell lung cancer
404426|NCT01068587|stage IIIB non-small cell lung cancer
404427|NCT01068587|stage IV non-small cell lung cancer
404428|NCT01068574|Acute illnesses in children under five
404429|NCT01068561|Retinitis pigmentosa
404430|NCT01068561|stem cell
404431|NCT01068561|bone marrow
404432|NCT01068535|metabolic syndrome
404433|NCT01068535|MetS
404434|NCT01068535|premenopausal women
404435|NCT01068535|vascular risk
404436|NCT01068535|atherosclerosis detection
404437|NCT01068522|Intracranial pressure
404438|NCT01068522|Intracranial pressure monitoring
404439|NCT01068522|Head injury
404440|NCT01068509|Cvac
404441|NCT01068483|Advanced solid tumors
404442|NCT01068483|Breast Cancer
404443|NCT01068483|Colon Cancer
404444|NCT01068483|Ovarian Cancer
404445|NCT01068483|Endometrium cancer
404446|NCT01068470|Interleukin-2
404447|NCT01068470|Melanoma
404448|NCT01068470|Kidney Cancer
404449|NCT01068470|Lymphokine Activated Killer cells
404450|NCT01068457|persistent pain
404451|NCT01068457|neuropathic pain
404452|NCT01068457|Thoracic Surgery, Video Assisted
404453|NCT01068457|Chronic Pain
404454|NCT01068444|NASH
404455|NCT01068444|Pioglitazone
404456|NCT01068444|Treatment
404457|NCT01068431|lymphedema
404458|NCT01068431|conservative treatment
404459|NCT01068431|compression therapy
404460|NCT01068431|interface pressure
404461|NCT01068418|Obesity
404462|NCT01068418|Renin Angiotensin System
404463|NCT01068418|Vitamin D deficiency
404464|NCT01068418|Hypertension
404465|NCT01068392|relapsed
404466|NCT01068392|marginal zone B-cell lymphoma
404467|NCT01068392|oxaliplatin
404468|NCT01068392|prednisolone
404469|NCT01068379|rhegmatogenous retinal detachment
404470|NCT01068379|cryopexy
404471|NCT01068379|photocoagulation
404472|NCT01068366|Nickel Allergic Syndrome
404473|NCT01068366|Septal Closure Devices
404474|NCT01068353|Alzheimer's disease
404475|NCT01068353|Dementia
404476|NCT01068353|TNF-alpha
404477|NCT01068353|Etanercept
404478|NCT01068340|Adhesions
404479|NCT01068340|Small Bowel Obstruction
404480|NCT01068340|Ileus
404481|NCT01068314|Endothelium
404482|NCT01068314|Vasodilatation
404483|NCT01068314|Vein
404484|NCT01068314|Compliance
404485|NCT01068314|Arteriovenous shunt, surgical
404486|NCT01068301|Allogeneic Stem Cell transplantation
404487|NCT01068301|Plerixafor
404488|NCT01068301|Acute Lymphoblastic leukemia
404489|NCT01068301|Acute Myeloid leukemia
404490|NCT01068301|Chronic Myeloid leukemia
404491|NCT01068301|Myelodysplastic Syndrome
404492|NCT01068301|Non-Hodgkin's Lymphoma
404493|NCT01068301|Other Leukemia
404494|NCT01068288|laparoscopic appendectomy
404495|NCT01068288|open appendectomy
404496|NCT01068288|expectant management
404497|NCT01068288|paediatric
404498|NCT01068275|anterior cruciate ligament
404499|NCT01068275|pain, postoperative
404500|NCT01068275|peripheral nerve catheter
404501|NCT01068275|nerve block
404502|NCT01068275|Children undergoing anterior cruciate ligament repair
404503|NCT01068249|Advanced
404504|NCT01068249|Recurrent
404505|NCT01068249|Progressive
404506|NCT01068249|Endometrial Cancer
404507|NCT01068249|Letrozole
404508|NCT01068249|RAD001
404509|NCT01068249|Afinitor
404510|NCT01068249|Everolimus
404511|NCT01068249|Femara
404512|NCT01068236|Teen girls
404513|NCT01068236|weightloss
404514|NCT01068236|healthy lifestyle
404515|NCT01068236|yoga
404516|NCT01068236|Weight loss and healthy lifestyle
404517|NCT01068223|Cetirizine, CR016609
404518|NCT01068210|Exercise Intervention
404519|NCT01068210|Lung Cancer
404520|NCT01068210|15-215
404521|NCT01068197|Low Glycemic Load diet
404522|NCT01068197|Low Glycemic Index diet
404523|NCT01068197|Low Fat diet
404524|NCT01068197|Obese Hispanic American children and adolescents
404525|NCT01068197|At risk for type 2 diabetes mellitus
404526|NCT01068184|AZD6553
404527|NCT01068184|Chronic
404528|NCT01068184|obstructive
404529|NCT01068184|pulmonary
404530|NCT01068184|lung
404531|NCT01068184|respiratory disease
404532|NCT01068184|placebo-controlled
404533|NCT01068184|COPD
404534|NCT01068184|Healthy Volunteers
404535|NCT01068184|COPD Patients
404536|NCT01068171|diabetes
404537|NCT01068171|foot ulcers
404538|NCT01068171|off-loading
404539|NCT01068171|collagen
404540|NCT01068171|Wagner 1
404541|NCT01068158|Head lice infestation
404542|NCT01068158|Pediculus humanus capitis
404543|NCT01068145|COPD
404544|NCT01068132|Colorectal Neoplasms
404545|NCT01068132|KRAS
404546|NCT01068132|PTEN
404547|NCT01068119|Acute coronary syndrome
404548|NCT01068119|percutaneous coronary angioplasty
404549|NCT01068119|Troponin negative
404550|NCT01068119|cardiac
404551|NCT01068080|fatty acid metabolism
404552|NCT01068080|insulin resistance
404553|NCT01068080|cardiac death
404554|NCT01068080|hemodialysis
404555|NCT01068080|normal coronary arteries
404556|NCT01068080|Predictive values of impaired myocardial fatty acid metabolism or insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries
404557|NCT01068054|vernal keratoconjunctivitis
404558|NCT01068054|FK-506
404559|NCT01068054|tacrolimus
404560|NCT01068054|cyclosporine
404561|NCT01068054|children
404562|NCT01068028|Healthy volunteer study
404563|NCT01068015|MSM
404564|NCT01068015|Intervention
404565|NCT01068015|Popular Opinion Leader
404566|NCT01068015|Male Circumcision
404567|NCT01068015|HIV
404568|NCT01068015|Syphilis
404569|NCT01068015|HSV-2
404570|NCT01068002|Hypertension Pregnancy
404571|NCT01067989|metronomic chemotherapy
404572|NCT01067989|anti-angiogenic effect
404573|NCT01067989|Breast cancer
404574|NCT01067976|Breast Cancer
404575|NCT01067976|Gadobutrol-enhanced MRI
404576|NCT01067976|Mammography
404577|NCT01067963|self-care
404578|NCT01067963|self-management
404579|NCT01067963|health behavior change
404580|NCT01067963|motivational interviewing
404581|NCT01067963|computer assisted learning
404582|NCT01067950|isolated pancreas transplant
404583|NCT01067950|intensive insulin therapy
404584|NCT01067937|Appendicitis
404585|NCT01067937|children
404586|NCT01067924|Type 2 diabetes, motivational interviewing, physical activity maintenance, physical activity adherence
404587|NCT01067911|Postprandial lipids
404588|NCT01067911|test meal
404589|NCT01067911|fatty acids
404590|NCT01067898|vitamin D supplementation
404591|NCT01067898|cholecalciferol
404592|NCT01067898|PTH
404593|NCT01067898|bone turnover markers
404594|NCT01067898|elderly women
404595|NCT01067885|Nitinol Stent
404596|NCT01067885|Superficial femoral artery
404597|NCT01067885|SFA
404598|NCT01067885|Angioplasty
404599|NCT01067885|peripheral artery disease
404600|NCT01067885|peripheral artery obstructive disease
404601|NCT01067885|PAOD
404602|NCT01067885|PAD
404603|NCT01067885|Peripheral Vascular Disease
404604|NCT01067859|Heart Failure
404605|NCT01067846|cocaine dependence
404606|NCT01067846|relapse prevention
404607|NCT01067846|computerized cognitive behavioral therapy (CBT)
404608|NCT01067846|D-cycloserine (DCS)
404609|NCT01067833|atrial fibrillation
404610|NCT01067833|AF
404611|NCT01067820|ApolipoproteinA1
404612|NCT01067820|HDL-C
404613|NCT01067820|Atherosclerosis
404614|NCT01067807|Pharmacokinetics
404615|NCT01067794|Metastatic
404616|NCT01067794|Advanced
404617|NCT01067794|Stage IIIB-IV
404618|NCT01067794|daily
404619|NCT01067794|hospital
404620|NCT01067794|practice
404621|NCT01067794|setting
404622|NCT01067781|Prevention of Travelers' Diarrhea
404623|NCT01067768|Urinary Tract Infections
404624|NCT01067768|Catheter-associated urinary tract infections
404625|NCT01067768|Prevention and control
404626|NCT01067768|Controlled clinical trial
404627|NCT01067755|navigation
404628|NCT01067755|bronchoscopy
404629|NCT01067755|lymphadenopathy
404630|NCT01067742|Mucolipidosis, retinal dystrophy, mucolipin-1,
404631|NCT01067742|lysosomal storage disease, gastrin, mental retardation,
404632|NCT01067742|dysmyelination, dysplastic corpus callosum,corneal clouding
404633|NCT01067729|Burn
404634|NCT01067729|Superficial burns
404635|NCT01067729|Partial thickness burns
404636|NCT01067729|Rate of healing
404637|NCT01067729|Infection rate
404638|NCT01067729|Pain perception
404639|NCT01067729|Non adherence
404640|NCT01067729|Scarring
404641|NCT01067703|remote ischaemic preconditioning, cardiac surgery
404642|NCT01067690|classical Kaposi's sarcoma
404643|NCT01067690|chemotherapy
404644|NCT01067690|indinavir
404645|NCT01067690|HIV protease inhibitor
404646|NCT01067690|Advanced classical (non HIV-associated) Kaposi's sarcoma
404647|NCT01067677|PONV
404648|NCT01067677|Post operative nausea and vomiting
404649|NCT01067677|rescue emetic therapy
404650|NCT01067599|Biomarkers of tobacco exposure
404651|NCT01067599|Smokeless Tobacco
404652|NCT01067586|Smokeless Tobacco
404653|NCT01067586|Biomarkers of tobacco exposure
404654|NCT01067573|MS
404655|NCT01067573|Serum Leptin Levels during relapse
404656|NCT01067573|Multiple sclerosis
404657|NCT01067573|relapse
404658|NCT01067560|Glucose
404659|NCT01067560|CSF
404660|NCT01067560|Cesarean section, spinal anesthesia
404661|NCT01067560|Nova Stat Strip
404662|NCT01067560|Abbott Precision Xtra
404663|NCT01067560|Roche Accucheck Inform 2
404664|NCT01067547|Iron deficiency
404665|NCT01067547|Inflammatory Bowel Disease
404666|NCT01067547|Crohn's Disease
404667|NCT01067547|Ulcerative colitis
404668|NCT01067521|Relapsing Remitting Multiple Sclerosis
404669|NCT01067521|Glatiramer Acetate
404670|NCT01067495|stroke
404671|NCT01067495|rehabilitation
404672|NCT01067495|exercise
404673|NCT01067495|walking
404674|NCT01067495|risk factors
404675|NCT01067482|OCT
404676|NCT01067482|spectral domain cirrus
404677|NCT01067482|glaucoma
404678|NCT01067482|glaucoma suspect
404679|NCT01067482|normal population
404680|NCT01067469|CNS
404681|NCT01067469|Central Nervous System
404682|NCT01067469|malignant brain tumor
404683|NCT01067469|Recurrent Glioblastoma Multiforme
404684|NCT01067469|GBM
404685|NCT01067469|Bevacizumab
404686|NCT01067469|Lomustine
404687|NCT01067469|CCNU
404688|NCT01067443|Phase II
404689|NCT01067443|Randomised clinical trial
404690|NCT01067443|Visceral Leishmaniasis
404691|NCT01067430|Rheumatoid Arthritis
404692|NCT01067430|Etoricoxib
404693|NCT01067430|Diclofenac
404694|NCT01067430|Pain
404695|NCT01067430|Stiffness
404696|NCT01067417|Hydroxychloroquine
404697|NCT01067417|Chloroquine
404698|NCT01067417|HIV Infection
404699|NCT01067417|Acquired Immunodeficiency Syndrome
404700|NCT01067417|Immune Activation
404701|NCT01067417|inflammation
404702|NCT01067417|treatment naive
404703|NCT01067417|disease progression
404704|NCT01067404|Influenza vaccines
404705|NCT01067404|Infant
404706|NCT01067404|Dose-Response relationship, immunologic
404707|NCT01067391|Hypotension in SCI males
404708|NCT01067391|Erectile Dysfunction
404709|NCT01067378|Interdisciplinary Health Team
404710|NCT01067378|Training
404711|NCT01067365|Secondary Hypogonadism
404712|NCT01067352|Infant, small for gestational age
404713|NCT01067352|Growth hormone
404714|NCT01067352|Saizen
404715|NCT01067339|coronary endothelial dysfunction
404716|NCT01067339|coronary vasospasm
404717|NCT01067326|Endothelial Dysfunction
404718|NCT01067326|Endothelial Function
404719|NCT01067326|Tekturna
404720|NCT01067326|Endothelial Peripheral Arterial Tomography (EndoPAT)
404721|NCT01067326|Progenitor Cells
404722|NCT01067326|renin inhibition
404723|NCT01067326|endothelial progenitor cells
404724|NCT01067326|early atherosclerosis
404725|NCT01067313|Intensive Care Unit
404726|NCT01067313|continuous hemodialysis
404727|NCT01067313|continuous hemofiltration
404728|NCT01067313|High Cut-off membrane
404729|NCT01067313|"Enhanced middle molecule clearance membrane"
404730|NCT01067313|Septic shock
404731|NCT01067313|Acute kidney injury
404732|NCT01067313|Blood purification
404733|NCT01067313|Renal replacement therapy
404734|NCT01067300|young
404735|NCT01067300|acute leukemia in remission
404736|NCT01067300|Children or young adults (< 35 years) with acute leukemia in remission
404737|NCT01067287|dendritic cell fusion vaccine
404738|NCT01067287|CT-011
404739|NCT01067287|autologous stem cell transplant
404740|NCT01067274|Acute Myeloid Leukemia
404741|NCT01067274|Aged of 65 to 79 years
404742|NCT01067274|Older Patients with Acute Myeloblastic Leukemia
404743|NCT01067261|Nerve stimulation
404744|NCT01067261|TMNS
404745|NCT01067261|Prostatectomy
404746|NCT01067261|Prevention
404747|NCT01067261|Restoration
404748|NCT01067261|Treatment
404749|NCT01067261|Vibration
404750|NCT01067261|Non-invasive
404751|NCT01067248|COPD
404752|NCT01067248|Osteoporosis
404753|NCT01067248|Pathophysiology
404754|NCT01067248|Mechanism
404755|NCT01067248|Bone markers
404756|NCT01067248|Bone turnover
404757|NCT01067248|Protein turnover
404758|NCT01067248|Ageing
404759|NCT01067248|Endocrinology
404760|NCT01067248|Vitamin D
404761|NCT01067235|Narcolespy
404762|NCT01067235|Cataplexy
404763|NCT01067235|Excesssive daytime Sleepiness
404764|NCT01067235|Sleep Disorders
404765|NCT01067235|Sleep attacks
404766|NCT01067235|Orphan Drug
404767|NCT01067235|Pitolisant
404768|NCT01067222|Narcolepsy
404769|NCT01067222|Excessive daytime Sleepiness
404770|NCT01067222|Cataplexy
404771|NCT01067222|Sleep Disorders
404772|NCT01067222|Sleep attacks
404773|NCT01067222|Orphan Drug
404774|NCT01067222|Pitolisant
404775|NCT01067209|Reversal of Obesity-related and Diabetic Cardiomyopathy
404776|NCT01067196|Proton Radiation
404777|NCT01067196|Central Nervous System Tumors
404778|NCT01067196|Brain
404779|NCT01067196|Spine
404780|NCT01067196|Cancer
404781|NCT01067183|stress reduction
404782|NCT01067183|physician wellness
404783|NCT01067170|Hemodialysis
404784|NCT01067170|Intradialytic hypotension
404785|NCT01067157|Obesity
404786|NCT01067157|overweight
404787|NCT01067157|childhood
404788|NCT01067157|adolescence
404789|NCT01067157|inpatient therapy
404790|NCT01067157|lifestyle intervention
404791|NCT01067157|cardiovascular risk
404792|NCT01067157|gene-lifestyle-interaction
404793|NCT01067157|Obesity and associated cardiovascular risk in childhood and adolescence,
404794|NCT01067157|health behaviour
404795|NCT01067131|Candida albicans
404796|NCT01067131|Fungal vaginal infection
404797|NCT01067131|Vulvovaginal candidiasis
404798|NCT01067131|Candidose
404799|NCT01067131|Vaccine
404800|NCT01067131|Virosome
404801|NCT01067105|Perennial allergic rhinitis
404802|NCT01067105|allergic rhinitis
404803|NCT01067105|ciclesonide
404804|NCT01067079|Rabies vaccine
404805|NCT01067079|Long-term Immunogenicity
404806|NCT01067066|TPI 287
404807|NCT01067066|microtubule inhibitor
404808|NCT01067066|Temozolomide
404809|NCT01067066|Temodar
404810|NCT01067066|cytotoxic agent
404811|NCT01067066|unresectable Stage III
404812|NCT01067066|Stage IV
404813|NCT01067066|Metastatic Melanoma
404814|NCT01067053|Bevacizumab
404815|NCT01067053|Capecitabine
404816|NCT01067053|Oxaliplatin
404817|NCT01067053|Metastatic colorectal cancer
404818|NCT01067027|Colic
404819|NCT01067027|Colic in Breast-fed Infants
404820|NCT01067014|Lumbar spinal stenosis
404821|NCT01067014|Decompression
404822|NCT01067014|Lumbar spinal decompression
404823|NCT01067014|Lumbar spinal decompressive surgery
404824|NCT01066988|lipid layer thickness
404825|NCT01066975|loaded backpack
404826|NCT01066975|unloaded backpack
404827|NCT01066962|HIV-infected antiretroviral naïve subjects
404828|NCT01066949|hemodialysis
404829|NCT01066949|behavior change
404830|NCT01066949|patient adherence
404831|NCT01066949|self management
404832|NCT01066923|firefighter
404833|NCT01066923|heat stress
404834|NCT01066923|platelet activation
404835|NCT01066923|aspirin
404836|NCT01066910|Obesity
404837|NCT01066910|Childhood Obesity
404838|NCT01066910|Exercise
404839|NCT01066910|Nutrition
404840|NCT01066871|Knee cartilage injury
404841|NCT01066871|fibroblast growth factor 18
404842|NCT01066871|FGF18
404843|NCT01066858|tenofovir
404844|NCT01066858|renal and bone toxicity
404845|NCT01066858|pregnancy
404846|NCT01066858|breastfeeding
404847|NCT01066858|mother to child transmission
404848|NCT01066832|Drug-eluting balloon
404849|NCT01066832|Paclitaxel
404850|NCT01066832|DIOR
404851|NCT01066832|short term registry
404852|NCT01066832|Valentines Trial
404853|NCT01066832|Drug-eluting balloon treatment of in-stent restenosis
404854|NCT01066780|cochlear implant
404855|NCT01066780|adults
404856|NCT01066780|HiResolution
404857|NCT01066780|Fidelity 120
404858|NCT01066780|listening benefits
404859|NCT01066780|noise
404860|NCT01066780|cochlear implant benefit
404861|NCT01066741|Epidermoid carcinoma
404862|NCT01066741|Hypopharynx
404863|NCT01066741|Oropharynx
404864|NCT01066741|Oral cavity
404865|NCT01066741|Oral mucosa
404866|NCT01066741|Cavum
404867|NCT01066741|Severe Oral mucositis
404868|NCT01066741|Radiotherapy
404869|NCT01066741|Phytotherapy
404870|NCT01066728|apnea
404871|NCT01066728|premature
404872|NCT01066728|infant
404873|NCT01066728|prematurity
404874|NCT01066715|Diabetes
404875|NCT01066715|Type 2
404876|NCT01066715|Mellitus
404877|NCT01066689|kidney transplantation, acute humoral rejection, rituximab
404878|NCT01066663|CLL
404879|NCT01066663|SLL
404880|NCT01066663|relapsed
404881|NCT01066663|pyrimethamine
404882|NCT01066650|TWENTE
404883|NCT01066650|randomized study
404884|NCT01066650|stent
404885|NCT01066650|coronary stent
404886|NCT01066650|drug-eluting stent
404887|NCT01066650|Zotarolimus
404888|NCT01066650|Everolimus
404889|NCT01066650|Xience V
404890|NCT01066650|Endeavor Resolute
404891|NCT01066650|head to head comparison
404892|NCT01066650|real world patients
404893|NCT01066650|target vessel failure
404894|NCT01066650|investigator initiated study
404895|NCT01066650|coronary artery disease
404896|NCT01066650|coronary arteries
404897|NCT01066650|atherosclerosis
404898|NCT01066650|non inferiority
404899|NCT01066637|Heart transplant patients
404900|NCT01066624|Mucositis
404901|NCT01066624|Multiple myeloma
404902|NCT01066624|Autologous hematopoietic stem cell transplantation
404903|NCT01066611|Allergic Rhinitis
404904|NCT01066611|Allergy
404905|NCT01066611|Phosphatidylinositol 3-kinase
404906|NCT01066598|graft versus host disease
404907|NCT01066598|chronic graft versus host disease
404908|NCT01066598|cGVHD
404909|NCT01066585|Head lice
404910|NCT01066585|Pediculus humanus capitis
404911|NCT01066546|Delirium
404912|NCT01066546|Dementia
404913|NCT01066546|Amnestic
404914|NCT01066546|Cognitive Disorders
404915|NCT01066546|Mental Disorders
404916|NCT01066546|Nervous System Diseases
404917|NCT01066546|Central Nervous System Diseases
404918|NCT01066533|MTA
404919|NCT01066533|NEC
404920|NCT01066533|Immunohistochemistry
404921|NCT01066533|fibronectin
404922|NCT01066533|tenascin
404923|NCT01066520|ankle sprain
404924|NCT01066520|traumeel
404925|NCT01066520|diclofenac
404926|NCT01066520|antiinflammatory
404927|NCT01066520|time to normal function
404928|NCT01066507|Her2
404929|NCT01066507|FISH
404930|NCT01066507|Breast cancer
404931|NCT01066507|Amplification
404932|NCT01066494|AML
404933|NCT01066494|Pgp
404934|NCT01066494|MDR
404935|NCT01066494|sAML
404936|NCT01066494|AS1413
404937|NCT01066494|Amonafide
404938|NCT01066481|Alzheimer's disease
404939|NCT01066481|clinical trial
404940|NCT01066481|memory loss
404941|NCT01066481|investigational drug
404942|NCT01066481|neurodegenerative disease
404943|NCT01066481|dementia
404944|NCT01066468|Chronic myeloid leukemia
404945|NCT01066468|CML
404946|NCT01066468|Philadelphia chromosome positive
404947|NCT01066468|acute lymphoblastic leukemia
404948|NCT01066468|PhGlivec,
404949|NCT01066468|Gleevec,
404950|NCT01066468|hypereosinophilic syndrome,
404951|NCT01066468|HES,
404952|NCT01066468|chronic eosinophilic leukemia,
404953|NCT01066468|CEL,
404954|NCT01066468|myelodysplastic syndrome,
404955|NCT01066468|MDS,
404956|NCT01066468|myeloproliferative disease,
404957|NCT01066468|MPD+ ALL
404958|NCT01066455|Cardiac
404959|NCT01066455|Muscular Dystrophy
404960|NCT01066455|Prospective
404961|NCT01066455|Pediatric
404962|NCT01066455|Echocardiogram
404963|NCT01066442|Excessive Daytime Sleepiness (EDS)
404964|NCT01066442|Parkinson's Disease
404965|NCT01066429|poor-prognosis diffuse large B-cell lymphoma
404966|NCT01066429|dose-adjusted
404967|NCT01066429|R-EDOCH-14
404968|NCT01066429|rituximab
404969|NCT01066429|age-adjusted IPI
404970|NCT01066429|toxicity
404971|NCT01066403|schizophrenia
404972|NCT01066403|cognitive deficits
404973|NCT01066403|dopamine
404974|NCT01066403|dopamine agonists
404975|NCT01066403|prefrontal cortex
404976|NCT01066403|D1 specific modulation
404977|NCT01066403|pergolide
404978|NCT01066403|executive control
404979|NCT01066403|working memory
404980|NCT01066403|Influence of pergolide on cognition in Schizophrenia
404981|NCT01066403|D1-specific modulation of prefrontal functions
404982|NCT01066403|Influence of pergolide on psychopathology and depression
404983|NCT01066403|Influence of pergolide on extrapyramidal symptoms
404984|NCT01066390|stage IIIC/IV melanoma
404985|NCT01066377|prebiotic
404986|NCT01066377|probiotic
404987|NCT01066377|influenza
404988|NCT01066377|vaccination
404989|NCT01066377|ageing
404990|NCT01066377|immunosenescence
404991|NCT01066364|NASH
404992|NCT01066364|NAFLD
404993|NCT01066364|Steatohepatitis
404994|NCT01066364|Nonalcoholic
404995|NCT01066364|Fatty Liver Disease
404996|NCT01066351|acute kidney injury
404997|NCT01066351|erythropoietin
404998|NCT01066351|cardiac surgery
404999|NCT01066338|SNP array
405000|NCT01066338|prognosis
405001|NCT01066338|acute myeloid leukemia
405002|NCT01066338|normal karyotype
405003|NCT01066338|acute myeloid leukemia with normal karyotype
405004|NCT01066325|Sit-n-Reach Test
405005|NCT01066325|Flexibility
405006|NCT01066325|Hamstring
405007|NCT01066325|Mindbody
405008|NCT01066325|Complementary and Alternative Medicine
405009|NCT01066325|Neuro Emotional Technique (NET)
405010|NCT01066312|Muscle testing
405011|NCT01066312|Kinesiology
405012|NCT01066312|Muscles
405013|NCT01066312|Complementary and Alternative Medicine
405014|NCT01066312|Practitioner Experience
405015|NCT01066312|This study is actually not a randomised controlled trial,
405016|NCT01066312|but an assessment of diagnostic test accuracy. We will be
405138|NCT01065792|HIV Infection
405017|NCT01066312|looking at the accuracy of MMT to distinguish congruent from
405018|NCT01066312|incongruent statements under varying levels of blinding.
405019|NCT01066299|oxytocin
405020|NCT01066299|psychophysiology
405021|NCT01066299|startle
405022|NCT01066299|anxiety
405023|NCT01066299|emotion
405024|NCT01066299|physiology
405025|NCT01066286|genome wide SNP-array
405026|NCT01066286|micro-cytogenetic lesion
405027|NCT01066286|KIT mutation
405028|NCT01066286|core binding factor
405029|NCT01066286|acute myeloid leukemia
405030|NCT01066286|The Approval status was changed from Pending to Approved.
405031|NCT01066260|Probiotics
405032|NCT01066260|Energy balance
405033|NCT01066247|spinal anesthesia
405034|NCT01066247|heart rate variability
405035|NCT01066247|premedication
405036|NCT01066247|heart rate
405037|NCT01066247|blood pressure
405038|NCT01066234|Microscopic N2 Non-small Cell Lung Cancer
405039|NCT01066234|Paclitaxel
405040|NCT01066234|Carboplatin
405041|NCT01066234|Cisplatin
405042|NCT01066221|clostridium difficile
405043|NCT01066208|Classification criteria
405044|NCT01066208|Diagnostic criteria
405045|NCT01066195|Non-Small Cell Lung Cancer
405046|NCT01066195|Never-Smoker and Adenocarcinoma patients
405047|NCT01066195|Pemetrexed (ALIMTA)
405048|NCT01066195|Gefitinib (IRESSA®)
405049|NCT01066182|DHA
405050|NCT01066182|Learning
405051|NCT01066182|Reading
405052|NCT01066182|Memory
405053|NCT01066182|Children
405054|NCT01066182|Omega 3
405055|NCT01066182|Education
405056|NCT01066182|Learning and behaviour in children
405057|NCT01066169|Pandemic Influenza A/H1N1
405058|NCT01066169|HIV
405059|NCT01066169|Antibodies
405060|NCT01066169|Replicaton
405061|NCT01066156|Post-traumatic Stress Disorder
405062|NCT01066156|PTSD
405063|NCT01066156|Seroquel
405064|NCT01066156|fMRI
405065|NCT01066143|Seroquel
405066|NCT01066143|Generalized Anxiety Disorder
405067|NCT01066143|fMRI
405068|NCT01066130|Diabetes Mellitus
405069|NCT01066130|Arthritis, Rheumatoid
405070|NCT01066130|psychosocial aspects
405071|NCT01066130|Patient Adherence
405072|NCT01066130|Social Work
405073|NCT01066130|Coping Behavior
405074|NCT01066130|Coping Skills
405075|NCT01066130|Adaptation, Psychological
405076|NCT01066117|urinary incontinent
405077|NCT01066091|Inflammatory response
405078|NCT01066091|High-fat meal
405079|NCT01066091|cytokines
405080|NCT01066091|Body composition
405081|NCT01066078|heart failure - congestive
405082|NCT01066078|Cardiovascular imaging agents/Techniques]
405083|NCT01066078|Echocardiography
405084|NCT01066078|Other diagnostic testing
405085|NCT01066078|Other Treatment
405086|NCT01066078|Recipients of cardiac resynchronization therapy systems
405087|NCT01066065|cardiovascular disease
405088|NCT01066065|HIV
405089|NCT01066065|metabolic disorder
405090|NCT01066065|HIV naive patients initiating HAART with Raltegravir or boosted Darunavir
405091|NCT01066052|Growth hormone
405092|NCT01066052|Turner syndrome
405093|NCT01066052|r-hGH
405094|NCT01066052|early treatment
405095|NCT01066039|Bisoprolol
405096|NCT01066039|Hypertension
405097|NCT01066039|Diabetes mellitus, Type II
405098|NCT01066039|Blood pressure
405099|NCT01066039|Glycemic level
405100|NCT01066026|metallic cannula
405101|NCT01066026|Hyaluronic acid
405102|NCT01066013|Antimicrobial De escalation
405103|NCT01066013|Meropenem
405104|NCT01066013|Piperacillin tazobactam
405105|NCT01066013|Medical patients
405106|NCT01066013|Appropriate use
405107|NCT01066013|Cost savings
405108|NCT01066013|Antimicrobial De-escalation strategy
405109|NCT01065974|Nutritional Intake
405110|NCT01065974|Psychosocial Outcome
405111|NCT01065961|anterior
405112|NCT01065961|cervical
405113|NCT01065961|fusion
405114|NCT01065961|swallowing
405115|NCT01065961|Swallowing after anterior cervical discectomy and fusion
405116|NCT01065961|Bony fusion rates post anterior cervical discectomy and fusion
405117|NCT01065948|subcutaneous glucose monitoring
405118|NCT01065948|diabetes
405119|NCT01065948|fluorescence
405120|NCT01065948|affinity
405121|NCT01065948|biosensor
405122|NCT01065948|type I Diabetes
405123|NCT01065948|type II diabetes
405124|NCT01065935|ALN-RSV01
405125|NCT01065935|RSV
405126|NCT01065935|Respiratory Syncytial Virus
405127|NCT01065896|spinal cord injury
405128|NCT01065896|coronary artery disease
405129|NCT01065857|Colonoscopy, Preparation, Evacuating, Bowel Cleansing.
405130|NCT01065844|Nelfinavir
405131|NCT01065831|motivational interviewing, lay health advisers
405132|NCT01065818|Esophageal cancer
405133|NCT01065818|FLT-PET
405134|NCT01065818|Chemoradiotherapy
405135|NCT01065805|18F-FLT
405136|NCT01065805|Positive Emission Tomography
405137|NCT01065805|Cancer
405139|NCT01065766|Diabetes Mellitus
405140|NCT01065766|Non-Insulin-Dependent
405141|NCT01065753|Rho kinase
405142|NCT01065753|Brain-derived neurotrophic factor
405143|NCT01065740|Peripheral arterial disease
405144|NCT01065740|Patient education
405145|NCT01065740|Physical activity coaching
405146|NCT01065740|Lifestyle modifications
405147|NCT01065740|Walking capacity
405148|NCT01065740|6 minutes walking test
405149|NCT01065727|Reemitting aggressive multiple sclerosis
405150|NCT01065714|Transepidermal water loss
405151|NCT01065714|Epidermal barrier
405152|NCT01065714|Skin hydration
405153|NCT01065688|distal gastrectomy
405154|NCT01065688|Billroth-I reconstruction
405155|NCT01065688|gastric cancer
405156|NCT01065688|QOL
405157|NCT01065675|Medication Reconciliation
405158|NCT01065675|Emergency Department
405159|NCT01065675|Nurse
405160|NCT01065675|Pharmacist
405161|NCT01065675|Certified Pharmacy Technician
405162|NCT01065675|Medication reconciliation: inpatients admitted from the ED
405163|NCT01065662|AZD2171
405164|NCT01065662|temsirolimus
405165|NCT01065662|advanced gynecological malignancies
405166|NCT01065649|reflux disease
405167|NCT01065649|heartburn
405168|NCT01065623|Phase I
405169|NCT01065623|Dose escalation
405170|NCT01065623|Immunoconjugate
405171|NCT01065597|electroconvulsive therapy
405172|NCT01065597|seizure
405173|NCT01065597|nonconvulsive
405174|NCT01065597|subconvulsive
405175|NCT01065597|major depression
405176|NCT01065597|bipolar disorder
405177|NCT01065584|liver transplantation
405178|NCT01065584|Patients undergoing liver transplantation
405179|NCT01065571|relapse
405180|NCT01065571|carrageenan
405181|NCT01065571|inflammation
405182|NCT01065558|Ecopipam
405183|NCT01065558|Lesch-Nyhan Disease
405184|NCT01065558|Safety
405185|NCT01065558|Self-Injurious Behavior
405186|NCT01065545|leukemia
405187|NCT01065532|Restenosis
405188|NCT01065532|PCI
405189|NCT01065532|Drug-eluting stent
405190|NCT01065532|Drug-eluting balloon
405191|NCT01065532|Optical Coherence Tomography
405192|NCT01065519|Coronary stent
405193|NCT01065519|Optical coherence tomography
405194|NCT01065519|Intravascular ultrasound
405195|NCT01065480|Training
405196|NCT01065480|Substance Abuse
405197|NCT01065480|Counseling
405198|NCT01065480|Motivational Interviewing
405199|NCT01065467|LBH589
405200|NCT01065467|panobinostat
405201|NCT01065454|Pulmonary Hypertension
405202|NCT01065454|Left ventricular dysfunction
405203|NCT01065441|breast cancer
405204|NCT01065441|colorectal cancer
405205|NCT01065441|prostate cancer
405206|NCT01065441|melanoma
405207|NCT01065441|ovarian cancer
405208|NCT01065441|GI cancer
405209|NCT01065441|Sarcoma
405210|NCT01065441|Renal Cell Carcinoma
405211|NCT01065428|neuromechanical efficiency
405212|NCT01065428|neuroventilatory efficiency
405213|NCT01065428|weaning
405214|NCT01065428|Respiration, Artificial
405215|NCT01065415|Magnetic Resonance Imaging/Positron Emission Tomography
405216|NCT01065415|Whole body imaging
405217|NCT01065415|Non-small cell lung cancer
405218|NCT01065415|staging
405219|NCT01065415|Diagnostic accuracy
405220|NCT01065402|Diabetes mellitus
405221|NCT01065402|continuous glucose monitoring system (CGMS)
405222|NCT01065389|Intradialysis
405223|NCT01065389|Resistance training
405224|NCT01065389|Protein Catabolic Rate
405225|NCT01065389|Urea kinetics
405226|NCT01065389|Quality of life
405227|NCT01065389|VO2 max
405228|NCT01065376|IVF
405229|NCT01065376|OHSS
405230|NCT01065376|cabergoline
405231|NCT01065363|Hepatitis B virus DNA
405232|NCT01065363|Metabolic factor
405233|NCT01065363|Body mass index
405234|NCT01065363|Obesity
405235|NCT01065363|Insulin resistance
405236|NCT01065363|Lifestyle factor
405237|NCT01065363|Preventive Medicine
405238|NCT01065363|Health Promotion
405239|NCT01065350|ketofol
405240|NCT01065350|hemodynamics
405241|NCT01065350|propofol
405242|NCT01065350|anesthesia
405243|NCT01065337|peripheral arterial occlusion disease (PAD)
405244|NCT01065337|diabetic foot
405245|NCT01065337|critical limb ischemia (CLI)
405246|NCT01065337|stem cell therapy
405247|NCT01065324|balloon
405248|NCT01065324|enteroscopy
405249|NCT01065324|bacteremia
405250|NCT01065311|Depressive Disorder
405251|NCT01065311|Psychotherapy
405252|NCT01065285|Influenza
405253|NCT01065285|autoimmune diseases
405254|NCT01065285|vaccination
405255|NCT01065285|H1N1
405256|NCT01065272|Dexamethasone
405257|NCT01065272|Bronchiolitis
405258|NCT01065259|attention deficit hyperactivity disorder
405259|NCT01065259|executive function
405260|NCT01065259|OROS MPH
405261|NCT01065259|atomoxetine
405262|NCT01065246|malignant ascites
405263|NCT01065246|second cycle
405264|NCT01065246|trifunctional
405265|NCT01065220|Serotonin Transporter
405266|NCT01065220|Hormone therapy
405267|NCT01065220|Gender Dysphoria
405268|NCT01065220|Transsexualism
405269|NCT01065181|shoulder
405270|NCT01065181|posterior inferior glenohumeral ligament
405271|NCT01065181|posterior capsule
405272|NCT01065181|capsular contracture
405273|NCT01065181|baseball
405274|NCT01065181|throwing injury
405275|NCT01065168|endometriosis
405276|NCT01065168|endometrioma
405277|NCT01065168|antimullerian hormone
405278|NCT01065168|cystectomy
405279|NCT01065142|Heart Failure
405280|NCT01065142|Patient Education as Topic
405281|NCT01065142|Primary Health Care
405282|NCT01065142|Quality of Life
405283|NCT01065116|Malaria
405284|NCT01065103|STEMI
405285|NCT01065103|Primary angioplasty
405286|NCT01065103|Non-culprit vessel at STEMI
405287|NCT01065103|Fractional Flow Reserve
405288|NCT01065103|ST-elevation myocardial infarction
405289|NCT01065103|Fractional Flow Reserve in non-culprit vessel at STEMI
405290|NCT01065090|Capacity for Work Questionnaire
405291|NCT01065090|exercise
405292|NCT01065090|AVONEX
405293|NCT01065090|SDMT: Symbol Digit Modalities Test
405294|NCT01065090|FSMC: Fatigue Scale for Motor and Cognitive functions
405295|NCT01065090|effects of exercise
405296|NCT01065090|EDSS: Expanded Disability Status Scale
405297|NCT01065077|Heart Failure
405298|NCT01065064|Multifocal IOL
405299|NCT01065064|ReSTOR IOL
405300|NCT01065051|Pulmonary Hypertension
405301|NCT01065051|Left ventricular dysfunction
405302|NCT01065025|4SC-205
405303|NCT01065025|Solid tumors
405304|NCT01065025|Lymphomas
405305|NCT01065025|Phase I
405306|NCT01064999|Neoadjuvant chemotherapy
405307|NCT01064999|locally advanced rectal cancer
405308|NCT01064999|intensity-modulated radiation therapy
405309|NCT01064999|pathological complete response
405310|NCT01064986|Immune System
405311|NCT01064973|autism
405312|NCT01064960|Neoplasms, Connective and Soft Tissue
405313|NCT01064960|Neoplasms, Muscle Tissue
405314|NCT01064960|Neoplasms
405315|NCT01064960|Myofibroma
405316|NCT01064960|Neoplasms by Histologic Type
405317|NCT01064960|Connective Tissue Diseases
405318|NCT01064960|Neoplasms, Connective Tissue
405319|NCT01064960|Leiomyoma
405320|NCT01064934|coronary heart disease
405321|NCT01064934|cerebrovascular disease
405322|NCT01064934|peripheral arterial disease
405323|NCT01064934|atherosclerosis
405324|NCT01064934|hyperlipoproteinemia
405325|NCT01064921|oropharyngeal cancer
405326|NCT01064921|recurrent squamous cell carcinoma of the oropharynx
405327|NCT01064908|Endarterectomy, Carotid
405328|NCT01064908|Carotid stenosis
405329|NCT01064908|Oxygen mask
405330|NCT01064895|Benephit
405331|NCT01064895|Acute Kidney Injury
405332|NCT01064895|Acute Renal Failure
405333|NCT01064895|Contrast Induced Nephropathy
405334|NCT01064895|Chronic Kidney Disease
405335|NCT01064869|Adherence
405336|NCT01064869|Asthma
405337|NCT01064869|medication
405338|NCT01064856|peripheral spondyloarthritis
405339|NCT01064856|adalimumab
405340|NCT01064856|humira
405341|NCT01064843|Edentulous
405342|NCT01064843|Edentulism
405343|NCT01064843|Lower denture
405344|NCT01064843|Mini dental implant
405345|NCT01064843|Imtec MDI
405346|NCT01064843|Denture stabilization
405347|NCT01064843|Case success rate of overdentures stabilized by MDI
405348|NCT01064843|General satisfaction of patients with this treatment
405349|NCT01064843|Oral health-related quality of life of these patients
405350|NCT01064843|Cost estimates
405351|NCT01064830|brittle nail
405352|NCT01064817|glaucoma, trabeculectomy
405353|NCT01064791|Renal transplantation
405354|NCT01064778|Glycemic Index
405355|NCT01064778|Brain
405356|NCT01064778|Intake Regulation
405357|NCT01064778|Weight Loss
405358|NCT01064778|Hunger
405359|NCT01064778|Diet
405360|NCT01064765|Heart failure
405361|NCT01064765|Self management
405362|NCT01064765|cognitive dysfunction
405363|NCT01064765|Self management of heart failure
405364|NCT01064752|Minocycline
405365|NCT01064752|HIV-1
405366|NCT01064752|Immune activation
405367|NCT01064752|Cerebrospinal fluid
405368|NCT01064752|Observational
405369|NCT01064739|Healthy Volunteers
405370|NCT01064739|Fava bean consumption
405371|NCT01064739|L-Dopa content in Fava Beans
405372|NCT01064739|Sodium
405373|NCT01064739|Potassium
405374|NCT01064739|Electrolyte Balance
405375|NCT01064739|Natriuresis
405376|NCT01064726|Allergic Rhinitis Nasal Allergen Challenge Inflammatory Markers
405377|NCT01064713|Tesetaxel
405378|NCT01064713|Second-line therapy
405379|NCT01064713|Metastatic melanoma
405380|NCT01064713|Normal serum LDH
405381|NCT01064700|Anxiety
405382|NCT01064700|Phototherapy
405383|NCT01064700|Psychic Anxiety
405384|NCT01064674|renal transplantation
405385|NCT01064674|cardiovascular morbidity
405386|NCT01064674|evaluation before renal transplantation
405387|NCT01064661|Probiotics
405388|NCT01064661|abdominal pain
405389|NCT01064661|abdominal discomfort
405390|NCT01064661|bloating
405391|NCT01064661|Functional Bowel Disorders
405392|NCT01064635|stage IA breast cancer
405393|NCT01064635|stage IB breast cancer
405394|NCT01064635|stage II breast cancer
405395|NCT01064635|stage IIIA breast cancer
405396|NCT01064635|stage IIIB breast cancer
405397|NCT01064635|stage IIIC breast cancer
405398|NCT01064596|obesity
405399|NCT01064596|fondaparinux
405400|NCT01064596|surgery
405401|NCT01064596|anti-Xa activity
405402|NCT01064570|Acute Promyelocytic Leukemia
405403|NCT01064570|APL
405404|NCT01064557|Acute promyelocytic Leukemia
405405|NCT01064544|Sleep problems
405406|NCT01064544|melatonin
405407|NCT01064544|mood
405408|NCT01064544|Hemodialysis
405409|NCT01064518|Lateral Canthal Lines
405410|NCT01064518|Crow's Feet Wrinkles
405411|NCT01064518|Facial Wrinkles
405412|NCT01064505|Ocular Neuroprotection
405413|NCT01064505|ocular neuroprotectant
405414|NCT01064505|NAION
405415|NCT01064505|NAAION
405416|NCT01064505|Non-arteritic ischemic optic neuropathy
405417|NCT01064505|Non-arteritic anterior ischemic optic neuropathy
405418|NCT01064505|chronic optic nerve atrophy
405419|NCT01064505|optic nerve atrophy
405420|NCT01064505|retinal degeneration
405421|NCT01064505|optic neuritis
405422|NCT01064505|end stage glaucoma
405423|NCT01064505|Leber's hereditary optic neuropathy
405424|NCT01064479|SCCHN
405425|NCT01064479|Oral cavity
405426|NCT01064479|Oropharynx
405427|NCT01064479|Hypopharynx
405428|NCT01064479|Larynx
405429|NCT01064479|Tarceva
405430|NCT01064479|Erlotinib
405431|NCT01064479|OSI-774
405432|NCT01064479|Docetaxel
405433|NCT01064479|Taxotere
405434|NCT01064479|Cisplatin
405435|NCT01064479|Platinol
405436|NCT01064479|CDDP
405437|NCT01064479|Placebo
405438|NCT01064479|Chemotherapy
405439|NCT01064466|SCLC
405440|NCT01064466|Etoposide
405441|NCT01064466|SNP
405442|NCT01064466|Topo
405443|NCT01064466|CYP
405444|NCT01064466|Genotype
405445|NCT01064466|Oncology
405446|NCT01064466|Genetics
405447|NCT01064466|Lung
405448|NCT01064466|Cancer
405449|NCT01064453|Menopause
405450|NCT01064453|Menopausal symptoms
405451|NCT01064453|Prevention of osteoporosis in menopausal women
405452|NCT01064453|Estrogen deficiency symptoms
405453|NCT01064453|Hormone replacement therapy
405454|NCT01064440|Painful legs
405455|NCT01064440|Ischemic legs
405456|NCT01064440|Treatment for Claudication
405457|NCT01064440|Gene therapy
405458|NCT01064427|breast cancer
405459|NCT01064427|fatigue
405460|NCT01064427|adjuvant chemotherapy
405461|NCT01064427|quality of life
405462|NCT01064414|Canagliflozin
405463|NCT01064414|JNJ 28431754
405464|NCT01064414|Placebo
405465|NCT01064414|Sodium-Glucose Transporter 2
405466|NCT01064414|hemoglobin A1c protein, Blood Glucose
405467|NCT01064414|reduced kidney function, Type 2 diabetes mellitus
405468|NCT01064388|Safety
405469|NCT01064375|DNA vaccine
405470|NCT01064375|Electroporation
405471|NCT01064362|Haemorrhage
405472|NCT01064362|Thromboprophylaxis
405473|NCT01064349|brain metastases
405474|NCT01064349|ErbB2 treatment
405475|NCT01064349|ErbB2+ breast cancer
405476|NCT01064336|Thrombocytopenia
405477|NCT01064336|Pregnancy
405478|NCT01064323|intermittent pneumatic leg compression
405479|NCT01064323|nitric oxide
405480|NCT01064323|vascular endothelial cells
405481|NCT01064323|IPC
405482|NCT01064323|EECP
405483|NCT01064323|atherosclerosis
405484|NCT01064310|renal cell carcinoma
405485|NCT01064310|Votrient
405486|NCT01064310|cancer
405487|NCT01064310|pazopanib
405488|NCT01064310|patient preference
405489|NCT01064310|quality of life
405490|NCT01064297|Pregnancy registry
405491|NCT01064297|Major congenital malformations
405492|NCT01064297|Pregnancy outcomes
405493|NCT01064297|Pregnancy
405494|NCT01064297|First trimester
405495|NCT01064297|Lamotrigine
405496|NCT01064284|Hemophilia A
405497|NCT01064284|Factor VIII inhibitors
405498|NCT01064284|vWF/FVIII
405499|NCT01064284|rFVIII
405500|NCT01064258|treatment
405501|NCT01064258|CPAP
405502|NCT01064258|sleep apnea
405503|NCT01064245|Asthma
405504|NCT01064245|Cough Variant Asthma
405505|NCT01064245|Mannitol
405506|NCT01064245|Methacholine
405507|NCT01064245|Cough
405508|NCT01064245|Hypersensitivity
405509|NCT01064219|hCG
405510|NCT01064219|Treg cells
405511|NCT01064219|implantation
405512|NCT01064219|pinopodes
405513|NCT01064219|endometrium
405514|NCT01064206|thrombangiitis obliterans
405515|NCT01064206|Buerger's disease
405516|NCT01064206|atheromatous arteritis
405517|NCT01064206|psychiatric disorders
405518|NCT01064206|personality disorders
405519|NCT01064206|addictive profile
405520|NCT01064206|addiction
405521|NCT01064206|tobacco
405522|NCT01064206|cannabis
405523|NCT01064193|In Vitro Fertilization
405524|NCT01064193|biopsy
405525|NCT01064193|pregnancy
405526|NCT01064193|Implantation
405527|NCT01064193|Embryo
405528|NCT01064193|first or second IVF tentative
405529|NCT01064167|Tranexamic Acid
405530|NCT01064167|off-pump coronary Artery Bypass
405531|NCT01064141|Dengue Fever
405532|NCT01064141|Dengue Hemorrhagic Fever
405533|NCT01064141|CYD Dengue Vaccine
405534|NCT01064141|Toddlers
405535|NCT01064128|Single-port
405536|NCT01064128|Laparoscopy
405537|NCT01064128|Hysterectomy
405538|NCT01064128|Pain
405539|NCT01064128|Cosmesis
405540|NCT01064128|Analgesics
405541|NCT01064089|HSP990
405542|NCT01064089|HSP90
405543|NCT01064089|Japan/Korea
405544|NCT01064089|Phase I
405545|NCT01064089|advanced solid tumors
405546|NCT01064089|dose escalation
405547|NCT01064089|maximum tolerated dose
405548|NCT01064089|MTD
405549|NCT01064089|Japanese paatients
405550|NCT01064089|Korean patients
405551|NCT01064076|ICD, defibrillator
405552|NCT01064050|tumoral obstruction of the main stem bronchus
405553|NCT01064050|bronchoscopy
405554|NCT01064050|silicone stent
405555|NCT01064037|Heart Failure
405556|NCT01064024|uUTI
405557|NCT01064024|Pain or burning associated with Uncomplicated Urinary Tract Infections
405558|NCT01063998|Renal cell
405559|NCT01063998|Carcinoma
405560|NCT01063998|Biomarkers
405561|NCT01063985|Skin testing for mouse allergies
405562|NCT01063959|Laparoscopic Sleeve Gastrectomy
405563|NCT01063959|Laparoscopic Gastric Bypass
405564|NCT01063933|influenza, Peramivir, children, pharmacokinetic, pharmacodynamic
405565|NCT01063920|LT-NS001
405566|NCT01063920|Gastric Ulcers
405567|NCT01063920|NSAID
405568|NCT01063920|Osteoarthritis
405569|NCT01063920|Naproxen
405570|NCT01063907|Leukemia
405571|NCT01063907|Immunoproliferative Disorder
405572|NCT01063907|Neoplasma by Histologic Type
405573|NCT01063907|Immune System Diseases
405574|NCT01063907|Hematologic Diseases
405575|NCT01063907|Blood Protein Disorders
405576|NCT01063907|Paraproteinemias
405577|NCT01063907|Multiple Myeloma
405578|NCT01063907|Hematologic Disorders
405579|NCT01063907|Leukemia, Chronic, B-cell
405580|NCT01063907|Leukemia, B-cell
405581|NCT01063907|Leukemia, Chronic
405582|NCT01063907|Neoplasms, Plasma Cell
405583|NCT01063907|Monoclonal Gammopathy of unknown significance (MGUS)
405584|NCT01063881|Sexual Dysfunction, physiological
405585|NCT01063881|R096769
405586|NCT01063881|Dapoxetine
405587|NCT01063881|Phase 3b
405588|NCT01063881|Premature Ejaculation
405589|NCT01063868|Diabetic neuropathy
405590|NCT01063868|Painful
405591|NCT01063868|Polyneuropathy
405592|NCT01063868|Peripheral neuropathy
405593|NCT01063855|Erectile Dysfunction
405594|NCT01063855|Sexual Dysfunction
405595|NCT01063855|Dapoxetine hydrochloride
405596|NCT01063855|PRILIGY
405597|NCT01063855|Premature ejaculation
405598|NCT01063855|Serotonin Uptake Inhibitors
405599|NCT01063855|Sildenafil (Viagra)
405600|NCT01063855|Vardenafil (Levitra)
405601|NCT01063855|Tadalafil (Cialis)
405602|NCT01063842|Drop-out rate
405603|NCT01063842|Osteoarthritis
405604|NCT01063842|Tolerability
405605|NCT01063842|Tramadol
405606|NCT01063842|Acetaminophen
405607|NCT01063829|HCMV
405608|NCT01063816|PARP Inhibitors
405609|NCT01063803|Open-label
405610|NCT01063803|Long-term safety study of ATN-103 in RA
405611|NCT01063790|Post-operative pain
405612|NCT01063790|inguinal hernia repair surgery
405613|NCT01063790|Patient education
405614|NCT01063777|Hip Osteoarthritis, Exercise therapy, Patient Education
405615|NCT01063764|Keppra
405616|NCT01063764|Levetiracetam
405617|NCT01063764|Children
405618|NCT01063764|Epilepsy
405619|NCT01063764|Partial Seizures
405620|NCT01063751|Osteoarthritis
405621|NCT01063751|Traumatic arthritis
405622|NCT01063751|Avascular Necrosis
405623|NCT01063738|Rehabilitation
405624|NCT01063738|Intensive Care
405625|NCT01063738|Critical illness
405626|NCT01063738|Physiotherapy
405627|NCT01063738|Nutritional supplementation
405628|NCT01063725|menopause
405629|NCT01063725|hot flashes
405630|NCT01063725|vasomotor symptoms
405631|NCT01063725|femarelle
405632|NCT01063725|soy extract
405633|NCT01063725|SERM
405634|NCT01063712|Ductus
405635|NCT01063712|Patent ductus Arterious
405636|NCT01063712|"Nit-Occlud® PDA-R"
405637|NCT01063712|Interventional closure of PDA
405638|NCT01063712|Percutaneous closure
405639|NCT01063699|biliary atresia - laparoscopy - kasai - portoenterostomy
405640|NCT01063686|Pregnancy
405641|NCT01063673|Running, overuse injury, limits humans
405642|NCT01063660|Treosulfan
405643|NCT01063660|Fludarabine
405644|NCT01063660|ATG
405645|NCT01063660|AML
405646|NCT01063647|Treosulfan
405647|NCT01063647|Allogeneic stem cell transplantation
405648|NCT01063647|Conditioning therapy
405649|NCT01063634|malignant biliary obstruction
405650|NCT01063634|viaduct
405651|NCT01063634|self-expandable metal stents
405652|NCT01063595|Octaplas LG
405653|NCT01063595|Octaplas SD
405654|NCT01063582|echocardiogram
405655|NCT01063582|electrocardiographic
405656|NCT01063582|risk factors
405657|NCT01063582|noise
405658|NCT01063569|Addison's disease
405659|NCT01063569|Glucocorticoid treatment
405660|NCT01063569|Continuous subcutaneous hydrocortisone infusion
405661|NCT01063569|CSHI
405662|NCT01063569|Quality of Life
405663|NCT01063569|Sleep
405664|NCT01063556|end-stage renal disease hemodialysis donepezil hydrochloride pharmacokinetics Cross-Over Study
405665|NCT01063543|fondaparinux
405666|NCT01063543|orthopedic surgery
405667|NCT01063543|patients with major orthopedic surgery
405668|NCT01063530|FLuoride
405669|NCT01063530|Dental Sensitivity
405670|NCT01063530|Abfraction
405671|NCT01063530|Cervical lesions
405672|NCT01063517|Poly(ADP ribose)
405673|NCT01063517|polymerase (PARP)
405674|NCT01063517|Gastric cancer
405675|NCT01063517|olaparib
405676|NCT01063517|PARP inhibitor
405677|NCT01063517|ATM AZD2281
405678|NCT01063517|Ku0059436
405679|NCT01063517|Homologous Recombination deficiency (HRD)
405680|NCT01063517|Recurrent gastric cancer
405681|NCT01063517|metastatic gastric cancer
405682|NCT01063491|coronary artery bypass graft surgery
405683|NCT01063491|bypass grafts
405684|NCT01063491|angiography
405685|NCT01063491|percutaneous coronary intervention
405686|NCT01063491|coronary imaging
405687|NCT01063491|coronary artery bypass graft surgery, bypass graft patency
405688|NCT01063478|Non-Small Cell
405689|NCT01063478|Lung Cancer
405690|NCT01063478|Unresectable advanced NSCLC
405691|NCT01063465|Achilles
405692|NCT01063465|Tendon
405693|NCT01063465|weightbearing
405694|NCT01063452|Urinary Catheterization
405695|NCT01063452|Urinary Tract Infections
405696|NCT01063439|DLBCL
405697|NCT01063439|NHL
405698|NCT01063426|Statin
405699|NCT01063426|Vein
405700|NCT01063413|Behavioral Research
405701|NCT01063413|Community-Based Participatory Research
405702|NCT01063387|cervical cancer,semaphorin 4C (Sema4C),
405703|NCT01063387|Prophylactic Irradiation
405704|NCT01063348|N-Acetyl Cysteine
405705|NCT01063348|Picking
405706|NCT01063348|Impulse Control Disorder
405707|NCT01063348|Obsessive Compulsive Disorder
405708|NCT01063335|CB1 Receptor
405709|NCT01063335|Schizophrenia
405710|NCT01063335|Positron Emission Tomography (PET)
405711|NCT01063335|Healthy Volunteers
405712|NCT01063335|HV
405713|NCT01063322|Mitral Regurgitation
405714|NCT01063322|Echocardiography
405715|NCT01063322|Cardiac Magnetic Resonance
405716|NCT01063322|Regurgitant Volume
405717|NCT01063322|Mitral Valve Regurgitation
405718|NCT01063309|Chronic Granulomatous Disease (CGD)
405719|NCT01063309|Atherosclerosis
405720|NCT01063309|Inflammatory Bowel Disease
405721|NCT01063309|Immune Deficiencies
405722|NCT01063309|Immune System Deficiences
405723|NCT01063309|Chronic Granulomatous Disease
405724|NCT01063309|CGD
405725|NCT01063296|cervical cancer
405726|NCT01063283|Non-squamous Non-Small Cell Lung Cancer
405727|NCT01063283|Bevacizumab
405728|NCT01063283|Ambulatory Blood Pressure Monitoring
405729|NCT01063270|Hidradenitis Suppurativa
405730|NCT01063270|Antibiotics
405731|NCT01063270|Laser
405732|NCT01063257|Myelodysplastic Syndrome
405733|NCT01063244|pregnancy
405734|NCT01063244|induction of Labor
405735|NCT01063244|Cervical ripening
405736|NCT01063244|Foley balloon
405737|NCT01063231|Colonic Diseases
405738|NCT01063231|bowel diseases
405739|NCT01063218|Dermatitis, Atopic
405740|NCT01063218|Corticoids, topic
405741|NCT01063218|Corticosteroids
405742|NCT01063205|Methamphetamine
405743|NCT01063205|NAC
405744|NCT01063205|N-acetylcysteine
405745|NCT01063192|Locally Advanced Pancreatic Cancer
405746|NCT01063179|Elderly patients
405747|NCT01063179|Bortezomib
405748|NCT01063179|Thalidomide
405749|NCT01063153|ADHD
405750|NCT01063153|Adults
405751|NCT01063153|Electroencephalography (EEG)
405752|NCT01063153|Concerta
405753|NCT01063140|Rabies Immune Globulin
405754|NCT01063140|Source Plasma Donors
405755|NCT01063140|Booster Immunization
405756|NCT01063127|Morbid obesity
405757|NCT01063127|Insulin resistance
405758|NCT01063127|Euglycemic clamp
405759|NCT01063114|proton beam radiation
405760|NCT01063088|Prophylaxis of seasonal influenza in adults
405761|NCT01063075|Cancer of Head
405762|NCT01063075|Cancer of Head and Neck
405763|NCT01063075|Cancer of Neck
405764|NCT01063075|Head and Neck Cancer
405765|NCT01063075|Head Cancer
405766|NCT01063075|Head Neoplasms
405767|NCT01063075|Head, Neck Neoplasms
405768|NCT01063075|Neck Cancer
405769|NCT01063075|Neck Neoplasms
405770|NCT01063075|Solid Neoplasm
405771|NCT01063075|Carcinoma
405772|NCT01063075|Sarcoma
405773|NCT01063010|sepsis
405774|NCT01063010|septic shock
405775|NCT01063010|Bevacizumab
405776|NCT01063010|Avastin
405777|NCT01062984|Renal Replacement Therapy
405778|NCT01062971|Open-angle glaucoma
405779|NCT01062971|Ocular hypertension
405780|NCT01062971|POAG
405781|NCT01062958|Neevo
405782|NCT01062958|Neevo DHA
405783|NCT01062958|L-methylfolate
405784|NCT01062958|anemia during pregnancy
405785|NCT01062958|folic acid
405786|NCT01062958|vitamin B12
405787|NCT01062958|prenatal vitamins
405788|NCT01062958|hemoglobin
405789|NCT01062958|iron deficiency
405790|NCT01062958|Pregnancy
405791|NCT01062945|Cocaine
405792|NCT01062945|Doxazosin
405793|NCT01062932|Cycloserine
405794|NCT01062932|Nicotine
405795|NCT01062932|Smoking
405796|NCT01062906|intravenous lidocaine
405797|NCT01062906|postoperative pain
405798|NCT01062906|laparoscopic surgery
405799|NCT01062906|opioids
405800|NCT01062906|opioids side-effects
405801|NCT01062893|labor pain treatment
405802|NCT01062893|duration analgesia
405803|NCT01062893|Analgesic duration with normal saline injection.
405804|NCT01062893|Analgesic duration without normal saline injection
405805|NCT01062867|Anaesthetic
405806|NCT01062854|snoring, sleep disordered breathing, polysomnography, sleep fragmentation
405807|NCT01062841|Long-Term Care
405808|NCT01062841|Nursing Homes
405809|NCT01062841|Infection Control
405810|NCT01062841|Multi-drug resistant pathogens
405811|NCT01062841|Long-term care residents with in-dwelling devices
405812|NCT01062828|Prematurity
405813|NCT01062828|Necrotizing Enterocolitis
405814|NCT01062828|Feeding Intolerance
405815|NCT01062815|PNALD
405816|NCT01062815|PNAC
405817|NCT01062815|Parenteral Nutrition-Associated Cholestasis
405818|NCT01062815|Congenital Anomalies of Gastrointestinal Tract
405819|NCT01062789|lung biopsy
405820|NCT01062789|computed tomograph
405821|NCT01062789|respiratory motion
405822|NCT01062789|Controlling respiratory motion in CT guided lung biopsies
405823|NCT01062789|biopsy
405824|NCT01062776|dehydration
405825|NCT01062776|fluid therapy
405826|NCT01062776|pharmacokinetics
405827|NCT01062776|hemoglobin
405828|NCT01062763|hypertension
405829|NCT01062763|spironolactone
405830|NCT01062763|antihypertensive treatment
405831|NCT01062763|Type-2 diabetes
405832|NCT01062750|Liver Cirrhosis
405833|NCT01062724|Cholestasis
405834|NCT01062724|TPN
405835|NCT01062724|Neonates
405836|NCT01062724|Primene
405837|NCT01062724|Trophamine
405838|NCT01062724|Methionine
405839|NCT01062724|Cysteine
405840|NCT01062724|Taurine
405841|NCT01062724|Total Parenteral Nutrition
405842|NCT01062711|sarcopenia
405843|NCT01062711|muscle
405844|NCT01062711|protein
405845|NCT01062711|muscle protein synthesis
405846|NCT01062711|muscle protein breakdown
405847|NCT01062711|whey
405848|NCT01062711|soy
405849|NCT01062711|casein
405850|NCT01062711|dose response
405851|NCT01062711|resistance exercise
405852|NCT01062711|unilateral
405853|NCT01062711|knee extension
405854|NCT01062711|whole body protein
405855|NCT01062698|mechanical Thrombectomy
405856|NCT01062698|CVA (Cerebrovascular Accident)
405857|NCT01062698|Cerebrovascular Accident, Acute
405858|NCT01062685|septic shock
405859|NCT01062685|sepsis
405860|NCT01062685|St02
405861|NCT01062685|Near Infrared Spectroscopy
405862|NCT01062685|NIRS
405863|NCT01062672|plasticity
405864|NCT01062672|reorganization
405865|NCT01062672|cortical
405866|NCT01062672|fMRI
405867|NCT01062672|rehabilitation
405868|NCT01062659|HCV
405869|NCT01062659|hepatitis C virus
405870|NCT01062659|CHC
405871|NCT01062659|chronic hepatitis c
405872|NCT01062659|interferon
405873|NCT01062659|ribavirin
405874|NCT01062659|Hepatitis, Viral, Human
405875|NCT01062659|Anti-Infective Agents
405876|NCT01062659|peginterferon alfa-2a
405877|NCT01062659|peginterferon alfa-2b
405878|NCT01062646|music therapy
405879|NCT01062646|multimodal psychotherapy
405880|NCT01062646|children
405881|NCT01062646|anxiety disorders
405882|NCT01062646|pediatric anxiety
405883|NCT01062633|dental caries
405884|NCT01062633|prevention
405885|NCT01062633|dietary supplements
405886|NCT01062607|bipolar disorders
405887|NCT01062607|everyday setting
405888|NCT01062607|treatment adherence
405889|NCT01062607|global
405890|NCT01062581|Recipient
405891|NCT01062581|Donor
405892|NCT01062581|Organ Transplant
405893|NCT01062581|Registry
405894|NCT01062581|University of Minnesota
405895|NCT01062568|adolescents
405896|NCT01062568|puberty
405897|NCT01062568|androgens
405898|NCT01062568|hyperandrogenemia
405899|NCT01062529|GH signalling
405900|NCT01062529|insulin resistance
405901|NCT01062529|somatostatin
405902|NCT01062529|acromegaly
405903|NCT01062516|acute coronary syndrome
405904|NCT01062516|acute myocardial infarction
405905|NCT01062516|percutaneous coronary intervention
405906|NCT01062516|aspirin
405907|NCT01062516|clopidogrel
405908|NCT01062516|esomeprazole
405909|NCT01062516|famotidine
405910|NCT01062516|platelet function
405911|NCT01062503|Cancer
405912|NCT01062503|Prostate
405913|NCT01062503|metastatic
405914|NCT01062490|Treosulfan
405915|NCT01062490|MDS
405916|NCT01062490|allogeneic stem cell transplantation
405917|NCT01062490|leukemia
405918|NCT01062490|Conditioning
405919|NCT01062477|Diphtheria Tetanus Pertussis Haemophilus Influenzae Type B
405920|NCT01062451|Methamphetamine
405921|NCT01062451|Perindopril
405922|NCT01062451|Candesartan
405923|NCT01062451|Angiotensin receptor blocker
405924|NCT01062451|ACE Inhibitor
405925|NCT01062438|localized osteosarcoma
405926|NCT01062438|metastatic osteosarcoma
405927|NCT01062399|adult glioblastoma
405928|NCT01062399|adult giant cell glioblastoma
405929|NCT01062399|adult gliosarcoma
405930|NCT01062386|prevalence
405931|NCT01062386|transmission
405932|NCT01062386|knowledge
405933|NCT01062386|attitude
405934|NCT01062386|practice
405935|NCT01062373|Premature Newborns
405936|NCT01062373|Human Milk
405937|NCT01062373|DHA
405938|NCT01062373|Mother-child
405939|NCT01062360|Sore Throat
405940|NCT01062360|Upper Respiratory Tract Infections
405941|NCT01062360|Nasal Congestion
405942|NCT01062347|To identify a new bio-marker for zinc status
405943|NCT01062334|Anastomotic leakage after LAR
405944|NCT01062321|Hepatitis E Virus
405945|NCT01062321|Cytokines
405946|NCT01062321|Pregnancy
405947|NCT01062308|Stroke
405948|NCT01062308|Taping
405949|NCT01062308|Pain
405950|NCT01062308|Shoulder Injury
405951|NCT01062295|passenger,
405952|NCT01062295|sleep,
405953|NCT01062295|rest,
405954|NCT01062282|Pulmonary Hypertension
405955|NCT01062269|Bile acid sequestrant
405956|NCT01062269|Resin
405957|NCT01062269|Cholesterol
405958|NCT01062269|Diabetes mellitus
405959|NCT01062269|Lipids
405960|NCT01062269|Glucose
405961|NCT01062269|Bile Acid Sequestrant Acceptability Scale (BASA)validation study
405962|NCT01062256|Cough assessment in upper respiratory infection
405963|NCT01062256|guaifenesin
405964|NCT01062256|honey
405965|NCT01062243|brain injury
405966|NCT01062243|family treatment
405967|NCT01062230|Cancer
405968|NCT01062230|Hematologic malignancy
405969|NCT01062204|Skin Graft donor sites
405970|NCT01062191|hydrogel
405971|NCT01062191|dressing
405972|NCT01062191|burn
405973|NCT01062191|joint
405974|NCT01062178|Small renal Mass
405975|NCT01062178|Contrast Enhanced Ultrasound
405976|NCT01062178|Renal Cell Carcinoma
405977|NCT01062178|noninvasive diagnosis of RCC
405978|NCT01062165|Echinocandin
405979|NCT01062165|Obesity
405980|NCT01062165|Pharmacokinetics
405981|NCT01062165|Pharmacodynamics
405982|NCT01062165|Fungal infection
405983|NCT01062152|Hematology
405984|NCT01062152|MDS
405985|NCT01062152|Myelodysplastic Syndrome
405986|NCT01062152|Low risk MDS
405987|NCT01062152|Patients with non-deletion(5q)
405988|NCT01062152|Non-deletion 5q
405989|NCT01062152|Non del(5q)
405990|NCT01062152|Revlimid
405991|NCT01062152|lenalidomide
405992|NCT01062152|Telintra
405993|NCT01062152|ezatiostat hydrochloride
405994|NCT01062152|ezatiostat
405995|NCT01062152|TLK199
405996|NCT01062152|Glutathione
405997|NCT01062152|Glutathione analog
405998|NCT01062152|Glutathione Transferase
405999|NCT01062152|Glutathione Transferase inhibitor
406000|NCT01062152|Glutathione Transferase P1-1 inhibitor
406001|NCT01062152|GSTp1-1 inhibitor
406002|NCT01062152|Apoptosis
406003|NCT01062152|Differentiation
406004|NCT01062152|Enzyme inhibitor
406005|NCT01062126|Pacemaker
406006|NCT01062126|Advanced Features
406007|NCT01062126|Clinical Outcomes
406134|NCT01061554|Soft gel capsules
406008|NCT01062113|Acute pain after oral surgery lateral mandibular Impacted third molar tooth extraction
406009|NCT01062100|breast cancer
406010|NCT01062100|molecular breast imaging
406011|NCT01062100|MRI
406012|NCT01062100|gamma camera
406013|NCT01062087|postoperative pain
406014|NCT01062087|tubal ligation
406015|NCT01062087|local anesthetic
406016|NCT01062061|Varicella
406017|NCT01062035|Advanced colon polyp
406018|NCT01062035|Adenomatous colon polyp
406019|NCT01062035|Adenoma, villous colon polyp
406020|NCT01062035|Advanced colorectal adenomas
406021|NCT01062035|Colonic neoplasms
406022|NCT01062035|High grade dysplasia
406023|NCT01062035|Telomere blood testing
406024|NCT01062022|intervention
406025|NCT01062022|combat wounded
406026|NCT01062022|family
406027|NCT01062022|Focus-CI
406028|NCT01061996|Ulcerative Colitis
406029|NCT01061983|Deep brain stimulation
406030|NCT01061983|Treatment refractory
406031|NCT01061983|Ventral internal capsule/ventral striatum
406032|NCT01061983|Neurosurgery
406033|NCT01061983|Neuroimaging
406034|NCT01061970|Hypogonadism
406035|NCT01061970|Chronic Obstructive Pulmonary Disease
406036|NCT01061970|COPD
406037|NCT01061957|Treatment outcome
406038|NCT01061957|HIV treatment
406039|NCT01061944|biopsy
406040|NCT01061944|tumor biopsy
406041|NCT01061944|genetic studies
406042|NCT01061931|MRI
406043|NCT01061931|left-sided atrial catheter ablation
406044|NCT01061931|paroxysmal atrial fibrillation
406045|NCT01061931|cryoballoon technique
406046|NCT01061931|mesh ablator catheter
406047|NCT01061931|stroke
406048|NCT01061931|silent stroke
406049|NCT01061931|major complications
406050|NCT01061918|Compare the visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs 6 months post cataract surgery.
406051|NCT01061905|health behavior
406052|NCT01061905|behavioral economics
406053|NCT01061905|calorie labeling
406054|NCT01061905|exercise
406055|NCT01061879|umbilical cord
406056|NCT01061879|umbilical cord blood collection
406057|NCT01061879|pregnancy
406058|NCT01061866|Thalidomide
406059|NCT01061866|Antiepileptic drugs
406060|NCT01061866|Refractory epilepsy
406061|NCT01061866|Sedative drugs
406062|NCT01061853|Oral lichen planus
406063|NCT01061853|chronic inflammatory
406064|NCT01061853|mucous membranes
406065|NCT01061853|erosive lesions
406066|NCT01061840|Ewings Sarcoma
406067|NCT01061840|Non Small Cell Lung Cancer
406068|NCT01061840|Liver Cancer
406069|NCT01061827|GMS-package;dementia;depression
406070|NCT01061814|ApoB (Apolipoprotein B)
406071|NCT01061814|LDL (low density lipoprotein)
406072|NCT01061814|mipomersen
406073|NCT01061814|ISIS301012
406074|NCT01061814|antisense
406075|NCT01061801|caregivers
406076|NCT01061801|cancer
406077|NCT01061801|emotion
406078|NCT01061801|protective buffering
406079|NCT01061788|Phase I
406080|NCT01061788|Solid Tumor
406081|NCT01061788|AMG 479
406082|NCT01061788|Panitumumab
406083|NCT01061788|Everolimus
406084|NCT01061788|RAD001
406085|NCT01061788|Duke
406086|NCT01061788|Subjects with refractory advanced solid tumors
406087|NCT01061788|non-small cell lung cancer
406088|NCT01061775|Hypothalamic Obesity
406089|NCT01061775|Exenatide
406090|NCT01061775|Byetta
406091|NCT01061775|Craniopharyngioma
406092|NCT01061762|Treatment adherence
406093|NCT01061762|Low literacy skills
406094|NCT01061762|HIV treatment
406095|NCT01061710|Smoking
406096|NCT01061710|smoking cessation
406097|NCT01061710|Japanese
406098|NCT01061710|varenicline
406099|NCT01061710|retreatment
406100|NCT01061710|Regulatory Post Marketing Commitment Plan
406101|NCT01061684|fatty liver disease
406102|NCT01061684|NASH
406103|NCT01061684|NAFLD
406104|NCT01061684|non-alcoholic steatohepatitis
406105|NCT01061671|Chronic Obstructive Pulmonary Disease
406106|NCT01061671|COPD
406107|NCT01061671|Exacerbation
406108|NCT01061671|Lung function
406109|NCT01061671|Cardiovascular
406110|NCT01061671|Smoking
406111|NCT01061671|Statins
406112|NCT01061671|Simvastatin
406113|NCT01061645|MDT and DLT
406114|NCT01061632|deadlift
406115|NCT01061632|motor control
406116|NCT01061632|exercises
406117|NCT01061632|pain
406118|NCT01061632|function
406119|NCT01061632|functional capacity
406120|NCT01061619|prediagnostic symptoms
406121|NCT01061619|sentinel events
406122|NCT01061619|pathway to diagnosis
406123|NCT01061593|TB
406124|NCT01061593|MDR-TB
406125|NCT01061593|XDR-TB
406126|NCT01061593|TB/HIV
406127|NCT01061580|Bone Marrow Concentrate
406128|NCT01061580|CABG
406129|NCT01061580|Cardiac
406130|NCT01061580|Stem Cell
406131|NCT01061554|Bioavailability
406132|NCT01061554|Eicosapentaenoic acid
406133|NCT01061554|Docosahexaenoic acid
406135|NCT01061554|Gastric stable emulsion
406136|NCT01061554|Omega-3
406137|NCT01061554|Tri-glycerides
406138|NCT01061554|Marine phospholipids
406139|NCT01061541|Pertussis
406140|NCT01061541|Tetanus
406141|NCT01061541|Hiberix™
406142|NCT01061541|Hepatitis B
406143|NCT01061541|DTPw-HBV vaccine
406144|NCT01061541|Tritanrix™-HepB
406145|NCT01061541|Haemophilus influenzae type b
406146|NCT01061541|Diphtheria
406147|NCT01061541|Hib vaccine
406148|NCT01061528|cigarette smoking
406149|NCT01061528|smoking cessation
406150|NCT01061528|nicotine dependence
406151|NCT01061502|Burns
406152|NCT01061502|Wounds and Injuries
406153|NCT01061502|Skin Grafts, Bioelectric
406154|NCT01061502|Grafting, skin
406155|NCT01061489|neuroplasticity
406156|NCT01061489|Mild Cognitive Impairment (MCI)
406157|NCT01061489|Alzheimer
406158|NCT01061489|sensory-cognitive training
406159|NCT01061489|physical fitness
406160|NCT01061476|sleep apnea
406161|NCT01061476|treatment
406162|NCT01061476|collapsibility
406163|NCT01061476|expiratory nasal resistance
406164|NCT01061463|Radiation cataracts
406165|NCT01061463|Lens opacities
406166|NCT01061463|X-rays
406167|NCT01061463|Interventional Cardiologists
406168|NCT01061463|Electrophysiologists
406169|NCT01061450|Diastolic dysfunction
406170|NCT01061450|hypertension
406171|NCT01061450|Statins
406172|NCT01061450|ACE inhibitor
406173|NCT01061450|Echocardiography
406174|NCT01061437|H. pylori
406175|NCT01061424|pediatric asthma
406176|NCT01061398|cardiac ct
406177|NCT01061398|stress testing
406178|NCT01061398|coronary artery disease
406179|NCT01061372|RLS
406180|NCT01061359|Breast Cancer
406181|NCT01061359|Neoadjuvant Treatment
406182|NCT01061359|Chemotherapy
406183|NCT01061359|Adjuvant
406184|NCT01061359|Epirubicin
406185|NCT01061346|Fructose
406186|NCT01061346|Glucose
406187|NCT01061320|Alpha-Tocopherol (Vitamin E)
406188|NCT01061320|Contrast induced nephropathy
406189|NCT01061320|Chronic kidney disease
406190|NCT01061320|Coronary procedures
406191|NCT01061307|Fe deficiency, Zn deficiency, vitamin A deficiency
406192|NCT01061294|Assess the efficacy, predictability and safety of the Advanced CustomVue™ iLASIK procedure.
406193|NCT01061281|Aphakia following refractive lensectomy to treat presbyopia
406194|NCT01061268|Relief of dry eye symptoms following implantation of TMF IOL
406195|NCT01061255|Stress
406196|NCT01061255|Cortisol
406197|NCT01061255|Clinical reasoning
406198|NCT01061255|Ambulatory setting
406199|NCT01061255|Medical students
406200|NCT01061255|Year 6 medical students
406201|NCT01061242|Neurocognitive function
406202|NCT01061242|Sleep quality
406203|NCT01061242|Critical care
406204|NCT01061242|Quality Assurance, health care
406205|NCT01061216|Diabetes
406206|NCT01061216|Insulin Therapy
406207|NCT01061216|Blood Glucose
406208|NCT01061216|Basal insulin
406209|NCT01061216|Diabetics
406210|NCT01061203|Rhinitis
406211|NCT01061203|allergic
406212|NCT01061203|Seasonal
406213|NCT01061203|grass
406214|NCT01061203|Asthma
406215|NCT01061190|Stroke
406216|NCT01061177|Leukemia
406217|NCT01061177|myeloid
406218|NCT01061177|myelogenous
406219|NCT01061177|chronic BCR-ABL positive
406220|NCT01061177|Nilotinib
406221|NCT01061138|breast cancer
406222|NCT01061138|screening mammograms
406223|NCT01061138|breast biopsy
406224|NCT01061125|atrial fibrillation
406225|NCT01061125|implantable loop recorder
406226|NCT01061125|TTM
406227|NCT01061112|drug interactions
406228|NCT01061112|genetics
406229|NCT01061112|healthy volunteers
406230|NCT01061112|normal controls
406231|NCT01061112|CYP2C9
406232|NCT01061099|Type II or Type III Osteogenesis imperfecta
406233|NCT01061099|OI
406234|NCT01061099|Mesenchymal Stromal Cells
406235|NCT01061099|MSC
406236|NCT01061086|Acute Coronary Syndromes
406237|NCT01061086|Epidemiology
406238|NCT01061086|Management of disease
406239|NCT01061086|Outcomes
406240|NCT01061086|Greece
406241|NCT01061060|Prostaglandin I2
406242|NCT01061060|Beraprost Na
406243|NCT01061060|Endothelial cell function
406244|NCT01061047|patients infected with a bacteria sensible to ertapeneme
406245|NCT01061034|pharmacokinetics
406246|NCT01061034|aspirin
406247|NCT01061034|proton pump inhiditor
406248|NCT01061021|HIV prevention
406249|NCT01061021|Treatment adherence
406250|NCT01061021|Treatment for Prevention
406251|NCT01061008|Exercise; arteriovenous fistula; chronic kidney disease
406252|NCT01060995|Informed Consent
406253|NCT01060995|Oral Health
406254|NCT01060995|Patient Decision-making
406255|NCT01060982|Primary hyperparathyroidism
406256|NCT01060982|High Intensity Focused Ultrasound
406257|NCT01060982|Parathyroid tumor
406258|NCT01060982|Parathyroid hormone
406259|NCT01060982|Calcium
406260|NCT01060969|Acute Mountain Sickness
406261|NCT01060969|travellers
406262|NCT01060969|Acetazolamide
406263|NCT01060969|Tadalafil
406264|NCT01060969|Acute Mountain Sickness assessed by Lake Louise score
406265|NCT01060969|High altitude pulmonary edema
406266|NCT01060969|High altitude cerebral edema
406267|NCT01060956|Urinary tract infection with two bacteria in culture
406268|NCT01060943|injectable collagen filler
406269|NCT01060943|correction of wrinkles and folds
406270|NCT01060943|enrolled : 73
406271|NCT01060943|withdrawal : 4
406272|NCT01060943|ongoing : 0
406273|NCT01060943|completed : 69
406274|NCT01060930|Nitric oxide
406275|NCT01060930|Diesel exhaust
406276|NCT01060930|Air pollution
406277|NCT01060930|Cardiac output
406278|NCT01060930|Healthy volunteers
406279|NCT01060917|diabetes
406280|NCT01060904|Antibodies, Monoclonal
406281|NCT01060904|Antibody-Drug Conjugate
406282|NCT01060904|Antigens, CD30
406283|NCT01060904|Disease, Hodgkin
406284|NCT01060904|Hematologic Diseases
406285|NCT01060904|Immunotherapy
406286|NCT01060904|Lymphoma
406287|NCT01060904|monomethyl auristatin E
406288|NCT01060891|patients infected with with multiresistant gram-negative bacteria
406289|NCT01060878|Early-stage
406290|NCT01060865|hypertension
406291|NCT01060865|aliskiren
406292|NCT01060865|Blood Pressure Monitoring, Ambulatory
406293|NCT01060839|counseling
406294|NCT01060826|acute pancreatits
406295|NCT01060813|cirrhosis
406296|NCT01060813|exercise
406297|NCT01060813|leucin
406298|NCT01060813|glutamine synthetase
406299|NCT01060800|Chiari
406300|NCT01060800|Chiari Type I
406301|NCT01060800|Chiari Type I Malformation
406302|NCT01060800|Familial Chiari
406303|NCT01060774|Bupivacaine
406304|NCT01060774|Lidocaine
406305|NCT01060774|Inflammation
406306|NCT01060774|Pain
406307|NCT01060774|Local Anesthetic
406308|NCT01060761|cancer
406309|NCT01060761|Rehabilitation program (patient and a relative together)
406310|NCT01060761|counselling
406311|NCT01060761|retreat weekend
406312|NCT01060748|Vaccination
406313|NCT01060748|Challenge
406314|NCT01060748|Diarrhea
406315|NCT01060748|ETEC illness
406316|NCT01060748|Travelers diarrhea
406317|NCT01060748|ETEC
406318|NCT01060748|Enterotoxigenic E.coli
406319|NCT01060735|Vitamin D
406320|NCT01060735|pregnancy
406321|NCT01060735|children
406322|NCT01060735|bone
406323|NCT01060735|quantitative ultrasound
406324|NCT01060735|Healthy pregnant women
406325|NCT01060722|Healthy Male Volunteers
406326|NCT01060709|Carbon dioxide
406327|NCT01060709|TcC02
406328|NCT01060709|Hypoventilation
406329|NCT01060709|endoscopic
406330|NCT01060709|elective colonoscopy and requiring sedation
406331|NCT01060696|Infertility
406332|NCT01060696|Saline infusion sonohysterography
406333|NCT01060696|Pain
406334|NCT01060696|Hyoscine
406335|NCT01060696|Mefenamic acid
406336|NCT01060696|women
406337|NCT01060683|hemoglobin
406338|NCT01060683|Coagulation variables
406339|NCT01060683|blood chemistry
406340|NCT01060683|Blood gas analysis
406341|NCT01060670|Foot Ulcer
406342|NCT01060670|Diabetic
406343|NCT01060670|Wound Healing
406344|NCT01060670|Integra Dermal Regeneration Template
406345|NCT01060670|Full Thickness
406346|NCT01060670|Neuropathic
406347|NCT01060670|Omnigraft
406348|NCT01060657|X-ray Computed Tomography
406349|NCT01060657|Coronary vessels
406350|NCT01060657|Radiation dosage
406351|NCT01060644|Maxillary Sinus
406352|NCT01060644|Bone Augmentation
406353|NCT01060644|Dental Implant
406354|NCT01060644|Sinus Membrane
406355|NCT01060631|bispectral index
406356|NCT01060631|lesions
406357|NCT01060631|consciousness
406358|NCT01060605|islet transplantation
406359|NCT01060605|insulin independence
406360|NCT01060605|C-peptide secretion
406361|NCT01060592|Gastric Band
406362|NCT01060592|LapBand
406363|NCT01060592|Bariatric Surgery
406364|NCT01060579|Glaucoma
406365|NCT01060553|Post-traumatic stress disorders
406366|NCT01060553|Acupuncture
406367|NCT01060553|Quality of life
406368|NCT01060553|sleep disorder
406369|NCT01060540|genetic screening
406370|NCT01060527|irritable bowel syndrome,protease activity,China
406371|NCT01060514|Lung cancer
406372|NCT01060514|Breast cancer
406373|NCT01060501|rectal cancer
406374|NCT01060501|adjuvant chemoradiotherapy
406375|NCT01060501|5-FU, interferon-alpha
406376|NCT01060501|Locally advanced resectable rectal cancer (UICC stage II and III)
406377|NCT01060488|GH secretion tests
406378|NCT01060488|adverse effects
406379|NCT01060488|adult growth hormone deficiency
406380|NCT01060488|growth-hormone releasing hormone and arginine test
406381|NCT01060488|insulin tolerance test
406382|NCT01060488|GHRH + Arginine test
406383|NCT01060475|Transplant
406384|NCT01060462|Defervescence rate
406385|NCT01060462|Defervescence timing
406386|NCT01060462|Itraconazole
406387|NCT01060449|cardiac resynchronization therapy
406388|NCT01060449|congestive heart failure
406389|NCT01060436|sleep apnea
406390|NCT01060436|sleep disordered breathing
406391|NCT01060436|CPAP
406392|NCT01060436|BiPAP
406393|NCT01060436|treatment outcomes
406394|NCT01060423|colorectal
406395|NCT01060423|liver metastasis
406396|NCT01060423|KRAS wildtype
406397|NCT01060423|chemoembolization
406398|NCT01060423|irinotecan eluting beads
406399|NCT01060410|Myelosuppression
406400|NCT01060410|Infection
406401|NCT01060410|Nausea
406402|NCT01060397|Alcohol
406403|NCT01060397|nurse
406404|NCT01060397|alcohol dependence
406405|NCT01060397|acute hospital
406406|NCT01060397|brief interventions
406407|NCT01060371|Spinocerebellar Ataxia
406408|NCT01060371|Natural History
406409|NCT01060371|Genetic Modifiers
406410|NCT01060371|DNA testing
406411|NCT01060358|lumbar spine
406412|NCT01060358|low back pain
406413|NCT01060345|DCIS
406414|NCT01060293|Heart Failure
406415|NCT01060293|Dopamine
406416|NCT01060293|Furosemide
406417|NCT01060293|Worsening Renal Function
406418|NCT01060293|Hypokalemia
406419|NCT01060293|Outcomes
406420|NCT01060293|Prognosis
406421|NCT01060280|low back pain
406422|NCT01060280|physiotherapy
406423|NCT01060280|exercise
406424|NCT01060280|active management
406425|NCT01060254|Interstitial cystitis (IC) and/or painful bladder syndrome (PBS)-related pain
406426|NCT01060254|Moderate to severe chronic bladder pain
406427|NCT01060254|JNJ-42160443
406428|NCT01060241|Remote Blood Glucose Monitoring System, Type 2 Diabetes
406429|NCT01060228|Paliperidone ER
406430|NCT01060228|INVEGA
406431|NCT01060228|Divalproex sodium
406432|NCT01060228|Depakote ER
406433|NCT01060228|Pharmacokinetics
406434|NCT01060228|Valproic Acid
406435|NCT01060228|Human Experimentation
406436|NCT01060215|effusion
406437|NCT01060215|osteoarthritis
406438|NCT01060215|knee
406439|NCT01060202|Multiple Myeloma
406440|NCT01060202|Bortezomib
406441|NCT01060202|Velcade
406442|NCT01060202|QoL
406443|NCT01060202|Proteasome inhibitor
406444|NCT01060202|EORTC QLQ C30
406445|NCT01060202|EQ 5D
406446|NCT01060189|ulinastatin
406447|NCT01060189|tranexamic acid
406448|NCT01060189|cardiac surgery procedures
406449|NCT01060189|hemostasis
406450|NCT01060189|anti-inflammation
406451|NCT01060176|tranexamic acid
406452|NCT01060176|cardiac surgery procedures
406453|NCT01060176|hemostasis
406454|NCT01060176|anti-inflammation
406455|NCT01060163|Clopidogrel
406456|NCT01060163|Tranexamic Acid
406457|NCT01060163|Cardiac Surgical Procedures
406458|NCT01060163|Hemostasis
406459|NCT01060150|Attention Deficit Hyperactivity Disorder
406460|NCT01060150|Methylphenidate hydrochloride
406461|NCT01060150|Methylphenidate
406462|NCT01060150|CONCERTA
406463|NCT01060137|fentanyl matrix
406464|NCT01060124|Pain; Cancer
406465|NCT01060124|TTS-Fentanyl D-trans
406466|NCT01060124|Durogesic D-trans
406467|NCT01060111|Migraine
406468|NCT01060111|Topiramate
406469|NCT01060111|Propranolol
406470|NCT01060085|Breast Cancer
406471|NCT01060059|diabetes; exenatide; Byetta; basal insulin; Amylin; Lilly
406472|NCT01060046|biologic mesh
406473|NCT01060046|ventral hernia repair
406474|NCT01060046|breast reconstruction
406475|NCT01060046|MMPs
406476|NCT01060033|Squamous cell cervical cancer
406477|NCT01060020|Aortic valve stenosis
406478|NCT01060020|Sildenafil
406479|NCT01060020|Phosphodiesterase inhibitors
406480|NCT01060020|Hypertension, Pulmonary
406481|NCT01059994|fatigue
406482|NCT01059994|aging
406483|NCT01059968|bone density
406484|NCT01059968|energy availability
406485|NCT01059968|menstrual status
406486|NCT01059968|female
406487|NCT01059968|adolescent
406488|NCT01059955|scleritis
406489|NCT01059955|anterior scleritis
406490|NCT01059955|nodular anterior scleritis
406491|NCT01059955|diffuse anterior scleritis
406492|NCT01059942|communication barriers
406493|NCT01059942|clinical competence
406494|NCT01059942|medical education
406495|NCT01059942|internship and residency
406496|NCT01059942|hospitalist
406497|NCT01059942|Quality Assurance, Healthcare
406498|NCT01059942|Patient Care
406499|NCT01059942|Internal Medicine
406500|NCT01059929|Hypnotics and Sedatives
406501|NCT01059929|Respiration, Artificial
406502|NCT01059929|Ventilators, Mechanical
406503|NCT01059929|Critical care
406504|NCT01059929|Intensive care
406505|NCT01059929|Physical therapy
406506|NCT01059929|Occupational therapy
406507|NCT01059929|Sedative medications
406508|NCT01059903|Rotigotine
406509|NCT01059903|Neupro®
406510|NCT01059903|Transdermal Patch
406511|NCT01059877|dementia alzheimers frontotemporal lyme,
406512|NCT01059877|lewy body cognitive impairment
406513|NCT01059864|cholesterol
406514|NCT01059864|lipids
406515|NCT01059864|rheumatoid arthritis
406516|NCT01059864|CP-690
406517|NCT01059864|550
406518|NCT01059838|pediatrics
406519|NCT01059838|cochlear implant
406520|NCT01059825|Phase 2
406521|NCT01059825|safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)
406522|NCT01059825|Type 2 diabetes mellitus
406523|NCT01059786|Monoclonal Antibody
406524|NCT01059786|Purine Analog
406525|NCT01059786|Soluble CD25
406526|NCT01059786|Minimal Residual Disease MRD
406527|NCT01059786|CD20
406528|NCT01059786|Hairy Cell Leukemia
406529|NCT01059773|Psoriasis
406530|NCT01059773|Ustekinumab
406531|NCT01059773|Stelara
406532|NCT01059773|Methotrexate
406533|NCT01059773|Biologic
406534|NCT01059760|Fasting
406535|NCT01059760|Short-term starvation
406536|NCT01059760|Diet
406537|NCT01059760|Coronary artery disease
406538|NCT01059734|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
406539|NCT01059734|adult acute myeloid leukemia with del(5q)
406540|NCT01059734|adult acute myeloid leukemia with inv(16)(p13;q22)
406541|NCT01059734|adult acute myeloid leukemia with t(16;16)(p13;q22)
406542|NCT01059734|adult acute myeloid leukemia with t(8;21)(q22;q22)
406543|NCT01059734|recurrent adult acute myeloid leukemia
406544|NCT01059734|untreated adult acute myeloid leukemia
406545|NCT01059734|adult erythroleukemia (M6a)
406546|NCT01059734|adult pure erythroid leukemia (M6b)
406547|NCT01059734|adult acute monoblastic leukemia (M5a)
406548|NCT01059734|adult acute monocytic leukemia (M5b)
406549|NCT01059734|adult acute myeloblastic leukemia with maturation (M2)
406550|NCT01059734|adult acute myeloblastic leukemia without maturation (M1)
406551|NCT01059734|adult acute myelomonocytic leukemia (M4)
406552|NCT01059734|secondary acute myeloid leukemia
406553|NCT01059734|adult acute minimally differentiated myeloid leukemia (M0)
406554|NCT01059734|adult acute megakaryoblastic leukemia (M7)
406555|NCT01059721|Centralisation
406556|NCT01059721|Patella dislocation
406557|NCT01059721|Open epiphyses
406558|NCT01059721|Malalignment syndrome
406559|NCT01059721|Relapse rate
406560|NCT01059708|outcomes carbon monoxide poisoning children pediatric
406561|NCT01059695|cervical cancer
406562|NCT01059695|retrospective
406563|NCT01059695|quality of life
406564|NCT01059695|treatment
406565|NCT01059669|Chronic pancreatitis
406566|NCT01059669|Pain
406567|NCT01059669|Exocrine insufficiency
406568|NCT01059669|Diabetes
406569|NCT01059669|Nutrition
406570|NCT01059669|Ultrasound
406571|NCT01059656|Dermatofibrosarcoma
406572|NCT01059656|Pazopanib¨
406573|NCT01059656|Phase II
406574|NCT01059630|follicular
406575|NCT01059630|follicular lymphoma
406576|NCT01059617|Pandemic
406577|NCT01059617|GSK Bio's influenza vaccine GSK2340274A
406578|NCT01059617|H1N1
406579|NCT01059617|Influenza
406580|NCT01059604|pregnancy outcomes
406581|NCT01059604|pregnancy
406582|NCT01059604|first trimester
406583|NCT01059604|Sumatriptan
406584|NCT01059604|major congenital malformations
406585|NCT01059604|naratriptan
406586|NCT01059604|sumatriptan-naproxen combination
406587|NCT01059604|pregnancy registry
406588|NCT01059591|First time in Human
406589|NCT01059591|Safety
406590|NCT01059591|Healthy subjects
406591|NCT01059591|NK1 antagonist and SSRI
406592|NCT01059578|Nk1 Antagonist and SSRI
406593|NCT01059578|Safety
406594|NCT01059578|First Time in Humans
406595|NCT01059578|Healthy Subjects
406596|NCT01059565|Cystic Fibrosis
406597|NCT01059565|Aztreonam Lysine
406598|NCT01059565|lung infection
406599|NCT01059565|Burkholderia
406600|NCT01059565|CFQ-R
406601|NCT01059565|inhaled antibiotic
406602|NCT01059552|lung cancer
406603|NCT01059552|locally advanced lung cancer
406604|NCT01059539|mania
406605|NCT01059539|acute mania
406606|NCT01059539|bipolar I disorder
406607|NCT01059526|HAE
406608|NCT01059513|T1c
406609|NCT01059513|T2a
406610|NCT01059513|T2b
406611|NCT01059500|Computer-derived, quantitative pretest probability (PTP)
406612|NCT01059500|Overtesting
406613|NCT01059500|Radiation
406614|NCT01059500|Intravenous Contrast
406615|NCT01059500|Anticoagulation
406616|NCT01059487|Traditional Chinese Medicine
406617|NCT01059487|Acupuncture
406618|NCT01059474|DMPS
406619|NCT01059474|mercury
406620|NCT01059461|Hypoxic Ischemic Encephalopathy (HIE)
406621|NCT01059461|Perinatal Asphyxia
406622|NCT01059461|Nerve growth factor
406623|NCT01059461|Cerebrolysin
406624|NCT01059461|Cerebral palsy
406625|NCT01059448|Amgen
406626|NCT01059448|RA
406627|NCT01059448|AMG 827
406628|NCT01059448|20090061
406629|NCT01059435|Amgen
406630|NCT01059435|First in Human
406631|NCT01059435|Postmenopausal
406632|NCT01059435|Phase 1
406633|NCT01059409|Meniscal Allografts
406634|NCT01059409|Osteoarthritis
406635|NCT01059383|Gastroesophageal Reflux
406636|NCT01059383|GERD
406637|NCT01059383|Nocturnal GERD
406638|NCT01059383|Heartburn
406639|NCT01059383|Nighttime Heartburn
406640|NCT01059370|Autonomic dysfunction
406641|NCT01059370|Spinal cord injured
406642|NCT01059370|Neurogenic bowel
406643|NCT01059370|Neurogenic bladder
406644|NCT01059344|Mesalamine
406645|NCT01059344|Asacol
406646|NCT01059344|Ulcerative colitis
406647|NCT01059344|induction therapy
406648|NCT01059344|acute disease
406649|NCT01059344|mild to moderate
406650|NCT01059344|Active Ulcerative Colitis (mild to moderate)
406651|NCT01059331|Kidney
406652|NCT01059318|Lymphangioleiomyomatosis,
406653|NCT01059318|High Resolution CT scan,
406654|NCT01059318|chest x-ray,
406655|NCT01059318|6 minute walk test,
406656|NCT01059318|pulse oximetry,
406657|NCT01059318|renal MRI,
406658|NCT01059318|Pikometer
406659|NCT01059305|Erlotinib
406660|NCT01059305|Erlotinib Hydrochloride
406661|NCT01059305|OSI-774
406662|NCT01059305|Tarceva
406663|NCT01059305|Squamous cell carcinoma of the skin
406664|NCT01059305|Aggressive cutaneous squamous cell carcinoma
406665|NCT01059305|CSCC
406666|NCT01059305|Local surgery
406667|NCT01059305|Radiation therapy
406668|NCT01059305|Epidermal growth factor receptor
406669|NCT01059305|EGFR
406670|NCT01059305|Small Molecule Tyrosine Kinase Inhibitor
406671|NCT01059292|we have complieted party research
406672|NCT01059279|Familial Mediterranean fever
406673|NCT01059279|Cytokines
406674|NCT01059279|Inflammatory proteins
406675|NCT01059279|MEFV
406676|NCT01059279|mutations
406677|NCT01059279|Heat Intolerance
406678|NCT01059279|Heat Tolerance Test
406679|NCT01059266|immunotherapy
406680|NCT01059266|grass pollen
406681|NCT01059266|seasonal allergy
406682|NCT01059266|dose tolerability
406683|NCT01059253|Falls
406684|NCT01059253|Balance
406685|NCT01059253|Elderly
406686|NCT01059253|Aged
406687|NCT01059240|Survival Motor Neuron 1 (SMN1)
406688|NCT01059240|Survival Motor Neuron 2 (SMN2)
406689|NCT01059240|Spinal Muscular Atrophy (SMA)
406690|NCT01059240|SMN Copy Number in Mali
406691|NCT01059240|Spinal Muscular Antrophy
406692|NCT01059240|SMA
406693|NCT01059227|Treatment
406694|NCT01059227|Anxiety
406695|NCT01059227|Fear
406696|NCT01059227|Fear Potentiated Startle
406697|NCT01059227|Healthy Volunteer
406698|NCT01059227|HV
406699|NCT01059214|Acute Myocardial Infarction
406700|NCT01059214|Reperfusion
406701|NCT01059214|MRI
406702|NCT01059214|Heart Attack
406703|NCT01059201|Autism Spectrum Disorder
406704|NCT01059201|Cholesterol
406705|NCT01059201|Exome Sequencing
406706|NCT01059201|Autistic Spectrum Disorder
406707|NCT01059201|ASD
406708|NCT01059188|stage IIIB non-small cell lung cancer
406709|NCT01059188|adenocarcinoma of the lung
406710|NCT01059188|adenosquamous cell lung cancer
406711|NCT01059188|large cell lung cancer
406712|NCT01059188|squamous cell lung cancer
406713|NCT01059175|Heart failure
406714|NCT01059175|Cardiac resynchronization therapy
406715|NCT01059175|Biventricular stimulation
406716|NCT01059175|Multisite stimulation
406717|NCT01059175|Non responders
406718|NCT01059162|Glaucoma Surgery
406719|NCT01059162|Filtering Surgery
406720|NCT01059162|Non Penetrating glaucoma surgery
406721|NCT01059149|Rehabilitation
406722|NCT01059149|Transcranial magnetic stimulation
406723|NCT01059149|Brain magnetic stimulation
406724|NCT01059149|Repetitive
406725|NCT01059149|Stroke
406726|NCT01059149|Subacute
406727|NCT01059136|Myocardial infarction
406728|NCT01059136|Outcome
406729|NCT01059136|Aldosterone
406730|NCT01059136|Spironolactone
406731|NCT01059123|Amoxicillin
406732|NCT01059123|Erysipelas
406733|NCT01059123|Short course
406734|NCT01059110|Occlusive dressings
406735|NCT01059110|Salicylate ointment
406736|NCT01059110|Cryotherapy
406737|NCT01059110|Topical 5-fluoro-uracil
406738|NCT01059110|Imiquimod
406739|NCT01059110|Randomized clinical trial
406740|NCT01059110|Plantar warts
406741|NCT01059084|HIV
406742|NCT01059084|Valacyclovir
406743|NCT01059084|Valtrex®
406744|NCT01059071|Refractory Neuroblastoma
406745|NCT01059071|Relapsed neuroblastoma
406746|NCT01059058|MI Paste Plus
406747|NCT01059058|Fluoride Varnish
406748|NCT01059058|CPP-ACP
406749|NCT01059058|White Spot Lesions
406750|NCT01059058|Remineralization
406751|NCT01059058|Orthodontic Treatment
406752|NCT01059019|Refractive Surgery
406753|NCT01059019|PRK
406754|NCT01059019|Photorefractive Keratectomy
406755|NCT01059019|Omega 3 Fatty Acids
406756|NCT01059019|Cornea
406757|NCT01059006|Reflective Surgery
406758|NCT01059006|Presbyopia
406759|NCT01059006|PresbyLASIK
406760|NCT01058993|neutropenia
406761|NCT01058993|myelokathexis
406762|NCT01058993|WHIM syndrome
406763|NCT01058993|AMD 3100
406764|NCT01058993|plerixafor
406765|NCT01058993|Myelokathexis syndrome
406766|NCT01058993|Neutropenia due to mutations of CXCR-4
406767|NCT01058980|catheter ablation
406768|NCT01058980|atrial fibrillation
406769|NCT01058980|adenosine
406770|NCT01058967|Code III trauma (highest acuity)
406771|NCT01058967|Life Flight aeromedical ambulance service
406772|NCT01058941|Alzheimer's disease
406773|NCT01058941|fish oil
406774|NCT01058941|lipoic acid
406775|NCT01058928|Tracheal tube
406776|NCT01058928|Size
406777|NCT01058915|ST-Segment Elevation Myocardial Infarction
406778|NCT01058902|Non small cell lung cancer
406779|NCT01058902|survival
406780|NCT01058902|aspirin
406781|NCT01058889|Diabetes mellitus Type 2
406782|NCT01058889|Telemedicine
406783|NCT01058889|Insulin
406784|NCT01058876|Smoking
406785|NCT01058876|nicotine
406786|NCT01058837|Sudden Cardiac Death
406787|NCT01058837|Implantable Cardioverter Defibrillator
406788|NCT01058837|Ventricular Fibrillation
406789|NCT01058824|Bioequivalence
406790|NCT01058824|Lincomycin Hydrocloride
406791|NCT01058811|lung cancer
406792|NCT01058798|Neuroblastoma
406793|NCT01058798|B4GALNT3
406794|NCT01058798|Prognosis
406795|NCT01058785|Gene therapy
406796|NCT01058785|Flow cytometry
406797|NCT01058785|Immunoenzyme technique
406798|NCT01058785|Laboratory biomarker analysis
406799|NCT01058785|Tumor cell-derivative vaccine therapy
406800|NCT01058772|Induced Labour
406801|NCT01058772|Expectant Management
406802|NCT01058772|C-section rate
406803|NCT01058772|Maternal Outcomes
406804|NCT01058772|Neonatal Outcomes
406805|NCT01058759|non-small cell lung cancer
406806|NCT01058759|NSCLC
406807|NCT01058759|Enoxaparin
406808|NCT01058759|Locally Advanced or Metastatic Non-small Cell Lung Cancer stadium IIIb/IV
406809|NCT01058746|pancreas
406810|NCT01058746|surgery
406811|NCT01058746|Pancreaticoduodenectomy
406812|NCT01058746|Central Pancreatectomy
406813|NCT01058746|Distal Pancreatectomy
406814|NCT01058746|resection
406815|NCT01058746|IV fluids
406816|NCT01058746|09-185
406817|NCT01058733|semi-automatic response system (SARS)
406818|NCT01058733|Diabetes Mellitus
406819|NCT01058733|Internet
406820|NCT01058733|ubiquitous health care system
406821|NCT01058720|Vitamin D
406822|NCT01058720|Supplementation
406823|NCT01058720|Adolescence
406824|NCT01058707|Solid tumors, MLN0128, TORC1/2 inhibitors
406825|NCT01058694|Mobile phones,
406826|NCT01058694|Medication Adherence
406827|NCT01058694|Micro-Electrical-Mechanical Systems
406828|NCT01058694|HIV Infections
406829|NCT01058681|LH pulsatility
406830|NCT01058681|GnRH regulation
406831|NCT01058681|isocaloric nutrition
406832|NCT01058681|hypercaloric nutrition
406833|NCT01058681|euglycemic clamps
406834|NCT01058681|hyperinsulinemic clamps
406835|NCT01058681|testosterone
406836|NCT01058681|LH
406837|NCT01058681|leptine
406838|NCT01058681|ghrelin
406839|NCT01058681|PYY
406840|NCT01058681|CCK
406841|NCT01058681|GLP-1
406842|NCT01058681|GIP
406843|NCT01058681|cortisol
406844|NCT01058668|Acute Mania
406845|NCT01058668|Bipolar I Disorder
406846|NCT01058655|Colorectal Cancer
406847|NCT01058642|pain
406848|NCT01058642|delta opioid receptor agonist
406849|NCT01058629|Hybrid
406850|NCT01058629|contact lens
406851|NCT01058629|myopia
406852|NCT01058629|hyperopia
406853|NCT01058629|near sighted
406854|NCT01058629|astigmatism
406855|NCT01058629|far sighted
406856|NCT01058603|Infertility
406857|NCT01058603|Cell Culture
406858|NCT01058603|AECC
406859|NCT01058603|Endocell
406860|NCT01058603|IVF
406861|NCT01058590|Inflammation
406862|NCT01058590|Adenotonsillectomy
406863|NCT01058577|diabetes
406864|NCT01058564|GERD
406865|NCT01058551|Sleep Apnea
406866|NCT01058551|Atrial Fibrillation
406867|NCT01058538|Interleukin, IL2, monoclonal, antibody, cytokine, tumour targeting, solid tumours, dose finding, renal cell carcinoma, fusion protein, RCC,
406868|NCT01058538|L19
406869|NCT01058512|hepatitis C
406870|NCT01058512|chronic HCV
406871|NCT01058512|viral HCV
406872|NCT01058512|genotype 1
406873|NCT01058512|failed treatment with pegylated interferon plus ribavirin
406874|NCT01058499|Chronic Obstructive Pulmonary Disease
406875|NCT01058499|COPD
406876|NCT01058486|Chronic Disease Management
406877|NCT01058486|Physical Activity
406878|NCT01058486|Self-efficacy
406879|NCT01058486|Self management
406880|NCT01058473|Sickle Cell Disease
406881|NCT01058473|Pain
406882|NCT01058473|Assessment
406883|NCT01058460|Cervical Intraepithelial Neoplasia, Grade III
406884|NCT01058460|Cervical Intraepithelial Neoplasia, Grade II
406885|NCT01058447|ADME
406886|NCT01058447|Healthy volunteers
406887|NCT01058434|Multiple myeloma
406888|NCT01058434|relapsed
406889|NCT01058434|refractory
406890|NCT01058434|t(4;14)
406891|NCT01058434|FGFR3
406892|NCT01058421|mechanical ventilation
406893|NCT01058421|acute respiratory failure
406894|NCT01058421|physical therapy
406895|NCT01058421|critical illness neuropathy
406896|NCT01058421|critical illness myopathy
406897|NCT01058408|advanced head and neck cancer
406898|NCT01058408|cisplatin
406899|NCT01058408|RAD001
406900|NCT01058408|radiation
406901|NCT01058408|HNSCC
406902|NCT01058395|Traumatic Brain Injury
406903|NCT01058395|Minocycline
406904|NCT01058395|Outcome
406905|NCT01058382|FET
406906|NCT01058382|Progesterone Support
406907|NCT01058382|Frozen Embryo Transfer
406908|NCT01058356|antibiotics associated colitis
406909|NCT01058356|lactobacilli
406910|NCT01058356|probiotics
406911|NCT01058356|prevention
406912|NCT01058356|pulmonary infection
406913|NCT01058356|Prevention of antibiotics associated colitis
406914|NCT01058356|the role of probiotics for prevention of antibiotics associated colitis
406915|NCT01058356|the lactobacilli effect for antibiotics associated colitis
406916|NCT01058356|antibiotic associated colitis on pulmonary infectious disease
406917|NCT01058343|SLE
406918|NCT01058330|Neurofibromatosis type 1
406919|NCT01058330|NF1
406920|NCT01058317|respiratory, papilloma, pediatric, juvenile
406921|NCT01058304|osteoarthritis
406922|NCT01058304|knee
406923|NCT01058304|physical therapy (specialty)
406924|NCT01058304|veterans
406925|NCT01058278|Glaucoma
406926|NCT01058278|Ocular Hypertension
406927|NCT01058278|Intraocular Pressure
406928|NCT01058278|Trabeculectomy
406929|NCT01058239|bortezomib
406930|NCT01058239|rituximab
406931|NCT01058239|PTLD
406932|NCT01058239|EBV
406933|NCT01058239|transplantation
406934|NCT01058226|Experimental malaria challenge
406935|NCT01058213|COPD
406936|NCT01058213|Pulmonary rehabilitation
406937|NCT01058213|Resistance Training
406938|NCT01058213|Aerobic Training
406939|NCT01058213|Dyspnea
406940|NCT01058174|Liver transplantation
406941|NCT01058174|Prophylaxis
406942|NCT01058174|Prevention
406943|NCT01058174|Mycoses
406944|NCT01058174|Invasive Fungal Infection
406945|NCT01058174|Micafungin
406946|NCT01058161|wrist and hand cartilage abnormalities in inflammatory and chronic rheumatisms
406947|NCT01058148|Cervical Cancer Screening
406948|NCT01058148|Cervical Precancer
406949|NCT01058148|Self-Collection
406950|NCT01058148|Cytology
406951|NCT01058148|Human Papilloma Virus (HPV)
406952|NCT01058135|insulin resistance
406953|NCT01058135|dietary fiber
406954|NCT01058135|resistant starch
406955|NCT01058122|Adverse drug reactions in patients on the oncology ward
406956|NCT01058109|bone health, bone density, bone mass
406957|NCT01058096|Acute Mania
406958|NCT01058096|Bipolar I Disorder
406959|NCT01058070|GERD
406960|NCT01058057|atorvastatin
406961|NCT01058057|percutaneous coronary intervention
406962|NCT01058057|periprocedural myocardial infarction
406963|NCT01058057|Hydroxymethylglutaryl-CoA Reductase Inhibitors
406964|NCT01058044|Cancer, Sunitinib, capecitabine, anastrozole, letrozole
406965|NCT01058044|adherence, anticancer treatment
406966|NCT01058018|Cholesterol
406967|NCT01058018|High density lipoprotein
406968|NCT01058018|Atherosclerosis
406969|NCT01058018|ApolipoproteinA1
406970|NCT01058018|Stable angina artery disease
406971|NCT01058005|MS
406972|NCT01057979|exercise
406973|NCT01057979|college students
406974|NCT01057979|Sedentary college students
406975|NCT01057966|Bioavailability
406976|NCT01057966|Ocular Vitamins
406977|NCT01057953|Colo-Rectal Cancer
406978|NCT01057914|Randomized controlled trial
406979|NCT01057914|Malnutrition
406980|NCT01057914|Aged
406981|NCT01057914|Aged 80 and over
406982|NCT01057914|Nutrition therapy
406983|NCT01057888|Immunization status for:
406984|NCT01057888|Tdap
406985|NCT01057888|Menactra
406986|NCT01057888|HPV (if female)
406987|NCT01057888|Well child care visit
406988|NCT01057862|Naltrexone
406989|NCT01057862|Pathological Gambling
406990|NCT01057862|Opioid Antagonist
406991|NCT01057849|schizophrenia
406992|NCT01057849|first episode
406993|NCT01057849|atypical antipsychotics
406994|NCT01057849|psychosocial intervention
406995|NCT01057849|outcome
406996|NCT01057849|effectiveness
406997|NCT01057823|aged
406998|NCT01057823|sleep deprivation
406999|NCT01057823|actigraphy
407000|NCT01057823|ambulatory monitoring
407001|NCT01057797|COPD
407002|NCT01057797|Pulmonary rehabilitation
407003|NCT01057797|Self-efficacy
407004|NCT01057797|Muscle strength
407005|NCT01057797|Dyspnea
407006|NCT01057797|Exercise adherence
407007|NCT01057784|obesity
407008|NCT01057784|bariatric
407009|NCT01057784|surgery
407010|NCT01057784|sleeve
407011|NCT01057784|gastric bypass
407012|NCT01057784|vitamin D
407013|NCT01057784|quality of life
407014|NCT01057784|body composition
407015|NCT01057784|bone density
407016|NCT01057784|adolescent
407017|NCT01057784|child
407018|NCT01057784|teenager
407019|NCT01057784|fertility
407020|NCT01057784|offspring
407021|NCT01057784|biomarker
407022|NCT01057784|epigenome
407023|NCT01057784|gene expression
407024|NCT01057771|meditation
407025|NCT01057771|exercise
407026|NCT01057771|immunity
407027|NCT01057771|respiratory infection
407028|NCT01057771|influenza
407029|NCT01057771|flu shot
407030|NCT01057771|immunomodulation
407031|NCT01057758|Suspicion of ventilator-associated pneumonia
407032|NCT01057745|woman
407033|NCT01057745|chemotherapy
407034|NCT01057745|radiation
407035|NCT01057745|fertility preservation
407036|NCT01057745|cryobank
407037|NCT01057719|cross-over design
407038|NCT01057719|mixed model
407039|NCT01057719|multiple sclerosis
407040|NCT01057719|physical performance measures
407041|NCT01057719|physical therapy
407042|NCT01057719|the Bobath concept
407043|NCT01057719|warm climate
407044|NCT01057719|6-minute walk test
407045|NCT01057706|chiropractic
407046|NCT01057706|exercise
407047|NCT01057706|seniors
407048|NCT01057693|Diabetic peripheral neuropathy
407049|NCT01057693|Lyrica
407050|NCT01057693|pregabalin
407051|NCT01057693|pain
407052|NCT01057680|Bone
407053|NCT01057680|Muscle
407054|NCT01057680|Strength
407055|NCT01057680|Kidney
407056|NCT01057680|Liver
407057|NCT01057680|Creatine
407058|NCT01057654|Cholesterol
407059|NCT01057641|PIDLSS, Spacer
407060|NCT01057628|ASP1941
407061|NCT01057628|Diabetes mellitus
407062|NCT01057628|Blood glucose
407063|NCT01057615|Asthma
407064|NCT01057615|Exercise-Induced Bronchoconstriction
407065|NCT01057615|Inflammation
407066|NCT01057615|Airway
407067|NCT01057615|Fish Oil
407068|NCT01057615|Ascorbic Acid
407069|NCT01057602|Dementia
407070|NCT01057602|Screening Tests
407071|NCT01057602|Cognition
407072|NCT01057602|Memory
407073|NCT01057602|MOST
407074|NCT01057589|Pharynx
407075|NCT01057589|Larynx
407076|NCT01057589|Cervical esophagus
407077|NCT01057589|Nose
407078|NCT01057589|Thyroid Gland
407079|NCT01057589|Parathyroid Gland
407080|NCT01057576|bioactives
407081|NCT01057576|insulin
407082|NCT01057576|botanicals
407083|NCT01057563|Coronary artery disease
407084|NCT01057563|Neointimal hyperplasia
407085|NCT01057563|Drug-eluting balloon
407086|NCT01057563|Optical coherence tomography
407087|NCT01057550|Stress urinary Incontinence
407088|NCT01057550|autologous slings
407089|NCT01057550|slings
407090|NCT01057550|tvt
407091|NCT01057550|grafts
407092|NCT01057550|surgery
407093|NCT01057537|Polypill
407094|NCT01057537|Red Heart Pill
407095|NCT01057537|Cardiovascular disease
407096|NCT01057537|Adherence
407097|NCT01057537|Secondary prevention
407098|NCT01057524|Airway clearance
407099|NCT01057524|Cystic fibrosis
407100|NCT01057524|High frequency chest wall oscillation
407101|NCT01057511|Crinone
407102|NCT01057511|progesterone
407103|NCT01057511|endometrial progesterone concentration
407104|NCT01057485|Atrial Fibrillation
407105|NCT01057485|Ablation
407106|NCT01057472|Repeatability of measurements
407107|NCT01057459|Stage II Grade 1 Contiguous Follicular Lymphoma
407108|NCT01057459|Stage II Grade 1 Non-Contiguous Follicular Lymphoma
407109|NCT01057459|Stage II Grade 2 Contiguous Follicular Lymphoma
407110|NCT01057459|Stage II Grade 2 Non-Contiguous Follicular Lymphoma
407111|NCT01057459|Stage II Grade 3 Contiguous Follicular Lymphoma
407112|NCT01057459|Stage II Grade 3 Non-Contiguous Follicular Lymphoma
407113|NCT01057459|stage III grade 1 follicular lymphoma
407114|NCT01057459|stage III grade 2 follicular lymphoma
407115|NCT01057459|stage III grade 3 follicular lymphoma
407116|NCT01057459|stage IV grade 1 follicular lymphoma
407117|NCT01057459|stage IV grade 2 follicular lymphoma
407118|NCT01057459|stage IV grade 3 follicular lymphoma
407119|NCT01057446|Colonoscopy preparation
407120|NCT01057446|sennoside
407121|NCT01057446|sodium phosphate
407122|NCT01057446|the aim is to assess the bowel cleansing effects of two different agents
407123|NCT01057433|Healthy Volunteers
407124|NCT01057407|Hyperphosphatemia
407125|NCT01057407|hemodialysis
407126|NCT01057407|CKD
407127|NCT01057407|ASP1585
407128|NCT01057394|Atrial Fibrillation
407129|NCT01057381|Adenotonsillectomy
407130|NCT01057381|Postoperative analgesia
407131|NCT01057381|Pediatrics
407132|NCT01057355|Intraductal papillary mucinous neoplasm
407133|NCT01057355|Mucinous cystic neoplasm
407134|NCT01057355|Endoscopic ultrasound
407135|NCT01057355|Endoscopic retrograde cholangiopancreatography
407136|NCT01057355|Pancreatic cyst
407137|NCT01057355|Pancreas cyst
407138|NCT01057355|Alcohol
407139|NCT01057342|extensive stage small cell lung cancer
407140|NCT01057329|TDM
407141|NCT01057329|Drug
407142|NCT01057329|Psychopharmacology
407143|NCT01057329|children
407144|NCT01057329|adolescents
407145|NCT01057303|childhood acute myeloid leukemia/other myeloid malignancies
407146|NCT01057290|childhood acute myeloid leukemia/other myeloid malignancies
407147|NCT01057277|Head and Neck Cancer
407148|NCT01057277|Advanced Inoperable Head & Neck Cancer
407149|NCT01057264|Liver
407150|NCT01057264|Cancer
407151|NCT01057264|Hepatic arterial infusion
407152|NCT01057264|HAI
407153|NCT01057264|Abraxane
407154|NCT01057264|Nab-Paclitaxel
407155|NCT01057264|Paclitaxel
407156|NCT01057264|ABI-007
407157|NCT01057264|Gemcitabine
407158|NCT01057264|Gemcitabine Hydrochloride
407159|NCT01057264|Gemzar
407160|NCT01057264|Bevacizumab
407161|NCT01057264|Avastin
407162|NCT01057264|Anti-VEGF monoclonal antibody
407163|NCT01057264|rhuMAb-VEGF
407164|NCT01057264|Filgrastim
407165|NCT01057264|G-CSF
407166|NCT01057264|Neupogen
407167|NCT01057251|Nebivolol
407168|NCT01057251|Bystolic TM
407169|NCT01057251|Hypertension
407170|NCT01057251|Stage 2 Hypertension
407171|NCT01057238|mechanical ventilation
407172|NCT01057238|critical care
407173|NCT01057212|advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
407174|NCT01057199|adult acute myeloid leukemia
407175|NCT01057199|childhood acute myeloid leukemia/other myeloid malignancies
407176|NCT01057173|Heart Valve Disease
407177|NCT01057173|Heart Valve Prosthesis
407178|NCT01057173|Heart Valve Prosthesis Implantation
407179|NCT01057173|Randomized Controlled Trial
407180|NCT01057121|HIV Infections
407181|NCT01057108|Hyperphosphatemia
407182|NCT01057108|chronic kidney disease
407183|NCT01057108|salivary phosphorus
407184|NCT01057095|adult acute myeloid leukemia with inv(16)(p13;q22)
407185|NCT01057095|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
407186|NCT01057095|adult acute myeloid leukemia with del(5q)
407187|NCT01057095|adult acute myeloid leukemia with t(16;16)(p13;q22)
407188|NCT01057095|adult acute myeloid leukemia in remission
407189|NCT01057095|recurrent adult acute myeloid leukemia
407190|NCT01057095|untreated adult acute myeloid leukemia
407191|NCT01057095|childhood acute myeloid leukemia in remission
407192|NCT01057095|recurrent childhood acute myeloid leukemia
407193|NCT01057095|untreated childhood acute myeloid leukemia and other myeloid malignancies
407194|NCT01057082|Sarcopenia
407195|NCT01057082|Aging
407196|NCT01057082|Muscle
407197|NCT01057082|Dietary Supplement
407198|NCT01057082|HMB
407199|NCT01057082|Arginine
407200|NCT01057082|Glutamine
407201|NCT01057069|Neo adjuvant
407202|NCT01057069|Triple negative
407203|NCT01057069|primary tumor over 2 cm and/or positive lymphnodes
407204|NCT01057056|patients in a sub-acute geriatric rehabilitation department
407205|NCT01057043|Osteoarthritis
407206|NCT01057017|colorectal cancer
407207|NCT01057004|heart failure
407208|NCT01056978|palliative care unit
407209|NCT01056978|bleeding
407210|NCT01056978|thromboembolic
407211|NCT01056978|hemorrhagic risk
407212|NCT01056978|antithrombotic prophylaxis
407213|NCT01056965|Frontotemporal Dementia
407214|NCT01056965|Corticobasal Degeneration
407215|NCT01056965|Progressive Nonfluent Aphasia
407216|NCT01056965|Progressive Supranuclear Palsy
407217|NCT01056965|FTLD
407218|NCT01056965|FTD
407219|NCT01056965|PNFA
407220|NCT01056965|CBD
407221|NCT01056965|PSP
407222|NCT01056965|Predicted tauopathies, including:
407223|NCT01056965|Progressive Supranuclear Palsy (PSP)
407224|NCT01056965|(CBS)
407225|NCT01056965|Progressive Nonfluent Aphasia (PNFA)
407226|NCT01056939|Ventilatory care, children, intensive care, NAVA
407227|NCT01056939|Children needing ventilatory care
407228|NCT01056926|smoking
407229|NCT01056926|nicotine
407230|NCT01056926|Effects of nicotine and non-nicotine factors on continuous working memory.
407231|NCT01056926|Effects of nicotine and non-nicotine factors on cue reactivity.
407232|NCT01056926|Use of nicotine patches, placebo patches, and denicotinized cigarettes.
407233|NCT01056926|memory
407234|NCT01056913|anastomotic leakage
407235|NCT01056913|bleeding from the anastomotic region
407236|NCT01056913|anastomotic stenosis
407237|NCT01056900|articular cartilage defects
407238|NCT01056900|ACI
407239|NCT01056900|Autologous Chondrocyte Implantation
407240|NCT01056900|Knee joint
407241|NCT01056900|chondron
407242|NCT01056887|diabetes insipidus
407243|NCT01056887|primary polydipsia
407244|NCT01056887|copeptin
407245|NCT01056887|Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test
407246|NCT01056874|Maraviroc
407247|NCT01056874|Digoxin
407248|NCT01056874|P-glycoprotein
407249|NCT01056874|Pharmacokinetics
407250|NCT01056874|Drug Interaction
407251|NCT01056874|HIV
407252|NCT01056861|cervical dystonia
407253|NCT01056861|torticollis
407254|NCT01056861|Botulinum toxin
407255|NCT01056861|magnetoencephalography
407256|NCT01056861|MEG
407257|NCT01056861|cortical organizational changes detected by MEG after botulinum toxin in patients with torticollis, correlating with improvement in the symptoms
407258|NCT01056848|Euvolemic Hyponatremia
407259|NCT01056848|Hypervolemic Hyponatremia
407260|NCT01056848|SIADH
407261|NCT01056848|Serum Sodium
407262|NCT01056809|Colorectal cancer
407263|NCT01056809|Metastases
407264|NCT01056809|Treatment strategies
407265|NCT01056809|Colorectal cancer with synchronous metastases
407266|NCT01056796|compression anastomosis
407267|NCT01056796|Colorectal cancer
407268|NCT01056796|Low anterior resection
407269|NCT01056796|Radiated to the pelvic area
407270|NCT01056796|Radiotherapy
407271|NCT01056783|EoE
407272|NCT01056770|Smallpox vaccine efficacy
407273|NCT01056757|metastatic breast cancer
407274|NCT01056757|ribavirin
407275|NCT01056757|eIF4E
407276|NCT01056744|coronary stent
407277|NCT01056744|optical coherence tomography
407278|NCT01056744|drug-eluting
407279|NCT01056744|neointimal proliferation
407280|NCT01056731|high blood pressure
407281|NCT01056731|aliskiren
407282|NCT01056731|hydrochlorothiazide
407283|NCT01056731|control rate
407284|NCT01056718|Diastolic Function
407285|NCT01056718|Nebivolol
407286|NCT01056705|Inactivated Poliomyelitis Vaccine
407287|NCT01056705|Sabin Strains
407288|NCT01056705|poliomyelitis
407289|NCT01056692|Asthma
407290|NCT01056692|bronchial allergen challenge
407291|NCT01056692|sputum eosinophiilia
407292|NCT01056653|father-child relations
407293|NCT01056653|paternal behaviour
407294|NCT01056653|early intervention
407295|NCT01056653|child-rearing
407296|NCT01056640|telemonitoring
407297|NCT01056640|usual care
407298|NCT01056640|elderly
407299|NCT01056640|hospitalization
407300|NCT01056640|Emergency room visits
407301|NCT01056601|insulinoma
407302|NCT01056601|cancer of pancreas
407303|NCT01056601|neoplasms, pancreas
407304|NCT01056601|alpha-cell tumor
407305|NCT01056601|glucagonoma
407306|NCT01056601|beta-cell tumor
407307|NCT01056601|somatostatinoma
407308|NCT01056588|adolescent smoking
407309|NCT01056588|Contingency management
407310|NCT01056588|Quit smoking
407311|NCT01056562|Prostate
407312|NCT01056562|GU
407313|NCT01056562|Urological Oncology
407314|NCT01056549|Intestinal lipoprotein
407315|NCT01056549|Apo B48 and apoB100
407316|NCT01056549|Pancreatic clamp
407317|NCT01056549|GLP-1 agonist
407318|NCT01056536|Travel
407319|NCT01056536|casual sexual relationships
407320|NCT01056536|condoms
407321|NCT01056536|Structured intervention
407322|NCT01056523|AML
407323|NCT01056497|diabetes
407324|NCT01056497|alpha lipoic acid
407325|NCT01056497|endoplasmic reticulum (ER) stress
407326|NCT01056497|insulin secretion
407327|NCT01056497|insulin sensitivity
407328|NCT01056484|Alcohol Dependence
407329|NCT01056484|Alcoholism
407330|NCT01056484|Substance Use Disorders
407331|NCT01056484|Substance Abuse
407332|NCT01056471|Multiple Sclerosis
407333|NCT01056471|Mesenchymal Stem Cells
407334|NCT01056471|Autologous
407335|NCT01056458|acupressure
407336|NCT01056458|perimenopause
407337|NCT01056458|menopause
407338|NCT01056458|anxiety
407339|NCT01056458|life quality
407340|NCT01056458|insomnia
407341|NCT01056445|Carotid artery stenting
407342|NCT01056445|Hemodynamic Instability
407343|NCT01056445|Valsalva Ratio
407344|NCT01056432|osteoporosis, bone fracture risk, bone ultrasonometry
407345|NCT01056419|Graves' ophthalmopathy
407346|NCT01056419|Total thyroidectomy
407347|NCT01056419|Anti-thyroid drug treatment
407348|NCT01056419|Clinical activity score
407349|NCT01056406|Pregnancy
407350|NCT01056406|Overweight
407351|NCT01056406|Obese
407352|NCT01056406|Nutrition intervention
407353|NCT01056393|HIV
407354|NCT01056380|influenza
407355|NCT01056380|influenza like illness
407356|NCT01056367|Resistant hypertension
407357|NCT01056367|Type-II-Diabetes Mellitus
407358|NCT01056367|Arterial stiffness
407359|NCT01056367|Ventricular function
407360|NCT01056354|Influenza
407361|NCT01056354|respiratory virus
407362|NCT01056354|pandemic
407363|NCT01056354|swine flu
407364|NCT01056354|infection
407365|NCT01056354|MERS-CoV
407366|NCT01056354|SARS-CoV
407367|NCT01056341|Infantile Hemangioma
407368|NCT01056341|Propranolol
407369|NCT01056315|Analgesia
407370|NCT01056315|Diabetic Neuropathy
407371|NCT01056315|Neuropathic pain
407372|NCT01056315|Painful
407373|NCT01056315|Chronic pain
407374|NCT01056302|Reconstructive surgical procedures
407375|NCT01056302|visuohaptic
407376|NCT01056276|Multiple Myeloma
407377|NCT01056276|Bendamustine
407378|NCT01056276|Bortezomib
407379|NCT01056276|Dexamethasone
407380|NCT01056263|retrospective trial
407381|NCT01056263|5-year survival
407382|NCT01056263|metastatic renal cancer cell
407383|NCT01056250|cholelithiasis
407384|NCT01056224|skull pin insertion
407385|NCT01056224|remifentanil
407386|NCT01056224|short acting opioid
407387|NCT01056224|craniotomy
407388|NCT01056224|cervical spine surgery
407389|NCT01056224|hemodynamic changes
407390|NCT01056224|dose requirement
407391|NCT01056224|age related
407392|NCT01056198|Diabetic Foot Ulcers
407393|NCT01056198|Diabetic Foot Wounds
407394|NCT01056185|influenza
407395|NCT01056185|flu
407396|NCT01056185|swine flu
407397|NCT01056185|respiratory virus
407398|NCT01056185|hospitalization
407399|NCT01056185|MERS-CoV
407400|NCT01056185|SARS-CoV
407401|NCT01056172|Chronic hepatitis C
407402|NCT01056172|Genotype 2
407403|NCT01056172|Rapid virologic response
407404|NCT01056172|Sustained virologic response
407405|NCT01056172|Peginterferon alfa-2a
407406|NCT01056172|Ribavirin
407407|NCT01056159|asthma
407408|NCT01056159|dry powder inhaler
407409|NCT01056159|short-acting beta2-agonist
407410|NCT01056159|SABA
407411|NCT01056159|bronchoconstriction
407412|NCT01056159|bronchodilation
407413|NCT01056159|bronchodilator
407414|NCT01056159|metered dose inhaler
407415|NCT01056146|TBI
407416|NCT01056146|intracranial edema
407417|NCT01056146|brain edema
407418|NCT01056146|craniocerebral trauma
407419|NCT01056146|head injury
407420|NCT01056146|brain hemorrhage, traumatic
407421|NCT01056146|subdural hematoma
407422|NCT01056146|brain concussion
407423|NCT01056146|head injuries, closed
407424|NCT01056146|epidural hematoma
407425|NCT01056146|extra-axial hemorrhage
407426|NCT01056146|cortical contusion
407427|NCT01056146|Additional relevant MeSH terms:
407428|NCT01056146|Nervous System Diseases
407429|NCT01056146|Wounds and Injuries
407430|NCT01056146|Disorders of Environmental Origin
407431|NCT01056146|Central Nervous System Diseases
407432|NCT01056146|Trauma, Nervous System
407433|NCT01056146|Brain Diseases
407434|NCT01056146|Brain Injuries
407435|NCT01056133|non-alcoholic fatty liver disease
407436|NCT01056133|non-alcoholic steatohepatitis
407437|NCT01056107|Constipation, Irritable Bowel Syndrome (IBS), Glucagon Like Peptide analogue
407438|NCT01056081|COPD
407439|NCT01056081|inspiratory muscles
407440|NCT01056081|diaphragm
407441|NCT01056055|Ankle
407442|NCT01056055|Chronic lateral instability
407443|NCT01056055|Modified Brostrom procedure
407444|NCT01056055|Suture anchor
407445|NCT01056055|Bone tunnel
407446|NCT01056042|pelvic pain
407447|NCT01056042|postoperative
407448|NCT01056042|medical therapy
407449|NCT01056029|Solid Tumors
407450|NCT01056016|ADHD
407451|NCT01056003|gastric inlet patch
407452|NCT01056003|prevalence
407453|NCT01056003|globus sensations
407454|NCT01055990|pandemic influenza A (H1N1) 2009
407455|NCT01055990|blood fix treatment
407456|NCT01055990|influenza A (H1N1) 2009 monovalent vaccine
407457|NCT01055990|effectiveness
407458|NCT01055990|immunogenicity
407459|NCT01055990|safety
407460|NCT01055977|statin therapy
407461|NCT01055977|treatment goal
407462|NCT01055977|dyslipidaemia
407463|NCT01055951|Insulin pumps
407464|NCT01055951|Diabetes
407465|NCT01055912|Congestive Heart Failure
407466|NCT01055912|Volume Overload
407467|NCT01055899|RA
407468|NCT01055886|PTSD
407469|NCT01055886|smoking cessation
407470|NCT01055886|nicotine patch
407471|NCT01055873|immune status
407472|NCT01055873|adolescents or young adults infected
407473|NCT01055873|impact of viral replication
407474|NCT01055860|uterine Prolapse
407475|NCT01055860|vaginal prolapse
407476|NCT01055860|mesh erosion
407477|NCT01055860|urinary incontinence
407478|NCT01055860|bowel symptoms
407479|NCT01055847|cystic fibrosis
407480|NCT01055847|CF
407481|NCT01055847|aztreonam
407482|NCT01055847|lung infection
407483|NCT01055847|Pseudomonas aeruginosa
407484|NCT01055834|Insomnia
407485|NCT01055834|primary insomnia
407486|NCT01055834|insomnia associated with psychiatric or physical disorder(s)
407487|NCT01055821|Hepatitis C
407488|NCT01055821|Vaccine
407489|NCT01055821|HCVac
407490|NCT01055821|MVA-HCV
407491|NCT01055808|Insulin
407492|NCT01055808|ITR-QOL
407493|NCT01055808|DTSQ
407494|NCT01055808|Diabetes Mellitus, Type 2
407495|NCT01055782|Colonoscopy
407496|NCT01055782|Endoguide
407497|NCT01055782|Pain perception
407498|NCT01055782|Colonoscopy to the coecum (success rate)
407499|NCT01055782|Patient's perception of pain
407500|NCT01055782|Duration of successful colonoscopies
407501|NCT01055769|Bio-equivalence
407502|NCT01055769|Linezolid OS
407503|NCT01055769|Linezolid tablet
407504|NCT01055756|Reduction of signs and symptoms and enhanced nasal flow
407505|NCT01055756|Nasal Flow
407506|NCT01055743|Fluorouracil Implants
407507|NCT01055743|Hepatocellular carcinoma
407508|NCT01055743|Radical resection
407509|NCT01055730|Pulmonary rehabilitation
407510|NCT01055730|Exercise therapy
407511|NCT01055730|Interstitial lung disease
407512|NCT01055730|Pulmonary fibrosis
407513|NCT01055730|Mobility limitation
407514|NCT01055730|Dyspnea
407515|NCT01055730|Mental health
407516|NCT01055717|avenanthramide
407517|NCT01055717|enriched
407518|NCT01055717|oat
407519|NCT01055717|phytochemical
407520|NCT01055717|bioavailability
407521|NCT01055704|Methylnaltrexone
407522|NCT01055704|Codeine
407523|NCT01055704|Gastrointestinal motility
407524|NCT01055704|Colonic transit
407525|NCT01055691|healthy volunteers
407526|NCT01055691|bioequivalence
407527|NCT01055691|dapagliflozin
407528|NCT01055691|metformin
407529|NCT01055678|breast cancer
407530|NCT01055678|ductal breast carcinoma in situ
407531|NCT01055678|breast cancer in situ
407532|NCT01055678|invasive carcinoma
407533|NCT01055678|invasive ductal carcinoma
407534|NCT01055678|invasive lobular carcinoma
407535|NCT01055652|Type 2 diabetes mellitus
407536|NCT01055652|Japanese
407537|NCT01055652|phase 1
407538|NCT01055652|safety
407539|NCT01055652|dapagliflozin
407540|NCT01055652|Pharmacokinetics
407541|NCT01055652|Drug-drug Interaction
407542|NCT01055652|voglibose
407543|NCT01055639|Chronic Pain
407544|NCT01055639|Acceptance and Commitment Therapy (ACT)
407545|NCT01055626|Body mass index
407546|NCT01055626|Body fat
407547|NCT01055626|Obesity
407548|NCT01055626|Overweight
407549|NCT01055626|Diabetes Mellitus, Type 2
407550|NCT01055626|Air displacement plethysmography
407551|NCT01055600|eltrombopag
407552|NCT01055600|pharmacokinetics
407553|NCT01055600|PROMACTA
407554|NCT01055600|lactation
407555|NCT01055600|milk-only study
407556|NCT01055587|major abdominal surgery
407557|NCT01055587|severe burn injury
407558|NCT01055587|infection
407559|NCT01055587|diagnostic
407560|NCT01055574|lumbar disc arthroplasty
407561|NCT01055574|total disc replacement
407562|NCT01055574|ProDisc L
407563|NCT01055574|anterior lumbar interbody fusion
407564|NCT01055574|lumbar spine surgery outcomes
407565|NCT01055561|Acupuncture
407566|NCT01055561|Behavioral and Psychological Symptoms of Dementia
407567|NCT01055561|BPSD
407568|NCT01055561|MMSE
407569|NCT01055561|BEHAVE-AD
407570|NCT01055561|The Questionnaire of Acupuncture Events
407571|NCT01055561|healthy volunteers
407572|NCT01055548|Preterm
407573|NCT01055548|Perinatal
407574|NCT01055548|Ultrasound
407575|NCT01055548|Cerebral palsy
407576|NCT01055548|Anxiety
407577|NCT01055548|Parents
407578|NCT01055522|Interleukin, IL2, monoclonal, antibody, cytokine, Dacarbazine, metastatic, melanoma, tumor targeting, Dose definition
407579|NCT01055522|, L19
407580|NCT01055509|Social Adjustment
407581|NCT01055509|Quality of life
407582|NCT01055509|Recurrence
407583|NCT01055509|Hospitalization
407584|NCT01055496|Non-Hodgkin's lymphoma
407585|NCT01055483|Acute myeloid leukemia
407586|NCT01055483|AML
407587|NCT01055483|relapsed acute myeloid leukemia
407588|NCT01055483|refractory acute myeloid leukemia
407589|NCT01055431|iron
407590|NCT01055431|bioavailability
407591|NCT01055431|status
407592|NCT01055431|deficiency
407593|NCT01055431|anaemia
407594|NCT01055431|functional foods
407595|NCT01055431|child bearing
407596|NCT01055418|Vitamin C
407597|NCT01055418|Cognitive performance
407598|NCT01055418|Cerebral blood flow
407599|NCT01055418|Trans cranial doppler
407600|NCT01055418|Near infrared spectroscopy
407601|NCT01055405|Exercise tolerance
407602|NCT01055405|COPD
407603|NCT01055405|Pulmonary hypertension
407604|NCT01055405|Sildenafil
407605|NCT01055392|mild cognitive impairment
407606|NCT01055392|Alzheimer's disease
407607|NCT01055392|Lithium
407608|NCT01055392|disease-modification
407609|NCT01055392|cognition
407610|NCT01055392|early Alzheimer`s disease
407611|NCT01055379|Rasagiline
407612|NCT01055379|Depressive Symptoms
407613|NCT01055379|Cognition
407614|NCT01055366|Open angle glaucoma
407615|NCT01055366|OAG
407616|NCT01055366|Elazop
407617|NCT01055366|Azarga
407618|NCT01055366|Brinzolamide/Timolol combination
407619|NCT01055353|Target organs damage
407620|NCT01055353|hypertensive patients
407621|NCT01055340|Ketogenesis
407622|NCT01055340|Glucose-Dependent Insulin Secretion
407623|NCT01055340|Graded Glucose Infusion
407624|NCT01055340|Oxyntomodulin
407625|NCT01055327|Isolated oral clefts
407626|NCT01055327|lamotrigine
407627|NCT01055327|EUROCAT
407628|NCT01055327|congenital malformations
407629|NCT01055327|anti-epileptic drugs
407630|NCT01055301|stage I multiple myeloma
407631|NCT01055301|stage II multiple myeloma
407632|NCT01055301|stage III multiple myeloma
407633|NCT01055275|iliac aneurysm
407634|NCT01055275|aortic aneurysm
407635|NCT01055275|endovascular grafts
407636|NCT01055262|Safety
407637|NCT01055262|tolerability
407638|NCT01055262|heatwrap
407639|NCT01055262|lower back
407640|NCT01055262|healthy subjects
407641|NCT01055249|UVB
407642|NCT01055249|pain
407643|NCT01055249|inflammation
407644|NCT01055249|model
407645|NCT01055249|healthy volunteers
407646|NCT01055249|Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers
407647|NCT01055236|sedation
407648|NCT01055223|thiazolidinediones
407649|NCT01055223|rosiglitazone
407650|NCT01055223|amiloride
407651|NCT01055223|pioglitazone
407652|NCT01055223|fracture
407653|NCT01055223|Spironolactone
407654|NCT01055210|Heart Failure
407655|NCT01055210|Pacemakers
407656|NCT01055197|extensive stage small cell lung cancer
407657|NCT01055184|Influenza
407658|NCT01055184|H1N1
407659|NCT01055171|alcohol dependence
407660|NCT01055171|PTSD
407661|NCT01055171|propanolol
407662|NCT01055171|craving
407663|NCT01055171|beta-block
407664|NCT01055171|cue exposure
407665|NCT01055171|addiction
407666|NCT01055171|memory
407667|NCT01055171|trauma
407668|NCT01055171|addictive behavior
407669|NCT01055158|HIV
407670|NCT01055145|Multidrug-resistant TB, sensitive to levofloxacin and moxifloxacin
407671|NCT01055106|bacterial vaginosis
407672|NCT01055106|vaginal infection
407673|NCT01055106|vaginal discharge
407674|NCT01055106|vaginal disease
407675|NCT01055093|diabetes mellitus
407676|NCT01055093|prospective observational study
407677|NCT01055093|diabetic complications
407678|NCT01055080|type 1 diabetes
407679|NCT01055080|beta-cell autoantibodies
407680|NCT01055080|cow's milk formula
407681|NCT01055080|bovine insulin
407682|NCT01055054|bariatrics
407683|NCT01055015|total knee arthroplasty
407684|NCT01055002|Health male volunteers
407685|NCT01055002|Male volunteers aged 18-45 years
407686|NCT01055002|Non-smokers and in good health
407687|NCT01054989|Healthy adults
407688|NCT01054989|Insulin sensitivity
407689|NCT01054976|Alzheimer's disease
407690|NCT01054976|Galantamine
407691|NCT01054976|Dementia
407692|NCT01054963|early inflammatory arthritis
407693|NCT01054963|chronic disease
407694|NCT01054963|peer support
407695|NCT01054963|peer mentor
407696|NCT01054963|peer counselling
407697|NCT01054937|4SC-203
407698|NCT01054937|Phase I
407699|NCT01054937|single dose
407700|NCT01054937|healthy volunteers
407701|NCT01054911|GIST
407702|NCT01054911|gastrointestinal stromal tumor
407703|NCT01054911|gastrointestinal stomach tumor
407704|NCT01054911|Sunitinib
407705|NCT01054898|depression
407706|NCT01054898|spouse abuse
407707|NCT01054898|intervention studies
407708|NCT01054885|COPD
407709|NCT01054885|Chronic Obstructive Pulmonary Disease
407710|NCT01054885|Efficacy
407711|NCT01054885|FEV1
407712|NCT01054885|Safety
407713|NCT01054872|HIV Seronegativity
407714|NCT01054872|HIV Preventive Vaccine
407715|NCT01054846|Bicycle helmet
407716|NCT01054820|FLECTORÂ® Patch
407717|NCT01054820|acute back strain
407718|NCT01054794|Gastroparesis
407719|NCT01054794|Gastric Electrical Stimulation
407720|NCT01054781|Diffuse Large B-Cell Lymphoma (DLBCL)
407721|NCT01054781|rituximab
407722|NCT01054781|CHOP
407723|NCT01054768|Antioxidant
407724|NCT01054768|Inflammation
407725|NCT01054768|Sickle Cell Disease
407726|NCT01054768|Oxidative Stress
407727|NCT01054768|Cytokines
407728|NCT01054768|anti-inflammatory
407729|NCT01054768|Acetylcarnitine
407730|NCT01054729|Chronic Hepatitis C infection Genotype 1
407731|NCT01054729|HCV
407732|NCT01054729|GT1
407733|NCT01054729|GT 1
407734|NCT01054716|RhD negative
407735|NCT01054716|RhD disease
407736|NCT01054716|fetal nucleic acid
407737|NCT01054716|fetal DNA
407738|NCT01054716|cell free fetal DNA
407739|NCT01054716|Fetal RHD genotype
407740|NCT01054690|Catheterization
407741|NCT01054690|Urinary Tract Infection
407742|NCT01054690|Elective Surgery
407743|NCT01054677|Infections in nursing homes
407744|NCT01054677|especially urinary tract infections
407745|NCT01054664|liver enzymes
407746|NCT01054664|peripheral mononuclear blood cells
407747|NCT01054664|hemodialysis
407748|NCT01054664|hepatitis C
407749|NCT01054664|RNA
407750|NCT01054651|Schistosoma mansoni
407751|NCT01054651|Praziquantel
407752|NCT01054651|Artesunate + Sulfamethoxypyrazine/pyrimethamine
407753|NCT01054651|Randomized open-label controlled clinical trial
407754|NCT01054638|amprenavir
407755|NCT01054638|fosamprenavir
407756|NCT01054638|HIV
407757|NCT01054638|HAART treatment
407758|NCT01054638|Epzicom
407759|NCT01054638|Trizivir
407760|NCT01054638|Combivir
407761|NCT01054638|zidovudine
407762|NCT01054638|lamivudine
407763|NCT01054638|cardiovascular disease
407764|NCT01054638|HIV Infections
407765|NCT01054625|Squamous Cell Carcinoma of the Head and Neck
407766|NCT01054625|Head and Neck Cancer
407767|NCT01054625|Head and Neck Neoplasms
407768|NCT01054625|anti-EGFr monoclonal antibody
407769|NCT01054625|Zalutumumab
407770|NCT01054612|Histology
407771|NCT01054612|Immunohistochemical
407772|NCT01054612|Gene Expression
407773|NCT01054612|Tissue Sectioning
407774|NCT01054599|epilepsy
407775|NCT01054599|memory
407776|NCT01054599|memantine
407777|NCT01054599|localization related epilepsy
407778|NCT01054599|focal epilepsy
407779|NCT01054586|antiretroviral therapy
407780|NCT01054586|hepatic impairment
407781|NCT01054586|HIV
407782|NCT01054573|Hepatitis C, Chronic
407783|NCT01054573|Telaprevir
407784|NCT01054573|Roll-over study
407785|NCT01054560|Ischemic Stroke
407786|NCT01054560|SOLITAIRE™ Device
407787|NCT01054560|SOLITAIRE™
407788|NCT01054560|MERCI® Device
407789|NCT01054560|MERCI®
407790|NCT01054560|Stroke
407791|NCT01054560|Ischemic
407792|NCT01054560|Mechanical Thrombectomy
407793|NCT01054560|Brain
407794|NCT01054560|Brain Clot
407795|NCT01054560|Brain Artery Revascularization
407796|NCT01054560|Recanalization
407797|NCT01054560|Brain Stroke
407798|NCT01054560|Clot Retriever
407799|NCT01054560|Device
407800|NCT01054560|Neurosurgery
407801|NCT01054560|Neurovascular Intervention
407802|NCT01054560|Interventional Neuroradiology
407803|NCT01054560|Brain study
407804|NCT01054560|neurovascular clinical trial
407805|NCT01054547|topical anesthetic
407806|NCT01054547|liposomal ropivacaine
407807|NCT01054547|dentistry
407808|NCT01054534|urinary incontinence
407809|NCT01054521|radiofrequency turbinate reduction
407810|NCT01054521|nasal obstruction
407811|NCT01054521|Temperature-controlled radiofrequency
407812|NCT01054521|Bipolar radiofrequency
407813|NCT01054521|chronic rhinitis.
407814|NCT01054495|Acupuncture
407815|NCT01054495|Sham acupuncture
407816|NCT01054495|Laser
407817|NCT01054495|Methodology
407818|NCT01054495|Control intervention
407819|NCT01054495|Pilot
407820|NCT01054495|Nausea and vomiting in early pregnancy
407821|NCT01054495|Patient's experience of different acu-stimulation
407822|NCT01054495|Blinding in acupuncture research
407823|NCT01054482|Neoadjuvant chemotherapy
407824|NCT01054482|neoadjuvant chemoradiotherapy
407825|NCT01054469|nephrectomy
407826|NCT01054456|LEC
407827|NCT01054456|Low Emetogenic Chemotherapy
407828|NCT01054456|Nausea and Vomiting
407829|NCT01054456|Nausea
407830|NCT01054456|Vomiting
407831|NCT01054456|Anti- emetic
407832|NCT01054443|Blood Platelet Disorders
407833|NCT01054443|Immune Thrombocytopenia (ITP)
407834|NCT01054443|Low Platelet Count
407835|NCT01054443|Thrombocytopaenia
407836|NCT01054443|S-888711
407837|NCT01054443|Splenectomy
407838|NCT01054443|Thrombopoiesis
407839|NCT01054443|Hematologic Disease
407840|NCT01054443|Auto-immune thrombocytopenic Purpura
407841|NCT01054443|Relapsed Persistent or Chronic ITP
407842|NCT01054443|Idiopathic Thrombocytopenic Purpura
407843|NCT01054443|Thrombotic Thrombocytopenic Purpura (TTP)
407844|NCT01054430|Avanafil
407845|NCT01054430|Hepatic
407846|NCT01054430|Erectile Dysfunction
407847|NCT01054430|Impairment
407848|NCT01054417|Appendicitis
407849|NCT01054417|Laparoscopy
407850|NCT01054417|Appendectomy
407851|NCT01054404|Brain Swelling
407852|NCT01054404|Brain Edema
407853|NCT01054404|Dehydration
407854|NCT01054352|Seasonal allergies
407855|NCT01054352|Allergic rhinitis
407856|NCT01054339|Alpha-1 antitrypsin deficiency
407857|NCT01054339|Adeno-associated virus vector
407858|NCT01054339|AAV
407859|NCT01054339|Gene therapy
407860|NCT01054339|Human gene transfer
407861|NCT01054326|arthroscopic subacromial decompression
407862|NCT01054326|exercise
407863|NCT01054326|physical therapy
407864|NCT01054326|rotator cuff
407865|NCT01054326|shoulder impingement syndrome
407866|NCT01054326|Subacromial impingement after arthroscopic subacromial decompression
407867|NCT01054313|Advanced Malignancies
407868|NCT01054313|Taxotere
407869|NCT01054313|Docetaxel
407870|NCT01054313|Rapamycin
407871|NCT01054313|Sirolimus
407872|NCT01054313|Rapamune
407873|NCT01054313|Prednisone
407874|NCT01054313|Resistant to standard therapy
407875|NCT01054274|esophageal cancer
407876|NCT01054274|dysphagia
407877|NCT01054274|stent
407878|NCT01054274|brachytherapy
407879|NCT01054261|avanafil, renal, impairment, TA-1790
407880|NCT01054248|pregnancy, malaria, artemisinin, vivax, falciparum
407881|NCT01054235|prenatal care
407882|NCT01054235|community-based randomized controlled trial
407883|NCT01054235|perinatal mortality
407884|NCT01054235|China
407885|NCT01054222|overactive bladder idiopathic
407886|NCT01054222|elderly fesoterodine SOFIA Portugal extension study
407887|NCT01054209|Inadvertent Peri-operative Hypothermia
407888|NCT01054209|Shivering
407889|NCT01054209|Caesarean Section
407890|NCT01054209|Elective
407891|NCT01054209|Warming Mattress
407892|NCT01054209|Regional Anaesthesia
407893|NCT01054183|respiratory failure, intubation, GlideScope, pediatric
407894|NCT01054170|Chronic
407895|NCT01054170|obstructive
407896|NCT01054170|pulmonary
407897|NCT01054170|lung
407898|NCT01054170|respiratory disease
407899|NCT01054170|efficacy
407900|NCT01054170|placebo-controlled
407901|NCT01054170|COPD
407902|NCT01054170|FEV1
407903|NCT01054170|St Georges Respiratory Questionnaire
407904|NCT01054170|Computed Tomography
407905|NCT01054170|MSCT
407906|NCT01054144|Newly Diagnosed Standard Risk Multiple Myeloma
407907|NCT01054144|Senior Adults
407908|NCT01054131|peer support
407909|NCT01054131|peer mentor
407910|NCT01054131|self-management
407911|NCT01054131|early inflammatory arthritis
407912|NCT01054131|chronic disease
407913|NCT01054118|Type 2 Diabetes Mellitus
407914|NCT01054105|Pulmonary hypertension
407915|NCT01054105|genes
407916|NCT01054105|mutation
407917|NCT01054105|drug therapy
407918|NCT01054092|ASP1941
407919|NCT01054092|Diabetes mellitus
407920|NCT01054092|Blood glucose
407921|NCT01054092|Food effect
407922|NCT01054066|Chronic Kidney Disease
407923|NCT01054066|Cardiovascular Disease
407924|NCT01054066|Hypertension
407925|NCT01054066|Anemia
407926|NCT01054053|Neisseria meningitidis B:14, P1-7, 16
407927|NCT01054053|Serum bactericidal activity
407928|NCT01054053|Menbvac
407929|NCT01054040|cardiovascular disease, portion plate
407930|NCT01054027|Retinopathy of Prematurity (ROP)
407931|NCT01054027|Eye exams
407932|NCT01054027|Premature infants
407933|NCT01054027|cyclomydril
407934|NCT01054014|CR016795
407935|NCT01054001|prostate cancer
407936|NCT01054001|prostatectomy
407937|NCT01054001|erectile dysfunction
407938|NCT01053988|Safety
407939|NCT01053988|Chronic Obstructive Pulmonary Disease
407940|NCT01053988|Efficacy
407941|NCT01053988|FEV1
407942|NCT01053988|COPD
407943|NCT01053975|RSR
407944|NCT01053975|SECG
407945|NCT01053975|SPECT
407946|NCT01053975|QCA
407947|NCT01053975|SCAD
407948|NCT01053962|Chronic Idiopathic Constipation
407949|NCT01053962|Constipation
407950|NCT01053962|Irritable Bowel Syndrome
407951|NCT01053949|Multiple myeloma
407952|NCT01053949|dexamethasone
407953|NCT01053949|pomalidomide
407954|NCT01053949|response
407955|NCT01053949|safety
407956|NCT01053936|Chronic Kidney Disease
407957|NCT01053936|Type 2 diabetes
407958|NCT01053936|Diabetic Nephropathy
407959|NCT01053923|Perianal Cancer
407960|NCT01053923|Anal Cancer
407961|NCT01053923|MRI scan
407962|NCT01053897|GBT009
407963|NCT01053897|incisional scar
407964|NCT01053897|breast reconstruction
407965|NCT01053884|Invasive Candidiasis
407966|NCT01053884|invasive fungal disease
407967|NCT01053884|Anidulafungin
407968|NCT01053871|normal
407969|NCT01053858|bevacizumab,triamcinolone, intravitreal injection
407970|NCT01053845|Neuropathic pain
407971|NCT01053832|ventricular pace suppression
407972|NCT01053832|pacemaker
407973|NCT01053832|efficacy
407974|NCT01053832|safety
407975|NCT01053832|support of intrinsic heart rhythm
407976|NCT01053819|psoriasis
407977|NCT01053819|melanoma
407978|NCT01053819|non-melanoma skin cancer
407979|NCT01053819|etanercept
407980|NCT01053819|Enbrel
407981|NCT01053806|MDS
407982|NCT01053806|Lenalidomide
407983|NCT01053806|5-Azacytidine.
407984|NCT01053806|ORR
407985|NCT01053806|PFS
407986|NCT01053806|myelodysplastic syndrome.High risk.
407987|NCT01053793|Glycemic index
407988|NCT01053793|Anthocyanin
407989|NCT01053793|Potato
407990|NCT01053793|Polyphenol
407991|NCT01053780|Intercessory Prayer, pregnants
407992|NCT01053767|Group B streptococcus
407993|NCT01053767|GBS
407994|NCT01053767|Vaccine
407995|NCT01053754|adrenocortical insufficiency
407996|NCT01053754|prolonged corticotherapy
407997|NCT01053715|Hemophilia
407998|NCT01053715|Quality of Life
407999|NCT01053689|Bioequivalence, Glimepiride, Crossover
408000|NCT01053676|Hyperphosphatemia
408001|NCT01053676|BE
408002|NCT01053676|Granule
408003|NCT01053676|Healthy volunteers
408004|NCT01053650|Healthy volunteers
408005|NCT01053650|Open / hidden
408006|NCT01053650|Placebo effect
408007|NCT01053637|lacerations
408008|NCT01053637|sutures
408009|NCT01053637|pediatrics
408010|NCT01053637|child
408011|NCT01053637|pain
408012|NCT01053637|Anxiety
408013|NCT01053624|Tracheostomy and thoracic surgery
408014|NCT01053624|postoperative complications
408015|NCT01053624|pulmonary surgical procedures
408016|NCT01053624|respiratory failure
408017|NCT01053611|composite variability index
408018|NCT01053611|bispectral index
408019|NCT01053611|pain
408020|NCT01053598|Mycobacterium tuberculosis
408021|NCT01053598|Nitrate Reductase Assay
408022|NCT01053598|NRA
408023|NCT01053598|REMA
408024|NCT01053598|RETA
408025|NCT01053598|Rezazurine
408026|NCT01053585|Gastro-esophageal junction, reflux, insertion angle, magnetic resonance imaging, manometry
408027|NCT01053572|Chronic low back pain
408028|NCT01053572|Post lumbar laminectomy syndrome
408029|NCT01053572|Lower extremity pain
408030|NCT01053572|Local anesthetic
408031|NCT01053572|Steroid
408032|NCT01053572|Percutaneous lumbar adhesiolysis
408033|NCT01053559|Crohn's
408034|NCT01053559|Inflammatory Bowel Disease
408035|NCT01053533|Chinese herbal medicines
408036|NCT01053533|pandemic H1N1 influenza
408037|NCT01053533|effectiveness
408038|NCT01053533|safety
408039|NCT01053507|Headache
408040|NCT01053507|Post-traumatic headache
408041|NCT01053507|Brain injury
408042|NCT01053507|Cognitive impairment
408043|NCT01053468|breast cancer
408044|NCT01053468|physical activity
408045|NCT01053468|quality of life
408046|NCT01053468|theory of planned behavior
408047|NCT01053468|behavior change
408048|NCT01053468|health promotion
408049|NCT01053455|Non-invasive ventilation
408050|NCT01053455|SiPAP
408051|NCT01053455|CPAP
408052|NCT01053455|low birth weight infants
408053|NCT01053455|respiratory distress syndrome
408054|NCT01053442|iron absorption
408055|NCT01053442|stable isotopes
408056|NCT01053442|NaFeEDTA
408057|NCT01053442|Non-transferrin-bound iron (NTBI)
408058|NCT01053442|Hepcidin
408059|NCT01053429|Regulatory Post-Marketing Surveillance
408060|NCT01053429|Regulatory Pharmacovigilance
408061|NCT01053429|ziprasidone
408062|NCT01053416|glaucoma
408063|NCT01053416|pigmentary glaucoma
408064|NCT01053416|laser iridotomy
408065|NCT01053403|MDMA
408066|NCT01053403|Ecstasy
408067|NCT01053403|MDMA effect on sleep
408068|NCT01053403|MDMA effect on water homeostasis
408069|NCT01053403|MDMA effect on neurocognitive function
408070|NCT01053403|Recreational Drug Use
408071|NCT01053403|Drug Abuse
408072|NCT01053390|gallbladder neoplasmas
408073|NCT01053390|Gallbladder Neoplasms,Advanced Stage,Chemotherapy,Somatostatin
408074|NCT01053377|Influenza
408075|NCT01053377|Tamiflu
408076|NCT01053377|Osteltamivir
408077|NCT01053377|Transmission
408078|NCT01053377|Prevention
408079|NCT01053377|Resistance
408080|NCT01053377|Post-Exposure Profylaxe
408081|NCT01053338|Bioequivalence,Ibuprofen Diphenhydramine Citrate,Crossover
408082|NCT01053325|Malaria
408083|NCT01053325|Pregnancy
408084|NCT01053325|Prevention
408085|NCT01053325|HIV
408086|NCT01053325|Sub-Sahara Africa
408087|NCT01053312|Amyloid
408088|NCT01053312|NPH Normal pressure hydrocephalus
408089|NCT01053312|PET Positron Emission Tomography
408090|NCT01053312|SUVR Standard uptake value ratios
408091|NCT01053299|Developmental dysplasia of the hip (DDH)
408092|NCT01053299|newborn
408093|NCT01053299|universal screening
408094|NCT01053299|Universal ultrasound-screening for DDH in newborns
408095|NCT01053299|The accuracy of ultrasound-recording of the hip in newborns
408096|NCT01053286|Dysphagia
408097|NCT01053286|Globus
408098|NCT01053286|Gastroesophageal reflux
408099|NCT01053273|Low back pain
408100|NCT01053273|Post lumbar laminectomy syndrome
408101|NCT01053273|Lumbar spinal stenosis
408102|NCT01053273|Local anesthetic steroid
408103|NCT01053273|Lumbar transforaminal epidural injection
408104|NCT01053273|Percutaneous epidural adhesiolysis
408105|NCT01053273|Caudal epidural injection
408106|NCT01053260|Contingency Management
408107|NCT01053260|Weight Loss
408108|NCT01053247|Atopic Dermatitis
408109|NCT01053234|Hyperglycaemia
408110|NCT01053234|Postprandial
408111|NCT01053234|Type 2 diabetes
408112|NCT01053234|Cardiovascular risk markers
408113|NCT01053221|mycophenolate
408114|NCT01053221|living donor
408115|NCT01053208|Bioequivalence,Ibuprofen Diphenhydramine Citrate,Crossover
408116|NCT01053195|Diabetes
408117|NCT01053195|prevention
408118|NCT01053195|intervention
408119|NCT01053182|esophageal cancer
408120|NCT01053182|postoperative complications
408121|NCT01053182|diaphragm
408122|NCT01053182|pulmonary function
408123|NCT01053169|Coagulopathy
408124|NCT01053169|Perioperative bleeding
408125|NCT01053169|Prothrombin complex
408126|NCT01053169|Liver disease
408127|NCT01053156|Fragile X syndrome
408128|NCT01053156|minocycline
408129|NCT01053156|targeted treatment
408130|NCT01053143|Influenza
408131|NCT01053143|Pandemic Influenza
408132|NCT01053143|Swine-Origin Influenza A/H1N1 Non-adjuvanted Vaccine
408133|NCT01053143|Influenza A Virus, H1N1 subtype
408134|NCT01053143|Adults
408135|NCT01053130|obesity
408136|NCT01053130|bariatric surgery
408137|NCT01053130|chronic kidney disease
408138|NCT01053130|weight loss
408139|NCT01053130|exercise
408140|NCT01053117|central venous catheter
408141|NCT01053117|arteriovenous fistula
408142|NCT01053117|hemodialysis
408143|NCT01053117|vascular access
408144|NCT01053117|dialysis
408145|NCT01053104|Colorectal cancer
408146|NCT01053104|Breast cancer
408147|NCT01053104|Capecitabine
408148|NCT01053104|Docetaxel
408149|NCT01053104|Mobile phone
408150|NCT01053104|Toxicity
408151|NCT01053104|Metastatic
408152|NCT01053091|exercise-base rehabilitation
408153|NCT01053091|diastolic heart failure
408154|NCT01053091|cardiovascular function
408155|NCT01053091|aerobic fitness
408156|NCT01053078|Type 1 diabetes
408157|NCT01053078|Hypoglycemia unawareness
408158|NCT01053078|low blood sugar
408159|NCT01053065|Atherosclerosis
408160|NCT01053065|Macrophages
408161|NCT01053065|Carotid arteries
408162|NCT01053065|Statin
408163|NCT01053052|Patency Tests, Fallopian Tubes
408164|NCT01053052|Hysterosalpingography
408165|NCT01053052|Sonography, Medical
408166|NCT01053026|Angiotensin receptor II antagonist
408167|NCT01053013|macrobead
408168|NCT01053013|biological
408169|NCT01053013|mouse cells
408170|NCT01053000|ACTINIC KERATOSES
408171|NCT01053000|HAND
408172|NCT01053000|FOREARM
408173|NCT01052987|Gout
408174|NCT01052987|Hyperuricemia
408175|NCT01052974|femoral neck fracture
408176|NCT01052974|analgesia
408177|NCT01052961|severe influenza
408178|NCT01052961|hospitalized adults
408179|NCT01052961|oseltamivir treatment
408180|NCT01052948|dopamine agonists
408181|NCT01052948|cabergoline
408182|NCT01052948|Parkinson's disease
408183|NCT01052948|hyperprolactinemia
408184|NCT01052948|epidemiology
408185|NCT01052948|cardiac valvulopathy
408186|NCT01052935|Group B streptococcus
408187|NCT01052935|GBS
408188|NCT01052935|Vaccine
408189|NCT01052922|Colorectal Neoplasms
408190|NCT01052922|Mass Screening
408191|NCT01052922|Population Surveillance
408192|NCT01052922|Randomized controlled trial
408193|NCT01052922|Occult Blood
408194|NCT01052922|Colonoscopy
408195|NCT01052922|Sigmoidoscopy
408196|NCT01052922|Health Behavior
408197|NCT01052909|Bioequivalence, Glimepiride, Crossover
408198|NCT01052896|Dyspepsia
408199|NCT01052896|Functional
408200|NCT01052883|TMC114-TiDP3-C182
408201|NCT01052883|TMC114-C182
408202|NCT01052883|TMC114
408203|NCT01052883|HIV
408204|NCT01052883|HIV Infections
408205|NCT01052870|pharmacogenomics, androgen receptor gene, androgen sensitivity, CAG repeats, androgenetic alopecia
408206|NCT01052870|Pharmacogenomics in treatment for androgenetic alopecia in women
408207|NCT01052857|to evaluate acupuncture as possible alternative treatment for induction of labor
408208|NCT01052857|Induction
408209|NCT01052857|treatment
408210|NCT01052857|posterm
408211|NCT01052844|Vomiting
408212|NCT01052844|Antiemetics
408213|NCT01052844|Dexamethasone
408214|NCT01052844|Cisplatin
408215|NCT01052844|Antineoplastic combined chemotherapy protocols
408216|NCT01052831|Compulsive Gambling
408217|NCT01052831|Compulsive Buying
408218|NCT01052831|Compulsive Shopping
408219|NCT01052831|Compulsive Eating
408220|NCT01052831|Hypersexuality
408221|NCT01052831|Dopamine Agonists
408222|NCT01052831|Mirapex
408223|NCT01052831|Pramipexole
408224|NCT01052831|Requip
408225|NCT01052831|Ropinirole
408226|NCT01052831|Impulse Control Disorders
408227|NCT01052818|Non small-cell lung cancer
408228|NCT01052818|Circulating tumor cells
408229|NCT01052818|Carcinoembryonic antigen
408230|NCT01052818|Cytokeratin
408231|NCT01052805|nerve
408232|NCT01052805|myelinated nerve
408233|NCT01052805|unmyelinated nerve
408234|NCT01052792|Bioequivalence
408235|NCT01052792|Naproxen
408236|NCT01052792|crossover
408237|NCT01052779|Iron deficiency anemia
408238|NCT01052779|chronic kidney disease
408239|NCT01052779|Feraheme
408240|NCT01052779|ferumoxytol
408241|NCT01052779|iron sucrose
408242|NCT01052779|iron deficiency anemia (IDA)
408243|NCT01052779|chronic kidney disease (CKD)
408244|NCT01052766|lung cancer
408245|NCT01052766|PET Scan
408246|NCT01052766|CT Scan
408247|NCT01052766|BH-PET scan
408248|NCT01052766|09-134
408249|NCT01052753|Attention-deficit/hyperactivity disorder
408250|NCT01052753|executive function
408251|NCT01052753|endophenotype
408252|NCT01052753|dopaminergic system
408253|NCT01052753|noradrenergic system
408254|NCT01052753|candidate gene
408255|NCT01052753|Family-based association study
408256|NCT01052740|Breast Cancer
408257|NCT01052740|Mammography
408258|NCT01052740|Screening
408259|NCT01052727|Laparoscopic Cholecystectomy
408260|NCT01052727|quality of life
408261|NCT01052714|Antipsychotic
408262|NCT01052714|Bipolar
408263|NCT01052714|Diabetes
408264|NCT01052714|Mental Illness
408265|NCT01052714|Nutrition
408266|NCT01052714|Obesity
408267|NCT01052714|Schizoaffective
408268|NCT01052714|Schizophrenia
408269|NCT01052714|Weight Gain
408270|NCT01052714|Weight Loss
408271|NCT01052688|Down syndrome, aneuploidy, amniocentesis, chorionic villus sampling, Trisomy
408272|NCT01052675|Drug and substance problematic use, abuse or dependence
408273|NCT01052662|Drug Abuse
408274|NCT01052649|MNC subpopulations
408275|NCT01052649|Gene Expression
408276|NCT01052649|Metabolomics
408277|NCT01052649|Immunological Status
408278|NCT01052636|Hip fracture
408279|NCT01052636|Intervention program
408280|NCT01052636|Elderly
408281|NCT01052623|GH/IGF-1
408282|NCT01052623|Ataxia telangiectasia (AT)
408283|NCT01052623|IGF-1 Generation Test
408284|NCT01052623|Growth hormone
408285|NCT01052610|SLIT
408286|NCT01052610|bronchial asthma
408287|NCT01052610|allergic rhinitis
408288|NCT01052597|Type 2 diabetes
408289|NCT01052597|Metabolic syndrome
408290|NCT01052597|cardiovascular risk
408291|NCT01052584|malaria
408292|NCT01052584|therapeutic efficacy
408293|NCT01052584|in vivo
408294|NCT01052584|artemether lumefantrine
408295|NCT01052584|coartem
408296|NCT01052584|chloroquine
408297|NCT01052584|Plasmodium falciparum
408298|NCT01052584|Plasmodium vivax
408299|NCT01052571|Chronic low back pain
408300|NCT01052571|Lumbar disc herniation
408301|NCT01052571|Lower extremity pain
408302|NCT01052571|Lumbar radiculitis
408303|NCT01052571|Local anesthetic
408304|NCT01052571|Steroid
408305|NCT01052571|Lumbar transforaminal epidural injection
408306|NCT01052558|Open angle
408307|NCT01052558|Glaucoma
408308|NCT01052558|Cataract
408309|NCT01052558|Surgery
408310|NCT01052558|Intraocular Pressure
408311|NCT01052545|urinary tract infection
408312|NCT01052545|urinary catheter
408313|NCT01052545|bacteriuria
408314|NCT01052545|clinical guidelines
408315|NCT01052545|audit-feedback
408316|NCT01052545|guidelines implementation
408317|NCT01052532|Mitral Regurgitation
408318|NCT01052532|LV remodeling
408319|NCT01052532|Reactive nitrogen species
408320|NCT01052532|Cardiac MRI
408321|NCT01052532|Adrenergic overdrive
408322|NCT01052519|Obesity
408323|NCT01052519|Esophageal Doppler monitoring
408324|NCT01052519|tissue oxygen tension
408325|NCT01052506|Human volunteers
408326|NCT01052493|obesity
408327|NCT01052493|pancreatic polypeptide
408328|NCT01052493|gut hormones
408329|NCT01052480|Antiviral
408330|NCT01052480|Anti-Influenza Immune Plasma
408331|NCT01052480|Emerging Infectious Disease
408332|NCT01052480|Swine Flu
408333|NCT01052454|hot flashes
408334|NCT01052454|mindfulness
408335|NCT01052454|stress
408336|NCT01052441|CCTA
408337|NCT01052441|Coronary Artery Stenosis
408338|NCT01052441|Iodinated Contrast
408339|NCT01052441|Invasive Coronary Angiography
408340|NCT01052428|Chronic MR
408341|NCT01052428|Volume Overload
408342|NCT01052428|Beta-1 receptor blocker
408343|NCT01052428|LV remodelling, LV dimensions
408344|NCT01052428|LV systolic function
408345|NCT01052428|LV diastolic dysfunction
408346|NCT01052428|Cardiac MRI
408347|NCT01052415|HIV
408348|NCT01052415|Stigma
408349|NCT01052415|POL
408350|NCT01052415|Service providers
408351|NCT01052415|China
408352|NCT01052415|Universal precaution
408353|NCT01052389|Schizophrenia
408354|NCT01052389|Pragmatic RCT
408355|NCT01052389|Aripiprazole
408356|NCT01052389|Olanzapine
408357|NCT01052389|Haloperidol
408358|NCT01052389|Metabolic syndrome
408359|NCT01052389|Drug discontinuation
408360|NCT01052376|nflammatory bowel diseases (IBD)
408361|NCT01052376|Familial adenomatous polyposis (FAP)
408362|NCT01052363|CNS tumors
408363|NCT01052350|Parkinson disease
408364|NCT01052350|PET imaging
408365|NCT01052350|PIB
408366|NCT01052350|dementia
408367|NCT01052311|Coronary artery disease
408368|NCT01052311|Endothelial function
408369|NCT01052311|Platelet function
408370|NCT01052311|Statins
408371|NCT01052311|Niacin
408372|NCT01052298|Ciprofloxacin
408373|NCT01052298|Inhalation
408374|NCT01052298|Pharmacokinetics
408375|NCT01052298|Safety
408376|NCT01052298|Tolerability
408377|NCT01052298|COPD
408378|NCT01052285|Transversus abdominis plane block
408379|NCT01052272|Diabetes
408380|NCT01052272|Acute MI
408381|NCT01052272|Ang II type-1 receptor blockade (AT1RB)
408382|NCT01052272|LV remodeling
408383|NCT01052272|ACE inhibitor therapy
408384|NCT01052272|XO inhibitor, Allopurinol
408385|NCT01052272|Systolic dysfunction
408386|NCT01052272|Diastolic dysfunction
408387|NCT01052272|LV dimensions
408388|NCT01052272|Cardiac MRI
408389|NCT01052259|Chronic rejection
408390|NCT01052259|Kidney
408391|NCT01052259|Transplantation
408392|NCT01052259|Immunosuppressive
408393|NCT01052246|acne vulgaris
408394|NCT01052246|laser surgery
408395|NCT01052246|pulsed dye lasers
408396|NCT01052246|benzoyl peroxidase
408397|NCT01052246|clindamycin
408398|NCT01052246|randomized controlled trial
408399|NCT01052233|Sham-surgery
408400|NCT01052233|Development of osteoarthritis
408401|NCT01052233|Randomized, double-blinded, placebo-controlled
408402|NCT01052220|Hypertension
408403|NCT01052220|Blood Pressure
408404|NCT01052220|End Stage Renal Disease
408405|NCT01052220|Hemodialysis
408406|NCT01052220|Interdialytic Weight Gain
408407|NCT01052220|Self-Regulation
408408|NCT01052207|Biological Response Modifiers
408409|NCT01052207|Endocrinology
408410|NCT01052207|Hormone Dysfunction
408411|NCT01052207|Hormones
408412|NCT01052207|Neuroendocrinology
408413|NCT01052194|Rheumatoid Arthritis
408414|NCT01052181|Vitamin D
408415|NCT01052181|Insulin sensitivity
408416|NCT01052181|Centrally obese
408417|NCT01052168|simulation
408418|NCT01052168|simulators
408419|NCT01052168|motion metrics
408420|NCT01052168|performance metrics
408421|NCT01052168|skills training
408422|NCT01052168|proficiency
408423|NCT01052168|laparoscopic
408424|NCT01052155|Controlled substances
408425|NCT01052155|Opioids
408426|NCT01052155|Benzodiazepines
408427|NCT01052155|Illicit drugs
408428|NCT01052155|Immunoassay drug testing
408429|NCT01052155|Point of care (POC) testing
408430|NCT01052155|Liquid Chromatography Tandem Mass Spectometry
408431|NCT01052142|Melanoma
408432|NCT01052142|Cancer vaccines
408433|NCT01052129|Bioequivalence
408434|NCT01052129|Naproxen
408435|NCT01052129|crossover
408436|NCT01052116|Asthma
408437|NCT01052116|Soy
408438|NCT01052116|Supplement
408439|NCT01052116|ACRC
408440|NCT01052116|SOYA
408441|NCT01052090|HCV
408442|NCT01052077|OPC-34712
408443|NCT01052077|Major Depressive Disorder
408444|NCT01052077|Adjunctive Treatment
408445|NCT01052064|Children
408446|NCT01052064|ADHD
408447|NCT01052064|rTMS
408448|NCT01052064|Safety
408449|NCT01052038|Sore throat
408450|NCT01052038|Dexamethasone
408451|NCT01052038|Pain
408452|NCT01052012|Postoperative pain
408453|NCT01052012|Post-operative pain
408454|NCT01052012|Opioid
408455|NCT01052012|Laparoscopic surgery
408456|NCT01052012|Bupivacaine
408457|NCT01052012|Local anesthetic
408458|NCT01051999|Glutamine
408459|NCT01051986|coronary artery bypass
408460|NCT01051986|off-pump surgery
408461|NCT01051986|composite graft
408462|NCT01051986|saphenous vein
408463|NCT01051986|internal thoracic artery
408464|NCT01051973|Cognitive behavior therapy
408465|NCT01051973|exposure
408466|NCT01051973|stress management
408467|NCT01051960|Systemic Sclerosis
408468|NCT01051960|connective tissue disease
408469|NCT01051960|Shortness of breath
408470|NCT01051960|Pulmonary Hypertension
408471|NCT01051947|Nebivolol
408472|NCT01051947|Metoprolol
408473|NCT01051947|central aortic pressure
408474|NCT01051947|hypertension
408475|NCT01051934|Recombinant Immunotoxin
408476|NCT01051934|Monoclonal Antibody
408477|NCT01051934|Pseudomonas Exotoxin
408478|NCT01051934|Targeted Therapy
408479|NCT01051934|Lung Cancer
408480|NCT01051934|Non-Small Cell Lung Cancer
408481|NCT01051921|HCV
408482|NCT01051921|Null Responder
408483|NCT01051895|Cervical intra-epithelial neoplasia
408484|NCT01051895|Colposcopy
408485|NCT01051895|HPV DNA testing
408486|NCT01051895|treatment failure
408487|NCT01051882|Mesenchymal Stromal Cells (MSC)
408488|NCT01051882|Amyotrophic Lateral Sclerosis (ALS)
408489|NCT01051882|Neuroprotection
408490|NCT01051882|Neurodegeneration
408491|NCT01051882|Stem cells
408492|NCT01051882|ALS
408493|NCT01051869|distal humerus
408494|NCT01051869|fractures
408495|NCT01051869|ulnar nerve
408496|NCT01051869|simple decompression
408497|NCT01051869|anterior transposition
408498|NCT01051843|Maternal Breastfeeding
408499|NCT01051843|Orofacial Difficulties
408500|NCT01051843|Rooming-in
408501|NCT01051843|Speech and Language Therapy
408502|NCT01051817|relapsing-remitting multiple sclerosis
408503|NCT01051817|RRMS
408504|NCT01051804|Dry eye
408505|NCT01051804|Visual Performance
408506|NCT01051791|RAD001
408507|NCT01051791|Everolimus
408508|NCT01051778|Recurrent abortion
408509|NCT01051778|Antiphospholipid syndrome
408510|NCT01051778|unfractionated heparin
408511|NCT01051778|Low Molecular Weight Heparin
408512|NCT01051752|Nontuberculous mycobacterial diseases
408513|NCT01051752|pharmacokinetics
408514|NCT01051752|pharmacodynamics
408515|NCT01051739|vision testing
408516|NCT01051739|perimetry
408517|NCT01051739|glaucoma
408518|NCT01051739|test variability
408519|NCT01051726|aromatherapy
408520|NCT01051726|childbirth
408521|NCT01051726|Obstetrics
408522|NCT01051726|Labour
408523|NCT01051726|Complementary Medicine
408524|NCT01051726|delivery, obstetric
408525|NCT01051713|obesity
408526|NCT01051713|behavioraladherence
408527|NCT01051713|weight loss
408528|NCT01051713|smartphone
408529|NCT01051700|GW786034
408530|NCT01051700|pazopanib
408531|NCT01051700|age-related macular degeneration
408532|NCT01051700|choroidal neovascularization
408533|NCT01051700|vascular endothelial growth factor
408534|NCT01051700|platelet derived growth factor
408535|NCT01051700|stem cell growth factor
408536|NCT01051700|repeat-dose
408537|NCT01051700|safety
408538|NCT01051700|tolerability
408539|NCT01051700|pharmacokinetics
408540|NCT01051687|vitiligo
408541|NCT01051674|Obesity
408542|NCT01051674|Type 2 diabetes
408543|NCT01051674|Fiber
408544|NCT01051674|Dietary fiber
408545|NCT01051674|Low-carbohydrate diet
408546|NCT01051674|High protein diet
408547|NCT01051661|Influenza
408548|NCT01051661|H1N1
408549|NCT01051661|Pandemic
408550|NCT01051648|Triamcinolone acetenoide
408551|NCT01051648|anterior vitrectomy
408552|NCT01051648|presence of vitreous in the anterior chamber.
408553|NCT01051648|effect of triamcinolone injection on IOP,intraocular infection
408554|NCT01051635|DNA Repair
408555|NCT01051635|DNA Damage
408556|NCT01051635|Advanced Cancer
408557|NCT01051635|Advanced Malignancies
408558|NCT01051635|Topoisomerase Inhibitor
408559|NCT01051622|PBMC (Peripheral Blood Mononuclear Cells)
408560|NCT01051622|Crohn's Disease
408561|NCT01051622|SPECT (Single Photon Emission Computerized Tomography)
408562|NCT01051609|Post Menopausal
408563|NCT01051609|Breast Cancer
408564|NCT01051596|metastatic
408565|NCT01051596|colorectal cancer
408566|NCT01051583|Neovascular glaucoma
408567|NCT01051583|diode laser
408568|NCT01051583|cyclophotocoagulation
408569|NCT01051583|Avastin
408570|NCT01051570|hormone-resistant prostate cancer
408571|NCT01051570|recurrent prostate cancer
408572|NCT01051570|stage IV prostate cancer
408573|NCT01051570|adenocarcinoma of the prostate
408574|NCT01051544|ITI
408575|NCT01051544|HAEMOPHILIA A
408576|NCT01051544|INHIBITORS
408577|NCT01051544|VWF/FVIII Concentrates
408578|NCT01051531|Schizophrenia
408579|NCT01051531|R092670
408580|NCT01051531|Paliperidone palmitate
408581|NCT01051531|Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
408582|NCT01051531|Intramuscular injection
408583|NCT01051505|Phase I
408584|NCT01051505|multiple ascending dose
408585|NCT01051505|Safety
408586|NCT01051505|Tolerability
408587|NCT01051505|Healthy Volunteer
408588|NCT01051479|PET Positron emission tomography
408589|NCT01051479|CT X-ray computed tomography
408590|NCT01051479|Patients with Locally Advanced Esophageal Cancer
408591|NCT01051440|lisdexamfetamine
408592|NCT01051440|vyvanse
408593|NCT01051440|bipolar disorder
408594|NCT01051440|depression
408595|NCT01051440|stimulant
408596|NCT01051440|magnetic resonance spectroscopy
408597|NCT01051440|functional magnetic resonance imaging
408598|NCT01051440|neuropsychological testing
408599|NCT01051427|Nasal packing
408600|NCT01051427|Haemostatic matrix
408601|NCT01051427|Epistaxis control
408602|NCT01051388|The efficacy of PPI
408603|NCT01051388|Patients receiving low-dose aspirin for vascular protection
408604|NCT01051375|anorexia nervosa
408605|NCT01051375|bulimia nervosa
408606|NCT01051375|EDNOS
408607|NCT01051362|Advanced Non-small Cell Lung Cancer
408608|NCT01051362|Pegylated liposomal doxorubicin
408609|NCT01051362|Carboplatin
408610|NCT01051362|Chemotherapy
408611|NCT01051349|MS
408612|NCT01051349|Multiple Sclerosis
408613|NCT01051336|TARIS Placebo
408614|NCT01051336|Bladder
408615|NCT01051336|Interstitial Cystitis
408616|NCT01051336|Normal Healthy Volunteers
408617|NCT01051297|Obstructive sleep apnea
408618|NCT01051297|venous thrombosis
408619|NCT01051297|pulmonary embolism
408620|NCT01051297|venous thromboembolism
408621|NCT01051284|Pancreas
408622|NCT01051284|Newly diagnosed
408623|NCT01051284|Cyberknife
408624|NCT01051284|Gemcitabine
408625|NCT01051271|metoclopramide
408626|NCT01051271|akathisia
408627|NCT01051271|midazolam
408628|NCT01051271|diphenhydramine
408629|NCT01051271|metoclopramide induced akathisia
408630|NCT01051258|Polymeric Lung Volume Reduction (PLVR)
408631|NCT01051258|Biologic Lung Volume Reduction (BLVR)
408632|NCT01051258|AeriSeal
408633|NCT01051258|treatment
408634|NCT01051258|device
408635|NCT01051258|breathing
408636|NCT01051258|COPD
408637|NCT01051258|emphysema
408638|NCT01051258|heterogeneous
408639|NCT01051258|homogeneous
408640|NCT01051258|Pathologic Processes
408641|NCT01051258|Respiratory Tract Diseases
408642|NCT01051258|Lung Diseases
408643|NCT01051258|Pulmonary Disease, Chronic Obstructive
408644|NCT01051245|Diabetes Mellitus, Type 2 [C18.452.394.750.149]
408645|NCT01051245|Case Management [N04.590.233.624.250]
408646|NCT01051245|Disease Management [N04.590.607]
408647|NCT01051245|Diabetes Complications [C19.246.099]
408648|NCT01051232|filibuvir
408649|NCT01051232|pharmacokinetics
408650|NCT01051232|Japanese
408651|NCT01051232|Asian
408652|NCT01051219|Losartan
408653|NCT01051219|Liver fibrosis
408654|NCT01051219|Nonalcoholic steatohepatitis
408655|NCT01051193|Seizures
408656|NCT01051193|oxcarbazepine
408657|NCT01051193|child
408658|NCT01051180|HEMORRHOIDS
408659|NCT01051180|TREATMENT
408660|NCT01051180|PILES
408661|NCT01051180|BLEEDING
408662|NCT01051180|HALO
408663|NCT01051154|Docosahexaenoic acid
408664|NCT01051154|Nutritional status
408665|NCT01051154|Acute lymphoblastic leukemia
408666|NCT01051154|Long chain polyunsaturated fatty acids
408667|NCT01051154|n-3 fatty acids
408668|NCT01051154|Remission-induction phase
408669|NCT01051141|alcohol use
408670|NCT01051141|brief intervention
408671|NCT01051141|risk behaviors
408672|NCT01051128|neurological disorders
408673|NCT01051128|multiple sclerosis
408674|NCT01051128|stroke
408675|NCT01051128|cerebral palsy
408676|NCT01051128|spinal cord
408677|NCT01051128|brain injuries
408678|NCT01051128|neurodegenerative diseases
408679|NCT01051115|CLL
408680|NCT01051115|refractory
408681|NCT01051115|dasatinib
408682|NCT01051115|fludarabine
408683|NCT01051089|type 2 diabetes mellitus
408684|NCT01051089|lifestyle modification
408685|NCT01051076|ITI
408686|NCT01051076|Haemophilia A
408687|NCT01051076|Inhibitors
408688|NCT01051076|Failed ITI
408689|NCT01051076|VWF/FVIII concentrates
408690|NCT01051063|adult
408691|NCT01051063|WT1
408692|NCT01051063|ASCI
408693|NCT01051063|complete remission with incomplete blood count recovery
408694|NCT01051063|partial remission
408695|NCT01051063|post-induction therapy
408696|NCT01051063|tumor antigen
408697|NCT01051063|Acute Myeloid Leukemia
408698|NCT01051063|Immunotherapy
408699|NCT01051050|Evidence based medicine
408700|NCT01051050|Improving surgical residents skills and application of EBM in surgical practice
408701|NCT01051037|lung tumors
408702|NCT01051037|central airways
408703|NCT01051024|Dietary supplement
408704|NCT01051024|Diamel
408705|NCT01051024|Polycystic Ovary Syndrome
408706|NCT01051024|Female Infertility
408707|NCT01050998|Rheumatoid Arthritis
408708|NCT01050998|Mavrilimumab
408709|NCT01050998|CAM-3001
408710|NCT01050985|advanced cancer
408711|NCT01050985|temsirolimus
408712|NCT01050985|capecitabine
408713|NCT01050972|Headache
408714|NCT01050972|Cervical Pain
408715|NCT01050972|Cognitive treatment
408716|NCT01050972|Relaxation
408717|NCT01050972|Exercise
408718|NCT01050946|Unrelated Umbilical Cord Blood Transplant(UCB)
408719|NCT01050946|CD34+ Selected mismatched related donor
408720|NCT01050946|Haploidentical donor
408721|NCT01050946|hematopoietic stem cell transplantation(HSCT)
408722|NCT01050946|ALL
408723|NCT01050946|Leukemia, Lymphocytic, Acute
408724|NCT01050946|AML
408725|NCT01050946|Leukemia, Myelocytic, Acute
408726|NCT01050946|CML
408727|NCT01050946|Leukemia, Myeloid, Chronic
408728|NCT01050946|NHL
408729|NCT01050946|Lymphoma, Non-Hodgkin
408730|NCT01050946|HL
408731|NCT01050946|Lymphoma, Hodgkins
408732|NCT01050933|Healthy volunteer
408733|NCT01050907|leishmaniasis
408734|NCT01050907|cutaneous disease
408735|NCT01050907|mucosal disease
408736|NCT01050907|miltefosine
408737|NCT01050894|osteoarthritis
408738|NCT01050881|blood donor notification
408739|NCT01050881|emotional response
408740|NCT01050881|variant Creutzfeldt-Jacob Disease
408741|NCT01050855|Non-malignant diseases
408742|NCT01050855|Immune deficiencies
408743|NCT01050855|Hemoglobinopathies
408744|NCT01050855|Reduced Intensity Conditioning(RIC)
408745|NCT01050829|Magnetic resonance imaging
408746|NCT01050829|Tumor
408747|NCT01050829|Contrast media
408748|NCT01050829|Gadobutrol
408749|NCT01050816|articular cartilage defects
408750|NCT01050816|ACI
408751|NCT01050816|ankle joint
408752|NCT01050816|chondron
408753|NCT01050803|Diabetes Mellitus
408754|NCT01050803|Intervention studies
408755|NCT01050803|Program effectiveness
408756|NCT01050790|stage I multiple myeloma
408757|NCT01050790|stage II multiple myeloma
408758|NCT01050790|stage III multiple myeloma
408759|NCT01050777|Cutaneous Leishmaniasis caused by l. tropica
408760|NCT01050751|Bioavailability
408761|NCT01050751|Bioequivalence
408762|NCT01050751|Lersivirine
408763|NCT01050751|UK-453
408764|NCT01050751|061
408765|NCT01050751|Pharmacokinetics
408766|NCT01050725|proteome
408767|NCT01050725|biomarkers
408768|NCT01050725|radiotherapy
408769|NCT01050725|cancer
408770|NCT01050699|critical illness
408771|NCT01050699|sleep
408772|NCT01050699|polysomnography
408773|NCT01050699|inflammatory cytokines
408774|NCT01050699|dexmedetomidine
408775|NCT01050699|acute lung injury
408776|NCT01050699|acute respiratory distress syndrome
408777|NCT01050699|midazolam
408778|NCT01050699|fentanyl
408779|NCT01050699|cytokines
408780|NCT01050686|ileostomy reversal
408781|NCT01050686|subcutaneous drain
408782|NCT01050686|hospital stay
408783|NCT01050686|postoperative wound infection
408784|NCT01050686|patients with elective ileostomy reversal
408785|NCT01050673|VERSAJET hydro-surgical debridement
408786|NCT01050673|traumatic wound
408787|NCT01050660|Parenteral nutrition associated liver disease
408788|NCT01050660|Direct bilirubin
408789|NCT01050660|Intravenous fat emulsion
408790|NCT01050660|Very low birth weight infants
408791|NCT01050660|PNAC
408792|NCT01050634|Aromatase inhibitor
408793|NCT01050634|Switch after Tamoxifen
408794|NCT01050634|Quality of Life
408795|NCT01050634|Safety
408796|NCT01050621|ascorbic acid
408797|NCT01050621|vitamin C
408798|NCT01050621|antioxidants
408799|NCT01050621|redox therapy
408800|NCT01050621|cytotoxic chemotherapy
408801|NCT01050608|Alcohol Rub
408802|NCT01050608|Hand Hygiene
408803|NCT01050608|Provider Feedback
408804|NCT01050608|Health Care Associated Infections
408805|NCT01050595|Intensive Care Unit
408806|NCT01050595|Constipation
408807|NCT01050595|Bowel Management
408808|NCT01050582|Schizophrenia
408809|NCT01050582|Bipolar Disorder
408810|NCT01050582|Autistic Disorder
408811|NCT01050582|Conduct and Other Disruptive Behavior Disorders
408812|NCT01050582|Risperidone
408813|NCT01050582|RISPERDAL
408814|NCT01050582|Antipsychotic Agents
408815|NCT01050582|Prolactin
408816|NCT01050582|Pediatrics
408817|NCT01050569|Smoking Cessation
408818|NCT01050569|Nicotine Free Cigarettes
408819|NCT01050556|arsenic
408820|NCT01050556|folate
408821|NCT01050556|folic acid
408822|NCT01050556|creatine
408823|NCT01050556|arsenicosis
408824|NCT01050556|nutrition
408825|NCT01050530|Cirrhosis
408826|NCT01050530|ascites
408827|NCT01050530|Tolvaptan
408828|NCT01050530|OPC-41061
408829|NCT01050491|asthma
408830|NCT01050491|airway remodeling
408831|NCT01050491|airway obstruction
408832|NCT01050478|acute agitation
408833|NCT01050478|aggression
408834|NCT01050478|psychosis
408835|NCT01050478|paliperidone extended release
408836|NCT01050465|HIV
408837|NCT01050465|Knee pain
408838|NCT01050465|Colonoscopy
408839|NCT01050465|Mammography
408840|NCT01050465|Vaccination
408841|NCT01050439|Allogeneic Stem Cell Transplant
408842|NCT01050439|Unrelated donor
408843|NCT01050439|Cord blood donor
408844|NCT01050413|Thymidine Kinase 1 activity
408845|NCT01050413|diagnosis
408846|NCT01050413|prognosis
408847|NCT01050413|follow-up
408848|NCT01050400|CYP2D6
408849|NCT01050400|Genetic Polymorphism
408850|NCT01050400|codeine
408851|NCT01050400|breastfeeding
408852|NCT01050387|Vitamin D Deficiency
408853|NCT01050387|VDD
408854|NCT01050387|Vitamin D Supplementation
408855|NCT01050387|Vitamin D Binding Protein
408856|NCT01050387|DBP
408857|NCT01050387|Nutritional rickets
408858|NCT01050387|rickets
408859|NCT01050387|25hydroxyvitamin D
408860|NCT01050387|25OHD
408861|NCT01050387|1,25OH2D
408862|NCT01050387|vitamin D metabolites
408863|NCT01050387|PTH
408864|NCT01050387|vitamin D homeostasis
408865|NCT01050361|To reduce perioperative morbidity and mortality associated with congestive heart failure for non-cardiac surgeries
408866|NCT01050322|receptor HER two positive
408867|NCT01050322|lapatinib
408868|NCT01050322|metastatic breast cancer
408869|NCT01050296|Neuroblastoma
408870|NCT01050296|Retinoblastoma
408871|NCT01050296|Osteosarcoma
408872|NCT01050296|Rhabdomyosarcoma
408873|NCT01050296|Ewing sarcoma
408874|NCT01050296|Non-rhabdomyosarcoma soft tissue sarcoma
408875|NCT01050296|Adrenocortical tumors
408876|NCT01050296|Liver malignancies
408877|NCT01050283|Advanced pancreatic adenocarcinoma
408878|NCT01050244|Soy protein
408879|NCT01050244|Milk protein
408880|NCT01050244|Neuropathic pain
408881|NCT01050231|stroke
408882|NCT01050231|cerebrovascular accident
408883|NCT01050231|robot
408884|NCT01050218|Diabetic Peripheral Neuropathy
408885|NCT01050205|Diabetes Prevention
408886|NCT01050205|Cardiovascular Risk Reduction
408887|NCT01050205|Lifestyle Intervention
408888|NCT01050205|Group Lifestyle Balance
408889|NCT01050192|Prematurity
408890|NCT01050192|Nutrition
408891|NCT01050192|Breast Feeding
408892|NCT01050179|chemosensitivity
408893|NCT01050166|islet transplantation
408894|NCT01050166|magnetic resonance
408895|NCT01050166|Type 1 DM
408896|NCT01050153|Prevention of venous thromboembolism
408897|NCT01050140|fructose
408898|NCT01050140|fatty liver disease
408899|NCT01050140|diet
408900|NCT01050127|Pharmacokinetics
408901|NCT01050127|Pharmacodynamics
408902|NCT01050127|Drug Safety
408903|NCT01050127|Phase 1 Clinical Trial
408904|NCT01050114|Botulinum Toxin
408905|NCT01050114|Oxybutynin
408906|NCT01050114|Overactive Bladder
408907|NCT01050114|Spinal Cord Injury
408908|NCT01050114|Urinary Incontinence
408909|NCT01050114|Nerve Growth Factor
408910|NCT01050114|Urine Biomarkers
408911|NCT01050101|Satiety
408912|NCT01050101|Fiber
408913|NCT01050101|Nutrition
408914|NCT01050101|Pre- and post-menopausal women
408915|NCT01050101|overweight
408916|NCT01050088|clubfoot
408917|NCT01050088|casting
408918|NCT01050088|ponseti
408919|NCT01050088|discomfort
408920|NCT01050075|male breast cancer
408921|NCT01050075|neurotoxicity
408922|NCT01050075|recurrent breast cancer
408923|NCT01050036|Leukemia, Myeloid
408924|NCT01050036|Primary complete remission
408925|NCT01050036|Favorable karyotype
408926|NCT01050036|Autologous hematopoietic cell transplantation
408927|NCT01050036|Hematopoietic cell transplantation
408928|NCT01050023|venous stasis ulcer
408929|NCT01050023|wound healing
408930|NCT01050023|Provant Wound Closure System
408931|NCT01050023|radiofrequency
408932|NCT01050023|Provant
408933|NCT01050023|pain relief
408934|NCT01050010|rheumatoid arthritis
408935|NCT01050010|clinical remission
408936|NCT01050010|synovitis
408937|NCT01050010|dedicated extremity MRI
408938|NCT01049997|Non ST Elevation Myocardial Infarction (NSTEMI)
408939|NCT01049997|Elderly
408940|NCT01049997|Frailty
408941|NCT01049984|Parkinson's Disease
408942|NCT01049984|UPDRS
408943|NCT01049984|Clinical Global Evaluation Illness Severity score
408944|NCT01049984|Clinical Global Evaluation Improvement
408945|NCT01049984|B-SIT
408946|NCT01049984|SCOPA - Sleep Daytime Sleepiness
408947|NCT01049984|PDQ -39
408948|NCT01049984|SCOPA - Cognition
408949|NCT01049984|Levodopa
408950|NCT01049984|rasagiline
408951|NCT01049984|Dopamine Agonist Therapy
408952|NCT01049984|monoamine oxidase type B inhibitor
408953|NCT01049971|colorectal surgery
408954|NCT01049971|wound infection
408955|NCT01049971|wound protector
408956|NCT01049971|laparoscopy
408957|NCT01049971|surgical site infection after laparoscopic colorectal surgery with minilaparotomy
408958|NCT01049958|asynchrony
408959|NCT01049958|mechanical ventilation
408960|NCT01049958|blunt trauma
408961|NCT01049932|HIV
408962|NCT01049932|Human Immunodeficiency Virus (HIV)
408963|NCT01049932|HIV Seronegativity
408964|NCT01049919|Critical Limb Ischemia
408965|NCT01049919|Peripheral Arterial Disease
408966|NCT01049919|Peripheral Vascular Disease
408967|NCT01049919|CLI
408968|NCT01049919|PAD
408969|NCT01049919|PVD
408970|NCT01049919|Angiogenesis
408971|NCT01049919|Stem Cells
408972|NCT01049919|Cell Therapy
408973|NCT01049919|Limb Salvage
408974|NCT01049919|Amputation
408975|NCT01049919|Leg Pain
408976|NCT01049906|foot surgery
408977|NCT01049906|ankle surgery
408978|NCT01049906|Patients scheduled for foot and ankle surgery
408979|NCT01049880|Ascorbic Acid
408980|NCT01049880|Gemcitabine
408981|NCT01049854|unrelated donor transplant
408982|NCT01049854|CD34 selection
408983|NCT01049841|pediatric
408984|NCT01049841|children
408985|NCT01049841|perifosine
408986|NCT01049841|temsirolimus
408987|NCT01049841|recurrent
408988|NCT01049841|progressive
408989|NCT01049841|09-124
408990|NCT01049828|Tinnitus
408991|NCT01049828|fcMRI
408992|NCT01049828|Neural Connectivity
408993|NCT01049828|Bother
408994|NCT01049815|hemodialysis
408995|NCT01049815|intimal media thickness
408996|NCT01049802|stroke
408997|NCT01049802|hemiplegia
408998|NCT01049802|TMS
408999|NCT01049789|youth
409000|NCT01049789|HIV
409001|NCT01049789|Depression
409002|NCT01049789|Cognitive Behavioral Therapy
409003|NCT01049789|Medication management
409004|NCT01049776|Lung Cancer Non Small Cell
409005|NCT01049763|obese adult
409006|NCT01049763|non obese healthy volunteers
409007|NCT01049763|oseltamivir carboxylate
409008|NCT01049763|pharmacokinetics
409009|NCT01049763|healthy volunteers
409010|NCT01049750|type 2 diabetes mellitus
409011|NCT01049750|male
409012|NCT01049750|erectile dysfunction
409013|NCT01049724|Myopia
409014|NCT01049724|refractive surgery
409015|NCT01049724|LASIK
409016|NCT01049724|PRK
409017|NCT01049724|Lacritin
409018|NCT01049724|Heparanase
409019|NCT01049711|erythropoietin
409020|NCT01049711|hemodialysis
409021|NCT01049711|cost utility
409022|NCT01049711|incremental cost-effectiveness ratio
409023|NCT01049711|Quality adjusted life year
409024|NCT01049711|quality of life
409025|NCT01049698|Obesity
409026|NCT01049698|Overweight
409027|NCT01049698|Older adults
409028|NCT01049698|resistance training
409029|NCT01049698|exercise
409030|NCT01049685|HIV
409031|NCT01049685|Antiretroviral Therapy, Highly Active
409032|NCT01049685|Efavirenz
409033|NCT01049685|Lopinavir
409034|NCT01049685|Comparative Effectiveness Research
409035|NCT01049685|Treatment Naive
409036|NCT01049659|pregnancy
409037|NCT01049659|iodine deficiency
409038|NCT01049659|neuropsychological development
409039|NCT01049646|renin-angiotensin system
409040|NCT01049646|apelin
409041|NCT01049646|systemic haemodynamics
409042|NCT01049633|Insulin dependence
409043|NCT01049633|Hypoglycemia
409044|NCT01049633|Hypoglycemia unawareness
409045|NCT01049633|Islet transplantation
409046|NCT01049620|XELOX
409047|NCT01049620|RAD001
409048|NCT01049620|phase 1
409049|NCT01049607|Patients undergoing hepatic resection
409050|NCT01049581|Gross motor function performance
409051|NCT01049581|pediatric aquatic therapy
409052|NCT01049581|spastic cerebral palsy
409053|NCT01049568|HIV
409054|NCT01049568|Cell phone
409055|NCT01049568|HAART
409056|NCT01049555|alzheimer
409057|NCT01049555|apathy
409058|NCT01049555|actigraphy
409059|NCT01049542|Astressin 2B
409060|NCT01049542|Forearm blood flow
409061|NCT01049542|vascular
409062|NCT01049542|plethysmography
409063|NCT01049542|heart failure
409064|NCT01049529|Docosahexaenoic acid
409065|NCT01049529|n-3 Long Chain Polyunsaturated Fatty Acids
409066|NCT01049529|omega 3 fatty acids
409067|NCT01049529|neonates
409068|NCT01049529|clinical outcomes
409069|NCT01049529|critically ill patients
409070|NCT01049529|Inflammatory and antiinflammatory cytokines
409071|NCT01049529|Length of intensive care stay
409072|NCT01049516|Military
409073|NCT01049516|Combat
409074|NCT01049516|Psychological Treatment
409075|NCT01049516|Psychotherapy
409076|NCT01049516|Trauma
409077|NCT01049516|Posttraumatic Stress
409078|NCT01049516|Posttraumatic Stress Disorder
409079|NCT01049516|PTSD
409080|NCT01049516|Prolonged Exposure
409081|NCT01049516|Exposure therapy
409082|NCT01049516|Behavior Therapy
409083|NCT01049516|Cognitive Behavior Therapy
409084|NCT01049516|Post-Traumatic Stress Disorders
409085|NCT01049516|Stress Disorders, Post-traumatic
409086|NCT01049503|Dentifrices
409087|NCT01049503|Fluoride
409088|NCT01049503|Nails
409089|NCT01049503|Plaque
409090|NCT01049490|Intradermal vaccination, H1N1, microneedle
409091|NCT01049477|Pregnancy
409092|NCT01049477|Cesarean Section
409093|NCT01049464|Atrial fibrillation
409094|NCT01049464|Hemodynamically unstable patients
409095|NCT01049464|Magnesium sulfate
409096|NCT01049464|Septic shock
409097|NCT01049464|Medical intensive care unit
409098|NCT01049464|New onset atrial fibrillation
409099|NCT01049464|Critically ill patients
409100|NCT01049451|Multiple Sclerosis
409101|NCT01049451|ACTH
409102|NCT01049451|Steroids
409103|NCT01049438|MRSA
409104|NCT01049438|Methicillin Resistant Staphylococcus aureus
409105|NCT01049438|Staphylococcus aureus
409106|NCT01049438|Skin Infections
409107|NCT01049438|Body Decolonization
409108|NCT01049425|anthracycline-free
409109|NCT01049425|OncotypDX
409110|NCT01049425|taxane
409111|NCT01049425|Her2 negative breast cancer
409112|NCT01049386|intestinal permeability
409113|NCT01049386|health
409114|NCT01049386|sugar absorption
409115|NCT01049386|intestinal permeability examined in different men (lean vs obese) and different conditions (no breakfast and high-fat breakfast)
409116|NCT01049373|low-back
409117|NCT01049373|pain
409118|NCT01049373|chronic
409119|NCT01049373|constitution
409120|NCT01049373|diathesism
409121|NCT01049373|homoeopathy
409122|NCT01049373|fixed combination
409123|NCT01049373|herbal preparation
409124|NCT01049373|chronic low back pain lasting more than 6 months
409125|NCT01049360|Chronic Obstructive Pulmonary Disease
409126|NCT01049360|COPD
409127|NCT01049360|Chronic Bronchitis
409128|NCT01049360|Emphysema
409129|NCT01049360|Airflow Obstruction, Chronic
409130|NCT01049360|Chronic Airflow Obstruction
409131|NCT01049360|Chronic Obstructive Airway Disease
409132|NCT01049360|Chronic Obstructive Lung Disease
409133|NCT01049347|depression
409134|NCT01049321|Dietary Approach to Stop Hypertension
409135|NCT01049321|weight
409136|NCT01049321|coagulation
409137|NCT01049321|DASH eating pattern.
409138|NCT01049308|heart failure
409139|NCT01049308|cognitive disorders
409140|NCT01049308|medication adherence
409141|NCT01049308|patient readmissions
409142|NCT01049295|taxanes
409143|NCT01049295|breast cancer
409144|NCT01049295|n3 fatty acids
409145|NCT01049295|inflammation
409146|NCT01049282|safety
409147|NCT01049282|immunogenicity
409148|NCT01049282|adjuvanted TB subunit vaccine
409149|NCT01049269|Body Scanning
409150|NCT01049269|Body Fat
409151|NCT01049269|Body Volume
409152|NCT01049269|Obesity
409153|NCT01049269|No Conditions
409154|NCT01049256|Periodic breathing
409155|NCT01049256|Heart Failure
409156|NCT01049256|Chemoreflex
409157|NCT01049256|Chemosensitivity
409158|NCT01049243|Atopic Dermatitis
409159|NCT01049243|Open-Label
409160|NCT01049243|Topical
409161|NCT01049243|Cream
409162|NCT01049243|Eczema
409163|NCT01049243|Vanos
409164|NCT01049230|proton beam radiation
409165|NCT01049230|CNS germ cell tumor
409166|NCT01049217|neuropathy
409167|NCT01049217|pain
409168|NCT01049217|HIV-1
409169|NCT01049217|HIV Infections
409170|NCT01049204|HIV
409171|NCT01049204|HIV-1 Infections
409172|NCT01049191|Osteoporosis
409173|NCT01049191|Fracture
409174|NCT01049191|microMRI
409175|NCT01049191|Bone architecture
409176|NCT01049191|Bone matrix
409177|NCT01049191|Bone and Bones
409178|NCT01049191|Magnetic Resonance Imaging
409179|NCT01049178|antioxidant enzymes
409180|NCT01049178|asthma
409181|NCT01049178|silymarin
409182|NCT01049178|RCT
409183|NCT01049152|Diabetes mellitus
409184|NCT01049152|ESRD
409185|NCT01049152|CGM
409186|NCT01049152|Inflammation markers
409187|NCT01049152|Hemodialysis
409188|NCT01049152|Diabetic patients
409189|NCT01049152|Nondiabetic patients
409190|NCT01049152|All with ESRD
409191|NCT01049152|All undergone hemodialysis
409192|NCT01049139|vaccination
409193|NCT01049139|HIV prevention
409194|NCT01049139|YMSM
409195|NCT01049139|youth
409196|NCT01049139|HIV Preventative Vaccine
409197|NCT01049126|Late Stage
409198|NCT01049113|Lymphoma
409199|NCT01049113|B-cell Acute Lymphocytic Leukemia
409200|NCT01049113|ALL
409201|NCT01049100|Surgical Staging
409202|NCT01049100|Cervical Cancer
409203|NCT01049100|Chemoradiation
409204|NCT01049100|Outcome
409205|NCT01049100|Toxicity
409206|NCT01049087|plasma volume
409207|NCT01049087|technetium-labeled albumin
409208|NCT01049087|radioiodine-labeled albumin
409209|NCT01049087|Healthy volunteers
409210|NCT01049074|Low Back Pain
409211|NCT01049074|Acupuncture
409212|NCT01049074|RCT
409213|NCT01049061|Cancer
409214|NCT01049061|FRα
409215|NCT01049048|Endothelial Function
409216|NCT01049048|Arterial stiffness
409217|NCT01049048|Vitamin D
409218|NCT01049035|Meningitis
409219|NCT01049035|Meningococcal Infection
409220|NCT01049035|Neisseria meningitidis
409221|NCT01049035|Tetravalent Meningococcal Vaccine
409222|NCT01049022|Pharmacokinetics
409223|NCT01049009|Nitric Oxide
409224|NCT01049009|Adrenergic beta-Antagonists
409225|NCT01049009|Antihypertensive Agents
409226|NCT01049009|Vasodilator Agents
409227|NCT01049009|Anti-Arrhythmia Agents
409228|NCT01049009|Sympatholytics
409229|NCT01049009|Vascular Resistance
409230|NCT01049009|Neurotransmitter Agents
409231|NCT01049009|Cardiovascular Diseases
409232|NCT01049009|Metoprolol succinate
409233|NCT01049009|Therapeutic Uses
409234|NCT01049009|Metoprolol
409235|NCT01049009|Vascular Diseases
409236|NCT01049009|Nebivolol
409237|NCT01049009|Cardiovascular Agents
409238|NCT01049009|Endothelium-Dependent Relaxing Factors
409239|NCT01048996|Acute Lung Injury
409240|NCT01048996|Acute Respiratory Distress Syndrome
409241|NCT01048996|Genetic Variability
409242|NCT01048996|Plasma Biomarkers
409243|NCT01048996|Pediatrics
409244|NCT01048983|Lung Cancer
409245|NCT01048983|NSCLC
409246|NCT01048983|Concurrent Chemoradiation Therapy
409247|NCT01048983|Side Effects
409248|NCT01048983|Armodafinil
409249|NCT01048983|Nuvigil
409250|NCT01048983|Bupropion
409251|NCT01048983|Wellbutrin
409252|NCT01048983|Wellbutrin SR
409253|NCT01048983|Zyban
409254|NCT01048983|Curcumin
409255|NCT01048983|Minocycline
409256|NCT01048983|Dynacin
409257|NCT01048983|Minocin
409258|NCT01048983|Minocin PAC
409259|NCT01048983|Myrac
409260|NCT01048983|Solodyn
409261|NCT01048970|Lung cancer
409262|NCT01048970|Eicosapentaenoic acid oral supplementation
409263|NCT01048970|Weight loss
409264|NCT01048970|Toxicity
409265|NCT01048970|Body composition
409266|NCT01048970|Inflammatory response
409267|NCT01048957|Nicotine
409268|NCT01048957|Craving
409269|NCT01048957|fMRI
409270|NCT01048957|EEG
409271|NCT01048957|Real Time fMRI Feedback
409272|NCT01048944|Electroencephalography
409273|NCT01048944|nicotine
409274|NCT01048944|bupropion
409275|NCT01048944|attention
409276|NCT01048944|drug withdrawal symptoms
409277|NCT01048931|Single-port, laparoscopic-assisted, vaginal hysterectomy
409278|NCT01048918|Circulating tumor cells in breast cancer
409279|NCT01048905|Pulmonary Hypertension
409280|NCT01048905|Sickle Cell Disease
409281|NCT01048905|Thalassemia
409282|NCT01048892|recurrent neuroblastoma
409283|NCT01048892|previously treated childhood rhabdomyosarcoma
409284|NCT01048892|recurrent childhood rhabdomyosarcoma
409285|NCT01048892|recurrent Wilms tumor and other childhood kidney tumors
409286|NCT01048892|recurrent retinoblastoma
409287|NCT01048892|recurrent adrenocortical carcinoma
409288|NCT01048892|recurrent gastrointestinal carcinoid tumor
409289|NCT01048879|oseltamivir
409290|NCT01048879|influenza
409291|NCT01048879|continuous renal replacement therapy
409292|NCT01048879|extracorporeal membrane oxygenation
409293|NCT01048879|pharmacokinetics
409294|NCT01048853|Cervix
409295|NCT01048853|Stage IA2 or IB1 Carcinoma
409296|NCT01048853|Conservative Surgery
409297|NCT01048853|Cervix Cancer recurrence
409298|NCT01048853|Quality of Life Factors
409299|NCT01048853|Pelvic lymph nodes
409300|NCT01048853|Pelvic Lymphadenectomy
409301|NCT01048853|parametrium
409302|NCT01048853|Cervical cone biopsy
409303|NCT01048853|Endocervical curettage
409304|NCT01048853|ECC
409305|NCT01048840|Gastroesophageal Reflux
409306|NCT01048827|AML
409307|NCT01048827|autologous transplant
409308|NCT01048801|History of fever
409309|NCT01048801|measured fever
409310|NCT01048788|Cirrhosis
409311|NCT01048788|ascites
409312|NCT01048788|Tolvaptan
409313|NCT01048788|OPC-41061
409314|NCT01048775|bispectral index
409315|NCT01048775|cardiac surgery
409316|NCT01048775|asymmetry
409317|NCT01048762|pulmonary cancer
409318|NCT01048762|radically operated
409319|NCT01048762|exercise training
409320|NCT01048762|dyspnea counseling
409321|NCT01048762|quality of life
409322|NCT01048762|physical therapy
409323|NCT01048749|Low back pain
409324|NCT01048749|nerve root compression
409325|NCT01048749|spinal height
409326|NCT01048736|obesity
409327|NCT01048736|exercise
409328|NCT01048736|intensity
409329|NCT01048736|weight loss
409330|NCT01048736|diet
409331|NCT01048723|Soft Tissue
409332|NCT01048723|Retroperitoneal
409333|NCT01048723|resectable
409334|NCT01048710|Knee osteoarthritis
409335|NCT01048710|knee osteonecrosis
409336|NCT01048710|osteotomy
409337|NCT01048697|Obesity
409338|NCT01048697|Pharmacokinetics
409339|NCT01048697|Pharmacodynamics
409340|NCT01048697|Dose individualization
409341|NCT01048697|Tuberculosis
409342|NCT01048684|Brain tumor
409343|NCT01048684|Intracranial pressure
409344|NCT01048671|HIV
409345|NCT01048658|Sevoflurane
409346|NCT01048658|anesthesia
409347|NCT01048658|abortion
409348|NCT01048658|blood loss
409349|NCT01048645|All-trans retinoic acid
409350|NCT01048645|non-small cell lung cancer
409351|NCT01048645|retinoic acid receptor beta
409352|NCT01048645|chemotherapy
409353|NCT01048632|Neonates with HLHS or variant with plan to undergo Norwood Procedure
409354|NCT01048619|Myelodysplastic Syndrome
409355|NCT01048619|MDS
409356|NCT01048606|Postmenopause
409357|NCT01048606|Overweight
409358|NCT01048606|Women
409359|NCT01048606|Phytoestrogens
409360|NCT01048606|Exercise
409361|NCT01048606|Cardiovascular Diseases
409362|NCT01048606|Risk Factors
409363|NCT01048606|Aging
409364|NCT01048593|ocular inflammation cataract surgery
409365|NCT01048593|post cataract surgery inflammation
409366|NCT01048580|Perifosine
409367|NCT01048580|Capecitabine
409368|NCT01048580|Colon Cancer
409369|NCT01048567|Antibiotics
409370|NCT01048567|Diarrhea
409371|NCT01048567|Clostridium difficile
409372|NCT01048567|Probiotics
409373|NCT01048567|Prevention & control
409374|NCT01048554|Melanoma
409375|NCT01048554|Brain mets
409376|NCT01048554|Bevacizumab
409377|NCT01048554|Temozolomide
409378|NCT01048554|Avastin
409379|NCT01048554|Temodar
409380|NCT01048554|Melanoma with brain mets
409381|NCT01048528|immune response to vaccines
409382|NCT01048528|stress management
409383|NCT01048528|perceived risk for breast cancer
409384|NCT01048515|Caffeine
409385|NCT01048515|Physiological Effects of Drugs
409386|NCT01048515|Central Nervous System Agents
409387|NCT01048502|healthy volunteer
409388|NCT01048476|AMD
409389|NCT01048463|gastric cancer
409390|NCT01048463|colorectal cancer
409391|NCT01048463|chemotherapy
409392|NCT01048463|eicosapentaenoic acid
409393|NCT01048463|enteral nutrition
409394|NCT01048450|arthritis
409395|NCT01048450|degeneration
409396|NCT01048424|Urinary incontinence
409397|NCT01048424|Paced respiration
409398|NCT01048411|stroke rehabilitation
409399|NCT01048411|outcome
409400|NCT01048411|barthel-index
409401|NCT01048411|geriatrics
409402|NCT01048411|elderly
409403|NCT01048398|ceophalic version
409404|NCT01048398|breech presentation
409405|NCT01048398|pregnancy
409406|NCT01048398|remifentanil
409407|NCT01048398|paracetamol
409408|NCT01048385|Mitochondrial dysfunction
409409|NCT01048385|Mitochondrial nutrients
409410|NCT01048385|Aneuploidy
409411|NCT01048385|Meiotic Spindle
409412|NCT01048385|Coenzyme Q10
409413|NCT01048385|Electron transfer chain
409414|NCT01048372|HIV
409415|NCT01048372|monoclonal antibody
409416|NCT01048372|immune therapy
409417|NCT01048372|pathogenesis
409418|NCT01048372|cytotoxic T lymphocyte
409419|NCT01048372|anti-CD4
409420|NCT01048372|anti-self
409421|NCT01048372|viral replication
409422|NCT01048372|Acute Infection
409423|NCT01048359|Drug abuse, injury, trauma, screening, brief intervention.
409424|NCT01048346|employment, disabilities
409425|NCT01048333|Chronic Obstructive Pulmonary Disease
409426|NCT01048333|Onset of effect
409427|NCT01048333|COPD
409428|NCT01048333|Oxis Turbuhaler
409429|NCT01048320|pancreatic cancer
409430|NCT01048320|toxicity
409431|NCT01048320|chemotherapy
409432|NCT01048320|dose finding
409433|NCT01048307|prontosan
409434|NCT01048307|wound cleansing
409435|NCT01048307|wound irrigation
409436|NCT01048307|phmb
409437|NCT01048307|polihexanide
409438|NCT01048307|betaine
409439|NCT01048294|Seasonal affective disorder
409440|NCT01048294|phototherapy
409441|NCT01048294|circadian rhythms
409442|NCT01048294|blue enriched light
409443|NCT01048294|melanopsin
409444|NCT01048294|Primary disease: Seasonal Affective Disorder, winter type
409445|NCT01048268|T1DM
409446|NCT01048268|T2DM
409447|NCT01048268|GIP
409448|NCT01048268|Glucose-dependent insulinotropic polypeptide
409449|NCT01048268|Incretin
409450|NCT01048216|colorectal liver cancer
409451|NCT01048216|metastatic
409452|NCT01048216|radiation therapy
409453|NCT01048203|14C ABR 215050 Metabolism and Mass Balance Study
409454|NCT01048203|tasquinimod
409455|NCT01048203|Metabolic pattern of 14C ABR-215050
409456|NCT01048190|Inactivated Poliomyelitis Vaccine
409457|NCT01048190|Sabin Strains
409458|NCT01048190|poliomyelitis
409459|NCT01048177|vulvodynia
409460|NCT01048177|interstitial cystitis
409461|NCT01048177|pelvic pain
409462|NCT01048164|Massage
409463|NCT01048164|Relaxation
409464|NCT01048151|Prostate
409465|NCT01048151|TNFerade Biologic
409466|NCT01048138|Biperiden
409467|NCT01048138|Post-traumatic Epilepsy
409468|NCT01048138|Traumatic Brain Injury
409469|NCT01048125|Stress-induced cardiomyopathy
409470|NCT01048125|Takotsubo cardiomyopathy
409471|NCT01048112|campylobacter
409472|NCT01048112|gastroenteritis
409473|NCT01048112|challenge models
409474|NCT01048099|Breast Cancer
409475|NCT01048099|Metastatic
409476|NCT01048099|PRO Onc Assay
409477|NCT01048099|FISH Testing
409478|NCT01048099|HER Negative
409479|NCT01048099|HER Overexpression
409480|NCT01048099|HER Activation
409481|NCT01048086|neuroblastoma
409482|NCT01048086|neuroendocrine tumor
409483|NCT01048086|NET
409484|NCT01048086|retinoic acid
409485|NCT01048073|lower respiratory tract infection
409486|NCT01048073|non influenza
409487|NCT01048073|PCR assay
409488|NCT01048047|aliskiren
409489|NCT01048047|amlodipine
409490|NCT01048047|hypertension
409491|NCT01048047|ankle-foot volume
409492|NCT01048047|mild and moderate hypertension
409493|NCT01048034|Myelodysplastic syndrome
409494|NCT01048034|Chronic myelomonocytic leukemia
409495|NCT01048034|Transfusion therapy
409496|NCT01048034|Transfusion dependency
409497|NCT01048034|Hypomethylating therapy
409498|NCT01048034|Azacitidine
409499|NCT01048034|DNA-methylation
409500|NCT01048034|Epigenetic modifications
409501|NCT01048021|Measurement of lung mechanics (FEV1, FVC and PEF)
409502|NCT01048008|Glioblastoma multiforme
409503|NCT01048008|Advanced cancers
409504|NCT01048008|Brain Neoplasms, Malignant, Primary
409505|NCT01048008|Brain Tumor, Recurrent
409506|NCT01048008|Advanced cancer
409507|NCT01047982|gestational diabetes
409508|NCT01047982|macrosomia
409509|NCT01047982|hypertension in pregnancy
409510|NCT01047982|HOMA-IR
409511|NCT01047982|obesity
409512|NCT01047969|locally invasive high-risk rectal adenocarcinoma
409513|NCT01047956|Methadone
409514|NCT01047956|NAC
409515|NCT01047956|opioids
409516|NCT01047930|Insomnia
409517|NCT01047930|Smoking
409518|NCT01047930|Cue reactivity
409519|NCT01047930|Exercise timing
409520|NCT01047930|Acute nicotine withdrawal
409521|NCT01047930|Mood disturbances
409522|NCT01047930|Smoking abstinence
409523|NCT01047930|Exercise intensity
409524|NCT01047930|Altered sleep
409525|NCT01047930|Exercise duration
409526|NCT01047930|Nonpharmacologic behavioral treatment
409527|NCT01047930|Smoking cessation
409528|NCT01047930|Exercise Test
409529|NCT01047930|Polysomnography
409530|NCT01047917|Meditation
409531|NCT01047917|Relaxation Therapy
409532|NCT01047917|Quality of Life
409533|NCT01047865|Type 1 Diabetes (T1D)
409534|NCT01047865|Autoimmunity
409535|NCT01047852|chronic respiratory disorders
409536|NCT01047852|hypercapnic respiratory failure
409537|NCT01047852|noninvasive ventilation
409538|NCT01047839|Pediatric
409539|NCT01047839|Japanese Encephalitis Vaccine
409540|NCT01047839|non-endemic countries
409541|NCT01047839|to assess immunogenicity of purified inactivated Japanese Encephalitis (JE) vaccine IC51
409542|NCT01047826|Fractured Tibia
409543|NCT01047826|Expert Tibial Nail
409544|NCT01047826|Minimally Invasive Plate Osteosynthesis (M.I.P.O)
409545|NCT01047826|Intramedullary Nailing
409546|NCT01047826|Locked Plate
409547|NCT01047826|distal third
409548|NCT01047826|43-A
409549|NCT01047813|Cognitive performance
409550|NCT01047813|Type 2 diabetes
409551|NCT01047813|Blood glucose
409552|NCT01047800|Functional gastrointestinal disorder
409553|NCT01047800|GERD
409554|NCT01047800|reflux
409555|NCT01047800|irritable bowel syndrome
409556|NCT01047800|Functional dyspepsia
409557|NCT01047800|postprandial fullness
409558|NCT01047800|counseling
409559|NCT01047800|service
409560|NCT01047787|Sleep apnea
409561|NCT01047787|Cheyne-Stokes Respiration
409562|NCT01047787|Congestive Heart Failure
409563|NCT01047774|soy protein
409564|NCT01047774|diet
409565|NCT01047761|Myasthenia Gravis
409566|NCT01047761|Exercise
409567|NCT01047761|Fitness
409568|NCT01047761|Body Composition
409569|NCT01047761|Physical Activity
409570|NCT01047761|Pulmonary Function
409571|NCT01047761|Balance
409572|NCT01047748|abortion
409573|NCT01047735|21+ years old
409574|NCT01047735|Address
409575|NCT01047735|Adult
409576|NCT01047735|Amputation
409577|NCT01047735|Area
409578|NCT01047735|Arm
409579|NCT01047735|Atheroscleroses
409580|NCT01047735|Atherosclerosis
409581|NCT01047735|Atherosclerotic
409582|NCT01047735|Cardiovascular Disease
409583|NCT01047735|Bariatrics
409584|NCT01047735|Behavior Conditioning Therapy
409585|NCT01047735|Behavior Modification
409586|NCT01047735|Behavior Therapy
409587|NCT01047735|Behavior Treatment
409588|NCT01047735|Behavior or Life Style Modifications
409589|NCT01047735|Behavioral
409590|NCT01047735|Behavioral Conditioning Therapy
409591|NCT01047735|Behavioral Modification
409592|NCT01047735|Behavioral Therapy
409593|NCT01047735|Behavioral Treatment
409594|NCT01047735|Beta Cell
409595|NCT01047735|Blindness
409596|NCT01047735|Blood Pressure, High
409597|NCT01047735|Blood Vessels
409598|NCT01047735|Body Composition
409599|NCT01047735|Body Weight decreased
409600|NCT01047735|Cancers
409601|NCT01047735|Cardiac infarction
409602|NCT01047735|Cardiovascular Diseases
409603|NCT01047735|Care, Health
409604|NCT01047735|Cause of Death
409605|NCT01047735|Cell Function
409606|NCT01047735|Cell Process
409607|NCT01047735|Cell physiology
409608|NCT01047735|Cellular Function
409609|NCT01047735|Cellular Physiology
409610|NCT01047735|Cellular Process
409611|NCT01047735|Cessation of life
409612|NCT01047735|Clinical
409613|NCT01047735|Clinical Trials Design
409614|NCT01047735|Communities
409615|NCT01047735|Conditioning Therapy
409616|NCT01047735|Controlled Clinical Trials, Randomized
409617|NCT01047735|Controlled Study
409618|NCT01047735|Country
409619|NCT01047735|D-Glucose
409620|NCT01047735|Death
409621|NCT01047735|Decision Making
409622|NCT01047735|Dextrose
409623|NCT01047735|Diabetes Mellitus
409624|NCT01047735|Diabetes Mellitus, Adult-Onset
409625|NCT01047735|Diabetes Mellitus, Ketosis-Resistant
409626|NCT01047735|Diabetes Mellitus, Non-Insulin-Dependent
409627|NCT01047735|Diabetes Mellitus, Noninsulin Dependent
409628|NCT01047735|Diabetes Mellitus, Slow-Onset
409629|NCT01047735|Diabetes Mellitus, Stable
409630|NCT01047735|Diabetes Mellitus, Type 2
409631|NCT01047735|Diabetes Mellitus, Type II
409632|NCT01047735|Diet
409633|NCT01047735|Disease
409634|NCT01047735|Disease remission
409635|NCT01047735|Disorder
409636|NCT01047735|Drugs
409637|NCT01047735|Dysfunction
409638|NCT01047735|Effectiveness
409639|NCT01047735|Epidemic
409640|NCT01047735|Functional disorder
409641|NCT01047735|Future
409642|NCT01047735|Gastric Bypass
409643|NCT01047735|Glucose
409644|NCT01047735|Health
409645|NCT01047735|Healthcare
409646|NCT01047735|Hepatic Disorder
409647|NCT01047735|Human, Adult
409648|NCT01047735|Hypertension
409649|NCT01047735|INFLM
409650|NCT01047735|Incidence
409651|NCT01047735|Inflammation
409652|NCT01047735|Insulin Cell
409653|NCT01047735|Insulin Resistance
409654|NCT01047735|Insulin Secreting Cell
409655|NCT01047735|Intestinal
409656|NCT01047735|Intestines
409657|NCT01047735|Intravenous Glucose Tolerance
409658|NCT01047735|Intravenous Glucose Tolerance Test
409659|NCT01047735|Kidney Failure
409660|NCT01047735|Kidney Insufficiency
409661|NCT01047735|Learning
409662|NCT01047735|Life Style
409663|NCT01047735|Life Style Modification
409664|NCT01047735|Lifestyle
409665|NCT01047735|Link
409666|NCT01047735|Liver diseases
409667|NCT01047735|Longitudinal Studies
409668|NCT01047735|MODY
409669|NCT01047735|Malignant Neoplasms
409670|NCT01047735|Malignant Tumor
409671|NCT01047735|Maturity-Onset Diabetes Mellitus
409672|NCT01047735|Measures
409673|NCT01047735|Medical
409674|NCT01047735|Medication
409675|NCT01047735|Metabolic
409676|NCT01047735|Methods
409677|NCT01047735|Modification
409678|NCT01047735|Morbid Obesity
409679|NCT01047735|Morbidity
409680|NCT01047735|Morbidity - disease rate
409681|NCT01047735|Mortality
409682|NCT01047735|Mortality Vital Statistics
409683|NCT01047735|Myocardial Infarct
409684|NCT01047735|Myocardial Infarction
409685|NCT01047735|NAFLD
409686|NCT01047735|NASH
409687|NCT01047735|NIDDM
409688|NCT01047735|Non-Insulin Dependent Diabetes
409689|NCT01047735|Non-Insulin-Dependent Diabetes Mellitus
409690|NCT01047735|Non-alcoholic steatohepatitis
409691|NCT01047735|Obesity
409692|NCT01047735|Obesity, Morbid
409693|NCT01047735|Operation
409694|NCT01047735|Operative Procedures
409695|NCT01047735|Operative Surgical Procedures
409696|NCT01047735|Outcome
409697|NCT01047735|Outcome Measure
409698|NCT01047735|PROV
409699|NCT01047735|Participant
409700|NCT01047735|Patients
409701|NCT01047735|Pharmaceutic Preparations
409702|NCT01047735|Pharmaceutical Preparations
409703|NCT01047735|Physical activity
409704|NCT01047735|Physiopathology
409705|NCT01047735|Pilot Projects
409706|NCT01047735|Population
409707|NCT01047735|Procedures
409708|NCT01047735|Programs (PT)
409709|NCT01047735|Programs [Publication Type]
409710|NCT01047735|Provider
409711|NCT01047735|Psychosocial Factor
409712|NCT01047735|Public Health
409713|NCT01047735|RMSN
409714|NCT01047735|Randomized
409715|NCT01047735|Randomized Controlled Clinical Trials
409716|NCT01047735|Randomized Controlled Trials
409717|NCT01047735|Remission
409718|NCT01047735|Renal Failure
409719|NCT01047735|Renal Insufficiency
409720|NCT01047735|Reporting
409721|NCT01047735|Resolution
409722|NCT01047735|Science
409723|NCT01047735|Severe obesity
409724|NCT01047735|Structure
409725|NCT01047735|Subcellular Process
409726|NCT01047735|Surgical
409727|NCT01047735|Surgical Interventions
409728|NCT01047735|Surgical Procedure
409729|NCT01047735|T2D
409730|NCT01047735|T2DM
409731|NCT01047735|Testing
409732|NCT01047735|Type 2 diabetes
409733|NCT01047735|Type II diabetes
409734|NCT01047735|United States
409735|NCT01047735|Upper arm
409736|NCT01047735|Vascular Hypertensive Disease
409737|NCT01047735|Vascular Hypertensive Disorder
409738|NCT01047735|Weight
409739|NCT01047735|Weight Loss
409740|NCT01047735|Weight Reduction
409741|NCT01047735|Work
409742|NCT01047735|adiposity
409743|NCT01047735|adult human (21+)
409744|NCT01047735|adult onset diabetes
409745|NCT01047735|atheromatosis
409746|NCT01047735|atherosclerotic vascular disease
409747|NCT01047735|bariatric surgery
409748|NCT01047735|behavior intervention
409749|NCT01047735|behavioral intervention
409750|NCT01047735|blood glucose regulation
409751|NCT01047735|body weight loss
409752|NCT01047735|bowel
409753|NCT01047735|cardiac infarct
409754|NCT01047735|cardiovascular disorder
409755|NCT01047735|cardiovascular risk
409756|NCT01047735|cardiovascular risk factor
409757|NCT01047735|clinical practice
409758|NCT01047735|comparative effectiveness
409759|NCT01047735|coronary attack
409760|NCT01047735|coronary infarct
409761|NCT01047735|coronary infarction
409762|NCT01047735|corpulence
409763|NCT01047735|corpulency
409764|NCT01047735|corpulentia
409765|NCT01047735|design
409766|NCT01047735|designing
409767|NCT01047735|diabetes
409768|NCT01047735|diabetic patient
409769|NCT01047735|disease/disorder
409770|NCT01047735|drug/agent
409771|NCT01047735|effective therapy
409772|NCT01047735|effectiveness research
409773|NCT01047735|fitness
409774|NCT01047735|gastric banding
409775|NCT01047735|gastric bypass surgery
409776|NCT01047735|glucose control
409777|NCT01047735|glucose homeostasis
409778|NCT01047735|glucose metabolism
409779|NCT01047735|glucose regulation
409780|NCT01047735|heart attack
409781|NCT01047735|heart infarct
409782|NCT01047735|heart infarction
409783|NCT01047735|hepatopathy
409784|NCT01047735|hyperpiesia
409785|NCT01047735|hyperpiesis
409786|NCT01047735|hypertensive disease
409787|NCT01047735|implantable gastric stimulation banding
409788|NCT01047735|insulin resistant
409789|NCT01047735|interest
409790|NCT01047735|ketosis resistant diabetes
409791|NCT01047735|life style intervention
409792|NCT01047735|lifestyle intervention
409793|NCT01047735|liver disorder
409794|NCT01047735|long-term study
409795|NCT01047735|malignancy
409796|NCT01047735|maturity onset diabetes
409797|NCT01047735|moderate obesity
409798|NCT01047735|neoplasm/cancer
409799|NCT01047735|non-alcohol fatty liver
409800|NCT01047735|non-alcohol induced steatohepatitis
409801|NCT01047735|non-alcoholic fatty liver
409802|NCT01047735|non-alcoholic steato-hepatitis
409803|NCT01047735|nonalcohol fatty liver
409804|NCT01047735|nonalcoholic fatty liver
409805|NCT01047735|nonalcoholic steato-hepatitis
409806|NCT01047735|nonalcoholic steatohepatitis
409807|NCT01047735|obese
409808|NCT01047735|obese people
409809|NCT01047735|obese person
409810|NCT01047735|obese population
409811|NCT01047735|obesity surgery
409812|NCT01047735|obesity, extreme
409813|NCT01047735|pathophysiology
409814|NCT01047735|pilot study
409815|NCT01047735|programs
409816|NCT01047735|psychosocial
409817|NCT01047735|psychosocial variables
409818|NCT01047735|public health medicine (field)
409819|NCT01047735|public health relevance
409820|NCT01047735|randomisation
409821|NCT01047735|randomization
409822|NCT01047735|randomized controlled study
409823|NCT01047735|randomized trial
409824|NCT01047735|randomly assigned
409825|NCT01047735|respiratory
409826|NCT01047735|response
409827|NCT01047735|stomach bypass
409828|NCT01047735|stomach stapling
409829|NCT01047735|surgery
409830|NCT01047735|trial comparing
409831|NCT01047735|vascular
409832|NCT01047735|weight loss intervention
409833|NCT01047735|weight loss surgery
409834|NCT01047735|wt-loss
409835|NCT01047722|platelet function test
409836|NCT01047722|platelets
409837|NCT01047722|in vivo test
409838|NCT01047722|aspirin
409839|NCT01047722|aspirin resistance
409840|NCT01047722|aspirin non-responsiveness
409841|NCT01047722|in-vivo
409842|NCT01047722|To assess the specificity and sensitivity of a novel in-vivo diagnostic test of platelet function
409843|NCT01047722|"To use this test to define and assess aspirin resistance"
409844|NCT01047683|hypertriglyceridemia
409845|NCT01047683|omega-3 fatty acids
409846|NCT01047683|statin
409847|NCT01047683|triglycerides
409848|NCT01047683|lipids
409849|NCT01047683|EPA
409850|NCT01047683|docosahexaenoic acid
409851|NCT01047683|fish
409852|NCT01047683|fatty acids
409853|NCT01047683|fibrates
409854|NCT01047683|niacin
409855|NCT01047683|lipid
409856|NCT01047683|atorvastatin
409857|NCT01047683|Lovaza
409858|NCT01047683|simvastatin
409859|NCT01047683|lovastatin
409860|NCT01047683|pravastatin
409861|NCT01047683|fluvastatin
409862|NCT01047683|rosuvastatin
409863|NCT01047683|Trilipix
409864|NCT01047683|Vytorin
409865|NCT01047683|Simcor
409866|NCT01047683|Niaspan
409867|NCT01047683|ezetimibe
409868|NCT01047683|Zetia
409869|NCT01047683|ethyl-EPA
409870|NCT01047683|ethyl icosapentate
409871|NCT01047683|Crestor
409872|NCT01047683|Zocor
409873|NCT01047683|Lipitor
409874|NCT01047683|LDL
409875|NCT01047683|HDL
409876|NCT01047683|cholesterol
409877|NCT01047683|dyslipidemia
409878|NCT01047683|VASCEPA
409879|NCT01047683|icosapent ethyl
409880|NCT01047670|sepsis, shock, adrenal insufficiency, hydrocortisone, children, paediatric intensive care.
409881|NCT01047670|number of days free of vasoactive support in 7 days
409882|NCT01047670|days free of mechanical ventilation
409883|NCT01047670|PICU mortality
409884|NCT01047670|mortality among patient with inappropriate response to the ACTH test
409885|NCT01047670|baseline cortisol/ PIM2 correlation
409886|NCT01047657|Asthma
409887|NCT01047657|Obesity
409888|NCT01047657|weight loss
409889|NCT01047644|port
409890|NCT01047644|catheter
409891|NCT01047644|infusion
409892|NCT01047644|flush
409893|NCT01047644|cleanse
409894|NCT01047644|chemotherapy
409895|NCT01047618|venous thromboembolism
409896|NCT01047605|qEEG
409897|NCT01047605|herbal medicine
409898|NCT01047605|cognitive function
409899|NCT01047605|Neurapas balance
409900|NCT01047605|Pascoflair
409901|NCT01047605|hypericum
409902|NCT01047605|passionflower
409903|NCT01047605|valerian
409904|NCT01047605|Healthy volunteers
409905|NCT01047605|Influence on quantitative electro-encephalogram (qEEG).
409906|NCT01047592|Schizophrenia
409907|NCT01047592|cognitive function
409908|NCT01047592|N-methyl-D-aspartate receptor
409909|NCT01047579|Alzheimer's Disease
409910|NCT01047579|Rivastigmine transdermal
409911|NCT01047579|caregiver preference
409912|NCT01047553|Chronic Obstructive Pulmonary Disease
409913|NCT01047553|COPD
409914|NCT01047553|Japanese
409915|NCT01047553|Phase 3
409916|NCT01047553|Safety
409917|NCT01047553|OT
409918|NCT01047553|Oxis
409919|NCT01047527|nicotine replacement therapy, smoking cessation, transdermal nicotine
409920|NCT01047501|hypertriglyceridemia
409921|NCT01047501|omega-3 fatty acids
409922|NCT01047501|statin
409923|NCT01047501|triglycerides
409924|NCT01047501|lipids
409925|NCT01047501|EPA
409926|NCT01047501|docosahexaenoic acid
409927|NCT01047501|fish
409928|NCT01047501|fatty acids
409929|NCT01047501|fibrates
409930|NCT01047501|niacin
409931|NCT01047501|lipid
409932|NCT01047501|atorvastatin
409933|NCT01047501|Lovaza
409934|NCT01047501|simvastatin
409935|NCT01047501|lovastatin
409936|NCT01047501|pravastatin
409937|NCT01047501|fluvastatin
409938|NCT01047501|rosuvastatin
409939|NCT01047501|Trilipix
409940|NCT01047501|Vytorin
409941|NCT01047501|Simcor
409942|NCT01047501|Niaspan
409943|NCT01047501|ezetimibe
409944|NCT01047501|Zetia
409945|NCT01047501|ethyl-EPA
409946|NCT01047501|ethyl icosapentate
409947|NCT01047501|Crestor
409948|NCT01047501|Zocor
409949|NCT01047501|Lipitor
409950|NCT01047501|LDL
409951|NCT01047501|HDL
409952|NCT01047501|cholesterol
409953|NCT01047501|dyslipidemia
409954|NCT01047501|VASCEPA
409955|NCT01047501|icosapent ethyl
409956|NCT01047488|polyneuropathy
409957|NCT01047488|neuropathic pain
409958|NCT01047488|treatment
409959|NCT01047475|MB-6
409960|NCT01047475|FOLFOX4
409961|NCT01047475|Metastatic Colorectal Cancer
409962|NCT01047449|saphenous vein graft patency
409963|NCT01047449|fish oil supplementation
409964|NCT01047449|coronary artery bypass surgery
409965|NCT01047449|coronary artery disease
409966|NCT01047436|Plasmodium infections
409967|NCT01047436|Remittent fever
409968|NCT01047436|Artemether
409969|NCT01047436|Artemisinins
409970|NCT01047436|quinine
409971|NCT01047436|Malaria
409972|NCT01047436|Protozoan Infections
409973|NCT01047436|Anti-Infective Agents
409974|NCT01047436|Antiprotozoal Agents
409975|NCT01047436|Schistosomicides
409976|NCT01047436|Pharmacologic Actions
409977|NCT01047436|Malaria, Falciparum
409978|NCT01047436|Antimalarials
409979|NCT01047436|Antiparasitic Agents
409980|NCT01047436|Parasitic Diseases
409981|NCT01047436|sublingual
409982|NCT01047423|Hypertension endothelial dysfunction statin prevention
409983|NCT01047410|physical exercise training
409984|NCT01047410|quality of life
409985|NCT01047410|exercise capacity
409986|NCT01047410|skeletal muscle strength
409987|NCT01047410|physical activity level
409988|NCT01047410|costeffectiveness
409989|NCT01047410|renal transplantation
409990|NCT01047410|hemodialysis
409991|NCT01047410|peritoneal dialysis
409992|NCT01047410|diet
409993|NCT01047397|hemodialysis
409994|NCT01047397|tolerability
409995|NCT01047397|pharmacokinetics
409996|NCT01047397|safety
409997|NCT01047397|anemia
409998|NCT01047397|renal impairment
409999|NCT01047397|repeat dose
410000|NCT01047345|Cervical cancer
410001|NCT01047345|Genital warts
410002|NCT01047345|Human papillomavirus vaccine
410003|NCT01047345|GARDASIL™
410004|NCT01047319|Relapsing Multiple Sclerosis
410005|NCT01047293|colorectal cancer
410006|NCT01047280|Conjugated linoleic acid
410007|NCT01047280|Body weight
410008|NCT01047280|Body composition
410009|NCT01047280|Blood lipid profile
410010|NCT01047280|Body inflammatory and oxidative status
410011|NCT01047267|candidiasis
410012|NCT01047267|invasive fungal disease
410013|NCT01047267|critically ill
410014|NCT01047267|anidulafungin
410015|NCT01047267|pharmacokinetics
410016|NCT01047241|Painful medical procedures
410017|NCT01047215|schizophrenia
410018|NCT01047215|bipolar
410019|NCT01047215|aripiprazole
410020|NCT01047215|quetiapine
410021|NCT01047189|Mild to moderate acne vulgaris
410022|NCT01047176|Statins
410023|NCT01047176|Coronary Heart Disease
410024|NCT01047176|Percutaneous coronary intervention (PCI)
410025|NCT01047163|Muscle soreness
410026|NCT01047163|Simvastatin
410027|NCT01047163|Men
410028|NCT01047163|Muscle Atrophy
410029|NCT01047150|Myocardial Perfusion Imaging
410030|NCT01047150|Repeat studies
410031|NCT01047150|Tetrofosmin
410032|NCT01047150|Sestamibi
410033|NCT01047137|Urticaria
410034|NCT01047137|Hives
410035|NCT01047137|Stress
410036|NCT01047137|Immune dysregulation
410037|NCT01047124|Depression
410038|NCT01047124|Collaborative Care
410039|NCT01047124|Cognitive Behaviour Therapy
410040|NCT01047124|Mental Health Services
410041|NCT01047124|Antidepressants
410042|NCT01047111|Esophageal Neoplasms
410043|NCT01047111|Esophagectomy
410044|NCT01047098|Lactation
410045|NCT01047098|Breastfeeding
410046|NCT01047098|Iron
410047|NCT01047098|Oxidative stress
410048|NCT01047098|Iron status and oxidative stress during lactation
410049|NCT01047085|cholecystolithiasis
410050|NCT01047085|cholecystectomy
410051|NCT01047085|gastroesophageal reflux
410052|NCT01047085|impedance pH
410053|NCT01047085|The relationship between cholecystolithiasis, cholecystectomy and gastroesophageal reflux by impedance pH-method.
410054|NCT01047072|Scleroderma, systemic sclerosis, allogeneic hematopoietic stem cell transplantation
410055|NCT01047059|NSCLC
410056|NCT01047059|Lung Cancer
410057|NCT01047046|SNM device
410058|NCT01047046|Chart review of patients with surgical placed SNM device
410059|NCT01047033|Poverty
410060|NCT01047033|Global health
410061|NCT01047033|International health
410062|NCT01047033|Latin America
410063|NCT01047033|Peru
410064|NCT01047033|Child health
410065|NCT01047033|Microcredit
410066|NCT01047033|Microenterprise
410067|NCT01047033|Microfinance
410068|NCT01047020|Impairments of musculoskeletal Health;
410069|NCT01047020|Physical activity;
410070|NCT01047020|Motor Proficiency;
410071|NCT01047007|Head and Neck Cancer
410072|NCT01047007|Esophageal Cancer
410073|NCT01047007|Gastric Cancer
410074|NCT01046981|Surgical site infections
410075|NCT01046981|Prevention
410076|NCT01046981|Prophylaxis
410077|NCT01046981|Tumescent
410078|NCT01046981|Intravenous
410079|NCT01046981|Antibiotic
410080|NCT01046981|Absorption
410081|NCT01046981|Pharmacokinetics
410082|NCT01046981|Bioavailability
410083|NCT01046968|Obesity
410084|NCT01046968|metabolic syndrome
410085|NCT01046968|C-reactive protein
410086|NCT01046968|Leptin
410087|NCT01046955|ESRD
410088|NCT01046942|Saphenous vein
410089|NCT01046942|Antiplatelet therapy
410090|NCT01046942|Hypercoagulable
410091|NCT01046942|Clopidogrel resistance
410092|NCT01046942|Aspirin resistance
410093|NCT01046942|Clopidogrel
410094|NCT01046942|Aspirin
410095|NCT01046942|Saphenous vein graft disease
410096|NCT01046942|TEG
410097|NCT01046942|Thrombelastography
410098|NCT01046942|Multiplate aggregometry
410099|NCT01046942|Multislice CT
410100|NCT01046942|Coronary artery bypass graft surgery
410101|NCT01046942|coagulation status
410102|NCT01046942|graft patency
410103|NCT01046942|CABG
410104|NCT01046929|limonene
410105|NCT01046929|breast cancer
410106|NCT01046929|cancer prevention
410107|NCT01046903|observational prolonged thromboprophylaxis
410108|NCT01046890|Darunavir
410109|NCT01046890|Echinacea purpurea
410110|NCT01046890|Interaction
410111|NCT01046890|Complementary Therapies
410112|NCT01046864|Gastro-Intestinal Cancer, NOS
410113|NCT01046838|Diastolic Heart Failure
410114|NCT01046825|Lymphoma
410115|NCT01046825|Leukemia
410116|NCT01046825|Non-Hodgkin's Lymphoma
410117|NCT01046812|questionnaire
410118|NCT01046812|halitosis
410119|NCT01046812|caphosol
410120|NCT01046812|Quality of life questionnaire assessing halitosis
410121|NCT01046799|hepatitis B
410122|NCT01046799|liver transplantation
410123|NCT01046799|shortterm HBIg
410124|NCT01046799|lamivudine resistance
410125|NCT01046786|spinal cord injury
410126|NCT01046786|cord blood mononuclear cell
410127|NCT01046786|Methylprednisolone
410128|NCT01046786|Lithium Carbonate
410129|NCT01046773|Children
410130|NCT01046773|Crohn's disease
410131|NCT01046773|Vitamin D
410132|NCT01046760|epilepsy
410133|NCT01046760|language
410134|NCT01046760|childhood
410135|NCT01046760|praxis
410136|NCT01046747|external fixation
410137|NCT01046747|pin tract infection
410138|NCT01046747|self drilling
410139|NCT01046734|Influenza
410140|NCT01046734|virus shedding
410141|NCT01046734|infection control
410142|NCT01046734|swine flu
410143|NCT01046721|blood pressure
410144|NCT01046721|superior mesenteric artery blood flow
410145|NCT01046721|cardiovascular effects
410146|NCT01046721|Exenatide
410147|NCT01046708|IUI
410148|NCT01046708|clomiphene citrate
410149|NCT01046708|utrogestan
410150|NCT01046695|VATS
410151|NCT01046695|Video-Assisted Thoracotomy
410152|NCT01046695|Thoracic Surgery, Video-Assisted
410153|NCT01046682|HIV
410154|NCT01046682|Endothelial dysfunction
410155|NCT01046682|Inflammation
410156|NCT01046682|Insulin resistance
410157|NCT01046656|nosocomial infection
410158|NCT01046656|diarrhea
410159|NCT01046656|Lactobacillus reuteri
410160|NCT01046656|gastroenteritis
410161|NCT01046656|rotavirus
410162|NCT01046643|Women
410163|NCT01046643|Healthy
410164|NCT01046643|Menopausal
410165|NCT01046643|Hormone treatment
410166|NCT01046630|Phase I
410167|NCT01046630|BOLD signal
410168|NCT01046630|fMRI
410169|NCT01046630|AZD6765
410170|NCT01046630|BOLD signal measured by fMRI
410171|NCT01046617|infantile colic
410172|NCT01046617|Lactobacillus reuteri
410173|NCT01046617|duration of crying
410174|NCT01046604|mitral valve regurgitation
410175|NCT01046604|omega 3 fatty acids
410176|NCT01046604|fish oil
410177|NCT01046604|cardiac
410178|NCT01046604|mitochondria
410179|NCT01046604|apoptosis
410180|NCT01046604|human heart
410181|NCT01046591|Cleft Palate
410182|NCT01046591|Cleft Lip
410183|NCT01046591|Obstructive Sleep Apnea
410184|NCT01046591|Sleep-Disordered Breathing
410185|NCT01046591|Behavior
410186|NCT01046591|Learning
410187|NCT01046578|Folliculogenesis
410188|NCT01046578|Letrozole
410189|NCT01046578|Aromatase Inhibitor
410190|NCT01046578|Estrogen
410191|NCT01046552|Choledocholithias
410192|NCT01046552|Common bile duct stones
410193|NCT01046552|Endoscopic retrograde cholangiopancreatography
410194|NCT01046552|endoscopic sphincterotomy
410195|NCT01046552|Preoperative
410196|NCT01046552|intraoperative
410197|NCT01046552|Laparoscopic common bile duct exploration
410198|NCT01046526|Psychopathology
410199|NCT01046526|Nicotine Patch
410200|NCT01046526|Eye Tracking
410201|NCT01046526|Attention
410202|NCT01046526|Schizophrenic Participants
410203|NCT01046513|Nicotinic Acetylcholine Receptors
410204|NCT01046513|Neuroimaging
410205|NCT01046513|Positron Emission Tomography (PET)
410206|NCT01046513|Alpha4beta2
410207|NCT01046513|Nicotine
410208|NCT01046513|Receptor Upregulation
410209|NCT01046500|insulin resistance
410210|NCT01046500|body mass index
410211|NCT01046500|myo-inositol
410212|NCT01046500|serum triglycerides and cholesterol
410213|NCT01046500|blood pressure
410214|NCT01046500|metformin
410215|NCT01046487|dermatofibrosarcoma
410216|NCT01046487|cylindroma
410217|NCT01046487|choroid melanoma
410218|NCT01046487|gastrointestinal stroma tumor
410219|NCT01046487|chordoma
410220|NCT01046487|ocular melanoma
410221|NCT01046487|conjunctival melanoma
410222|NCT01046487|malignant melanoma of the anus
410223|NCT01046487|gastric melanoma
410224|NCT01046487|desmoid tumor
410225|NCT01046474|school children
410226|NCT01046474|body mass index
410227|NCT01046474|sugar intake
410228|NCT01046474|beverage intake
410229|NCT01046461|Ramosetron
410230|NCT01046461|aprepitant
410231|NCT01046461|dexamethasone
410232|NCT01046461|cancer
410233|NCT01046461|chemotherapy
410234|NCT01046461|antiemetics
410235|NCT01046461|cisplatin
410236|NCT01046461|nausea
410237|NCT01046461|vomiting
410238|NCT01046461|high dose cisplatin
410239|NCT01046448|Children
410240|NCT01046448|chronic renal failure
410241|NCT01046448|chronic kidney disease
410242|NCT01046448|cardiovascular disease
410243|NCT01046448|cardiovascular morbidity
410244|NCT01046448|left ventricular hypertrophy
410245|NCT01046448|carotid intima media thickness
410246|NCT01046448|arterial stiffness
410247|NCT01046448|pulse wave velocity
410248|NCT01046448|augmentation index
410249|NCT01046448|left ventricular cardiac function
410250|NCT01046448|progression
410251|NCT01046448|genetic risk factors
410252|NCT01046448|vasculopathy
410253|NCT01046448|cardiopathy
410254|NCT01046448|whole genome analysis
410255|NCT01046448|haplotype analysis
410256|NCT01046448|SNP-screening
410257|NCT01046435|periodontitis
410258|NCT01046435|cardiovascular disease
410259|NCT01046435|diabetes
410260|NCT01046409|Coronary artery disease
410261|NCT01046409|Bifurcation
410262|NCT01046409|Myocardial infarction
410263|NCT01046409|Myocardial ischemia
410264|NCT01046409|Collateral
410265|NCT01046383|NON-SMALL CELL LUNG CANCER PATIENTS
410266|NCT01046383|WEIGHT LOSS
410267|NCT01046383|QUALITY OF LIFE
410268|NCT01046383|SURVIVAL
410269|NCT01046383|CHEMOTHERAPY
410270|NCT01046383|RADIOTHERAPY
410271|NCT01046383|SURGERY
410272|NCT01046383|CYSTEINE-RICH WHEY PROTEIN ISOLATE
410273|NCT01046383|IMN1207
410274|NCT01046383|CANCER-RELATED WASTING (CACHEXIA)
410275|NCT01046383|BODY WEIGHT
410276|NCT01046383|NUTRITIONAL PROTEIN SUPPLEMENT
410277|NCT01046357|First in human
410278|NCT01046357|Safety
410279|NCT01046305|Chronic Myeloid Leukemia
410280|NCT01046305|CML
410281|NCT01046305|Symptom Burden
410282|NCT01046305|M. D. Anderson Symptom Inventory
410283|NCT01046305|MDASI-CML
410284|NCT01046305|Severity
410285|NCT01046305|Interference
410286|NCT01046305|Questionnaire
410287|NCT01046305|Interview
410288|NCT01046292|Gait, Ginkgo biloba, mild cognitive impairment
410289|NCT01046253|Bioequivalence
410290|NCT01046253|Healthy Subjects
410291|NCT01046240|chemotherapy
410292|NCT01046240|emesis
410293|NCT01046240|palonosetron
410294|NCT01046227|Serology
410295|NCT01046227|Monovalent inactivated H1N1 vaccine
410296|NCT01046227|Pediatric haemato-oncology patients
410297|NCT01046188|Education
410298|NCT01046188|Internet
410299|NCT01046188|In vitro fertilization
410300|NCT01046175|Respiratory complications
410301|NCT01046175|respiratory insufficiency
410302|NCT01046175|respiratory therapy
410303|NCT01046162|Alprazolam
410304|NCT01046162|Tafil
410305|NCT01046162|Xanax
410306|NCT01046162|Bioequivalence
410307|NCT01046162|Drug Kinetics
410308|NCT01046149|Depression
410309|NCT01046149|Depressive Symptoms
410310|NCT01046149|postmenopause
410311|NCT01046149|RSA biofeedback
410312|NCT01046136|common cold
410313|NCT01046097|Pneumococcal vaccine
410314|NCT01046084|Bioequivalence
410315|NCT01046084|Healthy Subjects
410316|NCT01046071|Transversus abdominis plane block, postoperative pain.
410317|NCT01046058|TMC435-TiDP16-C113
410318|NCT01046058|TMC435-C113
410319|NCT01046058|TMC435
410320|NCT01046058|HCV
410321|NCT01046058|Protease Inhibitor
410322|NCT01046058|Hepatitis C
410323|NCT01046045|mammalian target-of-rapamycin inhibitors
410324|NCT01046045|chronic allograft dysfunction
410325|NCT01046045|everolimus
410326|NCT01046045|calcineurin inhibitors
410327|NCT01046032|Polycystic ovaries
410328|NCT01046032|Ovarian stimulation
410329|NCT01046032|IVF
410330|NCT01046032|Ovarian hyperstimulation
410331|NCT01046032|Metformin
410332|NCT01046019|DXA
410333|NCT01046019|Hip
410334|NCT01046019|Arthroplasty
410335|NCT01046006|lymphoma
410336|NCT01046006|Bortezomib
410337|NCT01046006|Rituximab
410338|NCT01045993|Pilot Study to Assess Methodologies
410339|NCT01045980|Peritoneal dialysis
410340|NCT01045980|Impedance, bioelectric
410341|NCT01045980|Hypertrophy, left ventricular
410342|NCT01045980|Fluid status
410343|NCT01045980|Volume overload
410344|NCT01045980|Congestive heart failure
410345|NCT01045980|Cardiovascular outcomes
410346|NCT01045980|Randomized controlled trial
410347|NCT01045967|Bioequivalence
410348|NCT01045967|Healthy Subjects
410349|NCT01045954|diabetes mellitus type 1
410350|NCT01045954|continuous glucose monitoring
410351|NCT01045941|Distal Pancreas
410352|NCT01045941|Adenocarcinoma
410353|NCT01045941|Laparoscopic
410354|NCT01045941|Gemcitabine
410355|NCT01045915|Stage IIIB, stage IIIC or stage IV melanoma
410356|NCT01045915|Progressive melanoma not responding to previous treatments
410357|NCT01045902|Pulmonary Abscess
410358|NCT01045902|Aspiration Pneumonia
410359|NCT01045889|HIV
410360|NCT01045889|non hodgkin lymphoma
410361|NCT01045889|peripheral blood stem cell transplantation
410362|NCT01045876|Randomized controlled trial
410363|NCT01045876|Dexamethasone
410364|NCT01045876|Single dose
410365|NCT01045876|Preoperative
410366|NCT01045876|Plasma Cortisol level
410367|NCT01045863|volunteer
410368|NCT01045850|coronary stents
410369|NCT01045850|non cardiac surgery
410370|NCT01045850|cardiovascular complications
410371|NCT01045850|hemorrhagic complications
410372|NCT01045850|antiplatelet agents
410373|NCT01045850|bare metal stent
410374|NCT01045850|drug eluting stent
410375|NCT01045850|surgery
410376|NCT01045837|Celiac disease, steroids, immunohistochemistry
410377|NCT01045824|Schizophrenia
410378|NCT01045824|DNA
410379|NCT01045824|MRI
410380|NCT01045811|Depression
410381|NCT01045811|Depressive Symptoms
410382|NCT01045811|postmenopause
410383|NCT01045811|RSA biofeedback
410384|NCT01045798|Candidiasis
410385|NCT01045798|Invasive Candidiasis
410386|NCT01045798|Fungal Infection
410387|NCT01045798|Empirical Therapy
410388|NCT01045785|aspirin resistance, platelet function assay, dialysis, end stage renal disease
410389|NCT01045772|Schnitler syndrome, Muckle-Wells syndrome, anti-IL-1
410390|NCT01045759|VENOUS THROMBOSIS
410391|NCT01045759|ultrasonography
410392|NCT01045759|intensive care unit
410393|NCT01045746|whole-body vibration
410394|NCT01045746|stochastic resonance Therapy
410395|NCT01045746|static balance
410396|NCT01045746|balance, mobility
410397|NCT01045746|elderly, reaction time
410398|NCT01045746|The focus of the study is effect of SRT on postural balance
410399|NCT01045733|Cataract
410400|NCT01045733|Toric
410401|NCT01045733|IOL
410402|NCT01045733|AcrySof
410403|NCT01045733|LRI
410404|NCT01045733|Astigmatism
410405|NCT01045720|Schizophrenia
410406|NCT01045720|clozapine
410407|NCT01045720|hypersalivation
410408|NCT01045720|Suo Quan Wan
410409|NCT01045720|Wu Lin San
410410|NCT01045694|Carpometacarpal Joints
410411|NCT01045694|Osteoarthritis
410412|NCT01045694|Basal thumb joint arthritis
410413|NCT01045694|Trapeziometacarpal arthritis
410414|NCT01045681|Multiple Myeloma
410415|NCT01045681|Elderly patients
410416|NCT01045681|first relapse
410417|NCT01045681|refractory to first line therapy
410418|NCT01045681|Bendamustine Velcade Dexamethasone Association
410419|NCT01045655|Depression
410420|NCT01045655|Perinatal care
410421|NCT01045655|Postpartum period
410422|NCT01045655|Pregnancy
410423|NCT01045655|Female
410424|NCT01045655|Low-income population
410425|NCT01045642|Bioequivalence
410426|NCT01045642|Omeprazole
410427|NCT01045642|Crossover
410428|NCT01045629|schizophrenia
410429|NCT01045629|PANSS
410430|NCT01045603|Instanyl
410431|NCT01045603|non-interventional
410432|NCT01045603|breakthrough cancer pain
410433|NCT01045603|BTP
410434|NCT01045603|BTCP
410435|NCT01045603|Intranasal fentanyl spray
410436|NCT01045577|Severe Psoriasis
410437|NCT01045577|Kinase Inhibitor
410438|NCT01045577|Masitinib
410439|NCT01045564|Immunogenicity
410440|NCT01045564|Vaccines
410441|NCT01045564|H5N1
410442|NCT01045564|Influenza
410443|NCT01045564|Pandemic
410444|NCT01045564|Human
410445|NCT01045564|Avian
410446|NCT01045564|Safety
410447|NCT01045551|Inflammatory rosacea
410448|NCT01045551|Papules and pustules
410449|NCT01045551|Moderate to severe erythema
410450|NCT01045551|Telangiectasia
410451|NCT01045538|gastric cancer
410452|NCT01045538|histone deacetylase inhibitor
410453|NCT01045538|1st line chemotherapy
410454|NCT01045525|Phlebotomy
410455|NCT01045525|Dysmetabolic liversiderosis
410456|NCT01045525|Hepatic Iron overload
410457|NCT01045512|immunosenescence
410458|NCT01045512|heart rate variability
410459|NCT01045512|autonomic nervous system
410460|NCT01045512|ageing
410461|NCT01045512|inflammatory/pathogen burden
410462|NCT01045512|physical activity
410463|NCT01045499|adolescent obesity surgery
410464|NCT01045499|bariatric surgery
410465|NCT01045499|adjustable gastric banding
410466|NCT01045486|Atopic dermatitis
410467|NCT01045486|Food allergy
410468|NCT01045486|Probiotics
410469|NCT01045473|MIS
410470|NCT01045473|Minimally Invasive Spine Surgery
410471|NCT01045473|Fusion
410472|NCT01045473|Spine
410473|NCT01045473|SMISS
410474|NCT01045460|Patients with active myeloma (Stage II/III) that have completed induction therapy and are eligible for an autologous stem cell transplant
410475|NCT01045434|Bioequivalence
410476|NCT01045434|omeprazole
410477|NCT01045434|crossover
410478|NCT01045421|NSCLC
410479|NCT01045421|SCLC
410480|NCT01045421|HNSCC
410481|NCT01045408|Helicobacter pylori
410482|NCT01045408|Berry extract
410483|NCT01045408|Triple therapy
410484|NCT01045395|Algae
410485|NCT01045395|Psoriasis
410486|NCT01045395|Lipid metabolism
410487|NCT01045395|Inflammation
410488|NCT01045395|Oxidative stress
410489|NCT01045382|HSC transplantation
410490|NCT01045382|HLA-mismatched
410491|NCT01045382|Mesenchymal stem cells
410492|NCT01045382|GVHD
410493|NCT01045382|co-infusion
410494|NCT01045369|HIV
410495|NCT01045369|Treatment Naive
410496|NCT01045343|heart failure
410497|NCT01045343|home monitoring
410498|NCT01045343|integrated diagnostics
410499|NCT01045343|Cardiac Resynchronization Therapy with Defibrillator (CRT D)
410500|NCT01045317|micro-dose
410501|NCT01045317|pharmacokinetics
410502|NCT01045317|open label
410503|NCT01045317|PF-04776548
410504|NCT01045278|Hepatitis C patients
410505|NCT01045278|Hepacivirus
410506|NCT01045252|hemodynamics
410507|NCT01045252|neonatal
410508|NCT01045239|Diabetic macular edema
410509|NCT01045239|Diabetic macular oedema
410510|NCT01045239|micropulse laser
410511|NCT01045239|laser treatment
410512|NCT01045239|macular thickness
410513|NCT01045213|Chronic obstructive pulmonary disease
410514|NCT01045213|COPD
410515|NCT01045200|rectal cancer
410516|NCT01045200|follow-up
410517|NCT01045200|specialist nurse
410518|NCT01045187|endometrial cancer
410519|NCT01045187|Uterine cancer
410520|NCT01045187|electronic brachytherapy
410521|NCT01045187|Xoft
410522|NCT01045174|Asthma
410523|NCT01045174|Pediatric
410524|NCT01045174|Emergency department
410525|NCT01045174|Nebulizer
410526|NCT01045161|Chronic Obstructive Pulmonary Disease
410527|NCT01045161|COPD
410528|NCT01045161|Chronic Bronchitis
410529|NCT01045161|Emphysema
410530|NCT01045161|Airflow Obstruction, Chronic
410531|NCT01045161|Chronic Airflow Obstruction
410532|NCT01045161|Chronic Obstructive Airway Disease
410533|NCT01045161|Chronic Obstructive Lung Disease
410534|NCT01045148|Prostatic Cancer
410535|NCT01045148|Prostatic Neoplasms
410536|NCT01045148|Prostate Neoplasms
410537|NCT01045148|Cancer of the Prostate
410538|NCT01045135|Pelvic organ prolapse
410539|NCT01045135|Levator hiatus
410540|NCT01045135|3 and 4 dimensional ultrasound
410541|NCT01045122|Obstructive Sleep Apnea
410542|NCT01045109|prostate
410543|NCT01045109|cancer
410544|NCT01045109|vitamin D3
410545|NCT01045109|early stage
410546|NCT01045109|active surveillance
410547|NCT01045096|Gastroesophageal Reflux
410548|NCT01045096|Erosive Esophagitis
410549|NCT01045096|Pharmacokinetics
410550|NCT01045096|Pediatrics
410551|NCT01045096|Drug Therapy
410552|NCT01045070|periodontitis and coronary heart disease
410553|NCT01045057|voice prosthesis, larynx cancer, laryngectomy
410554|NCT01045044|Breast cancer
410555|NCT01045044|Magnetic Resonance Imaging
410556|NCT01045044|Anthracycline based systemic chemotherapy
410557|NCT01045044|Tumor response
410558|NCT01045044|Cognitive Impairment
410559|NCT01045044|Chemo Brain
410560|NCT01045031|cognitive function, aging, brain-derived neurotrophic factor
410561|NCT01045018|colitis
410562|NCT01045018|ulcerative
410563|NCT01045018|ulcerative colitis
410564|NCT01045005|Type 1 diabetes
410565|NCT01045005|Endothelial dysfunction
410566|NCT01045005|Doppler Ultrasound Velocity Waveforms
410567|NCT01044992|Multi systemic atrophy
410568|NCT01044992|Parkinson Disease
410569|NCT01044992|PET investigation
410570|NCT01044992|Motor control
410571|NCT01044992|levodopa
410572|NCT01044992|MSA
410573|NCT01044992|Comparison with Parkinson disease and dopaminergic challenge.
410574|NCT01044979|Colloid osmotic pressure in interstitial fluid
410575|NCT01044979|Colloid osmotic pressure in plasma
410576|NCT01044979|Protein fractions in interstitial fluid
410577|NCT01044966|Glioblastoma
410578|NCT01044966|Subventricular
410579|NCT01044966|gliomagenesis
410580|NCT01044966|temozolomide
410581|NCT01044966|depocyt
410582|NCT01044953|injury incidence
410583|NCT01044953|male professional soccer
410584|NCT01044953|Change of injury incidence in professional soccer
410585|NCT01044940|Colloid Osmotic pressure in interstitial fluid
410586|NCT01044940|Colloid Osmotic pressure in plasma
410587|NCT01044940|Protein fractions in interstitial fluid
410588|NCT01044927|Chronic obstructive pulmonary disease
410589|NCT01044927|telemedicine
410590|NCT01044927|COPD
410591|NCT01044901|Sickle Cell Disease
410592|NCT01044901|Cardiac magnetic resonance imaging
410593|NCT01044901|Coronary Disease
410594|NCT01044901|Pulmonary Hypertension
410595|NCT01044888|Heparin responsiveness
410596|NCT01044888|Off-pump coronary artery bypass graft surgery
410597|NCT01044888|Risk factors
410598|NCT01044888|Myocardial infarction
410599|NCT01044875|Diabetic retinopathy
410600|NCT01044875|Laser treatment
410601|NCT01044875|Complications
410602|NCT01044875|Laser wavelength
410603|NCT01044862|Pregnancy
410604|NCT01044862|Infertility
410605|NCT01044862|Ovarian stimulation
410606|NCT01044862|Aromatase inhibitors
410607|NCT01044862|Follicle Stimulating Hormone
410608|NCT01044849|Blood Pressure
410609|NCT01044836|Healthy volunteer
410610|NCT01044823|RA
410611|NCT01044823|JRA
410612|NCT01044810|HIV
410613|NCT01044810|efavirenz
410614|NCT01044810|nevirapine
410615|NCT01044810|allergy
410616|NCT01044810|rash
410617|NCT01044810|Cohort Studies, Historical
410618|NCT01044810|Retrospective Study
410619|NCT01044810|exanthem
410620|NCT01044810|Antiretroviral Agents
410621|NCT01044810|Highly Active Antiretroviral Therapy
410622|NCT01044810|HAART
410623|NCT01044810|treatment failure
410624|NCT01044797|Healthy Volunteer
410625|NCT01044797|Given Capsule Manipulation
410626|NCT01044784|CRT
410627|NCT01044771|HIV
410628|NCT01044771|Human immunodeficiency virus
410629|NCT01044771|tenofovir
410630|NCT01044771|viread
410631|NCT01044771|truvada
410632|NCT01044771|proteinuria
410633|NCT01044758|Mild Cognitive Impairment
410634|NCT01044758|Amnestic Mild Cognitive Impairment
410635|NCT01044758|Functional Magnetic Resonance Imaging
410636|NCT01044758|Levetiracetam
410637|NCT01044758|Keppra
410638|NCT01044758|Medial Temporal Lobe
410639|NCT01044758|Memory Impairment
410640|NCT01044758|Alzheimer's Disease
410641|NCT01044758|AD
410642|NCT01044732|Colorectal
410643|NCT01044732|Neoplasms
410644|NCT01044732|Adenomas
410645|NCT01044732|Polyps
410646|NCT01044732|Miss rates
410647|NCT01044732|Detection rates
410648|NCT01044732|Colonoscope
410649|NCT01044732|Third Eye Retroscope
410650|NCT01044706|Bioequivalency
410651|NCT01044693|supine Hypertension
410652|NCT01044693|autonomic failure
410653|NCT01044693|nitric oxide
410654|NCT01044693|nebivolol
410655|NCT01044680|fiber
410656|NCT01044680|metabolic syndrome
410657|NCT01044680|overweight
410658|NCT01044680|satiety
410659|NCT01044654|HIV
410660|NCT01044654|Treatment Experienced
410661|NCT01044641|Colloid Osmotic pressure in interstitial fluid
410662|NCT01044641|Colloid Osmotic pressure in plasma
410663|NCT01044641|Protein fractions in interstitial fluid
410664|NCT01044628|COPD
410665|NCT01044628|CANOX
410666|NCT01044628|Oxygen therapy
410667|NCT01044628|Nocturnal
410668|NCT01044628|Desaturation
410669|NCT01044615|Mild Traumatic Brain Injury
410670|NCT01044615|Concussion
410671|NCT01044615|Magnetic Resonance Imaging (MRI)
410672|NCT01044615|Positron Emission Tomography(PET)
410673|NCT01044615|Computed Tomography (CT)
410674|NCT01044602|Obesity
410675|NCT01044602|Type 2 Diabetes Mellitus
410676|NCT01044602|Roux-en-Y Gastric Bypass Surgery
410677|NCT01044576|Multiple Sclerosis
410678|NCT01044563|Depression
410679|NCT01044563|Depressive Symptoms
410680|NCT01044563|postmenopause
410681|NCT01044563|RSA biofeedback
410682|NCT01044550|Diaphragm injury
410683|NCT01044550|Herniation
410684|NCT01044537|phase 1
410685|NCT01044537|safety and tolerability
410686|NCT01044537|PK
410687|NCT01044537|PD
410688|NCT01044537|type 2 diabetes mellitus
410689|NCT01044537|T2DM
410690|NCT01044524|14C labeled ADME (Aborption Distribution Metabolism and Elimination) study
410691|NCT01044524|Phase I
410692|NCT01044511|Esophageal cancer
410693|NCT01044511|Cardia cancer
410694|NCT01044511|Health Related quality of Life
410695|NCT01044511|SEMS
410696|NCT01044511|Home visits
410697|NCT01044485|HER-2 positive advanced or metastatic breast cancer
410698|NCT01044485|dose escalation study
410699|NCT01044485|lapatinib
410700|NCT01044485|docetaxel
410701|NCT01044472|CRT-D
410702|NCT01044459|Chronic Obstructive Pulmonary Disease
410703|NCT01044459|COPD
410704|NCT01044459|Chronic Bronchitis
410705|NCT01044459|Emphysema
410706|NCT01044459|Airflow Obstruction, Chronic
410707|NCT01044459|Chronic Airflow Obstruction
410708|NCT01044459|Chronic Obstructive Airway Disease
410709|NCT01044459|Chronic Obstructive Lung Disease
410710|NCT01044446|peritoneal dialysis
410711|NCT01044446|peritonitis
410712|NCT01044446|CAPD
410713|NCT01044446|end-stage renal disease
410714|NCT01044446|peritonitis outcome and ultrafiltration
410715|NCT01044407|respiration
410716|NCT01044407|sleep apnea
410717|NCT01044407|pacemaker
410718|NCT01044394|colonoscopy
410719|NCT01044394|bowel preparation
410720|NCT01044394|polyethylene glycol
410721|NCT01044394|Quality in endoscopy
410722|NCT01044394|Bowel Preparation for colonoscopy
410723|NCT01044381|Toenail
410724|NCT01044381|Fungal Infections
410725|NCT01044381|DSO
410726|NCT01044368|Remote Blood Glucose Monitoring System, Type 2 Diabetes
410727|NCT01044355|Resistant Hypertension
410728|NCT01044355|Obstructive Sleep Apnea
410729|NCT01044355|24 Hour Blood Pressure
410730|NCT01044355|Arterial Stiffness
410731|NCT01044355|Insulin Resistance
410732|NCT01044355|CPAP
410733|NCT01044355|APAP
410734|NCT01044342|Healthy Volunteers
410735|NCT01044342|EEG
410736|NCT01044316|Haemophilus influenzae type b (Hib)
410737|NCT01044316|Vaccine
410738|NCT01044316|Booster
410739|NCT01044303|Kidney Transplantation
410740|NCT01044303|Mycophenolic Acid
410741|NCT01044303|Donor-Specific Antibodies
410742|NCT01044303|Kidney Rejection
410743|NCT01044290|quality of life
410744|NCT01044290|end of life
410745|NCT01044290|self-disclosure
410746|NCT01044290|palliative care
410747|NCT01044277|glutathione
410748|NCT01044277|gluthathione peroxidases
410749|NCT01044277|GSH
410750|NCT01044264|Acne Vulgaris
410751|NCT01044264|bioequivalency
410752|NCT01044264|clindamycin
410753|NCT01044264|benzoyl peroxide
410754|NCT01044251|Medication overuse headache
410755|NCT01044251|Rebound headache
410756|NCT01044251|Analgesic overuse headache
410757|NCT01044251|Transitional therapy
410758|NCT01044251|Frovatriptan
410759|NCT01044251|Migraine
410760|NCT01044238|methamphetamine
410761|NCT01044238|methylphenidate
410762|NCT01044238|clinical trial
410763|NCT01044238|random assignment
410764|NCT01044238|double blind
410765|NCT01044238|abstinence
410766|NCT01044238|reduction in methamphetamine use
410767|NCT01044225|newly diagnosed glioblastoma
410768|NCT01044212|Urogynecology
410769|NCT01044199|rabies
410770|NCT01044199|rabies vaccine
410771|NCT01044199|purified cultured embryo chicken rabies vaccine
410772|NCT01044186|Deferasirox
410773|NCT01044186|ICL670A
410774|NCT01044186|Iron chelators
410775|NCT01044186|Deferiprone
410776|NCT01044186|Transfusional hemosiderosis
410777|NCT01044186|Congenital aplastic anemia (Diamond Blackfan anemia)
410778|NCT01044186|Red cell aplasia
410779|NCT01044186|Thalassemia
410780|NCT01044186|β thalassemia
410781|NCT01044173|acute abdomen
410782|NCT01044173|CT
410783|NCT01044173|MRI
410784|NCT01044173|fast imaging
410785|NCT01044160|cancer as trauma in children
410786|NCT01044160|PTG/PTSS/ PTSD in children with cancer vs healthy children
410787|NCT01044147|Obesity
410788|NCT01044147|Internet
410789|NCT01044121|mattress
410790|NCT01044121|pain
410791|NCT01044121|sleep
410792|NCT01044121|low back pain
410793|NCT01044121|back
410794|NCT01044121|neck
410795|NCT01044121|arousal
410796|NCT01044121|pillow
410797|NCT01044121|kingsdown
410798|NCT01044121|sleep to live
410799|NCT01044121|duke university
410800|NCT01044121|sleep to live institute
410801|NCT01044121|missouri
410802|NCT01044121|springfield
410803|NCT01044121|joplin
410804|NCT01044121|body diagnostic
410805|NCT01044121|dormo diagnostic
410806|NCT01044121|morning pain
410807|NCT01044095|seasonal influenza vaccine
410808|NCT01044095|avian influenza H5N1
410809|NCT01044095|cross reactivity
410810|NCT01044095|prime boost
410811|NCT01044082|Postpartum haemorrhage
410812|NCT01044082|Third stage of labour
410813|NCT01044082|Controlled cord traction
410814|NCT01044082|Randomized controlled trial
410815|NCT01044082|Prevention
410816|NCT01044069|Cyclophosphamide
410817|NCT01044069|T cell
410818|NCT01044069|leukapheresis
410819|NCT01044069|stem cell transplant
410820|NCT01044069|bone marrow transplant
410821|NCT01044069|09-114
410822|NCT01044030|otitis media
410823|NCT01044030|ear infection
410824|NCT01043991|STEMI
410825|NCT01043991|AMI,
410826|NCT01043991|acute myocardial infarct
410827|NCT01043991|Epo
410828|NCT01043991|Erythropoietin
410829|NCT01043991|ischemia-reperfusion
410830|NCT01043991|apoptosis
410831|NCT01043965|Diabetes Mellitus
410832|NCT01043965|Myocardial perfusion imaging
410833|NCT01043965|Heart diseases
410834|NCT01043965|Echocardiography
410835|NCT01043965|Endothelium
410836|NCT01043952|Propofol
410837|NCT01043952|Remifentanil
410838|NCT01043952|Bispectral Index Monitor
410839|NCT01043939|childhood cancers
410840|NCT01043939|cardiovascular disease
410841|NCT01043939|childhood cancer survivor
410842|NCT01043926|Hepatic Insufficiency
410843|NCT01043913|Fatigue
410844|NCT01043913|Breast Neoplasms
410845|NCT01043913|Quality of Life
410846|NCT01043913|Paullinia
410847|NCT01043900|Obsessive-Compulsive Disorder
410848|NCT01043900|rTMS
410849|NCT01043900|Transcranial Magnetic Stimulation
410850|NCT01043900|treatment
410851|NCT01043900|randomized controlled trials
410852|NCT01043887|Healthy Volunteers
410853|NCT01043887|Hepatic Insufficiency
410854|NCT01043874|Chronic phase
410855|NCT01043874|Chronic myelogenous leukemia
410856|NCT01043874|CML
410857|NCT01043874|Philadelphia chromosome positive
410858|NCT01043874|Ph+
410859|NCT01043874|Nilotinib
410860|NCT01043874|CML-CP
410861|NCT01043874|Suboptimal molecular response
410862|NCT01043848|neurogenic detrusor overactivity
410863|NCT01043848|neuromodulation
410864|NCT01043848|spinal cord injury
410865|NCT01043848|pudendal nerve stimulation
410866|NCT01043848|videocystometry
410867|NCT01043848|neurophysiology
410868|NCT01043848|neuroplasticity
410869|NCT01043835|Stomach Neoplasm
410870|NCT01043835|Laparoscopy
410871|NCT01043835|gastrectomy
410872|NCT01043822|Autism
410873|NCT01043822|mental retardation
410874|NCT01043822|pain
410875|NCT01043822|emotion
410876|NCT01043822|sensory profile
410877|NCT01043822|children
410878|NCT01043809|schools
410879|NCT01043809|handwashing
410880|NCT01043809|prevention and control
410881|NCT01043809|communicable diseases
410882|NCT01043809|absenteeism
410883|NCT01043796|Insecticide treated wall liners
410884|NCT01043796|Insecticide treated nets
410885|NCT01043796|Incidence cohort
410886|NCT01043783|Obesity
410887|NCT01043770|Metabolic syndrome
410888|NCT01043770|Primary prevention
410889|NCT01043770|Diabetes
410890|NCT01043770|Cardiovascular disease
410891|NCT01043770|Patient education
410892|NCT01043757|Sedentary lifestyle
410893|NCT01043757|physical exercise
410894|NCT01043757|behavioral economics
410895|NCT01043757|financial incentives
410896|NCT01043757|obesity
410897|NCT01043744|malaria
410898|NCT01043744|presumptive treatment
410899|NCT01043744|Integrated Management of Childhood Illness
410900|NCT01043744|fever
410901|NCT01043718|Obesity
410902|NCT01043718|Internet
410903|NCT01043705|Pacemaker infection
410904|NCT01043705|Defibrillator infection
410905|NCT01043705|ICD infection
410906|NCT01043705|CRT infection
410907|NCT01043705|Cardiovascular implantable electronic device infection
410908|NCT01043705|Infection
410909|NCT01043705|Pacemaker, Artificial
410910|NCT01043705|Defibrillators
410911|NCT01043692|Chronic Pain > 3 months
410912|NCT01043692|Acupuncture
410913|NCT01043692|Acceptability
410914|NCT01043692|Geriatrics
410915|NCT01043679|Bipolar, Mania
410916|NCT01043679|Utapine
410917|NCT01043679|Seroquel
410918|NCT01043666|Micturition
410919|NCT01043666|YM178
410920|NCT01043666|Urinary incontinence
410921|NCT01043666|Frequency
410922|NCT01043666|Overactive Bladder
410923|NCT01043666|Urgency
410924|NCT01043666|Urinary urge incontinence
410925|NCT01043653|recovery
410926|NCT01043653|serious mental illness
410927|NCT01043640|inherited metabolic disorders
410928|NCT01043614|Obesity
410929|NCT01043614|Obesity Prevention
410930|NCT01043614|Freshman women
410931|NCT01043614|Freshman 15 weight gain
410932|NCT01043614|Self efficacy
410933|NCT01043614|Activity and nutrition intervention
410934|NCT01043614|Peer education
410935|NCT01043588|Surgery
410936|NCT01043588|Prostate
410937|NCT01043588|Laser 532 nm
410938|NCT01043588|Photo selective Vaporization of the Prostate (PVP)
410939|NCT01043588|TransUrethral Resection of the Prostate (TURP)
410940|NCT01043588|Men health
410941|NCT01043575|rifapentine, pharmacokinetics, pharmacodynamics, tuberculosis
410942|NCT01043549|Gilles de la Tourette syndrome
410943|NCT01043549|Tics
410944|NCT01043549|Transcranial magnetic stimulation
410945|NCT01043536|IMRT
410946|NCT01043536|Radiotherapy escalation dose
410947|NCT01043536|glioblastoma
410948|NCT01043536|escalation radiotherapy dose
410949|NCT01043523|Liver neoplasms
410950|NCT01043523|Adenoma
410951|NCT01043523|Liver cell carcinoma
410952|NCT01043523|Hepatocellular
410953|NCT01043523|Liver abscess
410954|NCT01043484|Resectable rectal cancer
410955|NCT01043484|Radiotherapy
410956|NCT01043484|Bevacizumab
410957|NCT01043484|Capecitabine
410958|NCT01043471|Obesity
410959|NCT01043458|Pharmacokinetics
410960|NCT01043445|GPR 119
410961|NCT01043445|GLP-1 secretion
410962|NCT01043445|2-oleoyl-glycerol
410963|NCT01043445|Dietary supplementation
410964|NCT01043432|Traumatic Brain Injury
410965|NCT01043432|Suicide
410966|NCT01043432|Executive Function
410967|NCT01043419|Xenon Anesthesia
410968|NCT01043419|LENOXe™ (xénon 100 % v/v) anesthesia
410969|NCT01043419|Muscle Sympathetic Activity
410970|NCT01043419|Baroreflex reagibility
410971|NCT01043406|Epilepsy
410972|NCT01043406|Seizures
410973|NCT01043406|Advisory
410974|NCT01043406|Prediction
410975|NCT01043393|Plaque psoriasis
410976|NCT01043380|Heart Diseases
410977|NCT01043380|Hyperlipidemia
410978|NCT01043380|Atorvastatin
410979|NCT01043380|Ezetimibe
410980|NCT01043380|Cardiovascular Diseases
410981|NCT01043380|Hypercholesterolemia
410982|NCT01043380|Coronary Artery Disease
410983|NCT01043380|Dyslipidemias
410984|NCT01043380|Intravascular Ultrasound
410985|NCT01043367|Depression
410986|NCT01043367|Dietary supplement
410987|NCT01043367|Deprexil
410988|NCT01043354|cholesterol
410989|NCT01043354|diabetes
410990|NCT01043354|adherence
410991|NCT01043341|HPV
410992|NCT01043341|vaccines
410993|NCT01043341|knowledge
410994|NCT01043341|attitude
410995|NCT01043328|human papillomavirus
410996|NCT01043328|nested PCR
410997|NCT01043328|saliva
410998|NCT01043328|serum
410999|NCT01043328|oral tissues
411000|NCT01043315|Cognitive Function
411001|NCT01043315|Cognitive Impairment
411002|NCT01043315|Hospitalization
411003|NCT01043315|Cardiac Disease
411004|NCT01043302|lymphoma, intestine, outcome, quality of life
411005|NCT01043289|light therapy
411006|NCT01043289|antepartum depression
411007|NCT01043289|controlled trial
411008|NCT01043276|Healthy
411009|NCT01043250|schizophrenia
411010|NCT01043250|atypical antipsychotics
411011|NCT01043250|appetite
411012|NCT01043250|eating behavior
411013|NCT01043237|acoustic
411014|NCT01043237|digital
411015|NCT01043237|sound
411016|NCT01043237|vibration
411017|NCT01043237|coronary
411018|NCT01043237|auscultation
411019|NCT01043237|artery
411020|NCT01043237|diagnosis
411021|NCT01043211|Back Pain
411022|NCT01043211|Lidocaine
411023|NCT01043198|CGH array technology
411024|NCT01043198|mental retardation
411025|NCT01043198|chromosomal abnormalities
411026|NCT01043198|syndromic obesity
411027|NCT01043198|obesity
411028|NCT01043185|GERD
411029|NCT01043185|lesogaberan
411030|NCT01043185|impedance
411031|NCT01043185|pH
411032|NCT01043185|pharmacokinetics
411033|NCT01043185|safety
411034|NCT01043185|tolerability
411035|NCT01043146|anti-beta1 adrenergic receptor
411036|NCT01043146|autoantibody
411037|NCT01043146|cyclic peptide
411038|NCT01043146|heart failure
411039|NCT01043133|electronic medical records
411040|NCT01043133|documentation templates
411041|NCT01043133|clinical encounter notes
411042|NCT01043081|African American women who have sex with women
411043|NCT01043081|Sexually transmitted infections
411044|NCT01043081|Homosexuality
411045|NCT01043081|Human papillomavirus
411046|NCT01043081|Cervical intraepithelial neoplasia
411047|NCT01043081|Herpes simplex virus types 1 and 2
411048|NCT01043081|Chlamydia
411049|NCT01043081|Gonorrhea
411050|NCT01043081|Trichomoniasis
411051|NCT01043081|Bacterial vaginosis
411052|NCT01043081|Syphilis
411053|NCT01043081|Human immunodeficiency virus
411054|NCT01043068|cancer pain
411055|NCT01043068|opioid
411056|NCT01043068|guideline
411057|NCT01043055|Breast Cancer Screening
411058|NCT01043042|hypoglycemia among inpatients
411059|NCT01043042|hyperglycemia among inpatients
411060|NCT01043016|skin cancer
411061|NCT01043016|esophageal cancer
411062|NCT01043016|photodynamic therapy
411063|NCT01042990|Stroke
411064|NCT01042990|Exercise
411065|NCT01042990|Balance
411066|NCT01042990|Dynamic Gait
411067|NCT01042990|Cardiovascular Fitness
411068|NCT01042977|dapagliflozin
411069|NCT01042977|diabetes
411070|NCT01042977|cardiovascular disease
411071|NCT01042964|platelet adhesion and aggregation
411072|NCT01042964|acute coronary syndrome
411073|NCT01042964|myocardial infarction
411074|NCT01042964|stroke
411075|NCT01042964|inhibition of platelet adhesion to plaques
411076|NCT01042964|collagen-induced platelet aggregation
411077|NCT01042951|safety
411078|NCT01042951|immunogenicity
411079|NCT01042951|Healthy Participants
411080|NCT01042938|Radiation dermatitis in breast cancer patients
411081|NCT01042925|HER2 positive breast cancer
411082|NCT01042925|breast cancer
411083|NCT01042925|breast tumors
411084|NCT01042925|human mammary carcinoma
411085|NCT01042912|diagnosis
411086|NCT01042912|carotid
411087|NCT01042912|artery
411088|NCT01042912|disease
411089|NCT01042912|auscultation
411090|NCT01042912|sound
411091|NCT01042899|TBI
411092|NCT01042899|intracranial edema
411093|NCT01042899|brain edema
411094|NCT01042899|craniocerebral trauma
411095|NCT01042899|head injury
411096|NCT01042899|brain hemorrhage, traumatic
411097|NCT01042899|subdural hematoma
411098|NCT01042899|brain concussion
411099|NCT01042899|head injuries, closed
411100|NCT01042899|epidural hematoma
411101|NCT01042899|extra-axial hemorrhage
411102|NCT01042899|cortical contusion
411103|NCT01042899|wounds and injuries
411104|NCT01042899|disorders of environmental origin
411105|NCT01042899|trauma, nervous system
411106|NCT01042899|brain injuries
411107|NCT01042886|Non-blind, randomized controlled trial
411108|NCT01042886|Pilot study
411109|NCT01042873|Desensitization
411110|NCT01042873|beta adrenergic receptors
411111|NCT01042873|Healthy subjects
411112|NCT01042860|macular pigment
411113|NCT01042860|lutein
411114|NCT01042860|age-related macular degeneration
411115|NCT01042860|AMD
411116|NCT01042847|ovarian
411117|NCT01042834|air pollution
411118|NCT01042834|autonomic nervous system
411119|NCT01042834|sleep apnea
411120|NCT01042834|Heart rate variability
411121|NCT01042834|Healthy volunteers
411122|NCT01042821|anal fistula
411123|NCT01042821|advancement flap
411124|NCT01042821|incontinence
411125|NCT01042795|sunitinib
411126|NCT01042795|bladder neoplasm
411127|NCT01042795|adjuvant treatment
411128|NCT01042795|disease free survival
411129|NCT01042795|Patients with extravesical tumor (pT2-4,Nany, M0 or pTanyN+M0) after cystectomy and platin-based neoadjuvant chemotherapy
411130|NCT01042782|gastric cancer
411131|NCT01042782|RAD001
411132|NCT01042782|Mitomycin C
411133|NCT01042782|MTD
411134|NCT01042743|colon cancer
411135|NCT01042743|robot
411136|NCT01042743|laparoscopy
411137|NCT01042743|primary, right-side colon cancer
411138|NCT01042743|robot-assisted surgery
411139|NCT01042730|Pitavastatin
411140|NCT01042730|Coronary Artery Disease
411141|NCT01042730|Cardiovascular Disease
411142|NCT01042717|plerixafor
411143|NCT01042717|autologous transplantation
411144|NCT01042717|hematopoietic stem cell mobilization
411145|NCT01042717|multiple myeloma
411146|NCT01042717|non-Hodgkins lymphoma
411147|NCT01042704|Relapsed Myeloma
411148|NCT01042704|Refractory Myeloma
411149|NCT01042665|Glaucoma
411150|NCT01042665|intraocular pressure
411151|NCT01042665|latanoprost
411152|NCT01042665|retinal ganglion cell
411153|NCT01042665|pattern electroretinogram
411154|NCT01042652|Methadone
411155|NCT01042652|HIV
411156|NCT01042652|Raltegravir
411157|NCT01042652|Antiretroviral
411158|NCT01042652|Intravenous Drug User
411159|NCT01042652|Methadone Maintenance
411160|NCT01042652|Treatment Naive
411161|NCT01042639|osteopenia
411162|NCT01042639|very low birthweight infants
411163|NCT01042639|bone speed of sound
411164|NCT01042639|quantitative ultrasound
411165|NCT01042626|Receptors, Calcium sensing
411166|NCT01042626|Parathyroid Hormone
411167|NCT01042613|AccuVein AV300 device;
411168|NCT01042613|Intravenous cannulation
411169|NCT01042600|Respiratory distress syndrome
411170|NCT01042600|Surfactant
411171|NCT01042600|Tracheal intubation
411172|NCT01042600|Laryngeal mask airway
411173|NCT01042600|Newborn
411174|NCT01042587|bright light therapy
411175|NCT01042587|circadian rhythm,
411176|NCT01042587|entrainment
411177|NCT01042574|intracranial hemorrhage (ICH)
411178|NCT01042574|subarachnoid hemorrhage (SAH)
411179|NCT01042574|intracranial monitoring
411180|NCT01042574|external ventricular drain (ventriculostomy)
411181|NCT01042574|hypertension
411182|NCT01042561|vitamin d
411183|NCT01042561|prematurity
411184|NCT01042561|25(OH)D
411185|NCT01042561|infant
411186|NCT01042561|CRP
411187|NCT01042561|PTH
411188|NCT01042548|Proteomics
411189|NCT01042548|Breast Cancer Markers
411190|NCT01042548|Tissue Interstitial Fluid
411191|NCT01042509|Chronic Graft vs Host Disease
411192|NCT01042509|Alemtuzumab
411193|NCT01042509|Rituximab
411194|NCT01042509|Low-dose
411195|NCT01042509|Alemtuzumab and rituximab combination
411196|NCT01042496|Bipolar
411197|NCT01042496|depression
411198|NCT01042483|active stage
411199|NCT01042483|labor
411200|NCT01042483|progression
411201|NCT01042483|pregnant women during active phases of labor
411202|NCT01042470|pelvic organ prolapse
411203|NCT01042470|pelvic floor dysfunction
411204|NCT01042470|biomechanics
411205|NCT01042470|aspiration device
411206|NCT01042470|connective tissue
411207|NCT01042457|trough level
411208|NCT01042457|therapeutic drug monitoring
411209|NCT01042457|Mycophenolate mofetil
411210|NCT01042457|Mycophenolic acid
411211|NCT01042457|lupus nephritis
411212|NCT01042444|Heart disease
411213|NCT01042444|Embolic Protection Device
411214|NCT01042444|PCI
411215|NCT01042444|SVG
411216|NCT01042431|Nutritional status of ward patients and hospitalization outcome
411217|NCT01042418|satiety
411218|NCT01042418|grain structure
411219|NCT01042418|rye
411220|NCT01042392|Moderate systolic hypertension - adults - aliskiren -ramipril
411221|NCT01042379|I-SPY 2
411222|NCT01042379|Neoadjuvant
411223|NCT01042379|Breast
411224|NCT01042379|Cancer
411225|NCT01042379|Neoplasm
411226|NCT01042379|Adaptive
411227|NCT01042379|pCR
411228|NCT01042379|Pathologic Complete Response
411229|NCT01042379|Biomarkers signature
411230|NCT01042379|MRI Volume
411231|NCT01042366|Melanoma
411232|NCT01042340|nutrition
411233|NCT01042340|geriatric
411234|NCT01042340|supplement
411235|NCT01042340|energy
411236|NCT01042327|solute clearances
411237|NCT01042288|Non-Small-Cell Lung Cancer
411238|NCT01042288|NSCLC
411239|NCT01042288|Panitumumab
411240|NCT01042288|Vectibix
411241|NCT01042288|Pemetrexed
411242|NCT01042288|Alimta
411243|NCT01042288|Carboplatin
411244|NCT01042275|stress urinary incontinence
411245|NCT01042275|retropubic sling
411246|NCT01042275|transobturator sling
411247|NCT01042275|tension-free vaginal tape
411248|NCT01042275|transobturator tape
411249|NCT01042275|TVT
411250|NCT01042275|TVT-O
411251|NCT01042275|TOT
411252|NCT01042275|REMEEX
411253|NCT01042275|IVS
411254|NCT01042262|Superoxide dismutase
411255|NCT01042262|Oxygen
411256|NCT01042262|Oxygen free radicals
411257|NCT01042262|Labor and delivery
411258|NCT01042249|PFMT
411259|NCT01042249|Stroke
411260|NCT01042249|LUTS
411261|NCT01042249|Men
411262|NCT01042236|Phase 2 stress urinary incontinence Fesoterodine
411263|NCT01042223|Factors Predisposing or Causing
411264|NCT01042210|preeclampsia
411265|NCT01042210|agouti-related peptide
411266|NCT01042210|intrauterine growth
411267|NCT01042210|birth weight
411268|NCT01042210|Intrauterine growth restriction due to preeclampsia
411269|NCT01042197|Vitamin D
411270|NCT01042197|UVB
411271|NCT01042197|Dose-Response
411272|NCT01042197|Body surface area
411273|NCT01042184|H. pylori infected patients without prior eradication therapy
411274|NCT01042158|Tadalafil
411275|NCT01042158|Ambrisentan
411276|NCT01042158|Quality of Life
411277|NCT01042145|Primary Care
411278|NCT01042145|Treatment
411279|NCT01042145|Croup
411280|NCT01042145|Corticosteroids
411281|NCT01042145|Prednisone
411282|NCT01042145|Dexamethasone
411283|NCT01042145|Randomized trial
411284|NCT01042132|intramedullary reaming
411285|NCT01042132|inflammatory response
411286|NCT01042132|human
411287|NCT01042132|femoral shaft fracture
411288|NCT01042132|Reamer-irrigator-aspirator
411289|NCT01042119|botulinum neurotoxin type A
411290|NCT01042119|BoNT/A
411291|NCT01042119|Botox
411292|NCT01042119|overactive bladder syndrome
411293|NCT01042106|diabetes
411294|NCT01042093|Analgesia
411295|NCT01042093|postoperative pain
411296|NCT01042093|periarticular
411297|NCT01042093|arthroplasty
411298|NCT01042093|pain management
411299|NCT01042080|Mechanical ventilation
411300|NCT01042080|Neurally adjusted ventilatory assist (NAVA)
411301|NCT01042080|Acute respiratory failure
411302|NCT01042080|Chronic obstructive pulmonary disease
411303|NCT01042080|Weaning
411304|NCT01042080|Invasive mechanical ventilation
411305|NCT01042080|Positive Pressure support Ventilation
411306|NCT01042067|warfarin
411307|NCT01042067|genotyping
411308|NCT01042067|vitamin K
411309|NCT01042067|dosing
411310|NCT01042067|adverse events
411311|NCT01042067|initial phase of treatment
411312|NCT01042067|algorithm
411313|NCT01042054|Postoperative Care
411314|NCT01042054|Enhanced
411315|NCT01042054|Recovery
411316|NCT01042054|Hepatectomy
411317|NCT01042054|Analgesia
411318|NCT01042028|Pancreas cancer
411319|NCT01042028|Everolimus
411320|NCT01042028|Irinotecan
411321|NCT01042028|Cetuximab
411322|NCT01042028|Capecitabine
411323|NCT01042028|Oxaliplatin
411324|NCT01042028|Gemcitabine resistant pancreascancer
411325|NCT01042015|trauma
411326|NCT01042015|cardiac arrest
411327|NCT01042015|hemorrhagic shock
411328|NCT01042002|High intensity exercise
411329|NCT01042002|morbid obesity
411330|NCT01042002|gastric bypass
411331|NCT01041989|dementia
411332|NCT01041989|cognitive impairment
411333|NCT01041989|disability
411334|NCT01041989|intervention
411335|NCT01041989|elderly
411336|NCT01041989|lifestyle counseling
411337|NCT01041976|Veterans
411338|NCT01041976|Vocational Rehabilitation
411339|NCT01041963|ACEI
411340|NCT01041963|ARB
411341|NCT01041963|CAPD
411342|NCT01041963|Peritoneal membrane transport
411343|NCT01041950|intracerebral hemorrhage
411344|NCT01041950|intraventricular hemorrhage
411345|NCT01041950|hydrocephalus
411346|NCT01041950|Intracerebral hemorrhage with severe ventricular involvement and obstructive hydrocephalus
411347|NCT01041924|Sleep apnea
411348|NCT01041924|Periodic breathing
411349|NCT01041924|Heart Failure
411350|NCT01041911|Hemorrhoids
411351|NCT01041898|osteocalcin
411352|NCT01041898|insulin
411353|NCT01041898|body composition
411354|NCT01041898|bone mineral density
411463|NCT01041521|omega three fatty acids
411355|NCT01041898|Evaluate the effect of osteocalcin on bone mineral density
411356|NCT01041898|Evaluate the effect of osteocalcin on body fat distribution
411357|NCT01041898|Evaluate the effect of osteocalcin on insulin homeostasis
411358|NCT01041885|knee cartilage defect repair
411359|NCT01041885|cartilage lesion
411360|NCT01041885|autologous chondrocyte
411361|NCT01041885|scaffold
411362|NCT01041885|INSTRUCT
411363|NCT01041859|Diabetic Peripheral Neuropathy
411364|NCT01041859|Painful
411365|NCT01041859|Polyneuropathy
411366|NCT01041859|Peripheral neuropathy
411367|NCT01041846|Myelodysplastic Syndrome
411368|NCT01041846|Dacogen
411369|NCT01041846|Decitabine
411370|NCT01041846|Epigenetic therapy
411371|NCT01041846|Hypomethylating agent
411372|NCT01041833|All-trans retinoic acid
411373|NCT01041833|non-small cell lung cancer
411374|NCT01041833|retinoic acid receptor beta
411375|NCT01041820|exercise
411376|NCT01041820|bone marrow adipose tissue
411377|NCT01041820|bone mineral density
411378|NCT01041820|Children in the intervention condition will complete a supervised physical activity program 3 days/wk for 10 weeks
411379|NCT01041820|Control treatment will be provided no intervention
411380|NCT01041820|All participants will be instructed not to change their current dietary habits during the study period.
411381|NCT01041807|Hypertension
411382|NCT01041794|body composition
411383|NCT01041794|fat distribution
411384|NCT01041794|exercise
411385|NCT01041794|diet
411386|NCT01041781|adenocarcinoma of the lung
411387|NCT01041781|adenosquamous cell lung cancer
411388|NCT01041781|large cell lung cancer
411389|NCT01041781|squamous cell lung cancer
411390|NCT01041781|recurrent non-small cell lung cancer
411391|NCT01041781|stage IIIB non-small cell lung cancer
411392|NCT01041781|stage IV non-small cell lung cancer
411393|NCT01041768|Type 2 Diabetes Mellitus
411394|NCT01041755|Encephalopathy
411395|NCT01041755|Cirrhosis
411396|NCT01041716|Carbapenem
411397|NCT01041716|Klebsiella pneumoniae carbapenemase
411398|NCT01041716|Acinetobacter baumannii
411399|NCT01041716|Pseudomonas aeruginosa
411400|NCT01041703|untreated adult acute myeloid leukemia
411401|NCT01041703|secondary acute myeloid leukemia
411402|NCT01041703|adult acute minimally differentiated myeloid leukemia (M0)
411403|NCT01041703|adult acute myeloblastic leukemia without maturation (M1)
411404|NCT01041703|adult acute myeloblastic leukemia with maturation (M2)
411405|NCT01041703|adult acute myelomonocytic leukemia (M4)
411406|NCT01041703|adult acute monoblastic leukemia (M5a)
411407|NCT01041703|adult acute monocytic leukemia (M5b)
411408|NCT01041703|adult erythroleukemia (M6a)
411409|NCT01041703|adult pure erythroid leukemia (M6b)
411410|NCT01041703|adult acute megakaryoblastic leukemia (M7)
411411|NCT01041703|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
411412|NCT01041703|adult acute myeloid leukemia with del(5q)
411413|NCT01041703|adult acute myeloid leukemia with inv(16)(p13;q22)
411414|NCT01041703|adult acute myeloid leukemia with t(16;16)(p13;q22)
411415|NCT01041703|adult acute myeloid leukemia with t(8;21)(q22;q22)
411416|NCT01041690|Proliferative Diabetic Retinopathy
411417|NCT01041690|Vitrectomy
411418|NCT01041690|Bevacizumab
411419|NCT01041677|Obesity
411420|NCT01041677|Overweight
411421|NCT01041677|Body Weight
411422|NCT01041677|Body Size
411423|NCT01041677|Nutritional and Metabolic Diseases
411424|NCT01041664|nutrigenomics
411425|NCT01041664|admixture
411426|NCT01041664|Hispanic American
411427|NCT01041664|body composition
411428|NCT01041664|Association of diet and body composition
411429|NCT01041664|Association between genes and body composition
411430|NCT01041664|Association between gen by diet interaction and body composition
411431|NCT01041625|Lichen Planus
411432|NCT01041612|CBD
411433|NCT01041612|HBD
411434|NCT01041612|cancer of bile duct
411435|NCT01041612|pancreatic cancer
411436|NCT01041599|Diabetes Mellitus
411437|NCT01041599|Hypertension
411438|NCT01041599|Albuminuria
411439|NCT01041599|vascular stiffness
411440|NCT01041586|Emphysema
411441|NCT01041586|COPD
411442|NCT01041586|Lung Volume Reduction
411443|NCT01041586|BTVA
411444|NCT01041573|Pediatric
411445|NCT01041573|Japanese Encephalitis Vaccine
411446|NCT01041573|endemic countries
411447|NCT01041573|to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51
411448|NCT01041560|Stroke
411449|NCT01041560|Tone
411450|NCT01041560|Strength
411451|NCT01041547|Insulin sensitivity
411452|NCT01041547|Vascular function
411453|NCT01041547|Flow-mediated dilation
411454|NCT01041547|Arterial stiffness
411455|NCT01041547|Glucose tolerance
411456|NCT01041547|Hypertension
411457|NCT01041534|Adjustable gastric band, morbid obesity, bariatric surgery
411458|NCT01041521|HIV infection
411459|NCT01041521|Dyslipidemia
411460|NCT01041521|Elevated Triglyceride level
411461|NCT01041521|vascular function (BART)
411462|NCT01041521|arterial stiffness
411464|NCT01041521|complementary therapies
411465|NCT01041508|ALL
411466|NCT01041508|AML
411467|NCT01041508|Recurrence
411468|NCT01041508|Relapsed
411469|NCT01041508|Stem Cell Transplant
411470|NCT01041508|Non-myeloablastive
411471|NCT01041495|fibromyalgia
411472|NCT01041495|Pain
411473|NCT01041495|Sleep
411474|NCT01041495|Fatigue
411475|NCT01041482|sorafenib
411476|NCT01041482|renal cell carcinoma
411477|NCT01041482|disease free survival
411478|NCT01041482|Hand food skin reaction
411479|NCT01041469|Down syndrome, Humans,Clinical study,Immunity, Autoimmunity,
411480|NCT01041456|complicated biliopancreatic diversion
411481|NCT01041456|failed biliopancreatic diversion
411482|NCT01041456|revision gastric bypass
411483|NCT01041456|conversion bariatric surgery
411484|NCT01041456|revision bariatric surgery
411485|NCT01041456|re-operative bariatric surgery
411486|NCT01041456|malabsorptive syndrome
411487|NCT01041456|protein malnutrition
411488|NCT01041456|metabolic bone disease
411489|NCT01041430|Ambulatory Surgery
411490|NCT01041430|Aged
411491|NCT01041417|claudication
411492|NCT01041391|Surgical intervention vs Non-Surgical intervention
411493|NCT01041378|Pediatric patients (6 months-5 years) scheduled elective day-case orchiopexy
411494|NCT01041365|insulin sensitivity
411495|NCT01041365|vascular function
411496|NCT01041365|flow-mediated dilation
411497|NCT01041365|arterial stiffness
411498|NCT01041365|ethnicity
411499|NCT01041365|adolescents
411500|NCT01041365|females
411501|NCT01041365|glucose tolerance
411502|NCT01041365|diabetes
411503|NCT01041365|hypertension
411504|NCT01041365|cardiovascular
411505|NCT01041352|anaesthesia
411506|NCT01041352|laryngeal mask
411507|NCT01041352|prone position
411508|NCT01041339|LpPLA2
411509|NCT01041339|ST elevation
411510|NCT01041339|acute pericarditis
411511|NCT01041326|prostatectomy
411512|NCT01041326|radiation
411513|NCT01041326|neoadjuvant
411514|NCT01041313|Adjuvants, pharmaceuticals
411515|NCT01041313|Receptors, N-Methyl-D-Aspartate
411516|NCT01041313|Drug tolerance
411517|NCT01041313|Pain Measurement
411518|NCT01041300|Transcranial Magnetic Stimulation
411519|NCT01041300|TMS
411520|NCT01041300|Motor Threashold
411521|NCT01041300|Multiway
411522|NCT01041300|Magstim Rapid 2
411523|NCT01041300|Abductor policis brevis
411524|NCT01041300|Figure 8 coil
411525|NCT01041300|Double cone coil
411526|NCT01041300|Circular coil
411527|NCT01041300|Brainsway
411528|NCT01041300|Healthy participants.
411529|NCT01041274|Schizophrenia
411530|NCT01041274|Citalopram
411531|NCT01041274|First episode
411532|NCT01041274|fMRI
411533|NCT01041274|Cognitive behavioral therapy
411534|NCT01041274|Psychoeducation
411535|NCT01041261|Laparoscopic gastric bypass surgery
411536|NCT01041261|Medical food
411537|NCT01041261|Body composition
411538|NCT01041261|Dietary intervention
411539|NCT01041248|Relapsing Polychondritis
411540|NCT01041248|Single Patient Study
411541|NCT01041248|Tocilizumab
411542|NCT01041235|Solid Neoplasms
411543|NCT01041235|Carcinoma
411544|NCT01041235|Breast
411545|NCT01041235|Ovarian
411546|NCT01041235|Ovary
411547|NCT01041235|Pancreas
411548|NCT01041235|Pancreatic
411549|NCT01041235|Lung
411550|NCT01041235|NSCLC
411551|NCT01041235|Non Small Cell Lung
411552|NCT01041235|Prostate
411553|NCT01041235|Gastric
411554|NCT01041235|Head and Neck
411555|NCT01041222|Familial ALS
411556|NCT01041222|ALS
411557|NCT01041222|SOD1 Protein
411558|NCT01041222|ISIS 333611
411559|NCT01041222|SOD1Rx
411560|NCT01041209|Pneumonia
411561|NCT01041209|Children
411562|NCT01041196|obesity
411563|NCT01041196|ulcer disease
411564|NCT01041196|marginal ulcer
411565|NCT01041196|perforation
411566|NCT01041196|abdominal pain
411567|NCT01041196|bariatric surgery
411568|NCT01041196|weight loss surgery
411569|NCT01041183|Oral plus IV ramosetron may be more effective than
411570|NCT01041183|IV ramosetron and oral ramosetron for the prophylaxis of
411571|NCT01041183|PONV after laparoscopic cholecystectomy
411572|NCT01041170|Rimonabant
411573|NCT01041170|fMRI
411574|NCT01041170|Alternative Matrices
411575|NCT01041170|Brain Imaging
411576|NCT01041170|THC
411577|NCT01041157|Torticollis
411578|NCT01041157|Botulinum Toxins
411579|NCT01041144|Diabetes
411580|NCT01041144|PDA
411581|NCT01041144|Internet
411582|NCT01041144|HbA1c
411583|NCT01041131|Obesity
411584|NCT01041131|Obesity recidivism
411585|NCT01041131|Inadequate Initial Weight Loss
411586|NCT01041131|Technical bariatric complications
411587|NCT01041131|Complicated gastroplasty
411588|NCT01041131|Failed gastroplasty
411589|NCT01041131|Gastroesophageal reflux disease
411590|NCT01041131|Revisional gastric bypass
411591|NCT01041131|Conversion bariatric surgery
411592|NCT01041131|Re-operative bariatric surgery
411593|NCT01041131|Technical complications of vertical gastroplasty
411594|NCT01041131|Complicated vertical gastroplasty
411595|NCT01041105|Obesity
411596|NCT01041105|Gastroesophageal Reflux Disease
411597|NCT01041105|Nissen funduplication
411598|NCT01041105|Antireflux surgery
411599|NCT01041105|Revisional Gastric Bypass
411600|NCT01041105|Re-operative bariatric surgery
411601|NCT01041105|Bariatric surgery
411602|NCT01041105|Nissen
411603|NCT01041105|Conversion of Nissen to Gastric Bypass
411604|NCT01041079|ulcer disease
411605|NCT01041079|marginal ulcer
411606|NCT01041079|morbidity of gastric bypass
411607|NCT01041079|late morbidity of gastric bypass
411608|NCT01041079|chronic abdominal pain
411609|NCT01041079|GI hemorrhage
411610|NCT01041079|Perforation
411611|NCT01041079|Penetration
411612|NCT01041079|Obstruction
411613|NCT01041066|patients who are intubated for general anesthesia
411614|NCT01041040|Acute Myeloblastic Leukemia
411615|NCT01041014|Limited English proficiency
411616|NCT01041014|Cost-effectiveness
411617|NCT01041014|Emergency Departments
411618|NCT01041014|Language Discordance
411619|NCT01041014|Satisfaction
411620|NCT01041014|Limited English proficient patients
411621|NCT01041014|Spanish-speaking patients
411622|NCT01041001|Umbilical Cord Blood
411623|NCT01041001|Mesenchymal Stem Cells
411624|NCT01041001|cartilage injury
411625|NCT01041001|osteoarthritis
411626|NCT01040988|Pacemaker
411627|NCT01040988|Implantable cardioverter-defibrillator
411628|NCT01040962|neuropathy
411629|NCT01040962|diabetes
411630|NCT01040949|smoking cessation
411631|NCT01040949|pregnant Latinas
411632|NCT01040949|couples communication
411633|NCT01040949|Latino community
411634|NCT01040949|couples communication in Latino couples
411635|NCT01040936|acute coronary syndrome
411636|NCT01040936|intervention
411637|NCT01040936|outcome
411638|NCT01040936|patients diagnosed ad Non-ST elevation ACS
411639|NCT01040936|patients received PCI therapy
411640|NCT01040923|CAD
411641|NCT01040923|Diagnostic
411642|NCT01040910|cannabis
411643|NCT01040910|Crohn's disease
411644|NCT01040910|Ulcerative colitis
411645|NCT01040910|IBD
411646|NCT01040897|Obesity prevention
411647|NCT01040897|Health Literacy
411648|NCT01040897|Health Communication
411649|NCT01040858|cognitive strategy intervention
411650|NCT01040858|cognitive disorders
411651|NCT01040845|healthy
411652|NCT01040845|pharmacokinetics
411653|NCT01040845|drug-interaction
411654|NCT01040832|Head and Neck Cancer
411655|NCT01040832|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer
411656|NCT01040832|Cetuximab
411657|NCT01040832|EMD 1201081
411658|NCT01040819|Diabetes Mellitus
411659|NCT01040819|6-Ketoprostaglandin F1 alpha
411660|NCT01040819|15-epi-lipoxin A4
411661|NCT01040819|Thiazolidinediones
411662|NCT01040819|Pioglitazone
411663|NCT01040806|Diabetes
411664|NCT01040780|Efficacy
411665|NCT01040780|Safety
411666|NCT01040780|EGFR-TKI
411667|NCT01040780|phase III
411668|NCT01040780|NSCLC
411669|NCT01040767|Ultrasound education
411670|NCT01040767|Blended learning
411671|NCT01040767|Distance education
411672|NCT01040767|Trauma ultrasound
411673|NCT01040767|FAST
411674|NCT01040741|Pandemic influenza A (H1N1) vaccine
411675|NCT01040741|Adjuvanted
411676|NCT01040715|Rheumatoid arthritis
411677|NCT01040715|anti-drug antibodies
411678|NCT01040715|Rheumatoid arthritis with secondary loss of efficacy to anti-TNFa antagonists and anti-drug antibodies
411679|NCT01040676|Diabetes Mellitus
411680|NCT01040676|Telephone
411681|NCT01040676|Nutrition Support
411682|NCT01040676|Automated
411683|NCT01040676|Low English Proficiency
411684|NCT01040676|Hispanic
411685|NCT01040676|Latino
411686|NCT01040637|Healthy subjects
411687|NCT01040624|Prostate Cancer, Proton Radiation
411688|NCT01040611|music therapy
411689|NCT01040611|Tuberculosis
411690|NCT01040611|anxiety
411691|NCT01040611|physiological response
411692|NCT01040598|Eosinophilic Esophagitis
411693|NCT01040598|Xolair
411694|NCT01040598|Omalizumab
411695|NCT01040598|Esophagitis
411696|NCT01040598|Eosinophils
411697|NCT01040598|monoclonal antibody
411698|NCT01040585|cost effectiveness
411699|NCT01040585|linezolid
411700|NCT01040585|ventilator acquired pneumonia
411701|NCT01040585|central america
411702|NCT01040572|Obesity recidivism
411703|NCT01040572|Weight Regain
411704|NCT01040572|Weight recidivism
411705|NCT01040572|Morbidity
411706|NCT01040572|Complication
411707|NCT01040572|Late complications
411708|NCT01040572|Revisional gastric bypass
411709|NCT01040572|Re-operative gastric bypass
411710|NCT01040572|Revisional bariatric surgery
411711|NCT01040572|Re-operative bariatric surgery
411712|NCT01040546|Obesity
411713|NCT01040546|Metabolic syndrome
411714|NCT01040546|Weight control educational intervention
411715|NCT01040546|Food intake
411716|NCT01040533|Failed jejunoileal bypass
411717|NCT01040533|Complicated jejunoileal bypass
411718|NCT01040533|Revision gastric bypass
411719|NCT01040533|Revisional surgery
411720|NCT01040533|Reoperations
411721|NCT01040533|Metabolic and nutritional complications
411722|NCT01039545|Urinary tract infections
411723|NCT01039545|Anti-bacterial agents
411724|NCT01039532|Type 2 diabetes mellitus
411725|NCT01039532|Biphasic human insulin thrice a day
411726|NCT01039532|Basal bolus insulin
411727|NCT01039519|G.I. Stromal Tumor
411728|NCT01039519|GIST
411729|NCT01039506|UGT1A1, irinotecan
411730|NCT01039480|pharmacological biomarker
411731|NCT01039480|compliance monitoring
411732|NCT01039480|platelet aggregometry
411733|NCT01039480|resistance
411734|NCT01039480|Platelet Aggregation Inhibitors
411735|NCT01039480|Medication Non-Compliance
411736|NCT01039467|Managed Ventricular Pacing
411737|NCT01040520|CT-based autopsy
411738|NCT01040520|virtual autopsy
411739|NCT01040520|medical autopsy
411740|NCT01040520|quality control
411741|NCT01040507|severe obesity
411742|NCT01040507|morbid obesity
411743|NCT01040507|gastric bypass
411744|NCT01040507|efficacy of gastric bypass
411745|NCT01040494|Aliskiren
411746|NCT01040494|Congestive heart failure
411747|NCT01040494|Central hemodynamics
411748|NCT01040481|Failed gastric bypass
411749|NCT01040481|Malabsorptive distal gastric bypass
411750|NCT01040481|Distal gastric bypass
411751|NCT01040481|Malabsorptive gastric bypass
411752|NCT01040481|Adding malabsorption
411753|NCT01040481|Increasing malabsorption
411754|NCT01040481|Re-operative bariatric surgery
411755|NCT01040481|Revisional bariatric surgery
411756|NCT01040481|Revisional gastric bypass
411757|NCT01040481|Reoperations
411758|NCT01040481|Conversions
411759|NCT01040468|Type 2 Diabetes
411760|NCT01040468|Bariatric Surgery
411761|NCT01040468|Roux-en-Y Gastric Bypass
411762|NCT01040468|Gastric Banding
411763|NCT01040468|Obesity
411764|NCT01040468|Weight loss
411765|NCT01040468|Insulin sensitivity
411766|NCT01040468|GLP-1
411767|NCT01040468|Meal Challenge
411768|NCT01040468|Euglycemic Clamp
411769|NCT01040455|functional dyspepsia
411770|NCT01040455|lansoprazole
411771|NCT01040455|placebo effect
411772|NCT01040442|Postural Balance
411773|NCT01040442|Aging
411774|NCT01040442|Accidental Falls
411775|NCT01040442|Vibration
411776|NCT01040429|Adolescent
411777|NCT01040429|Clonidine
411778|NCT01040429|Autonomic nervous system
411779|NCT01040429|Stress
411780|NCT01040416|complicated marginal ulcer
411781|NCT01040416|complex marginal ulcer
411782|NCT01040416|complication after gastric bypass
411783|NCT01040416|gastrointestinal hemorrhage
411784|NCT01040390|Acne Vulgaris
411785|NCT01040390|Homoeopathy
411786|NCT01040390|Lappa Arctium
411787|NCT01040377|Inadequate Initial Weight Loss
411788|NCT01040377|Inadequate weight loss
411789|NCT01040377|Poor weight loss
411790|NCT01040377|Failed gastric bypass
411791|NCT01040377|Revision gastric bypass
411792|NCT01040364|Internal hernia
411793|NCT01040364|Mesocolic hernia
411794|NCT01040364|Petersen´s hernia
411795|NCT01040364|Jejunojejunostomy hernia
411796|NCT01040364|Bowel obstruction
411797|NCT01040364|Ischemic bowel
411798|NCT01040364|Complication after gastric bypass
411799|NCT01040364|Re-operative bariatric surgery
411800|NCT01040364|Chronic pain after gastric bypass
411801|NCT01040351|Infertility
411802|NCT01040351|Hydrosalpinx
411803|NCT01040351|IVF-ET
411804|NCT01040338|Smoking
411805|NCT01040338|Tobacco
411806|NCT01040338|Nicotine
411807|NCT01040338|Dependence
411808|NCT01040338|Genetics
411809|NCT01040312|UGT1A1, irinotecan
411810|NCT01040299|GangTrainer
411811|NCT01040299|Gait Rehabilitation
411812|NCT01040299|Cerebrovascular Disorders
411813|NCT01040299|Robot assisted
411814|NCT01040299|Transcranial direct current stimulation
411815|NCT01040286|Subjects, age>21, with Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal
411816|NCT01040286|pockets of 5-9 mm in depth demonstrating bleeding on probing without involving the
411817|NCT01040286|apex of the tooth and confirmed by dental X-ray.
411818|NCT01040260|tobacco use disorder
411819|NCT01040247|Infertility
411820|NCT01040247|Low Responder
411821|NCT01040247|IVF
411822|NCT01040247|Embryo Transfer
411823|NCT01040234|postoperative pain
411824|NCT01040234|abdominal surgery
411825|NCT01040234|bilateral dual TAP block
411826|NCT01040221|Autism, Autism Spectrum Disorder
411827|NCT01040221|ASD
411828|NCT01040221|Trichuris Suis Ova
411829|NCT01040221|TSO
411830|NCT01040221|Treatment
411831|NCT01040221|Clinical Trial
411832|NCT01040195|ankylosing spondylitis
411833|NCT01040195|undifferentiated spondyloarthropathy
411834|NCT01040195|spondyloarthropathy
411835|NCT01040195|inflammatory back pain
411836|NCT01040195|methotrexate
411837|NCT01040195|sulfasalazine
411838|NCT01040195|hydroxychloroquine
411839|NCT01040182|ischemic stroke patients
411840|NCT01040143|Pneumococci
411841|NCT01040143|Streptococcus pneumoniae
411842|NCT01040117|Equilibrium
411843|NCT01040117|Rehabilitation
411844|NCT01040117|Randomized Controlled Trial
411845|NCT01040117|Postural instability
411846|NCT01040117|Sensory-motor integration
411847|NCT01040104|wound healing
411848|NCT01040104|hypertrophic scar
411849|NCT01040104|skin transplantation
411850|NCT01040104|diabetes mellitus
411851|NCT01040091|HIV Seronegativity
411852|NCT01040091|Treatment Experienced
411853|NCT01040065|Acromioclavicular joint arthritis
411854|NCT01040065|distal clavicle resection
411855|NCT01040065|Mumford procedure
411856|NCT01040052|Diphtheria
411857|NCT01040052|Tetanus
411858|NCT01040052|Pertussis
411859|NCT01040052|Adacel®
411860|NCT01040039|HCV
411861|NCT01040039|HIV
411862|NCT01040013|LAPAROSCOPY,
411863|NCT01040013|LAPAROTOMY,
411864|NCT01040013|OXYGENATION,
411865|NCT01040013|ISCHEMIA-REPERFUSION INJURY
411866|NCT01040000|NPC-1C
411867|NCT01040000|Monoclonal antibody
411868|NCT01040000|Pancreatic Cancer
411869|NCT01040000|Adenocarcinoma of the pancreas
411870|NCT01040000|Ductal carcinoma of the pancreas
411871|NCT01040000|Duct cell carcinomas, pancreas
411872|NCT01040000|Carcinomas, pancreas duct cell
411873|NCT01040000|Pancreas duct cell carcinoma
411874|NCT01040000|Pancreatic duct cell carcinoma
411875|NCT01040000|Adenocarcinoma of the colon
411876|NCT01040000|Adenocarcinoma of the rectum
411877|NCT01040000|Colorectal cancer
411878|NCT01040000|Colorectal tumor
411879|NCT01040000|Colorectal neoplasm
411880|NCT01039987|Autosomal dominant polycystic kidney disease
411881|NCT01039987|ADPKD
411882|NCT01039987|kidney
411883|NCT01039987|Biomarker
411884|NCT01039987|MRI
411885|NCT01039974|ketoconazole
411886|NCT01039974|GSK962040
411887|NCT01039974|Drug-Drug Interaction
411888|NCT01039974|Phase I
411889|NCT01039961|healthy volunteers
411890|NCT01039961|IV formulation study
411891|NCT01039948|Neoplasms
411892|NCT01039948|Carcinoma
411893|NCT01039948|Carcinoma, Non-Small-Cell Lung
411894|NCT01039948|Lung Neoplasms
411895|NCT01039948|Respiratory Tract Neoplasms
411896|NCT01039948|Neoplasms, Glandular and Epithelial
411897|NCT01039948|Neoplasms by Histological Type
411898|NCT01039948|Thoracic Neoplasms
411899|NCT01039948|Neoplasms by Site
411900|NCT01039948|Lung Diseases
411901|NCT01039948|Respiratory Tract Diseases
411902|NCT01039948|Gefitinib
411903|NCT01039948|Antineoplastic Agents
411904|NCT01039948|Therapeutic Uses
411905|NCT01039948|Pharmacologic Actions
411906|NCT01039948|Protein Kinase Inhibitors
411907|NCT01039948|Enzyme Inhibitors
411908|NCT01039948|Molecular Mechanisms of Pharmacological Action
411909|NCT01039935|Odor Discrimination
411910|NCT01039922|Neuroendocrine Tumors
411911|NCT01039922|Registries
411912|NCT01039883|Healthy Volunteers
411913|NCT01039870|postthoracotomy pain
411914|NCT01039857|Psychotherapy
411915|NCT01039857|Depression
411916|NCT01039857|Adjustment Disorders
411917|NCT01039857|Neuropsychology
411918|NCT01039857|Rehabilitation
411919|NCT01039857|Coping Skills
411920|NCT01039857|Stroke
411921|NCT01039857|Caregivers
411922|NCT01039844|LOC-paclitaxel Injection
411923|NCT01039844|metastatic Melanoma
411924|NCT01039831|PIGD
411925|NCT01039831|tremor
411926|NCT01039831|falls
411927|NCT01039831|white matter
411928|NCT01039818|Graves Disease
411929|NCT01039818|Hyperthyroidism
411930|NCT01039818|Radioiodine
411931|NCT01039818|Clinical trial
411932|NCT01039805|GSK962040
411933|NCT01039805|13C octanoic acid breath test
411934|NCT01039805|pharmacokinetics
411935|NCT01039805|critically ill patients
411936|NCT01039805|gut motility
411937|NCT01039805|pharmacodynamics
411938|NCT01039805|tolerability
411939|NCT01039805|single dose
411940|NCT01039805|gastric emtpying
411941|NCT01039792|Autism
411942|NCT01039792|Pervasive Developmental Disorders
411943|NCT01039779|older fallers
411944|NCT01039779|tai chi
411945|NCT01039766|post traumatic stress disorder
411946|NCT01039766|prevention
411947|NCT01039766|oxytocin
411948|NCT01039753|acute kidney injury
411949|NCT01039753|renal replacement therapy
411950|NCT01039753|biomarkers
411951|NCT01039740|Pharmacogenomics
411952|NCT01039740|Prediction of Mirtazapine response
411953|NCT01039740|Depressed patients
411954|NCT01039740|Mirtazapine response
411955|NCT01039740|Adverse event
411956|NCT01039727|Pain [C10.597.617]
411957|NCT01039714|Hypocalcemia
411958|NCT01039714|Hypoparathyroidism
411959|NCT01039714|Vitamin D deficiency
411960|NCT01039714|Total thyroidectomy
411961|NCT01039714|calcium
411962|NCT01039714|PTH
411963|NCT01039701|safety
411964|NCT01039701|tolerability
411965|NCT01039701|mild to moderate Alzheimer's disease
411966|NCT01039701|To determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil in patients with mild to moderate Alzheimer's disease
411967|NCT01039688|oral JAK inhibitor
411968|NCT01039688|MTX
411969|NCT01039688|DMARD
411970|NCT01039688|clinical trial
411971|NCT01039688|joint diseases
411972|NCT01039688|autoimmune diseases
411973|NCT01039688|anti-Inflammatory agents
411974|NCT01039688|rheumatic diseases
411975|NCT01039675|long-acting beta2-receptor agonist
411976|NCT01039675|Safety and tolerability
411977|NCT01039675|pharmacodynamics
411978|NCT01039675|pharmacokinetics
411979|NCT01039675|long-acting muscarinic receptor antagonist
411980|NCT01039675|COPD
411981|NCT01039649|radiation
411982|NCT01039649|Tomography, Spiral Computed
411983|NCT01039649|Four-Dimensional Computed Tomography
411984|NCT01039649|Respiratory Function Tests
411985|NCT01039636|Beta-thalassemia
411986|NCT01039636|Sickle cell anemia
411987|NCT01039636|Transfusional iron overload
411988|NCT01039636|Iron overload
411989|NCT01039636|Iron chelation
411990|NCT01039623|Healthy volunteers
411991|NCT01039610|single dose
411992|NCT01039610|pharmacokinetics
411993|NCT01039610|GSK945237
411994|NCT01039610|tolerability
411995|NCT01039610|safety
411996|NCT01039610|antibiotics
411997|NCT01039610|linezolid
411998|NCT01039610|QTc
411999|NCT01039610|bacterial type II topoisomerase Inhibitors (BTI)
412000|NCT01039610|moxifloxacin
412001|NCT01039610|repeat dose
412002|NCT01039597|IBD
412003|NCT01039597|Ulcerative colitis
412004|NCT01039584|bioequivalence
412005|NCT01039584|butoconazole
412006|NCT01039584|vulvovaginal
412007|NCT01039584|candidiasis
412008|NCT01039571|rotator cuff tear
412009|NCT01039571|arthroscopic repair
412010|NCT01039571|single row repair
412011|NCT01039571|double row repair
412012|NCT01039571|retear rate
412013|NCT01039558|gastroesophageal reflux disease
412014|NCT01039558|lansoprazole
412015|NCT01039558|ecabet sodium
412016|NCT01039454|Food Reward
412017|NCT01039454|fMRI
412018|NCT01039454|Obese
412019|NCT01039454|Cognition
412020|NCT01039454|Food Addiction
412021|NCT01039454|Behaviour
412022|NCT01039454|Overweight
412023|NCT01039454|Food Reinforcement
412024|NCT01039454|Metabolic endpoints
412025|NCT01039428|hyperphosphatemia
412026|NCT01039428|hemodialysis
412027|NCT01039428|chitosan
412028|NCT01039415|marijuana
412029|NCT01039415|marijuana abuse
412030|NCT01039415|marijuana dependence
412031|NCT01039415|cannabis
412032|NCT01039415|substance-related disorder
412033|NCT01039415|abstinence
412034|NCT01039402|cardiovascular risk
412035|NCT01039402|France
412036|NCT01039402|Observational, descriptive study
412037|NCT01039389|Coronary Artery Disease
412038|NCT01039389|Stable
412039|NCT01039389|Coronary Collaterals
412040|NCT01039389|Therapeutic Collateral Promotion
412041|NCT01039389|Arteriogenesis
412042|NCT01039389|Bradycardia
412043|NCT01039376|maintenance therapy
412044|NCT01039376|anti-CD20 monoclonal antibody
412045|NCT01039376|ofatumumab
412046|NCT01039363|Relapse or refractory acute myeloid leukemia
412047|NCT01039350|Myelodysplastic syndrome
412048|NCT01039337|osteoarthritis
412049|NCT01039337|manual therapy
412050|NCT01039337|manipulation
412051|NCT01039337|hip school
412052|NCT01039337|chiropractic
412053|NCT01039337|patient education
412054|NCT01039324|Complex patients
412055|NCT01039324|Care transitions
412056|NCT01039324|Patient safety
412057|NCT01039324|Patient care
412058|NCT01039324|Health Information Technology
412059|NCT01039324|Health Information Exchange
412060|NCT01039324|Clinical Decision Support
412061|NCT01039324|Care coordination
412062|NCT01039324|Data sharing
412063|NCT01039311|Lung
412064|NCT01039311|cancer
412065|NCT01039311|bronchoscopy
412066|NCT01039311|optical
412067|NCT01039311|coherence
412068|NCT01039311|tomography
412069|NCT01039298|Oral cancer
412070|NCT01039298|fluorescence visualization
412071|NCT01039298|surgical margin
412072|NCT01039298|recurrence
412073|NCT01039285|Very premature infant
412074|NCT01039285|Surfactant
412075|NCT01039285|Respiratory Distress
412076|NCT01039285|Bronchopulmonary Dysplasia
412077|NCT01039272|oral cancer
412078|NCT01039272|EBV
412079|NCT01039272|PCR
412080|NCT01039259|adolescent
412081|NCT01039259|body piercing/adverse effects
412082|NCT01039259|tongue piercing
412083|NCT01039259|tongue/microbiology
412084|NCT01039246|biliary stones
412085|NCT01039181|Vitamin D
412086|NCT01039181|Calcitriol
412087|NCT01039181|cholangiocarcinoma
412088|NCT01039181|Clinical trial
412089|NCT01039168|Burnout
412090|NCT01039168|Sick leave
412091|NCT01039168|Intervention study
412092|NCT01039168|Prospective study
412093|NCT01039168|Work
412094|NCT01039142|Psoriasis
412095|NCT01039129|Gallstones
412096|NCT01039129|Appendicitis
412097|NCT01039129|Pelvic pain
412098|NCT01039129|Peritoneal mass
412099|NCT01039116|obesity
412100|NCT01039116|nutrition
412101|NCT01039116|type 2 diabetes
412102|NCT01039116|community-based.
412103|NCT01039103|PEG-liposomal prednisolone sodium phosphate
412104|NCT01039090|Not eligible for deep brain stimulation
412105|NCT01039090|Parkinsons's patients
412106|NCT01039038|prostate
412107|NCT01039038|curietherapy
412108|NCT01039038|radiotherapy
412109|NCT01039038|intermediate risk
412110|NCT01039025|Myeloma
412111|NCT01039025|Topotecan
412112|NCT01039025|Hycamtin
412113|NCT01039025|Melphalan
412114|NCT01039025|Alkeran
412115|NCT01039025|Cyclophosphamide
412116|NCT01039025|Cytoxan
412117|NCT01039025|Neosar
412118|NCT01039025|Stem Cell Harvest
412119|NCT01039025|Peripheral Blood Stem Cells
412120|NCT01039012|bone mineral density
412121|NCT01039012|osteoporosis
412122|NCT01039012|exercise
412123|NCT01039012|bone remodeling
412124|NCT01039012|biomotion analysis
412125|NCT01038999|Complementary Therapies
412126|NCT01038986|chronic wound
412127|NCT01038986|refractory wound
412128|NCT01038986|CureXcell
412129|NCT01038986|activated cell suspension
412130|NCT01038960|ICD, training
412131|NCT01038934|Buccal Mucosa
412132|NCT01038934|DNA
412133|NCT01038934|Polymerase Chain Reaction
412134|NCT01038921|Blood Pressure
412135|NCT01038921|Glucose levels
412136|NCT01038921|HDL levels
412137|NCT01038921|Triglyceride levels
412138|NCT01038921|Waist Circumference
412139|NCT01038908|sentinel lymph node biopsy (SLNB)
412140|NCT01038908|axillary lymph node dissection (ALND)
412141|NCT01038908|lymphatics
412142|NCT01038908|blue dye
412143|NCT01038895|Hypertension
412144|NCT01038895|type 2 diabetes
412145|NCT01038895|aliskiren
412146|NCT01038895|ramipril
412147|NCT01038895|microalbuminuria
412148|NCT01038895|blood pressure> 130/80 <180/105 mmHg at the end of the wash−out
412149|NCT01038895|type 2 diabetes mellitus well controlled by medication and / or
412150|NCT01038895|compliance with diet (HbA1c <7%)
412151|NCT01038895|Microalbuminuria in the upper range of normal (> 200 <300 mg/24 h)
412152|NCT01038882|sedation
412153|NCT01038882|midazolam
412154|NCT01038882|flexible bronchoscopy
412155|NCT01038882|tolerance
412156|NCT01038843|VA106483
412157|NCT01038843|Nocturia
412158|NCT01038843|males
412159|NCT01038843|nocturnal voids
412160|NCT01038843|anti-diuretic
412161|NCT01038843|hyponatraemia
412162|NCT01038817|tooth-decay
412163|NCT01038817|prevention
412164|NCT01038817|fluoride-varnish
412165|NCT01038817|institutionalised elderly people
412166|NCT01038804|Breast Cancer
412167|NCT01038804|Metastatic
412168|NCT01038804|HER2 Negative
412169|NCT01038804|YM155
412170|NCT01038791|chronic hypercapnic respiratory failure
412171|NCT01038791|COPD
412172|NCT01038791|RTD
412173|NCT01038791|sleep architecture
412174|NCT01038791|humidification
412175|NCT01038765|Recurrent Major Depressive Disorder
412176|NCT01038765|Mindfulness Based Cognitive Therapy
412177|NCT01038765|Randomized Controlled Trial
412178|NCT01038752|NSCLC
412179|NCT01038752|suramin
412180|NCT01038752|lung cancer
412181|NCT01038752|chemotherapy
412182|NCT01038726|Healthy Aging
412183|NCT01038700|Circulating endothelial compartment
412184|NCT01038700|microparticles
412185|NCT01038700|endothelial progenitors cells
412186|NCT01038700|circulating endothelial cells
412187|NCT01038700|transcriptome
412188|NCT01038700|aging
412189|NCT01038700|Healthy volunteers
412190|NCT01038687|functional constipation
412191|NCT01038687|bile acid
412192|NCT01038648|Sitagliptin
412193|NCT01038648|Type 2 diabetes
412194|NCT01038648|Prevention of type 2 diabetes
412195|NCT01038635|5-Azacytidine
412196|NCT01038635|5-Aza
412197|NCT01038635|Lenalidomide
412198|NCT01038635|Revlimid
412199|NCT01038635|CC-5103
412200|NCT01038635|Myelodysplastic Syndrome
412201|NCT01038635|MDS
412202|NCT01038635|Acute Myelogenous Leukemia
412203|NCT01038635|AML
412204|NCT01038622|L-arginine
412205|NCT01038622|Nasal NO
412206|NCT01038622|Nosocomial infection
412207|NCT01038622|Immune function
412208|NCT01038622|HLA-DR expression
412209|NCT01038622|Critically ill
412210|NCT01038622|Medical ICU patients
412211|NCT01038609|Postoperative Pain
412212|NCT01038596|osteoarthritis, mesenchymal stromal cells, proliferation
412213|NCT01038583|Aspirin
412214|NCT01038583|Prevention
412215|NCT01038583|Healthy
412216|NCT01038583|Over 65 years old
412217|NCT01038583|ASPREE
412218|NCT01038583|Aspirin in Reducing Events in the Elderly
412219|NCT01038583|Australia
412220|NCT01038583|Functional disability
412221|NCT01038583|Dementia
412222|NCT01038583|Heart Disease/ Stroke
412223|NCT01038583|Cancer
412224|NCT01038583|Bleeding
412225|NCT01038570|Prader Willi syndrome
412226|NCT01038570|adults
412227|NCT01038570|social behaviour
412228|NCT01038570|stress
412229|NCT01038570|anxiety
412230|NCT01038570|psychological tests
412231|NCT01038557|frozen
412232|NCT01038557|red blood cells
412233|NCT01038557|transfusion
412234|NCT01038557|trauma
412235|NCT01038544|Esophageal Cancer
412236|NCT01038544|Mediastinal lymph nodes
412237|NCT01038544|Staging
412238|NCT01038544|EBUS
412239|NCT01038544|EUS
412240|NCT01038544|Endobronchial Ultrasound
412241|NCT01038544|Endoscopic Ultrasound
412242|NCT01038531|Acute lung injury (ALI)
412243|NCT01038531|Adult respiratory distress syndrome (ARDS)
412244|NCT01038531|Low-tidal-volume strategy
412245|NCT01038531|ARDS Net
412246|NCT01038531|airway pressure release ventilation (APRV)
412247|NCT01038531|biomarkers of lung injury
412248|NCT01038518|epidemiology
412249|NCT01038518|risk factors
412250|NCT01038518|micronutrients
412251|NCT01038479|Xylitol
412252|NCT01038479|Mutans streptococci
412253|NCT01038479|Maternal consumption
412254|NCT01038479|Early childhood tooth decay
412255|NCT01038479|Early childhood caries
412256|NCT01038479|Childsmile
412257|NCT01038466|CHAT
412258|NCT01038466|breast cancer
412259|NCT01038466|non interventional observational study
412260|NCT01038440|Omega 3 fatty acids
412261|NCT01038440|Omega 3 Index
412262|NCT01038440|Stearidonic acid (SDA)
412263|NCT01038440|Eicosapentaenoic acid (EPA)
412264|NCT01038440|Red blood cells
412265|NCT01038440|Lipids
412266|NCT01038440|Inflammation markers
412267|NCT01038427|Rhinitis
412268|NCT01038427|Allergic
412269|NCT01038427|Seasonal
412270|NCT01038427|Mometasone Furoate
412271|NCT01038427|Equivalence
412272|NCT01038401|HIV infection
412273|NCT01038401|HAART
412274|NCT01038401|Viral DNA test positive-10063306
412275|NCT01038401|Blood HIV RNA 10049826
412276|NCT01038401|Treatment Experienced
412277|NCT01038388|Multiple Myeloma
412278|NCT01038375|hypertension
412279|NCT01038375|stroke
412280|NCT01038375|adherence
412281|NCT01038362|endothelium
412282|NCT01038362|almonds
412283|NCT01038362|dietary interventions
412284|NCT01038362|coronary artery disease
412285|NCT01038336|Hearing Loss - Noise-Induced
412286|NCT01038336|Prevention
412287|NCT01038336|Computer-assisted instruction
412288|NCT01038323|Fibromyalgia
412289|NCT01038323|FMS
412290|NCT01038310|Parkinson´s disease
412291|NCT01038310|FP-CIT-SPECT
412292|NCT01038297|Scarring
412293|NCT01038284|Patient Education
412294|NCT01038284|Drug Toxicity
412295|NCT01038271|palliative care
412296|NCT01038258|neoadjuvant chemotherapy
412297|NCT01038245|Receptor Up-Regulation
412298|NCT01038245|Smoking
412299|NCT01038245|Nicotine
412300|NCT01038245|Neuroimaging
412301|NCT01038232|Distress Tolerance
412302|NCT01038232|Cocaine Dependence
412303|NCT01038232|Relapse
412304|NCT01038232|Limbic System
412305|NCT01038232|Prefrontal Cortex
412306|NCT01038232|Healthy Volunteer
412307|NCT01038232|HV
412308|NCT01038219|fever
412309|NCT01038219|children
412310|NCT01038219|SUBJECTIVE ASSESSMENT
412311|NCT01038206|prevention
412312|NCT01038206|HIV
412313|NCT01038206|drugs
412314|NCT01038206|smoking
412315|NCT01038206|Hispanic
412316|NCT01038206|Adolescent
412317|NCT01038206|Familias Unidas
412318|NCT01038206|Parent-Preadolescent Training
412319|NCT01038206|parent-centered
412320|NCT01038206|unsafe sexual behavior
412321|NCT01038206|efficacy
412322|NCT01038206|intervention
412323|NCT01038193|Cognition, subarachnoid hemorrhage.
412324|NCT01038180|pacemaker
412325|NCT01038180|adverse effects
412326|NCT01038167|VX-950
412327|NCT01038154|advanced esophageal cancer and stomach cancer
412328|NCT01038154|Pravastatin
412329|NCT01038154|Survival
412330|NCT01038154|adverse effects
412331|NCT01038128|Bulimia nervosa
412332|NCT01038128|Bulimia
412333|NCT01038128|Body dysmorphic disorder
412334|NCT01038128|Eating disorders
412335|NCT01038128|Body image
412336|NCT01038128|Binge eating
412337|NCT01038128|purging
412338|NCT01038115|Catheter Ablation
412339|NCT01038102|Obesity
412340|NCT01038102|Diabetes
412341|NCT01038102|Insulin resistance
412342|NCT01038102|Fatty liver
412343|NCT01038102|NAFLD
412344|NCT01038102|Steatosis
412345|NCT01038102|Dietary fatty acids
412346|NCT01038089|endothelium
412347|NCT01038089|resveratrol
412348|NCT01038089|diabetes mellitus
412349|NCT01038076|HIV
412350|NCT01038076|AIDS
412351|NCT01038076|adherence
412352|NCT01038076|antiretroviral
412353|NCT01038076|aCASI
412354|NCT01038076|HAART
412355|NCT01038076|Complementary Therapies
412356|NCT01038076|Adherence Care Manager
412357|NCT01038050|Endothelial progenitor cell
412358|NCT01038050|endothelial function(FMD)
412359|NCT01038050|Gingko Biloba Extract
412360|NCT01038050|Type 2 Diabetes mellitus
412361|NCT01038050|Stable coronary artery disease
412362|NCT01038050|Endothelial progenitor cells Numbers
412363|NCT01038037|Lung Cancer
412364|NCT01038037|Non small cell lung cancer
412365|NCT01038037|Triple mutational status
412366|NCT01038037|KRAS
412367|NCT01038037|BRAF
412368|NCT01038037|PI3K
412369|NCT01038024|antioxidant supplement
412370|NCT01037998|adenocarcinoma
412371|NCT01037998|non-small-cell lung cancer
412372|NCT01037998|gefitinib
412373|NCT01037998|UFUR
412374|NCT01037985|Scarring
412375|NCT01037972|Galileo
412376|NCT01037972|Whole body vibration
412377|NCT01037972|Osteoarthritis
412378|NCT01037972|Knee
412379|NCT01037972|Physiotherapy
412380|NCT01037959|severe cirrhosis
412381|NCT01037959|Patients with severe cirrhosis
412382|NCT01037946|HIV
412383|NCT01037946|Family interventions
412384|NCT01037946|Thailand
412385|NCT01037933|Cancer
412386|NCT01037933|Humor
412387|NCT01037933|Distraction
412388|NCT01037933|Comedy
412389|NCT01037933|Chemotherapy
412390|NCT01037907|Oral treatment for MS
412391|NCT01037907|Oral drug for multiple sclerosis
412392|NCT01037907|Oral RRMS
412393|NCT01037907|Oral relapsing remitting multiple sclerosis
412394|NCT01037907|Gamma Linolenic Acid
412395|NCT01037907|GLA
412396|NCT01037907|Fatty acid
412397|NCT01037907|Triglyceride
412398|NCT01037907|Structured lipid
412399|NCT01037907|MRI
412400|NCT01037907|Magnetic resonance imaging
412401|NCT01037907|gadolinium enhancing lesions
412402|NCT01037907|expanded disability status scale
412403|NCT01037907|EDSS
412404|NCT01037907|Demyelination
412405|NCT01037907|Remyelination
412406|NCT01037907|TGFB1
412407|NCT01037907|Transforming growth factor beta 1
412408|NCT01037907|cytokines
412409|NCT01037907|disease modifying therapy
412410|NCT01037907|immunomodulator
412411|NCT01037907|Anti inflammatory
412412|NCT01037907|Pro inflammatory
412413|NCT01037907|TNF alpha
412414|NCT01037907|interleukin 1 beta
412415|NCT01037907|interferon gamma
412416|NCT01037907|Fayaz Master
412417|NCT01037907|Omega 6
412418|NCT01037907|Polyunsaturated fatty acid
412419|NCT01037907|Cytokine balance
412420|NCT01037907|Pleneva TM
412421|NCT01037907|BGC20-0134
412422|NCT01037907|RRMS
412423|NCT01037894|Acupuncture,Intracerebral hemorrhage, Stroke
412424|NCT01037868|depression
412425|NCT01037868|alcohol dependency syndrome
412426|NCT01037868|dual diagnosis
412427|NCT01037868|SMS text messages
412428|NCT01037855|Swine Flu H1N1 vaccine
412429|NCT01037855|Adjuvanted flu cell culture derived
412430|NCT01037816|Ankle Sprain
412431|NCT01037803|perioperative sublingual microcirculation SDF
412432|NCT01037777|individuals at risk for SCA1, SCA2, SCA3, SCA6 and SCA7
412433|NCT01037764|acute lymphoid leukemia
412434|NCT01037764|primary complete remission
412435|NCT01037764|secondary complete remission
412436|NCT01037764|postremission therapy
412437|NCT01037764|allogeneic hematopoietic cell transplantation
412438|NCT01037751|Cancer
412439|NCT01037751|Symptom burden
412440|NCT01037751|M. D. Anderson Symptom Inventory
412441|NCT01037751|MDASI-Ovarian Cancer
412442|NCT01037751|Symptoms
412443|NCT01037751|Daily functioning
412444|NCT01037751|Symptom severity
412445|NCT01037751|Questionnaire
412446|NCT01037751|Interview
412447|NCT01037738|ACL reconstruction
412448|NCT01037738|autologous conditioned serum
412449|NCT01037738|Orthokine
412450|NCT01037738|osteoarthritis
412451|NCT01037738|interleukin receptor antagonist
412452|NCT01037738|growth factors
412453|NCT01037738|WOMAC
412454|NCT01037738|IKDC
412455|NCT01037725|Healthy volunteer
412456|NCT01037725|first time in human
412457|NCT01037725|food effect
412458|NCT01037712|Foetuses infection with CMV
412459|NCT01037712|neurological handicap of infectious origin.
412460|NCT01037699|Ovarian stimulation
412461|NCT01037699|In Vitro Fertilization
412462|NCT01037699|Luteinizing Hormone
412463|NCT01037699|GnRH antagonist
412464|NCT01037699|Implantation rate in infertile patients undergoing In vitro fertilization and embryo transfer.
412465|NCT01037686|PD
412466|NCT01037686|DBS
412467|NCT01037660|endothelium
412468|NCT01037660|cardiovascular disease
412469|NCT01037660|dietary fat
412470|NCT01037660|insulin resistance
412471|NCT01037647|Type 2 diabetes
412472|NCT01037647|Diabetic dyslipidemia
412473|NCT01037647|VLDL-TG kinetics
412474|NCT01037647|VLDL-TG metabolism
412475|NCT01037634|Avian Influenza
412476|NCT01037634|H1N1 Influenza
412477|NCT01037634|Seasonal Influenza
412478|NCT01037621|Herpes simplex type 2
412479|NCT01037621|Hepatitis C virus
412480|NCT01037621|Valacyclovir
412481|NCT01037621|Herpes Simplex virus type 2 infection
412482|NCT01037608|Sativex
412483|NCT01037608|fMRI
412484|NCT01037608|Alternative Matrices
412485|NCT01037608|Brain Imaging
412486|NCT01037608|THC
412487|NCT01037595|hemodialysis
412488|NCT01037595|turmeric
412489|NCT01037595|pruritus
412490|NCT01037569|Toxicological Screening
412491|NCT01037569|Drugs
412492|NCT01037569|Alternative Matrices
412493|NCT01037569|Urine
412494|NCT01037569|Children
412495|NCT01037556|AML
412496|NCT01037556|Acute Myeloid Leukemia
412497|NCT01037556|Acute Myelogenous Leukemia
412498|NCT01037556|Refractory AML
412499|NCT01037556|Relapsed AML
412500|NCT01037556|Refractory Acute Myeloid Leukemia
412501|NCT01037556|Relapsed Acute Myeloid Leukemia
412502|NCT01037556|Refractory Acute Myelogenous Leukemia
412503|NCT01037556|Relapsed Acute Myelogenous Leukemia
412504|NCT01037556|ALL
412505|NCT01037556|Acute Lymphocytic Leukemia
412506|NCT01037556|Relapsed Acute Lymphocytic Leukemia
412507|NCT01037556|Refractory Acute Lymphocytic Leukemia
412508|NCT01037556|Relapsed ALL
412509|NCT01037556|Refractory ALL
412510|NCT01037530|ACE inhibitors
412511|NCT01037530|Intermittent claudication
412512|NCT01037530|Ramipril
412513|NCT01037517|Myeloma
412514|NCT01037517|Multiple Myeloma or Lymphoma Patients undergoing
412515|NCT01037517|mobilization for the purpose of autologous stem cell collection
412516|NCT01037504|safety
412517|NCT01037504|tolerability
412518|NCT01037504|healthy
412519|NCT01037504|inhalation
412520|NCT01037504|Healthy volunteers
412521|NCT01037491|aspirin, clopidogrel, peptic ulcer, proton pump inhibitor, rabeprazole, ulcer bleeding
412522|NCT01037478|Hodgkin's Lymphoma
412523|NCT01037478|HDAC
412524|NCT01037478|4SC-201
412525|NCT01037478|Resminostat
412526|NCT01037478|Phase II
412527|NCT01037465|endothelium
412528|NCT01037465|cell signaling
412529|NCT01037465|N-acetylcysteine
412530|NCT01037465|reactive oxygen species
412531|NCT01037452|Heartburn
412532|NCT01037452|antacid
412533|NCT01037452|PPI
412534|NCT01037452|Lansoprazole
412535|NCT01037452|calcium carbonate
412536|NCT01037452|magnesium hydroxide
412537|NCT01037452|Relief of heartburn following ingestion of a heartburn-inducing meal
412538|NCT01037426|SND Sinus Node Disease
412539|NCT01037426|Falls
412540|NCT01037426|Fractures
412541|NCT01037413|Scarring
412542|NCT01037400|Knee Replacement
412543|NCT01037400|Arthroplasty
412544|NCT01037374|risk
412545|NCT01037374|assessment
412546|NCT01037374|difficult
412547|NCT01037374|endotracheal
412548|NCT01037374|intubation
412549|NCT01037361|Children and Adolescents
412550|NCT01037361|Motor Control
412551|NCT01037361|Movement-Related Potential
412552|NCT01037361|Stereotypic Movement Disorder
412553|NCT01037361|Electroencephalogram (EEG)
412554|NCT01037348|Choroidal Neovascularisation
412555|NCT01037348|Pathological Myopia
412556|NCT01037335|bone graft
412557|NCT01037335|pain
412558|NCT01037335|chronic
412559|NCT01037322|crohn's disease
412560|NCT01037322|ulcerative colitis
412561|NCT01037322|cannabis
412562|NCT01037322|cannabidiol
412563|NCT01037296|catheter ablation
412564|NCT01037296|robotic navigation
412565|NCT01037283|Bipolar
412566|NCT01037283|Depressed
412567|NCT01037270|Patients with conditions (PE, Afib, DVT) requiring ongoing INR measurements.
412568|NCT01037231|hyperoxaluria
412569|NCT01037231|oxalate
412570|NCT01037231|PH
412571|NCT01037192|outpatient
412572|NCT01037192|skin and soft tissue infections
412573|NCT01037192|vancomycin intravenous
412574|NCT01037153|Intravenous
412575|NCT01037153|Rate of Delivery
412576|NCT01037153|Dose Responses
412577|NCT01037153|Variable Intervals
412578|NCT01037153|Multiple Rapid Injections
412579|NCT01037127|GSK1120212
412580|NCT01037127|BRAF Inhibitor
412581|NCT01037127|melanoma
412582|NCT01037127|MEK Inhibitor
412583|NCT01037114|Hepatitis A and hepatitis B
412584|NCT01037101|acrophobia
412585|NCT01037101|virtual reality
412586|NCT01037101|exposure therapy
412587|NCT01037101|In Vivo Exposure Therapy plus D-Cycloserine
412588|NCT01037101|In Vivo Exposure Therapy plus Placebo
412589|NCT01037101|Virtual Reality Exposure Therapy plus D-Cycloserine
412590|NCT01037101|Virtual Reality Exposure Therapy plus Placebo
412591|NCT01037101|Wait-List
412592|NCT01037088|cannabis
412593|NCT01037088|marijuana
412594|NCT01037088|neuropathy
412595|NCT01037088|antinociception
412596|NCT01037088|mood
412597|NCT01037088|cognition
412598|NCT01037088|neuropathic pain
412599|NCT01037075|Schizophrenia
412600|NCT01037075|Dual Diagnosis
412601|NCT01037075|Nicotine Nasal Spray
412602|NCT01037075|Drug Abuse/Dependence
412603|NCT01037075|Cognitive Processes
412604|NCT01037049|Rectal Cancer
412605|NCT01037049|6vs12
412606|NCT01037049|6 vs 12
412607|NCT01037049|Cancer
412608|NCT01037049|CRM
412609|NCT01037049|Circumferential Resection Margin
412610|NCT01037049|Quality of Life
412611|NCT01037049|MRI
412612|NCT01037049|Radiology
412613|NCT01037049|Abdominoperineal Excision
412614|NCT01037049|Anterior Resection
412615|NCT01037049|Surgery
412616|NCT01037049|Pathology
412617|NCT01037049|Radiotherapy
412618|NCT01037036|Ocular Hypertension
412619|NCT01037036|Open-Angle Glaucoma
412620|NCT01037036|Xalatan
412621|NCT01037036|IOP
412622|NCT01037023|PMS (post-marketing surveillance)
412623|NCT01037023|Topotecan
412624|NCT01036971|Physical Examination
412625|NCT01036971|Medical Information
412626|NCT01036971|Assessment
412627|NCT01036971|Blood Work
412628|NCT01036971|Screening
412629|NCT01036958|Pediatric cGVHD
412630|NCT01036958|Response Criteria
412631|NCT01036958|Symptoms
412632|NCT01036958|Quality of Life
412633|NCT01036958|Graft-Versus-Host Disease
412634|NCT01036958|GVHD
412635|NCT01036958|Pediatric GVHD
412636|NCT01036854|Ondansetron, EUR-1025
412637|NCT01036841|MNE with nocturnal polyuria
412638|NCT01036841|monosymptomatic nocturnal enuresis with nocturnal polyuria
412639|NCT01036802|sickle cell disease
412640|NCT01036802|pulmonary hypertension
412641|NCT01036802|coagulation activation
412642|NCT01036802|platelet activation
412643|NCT01036802|endothelial activation
412644|NCT01036711|Attention
412645|NCT01036711|Working Memory
412646|NCT01036711|Central Executive Processes
412647|NCT01036711|Response Preparation
412648|NCT01036711|Cigarettes
412649|NCT01036685|Children
412650|NCT01036685|fMRI
412651|NCT01036685|Task Development
412652|NCT01036685|Cognition
412653|NCT01036659|acute angiotensin converting enzyme inhibitor angioedema
412654|NCT01036646|Patients on stable OAT therapy for at least 3 months.
412655|NCT01036633|mucositis
412656|NCT01036594|Ketoconazole
412657|NCT01036594|Dexamethasone
412658|NCT01036581|Magnetic Resonance Imaging (MRI)
412659|NCT01036581|Functional Brain Imaging
412660|NCT01036581|Magnetic Resonance Spectroscopy
412661|NCT01036581|Diffusion Tensor Imaging
412662|NCT01036581|Drug Abuse
412663|NCT01036568|Psychosis
412664|NCT01036568|Smooth Pursuit
412665|NCT01036568|Motion Perception
412666|NCT01036568|Neurophysiology
412667|NCT01036568|fMRI
412668|NCT01036529|Spinal Cord Stimulation
412669|NCT01036529|Decompression
412670|NCT01036529|Fusion with or without instrumentation
412671|NCT01036529|Discectomy
412672|NCT01036529|Laminectomy
412673|NCT01036529|Laminotomy
412674|NCT01036529|Foraminotomy
412675|NCT01036516|Drug Cues
412676|NCT01036516|Dopamine Release
412677|NCT01036516|Psychomotor Stimulants
412678|NCT01036516|D2 Dopamine Receptor Subtype
412679|NCT01036516|Neuroimaging
412680|NCT01036412|Chlorhexidine
412681|NCT01036412|Chlorhexidine Gel Therapy
412682|NCT01036412|1% chlorhexidine gluconate gel
412683|NCT01036412|Cariogenic Oral Microflora
412684|NCT01036412|Irradiated Head and Neck Cancer Patients
412685|NCT01036412|caries-forming organisms
412686|NCT01036412|Radiation treatment
412687|NCT01036412|Mouth Cancer
412688|NCT01036412|Throat Cancer
412689|NCT01036412|Tooth decay
412690|NCT01036399|PTCL
412691|NCT01036360|Obesity
412692|NCT01036360|Acute exercise
412693|NCT01036360|Intensity of exercise
412694|NCT01036360|Energy balance regulation
412695|NCT01036360|Appetite
412696|NCT01036308|dietary fibre
412697|NCT01036308|legumes
412698|NCT01036308|lupin kernel fibre
412699|NCT01036308|soy fibre
412700|NCT01036308|bile acids
412701|NCT01036308|short-chain fatty acids
412702|NCT01036308|cholesterol metabolism
412703|NCT01036308|Subjects
412704|NCT01036243|digestive tolerance
412705|NCT01036243|night sleep
412706|NCT01036243|crying
412707|NCT01036243|growth
412708|NCT01036230|fMRI
412709|NCT01036230|Methylphenidate
412710|NCT01036230|Taste
412711|NCT01036230|Olfaction
412712|NCT01036230|Addiction
412713|NCT01036217|Recruitment
412714|NCT01036217|Adult
412715|NCT01036217|Telephone
412716|NCT01036217|Selection
412717|NCT01036217|Testing
412718|NCT01036139|EDS in Parkinson's Disease
412719|NCT01036126|Nicotine
412720|NCT01036126|Cocaine
412721|NCT01036126|N-Back
412722|NCT01036126|Craving
412723|NCT01036126|Dependence
412724|NCT01036113|EZN-2208 (PEG-SN38)
412725|NCT01036087|Inflammatory Breast Cancer
412726|NCT01036087|IBC
412727|NCT01036087|Primary breast carcinoma
412728|NCT01036087|HER2 negative overexpression
412729|NCT01036087|Panitumumab
412730|NCT01036087|Vectibix
412731|NCT01036087|Nab-paclitaxel
412732|NCT01036087|Paclitaxel
412733|NCT01036087|Abraxane
412734|NCT01036087|Carboplatin
412735|NCT01036087|Paraplatin
412736|NCT01036087|PNC
412737|NCT01036087|5-fluorouracil
412738|NCT01036087|5-FU
412739|NCT01036087|Adrucil
412740|NCT01036087|Efudex
412741|NCT01036087|Epirubicin
412742|NCT01036087|Ellence
412743|NCT01036087|Cyclophosphamide
412744|NCT01036087|Cytoxan
412745|NCT01036087|Neosar
412746|NCT01036087|FEC
412747|NCT01036074|Drug Abuse
412748|NCT01036074|Cocaine
412749|NCT01036074|Cocaine Dependence
412750|NCT01036074|Functional MRI
412751|NCT01036074|Pharmalogical MRI
412752|NCT01036074|Conditioning
412753|NCT01036061|compulsive discorders
412754|NCT01036061|addiction
412755|NCT01036048|saphenous vein graft
412756|NCT01036048|stent
412757|NCT01036035|Tolterodine
412758|NCT01036035|Over active Bladder (OAB)
412759|NCT01036035|Incontinence
412760|NCT01036022|GSK1399686
412761|NCT01036022|mesalazine
412762|NCT01036022|pharmacokinetics/dynamics
412763|NCT01036022|ulcerative colitis
412764|NCT01036009|Hematologic
412765|NCT01036009|Malignancy
412766|NCT01036009|Leukemia
412767|NCT01036009|Pre-leukemic
412768|NCT01036009|Allogeneic
412769|NCT01036009|Transplant
412770|NCT01036009|Pediatric
412771|NCT01035996|Classical Conditioning
412772|NCT01035996|fMRI
412773|NCT01035996|Schizophrenia
412774|NCT01035996|TD Model
412775|NCT01035996|Incentive Salience
412776|NCT01035983|menstrually associated migraine (MAM), Migraines,Menstrual Migraines, menstrually related migraines
412777|NCT01035944|Chronic wounds
412778|NCT01035944|Chronic wound debridement
412779|NCT01035944|Debridement
412780|NCT01035944|Bedside debridement
412781|NCT01035944|Surgical debridement
412782|NCT01035944|Wound debridement
412783|NCT01035944|Minimize bacterial re-colonization of wounds
412784|NCT01035944|HemCon ChitoGauze Dressings
412785|NCT01035944|HemCon Dressings
412786|NCT01035944|Chitosan-based dressings
412787|NCT01035788|PTSD
412788|NCT01035788|mindfulness meditation
412789|NCT01035788|cognitive behavior therapy
412790|NCT01035788|relationship function
412791|NCT01035788|couple therapy
412792|NCT01035775|Colonoscopy
412793|NCT01035775|Adenoma detection
412794|NCT01035775|Colorectal polyps
412795|NCT01035749|pandemic influenza
412796|NCT01035749|Clinical trial
412797|NCT01035749|H1N1
412798|NCT01035749|children
412799|NCT01035723|Prefrontal Cortex
412800|NCT01035723|Hippocampus
412801|NCT01035723|Amygdala
412802|NCT01035723|MRI
412803|NCT01035723|Cognitive Tasks
412804|NCT01035697|NICHD Neonatal Research Network
412805|NCT01035697|Very Low Birth Weight (VLBW)
412806|NCT01035697|Extremely Low Birth Weight (ELBW)
412807|NCT01035697|Prematurity
412808|NCT01035697|Pro-inflammatory cytokines
412809|NCT01035697|Anti-inflammatory cytokines
412810|NCT01035697|Interleukin-1 (IL-1β)
412811|NCT01035697|Interleukin-2 (IL-2)
412812|NCT01035697|Interleukin-3 (IL-3)
412813|NCT01035697|Interleukin-8 (IL-8)
412814|NCT01035697|Interleukin-9 (IL-9)
412815|NCT01035697|Tumor necrosis factor-α (TNF-α)
412816|NCT01035697|Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES)
412817|NCT01035658|Pazopanib
412818|NCT01035658|Doxil
412819|NCT01035658|Liposomal doxorubicin
412820|NCT01035658|Advanced relapsed
412821|NCT01035658|platinum-sensitive
412822|NCT01035658|platinum-resistant
412823|NCT01035645|First time in human
412824|NCT01035645|Interleukin-18
412825|NCT01035645|Healthy male subjects
412826|NCT01035645|Obese male subjects
412827|NCT01035645|Monoclonal antibody
412828|NCT01035645|Pharmacokinetics
412829|NCT01035645|Tolerability
412830|NCT01035645|Safety
412831|NCT01035645|Pharmacodynamics
412832|NCT01035632|Craving
412833|NCT01035632|Incubation
412834|NCT01035632|Relapse
412835|NCT01035632|Smoking Cues
412836|NCT01035632|Cortisol
412837|NCT01035619|onchocerciasis; river blindness; moxidectin; pediatric
412838|NCT01035606|attention
412839|NCT01035606|rehabilitation
412840|NCT01035606|training
412841|NCT01035606|functional MRI
412842|NCT01035606|executive function
412843|NCT01035606|brain injury
412844|NCT01035580|chemoprevention
412845|NCT01035580|curcumin
412846|NCT01035580|pharmacokinetics
412847|NCT01035580|safety
412848|NCT01035567|Multivessel coronary artery disease
412849|NCT01035567|Hybrid revascularization
412850|NCT01035567|Coronary Artery Bypass Grafting
412851|NCT01035567|Percutaneous Coronary Interventions
412852|NCT01035567|Drug eluting stents
412853|NCT01035554|high blood pressure
412854|NCT01035541|Major non-cardiac surgery,
412855|NCT01035541|hemodynamic management,
412856|NCT01035541|PiCCO,
412857|NCT01035541|acute kidney injury,
412858|NCT01035541|renal outcome
412859|NCT01035528|diastolic function, postmeal glucose, insulin glargine
412860|NCT01035515|Healthy subjects
412861|NCT01035502|Cancer
412862|NCT01035502|CP-4055
412863|NCT01035502|elacytarabine
412864|NCT01035502|combination
412865|NCT01035502|idarubicin
412866|NCT01035502|Acute myeloid leukaemia (AML)
412867|NCT01035489|Pacemaker treatment in heart failure
412868|NCT01035489|Cardiac resynchronization therapy
412869|NCT01035489|DDD pacemakers
412870|NCT01035476|ALS
412871|NCT01035476|nasal ventilation
412872|NCT01035476|data card recording
412873|NCT01035450|Coronary stent
412874|NCT01035437|obstructing
412875|NCT01035424|Batten Disease
412876|NCT01035424|Late Infantile Neuronal Lipofuscinosis
412877|NCT01035424|LINCL
412878|NCT01035411|COPD
412879|NCT01035398|stage 0 esophageal cancer
412880|NCT01035398|stage I esophageal cancer
412881|NCT01035398|stage II esophageal cancer
412882|NCT01035398|stage III esophageal cancer
412883|NCT01035398|stage IV esophageal cancer
412884|NCT01035385|FOFLOX4
412885|NCT01035385|resectable liver metastasis from colorectal cancer
412886|NCT01035372|healthy older people
412887|NCT01035359|radius
412888|NCT01035359|fracture
412889|NCT01035359|wrist
412890|NCT01035359|external
412891|NCT01035359|fixation
412892|NCT01035359|volar
412893|NCT01035359|plate
412894|NCT01035359|DASH
412895|NCT01035359|PRWE
412896|NCT01035346|Fever
412897|NCT01035346|antipyretic
412898|NCT01035346|uncomplicated acute viral infection
412899|NCT01035346|uncomplicated acute bacterial infections
412900|NCT01035333|gastric bypass surgery
412901|NCT01035307|childhood acute myeloid leukemia in remission
412902|NCT01035307|recurrent childhood acute myeloid leukemia
412903|NCT01035281|Diabetic Neuropathies
412904|NCT01035281|Neuropathic Pain
412905|NCT01035281|Cannabinoids
412906|NCT01035281|Tree Number C10.668.829.300
412907|NCT01035268|breast cancer treated by conservative surgery
412908|NCT01035255|chronic heart failure
412909|NCT01035255|cardiovascular death
412910|NCT01035255|hospitalization
412911|NCT01035255|outcome study
412912|NCT01035255|BNP
412913|NCT01035255|KCCQ
412914|NCT01035255|eGFR
412915|NCT01035242|OCD
412916|NCT01035242|obsessions
412917|NCT01035242|cognitive
412918|NCT01035229|Hepatocellular carcinoma
412919|NCT01035229|randomized trial
412920|NCT01035229|medical treatment
412921|NCT01035229|RAD001
412922|NCT01035229|placebo
412923|NCT01035229|Advanced Hepatocellular Carcinoma (HCC)
412924|NCT01035216|Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
412925|NCT01035190|Preterm Infants
412926|NCT01035190|Inhaled Corticosteroids
412927|NCT01035190|Bronchopulmonary Dysplasia
412928|NCT01035177|Bone Mineral Density (BMD);
412929|NCT01035177|Cortical bone;
412930|NCT01035177|Hip fracture;
412931|NCT01035177|Osteoporosis;
412932|NCT01035177|Quantitative Computed Tomography (QCT).
412933|NCT01035164|Alzheimer's Disease
412934|NCT01035164|Diagnostic Imaging
412935|NCT01035164|Neuroinflammation
412936|NCT01035164|PET Diagnosis
412937|NCT01035164|PET Tracer
412938|NCT01035151|randomized cluster design
412939|NCT01035151|tobacco cessation
412940|NCT01035151|smoking cessation
412941|NCT01035151|African American
412942|NCT01035125|Self-management
412943|NCT01035125|Self-efficacy
412944|NCT01035125|Coping
412945|NCT01035125|Health consumer
412946|NCT01035125|Patient education
412947|NCT01035125|Health related quality of life
412948|NCT01035099|Letrozole
412949|NCT01035099|IVF (in vitro fertilization)
412950|NCT01035099|Cryopreservation
412951|NCT01035099|Fertility Preservation
412952|NCT01035099|Breast Cancer
412953|NCT01035086|dietary fibre
412954|NCT01035086|lupin kernel fibre
412955|NCT01035086|bile acids
412956|NCT01035086|cholesterol metabolism
412957|NCT01035086|blood lipids
412958|NCT01035086|hypercholesterolemia
412959|NCT01035086|fibre-enriched food
412960|NCT01035086|moderate hypercholesterolemia
412961|NCT01035047|Acute Coronary Syndrome
412962|NCT01035047|Chest pain
412963|NCT01035047|Cardiac MRI
412964|NCT01035047|Risk Stratification
412965|NCT01035047|Emergency Department
412966|NCT01035008|pancreatic cysts
412967|NCT01034982|COPD
412968|NCT01034969|Hereditary angioedema
412969|NCT01034956|Soft tissue filler
412970|NCT01034956|Dermal filler
412971|NCT01034956|Complications
412972|NCT01034956|Patient satisfaction
412973|NCT01034943|radius
412974|NCT01034943|fracture
412975|NCT01034943|wrist
412976|NCT01034943|external
412977|NCT01034943|fixation
412978|NCT01034943|volar
412979|NCT01034943|plate
412980|NCT01034943|DASH
412981|NCT01034943|PRWE
412982|NCT01034930|MANDIBLE
412983|NCT01034930|IMPLANTS
412984|NCT01034930|OVERDENTURE
412985|NCT01034917|Active Comparator
412986|NCT01034917|Placebo Comparator
412987|NCT01034917|Sham Comparator
412988|NCT01034917|No intervention
412989|NCT01034917|Other
412990|NCT01034917|Treatment Experienced
412991|NCT01034904|Quality of Life
412992|NCT01034904|HRQoL
412993|NCT01034904|Hemophilia A
412994|NCT01034904|Helixate FS
412995|NCT01034891|BRCA mutation
412996|NCT01034891|benign breast disease
412997|NCT01034891|family history of breast cancer
412998|NCT01034891|strong family history of breast cancer
412999|NCT01034891|atypical ductal hyperplasia
413000|NCT01034891|atypical lobular hyperplasia
413001|NCT01034891|high risk for breast cancer
413002|NCT01034852|Atrial Fibrillation
413003|NCT01034852|Maze
413004|NCT01034852|Ablation
413005|NCT01034839|acute myeloid leukemia
413006|NCT01034839|prognosis
413007|NCT01034839|cytarabine
413008|NCT01034826|NGT, IGT, diabetes
413009|NCT01034813|contractures, range of motion, scar formation
413010|NCT01034800|HIV Positive
413011|NCT01034787|CP-675,206
413012|NCT01034787|Immunotherapy
413013|NCT01034787|AntiCTLA4
413014|NCT01034787|Clinical Trial
413015|NCT01034787|Unresectable or Metastatic
413016|NCT01034774|Human volunteers
413017|NCT01034761|Electronic prescribing
413018|NCT01034761|Inappropriate medications
413019|NCT01034761|Patient safety
413020|NCT01034761|Elderly patients in the hospital
413021|NCT01034748|Radiolabelled
413022|NCT01034748|Mass Balance
413023|NCT01034748|Healthy Volunteers
413024|NCT01034748|Pharmacokinetics
413025|NCT01034735|Saizen®
413026|NCT01034735|bioequivalence
413027|NCT01034735|recombinant human
413028|NCT01034735|Growth Hormone
413029|NCT01034735|treatment of growth failure in children
413030|NCT01034735|growth hormone deficiency in adults
413031|NCT01034722|Breast Milk
413032|NCT01034722|Fat Globules
413033|NCT01034709|Cytomegalovirus
413034|NCT01034709|CMV
413035|NCT01034657|MDS
413036|NCT01034657|bone marrow
413037|NCT01034657|anemia
413038|NCT01034657|cytopenia
413039|NCT01034657|transfusion dependance
413040|NCT01034657|EPO
413041|NCT01034657|ESA
413042|NCT01034657|erythropoietin
413043|NCT01034657|LBH589
413044|NCT01034657|Myelodysplastic Syndromes
413045|NCT01034657|hematopoietic improvement
413046|NCT01034657|IPSS Low
413047|NCT01034657|IPSS Int-1
413048|NCT01034657|HI-E
413049|NCT01034657|HDAC Inhibitor
413050|NCT01034657|HDAC-I
413051|NCT01034657|DAC-I
413052|NCT01034657|Deacetylase-Inhibitor
413053|NCT01034657|Histone Deacetylase-Inhibitor
413054|NCT01034657|red blood cell transfusions
413055|NCT01034644|Biomarkers
413056|NCT01034644|Genetic markers
413057|NCT01034631|Metastatic Kidney Cancer
413058|NCT01034631|BNC105P
413059|NCT01034618|Diabetes
413060|NCT01034618|protein
413061|NCT01034618|protein hydrolysate
413062|NCT01034579|Biomarkers
413063|NCT01034579|Genetic markers
413064|NCT01034527|Anterior Cruciate Ligament
413065|NCT01034527|Female Athlete
413066|NCT01034527|Sports Injuries
413067|NCT01034527|Injury Prevention
413068|NCT01034501|periodontitis
413069|NCT01034501|photodynamic therapy
413070|NCT01034475|acute myeloid leukemia
413071|NCT01034475|acute lymphoblastic leukemia
413072|NCT01034475|multiple myeloma
413073|NCT01034475|chronic myeloid\ leukemia in blast phase
413074|NCT01034462|Depression
413075|NCT01034462|Major Depressive Disorder
413076|NCT01034449|allo graft
413077|NCT01034449|cord blood
413078|NCT01034449|expansion
413079|NCT01034449|reduced-intensity conditioning
413080|NCT01034423|Focus: health effects from omega-3 fatty acids, from fish oil with different quality
413081|NCT01034410|AS1411
413082|NCT01034410|AML
413083|NCT01034410|relapsed
413084|NCT01034410|refractory
413085|NCT01034410|aptamer
413086|NCT01034410|nucleolin
413087|NCT01034384|fMRI
413088|NCT01034384|Smoking Withdrawal
413089|NCT01034384|Imaging
413090|NCT01034384|Memory
413091|NCT01034384|Mood
413092|NCT01034371|Coronary Artery Disease; Hybrid Revascularization;
413093|NCT01034371|Percutaneous Coronary Intervention; Coronary Artery Bypass
413094|NCT01034358|inflammatory bowel disease
413095|NCT01034358|Crohn disease
413096|NCT01034358|ulcerative colitis
413097|NCT01034358|Papillomavirus vaccines
413098|NCT01034345|Sirolimus
413099|NCT01034345|Liver Transplantation
413100|NCT01034345|Tolerance
413101|NCT01034345|Immune responses
413102|NCT01034345|Allograft tolerance
413103|NCT01034332|Esophageal cancer
413104|NCT01034332|Esophagectomy
413105|NCT01034332|Paclitaxel
413106|NCT01034332|Induction chemotherapy
413107|NCT01034319|type 2 diabetes
413108|NCT01034319|genetics
413109|NCT01034319|genetic counseling
413110|NCT01034319|diabetes prevention
413111|NCT01034293|feeding frequency
413112|NCT01034293|insulin metabolism
413113|NCT01034293|glucose metabolism
413114|NCT01034293|substrate partitioning
413115|NCT01034280|Down Syndrome
413116|NCT01034280|phenotype
413117|NCT01034280|genotype
413118|NCT01034280|patient family
413119|NCT01034267|Depression
413120|NCT01034267|Major Depressive Disorder
413121|NCT01034254|influenza
413122|NCT01034254|immunization
413123|NCT01034254|pregnancy
413124|NCT01034254|efficacy
413125|NCT01034254|pertussis
413126|NCT01034254|hepatitis E
413127|NCT01034241|milk protein
413128|NCT01034241|overweight
413129|NCT01034241|insulin metabolism
413130|NCT01034241|substrate partitioning
413131|NCT01034228|Diarrhoea
413132|NCT01034228|L-isoleucine
413133|NCT01034228|children
413134|NCT01034228|ORS
413135|NCT01034228|Antibacterial peptide
413136|NCT01034215|Behavioral
413137|NCT01034215|Quality of Life
413138|NCT01034215|Breast Cancer
413139|NCT01034189|Esophageal cancer
413140|NCT01034189|Chemoradiotherapy
413141|NCT01034189|Paclitaxel
413142|NCT01034189|Cetuximab
413143|NCT01034176|BK viremia
413144|NCT01034176|kidney transplantation
413145|NCT01034176|BK viremia in kidney transplant recipients
413146|NCT01034163|Phase III randomized
413147|NCT01034163|double blind
413148|NCT01034163|placebo controlled multi-center study
413149|NCT01034163|panobinostat
413150|NCT01034163|Hodgkin's lymphoma
413151|NCT01034163|at risk for relapse
413152|NCT01034163|autologous stem cell transplant
413153|NCT01034137|Treat-to-target, tight control, strategy study, TCZ, MTX
413154|NCT01034124|warfarin
413155|NCT01034124|midazolam
413156|NCT01034124|cranberry juice
413157|NCT01034124|pharmacokinetics
413158|NCT01034098|Obesity
413159|NCT01034098|Postmenopausal women
413160|NCT01034098|Mechanical ventilatory constraints
413161|NCT01034098|Dynamic lung volume
413162|NCT01034098|Expiratory flow limitation
413163|NCT01034085|Nicotine
413164|NCT01034085|Schizophrenia
413165|NCT01034085|Cognition
413166|NCT01034085|Genes
413167|NCT01034085|Smoking
413168|NCT01034085|Cigarette Smoking
413169|NCT01034046|Obesity
413170|NCT01034033|quality of life
413171|NCT01034020|Nasal Spray
413172|NCT01034020|Attention Network Test
413173|NCT01034020|Continuous Performance Test
413174|NCT01034020|Attentional Blink Test
413175|NCT01034007|tissue engineered vascular graft
413176|NCT01033994|Knee osteoarthritis
413177|NCT01033994|Fibroblast growth factor 18
413178|NCT01033994|Sprifermin
413179|NCT01033981|cost effectiveness
413180|NCT01033981|Sunitinib Central America and Caribbean Metastatic Renal Cell Carcinoma
413181|NCT01033968|lasers
413182|NCT01033968|pain measurement
413183|NCT01033968|photocoagulation
413184|NCT01033968|retina
413185|NCT01033955|critical care
413186|NCT01033955|H1N1/influenza infection
413187|NCT01033955|respiration
413188|NCT01033955|ventilation, artificial
413189|NCT01033955|critically ill patients
413190|NCT01033955|invasive mechanical ventilation
413191|NCT01033955|H1N1/influenza infection (suspected, probable or confirmed)
413192|NCT01033942|Pre-exposure prophylaxis
413193|NCT01033942|HIV Prevention
413194|NCT01033942|Truvada
413195|NCT01033942|Many Men, Many Voices
413196|NCT01033942|Emtricitabine
413197|NCT01033942|Tenofovir disoproxil fumarate
413198|NCT01033942|Young men who have sex with men
413199|NCT01033942|HIV Seronegativity
413200|NCT01033929|tuberculosis
413201|NCT01033929|ESAT-6
413202|NCT01033929|CFP-10
413203|NCT01033929|skin test
413204|NCT01033929|diagnostic test
413205|NCT01033916|Blood Glucose
413206|NCT01033916|Insulin/Administration and Dosage
413207|NCT01033916|Coronary Artery Bypass
413208|NCT01033903|Abortion, Spontaneous
413209|NCT01033903|Randomized Controlled Trial
413210|NCT01033890|local anesthesia
413211|NCT01033890|cochlear implant
413212|NCT01033890|sedation
413213|NCT01033890|3 patients submitted to cochlear implant surgery with local anesthesia with sedation
413214|NCT01033877|Immunisation, active
413215|NCT01033812|Networks
413216|NCT01033812|Index recruiter
413217|NCT01033799|Probiotic - Lactobacillus casei DN114-001
413218|NCT01033799|dairy product - infections - shiftworkers
413219|NCT01033799|Common infectious diseases,
413220|NCT01033799|occuring in healthy subjects,
413221|NCT01033799|including upper respiratory tract infections (defined as rhinopharyngitis, sore throat, sinusitis and otitis),
413222|NCT01033799|lower respiratory tract infections (defined as bronchitis,
413223|NCT01033799|pneumopathy and flu and flu-like syndromes), and
413224|NCT01033799|gastrointestinal tract infection defined as gastroenteritis.
413225|NCT01033773|Type 2 diabetes mellitus
413226|NCT01033773|Uncontrolled hyperglycemia
413227|NCT01033773|Emergency Department
413228|NCT01033760|Primary HIV-1 infection
413229|NCT01033760|antiretroviral treatment
413230|NCT01033760|HIV reservoirs
413231|NCT01033760|HIV-DNA levels
413232|NCT01033760|randomized
413233|NCT01033760|Treatment Naive
413234|NCT01033747|iron overload
413235|NCT01033747|iron chelation therapy
413236|NCT01033747|B-thalassemia
413237|NCT01033708|Psychotherapy
413238|NCT01033708|PTSD
413239|NCT01033708|Borderline personality disorders
413240|NCT01033695|Endoscopy
413241|NCT01033695|Endoscopic Ultrasound
413242|NCT01033695|Endoscopic Sonoelastography
413243|NCT01033695|Cancer
413244|NCT01033695|Interobserver agreement
413245|NCT01033669|Inhalation profiles
413246|NCT01033669|asthma
413247|NCT01033669|COPD
413248|NCT01033656|adult-onset Still's disease
413249|NCT01033656|anakinra
413250|NCT01033656|prednisolone
413251|NCT01033656|disease-modifying antirheumatic drug
413252|NCT01033656|methotrexate
413253|NCT01033656|efficacy
413254|NCT01033656|patients
413255|NCT01033617|Stem cells
413256|NCT01033617|Cellular therapy
413257|NCT01033617|Myocardial repair
413258|NCT01033591|Primary Health Care
413259|NCT01033591|Family PractiCe
413260|NCT01033591|Hearth Failure
413261|NCT01033591|Exercise
413262|NCT01033591|Randomized Controlled Trials
413263|NCT01033591|Multicenter Study
413264|NCT01033591|Quality of life
413265|NCT01033565|Impaired sleep maintenance
413266|NCT01033565|Autism Spectrum Disorders
413267|NCT01033565|Pediatric
413268|NCT01033539|Survive
413269|NCT01033539|safety
413270|NCT01033539|lactobacillus Reuteri
413271|NCT01033526|Symptomatic treatment of Common Cold symptoms
413272|NCT01033487|Safety
413273|NCT01033487|Pharmacokinetics
413274|NCT01033487|Pharmacodynamics
413275|NCT01033487|PF-03635659
413276|NCT01033487|COPD
413277|NCT01033474|Infertile Patients
413278|NCT01033461|probiotic
413279|NCT01033461|lactobacillus paracasei
413280|NCT01033461|calcium
413281|NCT01033461|faecal microbiota
413282|NCT01033461|cholesterol metabolism
413283|NCT01033435|Inflammation
413284|NCT01033435|Oxidative stress
413285|NCT01033435|HbA1c
413286|NCT01033435|Hemodialysis
413287|NCT01033422|Glaucoma
413288|NCT01033422|Ocular hypertension
413289|NCT01033422|Intraocular hypertension
413290|NCT01033409|Salmonella Typhi
413291|NCT01033409|pneumonia
413292|NCT01033409|oral
413293|NCT01033409|vaccine
413294|NCT01033396|Allergic rhinitis Environmental exposure unit
413295|NCT01033370|acute
413296|NCT01033370|aortic
413297|NCT01033370|emergencies
413298|NCT01033370|Aortic dissection
413299|NCT01033357|dialysis
413300|NCT01033357|hemodialysis
413301|NCT01033357|neointimal hyperplasia
413302|NCT01033344|Cat allergy
413303|NCT01033344|Rhinoconjunctivitis
413304|NCT01033344|Exposure chamber
413305|NCT01033344|Immunotherapy
413306|NCT01033344|Cat-PAD
413307|NCT01033331|Spinal Muscular atrophy
413308|NCT01033331|Valproic acid
413309|NCT01033331|HMAS
413310|NCT01033331|MRC scale
413311|NCT01033318|Hypertension
413312|NCT01033305|UC
413313|NCT01033292|ovarian
413314|NCT01033292|cancer
413315|NCT01033292|sensitive
413316|NCT01033292|PARP
413317|NCT01033292|recurrent
413318|NCT01033292|platinum-resistant recurrent ovarian cancer
413319|NCT01033279|Coaguchek
413320|NCT01033279|Portable coagulometer
413321|NCT01033279|Self-monitoring
413322|NCT01033279|Coumadin
413323|NCT01033279|Warfarin
413324|NCT01033279|Quality of life
413325|NCT01033279|Pharmacist
413326|NCT01033227|sickle cell disease
413327|NCT01033227|sickle cell anemia
413328|NCT01033227|pain crisis
413329|NCT01033227|nitric oxide
413330|NCT01033227|nitrite
413331|NCT01033227|vaso occlusive crisis
413332|NCT01033227|pain medication
413333|NCT01033227|sickled cells
413334|NCT01033227|blood flow
413335|NCT01033227|microcirculation
413336|NCT01033214|TAA
413337|NCT01033214|Thoracic
413338|NCT01033214|Descending Thoracic Aorta
413339|NCT01033214|TAArget
413340|NCT01033201|Lung rejection
413341|NCT01033188|double bundle
413342|NCT01033188|hamstring graft
413343|NCT01033188|ACL reconstruction
413344|NCT01033188|single bundle
413345|NCT01033175|COPD
413346|NCT01033175|anemia
413347|NCT01033175|exercise
413348|NCT01033175|cytokines
413349|NCT01033175|erythropoietin
413350|NCT01033123|ovarian
413351|NCT01033123|cancer
413352|NCT01033123|sensitive
413353|NCT01033123|PARP
413354|NCT01033123|recurrent
413355|NCT01033123|platinum-sensitive recurrent ovarian cancer
413356|NCT01033110|inactive
413357|NCT01033110|>45 years
413358|NCT01033110|female
413359|NCT01033097|Dermatitis
413360|NCT01033097|inflammatory skin disease
413361|NCT01033097|itch
413362|NCT01033097|eczema
413363|NCT01033084|Depressive Disorder, Major
413364|NCT01033071|Hypertensive
413365|NCT01033071|Blood Pressure, High
413366|NCT01033071|Cardiovascular disease
413367|NCT01033071|Vascular Disease
413368|NCT01033071|Drug Therapy
413369|NCT01033058|STEMI
413370|NCT01033058|atorvastatin
413371|NCT01033058|PCI
413372|NCT01033045|Hepatitis C
413373|NCT01033045|Viral
413374|NCT01033045|Non-A
413375|NCT01033045|Non-B
413376|NCT01033045|Parenterally-Transmitted
413377|NCT01033032|Metastatic Breast Cancer
413378|NCT01033032|Amrubicin
413379|NCT01033019|Basal cell carcinomas,
413380|NCT01033019|sporadic,
413381|NCT01033019|superficial and nodular,
413382|NCT01033019|skin
413383|NCT01033006|Peripheral Nerves
413384|NCT01033006|Axillary Block
413385|NCT01033006|MRI
413386|NCT01032993|CoQ10
413387|NCT01032993|Statins
413388|NCT01032993|Myalgia
413389|NCT01032993|Muscle Pain
413390|NCT01032993|Muscle Weakness
413391|NCT01032980|HUMENZA
413392|NCT01032980|PANENZA
413393|NCT01032980|Influenza
413394|NCT01032980|Swine-Origin Influenza A H1N1 Virus
413395|NCT01032980|Influenza virus vaccines
413396|NCT01032967|squamous cell carcinoma
413397|NCT01032967|esophagectomy
413398|NCT01032967|chemoradiotherapy
413399|NCT01032967|chemoradiation
413400|NCT01032967|Squamous cell carcinomas of the esophagus
413401|NCT01032954|Botulinum Toxin
413402|NCT01032954|Rejuvenation
413403|NCT01032954|Facial dynamic wrinkles
413404|NCT01032941|Portal Hypertension
413405|NCT01032941|Portal Pressure Measurement
413406|NCT01032941|VSL3
413407|NCT01032941|Cirrhosis
413408|NCT01032941|End Stage Liver Disease
413409|NCT01032941|Probiotics
413410|NCT01032928|Swallowing
413411|NCT01032928|Dysphagia
413412|NCT01032928|Breathing and swallowing
413413|NCT01032928|Oropharyngeal cancer
413414|NCT01032915|Quiescent uveitis
413415|NCT01032915|intermediate uveitis
413416|NCT01032915|panuveitis
413417|NCT01032915|posterior uveitis
413418|NCT01032915|uveitis
413419|NCT01032902|Human immunodeficiency virus
413420|NCT01032902|Rapid Test
413421|NCT01032902|HIV
413422|NCT01032902|HIV Seronegativity
413423|NCT01032876|Congenital Heart disease
413424|NCT01032876|Cardiopulmonary bypass
413425|NCT01032876|Neonatal brain injury
413426|NCT01032876|Deep Hypothermic Circulatory Arrest
413427|NCT01032876|Antegrade Cerebral Perfusion
413428|NCT01032863|Chronic musculoskeletal pain
413429|NCT01032863|Benign joint hypermobility syndrome
413430|NCT01032863|Fibromyalgia
413431|NCT01032850|INST 0820
413432|NCT01032850|sorafenib
413433|NCT01032850|capecitabine
413434|NCT01032850|hepatocellular carcinoma
413435|NCT01032850|lung
413436|NCT01032850|nexavar
413437|NCT01032850|xeloda
413438|NCT01032850|liver cancer
413439|NCT01032824|Complementary Therapies
413440|NCT01032811|ADHD, childhood cancer
413441|NCT01032811|ADHD/Secondary ADHD Among Survivors of Childhood Cancer
413442|NCT01032785|Patent Foramen Ovale
413443|NCT01032785|Patent Ductus Arteriosus
413444|NCT01032785|PFO
413445|NCT01032785|PDA
413446|NCT01032772|alcohol-exposed pregnancy
413447|NCT01032772|tobacco-exposed pregnancy
413448|NCT01032772|alcohol
413449|NCT01032772|contraception
413450|NCT01032772|smoking
413451|NCT01032772|pregnancy
413452|NCT01032746|colon cancer
413453|NCT01032746|rectal cancer
413454|NCT01032733|Weight Loss
413455|NCT01032733|Physical Function
413456|NCT01032733|Oxidative Stress
413457|NCT01032733|Inflammation
413458|NCT01032720|ultrasound
413459|NCT01032720|osteoarthritis
413460|NCT01032720|knee
413461|NCT01032720|corticosteroids
413462|NCT01032720|intra-articular
413463|NCT01032720|injections
413464|NCT01032694|Community-Acquired Pneumonia
413465|NCT01032694|Azithromycin SR
413466|NCT01032694|Amoxiclav
413467|NCT01032681|Solid tumor
413468|NCT01032681|B-Cell Non-Hodgkin Lymphoma
413469|NCT01032681|Immunocytokine
413470|NCT01032681|interleukin-2
413471|NCT01032681|immunotherapy
413472|NCT01032681|Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma
413473|NCT01032668|percutaneous coronary intervention, clopidogrel resistance, ASA resistance
413474|NCT01032655|Helicobacter pylori
413475|NCT01032655|sequential therapy
413476|NCT01032655|susceptibility-driven
413477|NCT01032655|rescue
413478|NCT01032655|levofloxacin
413479|NCT01032655|clarithromycin
413480|NCT01032655|salvage
413481|NCT01032655|treatment failure
413482|NCT01032655|those who fail from two standard eradication therapies
413483|NCT01032642|infertility fallopian tubes
413484|NCT01032629|Diabetes
413485|NCT01032629|Type 2 diabetes mellitus
413486|NCT01032629|Cardiovascular risk
413487|NCT01032629|Cardiovascular outcomes
413488|NCT01032629|Canagliflozin (JNJ-28431754)
413489|NCT01032629|Placebo
413490|NCT01032616|splanchnic bed
413491|NCT01032616|theronine and lysine metabolism uptake
413492|NCT01032616|isotopes
413493|NCT01032616|metabolism of two indispensable amino acids, threonine and lysine, by the splanchnic bed by Healthy Males
413494|NCT01032603|IXT
413495|NCT01032603|Exotropia
413496|NCT01032603|Strabismus
413497|NCT01032603|Intermittent exotropia
413498|NCT01032590|weight changes
413499|NCT01032590|cancer survivor
413500|NCT01032590|stage I colon cancer
413501|NCT01032590|stage II colon cancer
413502|NCT01032590|stage III colon cancer
413503|NCT01032590|stage I rectal cancer
413504|NCT01032590|stage II rectal cancer
413505|NCT01032590|stage III rectal cancer
413506|NCT01032577|ischemic cardiomyopathy
413507|NCT01032577|nonischemic cardiomyopathy
413508|NCT01032577|implant
413509|NCT01032577|bipolar sensing
413510|NCT01032577|extended bipolar sensing
413511|NCT01032564|estimate the interest of the measure of cervix elasticity degree by elastography in prediction of premature birth within a population of pregnant women
413512|NCT01032551|Coronary Angiogram
413513|NCT01032551|Decision Aid
413514|NCT01032551|Vascular Access
413515|NCT01032551|Radial
413516|NCT01032551|Femoral
413517|NCT01032538|Unicondylar Knee Replacement
413518|NCT01032525|Crohn's Disease
413519|NCT01032525|Ulcerative Colitis
413520|NCT01032525|IBD
413521|NCT01032525|Inflammatory Bowel Disease in Monroe County, NY
413522|NCT01032512|IMMUNE-ENHANCING
413523|NCT01032512|GLUTAMINE
413524|NCT01032512|ARGININE
413525|NCT01032512|OMEGA 3 FATTY ACIDS
413526|NCT01032512|ONCOLOGIC SURGERY
413527|NCT01032512|PREOPERATIVE NUTRITION
413528|NCT01032499|Acne Vulgaris
413529|NCT01032499|Boil
413530|NCT01032499|Taro Elixir
413531|NCT01032486|Rasagiline
413532|NCT01032486|Sleep
413533|NCT01032486|Sleepiness
413534|NCT01032486|Parkinson's Disease Sleep Scale
413535|NCT01032486|Epworth Sleepiness Scale
413536|NCT01032460|airway
413537|NCT01032460|airway device
413538|NCT01032460|cervical spine immobilisation
413539|NCT01032434|sertraline
413540|NCT01032434|Polysomnograph
413541|NCT01032421|women admitted to the In Vitro Fertilization unit
413542|NCT01032408|Influenza A Virus
413543|NCT01032408|Virus Diseases
413544|NCT01032408|Influenza, Human
413545|NCT01032408|HIV-1
413546|NCT01032408|Immunodeficiency Virus
413547|NCT01032408|H1N1
413548|NCT01032408|HIV Infection
413549|NCT01032408|Immunogenicity
413550|NCT01032408|safety
413551|NCT01032408|tolerability
413552|NCT01032395|H1N1
413553|NCT01032395|Pulmonary Disease
413554|NCT01032395|Heart Disease
413555|NCT01032395|Diabetes
413556|NCT01032395|Influenza
413557|NCT01032395|immunogenicity
413558|NCT01032395|safety
413559|NCT01032395|tolerability
413560|NCT01032382|leishmaniasis
413561|NCT01032382|cutaneous
413562|NCT01032382|WR 279,396
413563|NCT01032382|paromomycin
413564|NCT01032382|gentamicin
413565|NCT01032382|pharmacokinetics
413566|NCT01032382|safety
413567|NCT01032382|efficacy
413568|NCT01032369|"Over-weight or obese subjects with learning disability who have completed Nitzan Onim two-year training program and live in housing within the community"
413569|NCT01032356|Distal Radius fracture
413570|NCT01032343|Immunosuppression
413571|NCT01032343|Ultraviolet radiation
413572|NCT01032343|Nickel
413573|NCT01032343|Contact hypersensitivity
413574|NCT01032330|intermittent exotropia
413575|NCT01032330|IXT
413576|NCT01032330|natural history
413577|NCT01032330|occlusion therapy
413578|NCT01032330|occlusion
413579|NCT01032330|patching
413580|NCT01032330|strabismus
413581|NCT01032330|strabismus treatment
413582|NCT01032330|stereoacuity
413583|NCT01032330|motor alignment
413584|NCT01032317|Arrhythmia
413585|NCT01032317|Electrophysiology
413586|NCT01032317|Fibrillation
413587|NCT01032317|Tachycardia
413588|NCT01032317|Ablation
413589|NCT01032317|Atrial Fibrillation (AF)
413590|NCT01032317|Ischemic Ventricular Tachycardia (VT)
413591|NCT01032291|Colorectal cancer
413592|NCT01032291|Revlimid
413593|NCT01032291|Lenalidomide
413594|NCT01032291|Cetuximab
413595|NCT01032291|Erbitux
413596|NCT01032291|KRAS
413597|NCT01032278|cardiac toxicity
413598|NCT01032278|unspecified adult solid tumor, protocol specific
413599|NCT01032265|female
413600|NCT01032265|stress urinary incontinence
413601|NCT01032265|treatment
413602|NCT01032265|pelvic floor muscle training
413603|NCT01032265|cognitive behavioral therapy
413604|NCT01032265|internet
413605|NCT01032265|life style
413606|NCT01032265|pamphlet
413607|NCT01032265|eHealth
413608|NCT01032252|fall prevention
413609|NCT01032252|general practitioners setting
413610|NCT01032252|implementation
413611|NCT01032252|network
413612|NCT01032252|community dwelling older adults
413613|NCT01032252|exercise intervention
413614|NCT01032239|Severe spasticity in post-stroke patients
413615|NCT01032200|fatigue
413616|NCT01032200|cognitive/functional effects
413617|NCT01032200|adult giant cell glioblastoma
413618|NCT01032200|adult glioblastoma
413619|NCT01032200|adult gliosarcoma
413620|NCT01032200|adult anaplastic astrocytoma
413621|NCT01032200|adult anaplastic oligodendroglioma
413622|NCT01032200|adult mixed glioma
413623|NCT01032200|adult diffuse astrocytoma
413624|NCT01032200|adult pilocytic astrocytoma
413625|NCT01032200|adult pineal gland astrocytoma
413626|NCT01032200|adult subependymal giant cell astrocytoma
413627|NCT01032200|adult oligodendroglioma
413628|NCT01032200|adult anaplastic ependymoma
413629|NCT01032200|adult ependymoma
413630|NCT01032200|adult myxopapillary ependymoma
413631|NCT01032200|adult subependymoma
413632|NCT01032200|adult anaplastic meningioma
413633|NCT01032200|adult grade I meningioma
413634|NCT01032200|adult grade II meningioma
413635|NCT01032200|adult grade III meningioma
413636|NCT01032200|adult papillary meningioma
413637|NCT01032200|adult brain stem glioma
413638|NCT01032187|Visceral leishmaniasis
413639|NCT01032187|Amphotericin B deoxycholate
413640|NCT01032187|Meglumine antimoniate
413641|NCT01032187|Children
413642|NCT01032187|Brazil
413643|NCT01032174|Azithromycin SR Amoxiclav 1000 mg Maxillary Sinusitis
413644|NCT01032161|Delirium
413645|NCT01032161|Postoperative
413646|NCT01032161|Non-cardiovascular surgery
413647|NCT01032161|Post-anaesthesia care unit
413648|NCT01032161|patients between 3 to 12 years old
413649|NCT01032161|undergoing selective non-cardiac surgery
413650|NCT01032161|under general anesthesia
413651|NCT01032161|surgery
413652|NCT01032161|general anesthesia
413653|NCT01032148|Recurrent
413654|NCT01032148|Refractory
413655|NCT01032122|melanoma
413656|NCT01032122|rituximab
413657|NCT01032122|metastatic
413658|NCT01032122|stage IIIc/IV
413659|NCT01032122|stem cell
413660|NCT01032122|overall survival
413661|NCT01032122|disease free interval
413662|NCT01032122|anti-CD20 therapy
413663|NCT01032083|SSRI antidepressant
413664|NCT01032083|Negative symptoms
413665|NCT01032083|Schizophrenia
413666|NCT01032070|phase 2
413667|NCT01032070|erlotinib
413668|NCT01032070|pediatric
413669|NCT01032070|etoposide
413670|NCT01032070|ependymoma
413671|NCT01032057|adenocarcinoma of the pancreas
413672|NCT01032057|stage II pancreatic cancer
413673|NCT01032057|stage III pancreatic cancer
413674|NCT01032044|Barrett's esophagus
413675|NCT01032044|EsoGastroDuodenoscopy
413676|NCT01032044|Barrett's carcinoma
413677|NCT01032044|adenocarcinoma
413678|NCT01032044|Cellvizio
413679|NCT01032044|endomicroscopy
413680|NCT01032044|probe-based Confocal Laser Endomicroscopy
413681|NCT01032044|pCLE
413682|NCT01032044|Radio-frequency ablation
413683|NCT01032044|Endoscopic mucosal resection
413684|NCT01032044|Photodynamic therapy
413685|NCT01032031|Green tea
413686|NCT01032031|Vitamin C
413687|NCT01032031|Ultraviolet radiation
413688|NCT01032031|Inflammation
413689|NCT01032031|Photoageing
413690|NCT01032018|Acute coronary syndrome
413691|NCT01032018|Depression
413692|NCT01032018|Satisfaction with care
413693|NCT01031992|Hereditary hemorrhagic telangiectasia
413940|NCT01031212|cancer
413694|NCT01031992|Rendu-Osler-Weber syndrome
413695|NCT01031992|Epistaxis
413696|NCT01031992|Nosebleeds
413697|NCT01031992|Anemia
413698|NCT01031992|Tranexamic acid
413699|NCT01031992|Antifibrinolytics
413700|NCT01031979|PTSD
413701|NCT01031979|Prolonged Exposure
413702|NCT01031979|extinction
413703|NCT01031979|habituation
413704|NCT01031979|psychophysiology
413705|NCT01031966|ESRD
413706|NCT01031953|nausea and vomiting
413707|NCT01031953|unspecified adult solid tumor, protocol specific
413708|NCT01031927|obsessive compulsive disorder
413709|NCT01031927|sarcosine
413710|NCT01031927|glycine transporter I
413711|NCT01031927|NMDA receptor
413712|NCT01031914|Paced Breathing
413713|NCT01031914|OSA
413714|NCT01031914|sleep/wake detection
413715|NCT01031901|Tuberous Sclerosis
413716|NCT01031901|Neurofibromatoses
413717|NCT01031901|Angiofibroma
413718|NCT01031901|Neurofibroma
413719|NCT01031901|Sirolimus
413720|NCT01031888|Corneal re-epithelialization
413721|NCT01031888|Topical insulin application
413722|NCT01031888|pars planar vitrectomy
413723|NCT01031888|diabetic retinopathy
413724|NCT01031888|penetrating keratoplasty
413725|NCT01031875|recurrent bladder cancer
413726|NCT01031875|stage IV bladder cancer
413727|NCT01031875|recurrent urethral cancer
413728|NCT01031875|distal urethral cancer
413729|NCT01031875|proximal urethral cancer
413730|NCT01031875|urethral cancer associated with invasive bladder cancer
413731|NCT01031875|metastatic transitional cell cancer of the renal pelvis and ureter
413732|NCT01031875|recurrent transitional cell cancer of the renal pelvis and ureter
413733|NCT01031875|stage IV urethral cancer
413734|NCT01031862|healthy volunteer
413735|NCT01031862|reverse cholesterol transport
413736|NCT01031862|RCT
413737|NCT01031862|3H
413738|NCT01031849|HIV 1 patients
413739|NCT01031836|Systemic Lupus Erythematosus
413740|NCT01031836|Japanese
413741|NCT01031836|phase 2
413742|NCT01031836|safety
413743|NCT01031836|tolerability
413744|NCT01031836|MEDI-545
413745|NCT01031836|Autoimmune Disease
413746|NCT01031836|Immune System Diseases
413747|NCT01031823|Autism Spectrum Disorder
413748|NCT01031810|Treatment Resistant depression
413749|NCT01031810|Major Depression
413750|NCT01031810|MDD
413751|NCT01031810|Depression
413752|NCT01031797|SLE
413753|NCT01031797|Disease activity score
413754|NCT01031797|QT dispersion
413755|NCT01031784|liver metastasis
413756|NCT01031784|Liver tumors
413757|NCT01031784|microspheres
413758|NCT01031784|holmium
413759|NCT01031784|toxicity
413760|NCT01031771|Cerebral Palsy
413761|NCT01031771|Deglutition
413762|NCT01031771|Deglutition disorders
413763|NCT01031771|Endoscopy
413764|NCT01031758|Low HDL
413765|NCT01031758|High HDL
413766|NCT01031758|HDL
413767|NCT01031758|Reverse Cholesterol Transport
413768|NCT01031758|RCT
413769|NCT01031758|healthy volunteer
413770|NCT01031758|3H
413771|NCT01031758|Average HDL
413772|NCT01031745|Complementary Therapies
413773|NCT01031745|Drug Users
413774|NCT01031732|Minimally invasive
413775|NCT01031732|Total hip arthroplasty
413776|NCT01031732|Functional outcome
413777|NCT01031732|To compare the surgical results of 4 MIS THA techniques
413778|NCT01031732|To investigate the functional outcomes of 4 MIS THA techniques
413779|NCT01031732|To study the biochemical parameters after the MIS surgeries.
413780|NCT01031719|Influenza A Virus
413781|NCT01031719|Virus Diseases
413782|NCT01031719|Influenza, Human
413783|NCT01031719|H1N1
413784|NCT01031719|Immunogenicity
413785|NCT01031719|safety
413786|NCT01031719|tolerability
413787|NCT01031719|tumors
413788|NCT01031719|oncology
413789|NCT01031706|Hypertonic Saline
413790|NCT01031706|Pediatrics
413791|NCT01031706|Cystic Fibrosis
413792|NCT01031706|Mucociliary Clearance
413793|NCT01031706|Lung Clearance Index
413794|NCT01031693|Nicotine
413795|NCT01031693|Cigarettes
413796|NCT01031693|Tobacco
413797|NCT01031693|Transcranial Magnetic Stimulation (TMS)
413798|NCT01031693|Cue-Induced Craving
413799|NCT01031693|Smoking
413800|NCT01031680|dapagliflozin
413801|NCT01031680|diabetes
413802|NCT01031680|cardiovascular disease
413803|NCT01031680|hypertension
413804|NCT01031667|Patients treated with PCI with stent
413805|NCT01031641|Patient-Reported Outcomes
413806|NCT01031641|Symptoms
413807|NCT01031641|Instrument Development
413808|NCT01031641|Adverse Events
413809|NCT01031641|Questionnaire
413810|NCT01031641|Patient Reported Outcomes
413811|NCT01031628|GIST
413812|NCT01031628|Gastrointestinal stromal tumors
413813|NCT01031628|Exon 9
413814|NCT01031628|Gleevec
413815|NCT01031628|Imatinib blood levels
413941|NCT01031212|neoplasms
413816|NCT01031615|School age children and adolescents exposed to a potentially traumatic event
413817|NCT01031602|Cancer
413818|NCT01031602|Gynecology
413819|NCT01031602|Sexual Dysfunction
413820|NCT01031602|Depression
413821|NCT01031602|Anxiety
413822|NCT01031602|Underserved
413823|NCT01031602|Minority
413824|NCT01031602|Psychological distress
413825|NCT01031589|TMC278-TiDP15-C158
413826|NCT01031589|TMC278-C158
413827|NCT01031589|TMC278
413828|NCT01031589|HIV
413829|NCT01031589|Non-nucleoside reverse transcriptase inhibitor
413830|NCT01031589|HIV Seronegativity
413831|NCT01031576|Osteoarthritis, posture, knee
413832|NCT01031563|Risk Taking
413833|NCT01031563|Schizophrenia
413834|NCT01031563|Drug Abuse/Dependence
413835|NCT01031563|Comorbidity
413836|NCT01031563|Impulsivity
413837|NCT01031563|Drug Abuse
413838|NCT01031550|liver resection for liver disease
413839|NCT01031537|FSME-Immun
413840|NCT01031537|TBEV
413841|NCT01031537|TBE Researcher
413842|NCT01031537|Plavivirus
413843|NCT01031537|Anti-TBEV Levels
413844|NCT01031537|Tic-Borne Encephalitis
413845|NCT01031524|Plasmodium falciparum malaria
413846|NCT01031511|High-Functioning Autistic Spectrum Disorder
413847|NCT01031511|Anxiety
413848|NCT01031511|Cognitive Behavioural Therapy
413849|NCT01031511|Social Recreational
413850|NCT01031511|Parent Stress
413851|NCT01031498|Nausea
413852|NCT01031498|Vomiting
413853|NCT01031498|CINV
413854|NCT01031498|Leukemia
413855|NCT01031498|High-risk Myelodysplastic syndrome
413856|NCT01031498|AML
413857|NCT01031498|Hematologic malignancies
413858|NCT01031498|Hematologic Disorder
413859|NCT01031498|Continuous multi-day chemotherapy
413860|NCT01031498|High-dose cytarabine
413861|NCT01031498|Palonosetron
413862|NCT01031498|Aloxi
413863|NCT01031498|Ondansetron
413864|NCT01031498|Zofran
413865|NCT01031485|hypertension
413866|NCT01031485|blood pressure
413867|NCT01031485|milk peptides
413868|NCT01031485|bioactive peptides
413869|NCT01031485|randomized controlled trial
413870|NCT01031472|HIV, relative bioavailability, food effect, GSK2248761, healthy subjects
413871|NCT01031472|HIV Seronegativity
413872|NCT01031446|stage IV breast cancer
413873|NCT01031446|Human epidermal growth factor (HER2)-negative breast cancer
413874|NCT01031446|triple-negative breast cancer
413875|NCT01031446|hormone-resistant breast cancer
413876|NCT01031433|Tobacco Craving
413877|NCT01031433|Virtual Reality
413878|NCT01031433|Schizophrenia
413879|NCT01031433|Smoking
413880|NCT01031420|bladder
413881|NCT01031420|cancer
413882|NCT01031420|invasive
413883|NCT01031407|Adolescents and Adults
413884|NCT01031407|Autism
413885|NCT01031407|Functional Magnetic Resonance Imaging (fMRI)
413886|NCT01031407|MEG
413887|NCT01031407|Structural MRI
413888|NCT01031407|HV
413889|NCT01031407|Autism Spectrum Disorder
413890|NCT01031407|ASD
413891|NCT01031407|Autistic Disorder
413892|NCT01031407|Asperger Syndrome
413893|NCT01031407|Mental Retardation
413894|NCT01031407|Healthy Volunteer
413895|NCT01031394|exercise
413896|NCT01031394|resistance training
413897|NCT01031381|Recurrent
413898|NCT01031381|ovarian
413899|NCT01031381|fallopian tube
413900|NCT01031381|primary peritoneal
413901|NCT01031381|cancer
413902|NCT01031381|Recurrent ovarian, fallopian tube, primary peritoneal cancer
413903|NCT01031355|Female Contraception
413904|NCT01031355|Contraceptives, Oral
413905|NCT01031342|Colonoscopy
413906|NCT01031342|Gastrointestinal bleeding
413907|NCT01031316|Echocardiography
413908|NCT01031316|Infant, Premature
413909|NCT01031316|Infant, Very Low Birth Weight
413910|NCT01031303|Diphtheria
413911|NCT01031303|Tetanus
413912|NCT01031303|Pertussis
413913|NCT01031303|Poliomyelitis
413914|NCT01031303|PENTAXIM™
413915|NCT01031303|TETRAXIM™
413916|NCT01031290|Cue-Induced Craving
413917|NCT01031290|Cannabis
413918|NCT01031290|Functional Magnetic Resonance Imaging (fMRI)
413919|NCT01031290|Repetitive TMS (rTMS)
413920|NCT01031290|Cannabis Craving
413921|NCT01031277|Hypercholesterolemia
413922|NCT01031277|Update NCEP ATP111
413923|NCT01031277|Survey
413924|NCT01031264|social drinkers
413925|NCT01031238|PEM Uptake Value
413926|NCT01031238|PUV
413927|NCT01031238|Standardized Uptake Value
413928|NCT01031238|SUV
413929|NCT01031238|Malignancies of the Breast
413930|NCT01031238|[18F]-FDG-PET/CT scanning
413931|NCT01031238|Tumor
413932|NCT01031238|positron emission tomography/computed tomography
413933|NCT01031238|PET/CT scan
413934|NCT01031225|Synta
413935|NCT01031225|STA 9090
413936|NCT01031225|ganetespib)
413937|NCT01031225|Lung Cancer
413938|NCT01031225|Non Small Cell Lung Cancer
413939|NCT01031225|NSCLC
413942|NCT01031212|adult solid tumor
413943|NCT01031212|antineoplastic agents
413944|NCT01031199|Multiple sclerosis
413945|NCT01031199|Diagnostic imaging
413946|NCT01031199|Neuroinflammation
413947|NCT01031199|PET diagnosis
413948|NCT01031199|PET tracer
413949|NCT01031186|healthy male volunteers
413950|NCT01031186|GSK356278
413951|NCT01031186|first time in man
413952|NCT01031186|major depressive disorder
413953|NCT01031173|α galactosidase A
413954|NCT01031173|glycosphingolipid storage disorder
413955|NCT01031173|agalsidase alfa
413956|NCT01031173|enzyme replacement therapy
413957|NCT01031173|Replagal
413958|NCT01031173|agalsidase beta
413959|NCT01031173|Fabrazyme
413960|NCT01031160|Adolescence
413961|NCT01031160|Obesity
413962|NCT01031160|Substance Abuse
413963|NCT01031160|Etiology
413964|NCT01031160|Social and Environmental Contexts
413965|NCT01031160|Health Behaviors
413966|NCT01031147|Magnetic resonance angiography
413967|NCT01031147|Intracranial aneurysm
413968|NCT01031147|Digital subtraction angiography
413969|NCT01031147|Volume rendering
413970|NCT01031121|Cigarette Smoking
413971|NCT01031121|Biomarkers
413972|NCT01031121|Nicotine
413973|NCT01031121|Cotinine
413974|NCT01031121|Metabolites
413975|NCT01031095|percutaneous coronary intervention
413976|NCT01031095|low dose intracoronary heparin
413977|NCT01031069|Cervarix
413978|NCT01031069|Gardasil
413979|NCT01031069|Immunogenicity
413980|NCT01031069|Cervical cancer
413981|NCT01031069|Safety
413982|NCT01031069|HPV vaccine
413983|NCT01031043|IEM
413984|NCT01031030|stage I breast cancer
413985|NCT01031030|stage II breast cancer
413986|NCT01031030|stage IIIA breast cancer
413987|NCT01031030|stage IIIB breast cancer
413988|NCT01031030|stage IIIC breast cancer
413989|NCT01031017|twin pregnancies
413990|NCT01031017|preterm delivery
413991|NCT01031017|progesterone
413992|NCT01030991|Heart failure
413993|NCT01030991|Ejection fraction
413994|NCT01030991|Diastolic heart failure
413995|NCT01030991|Diastolic dysfunction
413996|NCT01030991|Ventricular-arterial coupling
413997|NCT01030991|Exercise testing
413998|NCT01030991|Echocardiography
413999|NCT01030991|Tissue Doppler imaging
414000|NCT01030991|Arterial tonometry
414001|NCT01030991|Genetics
414002|NCT01030991|Epidemiology
414003|NCT01030978|Impaired Glucose Tolerance
414004|NCT01030978|PreDiabetes
414005|NCT01030978|Diabetes Prevention
414006|NCT01030965|Chronic Bronchitis
414007|NCT01030965|Anticholinergic
414008|NCT01030965|Emphysema
414009|NCT01030965|Long-acting muscarinic antagonist
414010|NCT01030965|COPD
414011|NCT01030952|Diabetes Mellitus, Type 2
414012|NCT01030952|Nateglinide
414013|NCT01030952|Acarbose
414014|NCT01030952|glucose fluctuation
414015|NCT01030939|Healthy volunteers
414016|NCT01030939|Men and women
414017|NCT01030939|adults and elderly
414018|NCT01030939|repeat dose
414019|NCT01030913|Chronic Lymphocytic Leukemia
414020|NCT01030900|Immunosuppression
414021|NCT01030900|Microenvironment
414022|NCT01030900|Hodgkin Lymphoma
414023|NCT01030900|B-Cell Lymphoma
414024|NCT01030900|Microarray
414025|NCT01030900|Diffuse Large B-Cell Lymphoma
414026|NCT01030887|Cancer
414027|NCT01030887|Exercise
414028|NCT01030887|Physical Activity
414029|NCT01030887|Randomized controlled trial
414030|NCT01030874|hypotension, orthostatic
414031|NCT01030874|falls
414032|NCT01030874|rehabilitation
414033|NCT01030874|blood pressure
414034|NCT01030874|aging
414035|NCT01030861|type 1 diabetes
414036|NCT01030861|pre-diabetic
414037|NCT01030861|autoantibody positive
414038|NCT01030861|at risk for type 1 diabetes
414039|NCT01030861|glucose intolerance
414040|NCT01030861|relatives of people with type 1 diabetes
414041|NCT01030835|Screening Protocol
414042|NCT01030835|Comorbidity
414043|NCT01030835|Normal Controls
414044|NCT01030835|Substance Use Disorders
414045|NCT01030835|Substance Abuse Disorders
414046|NCT01030822|Catch-up vaccination
414047|NCT01030822|Safety
414048|NCT01030822|Pneumococcal vaccine
414049|NCT01030822|Pneumococcal disease
414050|NCT01030822|Booster vaccination
414051|NCT01030822|Immunogenicity
414052|NCT01030809|Crohn's disease
414053|NCT01030809|community based gastroenterology practices Canada and Belgium
414054|NCT01030809|Cluster randomization controlled trial
414055|NCT01030809|Remission
414056|NCT01030809|Corticosteroids
414057|NCT01030809|Documented diagnosis of Crohn's disease
414058|NCT01030770|Diabetes
414059|NCT01030770|Vitreous Haemorrhages
414060|NCT01030757|Liver Cancer
414061|NCT01030757|Metastatic Liver Cancer
414062|NCT01030757|Tomotherapy
414063|NCT01030757|Stereotactic Body Radiation Therapy
414064|NCT01030744|Gestational Diabetes
414065|NCT01030744|Self-Monitoring of Blood Glucose
414066|NCT01030731|Renal Dialysis, Ceftobiprole
414067|NCT01030731|Skin and soft tissue Infections
414068|NCT01030731|Staphylococcal Skin Infections
414069|NCT01030731|Streptococcal Infection
414070|NCT01030705|Bradycardia
414071|NCT01030705|pacemaker
414072|NCT01030692|Cocaine
414073|NCT01030692|Rivastigmine
414074|NCT01030692|Huperzine A
414075|NCT01030679|Diabetes Mellitus, type 2
414076|NCT01030679|Glitazone
414077|NCT01030666|periodontal regeneration
414078|NCT01030666|radiographic bone fill
414079|NCT01030666|infrabony defects
414080|NCT01030666|randomized placebo-controlled clinical trial
414081|NCT01030666|guided tissue regeneration, periodontal
414082|NCT01030653|Voriconazole
414083|NCT01030653|Pharmacokinetics
414084|NCT01030653|Obese
414085|NCT01030653|Healthy Volunteer
414086|NCT01030640|intraepidermal nerve fiber density
414087|NCT01030640|IENF
414088|NCT01030640|tanezumab
414089|NCT01030640|subcutaneous
414090|NCT01030640|healthy volunteers
414091|NCT01030627|Eclampsia
414092|NCT01030627|Preeclampsia
414093|NCT01030627|Magnesium sulfate
414094|NCT01030614|Laparoscopic cholecystectomy,postoperative symptoms
414095|NCT01030601|Diabetic
414096|NCT01030601|Macular Edema
414097|NCT01030601|Pseudophakic
414098|NCT01030601|Dexamethasone
414099|NCT01030601|Intravitreal
414100|NCT01030601|Cataract surgery
414101|NCT01030575|NICHD Neonatal Research Network
414102|NCT01030575|Pharmacokinetics
414103|NCT01030575|Inositol
414104|NCT01030575|Very Low Birth Weight (VLBW)
414105|NCT01030575|Extremely Low Birth Weight (ELBW)
414106|NCT01030575|Prematurity
414107|NCT01030562|adolescent, vaccine, human papillomavirus, HPV
414108|NCT01030549|cardiovascular magnetic resonance
414109|NCT01030549|ventricular volumes
414110|NCT01030549|ventricular function
414111|NCT01030549|Healthy normal individuals from 20 to 80 years of age
414112|NCT01030536|NHL
414113|NCT01030536|CLL
414114|NCT01030497|Cancer
414115|NCT01030497|Cervical Lymph Node Metastases
414116|NCT01030497|High-Resolution PET Imaging System
414117|NCT01030497|Upper Aerodigestive Tract
414118|NCT01030497|Head
414119|NCT01030497|Neck
414120|NCT01030497|HR PET Imaging System
414121|NCT01030497|High-Resolution PET
414122|NCT01030497|PET/CT
414123|NCT01030497|PEMFlex Solo II
414124|NCT01030497|positron emission tomography/computed tomography (PET/CT)
414125|NCT01030484|NAFLD
414126|NCT01030484|NASH
414127|NCT01030484|non-alcoholic steatohepatitis
414128|NCT01030484|fatty liver disease
414129|NCT01030471|adolescents
414130|NCT01030471|depression
414131|NCT01030471|adherence
414132|NCT01030471|family functioning
414133|NCT01030471|intervention
414134|NCT01030458|Blood pressure
414135|NCT01030458|Hypertension
414136|NCT01030458|Blacks
414137|NCT01030458|Africa
414138|NCT01030458|Blood pressure control
414139|NCT01030458|Side-effects
414140|NCT01030445|non-invasive cardiac output monitor
414141|NCT01030445|electrical velocimetry
414142|NCT01030445|Aesculon
414143|NCT01030445|Icon
414144|NCT01030445|pediatrics
414145|NCT01030445|normal reference
414146|NCT01030419|Aging
414147|NCT01030419|Quality of Life
414148|NCT01030419|Functional fitness
414149|NCT01030406|Abuse Liability
414150|NCT01030406|Abuse Prevention
414151|NCT01030406|Abuse Resistance
414152|NCT01030406|Abuse Deterrence
414153|NCT01030393|hCG
414154|NCT01030393|pregnancy
414155|NCT01030393|implantation
414156|NCT01030393|ICSI
414157|NCT01030393|IVF
414158|NCT01030380|Facial toning
414159|NCT01030380|Facial lift
414160|NCT01030380|Improve facial complexion
414161|NCT01030380|Improve facial tone
414162|NCT01030380|Improve radiance of the face
414163|NCT01030380|Reduce signs of facial aging
414164|NCT01030380|firming, lift, tone face
414165|NCT01030367|Coronary artery disease
414166|NCT01030354|Satiety
414167|NCT01030354|Meal Replacements
414168|NCT01030354|High Protein
414169|NCT01030354|Standard Protein
414170|NCT01030341|Diabetes
414171|NCT01030341|Gastroparesis
414172|NCT01030315|Erythropoietin
414173|NCT01030315|Long-acting
414174|NCT01030315|EPO
414175|NCT01030302|Bortezomib retreatment
414176|NCT01030302|Velcade
414177|NCT01030302|Proteasome inhibitor
414178|NCT01030302|Bortezomib
414179|NCT01030289|food cravings
414180|NCT01030250|Breast Cancer
414181|NCT01030250|Adjuvant Chemotherapy
414182|NCT01030237|Dry eye
414183|NCT01030237|artificial tears
414184|NCT01030224|Healthy volunteer
414185|NCT01030224|First time in human
414186|NCT01030211|Dengue
414187|NCT01030211|Platelet transfusion
414188|NCT01030211|Bleeding
414189|NCT01030211|Prevention
414190|NCT01030185|ascites
414191|NCT01030185|liver cirrhosis
414192|NCT01030159|Cancer Anemia Survey
414193|NCT01030159|Thai National Cancer Institute
414194|NCT01030133|pain
414195|NCT01030120|chronic idiopathic urticaria
414196|NCT01030120|etanercept
414197|NCT01030107|sleep
414198|NCT01030107|obesity
414199|NCT01030107|children
414200|NCT01030107|eating behaviors
414201|NCT01030107|activity
414202|NCT01030107|leptin
414203|NCT01030107|ghrelin
414204|NCT01030094|Topiramate
414205|NCT01030094|Carbamazepine
414206|NCT01030094|Valproic acid
414207|NCT01030094|Epilepsy
414208|NCT01030094|Bone mineral density
414209|NCT01030094|Monotherapy
414210|NCT01030081|24 hour blood pressure
414211|NCT01030081|morning blood pressure surge
414212|NCT01030081|amlodipine
414213|NCT01030081|nifedipine GITS
414214|NCT01030068|Smoking Cessation
414215|NCT01030068|Yoga
414216|NCT01030068|Wellness
414217|NCT01030068|Feasibility
414218|NCT01030068|Smoking Cessation Therapy
414219|NCT01030055|Neoplasms
414220|NCT01030055|Cancer
414221|NCT01030055|Tumors
414222|NCT01030055|Administration, oral
414223|NCT01030055|Capsules
414224|NCT01030055|CHIR258
414225|NCT01030055|CHIR-258
414226|NCT01030055|CHIR 258
414227|NCT01030055|TKI258
414228|NCT01030055|TKI-258
414229|NCT01030055|TKI 258
414230|NCT01030055|Bioavailability
414231|NCT01030055|Food
414232|NCT01030042|metastatic
414233|NCT01030042|colorectal cancer
414234|NCT01030042|two sequences therapy
414235|NCT01030029|auricular acupuncture
414236|NCT01030029|postoperative pain
414237|NCT01030029|opioid consumption
414238|NCT01030029|laparoscopic surgery
414239|NCT01030029|ACUPUNCTURE THERAPY (IM) + EAR, EXTERNAL (IM)
414240|NCT01030016|resistance exercise
414241|NCT01030016|beta-blockers
414242|NCT01030016|blood pressure
414243|NCT01030003|Sleep-Disordered Breathing
414244|NCT01030003|Snoring
414245|NCT01030003|Pregnancy
414246|NCT01030003|Fetal Growth Retardation
414247|NCT01030003|Pre-Eclampsia
414248|NCT01029990|participation
414249|NCT01029990|mass screening
414250|NCT01029990|cervical neoplasia
414251|NCT01029990|health economics
414252|NCT01029990|cost-benefit
414253|NCT01029964|Childhood obesity
414254|NCT01029964|Age-dependent
414255|NCT01029964|Long-term treatment
414256|NCT01029964|BMI SDS
414257|NCT01029964|Dropouts
414258|NCT01029951|Chiropractic; osteopathic physicians; manipulation; neck pain; adverse effects; randomized clinical trial
414259|NCT01029951|Subacute non-specific neck pain
414260|NCT01029938|Intracranial aneurysms;
414261|NCT01029938|Covered stent;
414262|NCT01029938|Coil embolization
414263|NCT01029925|metastatic breast cancer
414264|NCT01029925|lung cancer
414265|NCT01029925|Previously treated metastatic breast cancer
414266|NCT01029925|stage IIIb lung cancer
414267|NCT01029925|stage IV lung cancer
414268|NCT01029912|Stroke
414269|NCT01029912|Hemiplegia
414270|NCT01029912|Footdrop
414271|NCT01029912|Electrical Stimulation
414272|NCT01029912|Motor Relearning
414273|NCT01029912|Neuroplasticity
414274|NCT01029899|Colonoscopy
414275|NCT01029899|Force
414276|NCT01029899|Monitor
414277|NCT01029899|Endoscopist
414278|NCT01029899|Trainee
414279|NCT01029886|diabetes
414280|NCT01029886|exenatide once weekly
414281|NCT01029886|Byetta
414282|NCT01029886|liraglutide
414283|NCT01029886|Victoza
414284|NCT01029886|Amylin
414285|NCT01029886|Lilly
414286|NCT01029873|cancer
414287|NCT01029873|immunotherapy
414288|NCT01029873|targeted
414289|NCT01029873|metastatic
414290|NCT01029873|interleukin-2
414291|NCT01029873|IL-2
414292|NCT01029873|Cisplatin
414293|NCT01029873|antitumor
414294|NCT01029873|melanoma
414295|NCT01029873|TCR
414296|NCT01029873|T-cell receptor
414297|NCT01029873|p53
414298|NCT01029873|p53 gene
414299|NCT01029873|p53 tumor suppressor protein
414300|NCT01029860|Hypertension
414301|NCT01029860|Ambulatory measurement
414302|NCT01029847|Patients with axial spondyloarthritis
414303|NCT01029834|BMI >85%for age and gender
414304|NCT01029821|Low-Molecular-Weight-Heparin
414305|NCT01029821|Open Reduction and Internal Fixation
414306|NCT01029821|Thromboprophylaxis
414307|NCT01029808|carriers of hemophilia
414308|NCT01029782|Cellulitis
414309|NCT01029782|Emergency Department
414310|NCT01029782|Cefazolin
414311|NCT01029782|Probenecid
414312|NCT01029782|Cephalexin
414313|NCT01029756|Pentax Airway Scope AWS S100
414314|NCT01029756|Pentax AWS
414315|NCT01029756|Macintosh
414316|NCT01029756|Laryngoscope
414317|NCT01029756|Video Laryngoscope
414318|NCT01029743|TKR (Total Knee Replacement)
414319|NCT01029743|THR (Total Hip Replacement)
414320|NCT01029743|VTE (Venous Thromboembolism)
414321|NCT01029743|LMWH (Low Molecular Weight Heparin)
414322|NCT01029743|VKA (Vitamin K antagonist)
414323|NCT01029730|Low grade lymphoma
414324|NCT01029730|Previously untreated lymphoma
414325|NCT01029730|Lymphoma first line
414326|NCT01029730|bendamustine
414327|NCT01029730|Treanda
414328|NCT01029730|bortezomib
414329|NCT01029730|Velcade
414330|NCT01029730|rituximab
414331|NCT01029730|Rituxan
414332|NCT01029717|Central Venous Catheters
414333|NCT01029717|blood stream infection
414334|NCT01029717|children, intensive care
414335|NCT01029717|Heparin bonded
414336|NCT01029717|antibiotic coated
414337|NCT01029717|Children in Paediatric Intensive Care Unit
414338|NCT01029704|Diabetes Mellitus Type 2
414339|NCT01029691|Sleep disordered breathing
414340|NCT01029691|Preeclampsia
414341|NCT01029691|Positive Airway Pressure
414342|NCT01029678|Locally advanced lung cancer
414343|NCT01029678|Elderly patients
414344|NCT01029678|NSCLC
414345|NCT01029665|Hernia, Diaphragmatic
414346|NCT01029665|Asthma
414347|NCT01029665|Feeding and Eating Disorders of Childhood
414348|NCT01029665|Growth & Development
414349|NCT01029652|frequent flares
414350|NCT01029652|gout
414351|NCT01029652|anti-interleukin-1β monoclonal antibody
414352|NCT01029639|Pulsatile intravenous insulin
414353|NCT01029639|Oral carbohydrate loading
414354|NCT01029639|Respiratory Quotients
414355|NCT01029639|Hypoglycemia
414356|NCT01029639|Diabetes Mellitus, with complications
414357|NCT01029600|Randomized study capsulotomy vs distention with steroid
414358|NCT01029587|CAPS
414359|NCT01029587|Kidney transplant
414360|NCT01029587|Renal transplant
414361|NCT01029587|Catastrophic Antiphospholipid Antibody Syndrome
414362|NCT01029574|Rotator cuff lesions
414363|NCT01029574|Platelet rich plasma
414364|NCT01029574|Arthroscopic repair
414365|NCT01029561|Metabolic syndrome
414366|NCT01029561|Insulin Resistance
414367|NCT01029561|Adipokines
414368|NCT01029561|Proinflammatory markers
414369|NCT01029561|Obstructive Sleep Apnea Syndrome
414370|NCT01029561|Continuous Positive Airway Pressure
414371|NCT01029561|Obesity
414372|NCT01029561|Bariatric surgery
414373|NCT01029548|HIV
414374|NCT01029548|Therapeutic Vaccine
414375|NCT01029522|Dyslipidemia
414376|NCT01029509|Advanced Leukemia
414377|NCT01029509|Acute myeloid leukemia
414378|NCT01029509|ALL
414379|NCT01029509|Chronic myeloid leukemia blast crisis
414380|NCT01029509|CMS
414381|NCT01029509|Acute lymphocytic leukemia
414382|NCT01029509|Chronic lymphocytic leukemia
414383|NCT01029509|Myelodysplastic syndromes
414384|NCT01029509|MDS
414385|NCT01029509|OPB 31121
414386|NCT01029496|umbilical CORD CLAMPING
414387|NCT01029496|Neonatal anemia
414388|NCT01029496|Omphalitis
414389|NCT01029483|Obesity
414390|NCT01029483|Weight loss
414391|NCT01029483|low carbohydrate diets
414392|NCT01029483|high complex carbohydrate diets
414393|NCT01029483|Healthy adults
414394|NCT01029483|Body composition
414395|NCT01029483|Energy Expenditure
414396|NCT01029470|Luveris
414397|NCT01029470|hyporesponse
414398|NCT01029470|pituitary downregulation
414399|NCT01029470|IVF
414400|NCT01029470|Infertility women
414401|NCT01029444|Diabetes
414402|NCT01029444|Pulsatile intravenous insulin
414403|NCT01029444|Oral carbohydrate loading
414404|NCT01029444|Respiratory Quotients
414405|NCT01029444|Hypoglycemia
414406|NCT01029444|Hyperglycemia
414407|NCT01029444|Diabetes Mellitus, with complications
414408|NCT01029431|intubating laryngeal airway
414409|NCT01029431|pediatric
414410|NCT01029418|HCC
414411|NCT01029418|hepatocellular carcinoma
414412|NCT01029418|liver cancer
414413|NCT01029405|Topical
414414|NCT01029405|Plaque type psoriasis
414415|NCT01029392|Diabetes
414416|NCT01029392|Type I
414417|NCT01029392|Newly Diagnosis Type I Diabetes Mellitus
414418|NCT01029379|propofol
414419|NCT01029379|depth of anesthesia
414420|NCT01029379|pharmacogenetics
414421|NCT01029379|Depth of anesthesia in correlation to plasma concentrations of propofol
414422|NCT01029353|NICHD Neonatal Research Network
414423|NCT01029353|Very Low Birth Weight (VLBW)
414424|NCT01029353|Extremely Low Birth Weight (ELBW)
414425|NCT01029353|Prematurity
414426|NCT01029353|Laparotomy
414427|NCT01029353|Drainage
414428|NCT01029353|Isolated intestinal perforation
414429|NCT01029353|Focal intestinal perforation
414430|NCT01029340|Hemophilia A
414431|NCT01029340|Factor VIII
414432|NCT01029340|Prophylaxis
414433|NCT01029314|Thermometry
414434|NCT01029301|Skin aging
414435|NCT01029301|Skin Wrinkling
414436|NCT01029288|Diabetes
414437|NCT01029288|Decision aid
414438|NCT01029288|Cardiovascular risk
414439|NCT01029288|Patient education
414440|NCT01029275|Acromegaly
414441|NCT01029275|pituitary adenoma
414442|NCT01029275|octreotide
414443|NCT01029275|transsphenoïdal surgery
414444|NCT01029275|GH
414445|NCT01029275|IGF-1
414446|NCT01029262|Myelodysplastic Syndromes
414447|NCT01029262|MDS
414448|NCT01029262|transfusion dependent anemia
414449|NCT01029262|Erythropoiesis stimulating agents
414450|NCT01029262|non-del 5q
414451|NCT01029236|obesity
414452|NCT01029236|metabolism
414453|NCT01029236|weight loss
414454|NCT01029236|energy expenditure
414455|NCT01029236|thermogenesis
414456|NCT01029236|Metabolism-Boosting Beverages effect on REE
414457|NCT01029236|Metabolism-Boosting Beverages effect on appetite
414458|NCT01029210|osteoporosis
414459|NCT01029210|temporomandibular disorders
414460|NCT01029210|resonance magnetic
414461|NCT01029184|weaning
414462|NCT01029184|cereals
414463|NCT01029184|allergy
414464|NCT01029184|atopy
414465|NCT01029184|open allergenic test
414466|NCT01029171|falls
414467|NCT01029171|balance training
414468|NCT01029171|strength training
414469|NCT01029158|Healthy volunteers
414470|NCT01029158|Comparison of two formulations
414471|NCT01029158|Improvement of scar appearance
414472|NCT01029145|Bipolar disorder
414473|NCT01029145|New occured episode: manic depressive or mixed
414474|NCT01029132|Alzheimer's disease
414475|NCT01029132|Galantamine
414476|NCT01029132|Treatment response
414477|NCT01029132|Efficacy
414478|NCT01029132|Adverse Event
414479|NCT01029119|blood pressure
414480|NCT01029106|SUI
414481|NCT01029106|Stress Urinary Incontinence
414482|NCT01029106|Patients with Stress Urinary Incontinence
414483|NCT01029093|extremity with immobilisation
414484|NCT01029093|brain platicity
414485|NCT01029093|deprivation
414486|NCT01029093|MRI
414487|NCT01029080|Brain, blood flow
414488|NCT01029080|Measurement techniques, flow velocity waveform analysis
414489|NCT01029080|Monitoring, intensive care
414490|NCT01029080|Sepsis
414491|NCT01029080|transcranial doppler ultrasound (TCD)
414492|NCT01029080|Cerebrovascular autoregulation
414493|NCT01029080|sepsis-associated delir
414494|NCT01029067|schizophrenia
414495|NCT01029067|delusion
414496|NCT01029067|paranoia
414497|NCT01029067|psychosis
414498|NCT01029054|Multiple Myeloma
414499|NCT01029041|fibromyalgia, exercise, strength, stretch
414500|NCT01027442|Stereolithography
414501|NCT01027442|Dental implants,
414502|NCT01027442|Prosthetics
414503|NCT01027442|positioning-errors
414504|NCT01027442|logistic regression analysis
414505|NCT01027429|infant
414506|NCT01027429|newborn
414507|NCT01027429|sepsis
414508|NCT01027429|infection
414509|NCT01027429|community
414510|NCT01027416|ER positive
414511|NCT01027416|Tamoxifen
414512|NCT01027403|Heart failure
414513|NCT01027403|Adult stem cells
414514|NCT01027403|Circulating stem cells
414515|NCT01027403|Acute decompensated heart failure
414516|NCT01027390|neck/shoulder
414517|NCT01029015|OAB
414518|NCT01029015|Insomnia
414519|NCT01029015|Bladder function
414520|NCT01029015|cystometry
414521|NCT01029015|polysomnography
414522|NCT01029002|Vitamin D
414523|NCT01029002|CKD
414524|NCT01029002|proteinuria
414525|NCT01028989|Polycystic Ovary Syndrome
414526|NCT01028989|Insulin
414527|NCT01028989|Diet
414528|NCT01028989|Glycemic Load
414529|NCT01028976|randomized controlled trial
414530|NCT01028976|primary prevention
414531|NCT01028976|Vitamin C
414532|NCT01028976|Antioxidants
414533|NCT01028976|C-reactive protein
414534|NCT01028976|inflammation
414535|NCT01028976|anti-inflammatory agents
414536|NCT01028976|obesity
414537|NCT01028950|YM150
414538|NCT01028950|Bleeding
414539|NCT01028950|VTE
414540|NCT01028950|FXa inhibitor
414541|NCT01028950|Deep Vein Thrombosis
414542|NCT01028950|Venous thromboembolism
414543|NCT01028937|Hyperopia correction
414544|NCT01028937|Laser vision correction
414545|NCT01028937|Optimal keratoplasty
414546|NCT01028924|Thorough QTc-Study
414547|NCT01028924|Short Bowel Syndrome
414548|NCT01028924|Cardiac safety
414549|NCT01028911|Phase 1 Alzheimer's disease Safety Tolerability Pharmacokinetics
414550|NCT01028898|IBS
414551|NCT01028898|proteomics
414552|NCT01028898|fluorescent quantitation polymerase chain reaction
414553|NCT01028898|Western blot
414554|NCT01028898|immunohistochemistry staining (IHC)
414555|NCT01028898|ATP content
414556|NCT01028898|micRNA
414557|NCT01028872|higher-order aberrations, contrast sensitivity
414558|NCT01028859|Tubulin polymerization inhibitor
414559|NCT01028859|CKD-516
414560|NCT01028859|Phase I
414561|NCT01028859|Vascular disrupting agent
414562|NCT01028859|DCE MRI
414563|NCT01028846|Type 2 Diabetes
414564|NCT01028833|power wheelchairs
414565|NCT01028833|power mobility
414566|NCT01028833|young children
414567|NCT01028820|autism
414568|NCT01028820|asperger's
414569|NCT01028820|repetitive
414570|NCT01028820|restricted
414571|NCT01028820|compulsions
414572|NCT01028807|Early feeding
414573|NCT01028807|Bowel anastomosis
414574|NCT01028807|Children
414575|NCT01028794|stroke
414576|NCT01028794|bone marrow
414577|NCT01028794|mononuclear cell
414578|NCT01028794|angiogenesis
414579|NCT01028794|neurogenesis
414580|NCT01028768|Renal impairment
414581|NCT01028768|Renal impairment study
414582|NCT01028755|Maximum Tolerated Dose
414583|NCT01028742|Traumatic brain injury
414584|NCT01028742|Hypopituitarism
414585|NCT01028742|Incidence
414586|NCT01028703|Chronic kidney disease
414587|NCT01028703|left ventricular dysfunction
414588|NCT01028703|diastolic dysfunction
414589|NCT01028703|hypertension
414590|NCT01028690|Helicobacter pylori
414591|NCT01028690|Eradication therapy
414592|NCT01028690|Lactobacillus reuteri
414593|NCT01028690|Dyspeptic symptoms
414594|NCT01028677|oxytocin
414595|NCT01028677|social cognition
414596|NCT01028677|social skill
414597|NCT01028677|social functioning
414598|NCT01028677|paranoia
414599|NCT01028677|psychotic symptoms
414600|NCT01028677|schizophrenia
414601|NCT01028677|social deficits
414602|NCT01028677|intranasal administration
414603|NCT01028664|Glaucoma and ocular hypertension patients
414604|NCT01028651|PAH
414605|NCT01028651|Pulmonary Hypertension
414606|NCT01028651|Remodulin
414607|NCT01028651|Treprostinil
414608|NCT01028651|Quality of Life
414609|NCT01028638|VEGF imaging
414610|NCT01028638|everolimus
414611|NCT01028638|renal cell carcinoma
414612|NCT01028638|PET
414613|NCT01028638|bevacizumab
414614|NCT01028625|Heart failure
414615|NCT01028625|Depression
414616|NCT01028625|Self Care
414617|NCT01028625|Cognitive behavior therapy
414618|NCT01028599|Heart transplantation
414619|NCT01028599|Exercise capacity
414620|NCT01028599|Endothelial function
414621|NCT01028573|bowel preparation
414622|NCT01028573|colonoscopy
414623|NCT01028560|Wheezing
414624|NCT01028560|Asthma
414625|NCT01028560|Allergy
414626|NCT01028560|Immunotherapy
414627|NCT01028547|PONV
414628|NCT01028534|Continuous positive pressure ventilation
414629|NCT01028534|Blood pressure
414630|NCT01028534|Oxygen desaturation index
414631|NCT01028534|Endothelial dysfunction
414632|NCT01028534|Patient reported measurement
414633|NCT01028521|First time in man, safety study, Cm3.1-AC100
414634|NCT01028521|Male volunteer aged 18 to 50 years at Screening
414635|NCT01028508|Depression
414636|NCT01028508|ECT
414637|NCT01028508|electroconvulsive therapy
414638|NCT01028508|mood disorders
414639|NCT01028508|continuation ECT
414640|NCT01028508|continuation pharmacotherapy
414641|NCT01028508|geriatric
414642|NCT01028508|elderly
414643|NCT01028508|lithium
414644|NCT01028508|venlafaxine
414645|NCT01028482|severity of depression measured by MADRS and CGI
414646|NCT01028456|Seizures
414647|NCT01028456|Light Therapy
414648|NCT01027351|Children
414649|NCT01027351|Pre-school
414650|NCT01027351|Meningococcal disease
414651|NCT01027351|Prevention
414652|NCT01027351|Vaccination
414653|NCT01027325|Resistant Starch
414654|NCT01027325|Amylose
414655|NCT01027325|Amylopectin
414656|NCT01027325|LDL subclasses
414657|NCT01027325|Dietary carbohydrate
414658|NCT01027325|Postprandial insulinemia
414659|NCT01027312|Glaucoma
414660|NCT01027312|quality of life
414661|NCT01027312|daily living activities
414662|NCT01027312|visual fields
414663|NCT01027312|contrast sensitivity
414664|NCT01027299|cardiac failure
414665|NCT01027299|thoracic surgery
414666|NCT01027299|cardiac pacing, artificial
414667|NCT01027273|Stroke
414668|NCT01027273|Ischemic Stroke
414669|NCT01027273|Transient Ischemic Attack
414670|NCT01027273|Stroke Recurrence Prevention
414671|NCT01027273|Cerebrovascular Disorders
414672|NCT01027273|Brain Ischemia
414673|NCT01027273|Brain Infraction
414674|NCT01027273|Brain Diseases
414675|NCT01027273|Cerebral Infraction
414676|NCT01027273|Self-management
414677|NCT01027273|Peer-led
414678|NCT01027273|Community Based
414679|NCT01027247|Primary Glaucoma
414680|NCT01027234|Healthy volunteers
414681|NCT01027221|Low Dose Radiation
414682|NCT01027221|pancreatic cancer
414683|NCT01027221|Immunostimulation
414684|NCT01028430|Chronic Lymphocytic Leukemia
414685|NCT01028417|subcentimetre nodules
414686|NCT01028365|Fertility
414687|NCT01028365|Trying to Conceive
414688|NCT01028365|Trying to Get Pregnant
414689|NCT01028365|Pregnancy
414690|NCT01028339|traumatic brain injury
414691|NCT01028339|PtiO2
414692|NCT01028339|Cerebral microdialysis
414693|NCT01028339|Osmotherapy
414694|NCT01028339|hypertonic saline
414695|NCT01028339|mannitol
414696|NCT01028326|Pneumococcal pneumonia vaccine
414697|NCT01028313|Chronic Graft-Versus-Host Disease
414698|NCT01028313|GVHD
414699|NCT01028313|LBH589
414700|NCT01028313|Panobinostat
414701|NCT01028300|DDD
414702|NCT01028287|Diabetic Nephropathy
414703|NCT01028287|Nephrotic syndrome
414704|NCT01028274|Hypercholesterolemia
414705|NCT01028274|Hypertriglyceridemia
414706|NCT01028274|Fish Oil
414707|NCT01028274|Red Yeast Rice
414708|NCT01028261|Obese
414709|NCT01028261|Obesity
414710|NCT01028261|Overweight
414711|NCT01028248|Central Retinal Vein Occlusion
414712|NCT01028248|Retinal Vein Occlusive disease
414713|NCT01028235|Eosinophilic Esophagitis
414714|NCT01028222|Melanoma
414715|NCT01028222|AMN107
414716|NCT01028222|c-Kit
414717|NCT01028222|c-Kit mutated metastatic and/or inoperable melanoma
414718|NCT01028196|schizophrenia
414719|NCT01028196|schizoaffective disorder
414720|NCT01028196|recurrent depression
414721|NCT01028196|Bipolar disorders
414722|NCT01028183|therapeutics
414723|NCT01028183|safety
414724|NCT01028183|maternal
414725|NCT01028183|neonatal
414726|NCT01028170|Congestive Heart Failure
414727|NCT01028170|Renal Insufficiency
414728|NCT01028170|Cardio-renal Syndrome
414729|NCT01028157|HIV
414730|NCT01028157|risk reduction
414731|NCT01028157|behavioral intervention
414732|NCT01028144|Exercise
414733|NCT01028144|Physical Activity
414734|NCT01028144|Adolescent
414735|NCT01028144|Minority Health
414736|NCT01028131|cigarette smoking
414737|NCT01028131|pregnancy
414738|NCT01028131|intervention
414739|NCT01028131|efficacy
414740|NCT01028131|Motivational Interviewing
414741|NCT01028131|Contingency Management
414742|NCT01028118|domestic and sexual violence
414743|NCT01028118|menopause
414744|NCT01028118|professional improvement
414745|NCT01028118|social support network
414746|NCT01028105|Preoperative screening
414747|NCT01028105|MRSA
414748|NCT01028105|Incidence
414749|NCT01028105|Postoperative infection
414750|NCT01028105|Preoperative MRSA Screening Incidence
414751|NCT01028105|Postoperative MRSA Infection Rate
414752|NCT01028079|Back Pain
414753|NCT01028079|Acute low back pain
414754|NCT01028066|nutritional intervention
414755|NCT01028066|nutritional counseling
414756|NCT01028066|feeding behavior
414757|NCT01028066|food consumption
414758|NCT01028066|angioplasty
414759|NCT01028053|Mild Cognitive Impairment
414760|NCT01028053|Positron Emission Tomography
414761|NCT01028053|National Institute of Neurological and Communicative Disorders and Stroke
414762|NCT01028053|Alzheimer's Disease and Related Disorders Association
414763|NCT01028053|Assess Prognostic Usefulness of Flutemetamol Injection for Identifying Subjects who will Convert to Clinically Probable Alzheimer's Disease
414764|NCT01028040|Phase I
414765|NCT01028040|AZD3043
414766|NCT01028040|Japanese healthy volunteer
414767|NCT01028027|Blepharokeratoconjunctivitis
414768|NCT01027988|Retinal Microvascularisation
414769|NCT01027988|Fundus
414770|NCT01027988|mfERGs
414771|NCT01027988|CHF
414772|NCT01027988|Cardiovascular Disease
414773|NCT01027988|Coronarography
414774|NCT01027988|Macrovascularisation
414775|NCT01027988|The objectives are to assess if if any retinal vascular disorder in arterioles and venules can be predictive for cardiovascular morbidity and mortality
414776|NCT01027975|laparoscopy
414777|NCT01027975|fundoplication
414778|NCT01027975|Nissen
414779|NCT01027975|Thal
414780|NCT01027975|children
414781|NCT01027975|operative treatment of gastro-oesophageal reflux disease in children
414782|NCT01027962|Early Onset Psychosis
414783|NCT01027962|Laptop Computer
414784|NCT01027962|Brain Training
414785|NCT01027936|Healthy Volunteers
414786|NCT01027910|PCI-24781
414787|NCT01027910|doxorubicin
414788|NCT01027897|Pharmacokinetics
414789|NCT01027897|Pharmacodynamics
414790|NCT01027897|Doripenem
414791|NCT01027897|Trauma
414792|NCT01027897|sepsis
414793|NCT01027897|Trauma patients with sepsis
414794|NCT01027884|Idebenone
414795|NCT01027884|Duchenne Muscular Dystrophy (DMD)
414796|NCT01027884|Respiratory function
414797|NCT01027884|Ambulatory and non-ambulatory patients
414798|NCT01027884|Subjects not using glucocorticoids
414799|NCT01027858|exercise
414800|NCT01027858|aerobic exercise training
414801|NCT01027858|vascular cognitive impairment
414802|NCT01027858|Mild Sub-cortical Ischaemic Vascular Cognitive Impairment (SIVCI)
414803|NCT01027845|Pneumococcal disease
414804|NCT01027845|Immunogenicity
414805|NCT01027845|Booster vaccination
414806|NCT01027845|Pneumococcal vaccine
414807|NCT01027845|Primary vaccination
414808|NCT01027845|Safety
414809|NCT01027832|tracheobronchitis
414810|NCT01027819|Total knee arthroplasty
414811|NCT01027819|Mobile bearing
414812|NCT01027819|Fixed bearing
414813|NCT01027819|Range of motion
414814|NCT01027819|Knee Society Score
414815|NCT01027806|Children
414816|NCT01027806|Sleep
414817|NCT01027806|Obstructive Sleep Apnea
414818|NCT01027793|Stretch marks
414819|NCT01027793|Striae
414820|NCT01027793|Tretinoin
414821|NCT01027793|Superficial dermabrasion
414822|NCT01027780|Mindfulness-Based Stress Reduction
414823|NCT01027780|MBSR
414824|NCT01027780|Seniors
414825|NCT01027780|immune system
414826|NCT01027780|keyhole limpet hemocyanin (KLH)
414827|NCT01027767|Breast
414828|NCT01027767|MBI
414829|NCT01027767|Molecular
414830|NCT01027767|Molecular Breast Imaging
414831|NCT01027767|Dense breast tissue
414832|NCT01027767|Surgery
414833|NCT01027767|Radiation
414834|NCT01027767|BCT
414835|NCT01027754|methadone maintenance
414836|NCT01027715|Neonatal Seizures
414837|NCT01027715|Neonatal encephalopathy
414838|NCT01027702|Donor Lymphocyte Infusion
414839|NCT01027702|Immune Recovery
414840|NCT01027702|T cell depleted transplant
414841|NCT01027702|Mismatched related donor transplants
414842|NCT01027702|Unrelated donor transplants
414843|NCT01027689|alprazolam
414844|NCT01027689|bioequivalence
414845|NCT01027689|sublingual
414846|NCT01027676|Gefitinib
414847|NCT01027676|Vorinostat
414848|NCT01027663|anemia
414849|NCT01027663|malaria
414850|NCT01027637|breast reconstruction
414851|NCT01027637|tissue expander
414852|NCT01027637|Alloderm
414853|NCT01027637|tissue matrix
414854|NCT01027624|Pan South African Survey on the Undertreatment of Hypercholesterolaemia
414855|NCT01027611|Effectiveness of topical pain medicine for control of pain associated with intravitreal injections
414856|NCT01027611|Eye discomfort
414857|NCT01027598|Lung Cancer
414858|NCT01027598|Previously Treated Advanced Non Small Cell Lung Cancer
414859|NCT01027598|Erlotinib
414860|NCT01027598|Pazopanib
414861|NCT01027572|Vegetative state
414862|NCT01027572|Minimally conscious state
414863|NCT01027572|Thalamic stimulation
414864|NCT01027559|Major Depression
414865|NCT01027559|Functional Magnetic Resonance Imaging
414866|NCT01027559|Emotional Circuitry
414867|NCT01027559|Cognitive Behavioral Therapy
414868|NCT01027546|perioperative blood loss, spinal surgery
414869|NCT01027533|multifocal intraocular lens
414870|NCT01027533|visual acuity
414871|NCT01027533|presbiopia
414872|NCT01027520|Hand burn
414873|NCT01027520|skin graft
414874|NCT01027520|coban dressing
414875|NCT01027520|range of motion
414876|NCT01027494|ear tubes
414877|NCT01027494|ear drainage
414878|NCT01027494|ear infection
414879|NCT01027494|ear drops
414880|NCT01027494|tympanostomy tubes
414881|NCT01027481|lucentis, macular edema, branch retinal vein occlusion
414882|NCT01027468|bevacizumab, choroidal neovascularization
414883|NCT01027182|HIV
414884|NCT01027169|Hepatic impairment
414885|NCT01027169|Liver diseases
414886|NCT01027169|Pharmacokinetics
414887|NCT01027169|To Investigate Pharmacokinetics of Safinamide in Subjects With Mild and Moderate Hepatic Impairment as Compared to Healthy Subjects With Normal Hepatic Function
414888|NCT01027156|Public Health
414889|NCT01027156|Biochemistry
414890|NCT01027156|Ecological
414891|NCT01027143|Asthma
414892|NCT01027143|Obesity
414893|NCT01027143|Pharmacogenetics
414894|NCT01027143|Nutrigenetics
414895|NCT01027117|Bioavailability
414896|NCT01027117|Revatio
414897|NCT01027117|Healthy Volunteers
414898|NCT01027104|injury prevention
414899|NCT01027104|firearms
414900|NCT01027104|training
414901|NCT01027104|counseling
414902|NCT01027104|medical education
414903|NCT01027104|safety
414904|NCT01027104|anticipatory guidance
414905|NCT01027104|Firearm injury prevention anticipatory guidance
414906|NCT01027091|hypocalcemia
414907|NCT01027091|total thyroidectomy
414908|NCT01027065|interleukin-7
414909|NCT01027065|immune-based therapies
414910|NCT01027065|hepatitis B
414911|NCT01027065|HBe negative
414912|NCT01027065|HBV vaccination
414913|NCT01027065|entecavir
414914|NCT01027065|tenofovir
414915|NCT01027065|chronic hepatitis
414916|NCT01027065|immune specific responses to HBV
414917|NCT01027065|phase 1/2a
414918|NCT01027065|viral disease
414919|NCT01027065|liver disease
414920|NCT01027052|MDA
414921|NCT01027052|Spice
414922|NCT01027039|primary open angle glaucoma
414923|NCT01027039|pigmentary glaucoma
414924|NCT01027039|exfoliative glaucoma
414925|NCT01027039|angle closure glaucoma
414926|NCT01027039|low tension glaucoma
414927|NCT01027026|Cost analysis
414928|NCT01027026|Safety
414929|NCT01027026|Length of stay
414930|NCT01027026|Randomized controlled trials
414931|NCT01027026|Early discharge
414932|NCT01027000|refractory chronic lymphocytic leukemia
414933|NCT01027000|stage I chronic lymphocytic leukemia
414934|NCT01027000|stage II chronic lymphocytic leukemia
414935|NCT01027000|stage III chronic lymphocytic leukemia
414936|NCT01027000|stage IV chronic lymphocytic leukemia
414937|NCT01027000|B-cell chronic lymphocytic leukemia
414938|NCT01027000|contiguous stage II small lymphocytic lymphoma
414939|NCT01027000|noncontiguous stage II small lymphocytic lymphoma
414940|NCT01027000|recurrent small lymphocytic lymphoma
414941|NCT01027000|stage I small lymphocytic lymphoma
414942|NCT01027000|stage III small lymphocytic lymphoma
414943|NCT01027000|stage IV small lymphocytic lymphoma
414944|NCT01026974|Children
414945|NCT01026974|Pre-school
414946|NCT01026974|Meningococcal disease
414947|NCT01026974|Prevention
414948|NCT01026974|Vaccination
414949|NCT01026961|Safety
414950|NCT01026961|heart rate
414951|NCT01026961|systolic and diastolic blood pressure
414952|NCT01026961|arrhythmias
414953|NCT01026948|Induction of labour
414954|NCT01026948|Intraprtum fetal monitoring
414955|NCT01026935|open mesh repair
414956|NCT01026935|sutured
414957|NCT01026935|non-sutured
414958|NCT01026935|pro-grip
414959|NCT01026935|postoperative pain
414960|NCT01026922|antroduodenal manometry
414961|NCT01026922|gastric dysmotility
414962|NCT01026922|intestinal dysmotility
414963|NCT01026896|Mental practice
414964|NCT01026896|motor imagery
414965|NCT01026896|stroke
414966|NCT01026896|hemiplegia
414967|NCT01026896|motor recovery
414968|NCT01026896|neuroplasticity
414969|NCT01026883|hematocrit
414970|NCT01026883|layered resonant piezoelectric sensors
414971|NCT01026844|erlotinib
414972|NCT01026844|tarceva
414973|NCT01026844|hydroxychloroquine
414974|NCT01026844|NSCLC
414975|NCT01026818|Erectile Dysfunction
414976|NCT01026818|Radical Prostatectomy
414977|NCT01026805|morcellator
414978|NCT01026805|hysteroscope
414979|NCT01026805|myomectomy
414980|NCT01026805|polypectomy
414981|NCT01026805|uterine fibroids
414982|NCT01026779|rotavirus
414983|NCT01026779|gastroenteritis
414984|NCT01026779|vaccine
414985|NCT01026779|case-control study
414986|NCT01026779|serotype
414987|NCT01026766|Hypothermia
414988|NCT01026766|Obesity
414989|NCT01026766|Heat and moisture exchanger
414990|NCT01026766|Warming blanket
414991|NCT01026766|Warming fluids
414992|NCT01026766|Gynecological surgery
414993|NCT01026766|Intravenous anesthesia
414994|NCT01026766|Obese patients
414995|NCT01026766|Non obese patients
414996|NCT01026753|colorectal cancer
414997|NCT01026753|screening
414998|NCT01026753|fecal occult blood test
414999|NCT01026753|randomized control trial
415000|NCT01026753|primary care oncology
415001|NCT01026753|web site
415002|NCT01026753|provincial health contact center
415003|NCT01026740|Staphylococcal Skin Infections
415004|NCT01026740|Streptococcal Infections
415005|NCT01026727|HIV Infections
415006|NCT01026727|Acquired Immunodeficiency Syndrome
415007|NCT01026727|Virus Diseases
415008|NCT01026727|Sexually Transmitted Diseases, Viral
415009|NCT01026727|RNA Virus Infections
415010|NCT01026727|Slow Virus Diseases
415011|NCT01026727|Immune System Diseases
415012|NCT01026727|Sexually Transmitted Diseases
415013|NCT01026727|Lentivirus Infections
415014|NCT01026727|Infection
415015|NCT01026727|Retroviridae Infections
415016|NCT01026727|Immunologic Deficiency Syndromes
415017|NCT01026727|HIV
415018|NCT01026727|treatment experienced
415019|NCT01026727|bevirimat
415020|NCT01026701|Osteoblst effect
415021|NCT01026701|Velcade
415022|NCT01026701|Proteasome inhibitor
415023|NCT01026701|Bortezomib
415024|NCT01026701|Multjple Myeloma
415025|NCT01026688|Pragmatic randomized controlled trial
415026|NCT01026688|Cardiovascular risk reduction
415027|NCT01026688|Knowledge translation
415028|NCT01026688|Clinical practice guidelines
415029|NCT01026662|Aesthetic dermatology
415030|NCT01026649|hematoma formation
415031|NCT01026649|success rate
415032|NCT01026636|Staphylococcal Skin Infections
415033|NCT01026636|Skin Infections
415034|NCT01026636|Streptococcal Infections
415035|NCT01026610|Chronic hepatitis B
415036|NCT01026610|LB80380
415037|NCT01026610|treatment-naive
415038|NCT01026610|entecavir
415039|NCT01026571|Bicuspid aortic valve
415040|NCT01026558|Obesity, Ceftobiprole
415041|NCT01026558|Skin Infections
415042|NCT01026558|Staphylococcal Skin Infections
415043|NCT01026558|Bacterial Skin Infections
415044|NCT01026558|Streptococcal Infection
415045|NCT01026545|safety
415046|NCT01026545|tolerability
415047|NCT01026545|pharmacokinetics
415048|NCT01026545|multiple-dose
415049|NCT01026545|macrolide
415050|NCT01026506|c9,t11-CLA
415051|NCT01026506|allergic bronchial asthma
415052|NCT01026506|children and adolescents
415053|NCT01026493|adult giant cell glioblastoma
415054|NCT01026493|adult glioblastoma
415055|NCT01026493|adult gliosarcoma
415056|NCT01026493|recurrent adult brain tumor
415057|NCT01026493|adult anaplastic astrocytoma
415058|NCT01026493|adult anaplastic ependymoma
415059|NCT01026493|adult anaplastic oligodendroglioma
415060|NCT01026493|adult brain stem glioma
415061|NCT01026493|adult mixed glioma
415062|NCT01026493|adult pineal gland astrocytoma
415063|NCT01026480|Ileal Pouch Anal Anastomosis
415064|NCT01026480|IPAA
415065|NCT01026480|Pull through
415066|NCT01026480|IBD
415067|NCT01026480|Ulcerative colitis
415068|NCT01026480|Familial adenomatous polyposis
415069|NCT01026480|FAP
415070|NCT01026480|Hereditary nonpolyposis colorectal cancer
415071|NCT01026480|HNPCC
415072|NCT01026454|HSV
415073|NCT01026454|HIV
415074|NCT01026441|Aesthetic
415075|NCT01026428|safinamide
415076|NCT01026428|levodopa
415077|NCT01026428|drug -drug interaction
415078|NCT01026428|pharmacokinetics
415079|NCT01026428|Patients diagnosed with idiopathic Parkinson's disease, levodopa-responsive, treated with a stable dose of levodopa/carbidopa
415080|NCT01026415|Antibody-Drug Conjugate
415081|NCT01026415|Antigens, CD30
415082|NCT01026415|Disease, Hodgkin
415083|NCT01026415|Lymphoma, Large-Cell, Anaplastic
415084|NCT01026415|Lymphoma, Non-Hodgkin
415085|NCT01026415|monomethyl auristatin E
415086|NCT01026415|Drug Therapy
415087|NCT01026415|Immunotherapy
415088|NCT01026415|Hematologic Diseases
415089|NCT01026415|Lymphoma
415090|NCT01026415|Antibodies, Monoclonal
415091|NCT01026402|Phase I
415092|NCT01026402|cancer
415093|NCT01026402|advanced solid malignancies
415094|NCT01026402|dose escalation
415095|NCT01026402|AZD2014
415096|NCT01026402|mTor kinase inhibitor
415097|NCT01026402|safety
415098|NCT01026402|pharmacokinetics
415099|NCT01026389|MRA-Contrast agent comparison in peripheral disease
415100|NCT01026376|Myelodysplastic Syndromes
415101|NCT01026376|Decitabine
415102|NCT01026363|Vitamin D
415103|NCT01026363|Chronic Kidney Disease
415104|NCT01026350|modulating immune response to flu antigen
415105|NCT01026337|recurrent renal cell cancer
415106|NCT01026311|Coenzyme q10
415107|NCT01026311|statins
415108|NCT01026311|myalgias
415109|NCT01026311|anaerobic threshold
415110|NCT01026311|athletic performance
415111|NCT01026298|asthma
415112|NCT01026298|obstructive sleep apnea
415113|NCT01026298|severe asthma
415114|NCT01026298|OSA
415115|NCT01026285|Risperdal Consta
415116|NCT01026272|Endocannabinoid
415117|NCT01026272|Fish Oil
415118|NCT01026272|Multiple Sclerosis
415119|NCT01026272|Monocyte Migration
415120|NCT01026259|Surgical site infection
415121|NCT01026259|wound healing
415122|NCT01026259|tissue oxygen
415123|NCT01026259|angiogenesis
415124|NCT01026259|flow cytometry
415125|NCT01026259|immunohistochemistry
415126|NCT01026246|Ghana, malaria, vaccine, Plasmodium falciparum
415127|NCT01026233|Antibodies, Monoclonal
415128|NCT01026233|Antibody-Drug Conjugate
415129|NCT01026233|Antigens, CD30
415130|NCT01026233|Disease, Hodgkin
415131|NCT01026233|Drug Therapy
415132|NCT01026233|Hematologic Diseases
415133|NCT01026233|Immunotherapy
415134|NCT01026233|Lymphoma
415135|NCT01026233|monomethylauristatin E
415136|NCT01026233|Lymphoma, Large-Cell, Anaplastic
415137|NCT01026207|Diagnostic test
415138|NCT01026207|polysomnography
415139|NCT01026207|Obstructive Sleep Apnea Syndrome
415140|NCT01026207|Chronic Obstructive Pulmonary Disease
415141|NCT01026194|insulin resistance
415142|NCT01026155|Obese patients (BMI > 30 kg / m²)
415143|NCT01026103|gastric bypass
415144|NCT01026103|Gastric bypass surgery
415145|NCT01026077|Savella pregnant
415146|NCT01026077|savella pregnancy
415147|NCT01026077|fibromyalgia pregnant
415148|NCT01026077|fibromyalgia pregnancy
415149|NCT01026077|pregnancy registry savella
415150|NCT01026064|Macrolides
415151|NCT01026064|Inflammation
415152|NCT01026064|Azithromycin
415153|NCT01026064|Cantharidin induced skin blister model
415154|NCT01026051|Cancer Vaccine, Immunotherapy, Melanoma
415155|NCT01026038|Pneumococcal vaccine 13-valent
415156|NCT01026025|lobectomy
415157|NCT01026025|segmentectomy
415158|NCT01026025|pulmonary resection
415159|NCT01026012|Regadenoson
415160|NCT01026012|85% predicted heart rate
415161|NCT01026012|Myocardial perfusion stress testing
415162|NCT01025999|RYGB
415163|NCT01025999|Gastrostomy tube
415164|NCT01025999|DM
415165|NCT01025999|Gastric Bypass
415166|NCT01025960|colonoscopy
415167|NCT01025960|adenoma detection
415168|NCT01025960|polyps
415169|NCT01025947|Atrial fibrillation
415170|NCT01025947|Cryptogenic stroke
415171|NCT01025947|Implantable loop recorder
415172|NCT01025921|Tracheobronchitis
415173|NCT01025921|pneumonia
415174|NCT01025921|inhaled antibiotics
415175|NCT01025921|colistin
415176|NCT01025921|Ventilator associated tracheobronchitis
415177|NCT01025921|Ventilator associated pneumonia
415178|NCT01025908|psychotherapy
415179|NCT01025908|panic disorder
415180|NCT01025908|anxiety
415181|NCT01025908|behavior
415182|NCT01025908|cognition
415183|NCT01025895|arthroscopic surgical procedure
415184|NCT01025882|adenocarcinoma of the pancreas
415185|NCT01025882|stage I pancreatic cancer
415186|NCT01025882|stage II pancreatic cancer
415187|NCT01025882|stage III pancreatic cancer
415188|NCT01025856|liver fat
415189|NCT01025856|postprandial lipids metabolism
415190|NCT01025856|diet
415191|NCT01025856|exercise
415192|NCT01025856|type 2 diabetes
415193|NCT01025830|HIV;Bioequivalence;Triomune
415194|NCT01025817|Kidney transplant
415195|NCT01025817|renal transplant
415196|NCT01025817|immunosuppression
415197|NCT01025817|mycophenolate mofetil
415198|NCT01025817|tacrolimus
415199|NCT01025817|everolimus
415200|NCT01025804|Interfant-06
415201|NCT01025804|Infant ALL
415202|NCT01025804|Asparaginase
415203|NCT01025804|Pharmacokinetics of asparaginase
415204|NCT01025804|Antibody formation
415205|NCT01025778|Haploidentical hematopoietic stem cell transplantation
415206|NCT01025778|Graft versus host disease
415207|NCT01025778|Donor lymphocyte infusion
415208|NCT01025778|Graft versus leukemia effect
415209|NCT01025778|Immunological recovery
415210|NCT01025778|Bridge to transplant approach
415211|NCT01025778|Therapy resistant leukemia
415212|NCT01025778|Hematological malignancy
415213|NCT01025752|chronic pain
415214|NCT01025752|cognitive behavior therapy
415215|NCT01025752|low back pain
415216|NCT01025739|Gastroesophageal Reflux Disease (GERD)
415217|NCT01025739|EsophyX
415218|NCT01025713|Cystic Fibrosis
415219|NCT01025713|CF
415220|NCT01025713|Mucociliary Clearance
415221|NCT01025713|Epithelial Sodium Channel Inhibitor
415222|NCT01025713|ENaC Inhibitor
415223|NCT01025713|Airway Hydration
415224|NCT01025713|Amiloride
415225|NCT01025700|Efficacy
415226|NCT01025700|Marijuana
415227|NCT01025700|Reduction
415228|NCT01025700|Craving
415229|NCT01025687|girls
415230|NCT01025687|obesity
415231|NCT01025687|television viewing
415232|NCT01025687|puberty
415233|NCT01025674|School health program
415234|NCT01025674|Positive health behavior
415235|NCT01025674|School-wide climate
415236|NCT01025674|Mental health
415237|NCT01025674|Self-esteem
415238|NCT01025674|Social support
415239|NCT01025674|Exercise
415240|NCT01025674|Nutrition
415241|NCT01025674|Parent involvement
415242|NCT01025674|Community involvement
415243|NCT01025661|chiropractic
415244|NCT01025661|hip osteoarthritis
415245|NCT01025661|hip arthroplasty
415246|NCT01025661|pain
415247|NCT01025661|activities of daily living.
415248|NCT01025648|Mild to Moderate Asthma
415249|NCT01025648|Dyspnea
415250|NCT01025648|Wheezing
415251|NCT01025648|Status Asthmaticus
415252|NCT01025635|rosacea
415253|NCT01025635|papulopustular
415254|NCT01025635|azelaic acid
415255|NCT01025635|foam
415256|NCT01025622|Stem Cells
415257|NCT01025622|Liver Cirrhosis
415258|NCT01025622|Cell Therapy
415259|NCT01025609|spinal cord injury
415260|NCT01025609|cardiovascular disease
415261|NCT01025609|dietary patterns
415262|NCT01025596|interleukin-7
415263|NCT01025596|immune-based therapies
415264|NCT01025596|hepatitis C
415265|NCT01025596|chronic hepatitis
415266|NCT01025596|resistance to Peg-interferon and ribavirin bi-therapy
415267|NCT01025596|immune specific responses to HCV
415268|NCT01025596|phase 1
415269|NCT01025596|viral disease
415270|NCT01025596|liver disease
415271|NCT01025583|acute gastroenteritis
415272|NCT01025583|intestinal infection
415273|NCT01025583|intestinal fluid secretion
415274|NCT01025583|intestinal microflora
415275|NCT01025583|treatment of childhood acute diarrhea
415276|NCT01025570|pancreas
415277|NCT01025570|pancreatic
415278|NCT01025570|bosutinib
415279|NCT01025570|SKI-606
415280|NCT01025570|gemcitabine
415281|NCT01025570|gemzar
415282|NCT01025570|Patients with resected pancreatic cancer
415283|NCT01025557|Food intake
415284|NCT01025557|Blood glucose
415285|NCT01025557|Milk
415286|NCT01025544|Haemophilus influenzae type b (Hib)
415287|NCT01025544|Vaccine
415288|NCT01025544|Booster
415289|NCT01025531|Hepatitis C
415290|NCT01025518|Head and Neck Neoplasms
415291|NCT01025518|Resistance training
415292|NCT01025518|Muscle mass
415293|NCT01025518|Functional capacity
415294|NCT01025505|Untreated Ph+ ALL unfit for intense therapy and allo SCT
415295|NCT01025492|high density lipoprotein
415296|NCT01025492|arterial compliance
415297|NCT01025492|brachial artery flow-mediated dilatation
415298|NCT01025479|Osteoporosis
415299|NCT01025479|Prostate cancer
415300|NCT01025479|LHRH agonist and/or anti-androgen agent
415301|NCT01025479|Korean prostate cancer
415302|NCT01025453|thyroid
415303|NCT01025453|follicular cell
415304|NCT01025453|papillary cell
415305|NCT01025453|Hurthle cell
415306|NCT01025453|BAY 43-9006
415307|NCT01025453|Temsirolimus
415308|NCT01025453|Sorafenib
415309|NCT01025453|09-148
415310|NCT01025427|HIV
415311|NCT01025427|HIV persistence
415312|NCT01025427|HIV reservoirs
415313|NCT01025414|pancreatic fistula
415314|NCT01025401|epilepsy
415315|NCT01025401|seizures
415316|NCT01025401|movement
415317|NCT01025388|Hypercholesterolemia
415318|NCT01025388|The study is focusing on the undertreatment of hypercholesterolemia
415319|NCT01025375|overweight
415320|NCT01025349|bevacizumab
415321|NCT01025349|metastatic breast cancer
415322|NCT01025349|docetaxel
415323|NCT01025336|Antibody persistence
415324|NCT01025323|Pre hypertension
415325|NCT01025323|Lifestyle modification
415326|NCT01025323|DASH diet
415327|NCT01025310|eye movements
415328|NCT01025310|saccades
415329|NCT01025310|visual
415330|NCT01025310|stress
415331|NCT01025310|search coil
415332|NCT01025310|environment
415333|NCT01025310|Saccadic eye movements
415334|NCT01025310|Urban environment
415335|NCT01025297|interleukin-7
415336|NCT01025297|immune-based therapies
415337|NCT01025297|hepatitis C
415338|NCT01025297|chronic hepatitis
415339|NCT01025297|resistance to Peg-interferon and ribavirin bi-therapy
415340|NCT01025297|immune specific responses to HCV
415341|NCT01025297|phase 1/2a
415342|NCT01025297|viral disease
415343|NCT01025297|liver disease
415344|NCT01025271|meningitis
415345|NCT01025258|Cystic Fibrosis
415346|NCT01025258|Medication Adherence
415347|NCT01025258|Multidisciplinary Team
415348|NCT01025258|Clinical Outcomes
415349|NCT01025245|Remifentanil induced postoperative hyperalgesia
415350|NCT01025232|Antibodies, Monoclonal
415351|NCT01025232|Immunologic Factors
415352|NCT01025232|Eye Diseases
415353|NCT01025232|Retinal Degeneration
415354|NCT01025232|Macular Degeneration
415355|NCT01025232|Pharmacologic Actions
415356|NCT01025232|Retinal Diseases
415357|NCT01025219|Diagnosis of dependence on cocaine according to DSM-IV-TR criteria
415358|NCT01025206|Multiple Myeloma
415359|NCT01025206|monoclonal antibody
415360|NCT01025206|safety
415361|NCT01025206|pharmacokinetic
415362|NCT01025193|belimumab
415363|NCT01025193|Benlysta
415364|NCT01025193|LymphoStat B
415365|NCT01025193|BLyS specific inhibitors
415366|NCT01025180|safety
415367|NCT01025180|Procalcitonin
415368|NCT01025180|PCT
415369|NCT01025180|SOFA
415370|NCT01025180|Sepsis
415371|NCT01025180|Antibiotic
415372|NCT01025180|Strategy
415373|NCT01025180|SIRS
415374|NCT01025180|severe sepsis without obvious infection
415375|NCT01025167|cancer
415376|NCT01025167|enteral nutrition
415377|NCT01025167|omega-3-fatty acids
415378|NCT01025154|Leukemia
415379|NCT01025154|AML
415380|NCT01025154|chemotherapy-naïve
415381|NCT01025154|Clofarabine
415382|NCT01025154|Clofarex
415383|NCT01025154|Clolar
415384|NCT01025154|Idarubicin
415385|NCT01025154|Idamycin
415386|NCT01025154|Cytarabine
415387|NCT01025154|Ara-C
415388|NCT01025154|Cytosar
415389|NCT01025154|DepoCyt
415390|NCT01025154|Cytosine Arabinosine Hydrochloride
415391|NCT01025141|MINISCREW
415392|NCT01025141|space extraction closure
415393|NCT01025141|anchorage
415394|NCT01025141|Orthodontic Treatment
415395|NCT01025141|Extraction of 2 Maxillary Premolar
415396|NCT01025141|closing of extraction space
415397|NCT01025141|patient aged from 12 to 50 years old
415398|NCT01025115|Dietary supplement
415399|NCT01025115|Diamel
415400|NCT01025115|Metabolic Syndrome
415401|NCT01025089|Cetuximab
415402|NCT01025089|Cisplatin
415403|NCT01025089|Cyclophosphamide
415404|NCT01025089|09-038
415405|NCT01025076|Enlarged gastric pouch and stoma
415406|NCT01025076|Post bariatric surgery
415407|NCT01025063|Spectral OCT
415408|NCT01025063|Choroidal Neovascularization
415409|NCT01025063|Lucentis
415410|NCT01025063|Visudyne
415411|NCT01025063|PDT
415412|NCT01025063|anti-VEGF
415413|NCT01025050|Presbyopia
415414|NCT01025050|Intrastromal
415415|NCT01025050|Femtosecond Laser
415416|NCT01025050|minimal-invasive
415417|NCT01025050|INTRACOR
415418|NCT01025050|Enhance Near Visual Acuity
415419|NCT01025037|Rotator Cuff Tear, Large, Massive, Rotator, Cuff. Tear
415420|NCT01025024|SNP
415421|NCT01025024|single-nucleotide polymorphism
415422|NCT01025024|glaucoma
415423|NCT01025024|primary open angle glaucoma
415424|NCT01025011|retinal hemoglobin concentration
415425|NCT01025011|non-invasive hemoglobin measurement
415426|NCT01024998|Age-Related Macular Degeneration
415427|NCT01024998|AMD
415428|NCT01024998|Wet AMD
415429|NCT01024998|Neovascular AMD
415430|NCT01024998|Ocular
415431|NCT01024998|Ocular gene therapy
415432|NCT01024998|Subretinal neovascularization
415433|NCT01024985|optic neuritis
415434|NCT01024985|longitudinally extensive transverse myelitis
415435|NCT01024985|retinal nerve fiber layer
415436|NCT01024985|macular thickness
415437|NCT01024959|Prostate Cancer
415438|NCT01024959|Prostate Biopsy
415439|NCT01024959|PCA3
415440|NCT01024946|mesothelioma
415441|NCT01024946|pleural
415442|NCT01024946|RAD001
415443|NCT01024946|Everolimus
415444|NCT01024946|09-142
415445|NCT01024946|thoracic
415446|NCT01024946|lung
415447|NCT01024946|epithelioid
415448|NCT01024946|sarcomatoid
415449|NCT01024933|Hypertension
415450|NCT01024933|High Blood Pressure
415451|NCT01024894|interleukin-7
415452|NCT01024894|immune-based therapies
415453|NCT01024894|hepatitis C
415454|NCT01024894|chronic hepatitis
415455|NCT01024894|resistance to Peg-interferon and ribavirin bitherapy
415456|NCT01024894|immune specific responses to HCV
415457|NCT01024894|taiwan
415458|NCT01024894|phase 1/2a
415459|NCT01024894|viral disease
415460|NCT01024894|liver disease
415461|NCT01024881|catheterization success rate
415462|NCT01024868|Transversus Abdominis Plane Block
415463|NCT01024829|Non small cell lung cancer
415464|NCT01024829|Inoperable
415465|NCT01024829|HX4
415466|NCT01024816|Metabolic Syndrome
415467|NCT01024816|Restorative Yoga
415468|NCT01024816|Stretching
415469|NCT01024816|Visceral adiposity
415470|NCT01024816|Randomized controlled trial
415471|NCT01024803|Retina implant, Subretinal
415472|NCT01024803|Legal blindness
415473|NCT01024803|Genetic Diseases, Inborn
415474|NCT01024803|Eye Diseases
415475|NCT01024803|Retinitis Pigmentosa
415476|NCT01024803|Retinitis
415477|NCT01024803|Retinal Degeneration
415478|NCT01024803|Eye Diseases, Hereditary
415479|NCT01024803|Retinal Diseases
415480|NCT01024777|cholecalciferol
415481|NCT01024777|multiple sclerosis
415482|NCT01024777|vitamin D
415483|NCT01024777|D3
415484|NCT01024764|HIV
415485|NCT01024764|Tat protein
415486|NCT01024764|Preventive vaccine
415487|NCT01024725|A(H1N1)v influenza
415488|NCT01024725|vaccination
415489|NCT01024725|pandemic
415490|NCT01024712|recurrent non-small cell lung cancer
415491|NCT01024712|stage IIIB non-small cell lung cancer
415492|NCT01024712|stage IV non-small cell lung cancer
415493|NCT01024712|adenocarcinoma of the lung
415494|NCT01024712|bronchoalveolar cell lung cancer
415495|NCT01024712|large cell lung cancer
415496|NCT01024673|H1N1
415497|NCT01024660|Patients with Mild to Moderate Alzheimer's Disease
415498|NCT01024634|Arterial stiffness
415499|NCT01024634|Endothelial function
415500|NCT01024634|Autonomic function
415501|NCT01024634|Inflammation
415502|NCT01024621|gastric intestinal metaplasia
415503|NCT01024621|Confocal laser endomicroscopy
415504|NCT01024595|HIV
415505|NCT01024595|Tat protein
415506|NCT01024582|breast cancer
415507|NCT01024582|invasive breast cancer
415508|NCT01024582|adenocarcinoma of the breast
415509|NCT01024569|Severe Mental Illness
415510|NCT01024569|Recovery
415511|NCT01024569|Psychiatric Disability
415512|NCT01024569|Wellness
415513|NCT01024569|Peer Service
415514|NCT01024569|WRAP
415515|NCT01024556|HIV, HAART
415516|NCT01024543|Angiotensin II
415517|NCT01024530|hepatocellular carcinoma
415518|NCT01024530|HCC
415519|NCT01024530|NK
415520|NCT01024530|immune killer cells
415521|NCT01024517|Safety
415522|NCT01024517|Tolerability
415523|NCT01024517|Pharmacokinetics
415524|NCT01024504|Cancer
415525|NCT01024504|Colorectal cancer
415526|NCT01024504|Elderly
415527|NCT01024504|Chemotherapy
415528|NCT01024504|Capecitabine
415529|NCT01024504|Oxaliplatin
415530|NCT01024504|Bevacizumab
415531|NCT01024491|premature ejaculation
415532|NCT01024491|paroxetine
415533|NCT01024491|daily treatment
415534|NCT01024478|Coronary Artery
415535|NCT01024478|Magnetic Resonance Angiography
415536|NCT01024478|Coronary Artery disease
415537|NCT01024478|Multicenter Trial
415538|NCT01024478|Cardiac MRI
415539|NCT01024465|obesity
415540|NCT01024465|intragastric balloon
415541|NCT01024452|anticoagulation
415542|NCT01024452|warfarin
415543|NCT01024452|computer systems
415544|NCT01024452|international normalized ratio
415545|NCT01024452|nomograms
415546|NCT01024426|Uganda
415547|NCT01024426|malaria
415548|NCT01024426|enhanced health facility-based care
415549|NCT01024426|febrile illnesses
415550|NCT01024426|health services
415551|NCT01024413|Thoracic Neoplasms
415552|NCT01024413|Molecular Mechanisms of Pharmacological Action
415553|NCT01024413|Protein Kinase Inhibitors
415554|NCT01024413|Respiratory Tract Diseases
415555|NCT01024413|Lung Neoplasms
415556|NCT01024413|Erlotinib
415557|NCT01024413|Gefitinib
415558|NCT01024413|Epidermal growth factor receptor genes
415559|NCT01024400|Influenza
415560|NCT01024400|Vaccine
415561|NCT01024400|Pregnancy
415562|NCT01024387|AMG 479
415563|NCT01024361|Preterm infants
415564|NCT01024361|Nasal CPAP
415565|NCT01024361|Delivery room
415566|NCT01024361|Newborn
415567|NCT01024348|Surgery, knee arthroscopy
415568|NCT01024348|Pain, postoperative
415569|NCT01024348|tramadol, extended release
415570|NCT01024335|opioid dependence
415571|NCT01024335|naltrexone
415572|NCT01024335|vivitrol
415573|NCT01024335|dronabinol
415574|NCT01024335|marinol
415575|NCT01024322|Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration
415576|NCT01024309|total hip arthroplasty
415577|NCT01024283|Heat Shock Protein 90 Inhibitor (HSP90)
415578|NCT01024283|Pharmacodynamic
415579|NCT01024283|Blood
415580|NCT01024283|Biopsy
415581|NCT01024283|Solid malignancies
415582|NCT01024270|endometrial pathology of uterus
415583|NCT01024270|operative hysteroscopy
415584|NCT01024270|efficacy of misoprostol per different routes
415585|NCT01024257|beta-irradiation;conjunctival autograft;pterygium;recurrence; clinical trial
415586|NCT01024205|clear cell renal cell carcinoma
415587|NCT01024205|stage IV renal cell cancer
415588|NCT01024179|Optical Coherence Tomography
415589|NCT01024179|Coronary artery disease
415590|NCT01024179|Chronic total occlusion
415591|NCT01024166|Cancer
415592|NCT01024166|Patient-Reported Outcomes Computer System
415593|NCT01024166|PRO
415594|NCT01024166|Palliative Care
415595|NCT01024166|Symptoms
415596|NCT01024166|Questionnaire
415597|NCT01024166|Patients
415598|NCT01024166|Caregivers
415599|NCT01024166|Palliative Care Physicians
415600|NCT01024166|Palliative Care Nurses
415601|NCT01024153|active video games
415602|NCT01024153|children
415603|NCT01024153|physical activity
415604|NCT01024140|Posttraumatic Stress Disorder
415605|NCT01024140|Escitalopram
415606|NCT01024140|Efficacy
415607|NCT01024114|MBI
415608|NCT01024114|Molecular Breast Imaging
415609|NCT01024114|Breast Cancer
415610|NCT01024114|Positive Molecular Breast Imaging scan.
415611|NCT01024088|Guillain Barré syndrome
415612|NCT01024088|Swallowing disorders
415613|NCT01024088|Respiratory failure
415614|NCT01024075|Chronic Rhinosinusitis
415615|NCT01024075|Endoscopic sinus surgery
415616|NCT01024075|Sinufoam
415617|NCT01024075|Dexamethasone
415618|NCT01024075|For patients with Chronic Rhinosinusitis without nasal polyps
415619|NCT01024075|Focus: Define the postoperative sinonasal mucosal healing status of 2 Sinufoam mixtures
415620|NCT01024049|heart failure blood left ventricular dysfunction
415621|NCT01024036|Multicentric Castleman's Disease
415622|NCT01024036|MCD
415623|NCT01024036|CNTO 328
415624|NCT01024036|Best Supportive Care
415625|NCT01024036|Tumor
415626|NCT01024036|Symptomatic response
415627|NCT01024036|Pharmacokinetics
415628|NCT01024036|Interleukin-6
415629|NCT01024036|IL6
415630|NCT01024023|Early Walking Aid
415631|NCT01024023|Amputee
415632|NCT01024023|Trans-tibial
415633|NCT01024023|Quality of life
415634|NCT01023997|corneal thickness
415635|NCT01023997|exfoliation
415636|NCT01023984|RECTAL NEOPLASMS
415637|NCT01023945|ASP1941
415638|NCT01023945|Diabetes mellitus
415639|NCT01023945|Blood glucose
415640|NCT01023919|Optical coherence tomography
415641|NCT01023919|Drug eluting stent
415642|NCT01023919|Coronary Artery Disease
415643|NCT01023919|Diabetes Mellitus
415644|NCT01023906|Taste
415645|NCT01023906|general Labeled Magnitude Scale
415646|NCT01023906|Aging
415647|NCT01023906|Chronic Disease Risk
415648|NCT01023906|Smell
415649|NCT01023867|Alzheimer's disease
415650|NCT01023867|Mixed Dementia
415651|NCT01023867|Donepezil
415652|NCT01023867|Efficacy
415653|NCT01023867|Adverse Event
415654|NCT01023854|Paravertebral block
415655|NCT01023854|loco regional anesthesia
415656|NCT01023854|renal surgery
415657|NCT01023854|PCA morphine
415658|NCT01023828|K-RAS ONCOGENE MUTATION
415659|NCT01023828|NON-SMALL CELL LUNG CANCER
415660|NCT01023828|WOOD SMOKE
415661|NCT01023815|Immunosuppression
415662|NCT01023815|renal transplantation
415663|NCT01023815|once-a-day regimen
415664|NCT01023815|steroid withdrawal
415665|NCT01023815|drug minimization
415666|NCT01023815|immunosuppression for prevention of acute rejections
415667|NCT01023802|neoadjuvant therapy
415668|NCT01023802|chemotherapy
415669|NCT01023802|hormone therapy
415670|NCT01023802|breast cancer
415671|NCT01023802|MBI
415672|NCT01023802|Molecular Breast Imaging
415673|NCT01023789|Drug eluting stent
415674|NCT01023789|Stents
415675|NCT01023789|Angioplasty
415676|NCT01023789|Bioabsorbable
415677|NCT01023789|Bioresorbable
415678|NCT01023789|Scaffold
415679|NCT01023776|Swine Flu
415680|NCT01023776|H1N1
415681|NCT01023763|Nursing homes
415682|NCT01023763|Intravenous
415683|NCT01023763|Treatment
415684|NCT01023763|Patient trajectory
415685|NCT01023763|Hospital admissions
415686|NCT01023750|hypertriglyceridemia
415687|NCT01023750|Triglycerides
415688|NCT01023750|HDL
415689|NCT01023750|Insulin resistance
415690|NCT01023737|Malignant Solid Tumor
415691|NCT01023737|Solid Tumor
415692|NCT01023737|Hydroxychloroquine
415693|NCT01023737|Vorinostat
415694|NCT01023711|Influenza
415695|NCT01023698|Diabetic retinopathy
415696|NCT01023698|Diabetic macular edema
415697|NCT01023698|Panretinal photocoagulation
415698|NCT01023685|Active immunization
415699|NCT01023685|Alzheimer disease
415700|NCT01023685|Antibody
415701|NCT01023685|Central Nervous System diseases
415702|NCT01023685|Neurodegenerative diseases
415703|NCT01023685|Vaccine
415704|NCT01023672|Dementia with Lewy Bodies
415705|NCT01023672|hypersomnolence
415706|NCT01023672|cognition
415707|NCT01023672|neuropsychiatric morbidity
415708|NCT01023672|quality of life
415709|NCT01023659|Smoking cessation
415710|NCT01023659|Bupropion
415711|NCT01023659|Varenicline
415712|NCT01023659|Population-level
415713|NCT01023659|Mass distribution
415714|NCT01023659|Drug Therapy
415715|NCT01023646|Glycemic Index
415716|NCT01023646|Glycemic Load
415717|NCT01023646|Glucose
415718|NCT01023646|Insulin
415719|NCT01023646|Lipoproteins
415720|NCT01023646|Free fatty acids
415721|NCT01023633|to investigate the efficacy and feasibility of this novel treatment strategy in Chinese mCRC patients
415722|NCT01023633|Primary Endpoint:DDC
415723|NCT01023633|Secondary Endpoint:OS, RR,DCR, PFS,safety
415724|NCT01023620|HIV
415725|NCT01023620|Lipodystrophy
415726|NCT01023620|Lipoatrophy
415727|NCT01023620|Lipohypertrophy
415728|NCT01023620|Human Immunodeficiency Virus
415729|NCT01023607|optical coherence tomography
415730|NCT01023607|intravascular ultrasound
415731|NCT01023607|Coronary artery disease
415732|NCT01023607|Hyperlipidemia
415733|NCT01023594|Pancreatic fistula
415734|NCT01023594|Pancreatic leakage
415735|NCT01023594|Pancreatoduodenectomy
415736|NCT01023594|Pancreatic stent
415737|NCT01023581|Type 2 Diabetes mellitus
415738|NCT01023581|Non-insulin dependent diabetes mellitus
415739|NCT01023581|Drug Therapy
415740|NCT01023581|Hypoglycemia,
415741|NCT01023581|Hyperglycemia
415742|NCT01023568|intubation
415743|NCT01023568|pediatric
415744|NCT01023568|videolaryngoscope devices
415745|NCT01023555|Bacteremia
415746|NCT01023555|Blood Cultures
415747|NCT01023555|Sepsis
415748|NCT01023542|renal impairment
415749|NCT01023542|MELD>25
415750|NCT01023542|Liver transplantation
415751|NCT01023542|CNI-free
415752|NCT01023542|Bottom-Up
415753|NCT01023542|Everolimus
415754|NCT01023529|Prostatic Neoplasms
415755|NCT01023529|Rectal Neoplasms
415756|NCT01023529|Palliative treatment
415757|NCT01023529|Radiotherapy
415758|NCT01023529|Quality of life
415759|NCT01023516|Chronic
415760|NCT01023516|obstructive
415761|NCT01023516|pulmonary
415762|NCT01023516|lung
415763|NCT01023516|respiratory disease
415764|NCT01023516|efficacy
415765|NCT01023516|placebo-controlled
415766|NCT01023516|COPD
415767|NCT01023516|FEV1
415768|NCT01023516|St Georges Respiratory Questionnaire
415769|NCT01023503|Statins
415770|NCT01023503|Dyslipidemia
415771|NCT01023503|Spain
415772|NCT01023503|Rosuvastatin
415773|NCT01023503|Naive
415774|NCT01023503|Switching
415775|NCT01023503|New statins prescriptions in Spain (naive patients and switching)
415776|NCT01023490|back pain
415777|NCT01023490|hypovitaminosis D
415778|NCT01023477|Carcinoma, Intraductal, Noninfiltrating
415779|NCT01023477|Ductal Carcinoma In Situ
415780|NCT01023477|DCIS
415781|NCT01023477|Carcinoma, Intraductal
415782|NCT01023477|Breast Cancer
415783|NCT01023477|Breast Tumors
415784|NCT01023477|chloroquine
415785|NCT01023477|autophagy
415786|NCT01023477|Autophagic Cell Death
415787|NCT01023477|Autophagocytosis
415788|NCT01023477|Programmed Cell Death, Type II
415789|NCT01023477|Autophagy, Cellular
415790|NCT01023477|Autophagic Programmed Cell Death
415791|NCT01023464|tear film break-up time
415792|NCT01023451|Pulmonary hypertension
415793|NCT01023451|Sickle cell disease
415794|NCT01023451|Pediatric patients
415795|NCT01023451|Brain Natriuretic Peptide levels
415796|NCT01023425|naive group
415797|NCT01023425|switching group
415798|NCT01023425|treatment response
415799|NCT01023425|Efficacy
415800|NCT01023425|Adverse event
415801|NCT01023412|Immunonutrition
415802|NCT01023412|cancer
415803|NCT01023412|GI cancer surgery
415804|NCT01023386|YM155
415805|NCT01023386|Mass-balance
415806|NCT01023386|Phase I
415807|NCT01023386|Pharmacokinetics
415808|NCT01023373|Angioplasty
415809|NCT01023373|Atherosclerotic reno vascular disease (ARVD)
415810|NCT01023373|Cardio- and cerebro- vascular comorbidity
415811|NCT01023373|End stage renal disease (ERSD)
415812|NCT01023373|kidney diseases
415813|NCT01023373|High blood pressure
415814|NCT01023373|Hypertension
415815|NCT01023373|Ischemic nephropathy
415816|NCT01023373|Percutaneous transluminal renal artery stenting (PTRS)
415817|NCT01023373|Randomized controlled trials
415818|NCT01023373|Renal artery stenosis (RAS)
415819|NCT01023373|Renal insufficiency
415820|NCT01023373|Vascular diseases
415821|NCT01023347|NSCLC
415822|NCT01023334|Topical analgesia
415823|NCT01023334|FlACC Pain Scale
415824|NCT01023334|intracameral lignocaine
415825|NCT01023334|Anesthetics
415826|NCT01023334|Physiological Effects of Drugs
415827|NCT01023334|Lidocaine
415828|NCT01023321|Safety
415829|NCT01023321|Tolerability
415830|NCT01023321|Pharmacokinetics
415831|NCT01023308|Myeloma
415832|NCT01023308|DACi
415833|NCT01023308|Bortezomib
415834|NCT01023308|Combination
415835|NCT01023308|Panobinostat
415836|NCT01023308|LBH589D
415837|NCT01023308|relapsed
415838|NCT01023308|Velcade®
415839|NCT01023295|Polypoidal Choroidal Vasculopathy
415840|NCT01023295|PCV
415841|NCT01023295|Polypoid
415842|NCT01023295|oxigene
415843|NCT01023295|VDA
415844|NCT01023295|vascular disrupting agent
415845|NCT01023295|combretastatin
415846|NCT01023295|fosbretabulin
415847|NCT01023282|Parkinson's disease
415848|NCT01023282|Levodopa
415849|NCT01023282|Dyskinesia
415850|NCT01023282|ACR325
415851|NCT01023269|Neurogenic overactive bladder
415852|NCT01023269|Urinary incontinence due to incomplete spinal cord injury
415853|NCT01023269|Neuromodulation
415854|NCT01023269|Neuromodulation for treatment of neurogenic overactive bladder
415855|NCT01023269|Patients with Urge urinary incontinence and detrusor overactivity
415856|NCT01023256|Rheumatoid arthritis
415857|NCT01023256|GM-CSF
415858|NCT01023256|MOR103
415859|NCT01023243|foot exam
415860|NCT01023243|health services
415861|NCT01023243|practice improvement
415862|NCT01023243|quality
415863|NCT01023243|preventive services
415864|NCT01023243|Natural Language Processing
415865|NCT01023230|DV-601
415866|NCT01023230|hepatitis B
415867|NCT01023230|entecavir
415868|NCT01023230|therapeutic vaccine
415869|NCT01023217|Chronic hepatitis B
415870|NCT01023217|lamivudine
415871|NCT01023217|adefovir
415872|NCT01023217|entecavir
415873|NCT01023191|Dialysis
415874|NCT01023191|Peritoneal
415875|NCT01023191|Catheter
415876|NCT01023191|Surgery
415877|NCT01023165|Diabetes Mellitus
415878|NCT01023165|Metabolic Integrity
415879|NCT01023165|Intravenous Bolus Insulin
415880|NCT01023139|Adolescent
415881|NCT01023139|Obesity
415882|NCT01023139|Pharmacotherapy
415883|NCT01023139|Sibutramine
415884|NCT01023126|Obesity
415885|NCT01023126|Exercise
415886|NCT01023126|Psychotherapy
415887|NCT01023113|Diabetic retinopathy
415888|NCT01023113|laser
415889|NCT01023113|field loss
415890|NCT01023113|macular edema
415891|NCT01023113|Visual field loss
415892|NCT01023100|taste study open label investigational drug oral therapy
415893|NCT01023074|MS
415894|NCT01023074|CAP
415895|NCT01023048|preimplantation diagnosis
415896|NCT01023022|CareLink
415897|NCT01023022|Remote Monitoring
415898|NCT01023022|Cardiac Pacemaker, Artificial
415899|NCT01023022|Implantable Cardioverter-Defibrillators
415900|NCT01022528|Elective total abdominal hysterectomy (with or without salpingo-oophorectomy or minor bladder repair) or myomectomy
415901|NCT01022528|through a lower transverse or low midline incision under general anesthesia
415902|NCT01022515|pheochromocytoma
415903|NCT01022515|paraganglioma
415904|NCT01022515|hypertension
415905|NCT01022502|psoriasis, indigo naturalis
415906|NCT01022489|Schizophrenia, auditory hallucinations, TMS
415907|NCT01022476|Pharmacokinetics
415908|NCT01022476|Raltegravir
415909|NCT01022476|Immunosuppressive Agents
415910|NCT01022476|Severe hepatic insufficiency
415911|NCT01022476|Liver Transplantation
415912|NCT01022476|Additional Keywords
415913|NCT01022476|HIV Infection
415914|NCT01022476|Hepatocarcinoma
415915|NCT01022476|Hepatitis C
415916|NCT01022476|Hepatitis B
415917|NCT01022450|rhabdomyolysis
415918|NCT01022450|myopathy
415919|NCT01022450|acute renal failure
415920|NCT01022450|neuroleptic malignant syndrome
415921|NCT01022450|Pharmaceutical Preparations
415922|NCT01022450|Hydroxymethylglutaryl-CoA Reductase Inhibitors
415923|NCT01022450|fibrates
415924|NCT01022450|creatine kinase
415925|NCT01022424|ADPKD
415926|NCT01022424|Tolvaptan
415927|NCT01022424|OPC-41061
415928|NCT01023009|Occlusion
415929|NCT01023009|vitrectomy
415930|NCT01023009|small gauge vitrectomy
415931|NCT01023009|Postoperative occlusion
415932|NCT01022996|Hodgkin's Lymphoma
415933|NCT01022996|Hodgkin Lymphoma
415934|NCT01022996|Hodgkin's Disease
415935|NCT01022996|Hodgkin Disease
415936|NCT01022996|Lymphoma
415937|NCT01022996|Lymphoproliferative Disorders
415938|NCT01022996|Neoplasms by Histological type
415939|NCT01022996|Lymphatic Diseases
415940|NCT01022996|Hemic and Lymphatic Diseases
415941|NCT01022996|Recurrent Lymphoma
415942|NCT01022996|Refractory Lymphoma
415943|NCT01022996|Relapsed Lymphoma
415944|NCT01022996|Classical Hodgkin Lymphoma
415945|NCT01022996|Classical Hodgkin's Disease
415946|NCT01022996|Nodular sclerosing Hodgkin Lymphoma
415947|NCT01022996|Mixed-cellularity Hodgkin Lymphoma
415948|NCT01022996|Lymphocyte-rich Hodgkin Lymphoma
415949|NCT01022996|Lymphocyte depleted Hodgkin Lymphoma
415950|NCT01022970|Esophagitis
415951|NCT01022970|Digestive System Diseases
415952|NCT01022970|Esophageal disorder
415953|NCT01022970|Eosinophilic esophagitis
415954|NCT01022957|extra renal damages
415955|NCT01022944|Serous otitis media
415956|NCT01022944|Biofilm
415957|NCT01022944|Adenoidectomy
415958|NCT01022944|Chronic otitis media
415959|NCT01022931|Influenza A H1N1
415960|NCT01022931|Children
415961|NCT01022931|Epidemiology
415962|NCT01022931|Treatment
415963|NCT01022931|Oseltamivir
415964|NCT01022931|Genetics
415965|NCT01022918|unresectable glioblastoma
415966|NCT01022905|HIV infection
415967|NCT01022905|transplant
415968|NCT01022905|rheumatic disease
415969|NCT01022905|cancer
415970|NCT01022905|children
415971|NCT01022892|Endovascular
415972|NCT01022892|Abdominal
415973|NCT01022892|Aortic
415974|NCT01022892|Aneurysm
415975|NCT01022892|Repair
415976|NCT01022892|Surveillance
415977|NCT01022892|EVAR
415978|NCT01022892|CT
415979|NCT01022892|Scan
415980|NCT01022892|Endoleaks
415981|NCT01022892|Contrast
415982|NCT01022892|Enhanced
415983|NCT01022892|Ultrasound
415984|NCT01022892|Definity
415985|NCT01022892|AAA
415986|NCT01022892|imaging
415987|NCT01022892|No Endoleaks
415988|NCT01022879|Pain scale of pain
415989|NCT01022866|falls
415990|NCT01022866|older adults
415991|NCT01022827|stiff shoulder
415992|NCT01022827|massage
415993|NCT01022827|muscle stiffness
415994|NCT01022775|Degenerative rotator cuff disease
415995|NCT01022775|Impingement syndrome
415996|NCT01022775|Dynamic humeral centering
415997|NCT01022775|Randomized clinical trial
415998|NCT01022749|inflammatory bowel disease (IBD)
415999|NCT01022749|immunosuppressed or non-immunosuppressed
416000|NCT01022749|influenza vaccine
416001|NCT01022749|antibody titers
416002|NCT01022749|seroprotective titers
416003|NCT01022749|vaccine-associated adverse events
416004|NCT01022736|gabapentin
416005|NCT01022736|pharmacokinetics
416006|NCT01022736|visual analogue pain scale
416007|NCT01022736|cardiopulmonary bypass
416008|NCT01022723|Circulating tumor cells
416009|NCT01022723|metastasis
416010|NCT01022723|cancer
416011|NCT01022723|cell isolation
416012|NCT01022723|mircofludics
416013|NCT01022723|cell detection
416014|NCT01022710|hearing loss
416015|NCT01022710|otoacoustic emissions
416016|NCT01022684|atherosclerosis
416017|NCT01022684|vascular inflammation
416018|NCT01022684|LpPLA2
416019|NCT01022684|hsCRP
416020|NCT01022684|MCP-1
416021|NCT01022684|18FDG-PET
416022|NCT01022671|Belotecan
416023|NCT01022671|Camtobell inj
416024|NCT01022671|NSCLC
416025|NCT01022658|Insulin Therapy
416026|NCT01022658|Vago-sympathetic activity
416027|NCT01022658|arterial stiffness
416028|NCT01022658|endothelial function
416029|NCT01022645|Intrauterine device
416030|NCT01022645|Gestational diabetes
416031|NCT01022645|Postpartum contraception
416032|NCT01022645|Postpartum birth control
416033|NCT01022632|Depression
416034|NCT01022619|Sleep apnea
416035|NCT01022619|high risk pregnancy
416036|NCT01022619|fetal outcome
416037|NCT01022619|cord blood
416038|NCT01022580|nitric oxide
416039|NCT01022580|surfactant
416040|NCT01022580|bronchopulmonary dysplasia
416041|NCT01022580|BPD
416042|NCT01022580|prematurity
416043|NCT01022580|neonates
416044|NCT01022580|iNO
416045|NCT01022580|pulmonary outcome
416046|NCT01022580|neurodevelopmental outcome
416047|NCT01022580|Infasurf
416048|NCT01022580|lung function
416049|NCT01022580|Surfactant Dysfunction
416050|NCT01022411|brown rice
416051|NCT01022411|white rice
416052|NCT01022411|diabetes risk
416053|NCT01022398|Vitamin D3
416054|NCT01022398|HMG-CoA reductase inhibitors (statin)-related myalgias
416055|NCT01022359|haemodialysis
416056|NCT01022359|vascular access
416057|NCT01022359|central venous catheter
416058|NCT01022346|Cervical intraepithelial neoplasia
416059|NCT01022346|RO5217790
416060|NCT01022333|BRCA1
416061|NCT01022333|breast cancer
416062|NCT01022333|3,3'-di-indolylmethane
416063|NCT01022333|dietary intervention
416064|NCT01022333|estrogen metabolites
416065|NCT01022333|mRNA expression
416066|NCT01022333|BRCA1 protein
416067|NCT01022333|Estrogen
416068|NCT01022320|OSA
416069|NCT01022320|Blood pressure
416070|NCT01022320|Lateral Pharyngoplasty
416071|NCT01022307|behavioral data acquisition
416072|NCT01022307|MRI
416073|NCT01022294|children
416074|NCT01022294|analgesia
416075|NCT01022294|dental treatment
416076|NCT01022294|inhalation
416077|NCT01022281|Exfoliation
416078|NCT01022281|Scanning Laser Polarimetry
416079|NCT01022281|Corneal Thickness
416080|NCT01022255|autologous vaccine
416081|NCT01022255|follicular lymphoma
416082|NCT01022255|magnICON
416083|NCT01022255|plant-made vaccines
416084|NCT01022255|immune response
416085|NCT01022242|Surgical Adhesions
416086|NCT01022242|Post-surgical adhesions
416087|NCT01022242|Flexor tendon
416088|NCT01022229|Attention Deficit Disorder
416089|NCT01022229|Pediatrics
416090|NCT01022229|Attention
416091|NCT01022229|Impulsivity
416092|NCT01022229|Complementary Therapies
416093|NCT01022216|Wound
416094|NCT01022216|Skin lesion
416095|NCT01022216|Antimicrobial
416096|NCT01022216|Bioelectric
416097|NCT01022216|Diabetic foot
416098|NCT01022216|Pressure Ulcer
416099|NCT01022203|Couples Therapy
416100|NCT01022203|PTSD
416101|NCT01022190|Arthroplasty
416102|NCT01022190|Hip
416103|NCT01022190|Cemented
416104|NCT01022190|Heterotopic ossification
416105|NCT01022190|Selective Cyclooxygenase-2 Inhibitors
416106|NCT01022190|Arthroplasty, Replacement
416107|NCT01022190|Hip Prosthesis
416108|NCT01022190|Cyclooxygenase Inhibitors
416109|NCT01022164|fibrin glue
416110|NCT01022164|vitrectomy
416111|NCT01022164|safety and efficacy of fibrin glue
416112|NCT01022151|Aminophylline
416113|NCT01022151|sevoflurane
416114|NCT01022151|anaesthesia
416115|NCT01022151|recovery
416116|NCT01022151|cognitive function
416117|NCT01022151|entropy
416118|NCT01022138|HER2-negative breast cancer
416119|NCT01022138|stage IV breast cancer
416120|NCT01022138|recurrent breast cancer
416121|NCT01022125|TMC435-TiDP16-C121
416122|NCT01022125|TMC435-C121
416123|NCT01022125|TMC435
416124|NCT01022125|TMC435350
416125|NCT01022125|Protease inhibitor
416126|NCT01022125|HCV
416127|NCT01022125|Hepatitis C
416128|NCT01022112|TA-7284
416129|NCT01022112|JNJ-28431754
416130|NCT01022112|Canagliflozin
416131|NCT01022112|Type 2 diabetes mellitus
416132|NCT01022112|Sodium Glucose Co-transporter (SGLT2 inhibitor)
416133|NCT01022099|Total Knee Arthroplasty
416134|NCT01022099|Navigation
416135|NCT01022086|Breast Cancer
416136|NCT01022086|Cardiotoxicity
416137|NCT01022086|Trastuzumab
416138|NCT01022086|Cardiac MRI
416139|NCT01022073|Deep Brain Stimulation
416140|NCT01022073|Subthalamic Nucleus
416141|NCT01022073|Globus Pallidus
416142|NCT01022073|Parkinson Disease
416143|NCT01022060|Dietary supplement
416144|NCT01022060|Renalof
416145|NCT01022060|Recurrent calcic urolithiasis
416146|NCT01022060|Renal calculi
416147|NCT01022034|Rectal prolapse
416148|NCT01022034|mesh
416149|NCT01022034|recurrence
416150|NCT01022021|non-Hodgkin's lymphoma
416151|NCT01022021|autologous stem cell transplant
416152|NCT01022008|Exorbitism
416153|NCT01022008|Upper respiratory airways
416154|NCT01022008|Osteodistraction
416155|NCT01022008|Polysomnography
416156|NCT01021995|Safety of Echinacea in comparison to placebo
416157|NCT01021982|Pupillometer
416158|NCT01021982|Retinitis Pigmentosa
416159|NCT01021982|Glaucoma
416160|NCT01021982|Objective perimetry
416161|NCT01021956|Macular Degeneration
416162|NCT01021956|Age Related Macular Degeneration
416163|NCT01021956|Choroidal Neovascularization
416164|NCT01021956|AMD
416165|NCT01021956|CNV
416166|NCT01021956|WST11
416167|NCT01021956|Stakel
416168|NCT01021956|Photodynamic therapy
416169|NCT01021956|Vascular Targeted Photodynamic therapy
416170|NCT01021956|VTP
416171|NCT01021943|calcineurin inhibitors
416172|NCT01021943|fibrosis
416173|NCT01021943|spironolactone
416174|NCT01021943|Focus of the study is to assess if aldosterone blockade has an effect on interstitial fibrosis amongst kidney transplant recipients
416175|NCT01021930|Optical coherence tomography
416176|NCT01021930|Drug eluting stent
416177|NCT01021930|Coronary heart disease
416178|NCT01021930|Diabetes mellitus
416179|NCT01021917|Obesity
416180|NCT01021917|Weight Loss
416181|NCT01021917|Meal Replacements
416182|NCT01021904|Primary prevention
416183|NCT01021904|HPV Vaccination
416184|NCT01021904|HPV Infection
416185|NCT01021904|Cervical Cancer
416186|NCT01021904|HPV Related Diseases
416187|NCT01021891|Technosphere® Insulin Inhalation Powder
416188|NCT01021878|Peritoneal dialysis
416189|NCT01021878|Renal replacement therapy
416190|NCT01021878|Dialysis solutions
416191|NCT01021878|Icodextrin
416192|NCT01021865|GLP-1
416193|NCT01021865|Myocardial contrast echocardiography
416194|NCT01021865|Myocardial perfusion
416195|NCT01021839|renal dialysis
416196|NCT01021839|bioprosthesis
416197|NCT01021839|arteriovenous shunt
416198|NCT01021839|surgical
416199|NCT01021826|knee replacement
416200|NCT01021826|hip replacement
416201|NCT01021826|hyperglycemia
416202|NCT01021826|diabetes
416203|NCT01021826|osteoarthritis
416204|NCT01021800|Pancreatic tubular adenocarcinoma adjuvant setting
416205|NCT01021787|Sun Protection
416206|NCT01021735|Rheumatoid
416207|NCT01021735|Outcome
416208|NCT01021735|Cost effectiveness
416209|NCT01021735|Safety
416210|NCT01021722|sphincter
416211|NCT01021722|obstetric tears
416212|NCT01021722|long-term follow-up
416213|NCT01021709|depression
416214|NCT01021709|direct current stimulation
416215|NCT01021709|extracephalic electrode
416216|NCT01021696|Dementia
416217|NCT01021696|Nursing home
416218|NCT01021696|Pain treatment
416219|NCT01021696|Pain assessment
416220|NCT01021696|Agitation
416221|NCT01021683|Hematological neoplasms
416222|NCT01021683|Neutropenia
416223|NCT01021683|Fever
416224|NCT01021683|Itraconazole
416225|NCT01021683|Sporanox
416226|NCT01021683|Antifungal prophylaxis
416227|NCT01021683|Defeverscence
416228|NCT01021670|Dapoxetine hydrochloride
416229|NCT01021670|Priligy
416230|NCT01021670|Premature ejaculation
416231|NCT01021670|Non-dapoxetine hydrochloride treatment(s)
416232|NCT01021657|Glaucoma
416233|NCT01021657|Tenon's Capsule
416234|NCT01021657|Lipid profile
416235|NCT01021657|Assessment of lipid profile in Tenon's capsule in patients with Glaucoma
416236|NCT01021644|APOE
416237|NCT01021644|Apolipoprotein E
416238|NCT01021644|Cognition Disorders
416239|NCT01021644|Neurocognition
416240|NCT01021631|Cardiac surgery
416241|NCT01021631|Strategies of transfusion
416242|NCT01021631|Red blood cells
416243|NCT01021631|Liberal
416244|NCT01021631|Restrictive
416245|NCT01021631|Anemia
416246|NCT01020539|Allogeneic Stem Cell Transplantation
416247|NCT01020539|Targeted Immune Therapy
416248|NCT01020539|Acute Myelogenous Leukemia
416249|NCT01020539|Myelodysplastic Syndrome
416250|NCT01020539|Juvenile Myelomonocytic Leukemia
416251|NCT01020539|AML
416252|NCT01020539|MDS
416253|NCT01020539|JMML
416254|NCT01020487|Reduction of parathyroid hormone levels in pediatric patients with Chronic Kidney Disease Stage 3 and 4
416255|NCT01020474|juvenile primary fibromyalgia syndrome
416256|NCT01020474|pediatric fibromyalgia
416257|NCT01020474|pregabalin
416258|NCT01020474|and Lyrica
416259|NCT01020448|Locally advanced or metastatic Prostate Cancer
416260|NCT01020435|Hypertension
416261|NCT01020422|breast hypertrophy
416262|NCT01020422|mammaplasty
416263|NCT01020422|sexuality
416264|NCT01020422|depression
416265|NCT01020409|cardiac surgery
416266|NCT01020409|cardiopulmonary bypass
416267|NCT01020409|acute lung injury
416268|NCT01020409|acute respiratory distress syndrome
416269|NCT01020409|acute kidney injury
416270|NCT01020409|atrial fibrillation
416271|NCT01020409|postoperative psychosis
416272|NCT01020409|myocardial infarct
416273|NCT01020409|sepsis
416274|NCT01020396|Bioequivalence
416275|NCT01020396|Metronidazole
416276|NCT01020396|Vaginosis
416277|NCT01021592|Velcade
416278|NCT01021592|QoL
416279|NCT01021592|Proteasome inhibitor
416280|NCT01021592|Bortezomib
416281|NCT01021592|EORTC QLQ C30
416282|NCT01021592|EQ 5D
416283|NCT01021579|Polycystic ovary syndrome
416284|NCT01021579|Metformin
416285|NCT01021579|Simvastatin
416286|NCT01021566|Opiate addiction
416287|NCT01021566|Withdrawal symptoms
416288|NCT01021566|hemoperfusion
416289|NCT01021566|hemodialysis
416290|NCT01021566|methadone
416291|NCT01021553|Proof of Concept
416292|NCT01021553|Double Blind
416293|NCT01021540|Nephritis,Nephropathy
416294|NCT01021514|sRAGE
416295|NCT01021514|SUV
416296|NCT01021514|TBR
416297|NCT01021514|FDG PET CT
416298|NCT01021514|Type 2 DM
416299|NCT01021501|nifedipine controlled release tablets
416300|NCT01021501|hypertensive
416301|NCT01021501|chronic maintenance hemodialysis
416302|NCT01021501|Pharmacokinetics
416303|NCT01021488|Thrombosis
416304|NCT01021488|Vein
416305|NCT01021488|Statin
416306|NCT01021488|Prevention
416307|NCT01021475|Functional Dyspepsia, Visceral Manipulation
416308|NCT01021449|schizophrenia, BDNF, DNA methylation, histone modification
416309|NCT01021436|Pneumonia
416310|NCT01021436|Gram-negative bacteria
416311|NCT01021423|Mantle Cell Lymphoma
416312|NCT01021423|Non-Hodgkin's Lymphoma
416313|NCT01021423|CC-5013
416314|NCT01021423|Revlimid
416315|NCT01021423|Lenalidomide
416316|NCT01021410|acetaminophen
416317|NCT01021410|paracetamol
416318|NCT01021410|protein adduct
416319|NCT01021410|healthy volunteer
416320|NCT01021410|acetaminophen-protein adduct formation
416321|NCT01021397|Respiratory Tract Infection
416322|NCT01021384|Depression,
416323|NCT01021384|Early Intervention,
416324|NCT01021384|Behavior Disorder,
416325|NCT01021384|Parenting Skills,
416326|NCT01021384|Children with Special Health Care Needs,
416327|NCT01021384|Developmental Disabilities,
416328|NCT01021384|Family Support Programs
416329|NCT01021371|HRQOL
416330|NCT01021371|Rehabilitation
416331|NCT01021371|Cancer Patients
416332|NCT01021371|General Practice
416333|NCT01021332|Lower Urinary Tract Symptoms
416334|NCT01021332|Treatment
416335|NCT01021332|Solifenacin succinate
416336|NCT01021332|Tamsulosin hydrochloride OCAS
416337|NCT01021332|Benign Prostatic Hyperplasia
416338|NCT01021332|EC905
416339|NCT01021332|Vesomni
416340|NCT01021319|ischemic stroke
416341|NCT01021319|thrombolysis
416342|NCT01021319|magnetic resonance imaging
416343|NCT01021319|diffusion weighted imaging
416344|NCT01021319|fluid attenuated inversion recovery
416345|NCT01021319|time window
416346|NCT01021293|Poliorix
416347|NCT01021293|IPV
416348|NCT01021280|Bartter syndrome,
416349|NCT01021280|parathyroid hormone,
416350|NCT01021280|calcium sensing receptor,
416351|NCT01021280|ROMK channel
416352|NCT01021280|Barttin gene
416353|NCT01021280|PTH response to hypo- and hypercalcemia
416354|NCT01021267|sexual dysfunctions
416355|NCT01021267|benign prostatic hyperplasia
416356|NCT01021267|saw palmetto
416357|NCT01021228|Liver resection
416358|NCT01021228|Continuous volatile anesthesia
416359|NCT01021228|Continuous intravenous anesthesia
416360|NCT01021228|Preconditioning volatile anesthesia
416361|NCT01021228|Comparing three groups of anesthesia during the liver surgery according to their benefit on liver and outcome.
416362|NCT01021215|Cancer Prevention
416363|NCT01021215|Smoking-related lung disease
416364|NCT01021215|Smoking
416365|NCT01021215|Celecoxib
416366|NCT01021215|Celebrex
416367|NCT01021215|Zileuton
416368|NCT01021215|Zyflo CR
416369|NCT01021215|Prevention
416370|NCT01021202|tracheostomy
416371|NCT01021202|tracheotomy
416372|NCT01021202|dilational
416373|NCT01021202|dilatative
416374|NCT01021202|critical care
416375|NCT01021202|intensive care
416376|NCT01021202|COPD
416377|NCT01021202|chronic obstructive pulmonary disease
416378|NCT01021202|lung disease
416379|NCT01021202|pneumonia
416380|NCT01021202|prospective study
416381|NCT01021202|questionnaire
416382|NCT01021202|quality of life
416383|NCT01021202|outcome
416384|NCT01021202|mortality
416385|NCT01021189|safety
416386|NCT01021189|tolerability
416387|NCT01021189|AZD1446
416388|NCT01021189|AD
416389|NCT01021189|Japanese
416390|NCT01021176|Food Intake
416391|NCT01021176|Hunger
416392|NCT01021176|Lidocaine
416393|NCT01021176|Nose
416394|NCT01021176|smell
416395|NCT01021137|vestibular function tests
416396|NCT01021137|postural balance
416397|NCT01021137|neuroimaging
416398|NCT01021124|tuberculosis
416399|NCT01021124|bone marrow transplant
416400|NCT01021124|diagnosis
416401|NCT01021098|influenza
416402|NCT01021098|illness
416403|NCT01021098|active-duty
416404|NCT01021098|virus
416405|NCT01021098|flu
416406|NCT01021098|military
416407|NCT01021098|Influenza-like-illnesses
416408|NCT01021085|Assisted Reproductive Technology
416409|NCT01021085|circulating cell free fetal DNA
416410|NCT01021085|First trimester
416411|NCT01021059|Biological Effects of rhIL-15
416412|NCT01021059|Estimate Antitumor Activity
416413|NCT01021059|rhIL-15 Pharmacokinetics
416414|NCT01021059|Dose and Safety Determination of IL-15
416415|NCT01021059|Kidney Cancer
416416|NCT01021059|Melanoma
416417|NCT01021059|Renal Cell Cancer
416418|NCT01021046|deep anterior lamellar keratoplasty
416419|NCT01021046|rejection
416420|NCT01021046|high risk patients
416421|NCT01021046|acellular corneal tissue
416422|NCT01021033|Ischemia
416423|NCT01021033|Hemorrhage
416424|NCT01021033|Rehabilitation
416425|NCT01021033|Stroke
416426|NCT01021020|bioequivalence
416427|NCT01021020|fasting
416428|NCT01021020|fed
416429|NCT01021020|healthy
416430|NCT01020994|Superficial infected eczema
416431|NCT01020994|Superinfected eczema
416432|NCT01020981|OEF/OIF
416433|NCT01020981|Peer Group
416434|NCT01020981|Veterans
416435|NCT01020968|Ischemic Dilated Cardiomyopathy
416436|NCT01020968|Non-Ischemic Dilated Cardiomyopathy
416437|NCT01020968|ixmyelocel-T
416438|NCT01020955|GH and IGF-I
416439|NCT01020955|growth hormone deficiency and IGT or diabetes
416440|NCT01020942|ischemia
416441|NCT01020942|myocardial infarction
416442|NCT01020942|prognosis
416443|NCT01020942|pretreatment
416444|NCT01020942|electroacupuncture
416445|NCT01020942|stents
416446|NCT01020942|troponin
416447|NCT01020942|percutaneous coronary intervention
416448|NCT01020916|Induced hypothermia
416449|NCT01020916|Mild induced hypothermia
416450|NCT01020916|Therapeutic hypothermia
416451|NCT01020916|Cardiac arrest
416452|NCT01020916|Out-of-hospital cardiac arrest
416453|NCT01020916|Mortality
416454|NCT01020916|Neurological function
416455|NCT01020916|Randomised clinical trial
416456|NCT01020890|GERD diagnosis
416457|NCT01020890|GERD-Q
416458|NCT01020890|GERD patients' characteristics
416459|NCT01020890|GERD
416460|NCT01020877|Bioequivalence
416461|NCT01020877|Healthy Subjects
416462|NCT01020877|Healthy, Normal Subjects
416463|NCT01020864|Platinum-resistent head and neck cancer
416464|NCT01020864|Cetuximab
416465|NCT01020864|Carboplatin
416466|NCT01020864|Navelbine
416467|NCT01020864|Phase II trial
416468|NCT01020864|Combination chemotherapy
416469|NCT01020851|hypertension
416470|NCT01020851|stroke
416471|NCT01020851|cholesterol
416472|NCT01020851|adherence
416473|NCT01020838|Florbetaben
416474|NCT01020838|Amyloid beta-protein
416475|NCT01020838|Alzheimer's disease
416476|NCT01020825|Complex perianal fistula
416477|NCT01020825|Adipose-derived adult stem cells
416478|NCT01020825|Fibrin glue
416479|NCT01020799|Depression
416480|NCT01020786|Non-squamous
416481|NCT01020773|extubation,Respiration, Artificial
416482|NCT01020760|Macular hole
416483|NCT01020760|Vitrectomy
416484|NCT01020760|Prone posturing
416485|NCT01020734|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
416486|NCT01020734|adult acute myeloid leukemia with del(5q)
416487|NCT01020734|adult acute myeloid leukemia with t(16;16)(p13;q22)
416488|NCT01020734|recurrent adult acute myeloid leukemia
416489|NCT01020734|adult acute myeloid leukemia in remission
416490|NCT01020734|childhood acute myeloid leukemia in remission
416491|NCT01020734|recurrent childhood acute myeloid leukemia
416492|NCT01020734|adult acute minimally differentiated myeloid leukemia (M0)
416493|NCT01020734|childhood acute minimally differentiated myeloid leukemia (M0)
416494|NCT01020734|adult acute myeloblastic leukemia without maturation (M1)
416495|NCT01020734|childhood acute myeloblastic leukemia without maturation (M1)
416496|NCT01020734|adult acute myeloblastic leukemia with maturation (M2)
416497|NCT01020734|childhood acute myeloblastic leukemia with maturation (M2)
416498|NCT01020734|adult acute myelomonocytic leukemia (M4)
416499|NCT01020734|childhood acute myelomonocytic leukemia (M4)
416500|NCT01020734|adult acute monoblastic leukemia (M5a)
416501|NCT01020734|adult acute monocytic leukemia (M5b)
416502|NCT01020734|childhood acute monoblastic leukemia (M5a)
416503|NCT01020734|childhood acute monocytic leukemia (M5b)
416504|NCT01020734|adult erythroleukemia (M6a)
416505|NCT01020734|adult pure erythroid leukemia (M6b)
416506|NCT01020734|childhood acute erythroleukemia (M6)
416507|NCT01020734|adult acute megakaryoblastic leukemia (M7)
416508|NCT01020734|childhood acute megakaryocytic leukemia (M7)
416509|NCT01020721|CYP1B1 gene
416510|NCT01020708|colitis
416511|NCT01020708|inflammatory bowel disease
416512|NCT01020708|ulcerative colitis
416513|NCT01020708|rectal administration
416514|NCT01020708|enema
416515|NCT01020708|mesalamine
416516|NCT01020695|PTSD
416517|NCT01020695|EEG
416518|NCT01020695|QEEG
416519|NCT01020695|LORETA
416520|NCT01020682|apathy
416521|NCT01020682|parkinson
416522|NCT01020682|agonist dopaminergic
416523|NCT01020669|fMRI
416524|NCT01020669|Prenatal Drug Exposure
416525|NCT01020669|Decision Making
416526|NCT01020669|Working Memory
416527|NCT01020669|Vulnerability
416528|NCT01020656|anticoagulant agents
416529|NCT01020656|antiplatelet agents
416530|NCT01020656|vitreoretinal surgery
416531|NCT01020656|Patients suffered from retinal detachment
416532|NCT01020630|adenocarcinoma of stomach
416533|NCT01020630|adenocarcinoma of lower oesophagus
416534|NCT01020630|sunitinib
416535|NCT01020630|FOLFIRI
416536|NCT01020604|BMI
416537|NCT01020604|Prostate cancer
416538|NCT01020604|Recurrence
416539|NCT01020591|knee osteoarthritis
416540|NCT01020591|manual therapy
416541|NCT01020591|osteopathy
416542|NCT01020552|APHIA II
416543|NCT01020552|AIDS, Population, and Health Integrated Assistance project
416544|NCT01020552|DCF
416545|NCT01020552|data collection forms
416546|NCT01020552|FDA
416547|NCT01020552|Federal Drug Administration
416548|NCT01020552|FP
416549|NCT01020552|family planning
416550|NCT01020552|IRB
416551|NCT01020552|Institutional Review Board
416552|NCT01020552|PAC
416553|NCT01020552|postabortion care
416554|NCT01020552|To document the ESD PAC svc pkg including the provision of services, client satisfaction with those services and provider attitudes towards PAC services
416555|NCT01020552|To examine any differences in implementation of the ESD PAC services package for youth and adult clients
416556|NCT01020552|To assess the usefulness of five Youth-Friendly PAC Job Aids developed by ESD
416557|NCT01020370|Patients with RRMS who are participating in the CARE MS I and CARE MS II
416558|NCT01020357|preterm infants
416559|NCT01020357|very low birthweight
416560|NCT01020357|apnea of prematurity
416561|NCT01020357|methylxanthines
416562|NCT01020357|sleep disturbance
416563|NCT01020357|obstructive sleep apnea syndrome
416564|NCT01020357|polysomnography
416565|NCT01020357|sleep disruption
416566|NCT01020331|ALS
416567|NCT01020318|Traumatic Brain Injury
416568|NCT01020318|TBI
416569|NCT01020318|Brain Injuries
416570|NCT01020292|Adult subjects with a diagnosis of Grade IV Glioma
416571|NCT01020279|muscle pain
416572|NCT01020279|model
416573|NCT01020266|brain protection
416574|NCT01020266|cardiac surgery
416575|NCT01020266|heart valve replacement
416576|NCT01020266|electroacupuncture
416577|NCT01020266|pretreatment
416578|NCT01020266|preconditioning
416579|NCT01020266|Thoracic Surgery
416580|NCT01020253|bisphosphonate, vitamin D3
416581|NCT01020253|Total Hip arthroplasty
416582|NCT01020240|Immediate puerperium
416583|NCT01020240|physiotherapy in postpartum
416584|NCT01020240|cesarean complications
416585|NCT01020227|Postoperative Care
416586|NCT01020227|Quality of Life
416587|NCT01020227|Integrative Medicine
416588|NCT01020227|Coronary Artery Bypass Graft Surgery
416589|NCT01020201|Anesthesia, General
416590|NCT01020201|Elective Gynecological Operation
416591|NCT01020201|Chinese female patient
416592|NCT01020201|Adult
416593|NCT01020175|allogeneic transplantation
416594|NCT01020175|Leukemia
416595|NCT01020175|GvHD
416596|NCT01020175|MDS
416597|NCT01020162|Chronic pelvic pain
416598|NCT01020162|ilioinguinal nerve entrapment
416599|NCT01020162|randomized study
416600|NCT01020162|Chronic pelvic pain in women
416601|NCT01020149|Nerve transsection
416602|NCT01020136|Bioequivalence Pharmacokinetics
416603|NCT01020123|Type II Diabetes Mellitus
416604|NCT01020123|metformin
416605|NCT01020123|glipizide
416606|NCT01020110|perfusion chamber
416607|NCT01020110|thrombus D-Dimer
416608|NCT01020110|HUVEC
416609|NCT01020097|Stage 1 squamous cell carcinoma of the larynx
416610|NCT01020084|Saliva
416611|NCT01020084|Mastication
416612|NCT01020084|Communication
416613|NCT01020071|iridotomy
416614|NCT01020071|iridoplasty
416615|NCT01020071|angle closure glaucoma
416616|NCT01020045|HIV
416617|NCT01020045|Osteopenia
416618|NCT01020045|Osteoporosis
416619|NCT01020032|Music therapy
416620|NCT01020032|Pain
416621|NCT01020032|Anxiety
416622|NCT01020032|Depression
416623|NCT01020032|Controlled randomized trial
416624|NCT01020019|Cannabis Dependence
416625|NCT01020019|Marijuana Dependence
416626|NCT01020019|Marinol
416627|NCT01020019|Lofexidine
416628|NCT01020006|PCI-27483
416629|NCT01020006|Factor VIIa
416630|NCT01020006|Gemcitabine
416631|NCT01020006|4 months life expectancy
416632|NCT01020006|Pharmacyclics
416633|NCT01020006|Locally Advanced
416634|NCT01020006|Metastatic disease
416635|NCT01019993|Thoracotomy
416636|NCT01019993|one lung ventilation
416637|NCT01019993|HFPPV
416638|NCT01019993|right ventricular function.
416639|NCT01019980|Antipyretics
416640|NCT01019980|fever
416641|NCT01019980|diclofenac
416642|NCT01019980|acetaminophen
416643|NCT01019980|children
416644|NCT01019980|acute upper respiratory tract infections
416645|NCT01019967|Children and Adolescents
416646|NCT01019967|Obsessive-Compulsive Disorder
416647|NCT01019967|Magnetic Resonance Spectroscopy
416648|NCT01019967|Autism
416649|NCT01019967|OCD
416650|NCT01019967|Obsessive Compulsive Disorder
416651|NCT01019954|Adults with premalignant head and neck tumors and adults who have Carcinoma in situ of the head and neck in whom standard therapy is not indicated
416652|NCT01019941|Docetaxel
416653|NCT01019941|CKD-810
416654|NCT01019941|Taxotere inj.
416655|NCT01019941|Advanced Solid cancer
416656|NCT01019941|Pharmacokinetic evaluation
416657|NCT01019928|GERD
416658|NCT01019928|patient
416659|NCT01019928|esophagus
416660|NCT01019928|pain
416661|NCT01019915|CRT
416662|NCT01019915|heart failure
416663|NCT01019915|left bundle branch block
416664|NCT01019915|skeletal muscle
416665|NCT01019915|cytokines
416666|NCT01019915|VO2
416667|NCT01019915|pgc1alpha
416668|NCT01019902|iron
416669|NCT01019902|pregnancy
416670|NCT01019902|adolescents
416671|NCT01019902|auditory brainstem responses
416672|NCT01019902|anemia
416673|NCT01019902|neonate
416674|NCT01019889|upper respiratory tract infections
416675|NCT01019889|herbal medicine
416676|NCT01019876|Bone marrow Failure
416677|NCT01019876|Fanconi
416678|NCT01019876|SCID
416679|NCT01019850|disseminated neuroblastoma
416680|NCT01019850|localized unresectable neuroblastoma
416681|NCT01019850|recurrent neuroblastoma
416682|NCT01019850|regional neuroblastoma
416683|NCT01019837|Vaccine
416684|NCT01019824|nerve compression
416685|NCT01019824|compression radiculopathy
416686|NCT01019824|post-traumatic/post-surgical lumbar radiculopathy
416687|NCT01019811|Cross-finger flap
416688|NCT01019811|finger injuries
416689|NCT01019811|fingertip reconstruction
416690|NCT01019811|proper digital artery
416691|NCT01019811|proper digital nerve.
416692|NCT01019798|non small cell lung cancer
416693|NCT01019798|sunitinib
416694|NCT01019798|docetaxel
416695|NCT01019785|Pregnancy rate (pos test, live fetus at 12 weeks, baby home)
416696|NCT01019785|Pregnancy complication (Pregnancy hypertension, SGA, diab)
416697|NCT01019785|Thrombin generation
416698|NCT01019759|Atrial fibrillation
416699|NCT01019759|cardiac surgery
416700|NCT01019759|ablation
416701|NCT01019759|pulmonary veins
416702|NCT01019746|Hypnosis with propofol
416703|NCT01019733|Hypoxia
416704|NCT01019733|Ischemia
416705|NCT01019733|Brain
416706|NCT01019733|Children
416707|NCT01019733|Cerebral Palsy
416708|NCT01019707|crystal meth
416709|NCT01019707|methamphetamine
416710|NCT01019707|substance abuse
416711|NCT01019681|Cord blood injection in peripheral vascular disease
416712|NCT01019668|chorioretinopathy
416713|NCT01019668|photodynamic therapy
416714|NCT01019668|reduced fluence
416715|NCT01019668|reduced dose
416716|NCT01019655|thrombophilia
416717|NCT01019655|pregnancy
416718|NCT01019655|heparin
416719|NCT01019642|vitamin D
416720|NCT01019642|diabetes
416721|NCT01019642|C-reactive protein
416722|NCT01019642|insulin resistance
416723|NCT01019629|Fabry, Fabry Disease, Alpha-galactosidase A deficiency, GLA gene, mutations
416724|NCT01019603|Acne
416725|NCT01019551|Controlled viremia
416726|NCT01019551|Viral reservoirs
416727|NCT01019551|Virus eradication
416728|NCT01019551|Therapeutic intensification
416729|NCT01019551|Immunointervention
416730|NCT01019538|Oxygen
416731|NCT01019538|Hypoxemia
416732|NCT01019538|Air travel
416733|NCT01019525|respiration
416734|NCT01019525|respiratory disorders
416735|NCT01019525|Otolaryngology
416736|NCT01019525|Otorhinolaryngology
416737|NCT01019525|Posture
416738|NCT01019499|human
416739|NCT01019499|intervention
416740|NCT01019499|blood pressure
416741|NCT01019499|cardiovascular risk factors
416742|NCT01019499|polyphenols
416743|NCT01019499|bioavailability
416744|NCT01019486|Myocardial blood flow
416745|NCT01019486|Cardiac magnetic resonance imaging
416746|NCT01019486|Myocardial perfusion imaging
416747|NCT01019486|Coronary artery flow reserve
416748|NCT01019486|Regadenoson
416749|NCT01019473|Huntington's disease
416750|NCT01019473|Chorea
416751|NCT01019473|Dyskinesia
416752|NCT01019460|Small intestine
416753|NCT01019460|Magnetic resonance imaging
416754|NCT01019460|Computed tomography scanning
416755|NCT01019460|Capsule endoscopy
416756|NCT01019447|Surgical site infection
416757|NCT01019447|Antimicrobial triclosan-coated polyglactin 910 suture
416758|NCT01019447|Length of hospital stay
416759|NCT01019447|SSI
416760|NCT01019434|adult glioblastoma
416761|NCT01019421|Cognition
416762|NCT01019408|Clinical Trial
416763|NCT01019408|Chloroquine
416764|NCT01019408|Refugees
416765|NCT01019408|Afghanistan
416766|NCT01019408|Pakistan
416767|NCT01019395|Gram Positive Infection
416768|NCT01019395|Concurrent Antibiotic Treatment
416769|NCT01019382|pancreatic
416770|NCT01019382|carcinoma
416771|NCT01019382|cancer
416772|NCT01019382|fish
416773|NCT01019382|alternative
416774|NCT01019369|Contraception
416775|NCT01019369|Medroxyprogesterone 17-acetate
416776|NCT01019369|Self administration
416777|NCT01019356|PCOS
416778|NCT01019343|Magnetic Resonance Imaging (MRI)
416779|NCT01019343|Magnetoencephalogram
416780|NCT01019343|Electroencephalogram (EEG)
416781|NCT01019343|Transcranial Magnetic Stimulation (TMS)
416782|NCT01019343|Motor Deficit
416783|NCT01019343|Dystonia
416784|NCT01019343|Movement Disorder
416785|NCT01019343|Parkinson Disease
416786|NCT01019343|PD
416787|NCT01019343|Tourette Syndrome
416788|NCT01019343|TS
416789|NCT01019343|Tic Disorder
416790|NCT01019330|radial vs femoral
416791|NCT01019330|radial artery cardiac catheterization
416792|NCT01019317|Acute Myelogenous Leukemia
416793|NCT01019317|High-Risk Myelodysplastic Syndrome
416794|NCT01019317|Chronic myeloid leukemia
416795|NCT01019317|CML
416796|NCT01019317|Blast crisis
416797|NCT01019317|Cytarabine
416798|NCT01019317|Ara-C
416799|NCT01019317|Cytosar
416800|NCT01019317|DepoCyt
416801|NCT01019317|Cytosine arabinosine hydrochloride
416802|NCT01019317|Arabinosine Hydrochloride
416803|NCT01019317|Fludarabine
416804|NCT01019317|Fludarabine Phosphate
416805|NCT01019317|Fludara
416806|NCT01019317|Gemtuzumab Ozogamicin
416807|NCT01019317|Mylotarg
416808|NCT01019291|Indoor pollutants
416809|NCT01019265|Norspan patch
416810|NCT01019265|Buprenorphine transdermal patch (BTDS)
416811|NCT01019265|efficacy
416812|NCT01019265|buprenorphine
416813|NCT01019252|Adolescent
416814|NCT01019252|ADHD
416815|NCT01019239|Non-faeculant
416816|NCT01019239|Perforated
416817|NCT01019239|Diverticulitis
416818|NCT01019226|myocardium
416819|NCT01019226|Magnetic resonance imaging
416820|NCT01019213|His-pacing
416821|NCT01019200|psoriasis
416822|NCT01019200|heart disease
416823|NCT01019200|cardiovascular disease
416824|NCT01019200|hyperlipidemia
416825|NCT01019161|Acute Myeloid Leukaemia (AML)
416826|NCT01019161|AML
416827|NCT01019161|AZD1152
416828|NCT01019161|Pharmacokinetics
416829|NCT01019135|Women
416830|NCT01019135|Cardiac Care Facilities
416831|NCT01019135|Patient satisfaction
416832|NCT01019135|Patient participation
416833|NCT01019135|Patient compliance
416834|NCT01019135|Randomized Control Trial
416835|NCT01019135|Coronary artery bypass
416836|NCT01019135|Angioplasty, transluminal, percutaneous coronary
416837|NCT01019122|cerebral palsy
416838|NCT01019122|DEXA scan
416839|NCT01019122|bone density
416840|NCT01019109|scoliosis
416841|NCT01019096|iron
416842|NCT01019096|pregnancy
416843|NCT01019096|heme iron
416844|NCT01019096|non-heme iron
416845|NCT01019096|stable isotopes
416846|NCT01019096|women/adolescents
416847|NCT01019083|Cholera
416848|NCT01019083|Typhoid
416849|NCT01019083|Oral Vaccine
416850|NCT01019083|Immune response
416851|NCT01019083|Vaccine Evaluation
416852|NCT01019083|Nutrition
416853|NCT01019083|Child Health
416854|NCT01019057|DDD
416855|NCT01019057|decompression
416856|NCT01019057|spinous process plate
416857|NCT01019044|HIV
416858|NCT01019044|Viral reservoirs
416859|NCT01019044|Viral load
416860|NCT01019018|subtenon block
416861|NCT01019005|post-operative analgesia
416862|NCT01019005|opioid
416863|NCT01019005|catheter
416864|NCT01019005|tibial nerve block
416865|NCT01018992|PTSD
416866|NCT01018992|Anxiety Disorder
416867|NCT01018992|Corticotropin releasing factor
416868|NCT01018992|Women
416869|NCT01018927|Cardiac MR (CMR)
416870|NCT01018927|Early Myocardial Infiltration
416871|NCT01018927|Amyloid
416872|NCT01018927|Light Chain Deposition Disease
416873|NCT01018927|Multiple Myeloma
416874|NCT01018914|Prograf
416875|NCT01018914|Advagraf
416876|NCT01018914|Myfortic
416877|NCT01018888|Cornea
416878|NCT01018888|Transplantation, Cornea
416879|NCT01018888|Keratoplasty
416880|NCT01018888|Grafting, Corneal
416881|NCT01018849|Vitamin D
416882|NCT01018849|Cardiac Catheterization
416883|NCT01018849|Cardiovascular event
416884|NCT01018849|Cardiovascular Disease
416885|NCT01018836|tumors metastatic to brain
416886|NCT01018836|unspecified adult solid tumor, protocol specific
416887|NCT01018810|Psoriasis
416888|NCT01018797|INTRASTROMAL CORNEAL RING
416889|NCT01018797|ASTIGMATISM
416890|NCT01018797|POSTKERATOPLASTY
416891|NCT01018797|EYES
416892|NCT01018797|To evaluate the clinical outcomes of ICRS implantation to correct high-degree astigmatism on eyes with prior penetrating keratoplasty (PK)
416893|NCT01018784|Cancer
416894|NCT01018784|Mesothelin-positive
416895|NCT01018771|actifuse
416896|NCT01018771|INFUSE
416897|NCT01018771|InductOs
416898|NCT01018771|DDD
416899|NCT01018771|Degenerative disc disease
416900|NCT01018771|PLF
416901|NCT01018771|posterolateral lumbar fusion
416902|NCT01018771|bone substitute
416903|NCT01018771|bone graft
416904|NCT01018771|synthetic bone substitute
416905|NCT01018771|spinal surgery
416906|NCT01018758|Non-Hodgkin's lymphoma
416907|NCT01018758|Quality of life
416908|NCT01018758|Chemotherapy toxicity
416909|NCT01018758|aggressive Non Hodgkin's Lymphomas treated with moderately emetogenic chemotherapy
416910|NCT01018732|Meningococcal
416911|NCT01018732|ACWY
416912|NCT01018732|Conjugate Vaccine
416913|NCT01018732|Meningitis
416914|NCT01018732|Adolescents
416915|NCT01018732|Persistence
416916|NCT01018719|breast cancer radiotherapy cardiotoxicity multidetector CT
416917|NCT01018719|Radiotherapy
416918|NCT01018706|Primary pci
416919|NCT01018706|Stent
416920|NCT01018706|Medical Hystory
416921|NCT01018706|Antiplatelet therapy
416922|NCT01018706|Compliance
416923|NCT01018693|Seasonal allergic rhinitis,
416924|NCT01018693|late phase response,
416925|NCT01018693|alutard avanz,
416926|NCT01018693|immunotherapy,
416927|NCT01018693|visual analogue scale,
416928|NCT01018693|mini rhinitis quality of life,
416929|NCT01018693|immune modulation
416930|NCT01018667|Heart Failure
416931|NCT01018667|clinical trial
416932|NCT01018667|biventricular pacing
416933|NCT01018667|cardiac device
416934|NCT01018654|Substance Abuse
416935|NCT01018654|Substance Addiction
416936|NCT01018641|Staphylococcus aureus
416937|NCT01018641|Vaccine
416938|NCT01018615|chronic hepatitis C
416939|NCT01018615|silymarin
416940|NCT01018615|green tea catechins
416941|NCT01018615|green tea extract
416942|NCT01018615|pharmacokinetics
416943|NCT01018615|antioxidant activity
416944|NCT01018589|Post surgical scars
416945|NCT01018589|Epidermic burn
416946|NCT01018589|Cicatrix cream
416947|NCT01018576|delayed cord clamping
416948|NCT01018576|premature infants
416949|NCT01018576|hypothermia
416950|NCT01018576|anemia
416951|NCT01018576|intraventricular hemorrhage
416952|NCT01018576|Anemia in premature infants
416953|NCT01018563|Extension study
416954|NCT01018563|Epithelial ovarian cancer
416955|NCT01018537|Multiple Sclerosis
416956|NCT01018537|NARCOMS
416957|NCT01018537|Global Patient Registry
416958|NCT01018524|position of the mesh
416959|NCT01018524|recurrence rate
416960|NCT01018524|surgical procedure
416961|NCT01018524|long time outcome
416962|NCT01018511|Lower Urinary Tract Symptoms
416963|NCT01018511|Treatment
416964|NCT01018511|Solifenacin succinate
416965|NCT01018511|Tamsulosin hydrochloride OCAS
416966|NCT01018511|Benign Prostatic Hyperplasia
416967|NCT01018511|EC905
416968|NCT01018511|Vesomni
416969|NCT01018498|Irritable Bowel Syndrome
416970|NCT01018498|Children
416971|NCT01018472|cyanotic heart disease
416972|NCT01018472|congenital heart disease
416973|NCT01018472|intestinal microbiota
416974|NCT01018472|probiotics
416975|NCT01018459|malaria, vaccine, Burkina Faso
416976|NCT01018446|Hematopoietic stem cell transplantation with busulfan based conditioning
416977|NCT01018433|self-injury
416978|NCT01018433|non-suicidal self-injury
416979|NCT01018433|deliberate self-harm
416980|NCT01018433|self-mutilation
416981|NCT01018420|healthy
416982|NCT01018394|tobacco dependence
416983|NCT01018394|tobacco reduction
416984|NCT01018394|chewing tobacco
416985|NCT01018394|snuff
416986|NCT01018394|moist snuff
416987|NCT01018381|HCC
416988|NCT01018381|HBV
416989|NCT01018381|MGN-3
416990|NCT01018381|BioBran
416991|NCT01018381|Alternative Therapy
416992|NCT01018355|Patent foramen ovale
416993|NCT01018355|PFO
416994|NCT01018355|Stroke
416995|NCT01018355|TIA
416996|NCT01018355|Percutaneus closure
416997|NCT01018355|Intervention
416998|NCT01018329|Adult Brain Tumor
416999|NCT01018316|preoxygenation
417000|NCT01018316|UMOX
417001|NCT01018303|cystic fibrosis
417002|NCT01018303|vitamins
417003|NCT01018303|antioxidants
417004|NCT01018303|anthropometric measurements
417005|NCT01018303|pulmonary function
417006|NCT01018264|Overactive bladder
417007|NCT01018264|Urinary incontinence
417008|NCT01018264|Urinary frequency
417009|NCT01018264|Parkinson's disease
417010|NCT01018212|Cutaneous Groves
417011|NCT01018199|C-reactive protein
417012|NCT01018199|procalcitonin
417013|NCT01018199|community-acquired pneumonia
417014|NCT01018199|antibiotic therapy
417015|NCT01018160|Rabeprazole sodium
417016|NCT01018160|Gastroesophageal Reflux
417017|NCT01018160|GERD
417018|NCT01018160|Observational
417019|NCT01018147|stage IIIA non-small cell lung cancer
417020|NCT01018147|stage IIIB non-small cell lung cancer
417021|NCT01018147|stage IA non-small cell lung cancer
417022|NCT01018147|stage IB non-small cell lung cancer
417023|NCT01018147|stage IIA non-small cell lung cancer
417024|NCT01018147|stage IIB non-small cell lung cancer
417025|NCT01018134|Psoriasis
417026|NCT01018134|Topical corticosteroids
417027|NCT01018134|Plaque psoriasis
417028|NCT01018121|Behavioral Treatment
417029|NCT01018121|Preschool Children
417030|NCT01018121|Obesity Treatment
417031|NCT01018069|Acute
417032|NCT01018069|myeloid
417033|NCT01018069|leukemia
417034|NCT01018069|antisense
417035|NCT01018069|chemotherapy
417036|NCT01018069|idarubicin
417037|NCT01018069|cytarabine
417038|NCT01018069|Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen.
417039|NCT01018056|Tourette syndrome
417040|NCT01018056|glutamatergic therapy
417041|NCT01018056|D-serine
417042|NCT01018056|riluzole
417043|NCT01018056|glutamate
417044|NCT01018056|glutamate agonist
417045|NCT01018056|glutamate antagonist
417046|NCT01018056|Tourette syndrome treatment study
417047|NCT01018056|OCD
417048|NCT01018056|tics
417049|NCT01018043|Cancer Anemia Survey
417050|NCT01018043|Chulalongkorn hospital
417051|NCT01018030|uncomplicated acute rhinosinusitis
417052|NCT01018030|fluticasone furoate
417053|NCT01018030|sinusitis
417054|NCT01018004|stage IB melanoma
417055|NCT01018004|stage II melanoma
417056|NCT01017991|infants
417057|NCT01017991|formula
417058|NCT01017991|probiotic
417059|NCT01017991|crying
417060|NCT01017965|Type 1 diabetes
417061|NCT01017952|Safety
417062|NCT01017952|COPD
417063|NCT01017952|FEV1
417064|NCT01017952|Efficacy
417065|NCT01017939|Prostate neoplasms
417066|NCT01017939|Metastatic castration resistant prostate cancer
417067|NCT01017939|Metastatic castration refractory prostate cancer
417068|NCT01017939|Prostate cancer
417069|NCT01017939|Abiraterone acetate
417070|NCT01017939|CB7630
417071|NCT01017926|Triazolam bioequivalence
417072|NCT01017913|rehabilitation
417073|NCT01017913|electrotherapy
417074|NCT01017913|back pain
417075|NCT01017900|surgery
417076|NCT01017900|manual rupture
417077|NCT01017900|dorsal carpal ganglion
417078|NCT01017887|laparoscopy
417079|NCT01017887|airseal
417080|NCT01017887|carbon dioxide
417081|NCT01017887|insufflation
417082|NCT01017887|pneumoperitoneum
417083|NCT01017861|Temporal summation
417084|NCT01017861|Venipuncture pain
417085|NCT01017848|diabetes
417086|NCT01017848|urine pH
417087|NCT01017848|insulin resistance
417088|NCT01017848|metabolic syndrome
417089|NCT01017848|development of diabetes
417090|NCT01017835|statins
417091|NCT01017835|isolated hypertension
417092|NCT01017835|atherosclerosis
417093|NCT01017835|lipid profile
417094|NCT01017822|adenocarcinoma of the pancreas
417095|NCT01017822|stage III pancreatic cancer
417096|NCT01017809|ovarian
417097|NCT01017809|chemotherapy
417098|NCT01017809|nausea
417099|NCT01017796|Contrast induced nephropathy
417100|NCT01017770|Uncomplicated malaria
417101|NCT01017757|Interstitial lung disease
417102|NCT01017757|Immunosuppressive therapy
417103|NCT01017757|Renal transplant
417104|NCT01017744|Anesthetic Conserving Device
417105|NCT01017744|Anaconda®
417106|NCT01017744|Sevoflurane
417107|NCT01017744|Remifentanil
417108|NCT01017744|Sedation
417109|NCT01017744|Pressure support ventilation
417110|NCT01017744|Work of breathing
417111|NCT01017744|Intrinsic positive end expiratory pressure
417112|NCT01017744|Ventilatory dead space
417113|NCT01017744|Intensive care
417114|NCT01017744|Weaning of mechanical ventilation
417115|NCT01017744|Ventilated ICU patients in PSV
417116|NCT01017744|No more in acute state
417117|NCT01017744|No respiratory distress
417118|NCT01017744|Sedated by intravenous remifentanil
417119|NCT01017744|In light sedation as define by a Richmond Agitation Sedation Scale (RASS) of - 1 to - 2.
417120|NCT01017731|Advanced Solid tumor
417121|NCT01017731|Antibodies, Monoclonal
417122|NCT01017731|QTc
417123|NCT01017731|Metastatic
417124|NCT01017731|Malignant
417125|NCT01017718|Diabetes mellitus type I
417126|NCT01017718|nerve conduction velocity
417127|NCT01017718|Young score
417128|NCT01017718|long term vascular complications
417129|NCT01017666|Healthy Volunteer
417130|NCT01017653|Panitumumab
417131|NCT01017653|Vectibix
417132|NCT01017653|Irinotecan
417133|NCT01017653|CPT-11
417134|NCT01017653|Camptosar
417135|NCT01017653|Malignant glioma
417136|NCT01017653|Glioblastoma multiforme
417137|NCT01017653|Gliosarcoma
417138|NCT01017653|Duke
417139|NCT01017653|Vredenburgh
417140|NCT01017653|Pro00015447
417141|NCT01017627|ESRD
417142|NCT01017627|Anemia
417143|NCT01017627|Hospitalizations
417144|NCT01017627|Mortality
417145|NCT01017614|Inflammatory Bowel Disease
417146|NCT01017614|Iron deficiency
417147|NCT01017614|Iron deficiency anaemia
417148|NCT01017614|Anaemia
417149|NCT01017601|extensive stage small cell lung cancer
417150|NCT01017588|lumbar support
417151|NCT01017588|rubber tapper
417152|NCT01017562|To clarify the 18F-fluoride uptake patterns associated with aseptic or septic loosening
417153|NCT01017549|Stage I
417154|NCT01017549|Stage II
417155|NCT01017549|Breast
417156|NCT01017549|Cancer
417157|NCT01017536|HIV
417158|NCT01017536|Tuberculosis
417159|NCT01017536|Vaccine
417160|NCT01017523|diabetes
417161|NCT01017523|relationship
417162|NCT01017523|social support
417163|NCT01017523|telemedicine
417164|NCT01017497|Brain Metastases
417165|NCT01017484|blood pressure
417166|NCT01017484|DASH diet
417167|NCT01017484|hypertension
417168|NCT01017471|carpal tunnel syndrome
417169|NCT01017471|surgery
417170|NCT01017471|PSU retractor
417171|NCT01017471|carpal tunnel syndrome who failed to conservative treatment
417172|NCT01017458|Healthy Adults
417173|NCT01017445|osteoarthritis, exercise
417174|NCT01017419|hearing aids
417175|NCT01017419|counseling
417176|NCT01017406|plantar fasciitis
417177|NCT01017406|heel cushion
417178|NCT01017406|treatment
417179|NCT01017393|preemptive epidural ketamine
417180|NCT01017393|prevention of chronic post-thoracotomy pain
417181|NCT01017380|preemptive analgesia
417182|NCT01017380|cruciate ligament
417183|NCT01017367|RA
417184|NCT01017367|inflammatory joint disease
417185|NCT01017354|vitamin D
417186|NCT01017354|function
417187|NCT01017354|falls
417188|NCT01017354|25-hydroxyvitamin D
417189|NCT01017354|disability
417190|NCT01017341|hip fracture
417191|NCT01017341|back support
417192|NCT01017328|infants and children undergoing surgery with general anesthesia
417193|NCT01017315|baby talcum
417194|NCT01017315|pruritus
417195|NCT01017315|cast
417196|NCT01017276|Hyperphosphatemia
417197|NCT01017276|Peritoneal dialysis
417198|NCT01017276|CKD
417199|NCT01017276|ASP1585
417200|NCT01017263|ADHD
417201|NCT01017263|Glucose Intolerance
417202|NCT01017263|Obesity
417203|NCT01017263|Vyvanse
417204|NCT01017250|Recurrent
417205|NCT01017237|Dexmedetomidine sedation
417206|NCT01017237|Oral surgery sedation
417207|NCT01017237|Dexmedetomidine amnesia
417208|NCT01017211|Pain
417209|NCT01017211|Electromyography
417210|NCT01017211|Acupuncture
417211|NCT01017211|Randomized controlled trial
417212|NCT01017211|Rehabilitation
417213|NCT01017159|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
417214|NCT01017159|Subcutaneous immunoglobulin
417215|NCT01017146|Ance
417216|NCT01017120|Acne
417217|NCT01017107|acute pancreatitis
417218|NCT01017107|treatment
417219|NCT01017107|organ failure
417220|NCT01017107|activated protein c
417221|NCT01017094|Pin-site infection
417222|NCT01017094|silversulfadiazine
417223|NCT01017094|open fracture
417224|NCT01017094|open tibial fracture underwent external fixator
417225|NCT01017081|physiotherapy
417226|NCT01017081|children
417227|NCT01017081|clinical trial
417228|NCT01017068|GLAUCOMA
417229|NCT01017042|healthy
417230|NCT01017042|blood levels
417231|NCT01017003|healthy
417232|NCT01017003|pharmacokinetics
417233|NCT01016990|recurrent adult Hodgkin lymphoma
417234|NCT01016990|recurrent adult Burkitt lymphoma
417235|NCT01016990|recurrent adult diffuse large cell lymphoma
417236|NCT01016990|recurrent adult diffuse mixed cell lymphoma
417237|NCT01016990|recurrent adult lymphoblastic lymphoma
417238|NCT01016990|recurrent grade 3 follicular lymphoma
417239|NCT01016990|recurrent mantle cell lymphoma
417240|NCT01016990|recurrent grade 1 follicular lymphoma
417241|NCT01016990|recurrent grade 2 follicular lymphoma
417242|NCT01016990|recurrent marginal zone lymphoma
417243|NCT01016990|recurrent small lymphocytic lymphoma
417244|NCT01016990|refractory chronic lymphocytic leukemia
417245|NCT01016990|recurrent cutaneous T-cell non-Hodgkin lymphoma
417246|NCT01016990|peripheral T-cell lymphoma
417247|NCT01016990|AIDS-related peripheral/systemic lymphoma
417248|NCT01016990|AIDS-related diffuse large cell lymphoma
417249|NCT01016990|AIDS-related immunoblastic large cell lymphoma
417250|NCT01016990|AIDS-related small noncleaved cell lymphoma
417251|NCT01016990|AIDS-related diffuse mixed cell lymphoma
417252|NCT01016990|AIDS-related diffuse small cleaved cell lymphoma
417253|NCT01016990|AIDS-related lymphoblastic lymphoma
417254|NCT01016990|Waldenström macroglobulinemia
417255|NCT01016964|Androgenetic Alopecia
417256|NCT01016964|Hair Loss
417257|NCT01016964|Female Pattern Baldness
417258|NCT01016951|Phase I
417259|NCT01016951|Safety study
417260|NCT01016951|AZD9164
417261|NCT01016925|femoral perineural catheter
417262|NCT01016925|tunnelization
417263|NCT01016925|complication
417264|NCT01016925|colonization
417265|NCT01016925|infection
417266|NCT01016899|Electronic
417267|NCT01016899|Brachytherapy
417268|NCT01016899|Nonmelanoma
417269|NCT01016899|cancer
417270|NCT01016886|trastuzumab
417271|NCT01016886|cardiac MRI
417272|NCT01016886|beta-blocker
417273|NCT01016886|biomarkers
417274|NCT01016886|angiotensin converting enzyme inhibitor
417275|NCT01016886|cardiotoxicity
417276|NCT01016886|HER2 positive
417277|NCT01016873|Oraya
417278|NCT01016873|Oraya Therapeutics, Inc.
417279|NCT01016873|low voltage stereotactic radiotherapy
417280|NCT01016873|radiotherapy
417281|NCT01016873|IRay
417282|NCT01016873|Ranibizumab
417283|NCT01016873|Lucentis
417284|NCT01016873|AMD
417285|NCT01016873|Macular Degeneration
417286|NCT01016873|xray
417287|NCT01016873|radiation
417288|NCT01016873|x ray
417289|NCT01016873|external beam radiation
417290|NCT01016873|radiosurgery
417291|NCT01016860|OSI-906, irinotecan, colorectal cancer
417292|NCT01016834|migraine
417293|NCT01016834|treatment satisfaction
417294|NCT01016821|Oxycodone
417295|NCT01016821|Labour pain
417296|NCT01016821|Pregnancy
417297|NCT01016821|Pregnant women
417298|NCT01016808|Bunionectomy
417299|NCT01016808|Opioids
417300|NCT01016795|SCF
417301|NCT01016795|Priming
417302|NCT01016795|Mobilization
417303|NCT01016795|Lymphoma
417304|NCT01016795|Clinical Trial
417305|NCT01016782|Inflammatory Rosacea
417306|NCT01016782|Rosacea
417307|NCT01016769|Paclitaxel
417308|NCT01016769|Carboplatin
417309|NCT01016769|Temsirolimus
417310|NCT01016769|Head and Neck
417311|NCT01016769|recurrent and/or metastatic
417312|NCT01016769|09-131
417313|NCT01016756|PHACE syndrome
417314|NCT01016756|Hemangioma
417315|NCT01016756|Coarctation of aorta
417316|NCT01016756|Dandy Walker
417317|NCT01016756|Brain malformation
417318|NCT01016756|Eye anomaly
417319|NCT01016756|Sternal malformation
417320|NCT01016756|Genetic analysis
417321|NCT01016756|Cerebral artery anomaly
417322|NCT01016743|parkinson
417323|NCT01016743|rTMS
417324|NCT01016717|clopidogrel
417325|NCT01016717|platelet function
417326|NCT01016717|omeprazole
417327|NCT01016717|pantoprazole
417328|NCT01016717|coronary disease
417329|NCT01016665|Breast cancer
417330|NCT01016665|Short Term
417331|NCT01016665|Homontherapy
417332|NCT01016665|aromatase inhibitor
417333|NCT01016665|Short term hormonetherapy in breast cancer
417334|NCT01016639|Stomach cancer
417335|NCT01016639|Gall bladder cancer
417336|NCT01016639|Bile ductus cancer
417337|NCT01016639|Pancreas cancer
417338|NCT01016639|Colorectal cancer
417339|NCT01016639|Chemo radiotherapy
417340|NCT01016639|Phase I-II
417341|NCT01016639|Oxaliplatin
417342|NCT01016639|Capecitabine
417343|NCT01016639|Response
417344|NCT01016626|Pharmacokinetics
417345|NCT01016626|Healthy volunteers
417346|NCT01016626|Mycophenolate Mofetil
417347|NCT01016613|chronic kidney disease
417348|NCT01016613|glomerulonephritis
417349|NCT01016613|proteinuria
417350|NCT01016613|nephrotic syndrome
417351|NCT01016613|nephropathy
417352|NCT01016613|biobank
417353|NCT01016587|symptoms
417354|NCT01016587|dyspnea
417355|NCT01016587|pain
417356|NCT01016587|fatigue
417357|NCT01016587|anxiety
417358|NCT01016587|depression
417359|NCT01016587|sleeplessness
417360|NCT01016587|genetic markers
417361|NCT01016587|immune markers
417362|NCT01016587|COPD
417363|NCT01016587|Quality of Life
417364|NCT01016548|Lymphoma
417365|NCT01016548|Multiple myeloma
417366|NCT01016548|Leukemia, Lymphocytic, Chronic, B-Cell
417367|NCT01016548|Influenza A Virus, H1N1 Subtype
417368|NCT01016548|Influenza Vaccines
417369|NCT01016548|Bone Marrow Transplantation
417370|NCT01016535|Family Health Program
417371|NCT01016535|Hygiene
417372|NCT01016535|Child Health
417373|NCT01016522|ALS
417374|NCT01016522|Ketogenic Diet
417375|NCT01016509|restenosis
417376|NCT01016509|insulin
417377|NCT01016509|hyperglycemia
417378|NCT01016496|Cerebral Palsy
417379|NCT01016496|Mirror neurons
417380|NCT01016496|hemiplegia
417381|NCT01016496|action observation therapy
417382|NCT01016496|children affected by hemiplegia as a consequence of Cerebral Palsy
417383|NCT01016483|MEK inhibitor
417384|NCT01016483|cancer
417385|NCT01016483|pancreatic Adenocarcinoma
417386|NCT01016483|metastatic
417387|NCT01016483|chemo-naive
417388|NCT01016483|phase II
417389|NCT01016457|Diabetes Mellitus
417390|NCT01016444|asthma
417391|NCT01016444|albuterol
417392|NCT01016444|B2AR receptors
417393|NCT01016444|Acute asthma responsive and unresponsive to albuterol
417394|NCT01016431|cardiac pacing
417395|NCT01016431|heart failure
417396|NCT01016431|oxygen consumption
417397|NCT01016431|ventricular dysfunction
417398|NCT01016431|left, exercise tolerance
417399|NCT01016431|chronotropic incompetence
417400|NCT01016431|pacemaker programming
417401|NCT01016418|NASH
417402|NCT01016418|fatty liver disease
417403|NCT01016418|colostrum
417404|NCT01016405|Dry eye
417405|NCT01016405|incidence and severity
417406|NCT01016405|cataract surgery
417407|NCT01016392|Observational post-authorization safety study on Kuvan®.
417408|NCT01016379|untreated childhood acute lymphoblastic leukemia
417409|NCT01016379|recurrent childhood acute lymphoblastic leukemia
417410|NCT01016366|Friedreich's Ataxia
417411|NCT01016366|FRDA
417412|NCT01016366|Neurodegenerative
417413|NCT01016366|Erythropoietin
417414|NCT01016366|Carbamylated
417415|NCT01016366|Neuroprotection
417416|NCT01016366|Frataxin
417417|NCT01016353|ABThera
417418|NCT01016353|Barker's Vacuum Packing Technique
417419|NCT01016340|Male Oligoasthenospermia
417420|NCT01016340|MCS
417421|NCT01016327|Phase I study
417422|NCT01016327|Advanced Solid Tumors
417423|NCT01016327|Cdc7 kinase inhibitor
417424|NCT01016288|EUS-FNA
417425|NCT01016288|22 Gauge Needle
417426|NCT01016288|25 Gauge Needle
417427|NCT01016275|To obtain the first iliac long-term results for a patient cohort treated with nitinol stents only
417428|NCT01016262|Ulcerative proctitis
417429|NCT01016262|Proctocolitis
417430|NCT01016262|Inflammatory Bowel Disease
417431|NCT01016262|Gastrointestinal Diseases
417432|NCT01016262|Colonic Diseases
417433|NCT01016262|Mesalamine
417434|NCT01016262|5-ASA
417435|NCT01016249|Bronchiolitis, Viral
417436|NCT01016249|An acute inflammation of the upper RESPIRATORY TRACT
417437|NCT01016223|Eosinophilic esophagitis
417438|NCT01016223|Beclomethasone
417439|NCT01016223|Ultrasensitive CRP
417440|NCT01016210|pregnancy
417441|NCT01016210|IVF
417442|NCT01016197|Soft tissue mallet finger
417443|NCT01016184|Quality of life
417444|NCT01016158|Umbilical cord serum
417445|NCT01016158|Recurrent corneal erosion
417446|NCT01016145|Schizophrenia
417447|NCT01016145|predictors of response
417448|NCT01016145|antipsychotics
417449|NCT01016145|18-45 years old
417450|NCT01016145|non-refractory
417451|NCT01016106|eczema
417452|NCT01016106|atopic dermatitis
417453|NCT01016106|dry skin
417454|NCT01016106|ichthyosis vulgaris
417455|NCT01016093|Thalassemia
417456|NCT01016093|BMT
417457|NCT01016093|HSCT
417458|NCT01016080|glutathione
417459|NCT01016080|melanin
417460|NCT01016080|whitening
417461|NCT01016080|UV spots
417462|NCT01016080|skin pigment
417463|NCT01016067|Tibia
417464|NCT01016067|Tibial
417465|NCT01016067|Fracture
417466|NCT01016067|Nonunion
417467|NCT01016067|delayed
417468|NCT01016067|healing
417469|NCT01016067|iliac
417470|NCT01016067|crest
417471|NCT01016067|autograft
417472|NCT01016067|INFUSE
417473|NCT01016067|MASTERGRAFT
417474|NCT01016067|Fixation
417475|NCT01016067|Internal
417476|NCT01016054|Clinical Trial, Phase1
417477|NCT01016054|Combination Drug Therapy
417478|NCT01016054|pharmacokinetics
417479|NCT01016054|safety
417480|NCT01016054|Ovarian
417481|NCT01016041|drug-eluting stent
417482|NCT01016041|stable angina
417483|NCT01016041|ACS
417484|NCT01016041|MACE
417485|NCT01016041|safety
417486|NCT01016041|stent thrombosis
417487|NCT01016028|Cancer
417488|NCT01016028|Colorectum Cancer
417489|NCT01016028|Colorectal disease
417490|NCT01016028|neuropathic symptom tool
417491|NCT01016028|chemotherapy-induced peripheral neuropathy
417492|NCT01016028|CIPN
417493|NCT01016028|Pain
417494|NCT01016028|Quantitative Sensory Testing
417495|NCT01016028|QST
417496|NCT01016028|symptom measurement tools
417497|NCT01016028|platinum agents
417498|NCT01016028|cisplatin
417499|NCT01016028|oxaliplatin
417500|NCT01016028|taxanes
417501|NCT01016028|bortezomib
417502|NCT01015989|HIV treatment
417503|NCT01015989|ART adherence
417504|NCT01015989|Using new technology to improve adherence
417505|NCT01015989|CARE+
417506|NCT01015989|HIV-1 viral loads
417507|NCT01015976|Gastric Bypass
417508|NCT01015976|Sertraline
417509|NCT01015976|Pharmacokinetics
417510|NCT01015963|recurrent breast cancer
417511|NCT01015963|stage IIIA breast cancer
417512|NCT01015963|stage IIIB breast cancer
417513|NCT01015963|stage IIIC breast cancer
417514|NCT01015963|stage IV breast cancer
417515|NCT01015963|extensive stage small cell lung cancer
417516|NCT01015963|recurrent small cell lung cancer
417517|NCT01015963|recurrent non-small cell lung cancer
417518|NCT01015963|stage IIIA non-small cell lung cancer
417519|NCT01015963|stage IIIB non-small cell lung cancer
417520|NCT01015963|stage IV non-small cell lung cancer
417521|NCT01015963|stage IV bladder cancer
417522|NCT01015963|recurrent bladder cancer
417523|NCT01015963|stage III bladder cancer
417524|NCT01015963|recurrent lymphoepithelioma of the nasopharynx
417525|NCT01015963|recurrent squamous cell carcinoma of the nasopharynx
417526|NCT01015963|stage III lymphoepithelioma of the nasopharynx
417527|NCT01015963|stage III squamous cell carcinoma of the nasopharynx
417528|NCT01015963|stage IV lymphoepithelioma of the nasopharynx
417529|NCT01015963|stage IV squamous cell carcinoma of the nasopharynx
417530|NCT01015963|pulmonary carcinoid tumor
417531|NCT01015963|recurrent basal cell carcinoma of the lip
417532|NCT01015963|recurrent squamous cell carcinoma of the lip and oral cavity
417533|NCT01015963|stage III basal cell carcinoma of the lip
417534|NCT01015963|stage III squamous cell carcinoma of the lip and oral cavity
417535|NCT01015963|stage IV basal cell carcinoma of the lip
417536|NCT01015963|stage IV squamous cell carcinoma of the lip and oral cavity
417537|NCT01015963|recurrent adenoid cystic carcinoma of the oral cavity
417538|NCT01015963|recurrent mucoepidermoid carcinoma of the oral cavity
417539|NCT01015963|recurrent verrucous carcinoma of the oral cavity
417540|NCT01015963|stage III adenoid cystic carcinoma of the oral cavity
417541|NCT01015963|stage III mucoepidermoid carcinoma of the oral cavity
417542|NCT01015963|stage III verrucous carcinoma of the oral cavity
417543|NCT01015963|stage IV adenoid cystic carcinoma of the oral cavity
417544|NCT01015963|stage IV mucoepidermoid carcinoma of the oral cavity
417545|NCT01015963|stage IV verrucous carcinoma of the oral cavity
417546|NCT01015963|recurrent lymphoepithelioma of the oropharynx
417547|NCT01015963|recurrent squamous cell carcinoma of the oropharynx
417548|NCT01015963|stage III lymphoepithelioma of the oropharynx
417549|NCT01015963|stage III squamous cell carcinoma of the oropharynx
417550|NCT01015963|stage IV lymphoepithelioma of the oropharynx
417551|NCT01015963|stage IV squamous cell carcinoma of the oropharynx
417552|NCT01015963|recurrent squamous cell carcinoma of the hypopharynx
417553|NCT01015963|stage III squamous cell carcinoma of the hypopharynx
417554|NCT01015963|stage IV squamous cell carcinoma of the hypopharynx
417555|NCT01015963|recurrent squamous cell carcinoma of the larynx
417556|NCT01015963|recurrent verrucous carcinoma of the larynx
417557|NCT01015963|stage III squamous cell carcinoma of the larynx
417558|NCT01015963|stage III verrucous carcinoma of the larynx
417559|NCT01015963|stage IV squamous cell carcinoma of the larynx
417560|NCT01015963|stage IV verrucous carcinoma of the larynx
417561|NCT01015963|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
417562|NCT01015963|recurrent inverted papilloma of the paranasal sinus and nasal cavity
417563|NCT01015963|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
417564|NCT01015963|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
417565|NCT01015963|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
417566|NCT01015963|stage III inverted papilloma of the paranasal sinus and nasal cavity
417567|NCT01015963|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
417568|NCT01015963|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
417569|NCT01015963|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
417570|NCT01015963|stage IV inverted papilloma of the paranasal sinus and nasal cavity
417571|NCT01015963|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
417572|NCT01015963|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
417573|NCT01015963|recurrent salivary gland cancer
417574|NCT01015963|stage III salivary gland cancer
417575|NCT01015963|stage IV salivary gland cancer
417576|NCT01015963|recurrent metastatic squamous neck cancer with occult primary
417577|NCT01015963|unspecified adult solid tumor, protocol specific
417578|NCT01015963|tongue cancer
417579|NCT01015937|diabetes
417580|NCT01015937|nephropathy
417581|NCT01015937|turmeric
417582|NCT01015937|serum IL8
417583|NCT01015937|serum TGFb
417584|NCT01015937|serumINF
417585|NCT01015937|urinary IL8
417586|NCT01015937|urine TGFb
417587|NCT01015924|clavicle
417588|NCT01015924|TEN
417589|NCT01015924|Plate osteosynthesis
417590|NCT01015924|displaced
417591|NCT01015924|ESIN
417592|NCT01015924|displaced midshaft clavicular fractures
417593|NCT01015911|Antibodies, Monoclonal
417594|NCT01015911|Antibody-Drug Conjugate
417595|NCT01015911|Antigens, CD70
417596|NCT01015911|Lymphoma, Non-Hodgkin
417597|NCT01015911|Carcinoma, Renal Cell
417598|NCT01015911|Immunotherapy
417599|NCT01015911|Drug Therapy
417600|NCT01015911|monomethylauristatin F
417601|NCT01015898|basal cell carcinoma
417602|NCT01015898|photodynamic therapy
417603|NCT01015898|photo chemotherapy
417604|NCT01015898|basal cell epithelioma
417605|NCT01015872|sleep apnea syndrome
417606|NCT01015872|CPAP
417607|NCT01015872|prostanoids
417608|NCT01015859|AV conduction
417609|NCT01015859|Atrial fibrillation
417610|NCT01015846|Core
417611|NCT01015846|Redcord
417612|NCT01015846|RUSI
417613|NCT01015846|low back
417614|NCT01015820|Pancreatic Cancer
417615|NCT01015820|Duodenum
417616|NCT01015820|Spectroscopy
417617|NCT01015820|Fiberoptic probe
417618|NCT01015820|4D-ELF
417619|NCT01015807|postoperative
417620|NCT01015807|hyperalgesia
417621|NCT01015807|pain
417622|NCT01015807|transversus abdominis plane block
417623|NCT01015807|TAP block
417624|NCT01015807|cesarean section
417625|NCT01015781|Tinnitus
417626|NCT01015781|Counseling
417627|NCT01015781|Education
417628|NCT01015781|Rehabilitation of hearing impaired
417629|NCT01015781|Triage
417630|NCT01015781|Evaluation studies
417631|NCT01015781|Quality of health care
417632|NCT01015768|corneal staining
417633|NCT01015768|barrier function
417634|NCT01015768|contact lenses
417635|NCT01015768|contact lens care solutions
417636|NCT01015768|contact lens material and care solution bioincompatibility
417637|NCT01015755|thirst palliation and intensive care unit
417638|NCT01015755|thirst intensity and distress
417639|NCT01015755|predictors of thirst
417640|NCT01015742|AML
417641|NCT01015742|ALL
417642|NCT01015742|CML
417643|NCT01015729|Bioequivalence
417644|NCT01015729|ASA
417645|NCT01015729|Esomeprazole
417646|NCT01015729|peptic ulcer disease
417647|NCT01015729|pH measurements
417648|NCT01015716|Weight loss
417649|NCT01015716|Physical activity
417650|NCT01015716|Cognitive Behavioral Training
417651|NCT01015703|Vaccine, hypertension
417652|NCT01015690|unexplained infertility
417653|NCT01015690|hCG
417654|NCT01015690|early pregnancy loss
417655|NCT01015651|nociception, intraoperative, baroreflex
417656|NCT01015638|Healthy volunteers
417657|NCT01015625|breast cancer
417658|NCT01015625|ABCSG
417659|NCT01015625|POSYTIVE
417660|NCT01015625|growth factor
417661|NCT01015625|median survival
417662|NCT01015625|surgery on demand
417663|NCT01015625|surgical therapy
417664|NCT01015625|blood specimen
417665|NCT01015625|tissue specimen
417666|NCT01015625|VEGF
417667|NCT01015625|TGF
417668|NCT01015625|circulating tumor cells
417669|NCT01015625|stem cells
417670|NCT01015612|Aortic Valve Stenosis
417671|NCT01015612|Aortic Valve Insufficiency
417672|NCT01015599|Obesity prevention
417673|NCT01015599|after-school
417674|NCT01015599|physical activity
417675|NCT01015599|fruit
417676|NCT01015599|vegetable
417677|NCT01015599|children
417678|NCT01015586|Alcohol
417679|NCT01015586|Bipolar Disorder
417680|NCT01015586|Manic depression
417681|NCT01015586|Addiction
417682|NCT01015586|Alcoholism
417683|NCT01015586|Cognitive impairment
417684|NCT01015586|Executive function
417685|NCT01015586|Anxiety
417686|NCT01015586|Depression
417687|NCT01015586|Mania
417688|NCT01015586|Affective disorder
417689|NCT01015586|Psychosis
417690|NCT01015586|Carbohydrate deficient transferrin
417691|NCT01015586|Gammaglutamyltransferase
417692|NCT01015586|California Verbal Learning Test
417693|NCT01015586|Wisconsin Card Sort Test
417694|NCT01015586|Stroop Color and Word Test
417695|NCT01015586|Alcohol Stroop Test
417696|NCT01015586|Emotion Stroop Test
417697|NCT01015586|Point Scoring Reaction Time Test
417698|NCT01015586|Rey Osterrieth Complex Figure Test
417699|NCT01015586|Trail Making Test
417700|NCT01015586|Montgomery Asberg Depression Rating Scale
417701|NCT01015586|Young Mania Rating Scale
417702|NCT01015586|Timeline Follow Back
417703|NCT01015560|bone metastases
417704|NCT01015560|unspecified adult solid tumor, protocol specific
417705|NCT01015547|juvenile idiopathic arthritis
417706|NCT01015547|polyarthritis
417707|NCT01015547|combination therapy
417708|NCT01015547|biologic agents
417709|NCT01015547|TNF antagonists
417710|NCT01015547|infliximab
417711|NCT01015534|Brain metastases
417712|NCT01015534|Temozolomide
417713|NCT01015534|Whole-brain radiotherapy
417714|NCT01015534|Phase II trial
417715|NCT01015521|breast cancer
417716|NCT01015508|Weight loss and maintenance
417717|NCT01015508|body composition
417718|NCT01015508|energy expenditure
417719|NCT01015508|adipogenic capacity
417720|NCT01015508|physical activity
417721|NCT01015495|angioid streaks
417722|NCT01015495|CNV
417723|NCT01015495|intra vitreal ranibizumab
417724|NCT01015482|Sunburn
417725|NCT01015482|Remifentanil
417726|NCT01015482|Hyperalgesia
417727|NCT01015469|bariatric
417728|NCT01015469|surgery
417729|NCT01015469|obesity
417730|NCT01015469|Roux-en-Y
417731|NCT01015469|gastric
417732|NCT01015469|medical device
417733|NCT01015469|bypass
417734|NCT01015469|adiposity
417735|NCT01015469|GaBP-Ring
417736|NCT01015469|BMI
417737|NCT01015469|banded
417738|NCT01015469|laparoscopic
417739|NCT01015456|lupus nephritis
417740|NCT01015456|mycophenolate sodium
417741|NCT01015456|cyclophosphamide
417742|NCT01015443|Non-Small Cell Lung Carcinoma
417743|NCT01015443|Tecemotide
417744|NCT01015443|L-BLP25
417745|NCT01015443|Cyclophosphamide
417746|NCT01015443|placebo controlled
417747|NCT01015443|Non-Small Cell Lung Cancer
417748|NCT01015417|Acute lithiasic cholecystitis
417749|NCT01015417|Cholecystectomy
417750|NCT01015417|Postoperative antibiotherapy
417751|NCT01015417|Surgical site infection
417752|NCT01015417|Remote surgical site infection
417753|NCT01015404|Trafermin
417754|NCT01015404|Periodontitis
417755|NCT01015391|T2
417756|NCT01015391|AZA
417757|NCT01015391|remission
417758|NCT01015391|Crohn's disease
417759|NCT01015378|Recurrent sigmoid diverticulitis
417760|NCT01015378|diverticulitis
417761|NCT01015378|Colon
417762|NCT01015378|sigmoid
417763|NCT01015378|recurrence
417764|NCT01015365|Chronic infected hip arthroplasty
417765|NCT01015365|Fast-track
417766|NCT01015365|One-stage cementless revision
417767|NCT01015352|Myelodysplastic Syndromes
417768|NCT01015326|EGFRI
417769|NCT01015326|HRQL
417770|NCT01015326|Quality of Life
417771|NCT01015326|Development of a standardized HRQL instrument for anti-EGFR therapy induced
417772|NCT01015313|sodium, hypertension, volume overload
417773|NCT01015300|Hemangioblastoma
417774|NCT01015300|Von Hippel Lindau
417775|NCT01015300|VHL
417776|NCT01015300|lesion
417777|NCT01015300|EGFR
417778|NCT01015287|Acute Coronary Syndromes
417779|NCT01015287|Heart Disease
417780|NCT01015287|Percutaneous Coronary Intervention
417781|NCT01015287|P2Y12
417782|NCT01015287|NSTEMI
417783|NCT01015261|ALL
417784|NCT01015261|BMT
417785|NCT01015261|Chemotherapy
417786|NCT01015261|Allogenic
417787|NCT01015248|CD 20 positive
417788|NCT01015235|Ketorolac / therapeutic use
417789|NCT01015235|Analgesics. Non-narcotic / therapeutic use
417790|NCT01015235|Arthroplasty, replacement hip
417791|NCT01015235|Arthroplasty, replacement knee
417792|NCT01015235|Pain measurement / drug effect
417793|NCT01015235|Pain postoperative / drug therapy
417794|NCT01015222|Advanced Malignancies
417795|NCT01015222|Metastatic cancer
417796|NCT01015222|Bevacizumab
417797|NCT01015222|Avastin
417798|NCT01015222|Dasatinib
417799|NCT01015222|Sprycel
417800|NCT01015222|Paclitaxel
417801|NCT01015222|Taxol
417802|NCT01015209|Dry eye syndromes
417803|NCT01015196|acute myeloid leukemia in first complete remission
417804|NCT01015183|Mucositis
417805|NCT01015183|Bone Marrow Transplantation
417806|NCT01015183|BMT
417807|NCT01015183|HSCT
417808|NCT01015170|smoking cessation
417809|NCT01015170|nicotine addiction
417810|NCT01015170|Zyban
417811|NCT01015170|bupropion hydrochloride
417812|NCT01015157|Gastric bypass
417813|NCT01015157|staple line reinforcement
417814|NCT01015157|outcomes
417815|NCT01015157|per and postoperative blood loss
417816|NCT01015144|atorvastatin
417817|NCT01015144|dilated cardiomyopathy
417818|NCT01015144|heart failure
417819|NCT01015144|inflammation
417820|NCT01015105|patients with hip fracture
417821|NCT01015092|HIV
417822|NCT01015092|Cardiovascular
417823|NCT01015092|Coronary hear disease
417824|NCT01015092|HAART
417825|NCT01015092|antiretroviral
417826|NCT01015079|Pap smear screening
417827|NCT01015066|drug dependence
417828|NCT01015066|substance abuse
417829|NCT01015066|substance use disorders
417830|NCT01015066|buprenorphine
417831|NCT01015066|naltrexone
417832|NCT01015066|adolescents
417833|NCT01015053|postoperative pain
417834|NCT01015053|pediatric
417835|NCT01015053|umbilical hernia
417836|NCT01015053|ropivacaine
417837|NCT01015053|rectus sheath block
417838|NCT01015053|regional block
417839|NCT01015053|ultrasound-guided regional block
417840|NCT01015053|local infiltration
417841|NCT01015053|ambulatory surgery
417842|NCT01015040|solifenacin succinate
417843|NCT01015040|VESIcare
417844|NCT01015040|Healthy Volunteers
417845|NCT01015014|Gram negative
417846|NCT01015014|bacteria
417847|NCT01015014|infection
417848|NCT01015001|refractory schizophrenia
417849|NCT01015001|rTMS
417850|NCT01015001|auditory hallucinations
417851|NCT01014988|pandemic
417852|NCT01014988|seasonal influenza
417853|NCT01014988|Influenza B virus
417854|NCT01014988|H1N1
417855|NCT01014988|zanamivir
417856|NCT01014988|Influenza A virus, H1N1 Subtype
417857|NCT01014988|Relenza
417858|NCT01014988|influenza
417859|NCT01014988|neuraminidase inhibitor
417860|NCT01014975|stroke
417861|NCT01014975|plasmin
417862|NCT01014975|thrombus
417863|NCT01014975|ischemic
417864|NCT01014975|middle cerebral artery
417865|NCT01014975|thrombolysis
417866|NCT01014975|intra-arterial
417867|NCT01014975|fibrin
417868|NCT01014962|Pharmacokinetic
417869|NCT01014962|tolerability
417870|NCT01014962|multiple escalating doses
417871|NCT01014936|Phase 1
417872|NCT01014936|advanced solid tumors
417873|NCT01014936|refractory to standard therapy
417874|NCT01014923|motor vehicle
417875|NCT01014923|accidents, traffic
417876|NCT01014923|prevention and control
417877|NCT01014910|Bronchiolitis
417878|NCT01014910|Hypoxia
417879|NCT01014910|Pulse
417880|NCT01014910|Oximetry
417881|NCT01014910|Hospitalized
417882|NCT01014897|stroke
417883|NCT01014897|recovery
417884|NCT01014897|tDCS
417885|NCT01014897|direct current
417886|NCT01014897|electric stimulation
417887|NCT01014871|Forehead Wrinkles Toxin
417888|NCT01014858|Parkinson's disease
417889|NCT01014858|mild dementia
417890|NCT01014858|donepezil
417891|NCT01014858|NIHR HTA
417892|NCT01014845|hepatitis E
417893|NCT01014845|vaccine
417894|NCT01014845|efficacy
417895|NCT01014832|Diabetes, insulin.
417896|NCT01014819|Dermacorder
417897|NCT01014819|Electric field
417898|NCT01014819|basal cell carcinoma
417899|NCT01014819|Gorlin Syndrome
417900|NCT01014793|Acromegaly resistant
417901|NCT01014793|combined-treatment
417902|NCT01014793|dopamine agonist
417903|NCT01014780|dry eye
417904|NCT01014780|tear film
417905|NCT01014780|thickness
417906|NCT01014780|artificial tears
417907|NCT01014767|Choroid Plexus Tumors
417908|NCT01014767|Brain Tumor
417909|NCT01014767|Chemotherapy
417910|NCT01014767|Etoposide
417911|NCT01014767|Carboplatin
417912|NCT01014767|Vincristine
417913|NCT01014767|Cyclophosphamide
417914|NCT01014767|Methotrexate
417915|NCT01014767|Doxorubicin
417916|NCT01014767|Cisplatin
417917|NCT01014767|Dactinomycin
417918|NCT01014767|temozolomide
417919|NCT01014767|irinotecan
417920|NCT01014767|Pediatrics
417921|NCT01014741|Atrial Fibrillation
417922|NCT01014741|Catheter Ablation
417923|NCT01014741|Complex Fractionate Electrograms
417924|NCT01014715|Breast Cancer
417925|NCT01014702|Cataract
417926|NCT01014702|Capsulotomy
417927|NCT01014702|Capsulorrhexis
417928|NCT01014702|lens fragmentation
417929|NCT01014702|phacoemulsification
417930|NCT01014689|acne vulgaris
417931|NCT01014676|Costs and Cost Analysis
417932|NCT01014663|Parkinson's disease
417933|NCT01014663|exercise
417934|NCT01014663|training program
417935|NCT01014663|rehabilitation
417936|NCT01014663|boxing
417937|NCT01014650|glycine site partial agonist
417938|NCT01014650|normal volunteers
417939|NCT01014650|safety in normal volunteers
417940|NCT01014637|Dermatomycoses
417941|NCT01014637|Infection
417942|NCT01014637|Mycoses
417943|NCT01014637|Nail diseases
417944|NCT01014637|Ski diseases
417945|NCT01014637|Skin diseases/infectious
417946|NCT01014624|thienopyridine
417947|NCT01014624|pharmacologic action
417948|NCT01014624|prasugrel
417949|NCT01014624|clopidogrel
417950|NCT01014611|Heart failure
417951|NCT01014611|Skeletal muscle
417952|NCT01014611|Calcium
417953|NCT01014611|Ryanodine receptor
417954|NCT01014611|Mitochondria
417955|NCT01014611|Exercise training
417956|NCT01014611|Muscle biopsy
417957|NCT01014611|Healthy volunteers
417958|NCT01014585|Milnacipran
417959|NCT01014585|Pain
417960|NCT01014585|Durability of Effect
417961|NCT01014585|Loss of Therapeutic Response
417962|NCT01014585|Fatigue
417963|NCT01014585|Forest Research Institute
417964|NCT01014585|Savella ®
417965|NCT01014572|Clinical Trials, Phase II
417966|NCT01014572|Exercise
417967|NCT01014572|Exercise Tolerance
417968|NCT01014572|Aging
417969|NCT01014559|Constipation
417970|NCT01014559|Oxycodone
417971|NCT01014559|Oxycodone hydrochloride
417972|NCT01014559|Naloxone hydrochloride
417973|NCT01014559|Naloxone
417974|NCT01014533|Alcoholism
417975|NCT01014533|Alcohol dependence
417976|NCT01014533|Insomnia
417977|NCT01014533|Dim light melatonin onset
417978|NCT01014533|Gabapentin
417979|NCT01014520|Lumbar
417980|NCT01014520|Diskectomy
417981|NCT01014520|Laminectomy
417982|NCT01014481|HIV
417983|NCT01014481|tuberculosis
417984|NCT01014481|antiretroviral treatment
417985|NCT01014481|timing
417986|NCT01014468|ranibizumab
417987|NCT01014468|bevacizumab
417988|NCT01014468|AMD
417989|NCT01014468|Complications
417990|NCT01014468|Visual acuity
417991|NCT01014468|OCt
417992|NCT01014468|Age Macular Degeneration
417993|NCT01014455|surgery
417994|NCT01014429|Phase I dose escalation study
417995|NCT01014429|Advanced or metastatic solid tumors
417996|NCT01014429|PLK 1 inhibitor
417997|NCT01014429|Adult patients
417998|NCT01014416|Healthy Korean male
417999|NCT01014403|venous thromboembolism
418000|NCT01014403|enoxaparin
418001|NCT01014403|traumatic brain injury
418002|NCT01014403|Venous thromboembolism prophylaxis after traumatic brain injury
418003|NCT01014390|benign biliary strictures secondary to chronic pancreatitis/post abdominal surgery/post liver transplant
418004|NCT01014364|Acute lung injury
418005|NCT01014364|Acute respiratory distress syndrome
418006|NCT01014364|corticosteroids
418007|NCT01014364|inflammation
418008|NCT01014351|Metastatic Melanoma
418009|NCT01014351|Everolimus
418010|NCT01014351|Paclitaxel
418011|NCT01014351|Carboplatin
418012|NCT01014312|Depression
418013|NCT01014299|Intubation
418014|NCT01014299|Hypoxemia
418015|NCT01014299|Mechanical ventilation
418016|NCT01014299|Recruitment maneuver
418017|NCT01014299|Acute lung injury
418018|NCT01014299|Bacterial translocation
418019|NCT01014299|Hypoxemic ICU patients requiring invasive mechanical ventilation
418020|NCT01014273|Acute Coronary Syndrome
418021|NCT01014273|PCI
418022|NCT01014273|Percutaneous Coronary Intervention
418023|NCT01014273|Radial Access
418024|NCT01014260|Inflammatory markers of cardiovascular disease
418025|NCT01014247|Moxifloxacin
418026|NCT01014234|Immunosuppressive Agents
418027|NCT01014234|Immune system regulation
418028|NCT01014234|Regulatory T cells
418029|NCT01014234|Rapamycin
418030|NCT01014234|Tolerance
418031|NCT01014221|acupuncture
418032|NCT01014221|carpal tunnel syndrome
418033|NCT01014221|CTS
418034|NCT01014221|steroid
418035|NCT01014221|global symptom score (GSS)
418036|NCT01014208|The All Ireland Cooperative Oncology Research Group
418037|NCT01014208|GELTAMO
418038|NCT01014208|National Cancer Research Institute Lymphoma Clinical Studies Group
418039|NCT01014208|Genmab
418040|NCT01014208|ofatumumab
418041|NCT01014208|Japan Clinical Oncology Group
418042|NCT01014208|Oncology
418043|NCT01014208|Polish Lymphoma Research Group
418044|NCT01014208|Salvage chemotherapy
418045|NCT01014208|refractory
418046|NCT01014208|HOVON
418047|NCT01014208|DVD
418048|NCT01014208|relapsed
418049|NCT01014208|safety
418050|NCT01014208|efficacy
418051|NCT01014208|DHAP
418052|NCT01014208|rituximab
418053|NCT01014208|Autologous Stem Cell Transplant
418054|NCT01014208|Dutch-Belgian Cooperative Trial Group for Hematology-Oncology
418055|NCT01014208|Grupo Espanol de Linfomas
418056|NCT01014208|Nordic Lymphoma Group
418057|NCT01014195|Acute Lymphoblastic Leukemia
418058|NCT01014195|Neurocognitive function
418059|NCT01014195|ADHD
418060|NCT01014195|brain imaging
418061|NCT01014195|genetic polymorphisms
418062|NCT01014195|Psychopathology and neurocognitive Impairment in Leukemia Survivors
418063|NCT01014182|Early PCI
418064|NCT01014182|Myocardial Infarction
418065|NCT01014182|Thrombolysis
418066|NCT01014182|Optimal revascularization therapy in STEMI patients
418067|NCT01014169|Health education
418068|NCT01014169|Sudden Infant Death
418069|NCT01014169|Breast Feeding
418070|NCT01014169|Infant Equipment
418071|NCT01014156|pulmonary embolism
418072|NCT01014156|vasoconstriction
418073|NCT01014156|right ventricular dysfunction
418074|NCT01014156|epoprostenol
418075|NCT01014156|acute pulmonary embolism with right ventricular dysfunction
418076|NCT01014130|Non Small Cell Lung Cancer
418077|NCT01014130|Hypofractionated
418078|NCT01014130|Stereotactic Radiotherapy
418079|NCT01014104|Ovarian hyper stimulation syndrome
418080|NCT01014104|Methylprednisolone
418081|NCT01014104|IVF
418082|NCT01014091|influenza infection
418083|NCT01014091|GSK Bio's influenza vaccine GSK2340272A
418084|NCT01014065|sunitinib
418085|NCT01014065|cardiac MRI
418086|NCT01014065|maximal exercise testing
418087|NCT01014065|biomarkers
418088|NCT01014065|pharmacokinetics
418089|NCT01014026|Mass Screening
418090|NCT01014026|Polymerase Chain Reaction
418091|NCT01014026|Vaginal Smears
418092|NCT01013987|HIV-1
418093|NCT01013987|triple class failure
418094|NCT01013987|Maraviroc
418095|NCT01013987|Raltegravir
418096|NCT01013987|Darunavir/ritonavir
418097|NCT01013987|Maraviroc with raltegravir and darunavir/ritonavir
418098|NCT01013961|chronic lymphocytic leukemia
418099|NCT01013961|small lymphocytic lymphoma
418100|NCT01013961|CLL
418101|NCT01013961|elderly
418102|NCT01013961|low dose rituximab
418103|NCT01013961|alemtuzumab
418104|NCT01013961|monoclonal antibodies
418105|NCT01013948|Spirometry
418106|NCT01013948|Bronchitis
418107|NCT01013948|COPD
418108|NCT01013948|Chronic Obstructive Pulmonary Disease (COPD)
418109|NCT01013948|Emphysema
418110|NCT01013948|Chronic Bronchitis
418111|NCT01013935|HIV treatment
418112|NCT01013935|ART adherence
418113|NCT01013935|Using new technology to improve adherence
418114|NCT01013935|CARE+
418115|NCT01013935|HIV-1 viral loads
418116|NCT01013922|COPD
418117|NCT01013922|COPD-6
418118|NCT01013922|Spirometry
418119|NCT01013922|VC
418120|NCT01013922|FEV
418121|NCT01013922|FEV1
418122|NCT01013909|Bifonazole
418123|NCT01013909|Terbinafine
418124|NCT01013909|Reduced treatment duration
418125|NCT01013909|Efficacy
418126|NCT01013909|Safety
418127|NCT01013909|Athlete's foot
418128|NCT01013909|Moderate severity
418129|NCT01013883|systolic dysfunction
418130|NCT01013883|diastolic dysfunction
418131|NCT01013883|mortality
418132|NCT01013883|treatment
418133|NCT01013883|heart rate
418134|NCT01013870|mild traumatic brain injury
418135|NCT01013870|post-concussion syndrome
418136|NCT01013870|acute stress disorder
418137|NCT01013870|post-traumatic stress disorder
418138|NCT01013870|atorvastatin
418139|NCT01013844|skin self-examination
418140|NCT01013844|SSE
418141|NCT01013844|melanoma
418142|NCT01013805|Rectal Cancer
418143|NCT01013805|Chemotherapy
418144|NCT01013805|Radiotherapy
418145|NCT01013792|Diabetic
418146|NCT01013792|Foot
418147|NCT01013792|Ulcer
418148|NCT01013792|Neuropathic
418149|NCT01013792|Tegaderm Matrix Dressing
418150|NCT01013792|DFU
418151|NCT01013792|Wound Care
418152|NCT01013792|PHI
418153|NCT01013779|Merkel Cell Cancer
418154|NCT01013779|PET scanning
418155|NCT01013766|GSK1362885
418156|NCT01013766|Pharmacodynamics
418157|NCT01013766|Safety
418158|NCT01013766|Pharmacokinetics
418159|NCT01013766|T2DM
418160|NCT01013766|Tolerability
418161|NCT01013740|Neoplasms, Breast
418162|NCT01013727|Volunteers
418163|NCT01013727|healthy subjects
418164|NCT01013714|Sudden cardiac death
418165|NCT01013714|Ventricular tachycardia
418166|NCT01013714|Ventricular fibrillation
418167|NCT01013714|Cardiomyopathy
418168|NCT01013714|Internal cardiac defibrillator shocks
418169|NCT01013714|Internal cardiac defibrillator therapies
418170|NCT01013701|nasal polyps
418171|NCT01013701|nasal steroid
418172|NCT01013701|fluticasone furoate
418173|NCT01013688|Radiofrequency ablation
418174|NCT01013688|Maze
418175|NCT01013688|Atrial fibrillation
418176|NCT01013675|influenza
418177|NCT01013675|active-controlled
418178|NCT01013675|Phase 2
418179|NCT01013662|septic shock
418180|NCT01013662|glycemic control
418181|NCT01013662|icu
418182|NCT01013662|lipid metabolism
418183|NCT01013662|septic patients
418184|NCT01013623|melanoma
418185|NCT01013623|stage IV
418186|NCT01013623|resectable
418187|NCT01013623|surgery
418188|NCT01013623|medical therapy
418189|NCT01013610|Healthy Elderly Volunteers
418190|NCT01013597|thyroid
418191|NCT01013597|medullary
418192|NCT01013597|differentiated
418193|NCT01013597|radioiodine-resistant
418194|NCT01013597|LBH589
418195|NCT01013597|panobinostat
418196|NCT01013584|vitamin D
418197|NCT01013558|fetal pain
418198|NCT01013558|intrauterine
418199|NCT01013558|needling
418200|NCT01013545|joint engagement
418201|NCT01013545|augmentative communication (AAC)
418202|NCT01013545|enhanced milieu training
418203|NCT01013545|autism spectrum disorder
418204|NCT01013545|language
418205|NCT01013532|Ischemic Stroke
418206|NCT01013532|Intracranial Hemorrhage
418207|NCT01013532|Cilostazol
418208|NCT01013532|Probucol
418209|NCT01013506|estrogen receptor-positive breast cancer
418210|NCT01013506|progesterone receptor-positive breast cancer
418211|NCT01013506|stage IV breast cancer
418212|NCT01013506|recurrent breast cancer
418213|NCT01013493|breastfeeding
418214|NCT01013493|myopia
418215|NCT01013493|nearsightedness
418216|NCT01013493|children
418217|NCT01013480|Fragile X Syndrome
418218|NCT01013467|blood pressure
418219|NCT01013467|control
418220|NCT01013467|adherence
418221|NCT01013467|behaviour
418222|NCT01013454|varenicline percutaneous transcutaneous topical transdermal transdermal delivery system patch
418223|NCT01013441|Chronic Lymphocytic Leukemia
418224|NCT01013428|Traumatic Rupture of Tendon
418225|NCT01013415|Infection with HIV-1 with undetectable viral load on HAART therapy
418226|NCT01013402|Hypoglycemia
418227|NCT01013402|Home Blood Glucose Monitoring
418228|NCT01013402|Subjects are being investigated for the integrity of
418229|NCT01013402|pituitary-adrenal functions by insulin hypoglycemia test.
418230|NCT01013389|actifuse
418231|NCT01013389|INFUSE
418232|NCT01013389|InductOs
418233|NCT01013389|DDD
418234|NCT01013389|degenerative disk disease
418235|NCT01013389|PLIF
418236|NCT01013389|PITF
418237|NCT01013389|PLF
418238|NCT01013389|poterolateral lumber fusion
418239|NCT01013389|Bone substitute
418240|NCT01013389|bone graft
418241|NCT01013389|synthetic bone substitute
418242|NCT01013363|abortion
418243|NCT01013363|first trimester
418244|NCT01013363|suction aspiration
418245|NCT01013363|vacuum aspiration
418246|NCT01013363|music
418247|NCT01013363|anesthesia
418248|NCT01013363|analgesia
418249|NCT01013363|anxiolytic
418250|NCT01013363|pain
418251|NCT01013363|anxiety
418252|NCT01013363|blood pressure
418253|NCT01013363|heart rate
418254|NCT01013363|satisfaction
418255|NCT01013350|Multiple Sclerosis
418256|NCT01013350|Cladribine
418257|NCT01013350|PREMIERE
418258|NCT01013350|Observational study
418259|NCT01013324|endometrial cancer
418260|NCT01013324|endometrial carcinoma
418261|NCT01013324|carcinoma of the endometrium
418262|NCT01013324|cancer of the endometrium
418263|NCT01013311|Implantable Cardioverter-Defibrillator (ICD)- pre-existing
418264|NCT01013298|percutaneous tracheostomy
418265|NCT01013298|paratracheal insertion
418266|NCT01013298|tracheal injury
418267|NCT01013298|transtracheal needle
418268|NCT01013298|ventilatory parameters
418269|NCT01013285|adult giant cell glioblastoma
418270|NCT01013285|adult gliosarcoma
418271|NCT01013285|adult glioblastoma
418272|NCT01013272|entecavir
418273|NCT01013272|lamivudine
418274|NCT01013272|sequential therapy
418275|NCT01013259|E.coli
418276|NCT01013259|Mutaflor
418277|NCT01013259|grass pollen
418278|NCT01013259|rhinoconjunctivitis
418279|NCT01013259|rhinoconjunctivitis caused by grass pollen
418280|NCT01013246|Video games
418281|NCT01013246|Energy balance
418282|NCT01013246|Metabolism
418283|NCT01013246|Appetite control
418284|NCT01013233|cognitive dysfunction chemotherapy
418285|NCT01013220|depression
418286|NCT01013220|depression care management
418287|NCT01013220|financing
418288|NCT01013220|absenteeism
418289|NCT01013220|presenteeism
418290|NCT01013220|employer decisions to purchase health care benefits
418291|NCT01013207|CPAP compliance
418292|NCT01013194|Liver cirrhosis
418293|NCT01013194|Fetal stem cells
418294|NCT01013194|Stem cell transplantation
418295|NCT01013194|Liver transplant candidate
418296|NCT01013181|Immune Thrombopenia
418297|NCT01013181|Thrombocytopenia
418298|NCT01013181|romiplostim
418299|NCT01013181|compassionate program
418300|NCT01013168|OncoSorb
418301|NCT01013168|immune apheresis
418302|NCT01013168|sTNF-R1
418303|NCT01013168|sTNF-R2
418304|NCT01013168|sIL-2R
418305|NCT01013168|TNF
418306|NCT01013142|COPD
418307|NCT01013129|hereditary prostate cancer
418308|NCT01013129|prostate cancer
418309|NCT01013090|Epidural anesthesia
418310|NCT01013090|Spinal anesthesia
418311|NCT01013090|Combined spinal-epidural anesthesia
418312|NCT01013090|Fluid therapy
418313|NCT01013090|Crystalloid
418314|NCT01013090|Colloid
418315|NCT01013077|functional vision
418316|NCT01013077|contrast sensitivity
418317|NCT01013077|aberrometry
418318|NCT01013077|reading ability
418319|NCT01013064|Erythropoietin
418320|NCT01013064|Long acting
418321|NCT01013064|EPO
418322|NCT01013051|obesity
418323|NCT01013051|gastric bypass
418324|NCT01013051|metformin
418325|NCT01013051|pharmacokinetics
418326|NCT01013051|absorption
418327|NCT01013038|myocardial infarction
418328|NCT01013038|percutaneous coronary intervention
418329|NCT01013038|thrombus aspiration
418330|NCT01013025|prostate cancer
418331|NCT01013025|implant retrieval
418332|NCT01013012|highly susceptible patients following spine surgery
418333|NCT01012999|acute pain, intranasal, sufentanil,
418334|NCT01012999|Acute pain control with an intranasal opiate
418335|NCT01012973|Macular Edema
418336|NCT01012973|Central Retinal Vein Occlusion
418337|NCT01012973|CRVO
418338|NCT01012973|VEGF Trap-Eye
418339|NCT01012973|best-corrected visual acuity
418340|NCT01012960|methylnaltrexone
418341|NCT01012960|upper esophageal sphincter
418342|NCT01012960|lower esophageal sphincter
418343|NCT01012960|high resolution solid state manometry
418344|NCT01012960|opioid induced pharyngeal and esophageal dysfunction
418345|NCT01012947|MMSE
418346|NCT01012947|activity
418347|NCT01012921|GBR
418348|NCT01012921|GTR
418349|NCT01012921|Dental Implant surgery
418350|NCT01012869|Coronary chronic total occlusions
418351|NCT01012856|depressive episode
418352|NCT01012856|psychotherapy
418353|NCT01012856|cognitive therapy
418354|NCT01012856|emotional processing
418355|NCT01012856|RCT
418356|NCT01012856|exposure
418357|NCT01012856|dual process model
418358|NCT01012856|Implicit Association Test
418359|NCT01012856|mechanism of change
418360|NCT01012843|Perianal
418361|NCT01012843|Abscess
418362|NCT01012843|Fistulae in ano
418363|NCT01012843|Antibiotic
418364|NCT01012843|Anorectal
418365|NCT01012830|Schizophrenia
418366|NCT01012830|Cognitive Disorders
418367|NCT01012830|Dementia
418368|NCT01012830|Huperzine A
418369|NCT01012830|HupA
418370|NCT01012804|stage IV colon cancer
418371|NCT01012804|recurrent colon cancer
418372|NCT01012791|Zumba exercise
418373|NCT01012791|ApoE
418374|NCT01012778|Performance impairment
418375|NCT01012778|Yoga
418376|NCT01012778|Meditation
418377|NCT01012778|Peer mediated
418378|NCT01012765|COPD
418379|NCT01012765|indacaterol
418380|NCT01012765|QAB149
418381|NCT01012765|inspiratory capacity
418382|NCT01012739|asthma
418383|NCT01012739|QAB149
418384|NCT01012739|indacaterol
418385|NCT01012739|pulmonary function
418386|NCT01012713|Psoriasis
418387|NCT01012713|Excimer
418388|NCT01012713|Laser
418389|NCT01012713|Clobex
418390|NCT01012713|Vectical
418391|NCT01012713|clobetasol spray
418392|NCT01012713|calcitriol
418393|NCT01012713|Generalized plaque type psoriasis
418394|NCT01012674|carotid or vertebral artery disease
418395|NCT01012674|Contrast agent
418396|NCT01012674|MRA
418397|NCT01012661|Moderate to severe wrinkles and folds such as nasolabial folds
418398|NCT01012635|spinal cord injury
418399|NCT01012635|chronic pain
418400|NCT01012622|Attention Deficit Hyperactivity Disorder
418401|NCT01012622|Methylphenidate Hydrochloride
418402|NCT01012609|high-grade astrocytomas
418403|NCT01012609|newly diagnosed diffuse pontine tumors
418404|NCT01012609|External beam radiation therapy
418405|NCT01012609|cetuximab
418406|NCT01012609|irinotecan
418407|NCT01012609|POETIC
418408|NCT01012596|Natural Family Planning Methods
418409|NCT01012596|Ovulation Detection
418410|NCT01012596|Cervix Mucus
418411|NCT01012596|Intention
418412|NCT01012596|Behavior
418413|NCT01012596|Birth Control
418414|NCT01012596|Contraception
418415|NCT01012596|Pregnancy
418416|NCT01012596|Fertility
418417|NCT01012583|Optical coherence tomography
418418|NCT01012583|Drug eluting stent
418419|NCT01012583|Biodegradable polymer
418420|NCT01012583|Intimal
418421|NCT01012583|Coverage
418422|NCT01012583|assess intimal hyperplasia of drug eluting stent with biodegradable polymer
418423|NCT01012557|H1N1v
418424|NCT01012557|vaccine
418425|NCT01012557|pregnant
418426|NCT01012557|women
418427|NCT01012557|Assess whether the adjuvanted vaccine offers a meaningful benefit in pregnant women in terms of immune response over the non-adjuvanted vaccine.
418428|NCT01012557|Assess the persistence of immune response over a 15 month time period after one single vaccination of the pregnant mother.
418429|NCT01012557|Assess whether the immune response to H1N1 in pregnant women is different from that of non-pregnant women of similar age.
418430|NCT01012557|Gain insight on safety of the Novartis egg-based MF59 adjuvanted H1N1 vaccine Focetria in pregnant women and their babies.
418431|NCT01012557|Assess the maternally transferred specific antibodies against H1N1v in the newborn
418432|NCT01012557|Passive immunity transferred to the infant.
418433|NCT01012544|clopidogrel
418434|NCT01012544|pharmacokinetics
418435|NCT01012544|platelet function tests
418436|NCT01012544|platelet reactivity
418437|NCT01012518|percutaneous tracheostomy
418438|NCT01012518|paratracheal insertion
418439|NCT01012518|tracheal injury
418440|NCT01012518|transtracheal needle
418441|NCT01012518|ventilatory parameters
418442|NCT01012492|cancer
418443|NCT01012492|leukemia
418444|NCT01012492|transplant
418445|NCT01012492|bone marrow
418446|NCT01012479|Blood Pressure
418447|NCT01012479|Blood Pressure, High
418448|NCT01012479|Drug Therapy
418449|NCT01012466|pregnancy
418450|NCT01012466|birth
418451|NCT01012466|labor
418452|NCT01012466|labor pain
418453|NCT01012466|catastrophizing
418454|NCT01012453|Hand eczema
418455|NCT01012453|Hand dermatitis
418456|NCT01012453|Occupational skin disease
418457|NCT01012453|skindisease in health care workers
418458|NCT01012453|occupational hand dermatitis
418459|NCT01012453|occupational hand eczema
418460|NCT01012427|Kidney
418461|NCT01012427|Cryoablation
418462|NCT01012427|09-108
418463|NCT01012414|Vitamin D
418464|NCT01012414|Coronary Artery Disease (CAD)
418465|NCT01012414|Chronic Kidney Disease (CKD)
418466|NCT01012401|Lung cancer
418467|NCT01012401|Quality of life
418468|NCT01012401|Communication with physician
418469|NCT01012388|Moderate to severe wrinkles and folds such as nasolabial folds
418470|NCT01012375|Adult ADHD
418471|NCT01012362|Solid tumor malignancy
418472|NCT01012362|breast cancer
418473|NCT01012362|lung cancer
418474|NCT01012362|colon cancer
418475|NCT01012362|pancreatic cancer
418476|NCT01012362|head and neck cancer
418477|NCT01012362|kidney cancer
418478|NCT01012362|sarcoma
418479|NCT01012362|hepatocellular cancer
418480|NCT01012336|efficacy and safety of Aprepitant/Ramosetron/Dexamethasone in ovary cancer patients with taxol and carboplatin
418481|NCT01012323|PID
418482|NCT01012310|pharmacokinetics safety tolerability multiple dosing
418483|NCT01012284|Moderate Hepatic Impairment
418484|NCT01012284|Tuberculosis
418485|NCT01012284|TMC207
418486|NCT01012284|Mycobacterial adenosine triphosphate (ATP)-synthase
418487|NCT01012271|Wrist abnormalities
418488|NCT01012258|antitumor activity
418489|NCT01012258|safety
418490|NCT01012258|cetuximab in combination with radiotherapy
418491|NCT01012258|locally advanced squamous cell head & neck carcinoma
418492|NCT01012245|Xchange
418493|NCT01012245|Xalatan
418494|NCT01012245|Xalacom
418495|NCT01012245|Betablocker
418496|NCT01012245|observational
418497|NCT01012245|longterm
418498|NCT01012232|total knee arthroplasty
418499|NCT01012232|postoperative pain
418500|NCT01012206|Children
418501|NCT01012206|Overweight
418502|NCT01012206|Obesity
418503|NCT01012206|Food habits
418504|NCT01012206|Dietary assessment
418505|NCT01012206|Physical activity
418506|NCT01012193|adjunctive cilostazol
418507|NCT01012193|high-MD clopidogrel
418508|NCT01012193|CYP 2C19 polymorphism
418509|NCT01012193|high risk patients
418510|NCT01012180|Bipolar Disorder
418511|NCT01012180|Adaptation
418512|NCT01012180|Parents
418513|NCT01012180|Risk
418514|NCT01012180|Coping
418515|NCT01012180|Survey
418516|NCT01012167|Schizophrenia, oxytocin, galantamine
418517|NCT01012128|Temporal Artery Thermometer
418518|NCT01012128|Temperature
418519|NCT01012128|Preterm Infants
418520|NCT01012115|Histones
418521|NCT01012115|organ failure
418522|NCT01012115|sepsis
418523|NCT01012102|EMD 640744
418524|NCT01012102|Montanide
418525|NCT01012102|Advanced solid tumours
418526|NCT01012089|Hemodialysis
418527|NCT01012089|Peritoneal dialysis
418528|NCT01012089|Daptomycin
418529|NCT01012089|Pharmacokinetics
418530|NCT01012076|maternal synchrony
418531|NCT01012076|parent-child
418532|NCT01012076|parent child play
418533|NCT01012076|social communication
418534|NCT01012063|iron
418535|NCT01012063|erythropoietin
418536|NCT01012063|hemoglobin
418537|NCT01012063|Total knee replacement arthroplasty
418538|NCT01012050|Asthma
418539|NCT01012050|status asthmatics
418540|NCT01012011|Carcinoma, Hepatocellular
418541|NCT01012011|Carcinoma, Renal Cell
418542|NCT01011998|CML
418543|NCT01011998|Chronic Myelogenous leukemia
418544|NCT01011998|INST 0901
418545|NCT01011998|imatinib
418546|NCT01011998|valproic acid
418547|NCT01011998|Gleevec
418548|NCT01011985|end stage renal disease
418549|NCT01011985|inflammation
418550|NCT01011985|vascular access
418551|NCT01011985|hemodialysis
418552|NCT01011972|Dose escalation
418553|NCT01011972|XMT-1107
418554|NCT01011972|1107
418555|NCT01011972|Tumor
418556|NCT01011972|Phase 1
418557|NCT01011972|Fumagillol
418558|NCT01011972|PHF
418559|NCT01011972|Fleximer
418560|NCT01011972|cancer
418561|NCT01011972|maximum tolerated dose
418562|NCT01011972|MTD
418563|NCT01011920|newly diagnosed primary central nervous system lymphoma
418564|NCT01011894|Lenalidomide
418565|NCT01011894|CLL
418566|NCT01011894|09-045
418567|NCT01011881|pleuritis
418568|NCT01011881|empyema
418569|NCT01011881|procalcitonin
418570|NCT01011829|methamphetamine
418571|NCT01011829|crystal meth
418572|NCT01011829|addiction
418573|NCT01011829|los angeles
418574|NCT01011829|medication
418575|NCT01011829|meth
418576|NCT01011816|intervertebral disk
418577|NCT01011803|Deglutition
418578|NCT01011803|Phonation
418579|NCT01011790|Healing Rhythms™
418580|NCT01011790|Meditation
418581|NCT01011790|Biofeedback
418582|NCT01011790|Stress
418583|NCT01011777|bladder exstrophy epispadias complex
418584|NCT01011777|urinary incontinence
418585|NCT01011777|muscle derive cell therapy
418586|NCT01011777|stem cells
418587|NCT01011764|social networks
418588|NCT01011764|friendships
418589|NCT01011764|autism spectrum disorder
418590|NCT01011751|Drug Therapy
418591|NCT01011712|Genetics
418592|NCT01011712|Virus
418593|NCT01011712|Defense
418594|NCT01011712|Immune Defects
418595|NCT01011712|Respiratory Viruses
418596|NCT01011712|Herpesvirus
418597|NCT01011712|Cytomegalovirus
418598|NCT01011712|Human Papillomavirus
418599|NCT01011712|Adenovirus
418600|NCT01011699|nicotinamide
418601|NCT01011699|sevelamer hydrochloride
418602|NCT01011699|phosphatemia
418603|NCT01011699|cinacalcet
418604|NCT01011699|dyslipidemia
418605|NCT01011699|vascular calcification
418606|NCT01011699|bone mass loss
418607|NCT01011673|headache
418608|NCT01011673|tension-type headache
418609|NCT01011660|hypertension
418610|NCT01011660|cardiovascular risk factors
418611|NCT01011660|drugs intervention
418612|NCT01011660|lipid-lowering therapy
418613|NCT01011660|50-79 years of age
418614|NCT01011660|sign
418615|NCT01011660|the informed
418616|NCT01011660|consent
418617|NCT01011660|forms
418618|NCT01011634|abortion
418619|NCT01011634|uterine aspiration
418620|NCT01011634|pain control
418621|NCT01011621|Prednisolone acetate
418622|NCT01011621|Betamethasone valerate
418623|NCT01011595|lung cancer
418624|NCT01011595|mediastinoscopy
418625|NCT01011595|mediastinal lymph nodes
418626|NCT01011595|staging
418627|NCT01011595|EBUS
418628|NCT01011595|EUS
418629|NCT01011595|Endobronchial Ultrasound
418630|NCT01011595|Endoscopic Ultrasound
418631|NCT01011582|To evaluate biomarkers that cause critical illness in patients with novel H1N1 influenza and with seasonal influenza.
418632|NCT01011569|difference
418633|NCT01011556|Age Related Osteoporosis
418634|NCT01011556|Senile Osteoporosis
418635|NCT01011543|pulmonary tuberculosis
418636|NCT01011543|negative sputum exam
418637|NCT01011543|induced sputum
418638|NCT01011543|endoscopy
418639|NCT01011530|Melanoma
418640|NCT01011517|muscadine grapes
418641|NCT01011517|endothelial function
418642|NCT01011491|Obesity
418643|NCT01011491|Weight loss
418644|NCT01011491|meal replacements
418645|NCT01011491|inflammation
418646|NCT01011491|oxidative stress
418647|NCT01011491|visceral fat
418648|NCT01011478|adenomatous polyp
418649|NCT01011478|stage I colon cancer
418650|NCT01011478|stage II colon cancer
418651|NCT01011478|adenocarcinoma of the colon
418652|NCT01011465|Stress
418653|NCT01011465|Oxytocin
418654|NCT01011465|Social Support
418655|NCT01011465|Resilience
418656|NCT01011452|Acute Asthma Exacerbation
418657|NCT01011452|Montelukast
418658|NCT01011452|Management of acute asthma exacerbation
418659|NCT01011439|B3 and C malignant thymoma
418660|NCT01011426|laxative
418661|NCT01011426|postoperative care
418662|NCT01011426|ob-Gyn population
418663|NCT01011426|post-operative patients
418664|NCT01011426|obstetrical and gynecological surgery
418665|NCT01011413|HIV
418666|NCT01011413|ART
418667|NCT01011413|Efavirenz
418668|NCT01011413|Dose reduction
418669|NCT01011400|clitoris
418670|NCT01011387|Diabetic foot ulcers
418671|NCT01011374|Retinal vein occlusion
418672|NCT01011374|Ranibizumab
418673|NCT01011374|Lucentis
418674|NCT01011374|Depression
418675|NCT01011348|Gulf War Illness
418676|NCT01011348|Coenzyme Q10
418677|NCT01011348|Quality of Life
418678|NCT01011348|Fatigue
418679|NCT01011348|oxidative stress
418680|NCT01011335|Staphylococcus aureus
418681|NCT01011335|Skin and soft tissue infection
418682|NCT01011335|Methicillin-resistant Staphylococcus aureus
418683|NCT01011335|Recombinant alpha-toxoid (rAT)
418684|NCT01011335|Recombinant LukS subunit of Panton-Valentine Leukocidin (rLukS-PV)
418685|NCT01011309|Leishmaniasis
418686|NCT01011309|vaccine
418687|NCT01011309|immunotherapy
418688|NCT01011283|MDS
418689|NCT01011283|Myelodysplastic Syndromes
418690|NCT01011270|Back pain
418691|NCT01011270|postural balance
418692|NCT01011270|RDM
418693|NCT01011270|industrial operators
418694|NCT01011257|CAD
418695|NCT01011231|Gamma Knife radiosurgery
418696|NCT01011231|recurrent glioma
418697|NCT01011231|MRI
418698|NCT01011231|Spectroscopy
418699|NCT01011231|Recurrent grade IV glioma (glioblastoma), with two additional exploratory arms for patients with recurrent grade II and grade III gliomas
418700|NCT01011218|quality of life
418701|NCT01011205|Advagraf
418702|NCT01011205|Liver
418703|NCT01011205|Transplant
418704|NCT01011205|Immunosuppression
418705|NCT01011192|Intravenous anesthesia
418706|NCT01011192|propofol
418707|NCT01011192|pharmacokinetic model
418708|NCT01011192|Monitoring
418709|NCT01011192|bispectral index.
418710|NCT01011179|Teens Taking Charge
418711|NCT01011179|Managing Arthritis Online
418712|NCT01011179|juvenile idiopathic arthritis
418713|NCT01011179|internet
418714|NCT01011179|self-management
418715|NCT01011166|Chronic Hepatitis C
418716|NCT01011166|HepC
418717|NCT01011166|Hep C
418718|NCT01011140|Parenteral Hydration
418719|NCT01011140|Latin American Association for Palliative Care
418720|NCT01011140|ALCP
418721|NCT01011140|Spanish Society for Palliative Care
418722|NCT01011140|SECPAL
418723|NCT01011140|Online survey
418724|NCT01011140|Palliative care
418725|NCT01011140|Physicians' attitudes
418726|NCT01011140|End of life
418727|NCT01011140|Latin America
418728|NCT01011140|Spain
418729|NCT01011127|Statins
418730|NCT01011127|Insulin resistance
418731|NCT01011114|hypophosphatemia
418732|NCT01011114|hyperparathyroidism
418733|NCT01011114|renal transplant
418734|NCT01011101|Saccadic Eye Movements
418735|NCT01011101|Schizophrenia
418736|NCT01011101|Healthy Volunteer
418737|NCT01011101|HV
418738|NCT01011088|Paternity
418739|NCT01011088|Psychology
418740|NCT01011088|Risk factor
418741|NCT01011075|Lung cancer,
418742|NCT01011075|Non-small cell lung cancer
418743|NCT01011075|NSCLC
418744|NCT01011075|Metastatic
418745|NCT01011075|Gleevec
418746|NCT01011075|elderly
418747|NCT01011062|Adipose tissue
418748|NCT01011062|Adipokines
418749|NCT01011049|Influenza
418750|NCT01011049|Fluzone Vaccine
418751|NCT01011049|Intradermal Injections
418752|NCT01011049|Adults
418753|NCT01011036|healthy study subjects, no disease
418754|NCT01011023|Bowel anastomosis
418755|NCT01011023|nasogastric tube
418756|NCT01011023|children
418757|NCT01011010|adult primary hepatocellular carcinoma
418758|NCT01011010|localized unresectable adult primary liver cancer
418759|NCT01011010|recurrent adult primary liver cancer
418760|NCT01010997|AMD, CNV
418761|NCT01010984|metastatic melanoma
418762|NCT01010984|stage IV melanoma
418763|NCT01010984|metastatic melanoma to the liver
418764|NCT01010971|Mountain Cedar
418765|NCT01010945|Advanced Pancreatic Cancer
418766|NCT01010945|erlotinib
418767|NCT01010945|gemcitabine
418768|NCT01010945|nab-paclitaxel
418769|NCT01010945|Adenocarcinoma
418770|NCT01010945|Phase 1b
418771|NCT01010932|carotid or vertebral artery disease
418772|NCT01010932|Contrast agent
418773|NCT01010932|MRA
418774|NCT01010893|pandemic
418775|NCT01010893|prevention
418776|NCT01010893|influenza
418777|NCT01010893|infection
418778|NCT01010893|influenza vaccine
418779|NCT01010893|vaccine
418780|NCT01010893|influenza in humans
418781|NCT01010880|Multiple Myeloma
418782|NCT01010880|CXCR4
418783|NCT01010880|Stem Cells
418784|NCT01010880|Mobilization
418785|NCT01010880|Transplantation
418786|NCT01010880|Chemotherapy
418787|NCT01010867|Probiotics
418788|NCT01010867|Hematopoietic Stem Cell Transplantation
418789|NCT01010867|Pediatrics
418790|NCT01010854|breast cancer
418791|NCT01010854|advanced
418792|NCT01010854|local
418793|NCT01010841|Metabolic syndrome
418794|NCT01010841|Serum lipid
418795|NCT01010841|Dietary intervention
418796|NCT01010841|Lifestyle modification
418797|NCT01010841|Glycemic load
418798|NCT01010841|Phytochemical
418799|NCT01010841|Hops
418800|NCT01010841|Acacia
418801|NCT01010841|Mediterranean diet
418802|NCT01010841|Kinase modulator
418803|NCT01010815|ulcerative colitis
418804|NCT01010815|gut microbiome
418805|NCT01010815|metagenomics
418806|NCT01010802|Neuroprotection
418807|NCT01010802|Parkinson Disease
418808|NCT01010802|Erythropoietin
418809|NCT01010776|Schizophrenia
418810|NCT01010776|Paliperidone
418811|NCT01010750|ADHD
418812|NCT01010737|Multimeric
418813|NCT01010737|Vaccine
418814|NCT01010737|Influenza
418815|NCT01010737|elderly
418816|NCT01010737|phase 1/2
418817|NCT01010737|safety
418818|NCT01010737|efficacy
418819|NCT01010737|tolerability
418820|NCT01010737|reactogenicity
418821|NCT01010737|Montanide
418822|NCT01010737|hemagglutinin inhibition
418823|NCT01010737|HAI
418824|NCT01010737|TIV
418825|NCT01010711|migraine
418826|NCT01010711|children
418827|NCT01010711|dietary supplement
418828|NCT01010711|q10
418829|NCT01010711|prevention
418830|NCT01010698|cimetidine
418831|NCT01010698|acyclovir
418832|NCT01010698|pharmacokinetics
418833|NCT01010698|excipient
418834|NCT01010698|formulation
418835|NCT01010685|Natural Orifice Transluminal Endoscopic Surgery (NOTES)
418836|NCT01010685|Transgastric surgery
418837|NCT01010685|Surgical Procedures, Minimally Invasive
418838|NCT01010659|Dacryocystorhinostomy
418839|NCT01010646|hepatitis C
418840|NCT01010646|viral kinetics
418841|NCT01010646|antiviral response
418842|NCT01010646|Genotype 1 or 4
418843|NCT01010620|screening
418844|NCT01010620|research participation
418845|NCT01010620|substance abuse
418846|NCT01010620|Schizophrenia
418847|NCT01010620|nicotine
418848|NCT01010620|Healthy
418849|NCT01010620|cigarettes
418850|NCT01010620|smoking
418851|NCT01010620|marijuana
418852|NCT01010620|cocaine
418853|NCT01010581|Rheumatoid Arthritis
418854|NCT01010581|SC12267
418855|NCT01010581|4SC-101
418856|NCT01010581|Methotrexate
418857|NCT01010581|Phase II
418858|NCT01010568|CLL
418859|NCT01010568|SLL
418860|NCT01010568|Bendamustine
418861|NCT01010568|Ofatumumab
418862|NCT01010542|Single dose psoriasis study
418863|NCT01010529|Occupational Therapy
418864|NCT01010529|Parkinson's Disease
418865|NCT01010529|Feasibility
418866|NCT01010529|Effectiveness
418867|NCT01010529|RCT
418868|NCT01010529|Activities of daily living
418869|NCT01010529|Participation
418870|NCT01010529|Caregiver's Burden
418871|NCT01010490|PACHYMETRY
418872|NCT01010490|CELL LOSS
418873|NCT01010490|SAFETY
418874|NCT01010490|EFFICACY
418875|NCT01010490|PHACOEMULSIFICATION
418876|NCT01010490|Intraoperative complications
418877|NCT01010490|CLOCK TIME
418878|NCT01010490|FLUID USED
418879|NCT01010490|CORNEAL THICKNESS
418880|NCT01010490|ENDOTHELIUM CELL LOSS
418881|NCT01010477|smoking cessation
418882|NCT01010477|schizophrenia
418883|NCT01010477|nicotine nasal spray
418884|NCT01010477|behavioral counseling
418885|NCT01010464|Adhesions
418886|NCT01010464|Open abdomen
418887|NCT01010464|Laparotomy
418888|NCT01010451|pulpotomy
418889|NCT01010451|pulpectomy
418890|NCT01010451|primary teeth
418891|NCT01010451|dental care for children
418892|NCT01010438|sleep studies
418893|NCT01010438|sleep apnea
418894|NCT01010438|OSA
418895|NCT01010438|Referred for sleep studies by a medical professional
418896|NCT01010412|Ultrasound
418897|NCT01010412|Nerve blocks
418898|NCT01010412|Upper extremity
418899|NCT01010399|HIV
418900|NCT01010399|triglycerides
418901|NCT01010399|fosamprenavir
418902|NCT01010386|Pregnancy
418903|NCT01010386|Infertility
418904|NCT01010386|Physiologic Oxygen Tension
418905|NCT01010386|Atmospheric Oxygen Tension
418906|NCT01010373|Primary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) induced AML.
418907|NCT01010360|celiac ganglia
418908|NCT01010347|fractures
418909|NCT01010347|casting
418910|NCT01010347|splinting
418911|NCT01010347|pediatrics
418912|NCT01010334|INST 0813
418913|NCT01010334|Standard of Care
418914|NCT01010321|skin lesion suspect as BCC or SCC or others
418915|NCT01010308|infantile hemangioma
418916|NCT01010308|nadolol
418917|NCT01010295|NHL of the ocular adnexae
418918|NCT01010256|To evaluate the phosphate and tension homolog deleted on chromosome ten (PTEN) protein level in leukemia cells from patients with CMML.
418919|NCT01010256|To identify the PTEN genetic defect in patients with deficient PTEN protein levels.
418920|NCT01010256|To evaluate the role of PTEN deregulation in CMML pathogenesis.
418921|NCT01010243|multiple myeloma
418922|NCT01010243|anti-inflammatory
418923|NCT01010243|relapsed
418924|NCT01010243|refractory
418925|NCT01010243|progressive
418926|NCT01010230|Childhood cancer survivors
418927|NCT01010217|Hematologic Neoplasms
418928|NCT01010217|Blood Disorders
418929|NCT01010217|Blood Cancer
418930|NCT01010217|Transplantation, Blood And Marrow
418931|NCT01010217|Acute myelogenous leukemia
418932|NCT01010217|Myelodysplastic syndrome
418933|NCT01010217|Acute lymphocytic leukemia
418934|NCT01010217|Aplastic anemia
418935|NCT01010217|Chronic myelogenous leukemia
418936|NCT01010217|Chronic lymphocytic leukemia
418937|NCT01010217|Myeloproliferative disease
418938|NCT01010217|Hodgkin's disease
418939|NCT01010217|Non-Hodgkin's lymphoma
418940|NCT01010217|Multiple myeloma
418941|NCT01010217|Cyclophosphamide
418942|NCT01010217|Fludarabine
418943|NCT01010217|Melphalan
418944|NCT01010217|Mesna
418945|NCT01010217|Rituximab
418946|NCT01010217|Tacrolimus
418947|NCT01010217|Prograf
418948|NCT01010217|Mycofenolate mofetil
418949|NCT01010217|MMF
418950|NCT01010217|CellCept
418951|NCT01010217|G-CSF
418952|NCT01010217|Filgrastim
418953|NCT01010217|Neupogen
418954|NCT01010204|Varenicline
418955|NCT01010204|Chantix
418956|NCT01010204|Smoking
418957|NCT01010204|Bipolar Disorder
418958|NCT01010191|irritable bowel syndrome
418959|NCT01010191|no organic digestive disease
418960|NCT01010178|COPD
418961|NCT01010178|Macrolid
418962|NCT01010178|reversibility
418963|NCT01010178|Theophylline
418964|NCT01010178|Corticosteroids
418965|NCT01010178|symptoms PFT
418966|NCT01010165|acute arthritis
418967|NCT01010165|bacteria
418968|NCT01010165|crystal arthritis
418969|NCT01010165|proteomic
418970|NCT01010165|SELDI-TOF
418971|NCT01010113|infants
418972|NCT01010113|prebiotics
418973|NCT01010113|probiotics
418974|NCT01010113|safety
418975|NCT01010100|Metabolic Disease
418976|NCT01010100|IGT Impaired Glucose Tolerance
418977|NCT01010087|patients admitted to ICU
418978|NCT01010074|retina, Parkinson's disease, ganglion cell, pupillary
418979|NCT01010048|ESWL
418980|NCT01010048|urinary calculus
418981|NCT01010048|drugs treat
418982|NCT01010035|type 2 diabetes mellitus
418983|NCT01010035|dyslipidemia
418984|NCT01010035|kinetics
418985|NCT01010022|hypovolemia
418986|NCT01010022|surgical blood loss
418987|NCT01010022|orthopedic procedures
418988|NCT01010022|Treatment of reduced circulating blood volume (hypovolemia) including massive hemorrhage
418989|NCT01010009|resveratrol
418990|NCT01010009|cerebral blood flow
418991|NCT01010009|NIRS
418992|NCT01010009|cognitive performance
418993|NCT01009996|Coronary bifurcation lesions
418994|NCT01009983|triple-negative breast cancer
418995|NCT01009970|Diffuse Large B-Cell Lymphoma
418996|NCT01009957|ADPKD
418997|NCT01009957|CKD
418998|NCT01009957|Renal disease progression
418999|NCT01009957|Everolimus
419000|NCT01009944|High blood pressure
419001|NCT01009931|Acute Myelogenous Leukemia
419002|NCT01009931|Relapsed AML
419003|NCT01009931|Refractory AML
419004|NCT01009918|cardiac toxicity
419005|NCT01009918|HER2-positive breast cancer
419006|NCT01009918|recurrent breast cancer
419007|NCT01009918|stage IA breast cancer
419008|NCT01009918|stage IB breast cancer
419009|NCT01009918|stage II breast cancer
419010|NCT01009918|stage IIIA breast cancer
419011|NCT01009918|stage IIIB breast cancer
419012|NCT01009918|stage IIIC breast cancer
419013|NCT01009918|male breast cancer
419014|NCT01009879|rheumatoid arthritis
419015|NCT01009879|B lymphocytes
419016|NCT01009866|Malignant brain tumor
419017|NCT01009866|GBM
419018|NCT01009866|recurrent brain tumor
419019|NCT01009866|Supratentorial malignant brain tumor
419020|NCT01009866|astrocytomas
419021|NCT01009866|ependymomas
419022|NCT01009866|Residual, progressive, or recurrent supratentorial malignant brain tumor based on imaging studies with measurable
419023|NCT01009866|disease (>0.5cm).
419024|NCT01009840|Multiple Myeloma
419025|NCT01009840|Bone marrow transplant
419026|NCT01009840|Stem cell transplant
419027|NCT01009840|Busulfan
419028|NCT01009840|Bortezomib
419029|NCT01009827|Medication adherence
419030|NCT01009827|Substance use
419031|NCT01009827|Sexual risk behaviors
419032|NCT01009814|HIV, HIV attachment inhibitor, attachment inhibitor
419033|NCT01009801|adult primary hepatocellular carcinoma
419034|NCT01009801|recurrent adult primary liver cancer
419035|NCT01009801|localized resectable adult primary liver cancer
419036|NCT01009788|ABT-888
419037|NCT01009788|temozolomide
419038|NCT01009788|TMZ
419039|NCT01009775|Melanoma, Stage III
419040|NCT01009775|Melanoma, Stage IV
419041|NCT01009775|YM 155
419042|NCT01009775|Metastatic Melanoma
419043|NCT01009762|VACCINE
419044|NCT01009762|THERAPY
419045|NCT01009762|CELLULAR IMMUNITY
419046|NCT01009762|IMMUNITY
419047|NCT01009749|HAART
419048|NCT01009749|HIV
419049|NCT01009749|Adherence
419050|NCT01009736|stage I prostate cancer
419051|NCT01009736|stage IIB prostate cancer
419052|NCT01009736|stage IIA prostate cancer
419053|NCT01009736|stage III prostate cancer
419054|NCT01009736|stage IV prostate cancer
419055|NCT01009723|Preterm delivery
419056|NCT01009723|preterm labor
419057|NCT01009723|maternal-fetal care
419058|NCT01009723|maternal serum screening biomarkers
419059|NCT01009723|alphafetoprotein
419060|NCT01009723|AFP
419061|NCT01009723|human chorionic gonadotropin
419062|NCT01009723|hCG
419063|NCT01009723|unconjugated estriol
419064|NCT01009723|Inhibin A
419065|NCT01009723|pregnancy associated plasma protein
419066|NCT01009723|PAPP-A
419067|NCT01009723|maternal screening
419068|NCT01009684|Contraception
419069|NCT01009684|Estradiol valerate
419070|NCT01009671|knee osteoarthritis
419071|NCT01009658|Gastrointestinal motility
419072|NCT01009658|Gastroesophageal reflux
419073|NCT01009658|Gastric emptying
419074|NCT01009658|Sodium glutamate
419075|NCT01009658|Lower esophageal sphincter
419076|NCT01009645|education
419077|NCT01009645|vaccination
419078|NCT01009645|preventive service
419079|NCT01009645|Prevention & Control
419080|NCT01009619|Bronchiolitis Obliterans Syndrome
419081|NCT01009619|Acute allograft Rejection
419082|NCT01009619|Lymphocytic bronchiolitis
419083|NCT01009619|Respiratory infection
419084|NCT01009619|Survival
419085|NCT01009619|Mortality
419086|NCT01009619|Pulmonary function
419087|NCT01009619|FEV1
419088|NCT01009619|Broncho-alveolar lavage
419089|NCT01009619|Neutrophils
419090|NCT01009619|Interleukin
419091|NCT01009619|Culture
419092|NCT01009619|Azithromycin
419093|NCT01009606|Out-of-hospital
419094|NCT01009606|Emergency
419095|NCT01009606|Cardiac arrest
419096|NCT01009606|Post-traumatic stress disorder
419097|NCT01009593|Molecular Mechanisms of Pharmacological Action
419098|NCT01009593|Antineoplastic Agents
419099|NCT01009593|Growth Substances
419100|NCT01009593|Physiological Effects of Drugs
419101|NCT01009593|Enzyme Inhibitors
419102|NCT01009593|Angiogenesis Inhibitors
419103|NCT01009593|Inhibitors, Angiogenesis
419104|NCT01009593|Protein Kinase Inhibitors
419105|NCT01009593|Pharmacologic Actions
419106|NCT01009593|Growth Inhibitors
419107|NCT01009593|Angiogenesis Modulating Agents
419108|NCT01009593|Sorafenib
419109|NCT01009567|OHSS
419110|NCT01009554|Mouthwashes
419111|NCT01009541|pregabalin pharmacokinetics bioavailability bioequivalence
419112|NCT01009528|Quality of care
419113|NCT01009528|General Practice
419114|NCT01009528|Electronic Feedback System
419115|NCT01009515|metastatic
419116|NCT01009515|melanoma
419117|NCT01009515|skin cancer
419118|NCT01009515|paclitaxel
419119|NCT01009515|carboplatin
419120|NCT01009515|temozolomide
419121|NCT01009476|Dementia
419122|NCT01009476|Galantamine
419123|NCT01009476|Cholinesterase inhibitors
419124|NCT01009476|Nootropic agents
419125|NCT01009476|Alzheimer
419126|NCT01009476|Vascular dementia
419127|NCT01009476|Cognitive symptoms
419128|NCT01009476|Behavioural symptoms
419129|NCT01009476|Care giving times
419130|NCT01009463|COPD
419131|NCT01009463|Safety
419132|NCT01009463|FEV1
419133|NCT01009463|Efficacy
419134|NCT01009450|cirrhotic liver, gall bladder stone
419135|NCT01009437|HER2-negative breast cancer
419136|NCT01009437|HER2-positive breast cancer
419137|NCT01009437|estrogen receptor-positive breast cancer
419138|NCT01009437|triple-negative breast cancer
419139|NCT01009437|stage I breast cancer
419140|NCT01009437|stage II breast cancer
419141|NCT01009437|stage IIIA breast cancer
419142|NCT01009437|stage IIIB breast cancer
419143|NCT01009437|stage IIIC breast cancer
419144|NCT01009437|stage IV breast cancer
419145|NCT01009437|ductal breast carcinoma in situ
419146|NCT01009398|Anesthesia and Analgesia
419147|NCT01009398|Regional anesthesia
419148|NCT01009398|Thoracic Paravertebral block
419149|NCT01009398|Catheter location
419150|NCT01009385|cervical
419151|NCT01009385|epidural
419152|NCT01009385|epidural pressure
419153|NCT01009385|monitoring
419154|NCT01009372|surgeon's physiology
419155|NCT01009372|stress response
419156|NCT01009372|break scheme
419157|NCT01009359|Alzheimers disease
419158|NCT01009359|Diagnostic imaging
419159|NCT01009359|PET/CT diagnosis
419160|NCT01009359|PET tracer
419161|NCT01009333|urgency frequency
419162|NCT01009333|urinary urge incontinence
419163|NCT01009333|InterStim Therapy
419164|NCT01009320|Pacemaker
419165|NCT01009320|Magnets
419166|NCT01009320|Drape
419167|NCT01009320|Ferrite
419168|NCT01009320|Magnetic field
419169|NCT01009320|Pacemaker interference
419170|NCT01009307|adult anaplastic astrocytoma
419171|NCT01009307|adult diffuse astrocytoma
419172|NCT01009307|adult pilocytic astrocytoma
419173|NCT01009307|adult subependymal giant cell astrocytoma
419174|NCT01009307|adult anaplastic ependymoma
419175|NCT01009307|adult ependymoma
419176|NCT01009307|adult myxopapillary ependymoma
419177|NCT01009307|adult subependymoma
419178|NCT01009307|adult anaplastic oligodendroglioma
419179|NCT01009307|adult oligodendroglioma
419180|NCT01009307|adult brain stem glioma
419181|NCT01009307|adult giant cell glioblastoma
419182|NCT01009307|adult glioblastoma
419183|NCT01009307|recurrent adult brain tumor
419184|NCT01009307|adult gliosarcoma
419185|NCT01009307|adult mixed glioma
419186|NCT01009307|adult pineal gland astrocytoma
419187|NCT01009307|adult ependymoblastoma
419188|NCT01009307|adult medulloblastoma
419189|NCT01009307|adult supratentorial primitive neuroectodermal tumor (PNET)
419190|NCT01009307|adult pineoblastoma
419191|NCT01009307|adult pineocytoma
419192|NCT01009294|Duchenne muscular dystrophy
419193|NCT01009294|Becker muscular dystrophy
419194|NCT01009294|Nonsense mutation
419195|NCT01009294|Premature stop codon
419196|NCT01009294|DMD
419197|NCT01009294|BMD
419198|NCT01009294|Ataluren
419199|NCT01009294|PTC124
419200|NCT01009281|Crohn's Disease
419201|NCT01009281|Crohns
419202|NCT01009281|Bowel disease
419203|NCT01009281|digestive disorders
419204|NCT01009281|auto immune
419205|NCT01009281|diarrhea
419206|NCT01009281|Inflammatory Bowel Disease (IBD)
419207|NCT01009281|gastrointestinal diseases
419208|NCT01009281|digestive system diseases
419209|NCT01009281|Antibody
419210|NCT01009281|IL 17
419211|NCT01009281|anti IL-17
419212|NCT01009281|monoclonal antibody
419213|NCT01009281|Crohn's Disease (Chron's, CD)
419214|NCT01009255|Alzheimer's disease
419215|NCT01009255|placebo controlled
419216|NCT01009255|randomised
419217|NCT01009255|Histamine
419218|NCT01009255|H3 Antagonist
419219|NCT01009255|double blind
419220|NCT01009255|Cognition
419221|NCT01009242|CDP6038
419222|NCT01009216|Pharmacokinetics
419223|NCT01009216|Pharmacology
419224|NCT01009216|Drug Safety
419225|NCT01009216|Phase 1 Clinical Trials
419226|NCT01009203|squamous cell carcinoma
419227|NCT01009203|head
419228|NCT01009203|neck
419229|NCT01009203|aerodigestive
419230|NCT01009190|Dose finding PARPi Chemotherapy
419231|NCT01009177|Melanoma
419232|NCT01009177|Metastatic
419233|NCT01009177|DTIC
419234|NCT01009177|Bosentan
419235|NCT01009151|telemonitoring
419236|NCT01009151|internet
419237|NCT01009151|home monitoring system
419238|NCT01009151|heart failure
419239|NCT01009151|self management plan
419240|NCT01009151|web portal
419241|NCT01009138|Subthreshold Depression
419242|NCT01009138|Diabetes-related Distress
419243|NCT01009138|Minor Depression
419244|NCT01009138|Light affective Disorder
419245|NCT01009138|Subclinical depressive Symptoms
419246|NCT01009138|Diabetes mellitus
419247|NCT01009138|Late Complications
419248|NCT01009138|Markers of Inflammation
419249|NCT01009125|questionnaires
419250|NCT01009125|health care surveys/methods
419251|NCT01009125|motivation
419252|NCT01009125|living donors
419253|NCT01009125|living kidney donation
419254|NCT01009112|Sleep
419255|NCT01009112|Sleep Disorder
419256|NCT01009112|Veterans
419257|NCT01009112|Active Duty
419258|NCT01009112|OEF
419259|NCT01009112|OIF
419260|NCT01009112|PTSD
419261|NCT01009099|pulmonary disease
419262|NCT01009099|COPD
419263|NCT01009086|Arthritis, Psoriatic
419264|NCT01009086|Ustekinumab
419265|NCT01009086|CNTO 1275
419266|NCT01009086|Stelara
419267|NCT01009086|Psoriasis
419268|NCT01009060|H3 Antagonist
419269|NCT01009060|Schizophrenia
419270|NCT01009060|double blind
419271|NCT01009060|Histamine
419272|NCT01009060|randomised
419273|NCT01009060|placebo controlled
419274|NCT01009060|Cognition
419275|NCT01009047|Schizophrenia
419276|NCT01009047|Paliperidone
419277|NCT01009047|Aripiprazole
419278|NCT01009021|pain
419279|NCT01009021|retinal photocoagulation
419280|NCT01009021|potassium diclofenac
419281|NCT01009008|cancer
419282|NCT01009008|breast cancer
419283|NCT01009008|mastectomy
419284|NCT01009008|breast reconstruction
419285|NCT01009008|reconstruction
419286|NCT01009008|tissue expansion
419287|NCT01009008|two-stage breast reconstruction
419288|NCT01009008|tissue expander
419289|NCT01009008|AeroForm
419290|NCT01009008|AirXpander
419291|NCT01008995|psoriasis
419292|NCT01008995|asian patients
419293|NCT01008995|Chinese
419294|NCT01008995|ustekinumab
419295|NCT01008995|CNTO 1275
419296|NCT01008995|Stelara
419297|NCT01008982|Belimumab,Sjögren's Syndrome.
419298|NCT01008982|Have a diagnosis of primary SS according to the updated American European Consensus Group Criteria
419299|NCT01008969|Prostate
419300|NCT01008969|SPECT/CT
419301|NCT01008956|Influenza
419302|NCT01008956|H1N1
419303|NCT01008956|Pandemic
419304|NCT01008956|GSK Bio's influenza vaccine GSK2340274A
419305|NCT01008930|Peripheral Tumors
419306|NCT01008930|Arm
419307|NCT01008930|Leg
419308|NCT01008930|Head
419309|NCT01008930|Neck
419310|NCT01008930|HR PET Imaging System
419311|NCT01008930|High-Resolution PET
419312|NCT01008930|PET/CT
419313|NCT01008930|PEMFlex Solo II
419314|NCT01008930|positron emission tomography/computed tomography (PET/CT)
419315|NCT01008917|Hepatocellular carcinoma
419316|NCT01008917|HCC
419317|NCT01008917|Liver cancer
419318|NCT01008917|Hepatoma
419319|NCT01008904|cancer survivor
419320|NCT01008904|hot flashes
419321|NCT01008904|breast cancer
419322|NCT01008904|unspecified adult solid tumor, protocol specific
419323|NCT01008891|arthritis
419324|NCT01008891|ankle pain
419325|NCT01008891|foot pain
419326|NCT01008891|hindfoot fracture
419327|NCT01008891|ankle fracture
419328|NCT01008891|rheumatoid arthritis
419329|NCT01008891|arthrosis
419330|NCT01008891|Foot/Hindfoot Fusion
419331|NCT01008852|rheumatoid arthritis
419332|NCT01008852|seropositive
419333|NCT01008852|methotrexate
419334|NCT01008839|study sarcopenia, which muscle becomes weaker with age
419335|NCT01008826|sulforaphane
419336|NCT01008826|pharmacokinetics
419337|NCT01008813|HIV infection
419338|NCT01008813|adjuvanted and non-adjuvanted A(H1N1)v influenza vaccine
419339|NCT01008813|immunogenicity
419340|NCT01008813|safety
419341|NCT01008800|Autism Spectrum Disorder
419342|NCT01008800|language
419343|NCT01008800|social
419344|NCT01008800|toddlers
419345|NCT01008787|Cancer Prevention
419346|NCT01008787|Focus Group
419347|NCT01008787|Interview
419348|NCT01008787|Physical Activity
419349|NCT01008787|African American women
419350|NCT01008787|Exercise
419351|NCT01008787|Exercise habits
419352|NCT01008787|Health behavior
419353|NCT01008761|Pre-school child
419354|NCT01008761|Wheezy episode
419355|NCT01008748|Smoking
419356|NCT01008748|Latinos
419357|NCT01008748|Mexican American
419358|NCT01008748|Spanish-speaking smokers
419359|NCT01008748|Ecological momentary assessment
419360|NCT01008748|Nicotine patch
419361|NCT01008748|Smoking cessation counseling
419362|NCT01008748|Questionnaire
419363|NCT01008748|EMA
419364|NCT01008722|Atrial Fibrillation
419365|NCT01008722|Ablation
419366|NCT01008696|Reflux esophagitis
419367|NCT01008696|Rabeprazole
419368|NCT01008696|Lansoprazole
419369|NCT01008683|Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccinations
419370|NCT01008670|Cardiac resynchronization therapy
419371|NCT01008657|Radiofrequency-Extranodular-Multipolar ablation
419372|NCT01008657|Recurrence
419373|NCT01008644|carbon dioxide
419374|NCT01008644|ventilation
419375|NCT01008644|gender
419376|NCT01008644|osmolality
419377|NCT01008644|menstruation cycle
419378|NCT01008631|renal failure
419379|NCT01008631|sodium Thiosulfate
419380|NCT01008631|pharmakokinetic
419381|NCT01008618|Chronic pain
419382|NCT01008618|Osteoarthritis
419383|NCT01008618|Low back pain
419384|NCT01008618|Fentanyl
419385|NCT01008618|JNS020QD
419386|NCT01008618|Patch, transdermal
419387|NCT01008618|Opioid analgesics
419388|NCT01008605|Erectile Dysfunction
419389|NCT01008592|dermatographism, levocetirizine (Xyzal)
419390|NCT01008592|chronic idiopathic urticaria, dermatographism
419391|NCT01008579|Patient Reported Outcome Measures
419392|NCT01008579|falls
419393|NCT01008579|older adults
419394|NCT01008553|Postherpetic Neuralgia
419395|NCT01008553|Complex Regional Pain Syndromes (CRPS)
419396|NCT01008553|Postoperative Pain
419397|NCT01008553|Fentanyl
419398|NCT01008553|Patch, transdermal
419399|NCT01008553|Opioid analgesics
419400|NCT01008540|cytomegalovirus
419401|NCT01008540|resistance
419402|NCT01008540|transplantation
419403|NCT01008540|Patient coming to an French transplantation center for solid organ or bone marrow transplant, with information and signed consent
419404|NCT01008527|skin
419405|NCT01008527|cutaneous
419406|NCT01008527|immunotherapy
419407|NCT01008527|immunology
419408|NCT01008527|dose escalation
419409|NCT01008514|ductal breast carcinoma in situ
419410|NCT01008514|stage IA breast cancer
419411|NCT01008514|stage IB breast cancer
419412|NCT01008514|stage II breast cancer
419413|NCT01008501|hydatidiform moles
419414|NCT01008501|complete hydatidiform moles
419415|NCT01008501|partial hydatidiform moles
419416|NCT01008501|Molar pregnancy
419417|NCT01008501|NLRP7
419418|NCT01008501|pregnancy wastage
419419|NCT01008501|imprinting
419420|NCT01008501|sporadic hydatidiform moles
419421|NCT01008501|recurrent hydatidiform moles
419422|NCT01008488|colonic diverticulitis
419423|NCT01008488|diverticular disease
419424|NCT01008488|antibiotic therapy
419425|NCT01008475|EMD 525797
419426|NCT01008475|Cetuximab
419427|NCT01008475|Irinotecan
419428|NCT01008475|metastatic colorectal cancer
419429|NCT01008449|Staples
419430|NCT01008449|Sutures
419431|NCT01008449|Cesarean Delivery
419432|NCT01008449|Wound
419433|NCT01008449|Skin Closure
419434|NCT01008449|Wound infection
419435|NCT01008449|Wound disruption
419436|NCT01008436|Ability of topical drug to reduce acute and overall bleeding as well as blood transfusions
419437|NCT01008423|Proctitis
419438|NCT01008423|Proctosigmoiditis
419439|NCT01008423|Ulcerative
419440|NCT01008423|Salix
419441|NCT01008423|Budesonide foam
419442|NCT01008423|Budesonide
419443|NCT01008423|Rectal
419444|NCT01008423|Gastrointestinal
419445|NCT01008423|Colitis
419446|NCT01008423|UC
419447|NCT01008423|UP
419448|NCT01008423|UPS
419449|NCT01008423|Additional relevant MeSH terms:
419450|NCT01008423|Proctocolitis
419451|NCT01008423|Ulcer
419452|NCT01008423|Colitis, Ulcerative
419453|NCT01008423|Gastroenteritis
419454|NCT01008423|Gastrointestinal Diseases
419455|NCT01008423|Digestive System Diseases
419456|NCT01008423|Rectal Diseases
419457|NCT01008423|Intestinal Diseases
419458|NCT01008423|Colonic Diseases
419459|NCT01008423|Sigmoid Diseases
419460|NCT01008423|Pathologic Processes
419461|NCT01008423|Inflammatory Bowel Diseases
419462|NCT01008423|Bronchodilator Agents
419463|NCT01008423|Autonomic Agents
419464|NCT01008423|Peripheral Nervous System Agents
419465|NCT01008423|Physiological Effects of Drugs
419466|NCT01008423|Pharmacologic Actions
419467|NCT01008423|Anti-Asthmatic Agents
419468|NCT01008423|Respiratory System Agents
419469|NCT01008423|Therapeutic Uses
419470|NCT01008423|Glucocorticoids
419471|NCT01008423|Hormones
419472|NCT01008423|Hormones, Hormone Substitutes, and Hormone Antagonists
419473|NCT01008423|Anti-Inflammatory Agents
419474|NCT01008410|Proctitis
419475|NCT01008410|Proctosigmoiditis
419476|NCT01008410|Ulcerative
419477|NCT01008410|Salix
419478|NCT01008410|Budesonide foam
419479|NCT01008410|Budesonide
419480|NCT01008410|Rectal
419481|NCT01008410|Gastrointestinal
419482|NCT01008410|Colitis
419483|NCT01008410|UC
419484|NCT01008410|UP
419485|NCT01008410|UPS
419486|NCT01008410|Additional relevant MeSH terms:
419487|NCT01008410|Proctocolitis
419488|NCT01008410|Ulcer
419489|NCT01008410|Colitis, Ulcerative
419490|NCT01008410|Gastroenteritis
419491|NCT01008410|Gastrointestinal Diseases
419492|NCT01008410|Digestive System Diseases
419493|NCT01008410|Rectal Diseases
419494|NCT01008410|Intestinal Diseases
419495|NCT01008410|Colonic Diseases
419496|NCT01008410|Sigmoid Diseases
419497|NCT01008410|Pathologic Processes
419498|NCT01008410|Inflammatory Bowel Diseases
419499|NCT01008410|Bronchodilator Agents
419500|NCT01008410|Autonomic Agents
419501|NCT01008410|Peripheral Nervous System Agents
419502|NCT01008410|Physiological Effects of Drugs
419503|NCT01008410|Pharmacologic Actions
419504|NCT01008410|Anti-Asthmatic Agents
419505|NCT01008410|Respiratory System Agents
419506|NCT01008410|Therapeutic Uses
419507|NCT01008410|Glucocorticoids
419508|NCT01008410|Hormones
419509|NCT01008410|Hormones, Hormone Substitutes, and Hormone Antagonists
419510|NCT01008410|Anti-Inflammatory Agents
419511|NCT01008397|Rhinitis, Allergic, Seasonal
419512|NCT01008371|Obesity
419513|NCT01008371|Cholecystokinin
419514|NCT01008371|Oxytocin
419515|NCT01008371|Satiety
419516|NCT01008371|Gastric emptying
419517|NCT01008371|Anxiety
419518|NCT01008371|Depression
419519|NCT01008371|Panic Disorder
419520|NCT01008332|House Dust Mite Allergy
419521|NCT01008332|Immunotherapy
419522|NCT01008332|Rhinoconjunctivitis
419523|NCT01008332|Toleromune HDM
419524|NCT01008319|Anovulation
419525|NCT01008319|Ovulation induction
419526|NCT01008306|Cardiorespiratory fitness
419527|NCT01008306|physical activity
419528|NCT01008306|hypertension
419529|NCT01008306|overweight and obesity
419530|NCT01008306|metabolic syndrome
419531|NCT01008306|Body composition
419532|NCT01008241|Hospice
419533|NCT01008241|End of Life
419534|NCT01008241|Knowledge
419535|NCT01008241|Attitudes
419536|NCT01008241|Opinions
419537|NCT01008241|Advanced Care Planning
419538|NCT01008241|Death and Dying
419539|NCT01008241|Communication
419540|NCT01008241|Knowledge and Attitudes of South Florida Residents on Hospice Care
419541|NCT01008228|spontaneous
419542|NCT01008228|primary
419543|NCT01008228|first episode
419544|NCT01008215|INR Control
419545|NCT01008215|Warfarin dosing
419546|NCT01008215|Family physicians
419547|NCT01008215|Cluster randomization
419548|NCT01008176|Hypertension
419549|NCT01008176|Sleep
419550|NCT01008176|Blood Pressure
419551|NCT01008176|Inflammatory Markers
419552|NCT01008163|diabetes
419553|NCT01008150|breast cancer
419554|NCT01008150|neoadjuvant
419555|NCT01008150|neratinib
419556|NCT01008150|paclitaxel
419557|NCT01008150|trastuzumab
419558|NCT01008150|doxorubicin
419559|NCT01008150|cyclophosphamide
419560|NCT01008124|Benign Paroxysmal Positional Vertigo
419561|NCT01008124|BPPV
419562|NCT01008124|PC
419563|NCT01008124|BPPN
419564|NCT01008124|Vertigo
419565|NCT01008111|regeneration
419566|NCT01008111|tissue survival
419567|NCT01008111|biological processes
419568|NCT01008111|connective tissue
419569|NCT01008111|tissue
419570|NCT01008098|Posttraumatic Stress Disorder
419571|NCT01008098|Escitalopram
419572|NCT01008098|Magnetic Resonance Imaging
419573|NCT01008098|BDNF
419574|NCT01008085|STEMI
419575|NCT01008085|self-expandable
419576|NCT01008085|balloon-expandable
419577|NCT01008046|Polycystic ovary syndrome
419578|NCT01008046|clomiphene resistance
419579|NCT01008046|metformin
419580|NCT01008046|N-acetyl cysteine
419581|NCT01008020|tea catechin extracts
419582|NCT01008020|influenza infection
419583|NCT01008020|prophylaxis
419584|NCT01008020|supplements
419585|NCT01008020|adults over 20 years old
419586|NCT01008020|both men and women
419587|NCT01008007|Viusid
419588|NCT01008007|Dietary supplements
419589|NCT01008007|Acute fever
419590|NCT01008007|Viral etiology
419591|NCT01007994|Nocturnal hypertension
419592|NCT01007994|Pediatric
419593|NCT01007994|Renal Transplant
419594|NCT01007994|Pulse Wave Velocity
419595|NCT01007994|Echocardiogram
419596|NCT01007994|Pediatric Renal Transplant Recipient
419597|NCT01007968|solid tumors
419598|NCT01007968|hepatic function
419599|NCT01007968|advanced
419600|NCT01007968|panobinostat
419601|NCT01007942|Metastatic breast cancer
419602|NCT01007942|locally advanced breast cancer
419603|NCT01007942|HER2/neu positive breast cancer
419604|NCT01007942|HER2/neu over-expressing
419605|NCT01007942|progressive-free survival (PFS)
419606|NCT01007942|over survival (OS)
419607|NCT01007942|bolero
419608|NCT01007942|bolero 3
419609|NCT01007942|Breast cancer
419610|NCT01007942|everolimus
419611|NCT01007942|HER+
419612|NCT01007942|vinorelbine
419613|NCT01007942|herceptin
419614|NCT01007942|trastuzumab
419615|NCT01007929|ADME
419616|NCT01007929|safety
419617|NCT01007929|oral solution
419618|NCT01007890|ChemoFX
419619|NCT01007890|Operable
419620|NCT01007890|Breast
419621|NCT01007890|Cancer
419622|NCT01007890|Measurable
419623|NCT01007890|Disease
419624|NCT01007877|sleepiness
419625|NCT01007877|driving
419626|NCT01007864|Parkinson
419627|NCT01007864|piribedil
419628|NCT01007864|vigilance
419629|NCT01007864|dopamine agonist
419630|NCT01007864|cognition
419631|NCT01007851|GnRH agonist
419632|NCT01007851|GnRH antagonist
419633|NCT01007851|IVF
419634|NCT01007851|ICSI
419635|NCT01007851|assisted reproduction
419636|NCT01007851|luteal phase
419637|NCT01007838|Progressive Resistance Training/Exercise
419638|NCT01007838|Muscle wasting
419639|NCT01007838|Chronic Kidney Disease
419640|NCT01007786|Pediatric Hydrocephalus
419641|NCT01007786|Ultrasound Guided Surgery
419642|NCT01007773|Dexmedetomidine
419643|NCT01007773|Intracranial Pressure
419644|NCT01007773|Traumatic Brain Injury
419645|NCT01007760|Tobacco smoke
419646|NCT01007760|Oxidative stress
419647|NCT01007760|Endothelial Function
419648|NCT01007760|Atherosclerosis
419649|NCT01007760|Arterial Stiffness
419650|NCT01007760|Microvascular Function
419651|NCT01007747|Geranium oil
419652|NCT01007747|Neuropathy
419653|NCT01007734|Quality of life
419654|NCT01007734|COPD patients
419655|NCT01007734|Evaluation According to Gender the Determining Independent Factors of Quality of Life Related to Respiratory Status of Patient With Moderate to Severe COPD
419656|NCT01007695|breast cancer
419657|NCT01007682|intrusive memories
419658|NCT01007669|Physical activity
419659|NCT01007656|healthy adult subjects
419660|NCT01007656|safety evaluation
419661|NCT01007656|GD Antrodia camphorata
419662|NCT01007643|anterior knee pain
419663|NCT01007643|adolescents
419664|NCT01007643|female
419665|NCT01007643|interactive video games
419666|NCT01007643|patellofemoral syndrome
419667|NCT01007643|treatment
419668|NCT01007643|compliance
419669|NCT01007643|home exercises
419670|NCT01007630|Parkinson's
419671|NCT01007630|Parkinsons
419672|NCT01007630|Parkinson
419673|NCT01007630|Parkinson's Disease
419674|NCT01007630|PD
419675|NCT01007630|Rasagiline
419676|NCT01007630|Azilect
419677|NCT01007630|Olfactory
419678|NCT01007630|Sense of Smell
419679|NCT01007630|UPSIT
419680|NCT01007617|Children
419681|NCT01007617|Cancer
419682|NCT01007617|Mucositis
419683|NCT01007617|Laser
419684|NCT01007617|Prevention
419685|NCT01007617|Chemotherapy
419686|NCT01007617|Children with malignancies receiving chemotherapy and/or radiotherapy inducing severe mucositis
419687|NCT01007604|claudication
419688|NCT01007604|pneumatic compression device
419689|NCT01007578|Paclitaxel
419690|NCT01007578|Paclitaxel-coated balloon catheters
419691|NCT01007578|Peripheral arterial occlusive disease (PAOD)
419692|NCT01007578|Plasma levels
419693|NCT01007578|Femoral artery
419694|NCT01007578|Popliteal artery
419695|NCT01007578|Peripheral arterial disease (PAD) including stenotic or occluded femoro-popliteal arteries due to atherosclerosis
419696|NCT01007565|periarticular injection
419697|NCT01007552|Biliary Duct Cancer
419698|NCT01007552|Cancer of the Gallbladder
419699|NCT01007552|Adenocarcinoma of the Gall Bladder
419700|NCT01007552|Adenocarcinoma of the Biliary Ducts
419701|NCT01007552|Cholangiocarcinoma
419702|NCT01007552|Extrahepatic cholangiocarcinoma
419703|NCT01007526|Extranodal Lymphoma
419704|NCT01007526|Natural killer cell
419705|NCT01007526|T cell
419706|NCT01007526|Radiotherapy
419707|NCT01007526|Chemotherapy
419708|NCT01007513|Prematurity
419709|NCT01007513|Inflammation
419710|NCT01007513|Transvaginal ultrasound
419711|NCT01007513|Vaginal secretion
419712|NCT01007513|Inflammatory process
419713|NCT01007513|Neonatal morbidity
419714|NCT01007500|Postoperative nausea and vomiting after video-assisted thoracoscopic surgery
419715|NCT01007487|Plastic wound protector
419716|NCT01007487|Plastic wound retractor
419717|NCT01007487|Bacterial translocation
419718|NCT01007487|Surgical site infection
419719|NCT01007487|Abdominal surgery
419720|NCT01007487|Wound infection
419721|NCT01007461|Acute Myocardial Infarction (AMI)
419722|NCT01007461|STEMI
419723|NCT01007461|Acute ST-Segment Elevation Myocardial Infraction (STEMI)
419724|NCT01007448|CTCL
419725|NCT01007448|bexarotene
419726|NCT01007448|Targretin
419727|NCT01007448|Refractory Cutaneous T-cell Lymphoma
419728|NCT01007448|cutaneous T-cell Lymphoma
419729|NCT01007448|MF
419730|NCT01007448|Mycoses fungoides
419731|NCT01007422|unspecified adult solid tumor, protocol specific
419732|NCT01007422|pain
419733|NCT01007409|To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers
419734|NCT01007396|Interferon-gamma release assay
419735|NCT01007383|Safety and tolerability of LEO 27847
419736|NCT01007370|tracheal intubation
419737|NCT01007370|supraglottic airway devices
419738|NCT01007344|flaxseed
419739|NCT01007344|hypercholesterolemia
419740|NCT01007344|children
419741|NCT01007331|Infants
419742|NCT01007331|Atopic Dermatitis
419743|NCT01007331|SCORAD
419744|NCT01007331|IgE
419745|NCT01007331|Eosinophil Cation Protein
419746|NCT01007331|Calprotectin
419747|NCT01007331|Intestinal microflora
419748|NCT01007292|Non-Hodgkin's Lymphoma
419749|NCT01007292|relapsed
419750|NCT01007292|CD20-Positive
419751|NCT01007292|YM155
419752|NCT01007279|Percutaneous angioplasty
419753|NCT01007279|Myocardial Infarction
419754|NCT01007266|Type 2 Diabetes Mellitus
419755|NCT01007266|Adolescents
419756|NCT01007266|Pediatric
419757|NCT01007266|Patient Partner
419758|NCT01007266|Buddy
419759|NCT01007266|Obesity
419760|NCT01007266|Type 2 Diabetes
419761|NCT01007240|head and neck carcinoma
419762|NCT01007240|obturators
419763|NCT01007240|maxillectomy
419764|NCT01007240|soft liner
419765|NCT01007240|nano particles
419766|NCT01007240|antibacterial properties
419767|NCT01007240|patients post maxillectomy
419768|NCT01007214|Prostate cancer
419769|NCT01007214|Prostatectomy
419770|NCT01007201|Influenza
419771|NCT01007201|H1N1
419772|NCT01007201|vaccine
419773|NCT01007201|Immunogenicity
419774|NCT01007188|almond
419775|NCT01007188|nuts
419776|NCT01007188|energy value
419777|NCT01007188|cardiovascular disease
419778|NCT01007188|phytonutrient
419779|NCT01007188|gene expression
419780|NCT01007188|energy value of almonds
419781|NCT01007188|energy
419782|NCT01007175|TNF inhibitor
419783|NCT01007175|Multiple ascending dose study
419784|NCT01007149|Severe asthma,
419785|NCT01007149|non-atopic,
419786|NCT01007149|omalizumab
419787|NCT01007136|tDCS
419788|NCT01007136|stroke
419789|NCT01007136|functional MRI
419790|NCT01007136|TMS
419791|NCT01007123|Chronic idiopathic constipation
419792|NCT01007123|A3309
419793|NCT01007110|DHA
419794|NCT01007097|Diabetes Mellitus, Non Insulin Dependent
419795|NCT01007097|Diabetes Mellitus, Type II
419796|NCT01007097|Type 2 Diabetes Mellitus
419797|NCT01007097|Drug Therapy
419798|NCT01007084|pain
419799|NCT01007084|trauma
419800|NCT01007084|propranolol
419801|NCT01007058|Urinary Bladder
419802|NCT01007058|Non-muscle-invasive transitional cell carcinoma
419803|NCT01007058|Intact bladder
419804|NCT01007058|Intravesical Bladder Cancer Therapy
419805|NCT01007058|Tumor Recurrence
419806|NCT01007058|Surrogate markers of response
419807|NCT01007058|BCG
419808|NCT01007058|Bacillus Calmette Guérin
419809|NCT01007058|Interferon-alfa-2b
419810|NCT01007058|IFN-alfa-2b
419811|NCT01007058|Interferon
419812|NCT01007058|Fluorescence in situ hybridization
419813|NCT01007058|FISH
419814|NCT01007045|deep vein thrombosis
419815|NCT01007045|venous thromboembolic disorders
419816|NCT01007045|diagnostic ultrasound
419817|NCT01007032|anti-IGF-IR
419818|NCT01007032|monoclonal
419819|NCT01007032|solid tumor
419820|NCT01007032|insulin-like growth factor
419821|NCT01007019|Safety, tolerability and PK/PD
419822|NCT01007006|Telepharmacy Robotic Medicine Delivery Unit
419823|NCT01007006|Brain Injuries
419824|NCT01007006|Stress Disorders
419825|NCT01007006|Combat disorders
419826|NCT01007006|Polytrauma
419827|NCT01007006|Adherence
419828|NCT01006967|balance
419829|NCT01006967|gait
419830|NCT01006967|physical therapy
419831|NCT01006967|ActiveStep
419832|NCT01006954|Poor responder
419833|NCT01006954|Flare up
419834|NCT01006954|Micro dose GnRH agonist flare up
419835|NCT01006954|IVF/ICSI
419836|NCT01006941|Multiple sclerosis
419837|NCT01006941|safety
419838|NCT01006941|MRI
419839|NCT01006941|immunological
419840|NCT01006941|Helminths
419841|NCT01006941|Trichuris suis
419842|NCT01006928|Subjective health feeling
419843|NCT01006928|NICU
419844|NCT01006928|team support
419845|NCT01006915|Diabetic sensorimotor polyneuropathy
419846|NCT01006902|Elderly
419847|NCT01006902|Function
419848|NCT01006902|Oncologic therapy
419849|NCT01006902|Functional change with chemotherapy
419850|NCT01006876|coumadin
419851|NCT01006876|peri-procedural thromboembolism
419852|NCT01006876|RFCA
419853|NCT01006876|high risk atrial fibrillation
419854|NCT01006863|Ephedrine
419855|NCT01006863|phenylephrine
419856|NCT01006863|hypotension
419857|NCT01006863|propofol
419858|NCT01006863|anesthesia
419859|NCT01006863|cardiac valve surgery
419860|NCT01006850|Acute pain hydromorphone emergency department
419861|NCT01006837|trauma patients
419862|NCT01006837|severe injury
419863|NCT01006837|ISS ≥9
419864|NCT01006824|Capsule endoscopy
419865|NCT01006824|gastrointestinal hemorrhage
419866|NCT01006811|West syndrome
419867|NCT01006811|Hypsarrhythmia
419868|NCT01006798|Virus Diseases
419869|NCT01006798|Respiratory Tract Diseases
419870|NCT01006798|Vaccine
419871|NCT01006785|Breast Cancer
419872|NCT01006785|DLBS 1425
419873|NCT01006785|Cancer
419874|NCT01006785|Advanced/Metastatic (Stage IIIB/IV) Breast Cancer
419875|NCT01006772|Stroke
419876|NCT01006772|Ankle Foot Orthosis
419877|NCT01006772|Walking Speed
419878|NCT01006772|Gait
419879|NCT01006772|Rehabilitation
419880|NCT01006772|Hemiplegia
419881|NCT01006759|Leprosy
419882|NCT01006759|Disability Evaluation
419883|NCT01006759|Quality of Life
419884|NCT01006759|Sensation
419885|NCT01006746|Remote monitoring
419886|NCT01006746|Defibrillators
419887|NCT01006746|Survey
419888|NCT01006746|Indication for ICD (primary and secondary prevention)
419889|NCT01006733|pharmacogenetics
419890|NCT01006733|arthroplasty
419891|NCT01006733|VKORC1
419892|NCT01006733|thromboembolism
419893|NCT01006733|warfarin
419894|NCT01006720|Residual neuromuscular block
419895|NCT01006720|post-operative residual curarization
419896|NCT01006720|PORC
419897|NCT01006720|sugammadex
419898|NCT01006720|neostigmine
419899|NCT01006694|depression
419900|NCT01006694|collaborative care
419901|NCT01006694|Vietnam
419902|NCT01006694|behavioral activation
419903|NCT01006681|rheumatoid
419904|NCT01006681|SLE
419905|NCT01006681|Psoriatic arthritis
419906|NCT01006681|Ankylosing
419907|NCT01006681|Influenza H1N1
419908|NCT01006681|Vaccine
419909|NCT01006681|Vaccination against H1N1 in rheumatic diseases
419910|NCT01006668|Neonates
419911|NCT01006668|Intensive care
419912|NCT01006668|Endotracheal intubation
419913|NCT01006668|Neonates in intensive care
419914|NCT01006655|asthma
419915|NCT01006655|preschool children
419916|NCT01006655|bronchial hyperresponsiveness
419917|NCT01006655|beclometasone dipropionate - HFA
419918|NCT01006655|Qvar
419919|NCT01006655|Adenosine Challenge test
419920|NCT01006629|Efficacy of palivizumab
419921|NCT01006629|Respiratory syncytial virus (RSV) infection
419922|NCT01006629|Prevention of severe RSV infection
419923|NCT01006629|Preterm infants
419924|NCT01006629|Infants with bronchopulmonary dysplasia
419925|NCT01006629|Infants with hemodynamically significant congenital heart disease
419926|NCT01006603|Type 2 Diabetes Mellitus
419927|NCT01006603|elderly patients
419928|NCT01006603|saxagliptin
419929|NCT01006603|randomised
419930|NCT01006603|double-blind
419931|NCT01006590|Type 2 Diabetes Mellitus
419932|NCT01006590|Saxagliptin
419933|NCT01006590|Randomised
419934|NCT01006590|Double-blind
419935|NCT01006577|rectal cancer
419936|NCT01006577|side-to-end anastomosis
419937|NCT01006577|colon J pouch
419938|NCT01006577|fecal incontinence
419939|NCT01006577|anorectal function
419940|NCT01006577|Are there differences between side-to-end anastomosis and colon J pouch in
419941|NCT01006577|bowel function (fecal incontinence, frequency of bowel movements, rectal urgency, incomplete evacuation)
419942|NCT01006577|quality of life
419943|NCT01006577|postoperative complications
419944|NCT01006577|operation time/ institutional costs
419945|NCT01006564|Magnetic Resonance Imaging
419946|NCT01006564|Prostate Cancer
419947|NCT01006564|Magnetic Resonance Spectroscopy
419948|NCT01006564|Radiotherapy planning
419949|NCT01006551|Schizophrenia Spectrum Disorders
419950|NCT01006538|Wet Age-related Macular Degeneration
419951|NCT01006538|Predominantly classic
419952|NCT01006538|Minimally classic
419953|NCT01006538|Occult with no classic
419954|NCT01006538|Retinal Angiomatous Proliferation (RAP) lesions
419955|NCT01006499|neonatal sepsis
419956|NCT01006499|pentoxyfilline
419957|NCT01006499|pentaglobin
419958|NCT01006499|biomarker
419959|NCT01006499|To reduce mortality in neonatal sepsis
419960|NCT01006486|Oral anticoagulants
419961|NCT01006486|Warfarin
419962|NCT01006486|Anticoagulation clinic
419963|NCT01006486|Thrombosis
419964|NCT01006486|Hemorrhage
419965|NCT01006473|Chagas Disease
419966|NCT01006473|Chagas Cardiomyopathy
419967|NCT01006473|Exercise Movement Techniques
419968|NCT01006460|Quality of life and subjective well-being in middle aged women
419969|NCT01006447|tai chi
419970|NCT01006447|exercise
419971|NCT01006447|older adults
419972|NCT01006447|exercise persistence
419973|NCT01006434|Stroke
419974|NCT01006434|Thrombolysis
419975|NCT01006421|phototherapy
419976|NCT01006421|Gingko biloba
419977|NCT01006421|repigmentation
419978|NCT01006408|Neuropathy
419979|NCT01006395|Prostate Cancer
419980|NCT01006395|Androgen deprivation
419981|NCT01006395|Bone Health
419982|NCT01006395|Insulin resistance
419983|NCT01006395|Men with nonmetastatic prostate cancer receiving androgen deprivation
419984|NCT01006369|stage IV colon cancer
419985|NCT01006369|stage IV rectal cancer
419986|NCT01006369|recurrent colon cancer
419987|NCT01006369|recurrent rectal cancer
419988|NCT01006356|Hydromorphone hydrochloride Oral Osmotic System
419989|NCT01006356|Jurnista
419990|NCT01006317|Maternal health services
419991|NCT01006317|utilization
419992|NCT01006317|education
419993|NCT01006317|randomized controlled trial
419994|NCT01006317|cost
419995|NCT01006317|clinical skills
419996|NCT01006317|rural China
419997|NCT01006304|JNJ-39439335
419998|NCT01006304|Placebo
419999|NCT01006304|Pain
420000|NCT01006304|Pain Measurements
420001|NCT01006304|Adults
420002|NCT01006304|Men
420003|NCT01006278|biomarker
420004|NCT01006278|knee arthroscopy
420005|NCT01006278|pain
420006|NCT01006252|metastatic
420007|NCT01006252|second-line
420008|NCT01006239|Cancer
420009|NCT01006213|Motivational Intervention
420010|NCT01006200|granulation tissue
420011|NCT01006200|benign
420012|NCT01006200|tracheal stenosis
420013|NCT01006200|ultraflex
420014|NCT01006200|COPD
420015|NCT01006187|Analgesics
420016|NCT01006187|Influenza
420017|NCT01006187|Vapocoolant
420018|NCT01006187|vaccination
420019|NCT01006187|pain
420020|NCT01006148|Metopic Craniosynostosis
420021|NCT01006122|Randomized
420022|NCT01006122|double-blind
420023|NCT01006122|placebo-controlled
420024|NCT01006122|crossover study of PF-03654746 in Excessive Daytime Sleepiness associated with Narcolepsy
420025|NCT01006109|MEG
420026|NCT01006109|Repetitive TMS (rTMS)
420027|NCT01006109|Decision-Making
420028|NCT01006109|Healthy Volunteers
420029|NCT01006109|HV
420030|NCT01006109|Healthy Volunteer
420031|NCT01006096|Psoriasis
420032|NCT01006096|double-blind
420033|NCT01006096|randomized
420034|NCT01006096|placebo-controlled
420035|NCT01006096|erlotinib
420036|NCT01006096|efficacy
420037|NCT01006083|Aspirin
420038|NCT01006083|Plavix
420039|NCT01006083|antiplatelet therapy
420040|NCT01006083|Hemorrhage
420041|NCT01006083|ischemic events
420042|NCT01006070|multiple myeloma
420043|NCT01006070|spinal disease
420044|NCT01006044|Glioblastoma multiforme, vaccine, dendritic cells, glioma
420045|NCT01006031|Liver cirrhosis
420046|NCT01006031|Hepatitis C virus
420047|NCT01006031|HIV infection
420048|NCT01006031|Pegylated interferon alfa-2a
420049|NCT01006031|Ribavirin
420050|NCT01006031|Treatment experienced
420051|NCT01006018|Prediabetic State
420052|NCT01006005|HIV
420053|NCT01006005|Treatment experienced
420054|NCT01005992|Scars secondary to injuries to tissues caused by contact with physical (heat, electricity) o chemical agent.
420055|NCT01005979|Leukemia, Lymphocytic, Chronic, B-Cell
420056|NCT01005979|Chronic Lymphocytic Leukemia
420057|NCT01005979|Lymphoma, Small Lymphocytic
420058|NCT01005979|Lymphoma
420059|NCT01005979|Leukemia
420060|NCT01005966|remineralization
420061|NCT01005966|enamel
420062|NCT01005966|in situ
420063|NCT01005966|fluoride
420064|NCT01005966|caries
420065|NCT01005953|Autism
420066|NCT01005953|Behavioral Observations
420067|NCT01005953|Electronic diaries
420068|NCT01005953|Professionals treating children 3-10 with lower functioning autism
420069|NCT01005940|Sleep Apnea Syndromes
420070|NCT01005940|Insulin Resistance
420071|NCT01005940|Mandibular advancement device
420072|NCT01005927|Calcium
420073|NCT01005927|Bone and Bones
420074|NCT01005927|Girls
420075|NCT01005927|Bone Mineralization
420076|NCT01005927|Fiber
420077|NCT01005927|Fructooligosaccharide
420078|NCT01005927|Female
420079|NCT01005927|Healthy
420080|NCT01005927|Adolescents
420081|NCT01005914|adults
420201|NCT01005407|Prevention & Control
420082|NCT01005914|Philadelphia chromosome precursor ALL,
420083|NCT01005914|T-cell ALL
420084|NCT01005914|untreated ALL
420085|NCT01005901|COPD
420086|NCT01005901|NVA
420087|NCT01005901|FEV1
420088|NCT01005888|Hereditary angioedema
420089|NCT01005888|HAE
420090|NCT01005888|C1 esterase inhibitor (human)
420091|NCT01005888|C1INH-nf
420092|NCT01005875|Hepatocellular carcinoma
420093|NCT01005875|HCC
420094|NCT01005875|Liver Cancer
420095|NCT01005875|adult primary hepatocellular carcinoma
420096|NCT01005862|Alzheimer's disease antibody leucine ABeta
420097|NCT01005849|Probiotics
420098|NCT01005849|Traveler's diarrhea
420099|NCT01005849|Prevention
420100|NCT01005836|Cognitive behavioral therapy
420101|NCT01005836|Anxiety treatment
420102|NCT01005836|Depression treatment
420103|NCT01005836|Child treatment
420104|NCT01005836|Usual care
420105|NCT01005797|Renal Cancer
420106|NCT01005797|Non Small Cell Lung Cancer (NSCLC)
420107|NCT01005797|Solid Tumor
420108|NCT01005797|Soft tissue sarcoma
420109|NCT01005797|Sorafenib
420110|NCT01005797|Panobinostat
420111|NCT01005784|GnRH antagonists
420112|NCT01005771|Secondarily infected traumatic lesions
420113|NCT01005758|untreated adult acute lymphoblastic leukemia
420114|NCT01005758|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
420115|NCT01005758|L1 adult acute lymphoblastic leukemia
420116|NCT01005758|L2 adult acute lymphoblastic leukemia
420117|NCT01005758|T-cell adult acute lymphoblastic leukemia
420118|NCT01005745|skin
420119|NCT01005745|adoptive cell therapy
420120|NCT01005745|tumor-infiltrating lymphocytes (TIL)
420121|NCT01005745|lymphodepletion
420122|NCT01005732|hypertrophic
420123|NCT01005732|scar
420124|NCT01005732|burn
420125|NCT01005732|cicatrix
420126|NCT01005732|pressure
420127|NCT01005732|garment
420128|NCT01005693|unspecified adult solid tumor, protocol specific
420129|NCT01005667|Nulliparous women in spontaneous labor
420130|NCT01005654|Gene Expression
420131|NCT01005654|Epigenetics
420132|NCT01005654|Tissues Histological Evaluations
420133|NCT01005654|Establishment of Tumor Cell Lines
420134|NCT01005654|Metabolite and Protein Expression
420135|NCT01005654|Adrenal Cancer
420136|NCT01005654|Endocrine Tumor
420137|NCT01005654|Thyroid Cancer
420138|NCT01005641|advanced breast cancer
420139|NCT01005641|hormone-responsive
420140|NCT01005641|metastatic breast cancer
420141|NCT01005628|Bortezomib postmarketing surveillance
420142|NCT01005628|Korea bortezomib PMS
420143|NCT01005602|Digoxin
420144|NCT01005602|Pharmacokinetics
420145|NCT01005602|Dosing
420146|NCT01005602|Heart Failure
420147|NCT01005589|Neonatal sepsis
420148|NCT01005589|Necrotizing enterocolitis
420149|NCT01005589|CD64 antigen
420150|NCT01005589|Receptors, IgG
420151|NCT01005576|Thalassemia
420152|NCT01005576|Alemtuzumab
420153|NCT01005576|Hematopoietic cell transplant
420154|NCT01005576|non-myeloablative
420155|NCT01005550|Unilateral spinal anaesthesia
420156|NCT01005550|Hypobaric anaesthesia
420157|NCT01005550|Ropivacaine
420158|NCT01005550|Traumatic hip surgery
420159|NCT01005537|stage IV melanoma
420160|NCT01005524|brain computer interface
420161|NCT01005524|P3Speller
420162|NCT01005524|P300
420163|NCT01005524|Event Related potential
420164|NCT01005524|tetraplegia
420165|NCT01005524|Guillain barre syndrome
420166|NCT01005524|Feasibility
420167|NCT01005524|Speed of spelling
420168|NCT01005524|Accuracy
420169|NCT01005511|Bruxism
420170|NCT01005498|Low carbohydrate diet. Dietary treatment of diabetes mellitus.
420171|NCT01005498|Diabetes mellitus type 2 and dietary treatment.
420172|NCT01005485|Myocardial Infarction (MI)
420173|NCT01005485|Circulating Endothelial Cells (CEC)
420174|NCT01005485|Control Group A: (Vascular Surgery)
420175|NCT01005485|Control Group B: (Healthy controls)
420176|NCT01005472|stage III melanoma
420177|NCT01005472|stage IV melanoma
420178|NCT01005472|recurrent melanoma
420179|NCT01005472|ciliary body and choroid melanoma, medium/large size
420180|NCT01005472|extraocular extension melanoma
420181|NCT01005472|iris melanoma
420182|NCT01005472|metastatic intraocular melanoma
420183|NCT01005472|recurrent intraocular melanoma
420184|NCT01005459|labor pain
420185|NCT01005459|combined spinal epidural labor analgesia
420186|NCT01005459|CSE analgesia
420187|NCT01005459|labor analgesia
420188|NCT01005433|dexmedetomidine
420189|NCT01005433|stress response
420190|NCT01005433|cesarean delivery
420191|NCT01005420|Insulin Sensitivity
420192|NCT01005420|Pre-diabetes
420193|NCT01005420|Diabetes
420194|NCT01005420|Blueberries
420195|NCT01005420|Anthocyanins
420196|NCT01005407|HBV vaccine
420197|NCT01005407|Hepatitis B vaccine
420198|NCT01005407|Hepatitis B
420199|NCT01005407|Hepatitis
420200|NCT01005407|HBV
420202|NCT01005407|Healthy
420203|NCT01005407|Healthy volunteers
420204|NCT01005381|Calcium
420205|NCT01005381|Vitamin D
420206|NCT01005381|Particle Size
420207|NCT01005381|Adolescents
420208|NCT01005381|Bone
420209|NCT01005381|Osteoporosis
420210|NCT01005368|chronic lymphocytic leukemia
420211|NCT01005355|Solid tumor
420212|NCT01005355|recombinant human IgG1
420213|NCT01005355|MAB
420214|NCT01005355|monoclonal antibody
420215|NCT01005355|VEGFR 2
420216|NCT01005355|human vascular endothelial growth factor receptor 2
420217|NCT01005342|gene expression
420218|NCT01005342|oats
420219|NCT01005342|rye
420220|NCT01005342|sugar beet fiber
420221|NCT01005342|glucose
420222|NCT01005342|insulin
420223|NCT01005342|triglyceride
420224|NCT01005342|decreased postprandial glucose
420225|NCT01005342|decreased postprandial insulin
420226|NCT01005342|glycemic index
420227|NCT01005316|cohort study
420228|NCT01005316|allo-antibodies
420229|NCT01005316|allosensitization
420230|NCT01005303|Heart Failure
420231|NCT01005303|Micronutrients
420232|NCT01005303|Vitamin D
420233|NCT01005303|Inflammation
420234|NCT01005303|Oxidative Stress
420235|NCT01005303|Quality of Life
420236|NCT01005303|Physical Functioning
420237|NCT01005290|cardiovascular
420238|NCT01005290|fixed
420239|NCT01005290|dose
420240|NCT01005290|combination
420241|NCT01005290|pill
420242|NCT01005290|hypertension
420243|NCT01005277|childhood acute lymphoblastic leukemia in remission
420244|NCT01005277|recurrent childhood acute lymphoblastic leukemia
420245|NCT01005277|childhood acute myeloid leukemia in remission
420246|NCT01005277|childhood acute myeloid leukemia/other myeloid malignancies
420247|NCT01005277|recurrent childhood acute myeloid leukemia
420248|NCT01005277|secondary acute myeloid leukemia
420249|NCT01005277|adult acute myeloid leukemia with inv(16)(p13;q22)
420250|NCT01005277|adult acute myeloid leukemia with t(15;17)(q22;q12)
420251|NCT01005277|adult acute myeloid leukemia with t(8;21)(q22;q22)
420252|NCT01005264|diabetic foot
420253|NCT01005264|neuropathic plantar ulcer
420254|NCT01005264|ulcer healing
420255|NCT01005264|non-removable total contact cast
420256|NCT01005264|removable cast walker
420257|NCT01005251|GERD treatment
420258|NCT01005251|Acid and non-acid Reflux
420259|NCT01005251|Heartburn
420260|NCT01005251|Regurgitation
420261|NCT01005251|Add-on treatment to PPI
420262|NCT01005225|Solid tumor
420263|NCT01005225|prostate cancer
420264|NCT01005225|colon cancer
420265|NCT01005212|EVAR
420266|NCT01005212|Ultrasounds
420267|NCT01005212|AAA
420268|NCT01005212|endoleaks after endovascular repair of AAA
420269|NCT01005199|adult primary hepatocellular carcinoma
420270|NCT01005199|localized unresectable adult primary liver cancer
420271|NCT01005173|Acetaminophen
420272|NCT01005173|APAP
420273|NCT01005160|Mellitus, type 2
420274|NCT01005160|pharmacokinetic evaluation
420275|NCT01005160|drug interaction between CKD-501 and metformin
420276|NCT01005147|tranexamic acid
420277|NCT01005147|upper GI bleeding
420278|NCT01005147|blood transfusion
420279|NCT01005147|GI bleeding
420280|NCT01005108|Hot Flashes for Breast Cancer Patients
420281|NCT01005082|Low salt diet, idiopathic hypercalciuria, calcium stone formers
420282|NCT01005082|Calcium stone formers with idiopathic hypercalciuria
420283|NCT01005069|diabetes mellitus
420284|NCT01005069|DLBS-32
420285|NCT01005069|fasting plasma glucose
420286|NCT01005069|insulin resistance
420287|NCT01005043|non-resectable osteosarcoma
420288|NCT01005043|heavy ion radiotherapy
420289|NCT01005043|particle therapy
420290|NCT01005043|safety
420291|NCT01005043|toxicity
420292|NCT01005043|survival
420293|NCT01005043|radiotherapy
420294|NCT01005030|Parkinson Disease
420295|NCT01005030|blood
420296|NCT01005030|plasma
420297|NCT01005030|metabolomics
420298|NCT01005030|spectroscopy
420299|NCT01005030|oxidative stress.
420300|NCT01005017|Radiofrequent ablation
420301|NCT01005017|Percutaneous radiofrequent therapy
420302|NCT01005004|PMD
420303|NCT01005004|stem cells
420304|NCT01005004|Pelizaeus-Merzbacher Disease
420305|NCT01005004|human stem cells
420306|NCT01005004|central nervous system stem cells
420307|NCT01004965|untreated adult acute lymphoblastic leukemia
420308|NCT01004965|untreated adult acute myeloid leukemia
420309|NCT01004965|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
420310|NCT01004965|adult acute myeloid leukemia with inv(16)(p13;q22)
420311|NCT01004965|adult acute myeloid leukemia with t(15;17)(q22;q12)
420312|NCT01004965|adult acute myeloid leukemia with t(16;16)(p13;q22)
420313|NCT01004965|adult acute myeloid leukemia with t(8;21)(q22;q22)
420314|NCT01004952|Skin
420315|NCT01004952|Sunscreen
420316|NCT01004952|UVR Protection
420317|NCT01004952|09-137
420318|NCT01004939|prophylaxis
420319|NCT01004939|venous thromboembolism
420320|NCT01004939|postpartum
420321|NCT01004939|fondaparinux
420322|NCT01004939|pregnancy
420323|NCT01004926|Unilateral trans-tibial amputees
420324|NCT01004913|Benign paroxysmal positional vertigo
420325|NCT01004913|Vestibular evoked myogenic potentials
420326|NCT01004913|Sacculo-colic reflex
420327|NCT01004900|Glaucoma, Angle Closure
420328|NCT01004900|Selective laser trabeculoplasty
420329|NCT01004900|Primary Angle Closure Disease
420330|NCT01004887|adult anaplastic astrocytoma
420331|NCT01004887|adult giant cell glioblastoma
420332|NCT01004887|adult gliosarcoma
420333|NCT01004887|childhood high-grade cerebellar astrocytoma
420334|NCT01004887|childhood high-grade cerebral astrocytoma
420335|NCT01004874|malignant glioma
420336|NCT01004874|glioblastoma multiforme
420337|NCT01004874|gliosarcoma
420338|NCT01004874|Avastin
420339|NCT01004874|bevacizumab
420340|NCT01004874|Topotecan
420341|NCT01004874|Hycamtin
420342|NCT01004874|Temozolomide
420343|NCT01004874|Temodar
420344|NCT01004874|Pro00019960
420345|NCT01004874|Vredenburgh
420346|NCT01004874|Duke
420347|NCT01004861|PVNS
420348|NCT01004848|Pre-diabetes
420349|NCT01004848|pre-diabetic state
420350|NCT01004848|community-based participatory research
420351|NCT01004848|overweight
420352|NCT01004848|weight loss intervention, peer-led lifestyle education
420353|NCT01004835|migraine
420354|NCT01004822|Treatment Non-Randomized Single Group Assignment Safety Study Neoplasms Carcinoma Cancer Malignancy
420355|NCT01004809|Dutasteride
420356|NCT01004796|breast cancer
420357|NCT01004783|stage I Wilms tumor
420358|NCT01004783|stage II Wilms tumor
420359|NCT01004783|epithelial predominant Wilms tumor
420360|NCT01004770|CECT - Contrast-enhanced computed tomography
420361|NCT01004770|HCG - Human Chorionic Gonadotropin
420362|NCT01004770|HU - Hounsfield Units
420363|NCT01004770|Patient Safety
420364|NCT01004770|Tolerance
420365|NCT01004770|Pharmacokinetic
420366|NCT01004757|diastolic function
420367|NCT01004757|postmeal glucose
420368|NCT01004757|insulin resistance
420369|NCT01004757|low carb diet
420370|NCT01004757|type 2 diabetes
420371|NCT01004744|Postmenopausal women
420372|NCT01004744|ER+
420373|NCT01004744|Estrogen positive
420374|NCT01004744|PR+
420375|NCT01004744|Progesterone positive
420376|NCT01004731|EGFr
420377|NCT01004731|cetuximab
420378|NCT01004731|gemcitabine
420379|NCT01004731|carboplatin
420380|NCT01004731|NSCLC
420381|NCT01004705|cardiovascular
420382|NCT01004705|fixed
420383|NCT01004705|dose
420384|NCT01004705|combination
420385|NCT01004705|pill
420386|NCT01004705|LDL
420387|NCT01004705|cholesterol
420388|NCT01004666|Breast cancer
420389|NCT01004666|Scintimammography
420390|NCT01004666|CZT
420391|NCT01004666|High-risk
420392|NCT01004640|chronic myelogenous leukemia
420393|NCT01004627|fistula
420394|NCT01004627|ultrasound
420395|NCT01004627|angioaccess
420396|NCT01004627|preoperative vein mapping
420397|NCT01004627|Haemodialysis
420398|NCT01004627|Angioaccess surgery
420399|NCT01004601|pretreated failure advanced stage IIIb/IV NSCLC
420400|NCT01004588|elderly
420401|NCT01004588|sarcopenia
420402|NCT01004588|protein drink
420403|NCT01004588|resistance training
420404|NCT01004575|stents
420405|NCT01004575|bare metal stents
420406|NCT01004562|breast cancer
420407|NCT01004549|Patients who have previously undergone bilateral intraocular lens implantation
420408|NCT01004523|childhood low-grade cerebellar astrocytoma
420409|NCT01004523|childhood low-grade cerebral astrocytoma
420410|NCT01004523|childhood mixed glioma
420411|NCT01004523|adult mixed glioma
420412|NCT01004523|adult diffuse astrocytoma
420413|NCT01004523|childhood oligodendroglioma
420414|NCT01004523|adult oligodendroglioma
420415|NCT01004510|malignant pleural effusion
420416|NCT01004510|non small cell lung cancer
420417|NCT01004497|Acute lymphoblastic leukemia, adult, dasatinib
420418|NCT01004484|non-patients
420419|NCT01004484|non-diarrhea functional bowel symptoms
420420|NCT01004471|Nasal dilator strip
420421|NCT01004471|Sleep disordered breathing
420422|NCT01004458|fibromyalgia
420423|NCT01004458|cognitive behavioral therapy
420424|NCT01004458|women
420425|NCT01004458|pain
420426|NCT01004458|stress
420427|NCT01004458|type A behavior
420428|NCT01004445|Pneumonia
420429|NCT01004445|Adjunctive treatment
420430|NCT01004445|Gram-negative bacteria
420431|NCT01004432|humira, remicade
420432|NCT01004432|rheumatoid arthritis
420433|NCT01004432|enbrel failure
420434|NCT01004432|humira failure
420435|NCT01004432|arthritis
420436|NCT01004432|enbrel
420437|NCT01004419|non small cell lung cancer
420438|NCT01004419|vandetanib
420439|NCT01004419|ZD6474
420440|NCT01004419|fulvestrant
420441|NCT01004419|faslodex
420442|NCT01004419|phase 1
420443|NCT01004406|plaque
420444|NCT01004406|LDL
420445|NCT01004406|statin
420446|NCT01004406|endothelial
420447|NCT01004406|apheresis
420448|NCT01004406|acute coronary syndrome
420449|NCT01004393|Methylnaltrexone
420450|NCT01004393|Constipation
420451|NCT01004393|Narcotic Antagonists
420452|NCT01004393|Analgesics, Opioid
420453|NCT01004393|Neoplasms
420454|NCT01004380|Epithelial Ovarian Cancer
420455|NCT01004380|Ovarian Cancer
420456|NCT01004367|Promoting healthy lifestyles in adolescents in Ecuador to prevent overweight
420457|NCT01004354|Psychiatric illnesses
420458|NCT01004354|Vitamin D deficiency
420459|NCT01004354|Obesity
420460|NCT01004341|pediatric obesity
420461|NCT01004341|parenting style
420462|NCT01004341|feeding style
420463|NCT01004341|behavioral skills
420464|NCT01004341|parenting skills
420465|NCT01004341|family meals
420466|NCT01004328|patient safety
420467|NCT01004328|care transitions
420468|NCT01004328|therapeutic monitoring
420469|NCT01004328|skilled nursing facilities
420470|NCT01004328|Adverse outcomes after discharge from a SNF to home
420471|NCT01004315|Overactive bladder
420472|NCT01004315|Frequency
420473|NCT01004315|Micturition
420474|NCT01004315|Urgency
420475|NCT01004315|Urge urinary incontinence
420476|NCT01004315|OAB
420477|NCT01004302|Obsessive-compulsive disorder
420478|NCT01004302|Radiosurgery
420479|NCT01004302|Psychosurgery
420480|NCT01004302|Treatment outcome
420481|NCT01004302|Randomized Controlled Trials
420482|NCT01004289|Acute myocardial infarction
420483|NCT01004289|Primary percutaneous coronary intervention
420484|NCT01004289|Postconditioning
420485|NCT01004276|primary health care
420486|NCT01004276|delivery of health care
420487|NCT01004276|smoking cessation
420488|NCT01004276|chronic disease
420489|NCT01004276|disease management
420490|NCT01004276|pilot projects
420491|NCT01004263|acute migraine with or without aura in adolescents
420492|NCT01004237|insulin resistance
420493|NCT01004237|hypertensive
420494|NCT01004237|hypercholesterolemic patients
420495|NCT01004224|advanced solid tumors
420496|NCT01004224|lung cancer
420497|NCT01004224|bladder cancer
420498|NCT01004224|BGJ398
420499|NCT01004224|FGFR
420500|NCT01004224|kinase inhibitor
420501|NCT01004224|advanced solid malignancies
420502|NCT01004211|bladder cancer
420503|NCT01004211|recurrence
420504|NCT01004198|Trauma
420505|NCT01004198|Hemorrhage
420506|NCT01004198|Hemorrhagic shock
420507|NCT01004198|Lactic acidosis
420508|NCT01004198|Oxygen carriers
420509|NCT01004198|Oxygen therapeutics
420510|NCT01004198|Hemoglobin solutions
420511|NCT01004198|Hemoglobin substitutes
420512|NCT01004198|Red cell substitutes
420513|NCT01004198|PEG-hemoglobin
420514|NCT01004172|carboplatin
420515|NCT01004172|bevacizumab
420516|NCT01004159|Colorectal cancer
420517|NCT01004159|KRAS wild type tumors
420518|NCT01004146|incentive spirometry
420519|NCT01004146|bariatric surgery
420520|NCT01004146|obesity
420521|NCT01004133|Age 80 or older
420522|NCT01004133|No chronic disease
420523|NCT01004094|children
420524|NCT01004094|video games
420525|NCT01004094|internet
420526|NCT01004094|parents
420527|NCT01004094|fruit
420528|NCT01004094|vegetable
420529|NCT01004094|implementation intention
420530|NCT01004094|goal setting
420531|NCT01004094|fruit and vegetable consumption
420532|NCT01004094|obesity prevention
420533|NCT01004094|cancer prevention
420534|NCT01004081|Cancer of Breast
420535|NCT01004081|Cancer of the Breast
420536|NCT01004068|Clomiphene
420537|NCT01004068|Diet
420538|NCT01004068|Exercise
420539|NCT01004068|Infertility
420540|NCT01004068|PCOS
420541|NCT01004068|Physical activity
420542|NCT01004068|Treatment
420543|NCT01004055|Wound
420544|NCT01004055|Skin lesion
420545|NCT01004055|Antimicrobial
420546|NCT01004055|Bioelectric
420547|NCT01004042|Depression
420548|NCT01004042|Botulinum toxin
420549|NCT01004042|Glabella
420550|NCT01004042|Quality of life
420551|NCT01004042|Self-steem
420552|NCT01004029|17P
420553|NCT01004029|hydroxyprogesterone caproate
420554|NCT01004029|preterm birth
420555|NCT01004029|progesterone
420556|NCT01004029|women with a singleton pregnancy aged 18 years or older with a history of a previous singleton spontaneous preterm delivery
420557|NCT01004016|Spinocerebellar degeneration
420558|NCT01004016|Thyrotropin-Releasing Hormone (TRH)
420559|NCT01004016|SCD
420560|NCT01003990|Treatment experienced
420561|NCT01003964|NON-SMALL CELL LUNG CANCER
420562|NCT01003964|excision repair cross-complementing 1
420563|NCT01003964|Gemcitabine and cisplatin
420564|NCT01003964|Irinotecan and cisplatin
420565|NCT01003964|Pemetrexed
420566|NCT01003964|Docetaxel
420567|NCT01003964|advanced NSCLC
420568|NCT01003951|Lymphedema
420569|NCT01003951|Acupuncture
420570|NCT01003951|09-136
420571|NCT01003938|chemotherapy
420572|NCT01003938|combination therapy
420573|NCT01003938|targeted therapy
420574|NCT01003938|second-line
420575|NCT01003925|Knee pain, osteoarthritis, non-surgical treatment, age 65+
420576|NCT01003912|Lysosomal Storage Diseases
420577|NCT01003912|Inborn Errors of Metabolism
420578|NCT01003912|Krabbe
420579|NCT01003912|Infantile metachromatic leukodystrophy disease
420580|NCT01003912|MLD
420581|NCT01003912|Tay Sachs
420582|NCT01003912|Sandhoff
420583|NCT01003912|GM2 gangliosidoses
420584|NCT01003912|Pelizaeus-Merzbacher disease
420585|NCT01003912|PMD
420586|NCT01003886|post marketing surveillance Filipino benign prostatic hyperplasia BPH Doxazosin GITS
420587|NCT01003873|morbid obesity
420588|NCT01003873|bariatric surgery
420589|NCT01003873|lifestyle intervention
420590|NCT01003873|endocannabinoids system
420591|NCT01003860|postoperative analgesia
420592|NCT01003847|Insulin resistance
420593|NCT01003834|substance use
420594|NCT01003834|drug use
420595|NCT01003834|drug abuse
420596|NCT01003782|cholangitis
420597|NCT01003782|antibiotic
420598|NCT01003782|bacteriobilia
420599|NCT01003782|bile
420600|NCT01003782|ERCP
420601|NCT01003756|Preoperative
420602|NCT01003756|Exercise
420603|NCT01003756|Joint Replacement
420604|NCT01003756|Hip
420605|NCT01003756|Knee
420606|NCT01002781|Tocilizumab Still
420607|NCT01002755|Leukemia
420608|NCT01002755|CLL
420609|NCT01002755|SLL
420610|NCT01002755|Lenalidomide
420611|NCT01002755|Ofatumumab
420612|NCT01002742|GVHD
420613|NCT01002729|Oseltamivir Pharmacokinetics Obesity
420614|NCT01002729|Oseltamivir Pharmacokinetics in Obesity
420615|NCT01002716|rheumatoid influenza vaccine cell immunity
420616|NCT01002703|Lenalidomide
420617|NCT01002703|Bendamustine
420618|NCT01002703|Multiple Myeloma
420619|NCT01002703|Myeloma
420620|NCT01002703|Revlimid
420621|NCT01002703|Phase I/II
420622|NCT01002703|refractory Myeloma
420623|NCT01002703|relapsed Myeloma
420624|NCT01002690|Asthma
420625|NCT01002690|Allergen challenge
420626|NCT01002690|Airway responsiveness
420627|NCT01002690|Prostaglandins
420628|NCT01002690|Eicosanoids
420629|NCT01002677|brain injury
420630|NCT01002677|traumatic brain injury
420631|NCT01002677|training
420632|NCT01002677|teaching
420633|NCT01002677|curriculum
420634|NCT01002664|Benign Prostatic Hyperplasia
420635|NCT01002664|Multi-carotenoids
420636|NCT01002664|MCS-2
420637|NCT01002664|Lower Urinary Tract Symptoms
420638|NCT01002664|International prostate symptom scores
420639|NCT01002651|gastrointestinal health
420640|NCT01002651|healthy subjects
420641|NCT01002625|Double-Blind Randomized Placebo-Controlled 2-Way Crossover Polysomnographic Endpoints
420642|NCT01002612|Nutritional status
420643|NCT01002612|Thai HIV-infected children
420644|NCT01002599|bariatric surgery
420645|NCT01002599|morbidly obese
420646|NCT01002599|BMI >35
420647|NCT01002599|CPAP
420648|NCT01002599|Venturi
420649|NCT01002599|Boussignac
420650|NCT01002599|Ventilation
420651|NCT01002599|Pulmonary function
420652|NCT01002599|Morbidly Obese Patients undergoing bariatric surgery
420653|NCT01002586|Alzheimer's dementia
420654|NCT01002586|Wii-Fit
420655|NCT01002586|Walking
420656|NCT01002586|Falls
420657|NCT01003730|Intraoperative protective ventilation strategies
420658|NCT01003691|Phase 1b Advanced Dry Age-Related Macular Degeneration RN6G
420659|NCT01003678|Myelodysplastic syndrome
420660|NCT01003678|Clofarabine
420661|NCT01003678|low-dose oral clofarabine
420662|NCT01003678|intermediate risk Myelodysplastic syndrome
420663|NCT01003678|high risk Myelodysplastic syndrome
420664|NCT01003652|goiter
420665|NCT01003639|papilledema
420666|NCT01003639|vision loss
420667|NCT01003639|headache
420668|NCT01003639|obesity
420669|NCT01003639|women
420670|NCT01003639|diplopia
420671|NCT01003639|tinnitus
420672|NCT01003626|Advanced cutaneous melanoma
420673|NCT01003626|Tumor Pressure
420674|NCT01003626|Tumor IFP
420675|NCT01003626|Interstitial Fluid Pressure
420676|NCT01003626|IFP
420677|NCT01003626|Transducer-tipped catheter Mikro-Tip SPC-320
420678|NCT01003626|Transducer Millar
420679|NCT01003626|Power Lab 8/30 amplifier
420680|NCT01003613|Tranilast
420681|NCT01003613|fibrin glue
420682|NCT01003613|primary pterygium
420683|NCT01003613|conjunctival autograft
420684|NCT01003600|Survivorship
420685|NCT01003600|Quality of Life
420686|NCT01003600|Questionnaire
420687|NCT01003600|09-133
420688|NCT01003587|India
420689|NCT01003587|evidence-based policy
420690|NCT01003587|knowledge translation
420691|NCT01003587|disease control priorities
420692|NCT01003587|decision-makers
420693|NCT01003587|health spending
420694|NCT01003587|health services delivery
420695|NCT01003587|maternal and child health
420696|NCT01003587|policy making
420697|NCT01003587|delivery of health care
420698|NCT01003574|cardiovascular health outcomes in cancer survivors
420699|NCT01003561|ultrasonographic exam on upper and lower extremities
420700|NCT01003548|Embryo culture
420701|NCT01003548|IVF
420702|NCT01003548|Microfluidics
420703|NCT01003548|infertility
420704|NCT01003535|Parkinson´s disease
420705|NCT01003535|Acetylcholine receptors
420706|NCT01003522|Bronchial stents
420707|NCT01003522|Airway obstruction
420708|NCT01003522|Non-small cell lung cancer
420709|NCT01003509|inguinal
420710|NCT01003509|hernia
420711|NCT01003509|new
420712|NCT01003509|repair
420713|NCT01003509|modified shouldice
420714|NCT01003509|double
420715|NCT01003496|Cocaine
420716|NCT01003496|crack
420717|NCT01003496|heroin
420718|NCT01003496|non-prescribed opioids
420719|NCT01003496|contingency management
420720|NCT01003496|community reinforcement approach
420721|NCT01003496|facilitated therapeutic alliance
420722|NCT01003496|chronic disease treatment models
420723|NCT01003483|metformin
420724|NCT01003483|orlistat
420725|NCT01003483|pcos
420726|NCT01003483|obese
420727|NCT01003470|cerebral infarction
420728|NCT01003470|Paralysis
420729|NCT01003470|acupuncture
420730|NCT01003470|rehabilitation
420731|NCT01003470|trial
420732|NCT01003444|Muscle biopsy Malonyl CoA Biomarker assay
420733|NCT01003418|GSK2340272A
420734|NCT01003418|H1N1 pandemic influenza
420735|NCT01003405|Overactive bladder
420736|NCT01003405|Frequency
420737|NCT01003405|Micturition
420738|NCT01003405|Urgency
420739|NCT01003405|Urge urinary incontinence
420740|NCT01003405|OAB
420741|NCT01003392|Coronary artery disease
420742|NCT01003392|Coffee
420743|NCT01003392|Heart system
420744|NCT01003379|cognitive dysfunction
420745|NCT01003379|schizophrenia
420746|NCT01003379|Phase 2
420747|NCT01003366|safety during central venous catheterization
420748|NCT01003353|Stroke
420749|NCT01003353|Strength training
420750|NCT01003353|exercise therapy
420751|NCT01003340|asthma
420752|NCT01003340|children
420753|NCT01003340|community health workers
420754|NCT01003340|home intervention
420755|NCT01003327|laryngeal mask, leak pressure
420756|NCT01003327|leak pressure
420757|NCT01003314|Vaccine
420758|NCT01003314|Safety
420759|NCT01003314|Immunogenicity
420760|NCT01003314|Protection
420761|NCT01003314|Sporozoite challenge
420762|NCT01003301|cat allergy
420763|NCT01003288|H1N1 pandemic vaccine immunogenicity safety
420764|NCT01003288|Health employees
420765|NCT01003275|Chronic kidney disease
420766|NCT01003275|Vitamin D
420767|NCT01003275|Paricalcitol
420768|NCT01003275|Placebo
420769|NCT01003275|Kidney
420770|NCT01003275|Renal
420771|NCT01003275|Oxidative Stress
420772|NCT01003275|Immune cell function
420773|NCT01003275|Glucose
420774|NCT01003275|Glucose tolerance
420775|NCT01003262|Observation Unit
420776|NCT01003262|Emergency Department
420777|NCT01003249|over distention of bladder
420778|NCT01003249|Dysfunctional voiding
420779|NCT01003249|dysfunctional elimination syndrome
420780|NCT01003236|Diabetic nephropathy
420781|NCT01003236|Type II Diabetes
420782|NCT01003236|Milk Thistle extract
420783|NCT01003236|Silymarin
420784|NCT01003223|phosphorus
420785|NCT01003223|dialysis
420786|NCT01003223|PhosLo
420787|NCT01003223|CKD stage V
420788|NCT01003210|otitis media
420789|NCT01003210|children
420790|NCT01003210|homeopathy
420791|NCT01003197|Development
420792|NCT01003197|Validation
420793|NCT01003197|Prediction Score
420794|NCT01003197|Complication
420795|NCT01003197|Liver resection
420796|NCT01003197|develop and validate a score to predict serious complications following liver resection using pre-operative risk factors.
420797|NCT01003184|diabetes
420798|NCT01003184|exenatide once weekly
420799|NCT01003184|Byetta
420800|NCT01003184|insulin detemir
420801|NCT01003184|Levemir
420802|NCT01003184|Amylin
420803|NCT01003184|Lilly
420804|NCT01003171|Pharmacokinetics
420805|NCT01003171|PK
420806|NCT01003171|MCS
420807|NCT01003171|Benign Prostatic Hyperplasia
420808|NCT01003171|Multi-Carotenoids
420809|NCT01003171|Healthy subjects
420810|NCT01003158|Cancer
420811|NCT01003158|tumour
420812|NCT01003158|metastatic
420813|NCT01003158|breast cancer
420814|NCT01003145|Influenza
420815|NCT01003145|vaccine
420816|NCT01003145|Immunogenicity
420817|NCT01003132|Psychosis
420818|NCT01003132|Distress
420819|NCT01003132|Mindfulness
420820|NCT01003132|Acceptance
420821|NCT01003132|Values
420822|NCT01003119|Alcohol addiction
420823|NCT01003119|Alcohol treatment
420824|NCT01003119|Alcohol recovery
420825|NCT01003119|Post residential treatment DSM-IV diagnosis of alcohol dependence
420826|NCT01003106|RVO
420827|NCT01003106|BRVO
420828|NCT01003106|CRVO
420829|NCT01003106|Vein occlusion
420830|NCT01003093|Tuberculosis
420831|NCT01003093|Vaccine
420832|NCT01003093|Ag85B
420833|NCT01003093|ESAT-6
420834|NCT01003093|IC31
420835|NCT01003080|The evaluation of hemostasis during total knee arthroplasty using the aquamantys device.
420836|NCT01003054|Leukemia
420837|NCT01003054|CML
420838|NCT01003054|Busulfan
420839|NCT01003054|Busulfex
420840|NCT01003054|Myleran
420841|NCT01003054|Cyclophosphamide
420842|NCT01003054|Cytoxan
420843|NCT01003054|Neosar
420844|NCT01003054|Imatinib Mesylate
420845|NCT01003054|Gleevec
420846|NCT01003054|Autologous Stem Cell Transplantation
420847|NCT01003054|Stem Cell Transplant
420848|NCT01003041|healthy normal infants
420849|NCT01003028|Total intravenous anesthesia
420850|NCT01003028|Maximum plasma concentration of remifentanil
420851|NCT01003015|HCC
420852|NCT01003015|Safety
420853|NCT01003015|BAY73-4506
420854|NCT01003002|Parkinson's disease
420855|NCT01003002|Dyskinesia
420856|NCT01003002|Movement Disorders
420857|NCT01002989|ankle brachial index
420858|NCT01002989|WatchBP Office
420859|NCT01002989|oscillometric measurement
420860|NCT01002937|Biomarkers
420861|NCT01002937|Prognosis response to treatment
420862|NCT01002937|Renal cancer
420863|NCT01002924|Cancer
420864|NCT01002924|Adenocarcinoma
420865|NCT01002924|Phase II
420866|NCT01002924|Lung
420867|NCT01002924|Non-small cell lung cancer
420868|NCT01002924|NSCLC
420869|NCT01002924|extension
420870|NCT01002924|EC145
420871|NCT01002924|Prior exposure to EC145
420872|NCT01002911|Device procedure
420873|NCT01002911|pacemaker
420874|NCT01002911|ICD
420875|NCT01002911|antibiotics
420876|NCT01002898|HIV-1 RNA
420877|NCT01002898|Treatment experienced
420878|NCT01002885|Infertility
420879|NCT01002885|FSH Receptor Polymorphisms
420880|NCT01002872|FGF23
420881|NCT01002872|CKD
420882|NCT01002872|Fosrenol
420883|NCT01002872|Hyperphosphatemia
420884|NCT01002859|Coronary artery bypass graft surgery (CABG)
420885|NCT01002859|Cardiopulmonary Bypass (CPB)
420886|NCT01002859|Cyclosporine
420887|NCT01002859|ischaemia reperfusion
420888|NCT01002846|Efficacy
420889|NCT01002846|Acupuncture
420890|NCT01002846|Hypertension
420891|NCT01002833|Plasmodium falciparum
420892|NCT01002833|Malaria
420893|NCT01002820|Epileptic Seizures
420894|NCT01002820|Seizure Disorder
420895|NCT01002820|Seizures
420896|NCT01002820|Convulsions
420897|NCT01002820|Anticonvulsant
420898|NCT01002820|Anticonvulsive
420899|NCT01002820|Antiepileptic
420900|NCT01002820|Ganaxolone
420901|NCT01002794|Degenerative meniscal tear
420902|NCT01002794|Arthroscopy
420903|NCT01002794|Exercise therapy
420904|NCT01002573|Pediatric
420905|NCT01002573|Fever
420906|NCT01002560|Melanoma
420907|NCT01002560|Novel Prognostic Markers
420908|NCT01002547|steatohepatitis
420909|NCT01002547|type 2 diabetes
420910|NCT01002547|fatty liver
420911|NCT01002534|Cystic Fibrosis
420912|NCT01002534|Vardenafil
420913|NCT01002534|Nasal instillation
420914|NCT01002534|Nasal Potential difference
420915|NCT01002521|Diabetes
420916|NCT01002521|vascular
420917|NCT01002521|haptoglobin
420918|NCT01002521|tumor
420919|NCT01002521|necrosis
420920|NCT01002521|factor
420921|NCT01002521|alpha
420922|NCT01002521|traps
420923|NCT01002521|impaired
420924|NCT01002521|wound
420925|NCT01002521|healing
420926|NCT01002521|Impaired wound healing in patients with diabetes mellitus
420927|NCT01002508|influenza vaccine scleroderma immunogenicity safety
420928|NCT01002495|myocardial
420929|NCT01002495|ischemia
420930|NCT01002495|coronary disease
420931|NCT01002495|angina
420932|NCT01002482|Hyperglycemia
420933|NCT01002482|Hypoglycemia
420934|NCT01002482|Intensive Care Unit
420935|NCT01002482|Glucose Control
420936|NCT01002482|Insulin
420937|NCT01002482|Computer Protocol
420938|NCT01002482|Metabolic Disorders
420939|NCT01002469|isotope ratio measurement
420940|NCT01002469|urea cycle
420941|NCT01002469|13C acetate
420942|NCT01002469|Healthy adults
420943|NCT01002456|Adrenergic beta-Antagonists
420944|NCT01002456|Guideline Adherence
420945|NCT01002456|Drug Prescriptions
420946|NCT01002456|target dose
420947|NCT01002443|Helicobacter pylori
420948|NCT01002443|glandular atrophy
420949|NCT01002443|intestinal metaplasia
420950|NCT01002443|subtotal gastrectomy
420951|NCT01002443|gastric cancer
420952|NCT01002443|Precancerous lesion of gastric cancer
420953|NCT01002430|Myocardial ischemia
420954|NCT01002430|Refractory angina pectoris
420955|NCT01002430|Vascular endothelial growth factor
420956|NCT01002430|Gene therapy
420957|NCT01002430|Perfusion
420958|NCT01002417|Benign Prostatic Hyperplasia
420959|NCT01002417|Multi-carotenoids
420960|NCT01002417|MCS-2
420961|NCT01002417|Lower Urinary Tract Symptoms
420962|NCT01002417|International prostate symptom scores
420963|NCT01002404|ERCP
420964|NCT01002404|deep biliary cannulation
420965|NCT01002404|guide wire cannulation
420966|NCT01002404|post-ERCP pancreatitis
420967|NCT01002404|Success of deep biliary cannulation
420968|NCT01002404|Rate of post-ERCP pancreatitis
420969|NCT01002404|Time used to deep biliary cannulation
420970|NCT01002391|breast hypertrophy
420971|NCT01002391|mammaplasty
420972|NCT01002391|bandages
420973|NCT01002391|surgical site infection
420974|NCT01002391|skin colonization
420975|NCT01002352|obesity
420976|NCT01002352|bariatric
420977|NCT01002352|BOLD
420978|NCT01002352|weightloss
420979|NCT01002352|database
420980|NCT01002352|data registry
420981|NCT01002326|Pediatric
420982|NCT01002326|Body Dysmorphic Disorder
420983|NCT01002326|BDD
420984|NCT01002326|CBT
420985|NCT01002326|Cognitive-Behavioral Therapy
420986|NCT01002300|Social Cognition
420987|NCT01002300|Oxytocin
420988|NCT01002274|Benign Prostatic Hyperplasia
420989|NCT01002274|BPH
420990|NCT01002274|MCS-2
420991|NCT01002274|Multi-Carotenoids
420992|NCT01002274|Lower Urinary Tract Symptoms
420993|NCT01002274|International prostate symptom score
420994|NCT01002261|Galactose
420995|NCT01002261|PET/CT
420996|NCT01002261|Liver physiology
420997|NCT01002261|Liver pathophysiology
420998|NCT01002248|Multiple Myeloma
420999|NCT01002248|Relapsed multiple myeloma
421000|NCT01002248|Refractory multiple myeloma
421001|NCT01002248|Relapsed refractory multiple myeloma
421002|NCT01002235|Diabetic
421003|NCT01002235|Neuropathy
421004|NCT01002235|peripheral
421005|NCT01002235|diabetes
421006|NCT01002222|Benign Prostatic Hyperplasia
421007|NCT01002222|MCS-2
421008|NCT01002222|Multi-Carotenoids
421009|NCT01002222|Lower Urinary Tract Symptoms
421010|NCT01002222|International prostate symptom score
421011|NCT01002209|Diabetes
421012|NCT01002209|Vascular Surgery
421013|NCT01002209|Hyperbaric oxygen
421014|NCT01002209|Surgical complications
421015|NCT01002209|Wound complication
421016|NCT01002209|Randomized
421017|NCT01002209|Controlled
421018|NCT01002196|Selective Mutism
421019|NCT01002196|Intervention
421020|NCT01002183|Malaria
421021|NCT01002183|Plasmodium falciparum
421022|NCT01002183|acute uncomplicated
421023|NCT01002170|Tuberculosis
421024|NCT01002170|Cycloserine
421025|NCT01002170|Pharmacokinetics
421026|NCT01002157|Coronary Artery Calcification
421027|NCT01002157|Vitamin K
421028|NCT01002157|Trial
421029|NCT01002157|Treatment
421030|NCT01002131|Digital Volume Tomography
421031|NCT01002131|Cone Beam CT
421032|NCT01002131|impacted and supernumerary teeth
421033|NCT01002131|dental and maxillofacial radiology
421034|NCT01002118|heart rate variability
421035|NCT01002118|Dialysis
421036|NCT01002105|Baclofen
421037|NCT01002105|Alcohol
421038|NCT01002105|Baclofen as add-on to standard treatment of alcohol
421039|NCT01002092|Osteosarcoma
421040|NCT01002092|Endostar
421041|NCT01002092|Chemotherapy
421042|NCT01002066|Fever
421043|NCT01002066|Malaria
421044|NCT01002066|RDT
421045|NCT01002066|IMCI
421046|NCT01002066|Children<5 years of age
421047|NCT01002066|ACT
421048|NCT01002053|diabetes
421049|NCT01002053|neuropathy
421050|NCT01002053|ankle block
421051|NCT01002053|regional anesthesia
421052|NCT01002053|ultrasound
421053|NCT01002053|nerve localization
421054|NCT01002053|Nerve localization in patients undergoing foot surgery and having ankle block
421055|NCT01002040|HIV
421056|NCT01002040|vaccine,
421057|NCT01002040|H1N1
421058|NCT01002040|influenza
421059|NCT01002040|H1N1 Influenza vaccine
421060|NCT01002040|Arepanrix
421061|NCT01002040|Pandemic
421062|NCT01002040|H1N1 2009 Influenza
421063|NCT01002040|HIV preventive vaccine
421064|NCT01002027|Postnatal Depression
421065|NCT01002027|CBT-Counselling
421066|NCT01002027|Primary care
421067|NCT01002014|Breast Cancer
421068|NCT01002014|Skin Sparing Mastectomy
421069|NCT01002014|Breast Cancer Prophylaxis
421070|NCT01002014|Nipple Sparing Mastectomy
421071|NCT01002014|Nipple Areolar Complex
421072|NCT01002014|Mastectomy
421073|NCT01002014|Breast Reconstruction
421074|NCT01002014|Local recurrence following nipple sparing mastectomy
421075|NCT01002014|Cosmetic outcomes following nipple sparing mastectomy
421076|NCT01002014|Complications following nipple sparing mastectomy
421077|NCT01001988|Encephalitis
421078|NCT01001988|Japanese Encephalitis
421079|NCT01001988|Japanese Encephalitis Chimeric Virus Vaccine
421080|NCT01001988|Toddlers
421081|NCT01001975|Sunscreens
421082|NCT01001962|Hypertension in type II diabetes
421083|NCT01001962|Cardiovascular morbidity and mortality
421084|NCT01001936|PHASE 1 SKI-606 Solid tumor
421085|NCT01001897|IUD insertion
421086|NCT01001897|nulliparous women
421087|NCT01001897|contraception
421088|NCT01001884|caregiver, psychoeducational, colon
421089|NCT01001871|Iron deficiency anemia
421090|NCT01001871|Sprinkles®
421091|NCT01001871|micronutrients
421092|NCT01001871|malaria incidence
421093|NCT01001871|iron supplement
421094|NCT01001858|OSA
421095|NCT01001858|CPAP compliance
421096|NCT01001858|nurse domiciliary led
421097|NCT01001858|sleep disease
421098|NCT01001845|hemodialysis
421099|NCT01001845|oxidative stress
421100|NCT01001845|plasma malondialdehyde
421101|NCT01001845|Glutathion peroxidase
421102|NCT01001780|Graft versus Host Disease
421103|NCT01001780|Allogeneic Hematopoietic Stem Cell Transplant
421104|NCT01001767|Omega-3 Fatty Acids
421105|NCT01001767|HIV
421106|NCT01001767|Heart Disease
421107|NCT01001767|Treatment experienced
421108|NCT01001754|Hepatitis C
421109|NCT01001754|Hepatitis C, Chronic
421110|NCT01001754|PEGylated recombinant interleukin 29
421111|NCT01001754|PEG-interferon lambda
421112|NCT01001754|Interleukin 29
421113|NCT01001754|Virus
421114|NCT01001754|Infection
421115|NCT01001754|Liver Diseases
421116|NCT01001741|HIV
421117|NCT01001741|Antiretrovirals
421118|NCT01001741|Adherence
421119|NCT01001741|Text messaging
421120|NCT01001741|Antiretroviral adherence
421121|NCT01001741|Treatment experienced
421122|NCT01001728|Breast Cancer
421123|NCT01001728|Radiotherapy
421124|NCT01001728|Prone position
421125|NCT01001702|Open Label
421126|NCT01001702|Aripiprazole
421127|NCT01001689|Pregnancy
421128|NCT01001689|Preventive health care
421129|NCT01001689|Fitness
421130|NCT01001689|Nutrition
421131|NCT01001689|Obesity
421132|NCT01001689|Diabetes
421133|NCT01001689|Weight gain
421134|NCT01001676|renal failure
421135|NCT01001676|Restenosis
421136|NCT01001676|Dialysis access
421137|NCT01001676|Paclitaxel
421138|NCT01001676|Angioplasty
421139|NCT01001676|Intimal hyperplasia
421140|NCT01001663|CAG
421141|NCT01001650|Malaria Vaccine
421142|NCT01001650|Plasmodium falciparum
421143|NCT01001637|curcumin
421144|NCT01001637|alzheimer's
421145|NCT01001637|longVida
421146|NCT01001637|dementia
421147|NCT01001624|Cosmetic
421148|NCT01001624|Facial cream
421149|NCT01001624|Melasma
421150|NCT01001624|Melanil
421151|NCT01001611|Diabetes Mellitus, Type 2
421152|NCT01001611|glitazone
421153|NCT01001611|Type II Diabetes
421154|NCT01001611|Hypolipidemic
421155|NCT01001611|oral hypoglycemic agent
421156|NCT01001585|mitochondrial disease
421157|NCT01001585|sevoflurane
421158|NCT01001585|mitochondrial disease and sevoflurane sensitivity
421159|NCT01001572|Blood pressure
421160|NCT01001572|hypertension
421161|NCT01001572|Exforge
421162|NCT01001572|valsartan/amlodipine
421163|NCT01001559|Depression
421164|NCT01001559|Combination therapy
421165|NCT01001559|antidepressant
421166|NCT01001559|Deplin
421167|NCT01001559|folate
421168|NCT01001559|methylfolate
421169|NCT01001546|Veterans
421170|NCT01001546|Smoking cessation
421171|NCT01001546|Operation Enduring Freedom
421172|NCT01001546|Operation Iraqi Freedom
421173|NCT01001533|Electrical Cardiometry
421174|NCT01001533|Dexmedetomidine
421175|NCT01001533|ICON
421176|NCT01001533|bio-impedance
421177|NCT01001533|cardiac monitor
421178|NCT01001520|Genetics
421179|NCT01001520|Nicotine
421180|NCT01001520|Cognition
421181|NCT01001520|fMRI
421182|NCT01001507|Family planning
421183|NCT01001507|HIV
421184|NCT01001507|Integrated services
421185|NCT01001507|Unintended pregnancy
421186|NCT01001507|Kenya
421187|NCT01001494|Chronic Obstructive Pulmonary Disease
421188|NCT01001494|antimuscarinic
421189|NCT01001494|COPD
421190|NCT01001481|Treatment review
421191|NCT01001481|Schizophrenia
421192|NCT01001481|Observational
421193|NCT01001481|Prospective studies
421194|NCT01001481|Australia
421195|NCT01001468|Psoriasis
421196|NCT01001455|BP
421197|NCT01001442|Multiple myeloma
421198|NCT01001442|Relapsed
421199|NCT01001442|Refractory
421200|NCT01001429|sedation for vitreoretinal surgery
421201|NCT01001390|Acute Lymphoblastic leukemia
421202|NCT01001377|Panitumumab
421203|NCT01001377|Vectibix
421204|NCT01001377|Colon Cancer
421205|NCT01001377|Colorectal Cancer
421206|NCT01001377|Rectal Cancer
421207|NCT01001377|Cetuximab
421208|NCT01001377|Erbitux
421209|NCT01001377|Metastatic
421210|NCT01001351|Chronic Kidney Disease
421211|NCT01001351|Arteriovenous Grafts (AVG)
421212|NCT01001351|Hemodialysis
421213|NCT01001351|Vascular Access
421214|NCT01001351|Dialysis
421215|NCT01001351|Graft
421216|NCT01001351|Access
421217|NCT01001351|vonapanitase
421218|NCT01001351|kidney
421219|NCT01001351|renal
421220|NCT01001325|influenza
421221|NCT01001325|vaccine
421222|NCT01001325|observer blind
421223|NCT01001312|Heart Failure
421224|NCT01001312|Therapeutics
421225|NCT01001312|Blood volume
421226|NCT01001286|dropout youth in low income communities in Amman, Jordan
421227|NCT01001273|Pancreas Transplantation
421228|NCT01001273|Kidney Transplantation
421229|NCT01001273|Organ Transplantation
421230|NCT01001273|Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients
421231|NCT01001260|Prostaglandins
421232|NCT01001260|vascular injury
421233|NCT01001247|TMC278-TiDP6-C154
421234|NCT01001247|TMC278-C154
421235|NCT01001247|TMC278
421236|NCT01001247|Healthy volunteers
421237|NCT01001247|omeprazole
421238|NCT01001247|proton pump inhibitor
421239|NCT01001247|HIV
421240|NCT01001208|Etanercept
421241|NCT01001208|Methotrexate
421242|NCT01001208|Psoriasis
421243|NCT01001182|observational
421244|NCT01001182|non-interventional
421245|NCT01001182|prospective
421246|NCT01001169|GSK Bio's influenza vaccine GSK2340274A
421247|NCT01001169|influenza infection
421248|NCT01001156|Aged
421249|NCT01001156|Breathing Muscles
421250|NCT01001156|Strength Muscles
421251|NCT01001156|Institution of long Permanence for elderly
421252|NCT01001130|avamys
421253|NCT01001130|Allergic Rhinitis
421254|NCT01001130|post marketing surveillance
421255|NCT01001130|Seasonal Allergic Rhinitis
421256|NCT01001130|Perennial Allergic Rhinitis (PAR)
421257|NCT01001117|Cataract
421258|NCT01001117|Capsulotomy
421259|NCT01001117|Capsulorrhexis
421260|NCT01001117|Phacoemulsification
421261|NCT01001104|Metabolic Diseases
421262|NCT01001104|Glucose Metabolism Disorders
421263|NCT01001104|Diabetes
421264|NCT01001104|GLP-1
421265|NCT01001104|Lilly
421266|NCT01001091|Conjunctivitis
421267|NCT01001091|conjunctival inflammation
421268|NCT01001091|ocular allergies
421269|NCT01001078|supraglottic airway devices
421270|NCT01001078|I-Gel
421271|NCT01001078|Supreme Laryngeal mask airway
421272|NCT01001078|Airway leak pressure
421273|NCT01001078|peak airway pressure
421274|NCT01001052|Healthy
421275|NCT01001052|bioavailability
421276|NCT01001039|chronic sinusitis
421277|NCT01001039|facial pain
421278|NCT01001026|vaccine
421279|NCT01001026|H1N1
421280|NCT01001026|influenza
421281|NCT01001026|H1N1 influenza vaccine
421282|NCT01001026|pandemic
421283|NCT01000987|alcohol
421284|NCT01000987|reactivity
421285|NCT01000987|smoking cessation medications
421286|NCT01000974|booster vaccination
421287|NCT01000974|Gram-negative bacterial infections
421288|NCT01000974|immunogenicity
421289|NCT01000974|vaccines, conjugate
421290|NCT01000974|primary vaccination course
421291|NCT01000974|Haemophilus influenzae type b
421292|NCT01000974|safety
421293|NCT01000974|infants, children
421294|NCT01000961|cystinosis
421295|NCT01000961|cysteamine
421296|NCT01000961|inheritable disease
421297|NCT01000961|orphan disease
421298|NCT01000961|CTNS protein, human
421299|NCT01000961|metabolic disease
421300|NCT01000961|nephropathic cystinosis
421301|NCT01000948|Prostate cancer
421302|NCT01000948|Castration resistant
421303|NCT01000948|Chemotherapy resistant
421304|NCT01000948|Endothelial receptor A inhibitor
421305|NCT01000948|ZD4054
421306|NCT01000935|Rotator Cuff Decompression Repair
421307|NCT01000922|Mealtime Insulin
421308|NCT01000922|Rapid acting insulin
421309|NCT01000922|Ultra fast VIAject
421310|NCT01000922|prandial insulin
421311|NCT01000896|Phase I
421312|NCT01000896|cancer
421313|NCT01000896|solid tumors
421314|NCT01000896|advanced solid malignancies
421315|NCT01000896|NSCLC
421316|NCT01000896|epithelial ovarian cancer
421317|NCT01000896|dose escalation
421318|NCT01000896|combination treatment
421319|NCT01000896|src inhibitor
421320|NCT01000896|Japanese
421321|NCT01000883|stage IIIA breast cancer
421322|NCT01000883|stage IIIB breast cancer
421323|NCT01000883|stage IIIC breast cancer
421324|NCT01000883|stage IV breast cancer
421325|NCT01000883|recurrent breast cancer
421326|NCT01000857|controlled-release tablet
421327|NCT01000857|repeat dose
421328|NCT01000857|immediate-release tablet
421329|NCT01000857|paroxetine
421330|NCT01000857|safety
421331|NCT01000857|crossover
421332|NCT01000857|pharmacokinetics
421333|NCT01000857|steady-state
421334|NCT01000857|Japanese healthy male volunteers
421335|NCT01000857|tolerance
421336|NCT01000844|Hemophilia
421337|NCT01000844|Joint
421338|NCT01000844|Cartilage
421339|NCT01000844|Damage
421340|NCT01000844|Prophylaxis
421341|NCT01000844|Factor VIII
421342|NCT01000844|FVIII
421343|NCT01000844|Disease
421344|NCT01000844|Arthropathy
421345|NCT01000831|vaccine
421346|NCT01000831|influenza
421347|NCT01000831|H1N1 influenza vaccine
421348|NCT01000831|influenza vaccine
421349|NCT01000831|Arepanrix
421350|NCT01000818|Treatment experienced
421351|NCT01000779|Non Cirrhotic Portal Hypertension, secondary prophylaxis
421352|NCT01000753|adult diffuse small cleaved cell lymphoma
421353|NCT01000753|adult diffuse mixed cell lymphoma
421354|NCT01000753|grade 1 follicular lymphoma
421355|NCT01000753|grade 2 follicular lymphoma
421356|NCT01000753|grade 3 follicular lymphoma
421357|NCT01000753|childhood immunoblastic large cell lymphoma
421358|NCT01000753|adult immunoblastic large cell lymphoma
421359|NCT01000753|mantle cell lymphoma
421360|NCT01000753|marginal zone lymphoma
421361|NCT01000753|small lymphocytic lymphoma
421362|NCT01000753|primary central nervous system non-Hodgkin lymphoma
421363|NCT01000753|cutaneous B-cell non-Hodgkin lymphoma
421364|NCT01000753|cutaneous T-cell non-Hodgkin lymphoma
421365|NCT01000753|lymphoproliferative disorder
421366|NCT01000740|EAP
421367|NCT01000740|Long term survival (3 years)
421368|NCT01000740|Gefitinib
421369|NCT01000740|efficacy
421370|NCT01000727|Atherosclerosis
421371|NCT01000727|Heart disease
421372|NCT01000727|Cardiovascular disease
421373|NCT01000727|Lp-PLA2 inhibitor
421374|NCT01000727|The TIMI Study Group
421375|NCT01000727|Coronary Heart Disease (CHD)
421376|NCT01000727|Acute Coronary Syndrome (ACS)
421377|NCT01000701|Inflammation
421378|NCT01000701|ACS
421379|NCT01000701|Prevention
421380|NCT01000701|Education
421381|NCT01000701|Clinical management
421382|NCT01000675|aneurysm
421383|NCT01000675|coils
421384|NCT01000662|whole breast radiotherapy
421385|NCT01000662|tumor bed boost
421386|NCT01000649|V1a agonist
421387|NCT01000636|Renal transplant patients
421388|NCT01000636|Actinic Keratoses
421389|NCT01000636|Metvix PDT
421390|NCT01000636|Field cancerisation
421391|NCT01000636|Gene expression
421392|NCT01000597|pharmacokinetics
421393|NCT01000597|serum cortisol
421394|NCT01000597|pharmacodynamics
421395|NCT01000597|fluticasone furoate
421396|NCT01000597|healthy Caucasian, Japanese, Korean and Chinese subjects
421397|NCT01000584|vaccine
421398|NCT01000584|H1N1
421399|NCT01000584|influenza
421400|NCT01000584|H1N1 influenza vaccine
421401|NCT01000584|influenza vaccine
421402|NCT01000584|seasonal Influenza
421403|NCT01000571|H1N1 pandemic flu
421404|NCT01000558|non-Hodgkin lymphoma
421405|NCT01000545|Diabetes Mellitus
421406|NCT01000545|Chronic Kidney Disease
421407|NCT01000545|Glycosaminoglycans
421408|NCT01000545|Sulodexide
421409|NCT01000545|Macroalbuminuria
421410|NCT01000545|Safety and Efficacy
421411|NCT01000532|steroid, leads, threshold, pacemaker
421412|NCT01000519|Diabetes mellitus
421413|NCT01000519|Randomized control trial
421414|NCT01000519|Exercise
421415|NCT01000519|Hemoglobin A, Glycosylated
421416|NCT01000506|Dose-ranging
421417|NCT01000506|Safety
421418|NCT01000506|Pharmacodynamics
421419|NCT01000506|eosinophils
421420|NCT01000506|SB-240563
421421|NCT01000506|Efficacy
421422|NCT01000506|Severe refractory asthma
421423|NCT01000506|mepolizumab
421424|NCT01000506|Placebo
421425|NCT01000493|efficacy
421426|NCT01000493|double-blind
421427|NCT01000493|Clinician Administered PTSD Scale
421428|NCT01000493|placebo
421429|NCT01000493|Sleep
421430|NCT01000493|safety
421431|NCT01000493|CAPS
421432|NCT01000493|neurokinin-1 antagonist
421433|NCT01000493|orvepitant
421434|NCT01000493|PTSD
421435|NCT01000493|randomized
421436|NCT01000493|Post traumatic stress disorder
421437|NCT01000493|Phase II
421438|NCT01000467|PK assessment for healthy male volunteer
421439|NCT01000467|Healthy male subjects aged 20 to 40 years
421440|NCT01000441|Rheumatoid arthritis with inadequate response to 1 anti-TNF
421441|NCT01000428|NSCLC
421442|NCT01000428|Tarceva
421443|NCT01000428|Positron emission technology
421444|NCT01000428|FLT
421445|NCT01000428|FDG
421446|NCT01000415|Stage Ib2-early IIb of cervical cancer
421447|NCT01000415|Neoadjuvant chemotherapy
421448|NCT01000415|Cisplatin plus gemcitabine
421449|NCT01000415|Radical hysterectomy with pelvic lymphadenectomy
421450|NCT01000415|Quality of life
421451|NCT01000415|Stage Ib2-IIb of cervical cancer patients
421452|NCT01000402|Bipolar Disorder
421453|NCT01000402|Attention-Deficit/Hyperactivity Disorder
421454|NCT01000402|Genetics
421455|NCT01000402|Environmental Factors
421456|NCT01000402|Family Factors
421457|NCT01000376|Cancer
421458|NCT01000376|solid tumors
421459|NCT01000350|orthostatic intolerance
421460|NCT01000350|exercise capacity
421461|NCT01000350|tachycardia
421462|NCT01000350|POTS
421463|NCT01000337|Liver Apoptosis
421464|NCT01000324|Hepatitis A
421465|NCT01000324|Hepatitis B
421466|NCT01000311|MenACWY conjugate vaccine in infants
421467|NCT01000311|Meningococcal vaccine in infants
421468|NCT01000311|MenACWY
421469|NCT01000246|mammacarcinoma
421470|NCT01000246|breastcancer
421471|NCT01000246|chemotherapy
421472|NCT01000246|heart failure
421473|NCT01000246|influenza virus vaccine
421474|NCT01000233|PATOLOGIC CALCIFICATION
421475|NCT01000233|AORTIC VALVE STENOSIS
421476|NCT01000233|INOSITOL HEXAPHOSPHATE
421477|NCT01000207|Influenza A
421478|NCT01000207|H1N1 subtype
421479|NCT01000207|Children/adolescent
421480|NCT01000207|Vaccine
421481|NCT01000207|Adjuvant
421482|NCT01000194|postprandial
421483|NCT01000194|gene expression profiles
421484|NCT01000194|microarray
421485|NCT01000168|Brain Injury
421486|NCT01000168|Rehabilitation
421487|NCT01000168|Treadmill therapy
421488|NCT01000155|fetal hemoglobin
421489|NCT01000155|vorinostat
421490|NCT01000155|HDAC inhibitor
421491|NCT01000155|SAHA
421492|NCT01000142|Osteopathic
421493|NCT01000142|Manipulation
421494|NCT01000142|Preventative
421495|NCT01000142|Elderly
421496|NCT01000142|Nursing Home
421497|NCT01000142|Prevention: General Health Status
421498|NCT01000129|Radiotherapy
421499|NCT01000129|Bladder cancer
421500|NCT01000129|Adaptive planning
421501|NCT01000116|Tapp
421502|NCT01000116|Early pain
421503|NCT01000116|well-being
421504|NCT01000116|Seroma
421505|NCT01000116|Haematoma
421506|NCT01000116|Fibrin glue
421507|NCT01000116|tacks
421508|NCT01000103|Stroke
421509|NCT01000103|Visuospatial neglect
421510|NCT01000103|Visuospatial extinction
421511|NCT01000103|Transcranial Magnetic Stimulation (TMS)
421512|NCT01000103|Non-invasive brain stimulation
421513|NCT01000103|Neuromodulation
421514|NCT01000103|Brain parietal cortex
421515|NCT01000103|Neurological sequels
421516|NCT01000103|Cognitive rehabilitation
421517|NCT01000090|Acromegaly
421518|NCT01000090|Somatostatin analogues
421519|NCT01000090|Treatment
421520|NCT01000077|Regenerative Medicine
421521|NCT01000077|Tissue Collection
421522|NCT01000077|Cell Culture Systems
421523|NCT01000077|Routine Surgery
421524|NCT01000064|Traumatic Brain Injury
421525|NCT01000064|Attention Deficit
421526|NCT01000064|TBI
421527|NCT01000051|Transplant Thrombocytopenia
421528|NCT01000051|Hematopoietic cell transplantation
421529|NCT01000051|HCT
421530|NCT01000051|Low platelet count
421531|NCT01000051|Bleeding
421532|NCT01000051|Blood clot
421533|NCT01000051|Stem Cell Transplant
421534|NCT01000051|Blood And Marrow Transplantation
421535|NCT01000051|Eltrombopag
421536|NCT01000051|Promacta
421537|NCT01000038|Wii-Fit
421538|NCT01000038|Assisted living
421539|NCT01000038|Alzheimer's dementia
421540|NCT01000025|stage IIIB non-small cell lung cancer
421541|NCT01000025|stage IV non-small cell lung cancer
421542|NCT01000025|recurrent non-small cell lung cancer
421543|NCT00999999|Craniotomy outcome
421544|NCT00999999|CSF leakage
421545|NCT00999999|Dural sealant
421546|NCT00999960|Laparoscopy
421547|NCT00999960|Prostate
421548|NCT00999960|Cancer
421549|NCT00999960|Learning
421550|NCT00999960|Simulation
421551|NCT00999960|Simulator
421552|NCT00999947|genetics
421553|NCT00999947|mutation screening
421554|NCT00999947|phenotype-genotype analysis
421555|NCT00999947|desmosomal genes
421556|NCT00999921|Fibrocystic Breast Disease
421557|NCT00999921|Fibroadenoma
421558|NCT00999921|Mastalgia
421559|NCT00999908|COPD
421560|NCT00999908|indacaterol
421561|NCT00999908|tiotropium
421562|NCT00999895|Schizophrenia
421563|NCT00999895|Switch of antipsychotic treatment
421564|NCT00999895|Outcome evaluation
421565|NCT00999895|monotherapy
421566|NCT00999895|Greece
421567|NCT00999882|mTor Kinase Inhibitor
421568|NCT00999882|Phase I/II
421569|NCT00999882|Dose escalation
421570|NCT00999882|Hepatocellular carcinoma (HCC)
421571|NCT00999882|Asia
421572|NCT00999882|HCC
421573|NCT00999882|Safety and pharmacokinetics
421574|NCT00999869|Newly diagnosed
421575|NCT00999869|Alopecia areata
421576|NCT00999869|Botulinum toxin A
421577|NCT00999869|Corticosteroid
421578|NCT00999869|Intralesional injection
421579|NCT00999856|medical device,
421580|NCT00999856|sub-conjunctival insert
421581|NCT00999856|photometer
421582|NCT00999856|fluorescence
421583|NCT00999856|subconjunctival interstitial fluid glucose
421584|NCT00999856|non-invasive measurement
421585|NCT00999843|Sorafenib
421586|NCT00999843|Three-dimensional conformal radiation therapy
421587|NCT00999843|Intensity-modulated radiation therapy
421588|NCT00999843|Transcatheter arterial chemoembolization
421589|NCT00999817|Drug-Drug interaction Study CYP2D6 inhibition Healthy Subjects
421590|NCT00999804|Locally Advanced Breast Cancer Neoadjuvant Endocrine
421591|NCT00999778|Autism
421592|NCT00999778|Social and Communication Deficits in Autism
421593|NCT00999778|Parent and Caregiver interventions with children with Autism
421594|NCT00999778|Autism Spectrum Disorder
421595|NCT00999778|ASD
421596|NCT00999765|Bipolar Disorder
421597|NCT00999765|Bipolar Depression
421598|NCT00999765|Mindfulness-Based Cognitive Therapy
421599|NCT00999765|MBCT
421600|NCT00999765|Maintenance
421601|NCT00999765|Euthymic
421602|NCT00999765|Efficacy
421603|NCT00999765|Feasibility
421604|NCT00999752|Hypertension
421605|NCT00999752|African Americans
421606|NCT00999752|Arterial Stiffness
421607|NCT00999752|Vascular Resistance
421608|NCT00999739|pneumococcal vaccines
421609|NCT00999739|HIV
421610|NCT00999739|antibody response
421611|NCT00999739|antibody affinity
421612|NCT00999739|Antibody formation
421613|NCT00999739|Phagocytosis
421614|NCT00999713|Acute Lung Injury
421615|NCT00999713|Cancer
421616|NCT00999713|Pediatrics
421617|NCT00999700|Locally advanced HNSCC
421618|NCT00999700|Chemo-radiation
421619|NCT00999700|Induction chemotherapy
421620|NCT00999700|Stage III/IV
421621|NCT00999700|Unresectable disease
421622|NCT00999687|Nail psoriasis
421623|NCT00999687|Indigo naturalis
421624|NCT00999674|Exercise
421625|NCT00999648|Tinnitus
421626|NCT00999648|Myofascial Trigger Points
421627|NCT00999648|Myofascial Pain Syndrome
421628|NCT00999648|Controlled Clinical Trial
421629|NCT00999635|Insoles
421630|NCT00999635|Prevention of Ulceration
421631|NCT00999635|Diabetic Foot
421632|NCT00999635|Neuropathic
421633|NCT00999622|infection
421634|NCT00999622|adult anaplastic astrocytoma
421635|NCT00999622|adult anaplastic oligodendroglioma
421636|NCT00999622|adult giant cell glioblastoma
421637|NCT00999622|adult gliosarcoma
421638|NCT00999622|adult oligodendroglioma
421639|NCT00999622|adult glioblastoma
421640|NCT00999622|adult diffuse astrocytoma
421641|NCT00999622|adult pilocytic astrocytoma
421642|NCT00999622|adult pineal gland astrocytoma
421643|NCT00999622|adult subependymal giant cell astrocytoma
421644|NCT00999609|Adeno-associated virus
421645|NCT00999609|AAV
421646|NCT00999609|Leber congenital amaurosis
421647|NCT00999609|RPE65
421648|NCT00999609|Gene therapy
421649|NCT00999609|Gene transfer
421650|NCT00999596|Breast Cancer
421651|NCT00999596|Digital Mammography
421652|NCT00999583|Cardiac arrest
421653|NCT00999583|erythropoietin
421654|NCT00999583|post-anoxic encephalopathy
421655|NCT00999583|neuroprotective drugs
421656|NCT00999570|outcome
421657|NCT00999570|quality of life
421658|NCT00999570|total knee arthroplasty
421659|NCT00999570|clinical outcome scores post total knee arthroplasty
421660|NCT00999570|quality of life scores post total knee arthroplasty
421661|NCT00999557|breast cancer
421662|NCT00999557|male breast cancer
421663|NCT00999557|alopecia
421664|NCT00999544|opioid
421665|NCT00999544|oxycodone
421666|NCT00999544|NK1 antagonist
421667|NCT00999544|aprepitant
421668|NCT00999544|intranasal
421669|NCT00999544|abuse
421670|NCT00999531|Cystic Fibrosis
421671|NCT00999531|CF
421672|NCT00999531|Mucociliary Clearance
421673|NCT00999531|Epithelial Sodium Channel Inhibitor
421674|NCT00999531|ENaC Inhibitor
421675|NCT00999531|Airway Hydration
421676|NCT00999531|Amiloride
421677|NCT00999518|Randomized double blind placebo-controlled parallel-group dose-range finding interstitial cystitis efficacy pain urinary symptoms safety
421678|NCT00999505|Schizophrenia
421679|NCT00999505|Amantadine
421680|NCT00999505|Residual symptoms
421681|NCT00999492|Tecnis Multifocal
421682|NCT00999492|Patients scheduled for cataract or lens replacement surgery with implantation of multifocal intraocular lenses
421683|NCT00999453|LDL-cholesterol
421684|NCT00999453|Prevalent peritoneal dialysis patients with hypercholesterolemia
421685|NCT00999440|Chronic Pain
421686|NCT00999440|Methadone
421687|NCT00999440|Perceived Sleep
421688|NCT00999440|QTc
421689|NCT00999427|Povidone-iodine
421690|NCT00999427|prostate cancer
421691|NCT00999427|biopsy
421692|NCT00999427|transrectal ultrasound
421693|NCT00999427|urinary tract infection
421694|NCT00999427|fever
421695|NCT00999427|sepsis
421696|NCT00999427|antisepsis
421697|NCT00999427|prevention
421698|NCT00999427|complications
421699|NCT00999414|MM
421700|NCT00999388|Lifestyle
421701|NCT00999388|Environment
421702|NCT00999388|Neurodegenerative Diseases
421703|NCT00999388|Elderly
421704|NCT00999388|Public Health
421705|NCT00999388|PD
421706|NCT00999388|Parkinson Disease
421707|NCT00999375|Type 1 Diabetes
421708|NCT00999375|Diet
421709|NCT00999375|Behavioral Intervention
421710|NCT00999375|Children
421711|NCT00999375|Adolescents
421712|NCT00999362|calcineurin activity
421713|NCT00999362|real-time PCR
421714|NCT00999362|Gene expression of calcineurin
421715|NCT00999362|T-lymphocytes
421716|NCT00999362|interferon-gamma
421717|NCT00999362|Pharmacodynamics
421718|NCT00999362|Pharmacokinetics
421719|NCT00999362|tacrolimus
421720|NCT00999362|western blot
421721|NCT00999362|Hoechst
421722|NCT00999349|iron overload condition
421723|NCT00999349|regular desferrioxamine administration
421724|NCT00999349|receiving continuous blood transfusions
421725|NCT00999336|Betrixaban
421726|NCT00999336|Renal impairment
421727|NCT00999336|Healthy
421728|NCT00999336|Kidney dysfunction
421729|NCT00999310|Klinefelter syndrome
421730|NCT00999310|Neuropsychology
421731|NCT00999310|Neuroradiology
421732|NCT00999310|Genetics
421733|NCT00999297|thermogenesis
421734|NCT00999297|respiratory quotient
421735|NCT00999297|fat oxidation
421736|NCT00999284|ZK200775 is tested for its effects on vision on healthy probands.
421737|NCT00999271|Glucose-dependent insulinotropic polypeptide
421738|NCT00999271|gastric emptying
421739|NCT00999271|appetite
421740|NCT00999271|energy intake
421741|NCT00999271|lipid metabolism
421742|NCT00999258|glomerular filtration rate
421743|NCT00999258|chronic allograft nephropathy
421744|NCT00999258|Kidney transplantation
421745|NCT00999258|African American
421746|NCT00999232|erythromycin
421747|NCT00999232|prokinetics
421748|NCT00999232|nasojejunal tubes
421749|NCT00999232|Bengmark feeding tube
421750|NCT00999232|post-pyloric feeding
421751|NCT00999232|pancreatitis
421752|NCT00999232|Non-critically ill patients having pancreatitis who require jejunal enteral nutrition
421753|NCT00999219|FK199B
421754|NCT00999219|Zolpidem
421755|NCT00999206|Influenza
421756|NCT00999206|Vaccine
421757|NCT00999206|CHMP criteria
421758|NCT00999193|Shoulder
421759|NCT00999193|Fracture
421760|NCT00999193|Locking Plate
421761|NCT00999193|Hemiarthroplasty
421762|NCT00999193|Conservative
421763|NCT00999193|Comminuted Proximal Humerus Fracture
421764|NCT00999180|Botulinum Toxin
421765|NCT00999180|Rehabilitation
421766|NCT00999180|Stroke
421767|NCT00999167|Cirrhosis
421768|NCT00999167|Episodic Hepatic Encephalopathy
421769|NCT00999167|HE
421770|NCT00999167|HPN-100
421771|NCT00999167|GT4P
421772|NCT00999167|glycerol phenylbutyrate
421773|NCT00999154|Energy Expenditure
421774|NCT00999154|Dietary Intake
421775|NCT00999154|Physical Activity
421776|NCT00999154|Body Weight Regulation
421777|NCT00999154|Sedentary
421778|NCT00999154|HV
421779|NCT00999154|Healthy Volunteer
421780|NCT00999128|PI3K inhibitor
421781|NCT00999128|PI3 kinase
421782|NCT00999128|PI3 kinase inhibitor
421783|NCT00999115|Rectovaginal Fistula
421784|NCT00999115|Crohn Disease
421785|NCT00999115|Allogenic
421786|NCT00999115|Adipose-Derived Stem Cells
421787|NCT00999102|hypertension
421788|NCT00999102|beta blockers
421789|NCT00999102|Metoprolol
421790|NCT00999102|blood pressure, high
421791|NCT00999102|antihypertensive agents
421792|NCT00999102|vascular resistance
421793|NCT00999102|adrenergic beta-receptor blockaders
421794|NCT00999102|beta-Adrenergic blockers
421795|NCT00999102|beta-Adrenergic Blocking Agents
421796|NCT00999102|beta-Adrenergic Receptor Blockaders
421797|NCT00999102|beta-Blockers, Adrenergic
421798|NCT00999102|Bystolic
421799|NCT00999102|Nebivolol
421800|NCT00999102|Nebivololum
421801|NCT00999102|Nebivololum [Latin]
421802|NCT00999102|R65,824
421803|NCT00999102|Beloc- Zok
421804|NCT00999102|H 93/26 succinate
421805|NCT00999102|Metoprolol succinate
421806|NCT00999102|Seloken ZOC
421807|NCT00999102|Selozok
421808|NCT00999102|Spesicor Dos
421809|NCT00999102|Toprol XL
421810|NCT00999102|Toprol-XL
421811|NCT00999102|UNII-TH25PD4CCB
421812|NCT00999089|Coronary disease
421813|NCT00999089|Coronary artery bypass grafting
421814|NCT00999089|Cardiopulmonary bypass
421815|NCT00999089|Extracorporeal circulation
421816|NCT00999089|Cardioplegia
421817|NCT00999089|Off pump
421818|NCT00999063|GerdQ
421819|NCT00999050|type two diabetes
421820|NCT00999050|gastric bypass surgery
421821|NCT00999050|overweight or moderately obese
421822|NCT00999011|critical care
421823|NCT00999011|inflammatory biomarkers
421824|NCT00999011|cytokines
421825|NCT00999011|mechanical ventilation
421826|NCT00999011|activity
421827|NCT00999011|mobility therapy
421828|NCT00999011|More than 48 hours of mechanical ventilation
421829|NCT00998998|iron deficiency anemia
421830|NCT00998998|infant behavior
421831|NCT00998998|infant development
421832|NCT00998972|kidney graft,
421833|NCT00998972|delayed graft function
421834|NCT00998972|N-acetylcysteine
421835|NCT00998959|Depression
421836|NCT00998959|Major Depression
421837|NCT00998946|Relapsed
421838|NCT00998946|Refractory
421839|NCT00998946|Non-Hodgkin's
421840|NCT00998933|Testosterone replacement therapy
421841|NCT00998920|Healthy volunteers
421842|NCT00998907|Open Abdominal Surgery
421843|NCT00998907|Fascial Closure
421844|NCT00998894|BIS
421845|NCT00998894|MAC
421846|NCT00998894|MAP
421847|NCT00998881|insulin resistance
421848|NCT00998868|Rotator Cuff
421849|NCT00998868|Tendinopathy
421850|NCT00998868|ultrasonography
421851|NCT00998855|Exercise in obesity
421852|NCT00998842|ECG
421853|NCT00998842|EKG
421854|NCT00998842|healthy subjects
421855|NCT00998842|electrocardiography, ambulatory
421856|NCT00998829|psoriasis
421857|NCT00998829|psoriatic arthritis
421858|NCT00998829|epidemiology
421859|NCT00998829|prevalence
421860|NCT00998816|thoracotomy
421861|NCT00998816|chronic
421862|NCT00998816|pain
421863|NCT00998816|pregabalin
421864|NCT00998816|Lyrica
421865|NCT00998803|Influenza virus
421866|NCT00998790|Urinary Incontinence, Stress
421867|NCT00998790|Intrinsic sphincter deficiency
421868|NCT00998790|Secondary
421869|NCT00998790|TUR
421870|NCT00998790|TURP
421871|NCT00998790|Radical prostatectomy
421872|NCT00998790|Open prostatectomy
421873|NCT00998790|Post-suprapubic prostatectomy
421874|NCT00998777|tubing program
421875|NCT00998777|shoulder strengthening
421876|NCT00998777|injury prevention
421877|NCT00998764|antibody
421878|NCT00998764|immunotherapy
421879|NCT00998751|cKIT inhibitor
421880|NCT00998751|GIST
421881|NCT00998712|gestational diabetes mellitus
421882|NCT00998712|pregnancy
421883|NCT00998712|cardiovascular disease risk
421884|NCT00998699|Diabetes
421885|NCT00998699|Type 1
421886|NCT00998686|diabetes
421887|NCT00998686|DPP4 inhibitor
421888|NCT00998686|dutogliptin
421889|NCT00998673|Silica gel fiber
421890|NCT00998673|Chronic venous leg ulcers
421891|NCT00998673|Venous ulcer
421892|NCT00998673|Stasis ulcer
421893|NCT00998673|Varicose ulcer
421894|NCT00998660|Parkinson's disease
421895|NCT00998660|Essential Tremor
421896|NCT00998660|Dystonia (where indication is approved)
421897|NCT00998660|Deep brain stimulation
421898|NCT00998660|Activa RC
421899|NCT00998647|modified ultrafiltration
421900|NCT00998647|cardiac surgery
421901|NCT00998647|ROTEM
421902|NCT00998647|Multiple Electrode Aggregometry
421903|NCT00998634|SCA2
421904|NCT00998634|Lithium
421905|NCT00998621|Hepatitis C, Chronic
421906|NCT00998621|HIV Infection
421907|NCT00998621|Medication Adherence
421908|NCT00998621|Questionnaire Design
421909|NCT00998621|Treatment experienced
421910|NCT00998595|Diabetes, Gestational
421911|NCT00998595|Postpartum Period
421912|NCT00998595|Reproductive Health Services
421913|NCT00998595|Health Promotion
421914|NCT00998595|Health Personnel
421915|NCT00998582|Cardiovascular Disease
421916|NCT00998582|HIV Infection
421917|NCT00998582|Abacavir
421918|NCT00998582|Artery Elasticity
421919|NCT00998582|Treatment experienced
421920|NCT00998556|Peripartum cardiomyopathy
421921|NCT00998556|Bromocriptine
421922|NCT00998543|Smallpox Vaccinia Virus Smallpox Vaccine Variola Virus
421923|NCT00998530|Trichomonas vaginalis
421924|NCT00998530|trichomoniasis
421925|NCT00998530|MLST
421926|NCT00998530|Multilocus sequence typing
421927|NCT00998517|Malnutrition
421928|NCT00998517|Supplemental Food
421929|NCT00998517|CSB++
421930|NCT00998517|Supplementary Plumpy
421931|NCT00998504|impaired fat oxidation
421932|NCT00998504|fat accumulation
421933|NCT00998504|mitochondrial dysfunction
421934|NCT00998504|mitochondrial biogenesis
421935|NCT00998465|Obesity
421936|NCT00998465|Hypertension
421937|NCT00998465|Salt sensitivity
421938|NCT00998465|Laparoscopic gastric bypass
421939|NCT00998465|Bariatric surgery
421940|NCT00998452|Weight
421941|NCT00998452|Diet
421942|NCT00998452|Physical Activity
421943|NCT00998452|Veterans
421944|NCT00998452|MOVE! Program
421945|NCT00998439|in stent restenosis
421946|NCT00998439|paclitaxel coated balloon catheter
421947|NCT00998439|pepcad
421948|NCT00998439|drug eluting balloon
421949|NCT00998426|hepatitis B immune globulin
421950|NCT00998426|HBIG
421951|NCT00998426|HepaGam B
421952|NCT00998426|orthotopic liver transplant
421953|NCT00998413|asthma
421954|NCT00998413|overweight
421955|NCT00998413|obesity
421956|NCT00998413|children
421957|NCT00998400|Cognitive-behavioral treatment
421958|NCT00998400|Well-being therapy
421959|NCT00998400|Depression
421960|NCT00998400|Demoralization
421961|NCT00998400|Acute coronary syndrome
421962|NCT00998361|Sarcoma
421963|NCT00998361|allogeneic
421964|NCT00998361|Hemopoietic stem cell transplant
421965|NCT00998348|parenting
421966|NCT00998348|diet
421967|NCT00998348|physical activity
421968|NCT00998348|family
421969|NCT00998348|home
421970|NCT00998348|child
421971|NCT00998335|Type 2 diabetes mellitus
421972|NCT00998335|Insulin therapy
421973|NCT00998335|Detemir (Levemir)
421974|NCT00998335|Aspart (Novolog)
421975|NCT00998335|Hepatic steatosis
421976|NCT00998322|metastatic
421977|NCT00998322|pancreatic
421978|NCT00998322|adenocarcinoma
421979|NCT00998322|REOLYSIN
421980|NCT00998322|chemotherapy
421981|NCT00998322|gemcitabine
421982|NCT00998309|skin infection
421983|NCT00998309|soft tissue infection
421984|NCT00998309|sexually-transmitted infection
421985|NCT00998309|infection oral
421986|NCT00998309|Regulatory Post Marketing Commitment Plan
421987|NCT00998270|MM
421988|NCT00998257|Contraception
421989|NCT00998257|Premenstrual Dysphoric Disorder
421990|NCT00998257|PMDD
421991|NCT00998257|Acne
421992|NCT00998244|low carbohydrate
421993|NCT00998244|low fat
421994|NCT00998244|diet
421995|NCT00998244|overweight
421996|NCT00998244|GERD
421997|NCT00998244|gastroesophageal reflux disease
421998|NCT00998244|acid reflux
421999|NCT00998244|heartburn
422000|NCT00998218|Sudden Cardiac Death
422001|NCT00998218|Arrythmias
422002|NCT00998218|Triggered activity
422003|NCT00998218|left ventricular dysfunction
422004|NCT00998192|carcinoma
422005|NCT00998192|squamous cell
422006|NCT00998192|lung
422007|NCT00998192|REOLYSIN
422008|NCT00998192|chemotherapy
422009|NCT00998192|carboplatin
422010|NCT00998192|paclitaxel
422011|NCT00998192|Carcinoma, Squamous Cell of the Lung
422012|NCT00998179|TENS
422013|NCT00998179|acupuncture
422014|NCT00998179|FEV1
422015|NCT00998179|Normal Healthy subjects
422016|NCT00998166|NSCLC
422017|NCT00998153|substance use
422018|NCT00998153|PTSD
422019|NCT00998153|risky behaviors
422020|NCT00998153|revictimization
422021|NCT00998140|resuscitation
422022|NCT00998140|sudden death
422023|NCT00998140|cardiopulmonary resuscitation
422024|NCT00998140|emergency medical services
422025|NCT00998140|termination of resuscitation
422026|NCT00998140|ventricular fibrillation
422027|NCT00998140|out-of-hospital cardiac arrest
422028|NCT00998140|asystole
422029|NCT00998140|medical futility
422030|NCT00998140|withdrawing treatment
422031|NCT00998140|transportation of patients
422032|NCT00998140|health expenditures
422033|NCT00998140|healthcare costs
422034|NCT00998127|Dual Anti-Platelet Therapy
422035|NCT00998127|Non-adherence
422036|NCT00998127|MACE
422037|NCT00998127|NACE
422038|NCT00998114|Early Cardiac Diastolic Dysfunction
422039|NCT00998114|Aerobic Exercise
422040|NCT00998114|Weight Reduction
422041|NCT00998101|stage IIIB non-small cell lung cancer
422042|NCT00998101|stage IV non-small cell lung cancer
422043|NCT00998101|recurrent non-small cell lung cancer
422044|NCT00998088|Blood management
422045|NCT00998088|Orthopedic surgery
422046|NCT00998088|elective
422047|NCT00998088|randomized study
422048|NCT00998088|adults
422049|NCT00998088|hip replacement
422050|NCT00998088|knee replacement
422051|NCT00998075|Bioequivalence
422052|NCT00998075|ASA
422053|NCT00998075|Esomeprazole
422054|NCT00998075|peptic ulcer disease
422055|NCT00998075|primary cardiovascular protection
422056|NCT00998075|healthy volunteers
422057|NCT00998062|Dyslipaemia
422058|NCT00998062|atherosclerosis risk
422059|NCT00998062|increased hsCRP
422060|NCT00998062|inflammatory and oxidative status in the Spanish population
422061|NCT00998036|TNBC
422062|NCT00998023|Angiogram
422063|NCT00998023|Catheter Angiogram
422064|NCT00998010|adult giant cell glioblastoma
422065|NCT00998010|adult glioblastoma
422066|NCT00998010|adult gliosarcoma
422067|NCT00997997|Skin Diseases, Bacterial
422068|NCT00997997|Product Surveillance
422069|NCT00997997|Postmarketing
422070|NCT00997984|ADHD
422071|NCT00997971|Hydrolysed rice protein formula
422072|NCT00997971|Cow's milk protein allergy
422073|NCT00997971|Infant formula
422074|NCT00997971|Gastrointestinal tolerance
422075|NCT00997945|Phase I, advanced solid malignancies, advance solid tumour
422076|NCT00997945|advanced cancer
422077|NCT00997945|ZD4054 (Zibotentan)
422078|NCT00997945|china
422079|NCT00997945|PK
422080|NCT00997945|pharmacokinetics
422081|NCT00997932|levonorgestrel releasing intrauterine device
422082|NCT00997932|levonorgestrel releasing intrauterine contraception
422083|NCT00997932|unintended pregnancy prevention
422084|NCT00997932|postpartum contraception
422085|NCT00997906|stage III lymphoepithelioma of the nasopharynx
422086|NCT00997906|stage III squamous cell carcinoma of the nasopharynx
422087|NCT00997906|stage IV lymphoepithelioma of the nasopharynx
422088|NCT00997906|stage IV squamous cell carcinoma of the nasopharynx
422089|NCT00997893|menopause
422090|NCT00997893|hot flashes
422091|NCT00997893|soy
422092|NCT00997893|estrogen
422093|NCT00997893|anxiety
422094|NCT00997880|rosuvastatin
422095|NCT00997867|Pain
422096|NCT00997867|Surgery
422097|NCT00997867|Catheter
422098|NCT00997867|Nerve Block
422099|NCT00997867|Popliteal
422100|NCT00997867|Sciatic
422101|NCT00997867|Femoral
422102|NCT00997867|Interscalene
422103|NCT00997867|UCSD
422104|NCT00997867|Moderate-to-severe pain
422105|NCT00997867|Perineural Catheter
422106|NCT00997867|Orthopedic Surgery
422107|NCT00997854|Feeding
422108|NCT00997854|Intolerance
422109|NCT00997854|Preterm
422110|NCT00997854|Bolus
422111|NCT00997841|POC
422112|NCT00997841|ROTEM
422113|NCT00997841|Multiplate
422114|NCT00997841|bleeding tendency
422115|NCT00997841|coagulation management
422116|NCT00997841|amount of transfused red blood cell concentrates,
422117|NCT00997841|FFP
422118|NCT00997841|platelet concentrates
422119|NCT00997841|rate of rethoracotomy
422120|NCT00997841|ventilation time
422121|NCT00997828|Coronary Artery Disease
422122|NCT00997828|stent
422123|NCT00997828|coronary artery bypass graft surgery
422124|NCT00997828|multivessel coronary artery disease
422125|NCT00997815|Recalcitrant
422126|NCT00997815|Alopecia totalis
422127|NCT00997815|Alopecia universalis
422128|NCT00997815|Botulinum toxin A
422129|NCT00997802|Computed Tomographic Colonography
422130|NCT00997802|Colonic Polyps
422131|NCT00997802|Colonic Neoplasms
422132|NCT00997802|Computer Aided Diagnosis
422133|NCT00997789|Rebamipide
422134|NCT00997789|Bioequivalence
422135|NCT00997789|ABCB1 genetic polymorphisms
422136|NCT00997776|Hip Fracture
422137|NCT00997776|Exercise
422138|NCT00997776|Rehabilitation
422139|NCT00997776|Functional Performance
422140|NCT00997763|stenting, XIENCE V, CYPHER
422141|NCT00997750|ACS
422142|NCT00997750|Acute Coronary Syndrome
422143|NCT00997750|NSAID
422144|NCT00997750|Lornoxicam
422145|NCT00997750|Xefocam
422146|NCT00997737|incentive spirometry
422147|NCT00997737|diaphragm mobility
422148|NCT00997737|ultrasound
422149|NCT00997737|diaphragmatic breathing
422150|NCT00997724|assisted-VATS (video-assisted thoracoscopic surgery)
422151|NCT00997724|sleeve lobectomy
422152|NCT00997724|bronchoplasty
422153|NCT00997711|Diabetes
422154|NCT00997711|death
422155|NCT00997711|MI
422156|NCT00997711|TVR
422157|NCT00997698|Intracranial aneurysm
422158|NCT00997698|Magnetic resonance angiography
422159|NCT00997698|Epidemiology
422160|NCT00997685|XELOX
422161|NCT00997685|potentially resectable liver metastasis from CRC
422162|NCT00997672|MSA
422163|NCT00997672|Lithium
422164|NCT00997672|Lithium carbonate
422165|NCT00997672|MSA-P
422166|NCT00997672|MSA-C
422167|NCT00997659|chromium picolinate
422168|NCT00997659|insulin resistance
422169|NCT00997659|obesity
422170|NCT00997646|Performance
422171|NCT00997646|hospitalist
422172|NCT00997646|ward
422173|NCT00997646|hospitalization
422174|NCT00997633|Intraperitoneal volume
422175|NCT00997633|peritoneal carcinomatosis
422176|NCT00997633|cytoreductive surgery
422177|NCT00997633|SPECT
422178|NCT00997633|intraperitoneal chemotherapy
422179|NCT00997620|Hay Fever
422180|NCT00997620|Daytime somnolence
422181|NCT00997620|Cognition
422182|NCT00997607|Vaccine
422183|NCT00997594|adrenal gland
422184|NCT00997581|Gout
422185|NCT00997568|transesophageal
422186|NCT00997568|transducer
422187|NCT00997568|TEE
422188|NCT00997555|inhalation
422189|NCT00997555|bronchoscopy
422190|NCT00997555|burn
422191|NCT00997555|pneumonia
422192|NCT00997529|Stem cell transplant
422193|NCT00997529|Non-myeloablative
422194|NCT00997529|Metastatic Solid Tumor
422195|NCT00997529|Donor Leukocyte Infusion
422196|NCT00997516|Laparoscopy
422197|NCT00997516|Appendicitis
422198|NCT00997516|Single-incision laparoscopic surgery
422199|NCT00997516|SILS
422200|NCT00997490|depression
422201|NCT00997490|HAMD 21
422202|NCT00997490|anxiety
422203|NCT00997490|HAMA
422204|NCT00997490|Hypericum
422205|NCT00997490|Valerian
422206|NCT00997490|Passionflower
422207|NCT00997490|F32.0
422208|NCT00997490|F33.0
422209|NCT00997477|aerolizer
422210|NCT00997477|formoterol
422211|NCT00997477|budesonide
422212|NCT00997477|asthma
422213|NCT00997451|Medically unexplained chronic fatigue
422214|NCT00997451|Chronic fatigue syndrome
422215|NCT00997451|Cognitive-behavior therapy
422216|NCT00997451|Self-management
422217|NCT00997451|Primary care
422218|NCT00997451|Nurses
422219|NCT00997451|Economic analysis
422220|NCT00997451|Cost effectiveness
422221|NCT00997451|One year follow-up
422222|NCT00997425|wandering
422223|NCT00997425|subjective exit barriers
422224|NCT00997399|Ph I
422225|NCT00997399|panobinostat (DACi)
422226|NCT00997399|PK & safety
422227|NCT00997399|solid tumors
422228|NCT00997399|varying renal function
422229|NCT00997399|advanced
422230|NCT00997386|Hematologic malignancies
422231|NCT00997386|lymphoma, leukemia, MDS (myelodysplastic syndrome)
422232|NCT00997386|reduced-intensity preparative regimen
422233|NCT00997386|allogeneic peripheral blood stem cell transplant
422234|NCT00997386|myelofibrosis or other myeloproliferative syndromes
422235|NCT00997373|Endometrial Cancer
422236|NCT00997373|Endometrial Carcinoma
422237|NCT00997373|Aromatase Inhibitor
422238|NCT00997373|Letrozole
422239|NCT00997373|Femara
422240|NCT00997360|Phase 1
422241|NCT00997360|Maximum tolerated dose
422242|NCT00997360|Solid tumors
422243|NCT00997334|erlotinib
422244|NCT00997334|EGFR mutation
422245|NCT00997334|NSCLC
422246|NCT00997321|ketamine
422247|NCT00997321|propofol
422248|NCT00997321|procedural sedation
422249|NCT00997321|moderate procedural sedation in the ED
422250|NCT00997308|AZD1446
422251|NCT00997308|to investigate safety and tolerability in Healthy subjects during 4 weeks of administration
422252|NCT00997295|low flow gas
422253|NCT00997295|Heat and moisture exchanger
422254|NCT00997295|Humidity
422255|NCT00997295|Temperature
422256|NCT00997295|Core temperature
422257|NCT00997295|Women
422258|NCT00997269|CoQ-10
422259|NCT00997269|statin
422260|NCT00997269|muscle pain
422261|NCT00997269|cardiovascular
422262|NCT00997256|sleep-EEG
422263|NCT00997256|sleep architecture
422264|NCT00997256|sleep duration
422265|NCT00997256|sleep continuity
422266|NCT00997256|REM-sleep
422267|NCT00997256|vigilance
422268|NCT00997256|well-being
422269|NCT00997256|Healthy volunteers
422270|NCT00997243|de novo myelodysplastic syndromes
422271|NCT00997243|secondary myelodysplastic syndromes
422272|NCT00997243|chronic myelomonocytic leukemia
422273|NCT00997243|refractory anemia with excess blasts in transformation
422274|NCT00997243|refractory anemia with excess blasts
422275|NCT00997243|refractory anemia with ringed sideroblasts
422276|NCT00997243|refractory anemia
422277|NCT00997243|refractory cytopenia with multilineage dysplasia
422278|NCT00997230|EGFR mutation ,newly diagnosed NSCLC, locally advanced or metastatic NSCLC
422279|NCT00997217|RIPC
422280|NCT00997217|cardiac surgery
422281|NCT00997217|ischemic preconditioning
422282|NCT00997217|cardiac surgical procedures
422283|NCT00997204|HAE
422284|NCT00997204|Type I HAE
422285|NCT00997204|Type II HAE
422286|NCT00997191|Bevacizumab
422287|NCT00997191|Diabetes
422288|NCT00997191|Intravitreal
422289|NCT00997191|Macular edema
422290|NCT00997191|triamcinolone
422291|NCT00997191|VEGF
422292|NCT00997178|Diabetes
422293|NCT00997178|Diabetes Mellitus
422294|NCT00997178|Periodontal Disease
422295|NCT00997178|Periodontitis
422296|NCT00997178|Glycosylated Hemoglobin
422297|NCT00997178|HbA1c
422298|NCT00997165|fatty liver
422299|NCT00997165|adipose tissue
422300|NCT00997152|Diabetes
422301|NCT00997139|healthcare
422302|NCT00997139|staphylococcus aureus
422303|NCT00997139|nasal
422304|NCT00997126|propofol
422305|NCT00997126|alfentanil
422306|NCT00997126|nitrous oxide
422307|NCT00997126|moderate procedural sedation
422308|NCT00997126|Moderate Procedural Sedation in the Emergency Department
422309|NCT00997113|propofol
422310|NCT00997113|alfentanil
422311|NCT00997113|procedural sedation
422312|NCT00997113|stress biomarkers
422313|NCT00997113|Deep procedural sedation in the ED
422314|NCT00997100|Systemic Lupus Erythematosus (SLE)
422315|NCT00997100|ABR-215757
422316|NCT00997100|Change in Biomarkers
422317|NCT00997087|OCD
422318|NCT00997074|pain after abortion
422319|NCT00997074|abortion
422320|NCT00997035|Fungal Infections
422321|NCT00997035|Eye Disease
422322|NCT00997035|Fungal Keratitis
422323|NCT00997035|Visual Acuity
422324|NCT00997022|HCC
422325|NCT00997022|High-risk Hepatocellular Cancer
422326|NCT00997009|EGFR
422327|NCT00997009|chemotherapy
422328|NCT00996996|Radioimmunotherapy
422329|NCT00996996|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody
422330|NCT00996996|Tositumomab and Iodine I 131 Tositumomab
422331|NCT00996996|non-Hodgkin's Lymphoma
422332|NCT00996996|Bexxar
422333|NCT00996970|HIV
422334|NCT00996970|H1N1
422335|NCT00996970|Influenza
422336|NCT00996970|Vaccination
422337|NCT00996970|Seroresponse
422338|NCT00996970|Immunogenicity
422339|NCT00996970|Vaccine
422340|NCT00996944|ropinirole
422341|NCT00996944|haemodialysis
422342|NCT00996944|restless legs syndrome
422343|NCT00996931|autistic spectrum disorder
422344|NCT00996931|lenalidomide
422345|NCT00996918|antibody
422346|NCT00996905|Epidural Analgesia
422347|NCT00996905|Ultrasound
422348|NCT00996905|Training, Inservice
422349|NCT00996892|GDC0941
422350|NCT00996892|GDC0973
422351|NCT00996892|MEK
422352|NCT00996892|MEK Inhibitor
422353|NCT00996892|PI3K
422354|NCT00996892|PI3K Inhibitor
422355|NCT00996892|PI3 Kinase
422356|NCT00996892|PI3 Kinase Inhibitor
422357|NCT00996879|Human Volunteers
422358|NCT00996853|safety
422359|NCT00996853|Influenza
422360|NCT00996853|vaccine
422361|NCT00996853|reactogenicity
422362|NCT00996853|swine flu
422363|NCT00996840|dilmapimod
422364|NCT00996840|p38
422365|NCT00996840|SB-681323
422366|NCT00996840|Acute Lung Injury (ALI)
422367|NCT00996840|Acute Respiratory Distress Syndrome (ARDS)
422368|NCT00996827|Melanoma
422369|NCT00996827|Skin cancer
422370|NCT00996827|Vitamin D
422371|NCT00996827|Vitamin D receptor
422372|NCT00996827|Sunlight
422373|NCT00996827|Cytokine
422374|NCT00996814|Bioethics
422375|NCT00996788|Patients suffering of dyspepsia due to chronic gastritis
422376|NCT00996775|Alcohol Consumption
422377|NCT00996762|bioequivalence, lapatinib, GW572016
422378|NCT00996736|Fungal Infections
422379|NCT00996736|Eye Disease
422380|NCT00996736|Fungal Keratitis
422381|NCT00996736|Visual Acuity
422382|NCT00996710|Genome-wide
422383|NCT00996710|09-068
422384|NCT00996697|COPD (chronic obstructive pulmonary disease)
422385|NCT00996684|Wet age related macular degeneration (AMD)
422386|NCT00996684|Wet AMD
422387|NCT00996684|Vitreomacular adhesion (VMA)
422388|NCT00996684|Vitreomacular traction (VMT)
422389|NCT00996684|Neovascular age related macular degeneration
422390|NCT00996671|focal adhesion kinase inhibitor
422391|NCT00996671|healthy volunteers
422392|NCT00996671|first time in human
422393|NCT00996645|Diabetes Mellitus, Type 2
422394|NCT00996645|Coronary Artery Disease
422395|NCT00996645|Primary Health Care
422396|NCT00996645|Feedback, Psychological
422397|NCT00996645|Quality Assurance, Health Care
422398|NCT00996632|breast cancer
422399|NCT00996632|ultrasonic knife
422400|NCT00996632|volume drainage
422401|NCT00996593|Tositumomab
422402|NCT00996593|radioimmunotherapy
422403|NCT00996593|rituximab
422404|NCT00996593|anti-B1
422405|NCT00996593|I 131
422406|NCT00996593|Bexxar
422407|NCT00996593|iodine
422408|NCT00996593|non-Hodgkin's lymphoma
422409|NCT00996580|Contraception
422410|NCT00996580|Oral contraceptives
422411|NCT00996567|Malignant mesothelioma
422412|NCT00996554|Hand-sutured colo-colonic and ileo-colonic anastomoses in elective surgery
422413|NCT00996541|Runaway youth
422414|NCT00996541|Homeless youth
422415|NCT00996541|Family intervention
422416|NCT00996541|Family functioning
422417|NCT00996541|HIV risk behavior
422418|NCT00996541|HIV Seronegativity
422419|NCT00996528|fetal alcohol syndrome
422420|NCT00996528|alcohol abuse
422421|NCT00996528|HIV
422422|NCT00996528|malnutrition
422423|NCT00996528|children
422424|NCT00996528|mentor mother
422425|NCT00996528|behavioral intervention
422426|NCT00996528|South Africa
422427|NCT00996528|Maternal alcohol use
422428|NCT00996528|HIV-related transmission behaviors
422429|NCT00996528|low birth weight babies and low-weight children
422430|NCT00996528|HIV Seronegativity
422431|NCT00996515|Advanced Solid Tumor Malignancies
422432|NCT00996515|Erlotinib
422433|NCT00996515|Vidaza
422434|NCT00996515|Tarceva
422435|NCT00996515|5-azacytidine
422436|NCT00996476|Hepatitis C
422437|NCT00996476|Hepatitis C virus
422438|NCT00996476|Interferon Alfa-2a
422439|NCT00996476|Ribavirin
422440|NCT00996476|Viral RNA
422441|NCT00996450|brain tumour
422442|NCT00996437|vitreous
422443|NCT00996437|hemorrhage
422444|NCT00996437|proliferative
422445|NCT00996437|diabetic
422446|NCT00996437|retinopathy
422447|NCT00996437|intravitreal
422448|NCT00996437|ranibizumab
422449|NCT00996437|Lucentis
422450|NCT00996437|saline
422451|NCT00996437|vitrectomy
422452|NCT00996411|Healthy volunteers are being studied to evaluate the subject-rated, behavioral, and abuse liability effects of salvinorin A
422453|NCT00996398|Cryotherapy
422454|NCT00996398|Joint Position Sense
422455|NCT00996398|Proprioception
422456|NCT00996398|Pre Cooling
422457|NCT00996398|Knee Injury
422458|NCT00996398|Physical Therapy Modalities
422459|NCT00996398|Physical Therapy Techniques
422460|NCT00996398|Weightbearing
422461|NCT00996398|NonWeightbearing
422462|NCT00996398|Randomised Control Trial
422463|NCT00996385|Pleural Mesothelioma
422464|NCT00996385|Peritoneal Mesothelioma
422465|NCT00996359|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
422466|NCT00996359|adult acute myeloid leukemia with inv(16)(p13;q22)
422467|NCT00996359|adult acute myeloid leukemia with t(15;17)(q22;q12)
422468|NCT00996359|adult acute myeloid leukemia with t(16;16)(p13;q22)
422469|NCT00996359|adult acute myeloid leukemia with t(8;21)(q22;q22)
422470|NCT00996359|recurrent adult acute myeloid leukemia
422471|NCT00996359|adult acute myeloid leukemia in remission
422472|NCT00996359|recurrent adult acute lymphoblastic leukemia
422473|NCT00996359|adult acute lymphoblastic leukemia in remission
422474|NCT00996359|relapsing chronic myelogenous leukemia
422475|NCT00996359|accelerated phase chronic myelogenous leukemia
422476|NCT00996359|chronic phase chronic myelogenous leukemia
422477|NCT00996359|blastic phase chronic myelogenous leukemia
422478|NCT00996359|refractory chronic lymphocytic leukemia
422479|NCT00996359|de novo myelodysplastic syndromes
422480|NCT00996359|previously treated myelodysplastic syndromes
422481|NCT00996359|secondary myelodysplastic syndromes
422482|NCT00996359|chronic myelomonocytic leukemia
422483|NCT00996359|recurrent adult diffuse large cell lymphoma
422484|NCT00996359|recurrent grade 1 follicular lymphoma
422485|NCT00996359|recurrent grade 2 follicular lymphoma
422486|NCT00996359|recurrent grade 3 follicular lymphoma
422487|NCT00996359|recurrent mantle cell lymphoma
422488|NCT00996359|recurrent adult diffuse small cleaved cell lymphoma
422489|NCT00996359|recurrent marginal zone lymphoma
422490|NCT00996359|recurrent small lymphocytic lymphoma
422491|NCT00996359|recurrent adult Burkitt lymphoma
422492|NCT00996359|recurrent adult diffuse mixed cell lymphoma
422493|NCT00996359|recurrent adult immunoblastic large cell lymphoma
422494|NCT00996359|recurrent adult lymphoblastic lymphoma
422495|NCT00996359|recurrent adult T-cell leukemia/lymphoma
422496|NCT00996359|recurrent cutaneous T-cell non-Hodgkin lymphoma
422497|NCT00996359|recurrent mycosis fungoides/Sezary syndrome
422498|NCT00996359|adult nasal type extranodal NK/T-cell lymphoma
422499|NCT00996359|peripheral T-cell lymphoma
422500|NCT00996359|hepatosplenic T-cell lymphoma
422501|NCT00996359|anaplastic large cell lymphoma
422502|NCT00996359|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
422503|NCT00996359|nodal marginal zone B-cell lymphoma
422504|NCT00996359|splenic marginal zone lymphoma
422505|NCT00996359|recurrent adult Hodgkin lymphoma
422506|NCT00996359|refractory multiple myeloma
422507|NCT00996359|childhood acute myeloid leukemia in remission
422508|NCT00996359|recurrent childhood acute myeloid leukemia
422509|NCT00996359|childhood acute lymphoblastic leukemia in remission
422510|NCT00996359|recurrent childhood acute lymphoblastic leukemia
422511|NCT00996359|childhood diffuse large cell lymphoma
422512|NCT00996359|recurrent childhood large cell lymphoma
422513|NCT00996359|Burkitt lymphoma
422514|NCT00996359|childhood immunoblastic large cell lymphoma
422515|NCT00996359|angioimmunoblastic T-cell lymphoma
422516|NCT00996359|recurrent childhood lymphoblastic lymphoma
422517|NCT00996359|recurrent childhood anaplastic large cell lymphoma
422518|NCT00996359|recurrent childhood grade III lymphomatoid granulomatosis
422519|NCT00996359|recurrent childhood small noncleaved cell lymphoma
422520|NCT00996359|childhood nasal type extranodal NK/T-cell lymphoma
422521|NCT00996346|INST 0909
422522|NCT00996346|Irinotecan
422523|NCT00996346|Temsirolimus
422524|NCT00996346|refractory sarcomas
422525|NCT00996346|3066K1
422526|NCT00996346|3066K1-1208
422527|NCT00996346|20091334
422528|NCT00996333|Stage IVB
422529|NCT00996320|Internship and Residency
422530|NCT00996320|Medical Errors
422531|NCT00996320|Burnout, Professional
422532|NCT00996320|Burnout
422533|NCT00996320|Depression
422534|NCT00996320|Actigraphy
422535|NCT00996320|Personnel Staffing and Scheduling
422536|NCT00996320|Sleep Deprivation
422537|NCT00996320|Workload
422538|NCT00996320|Humans
422539|NCT00996320|Adult
422540|NCT00996320|Male
422541|NCT00996320|Female
422542|NCT00996320|Intensive Care Units
422543|NCT00996320|Prospective Studies
422544|NCT00996320|Crossover Studies
422545|NCT00996320|Work Schedule Tolerance
422546|NCT00996320|Disorders of Excessive Somnolence
422547|NCT00996320|Guideline Adherence
422548|NCT00996320|Internal Medicine Education
422549|NCT00996307|Swine Flu
422550|NCT00996307|Flu
422551|NCT00996307|Vaccine
422552|NCT00996307|Children
422553|NCT00996307|Adjuvant
422554|NCT00996307|A/H1N1 2009 Influenza
422555|NCT00996281|Hypertensive
422556|NCT00996281|Blood Pressure, High
422557|NCT00996281|Cardiovascular disease
422558|NCT00996281|Vascular Disease
422559|NCT00996281|Drug Therapy
422560|NCT00996268|hypertriglyceridemia
422561|NCT00996268|GSK2212836
422562|NCT00996268|relative bioavailability
422563|NCT00996242|Schizophrenia
422564|NCT00996242|L-lysine
422565|NCT00996242|PANSS
422566|NCT00996229|Diet
422567|NCT00996229|elderly
422568|NCT00996229|cognition
422569|NCT00996229|prevention
422570|NCT00996229|cognitive decline
422571|NCT00996229|Lifestyle
422572|NCT00996216|Peginterferon
422573|NCT00996216|Platelets
422574|NCT00996216|Ribavirin
422575|NCT00996216|Hepatitis C-related thrombocytopenia
422576|NCT00996216|Thrombocytopenia
422577|NCT00996216|Hepatitis C
422578|NCT00996216|Thrombopoietin
422579|NCT00996190|transthoracic bioreactance
422580|NCT00996190|noninvasive monitoring
422581|NCT00996190|vasopressor
422582|NCT00996190|blood pressure
422583|NCT00996177|Pain
422584|NCT00996177|Patient-controlled analgesia
422585|NCT00996177|Postoperative pain
422586|NCT00996177|Transdermal fentanyl
422587|NCT00996177|Surgical pain
422588|NCT00996177|Opioid analgesics
422589|NCT00996151|Hypergonadism
422590|NCT00996151|Testosterone Transfer
422591|NCT00996138|Influenza A
422592|NCT00996138|H1N1 subtype
422593|NCT00996138|Adult
422594|NCT00996138|Vaccine
422595|NCT00996138|Adjuvant
422596|NCT00996138|Swine-Origin Influenza A H1N1 Virus
422597|NCT00996125|Immunogenicity
422598|NCT00996125|Safety
422599|NCT00996125|Human papillomavirus
422600|NCT00996125|China
422601|NCT00996125|HPV vaccine
422602|NCT00996112|primary health care
422603|NCT00996099|continuous glucose monitoring
422604|NCT00996099|intensive insulin therapy
422605|NCT00996099|critically ill
422606|NCT00996099|cardiac surgery
422607|NCT00996099|hyperglycemia of critically ill
422608|NCT00996073|Degenerative disc disease
422609|NCT00996073|Spondylolisthesis
422610|NCT00996073|Spinal stenosis
422611|NCT00996073|Stem cells
422612|NCT00996073|Adult Stem Cells
422613|NCT00996073|Spinal Fusion
422614|NCT00996073|Lumbar Spinal Fusion
422615|NCT00996073|TLIF
422616|NCT00996073|PLIF
422617|NCT00996073|Mesoblast
422618|NCT00996060|Lung Cancer
422619|NCT00996060|Advanced Lung Cancer
422620|NCT00996060|Unresectable Lung cancer
422621|NCT00996060|Previously treated lung cancer
422622|NCT00996047|untreated adult acute lymphoblastic leukemia
422623|NCT00996047|accelerated phase chronic myelogenous leukemia
422624|NCT00996047|acute undifferentiated leukemia
422625|NCT00996047|adult acute lymphoblastic leukemia in remission
422626|NCT00996047|adult acute myeloid leukemia in remission
422627|NCT00996047|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
422628|NCT00996047|adult acute myeloid leukemia with inv(16)(p13;q22)
422629|NCT00996047|adult acute myeloid leukemia with t(15;17)(q22;q12)
422630|NCT00996047|adult acute myeloid leukemia with t(16;16)(p13;q22)
422631|NCT00996047|adult acute myeloid leukemia with t(8;21)(q22;q22)
422632|NCT00996047|atypical chronic myeloid leukemia, BCR-ABL1 negative
422633|NCT00996047|blastic phase chronic myelogenous leukemia
422634|NCT00996047|childhood acute lymphoblastic leukemia in remission
422635|NCT00996047|childhood acute myeloid leukemia in remission
422636|NCT00996047|childhood chronic myelogenous leukemia
422637|NCT00996047|chronic myelomonocytic leukemia
422638|NCT00996047|chronic phase chronic myelogenous leukemia
422639|NCT00996047|juvenile myelomonocytic leukemia
422640|NCT00996047|mast cell leukemia
422641|NCT00996047|meningeal chronic myelogenous leukemia
422642|NCT00996047|progressive hairy cell leukemia, initial treatment
422643|NCT00996047|prolymphocytic leukemia
422644|NCT00996047|recurrent adult acute lymphoblastic leukemia
422645|NCT00996047|recurrent adult acute myeloid leukemia
422646|NCT00996047|recurrent childhood acute lymphoblastic leukemia
422647|NCT00996047|recurrent childhood acute myeloid leukemia
422648|NCT00996047|refractory chronic lymphocytic leukemia
422649|NCT00996047|refractory hairy cell leukemia
422650|NCT00996047|relapsing chronic myelogenous leukemia
422651|NCT00996047|secondary acute myeloid leukemia
422652|NCT00996047|stage I chronic lymphocytic leukemia
422653|NCT00996047|stage II chronic lymphocytic leukemia
422654|NCT00996047|stage III chronic lymphocytic leukemia
422655|NCT00996047|stage IV chronic lymphocytic leukemia
422656|NCT00996047|T-cell large granular lymphocyte leukemia
422657|NCT00996047|untreated adult acute myeloid leukemia
422658|NCT00996047|untreated childhood acute lymphoblastic leukemia
422659|NCT00996047|untreated childhood acute myeloid leukemia and other myeloid malignancies
422660|NCT00996047|untreated hairy cell leukemia
422661|NCT00996047|childhood myelodysplastic syndromes
422662|NCT00996047|de novo myelodysplastic syndromes
422663|NCT00996047|previously treated myelodysplastic syndromes
422664|NCT00996047|secondary myelodysplastic syndromes
422665|NCT00996047|myelodysplastic/myeloproliferative neoplasm, unclassifiable
422666|NCT00996047|myelodysplastic/myeloproliferative neoplasms
422667|NCT00996034|Nicotine, SPECT, vaccine, receptor
422668|NCT00996021|GSK1349572
422669|NCT00996021|moxifloxacin
422670|NCT00996021|Avelox
422671|NCT00996021|QTc
422672|NCT00995982|Influenza
422673|NCT00995982|Healthy
422674|NCT00995982|Immunity
422675|NCT00995982|Preventive
422676|NCT00995982|Flu
422677|NCT00995982|HV
422678|NCT00995982|Healthy Volunteer
422679|NCT00995969|Mild to moderate psoriasis vulgaris
422680|NCT00995956|Albumin
422681|NCT00995956|Mycophenolic acid
422682|NCT00995956|IMPDH
422683|NCT00995956|Free fraction
422684|NCT00995930|Atherosclerosis,
422685|NCT00995930|Type 2 Diabetes Mellitus, T2DM,
422686|NCT00995930|Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab
422687|NCT00995917|acupuncture
422688|NCT00995917|menstrual pain
422689|NCT00995917|dysmenorrhea
422690|NCT00995917|menstrual cramps
422691|NCT00995917|vitamin K1
422692|NCT00995904|asthmatic children
422693|NCT00995891|Laboratory Research Specimens
422694|NCT00995891|Biologic Samples
422695|NCT00995891|Sample Collection
422696|NCT00995891|Tissue Procurement
422697|NCT00995891|HV
422698|NCT00995891|Healthy Volunteer
422699|NCT00995878|Uterine fibroids
422700|NCT00995878|Fibroids
422701|NCT00995878|Uterine leiomyomas
422702|NCT00995878|UAE
422703|NCT00995878|UFE
422704|NCT00995878|Magnetic resonance guided focused ultrasound
422705|NCT00995878|MRgFUS
422706|NCT00995878|Pelvic pain
422707|NCT00995865|Prevention of yellow fever virus infection
422708|NCT00995852|Endoscopic lung volume reduction
422709|NCT00995852|emphysema
422710|NCT00995852|COPD
422711|NCT00995852|Patients with bilateral heterogeneous pulmonary emphysema
422712|NCT00995839|terlipressin
422713|NCT00995839|vasopressin
422714|NCT00995839|sepsis
422715|NCT00995839|septic shock
422716|NCT00995839|norepinephrine
422717|NCT00995813|Intestinal failure
422718|NCT00995813|Rotavirus vaccine
422719|NCT00995813|Infants
422720|NCT00995800|Asthma
422721|NCT00995787|Type II diabetes mellitus
422722|NCT00995787|metformin
422723|NCT00995787|sulfonylurea
422724|NCT00995774|stroke
422725|NCT00995774|function
422726|NCT00995774|arm
422727|NCT00995774|hand
422728|NCT00995774|robotic
422729|NCT00995774|therapy
422730|NCT00995774|motor
422731|NCT00995774|movement
422732|NCT00995774|treatment
422733|NCT00995761|biweekly
422734|NCT00995761|docetaxel
422735|NCT00995761|cisplatin
422736|NCT00995761|non-small cell lung cancer
422737|NCT00995735|NOTES
422738|NCT00995735|Natural Orifice Translumenal Endoscopic surgery
422739|NCT00995735|Cholecystectomy
422740|NCT00995735|Appendectomy
422741|NCT00995735|Endoscopy
422742|NCT00995735|Laparoscopy
422743|NCT00995735|Minimally invasive surgery
422744|NCT00995735|clinical trials
422745|NCT00995722|Ocular myasthenia gravis
422746|NCT00995722|Prednisone
422747|NCT00995722|Steroids
422748|NCT00995709|Behçet's disease,
422749|NCT00995709|intermediate uveitis
422750|NCT00995709|panuveitis
422751|NCT00995709|posterior uveitis
422752|NCT00995709|uveitis
422753|NCT00995696|Interactive Voice Response (IVR)
422754|NCT00995696|Antidepressant
422755|NCT00995683|intracranial hypertension
422756|NCT00995683|neurological outcome
422757|NCT00995683|osmotherapy
422758|NCT00995670|hyperglycemia
422759|NCT00995670|statin
422760|NCT00995670|blood vessels
422761|NCT00995670|ischemic preconditioning
422762|NCT00995670|Anesthesia, inhalational
422763|NCT00995670|endothelium
422764|NCT00995670|5% dextrose
422765|NCT00995644|smoking
422766|NCT00995644|smoking cessation
422767|NCT00995644|tobacco use cessation
422768|NCT00995644|tobacco use disorder
422769|NCT00995631|liposuction
422770|NCT00995631|adipose tissue
422771|NCT00995631|dietary fatty acids
422772|NCT00995631|triglyceride storage
422773|NCT00995631|Normal healthy aging
422774|NCT00995618|Gout
422775|NCT00995618|Hyperuricemia
422776|NCT00995592|nutrition
422777|NCT00995592|child weight
422778|NCT00995592|undernourishment
422779|NCT00995592|mentor mother
422780|NCT00995592|South Africa
422781|NCT00995579|Physical Activity
422782|NCT00995579|Energy Expenditure
422783|NCT00995540|T1DM
422784|NCT00995540|Regeneration
422785|NCT00995540|Islet
422786|NCT00995540|Beta cell
422787|NCT00995540|INGAP Peptide
422788|NCT00995527|Post Swine Flu Blood Samples
422789|NCT00995527|Biologic Sample Collection
422790|NCT00995527|Laboratory Research Samples
422791|NCT00995527|H1N1 Vaccine Samples
422792|NCT00995527|HV
422793|NCT00995527|Healthy Volunteer
422794|NCT00995514|acute coronary syndrome
422795|NCT00995514|cardiovascular death
422796|NCT00995514|non-fatal MI
422797|NCT00995514|non-fatal stroke
422798|NCT00995514|genetic testing
422799|NCT00995514|CYP2C19
422800|NCT00995514|clopidogrel
422801|NCT00995514|prasugrel
422802|NCT00995514|antiplatelet therapy
422803|NCT00995514|genotyping
422804|NCT00995514|bleeding
422805|NCT00995501|steroid administration
422806|NCT00995501|tight glucose control
422807|NCT00995501|light anesthesiReducing inflammatory response to surgical stress
422808|NCT00995501|a
422809|NCT00995488|Urothelial Cancer
422810|NCT00995488|ABI-007
422811|NCT00995488|Bladder Cancer
422812|NCT00995488|front-line
422813|NCT00995449|Rheumatoid Arthritis
422814|NCT00995449|Biologics-Inadequate
422815|NCT00995449|KB003
422816|NCT00995449|GM-CSF
422817|NCT00995436|Extractions
422818|NCT00995436|Anchorage supplementation
422819|NCT00995423|Coronary Artery Disease
422820|NCT00995423|stent
422821|NCT00995410|Subjects Who are at Risk for Developing Aspirin-ASA
422822|NCT00995410|Subject must have a pre-existing condition for which aspirin is already indicated
422823|NCT00995410|Gastric Ulcers
422824|NCT00995397|Insect bites
422825|NCT00995397|Dexchlorpheniramine
422826|NCT00995397|Lotion
422827|NCT00995397|Cream
422828|NCT00995371|Spinal Stenosis
422829|NCT00995371|Lumbar Spinal Stenosis
422830|NCT00995371|Laminotomy
422831|NCT00995371|Laminectomy
422832|NCT00995371|Spine Surgery
422833|NCT00995358|Epitope peptide
422834|NCT00995358|CTL
422835|NCT00995358|Esophageal cancer
422836|NCT00995358|Vaccination
422837|NCT00995345|Type 2 Diabetes
422838|NCT00995345|Metformin
422839|NCT00995332|Acute myelogenous leukemia
422840|NCT00995332|all-trans retinoic acid
422841|NCT00995332|valproic acid
422842|NCT00995332|cytarabine
422843|NCT00995332|Disease stabilization
422844|NCT00995332|survival
422845|NCT00995332|toxicity
422846|NCT00995319|mouth
422847|NCT00995319|Mucositis
422848|NCT00995319|Dysphagia
422849|NCT00995319|malnutrition
422850|NCT00995319|Xerostomia
422851|NCT00995319|saliva
422852|NCT00995319|tooth injuries
422853|NCT00995306|Active comparator
422854|NCT00995306|Active civamide cream, 0.075%
422855|NCT00995306|Active civamide cream, 0.01%
422856|NCT00995280|follicle flushing
422857|NCT00995280|oocyte retrieval
422858|NCT00995280|needle
422859|NCT00995267|childhood obesity
422860|NCT00995267|nutrition
422861|NCT00995267|exercise
422862|NCT00995267|Alfred Adler
422863|NCT00995267|schoolchildren
422864|NCT00995267|intervention study
422865|NCT00995267|community-based trial
422866|NCT00995267|parent-child interaction
422867|NCT00995267|nutritional behaviors
422868|NCT00995254|secondhand smoke
422869|NCT00995254|children
422870|NCT00995254|Chinese
422871|NCT00995254|respiratory symptoms
422872|NCT00995254|household smoking policy
422873|NCT00995254|Respiratory illnesses among children
422874|NCT00995241|Raltegravir
422875|NCT00995241|intracellular concentration
422876|NCT00995241|plasmatic concentration
422877|NCT00995241|HIV
422878|NCT00995241|Treatment experienced
422879|NCT00995228|overhydration
422880|NCT00995228|fluid restriction
422881|NCT00995228|post-anesthesia care unit
422882|NCT00995215|spinal cord injury
422883|NCT00995215|SCI
422884|NCT00995215|paralysis
422885|NCT00995215|cough
422886|NCT00995215|cervical spinal cord injury
422887|NCT00995215|thoracic spinal cord injury
422888|NCT00995202|stage II colon cancer
422889|NCT00995202|stage II rectal cancer
422890|NCT00995202|stage III colon cancer
422891|NCT00995202|stage III rectal cancer
422892|NCT00995202|adenocarcinoma of the colon
422893|NCT00995202|adenocarcinoma of the rectum
422894|NCT00995189|contact lens wear
422895|NCT00995189|multi-purpose solution
422896|NCT00995189|corneal staining
422897|NCT00995176|Prevention
422898|NCT00995176|HIV
422899|NCT00995176|HIV seronegativity
422900|NCT00995163|outcomes study
422901|NCT00995163|hemodialysis
422902|NCT00995163|CKD-MBD
422903|NCT00995150|contraception
422904|NCT00995150|intrauterine
422905|NCT00995150|long-term
422906|NCT00995150|reversible
422907|NCT00995137|Relapsed or refractory B-Lineage ALL
422908|NCT00995124|ovicide
422909|NCT00995124|head lice infestation
422910|NCT00995098|Acute severe pancreatitis
422911|NCT00995098|nutritional support
422912|NCT00995098|enteral nutrition
422913|NCT00995098|parenteral nutrition
422914|NCT00995085|ADHD
422915|NCT00995085|ADD
422916|NCT00995085|TOVA
422917|NCT00995085|METADOXINE
422918|NCT00995072|sexual dysfunction
422919|NCT00995072|female
422920|NCT00995072|hypertension
422921|NCT00995072|high blood pressure
422922|NCT00995072|beta blockers
422923|NCT00995072|metoprolol
422924|NCT00995072|nebivolol
422925|NCT00995072|Bystolic
422926|NCT00995072|Toprol XL
422927|NCT00995059|stage I multiple myeloma
422928|NCT00995059|stage II multiple myeloma
422929|NCT00995059|stage III multiple myeloma
422930|NCT00995046|Hemophilia A
422931|NCT00995046|prophylaxis
422932|NCT00995046|thrombin generation test (TGT)
422933|NCT00995033|Smoking cessation
422934|NCT00995033|Smoking lapse behavior
422935|NCT00995033|Smoking Relapse behavior
422936|NCT00995033|Varenicline
422937|NCT00995033|Nicotine conjugate vaccine
422938|NCT00995033|Medication effect on smoking lapse behavior
422939|NCT00995020|Cone biopsy
422940|NCT00995020|Conization
422941|NCT00995020|Loop electrosurgical excisional procedures
422942|NCT00995020|Large Loop Excision of Transformation Zone
422943|NCT00995020|Needle Excision of Transformation Zone
422944|NCT00995020|Straight Wire Excision of Transformation Zone
422945|NCT00995020|Electrosurgery
422946|NCT00995007|Brain Tumor
422947|NCT00995007|Chemotherapy
422948|NCT00995007|Antiangiogenesis
422949|NCT00995007|Radiation
422950|NCT00995007|Progression
422951|NCT00995007|Glioma
422952|NCT00995007|Glioblastoma Multiforme
422953|NCT00994994|pediatric cardiac surgery
422954|NCT00994994|bleeding
422955|NCT00994994|tranexamic acid
422956|NCT00994994|fibrinolysis
422957|NCT00994994|blood loss in pediatric cardiac surgery
422958|NCT00994981|magnesium and reperfusion injury
422959|NCT00994968|stage II breast cancer
422960|NCT00994968|stage III breast cancer
422961|NCT00994955|SRT
422962|NCT00994955|laser
422963|NCT00994955|diabetic macular edema
422964|NCT00994955|diabetes
422965|NCT00994955|Clinically significant diabetic macular edema
422966|NCT00994929|biologic effects
422967|NCT00994929|von Willebrand disease
422968|NCT00994929|hemophilia
422969|NCT00994929|interleukin-11
422970|NCT00994929|DDAVp
422971|NCT00994916|Lambert-Eaton myasthenic syndrome
422972|NCT00994916|3,4 diaminopyridine
422973|NCT00994903|Statin
422974|NCT00994903|Colon
422975|NCT00994903|Colorectal
422976|NCT00994903|Intestinal Neoplasms
422977|NCT00994903|ERAS
422978|NCT00994903|Perioperative Care
422979|NCT00994890|Double-blind safety
422980|NCT00994825|levosimendan
422981|NCT00994825|cardiac surgery
422982|NCT00994825|cardiac anesthesia
422983|NCT00994825|mortality
422984|NCT00994825|survival
422985|NCT00994825|inotropic drugs
422986|NCT00994812|Polycystic ovary syndrome
422987|NCT00994812|PCOS
422988|NCT00994812|Metformin
422989|NCT00994812|Miscarriage
422990|NCT00994812|Infertility
422991|NCT00994812|Complications of pregnancy
422992|NCT00994786|treatment-resistant
422993|NCT00994786|refractory
422994|NCT00994786|obsessive compulsive disorder
422995|NCT00994786|Lyrica
422996|NCT00994786|pregabalin
422997|NCT00994786|Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder
422998|NCT00994773|Hepatitis B
422999|NCT00994773|simvastatin
423000|NCT00994773|HBV DNA
423001|NCT00994760|intranasal fentanyl spray
423002|NCT00994747|infancy
423003|NCT00994747|nutrition
423004|NCT00994747|protein hydrolysate formula
423005|NCT00994747|flavor preferences
423006|NCT00994747|food preferences
423007|NCT00994747|growth
423008|NCT00994747|emotional development
423009|NCT00994747|mother-infant interaction
423010|NCT00994747|infant temperament
423011|NCT00994747|feeding patterning
423012|NCT00994747|taste receptor and obesity genotype
423013|NCT00994747|sensitive period
423014|NCT00994721|Pancreatic Cancer
423015|NCT00994695|Trivalent meningococcal polysaccharide vaccine
423016|NCT00994695|Children
423017|NCT00994695|Safety
423018|NCT00994695|Immunogenicity
423019|NCT00994695|To assess Safety of trivalent meningococcal polysaccharide vaccine in children
423020|NCT00994695|To assess the immunogenicity of the trivalent polysaccharide vaccine in children
423021|NCT00994682|Additional relevant MeSH terms:
423022|NCT00994682|Hypoglycemic Agents
423023|NCT00994682|Physiological Effects of Drugs
423024|NCT00994682|Pharmacologic Actions
423025|NCT00994682|Pioglitazone
423026|NCT00994656|invasive procedures
423027|NCT00994656|hypovolemia
423028|NCT00994643|NHL
423029|NCT00994643|Non Hodgkin's Lymphoma
423030|NCT00994643|Lymphoma
423031|NCT00994591|Nicotine
423032|NCT00994591|Cotinine
423033|NCT00994591|CYP2A6
423034|NCT00994578|Advanced cancer
423035|NCT00994565|Physical activity
423036|NCT00994565|health behaviour
423037|NCT00994565|lifestyle
423038|NCT00994565|productivity
423039|NCT00994565|outcomes
423040|NCT00994526|Colorectal cancer
423041|NCT00994526|Processed meat
423042|NCT00994526|Calcium
423043|NCT00994526|Vitamin E
423044|NCT00994526|Preventive strategies
423045|NCT00994513|Antioxidant
423046|NCT00994513|Obesity
423047|NCT00994487|Childhood Obesity
423048|NCT00994487|Breastfeeding
423049|NCT00994487|Bottle Feeding
423050|NCT00994487|Dietary Intake
423051|NCT00994487|Preload
423052|NCT00994487|Compensation
423053|NCT00994487|Parental Feeding Style
423054|NCT00994474|Laser surgery
423055|NCT00994474|Profilometry
423056|NCT00994474|Fitzpatrick wrinkle score
423057|NCT00994474|Patient Benefit Index
423058|NCT00994474|Patient satisfaction
423059|NCT00994461|Endoscopy
423060|NCT00994448|Adolescents
423061|NCT00994448|Methamphetamine abuse
423062|NCT00994448|Bupropion
423063|NCT00994448|Addiction
423064|NCT00994448|Pharmacotherapy
423065|NCT00994448|Cognitive Behavioral Therapy
423066|NCT00994448|Contingency Management
423067|NCT00994448|Teens
423068|NCT00994435|obesity
423069|NCT00994422|PEDICULUS HUMANUS CAPITIS
423070|NCT00994422|Head Lice
423071|NCT00994409|Stroke
423072|NCT00994370|Pro-angiogenic markers
423073|NCT00994370|SIRT
423074|NCT00994370|hepatic metastases
423075|NCT00994357|Real-time Continuous Glucose Monitoring
423076|NCT00994357|Macrosomia
423077|NCT00994344|Darunavir
423078|NCT00994344|Lopinavir
423079|NCT00994344|Monotherapy
423080|NCT00994344|Antiretroviral simplification strategy
423081|NCT00994344|HIV
423082|NCT00994344|Treatment experienced
423083|NCT00994331|Percutaneous Coronary Intervention
423084|NCT00994331|Magnetic Navigation
423085|NCT00994331|Computed Tomography
423086|NCT00994318|Ferinject Iron Deficiency Anaemia Chronic Kidney Disease
423087|NCT00994305|kidney transplantation
423088|NCT00994305|oxidative stress
423089|NCT00994305|acetylcysteine
423090|NCT00994305|graft rejection
423091|NCT00994292|Factor Xa
423092|NCT00994292|Anticoagulant
423093|NCT00994292|YM150
423094|NCT00994292|Acute Coronary Syndrome
423095|NCT00994279|fatigue
423096|NCT00994279|depression
423097|NCT00994279|sleep disorders
423098|NCT00994279|stage IA breast cancer
423099|NCT00994279|stage IB breast cancer
423100|NCT00994279|stage II breast cancer
423101|NCT00994279|stage IIIA breast cancer
423102|NCT00994279|stage IIIB breast cancer
423103|NCT00994279|stage IIIC breast cancer
423104|NCT00994279|recurrent breast cancer
423105|NCT00994266|Type 2 diabetes
423106|NCT00994266|Diamel
423107|NCT00994266|Dietary supplement
423108|NCT00994227|electron microscopy
423109|NCT00994227|internal limiting membrane
423110|NCT00994227|macular disease
423111|NCT00994227|optical coherence tomography
423112|NCT00994188|Renal tumor
423113|NCT00994188|Ureteral tumor
423114|NCT00994188|Ureteral stricture
423115|NCT00994188|Restored kidney
423116|NCT00994188|Renal transplantation
423117|NCT00994188|Family members
423118|NCT00994175|Pioglitazone
423119|NCT00994175|Severe, Refractory Asthma
423120|NCT00994175|Peroxisome Proliferator-Activated Receptor Gamma
423121|NCT00994175|Airflow Obstruction
423122|NCT00994175|Airway Inflammation
423123|NCT00994175|Asthma
423124|NCT00994162|NPWT
423125|NCT00994162|Gauze-based filler
423126|NCT00994162|Acute or Chronic Wounds
423127|NCT00994162|Efficacy
423128|NCT00994149|Infants of Diabetic Mothers
423129|NCT00994149|Hypoglycemia
423130|NCT00994149|Diazoxide
423131|NCT00994149|Large for Gestation Infants
423132|NCT00994136|Catheters, indwelling
423133|NCT00994136|Catheterization, Central Venous
423134|NCT00994136|Withdrawal occlusion
423135|NCT00994136|Heparin lock
423136|NCT00994123|Non-Small Cell Lung Cancer
423137|NCT00994123|NSCLC
423138|NCT00994123|Advanced Non-Small Cell Lung Cancer
423139|NCT00994123|Metastatic Non-Small Cell Lung Cancer
423140|NCT00994123|Lung Cancer
423141|NCT00994123|Erlotinib
423142|NCT00994123|Tarceva
423143|NCT00994123|MM-121
423144|NCT00994123|ErbB3
423145|NCT00994123|Her3
423146|NCT00994123|Epidermal Growth Factor Receptor
423147|NCT00994123|anti-ErbB3 human monoclonal antibody
423148|NCT00994123|ErbB3 antagonist
423149|NCT00994110|PANCREAS
423150|NCT00994110|Pasireotide
423151|NCT00994110|SOM230
423152|NCT00994110|saline placebo
423153|NCT00994110|09-039
423154|NCT00994097|NGR-hTNF
423155|NCT00994097|Randomized controlled trial
423156|NCT00994097|Gemcitabine
423157|NCT00994097|Cisplatin
423158|NCT00994097|Pemetrexed
423159|NCT00994097|Carcinoma, non-small cell lung
423160|NCT00994084|Obesity
423161|NCT00994084|Minority children
423162|NCT00994084|Community intervention program
423163|NCT00994084|Lifestyle changes
423164|NCT00994084|Physical activities
423165|NCT00994084|Nutrition lessons
423166|NCT00994084|Behavior modification
423167|NCT00994071|Brain Tumor
423168|NCT00994071|CNC Tumor
423169|NCT00994071|Pediatric
423170|NCT00994071|PARP Inhibitor
423171|NCT00994071|Oral Chemotherapy
423172|NCT00994058|Preterm Labor
423173|NCT00994058|Uterine Inhibitor
423174|NCT00994058|Electro-Inhibition
423175|NCT00994045|Thoraco-Abdominal Aneurysm (TAAA)
423176|NCT00994045|Coagulopathy
423177|NCT00994045|Fresh Frozen Plasma
423178|NCT00994045|Fibrinogen Concentrate
423179|NCT00994032|vertebroplasty
423180|NCT00994032|disability evaluation
423181|NCT00994032|outcome assessment
423182|NCT00994032|pain measurement
423183|NCT00994019|HPV
423184|NCT00994019|oral cancer
423185|NCT00994019|young adults
423186|NCT00994006|Magnesium
423187|NCT00994006|nutrition
423188|NCT00994006|platelets
423189|NCT00994006|aggregation
423190|NCT00993993|cleft palate
423191|NCT00993980|qigong
423192|NCT00993980|traditional chinese medicine
423193|NCT00993980|exercise therapy
423194|NCT00993980|low back pain
423195|NCT00993967|FRDA
423196|NCT00993967|idebenone
423197|NCT00993967|FRDA disease
423198|NCT00993954|Nurse Treatment
423199|NCT00993954|Pulled Elbow
423200|NCT00993941|BMSC
423201|NCT00993941|Stem cells
423202|NCT00993941|Liver cirrhosis
423203|NCT00993941|Transplantation
423204|NCT00993928|psychosocial effects of cancer and its treatment
423205|NCT00993928|fatigue
423206|NCT00993928|sleep disorders
423207|NCT00993928|cancer survivor
423208|NCT00993915|Coronary Artery Disease
423209|NCT00993915|Hyperlipidemia
423210|NCT00993915|Atorvastatin
423211|NCT00993902|Double IUI
423212|NCT00993902|Intrauterine insemination
423213|NCT00993902|Unexplained infertility
423214|NCT00993889|Virtual Reality Peds
423215|NCT00993876|Depression
423216|NCT00993876|CREB
423217|NCT00993876|cognitive performance
423218|NCT00993876|psychotherapy
423219|NCT00993876|SSRI
423220|NCT00993876|SNRI
423221|NCT00993863|delta opioid agonist
423222|NCT00993863|dental pain
423223|NCT00993850|Bipolar disorder
423224|NCT00993850|Insomnia
423225|NCT00993850|Sleep disturbance
423226|NCT00993850|Cognitive behavioral therapy
423227|NCT00993837|endoscopic thyroidectomy
423228|NCT00993837|thyroid carcinoma
423229|NCT00993811|male circumcision
423230|NCT00993811|HIV
423231|NCT00993811|Africa
423232|NCT00993811|HIV Seronegativity
423233|NCT00993798|Post operative pain
423234|NCT00993798|Local anaesthesia
423235|NCT00993798|Postoperative pain after arthroscopic shoulder surgery
423236|NCT00993759|common cold
423237|NCT00993759|rhinovirus
423238|NCT00993759|prevention
423239|NCT00993746|Ultrasound guided infraclavicular brachial plexus block
423240|NCT00993746|Bupivacaine
423241|NCT00993746|Bupivacaine plus lidocaine
423242|NCT00993746|End stage renal disease
423243|NCT00993746|Arteriovenous fistula
423244|NCT00993733|hemodiafiltration
423245|NCT00993733|cost
423246|NCT00993733|dialysis solution
423247|NCT00993733|acute renal failure
423248|NCT00993733|intensive care unit
423249|NCT00993720|patients with type 1 diabetes mellitus
423250|NCT00993707|Chronic Obstructive Pulmonary Disease (COPD)
423251|NCT00993694|methemoglobinemia
423252|NCT00993694|aplastic anemia
423253|NCT00993694|accelerated phase chronic myelogenous leukemia
423254|NCT00993694|acute undifferentiated leukemia
423255|NCT00993694|atypical chronic myeloid leukemia, BCR-ABL negative
423256|NCT00993694|blastic phase chronic myelogenous leukemia
423257|NCT00993694|childhood acute lymphoblastic leukemia in remission
423258|NCT00993694|childhood acute myeloid leukemia in remission
423259|NCT00993694|childhood chronic myelogenous leukemia
423260|NCT00993694|chronic myelomonocytic leukemia
423261|NCT00993694|chronic phase chronic myelogenous leukemia
423262|NCT00993694|juvenile myelomonocytic leukemia
423263|NCT00993694|mast cell leukemia
423264|NCT00993694|meningeal chronic myelogenous leukemia
423265|NCT00993694|progressive hairy cell leukemia, initial treatment
423266|NCT00993694|prolymphocytic leukemia
423267|NCT00993694|recurrent childhood acute lymphoblastic leukemia
423268|NCT00993694|recurrent childhood acute myeloid leukemia
423269|NCT00993694|refractory chronic lymphocytic leukemia
423270|NCT00993694|refractory hairy cell leukemia
423271|NCT00993694|relapsing chronic myelogenous leukemia
423272|NCT00993694|secondary acute myeloid leukemia
423273|NCT00993694|stage 0 chronic lymphocytic leukemia
423274|NCT00993694|stage I chronic lymphocytic leukemia
423275|NCT00993694|stage II chronic lymphocytic leukemia
423276|NCT00993694|stage III chronic lymphocytic leukemia
423277|NCT00993694|stage IV chronic lymphocytic leukemia
423278|NCT00993694|T-cell large granular lymphocyte leukemia
423279|NCT00993694|AIDS-related diffuse large cell lymphoma
423280|NCT00993694|AIDS-related diffuse mixed cell lymphoma
423281|NCT00993694|AIDS-related diffuse small cleaved cell lymphoma
423282|NCT00993694|AIDS-related immunoblastic large cell lymphoma
423283|NCT00993694|AIDS-related lymphoblastic lymphoma
423284|NCT00993694|AIDS-related peripheral/systemic lymphoma
423285|NCT00993694|AIDS-related primary CNS lymphoma
423286|NCT00993694|AIDS-related small noncleaved cell lymphoma
423287|NCT00993694|HIV-associated Hodgkin lymphoma
423288|NCT00993694|recurrent/refractory childhood Hodgkin lymphoma
423289|NCT00993694|stage I childhood Hodgkin lymphoma
423290|NCT00993694|stage II childhood Hodgkin lymphoma
423291|NCT00993694|stage IV childhood Hodgkin lymphoma
423292|NCT00993694|anaplastic large cell lymphoma
423293|NCT00993694|angioimmunoblastic T-cell lymphoma
423294|NCT00993694|cutaneous B-cell non-Hodgkin lymphoma
423295|NCT00993694|recurrent cutaneous T-cell non-Hodgkin lymphoma
423296|NCT00993694|stage I cutaneous T-cell non-Hodgkin lymphoma
423297|NCT00993694|stage II cutaneous T-cell non-Hodgkin lymphoma
423298|NCT00993694|stage III cutaneous T-cell non-Hodgkin lymphoma
423299|NCT00993694|stage IV cutaneous T-cell non-Hodgkin lymphoma
423300|NCT00993694|recurrent mycosis fungoides/Sezary syndrome
423301|NCT00993694|stage I mycosis fungoides/Sezary syndrome
423302|NCT00993694|stage II mycosis fungoides/Sezary syndrome
423303|NCT00993694|stage III mycosis fungoides/Sezary syndrome
423304|NCT00993694|stage IV mycosis fungoides/Sezary syndrome
423305|NCT00993694|Waldenstrom macroglobulinemia
423306|NCT00993694|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
423307|NCT00993694|nodal marginal zone B-cell lymphoma
423308|NCT00993694|splenic marginal zone lymphoma
423309|NCT00993694|contiguous stage II grade 1 follicular lymphoma
423310|NCT00993694|contiguous stage II grade 2 follicular lymphoma
423311|NCT00993694|contiguous stage II grade 3 follicular lymphoma
423312|NCT00993694|contiguous stage II mantle cell lymphoma
423313|NCT00993694|contiguous stage II marginal zone lymphoma
423314|NCT00993694|contiguous stage II small lymphocytic lymphoma
423315|NCT00993694|stage I grade 1 follicular lymphoma
423316|NCT00993694|stage I grade 2 follicular lymphoma
423317|NCT00993694|stage I grade 3 follicular lymphoma
423318|NCT00993694|stage I mantle cell lymphoma
423319|NCT00993694|stage I marginal zone lymphoma
423320|NCT00993694|stage I small lymphocytic lymphoma
423321|NCT00993694|noncontiguous stage II grade 1 follicular lymphoma
423322|NCT00993694|noncontiguous stage II grade 2 follicular lymphoma
423323|NCT00993694|noncontiguous stage II grade 3 follicular lymphoma
423324|NCT00993694|noncontiguous stage II mantle cell lymphoma
423325|NCT00993694|noncontiguous stage II marginal zone lymphoma
423326|NCT00993694|noncontiguous stage II small lymphocytic lymphoma
423327|NCT00993694|stage I childhood large cell lymphoma
423328|NCT00993694|stage I childhood lymphoblastic lymphoma
423329|NCT00993694|stage I childhood small noncleaved cell lymphoma
423330|NCT00993694|stage II childhood large cell lymphoma
423331|NCT00993694|stage II childhood lymphoblastic lymphoma
423332|NCT00993694|stage II childhood small noncleaved cell lymphoma
423333|NCT00993694|stage III childhood large cell lymphoma
423334|NCT00993694|stage III childhood lymphoblastic lymphoma
423335|NCT00993694|stage III childhood small noncleaved cell lymphoma
423336|NCT00993694|stage III grade 1 follicular lymphoma
423337|NCT00993694|stage III grade 2 follicular lymphoma
423338|NCT00993694|stage III grade 3 follicular lymphoma
423339|NCT00993694|stage III mantle cell lymphoma
423340|NCT00993694|stage III marginal zone lymphoma
423341|NCT00993694|stage III small lymphocytic lymphoma
423342|NCT00993694|stage IV childhood large cell lymphoma
423343|NCT00993694|stage IV childhood lymphoblastic lymphoma
423344|NCT00993694|stage IV childhood small noncleaved cell lymphoma
423345|NCT00993694|stage IV grade 1 follicular lymphoma
423346|NCT00993694|stage IV grade 2 follicular lymphoma
423347|NCT00993694|stage IV grade 3 follicular lymphoma
423348|NCT00993694|stage IV mantle cell lymphoma
423349|NCT00993694|stage IV marginal zone lymphoma
423350|NCT00993694|stage IV small lymphocytic lymphoma
423351|NCT00993694|recurrent childhood grade III lymphomatoid granulomatosis
423352|NCT00993694|recurrent childhood large cell lymphoma
423353|NCT00993694|recurrent childhood lymphoblastic lymphoma
423354|NCT00993694|recurrent childhood small noncleaved cell lymphoma
423355|NCT00993694|recurrent grade 1 follicular lymphoma
423356|NCT00993694|recurrent grade 2 follicular lymphoma
423357|NCT00993694|recurrent grade 3 follicular lymphoma
423358|NCT00993694|recurrent mantle cell lymphoma
423359|NCT00993694|recurrent marginal zone lymphoma
423360|NCT00993694|recurrent small lymphocytic lymphoma
423361|NCT00993694|Burkitt lymphoma
423476|NCT00993330|macular pigment
423362|NCT00993694|childhood diffuse large cell lymphoma
423363|NCT00993694|childhood grade III lymphomatoid granulomatosis
423364|NCT00993694|childhood immunoblastic large cell lymphoma
423365|NCT00993694|childhood nasal type extranodal NK/T-cell lymphoma
423366|NCT00993694|intraocular lymphoma
423367|NCT00993694|primary central nervous system non-Hodgkin lymphoma
423368|NCT00993694|post-transplant lymphoproliferative disorder
423369|NCT00993694|chronic eosinophilic leukemia
423370|NCT00993694|chronic neutrophilic leukemia
423371|NCT00993694|primary myelofibrosis
423372|NCT00993694|essential thrombocythemia
423373|NCT00993694|polycythemia vera
423374|NCT00993694|extramedullary plasmacytoma
423375|NCT00993694|isolated plasmacytoma of bone
423376|NCT00993694|stage I multiple myeloma
423377|NCT00993694|stage II multiple myeloma
423378|NCT00993694|stage III multiple myeloma
423379|NCT00993694|primary systemic amyloidosis
423380|NCT00993694|refractory multiple myeloma
423381|NCT00993694|de novo myelodysplastic syndromes
423382|NCT00993694|previously treated myelodysplastic syndromes
423383|NCT00993694|secondary myelodysplastic syndromes
423384|NCT00993694|myelodysplastic/myeloproliferative neoplasm, unclassifiable
423385|NCT00993694|childhood myelodysplastic syndromes
423386|NCT00993694|recurrent childhood anaplastic large cell lymphoma
423387|NCT00993694|stage I childhood anaplastic large cell lymphoma
423388|NCT00993694|stage II childhood anaplastic large cell lymphoma
423389|NCT00993694|stage III childhood anaplastic large cell lymphoma
423390|NCT00993694|stage IV childhood anaplastic large cell lymphoma
423391|NCT00993694|stage III childhood Hodgkin lymphoma
423392|NCT00993681|Prevention of Travelers' Diarrhea
423393|NCT00993668|influenza
423394|NCT00993668|vaccine
423395|NCT00993668|pneumococcal vaccine
423396|NCT00993668|certolizumab pegol
423397|NCT00993668|Cimzia
423398|NCT00993655|peritoneal cavity cancer
423399|NCT00993655|fallopian tube cancer
423400|NCT00993655|stage II ovarian epithelial cancer
423401|NCT00993655|stage III ovarian epithelial cancer
423402|NCT00993655|stage IV ovarian epithelial cancer
423403|NCT00993655|malignant pleural effusion
423404|NCT00993655|ovarian clear cell cystadenocarcinoma
423405|NCT00993655|ovarian clear cell tumor with proliferating activity
423406|NCT00993642|estrogen receptor positive tamoxifen resistant breast cancer
423407|NCT00993629|PTSD
423408|NCT00993629|Depression
423409|NCT00993629|Neurosteroids
423410|NCT00993603|Lifestyle
423411|NCT00993603|Diabetes Mellitus
423412|NCT00993603|prevention/onset delay.
423413|NCT00993590|Persistent asthma
423414|NCT00993590|Asthma related emergency room visits
423415|NCT00993590|Asthma control, adolescents
423416|NCT00993590|Adherence, asthma control medications
423417|NCT00993577|Stretching
423418|NCT00993577|Pain
423419|NCT00993564|Therapeutic hypothermia
423420|NCT00993564|Head cooling
423421|NCT00993564|Hypoxic ischemic encephalopathy
423422|NCT00993564|Newborn
423423|NCT00993551|cleft palate
423424|NCT00993551|paediatric
423425|NCT00993551|pediatric
423426|NCT00993551|surgery
423427|NCT00993551|speech
423428|NCT00993551|velopharyngeal
423429|NCT00993538|Leukaemia
423430|NCT00993538|Blood and marrow cells culture
423431|NCT00993538|Cell growth
423432|NCT00993538|Cell differentiation
423433|NCT00993525|diabetic retinopathy
423434|NCT00993525|ranibizumab
423435|NCT00993525|new vessels
423436|NCT00993525|intravitreal injection
423437|NCT00993525|Persistent retina new vessels
423438|NCT00993512|photochemical internalisation
423439|NCT00993512|photosensitiser
423440|NCT00993512|cutaneous tumour
423441|NCT00993512|sub-cutaneous tumour
423442|NCT00993512|dose escalation
423443|NCT00993486|Haploidentical stem cell transplantation
423444|NCT00993486|Graft-versus-host disease
423445|NCT00993486|Immune reconstitution
423446|NCT00993486|Alloreactive T-cells
423447|NCT00993486|Photodepletion
423448|NCT00993486|TH9402
423449|NCT00993486|Transplant related mortality
423450|NCT00993486|Hematologic malignancy
423451|NCT00993460|Obesity
423452|NCT00993460|Insulin sensitivity
423453|NCT00993460|Inflammation
423454|NCT00993447|Dengue
423455|NCT00993447|Dengue hemorrhagic fever
423456|NCT00993447|Dengue virus
423457|NCT00993447|Dengue fever
423458|NCT00993447|Sanofi pasteur's CYD Dengue vaccine
423459|NCT00993434|Child
423460|NCT00993395|addiction
423461|NCT00993395|peer mentor
423462|NCT00993395|adherence
423463|NCT00993369|Prediction of neuro developmental delay
423464|NCT00993356|Acromegaly
423465|NCT00993356|Macroadenomas
423466|NCT00993356|Lanreotide
423467|NCT00993356|Transsphenoidal neurosurgery
423468|NCT00993356|Preoperative
423469|NCT00993343|GVHD
423470|NCT00993343|tacrolimus
423471|NCT00993343|sirolimus
423472|NCT00993343|cyclosporine
423473|NCT00993343|allogeneic
423474|NCT00993343|stem cell transplantation
423475|NCT00993343|Relapse-free survival
423477|NCT00993330|to measure macular pigment in the retina
423478|NCT00993317|CDP870
423479|NCT00993317|Korea
423480|NCT00993317|CIMZIA
423481|NCT00993291|Parkinson's Disease
423482|NCT00993291|DBS
423483|NCT00993291|Frequency
423484|NCT00993291|Deep brain stimulation
423485|NCT00993265|Trichotillomania
423486|NCT00993265|Hair pulling
423487|NCT00993265|glutamate
423488|NCT00993265|N-Acetylcysteine
423489|NCT00993265|Children
423490|NCT00993252|head injury
423491|NCT00993252|radiography
423492|NCT00993252|clinical impact
423493|NCT00993252|dissemination
423494|NCT00993226|Postoperative pain
423495|NCT00993226|Local anaesthesia
423496|NCT00993226|Postoperative pain after open abdominal hysterectomy surgery
423497|NCT00993213|fat mass
423498|NCT00993213|body composition
423499|NCT00993200|Warfarin
423500|NCT00993200|Pharmacogenetic
423501|NCT00993161|Neuromuscular disorders
423502|NCT00993161|Evaluation
423503|NCT00993161|Strength
423504|NCT00993161|Upper limb
423505|NCT00993148|Treatment naive
423506|NCT00993135|renal toxicity
423507|NCT00993135|childhood acute lymphoblastic leukemia
423508|NCT00993135|adult acute lymphoblastic leukemia
423509|NCT00993122|pre treatment
423510|NCT00993122|therapy compliance
423511|NCT00993122|SVR
423512|NCT00993122|sustained virological response
423513|NCT00993122|TH1 TH2 ratio
423514|NCT00993109|Nifedipine GITS/OROS (Adalat®)
423515|NCT00993109|Valsartan (Diovan®)
423516|NCT00993109|Hypertension
423517|NCT00993083|Influenza
423518|NCT00993083|Vaccine
423519|NCT00993070|capsaicin
423520|NCT00993070|placebo
423521|NCT00993070|trial
423522|NCT00993070|diabetic polyneuropathy
423523|NCT00993070|neuropathic pain
423524|NCT00993057|Euglycemia
423525|NCT00993057|craniotomy
423526|NCT00993057|neurosurgery
423527|NCT00993057|hypoglycemia
423528|NCT00993057|insulin
423529|NCT00993031|HIV
423530|NCT00993031|Placental Malaria
423531|NCT00993031|Pregnancy
423532|NCT00993031|Uganda
423533|NCT00993031|Protease inhibitors
423534|NCT00993031|Trimethoprim-sulfamethoxazole
423535|NCT00993031|Treatment experienced
423536|NCT00993018|Diabetic Neuropathy
423537|NCT00993018|Diabetic painful neuropathy
423538|NCT00993018|JNJ-42160443
423539|NCT00993018|Neuropathic pain
423540|NCT00993018|Pain
423541|NCT00993018|Pharmacokinetics
423542|NCT00993005|Hypertrophic scars
423543|NCT00993005|Keloids
423544|NCT00993005|Asian Gotu Kola
423545|NCT00993005|Asian Pennywort
423546|NCT00992992|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
423547|NCT00992992|Tositumomab
423548|NCT00992992|Tositumomab and Iodine I-131 tostumomab
423549|NCT00992992|Bexxar
423550|NCT00992992|Iodine-131 Anti-B1 Antibody
423551|NCT00992992|Mantle Cell
423552|NCT00992992|radioimmunotherapy
423553|NCT00992979|Addiction
423554|NCT00992979|Anxiety
423555|NCT00992979|Withdrawal
423556|NCT00992979|Psychoactive Drugs
423557|NCT00992979|Therapeutic Massage
423558|NCT00992966|to acquire database of pneumonia cases in children
423559|NCT00992953|Virtual Reality
423560|NCT00992953|Post Traumatic Stress Disorder
423561|NCT00992953|Combat
423562|NCT00992953|Military
423563|NCT00992953|Major Depressive Disorder
423564|NCT00992953|Anxiety
423565|NCT00992953|Virtual Reality Exposure with Stimulus Control
423566|NCT00992953|Treatment as Usual
423567|NCT00992940|awake craniotomy
423568|NCT00992940|patient-controlled sedation analgesia
423569|NCT00992940|anesthetist-controlled sedation analgesia
423570|NCT00992940|remifentanil-propofol
423571|NCT00992940|tumour surgery
423572|NCT00992927|Injections, Intra-Articular
423573|NCT00992927|Range of Motion, Articular
423574|NCT00992927|Pain
423575|NCT00992914|Hot flushes (vasomotor symptoms)
423576|NCT00992901|gastric bypass surgery
423577|NCT00992901|glucose tolerance
423578|NCT00992901|Insulin response to meal ingestion
423579|NCT00992901|Gut hormone and neural response to meal ingestion
423580|NCT00992888|Alcoholic Hepatitis
423581|NCT00992888|Alcohol
423582|NCT00992888|Endotoxin
423583|NCT00992888|LPS
423584|NCT00992888|Liver dialysis
423585|NCT00992888|Innate immunity
423586|NCT00992888|Toll Like receptors
423587|NCT00992875|Healthy but stressed individuals
423588|NCT00992849|Corneal neovascularization
423589|NCT00992849|bevacizumab
423590|NCT00992836|Influenza A Virus, H1N1 Subtype
423591|NCT00992836|Vaccine
423592|NCT00992836|Children
423593|NCT00992836|Adolescents
423594|NCT00992836|HIV-Infected
423595|NCT00992836|Perinatal HIV Infection
423596|NCT00992836|Treatment experienced
423597|NCT00992823|Iron
423598|NCT00992823|anemia
423599|NCT00992823|supplementation
423600|NCT00992823|preschoolers
423601|NCT00992823|prevalence
423602|NCT00992823|preschoolers children from public day care centers
423603|NCT00992810|upper limb
423604|NCT00992810|hand
423605|NCT00992810|arm
423606|NCT00992810|surgery
423607|NCT00992810|supraclavicular nerve block
423608|NCT00992810|brachial plexus nerve block
423609|NCT00992810|ultrasound-guided regional anesthesia
423610|NCT00992797|Insulin resistance
423611|NCT00992797|Insulin secretory dysfunction
423612|NCT00992797|Inflammation
423613|NCT00992797|Vascular stiffness
423614|NCT00992784|Influenza Vaccines
423615|NCT00992784|GSK Bio's influenza vaccine GSK2186877A
423616|NCT00992784|influenza infection
423617|NCT00992758|bone marrow
423618|NCT00992758|Radioimmunotherapy
423619|NCT00992758|non-Hodgkin's lymphoma
423620|NCT00992758|Bexxar
423621|NCT00992758|anti-B1 antibody
423622|NCT00992758|tositumomab and iodine I-131 tositumomab
423623|NCT00992758|NHL
423624|NCT00992758|tositumomab
423625|NCT00992745|prostate cancer
423626|NCT00992745|imaging
423627|NCT00992745|metastases
423628|NCT00992745|PSMA
423629|NCT00992745|ProstaScint®
423630|NCT00992719|H1N1, influenza A viruses, vaccine, pregnant women
423631|NCT00992706|palmar-plantar erythrodysesthesia
423632|NCT00992706|stage IV breast cancer
423633|NCT00992706|male breast cancer
423634|NCT00992693|Crimean-Congo Hemorrhagic Fever
423635|NCT00992693|Lassa Fever
423636|NCT00992693|CCHF
423637|NCT00992693|LF
423638|NCT00992693|Viral Hemorrhagic Fever
423639|NCT00992693|VHF
423640|NCT00992693|Ribavirin
423641|NCT00992680|Lung Disease
423642|NCT00992680|Chronic Airflow Obstruction
423643|NCT00992680|Chronic Bronchitis
423644|NCT00992680|Pulmonary Emphysema
423645|NCT00992680|Walk
423646|NCT00992667|apocynin
423647|NCT00992667|asthma
423648|NCT00992654|Open Label Access Program
423649|NCT00992654|Treatment experienced
423650|NCT00992641|Systems biology
423651|NCT00992641|Nutrition
423652|NCT00992641|Nordic diet
423653|NCT00992641|Dietary recommendations
423654|NCT00992641|Metabolic syndrome
423655|NCT00992641|Features of metabolic syndrome
423656|NCT00992628|GlideScope Video Laryngoscope
423657|NCT00992628|Macintosh Direct Laryngoscope
423658|NCT00992628|Intubation
423659|NCT00992628|Applied Forces
423660|NCT00992628|Elective surgery where endotracheal intubation required
423661|NCT00992589|Gastroesophageal Reflux
423662|NCT00992589|Gastroesophageal Reflux Disease
423663|NCT00992589|GERD
423664|NCT00992589|Proton Pump Inhibitor
423665|NCT00992589|PPI
423666|NCT00992589|Regurgitation
423667|NCT00992589|Infants
423668|NCT00992589|AcipHex, PARIET
423669|NCT00992589|ALFENCE
423670|NCT00992576|Confirmatory
423671|NCT00992576|Constipation
423672|NCT00992576|Pain
423673|NCT00992576|Hydromorphone
423674|NCT00992576|Naloxone
423675|NCT00992563|wet age-related macular degeneration, exudative
423676|NCT00992550|hookah
423677|NCT00992550|cigarette
423678|NCT00992550|smoking
423679|NCT00992524|Misoprostol
423680|NCT00992524|Labor, Obstetric
423681|NCT00992524|Labor, Induced
423682|NCT00992511|influenza infection
423683|NCT00992511|GSK Bio's influenza vaccine GSK2340272A
423684|NCT00992498|COPD (Chronic Obstructive Pulmonary Disease)
423685|NCT00992498|outpatients
423686|NCT00992498|rehabilitation
423687|NCT00992498|comorbidities
423688|NCT00992498|patient-centered outcome
423689|NCT00992459|Urea Cycle Disorder (UCD)
423690|NCT00992459|UCD
423691|NCT00992459|hyperammonemia
423692|NCT00992459|Buphenyl (NaPBA)
423693|NCT00992459|glycerol phenylbutyrate (GPB)
423694|NCT00992459|Sodium Phenylbutyrate (NaPBA)
423695|NCT00992446|Autologous stem cell transplant
423696|NCT00992446|NHL
423697|NCT00992446|maintenance therapy
423698|NCT00992433|influenza, H1N1, vaccine, human immunodeficiency virus
423699|NCT00992420|thienopyridine
423700|NCT00992420|platelets
423701|NCT00992420|CYP2C19
423702|NCT00992420|clopidogrel
423703|NCT00992420|platelet function tests
423704|NCT00992420|platelet
423705|NCT00992420|genes
423706|NCT00992420|cytochrome P450
423707|NCT00992420|single nucleotide polymorphisms
423708|NCT00992420|Platelet Aggregation Inhibitors
423709|NCT00992407|Schizophrenia
423710|NCT00992407|Risperidone
423711|NCT00992407|Risperdal
423712|NCT00992394|Plaque psoriasis - etanercept - response maintenance
423713|NCT00992381|GI Pain
423714|NCT00992381|healthy participants
423715|NCT00992381|Safety
423716|NCT00992381|bioavailability
423717|NCT00992368|Quality-Adjusted Life Years:A measurement index
423718|NCT00992368|Cost-Benefit Analysis:A method of comparing costs
423719|NCT00992368|Mammaplasty
423720|NCT00992368|QALY
423721|NCT00992368|Health-related quality of life
423722|NCT00992368|Cost-effectiveness
423723|NCT00992368|Breast
423724|NCT00992355|Cataract
423725|NCT00992355|Phacoemulsification
423726|NCT00992355|Treatment duration
423727|NCT00992329|ciprofloxacin
423728|NCT00992329|pharmacokinetics
423729|NCT00992329|formulation
423730|NCT00992316|Inflammatory pain
423731|NCT00992303|unspecified adult solid tumor, protocol specific
423732|NCT00992290|cirrhosis
423733|NCT00992290|hepatic encephalopathy
423734|NCT00992290|complications
423735|NCT00992290|probiotic
423736|NCT00992290|lactobacillus GG
423737|NCT00992264|Cigarette Smoking
423738|NCT00992264|Health Behavior
423739|NCT00992264|Intervention Studies
423740|NCT00992264|Personal Communication
423741|NCT00992251|prostate cancer
423742|NCT00992225|Metastatic
423743|NCT00992212|Pandemic influenza
423744|NCT00992212|vaccine
423745|NCT00992199|intraperitoneal chemotherapy
423746|NCT00992199|cisplatin
423747|NCT00992199|fluorouracil
423748|NCT00992199|advanced gastric cancer
423749|NCT00992186|Prostate cancer
423750|NCT00992186|Infusion
423751|NCT00992186|Carlumab
423752|NCT00992186|CNTO 888
423753|NCT00992173|Neuroblastoma
423754|NCT00992173|MIBG
423755|NCT00992173|Iobenguane
423756|NCT00992160|Polysomnography (PSG)
423757|NCT00992160|Adults
423758|NCT00992160|Primary Insomnia
423759|NCT00992134|Lymphoma, Mantle-Cell
423760|NCT00992134|Bendamustine
423761|NCT00992134|Cytarabine
423762|NCT00992134|Rituximab
423763|NCT00992134|Treatment
423764|NCT00992134|Combination chemotherapy
423765|NCT00992121|pazopanib
423766|NCT00992121|Renal Cell Carcinoma
423767|NCT00992121|Kidney
423768|NCT00992121|cancer
423769|NCT00992121|bevacizumab
423770|NCT00992108|Bruxism
423771|NCT00992108|Myofascial pain
423772|NCT00992108|EMG
423773|NCT00992108|Ultrasound
423774|NCT00992108|Masticatory myofascial face pain from bruxism and clenching
423775|NCT00992082|Postoperative pain
423776|NCT00992082|Local Infiltration Analgesia
423777|NCT00992082|Knee arthroplasty
423778|NCT00992069|ARV
423779|NCT00992069|Pharmacokinetics
423780|NCT00992069|TMC207
423781|NCT00992069|Efavirenz
423782|NCT00992043|creatine supplementation
423783|NCT00992043|exercise training
423784|NCT00992017|Vaccine
423785|NCT00992017|Pregnant
423786|NCT00992017|Perinatal
423787|NCT00992004|Osteoarthritis, Knee
423788|NCT00992004|Osteoarthritis
423789|NCT00992004|Joint Diseases
423790|NCT00992004|Arthritis
423791|NCT00992004|Rheumatic Diseases
423792|NCT00991991|stage I melanoma
423793|NCT00991991|stage II melanoma
423794|NCT00991991|stage III melanoma
423795|NCT00991978|breast cancer
423796|NCT00991978|VEGF
423797|NCT00991978|Screening
423798|NCT00991965|Alveolar Ridge Augmentation
423799|NCT00991965|Dental Implantation, Endosseous
423800|NCT00991965|Osseointegration
423801|NCT00991965|Bone Morphogenetic Proteins
423802|NCT00991939|Immune thrombocytopenic purpura
423803|NCT00991939|ITP
423804|NCT00991939|Dexamethasone
423805|NCT00991939|Prednisone
423806|NCT00991926|obesity
423807|NCT00991926|GH/IGF-1 axis
423808|NCT00991926|postprandial NEFA
423809|NCT00991913|Delirium
423810|NCT00991913|Postoperative
423811|NCT00991913|Non-cardiovascular surgery
423812|NCT00991913|Post-anaesthesia care unit
423813|NCT00991887|OTA 13C1
423814|NCT00991887|OTA 13C2
423815|NCT00991887|OTA 13C3
423816|NCT00991887|OTA 21B1
423817|NCT00991887|OTA 21B2
423818|NCT00991887|OTA 21B3
423819|NCT00991887|OTA 21C1
423820|NCT00991887|OTA 21C2
423821|NCT00991887|OTA 21C3
423822|NCT00991887|Distal humerus intraarticular fractures with or without proximal radius/ulna fractures - open or closed
423823|NCT00991887|Fracture-dislocations of the elbow (ulno-humeral dislocation associated with proximal ulna and/or radius fractures) - open or closed
423824|NCT00991874|Nitric oxide
423825|NCT00991874|Asthma
423826|NCT00991874|Longitudinal studies
423827|NCT00991874|Child
423828|NCT00991861|Actinic Keratosis
423829|NCT00991861|AK
423830|NCT00991861|NMSC
423831|NCT00991848|Lidocaine;
423832|NCT00991848|Fibromyalgia
423833|NCT00991848|signs
423834|NCT00991848|symptoms
423835|NCT00991822|open angle glaucoma
423836|NCT00991822|timolol
423837|NCT00991822|dorzolamide
423838|NCT00991809|opioid induced hyperalgesia
423839|NCT00991783|Fimasartan
423840|NCT00991783|Drug interaction
423841|NCT00991770|Discomfort
423842|NCT00991770|Port-a-Catheters
423843|NCT00991770|Complementary and Alternative Medicine
423844|NCT00991770|Massage
423845|NCT00991757|RWJ-333369
423846|NCT00991757|Anticonvulsants
423847|NCT00991757|Antiepileptic drugs
423848|NCT00991757|Epilepsy, Focal
423849|NCT00991757|Seizure Disorder
423850|NCT00991744|Leukemia
423851|NCT00991744|Central nervous system
423852|NCT00991744|Neurotoxicity
423853|NCT00991744|Liposomal cytarabine
423854|NCT00991744|Children
423855|NCT00991744|Acute lymphoblastic leukemia
423856|NCT00991744|Childhood acute lymphoblastic leukemia
423857|NCT00991744|Intrathecal
423858|NCT00991744|Efficacy
423859|NCT00991744|Safety
423860|NCT00991731|Physical Activity
423861|NCT00991731|Faith based
423862|NCT00991731|Non faith based
423863|NCT00991731|African American
423864|NCT00991731|Female
423865|NCT00991731|Pedometers
423866|NCT00991718|GDC0449
423867|NCT00991705|Fimasartan, Atorvastatin
423868|NCT00991692|Pediatric CI Therapy
423869|NCT00991692|ACQUIREc Therapy
423870|NCT00991692|Dosage
423871|NCT00991692|Occupational Therapy
423872|NCT00991692|Physical Therapy
423873|NCT00991692|Cerebral Palsy
423874|NCT00991692|Hemiparesis
423875|NCT00991679|Dry eye syndrome
423876|NCT00991679|CXCL9 chemokine
423877|NCT00991679|CXCL10 chemokine
423878|NCT00991679|CXCL11 chemokine
423879|NCT00991679|CXCR3 receptor
423880|NCT00991666|AMD
423881|NCT00991666|rigidity
423882|NCT00991666|pulsatile ocular blood flow
423883|NCT00991666|Physiology of the eye
423884|NCT00991653|Weight
423885|NCT00991653|Breast
423886|NCT00991653|Cancer
423887|NCT00991627|Ephedrine
423888|NCT00991627|Adrenergic Agents
423889|NCT00991627|Central Nervous System Stimulants
423890|NCT00991627|Sympathomimetics
423891|NCT00991627|Vasoconstrictor Agents
423892|NCT00991627|Bupivacaine
423893|NCT00991627|Anesthetics, Local
423894|NCT00991627|Atropine
423895|NCT00991627|Adjuvants, Anesthesia
423896|NCT00991627|Anti-Arrhythmia Agents
423897|NCT00991627|Bronchodilator Agents
423898|NCT00991627|Muscarinic Antagonists
423899|NCT00991627|Mydriatics
423900|NCT00991627|Parasympatholytics
423901|NCT00991627|Morphine
423902|NCT00991627|Analgesics, Opioid
423903|NCT00991627|Narcotics
423904|NCT00991627|Ringer's Lactate
423905|NCT00991627|Isotonic Solutions
423906|NCT00991627|Hypotension
423907|NCT00991627|Blood pressure
423908|NCT00991627|Signs and Symptoms
423909|NCT00991627|Pregnancy
423910|NCT00991627|Anesthesia, Obstetrical
423911|NCT00991627|Inferior Vena Cava
423912|NCT00991601|liver
423913|NCT00991601|pancreas
423914|NCT00991601|cancer
423915|NCT00991601|tumor
423916|NCT00991601|FNAC
423917|NCT00991588|PCL
423918|NCT00991588|Posterolateral
423919|NCT00991575|Diabetes mellitus, type1
423920|NCT00991575|cardiovascular disease
423921|NCT00991575|diabetes complications
423922|NCT00991575|Glycation end products, advanced
423923|NCT00991562|relapsed or relapsed/refractory multiple myeloma
423924|NCT00991549|overweight
423925|NCT00991549|obesity
423926|NCT00991549|glucose intolerance
423927|NCT00991549|pre-diabetes
423928|NCT00991523|resistance
423929|NCT00991523|exercise
423930|NCT00991523|protein
423931|NCT00991523|recovery
423932|NCT00991510|renal transplantation
423933|NCT00991510|mycophenolate mofetil
423934|NCT00991510|pharmacokinetics
423935|NCT00991510|immunosuppression
423936|NCT00991497|varicose veins
423937|NCT00991497|foam sclerotherapy
423938|NCT00991497|compression bandaging
423939|NCT00991497|duration
423940|NCT00991484|ventral
423941|NCT00991484|inguinal
423942|NCT00991484|hernia
423943|NCT00991484|inheritance
423944|NCT00991484|genetics
423945|NCT00991471|Emergency Department Wait Times
423946|NCT00991471|Physician Nurse at Triage
423947|NCT00991471|Overcrowding
423948|NCT00991471|CostEffectiveness
423949|NCT00991445|Unicompartmental knee arthroplasty
423950|NCT00991445|Surgical exposure
423951|NCT00991445|Minimal invasive surgery
423952|NCT00991445|Local Infiltration Analgesia
423953|NCT00991445|Knee Arthroplasty
423954|NCT00991432|Alveolar Ridge Augmentation
423955|NCT00991432|Dental Implantation, Endosseous
423956|NCT00991432|Osseointegration
423957|NCT00991432|Space Maintenance
423958|NCT00991432|Bone Morphogenetic Proteins
423959|NCT00991419|PET
423960|NCT00991419|Alzheimer's disease
423961|NCT00991419|diagnostic
423962|NCT00991406|Electric Stimulation
423963|NCT00991406|Hemiplegia
423964|NCT00991406|walking
423965|NCT00991393|Maxillary Sinus Augmentation
423966|NCT00991393|Dental Implantation
423967|NCT00991393|Osseointegration
423968|NCT00991393|Bone Morphogenetic Proteins
423969|NCT00991367|Post-surgical scars
423970|NCT00991367|Asian Gotu Kola
423971|NCT00991367|Asian Pennywort
423972|NCT00991354|HIV Seronegativity
423973|NCT00991354|HIV Preventive Vaccine
423974|NCT00991341|Cardiac surgery
423975|NCT00991341|Red blood cell
423976|NCT00991341|Transfusion
423977|NCT00991328|PD
423978|NCT00991328|POCD
423979|NCT00991328|Post-op Delirium (PD)
423980|NCT00991328|Post-op Cognitive Dysfunction (POCD)
423981|NCT00991315|prostate cancer
423982|NCT00991302|Adherence
423983|NCT00991302|Behavioral Intervention
423984|NCT00991302|Antiretroviral Therapy
423985|NCT00991302|ART
423986|NCT00991302|Highly Active Antiretroviral Therapy
423987|NCT00991302|HAART
423988|NCT00991302|Treatment experienced
423989|NCT00991289|Hepatitis C genotype 1
423990|NCT00991289|HCV treatment naive
423991|NCT00991289|HCV/HIV coinfection
423992|NCT00991289|Antiretroviral
423993|NCT00991289|Ribavirin
423994|NCT00991289|Pegylated Interferon alfa
423995|NCT00991289|Nitazoxanide
423996|NCT00991276|restless legs syndrome RLS polysomnography PSG sleep disturbance patient reported outcome
423997|NCT00991263|stage II breast cancer
423998|NCT00991263|stage IIIA breast cancer
423999|NCT00991250|Malignant melanoma
424000|NCT00991237|NRS
424001|NCT00991237|GPE
424002|NCT00991237|pain reduction
424003|NCT00991237|quality of life
424004|NCT00991224|HIV
424005|NCT00991224|HIV therapeutic vaccine
424006|NCT00991211|Comparison
424007|NCT00991211|Bendamustine + Rituximab
424008|NCT00991211|CHOP + Rituximab
424009|NCT00991211|Progression free survival
424010|NCT00991211|Overall survival
424011|NCT00991211|Toxicity
424012|NCT00991211|Safety
424013|NCT00991198|Topically dissolved oxygen
424014|NCT00991198|inflammatory cutaneous disease
424015|NCT00991198|rosacea
424016|NCT00991198|acne vulgaris
424017|NCT00991198|atopic dermatitis
424018|NCT00991198|seborrheic dermatitis
424019|NCT00991198|photodamage
424020|NCT00991185|Infections in Children
424021|NCT00991172|sciatica
424022|NCT00991172|sciatic pain
424023|NCT00991172|pain
424024|NCT00991172|back pain
424025|NCT00991159|Endocrinology; Hypercholesterolemia; Hyperlipidemia; Lipid Metabolism Disorders RN316 PF-04950615
424026|NCT00991146|CAPS
424027|NCT00991146|FCAS
424028|NCT00991146|MWS
424029|NCT00991146|NOMID
424030|NCT00991146|cryopyrin-associated periodic syndromes
424031|NCT00991146|Familial Cold Autoinflammatory Syndrome
424032|NCT00991146|Muckle-Wells Syndrome
424033|NCT00991146|Neonatal Onset Multisystem Inflammatory Disease
424034|NCT00991146|canakinumab
424035|NCT00991146|ACZ885
424036|NCT00991146|children
424037|NCT00991146|systemic autoinflammatory disease
424038|NCT00991146|NALP-3
424039|NCT00991146|human monoclonal anti-human interleukin-1beta (IL-1beta)antibody
424040|NCT00991146|autosomal dominant
424041|NCT00991146|familial autoinflammatory syndrome
424042|NCT00991107|phase I
424043|NCT00991107|safety
424044|NCT00991107|tolerance
424045|NCT00991107|insulin resistance
424046|NCT00991107|obese
424047|NCT00991094|Proton Therapy
424048|NCT00991094|Proton Therapy Treatment Plan
424049|NCT00991094|Proton Dose Distributions
424050|NCT00991094|Side Effects
424051|NCT00991094|Symptoms
424052|NCT00991094|Normal Tissue Toxicity
424053|NCT00991094|Dose Response Relationship
424054|NCT00991081|pharmacogenetics
424055|NCT00991081|genetic counseling
424056|NCT00991081|genetic feedback
424057|NCT00991081|nicotine replacement
424058|NCT00991081|bupropion
424059|NCT00991081|smoking cessation
424060|NCT00991081|primary care
424061|NCT00991081|telehealth
424062|NCT00991081|motivational interviewing
424063|NCT00991068|Pain
424064|NCT00991068|Mild to moderate Carpal Tunnel Syndrome
424065|NCT00991042|Cytokines
424066|NCT00991042|Low back pain
424067|NCT00991042|Intervertebral disk displacement
424068|NCT00991042|Interleukins
424069|NCT00991042|Tumor necrosis factor-alpha
424070|NCT00991029|Transient Ischemic Attack
424071|NCT00991029|TIA
424072|NCT00991029|minor stroke
424073|NCT00991003|Colon Capsule Endoscopy
424074|NCT00991003|Colorectal Cancer
424075|NCT00991003|Colonoscopy
424076|NCT00990990|Safety tolerability pharmacokinetics (PK) pharmacodynamics whole blood activity (WBA) PNU-100480 linezolid pyrazinamide multiple dose
424077|NCT00990977|breast cancer
424078|NCT00990977|supportive care
424079|NCT00990977|post-treatment
424080|NCT00990977|intervention
424081|NCT00990977|MBSR
424082|NCT00990977|mindfulness
424083|NCT00990977|anxiety
424084|NCT00990977|depression
424085|NCT00990977|lifestyle
424086|NCT00990977|diet
424087|NCT00990977|alcohol consumption
424088|NCT00990977|smoking
424089|NCT00990977|exercise
424090|NCT00990977|spirituality
424091|NCT00990977|existential well-being
424092|NCT00990977|physical symptoms
424093|NCT00990977|women
424094|NCT00990925|Obesity
424095|NCT00990925|Schizophrenia
424096|NCT00990925|Schizoaffective disorder
424097|NCT00990925|weight loss
424098|NCT00990899|hypertension
424099|NCT00990899|obstructive sleep apnea
424100|NCT00990899|pediatrics
424101|NCT00990886|Oxybutynin
424102|NCT00990886|Ditropan
424103|NCT00990886|Menopause Treatment
424104|NCT00990886|Vasomotor symptoms
424105|NCT00990886|Hot Flashes
424106|NCT00990886|Non-hormonal therapy for Vasomotor symptoms
424107|NCT00990873|stage I non-small cell lung cancer
424108|NCT00990860|Combination of TACE With Sorafenib
424109|NCT00990834|Statin
424110|NCT00990834|Myopathy
424111|NCT00990834|Hydroxymethylglutaryl-CoA Reductase Inhibitors
424112|NCT00990834|Atrogin-1
424113|NCT00990795|open heart surgery
424114|NCT00990795|cyclosporine
424115|NCT00990795|myocardial protection
424116|NCT00990769|Emergence delirium
424117|NCT00990769|Bispectral Index
424118|NCT00990769|Depth of anesthesia
424119|NCT00990743|Ocular hypertension
424120|NCT00990743|Glaucoma
424121|NCT00990743|Beta-blocker
424122|NCT00990730|rheumatoid arthritis
424123|NCT00990730|endothelial dysfunction
424124|NCT00990730|lipoproteins
424125|NCT00990730|inflammation
424126|NCT00990730|oxidative stress
424127|NCT00990730|arterial stiffness
424128|NCT00990717|natural killer cells
424129|NCT00990717|leukemia
424130|NCT00990717|lymphoma
424131|NCT00990717|myeloma
424132|NCT00990717|Hodgkin's disease
424133|NCT00990717|cell therapy
424134|NCT00990704|Secondary hyperparathyroidism
424135|NCT00990704|Hemodialysis
424136|NCT00990704|paricalcitol
424137|NCT00990704|maxacalcitol
424138|NCT00990691|Rett syndrome
424139|NCT00990678|HIV-1
424140|NCT00990678|humans
424141|NCT00990678|vitamin D
424142|NCT00990678|1-hydroxy-vitamin D
424143|NCT00990678|Rocaltrol
424144|NCT00990678|calcium
424145|NCT00990678|complementary therapies
424146|NCT00990665|CRT
424147|NCT00990665|Heart Failure
424148|NCT00990665|LV Leads
424149|NCT00990652|brain tumor
424150|NCT00990639|hepatic fibrosis
424151|NCT00990639|angiotensin II blocking agents
424152|NCT00990639|alcoholic liver disease
424153|NCT00990626|Seroquel XR
424154|NCT00990626|schizophrenia relapse prevention
424155|NCT00990613|percutaneous transcutaneous dimebon transdermal pharmacokinetics
424156|NCT00990600|adherence
424157|NCT00990600|Qol
424158|NCT00990600|virologic efficacy
424159|NCT00990600|immunologic efficacy
424160|NCT00990600|patients' preference
424161|NCT00990600|once-daily
424162|NCT00990600|HAART
424163|NCT00990600|treatment experienced
424164|NCT00990587|relapsed and refractory hematologic malignancy
424165|NCT00990587|ALL (acute lymphoid leukemia)
424166|NCT00990587|CLL (chronic lymphoid leukemia)
424167|NCT00990587|High risk myelodysplasia (MDS) with an IPSS (International Prognostic Scoring System) score >2.5
424168|NCT00990587|CML (chronic myelogenous leukemia) blast crisis
424169|NCT00990587|Relapsed or refractory acute myeloid leukemia (AML)
424170|NCT00990548|Cardiac Caregivers
424171|NCT00990548|Cardiac Patient Clinical Outcomes
424172|NCT00990548|Prevention of CVD
424173|NCT00990535|neuroendocrine tumors
424174|NCT00990535|octreotide
424175|NCT00990535|somatostatin analogues
424176|NCT00990522|sharp debridment
424177|NCT00990522|patients with full thickness wounds of greater than 30 days duration
424178|NCT00990509|Primary ICH
424179|NCT00990509|Albumin
424180|NCT00990509|MRI
424181|NCT00990509|Neuroimaging outcome
424182|NCT00990509|Placebo-controlled
424183|NCT00990509|Phase II
424184|NCT00990509|Blinded
424185|NCT00990509|Safety
424186|NCT00990509|Acute ICH
424187|NCT00990509|ICH
424188|NCT00990509|Primary acute (< 48 hours) supratentorial ICH
424189|NCT00990496|Glioblastoma multiforme
424190|NCT00990496|GBM
424191|NCT00990496|Cytomegalovirus
424192|NCT00990496|CMV
424193|NCT00990496|Cytotoxic T lymphocyte
424194|NCT00990496|CTL
424195|NCT00990470|Transplantation
424196|NCT00990470|Liver
424197|NCT00990470|Endoscopy
424198|NCT00990470|Colonoscopy
424199|NCT00990470|Gastroscopy
424200|NCT00990457|Exercise
424201|NCT00990457|Weight loss diet
424202|NCT00990457|Obesity
424203|NCT00990457|Overweight
424204|NCT00990457|Abdominal obesity
424205|NCT00990457|Cardiovascular function
424206|NCT00990457|Body composition
424207|NCT00990444|blood glucose
424208|NCT00990444|blood insulin
424209|NCT00990444|dextran
424210|NCT00990444|diabetes
424211|NCT00990444|hyperglycemia
424212|NCT00990444|hypoglycemia
424213|NCT00990444|oral delivery
424214|NCT00990444|portal delivery
424215|NCT00990431|skin aging
424216|NCT00990431|laser surgery
424217|NCT00990431|fractional photothermolysis
424218|NCT00990431|comparative study
424219|NCT00990431|Ablative fractional treatment of peri-orbital rhytides
424220|NCT00990418|Postoperative pain
424344|NCT00989950|adhd rating scales
424221|NCT00990418|E-TRANS System, fentanyl HCl System
424222|NCT00990418|E-TRANSS (fentanyl HCl) System
424223|NCT00990418|Acute postoperative pain
424224|NCT00990405|Rome III criteria
424225|NCT00990392|Blood stream infections
424226|NCT00990392|Catheter related infections
424227|NCT00990392|Central venous catheter related infections
424228|NCT00990392|Line sepsis
424229|NCT00990392|Topical antibiotics
424230|NCT00990392|Bacitracin
424231|NCT00990392|Polymixin
424232|NCT00990392|Gramicidin
424233|NCT00990392|Polysporin Triple Therapy
424234|NCT00990392|Intensive care unit
424235|NCT00990379|HIV
424236|NCT00990379|brain diseases
424237|NCT00990379|spinal fluid
424238|NCT00990379|HIV positive
424239|NCT00990366|antireflux valve
424240|NCT00990366|biliary obstruction
424241|NCT00990366|cholangitis
424242|NCT00990366|biliary stent
424243|NCT00990353|Spatial neglect
424244|NCT00990353|hemineglect
424245|NCT00990353|stroke
424246|NCT00990353|cognition
424247|NCT00990353|prism adaptation
424248|NCT00990353|Hierarchical linear modeling
424249|NCT00990353|growth curve modeling
424250|NCT00990327|Coronary artery disease
424251|NCT00990327|Myocardial Perfusion Imaging
424252|NCT00990301|Healthy Subjects
424253|NCT00990301|Bioequivalence
424254|NCT00990288|To decrease blood loss during knee surgery
424255|NCT00990262|acute chest pain
424256|NCT00990262|emergency department
424257|NCT00990262|cardiac computed tomography
424258|NCT00990249|Acute Lymphoblastic Leukemia
424259|NCT00990249|ALL
424260|NCT00990249|Acute lymphoblastic lymphoma
424261|NCT00990249|acute biphenotypic leukemia
424262|NCT00990249|Allogeneic hematopoietic cell transplantation
424263|NCT00990249|HCT
424264|NCT00990249|Stem Cell Transplant
424265|NCT00990249|Treatment-related mortality
424266|NCT00990249|Tyrosine kinase inhibitors
424267|NCT00990249|TKI
424268|NCT00990249|Busulfan
424269|NCT00990249|Busulfex
424270|NCT00990249|Myleran
424271|NCT00990249|Clofarabine
424272|NCT00990249|Clolar
424273|NCT00990249|Clofarex
424274|NCT00990249|Gleevec
424275|NCT00990249|Imatinib Mesylate
424276|NCT00990236|deep vein thrombosis
424277|NCT00990236|superficial venous thrombosis
424278|NCT00990236|pulmonary embolus
424279|NCT00990223|Eplerenone Aldosterone and Plasma Renin Activity responses Pharmacodynamics
424280|NCT00990197|Pilot study
424281|NCT00990197|Randomized clinical trial
424282|NCT00990197|Smoking cessation
424283|NCT00990197|Acute coronary syndrome
424284|NCT00990197|Transdermal nicotine patch
424285|NCT00990184|Impaired Fasting Glucose
424286|NCT00990184|PreDiabetes
424287|NCT00990171|peritoneal Dialysis
424288|NCT00990171|wasting and malnutrition
424289|NCT00990171|nutrition status
424290|NCT00990171|bioelectrical impedance analysis
424291|NCT00990171|body composition
424292|NCT00990158|Vitamin K1 (phytonadione)
424293|NCT00990158|Randomized controlled trial
424294|NCT00990158|Warfarin
424295|NCT00990158|Coagulopathy
424296|NCT00990158|Time in therapeutic range
424297|NCT00990158|Bleeding
424298|NCT00990158|Thrombosis
424299|NCT00990158|VKORC1 and CYP2C9 genotypes
424300|NCT00990158|Time INR in therapeutic range
424301|NCT00990132|COPD
424302|NCT00990132|Respiratory failure
424303|NCT00990132|Non-invasive ventilation
424304|NCT00990132|Home mechanical ventilation
424305|NCT00990119|high flow therapy
424306|NCT00990119|high flow nasal cannula
424307|NCT00990119|chronic obstructive pulmonary disease
424308|NCT00990119|respiratory insufficiency
424309|NCT00990106|posttraumatic stress disorder
424310|NCT00990106|PTSD
424311|NCT00990106|nightmares
424312|NCT00990106|prazosin
424313|NCT00990106|sleep disturbance
424314|NCT00990106|combat trauma
424315|NCT00990067|MDMA
424316|NCT00990067|serotonin
424317|NCT00990067|norepinephrine
424318|NCT00990067|Ecstasy
424319|NCT00990067|stimulant
424320|NCT00990054|Cytarabine,
424321|NCT00990054|Daunorubicin,
424322|NCT00990054|De Novo,
424323|NCT00990054|Acute Myeloid Leukemia,
424324|NCT00990054|AML
424325|NCT00990041|periodontitis
424326|NCT00990041|find cytokines in blood of periodontal patients
424327|NCT00990028|moderate head injury
424328|NCT00990028|rosuvastatin
424329|NCT00990028|statin
424330|NCT00990028|amnesia
424331|NCT00990028|orientation
424332|NCT00990015|Safety; tolerability; pharmacokinetics/pharmacodynamics
424333|NCT00989989|DME
424334|NCT00989989|Diabetic
424335|NCT00989989|macula
424336|NCT00989989|edema
424337|NCT00989989|ranibizumab
424338|NCT00989989|REVEAL
424339|NCT00989976|Sleep
424340|NCT00989976|Diabetes Risk
424341|NCT00989963|PAH
424342|NCT00989950|daytrana
424343|NCT00989950|sleep latency
424345|NCT00989950|ADHD
424346|NCT00989937|oxytocin
424347|NCT00989924|Diabetes mellitus
424348|NCT00989924|Coronary heart disease
424349|NCT00989924|Magnetocardiography
424350|NCT00989911|Single ventricle congenital heart disease
424351|NCT00989898|T1D, closed-loop systems, overnight hypoglycaemia
424352|NCT00989885|Evaluation
424353|NCT00989885|Obstructive sleep apnea
424354|NCT00989885|Polysomnography
424355|NCT00989872|Macrolides
424356|NCT00989872|Antibiotics
424357|NCT00989872|Safety
424358|NCT00989872|Tolerability
424359|NCT00989872|Pharmacokinetics
424360|NCT00989872|Phase I
424361|NCT00989872|MRSA/SSTI
424362|NCT00989859|monitoring
424363|NCT00989846|biomarker
424364|NCT00989846|lung disease
424365|NCT00989833|Exercise induced asthma
424366|NCT00989833|Mild intermittent asthma
424367|NCT00989833|Exercise induced bronchoconstriction
424368|NCT00989820|osteoradionecrosis
424369|NCT00989820|mandible
424370|NCT00989820|radiotherapy
424371|NCT00989820|hyperbaric oxygen therapy
424372|NCT00989807|CF
424373|NCT00989807|Cystic fibrosis
424374|NCT00989807|Pseudomonas aeruginosa
424375|NCT00989807|EAP
424376|NCT00989807|Expanded access
424377|NCT00989807|AZLI
424378|NCT00989807|Aztreonam lysine
424379|NCT00989794|cartilage
424380|NCT00989794|implantation
424381|NCT00989794|chondrocyte
424382|NCT00989794|condyle
424383|NCT00989781|PCOS, Androgens, ovary, polycystic
424384|NCT00989768|Botulinum toxin type A
424385|NCT00989768|field effects
424386|NCT00989768|dose-equivalence
424387|NCT00989768|anhydrotic action halos
424388|NCT00989755|Tobacco dependence treatment in primary health care setting
424389|NCT00989755|Fax to Quit
424390|NCT00989755|Fax to Quit plus Enhanced Academic Detailing
424391|NCT00989755|Fax referral
424392|NCT00989755|Quitline
424393|NCT00989742|lymphangioleiomatosis
424394|NCT00989742|LAM
424395|NCT00989742|tuberous sclerosis
424396|NCT00989742|doxycycline
424397|NCT00989742|matrix metalloproteinases
424398|NCT00989742|MMP
424399|NCT00989729|Endovascular Aortic Repair
424400|NCT00989729|Methylprednisolone
424401|NCT00989729|Systemic inflammatory response syndrome
424402|NCT00989703|Safety
424403|NCT00989703|Tolerability
424404|NCT00989703|Pharmacokinetics
424405|NCT00989690|recurrent non-small cell lung cancer
424406|NCT00989690|stage IIIB non-small cell lung cancer
424407|NCT00989690|stage IV non-small cell lung cancer
424408|NCT00989664|non-Hodgkin's Lymphoma
424409|NCT00989664|radioimmunotherapy
424410|NCT00989664|NHL
424411|NCT00989664|Bexxar
424412|NCT00989664|lymphoma
424413|NCT00989664|Tositumomab
424414|NCT00989625|migraine
424415|NCT00989625|single dose
424416|NCT00989625|healthy volunteer
424417|NCT00989625|adolescence
424418|NCT00989625|pharmacokinetics
424419|NCT00989612|influenza infection
424420|NCT00989612|GSK Biologicals' influenza vaccine GSK2340272A
424421|NCT00989599|phlebitis
424422|NCT00989599|Chamomilla recutita
424423|NCT00989599|Catheterization peripheral
424424|NCT00989586|recurrent mantle cell lymphoma
424425|NCT00989586|recurrent grade 1 follicular lymphoma
424426|NCT00989586|recurrent grade 2 follicular lymphoma
424427|NCT00989586|recurrent grade 3 follicular lymphoma
424428|NCT00989586|MALT lymphoma
424429|NCT00989586|nodal marginal zone B-cell lymphoma
424430|NCT00989586|splenic marginal zone lymphoma
424431|NCT00989586|recurrent marginal zone lymphoma
424432|NCT00989586|Waldenstrom macroglobulinemia
424433|NCT00989534|shift work
424434|NCT00989534|diabetes
424435|NCT00989534|Affects of shift work and sleep loss on health
424436|NCT00989521|Asthma
424437|NCT00989521|bronchial diseases
424438|NCT00989521|lung diseases
424439|NCT00989521|bronchitis
424440|NCT00989521|respiratory tract diseases
424441|NCT00989508|Perhexiline
424442|NCT00989508|Aortic Valve Stenosis
424443|NCT00989508|Hypertrophy, Left Ventricular
424444|NCT00989508|Myocardial Reperfusion Injury
424445|NCT00989508|Cardiac Output, Low
424446|NCT00989508|Troponin
424447|NCT00989495|AIS
424448|NCT00989456|chronic obstructive pulmonary disease
424449|NCT00989456|Heart failure
424450|NCT00989456|Stroke
424451|NCT00989456|quality of life
424452|NCT00989456|self management education
424453|NCT00989456|physical exercise
424454|NCT00989456|primary health care
424455|NCT00989443|Cervix Intraepithelial Neoplasia grades 2 and 3
424456|NCT00989430|stroke
424457|NCT00989430|CVA
424458|NCT00989430|cerebrovascular accident
424459|NCT00989430|rehabilitation
424460|NCT00989417|Remote monitoring
424461|NCT00989417|Defibrillators, Implantable
424462|NCT00989417|Home monitoring
424463|NCT00989417|Shock
424464|NCT00989417|Implantable cardioverter-defibrillator Therapy
424465|NCT00989404|pk
424466|NCT00989404|healthy subjects
424467|NCT00989404|influenza virus
424468|NCT00989404|Safety
424469|NCT00989404|pandemic
424470|NCT00989391|Phase 1 multiple dose safety toleration pharmacokinetic
424471|NCT00989378|sleep
424472|NCT00989378|insulin
424473|NCT00989378|diabetes
424474|NCT00989378|determine association between sleep characteristics and diabetes risk
424475|NCT00989365|Aerobic Exercise
424476|NCT00989365|Exercise
424477|NCT00989352|PCNSL
424478|NCT00989352|Lymphoma
424479|NCT00989352|Methotrexate
424480|NCT00989352|Lomustine
424481|NCT00989352|Procarbazine
424482|NCT00989352|Rituximab
424483|NCT00989352|Elderly
424484|NCT00989352|Chemotherapy
424485|NCT00989339|lipid emulsion
424486|NCT00989339|endothelial function
424487|NCT00989339|inflammatory markers
424488|NCT00989339|oxidative stress
424489|NCT00989339|insulin sensitivity
424490|NCT00989339|carbohydrate metabolism
424491|NCT00989326|Remote monitoring
424492|NCT00989326|Pacemaker
424493|NCT00989326|Follow up
424494|NCT00989326|Follow-up studies
424495|NCT00989313|Peplin
424496|NCT00989313|Actinic keratosis
424497|NCT00989313|PEP005
424498|NCT00989300|Drug-Drug interaction
424499|NCT00989300|Clopidogrel
424500|NCT00989300|Rabeprazol
424501|NCT00989300|Omeprazol
424502|NCT00989300|Pharmacodynamic Study
424503|NCT00989287|GSK Bio's influenza vaccine GSK2340272A
424504|NCT00989287|influenza infection
424505|NCT00989274|Influenza
424506|NCT00989274|Vaccination
424507|NCT00989274|Immunology
424508|NCT00989274|Immunogenicity
424509|NCT00989274|Reactogenicity
424510|NCT00989274|Safety
424511|NCT00989274|Influenza vaccine
424512|NCT00989274|Immune response
424513|NCT00989274|Adverse effects
424514|NCT00989261|AML
424515|NCT00989261|AC220
424516|NCT00989261|acute
424517|NCT00989261|FLT3
424518|NCT00989261|inhibitor
424519|NCT00989261|kinase
424520|NCT00989261|leukemia
424521|NCT00989261|leukaemia
424522|NCT00989261|myeloid
424523|NCT00989261|relapsed
424524|NCT00989261|refractory
424525|NCT00989248|Ergospirometry
424526|NCT00989248|Cardiopulmonary Exercise Test
424527|NCT00989248|Exercises
424528|NCT00989248|Immersion
424529|NCT00989235|NOS
424530|NCT00989222|Distal radius fractures
424531|NCT00989222|Fractures of the distal radius
424532|NCT00989222|Volar plate
424533|NCT00989222|External fixation
424534|NCT00989209|facial paralysis
424535|NCT00989209|asymmetry
424536|NCT00989209|myofunctional therapy
424537|NCT00989209|botulinum toxin
424538|NCT00989209|facial evaluation
424539|NCT00989183|Ovaries
424540|NCT00989183|Reproductive Age
424541|NCT00989183|Oophorectomy
424542|NCT00989157|Gastric Bypass
424543|NCT00989157|Duloxetine
424544|NCT00989157|Cymbalta
424545|NCT00989157|Pharmacokinetics
424546|NCT00989144|HIV seronegative
424547|NCT00989144|acute infection
424548|NCT00989131|Ovarian Cancer
424549|NCT00989105|stage I prostate cancer
424550|NCT00989105|stage IIB prostate cancer
424551|NCT00989105|stage IIA prostate cancer
424552|NCT00989105|stage III prostate cancer
424553|NCT00989105|stage IV prostate cancer
424554|NCT00989105|recurrent prostate cancer
424555|NCT00989092|anemia of cancer
424556|NCT00989092|darbepoetin alfa
424557|NCT00989092|Aranesp
424558|NCT00989079|Single Ascending Dose Study in healthy subjects
424559|NCT00989066|Xience V
424560|NCT00989066|stent
424561|NCT00989066|coronary disease
424562|NCT00989053|depression
424563|NCT00989053|anxiety
424564|NCT00989053|stress
424565|NCT00989053|antidepressant therapy
424566|NCT00989053|SSRI
424567|NCT00989053|infertility
424568|NCT00989053|in vitro fertilization (IVF)
424569|NCT00989053|immunological factors
424570|NCT00989053|depressive and anxiety symptoms in women undergoing IVF treatment
424571|NCT00989040|NPZ
424572|NCT00989040|Pain
424573|NCT00989027|Uterine contraction
424574|NCT00989027|Dose-response
424575|NCT00989027|Oxytocin pre-treatment
424576|NCT00989014|Erythematotelangiectatic
424577|NCT00989014|Rosacea
424578|NCT00989001|Atrial Fibrillation
424579|NCT00989001|RSD1235
424580|NCT00989001|Vernakalant
424581|NCT00989001|conversion
424582|NCT00988988|Multiple Sclerosis
424583|NCT00988988|AGEE
424584|NCT00988988|histamine response
424585|NCT00988962|pain
424586|NCT00988962|opioids
424587|NCT00988949|Proof of mechanism study
424588|NCT00988936|[F-18]RGD-K5
424589|NCT00988936|RGD-K5
424590|NCT00988936|K5-101
424591|NCT00988936|Avastin
424592|NCT00988936|angiogenesis
424593|NCT00988936|anti-angiogenesis
424594|NCT00988936|chemotherapy
424595|NCT00988936|breast cancer
424596|NCT00988936|colon cancer
424597|NCT00988936|rectal cancer
424598|NCT00988936|lung cancer
424599|NCT00988936|non-squamous
424600|NCT00988936|non small cell
424601|NCT00988910|Combined Oral Contraceptives
424602|NCT00988910|COC
424603|NCT00988871|PICC (peripherally inserted central venous catheter)
424604|NCT00988871|CICC (centrally inserted central venous catheter
424605|NCT00988871|CVP (central venous pressure)
424606|NCT00988871|LT (liver transplantation)
424607|NCT00988871|agreement
424608|NCT00988845|dietary supplement
424609|NCT00988845|indole 3 carbinol
424610|NCT00988845|estrogen
424611|NCT00988806|Advanced heart failure
424612|NCT00988806|Levosimendan
424613|NCT00988806|Intermittent long-term infusions
424614|NCT00988780|Immune reconstitution inflammatory syndrome
424615|NCT00988780|CCR5 antagonist
424616|NCT00988780|Maraviroc
424617|NCT00988780|HIV
424618|NCT00988780|treatment naive
424619|NCT00988767|Hepatitis B
424620|NCT00988767|DNA vaccine
424621|NCT00988767|immunotherapy
424622|NCT00988754|Obesity
424623|NCT00988754|childhood and adolescence
424624|NCT00988754|school and family-based lifestyle intervention
424625|NCT00988754|cardiovascular risk
424626|NCT00988754|Obesity and associated cardiovascular risk in childhood and adolescence,
424627|NCT00988754|health behaviour
424628|NCT00988741|Unresectable
424629|NCT00988741|Hepatocellular
424630|NCT00988741|Carcinoma
424631|NCT00988702|Dan Tian Breathing
424632|NCT00988702|Physiological measurement
424633|NCT00988702|progressive muscle relaxation
424634|NCT00988702|Monitoring, Physiologic
424635|NCT00988689|starch
424636|NCT00988689|carbohydrates
424637|NCT00988689|blood glucose
424638|NCT00988689|food intake
424639|NCT00988689|satiety
424640|NCT00988689|appetite
424641|NCT00988663|electroconvulsive therapy
424642|NCT00988663|memantine
424643|NCT00988663|cognitive function
424644|NCT00988663|memory
424645|NCT00988650|Metabolic syndrome
424646|NCT00988650|Mediterranean diet
424647|NCT00988650|Blood lipids
424648|NCT00988650|Coronary heart disease
424649|NCT00988650|Apolipoprotein
424650|NCT00988624|bioavailability pharmacokinetics Alzheimer's Disease Huntington Disease
424651|NCT00988611|Reproductive aging
424652|NCT00988598|phase 1 Alzheimer's disease donepezil
424653|NCT00988585|Heart Disease Risk Reduction
424654|NCT00988572|Wrist fractures
424655|NCT00988572|Vestibular asymmetry
424656|NCT00988572|Vestibular rehabilitation
424657|NCT00988572|Fall-related wrist fractures
424658|NCT00988572|Patients 50 years or older
424659|NCT00988559|high grade cervical dysplasia
424660|NCT00988559|treatment vaccine
424661|NCT00988559|therapeutic
424662|NCT00988559|HPV
424663|NCT00988559|DNA vaccine
424664|NCT00988559|gene therapy
424665|NCT00988559|gene gun
424666|NCT00988559|pre-cancerous
424667|NCT00988546|Disability Evaluation
424668|NCT00988546|Joint Diseases
424669|NCT00988546|Joint Disability
424670|NCT00988533|Head Lice
424671|NCT00988533|Pediculus
424672|NCT00988520|Neuromuscular Blocking Agents
424673|NCT00988481|Bulimia Nervosa
424674|NCT00988481|Topiramate
424675|NCT00988481|Augmentation
424676|NCT00988468|Knee Osteoarthritis
424677|NCT00988468|Manual Therapy
424678|NCT00988468|Therapeutic Exercise
424679|NCT00988468|Ultrasound
424680|NCT00988468|Effusion
424681|NCT00988455|basal cell carcinoma
424682|NCT00988455|photodynamic therapy
424683|NCT00988455|photo chemotherapy
424684|NCT00988455|basal cell epithelioma
424685|NCT00988442|Adherence
424686|NCT00988442|Treatment
424687|NCT00988442|Adherence Intervention
424688|NCT00988442|Telephone Intervention
424689|NCT00988442|treatment experienced
424690|NCT00988429|Refractory
424691|NCT00988429|partial
424692|NCT00988429|epilepsy
424693|NCT00988429|efficacy
424694|NCT00988429|eslicarbazepine
424695|NCT00988429|safety
424696|NCT00988416|IPMN
424697|NCT00988390|mothers living with HIV
424698|NCT00988390|family intervention
424699|NCT00988390|family functioning
424700|NCT00988390|conflict
424701|NCT00988390|Mental health
424702|NCT00988390|and physical health
424703|NCT00988390|Family relationships (functioning and conflict)
424704|NCT00988377|whey protein
424705|NCT00988377|subjective appetite
424706|NCT00988377|shor-term food intake
424707|NCT00988377|blood glucose
424708|NCT00988364|Metabolic Syndrome
424709|NCT00988364|LDL subfraction L5
424710|NCT00988364|The reduction of LDL Chol in patients with Metabolic Syndrome
424711|NCT00988364|The prevalence of L5 in patients with Metabolic Syndrome
424712|NCT00988364|The reduction of L5 subfraction in patients with Metabolic Syndrome
424713|NCT00988351|sleep apnea
424714|NCT00988351|positive airway pressure
424715|NCT00988351|portable monitoring
424716|NCT00988351|auto positive airway pressure
424717|NCT00988338|Trinity Evolution
424718|NCT00988338|Arthrodesis
424719|NCT00988338|Foot Fusion
424720|NCT00988338|Ankle Fusion
424721|NCT00988338|Allograft
424722|NCT00988312|dendritic cells (DC)
424723|NCT00988312|idiotype (Id)
424724|NCT00988312|immunotherapy
424725|NCT00988299|older
424726|NCT00988299|NEAT
424727|NCT00988299|exercise
424728|NCT00988299|RMR
424729|NCT00988299|energy expenditure
424730|NCT00988273|Crohn's disease
424731|NCT00988273|Ulcerative colitis
424732|NCT00988273|dysplasia
424733|NCT00988247|Rhinitis, Allergic, Perennial
424734|NCT00988247|BDP-HFA
424735|NCT00988247|Hay fever
424736|NCT00988247|Allergic rhinitis
424737|NCT00988234|Lumbar plexus block
424738|NCT00988234|sciatic nerve block
424739|NCT00988234|position
424740|NCT00988234|ultrasound guidance
424741|NCT00988234|elective lower limb surgery
424742|NCT00988208|Castrate-Resistant Prostate Cancer
424743|NCT00988208|Revlimid
424744|NCT00988208|Lenalidomide
424745|NCT00988195|Neoplasm
424746|NCT00988195|Hepatocellular Carcinoma
424747|NCT00988182|Whey protein
424748|NCT00988182|Hydrolysate whey protein
424749|NCT00988182|Blood glucose
424750|NCT00988182|Insulin
424751|NCT00988169|AT-101
424752|NCT00988169|erlotinib
424753|NCT00988169|Unresectable Stage IIIB
424754|NCT00988169|09-026
424755|NCT00988156|Epilepsy
424756|NCT00988156|Partial
424757|NCT00988156|Refractory
424758|NCT00988156|Children
424759|NCT00988156|Adolescents
424760|NCT00988156|Adjunctive
424761|NCT00988156|Randomised
424762|NCT00988156|Double-blind
424763|NCT00988156|Placebo-controlled
424764|NCT00988156|Parallel-group
424765|NCT00988143|Influenza
424766|NCT00988143|Trivalent Influenza Virus Vaccine
424767|NCT00988143|Quadrivalent Influenza Virus Vaccine
424768|NCT00988130|sexual dysfunction
424769|NCT00988130|stage I prostate cancer
424770|NCT00988130|stage IIB prostate cancer
424771|NCT00988130|stage IIA prostate cancer
424772|NCT00988130|stage III prostate cancer
424773|NCT00988117|PDD
424774|NCT00988117|Parkinson's Disease with Dementia
424775|NCT00988117|rivastigmine
424776|NCT00988117|rivastigmine patch
424777|NCT00988117|open label
424778|NCT00988117|Parkinson's Disease
424779|NCT00988117|Parkinsons Disease
424780|NCT00988117|memory
424781|NCT00988117|Exelon
424782|NCT00988117|Exelon Patch
424783|NCT00988104|Behavior Therapy
424784|NCT00988104|Randomized Controlled Trial
424785|NCT00988078|metformin
424786|NCT00988078|Hyperandrogenism
424787|NCT00988078|Metabolic Syndrome X
424788|NCT00988078|adolescents
424789|NCT00988078|melatonin
424790|NCT00988078|Polycystic Ovary Syndrome
424791|NCT00988078|Insulin Resistance
424792|NCT00988078|Menstrual Cycle
424793|NCT00988052|Relapsing Multiple Sclerosis
424794|NCT00988039|Human Immunodeficiency virus
424795|NCT00988039|second line therapy
424796|NCT00988039|raltegravir
424797|NCT00988039|aluvia
424798|NCT00988039|monotherapy
424799|NCT00988039|integrase inhibitor
424800|NCT00988039|protease inhibitor
424801|NCT00988039|Randomized Controlled Trial
424802|NCT00988013|total marrow irradiation
424803|NCT00988013|intensity modulated radiation
424804|NCT00988013|leukemia
424805|NCT00988013|hematologic diseases
424806|NCT00988000|outpatients
424807|NCT00987987|hematological malignancy
424808|NCT00987987|allogeneic hematopoietic stem cell transplantation
424809|NCT00987987|donor lymphocyte infusion
424810|NCT00987987|antitumor immunotherapy
424811|NCT00987987|graft-versus-tumor effect
424812|NCT00987987|regulatory T cells
424813|NCT00987987|adult
424814|NCT00987974|ischemia reperfusion injury
424815|NCT00987974|endothelial dysfunction
424816|NCT00987974|statins
424817|NCT00987974|rosuvastatin
424818|NCT00987974|atorvastatin
424819|NCT00987974|placebo
424820|NCT00987974|ecto-5'-nucleotidase
424821|NCT00987974|flow mediated dilation
424822|NCT00987961|opioid dependence
424823|NCT00987961|suboxone
424824|NCT00987961|HIV risk behavior
424825|NCT00987948|HIV
424826|NCT00987948|dementia
424827|NCT00987948|High HIV DNA within CD14+ PBMCs
424828|NCT00987948|treatment experienced
424829|NCT00987922|Stroke
424830|NCT00987922|Acute
424831|NCT00987922|Infarction
424832|NCT00987922|Ischemic
424833|NCT00987922|Thrombolysis
424834|NCT00987922|Mild
424835|NCT00987922|Hypothermia
424836|NCT00987909|Cat
424837|NCT00987909|Allergy
424838|NCT00987909|Immunotherapy
424839|NCT00987909|Sublingual
424840|NCT00987909|Exposure chamber
424841|NCT00987909|Safety
424842|NCT00987909|Rhinoconjunctivitis
424843|NCT00987896|colonoscopy
424844|NCT00987896|polypectomy
424845|NCT00987896|NOTES
424846|NCT00987883|Nutritional Support
424847|NCT00987870|Stable plaque Psoriasis
424848|NCT00987870|inflammatory skin
424849|NCT00987870|with or without arthritis
424850|NCT00987857|esophageal cancer
424851|NCT00987857|adenocarcinoma of the esophagus
424852|NCT00987857|Barrett esophagus
424853|NCT00987831|SLE
424854|NCT00987831|lupus
424855|NCT00987831|biomarkers
424856|NCT00987831|depomedrol
424857|NCT00987831|flare
424858|NCT00987831|disease activity
424859|NCT00987818|Biomarkers
424860|NCT00987818|Antibiotic therapy
424861|NCT00987805|Functional dyspepsia
424862|NCT00987805|Banhasasim-tang
424863|NCT00987805|Gastrointestinal Symptom score
424864|NCT00987805|Visual Analogue Scale
424865|NCT00987805|Functional Dyspepsia-related Quality of Life
424866|NCT00987805|Electrogastrography
424867|NCT00987792|Community Acquired Pneumonia
424868|NCT00987779|Bioequivalence study
424869|NCT00987779|Food effect study
424870|NCT00987779|Pharmacokinetics
424871|NCT00987779|Gabapentin
424872|NCT00987766|advanced adult primary liver cancer
424873|NCT00987766|stage III pancreatic cancer
424874|NCT00987766|stage IV pancreatic cancer
424875|NCT00987766|periampullary adenocarcinoma
424876|NCT00987766|small intestine adenocarcinoma
424877|NCT00987766|adenocarcinoma of the extrahepatic bile duct
424878|NCT00987766|adenocarcinoma of the gallbladder
424879|NCT00987766|unresectable extrahepatic bile duct cancer
424880|NCT00987766|unresectable gallbladder cancer
424881|NCT00987753|L-377202, prostate cancer, PSA
424882|NCT00987714|Organ Donors
424883|NCT00987714|Recipients
424884|NCT00987701|Neurobehavior
424885|NCT00987701|Development
424886|NCT00987701|Fluid management
424887|NCT00987701|Neuraxial anesthesia
424888|NCT00987675|stage I prostate cancer
424889|NCT00987675|stage IIB prostate cancer
424890|NCT00987675|stage IIA prostate cancer
424891|NCT00987675|stage III prostate cancer
424892|NCT00987662|irbesartan
424893|NCT00987662|amlodipine
424894|NCT00987662|obesity
424895|NCT00987662|ambulatory blood pressure monitoring
424896|NCT00987662|new onset diabetes
424897|NCT00987649|pelvic mass
424898|NCT00987649|ovarian cancer
424899|NCT00987649|adnexal mass
424900|NCT00987649|CA125
424901|NCT00987649|HE4
424902|NCT00987636|Ewing Sarcoma
424903|NCT00987636|localized
424904|NCT00987636|disseminated
424905|NCT00987636|metastases
424906|NCT00987636|bone
424907|NCT00987636|soft tissue
424908|NCT00987610|Percutaneous coronary intervention
424909|NCT00987610|chronic total occlusion
424910|NCT00987610|guidewire
424911|NCT00987610|Angioplasty, Transluminal, Percutaneous Coronary
424912|NCT00987610|Angioplasty
424913|NCT00987610|Percutaneous Coronary
424914|NCT00987597|Smoking
424915|NCT00987597|nicotine replacement
424916|NCT00987597|psychological behaviour
424917|NCT00987597|Smoking > 5 cigarettes per day
424918|NCT00987597|Hospitalisation for acute coronary syndrome
424919|NCT00987571|carpal tunnel syndrome
424920|NCT00987571|median nerve
424921|NCT00987571|ultrasound
424922|NCT00987571|electrodiagnosis
424923|NCT00987571|Normal subjects
424924|NCT00987558|Eslicarbazepine acetate
424925|NCT00987558|simvastatin
424926|NCT00987545|Keloids
424927|NCT00987545|recurrence
424928|NCT00987532|preschool
424929|NCT00987532|participatory intervention
424930|NCT00987532|cluster-randomization
424931|NCT00987532|children
424932|NCT00987532|obesity prevention
424933|NCT00987519|acute bronchiolitis
424934|NCT00987519|acute gastroenteritis
424935|NCT00987519|febrile convulsion
424936|NCT00987519|viral agents
424937|NCT00987519|molecular methods
424938|NCT00987506|drug eluting stents
424939|NCT00987506|Stents
424940|NCT00987506|Angioplasty
424941|NCT00987506|Chronic coronary occlusion
424942|NCT00987506|Stent thrombosis
424943|NCT00987506|Vascular disease
424944|NCT00987506|Myocardial ischemia
424945|NCT00987506|Coronary artery stenosis
424946|NCT00987506|Coronary Disease
424947|NCT00987506|Coronary Artery Disease
424948|NCT00987506|Coronary Restenosis
424949|NCT00987493|recurrent adult diffuse large cell lymphoma
424950|NCT00987493|recurrent grade 3 follicular lymphoma
424951|NCT00987480|Stem Cell Transplantation
424952|NCT00987480|Anemia
424953|NCT00987480|Busulfan
424954|NCT00987480|Cyclophosphamide
424955|NCT00987480|Fludarabine
424956|NCT00987480|08-031
424957|NCT00987467|Atopic
424958|NCT00987467|Keratoconjunctivitis
424959|NCT00987467|Restasis
424960|NCT00987467|Cyclosporine
424961|NCT00987441|Neurobehavior
424962|NCT00987441|Epidural analgesia
424963|NCT00987441|Local anesthetic
424964|NCT00987441|Opioid
424965|NCT00987428|ERCP
424966|NCT00987428|EUS
424967|NCT00987428|Pancreatitis biliary
424968|NCT00987428|Severe
424969|NCT00987428|Interventional endoscopy
424970|NCT00987428|Choledocolithiasis
424971|NCT00987402|Surgery
424972|NCT00987402|hand scrubbing
424973|NCT00987402|post-operative infection
424974|NCT00987402|surgical site infection
424975|NCT00987402|surgical hand preparation
424976|NCT00987402|plain soap and water
424977|NCT00987402|alcohol-based hand rub
424978|NCT00987402|Cost of surgical hand preparation agent
424979|NCT00987402|Side effects of use of hand preparation agent
424980|NCT00987389|Vasculitis
424981|NCT00987389|Granulomatosis with Polyangiitis
424982|NCT00987389|Microscopic Polyangiitis
424983|NCT00987389|Wegener's
424984|NCT00987389|ANCA-Associated Vasculitis
424985|NCT00987389|GPA
424986|NCT00987389|MPA
424987|NCT00987389|Treatment
424988|NCT00987389|Plasma exchange
424989|NCT00987389|Glucocorticoids
424990|NCT00987389|ANCA-Positive
424991|NCT00987363|critical limb ischemia (CLI)
424992|NCT00987363|diabetic foot
424993|NCT00987363|bone marrow derived mononuclear cells
424994|NCT00987363|cell therapy
424995|NCT00987350|Jet Injector
424996|NCT00987350|Vaccine
424997|NCT00987350|Influenza
424998|NCT00987337|Hepatitis C Polymerase Inhibitor PF-00868554 Filibuvir
424999|NCT00987311|Probiotics
425000|NCT00987311|intestinal immune system
425001|NCT00987311|human
425002|NCT00987311|healthy subjects
425003|NCT00987311|dairy drink
425004|NCT00987311|Healthy adults
425005|NCT00987298|Abdominal Fat
425006|NCT00987298|Visceral Fat
425007|NCT00987298|Subcutaneous Fat
425008|NCT00987298|Dual-energy x-ray absorptiometry
425009|NCT00987298|DXA
425010|NCT00987298|Computed Tomography
425011|NCT00987298|CT
425012|NCT00987298|Body Mass Index
425013|NCT00987298|Body composition
425014|NCT00987298|Percent fat
425015|NCT00987298|Waist circumference
425016|NCT00987298|Hip circumference
425017|NCT00987285|RE AIM model
425018|NCT00987285|Type 2 Diabetes Mellitus
425019|NCT00987285|Interactive voice recognition
425020|NCT00987285|Computer Assisted Self Management
425021|NCT00987272|Allergies
425022|NCT00987272|Ocular
425023|NCT00987259|Myocardial infarction
425024|NCT00987259|Myocardial oedema
425025|NCT00987259|Magnetic resonance
425026|NCT00987246|Actinic Keratosis
425027|NCT00987246|AK
425028|NCT00987246|NMSC
425029|NCT00987246|Combination
425030|NCT00987220|CSF Biomarkers Acetylcholine
425031|NCT00987207|Postconditioning
425032|NCT00987207|cyclosporine A
425033|NCT00987207|myocardial ischemia
425034|NCT00987207|cardiac surgery
425035|NCT00987207|aortic valvulopathy
425036|NCT00987194|HIV
425037|NCT00987194|rapid testing
425038|NCT00987194|HIV seronegativity
425039|NCT00987181|Pulse wave velocity
425040|NCT00987181|Non contact
425041|NCT00987181|Non-invasive
425042|NCT00987181|Photoplethysmography
425043|NCT00987181|Doppler flow velocimetry
425044|NCT00987168|Congenital Hyperinsulinism
425045|NCT00987168|Hypoglycemia,
425046|NCT00987168|Sandostatine subcutaneous in 3 daily injections
425047|NCT00987168|Intramuscular injection of Sandostatine® LP per month
425048|NCT00987155|Functional electrical stimulation cycling
425049|NCT00987155|arm crank
425050|NCT00987155|wheelchair
425051|NCT00987155|ergometry
425052|NCT00987155|paraplegia
425053|NCT00987155|spinal cord injury
425054|NCT00987155|exercise testing
425055|NCT00987129|DHA
425056|NCT00987129|EPA
425057|NCT00987129|AMD
425058|NCT00987129|drusen
425059|NCT00987129|omega-3 fatty acids
425060|NCT00987129|omega6:omega3 ratio
425061|NCT00987116|Myasthenia gravis
425062|NCT00987116|Steroids side effects
425063|NCT00987116|Comparison of strategies for tapering steroids
425064|NCT00987116|Generalized MG corresponding to grade III, IV or V of MGFA
425065|NCT00987103|renal transplantation
425066|NCT00987103|tacrolimus
425067|NCT00987103|pharmacokinetics
425068|NCT00987103|rectal
425069|NCT00987103|sublingual
425070|NCT00987103|rectal administration
425071|NCT00987103|sublingual administration
425072|NCT00987090|subjects developing symptoms of Alzheimer Disease
425073|NCT00987077|CSC
425074|NCT00987077|SRT
425075|NCT00987064|Protexo
425076|NCT00987064|Asthma
425077|NCT00987064|Temperature controlled Laminar Airflow
425078|NCT00987064|Perennial allergy
425079|NCT00987064|Quality of life
425080|NCT00987064|MiniAQLQ
425081|NCT00987064|FeNO
425082|NCT00987064|FEV1
425083|NCT00987064|PEF
425084|NCT00987051|sentinel node procedure
425085|NCT00987051|radiocolloid
425086|NCT00987051|patent blue
425087|NCT00987038|drug interaction CYP3A4 glucocorticoids midazolam
425088|NCT00987025|hypertension
425089|NCT00987025|telehealth
425090|NCT00987025|nurse monitor
425091|NCT00987025|nutrition center
425092|NCT00986999|HIV infected
425093|NCT00986999|treatment experienced
425094|NCT00986986|Human immunodeficiency virus
425095|NCT00986986|Low high density lipoprotein
425096|NCT00986986|Endothelial function
425097|NCT00986986|Flow-mediated vasodilation
425098|NCT00986973|PKU
425099|NCT00986973|BH4
425100|NCT00986973|KUVAN
425101|NCT00986973|PET scan
425102|NCT00986973|Neurodevelopment
425103|NCT00986960|multiple sclerosis
425104|NCT00986960|relapsing remitting
425105|NCT00986960|RRMS
425106|NCT00986921|Length of time for procedure to be completed
425107|NCT00986921|Need for additional dilation
425108|NCT00986921|Subject satisfaction with procedure
425109|NCT00986895|HPN-100
425110|NCT00986895|GT4P
425111|NCT00986895|Glyceryl tri-(4-phenylbutyrate)
425112|NCT00986882|Postoperative pain
425113|NCT00986869|Safety
425114|NCT00986869|Bronchoscopy
425115|NCT00986869|Pulmonary
425116|NCT00986869|Hypertension
425117|NCT00986843|HM30181A
425118|NCT00986843|Irinotecan
425119|NCT00986843|MTD
425120|NCT00986843|DLT
425121|NCT00986830|Rhinosinusitis
425122|NCT00986830|Balloon catheters
425123|NCT00986830|Office treatment
425124|NCT00986830|Otorhinolaryngologic Diseases
425125|NCT00986830|Respiratory Tract Infections
425126|NCT00986830|Respiratory Tract Diseases
425127|NCT00986830|FinESS Sinus Treatment
425128|NCT00986830|endoscopic sinus surgery
425129|NCT00986817|Refractory ascites
425130|NCT00986817|Cirrhosis Terlipressin
425131|NCT00986817|Paracentesis
425132|NCT00986791|risk reduction
425133|NCT00986765|Fetal growth restriction
425134|NCT00986765|Abruptio placentae
425135|NCT00986765|Perinatal death
425136|NCT00986752|stent
425137|NCT00986752|atherectomy
425138|NCT00986752|paclitaxel-eluting balloon
425139|NCT00986739|Chronic pathologies
425140|NCT00986739|elderly
425141|NCT00986739|atmospheric pollution
425142|NCT00986739|unplanned hospitalization
425143|NCT00986739|case-crossover
425144|NCT00986687|Oocyte cryopreservation
425145|NCT00986687|vitrification
425146|NCT00986674|Advanced Non-small Cell Lung Cancer
425147|NCT00986674|Carboplatin
425148|NCT00986674|Paclitaxel
425149|NCT00986674|Cetuximab
425150|NCT00986674|IMC-A12
425151|NCT00986648|acute liver failure
425152|NCT00986648|hepatic encephalopathy
425153|NCT00986648|acetaminophen toxicity
425154|NCT00986635|Activated partial thromboplastin time
425155|NCT00986635|Thrombin clotting Time
425156|NCT00986635|Anti-Xa-activity
425157|NCT00986635|Factor X-activity
425158|NCT00986635|Factor XIII-activity
425159|NCT00986635|Antithrombin (based on factor II)
425160|NCT00986635|Antithrombin (based on factor X<9
425161|NCT00986596|vitamin D
425162|NCT00986596|skeletal muscle
425163|NCT00986596|vitamin D receptor
425164|NCT00986583|Succinylcholine
425165|NCT00986583|Statins
425166|NCT00986583|myalgias
425167|NCT00986583|statins with succinylcholine and pain
425168|NCT00986570|Botulinum Toxin A
425169|NCT00986570|Wrinkles
425170|NCT00986557|cytomegalovirus infection
425171|NCT00986557|graft versus host disease
425172|NCT00986544|Laparoscopy
425173|NCT00986544|cholecystectomy
425174|NCT00986544|drainage
425175|NCT00986531|schizophrenia
425176|NCT00986531|early phase trials
425177|NCT00986518|Advanced Colorectal Cancer
425178|NCT00986518|Hepatic and/or lung metastasis
425179|NCT00986518|Adaptive autologous cell immunotherapy
425180|NCT00986518|T- regulatory lymphocyte depletion
425181|NCT00986518|Neo-adjuvant reduced intensity chemotherapeutic conditioning
425182|NCT00986505|lidocaine
425183|NCT00986505|fibromyalgia
425184|NCT00986505|intravenous lidocaine
425185|NCT00986505|manifestations
425186|NCT00986492|Sleep deprivation
425187|NCT00986492|Food intake
425188|NCT00986492|Motor activity
425189|NCT00986492|Normal, healthy subjects
425190|NCT00986479|Patients
425191|NCT00986466|exercise
425192|NCT00986466|falls
425193|NCT00986466|physical functioning
425194|NCT00986466|vitamin D
425195|NCT00986466|mobility function
425196|NCT00986466|neuromuscular functioning¨
425197|NCT00986466|quality of life
425198|NCT00986466|number of fallers
425199|NCT00986466|fall-related injuries including bone fractures
425200|NCT00986466|bone mass
425201|NCT00986453|Breast Reduction
425202|NCT00986453|PlasmaBlade
425203|NCT00986453|Electrosurgery
425204|NCT00986453|PEAK Surgical
425205|NCT00986453|Medtronic Advanced Energy
425206|NCT00986453|Medtronic
425207|NCT00986414|Parkinson Disease
425208|NCT00986414|L-dopa
425209|NCT00986414|Levodopa
425210|NCT00986414|dyskinesia
425211|NCT00986401|Adults
425212|NCT00986375|Randomized Controlled Trial
425213|NCT00986375|evidence- and theory-based behavioral intervention
425214|NCT00986375|expert system
425215|NCT00986375|stages of change
425216|NCT00986375|motivational interviewing
425217|NCT00986375|tailoring
425218|NCT00986375|Self Care
425219|NCT00986375|Rehabilitation
425220|NCT00986375|Expert Systems
425221|NCT00986375|Behavior
425222|NCT00986375|Motivation
425223|NCT00986362|Safety in pediatrics
425224|NCT00986349|Diabetes
425225|NCT00986349|Weight Loss
425226|NCT00986349|GI Dynamics
425227|NCT00986349|EndoBarrier
425228|NCT00986336|topiramate
425229|NCT00986336|risperidone, bipolar disorder
425230|NCT00986323|Asthma
425231|NCT00986323|Temperature controlled Laminar Airflow
425232|NCT00986323|TLA
425233|NCT00986323|Perennial allergy
425234|NCT00986323|Quality of life
425235|NCT00986323|Environmental control
425236|NCT00986310|fluoxetine
425237|NCT00986310|epilepsy
425238|NCT00986310|Prozac
425239|NCT00986297|recurrent non-small cell lung cancer
425240|NCT00986297|stage II non-small cell lung cancer
425241|NCT00986297|stage IIIA non-small cell lung cancer
425242|NCT00986297|stage IIIB non-small cell lung cancer
425243|NCT00986297|stage IV non-small cell lung cancer
425244|NCT00986297|adenocarcinoma of the lung
425245|NCT00986297|adenosquamous cell lung cancer
425246|NCT00986297|bronchoalveolar cell lung cancer
425247|NCT00986297|large cell lung cancer
425248|NCT00986297|squamous cell lung cancer
425249|NCT00986284|Non Small Cell Lung Cancer
425250|NCT00986284|Gefitinib
425251|NCT00986284|Neoadjuvant Therapy
425252|NCT00986271|severe sepsis, intensive care units
425253|NCT00986258|pain assessment
425254|NCT00986258|tapentadol
425255|NCT00986258|centrally acting analgesic
425256|NCT00986245|Parkinson disease
425257|NCT00986245|Ropinirole
425258|NCT00986219|Asthma
425259|NCT00986219|Language
425260|NCT00986219|Symptoms,
425261|NCT00986219|Limitation of Daily activities
425262|NCT00986219|Patients
425263|NCT00986219|Physicians
425264|NCT00986219|Greece
425265|NCT00986206|ovarian epithelial cancer
425266|NCT00986206|BRCA1 mutation carrier
425267|NCT00986206|BRCA2 mutation carrier
425268|NCT00986206|stage IA ovarian epithelial cancer
425269|NCT00986206|stage IB ovarian epithelial cancer
425270|NCT00986206|stage IC ovarian epithelial cancer
425271|NCT00986206|stage IIA ovarian epithelial cancer
425272|NCT00986206|stage IIB ovarian epithelial cancer
425273|NCT00986206|stage IIC ovarian epithelial cancer
425274|NCT00986206|stage IIIA ovarian epithelial cancer
425275|NCT00986206|stage IIIB ovarian epithelial cancer
425276|NCT00986206|stage IIIC ovarian epithelial cancer
425277|NCT00986206|stage IV ovarian epithelial cancer
425278|NCT00986193|Aortic Valve Stenosis
425279|NCT00986193|Stent Valve
425280|NCT00986193|Biological Aortic Valve Prosthesis
425281|NCT00986180|Acute Low Back Pain
425282|NCT00986180|Low Back Pain With Leg Pain Below The Knee
425283|NCT00986180|Radiculopathy, Oxycodone
425284|NCT00986180|Tapentadol
425285|NCT00986180|NUCYNTA
425286|NCT00986167|Psychosis
425287|NCT00986167|Aggression
425288|NCT00986167|Acute
425289|NCT00986167|Quetiapine XR
425290|NCT00986154|Recurrent Thrombosis
425291|NCT00986154|Recurrent Pulmonary Embolism
425292|NCT00986154|Symptomatic Deep Vein Thrombosis
425293|NCT00986154|Symptomatic Pulmonary Embolism
425294|NCT00986154|Venous Thromboembolism (VTE)
425295|NCT00986128|Topiramate
425296|NCT00986128|Lithium
425297|NCT00986128|Bipolar disorder
425298|NCT00986115|epilepsy
425299|NCT00986115|memory
425300|NCT00986115|cognition
425301|NCT00986115|memantine
425302|NCT00986102|Carbapenem
425303|NCT00986102|Doripenem
425304|NCT00986102|Doribax
425305|NCT00986102|Nosocomial pneumonia, Intra-abdominal infections
425306|NCT00986102|Urinary tract infection
425307|NCT00986089|post-placental
425308|NCT00986089|IUD
425309|NCT00986089|Copper IUD
425310|NCT00986089|cesarean section
425311|NCT00986089|immediate post-partum
425312|NCT00986089|continuation
425313|NCT00986076|Pediatric Cataract Surgery
425314|NCT00986076|Low-Molecular weight Heparin
425315|NCT00986076|Intraocular infusion
425316|NCT00986076|Anti-inflammatory effect
425317|NCT00986063|Nevirapine induced rash
425318|NCT00986063|Hepatitis
425319|NCT00986063|Pharmacogenomics
425320|NCT00986063|AIDS
425321|NCT00986063|HIV
425322|NCT00986063|treatment naive
425323|NCT00986050|STEMI
425324|NCT00986050|DES
425325|NCT00986050|BMS
425326|NCT00986050|abciximab
425327|NCT00986037|Adverse events
425328|NCT00986037|Pharmacokinetics
425329|NCT00986024|Exercise therapy
425330|NCT00986011|obesity
425331|NCT00986011|weight changes
425332|NCT00986011|healthy, no evidence of disease
425333|NCT00985998|nimotuzumab
425334|NCT00985998|non-small cell lung cancer
425335|NCT00985998|chemotherapy
425336|NCT00985985|smoking cessation
425337|NCT00985985|nicotine lozenge
425338|NCT00985985|nicotine replacement therapy
425339|NCT00985972|PHYSICAL ACTIVITY
425340|NCT00985972|SCHOOL
425341|NCT00985972|NUTRITION
425342|NCT00985972|EDUCATION
425343|NCT00985972|OVERWEIGHT
425344|NCT00985959|Multiple myeloma
425345|NCT00985959|Hematopoietic stem cell transplant
425346|NCT00985959|HSCT
425347|NCT00985959|Melphalan
425348|NCT00985959|Prednisolone
425349|NCT00985959|Bortezomib
425350|NCT00985959|JNJ-26866138
425351|NCT00985933|Healthy normal volunteers
425352|NCT00985920|blood loss
425353|NCT00985920|postoperative
425354|NCT00985907|myeloma
425355|NCT00985907|DMV
425356|NCT00985894|Teledermatology
425357|NCT00985894|Telemedicine
425358|NCT00985894|Atopic Dermatitis
425359|NCT00985881|Artificial limbs
425360|NCT00985881|Gait
425361|NCT00985881|Posture
425362|NCT00985881|Prosthesis
425363|NCT00985881|Vibration
425364|NCT00985868|unspecified childhood solid tumor, protocol specific
425365|NCT00985842|Artificial limbs
425366|NCT00985842|Gait
425367|NCT00985842|Oximetry
425368|NCT00985842|Prosthesis
425369|NCT00985842|Rehabilitation
425370|NCT00985829|basal cell carcinoma
425371|NCT00985829|photodynamic therapy
425372|NCT00985829|photo chemotherapy
425373|NCT00985829|basal cell epithelioma
425374|NCT00985816|Preterm
425375|NCT00985816|newborns
425376|NCT00985816|Gastric
425377|NCT00985816|Motility
425378|NCT00985816|Mucosal
425379|NCT00985816|immunity
425380|NCT00985803|Systemic Lupus Erythematosus
425381|NCT00985803|Activity Physical
425382|NCT00985803|Activity Disease,trials randomized
425383|NCT00985790|vaccine
425384|NCT00985790|Influenza
425385|NCT00985777|pancreas
425386|NCT00985777|resectable
425387|NCT00985777|pancreatic tumor
425388|NCT00985777|pancreatic ductal adenocarcinoma
425389|NCT00985777|intraductal papillary mucinous neoplasm of the pancreas
425390|NCT00985777|mucinous cystic neoplasm
425391|NCT00985777|pancreatic exocrine neoplasia
425392|NCT00985751|immunogenicity
425393|NCT00985751|toddlers
425394|NCT00985751|Pneumococcal vaccine
425395|NCT00985751|Haemophilus influenzae
425396|NCT00985751|safety
425397|NCT00985751|Streptococcus pneumoniae
425398|NCT00985751|Streptococcus Pneumoniae Vaccines
425399|NCT00985738|Prostate Cancer
425400|NCT00985738|Early Stage Prostate Cancer
425401|NCT00985725|Major Depressive Disorder
425402|NCT00985699|non-Hodgkin lymphoma
425403|NCT00985699|cutaneous B-cell non-Hodgkin lymphoma
425404|NCT00985699|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
425405|NCT00985699|nodal marginal zone B-cell lymphoma
425406|NCT00985686|e-mental health
425407|NCT00985686|Adolescent mental health
425408|NCT00985686|Spirituality
425409|NCT00985673|GSK Bio's influenza vaccine GSK2340274A
425410|NCT00985673|influenza infection
425411|NCT00985673|GSK Bio's influenza vaccine GSK2340273A
425412|NCT00985647|HIV
425413|NCT00985647|HAART
425414|NCT00985647|ART
425415|NCT00985647|Pharmacokinetic
425416|NCT00985647|Healthy volunteers
425417|NCT00985647|3TC
425418|NCT00985647|Lamivudine
425419|NCT00985634|off pump bypass OPCAB
425420|NCT00985634|OPCAB
425421|NCT00985621|monoclonal antibody
425422|NCT00985621|RN624
425423|NCT00985621|PF-04383119
425424|NCT00985621|nerve growth factor
425425|NCT00985621|OA
425426|NCT00985621|pain
425427|NCT00985621|arthritis
425428|NCT00985608|H pylori
425429|NCT00985608|eradication therapy
425430|NCT00985595|Adolescent
425431|NCT00985595|substance abuse
425432|NCT00985582|Influenza A Virus (H1N1)
425433|NCT00985569|Constipation
425434|NCT00985569|Nursing Home
425435|NCT00985569|Quality Indicator
425436|NCT00985556|recurrent gastric cancer
425437|NCT00985556|adenocarcinoma of the stomach
425438|NCT00985556|stage IIIA gastric cancer
425439|NCT00985556|stage IIIB gastric cancer
425440|NCT00985556|stage IIIC gastric cancer
425441|NCT00985556|stage IV gastric cancer
425442|NCT00985543|HIV
425443|NCT00985543|ART
425444|NCT00985543|HAART
425445|NCT00985543|Pharmacokinetics
425446|NCT00985543|Lopinavir/ritonavir
425447|NCT00985543|Lower dose selection
425448|NCT00985517|Parkinson's disease
425449|NCT00985517|Movement Disorders
425450|NCT00985517|Gene Therapy
425451|NCT00985517|Neurotrophic Factors
425452|NCT00985517|GDNF
425453|NCT00985517|Neurturin
425454|NCT00985517|DBS
425455|NCT00985517|Dopamine
425456|NCT00985504|Major Depressive Disorder
425457|NCT00985504|Apathy
425458|NCT00985504|Duloxetine Hydrochloride
425459|NCT00985504|SSRI
425460|NCT00985504|Escitalopram
425461|NCT00985491|obesity
425462|NCT00985478|First in Man
425463|NCT00985478|SLV342
425464|NCT00985478|Atherosclerosis
425465|NCT00985465|Booster vaccination
425466|NCT00985465|Pneumococcal vaccine
425467|NCT00985465|Catch-up vaccination
425468|NCT00985465|Pneumococcal disease
425469|NCT00985465|Safety
425470|NCT00985465|Immunogenicity
425471|NCT00985452|Medication
425472|NCT00985452|Adherence
425473|NCT00985452|Hypertension
425474|NCT00985426|chronic kidney disease
425475|NCT00985426|kidney failure
425476|NCT00985426|kidney failure,chronic
425477|NCT00985426|chronic kidney failure
425478|NCT00985426|hepatitis B virus (HBV) vaccine
425479|NCT00985426|hepatitis B vaccine
425480|NCT00985426|hepatitis B
425481|NCT00985426|hepatitis
425482|NCT00985426|HBV
425483|NCT00985426|prevention and control
425484|NCT00985426|dialysis
425485|NCT00985413|Cockayne Syndrome
425486|NCT00985413|pediatrics
425487|NCT00985413|growth
425488|NCT00985413|hearing
425489|NCT00985413|Ageing
425490|NCT00985400|recurrent colon cancer
425491|NCT00985400|stage IV colon cancer
425492|NCT00985400|Gastrointestinal
425493|NCT00985400|Exercise
425494|NCT00985400|Relaxation
425495|NCT00985400|Meditation
425496|NCT00985387|Solifenacin
425497|NCT00985387|Overactive bladder
425498|NCT00985387|persistency of the treatment
425499|NCT00985387|Vesicare
425500|NCT00985348|Levetiracetam
425501|NCT00985348|Healthy volunteers
425502|NCT00985348|Healthy Subjects
425503|NCT00985322|Hemodialysis
425504|NCT00985309|unsatisfactory
425505|NCT00985309|Pap smear
425506|NCT00985296|Allergic rhinitis
425507|NCT00985296|Allergic conjunctivitis
425508|NCT00985283|prevention
425509|NCT00985283|older adults
425510|NCT00985283|function
425511|NCT00985283|participation
425512|NCT00985283|life satisfaction
425513|NCT00985283|self-rated health
425514|NCT00985244|COPD
425515|NCT00985244|COPD exacerbation
425516|NCT00985244|macrolide
425517|NCT00985244|diseae progression
425518|NCT00985244|bacterial colonisation
425519|NCT00985218|infertility
425520|NCT00985218|embryo development
425521|NCT00985205|Randomized Clinical Trial
425522|NCT00985205|Glutamine
425523|NCT00985205|Themal Burn Injuries
425524|NCT00985205|Nutrition
425525|NCT00985205|Outcome Assessment
425526|NCT00985205|Critical Care
425527|NCT00985205|Total Burn Surface Area
425528|NCT00985192|adenocarcinoma of the esophagus
425529|NCT00985192|adenocarcinoma of the stomach
425530|NCT00985192|recurrent esophageal cancer
425531|NCT00985192|stage III esophageal cancer
425532|NCT00985192|stage IV esophageal cancer
425533|NCT00985192|recurrent gastric cancer
425534|NCT00985192|stage III gastric cancer
425535|NCT00985192|stage IV gastric cancer
425536|NCT00985179|Randomized Controlled Trial
425537|NCT00985179|evidence- and theory-based behavioral intervention
425538|NCT00985179|expert system
425539|NCT00985179|stages of change
425540|NCT00985179|motivational interviewing
425541|NCT00985179|tailoring
425542|NCT00985179|Self Care
425543|NCT00985179|Expert Systems
425544|NCT00985127|Hyperuricemia
425545|NCT00985127|Gout
425546|NCT00985114|Type II Diabetes
425547|NCT00985114|Obesity
425548|NCT00985088|GSK Bio's influenza vaccine GSK2340274A
425549|NCT00985088|influenza infection
425550|NCT00985088|GSK Bio's influenza vaccine GSK2340273A
425551|NCT00985075|Allergic rhinitis
425552|NCT00985075|Allergic conjunctivitis
425553|NCT00985062|Folic Acid
425554|NCT00985062|Homocysteine
425555|NCT00985062|Ovarian response
425556|NCT00985062|In Vitro Fertilization
425557|NCT00985036|glioma
425558|NCT00985036|meningioma
425559|NCT00985036|VEGF
425560|NCT00985023|Unstable
425561|NCT00985023|Lisfranc
425562|NCT00985023|fracture
425563|NCT00985023|dislocation
425564|NCT00985023|midfoot
425565|NCT00985010|hepatic encephalopathy
425566|NCT00985010|hepatitis C
425567|NCT00985010|manganese
425568|NCT00985010|mortality
425569|NCT00985010|prognosis.
425570|NCT00984997|Superior Sulcus Tumor
425571|NCT00984997|Lung Cancer
425572|NCT00984997|Non-Small Cell
425573|NCT00984997|Multimodality Treatment
425574|NCT00984997|Surgery
425575|NCT00984997|Segmentectomy
425576|NCT00984997|Lobectomy
425577|NCT00984997|Cisplatin
425578|NCT00984997|CDDP
425579|NCT00984997|Etoposide
425580|NCT00984997|VP-16
425581|NCT00984997|VePesid
425582|NCT00984997|Radiation Therapy
425583|NCT00984997|Radiotherapy
425584|NCT00984997|Chest Irradiation
425585|NCT00984997|Prophylactic Cranial Irradiation
425586|NCT00984997|PCI
425587|NCT00984971|Microbicides
425588|NCT00984971|Tenofovir
425589|NCT00984971|HIV seronegativity
425590|NCT00984945|pandemic vaccine
425591|NCT00984945|influenza
425592|NCT00984945|H5N1
425593|NCT00984945|Virus Like Particle (VLP)
425594|NCT00984932|systemic sclerosis
425595|NCT00984932|pulmonary hypertension
425596|NCT00984932|rosuvastatin
425597|NCT00984919|recurrent prostate cancer
425598|NCT00984919|stage I prostate cancer
425599|NCT00984919|stage II prostate cancer
425600|NCT00984919|stage III prostate cancer
425601|NCT00984919|stage IV prostate cancer
425602|NCT00984893|Osteoporosis
425603|NCT00984893|Bone Mineral density
425604|NCT00984893|fragility fractures
425605|NCT00984893|zoledronic acid.
425606|NCT00984893|Treatment
425607|NCT00984880|Sedation
425608|NCT00984880|anaesthesia
425609|NCT00984880|Safety
425610|NCT00984880|Tolerability
425611|NCT00984880|Pharmacokinetics
425612|NCT00984880|Pharmacodynamics
425613|NCT00984867|Dapagliflozin DPP IV inhibitor add on study
425614|NCT00984867|Inadequate control
425615|NCT00984854|Cicatrix
425616|NCT00984854|Scar
425617|NCT00984854|Wound-healing
425618|NCT00984854|Re-epithelialisation
425619|NCT00984854|RN1004
425620|NCT00984854|Mannose-6-phosphate
425621|NCT00984854|M6P
425622|NCT00984854|Juvidex
425623|NCT00984841|Diabetes Mellitus targeted mailing
425624|NCT00984828|multiple myeloma
425625|NCT00984828|autologous stem cell transplantation
425626|NCT00984828|velcade
425627|NCT00984815|NSAID
425628|NCT00984815|Chronic Pain
425629|NCT00984815|Osteoarthritis
425630|NCT00984815|Rheumatoid Arthritis
425631|NCT00984789|Transdermal Patch
425632|NCT00984789|Bleeding
425633|NCT00984789|Pregnancy
425634|NCT00984776|coronary artery
425635|NCT00984776|MRI
425636|NCT00984776|vessel wall imaging
425637|NCT00984763|Malaria
425638|NCT00984763|Vaccine
425639|NCT00984724|Smoking
425640|NCT00984724|Motivation and Problem Solving
425641|NCT00984724|MAPS
425642|NCT00984724|Low Income Smokers
425643|NCT00984724|HCHD community clinics
425644|NCT00984724|Telephone-based counseling
425645|NCT00984698|Posttraumatic Stress Disorder
425646|NCT00984698|Depression
425647|NCT00984698|Sleep Initiation and Maintenance Disorders
425648|NCT00984698|Insomnia
425649|NCT00984698|Psychotherapy, Group
425650|NCT00984698|Cognitive Behavioral Therapy
425651|NCT00984698|Randomized Controlled Trial
425652|NCT00984698|Veterans
425653|NCT00984698|Social Rhythms
425654|NCT00984672|Lumbar Degenerative Disease
425655|NCT00984672|Bone Morphogenetic Protein
425656|NCT00984672|TLIF
425657|NCT00984659|Pulmonary Disease, Chronic Obstructive
425658|NCT00984659|Dyspnea
425659|NCT00984646|Cicatrix
425660|NCT00984646|Scar
425661|NCT00984646|Wound-healing
425662|NCT00984646|Prevascar
425663|NCT00984646|Interleukin-10 (IL-10)
425664|NCT00984646|Ilodecakin
425665|NCT00984646|RN1003
425666|NCT00984633|Neuromuscular Blocking Agents
425667|NCT00984607|Laparoscopic Gastric Band
425668|NCT00984607|LAP BAND system
425669|NCT00984594|allograft
425670|NCT00984594|knee injury
425671|NCT00984594|cartilage injury
425672|NCT00984581|Cicatrix
425673|NCT00984581|Scar
425674|NCT00984581|Wound healing
425675|NCT00984581|Avotermin
425676|NCT00984581|TGF beta 3
425677|NCT00984581|Juvista
425678|NCT00984581|RN1001
425679|NCT00984555|Biomarkers
425680|NCT00984555|Semen Exposure
425681|NCT00984542|recurrent small cell lung cancer
425682|NCT00984529|Chronic heart failure
425683|NCT00984529|candesartan cilexetil
425684|NCT00984529|clinical signs
425685|NCT00984529|symptoms
425686|NCT00984516|Cicatrix
425687|NCT00984516|Scar
425688|NCT00984516|Wound-healing
425689|NCT00984516|Juvidex
425690|NCT00984516|Mannose-6-phosphate
425691|NCT00984516|M6P
425692|NCT00984516|RN1004
425693|NCT00984503|Cicatrix
425694|NCT00984503|Scar
425695|NCT00984503|Wound healing
425696|NCT00984503|Avotermin
425697|NCT00984503|TGF beta 3
425698|NCT00984503|Juvista
425699|NCT00984503|RN1001
425700|NCT00984490|stage I breast cancer
425701|NCT00984490|stage II breast cancer
425702|NCT00984477|Healthy volunteer
425703|NCT00984477|healthy subjects
425704|NCT00984477|AZD5122
425705|NCT00984477|single oral dose
425706|NCT00984477|phase 1
425707|NCT00984477|Healthy volunteer phase 1 study
425708|NCT00984464|metastatic
425709|NCT00984464|melanoma
425710|NCT00984464|REOLYSIN
425711|NCT00984464|chemotherapy
425712|NCT00984464|carboplatin
425713|NCT00984464|paclitaxel
425714|NCT00984451|Antibody Treatment
425715|NCT00984451|Immune Therapy
425716|NCT00984451|Infectious Diseases
425717|NCT00984451|IVIG
425718|NCT00984451|Plasma Apheresis
425719|NCT00984451|Influenza A
425720|NCT00984451|Swine Flu
425721|NCT00984399|vaginitis
425722|NCT00984399|Postmenopausal
425723|NCT00984399|17-β estradiol
425724|NCT00984399|09-110
425725|NCT00984386|Cicatrix
425726|NCT00984386|Scar
425727|NCT00984386|Wound-healing
425728|NCT00984386|Zesteem
425729|NCT00984386|17β-Estradiol
425730|NCT00984386|RN1002
425731|NCT00984373|Schizophrenia epidemiology
425732|NCT00984373|Schizophrenic patients' social and health characteristics
425733|NCT00984360|Meth
425734|NCT00984360|Methamphetamine Addiction
425735|NCT00984360|Methamphetamine Treatment
425736|NCT00984360|Naltrexone
425737|NCT00984360|Vivitrol
425738|NCT00984360|A118G
425739|NCT00984360|OPRM1
425740|NCT00984347|nipple stimulation
425741|NCT00984347|Oxytocin
425742|NCT00984347|induction of labor
425743|NCT00984347|term pregnancies
425744|NCT00984347|grandmultipara
425745|NCT00984347|VBAC
425746|NCT00984347|PROM
425747|NCT00984347|comparison of two methods for induction of labor
425748|NCT00984334|pain
425749|NCT00984334|opioid
425750|NCT00984334|constipation
425751|NCT00984334|Subjects taking opioids for chronic non-cancer pain, who
425752|NCT00984334|experience symptoms of opioid induced constipation
425753|NCT00984321|Geriatric
425754|NCT00984321|Elderly
425755|NCT00984321|Counseling
425756|NCT00984321|Depression
425757|NCT00984321|Anxiety
425758|NCT00984321|Intervention
425759|NCT00984321|Psychoeducational
425760|NCT00984321|09-116
425761|NCT00984308|sleep apnea
425762|NCT00984308|hypertension
425763|NCT00984308|brain ischemia
425764|NCT00984282|RAI-Refractory
425765|NCT00984282|Differentiated
425766|NCT00984282|Follicular
425767|NCT00984282|Papillary
425768|NCT00984282|Hurthle
425769|NCT00984256|Malaria
425770|NCT00984256|Prophylaxis
425771|NCT00984256|Atovaquone
425772|NCT00984256|Malarone
425773|NCT00984256|Challenge
425774|NCT00984243|lung cancer
425775|NCT00984230|Infant Formula
425776|NCT00984230|Gut
425777|NCT00984217|panitumumab
425778|NCT00984217|salivary gland malignancies
425779|NCT00984217|radiotherapy
425780|NCT00984204|cavo-tricuspid dependent
425781|NCT00984191|Papillary thyroid cancer
425782|NCT00984191|99mTechnetium MIBI SPECT CT
425783|NCT00984191|preoperative
425784|NCT00984191|cervical lymphadenopathy
425785|NCT00984191|cervical metastasis
425786|NCT00984178|Reperfusion
425787|NCT00984178|acute myocardial infarction
425788|NCT00984178|stem cell therapy
425789|NCT00984178|GCSF
425790|NCT00984178|bone marrow mononuclear cells
425791|NCT00984178|magnetic resonance
425792|NCT00984165|Allotransplant
425793|NCT00984165|Relapse
425794|NCT00984165|Radiation
425795|NCT00984165|Donor Lymphocyte Infusion
425796|NCT00984165|Hematologic Malignancies
425797|NCT00984165|Multiple Myeloma
425798|NCT00984165|Hodgkin Lymphoma
425799|NCT00984165|Non-Hodgkin Lymphoma
425800|NCT00984165|Chronic Lymphocytic Leukemia
425801|NCT00984152|HIV
425802|NCT00984152|Raltegravir
425803|NCT00984152|Women
425804|NCT00984152|Viral Suppression
425805|NCT00984152|Viral Reservoir
425806|NCT00984152|Immune Parameters
425807|NCT00984152|Gut
425808|NCT00984152|Genital Tract
425809|NCT00984139|persistence
425810|NCT00984139|HBV
425811|NCT00984139|Long-term
425812|NCT00984139|Engerix™-B Kinder
425813|NCT00984139|Hepatitis B
425814|NCT00984139|adolescent
425815|NCT00984113|Elinogrel
425816|NCT00984113|Renal impairment
425817|NCT00984113|Healthy
425818|NCT00984113|Kidney dysfunction
425819|NCT00984100|Cholelithiasis
425820|NCT00984100|Biliary dyskinesia
425821|NCT00984087|depression
425822|NCT00984087|TMS
425823|NCT00984087|adolescent
425824|NCT00984087|transcranial magnetic stimulation
425825|NCT00984087|MDD
425826|NCT00984087|Major depression
425827|NCT00984087|mood disorders
425828|NCT00984074|stage III salivary gland cancer
425829|NCT00984074|recurrent squamous cell carcinoma of the hypopharynx
425830|NCT00984074|stage I squamous cell carcinoma of the hypopharynx
425831|NCT00984074|stage II squamous cell carcinoma of the hypopharynx
425832|NCT00984074|stage III squamous cell carcinoma of the hypopharynx
425833|NCT00984074|recurrent squamous cell carcinoma of the larynx
425834|NCT00984074|recurrent verrucous carcinoma of the larynx
425835|NCT00984074|stage I squamous cell carcinoma of the larynx
425836|NCT00984074|stage I verrucous carcinoma of the larynx
425837|NCT00984074|stage II squamous cell carcinoma of the larynx
425838|NCT00984074|stage II verrucous carcinoma of the larynx
425839|NCT00984074|stage III squamous cell carcinoma of the larynx
425840|NCT00984074|stage III verrucous carcinoma of the larynx
425841|NCT00984074|recurrent adenoid cystic carcinoma of the oral cavity
425842|NCT00984074|recurrent mucoepidermoid carcinoma of the oral cavity
425843|NCT00984074|recurrent verrucous carcinoma of the oral cavity
425844|NCT00984074|stage I adenoid cystic carcinoma of the oral cavity
425845|NCT00984074|stage I mucoepidermoid carcinoma of the oral cavity
425846|NCT00984074|stage I verrucous carcinoma of the oral cavity
425847|NCT00984074|stage II adenoid cystic carcinoma of the oral cavity
425848|NCT00984074|stage II mucoepidermoid carcinoma of the oral cavity
425849|NCT00984074|stage II verrucous carcinoma of the oral cavity
425850|NCT00984074|stage III adenoid cystic carcinoma of the oral cavity
425851|NCT00984074|stage III mucoepidermoid carcinoma of the oral cavity
425852|NCT00984074|stage III verrucous carcinoma of the oral cavity
425853|NCT00984074|stage I squamous cell carcinoma of the lip and oral cavity
425854|NCT00984074|stage II squamous cell carcinoma of the lip and oral cavity
425855|NCT00984074|stage III squamous cell carcinoma of the lip and oral cavity
425856|NCT00984074|recurrent basal cell carcinoma of the lip
425857|NCT00984074|recurrent squamous cell carcinoma of the lip and oral cavity
425858|NCT00984074|stage I basal cell carcinoma of the lip
425859|NCT00984074|stage II basal cell carcinoma of the lip
425860|NCT00984074|stage III basal cell carcinoma of the lip
425861|NCT00984074|recurrent metastatic squamous neck cancer with occult primary
425862|NCT00984074|untreated metastatic squamous neck cancer with occult primary
425863|NCT00984074|recurrent lymphoepithelioma of the nasopharynx
425864|NCT00984074|recurrent squamous cell carcinoma of the nasopharynx
425865|NCT00984074|stage I lymphoepithelioma of the nasopharynx
425866|NCT00984074|stage I squamous cell carcinoma of the nasopharynx
425867|NCT00984074|stage II lymphoepithelioma of the nasopharynx
425868|NCT00984074|stage II squamous cell carcinoma of the nasopharynx
425869|NCT00984074|stage III lymphoepithelioma of the nasopharynx
425870|NCT00984074|stage III squamous cell carcinoma of the nasopharynx
425871|NCT00984074|recurrent lymphoepithelioma of the oropharynx
425872|NCT00984074|recurrent squamous cell carcinoma of the oropharynx
425873|NCT00984074|stage I lymphoepithelioma of the oropharynx
425874|NCT00984074|stage I squamous cell carcinoma of the oropharynx
425875|NCT00984074|stage II lymphoepithelioma of the oropharynx
425876|NCT00984074|stage II squamous cell carcinoma of the oropharynx
425877|NCT00984074|stage III lymphoepithelioma of the oropharynx
425878|NCT00984074|stage III squamous cell carcinoma of the oropharynx
425879|NCT00984074|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
425880|NCT00984074|recurrent inverted papilloma of the paranasal sinus and nasal cavity
425881|NCT00984074|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
425882|NCT00984074|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
425883|NCT00984074|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
425884|NCT00984074|stage I inverted papilloma of the paranasal sinus and nasal cavity
425885|NCT00984074|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
425886|NCT00984074|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
425887|NCT00984074|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
425888|NCT00984074|stage II inverted papilloma of the paranasal sinus and nasal cavity
425889|NCT00984074|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
425890|NCT00984074|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
425891|NCT00984074|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
425892|NCT00984074|stage III inverted papilloma of the paranasal sinus and nasal cavity
425893|NCT00984074|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
425894|NCT00984074|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
425895|NCT00984074|high-grade salivary gland mucoepidermoid carcinoma
425896|NCT00984074|low-grade salivary gland mucoepidermoid carcinoma
425897|NCT00984074|recurrent salivary gland cancer
425898|NCT00984074|salivary gland acinic cell tumor
425899|NCT00984074|salivary gland adenocarcinoma
425900|NCT00984074|salivary gland adenoid cystic carcinoma
425901|NCT00984074|salivary gland anaplastic carcinoma
425902|NCT00984074|salivary gland malignant mixed cell type tumor
425903|NCT00984074|salivary gland poorly differentiated carcinoma
425904|NCT00984074|salivary gland squamous cell carcinoma
425905|NCT00984074|stage I salivary gland cancer
425906|NCT00984074|stage II salivary gland cancer
425907|NCT00984074|tongue cancer
425908|NCT00984061|healthy
425909|NCT00984061|pharmacokinetics
425910|NCT00984061|drug-drug interaction
425911|NCT00984048|Colorectal cancer
425912|NCT00984048|FOLFOX
425913|NCT00984048|FOLFIRI
425914|NCT00984048|Avastin
425915|NCT00984048|Metastases
425916|NCT00984048|Liver
425917|NCT00984048|Colon cancer
425918|NCT00984048|Biomarkers
425919|NCT00984048|Resistance
425920|NCT00984048|Biobanking
425921|NCT00984048|Colorectal cancer with unresectable metastases to the liver
425922|NCT00984022|abscess
425923|NCT00984022|MRSA
425924|NCT00984022|Aquacel dressing
425925|NCT00984022|Iodoform dressing
425926|NCT00984009|healthy
425927|NCT00984009|pharmacokinetics
425928|NCT00984009|grapefruit juice
425929|NCT00984009|furanocoumarins
425930|NCT00984009|cytochrome p450 3A4
425931|NCT00983983|Amyotrophic Lateral Sclerosis
425932|NCT00983983|ALS
425933|NCT00983983|Motor Neuron Disease
425934|NCT00983983|MND
425935|NCT00983983|Fat
425936|NCT00983983|Lipid
425937|NCT00983983|Cholesterol
425938|NCT00983983|Omega-3 fatty acid
425939|NCT00983983|Diet
425940|NCT00983983|Tube feed
425941|NCT00983983|Gastrostomy
425942|NCT00983983|PEG
425943|NCT00983983|Adults with Amyotrophic Lateral Sclerosis (ALS)
425944|NCT00983970|Adolescents
425945|NCT00983970|Obesity
425946|NCT00983970|Exercise
425947|NCT00983970|Music
425948|NCT00983970|Virtual Reality
425949|NCT00983944|contiguous stage II adult diffuse large cell lymphoma
425950|NCT00983944|noncontiguous stage II adult diffuse large cell lymphoma
425951|NCT00983944|stage I adult diffuse large cell lymphoma
425952|NCT00983944|stage III adult diffuse large cell lymphoma
425953|NCT00983944|stage IV adult diffuse large cell lymphoma
425954|NCT00983944|childhood diffuse large cell lymphoma
425955|NCT00983944|stage I childhood large cell lymphoma
425956|NCT00983944|stage II childhood large cell lymphoma
425957|NCT00983944|stage III childhood large cell lymphoma
425958|NCT00983944|stage IV childhood large cell lymphoma
425959|NCT00983931|healthy
425960|NCT00983931|adult
425961|NCT00983931|colchicine
425962|NCT00983931|cyclosporine
425963|NCT00983931|blood levels over time
425964|NCT00983905|healthy;
425965|NCT00983905|adult;
425966|NCT00983905|blood levels over time
425967|NCT00983892|Cancer
425968|NCT00983892|caregiver
425969|NCT00983892|pain
425970|NCT00983892|symptom
425971|NCT00983892|information technology
425972|NCT00983892|palliative care
425973|NCT00983879|Infantile globoid cell leukodystrophy
425974|NCT00983879|GLD
425975|NCT00983879|Krabbe disease
425976|NCT00983879|Natural History Study
425977|NCT00983853|VX-950
425978|NCT00983853|INCIVEK
425979|NCT00983853|INCIVO
425980|NCT00983840|diet
425981|NCT00983840|African-American families
425982|NCT00983840|web-based
425983|NCT00983814|Attention Deficit Hyperactivity Disorder
425984|NCT00983814|ADHD
425985|NCT00983814|Adult ADHD
425986|NCT00983814|Adult Attention Deficit Hyperactivity Disorder
425987|NCT00983788|CPT II
425988|NCT00983788|VLCAD
425989|NCT00983775|Pharmacokinetic profile
425990|NCT00983775|Pharmacodynamic profile
425991|NCT00983775|insulin
425992|NCT00983775|jet injector
425993|NCT00983762|Knee osteoarthritis
425994|NCT00983762|Leg strength
425995|NCT00983762|Functional outcomes
425996|NCT00983762|Minimally Invasive Surgery Mini-Incision (MIS) TKA
425997|NCT00983762|Unicompartmental knee arthroplasty
425998|NCT00983762|Standard Para-patellar surgery TKA
425999|NCT00983762|gait
426000|NCT00983762|knee arthroplasty
426001|NCT00983749|External Counterpulsation
426002|NCT00983749|Counterpulsation, Diastolic
426003|NCT00983749|Ultrasonography, Doppler, Transcranial
426004|NCT00983749|Blood Flow Velocity
426005|NCT00983749|Neurologic Deficit
426006|NCT00983723|Patient Foramen Ovale
426007|NCT00983723|PFO
426008|NCT00983723|Stroke
426009|NCT00983723|Ischemic Brain Injury
426010|NCT00983723|Neurovascular Disease
426011|NCT00983710|prostate neoplasms
426012|NCT00983697|stage II squamous cell carcinoma of the larynx
426013|NCT00983697|stage II squamous cell carcinoma of the lip and oral cavity
426014|NCT00983697|stage II squamous cell carcinoma of the oropharynx
426015|NCT00983697|stage III squamous cell carcinoma of the larynx
426016|NCT00983697|stage III squamous cell carcinoma of the lip and oral cavity
426017|NCT00983697|stage III squamous cell carcinoma of the oropharynx
426018|NCT00983697|stage IV squamous cell carcinoma of the larynx
426019|NCT00983697|stage IV squamous cell carcinoma of the lip and oral cavity
426020|NCT00983697|stage IV squamous cell carcinoma of the oropharynx
426021|NCT00983697|stage II verrucous carcinoma of the oral cavity
426022|NCT00983697|stage III verrucous carcinoma of the oral cavity
426023|NCT00983697|stage IV verrucous carcinoma of the oral cavity
426024|NCT00983697|tongue cancer
426025|NCT00983684|Neoplasms by Site
426026|NCT00983684|Breast Neoplasms
426027|NCT00983684|Breast Diseases
426028|NCT00983684|Breast Cancer
426029|NCT00983684|Cancer of Breast
426030|NCT00983684|Cancer of the Breast
426031|NCT00983684|Carcinoma
426032|NCT00983671|Asthma
426033|NCT00983671|cystic fibrosis
426034|NCT00983671|chronic lung disease
426035|NCT00983671|bronchopulmonary dysplasia
426036|NCT00983671|pneumonia
426037|NCT00983658|Anti-OX40L
426038|NCT00983658|Mild Allergic Asthma
426039|NCT00983658|Allergies
426040|NCT00983658|Allergic Asthma
426041|NCT00983658|Adult Asthma
426042|NCT00983645|Kidney Transplantation
426043|NCT00983645|Immunosuppression
426044|NCT00983632|vagus nerve stimulation
426045|NCT00983632|heart rate
426046|NCT00983632|systolic arterial pressure
426047|NCT00983619|Cancer
426048|NCT00983593|Mind Body Bridging
426049|NCT00983593|Domestic Violence Offender Treatment
426050|NCT00983593|Batterer Treatment
426051|NCT00983554|testosterone
426052|NCT00983554|insulin
426053|NCT00983554|obesity
426054|NCT00983554|aromatase
426055|NCT00983554|5 alpha reductase
426056|NCT00983541|intra or extrahepatic cholangiocarcinoma
426057|NCT00983541|liver cancer
426058|NCT00983541|liver
426059|NCT00983541|HCC
426060|NCT00983541|EHCC
426061|NCT00983528|cancer
426062|NCT00983528|lymphoblastic
426063|NCT00983528|leukemia
426064|NCT00983502|Idiopathic Chronic Fatigue
426065|NCT00983502|Chronic Fatigue Syndrome
426066|NCT00983502|Myalgic encephalomyelitis
426067|NCT00983489|breast feeding
426068|NCT00983489|counselling
426069|NCT00983489|video demonstration
426070|NCT00983476|Randomized controlled trial
426071|NCT00983476|Obesity
426072|NCT00983476|Comparative Effectiveness
426073|NCT00983476|Clinical practice guidelines
426074|NCT00983476|Medical Informatics Computing
426075|NCT00983476|Services, Mental Health
426076|NCT00983476|Self-care
426077|NCT00983476|Psychotic disorders
426078|NCT00983476|Mental Health Care
426079|NCT00983476|Veterans
426080|NCT00983463|Nonalcoholic fatty liver disease (NAFLD)
426081|NCT00983463|Nonalcoholic steatohepatitis (NASH)
426082|NCT00983463|Obesity
426083|NCT00983463|Lipidomics
426084|NCT00983463|Proteomics
426085|NCT00983424|Breast Cancer
426086|NCT00983411|non-invasive intermittent positive-pressure ventilation
426087|NCT00983411|work of breathing
426088|NCT00983411|Pulse transit time
426089|NCT00983385|low back pain
426090|NCT00983385|pain
426091|NCT00983385|assessment
426092|NCT00983385|tapentadol
426093|NCT00983385|centrally acting analgesic
426094|NCT00983372|healthy; adult; volunteer; colchicine; diltiazem; blood levels over time
426095|NCT00983359|tumors metastatic to brain
426096|NCT00983359|unspecified adult solid tumor, protocol specific
426097|NCT00983346|cancer
426098|NCT00983346|myeloma
426099|NCT00983346|multiple myeloma
426100|NCT00983346|smoldering myeloma
426101|NCT00983333|Health communication
426102|NCT00983333|Health literacy
426103|NCT00983333|Patient
426104|NCT00983333|Health Care Professional
426105|NCT00983333|Satisfaction
426106|NCT00983320|Fibromyalgia
426107|NCT00983320|pain
426108|NCT00983320|quetiapine
426109|NCT00983320|randomized placebo controlled trial
426110|NCT00983307|Radiation
426111|NCT00983307|Erlotinib
426112|NCT00983307|Tarceva
426113|NCT00983294|blood levels over time;
426114|NCT00983294|colchicine;
426115|NCT00983294|azithromycin;
426116|NCT00983294|healthy
426117|NCT00983281|Combat casualty care
426118|NCT00983281|Hextend
426119|NCT00983281|Colloid
426120|NCT00983268|periampullary adenocarcinoma
426121|NCT00983268|stage I pancreatic cancer
426122|NCT00983268|stage II pancreatic cancer
426123|NCT00983268|stage III pancreatic cancer
426124|NCT00983229|difficult airway
426125|NCT00983229|fibreoptic intubation
426126|NCT00983229|supraglottic airways
426127|NCT00983229|laryngeal mask airway
426128|NCT00983216|blood levels over time;
426129|NCT00983216|pharmacokinetics;
426130|NCT00983216|healthy adult;
426131|NCT00983216|cytochrome p450
426132|NCT00983203|Dry eye
426133|NCT00983203|artificial tears
426134|NCT00983190|HeartMate II
426135|NCT00983190|BeneMACS
426136|NCT00983190|LVAD
426137|NCT00983190|Thoratec Corporation
426138|NCT00983164|antiviral therapy
426139|NCT00983164|antioxidant therapy
426140|NCT00983164|hepatitis C virus
426141|NCT00983164|oxidative stress
426142|NCT00983164|vitamin E
426143|NCT00983125|Labour
426144|NCT00983125|Epidural analgesia
426145|NCT00983125|Clonidine
426146|NCT00983125|Levobupivacaine
426147|NCT00983125|Opiates
426148|NCT00983125|Patient-controlled
426149|NCT00983125|Active spontaneous labour requiring epidural analgesia
426150|NCT00983112|Gonarthrosis
426151|NCT00983112|Knee prosthesis insertion
426152|NCT00983112|Bleeding
426153|NCT00983112|Undergoing a total knee prothesis surgery
426154|NCT00983112|knee prothesis surgery
426155|NCT00983112|Knee arthrosis
426156|NCT00983112|Thrombosis
426157|NCT00983086|Flavanones and vascular function
426158|NCT00983073|Osteoarthritis
426159|NCT00983073|Pain
426160|NCT00983073|Assessment
426161|NCT00983073|Tapentadol
426162|NCT00983073|Centrally acting analgesic
426163|NCT00983073|Chronic pain due to osteoarthritis
426164|NCT00983060|NIM811
426165|NCT00983060|chronic hepatitis
426166|NCT00983060|chronic hepatitis C
426167|NCT00983060|chronic hepatitis C genotype-1
426168|NCT00983060|HCV
426169|NCT00983060|HCV-1
426170|NCT00983060|relapser
426171|NCT00983047|Nimotuzumab
426172|NCT00983047|NSCLC
426173|NCT00983047|Docetaxel
426174|NCT00983034|nephrotic syndrome
426175|NCT00983034|Helicobacter pylori infection
426176|NCT00983034|proteinuria
426177|NCT00983034|membranous nephropathy
426178|NCT00983008|Signs and Symptoms
426179|NCT00983008|Fatigue
426180|NCT00983008|Sleep Deprivation
426181|NCT00983008|Internship and Residency
426182|NCT00983008|Depression
426183|NCT00983008|Medical Errors
426184|NCT00983008|Burnout, Professional
426185|NCT00983008|Burnout
426186|NCT00983008|Actigraphy
426187|NCT00983008|Personnel Staffing and Scheduling
426188|NCT00983008|Workload
426189|NCT00983008|Humans
426190|NCT00983008|Adult
426191|NCT00983008|Male
426192|NCT00983008|Female
426193|NCT00983008|Intensive Care Units
426194|NCT00983008|Prospective Studies
426195|NCT00983008|Work Schedule Tolerance
426196|NCT00983008|Disorders of Excessive Somnolence
426197|NCT00983008|Guideline Adherence
426198|NCT00983008|Internal Medicine Education
426199|NCT00982982|Schizophrenia
426200|NCT00982982|Mental Disorders
426201|NCT00982982|Psychotic Disorders
426202|NCT00982982|Schizophrenia and Disorders with Psychotic Features
426203|NCT00982982|Cannabis
426204|NCT00982969|tuberculosis
426205|NCT00982969|pneumonia
426206|NCT00982969|QuantiFERON-TB Gold in-tube
426207|NCT00982969|Tuberculin skin test
426208|NCT00981981|humans
426209|NCT00981981|randomized clinical trial
426210|NCT00981981|dietary fiber
426211|NCT00981981|nutrition
426212|NCT00981981|beta-glucan
426213|NCT00981981|oats
426214|NCT00981981|LDL cholesterol
426215|NCT00981981|coronary heart disease
426216|NCT00981955|Caffeine
426217|NCT00981955|Ltheanine
426218|NCT00981955|Near Infrared Spectroscopy
426219|NCT00981955|Cerebral Blood Flow
426220|NCT00981955|Cognitive Function
426221|NCT00981955|Mood
426222|NCT00981942|Nephrogenic systemic fibrosis
426223|NCT00981942|Imatinib mesylate
426224|NCT00981942|Glivec
426225|NCT00981942|Gleevec
426226|NCT00981929|CYP2D6
426227|NCT00981929|CYP2C9
426228|NCT00981929|CYP2C19
426229|NCT00981929|CYP1A2
426230|NCT00981916|determination of depth to epidural space using ultrasound
426231|NCT00981903|VTE in cancer patients
426232|NCT00981890|Brain Metastases
426233|NCT00981890|Stereotactic radiosurgery
426234|NCT00981890|Sunitinib
426235|NCT00981890|Patients with Brain Metastases
426236|NCT00981877|acute diarrhea
426237|NCT00981877|rotavirus
426238|NCT00981877|probiotic
426239|NCT00981877|children
426240|NCT00981864|radiation therapy in breast cancer
426241|NCT00981864|concurrent radiation
426242|NCT00981864|Breast cancer patients
426243|NCT00981851|intervention study
426244|NCT00981851|interaction
426245|NCT00981851|COPD
426246|NCT00982930|Tobramycin Inhalation Powder
426247|NCT00982930|Cystic fibrosis
426248|NCT00982930|Lung diseases
426249|NCT00982930|Anti-Bacterial Agents
426250|NCT00982917|playground
426251|NCT00982917|injury prevention
426252|NCT00982904|neglected disease
426253|NCT00982904|africa
426254|NCT00982904|new drug
426255|NCT00982904|oral drug
426256|NCT00982904|parasite
426257|NCT00982891|chronic obstructive pulmonary disease
426258|NCT00982891|palliation
426259|NCT00982891|opioids
426260|NCT00982878|treatment experienced
426261|NCT00982865|MEK inhibitor
426262|NCT00982865|Cancer
426263|NCT00982865|Solid tumors
426264|NCT00982852|Angioplasty
426265|NCT00982852|Coronary Vessels
426266|NCT00982852|Heart Disease
426267|NCT00982852|Cardiology
426268|NCT00982852|Atherosclerosis
426269|NCT00982852|Catheterization
426270|NCT00982826|Phase 1
426271|NCT00982826|Single and Multiple Ascending Dose
426272|NCT00982826|Food Effect
426273|NCT00982813|Periodontal disease
426274|NCT00982813|Per-term delivery
426275|NCT00982813|Sulcular bleeding index
426276|NCT00982813|Bacteriological gingival presence
426277|NCT00982813|Cytokines
426278|NCT00982813|Active periodontal disease with sulcular bleeding index
426279|NCT00982813|Bacteriological sampling in periodontal pocketing
426280|NCT00982813|Cytokines in the periodontal pocketing
426281|NCT00982800|gabapentin
426282|NCT00982800|opioid consumption
426283|NCT00982800|analgesic
426284|NCT00982800|anxiety
426285|NCT00982800|quality of life
426286|NCT00982787|Epilepsy
426287|NCT00982787|Seizures
426288|NCT00982787|Passiflora
426289|NCT00982774|PKDL
426290|NCT00982761|occupational drivers
426291|NCT00982761|health status
426292|NCT00982748|Fatigue
426293|NCT00982748|Chemotherapy
426294|NCT00982748|Yoga
426295|NCT00982748|Breathing
426296|NCT00982748|Cancer
426297|NCT00982748|Anxiety
426298|NCT00982748|Pranayama
426299|NCT00982748|Stress
426300|NCT00982748|Fatigue-associated symptoms in chemotherapy patients
426301|NCT00982748|Quality of life in chemotherapy patients
426302|NCT00982722|primary hyperparathyroidism
426303|NCT00982722|postoperative vitamin D supplementation
426304|NCT00982696|head and neck cancer
426305|NCT00982696|opioid growth factor
426306|NCT00982683|Surgery
426307|NCT00982683|Moon phases
426308|NCT00982683|hemorrhage
426309|NCT00982670|Metabolic syndrome
426310|NCT00982670|Systemic lupus erythematosus
426311|NCT00982657|Phase Ib Phase II Advanced solid tumor Clear cell renal cancer Sunitinib plus / minus CVX-060
426312|NCT00982631|temsirolimus (Torisel®)
426313|NCT00982631|pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®)
426314|NCT00982579|HIV preventive vaccine
426315|NCT00982553|Healthy Volunteers
426316|NCT00982540|empiric antifungal therapy
426317|NCT00982540|preemptive antifungal therapy
426318|NCT00982540|febrile neutropenia
426319|NCT00982540|risk stratification
426320|NCT00982540|invasive fungal infection
426321|NCT00982527|cardiopulmonary bypass
426322|NCT00982527|pediatric cardiac surgery
426323|NCT00982527|acute renal failure
426324|NCT00982527|renal biomarkers
426325|NCT00982527|fenoldopam
426326|NCT00982527|Focus on optimization of perfusion during pediatric CPB
426327|NCT00982514|Asparaginase
426328|NCT00982514|thrombosis
426329|NCT00982514|ALL
426330|NCT00982514|central line
426331|NCT00982501|(BMI 25-29,9 kg/m2)
426332|NCT00982475|pulmonary vein isolation
426333|NCT00982475|robotic navigation
426334|NCT00982475|atrial fibrillation
426335|NCT00982462|cognition
426336|NCT00982462|vision
426337|NCT00982462|immunology
426338|NCT00982462|DHA
426339|NCT00982462|ARA
426340|NCT00982462|infant
426341|NCT00982462|nutrition
426342|NCT00982449|EBV+ malignancies
426343|NCT00982449|KSHV+ malignancies
426344|NCT00982449|HIV-associated lymphomas
426345|NCT00982449|Hodgkin Lymphoma
426346|NCT00982449|nonHodgkin Lymphoma or
426347|NCT00982449|nonHodgkins Lymphoproliferative Disease
426348|NCT00982449|Primary Effusion Lymphoma
426349|NCT00982449|Kaposi's Sarcoma
426350|NCT00982449|Gastric Cancer
426351|NCT00982449|Nasopharyngeal Cancer
426352|NCT00982436|Combined Modality Therapy
426353|NCT00982436|Neoadjuvant Therapy
426354|NCT00982436|Head and neck neoplasms
426355|NCT00982423|heart failure
426356|NCT00982423|heart failure with and without kidney dysfunction
426357|NCT00982410|pain
426358|NCT00982410|alcohol
426359|NCT00982410|illicit drugs
426360|NCT00982410|pain management
426361|NCT00982384|Chronic obstructive pulmonary disease
426362|NCT00982384|Disease management
426363|NCT00982384|Pulmonary rehabilitation
426364|NCT00982384|Quality of life
426365|NCT00982371|type 2 diabetes mellitus
426366|NCT00982371|osteoporosis
426367|NCT00982371|bone quality
426368|NCT00982371|magnetic resonance imaging
426369|NCT00982371|fracture
426370|NCT00982371|postmenopausal women >65 years old
426371|NCT00982345|Depression
426372|NCT00982345|Anxiety
426373|NCT00982345|Seroquel
426374|NCT00982345|Quetiapine
426375|NCT00982345|fMRI
426376|NCT00982345|pictures
426377|NCT00982332|polymyalgia rheumatica
426378|NCT00982319|Broccoli Sprout Extract
426379|NCT00982319|Breast Cancer
426380|NCT00982306|alcohol
426381|NCT00982306|brief interventions
426382|NCT00982306|counseling
426383|NCT00982306|harmful/hazardous alcohol drinkers
426384|NCT00982280|Osteoarthritis
426385|NCT00982280|pain assessment
426386|NCT00982280|tapentadol
426387|NCT00982280|centrally acting analgesic
426388|NCT00982267|cancer
426389|NCT00982254|Type 2 Diabetes
426390|NCT00982254|Oral Insulin
426391|NCT00982254|Pharmacokinetics
426392|NCT00982254|Pharmacodynamics
426393|NCT00982241|OAB
426394|NCT00982241|urine
426395|NCT00982241|osmolality
426396|NCT00982241|urge
426397|NCT00982241|fluid intake
426398|NCT00982241|PPIUS
426399|NCT00982241|urge score
426400|NCT00982241|bladder
426401|NCT00982215|Paracetamol
426402|NCT00982215|per-oral mucosa PMB
426403|NCT00982215|No disease, healthy volunteers
426404|NCT00982202|PPAR-gamma
426405|NCT00982202|inflammation
426406|NCT00982189|treatment experienced
426407|NCT00982176|Anatomo-functional determinants
426408|NCT00982176|cognitive impairment
426409|NCT00982176|coronary syndrome
426410|NCT00982176|brain MRI
426411|NCT00982176|cerebral perfusion scintigraphy
426412|NCT00982150|Talampanel
426413|NCT00982150|Open-Label Study
426414|NCT00982150|Amyotrophic Lateral Sclerosis
426415|NCT00982137|Japanese Encephalitis
426416|NCT00982137|Yellow Fever
426417|NCT00982137|ChimeriVax™-JE
426418|NCT00982137|STAMARIL®
426419|NCT00982137|Adult
426420|NCT00982124|Osteogenesis Imperfecta
426421|NCT00982124|Infants with moderate to severe Osteogenesis Imperfecta
426422|NCT00982111|Nonsquamous
426423|NCT00982111|Non Small Cell Lung Cancer
426424|NCT00982111|First line treatment
426425|NCT00982111|Monoclonal
426426|NCT00982111|Antibodies
426427|NCT00982111|Epidermal Growth Factor Receptor (EGFR)
426428|NCT00982098|Prostatectomy
426429|NCT00982098|Prostatic cancer
426430|NCT00982098|Urinary incontinence
426431|NCT00982098|Exercise
426432|NCT00982098|Electric stimulation therapy
426433|NCT00982098|Counseling
426434|NCT00982085|Asthma
426435|NCT00982085|Allergic rhinitis
426436|NCT00982085|Military
426437|NCT00982072|nephrotic minimal change tacrolimus prednisolone
426438|NCT00982059|Colorectal cancer screening
426439|NCT00982059|Cancer survivor
426440|NCT00982059|Radiation therapy
426441|NCT00982046|contact lenses
426442|NCT00982046|disinfection solutions
426443|NCT00982046|contact lens care
426444|NCT00982033|Heart failure with normal ejection fraction
426445|NCT00982033|Elderly
426446|NCT00982020|safety
426447|NCT00982020|schizophrenia
426448|NCT00982020|bipolar I (manic or mixed)
426449|NCT00982020|adolescents
426450|NCT00982020|weight management
426451|NCT00982007|IDA
426452|NCT00981994|respiratory infection
426453|NCT00981994|antimicrobial drugs
426454|NCT00981994|decision support
426455|NCT00981994|Adult patients
426456|NCT00981812|PET
426457|NCT00981812|PEM
426458|NCT00981812|Positron Emission Mammography
426459|NCT00981812|Breast Biopsy
426460|NCT00981799|Relapse
426461|NCT00981799|T cell
426462|NCT00981799|Lymphoblastic
426463|NCT00981799|Leukemia
426464|NCT00981799|Lymphoma
426465|NCT00981799|Nelarabine
426466|NCT00981799|TACL
426467|NCT00981799|NECTAR
426468|NCT00981786|24-hour IOP control
426469|NCT00981786|brinzolamide/timolol
426470|NCT00981786|brimonidine/timolol
426471|NCT00981786|travoprost
426472|NCT00981773|HIV switch
426473|NCT00981773|HIV
426474|NCT00981773|treatment experienced
426475|NCT00981734|Aging
426476|NCT00981734|functionality
426477|NCT00981734|life style
426478|NCT00981734|To have more than sixty years
426479|NCT00981721|Phase I
426480|NCT00981721|Advanced solid malignancies
426481|NCT00981721|Advanced solid tumour
426482|NCT00981721|Advanced cancer
426483|NCT00981721|Cediranib (RECENTIN™, AZD2171)
426484|NCT00981721|China
426485|NCT00981721|PK
426486|NCT00981721|pharmacokinetics
426487|NCT00981708|Amyloidosis
426488|NCT00981708|lenalidomide
426489|NCT00981708|newly diagnosed
426490|NCT00981708|relapsed
426491|NCT00981708|primary systemic AL amyloidosis
426492|NCT00981695|HIV
426493|NCT00981695|Vaccine
426494|NCT00981695|MVA
426495|NCT00981695|PMTCT
426496|NCT00981695|HIV preventive vaccine
426497|NCT00981695|HIV seronegativity
426498|NCT00981682|decrease in the number of nocturic episodes for patients with nocturia
426499|NCT00981669|brazilian pentavalent rotavirus vaccine
426500|NCT00981669|safety
426501|NCT00981669|tolerability
426502|NCT00981669|immunogenicity
426503|NCT00981656|stage I bladder cancer
426504|NCT00981656|transitional cell carcinoma of the bladder
426505|NCT00981643|Meditation
426506|NCT00981643|Multiple Sclerosis
426507|NCT00981643|Peripheral Neuropathy
426508|NCT00981630|Japanese Encephalitis
426509|NCT00981630|ChimeriVax™-JE Vaccine
426510|NCT00981630|Adult
426511|NCT00981604|SILS
426512|NCT00981604|Laparoscopic Cholecystectomy
426513|NCT00981604|Children
426514|NCT00981591|Iloprost
426515|NCT00981591|Nitric oxide
426516|NCT00981591|Mechanical ventilator
426517|NCT00981578|bone cancer
426518|NCT00981578|pain palliation
426519|NCT00981578|metastasis
426520|NCT00981578|breast cancer
426521|NCT00981578|lung cancer
426522|NCT00981578|prostate cancer
426523|NCT00981578|cancer related pain
426524|NCT00981578|tumors
426525|NCT00981565|Carpal tunnel syndrome
426526|NCT00981565|CTS
426527|NCT00981565|medianus impingement
426528|NCT00981552|Cervix Cancer
426529|NCT00981552|IMRT
426530|NCT00981552|Organ Motion
426531|NCT00981552|Target Definition
426532|NCT00981539|The focus of this study is to determine whether it is beneficial to administer enemas before surgery
426533|NCT00981526|Schizophrenia
426534|NCT00981526|Cognition
426535|NCT00981526|Metabolism
426536|NCT00981526|Antipsychotics
426537|NCT00981526|Psychopathology
426538|NCT00981500|obesity
426539|NCT00981500|gastric bypass
426540|NCT00981500|gastric banding
426541|NCT00981500|weight loss
426542|NCT00981500|insulin sensitivity
426543|NCT00981500|sleeve gastrectomy
426544|NCT00981500|fibroblast growth factor 21
426545|NCT00981500|fibroblast growth factor 19
426546|NCT00981474|cardiac surgery; brain injury; cerebral autoregulation
426547|NCT00981461|Andregenetic Alopecia
426548|NCT00981461|Hair Loss
426549|NCT00981461|Female Pattern Baldness
426550|NCT00981448|zinc
426551|NCT00981448|diabetes
426552|NCT00981448|genetics
426553|NCT00981435|Glaucoma
426554|NCT00981435|Trabeculoplasty
426555|NCT00981435|Selective laser trabeculoplasty
426556|NCT00981435|Intraocular pressure
426557|NCT00981422|glaucoma
426558|NCT00981422|immunology
426559|NCT00981422|immunophenotype
426560|NCT00981409|Fondaparinux sodium
426561|NCT00981409|contrast-enhanced MDCT
426562|NCT00981409|Deep Vein Thrombosis
426563|NCT00981409|Pulmonary thromboembolism
426564|NCT00981396|smoking
426565|NCT00981396|EFT (Emotional Freedom Techniques)
426566|NCT00981396|CBT (cognitive behavior therapy)
426567|NCT00981396|cravings
426568|NCT00981396|trauma
426569|NCT00981383|Fatty Acids, Omega-3
426570|NCT00981370|Sickle Cell Disease
426571|NCT00981370|Sickle Cell Anemia
426572|NCT00981370|Iron Overload
426573|NCT00981370|Chelation Therapy
426574|NCT00981370|Iron overload from blood transfusions
426575|NCT00981370|Heart rate variability
426576|NCT00981370|Autonomic dysfunction
426577|NCT00981357|Cross-over evaluate the efficacy of PF-04457845 in relieving pain due to osteoarthritis OA knee osteoarthritis of knee pain due to osteoarthritis
426578|NCT00981344|wheelchair
426579|NCT00981344|mobility disability
426580|NCT00981344|evidence based practice
426581|NCT00981344|self help devices
426582|NCT00981344|Veterans prescribed mobility aids
426583|NCT00981331|Subtalar joint
426584|NCT00981331|Musculoskeletal Manipulations
426585|NCT00981331|Manipulation, Chiropractic
426586|NCT00981331|Ankle sprain
426587|NCT00981331|Inversion sprain
426588|NCT00981331|Range of motion, Articular
426589|NCT00981331|Quaternion
426590|NCT00981331|Eigen analysis
426591|NCT00981318|Acquired Immunodeficiency Syndrome
426592|NCT00981318|HIV
426593|NCT00981318|AIDS
426594|NCT00981318|treatment experienced
426595|NCT00981305|dyspareunia
426596|NCT00981305|breast cancer
426597|NCT00981305|sexual dysfunction
426598|NCT00981305|vaginal lubricant
426599|NCT00981292|Epigallocatechin Gallate
426600|NCT00981292|cerebral blood flow
426601|NCT00981292|Near Infrared spectroscopy
426602|NCT00981292|Electroencephalography
426603|NCT00981292|cognitive function
426604|NCT00981292|mood
426605|NCT00981292|cerebro-electrical activity
426606|NCT00981279|Health Profile
426607|NCT00981279|AIDS
426608|NCT00981279|Health Promotion
426609|NCT00981279|HIV
426610|NCT00981279|treatment experienced
426611|NCT00981266|Augmentation
426612|NCT00981266|Augmentation Revision
426613|NCT00981253|Stress Management Training
426614|NCT00981253|Cardiac Rehabilitation
426615|NCT00981253|Stress
426616|NCT00981253|Depression
426617|NCT00981227|pain herpetic neuralgia
426618|NCT00981214|Cystic fibrosis
426619|NCT00981214|Exocrine Pancreatic Insufficiency
426620|NCT00981214|Zenpep-1009
426621|NCT00981201|Smoking
426622|NCT00981201|Cancer Prevention
426623|NCT00981201|Celecoxib
426624|NCT00981201|Celebrex
426625|NCT00981201|Placebo
426626|NCT00981175|Japanese Encephalitis
426627|NCT00981175|Japanese Encephalitis Vaccines
426628|NCT00981175|Adult
426629|NCT00981136|Appendicitis
426630|NCT00981136|Appendectomy
426631|NCT00981136|Children
426632|NCT00981136|Laparoscopic
426633|NCT00981136|SILS
426634|NCT00981110|Surgical site infections (SSI)
426635|NCT00981110|Advanced antimicrobial dressing and clean surgery
426636|NCT00981110|Hydrofibre dressing
426637|NCT00981097|HIV infection
426638|NCT00981097|HIV-associated Hodgkin lymphoma
426639|NCT00981097|stage I adult Hodgkin lymphoma
426640|NCT00981097|stage II adult Hodgkin lymphoma
426641|NCT00981097|stage III adult Hodgkin lymphoma
426642|NCT00981097|stage IV adult Hodgkin lymphoma
426643|NCT00981097|contiguous stage II adult Burkitt lymphoma
426644|NCT00981097|noncontiguous stage II adult Burkitt lymphoma
426645|NCT00981097|stage I adult Burkitt lymphoma
426646|NCT00981097|stage III adult Burkitt lymphoma
426647|NCT00981097|stage IV adult Burkitt lymphoma
426648|NCT00981097|contiguous stage II adult diffuse large cell lymphoma
426649|NCT00981097|noncontiguous stage II adult diffuse large cell lymphoma
426650|NCT00981097|stage I adult diffuse large cell lymphoma
426651|NCT00981097|stage III adult diffuse large cell lymphoma
426652|NCT00981097|stage IV adult diffuse large cell lymphoma
426653|NCT00981097|contiguous stage II adult immunoblastic large cell lymphoma
426654|NCT00981097|noncontiguous stage II adult immunoblastic large cell lymphoma
426655|NCT00981097|stage I adult immunoblastic large cell lymphoma
426656|NCT00981097|stage III adult immunoblastic large cell lymphoma
426657|NCT00981097|stage IV adult immunoblastic large cell lymphoma
426658|NCT00981071|Tuberculosis
426659|NCT00981071|QuantiFERON
426660|NCT00981071|Outbreak
426661|NCT00981071|Conversion
426662|NCT00981058|Squamous
426663|NCT00981058|Non Small Cell Lung Cancer
426664|NCT00981058|First line treatment
426665|NCT00981058|Monoclonal
426666|NCT00981058|Antibodies
426667|NCT00981058|Epidermal Growth Factor Receptor (EGFR)
426668|NCT00981045|IDA
426669|NCT00981032|Aspirin
426670|NCT00981032|Behavior
426671|NCT00981032|Cardiovascular Disease
426672|NCT00981019|survival rates
426673|NCT00981019|risk communication
426674|NCT00981019|screening counselling
426675|NCT00981019|screening recommendation
426676|NCT00981019|understanding of medical risk
426677|NCT00981006|ischemic cardiomyopathy (ICM)
426678|NCT00980993|Prostate
426679|NCT00980993|Motion
426680|NCT00980993|Respiration
426681|NCT00980980|MRSA infection
426682|NCT00980967|Lung transplantation
426683|NCT00980967|Chronic lung rejection
426684|NCT00980967|Obliterative bronchiolitis
426685|NCT00980967|Predictive factors
426686|NCT00980954|cervical adenocarcinoma
426687|NCT00980954|cervical adenosquamous cell carcinoma
426688|NCT00980954|cervical squamous cell carcinoma
426689|NCT00980954|stage IA cervical cancer
426690|NCT00980954|stage IB cervical cancer
426691|NCT00980954|stage IIA cervical cancer
426692|NCT00980941|starch
426693|NCT00980941|carbohydrates
426694|NCT00980941|blood glucose
426695|NCT00980941|food intake
426696|NCT00980941|satiety
426697|NCT00980941|appetite
426698|NCT00980915|Acute Lung Injury
426699|NCT00980915|Acute Respiratory Distress Syndrome
426700|NCT00980915|Respiratory Distress
426701|NCT00980915|pneumonia
426702|NCT00980915|sepsis
426703|NCT00980915|aspiration
426704|NCT00980915|pancreatitis
426705|NCT00980889|bile duct obstruction
426706|NCT00980889|jaundice
426707|NCT00980889|metal stent
426708|NCT00980850|Flu vaccine
426709|NCT00980850|H1N1 swine flu virus
426710|NCT00980850|Immunogenicity
426711|NCT00980850|Reactogenicity
426712|NCT00980824|cognitive behaviour therapy
426713|NCT00980824|self harm
426714|NCT00980824|personality disorder
426715|NCT00980824|complex comorbidity
426716|NCT00980824|mental health
426717|NCT00980798|Osteoarthritis
426718|NCT00980798|Strong pain killer
426719|NCT00980798|Strong opioid
426720|NCT00980798|Low starting dose
426721|NCT00980798|Fewer side effects
426722|NCT00980798|Physical functioning
426723|NCT00980798|Pain control
426724|NCT00980798|Quality of life
426725|NCT00980798|Sleep quality
426726|NCT00980785|Alzheimer's Disease
426727|NCT00980785|Hypertension
426728|NCT00980759|Extended-field Irradiation (EFI)
426729|NCT00980759|Cervical cancer
426730|NCT00980759|Hypoxia
426731|NCT00980759|Carbonic anhydrase 9 (CA9)
426732|NCT00980759|locally advanced uterine cervical cancer
426733|NCT00980746|pain diabetes neuropathy
426734|NCT00980733|Micronutrients
426735|NCT00980733|zinc
426736|NCT00980733|iron
426737|NCT00980733|iodine
426738|NCT00980733|fortification
426739|NCT00980733|school children
426740|NCT00980707|versican
426741|NCT00980707|hyaluronan
426742|NCT00980707|sputum
426743|NCT00980694|ubiquinol
426744|NCT00980694|coenzyme Q10
426745|NCT00980694|Huntington disease
426746|NCT00980681|Renal disease
426747|NCT00980681|Contrast agent
426748|NCT00980681|MRA
426749|NCT00980642|surgery
426750|NCT00980642|temperature
426751|NCT00980642|temperature monitor
426752|NCT00980642|non-invasive
426753|NCT00980642|interoperative core temperature
426754|NCT00980616|Arthroplasty, hip
426755|NCT00980616|blood losses
426756|NCT00980616|pain
426757|NCT00980616|local analgesia
426758|NCT00980616|epinephrine
426759|NCT00980616|Primary total hip arthroplasty
426760|NCT00980603|gastric cancer
426761|NCT00980603|metastatic
426762|NCT00980603|docetaxel
426763|NCT00980603|cisplatin
426764|NCT00980603|S-1
426765|NCT00980590|supine emergency intubations
426766|NCT00980590|emergency intubations
426767|NCT00980538|TMC125-TiDP35-C239
426768|NCT00980538|TMC125-C239
426769|NCT00980538|TMC125
426770|NCT00980538|HIV
426771|NCT00980538|Etravirine
426772|NCT00980538|Intelence
426773|NCT00980538|IntelenceTM
426774|NCT00980525|healthy
426775|NCT00980512|behavior problems
426776|NCT00980512|parent training
426777|NCT00980512|foster care
426778|NCT00980486|Antibiotic Concentration
426779|NCT00980486|Tissue
426780|NCT00980486|Obesity
426781|NCT00980486|Cesarean
426782|NCT00980473|Primary Angle Closure Disease
426783|NCT00980447|H5N1
426784|NCT00980447|Vaccine
426785|NCT00980447|Influenza H5N1
426786|NCT00980447|Avian influenza H5N1
426787|NCT00980447|Pandemic
426788|NCT00980434|vertebral fracture
426789|NCT00980434|spinal cord injury
426790|NCT00980421|iron
426791|NCT00980421|iron toxicity markers
426792|NCT00980421|oxidative stress markers
426793|NCT00980421|iron supplementation
426794|NCT00980421|NTBI
426795|NCT00980421|iron over load
426796|NCT00980421|interleukin levels
426797|NCT00980421|iron status
426798|NCT00980421|acut phase reactants
426799|NCT00980421|preschool children
426800|NCT00980395|recurrent mantle cell lymphoma
426801|NCT00980395|stage III mantle cell lymphoma
426802|NCT00980395|stage IV mantle cell lymphoma
426803|NCT00980395|recurrent marginal zone lymphoma
426804|NCT00980395|stage III marginal zone lymphoma
426805|NCT00980395|stage IV marginal zone lymphoma
426806|NCT00980395|Waldenstrom macroglobulinemia
426807|NCT00980395|recurrent small lymphocytic lymphoma
426808|NCT00980395|stage III small lymphocytic lymphoma
426809|NCT00980395|stage IV small lymphocytic lymphoma
426810|NCT00980395|recurrent grade 1 follicular lymphoma
426811|NCT00980395|recurrent grade 2 follicular lymphoma
426812|NCT00980395|recurrent grade 3 follicular lymphoma
426813|NCT00980395|stage III grade 1 follicular lymphoma
426814|NCT00980395|stage III grade 2 follicular lymphoma
426815|NCT00980395|stage III grade 3 follicular lymphoma
426816|NCT00980395|stage IV grade 1 follicular lymphoma
426817|NCT00980395|stage IV grade 2 follicular lymphoma
426818|NCT00980395|stage IV grade 3 follicular lymphoma
426819|NCT00980395|extranodal marginal zone BCL mucosa assoc lymphoid tissue
426820|NCT00980395|nodal marginal zone B Cell lymphoma
426821|NCT00980395|splenic marginal zone lymphoma
426822|NCT00980382|Stomach Neoplasms
426823|NCT00980382|phase I/II
426824|NCT00980382|Combination chemotherapy
426825|NCT00980382|S-1
426826|NCT00980382|Docetaxel
426827|NCT00980369|Lateral internal sphincterotomy
426828|NCT00980369|Anal fissure
426829|NCT00980369|Surgical technique
426830|NCT00980369|Incision
426831|NCT00980369|Wound healing
426832|NCT00980356|Diabetes Kidney transplantation
426833|NCT00980356|New onset diabetes mellitus after transplantation
426834|NCT00980330|Hepatitis C
426835|NCT00980330|Peginterferon alpha-2a
426836|NCT00980330|PegIFNalpha-2a
426837|NCT00980330|RBV
426838|NCT00980330|Ribavirin
426839|NCT00980330|Placebo
426840|NCT00980330|TMC435-TIDP16-C206
426841|NCT00980330|TMC435-C206
426842|NCT00980330|TMC435
426843|NCT00980330|HCV
426844|NCT00980317|Renal tumor
426845|NCT00980317|Restored kidney
426846|NCT00980317|Renal transplantation
426847|NCT00980317|Third party
426848|NCT00980304|Diffuse large B cell lymphomas
426849|NCT00980278|sinus lift
426850|NCT00980278|tooth extraction
426851|NCT00980278|dental implant
426852|NCT00980252|Schizophrenia
426853|NCT00980252|Cognitive Behavioral Therapy
426854|NCT00980252|Compliance
426855|NCT00980252|Medication Adherence
426856|NCT00980252|Psychotic Disorders
426857|NCT00980252|Mental Disorders
426858|NCT00980252|Outcomes
426859|NCT00980252|Psychoeducation
426860|NCT00980252|Adherence Attitudes
426861|NCT00980252|Intervention
426862|NCT00980252|Nonadherence
426863|NCT00980252|Schizophrenia and Disorders with Psychotic Features
426864|NCT00980239|Solid Tumors
426865|NCT00980239|Liver
426866|NCT00980239|hepatic arterial infusion
426867|NCT00980239|HAI
426868|NCT00980239|Bevacizumab
426869|NCT00980239|Avastin
426870|NCT00980239|Cetuximab
426871|NCT00980239|Erbitux
426872|NCT00980239|Irinotecan
426873|NCT00980239|Camptosar
426874|NCT00980239|Oxaliplatin
426875|NCT00980239|Eloxatin
426876|NCT00980213|renal cell cancer
426877|NCT00980213|sunitinib
426878|NCT00980213|costs
426879|NCT00980213|quality of life
426880|NCT00980200|GW642444
426881|NCT00980200|once daily dosing
426882|NCT00980200|asthma
426883|NCT00980200|efficacy
426884|NCT00980200|safety
426885|NCT00980200|FEV1
426886|NCT00980187|blood tests
426887|NCT00980187|cardiac function
426888|NCT00980187|endothelial function
426889|NCT00980187|arterial function
426890|NCT00980174|men
426891|NCT00980174|male
426892|NCT00980174|denosumab
426893|NCT00980174|BMD
426894|NCT00980174|lumbar spine
426895|NCT00980174|ADAMO
426896|NCT00980174|The ADAMO Trial
426897|NCT00980174|male osteoporosis
426898|NCT00980174|osteoporosis in men
426899|NCT00980174|males with low bone mineral density
426900|NCT00980161|Hepatitis C
426901|NCT00980161|Peginterferon
426902|NCT00980161|Ribavirin
426903|NCT00980161|MicroRNA
426904|NCT00980148|Chlamydia trachomatis, Chlamydia, Doxycycline, Azithromycin
426905|NCT00980135|Sinecort
426906|NCT00980135|Hydrocortison
426907|NCT00980135|Mild atopic dermatitis
426908|NCT00980135|Efficacy, safety
426909|NCT00980122|Advanced cancer patients dying in hospital receive aggressive cancer-specific therapy and supportive measures.
426910|NCT00980109|Influenza Prophylaxis
426911|NCT00980109|Long Term
426912|NCT00980109|Oral Oseltamivir
426913|NCT00980109|Inhaled Zanamivir
426914|NCT00980083|GLP-1
426915|NCT00980083|exendin(9-39)
426916|NCT00980083|gastric emptying
426917|NCT00980083|incretin
426918|NCT00980083|human
426919|NCT00980070|lumbar puncture positioning device
426920|NCT00980031|Aldosterone Blockade
426921|NCT00980031|Aldosterone Receptor Blockers
426922|NCT00980031|cardiac chamber size
426923|NCT00980031|wall thickness
426924|NCT00980031|left ventricular ejection fraction
426925|NCT00980031|left atrial volumes
426926|NCT00980031|diastolic function
426927|NCT00980018|CML
426928|NCT00980018|Leukemia
426929|NCT00980018|Tasigna
426930|NCT00980018|nilotinib
426931|NCT00980018|AMN107
426932|NCT00980018|CML-CP
426933|NCT00980018|Chronic Phase
426934|NCT00980005|GSK Biologicals influenza vaccine GSK1557482A
426935|NCT00980005|influenza infection
426936|NCT00979979|Hepatitis C
426937|NCT00979979|Genotype
426938|NCT00979979|Realtime PCR
426939|NCT00979966|Locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC)
426940|NCT00979953|delta opioid receptor agonist
426941|NCT00979953|osteoarthritis
426942|NCT00979953|pain
426943|NCT00979940|atorvastatin
426944|NCT00979940|clopidogrel
426945|NCT00979940|percutaneous intervention
426946|NCT00979940|periprocedural myonecrosis
426947|NCT00979927|Antisense
426948|NCT00979927|miR-122 antagonist
426949|NCT00979927|safety in healthy Volunteers
426950|NCT00979927|Hepatitis C
426951|NCT00979914|osteoarthritis
426952|NCT00979914|patient education
426953|NCT00979914|function
426954|NCT00979914|physio therapy
426955|NCT00979888|dyspnea
426956|NCT00979888|depression
426957|NCT00979888|fatigue
426958|NCT00979888|anxiety disorder
426959|NCT00979888|small cell lung cancer
426960|NCT00979888|non-small cell lung cancer
426961|NCT00979875|insulin
426962|NCT00979875|recombinant human hyaluronidase
426963|NCT00979875|Healthy volunteers
426964|NCT00979849|safety
426965|NCT00979849|tolerability
426966|NCT00979849|healthy
426967|NCT00979849|inhalation
426968|NCT00979836|venous
426969|NCT00979836|ulcer
426970|NCT00979836|phlebotonic
426971|NCT00979836|calcium dobesilate
426972|NCT00979836|clinical trial
426973|NCT00979810|PET scan
426974|NCT00979810|CT scan
426975|NCT00979810|09-060
426976|NCT00979810|CNS
426977|NCT00979797|Community IMCI
426978|NCT00979797|C-IMCI
426979|NCT00979797|CHW
426980|NCT00979797|Children
426981|NCT00979797|Evaluation
426982|NCT00979797|Behaviour
426983|NCT00979797|Counselling
426984|NCT00979797|Under 5 mortality
426985|NCT00979797|Under 5 Nutrition
426986|NCT00979784|obesity
426987|NCT00979784|primary care
426988|NCT00979771|GSK706769
426989|NCT00979771|Enbrel
426990|NCT00979771|Rheumatoid Arthritis
426991|NCT00979745|Erythropoietic Protoporphyria
426992|NCT00979745|EPP
426993|NCT00979745|Afamelanotide
426994|NCT00979732|high blood pressure
426995|NCT00979732|dietary supplements
426996|NCT00979732|nutrition
426997|NCT00979719|Randomized Controlled Trial
426998|NCT00979719|evidence- and theory-based behavioral intervention
426999|NCT00979719|expert system
427000|NCT00979719|stages of change
427001|NCT00979719|motivational interviewing
427002|NCT00979719|tailoring
427003|NCT00979719|Self Care
427004|NCT00979719|Rehabilitation
427005|NCT00979719|Expert Systems
427006|NCT00979693|anxiety
427007|NCT00979693|stage IV melanoma
427008|NCT00979693|depression
427009|NCT00979693|spirituality
427010|NCT00979693|pain
427011|NCT00979680|sphincter preservation
427012|NCT00979680|neoadjuvant therapy
427013|NCT00979667|Upper respiratory tract infection
427014|NCT00979667|Influenza A
427015|NCT00979667|Human Swine Influenza
427016|NCT00979654|Sifalimumab
427017|NCT00979654|MEDI-545
427018|NCT00979641|breast cancer
427019|NCT00979641|metastatic
427020|NCT00979641|chemotherapy
427021|NCT00979641|bevacizumab
427022|NCT00979641|docetaxel
427023|NCT00979641|Phase II
427024|NCT00979641|first line chemotherapy
427025|NCT00979641|metastatic breast cancer patients
427026|NCT00979628|Type 2 Diabetes
427027|NCT00979628|Inpatient Hyperglycemia
427028|NCT00979615|vasomotor rhinitis
427029|NCT00979615|chronic non-allergic rhinitis
427030|NCT00979615|VMR
427031|NCT00979602|GSK Bio's influenza vaccine GSK2340274A
427032|NCT00979602|Influenza Vaccines
427033|NCT00979602|GSK Bio's influenza vaccine GSK2340273A
427034|NCT00979602|influenza infection
427035|NCT00979589|stroke
427036|NCT00979589|transient ischemic attack
427037|NCT00979589|acute treatment
427038|NCT00979589|acute non-disabling cerebrovascular event
427039|NCT00979589|clopidogrel
427040|NCT00979589|clopidogrel combined with ASA
427041|NCT00979589|recurrence of stroke and other vascular events
427042|NCT00979563|HM30181AK
427043|NCT00979563|Irinotecan tablet
427044|NCT00979563|MTD
427045|NCT00979563|DLT
427046|NCT00979550|laser
427047|NCT00979550|pediatric
427048|NCT00979550|skin pigmentation
427049|NCT00979524|Depressive symptoms
427050|NCT00979524|Mental health services
427051|NCT00979524|Adolescents
427052|NCT00979524|Young adults
427053|NCT00979524|African-American
427054|NCT00979511|osteoporosis
427055|NCT00979511|calcium
427056|NCT00979511|weight-bearing exercise
427057|NCT00979511|bone mass
427058|NCT00979511|prepubertal girls
427059|NCT00978653|allopurinol
427060|NCT00978653|chronic kidney disease
427061|NCT00978653|endothelial dysfunction
427062|NCT00978653|hyperuricemia
427063|NCT00978653|uric acid
427064|NCT00978653|vascular endothelium
427065|NCT00978653|xanthine oxidase inhibitor
427066|NCT00978640|Sirt1 activity
427067|NCT00978601|post-operative analgesia
427068|NCT00978601|early discharge,
427069|NCT00978601|fast recovery,
427070|NCT00978601|minimally invasive myomectomy,
427071|NCT00978601|laparoscopy,
427072|NCT00978601|laparoscopically assisted myomectomy
427073|NCT00978601|patient discharge
427074|NCT00978601|Anesthesia Recovery Period
427075|NCT00978575|Iron treatment
427076|NCT00978575|Upper gastrointestinal bleeding
427077|NCT00978549|pain
427078|NCT00978549|nausea and vomiting
427079|NCT00978549|adenocarcinoma of the esophagus
427080|NCT00978549|adenocarcinoma of the stomach
427081|NCT00978549|adenocarcinoma of the gastroesophageal junction
427082|NCT00978549|recurrent gastric cancer
427083|NCT00978549|stage IIIA gastric cancer
427084|NCT00978549|stage IIIB gastric cancer
427085|NCT00978549|stage IIIC gastric cancer
427086|NCT00978549|stage IV gastric cancer
427087|NCT00978549|recurrent esophageal cancer
427088|NCT00978549|stage IIIA esophageal cancer
427089|NCT00978549|stage IIIB esophageal cancer
427090|NCT00978549|stage IIIC esophageal cancer
427091|NCT00978549|stage IV esophageal cancer
427092|NCT00978536|Multiple sclerosis
427093|NCT00978536|cognitive deterioration
427094|NCT00978536|biomarkers
427095|NCT00978536|cerebrospinal fluid
427096|NCT00978536|Alzheimer disease
427097|NCT00979485|Pediatric IBD
427098|NCT00979485|Microparticles
427099|NCT00979472|Solifenacin
427100|NCT00979472|Overactive bladder
427101|NCT00979472|Micturition
427102|NCT00979472|Urinary urgency
427103|NCT00979472|Vesicare
427104|NCT00979446|Interactive phone-based intervention with written materials
427105|NCT00979446|Older adults
427106|NCT00979446|Physical activity
427107|NCT00979446|Cognitive stimulation
427108|NCT00979446|Social engagement
427109|NCT00979433|Extubation failure
427110|NCT00979433|Continuous positive airway pressure
427111|NCT00979433|Bubble CPAP
427112|NCT00979420|treatment experienced
427113|NCT00979407|influenza infection
427114|NCT00979407|GSK Biologicals' influenza vaccine GSK2340272A and GSK2340274A
427115|NCT00979394|Diabetes Care at GPs in Austria
427116|NCT00979394|Characteristic of diabetes patients at GPs in Austria
427117|NCT00979381|sunitinib
427118|NCT00979381|sorafenib
427119|NCT00979381|immune response
427120|NCT00979355|Whole body
427121|NCT00979355|SPECT
427122|NCT00979342|morcellator
427123|NCT00979342|hysteroscope
427124|NCT00979342|myomectomy
427125|NCT00979342|polypectomy
427126|NCT00979342|uterine fibroids
427127|NCT00979342|uterine polyps
427128|NCT00979342|local anesthetic
427129|NCT00979342|cervical block
427130|NCT00979342|pain management
427131|NCT00979329|sunitinib
427132|NCT00979329|sorafenib
427133|NCT00979329|fatigue
427134|NCT00979329|depression
427135|NCT00979329|quality of life
427136|NCT00979329|metastatic RCC
427137|NCT00979329|colorectal cancer
427138|NCT00979329|GIST
427139|NCT00979303|Pediatric
427140|NCT00979303|Electrophysiology
427141|NCT00979303|Ablation
427142|NCT00979303|Radiation
427143|NCT00979303|Devices
427144|NCT00979303|SVT
427145|NCT00979290|Fix-dose combination anti-TB drug
427146|NCT00979290|adverse effect
427147|NCT00979290|efficiency
427148|NCT00979264|Quality Improvement
427149|NCT00979251|Influenza
427150|NCT00979251|Immunocompromised
427151|NCT00979251|HIV
427152|NCT00979251|History of transplant
427153|NCT00979238|Hemophilia B
427154|NCT00979238|Factor IX Gene
427155|NCT00979238|Factor IX Protein
427156|NCT00979238|Vector
427157|NCT00979225|health information technology
427158|NCT00979225|clinical decision support
427159|NCT00979225|medication management
427160|NCT00979225|medication adherence
427161|NCT00979212|stage IIIA non-small cell lung cancer
427162|NCT00979212|adenocarcinoma of the lung
427163|NCT00979212|adenosquamous cell lung cancer
427164|NCT00979212|bronchoalveolar cell lung cancer
427165|NCT00979212|large cell lung cancer
427166|NCT00979212|squamous cell lung cancer
427167|NCT00979199|IHD
427168|NCT00979199|CAD
427169|NCT00979199|Non invasive imaging
427170|NCT00979199|SPECT
427171|NCT00979199|PET
427172|NCT00979199|CMR
427173|NCT00979199|Echocardiography
427174|NCT00979186|transgastric cholecystectomy
427175|NCT00979173|malignant glioma
427176|NCT00979173|glioblastoma multiforme
427177|NCT00979173|gliosarcoma
427178|NCT00979173|anaplastic astrocytoma
427179|NCT00979173|anaplastic oligodendroglioma
427180|NCT00979173|anaplastic mixed glioma
427181|NCT00979173|Pro00018751
427182|NCT00979173|Duke
427183|NCT00979173|Ambit
427184|NCT00979173|AC480
427185|NCT00979147|knee arthritis
427186|NCT00979147|total knee arthroplasty
427187|NCT00979147|total knee replacement
427188|NCT00979147|metal backed tibial component
427189|NCT00979147|all-polyethylene tibia
427190|NCT00979147|modular polished tibial baseplate
427191|NCT00979134|Cancer
427192|NCT00979134|Tumour
427193|NCT00979134|Advanced Solid Malignancies
427194|NCT00979134|FGFR
427195|NCT00979134|Squamous NSCLC
427196|NCT00979134|Gastric adenocarcinoma
427197|NCT00979121|ALI
427198|NCT00979121|Sepsis
427199|NCT00979121|statin
427200|NCT00979108|Radiculopathy
427201|NCT00979108|Neck pain
427202|NCT00979108|Physical therapy modalities
427203|NCT00979108|Rehabilitation
427204|NCT00979095|multiple hernia
427205|NCT00979056|Traveller's diarrhoea
427206|NCT00979056|Prevention
427207|NCT00979043|knee osteoarthritis
427208|NCT00979043|weight-loss
427209|NCT00979043|exercise
427210|NCT00979043|obesity
427211|NCT00979043|physical function
427212|NCT00979043|total mortality
427213|NCT00979017|malignant glioma
427214|NCT00979017|glioblastoma multiforme
427215|NCT00979017|gliosarcoma
427216|NCT00979017|Avastin
427217|NCT00979017|bevacizumab
427218|NCT00979017|Temodar
427219|NCT00979017|temozolomide
427220|NCT00979017|Irinotecan
427221|NCT00979017|CPT-11
427222|NCT00979017|Pro00019065
427223|NCT00979017|Vredenburgh
427224|NCT00979017|Duke
427225|NCT00979004|Photosensitivity
427226|NCT00979004|Epilepsy
427227|NCT00979004|Seizures
427228|NCT00978991|Benign prostate hyperplasia
427229|NCT00978991|Erectile dysfunction
427230|NCT00978965|kidney transplantation
427231|NCT00978965|immunosuppression
427232|NCT00978965|single nucleotide polymorphism
427233|NCT00978965|IMPDH
427234|NCT00978926|Anti-Vascular Endothelial growth factor
427235|NCT00978913|dendritic cell
427236|NCT00978913|cancervaccine
427237|NCT00978913|breast cancer
427238|NCT00978913|malignant melanoma
427239|NCT00978913|Cyclophosphamide
427240|NCT00978900|satiety peptides
427241|NCT00978900|GLP-1
427242|NCT00978900|PYY
427243|NCT00978900|ghrelin
427244|NCT00978900|appetite profile
427245|NCT00978900|Sweetening Agents
427246|NCT00978887|Facial cream
427247|NCT00978887|natural product
427248|NCT00978887|facial wrinkles
427249|NCT00978874|recurrent cervical cancer
427250|NCT00978874|stage IB cervical cancer
427251|NCT00978874|stage IIA cervical cancer
427252|NCT00978874|stage IIB cervical cancer
427253|NCT00978874|stage III cervical cancer
427254|NCT00978874|stage IVA cervical cancer
427255|NCT00978874|stage IVB cervical cancer
427256|NCT00978848|trichomonas
427257|NCT00978848|chlamydia
427258|NCT00978848|gonorrhea
427259|NCT00978848|emergency contraception
427260|NCT00978848|emergency contraception use
427261|NCT00978835|Diabetes
427262|NCT00978835|Hypertension
427263|NCT00978835|Physical Activity
427264|NCT00978835|Diet
427265|NCT00978835|Medication Adherence
427266|NCT00978822|Subarachnoid hemorrhage
427267|NCT00978822|Hypertension
427268|NCT00978822|brain Aneurysm
427269|NCT00978822|intracerebral hemorrhage
427270|NCT00978822|antihypertensive
427271|NCT00978822|calcium channel blockers
427272|NCT00978822|infusion
427273|NCT00978822|neurocritical care
427274|NCT00978809|BPPV
427275|NCT00978809|postural stability
427276|NCT00978809|Epley
427277|NCT00978809|Semont
427278|NCT00978796|Diabetes Mellitus
427279|NCT00978796|Type 1 diabetes
427280|NCT00978796|glucose variability
427281|NCT00978783|Phonation
427282|NCT00978783|Tracheostomy
427283|NCT00978783|phonation valve
427284|NCT00978783|positive end expiratory pressure
427285|NCT00978770|stage II breast cancer
427286|NCT00978770|stage IIIA breast cancer
427287|NCT00978770|stage IIIB breast cancer
427288|NCT00978770|stage IIIC breast cancer
427289|NCT00978757|hepatectomy
427290|NCT00978757|IL 6
427291|NCT00978757|organ failure
427292|NCT00978757|ketamine
427293|NCT00978757|Pringle
427294|NCT00978744|Clinical Health Record
427295|NCT00978744|Computerized Decision Support
427296|NCT00978744|Patient Safety
427297|NCT00978744|Resource Utilization
427298|NCT00978718|prostate cancer
427299|NCT00978705|Keratinocyte Cell
427300|NCT00978705|severe burn wound
427301|NCT00978692|Myopia
427302|NCT00978692|Astigmatism
427303|NCT00978692|Orthokeratology
427304|NCT00978692|Corneal thickness
427305|NCT00978692|Corneal curvatures
427306|NCT00978692|Corneal biomechanics
427307|NCT00978679|Children
427308|NCT00978679|Peripheral refraction
427309|NCT00978679|Aberration
427310|NCT00978679|Eyeball length
427311|NCT00978679|Myopic control
427312|NCT00978679|Myopia
427313|NCT00978679|Corneal reshaping
427314|NCT00978679|Orthokeratology
427315|NCT00978510|Tuberculosis
427316|NCT00978510|Disease transmission
427317|NCT00978510|Exposure to biological agents
427318|NCT00978510|Health personnel
427319|NCT00978484|PTSD
427320|NCT00978484|Depression
427321|NCT00978484|Anxiety
427322|NCT00978484|Virtual Reality
427323|NCT00978484|Computer Therapy
427324|NCT00978484|Exposure Therapy
427325|NCT00978484|Prolonged Exposure
427326|NCT00978484|Military Medicine
427327|NCT00978484|Combat
427328|NCT00978484|Iraq
427329|NCT00978484|Afghanistan
427330|NCT00978484|Air Force Personnel
427331|NCT00978484|Armed Forces Personnel
427332|NCT00978484|Army Personnel
427333|NCT00978484|Coast Guard
427334|NCT00978484|psychology
427335|NCT00978484|military psychiatry
427336|NCT00978484|combat disorders
427337|NCT00978484|combat neurosis
427338|NCT00978484|Marines
427339|NCT00978484|Military
427340|NCT00978484|Navy Personnel
427341|NCT00978484|Sailors
427342|NCT00978484|Soldiers
427343|NCT00978471|Conventional chemotherapy
427344|NCT00978471|cytapheresis
427345|NCT00978471|Peripheral stem cell autograft
427346|NCT00978471|Surgical resection
427347|NCT00978471|Thiotepa
427348|NCT00978458|neurotoxicity
427349|NCT00978458|adult diffuse astrocytoma
427350|NCT00978458|adult oligodendroglioma
427351|NCT00978458|recurrent adult brain tumor
427352|NCT00978458|adult mixed glioma
427353|NCT00978445|Systemic embolic events
427354|NCT00978445|Thromboembolic Complications with Atrial Fibrillation
427355|NCT00978445|Prophylaxis with Atrial Fibrillation
427356|NCT00978445|Mechanical Cardiac Valve Replacement
427357|NCT00978432|NHL
427358|NCT00978432|DLBCL
427359|NCT00978432|recurrent
427360|NCT00978432|refractory
427361|NCT00978432|de novo
427362|NCT00978419|Statins
427363|NCT00978419|Burns
427364|NCT00978419|Sedatives
427365|NCT00978419|Neurocognitive
427366|NCT00978419|Septic
427367|NCT00978419|Mortality
427368|NCT00978419|C Reactive Protein
427369|NCT00978419|Septic shock
427370|NCT00978419|Sedation
427371|NCT00978419|Neurocognitive function
427372|NCT00978406|Dietary Assessment Methods
427373|NCT00978406|Measurement of Diet
427374|NCT00978406|24-Hour Diet Recall
427375|NCT00978406|Validation
427376|NCT00978406|Feeding Study
427377|NCT00978367|Cicatrix
427378|NCT00978367|Scar
427379|NCT00978367|Avotermin
427380|NCT00978367|Juvista
427381|NCT00978367|RN1001
427382|NCT00978367|TGF beta 3
427383|NCT00978354|acute kidney injury
427384|NCT00978354|acute renal failure
427385|NCT00978354|loop diuretic
427386|NCT00978354|critical illness
427387|NCT00978354|sepsis
427388|NCT00978354|renal replacement therapy
427389|NCT00978354|dialysis
427390|NCT00978354|renal recovery
427391|NCT00978354|survival
427392|NCT00978341|Clinical Trial Methodology study Neuropathic pain in Spinal cord injury patients Pain endpoints Crossover design
427393|NCT00978328|Pain conditions
427394|NCT00978328|Oxycodone immediate release
427395|NCT00978328|Percocet®, Tylox®
427396|NCT00978328|Roxicodone®
427397|NCT00978328|Registry
427398|NCT00978328|Side effects
427399|NCT00978328|Observational
427400|NCT00978328|Pain management
427401|NCT00978302|Cicatrix
427402|NCT00978302|Scar
427403|NCT00978302|Wound healing
427404|NCT00978302|Avotermin
427405|NCT00978302|TGF beta 3
427406|NCT00978302|Juvista
427407|NCT00978302|RN1001
427408|NCT00978289|obesity
427409|NCT00978289|gastric bypass surgery
427410|NCT00978276|Receptors
427411|NCT00978276|Immunohistochemistry
427412|NCT00978276|Breast
427413|NCT00978276|Over expression of Hormone receptors in carcinoma of the breast sues
427414|NCT00978250|DNA Methylation
427415|NCT00978250|Advanced Cancer
427416|NCT00978250|Methyltransferase Inhibitor
427417|NCT00978250|Epigenetics
427418|NCT00978250|Gene Re-Expression
427419|NCT00978250|Breast Cancer
427420|NCT00978250|Head and Neck Cancer
427421|NCT00978250|Lung Cancer
427422|NCT00978250|Non-Small Cell Lung Cancer
427423|NCT00978250|Bladder Cancer
427424|NCT00978237|HIV - Lipoatrophy
427425|NCT00978237|treatment experienced
427426|NCT00978224|dietary supplement
427427|NCT00978224|hemodialysis
427428|NCT00978224|Chronic Inflammatory Syndrome
427429|NCT00978224|Viusid
427430|NCT00978211|DOTATOC
427431|NCT00978211|somatostatin
427432|NCT00978211|radiopeptide
427433|NCT00978211|Yttrium
427434|NCT00978211|Lutetium
427435|NCT00978211|neuroendocrine
427436|NCT00978211|cancer
427437|NCT00978198|Pharmacokinetics
427438|NCT00978198|Safety and tolerability
427439|NCT00978198|Plasma concentration
427440|NCT00978198|ASP1517
427441|NCT00978198|FG-4592
427442|NCT00978185|nausea and vomiting
427443|NCT00978185|anxiety disorder
427444|NCT00978185|unspecified adult solid tumor, protocol specific
427445|NCT00978159|esomeprazole
427446|NCT00978159|famotidine
427447|NCT00978159|aspirin
427448|NCT00978159|dyspepsia
427449|NCT00978133|Colectomy
427450|NCT00978133|Closure
427451|NCT00978133|Wound
427452|NCT00978133|Dermabond
427453|NCT00978133|Propen
427454|NCT00978120|Influenza A Virus, H1N1 Subtype
427455|NCT00978120|Vaccine
427456|NCT00978107|Hepatic tumors
427457|NCT00978107|Metastatic colorectal cancer
427458|NCT00978081|precancerous condition
427459|NCT00978081|stage 0 hypopharyngeal cancer
427460|NCT00978081|stage 0 laryngeal cancer
427461|NCT00978081|stage 0 lip and oral cavity cancer
427462|NCT00978081|stage 0 nasopharyngeal cancer
427463|NCT00978081|stage 0 oropharyngeal cancer
427464|NCT00978081|stage 0 paranasal sinus and nasal cavity cancer
427465|NCT00978068|Pediatric HIV
427466|NCT00978068|Malaria
427467|NCT00978068|Uganda
427468|NCT00978068|Nevirapine
427469|NCT00978068|Zidovudine
427470|NCT00978068|Lamivudine
427471|NCT00978068|Lopinavir/ritonavir
427472|NCT00978068|Stavudine
427473|NCT00978068|Efavirenz
427474|NCT00978068|HIV
427475|NCT00978029|immunotherapy
427476|NCT00978016|GERD
427477|NCT00978003|Vasti Medialis
427478|NCT00978003|Knee
427479|NCT00978003|MR Imaging
427480|NCT00978003|Vasti Lateralis
427481|NCT00978003|HV
427482|NCT00978003|Healthy Volunteer
427483|NCT00977990|Skin Swab
427484|NCT00977990|Self-Sample
427485|NCT00977977|Nephrotic Syndrome
427486|NCT00977977|Renal Disease
427487|NCT00977977|Autoimmune Diseases
427488|NCT00977977|Clinical Trial
427489|NCT00977977|Proteinuria
427490|NCT00977964|Infant
427491|NCT00977951|Cicatrix
427492|NCT00977951|Scar
427493|NCT00977951|Avotermin
427494|NCT00977951|Juvista
427495|NCT00977951|RN1001
427496|NCT00977951|TGF beta 3
427497|NCT00977938|Acute Coronary Syndrome
427498|NCT00977938|Adverse event
427499|NCT00977938|Antiplatelet therapy
427500|NCT00977938|Sirolimus
427501|NCT00977938|Everolimus
427502|NCT00977938|Paclitaxel
427503|NCT00977938|Zotarolimus
427504|NCT00977938|Bare Metal Stent
427505|NCT00977938|Drug Eluting Stent
427506|NCT00977938|Clinical Events Committee
427507|NCT00977938|Dual antiplatelet therapy
427508|NCT00977938|Harvard Clinical Research Institute
427509|NCT00977938|Major Adverse Cardiac and Cerebral Event
427510|NCT00977938|Major Bleeding
427511|NCT00977938|Myocardial infarction
427512|NCT00977938|Myocardial ischemia
427513|NCT00977938|Percutaneous coronary intervention
427514|NCT00977938|Stent placement
427515|NCT00977938|Stent Thrombosis
427516|NCT00977938|Thienopyridine
427517|NCT00977938|Clopidogrel
427518|NCT00977938|Prasugrel
427519|NCT00977925|Hemostasis
427520|NCT00977912|B. lactis
427521|NCT00977912|Preterm
427522|NCT00977912|Necrotizing Enterocolitis (NEC)
427523|NCT00977899|Plasmodium Falciparum
427524|NCT00977899|Alum Adsorbed
427525|NCT00977899|Ookinete Surface Protein
427526|NCT00977899|Malaria Vaccine
427527|NCT00977899|Healthy Volunteer
427528|NCT00977899|HV
427529|NCT00977860|Prostate
427530|NCT00977860|Stereotactic
427531|NCT00977860|Radiosurgery
427532|NCT00977847|Family History
427533|NCT00977847|Electronic Health Record
427534|NCT00977834|Geriatric Assessment
427535|NCT00977808|Artificial pancreas
427536|NCT00977808|Closed-Loop control
427537|NCT00977795|Brain Neoplasms
427538|NCT00977795|5-ALA
427539|NCT00977795|Aminolevulinic acid
427540|NCT00977795|Fluorescence
427541|NCT00977795|Gliomas
427542|NCT00977795|Glioblastoma
427543|NCT00977795|Surgery
427544|NCT00977782|Leukemia
427545|NCT00977782|AML
427546|NCT00977782|MDS
427547|NCT00977782|FLT3
427548|NCT00977782|midostaurin
427549|NCT00977782|wild type FLT3
427550|NCT00977782|mutated FLT3
427551|NCT00977769|cesarean delivery
427552|NCT00977769|blood pressure
427553|NCT00977769|cardiac output
427554|NCT00977756|Treatment
427555|NCT00977756|Children
427556|NCT00977756|Integrase Inhibitors
427557|NCT00977756|Entry Inhibitors
427558|NCT00977756|Treatment Experienced
427559|NCT00977730|Hepatitis
427560|NCT00977730|Fatty Liver
427561|NCT00977730|Non Alcoholic Steatohepatitis
427562|NCT00977730|Protandim
427563|NCT00977717|oxaliplatin
427564|NCT00977717|neuropathy
427565|NCT00977717|SNPs
427566|NCT00977704|Correction of peri-oral wrinkles
427567|NCT00977691|Peripheral Blood Stem Cell Transplantation
427568|NCT00977691|Anemia, Sickle Cell
427569|NCT00977691|Graft-Versus-Host Disease
427570|NCT00977691|Sirolimus (Rapamune )
427571|NCT00977691|Alemtuzumab (Campath )
427572|NCT00977691|Thalassemia
427573|NCT00977691|Sickle Cell Disease
427574|NCT00977678|open access gastroscopy
427575|NCT00977652|fecal incontinence
427576|NCT00977626|Safety
427577|NCT00977626|Tolerability
427578|NCT00977626|Healthy
427579|NCT00977626|Pharmacokinetics
427580|NCT00977626|Healthy volunteers
427581|NCT00977613|Treated Stage 2 and Stage 3 colorectal cancer
427582|NCT00977600|Ammonul
427583|NCT00977600|Sodium phenylacetate
427584|NCT00977600|sodium benzoate
427585|NCT00977600|Buphenyl
427586|NCT00977600|sodium phenylbutyrate
427587|NCT00977600|HPN-100
427588|NCT00977600|GT4P
427589|NCT00977600|Glyceryl tri-(4-phenylbutyrate)
427590|NCT00977600|Healthy Volunteers
427591|NCT00977587|irritable bowel syndrome
427592|NCT00977587|faecal serine proteases
427593|NCT00977561|Small Cell Lung Cancer
427594|NCT00977561|Extensive stage disease
427595|NCT00977561|SCLC
427596|NCT00977561|IGF-1R inhibitor
427597|NCT00977548|MDS
427598|NCT00977548|blood diseases
427599|NCT00977548|bone marrow
427600|NCT00977548|hematopoietic
427601|NCT00977548|leukemia
427602|NCT00977522|schizophrenia negative symptoms adjunctive
427603|NCT00977509|genes
427604|NCT00977509|mutation
427605|NCT00977509|non-small cell lung cancer
427606|NCT00977509|cancer cells
427607|NCT00977496|hemodialysis
427608|NCT00977496|microbiota
427609|NCT00977496|Staphylococcus aureus
427610|NCT00977470|NSCLC
427611|NCT00977470|HCQ
427612|NCT00977470|erlotinib
427613|NCT00977470|Tarceva
427614|NCT00977457|stage I prostate cancer
427615|NCT00977457|stage II prostate cancer
427616|NCT00977457|stage III prostate cancer
427617|NCT00977457|stage IV prostate cancer
427618|NCT00977444|knee
427619|NCT00977444|osteoarthritis
427620|NCT00977418|Healthy Aging
427621|NCT00977418|Exercise
427622|NCT00977418|Cognition
427623|NCT00977418|Cognitive Training
427624|NCT00977418|Keeping healthy seniors as mentally efficient as possible
427625|NCT00977405|Wound infection
427626|NCT00977405|Gentamicin
427627|NCT00977405|Contaminated wounds
427628|NCT00977392|human papilloma virus infection
427629|NCT00977392|health status unknown
427630|NCT00977353|Major depressive disorder
427631|NCT00977353|Depression
427632|NCT00977353|Sarcosine
427633|NCT00977353|N-methylglycine
427634|NCT00977353|NMDA
427635|NCT00977340|Chronic nightmare sufferers
427636|NCT00977340|nightmares
427637|NCT00977340|Imagery Rehearsal Therapy IRT
427638|NCT00977340|sleep disturbance
427639|NCT00977340|treatment of nightmares
427640|NCT00977340|confrontation
427641|NCT00977340|People who suffer of chronic nightmares
427642|NCT00977327|Glioma
427643|NCT00977327|Intraoperative MR
427644|NCT00977327|Intraoperative Ultrasound
427645|NCT00977327|resection
427646|NCT00977327|Intraoperative navigation
427647|NCT00977327|Extent of resection
427648|NCT00977314|Unilateral Hearing Loss
427649|NCT00977301|HIV infection
427650|NCT00977301|interaction
427651|NCT00977301|pharmacokinetics
427652|NCT00977275|early stage invasive breast cancer
427653|NCT00977275|Partial breast irradiation
427654|NCT00977275|interstitial implant
427655|NCT00977262|fatty acids
427656|NCT00977262|peripheral blood mononuclear cells
427657|NCT00977262|inflammation
427658|NCT00977262|nutrigenomics
427659|NCT00977249|long term nicotine gum use
427660|NCT00977249|varenicline
427661|NCT00977249|adverse effects
427662|NCT00977236|children
427663|NCT00977236|corneal reshaping
427664|NCT00977236|myopia
427665|NCT00977236|myopia control
427666|NCT00977236|orthokeratology
427667|NCT00977223|Aldosterone
427668|NCT00977223|Substance P
427669|NCT00977223|Cortisol
427670|NCT00977223|Aprepitant
427671|NCT00977223|Adrenal glands
427672|NCT00977210|Phase 1
427673|NCT00977210|oxi4503
427674|NCT00977210|oxigene
427675|NCT00977210|cruk
427676|NCT00977210|solid tumors
427677|NCT00977210|VDA
427678|NCT00977210|vascular disrupting agent
427679|NCT00977184|Parkinson's Disease
427680|NCT00977184|Transcranial Magnetic Stimulation (TMS)
427681|NCT00977184|Treatment Study
427682|NCT00977184|PD
427683|NCT00977184|Parkinson Disease
427684|NCT00977171|chronic fatigue syndrome
427685|NCT00977171|CFS
427686|NCT00977171|neurally mediated hypotension
427687|NCT00977171|NMH
427688|NCT00977171|neurogenic orthostatic hypotension
427689|NCT00977171|NOH
427690|NCT00977171|orthostatic hypotension
427691|NCT00977171|droxidopa
427692|NCT00977158|Cystic Fibrosis
427693|NCT00977158|Microbiota
427694|NCT00977158|upper respiratory tract
427695|NCT00977158|16S rRNA sequence analysis
427696|NCT00977158|Staphylococcus aureus
427697|NCT00977158|Pseudomonas aeruginosa
427698|NCT00977158|Burkholderia cepacia
427699|NCT00977158|Haemophilus influenzae
427700|NCT00977158|Streptococcus pneumoniae
427701|NCT00977145|melanoma
427702|NCT00977145|peptide vaccine
427703|NCT00977145|interferon gamma
427704|NCT00977145|immunotherapy
427705|NCT00977132|Myelodysplastic Syndromes
427706|NCT00977132|Valproic acid
427707|NCT00977132|Lenalidomide
427708|NCT00977119|breast cancer
427709|NCT00977119|capecitabine
427710|NCT00977093|Coronary artery disease
427711|NCT00977093|Cardiac magnetic resonance imaging
427712|NCT00977093|single photon emission computed tomography
427713|NCT00977093|invasive coronary angiography
427714|NCT00977080|Zemplar
427715|NCT00977080|paricalcitol
427716|NCT00977080|IMPACT SHPT
427717|NCT00977080|Hemodialysis
427718|NCT00977080|Chronic Kidney Disease Stage 5
427719|NCT00977067|GDC0152
427720|NCT00977067|IAP
427721|NCT00977067|IAP Antagonist
427722|NCT00977054|Hepatitis C
427723|NCT00977054|Peginterferon alfa-2a
427724|NCT00977054|Ribavirin
427725|NCT00977054|Plasmapheresis
427726|NCT00977054|Genotype 1
427727|NCT00977041|Neurofeedback
427728|NCT00977028|Tumescent
427729|NCT00977028|Local Anesthesia
427730|NCT00977028|Lidocaine
427731|NCT00977028|Dosage Maximum
427732|NCT00977028|Subcutaneous infiltration
427733|NCT00977028|maximum Safe mg per kg dosage of lidocaine
427734|NCT00977028|Tumescent Local Anesthesia
427735|NCT00977002|noninvasive ventilation
427736|NCT00977002|extubation
427737|NCT00977002|Respiratory failure
427738|NCT00977002|reintubation
427739|NCT00976976|Resected advanced gastric cancer stage IIIB and IV
427740|NCT00976963|UTI
427741|NCT00976924|blood glucose
427742|NCT00976898|proton beam radiation
427743|NCT00976872|omega 3
427744|NCT00976872|inflammation
427745|NCT00976872|augmentation index
427746|NCT00976872|endothelial function
427747|NCT00976859|childhood sexual abuse
427748|NCT00976859|CSA
427749|NCT00976859|posttraumatic stress disorder
427750|NCT00976859|PTSD, feeling of being polluted
427751|NCT00976859|mental pollution, mental contamination
427752|NCT00976859|feeling of being contaminated
427753|NCT00976859|sexual assault
427754|NCT00976859|disgust, shame
427755|NCT00976846|hemodialysis
427756|NCT00976846|on line
427757|NCT00976846|postdilution
427758|NCT00976846|high-flux dialyzer
427759|NCT00976846|hemodiafiltration
427760|NCT00976833|Acute Respiratory Failure
427761|NCT00976833|Early ICU Mobility
427762|NCT00976833|Early Physical Therapy
427763|NCT00976833|Critical Care
427764|NCT00976833|Intensive Care
427765|NCT00976833|ICU
427766|NCT00976820|influenza infection
427767|NCT00976820|Influenza Vaccines
427768|NCT00976820|GSK Bio's influenza vaccine GSK2340273A
427769|NCT00976820|GSK Bio's influenza vaccine GSK2340274A
427770|NCT00976807|critical care
427771|NCT00976807|intensive care
427772|NCT00976807|weakness
427773|NCT00976807|myopathy
427774|NCT00976807|paresis
427775|NCT00976807|rehabilitation
427776|NCT00976794|BD I
427777|NCT00976768|Advanced gastric cancer
427778|NCT00976768|FOLFIRI
427779|NCT00976755|adenocarcinoma of the prostate
427780|NCT00976755|hormone-resistant prostate cancer
427781|NCT00976755|stage III prostate cancer
427782|NCT00976755|stage IV prostate cancer
427783|NCT00976742|plasma lipoprotein lipids
427784|NCT00976742|body composition
427785|NCT00976742|glucose tolerance
427786|NCT00976742|inflammation markers
427787|NCT00976742|insulin sensitivity
427788|NCT00976742|coagulation markers
427789|NCT00976729|monocyte chemoattractant protein-1 (MCP-1)
427790|NCT00976729|L-oligonucleotide aptamer
427791|NCT00976729|Spiegelmer
427792|NCT00976716|posttraumatic pain
427793|NCT00976703|cervical foley catheter
427794|NCT00976690|Crohn's Disease
427795|NCT00976690|Ileocolic resection
427796|NCT00976690|Endoscopic recurrence
427797|NCT00976690|Ileocolic or colon resection (>50cm)
427798|NCT00976651|infertility
427799|NCT00976651|ICSI
427800|NCT00976651|hCG
427801|NCT00976651|infertility treatment
427802|NCT00976638|Antimicrobial Resistant Bacteria
427803|NCT00976638|Hospital acquired infections
427804|NCT00976638|Colonization
427805|NCT00976638|Bacteremia
427806|NCT00976638|MRSA
427807|NCT00976638|VRE
427808|NCT00976638|ESBL
427809|NCT00976638|Intensive Care
427810|NCT00976638|ICU
427811|NCT00976625|diastolic function
427812|NCT00976625|aortic regurgitation
427813|NCT00976625|aortic valve replacement
427814|NCT00976625|left ventricular hypertrophy
427815|NCT00976625|myocardial structure
427816|NCT00976625|LV remodeling
427817|NCT00976625|Muscular regression
427818|NCT00976625|LV fibrous tissue
427819|NCT00976612|Gastrointestinal stromal tumor
427820|NCT00976612|pharmacokinetics
427821|NCT00976612|nilotinib
427822|NCT00976586|Incontinentia pigmenti
427823|NCT00976586|recombination
427824|NCT00976586|IKBKG
427825|NCT00976586|IKBKGP
427826|NCT00976573|Stage IV Skin Melanoma
427827|NCT00976573|recurrent melanoma
427828|NCT00976560|Lack of interest and energy
427829|NCT00976560|Psychomotor retardation
427830|NCT00976560|Cytokines
427831|NCT00976560|Major Depressive disorder
427832|NCT00976547|tinnitus
427833|NCT00976547|depression
427834|NCT00976547|audiometry
427835|NCT00976547|measurement
427836|NCT00976534|Analgesic effect
427837|NCT00976534|Peripheral Neuropathic pain
427838|NCT00976534|Posttraumatic Neuralgia (PTN)
427839|NCT00976534|Postherpetic Neuralgia (PHN)
427840|NCT00976508|advanced solid tumors cancer refractory cancer figitumumab pegvisomant
427841|NCT00976482|Cardiovascular
427842|NCT00976482|Pacemaker
427843|NCT00976482|Mortality
427844|NCT00976482|Physiologic pacing
427845|NCT00976456|lung cancer
427846|NCT00976456|NSCLC
427847|NCT00976456|elderly
427848|NCT00976456|non-squamous
427849|NCT00976456|Elderly patients at least 65 years old
427850|NCT00976456|first line therapy
427851|NCT00976456|non-squamous non-small cell lung cancer stage IIIb or IV
427852|NCT00976443|Obesity
427853|NCT00976443|Gastric Emptying
427854|NCT00976443|Satiation
427855|NCT00976443|Endosonography
427856|NCT00976443|Endoscopy
427857|NCT00976443|Feeding Behavior
427858|NCT00976430|Autologous Stem Cells.
427859|NCT00976404|HIV-1 infection
427860|NCT00976404|Treatment intensification
427861|NCT00976404|Immunomodulation
427862|NCT00976404|HIV-rAd5 vaccine
427863|NCT00976391|open-label
427864|NCT00976391|albiglutide
427865|NCT00976391|insulin glargine
427866|NCT00976391|preprandial insulin
427867|NCT00976378|stromal cell-derived factor-1 (SDF-1)
427868|NCT00976378|L-oligonucleotide aptamer
427869|NCT00976378|Spiegelmer
427870|NCT00976365|Breast Cancer
427871|NCT00976352|Gene Therapy
427872|NCT00976352|Pompe Disease
427873|NCT00976352|Glycogen Storage Disease
427874|NCT00976339|Breast cancer
427875|NCT00976339|Vitamin D
427876|NCT00976339|Premenopausal
427877|NCT00976313|thoracic epidural analgesia
427878|NCT00976313|urinary micturition
427879|NCT00976313|thoracotomy
427880|NCT00976300|SLE
427881|NCT00976300|lupus nephritis
427882|NCT00976300|cyclosporine A
427883|NCT00976300|cyclophosphamide
427884|NCT00976300|active proliferative lupus nephritis (class III or IV according to WHO)
427885|NCT00976287|Stem cells
427886|NCT00976287|Liver cirrhosis
427887|NCT00976287|Radiology
427888|NCT00976287|Interventional
427889|NCT00976287|Transplantation
427890|NCT00976274|Korean red ginseng
427891|NCT00976274|metabolic syndrome
427892|NCT00976274|blood pressure
427893|NCT00976274|arterial stiffness
427894|NCT00976274|inflammation
427895|NCT00976274|oxidative stress
427896|NCT00976261|type 2 diabetes
427897|NCT00976261|single dose
427898|NCT00976261|3-O-methylglucose
427899|NCT00976261|healthy volunteer
427900|NCT00976261|repeat dose
427901|NCT00976248|everolimus
427902|NCT00976248|RAD001
427903|NCT00976248|WM
427904|NCT00976235|Macular Degeneration
427905|NCT00976235|Visual Impairment
427906|NCT00976235|Quality of Life
427907|NCT00976235|Telescope Prosthesis
427908|NCT00976196|Aspirin
427909|NCT00976196|Blood platelets
427910|NCT00976196|proteomics
427911|NCT00976196|Platelet reactivity
427912|NCT00976183|ovarian cancer
427913|NCT00976183|gynecologic oncology
427914|NCT00976183|vorinostat
427915|NCT00976183|treatment
427916|NCT00976170|Advanced or metastatic HCC
427917|NCT00976157|STREM-1
427918|NCT00976157|BAL
427919|NCT00976157|VAP
427920|NCT00976144|safety
427921|NCT00976144|LAMA
427922|NCT00976144|pharmacodynamics
427923|NCT00976144|tolerability
427924|NCT00976144|Muscarinic receptor antagonist,
427925|NCT00976144|anticholinergic,
427926|NCT00976144|beta-2 agonist
427927|NCT00976144|healthy Japanese subjects
427928|NCT00976144|LABA
427929|NCT00976144|Chronic Obstructive Pulmonary Disease (COPD)
427930|NCT00976144|pharmacokinetics
427931|NCT00976131|Breast Cancer
427932|NCT00976131|Early Stage Breast Cancer
427933|NCT00976131|Complementary and Alternative Medicine
427934|NCT00976131|CAM
427935|NCT00976118|Dementia of Alzheimer's type
427936|NCT00976118|mild to moderate Alzheimer's Disease
427937|NCT00976105|Pharmacokinetics
427938|NCT00976105|Pharmacodynamics
427939|NCT00976105|Safety and tolerability
427940|NCT00976105|Repeat dose
427941|NCT00976105|Personality traits
427942|NCT00976105|Fat mass
427943|NCT00976105|Healthy volunteers
427944|NCT00976092|myocardial infarction
427945|NCT00976092|clopidogrel
427946|NCT00976092|prasugrel
427947|NCT00976092|bivalirudin
427948|NCT00976092|primary PCI
427949|NCT00976079|Tibial femoral knee osteoarthritis
427950|NCT00976079|Osteoarthritis
427951|NCT00976066|Obesity
427952|NCT00976066|Naltrexone
427953|NCT00976066|Carfentanil
427954|NCT00976066|Receptor Occupancy
427955|NCT00976066|mu-opioid Receptor
427956|NCT00976066|PET (Positron Emission Tomography)
427957|NCT00976066|BOLD-fMRI
427958|NCT00976053|Myocardial perfusion imaging
427959|NCT00976053|Single photon emission computed tomography
427960|NCT00976053|Positron emission tomography
427961|NCT00976040|HIV-1
427962|NCT00976040|Africa
427963|NCT00976040|Botswana
427964|NCT00976040|Highly active antiretroviral therapy
427965|NCT00976040|treatment naive
427966|NCT00976027|Influenza
427967|NCT00976027|Respiratory Tract Infections
427968|NCT00976027|Influenza-like illness
427969|NCT00976027|Elderly
427970|NCT00976027|Fluzone®
427971|NCT00976027|Efficacy
427972|NCT00976001|Follow-up after stroke
427973|NCT00975988|PMS (post-marketing surveillance)
427974|NCT00975988|TYKERB® tablets
427975|NCT00975975|Paroxysmal nocturnal hemoglobinuria
427976|NCT00975975|severe aplastic anemia
427977|NCT00975975|Mantle cell
427978|NCT00975962|Stroke
427979|NCT00975962|Neuroprotection
427980|NCT00975962|remote preconditioning
427981|NCT00975962|Salvage index (%): Difference in infarct growth (PWI-DWI)
427982|NCT00975949|fluconazole prophylaxis
427983|NCT00975949|fungal colonization
427984|NCT00975949|fungal infection
427985|NCT00975949|preterm infants
427986|NCT00975949|long term outcomes
427987|NCT00975949|quality of life
427988|NCT00975936|Phase 0
427989|NCT00975936|Microdose
427990|NCT00975936|Ketoconazole
427991|NCT00975936|Drug-Drug Interaction
427992|NCT00975923|Quality Improvement
427993|NCT00975923|Critical Care
427994|NCT00975923|Collaboratives
427995|NCT00975923|Patient Safety
427996|NCT00975923|Tool Kit
427997|NCT00975910|Supratentorial Craniotomy
427998|NCT00975897|adenocarcinoma of the colon
427999|NCT00975897|recurrent colon cancer
428000|NCT00975897|stage III colon cancer
428001|NCT00975897|stage IV colon cancer
428002|NCT00975897|adenocarcinoma of the rectum
428003|NCT00975897|recurrent rectal cancer
428004|NCT00975897|stage III rectal cancer
428005|NCT00975897|stage IV rectal cancer
428006|NCT00975884|GSK Bio's influenza vaccine GSK2340272A
428007|NCT00975884|influenza infection
428008|NCT00975884|Influenza vaccine
428009|NCT00975871|Livedo vasculitis
428010|NCT00975871|Genetic pleomorphism
428011|NCT00975858|Symptomatic Coronary Artery Disease Patients
428012|NCT00975845|ACL
428013|NCT00975845|Anterior Cruciate Ligament
428014|NCT00975845|Torn tendon
428015|NCT00975845|ACL Repair
428016|NCT00975845|ACL reconstruction
428017|NCT00975832|The independent effect of PCOS and obesity on adipose expression and plasma levels of adipocytokines
428018|NCT00975793|Sepsis
428019|NCT00975793|Severe sepsis
428020|NCT00975793|Septic shock
428021|NCT00975780|Pneumonia
428022|NCT00975780|Lower respiratory tract infection
428023|NCT00975780|Lower respiratory tract infection other than pneumonia
428024|NCT00975754|Inhalation
428025|NCT00975754|lung deposition
428026|NCT00975741|Asthma
428027|NCT00975741|Mometasone furoate
428028|NCT00975741|Inhalation devices
428029|NCT00975741|Forced expiratory volume
428030|NCT00975728|Anti-oxidant
428031|NCT00975728|Açai
428032|NCT00975728|Food supplement
428033|NCT00975728|Sun protection
428034|NCT00975728|Skin erythema prevention
428035|NCT00975728|Anti-oxidant efficacy
428036|NCT00975728|Anti-age efficacy
428037|NCT00975728|Skin photo-induced damage protection
428038|NCT00975715|Seizures
428039|NCT00975715|oxcarbazepine
428040|NCT00975715|child
428041|NCT00975702|Remote ischemic preconditioning
428042|NCT00975702|deceased organ donors
428043|NCT00975702|ischemia reperfusion injury
428044|NCT00975702|Delayed graft function
428045|NCT00975702|Clinical outcomes in kidney transplant recipients
428046|NCT00975702|Clinical outcomes in liver transplant recipients
428047|NCT00975702|Clinical outcomes in pancreas transplant recipients
428048|NCT00975689|Niemann-Pick Disease, Type C
428049|NCT00975689|Biomarkers
428050|NCT00975689|N-Acetyl Cysteine
428051|NCT00975689|Oxidized Cholesterol
428052|NCT00975689|Neurodegeneration
428053|NCT00975689|NPC
428054|NCT00975676|estrogen receptor-positive breast cancer
428055|NCT00975676|progesterone receptor-positive breast cancer
428056|NCT00975676|stage IA breast cancer
428057|NCT00975676|stage IB breast cancer
428058|NCT00975676|stage II breast cancer
428059|NCT00975676|stage IIIA breast cancer
428060|NCT00975663|Lung transplantation
428061|NCT00975663|heart-lung transplantation
428062|NCT00975663|therapeutic drug monitoring
428063|NCT00975663|tacrolimus
428064|NCT00975663|mycophenolate
428065|NCT00975663|immunosuppressant
428066|NCT00975663|pharmacokinetics
428067|NCT00975650|Primary Hypogonadism
428068|NCT00975650|Secondary Hypogonadism
428069|NCT00975611|schizophrenia
428070|NCT00975611|schizoaffective disorder
428071|NCT00975611|paliperidone ER
428072|NCT00975611|risperidone Consta
428073|NCT00975611|prolactin
428074|NCT00975611|hyperprolactinemia
428075|NCT00975572|Flu
428076|NCT00975572|adjuvanted H1N1 vaccine
428077|NCT00975572|non-adjuvanted H1N1 vaccine
428078|NCT00975572|Immunogenictiy
428079|NCT00975572|Safety
428080|NCT00975546|fertility
428081|NCT00975546|HIV discordant
428082|NCT00975546|HIV
428083|NCT00975546|Infertility in HIV-discordant couples
428084|NCT00975546|HIV seronegativity
428085|NCT00975533|type 2 diabetes mellitus
428086|NCT00975533|obesity
428087|NCT00975520|Neurotropic
428088|NCT00975520|Melanoma
428089|NCT00975520|Observation
428090|NCT00975520|Radiation Therapy
428091|NCT00975520|Relapse
428092|NCT00975494|pde5-inhibition
428093|NCT00975494|sildenafil
428094|NCT00975494|LV diastolic function
428095|NCT00975494|heart failure patients
428096|NCT00975481|oral single-dose 6-way crossover recreational drug users abuse potential pharmacodynamics safety
428097|NCT00975468|pressure-controlled
428098|NCT00975468|volume-controlled
428099|NCT00975468|one lung
428100|NCT00975468|ventilation
428101|NCT00975468|lung injury
428102|NCT00975468|thoracotomy
428103|NCT00975442|Elbow
428104|NCT00975442|Tendinitis
428105|NCT00975442|Sports Medicine
428106|NCT00975442|Athletic injuries
428107|NCT00975429|Prostatic Disease
428108|NCT00975429|Genital neoplasm, male
428109|NCT00975429|Urogenital neoplasm
428110|NCT00975429|Genital disease,male
428111|NCT00975429|Male urogenital disease
428112|NCT00975429|Neoplasms
428113|NCT00975429|Neoplasm by site
428114|NCT00975429|Prostatic neoplasm
428115|NCT00975429|Carcinoma
428116|NCT00975416|Drug Dependence
428117|NCT00975416|Cognitive Behavior
428118|NCT00975416|Oxytocin
428119|NCT00975416|Cocaine
428120|NCT00975416|Heroin
428121|NCT00975416|fMRI
428122|NCT00975403|mild COPD
428123|NCT00975403|dyspnea
428124|NCT00975403|exercise
428125|NCT00975403|respiratory mechanics
428126|NCT00975403|COPD
428127|NCT00975390|Glycogen
428128|NCT00975390|Carbohydrate
428129|NCT00975390|Protein
428130|NCT00975390|Caffeine
428131|NCT00975390|Post exercise muscle glycogen synthesis
428132|NCT00975390|Sports nutrition
428133|NCT00975377|hair removal
428134|NCT00975377|hair clipping
428135|NCT00975377|surgical site infection
428136|NCT00975377|incisional infection
428137|NCT00975377|wound infection
428138|NCT00975364|Folate
428139|NCT00975364|Methylenetetrahydrofolate reductase
428140|NCT00975364|Speciation
428141|NCT00975364|Nutrient status
428142|NCT00975364|Bioavailability
428143|NCT00975364|Polymorphism, single nucleotide
428144|NCT00975351|folates
428145|NCT00975351|5-methyltetrahydrofolic acid
428146|NCT00975351|pharmacokinetics
428147|NCT00975351|bioavailability
428148|NCT00975351|biotransformation
428149|NCT00975338|health care transition, young adults, rehabilitation
428150|NCT00975325|Bioequivalency
428151|NCT00975312|lentigo
428152|NCT00975312|hydroquinone
428153|NCT00975312|tretinoin
428154|NCT00975312|fluocinolone acetonide
428155|NCT00975299|Neoplasm
428156|NCT00975299|PET/CT diagnosis
428157|NCT00975299|PET tracer
428158|NCT00975273|Asthma
428159|NCT00975273|Dyspnea
428160|NCT00975273|Paroxysmal
428161|NCT00975273|Pulmonary
428162|NCT00975273|Respiratory hypersensitivity
428163|NCT00975273|Airway inflammation
428164|NCT00975273|Airway obstruction
428165|NCT00975273|Wheezing
428166|NCT00975247|Quality Improvement
428167|NCT00975247|Colonoscopy
428168|NCT00975247|Screening
428169|NCT00975247|Colon Cancer
428170|NCT00975247|Polyp detection rates
428171|NCT00975247|Colonoscopy completion rates
428172|NCT00975247|Scope Withdrawal time
428173|NCT00975247|Reduce costs through improving bowel prep quality
428174|NCT00975234|Intra-lesion injection of autologous myoblasts
428175|NCT00975221|Primary hyperparathyroidism
428176|NCT00975221|Parathyroidectomy
428177|NCT00975221|Hypercalcemia
428178|NCT00975208|Osteogenesis [G07.700.320.500.325.377.625.100.729]
428179|NCT00975208|Tooth Eruption [G10.549.235.726]
428180|NCT00975182|PI3K
428181|NCT00975182|NSCLC
428182|NCT00975182|Tarceva
428183|NCT00975143|isotretinoin
428184|NCT00975143|dermatology
428185|NCT00975143|skin
428186|NCT00975117|Dietary supplement
428187|NCT00975117|male infertility
428188|NCT00975117|spermatogenesis
428189|NCT00975104|Aging
428190|NCT00975104|Frailty
428191|NCT00975104|Sedentary
428192|NCT00975104|Immobilization
428193|NCT00975104|Atrophy
428194|NCT00975104|Muscle Wasting
428195|NCT00975104|Physical Activity
428196|NCT00975078|dexamethasone-suppression-test
428197|NCT00975078|high dose glucocorticoid treatment
428198|NCT00975078|Population at Risk
428199|NCT00975065|Galvus
428200|NCT00975039|Inoperable
428201|NCT00975039|Inoperable Cholangiocarcinoma
428202|NCT00975039|Non-resectable
428203|NCT00975039|Non-resectable Cholangiocarcinoma
428204|NCT00975039|Carcinoma
428205|NCT00975026|Massage
428206|NCT00975026|Chair Massage
428207|NCT00975026|Pain
428208|NCT00975026|Discomfort
428209|NCT00975026|Stretching
428210|NCT00975026|Stretching Exercises
428211|NCT00975026|Sonographer
428212|NCT00975026|Cardiac Sonographer
428213|NCT00975013|Laparoscopic Gastric Bypass
428214|NCT00975013|Morbid Obesity
428215|NCT00975013|Bone Mineral Density
428216|NCT00975000|Intervention
428217|NCT00975000|Cinacalcet
428218|NCT00975000|Sensipar
428219|NCT00975000|Mimpara
428220|NCT00975000|hyperparathyroidism
428221|NCT00975000|calcium
428222|NCT00975000|osteodystrophy
428223|NCT00975000|hypercalcemia
428224|NCT00975000|renal
428225|NCT00975000|transplant
428226|NCT00975000|acute rejection
428227|NCT00975000|kidney transplant failure
428228|NCT00975000|hypophosphatemia
428229|NCT00974987|adult giant cell glioblastoma
428230|NCT00974987|adult glioblastoma
428231|NCT00974987|adult gliosarcoma
428232|NCT00974974|Parkinson's Disease
428233|NCT00974961|Levobupivacaine
428234|NCT00974961|HRV
428235|NCT00974961|Spinal Anesthesia
428236|NCT00974961|Responses of ANS to these two drugs
428237|NCT00974948|Pancreatic cancer
428238|NCT00974948|Therapy
428239|NCT00974948|Neurolysis
428240|NCT00974935|Staphylococcal enterotoxin B, vaccine, Staphylococcus aureus, toxic shock syndrome
428241|NCT00974922|Vitamin D
428242|NCT00974922|Hypertension
428243|NCT00974909|Fecal incontinence
428244|NCT00974896|Advanced Solid Tumors
428245|NCT00974896|AMG 479
428246|NCT00974896|Amgen
428247|NCT00974896|Oncology
428248|NCT00974896|Phase 1b
428249|NCT00974883|ultrasound
428250|NCT00974883|GCA
428251|NCT00974883|temporal arteritis
428252|NCT00974883|biopsy
428253|NCT00974857|Hemodialysis
428254|NCT00974857|Left Ventricular Hypertrophy
428255|NCT00974857|Body Composition Monitor
428256|NCT00974844|posterior assisted levitation
428257|NCT00974844|Pars Plana
428258|NCT00974844|Dropped nucleus
428259|NCT00974844|cataract
428260|NCT00974844|complication of
428261|NCT00974844|surgery
428262|NCT00974818|Bladder
428263|NCT00974818|Mitomycin C
428264|NCT00974818|MMC
428265|NCT00974818|TheracysR Bacillus Calmette-Guerin
428266|NCT00974818|BCG
428267|NCT00974818|intravesical
428268|NCT00974818|09-118
428269|NCT00974805|COPD
428270|NCT00974805|Emphysema
428271|NCT00974805|Bronchitis
428272|NCT00974792|stage III adult diffuse large cell lymphoma
428273|NCT00974792|stage IV adult diffuse large cell lymphoma
428274|NCT00974779|kidney failure chronic
428275|NCT00974779|renal dialysis
428276|NCT00974779|inflammation
428277|NCT00974779|monocytes
428278|NCT00974779|end stage renal disease on regular thrice weekly hemodialysis
428279|NCT00974766|bronchial asthma
428280|NCT00974766|allergic bronchopulmonary aspergillosis
428281|NCT00974753|epiretinal membrane
428282|NCT00974740|type 1 diabetes
428283|NCT00974727|Childhood overweight
428284|NCT00974727|Gardening
428285|NCT00974727|Summer weight gain
428286|NCT00974714|chronic hypertension in pregnancy
428287|NCT00974701|symptoms of acute overt upper gastrointestinal hemorrhage
428288|NCT00974688|Congenital
428289|NCT00974688|physical activity participation
428290|NCT00974688|Moderate-to-vigorous physical activity
428291|NCT00974662|Non-Small Cell Lung Cancer
428292|NCT00974662|Lung Cancer
428293|NCT00974662|NSCLC
428294|NCT00974649|drop-out
428295|NCT00974649|predictors of treatment continuation/discontinuation
428296|NCT00974649|IVF/ICSI
428297|NCT00974649|infertility
428298|NCT00974649|counseling
428299|NCT00974649|psychology
428300|NCT00974649|Assisted Reproduction
428301|NCT00974649|Counselling
428302|NCT00974636|Kidney Disease
428303|NCT00974636|Albuminuria
428304|NCT00974636|Glomerular filtration rate
428305|NCT00974636|Volume status
428306|NCT00974636|Bioimpedance analysis
428307|NCT00974623|Bone growth substitute
428308|NCT00974623|Autograft
428309|NCT00974623|Allograft
428310|NCT00974623|Spine fusion
428311|NCT00974610|stage IV melanoma
428312|NCT00974610|recurrent melanoma
428313|NCT00974610|stage IV non-small cell lung cancer
428314|NCT00974610|recurrent non-small cell lung cancer
428315|NCT00974610|extensive stage small cell lung cancer
428316|NCT00974610|recurrent small cell lung cancer
428317|NCT00974610|stage IV breast cancer
428318|NCT00974610|recurrent breast cancer
428319|NCT00974610|male breast cancer
428320|NCT00974610|stage III pancreatic cancer
428321|NCT00974610|stage IV pancreatic cancer
428322|NCT00974610|recurrent pancreatic cancer
428323|NCT00974610|stage IV colon cancer
428324|NCT00974610|recurrent colon cancer
428325|NCT00974610|stage IV rectal cancer
428326|NCT00974610|recurrent rectal cancer
428327|NCT00974597|burn
428328|NCT00974597|donor site
428329|NCT00974597|treatment of burns
428330|NCT00974597|Treatment of Donor Sites
428331|NCT00974584|NSCLC
428332|NCT00974584|PI3K
428333|NCT00974584|Avastin
428334|NCT00974558|dyspnea
428335|NCT00974558|fan
428336|NCT00974532|balance
428337|NCT00974532|chronic kidney disease
428338|NCT00974532|calcium
428339|NCT00974532|phosphorus
428340|NCT00974519|ADIS
428341|NCT00974519|complementary therapies
428342|NCT00974506|geriatric patients living in residential community (shared flats), multiple disease-conditions
428343|NCT00974493|oral
428344|NCT00974493|intravenous
428345|NCT00974493|antibiotics
428346|NCT00974493|bone
428347|NCT00974493|joint
428348|NCT00974493|infection
428349|NCT00974480|Skin
428350|NCT00974480|Aging
428351|NCT00974480|Rejuva-a
428352|NCT00974480|Redermic
428353|NCT00974454|AIDS
428354|NCT00974454|complementary therapies
428355|NCT00974454|treatment experienced
428356|NCT00974441|Bioequivalence
428357|NCT00974428|Osteoarthritis
428358|NCT00974428|Disease of joints
428359|NCT00974428|Wobenzym® N
428360|NCT00974428|WOMAC pain score
428361|NCT00974428|Subject reported pain (VAS)
428362|NCT00974415|BMI classification-overweight
428363|NCT00974402|Active duty
428364|NCT00974402|Afghanistan
428365|NCT00974402|Anger
428366|NCT00974402|Anxiety
428367|NCT00974402|Avoidance
428368|NCT00974402|BAMC
428369|NCT00974402|Brooke Army Medical Center
428370|NCT00974402|Cognitive Behavioral Therapy
428371|NCT00974402|Combat
428372|NCT00974402|Combat Disorder
428373|NCT00974402|Coping
428374|NCT00974402|Counseling
428375|NCT00974402|Counselor
428376|NCT00974402|Deployment
428377|NCT00974402|Depression
428378|NCT00974402|Exposure
428379|NCT00974402|Fear
428380|NCT00974402|Feeling alone
428381|NCT00974402|Flashbacks
428382|NCT00974402|Guard
428383|NCT00974402|Guilt
428384|NCT00974402|Hospitalization
428385|NCT00974402|Iraq
428386|NCT00974402|Mental Health
428387|NCT00974402|Military
428388|NCT00974402|Military member
428389|NCT00974402|Military personnel
428390|NCT00974402|Neuroses
428391|NCT00974402|Nightmares
428392|NCT00974402|OEF
428393|NCT00974402|OIF
428394|NCT00974402|Prolonged Exposure Therapy
428395|NCT00974402|Psychiatric
428396|NCT00974402|Psychiatric medication
428397|NCT00974402|Psychological distress
428398|NCT00974402|Psychotherapy
428399|NCT00974402|Reserve
428400|NCT00974402|Retired
428401|NCT00974402|Sadness
428402|NCT00974402|Separated
428403|NCT00974402|Sleeplessness
428404|NCT00974402|Soldier
428405|NCT00974402|Stress
428406|NCT00974402|Stress disorder
428407|NCT00974402|Stress management
428408|NCT00974402|STRONG STAR
428409|NCT00974402|Suicidal
428410|NCT00974402|Suicide
428411|NCT00974402|Therapy
428412|NCT00974402|Trauma
428413|NCT00974402|Traumatic Event
428414|NCT00974402|Trouble Sleeping
428415|NCT00974402|Veteran
428416|NCT00974402|Veterans
428417|NCT00974402|War
428418|NCT00974402|WHMC
428419|NCT00974402|Wilford Hall Medical Center
428420|NCT00974402|PTSD
428421|NCT00974402|Posttraumatic Stress Disorders
428422|NCT00974389|stage III colon cancer
428423|NCT00974389|stage III rectal cancer
428424|NCT00974389|stage IV colon cancer
428425|NCT00974389|stage IV rectal cancer
428426|NCT00974389|recurrent colon cancer
428427|NCT00974389|recurrent rectal cancer
428428|NCT00974376|Cannabis Treatment
428429|NCT00974376|Cannabis Use
428430|NCT00974376|Cannabis Dependence
428431|NCT00974376|Executive Functioning
428432|NCT00974376|Cognitive Deficits
428433|NCT00974363|meningococcal vaccine GSK 134612
428434|NCT00974350|Post-operative pain
428435|NCT00974350|hernia surgery
428436|NCT00974350|opioid
428437|NCT00974337|Adrenal insufficiency
428438|NCT00974337|cortisol
428439|NCT00974337|preterm
428440|NCT00974337|shock
428441|NCT00974337|neonate
428442|NCT00974324|peripheral T cell lymphoma
428443|NCT00974324|chemotherapy
428444|NCT00974324|anti-angiogeneses
428445|NCT00974311|MDV3100
428446|NCT00974311|Prostate Cancer
428447|NCT00974311|Castration-resistant
428448|NCT00974285|AIDS
428449|NCT00974285|complementary therapies
428450|NCT00974259|Hypoxia
428451|NCT00974259|Ischemia
428452|NCT00974259|Intracranial hypertension
428453|NCT00974259|Neurocritical care
428454|NCT00974246|COPD
428455|NCT00974246|Depression
428456|NCT00974246|Nursing Home
428457|NCT00974233|CLL
428458|NCT00974233|SLL
428459|NCT00974220|inhaled fentanyl
428460|NCT00974220|dyspnea
428461|NCT00974220|exercise
428462|NCT00974220|COPD
428463|NCT00974194|Cholecystolithiasis
428464|NCT00974194|Cholecystectomy
428465|NCT00974194|Laparoscopic surgery
428466|NCT00974194|Single port
428467|NCT00974168|pain
428468|NCT00974168|radiation toxicity
428469|NCT00974168|spinal cord compression
428470|NCT00974168|unspecified adult solid tumor, protocol specific
428471|NCT00974155|Major
428472|NCT00974155|Depression
428473|NCT00974155|Disorder
428474|NCT00974142|COPD
428475|NCT00974142|Chronic Obstructive Pulmonary Disease
428476|NCT00974142|Cyclosporine
428477|NCT00974142|Oral Immunotherapy
428478|NCT00974142|Advanced stage
428479|NCT00974103|low back pain
428480|NCT00974103|pelvic pain
428481|NCT00974103|pelvic girdle pain
428482|NCT00974103|post partum
428483|NCT00974090|insulin resistance
428484|NCT00974077|recurrent depression,
428485|NCT00974077|mindfulness training
428486|NCT00974077|attention
428487|NCT00974077|Evoked EEG potentials
428488|NCT00974077|Relapse prevention in recurrent depression
428489|NCT00974064|COPD
428490|NCT00974064|Lung disease
428491|NCT00974064|Chronic bronchitis
428492|NCT00974064|Emphysema
428493|NCT00974064|Smoking
428494|NCT00974064|Smoking cessation
428495|NCT00974064|Quit smoking
428496|NCT00974064|Healthy smoker
428497|NCT00974064|Smoker
428498|NCT00974064|Non-smoker
428499|NCT00974051|Children
428500|NCT00974051|Exercise
428501|NCT00974051|Hypoglycemia
428502|NCT00974038|Bulimia Nervosa, EDNOS, Adolescents
428503|NCT00974012|Bioequivalence
428504|NCT00973999|Botulinum Toxin
428505|NCT00973999|Saliva
428506|NCT00973999|Tracheostomy tube
428507|NCT00973986|atorvastatin
428508|NCT00973986|genetic polymorphisms
428509|NCT00973986|coronary heart disease
428510|NCT00973986|pharmacokinetics
428511|NCT00973986|CYP3A
428512|NCT00973973|Pelvic Pain
428513|NCT00973973|NBI-56418
428514|NCT00973973|Endometriosis
428515|NCT00973947|stage I squamous cell carcinoma of the hypopharynx
428516|NCT00973947|stage II squamous cell carcinoma of the hypopharynx
428517|NCT00973947|stage III squamous cell carcinoma of the hypopharynx
428518|NCT00973947|stage IV squamous cell carcinoma of the hypopharynx
428519|NCT00973947|stage I squamous cell carcinoma of the larynx
428520|NCT00973947|stage I verrucous carcinoma of the larynx
428521|NCT00973947|stage II squamous cell carcinoma of the larynx
428522|NCT00973947|stage II verrucous carcinoma of the larynx
428523|NCT00973947|stage III squamous cell carcinoma of the larynx
428524|NCT00973947|stage III verrucous carcinoma of the larynx
428525|NCT00973947|stage IV squamous cell carcinoma of the larynx
428526|NCT00973947|stage IV verrucous carcinoma of the larynx
428527|NCT00973947|stage I adenoid cystic carcinoma of the oral cavity
428528|NCT00973947|stage I mucoepidermoid carcinoma of the oral cavity
428529|NCT00973947|stage I verrucous carcinoma of the oral cavity
428530|NCT00973947|stage II adenoid cystic carcinoma of the oral cavity
428531|NCT00973947|stage II mucoepidermoid carcinoma of the oral cavity
428532|NCT00973947|stage II verrucous carcinoma of the oral cavity
428533|NCT00973947|stage III adenoid cystic carcinoma of the oral cavity
428534|NCT00973947|stage III mucoepidermoid carcinoma of the oral cavity
428535|NCT00973947|stage III verrucous carcinoma of the oral cavity
428536|NCT00973947|stage IV adenoid cystic carcinoma of the oral cavity
428537|NCT00973947|stage IV mucoepidermoid carcinoma of the oral cavity
428538|NCT00973947|stage IV verrucous carcinoma of the oral cavity
428539|NCT00973947|stage I squamous cell carcinoma of the lip and oral cavity
428540|NCT00973947|stage II squamous cell carcinoma of the lip and oral cavity
428541|NCT00973947|stage III squamous cell carcinoma of the lip and oral cavity
428542|NCT00973947|stage IV squamous cell carcinoma of the lip and oral cavity
428543|NCT00973947|stage I basal cell carcinoma of the lip
428544|NCT00973947|stage II basal cell carcinoma of the lip
428545|NCT00973947|stage III basal cell carcinoma of the lip
428546|NCT00973947|stage IV basal cell carcinoma of the lip
428547|NCT00973947|metastatic squamous neck cancer with occult primary squamous cell carcinoma
428548|NCT00973947|untreated metastatic squamous neck cancer with occult primary
428549|NCT00973947|stage I lymphoepithelioma of the nasopharynx
428550|NCT00973947|stage I squamous cell carcinoma of the nasopharynx
428551|NCT00973947|stage II lymphoepithelioma of the nasopharynx
428552|NCT00973947|stage II squamous cell carcinoma of the nasopharynx
428553|NCT00973947|stage III lymphoepithelioma of the nasopharynx
428554|NCT00973947|stage III squamous cell carcinoma of the nasopharynx
428555|NCT00973947|stage IV lymphoepithelioma of the nasopharynx
428556|NCT00973947|stage IV squamous cell carcinoma of the nasopharynx
428557|NCT00973947|stage I lymphoepithelioma of the oropharynx
428558|NCT00973947|stage I squamous cell carcinoma of the oropharynx
428559|NCT00973947|stage II lymphoepithelioma of the oropharynx
428560|NCT00973947|stage II squamous cell carcinoma of the oropharynx
428561|NCT00973947|stage III lymphoepithelioma of the oropharynx
428562|NCT00973947|stage III squamous cell carcinoma of the oropharynx
428563|NCT00973947|stage IV lymphoepithelioma of the oropharynx
428564|NCT00973947|stage IV squamous cell carcinoma of the oropharynx
428565|NCT00973947|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
428566|NCT00973947|stage I inverted papilloma of the paranasal sinus and nasal cavity
428567|NCT00973947|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
428568|NCT00973947|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
428569|NCT00973947|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
428570|NCT00973947|stage II inverted papilloma of the paranasal sinus and nasal cavity
428571|NCT00973947|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
428572|NCT00973947|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
428573|NCT00973947|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
428574|NCT00973947|stage III inverted papilloma of the paranasal sinus and nasal cavity
428575|NCT00973947|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
428576|NCT00973947|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
428577|NCT00973947|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
428578|NCT00973947|stage IV inverted papilloma of the paranasal sinus and nasal cavity
428579|NCT00973947|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
428580|NCT00973947|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
428581|NCT00973947|stage I salivary gland cancer
428582|NCT00973947|stage II salivary gland cancer
428583|NCT00973947|stage III salivary gland cancer
428584|NCT00973947|stage IV salivary gland cancer
428585|NCT00973947|recurrent lymphoepithelioma of the nasopharynx
428586|NCT00973947|recurrent lymphoepithelioma of the oropharynx
428587|NCT00973947|recurrent squamous cell carcinoma of the hypopharynx
428588|NCT00973947|recurrent squamous cell carcinoma of the nasopharynx
428589|NCT00973947|recurrent squamous cell carcinoma of the oropharynx
428590|NCT00973947|recurrent squamous cell carcinoma of the larynx
428591|NCT00973947|recurrent verrucous carcinoma of the larynx
428592|NCT00973947|recurrent squamous cell carcinoma of the lip and oral cavity
428593|NCT00973947|recurrent basal cell carcinoma of the lip
428594|NCT00973947|recurrent adenoid cystic carcinoma of the oral cavity
428595|NCT00973947|recurrent mucoepidermoid carcinoma of the oral cavity
428596|NCT00973947|recurrent verrucous carcinoma of the oral cavity
428597|NCT00973947|recurrent metastatic squamous neck cancer with occult primary
428598|NCT00973947|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
428599|NCT00973947|recurrent inverted papilloma of the paranasal sinus and nasal cavity
428600|NCT00973947|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
428601|NCT00973947|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
428602|NCT00973947|recurrent salivary gland cancer
428603|NCT00973921|Stent
428604|NCT00973921|under-expansion
428605|NCT00973921|StentOp
428606|NCT00973921|StentOptimizer
428607|NCT00973921|IVUS
428608|NCT00973921|IC-PRO
428609|NCT00973921|image enhancement
428610|NCT00973908|Clostridium difficile associated diarrhoea
428611|NCT00973908|antibiotic associated diarrhoea
428612|NCT00973895|Influenza
428613|NCT00973895|Healthy
428614|NCT00973895|Immunity
428615|NCT00973895|Preventive
428616|NCT00973895|Pandemic
428617|NCT00973882|Hormone resistant prostate cancer
428618|NCT00973882|Neuro-endocrine marker
428619|NCT00973882|Carboplatin-Etoposide combination
428620|NCT00973882|Neuro-endocrine differentiation
428621|NCT00973869|colon cancer
428622|NCT00973869|rectal cancer
428623|NCT00973830|Changes in HbA1c
428624|NCT00973817|Hepatitis
428625|NCT00973817|AOCH
428626|NCT00973804|Reduced Intensity Conditioning
428627|NCT00973804|Umbilical Cord Blood Transplant
428628|NCT00973804|Targeted Immune Depletion
428629|NCT00973804|Leukemia
428630|NCT00973804|Lymphoma
428631|NCT00973804|Multiple Myeloma
428632|NCT00973804|Non-Hodgkins Lymphoma
428633|NCT00973804|Hodgkins Lymphoma
428634|NCT00973791|Spinal anesthesia
428635|NCT00973791|Fluid therapy
428636|NCT00973778|Intensity Modulated Radiation Therapy
428637|NCT00973778|Capecitabine
428638|NCT00973778|Resectable Rectal Carcinoma
428639|NCT00973765|abcess
428640|NCT00973765|MRSA
428641|NCT00973765|cellulitis
428642|NCT00973765|antibiotics
428643|NCT00973765|uncomplicated abscesses
428644|NCT00973752|ALL
428645|NCT00973739|NF-2
428646|NCT00973739|NF-2 related tumors
428647|NCT00973739|Schwannoma, Acoustic, Bilateral
428648|NCT00973739|schwannomas
428649|NCT00973739|Neurilemmoma of other cranial and peripheral nerves
428650|NCT00973739|NF2 related benign intracranial tumors including
428651|NCT00973739|NF2 related meningiomas
428652|NCT00973739|NF2 related ependymomas
428653|NCT00973739|NF2 related spinal neurofibromas
428654|NCT00973739|NF2 related gliomas
428655|NCT00973713|Advanced cholangiocarcinoma
428656|NCT00973700|Swine Flu
428657|NCT00973700|Flu
428658|NCT00973700|Vaccine
428659|NCT00973700|Adjuvant
428660|NCT00973687|pediatric
428661|NCT00973687|dexamethasone
428662|NCT00973687|management
428663|NCT00973687|corticosteroids
428664|NCT00973687|asthma
428665|NCT00973661|Overweight
428666|NCT00973661|Diagnosis
428667|NCT00973661|Counseling
428668|NCT00973661|Medical Records Systems, Computerized
428669|NCT00973648|Tinnitus
428670|NCT00973648|Ringing in ears
428671|NCT00973648|Functional connectivity MRI
428672|NCT00973648|Voluntary control of tinnitus
428673|NCT00973635|education
428674|NCT00973635|web-based intervention
428675|NCT00973635|patient care
428676|NCT00973622|Tobacco cessation
428677|NCT00973622|Tobacco dependence
428678|NCT00973622|Transcranial Magnetic Stimulation
428679|NCT00973622|Nicotine Dependence
428680|NCT00973622|Delayed Discounting
428681|NCT00973609|metastatic colorectal cancer
428682|NCT00973609|Bevacizumab
428683|NCT00973609|Avastin®
428684|NCT00973609|phase 3
428685|NCT00973609|maintenance treatment
428686|NCT00973609|treatment pause
428687|NCT00973609|drug holiday
428688|NCT00973609|stage IV
428689|NCT00973583|vitamin D
428690|NCT00973583|infection
428691|NCT00973583|Vitamin D for the prevention of respiratory tract infections
428692|NCT00973570|tobacco cessation
428693|NCT00973570|evaluation
428694|NCT00973570|epidémiology
428695|NCT00973570|adolescent
428696|NCT00973570|apprentices
428697|NCT00973557|bevacizumab
428698|NCT00973544|breast reconstruction complications
428699|NCT00973544|drains
428700|NCT00973544|silicone implant
428701|NCT00973531|Sleep Disordered Breathing
428702|NCT00973531|Sleep Apnea
428703|NCT00973531|Hypertension
428704|NCT00973531|Continuous Positive Airway Pressure
428705|NCT00973518|Alzheimer's Disease
428706|NCT00973518|AD
428707|NCT00973518|Healthy Control
428708|NCT00973505|Breast neoplasms
428709|NCT00973505|Aromatase inhibitors
428710|NCT00973505|Genetic polymorphisms
428711|NCT00973505|Arthralgia
428712|NCT00973505|Arthritis
428713|NCT00973492|type 1 diabetes
428714|NCT00973492|functional insulinotherapy
428715|NCT00973479|Arthritis, Rheumatoid
428716|NCT00973479|Active rheumatoid arthritis
428717|NCT00973479|Golimumab
428718|NCT00973479|CNTO148
428719|NCT00973479|Anti-TNFalpha monoclonal antibody
428720|NCT00973479|Methotrexate
428721|NCT00973479|Intravenous
428722|NCT00973466|HIV-infection
428723|NCT00973466|Neisseria gonorrhea
428724|NCT00973466|Chlamydia trachomatis
428725|NCT00973466|Herpes simplex virus
428726|NCT00973466|prevalence
428727|NCT00973453|non-seasonal allergy
428728|NCT00973453|house dust mite
428729|NCT00973453|immunotherapy
428730|NCT00973453|dose tolerability
428731|NCT00973440|geriatric assessment
428732|NCT00973427|NSCLC
428733|NCT00973414|Combined epidural spinal anesthesia
428734|NCT00973414|Fluid therapy
428735|NCT00973388|VX-950-TiDP24-C136
428736|NCT00973388|VX-950-C136
428737|NCT00973388|VX-950
428738|NCT00973388|HEPATITIS
428739|NCT00973388|Telaprevir
428740|NCT00973388|Moxifloxacin
428741|NCT00973388|ECG
428742|NCT00973388|QT
428743|NCT00973388|QTc
428744|NCT00973375|Drug-eluting stent
428745|NCT00973375|coronary restenosis
428746|NCT00973375|coronary thrombosis
428747|NCT00973362|Cervix Cancer
428748|NCT00973362|Cervical Intraepithelial Neoplasia (CIN)
428749|NCT00973362|Human Papillomavirus Virus (HPV)
428750|NCT00973362|APTIMA HPV Assay
428751|NCT00973362|FDA-Approved HPV DNA Test
428752|NCT00973362|TIGRIS DTS (direct tube sampling) System
428753|NCT00973362|Clinical Sensitivity (%)
428754|NCT00973362|Clinical Specificity (%)
428755|NCT00973362|Positive Predictive Value [PPV] (%)
428756|NCT00973362|Negative Predictive Value [NPV] (%)
428757|NCT00973362|Atypical Squamous Cells Undetermined Significance (ASC-US)
428758|NCT00973362|Relative Risk
428759|NCT00973349|Swine Flu
428760|NCT00973349|Flu
428761|NCT00973349|Vaccine
428762|NCT00973349|Adults
428763|NCT00973349|Elderly
428764|NCT00973349|Non-Elderly
428765|NCT00973349|Adjuvant
428766|NCT00973336|postoperative follow-up
428767|NCT00973323|BAY59-7939
428768|NCT00973323|Rivaroxaban
428769|NCT00973323|Non-valvular atrial fibrillation
428770|NCT00973323|Japanese Patients
428771|NCT00973323|Phase II
428772|NCT00973310|Non-small-cell lung cancer
428773|NCT00973310|Radiation therapy
428774|NCT00973310|Epidermal growth factor receptor
428775|NCT00973310|Tyrosine kinase inhibitor
428776|NCT00973297|Falls
428777|NCT00973284|Prevention of acute gastroenteritis due to infection with and experimental Norwalk Virus
428778|NCT00973271|hypertriglyceridemia
428779|NCT00973245|BAY59-7939
428780|NCT00973245|Rivaroxaban
428781|NCT00973245|Non-valvular atrial fibrillation
428782|NCT00973245|Japanese Patients
428783|NCT00973245|Phase II
428784|NCT00973232|Tramadol
428785|NCT00973232|Acetaminophen
428786|NCT00973232|combination
428787|NCT00973232|pharmacokinetics
428788|NCT00973232|bioavailability
428789|NCT00973232|Zaldiar
428790|NCT00973232|Ultracet
428791|NCT00973232|fed
428792|NCT00973232|fasted
428793|NCT00973232|single-dose
428794|NCT00973232|multiple-dose
428795|NCT00973232|healthy
428796|NCT00973232|volunteers
428797|NCT00973232|Healthy volunteers
428798|NCT00973219|HBsAg loss
428799|NCT00973219|HBsAg seroconversion
428800|NCT00973219|chronic hepatitis B
428801|NCT00973219|low viral load
428802|NCT00973219|inactive carrier hepatitis B
428803|NCT00973206|cardiovascular morbidity
428804|NCT00973206|mortality community study
428805|NCT00973193|rectum
428806|NCT00973193|colorectal
428807|NCT00973193|cancer
428808|NCT00973193|adenocarcinoma
428809|NCT00973193|anti-EGFR
428810|NCT00973193|monoclonal antibodies
428811|NCT00973193|neoadjuvant therapy
428812|NCT00973193|preoperative radiotherapy
428813|NCT00973180|Prescription medication understanding among diabetic and hypertension patients.
428814|NCT00973180|Prescription medication use among diabetic and hypertension patients.
428815|NCT00973180|Hemoglobin A1c changes among diabetic patients.
428816|NCT00973180|Blood pressure changes among hypertension patients.
428817|NCT00973167|Fracture rate
428818|NCT00973167|Fracture risks
428819|NCT00973154|Pneumonia
428820|NCT00973154|Corticosteroids
428821|NCT00973154|clinical stability
428822|NCT00973141|Moderate to severe, osteoarthritis-related pain
428823|NCT00973141|Osteoarthritis-related pain
428824|NCT00973141|Moderate to severe chronic pain
428825|NCT00973141|JNJ-42160443
428826|NCT00973089|Primary tooth
428827|NCT00973089|Caries, Dental
428828|NCT00973089|Alternative treatment
428829|NCT00973076|Phase I, cancer
428830|NCT00973076|solid tumors
428831|NCT00973076|advanced solid malignancies
428832|NCT00973076|dose escalation
428833|NCT00973076|mTOR Kinase Inhibitor
428834|NCT00973076|Japanese
428835|NCT00973063|bacteremia
428836|NCT00973063|blood culture
428837|NCT00973063|contamination
428838|NCT00973050|Bioequivalence
428839|NCT00973037|Breast neoplasms
428840|NCT00973037|Tamoxifen
428841|NCT00973037|Genotype
428842|NCT00973037|CYP2D6
428843|NCT00973024|JNJ-42160443
428844|NCT00973024|Low back pain-related pain
428845|NCT00973024|moderate to severe, chronic pain
428846|NCT00973011|GA
428847|NCT00972998|anal sphincter pressure
428848|NCT00972998|phenyephrine
428849|NCT00972985|Healthy Control subjects
428850|NCT00972972|fruit polyphenols
428851|NCT00972972|phytochemicals
428852|NCT00972972|neurocognition
428853|NCT00972972|neuropsychology
428854|NCT00972972|psychopharmacology
428855|NCT00972972|gene expression
428856|NCT00972972|biochemistry
428857|NCT00972959|multiple myeloma
428858|NCT00972959|1-3 Prior Lines of Therapy
428859|NCT00972959|bortezomib (Velcade)
428860|NCT00972959|zoledronic acid (Zometa)
428861|NCT00972959|Dexamethasone
428862|NCT00972959|bone mineral density
428863|NCT00972959|bone pain
428864|NCT00972959|bone metabolism
428865|NCT00972959|osteolytic lesions
428866|NCT00972959|DEXA-scans
428867|NCT00972959|X-ray radiography
428868|NCT00972946|MRI
428869|NCT00972946|SPIO
428870|NCT00972933|Immunogenicity Analysis
428871|NCT00972933|Biomarker Analysis
428872|NCT00972933|experimental
428873|NCT00972920|Transversus abdominis plane
428874|NCT00972920|Acute pain service
428875|NCT00972920|Ultrasound
428876|NCT00972907|anal fissure
428877|NCT00972907|pain
428878|NCT00972907|nifedipine
428879|NCT00972894|Group B streptococcus
428880|NCT00972894|Polymerase chain reaction
428881|NCT00972894|PCR
428882|NCT00972894|Intrapartum screening
428883|NCT00972894|Risk factors
428884|NCT00972894|arly onset Group B streptococcus infection
428885|NCT00972881|adenocarcinoma of the rectum
428886|NCT00972881|Locally advanced rectal cancer
428887|NCT00972868|Unidirectional mask
428888|NCT00972868|NPPV
428889|NCT00972868|COPD
428890|NCT00972868|respiratory physiology
428891|NCT00972855|Bioequivalence
428892|NCT00972842|PTCL
428893|NCT00972842|Peripheral T-Cell Non-Hodgkin's Lymphoma
428894|NCT00972842|Vorinostat
428895|NCT00972842|Lenalidomid
428896|NCT00972829|Hypercholesterolemia
428897|NCT00972816|Swine Flu
428898|NCT00972816|Flu
428899|NCT00972816|Vaccine
428900|NCT00972816|Children
428901|NCT00972816|Adjuvant
428902|NCT00972803|gingivitis
428903|NCT00972803|dental plaque
428904|NCT00972803|mouthrinse
428905|NCT00972790|brain tumor
428906|NCT00972790|un-ruptured aneurysm
428907|NCT00972790|arteriovenous malformation
428908|NCT00972790|epileptic focus
428909|NCT00972790|supratentorial
428910|NCT00972764|Laryngomalacia
428911|NCT00972764|Factors Associated or Predisposing
428912|NCT00972751|stage II rectal cancer
428913|NCT00972751|stage III rectal cancer
428914|NCT00972751|adenocarcinoma of the rectum
428915|NCT00972725|Chloroquine
428916|NCT00972725|Human Immunodeficiency Virus
428917|NCT00972712|Multiple Myeloma
428918|NCT00972699|Human Immunodeficiency Virus
428919|NCT00972699|Acquired Immune Deficiency Syndrome
428920|NCT00972699|Tuberculosis
428921|NCT00972699|Women
428922|NCT00972699|Pregnancy
428923|NCT00972699|Vertical Transmission of Human Immunodeficiency Virus
428924|NCT00972699|South Africa
428925|NCT00972699|Low Birth Weight
428926|NCT00972686|solid tumors
428927|NCT00972686|lymphoma
428928|NCT00972686|Phosphoinositide 3-kinase inhibitor
428929|NCT00972660|Mesenchymal stem cell
428930|NCT00972660|Efficacy
428931|NCT00972660|Safety
428932|NCT00972647|fracture
428933|NCT00972647|fixation
428934|NCT00972647|fluoroscopy
428935|NCT00972647|laser
428936|NCT00972647|radiation
428937|NCT00972634|depression
428938|NCT00972634|cachexia
428939|NCT00972634|pain
428940|NCT00972634|unspecified adult solid tumor, protocol specific
428941|NCT00972608|congenital heart disease
428942|NCT00972608|surgical planning
428943|NCT00972582|leucine intake
428944|NCT00972582|tolerable upper limit
428945|NCT00972582|adults
428946|NCT00972582|amino acid supplements
428947|NCT00972582|Excessive Leucine Intake
428948|NCT00972569|BNP with or without PDE-V in heart failure
428949|NCT00972556|Mineral Trioxide Aggregate
428950|NCT00972556|Formocresol
428951|NCT00972556|pulpotomy
428952|NCT00972556|primary molar
428953|NCT00972556|treatment outcome
428954|NCT00972543|Moderate to severe chronic plaque psoriasis
428955|NCT00972543|palms and/or soles
428956|NCT00972543|with or without pustules
428957|NCT00972530|rheumatoid arthritis
428958|NCT00972530|treatment
428959|NCT00972517|GSK Bio's influenza vaccine GSK2340272A
428960|NCT00972517|influenza infection
428961|NCT00972504|Proof of concept
428962|NCT00972465|nimotuzumab colorectal cancer chemotherapy
428963|NCT00972452|Type II Diabetes
428964|NCT00972452|Insulin Resistance
428965|NCT00972452|Exercise
428966|NCT00972452|Continuous Glucose Monitoring
428967|NCT00972439|Oral Contraceptives
428968|NCT00972439|Breast Tissue
428969|NCT00972413|breast cancer
428970|NCT00972413|cone beam computed tomography
428971|NCT00972400|psychosocial effects of cancer and its treatment
428972|NCT00972400|fatigue
428973|NCT00972400|cancer survivor
428974|NCT00972400|breast cancer
428975|NCT00972387|carbohydrate-protein
428976|NCT00972387|endurance exercise
428977|NCT00972387|supplement
428978|NCT00972361|Adenoidectomy
428979|NCT00972361|Tonsillectomy
428980|NCT00972361|Ventilation Tubes
428981|NCT00972361|Preoperational screening
428982|NCT00972361|Coagulation Profile
428983|NCT00972361|Lupus anticoagulant
428984|NCT00972348|HIV
428985|NCT00972348|Personal Health Record
428986|NCT00972348|Laboratory values: CD4 cells and HIV Viral load
428987|NCT00972348|Medication Reconciliation
428988|NCT00972335|Avastin
428989|NCT00972335|RAD001
428990|NCT00972335|Meningioma
428991|NCT00972335|Bevacizumab
428992|NCT00972335|Everolimus
428993|NCT00972335|Brain
428994|NCT00972309|Epotope-Enhanced TARP Peptide
428995|NCT00972309|Prostate Cancer
428996|NCT00972309|TARP Peptide-Pulsed Dendritic Cells
428997|NCT00972309|PSADT
428998|NCT00972309|HLA-A*0201
428999|NCT00972270|Arterial Occlusive Disease
429000|NCT00972270|Heart Diseases
429001|NCT00972270|Myocardial Ischemia
429002|NCT00972270|Vascular Disease
429003|NCT00972270|Arteriosclerosis
429004|NCT00972270|Ischemia
429005|NCT00972257|24-hour IOP control
429006|NCT00972257|primary open-angle glaucoma
429007|NCT00972257|brimonidine/timolol
429008|NCT00972257|dorzolamide/timolol
429009|NCT00972244|Type 2 diabetes mellitus
429010|NCT00972244|Japanese
429011|NCT00972244|phase 2
429012|NCT00972244|efficacy
429013|NCT00972244|safety
429014|NCT00972244|dapagliflozin
429015|NCT00972231|Thalassemia Major
429016|NCT00972231|Thalassemia Intermedia
429017|NCT00972231|Sickle Cell Anemia
429018|NCT00972231|Sickle Cell Thalassemia
429019|NCT00972231|Iron Overload
429020|NCT00972231|Growth Velocity
429021|NCT00972218|Spondyloarthritis
429022|NCT00972218|Ankylosing Spondylitis
429023|NCT00972218|Crohn's disease
429024|NCT00972218|adalimumab
429025|NCT00972218|treatment
429026|NCT00972205|Pgp
429027|NCT00972205|Solid Tumors
429028|NCT00972205|Drug Resistance
429029|NCT00972205|Sestamibi
429030|NCT00972205|Cancer
429031|NCT00972205|Solid Tumor
429032|NCT00972192|HIV testing
429033|NCT00972192|HIV risk behavior
429034|NCT00972192|access to care
429035|NCT00972179|healthy volunteers
429036|NCT00972153|Decrease in CFU density at surgery site
429037|NCT00972153|Decrease in airborne particulate at surgery site
429038|NCT00972140|Patients with stable COPD
429039|NCT00972101|Blood And Marrow Transplantation
429040|NCT00972101|Leukemia
429041|NCT00972101|Lymphoma
429042|NCT00972101|Pediatrics
429043|NCT00972101|Etoposide
429044|NCT00972101|Expanded Cord Blood T Cells
429045|NCT00972101|Filgrastim
429046|NCT00972101|Fludarabine
429047|NCT00972101|Melphalan
429048|NCT00972101|Mycophenolate Mofetil
429049|NCT00972101|Rituximab
429050|NCT00972101|Tacrolimus
429051|NCT00972101|Thiotepa
429052|NCT00972101|Thymoglobulin
429053|NCT00972101|Total Body Irradiation
429054|NCT00972088|inflammation of the small bowel
429055|NCT00972075|totally blind subjects
429056|NCT00972062|Subcutaneous injections
429057|NCT00972062|Skin abnormalities
429058|NCT00972049|safety
429059|NCT00972049|tolerability
429060|NCT00972049|AZD2516
429061|NCT00972049|pain
429062|NCT00972049|Japanese
429063|NCT00972036|COLON
429064|NCT00972036|LIVER
429065|NCT00972036|RECTUM
429066|NCT00972036|SIR-Spheres
429067|NCT00972036|09-030
429068|NCT00972023|triple-negative breast cancer
429069|NCT00972023|stage I breast cancer
429070|NCT00972023|stage II breast cancer
429071|NCT00972023|stage IIIA breast cancer
429072|NCT00972023|stage IIIB breast cancer
429073|NCT00972023|stage IIIC breast cancer
429074|NCT00972010|Breast
429075|NCT00972010|Cancer
429076|NCT00972010|Lumpectomies
429077|NCT00972010|PlasmaBlade
429078|NCT00972010|Breast conservation therapy
429079|NCT00971971|Hypotension
429080|NCT00971971|Acute renal failure
429081|NCT00971971|acute kidney injury
429082|NCT00971971|dialysis
429083|NCT00971971|ICU
429084|NCT00971958|HIV prevention
429085|NCT00971958|infant, neonatal, male circumcision
429086|NCT00971932|Recurrent and/or metastatic
429087|NCT00971932|SCCHN
429088|NCT00971919|pain
429089|NCT00971919|perioperative/postoperative complications
429090|NCT00971919|breast cancer in situ
429091|NCT00971919|stage IA breast cancer
429092|NCT00971919|stage IB breast cancer
429093|NCT00971919|stage II breast cancer
429094|NCT00971919|stage IIIA breast cancer
429095|NCT00971919|stage IIIB breast cancer
429096|NCT00971919|stage IIIC breast cancer
429097|NCT00971906|Pandemic influenza
429098|NCT00971906|Vaccine
429099|NCT00971893|Acute Exacerbation of Bronchial Asthma Acute Asthma
429100|NCT00971880|Blood transfusions
429101|NCT00971880|Adverse events
429102|NCT00971880|Hepatitis C
429103|NCT00971880|HIV
429104|NCT00971854|Dystonia
429105|NCT00971828|Myositis
429106|NCT00971828|polymyositis
429107|NCT00971828|dermatomyositis
429108|NCT00971815|HPA-axis
429109|NCT00971815|fetal programming
429110|NCT00971789|Sirolimus
429111|NCT00971789|Cowden Syndrome
429112|NCT00971789|PTEN Mutation
429113|NCT00971789|Hamartoma Syndrome
429114|NCT00971776|Patient receiving AB5000 ventricle potentially recoverable
429115|NCT00971763|stage I adult diffuse large cell lymphoma
429116|NCT00971763|contiguous stage II adult diffuse large cell lymphoma
429117|NCT00971763|noncontiguous stage II adult diffuse large cell lymphoma
429118|NCT00971763|stage III adult diffuse large cell lymphoma
429119|NCT00971763|stage IV adult diffuse large cell lymphoma
429120|NCT00971750|ultrasonography
429121|NCT00971750|gallbladder
429122|NCT00971750|cholelithiasis
429123|NCT00971750|laparoscopic
429124|NCT00971750|gastric bypass
429125|NCT00971750|obesity
429126|NCT00971750|bariatric surgery
429127|NCT00971737|stage IV breast cancer
429128|NCT00971737|male breast cancer
429129|NCT00971724|Prednisolone
429130|NCT00971724|Glucocorticoids
429131|NCT00971711|IBS
429132|NCT00971711|irritable bowel syndrome
429133|NCT00971711|abdominal pain
429134|NCT00971711|urgency
429135|NCT00971711|bloating
429136|NCT00971711|diarrhea
429137|NCT00971698|Splenectomy
429138|NCT00971698|Thrombocytosis
429139|NCT00971698|Infections
429140|NCT00971698|Spleen
429141|NCT00971698|Sickle Cell Thalassemia
429142|NCT00971672|Infants
429143|NCT00971672|Iron Deficiency
429144|NCT00971672|Anemia
429145|NCT00971672|Healthy infants that attend the pediatric community clinics
429146|NCT00971659|type 2 diabetes
429147|NCT00971646|overactive bladder
429148|NCT00971646|self-consciousness
429149|NCT00971646|perceptual urge sensation
429150|NCT00971620|Cutaneous Leiomyomas
429151|NCT00971620|Skin Pain
429152|NCT00971620|Botox Therapy
429153|NCT00971620|Hereditary Leiomyomatosis
429154|NCT00971620|Renal Cell Cancer
429155|NCT00971620|Cutaneous Leiomyoma
429156|NCT00971607|Acute myocardial infarction
429157|NCT00971607|Postconditioning
429158|NCT00971607|Sevoflurane
429159|NCT00971594|weight loss
429160|NCT00971594|glucose metabolism
429161|NCT00971568|Interstitial cystitis
429162|NCT00971568|Painful bladder syndrome
429163|NCT00971555|Transient Hypothyroxinemia
429164|NCT00971555|Late Preterm Infants
429165|NCT00971555|Total T4
429166|NCT00971555|TSH
429167|NCT00971555|Illness severity
429168|NCT00971555|NICU
429169|NCT00971542|Pandemic influenza
429170|NCT00971542|Vaccine
429171|NCT00971529|Smoking cessation
429172|NCT00971529|tea filter
429173|NCT00971516|diabetes
429174|NCT00971516|implants
429175|NCT00971516|cytokines
429176|NCT00971503|Diabetes type 1
429177|NCT00971503|Adult Stem cells
429178|NCT00971503|Local injection
429179|NCT00971503|Catheter delivery
429180|NCT00971503|Bone marrow
429181|NCT00971490|COPD
429182|NCT00971490|FEV1
429183|NCT00971490|beta endorphin
429184|NCT00971490|SGRQ
429185|NCT00971490|Acu-TENS
429186|NCT00971477|Teledermatology
429187|NCT00971477|Telemedicine
429188|NCT00971477|Psoriasis
429189|NCT00971464|AMD
429190|NCT00971464|EV
429191|NCT00971464|CCTV
429192|NCT00971464|Reading
429193|NCT00971464|vision
429194|NCT00971451|Anterior cruciate ligament
429195|NCT00971451|ACL
429196|NCT00971438|appendicitis
429197|NCT00971438|diagnosis
429198|NCT00971438|diagnostic imaging
429199|NCT00971438|clinical scoring system
429200|NCT00971425|influenza infection
429201|NCT00971425|GSK Bio's influenza vaccine GSK2340272A
429202|NCT00971386|Heart Failure
429203|NCT00971373|antimicrobial
429204|NCT00971373|epidemiology
429205|NCT00971373|bacteriology
429206|NCT00971373|CFU
429207|NCT00971360|conversion
429208|NCT00971360|cytokine
429209|NCT00971360|inflammation
429210|NCT00971347|obesity
429211|NCT00971347|overweight
429212|NCT00971347|weight loss
429213|NCT00971347|randomized controlled trial
429214|NCT00971347|chewing gum
429215|NCT00971334|Down Syndrome
429216|NCT00971334|Aneuploidy
429217|NCT00971334|Amniocentesis
429218|NCT00971334|CVS
429219|NCT00971321|influenza infection
429220|NCT00971321|GSK Bio's influenza vaccine GSK2340272A
429221|NCT00971295|eslicarbazepine acetate
429222|NCT00971295|zebinix
429223|NCT00971295|metformin
429224|NCT00971256|Bladder
429225|NCT00971256|Cancer
429226|NCT00971256|Cytology
429227|NCT00971243|Insulin resistance
429228|NCT00971230|HIV
429229|NCT00971230|Human Immunodeficiency Virus
429230|NCT00971217|Internet based Cognitive-Behavioural Intervention
429231|NCT00971217|Exercise Intervention
429232|NCT00971217|Depression
429233|NCT00971217|Perceived Social Support
429234|NCT00971217|Physical Self-Concept
429235|NCT00971204|atrial fibrillation
429236|NCT00971204|PAF
429237|NCT00971191|Stage I - III surgical resection molecular change brief pre-operative exposure
429238|NCT00971178|Analgesia
429239|NCT00971178|Dental pain
429240|NCT00971178|Dexmedetomidine
429241|NCT00971178|Pain
429242|NCT00971178|Peripheral effects
429243|NCT00971165|Hypertension
429244|NCT00971165|Chlorthalidone
429245|NCT00971165|Amiloride
429246|NCT00971165|Losartan
429247|NCT00971165|treatment
429248|NCT00971152|IVF
429249|NCT00971152|dose comparison of gonadotrophins
429250|NCT00971152|poor responder to ovarian stimulation
429251|NCT00971139|Online patient-provider communication
429252|NCT00971139|Organizational change
429253|NCT00971139|Symptom management
429254|NCT00971126|hepatocellular carcinoma
429255|NCT00971100|Pandemic influenza
429256|NCT00971100|Vaccine
429257|NCT00971087|Breast cancer
429258|NCT00971087|breast cancer screening
429259|NCT00971074|Arthralgia
429260|NCT00971074|Viscosupplementation
429261|NCT00971074|Knee
429262|NCT00971074|Menisci, Tibial
429263|NCT00971074|Surgery, Outpatient
429264|NCT00971061|Ahmed valve
429265|NCT00971061|single-plate Molteno implant
429266|NCT00971061|refractory glaucoma
429267|NCT00971061|surgical treatment
429268|NCT00971048|pressure ulcers
429269|NCT00971048|PU
429270|NCT00971048|diabetic foot ulcers
429271|NCT00971048|DFU
429272|NCT00971048|Bates-Jensen Wound Assessment
429273|NCT00971035|MILR1444A
429274|NCT00971022|Low-income populations
429275|NCT00971022|Chronic health condition
429276|NCT00971022|Prescription medication
429277|NCT00971022|Prescription drugs
429278|NCT00971022|Discount generic prescription programs
429279|NCT00971022|Survey
429280|NCT00971022|Awareness
429281|NCT00971022|Focus Group
429282|NCT00971022|Houston
429283|NCT00971009|Symptom management
429284|NCT00971009|Interactive Health Communication Application
429285|NCT00971009|Patient-provider communication
429286|NCT00971009|Health care costs
429287|NCT00970996|Melanoma
429288|NCT00970996|Abraxane
429289|NCT00970996|Nab-paclitaxel
429290|NCT00970996|Paclitaxel (protein-bound)
429291|NCT00970996|ABI-007
429292|NCT00970996|Cisplatin
429293|NCT00970996|Platinol-AQ
429294|NCT00970996|Platinol
429295|NCT00970996|CDDP
429296|NCT00970996|Interleukin 2
429297|NCT00970996|IL-2
429298|NCT00970996|Proleukin
429299|NCT00970996|Intron A
429300|NCT00970996|Interferon alpha 2b
429301|NCT00970996|Interferon alfa-2b
429302|NCT00970996|Temodar
429303|NCT00970996|Temozolomide
429304|NCT00970970|Vascular endothelial growth factor
429305|NCT00970970|von Hippel Lindau disease
429306|NCT00970970|molecular imaging
429307|NCT00970970|biomarker
429308|NCT00970957|Macular edema
429309|NCT00970957|Retinal Vein Occlusion
429310|NCT00970957|Bevacizumab
429311|NCT00970944|Traumatic Brain Injury
429312|NCT00970944|Rehabilitation
429313|NCT00970944|Disorders of Consciousness
429314|NCT00970944|Functional Outcome
429315|NCT00970944|Amantadine Hydrochloride
429316|NCT00970931|hypertension
429317|NCT00970931|diuretics
429318|NCT00970918|Cardiovascular disease
429319|NCT00970918|Carotid Intima Media Thickness
429320|NCT00970905|Radiation
429321|NCT00970905|Nausea
429322|NCT00970905|Vomiting
429323|NCT00970905|Ondansetron
429324|NCT00970905|Aprepitant
429325|NCT00970892|Anticoagulation
429326|NCT00970892|warfarin
429327|NCT00970892|VKORC1
429328|NCT00970892|CYP2C9
429329|NCT00970892|thromboembolism
429330|NCT00970892|pharmacogenetics
429331|NCT00970879|malaria
429332|NCT00970879|pregnancy
429333|NCT00970879|HIV
429334|NCT00970879|prevention
429335|NCT00970879|cotrimoxazole
429336|NCT00970879|mefloquine
429337|NCT00970866|multiple micronutrients
429338|NCT00970866|home fortification
429339|NCT00970866|complementary foods
429340|NCT00970866|infant feeding
429341|NCT00970866|lipid-based nutrient supplements
429342|NCT00970853|Evaluate developmental outcomes
429343|NCT00970853|Evaluate child cognitive, academic, and behavioral outcomes
429344|NCT00970840|Acceptability
429345|NCT00970840|Supplements
429346|NCT00970840|Home-fortification
429347|NCT00970827|Coronary artery disease
429348|NCT00970827|PCI
429349|NCT00970827|Postconditioning
429350|NCT00970827|Elective or urgent PCI
429351|NCT00970814|Alcoholism
429352|NCT00970814|Alcohol Drinking
429353|NCT00970814|Alcoholic Intoxication
429354|NCT00970814|Alcohol Abuse
429355|NCT00970801|Atypical mycobacteria
429356|NCT00970775|Phase I
429357|NCT00970775|Japanese healthy volunteer
429358|NCT00970775|AZD2423
429359|NCT00970749|chlamydia
429360|NCT00970749|healthy women
429361|NCT00970749|history of endocervical chlamydia
429362|NCT00970749|no history of endocervical chlamydia
429363|NCT00970736|Motor cortex
429364|NCT00970736|Motor control
429365|NCT00970736|Neuroplasticity
429366|NCT00970736|Aging
429367|NCT00970736|Swallowing
429368|NCT00970723|Diabetic retinopathy
429369|NCT00970723|Macula edema
429370|NCT00970723|Sleep apnea
429371|NCT00970723|High blood pressure
429372|NCT00970697|MARTORELL'S ULCER
429373|NCT00970697|hydrogel
429374|NCT00970697|Hypertensive leg ulcer
429375|NCT00970684|recurrent non-small cell lung cancer
429376|NCT00970684|stage IIIB non-small cell lung cancer
429377|NCT00970684|stage IV non-small cell lung cancer
429378|NCT00970684|adenocarcinoma of the lung
429379|NCT00970684|bronchoalveolar cell lung cancer
429380|NCT00970684|large cell lung cancer
429381|NCT00970671|scar
429382|NCT00970671|laser therapy
429383|NCT00970671|lasers, pulsed dye
429384|NCT00970658|Plaster
429385|NCT00970658|injuries
429386|NCT00970658|regions miofasciais articulated
429387|NCT00970658|Reducing signs, symptoms
429388|NCT00970645|Non small cell lung cancer
429389|NCT00970645|mediastinum
429390|NCT00970645|endobronchial ultrasound fine needle aspiration
429391|NCT00970645|endoscopic ultrasound
429392|NCT00970645|mediastinoscopy
429393|NCT00970645|surgical or minimally invasive evaluation of mediastinum
429394|NCT00970645|NSCLC
429395|NCT00970606|ARDS
429396|NCT00970606|H1N1
429397|NCT00970606|Influenza
429398|NCT00970606|Statin
429399|NCT00970580|BIIB022
429400|NCT00970580|Stage IV
429401|NCT00970580|Taxol
429402|NCT00970580|Stage IIIB
429403|NCT00970580|Carboplatin
429404|NCT00970580|Paclitaxel
429405|NCT00970580|Non Small Cell Lung Cancer
429406|NCT00970580|Treatment Naive
429407|NCT00970580|Anti IGF1R
429408|NCT00970580|NSCLC
429409|NCT00970580|Open Label
429410|NCT00970580|IGF1R
429411|NCT00970580|Paraplatin
429412|NCT00970580|Cytotoxic
429413|NCT00970580|Mitotic Inhibitor
429414|NCT00970580|Taxane
429415|NCT00970580|Alkylating agent
429416|NCT00970567|therapy after positive ketone bodies in the blood
429417|NCT00970567|timepoint of diagnosis
429418|NCT00970567|timepoint of metabolic normalisation
429419|NCT00970554|Amblyopia
429420|NCT00970554|Telescopic magnification
429421|NCT00970554|Patching
429422|NCT00970541|Cinnamon
429423|NCT00970541|PCOS
429424|NCT00970541|low blood sugar
429425|NCT00970541|Insulin
429426|NCT00970541|Glucose
429427|NCT00970528|Oral Hypoglycemic Agent
429428|NCT00970515|Laparoscopy
429429|NCT00970515|Incisional hernia
429430|NCT00970515|Umbilical hernia
429431|NCT00970515|Mesh repair
429432|NCT00970515|Postoperative complications
429433|NCT00970489|atrial fibrillation
429434|NCT00970489|fish oil
429435|NCT00970463|The GH-system and cardiac function
429436|NCT00970450|Paracetamol
429437|NCT00970450|Tropisetron
429438|NCT00970450|Central analgesic effect
429439|NCT00970450|Area of allodynia
429440|NCT00970450|Secondary hyperalgesia
429441|NCT00970398|Infant formula
429442|NCT00970398|Bovine milk Osteopontin
429443|NCT00970398|growth
429444|NCT00970398|health
429445|NCT00970398|immune functions
429446|NCT00970372|Coercion
429447|NCT00970359|thyroid
429448|NCT00970359|metastases
429449|NCT00970359|AZD6244
429450|NCT00970359|09-048
429451|NCT00970346|Digestive System Diseases
429452|NCT00970346|Genetic Diseases
429453|NCT00970346|Inborn
429454|NCT00970346|Respiratory Tract Diseases
429455|NCT00970346|Cystic Fibrosis
429456|NCT00970346|Lung Disease
429457|NCT00970346|Pancreatic Diseases
429458|NCT00970333|Alzheimer disease
429459|NCT00970333|Parkinson disease
429460|NCT00970333|Multiple Sclerosis
429461|NCT00970320|Anal Incontinence
429462|NCT00970320|urinary incontinence
429463|NCT00970320|primiparas
429464|NCT00970320|prevalence
429465|NCT00970320|pelvic floor exercise treatment
429466|NCT00970320|Quality of Life (QoL)
429467|NCT00970294|diabetes
429468|NCT00970268|COPD
429469|NCT00970268|Chronic Obstructive Pulmonary Disease
429470|NCT00970268|Chronic Bronchitis
429471|NCT00970268|Emphysema
429472|NCT00970268|Airflow Obstruction, Chronic
429473|NCT00970268|Chronic Airflow Obstruction
429474|NCT00970268|Chronic Obstructive Airway Disease
429475|NCT00970268|Chronic Obstructive Lung Disease
429476|NCT00970255|Breastfeeding difficulties
429477|NCT00970255|lingual frenulum
429478|NCT00970255|labial frenulum
429479|NCT00970255|frenotomy
429480|NCT00970216|HBV DNA non-detectability
429481|NCT00970203|Vaccine
429482|NCT00970203|Androgen Ablation
429483|NCT00970203|PSA Progression
429484|NCT00970190|sinusitis
429485|NCT00970177|Pandemic influenza vaccine
429486|NCT00970151|Fetal Inflammation
429487|NCT00970151|Birth Outcome
429488|NCT00970151|Pregnancy
429489|NCT00970138|Progress free survival
429490|NCT00970138|Toxicity
429491|NCT00970138|Response rate
429492|NCT00970138|Overall survival
429493|NCT00970138|Quality of live
429494|NCT00970125|advance care planning
429495|NCT00970125|cancer
429496|NCT00970112|pain
429497|NCT00970112|pain assessment
429498|NCT00970086|measure of postoperative pain
429499|NCT00970086|children undergoing groin surgery
429500|NCT00970073|calcineurin inhibitor delay
429501|NCT00970073|Kidney
429502|NCT00970060|neuropathy
429503|NCT00970060|diabetes
429504|NCT00970047|pregnant
429505|NCT00970047|fetal sex determination
429506|NCT00970047|gender determination
429507|NCT00970047|noninvasive test
429508|NCT00970047|fetal DNA
429509|NCT00970034|Atrial fibrillation, apoptosis, oligonucleotide microarray
429510|NCT00970008|Osteoarthritis
429511|NCT00970008|Knee
429512|NCT00969995|inflammation
429513|NCT00969995|migraine
429514|NCT00969995|headache
429515|NCT00969982|Pregnancy termination
429516|NCT00969982|abortion
429517|NCT00969982|medical abortion
429518|NCT00969982|2nd trimester
429519|NCT00969982|mifepristone
429520|NCT00969982|misoprostol
429521|NCT00969969|First MTP Joint
429522|NCT00969969|Hallux Rigidus
429523|NCT00969969|Hallux Limitus
429524|NCT00969969|Cartilage Replacement
429525|NCT00969969|Osteoarthritis
429526|NCT00969969|First MTP Joint Osteoarthritis
429527|NCT00969969|Big Toe Pain
429528|NCT00969956|Diabetes, Complication, Cardio-vascular disease
429529|NCT00969943|HPA axis
429530|NCT00969930|COMT
429531|NCT00969930|ApoE
429532|NCT00969930|BDNF
429533|NCT00969930|executive function
429534|NCT00969930|bipolar
429535|NCT00969930|cognition
429536|NCT00969930|Cognitive deficits and Bipolar disease type I
429537|NCT00969878|Cocaine Vaccine, TA-CD 09
429538|NCT00969865|Atherosclerosis
429539|NCT00969852|Sertraline
429540|NCT00969852|PET
429541|NCT00969852|Serotonin receptor occupancy
429542|NCT00969852|PK-PD Model
429543|NCT00969839|Fracture
429544|NCT00969839|Humerus
429545|NCT00969839|Intramedullary
429546|NCT00969839|Fixation
429547|NCT00969826|GCPGC
429548|NCT00969826|Pharmacokinetics
429549|NCT00969826|Pharmacodynamics
429550|NCT00969813|Hepatic impairment
429551|NCT00969800|Common cold
429552|NCT00969800|Influenza
429553|NCT00969800|Pneumonia
429554|NCT00969774|Face
429555|NCT00969774|Cephalometry
429556|NCT00969774|Anthropometry
429557|NCT00969774|Photography
429558|NCT00969774|Diagnosis
429559|NCT00969774|Adult
429560|NCT00969774|Morphology
429561|NCT00969774|Comparative Study
429562|NCT00969735|Atrial fibrillation
429563|NCT00969735|Catheter ablation
429564|NCT00969735|Cryoenergy
429565|NCT00969735|Implantable loop recorder
429566|NCT00969735|Pulmonary vein
429567|NCT00969722|Neuroblastoma
429568|NCT00969722|3F8
429569|NCT00969722|Primary refractory
429570|NCT00969709|Depression
429571|NCT00969709|Major Depressive Disorder
429572|NCT00969696|ability to learn, working memory
429573|NCT00969657|rectal cancer stage I-III
429574|NCT00969657|concurrent chemoradiotherapie
429575|NCT00969657|response prediction
429576|NCT00969631|Polycystic ovary syndrome
429577|NCT00969631|clomiphene resistance
429578|NCT00969631|metformin
429579|NCT00969631|laparoscopic ovarian diathermy
429580|NCT00969618|ADHD
429581|NCT00969605|weaning
429582|NCT00969605|adaptive support ventilation
429583|NCT00969605|COPD
429584|NCT00969592|diabetes
429585|NCT00969579|Cancer
429586|NCT00969579|Psychosocial Stress
429587|NCT00969579|Parenting
429588|NCT00969566|Diabetes
429589|NCT00969566|Sitagliptin
429590|NCT00969566|C-peptide
429591|NCT00969566|Glucagon
429592|NCT00969540|Back Pain
429593|NCT00969540|Sleep
429594|NCT00969527|Oncoxin
429595|NCT00969527|Viusid
429596|NCT00969527|dietary supplements
429597|NCT00969527|rheumatoid arthritis
429598|NCT00969514|Robotic cystectomy
429599|NCT00969514|Bladder
429600|NCT00969488|matern diet
429601|NCT00969488|obese
429602|NCT00969488|postpartum
429603|NCT00969488|body weight change
429604|NCT00969488|Women with overweight
429605|NCT00969475|scar revision
429606|NCT00969475|intraoperative
429607|NCT00969475|fractional carbon dioxide laser
429608|NCT00969462|Doxorubicin
429609|NCT00969462|pharmacokinetics
429610|NCT00969462|non-Hodgkin's lymphoma
429611|NCT00969462|response
429612|NCT00969462|association between response to chemotherapy
429613|NCT00969462|myelosuppression degree
429614|NCT00969462|doxorubicin pharmacokinetics
429615|NCT00969449|Naproxen Sodium
429616|NCT00969436|Mumps
429617|NCT00969436|Immunogenicity
429618|NCT00969436|Vaccines
429619|NCT00969436|Safety
429620|NCT00969436|Rubella
429621|NCT00969436|Combined Vaccine
429622|NCT00969436|Varicella Vaccine
429623|NCT00969436|Children
429624|NCT00969436|Measles
429625|NCT00969436|Humans
429626|NCT00969423|persistent pain
429627|NCT00969423|neuropathic pain
429628|NCT00969423|Chronic Pain
429629|NCT00969423|VATS
429630|NCT00969423|Primary spontaneous pneumothorax patients
429631|NCT00969410|Neoplasms
429632|NCT00969410|Neoplasm metastasis
429633|NCT00969410|Liver neoplasms
429634|NCT00969410|Neoplastic processes
429635|NCT00969410|Pathologic processes
429636|NCT00969410|Digestive system neoplasms
429637|NCT00969410|Neoplasms by site
429638|NCT00969410|Digestive system diseases
429639|NCT00969410|Liver diseases
429640|NCT00969397|Birthmark
429641|NCT00969397|PWS
429642|NCT00969384|Physical health
429643|NCT00969384|Mental illness
429644|NCT00969384|prevention
429645|NCT00969384|Waist circumference
429646|NCT00969371|posterior chamber intraocular lens
429647|NCT00969371|PCIOL
429648|NCT00969371|IOL
429649|NCT00969345|Healthy Elderly Subjects
429650|NCT00969345|Respiratory Yoga Exercises
429651|NCT00969345|Heart Rate Variability
429652|NCT00969345|Baroreflex
429653|NCT00969345|Quality of Life
429654|NCT00969332|liver
429655|NCT00969332|Parenteral Nutrition
429656|NCT00969332|fish oil
429657|NCT00969332|Omegaven
429658|NCT00969332|children
429659|NCT00969319|Octocog alfa
429660|NCT00969319|Hemophilia A
429661|NCT00969293|Macular Edema
429662|NCT00969293|Occlusive retinal vascular disease
429663|NCT00969293|Central Retinal Vein Occlusion
429664|NCT00969293|CRVO
429665|NCT00969280|Acupuncture
429666|NCT00969280|Dry eye syndrome
429667|NCT00969280|Ocular Surface Disease Index
429668|NCT00969280|Schirmer test
429669|NCT00969280|Tear film Break-up time
429670|NCT00969267|ear acupuncture
429671|NCT00969267|obese
429672|NCT00969267|obese women
429673|NCT00969267|women
429674|NCT00969254|Pílulas de Lussen
429675|NCT00969254|Efficacy
429676|NCT00969254|Safety
429677|NCT00969254|Dysuria
429678|NCT00969254|Symptomatic control
429679|NCT00969241|saliva
429680|NCT00969241|free-radicals
429681|NCT00969241|periodontitis
429682|NCT00969228|Gastroenteritis
429683|NCT00969215|burn scar
429684|NCT00969215|fractional carbon dioxide laser
429685|NCT00969215|scar revision
429686|NCT00969202|Prostate Cancer
429687|NCT00969202|Cancer of the Prostate
429688|NCT00969202|Prostate Tumor
429689|NCT00969202|Novalis Tx
429690|NCT00969202|Novalis
429691|NCT00969202|Stereotactic Radiosurgery
429692|NCT00969202|Radiosurgery
429693|NCT00969202|Radiation
429694|NCT00969189|anesthesia
429695|NCT00969189|child
429696|NCT00969189|infant
429697|NCT00969189|laryngeal mask
429698|NCT00969176|pain
429699|NCT00969176|fever
429700|NCT00969176|neonate
429701|NCT00969176|preterm
429702|NCT00969176|term
429703|NCT00969176|newborn
429704|NCT00969163|Biomarkers of Skin Androgenization
429705|NCT00969150|Major Depressive Disorder
429706|NCT00969150|Depression
429707|NCT00969137|smoking, nicotine, cigarettes
429708|NCT00969124|colonoscopy
429709|NCT00969124|polyps
429710|NCT00969124|adenomas
429711|NCT00969124|miss rates
429712|NCT00969111|Proton Radiation, Prostate Cancer
429713|NCT00969098|Histologically proven of Malignant pleural mesothelioma;
429714|NCT00969098|Patients not candidate to radical surgery;
429715|NCT00969098|Candidate to first-line pemetrexed-based chemotherapy;
429716|NCT00969085|Cutaneous T-cell lymphoma
429717|NCT00969085|Skin
429718|NCT00969085|Mycosis fungoides
429719|NCT00969085|MF
429720|NCT00969085|Sézary syndrome
429721|NCT00969085|SS
429722|NCT00969085|Curcumin
429723|NCT00969085|Turmeric
429724|NCT00969072|GI198745
429725|NCT00969072|Long term extension study
429726|NCT00969072|BPH
429727|NCT00969059|peripheral nerve injury
429728|NCT00969059|p38 kinase inhibitor
429729|NCT00969059|neuropathic pain
429730|NCT00969046|Colon cancer
429731|NCT00969046|MTD
429732|NCT00969046|DLT
429733|NCT00969046|EPO906
429734|NCT00969046|patupilone
429735|NCT00969020|Length of stay
429736|NCT00969020|Timed up and go
429737|NCT00968994|Wound Healing
429738|NCT00968994|Wound Infection
429739|NCT00968981|Hedgehog
429740|NCT00968981|BCC
429741|NCT00968981|basal cell carcinoma
429990|NCT00968253|Pegfilgrastim
429742|NCT00968955|Postoperative acute pain
429743|NCT00968955|Total hip arthroplasty
429744|NCT00968955|Local infiltration analgesia
429745|NCT00968942|Lateral Canthal Lines
429746|NCT00968942|Crow's Feet
429747|NCT00968942|Facial Wrinkles
429748|NCT00968929|pulmonary embolism
429749|NCT00968929|thrombolysis
429750|NCT00968929|massive
429751|NCT00968929|submassive
429752|NCT00968929|recombinant streptokinase
429753|NCT00968929|urokinase
429754|NCT00968903|Hip arthroplasty
429755|NCT00968903|Methylprednisolone
429756|NCT00968903|Post-operative pain
429757|NCT00968890|GSK Bio's influenza vaccine GSK2340272A
429758|NCT00968890|Influenza infection
429759|NCT00968877|Renal Insufficiency
429760|NCT00968877|Cholecalciferol
429761|NCT00968877|Kidney Disease
429762|NCT00968877|Kidney Failure
429763|NCT00968877|Vitamin D
429764|NCT00968877|Vitamin D Deficiency
429765|NCT00968877|Vitamin D3
429766|NCT00968864|T cell depleted
429767|NCT00968864|Matched unrelated donors
429768|NCT00968864|Haplocompatible donors
429769|NCT00968851|Schizophrenia
429770|NCT00968851|Central nervous System Diseases
429771|NCT00968851|Cognition
429772|NCT00968838|White Blood Cell Transfusion
429773|NCT00968838|Radiated Cells
429774|NCT00968838|Unradiated Cells
429775|NCT00968838|Leukocyte Transfusions
429776|NCT00968838|Life-threatening Infections
429777|NCT00968825|Lateral Canthal Lines
429778|NCT00968825|Crow's Feet
429779|NCT00968825|Facial Wrinkles
429780|NCT00968812|Diabetes
429781|NCT00968812|Metformin
429782|NCT00968812|Glimepiride
429783|NCT00968812|Hemoglobin A1c
429784|NCT00968812|Type 2 diabetes mellitus
429785|NCT00968812|Canagliflozin
429786|NCT00968799|Ovarian Neoplasms
429787|NCT00968799|Recurrence
429788|NCT00968799|Hyperthermia, Induced
429789|NCT00968799|Peritoneal Neoplasms
429790|NCT00968799|recurrent epithelial ovarian cancer
429791|NCT00968799|recurrent fallopian tube carcinoma
429792|NCT00968786|hypertension
429793|NCT00968786|type 2 diabetes
429794|NCT00968786|home monitoring
429795|NCT00968773|inguinal hernia
429796|NCT00968773|mesh
429797|NCT00968773|hernia repair device
429798|NCT00968760|CD19+ lymphoid malignancies
429799|NCT00968760|non-Hodgkin's Lymphoma
429800|NCT00968760|NHL
429801|NCT00968760|small lymphocytic lymphoma
429802|NCT00968760|SLL
429803|NCT00968760|follicular lymphoma
429804|NCT00968760|mantle cell lymphoma
429805|NCT00968760|gene cell transfer
429806|NCT00968760|CD19-specific T cells
429807|NCT00968760|Stem Cell Transplant
429808|NCT00968760|T Cell Infusion
429809|NCT00968760|Chemotherapy
429810|NCT00968760|Leukapheresis
429811|NCT00968760|BCNU
429812|NCT00968760|carmustine
429813|NCT00968760|Cytarabine
429814|NCT00968760|Etoposide
429815|NCT00968760|Interleukin-2
429816|NCT00968760|Proleukin
429817|NCT00968760|Melphalan
429818|NCT00968760|Rituximab
429819|NCT00968760|T cell therapy
429820|NCT00968747|Fasting
429821|NCT00968747|Fast
429822|NCT00968747|healthy
429823|NCT00968747|diet
429824|NCT00968747|study
429825|NCT00968747|manipulation
429826|NCT00968747|dietary
429827|NCT00968747|FGF21
429828|NCT00968747|Fibroblast growth factor
429829|NCT00968747|PTRF
429830|NCT00968747|Polymerase 1 and transcript release factor
429831|NCT00968747|adipose
429832|NCT00968747|fat
429833|NCT00968747|blood
429834|NCT00968747|inpatient
429835|NCT00968747|outpatient
429836|NCT00968747|NAFLD
429837|NCT00968747|metabolism
429838|NCT00968734|Vitamin D
429839|NCT00968734|colecalciferol
429840|NCT00968734|absorption by Vitamin D
429841|NCT00968721|Inflammatory bowel disease
429842|NCT00968721|Crohn's disease
429843|NCT00968721|Ulcerative colitis
429844|NCT00968721|medication adherence
429845|NCT00968721|Decisional influences
429846|NCT00968708|Diabetes Mellitus - Type 2
429847|NCT00968708|Diabetes Mellitus
429848|NCT00968708|cardiovascular outcomes
429849|NCT00968708|heart attack
429850|NCT00968708|stroke
429851|NCT00968708|dipeptidyl-peptidase IV inhibitors
429852|NCT00968708|metabolic disorders
429853|NCT00968708|metabolic diseases
429854|NCT00968708|glucose metabolism disorders
429855|NCT00968682|cardiac toxicity
429856|NCT00968682|HER2-positive breast cancer
429857|NCT00968682|stage IA breast cancer
429858|NCT00968682|stage IB breast cancer
429859|NCT00968682|stage II breast cancer
429860|NCT00968682|stage IIIA breast cancer
429861|NCT00968682|stage IIIB breast cancer
429862|NCT00968682|stage IIIC breast cancer
429863|NCT00968656|Breast cancer
429864|NCT00968656|Head and Neck Cancer
429865|NCT00968656|Diffuse Large B-cell lymphoma
429866|NCT00968656|Cellular proliferation
429867|NCT00968643|spinal cord compression
429868|NCT00968643|unspecified adult solid tumor, protocol specific
429869|NCT00968617|Anemia
429870|NCT00968604|Pancreatic Cancer
429871|NCT00968604|Pancreas
429872|NCT00968604|Liver
429873|NCT00968604|Liver Tumor Biopsy
429874|NCT00968604|BikDD Nanoparticle
429875|NCT00968604|C-VISA BikDD
429876|NCT00968591|Hepatic insufficiency
429877|NCT00968591|liver disease
429878|NCT00968591|cirrhosis
429879|NCT00968591|pharmacokinetics
429880|NCT00968578|Knee arthroplasty
429881|NCT00968578|Methylprednisolone
429882|NCT00968578|Post-operative pain
429883|NCT00968565|Heart Defects, Congenital
429884|NCT00968565|Extracorporeal Membrane Oxygenation
429885|NCT00968565|Citric Acid
429886|NCT00968565|Heparin
429887|NCT00968565|Respiratory Insufficiency
429888|NCT00968552|Any Gastrointestinal problem that would require an endoscopically placed stent
429889|NCT00968539|GSK Bio's influenza vaccine GSK2340272A
429890|NCT00968539|influenza infection
429891|NCT00968526|influenza infection
429892|NCT00968526|GSK Bio's influenza vaccine GSK2340272A
429893|NCT00968513|Smoking Cessation, Inpatient Psychiatry, Stages of Change
429894|NCT00968500|Grief
429895|NCT00968500|bereavement
429896|NCT00968500|questionnaires
429897|NCT00968500|09-107
429898|NCT00968487|Lyophilized Plasma
429899|NCT00968487|Fresh Frozen Plasma
429900|NCT00968487|Hemorrhage
429901|NCT00968487|Coagulopathy
429902|NCT00968487|Autologous
429903|NCT00968487|HemCon
429904|NCT00968487|Plasmapheresis
429905|NCT00968487|Freeze Drying
429906|NCT00968487|Transfusion
429907|NCT00968487|Resuscitation
429908|NCT00968487|Safety of Lyophilized Plasma in Normal, Healthy Volunteers
429909|NCT00968461|Chronic lymphocytic leukemia
429910|NCT00968461|CLL
429911|NCT00968461|PEITC
429912|NCT00968461|Phenethyl Isothiocyanate
429913|NCT00968461|Fludarabine
429914|NCT00968448|respiratory muscle
429915|NCT00968448|breathing pattern
429916|NCT00968448|exercise performance
429917|NCT00968435|bevacizumab
429918|NCT00968435|cisplatin
429919|NCT00968435|cetuximab
429920|NCT00968435|radiation therapy
429921|NCT00968435|Phase II
429922|NCT00968435|09-083
429923|NCT00968422|Pharmacology
429924|NCT00968422|Drug Safety
429925|NCT00968422|Phase 1 Clinical Trials
429926|NCT00968422|Pharmacokinetics
429927|NCT00968409|Breast Cancer
429928|NCT00968409|Hormone Receptor
429929|NCT00968396|Myeloma
429930|NCT00968396|Ex-Vivo Depletion of Myeloma Cells
429931|NCT00968396|Peripheral Blood Progenitor Cell Grafts
429932|NCT00968396|PBPC
429933|NCT00968396|Stem Cell Transplant
429934|NCT00968396|Bone marrow stem cells
429935|NCT00968396|Melphalan
429936|NCT00968396|Alkeran
429937|NCT00968396|Apheresis
429938|NCT00968383|Acute Coronary Syndrome
429939|NCT00968383|Myocardial infarction
429940|NCT00968383|Infarct Related Artery
429941|NCT00968383|Percutaneous Coronary Intervention
429942|NCT00968383|Medical treatment
429943|NCT00968383|Tissue Viability
429944|NCT00968383|Magnetic Resonance
429945|NCT00968370|Severe and very severe pneumonia
429946|NCT00968370|severe malnutrition
429947|NCT00968370|children
429948|NCT00968370|day-care management
429949|NCT00968370|hospital management
429950|NCT00968357|SCV-07
429951|NCT00968357|relapsers
429952|NCT00968357|Hepatitis C
429953|NCT00968331|relapsed and refractory DLBCL
429954|NCT00968318|Tissue expander
429955|NCT00968318|seroma
429956|NCT00968318|extrusion
429957|NCT00968318|lymphatics
429958|NCT00968318|deep fascia
429959|NCT00968318|Rate of seroma formation after excision of strip of deep fascia
429960|NCT00968305|African American children with stable asthma
429961|NCT00968305|Asthma severity
429962|NCT00968305|Interleukin 13 from PHA stimulated PBMC
429963|NCT00968305|Lung function (FEV1%)
429964|NCT00968305|Total serum IgE
429965|NCT00968305|Pediatrics
429966|NCT00968292|K3 Promoter prosthetic foot Tensegrity Prosthetics Jerome Rifkin
429967|NCT00968279|Patients with atrial fibrillation
429968|NCT00968266|Adherence
429969|NCT00968266|Compliance
429970|NCT00968266|Rheumatoid Arthritis
429971|NCT00968266|Intervention
429972|NCT00968266|Beliefs about medication
429973|NCT00968266|Motivational Interviewing
429974|NCT00968266|Medication adherence
429975|NCT00968266|Patient compliance
429976|NCT00968266|Intervention studies
429977|NCT00968253|Acute Lymphocytic Leukemia
429978|NCT00968253|ALL
429979|NCT00968253|Hyper-CVAD
429980|NCT00968253|Everolimus
429981|NCT00968253|6-mercaptopurine
429982|NCT00968253|Citrovorum
429983|NCT00968253|Cyclophosphamide
429984|NCT00968253|Cytarabine
429985|NCT00968253|Dexamethasone
429986|NCT00968253|Doxorubicin
429987|NCT00968253|G-CSF
429988|NCT00968253|Methotrexate
429989|NCT00968253|MESNA
429991|NCT00968253|Prednisone
429992|NCT00968253|RAD001
429993|NCT00968253|Solumedrol
429994|NCT00968253|Vincristine Sulfate
429995|NCT00968240|GBM
429996|NCT00968240|AA
429997|NCT00968240|AO
429998|NCT00968240|Brain
429999|NCT00968240|Tumors
430000|NCT00968240|Malignant
430001|NCT00968240|Glioblastoma
430002|NCT00968240|Multiforme
430003|NCT00968240|Anaplastic
430004|NCT00968240|Astrocytoma
430005|NCT00968227|subarachnoid hemorrhage
430006|NCT00968227|vasospasm
430007|NCT00968227|transfusion
430008|NCT00968227|cerebral oxygen delivery
430009|NCT00968227|hemoglobin
430010|NCT00968214|stage IA breast cancer
430011|NCT00968214|stage IB breast cancer
430012|NCT00968214|stage II breast cancer
430013|NCT00968214|stage IIIA breast cancer
430014|NCT00968214|stage IIIB breast cancer
430015|NCT00968214|stage IIIC breast cancer
430016|NCT00968214|estrogen receptor-positive breast cancer
430017|NCT00968214|progesterone receptor-positive breast cancer
430018|NCT00968188|HIV Risk
430019|NCT00968188|Internet Intervention
430020|NCT00968188|Homosexuality, Male
430021|NCT00968188|HIV Seronegativity
430022|NCT00968175|Ultrasound guided celiac plexus neurolysis
430023|NCT00968175|CPN
430024|NCT00968175|Pancreatic Cancer
430025|NCT00968175|Pain Management
430026|NCT00968162|Bone Marrow Transplant
430027|NCT00968162|Sickle Cell Disease
430028|NCT00968136|refractory infantile spasms
430029|NCT00968110|Milk Allergy
430030|NCT00968097|Alzheimer' disease
430031|NCT00968097|SPECT imaging
430032|NCT00968084|Diagnostic Work Up
430033|NCT00968084|Normal Volunteers
430034|NCT00968084|HV
430035|NCT00968084|Inflammatory Disease
430036|NCT00968084|Autoimmune Disease
430037|NCT00968084|Immunologic Disease
430038|NCT00968084|Healthy Volunteer
430039|NCT00968071|Leukemia
430040|NCT00968071|AML
430041|NCT00968071|MDS
430042|NCT00968071|High-Risk Myelodysplastic Syndrome
430043|NCT00968071|Decitabine
430044|NCT00968071|5-aza-2 deoxycytidine
430045|NCT00968071|Dacogen
430046|NCT00968071|Gemtuzumab Ozogamicin
430047|NCT00968071|Mylotarg
430048|NCT00968058|Leak Pressure
430049|NCT00968058|Intubation, Endotracheal
430050|NCT00968058|Pediatric
430051|NCT00968058|Temporal Variation
430052|NCT00968045|Fibrinogen
430053|NCT00968045|Postoperative bleeding
430054|NCT00968045|Transfusions
430055|NCT00968045|CABG
430056|NCT00968032|PFO
430057|NCT00968032|Patent Foramen Ovale
430058|NCT00968006|diabetes
430059|NCT00968006|endothelium
430060|NCT00968006|stem cells
430061|NCT00967993|hyperphosphatemia
430062|NCT00967993|end-stage renal disease
430063|NCT00967993|ESRD
430064|NCT00967993|hemodialysis
430065|NCT00967993|diabetes
430066|NCT00967993|dialysis
430067|NCT00967980|pain
430068|NCT00967980|Hip Resurfacing
430069|NCT00967980|catheter
430070|NCT00967980|nerve block
430071|NCT00967980|UCSD
430072|NCT00967980|hip surgery
430073|NCT00967980|psoas
430074|NCT00967980|femoral
430075|NCT00967980|ambulation
430076|NCT00967980|hip flexion
430077|NCT00967980|infusion
430078|NCT00967967|control
430079|NCT00967967|symptoms
430080|NCT00967954|stage IIB prostate cancer
430081|NCT00967954|stage IIA prostate cancer
430082|NCT00967954|stage III prostate cancer
430083|NCT00967954|stage IV prostate cancer
430084|NCT00967941|Vascular Surgery
430085|NCT00967928|Stage IV or Recurrent Cervical cancer
430086|NCT00967915|Ankyloglossia
430087|NCT00967915|Tongue tie
430088|NCT00967915|Frenotomy
430089|NCT00967915|Frenulectomy
430090|NCT00967915|Breast feeding
430091|NCT00967915|HATLFF
430092|NCT00967915|IBFAT
430093|NCT00967902|intracoronary stent
430094|NCT00967902|drug eluting stent
430095|NCT00967902|sirolimus
430096|NCT00967902|endothelial progenitor cells
430097|NCT00967889|stage III prostate cancer
430098|NCT00967889|stage IV prostate cancer
430099|NCT00967889|recurrent prostate cancer
430100|NCT00967876|Men or women of any ethnic group scheduled to undergo conventional coronary angiography for suspected coronary artery stent stenosis
430101|NCT00967863|adenocarcinoma of the prostate
430102|NCT00967863|stage III prostate cancer
430103|NCT00967863|stage IV prostate cancer
430104|NCT00967850|High Myopia
430105|NCT00967850|Bevacizumab
430106|NCT00967850|Photodynamic therapy
430107|NCT00967837|Diabetes with complications
430108|NCT00967837|Wound healing
430109|NCT00967824|breast cancer
430110|NCT00967798|cystic fibrosis
430111|NCT00967798|diabetes
430112|NCT00967798|inflammation
430113|NCT00967798|oxidative stress
430114|NCT00967798|redox balance
430115|NCT00967798|lung disease
430116|NCT00967785|WHIM
430117|NCT00967785|Mozobil (TM)
430118|NCT00967785|Neutrophil Disorder
430119|NCT00967785|Plerixafor
430120|NCT00967772|Pharmacokinetics
430121|NCT00967772|Safety
430122|NCT00967772|tolerability
430123|NCT00967759|common cold
430124|NCT00967759|treatment
430125|NCT00967759|inflammatory symptoms of superior air passages affection
430126|NCT00967694|Glaucoma
430127|NCT00967694|Nitrous oxide
430128|NCT00967668|Counseling
430129|NCT00967668|Veterans
430130|NCT00967668|Weight loss
430131|NCT00967668|Physical activity
430132|NCT00967668|Diet
430133|NCT00967655|adenocarcinoma of the rectum
430134|NCT00967655|stage I rectal cancer
430135|NCT00967655|stage II rectal cancer
430136|NCT00967655|stage III rectal cancer
430137|NCT00967642|Patients with Diabetes Mellitus Submitted to Percutaneous Coronary Intervention with Stent
430138|NCT00967629|Diabetic nephropathy
430139|NCT00967629|CKD progression
430140|NCT00967629|AGEs
430141|NCT00967629|oxidative stress
430142|NCT00967629|dietary AGEs
430143|NCT00967616|metastatic
430144|NCT00967616|colon
430145|NCT00967616|rectum
430146|NCT00967616|combination
430147|NCT00967616|chemotherapy
430148|NCT00967603|adenocarcinoma of the pancreas
430149|NCT00967603|stage IV pancreatic cancer
430150|NCT00967564|Myelodysplastic Syndrome
430151|NCT00967564|Quality of Life
430152|NCT00967564|Anemia
430153|NCT00967564|Epoetin alfa
430154|NCT00967564|Eprex
430155|NCT00967551|Diarrhea
430156|NCT00967551|Pneumonia
430157|NCT00967551|Upper respiratory infections
430158|NCT00967551|Acute gastroenteritis
430159|NCT00967538|psoriasis
430160|NCT00967538|etanercept
430161|NCT00967538|efficacy
430162|NCT00967538|response
430163|NCT00967538|anti-TNF alpha
430164|NCT00967538|treatment efficacy
430165|NCT00967525|AML
430166|NCT00967525|ALL
430167|NCT00967525|leukemia
430168|NCT00967525|CML
430169|NCT00967525|Myelodysplastic Syndrome
430170|NCT00967525|malignancies
430171|NCT00967525|Undifferentiated leukemia
430172|NCT00967525|High risk malignancies
430173|NCT00967512|Oligonucleotides, Antisense
430174|NCT00967512|Tumor Suppressor Protein p53
430175|NCT00967512|idarubicin
430176|NCT00967512|cytarabine
430177|NCT00967499|PONV
430178|NCT00967499|rescue
430179|NCT00967473|Astigmatism
430180|NCT00967473|cataract
430181|NCT00967473|corneal astigmatism
430182|NCT00967473|IOL
430183|NCT00967473|AcrySof
430184|NCT00967460|Childhood obesity
430185|NCT00967460|Children
430186|NCT00967460|Inactivity
430187|NCT00967460|Physical activity
430188|NCT00967460|Motor skills
430189|NCT00967460|Motor fitness
430190|NCT00967460|Quality of life
430191|NCT00967460|Nutrition
430192|NCT00967460|Family
430193|NCT00967434|infarction
430194|NCT00967434|ischemia
430195|NCT00967434|surgery
430196|NCT00967434|perioperative
430197|NCT00967434|statins
430198|NCT00967421|Driving
430199|NCT00967421|DUI
430200|NCT00967421|Driving simulation
430201|NCT00967421|Drugs
430202|NCT00967421|Ethanol
430203|NCT00967408|Stroke
430204|NCT00967408|Antidepressive Agents,Second-Generation
430205|NCT00967408|Treatment Outcome
430206|NCT00967408|Rehabilitation
430207|NCT00967382|Pregnancy
430208|NCT00967382|Thrombophilia
430209|NCT00967382|High-risk pregnancy
430210|NCT00967382|LMWH prophylaxis
430211|NCT00967382|Placenta mediated pregnancy complications
430212|NCT00967369|Lymphoma
430213|NCT00967369|Classical Hodgkin Lymphoma
430214|NCT00967369|Cancer
430215|NCT00967369|Bortezomib
430216|NCT00967369|Velcade
430217|NCT00967369|Chemotherapy
430218|NCT00967369|ICE
430219|NCT00967369|Ifosfamide
430220|NCT00967369|Ifex
430221|NCT00967369|Mesna
430222|NCT00967369|Mesnex
430223|NCT00967369|Carboplatin
430224|NCT00967369|Paraplatin
430225|NCT00967369|Etoposide
430226|NCT00967369|VePesid
430227|NCT00967369|BICE
430228|NCT00967369|Pegfilgrastim
430229|NCT00967369|Neulasta
430230|NCT00967356|Healthy volunteers
430231|NCT00967343|Haploidentical stem cell transplantation
430232|NCT00967343|Graft-versus-host disease
430233|NCT00967343|Immune reconstitution
430234|NCT00967343|Alloreactive T-cells
430235|NCT00967343|Photodepletion
430236|NCT00967343|TH9402
430237|NCT00967343|Transplant related mortality
430238|NCT00967343|Hematologic malignancy
430239|NCT00967317|Auris-Sedina
430240|NCT00967317|Otitis
430241|NCT00967317|Efficacy
430242|NCT00967317|Tolerability
430243|NCT00967304|Unprovoked Venous thromboembolism
430244|NCT00967304|Clinical decision rule
430245|NCT00967304|Anticoagulants
430246|NCT00967304|Recurrence
430247|NCT00967304|Prognostic
430248|NCT00967304|Risk stratification
430249|NCT00967291|acinar cell adenocarcinoma of the pancreas
430250|NCT00967291|duct cell adenocarcinoma of the pancreas
430251|NCT00967291|stage IV pancreatic cancer
430252|NCT00967291|recurrent pancreatic cancer
430253|NCT00967278|OPCAB
430254|NCT00967278|pulmonary artery catheter
430255|NCT00967278|esophageal doppler
430256|NCT00967278|hemodynamics
430257|NCT00967265|Introduction seminar
430258|NCT00967265|Psychoeducation
430259|NCT00967265|Waiting list
430260|NCT00967265|Patient participation
430261|NCT00967265|Mental disorders
430262|NCT00967252|surgery
430263|NCT00967252|inflammation
430264|NCT00967252|infection
430265|NCT00967252|statins
430266|NCT00967239|ductal breast carcinoma in situ
430267|NCT00967239|invasive ductal breast carcinoma
430268|NCT00967239|invasive lobular breast carcinoma
430269|NCT00967239|invasive lobular breast carcinoma with predominant in situ component
430270|NCT00967226|hemangioma
430271|NCT00967200|adult anaplastic astrocytoma
430272|NCT00967200|adult diffuse astrocytoma
430273|NCT00967200|adult glioblastoma
430274|NCT00967200|adult giant cell glioblastoma
430275|NCT00967200|adult gliosarcoma
430276|NCT00967200|adult pilocytic astrocytoma
430277|NCT00967200|adult pineal gland astrocytoma
430278|NCT00967200|adult subependymal giant cell astrocytoma
430279|NCT00967200|adult brain stem glioma
430280|NCT00967200|adult choroid plexus tumor
430281|NCT00967200|adult craniopharyngioma
430282|NCT00967200|adult ependymoblastoma
430283|NCT00967200|adult medulloblastoma
430284|NCT00967200|adult supratentorial primitive neuroectodermal tumor (PNET)
430285|NCT00967200|adult anaplastic ependymoma
430286|NCT00967200|adult ependymoma
430287|NCT00967200|adult myxopapillary ependymoma
430288|NCT00967200|adult subependymoma
430289|NCT00967200|meningeal melanocytoma
430290|NCT00967200|adult meningeal hemangiopericytoma
430291|NCT00967200|adult grade I meningioma
430292|NCT00967200|adult grade II meningioma
430293|NCT00967200|adult anaplastic meningioma
430294|NCT00967200|adult papillary meningioma
430295|NCT00967200|adult anaplastic oligodendroglioma
430296|NCT00967200|adult oligodendroglioma
430297|NCT00967200|adult pineoblastoma
430298|NCT00967200|adult pineocytoma
430299|NCT00967200|adult mixed glioma
430300|NCT00967200|recurrent adult brain tumor
430301|NCT00967161|knee replacement motion analysis
430302|NCT00967135|Thoracotomy
430303|NCT00967135|Neuropathic pain
430304|NCT00967122|adjustment, hunger
430305|NCT00967122|Hunger/satiety changes before and after gastric band adjustment
430306|NCT00967109|Anemia
430307|NCT00967109|Tissue oxygenation
430308|NCT00967109|Spine surgery
430309|NCT00967096|rifaximin
430310|NCT00967096|acute graft versus host disease
430311|NCT00967096|bone marrow transplant
430312|NCT00967096|non-malignancy requiring BMT
430313|NCT00967083|Quality of Life
430314|NCT00967083|Questionnaires
430315|NCT00967083|Interviews
430316|NCT00967083|family members
430317|NCT00967083|care givers
430318|NCT00967083|09-104
430319|NCT00967057|recurrent childhood acute lymphoblastic leukemia
430320|NCT00967057|T-cell childhood acute lymphoblastic leukemia
430321|NCT00967044|Relapsed or Refractory Lymphoma
430322|NCT00967044|Hodgkin's lymphoma
430323|NCT00967044|Non Hodgkin's Lymphoma
430324|NCT00967044|NHL
430325|NCT00967044|LBH589
430326|NCT00967044|Panobinostat
430327|NCT00967044|RAD001
430328|NCT00967044|Everolimus
430329|NCT00967031|HER2-positive breast cancer
430330|NCT00967031|male breast cancer
430331|NCT00967031|stage IV breast cancer
430332|NCT00967031|tumors metastatic to brain
430333|NCT00967018|Safety parameters
430334|NCT00967018|ECG, blood and urine samples
430335|NCT00967018|general health state
430336|NCT00967005|N acetyl cysteine
430337|NCT00967005|Pathological gambling
430338|NCT00967005|Nicotine dependence
430339|NCT00966992|Uterine Cervical Cancer
430340|NCT00966992|Cancer of Cervix
430341|NCT00966992|Cervix Cancer
430342|NCT00966979|Osteoarthritis, Post-traumatic arthritis
430343|NCT00966966|Alzheimer Disease
430344|NCT00966940|Glaucoma
430345|NCT00966940|IOP
430346|NCT00966940|Travoprost
430347|NCT00966927|quality of life
430348|NCT00966927|functional independence
430349|NCT00966927|spina bifid
430350|NCT00966888|stage II breast cancer
430351|NCT00966875|rheumatoid arthritis
430352|NCT00966875|RA
430353|NCT00966849|Randomized Controlled Trial
430354|NCT00966849|Financial Support
430355|NCT00966849|Poverty
430356|NCT00966849|Child, Orphaned
430357|NCT00966849|HIV
430358|NCT00966836|Heart Transplantation
430359|NCT00966836|Cardiac Allograft Vasculopathy
430360|NCT00966836|Cytomegalovirus Infection
430361|NCT00966836|Everolimus
430362|NCT00966836|Valganciclovir
430363|NCT00966836|Mycophenolate
430364|NCT00966823|Diaphragm
430365|NCT00966823|Trachea
430366|NCT00966823|Lung development
430367|NCT00966823|Lung growth
430368|NCT00966823|Tracheal occlusion
430369|NCT00966823|ECMO
430370|NCT00966823|Neonatal death
430371|NCT00966810|chronic myelocytic leukemia
430372|NCT00966810|allogeneic stem cell transplantation
430373|NCT00966810|T cell depletion
430374|NCT00966810|donor lymphocyte infusion
430375|NCT00966810|GvHD
430376|NCT00966810|transplant related mortality
430377|NCT00966771|contraception
430378|NCT00966771|emergency contraception
430379|NCT00966771|pregnancy prevention after unprotected intercourse
430380|NCT00966745|surgical field condition
430381|NCT00966719|Jaundice
430382|NCT00966719|Breastfeeding
430383|NCT00966719|Infants
430384|NCT00966706|adenocarcinoma of the pancreas
430385|NCT00966706|stage III pancreatic cancer
430386|NCT00966706|stage IV pancreatic cancer
430387|NCT00966693|Relapsed/Refractory Multiple Myeloma
430388|NCT00966693|RRMM
430389|NCT00966693|Lenalidomide
430390|NCT00966693|Revlimid
430391|NCT00966693|CC-5013
430392|NCT00966693|Thalidomide
430393|NCT00966693|Thalomid
430394|NCT00966693|Dexamethasone
430395|NCT00966693|Decadron
430396|NCT00966680|general anesthesia
430397|NCT00966680|spinal anesthesia
430398|NCT00966680|emergency cesarean delivery
430399|NCT00966667|cancer survivor
430400|NCT00966667|stage I colon cancer
430401|NCT00966667|stage II colon cancer
430402|NCT00966667|stage III colon cancer
430403|NCT00966667|stage I rectal cancer
430404|NCT00966667|stage II rectal cancer
430405|NCT00966667|stage III rectal cancer
430406|NCT00966654|CABG
430407|NCT00966654|Cardiac Surgical Patient
430408|NCT00966628|pediatric
430409|NCT00966628|dengue
430410|NCT00966628|hypertonic sodium lactate
430411|NCT00966628|fluid resuscitation
430412|NCT00966628|Ringer's lactate
430413|NCT00966615|malnutrition
430414|NCT00966615|fluid status
430415|NCT00966615|survival
430416|NCT00966589|groin pain
430417|NCT00966589|sportsman hernia
430418|NCT00966589|osteitis pubis
430419|NCT00966589|laparoscopic surgery
430420|NCT00966576|Glaucoma
430421|NCT00966576|IOP
430422|NCT00966576|AZARGA
430423|NCT00966563|Mangafodipir
430424|NCT00966563|Primary Percutaneous Coronary Intervention
430425|NCT00966563|Myocardial infarction
430426|NCT00966563|Troponin
430427|NCT00966563|CK-MB
430428|NCT00966563|Magnetic Resonance Imaging
430429|NCT00966550|Tomato
430430|NCT00966550|Nutrition
430431|NCT00966537|to study the clinical application of 3D/4D ultrasound for fetal scanning
430432|NCT00966537|to study the clinical application of 3D/4D ultrasound for pelvic scanning;
430433|NCT00966537|to demonstrate how to optimally display the different organs.
430434|NCT00966537|to correlate our findings with other diagnostic tools like MRI, CT;
430435|NCT00966537|to correlate our findings with clinical outcome.
430436|NCT00966524|Endotracheal intubation
430437|NCT00966511|lung cancer
430438|NCT00966511|lung resection
430439|NCT00966511|lobectomy
430440|NCT00966511|pneumonectomy
430441|NCT00966511|lung function
430442|NCT00966511|perfusion
430443|NCT00966498|malignancy
430444|NCT00966498|solid tumor
430445|NCT00966498|recurrent
430446|NCT00966498|high risk
430447|NCT00966485|ASA resistance
430448|NCT00966485|coronary stenting
430449|NCT00966485|platelet function
430450|NCT00966485|laboratory ASA resistance
430451|NCT00966485|MACE
430452|NCT00966485|Positive SPECT
430453|NCT00966472|Rosuvastatin
430454|NCT00966472|Erlotinib
430455|NCT00966472|Squamous Cell Carcinoma
430456|NCT00966472|Nom-Small Cell Lung Cancer
430457|NCT00966459|COPD
430458|NCT00966446|MRSA; household; infection; colonization
430459|NCT00966433|Proseal™ LMA
430460|NCT00966433|children
430461|NCT00966433|ventilation
430462|NCT00966433|general anesthesia
430463|NCT00966433|Children under general anesthesia for outpatient surgery
430464|NCT00966407|Metabolic Syndrome
430465|NCT00966407|Obesity
430466|NCT00966407|Genetic risk markers
430467|NCT00966407|Single Nucleotide Polymorphisms
430468|NCT00966407|Young adults
430469|NCT00966407|Fitness testing
430470|NCT00966394|ADHD, saliva, caries
430471|NCT00966381|breastfeeding
430472|NCT00966381|bone mineral density
430473|NCT00966381|exercise
430474|NCT00966381|diet
430475|NCT00966355|Cirrhosis, Esophagus Disorders, Varicose Veins
430476|NCT00966342|vaccine
430477|NCT00966342|influenza
430478|NCT00966342|influenza vaccine
430479|NCT00966342|pandemic preparedness
430480|NCT00966329|Switching
430481|NCT00966329|Maraviroc
430482|NCT00966329|Virological efficacy
430483|NCT00966329|Lipid profile
430484|NCT00966329|Tropism
430485|NCT00966316|Acute Ischemic Stroke；clinical pathway;TCM；
430486|NCT00966303|rehabilitation
430487|NCT00966303|dyspnea
430488|NCT00966303|strength
430489|NCT00966290|anticoagulants
430490|NCT00966290|management
430491|NCT00966290|anticoagulation clinics
430492|NCT00966290|randomized comparison
430493|NCT00966277|Pancreas
430494|NCT00966277|Primary venous thromboembolism
430495|NCT00966277|VTE
430496|NCT00966277|Chemotherapy
430497|NCT00966277|Deep venous thrombosis
430498|NCT00966277|Pulmonary embolism
430499|NCT00966277|Dalteparin
430500|NCT00966277|Fragmin
430501|NCT00966277|Thromboprophylaxis
430502|NCT00966264|randomized controlled trial
430503|NCT00966264|menorrhagia
430504|NCT00966264|LNG-IUS
430505|NCT00966264|hysterectomy
430506|NCT00966251|Primary Hepatocellular Carcinoma
430507|NCT00966238|influenza
430508|NCT00966238|vaccine
430509|NCT00966199|blood pressure
430510|NCT00966199|aging
430511|NCT00966199|cerebrovascular circulation
430512|NCT00966199|hypertension
430513|NCT00966186|ProSeal Laryngeal Mask Airway
430514|NCT00966186|Rotational technique
430515|NCT00966186|Success rate
430516|NCT00966186|Postoperative complications
430517|NCT00966160|treatment naive
430518|NCT00966134|mountain medicine
430519|NCT00966134|ghrelin
430520|NCT00966134|growth hormone
430521|NCT00966134|hypoxia
430522|NCT00966134|physiology of hormonal adaptation to high altitude
430523|NCT00966121|Cirrhosis
430524|NCT00966121|Esophagus Disorders
430525|NCT00966121|Varicose Veins
430526|NCT00966095|prostate cancer
430527|NCT00966082|Cirrhosis
430528|NCT00966082|Esophagus Disorders
430529|NCT00966082|Varicose Veins
430530|NCT00966069|Respiratory tract infections
430531|NCT00966069|Viral infections
430532|NCT00966069|Pediatrics
430533|NCT00966069|Specimen collection
430534|NCT00966056|Nasal adhesions
430535|NCT00966056|Nasal synechiae
430536|NCT00966056|Mitomycin
430537|NCT00966056|Mitomycin c
430538|NCT00966056|Teflon
430539|NCT00966056|Splints
430540|NCT00966056|Septal splints
430541|NCT00966017|PET Scan
430542|NCT00966004|Urge incontinence
430543|NCT00966004|YM178
430544|NCT00966004|Overactive Bladder
430545|NCT00966004|Urgency
430546|NCT00966004|Urinary incontinence
430547|NCT00966004|mirabegron
430548|NCT00966004|Micturition
430549|NCT00965991|Gestational diabetes
430550|NCT00965991|Metformin
430551|NCT00965991|Glyburide
430552|NCT00965991|oral agents
430553|NCT00965978|ONO-5920
430554|NCT00965978|YM529
430555|NCT00965978|Minodronic Acid
430556|NCT00965978|Food Effect
430557|NCT00965965|health behavior
430558|NCT00965965|randomized controlled trials
430559|NCT00965965|self-efficacy
430560|NCT00965965|patient education
430561|NCT00965965|comprehension
430562|NCT00965965|mass screening
430563|NCT00965965|prevention and control
430564|NCT00965926|Overactive Bladder
430565|NCT00965926|Urinary incontinence
430566|NCT00965926|YM178
430567|NCT00965926|mirabegron
430568|NCT00965900|Cirrhosis
430569|NCT00965900|Esophagus Disorders
430570|NCT00965900|Varicose Veins
430571|NCT00965874|Rapid Atrial Fibrillation
430572|NCT00965874|Magnesium Sulfate
430573|NCT00965874|Cardiac arrhythmia
430574|NCT00965861|Tissue Registry
430575|NCT00965861|Tissue Collection
430576|NCT00965861|Unknown Primary
430577|NCT00965861|Breast
430578|NCT00965861|Lung
430579|NCT00965861|Gastrointestinal
430580|NCT00965861|Bone Marrow Transplant
430581|NCT00965861|Chronic Lymphocytic Leukemia
430582|NCT00965861|Central Nervous System
430583|NCT00965861|Head and Neck
430584|NCT00965861|Melanoma
430585|NCT00965861|Myelodysplastic syndrome
430586|NCT00965861|Multiple Myeloma
430587|NCT00965861|Lymphoma
430588|NCT00965861|Gynecologic
430589|NCT00965861|Genitourinary
430590|NCT00965861|Refractory Malignancy
430591|NCT00965848|Pneumonia, Ventilator-Associated
430592|NCT00965848|Intra-abdominal Infections
430593|NCT00965848|Urinary tract Infections
430594|NCT00965848|Doripenem
430595|NCT00965848|Doribax
430596|NCT00965835|PET Scan
430597|NCT00965822|URTI
430598|NCT00965822|Natural Health Products
430599|NCT00965796|Intravenous lidocaine
430600|NCT00965796|postoperative analgesia
430601|NCT00965783|Sleep, Apnea, OSA, obese, middle-aged
430602|NCT00965770|abortion
430603|NCT00965770|intrauterine device
430604|NCT00965770|cost-effectiveness
430605|NCT00965744|Ligasure vessel sealing system
430606|NCT00965744|Azygoportal Disconnection
430607|NCT00965744|Splenectomy
430608|NCT00965744|Portal hypertension
430609|NCT00965731|Lung Neoplasms
430610|NCT00965731|Crizotinib
430611|NCT00965718|advanced pancreatic cancer
430612|NCT00965705|Binge Eating Disorder
430613|NCT00965705|overeating
430614|NCT00965705|binge eating
430615|NCT00965705|women
430616|NCT00965705|overweight
430617|NCT00965705|compulsive overeating
430618|NCT00965679|Cardiac CT
430619|NCT00965679|Iodinated Radiocontrast
430620|NCT00965679|Ionizing Radiation
430621|NCT00965679|Aortic Valve Stenosis
430622|NCT00965679|Percutaneous Aortic Valve Replacement
430623|NCT00965679|Heart Valve
430624|NCT00965666|Fanconi Anemia
430625|NCT00965666|Hemic and Lymphatic Diseases
430626|NCT00965666|Anti-Rheumatic Agents
430627|NCT00965666|Anemia, Hypoplastic, Congenital
430628|NCT00965666|DNA Repair-Deficiency Disorders
430629|NCT00965666|Congenital, Hereditary, and
430630|NCT00965666|Neonatal Diseases and Abnormalities
430631|NCT00965640|male pattern baldness
430632|NCT00965640|androgenetic alopecia
430633|NCT00965640|hair loss
430634|NCT00965614|diagnose cardiac arrhythmia and CAD.
430635|NCT00965614|we'll try to establish the specific model to detect and diagnose cardiac arrhythmia and CAD.
430636|NCT00965601|Fibromyalgia
430637|NCT00965588|Alzheimer's disease
430638|NCT00965588|amyloid beta
430639|NCT00965588|vaccine
430640|NCT00965575|epilepsy
430641|NCT00965575|sleep
430642|NCT00965575|seizures
430643|NCT00965575|cognition
430644|NCT00965562|Premenstrual syndrome
430645|NCT00965562|PMS
430646|NCT00965562|calcium
430647|NCT00965536|Schizophrenia
430648|NCT00965536|Bipolar Disorder
430649|NCT00965536|Manic Disorder
430650|NCT00965536|Register study
430651|NCT00965536|Quetiapine
430652|NCT00965536|Quetiapine Prolong
430653|NCT00965536|Seroquel
430654|NCT00965536|Seroquel Prolong
430655|NCT00965536|Seroquel XR
430656|NCT00965536|In-patient
430657|NCT00965523|Cancer
430658|NCT00965523|breast cancer
430659|NCT00965523|neoplasm
430660|NCT00965523|E7389
430661|NCT00965523|Eribulin
430662|NCT00965510|diabetes
430663|NCT00965497|Amyotrophic Lateral Sclerosis
430664|NCT00965497|ALS
430665|NCT00965497|Multiple Sclerosis
430666|NCT00965497|MS
430667|NCT00965497|Major Depression
430668|NCT00965497|Depression
430669|NCT00965497|Major Depressive Disorder
430670|NCT00965497|antidepressants
430671|NCT00965497|Escitalopram
430672|NCT00965497|Lexapro
430673|NCT00965484|Genotropin Medical device Patient reported outcome
430674|NCT00965471|percutaneous coronary artery intervention
430675|NCT00965471|coronary artery bypass graft
430676|NCT00965471|acute coronary syndrome
430677|NCT00965458|New-onset Type 1 Diabetes Mellitus
430678|NCT00965458|New-onset T1DM
430679|NCT00965458|New-onset T1D
430680|NCT00965458|Alefacept
430681|NCT00965458|Amevive®
430682|NCT00965445|isoprostanes
430683|NCT00965445|mass spectrometry
430684|NCT00965406|acute coronary syndrome
430685|NCT00965406|glucose insulin potassium
430686|NCT00965393|Ischaemia reperfusion
430687|NCT00965393|Platelet activation
430688|NCT00965393|Endothelial function
430689|NCT00965393|Remote ischaemic preconditioning
430690|NCT00965393|Bradykinin
430691|NCT00965380|Trinity Evolution
430692|NCT00965380|Symptomatic lumbar degenerative disc disease
430693|NCT00965380|Posterior lumbar interbody fusion
430694|NCT00965380|Transforaminal lumbar interbody fusion
430695|NCT00965367|POV tonsillectomy adenoidectomy acupuncture acupressure child
430696|NCT00965367|Effectiveness of acupuncture on
430697|NCT00965354|severe
430698|NCT00965354|acute
430699|NCT00965354|influenza
430700|NCT00965354|consortium
430701|NCT00965354|swine
430702|NCT00965354|flu
430703|NCT00965354|influenza A
430704|NCT00965354|H1N1
430705|NCT00965354|hospital
430706|NCT00965354|admission
430707|NCT00965341|Cancer
430708|NCT00965341|Fatigue
430709|NCT00965341|Testosterone Replacement Therapy
430710|NCT00965341|Depo-Testosterone
430711|NCT00965341|Testosterone cypionate
430712|NCT00965341|Testosterone enanthate
430713|NCT00965341|Hypogonadic
430714|NCT00965341|Functional Assessment of Cancer Therapy-Fatigue subscale
430715|NCT00965341|FACIT-F
430716|NCT00965328|anticoagulation
430717|NCT00965328|hemofiltration
430718|NCT00965328|acute kidney injury
430719|NCT00965328|heparin
430720|NCT00965328|hemostasis
430721|NCT00965328|nadroparin
430722|NCT00965328|anti-Xa
430723|NCT00965328|endogenous thrombin potential
430724|NCT00965315|CV (cardiovascular)
430725|NCT00965315|MI (myocardial infarction)
430726|NCT00965315|fenofibrate
430727|NCT00965315|rosuvastatin
430728|NCT00965315|this trial is to test the hypothesis that the addition of fenofibrate on rosuvastatin would provide a further reduction in the time
430729|NCT00965302|Obesity
430730|NCT00965302|Diabetes mellitus, Type 2
430731|NCT00965302|Sleeve gastrectomy
430732|NCT00965302|Metabolic surgery
430733|NCT00965289|Aggressive large B-cell lymphoma (DLBCL)
430734|NCT00965289|Intensive chemotherapy
430735|NCT00965289|Rituximab
430736|NCT00965289|ASCT
430737|NCT00965276|Adjuvant Therapy
430738|NCT00965276|Paclitaxel
430739|NCT00965276|Chemoresistance
430740|NCT00965276|Serine/Threonine Kinase
430741|NCT00965276|Cell Survival
430742|NCT00965276|Breast Cancer
430743|NCT00965263|Cocaine
430744|NCT00965263|immunotherapy
430745|NCT00965263|vaccination
430746|NCT00965263|antibody
430747|NCT00965263|addiction
430748|NCT00965263|dependence
430749|NCT00965250|Thymic Malignancies
430750|NCT00965250|IMC-A12
430751|NCT00965250|Insulin-Like Growth Factor
430752|NCT00965224|AML (acute myeloid leukemia)
430753|NCT00965224|CML (chronic myeloid leukemia)
430754|NCT00965224|MM (multiple myeloma)
430755|NCT00965211|Tourette's, OCD, dTMS, YGTSS, YBOCS, supplementary motor cortex
430756|NCT00965211|Tourette's syndrome and Obsessive compulsive disorder
430757|NCT00965198|Catheters, Indwelling
430758|NCT00965198|Biofilms
430759|NCT00965185|Cardiovascular Disease
430760|NCT00965185|HIV
430761|NCT00965185|Atherosclerosis
430762|NCT00965185|Inflammation
430763|NCT00965185|Statins
430764|NCT00965185|treatment experienced
430765|NCT00965172|Cancer
430766|NCT00965172|Mucositis
430767|NCT00965172|Chemotherapy
430768|NCT00965172|Caphosol
430769|NCT00965172|Calcium phosphate
430770|NCT00965172|Sodium Bicarbonate
430771|NCT00965172|Baking Soda Solution
430772|NCT00965172|Multi-cycle chemotherapy
430773|NCT00965146|Osteoarthritis, traumatic arthritis, avascular necrosis
430774|NCT00965120|Ischaemia reperfusion
430775|NCT00965120|Bradykinin
430776|NCT00965120|Platelet activation
430777|NCT00965120|Endothelial function
430778|NCT00965068|Autism
430779|NCT00965068|Autism Spectrum Disorder
430780|NCT00965068|Cholesterol
430781|NCT00965068|Smith-Lemli-Opitz Syndrome
430782|NCT00965068|ASD
430783|NCT00965068|Pervasive Developmental Disorder
430784|NCT00965068|PPD-NOS
430785|NCT00965042|Ceftobiprole
430786|NCT00965042|ZEVTERA
430787|NCT00965042|ZEFTERA
430788|NCT00965042|Intestinal Microflora
430789|NCT00965029|COPD
430790|NCT00965029|Spirometry
430791|NCT00965029|Weaning
430792|NCT00965016|Extracorporeal membrane oxygenation，induced hypothermia
430793|NCT00964990|Moderate to severe chronic peripheral neuropathic pain
430794|NCT00964990|Postherpetic neuralgia
430795|NCT00964990|Post-traumatic neuralgia
430796|NCT00964990|Moderate to severe chronic pain
430797|NCT00964990|JNJ-42160443
430798|NCT00964977|pN1
430799|NCT00964977|head and neck cancer
430800|NCT00964977|radiation
430801|NCT00964977|prognosis
430802|NCT00964977|comprehensive cohort design
430803|NCT00964951|H1N1, influenza A viruses, vaccine, elderly
430804|NCT00964938|Hemodynamic response
430805|NCT00964938|Cardiac resynchronization therapy
430806|NCT00964886|chronic pain
430807|NCT00964886|back pain
430808|NCT00964886|antidepressants
430809|NCT00964873|Synta
430810|NCT00964873|STA-9090
430811|NCT00964873|ganetespib
430812|NCT00964873|Hematologic Cancers
430813|NCT00964873|Acute Myeloid Leukemia
430814|NCT00964873|Acute Lymphoblastic Leukemia
430815|NCT00964873|Blast-phase Chronic Myelogenous Leukemia
430816|NCT00964873|AML
430817|NCT00964873|ALL
430818|NCT00964873|CML
430819|NCT00964873|HSP90 Inhibitor
430820|NCT00964847|hypertension
430821|NCT00964847|cardiovascular disease
430822|NCT00964847|yoga
430823|NCT00964821|stage III adult Burkitt lymphoma
430824|NCT00964821|stage III adult diffuse large cell lymphoma
430825|NCT00964821|stage III adult diffuse mixed cell lymphoma
430826|NCT00964821|stage III adult diffuse small cleaved cell lymphoma
430827|NCT00964821|stage III adult Hodgkin lymphoma
430828|NCT00964821|stage III adult immunoblastic large cell lymphoma
430829|NCT00964821|stage III adult lymphoblastic lymphoma
430830|NCT00964821|stage III grade 1 follicular lymphoma
430831|NCT00964821|stage III grade 2 follicular lymphoma
430832|NCT00964821|stage III grade 3 follicular lymphoma
430833|NCT00964821|stage III mantle cell lymphoma
430834|NCT00964821|stage III marginal zone lymphoma
430835|NCT00964821|stage III small lymphocytic lymphoma
430836|NCT00964821|stage IV adult Burkitt lymphoma
430837|NCT00964821|stage IV adult diffuse large cell lymphoma
430838|NCT00964821|stage IV adult diffuse mixed cell lymphoma
430839|NCT00964821|stage IV adult diffuse small cleaved cell lymphoma
430840|NCT00964821|stage IV adult Hodgkin lymphoma
430841|NCT00964821|stage IV adult immunoblastic large cell lymphoma
430842|NCT00964821|stage IV adult lymphoblastic lymphoma
430843|NCT00964821|stage IV grade 1 follicular lymphoma
430844|NCT00964821|stage IV grade 2 follicular lymphoma
430845|NCT00964821|stage IV grade 3 follicular lymphoma
430846|NCT00964821|stage IV mantle cell lymphoma
430847|NCT00964821|stage IV marginal zone lymphoma
430949|NCT00964691|Anemia
430848|NCT00964821|stage IV small lymphocytic lymphoma
430849|NCT00964821|recurrent adult Burkitt lymphoma
430850|NCT00964821|recurrent adult diffuse large cell lymphoma
430851|NCT00964821|recurrent adult diffuse mixed cell lymphoma
430852|NCT00964821|recurrent adult diffuse small cleaved cell lymphoma
430853|NCT00964821|recurrent adult Hodgkin lymphoma
430854|NCT00964821|recurrent adult immunoblastic large cell lymphoma
430855|NCT00964821|recurrent adult lymphoblastic lymphoma
430856|NCT00964821|recurrent childhood large cell lymphoma
430857|NCT00964821|recurrent cutaneous T-cell non-Hodgkin lymphoma
430858|NCT00964821|recurrent grade 1 follicular lymphoma
430859|NCT00964821|recurrent grade 2 follicular lymphoma
430860|NCT00964821|recurrent grade 3 follicular lymphoma
430861|NCT00964821|recurrent mantle cell lymphoma
430862|NCT00964821|recurrent marginal zone lymphoma
430863|NCT00964821|recurrent small lymphocytic lymphoma
430864|NCT00964821|recurrent mycosis fungoides/Sezary syndrome
430865|NCT00964821|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
430866|NCT00964821|nodal marginal zone B-cell lymphoma
430867|NCT00964821|splenic marginal zone lymphoma
430868|NCT00964821|noncontiguous stage II adult Burkitt lymphoma
430869|NCT00964821|noncontiguous stage II adult diffuse large cell lymphoma
430870|NCT00964821|noncontiguous stage II adult diffuse mixed cell lymphoma
430871|NCT00964821|noncontiguous stage II adult diffuse small cleaved cell lymphoma
430872|NCT00964821|noncontiguous stage II adult immunoblastic large cell lymphoma
430873|NCT00964821|noncontiguous stage II adult lymphoblastic lymphoma
430874|NCT00964821|noncontiguous stage II grade 1 follicular lymphoma
430875|NCT00964821|noncontiguous stage II grade 2 follicular lymphoma
430876|NCT00964821|noncontiguous stage II grade 3 follicular lymphoma
430877|NCT00964821|noncontiguous stage II mantle cell lymphoma
430878|NCT00964821|noncontiguous stage II marginal zone lymphoma
430879|NCT00964821|noncontiguous stage II small lymphocytic lymphoma
430880|NCT00964821|accelerated phase chronic myelogenous leukemia
430881|NCT00964821|adult acute lymphoblastic leukemia in remission
430882|NCT00964821|adult acute myeloid leukemia in remission
430883|NCT00964821|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
430884|NCT00964821|adult acute myeloid leukemia with inv(16)(p13;q22)
430885|NCT00964821|adult acute myeloid leukemia with t(15;17)(q22;q12)
430886|NCT00964821|adult acute myeloid leukemia with t(16;16)(p13;q22)
430887|NCT00964821|adult acute myeloid leukemia with t(8;21)(q22;q22)
430888|NCT00964821|atypical chronic myeloid leukemia, BCR-ABL negative
430889|NCT00964821|blastic phase chronic myelogenous leukemia
430890|NCT00964821|chronic myelomonocytic leukemia
430891|NCT00964821|chronic phase chronic myelogenous leukemia
430892|NCT00964821|recurrent adult acute lymphoblastic leukemia
430893|NCT00964821|recurrent adult acute myeloid leukemia
430894|NCT00964821|refractory chronic lymphocytic leukemia
430895|NCT00964821|refractory hairy cell leukemia
430896|NCT00964821|relapsing chronic myelogenous leukemia
430897|NCT00964821|secondary acute myeloid leukemia
430898|NCT00964821|stage III chronic lymphocytic leukemia
430899|NCT00964821|stage IV chronic lymphocytic leukemia
430900|NCT00964821|chronic eosinophilic leukemia
430901|NCT00964821|primary myelofibrosis
430902|NCT00964821|chronic neutrophilic leukemia
430903|NCT00964821|de novo myelodysplastic syndromes
430904|NCT00964821|myelodysplastic/myeloproliferative neoplasm, unclassifiable
430905|NCT00964821|previously treated myelodysplastic syndromes
430906|NCT00964821|secondary myelodysplastic syndromes
430907|NCT00964821|stage I multiple myeloma
430908|NCT00964821|stage II multiple myeloma
430909|NCT00964821|stage III multiple myeloma
430910|NCT00964821|refractory multiple myeloma
430911|NCT00964821|aplastic anemia
430912|NCT00964808|Hip fractures
430913|NCT00964808|Treatment Outcome
430914|NCT00964808|Painkiller
430915|NCT00964795|Eyes
430916|NCT00964795|Neovascular
430917|NCT00964795|Macular Degeneration
430918|NCT00964795|Retina
430919|NCT00964795|AMD
430920|NCT00964795|VEGF Trap-Eye
430921|NCT00964795|Best Corrected Visual Acuity
430922|NCT00964782|Fontan
430923|NCT00964782|sildenafil
430924|NCT00964782|exercise capacity
430925|NCT00964782|Patients with Fontan Circulation
430926|NCT00964769|Pneumococcal Vaccine
430927|NCT00964769|Aged
430928|NCT00964756|ovarian cancer
430929|NCT00964756|Recurrent ovarian cancer and other gynecologic cancers
430930|NCT00964743|Neurologic Oncology
430931|NCT00964743|Neoplastic Meningitis from solid tumors
430932|NCT00964743|Brain and Nervous System
430933|NCT00964743|Breast Cancer
430934|NCT00964730|Thorough QT Study
430935|NCT00964730|Talampanel
430936|NCT00964730|Cardiac Repolarizatiom
430937|NCT00964730|Healthy Volunteers
430938|NCT00964717|back pain
430939|NCT00964717|neck pain
430940|NCT00964717|anxiety
430941|NCT00964717|range of motion
430942|NCT00964691|malaria
430943|NCT00964691|IPTp
430944|NCT00964691|Fansidar
430945|NCT00964691|Intermittent Preventive Treatment in pregnancy
430946|NCT00964691|pregnancy
430947|NCT00964691|prophylaxis
430948|NCT00964691|Chloroquine
430950|NCT00964691|Prevention
430951|NCT00964691|Placental malaria
430952|NCT00964691|Solomon Islands
430953|NCT00964691|Low birth weight
430954|NCT00964665|Hepatitis B,
430955|NCT00964665|Chronic,
430956|NCT00964665|Hepatitis B e Antigens positive
430957|NCT00964652|treadmill
430958|NCT00964652|body load
430959|NCT00964652|Parkinson's disease
430960|NCT00964652|gait
430961|NCT00964639|Pain
430962|NCT00964639|Postoperative
430963|NCT00964639|Local infiltration analgesia
430964|NCT00964639|Cerebral palsy
430965|NCT00964639|r-FLACC
430966|NCT00964626|stage IA ovarian epithelial cancer
430967|NCT00964626|stage IB ovarian epithelial cancer
430968|NCT00964626|stage IC ovarian epithelial cancer
430969|NCT00964626|stage IIA ovarian epithelial cancer
430970|NCT00964626|stage IIB ovarian epithelial cancer
430971|NCT00964626|stage IIC ovarian epithelial cancer
430972|NCT00964626|stage IIIA ovarian epithelial cancer
430973|NCT00964626|stage IIIB ovarian epithelial cancer
430974|NCT00964626|stage IIIC ovarian epithelial cancer
430975|NCT00964626|stage IV ovarian epithelial cancer
430976|NCT00964613|Pars Plana
430977|NCT00964613|Surgical Capsulotomy
430978|NCT00964613|Posterior capsule opacification
430979|NCT00964613|visual outcome
430980|NCT00964613|Complications
430981|NCT00964600|transversus abdominis block
430982|NCT00964600|postoperative pain
430983|NCT00964600|cesarean
430984|NCT00964587|diabetes self management education
430985|NCT00964587|problem-solving training
430986|NCT00964587|health behavior change
430987|NCT00964587|health literacy
430988|NCT00964548|vasospasm
430989|NCT00964548|subarachnoid hemorrhage
430990|NCT00964548|neurocritical care
430991|NCT00964548|dantrolene
430992|NCT00964548|vasorelaxation
430993|NCT00964522|Quality of life
430994|NCT00964522|Breast Cancer
430995|NCT00964522|Nursing Care
430996|NCT00964522|Education
430997|NCT00964522|Chemotherapy
430998|NCT00964496|vascular malformation
430999|NCT00964496|gastrointestinal bleeding
431000|NCT00964496|thalidomide
431001|NCT00964483|Hypertension
431002|NCT00964470|Burn, donor site, skin graft, dressing, AWBAT™-D, XEROFORM™, GLUCAN II™
431003|NCT00964457|cetuximab
431004|NCT00964457|rectum cancer
431005|NCT00964457|radiation
431006|NCT00964457|MRI
431007|NCT00964444|Labor and delivery
431008|NCT00964444|Vaginal delivery
431009|NCT00963391|Health Production
431010|NCT00963391|Government Policy; Regulation; Public Health
431011|NCT00963391|Government Policy; Provision and Effects of Welfare Programs
431012|NCT00963391|Gastrointestinal diseases
431013|NCT00963391|Respiratory Tract Infections
431014|NCT00963391|Diarrhea
431015|NCT00963391|Ethanol
431016|NCT00963391|Child, Preschool
431017|NCT00963391|Handwashing
431018|NCT00963365|Phase 1
431019|NCT00963365|Healthy volunteers
431020|NCT00963352|Colon cancer
431021|NCT00963352|Open surgery resection
431022|NCT00963352|Laparoscopic surgery resection
431023|NCT00963352|Morbidity
431024|NCT00963352|Mortality
431025|NCT00963352|Metastases
431026|NCT00963352|Oncology
431027|NCT00963352|Freedom of malignant disease recurrence
431028|NCT00963352|Safety of intervention open and laparoscopic
431029|NCT00963352|Examination of adverse markers
431030|NCT00963352|Development of metastases in lungs and other organs
431031|NCT00963339|AMD
431032|NCT00963326|stage I squamous cell carcinoma of the hypopharynx
431033|NCT00963326|stage I squamous cell carcinoma of the larynx
431034|NCT00963326|stage I squamous cell carcinoma of the nasopharynx
431035|NCT00963326|stage I squamous cell carcinoma of the oropharynx
431036|NCT00963326|stage II squamous cell carcinoma of the hypopharynx
431037|NCT00963326|stage II squamous cell carcinoma of the larynx
431038|NCT00963326|stage II squamous cell carcinoma of the nasopharynx
431039|NCT00963326|stage II squamous cell carcinoma of the oropharynx
431040|NCT00963326|stage III squamous cell carcinoma of the hypopharynx
431041|NCT00963326|stage III squamous cell carcinoma of the larynx
431042|NCT00963326|stage III squamous cell carcinoma of the nasopharynx
431043|NCT00963326|stage III squamous cell carcinoma of the oropharynx
431044|NCT00963326|stage IV squamous cell carcinoma of the hypopharynx
431045|NCT00963326|stage IV squamous cell carcinoma of the larynx
431046|NCT00963326|stage IV squamous cell carcinoma of the nasopharynx
431047|NCT00963326|stage IV squamous cell carcinoma of the oropharynx
431048|NCT00963326|recurrent squamous cell carcinoma of the hypopharynx
431049|NCT00963326|recurrent squamous cell carcinoma of the larynx
431050|NCT00963326|recurrent squamous cell carcinoma of the nasopharynx
431051|NCT00963326|recurrent squamous cell carcinoma of the oropharynx
431052|NCT00963326|recurrent verrucous carcinoma of the oral cavity
431053|NCT00963326|stage I verrucous carcinoma of the oral cavity
431054|NCT00963326|stage II verrucous carcinoma of the oral cavity
431055|NCT00963326|stage III verrucous carcinoma of the oral cavity
431056|NCT00963326|stage IV verrucous carcinoma of the oral cavity
431175|NCT00964106|caffeine
431057|NCT00963326|recurrent verrucous carcinoma of the larynx
431058|NCT00963326|stage I verrucous carcinoma of the larynx
431059|NCT00963326|stage II verrucous carcinoma of the larynx
431060|NCT00963326|stage III verrucous carcinoma of the larynx
431061|NCT00963326|stage IV verrucous carcinoma of the larynx
431062|NCT00963326|tongue cancer
431063|NCT00963313|Axial psoriatic arthritis
431064|NCT00963313|Adalimumab
431065|NCT00963313|Humira
431066|NCT00963313|anti-TNF
431067|NCT00963300|adenocarcinoma of the prostate
431068|NCT00963300|stage I prostate cancer
431069|NCT00963300|stage IIB prostate cancer
431070|NCT00963300|stage IIA prostate cancer
431071|NCT00963300|stage III prostate cancer
431072|NCT00963300|stage IV prostate cancer
431073|NCT00963287|alternative medicine
431074|NCT00963287|traditional Chinese medicine
431075|NCT00963274|refractory chronic lymphocytic leukemia
431076|NCT00963274|stage I chronic lymphocytic leukemia
431077|NCT00963274|stage II chronic lymphocytic leukemia
431078|NCT00963274|stage III chronic lymphocytic leukemia
431079|NCT00963274|stage IV chronic lymphocytic leukemia
431080|NCT00963274|recurrent small lymphocytic lymphoma
431081|NCT00963274|contiguous stage II small lymphocytic lymphoma
431082|NCT00963274|noncontiguous stage II small lymphocytic lymphoma
431083|NCT00963274|stage I small lymphocytic lymphoma
431084|NCT00963274|stage III small lymphocytic lymphoma
431085|NCT00963274|stage IV small lymphocytic lymphoma
431086|NCT00963274|adult nasal type extranodal NK/T-cell lymphoma
431087|NCT00963274|anaplastic large cell lymphoma
431088|NCT00963274|angioimmunoblastic T-cell lymphoma
431089|NCT00963274|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
431090|NCT00963274|hepatosplenic T-cell lymphoma
431091|NCT00963274|nodal marginal zone B-cell lymphoma
431092|NCT00963274|peripheral T-cell lymphoma
431093|NCT00963261|melanoma
431094|NCT00963261|interferon-a
431095|NCT00963261|quality of life
431096|NCT00963261|psychological distress
431097|NCT00963261|depressive symptoms
431098|NCT00963261|side effects
431099|NCT00963248|EBV
431100|NCT00963248|PTLD
431101|NCT00963248|RTx
431102|NCT00963248|pediatric
431103|NCT00963235|vaccine
431104|NCT00963235|13-valent pneumococcal conjugate vaccine
431105|NCT00963235|human immunodeficiency virus
431106|NCT00963222|Atherosclerosis
431107|NCT00963222|Coronary Artery Disease
431108|NCT00963222|Vitamin A
431109|NCT00963222|CD4-Positive T-Lymphocytes
431110|NCT00963222|Th1 Cells
431111|NCT00963222|Th2 Cells
431112|NCT00963209|endocrine sensitive
431113|NCT00963209|breast cancer
431114|NCT00963209|tamoxifen
431115|NCT00963209|genotyping
431116|NCT00963209|phenotyping
431117|NCT00963209|Pharmacokinetics
431118|NCT00963209|Endoxifen
431119|NCT00964379|Intra versus extraperitoneal colostomy
431120|NCT00964353|coumadine
431121|NCT00964353|genotype
431122|NCT00964353|genes
431123|NCT00964353|Warfarin
431124|NCT00964327|TMC114-C201
431125|NCT00964327|TMC114
431126|NCT00964327|HIV
431127|NCT00964327|darunavir
431128|NCT00964314|advanced cancer
431129|NCT00964314|TCM five elements music therapy
431130|NCT00964314|quality of life (QOL)
431131|NCT00964301|Asthma
431132|NCT00964301|Low-income
431133|NCT00964301|Quality of life
431134|NCT00964301|Children
431135|NCT00964288|electrical hyperalgesia
431136|NCT00964288|threshold tracking
431137|NCT00964288|pain
431138|NCT00964275|unspecified adult solid tumor, protocol specific
431139|NCT00964275|thromboembolism
431140|NCT00964262|diabetes
431141|NCT00964262|exenatide
431142|NCT00964262|SR exenatide
431143|NCT00964262|Peptron
431144|NCT00964236|sapropterin
431145|NCT00964236|Kuvan
431146|NCT00964236|cognition
431147|NCT00964236|brain
431148|NCT00964223|Acne vulgaris
431149|NCT00964210|Juvenile Idiopathic Arthritis
431150|NCT00964210|Inflammatory Bowel Disease
431151|NCT00964210|Acute Lymphoblastic Leukemia
431152|NCT00964210|Chronic Renal Disease
431153|NCT00964210|Solid Organ Transplant
431154|NCT00964197|FemmeJock
431155|NCT00964197|Pelvic Organ Prolapse
431156|NCT00964184|Maturity onset diabetes of the young 3 protein, human
431157|NCT00964171|adenocarcinoma of the pancreas
431158|NCT00964171|recurrent pancreatic cancer
431159|NCT00964171|stage IV pancreatic cancer
431160|NCT00964158|influenza infection
431161|NCT00964158|GSK Bio's influenza vaccine GSK2340272A
431162|NCT00964145|Nulliparous women
431163|NCT00964145|ultrasound
431164|NCT00964132|Non-Small Cell Lung Cancer
431165|NCT00964132|NSCLC
431166|NCT00964132|Rexinoid
431167|NCT00964132|NRX194204
431168|NCT00964132|Lung Cancer
431169|NCT00964132|RXR
431170|NCT00964106|inducer
431171|NCT00964106|midazolam
431172|NCT00964106|inhibitor
431173|NCT00964106|rosiglitazone
431174|NCT00964106|dextromethorphan
431176|NCT00964106|cocktail
431177|NCT00964106|pioglitazone
431178|NCT00964106|omeprazole
431179|NCT00964106|CYP
431180|NCT00964106|rosuvastatin
431181|NCT00964106|probe drug
431182|NCT00964106|drug interaction
431183|NCT00964106|flurbiprofen
431184|NCT00964093|premature
431185|NCT00964093|infection
431186|NCT00964093|central line
431187|NCT00964093|very low birth weight
431188|NCT00964093|silver alginate
431189|NCT00964093|Algidex
431190|NCT00964093|neonatal
431191|NCT00964093|NICU
431192|NCT00964067|rehabilitation outcome
431193|NCT00964067|cardiac patients
431194|NCT00964067|exercise intensity
431195|NCT00964054|adolescents
431196|NCT00964054|exercise
431197|NCT00964054|depression
431198|NCT00964054|dose response
431199|NCT00964054|pilot study
431200|NCT00964041|Cognitive Impairment
431201|NCT00964041|Neuroplasticity
431202|NCT00964041|D-cycloserine
431203|NCT00964041|N-methyl-D-aspartate (NMDA)
431204|NCT00964041|Anti-Bacterial Agents
431205|NCT00964041|Mental Disorders
431206|NCT00964041|Psychotic Disorders
431207|NCT00964041|Antitubercular Agents
431208|NCT00964041|Schizophrenia and Disorders with Psychotic Features
431209|NCT00964041|Schizoaffective Disorder
431210|NCT00964028|Combined vaccine
431211|NCT00964015|colloid fluid
431212|NCT00964015|crystalloid fluid
431213|NCT00964015|surgery
431214|NCT00964015|coronary artery bypass grafting
431215|NCT00964015|renal function
431216|NCT00964015|Patients undergoing coronary artery bypass surgery
431217|NCT00964002|recurrent prostate cancer
431218|NCT00964002|stage IV prostate cancer
431219|NCT00963989|Acute stroke
431220|NCT00963989|Large cerebral vessel occlusion
431221|NCT00963989|Core infarct volume
431222|NCT00963989|Penumbra System
431223|NCT00963989|Revascularization
431224|NCT00963989|Intracerebral hemorrhage
431225|NCT00963989|mRS
431226|NCT00963989|NIHSS
431227|NCT00963989|Procedural serious adverse events
431228|NCT00963989|All cause mortality
431229|NCT00963976|Stroke
431230|NCT00963976|Hypertension
431231|NCT00963976|Cerebral Blood Flow
431232|NCT00963976|CT Perfusion
431233|NCT00963963|sexual health
431234|NCT00963963|adolescent health
431235|NCT00963963|parent education
431236|NCT00963963|HIV Seronegativity
431237|NCT00963963|treatment experienced
431238|NCT00963950|cholecystectomy
431239|NCT00963937|adolescent
431240|NCT00963937|sumatriptan
431241|NCT00963937|children
431242|NCT00963937|migraine
431243|NCT00963924|Cognitive Impairment
431244|NCT00963924|Neuroplasticity
431245|NCT00963924|D-cycloserine
431246|NCT00963924|NMDA
431247|NCT00963924|Anti-Bacterial Agents
431248|NCT00963924|Mental Disorders
431249|NCT00963924|Psychotic Disorders
431250|NCT00963924|Antitubercular Agents
431251|NCT00963924|Schizophrenia and Disorders with Psychotic Features
431252|NCT00963924|Schizoaffective Disorder
431253|NCT00963911|colon cancer
431254|NCT00963911|rectal cancer
431255|NCT00963911|non-small cell lung cancer
431256|NCT00963911|small cell lung cancer
431257|NCT00963911|hypopharyngeal squamous cell carcinoma
431258|NCT00963911|laryngeal squamous cell carcinoma
431259|NCT00963911|laryngeal verrucous carcinoma
431260|NCT00963911|lip and oral cavity squamous cell carcinoma
431261|NCT00963911|oral cavity verrucous carcinoma
431262|NCT00963911|nasopharyngeal squamous cell carcinoma
431263|NCT00963911|oropharyngeal squamous cell carcinoma
431264|NCT00963911|paranasal sinus and nasal cavity squamous cell carcinoma
431265|NCT00963911|salivary gland squamous cell carcinoma
431266|NCT00963911|prostate cancer
431267|NCT00963911|breast cancer
431268|NCT00963911|adult non-Hodgkin lymphoma
431269|NCT00963898|Intravenous sedation
431270|NCT00963898|Target controlled infusion
431271|NCT00963898|Bispectral index
431272|NCT00963898|Dental treatment
431273|NCT00963898|Mental Retardation
431274|NCT00963898|Deep sedation
431275|NCT00963859|Robotic-assisted laparoscopic surgery
431276|NCT00963859|Extended pelvic lymph node dissection
431277|NCT00963859|RA-PLND
431278|NCT00963859|Second-look open lymph node dissection
431279|NCT00963859|O-PLND
431280|NCT00963859|Radical Cystectomy
431281|NCT00963859|Urinary diversion
431282|NCT00963859|Bladder
431283|NCT00963846|schizophrenia
431284|NCT00963846|cognition
431285|NCT00963846|functioning
431286|NCT00963833|Multiple Sclerosis
431287|NCT00963833|MS
431288|NCT00963833|Non-interventional
431289|NCT00963820|Relapsed multiple myeloma
431290|NCT00963820|Refractory multiple myeloma
431291|NCT00963820|Drug therapy
431292|NCT00963794|Rectal cancer
431293|NCT00963794|Population screening
431294|NCT00963794|Early detection
431295|NCT00963781|Coronary Artery Disease
431296|NCT00963781|Drug-Eluting Stents
431297|NCT00963781|Coronary Thrombosis
431298|NCT00963781|Platelet Aggregation Inhibitors
431299|NCT00963781|Coronary Restenosis
431300|NCT00963768|Diabetes Mellitus, Type 2
431301|NCT00963768|JNJ-28431754
431302|NCT00963768|Canagliflozin
431303|NCT00963768|Sodium Glucose Co-transporter (SGLT2 inhibitor)
431304|NCT00963768|Pharmacokinetics
431305|NCT00963768|Pharmacodynamics
431306|NCT00963755|Imaging
431307|NCT00963755|Positron emission tomography
431308|NCT00963755|F-18-FCH
431309|NCT00963755|Magnetic resonance imaging
431310|NCT00963755|Magnetic resonance spectroscopy
431311|NCT00963742|cataract surgery
431312|NCT00963742|IOL
431313|NCT00963742|Intraocular lens
431314|NCT00963729|estrogen receptor-positive breast cancer
431315|NCT00963729|recurrent breast cancer
431316|NCT00963729|stage II breast cancer
431317|NCT00963729|stage IIIA breast cancer
431318|NCT00963729|stage IIIB breast cancer
431319|NCT00963729|stage IIIC breast cancer
431320|NCT00963716|endobronchial biopsy
431321|NCT00963716|bronchoscopy
431322|NCT00963716|interventional pulmonology
431323|NCT00963677|Shikani optical stylet(SOS)
431324|NCT00963677|difficult airways
431325|NCT00963677|intubation
431326|NCT00963664|melanoma
431327|NCT00963664|malignant melanoma
431328|NCT00963664|interferon
431329|NCT00963664|interferon alfa-2b
431330|NCT00963664|Intron-A
431331|NCT00963664|Intron A
431332|NCT00963664|Intron
431333|NCT00963664|lovastatin
431334|NCT00963664|mevinolin
431335|NCT00963664|Mevacor
431336|NCT00963664|statin
431337|NCT00963664|HRI
431338|NCT00963651|Pulmonary nodule, solitary
431339|NCT00963651|Multiple pulmonary nodules
431340|NCT00963625|Blastocyst transfer
431341|NCT00963625|endometrial receptivity
431342|NCT00963625|IVF
431343|NCT00963625|in vitro fertilization
431344|NCT00963625|embryo cryopreservation
431345|NCT00963612|Microvascular Invasion
431346|NCT00963612|Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)
431347|NCT00963560|ReSTOR +3
431348|NCT00963547|Documented to be HER2+
431349|NCT00963534|Mantle cell lymphoma
431350|NCT00963534|Lenalidomide
431351|NCT00963534|Bendamustine
431352|NCT00963534|Rituximab
431353|NCT00963534|Nordic Lymphoma Group
431354|NCT00963534|MTD for lenalidomide
431355|NCT00963534|Untreated patients
431356|NCT00963534|Patients with mantle cell lymphoma, age over 65 years
431357|NCT00963521|adult acute myelomonocytic leukemia (M4)
431358|NCT00963521|adult acute monoblastic leukemia (M5a)
431359|NCT00963521|adult acute monocytic leukemia (M5b)
431360|NCT00963521|adult acute myeloid leukemia in remission
431361|NCT00963521|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
431362|NCT00963521|adult acute myeloid leukemia with inv(16)(p13;q22)
431363|NCT00963521|adult acute myeloid leukemia with t(16;16)(p13;q22)
431364|NCT00963508|Head Lice
431365|NCT00963495|clioquinol
431366|NCT00963495|relapsed and refractory hematologic malignancy
431367|NCT00963495|ALL
431368|NCT00963495|HD
431369|NCT00963495|CLL
431370|NCT00963495|High risk myelodysplasia (MDS) with an IPSS score >2.5
431371|NCT00963495|CML blast crisis
431372|NCT00963495|Relapsed or refractory acute myeloid leukemia (AML)
431373|NCT00963482|Smoking
431374|NCT00963482|Alcohol
431375|NCT00963482|Outcome
431376|NCT00963482|Harm reduction
431377|NCT00963482|Alcohol drinking
431378|NCT00963482|Treatment outcome
431379|NCT00963482|Treatment effectiveness
431380|NCT00963443|Aspirin Complex
431381|NCT00963443|Acetylsalicylic Acid
431382|NCT00963443|Pseudoephedrine
431383|NCT00963443|Common Cold
431384|NCT00963430|H1N1, influenza A viruses, pregnant women
431385|NCT00963417|osteoporosis
431386|NCT00963417|estrogen receptor-positive breast cancer
431387|NCT00963417|progesterone receptor-positive breast cancer
431388|NCT00963417|stage IA breast cancer
431389|NCT00963417|stage IB breast cancer
431390|NCT00963417|stage II breast cancer
431391|NCT00963417|stage IIIA breast cancer
431392|NCT00963404|Image-guided Radiotherapy
431393|NCT00963404|Fiducial marker
431394|NCT00963404|Adverse effects
431395|NCT00963183|Safety
431396|NCT00963183|Tolerability
431397|NCT00963183|Healthy
431398|NCT00963183|Inhalation
431399|NCT00963157|H1N1, influenza A viruses, vaccine, elderly
431400|NCT00963144|Gerd Questionnaire
431401|NCT00963131|Central serous chorioretinopathy,antioxidants
431402|NCT00963118|Angelica keiskei
431403|NCT00963118|Glycine max
431404|NCT00963118|metabolic syndrome
431405|NCT00963092|adenocarcinoma of the gastroesophageal junction
431406|NCT00963092|recurrent gastric cancer
431407|NCT00963092|stage IV gastric cancer
431408|NCT00963092|adenocarcinoma of the stomach
431409|NCT00963092|adenocarcinoma of the esophagus
431410|NCT00963092|recurrent esophageal cancer
431411|NCT00963092|stage I esophageal cancer
431412|NCT00963092|stage II esophageal cancer
431413|NCT00963092|stage III esophageal cancer
431414|NCT00963092|stage IV esophageal cancer
431415|NCT00963092|stage IA gastric cancer
431416|NCT00963092|stage IB gastric cancer
431417|NCT00963092|stage IIA gastric cancer
431418|NCT00963092|stage IIB gastric cancer
431419|NCT00963092|stage IIIA gastric cancer
431420|NCT00963092|stage IIIB gastric cancer
431421|NCT00963092|stage IIIC gastric cancer
431422|NCT00963079|IVF
431423|NCT00963079|in vitro fertilization
431424|NCT00963079|blastocyst transfer
431425|NCT00963079|endometrial receptivity
431426|NCT00963079|embryo cryopreservation
431427|NCT00963066|NAVA
431428|NCT00963066|Acute Lung Injury
431429|NCT00963066|Pressure Support Ventilation
431430|NCT00963066|Intubation
431431|NCT00963066|Tracheostomy
431432|NCT00963066|Mechanical ventilation
431433|NCT00963053|dysmenorrhoea
431434|NCT00963053|dysmenorrhea
431435|NCT00963053|pain
431436|NCT00963053|pre-emptive
431437|NCT00963040|intranasal oxytocin
431438|NCT00963040|acute headache treatment
431439|NCT00963040|chronic daily headache
431440|NCT00963027|Hypertension, Pulmonary
431441|NCT00963027|Treprostinil
431442|NCT00963027|Pharmacokinetics
431443|NCT00963027|Treprostinil Diethanolamine
431444|NCT00963027|Pulmonary Arterial Hypertension
431445|NCT00963027|Esomeprazole
431446|NCT00963001|Hypertension, Pulmonary
431447|NCT00963001|Treprostinil
431448|NCT00963001|Pharmacokinetics
431449|NCT00963001|Treprostinil Diethanolamine
431450|NCT00963001|Pulmonary Arterial Hypertension
431451|NCT00962988|Cerebrovascular disease
431452|NCT00962988|stroke
431453|NCT00962988|Transient Ischemic Attack
431454|NCT00962988|smoking cessation
431455|NCT00962988|Pharmacotherapy
431456|NCT00962962|Abnormal fasting glucose
431457|NCT00962949|POTS
431458|NCT00962949|Orthostatic intolerance
431459|NCT00962936|Chronic Hepatitis C
431460|NCT00962936|HCV Genotype I infection
431461|NCT00962936|Liver disease
431462|NCT00962923|Systemic sclerosis
431463|NCT00962923|Mesenchymal Stem Cells
431464|NCT00962923|Transplantation
431465|NCT00962910|Femoral Fractures
431466|NCT00962910|Critical Pathway
431467|NCT00962910|Cluster Randomized Controlled Trial
431468|NCT00962910|Safety
431469|NCT00962910|Efficiency
431470|NCT00962897|atherosclerosis
431471|NCT00962897|covered stent
431472|NCT00962897|percutaneous intervention
431473|NCT00962897|stent
431474|NCT00962897|angioplasty
431475|NCT00962884|Orthostatic hypotension
431476|NCT00962884|Breathing
431477|NCT00962884|Blood pressure
431478|NCT00962884|standing
431479|NCT00962845|stage III melanoma
431480|NCT00962845|stage IV melanoma
431481|NCT00962832|rhuMAb IFNalpha
431482|NCT00962832|SLE
431483|NCT00962819|Mumps
431484|NCT00962819|Immunity
431485|NCT00962819|Vaccine
431486|NCT00962819|Mumps antibodies
431487|NCT00962819|Mumps immunity
431488|NCT00962806|Pediatric obesity
431489|NCT00962806|Insulin resistance
431490|NCT00962806|Diabetes
431491|NCT00962806|Mitochondria
431492|NCT00962793|latent tuberculosis prevalence of health care workers
431493|NCT00962780|vaccine
431494|NCT00962780|13-valent pneumococcal conjugate vaccine
431495|NCT00962780|23-valent pneumococcal polysaccharide vaccine
431496|NCT00962780|human immunodeficiency virus
431497|NCT00962767|Oncology comparison study
431498|NCT00962754|recording fluid balance
431499|NCT00962754|reliability
431500|NCT00962754|utility
431501|NCT00962754|sick neonate
431502|NCT00962754|fluid balance
431503|NCT00962754|inpatient
431504|NCT00962754|sick
431505|NCT00962728|heart rate
431506|NCT00962728|tachycardia
431507|NCT00962728|orthostatic intolerance
431508|NCT00962715|Leukemia
431509|NCT00962715|CLL
431510|NCT00962715|Influenza Vaccine Trivalent Inactivated
431511|NCT00962715|TIV
431512|NCT00962715|Flu
431513|NCT00962715|Pegasys
431514|NCT00962715|Pegylated interferon
431515|NCT00962715|Roferon
431516|NCT00962715|Interferon
431517|NCT00962702|Exclusion
431518|NCT00962702|Left Atrial Appendage
431519|NCT00962702|Surgical
431520|NCT00962702|Open chest
431521|NCT00962689|chronic rhinosinusitis
431522|NCT00962689|biofilm
431523|NCT00962689|sinus tissue
431524|NCT00962689|nasal secretions
431525|NCT00962689|proteomics
431526|NCT00962689|diagnosis
431527|NCT00962689|decreased antibiotics
431528|NCT00962689|Develop a test to identify patients with sinusitis subtypes
431529|NCT00962676|suspicious of tuberculosis
431530|NCT00962676|immunocompromised patients
431531|NCT00962650|abdominal adhesions
431532|NCT00962650|diagnostic peritoneoscopy
431533|NCT00962650|Natural Orifice Transluminal Endoscopic Surgery
431534|NCT00962650|NOTES
431535|NCT00962637|Secondary Hypogonadism
431536|NCT00962624|Meningococcal
431537|NCT00962624|Vaccine
431538|NCT00962624|Meningitis
431539|NCT00962611|Solid tumors
431540|NCT00962611|Advanced cancer
431541|NCT00962598|Adolescents
431542|NCT00962598|Major Depressive Disorder
431543|NCT00962598|Proton Magnetic Resonance Spectroscopy
431544|NCT00962598|Immune System Activation
431545|NCT00962598|Omega-3 Fatty Acids
431546|NCT00962572|Outcomes
431547|NCT00962572|Cancer
431548|NCT00962572|Radiotherapy
431549|NCT00962572|Socio-economic
431550|NCT00962546|cerebral aneurysm
431551|NCT00962546|subarachnoid hemorrhage
431552|NCT00962546|cerebral vasospasm
431553|NCT00962546|computed tomographic perfusion
431554|NCT00962546|computed tomographic angiography
431555|NCT00962533|Chronic Hepatitis B
431556|NCT00962520|pancreatic cancer
431557|NCT00962520|resectable
431558|NCT00962520|Tarceva
431559|NCT00962507|recurrent adult T-cell leukemia/lymphoma
431560|NCT00962507|adult nasal type extranodal NK/T-cell lymphoma
431561|NCT00962507|anaplastic large cell lymphoma
431562|NCT00962507|angioimmunoblastic T-cell lymphoma
431563|NCT00962507|splenic marginal zone lymphoma
431564|NCT00962507|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
431565|NCT00962507|nodal marginal zone B-cell lymphoma
431566|NCT00962507|recurrent adult Hodgkin lymphoma
431567|NCT00962507|recurrent adult Burkitt lymphoma
431568|NCT00962507|recurrent adult diffuse large cell lymphoma
431569|NCT00962507|recurrent adult diffuse mixed cell lymphoma
431570|NCT00962507|recurrent adult diffuse small cleaved cell lymphoma
431571|NCT00962507|recurrent adult grade III lymphomatoid granulomatosis
431572|NCT00962507|recurrent adult immunoblastic large cell lymphoma
431573|NCT00962507|recurrent adult lymphoblastic lymphoma
431574|NCT00962507|recurrent cutaneous T-cell non-Hodgkin lymphoma
431575|NCT00962507|recurrent mycosis fungoides/Sezary syndrome
431576|NCT00962507|recurrent grade 1 follicular lymphoma
431577|NCT00962507|recurrent grade 2 follicular lymphoma
431578|NCT00962507|recurrent grade 3 follicular lymphoma
431579|NCT00962507|recurrent mantle cell lymphoma
431580|NCT00962507|recurrent marginal zone lymphoma
431581|NCT00962507|recurrent small lymphocytic lymphoma
431582|NCT00962507|cutaneous B-cell non-Hodgkin lymphoma
431583|NCT00962507|Waldenstrom macroglobulinemia
431584|NCT00962507|refractory multiple myeloma
431585|NCT00962468|Pulmonary Disease, Chronic Obstructive
431586|NCT00962468|Critical Pathway
431587|NCT00962468|Cluster Randomized Controlled Trial
431588|NCT00962468|Safety
431589|NCT00962468|Efficiency
431590|NCT00962455|Spirometry
431591|NCT00962455|Family Practice
431592|NCT00962455|Randomized Controlled Trial
431593|NCT00962455|Feedback
431594|NCT00962455|Intervention Studies
431595|NCT00962442|alcoholic hepatitis
431596|NCT00962442|N-Acetylcysteine
431597|NCT00962442|enteral nutrition
431598|NCT00962442|oxidative stress
431599|NCT00962442|severe acute alcoholic hepatitis
431600|NCT00962429|neuropathy, lipoic acid
431601|NCT00962416|Drug eluting stent
431602|NCT00962416|Biolimus
431603|NCT00962416|Biodegradable stent
431604|NCT00962416|ST-elevation myocardial infarction
431605|NCT00962416|Coronary artery disease
431606|NCT00962403|post traumatic stress disorder
431607|NCT00962403|yoga
431608|NCT00962403|meditation
431609|NCT00962403|military
431610|NCT00962403|veteran
431611|NCT00962403|trauma
431612|NCT00962403|stress
431613|NCT00962403|depression
431614|NCT00962403|anxiety
431615|NCT00962403|insomnia
431616|NCT00962403|autonomic
431617|NCT00962377|molecular expression testing
431618|NCT00962377|right ventricular endomyocardial biopsy
431619|NCT00962351|total hip replacement
431620|NCT00962351|primary cementless total hip arthroplasty
431621|NCT00962351|metal ion
431622|NCT00962351|metal-on-metal
431623|NCT00962338|convalescence
431624|NCT00962338|pain
431625|NCT00962338|nausea
431626|NCT00962338|vomiting
431627|NCT00962338|sexual dysfunction
431628|NCT00962325|Physical activity
431629|NCT00962325|Obesity
431630|NCT00962325|Bariatric surgery
431631|NCT00962325|Weight Loss
431632|NCT00962312|adenocarcinoma of the pancreas
431633|NCT00962312|recurrent pancreatic cancer
431634|NCT00962312|stage IV pancreatic cancer
431635|NCT00962299|Child
431636|NCT00962299|Wheezing
431637|NCT00962299|Dyspnea
431638|NCT00962299|Inhaled corticosteroids
431639|NCT00962286|Furosemide
431640|NCT00962286|obesity
431641|NCT00962273|health personnel
431642|NCT00962273|communicable diseases
431643|NCT00962273|stress, psychological
431644|NCT00962273|resilience, psychological
431645|NCT00962273|disaster planning
431646|NCT00962273|education
431647|NCT00962273|online
431648|NCT00962260|glucocerebrosidase
431649|NCT00962260|enzyme replacement therapy
431650|NCT00962260|Gaucher disease
431651|NCT00962260|plant cell culture
431652|NCT00962260|splenomegaly
431653|NCT00962260|hepatomegaly
431654|NCT00962260|anemia
431655|NCT00962260|thrombocytopenia
431656|NCT00962247|physical activity
431657|NCT00962247|relative reinforcing value
431658|NCT00962247|sedentary behavior
431659|NCT00962247|obesity
431660|NCT00962247|reduce sedentary behaviors in children and increase physical activity
431661|NCT00962234|Lipogenesis
431662|NCT00962234|Lipolysis
431663|NCT00962234|Phospholipids
431664|NCT00962234|Body Composition
431665|NCT00962234|Nutritional Status
431666|NCT00962234|Lipid Metabolism
431667|NCT00962221|LDL lipoprotein subclasses in subclinical hypothyroidism
431668|NCT00962208|children
431669|NCT00962208|corneal reshaping
431670|NCT00962208|myopia
431671|NCT00962208|myopia control
431672|NCT00962208|orthokeratology
431673|NCT00962195|health
431674|NCT00962195|blood pressure
431675|NCT00962195|liver enzymes
431676|NCT00962195|insulin resistance
431677|NCT00962182|celiac disease
431678|NCT00962182|transglutaminase antibody
431679|NCT00962169|Guideline adherence
431680|NCT00962169|Implementation
431681|NCT00962169|Physical therapy
431682|NCT00962169|Low back pain
431683|NCT00962169|Health plan implementation
431684|NCT00962156|Sepsis
431685|NCT00962156|Shock
431686|NCT00962156|Fluid therapy
431687|NCT00962156|Plasma expanders
431688|NCT00962143|Acute Achilles Tendon Tear
431689|NCT00962143|Acute Achilles Tendon Repair
431690|NCT00962130|tissue perfusion
431691|NCT00962130|reconstructive surgery
431692|NCT00962130|continuous glucose monitoring
431693|NCT00962117|Food Reinforcement
431694|NCT00962117|Energy Intake
431695|NCT00962117|Obesity
431696|NCT00962117|Dopamine
431697|NCT00962104|ADHD
431698|NCT00962091|Area under the plasma concentration versus time curve (AUC)
431699|NCT00962091|Maximum plasma concentration (Cmax)
431700|NCT00962091|Area under the plasma concentration versus time curve zero to the time of the last quantifiable concentration (AUC0-tlast)
431701|NCT00962091|Confidence intervals (CI)
431702|NCT00962091|Time of first observed maximum plasma concentration (Tmax)
431703|NCT00962078|COPD
431704|NCT00962078|Pre-Lung-Transplantation
431705|NCT00962078|Intervall versus continuous training
431706|NCT00962078|6 MWD
431707|NCT00962039|Abdominal Pain
431708|NCT00962039|Anxiety
431709|NCT00962026|Interleukin 1
431710|NCT00962026|Type 1 diabetes mellitus
431711|NCT00962026|Rilonacept
431712|NCT00962026|Arcalyst
431713|NCT00962000|Hemodialysis
431714|NCT00962000|Dialysis, Renal
431715|NCT00961987|Maternity care
431716|NCT00961987|Interprofessional collaboration
431717|NCT00961987|Continuity of Care
431718|NCT00961987|Integration
431719|NCT00961974|type 1 diabetes
431720|NCT00961974|hemoglobin A1c
431721|NCT00961974|family
431722|NCT00961974|involvement
431723|NCT00961974|responsibility
431724|NCT00961974|conflict
431725|NCT00961974|quality of life
431726|NCT00961974|children
431727|NCT00961961|Bipolar Disorder
431728|NCT00961961|Manic Depression
431729|NCT00961961|Major Depressive Episode
431730|NCT00961961|Mania
431731|NCT00961961|Hypomania
431732|NCT00961961|Long Term Treatment
431733|NCT00961948|Indigo carmine dye spraying
431734|NCT00961948|Narrow band imaging (NBI)
431735|NCT00961948|Confocal Microscopy
431736|NCT00961935|bipolar disorder
431737|NCT00961935|child bipolar disorder
431738|NCT00961935|adolescent bipolar disorder
431739|NCT00961935|pediatric bipolar disorder
431740|NCT00961935|fMRI
431741|NCT00961935|MRI
431742|NCT00961935|EEG
431743|NCT00961935|neurocognitive tasks
431744|NCT00961922|childhood brain tumour survivors
431745|NCT00961896|Basal Cell Carcinoma
431746|NCT00961896|Gorlin Syndrome,
431747|NCT00961896|Gorlin-Goltz Syndrome,
431748|NCT00961896|Basal Cell Nevus Syndrome,
431749|NCT00961896|Nevoid Basal Cell Carcinoma Syndrome,
431750|NCT00961896|Basal Cell Carcinoma Nevus Syndrome
431751|NCT00961883|HIV
431752|NCT00961883|Vaccine
431753|NCT00961883|HIV Seronegativity
431754|NCT00961883|Preventive Vaccine
431755|NCT00961870|bone
431756|NCT00961870|motor neuron excitability
431757|NCT00961870|forearm vibration
431758|NCT00961870|Mechanical Loading
431759|NCT00961831|Neoplasm
431760|NCT00961831|PET/CT diagnosis
431761|NCT00961831|PET tracer
431762|NCT00961818|Voice
431763|NCT00961818|Voice Quality
431764|NCT00961818|Voice Training
431765|NCT00961818|Evaluation
431766|NCT00961805|Fibromyalgia
431767|NCT00961805|Treatment
431768|NCT00961805|Dance
431769|NCT00961805|Randomized controlled study
431770|NCT00961805|Exercise
431771|NCT00961753|PDA
431772|NCT00961753|Ibuprofen
431773|NCT00961753|Preterm
431774|NCT00961753|Neonate
431775|NCT00961740|Childhood Obesity
431776|NCT00961740|CBT
431777|NCT00961740|Family
431778|NCT00961740|Lifestyle change
431779|NCT00961727|Bedside Pews
431780|NCT00961727|Credit Valley Hospital
431781|NCT00961727|The Bedside Paediatric Early Warning System
431782|NCT00961727|clinically deteriorating
431783|NCT00961714|VCF
431784|NCT00961688|PCOS
431785|NCT00961688|polycystic ovary syndrome
431786|NCT00961688|Polycystic ovarian syndrome
431787|NCT00961688|infertility
431788|NCT00961688|ovulation
431789|NCT00961675|otitis
431790|NCT00961675|acute
431791|NCT00961675|externa
431792|NCT00961675|ear
431793|NCT00961649|Open-Angle Glaucoma
431794|NCT00961649|Ocular Hypertension
431795|NCT00961649|Brinzolamide
431796|NCT00961649|Brimonidine
431797|NCT00961649|Intraocular Pressure
431798|NCT00961610|internet support
431799|NCT00961610|cancer
431800|NCT00961610|rehabilitation
431801|NCT00961597|Meniscus
431802|NCT00961597|Avascular region
431803|NCT00961597|Platelet rich plasma
431804|NCT00961571|colorectal cancer
431805|NCT00961571|sunitinib
431806|NCT00961571|capecitabine
431807|NCT00961558|varicocelectomy
431808|NCT00961558|male infertility
431809|NCT00961558|clinical varicoceles
431810|NCT00961558|randomized control trial
431811|NCT00961532|intracerebral hemorrhage
431812|NCT00961532|platelets
431813|NCT00961506|cholecystectomy
431814|NCT00961506|gallbladder
431815|NCT00961506|laparoscopy
431816|NCT00961506|laparoendoscopic
431817|NCT00961467|Relapsed/ refractory Multiple Myeloma
431818|NCT00961454|Major depressive disorder, anxiety disorders, treatments, photobiomodulation, near infra-red phototherapy, cerebral blood flow
431819|NCT00961441|Levetiracetam
431820|NCT00961441|Epilepsy
431821|NCT00961441|Children
431822|NCT00961441|Adults
431823|NCT00961428|Anorexia Nervosa
431824|NCT00961428|Eating Disorders
431825|NCT00961428|Exercise
431826|NCT00961428|Physical Activity
431827|NCT00961402|Exercise
431828|NCT00961402|PostParum Depression
431829|NCT00961389|delirium
431830|NCT00961389|critical care
431831|NCT00961389|risk factors
431832|NCT00961389|prediction
431833|NCT00961389|inflammation
431834|NCT00961376|melanoma
431835|NCT00961376|unresectable stage III or IV melanoma
431836|NCT00961350|PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.
431837|NCT00961337|school children
431838|NCT00961337|influenza vaccination
431839|NCT00961337|vaccine effectiveness
431840|NCT00961337|influenza attack rate
431841|NCT00961337|absenteeism
431842|NCT00961337|Influenza vaccine
431843|NCT00961311|Balloon
431844|NCT00961311|Angioplasty
431845|NCT00961311|Coronary Artery
431846|NCT00961311|PCI
431847|NCT00961311|PTCA
431848|NCT00961311|Heart Disease
431849|NCT00961311|Myocardial Ischemia
431850|NCT00961298|IBS
431851|NCT00961298|Irritable Bowel Syndrome
431852|NCT00961298|GAD
431853|NCT00961298|Generalized Anxiety Disorder
431854|NCT00961285|pharmacogenomics
431855|NCT00961285|genotyping
431856|NCT00961272|Pre-menopausal
431857|NCT00961272|Pharmacokinetics
431858|NCT00961272|Raltegravir
431859|NCT00961272|Women
431860|NCT00961272|HIV-infected
431861|NCT00961259|healthy
431862|NCT00961259|pharmacokinetics
431863|NCT00961259|therapeutic equivalency
431864|NCT00961259|fenofibric acid
431865|NCT00961246|web based intervention
431866|NCT00961246|individually-tailored
431867|NCT00961246|Chinese-American children
431868|NCT00961246|compared the changes in physical activity level
431869|NCT00961246|changes in dietary intake
431870|NCT00961246|changes in coping strategy used
431871|NCT00961246|changes in BMI
431872|NCT00961233|eosinophilic esophagitis
431873|NCT00961194|Ketamine
431874|NCT00961194|pain
431875|NCT00961194|neuropathic pain
431876|NCT00961194|chronic
431877|NCT00961181|paclitaxel
431878|NCT00961181|in-stent restenosis
431879|NCT00961181|BMS-ISR
431880|NCT00961181|DES-ISR
431881|NCT00961181|drug eluting balloon
431882|NCT00961168|Mechanical Ventilation
431883|NCT00961155|asthma
431884|NCT00961155|children
431885|NCT00961155|EBC
431886|NCT00961155|exposure to tabacco
431887|NCT00961155|antiasthma treatment
431888|NCT00961142|Haploidentical Transplantation
431889|NCT00961142|CD3/CD19 Depletion
431890|NCT00961142|AML
431891|NCT00961142|ALL
431892|NCT00961142|Reduced Intensity Conditioning
431893|NCT00961129|colorectal cancer
431894|NCT00961129|needs
431895|NCT00961129|survivors
431896|NCT00961129|any stage
431897|NCT00961116|healthy
431898|NCT00961116|pharmacokinetics
431899|NCT00961116|therapeutic equivalency
431900|NCT00961116|fasting
431901|NCT00961116|procetofen
431902|NCT00961116|fenofibric acid
431903|NCT00961103|spinal muscular atrophy
431904|NCT00961103|motor development
431905|NCT00961103|orthoses
431906|NCT00961090|Brain tumor
431907|NCT00961090|glioma
431908|NCT00961090|surgical resection
431909|NCT00961090|ALA
431910|NCT00961090|ultraviolet light
431911|NCT00961077|elderly
431912|NCT00961077|S-1
431913|NCT00961077|Oxaliplatin
431914|NCT00961077|relapsed or metastatic gastric cancer
431915|NCT00961064|Promacta
431916|NCT00961064|Thrombocytopenia
431917|NCT00961064|Myelodysplastic Syndrome
431918|NCT00961064|MDS
431919|NCT00961051|adapted contact lens wearers
431920|NCT00961038|Ciprofloxacin
431921|NCT00961038|Inhalation
431922|NCT00961038|Pharmacokinetics
431923|NCT00961038|Safety
431924|NCT00961038|Tolerability
431925|NCT00961038|COPD
431926|NCT00961012|Randomized control trial
431927|NCT00961012|pressure mapping
431928|NCT00961012|High Fowler's position
431929|NCT00961012|bed
431930|NCT00961012|ventilation
431931|NCT00961012|slow vital capacity
431932|NCT00961012|older adult population
431933|NCT00961012|65 years and older
431934|NCT00960999|stage I non-small cell lung cancer
431935|NCT00960999|squamous cell lung cancer
431936|NCT00960999|adenocarcinoma of the lung
431937|NCT00960999|large cell lung cancer
431938|NCT00960973|vitamin K
431939|NCT00960973|beta cell
431940|NCT00960973|glucose metabolism
431941|NCT00960973|insulin resistance
431942|NCT00960960|MBC
431943|NCT00960960|PI3K
431944|NCT00960960|Avastin
431945|NCT00960960|Herceptin
431946|NCT00960934|Osteoporosis
431947|NCT00960934|Postmenopausal
431948|NCT00960934|MK-5442
431949|NCT00960921|Pulmonary artery pressure
431950|NCT00960921|Hypoxia
431951|NCT00960921|Iron
431952|NCT00960921|Hypoxia-inducible factor
431953|NCT00960921|High altitude
431954|NCT00960908|Zotarolimus
431955|NCT00960908|Drug eluting stent
431956|NCT00960908|Endeavor Resolute
431957|NCT00960895|Lymphangioleiomyomatosis
431958|NCT00960895|Pulmonary hypertension
431959|NCT00960882|Pharmacokinetics
431960|NCT00960882|Diabetes
431961|NCT00960882|gastric tolerability
431962|NCT00960869|PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.
431963|NCT00960856|pharmacokinetics
431964|NCT00960843|Morbid Obesity
431965|NCT00960843|Gastric Banding
431966|NCT00960843|Bariatric Banding
431967|NCT00960843|Swedish Adjustable Gastric Band
431968|NCT00960817|Normal coronary artery with slow blood flow
431969|NCT00960804|OA
431970|NCT00960791|Type II diabetes mellitus
431971|NCT00960791|absorption
431972|NCT00960791|distribution
431973|NCT00960791|metabolism
431974|NCT00960791|excretion
431975|NCT00960791|14C-labelled
431976|NCT00960778|gender
431977|NCT00960778|nicotine dependence
431978|NCT00960778|nicotine replacement therapy
431979|NCT00960778|extinction
431980|NCT00960778|denicotinized cigarettes
431981|NCT00960765|Type 2 Diabetes Mellitus
431982|NCT00960765|Gastric Bypass
431983|NCT00960765|Gastric Banding
431984|NCT00960765|Endotoxin
431985|NCT00960752|gp100 peptide
431986|NCT00960752|MAGE-3 peptide
431987|NCT00960752|R848
431988|NCT00960752|Resiquimod
431989|NCT00960752|Toll Like Receptor
431990|NCT00960752|TLR
431991|NCT00960752|T-cells
431992|NCT00960752|Tumor
431993|NCT00960752|Metastatic
431994|NCT00960752|Lesions
431995|NCT00960752|Injection Site
431996|NCT00960739|disseminated neuroblastoma
431997|NCT00960739|localized unresectable neuroblastoma
431998|NCT00960739|recurrent neuroblastoma
431999|NCT00960739|stage 4S neuroblastoma
432000|NCT00960726|Leukemia
432001|NCT00960726|NOV-002
432002|NCT00960726|Myelodysplastic Syndrome
432003|NCT00960726|MDS
432004|NCT00960713|observational cohort
432005|NCT00960713|rituximab
432006|NCT00960713|off-label use
432007|NCT00960713|auto-immunity
432008|NCT00960713|cytopenia
432009|NCT00960700|MFlex
432010|NCT00960700|Multifocal
432011|NCT00960700|630F
432012|NCT00960687|healthy
432013|NCT00960687|pharmacokinetics
432014|NCT00960687|therapeutic equivalency
432015|NCT00960661|diabetes
432016|NCT00960661|exenatide
432017|NCT00960661|Byetta
432018|NCT00960661|insulin lispro
432019|NCT00960661|Humalog
432020|NCT00960661|insulin glargine
432021|NCT00960661|Lantus
432022|NCT00960661|Amylin
432023|NCT00960661|Lilly
432024|NCT00960648|Everolimus
432025|NCT00960648|Sirolimus
432026|NCT00960648|Drug eluting stent
432027|NCT00960635|new-onset
432028|NCT00960622|treatment experienced
432029|NCT00960609|Communicating veins
432030|NCT00960609|hepatic venous anastomosis
432031|NCT00960609|intra-operative ultrasonography
432032|NCT00960609|hepatic resection
432033|NCT00960609|hepatic neoplasm
432034|NCT00960609|Primary and metastatic liver tumors
432035|NCT00960596|educational intervention
432036|NCT00960596|asthma
432037|NCT00960596|Environmental Tobacco Smoke(ETS)
432038|NCT00960596|children
432039|NCT00960583|Chronic low back pain
432040|NCT00960583|Multidisciplinary rehabilitation
432041|NCT00960583|Exercise
432042|NCT00960583|Cost-effectiveness
432043|NCT00960570|healthy
432044|NCT00960570|adult
432045|NCT00960570|efavirenz
432046|NCT00960570|fenofibric acid
432047|NCT00960570|blood levels
432048|NCT00960557|hepatic tumor burden
432049|NCT00960557|liver cancer
432050|NCT00960557|liver carcinoma
432051|NCT00960557|carcinoma
432052|NCT00960557|hepatic cancer
432053|NCT00960557|hepatic carcinoma
432054|NCT00960557|VDA
432055|NCT00960557|Vascular Disrupting Agent
432056|NCT00960544|Capecitabine
432057|NCT00960544|Xeloda
432058|NCT00960544|Gene expression
432059|NCT00960544|Pharmacokinetic testing
432060|NCT00960544|PK sampling
432061|NCT00960544|DNA analysis
432062|NCT00960518|HBV-related unresectable HCC
432063|NCT00960518|TACE
432064|NCT00960518|adefovir
432065|NCT00960518|recurrence rate
432066|NCT00960505|Diet
432067|NCT00960505|Coronary heart disease
432068|NCT00960505|Obesity
432069|NCT00960505|Weight loss
432070|NCT00960505|Weight maintenance
432071|NCT00960492|Astrocytic tumor
432072|NCT00960492|Glioblastoma with oligodendroglial components
432073|NCT00960466|Stress, Psychological
432074|NCT00960466|Neoplasms/psychology
432075|NCT00960466|Psychology
432076|NCT00960440|randomized double-blind placebo-controlled investigational drug oral therapy safety and efficacy
432077|NCT00960427|adenocarcinoma of the rectum
432078|NCT00960427|stage II rectal cancer
432079|NCT00960427|stage III rectal cancer
432080|NCT00960414|obesity
432081|NCT00960414|randomized controlled trial
432082|NCT00960414|weight loss
432083|NCT00960414|metabolic syndrome
432084|NCT00960401|coronary calcium scoring
432085|NCT00960401|breast cancer patients
432086|NCT00960401|radiation treatment
432087|NCT00960375|smoking cessation
432088|NCT00960375|serious mental illness
432089|NCT00960349|Gastric cancer
432090|NCT00960349|Japanese
432091|NCT00960349|PhI
432092|NCT00960349|Safety and tolerability
432093|NCT00960349|Cediranib in combination with cisplatin plus a fluoropyrimidine
432094|NCT00960349|Cediranib
432095|NCT00960349|Capecitabine
432096|NCT00960349|S-1
432097|NCT00960349|Cisplatin
432098|NCT00960349|Untreated locally advanced or metastatic unresectable gastric cancer (GC)
432099|NCT00960336|HER2-negative breast cancer
432100|NCT00960336|recurrent breast cancer
432101|NCT00960336|stage IV breast cancer
432102|NCT00960336|invasive ductal breast carcinoma
432103|NCT00960336|invasive lobular breast carcinoma
432104|NCT00960323|pharmacokinetics
432105|NCT00960310|Treatment
432106|NCT00960297|Non-Small Cell Lung Cancer
432107|NCT00960297|NSCLC
432108|NCT00960297|Preoperative chemotherapy
432109|NCT00960297|Bevacizumab
432110|NCT00960297|Avastin
432111|NCT00960284|stage IB pancreatic cancer
432112|NCT00960284|stage II pancreatic cancer
432113|NCT00960284|stage III pancreatic cancer
432114|NCT00960284|adenocarcinoma of the pancreas
432115|NCT00960271|Non-small cell lung cancer
432116|NCT00960271|mediastinal lymph node
432117|NCT00960271|resectable
432118|NCT00960271|EBUS
432119|NCT00960271|stage IIIA
432120|NCT00960271|significant mediastinal lymph node at thoracic CT Scan
432121|NCT00960258|Solid Tumors
432122|NCT00960232|vitamin D
432123|NCT00960232|blood pressure
432124|NCT00960232|lipids
432125|NCT00960232|infection
432126|NCT00960232|depression
432127|NCT00960193|blood levels over time
432128|NCT00960193|colchicine
432129|NCT00960193|seville orange juice
432130|NCT00960193|pharmacokinetics
432131|NCT00960167|HCC
432132|NCT00960167|radiotherapy
432133|NCT00960167|dose escalation
432134|NCT00960167|Toxicity
432135|NCT00960167|Local control
432136|NCT00960154|Lumpectomy
432137|NCT00960154|PlasmaBlade
432138|NCT00960154|Electrosurgery
432139|NCT00960154|PEAK Surgical
432140|NCT00960154|Medtronic Advanced Energy
432141|NCT00960154|Medtronic
432142|NCT00960115|NSCLC
432143|NCT00960115|Stage III
432144|NCT00960115|EMD531444
432145|NCT00960115|L-BLP25
432146|NCT00960115|Cyclophosphamide
432147|NCT00960115|Immunotherapy
432148|NCT00960115|Tecemotide
432149|NCT00960102|cochlear implantation
432150|NCT00960089|Toenail
432151|NCT00960089|Fungus
432152|NCT00960089|Onychomycosis
432153|NCT00960089|Dermatophyte
432154|NCT00960076|T2DM
432155|NCT00960076|Metformin
432156|NCT00960076|A1c
432157|NCT00960050|methemoglobinemia
432158|NCT00960050|aplastic anemia
432159|NCT00960050|childhood acute lymphoblastic leukemia
432160|NCT00960050|childhood acute myeloid leukemia/other myeloid malignancies
432161|NCT00960050|childhood chronic myelogenous leukemia
432162|NCT00960050|juvenile myelomonocytic leukemia
432163|NCT00960050|childhood Hodgkin lymphoma
432164|NCT00960050|childhood large cell lymphoma
432165|NCT00960050|childhood lymphoblastic lymphoma
432166|NCT00960050|childhood small noncleaved cell lymphoma
432167|NCT00960050|childhood anaplastic large cell lymphoma
432168|NCT00960050|childhood diffuse large cell lymphoma
432169|NCT00960050|childhood grade III lymphomatoid granulomatosis
432170|NCT00960050|childhood immunoblastic large cell lymphoma
432171|NCT00960050|childhood nasal type extranodal NK/T-cell lymphoma
432172|NCT00960050|childhood myelodysplastic syndromes
432173|NCT00960037|Vitamin D3
432174|NCT00960037|obesity
432175|NCT00960037|cholecalciferol
432176|NCT00960024|Vocational rehabilitation
432177|NCT00960024|Severe mental illness
432178|NCT00960024|Psychosis
432179|NCT00960024|Mental Health
432180|NCT00960011|Inguinal hernia
432181|NCT00960011|mesh
432182|NCT00960011|progrip
432183|NCT00959998|Persistent Cancer-Related Fatigue
432184|NCT00959985|compression sleeve
432185|NCT00959985|compression bandage
432186|NCT00959972|Varenicline
432187|NCT00959972|transdermal nicotine patch
432188|NCT00959972|cardiovascular disease
432189|NCT00959972|prevention
432190|NCT00959972|coronary heart disease
432191|NCT00959972|Smoking cessation
432192|NCT00959959|CRPC
432193|NCT00959959|HRPC
432194|NCT00959959|TOK-001
432195|NCT00959959|ARMOR
432196|NCT00959959|ARMOR1
432197|NCT00959946|Phase 1/2
432198|NCT00959946|2-part study
432199|NCT00959946|bosutinib and capecitabine
432200|NCT00959920|Indwelling bladder catheter
432201|NCT00959920|Intermittent straight catheterization
432202|NCT00959920|Labor and Delivery
432203|NCT00959920|Time to delivery during labor
432204|NCT00959907|Muscular activity
432205|NCT00959907|wrinkles in frontal area
432206|NCT00959907|action halos
432207|NCT00959894|HIV
432208|NCT00959894|Infection
432209|NCT00959894|Treatment Naive
432210|NCT00959894|Adults
432211|NCT00959894|Once
432212|NCT00959894|Daily
432213|NCT00959894|Etravirine
432214|NCT00959894|HIV-1 Infection
432215|NCT00959881|Alzheimer Disease
432216|NCT00959868|Bladder cancer
432217|NCT00959868|Superficial bladder cancer (Ta or T1)
432218|NCT00959868|Muscle invasive bladder cancer (T2)
432219|NCT00959868|Transurethral resection
432220|NCT00959868|Radical cystectomy
432221|NCT00959868|OGX-427
432222|NCT00959868|Antisense oligonucleotide
432223|NCT00959868|Heat shock protein 27
432224|NCT00959868|superficial bladder tumour (Ta or T1) or CIS prior to a transurethral resection
432225|NCT00959868|Muscle invasive (T2) bladder cancer prior to radical cystectomy
432226|NCT00959855|COPD
432227|NCT00959855|Pulmonary Rehabilitation
432228|NCT00959855|Inflammation
432229|NCT00959855|Oxidative Stress
432230|NCT00959855|Steps
432231|NCT00959855|Free Living Activities
432232|NCT00959855|Exacerbation
432233|NCT00959842|hypertriglyceridemia
432234|NCT00959842|Omega-3 Fatty Acids
432235|NCT00959842|Lipoprotein
432236|NCT00959842|Statin
432237|NCT00959842|Lovaza
432238|NCT00959829|Communication
432239|NCT00959829|Complementary Therapies
432240|NCT00959829|Intensive Care
432241|NCT00959829|Ethics
432242|NCT00959816|Volunteers
432243|NCT00959803|Phase 1
432244|NCT00959803|Pharmacokinetics
432245|NCT00959803|Healthy Young Adult
432246|NCT00959803|Japanese
432247|NCT00959803|Healthy Elderly
432248|NCT00959803|Alzheimer disease
432249|NCT00959790|Health
432250|NCT00959790|Obesity
432251|NCT00959790|Oxidative stress
432252|NCT00959790|Challenge concept
432253|NCT00959790|Vegetables
432254|NCT00959751|migraine
432255|NCT00959738|loop ileostomy
432256|NCT00959738|quality of life
432257|NCT00959738|morbidity
432258|NCT00959738|Rectal Neoplasms
432259|NCT00959725|Infliximab
432260|NCT00959725|Diabetes
432261|NCT00959725|Macular Edema
432262|NCT00959699|coinfection
432263|NCT00959699|protease inhibitor
432264|NCT00959699|HIV
432265|NCT00959686|Bendamustine refractory or relapsed T-cell lymphoma.
432266|NCT00959660|Diastolic heart failure
432267|NCT00959660|Heart Failure
432268|NCT00959660|Elderly
432269|NCT00959660|Obesity
432270|NCT00959647|Hedgehog pathway inhibitor
432271|NCT00959621|Habitual abortion
432272|NCT00959621|recurrent abortion
432273|NCT00959621|hereditary and acquired
432274|NCT00959621|thrombophilia
432275|NCT00959621|preeclampsia
432276|NCT00959621|premature birth
432277|NCT00959621|miscarriage
432278|NCT00959621|stillbirth
432279|NCT00959621|LMWH (low molecular weigh heparin)
432280|NCT00959621|ASA
432281|NCT00959621|aspirin
432282|NCT00959608|Weight Management in adults
432283|NCT00959608|Reducing Health Disparities
432284|NCT00959595|Diabetes mellitus
432285|NCT00959595|neuropathy
432286|NCT00959595|foot
432287|NCT00959595|sensibility
432288|NCT00959595|brain plasticity
432289|NCT00959582|Relapsed ovarian cancer
432290|NCT00959569|esmolol
432291|NCT00959569|cardiac surgery
432292|NCT00959569|cardiac anesthesia
432293|NCT00959569|mortality
432294|NCT00959569|beta blockers
432295|NCT00959569|beta-blockers
432296|NCT00959569|cardiac protection
432297|NCT00959556|recurrent breast cancer
432298|NCT00959556|stage IA breast cancer
432299|NCT00959556|stage IB breast cancer
432300|NCT00959556|stage II breast cancer
432301|NCT00959556|stage IIIA breast cancer
432302|NCT00959556|stage IIIB breast cancer
432303|NCT00959556|stage IIIC breast cancer
432304|NCT00959556|stage IV breast cancer
432305|NCT00959530|complete dentures
432306|NCT00959530|patient satisfaction
432307|NCT00959530|treatment cost
432308|NCT00959517|Placebo controlled
432309|NCT00959517|Efficacy
432310|NCT00959517|Artemisinin-based combination therapy
432311|NCT00959517|Primaquine
432312|NCT00959517|Gametocytes
432313|NCT00959491|Colonoscopy
432314|NCT00959491|Occult Blood
432315|NCT00959491|Fecal
432316|NCT00959478|Carbon Monoxide (CO)
432317|NCT00959478|Carbon Monoxide Poisoning
432318|NCT00959478|Carbon Monoxide Alarm/Detector
432319|NCT00959478|Precaution Adoption Process Model (PAPM)
432320|NCT00959478|Injury Prevention
432321|NCT00959478|Emergency Department
432322|NCT00959452|Hypochondria
432323|NCT00959452|Cognitive behavioural therapy
432324|NCT00959452|Long term follow-up
432325|NCT00959452|Psychosomatics
432326|NCT00959452|Psychotherapy
432327|NCT00959426|- Mutliple Ascending Dose Study in Overweight Subjects - Body Weight - Signs and Symptoms
432328|NCT00959400|Fentanyl Transdermal
432329|NCT00959400|Pain
432330|NCT00959400|Cancer
432331|NCT00959387|head and neck cancer
432332|NCT00959387|induction chemotherapy
432333|NCT00959374|Abdominoplasty
432334|NCT00959374|Reduction Mammaplasty
432335|NCT00959374|Mastopexy
432336|NCT00959361|patient compliance
432337|NCT00959361|guidelines adherence
432338|NCT00959361|advance directive adherence
432339|NCT00959361|treatment refusal
432340|NCT00959361|directly observed therapy
432341|NCT00959361|anti-retroviral agents
432342|NCT00959361|HIV seropositivity
432343|NCT00959361|HIV infections
432344|NCT00959361|HIV
432345|NCT00959361|pharmaceutical services
432346|NCT00959361|HIV-positives patients
432347|NCT00959361|treatment experienced
432348|NCT00959348|Asthma
432349|NCT00959348|Diabetes
432350|NCT00959348|Impaired glucose tolerance
432351|NCT00959348|Insulin resistance
432352|NCT00959335|treatment
432353|NCT00959322|Capsulotomy
432354|NCT00959309|pediatrics
432355|NCT00959309|media
432356|NCT00959309|MUPS
432357|NCT00959296|Registry
432358|NCT00959296|Pain
432359|NCT00959296|Chronic Pain
432360|NCT00959296|Back Pain
432361|NCT00959296|Intractable Spasticity
432362|NCT00959296|Parkinson's Disease
432363|NCT00959296|Essential Tremor
432364|NCT00959296|Dystonia
432365|NCT00959296|Implantable Pumps
432366|NCT00959296|Incontinence
432367|NCT00959283|acute myeloid leukemia/transient myeloproliferative disorder
432368|NCT00959257|Asthma
432369|NCT00959257|Inhaled corticosteroids
432370|NCT00959257|Cardiovascular morbidities
432371|NCT00959257|Systemic inflammation
432372|NCT00959244|ductal breast carcinoma in situ
432373|NCT00959244|stage I breast cancer
432374|NCT00959244|stage II breast cancer
432375|NCT00959244|stage IIIA breast cancer
432376|NCT00959244|stage IIIB breast cancer
432377|NCT00959244|stage IIIC breast cancer
432378|NCT00959244|stage IV breast cancer
432379|NCT00959231|hematopoietic/lymphoid cancer
432380|NCT00959218|Dronabinol
432381|NCT00959218|(-)trans-delta9-tetrahydrocannabinol
432382|NCT00959218|central neuropathic pain
432383|NCT00959218|multiple sclerosis
432384|NCT00959218|analgesic
432385|NCT00959218|Central neuropathic pain related to multiple sclerosis
432386|NCT00959179|CHF
432387|NCT00959166|Acute hepatitis C
432388|NCT00959166|HIV
432389|NCT00959166|Neurocognitive function
432390|NCT00959166|Neuroinflammation
432391|NCT00959153|Fragmenting of kidney stones
432392|NCT00959153|extracorporeal shockwave lithotripsy
432393|NCT00959140|Allo PBSC
432394|NCT00959140|HSCT
432395|NCT00959140|Bone Marrow Transplant
432396|NCT00959140|Allogeneic Bone Marrow Transplant
432397|NCT00959140|Matched Related Donor Transplant
432398|NCT00959140|MRD HSCT
432399|NCT00959127|Colorectal Adenocarcinoma
432400|NCT00959127|Colon Cancer
432401|NCT00959127|Rectal Cancer
432402|NCT00959114|Celiac Disease
432403|NCT00959114|Coeliac Disease
432404|NCT00959114|Celiac Sprue
432405|NCT00959114|Keliakia
432406|NCT00959075|Thiamin supplementation
432407|NCT00959075|Thiamin deficiency
432408|NCT00959075|Heart failure
432409|NCT00959075|Improve heart function
432410|NCT00959075|Vitamin B1 supplementation
432411|NCT00959062|Pilot Study
432412|NCT00959062|Randomized Controlled Trial
432413|NCT00959062|Critically Ill
432414|NCT00959062|Child
432415|NCT00959062|Pediatric
432416|NCT00959062|Clonidine
432417|NCT00959062|Sedation
432418|NCT00959023|stage I prostate cancer
432419|NCT00959023|stage IIB prostate cancer
432420|NCT00959023|stage IIA prostate cancer
432421|NCT00959023|stage III prostate cancer
432422|NCT00959023|stage IV prostate cancer
432423|NCT00959023|recurrent prostate cancer
432424|NCT00959010|Omega 3
432425|NCT00959010|Cystic Fibrosis
432426|NCT00959010|Inflammatory markers
432427|NCT00958997|diabetes
432428|NCT00958997|islet
432429|NCT00958997|pancreas
432430|NCT00958997|beta cell mass
432431|NCT00958997|PET imaging
432432|NCT00958997|FPDTBZ
432433|NCT00958997|arginine stimulus test
432434|NCT00958984|pediatric
432435|NCT00958984|solid organ transplant
432436|NCT00958984|hemoglobin
432437|NCT00958971|Breast cancer
432438|NCT00958971|HER2 negative
432439|NCT00958971|FGFR1
432440|NCT00958958|Acute Coronary Syndrome
432441|NCT00958958|randomized cluster trial
432442|NCT00958958|quality improvement
432443|NCT00958945|Postoperative Hematocrit
432444|NCT00958945|Postoperative Hemoglobin
432445|NCT00958919|breathlessness intensity
432446|NCT00958919|breathlessness unpleasantness
432447|NCT00958919|endorphins
432448|NCT00958919|resistive breathing loads
432449|NCT00958906|Infliximab
432450|NCT00958906|Uveitis
432451|NCT00958906|Macular Edema
432452|NCT00958906|Intraocular Inflammation
432453|NCT00958893|Uterine fibroids
432454|NCT00958867|Resistance exercise training
432455|NCT00958867|aerobic exercise training
432456|NCT00958854|angioimmunoblastic T-cell lymphoma
432457|NCT00958841|Rare tumors of neuroendocrine origin
432458|NCT00958841|NETs of the pancreatic
432459|NCT00958841|Pituitary NETs
432460|NCT00958841|EAS Tumors
432461|NCT00958841|Nelson's Syndrome
432462|NCT00958841|Pancreatic neoplasm
432463|NCT00958841|pituitary neoplasm
432464|NCT00958841|Nelson Syndrome
432465|NCT00958841|ectopic ACTH syndrome
432466|NCT00958841|pasireotide LAR
432467|NCT00958841|PNETs
432468|NCT00958841|PiNETS
432469|NCT00958815|vascular imaging
432470|NCT00958815|diabetes
432471|NCT00958815|rupture prone plaques
432472|NCT00958815|HIV
432473|NCT00958815|treatment experienced
432474|NCT00958802|tissue engineering
432475|NCT00958776|Influenza
432476|NCT00958776|Hospitalized
432477|NCT00958776|Antiviral
432478|NCT00958776|Flu
432479|NCT00958763|HCV
432480|NCT00958763|Alcohol
432481|NCT00958763|Methadone Maintained
432482|NCT00958750|Androgenetic alopecia
432483|NCT00958750|female pattern hair loss
432484|NCT00958737|stage III colon cancer
432485|NCT00958737|adenocarcinoma of the colon
432486|NCT00958724|HKI-272
432487|NCT00958724|Vinorelbine
432488|NCT00958724|Combination
432489|NCT00958724|Solid Tumor
432490|NCT00958698|psychosocial effects of cancer and its treatment
432491|NCT00958698|recurrent ovarian epithelial cancer
432492|NCT00958698|recurrent fallopian tube cancer
432493|NCT00958698|recurrent primary peritoneal cavity cancer
432494|NCT00958685|ginger extract
432495|NCT00958685|ARDS
432496|NCT00958685|enteral feeding
432497|NCT00958685|mechanical ventilation
432498|NCT00958685|ICU
432499|NCT00958646|OMT
432500|NCT00958646|biomarker
432501|NCT00958646|Manipulation, osteopathic
432502|NCT00958633|Bipolar I disorder
432503|NCT00958633|Depression
432504|NCT00958633|Antidepressant
432505|NCT00958620|Chronic Achilles Tendinopathy
432506|NCT00958607|Caregivers
432507|NCT00958607|Stroke
432508|NCT00958607|Social support
432509|NCT00958607|Phase specific care
432510|NCT00958542|cerebral palsy
432511|NCT00958542|scoliosis
432512|NCT00958542|children
432513|NCT00958529|fiber
432514|NCT00958529|inulin
432515|NCT00958529|gastrointestinal tolerance
432516|NCT00958516|volunteers
432517|NCT00958503|safety
432518|NCT00958503|biomarker
432519|NCT00958503|thiamphenicol
432520|NCT00958503|EAAT2
432521|NCT00958477|Safety
432522|NCT00958477|tolerability
432523|NCT00958477|pharmacokinetics
432524|NCT00958477|pharmacodynamics of EMD 525797
432525|NCT00958477|prostate cancer patients
432526|NCT00958464|MRI
432527|NCT00958464|Perthes'disease
432528|NCT00958464|hip
432529|NCT00958464|cartilage
432530|NCT00958451|Calcium
432531|NCT00958451|Vitamin D deficiency
432532|NCT00958451|Chronic Kidney disease
432533|NCT00958438|Intercritical Gout
432534|NCT00958438|Metabolism, Inborn Errors
432535|NCT00958438|Allopurinol
432536|NCT00958438|Metabolic Diseases
432537|NCT00958438|Genetic Diseases, Inborn
432538|NCT00958438|Musculoskeletal Diseases
432539|NCT00958438|Joint Diseases
432540|NCT00958438|Arthritis
432541|NCT00958438|Rheumatic Diseases
432542|NCT00958438|Metabolic disorder
432543|NCT00958438|Purine-Pyrimidine Metabolism, Inborn Errors
432544|NCT00958438|Gout
432545|NCT00958412|Endometriosis
432546|NCT00958412|Pelvic pain
432547|NCT00958412|Oral progesterone blocker
432548|NCT00958399|satiety
432549|NCT00958399|fiber
432550|NCT00958399|food intake
432551|NCT00958399|gut hormones
432552|NCT00958399|visual analog scales
432553|NCT00958399|microflora
432554|NCT00958386|colorectal cancer
432555|NCT00958386|Panitumumab
432556|NCT00958386|irinotecan
432557|NCT00958373|Scoliosis
432558|NCT00958373|adolescent idiopathic scoliosis
432559|NCT00958373|spine curve
432560|NCT00958373|pediatric
432561|NCT00958373|mental health
432562|NCT00958373|screening
432563|NCT00958360|vision, low
432564|NCT00958334|Uterine fibroids
432565|NCT00958321|adenocarcinoma of the lung
432566|NCT00958321|large cell lung cancer
432567|NCT00958321|squamous cell lung cancer
432568|NCT00958321|malignant pleural effusion
432569|NCT00958321|stage IIIA non-small cell lung cancer
432570|NCT00958321|stage IIIB non-small cell lung cancer
432571|NCT00958321|stage IA non-small cell lung cancer
432572|NCT00958321|stage IB non-small cell lung cancer
432573|NCT00958321|stage IIA non-small cell lung cancer
432574|NCT00958321|stage IIB non-small cell lung cancer
432575|NCT00958308|Probiotic
432576|NCT00958308|Antibiotic-Associated Diarrhea (AAD) Prevention
432577|NCT00958308|Clostridium Difficile-Associated Diarrhea (CDAD)Prevention
432578|NCT00958295|urinary tract infection
432579|NCT00958295|cystitis
432580|NCT00958282|cocaine
432581|NCT00958282|treatment
432582|NCT00958282|lisdexamfetamine
432583|NCT00958282|dependence
432584|NCT00958282|addiction
432585|NCT00958282|crack
432586|NCT00958269|diabetes
432587|NCT00958269|DPP4 inhibitor
432588|NCT00958269|dutogliptin
432589|NCT00958269|PHX1149
432590|NCT00958256|Mantle Cell Lymphoma
432591|NCT00958256|Lymphoma
432592|NCT00958256|Bortezomib
432593|NCT00958256|Velcade
432594|NCT00958256|Rituximab
432595|NCT00958256|Rituxan
432596|NCT00958256|Cyclophosphamide
432597|NCT00958256|Cytoxan
432598|NCT00958256|Neosar
432599|NCT00958256|Mesna
432600|NCT00958256|Mesnex
432601|NCT00958256|G-CSF
432602|NCT00958256|Filgrastim
432603|NCT00958256|Neupogen
432604|NCT00958230|endarterectomy
432605|NCT00958230|dCell
432606|NCT00958230|Tissue Regenix Ltd
432607|NCT00958230|TRL
432608|NCT00958230|Vascular Patch
432609|NCT00958230|Treatment
432610|NCT00958217|Depressive symptoms
432611|NCT00958217|Substance-related disorders
432612|NCT00958217|Posttraumatic stress disorders
432613|NCT00958217|Psychotherapy
432614|NCT00958204|Depression
432615|NCT00958204|rating scales
432616|NCT00958204|RCT
432617|NCT00958204|combination treatment
432618|NCT00958204|light therapy
432619|NCT00958204|negative ion therapy
432620|NCT00958204|fluoxetine
432621|NCT00958204|antidepressants
432622|NCT00958165|Treatment of PAF using EAS-AC
432623|NCT00958152|VX-950
432624|NCT00958152|VX-222
432625|NCT00958152|STAT-C
432626|NCT00958139|Lyme disease
432627|NCT00958139|tick
432628|NCT00958100|raltegravir switch toxicity
432629|NCT00958100|treatment experienced
432630|NCT00958061|CVD
432631|NCT00958048|Amyotrophic Lateral Sclerosis
432632|NCT00958048|hypoventilation
432633|NCT00957996|influenza
432634|NCT00957996|hospitalized
432635|NCT00957996|flu
432636|NCT00957996|antiviral
432637|NCT00957970|Stress shielding
432638|NCT00957970|Bone mineral density
432639|NCT00957970|stemless femoral component
432640|NCT00957944|Rotigotine
432641|NCT00957944|Neupro®
432642|NCT00957918|levodopa-induced dyskinesia
432643|NCT00957918|Parkinson's disease
432644|NCT00957918|parkinsonian
432645|NCT00957918|levodopa-induced dyskinesias in Parkinson's disease
432646|NCT00957892|Healthy Infants
432647|NCT00957892|Satiation
432648|NCT00957892|Satiety
432649|NCT00957892|Intake Regulation
432650|NCT00957892|Infant Feeding
432651|NCT00957892|Infant Formula Feeding
432652|NCT00957879|Vitamin D
432653|NCT00957879|FGF23
432654|NCT00957879|FGF-23
432655|NCT00957879|Phosphate
432656|NCT00957866|The number of cases in the database thus far (4,477) is clearly sufficient to achieve meaningful results
432657|NCT00957853|Head and Neck Cancer
432658|NCT00957853|Squamous cell carcinoma of the head and neck
432659|NCT00957853|HNSCC
432660|NCT00957853|Cetuximab
432661|NCT00957853|IMC-A12
432662|NCT00957853|Tumor
432663|NCT00957853|Biomarkers
432664|NCT00957853|Phospho-AKT
432665|NCT00957853|Surgical resection
432666|NCT00957840|Omaya reservoirs
432667|NCT00957840|cerebral oxygenation
432668|NCT00957840|VP shunt
432669|NCT00957840|IVH
432670|NCT00957840|post hemorrhagic ventricular dilation (PVHD)
432671|NCT00957814|nutritional education
432672|NCT00957814|diet adherence
432673|NCT00957814|nutritional knowledge
432674|NCT00957814|life quality
432675|NCT00957814|nutritional status
432676|NCT00957814|impact of nutritional orientations by a systematic education program applied to outpatients with HF, in comparison to patients in a conventional treatment.
432677|NCT00957801|Sarcopenia
432678|NCT00957801|Aging muscle
432679|NCT00957801|Androgen
432680|NCT00957801|Cytokines
432681|NCT00957801|Muscle metabolism
432682|NCT00957788|tinnitus
432683|NCT00957788|acouphenes
432684|NCT00957788|ear
432685|NCT00957788|ringing
432686|NCT00957788|buzzing
432687|NCT00957788|roaring
432688|NCT00957788|hissing
432689|NCT00957788|clicking
432690|NCT00957775|Substance Abuse Treatment
432691|NCT00957775|Adolescents
432692|NCT00957775|Substance-Related Disorders
432693|NCT00957775|Alcohol-Related Disorders
432694|NCT00957775|Marijuana Abuse
432695|NCT00957762|Body Composition
432696|NCT00957762|Glucose Tolerance
432697|NCT00957762|Insulin Sensitivity
432698|NCT00957762|Metabolic Syndrome
432699|NCT00957736|graft versus host disease
432700|NCT00957736|stage III adult Burkitt lymphoma
432701|NCT00957736|stage III adult diffuse large cell lymphoma
432702|NCT00957736|stage III adult diffuse mixed cell lymphoma
432703|NCT00957736|stage III adult diffuse small cleaved cell lymphoma
432704|NCT00957736|stage III adult Hodgkin lymphoma
432705|NCT00957736|stage III adult immunoblastic large cell lymphoma
432706|NCT00957736|stage III adult lymphoblastic lymphoma
432707|NCT00957736|stage III grade 1 follicular lymphoma
432708|NCT00957736|stage III grade 2 follicular lymphoma
432709|NCT00957736|stage III grade 3 follicular lymphoma
432710|NCT00957736|stage III mantle cell lymphoma
432711|NCT00957736|stage III marginal zone lymphoma
432712|NCT00957736|stage III small lymphocytic lymphoma
432713|NCT00957736|stage IV adult Burkitt lymphoma
432714|NCT00957736|stage IV adult diffuse large cell lymphoma
432715|NCT00957736|stage IV adult diffuse mixed cell lymphoma
432716|NCT00957736|stage IV adult diffuse small cleaved cell lymphoma
432717|NCT00957736|stage IV adult Hodgkin lymphoma
432718|NCT00957736|stage IV adult immunoblastic large cell lymphoma
432719|NCT00957736|stage IV adult lymphoblastic lymphoma
432720|NCT00957736|stage IV grade 1 follicular lymphoma
432721|NCT00957736|stage IV grade 2 follicular lymphoma
432722|NCT00957736|stage IV grade 3 follicular lymphoma
432723|NCT00957736|stage IV mantle cell lymphoma
432724|NCT00957736|stage IV marginal zone lymphoma
432725|NCT00957736|stage IV small lymphocytic lymphoma
432726|NCT00957736|recurrent adult Burkitt lymphoma
432727|NCT00957736|recurrent adult diffuse large cell lymphoma
432728|NCT00957736|recurrent adult diffuse mixed cell lymphoma
432729|NCT00957736|recurrent adult diffuse small cleaved cell lymphoma
432730|NCT00957736|recurrent adult Hodgkin lymphoma
432731|NCT00957736|recurrent adult immunoblastic large cell lymphoma
432732|NCT00957736|recurrent adult lymphoblastic lymphoma
432733|NCT00957736|recurrent childhood large cell lymphoma
432734|NCT00957736|recurrent childhood lymphoblastic lymphoma
432735|NCT00957736|recurrent childhood small noncleaved cell lymphoma
432736|NCT00957736|recurrent cutaneous T-cell non-Hodgkin lymphoma
432737|NCT00957736|recurrent grade 1 follicular lymphoma
432738|NCT00957736|recurrent grade 2 follicular lymphoma
432739|NCT00957736|recurrent grade 3 follicular lymphoma
432740|NCT00957736|recurrent mantle cell lymphoma
432741|NCT00957736|recurrent marginal zone lymphoma
432742|NCT00957736|recurrent small lymphocytic lymphoma
432743|NCT00957736|recurrent/refractory childhood Hodgkin lymphoma
432744|NCT00957736|recurrent mycosis fungoides/Sezary syndrome
432745|NCT00957736|nodal marginal zone B-cell lymphoma
432746|NCT00957736|splenic marginal zone lymphoma
432747|NCT00957736|noncontiguous (NC) stage II adult Burkitt lymphoma
432748|NCT00957736|NC stage II adult diffuse large cell lymphoma
432749|NCT00957736|NC stage II adult diffuse mixed cell lymphoma
432750|NCT00957736|NC stage II adult diffuse small cleaved cell lymphoma
432751|NCT00957736|NC stage II adult immunoblastic large cell lymphoma
432752|NCT00957736|NC stage II adult lymphoblastic lymphoma
432753|NCT00957736|NC stage II grade 1 follicular lymphoma
432754|NCT00957736|NC stage II grade 2 follicular lymphoma
432755|NCT00957736|NC stage II grade 3 follicular lymphoma
432756|NCT00957736|NC stage II mantle cell lymphoma
432757|NCT00957736|NC stage II marginal zone lymphoma
432758|NCT00957736|NC stage II small lymphocytic lymphoma
432759|NCT00957736|accelerated phase chronic myelogenous leukemia
432760|NCT00957736|adult acute lymphoblastic leukemia in remission
432761|NCT00957736|adult acute myeloid leukemia in remission
432762|NCT00957736|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
432763|NCT00957736|adult acute myeloid leukemia with inv(16)(p13;q22)
432764|NCT00957736|adult acute myeloid leukemia with t(15;17)(q22;q12)
432765|NCT00957736|adult acute myeloid leukemia with t(16;16)(p13;q22)
432766|NCT00957736|adult acute myeloid leukemia with t(8;21)(q22;q22)
432767|NCT00957736|atypical chronic myeloid leukemia, BCR-ABL negative
432768|NCT00957736|blastic phase chronic myelogenous leukemia
432769|NCT00957736|childhood acute lymphoblastic leukemia in remission
432770|NCT00957736|childhood acute myeloid leukemia in remission
432771|NCT00957736|childhood chronic myelogenous leukemia
432772|NCT00957736|chronic myelomonocytic leukemia
432773|NCT00957736|chronic phase chronic myelogenous leukemia
432774|NCT00957736|juvenile myelomonocytic leukemia
432775|NCT00957736|recurrent adult acute lymphoblastic leukemia
432776|NCT00957736|recurrent adult acute myeloid leukemia
432777|NCT00957736|recurrent childhood acute lymphoblastic leukemia
432778|NCT00957736|recurrent childhood acute myeloid leukemia
432779|NCT00957736|refractory chronic lymphocytic leukemia
432780|NCT00957736|refractory hairy cell leukemia
432781|NCT00957736|relapsing chronic myelogenous leukemia
432782|NCT00957736|secondary acute myeloid leukemia
432783|NCT00957736|stage III chronic lymphocytic leukemia
432784|NCT00957736|stage IV chronic lymphocytic leukemia
432785|NCT00957736|childhood myelodysplastic syndromes
432786|NCT00957736|chronic eosinophilic leukemia
432787|NCT00957736|primary myelofibrosis
432788|NCT00957736|chronic neutrophilic leukemia
432789|NCT00957736|de novo myelodysplastic syndromes
432790|NCT00957736|disseminated neuroblastoma
432791|NCT00957736|myelodysplastic/myeloproliferative neoplasm, unclassifiable
432792|NCT00957736|poor prognosis metastatic gestational trophoblastic tumor
432793|NCT00957736|previously treated childhood rhabdomyosarcoma
432794|NCT00957736|previously treated myelodysplastic syndromes
432795|NCT00957736|recurrent Wilms tumor and other childhood kidney tumors
432796|NCT00957736|recurrent childhood rhabdomyosarcoma
432797|NCT00957736|recurrent neuroblastoma
432798|NCT00957736|recurrent ovarian epithelial cancer
432799|NCT00957736|recurrent ovarian germ cell tumor
432800|NCT00957736|recurrent malignant testicular germ cell tumor
432801|NCT00957736|secondary myelodysplastic syndromes
432802|NCT00957736|stage I multiple myeloma
432803|NCT00957736|stage II multiple myeloma
432804|NCT00957736|stage III multiple myeloma
432805|NCT00957736|stage II ovarian epithelial cancer
432806|NCT00957736|stage III ovarian epithelial cancer
432807|NCT00957736|stage IV ovarian epithelial cancer
432808|NCT00957736|stage III malignant testicular germ cell tumor
432809|NCT00957736|stage IIIA breast cancer
432810|NCT00957736|stage IIIB breast cancer
432811|NCT00957736|stage IIIC breast cancer
432812|NCT00957736|stage IV breast cancer
432813|NCT00957736|refractory multiple myeloma
432814|NCT00957710|progressive aphasia
432815|NCT00957710|semantic dementia
432816|NCT00957710|neuroimaging
432817|NCT00957710|treatment
432818|NCT00957710|errorless learning
432819|NCT00957697|Central Neuropathic Pain
432820|NCT00957697|Central Post-Stroke Pain
432821|NCT00957697|Stroke
432822|NCT00957697|Pain
432823|NCT00957684|refractory
432824|NCT00957684|partial
432825|NCT00957684|epilepsy
432826|NCT00957671|TBI
432827|NCT00957671|Traumatic Brain injury
432828|NCT00957671|Growth hormone deficiency
432829|NCT00957671|Anterior pituitary hormone
432830|NCT00957658|Osteoarthritis
432831|NCT00957645|Central post-stroke pain
432832|NCT00957645|post-stroke pain
432833|NCT00957645|shoulder pain
432834|NCT00956787|Myelodysplastic Syndrome
432835|NCT00956774|HSG
432836|NCT00956774|Cannula
432837|NCT00956774|HSG procedure
432838|NCT00956774|infertility evaluation
432839|NCT00956761|Influenza vaccine
432840|NCT00956748|chronic suppurative otitis media with persistent otorrhea
432841|NCT00956735|Cardiovascular Disease
432842|NCT00956735|Type II Diabetes
432843|NCT00956735|Nutrition
432844|NCT00956735|Pistachios
432845|NCT00956735|Cardiovascular disease risk factors in adults with Type II diabetes
432846|NCT00956696|Epilepsy
432847|NCT00956696|mental retardation
432848|NCT00956683|infraclavicular nerve block ultrasound dual endpoint stimulation
432849|NCT00956657|Randomised Controlled Trial
432850|NCT00956657|Adherence
432851|NCT00956657|Patient Participation
432852|NCT00957619|pentoxyfilline
432853|NCT00957619|liver regeneration
432854|NCT00957619|major liver resection
432855|NCT00957619|reduction of the I/R injury
432856|NCT00957606|Prostate cancer
432857|NCT00957606|androgen deprivation therapy
432858|NCT00957606|osteoporosis
432859|NCT00957593|Induction of labor in term pregnancies
432860|NCT00957593|Term pregnancy
432861|NCT00957593|Cesarean delivery
432862|NCT00957580|MEK Inhibitor
432863|NCT00957580|Pimasertib
432864|NCT00957580|Acute Myeloid Leukemia
432865|NCT00957580|Hematological Malignancies
432866|NCT00957580|Elderly Patients
432867|NCT00957580|Phase II
432868|NCT00957541|NYHA Class III or IV
432869|NCT00957541|Implantable Cardiac Defibrillator
432870|NCT00957541|Cardiac Resynchronization Therapy
432871|NCT00957528|Low Normal Testosterone
432872|NCT00957528|Male
432873|NCT00957528|Aging
432874|NCT00957489|Orthodontic treatment of Class II division 1 malocclusion
432875|NCT00957476|Pregnancy
432876|NCT00957476|Metabolic Diseases
432877|NCT00957476|Obesity
432878|NCT00957476|Fetal adiposity
432879|NCT00957476|Omega-3
432880|NCT00957476|Inflammation
432881|NCT00957476|Insulin Resistance
432882|NCT00957463|endothelial function
432883|NCT00957450|cervix cancer
432884|NCT00957450|intra-pelvic organ motion
432885|NCT00957450|cervical cancer and CBCT
432886|NCT00957437|Phase 1
432887|NCT00957437|healthy volunteer
432888|NCT00957437|male
432889|NCT00957437|pharmacokinetics
432890|NCT00957437|AZD1305
432891|NCT00957424|tobacco use disorder
432892|NCT00957424|bladder cancer
432893|NCT00957424|cervical cancer
432894|NCT00957424|esophageal cancer
432895|NCT00957424|gastric cancer
432896|NCT00957424|renal cell carcinoma
432897|NCT00957424|adult primary liver cancer
432898|NCT00957424|non-small cell lung cancer
432899|NCT00957424|small cell lung cancer
432900|NCT00957424|pancreatic cancer
432901|NCT00957424|hypopharyngeal cancer
432902|NCT00957424|laryngeal cancer
432903|NCT00957424|lip and oral cavity cancer
432904|NCT00957424|nasopharyngeal cancer
432905|NCT00957424|oropharyngeal cancer
432906|NCT00957424|paranasal sinus and nasal cavity cancer
432907|NCT00957424|adult acute myeloid leukemia
432908|NCT00957411|stage IB cervical cancer
432909|NCT00957411|stage IIA cervical cancer
432910|NCT00957411|stage IIB cervical cancer
432911|NCT00957411|stage III cervical cancer
432912|NCT00957411|cervical adenocarcinoma
432913|NCT00957411|cervical squamous cell carcinoma
432914|NCT00957398|Irritable Bowel Syndrome
432915|NCT00957398|Irritable Bowel Syndrome subgroups
432916|NCT00957398|Motility
432917|NCT00957385|Leukemia
432918|NCT00957385|Remission
432919|NCT00957372|epilepsy
432920|NCT00957359|Cancer
432921|NCT00957359|Anxiety
432922|NCT00957359|Depression
432923|NCT00957359|Hallucinogens
432924|NCT00957346|Pregnancy termination
432925|NCT00957346|abortion
432926|NCT00957346|medical abortion
432927|NCT00957346|2nd trimester
432928|NCT00957346|mifepristone
432929|NCT00957346|misoprostol
432930|NCT00957333|ketamine
432931|NCT00957333|bladder dysfunction
432932|NCT00957333|bladder mucosa
432933|NCT00957333|mechanisms
432934|NCT00957320|leukemia
432935|NCT00957320|cancer
432936|NCT00957320|oncology
432937|NCT00957320|sirolimus
432938|NCT00957320|ALL
432939|NCT00957281|Asthma
432940|NCT00957281|Systemic inflammation
432941|NCT00957281|Oxidative stress
432942|NCT00957281|Cardiovascular morbidity
432943|NCT00957281|Airway inflammation
432944|NCT00957268|Type 2 diabetes mellitus
432945|NCT00957268|Non-insulin dependent diabetes mellitus
432946|NCT00957268|Drug therapy
432947|NCT00957268|Pediatrics
432948|NCT00957255|rotator cuff tear
432949|NCT00957255|rotator cuff repair
432950|NCT00957242|IPF
432951|NCT00957242|Warfarin
432952|NCT00957216|adult onset ataxia
432953|NCT00957203|Parkinson's disease
432954|NCT00957203|levodopa
432955|NCT00957203|end of dose wearing off
432956|NCT00957203|OFF time
432957|NCT00957190|Ocular Hypertension
432958|NCT00957190|Open Angle Glaucoma
432959|NCT00957164|Chronic pain
432960|NCT00957164|PTSD
432961|NCT00957151|chronic pancreatitis
432962|NCT00957151|exocrine pancreatic insufficiency
432963|NCT00957151|enzyme therapy
432964|NCT00957151|patients with chronic pancreatitis and exocrine pancreatic insufficiency
432965|NCT00957151|taking enzyme replacement therapy
432966|NCT00957125|Localized primary breast cancer
432967|NCT00957125|Inflammatory breast cancer
432968|NCT00957112|anxiety disorder
432969|NCT00957112|depression
432970|NCT00957112|fatigue
432971|NCT00957112|stage IA breast cancer
432972|NCT00957112|stage IB breast cancer
432973|NCT00957112|stage II breast cancer
432974|NCT00957112|stage IIIA breast cancer
432975|NCT00957086|Phase III Adjuvant Concurrent Chemo-RT +/- nimotuzumab
432976|NCT00957073|Heart Failure
432977|NCT00957073|Diastolic dysfunction
432978|NCT00957047|refractory
432979|NCT00957047|partial
432980|NCT00957047|epilepsy
432981|NCT00957021|Knee
432982|NCT00956982|Hepatitis C Virus Pegylated Interferon Ribavirin Older
432983|NCT00956969|headaches
432984|NCT00956969|stress management
432985|NCT00956969|assertiveness training
432986|NCT00956969|relaxation training
432987|NCT00956969|emotional expression
432988|NCT00956956|An investigator and subject blinded (sponsor open)
432989|NCT00956956|multiple dose
432990|NCT00956956|dose escalation design with PF 04455242 and matching placebo.
432991|NCT00956943|nicotine dependence
432992|NCT00956943|nicotine replacement therapy
432993|NCT00956943|transdermal nicotine
432994|NCT00956943|nicotine metabolism
432995|NCT00956943|high dose
432996|NCT00956930|advanced adult primary liver cancer
432997|NCT00956930|localized unresectable adult primary liver cancer
432998|NCT00956930|recurrent adult primary liver cancer
432999|NCT00956930|adult primary hepatocellular carcinoma
433000|NCT00956904|Prostate Cancer
433001|NCT00956904|Prostatectomy
433002|NCT00956904|Transrectal Ultrasound
433003|NCT00956904|Tandem RALP
433004|NCT00956891|short-term effects
433005|NCT00956891|long-term follow-up
433006|NCT00956891|liver failure patients
433007|NCT00956891|autologous MSCs transplantation
433008|NCT00956878|Cancer
433009|NCT00956878|Pain
433010|NCT00956878|SNP
433011|NCT00956865|Glaucoma
433012|NCT00956865|Intervention
433013|NCT00956865|Follow up
433014|NCT00956839|Tropical calcific pancreatitis
433015|NCT00956839|Tropical chronic pancreatitis
433016|NCT00956839|Chronic pancreatitis
433017|NCT00956839|Vitamin D
433018|NCT00956839|Vitamin D deficiency
433019|NCT00956839|Cholecalciferol
433020|NCT00956839|Intramuscular vitamin D3
433021|NCT00956826|electrode vacuum delivery
433022|NCT00956813|menopausal symptoms
433023|NCT00956813|hot flashes
433024|NCT00956813|breast cancer
433025|NCT00956813|unspecified adult solid tumor, protocol specific
433026|NCT00956631|Spinal Stenosis
433027|NCT00956631|Lumbar Spinal Stenosis
433028|NCT00956605|EEG-biofeedback
433029|NCT00956605|neurofeedback
433030|NCT00956605|computer attention training systems
433031|NCT00956605|ADHD
433032|NCT00956605|ADD
433033|NCT00956605|child
433034|NCT00956605|children
433035|NCT00956592|Video laryngoscopy
433036|NCT00956592|Intubation success
433037|NCT00956592|Difficult airway
433038|NCT00956592|CMAC laryngoscope
433039|NCT00956579|autism
433040|NCT00956579|autistic
433041|NCT00956579|sensory
433042|NCT00956579|MEG
433043|NCT00956579|connectivity
433044|NCT00956579|brain
433045|NCT00956579|MRI
433046|NCT00956579|language
433047|NCT00956579|developmental
433048|NCT00956579|neurodevelopmental
433049|NCT00956579|aspergers
433050|NCT00956579|asperger's
433051|NCT00956579|dyslexia
433052|NCT00956579|coherence
433053|NCT00956553|HPV
433054|NCT00956553|Human Papilloma Virus
433055|NCT00956553|Cervical cancer vaccine
433056|NCT00956540|Tracheostomy
433057|NCT00956540|decannulation
433058|NCT00956540|weaning
433059|NCT00956540|Tracheostomy Weaning
433060|NCT00956527|Adolescent
433061|NCT00956527|Substance Use
433062|NCT00956527|Early Intervention
433063|NCT00956527|Martial Arts
433064|NCT00956527|Karate
433065|NCT00956514|depression
433066|NCT00956514|major depressive disorder
433067|NCT00956514|transcranial magnetic stimulation
433068|NCT00956514|TMS
433069|NCT00956514|EEG
433070|NCT00956514|electroencephalography
433071|NCT00956514|Major Depression,
433072|NCT00956501|fall
433073|NCT00956501|balance
433074|NCT00956488|Exercise for Amyotrophic lateral sclerosis
433075|NCT00956475|anxiety disorder
433076|NCT00956475|long-term effects secondary to cancer therapy in adults
433077|NCT00956475|fatigue
433078|NCT00956475|pain
433079|NCT00956475|psychosocial effects of cancer and its treatment
433080|NCT00956475|cancer survivor
433081|NCT00956475|accelerated phase chronic myelogenous leukemia
433082|NCT00956475|acute undifferentiated leukemia
433083|NCT00956475|adult acute lymphoblastic leukemia in remission
433084|NCT00956475|adult acute myeloid leukemia in remission
433085|NCT00956475|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
433086|NCT00956475|adult acute myeloid leukemia with inv(16)(p13;q22)
433087|NCT00956475|adult acute myeloid leukemia with t(15;17)(q22;q12)
433088|NCT00956475|adult acute myeloid leukemia with t(16;16)(p13;q22)
433089|NCT00956475|adult acute myeloid leukemia with t(8;21)(q22;q22)
433090|NCT00956475|atypical chronic myeloid leukemia
433091|NCT00956475|blastic phase chronic myelogenous leukemia
433092|NCT00956475|chronic myelomonocytic leukemia
433093|NCT00956475|chronic phase chronic myelogenous leukemia
433094|NCT00956475|mast cell leukemia
433095|NCT00956475|meningeal chronic myelogenous leukemia
433096|NCT00956475|progressive hairy cell leukemia, initial treatment
433097|NCT00956475|prolymphocytic leukemia
433098|NCT00956475|recurrent adult acute lymphoblastic leukemia
433099|NCT00956475|recurrent adult acute myeloid leukemia
433100|NCT00956475|refractory chronic lymphocytic leukemia
433101|NCT00956475|refractory hairy cell leukemia
433102|NCT00956475|relapsing chronic myelogenous leukemia
433103|NCT00956475|secondary acute myeloid leukemia
433104|NCT00956475|stage I chronic lymphocytic leukemia
433105|NCT00956475|stage II chronic lymphocytic leukemia
433106|NCT00956475|stage III chronic lymphocytic leukemia
433107|NCT00956475|stage IV chronic lymphocytic leukemia
433108|NCT00956475|T-cell large granular lymphocyte leukemia
433109|NCT00956475|stage I adult Burkitt lymphoma
433110|NCT00956475|stage I adult diffuse large cell lymphoma
433111|NCT00956475|stage I adult diffuse mixed cell lymphoma
433112|NCT00956475|stage I adult diffuse small cleaved cell lymphoma
433113|NCT00956475|stage I adult Hodgkin lymphoma
433114|NCT00956475|stage I adult immunoblastic large cell lymphoma
433115|NCT00956475|stage I adult lymphoblastic lymphoma
433116|NCT00956475|stage I adult T-cell leukemia/lymphoma
433117|NCT00956475|stage I cutaneous T-cell non-Hodgkin lymphoma
433118|NCT00956475|stage I grade 1 follicular lymphoma
433119|NCT00956475|stage I grade 2 follicular lymphoma
433120|NCT00956475|stage I grade 3 follicular lymphoma
433121|NCT00956475|stage I mantle cell lymphoma
433122|NCT00956475|stage I marginal zone lymphoma
433123|NCT00956475|stage I small lymphocytic lymphoma
433124|NCT00956475|stage II adult Hodgkin lymphoma
433125|NCT00956475|stage II adult T-cell leukemia/lymphoma
433126|NCT00956475|stage II cutaneous T-cell non-Hodgkin lymphoma
433127|NCT00956475|stage III adult Burkitt lymphoma
433128|NCT00956475|stage III adult diffuse large cell lymphoma
433129|NCT00956475|stage III adult diffuse mixed cell lymphoma
433130|NCT00956475|stage III adult diffuse small cleaved cell lymphoma
433131|NCT00956475|stage III adult Hodgkin lymphoma
433132|NCT00956475|stage III adult immunoblastic large cell lymphoma
433133|NCT00956475|stage III adult lymphoblastic lymphoma
433134|NCT00956475|stage III adult T-cell leukemia/lymphoma
433135|NCT00956475|stage III cutaneous T-cell non-Hodgkin lymphoma
433136|NCT00956475|stage III grade 1 follicular lymphoma
433137|NCT00956475|stage III grade 2 follicular lymphoma
433138|NCT00956475|stage III grade 3 follicular lymphoma
433139|NCT00956475|stage III mantle cell lymphoma
433140|NCT00956475|stage III marginal zone lymphoma
433141|NCT00956475|stage III small lymphocytic lymphoma
433142|NCT00956475|stage IV adult Burkitt lymphoma
433143|NCT00956475|stage IV adult diffuse large cell lymphoma
433144|NCT00956475|stage IV adult diffuse mixed cell lymphoma
433145|NCT00956475|stage IV adult diffuse small cleaved cell lymphoma
433146|NCT00956475|stage IV adult Hodgkin lymphoma
433147|NCT00956475|stage IV adult immunoblastic large cell lymphoma
433148|NCT00956475|stage IV adult lymphoblastic lymphoma
433149|NCT00956475|stage IV adult T-cell leukemia/lymphoma
433150|NCT00956475|stage IV cutaneous T-cell non-Hodgkin lymphoma
433151|NCT00956475|stage IV grade 1 follicular lymphoma
433152|NCT00956475|stage IV grade 2 follicular lymphoma
433153|NCT00956475|stage IV grade 3 follicular lymphoma
433154|NCT00956475|stage IV mantle cell lymphoma
433155|NCT00956475|stage IV marginal zone lymphoma
433156|NCT00956475|stage IV small lymphocytic lymphoma
433157|NCT00956475|recurrent adult Burkitt lymphoma
433158|NCT00956475|recurrent adult diffuse large cell lymphoma
433159|NCT00956475|recurrent adult diffuse mixed cell lymphoma
433160|NCT00956475|recurrent adult diffuse small cleaved cell lymphoma
433161|NCT00956475|recurrent adult grade III lymphomatoid granulomatosis
433162|NCT00956475|recurrent adult Hodgkin lymphoma
433163|NCT00956475|recurrent adult immunoblastic large cell lymphoma
433164|NCT00956475|recurrent adult lymphoblastic lymphoma
433165|NCT00956475|recurrent adult T-cell leukemia/lymphoma
433166|NCT00956475|recurrent cutaneous T-cell non-Hodgkin lymphoma
433167|NCT00956475|recurrent grade 1 follicular lymphoma
433168|NCT00956475|recurrent grade 2 follicular lymphoma
433169|NCT00956475|recurrent grade 3 follicular lymphoma
433170|NCT00956475|recurrent mantle cell lymphoma
433171|NCT00956475|recurrent marginal zone lymphoma
433172|NCT00956475|recurrent small lymphocytic lymphoma
433173|NCT00956475|anaplastic large cell lymphoma
433174|NCT00956475|angioimmunoblastic T-cell lymphoma
433175|NCT00956475|recurrent mycosis fungoides/Sezary syndrome
433176|NCT00956475|stage I mycosis fungoides/Sezary syndrome
433177|NCT00956475|stage II mycosis fungoides/Sezary syndrome
433178|NCT00956475|stage III mycosis fungoides/Sezary syndrome
433179|NCT00956475|stage IV mycosis fungoides/Sezary syndrome
433180|NCT00956475|adult grade III lymphomatoid granulomatosis
433181|NCT00956475|adult nasal type extranodal NK/T-cell lymphoma
433182|NCT00956475|Waldenstrom macroglobulinemia
433183|NCT00956475|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
433184|NCT00956475|nodal marginal zone B-cell lymphoma
433185|NCT00956475|splenic marginal zone lymphoma
433186|NCT00956475|contiguous stage II adult Burkitt lymphoma
433187|NCT00956475|contiguous stage II adult diffuse large cell lymphoma
433188|NCT00956475|contiguous stage II adult diffuse mixed cell lymphoma
433300|NCT00956176|Vistide
433189|NCT00956475|contiguous stage II adult diffuse small cleaved cell lymphoma
433190|NCT00956475|contiguous stage II adult immunoblastic large cell lymphoma
433191|NCT00956475|contiguous stage II adult lymphoblastic lymphoma
433192|NCT00956475|contiguous stage II grade 1 follicular lymphoma
433193|NCT00956475|contiguous stage II grade 2 follicular lymphoma
433194|NCT00956475|contiguous stage II grade 3 follicular lymphoma
433195|NCT00956475|contiguous stage II mantle cell lymphoma
433196|NCT00956475|contiguous stage II marginal zone lymphoma
433197|NCT00956475|contiguous stage II small lymphocytic lymphoma
433198|NCT00956475|noncontiguous stage II adult Burkitt lymphoma
433199|NCT00956475|noncontiguous stage II adult diffuse large cell lymphoma
433200|NCT00956475|noncontiguous stage II adult diffuse mixed cell lymphoma
433201|NCT00956475|noncontiguous stage II adult diffuse small cleaved cell lymphoma
433202|NCT00956475|noncontiguous stage II adult immunoblastic large cell lymphoma
433203|NCT00956475|noncontiguous stage II adult lymphoblastic lymphoma
433204|NCT00956475|noncontiguous stage II grade 1 follicular lymphoma
433205|NCT00956475|noncontiguous stage II grade 2 follicular lymphoma
433206|NCT00956475|noncontiguous stage II grade 3 follicular lymphoma
433207|NCT00956475|noncontiguous stage II mantle cell lymphoma
433208|NCT00956475|noncontiguous stage II marginal zone lymphoma
433209|NCT00956475|noncontiguous stage II small lymphocytic lymphoma
433210|NCT00956475|intraocular lymphoma
433211|NCT00956475|primary central nervous system lymphoma
433212|NCT00956475|post-transplant lymphoproliferative disorder
433213|NCT00956475|cutaneous B-cell non-Hodgkin lymphoma
433214|NCT00956475|small intestine lymphoma
433215|NCT00956462|intraocular pressure
433216|NCT00956462|Ahmed valve
433217|NCT00956462|NSAIDS
433218|NCT00956462|steroids
433219|NCT00956449|flu
433220|NCT00956449|influenza
433221|NCT00956449|seasonal influenza
433222|NCT00956449|influenza vaccine antigen
433223|NCT00956449|immunogenicity
433224|NCT00956449|safety
433225|NCT00956449|tolerability
433226|NCT00956449|antibody response
433227|NCT00956449|intra muscular
433228|NCT00956449|elderly
433229|NCT00956449|non-elderly
433230|NCT00956436|Liver Cancer
433231|NCT00956436|Hepatocellular Carcinoma
433232|NCT00956436|Sorafenib
433233|NCT00956436|HCC
433234|NCT00956436|BIIB022
433235|NCT00956436|Open-Label
433236|NCT00956436|IGF-1R
433237|NCT00956436|Nexavar
433238|NCT00956423|obstructive sleep apnea
433239|NCT00956423|exercise training
433240|NCT00956423|aerobic exercise
433241|NCT00956423|resistance exercise
433242|NCT00956410|Active immunization
433243|NCT00956410|Alzheimer disease
433244|NCT00956410|Antibody
433245|NCT00956410|Central Nervous System Diseases
433246|NCT00956410|Neurodegenerative diseases
433247|NCT00956410|Vaccine
433248|NCT00956397|Functional Dyspepsia
433249|NCT00956397|Small Intestinal Bacterial Overgrowth
433250|NCT00956397|chronic abdominal discomfort
433251|NCT00956384|Breast reconstruction
433252|NCT00956384|Early stage
433253|NCT00956384|Skin-saving mastectomy
433254|NCT00956384|Prophylactic mastectomy
433255|NCT00956384|Acellular dermal matrix
433256|NCT00956384|BRCA Mutation Carriers
433257|NCT00956371|ONO-7746
433258|NCT00956371|Healthy adult subjects
433259|NCT00956358|bronchiolitis obliterans syndrome
433260|NCT00956332|Peripheral arterial disease (PAD)
433261|NCT00956332|Peripheral vascular disease (PVD)
433262|NCT00956332|Critical limb ischemia (CLI)
433263|NCT00956332|Cell therapy
433264|NCT00956332|Gene therapy
433265|NCT00956332|Endothelial cells
433266|NCT00956332|Smooth muscle cells
433267|NCT00956332|Angiogenesis
433268|NCT00956332|Arteriogenesis
433269|NCT00956332|amputation
433270|NCT00956332|diabetic foot
433271|NCT00956319|Insomnia
433272|NCT00956319|Zolpidem
433273|NCT00956319|Estazolam
433274|NCT00956306|Udenafil,DA-8159,hepatic impairment,healthy volunteers
433275|NCT00956280|The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC
433276|NCT00956280|KRAS mutation in population with advanced NSCLC
433277|NCT00956267|Polycystic ovary syndrome
433278|NCT00956267|clomiphene resistance
433279|NCT00956267|letrozole
433280|NCT00956267|Laparoscopic ovarian diathermy
433281|NCT00956254|mucositis
433282|NCT00956254|unspecified adult solid tumor, protocol specific
433283|NCT00956254|pain
433284|NCT00956241|rectal cancer
433285|NCT00956241|colonic pouch
433286|NCT00956241|side-to-end anastomosis
433287|NCT00956241|preoperative radiotherapy
433288|NCT00956215|post operative
433289|NCT00956215|obese
433290|NCT00956202|Influenza
433291|NCT00956202|Pandemic Flu
433292|NCT00956202|Swine-origin A/H1N1 Influenza
433293|NCT00956202|Inactivated split-virion vaccine
433294|NCT00956202|Adjuvant
433295|NCT00956189|Antipsychotic Agents
433296|NCT00956189|Metabolic Syndrome X
433297|NCT00956189|Identification
433298|NCT00956189|Prediction
433299|NCT00956176|Cidofovir
433301|NCT00956176|Adenovirus
433302|NCT00956176|BK virus infections
433303|NCT00956176|HSCT
433304|NCT00956176|Hemorrhagic Cystitis
433305|NCT00956176|Foley catheter
433306|NCT00956176|Viral infection
433307|NCT00956176|Bladder instillation
433308|NCT00956176|Intravesical
433309|NCT00956176|Transurethral catheter
433310|NCT00956176|Transplantation
433311|NCT00956150|Chronic Multisymptom Complex
433312|NCT00956150|Small Intestinal Bacterial Overgrowth
433313|NCT00956150|Gulf War Syndrome
433314|NCT00956150|Chronic Multisymptom Illness Complex
433315|NCT00956137|spinal anesthesia
433316|NCT00956137|ultrasound
433317|NCT00956137|palpation
433318|NCT00956137|knee
433319|NCT00956137|hip
433320|NCT00956137|surgery
433321|NCT00956137|intervertebral space
433322|NCT00956111|Novel Influenza A/H1N1 Vaccine
433323|NCT00956111|Immunogenictiy
433324|NCT00956111|Safety
433325|NCT00956085|OCD
433326|NCT00956072|gastrointestinal stromal tumor
433327|NCT00956059|focal segmental glomerulosclerosis
433328|NCT00956059|prednisone
433329|NCT00956059|mycophenolate mofetil
433330|NCT00956059|FK506
433331|NCT00956046|Influenza
433332|NCT00956046|Pandemic Flu
433333|NCT00956046|Swine-origin A/H1N1 Influenza
433334|NCT00956046|Swine-origin Influenza Virus
433335|NCT00956046|Infants
433336|NCT00956033|Cancer
433337|NCT00956033|Peripheral Neuropathy
433338|NCT00956033|Bortezomib
433339|NCT00956020|platelet rich plasma
433340|NCT00956020|fibrin matrix
433341|NCT00956020|dermal filler
433342|NCT00956007|stage III squamous cell carcinoma of the larynx
433343|NCT00956007|stage III verrucous carcinoma of the larynx
433344|NCT00956007|stage IV squamous cell carcinoma of the larynx
433345|NCT00956007|stage IV verrucous carcinoma of the larynx
433346|NCT00956007|stage III squamous cell carcinoma of the lip and oral cavity
433347|NCT00956007|stage IV squamous cell carcinoma of the lip and oral cavity
433348|NCT00956007|stage III verrucous carcinoma of the oral cavity
433349|NCT00956007|stage IV verrucous carcinoma of the oral cavity
433350|NCT00956007|stage III squamous cell carcinoma of the oropharynx
433351|NCT00956007|stage IV squamous cell carcinoma of the oropharynx
433352|NCT00956007|tongue cancer
433353|NCT00955968|HIV Infection
433354|NCT00955968|HAART
433355|NCT00955968|Maternal Health
433356|NCT00955955|Depression
433357|NCT00955955|Medical food
433358|NCT00955942|radiation toxicity
433359|NCT00955942|stage IIIA non-small cell lung cancer
433360|NCT00955942|stage IIIB non-small cell lung cancer
433361|NCT00955942|recurrent non-small cell lung cancer
433362|NCT00955942|stage IV non-small cell lung cancer
433363|NCT00955929|Penis
433364|NCT00955929|PLACEBO
433365|NCT00955929|SILDENAFIL CITRATE
433366|NCT00955929|TRIMIX
433367|NCT00955929|Bimix
433368|NCT00955929|Viagra
433369|NCT00955929|09-005
433370|NCT00955929|Erectile Dysfunction following Bilateral Nerve-Sparing
433371|NCT00955916|relapsed
433372|NCT00955916|refractory
433373|NCT00955916|acute
433374|NCT00955916|myeloid
433375|NCT00955916|AML
433376|NCT00955916|CML
433377|NCT00955916|blast crisis
433378|NCT00955903|glucose
433379|NCT00955903|insulin
433380|NCT00955903|lipids
433381|NCT00955903|C-reactive protein
433382|NCT00955903|adiponectin
433383|NCT00955903|leptin
433384|NCT00955903|TNF alpha
433385|NCT00955903|IL-6
433386|NCT00955903|Quality of Life
433387|NCT00955903|functional status
433388|NCT00955890|cardioprotection
433389|NCT00955890|anthracycline chemotherapy
433390|NCT00955890|breast cancer
433391|NCT00955877|extended-release epidural morphine
433392|NCT00955877|DepoDur
433393|NCT00955877|Spastic Cerebral Palsy
433394|NCT00955864|Cervix
433395|NCT00955864|Colposcope
433396|NCT00955864|Polarized Light
433397|NCT00955864|Cervix Structure
433398|NCT00955864|Collagen
433399|NCT00955864|HV
433400|NCT00955864|Healthy Volunteer
433401|NCT00955864|Healthy Women
433402|NCT00955825|allergic rhinoconjunctivitis
433403|NCT00955812|OPB-31121
433404|NCT00955812|Advanced Solid Tumor
433405|NCT00955812|STAT3
433406|NCT00955812|IL-6-induced STAT3 phosphorylation
433407|NCT00955799|Subjective, Tinnitus
433408|NCT00955786|Solid Tumors
433409|NCT00955786|Lymphoma
433410|NCT00955786|G-Quadruplex
433411|NCT00955773|GSK1120212, everolimus, solid tumors, pancreatic cancer, non-small lung cancer, KRAS-mutant
433412|NCT00955773|cancer
433413|NCT00955760|Healthy subjects
433414|NCT00955734|wrist
433415|NCT00955734|fracture
433416|NCT00955734|motion
433417|NCT00955734|surgery
433418|NCT00955721|Cholangiocarcinoma
433419|NCT00955721|Biliary Tract Cancer
433420|NCT00955721|Gallbladder Cancer
433421|NCT00955695|adenocarcinoma of the lung
433422|NCT00955695|adenosquamous cell lung cancer
433423|NCT00955695|bronchoalveolar cell lung cancer
433424|NCT00955695|large cell lung cancer
433425|NCT00955695|squamous cell lung cancer
433426|NCT00955695|stage IIIB non-small cell lung cancer
433427|NCT00955695|stage IV non-small cell lung cancer
433428|NCT00955682|Meningococcal vaccine GSK134612
433429|NCT00955669|mesenchymal stem cells
433430|NCT00955669|mononuclear cells
433431|NCT00955656|Characteristics of medical practices
433432|NCT00955656|Practitioners providing care to children with asthma
433433|NCT00955656|Medically underserved and impoverished Arkansas Delta region
433434|NCT00955656|Characteristics of medical practices and practitioners
433435|NCT00955656|Disadvantaged populations
433436|NCT00955643|periodontitis
433437|NCT00955643|hyperbaric oxygen therapy
433438|NCT00955630|Histoplasmosis
433439|NCT00955630|Lucentis
433440|NCT00955630|Ranibizumab
433441|NCT00955630|OHS
433442|NCT00955617|Dotarem
433443|NCT00955617|Gadovist
433444|NCT00955617|Peripheral arterial disease
433445|NCT00955617|MRA
433446|NCT00955604|Parkinson's Disease
433447|NCT00955604|Serotonin Toxicity
433448|NCT00955604|Rasagiline
433449|NCT00955604|Antidepressants
433450|NCT00955604|Chart Review
433451|NCT00955604|Retrospective
433452|NCT00955591|human papilloma virus infection
433453|NCT00955591|anal cancer
433454|NCT00955591|HIV infection
433455|NCT00955552|osteoarthritis (OA)
433456|NCT00955552|knee
433457|NCT00955539|Heart Failure
433458|NCT00955539|Cardiac resynchronization therapy
433459|NCT00955539|Optimization
433460|NCT00955539|Viability
433461|NCT00955539|Mechanical dyssynchrony
433462|NCT00955526|Parkinson's disease
433463|NCT00955526|levodopa
433464|NCT00955526|end of dose wearing off
433465|NCT00955526|OFF time
433466|NCT00955513|Ankle sprain
433467|NCT00955513|soft tissue injury
433468|NCT00955500|Hepatic encephalopathy
433469|NCT00955500|Cirrhosis
433470|NCT00955500|Proteins of the diet
433471|NCT00955500|Branched-chain amino acids
433472|NCT00955487|Premature Newborns
433473|NCT00955487|Inhaled Nitric Oxide
433474|NCT00955448|Anterior pelvic organ prolapse
433475|NCT00955448|Surgical repair
433476|NCT00955448|Pelvic floor surgery
433477|NCT00955448|Randomized clinical trial
433478|NCT00955435|adenocarcinoma of the prostate
433479|NCT00955435|stage I prostate cancer
433480|NCT00955435|stage IIB prostate cancer
433481|NCT00955435|stage IIA prostate cancer
433482|NCT00955435|stage III prostate cancer
433483|NCT00955422|Diagnosis
433484|NCT00955422|Alzheimer's Disease
433485|NCT00955422|Memory Disorder
433486|NCT00955422|Dementia
433487|NCT00955422|Alzheimer Disease
433488|NCT00955422|Memory Loss
433489|NCT00955396|sodium channel blocker
433490|NCT00955396|ambulatory blood pressure
433491|NCT00955383|Japanese
433492|NCT00955370|Uncertainty
433493|NCT00955370|Undiagnosed
433494|NCT00955370|Rare Diseases
433495|NCT00955370|Parents
433496|NCT00955370|Multiple Abnormalities
433497|NCT00955357|Epilepsy Treatment
433498|NCT00955357|Anti-epileptic drugs
433499|NCT00955357|Seizures
433500|NCT00955357|Vimpat
433501|NCT00955344|colorectal cancer screening
433502|NCT00955344|American Board of Internal Medicine Maintenance of Certification program
433503|NCT00955344|Currently enrolled in or plan to enroll in the American Board of Internal Medicine Maintenance of Certification program
433504|NCT00955305|Non-Small Cell Lung Cancer
433505|NCT00955305|cixutumumab
433506|NCT00955292|Solid Tumors
433507|NCT00955292|Lymphoma
433508|NCT00955292|G-Quadruplex
433509|NCT00955279|Ustekinumab
433510|NCT00955279|CNTO 1275
433511|NCT00955279|Stelara
433512|NCT00955279|Golimumab
433513|NCT00955279|CNTO 148
433514|NCT00955279|Simponi
433515|NCT00955279|Sarcoidosis
433516|NCT00955279|Sarcoid
433517|NCT00955279|Pulmonary Sarcoidosis
433518|NCT00955279|Skin Sarcoidosis
433519|NCT00955266|Separation
433520|NCT00955266|Cardiopulmonary bypass
433521|NCT00955266|Calcium chloride
433522|NCT00955253|Neglect
433523|NCT00955253|Attention
433524|NCT00955253|Vigilance
433525|NCT00955253|Stroke
433526|NCT00955253|Hemineglect
433527|NCT00955253|Unilateral Neglect
433528|NCT00955253|Spatial Neglect
433529|NCT00955240|stage II anal cancer
433530|NCT00955240|stage IIIA anal cancer
433531|NCT00955240|stage IIIB anal cancer
433532|NCT00955240|squamous cell carcinoma of the anus
433533|NCT00955227|Omega-3 Fatty acid
433534|NCT00955227|ALA (alpha linolenic acid)
433535|NCT00955227|Ezetimibe
433536|NCT00955227|Flaxseed oil capsules
433537|NCT00955214|TAXUS Liberté
433538|NCT00955214|Small coronary artery disease
433539|NCT00955214|Paclitaxel-eluting stent
433540|NCT00955201|diabetes mellitus
433541|NCT00955201|diabetic neuropathies
433542|NCT00955201|Aerobic Exercise
433543|NCT00955201|Exercise Therapy
433544|NCT00955201|electromyography
433545|NCT00955201|United States Veterans
433546|NCT00955188|colon cancer
433547|NCT00955188|rectal cancer
433548|NCT00955175|stage I non-small cell lung cancer
433549|NCT00955175|stage II non-small cell lung cancer
433550|NCT00955175|stage IIIA non-small cell lung cancer
433551|NCT00955175|stage IIIB non-small cell lung cancer
433552|NCT00955162|Substance Abuse, Intravenous
433553|NCT00955162|Buprenorphine
433554|NCT00955149|Primary sclerosing cholangitis
433555|NCT00955149|Trisomy 7
433556|NCT00955149|Cholangiocarcinoma
433557|NCT00955149|Chemoprevention
433558|NCT00955149|Erlotinib
433559|NCT00955136|ST elevated myocardial infarction
433560|NCT00955136|Acute coronary syndrome
433561|NCT00955136|MRX 801
433562|NCT00955136|Echocardiography
433563|NCT00955123|Inflammation
433564|NCT00955123|Urea synthesis
433565|NCT00955123|Catabolism
433566|NCT00955123|Nitrogen balance
433567|NCT00955110|Opioid
433568|NCT00955110|Recreational
433569|NCT00955110|Oxymorphone
433570|NCT00955110|Oxycodone
433571|NCT00955110|Extended Release
433572|NCT00955110|Healthy NonDependent Recreational Opioid Users
433573|NCT00955097|Definity
433574|NCT00955097|liver tumors
433575|NCT00955097|intra operative contrast
433576|NCT00955097|liver cancer
433577|NCT00955097|hepatic tumors
433578|NCT00955097|identify liver tumors
433579|NCT00955097|surgery liver tumors
433580|NCT00955097|Patients with known hepatic tumors
433581|NCT00955071|exercise
433582|NCT00955071|physical activity
433583|NCT00955071|diet
433584|NCT00955071|metabolic risk
433585|NCT00955071|visceral fat
433586|NCT00955071|Insulin Resistance
433587|NCT00955058|PSA
433588|NCT00955058|PCO
433589|NCT00955058|PCOS
433590|NCT00955045|long-term tolerability and safety
433591|NCT00955045|istradefylline treatment
433592|NCT00955045|levodopa/carbidopa
433593|NCT00955032|Parkinson's disease
433594|NCT00955032|Apathy
433595|NCT00955032|rTMS
433596|NCT00955032|Repetitive transcranial magnetic stimulation
433597|NCT00955032|Depression
433598|NCT00955019|Barrett's
433599|NCT00955019|Esophagus
433600|NCT00955019|Reflux
433601|NCT00955019|dysplasia
433602|NCT00955019|adenocarcinoma
433603|NCT00955006|HIV Seronegativity
433604|NCT00955006|HIV Preventive Vaccine
433605|NCT00954993|Hepatitis C Virus (HCV)
433606|NCT00954993|Vaniprevir
433607|NCT00954993|MK-7009
433608|NCT00954980|Varicose Veins
433609|NCT00954980|Superficial Thrombophlebitis
433610|NCT00954980|Deep Vein Thrombosis
433611|NCT00954980|Ulceration
433612|NCT00954980|leg pain
433613|NCT00954980|leg swelling
433614|NCT00954967|Diabetes Mellitus
433615|NCT00954967|Smoking Cessation
433616|NCT00954967|Primary Health Care
433617|NCT00954967|Motivational Interview
433618|NCT00954954|Arthroplasty
433619|NCT00954954|Replacement
433620|NCT00954954|Knee
433621|NCT00954954|Range of Motion
433622|NCT00954941|Hematologic Disorder
433623|NCT00954941|Acute myelogenous leukemia
433624|NCT00954941|AML
433625|NCT00954941|High-risk myelodysplastic syndrome
433626|NCT00954941|HR-MDS
433627|NCT00954941|Chronic Myelogenous Leukemia
433628|NCT00954941|CML
433629|NCT00954941|Ondansetron
433630|NCT00954941|Zofran
433631|NCT00954941|Aprepitant
433632|NCT00954941|Emend
433633|NCT00954941|L 754030
433634|NCT00954941|MK 869
433635|NCT00954941|Emesis
433636|NCT00954941|Nausea
433637|NCT00954941|Vomiting
433638|NCT00954928|hand
433639|NCT00954928|wrist
433640|NCT00954928|anticoagulation
433641|NCT00954928|surgery
433642|NCT00954928|patients on anticoagulant medication
433643|NCT00954915|chronic plaque psoriasis
433644|NCT00954915|psoriatic arthritis
433645|NCT00954902|Spice
433646|NCT00954902|responses to stress
433647|NCT00954902|Inflammatory
433648|NCT00954837|Thyroid cancer
433649|NCT00954837|thyroid FNA
433650|NCT00954837|repeat FNA
433651|NCT00954837|thyroid screening
433652|NCT00954837|thyroid ultrasonography
433653|NCT00954837|FNA screening
433654|NCT00954811|pregnancy
433655|NCT00954798|Influenza
433656|NCT00954798|Pandemic Flu
433657|NCT00954798|Swine-origin Influenza
433658|NCT00954798|Inactivated split-virion vaccine
433659|NCT00954798|Adjuvant
433660|NCT00954798|Adult
433661|NCT00954785|ankle
433662|NCT00954785|ligament
433663|NCT00954785|sprain
433664|NCT00954785|non-steroidal anti-inflammatory drugs
433665|NCT00954785|treatment
433666|NCT00954785|Acute ankle ligament sprain
433667|NCT00954772|Staged versus Simultaneous Bilateral DBS
433668|NCT00954759|Infantile colic
433669|NCT00954759|Chiropractic
433670|NCT00954759|Manipulation
433671|NCT00954759|Randomized controlled trial
433672|NCT00954746|Advanced Dupuytren's Disease
433673|NCT00954746|Muscular Diseases
433674|NCT00954746|Musculoskeletal Diseases
433675|NCT00954746|Contracture Joint Diseases
433676|NCT00954746|Connective Tissue Diseases
433677|NCT00954746|Dupuytren's Contracture
433678|NCT00954733|Hysteroscopic surgery
433679|NCT00954733|Hypoventilation
433680|NCT00954733|Co2
433681|NCT00954733|Transcutaneous Co2 Monitor
433682|NCT00954720|AML
433683|NCT00954720|ALL
433684|NCT00954720|MDS
433685|NCT00954720|iron overload
433686|NCT00954707|Atherosclerosis
433687|NCT00954681|Cannabis
433688|NCT00954681|quetiapine
433689|NCT00954668|Non-ST-elevation myocardial infarction
433690|NCT00954668|angiography
433691|NCT00954668|percutaneous coronary intervention
433692|NCT00954668|timing
433693|NCT00954655|gastrointestinal stromal tumor
433694|NCT00954642|Solid Tumor
433695|NCT00954642|Locally Advanced Solid Tumor
433696|NCT00954642|Avastin
433697|NCT00954629|Osteoarthritis
433698|NCT00954629|Pain
433699|NCT00954629|Knee
433700|NCT00954616|Inappropriate Medications Associated
433701|NCT00954616|Alzheimer's disease
433702|NCT00954603|delirium rating scale
433703|NCT00954603|clinical global improvement
433704|NCT00954603|extrapyramidal side effect
433705|NCT00954577|obesity
433706|NCT00954577|diabetes
433707|NCT00954577|exercise
433708|NCT00954577|education
433709|NCT00954577|child
433710|NCT00954564|arthralgia
433711|NCT00954564|stage I breast cancer
433712|NCT00954564|stage II breast cancer
433713|NCT00954564|stage IIIA breast cancer
433714|NCT00954525|Pancreatic Cancer
433715|NCT00954512|Antibodies, neoplasm
433716|NCT00954499|tactile stimulation
433717|NCT00954499|pain
433718|NCT00954499|immunization
433719|NCT00954499|infant
433720|NCT00954460|VPRIV
433721|NCT00954460|Enzyme Replacement Therapy
433722|NCT00954460|Gaucher disease
433723|NCT00954460|glucocerebrosidase
433724|NCT00954460|beta-glucocerebrosidase
433725|NCT00954460|Acid beta-glucocerebrosidase
433726|NCT00954460|glucosylceramidase
433727|NCT00954460|D-glucosyl-N-acylsphingosine glucohydrolase
433728|NCT00954460|gene activation
433729|NCT00954460|human
433730|NCT00954395|vitamin K antagonists, D-dimer,
433731|NCT00954395|deep vein thrombosis, pulmonary embolism,
433732|NCT00954382|Down syndrome
433733|NCT00954382|IQ
433734|NCT00954382|mental age
433735|NCT00954382|neuropsychological function
433736|NCT00954369|Alzheimer's disease
433737|NCT00954369|AD
433738|NCT00954369|W372
433739|NCT00954369|W372000
433740|NCT00954369|[F-18]W372
433741|NCT00954369|exploratory
433742|NCT00954369|imaging
433743|NCT00954356|Pain following 3rd molar/wisdom tooth extraction
433744|NCT00954343|Foot Ulcers
433745|NCT00954343|Extracorporeal Shockwave
433746|NCT00954343|Chronic wound
433747|NCT00954330|rct, intervention, surgery, lateral ligament injury of the ankle
433748|NCT00954330|REturn to pre-injury level
433749|NCT00954317|epidural
433750|NCT00954317|labour analgesia
433751|NCT00954304|Pgp inhibitor
433752|NCT00954304|P-glycoprotein inhibitor
433753|NCT00954291|antinauseant and antiemetic
433754|NCT00954278|non small cell lung cancer
433755|NCT00954278|phase 1
433756|NCT00954278|sorafenib
433757|NCT00954278|intrapatient dose escalation
433758|NCT00954265|pregnancy occurence
433759|NCT00954265|OHSS
433760|NCT00954226|Head & Neck squamous cell carcinoma
433761|NCT00954226|HN cancer
433762|NCT00954226|Surgery
433763|NCT00954226|Erlotinib
433764|NCT00954226|Biomarkers
433765|NCT00954226|Phosphorylation of AKT
433766|NCT00954161|First aid
433767|NCT00954161|Helping behaviour
433768|NCT00954161|Health education
433769|NCT00954161|Myocardial infarction
433770|NCT00954161|Emergencies
433771|NCT00954148|cancer
433772|NCT00954148|colorectal
433773|NCT00954148|head/neck
433774|NCT00954148|lung
433775|NCT00954148|PET/CT
433776|NCT00954135|neoadjuvant therapy, sorafenib, letrozolo, cyclophosphamide
433777|NCT00954122|Acute schizophrenia
433778|NCT00954109|Insulin Resistance
433779|NCT00954109|Type 2 Diabetes
433780|NCT00954070|gastroesophageal reflux disease
433781|NCT00954057|TED
433782|NCT00954044|randomized clinical trial
433783|NCT00954044|prostate cancer
433784|NCT00954044|partnered exercise
433785|NCT00954005|relapsed indolent lymphoma
433786|NCT00954005|gemcitabine
433787|NCT00954005|oxaliplatin
433788|NCT00954005|rituximab
433789|NCT00953992|acute kidney disease
433790|NCT00953992|prognosis
433791|NCT00953992|oxidative stress
433792|NCT00953992|inflammation
433793|NCT00953992|gene polymorphism
433794|NCT00953979|ankylosing spondylitis
433795|NCT00953979|treatment
433796|NCT00953979|Sulfasalazine
433797|NCT00953979|kunxian capsule
433798|NCT00953914|pyridostigmine
433799|NCT00953914|autonomic modulation
433800|NCT00953914|diabetes mellitus
433801|NCT00953914|heart rate variability
433802|NCT00953888|Healthy volunteer
433803|NCT00953888|Single ascending dose
433804|NCT00953888|Safety
433805|NCT00953888|Tolerability
433806|NCT00953888|Healthy volunteer study
433807|NCT00953862|ADHD
433808|NCT00953862|Substance Use Disorder
433809|NCT00953862|Residential Treatment Facility
433810|NCT00953849|Calcitriol
433811|NCT00953849|Celecoxib
433812|NCT00953849|Immunotherapy
433813|NCT00953836|kinetics
433814|NCT00953836|alkylresorcinol metabolites
433815|NCT00953836|rye fiber
433816|NCT00953823|Thiamin supplementation
433817|NCT00953823|Thiamin deficiency
433818|NCT00953823|Heart failure
433819|NCT00953823|Heart function
433820|NCT00953823|Vitamin B1 supplementation
433821|NCT00953810|heart failure
433822|NCT00953810|education
433823|NCT00953810|non-pharmacological management
433824|NCT00953810|prognosis
433825|NCT00953797|Resistant Hypertension
433826|NCT00953797|Endothelial dysfunction
433827|NCT00953797|Enhanced External Counterpulsation
433828|NCT00953784|surgery
433829|NCT00953784|wound infections
433830|NCT00953784|colorectal
433831|NCT00953771|TTP
433832|NCT00953771|Thrombotic Thrombocytopenic Purpura
433833|NCT00953758|Chronic Myeloid Leukemia Myelofibrosis Myelodysplastic Syndrome Acute myeloid Leukemia Hedgehog inhibitor
433834|NCT00953745|Depression
433835|NCT00953745|Neuroimaging
433836|NCT00953745|Aripiprazole
433837|NCT00953745|Mood disorder
433838|NCT00953745|PET Scan
433839|NCT00953745|fMRI
433840|NCT00953732|Peplin
433841|NCT00953732|Actinic keratosis
433842|NCT00953732|PEP005
433843|NCT00953719|Hip arthroplasty
433844|NCT00953719|Acetabular cup
433845|NCT00953719|Ceramic-on-polyethylene
433846|NCT00953706|Fibrosis
433847|NCT00953706|Pancreatic Diseases
433848|NCT00953706|Digestive System Diseases
433849|NCT00953706|Lung Diseases
433850|NCT00953706|Respiratory Tract Diseases
433851|NCT00953706|Genetic Diseases, Inborn
433852|NCT00953706|Infant, Newborn, Diseases
433853|NCT00953706|Pathologic Processes
433854|NCT00953693|Induced pluripotent stem cells
433855|NCT00953693|Hepatic disorders
433856|NCT00953693|Eye disorders
433857|NCT00953693|Blood groups
433858|NCT00953654|Generalized Anxiety Disorder
433859|NCT00953654|Exercise Training
433860|NCT00953654|Strength Training
433861|NCT00953654|Mental Health
433862|NCT00953641|Vaginal Misoprostol
433863|NCT00953641|Cervical ripening
433864|NCT00953641|Endometrial biopsy
433865|NCT00953628|endometrium
433866|NCT00953628|histology
433867|NCT00953628|pregnancy
433868|NCT00953615|PSC
433869|NCT00953615|Thalidomide
433870|NCT00953589|treatment naive
433871|NCT00953576|castration resistant prostate cancer
433872|NCT00953576|KHAD
433873|NCT00953563|Venous Leg Ulcers
433874|NCT00953537|stage IV breast cancer
433875|NCT00953524|Influenza
433876|NCT00953524|Pandemic Flu
433877|NCT00953524|Swine-origin A/H1N1 Influenza
433878|NCT00953524|Adult
433879|NCT00953511|esophagus
433880|NCT00953511|chemoradiation
433881|NCT00953511|excision repair cross-complementing gene
433882|NCT00953511|polymorphism
433883|NCT00953511|response prediction
433884|NCT00953498|diabetes
433885|NCT00953498|glitazones
433886|NCT00953498|HDL
433887|NCT00953485|Sjogren's Syndrome
433888|NCT00953485|Mesenchymal Stem Cells
433889|NCT00953485|Transplantation
433890|NCT00953472|hypertension treatment
433891|NCT00953459|extensive stage small cell lung cancer
433892|NCT00953459|recurrent small cell lung cancer
433893|NCT00953446|metastatic renal cell carcinoma
433894|NCT00953446|ASL MRI
433895|NCT00953446|sunitinib
433896|NCT00953446|AMG386
433897|NCT00953433|Intratracheal
433898|NCT00953420|nasopharyngeal carcinoma
433899|NCT00953420|Carboplatin
433900|NCT00953420|Docetaxel
433901|NCT00953420|Epstein-Barr Virus
433902|NCT00953420|T Lymphocytes
433903|NCT00953420|EBV-CTLs
433904|NCT00953394|octreotide LAR
433905|NCT00953394|neuroendocrine carcinoma
433906|NCT00953394|metronomic 5fluorouracil
433907|NCT00953381|Ilaprazole
433908|NCT00953381|Proton pump inhibitor
433909|NCT00953381|Duodenal ulcer
433910|NCT00953381|Acid suppression
433911|NCT00953381|Randomized trial
433912|NCT00953368|remote ischemic preconditioning
433913|NCT00953368|cognitive function
433914|NCT00953368|off-pump coronary artery bypass graft
433915|NCT00953342|AEROBIC EXERCISE
433916|NCT00953342|ASTHMA CONTROL
433917|NCT00953342|ASTHMA QUALITY OF LIFE
433918|NCT00953342|INFLAMMATION
433919|NCT00953342|TREATMENT
433920|NCT00953303|heart failure
433921|NCT00953303|prednisone
433922|NCT00953303|cardiovascular mortality
433923|NCT00953303|renal function
433924|NCT00953290|Cellulite
433925|NCT00953290|Adipose tissue
433926|NCT00953290|Circumference
433927|NCT00953290|Reduction
433928|NCT00953290|Thigh
433929|NCT00953277|Nerve Repair
433930|NCT00953277|Erectile Function
433931|NCT00953277|Prostate Cancer
433932|NCT00953277|Robot Assisted Laparoscopic Prostatectomy
433933|NCT00953277|Continence
433934|NCT00953251|high sensitive troponin T; non-STEMI; early detection.
433935|NCT00953251|To detect non-STEMI in a cohort of patients with acute coronary syndrome
433936|NCT00953225|prostate cancer
433937|NCT00953225|vitamin D
433938|NCT00953212|atrial fibrillation
433939|NCT00953212|cardiac surgery
433940|NCT00953212|open heart surgery
433941|NCT00953199|endoscopic retrograde cholangiopancreatography
433942|NCT00953199|ERCP
433943|NCT00953199|pancreatitis
433944|NCT00953199|lidocaine
433945|NCT00953199|post-ERCP pancreatitis
433946|NCT00953186|Diabetes
433947|NCT00953186|Foot ulcer
433948|NCT00953186|Neuropathy
433949|NCT00953186|Ischemia
433950|NCT00953160|Cellulite
433951|NCT00953160|Adipose tissue
433952|NCT00953160|Circumference
433953|NCT00953160|Reduction
433954|NCT00953160|Thigh
433955|NCT00953160|Abdomen
433956|NCT00953160|Flank
433957|NCT00953134|periconceptional
433958|NCT00953134|iron
433959|NCT00953134|folic acid
433960|NCT00953134|supplementation
433961|NCT00953121|irinotecan
433962|NCT00953121|carboplatin
433963|NCT00953121|bevacizumab
433964|NCT00953121|Avastin
433965|NCT00953095|Autism Spectrum Disorder
433966|NCT00953095|treatment
433967|NCT00953095|joint attention
433968|NCT00953095|communication
433969|NCT00953095|language
433970|NCT00953043|lubiprostone
433971|NCT00953043|colon
433972|NCT00953043|motility
433973|NCT00953043|sensation
433974|NCT00953017|Efficacy of bowel cleansing
433975|NCT00953017|Patient tolerability
433976|NCT00953017|Amitiza
433977|NCT00953017|Dulcolax
433978|NCT00953017|Miralax
433979|NCT00953017|Colonoscopy preparation
433980|NCT00953017|Bowel preparation
433981|NCT00953017|Screening colonoscopy
433982|NCT00953004|dietary fiber
433983|NCT00953004|obesity
433984|NCT00953004|apparent energy digestibility
433985|NCT00952978|Ilaprazole
433986|NCT00952978|Proton pump inhibitor
433987|NCT00952978|Duodenal ulcer
433988|NCT00952978|Acid suppression
433989|NCT00952978|Randomized trial
433990|NCT00952965|BP
433991|NCT00952939|ciliary body and choroid melanoma, small size
433992|NCT00952939|iris melanoma
433993|NCT00952939|intraocular melanoma
433994|NCT00952939|ciliary body and choroid melanoma, medium/large size
433995|NCT00952926|Watchful Waiting
433996|NCT00952926|Rectal cancer
433997|NCT00952926|Observation
433998|NCT00952926|Avoid operation
433999|NCT00952900|TMJMD
434000|NCT00952900|Acute Pain
434001|NCT00952900|RDC/TMD
434002|NCT00952900|Community Treatment Clinics
434003|NCT00952900|RCT
434004|NCT00952900|Evidence-Based Outcomes
434005|NCT00952900|Short- and long-term follow-up
434006|NCT00952900|Biopsychosocial
434007|NCT00952900|Assessment and Treatment
434008|NCT00952900|Ability to read and write English
434009|NCT00952900|6 months' or less duration of TMD
434010|NCT00952900|No other pain-related conditions
434011|NCT00952874|anal cancer
434012|NCT00952874|Molecular biology
434013|NCT00952874|HIV status
434014|NCT00952874|HPV infection
434015|NCT00952874|Microsatellite instability
434016|NCT00952874|Biopsy proven Squamous Cell carcinoma of the Anus
434017|NCT00952874|Squamous Cell carcinoma of the Anus
434018|NCT00952861|Chronic obstructive pulmonary disease
434019|NCT00952861|Infection
434020|NCT00952861|Antibiotics
434021|NCT00952848|pain
434022|NCT00952848|neurotoxicity
434023|NCT00952848|chemotherapeutic agent toxicity
434024|NCT00952848|unspecified adult solid tumor, protocol specific
434025|NCT00952848|peripheral neuropathy
434026|NCT00952835|Asthma
434027|NCT00952835|rhinitis
434028|NCT00952835|EIB
434029|NCT00952835|Exhaled Nitric oxide
434030|NCT00952835|lung function
434031|NCT00952835|vitamin d
434032|NCT00952796|intra-abdominal infection
434033|NCT00952796|moxifloxacin
434034|NCT00952796|ampicillin/sulbactam
434035|NCT00952783|Peplin
434036|NCT00952783|Actinic keratosis
434037|NCT00952783|PEP005
434038|NCT00952770|Coronary artery disease
434039|NCT00952770|Coronary intervention
434040|NCT00952770|intima-media thickness
434041|NCT00952757|APS-related hyperprolactinaemia
434042|NCT00952757|Quetiapine
434043|NCT00952757|Schizophrenia
434044|NCT00952757|Bipolar
434045|NCT00952744|acute myocardial infarction
434046|NCT00952744|ST-segment elevation myocardial infarction
434047|NCT00952744|STEMI
434048|NCT00952744|non-ST-segment elevation myocardial infarction
434049|NCT00952744|NSTEMI
434050|NCT00952744|unstable angina
434051|NCT00952744|unstable angina pectoris
434052|NCT00952744|UA
434053|NCT00952744|UAP
434054|NCT00952692|breast cancer
434055|NCT00952692|HER2
434056|NCT00952692|Lapatinib
434057|NCT00952692|dHER2 ASCI
434058|NCT00952692|overexpressing HER2
434059|NCT00952692|refractory to trastuzumab
434060|NCT00952679|The investigators evaluated the new method by comparing lymph nodes defined by CT and traditional ways.
434061|NCT00952666|Prostate Cancer
434062|NCT00952666|Transrectal Ultrasound Imaging of Prostate
434063|NCT00952666|Neurovascular Bundles
434064|NCT00952666|Robot Assisted Laparoscopic Radical Prostatectomy
434065|NCT00952653|depression
434066|NCT00952640|vitamin A
434067|NCT00952640|post-partum
434068|NCT00952640|infant
434069|NCT00952640|acute phase response
434070|NCT00952627|Cardiac fibrosis
434071|NCT00952627|Diastolic dysfunction
434072|NCT00952627|Hypertension
434073|NCT00952614|retinal vein occlusion
434074|NCT00952614|sustained drug delivery implant
434075|NCT00952614|steroid
434076|NCT00952614|macular edema
434077|NCT00952601|Tourette
434078|NCT00952601|Atkins
434079|NCT00952601|Ketosis
434080|NCT00952601|Tic
434081|NCT00952588|Acute Myeloid Leukaemia,
434082|NCT00952588|AML
434083|NCT00952575|Prevention of foeto-maternal allo-immunisation
434084|NCT00952562|vitamin d
434085|NCT00952562|calcium
434086|NCT00952562|blood pressure
434087|NCT00952536|Randomised controlled trial
434088|NCT00952536|Double blind fully masked
434089|NCT00952536|Dietary supplement
434090|NCT00952523|acne
434091|NCT00952523|irritation
434092|NCT00952523|objective sensory methods
434093|NCT00952510|Range of motion, articular
434094|NCT00952510|Cervical spine
434095|NCT00952497|Gastric Cancer
434096|NCT00952497|Gastro-Esophageal Cancer
434097|NCT00952497|GE-Junction
434098|NCT00952497|Advanced Gastric Cancer
434099|NCT00952484|Hypophosphatasia
434100|NCT00952484|HPP
434101|NCT00952484|Bone Disease
434102|NCT00952484|Soft Bones
434103|NCT00952484|Low Alkaline Phosphatase
434104|NCT00952484|genetic metabolic disorder
434105|NCT00952484|alkaline phosphatase
434106|NCT00952484|tissue non-specific alkaline phosphatase
434107|NCT00952484|rickets
434108|NCT00952484|osteomalacia
434109|NCT00952471|Asthma
434110|NCT00952471|Children
434111|NCT00952471|CPOE
434112|NCT00952471|Decision Support
434113|NCT00952471|Framing
434114|NCT00952471|Heuristic
434115|NCT00952471|Order Sets
434116|NCT00952458|Safety
434117|NCT00952458|Midazolam and propofol sedation
434118|NCT00952458|ERCP
434119|NCT00952458|Bispectral Index monitoring
434120|NCT00952432|Carpal Tunnel Syndrome
434121|NCT00952432|Multiple Excitability Test
434122|NCT00952432|Nerve Conduction Study
434123|NCT00952432|QtracW
434124|NCT00952432|carbamazepine
434125|NCT00952432|Acupuncture
434126|NCT00952419|Influenza
434127|NCT00952419|Pandemic Flu
434128|NCT00952419|Swine-origin A/H1N1 Influenza
434129|NCT00952419|Children
434130|NCT00952406|Pelvic Floor Disorders
434131|NCT00952406|Sexual Function
434132|NCT00952406|Incontinence
434133|NCT00952406|Pelvic Organ Prolapse
434134|NCT00952393|receptors nicotinic
434135|NCT00952380|VTE
434136|NCT00952354|Down syndrome
434137|NCT00952354|MLU
434138|NCT00952354|language development
434139|NCT00952354|language assessment
434140|NCT00952341|CINV
434141|NCT00952328|breastfeeding outcomes
434142|NCT00952328|breastfeeding self-efficacy
434143|NCT00952328|infant weight loss
434144|NCT00952315|kidney stones
434145|NCT00952315|intracorporeal lithotriptors
434146|NCT00952315|kidney stone removal
434147|NCT00952302|Hypoxia
434148|NCT00952302|Iron
434149|NCT00952302|Hypoxia-Inducible Factor 1
434150|NCT00952302|Chronic mountain sickness
434151|NCT00952289|Myelofibrosis
434152|NCT00952289|Post-Polycythemia Vera Myelofibrosis
434153|NCT00952289|Post-Essential Thrombocythemia Myelofibrosis
434154|NCT00952276|Influenza Pandemic Flu Swine-origin A/H1N1 Influenza Adults
434155|NCT00952263|Hepatitis C
434156|NCT00952263|Phase I
434157|NCT00952263|Infusion
434158|NCT00952263|Pharmacokinetics
434159|NCT00952263|MBL-HCV1
434160|NCT00952263|Monoclonal antibody
434161|NCT00952263|Safety Assessment
434162|NCT00952250|quality improvement
434163|NCT00952237|Autologous Peripheral Blood Stem Cell Transplant
434164|NCT00952237|IL-2
434165|NCT00952237|GM-CSF
434166|NCT00952224|myocardial salvage
434167|NCT00952224|cardiovascular magnetic resonance
434168|NCT00952224|magnetic resonance imaging
434169|NCT00952224|myocardial infarction
434170|NCT00952224|prognosis
434171|NCT00952211|stroke
434172|NCT00952211|obstructive sleep apnea
434173|NCT00952211|fatigue
434174|NCT00952211|quality of life
434175|NCT00952185|viral infection
434176|NCT00952185|aplastic anemia
434177|NCT00952185|accelerated phase chronic myelogenous leukemia
434178|NCT00952185|acute undifferentiated leukemia
434179|NCT00952185|adult acute lymphoblastic leukemia in remission
434180|NCT00952185|adult acute myeloid leukemia in remission
434181|NCT00952185|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
434182|NCT00952185|adult acute myeloid leukemia with inv(16)(p13;q22)
434183|NCT00952185|adult acute myeloid leukemia with t(15;17)(q22;q12)
434184|NCT00952185|adult acute myeloid leukemia with t(16;16)(p13;q22)
434185|NCT00952185|adult acute myeloid leukemia with t(8;21)(q22;q22)
434186|NCT00952185|atypical chronic myeloid leukemia, BCR-ABL negative
434187|NCT00952185|blastic phase chronic myelogenous leukemia
434188|NCT00952185|chronic myelomonocytic leukemia
434189|NCT00952185|chronic phase chronic myelogenous leukemia
434190|NCT00952185|mast cell leukemia
434191|NCT00952185|meningeal chronic myelogenous leukemia
434192|NCT00952185|progressive hairy cell leukemia, initial treatment
434193|NCT00952185|prolymphocytic leukemia
434194|NCT00952185|recurrent adult acute lymphoblastic leukemia
434195|NCT00952185|recurrent adult acute myeloid leukemia
434196|NCT00952185|recurrent adult T-cell leukemia/lymphoma
434197|NCT00952185|refractory chronic lymphocytic leukemia
434198|NCT00952185|refractory hairy cell leukemia
434199|NCT00952185|relapsing chronic myelogenous leukemia
434200|NCT00952185|secondary acute myeloid leukemia
434201|NCT00952185|stage 0 chronic lymphocytic leukemia
434202|NCT00952185|stage I adult T-cell leukemia/lymphoma
434203|NCT00952185|stage I chronic lymphocytic leukemia
434204|NCT00952185|stage II adult T-cell leukemia/lymphoma
434205|NCT00952185|stage II chronic lymphocytic leukemia
434206|NCT00952185|stage III adult T-cell leukemia/lymphoma
434207|NCT00952185|stage III chronic lymphocytic leukemia
434208|NCT00952185|stage IV adult T-cell leukemia/lymphoma
434209|NCT00952185|stage IV chronic lymphocytic leukemia
434210|NCT00952185|T-cell large granular lymphocyte leukemia
434211|NCT00952185|recurrent adult Hodgkin lymphoma
434212|NCT00952185|stage I adult Hodgkin lymphoma
434213|NCT00952185|stage II adult Hodgkin lymphoma
434214|NCT00952185|stage III adult Hodgkin lymphoma
434215|NCT00952185|stage IV adult Hodgkin lymphoma
434216|NCT00952185|anaplastic large cell lymphoma
434217|NCT00952185|angioimmunoblastic T-cell lymphoma
434218|NCT00952185|cutaneous B-cell non-Hodgkin lymphoma
434219|NCT00952185|recurrent cutaneous T-cell non-Hodgkin lymphoma
434220|NCT00952185|stage I cutaneous T-cell non-Hodgkin lymphoma
434221|NCT00952185|stage II cutaneous T-cell non-Hodgkin lymphoma
434222|NCT00952185|stage III cutaneous T-cell non-Hodgkin lymphoma
434223|NCT00952185|stage IV cutaneous T-cell non-Hodgkin lymphoma
434224|NCT00952185|recurrent mycosis fungoides/Sezary syndrome
434225|NCT00952185|stage I mycosis fungoides/Sezary syndrome
434226|NCT00952185|stage II mycosis fungoides/Sezary syndrome
434227|NCT00952185|stage III mycosis fungoides/Sezary syndrome
434228|NCT00952185|stage IV mycosis fungoides/Sezary syndrome
434229|NCT00952185|adult grade III lymphomatoid granulomatosis
434230|NCT00952185|adult nasal type extranodal NK/T-cell lymphoma
434231|NCT00952185|Waldenstrom macroglobulinemia
434232|NCT00952185|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
434233|NCT00952185|nodal marginal zone B-cell lymphoma
434234|NCT00952185|splenic marginal zone lymphoma
434235|NCT00952185|contiguous stage II adult Burkitt lymphoma
434236|NCT00952185|contiguous stage II adult diffuse large cell lymphoma
434237|NCT00952185|contiguous stage II adult diffuse mixed cell lymphoma
434238|NCT00952185|contiguous stage II adult diffuse small cleaved cell lymphoma
434239|NCT00952185|contiguous stage II adult immunoblastic large cell lymphoma
434240|NCT00952185|contiguous stage II adult lymphoblastic lymphoma
434241|NCT00952185|contiguous stage II grade 1 follicular lymphoma
434242|NCT00952185|contiguous stage II grade 2 follicular lymphoma
434243|NCT00952185|contiguous stage II grade 3 follicular lymphoma
434244|NCT00952185|contiguous stage II mantle cell lymphoma
434245|NCT00952185|contiguous stage II marginal zone lymphoma
434246|NCT00952185|contiguous stage II small lymphocytic lymphoma
434247|NCT00952185|stage I adult Burkitt lymphoma
434248|NCT00952185|stage I adult diffuse large cell lymphoma
434249|NCT00952185|stage I adult diffuse mixed cell lymphoma
434250|NCT00952185|stage I adult diffuse small cleaved cell lymphoma
434251|NCT00952185|stage I adult immunoblastic large cell lymphoma
434252|NCT00952185|stage I adult lymphoblastic lymphoma
434253|NCT00952185|stage I grade 1 follicular lymphoma
434254|NCT00952185|stage I grade 2 follicular lymphoma
434255|NCT00952185|stage I grade 3 follicular lymphoma
434256|NCT00952185|stage I mantle cell lymphoma
434257|NCT00952185|stage I marginal zone lymphoma
434258|NCT00952185|stage I small lymphocytic lymphoma
434259|NCT00952185|noncontiguous stage II adult Burkitt lymphoma
434260|NCT00952185|noncontiguous stage II adult diffuse large cell lymphoma
434261|NCT00952185|noncontiguous stage II adult diffuse mixed cell lymphoma
434262|NCT00952185|noncontiguous stage II adult diffuse small cleaved cell lymphoma
434263|NCT00952185|noncontiguous stage II adult immunoblastic large cell lymphoma
434264|NCT00952185|noncontiguous stage II adult lymphoblastic lymphoma
434265|NCT00952185|noncontiguous stage II grade 1 follicular lymphoma
434266|NCT00952185|noncontiguous stage II grade 2 follicular lymphoma
434267|NCT00952185|noncontiguous stage II grade 3 follicular lymphoma
434268|NCT00952185|noncontiguous stage II mantle cell lymphoma
434269|NCT00952185|noncontiguous stage II marginal zone lymphoma
434270|NCT00952185|noncontiguous stage II small lymphocytic lymphoma
434271|NCT00952185|stage III adult Burkitt lymphoma
434272|NCT00952185|stage III adult diffuse large cell lymphoma
434273|NCT00952185|stage III adult diffuse mixed cell lymphoma
434274|NCT00952185|stage III adult diffuse small cleaved cell lymphoma
434275|NCT00952185|stage III adult immunoblastic large cell lymphoma
434276|NCT00952185|stage III adult lymphoblastic lymphoma
434277|NCT00952185|stage III grade 1 follicular lymphoma
434278|NCT00952185|stage III grade 2 follicular lymphoma
434279|NCT00952185|stage III grade 3 follicular lymphoma
434280|NCT00952185|stage III mantle cell lymphoma
434281|NCT00952185|stage III marginal zone lymphoma
434282|NCT00952185|stage III small lymphocytic lymphoma
434283|NCT00952185|stage IV adult Burkitt lymphoma
434284|NCT00952185|stage IV adult diffuse large cell lymphoma
434285|NCT00952185|stage IV adult diffuse mixed cell lymphoma
434286|NCT00952185|stage IV adult diffuse small cleaved cell lymphoma
434287|NCT00952185|stage IV adult immunoblastic large cell lymphoma
434288|NCT00952185|stage IV adult lymphoblastic lymphoma
434289|NCT00952185|stage IV grade 1 follicular lymphoma
434290|NCT00952185|stage IV grade 2 follicular lymphoma
434291|NCT00952185|stage IV grade 3 follicular lymphoma
434292|NCT00952185|stage IV mantle cell lymphoma
434293|NCT00952185|stage IV marginal zone lymphoma
434294|NCT00952185|stage IV small lymphocytic lymphoma
434295|NCT00952185|recurrent adult Burkitt lymphoma
434296|NCT00952185|recurrent adult diffuse large cell lymphoma
434297|NCT00952185|recurrent adult diffuse mixed cell lymphoma
434298|NCT00952185|recurrent adult diffuse small cleaved cell lymphoma
434299|NCT00952185|recurrent adult grade III lymphomatoid granulomatosis
434300|NCT00952185|recurrent adult immunoblastic large cell lymphoma
434301|NCT00952185|recurrent adult lymphoblastic lymphoma
434302|NCT00952185|recurrent grade 1 follicular lymphoma
434303|NCT00952185|recurrent grade 2 follicular lymphoma
434304|NCT00952185|recurrent grade 3 follicular lymphoma
434305|NCT00952185|recurrent mantle cell lymphoma
434306|NCT00952185|recurrent marginal zone lymphoma
434307|NCT00952185|recurrent small lymphocytic lymphoma
434308|NCT00952185|intraocular lymphoma
434309|NCT00952185|primary central nervous system non-Hodgkin lymphoma
434310|NCT00952185|primary central nervous system Hodgkin lymphoma
434311|NCT00952185|post-transplant lymphoproliferative disorder
434312|NCT00952185|chronic eosinophilic leukemia
434313|NCT00952185|chronic neutrophilic leukemia
434314|NCT00952185|primary myelofibrosis
434315|NCT00952185|essential thrombocythemia
434316|NCT00952185|polycythemia vera
434317|NCT00952185|extramedullary plasmacytoma
434318|NCT00952185|isolated plasmacytoma of bone
434319|NCT00952185|stage I multiple myeloma
434320|NCT00952185|stage II multiple myeloma
434321|NCT00952185|stage III multiple myeloma
434322|NCT00952185|primary systemic amyloidosis
434323|NCT00952185|refractory multiple myeloma
434324|NCT00952185|de novo myelodysplastic syndromes
434325|NCT00952185|previously treated myelodysplastic syndromes
434326|NCT00952185|secondary myelodysplastic syndromes
434327|NCT00952185|myelodysplastic/myeloproliferative neoplasm, unclassifiable
434328|NCT00952172|Stair stepping training
434329|NCT00952172|OSAS
434330|NCT00952172|cardiopulmonary fitness
434331|NCT00952172|sleep disturbance
434332|NCT00952172|Actigraphy
434333|NCT00952159|tramadol
434334|NCT00952159|CYP2D6
434335|NCT00952159|O-demethyl-tramadol
434336|NCT00952159|poor metabolizer
434337|NCT00952159|genotyping
434338|NCT00952159|phenotyping
434339|NCT00952146|NOTES
434340|NCT00952146|Transgastric
434341|NCT00952146|Appendectomy
434342|NCT00952146|Safety
434343|NCT00952146|Feasibility
434344|NCT00952133|PONV
434345|NCT00952133|Outpatient surgery
434346|NCT00952133|Laparoscopic abdominal surgery
434347|NCT00952133|Laparoscopic gynecologic surgery
434348|NCT00952120|Wound healing
434349|NCT00952120|Negative pressure wound therapy
434350|NCT00952120|Skin graft
434351|NCT00952107|breast cancer
434352|NCT00952107|breast reconstructive surgery
434353|NCT00952107|flap assessment
434354|NCT00952094|Healthy volunteer
434355|NCT00952081|Hypertension
434356|NCT00952081|Neurosurgery
434357|NCT00952081|bloodpressure control
434358|NCT00952081|brain tumor resection
434359|NCT00952081|epilepsy focus resection
434360|NCT00952068|Back Pain
434361|NCT00952055|neopterin
434362|NCT00952055|macrophage
434363|NCT00952055|inflammation
434364|NCT00952042|Tendinopathy, Achilles, Eccentric training, Heavy slow resistance training
434365|NCT00952029|stage IV colon cancer
434366|NCT00952029|stage IV rectal cancer
434367|NCT00952016|colorectal cancer
434368|NCT00952016|MSH2
434369|NCT00952016|metastatic
434370|NCT00952003|Avastin
434371|NCT00952003|Campto
434372|NCT00952003|Oxaliplatin
434373|NCT00952003|Taxotere
434374|NCT00951977|End Stage Renal Disease
434375|NCT00951977|Transplantation
434376|NCT00951977|Living Kidney Donation
434377|NCT00951977|ESRD
434378|NCT00951977|Kidney Transplant
434379|NCT00951938|Trinity Evolution
434380|NCT00951938|Anterior Cervical Discectomy and Fusion
434381|NCT00951938|Allograft
434382|NCT00951925|Any patient undergoing diagnostic bone marrow biopsies
434383|NCT00951925|Any patient undergoing bone marrow harvesting for autologous bone marrow transplantation.
434384|NCT00951912|genistein
434385|NCT00951912|daidzein
434386|NCT00951912|impaired glucose regulation
434387|NCT00951912|glucose metabolism
434388|NCT00951912|lipids metabolism
434389|NCT00951912|inflammation
434390|NCT00951912|women
434391|NCT00951899|Incretins
434392|NCT00951899|colesevelam
434393|NCT00951899|hepatobiliary circulation
434394|NCT00951886|Ataxia Teleangiectasia
434395|NCT00951886|Spirometry
434396|NCT00951886|Respiratory rare diseases
434397|NCT00951860|Fullterm Birth
434398|NCT00951860|Neonate
434399|NCT00951860|Prematurity
434400|NCT00951860|Neurodevelopment
434401|NCT00951860|Autonomic Nervous System activity
434402|NCT00951847|Oxcarbazepine oral suspension fed study
434403|NCT00951834|Alzheimer´s Disease
434404|NCT00951834|Epigallocatechin-Gallate
434405|NCT00951834|Neuroprotection
434406|NCT00951834|ADAS-COG
434407|NCT00951834|early stage of Alzheimer's Disease
434408|NCT00951821|Suicidal Ideation
434409|NCT00951821|Suicide Attempts
434410|NCT00951808|Anemia, Sickle Cell
434411|NCT00951808|Acute Chest Syndrome
434412|NCT00951808|Secretory phospholipase A2(sPLA2)
434413|NCT00951795|HIV
434414|NCT00951795|AIDS
434415|NCT00951795|CD4
434416|NCT00951782|COPD
434417|NCT00951756|Dietary fat
434418|NCT00951756|Microbiome composition
434419|NCT00951756|Controlled feeding experiment
434420|NCT00951743|AIDS
434421|NCT00951743|HIV
434422|NCT00951743|mDAPTA
434423|NCT00951730|Down Syndrome
434424|NCT00951730|Adult
434425|NCT00951730|Children
434426|NCT00951730|Sleep apnea
434427|NCT00951730|Sleep hypopnea
434428|NCT00951730|Polysomnography
434429|NCT00951717|Postpartum Depressive Symptoms
434430|NCT00951717|Physical Symptoms
434431|NCT00951717|Emotional Symptoms
434432|NCT00951717|Infant Colic
434433|NCT00951717|Social Support
434434|NCT00951717|Breastfeeding
434435|NCT00951704|Open-chest
434436|NCT00951704|CPR
434437|NCT00951704|Tissue Perfusion
434438|NCT00951704|invasive arterial pressure
434439|NCT00951704|exhaled carbon dioxide
434440|NCT00951704|Quality of life
434441|NCT00951704|Quality of chest compressions
434442|NCT00951704|Epidemiology of sudden cardiac arrest(OHCA)
434443|NCT00951691|Elderly
434444|NCT00951691|Acute Medical Rehabilitation
434445|NCT00951678|ultrasound
434446|NCT00951678|femoral vein
434447|NCT00951678|internal jugular vein
434448|NCT00951665|Trastuzumab DM1 (T-DM1)
434449|NCT00951665|Trastuzumab emtansine
434450|NCT00951665|Armed Herceptin
434451|NCT00951665|HER2
434452|NCT00951665|HER2+
434453|NCT00951665|HER2 Positive Breast Cancer
434454|NCT00951652|CBT
434455|NCT00951652|GAD
434456|NCT00951652|Interpersonal Therapy
434457|NCT00951652|Emotion-Focused Therapy
434458|NCT00951639|Cassia
434459|NCT00951639|Cinnamon
434460|NCT00951639|Blood Glucose
434461|NCT00951639|Endurance exercise
434462|NCT00951639|Acute exercise
434463|NCT00951639|Overweight
434464|NCT00951639|Obesity
434465|NCT00951639|Women
434466|NCT00951626|psychosocial effects of cancer and its treatment
434467|NCT00951626|therapy-related toxicity
434468|NCT00951626|stage III adult Burkitt lymphoma
434469|NCT00951626|stage III adult diffuse large cell lymphoma
434470|NCT00951626|stage III adult diffuse mixed cell lymphoma
434471|NCT00951626|stage III adult diffuse small cleaved cell lymphoma
434472|NCT00951626|stage III adult Hodgkin lymphoma
434473|NCT00951626|stage III adult immunoblastic large cell lymphoma
434474|NCT00951626|stage III adult lymphoblastic lymphoma
434475|NCT00951626|stage III grade 1 follicular lymphoma
434476|NCT00951626|stage III grade 2 follicular lymphoma
434477|NCT00951626|stage III grade 3 follicular lymphoma
434478|NCT00951626|stage III mantle cell lymphoma
434479|NCT00951626|stage III marginal zone lymphoma
434480|NCT00951626|stage III small lymphocytic lymphoma
434481|NCT00951626|stage IV adult Burkitt lymphoma
434482|NCT00951626|stage IV adult diffuse large cell lymphoma
434483|NCT00951626|stage IV adult diffuse mixed cell lymphoma
434484|NCT00951626|stage IV adult diffuse small cleaved cell lymphoma
434485|NCT00951626|stage IV adult Hodgkin lymphoma
434486|NCT00951626|stage IV adult immunoblastic large cell lymphoma
434487|NCT00951626|stage IV adult lymphoblastic lymphoma
434488|NCT00951626|stage IV grade 1 follicular lymphoma
434489|NCT00951626|stage IV grade 2 follicular lymphoma
434490|NCT00951626|stage IV grade 3 follicular lymphoma
434491|NCT00951626|stage IV mantle cell lymphoma
434492|NCT00951626|stage IV marginal zone lymphoma
434493|NCT00951626|stage IV small lymphocytic lymphoma
434494|NCT00951626|recurrent adult Burkitt lymphoma
434495|NCT00951626|recurrent adult diffuse large cell lymphoma
434496|NCT00951626|recurrent adult diffuse mixed cell lymphoma
434497|NCT00951626|recurrent adult diffuse small cleaved cell lymphoma
434498|NCT00951626|recurrent adult Hodgkin lymphoma
434499|NCT00951626|recurrent adult immunoblastic large cell lymphoma
434500|NCT00951626|recurrent adult lymphoblastic lymphoma
434501|NCT00951626|recurrent cutaneous T-cell non-Hodgkin lymphoma
434502|NCT00951626|recurrent grade 1 follicular lymphoma
434503|NCT00951626|recurrent grade 2 follicular lymphoma
434504|NCT00951626|recurrent grade 3 follicular lymphoma
434505|NCT00951626|recurrent mantle cell lymphoma
434506|NCT00951626|recurrent marginal zone lymphoma
434507|NCT00951626|recurrent small lymphocytic lymphoma
434508|NCT00951626|recurrent mycosis fungoides/Sezary syndrome
434509|NCT00951626|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
434510|NCT00951626|nodal marginal zone B-cell lymphoma
434511|NCT00951626|splenic marginal zone lymphoma
434512|NCT00951626|noncontiguous stage II adult Burkitt lymphoma
434513|NCT00951626|noncontiguous stage II adult diffuse large cell lymphoma
434514|NCT00951626|noncontiguous stage II adult diffuse mixed cell lymphoma
434515|NCT00951626|noncontiguous stage II adult diffuse small cleaved cell lymphoma
434516|NCT00951626|noncontiguous stage II adult immunoblastic large cell lymphoma
434517|NCT00951626|noncontiguous stage II adult lymphoblastic lymphoma
434518|NCT00951626|noncontiguous stage II grade 1 follicular lymphoma
434519|NCT00951626|noncontiguous stage II grade 2 follicular lymphoma
434520|NCT00951626|noncontiguous stage II grade 3 follicular lymphoma
434521|NCT00951626|noncontiguous stage II mantle cell lymphoma
434522|NCT00951626|noncontiguous stage II marginal zone lymphoma
434523|NCT00951626|noncontiguous stage II small lymphocytic lymphoma
434524|NCT00951626|accelerated phase chronic myelogenous leukemia
434525|NCT00951626|adult acute lymphoblastic leukemia in remission
434526|NCT00951626|adult acute myeloid leukemia in remission
434527|NCT00951626|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
434528|NCT00951626|adult acute myeloid leukemia with inv(16)(p13;q22)
434529|NCT00951626|adult acute myeloid leukemia with t(15;17)(q22;q12)
434530|NCT00951626|adult acute myeloid leukemia with t(16;16)(p13;q22)
434531|NCT00951626|adult acute myeloid leukemia with t(8;21)(q22;q22)
434532|NCT00951626|atypical chronic myeloid leukemia, BCR-ABL negative
434533|NCT00951626|blastic phase chronic myelogenous leukemia
434534|NCT00951626|recurrent adult acute lymphoblastic leukemia
434535|NCT00951626|recurrent adult acute myeloid leukemia
434536|NCT00951626|refractory chronic lymphocytic leukemia
434537|NCT00951626|refractory hairy cell leukemia
434538|NCT00951626|relapsing chronic myelogenous leukemia
434539|NCT00951626|secondary acute myeloid leukemia
434540|NCT00951626|stage III chronic lymphocytic leukemia
434541|NCT00951626|stage IV chronic lymphocytic leukemia
434542|NCT00951626|chronic eosinophilic leukemia
434543|NCT00951626|primary myelofibrosis
434544|NCT00951626|chronic neutrophilic leukemia
434545|NCT00951626|de novo myelodysplastic syndromes
434546|NCT00951626|myelodysplastic/myeloproliferative neoplasm, unclassifiable
434547|NCT00951626|previously treated myelodysplastic syndromes
434548|NCT00951626|secondary myelodysplastic syndromes
434549|NCT00951626|refractory multiple myeloma
434550|NCT00951613|small cell lung cancer
434551|NCT00951613|carcinoma, lung
434552|NCT00951613|Sensitive-relapsed or refractory-relapsed small cell lung cancer
434553|NCT00951600|Oxcarbazepine oral suspension fasting study
434554|NCT00951587|Colonic Diseases
434555|NCT00951574|thromboembolism
434556|NCT00951574|cancer
434557|NCT00951574|chemotherapy
434558|NCT00951574|low-molecular-weight-heparin
434559|NCT00951574|nadroparin
434560|NCT00951561|Dysmenorrhea
434561|NCT00951548|Probiotics
434562|NCT00951548|VSL#3
434563|NCT00951548|Double-blind
434564|NCT00951548|Placebo controlled
434565|NCT00951535|stage I prostate cancer
434566|NCT00951535|stage IIB prostate cancer
434567|NCT00951535|stage IIA prostate cancer
434568|NCT00951535|stage III prostate cancer
434569|NCT00951522|Cystic Fibrosis
434570|NCT00951522|CF
434571|NCT00951522|Mucociliary Clearance
434572|NCT00951522|Epithelial Sodium Channel Inhibitor
434573|NCT00951522|ENaC Inhibitor
434574|NCT00951522|Airway Hydration
434575|NCT00951522|Amiloride
434576|NCT00951509|Electric power wheelchair driving
434577|NCT00951509|rehabilitation
434578|NCT00951509|driving assessments
434579|NCT00951483|Cardiovascular Biomarkers
434580|NCT00951483|Depression
434581|NCT00951483|Quetiapine
434582|NCT00951470|Head and neck lymphedema
434583|NCT00951470|Complete Decongestive Therapy
434584|NCT00951470|CDT
434585|NCT00951470|Oral cavity cancer
434586|NCT00951470|Oropharyngeal cancer
434587|NCT00951457|CLL
434588|NCT00951457|pretreated
434589|NCT00951457|immune therapy
434590|NCT00951457|dose escalation
434591|NCT00951457|maintenance therapy
434592|NCT00951457|Bendamustine
434593|NCT00951457|Alemtuzumab
434594|NCT00951444|adenosquamous cell lung cancer
434595|NCT00951444|squamous cell lung cancer
434596|NCT00951444|recurrent non-small cell lung cancer
434597|NCT00951444|stage IIIB non-small cell lung cancer
434598|NCT00951444|stage IV non-small cell lung cancer
434599|NCT00951431|Functional dyspepsia
434600|NCT00951431|PPI
434601|NCT00951431|postprandial fullness
434602|NCT00951431|delayed gastric emptying
434603|NCT00951418|clozapine
434604|NCT00951418|schizophrenia
434605|NCT00951418|cognition
434606|NCT00951418|t-wave morphology
434607|NCT00951392|Insulin sensitivity
434608|NCT00951392|aging
434609|NCT00951392|lipid metabolism
434610|NCT00951392|hyperinsulinemic clamp
434611|NCT00951392|gene expression
434612|NCT00951392|sirtuins
434613|NCT00951366|For clinicians and researchers to better understand BPD
434614|NCT00951366|To improve care of individuals with BPD
434615|NCT00951366|To examine quality improvement initiatives
434616|NCT00951366|To examine changing health care issues
434617|NCT00951366|To determine eligibility of clinical research studies
434618|NCT00951353|Transplantation
434619|NCT00951353|Kidney Failure
434620|NCT00951353|End Stage Renal Disease
434621|NCT00951353|Pediatric
434622|NCT00951340|CBT
434623|NCT00951340|Emotional-Focused Therapy
434624|NCT00951340|Interpersonal Therapy
434625|NCT00951327|Primary sclerosing cholangitis
434626|NCT00951314|Genetic Polymorphisms
434627|NCT00951314|Metabotropic Glutamate Receptors
434628|NCT00951314|Positron Emission Tomograhy (PET)
434629|NCT00951314|Cocaine Dependence
434630|NCT00951314|Cue-Induced Craving
434631|NCT00951314|Drug Abuse
434632|NCT00951288|AMD
434633|NCT00951288|Retinal Function
434634|NCT00951288|Neuroprotection
434635|NCT00951262|life review
434636|NCT00951262|quality of life
434637|NCT00951262|advanced cancer patients
434638|NCT00951249|MSM
434639|NCT00951249|HIV infections
434640|NCT00951249|HIV Seronegativity
434641|NCT00951236|Trigger Finger
434642|NCT00951236|Trigger Thumb
434643|NCT00951210|Peripheral Artery Disease
434644|NCT00951210|Peripheral Vascular Disease
434645|NCT00951210|Critical limb ischemia
434646|NCT00951210|PAD
434647|NCT00951210|CLI
434648|NCT00951197|dementia
434649|NCT00951197|Alzheimer's Disease
434650|NCT00951197|diagnostic
434651|NCT00951197|biomarkers
434652|NCT00951197|neuroimaging
434653|NCT00951197|PET
434654|NCT00951197|MRI
434655|NCT00951197|mild cognitive impairment
434656|NCT00951184|depression
434657|NCT00951184|unspecified adult solid tumor, protocol specific
434658|NCT00951158|Conjugated Linoleic Acid
434659|NCT00951158|Clarinol
434660|NCT00951158|S14 Expression
434661|NCT00951132|Inflammation
434662|NCT00951132|Atherosclerosis
434663|NCT00951132|Hydroxymethylglutaryl-CoA Reductase Inhibitors
434664|NCT00951119|type 2 diabetes
434665|NCT00951119|hypertension
434666|NCT00951119|treatment
434667|NCT00951119|non-medical
434668|NCT00951106|Peru
434669|NCT00951106|Sulfadoxine-pyrimethamine
434670|NCT00951106|Drug resistance
434671|NCT00951093|GERD
434672|NCT00951093|Gastric bypass
434673|NCT00951080|ulcer
434674|NCT00951080|venous
434675|NCT00951080|diabetic
434676|NCT00951080|wounds and injuries
434677|NCT00951067|Lymphedema
434678|NCT00951067|Breast Cancer
434679|NCT00951067|Upper Extremity
434680|NCT00951067|Arm
434681|NCT00951054|breast cancer
434682|NCT00951054|triple negative
434683|NCT00951054|ER-negative
434684|NCT00951054|PR-negative
434685|NCT00951054|HER2-negative
434686|NCT00951054|ER-, PR-, HER2- (Triple Negative) breast cancer
434687|NCT00951041|influenza infection
434688|NCT00951041|GSK Bio's influenza vaccine GSK2340272A
434689|NCT00951028|Adherence
434690|NCT00951015|GSK1349572
434691|NCT00951015|emtricitabine
434692|NCT00951015|tenofovir
434693|NCT00951015|efavirenz
434694|NCT00951015|abacavir
434695|NCT00951015|antiretroviral therapy naive
434696|NCT00951015|dose selection
434697|NCT00951015|HIV-1 Infection
434698|NCT00951015|integrase inhibitor
434699|NCT00951015|HIV infection
434700|NCT00951015|once daily
434701|NCT00951015|lamivudine
434702|NCT00951002|anal fistula
434703|NCT00951002|acellular dermal matrix
434704|NCT00951002|treatment
434705|NCT00951002|postoperative complications
434706|NCT00951002|recurrence
434707|NCT00950989|Autoimmune Diseases
434708|NCT00950989|Musculoskeletal Diseases
434709|NCT00950989|Joint Diseases
434710|NCT00950989|Arthritis
434711|NCT00950989|Connective Tissue Diseases
434712|NCT00950989|Arthritis, Rheumatoid
434713|NCT00950989|Rheumatic Diseases
434714|NCT00950963|Diabetes, Nurse phone intervention, lipid control
434715|NCT00950950|Amgen
434716|NCT00950950|Postmenopausal
434717|NCT00950950|Bone Density
434718|NCT00950924|Hyperopia
434719|NCT00950924|Refractive Error
434720|NCT00950924|Ocular Biometrics
434721|NCT00950924|Axial Length
434722|NCT00950924|Contact Lenses
434723|NCT00950924|Bifocal Contact Lenses
434724|NCT00950911|Bone metastases
434725|NCT00950911|Hormone-refractory prostate cancer
434726|NCT00950911|Multiple myeloma
434727|NCT00950911|Denosumab
434728|NCT00950911|Breast cancer
434729|NCT00950911|20050103
434730|NCT00950911|20050136
434731|NCT00950911|20050244
434732|NCT00950911|Advanced cancer
434733|NCT00950911|Tumor
434734|NCT00950911|Prostate cancer
434735|NCT00950911|Zoledronic acid
434736|NCT00950898|coffee
434737|NCT00950898|caffeine
434738|NCT00950898|glucose metabolism
434739|NCT00950898|insulin sensitivity
434740|NCT00950898|diabetes
434741|NCT00950885|sleep
434742|NCT00950885|alertness
434743|NCT00950885|performance
434744|NCT00950885|vigilance
434745|NCT00950885|circadian
434746|NCT00950859|treatment experienced
434747|NCT00950859|HIV Infection
434748|NCT00950859|raltegravir resistance
434749|NCT00950859|GSK1349572
434750|NCT00950859|optimized background regimen
434751|NCT00950859|integrase inhibitor
434752|NCT00950846|Congenital Pediatric Disorders
434753|NCT00950846|Umbilical Cord Blood Transplant
434754|NCT00950846|Congenital Abnormalities
434755|NCT00950846|Cord Blood Stem Cell Transplantation
434756|NCT00950846|Busulfan
434757|NCT00950846|Cytoxan
434758|NCT00950846|Cyclophosphamide
434759|NCT00950846|Fludarabine
434760|NCT00950833|Catch-up vaccination
434761|NCT00950833|Pneumococcal vaccine
434762|NCT00950833|Immune memory
434763|NCT00950833|Nasopharyngeal carriage
434764|NCT00950833|Immunogenicity
434765|NCT00950833|Pneumococcal disease
434766|NCT00950833|Safety
434767|NCT00950820|Open-label
434768|NCT00950820|Phase-II-Study
434769|NCT00950820|Randomized
434770|NCT00950820|Metastatic
434771|NCT00950820|Colorectal
434772|NCT00950820|Cancer
434773|NCT00950820|Panitumumab
434774|NCT00950820|Vectibix®
434775|NCT00950820|second-line-treatment
434776|NCT00950820|KRAS
434777|NCT00950807|Dose ranging
434778|NCT00950807|Chronic Bronchitis
434779|NCT00950807|Long-acting muscarinic antagonist
434780|NCT00950807|cross-over
434781|NCT00950807|COPD
434782|NCT00950807|Emphysema
434783|NCT00950807|Chronic Obstructive Pulmonary Disease (COPD)
434784|NCT00950807|anticholinergic
434785|NCT00950794|Long acting beta2-agonist
434786|NCT00950781|Menopause
434787|NCT00950781|Cortisol
434788|NCT00950781|ACTH
434789|NCT00950768|Myeloma
434790|NCT00950768|Melphalan
434791|NCT00950768|Autologous transplantation
434792|NCT00950729|car driving simulator
434793|NCT00950729|orthopedic leg immobilisation
434794|NCT00950729|braking time
434795|NCT00950729|braking force
434796|NCT00950716|type II diabetes
434797|NCT00950716|peer support
434798|NCT00950716|empowerment
434799|NCT00950703|Assessing the perceptions of Canadian Primary care physicians towards global Cardiovascular risk assessment.
434800|NCT00950690|observational safety study
434801|NCT00950677|Diabetes
434802|NCT00950677|pramlintide
434803|NCT00950677|Symlin
434804|NCT00950677|exenatide
434805|NCT00950677|byetta
434806|NCT00950677|glucagon
434807|NCT00950677|gastric emptying
434808|NCT00950664|cervical dystonia
434809|NCT00950664|botulinum toxin
434810|NCT00950638|AMD
434811|NCT00950625|intraperitoneal analgesia
434812|NCT00950625|laparoscopic cholecystectomy
434813|NCT00950625|lignocaine
434814|NCT00950625|bupevacaine
434815|NCT00950612|Tuberculosis vaccine
434816|NCT00950586|Drug interaction
434817|NCT00950586|Saftey
434818|NCT00950586|Pharmacokinetics
434819|NCT00950586|Cognition
434820|NCT00950573|cardiovascular disease
434821|NCT00950573|endstage renal disease
434822|NCT00950547|Blood Transfusion
434823|NCT00950547|Cell Saver
434824|NCT00950547|Cardiac Surgery
434825|NCT00950547|Evaluate the efficacy of cell salvage CardioPAT routinely used in cardiac surgery in reducing blood transfusions.
434826|NCT00950521|Stroke
434827|NCT00950521|Stem Cell
434828|NCT00950521|Cell Therapy
434829|NCT00950521|CD34 Stem cell
434830|NCT00950521|Peripheral blood Stem cell
434831|NCT00950495|Parallel design
434832|NCT00950495|Oral appliance
434833|NCT00950495|Mandibular advancement device
434834|NCT00950495|Continuous positive airway pressure
434835|NCT00950495|Placebo
434836|NCT00950495|Therapy
434837|NCT00950495|Side-effects
434838|NCT00950495|Compliance
434839|NCT00950482|Menopause
434840|NCT00950482|Acupuncture
434841|NCT00950482|Hotflash
434842|NCT00950469|high sensitive troponin T; cardiac necrosis; early detection; myoglobin; h-FABP
434843|NCT00950469|early identification and risk stratification of patients with suspicious acute coronary syndrome
434844|NCT00950443|Upper airway obstruction
434845|NCT00950443|child
434846|NCT00950443|acoustic reflection method
434847|NCT00950443|endoscopy
434848|NCT00950443|work of breathing
434849|NCT00950443|sleep study
434850|NCT00950443|CT scan
434851|NCT00950430|Imaging
434852|NCT00950430|PET
434853|NCT00950430|PiB
434854|NCT00950430|FDG
434855|NCT00950430|MCI
434856|NCT00950430|Dementia
434857|NCT00950430|Alzheimer's Disease
434858|NCT00950430|Brain Amyloid
434859|NCT00950417|nimotuzumab esophageal chemo-radiotherapy
434860|NCT00950404|Bioavailability Pharmacokinetic Formulation
434861|NCT00950391|peripheral nerve injury
434862|NCT00950391|peripheral nerve surgery
434863|NCT00950391|nerve repair
434864|NCT00950391|nerve graft
434865|NCT00950378|edema
434866|NCT00950378|blood supply
434867|NCT00950378|lower legs
434868|NCT00950378|venous stasis
434869|NCT00950365|recurrent non-small cell lung cancer
434870|NCT00950365|stage IIIB non-small cell lung cancer
434871|NCT00950365|stage IV non-small cell lung cancer
434872|NCT00950365|progressive or recurrent stage III or stage IV non-small cell lung cancer
434873|NCT00950352|methamphetamine
434874|NCT00950352|Citicoline
434875|NCT00950352|CDP-Choline
434876|NCT00950352|Neuroimaging
434877|NCT00950352|MRI
434878|NCT00950352|Brain
434879|NCT00950352|MRS
434880|NCT00950352|DTI
434881|NCT00950339|GI bleeding
434882|NCT00950339|clopidogrel
434883|NCT00950339|aspirin
434884|NCT00950339|prevention
434885|NCT00950339|angiography
434886|NCT00950326|osteoarthritis
434887|NCT00950326|hydrotherapy
434888|NCT00950326|affusion
434889|NCT00950326|conventional physiotherapy
434890|NCT00950326|comparison
434891|NCT00950313|Diabetes
434892|NCT00950313|Screening
434893|NCT00950313|Risk
434894|NCT00950313|Self assessment
434895|NCT00950287|apnea-bradycardias
434896|NCT00950287|preterm infants
434897|NCT00950274|Cell therapy
434898|NCT00950274|Bone marrow
434899|NCT00950274|CD133
434900|NCT00950274|Bypass surgery
434901|NCT00950274|Stem cells
434902|NCT00950274|Myocardial infarction
434903|NCT00950274|Myocardial ischemia
434904|NCT00950261|Cervical neoplasms
434905|NCT00950261|Cisplatin
434906|NCT00950261|Concurrent Chemoradiation
434907|NCT00950248|Idebenone
434908|NCT00950248|Magnetic Resonance Imaging (MRI)
434909|NCT00950248|Magnetic Resonance Spectroscopy
434910|NCT00950248|Mitochondrial Enhancer
434911|NCT00950248|Multiple Sclerosis
434912|NCT00950248|MS
434913|NCT00950248|Primary Progressive Multiple Sclerosis
434914|NCT00950235|obese
434915|NCT00950235|pregnant
434916|NCT00950235|large for gestational age
434917|NCT00950235|large for gestational age baby
434918|NCT00950222|Intensive care unit
434919|NCT00950222|Ventilator associated pneumonia
434920|NCT00950222|Gram negative bacilli infection
434921|NCT00950222|Empirical antibiotic therapy
434922|NCT00950222|Pharmacokinetic / pharmacodynamic
434923|NCT00950222|Imipenem
434924|NCT00950222|Amikacin
434925|NCT00950222|Gram negative bacilli
434926|NCT00950209|type 2 diabetic patients in the fed state
434927|NCT00950183|cryotherapy
434928|NCT00950183|postoperative pain
434929|NCT00950183|Iceman
434930|NCT00950183|primary first metatarsal osteotomy (PMO)
434931|NCT00950183|lateral ankle ligament reconstruction (LAR)
434932|NCT00950170|ReFacto AF
434933|NCT00950170|factor VIII
434934|NCT00950170|inhibitors
434935|NCT00950170|antibodies
434936|NCT00950144|pain
434937|NCT00950144|depression
434938|NCT00950144|fatigue
434939|NCT00950144|stage III colon cancer
434940|NCT00950144|stage IV colon cancer
434941|NCT00950144|recurrent colon cancer
434942|NCT00950144|stage III rectal cancer
434943|NCT00950144|stage IV rectal cancer
434944|NCT00950144|recurrent rectal cancer
434945|NCT00950144|stage III pancreatic cancer
434946|NCT00950144|stage IV pancreatic cancer
434947|NCT00950144|recurrent pancreatic cancer
434948|NCT00950144|adult primary hepatocellular carcinoma
434949|NCT00950144|advanced adult primary liver cancer
435076|NCT00949637|fruits and vegetables
434950|NCT00950144|localized unresectable adult primary liver cancer
434951|NCT00950144|recurrent adult primary liver cancer
434952|NCT00950118|Congenital Diaphragmatic Hernia (CDH)
434953|NCT00950118|Genes
434954|NCT00950118|Genetic
434955|NCT00950118|chromosome
434956|NCT00950118|chromosome microarray
434957|NCT00950118|microarray
434958|NCT00950105|CPSI2364
434959|NCT00950105|Semapimod
434960|NCT00950105|Anti TNF alpha
434961|NCT00950105|Crohn's Disease
434962|NCT00950105|Safety
434963|NCT00950105|Tolerability
434964|NCT00950105|Pharmacokinetics
434965|NCT00950092|AF
434966|NCT00950092|atrial fibrillation
434967|NCT00950092|ablation
434968|NCT00950092|surgical ablation
434969|NCT00950092|afib
434970|NCT00950092|coagulation
434971|NCT00950092|RF
434972|NCT00950092|epicardial
434973|NCT00950092|Arrhythmias
434974|NCT00950079|sodium bicarbonate
434975|NCT00950079|diabetes mellitus
434976|NCT00950079|coronary angiography or intervention
434977|NCT00950040|At-risk drinking
434978|NCT00950040|Type 2 diabetes
434979|NCT00950040|Treatment adherence
434980|NCT00950040|At-risk drinking among Type 2 diabetic patients
434981|NCT00950014|Numeracy
434982|NCT00950001|Brain tumors
434983|NCT00950001|Metastatic brain disease
434984|NCT00950001|Post-surgical
434985|NCT00950001|Stereotactic radiosurgery
434986|NCT00950001|SRS
434987|NCT00950001|Whole brain radiotherapy
434988|NCT00950001|MRI
434989|NCT00950001|Magnetic Resonance Imaging
434990|NCT00950001|Outpatient radiation procedure
434991|NCT00949988|Chronic Lymphocytic Leukemia
434992|NCT00949988|CLL
434993|NCT00949988|Dasatinib
434994|NCT00949988|Rituximab
434995|NCT00949988|Relapsed
434996|NCT00949988|Refractory
434997|NCT00949975|Chronic
434998|NCT00949975|Obstructive
434999|NCT00949975|Pulmonary
435000|NCT00949975|Lung
435001|NCT00949975|Respiratory disease
435002|NCT00949975|Efficacy
435003|NCT00949975|Safety and tolerability
435004|NCT00949975|Placebo-controlled
435005|NCT00949975|Pharmacokinetics
435006|NCT00949975|COPD
435007|NCT00949962|stage I prostate cancer
435008|NCT00949962|stage IIB prostate cancer
435009|NCT00949962|stage IIA prostate cancer
435010|NCT00949962|stage III prostate cancer
435011|NCT00949936|Spine surgery
435012|NCT00949923|Postmenopausal women
435013|NCT00949923|Suspicious for breast ca
435014|NCT00949897|Adult Acquired Flatfoot
435015|NCT00949897|Biofoam Porous Metal Implant
435016|NCT00949897|Allograft Bone Wedge
435017|NCT00949871|stage I breast cancer
435018|NCT00949871|stage II breast cancer
435019|NCT00949871|stage IIIA breast cancer
435020|NCT00949871|stage IIIB breast cancer
435021|NCT00949871|stage IIIC breast cancer
435022|NCT00949871|stage IV breast cancer
435023|NCT00949871|cancer survivor
435024|NCT00949858|Sleep Disorders
435025|NCT00949858|Obstructive Sleep Apnea
435026|NCT00949858|Restless Leg Syndrome
435027|NCT00949858|Insomnia
435028|NCT00949858|Actigraphy
435029|NCT00949845|Effect of Inflammatory challenge on depressed mood
435030|NCT00949845|Effect of inflammatory challenge on social pain
435031|NCT00949832|rickets
435032|NCT00949832|calcium
435033|NCT00949832|vitamin D
435034|NCT00949832|nutrition
435035|NCT00949832|child
435036|NCT00949819|Prostate Cancer
435037|NCT00949819|Low risk
435038|NCT00949819|Gleason 6
435039|NCT00949819|Active surveillance
435040|NCT00949806|Botulinum toxin
435041|NCT00949793|Pathology
435042|NCT00949793|Microscopy, Confocal
435043|NCT00949793|Microscopy, Fluorescence
435044|NCT00949793|Intraoperative Procedures
435045|NCT00949780|ABR
435046|NCT00949780|Chloral Hydrate
435047|NCT00949780|Sedation
435048|NCT00949780|Children
435049|NCT00949754|honeybee venom
435050|NCT00949754|osteoarthritis
435051|NCT00949754|pain
435052|NCT00949754|knees
435053|NCT00949728|Pterygium
435054|NCT00949728|Autologous Transplantation
435055|NCT00949728|Conjunctiva
435056|NCT00949728|Fibrin Tissue Adhesive
435057|NCT00949728|Recurrence
435058|NCT00949715|Pacemaker
435059|NCT00949715|Implantable Pulse Generator (IPG)
435060|NCT00949715|AV Conduction Disturbance
435061|NCT00949715|Selective Site Pacing
435062|NCT00949689|adolescence
435063|NCT00949689|insomnia
435064|NCT00949689|depression
435065|NCT00949689|sleep problems
435066|NCT00949689|cognitive therapy
435067|NCT00949663|Diabetes
435068|NCT00949663|Blood Sugar
435069|NCT00949663|Xenin-25
435070|NCT00949663|GIP
435071|NCT00949663|Insulin
435072|NCT00949637|obesity prevention
435073|NCT00949637|girl scouts
435074|NCT00949637|physical activity
435075|NCT00949637|family meals
435077|NCT00949637|health promotion
435078|NCT00949624|PDGFr Inhibition;
435079|NCT00949624|VEGFr inhibition;
435080|NCT00949624|targeted therapy
435081|NCT00949611|Decision Aid
435082|NCT00949611|Shared Decision Making
435083|NCT00949611|Shared Medical Decision Making
435084|NCT00949598|estrogen receptor-positive breast cancer
435085|NCT00949598|stage IA breast cancer
435086|NCT00949598|stage IB breast cancer
435087|NCT00949598|stage II breast cancer
435088|NCT00949598|stage IIIA breast cancer
435089|NCT00949585|randomized, controlled feeding study;
435090|NCT00949585|crossover design
435091|NCT00949585|potassium intake
435092|NCT00949572|mucosal immunity
435093|NCT00949572|immunization
435094|NCT00949572|sublingual
435095|NCT00949520|patients
435096|NCT00949520|functional evaluation
435097|NCT00949520|known coronary artery lesion
435098|NCT00949494|knee osteoarthritis, synvisc, hyaluronan, dGEMRIC,cartilage
435099|NCT00949481|postpartum
435100|NCT00949481|family planning
435101|NCT00949481|job aid
435102|NCT00949481|immunization
435103|NCT00949481|pregnancy test
435104|NCT00949468|Keratitis
435105|NCT00949455|stage IV bladder cancer
435106|NCT00949455|transitional cell carcinoma of the bladder
435107|NCT00949429|postoperative pain
435108|NCT00949429|cardiac surgery
435109|NCT00949429|risk factors
435110|NCT00949416|genetic
435111|NCT00949403|Non-Alcoholic Fatty Liver disease
435112|NCT00949390|Advanced Cancer
435113|NCT00949390|Advanced Malignancy
435114|NCT00949390|Complementary and Alternative Medicine
435115|NCT00949390|CAM
435116|NCT00949390|Investigational Cancer Therapeutics
435117|NCT00949390|Phase I Clinical Trials
435118|NCT00949377|Constipation
435119|NCT00949377|opioid
435120|NCT00949364|Myeloproliferative Neoplasms
435121|NCT00949364|Pomalidomide
435122|NCT00949364|Fibrotic Stage
435123|NCT00949364|Patients with Myeloproliferative Neoplasms in Fibrotic Stage
435124|NCT00949351|ACEI, ARB, DN, aliskiren, proteinuria
435125|NCT00949338|stage I prostate cancer
435126|NCT00949338|stage IIB prostate cancer
435127|NCT00949338|stage IIA prostate cancer
435128|NCT00949338|stage III prostate cancer
435129|NCT00949338|stage IV prostate cancer
435130|NCT00949338|recurrent prostate cancer
435131|NCT00949325|osteosarcoma
435132|NCT00949325|soft tissue sarcoma
435133|NCT00949325|rhabdomyosarcoma
435134|NCT00949325|leiomyosarcoma
435135|NCT00949325|Ewing's sarcoma
435136|NCT00949325|chondrosarcoma
435137|NCT00949325|liposarcoma
435138|NCT00949325|malignant fibrous histiocytoma
435139|NCT00949325|malignant peripheral nerve sheath tumor
435140|NCT00949325|pleiomorphic sarcoma
435141|NCT00949325|spindle cell sarcoma
435142|NCT00949325|synovial sarcoma
435143|NCT00949325|cancer stem cell
435144|NCT00949312|stage II colon cancer
435145|NCT00949286|Diabetes Mellitus, Type 2
435146|NCT00949273|cylindrical abdominoperineal resection
435147|NCT00949273|rectal cancer
435148|NCT00949273|acellular dermal matrix
435149|NCT00949273|pelvic reconstruction
435150|NCT00949273|circumferential resection margin
435151|NCT00949273|overall survival
435152|NCT00949260|PIH
435153|NCT00949260|pregnancy induced hypertension
435154|NCT00949260|pregnancy
435155|NCT00949260|bioimpedance
435156|NCT00949260|noninvasive monitoring
435157|NCT00949260|Cardiac Output
435158|NCT00949260|Blood Pressure
435159|NCT00949247|stage I breast cancer
435160|NCT00949247|stage II breast cancer
435161|NCT00949247|stage IIIA breast cancer
435162|NCT00949247|stage IIIB breast cancer
435163|NCT00949247|stage IIIC breast cancer
435164|NCT00949247|HER2-positive breast cancer
435165|NCT00949234|post exposure prophylaxis
435166|NCT00949234|biomedical prevention
435167|NCT00949234|HIV seronegativity
435168|NCT00949221|Type 1 diabetes
435169|NCT00949221|Paediatric
435170|NCT00949221|Real Time Continuous Glucose Monitoring
435171|NCT00949221|Glycemic control
435172|NCT00949221|Therapeutic education
435173|NCT00949208|Healthy people
435174|NCT00949195|COPD
435175|NCT00949195|healthy patients
435176|NCT00949195|PAP
435177|NCT00949195|CPX
435178|NCT00949195|SSE
435179|NCT00949195|hsCRP
435180|NCT00949195|FMD
435181|NCT00949182|localized unresectable adult primary liver cancer
435182|NCT00949182|adult primary hepatocellular carcinoma
435183|NCT00949169|Atherosclerosis
435184|NCT00949169|Carotid IMT
435185|NCT00949169|Multidetector CT
435186|NCT00949169|Type 2 diabetes
435187|NCT00949156|Craniopharyngiomas
435188|NCT00949156|Classification
435189|NCT00949156|Membranous structure
435190|NCT00949156|Pituitary stalk
435191|NCT00949156|Obesity
435192|NCT00949156|panhypopituitarism
435193|NCT00949143|wheelchair user
435194|NCT00949117|malnutrition
435195|NCT00949117|weight changes
435196|NCT00949117|childhood acute lymphoblastic leukemia in remission
435197|NCT00949117|recurrent childhood acute lymphoblastic leukemia
435198|NCT00949117|untreated childhood acute lymphoblastic leukemia
435199|NCT00949117|childhood acute myeloid leukemia in remission
435200|NCT00949117|recurrent childhood acute myeloid leukemia
435201|NCT00949117|untreated childhood acute myeloid leukemia
435202|NCT00949117|other myeloid malignancies
435203|NCT00949117|stage I childhood Hodgkin lymphoma
435204|NCT00949117|stage II childhood Hodgkin lymphoma
435205|NCT00949117|stage III childhood Hodgkin lymphoma
435206|NCT00949117|stage IV childhood Hodgkin lymphoma
435207|NCT00949117|recurrent/refractory childhood Hodgkin lymphoma
435208|NCT00949117|recurrent childhood anaplastic large cell lymphoma
435209|NCT00949117|stage I childhood anaplastic large cell lymphoma
435210|NCT00949117|stage II childhood anaplastic large cell lymphoma
435211|NCT00949117|stage III childhood anaplastic large cell lymphoma
435212|NCT00949117|stage IV childhood anaplastic large cell lymphoma
435213|NCT00949117|recurrent childhood grade III lymphomatoid granulomatosis
435214|NCT00949117|childhood diffuse large cell lymphoma
435215|NCT00949117|childhood immunoblastic large cell lymphoma
435216|NCT00949117|recurrent childhood large cell lymphoma
435217|NCT00949117|stage I childhood large cell lymphoma
435218|NCT00949117|stage II childhood large cell lymphoma
435219|NCT00949117|stage III childhood large cell lymphoma
435220|NCT00949117|stage IV childhood large cell lymphoma
435221|NCT00949117|recurrent childhood lymphoblastic lymphoma
435222|NCT00949117|stage I childhood lymphoblastic lymphoma
435223|NCT00949117|stage II childhood lymphoblastic lymphoma
435224|NCT00949117|stage III childhood lymphoblastic lymphoma
435225|NCT00949117|stage IV childhood lymphoblastic lymphoma
435226|NCT00949117|childhood nasal type extranodal NK/T-cell lymphoma
435227|NCT00949117|childhood Burkitt lymphoma
435228|NCT00949117|recurrent childhood small noncleaved cell lymphoma
435229|NCT00949117|stage I childhood small noncleaved cell lymphoma
435230|NCT00949117|stage II childhood small noncleaved cell lymphoma
435231|NCT00949117|stage III childhood small noncleaved cell lymphoma
435232|NCT00949117|stage IV childhood small noncleaved cell lymphoma
435233|NCT00949117|childhood myelodysplastic syndromes
435234|NCT00949117|de novo myelodysplastic syndromes
435235|NCT00949117|previously treated myelodysplastic syndromes
435236|NCT00949117|secondary myelodysplastic syndromes
435237|NCT00949117|unspecified childhood solid tumor, protocol specific
435238|NCT00949104|Sucrose
435239|NCT00949104|pain
435240|NCT00949104|neonate
435241|NCT00949104|preterm
435242|NCT00949104|orogastric tube
435243|NCT00949091|Diabetes Mellitus, Non Insulin Dependent
435244|NCT00949091|Diabetes Mellitus, Type II
435245|NCT00949091|Type 2 Diabetes Mellitus
435246|NCT00949091|Drug Therapy
435247|NCT00949078|peanut
435248|NCT00949078|allergy
435249|NCT00949065|complex regional pain syndrome
435250|NCT00949065|sympathetic reflex dystrophy
435251|NCT00949065|intravenous immunoglobulins
435252|NCT00949065|autoimmune disease
435253|NCT00949052|cancer survivor
435254|NCT00949052|stage III adult Burkitt lymphoma
435255|NCT00949052|stage III adult diffuse large cell lymphoma
435256|NCT00949052|stage III adult diffuse mixed cell lymphoma
435257|NCT00949052|stage III adult diffuse small cleaved cell lymphoma
435258|NCT00949052|stage III adult Hodgkin lymphoma
435259|NCT00949052|stage III adult immunoblastic large cell lymphoma
435260|NCT00949052|stage III adult lymphoblastic lymphoma
435261|NCT00949052|stage III grade 1 follicular lymphoma
435262|NCT00949052|stage III grade 2 follicular lymphoma
435263|NCT00949052|stage III grade 3 follicular lymphoma
435264|NCT00949052|stage III mantle cell lymphoma
435265|NCT00949052|stage III marginal zone lymphoma
435266|NCT00949052|stage III small lymphocytic lymphoma
435267|NCT00949052|stage IV adult Burkitt lymphoma
435268|NCT00949052|stage IV adult diffuse large cell lymphoma
435269|NCT00949052|stage IV adult diffuse mixed cell lymphoma
435270|NCT00949052|stage IV adult diffuse small cleaved cell lymphoma
435271|NCT00949052|stage IV adult Hodgkin lymphoma
435272|NCT00949052|stage IV adult immunoblastic large cell lymphoma
435273|NCT00949052|stage IV adult lymphoblastic lymphoma
435274|NCT00949052|stage IV grade 1 follicular lymphoma
435275|NCT00949052|stage IV grade 2 follicular lymphoma
435276|NCT00949052|stage IV grade 3 follicular lymphoma
435277|NCT00949052|stage IV mantle cell lymphoma
435278|NCT00949052|stage IV marginal zone lymphoma
435279|NCT00949052|stage IV small lymphocytic lymphoma
435280|NCT00949052|recurrent adult Burkitt lymphoma
435281|NCT00949052|recurrent adult diffuse large cell lymphoma
435282|NCT00949052|recurrent adult diffuse mixed cell lymphoma
435283|NCT00949052|recurrent adult diffuse small cleaved cell lymphoma
435284|NCT00949052|recurrent adult Hodgkin lymphoma
435285|NCT00949052|recurrent adult immunoblastic large cell lymphoma
435286|NCT00949052|recurrent adult lymphoblastic lymphoma
435287|NCT00949052|recurrent childhood large cell lymphoma
435288|NCT00949052|recurrent childhood lymphoblastic lymphoma
435289|NCT00949052|recurrent childhood small noncleaved cell lymphoma
435290|NCT00949052|recurrent cutaneous T-cell non-Hodgkin lymphoma
435291|NCT00949052|recurrent grade 1 follicular lymphoma
435292|NCT00949052|recurrent grade 2 follicular lymphoma
435293|NCT00949052|recurrent grade 3 follicular lymphoma
435294|NCT00949052|recurrent mantle cell lymphoma
435295|NCT00949052|recurrent marginal zone lymphoma
435296|NCT00949052|recurrent small lymphocytic lymphoma
435297|NCT00949052|recurrent/refractory childhood Hodgkin lymphoma
435298|NCT00949052|recurrent mycosis fungoides/Sezary syndrome
435299|NCT00949052|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
435300|NCT00949052|nodal marginal zone B-cell lymphoma
435301|NCT00949052|splenic marginal zone lymphoma
435302|NCT00949052|noncontiguous stage II adult Burkitt lymphoma
435303|NCT00949052|noncontiguous stage II adult diffuse large cell lymphoma
435304|NCT00949052|noncontiguous stage II adult diffuse mixed cell lymphoma
435305|NCT00949052|noncontiguous stage II adult diffuse small cleaved cell lymphoma
435306|NCT00949052|noncontiguous stage II adult immunoblastic large cell lymphoma
435307|NCT00949052|noncontiguous stage II adult lymphoblastic lymphoma
435308|NCT00949052|noncontiguous stage II grade 1 follicular lymphoma
435309|NCT00949052|noncontiguous stage II grade 2 follicular lymphoma
435310|NCT00949052|noncontiguous stage II grade 3 follicular lymphoma
435311|NCT00949052|noncontiguous stage II mantle cell lymphoma
435312|NCT00949052|noncontiguous stage II marginal zone lymphoma
435313|NCT00949052|noncontiguous stage II small lymphocytic lymphoma
435314|NCT00949052|accelerated phase chronic myelogenous leukemia
435315|NCT00949052|adult acute lymphoblastic leukemia in remission
435316|NCT00949052|adult acute myeloid leukemia in remission
435317|NCT00949052|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
435318|NCT00949052|adult acute myeloid leukemia with inv(16)(p13;q22)
435319|NCT00949052|adult acute myeloid leukemia with t(15;17)(q22;q12)
435320|NCT00949052|adult acute myeloid leukemia with t(16;16)(p13;q22)
435321|NCT00949052|adult acute myeloid leukemia with t(8;21)(q22;q22)
435322|NCT00949052|atypical chronic myeloid leukemia, BCR-ABL negative
435323|NCT00949052|blastic phase chronic myelogenous leukemia
435324|NCT00949052|childhood acute lymphoblastic leukemia in remission
435325|NCT00949052|childhood acute myeloid leukemia in remission
435326|NCT00949052|childhood chronic myelogenous leukemia
435327|NCT00949052|chronic myelomonocytic leukemia
435328|NCT00949052|chronic phase chronic myelogenous leukemia
435329|NCT00949052|juvenile myelomonocytic leukemia
435330|NCT00949052|recurrent adult acute lymphoblastic leukemia
435331|NCT00949052|recurrent adult acute myeloid leukemia
435332|NCT00949052|recurrent childhood acute lymphoblastic leukemia
435333|NCT00949052|recurrent childhood acute myeloid leukemia
435334|NCT00949052|refractory chronic lymphocytic leukemia
435335|NCT00949052|refractory hairy cell leukemia
435336|NCT00949052|relapsing chronic myelogenous leukemia
435337|NCT00949052|secondary acute myeloid leukemia
435338|NCT00949052|stage III chronic lymphocytic leukemia
435339|NCT00949052|stage IV chronic lymphocytic leukemia
435340|NCT00949052|childhood myelodysplastic syndromes
435341|NCT00949052|chronic eosinophilic leukemia
435342|NCT00949052|primary myelofibrosis
435343|NCT00949052|chronic neutrophilic leukemia
435344|NCT00949052|de novo myelodysplastic syndromes
435345|NCT00949052|disseminated neuroblastoma
435346|NCT00949052|myelodysplastic/myeloproliferative neoplasm, unclassifiable
435347|NCT00949052|poor prognosis metastatic gestational trophoblastic tumor
435348|NCT00949052|previously treated childhood rhabdomyosarcoma
435349|NCT00949052|previously treated myelodysplastic syndromes
435350|NCT00949052|recurrent Wilms tumor and other childhood kidney tumors
435351|NCT00949052|recurrent childhood rhabdomyosarcoma
435352|NCT00949052|recurrent neuroblastoma
435353|NCT00949052|recurrent ovarian epithelial cancer
435354|NCT00949052|recurrent ovarian germ cell tumor
435355|NCT00949052|recurrent malignant testicular germ cell tumor
435356|NCT00949052|secondary myelodysplastic syndromes
435357|NCT00949052|stage I multiple myeloma
435358|NCT00949052|stage II multiple myeloma
435359|NCT00949052|stage III multiple myeloma
435360|NCT00949052|stage II ovarian epithelial cancer
435361|NCT00949052|stage III ovarian epithelial cancer
435362|NCT00949052|stage IV ovarian epithelial cancer
435363|NCT00949052|stage III malignant testicular germ cell tumor
435364|NCT00949052|stage IIIA breast cancer
435365|NCT00949052|stage IIIB breast cancer
435366|NCT00949052|stage IIIC breast cancer
435367|NCT00949052|stage IV breast cancer
435368|NCT00949052|refractory multiple myeloma
435369|NCT00949026|Brain Cancer
435370|NCT00949026|Brain Neoplasms, Malignant
435371|NCT00949013|stage IA breast cancer
435372|NCT00949013|stage IB breast cancer
435373|NCT00949013|stage II breast cancer
435374|NCT00949013|stage IIIA breast cancer
435375|NCT00949013|stage IIIB breast cancer
435376|NCT00949013|stage IIIC breast cancer
435377|NCT00948987|aspirin resistance
435378|NCT00948987|cardiovascular risk
435379|NCT00948987|prostaglandins
435380|NCT00948987|platelet inhibition
435381|NCT00948974|social anxiety
435382|NCT00948974|treatment
435383|NCT00948974|Cognitive Behavioral Therapy
435384|NCT00948974|Acceptance and Commitment Therapy
435385|NCT00948974|Cognitive Therapy
435386|NCT00948961|NYESO1
435387|NCT00948961|cancer vaccine
435388|NCT00948961|immunotherapy
435389|NCT00948961|breast cancer
435390|NCT00948961|ovarian cancer
435391|NCT00948961|non-small cell lung cancer
435392|NCT00948961|myeloma
435393|NCT00948961|sarcoma
435394|NCT00948961|melanoma
435395|NCT00948961|Resiquimod
435396|NCT00948961|Poly-ICLC
435397|NCT00948961|Hiltonol
435398|NCT00948961|esophageal cancer
435399|NCT00948961|bladder cancer
435400|NCT00948961|chondrosarcoma
435401|NCT00948961|adenocarcinoma
435402|NCT00948935|Biliary Cancer
435403|NCT00948935|Cholangiocarcinoma
435404|NCT00948935|Panitumumab
435405|NCT00948922|multiple myeloma
435406|NCT00948922|myeloma
435407|NCT00948922|myeloma proteins
435408|NCT00948922|autologous
435409|NCT00948922|allogeneic
435410|NCT00948896|Chemoprevention
435411|NCT00948896|Uganda
435412|NCT00948896|Malaria
435413|NCT00948896|Trimethoprim-sulfamethoxazole
435414|NCT00948896|Sulfadoxine-pyrimethamine
435415|NCT00948896|Dihydroartemisinin-piperaquine
435416|NCT00948883|organ transplant
435417|NCT00948883|cancer
435418|NCT00948883|biobank
435419|NCT00948883|immunosuppressive drugs
435420|NCT00948883|lymphoma
435421|NCT00948870|alternative medicine
435422|NCT00948857|DHEA
435423|NCT00948857|POF
435424|NCT00948857|Pregnancy
435425|NCT00948857|Ovarian Failure
435426|NCT00948857|Otherwise Unexplained infertility
435427|NCT00948857|Ovarian aging
435428|NCT00948844|falls
435429|NCT00948844|Missteps
435430|NCT00948831|biologics
435431|NCT00948831|fusion rates
435432|NCT00948831|lumbar fusion
435433|NCT00948831|ALIF
435434|NCT00948818|Irritable Bowel Syndrome
435435|NCT00948818|Constipation
435436|NCT00948818|Linaclotide
435437|NCT00948805|corpus luteum rescue
435438|NCT00948805|Gonadotropin Releasing Hormone (GnRH agonist)
435439|NCT00948805|human Chorionic Gonadotropin (hCG)
435440|NCT00948805|infertility
435441|NCT00948805|pregnancy rate
435442|NCT00948792|platelets
435443|NCT00948792|transfusion
435444|NCT00948792|thrombocytopenia
435445|NCT00948779|Patient education
435446|NCT00948779|Antibiotic
435447|NCT00948779|Child
435448|NCT00948779|Respiratory tract infection
435449|NCT00948779|Patient satisfaction
435450|NCT00948779|Parental knowledge
435451|NCT00948779|Adherence
435452|NCT00948766|Alzheimer's disease
435453|NCT00948766|dementia
435454|NCT00948766|Alzheimer's type
435455|NCT00948753|Graft-versus-host disease
435456|NCT00948753|GVHD
435457|NCT00948753|Maraviroc
435458|NCT00948753|non-myeloablative allogeneic stem-cell transplantation
435459|NCT00948753|Hematopoietic stem cell transplantation
435460|NCT00948740|vitamin D
435461|NCT00948701|Breast cancer
435462|NCT00948701|Exercise
435463|NCT00948701|Physical activity
435464|NCT00948701|Community volunteers
435465|NCT00948701|Peer mentors
435466|NCT00948701|Peer coaches
435467|NCT00948701|Social support
435468|NCT00948688|Zolinza
435469|NCT00948675|Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology
435470|NCT00948675|Advanced Lung Cancer
435471|NCT00948675|Non-Small Cell Lung Cancer
435472|NCT00948675|Lung Cancer
435473|NCT00948662|Safety
435474|NCT00948662|tolerability
435475|NCT00948662|ascending single doses
435476|NCT00948662|healthy subjects
435477|NCT00948649|Varenicline, Working memory
435478|NCT00948623|COPD
435479|NCT00948623|physical activity
435480|NCT00948623|pulmonary rehabilitation
435481|NCT00948623|counseling
435482|NCT00948610|Rheumatoid Arthritis
435483|NCT00948597|propofol
435484|NCT00948597|elective surgical procedure
435485|NCT00948597|Obese subjects
435486|NCT00948584|Diabetes Mellitus, Type 2
435487|NCT00948584|Insulin dose titration system
435488|NCT00948571|Vital capacity, FEV1, airway resistance
435489|NCT00948571|perioperative changes in lung function
435490|NCT00948558|citrate anticoagulation
435491|NCT00948558|pharmacokinetic
435492|NCT00948558|critically ill
435493|NCT00948558|acute kidney failure
435494|NCT00948545|Autonomic nervous system
435495|NCT00948545|Bariatric surgery
435496|NCT00948545|Observational study for individuals having bariatric surgery
435497|NCT00948532|degenerative disc disease
435498|NCT00948532|lumbar spine
435499|NCT00948532|XLIF
435500|NCT00948532|Degenerative conditions
435501|NCT00948519|Rhinosinusitis, sinusitis, chronic, nasal polyps, phototherapy, laser,laser therapy, antibiotic, safety laser, ICG, indocyanine green
435502|NCT00948519|Chronic Rhinosinusitis with or without nasal polyposis
435503|NCT00947505|Androgenetic alopecia
435504|NCT00947505|Hair loss
435505|NCT00947505|Male Pattern baldness
435506|NCT00947492|Rheumatoid Arthritis patients
435507|NCT00947492|treated with new immunosuppressive drugs : Orencia* (abatacept) and RoActemra* (tocilizumab).
435508|NCT00948493|diabetes
435509|NCT00948493|insulin therapy
435510|NCT00948480|autologous tumor cell vaccine
435511|NCT00948480|metastatic melanoma
435512|NCT00948480|sargramostim (GM-CSF)
435513|NCT00948467|Advanced nonhematologic malignancies
435514|NCT00948467|Advanced metastatic melanoma
435515|NCT00948467|BRAF gene
435516|NCT00948454|smoking
435517|NCT00948441|intestinal insufficiency
435518|NCT00948441|central venous catheter
435519|NCT00948441|Catheter-Related Infections
435520|NCT00948441|pediatrics
435521|NCT00948441|ethanol
435522|NCT00948428|actinic keratoses
435523|NCT00948428|imiquimod
435524|NCT00948428|therapeutic equivalence
435525|NCT00948428|bioequivalence
435526|NCT00948415|Obesity
435527|NCT00948415|Weight loss
435528|NCT00948415|Internet
435529|NCT00948402|PED/PEA-15 protein
435530|NCT00948402|PCOS
435531|NCT00948402|IR
435532|NCT00948402|metformin
435533|NCT00948402|OCP
435534|NCT00948402|Oral Contraceptive
435535|NCT00948376|Natural history
435536|NCT00948376|IFT80
435537|NCT00948376|short ribs
435538|NCT00948376|multivisceral involvement
435539|NCT00948363|Kiwi fruits
435540|NCT00948363|Blood pressure
435541|NCT00948363|Endothelial function
435542|NCT00948363|Antioxidant capacity
435543|NCT00948350|cervical instability
435544|NCT00948350|awake intubation
435545|NCT00948350|laryngeal anesthesia
435546|NCT00948324|ype 2 diabetes mellitus, continuous subcutaneous insulin infusion,
435547|NCT00948324|α-lipoic acid ,rosiglitazone ,metformin，therapy
435548|NCT00948298|cardiovascular disease
435549|NCT00948298|vitamin D
435550|NCT00948298|african american
435551|NCT00948298|low vitamin D levels
435552|NCT00948285|breast cancer
435553|NCT00948285|magnetic resonance imaging
435554|NCT00948272|Rabies
435555|NCT00948272|Rabies virus
435556|NCT00948272|Purified Vero Rabies Vaccine
435557|NCT00948272|Serum Free
435558|NCT00948259|safety
435559|NCT00948259|GSK inhibitor
435560|NCT00948259|Alzheimer
435561|NCT00948233|Tobacco
435562|NCT00948233|Smoking Cessation
435563|NCT00948233|Prevention
435564|NCT00948233|Smokeless tobacco
435565|NCT00948233|Habit
435566|NCT00948220|HCV
435567|NCT00948220|hepatitis C virus
435568|NCT00948220|CHC
435569|NCT00948220|chronic hepatitis c
435570|NCT00948220|interferon
435571|NCT00948220|ribavirin
435572|NCT00948220|DEXA
435573|NCT00948220|BMD
435574|NCT00948220|bone mineral density
435575|NCT00948220|osteoporosis
435576|NCT00948220|osteopenia
435577|NCT00948220|osteodystrophy
435578|NCT00948220|osteodensitometry
435579|NCT00948220|Bone Density
435580|NCT00948220|Hepatitis, Viral, Human
435581|NCT00948220|Anti-Infective Agents
435582|NCT00948220|peginterferon alfa-2a
435583|NCT00948207|Metastatic Cancer
435584|NCT00948207|Recurrent Cancer
435585|NCT00948207|Distributed Hematological Cancer
435586|NCT00948207|Advanced Cancer
435587|NCT00948207|Terminal Cancer
435588|NCT00948207|Stage III Cancer
435589|NCT00948207|Stage IV Cancer
435590|NCT00948194|Extended Donor Criteria
435591|NCT00948181|Epinephrine, Norepinephrine, normetanephrine
435592|NCT00948181|Catecholamine concentrations during surgery
435593|NCT00948168|T2DM
435594|NCT00948168|exenatide
435595|NCT00948168|HbA1c
435596|NCT00948168|weight
435597|NCT00948168|waist circumference
435598|NCT00948168|insulin sensitivity
435599|NCT00948168|beta-cell function
435600|NCT00948155|smoking
435601|NCT00948155|nicotine
435602|NCT00948155|varenicline
435603|NCT00948142|Acute Bacterial Skin and Skin Struction Infections; Bacterial Skin Diseases; Staphylococcal Skin Infections; MRSA
435604|NCT00948129|Smoking Cessation
435605|NCT00948129|Low-Income
435606|NCT00948129|Cigarette smoking
435607|NCT00948129|Uninsured and underinsured
435608|NCT00948129|NRT
435609|NCT00948129|Nicoderm CQ
435610|NCT00948129|Habits
435611|NCT00948116|Diabetes mellitus
435612|NCT00948116|Renal Impairment
435613|NCT00948116|Acute Kidney Injury
435614|NCT00948116|Coronary revascularisation
435615|NCT00948116|eGFR <60ml/min
435616|NCT00948103|Nitrous Oxide
435617|NCT00948103|Administration, Intravesical Drug
435618|NCT00948103|Botulinum toxin
435619|NCT00948090|Hodgkin Lymphoma
435620|NCT00948090|Non-Hodgkin's Lymphoma
435621|NCT00948090|Bone marrow transplant
435622|NCT00948090|stem cell transplant
435623|NCT00948090|busulfan
435624|NCT00948090|cyclophosphamide
435625|NCT00948090|etoposide
435626|NCT00948077|tuberculosis
435627|NCT00948077|pharmacokinetic
435628|NCT00948077|first-line drugs
435629|NCT00948064|Leukemia
435630|NCT00948064|Acute Myelogenous Leukemia
435631|NCT00948064|AML
435632|NCT00948064|Myelodysplastic Syndrome
435633|NCT00948064|MDS
435634|NCT00948064|Vorinostat
435635|NCT00948064|SAHA
435636|NCT00948064|Suberoylanilide Hydroxamic Acid
435637|NCT00948064|MSK-390
435638|NCT00948064|Zolinza
435639|NCT00948064|Azacitidine
435640|NCT00948064|5-Azacitidine
435641|NCT00948064|5-Aza
435642|NCT00948064|Vidaza
435643|NCT00948064|5-AZC
435644|NCT00948064|AZA-CR
435645|NCT00948064|Ladakamycin
435646|NCT00948064|NSC-102816
435647|NCT00948038|Inflammation
435648|NCT00948038|Oxidative stress
435649|NCT00948025|Peripheral Nerve Repair
435650|NCT00948025|Conduit
435651|NCT00948025|AVANCE
435652|NCT00948025|Neuroma Resection
435653|NCT00948025|Nerve Gap Repair
435654|NCT00948025|Digital Nerve Repair
435655|NCT00948012|Sickle Cell Anemia
435656|NCT00948012|Pulmonary Hypertension
435657|NCT00948012|Exercise echocardiography
435658|NCT00948012|Echocardiography
435659|NCT00947973|Attention Deficit Hyperactivity Disorder
435660|NCT00947973|ADHD
435661|NCT00947973|School Based
435662|NCT00947973|Intervention
435663|NCT00947973|Psychosocial
435664|NCT00947973|Academic Intervention
435665|NCT00947973|Behavioral
435666|NCT00947960|Adult Polyglucosan Body Disease (APBD)
435667|NCT00947960|Glycogen Brancher Enzyme (GBE1) Deficiency
435668|NCT00947947|condom use
435669|NCT00947947|HIV prevention
435670|NCT00947947|African American
435671|NCT00947947|Behavioral intervention
435672|NCT00947947|HIV Seronegativity
435673|NCT00947934|Alzheimer disease,hypothalamus,Deep Brain Stimulation
435674|NCT00947921|Functional MItral regurgitation
435675|NCT00947908|Hymenoptera venom allergy
435676|NCT00947908|Dendritic cells (DC)
435677|NCT00947895|ACTH
435678|NCT00947895|Acthar gel
435679|NCT00947895|adrenocorticotropin
435680|NCT00947895|methylprednisolone
435681|NCT00947895|solumedrol
435682|NCT00947895|MS
435683|NCT00947895|multiple
435684|NCT00947895|sclerosis
435685|NCT00947895|relapse
435686|NCT00947895|exacerbation
435687|NCT00947895|sub-responsive
435688|NCT00947895|IV
435689|NCT00947856|Antibodies, Monoclonal
435690|NCT00947856|Antibody-Drug Conjugate
435691|NCT00947856|Antigens, CD30
435692|NCT00947856|Drug Therapy
435693|NCT00947856|Hematologic Diseases
435694|NCT00947856|Immunotherapy
435695|NCT00947856|Monomethylauristatin E
435696|NCT00947843|CHD
435697|NCT00947843|CHD equivalents
435698|NCT00947830|CML
435699|NCT00947830|intracellular imatinib level
435700|NCT00947830|OCT-1
435701|NCT00947804|Acute Coronary Artery Syndrome Risk Stratification Score
435702|NCT00947791|Bipolar Disorder
435703|NCT00947791|Depression
435704|NCT00947791|Treatment-Resistant
435705|NCT00947791|ketamine
435706|NCT00947791|antidepressant
435707|NCT00947791|glutamate
435708|NCT00947765|Tennis Elbow
435709|NCT00947765|Epicondylitis, Lateral Humeral
435710|NCT00947752|Multiple Sclerosis
435711|NCT00947752|Relapsing Remitting Multiple Sclerosis (RRMS)
435712|NCT00947752|Glatiramer Acetate (GA)
435713|NCT00947739|CZ
435714|NCT00947739|Stehlin
435715|NCT00947739|Lymphomas
435716|NCT00947713|Human chorionic gonadotropin
435717|NCT00947713|Clomiphene citrate
435718|NCT00947713|chronic anovulation
435719|NCT00947713|Polycystic Ovary Syndrome
435720|NCT00947713|Follicolugenesis
435721|NCT00947700|Infants
435722|NCT00947700|Risk markers
435723|NCT00947700|ERP
435724|NCT00947700|Parent child interaction
435725|NCT00947700|Promoting First Relations
435726|NCT00947700|Social Communication
435727|NCT00947687|influenza
435728|NCT00947687|healthy subject
435729|NCT00947687|virus inoculation
435730|NCT00947687|symptom scores
435731|NCT00947687|viral shedding
435732|NCT00947687|bioaerosol output
435733|NCT00947674|Cellsorba EX
435734|NCT00947661|glaucoma latanoprost
435735|NCT00947648|acute myelogenous leukemia
435736|NCT00947648|AML
435737|NCT00947648|myelodysplastic syndrome
435738|NCT00947648|MDS
435739|NCT00947648|Neutropenia
435740|NCT00947648|raw fruits and vegetables
435741|NCT00947635|Type 1 diabetes
435742|NCT00947635|Transplants
435743|NCT00947635|Immunosuppression
435744|NCT00947635|Hyperlipidemia
435745|NCT00947635|Nutrition Therapy
435746|NCT00947622|Fibromyalgia
435747|NCT00947622|Neuromodulation
435748|NCT00947622|Transcranial Direct Current Stimulation
435749|NCT00947622|Occipital
435750|NCT00947609|Latent tuberculosis
435751|NCT00947609|HIV
435752|NCT00947609|Children
435753|NCT00947609|Interferon gamma release assays
435754|NCT00947609|Thailand
435755|NCT00947609|QuantiFERON TB Gold In-tube
435756|NCT00947609|T-Spot.TB
435757|NCT00947596|Atropine
435758|NCT00947596|Aerosol
435759|NCT00947596|Inhaler
435760|NCT00947596|Dry Powder
435761|NCT00947583|fusion rates
435762|NCT00947583|TLIF
435763|NCT00947583|Osteocel Plus
435764|NCT00947583|biologics
435765|NCT00947583|lumbar fusion
435766|NCT00947570|Cognitive Behavioral Therapy
435767|NCT00947570|Functional Brain Imaging
435768|NCT00947570|Psychotherapy
435769|NCT00947570|Treatment
435770|NCT00947570|Brain Imaging
435771|NCT00947544|Urea Cycle Disorder
435772|NCT00947544|UCD
435773|NCT00947544|GT4P
435774|NCT00947544|Buphenyl
435775|NCT00947544|hyperammonemia
435776|NCT00947544|sodium phenylbutyrate
435777|NCT00947518|chlorhexidine
435778|NCT00947518|preterm
435779|NCT00947518|newborn
435780|NCT00947518|skin condition
435781|NCT00947518|temperature
435782|NCT00947518|skin flora
435783|NCT00947479|obstructive sleep apnea
435784|NCT00947479|pulse-wave velocity,
435785|NCT00947479|acute kidney injury
435786|NCT00947479|biomarkers of acute kidney injury
435787|NCT00947466|Buprenorphine transdermal patch (BTDS)
435788|NCT00947466|Moderate to severe mouth pain
435789|NCT00947466|Chemotherapy induced mucositis
435790|NCT00947466|Pharmacokinetic
435791|NCT00947453|asthma
435792|NCT00947453|montelukast
435793|NCT00947440|Phase 1
435794|NCT00947440|Bioavailability
435795|NCT00947427|type 1 diabetes
435796|NCT00947427|newly diagnosed T1D
435797|NCT00947427|T1D
435798|NCT00947427|canakinumab
435799|NCT00947427|anti IL-1
435800|NCT00947414|cellulite; shockwave; microcirculation; skin
435801|NCT00947401|Surgery, elective
435802|NCT00947401|Fluids
435803|NCT00947401|Post Anesthesia Care Unit
435804|NCT00947401|PACU
435805|NCT00947401|Fluid management
435806|NCT00947388|Refractory Chronic Lymphocytic Leukemia
435807|NCT00947388|Bendamustine
435808|NCT00947388|Alemtuzumab
435809|NCT00947388|Phase I
435810|NCT00947388|CLL
435811|NCT00947375|schizophrenia
435812|NCT00947375|lamictal TM
435813|NCT00947375|haloperidol decanoate
435814|NCT00947323|simvastatin
435815|NCT00947323|endothelial dysfunction
435816|NCT00947323|erectile dysfunction
435817|NCT00947310|Inappropriate therapy
435818|NCT00947310|ICD therapy
435819|NCT00947310|Primary prevention
435820|NCT00947297|Urea Cycle Disorder
435821|NCT00947297|UCD
435822|NCT00947297|hyperammonemia
435823|NCT00947297|Buphenyl
435824|NCT00947297|Sodium Phenylbutyrate
435825|NCT00947271|STD
435826|NCT00947271|STI
435827|NCT00947271|Sexual Behavior
435828|NCT00947271|Prevention
435829|NCT00947271|HIV seronegativity
435830|NCT00947258|Muscle Strength
435831|NCT00947258|Torque
435832|NCT00947258|Muscle Stretching Exercises
435833|NCT00947258|Range of Motion
435834|NCT00947232|major depressive disorder
435835|NCT00947232|physical activity
435836|NCT00947232|aging with physical disability
435837|NCT00947232|motivational interviewing
435838|NCT00947219|Androgenetic Alopecia
435839|NCT00947219|Hair Loss
435840|NCT00947219|Male Pattern Baldness
435841|NCT00947206|Chinese Americans
435842|NCT00947206|lay health worker outreach
435843|NCT00947206|colorectal cancer screening
435844|NCT00947193|Hemophilia A
435845|NCT00947193|Hemophilia B
435846|NCT00947193|Factor VIII
435847|NCT00947193|Factor IX
435848|NCT00947193|FVIII
435849|NCT00947193|FIX
435850|NCT00947193|Nonsense mutation
435851|NCT00947193|Premature stop codon
435852|NCT00947193|HA
435853|NCT00947193|HB
435854|NCT00947193|PTC124
435855|NCT00947193|Ataluren
435856|NCT00947180|Biofeedback
435857|NCT00947180|Pelvic floor
435858|NCT00947180|Levator ani syndrome
435859|NCT00947180|Chronic proctalgia
435860|NCT00947180|Electrogalvanic stimulation
435861|NCT00947180|Massage
435862|NCT00947154|trichotillomania
435863|NCT00947154|aripiprazole
435864|NCT00947154|treatment
435865|NCT00947141|Optimising treatment of cytomegalovirus infection
435866|NCT00947128|Antiemetic
435867|NCT00947115|Cervical cancer
435868|NCT00947115|HPV vaccine
435869|NCT00947102|pancreatic tubular adenocarcinoma
435870|NCT00947102|gemcitabine
435871|NCT00947102|gene expression
435872|NCT00947102|immunological status
435873|NCT00947102|serological status
435874|NCT00947102|pancreatic tubular adenocarcinoma adjuvant setting
435875|NCT00947089|ORC (oxidized regenerated cellulose)
435876|NCT00947089|SSI (Surgical site infections)
435877|NCT00947076|Antidepressant
435878|NCT00947063|Antihistamine
435879|NCT00947050|CAD
435880|NCT00947050|prompt physical exercise
435881|NCT00947050|collateral function
435882|NCT00947011|Healthy volunteers
435883|NCT00947011|GLP-1
435884|NCT00947011|Januvia
435885|NCT00947011|Sitagliptin
435886|NCT00946998|Chronic Kidney Disease
435887|NCT00946998|Depression
435888|NCT00946998|Antidepressants
435889|NCT00946998|randomized controlled trial
435890|NCT00946998|treatment
435891|NCT00946998|Sertraline
435892|NCT00946985|Schizophrenia
435893|NCT00946985|Risperidone
435894|NCT00946985|Risperdal
435895|NCT00946985|Paliperidone Palmitate
435896|NCT00946985|Invega Sustenna
435897|NCT00946972|Diabetes Mellitus, Type 2
435898|NCT00946959|cardiac surgery
435899|NCT00946959|angioplasty
435900|NCT00946959|cognitive decline
435901|NCT00946946|Randomized
435902|NCT00946946|Crohn's Disease
435903|NCT00946946|Prevention
435904|NCT00946946|Azathioprine
435905|NCT00946946|mesalazine
435906|NCT00946946|mesalamine
435907|NCT00946946|TPMT
435908|NCT00946933|acid-base balance
435909|NCT00946933|ventilatory control
435910|NCT00946933|dyspnea
435911|NCT00946933|exercise
435912|NCT00946933|modified rebreathing procedure
435913|NCT00946933|Normal
435914|NCT00946933|older
435915|NCT00946907|acute pericarditis
435916|NCT00946907|treatment
435917|NCT00946907|recurrence
435918|NCT00946894|Total thyroidectomy
435919|NCT00946894|Subtotal thyroidectomy
435920|NCT00946894|Dunhill operation
435921|NCT00946894|Recurrent nodular goiter
435922|NCT00946894|Completion thyroidectomy
435923|NCT00946894|Recurrent laryngeal nerve palsy
435924|NCT00946894|Hypoparathyroidism following thyroidectomy
435925|NCT00946894|Recurrent goiter
435926|NCT00946881|Prostatic disease
435927|NCT00946881|genital neoplasm, male
435928|NCT00946881|Urogenital neoplasm
435929|NCT00946881|Genital disease
435930|NCT00946881|male
435931|NCT00946881|Male urogenital disease
435932|NCT00946881|Neoplasms
435933|NCT00946881|Neoplasm by site
435934|NCT00946881|prostatic neoplasm
435935|NCT00946881|Carcinoma
435936|NCT00946868|intermittent claudication
435937|NCT00946868|metabolic syndrome
435938|NCT00946855|soccer
435939|NCT00946855|laboratory
435940|NCT00946855|reference
435941|NCT00946855|exercise
435942|NCT00946855|variability
435943|NCT00946855|season
435944|NCT00946855|elite athletes
435945|NCT00946855|Define reference blood parameters in elite athletes
435946|NCT00946842|Healthy
435947|NCT00946842|Bioavailability
435948|NCT00946842|Relative bioavailability
435949|NCT00946842|TMC207
435950|NCT00946842|Fed condition
435951|NCT00946842|Fasted condition
435952|NCT00946803|Pain
435953|NCT00946803|Fatigue
435954|NCT00946803|Sleep
435955|NCT00946803|Cancer
435956|NCT00946803|Complementary therapies
435957|NCT00946790|Immunosuppressant and Antirheumatic
435958|NCT00946777|Dry Eye Signs
435959|NCT00946777|barrier function
435960|NCT00946764|Antidepressant
435961|NCT00946751|Anticonvulsant
435962|NCT00946738|Raynaud's phenomenon
435963|NCT00946738|biofeedback
435964|NCT00946738|deep oscillation
435965|NCT00946738|systemic sclerosis
435966|NCT00946738|physiotherapy
435967|NCT00946725|Angina (Chest Pain)
435968|NCT00946725|Hypertension
435969|NCT00946660|Contingency Management
435970|NCT00946660|Drug Self-Administration
435971|NCT00946647|Myelodysplastic Syndromes
435972|NCT00946647|Chronic Myelomonocytic Leukemia
435973|NCT00946647|Acute Myeloid Leukemia
435974|NCT00946647|hypomethylating therapy
435975|NCT00946647|deacetylase inhibitor
435976|NCT00946647|MDS
435977|NCT00946647|CMML
435978|NCT00946647|AML
435979|NCT00946608|Antihistamine
435980|NCT00946595|Undetectable
435981|NCT00946595|HIV infections
435982|NCT00946595|Monotherapy
435983|NCT00946595|Lopinavir/ritonavir
435984|NCT00946595|Protease inhibitor
435985|NCT00946595|Treatment experienced
435986|NCT00946582|parenting management program
435987|NCT00946582|ADHD
435988|NCT00946569|Asthma
435989|NCT00946569|Persistent asthma
435990|NCT00946569|Adults with persistent asthma
435991|NCT00946569|Chronic asthma
435992|NCT00946569|JNJ-39758979
435993|NCT00946569|Placebo
435994|NCT00946556|herpes simplex virus type 2
435995|NCT00946556|HIV
435996|NCT00946556|genital immunology
435997|NCT00946556|CD4+ T cell
435998|NCT00946556|valacyclovir
435999|NCT00946556|HIV seronegativity
436000|NCT00946543|stage IIB prostate cancer
436001|NCT00946543|stage IIA prostate cancer
436002|NCT00946543|stage III prostate cancer
436003|NCT00946543|stage IV prostate cancer
436004|NCT00946491|Typical Antipsychotic
436005|NCT00946478|atopic dermatitis
436006|NCT00946478|elidel
436007|NCT00946478|pimecrolimus
436008|NCT00946478|CASM981
436009|NCT00946478|immunity
436010|NCT00946478|cathelicidin
436011|NCT00946478|antimicrobial peptide
436012|NCT00946478|eczema
436013|NCT00946452|Control
436014|NCT00946452|Satisfaction
436015|NCT00946439|training exercise gait
436016|NCT00946413|CBT, Depressed and suicidal adolescents
436017|NCT00946400|Heparin-induced thrombocytopenia
436018|NCT00946400|HIT
436019|NCT00946400|4Ts
436020|NCT00946400|Chong scale
436021|NCT00946400|interobserver variability
436022|NCT00946387|Antiemetic
436023|NCT00946374|Mantle-Cell-Lymphoma
436024|NCT00946374|MCL
436025|NCT00946374|Non Hodgkin´s Lymphoma
436026|NCT00946374|NHL
436027|NCT00946374|Immunochemotherapy
436028|NCT00946374|R-CHOP
436029|NCT00946374|CHOP
436030|NCT00946374|High-dose chemotherapy
436031|NCT00946374|BEAM
436032|NCT00946374|HD-BEAM
436033|NCT00946374|Autologous stem cell transplantation
436034|NCT00946374|Reduced conditioning regimen
436035|NCT00946374|Unrelated donor
436036|NCT00946374|Sibling donor
436037|NCT00946374|Total Body Irradiation
436038|NCT00946374|TBI
436039|NCT00946374|Allogenic stem cell transplantation
436040|NCT00946374|ABSCT
436041|NCT00946374|ASCT
436042|NCT00946374|Fludarabine+TBI
436043|NCT00946348|Dronabinol
436044|NCT00946348|Schizophrenia
436045|NCT00946348|Dual Diagnosis
436046|NCT00946348|Substance Abuse
436047|NCT00946348|Cannabis Use Disorder
436048|NCT00946322|post-traumatic stress disorder
436049|NCT00946322|alcohol-related disorders
436050|NCT00946322|substance use disorders
436051|NCT00946322|couple therapy
436052|NCT00946296|Graves Disease
436053|NCT00946283|stage III adult Burkitt lymphoma
436054|NCT00946283|stage III adult diffuse large cell lymphoma
436055|NCT00946283|stage III adult diffuse mixed cell lymphoma
436056|NCT00946283|stage III adult diffuse small cleaved cell lymphoma
436057|NCT00946283|stage III adult Hodgkin lymphoma
436058|NCT00946283|stage III adult immunoblastic large cell lymphoma
436059|NCT00946283|stage III adult lymphoblastic lymphoma
436060|NCT00946283|stage III grade 1 follicular lymphoma
436061|NCT00946283|stage III grade 2 follicular lymphoma
436062|NCT00946283|stage III grade 3 follicular lymphoma
436063|NCT00946283|stage III mantle cell lymphoma
436064|NCT00946283|stage III marginal zone lymphoma
436065|NCT00946283|stage III small lymphocytic lymphoma
436066|NCT00946283|stage IV adult Burkitt lymphoma
436067|NCT00946283|stage IV adult diffuse large cell lymphoma
436068|NCT00946283|stage IV adult diffuse mixed cell lymphoma
436069|NCT00946283|stage IV adult diffuse small cleaved cell lymphoma
436070|NCT00946283|stage IV adult Hodgkin lymphoma
436071|NCT00946283|stage IV adult immunoblastic large cell lymphoma
436072|NCT00946283|stage IV adult lymphoblastic lymphoma
436073|NCT00946283|stage IV grade 1 follicular lymphoma
436074|NCT00946283|stage IV grade 2 follicular lymphoma
436075|NCT00946283|stage IV grade 3 follicular lymphoma
436076|NCT00946283|stage IV mantle cell lymphoma
436077|NCT00946283|stage IV marginal zone lymphoma
436078|NCT00946283|stage IV small lymphocytic lymphoma
436079|NCT00946283|recurrent adult Burkitt lymphoma
436080|NCT00946283|recurrent adult diffuse large cell lymphoma
436081|NCT00946283|recurrent adult diffuse mixed cell lymphoma
436082|NCT00946283|recurrent adult diffuse small cleaved cell lymphoma
436083|NCT00946283|recurrent adult Hodgkin lymphoma
436084|NCT00946283|recurrent adult immunoblastic large cell lymphoma
436085|NCT00946283|recurrent adult lymphoblastic lymphoma
436086|NCT00946283|recurrent cutaneous T-cell non-Hodgkin lymphoma
436087|NCT00946283|recurrent grade 1 follicular lymphoma
436088|NCT00946283|recurrent grade 2 follicular lymphoma
436089|NCT00946283|recurrent grade 3 follicular lymphoma
436090|NCT00946283|recurrent mantle cell lymphoma
436091|NCT00946283|recurrent marginal zone lymphoma
436092|NCT00946283|recurrent small lymphocytic lymphoma
436093|NCT00946283|recurrent mycosis fungoides/Sezary syndrome
436094|NCT00946283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
436095|NCT00946283|nodal marginal zone B-cell lymphoma
436096|NCT00946283|splenic marginal zone lymphoma
436097|NCT00946283|noncontiguous stage II adult Burkitt lymphoma
436098|NCT00946283|noncontiguous stage II adult diffuse large cell lymphoma
436099|NCT00946283|noncontiguous stage II adult diffuse mixed cell lymphoma
436100|NCT00946283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
436101|NCT00946283|noncontiguous stage II adult immunoblastic large cell lymphoma
436102|NCT00946283|noncontiguous stage II adult lymphoblastic lymphoma
436103|NCT00946283|noncontiguous stage II grade 1 follicular lymphoma
436104|NCT00946283|noncontiguous stage II grade 2 follicular lymphoma
436105|NCT00946283|noncontiguous stage II grade 3 follicular lymphoma
436106|NCT00946283|noncontiguous stage II mantle cell lymphoma
436107|NCT00946283|noncontiguous stage II marginal zone lymphoma
436108|NCT00946283|noncontiguous stage II small lymphocytic lymphoma
436109|NCT00946283|accelerated phase chronic myelogenous leukemia
436110|NCT00946283|adult acute lymphoblastic leukemia in remission
436111|NCT00946283|adult acute myeloid leukemia in remission
436112|NCT00946283|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
436113|NCT00946283|adult acute myeloid leukemia with inv(16)(p13;q22)
436114|NCT00946283|adult acute myeloid leukemia with t(15;17)(q22;q12)
436115|NCT00946283|adult acute myeloid leukemia with t(16;16)(p13;q22)
436232|NCT00945932|GW870086X
436116|NCT00946283|adult acute myeloid leukemia with t(8;21)(q22;q22)
436117|NCT00946283|atypical chronic myeloid leukemia, BCR-ABL negative
436118|NCT00946283|blastic phase chronic myelogenous leukemia
436119|NCT00946283|chronic myelomonocytic leukemia
436120|NCT00946283|chronic phase chronic myelogenous leukemia
436121|NCT00946283|recurrent adult acute lymphoblastic leukemia
436122|NCT00946283|recurrent adult acute myeloid leukemia
436123|NCT00946283|refractory chronic lymphocytic leukemia
436124|NCT00946283|refractory hairy cell leukemia
436125|NCT00946283|relapsing chronic myelogenous leukemia
436126|NCT00946283|secondary acute myeloid leukemia
436127|NCT00946283|stage III chronic lymphocytic leukemia
436128|NCT00946283|stage IV chronic lymphocytic leukemia
436129|NCT00946283|chronic eosinophilic leukemia
436130|NCT00946283|primary myelofibrosis
436131|NCT00946283|chronic neutrophilic leukemia
436132|NCT00946283|de novo myelodysplastic syndromes
436133|NCT00946283|disseminated neuroblastoma
436134|NCT00946283|myelodysplastic/myeloproliferative neoplasm, unclassifiable
436135|NCT00946283|previously treated myelodysplastic syndromes
436136|NCT00946283|recurrent neuroblastoma
436137|NCT00946283|recurrent ovarian epithelial cancer
436138|NCT00946283|recurrent ovarian germ cell tumor
436139|NCT00946283|recurrent malignant testicular germ cell tumor
436140|NCT00946283|secondary myelodysplastic syndromes
436141|NCT00946283|stage II multiple myeloma
436142|NCT00946283|stage III multiple myeloma
436143|NCT00946283|stage II ovarian epithelial cancer
436144|NCT00946283|stage III ovarian epithelial cancer
436145|NCT00946283|stage IV ovarian epithelial cancer
436146|NCT00946283|stage III malignant testicular germ cell tumor
436147|NCT00946283|stage IIIA breast cancer
436148|NCT00946283|stage IIIB breast cancer
436149|NCT00946283|stage IIIC breast cancer
436150|NCT00946283|stage IV breast cancer
436151|NCT00946283|refractory multiple myeloma
436152|NCT00946270|CC-4047
436153|NCT00946270|Pomalidomide
436154|NCT00946270|polycythemia vera
436155|NCT00946270|essential thrombocythemia myelofibrosis
436156|NCT00946257|Type 1 Diabetes Mellitus
436157|NCT00946244|Early intervention
436158|NCT00946244|Mother-child interaction
436159|NCT00946244|Neurodevelopment
436160|NCT00946244|Parenting
436161|NCT00946244|Prematurity
436162|NCT00946244|Preschool age
436163|NCT00946231|Heart Failure
436164|NCT00946231|BNP
436165|NCT00946231|B-type natriuretic peptide
436166|NCT00946231|home testing
436167|NCT00946205|rectal prolapse
436168|NCT00946205|laparoscopic rectopexy
436169|NCT00946205|obstructed defecation
436170|NCT00946192|Amenorrhea
436171|NCT00946192|Adolescent
436172|NCT00946192|Endurance
436173|NCT00946192|Athletes
436174|NCT00946192|Females
436175|NCT00946192|Osteopenia
436176|NCT00946192|Osteoporosis
436177|NCT00946192|Estrogen
436178|NCT00946179|Influenza
436179|NCT00946179|Influenza virus vaccine
436180|NCT00946179|Split virion
436181|NCT00946166|pneumonia
436182|NCT00946166|statins
436183|NCT00946166|cytokines
436184|NCT00946153|Carcinoma
436185|NCT00946153|Hepatocellular
436186|NCT00946140|Ovary
436187|NCT00946140|MRI
436188|NCT00946140|08-132
436189|NCT00946127|Normal Pressure Hydrocephalus
436190|NCT00946127|Communicating Hydrocephalus
436191|NCT00946127|Gait disorder
436192|NCT00946127|Cognition
436193|NCT00946127|Shunt
436194|NCT00946127|Endoscopic Third Ventriculostomy.
436195|NCT00946101|randomized, double-blind, placebo-controlled
436196|NCT00946062|low vision
436197|NCT00946062|ophthalmology
436198|NCT00946062|randomised controlled trial
436199|NCT00946062|mobility
436200|NCT00946062|orientation
436201|NCT00946062|cane
436202|NCT00946062|aged
436203|NCT00946049|Checking clinical antibacterial effect of Vicryl Plus compared to conventional Vicryl in intraoral surgery
436204|NCT00946049|Bacteria
436205|NCT00946023|lymphoma
436206|NCT00946023|non hodgkin lymphoma
436207|NCT00946023|allogeneic
436208|NCT00946023|bone marrow transplantation
436209|NCT00946023|nonmyeloablative
436210|NCT00946023|cyclophosphamide
436211|NCT00946023|rituximab
436212|NCT00946010|Hepatitis B
436213|NCT00946010|Hepatitis C
436214|NCT00946010|genotype
436215|NCT00946010|DNA level
436216|NCT00946010|RNA level
436217|NCT00946010|Taiwan
436218|NCT00945997|misoprostol
436219|NCT00945997|mifepristone
436220|NCT00945997|medical abortion
436221|NCT00945997|randomised controlled trial
436222|NCT00945984|Localized renal cell carcinoma
436223|NCT00945971|Attention Deficit Hyperactivity Disorder
436224|NCT00945971|Catecholamine
436225|NCT00945971|Children
436226|NCT00945971|Physical Activity
436227|NCT00945958|Glaucoma
436228|NCT00945958|Ocular hypertension
436229|NCT00945945|Osteoarthritis, Knee
436230|NCT00945945|Pain
436231|NCT00945932|asthma
436233|NCT00945932|Efficacy
436234|NCT00945932|FEV1
436235|NCT00945932|repeat-dose
436236|NCT00945919|Oral morphine
436237|NCT00945919|oxycodone
436238|NCT00945919|OPANA
436239|NCT00945919|Oxymorphone
436240|NCT00945919|pain
436241|NCT00945919|nociceptive
436242|NCT00945919|neuropathic
436243|NCT00945919|rotation
436244|NCT00945919|titration
436245|NCT00945919|mixed origin non-cancer pain
436246|NCT00945906|Hereditary Factor XIII deficiency
436247|NCT00945906|Factor XIII
436248|NCT00945880|HCV
436249|NCT00945880|Hepatitis C
436250|NCT00945880|Hepatitis
436251|NCT00945867|flecainide
436252|NCT00945867|pharmacogenetics
436253|NCT00945854|wholegrain cereals
436254|NCT00945854|glycemic index
436255|NCT00945854|metabolic syndrome
436256|NCT00945854|insulin sensitivity
436257|NCT00945841|influenza vaccine
436258|NCT00945841|vaccine
436259|NCT00945828|pediatric cancer, neurocognitive outcomes for pediatric cancer
436260|NCT00945828|acute lymphoblastic leukemia
436261|NCT00945828|central nervous system tumors
436262|NCT00945828|lymphoma
436263|NCT00945815|B-cell adult acute lymphoblastic leukemia
436264|NCT00945815|L1 adult acute lymphoblastic leukemia
436265|NCT00945815|L2 adult acute lymphoblastic leukemia
436266|NCT00945815|recurrent adult acute lymphoblastic leukemia
436267|NCT00945789|Asphyxia neonatorum
436268|NCT00945789|Infants
436269|NCT00945789|EEG
436270|NCT00945789|Brain MRI
436271|NCT00945789|Nitric oxide
436272|NCT00945776|OSA
436273|NCT00945776|CPAP
436274|NCT00945763|Dental Pain
436275|NCT00945737|hypercholesterolemia
436276|NCT00945737|cholesterol
436277|NCT00945737|soy
436278|NCT00945711|dual diagnosis
436279|NCT00945698|Stunting
436280|NCT00945698|Growth failure
436281|NCT00945698|Malnutrition
436282|NCT00945698|Lipid based nutrient supplement
436283|NCT00945698|LNS
436284|NCT00945698|Prevention
436285|NCT00945698|Malawi
436286|NCT00945698|Sub-Saharan Africa
436287|NCT00945698|Dietary supplementation
436288|NCT00945698|Efficacy
436289|NCT00945685|Skin Aging
436290|NCT00945685|Skin Wrinkling
436291|NCT00945672|Alzheimer's disease amyloid imaging antibody
436292|NCT00945633|Obesity
436293|NCT00945633|unhealthy weight gain
436294|NCT00945620|Trans-abdominis block
436295|NCT00945620|post-cesarean
436296|NCT00945607|Complementary Medicine
436297|NCT00945607|Alternative Medicine
436298|NCT00945607|Breast Cancer
436299|NCT00945594|flexible cystoscopy
436300|NCT00945594|rigid cystoscopy
436301|NCT00945594|bladder
436302|NCT00945594|outcome assessment
436303|NCT00945594|pain measurement
436304|NCT00945581|Healthy Elderly volunteers
436305|NCT00945568|QOL
436306|NCT00945568|liver
436307|NCT00945555|Antibacterials
436308|NCT00945555|Classification of antibacterial agent
436309|NCT00945555|Febrile neutropenia
436310|NCT00945555|Turkey
436311|NCT00945542|Trauma
436312|NCT00945542|Coagulopathy
436313|NCT00945542|Transfusion
436314|NCT00945542|Plasma
436315|NCT00945542|Massive Transfusion
436316|NCT00945529|Fontan
436317|NCT00945516|Metal stent
436318|NCT00945516|Bile duct stricture
436319|NCT00945516|Stent migration
436320|NCT00945516|Feasibility
436321|NCT00945516|Safety
436322|NCT00945516|Removability
436323|NCT00945503|Glycine Tranporter
436324|NCT00945503|MRI
436325|NCT00945503|PET
436326|NCT00945490|Benign prostatic hyperplasia
436327|NCT00945490|BPH
436328|NCT00945490|Enlarged prostate
436329|NCT00945451|stage IIIA non-small cell lung cancer
436330|NCT00945451|stage IIIB non-small cell lung cancer
436331|NCT00945451|stage II non-small cell lung cancer
436332|NCT00945438|Influenza
436333|NCT00945438|Influenza virus vaccine
436334|NCT00945438|Split virion
436335|NCT00945438|Intradermal
436336|NCT00945425|Phase I
436337|NCT00945425|Volunteer
436338|NCT00945412|microdebrider tonsillotomy
436339|NCT00945412|Post-tonsillectomy hemorrhage
436340|NCT00945386|children
436341|NCT00945386|critically ill
436342|NCT00945386|furosemide
436343|NCT00945386|acoustic emission
436344|NCT00945373|rosacea
436345|NCT00945373|telangiectasias
436346|NCT00945373|topical treatment
436347|NCT00945373|pulsed dye laser
436348|NCT00945360|Leiomyoma
436349|NCT00945360|perimenopause
436350|NCT00945360|aromatase inhibitor
436351|NCT00945347|Cystic fibrosis
436352|NCT00945347|miglustat
436353|NCT00945347|nasal instillation
436354|NCT00945347|nasal potential difference
436355|NCT00945334|Constipation predominant Irritable Bowel Syndrome
436356|NCT00945308|Primary PCI
436357|NCT00945308|Acute myocardial infarction
436358|NCT00945308|Myocardial blush
436477|NCT00944957|HIV
436359|NCT00945308|Primary coronary intervention in acute myocardial infarction
436360|NCT00945308|focusing on the effect of the study drug on the immediate TIMI
436361|NCT00945308|flow at the infarct related artery and on the myocardial
436362|NCT00945308|perfusion evaluated by the TIMI myocardial perfusion grade or
436363|NCT00945308|blush
436364|NCT00945295|Cerebrovascular Accident/Rehabilitation
436365|NCT00945295|Muscle Spasticity
436366|NCT00945295|Botulinum Neurotoxin Type A
436367|NCT00945295|Post-stroke focal upper limb spasticity
436368|NCT00945282|IDX12899
436369|NCT00945282|adaptive
436370|NCT00945282|monotherapy
436371|NCT00945282|pharmacokinetics
436372|NCT00945282|Treatment-naive
436373|NCT00945282|HIV-1
436374|NCT00945282|GSK2248761
436375|NCT00945282|NNRTI
436376|NCT00945282|HIV Infections
436377|NCT00945282|treatment naive
436378|NCT00945256|metabolism
436379|NCT00945256|exercise
436380|NCT00945256|sodium nitroprusside
436381|NCT00945243|SCDD
436382|NCT00945230|Neurosurgical outcome
436383|NCT00945230|Actigraphy
436384|NCT00945230|Treatment Response Measurement
436385|NCT00945217|Atherogenic dyslipidemia
436386|NCT00945217|Non-HDL-C
436387|NCT00945217|Postmenopausal women
436388|NCT00945217|SAH gene family
436389|NCT00945204|type 2 diabetes
436390|NCT00945204|intermediate care
436391|NCT00945204|primary care
436392|NCT00945204|randomised controlled trial
436393|NCT00945191|ovarian
436394|NCT00945191|cancer
436395|NCT00945191|metastatic
436396|NCT00945191|locally
436397|NCT00945191|advanced
436398|NCT00945191|chemotherapy
436399|NCT00945191|neoplasm
436400|NCT00945178|Safety
436401|NCT00945178|Tolerability
436402|NCT00945178|Healthy
436403|NCT00945178|Pharmacokinetics
436404|NCT00945165|Continuous Glucose Monitoring System
436405|NCT00945165|Exercise
436406|NCT00945152|Elimination of MRSA in open wounds
436407|NCT00945152|MRSA infected open wounds
436408|NCT00945126|Allogeneic stem cell transplantation in pediatric patients
436409|NCT00945126|CD3/CD19 depleted stem cells
436410|NCT00945126|malignant and non-malignant high risk diseases
436411|NCT00945113|pilot
436412|NCT00945113|stammer
436413|NCT00945113|stutter
436414|NCT00945113|children
436415|NCT00945113|randomised controlled trial
436416|NCT00945113|RCT
436417|NCT00945113|Speech and Language Therapy
436418|NCT00945113|Stuttering
436419|NCT00945100|Amblyopia
436420|NCT00945100|patching
436421|NCT00945100|occlusion
436422|NCT00945087|bacteriophage
436423|NCT00945087|bacteriophage preparation
436424|NCT00945087|bacterial infection
436425|NCT00945087|antibiotic-resistant infection
436426|NCT00945087|multidrug-resistant bacteria
436427|NCT00945087|MRSA
436428|NCT00945074|Acupuncture
436429|NCT00945074|Moxibustion
436430|NCT00945074|Traditional Chinese Medicine
436431|NCT00945074|Complementary Medicine
436432|NCT00945074|Irritable Bowel Syndrome
436433|NCT00945074|IBS
436434|NCT00945061|ductal breast carcinoma in situ
436435|NCT00945061|recurrent breast cancer
436436|NCT00945061|invasive ductal breast carcinoma
436437|NCT00945061|medullary ductal breast carcinoma with lymphocytic infiltrate
436438|NCT00945061|mucinous ductal breast carcinoma
436439|NCT00945061|papillary ductal breast carcinoma
436440|NCT00945061|tubular ductal breast carcinoma
436441|NCT00945061|male breast cancer
436442|NCT00945022|General Surgery
436443|NCT00944996|PACAP (Pituitary Adenylate Cyclase Activating Polypeptide)
436444|NCT00944996|Major Depression
436445|NCT00944996|Receptors
436446|NCT00944996|Gene polymorphism
436447|NCT00944996|PACAP signaling system
436448|NCT00944996|Etiology of major depression
436449|NCT00944996|Mechanism of antidepressants action
436450|NCT00944996|PACAP receptors gene polymorphism
436451|NCT00944996|Pathogenesis of major depression
436452|NCT00944996|Responsiveness to the antidepressant drugs
436453|NCT00944983|Hypertension
436454|NCT00944983|Hypotension
436455|NCT00944983|Clinical Validation
436456|NCT00944983|Blood Pressure Accuracy
436457|NCT00944983|ISO 81600 Standard
436458|NCT00944983|British Hypertension Society
436459|NCT00944983|European Society of Hypertension
436460|NCT00944983|International Protocol
436461|NCT00944970|Coronary artery disease
436462|NCT00944970|Angina
436463|NCT00944970|Anginal symptoms
436464|NCT00944970|Ischemic heart disease
436465|NCT00944970|Ischemia
436466|NCT00944970|Single photon emission computed tomography
436467|NCT00944970|Pharmacologic stress
436468|NCT00944970|Myocardial perfusion imaging
436469|NCT00944970|Suspected coronary artery disease
436470|NCT00944970|known coronary artery disease
436471|NCT00944970|typical or atypical anginal symptoms
436472|NCT00944957|Raltegravir
436473|NCT00944957|efavirenz
436474|NCT00944957|anxiety
436475|NCT00944957|depression
436476|NCT00944957|sleep quality
436478|NCT00944957|NNRTI
436479|NCT00944957|Tritherapy
436480|NCT00944957|compliance
436481|NCT00944957|stocrin
436482|NCT00944957|treatment experienced
436483|NCT00944944|CORPUS UTERI,
436484|NCT00944944|ENDOMETRIUM
436485|NCT00944944|FALLOPIAN TUBE
436486|NCT00944944|OVARY
436487|NCT00944944|VAGINA
436488|NCT00944944|Lymphedema
436489|NCT00944944|Questionnaire
436490|NCT00944944|Quality of Life
436491|NCT00944944|09-077
436492|NCT00944944|Fallopian Tubes
436493|NCT00944931|Cerebral Cortex
436494|NCT00944931|Cognition
436495|NCT00944931|Motor Cortex
436496|NCT00944931|Cognitive Enhancement
436497|NCT00944931|Prefrontal Cortex
436498|NCT00944931|Healthy Volunteer
436499|NCT00944918|Breast Cancer
436500|NCT00944879|HIV
436501|NCT00944879|vaccine
436502|NCT00944879|prevention
436503|NCT00944879|HPV
436504|NCT00944879|adolescents
436505|NCT00944853|zinc supplement
436506|NCT00944853|prevention
436507|NCT00944853|zinc deficiency
436508|NCT00944853|plasma zinc concentration
436509|NCT00944840|Intermittent Preventive Treatment
436510|NCT00944840|Home based management of malaria
436511|NCT00944827|Green Tea Extract
436512|NCT00944827|Catechins
436513|NCT00944827|Statin
436514|NCT00944827|atorvastatin
436515|NCT00944827|body composition
436516|NCT00944827|visceral fat
436517|NCT00944827|steatosis
436518|NCT00944827|oxidative stress
436519|NCT00944827|quality of life
436520|NCT00944827|OGTT
436521|NCT00944827|OGIS
436522|NCT00944827|ISI matsuda
436523|NCT00944814|Lipid-based nutrient supplement
436524|NCT00944814|Prevention of malnutrition
436525|NCT00944814|Prevention of micronutrient deficiencies
436526|NCT00944814|Zinc
436527|NCT00944801|glioblastoma
436528|NCT00944801|first-line
436529|NCT00944801|clinical trial
436530|NCT00944801|PEG-liposomal doxorubicin
436531|NCT00944801|temozolomide
436532|NCT00944801|radiotherapy
436533|NCT00944801|phase 1
436534|NCT00944801|phase 2
436535|NCT00944788|physical activity
436536|NCT00944788|aging
436537|NCT00944788|inpatients
436538|NCT00944788|quality of life
436539|NCT00944788|depression
436540|NCT00944775|Exercise
436541|NCT00944775|Dialysis
436542|NCT00944775|Non-invasive cardiac measures
436543|NCT00944775|Exercise trained patients
436544|NCT00944775|Controls
436545|NCT00944762|Stroke
436546|NCT00944749|H- ATG
436547|NCT00944749|Anti -Thymocyte Globulin
436548|NCT00944749|Lymphocyte Immune Globulin
436549|NCT00944749|Aplastic Anemia
436550|NCT00944736|Crohn's Disease
436551|NCT00944736|Pediatric
436552|NCT00944736|VSL#3
436553|NCT00944736|Permeability
436554|NCT00944736|Probiotic
436555|NCT00944736|Zonulin
436556|NCT00944723|zinc fortification
436557|NCT00944723|zinc supplementation
436558|NCT00944723|plasma zinc concentration
436559|NCT00944710|Amblyopia
436560|NCT00944710|atropine
436561|NCT00944710|Plano lens
436562|NCT00944684|Chronic hepatitis C
436563|NCT00944684|Antiviral treatment
436564|NCT00944684|Ribavirin
436565|NCT00944684|Sustained virological response
436566|NCT00944684|Hemolytic anemia
436567|NCT00944684|Erythropoetin
436568|NCT00944658|Ankylosing spondylitis
436569|NCT00944658|Imaging
436570|NCT00944580|MAGE-A1
436571|NCT00944580|MAGE-A3
436572|NCT00944580|NY-ESO-1
436573|NCT00944580|antigen
436574|NCT00944580|vaccine
436575|NCT00944580|dendritic cells
436576|NCT00944580|immunohistochemistry
436577|NCT00944580|immunology
436578|NCT00944567|Primary Mediastinal B-Cell Lymphoma
436579|NCT00944567|Positron emission tomography
436580|NCT00944554|Relapse
436581|NCT00944554|Smoking Cessation
436582|NCT00944554|Substance Abuse
436583|NCT00944541|maraviroc
436584|NCT00944541|immune restoration
436585|NCT00944541|treatment intensification
436586|NCT00944528|Cancer of Breast
436587|NCT00944528|Cancer of the Breast
436588|NCT00944528|Neoplasms, Breast
436589|NCT00944528|Single dose radiation
436590|NCT00944528|Radiotherapy
436591|NCT00944528|Preoperative
436592|NCT00944515|sinusitis
436593|NCT00944515|azithromycin
436594|NCT00944502|Neuralgy
436595|NCT00944502|Dexamethasone
436596|NCT00944502|Complex Vitamins
436597|NCT00944502|Injection
436598|NCT00944502|Symptoms of neuralgy of various origins
436599|NCT00944489|Hypertension
436600|NCT00944489|Health-Related Quality of Life Adherence to the antihypertension treatment
436601|NCT00944489|Ambulatory Patients
436602|NCT00944489|MINICHAL score
436603|NCT00944489|Treatment Adherence Scale (MMAS)
436604|NCT00944489|Quality of life
436605|NCT00944489|Adherence to treatment
436606|NCT00944476|Sarcoma
436607|NCT00944476|soft tissue
436608|NCT00944476|MRI
436609|NCT00944476|Questionnaire
436610|NCT00944476|09-078
436611|NCT00944463|advanced pancreatic cancer
436612|NCT00944463|gemcitabine
436613|NCT00944463|simvastatin
436614|NCT00944463|placebo
436615|NCT00944437|Ventilation, Mechanical
436616|NCT00944437|Positive-Pressure Respiration
436617|NCT00944437|Continuous Positive Airway Pressure
436618|NCT00944424|Vitamin D in patients with metastatic breast cancer
436619|NCT00944398|Zinc fortification
436620|NCT00944398|Plasma zinc concentration
436621|NCT00944398|Assessment of zinc status
436622|NCT00944372|Tumor
436623|NCT00944372|somatostatin receptor
436624|NCT00944359|zinc supplementation
436625|NCT00944359|diarrhea management
436626|NCT00944359|zinc deficiency
436627|NCT00944359|malaria
436628|NCT00944333|second generation DES
436629|NCT00944333|clopidogrel
436630|NCT00944333|dual platelet therapy
436631|NCT00944333|patients with documented silent ischemia
436632|NCT00944333|unstable angina pectoris (Braunwald Classification)
436633|NCT00944333|Diagnosis of angina pectoris (CCS)
436634|NCT00944307|HIV
436635|NCT00944307|antiretroviral
436636|NCT00944307|drug interaction
436637|NCT00944307|human immunodeficiency virus
436638|NCT00944294|Coronary artery disease
436639|NCT00944294|Angina
436640|NCT00944294|Anginal symptoms
436641|NCT00944294|Ischemic heart disease
436642|NCT00944294|Ischemia
436643|NCT00944294|Single photon emission computed tomography
436644|NCT00944294|Pharmacologic stress
436645|NCT00944294|Myocardial perfusion imaging
436646|NCT00944294|typical or atypical anginal symptoms
436647|NCT00944294|Suspected coronary artery disease
436648|NCT00944294|known coronary artery disease
436649|NCT00944281|point-of-use fortification
436650|NCT00944281|zinc supplement
436651|NCT00944281|lipid-based nutrient supplement
436652|NCT00944281|zinc deficiency
436653|NCT00944281|micronutrient deficiency
436654|NCT00944281|anemia
436655|NCT00944268|Passiflora, Crataegus and Salix
436656|NCT00944268|Mild and Moderate anxiety
436657|NCT00944268|Tablet
436658|NCT00944268|To evaluate the efficacy and tolerability of the combination
436659|NCT00944229|Heart Failure
436660|NCT00944229|omega 3
436661|NCT00944229|lovaza
436662|NCT00944229|VO2 max
436663|NCT00944216|keratosis pilaris
436664|NCT00944203|jellyfish
436665|NCT00944203|jellyfish venom
436666|NCT00944203|jellyfish dermatitis
436667|NCT00944203|jellyfish stings
436668|NCT00944203|Ipomea pes-caprae
436669|NCT00944190|pain
436670|NCT00944190|fatigue
436671|NCT00944190|depression
436672|NCT00944190|cognitive difficulties
436673|NCT00944190|self-management
436674|NCT00944151|pain
436675|NCT00944151|UCSD
436676|NCT00944151|catheter
436677|NCT00944151|nerve block
436678|NCT00944151|hernia
436679|NCT00944151|post-surgery pain
436680|NCT00944151|abdominal pain
436681|NCT00944151|pelvic pain
436682|NCT00944151|Transversus abdominal plane
436683|NCT00944151|Hernia Repair
436684|NCT00944151|Transversus Abdominal Plane Block
436685|NCT00944138|Obesity
436686|NCT00944138|meditation
436687|NCT00944138|chronic kidney disease
436688|NCT00944112|Intensive care
436689|NCT00944112|Blood Transfusion
436690|NCT00944112|Anemia
436691|NCT00944099|intervention studies
436692|NCT00944099|feeding behavior
436693|NCT00944099|eating frequency
436694|NCT00944099|weight loss
436695|NCT00944099|dietary intake
436696|NCT00944086|Recruitment
436697|NCT00944086|Oxygen Concentration
436698|NCT00944086|pneumoperitoneum
436699|NCT00944086|laparoscopy
436700|NCT00944073|H1N1, influenza A viruses, vaccine, infants, children
436701|NCT00944047|invasive breast cancer
436702|NCT00944047|HER2
436703|NCT00944047|primary breast cancer
436704|NCT00944047|neo-adjuvant therapy
436705|NCT00944047|Trastuzumab
436706|NCT00944047|Nab-paclitaxel
436707|NCT00944034|Meningococcal meningitis
436708|NCT00944034|prevention
436709|NCT00944034|vaccination
436710|NCT00944034|toddler
436711|NCT00944021|Early Bactericidal Activity
436712|NCT00944021|EBA
436713|NCT00944021|Pulmonary Tuberculosis
436714|NCT00944021|PA-824
436715|NCT00944021|pretomanid
436716|NCT00944008|Acute Lymphoblastic Leukemia (ALL)
436717|NCT00944008|Depocyte®
436718|NCT00944008|Neuromeningeal relapse
436719|NCT00944008|Between 16 and 30 years old
436720|NCT00944008|Standard risk
436721|NCT00943995|End Stage Kidney Disease
436722|NCT00943995|Kidney Failure
436723|NCT00943995|Short stature
436724|NCT00943995|Growth Hormone therapy
436725|NCT00943982|Cystoid Macular Edema
436726|NCT00943982|Intermediate Uveitis
436727|NCT00943982|Uveitis
436728|NCT00943982|OCT
436729|NCT00943982|Interferon-Gamma (IFN-Gamma)
436730|NCT00943969|obesity
436731|NCT00943969|gastric bypass
436732|NCT00943969|morphine
436733|NCT00943969|pharmacokinetic
436734|NCT00943969|absorption
436735|NCT00943956|stage III prostate cancer
436736|NCT00943956|stage IV prostate cancer
436737|NCT00943943|acute myelogenous leukemia
436738|NCT00943943|AML
436739|NCT00943943|Leukemia
436740|NCT00943943|myeloid leukemias
436741|NCT00943943|mutated fms-like tyrosine kinase receptor-3
436742|NCT00943943|FLT3 Mutations
436743|NCT00943943|G-CSF
436744|NCT00943943|Granulocyte Colony Stimulating Factor
436745|NCT00943943|Filgrastim
436746|NCT00943943|Neupogen
436747|NCT00943943|Plerixafor
436748|NCT00943943|Mobozil
436749|NCT00943943|Sorafenib
436750|NCT00943943|BAY 43-9006
436751|NCT00943904|urinary leakage associated with urinary urgency
436752|NCT00943904|unable to fully empty bladder
436753|NCT00943904|Comparison: Motor&Sensory Response to Interstim Stimulation
436754|NCT00943878|H1N1, influenza A viruses, vaccine, elderly, TIV
436755|NCT00943865|metabolic syndrome
436756|NCT00943865|lifestyle
436757|NCT00943865|exercise
436758|NCT00943865|endothelial dysfunction
436759|NCT00943865|insulin sensitivity
436760|NCT00943865|lipids
436761|NCT00943839|stage IV renal cell cancer
436762|NCT00943813|communication
436763|NCT00943813|survey
436764|NCT00943813|video
436765|NCT00943813|09-043
436766|NCT00943800|Appropriate candidate for transplantation
436767|NCT00943800|An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.
436768|NCT00943774|Physiology
436769|NCT00943774|Phenotype
436770|NCT00943774|Genetics
436771|NCT00943774|Genomics
436772|NCT00943774|Stress
436773|NCT00943774|Baroreflex
436774|NCT00943774|Blood Pressure
436775|NCT00943774|Arterial stiffness
436776|NCT00943761|hepatitis C
436777|NCT00943735|Overactive Bladder Incontinence Adherence Behavioral interventions
436778|NCT00943709|hyperglycemia
436779|NCT00943709|recurrent adult acute lymphoblastic leukemia
436780|NCT00943709|untreated adult acute lymphoblastic leukemia
436781|NCT00943709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
436782|NCT00943709|adult acute myeloid leukemia with inv(16)(p13;q22)
436783|NCT00943709|adult acute myeloid leukemia with t(15;17)(q22;q12)
436784|NCT00943709|adult acute myeloid leukemia with t(16;16)(p13;q22)
436785|NCT00943709|adult acute myeloid leukemia with t(8;21)(q22;q22)
436786|NCT00943709|recurrent adult acute myeloid leukemia
436787|NCT00943709|untreated adult acute myeloid leukemia
436788|NCT00943670|MBC
436789|NCT00943670|TDM1
436790|NCT00943670|Armed Herceptin
436791|NCT00943670|Herceptin
436792|NCT00943670|Trastuzumab emtansine
436793|NCT00943644|MBI
436794|NCT00943644|Breast
436795|NCT00943644|Breast Cancer
436796|NCT00943631|H1N1, influenza A viruses, vaccine, elderly
436797|NCT00943618|Smoking Cessation
436798|NCT00943618|Nicotine Withdrawal
436799|NCT00943618|Smoking Reduction
436800|NCT00943618|Varenicline
436801|NCT00943618|Chantix
436802|NCT00943618|Bupropion
436803|NCT00943618|Zyban
436804|NCT00943605|Mastectomy
436805|NCT00943605|PlasmaBlade
436806|NCT00943605|Electrosurgery
436807|NCT00943605|PEAK Surgical
436808|NCT00943605|Medtronic Advanced Energy
436809|NCT00943605|Medtronic
436810|NCT00943592|Melphalan
436811|NCT00943592|Alemtuzumab
436812|NCT00943592|Clofarabine
436813|NCT00943579|autism
436814|NCT00943579|autistic disorder
436815|NCT00943579|tetrahydrobiopterin
436816|NCT00943579|sapropterin
436817|NCT00943579|treatment
436818|NCT00943566|Pain
436819|NCT00943566|Cancer
436820|NCT00943566|Morphine
436821|NCT00943553|AML
436822|NCT00943540|pharmacokinetics
436823|NCT00943540|single dose
436824|NCT00943540|raltegravir
436825|NCT00943540|Treatment experienced
436826|NCT00943527|Breast
436827|NCT00943527|Menstrual Cycle
436828|NCT00943527|Breast Cancer
436829|NCT00943527|Hormone
436830|NCT00943527|MBI
436831|NCT00943527|Molecular Breast Imaging
436832|NCT00943527|Breast Imaging
436833|NCT00943514|Primary Ciliary Dyskinesia
436834|NCT00943514|Variant Cystic Fibrosis
436835|NCT00943514|Bronchopulmonary Mycosis
436836|NCT00943514|Airway Infection Susceptibility
436837|NCT00943514|Chronic Respiratory Infection
436838|NCT00943514|Bronchiectasis
436839|NCT00943488|influenza A viruses, H1N1, elderly
436840|NCT00943475|DPNB, pain, hemodynamics effects, circumcision
436841|NCT00943449|Hepatocellular Carcinoma
436842|NCT00943449|Sorafenib
436843|NCT00943449|HDAC
436844|NCT00943449|4SC-201
436845|NCT00943449|Phase II
436846|NCT00943449|Resminostat
436847|NCT00943436|Exercise
436848|NCT00943436|Sedentary
436849|NCT00943436|Energy Expenditure
436850|NCT00943436|Energy Balance
436851|NCT00943436|Macronutrient Intake
436852|NCT00943436|Energy and Macronutrient intake
436853|NCT00943436|Exercise and Energy Balance
436854|NCT00943423|stage I adult Hodgkin lymphoma
436855|NCT00943423|stage II adult Hodgkin lymphoma
436856|NCT00943410|HER2-positive breast cancer
436857|NCT00943410|inflammatory breast cancer
436858|NCT00943410|recurrent breast cancer
436859|NCT00943410|stage IIIA breast cancer
436860|NCT00943410|stage IIIB breast cancer
436861|NCT00943410|stage IIIC breast cancer
436862|NCT00943410|stage IV breast cancer
436863|NCT00943358|influenza
436864|NCT00943358|immunogenicity
436865|NCT00943358|vaccine
436866|NCT00943345|GI
436867|NCT00943345|gastrointestinal
436868|NCT00943345|permeability
436869|NCT00943345|indometacin
436870|NCT00943345|indomethacin
436871|NCT00943345|coeliac
436872|NCT00943332|Orthopedic Procedures
436873|NCT00943332|Fracture Fixation, Internal
436874|NCT00943332|Fracture Fixation, External
436875|NCT00943332|femur fracture
436876|NCT00943332|pediatrics
436877|NCT00943319|Cancers of the blood
436878|NCT00943306|Homozygous
436879|NCT00943306|Familial
436880|NCT00943306|Hypercholesterolemia
436881|NCT00943306|MTP
436882|NCT00943306|Apheresis
436883|NCT00943306|lomitapide
436884|NCT00943306|Homozygous Familial Hypercholesterolemia (HoFH)
436885|NCT00943293|GVHD
436886|NCT00943280|probability of patient participation in each of the Groups 1, 2 and 3.
436887|NCT00943280|Identification of factors predicting poor participation in screening for Barrett's esophagus.
436888|NCT00943267|Activated Protein C
436889|NCT00943267|Lipopolysaccharides
436890|NCT00943267|Inflammation, Pulmonary
436891|NCT00943254|Metabolic Cardiovascular Syndrome
436892|NCT00943241|Breast
436893|NCT00943241|Breast Cancer
436894|NCT00943241|MBI
436895|NCT00943241|Molecular Breast Imaging
436896|NCT00943241|Molecular Imaging
436897|NCT00943228|Renal transplantation
436898|NCT00943228|Adequate exposure
436899|NCT00943228|Acute rejection
436900|NCT00943228|mycophenolate mofetil
436901|NCT00943228|immunosuppression
436902|NCT00943215|CALERIE II Follow-up
436903|NCT00943202|H1N1, influenza A viruses, TIV, vaccine, infants, children
436904|NCT00943189|Fetal anomalies scan at the time of NT study
436905|NCT00943176|Fatigue
436906|NCT00943163|cyclorotation
436907|NCT00943163|pupil
436908|NCT00943163|laser refractive surgery
436909|NCT00943150|Abdominoplasty
436910|NCT00943150|PlasmaBlade
436911|NCT00943150|Electrosurgery
436912|NCT00943150|PEAK Surgical
436913|NCT00943150|Medtronic Advanced Energy
436914|NCT00943150|Medtronic
436915|NCT00943111|Gaucher disease,
436916|NCT00943111|Genz-112638,
436917|NCT00943111|beta-glucosidase,
436918|NCT00943111|acid ß-glucosidase,
436919|NCT00943111|glucocerebrosidase,
436920|NCT00943111|glucosylceramide,
436921|NCT00943111|D-glucosyl-N-acylsphingosine glucohydrolase,
436922|NCT00943111|substrate reduction therapy
436923|NCT00943085|Early Signs of Bipolar Disorder
436924|NCT00943085|High Risk Youth
436925|NCT00943085|Adolescence
436926|NCT00943085|Childhood
436927|NCT00943072|Macular edema
436928|NCT00943072|Retinal vein occlusion
436929|NCT00943072|CRVO
436930|NCT00943072|VEGF Trap-Eye
436931|NCT00943072|best-corrected visual acuity
436932|NCT00943072|Regeneron
436933|NCT00943072|COPERNICUS
436934|NCT00943059|Mitochondrial function
436935|NCT00943059|Diabetes
436936|NCT00943059|Cardiomyopathy
436937|NCT00943059|insulin resistance
436938|NCT00943059|lipid lowering
436939|NCT00943059|triglycerides
436940|NCT00943059|Acipimox
436941|NCT00943046|leads
436942|NCT00943046|pacemaker
436943|NCT00943046|efficacy
436944|NCT00943046|safety
436945|NCT00943033|MBCT
436946|NCT00943033|Mindfulness-Based Cognitive Therapy
436947|NCT00943033|Mindfulness
436948|NCT00943033|Meditation
436949|NCT00943033|Relapse Prevention
436950|NCT00943033|Recurrent Depression
436951|NCT00943033|Depression
436952|NCT00943033|Major Depressive Disorder
436953|NCT00943020|Dietary supplement
436954|NCT00943020|Carbohydrate loading
436955|NCT00943020|Healthy volunteers
436956|NCT00943020|Anaesthesia
436957|NCT00943020|Surgery
436958|NCT00943020|Glutamine
436959|NCT00942994|Hypertension
436960|NCT00942994|Aliskiren
436961|NCT00942994|Amlodipine
436962|NCT00942994|HCTZ
436963|NCT00942994|Systolic blood pressure
436964|NCT00942994|Diastolic blood pressure
436965|NCT00942994|Stage II
436966|NCT00942994|Combination
436967|NCT00942981|PET Study
436968|NCT00942981|(18F) Fallypride
436969|NCT00942981|(11C)NNC-112
436970|NCT00942981|Schizoaffective Disorder
436971|NCT00942981|Schizophrenia
436972|NCT00942981|Healthy Volunteer
436973|NCT00942981|HV
436974|NCT00941889|HIV
436975|NCT00941889|HPV
436976|NCT00941889|Anal condylomata
436977|NCT00941889|Vaccine
436978|NCT00941889|HIV positive patients
436979|NCT00941889|Anal condylomata or anal warts
436980|NCT00941876|AE
436981|NCT00941876|adverse event
436982|NCT00941876|AIDS
436983|NCT00941876|acquired immunodeficiency syndrome
436984|NCT00941876|ALT (SGPT)
436985|NCT00941876|alanine aminotransferase
436986|NCT00941876|ART
436987|NCT00941876|antiretroviral therapy
436988|NCT00941876|AST (SGOT)
436989|NCT00941876|aspartate aminotransferase
436990|NCT00941876|DCF
436991|NCT00941876|data collection forms
436992|NCT00941876|DMC
436993|NCT00941876|Data Monitoring Committee
436994|NCT00941876|FDA
436995|NCT00941876|(U.S.) Food and Drug Administration
436996|NCT00941876|GCP
436997|NCT00941876|Good Clinical Practice guidelines
436998|NCT00941876|HB sAg
436999|NCT00941876|Hepatitis B surface antigen
437000|NCT00941876|ICH
437001|NCT00941876|International Conference of Harmonisation
437002|NCT00941876|IND
437003|NCT00941876|Investigational New Drug Application
437004|NCT00941876|IRB
437005|NCT00941876|Institutional Review Board
437006|NCT00941876|IU
437007|NCT00941876|International units
437008|NCT00941876|mg
437009|NCT00941876|milligram(s)
437010|NCT00941876|mm3
437011|NCT00941876|cubic millimeter(s)
437012|NCT00941876|PCR
437013|NCT00941876|polymerase chain reaction
437014|NCT00941876|SAE
437015|NCT00941876|serious adverse event
437016|NCT00941876|µg
437017|NCT00941876|microgram
437018|NCT00941876|ULN
437019|NCT00941876|upper limit of the normal range
437020|NCT00941876|WB
437021|NCT00941876|Western Blot
437022|NCT00941876|To inform the Ministry of Health strategy for integrating FP and HIV/AIDS Care and Treatment Services in Tanzania
437023|NCT00941876|HIV seronegativity
437024|NCT00941863|Sorafenib
437025|NCT00941863|Advanced Solid Tumors
437026|NCT00941863|Maximum tolerated dose
437027|NCT00941863|Carboplatin and paclitaxel chemotherapy combination
437028|NCT00941850|Cardiac resynchronizton therapy
437029|NCT00941850|CRT
437030|NCT00941850|Heart failure
437031|NCT00941850|Dyssynchrony
437032|NCT00941850|Echocardiography
437033|NCT00941850|Pacemakers
437034|NCT00941850|Nonresponders
437035|NCT00942929|anorexia nervosa
437036|NCT00942929|adolescents
437037|NCT00942929|lung function tests
437038|NCT00942929|refeeding
437039|NCT00942916|Make sure the difference of the serum inflammatory marker between the two groups
437040|NCT00942903|HME
437041|NCT00942903|Provox
437042|NCT00942903|voice prosthesis
437043|NCT00942903|laryngectomy
437044|NCT00942890|Case Management
437045|NCT00942890|Amputation
437046|NCT00942890|Muscle strength
437047|NCT00942890|phantom limb pain
437048|NCT00942877|VEGF
437049|NCT00942877|Antiangiogenesis
437050|NCT00942877|Tyrosine Kinase Inhibitor
437051|NCT00942877|Advanced Cancer
437052|NCT00942877|Alveolar Soft Part Sarcoma
437053|NCT00942877|Sarcoma
437054|NCT00942851|Dystonia
437055|NCT00942851|Blepharospasm
437056|NCT00942851|Botulinum Toxin
437057|NCT00942851|Treatment
437058|NCT00942851|Clinical Trial
437059|NCT00942851|Focal Dystonia
437060|NCT00942838|Recurrent Ovarian Carcinoma
437061|NCT00942838|Cancer
437062|NCT00942825|NSCL
437063|NCT00942825|non-squamous non small cell lung cancer
437064|NCT00942825|Lung Cancer
437065|NCT00942825|Lung
437066|NCT00942825|non-squamous
437067|NCT00942825|metastatic
437068|NCT00942825|pleural effusion
437069|NCT00942825|Stage IIIb
437070|NCT00942825|Stage IV
437071|NCT00942825|NSCLC
437072|NCT00942812|Children
437073|NCT00942812|Recovery
437074|NCT00942812|Diarrhea Pack
437075|NCT00942812|Social Marketing
437076|NCT00942799|Genz-644282
437077|NCT00942799|Topoisomerase I inhibitors
437078|NCT00942799|Top1
437079|NCT00942799|solid tumors
437080|NCT00942799|dose-escalation
437081|NCT00942799|pharmacokinetic (PK)
437082|NCT00942799|MTD (Maximum Tolerated Dose)
437083|NCT00942799|oncology
437084|NCT00942799|cancer
437085|NCT00942786|natriuretic peptides
437086|NCT00942786|emergency non-cardiac surgery
437087|NCT00942773|Healthy volunteer
437088|NCT00942747|temsirolimus, primary CNS lymphoma, PCNSL, salvage treatment
437089|NCT00942734|Head and Neck
437090|NCT00942734|Squamous Cell Carcinoma
437091|NCT00942734|RAD001
437092|NCT00942734|Erlotinib
437093|NCT00942734|Everolimus
437094|NCT00942734|OSI-774
437095|NCT00942734|Tarceva
437096|NCT00942721|Web-based Intervention
437097|NCT00942721|CBT Treatment
437098|NCT00942708|Pulmonary Arterial Hypertension
437099|NCT00942708|Pulmonary Hypertension
437100|NCT00942695|pistachio
437101|NCT00942695|nuts
437102|NCT00942695|energy value
437103|NCT00942695|cardiovascular disease
437104|NCT00942695|phytonutrient
437105|NCT00942695|gene expression
437106|NCT00942695|energy value of pistachio nuts
437107|NCT00942682|sorafenib
437108|NCT00942682|RAD001
437109|NCT00942669|Sleep Apnea Syndrome
437110|NCT00942669|SAS
437111|NCT00942669|SleepStrip OTC
437112|NCT00942656|trans fatty acids
437113|NCT00942656|ruminant
437114|NCT00942656|cardiovascular disease
437115|NCT00942630|percutaneous
437116|NCT00942630|transhepatic
437117|NCT00942630|biliary
437118|NCT00942630|drainage
437119|NCT00942630|cholangioscopy
437120|NCT00942617|platelet aggregation
437121|NCT00942617|granule secretion
437122|NCT00942617|thromboxane production
437123|NCT00942617|cyclooxygenase-1
437124|NCT00942617|ATP release
437125|NCT00942617|aspirin resistance
437126|NCT00942617|platelet activation
437127|NCT00942617|flow cytometry
437128|NCT00942617|Platelet aggregation in healthy volunteers
437129|NCT00942604|Peplin
437130|NCT00942604|Actinic keratosis
437131|NCT00942604|PEP005
437132|NCT00942591|multiple sclerosis
437133|NCT00942591|interferon beta
437134|NCT00942591|atorvastatin
437135|NCT00942578|Dual Antiangiogenic Combination Therapy for mCRPC
437136|NCT00942578|Efficacy and Toxicity Profile
437137|NCT00942578|Single Stage Phase 2 With Early Stopping, Run In Phase For Toxicity
437138|NCT00942578|Correlative Measurements
437139|NCT00942578|Overall Survival Assessment
437140|NCT00942578|Metastatic Prostate Cancer
437141|NCT00942578|Prostate Cancer
437142|NCT00942565|Open gynecological surgery
437143|NCT00942539|Neonates
437144|NCT00942526|esophageal cancer
437145|NCT00942526|anastomotic leakage
437146|NCT00942526|Prevention of anastomotic leakage after esophageal surgery
437147|NCT00942513|substrate absorption
437148|NCT00942513|substrate oxidation
437149|NCT00942513|glucose regulation
437150|NCT00942513|whey protein
437151|NCT00942513|soy protein
437152|NCT00942513|sucrose
437153|NCT00942513|fructose
437154|NCT00942513|lactose
437155|NCT00942500|Post-conditioning
437156|NCT00942500|ST-elevation myocardial infarction
437157|NCT00942500|Angioplasty, Transluminal, Percutaneous Coronary
437158|NCT00942487|arterial hypertension
437159|NCT00942474|The focus of the study is to assess the ability of the nerve access tool to facilitate nerve lead placement
437160|NCT00942461|a-defensins
437161|NCT00942461|TLRs
437162|NCT00942461|Inflammatory Cytokines
437163|NCT00942461|CRP
437164|NCT00942461|No metastases
437165|NCT00942461|No other obvious inflammation
437166|NCT00942461|No chronic diseases
437167|NCT00942435|YM150
437168|NCT00942435|Bleeding
437169|NCT00942435|VTE
437170|NCT00942435|FXa inhibitor
437171|NCT00942435|Deep Vein Thrombosis
437172|NCT00942435|Venous thromboembolism
437173|NCT00942422|monoclonal gammopathy of undetermined significance
437174|NCT00942422|smoldering multiple myeloma
437175|NCT00942396|Mammography
437176|NCT00942383|liver tumor
437177|NCT00942383|liver tumors
437178|NCT00942383|liver cancer
437179|NCT00942383|hepatocellular carcinoma
437180|NCT00942383|metastatic colorectal cancer
437181|NCT00942383|metastatic cancer to the liver
437182|NCT00942383|metastatic cancer
437183|NCT00942383|metastatic neuroendocrine cancer
437184|NCT00942383|liver
437185|NCT00942383|liver surgery
437186|NCT00942383|radiofrequency ablation
437187|NCT00942383|microwave ablation
437188|NCT00942370|mechanography
437189|NCT00942370|electromyography
437190|NCT00942370|effort cough
437191|NCT00942344|Amlodipine
437192|NCT00942344|Losartan
437193|NCT00942344|Hypertension
437194|NCT00942318|Type 2 Diabetes Mellitus
437195|NCT00942318|Continuous subcutaneous insulin infusion
437196|NCT00942318|Insulin external pump
437197|NCT00942318|Multiple daily injections
437198|NCT00942318|Basal-bolus regimen
437199|NCT00942318|Education
437200|NCT00942305|Allogeneic stem cell transplant
437201|NCT00942305|CMV seropositive (R+)
437202|NCT00942305|transplant
437203|NCT00942305|Allogeneic stem cell transplant recipients who were CMV seropositive (R+) at the time of transplant will be eligible for enrollment
437204|NCT00942292|Hepatic
437205|NCT00942292|colorectal
437206|NCT00942292|metastases
437207|NCT00942292|TPN
437208|NCT00942292|Fish oil
437209|NCT00942253|RLS
437210|NCT00942253|Muscle
437211|NCT00942253|Dialysis
437212|NCT00942253|exercise
437213|NCT00942253|dopamine agonist
437214|NCT00942253|Sleep
437215|NCT00942227|Sciatica
437216|NCT00942227|Radiculopathy
437217|NCT00942227|Physical therapy modalities
437218|NCT00942227|Rehabilitation
437219|NCT00942214|Multiple sclerosis
437220|NCT00942214|natalizumab
437221|NCT00942214|pharmacogenomics
437222|NCT00942201|Asthma
437223|NCT00942201|Dexamethasone
437224|NCT00942201|Emergency Department
437225|NCT00942188|Diabetes
437226|NCT00942188|Type 2 Diabetes
437227|NCT00942175|Pharmacology
437228|NCT00942175|Stomach Ulcer
437229|NCT00942175|Esophagitis, Peptic
437230|NCT00942175|Zollinger-Ellison Syndrome
437231|NCT00942175|Platelet function
437232|NCT00942175|PPI
437233|NCT00942175|clopidogrel
437234|NCT00942175|Pharmacokinetics and Pharmacodynamics
437235|NCT00942162|PREDICT
437236|NCT00942162|ASCI
437237|NCT00942162|Tumor antigen
437238|NCT00942162|Melanoma
437239|NCT00942162|Immunotherapeutic
437240|NCT00942149|Infants
437241|NCT00942149|Daptomycin
437242|NCT00942136|HIV
437243|NCT00942136|GSK1349572
437244|NCT00942136|omeprazole
437245|NCT00942136|Prilosec
437246|NCT00942136|supratherapeutic dose
437247|NCT00942136|pharmacokinetics
437248|NCT00942136|drug interaction
437249|NCT00942136|HIV Infections
437250|NCT00942110|Postprandial glucose, lipid metabolism
437251|NCT00942110|humoral factors
437252|NCT00942097|Homeopathy
437253|NCT00942097|overweight
437254|NCT00942097|obesity
437255|NCT00942097|mental disorder
437256|NCT00942097|pregnancy
437257|NCT00942097|Overweight pregnant women with suspicious mental disorder
437258|NCT00942084|HSV
437259|NCT00942084|Acyclovir
437260|NCT00942084|Pharmacokinetics
437261|NCT00942084|Neonate
437262|NCT00942084|Premature
437263|NCT00942084|Sepsis
437264|NCT00942071|Influenza
437265|NCT00942071|Vaccine
437266|NCT00942058|biological markers
437267|NCT00942058|CA9 protein
437268|NCT00942058|metastatic conventional renal cell cancer
437269|NCT00942058|kidney cancer
437270|NCT00942045|cervical spine
437271|NCT00942045|ACDF
437272|NCT00942045|biologics
437273|NCT00942045|fusion rates
437274|NCT00942019|BMI
437275|NCT00942019|obesity
437276|NCT00942019|CO
437277|NCT00942019|tobacco smoking
437278|NCT00942019|adolescents
437279|NCT00942006|Lyme neuroborreliosis
437280|NCT00942006|Lyme borreliosis
437281|NCT00942006|erythema migrans
437282|NCT00942006|doxycycline treatment
437283|NCT00942006|ceftriaxone treatment
437284|NCT00942006|outcome
437285|NCT00942006|subjective symptoms
437286|NCT00941980|biologics
437287|NCT00941980|fusion rates
437288|NCT00941980|PLIF
437289|NCT00941980|lumbar fusion
437290|NCT00941967|adult primary hepatocellular carcinoma
437291|NCT00941967|localized unresectable adult primary liver cancer
437292|NCT00941967|recurrent adult primary liver cancer
437293|NCT00941967|advanced adult primary liver cancer
437294|NCT00941954|Physical activity
437295|NCT00941954|Diabetes
437296|NCT00941954|Prevention
437297|NCT00941954|Pedometer
437298|NCT00941954|Walking
437299|NCT00941954|Structured education
437300|NCT00941954|Randomized
437301|NCT00941954|Risk score
437302|NCT00941954|Impaired glucose regulation
437303|NCT00941941|Inguinal
437304|NCT00941941|Hernia
437305|NCT00941941|Hernia-repair
437306|NCT00941941|Non-mesh
437307|NCT00941941|Mesh
437308|NCT00941941|Desarda
437309|NCT00941941|Lichtenstein
437310|NCT00941928|Blood And Marrow Transplantation
437311|NCT00941928|Relapsed Acute Lymphoblastic Leukemia
437312|NCT00941928|ALL
437313|NCT00941928|Leukemia
437314|NCT00941928|Pediatrics
437315|NCT00941928|Haploidentical NK cells
437316|NCT00941928|Cyclophosphamide
437317|NCT00941928|Cytoxan
437318|NCT00941928|Neosar
437319|NCT00941928|Epratuzumab
437320|NCT00941928|Fludarabine
437321|NCT00941928|Fludarabine Phosphate
437322|NCT00941928|Fludara
437323|NCT00941928|Interleukin-2
437324|NCT00941928|IL-2
437325|NCT00941928|Proleukin
437326|NCT00941928|Low-dose interleukin
437327|NCT00941928|Mesna
437328|NCT00941928|Mesnex
437329|NCT00941928|Natural Killer Cells
437330|NCT00941928|NK Cells Transplant
437331|NCT00941915|CaP
437332|NCT00941915|SBRT
437333|NCT00941915|Prostate
437334|NCT00941915|ExacTrac
437335|NCT00941915|Calypso
437336|NCT00941915|IMRT
437337|NCT00941915|Radiation
437338|NCT00941915|Cancer of Prostate
437339|NCT00941915|Prostatic Neoplasms
437340|NCT00941902|human asialoglycoprotein receptor (ASGPR)
437341|NCT00941902|hepatocytes
437342|NCT00941902|bariatric surgery
437343|NCT00941837|Palm olein
437344|NCT00941837|homocsyteine
437345|NCT00941837|Cholesterol
437346|NCT00941837|lipoproteins
437347|NCT00941837|Interleukins
437348|NCT00941837|CRP
437349|NCT00941837|Blood Pressure
437350|NCT00941837|Total homocystein
437351|NCT00941837|Serum lipid profile
437352|NCT00941837|Serum apolipoproteins
437353|NCT00941837|Inflammatory markers
437354|NCT00941824|pharmacokinetic
437355|NCT00941824|mycophénolate acid
437356|NCT00941824|kidney transplantation
437357|NCT00941798|Asthma
437358|NCT00941798|LABA
437359|NCT00941798|Safety
437360|NCT00941785|Malaria
437361|NCT00941785|Intermittent Preventive Treatment
437362|NCT00941785|IPTc
437363|NCT00941785|sIPTc
437364|NCT00941785|Burkina Faso
437365|NCT00941772|Nasogastric tube verification with ultrasonography
437366|NCT00941772|ultrasonography
437367|NCT00941759|Breast
437368|NCT00941759|Blood and tissue collection
437369|NCT00941759|Epidemiologic
437370|NCT00941759|Questionnaire
437371|NCT00941759|TBCRC (Translational Breast Cancer Research Consortium)
437372|NCT00941759|09-056
437373|NCT00941733|BTK
437374|NCT00941733|CLI
437375|NCT00941733|PTA
437376|NCT00941720|stage I multiple myeloma
437377|NCT00941720|stage II multiple myeloma
437378|NCT00941720|stage III multiple myeloma
437379|NCT00941707|Rheumatoid Arthritis
437380|NCT00941707|JNJ-38518168
437381|NCT00941694|asthma
437382|NCT00941694|aged
437383|NCT00941694|self care
437384|NCT00941681|omecamtiv mecarbil
437385|NCT00941655|Gastric Carcinoma
437386|NCT00941655|Chemotherapy
437387|NCT00941655|Liver Tumors
437388|NCT00941655|Peritoneal Tumors
437389|NCT00941655|Metastatic Gastric Cancer
437390|NCT00941655|Stomach Cancer
437391|NCT00941655|Gastric Cancer
437392|NCT00941642|Nonalcoholic Fatty Liver Disease (NAFLD)
437393|NCT00941642|Lovaza
437394|NCT00941642|Steatosis
437395|NCT00941642|Non-Alcoholic steatohepatitis (NASH)
437396|NCT00941629|PTSD
437397|NCT00941629|Telemedicine
437398|NCT00941629|Clinical Trial
437399|NCT00941629|Psychotherapy
437400|NCT00941616|Von Willebrand Disease
437401|NCT00941590|tick borne encephalitis
437402|NCT00941590|clinical outcome
437403|NCT00941590|postencephalitic symptoms
437404|NCT00941577|Hypersensitivity
437405|NCT00941577|Lung Diseases, Obstructive
437406|NCT00941577|Immune System Diseases
437407|NCT00941577|Respiratory Tract Diseases
437408|NCT00941577|Bronchial Diseases
437409|NCT00941577|Lung Diseases
437410|NCT00941577|Hypersensitivity, Immediate
437411|NCT00941577|Asthma
437412|NCT00941577|Respiratory Hypersensitivity
437413|NCT00941551|Thyroid lobectomy,
437414|NCT00941551|prophylactic levothyroxine treatment,
437415|NCT00941551|recurrent nodular goiter,
437416|NCT00941551|iodine deficiency,
437417|NCT00941551|long-term follow-up,
437418|NCT00941551|completion thyroidectomy
437419|NCT00941538|nasopharyngeal cancer
437420|NCT00941538|screening
437421|NCT00941538|biomarker
437422|NCT00941538|early detection
437423|NCT00941538|epidemiological survey
437424|NCT00941525|Central corneal thickness
437425|NCT00941525|24hour fluctuation of intraocular pressure
437426|NCT00941525|Open angle glaucoma
437427|NCT00941525|Ocular hypertension
437428|NCT00941512|Colposcopy
437429|NCT00941499|Advanced Cancers
437430|NCT00941499|Liver
437431|NCT00941499|Oxaliplatin
437432|NCT00941499|Eloxatin
437433|NCT00941499|Bevacizumab
437434|NCT00941499|Avastin
437435|NCT00941499|Anit-VEGF monoclonal antibody
437436|NCT00941499|rhuMAb-VEGF
437437|NCT00941499|5-fluorouracil
437438|NCT00941499|5-FU
437439|NCT00941499|Adrucil
437440|NCT00941499|Efudex
437441|NCT00941499|Leucovorin
437442|NCT00941499|Citrovorum
437443|NCT00941499|Wellcovorin
437444|NCT00941499|Cetuximab
437445|NCT00941499|C225
437446|NCT00941499|Erbitux
437447|NCT00941499|IMC-C225
437448|NCT00941473|Epidural Injection
437449|NCT00941473|Bone Density
437450|NCT00941460|progressive or recurrent glioblastoma
437451|NCT00941460|temozolomide
437452|NCT00941460|dose intensification
437453|NCT00941460|comparison of two dosing regimens
437454|NCT00941447|Type 2 Diabetes
437455|NCT00941447|Obesity
437456|NCT00941447|Self-Regulation
437457|NCT00941447|Self-Efficacy
437458|NCT00941434|RUTF
437459|NCT00941434|SAM
437460|NCT00941434|Nutributter
437461|NCT00941395|Cancer Prevention
437462|NCT00941395|College students
437463|NCT00941395|Prevention intervention
437464|NCT00941395|Smoking
437465|NCT00941395|Tobacco
437466|NCT00941395|Internet-based
437467|NCT00941395|Cognitive Behavioral Therapy
437468|NCT00941395|Nicotine lozenges
437469|NCT00941382|sibutramine
437470|NCT00941382|metformin
437471|NCT00941382|obesity
437472|NCT00941356|MRSA nasal colonisation
437473|NCT00941356|Probiotics
437474|NCT00941330|Breast, Male
437475|NCT00941330|Breast, Female
437476|NCT00941317|onychomycosis
437477|NCT00941317|micro-drilling
437478|NCT00941291|idiopathic macular hole
437479|NCT00941291|cataract
437480|NCT00941291|edema
437481|NCT00941291|Reopening
437482|NCT00941265|treatment of anomia
437483|NCT00941265|levodopa
437484|NCT00941265|"patient with aphasia hospitalised at the Service de neurorehabilitation with presence of anomia"
437485|NCT00941239|Metformin ER
437486|NCT00941239|Pharmacokinetics
437487|NCT00941239|Tolerability
437488|NCT00941239|Healthy volunteers
437489|NCT00941226|Cerebral Palsy
437490|NCT00941226|Caregivers
437491|NCT00941226|Quality of Life
437492|NCT00941213|fractures of vertebral bodies Th10-L2
437493|NCT00941213|(AO A1 with kyphosis, A2.3, B or C-type)
437494|NCT00941187|pulmonary embolism
437495|NCT00941187|pulmonary capillary blood volume
437496|NCT00941187|double diffusion NO/CO method
437497|NCT00941174|(13C5) Calcium Leucovorin
437498|NCT00941174|Folate absorption across the large intestine
437499|NCT00941174|Folate Bioavailability
437500|NCT00941122|MRSA, VRE
437501|NCT00941109|MDS
437502|NCT00941096|Glaucoma
437503|NCT00941096|Ocular Hypertension
437504|NCT00941096|Lumigan
437505|NCT00941096|Ganfort
437506|NCT00941083|Simplification from protease inhibitors to raltegravir
437507|NCT00941083|Treatment Experienced
437508|NCT00941083|HIV-1 Infections
437509|NCT00941044|non-invasive ventilation
437510|NCT00941044|diaphragm
437511|NCT00941044|electrical activity
437512|NCT00941044|neurally adjusted ventilatory assist
437513|NCT00941044|volunteers
437514|NCT00941031|Moderate to severe chronic plaque-type psoriasis
437515|NCT00941031|AIN457
437516|NCT00941031|dermatology
437517|NCT00941018|Resolvins
437518|NCT00941018|RvE1
437519|NCT00941018|Healthy volunteers
437520|NCT00940979|Integuseal microbial sealant
437521|NCT00940979|Infection prophylaxis
437522|NCT00940979|Postoperative wound infection
437523|NCT00940979|Arterial bypass surgery
437524|NCT00940966|ADA diet
437525|NCT00940966|low carbohydrate diet
437526|NCT00940966|Metabolic syndrome
437527|NCT00940927|Albuterol
437528|NCT00940927|Forced expiratory volume in one second
437529|NCT00940927|Dose at fifty percent of maximum effect
437530|NCT00940927|Maximum effective dose
437531|NCT00940927|Metered dose inhaler
437532|NCT00940927|Nebulizer
437533|NCT00940914|Parkinson's disease
437534|NCT00940914|pain
437535|NCT00940914|dopamine transporters imaging
437536|NCT00940901|priapism
437537|NCT00940901|sickle cell disease
437538|NCT00940888|ICD
437539|NCT00940888|CRTD
437540|NCT00940888|Heart Failure
437541|NCT00940888|DF4
437542|NCT00940862|psoriasis
437543|NCT00940862|vascular inflammation
437544|NCT00940862|coronary atherosclerosis
437545|NCT00940836|Anti-cold
437546|NCT00940836|Cold preparation
437547|NCT00940836|RCT
437548|NCT00940823|Glaucoma Drainage Device
437549|NCT00940823|Aqueous Shunt Implant
437550|NCT00940823|Ahmed Valve
437551|NCT00940823|Baerveldt Tube
437552|NCT00940823|Refractory Glaucoma
437553|NCT00940797|diabetes
437554|NCT00940797|Type 2
437555|NCT00940797|monotherapy
437556|NCT00940797|antidiabetics
437557|NCT00940797|metformin
437558|NCT00940771|HIV
437559|NCT00940771|Lipids
437560|NCT00940771|Atazanavir
437561|NCT00940771|Pediatric
437562|NCT00940771|treatment experienced
437563|NCT00940745|HICH
437564|NCT00940745|Suction drainages
437565|NCT00940745|TTAC
437566|NCT00940732|Help-seeking
437567|NCT00940732|Mental Health
437568|NCT00940732|Athletes
437569|NCT00940719|Multiple Sclerosis
437570|NCT00940719|Regulatory T cell function
437571|NCT00940719|Vitamin D
437572|NCT00940719|Vitamin D3
437573|NCT00940719|25-hydroxyvitamin D
437574|NCT00940706|Cerebral Palsy
437575|NCT00940706|Activity monitoring
437576|NCT00940706|Treadmill
437577|NCT00940706|Group training
437578|NCT00940706|Physical active life style
437579|NCT00940693|Attention Deficit Disorder with Hyperactivity
437580|NCT00940693|Duloxetine
437581|NCT00940693|Adult
437582|NCT00940693|ADDH
437583|NCT00940693|ADHD
437584|NCT00940680|Amlodipine
437585|NCT00940680|Losartan
437586|NCT00940680|hypertension
437587|NCT00940667|Amlodipine
437588|NCT00940667|Losartan
437589|NCT00940667|hypertension
437590|NCT00940654|Fever
437591|NCT00940654|Antipyretic
437592|NCT00940654|Infection
437593|NCT00940654|Mortality
437594|NCT00940654|Cooling
437595|NCT00940654|Non steroid anti inflammatory drugs
437596|NCT00940654|Acetaminophen
437597|NCT00940654|Steroid
437598|NCT00940654|ICU
437599|NCT00940654|Intensive care
437600|NCT00940654|Critically ill
437601|NCT00940641|Healthy Volunteer
437602|NCT00940615|traumatic brain injury
437603|NCT00940615|aerobic exercise
437604|NCT00940615|Diffusion Tensor Imaging
437605|NCT00940615|Neuropsychology
437606|NCT00940615|Rehabilitation
437607|NCT00940602|TELESTO
437608|NCT00940602|MDS Study
437609|NCT00940602|Myelodysplastic Syndromes
437610|NCT00940602|Myelodysplastic Syndromes (low-int-1 risk)
437611|NCT00940589|Alzheimer's Disease
437612|NCT00940589|Acetylcholinesterase inhibitor
437613|NCT00940589|cognitive function
437614|NCT00940589|Circadin
437615|NCT00940589|Sleep disturbances
437616|NCT00940576|mare's milk, Crohn's disease, ulcerative colitis, clinical
437617|NCT00940563|GIST
437618|NCT00940563|imatinib
437619|NCT00940563|advanced GIST
437620|NCT00940537|Obese
437621|NCT00940537|MRS
437622|NCT00940537|hepatic triglyceride content
437623|NCT00940537|MR spectroscopy
437624|NCT00940524|Leukemia
437625|NCT00940524|ALL
437626|NCT00940524|ALLOPURINOL
437627|NCT00940524|CARMUSTINE (BCNU)
437628|NCT00940524|CYCLOPHOSPHAMIDE (CYTOXAN)
437629|NCT00940524|CYTARABINE (ARA-C)
437630|NCT00940524|DACTINOMYCIN
437631|NCT00940524|DASATINIB
437632|NCT00940524|DEXAMETHASONE
437633|NCT00940524|DOXORUBICIN/ADRIAMYCIN
437634|NCT00940524|ETOPOSIDE (VP-16)
437635|NCT00940524|MERCAPTOPURINE
437636|NCT00940524|METHOTREXATE
437637|NCT00940524|MITOXANTRONE
437638|NCT00940524|PEGASPERGASE
437639|NCT00940524|VINCRISTINE
437640|NCT00940511|All conditions faced by disabled Medicaid recipients
437641|NCT00940498|Phase 1
437642|NCT00940498|Dose Finding
437643|NCT00940498|Solid Tumors
437644|NCT00940498|Tumors
437645|NCT00940498|PF-05212384
437646|NCT00940472|type 2 diabetes
437647|NCT00940472|monotherapy
437648|NCT00940472|antidiabetics
437649|NCT00940472|metformin
437650|NCT00940459|contact lenses
437651|NCT00940459|conjunctival staining
437652|NCT00940459|contact lens wear
437653|NCT00940446|Insorb staples
437654|NCT00940446|Metal Staples
437655|NCT00940433|Minimally invasive
437656|NCT00940433|Inguinal hernia
437657|NCT00940433|Pro-peritoneal repair
437658|NCT00940407|dry AMD
437659|NCT00940407|light treatment
437660|NCT00940407|ARMD
437661|NCT00940407|photobiomodulation
437662|NCT00940407|macular
437663|NCT00940407|eye disease
437664|NCT00940407|ageing eye disease
437665|NCT00940394|mutual support group
437666|NCT00940394|psychoeducation group
437667|NCT00940394|family caregivers
437668|NCT00940394|schizophrenia
437669|NCT00940381|Advanced Malignancies
437670|NCT00940381|Sirolimus
437671|NCT00940381|Rapamune
437672|NCT00940381|Cetuximab
437673|NCT00940381|C225
437674|NCT00940381|Erbitux
437675|NCT00940381|IMC-225
437676|NCT00940368|Nausea
437677|NCT00940368|Vomiting
437678|NCT00940368|Chemotherapy
437679|NCT00940355|COPD
437680|NCT00940355|Health Status
437681|NCT00940355|Intervention
437682|NCT00940355|Secondary prevention
437683|NCT00940355|patient-tailored treatment
437684|NCT00940342|Chronic Lymphocytic Leukemia
437685|NCT00940342|Rituximab
437686|NCT00940342|Leukemia
437687|NCT00940342|Sargramostim
437688|NCT00940342|GM-CSF
437689|NCT00940329|Drug interactions
437690|NCT00940329|Pharmacodynamic interactions
437691|NCT00940329|Pharmacokinetic interactions
437692|NCT00940329|Formoterol
437693|NCT00940329|Healthy subjects
437694|NCT00940329|Phase I study
437695|NCT00940329|Roflumilast
437696|NCT00940316|recurrent colon cancer
437697|NCT00940316|stage IV colon cancer
437698|NCT00940316|recurrent rectal cancer
437699|NCT00940316|stage IV rectal cancer
437700|NCT00940290|practice guideline as topic
437701|NCT00940290|decision making
437702|NCT00940290|evidence based medicine
437703|NCT00940277|women couples counseling groups support intervention marriage
437704|NCT00940264|symptomatic cholecystolithiasis
437705|NCT00940251|Ayurvedic formulation
437706|NCT00940251|type 2 diabetes mellitus
437707|NCT00940251|secondary failure to oral hypoglycemic agents
437708|NCT00940251|antidiabetic
437709|NCT00940225|Breast Cancer
437710|NCT00940225|Melanoma
437711|NCT00940225|Stomach or Gastroesophageal Junction Carcinoma
437712|NCT00940225|Hepatocellular Carcinoma (HCC)
437713|NCT00940225|Small Cell Lung Cancer (SCLC)
437714|NCT00940225|Non-Small Cell Lung Cancer (NSCLC)
437715|NCT00940225|Ovarian Cancer
437716|NCT00940225|Pancreatic Cancer
437717|NCT00940225|Prostate Cancer
437718|NCT00940212|Safety
437719|NCT00940212|tolerability
437720|NCT00940212|healthy
437721|NCT00940212|pharmacokinetics
437722|NCT00940199|Breast cancer, sentinel lymph node mapping, biopsy
437723|NCT00940173|xenotransplantation
437724|NCT00940173|type I diabetes
437725|NCT00940173|porcine islets
437726|NCT00940160|Asthma
437727|NCT00940134|obesity
437728|NCT00940134|energy expenditure
437729|NCT00940134|incretins
437730|NCT00940134|appetite regulation
437731|NCT00940134|GLP-1
437732|NCT00940134|PYY
437733|NCT00940134|ad libitum energy intake
437734|NCT00940121|Healthy volunteer subjects
437735|NCT00940121|pharmacokinetics
437736|NCT00940121|YM178
437737|NCT00940121|mirabegron
437738|NCT00940121|IV infusion
437739|NCT00940121|oral administration
437740|NCT00940095|Aneurysmal
437741|NCT00940095|Subarachnoid
437742|NCT00940095|Hemorrhage
437743|NCT00940095|vasospasm
437744|NCT00940095|clazosentan
437745|NCT00940095|PIVLAZ
437746|NCT00940095|Actelion
437747|NCT00940095|surgical clipping
437748|NCT00940082|Diabetes;
437749|NCT00940082|Echocardiography;
437750|NCT00940082|High-sensitive C-reactive protein;
437751|NCT00940082|homocysteine;
437752|NCT00940082|TNF-α
437753|NCT00940069|TS
437754|NCT00940069|polymorphism
437755|NCT00940069|lung cancer
437756|NCT00940069|adenocarcinoma
437757|NCT00940069|pemetrexed
437758|NCT00940056|Atrial fibrillation
437759|NCT00940056|Ablation
437760|NCT00940056|Thoracoscopy
437761|NCT00940056|Atrial function
437762|NCT00940043|bedside test
437763|NCT00940043|interleukins
437764|NCT00940043|inflammation
437765|NCT00940043|vaginal secretions
437766|NCT00940030|Mechanical Bowel Preparation (MBP)
437767|NCT00940030|enema
437768|NCT00940017|PK
437769|NCT00940017|fungal infection
437770|NCT00940004|dendritic cell vaccination
437771|NCT00940004|melanoma
437772|NCT00940004|toll like receptor ligands
437773|NCT00940004|vaccines
437774|NCT00939991|GBM
437775|NCT00939965|localized unresectable neuroblastoma
437776|NCT00939965|recurrent neuroblastoma
437777|NCT00939965|stage 4S neuroblastoma
437778|NCT00939952|ertapenem
437779|NCT00939952|CAPD
437780|NCT00939952|dialysis
437781|NCT00939913|contrast nephropathy
437782|NCT00939913|intravenous n-acetlycysteine
437783|NCT00939900|avascular necrosis of femoral head
437784|NCT00939900|bisphosphonate
437785|NCT00939900|collapse
437786|NCT00939874|HIV+
437787|NCT00939874|Raltegravir
437788|NCT00939874|Tenofovir
437789|NCT00939874|osteopenia
437790|NCT00939874|osteoporosis
437791|NCT00939874|bone markers
437792|NCT00939874|treatment experienced
437793|NCT00939861|colorectal endometriosis, laparoscopy, laparotomy
437794|NCT00939861|gynecologic and digestive symptoms
437795|NCT00939861|quality of life (SF-36 questionnaire)
437796|NCT00939861|morbidity
437797|NCT00939861|fertility
437798|NCT00939848|Disease-Free Survival
437799|NCT00939770|unspecified childhood solid tumor, protocol specific
437800|NCT00939770|recurrent neuroblastoma
437801|NCT00939770|recurrent childhood anaplastic large cell lymphoma
437802|NCT00939770|recurrent childhood brain stem glioma
437803|NCT00939770|recurrent childhood cerebellar astrocytoma
437804|NCT00939770|recurrent childhood cerebral astrocytoma
437805|NCT00939770|recurrent childhood anaplastic astrocytoma
437806|NCT00939770|recurrent childhood anaplastic oligoastrocytoma
437807|NCT00939770|recurrent childhood anaplastic oligodendroglioma
437808|NCT00939770|recurrent childhood fibrillary astrocytoma
437809|NCT00939770|recurrent childhood gemistocytic astrocytoma
437810|NCT00939770|recurrent childhood giant cell glioblastoma
437811|NCT00939770|recurrent childhood glioblastoma
437812|NCT00939770|recurrent childhood gliomatosis cerebri
437813|NCT00939770|recurrent childhood gliosarcoma
437814|NCT00939770|recurrent childhood oligoastrocytoma
437815|NCT00939770|recurrent childhood oligodendroglioma
437816|NCT00939770|recurrent childhood pilocytic astrocytoma
437817|NCT00939770|recurrent childhood pilomyxoid astrocytoma
437818|NCT00939770|recurrent childhood pleomorphic xanthoastrocytoma
437819|NCT00939770|recurrent childhood protoplasmic astrocytoma
437820|NCT00939770|recurrent childhood subependymal giant cell astrocytoma
437821|NCT00939770|recurrent childhood visual pathway and hypothalamic glioma
437822|NCT00939770|recurrent childhood visual pathway glioma
437823|NCT00939770|recurrent childhood medulloblastoma
437824|NCT00939770|recurrent childhood ependymoma
437825|NCT00939770|recurrent childhood pineoblastoma
437826|NCT00939770|recurrent childhood supratentorial primitive neuroectodermal tumor
437827|NCT00939770|childhood choroid plexus tumor
437828|NCT00939770|childhood craniopharyngioma
437829|NCT00939770|childhood ependymoblastoma
437830|NCT00939770|childhood medulloepithelioma
437831|NCT00939770|childhood grade I meningioma
437832|NCT00939770|childhood grade II meningioma
437833|NCT00939770|childhood grade III meningioma
437834|NCT00939770|childhood central nervous system germ cell tumor
437835|NCT00939770|recurrent childhood spinal cord neoplasm
437836|NCT00939770|childhood infratentorial ependymoma
437837|NCT00939770|childhood supratentorial ependymoma
437838|NCT00939770|childhood high-grade cerebellar astrocytoma
437839|NCT00939770|childhood high-grade cerebral astrocytoma
437959|NCT00939172|TTP607
437840|NCT00939770|childhood low-grade cerebellar astrocytoma
437841|NCT00939770|childhood low-grade cerebral astrocytoma
437842|NCT00939770|childhood atypical teratoid/rhabdoid tumor
437843|NCT00939757|Healthy volunteer subjects
437844|NCT00939757|pharmacokinetics
437845|NCT00939757|YM178
437846|NCT00939757|mirabegron
437847|NCT00939757|food
437848|NCT00939744|contractile activity
437849|NCT00939744|eicosanoids
437850|NCT00939744|pregnant women
437851|NCT00939744|obstetrics complications
437852|NCT00939731|bioavailability, capsule, tablet, healthy volunteer
437853|NCT00939718|depression;vitamin B12;randomized control trial
437854|NCT00939679|obesity
437855|NCT00939679|bariatric surgery
437856|NCT00939679|energy expenditure
437857|NCT00939679|incretins
437858|NCT00939679|appetite regulation
437859|NCT00939679|body composition
437860|NCT00939679|GLP-1
437861|NCT00939666|Rectal cancer
437862|NCT00939666|Chemoradiation
437863|NCT00939666|Response
437864|NCT00939666|Wait-and-see policy
437865|NCT00939666|Transanal endoscopic microsurgery
437866|NCT00939653|relapsed
437867|NCT00939653|relapse
437868|NCT00939653|refractory
437869|NCT00939653|AML
437870|NCT00939653|Acute myelogenous leukemia
437871|NCT00939653|Relapsed AML
437872|NCT00939640|Diet
437873|NCT00939640|Sodium
437874|NCT00939640|Hypertension
437875|NCT00939640|Potassium
437876|NCT00939640|Antioxidants
437877|NCT00939640|congestive heart failure
437878|NCT00939640|Heart failure with normal ejection fraction
437879|NCT00939640|Heart failure with preserved systolic function
437880|NCT00939601|Obstructive Sleep Apnea
437881|NCT00939601|OSA
437882|NCT00939601|Adherence
437883|NCT00939601|CPAP
437884|NCT00939601|Cognition
437885|NCT00939588|Aliskiren,
437886|NCT00939588|hypertension,
437887|NCT00939588|renin-angiotensin-aldosterone system
437888|NCT00939575|preeclampsia, metabolomics, blood, urine
437889|NCT00939562|Bioequivalence
437890|NCT00939549|High dose cyclophosphamide
437891|NCT00939523|recurrent nonfunctioning adenoma
437892|NCT00939523|prolactinomas
437893|NCT00939523|resistant pituitary tumors
437894|NCT00939523|aggressive pituitary tumors
437895|NCT00939523|malignant pituitary adenomas
437896|NCT00939510|adenocarcinoma of the prostate
437897|NCT00939510|hormone-resistant prostate cancer
437898|NCT00939510|recurrent prostate cancer
437899|NCT00939510|stage IV prostate cancer
437900|NCT00939432|incontinence
437901|NCT00939432|urinary
437902|NCT00939432|taboo
437903|NCT00939432|shame
437904|NCT00939432|embarrassment
437905|NCT00939432|treatment
437906|NCT00939432|depression
437907|NCT00939432|cancer
437908|NCT00939419|Tuberculosis care
437909|NCT00939419|community tuberculosis care
437910|NCT00939419|Health facility based tuberculosis care
437911|NCT00939380|hematopoietic stem cell transplant
437912|NCT00939380|bone marrow transplant
437913|NCT00939380|children
437914|NCT00939380|parents
437915|NCT00939380|counseling
437916|NCT00939380|depression
437917|NCT00939354|Asthma in subjects over the age of 65
437918|NCT00939341|Symbicort SMART
437919|NCT00939328|B-cell chronic lymphocytic leukemia
437920|NCT00939328|refractory chronic lymphocytic leukemia
437921|NCT00939315|Glioma, diagnosis
437922|NCT00939315|Imaging
437923|NCT00939315|Positron emission tomography
437924|NCT00939315|Magnetic resonance imaging
437925|NCT00939315|Magnetic resonance spectroscopy
437926|NCT00939289|Continuous glucose monitoring
437927|NCT00939276|cataract surgery
437928|NCT00939276|macular edema
437929|NCT00939276|prevention
437930|NCT00939263|deglutition disorders
437931|NCT00939263|esophageal diseases
437932|NCT00939263|eosinophilia
437933|NCT00939250|Diabetes
437934|NCT00939250|Depression
437935|NCT00939250|Disease Self Management
437936|NCT00939250|Measurement Based Care
437937|NCT00939237|Coronary heart disease
437938|NCT00939237|Carotid intima-media thickness
437939|NCT00939237|Biomarkers
437940|NCT00939224|Near-infrared spectroscopy (NIRS)
437941|NCT00939224|Regional oxygen saturation
437942|NCT00939224|Pediatrics
437943|NCT00939224|Cardiac catheterization
437944|NCT00939224|Congenital heart disease
437945|NCT00939211|Chronic Obstructive Pulmonary Disease (COPD)
437946|NCT00939211|efficacy
437947|NCT00939211|safety
437948|NCT00939211|inhalation
437949|NCT00939211|long-acting muscarinic receptor antagonist (LAMA)
437950|NCT00939198|Hookworm
437951|NCT00939198|Allergy
437952|NCT00939198|Vaccine
437953|NCT00939198|Skin Test
437954|NCT00939198|Immediate-type hypersensitivity to Na-ASP-2 hookworm antigen
437955|NCT00939185|Compliance and Safety Study in Children with Upper and Lower Respiratory Tract Infections
437956|NCT00939172|Advanced Refractory Solid Malignancies
437957|NCT00939172|Solid tumor
437958|NCT00939172|Lymphoma
437960|NCT00939159|Low or Intermediate-1 Risk Myelodysplastic Syndrome
437961|NCT00939159|MDS
437962|NCT00939159|Cancer
437963|NCT00939159|LBH589
437964|NCT00939146|self management
437965|NCT00939146|quality of life
437966|NCT00939146|end of life
437967|NCT00939133|acne
437968|NCT00939133|tretinoin
437969|NCT00939133|isotretinoin
437970|NCT00939133|recurrence
437971|NCT00939133|Retin A micro
437972|NCT00939120|Benign prostatic hyperplasia (BPH)
437973|NCT00939120|dutasteride
437974|NCT00939120|tolterodine ER
437975|NCT00939107|low back pain
437976|NCT00939107|Intervertebral disc
437977|NCT00939107|McKenzie
437978|NCT00939107|Physical Therapy
437979|NCT00939107|Spinal manipulation
437980|NCT00939107|Chiropractics
437981|NCT00939107|Patient education
437982|NCT00939107|Exercise therapy
437983|NCT00939107|Random allocation
437984|NCT00939094|Pain, Mechanical Hypersensitivity
437985|NCT00939094|Allodynia
437986|NCT00939094|Efficacy
437987|NCT00939094|analgesia
437988|NCT00939094|Neuropathic
437989|NCT00939081|Obesity
437990|NCT00939081|Women's health
437991|NCT00939081|Minority health
437992|NCT00939081|Obesity prevention
437993|NCT00939068|Chronic hepatitis B, Telbivudine, Intrauterine transmission
437994|NCT00939029|tobacco use
437995|NCT00939029|smokeless tobacco
437996|NCT00939029|chewing tobacco
437997|NCT00939029|snuff
437998|NCT00939029|nicotine replacement
437999|NCT00939029|tobacco dependence
438000|NCT00939029|tobacco cessation
438001|NCT00939029|tobacco abstinence
438002|NCT00939016|Dietary Assessment
438003|NCT00939016|24-hour dietary recall
438004|NCT00939016|Dietary Restraint
438005|NCT00939016|Social Desirability
438006|NCT00939016|Portion estimation
438007|NCT00939016|Underreporting
438008|NCT00938977|Obesity Hypoventilation syndrome
438009|NCT00938977|cytokines
438010|NCT00938977|Adipokines
438011|NCT00938977|continuous positive airway pressure
438012|NCT00938977|bilevel support ventilation
438013|NCT00938977|Response to continuous positive airway pressure
438014|NCT00938964|Cognition
438015|NCT00938951|Dry Eye
438016|NCT00938951|Visual Performance
438017|NCT00938938|risk communication
438018|NCT00938938|medical reporting
438019|NCT00938938|Mass media
438020|NCT00938925|aggressive debridement
438021|NCT00938925|nail lacquer
438022|NCT00938925|onychomycosis
438023|NCT00938925|podiatry
438024|NCT00938925|chiropody
438025|NCT00938925|podiatry care
438026|NCT00938912|Lacosamide (VIMPAT)
438027|NCT00938899|TMC435350-TiDP16-C101
438028|NCT00938899|TMC435350-C101
438029|NCT00938899|TMC435350
438030|NCT00938899|HCV
438031|NCT00938873|MBCT
438032|NCT00938873|identity
438033|NCT00938873|depression
438034|NCT00938873|recurrent
438035|NCT00938873|homework
438036|NCT00938860|Hepatitis C
438037|NCT00938860|liver transplantation
438038|NCT00938860|anti-viral therapy
438039|NCT00938847|left ventricular dysfunction
438040|NCT00938847|myocardial infarction
438041|NCT00938847|left ventricular dysfunction (LVDF) after acute myocardial infarction
438042|NCT00938808|Osteoarthritis
438043|NCT00938808|Obesity
438044|NCT00938808|Weight loss
438045|NCT00938808|Dietary instruction
438046|NCT00938808|Formula diet
438047|NCT00938808|Attention
438048|NCT00938795|liver disease
438049|NCT00938795|uncertainty
438050|NCT00938795|self management
438051|NCT00938769|cancer
438052|NCT00938769|caregiver
438053|NCT00938769|symptom
438054|NCT00938769|self management
438055|NCT00938756|leptomeningeal metastases
438056|NCT00938756|male breast cancer
438057|NCT00938756|stage IV breast cancer
438058|NCT00938756|tumors metastatic to brain
438059|NCT00938756|adult meningioma
438060|NCT00938743|ADHD
438061|NCT00938743|adults
438062|NCT00938743|driving performance
438063|NCT00938743|atomoxetine
438064|NCT00938730|Nonvalvular Atrial Fibrillation (NVAF)
438065|NCT00938730|Factor Xa Inhibitor
438066|NCT00938730|Stroke
438067|NCT00938730|Thromboembolism
438068|NCT00938730|Transient Ischemic attack
438069|NCT00938730|Anticoagulants
438070|NCT00938730|Prevention
438071|NCT00938730|YM150
438072|NCT00938730|Warfarin
438073|NCT00938717|IBS
438074|NCT00938691|Scar
438075|NCT00938691|Appearance
438076|NCT00938691|Spread
438077|NCT00938678|Healthy volunteers
438078|NCT00938665|Alzheimer
438079|NCT00938665|Memory disorder
438080|NCT00938665|dementia
438081|NCT00938665|cognitive behavioral decline
438082|NCT00938665|vascular dementia
438083|NCT00938665|front temporal dementia
438084|NCT00938652|triple negative breast cancer
438085|NCT00938652|metastatic breast cancer
438086|NCT00938652|Triple negative metastatic breast cancer
438087|NCT00938626|refractory multiple myeloma
438088|NCT00938626|stage I multiple myeloma
438089|NCT00938626|stage II multiple myeloma
438090|NCT00938626|stage III multiple myeloma
438091|NCT00938613|SAR
438092|NCT00938600|pharmacokinetics
438093|NCT00938600|safety
438094|NCT00938587|Rheumatoid Arthritis Glucocorticoids Prednisone
438095|NCT00938561|Chronic Kidney Disease
438096|NCT00938561|Glomerular Filtration Rate
438097|NCT00938561|Kidney function
438098|NCT00938561|Markers
438099|NCT00938548|mastectomy
438100|NCT00938548|pain, postoperative
438101|NCT00938548|pregabalin
438102|NCT00938535|Obesity
438103|NCT00938535|Women's health
438104|NCT00938535|Minority health
438105|NCT00938535|Obesity prevention
438106|NCT00938522|Cilostazol loading
438107|NCT00938522|Angioplasty, Transluminal, Percutaneous Coronary
438108|NCT00938509|IBUPROFEN
438109|NCT00938509|CHILDREN
438110|NCT00938509|FEVER
438111|NCT00938483|infant formula
438112|NCT00938483|cow's milk allergy
438113|NCT00938470|adenocarcinoma of the esophagus
438114|NCT00938470|adenocarcinoma of the gastroesophageal junction
438115|NCT00938470|stage IIIA gastric cancer
438116|NCT00938470|stage IIIB gastric cancer
438117|NCT00938470|stage IIIC gastric cancer
438118|NCT00938470|stage IIIA esophageal cancer
438119|NCT00938470|stage IIIB esophageal cancer
438120|NCT00938470|stage IIIC esophageal cancer
438121|NCT00938457|protocol specific
438122|NCT00938444|Patients with moderate to severe RA
438123|NCT00938431|Lacosamide
438124|NCT00938431|Vimpat
438125|NCT00938431|Children
438126|NCT00938431|Epilepsy
438127|NCT00938431|Seizures
438128|NCT00938431|Anti-epileptic
438129|NCT00938405|type 1 diabetes mellitus
438130|NCT00938405|colesevelam
438131|NCT00938405|LDL
438132|NCT00938405|cholesterol
438133|NCT00938405|A1c
438134|NCT00938405|target range glucose values
438135|NCT00938392|influenza infection
438136|NCT00938392|GSK Bio's influenza vaccine GSK2186877A
438137|NCT00938379|mosquito
438138|NCT00938379|repellent
438139|NCT00938379|vector control
438140|NCT00938379|malaria
438141|NCT00938353|Moderate croup (Westley score 3-8)
438142|NCT00938340|Cardiovascular Disease
438143|NCT00938327|Gastroenteritis
438144|NCT00938301|healthy volunteer, first in human, safety and tolerability
438145|NCT00938288|Antithrombin
438146|NCT00938288|Thrombosis
438147|NCT00938288|Pharmacokinetics
438148|NCT00938288|Hereditary Antithrombin Deficiency
438149|NCT00938288|Congenital Antithrombin Deficiency
438150|NCT00938249|Moderately Elevated Serum Triglyceride
438151|NCT00938236|lung transplant
438152|NCT00938236|lung transplant recipient
438153|NCT00938236|bronchiolitis obliterans syndrome
438154|NCT00938236|bronchiolitis obliterans
438155|NCT00938236|single lung transplant
438156|NCT00938236|double lung transplant
438157|NCT00938236|heart-lung transplant
438158|NCT00938236|Aerosol
438159|NCT00938223|melanoma
438160|NCT00938223|peptide
438161|NCT00938223|vaccine
438162|NCT00938223|adjuvant
438163|NCT00938223|advanced
438164|NCT00938210|Colonic surgery
438165|NCT00938210|Postoperative care
438166|NCT00938210|Fatigue
438167|NCT00938210|Physical function
438168|NCT00938210|Quality of life
438169|NCT00938197|Fimasartan
438170|NCT00938197|Drug interaction
438171|NCT00938184|tolerance
438172|NCT00938184|single dose
438173|NCT00938184|paroxetine
438174|NCT00938184|controlled-release tablet
438175|NCT00938184|safety
438176|NCT00938184|pharmacokinetics
438177|NCT00938184|Japanese healthy male subjects
438178|NCT00938171|Cytokine
438179|NCT00938171|Anesthesia
438180|NCT00938171|Local anesthesia
438181|NCT00938171|surgery
438182|NCT00938171|breast cancer
438183|NCT00938158|albiglutide
438184|NCT00938158|hemodialysis
438185|NCT00938158|pharmacokinetics
438186|NCT00938158|renal
438187|NCT00938145|recurrent bladder cancer
438188|NCT00938145|stage II bladder cancer
438189|NCT00938145|stage III bladder cancer
438190|NCT00938145|stage IV bladder cancer
438191|NCT00938132|fimasartan
438192|NCT00938132|drug interaction
438193|NCT00938119|Cardiovascular disease
438194|NCT00938119|Diabetes
438195|NCT00938106|Intra-uterine Brachytherapy
438196|NCT00938106|cervix cancer
438197|NCT00938106|Patients suitable for intra-uterine brachytherapy for invasive carcinoma of the cervix.
438198|NCT00938067|Injuries, Trauma
438199|NCT00938054|Outcome
438200|NCT00938054|Autism
438201|NCT00938054|Pervasive Developmental Disorder
438202|NCT00938028|microbiome
438203|NCT00938028|metabolome
438204|NCT00938028|stool
438205|NCT00938028|fecal samples
438206|NCT00938028|handling
438207|NCT00938028|toddler
438208|NCT00938015|postmarketing surveillance
438209|NCT00938015|Enbrel
438210|NCT00938015|psoriatic arthritis
438211|NCT00937989|ductal breast carcinoma in situ
438212|NCT00937989|lobular breast carcinoma in situ
438213|NCT00937989|male breast cancer
438214|NCT00937989|stage I breast cancer
438215|NCT00937989|stage II breast cancer
438216|NCT00937989|stage IIIA breast cancer
438217|NCT00937989|stage IIIB breast cancer
438218|NCT00937989|stage IIIC breast cancer
438219|NCT00937976|Hemodialysis and peritoneal dialysis
438220|NCT00937963|cholesterol
438221|NCT00937963|cardiovascular
438222|NCT00937963|CVD
438223|NCT00937963|Triglycerides
438224|NCT00937963|Heart
438225|NCT00937950|HPV
438226|NCT00937950|Papillomavirus
438227|NCT00937950|Human papillomavirus
438228|NCT00937950|Cervical cancer
438229|NCT00937950|HPV vaccine
438230|NCT00937924|EUS
438231|NCT00937924|ERCP
438232|NCT00937924|Sedation Level
438233|NCT00937924|Adverse Symptoms
438234|NCT00937924|Recovery time
438235|NCT00937911|YM150
438236|NCT00937911|Bleeding
438237|NCT00937911|Anticoagulant
438238|NCT00937911|Venous thromboembolism
438239|NCT00937911|FXa inhibitor
438240|NCT00937898|lean beef
438241|NCT00937898|cholesterol
438242|NCT00937898|lipids
438243|NCT00937898|diet intervention
438244|NCT00937885|Reminiscence
438245|NCT00937885|Nursing home staff
438246|NCT00937885|Nursing home residents
438247|NCT00937885|Elderly
438248|NCT00937846|Cognitive impairment
438249|NCT00937846|Schizophrenia
438250|NCT00937846|Alzheimer's Disease
438251|NCT00937846|PET
438252|NCT00937833|prostate cancer
438253|NCT00937833|prostatectomy
438254|NCT00937833|incontinence
438255|NCT00937820|YM150
438256|NCT00937820|Bleeding
438257|NCT00937820|VTE
438258|NCT00937820|FXa inhibitor
438259|NCT00937820|Venous thromboembolism
438260|NCT00937807|hemodynamic stability
438261|NCT00937807|xenon
438262|NCT00937807|carotid surgery
438263|NCT00937807|general anesthesia
438264|NCT00937781|stage III melanoma
438265|NCT00937781|recurrent melanoma
438266|NCT00937755|schizophrenia
438267|NCT00937755|antipsychotics
438268|NCT00937755|glucose homeostasis
438269|NCT00937755|metabolic disturbance
438270|NCT00937742|cardiovascular disease
438271|NCT00937742|Lycopene
438272|NCT00937742|Tomato
438273|NCT00937729|uncompliant patients with virological failure
438274|NCT00937729|Treatment experienced
438275|NCT00937716|schizophrenia
438276|NCT00937716|treatment response
438277|NCT00937716|risperidone
438278|NCT00937716|functional magnetic resonance
438279|NCT00937716|functional magnetic spectroscopy
438280|NCT00937690|melanoma
438281|NCT00937690|cutaneous
438282|NCT00937690|imaging
438283|NCT00937677|Tysabri
438284|NCT00937677|VWMTR
438285|NCT00937664|Phase I
438286|NCT00937664|cancer
438287|NCT00937664|solid tumors
438288|NCT00937664|advanced solid malignancies
438289|NCT00937664|dose escalation
438290|NCT00937664|combination treatment
438291|NCT00937664|CHK inhibitor
438292|NCT00937664|Japanese
438293|NCT00937651|Fimasartan
438294|NCT00937651|Essential Hypertension
438295|NCT00937638|Metabolic syndrome
438296|NCT00937638|Lean Beef
438297|NCT00937638|CVD
438298|NCT00937612|Head and Neck Neoplasms
438299|NCT00937612|Chemotherapy
438300|NCT00937612|Radiotherapy, Adjuvant
438301|NCT00937612|Surgery
438302|NCT00937599|obese
438303|NCT00937599|brazil nuts
438304|NCT00937599|oxidative stress
438305|NCT00937599|microcirculatory
438306|NCT00937599|metabolic profile
438307|NCT00937586|Metastatic Prostate Cancer
438308|NCT00937586|Prostate Cancer Risk Assessment
438309|NCT00937573|stents
438310|NCT00937573|mortality
438311|NCT00937573|revascularization
438312|NCT00937573|stent thrombosis
438313|NCT00937573|Drug-Eluting Stents
438314|NCT00937547|cervical cancer
438315|NCT00937547|Human Papillomavirus Infection
438316|NCT00937534|Fimasartan
438317|NCT00937534|healthy elderly and young male volunteer
438318|NCT00937534|pharmacokinetic
438319|NCT00937521|Immunogenicity
438320|NCT00937521|Meningitis
438321|NCT00937521|Antibody
438322|NCT00937521|Infants
438323|NCT00937508|smoking
438324|NCT00937508|quitting
438325|NCT00937508|varenicline
438326|NCT00937508|preoperative
438327|NCT00937508|long term abstinence
438328|NCT00937469|Social skills training for children with ADHD
438329|NCT00937469|Children with ADHD
438330|NCT00937456|Esophagus
438331|NCT00937456|Cancer
438332|NCT00937456|Surgery
438333|NCT00937456|Laparoscopy
438334|NCT00937456|Randomized trial
438335|NCT00937456|Esophageal cancer deemed to be resectable
438336|NCT00937443|Physical Activity
438337|NCT00937443|Cardiac Heart Failure
438338|NCT00937443|Exercise Regimen
438339|NCT00937443|Cardioreparative Factors
438340|NCT00937430|Pelvic organ prolapse
438341|NCT00937430|Bowel preparation
438342|NCT00937417|unspecified adult solid tumor, protocol specific
438343|NCT00937417|recurrent non-small cell lung cancer
438344|NCT00937417|stage IV non-small cell lung cancer
438345|NCT00937417|stage IV breast cancer
438346|NCT00937417|recurrent squamous cell carcinoma of the hypopharynx
438347|NCT00937417|stage IV squamous cell carcinoma of the hypopharynx
438348|NCT00937417|recurrent squamous cell carcinoma of the larynx
438349|NCT00937417|recurrent verrucous carcinoma of the larynx
438350|NCT00937417|stage IV squamous cell carcinoma of the larynx
438351|NCT00937417|stage IV verrucous carcinoma of the larynx
438352|NCT00937417|recurrent adenoid cystic carcinoma of the oral cavity
438353|NCT00937417|recurrent mucoepidermoid carcinoma of the oral cavity
438354|NCT00937417|recurrent squamous cell carcinoma of the lip and oral cavity
438355|NCT00937417|recurrent verrucous carcinoma of the oral cavity
438356|NCT00937417|recurrent basal cell carcinoma of the lip
438357|NCT00937417|stage IV adenoid cystic carcinoma of the oral cavity
438358|NCT00937417|stage IV basal cell carcinoma of the lip
438359|NCT00937417|stage IV mucoepidermoid carcinoma of the oral cavity
438360|NCT00937417|stage IV squamous cell carcinoma of the lip and oral cavity
438361|NCT00937417|stage IV verrucous carcinoma of the oral cavity
438362|NCT00937417|recurrent metastatic squamous neck cancer with occult primary
438363|NCT00937417|recurrent lymphoepithelioma of the nasopharynx
438364|NCT00937417|recurrent squamous cell carcinoma of the nasopharynx
438365|NCT00937417|stage IV lymphoepithelioma of the nasopharynx
438366|NCT00937417|stage IV squamous cell carcinoma of the nasopharynx
438367|NCT00937417|recurrent lymphoepithelioma of the oropharynx
438368|NCT00937417|recurrent squamous cell carcinoma of the oropharynx
438369|NCT00937417|stage IV lymphoepithelioma of the oropharynx
438370|NCT00937417|stage IV squamous cell carcinoma of the oropharynx
438371|NCT00937417|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
438372|NCT00937417|recurrent inverted papilloma of the paranasal sinus and nasal cavity
438373|NCT00937417|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
438374|NCT00937417|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
438375|NCT00937417|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
438376|NCT00937417|stage IV inverted papilloma of the paranasal sinus and nasal cavity
438377|NCT00937417|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
438378|NCT00937417|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
438379|NCT00937417|recurrent salivary gland cancer
438380|NCT00937417|stage IV salivary gland cancer
438381|NCT00937417|anaplastic thyroid cancer
438382|NCT00937417|stage IV follicular thyroid cancer
438383|NCT00937417|insular thyroid cancer
438384|NCT00937417|stage IV papillary thyroid cancer
438385|NCT00937417|recurrent thyroid cancer
438386|NCT00937417|thyroid gland medullary carcinoma
438387|NCT00937417|recurrent prostate cancer
438388|NCT00937417|hormone-resistant prostate cancer
438389|NCT00937417|recurrent breast cancer
438390|NCT00937417|stage IV prostate cancer
438391|NCT00937417|male breast cancer
438392|NCT00937404|IPV
438393|NCT00937391|MRI agents
438394|NCT00937391|Magnevist
438395|NCT00937365|Pregnancy
438396|NCT00937365|Pain
438397|NCT00937365|Low back pain
438398|NCT00937365|Pubic symphysis pain
438399|NCT00937365|CAM
438400|NCT00937365|Complementary & Alternative Medicine
438401|NCT00937365|Exercise
438402|NCT00937365|Chiropractic
438403|NCT00937365|Spinal manipulation
438404|NCT00937365|Adjustments
438405|NCT00937365|Neuroemotional technique
438406|NCT00937365|Mind body
438407|NCT00937365|Mind body therapy
438408|NCT00937365|Attachment
438409|NCT00937365|Maternal Fetal relationship
438410|NCT00937365|Intrauterine attachment
438411|NCT00937365|Heart rate variability
438412|NCT00937365|VAS
438413|NCT00937365|Visual analog scale
438414|NCT00937365|Roland Morris Disability Index
438415|NCT00937352|Mild to moderate Alzheimer's disease
438416|NCT00937339|cerebrovascular accident
438417|NCT00937339|bone
438418|NCT00937339|muscle
438419|NCT00937339|vibration
438420|NCT00937287|HPV
438421|NCT00937287|African American
438422|NCT00937287|Rural
438423|NCT00937274|ETEC EPEC diarrhoea
438424|NCT00937274|phage therapy
438425|NCT00937274|ORS
438426|NCT00937248|Cone Beam CT in rectal cancer patients
438427|NCT00937248|Immobilizing rectal cancer patients
438428|NCT00937248|Image guided radiotherapy in rectal cancer patients
438429|NCT00937235|Smoking Cessation
438430|NCT00937235|Anxiety
438431|NCT00937235|Behavior Therapy
438432|NCT00937235|Varenicline
438433|NCT00937222|diabetes
438434|NCT00937222|cholesterol
438435|NCT00937222|peanuts
438436|NCT00937222|peanut butter
438437|NCT00937222|dietary intervention
438438|NCT00937222|HDL cholesterol
438439|NCT00937183|Waldenström macroglobulinemia
438440|NCT00937183|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
438441|NCT00937183|stage I grade 1 follicular lymphoma
438442|NCT00937183|stage I grade 2 follicular lymphoma
438443|NCT00937183|stage I grade 3 follicular lymphoma
438444|NCT00937183|stage II grade 1 follicular lymphoma
438445|NCT00937183|stage II grade 2 follicular lymphoma
438446|NCT00937183|stage II grade 3 follicular lymphoma
438447|NCT00937183|stage III grade 1 follicular lymphoma
438448|NCT00937183|stage III grade 2 follicular lymphoma
438449|NCT00937183|stage III grade 3 follicular lymphoma
438450|NCT00937183|stage I small lymphocytic lymphoma
438451|NCT00937183|stage II small lymphocytic lymphoma
438452|NCT00937183|stage III small lymphocytic lymphoma
438453|NCT00937183|stage I marginal zone lymphoma
438454|NCT00937183|stage II marginal zone lymphoma
438455|NCT00937183|stage III marginal zone lymphoma
438456|NCT00937183|stage I adult diffuse large cell lymphoma
438457|NCT00937183|stage II adult diffuse large cell lymphoma
438458|NCT00937183|stage III adult diffuse large cell lymphoma
438459|NCT00937183|recurrent mantle cell lymphoma
438460|NCT00937183|stage I mantle cell lymphoma
438461|NCT00937183|stage II mantle cell lymphoma
438462|NCT00937183|stage III mantle cell lymphoma
438463|NCT00937183|stage I multiple myeloma
438464|NCT00937183|stage II multiple myeloma
438465|NCT00937183|stage III multiple myeloma
438466|NCT00937183|B-cell chronic lymphocytic leukemia
438467|NCT00937183|stage I chronic lymphocytic leukemia
438468|NCT00937183|stage II chronic lymphocytic leukemia
438469|NCT00937183|stage III chronic lymphocytic leukemia
438470|NCT00937170|Total Knee Replacement
438471|NCT00937170|Gender Specific Design
438472|NCT00937157|Inflammation
438473|NCT00937157|Multiple Sclerosis
438474|NCT00937157|Glatiramer Acetate
438475|NCT00937157|Gd enhancing lesions
438476|NCT00937157|1.5T protocol
438477|NCT00937157|3T protocol
438478|NCT00937157|Magnetization transfer imaging (MTI)
438479|NCT00937157|Lesion activity analysis
438480|NCT00937157|Copaxone
438481|NCT00937144|endothelial function
438482|NCT00937144|endothelial progenitor stem cells
438483|NCT00937118|laparotomy
438484|NCT00937118|duodenal injury
438485|NCT00937118|pancreatic injury
438486|NCT00937118|trauma
438487|NCT00937092|Heart Failure
438488|NCT00937092|Dopamine
438489|NCT00937092|Furosemide
438490|NCT00937092|Worsening Renal Function
438491|NCT00937092|Hypokalemia
438492|NCT00937092|Outcomes
438493|NCT00937092|Prognosis
438494|NCT00937079|Glucagon-like peptide-1 receptor targeting
438495|NCT00937079|Insulinoma imaging
438496|NCT00937079|Exendin-4
438497|NCT00937079|molecular imaging
438498|NCT00937066|Cost-effectiveness analysis
438499|NCT00937066|Symbicort
438500|NCT00937053|Neutropenia
438501|NCT00937053|Transfusions
438502|NCT00937053|Hemoglobin
438503|NCT00937053|Bone marrow transplant
438504|NCT00937053|Hematopoietic stem cell transplant
438505|NCT00937040|Osmotic Release Oral System (OROS®) Extended Release Methylphenidate HCl
438506|NCT00937040|CONCERTA® (OROS MPH)
438507|NCT00937027|Antifolate
438508|NCT00937027|Psoriasis
438509|NCT00937027|Antiinflammatory drug
438510|NCT00937027|Autoimmune disease
438511|NCT00937027|Treatment
438512|NCT00937014|infant formula
438513|NCT00937014|growth
438514|NCT00937014|weight
438515|NCT00937001|myopathy
438516|NCT00937001|respiratory failure
438517|NCT00937001|cognitive impairment
438518|NCT00937001|delirium
438519|NCT00936988|Hyperparathyroidism, Primary
438520|NCT00936988|cinacalcet
438521|NCT00936962|Meningococcal C vaccine
438522|NCT00936962|Meningitis study
438523|NCT00936962|Canadian vaccine schedule
438524|NCT00936962|Prevention of Meningococcal C disease
438525|NCT00936949|total hip arthroplasty
438526|NCT00936949|posterolateral
438527|NCT00936949|modified lateral
438528|NCT00936936|Testis
438529|NCT00936936|Relapsed Testicular Cancer
438530|NCT00936936|Bevacizumab
438531|NCT00936936|Avastin
438532|NCT00936936|Anti-VEGF monoclonal antibody
438533|NCT00936936|rhuMAb-VEGF
438534|NCT00936936|Carboplatin
438535|NCT00936936|Paraplatin
438536|NCT00936936|Docetaxel
438537|NCT00936936|Taxotere
438538|NCT00936936|Etoposide
438539|NCT00936936|VePesid
438540|NCT00936936|Gemcitabine
438541|NCT00936936|Gemcitabine Hydrochloride
438542|NCT00936936|Gemzar
438543|NCT00936936|Ifosfamide
438544|NCT00936936|Ifex
438545|NCT00936936|Melphalan
438546|NCT00936936|Alkeran
438547|NCT00936923|CAPD
438548|NCT00936923|Diuretics
438549|NCT00936923|Residual Renal Function
438550|NCT00936923|furosemide
438551|NCT00936910|central line fungal infections
438552|NCT00936910|antifungal lock therapy
438553|NCT00936910|Ambisome lock therapy
438554|NCT00936884|Opioid Induced Constipation
438555|NCT00936871|lersivirine QT QTc ECG HIV NNRTI
438556|NCT00936858|radioiodine refractory thyroid cancer
438557|NCT00936858|RAD001
438558|NCT00936832|stage IV rectal cancer
438559|NCT00936832|adenocarcinoma of the rectum
438560|NCT00936832|liver metastases
438561|NCT00936832|lung metastases
438562|NCT00936819|Stent
438563|NCT00936819|endothelial progenitor cells
438564|NCT00936819|nitric oxide
438565|NCT00936819|myocardial infarction
438566|NCT00936819|MRI
438567|NCT00936806|Intracranial tumor patients
438568|NCT00936793|Drug Interaction
438569|NCT00936793|Asthma
438570|NCT00936793|HIV
438571|NCT00936793|Beclomethasone
438572|NCT00936793|Protease Inhibitors
438573|NCT00936793|HV
438574|NCT00936793|Healthy Volunteer
438575|NCT00936793|HIV Infections
438576|NCT00936780|Coronary Artery Disease
438577|NCT00936780|Restenosis
438578|NCT00936780|Stent thrombosis
438579|NCT00936780|Coronary stents
438580|NCT00936780|Angioplasty
438581|NCT00936780|Drug Eluting Stents (DES)
438582|NCT00936767|falciparum malaria
438583|NCT00936767|artemisone
438584|NCT00936767|artesunate
438585|NCT00936767|resistance
438586|NCT00936754|Glycemic index
438587|NCT00936754|Reduction of glycemic index of ingested foods
438588|NCT00936741|Cushing's Disease
438589|NCT00936741|Cushing's Syndrome
438590|NCT00936741|Cushings
438591|NCT00936741|Pituitary
438592|NCT00936741|ACTH
438593|NCT00936741|Adrenocorticotropic hormone
438594|NCT00936741|Ectopic
438595|NCT00936741|Adrenal adenoma
438596|NCT00936741|Adrenal carcinoma
438597|NCT00936741|Adrenal autonomy
438598|NCT00936741|Cortisol
438599|NCT00936741|Hypercortisolemia
438600|NCT00936741|Cushingoid
438601|NCT00936741|Moon facies
438602|NCT00936741|Dorsocervical fat
438603|NCT00936741|Plethora
438604|NCT00936741|Hirsutism
438605|NCT00936741|Violaceous striae
438606|NCT00936741|Hormone
438607|NCT00936741|Contraceptive
438608|NCT00936741|Endocrine
438609|NCT00936741|Cushing Syndrome
438610|NCT00936741|Ectopic ACTH Secretion
438611|NCT00936715|prevention of chronic hepatitis B recurrence
438612|NCT00936715|post orthotopic liver transplant
438613|NCT00936715|Prevention of chronic hepatitis B recurrence in patients who have undergone orthotopic liver transplant
438614|NCT00936702|Newly Diagnosed Carcinoma of Unknown Primary Origin
438615|NCT00936702|Squamous Cell Carcinoma of Unknown Primary Origin
438616|NCT00936702|Undifferentiated Carcinoma of Unknown Primary
438617|NCT00936702|newly diagnosed carcinoma of unknown primary
438618|NCT00936689|Hepatocellular carcinoma;
438619|NCT00936689|Chemoembolization;
438620|NCT00936689|DC-Beads.
438621|NCT00936676|parkinson's
438622|NCT00936676|long-term effects
438623|NCT00936676|adagio
438624|NCT00936676|rasagiline
438625|NCT00936676|delayed start
438626|NCT00936663|Diabetes
438627|NCT00936663|Kidney Transplant
438628|NCT00936663|Sitagliptin
438629|NCT00936650|Hyperparathyroidism, Primary
438630|NCT00936650|cinacalcet
438631|NCT00936624|Persistent asthma
438632|NCT00936611|LBH589
438633|NCT00936611|WM
438634|NCT00936611|panobinostat
438635|NCT00936611|relapsed
438636|NCT00936611|waldenstrom
438637|NCT00936611|macroglobulinemia
438638|NCT00936598|Sleep
438639|NCT00936598|Endometrial Neoplasms
438640|NCT00936598|Pain
438641|NCT00936585|Crohn's Disease
438642|NCT00936585|Infusion
438643|NCT00936585|Anti IL-17 Monoclonal Antibody
438644|NCT00936585|Placebo
438645|NCT00936585|Crohn Disease
438646|NCT00936585|Inflammatory Bowel Disease
438647|NCT00936572|Probiotics
438648|NCT00936572|La1
438649|NCT00936572|BB536
438650|NCT00936572|Colorectal surgery
438651|NCT00936572|Intestinal immunity
438652|NCT00936572|Dendritic cells
438653|NCT00936572|Lymphocyte
438654|NCT00936572|Microbiota
438655|NCT00936559|rotator cuff tear repair
438656|NCT00936559|open surgical technique
438657|NCT00936559|safety
438658|NCT00936520|Diabetic Macular Edema
438659|NCT00936520|DME
438660|NCT00936520|Pars Plana Vitrectomy
438661|NCT00936520|Ocular Inflammation
438662|NCT00936507|energy density
438663|NCT00936507|portion size
438664|NCT00936507|child feeding
438665|NCT00936494|obstructive sleep apnea
438666|NCT00936494|sleep related breathing disorder
438667|NCT00936494|snoring
438668|NCT00936494|disturbed sleeping
438669|NCT00936494|open mouth breathing
438670|NCT00936494|upper airway resistance syndrome
438671|NCT00936481|OSA
438672|NCT00936468|Elderly influenza vaccine
438673|NCT00936455|telemedicine
438674|NCT00936455|telephone
438675|NCT00936455|outcomes
438676|NCT00936442|Compliance
438677|NCT00936442|Early Breast Cancer
438678|NCT00936429|Dengue fever
438679|NCT00936429|Dengue hemorrhagic fever
438680|NCT00936429|Dengue shock syndrome
438681|NCT00936429|Vaccine
438682|NCT00936429|Hawaii Biotech
438683|NCT00936416|Glomerular Filtration Rate
438684|NCT00936416|Renal Blood Flow
438685|NCT00936416|MRI
438686|NCT00936416|Inulin
438687|NCT00936416|Para-Aminohippuric Acid
438688|NCT00936390|adenocarcinoma of the prostate
438689|NCT00936390|stage IIB prostate cancer
438690|NCT00936390|stage IIA prostate cancer
438691|NCT00936351|schizophrenia
438692|NCT00936351|intervention studies
438693|NCT00936351|mindfulness meditation
438694|NCT00936351|vocational rehabilitation
438695|NCT00936351|schizoaffective disorder
438696|NCT00936351|psychotic disorders
438697|NCT00936338|anterior disc displacement without reduction of temporomandibular disorders
438698|NCT00936325|SCLS
438699|NCT00936325|Systemic Capillary Leak Syndrome
438700|NCT00936299|Adolescents
438701|NCT00936299|Substance Use Disorder
438702|NCT00936299|Attention Deficit Hyperactivity Disorder
438703|NCT00936299|Cognitive Behavioral Therapy
438704|NCT00936286|Obstructive Sleep Apnea Syndrome
438705|NCT00936286|Respiratory Muscle Training
438706|NCT00936286|Normocapnic Hyperpnea
438707|NCT00936286|SpiroTiger
438708|NCT00936286|Polysomnography
438709|NCT00936273|Sleep apnea syndrome
438710|NCT00936273|SAS
438711|NCT00936273|double loop gain
438712|NCT00936273|DLI
438713|NCT00936273|double loop index
438714|NCT00936273|periodic breathing
438715|NCT00936273|polysomnography
438716|NCT00936260|osteoporosis
438717|NCT00936260|postmenopausal
438718|NCT00936260|alendronate
438719|NCT00936234|CAD
438720|NCT00936234|diabetes
438721|NCT00936234|SDF-1
438722|NCT00936234|endothelial function
438723|NCT00936221|BRAF mutation positive
438724|NCT00936221|advanced melanoma
438725|NCT00936221|Advanced cutaneous melanoma
438726|NCT00936221|Unknown primary melanoma
438727|NCT00936195|HIV
438728|NCT00936195|pregnancy
438729|NCT00936195|breastfeeding
438730|NCT00936195|PMTCT
438731|NCT00936195|ARV treatment
438732|NCT00936195|treatment naive
438733|NCT00936169|Patients with at least one complex lesion suitable for implantation of a drug-eluting stent
438734|NCT00936143|Spondylitis, Ankylosing
438735|NCT00936143|infliximab
438736|NCT00936143|Antibodies, Monoclonal
438737|NCT00936130|Roux-en-Y gastric bypass surgery
438738|NCT00936130|Sleeve gastrectomy (SGx) surgery
438739|NCT00936130|Gastric banding (GBx) surgery
438740|NCT00936130|Low calorie diet program
438741|NCT00936117|Cancer of the Blood
438742|NCT00936117|Cancer of Bone Marrow
438743|NCT00936117|Acute Leukemia
438744|NCT00936117|AML
438745|NCT00936117|Fungal infection
438746|NCT00936117|Prophylaxis
438747|NCT00936117|Posaconazole
438748|NCT00936117|SCH 56592
438749|NCT00936117|Noxafil
438750|NCT00936117|Chemotherapy
438751|NCT00936104|pancreas
438752|NCT00936104|cancer
438753|NCT00936104|stem cell
438754|NCT00936091|intestinal parasitic infections
438755|NCT00936091|malnutrition
438756|NCT00936091|Anemia
438757|NCT00936078|kidney transplantation
438758|NCT00936078|cohort study
438759|NCT00936078|qualitative research
438760|NCT00936078|health services research
438761|NCT00936078|hypertension
438762|NCT00936065|Etanercept
438763|NCT00936065|Acitretin
438764|NCT00936065|Psoriasis
438765|NCT00936052|glioblastomas
438766|NCT00936052|GBM
438767|NCT00936052|gliosarcoma
438768|NCT00936052|blastoma
438769|NCT00936052|sarcoma
438770|NCT00936013|novel influenza A(H1N1)
438771|NCT00936013|chinese medicinal herbs
438772|NCT00936000|alcohol abuse
438773|NCT00936000|alveolar capillary permeability
438774|NCT00935987|Primary Myelofibrosis
438775|NCT00935987|Post-Polycythemia Vera
438776|NCT00935987|Post-Essential Thrombocythemia
438777|NCT00935987|CYT387
438778|NCT00935961|CISPLATIN
438779|NCT00935961|RAD001
438780|NCT00935961|TAXOTERE (DOCETAXEL)
438781|NCT00935961|09-028
438782|NCT00935961|Squamous Cell Carcinoma
438783|NCT00935961|Local-Regional Advanced Head and Neck
438784|NCT00935948|hemorrhoids
438785|NCT00935948|hemorrhoidal disease
438786|NCT00935948|water smartweed
438787|NCT00935948|hamamelis
438788|NCT00935948|RCT
438789|NCT00935935|Treatment experienced
438790|NCT00935922|Flaxseed
438791|NCT00935922|Weight loss
438792|NCT00935922|Heart health
438793|NCT00935922|Diabetes
438794|NCT00935909|IV cannulation
438795|NCT00935896|Ventilator-associated lung injury
438796|NCT00935896|Tumor necrosis factor-alpha
438797|NCT00935896|Interleukin-8
438798|NCT00935896|Mechanical ventilation
438799|NCT00935896|Low tidal volume ventilation
438800|NCT00935896|Normal lungs
438801|NCT00935883|Age Related macular Degeneration
438802|NCT00935883|Macular Degeneration
438803|NCT00935883|Drusen
438804|NCT00935883|Geographic atrophy
438805|NCT00935883|Eculizumab
438806|NCT00935883|Soliris
438807|NCT00935857|Balloon Enteroscopy
438808|NCT00935857|Looping
438809|NCT00935844|Advanced solid tumors
438810|NCT00935844|Lymphoma
438811|NCT00935831|Tolerability
438812|NCT00935831|Safety
438813|NCT00935831|Pharmacokinetics
438814|NCT00935831|Pharmacodynamics
438815|NCT00935818|smoking
438816|NCT00935818|nicotine
438817|NCT00935818|tobacco
438818|NCT00935818|dependence
438819|NCT00935818|cessation
438820|NCT00935818|abstinence
438821|NCT00935805|Diabetes Mellitus
438822|NCT00935805|Arterial Hypertension
438823|NCT00935805|Treatment
438824|NCT00935805|Primary Care
438825|NCT00935792|hematopoietic cancer
438826|NCT00935792|lymphoid cancer
438827|NCT00935779|Stomach Neoplasms
438828|NCT00935779|Peritoneum
438829|NCT00935766|Latinos Using Cardio Health Actions to Reduce Risk
438830|NCT00935766|Omega three Fatty Acids
438831|NCT00935766|Vascular Function and Inflammation
438832|NCT00935753|Lesch-Nyhan Disease
438833|NCT00935753|self-mutilating behavior
438834|NCT00935740|thromboembolic disease
438835|NCT00935740|thromboplastin
438836|NCT00935740|hypercoagulability
438837|NCT00935740|congestive heart failure
438838|NCT00935727|renal transplant
438839|NCT00935727|ultrasound
438840|NCT00935727|elastography
438841|NCT00935714|Arm
438842|NCT00935714|Lymphedema
438843|NCT00935714|Breast Cancer
438844|NCT00935714|Exercise
438845|NCT00935714|Breast Cancer related Lymphedema
438846|NCT00935701|Autism Spectrum Disorder
438847|NCT00935701|Acupressure
438848|NCT00935701|Acupuncture
438849|NCT00935688|malaria
438850|NCT00935688|rapid diagnostic tests
438851|NCT00935688|afghanistan
438852|NCT00935688|Non-specific fever
438853|NCT00935675|Patients with head and neck squamous cell carcinomas
438854|NCT00935675|head and neck squamous cell carcinomas
438855|NCT00935662|First time in man
438856|NCT00935662|Safety study
438857|NCT00935662|AZD8329
438858|NCT00935649|Toenail Fungus
438859|NCT00935649|PinPointe
438860|NCT00935649|FootLaser
438861|NCT00935649|Onychomycosis
438862|NCT00935649|Fungal nails
438863|NCT00935636|Intubation
438864|NCT00935623|Malaria, Plasmodium vivax
438865|NCT00935610|Elderly persons
438866|NCT00935610|Muscle function and strength
438867|NCT00935610|Body composition
438868|NCT00935610|Inflammatory cytokine levels
438869|NCT00935610|Cognitive functions
438870|NCT00935610|Cysteine-rich whey protein isolate
438871|NCT00935610|Immunocal
438872|NCT00935610|Resistance training
438873|NCT00935610|Improved muscle function
438874|NCT00935610|Improved quality of life
438875|NCT00935610|Aging processes
438876|NCT00935610|Quality of life
438877|NCT00935597|Relapsed Non-Hodgkin's Lymphoma
438878|NCT00935597|Hodgkin's Disease
438879|NCT00935597|Multiple Myeloma
438880|NCT00935597|Chronic Lymphocytic Lymphoma
438881|NCT00935597|Relapsed Non-Hodgkin's lymphoma (excluding follicular lymphoma and marginal zone lymphoma)
438882|NCT00935584|Communication
438883|NCT00935584|Doctor-patient relations
438884|NCT00935584|medical informatics
438885|NCT00935584|patient-centered care
438886|NCT00935584|medical records systems, computerized
438887|NCT00935558|dendritic cell
438888|NCT00935558|cancer vaccine
438889|NCT00935558|breast cancer
438890|NCT00935558|aromatase inhibitor
438891|NCT00935558|Zadaxin
438892|NCT00935545|Brain Tumors
438893|NCT00935545|High Grade
438894|NCT00935545|CNS
438895|NCT00935532|diabetes; exenatide once weekly; Byetta; glargine; Lantus; Amylin; Lilly
438896|NCT00935519|total hip arthroplasty, ceramic, survival
438897|NCT00935493|guanfacine
438898|NCT00935493|aging
438899|NCT00935493|cognitive aging
438900|NCT00935493|prefrontal cognitive function
438901|NCT00935493|executive function
438902|NCT00935493|prefrontal cortex
438903|NCT00935480|HIV
438904|NCT00935480|INTEGRASE INHIBITOR
438905|NCT00935480|Inhibitor on the lymphoid reservoir
438906|NCT00935480|Residual HIV replication
438907|NCT00935480|treatment experienced
438908|NCT00935454|hepatocyte matrix implantation
438909|NCT00935454|endstage liver disease
438910|NCT00935454|liver cirrhosis
438911|NCT00935454|impaired liver parenchyma
438912|NCT00935454|improvement of liver function
438913|NCT00935441|Diabetes mellitus
438914|NCT00935441|chronic care
438915|NCT00935441|case management
438916|NCT00935441|telemedicine
438917|NCT00935428|Equestrian injury
438918|NCT00935428|Horse injury
438919|NCT00935428|Trauma
438920|NCT00935428|Horse
438921|NCT00935428|Equestrian
438922|NCT00935415|asthma
438923|NCT00935415|exercise-induced bronchoconstriction
438924|NCT00935415|montelukast
438925|NCT00935415|clinical protection
438926|NCT00935415|children
438927|NCT00935415|time effect
438928|NCT00935402|Energy balance
438929|NCT00935402|Weight management
438930|NCT00935402|Food intake
438931|NCT00935402|Energy expenditure
438932|NCT00935376|Sleep Management
438933|NCT00935376|Awareness Training Programs
438934|NCT00935376|Mindfulness Meditation
438935|NCT00935376|Mind Body Bridging
438936|NCT00935363|glyburide
438937|NCT00935363|pharmacokinetics
438938|NCT00935363|pharmacodynamics
438939|NCT00935363|drug interaction
438940|NCT00935363|Healthy Volunteers
438941|NCT00935350|viscous
438942|NCT00935350|fibre
438943|NCT00935350|polysaccharide
438944|NCT00935350|blood glucose
438945|NCT00935350|postprandial
438946|NCT00935337|Sleep problems
438947|NCT00935337|Awareness training program
438948|NCT00935337|Mind body bridging
438949|NCT00935324|allo-SCT, GvHD, CK18-F
438950|NCT00935298|Renal Transplantation
438951|NCT00935298|Tacrolimus
438952|NCT00935298|CYP3A5
438953|NCT00935298|Genotyping
438954|NCT00935285|Ventilator-associated pneumonia (VAP)
438955|NCT00935285|Intensive care unit (ICU)
438956|NCT00935285|Toll-like receptors
438957|NCT00935259|Hypercholesterolemia, Dyslipidemia, simvastatin, Zocor
438958|NCT00935246|Genomic devices
438959|NCT00935246|Prediction of Escitalopram Response
438960|NCT00935246|Depressed Patients
438961|NCT00935233|ductal breast carcinoma in situ
438962|NCT00935207|Pain
438963|NCT00935207|Pediatric Pain
438964|NCT00935207|Pain Diary
438965|NCT00935207|Pediatric Pain Measurement
438966|NCT00935207|Pain Measurement
438967|NCT00935194|Novel Influenza A(H1N1)
438968|NCT00935194|Oseltamivir
438969|NCT00935194|Chinese Medicinal Herbs
438970|NCT00935181|COPD
438971|NCT00935181|diaphragm
438972|NCT00935181|muscle
438973|NCT00935181|stretching
438974|NCT00935181|exercises
438975|NCT00935181|dyspnea
438976|NCT00935181|respiratory muscle stretching
438977|NCT00935181|pulmonary rehabilitation
438978|NCT00935181|exercise training
438979|NCT00935181|improved exercise capacity, dyspnea, quality of life
438980|NCT00935168|Intensive Care
438981|NCT00935168|Fluid Resuscitation
438982|NCT00935168|Saline
438983|NCT00935168|Hydroxy-ethyl starch
438984|NCT00935155|exercise therapy
438985|NCT00935155|Knee arthroplasty
438986|NCT00935155|Acupuncture Analgesia
438987|NCT00935155|Arthroplasty, Replacement, Knee
438988|NCT00935155|rehabilitation
438989|NCT00935142|stage IV cancer with no treatment options
438990|NCT00935142|non-curative
438991|NCT00935129|Treatment satisfaction
438992|NCT00935129|OmniPod
438993|NCT00935129|Insulin pump
438994|NCT00935129|diabetes
438995|NCT00935103|Addiction
438996|NCT00935103|Psychoeducation
438997|NCT00935103|Risk reduction behaviour
438998|NCT00935103|Drop in center (DIC)
438999|NCT00935090|unspecified adult solid tumor, protocol specific
439000|NCT00935090|accelerated phase chronic myelogenous leukemia
439001|NCT00935090|acute undifferentiated leukemia
439002|NCT00935090|adult acute lymphoblastic leukemia in remission
439003|NCT00935090|adult acute myeloid leukemia in remission
439004|NCT00935090|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
439005|NCT00935090|adult acute myeloid leukemia with inv(16)(p13;q22)
439006|NCT00935090|adult acute myeloid leukemia with t(15;17)(q22;q12)
439007|NCT00935090|adult acute myeloid leukemia with t(16;16)(p13;q22)
439008|NCT00935090|adult acute myeloid leukemia with t(8;21)(q22;q22)
439009|NCT00935090|atypical chronic myeloid leukemia, BCR-ABL negative
439010|NCT00935090|blastic phase chronic myelogenous leukemia
439011|NCT00935090|chronic myelomonocytic leukemia
439012|NCT00935090|chronic phase chronic myelogenous leukemia
439013|NCT00935090|mast cell leukemia
439014|NCT00935090|meningeal chronic myelogenous leukemia
439015|NCT00935090|progressive hairy cell leukemia, initial treatment
439016|NCT00935090|prolymphocytic leukemia
439017|NCT00935090|recurrent adult acute lymphoblastic leukemia
439018|NCT00935090|recurrent adult acute myeloid leukemia
439019|NCT00935090|recurrent adult T-cell leukemia/lymphoma
439020|NCT00935090|refractory chronic lymphocytic leukemia
439021|NCT00935090|refractory hairy cell leukemia
439022|NCT00935090|relapsing chronic myelogenous leukemia
439023|NCT00935090|secondary acute myeloid leukemia
439024|NCT00935090|stage I adult T-cell leukemia/lymphoma
439025|NCT00935090|stage I chronic lymphocytic leukemia
439026|NCT00935090|stage II adult T-cell leukemia/lymphoma
439027|NCT00935090|stage II chronic lymphocytic leukemia
439028|NCT00935090|stage III adult T-cell leukemia/lymphoma
439029|NCT00935090|stage III chronic lymphocytic leukemia
439030|NCT00935090|stage IV adult T-cell leukemia/lymphoma
439031|NCT00935090|stage IV chronic lymphocytic leukemia
439032|NCT00935090|T-cell large granular lymphocyte leukemia
439033|NCT00935090|untreated adult acute lymphoblastic leukemia
439034|NCT00935090|untreated adult acute myeloid leukemia
439035|NCT00935090|untreated hairy cell leukemia
439036|NCT00935090|recurrent adult Hodgkin lymphoma
439037|NCT00935090|stage I adult Hodgkin lymphoma
439038|NCT00935090|stage II adult Hodgkin lymphoma
439039|NCT00935090|stage III adult Hodgkin lymphoma
439040|NCT00935090|stage IV adult Hodgkin lymphoma
439041|NCT00935090|anaplastic large cell lymphoma
439042|NCT00935090|angioimmunoblastic T-cell lymphoma
439043|NCT00935090|cutaneous B-cell non-Hodgkin lymphoma
439044|NCT00935090|recurrent cutaneous T-cell non-Hodgkin lymphoma
439045|NCT00935090|stage I cutaneous T-cell non-Hodgkin lymphoma
439046|NCT00935090|stage II cutaneous T-cell non-Hodgkin lymphoma
439047|NCT00935090|stage III cutaneous T-cell non-Hodgkin lymphoma
439048|NCT00935090|stage IV cutaneous T-cell non-Hodgkin lymphoma
439049|NCT00935090|recurrent mycosis fungoides/Sezary syndrome
439050|NCT00935090|stage I mycosis fungoides/Sezary syndrome
439051|NCT00935090|stage II mycosis fungoides/Sezary syndrome
439052|NCT00935090|stage III mycosis fungoides/Sezary syndrome
439053|NCT00935090|stage IV mycosis fungoides/Sezary syndrome
439054|NCT00935090|adult grade III lymphomatoid granulomatosis
439055|NCT00935090|adult nasal type extranodal NK/T-cell lymphoma
439056|NCT00935090|Waldenstrom macroglobulinemia
439057|NCT00935090|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
439058|NCT00935090|nodal marginal zone B-cell lymphoma
439059|NCT00935090|splenic marginal zone lymphoma
439060|NCT00935090|contiguous stage II adult Burkitt lymphoma
439061|NCT00935090|contiguous stage II adult diffuse large cell lymphoma
439062|NCT00935090|contiguous stage II adult diffuse mixed cell lymphoma
439063|NCT00935090|contiguous stage II adult diffuse small cleaved cell lymphoma
439064|NCT00935090|contiguous stage II adult immunoblastic large cell lymphoma
439065|NCT00935090|contiguous stage II adult lymphoblastic lymphoma
439066|NCT00935090|contiguous stage II grade 1 follicular lymphoma
439067|NCT00935090|contiguous stage II grade 2 follicular lymphoma
439068|NCT00935090|contiguous stage II grade 3 follicular lymphoma
439069|NCT00935090|contiguous stage II mantle cell lymphoma
439070|NCT00935090|contiguous stage II marginal zone lymphoma
439071|NCT00935090|contiguous stage II small lymphocytic lymphoma
439072|NCT00935090|stage I adult Burkitt lymphoma
439073|NCT00935090|stage I adult diffuse large cell lymphoma
439074|NCT00935090|stage I adult diffuse mixed cell lymphoma
439075|NCT00935090|stage I adult diffuse small cleaved cell lymphoma
439076|NCT00935090|stage I adult immunoblastic large cell lymphoma
439077|NCT00935090|stage I adult lymphoblastic lymphoma
439078|NCT00935090|stage I grade 1 follicular lymphoma
439079|NCT00935090|stage I grade 2 follicular lymphoma
439080|NCT00935090|stage I grade 3 follicular lymphoma
439081|NCT00935090|stage I mantle cell lymphoma
439082|NCT00935090|stage I marginal zone lymphoma
439083|NCT00935090|stage I small lymphocytic lymphoma
439084|NCT00935090|noncontiguous stage II adult Burkitt lymphoma
439085|NCT00935090|noncontiguous stage II adult diffuse large cell lymphoma
439086|NCT00935090|noncontiguous stage II adult diffuse mixed cell lymphoma
439087|NCT00935090|noncontiguous stage II adult diffuse small cleaved cell lymphoma
439088|NCT00935090|noncontiguous stage II adult immunoblastic large cell lymphoma
439089|NCT00935090|noncontiguous stage II adult lymphoblastic lymphoma
439090|NCT00935090|noncontiguous stage II grade 1 follicular lymphoma
439091|NCT00935090|noncontiguous stage II grade 2 follicular lymphoma
439092|NCT00935090|noncontiguous stage II grade 3 follicular lymphoma
439093|NCT00935090|noncontiguous stage II mantle cell lymphoma
439094|NCT00935090|noncontiguous stage II marginal zone lymphoma
439095|NCT00935090|noncontiguous stage II small lymphocytic lymphoma
439096|NCT00935090|stage III adult Burkitt lymphoma
439097|NCT00935090|stage III adult diffuse large cell lymphoma
439098|NCT00935090|stage III adult diffuse mixed cell lymphoma
439099|NCT00935090|stage III adult diffuse small cleaved cell lymphoma
439100|NCT00935090|stage III adult immunoblastic large cell lymphoma
439101|NCT00935090|stage III adult lymphoblastic lymphoma
439102|NCT00935090|stage III grade 1 follicular lymphoma
439103|NCT00935090|stage III grade 2 follicular lymphoma
439104|NCT00935090|stage III grade 3 follicular lymphoma
439105|NCT00935090|stage III mantle cell lymphoma
439106|NCT00935090|stage III marginal zone lymphoma
439107|NCT00935090|stage III small lymphocytic lymphoma
439108|NCT00935090|stage IV adult Burkitt lymphoma
439109|NCT00935090|stage IV adult diffuse large cell lymphoma
439110|NCT00935090|stage IV adult diffuse mixed cell lymphoma
439111|NCT00935090|stage IV adult diffuse small cleaved cell lymphoma
439112|NCT00935090|stage IV adult immunoblastic large cell lymphoma
439113|NCT00935090|stage IV adult lymphoblastic lymphoma
439114|NCT00935090|stage IV grade 1 follicular lymphoma
439115|NCT00935090|stage IV grade 2 follicular lymphoma
439116|NCT00935090|stage IV grade 3 follicular lymphoma
439117|NCT00935090|stage IV mantle cell lymphoma
439118|NCT00935090|stage IV marginal zone lymphoma
439119|NCT00935090|stage IV small lymphocytic lymphoma
439120|NCT00935090|recurrent adult Burkitt lymphoma
439121|NCT00935090|recurrent adult diffuse large cell lymphoma
439122|NCT00935090|recurrent adult diffuse mixed cell lymphoma
439123|NCT00935090|recurrent adult diffuse small cleaved cell lymphoma
439124|NCT00935090|recurrent adult grade III lymphomatoid granulomatosis
439125|NCT00935090|recurrent adult immunoblastic large cell lymphoma
439126|NCT00935090|recurrent adult lymphoblastic lymphoma
439127|NCT00935090|recurrent grade 1 follicular lymphoma
439128|NCT00935090|recurrent grade 2 follicular lymphoma
439129|NCT00935090|recurrent grade 3 follicular lymphoma
439130|NCT00935090|recurrent mantle cell lymphoma
439131|NCT00935090|recurrent marginal zone lymphoma
439132|NCT00935090|recurrent small lymphocytic lymphoma
439133|NCT00935090|intraocular lymphoma
439134|NCT00935090|primary central nervous system non-Hodgkin lymphoma
439135|NCT00935090|primary central nervous system Hodgkin lymphoma
439136|NCT00935090|post-transplant lymphoproliferative disorder
439137|NCT00935090|chronic eosinophilic leukemia
439138|NCT00935090|chronic neutrophilic leukemia
439139|NCT00935090|primary myelofibrosis
439140|NCT00935090|essential thrombocythemia
439141|NCT00935090|polycythemia vera
439142|NCT00935090|extramedullary plasmacytoma
439143|NCT00935090|isolated plasmacytoma of bone
439144|NCT00935090|stage I multiple myeloma
439145|NCT00935090|stage II multiple myeloma
439146|NCT00935090|stage III multiple myeloma
439147|NCT00935090|primary systemic amyloidosis
439148|NCT00935090|refractory multiple myeloma
439149|NCT00935090|de novo myelodysplastic syndromes
439150|NCT00935090|previously treated myelodysplastic syndromes
439151|NCT00935090|secondary myelodysplastic syndromes
439152|NCT00935090|myelodysplastic/myeloproliferative neoplasm, unclassifiable
439153|NCT00935077|Hypertension
439154|NCT00935077|Pharmacist Physician Collaborative Management of Hypertension
439155|NCT00935064|Diabetes
439156|NCT00935051|type 1 diabetes
439157|NCT00935051|type 2 diabetes
439158|NCT00935051|Diabetic foot ulcer
439159|NCT00935025|Phase I
439160|NCT00935025|Japanese healthy volunteer
439161|NCT00935025|AZD1305
439162|NCT00935025|Japanese and Caucasian
439163|NCT00934986|Chronic Lymphocytic Leukemia
439164|NCT00934986|NK Cells
439165|NCT00934973|irritable bowel syndrome
439166|NCT00934973|treatment
439167|NCT00934960|vision
439168|NCT00934960|Intraocular lenses
439169|NCT00934947|Burns
439170|NCT00934947|Pain
439171|NCT00934934|Candida
439172|NCT00934934|ventilator associated pneumonia
439173|NCT00934934|respiratory tract infection
439174|NCT00934934|antifungal
439175|NCT00934934|biomarker
439176|NCT00934921|Bioequivalence
439177|NCT00934908|Zyprexa®
439178|NCT00934908|Green Tea
439179|NCT00934908|ALL
439180|NCT00934895|stage IIIA breast cancer
439181|NCT00934895|stage IIIB breast cancer
439182|NCT00934895|stage IIIC breast cancer
439183|NCT00934895|stage IV breast cancer
439184|NCT00934895|HER2-negative breast cancer
439185|NCT00934895|recurrent breast cancer
439186|NCT00934882|Colorectal cancer
439187|NCT00934882|Targeted therapy
439188|NCT00934882|Multi-kinase inhibitor
439189|NCT00934882|FOLFOX
439190|NCT00934882|FOLFIRI
439191|NCT00934843|Cardiopulmonary Bypass (CPB)
439192|NCT00934843|System Inflammatory Response
439193|NCT00934843|Low Cardiac Output Syndrome (LCOS) in Neonates
439194|NCT00934843|Methylprednisolone
439195|NCT00934843|Cardiopulmonary Bypass (CPB) in Neonates
439196|NCT00934843|Glucocorticoid Use in Neonatal Cardiac Surgery
439197|NCT00934843|Steroid
439198|NCT00934830|Antibiotic
439199|NCT00934830|Ultrasound
439200|NCT00934830|Efficacy
439201|NCT00934830|Treatment
439202|NCT00934817|Volunteer
439203|NCT00934804|refractive surgery
439204|NCT00934791|Kidney Transplant
439205|NCT00934791|Autosomal dominant polycystic kidney disease
439206|NCT00934791|Polycystic liver disease
439207|NCT00934778|Confocal microscopy
439208|NCT00934778|Endocytoscopy
439209|NCT00934778|Diffuse lung disease
439210|NCT00934778|Minimally invasive
439211|NCT00934778|Lung cancer and dysplasia
439212|NCT00934765|overweight, obesity, male, fertility
439213|NCT00934752|de novo stenotic lesions
439214|NCT00934739|High-Risk Oral Cavity Cancer,
439215|NCT00934739|Anti-Angiogenesis
439216|NCT00934726|Quality of Life
439217|NCT00934726|Patient satisfaction
439218|NCT00934726|Schizophrenia
439219|NCT00934726|Investigate quality of life in schizophrenia
439220|NCT00934713|montelukast, very young children, lung function tests
439221|NCT00934700|perinatal asphyxia
439222|NCT00934700|encephalopathy
439223|NCT00934700|neuroprotection
439224|NCT00934687|depression
439225|NCT00934687|depressive
439226|NCT00934687|botulinum
439227|NCT00934687|botox
439228|NCT00934674|Healthy Subjects
439229|NCT00934661|hip resurfacing
439230|NCT00934661|hip arthroplasty
439231|NCT00934635|D2-receptor occupancy
439232|NCT00934635|Antipsychotic drugs
439233|NCT00934635|Paliperidone ER, Oral risperidone
439234|NCT00934635|Dopamine
439235|NCT00934635|Fallypride
439236|NCT00934635|Plasma concentration
439237|NCT00934635|Therapeutic window, Healthy controls
439238|NCT00934622|AcrySof
439239|NCT00934622|ReSTOR
439240|NCT00934622|Aspheric IOL
439241|NCT00934622|Cataract
439242|NCT00934609|Exercise
439243|NCT00934609|heart failure
439244|NCT00934609|dilated cardiomyopathy
439245|NCT00934609|Endurance training
439246|NCT00934596|Cardiac de-airing
439247|NCT00934596|CO2 insufflation
439248|NCT00934596|Air emboli
439249|NCT00934596|Trans cranial doppler
439250|NCT00934596|Intraoperative echocardiography
439251|NCT00934583|Bulimia Nervosa
439252|NCT00934583|Binge Eating
439253|NCT00934583|Binge-Eating Disorder
439254|NCT00934570|Obesity
439255|NCT00934570|Metformin
439256|NCT00934570|Physical activity
439257|NCT00934570|Cardiovascular health
439258|NCT00934544|Myelofibrosis
439259|NCT00934544|Post-Polycythemia Vera Myelofibrosis
439260|NCT00934544|Post-Essential Thrombocythemia Myelofibrosis
439261|NCT00934531|Mild Cognitive Impairment (MCI)
439262|NCT00934531|Falls
439263|NCT00934531|donepezil
439264|NCT00934531|gait variability
439265|NCT00934518|Squamous cell carcinoma, Head and Neck cancer
439266|NCT00934505|Positron-Emission Tomography
439267|NCT00934505|PET Scan
439268|NCT00934505|FDG
439269|NCT00934505|oesophageal cancer
439270|NCT00934505|chemo-Radiation Oncology
439271|NCT00934505|SUV
439272|NCT00934492|Malnutrition
439273|NCT00934492|Wasting
439274|NCT00934492|Kwashiorkor
439275|NCT00934492|Immune deficiency
439276|NCT00934492|Infection
439277|NCT00934492|Prophylaxis
439278|NCT00934492|Mortality
439279|NCT00934492|Kenya
439280|NCT00934479|Chronic Constipation
439281|NCT00934479|Constipation Predominant Irritable Bowel Syndrome
439282|NCT00934479|Intestinal Microecology
439283|NCT00934453|Healthy adult volunteers
439284|NCT00934453|Lactobacillus rhamnosus GG
439285|NCT00934453|probiotic
439286|NCT00934453|dietary supplement
439287|NCT00934453|safety
439288|NCT00934453|Safety Assessment
439289|NCT00934440|kidney cancer
439290|NCT00934440|renal cell
439291|NCT00934427|Raynaud's
439292|NCT00934427|scleroderma
439293|NCT00934427|nitroglycerin
439294|NCT00934427|MQX-503
439295|NCT00934427|treatment
439296|NCT00934401|FLT
439297|NCT00934401|fluorolabeled thymidine
439298|NCT00934401|breast cancer
439299|NCT00934401|Positron-Emission Mammography
439300|NCT00934388|Sportsmans groin, Gilmores groin
439301|NCT00934375|Mild Cognitive Impairment
439302|NCT00934349|Comoro Island
439303|NCT00934349|vit B1 intake
439304|NCT00934349|Thiamine status
439305|NCT00934349|Genetic factor
439306|NCT00934323|volunteer
439307|NCT00934310|Patient Safety
439308|NCT00934310|Team work
439309|NCT00934310|Communication
439310|NCT00934310|Ambulatory surgical patients
439311|NCT00934297|MRI visible breast lesions that are occult under ultrasound
439312|NCT00934284|sciatic neuropathy
439313|NCT00934284|physical therapy
439314|NCT00934284|spinal injections
439315|NCT00934271|acromegaly
439316|NCT00934271|irradiation
439317|NCT00934271|remission
439318|NCT00934271|pituitary function
439319|NCT00934258|genes
439320|NCT00934258|rosuvastatin
439321|NCT00934258|fenofibrate
439322|NCT00934258|Cardiovascular (CV) diseases
439323|NCT00934258|dyslipidemia
439324|NCT00934258|metabolic syndrome
439325|NCT00934258|identify genetic determinants of the wide range of interindividual variability in phenotypic and clinical response to the lipid-lowering drug classes
439326|NCT00934258|identify genetic susceptibility to drug-related side effects.
439327|NCT00934245|Influenza
439328|NCT00934245|India
439329|NCT00934245|Children
439330|NCT00934245|Trivalent Influenza Vaccine (TIV)
439331|NCT00934245|Inactivated poliovirus vaccine (IPV)
439332|NCT00934245|Direct vaccine effectiveness
439333|NCT00934245|Indirect vaccine effectiveness
439334|NCT00934232|cancer
439335|NCT00934232|myeloma
439336|NCT00934219|hypertriglyceridemia
439337|NCT00934219|triglycerides
439338|NCT00934219|familial hypertriglyceridemia
439339|NCT00934206|Exercise
439340|NCT00934206|healthy subjects
439341|NCT00934180|Bioequivalence
439342|NCT00934154|multiple myeloma
439343|NCT00934154|thalidomide
439344|NCT00934154|melphalan
439345|NCT00934154|prednisolone
439346|NCT00934154|newly diagnosed
439347|NCT00934154|elderly
439348|NCT00934154|not eligible for transplantation
439349|NCT00934141|Organizational change
439350|NCT00934141|process improvement
439351|NCT00934141|addiction treatment
439352|NCT00934141|cost effectiveness study
439353|NCT00934128|Advanced Cancer
439354|NCT00934128|Persistent Dyspnea
439355|NCT00934128|Shortness of breath
439356|NCT00934128|Specialized breathing devices
439357|NCT00934128|Bilevel positive airway pressure device
439358|NCT00934128|BIPAP
439359|NCT00934128|High flow oxygen delivery device
439360|NCT00934128|VapoTherm
439361|NCT00934128|Edmonton Symptom Assessment Scale
439362|NCT00934128|ESAS
439363|NCT00934115|To define the incidence, categories of infections by organ systems, etiologic agents and risk
439364|NCT00934037|Coronary Artery Disease
439365|NCT00934037|Computed Tomography
439366|NCT00934037|Myoperfusion
439367|NCT00934037|Angiography
439368|NCT00934037|SPECT
439369|NCT00934024|nicotine dependence
439370|NCT00934024|tobacco
439371|NCT00934024|smoking
439372|NCT00934011|C-reactive protein
439373|NCT00934011|procalcitonin
439374|NCT00934011|sepsis
439375|NCT00934011|antibiotic therapy
439376|NCT00933998|DPN
439377|NCT00933959|Sleep problems
439378|NCT00933959|Awareness training program
439379|NCT00933959|Mind body bridging
439380|NCT00933920|Aliskiren,
439381|NCT00933920|hypertension,
439382|NCT00933920|renin-angiotensin-aldosterone system,
439383|NCT00933920|pharmacokinetics,
439384|NCT00933920|pharmacodynamics
439385|NCT00933894|VX-950-TiDP24-C133
439386|NCT00933894|VX-950-C133
439387|NCT00933894|VX950
439388|NCT00933894|HCV
439389|NCT00933894|telaprevir
439390|NCT00933894|escitalopram
439391|NCT00933881|GDM
439392|NCT00933868|A stroke that occurred three months to four years ago
439393|NCT00933855|Training Workshop
439394|NCT00933855|Communication
439395|NCT00933855|Questionnaires
439396|NCT00933855|Multiple Diseases
439397|NCT00933829|absorbable sutures
439398|NCT00933829|non-absorbable sutures
439399|NCT00933829|wound management
439400|NCT00933816|sorafenib
439401|NCT00933816|intraarterial infusion chemotherapy
439402|NCT00933816|Low dose FP
439403|NCT00933816|cisplatin
439404|NCT00933816|fluorouracil
439405|NCT00933790|TB
439406|NCT00933790|HIV
439407|NCT00933790|ARR
439408|NCT00933790|Short course chemotherapy
439409|NCT00933790|Drug resistance
439410|NCT00933751|central venous oxygen saturation
439411|NCT00933751|oxygen transport
439412|NCT00933751|physiologic monitoring
439413|NCT00933751|tissue oxygenation
439414|NCT00933751|Patients before high risk abdominal surgery
439415|NCT00933738|Patients needing OAT (Oral Anticoagulation Therapy)
439416|NCT00933725|menopausal syndrome
439417|NCT00933725|TCM intervention
439418|NCT00933673|NK/T cell lymphoma
439419|NCT00933673|DICE
439420|NCT00933673|L-asparaginase
439421|NCT00933660|Education
439422|NCT00933660|Retention
439423|NCT00933660|Retrieval
439424|NCT00933647|Camellia sinensis
439425|NCT00933647|Ilex paraguariensis
439426|NCT00933647|Green tea
439427|NCT00933647|Yerba mate tea
439428|NCT00933647|Maté
439429|NCT00933647|Dyslipidemia
439430|NCT00933647|Inflammation
439431|NCT00933647|Obesity
439432|NCT00933634|atrial fibrillation
439433|NCT00933634|electrical cardioversion
439434|NCT00933634|pharmacological cardioversion
439435|NCT00933608|subjective memory complaints
439436|NCT00933608|cognitively healthy
439437|NCT00933608|family history
439438|NCT00933608|AD
439439|NCT00933595|HIV
439440|NCT00933595|Lung
439441|NCT00933582|Osteoarthritis, Knee
439442|NCT00933582|Knee Pain
439443|NCT00933582|Pain Measurement
439444|NCT00933582|Naproxen
439445|NCT00933582|Placebo
439446|NCT00933582|Treatment Outcome
439447|NCT00933556|infection
439448|NCT00933556|probiotics
439449|NCT00933543|Acne Vulgaris
439450|NCT00933543|Moderate to severe
439451|NCT00933517|breast cancer, neoadjuvant therapies, chemotherapy, targeted therapy
439452|NCT00933491|healthy
439453|NCT00933478|Patulous Eustachian Tube Dysfunction
439454|NCT00933465|Fecal incontinence
439455|NCT00933452|duloxetine
439456|NCT00933452|pharmacokinetics
439457|NCT00933452|antidepressant
439458|NCT00933452|antidepressive agents
439459|NCT00933452|depression
439460|NCT00933452|psychotropic drugs
439461|NCT00933452|safety
439462|NCT00933452|Chinese
439463|NCT00933452|HAN
439464|NCT00933452|BDNF
439465|NCT00933439|Depression
439466|NCT00933439|Major Depressive Disorder
439467|NCT00933439|Cognitive Function
439468|NCT00933439|Psychosocial Function
439469|NCT00933426|Castration-Resistant Prostate Cancer
439470|NCT00933426|CRPC
439471|NCT00933426|Prostate
439472|NCT00933426|Lenalidomide
439473|NCT00933426|Revlimid
439474|NCT00933426|CC-5103
439475|NCT00933426|Paclitaxel
439476|NCT00933426|Taxol
439477|NCT00933426|Taxanes
439478|NCT00933400|Computed Tomography
439479|NCT00933400|CTA
439480|NCT00933400|Cardiac CT
439481|NCT00933400|CT
439482|NCT00933400|Cardiac CTA
439483|NCT00933400|Chest Pain
439484|NCT00933400|Heart Attack
439485|NCT00933400|Emergency Department
439486|NCT00933400|Myocardial Infarction
439487|NCT00933400|Cost Effectiveness
439488|NCT00933400|Acute Coronary Event
439489|NCT00933400|Heart Imaging
439490|NCT00933387|oral squamous cell carcinoma
439491|NCT00933387|neoadjuvant bio-chemotherapy
439492|NCT00933387|concurrent bio-radiotherapy
439493|NCT00933387|biomarker
439494|NCT00933374|bladder cancer
439495|NCT00933374|RAD001
439496|NCT00933374|Paclitaxel
439497|NCT00933361|Adult
439498|NCT00933348|ulcer
439499|NCT00933348|venous
439500|NCT00933348|pressure
439501|NCT00933348|wound
439502|NCT00933348|treatment
439503|NCT00933322|ruminant
439504|NCT00933322|industrial
439505|NCT00933322|endothelial function
439506|NCT00933322|flow-mediated dilation
439507|NCT00933322|blood lipids
439508|NCT00933322|nutrition
439509|NCT00933322|trans fatty acids
439510|NCT00933322|coronary disease
439511|NCT00933322|endothelial function of the brachial artery
439512|NCT00933322|inflammation
439513|NCT00933322|insulin resistancy
439514|NCT00933322|coagulation
439515|NCT00933309|Breast
439516|NCT00933309|Obese
439517|NCT00933309|Obesity Treatment
439518|NCT00933309|Exemestane
439519|NCT00933309|Aromasin
439520|NCT00933309|Metformin and Rosiglitazone
439521|NCT00933309|Avandamet
439522|NCT00933309|Postmenopausal
439523|NCT00933309|Hormone-sensitive
439524|NCT00933309|Hormone-receptive-positive breast cancer
439525|NCT00933296|Schnitzler syndrome
439526|NCT00933296|Waldentsröm's disease
439527|NCT00933296|anakinra
439528|NCT00933283|Healthy participants
439529|NCT00933283|Pharmacokinetics
439530|NCT00933283|Pharmacodynamic
439531|NCT00933283|Potential interaction
439532|NCT00933283|VX-950-TiDP24-C135
439533|NCT00933283|VX-950
439534|NCT00933283|Methadone
439535|NCT00933283|Telaprevir
439536|NCT00933283|Steady-state
439537|NCT00933270|Superficial Femoral Artery or SFA
439538|NCT00933244|Vitamin D
439539|NCT00933244|Cholecalciferol
439540|NCT00933244|Parathyroid Hormone
439541|NCT00933244|Calcium Absorption
439542|NCT00933244|Bone Mineral Density
439543|NCT00933244|Muscle Function
439544|NCT00933231|Tacrolimus
439545|NCT00933231|Kidney Transplantation
439546|NCT00933231|Advagraf
439547|NCT00933231|Immunosuppression
439548|NCT00933231|Angiotensin-Converting Enzyme Inhibitors
439549|NCT00933179|Prevention of pregnancy
439550|NCT00933153|Elderly
439551|NCT00933153|Malnutrition
439552|NCT00933153|Oral Nutrition Supplement
439553|NCT00933153|Meals on Wheels
439554|NCT00933140|HIV
439555|NCT00933140|women
439556|NCT00933140|anal cytology
439557|NCT00933127|contiguous stage II grade 1 follicular lymphoma
439558|NCT00933127|contiguous stage II grade 2 follicular lymphoma
439559|NCT00933127|contiguous stage II grade 3 follicular lymphoma
439560|NCT00933127|noncontiguous stage II grade 1 follicular lymphoma
439561|NCT00933127|noncontiguous stage II grade 2 follicular lymphoma
439562|NCT00933127|noncontiguous stage II grade 3 follicular lymphoma
439563|NCT00933127|stage III grade 1 follicular lymphoma
439564|NCT00933127|stage III grade 2 follicular lymphoma
439565|NCT00933127|stage III grade 3 follicular lymphoma
439566|NCT00933127|stage IV grade 1 follicular lymphoma
439567|NCT00933127|stage IV grade 2 follicular lymphoma
439568|NCT00933127|stage IV grade 3 follicular lymphoma
439569|NCT00933114|DCE MRI
439570|NCT00933114|PET
439571|NCT00933114|Perfusion
439572|NCT00933114|Permeability
439573|NCT00933114|Cancer of the head and neck
439574|NCT00933114|Head, Neck neoplasms
439575|NCT00933088|adolescent coping strategies
439576|NCT00933088|stress response
439577|NCT00933088|breast cancer
439578|NCT00933049|Efficacy
439579|NCT00933049|children
439580|NCT00933049|pneumonia
439581|NCT00933049|cotrimoxazole
439582|NCT00933049|amoxicillin
439583|NCT00933036|Osteoporosis
439584|NCT00933036|VCF
439585|NCT00933036|PVA
439586|NCT00933036|Vertebroplasty
439587|NCT00933036|Kyphoplasty
439588|NCT00933036|Vertebral fracture
439589|NCT00933036|Pathologic fracture
439590|NCT00933036|Vertebral augmentation
439591|NCT00933010|metabolic syndrome
439592|NCT00933010|lipids
439593|NCT00933010|waist circumference
439594|NCT00933010|HDL
439595|NCT00933010|hypertension
439596|NCT00932997|psychosocial effects of cancer and its treatment
439597|NCT00932997|stage I breast cancer
439598|NCT00932997|stage II breast cancer
439599|NCT00932997|stage IIIA breast cancer
439600|NCT00932997|cancer survivor
439601|NCT00932958|Myocardial Infarction
439602|NCT00932919|Agoraphobia
439603|NCT00932919|Cognitive therapy
439604|NCT00932919|Thought field therapy
439605|NCT00932919|Psychotherapy research
439606|NCT00932906|Education
439607|NCT00932906|Retention
439608|NCT00932906|Retrieval
439609|NCT00932906|Self training
439610|NCT00932893|Lung Neoplasms ALK gene crizotinib
439611|NCT00932867|Arterial Hypertension
439612|NCT00932854|Mediastinal lymphadenopathy
439613|NCT00932854|EBUS
439614|NCT00932854|Bronchoscopy
439615|NCT00932854|Sarcoidosis
439616|NCT00932828|Peanut allergy
439617|NCT00932802|Non-Interventional
439618|NCT00932802|Observational
439619|NCT00932802|NIS
439620|NCT00932802|Moxifloxacin
439621|NCT00932802|MXF
439622|NCT00932802|Avelox
439623|NCT00932802|AECB
439624|NCT00932750|Body composition
439625|NCT00932750|Weight loss
439626|NCT00932750|Weight management
439627|NCT00932750|Beverages
439628|NCT00932750|Diet
439629|NCT00932724|Metastatic
439630|NCT00932724|Colorectal
439631|NCT00932724|Cancer
439632|NCT00932724|refractory
439633|NCT00932724|Phase II
439634|NCT00932724|randomised
439635|NCT00932724|double-blind
439636|NCT00932724|controlled
439637|NCT00932724|multicenter
439638|NCT00932724|CY-503
439639|NCT00932724|Cytavis
439640|NCT00932711|COPD
439641|NCT00932698|Relapsed multiple myeloma
439642|NCT00932698|Refractory multiple myeloma
439643|NCT00932698|IXAZOMIB Proteasome inhibitor
439644|NCT00932685|pediatric emergence agitation and pain
439645|NCT00932672|Prostate Cancer
439646|NCT00932672|Atkins
439647|NCT00932659|End-Stage Renal Disease
439648|NCT00932659|Hemodialysis
439649|NCT00932659|Cardiac Arrhythmias
439650|NCT00932633|neonatal brain injury
439651|NCT00932633|congenital heart disease
439652|NCT00932633|magnetic resonance imaging
439653|NCT00932633|cardiopulmonary bypass
439654|NCT00932633|neurodevelopmental outcome
439655|NCT00932620|hypercholesterolemia
439656|NCT00932620|statins
439657|NCT00932620|simvastatin
439658|NCT00932620|ezetimibe
439659|NCT00932620|LDL particles
439660|NCT00932607|seasonal
439661|NCT00932607|rhinitis
439662|NCT00932607|rhinoconjunctivitis
439663|NCT00932607|birch pollen
439664|NCT00932607|immunotherapy
439665|NCT00932607|sublingual
439666|NCT00932594|Create the New Serial Treatment of TMD
439667|NCT00932594|Promote the Classification of Biodynamics in the TMD
439668|NCT00932594|Evaluate the Effect of Adjusting TMJ Treatment
439669|NCT00932594|Establish the New Standard of the TMJ Treatment
439670|NCT00932594|Invent New Device to Measure Pressure without Trauma
439671|NCT00932581|Parkinson's Disease
439672|NCT00932581|Movement Disorders
439673|NCT00932581|Unified Parkinson's Disease Rating Scale
439674|NCT00932581|Short Parkinson's Evaluation Scale
439675|NCT00932581|Scales for Outcomes in Parkinson's Disease
439676|NCT00932581|Motor Evaluation
439677|NCT00932581|Schwab and England activities of daily living
439678|NCT00932581|Bradykinesia
439679|NCT00932581|psychometrics
439680|NCT00932581|order effects
439681|NCT00932581|hoehn yahr aging
439682|NCT00932581|assessments
439683|NCT00932555|Octocog alfa
439684|NCT00932555|Hemophilia A
439685|NCT00932542|Hemorrhoidectomy
439686|NCT00932529|Antipsychotic drugs
439687|NCT00932529|Treatment effectiveness
439688|NCT00932529|Randomized controlled trial
439689|NCT00932516|South Beach Diet™
439690|NCT00932516|overweight
439691|NCT00932516|obesity
439692|NCT00932516|satiety
439693|NCT00932516|weight loss
439694|NCT00932503|Vicryl plus
439695|NCT00932503|wound infection
439696|NCT00932503|coated suture material
439697|NCT00932503|open abdominal surgery
439698|NCT00932503|transverse laparotomy
439699|NCT00932451|Lung Neoplasms ALK gene Crizotinib
439700|NCT00932438|colon cancer
439701|NCT00932438|liver metastases
439702|NCT00932425|Stroke
439703|NCT00932425|Cryptogenic
439704|NCT00932425|Cardioembolic
439705|NCT00932425|Atrial Fibrillation
439706|NCT00932412|Younger Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML).
439707|NCT00932386|Lower extremity surgery with tourniquet use
439708|NCT00932373|HER2-positive breast cancer
439709|NCT00932373|MBC
439710|NCT00932373|Trastuzumab emtansine
439711|NCT00932373|Herceptin
439712|NCT00932373|T-DM1
439713|NCT00932360|Fibromyalgia
439714|NCT00932360|Transcutaneous Electrical Nerve Stimulation (TENS)
439715|NCT00932347|Camellia sinensis
439716|NCT00932347|volatile sulfur compounds
439717|NCT00932334|kidney
439718|NCT00932334|transplant
439719|NCT00932334|donation
439720|NCT00932321|Contraception
439721|NCT00932295|tobacco
439722|NCT00932295|cigarette
439723|NCT00932295|nicotine
439724|NCT00932282|Peanut
439725|NCT00932282|Allergy
439726|NCT00932282|Hypersensitivity
439727|NCT00932269|Diphtheria
439728|NCT00932269|Tetanus
439729|NCT00932269|Pertussis
439730|NCT00932269|Polio
439731|NCT00932269|Haemophilus influenzae type B
439732|NCT00932269|Hib
439733|NCT00932269|Measles
439734|NCT00932269|Mumps
439735|NCT00932269|Rubella
439736|NCT00932269|Hepatitis B
439737|NCT00932269|Vaccine
439738|NCT00932269|Vaccination
439739|NCT00932269|Immunity
439740|NCT00932269|Vaccination program
439741|NCT00932269|Sweden
439742|NCT00932269|ELISA
439743|NCT00932256|Rhinitis, Allergic, Seasonal
439744|NCT00932243|bacteremia
439745|NCT00932243|sepsis
439746|NCT00932243|Toll-Like-Receptors (TLRs)
439747|NCT00932204|obsessive-compulsive disorder
439748|NCT00932204|repetitive transcranial magnetic stimulation
439749|NCT00932204|right dorsolateral prefrontal cortex
439750|NCT00932204|supplementary motor area (SMA)
439751|NCT00932191|Cataract
439752|NCT00932191|Corneal endothelial cell loss
439753|NCT00932191|Ultrasound power
439754|NCT00932191|Corneal endothelium
439755|NCT00932178|Anxiety
439756|NCT00932178|Worry
439757|NCT00932178|nervousness
439758|NCT00932178|Older Adult
439759|NCT00932152|advanced non-small cell lung cancer
439760|NCT00932152|postmenopausal
439761|NCT00932152|bevacizumab
439762|NCT00932152|fulvestrant
439763|NCT00932152|anastrozole
439764|NCT00932139|Hypertension
439765|NCT00932139|blood pressure
439766|NCT00932139|arrhythmias
439767|NCT00932139|mild to moderate hypertension (145-199/90-110)
439768|NCT00932126|Phase 1 dose escalation dose finding pharmacokinetic and pharmacodynamic study
439769|NCT00932113|tumor necrosis factor (TNF) inhibitor
439770|NCT00932113|tumor necrosis factor (TNF) blockade
439771|NCT00932113|Methotrexate
439772|NCT00932113|treatment
439773|NCT00932113|mechanism
439774|NCT00932113|psoriasis
439775|NCT00932100|ACS
439776|NCT00932100|Acute Coronary Syndrome
439777|NCT00932100|Catheterization
439778|NCT00932087|Platelet function
439779|NCT00932087|diabetes
439780|NCT00932087|metabolic syndrome
439781|NCT00932074|Atopic Dermatitis
439782|NCT00932061|Fibromyalgia
439783|NCT00932061|Healthy controls
439784|NCT00932061|Acupuncture
439785|NCT00932061|Sham Acupuncture
439786|NCT00932061|fMRI
439787|NCT00932061|Biological marker
439788|NCT00932048|Diabetes Mellitus
439789|NCT00932048|Statins
439790|NCT00932048|PET
439791|NCT00932035|breast cancer
439792|NCT00932035|axillary mapping
439793|NCT00932035|lymphedema
439794|NCT00932009|Human papillomavirus infection
439795|NCT00932009|Tanzanian men
439796|NCT00932009|Prevalence
439797|NCT00931996|schizophrenia
439798|NCT00931996|antipsychotic
439799|NCT00931996|risperidone
439800|NCT00931983|Incomplete spinal cord injuries
439801|NCT00931983|Walking
439802|NCT00931983|Treadmill
439803|NCT00931983|Training
439804|NCT00931970|Hemodialysis
439805|NCT00931970|Peritoneal dialysis
439806|NCT00931970|Mortality
439807|NCT00931970|Prospective cohort
439808|NCT00931970|Clinical study
439809|NCT00931957|Etanercept
439810|NCT00931957|Behcet's syndrome
439811|NCT00931957|Behcet's Disease
439812|NCT00931957|Ocular Lesions
439813|NCT00931957|Uveitis
439814|NCT00931957|Retinal Vasculitis
439815|NCT00931944|ALS
439816|NCT00931944|Amyotrophic Lateral Sclerosis
439817|NCT00931944|Lou Gehrig
439818|NCT00931944|Lou Gehrig's
439819|NCT00931944|Lou Gehrig's disease
439820|NCT00931944|Motor Neuron Disease
439821|NCT00931944|Nervous System Diseases
439822|NCT00931944|KNS-760704
439823|NCT00931944|RTPB
439824|NCT00931905|This study included workers exposed to lead.
439825|NCT00931892|celiac disease
439826|NCT00931892|gluten challenge
439827|NCT00931866|diclofenac
439828|NCT00931866|acute pain
439829|NCT00931866|topical
439830|NCT00931866|patch
439831|NCT00931866|Acute Pain due to Mild to Moderate Soft Tissue Injury
439832|NCT00931840|EZN-2208 (PEG-SN38)
439833|NCT00931827|Contraception
439834|NCT00931814|Depression
439835|NCT00931814|physical function
439836|NCT00931814|Quality of life
439837|NCT00931801|AIDS
439838|NCT00931801|HIV
439839|NCT00931801|Atazanavir
439840|NCT00931801|Raltegravir
439841|NCT00931801|Tenofovir
439842|NCT00931801|protease inhibitors
439843|NCT00931788|Management of hypertension and cholesterol
439844|NCT00931788|stroke
439845|NCT00931788|TIA
439846|NCT00931775|Major depressive disorder, citalopram, pindolol, HDRS
439847|NCT00931762|Bone marrow
439848|NCT00931762|Myelofibrosis
439849|NCT00931762|JAK2mutation
439850|NCT00931762|Post-Polycythemia Vera
439851|NCT00931762|Post-Essential Thrombocytopenia
439852|NCT00931749|ultrasound therapy
439853|NCT00931749|knee cartilage thickness
439854|NCT00931749|knee cartilage volume
439855|NCT00931749|mild knee osteoarthritis
439856|NCT00931749|moderate knee osteoarthritis
439857|NCT00931736|Tuberculosis
439858|NCT00931723|Acute Mania
439859|NCT00931723|Mania, Adults
439860|NCT00931723|Seroquel
439861|NCT00931723|Acute Mania in Adult Patients
439862|NCT00931710|Hypertension
439863|NCT00931710|combination therapy
439864|NCT00931710|valsartan
439865|NCT00931710|cardiovascular diseases
439866|NCT00931697|Mefloquine
439867|NCT00931697|Malaria
439868|NCT00931697|(+) Mefloquine
439869|NCT00931697|Pharmacokinetics
439870|NCT00931671|Physical fitness
439871|NCT00931671|Cerebral circulation
439872|NCT00931671|Walking
439873|NCT00931645|Chronic lymphocytic leukemia,
439874|NCT00931645|autologous stem cell transplantation
439875|NCT00931632|Bronchopulmonary Dysplasia, BPD
439876|NCT00931619|Fluorine-18 Fluorodeoxyglucose
439877|NCT00931619|Epilepsy
439878|NCT00931619|Epileptic Focus
439879|NCT00931619|Temporal Lobe Epilepsy
439880|NCT00931619|Depression
439881|NCT00931619|Major Depressive Disorder
439882|NCT00931619|Healthy Volunteer
439883|NCT00931619|HV
439884|NCT00931606|anemia
439885|NCT00931606|metastatic
439886|NCT00931606|breast
439887|NCT00931606|cancer
439888|NCT00931593|Transient lower esophageal sphincter relaxation
439889|NCT00931593|high resolution manometry
439890|NCT00931593|dentsleeve probe
439891|NCT00931593|healthy volunteers
439892|NCT00931580|Vitamin D
439893|NCT00931580|Adolescent
439894|NCT00931580|African American
439895|NCT00931580|White
439896|NCT00931541|Safety
439897|NCT00931541|Tolerability
439898|NCT00931541|Healthy
439899|NCT00931528|sexual dysfunction
439900|NCT00931528|stage IIB prostate cancer
439901|NCT00931528|stage IIA prostate cancer
439902|NCT00931528|adenocarcinoma of the prostate
439903|NCT00931515|DDD
439904|NCT00931502|Stent thrombosis
439905|NCT00931502|Acute Coronary Syndrome
439906|NCT00931502|ACS
439907|NCT00931502|Stenting
439908|NCT00931502|Interventional Cardiology
439909|NCT00931502|Cardiology
439910|NCT00931502|Cardiovascular Research
439911|NCT00931502|Registry
439912|NCT00931489|Age Related Macular Degeneration
439913|NCT00931489|Lucentis
439914|NCT00931489|Ranibizumab
439915|NCT00931489|Antibodies
439916|NCT00931489|Retinal and RPE Autoimmunity
439917|NCT00931463|second line therapy
439918|NCT00931463|combination antiretroviral therapy
439919|NCT00931463|first-line failure
439920|NCT00931463|AIDS
439921|NCT00931463|treatment experienced
439922|NCT00931450|estrogen receptor-positive breast cancer
439923|NCT00931450|HER2-negative breast cancer
439924|NCT00931450|stage IA breast cancer
439925|NCT00931450|stage IB breast cancer
439926|NCT00931450|stage II breast cancer
439927|NCT00931450|stage IIIA breast cancer
439928|NCT00931450|stage IIIB breast cancer
439929|NCT00931437|vitamin K
439930|NCT00931437|Bio-availability
439931|NCT00931424|Primary Chronic Venous Insufficiency
439932|NCT00931424|surgery
439933|NCT00931424|reconstruction
439934|NCT00931424|valve
439935|NCT00931411|Atopic Dermatitis
439936|NCT00931411|Vitamin B3
439937|NCT00931372|Insulin release
439938|NCT00931372|Diabetes mellitus type 2
439939|NCT00931372|GLP-1 agonist
439940|NCT00931359|axillary
439941|NCT00931359|hyperhidrosis
439942|NCT00931359|primary focal
439943|NCT00931346|HIV
439944|NCT00931346|Human Immunodeficiency Virus
439945|NCT00931333|Vertebroplasty
439946|NCT00931333|spine
439947|NCT00931333|vertebra height
439948|NCT00931333|adverse events
439949|NCT00931333|calcium phosphate bone cement
439950|NCT00931320|Ratio improvement
439951|NCT00931320|LDL-C
439952|NCT00931320|HDL-C
439953|NCT00931320|Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
439954|NCT00931320|High Density Lipoprotein Cholesterol
439955|NCT00931281|Multiple Ascending Doses
439956|NCT00931268|Lipoatrophy
439957|NCT00931268|Buttock treatment
439958|NCT00931255|kidney transplant
439959|NCT00931255|tacrolimus
439960|NCT00931255|sirolimus
439961|NCT00931255|delayed graft function
439962|NCT00931255|Graft survival
439963|NCT00931255|Acute rejection
439964|NCT00931255|Chronic allograft nephropathy
439965|NCT00931242|eczema
439966|NCT00931242|dermatitis
439967|NCT00931242|TNF blockade
439968|NCT00931242|PDE4 inhibitor
439969|NCT00931242|T cell inhibitor
439970|NCT00931229|hepatitis B reactivation
439971|NCT00931216|PMTCT
439972|NCT00931216|Vertical transmission of HIV
439973|NCT00931216|Pregnant women
439974|NCT00931216|Infant HIV testing
439975|NCT00931216|Kenya
439976|NCT00931216|AIDS
439977|NCT00931164|phase I/II study
439978|NCT00931164|effects of sodium oxybate
439979|NCT00931164|cohort of 6 children and young adults
439980|NCT00931164|AHC
439981|NCT00931138|Acute Myeloid Leukemia in adults
439982|NCT00931138|Newly-diagnosed untreated AML
439983|NCT00931138|Patient aged 50 to 70 years
439984|NCT00931125|Severe proliferative diabetic retinopathy
439985|NCT00931112|Peripheral Arterial Disease
439986|NCT00931112|Walking ability
439987|NCT00931112|Quality of life
439988|NCT00931112|Exercise training
439989|NCT00931099|pregnancy
439990|NCT00931099|sleep disordered breathing
439991|NCT00931099|obstructive sleep apnea
439992|NCT00931086|Rheumatoid Arthritis
439993|NCT00931086|RA
439994|NCT00931073|Drug Interactions
439995|NCT00931073|pharmacokinetics
439996|NCT00931073|CYP2D6
439997|NCT00931073|CYP2C19
439998|NCT00931073|ketoconazole
439999|NCT00931073|omeprazole
440000|NCT00931060|Ammonia
440001|NCT00931060|Citric acid cycle
440002|NCT00931060|Branched Chain Amino Acids
440003|NCT00931034|South Beach Diet™
440004|NCT00931034|overweight
440005|NCT00931034|obesity
440006|NCT00931034|satiety
440007|NCT00931034|weight loss
440008|NCT00931034|diabetes
440009|NCT00931008|Locally Advanced or Metastatic Non-Small Cell Lung Cancer
440010|NCT00930982|Ciprofloxacin
440011|NCT00930982|Airway infection
440012|NCT00930982|Bronchiectasis
440013|NCT00930969|Cardiac Ischemia
440014|NCT00930969|ST segment elevated Myocardial Infarction (STEMI)
440015|NCT00930969|Non-ST Segment elevated Myocardial Infarction (NSTEMI)
440016|NCT00930969|Implantable Cardioverter Defibrillator (ICD)
440017|NCT00930969|Cardiac Electrogram (EGM)
440018|NCT00930969|Coronary Artery Disease (CAD)
440019|NCT00930956|Diabetes
440020|NCT00930956|Obesity
440021|NCT00930956|Hyperglycemia
440022|NCT00930956|Dietary Fiber
440023|NCT00930956|Wheat
440024|NCT00930956|Grain
440025|NCT00930943|opioid tolerant
440026|NCT00930943|chronic pain
440027|NCT00930930|triple-negative breast cancer
440028|NCT00930930|stage II breast cancer
440029|NCT00930930|stage IIIA breast cancer
440030|NCT00930930|stage IIIB breast cancer
440031|NCT00930930|stage IIIC breast cancer
440032|NCT00930930|male breast cancer
440033|NCT00930917|delivery room, polyethylene cap, preterm infant, temperature
440034|NCT00930891|Extensive-Disease Small-Cell Lung Cancer
440035|NCT00930878|registry
440036|NCT00930878|drug eluting coronary stent system
440037|NCT00930878|observational
440038|NCT00930878|prospective
440039|NCT00930878|open-label
440040|NCT00930852|Migraine
440041|NCT00930852|Children
440042|NCT00930852|Primary headache disorders
440043|NCT00930852|Appetite
440044|NCT00930852|Obesity
440045|NCT00930852|Feeding Behavior
440046|NCT00930839|Niacin
440047|NCT00930839|Prostaglandin D2
440048|NCT00930839|Flushing
440049|NCT00930839|Nicotinic acid stimulated release of prostaglandin D2
440050|NCT00930826|The effect of bronchial asthma on school performance
440051|NCT00930813|Drug coated balloon
440052|NCT00930813|SFA disease
440053|NCT00930813|Femoropopliteal disease
440054|NCT00930813|Angioplasty
440055|NCT00930813|PAD
440056|NCT00930813|Paclitaxel
440057|NCT00930813|Tubulin modulators
440058|NCT00930813|Antineoplastic Agents
440059|NCT00930813|Mitosis Modulators
440060|NCT00930813|Balloon angioplasty
440061|NCT00930813|Local drug delivery
440062|NCT00930813|Restenosis
440063|NCT00930813|Drug-coated balloon
440064|NCT00930800|Exercise capacity
440065|NCT00930800|Physical activity
440066|NCT00930800|Quality of life
440067|NCT00930787|hernia repair, surgical mesh, co-morbidities
440068|NCT00930774|traumatic brain injury
440069|NCT00930774|rehabilitation
440070|NCT00930774|auditory processing disorder
440071|NCT00930761|breast feeding
440072|NCT00930761|music therapy
440073|NCT00930761|maternal welfare
440074|NCT00930761|infant, newborn
440075|NCT00930722|Quinapril non-interventional/observational study safety
440076|NCT00930709|Botulinum Toxin Type A
440077|NCT00930709|Exercise
440078|NCT00930709|Randomized Controlled Trial
440079|NCT00930709|Muscle Stretching Exercises
440080|NCT00930709|Strength Training
440081|NCT00930709|Treatment Outcome
440082|NCT00930696|endometriosis
440083|NCT00930696|abdominal lavage
440084|NCT00930696|bowel perforation
440085|NCT00930696|discoid resection
440086|NCT00930696|laparoscopy
440087|NCT00930670|ranitidine
440088|NCT00930670|pantoprazole
440089|NCT00930670|esomeprazole
440090|NCT00930670|omeprazole
440091|NCT00930670|atorvastatin
440092|NCT00930670|rosuvastatin
440093|NCT00930670|statin
440094|NCT00930670|clopidogrel resistance
440095|NCT00930670|antiplatelet therapy
440096|NCT00930670|coronary artery disease
440097|NCT00930670|percutaneous coronary intervention
440098|NCT00930670|stent
440099|NCT00930670|clopidogrel
440100|NCT00930670|proton pump inhibitors
440101|NCT00930670|drug interactions
440102|NCT00930670|drug resistance
440103|NCT00930670|genetic polymorphism
440104|NCT00930657|Panic Disorder
440105|NCT00930657|Separation Anxiety
440106|NCT00930657|Familial
440107|NCT00930657|Risk
440108|NCT00930657|Respiratory Physiology
440109|NCT00930644|short bowel syndrome
440110|NCT00930644|parenteral nutrition
440111|NCT00930644|PN
440112|NCT00930644|HPN
440113|NCT00930644|TPN
440114|NCT00930644|SBS
440115|NCT00930631|CAD
440116|NCT00930631|Pharmacokinetics
440117|NCT00930631|BMS747158
440118|NCT00930618|Prolonged pregnancy
440119|NCT00930618|Nulliparity
440120|NCT00930618|Cervical ripening
440121|NCT00930618|Induced labor
440122|NCT00930618|Cesarean section
440123|NCT00930592|Psoriasis
440124|NCT00930592|Metabolic Syndrome
440125|NCT00930592|Cardiovascular Risk
440126|NCT00930566|Allogeneic Hematopoietic Stem Cell Transplantation
440127|NCT00930566|Extracorporeal Photopheresis
440128|NCT00930553|Multiple Sclerosis
440129|NCT00930501|chemotherapy
440130|NCT00930501|cancer
440131|NCT00930501|AMH
440132|NCT00930501|gonadotoxicity
440133|NCT00930501|ovarian reserve
440134|NCT00930501|patients exposed to chemotherapy
440135|NCT00930488|Moxifloxacin
440136|NCT00930488|MXF
440137|NCT00930488|Avelox
440138|NCT00930488|Sinusitis
440139|NCT00930488|Acute bacterial sinusitis, ABS
440140|NCT00930462|colonoscopy
440141|NCT00930462|cap
440142|NCT00930462|hood
440143|NCT00930462|cecal intubation time
440144|NCT00930462|polyp detection rate
440145|NCT00930462|performance
440146|NCT00930449|Pediatrics
440147|NCT00930449|Attention-Deficit Hyperactivity Disorder
440148|NCT00930449|Learning Disorder
440149|NCT00930449|Computerized Working Memory Training Program
440150|NCT00930436|chronic kidney disease
440151|NCT00930410|pancreas neoplasms
440152|NCT00930410|bile duct diseases
440153|NCT00930410|Cholangiopancreatography, Endoscopic Retrograde
440154|NCT00930410|ERCP
440155|NCT00930397|Pre-eclampsia
440156|NCT00930397|UTERO-placental unit vascularization
440157|NCT00930397|Hypertension, pregnancy- induced
440158|NCT00930397|IUGR
440159|NCT00930397|Screening
440160|NCT00930397|3D Doppler Ultrasound
440161|NCT00930384|psoriasis
440162|NCT00930384|fatty liver
440163|NCT00930384|metabolic syndrome
440164|NCT00930371|fatty liver
440165|NCT00930371|insulin resistance
440166|NCT00930371|diet
440167|NCT00930371|inflammation
440168|NCT00930371|oxidative stress
440169|NCT00930358|Sedation
440170|NCT00930358|Colonoscopy
440171|NCT00930358|General anesthesia
440172|NCT00930345|Renal cell carcinoma
440173|NCT00930345|Antiangiogenics
440174|NCT00930345|Biomarkers
440175|NCT00930345|Imagery
440176|NCT00930332|sleep disorders
440177|NCT00930332|nausea and vomiting
440178|NCT00930332|unspecified adult solid tumor, protocol specific
440179|NCT00930332|pain
440180|NCT00930306|Chronic Pain
440181|NCT00930306|AZD2066
440182|NCT00930293|Interpersonal Psychotherapy
440183|NCT00930280|stroke
440184|NCT00930280|brain attack
440185|NCT00930280|hemorrhagic stroke
440186|NCT00930280|risk factors
440187|NCT00930267|fever
440188|NCT00930267|children
440189|NCT00930267|cancer
440190|NCT00930267|leukemia
440191|NCT00930267|stem cell transplantation
440192|NCT00930267|infections in pediatric cancer patients presenting with fever during or following chemotherapy.
440193|NCT00930254|pediatric nursing
440194|NCT00930254|peripheral catheterization
440195|NCT00930254|ultrasonics
440196|NCT00930254|intravenous infusions
440197|NCT00930241|Lung Transplantation
440198|NCT00930241|Tacrolimus
440199|NCT00930241|Deterioration of graft function
440200|NCT00930228|Luteinizing hormone
440201|NCT00930228|Testosterone
440202|NCT00930215|Healthy volunteer
440203|NCT00930215|Japanese males
440204|NCT00930215|homo-EM
440205|NCT00930215|Bioequivalence study
440206|NCT00930202|Traumatic Brain Injury
440207|NCT00930202|Conivaptan
440208|NCT00930202|Vaprisol
440209|NCT00930202|Sodium
440210|NCT00930189|age related macular degeneration
440211|NCT00930163|Adult Asthma
440212|NCT00930150|Schizoaffective Disorder
440213|NCT00930137|Cardiovascular disease
440214|NCT00930137|Trans fatty acids
440215|NCT00930137|Ruminant
440216|NCT00930137|Blood lipids
440217|NCT00930137|Lipoproteins
440218|NCT00930137|Women
440219|NCT00930124|cleft lip and palate
440220|NCT00930124|distraction osteogenesis
440221|NCT00930124|conventional orthognathic surgery
440222|NCT00930124|stability
440223|NCT00930124|morbidity
440224|NCT00930124|soft tissue changes
440225|NCT00930124|psychological adjustment
440226|NCT00930124|speech changes
440227|NCT00930124|velopharyngeal function
440228|NCT00930111|inpatient
440229|NCT00930111|hospitalists
440230|NCT00930111|residency
440231|NCT00930111|job satisfaction
440232|NCT00930111|burnout, professional
440233|NCT00930111|professional practice
440234|NCT00930111|medical education
440235|NCT00930098|acute lymphoblastic leukemia
440236|NCT00930098|clolar
440237|NCT00930098|evoltra
440238|NCT00930098|clofarabine
440239|NCT00930098|refractory/relapsed acute leukemia
440240|NCT00930098|pediatric acute leukemia
440241|NCT00930085|sepsis
440242|NCT00930085|septic shock
440243|NCT00930059|Alzheimer's disease
440244|NCT00930059|PF-04447943
440245|NCT00930059|efficacy
440246|NCT00930059|safety
440247|NCT00930059|plasma concentrations
440248|NCT00930046|ropivacaine
440249|NCT00930046|pediatric
440250|NCT00930046|children
440251|NCT00930046|continuous
440252|NCT00930046|wound
440253|NCT00930046|catheter
440254|NCT00930046|infusion
440255|NCT00930046|pyeloplasty
440256|NCT00930033|Nephrectomy,
440257|NCT00930033|metastatic renal cell carcinoma,
440258|NCT00930033|sunitinib
440259|NCT00930020|ischemic stroke recovery
440260|NCT00930020|minocycline
440261|NCT00930020|neuroprotection
440262|NCT00930020|acute stroke
440263|NCT00930007|Luteinizing hormone
440264|NCT00930007|Puberty
440265|NCT00929994|cardiac rehab
440266|NCT00929981|Contact Dermatitis
440267|NCT00929981|Allergic Dermatitis
440268|NCT00929968|Allergic rhinitis,
440269|NCT00929968|atopic patients,
440270|NCT00929968|seasonal allergy,
440271|NCT00929968|ragweed allergy
440272|NCT00929955|Anti inflammatory
440273|NCT00929955|Schizophrenia
440274|NCT00929955|Simvastatin
440275|NCT00929955|ondansetron
440276|NCT00929942|lung transplantation
440277|NCT00929942|bronchial stenosis
440278|NCT00929942|biodegradable stent
440279|NCT00929929|Aging
440280|NCT00929929|Functionality
440281|NCT00929929|Sarcopenia
440282|NCT00929929|Leucine
440283|NCT00929929|Progressive resistance exercise
440284|NCT00929916|colonoscopy
440285|NCT00929916|MoviPrep
440286|NCT00929890|Obesity
440287|NCT00929890|Exercise
440288|NCT00929890|Diet
440289|NCT00929890|Lifestyle
440290|NCT00929890|Vascular reactivity
440291|NCT00929890|Body composition
440292|NCT00929890|Lipids
440293|NCT00929890|Glucose
440294|NCT00929890|Insulin resistance
440295|NCT00929838|Diabetes Mellitus, Type 2
440296|NCT00929838|Diabetes Mellitus, Adult-Onset
440297|NCT00929838|Diabetes Mellitus, Non-Insulin-Dependent
440298|NCT00929838|African Americans
440299|NCT00929838|Blacks
440300|NCT00929838|Randomized Controlled Trial
440301|NCT00929838|Controlled Clinical Trial
440302|NCT00929838|Behavioral Research
440303|NCT00929838|Behavioral Medicine
440304|NCT00929825|Salivary stimulation
440305|NCT00929825|Transplantation of hematopoietic stem cells
440306|NCT00929825|Hyperboloid
440307|NCT00929825|Transcutaneous Electrical Stimulation
440308|NCT00929812|obesity
440309|NCT00929812|food intake
440310|NCT00929812|glucagon
440311|NCT00929812|ghrelin
440312|NCT00929812|glucose
440313|NCT00929812|insulin
440314|NCT00929786|Plasma levels isoniazid rifampicin pyrazinamide
440315|NCT00929760|Chronic Kidney disease
440316|NCT00929760|Nephrologists
440317|NCT00929760|Primary Care
440318|NCT00929760|Death
440319|NCT00929760|Renal Replacement Therapy
440320|NCT00929760|Specialised renal care
440321|NCT00929747|Cataract
440322|NCT00929747|Toric
440323|NCT00929747|IOL
440324|NCT00929747|AcrySof, LRI
440325|NCT00929734|Inflammation
440326|NCT00929734|Atherosclerosis
440327|NCT00929734|Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors
440328|NCT00929721|CAP
440329|NCT00929708|COPD
440330|NCT00929708|Efficacy
440331|NCT00929708|Safety
440332|NCT00929708|Inhalation
440333|NCT00929682|Labor
440334|NCT00929682|Epidural analgesia
440335|NCT00929682|Local anesthetics
440336|NCT00929682|Levobupivacaine
440337|NCT00929682|Opiates
440338|NCT00929682|Patient-controlled
440339|NCT00929682|Active spontaneous labor requiring epidural analgesia
440340|NCT00929669|pituitary tumor
440341|NCT00929669|endocrine
440342|NCT00929656|Rehabilitation
440343|NCT00929656|Neurophysiology
440344|NCT00929656|Upper Extremity
440345|NCT00929643|health care costs
440346|NCT00929643|Intra-Abdominal Infection
440347|NCT00929630|fibrin glue
440348|NCT00929630|transsphincteric anal fistulas
440349|NCT00929630|seton
440350|NCT00929630|incontinence
440351|NCT00929630|prospective randomised trial
440352|NCT00929617|breast cancer
440353|NCT00929617|physical activity
440354|NCT00929617|exercise
440355|NCT00929617|quality of life
440356|NCT00929617|doubly labeled water
440357|NCT00929604|HIV
440358|NCT00929604|AIDS
440359|NCT00929604|Zambia
440360|NCT00929604|viral load
440361|NCT00929604|antiretroviral therapy
440362|NCT00929604|cluster randomization
440363|NCT00929604|ART monitoring
440364|NCT00929604|treatment failure
440365|NCT00929604|randomized clinical trial
440366|NCT00929604|treatment naive
440367|NCT00929591|stage II breast cancer
440368|NCT00929591|stage IIIA breast cancer
440369|NCT00929578|Psoriasis
440370|NCT00929578|T-lymphocytes
440371|NCT00929578|Fluphenazine
440372|NCT00929565|hemoptysis
440373|NCT00929552|Blood pressure
440374|NCT00929552|Insulin sensitivity
440375|NCT00929552|Blood lipid profile
440376|NCT00929539|Diabetes
440377|NCT00929526|HPV vaccine
440378|NCT00929526|cervical intraepithelial neoplasia (CIN)
440379|NCT00929526|including new onset of autoimmune disease [NOAD])
440380|NCT00929526|new onset of chronic disease (NOCD)
440381|NCT00929526|medically significant condition (MSC)
440382|NCT00929487|contact lens wear
440383|NCT00929487|contact lens solution
440384|NCT00929487|corneal staining
440385|NCT00929461|omega-3 fatty acids
440386|NCT00929461|lactate
440387|NCT00929461|surgery
440388|NCT00929461|gastric cancer
440389|NCT00929461|address the effect of postoperative administration of omega-3 fatty acids on cellular hypoperfusion associated with major gastric surgery.
440390|NCT00929448|Traumatic brain injury
440391|NCT00929435|MRSA
440392|NCT00929435|Contact isolation
440393|NCT00929435|Incidence
440394|NCT00929422|spinal cord injury
440395|NCT00929422|PET
440396|NCT00929422|cerebral function
440397|NCT00929422|cortical reorganization
440398|NCT00929409|Postpartum anemia, iron-deficiency
440399|NCT00929396|Tuberculosis
440400|NCT00929396|Vaccine
440401|NCT00929396|Ag85B
440402|NCT00929396|ESAT-6
440403|NCT00929396|IC31
440404|NCT00929383|Intracranial Atherosclerosis
440405|NCT00929383|Stenosis
440406|NCT00929383|ICAD
440407|NCT00929383|atherosclerotic lesions
440408|NCT00929383|stenting
440409|NCT00929370|Schizophrenia
440410|NCT00929370|GSK1018921
440411|NCT00929370|GlyT-1 inhibitor
440412|NCT00929370|Healthy Volunteers
440413|NCT00929370|CSF
440414|NCT00929370|Patient
440415|NCT00929370|Midazolam
440416|NCT00929344|Alcohol
440417|NCT00929344|Alcohol treatment
440418|NCT00929344|Alcoholism
440419|NCT00929344|Alcohol Abuse
440420|NCT00929344|Alcohol Dependence
440421|NCT00929331|Influenza
440422|NCT00929331|Fluviral®
440423|NCT00929305|chronic pain
440424|NCT00929305|neck
440425|NCT00929305|shoulder
440426|NCT00929305|musculoskeletal origin
440427|NCT00929292|Infant formula
440428|NCT00929292|Alpha-lactalbumin
440429|NCT00929292|Protein composition
440430|NCT00929292|Colic
440431|NCT00929292|Probiotics
440432|NCT00929279|Acute coronary syndrome
440433|NCT00929279|Abciximab
440434|NCT00929279|Bolus
440435|NCT00929279|Infusion
440436|NCT00929279|platelet inhibition
440437|NCT00929279|Non ST segment elevation acute coronary syndrome
440438|NCT00929266|peripheral stem cells (PSC) donors
440439|NCT00929266|cultured red blood cells
440440|NCT00929266|In vivo half life
440441|NCT00929253|Opioid Dependence
440442|NCT00929253|Opiates
440443|NCT00929253|Hydrocodone
440444|NCT00929253|Oxycodone
440445|NCT00929253|Oxycontin
440446|NCT00929253|Narcotic Abuse
440447|NCT00929227|Atherosclerosis
440448|NCT00929227|Myocardial Ischemia
440449|NCT00929227|Diagnostic Testing
440450|NCT00929227|Cardiac Commuted Tomography
440451|NCT00929227|Cardiac Magnetic Resonance Imaging
440452|NCT00929227|Coronary Artery Disease
440453|NCT00929214|Breast Cancer
440454|NCT00929214|Metastasized
440455|NCT00929214|Limited bone-only metastasis
440456|NCT00929214|Local Therapy
440457|NCT00929214|Radiation
440458|NCT00929214|Radiation Therapy
440459|NCT00929214|RT
440460|NCT00929214|Surgery
440461|NCT00929214|Standard Therapy
440462|NCT00929214|Chemotherapy
440463|NCT00929214|Endocrine Therapy
440464|NCT00929188|Moderate to severe chronic, cancer-related pain related to an active cancer
440465|NCT00929188|Cancer-related pain
440466|NCT00929188|Moderate to severe chronic pain
440467|NCT00929188|JNJ-42160443
440468|NCT00929175|Hypertension
440469|NCT00929175|Resistant Hypertension
440470|NCT00929175|Sleep apnea syndrome
440471|NCT00929175|Treatment
440472|NCT00929162|ovarian
440473|NCT00929162|cancer
440474|NCT00929162|chemotherapy
440475|NCT00929162|sensitive
440476|NCT00929162|ZD4054
440477|NCT00929136|Endotoxin
440478|NCT00929136|Insulin resistance
440479|NCT00929136|Lipolysis
440480|NCT00929136|Proteolysis
440481|NCT00929136|Intracellular Insulin Signaling
440482|NCT00929136|Regional effects of inflammation/endotoxin
440483|NCT00929123|manual therapy
440484|NCT00929123|carpal tunnel syndrome
440485|NCT00929123|central sensitization
440486|NCT00929110|COPD
440487|NCT00929110|NVA237
440488|NCT00929110|glycopyrronium bromide
440489|NCT00929097|Colorectal Neoplasms, (Hereditary Nonpolyposis)
440490|NCT00929097|Guideline
440491|NCT00929097|Health Plan Implementation
440492|NCT00929097|Decision Support Techniques
440493|NCT00929097|Risk assessment
440494|NCT00929097|Familial colorectal cancer risk
440495|NCT00929097|Risk assessment tool
440496|NCT00929084|Race Disparities
440497|NCT00929084|Breast Cancer
440498|NCT00929084|Quality of Life
440499|NCT00929084|Treatment Adherence
440500|NCT00929071|wrinkles
440501|NCT00929071|dermal filler
440502|NCT00929071|collagen
440503|NCT00929071|soft tissue augmentation
440504|NCT00929071|lidocaine
440505|NCT00929071|aesthetic
440506|NCT00929045|Growth Hormone replacement
440507|NCT00929045|subject 8 to 21
440508|NCT00929045|moderate to severe traumatic brain injury
440509|NCT00929045|growth hormone deficient
440510|NCT00929032|Liver Transplantation
440511|NCT00929032|Immunosystem of the Liver
440512|NCT00929032|Marginal and Non-marginal grafts
440513|NCT00929019|uveal melanoma
440514|NCT00929019|chromosome 3
440515|NCT00929019|high risk
440516|NCT00929019|immunotherapy
440517|NCT00929019|adjuvant
440518|NCT00929019|high risk genetic profile
440519|NCT00929019|loss of chromosome 3
440520|NCT00929006|hyperandrogenemia
440521|NCT00929006|pubertal
440522|NCT00929006|polycystic ovary syndrome
440523|NCT00928993|actigraphy
440524|NCT00928993|polysomnography
440525|NCT00928993|pediatrics
440526|NCT00928993|sleep
440527|NCT00928993|To validate Actigraphy against polysomnography
440528|NCT00928980|Recurrent Major Depressive Disorder
440529|NCT00928980|Mindfulness Based Cognitive Therapy
440530|NCT00928980|Cost-effectiveness
440531|NCT00928980|Antidepressant medication
440532|NCT00928980|Randomized Controlled Trial
440533|NCT00928967|Multiple Sclerosis
440534|NCT00928967|Quality of life
440535|NCT00928954|gabapentin
440536|NCT00928954|memantine
440537|NCT00928954|nystagmus
440538|NCT00928954|Drug treatment
440539|NCT00928941|PTSD
440540|NCT00928941|rehabilitation
440541|NCT00928928|Lipid peroxidation
440542|NCT00928928|Protein peroxidation
440543|NCT00928928|DNA peroxidation
440544|NCT00928928|RNA peroxidation
440545|NCT00928928|Cytokines
440546|NCT00928928|hsCRP
440547|NCT00928928|Oxidative stress markers
440548|NCT00928928|Open surgery
440549|NCT00928928|Laparoscopic surgery
440550|NCT00928915|Intracranial Hemorrhages
440551|NCT00928915|Vitamin-K antagonist
440552|NCT00928915|Hemostatic treatment
440553|NCT00928915|Prothrombin complex
440554|NCT00928915|Fresh frozen plasma
440555|NCT00928915|Intracranial Hemorrhages related to vitamin-K antagonist
440556|NCT00928902|melanoma
440557|NCT00928902|vaccine
440558|NCT00928902|peptides
440559|NCT00928902|adjuvant
440560|NCT00928902|immunogenicity
440561|NCT00928902|stage IIB, stage III or resected stage IV
440562|NCT00928889|diabetes mellitus, type 2
440563|NCT00928889|nateglinide
440564|NCT00928889|acarbose
440565|NCT00928889|hyperglycemia
440566|NCT00928889|dyslipidemias
440567|NCT00928889|C-reactive protein
440568|NCT00928876|anakinra
440569|NCT00928876|Diabetes mellitus, type 2
440570|NCT00928876|Insulin resistance
440571|NCT00928876|Interleukin-1beta
440572|NCT00928863|haemorrhagia postpartum
440573|NCT00928863|implementation guidelines
440574|NCT00928863|maternal morbidity
440575|NCT00928863|management of obstetrics and trauma
440576|NCT00928850|Prostate
440577|NCT00928850|Radical Prostatectomy
440578|NCT00928850|urethral irrigation
440579|NCT00928850|fascial suturing
440580|NCT00928850|09-051
440581|NCT00928811|Simulect
440582|NCT00928811|de novo kidney transplant subjects
440583|NCT00928811|calcineurin inhibitors
440584|NCT00928811|Prograf
440585|NCT00928785|Tetanus Vaccine
440586|NCT00928785|Tdap-IPV vaccine
440587|NCT00928772|Cranial Electro Stimulation
440588|NCT00928772|First Eye Cataract Surgery
440589|NCT00928772|Preoperative sedation
440590|NCT00928772|Perioperative sedation
440591|NCT00928759|Obesity
440592|NCT00928759|Polycystic Ovary Syndrome
440593|NCT00928733|Permeability
440594|NCT00928733|tight junctions
440595|NCT00928733|cytokines
440596|NCT00928733|inflammatory bowel diseases
440597|NCT00928733|The effect of alcohol on the intestinal permeability may have major consequences on health.
440598|NCT00928733|It's generally accepted that an increased intestinal permeability in alcoholic subjects lead
440599|NCT00928733|to translocation of bacterial endotoxins from the gut lumen into the portal vein and then to the liver.
440600|NCT00928733|In the liver, endotoxins trigger the immune system and activate the resident macrophages, Kupffer cells.
440601|NCT00928733|Activation of Kupffer cells leads to production of chemokines (IL-8) and
440602|NCT00928733|proinflammatory cytokines (IL-1, TNFα),resulting in hepatocytes damage, inflammation, fibrosis and finally cirrhosis.
440603|NCT00928720|fibromyalgia
440604|NCT00928720|pain
440605|NCT00928720|sleep disturbance
440606|NCT00928720|fatigue
440607|NCT00928720|depression
440608|NCT00928720|functional magnetic resonance imaging
440609|NCT00928707|Polycythemia Vera
440610|NCT00928707|GIVINOSTAT
440611|NCT00928707|ITF2357
440612|NCT00928655|apnea
440613|NCT00928655|sleep
440614|NCT00928655|altitude
440615|NCT00928655|hypoxia
440616|NCT00928655|treatment
440617|NCT00928655|CPAP
440618|NCT00928642|ovarian
440619|NCT00928642|cancer
440620|NCT00928642|peritoneal
440621|NCT00928642|endometrioid
440622|NCT00928642|mucinous
440623|NCT00928642|serous
440624|NCT00928642|clear cell
440625|NCT00928629|Peripheral Arterial Disease
440626|NCT00928629|Cardiovascular Disease
440627|NCT00928629|Vascular Disease
440628|NCT00928616|hyperlipidemia
440629|NCT00928616|plant sterols
440630|NCT00928616|monocytes
440631|NCT00928603|prostate cancer
440632|NCT00928603|therapy
440633|NCT00928590|open-angle glaucoma
440634|NCT00928590|ocular hypertension
440635|NCT00928590|pseudoexfoliation
440636|NCT00928590|pigment dispersion
440637|NCT00928577|Smallpox
440638|NCT00928577|Smallpox Vaccine
440639|NCT00928577|Vaccinia virus
440640|NCT00928577|Military
440641|NCT00928564|Pelvic floor muscle spasm
440642|NCT00928564|Pelvic pain
440643|NCT00928564|physical therapy
440644|NCT00928564|pudendal block
440645|NCT00928538|Female Contraception
440646|NCT00928538|Home Visits
440647|NCT00928538|CONTRACEPTIVE AGENTS
440648|NCT00928538|CONTRACEPTIVE DEVICES
440649|NCT00928525|PDGFr alpha
440650|NCT00928525|PDGFr beta
440651|NCT00928525|KIT
440652|NCT00928512|Rheumatoid Arthritis, RA, ACR, inflammatory joints
440653|NCT00928499|urge/frequency
440654|NCT00928499|urge incontinence
440655|NCT00928499|Interstim
440656|NCT00928499|after success Interstim planning IPG placement
440657|NCT00928460|Electrocardiogram
440658|NCT00928460|Electrocardiography
440659|NCT00928460|Perioperative care
440660|NCT00928460|Preoperative care
440661|NCT00928460|Preanesthesia Evaluation
440662|NCT00928460|Acute Coronary Syndrome
440663|NCT00928460|Postoperative Myocardial Infarction
440664|NCT00928460|Myocardial ischaemia
440665|NCT00928460|Postoperative Cardiac Death
440666|NCT00928460|Intraoperative complications
440667|NCT00928460|Postoperative complications
440668|NCT00928460|Cost-effectiveness analysis
440669|NCT00928447|rHuPH20
440670|NCT00928447|Recombinant Human hyaluronidase
440671|NCT00928421|Varicose Veins
440672|NCT00928395|Urgent PC
440673|NCT00928395|Overactive Bladder
440674|NCT00928395|SUmiT Trial
440675|NCT00928395|Overactive Urinary Bladder
440676|NCT00928382|Spinal Cord
440677|NCT00928382|Healthy Volunteer
440678|NCT00928382|Metastasis
440679|NCT00928382|Samples
440680|NCT00928382|Spinal Cord Vertebrae
440681|NCT00928382|Cancer
440682|NCT00928382|HV
440683|NCT00928356|Coronary Artery Disease
440684|NCT00928356|Robotic Coronary Artery Bypass Surgery
440685|NCT00928356|Percutaneous Coronary Intervention
440686|NCT00928356|Hybrid Coronary Revascularization
440687|NCT00928343|Safety
440688|NCT00928343|Tolerability
440689|NCT00928343|Pharmacokinetics
440690|NCT00928330|TDM-1
440691|NCT00928330|HER2
440692|NCT00928330|HER2+
440693|NCT00928330|HER2+ Breast Cancer
440694|NCT00928330|HER-2
440695|NCT00928330|MBC
440696|NCT00928330|Trastuzumab emtansine
440697|NCT00928304|Amyloid beta-protein
440698|NCT00928304|Down Syndrome
440699|NCT00928291|procalcitonin
440700|NCT00928291|neutropenia
440701|NCT00928291|febrile neutropenia
440702|NCT00928291|antibiotic therapy
440703|NCT00928291|neutropenic patients
440704|NCT00928265|intracranial
440705|NCT00928265|stenting
440706|NCT00928265|endovascular treatment
440707|NCT00928265|stent-assisted coiling
440708|NCT00928265|cerebrovascular disease
440709|NCT00928252|Hormone Refractory Prostate Cancer
440710|NCT00928252|Castrate Resistant Prostate Cancer
440711|NCT00928239|vaginal vault prolapse
440712|NCT00928239|laparoscopic sacropexy
440713|NCT00928213|Preeclampsia
440714|NCT00928213|IUGR
440715|NCT00928213|GH
440716|NCT00928213|PP13
440717|NCT00928213|Doppler
440718|NCT00928213|placenta
440719|NCT00928213|PTD
440720|NCT00928213|Preterm delivery
440721|NCT00928200|Relapsed
440722|NCT00928200|Allergy
440723|NCT00928200|Erwinia
440724|NCT00928200|Acute
440725|NCT00928200|Lymphoblastic
440726|NCT00928200|Leukemia
440727|NCT00928187|HIV
440728|NCT00928187|Second line treatment
440729|NCT00928187|WHO recommendations
440730|NCT00928187|Africa
440731|NCT00928187|Treatment strategies
440732|NCT00928187|treatment experienced
440733|NCT00928174|Androgen insensitive prostate cancer
440734|NCT00928161|Reflux Disease
440735|NCT00928161|Acid-reflux
440736|NCT00928161|Head and Neck Cancer
440737|NCT00928161|HNC
440738|NCT00928161|Radiation Therapy
440739|NCT00928161|Mucositis
440740|NCT00928161|Radiation-induced xerostomia
440741|NCT00928161|RIX
440742|NCT00928161|Dry Mouth
440743|NCT00928161|Heartburn
440744|NCT00928161|Dexlansoprazole
440745|NCT00928161|Prevacid
440746|NCT00928161|Prevacid Solu-Tab
440747|NCT00928161|GERD
440748|NCT00928109|eating disorders
440749|NCT00928109|couples therapy
440750|NCT00928096|Lymphoma
440751|NCT00928096|Radiotherapy
440752|NCT00928096|Positron-Emission Tomography
440753|NCT00928096|CT scan
440754|NCT00928083|Phase I
440755|NCT00928083|Safety and tolerability
440756|NCT00928083|Pharmacokinetic
440757|NCT00928083|synthetic peroxide
440758|NCT00928083|trioxolane
440759|NCT00928083|treatment of erythrocytic stages of malaria
440760|NCT00928070|Urgency Urinary Incontinence OAB
440761|NCT00928057|Pen Needle
440762|NCT00928057|Diabetes
440763|NCT00928057|Insulin
440764|NCT00928057|Glycemic
440765|NCT00928057|Pain
440766|NCT00928057|Fructosamine
440767|NCT00928057|Leakage
440768|NCT00928057|Hypoglycemia
440769|NCT00928057|Hyperglycemia
440770|NCT00928018|allogeneic stem cell transplant
440771|NCT00928018|reduced intensity conditioning
440772|NCT00928018|graft versus host disease
440773|NCT00928018|GVHD
440774|NCT00928018|RIC transplantation
440775|NCT00928005|Weight loss diet
440776|NCT00928005|Exercise training
440777|NCT00928005|Type 2 diabetes
440778|NCT00928005|Prediabetes
440779|NCT00928005|Cardiovascular health
440780|NCT00927966|RAD001
440781|NCT00927966|CP-751,871
440782|NCT00927966|advanced sarcoma
440783|NCT00927966|advanced malignant solid tumor
440784|NCT00927953|West Nile virus
440785|NCT00927953|WNV
440786|NCT00927953|Encephalitis
440787|NCT00927953|Meningitis
440788|NCT00927953|Acute Flaccid Paralysis
440789|NCT00927953|Monoclonal Antibody
440790|NCT00927953|WNND
440791|NCT00927953|West Nile Fever
440792|NCT00927953|WNF
440793|NCT00927940|TARGET VESSEL REVASCULARIZATION (TVR)
440794|NCT00927940|MYOCARDIAL INFARCTION (MI)
440795|NCT00927940|TARGET VESSEL FAILURE (TVF)
440796|NCT00927940|TARGET LESION REVASCULARIZATION (TLR)
440797|NCT00927940|TARGET LESION FAILURE (TLF)
440798|NCT00927940|STENT THROMBOSIS
440799|NCT00927940|RESTENOTIC LESION
440800|NCT00927940|PERCUTANEOUS CORONARY INTERVENTION (PCI)
440801|NCT00927901|QAB149
440802|NCT00927901|asthma
440803|NCT00927901|indacaterol salts (acetate, maleate, and xinafoate)
440804|NCT00927901|orally inhaled indacaterol salts
440805|NCT00927901|persistent asthma
440806|NCT00927862|warfarin metabolism
440807|NCT00927862|CYP2C9
440808|NCT00927862|genotyping
440809|NCT00927862|VKORC1
440810|NCT00927862|anticoagulation
440811|NCT00927862|atrial fibrillation
440812|NCT00927862|deep vein thrombosis
440813|NCT00927862|pulmonary embolism
440814|NCT00927862|Patients initiating warfarin for thromboembolic conditions
440815|NCT00927849|anal hypertonia
440816|NCT00927849|sphincterotomy
440817|NCT00927849|incontinence
440818|NCT00927849|manometry
440819|NCT00927810|Gout
440820|NCT00927810|Gouty arthritis
440821|NCT00927810|Gout flares
440822|NCT00927810|Anti-interleukin-1β monoclonal antibody
440823|NCT00927797|immunochemotherapy
440824|NCT00927797|Pentostatin
440825|NCT00927797|Cyclophosphamide
440826|NCT00927797|Rituximab
440827|NCT00927797|Maintenance
440828|NCT00927797|indolent B-NHL
440829|NCT00927797|B-CLL
440830|NCT00927797|B-NHL
440831|NCT00927784|Mesenchymal Precursor Cells
440832|NCT00927784|Left Ventricular Assist Device
440833|NCT00927784|LVAD
440834|NCT00927784|Congestive Heart Failure
440835|NCT00927784|Stem Cells
440836|NCT00927771|melanosis
440837|NCT00927771|melasma
440838|NCT00927771|azelaic acid
440839|NCT00927771|hydroquinone
440840|NCT00927745|Respiration Artificial
440841|NCT00927745|Positive-Pressure Respiration
440842|NCT00927745|Critical Care
440843|NCT00927745|Intensive Care Units
440844|NCT00927732|Brugada
440845|NCT00927732|hydroquinidine
440846|NCT00927732|ventricular arrhythmia
440847|NCT00927732|patients with Brugada syndrome, high cardiac arrhythmic risk and implanted with an implantable cardioverter defibrillator
440848|NCT00927719|Smallpox
440849|NCT00927719|Smallpox Vaccine
440850|NCT00927719|Vaccinia virus
440851|NCT00927719|Military
440852|NCT00927706|Assistive Technology
440853|NCT00927706|Mobility Limitation
440854|NCT00927706|Physical Disability
440855|NCT00927706|Caregiver
440856|NCT00927706|Participation
440857|NCT00927693|Atherosclerosis
440858|NCT00927693|Coronary Artery Disease
440859|NCT00927693|Cardiac Risk Factors
440860|NCT00927693|Coronary Calcium Scan
440861|NCT00927693|Prevention
440862|NCT00927680|Colorectal Cancer
440863|NCT00927680|Familial Colorectal Cancer
440864|NCT00927680|Genetics
440865|NCT00927680|Hispanics
440866|NCT00927667|Hemophilia A
440867|NCT00927667|Joint Status
440868|NCT00927667|Bleeds
440869|NCT00927667|Magnetic Resonce Imaging
440870|NCT00927654|Iloprost
440871|NCT00927654|pulmonary hypertension
440872|NCT00927654|cardio pulmonary morbidity
440873|NCT00927654|high risk cardiac surgical patients
440874|NCT00927641|Ankle Sprain
440875|NCT00927628|vitrectomy
440876|NCT00927628|macular hole
440877|NCT00927628|ILM peeling
440878|NCT00927615|myocardial infarction
440879|NCT00927615|glycoprotein IIb/IIIa
440880|NCT00927615|percutaneous coronary intervention
440881|NCT00927615|thrombus aspiration
440882|NCT00927615|myocardial perfusion
440883|NCT00927602|renal failure
440884|NCT00927602|medical patient
440885|NCT00927602|venous thromboembolism
440886|NCT00927602|prophylaxis
440887|NCT00927602|fondaparinux
440888|NCT00927589|HER2+ Metastatic Cancer
440889|NCT00927589|HER2+ Locally Advanced Inoperable Cancer
440890|NCT00927589|HER2+ Solid Malignancy
440891|NCT00927576|cognitive training
440892|NCT00927576|neuroplasticity
440893|NCT00927576|cognitive impairment
440894|NCT00927576|recovery of function
440895|NCT00927576|memory
440896|NCT00927576|attention
440897|NCT00927563|Gambling
440898|NCT00927563|Addiction
440899|NCT00927550|resistant depression
440900|NCT00927550|lithium
440901|NCT00927550|RCT
440902|NCT00927550|lithium therapy
440903|NCT00927550|standard therapy
440904|NCT00927537|Hypertension
440905|NCT00927524|Insulin analogs
440906|NCT00927524|diabetes
440907|NCT00927511|metastatic hormone-responsive breast cancer menopausal women
440908|NCT00927498|Acute myeloid Leukemia
440909|NCT00927498|patient aged 50 to 70 years
440910|NCT00927485|Familial Adenomatous Polyposis (FAP)
440911|NCT00927485|Curcumin
440912|NCT00927485|Colorectal polyps
440913|NCT00927485|Duodenal polyps
440914|NCT00927472|Head Lice
440915|NCT00927459|cholesterol
440916|NCT00927459|coronary artery disease
440917|NCT00927446|esophageal cancer
440918|NCT00927446|head and neck cancer
440919|NCT00927446|narrow band imaging
440920|NCT00927446|endoscopy
440921|NCT00927446|screening
440922|NCT00927433|Fatigue
440923|NCT00927433|Cancer
440924|NCT00927433|Radiation therapy
440925|NCT00927433|Chemotherapy
440926|NCT00927433|Hormones
440927|NCT00927433|Surgery
440928|NCT00927433|Breast cancer
440929|NCT00927420|Bipolar disorder
440930|NCT00927420|adherence
440931|NCT00927420|treatment
440932|NCT00927420|real life practice
440933|NCT00927407|Head Lice
440934|NCT00927394|Hypertension, Type II Diabetes, Aliskiren, Valsartan,
440935|NCT00927394|Systolic blood pressure, Diastolic blood pressure,
440936|NCT00927394|Stage II, Combination
440937|NCT00927368|TKA
440938|NCT00927368|total knee replacement
440939|NCT00927355|pioglitazone
440940|NCT00927355|human bone marrow stem cells
440941|NCT00927355|adipocytes
440942|NCT00927355|osteoblasts
440943|NCT00927355|bone mineral density
440944|NCT00927355|adiponectin
440945|NCT00927355|leptin
440946|NCT00927355|CTX
440947|NCT00927355|P1NP
440948|NCT00927355|Osteocalcin
440949|NCT00927342|Air leak
440950|NCT00927342|Thoracic Surgery
440951|NCT00927342|Sealants
440952|NCT00927329|Dermatophagoides
440953|NCT00927329|farinae
440954|NCT00927329|allergen
440955|NCT00927329|dust
440956|NCT00927329|allergic
440957|NCT00927329|mite
440958|NCT00927329|allergy
440959|NCT00927316|Report of Urinary Tract Infection episode
440960|NCT00927303|retinal thickness
440961|NCT00927303|threshold algorithm
440962|NCT00927303|optical coherence tomography
440963|NCT00927290|hepatitis C; insulin resistance; glitazones; pioglitazone; steatosis; viral kinetics; antiviral response
440964|NCT00927264|tobacco smoke exposure smoking
440965|NCT00927251|heart failure
440966|NCT00927251|cardiac pacing
440967|NCT00927251|cardiac resynchronization therapy
440968|NCT00927251|left ventricular lead
440969|NCT00927238|Single Level
440970|NCT00927238|Lumbar Disc Disease
440971|NCT00927238|DDD
440972|NCT00927199|High-Oleic Canola Oil
440973|NCT00927199|Flaxseed Oil
440974|NCT00927199|Monounsaturated Fatty Acids
440975|NCT00927199|Polyunsaturated Fatty Acids
440976|NCT00927199|Alpha Linolenic Acid
440977|NCT00927199|Cardiovascular
440978|NCT00927199|Hypercholesterolemia
440979|NCT00927199|Lipids
440980|NCT00927199|Inflammation
440981|NCT00927199|Metabolism
440982|NCT00927186|osteoporosis
440983|NCT00927186|teriparatide
440984|NCT00927186|zoledronic acid
440985|NCT00927186|histomorphometry
440986|NCT00927186|bone biopsy
440987|NCT00927186|postmenopausal
440988|NCT00927173|TMS
440989|NCT00927173|Transcranial Magnetic Stimulation
440990|NCT00927173|MDD
440991|NCT00927173|Major Depressive Disorder
440992|NCT00927160|Mobile Acute Care of the Elderly Unit
440993|NCT00927160|Geriatric Models of Care
440994|NCT00927147|head and neck cancer
440995|NCT00927147|boron neutron capture therapy
440996|NCT00927147|cetuximab
440997|NCT00927147|epidermal growth factor receptor
440998|NCT00927147|safety
440999|NCT00927147|efficacy
441000|NCT00927147|survival
441001|NCT00927134|Chronic Granulomatous Disease in children (=or< 18 years)
441002|NCT00927108|Adult Progenitor Stem cells
441003|NCT00927108|Alzheimer's disease
441004|NCT00927108|Parkinson's disease
441005|NCT00927108|Multiple sclerosis
441006|NCT00927095|PMDD
441007|NCT00927095|Oral contraceptives
441008|NCT00927095|steroid hormones
441009|NCT00927095|neurosteroids
441010|NCT00927069|Adalimumab
441011|NCT00927030|Autism
441012|NCT00927030|children
441013|NCT00927030|sleep
441014|NCT00927030|insomnia
441015|NCT00927017|Healthy volunteers
441016|NCT00927004|mechanical hyperalgesia
441017|NCT00927004|cold hyperalgesia
441018|NCT00927004|chronic pain
441019|NCT00926978|Thyroid
441020|NCT00926978|I-124
441021|NCT00926965|tardive dyskinesia
441022|NCT00926965|neurocognitive function
441023|NCT00926952|Actinic keratoses
441024|NCT00926952|actinic keratosis
441025|NCT00926952|methylamonolevulinate
441026|NCT00926952|photodynamic therapy
441027|NCT00926952|without occlusion
441028|NCT00926952|short incubation
441029|NCT00926939|Cigarette
441030|NCT00926939|Nicotine
441031|NCT00926939|Smoking
441032|NCT00926939|Contingency Management
441033|NCT00926939|Voucher reinforcement
441034|NCT00926939|Smoking Abstinence
441035|NCT00926939|Internet-based treatment
441036|NCT00926926|Healthy volunteer
441037|NCT00926913|Macular Degeneration
441038|NCT00926900|Alcoholism
441039|NCT00926900|D-cycloserine
441040|NCT00926900|extinction
441041|NCT00926900|cue-exposure
441042|NCT00926874|ischaemic stroke
441043|NCT00926874|acute coronary syndrome
441044|NCT00926874|obstructive sleep apnea syndrome
441045|NCT00926874|brachial endothelial function
441046|NCT00926874|blood pressure
441047|NCT00926874|aortic stiffness
441048|NCT00926861|age-related macular degeneration
441049|NCT00926861|detachment of the posterior hyaloid
441050|NCT00926861|AMD
441051|NCT00926848|coronary heart disease
441052|NCT00926848|cardiac rehabilitation
441053|NCT00926848|lifestyle change
441054|NCT00926848|coronary artery bypass graft
441055|NCT00926848|social support
441056|NCT00926848|social cognitive learning theory
441057|NCT00926809|endoscopic mucosal resection
441058|NCT00926809|iatrogenic
441059|NCT00926796|gonorrhea, gonococcal infections, Neisseria gonorrhoeae
441060|NCT00926783|paroxysmal
441061|NCT00926783|persistent
441062|NCT00926783|targeted
441063|NCT00926783|generalized
441064|NCT00926783|CFAE
441065|NCT00926757|lymphoma
441066|NCT00926757|CD20
441067|NCT00926757|Hepatitis B virus
441068|NCT00926757|reactivation
441069|NCT00926757|Rituximab
441070|NCT00926744|physical activity
441071|NCT00926744|nutrition
441072|NCT00926744|cardiovascular diseases
441073|NCT00926744|musculo-skeletal problems
441074|NCT00926731|Acute Myeloid Leukaemia (AML)
441075|NCT00926718|BIS monitor
441076|NCT00926718|rocuronium
441077|NCT00926718|The effect of the neuromuscular blocking drug rocuronium on the response of the Composite Variability Index to laryngoscopy
441078|NCT00926705|Dexmedetomidine
441079|NCT00926705|Fentanyl
441080|NCT00926705|Pain
441081|NCT00926705|Pediatrics
441082|NCT00926692|B-cells
441083|NCT00926692|CD5+
441084|NCT00926692|B1 Cells
441085|NCT00926692|Healthy Controls
441086|NCT00926666|Ageing
441087|NCT00926666|Pain
441088|NCT00926666|Pharmacology
441089|NCT00926666|Imaging
441090|NCT00926666|Anaesthesiology
441091|NCT00926666|Musculoskeletal disease
441092|NCT00926653|Geriatric Depression
441093|NCT00926640|Solid Tumors
441094|NCT00926640|Histone deacetylase inhibitors
441095|NCT00926640|EP &amp; Belinostat
441096|NCT00926640|Phase I
441097|NCT00926640|SCLC
441098|NCT00926640|Small Cell Lung Cancer
441099|NCT00926627|endothelin receptor antagonist
441100|NCT00926627|bosentan
441101|NCT00926614|GT1
441102|NCT00926614|HCV
441103|NCT00926614|non responder
441104|NCT00926614|relapser
441105|NCT00926588|Pain
441106|NCT00926588|Telecare
441107|NCT00926588|Collaborative care
441108|NCT00926575|BDP
441109|NCT00926575|orBec
441110|NCT00926575|GVHD
441111|NCT00926575|beclomethasone dipropionate
441112|NCT00926575|bone marrow transplant
441113|NCT00926575|hematopoietic cell transplant
441114|NCT00926575|HCT
441115|NCT00926575|stem cell transplant
441116|NCT00926575|marrow transplant
441117|NCT00926575|SCT
441118|NCT00926575|beclomethasone 17,21-dipropionate
441119|NCT00926562|Contrast Induced Nephropathy
441120|NCT00926562|CIN
441121|NCT00926562|Cardiac Catheterization
441122|NCT00926549|spectral domain-OCT
441123|NCT00926549|macular thickness
441124|NCT00926549|myopia
441125|NCT00926549|hypermetropia
441126|NCT00926549|normal
441127|NCT00926523|Pulmonary Hypertension
441128|NCT00926523|Pulmonary Arterial Hypertension
441129|NCT00926523|Interstitial Lung Disease
441130|NCT00926523|MIF
441131|NCT00926497|antibiotic therapy
441132|NCT00926497|early-onset sepsis
441133|NCT00926497|interventions study
441134|NCT00926497|procalcitonin
441135|NCT00926497|term and near-term neonates
441136|NCT00926484|Dentin hypersensitivity
441137|NCT00926484|Tooth Mousse
441138|NCT00926484|fluoride varnish
441139|NCT00926471|Autism
441140|NCT00926471|Anxiety
441141|NCT00926471|Autism Spectrum Disorders with Comorbid Anxiety
441142|NCT00926458|stress echocardiography
441143|NCT00926458|coronary angiography
441144|NCT00926458|coronary artery disease
441145|NCT00926445|Pain behavior
441146|NCT00926432|Balance
441147|NCT00926432|Spine disorders
441148|NCT00926432|equilibrium
441149|NCT00926419|Varicella
441150|NCT00926419|Hepatitis A
441151|NCT00926419|Vaccine
441152|NCT00926419|Injector
441153|NCT00926419|Fractional dose
441154|NCT00926419|Intradermal
441155|NCT00926419|Children
441156|NCT00926406|Environmental lead exposure, maintenance hemodialysis; blood lead levels, EDTA chelating agents, malnutrition, anemia, inflammation, mortality.
441157|NCT00926406|To determine whether lead chelation therapy improves the anemia, malnutrition, inflammation, morbidity or mortality in hemodialysis patients.
441158|NCT00926393|inpatient
441159|NCT00926393|bipolar depression
441160|NCT00926393|quetiapine
441161|NCT00926393|Seroquel IR
441162|NCT00926393|Seroquel XR
441163|NCT00926393|safety
441164|NCT00926393|tolerability
441165|NCT00926380|osteoporosis
441166|NCT00926380|postmenopausal
441167|NCT00926380|denosumab
441168|NCT00926380|teriparatide
441169|NCT00926380|Forteo®
441170|NCT00926380|DXA
441171|NCT00926380|Bone Mineral Density
441172|NCT00926380|pQCT
441173|NCT00926367|Acne
441174|NCT00926341|Metabolic syndrome
441175|NCT00926341|inflammatory markers
441176|NCT00926341|Thiazolidinediones
441177|NCT00926341|Angiotensin receptor blockers
441178|NCT00926328|Gingivitis and Plaque
441179|NCT00926315|Breast Neoplasms
441180|NCT00926315|Calcitriol
441181|NCT00926315|Postmenopausal
441182|NCT00926315|Cell Proliferation
441183|NCT00926315|Gene Expression Profiling
441184|NCT00926302|The bioequivalence of Levetiracetam vs. Keppra
441185|NCT00926302|volunteer
441186|NCT00926276|Gastroesophageal Reflux Disease (GERD)
441187|NCT00926276|Bronchopulmonary Dysplasia (BPD)
441188|NCT00926276|Fundoplication
441189|NCT00926263|Pharmacokinetics
441190|NCT00926263|Pharmacodynamics
441191|NCT00926263|QTc interval prolongation
441192|NCT00926250|Sarcopenia
441193|NCT00926237|Tinnitus
441194|NCT00926237|Transcranial Magnetic Stimulation
441195|NCT00926237|TMS
441196|NCT00926237|rTMS
441197|NCT00926224|Adult patients with chronic liver disease scheduled for a liver biopsy and a BMI superior or equal to 28 kg/m²
441198|NCT00926198|Upper airway infections
441199|NCT00926198|pharyngotonsillitis
441200|NCT00926198|GABHS
441201|NCT00926185|Dry Eye
441202|NCT00926185|ophthalmic delivery
441203|NCT00926172|Magnetic resonance angiography
441204|NCT00926172|Intracranial aneurysm
441205|NCT00926172|cerebral aneurysm
441206|NCT00926172|unruptured aneurysm
441207|NCT00926172|Epidemiology
441208|NCT00926172|Magnetic Resonance Imaging
441209|NCT00926159|Cardiomyopathies
441210|NCT00926146|Hepatitis B and C
441211|NCT00926146|HIV
441212|NCT00926146|nurse case management
441213|NCT00926146|HIV seronegativity
441214|NCT00926120|Chronic Hepatitis C
441215|NCT00926081|Peripheral Artery Disease
441216|NCT00926081|Quality of Life
441217|NCT00926081|Outcome
441218|NCT00926081|Endothelial Progenitor Cells
441219|NCT00926081|Microcirculation
441220|NCT00926068|Diabetes Mellitus
441221|NCT00926068|Foot Ulcer
441222|NCT00926068|DFU
441223|NCT00926068|Wound healing
441224|NCT00926055|high risk patients in atherosclerosis
441225|NCT00926042|Healthy
441226|NCT00926042|volunteer
441227|NCT00926042|Healthy controls
441228|NCT00926042|Normal controls
441229|NCT00926016|Hepatitis C
441230|NCT00926003|HIV
441231|NCT00926003|Children
441232|NCT00926003|Africa
441233|NCT00926003|Neuropsychology
441234|NCT00926003|cognitive rehabilitation
441235|NCT00926003|computers
441236|NCT00925990|HCV
441237|NCT00925990|interferon-naive
441238|NCT00925977|treatment satisfaction
441239|NCT00925977|insulin Glargine
441240|NCT00925977|insulin Apidra
441241|NCT00925977|NPH insulin
441242|NCT00925951|Persistent Non-specific Low Back Pain
441243|NCT00925951|wet cupping
441244|NCT00925951|cupping
441245|NCT00925951|Numerical Rating Scale
441246|NCT00925938|Hysteroscopy
441247|NCT00925938|Cervical priming
441248|NCT00925938|Cervical dilatation
441249|NCT00925938|Misoprostol
441250|NCT00925938|Endoscopy, uterine
441251|NCT00925925|Low birth weight
441252|NCT00925925|small for gestational age
441253|NCT00925925|B-cell function
441254|NCT00925925|epigenetics
441255|NCT00925925|B1a
441256|NCT00925925|B1b
441257|NCT00925925|CD19
441258|NCT00925925|CD5
441259|NCT00925912|Hemorrhoidectomy
441260|NCT00925912|perianal block
441261|NCT00925912|local anesthesia
441262|NCT00925912|spinal anesthesia
441263|NCT00925899|Melatonin
441264|NCT00925899|Palliative care
441265|NCT00925899|Advanced cancer
441266|NCT00925899|Symptoms
441267|NCT00925899|Quality of life
441268|NCT00925899|Randomized controlled trial
441269|NCT00925886|Astigmatism
441270|NCT00925886|Cataract
441271|NCT00925873|Fludarabine
441272|NCT00925873|AML
441273|NCT00925873|elderly patients
441274|NCT00925847|Amyotrophic lateral sclerosis
441275|NCT00925847|Lithium
441276|NCT00925847|Survival
441277|NCT00925834|Coronary angiography
441278|NCT00925834|Placebo effect
441279|NCT00925834|Suggestion
441280|NCT00925821|Allogeneic stem cell transplantation
441281|NCT00925821|Lenalidomide
441282|NCT00925821|IMiD
441283|NCT00925808|Unsuspected Venous Thromboembolism
441284|NCT00925808|VTE
441285|NCT00925808|Routine Computed Tomography
441286|NCT00925808|CT Scans
441287|NCT00925795|HIV
441288|NCT00925795|atherosclerosis
441289|NCT00925795|extra virgin olive oil
441290|NCT00925795|Alternative therapies
441291|NCT00925795|Treatment experienced+
441292|NCT00925782|autologous stem cell transplantation
441293|NCT00925756|HIV
441294|NCT00925756|low CD4 recovery
441295|NCT00925756|Low CD4 recovery despite HIV control
441296|NCT00925756|Treatment experienced
441297|NCT00925743|Phase 1
441298|NCT00925743|XRP6258
441299|NCT00925743|cisplatin
441300|NCT00925743|Antineoplastic Combined Chemotherapy Protocols
441301|NCT00925730|Atopic dermatitis
441302|NCT00925730|AD
441303|NCT00925730|pimecrolimus
441304|NCT00925730|blood
441305|NCT00925730|absorption
441306|NCT00925730|systemic
441307|NCT00925717|ADA recommendation
441308|NCT00925665|Intubation
441309|NCT00925665|Glidescope
441310|NCT00925665|Macintosh
441311|NCT00925665|Abscess
441312|NCT00925665|Difficult intubations in patients with odontogenic abscesses
441313|NCT00925652|CM
441314|NCT00925652|bevacizumab
441315|NCT00925652|cyclophosphamide
441316|NCT00925652|methotrexate
441317|NCT00925652|exercise intervention
441318|NCT00925652|diet intervention
441319|NCT00925639|phytoestrogen
441320|NCT00925639|coagulation
441321|NCT00925639|menopause
441322|NCT00925639|ddimer
441323|NCT00925639|antithrombin
441324|NCT00925639|hypercoagulation
441325|NCT00925613|Exchanging double lumen tube with laryngeal mask Proseal
441326|NCT00925613|Exchange double lumen tube with tracheal tube
441327|NCT00925613|Exchange double lumen tube before emergence decrease cough
441328|NCT00925613|thoracoscopy and postoperative respiratory complications
441329|NCT00925613|thoracostomy and postoperative respiratory complications
441330|NCT00925613|postoperative cough
441331|NCT00925613|postoperative respiratory complications
441332|NCT00925613|laryngeal mask and postoperative respiratory complications
441333|NCT00925600|Lens Opacification
441334|NCT00925600|Bone Loss
441335|NCT00925600|Androgen Deprivation Therapy
441336|NCT00925600|Non-metastatic prostate cancer
441337|NCT00925587|CKD
441338|NCT00925587|Anemia
441339|NCT00925587|correction
441340|NCT00925587|darbepoetin alfa
441341|NCT00925574|CNTO 1959
441342|NCT00925574|Healthy Volunteers
441343|NCT00925574|Psoriasis
441344|NCT00925561|Coronary Artery Calcification
441345|NCT00925548|Phase III trial
441346|NCT00925548|randomized
441347|NCT00925548|cancer vaccine
441348|NCT00925548|MUC1
441349|NCT00925548|BLP25
441350|NCT00925548|advanced breast cancer
441351|NCT00925548|postmenopausal breast cancer
441352|NCT00925548|immunotherapy of breast cancer
441353|NCT00925548|Inoperable locally advanced, recurrent, or metastatic endocrine-sensitive Breast Cancer
441354|NCT00925535|Pharmacokinetics HIV Tuberculosis Lersivirine UK-453
441355|NCT00925535|061 Rifabutin
441356|NCT00925535|HIV Infections
441357|NCT00925509|upper digestive tract cancer
441358|NCT00925509|implants
441359|NCT00925509|implants insertion
441360|NCT00925509|radio-surgical guidance
441361|NCT00925509|accuracy of implants insertion
441362|NCT00925509|cranial/facial radiotherapy or brachytherapy and/or microvascular fibula transfer.
441363|NCT00925509|Bone volume sufficient to support an implant
441364|NCT00925496|Omarthrosis shoulder joint
441365|NCT00925483|left ventricular mass
441366|NCT00925483|cardiac MRI
441367|NCT00925483|long dialysis
441368|NCT00925483|daily dialysis
441369|NCT00925470|Target organs impairment
441370|NCT00925470|High blood pressure
441371|NCT00925470|Evaluation of target organs impairment on patients suffering from high blood pressure without known cardiovascular or renal disease
441372|NCT00925457|Serious ventricular arrhythmia
441373|NCT00925457|Sudden cardiac death
441374|NCT00925457|Domperidone
441375|NCT00925457|Case-control study
441376|NCT00925457|Saskatchewan residents
441377|NCT00925457|Observational Study
441378|NCT00925444|Absorbable implants
441379|NCT00925444|Humans
441380|NCT00925444|Alginates
441381|NCT00925444|Pneumonectomy/methods
441382|NCT00925444|Pneumonectomy/instrumentation
441383|NCT00925444|Surgical Stapling
441384|NCT00925444|Thoracic surgery
441385|NCT00925444|Tissue Adhesives
441386|NCT00925444|Prospective studies
441387|NCT00925418|Neoplasm
441388|NCT00925418|breast Neoplasm
441389|NCT00925418|docetaxel
441390|NCT00925418|Glove
441391|NCT00925405|Breast Cancer
441392|NCT00925405|Hodgkin's lymphoma
441393|NCT00925405|Mantle-field Irradiation
441394|NCT00925405|Mammogram
441395|NCT00925405|Magnetic resonance imaging
441396|NCT00925405|MRI Breast Cancer Screening
441397|NCT00925392|doripenem
441398|NCT00925392|epithelial lining fluid
441399|NCT00925392|alveolar macrophages
441400|NCT00925392|pharmacokinetics
441401|NCT00925392|Healthy adult subjects
441402|NCT00925366|Shoulder
441403|NCT00925366|MRI
441404|NCT00925366|MR arthrography
441405|NCT00925366|CT arthrography
441406|NCT00925366|Rotator cuff tear
441407|NCT00925366|Arthroscopy
441408|NCT00925353|lidocaine
441409|NCT00925353|pre-medication
441410|NCT00925353|mammography
441411|NCT00925353|pain
441412|NCT00925353|safety
441413|NCT00925340|Alcohol
441414|NCT00925340|Substance Abuse
441415|NCT00925340|Adolescent
441416|NCT00925340|Family functioning
441417|NCT00925314|Stage III Melanoma
441418|NCT00925314|Melanoma
441419|NCT00925314|TLI
441420|NCT00925314|Transgenic Lymphocyte Immunization
441421|NCT00925314|CB-10-01-02
441422|NCT00925301|AmicusTherapeutics
441423|NCT00925301|AT1001
441424|NCT00925301|Migalastat
441425|NCT00925301|Pharmacokinetics
441426|NCT00925301|Substrate
441427|NCT00925288|Female sex worker
441428|NCT00925288|Peru
441429|NCT00925288|Cervical infection
441430|NCT00925288|Cervical abnormality
441431|NCT00925288|Serum antibody
441432|NCT00925288|Vaccine acceptance
441433|NCT00925288|Alternative schedule
441434|NCT00925288|Viral infections
441435|NCT00925288|Human papillomavirus vaccine
441436|NCT00925288|Human papillomavirus (HPV)
441437|NCT00925288|non inferiority
441438|NCT00925275|Solid tumors
441439|NCT00925275|Refractory
441440|NCT00925275|Relapsed
441441|NCT00925275|Radiation
441442|NCT00925275|Dosimetry
441443|NCT00925275|Radiopharmaceutical
441444|NCT00925275|Biodistribution
441445|NCT00925275|Pharmacokinetics
441446|NCT00925275|Cancer
441447|NCT00925275|Phase I
441448|NCT00925262|mental health
441449|NCT00925262|randomized controlled trial
441450|NCT00925262|torture
441451|NCT00925249|rheumatoid arthritis
441452|NCT00925249|RA
441453|NCT00925249|TB
441454|NCT00925249|tuberculosis
441455|NCT00925249|anti-TNF therapy
441456|NCT00925249|biologic therapy
441457|NCT00925249|quantiferon
441458|NCT00925249|IGRA
441459|NCT00925249|Newly diagnosed rheumatoid arthritis (RA) in the Tricare system
441460|NCT00925236|MYH9 gene
441461|NCT00925236|macrothrombocytopenia
441462|NCT00925236|leukocyte inclusions
441463|NCT00925236|cataracts deafness
441464|NCT00925236|nephritis
441465|NCT00925236|MYH9 Related Disorders
441466|NCT00925223|IBS
441467|NCT00925223|BDNf
441468|NCT00925223|visceral hypersensitivity
441469|NCT00925210|Endobronchial ultrasound
441470|NCT00925210|Electromagnetic Navigation Bronchoscopy
441471|NCT00925210|Bronchoscopy
441472|NCT00925210|Ultrasonography
441473|NCT00925197|anticoagulation
441474|NCT00925197|fluindione
441475|NCT00925197|patient self-testing
441476|NCT00925197|coaguchek
441477|NCT00925197|inratio
441478|NCT00925197|Post operative antivitamin K therapy
441479|NCT00925184|questionnaire, medical education, medical students.
441480|NCT00925171|Chronic obstructive pulmonary disease
441481|NCT00925171|Pulmonary rehabilitation
441482|NCT00925171|Chronic Respiratory Questionnaire
441483|NCT00925158|Rhytidoplasty
441484|NCT00925158|Video-Assisted Surgery
441485|NCT00925158|Surgical instruments
441486|NCT00925158|Dissection
441487|NCT00925158|Innovative therapies
441488|NCT00925158|Face
441489|NCT00925158|Aging
441490|NCT00925158|Premature aging
441491|NCT00925158|Rejuvenation
441492|NCT00925132|Metastatic
441493|NCT00925132|Melanoma
441494|NCT00925132|Epigenetic
441495|NCT00925132|Temozolomide
441496|NCT00925132|Decitabine
441497|NCT00925132|Panobinostat
441498|NCT00925132|LBH589
441499|NCT00925119|Diabetes
441500|NCT00925119|Atenolol
441501|NCT00925119|Genetic
441502|NCT00925106|Bioavailability, pharmacokinetics, celecoxib
441503|NCT00925093|vancomycin
441504|NCT00925093|teicoplanin
441505|NCT00925093|linezolid
441506|NCT00925093|intravenous
441507|NCT00925093|cerebrospinal fluid
441508|NCT00925093|CSF
441509|NCT00925093|pharmacokinetics
441510|NCT00925093|penetration
441511|NCT00925093|blood-brain barrier
441512|NCT00925093|Pharmacokinetics of three antibiotics in relation to cerebrospinal fluid
441513|NCT00925067|Inguinal hernia
441514|NCT00925067|Laparoscopic repair
441515|NCT00925067|Prostheses
441516|NCT00925067|Male fertility
441517|NCT00925054|PKU
441518|NCT00925054|PEG PAL
441519|NCT00925054|BioMarin
441520|NCT00924989|ACC
441521|NCT00924989|Adrenocortical carcinoma
441522|NCT00924989|OSI-906
441523|NCT00924989|Insulin-like growth factor-1 receptor (IGF-1R)
441524|NCT00924989|GALACCTIC
441525|NCT00924963|Pain of venipuncture or IV insertion
441526|NCT00924950|Psoriasis
441527|NCT00924950|Plaque psoriasis, with bilateral symmetrical lesions.
441528|NCT00924950|A diagnosis of stable plaque-type psoriasis vulgaris
441529|NCT00924950|with at least one pair of symmetric lesions on either
441530|NCT00924950|the trunk, arms, or legs that would serve as target lesions.
441531|NCT00924937|Cardiovascular events
441532|NCT00924937|Blood pressure
441533|NCT00924937|Incidence of Cancer
441534|NCT00924937|Cognitive decline
441535|NCT00924937|Mediterranean Diet
441536|NCT00924937|Secondary Prevention
441537|NCT00924937|Low fat diet
441538|NCT00924924|health promotion
441539|NCT00924924|prevention
441540|NCT00924924|worksite wellness
441541|NCT00924924|behavior change
441542|NCT00924924|healthy volunteers
441543|NCT00924911|GSK1322322, relative bioavailability, single dose, food effect, H2 blocker, healthy subjects, open label, PIB, tablet
441544|NCT00924898|Acute HIV
441545|NCT00924898|HIV
441546|NCT00924898|Acute Infections
441547|NCT00924898|Acute Infection
441548|NCT00924885|Reproductive Medicine
441549|NCT00924885|Fertilization in Vitro
441550|NCT00924885|Oocyte retrieval
441551|NCT00924885|Local anaesthesia
441552|NCT00924885|Aspiration needle
441553|NCT00924872|stroke
441554|NCT00924872|power wheelchair skills
441555|NCT00924872|training
441556|NCT00924872|safety
441557|NCT00924859|cerebral venous thrombosis
441558|NCT00924859|stroke
441559|NCT00924859|coagulation
441560|NCT00924846|high frequency oscillatory ventilation
441561|NCT00924846|respiratory failure
441562|NCT00924846|children
441563|NCT00924846|inhaled nitric oxide
441564|NCT00924833|hypoxia
441565|NCT00924833|autonomic nervous system
441566|NCT00924833|blood pressure
441567|NCT00924833|heart rate
441568|NCT00924833|exercise
441569|NCT00924833|heart failure
441570|NCT00924833|receptors, adrenergic, beta.
441571|NCT00924820|Neoplastic Meningitis
441572|NCT00924820|NM
441573|NCT00924820|Advanced Cancers
441574|NCT00924820|Brain Cancer
441575|NCT00924820|Advanced Cancer
441576|NCT00924820|Brain Diseases
441577|NCT00924820|Central Nervous System Disorders
441578|NCT00924820|CNS
441579|NCT00924820|Bevacizumab
441580|NCT00924820|Avastin
441581|NCT00924820|Anti-VEGF monoclonal antibody
441582|NCT00924820|rhuMAb-VEGF
441583|NCT00924820|Spinal Cord
441584|NCT00924820|meninges
441585|NCT00924820|cerebrospinal fluid
441586|NCT00924820|CSF
441587|NCT00924807|Prostate Cancer
441588|NCT00924807|Combined Androgen Blockade
441589|NCT00924807|Radiotherapy
441590|NCT00924807|Sorafenib
441591|NCT00924781|Anemia associated with chronic kidney disease (CKD)
441592|NCT00924781|Hemodialysis
441593|NCT00924768|Otherwise healthy current cigarette smokers
441594|NCT00924768|current cigarette smokers
441595|NCT00924755|Surgical mesh
441596|NCT00924742|The PK of Tapimycin
441597|NCT00924742|volunteer
441598|NCT00924690|Colon
441599|NCT00924690|Cancer
441600|NCT00924690|Screening
441601|NCT00924690|Prevention
441602|NCT00924690|Information
441603|NCT00924677|genicular nerve
441604|NCT00924677|osteoarthritis
441605|NCT00924677|knee
441606|NCT00924677|neurotomy
441607|NCT00924664|low back pain monoclonal antibody nerve growth factor
441608|NCT00924651|fatigue
441609|NCT00924651|unspecified adult solid tumor, protocol specific
441610|NCT00924638|atrial fibrillation
441611|NCT00924638|cryptogenic stroke
441612|NCT00924638|continuous monitoring
441613|NCT00924638|implantable loop recorder
441614|NCT00924638|insertable cardiac monitor
441615|NCT00924612|Primary hypogonadism
441616|NCT00924612|Secondary hypogonadism
441617|NCT00924599|Recurring Gestational Diabetes
441618|NCT00924599|Prevention
441619|NCT00924573|Glimepiride
441620|NCT00924573|Metformin
441621|NCT00924573|Combination Drug Therapy
441622|NCT00924560|Adolescents
441623|NCT00924560|Bone Mineral Density
441624|NCT00924560|Oral Contraceptive
441625|NCT00924547|Cystic Fibrosis
441626|NCT00924547|Docosahexanoic Acid
441627|NCT00924547|DHA
441628|NCT00924547|isoprostanes
441629|NCT00924547|fatty acid
441630|NCT00924534|type 2 diabetes
441631|NCT00924534|interventional
441632|NCT00924534|placebo
441633|NCT00924534|controlled
441634|NCT00924534|PK
441635|NCT00924534|PD
441636|NCT00924534|safety
441637|NCT00924521|grains
441638|NCT00924521|fiber
441639|NCT00924521|metabolic syndrome
441640|NCT00924521|insulin
441641|NCT00924508|eczema
441642|NCT00924508|at least 3 patches of eczema
441643|NCT00924495|low back pain
441644|NCT00924495|motor control
441645|NCT00924495|cortical regulation
441646|NCT00924495|transcranial magnetic stimulation
441647|NCT00924482|cardiac output
441648|NCT00924482|ECOM
441649|NCT00924482|Endotracheal Cardiac Output Monitor
441650|NCT00924482|Perioperative medical care
441651|NCT00924469|Prostate cancer
441652|NCT00924469|Abiraterone acetate
441653|NCT00924469|Leuprolide acetate
441654|NCT00924469|Prednisone
441655|NCT00924469|CB7630
441656|NCT00924469|Testosterone
441657|NCT00924456|Transcendental Meditation
441658|NCT00924456|blood pressure
441659|NCT00924456|psychological distress
441660|NCT00924456|high psychological distress
441661|NCT00924443|acute myelogenous leukemia
441662|NCT00924443|acute myeloid leukemia
441663|NCT00924443|clolar
441664|NCT00924443|evoltra
441665|NCT00924443|clofarabine
441666|NCT00924443|untreated acute leukemia
441667|NCT00924443|adult acute leukemia
441668|NCT00924430|Interaction SLV337 and simvastatin
441669|NCT00924430|Type 2 diabetes mellitus
441670|NCT00924417|Pain associated with peripheral intravenous line placement
441671|NCT00924404|Xylitol
441672|NCT00924404|sinusitis
441673|NCT00924404|Comparing efficacy of twice daily xylitol nasal rinse with saline rinse presently current standard, comparing outcomes like quality of life and exacerbations
441674|NCT00924391|cholesterol
441675|NCT00924391|plant sterols
441676|NCT00924391|cholesterol absorption
441677|NCT00924365|Children
441678|NCT00924365|AIDS
441679|NCT00924365|Toxicity
441680|NCT00924365|Development
441681|NCT00924365|Puberty
441682|NCT00924365|HIV
441683|NCT00924365|Pediatrics
441684|NCT00924365|HIV Infections
441685|NCT00924352|Metastatic Breast Cancer
441686|NCT00924339|soy protein
441687|NCT00924339|familial hypercholesterolaemia
441688|NCT00924339|children and adolescents
441689|NCT00924339|isoflavones
441690|NCT00924339|FH
441691|NCT00924326|B Cell Malignancies
441692|NCT00924326|T Cell Persistence
441693|NCT00924326|Immunotherapy
441694|NCT00924326|Cell Transfer
441695|NCT00924326|Leukemia
441696|NCT00924326|Chronic Lymphocytic Leukemia
441697|NCT00924326|CLL
441698|NCT00924326|Lymphoma
441699|NCT00924313|Prostate Cancer
441700|NCT00924313|MRI
441701|NCT00924313|C-11 Acetate
441702|NCT00924313|PET
441703|NCT00924300|feasibility of MEG in pediatric populations
441704|NCT00924287|Metastatic Cancer
441705|NCT00924287|Tumor Regression
441706|NCT00924287|Immunotherapy
441707|NCT00924287|Safety
441708|NCT00924287|Cancer
441709|NCT00924261|hip
441710|NCT00924261|gait
441711|NCT00924261|walking
441712|NCT00924261|falls
441713|NCT00924261|stretching
441714|NCT00924261|Flexibility
441715|NCT00924261|Aged
441716|NCT00924248|Liver MRI
441717|NCT00924209|Neoadjuvant
441718|NCT00924209|Stage IIIA (N2)
441719|NCT00924209|Cisplatin
441720|NCT00924209|Gemcitabine
441721|NCT00924209|Bevacizumab
441722|NCT00924209|Non-Small Cell Lung Cancer
441723|NCT00924209|NSCLC
441724|NCT00924196|Plexiform Neurofibroma
441725|NCT00924196|Optic Pathway Tumor
441726|NCT00924196|Neurofibroma
441727|NCT00924196|Malignant Peripheral Nerve Sheath Tumor
441728|NCT00924196|Volumetric MRI
441729|NCT00924196|Neurofibromatosis Type 1
441730|NCT00924196|NF1
441731|NCT00924196|Optic Glioma
441732|NCT00924183|Depression
441733|NCT00924183|Symptom scales
441734|NCT00924183|Symptom measures
441735|NCT00924183|Vancouver Semi-Structured Interview for Depression
441736|NCT00924183|V-SID
441737|NCT00924183|VSID
441738|NCT00924183|treatment-as-usual
441739|NCT00924183|treatment as usual
441740|NCT00924183|open-label
441741|NCT00924183|open label
441742|NCT00924183|Major Depressive Episode
441743|NCT00924183|MDE
441744|NCT00924170|Immunotoxin
441745|NCT00924170|CD25
441746|NCT00924170|Immunogenicity
441747|NCT00924170|Neutralization
441748|NCT00924170|Neutralizing Antibodies
441749|NCT00924170|Adult T-Cell Leukemia
441750|NCT00924170|Leukemia
441751|NCT00924170|ATL
441752|NCT00924131|Late Effects
441753|NCT00924131|Radiation
441754|NCT00924131|Chemotherapy
441755|NCT00924131|Hodgkin's Disease
441756|NCT00924131|Lymphoma
441757|NCT00924131|Hodgkin Disease
441758|NCT00924118|Acute myocardial infarction
441759|NCT00924118|Reperfusion injury
441760|NCT00924118|Nitric oxide
441761|NCT00924092|Immunotherapy
441762|NCT00924092|Lung Cancer
441763|NCT00924092|Colorectal Cancer
441764|NCT00924092|Head and Neck Cancer
441765|NCT00924092|Prostate
441766|NCT00924092|Breast Cancer
441767|NCT00924079|Analysis of plasma concentration of nalbuphine
441768|NCT00924066|Ixabepilone
441769|NCT00924066|BMS-247550
441770|NCT00924066|Ixempra
441771|NCT00924066|Cervical Cancer
441772|NCT00924066|Epothilone
441773|NCT00924053|Diabetes Mellitus Type 2
441774|NCT00924040|BL22 in HCL after Immunotoxin
441775|NCT00924040|Hairy Cell Leukemia
441776|NCT00924040|Leukemia
441777|NCT00924027|Radiation
441778|NCT00924027|Cancer
441779|NCT00924027|HDR
441780|NCT00924027|Brachytherapy
441781|NCT00924027|Training
441782|NCT00924014|heart failure
441783|NCT00924001|Clinical Response
441784|NCT00924001|Immunotherapy
441785|NCT00924001|Cancer
441786|NCT00924001|Cytokines
441787|NCT00924001|Adoptive Cell Therapy
441788|NCT00924001|Melanoma
441789|NCT00924001|Metastatic Melanoma
441790|NCT00923988|Secondhand smoke
441791|NCT00923988|passive smoking
441792|NCT00923988|platelet function
441793|NCT00923988|endothelial function
441794|NCT00923962|Basic science
441795|NCT00923962|Type 2 Diabetes mellitus
441796|NCT00923962|Glucagon like peptid-1
441797|NCT00923962|Coronary Bloodflow
441798|NCT00923962|Metabolite uptake
441799|NCT00923949|NSCLC Stage Ia-IIb
441800|NCT00923949|Resectable NSCLC
441801|NCT00923949|Non-Small Cell Lung Cancer
441802|NCT00923949|NSCLC
441803|NCT00923936|Kaposi's Sarcoma
441804|NCT00923936|HIV
441805|NCT00923936|Doxil
441806|NCT00923936|VEGF
441807|NCT00923936|Bevacizumab
441808|NCT00923936|Kaposi Sarcoma
441809|NCT00923923|stress reactivity
441810|NCT00923923|PTSD
441811|NCT00923923|alcohol dependence
441812|NCT00923923|drinking
441813|NCT00923923|craving
441814|NCT00923910|WT1 Peptide Dendritic Cell Vaccine
441815|NCT00923910|Hematologic Malignancies
441816|NCT00923910|Relapse After Allogeneic Stem Cell Transplantation
441817|NCT00923910|Donor Lymphocyte Infusions
441818|NCT00923910|WT1-Positive
441819|NCT00923910|Dendritic Cell Vaccine
441820|NCT00923910|Tumor Immunotherapy
441821|NCT00923910|Allogeneic Adoptive Immunotherapy
441822|NCT00923910|Hodgkins Lymphoma
441823|NCT00923910|Leukemia
441824|NCT00923910|Acute Myelogenous Leukemia
441825|NCT00923910|AML
441826|NCT00923910|Acute Lymphocytic Leukemia
441827|NCT00923910|ALL
441828|NCT00923910|Chronic Myelogenous Leukemia
441829|NCT00923910|CML
441830|NCT00923910|Myelodysplasia Syndrome
441831|NCT00923910|Non-Hodgkin Lymphoma
441832|NCT00923897|Hepatocellular Carcinoma
441833|NCT00923897|Hepatic Metastasis
441834|NCT00923897|Palliative Radiation Therapy
441835|NCT00923897|Locally advanced HCC and Hepatic Metastasis
441836|NCT00923884|NSCLC
441837|NCT00923884|Genotype
441838|NCT00923884|SCLC
441839|NCT00923884|Lung Cancer
441840|NCT00923884|Non-Small Cell Lung Cancer
441841|NCT00923884|Small Cell Lung Cancer
441842|NCT00923871|CBCT
441843|NCT00923871|Breast Cancer
441844|NCT00923858|Rotator Cuff
441845|NCT00923858|Ultrasound
441846|NCT00923858|Pain
441847|NCT00923858|Tear Progression
441848|NCT00923845|Metastatic Renal Cell Carcinoma
441849|NCT00923845|Allogeneic Hematopoietic Stem Cell Transplant
441850|NCT00923845|Th2 Cells
441851|NCT00923845|Sirolimus
441852|NCT00923845|Pentostatin
441853|NCT00923845|Kidney Cancer
441854|NCT00923845|Renal Cell Carcinoma
441855|NCT00923845|Metastatic Renal Cell Cancer
441856|NCT00923832|Fungal Infections
441857|NCT00923832|PCR Assays
441858|NCT00923832|Cell Wall Derived Biomarkers
441859|NCT00923832|EORTC/MSG Definitions
441860|NCT00923832|Molecular Assays
441861|NCT00923832|Lung Fungal Infection
441862|NCT00923832|Invasive Pulmonary Fungal Infection
441863|NCT00923832|Invasive Pulmonary Aspegillosis
441864|NCT00923832|Invasive Pulmonary Zycomycosis
441865|NCT00923819|Adolescents
441866|NCT00923819|Gastric Bypass
441867|NCT00923819|Quality of Life
441868|NCT00923819|Mental Health
441869|NCT00923819|Lifestyle
441870|NCT00923806|Metastatic Cancer
441871|NCT00923806|Tumor Regression
441872|NCT00923806|Safety
441873|NCT00923806|Immunotherapy
441874|NCT00923793|skull defects
441875|NCT00923793|Hydroxylapatite implant
441876|NCT00923793|Titanium implant
441877|NCT00923793|calotte defects without the possibility to be covered with the missing own bone
441878|NCT00923780|Tissue Acquisition
441879|NCT00923780|Gene Expression
441880|NCT00923780|Class Predictor Model
441881|NCT00923780|Endocrine Tumor
441882|NCT00923741|Lung Cancer
441883|NCT00923741|Immunity
441884|NCT00923741|Clinical Response
441885|NCT00923741|Cytokines
441886|NCT00923741|Elispot Assay
441887|NCT00923741|Non-Small Cell Lung Cancer
441888|NCT00923741|NSCLC
441889|NCT00923728|AVN - 944
441890|NCT00923728|Phase I
441891|NCT00923728|Adult Solid Tumors
441892|NCT00923728|Cancer
441893|NCT00923728|Solid Tumor
441894|NCT00923715|Diabetes Mellitus, Type 1
441895|NCT00923715|Exenatide
441896|NCT00923715|Pramlintide
441897|NCT00923676|Hyperlipidemia
441898|NCT00923676|LDL-cholesterol
441899|NCT00923676|HDL-cholesterol
441900|NCT00923676|triglycerides
441901|NCT00923676|IIEF
441902|NCT00923676|FSFI
441903|NCT00923676|Male and female sexual dysfunctions
441904|NCT00923663|MALT lymphoma
441905|NCT00923663|Advanced or Helicobacter pylori-refractory MALT lymphoma
441906|NCT00923650|Informed Consent
441907|NCT00923650|Pediatric Phase I Clinical Trials
441908|NCT00923650|Assent
441909|NCT00923650|Questionnaires
441910|NCT00923650|Osteosarcoma
441911|NCT00923650|Ewing's Sarcoma
441912|NCT00923650|Neuroblastoma
441913|NCT00923650|Brain Tumors
441914|NCT00923650|Leukemia
441915|NCT00923637|Non small cell lung cancer
441916|NCT00923637|video assisted thoracic surgery
441917|NCT00923637|Adjuvant chemotherapy
441918|NCT00923637|Pemetrexed
441919|NCT00923637|Oxaliplatin
441920|NCT00923624|electronic medical record
441921|NCT00923624|antiretroviral medication adherence
441922|NCT00923611|Hypertension
441923|NCT00923611|Fimasartan
441924|NCT00923598|TKA
441925|NCT00923598|Bilateral
441926|NCT00923598|Cleveland Clinic
441927|NCT00923598|UCSD
441928|NCT00923598|Catheter
441929|NCT00923598|Nerve block
441930|NCT00923598|Postoperative pain
441931|NCT00923598|Femoral Catheter
441932|NCT00923598|Bilateral Total Knee Arthroplasty
441933|NCT00923598|Bilateral Femoral Catheter
441934|NCT00923572|Oral contraceptive
441935|NCT00923533|Fimasartan
441936|NCT00923533|Drug interaction
441937|NCT00923520|Solid Tumors
441938|NCT00923520|Phase I
441939|NCT00923520|Lymphoma
441940|NCT00923520|Dimethane Sulfonate (DMS612, NSC 281612)
441941|NCT00923520|Cancer
441942|NCT00923520|Solid Tumor
441943|NCT00923520|Renal Cell Cancer
441944|NCT00923520|Kidney Cancer
441945|NCT00923520|Breast Cancer
441946|NCT00923520|Colon Cancer
441947|NCT00923520|Lung Disease
441948|NCT00923520|Non-Hodgkin Lymphoma
441949|NCT00923520|NHL
441950|NCT00923507|Gene Expression
441951|NCT00923507|Prognosis
441952|NCT00923507|Watch and Wait
441953|NCT00923507|Molecular Genetics
441954|NCT00923507|Biologic Markers
441955|NCT00923507|Leukemia
441956|NCT00923507|Lymphoma
441957|NCT00923494|Anesthesia
441958|NCT00923481|Multi-Kinase Inhibitor
441959|NCT00923481|Neoplasms
441960|NCT00923481|Advanced Cancer
441961|NCT00923481|Kidney Cancer
441962|NCT00923481|Liver Cancer
441963|NCT00923481|Pheochromocytoma
442093|NCT00923104|Healthy Volunteer
441964|NCT00923481|Non-Small Cell Lung Cancer
441965|NCT00923481|Colorectal Cancer
441966|NCT00923481|Head and Neck Cancer
441967|NCT00923468|Pharmacokinetics
441968|NCT00923468|Phase I Trials
441969|NCT00923468|Children
441970|NCT00923468|Relaspsed Solid Tumors
441971|NCT00923468|Relapsed Leukemia
441972|NCT00923468|Relapsed Brain Tumors
441973|NCT00923442|Acute Lymphoblastic Leukemia
441974|NCT00923442|Acute Lymphocytic Leukemia
441975|NCT00923442|Pediatric Blood Disorders
441976|NCT00923442|Hodgkins and non-Hodgkins lymphoma
441977|NCT00923442|MDS
441978|NCT00923429|Manual therapy
441979|NCT00923429|Low back pain
441980|NCT00923429|Pain
441981|NCT00923429|Return to work
441982|NCT00923416|Intra-Prostate Markers
441983|NCT00923416|Transrectal Ultrasound
441984|NCT00923416|Prostate Cancer Patients
441985|NCT00923403|plant sterols
441986|NCT00923403|diet
441987|NCT00923403|soymilk
441988|NCT00923403|cholesterol
441989|NCT00923390|Renal Cancer
441990|NCT00923390|Immunotherapy
441991|NCT00923390|Clinical Response
441992|NCT00923390|Toxicity
441993|NCT00923390|Gene Therapy
441994|NCT00923390|Kidney Cancer
441995|NCT00923377|Breast Cancer
441996|NCT00923377|Breast Cancer Prevention
441997|NCT00923377|High Risk
441998|NCT00923377|Breast Stem Cells
441999|NCT00923377|Mammographic Density
442000|NCT00923377|Breast Cancer Risk
442001|NCT00923364|GATA2
442002|NCT00923364|Transplant
442003|NCT00923364|Immunodeficiency
442004|NCT00923364|Myelodysplasia
442005|NCT00923364|MonoMAC
442006|NCT00923351|Vaccine
442007|NCT00923351|Immunotherapy
442008|NCT00923351|Cancer
442009|NCT00923351|Chemotherapy
442010|NCT00923351|Ewings Sarcoma
442011|NCT00923351|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
442012|NCT00923351|Neuroblastoma
442013|NCT00923351|Autologous Lymphocyte Infusion
442014|NCT00923351|Ewing's Sarcoma
442015|NCT00923351|Rhabdomyosarcoma
442016|NCT00923338|fistula
442017|NCT00923338|vesico-vaginal fistula
442018|NCT00923325|Biomarker Analysis
442019|NCT00923325|Sarcomas
442020|NCT00923325|Ewing's Sarcoma
442021|NCT00923325|Osteosarcoma
442022|NCT00923325|Rhabdomyosarcoma
442023|NCT00923325|Synovial Sarcoma
442024|NCT00923325|Other Sarcoma
442025|NCT00923299|stage IV pancreatic cancer
442026|NCT00923299|recurrent pancreatic cancer
442027|NCT00923299|adenocarcinoma of the pancreas
442028|NCT00923273|Pemetrexed
442029|NCT00923273|Sirolimus
442030|NCT00923273|Non-Small Cell Lung Cancer
442031|NCT00923273|Phase I/II
442032|NCT00923273|mTOR Inhibitor
442033|NCT00923273|NSCLC
442034|NCT00923273|Lung Cancer
442035|NCT00923260|Omentectomy
442036|NCT00923260|metabolic syndrome
442037|NCT00923260|acute phase reactants
442038|NCT00923247|Vandetanib
442039|NCT00923247|Bortezomib
442040|NCT00923247|Medullary Thyroid
442041|NCT00923247|Proteasome Inhibitor
442042|NCT00923247|Cancer
442043|NCT00923247|Solid Tumor
442044|NCT00923247|Thyroid Cancer
442045|NCT00923247|Medullary Thyroid Cancer
442046|NCT00923234|monosomy 5
442047|NCT00923234|del5q
442048|NCT00923234|lenalidomide
442049|NCT00923234|azacitidine
442050|NCT00923221|Blood
442051|NCT00923221|Prostate Cancer
442052|NCT00923221|Genotyping
442053|NCT00923195|Metastatic Melanoma
442054|NCT00923195|Tumor Regression
442055|NCT00923195|Safety
442056|NCT00923195|Immunotherapy
442057|NCT00923182|Relapsed or Refractory Chronic Lymphocytic Leukemia,
442058|NCT00923182|CLL
442059|NCT00923169|Renal Cell
442060|NCT00923169|Melanoma
442061|NCT00923169|Monoclonal Antibodies
442062|NCT00923169|Phase I
442063|NCT00923169|TGF-B
442064|NCT00923156|Heart failure
442065|NCT00923156|Systolic
442066|NCT00923156|Aliskiren
442067|NCT00923156|Ramipril
442068|NCT00923156|Angiotensin II
442069|NCT00923156|Ang II
442070|NCT00923156|Plasma Renin Activity
442071|NCT00923156|PRA
442072|NCT00923156|Plasma Renin Concentration
442073|NCT00923156|PR,
442074|NCT00923156|brain natriuretic peptide
442075|NCT00923156|BNP
442076|NCT00923156|urinary aldosterone
442077|NCT00923156|Escape
442078|NCT00923156|Pharmacokinetic
442079|NCT00923156|PK
442080|NCT00923130|Renal Cell Carcinoma
442081|NCT00923130|Bevacizumab
442082|NCT00923130|Ixabepilone
442083|NCT00923130|Phase II
442084|NCT00923117|Glioblastoma
442085|NCT00923117|Chemotherapy
442086|NCT00923117|Anti-Angiogenesis
442087|NCT00923117|Radiation
442088|NCT00923117|Brain Tumor
442089|NCT00923117|Malignant Glioma
442090|NCT00923117|Glioblastoma Multiforme
442091|NCT00923104|Radiation
442092|NCT00923104|Blister
442094|NCT00923104|Samples
442095|NCT00923104|Prostate Cancer
442096|NCT00923104|Breast Cancer
442097|NCT00923104|HV
442098|NCT00923091|triple combination
442099|NCT00923091|parallel group
442100|NCT00923091|dual combination
442101|NCT00923078|schizophrenia
442102|NCT00923078|cognitive remediation
442103|NCT00923078|rehabilitation
442104|NCT00923078|evoked potentials
442105|NCT00923078|neuropsychology
442106|NCT00923065|Cancer
442107|NCT00923065|Oncology
442108|NCT00923065|Standard Care
442109|NCT00923052|Cancer Stem Cells
442110|NCT00923052|Biomarkers
442111|NCT00923052|Surgery
442112|NCT00923052|Solid Organ Cancers
442113|NCT00923052|Natural History
442114|NCT00923052|Cancer
442115|NCT00923052|Solid Organ Cancer
442116|NCT00923052|Liver Cancer
442117|NCT00923052|Colorectal Cancer
442118|NCT00923052|Breast Cancer
442119|NCT00923052|Gastric Cancer
442120|NCT00923052|Pancreatic Ductal Cancer
442121|NCT00923039|The early origin of cardiovascular disease
442122|NCT00923026|Gene Therapy
442123|NCT00923026|Follow-Up
442124|NCT00923026|Delayed Toxicity
442125|NCT00923026|Adenocarcinoma
442126|NCT00923026|Melanoma
442127|NCT00923026|Neuroendocrine Tumors
442128|NCT00923026|Carcinoma
442129|NCT00923013|Hairy Cell Leukemia
442130|NCT00923013|Cladribine
442131|NCT00923013|Rituximab
442132|NCT00923013|Minimal Residual Disease
442133|NCT00923013|Leukemia
442134|NCT00923000|Herb Drug
442135|NCT00923000|volunteers
442136|NCT00922987|lyrica pregabalin epilepsy partial seizures
442137|NCT00922974|spinal bone metastases
442138|NCT00922974|pain
442139|NCT00922961|brachytherapy, late cutaneous toxicity
442140|NCT00922948|Radiofrequency ablation
442141|NCT00922948|Cryosurgery
442142|NCT00922948|Renal cancers
442143|NCT00922896|Gemcitabine
442144|NCT00922896|Cisplatin
442145|NCT00922896|Erlotinib
442146|NCT00922883|Promacta
442147|NCT00922883|SAA
442148|NCT00922883|Aplastic Anemia
442149|NCT00922883|Thrombocytopenia
442150|NCT00922857|Respiratory Insufficiency
442151|NCT00922857|Muscular Atrophy
442152|NCT00922857|Respiratory rehabilitation
442153|NCT00922844|hypotension
442154|NCT00922844|low blood pressure
442155|NCT00922844|vasopressor need
442156|NCT00922831|Cognition, Affective MS symptoms
442157|NCT00922818|Perineal
442158|NCT00922818|Prostatectomy
442159|NCT00922818|Nerve
442160|NCT00922818|Anatomic
442161|NCT00922818|Surgery
442162|NCT00922818|Neoplasms, Prostatic
442163|NCT00922818|Prostate Cancer
442164|NCT00922818|Prostate Neoplasms
442165|NCT00922818|Prostatic Cancer
442166|NCT00922818|Prostate
442167|NCT00922818|Cancer
442168|NCT00922818|Recurrent
442169|NCT00922805|Pediatrics, short bowel syndrome, soluble fiber
442170|NCT00922766|dalteparin non-ST segment elevated acute coronary syndromes
442171|NCT00922753|Preoxygenation
442172|NCT00922753|Inspiratory
442173|NCT00922753|Support
442174|NCT00922753|Healthy
442175|NCT00922753|EndtidalO2
442176|NCT00922740|Nocturia
442177|NCT00922740|Pharmacokinetics
442178|NCT00922740|Pharmacodynamics
442179|NCT00922740|Water-loading
442180|NCT00922740|Elderly
442181|NCT00922740|Males
442182|NCT00922727|L. reuteri
442183|NCT00922727|Cytokines
442184|NCT00922727|Toll like receptors
442185|NCT00922727|Healthy Adults
442186|NCT00922727|Probiotics
442187|NCT00922714|Glutamine
442188|NCT00922714|ICU patients
442189|NCT00922714|Critically ill
442190|NCT00922714|Nutrition
442191|NCT00922701|Peritoneal dialysis
442192|NCT00922701|L-carnitine
442193|NCT00922688|Dipeptide Alanyl-Glutamine
442194|NCT00922688|Insulin sensitivity
442195|NCT00922688|Intracellular signaling
442196|NCT00922688|Antioxidant/oxidant parameters
442197|NCT00922688|Lipolysis
442198|NCT00922688|Inflammatory response in the liver
442199|NCT00922675|ST-elevation myocardial infarction
442200|NCT00922662|coronary artery disease
442201|NCT00922662|chest pain
442202|NCT00922662|CCTA
442203|NCT00922623|Nasolabial folds
442204|NCT00922597|Continuous infusion
442205|NCT00922597|Surgery
442206|NCT00922597|Severe haemophilia A
442207|NCT00922584|non-small cell lung cancer
442208|NCT00922584|Sorafenib
442209|NCT00922584|targeted therapy
442210|NCT00922571|Cataract
442211|NCT00922571|Femtosecond laser
442212|NCT00922558|tetra-axiametric posturography
442213|NCT00922558|postural control
442214|NCT00922558|tetrax
442215|NCT00922558|children
442216|NCT00922545|Chronic obstructive pulmonary disease
442217|NCT00922545|Quality of life
442218|NCT00922545|Primary health care
442219|NCT00922532|Hypoxic Respiratory Failure (HRF), Pulmonary Hypertension
442220|NCT00922519|Positron Emission Tomography
442221|NCT00922519|Sodium 18F-Fluoride
442222|NCT00922519|99mTc-MDP
442223|NCT00922519|Bone Scan
442224|NCT00922506|Overactive bladder
442225|NCT00922506|Benign prostate hyperplasia
442226|NCT00922506|Doxazosin
442227|NCT00922506|Tolterodine
442228|NCT00922493|weaning
442229|NCT00922493|inspiratory muscle training
442230|NCT00922493|maximum inspiratory pressure (MIP)
442231|NCT00922493|index of Tobin (IT)
442232|NCT00922493|intubated
442233|NCT00922493|intensive care unit
442234|NCT00922493|elderly
442235|NCT00922480|Hypertension
442236|NCT00922480|Losartan
442237|NCT00922454|patients will be matched based on AAA neck length and neck and iliac angulation
442238|NCT00922441|Fimasartan
442239|NCT00922441|Essential Hypertension
442240|NCT00922441|24hour ABPM
442241|NCT00922441|Population PK
442242|NCT00922428|rheumatism
442243|NCT00922428|arthralgia
442244|NCT00922428|myalgia
442245|NCT00922428|lumbago
442246|NCT00922428|homoeopathy
442247|NCT00922428|injection
442248|NCT00922428|PASCOE-Agil HOM Injektopas
442249|NCT00922428|efficacy
442250|NCT00922428|tolerability
442251|NCT00922428|acceptance
442252|NCT00922428|safety
442253|NCT00922415|Crohn's disease
442254|NCT00922415|calprotectin
442255|NCT00922402|Acute
442256|NCT00922402|heart failure
442257|NCT00922402|hyperglycemia
442258|NCT00922402|Acute heart failure with high levels of glycemia
442259|NCT00922389|Diabetes Complications
442260|NCT00922389|Lower limb ischemia
442261|NCT00922389|Adult stem cells
442262|NCT00922389|peripheral blood stem cells
442263|NCT00922376|Diabetes
442264|NCT00922376|self- management
442265|NCT00922376|glycemic control
442266|NCT00922376|telehealth
442267|NCT00922376|mhealth
442268|NCT00922363|safety
442269|NCT00922363|vaccine
442270|NCT00922363|tuberculosis
442271|NCT00922363|CAF01
442272|NCT00922363|Ag85B-ESAT-6
442273|NCT00922363|prevention
442274|NCT00922350|asthma
442275|NCT00922350|heliox
442276|NCT00922350|bronchodilators
442277|NCT00922350|posture
442278|NCT00922337|distal embolization
442279|NCT00922337|thrombotic lesions
442280|NCT00922337|AMI
442281|NCT00922337|ACS
442282|NCT00922337|SVG
442283|NCT00922324|Healthy volunteers
442284|NCT00922311|Proteinuria
442285|NCT00922285|psychosocial effects of cancer and its treatment
442286|NCT00922285|health status unknown
442287|NCT00922272|Schizophrenia
442288|NCT00922259|Flu
442289|NCT00922259|Influenza
442290|NCT00922259|Vaccine
442291|NCT00922259|Prevention
442292|NCT00922246|overuse injuries
442293|NCT00922246|conscript
442294|NCT00922246|prevention
442295|NCT00922233|Contraception
442296|NCT00922220|low back pain
442297|NCT00922220|spinal manipulation
442298|NCT00922220|central sensitization
442299|NCT00922220|manual therapy
442300|NCT00922194|Type 2 diabetes
442301|NCT00922194|Obesity
442302|NCT00922194|Extended Release Metformin
442303|NCT00922181|malignancy
442304|NCT00922181|liver
442305|NCT00922181|microwave
442306|NCT00922181|surgery
442307|NCT00922168|Sleep
442308|NCT00922168|apnea
442309|NCT00922168|obstructive
442310|NCT00922168|central
442311|NCT00922155|endobronchial ultrasound
442312|NCT00922155|guide sheath
442313|NCT00922155|peripheral pulmonary lesions
442314|NCT00922129|Sirolimus
442315|NCT00922129|Calcineurin inhibitor
442316|NCT00922129|prostate cancer
442317|NCT00922103|Colitis, Ulcerative
442318|NCT00922103|Ileo Neo Rectal Anastomosis
442319|NCT00922103|Ileal Pouch Anal Anastomosis
442320|NCT00922103|Quality of Life
442321|NCT00922103|functional results
442322|NCT00922103|reconstructive surgery
442323|NCT00922103|surgery
442324|NCT00922090|Schizophrenia
442325|NCT00922090|Seroquel XR
442326|NCT00922090|CGI-CB
442327|NCT00922090|SWN-K
442328|NCT00922051|COPD
442329|NCT00922051|FEV1
442330|NCT00922051|beta endorphin
442331|NCT00922051|TENS
442332|NCT00922051|acupuncture
442333|NCT00922025|NSCLC
442334|NCT00922025|Male
442335|NCT00922025|Smoking Pattern
442336|NCT00922025|Efficacy
442337|NCT00922012|Electromagnetic Stimulation Therapy
442338|NCT00922012|Chronic Prostatitis
442339|NCT00922012|Chronic Pelvic Pain Syndrome
442340|NCT00921999|Chickenpox
442341|NCT00921999|Shingles
442342|NCT00921999|Varicella
442343|NCT00921999|Zoster
442344|NCT00921999|Vaccine
442345|NCT00921986|genetics
442346|NCT00921986|biorepository
442347|NCT00921986|cardiac death
442348|NCT00921986|atrial fibrillation
442349|NCT00921986|ventricular fibrillation
442350|NCT00921986|ventricular tachycardia
442351|NCT00921986|supraventricular tachycardias
442352|NCT00921986|premature ventricular complexes
442353|NCT00921986|premature atrial complexes
442354|NCT00921986|atrioventricular and intraventricular blocks
442355|NCT00921986|sinus node dysfunction
442356|NCT00921986|syncope
442357|NCT00921986|vasovagal reactivity
442358|NCT00921986|postural orthostatic tachycardia syndrome
442359|NCT00921973|influenza
442360|NCT00921973|universal influenza vaccine
442361|NCT00921960|Left ventricular dysfunction
442362|NCT00921960|Left ventricular systolic dysfunction
442363|NCT00921960|Left ventricular diastolic dysfunction
442364|NCT00921960|Myocardial Infarction
442365|NCT00921960|Hypertension
442366|NCT00921960|Diabetes
442367|NCT00921960|Obesity
442368|NCT00921960|Dyslipidaemia
442369|NCT00921960|Heart Failure
442370|NCT00921960|Prevention
442371|NCT00921960|Screening
442372|NCT00921960|Cardiovascular Risk Factors
442373|NCT00921960|Echocardiography
442374|NCT00921960|Natriuretic Peptides
442375|NCT00921947|influenza vaccine
442376|NCT00921947|M2e
442377|NCT00921947|Universal influenza vaccine
442378|NCT00921934|Herpes
442379|NCT00921934|Shingles
442380|NCT00921934|virus disease
442381|NCT00921934|vitamin C
442382|NCT00921934|ascorbic acid
442383|NCT00921934|antioxidant
442384|NCT00921934|oxidative stress
442385|NCT00921908|total hip arthroplasty
442386|NCT00921895|Pink Eye,
442387|NCT00921895|Viral conjunctivitis
442388|NCT00921895|Adenoviral conjunctivitis
442389|NCT00921895|Keratoconjunctivitis
442390|NCT00921882|Type 2 diabetes
442391|NCT00921882|Post-partum screening
442392|NCT00921869|Cancer
442393|NCT00921869|Gastrointestinal Cancer
442394|NCT00921856|Acetylcholine
442395|NCT00921843|Pediatric patients undergoing surgery
442396|NCT00921830|ibuprofen
442397|NCT00921830|healthy volunteers
442398|NCT00921830|bioavailability
442399|NCT00921830|pharmacokinetics
442400|NCT00921830|suppository
442401|NCT00921817|healthy children
442402|NCT00921804|Schizophrenia
442403|NCT00921804|Hallucinations
442404|NCT00921804|Paranoia
442405|NCT00921804|Inpatient schizophrenia clinical trial
442406|NCT00921791|Hypertension
442407|NCT00921791|Blood pressure
442408|NCT00921791|Home Blood Pressure Monitoring
442409|NCT00921791|Ambulatory Blood Pressure Monitoring
442410|NCT00921791|Pharmaceutical care
442411|NCT00921778|Laparoscopic supracervical hysterectomy
442412|NCT00921778|Vaginal bleeding
442413|NCT00921778|Patient satisfaction
442414|NCT00921778|vaginal bleeding after laparoscopic hysterectomy
442415|NCT00921765|Pain
442416|NCT00921765|Naloxone
442417|NCT00921765|Ketamine
442418|NCT00921765|Third Molar
442419|NCT00921765|Surgery
442420|NCT00921752|Lipid therapy
442421|NCT00921752|high CV risk
442422|NCT00921752|lipid goal attainment
442423|NCT00921752|High cardiovascular risk patients
442424|NCT00921739|Non small cell lung cancer
442425|NCT00921739|Small cell lung cancer
442426|NCT00921739|Thymoma unresectable
442427|NCT00921739|Thymic carcinoma unresectable
442428|NCT00921726|Drug Interaction
442429|NCT00921713|Early cancer care
442430|NCT00921700|Paracetamol
442431|NCT00921700|Acetaminophen
442432|NCT00921700|Ibuprofen
442433|NCT00921700|Pain
442434|NCT00921700|Postoperative pain
442435|NCT00921700|third molar
442436|NCT00921674|therapeutic equivalency
442437|NCT00921674|pharmacokinetics
442438|NCT00921674|food
442439|NCT00921674|Healthy Volunteers
442440|NCT00921661|oxaliplatin
442441|NCT00921661|5-FU
442442|NCT00921661|Folinic Acid
442443|NCT00921648|EEG
442444|NCT00921648|general paresis
442445|NCT00921648|MRI
442446|NCT00921648|neurosyphilis
442447|NCT00921635|Haemoglobin
442448|NCT00921622|Blood pressure
442449|NCT00921622|Vitamin C
442450|NCT00921622|Vitamin D
442451|NCT00921609|Acromegaly
442452|NCT00921609|OGTT
442453|NCT00921609|post-op
442454|NCT00921596|Surgical Procedures, Cardiac
442455|NCT00921596|Minimally Invasive Surgical Procedures
442456|NCT00921596|Thoracoscopes
442457|NCT00921596|Cardiopulmonary Bypass
442458|NCT00921583|survival rate
442459|NCT00921583|success rate
442460|NCT00921570|TWEAK
442461|NCT00921570|FMD
442462|NCT00921570|PTX3
442463|NCT00921570|Valsartan
442464|NCT00921570|Amlodipine
442465|NCT00921570|Renin Angiotensin System
442466|NCT00921557|Bone mineral density
442467|NCT00921544|ROP
442468|NCT00921544|sucrose
442469|NCT00921544|pain
442470|NCT00921531|Hepatocellular carcinoma
442471|NCT00921531|thalidomide
442472|NCT00921531|TACE
442473|NCT00921531|Child-Pugh Class A or B
442474|NCT00921518|Cardiac surgery
442475|NCT00921518|Sodium bicarbonate
442476|NCT00921518|Acute kidney injury
442477|NCT00921518|Saline
442478|NCT00921505|Acetaminophen
442479|NCT00921505|Ibuprofen
442480|NCT00921505|Platelets
442481|NCT00921505|Leukocytes
442482|NCT00921505|Oxygen species
442483|NCT00921505|Humans
442484|NCT00921505|Blood Platelets
442485|NCT00921505|Reactive Oxygen Species
442486|NCT00921505|Platelet Activation
442487|NCT00921492|Luteinizing hormone
442488|NCT00921492|Cortisol
442489|NCT00921492|HPA axis
442490|NCT00921492|HPO axis
442491|NCT00921492|Ovulation
442492|NCT00921492|Heart rate variability
442493|NCT00921492|Psychological distress and quality of life
442494|NCT00921479|third molar
442495|NCT00921479|quality of life
442496|NCT00921479|postoperative swelling
442497|NCT00921479|postoperative pain
442498|NCT00921479|Surgical Procedures, Operative
442499|NCT00921479|Postoperative Period
442500|NCT00921466|Evaluate the clinical content of the e-SSRS-IVR
442501|NCT00921453|Internet
442502|NCT00921453|Information supply
442503|NCT00921453|Tailoring
442504|NCT00921453|Patient empowerment
442505|NCT00921453|Headaches
442506|NCT00921453|Meta-search
442507|NCT00921453|Consumer Health Information
442508|NCT00921453|Information Services
442509|NCT00921453|Information Storage and Retrieval
442510|NCT00921453|Information Systems
442511|NCT00921440|coronary artery
442512|NCT00921440|stenosis
442513|NCT00921427|Hemianopia
442514|NCT00921427|Rehabilitation
442515|NCT00921427|Transcranial direct current stimulation
442516|NCT00921427|Visual field
442517|NCT00921414|Mantle cell lymphoma
442518|NCT00921414|R DHAP
442519|NCT00921414|ASCT
442520|NCT00921414|Rituximab Maintenance
442521|NCT00921388|Smoking Cessation
442522|NCT00921388|Exercise
442523|NCT00921388|Postmenopausal women
442524|NCT00921388|CHANTIX
442525|NCT00921388|varenicline
442526|NCT00921362|Schizophrenia
442527|NCT00921349|Prophylaxis
442528|NCT00921349|ligation
442529|NCT00921349|beta blockers
442530|NCT00921349|First bleeding rate
442531|NCT00921336|subjects with advanced Solid tumor who have not responded to standard therapy or for whom no standard therapy is available
442532|NCT00921323|Obesity
442533|NCT00921323|Physical activity
442534|NCT00921323|pedometers
442535|NCT00921323|children
442536|NCT00921310|Temsirolimus and pemetrexed for recurrent or refractory NSCLC
442537|NCT00921297|Alzheimer's Disease
442538|NCT00921297|vision impairment
442539|NCT00921297|cataract
442540|NCT00921297|quality of life
442541|NCT00921297|retinal nerve fiber layer
442542|NCT00921271|Compartment syndrome
442543|NCT00921258|latent prostate cancer
442544|NCT00921258|Patient with latent prostate cancer
442545|NCT00921258|PSA ≤ 10 ng/ml
442546|NCT00921258|Clinical stage T1c or T2a
442547|NCT00921258|Patient who accept just be control
442548|NCT00921245|Overactive Bladder
442549|NCT00921232|Life-ending patient
442550|NCT00921232|caregiver
442551|NCT00921219|therapeutic equivalency
442552|NCT00921219|pharmacokinetics
442553|NCT00921219|food
442554|NCT00921219|Healthy volunteers
442555|NCT00921206|influenza
442556|NCT00921206|influenza vaccine
442557|NCT00921206|universal influenza vaccine
442558|NCT00921206|Matrix 2e protein
442559|NCT00921206|M2e
442560|NCT00921206|Immune response
442561|NCT00921193|Prostate
442562|NCT00921193|fiducials
442563|NCT00921193|radiation Therapy
442564|NCT00921193|Tracking
442565|NCT00921193|Localization
442566|NCT00921180|Hepatitis B, chronic
442567|NCT00921180|Peginterferon alfa-2a
442568|NCT00921180|Entecavir
442569|NCT00921167|Glioblastoma
442570|NCT00921167|Astrocytoma
442571|NCT00921167|Chemotherapy
442572|NCT00921154|therapeutic equivalency
442573|NCT00921154|pharmacokinetics
442574|NCT00921154|fasting
442575|NCT00921154|Healthy Volunteers
442576|NCT00921141|Implantable central venous access ports, cancer
442577|NCT00921128|Muscimol
442578|NCT00921128|Convection-Enhanced Delivery
442579|NCT00921128|Parkinson's Disease
442580|NCT00921128|Deep Brain Stimulation
442581|NCT00921128|Parkinson Disease
442582|NCT00921128|PD
442583|NCT00921115|hormone receptor positive
442584|NCT00921115|invasive breast cancer
442585|NCT00921115|endocrine therapy
442586|NCT00921115|Anastrazole
442587|NCT00921115|Fulvestrant
442588|NCT00921115|breast tumors
442589|NCT00921115|postmenopausal
442590|NCT00921102|Atropine
442591|NCT00921102|Morphine
442592|NCT00921102|Analgesics, Opioid
442593|NCT00921102|Antiemetics
442594|NCT00921089|Atherosclerosis
442595|NCT00921089|Cardiovascular disease
442596|NCT00921089|Hemodialysis
442597|NCT00921089|Inflammation
442598|NCT00921089|Vascular calcification
442599|NCT00921050|subclinical hypothyroidism
442600|NCT00921050|elderly
442601|NCT00921050|mild cognitive impairment
442602|NCT00921050|neuropsychological test
442603|NCT00921050|NEUROPSI
442604|NCT00921037|Neurofibromatosis Type 1
442605|NCT00921037|Morbus Recklinghausen
442606|NCT00921037|cutaneous neurofibromas
442607|NCT00921037|Erbium-YAG-Laser
442608|NCT00921037|Vaporisation
442609|NCT00921037|Thermal Necrosis
442610|NCT00921024|Complicated Urinary Tract Infection
442611|NCT00921024|Pyelonephritis
442612|NCT00921024|Antimicrobial
442613|NCT00921024|Cephalosporin
442614|NCT00921024|Intravenous
442615|NCT00921011|hypertension
442616|NCT00921011|diabetes
442617|NCT00921011|smoking
442618|NCT00921011|hyperlipidemia
442619|NCT00921011|atherosclerosis risk
442620|NCT00920998|Z-338
442621|NCT00920998|YM443
442622|NCT00920998|healthy volunteers
442623|NCT00920985|Pregnancy prevention
442624|NCT00920985|Female contraception
442625|NCT00920985|Patch
442626|NCT00920972|Bone marrow
442627|NCT00920972|Transplant
442628|NCT00920972|Transplantation
442629|NCT00920972|Hematopoietic
442630|NCT00920972|Umbilical cord
442631|NCT00920972|Related
442632|NCT00920972|Unrelated
442633|NCT00920972|Reduced
442634|NCT00920972|Non-myeloablative
442635|NCT00920972|Nonmyeloablative
442636|NCT00920972|Non-malignant
442637|NCT00920972|Nonmalignant
442638|NCT00920946|Huntington
442639|NCT00920946|Dimebon
442640|NCT00920946|HD
442641|NCT00920946|Huntingtin
442642|NCT00920933|Ozone challenge
442643|NCT00920933|airway neutrophilia
442644|NCT00920933|induced sputum
442645|NCT00920933|Healthy volunteers
442646|NCT00920920|3D-4D MRI-based Brachytherapy
442647|NCT00920920|Cervical Cancer
442648|NCT00920920|Multicenter Clinical Study
442649|NCT00920920|Locally advanced cervical cancer
442650|NCT00920881|Continuous glucose monitoring
442651|NCT00920881|Accuracy
442652|NCT00920881|Continuous glucose-error grid analysis
442653|NCT00920868|Phase I
442654|NCT00920868|Solid Tumor
442655|NCT00920868|Colorectal
442656|NCT00920868|Dasatinib
442657|NCT00920868|Sprycel
442658|NCT00920868|Bevacizumab
442659|NCT00920868|Avastin
442660|NCT00920868|Oxaliplatin
442661|NCT00920868|Eloxatin
442662|NCT00920868|Capecitabine
442663|NCT00920868|Xeloda
442664|NCT00920868|Duke
442665|NCT00920868|Any Solid Tumor (Phase I)
442666|NCT00920868|Metastatic Colorectal Cancer (Expanded Cohort)
442667|NCT00920842|metabolic syndrome
442668|NCT00920842|long-term effects secondary to cancer therapy in children
442669|NCT00920842|cardiovascular complications
442670|NCT00920842|cancer survivor
442671|NCT00920842|childhood acute lymphoblastic leukemia in remission
442672|NCT00920842|childhood acute myeloid leukemia in remission
442673|NCT00920842|childhood chronic myelogenous leukemia
442674|NCT00920842|juvenile myelomonocytic leukemia
442675|NCT00920842|stage I chronic lymphocytic leukemia
442676|NCT00920842|stage II chronic lymphocytic leukemia
442677|NCT00920842|stage III chronic lymphocytic leukemia
442678|NCT00920842|stage IV chronic lymphocytic leukemia
442679|NCT00920829|Alcohol Dependence
442680|NCT00920829|Alcoholism
442681|NCT00920829|Naltrexone
442682|NCT00920829|Substance Abuse
442683|NCT00920829|Genetics
442684|NCT00920816|Axitinib in First & Second Line Treatment of Patients With Metastatic Renal Cell Cancer
442685|NCT00920777|CBT
442686|NCT00920777|Fukuda criteria
442687|NCT00920777|Mental functioning
442688|NCT00920777|Physical functioning
442689|NCT00920764|CKD Stages 3&4
442690|NCT00920764|Endothelin antagonist
442691|NCT00920764|Proteinuria
442692|NCT00920751|water infusion
442693|NCT00920751|air insufflation
442694|NCT00920751|colonoscopy
442695|NCT00920751|colorectal cancer screening
442696|NCT00920738|metabolic syndrome
442697|NCT00920738|cancer survivor
442698|NCT00920738|childhood soft tissue sarcoma
442699|NCT00920738|unspecified childhood solid tumor, protocol specific
442700|NCT00920738|childhood acute lymphoblastic leukemia
442701|NCT00920738|childhood chronic myelogenous leukemia
442702|NCT00920738|childhood Hodgkin lymphoma
442703|NCT00920738|childhood non-Hodgkin lymphoma
442704|NCT00920738|childhood acute myeloid leukemia/other myeloid malignancies
442705|NCT00920738|chronic lymphocytic leukemia
442706|NCT00920738|childhood brain stem glioma
442707|NCT00920738|childhood cerebellar astrocytoma
442708|NCT00920738|childhood cerebral astrocytoma/malignant glioma
442709|NCT00920738|childhood choroid plexus tumor
442710|NCT00920738|childhood craniopharyngioma
442711|NCT00920738|childhood embryonal tumor
442712|NCT00920738|childhood ependymoma
442713|NCT00920738|childhood oligodendroglioma
442714|NCT00920738|childhood pineal parenchymal tumor
442715|NCT00920738|childhood mixed glioma
442716|NCT00920738|childhood subependymal giant cell astrocytoma
442717|NCT00920738|childhood visual pathway and hypothalamic glioma
442718|NCT00920725|DKA
442719|NCT00920712|chronic atrophic gastritis
442720|NCT00920712|Traditional Chinese Medicine
442721|NCT00920686|Migraine
442722|NCT00920686|aura
442723|NCT00920673|child
442724|NCT00920647|hunters syndrome
442725|NCT00920647|hunter's syndrome
442726|NCT00920647|hunter disease
442727|NCT00920647|hunters disease
442728|NCT00920647|hunter's disease
442729|NCT00920647|Mucopolysaccharidosis(MPS) II
442730|NCT00920647|Mucopolysaccharidosis(MPS)2
442731|NCT00920647|Mucopolysaccharidosis (MPS) 2
442732|NCT00920647|Mucopolysaccharidosis (mps) ii
442733|NCT00920647|mucopolysaccharides
442734|NCT00920647|lysosomal storage disease
442735|NCT00920647|lysosomal storage disorder
442736|NCT00920647|chronic ear infection
442737|NCT00920647|enlarged adenoids
442738|NCT00920647|mps symptoms
442739|NCT00920647|mps diagnosis
442740|NCT00920647|ert treatment
442741|NCT00920647|elaprase
442742|NCT00920647|idursulfase
442743|NCT00920647|iduronate sulfatase
442744|NCT00920647|iduronate 2 sulfatase
442745|NCT00920647|enzyme replacement therapy
442746|NCT00920647|hunter syndrome treatment
442747|NCT00920647|hunter's syndrome treatment
442748|NCT00920647|hunter syndrome therapy
442749|NCT00920647|hunter's disease treatment
442750|NCT00920647|mps society
442751|NCT00920621|Asthma
442752|NCT00920621|Vitamin D
442753|NCT00920621|Randomized Control Trial
442754|NCT00920608|AZD9056
442755|NCT00920608|Pharmacokinetics
442756|NCT00920608|interaction
442757|NCT00920608|Methotrexate
442758|NCT00920608|Rheumatoid Arthritis
442759|NCT00920595|Cancer
442760|NCT00920582|Teplizumab
442761|NCT00920582|Protege
442762|NCT00920582|Protege Encore
442763|NCT00920582|MGA031
442764|NCT00920582|Monoclonal antibody
442765|NCT00920582|Type 1 Diabetes Mellitus
442766|NCT00920582|T1DM
442767|NCT00920582|MacroGenics
442768|NCT00920582|Recent Onset Diabetes
442769|NCT00920582|hOKT3γ1 (Ala-Ala)
442770|NCT00920582|Encore
442771|NCT00920569|cardiac output
442772|NCT00920569|recirculation
442773|NCT00920569|oxygenator blood volume
442774|NCT00920569|venoarterial extracorporeal membrane oxygenation
442775|NCT00920569|venovenous extracorporeal membrane oxygenation
442776|NCT00920530|Screening
442777|NCT00920530|real time PCR
442778|NCT00920530|Streptococcus agalactiae
442779|NCT00920530|Pregnant women
442780|NCT00920504|Mesh: patient education as topic
442781|NCT00920504|Mesh: neoplasms
442782|NCT00920504|Mesh: medication therapy management
442783|NCT00920504|pain self management
442784|NCT00920504|symptom management
442785|NCT00920504|education of patients with pain from neoplasm metastases
442786|NCT00920491|Chief complaint
442787|NCT00920491|non-specific symptoms
442788|NCT00920491|general weakness / general deterioration
442789|NCT00920491|risk assessment in ED patients with non-specific symptoms
442790|NCT00920478|Rheumatoid arthritis
442791|NCT00920478|Musculoskeletal Ultrasound
442792|NCT00920478|Synovitis
442793|NCT00920478|DMARD
442794|NCT00920478|Etanercept
442795|NCT00920478|Biomarkers
442796|NCT00920478|Undifferentiated Inflammatory Polyarthritis
442797|NCT00920452|implantable cardioverter defibrillator (ICD)
442798|NCT00920452|defibrillation leads, cardiac resynchronization therapy (CRT)
442799|NCT00920439|Poliomyelitis Vaccines
442800|NCT00920439|IPV
442801|NCT00920426|HIV
442802|NCT00920426|naive
442803|NCT00920426|Phase II
442804|NCT00920426|integrase inhibitor
442805|NCT00920426|GSK1265744
442806|NCT00920426|newly diagnosed
442807|NCT00920426|pharmacokinetics
442808|NCT00920426|AIDS
442809|NCT00920426|integrase
442810|NCT00920426|HIV Infections
442811|NCT00920426|Treatment naive
442812|NCT00920387|Anxiety
442813|NCT00920387|quality of life
442814|NCT00920387|psychotherapy
442815|NCT00920387|potentially fatal illness
442816|NCT00920387|lysergic acid diethylamide
442817|NCT00920374|Influenza
442818|NCT00920348|Chronic obstructive pulmonary disease
442819|NCT00920348|COPD
442820|NCT00920348|Cohort study
442821|NCT00920348|prospective longitudinal study
442822|NCT00920348|tissue bank
442823|NCT00920335|Adult intracranial ependymoma
442824|NCT00920322|Depression
442825|NCT00920322|Transcranial Magnetic Stimulation
442826|NCT00920309|Autosomal Dominant Polycystic Kidney Disease
442827|NCT00920309|rapamycin
442828|NCT00920309|ADPKD
442829|NCT00920296|drug interaction
442830|NCT00920296|integrase inhibitor
442831|NCT00920283|Stents
442832|NCT00920283|Bare Metal Stents
442833|NCT00920283|PCI
442834|NCT00920283|Coronary Artery Disease
442835|NCT00920283|Coronary Artery Stenosis
442836|NCT00920283|Stent Thrombosis
442837|NCT00920283|Vascular Disease
442838|NCT00920283|Myocardial Ischemia
442839|NCT00920270|Hospital-Acquired Pneumonia
442840|NCT00920270|Gram Negative Bacteria
442841|NCT00920257|lymphoma
442842|NCT00920257|breast cancer
442843|NCT00920257|oncology
442844|NCT00920257|solid tumors
442845|NCT00920257|AKT inhibitor
442846|NCT00920257|endometrial cancer
442847|NCT00920257|first time in human
442848|NCT00920257|GSK2141795
442849|NCT00920244|Resuscitation
442850|NCT00920244|Cardiac arrest
442851|NCT00920244|State-transitions
442852|NCT00920244|Markov
442853|NCT00920218|Vaccine
442854|NCT00920218|Immunogenicity
442855|NCT00920218|Stem cell transplantation
442856|NCT00920218|Safety
442857|NCT00920218|Herpes Zoster
442858|NCT00920205|MPC-3100
442859|NCT00920205|HSP90 inhibitor
442860|NCT00920205|oral drug
442861|NCT00920205|cancer
442862|NCT00920192|c-MET
442863|NCT00920192|Advanced hepatocellular carcinoma
442864|NCT00920192|VEGFR2
442865|NCT00920179|dry eye, in vivo confocal microscopy, inflammation, acinar unit density, lacrimal gland
442866|NCT00920166|Infant formula
442867|NCT00920166|Alpha-lactalbumin
442868|NCT00920166|Symbiotic
442869|NCT00920166|Allergy
442870|NCT00920166|Gastrointestinal tolerance
442871|NCT00920166|Bacterial colonization
442872|NCT00920166|Faecal IgA analysis
442873|NCT00920153|stage I adult Hodgkin lymphoma
442874|NCT00920153|stage II adult Hodgkin lymphoma
442875|NCT00920153|stage III adult Hodgkin lymphoma
442876|NCT00920153|stage IV adult Hodgkin lymphoma
442877|NCT00920140|Oncology, GSK1120212, MEK inhibitor, hematological malignancies, AML
442878|NCT00920140|CMML
442879|NCT00920140|MDS
442880|NCT00920127|AKL1
442881|NCT00920127|COPD
442882|NCT00920101|atherosclerotic plaques
442883|NCT00920101|hypercholesterolemia
442884|NCT00920101|HMG-CoA reductase inhibitor
442885|NCT00920101|statin
442886|NCT00920101|lipid-lowering therapy
442887|NCT00920088|probes
442888|NCT00920088|NNRTI
442889|NCT00920088|drug interaction
442890|NCT00920088|protease inhitibor
442891|NCT00920075|Juvenile Osteoporosis
442892|NCT00920075|Bone Mineral Density
442893|NCT00920075|Fosamax
442894|NCT00920075|Dual Energy X-Ray Absorptiometry
442895|NCT00920075|Fracture
442896|NCT00920062|recirculation
442897|NCT00920062|ultrasound dilution
442898|NCT00920062|venovenous extracorporeal membrane oxygenation
442899|NCT00920049|Driving
442900|NCT00920049|Injury
442901|NCT00920049|Prevention
442902|NCT00920049|Intervention
442903|NCT00920049|Parents
442904|NCT00920036|PTSD
442905|NCT00920036|Combat
442906|NCT00920036|Biofeedback
442907|NCT00920036|Psychophysiology
442908|NCT00920023|SPIO MRI
442909|NCT00920023|Feridex
442910|NCT00920010|non-small cell lung cancer
442911|NCT00920010|small cell lung cancer
442912|NCT00919997|human papilloma virus infection
442913|NCT00919997|HIV infection
442914|NCT00919997|HIV Infections
442915|NCT00919984|OVARIAN NEOPLASMS
442916|NCT00919984|ADJUVANT CHEMOTHERAPY
442917|NCT00919984|INTRAPERITONEAL CHEMOTHERAPY
442918|NCT00919971|Bi spectral Index
442919|NCT00919971|Sedation depth monitoring
442920|NCT00919971|Out of hospital ventilated patients
442921|NCT00919958|Peripheral Artery Disease
442922|NCT00919958|Peripheral Vascular Disease
442923|NCT00919958|Critical limb ischemia
442924|NCT00919945|Neonates
442925|NCT00919945|Congenital Heart Disease
442926|NCT00919945|Postoperative Feeding
442927|NCT00919945|Splanchnic Blood Flow
442928|NCT00919932|Depression
442929|NCT00919932|CBT
442930|NCT00919932|Texting
442931|NCT00919932|SMS
442932|NCT00919919|menopause
442933|NCT00919919|Endometrial Thickness
442934|NCT00919919|progesterone
442935|NCT00919906|haptic
442936|NCT00919906|rehabilitation
442937|NCT00919906|fine-motor skill
442938|NCT00919906|handwriting
442939|NCT00919893|chronic prostatitis symptom index
442940|NCT00919893|male
442941|NCT00919893|inflammatory
442942|NCT00919893|CP-CPPS
442943|NCT00919893|Cernilton
442944|NCT00919893|pelvic pain
442945|NCT00919893|symptoms
442946|NCT00919867|Normal, healthy volunteers (for this Phase 1 study)
442947|NCT00919854|Human immunodeficiency virus 1
442948|NCT00919854|HIV-1
442949|NCT00919854|Darunavir
442950|NCT00919854|Ritonavir
442951|NCT00919854|Norvir
442952|NCT00919841|postpartum
442953|NCT00919841|involution
442954|NCT00919841|three-dimension sonography
442955|NCT00919841|size of the uterus
442956|NCT00919815|Leprosy
442957|NCT00919815|Type 1 Reactions
442958|NCT00919815|Prednisolone
442959|NCT00919815|Ciclosporin
442960|NCT00919802|Interstitial cystitis (IC)
442961|NCT00919776|Leprosy
442962|NCT00919776|ENL
442963|NCT00919776|Erythema Nodosum Leprosum
442964|NCT00919776|Prednisolone
442965|NCT00919776|Ciclosporin
442966|NCT00919763|Atopic Dermatitis
442967|NCT00919737|NPC-08
442968|NCT00919737|carmustine
442969|NCT00919737|nitrosourea
442970|NCT00919737|safety
442971|NCT00919724|AIDS
442972|NCT00919724|Endothelial Function
442973|NCT00919724|Inflammation
442974|NCT00919724|Immune Activation
442975|NCT00919724|treatment naive
442976|NCT00919711|Menopausal Osteoporosis
442977|NCT00919698|Hypnotics and Sedatives
442978|NCT00919698|Respiration, Artificial
442979|NCT00919698|Ventilators, Mechanical
442980|NCT00919698|Critical care
442981|NCT00919698|Intensive care
442982|NCT00919672|Irritable bowel syndrome
442983|NCT00919672|Sacral nerve stimulation
442984|NCT00919672|Motility
442985|NCT00919672|Pain perception
442986|NCT00919672|GSRS-IBS
442987|NCT00919672|IBS-IS
442988|NCT00919659|parenteral nutrition
442989|NCT00919659|cancer cachexia
442990|NCT00919659|pancreatic cancer
442991|NCT00919633|hepatitis C
442992|NCT00919633|HCV
442993|NCT00919633|genotype
442994|NCT00919633|sustained virological response
442995|NCT00919633|rapid virological response
442996|NCT00919633|interferon
442997|NCT00919620|Psychotic disorders
442998|NCT00919620|Psychoses
442999|NCT00919607|quetiapine fumarate(SEROQUEL) extended-release(XR) China PK Study
443000|NCT00919607|pharmacokinetics parameters
443001|NCT00919594|Interpersonal Psychotherapy
443002|NCT00919594|Depression
443003|NCT00919594|Mothers
443004|NCT00919581|Spinal cord injury
443005|NCT00919555|ALS Treatment
443006|NCT00919555|Tretinoin
443007|NCT00919555|Pioglitazone HCL
443008|NCT00919555|Actos
443009|NCT00919555|Tau levels
443010|NCT00919555|ALS
443011|NCT00919542|Leprosy
443012|NCT00919542|ENL
443013|NCT00919542|Erythema Nodosum Leprosum
443014|NCT00919542|Prednisolone
443015|NCT00919542|Ciclosporin
443016|NCT00919516|Bone marrow transplantation
443017|NCT00919516|Ischemia
443018|NCT00919516|Neoangiogenesis
443019|NCT00919516|Peripheral arterial disease
443020|NCT00919516|Stem cell therapy
443021|NCT00919503|nonmalignant diseases
443022|NCT00919503|nonmalignant inherited disorders
443023|NCT00919503|primary immunodeficiency diseases
443024|NCT00919503|primary immune deficiency disorders
443025|NCT00919503|chronic granulomatous
443026|NCT00919503|disease
443027|NCT00919503|IPEX syndrome
443028|NCT00919503|hemophagocytic lymphohistiocytosis
443029|NCT00919503|Wiskott Aldrich Syndrome
443030|NCT00919503|bone marrow failure syndromes
443031|NCT00919503|Shwachman Diamond Syndrome
443032|NCT00919503|Dyskeratosis Congenita
443033|NCT00919503|Diamond Blackfan Anemia
443034|NCT00919503|inborn errors of metabolism
443035|NCT00919503|metabolic diseases
443036|NCT00919503|hemoglobinopathies
443037|NCT00919503|sickle cell disease
443038|NCT00919503|thalassemia
443039|NCT00919503|reduced intensity transplantation
443040|NCT00919503|hematopoietic cell transplantation
443041|NCT00919503|bone marrow transplantation
443042|NCT00919503|umbilical cord blood transplantation
443043|NCT00919490|Healthy Volunteers
443044|NCT00919477|Prostate cancer
443045|NCT00919477|Casodex
443046|NCT00919477|Monotherapy
443047|NCT00919464|Compartment pressure
443048|NCT00919464|compartment syndrome
443049|NCT00919464|femur fracture
443050|NCT00919451|Leprosy
443051|NCT00919451|Type 1 Reaction
443052|NCT00919451|Prednisolone
443053|NCT00919451|Ciclosporin
443054|NCT00919425|stage 0 chronic lymphocytic leukemia
443055|NCT00919425|stage I chronic lymphocytic leukemia
443056|NCT00919425|stage II chronic lymphocytic leukemia
443057|NCT00919425|stage III chronic lymphocytic leukemia
443058|NCT00919425|stage IV chronic lymphocytic leukemia
443059|NCT00919425|recurrent adult acute myeloid leukemia
443060|NCT00919425|recurrent adult acute lymphoblastic leukemia
443061|NCT00919425|relapsing chronic myelogenous leukemia
443062|NCT00919425|refractory chronic lymphocytic leukemia
443063|NCT00919425|chronic phase chronic myelogenous leukemia
443064|NCT00919425|accelerated phase chronic myelogenous leukemia
443065|NCT00919425|blastic phase chronic myelogenous leukemia
443066|NCT00919425|meningeal chronic myelogenous leukemia
443067|NCT00919425|untreated adult acute lymphoblastic leukemia
443068|NCT00919425|untreated adult acute myeloid leukemia
443069|NCT00919425|adult acute myeloid leukemia with t(8;21)(q22;q22)
443070|NCT00919425|adult acute myeloid leukemia with t(16;16)(p13;q22)
443071|NCT00919425|adult acute myeloid leukemia with inv(16)(p13;q22)
443072|NCT00919425|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
443073|NCT00919425|adult acute myeloid leukemia with t(15;17)(q22;q12)
443074|NCT00919425|adult acute lymphoblastic leukemia in remission
443075|NCT00919425|childhood acute lymphoblastic leukemia in remission
443076|NCT00919425|adult acute myeloid leukemia in remission
443077|NCT00919425|childhood acute myeloid leukemia in remission
443078|NCT00919425|recurrent childhood acute myeloid leukemia
443196|NCT00918944|quality of life survey
443079|NCT00919425|untreated childhood acute myeloid leukemia and other myeloid malignancies
443080|NCT00919425|recurrent childhood acute lymphoblastic leukemia
443081|NCT00919425|untreated childhood acute lymphoblastic leukemia
443082|NCT00919425|childhood chronic myelogenous leukemia
443083|NCT00919425|de novo myelodysplastic syndromes
443084|NCT00919425|previously treated myelodysplastic syndromes
443085|NCT00919425|secondary myelodysplastic syndromes
443086|NCT00919425|secondary acute myeloid leukemia
443087|NCT00919425|atypical chronic myeloid leukemia, BCR-ABL1 negative
443088|NCT00919425|chronic myelomonocytic leukemia
443089|NCT00919425|juvenile myelomonocytic leukemia
443090|NCT00919425|myelodysplastic/myeloproliferative neoplasm, unclassifiable
443091|NCT00919425|childhood myelodysplastic syndromes
443092|NCT00919412|Non Invasive Biomarkers Preterm Delivery
443093|NCT00919399|breast cancer
443094|NCT00919399|locally advanced
443095|NCT00919399|Menopausal patient
443096|NCT00919399|aromasin
443097|NCT00919399|tamoxifen
443098|NCT00919399|efficacy
443099|NCT00919386|Ureteric Measurement
443100|NCT00919373|Catheter Ablation
443101|NCT00919373|Defibrillators, Implantable
443102|NCT00919347|Cardiovascular Autonomic Neuropathy
443103|NCT00919347|Diabetic Autonomic Neuropathy
443104|NCT00919347|Autonomic Dysfunction
443105|NCT00919334|Myopia progression
443106|NCT00919334|Myopia control
443107|NCT00919334|Simultaneous vision
443108|NCT00919334|Myopic defocus
443109|NCT00919321|CLL
443110|NCT00919321|PPV
443111|NCT00919321|PCV
443112|NCT00919308|Simulation
443113|NCT00919308|Invasive procedures
443114|NCT00919295|Fibromyalgia syndrome
443115|NCT00919295|mirtazapine
443116|NCT00919295|randomized controlled trial
443117|NCT00919295|pilot study
443118|NCT00919282|pancreatic cancer
443119|NCT00919282|gemcitabine
443120|NCT00919282|combination
443121|NCT00919243|prednisone
443122|NCT00919243|allopurinol
443123|NCT00919243|heart failure
443124|NCT00919243|hyperuricemia
443125|NCT00919230|Hip fracture
443126|NCT00919230|iron therapy
443127|NCT00919230|anaemia
443128|NCT00919217|Multiple Sclerosis
443129|NCT00919217|MS
443130|NCT00919217|Relapsing-remitting multiple sclerosis
443131|NCT00919217|RR-MS
443132|NCT00919217|Women
443133|NCT00919204|AG-013736, axitinib, pharmacokinetics, healthy, Chinese
443134|NCT00919191|acne
443135|NCT00919191|irritation
443136|NCT00919191|objective sensory methods
443137|NCT00919178|Dengue virus
443138|NCT00919178|Vaccine
443139|NCT00919178|DEN4
443140|NCT00919178|Dengue
443141|NCT00919165|carotid stenting
443142|NCT00919165|cognitive function
443143|NCT00919165|pre and post stent
443144|NCT00919165|severe carotid artery stenosis
443145|NCT00919152|stress ulcer prophylaxis
443146|NCT00919152|intensive care
443147|NCT00919152|Critically ill
443148|NCT00919152|proton pump inhibitors
443149|NCT00919152|pharmacoeconomics
443150|NCT00919139|multiple myeloma
443151|NCT00919139|Waldenström macroglobulinemia
443152|NCT00919139|monoclonal gammopathy of undetermined significance
443153|NCT00919139|primary systemic amyloidosis
443154|NCT00919126|Xenon in Anaesthesia
443155|NCT00919113|Bladder Pain
443156|NCT00919113|GAG replacement therapy
443157|NCT00919113|IC/PBS
443158|NCT00919100|pediatric
443159|NCT00919100|venipuncture
443160|NCT00919100|pain
443161|NCT00919100|vibration
443162|NCT00919100|vapocoolant
443163|NCT00919074|Patients undergoing endoscopic retrograde cholangiopancreatography for the first time
443164|NCT00919074|Particular focus on patients who meet predefined criteria for a difficult bile duct cannulation
443165|NCT00919061|GALL BLADDER
443166|NCT00919061|BILE DUCTS
443167|NCT00919061|BAY 43-9006
443168|NCT00919061|SORAFENIB
443169|NCT00919061|CISPLATIN
443170|NCT00919061|GEMCITABINE
443171|NCT00919061|09-029
443172|NCT00919035|prostate cancer
443173|NCT00919035|androgen-independent prostate cancer (AIPC) Prostate Cancer
443174|NCT00919022|Inoperable Prostate Cancer
443175|NCT00919022|Erectile Dysfunction
443176|NCT00919009|TACE
443177|NCT00919009|Sorafenib
443178|NCT00918996|Cesarean Section
443179|NCT00918996|Bladder Flap
443180|NCT00918996|Operating time
443181|NCT00918983|Benign prostatic hyperplasia
443182|NCT00918983|BPH
443183|NCT00918983|Enlarged prostate
443184|NCT00918970|autonomous nervous system
443185|NCT00918970|brain death
443186|NCT00918970|organs transplantation
443187|NCT00918957|Tobramycin Inhalation Powder
443188|NCT00918957|Cystic fibrosis
443189|NCT00918957|Lung diseases
443190|NCT00918957|Anti-Bacterial Agents
443191|NCT00918957|Treatment of infections with P. aeruginosa in cystic fibrosis subjects
443192|NCT00918944|clinical decision support tool
443193|NCT00918944|electronic health record
443194|NCT00918944|control tool
443195|NCT00918944|spirometry
443197|NCT00918944|provider survey
443198|NCT00918931|Leukemia
443199|NCT00918931|Systemic Mastocytosis
443200|NCT00918931|SM
443201|NCT00918931|Obatoclax mesylate
443202|NCT00918931|GX15-070MS
443203|NCT00918918|Alcohol Consumption
443204|NCT00918918|High Density Lipoprotein (HDL)
443205|NCT00918918|lipopolysaccharides (LPS)
443206|NCT00918918|Apolipoproteins
443207|NCT00918918|Inflammation
443208|NCT00918905|pervasive healthcare
443209|NCT00918905|telecare
443210|NCT00918905|telemedicine
443211|NCT00918905|COPD
443212|NCT00918892|breast cancer
443213|NCT00918892|estrogen receptor-negative breast cancer
443214|NCT00918892|estrogen receptor-positive breast cancer
443215|NCT00918892|progesterone receptor-negative breast cancer
443216|NCT00918892|progesterone receptor-positive breast cancer
443217|NCT00918892|triple-negative breast cancer
443218|NCT00918892|HER2-negative breast cancer
443219|NCT00918892|HER2-positive breast cancer
443220|NCT00918879|DPP-4 inhibitors
443221|NCT00918879|HbA1c
443222|NCT00918879|Incretins
443223|NCT00918866|Phase 4
443224|NCT00918866|DEFINITY®
443225|NCT00918866|hemodynamics
443226|NCT00918866|pulmonary artery pressure
443227|NCT00918853|pancreas
443228|NCT00918853|adenocarcinoma
443229|NCT00918840|HIV
443230|NCT00918840|Vaccine
443231|NCT00918840|Immune Therapy
443232|NCT00918840|DermaVir
443233|NCT00918840|Treatment experienced
443234|NCT00918827|adenocarcinoma of the colon
443235|NCT00918827|stage III colon cancer
443236|NCT00918801|T1DM
443237|NCT00918801|MRI
443238|NCT00918788|breast cancer
443239|NCT00918775|Renal Cell Carcinoma
443240|NCT00918775|RCC
443241|NCT00918775|Kidney
443242|NCT00918775|Metastasectomy
443243|NCT00918775|Surgery
443244|NCT00918775|Tumor Removal
443245|NCT00918762|perioperative/postoperative complications
443246|NCT00918762|precancerous condition
443247|NCT00918762|stage I squamous cell carcinoma of the hypopharynx
443248|NCT00918762|stage II squamous cell carcinoma of the hypopharynx
443249|NCT00918762|stage III squamous cell carcinoma of the hypopharynx
443250|NCT00918762|stage I squamous cell carcinoma of the larynx
443251|NCT00918762|stage I verrucous carcinoma of the larynx
443252|NCT00918762|stage II squamous cell carcinoma of the larynx
443253|NCT00918762|stage II verrucous carcinoma of the larynx
443254|NCT00918762|stage III squamous cell carcinoma of the larynx
443255|NCT00918762|stage III verrucous carcinoma of the larynx
443256|NCT00918762|stage I lymphoepithelioma of the nasopharynx
443257|NCT00918762|stage I squamous cell carcinoma of the nasopharynx
443258|NCT00918762|stage II lymphoepithelioma of the nasopharynx
443259|NCT00918762|stage II squamous cell carcinoma of the nasopharynx
443260|NCT00918762|stage III lymphoepithelioma of the nasopharynx
443261|NCT00918762|stage III squamous cell carcinoma of the nasopharynx
443262|NCT00918762|stage I lymphoepithelioma of the oropharynx
443263|NCT00918762|stage I squamous cell carcinoma of the oropharynx
443264|NCT00918762|stage II lymphoepithelioma of the oropharynx
443265|NCT00918762|stage II squamous cell carcinoma of the oropharynx
443266|NCT00918762|stage III lymphoepithelioma of the oropharynx
443267|NCT00918762|stage III squamous cell carcinoma of the oropharynx
443268|NCT00918736|Ankle joint
443269|NCT00918736|Balance
443270|NCT00918736|Hyaluronic acid
443271|NCT00918736|Osteoarthritis
443272|NCT00918710|Squamous cell carcinoma of Oropharynx
443273|NCT00918710|Human papillomavirus.
443274|NCT00918710|Biological prognostic markers.
443275|NCT00918697|photorefractive keratectomy
443276|NCT00918697|PRK
443277|NCT00918697|alcohol-assisted debridement
443278|NCT00918697|mechanical debridement
443279|NCT00918697|confocal scan
443280|NCT00918697|confocal microscopy
443281|NCT00918684|Depression
443282|NCT00918671|Headache
443283|NCT00918671|Medication overuse
443284|NCT00918671|chronic
443285|NCT00918671|relapse
443286|NCT00918658|childhood chronic myelogenous leukemia
443287|NCT00918658|chronic myelogenous leukemia
443288|NCT00918658|adult acute lymphoblastic leukemia
443289|NCT00918658|childhood acute lymphoblastic leukemia
443290|NCT00918658|adult acute myeloid leukemia
443291|NCT00918658|childhood acute myeloid leukemia/other myeloid malignancies
443292|NCT00918658|multiple myeloma
443293|NCT00918645|stage IV prostate cancer
443294|NCT00918645|recurrent prostate cancer
443295|NCT00918645|bone metastases
443296|NCT00918632|food-effect pharmacokinetics AG-013736 food fasting
443297|NCT00918619|randomized,
443298|NCT00918619|controlled,
443299|NCT00918619|haemostatic agents,
443300|NCT00918619|Sangustop,
443301|NCT00918619|Tachosil,
443302|NCT00918619|liver resection,
443303|NCT00918619|haemostasis
443304|NCT00918593|Metastases
443305|NCT00918593|Cutaneous
443306|NCT00918593|Ulcerating
443307|NCT00918593|Palliative
443308|NCT00918593|ulcerating metastases
443309|NCT00918567|ADHD
443434|NCT00917917|Metabolic syndrome
443310|NCT00918567|impact of atomoxetine with and and without behavior therapy at school and home
443311|NCT00918554|Sarcoid-associated uveitis
443312|NCT00918554|Macular oedema
443313|NCT00918554|Methotrexate
443314|NCT00918554|Conventional corticosteroids sparing agent.
443315|NCT00918541|atherosclerotic disease
443316|NCT00918541|progression
443317|NCT00918541|natural progression of atherosclerotic disease
443318|NCT00918541|natural history of atherosclerosis at the level of the carotid artery as evaluated by MRI
443319|NCT00918528|Urethral stricture
443320|NCT00918528|Mitomycin C
443321|NCT00918528|Internal Urethrotomy
443322|NCT00918515|Sedation
443323|NCT00918515|Anaesthesia
443324|NCT00918515|Safety
443325|NCT00918515|tolerability
443326|NCT00918515|pharmacokinetics
443327|NCT00918515|pharmacodynamics
443328|NCT00918515|healthy male volunteers
443329|NCT00918489|soft tissue sarcoma
443330|NCT00918489|metastatic
443331|NCT00918489|vorinostat
443332|NCT00918463|lymphoma
443333|NCT00918463|diffuse
443334|NCT00918463|refractory
443335|NCT00918437|uvulopalatoplasty
443336|NCT00918437|postoperative pain
443337|NCT00918437|quality of life
443338|NCT00918411|diarrhea
443339|NCT00918411|IBS
443340|NCT00918411|Colonic diseases
443341|NCT00918411|YM060
443342|NCT00918385|hormone resistant prostate cancer
443343|NCT00918385|castration resistant prostate cancer
443344|NCT00918385|hormone refractory prostate cancer
443345|NCT00918385|metastatic prostate cancer
443346|NCT00918385|hormonal therapy
443347|NCT00918385|antiandrogen therapy
443348|NCT00918385|androgen receptor
443349|NCT00918385|nilutamide
443350|NCT00918385|dasatinib
443351|NCT00918385|genomics
443352|NCT00918385|genomic signature
443353|NCT00918385|genomic predictor
443354|NCT00918385|genomic analysis
443355|NCT00918385|genomic expression profile
443356|NCT00918372|MSCTA
443357|NCT00918372|Marathon runners
443358|NCT00918346|Ocular hypertension
443359|NCT00918320|Temozolomide
443360|NCT00918320|Topotecan
443361|NCT00918320|paediatric solid tumours
443362|NCT00918320|Miscellaneous other solid tumours
443363|NCT00918307|Tobacco Dependence
443364|NCT00918307|HIV infection
443365|NCT00918307|varenicline
443366|NCT00918294|CRT
443367|NCT00918294|heart failure
443368|NCT00918294|optimization
443369|NCT00918294|Timing cycle optimization methods
443370|NCT00918268|Influenza vaccine
443371|NCT00918255|Hidradenitis Suppurativa
443372|NCT00918255|Adalimumab
443373|NCT00918255|Nodule
443374|NCT00918255|Abscess
443375|NCT00918255|Fistula
443376|NCT00918255|Physicians Global Assessment
443377|NCT00918255|Hurley Stage
443378|NCT00918255|Sartorius Scale
443379|NCT00918242|Coronary Heart Disease
443380|NCT00918242|computed tomography
443381|NCT00918242|prevalence of coronary artery disease
443382|NCT00918229|Prostate
443383|NCT00918229|cancer
443384|NCT00918229|radiation
443385|NCT00918229|biodegradable implantable balloon
443386|NCT00918229|intrarectal balloon
443387|NCT00918216|breast cancer
443388|NCT00918203|Lung neoplasms
443389|NCT00918203|IMC-3G3
443390|NCT00918203|carboplatin
443391|NCT00918203|paclitaxel
443392|NCT00918203|PDGFr
443393|NCT00918190|Postoperative nausea and vomiting
443394|NCT00918190|Pediatric
443395|NCT00918190|Strabismus
443396|NCT00918190|Late onset postoperative nausea and vomiting
443397|NCT00918112|Parkinson's Disease
443398|NCT00918099|Mesh
443399|NCT00918099|vaginal prolapse
443400|NCT00918099|Recurrence rate
443401|NCT00918086|Vitamin D
443402|NCT00918086|Tuberculosis
443403|NCT00918073|HIV infected smokers
443404|NCT00918073|HIV
443405|NCT00918034|BPH
443406|NCT00918034|LUTS
443407|NCT00918034|talaporfin sodium
443408|NCT00918008|URINARY BLADDER
443409|NCT00918008|Bladder
443410|NCT00918008|Blood sample
443411|NCT00918008|Lymph Nodes
443412|NCT00917995|parastomal hernia
443413|NCT00917995|prophylactic mesh
443414|NCT00917995|colostomy
443415|NCT00917995|hernia
443416|NCT00917956|Lithium
443417|NCT00917956|IBM
443418|NCT00917956|InclusionIBM
443419|NCT00917956|Myositis
443420|NCT00917943|smoking
443421|NCT00917943|pregnancy
443422|NCT00917943|counseling
443423|NCT00917943|prevention
443424|NCT00917943|tailored intervention
443425|NCT00917943|postpartum
443426|NCT00917943|women
443427|NCT00917943|cessation
443428|NCT00917930|exercise training
443429|NCT00917930|functional recovery
443430|NCT00917930|heart diseases
443431|NCT00917930|altered glucose metabolism early after an acute cardiac event
443432|NCT00917930|non diabetes CAD patients
443433|NCT00917930|glycometabolic state
443435|NCT00917917|exercise training
443436|NCT00917917|abdominal fat mass
443437|NCT00917917|endothelial function
443438|NCT00917917|diastolic function
443439|NCT00917904|HIV Infections
443440|NCT00917904|Acquired Immunodeficiency Syndrome
443441|NCT00917904|Healthy
443442|NCT00917904|HIV seronegativity
443443|NCT00917891|HIV Infections
443444|NCT00917891|Acquired Immunodeficiency Syndrome
443445|NCT00917891|Healthy
443446|NCT00917891|HIV seronegativity
443447|NCT00917878|Milk
443448|NCT00917878|Postprandial hyperlipidemia
443449|NCT00917878|Postprandial inflammation
443450|NCT00917878|Overweight
443451|NCT00917852|aorta
443452|NCT00917852|trauma
443453|NCT00917852|transection
443454|NCT00917839|neuroprotection
443455|NCT00917839|multiple sclerosis
443456|NCT00917839|brain atrophy
443457|NCT00917839|mr-spectroscopy
443458|NCT00917813|HIV
443459|NCT00917813|monoclonal antibody
443460|NCT00917813|KD-247
443461|NCT00917813|treatment naive
443462|NCT00917800|angiography
443463|NCT00917800|exercise testing
443464|NCT00917800|high frequency ECG
443465|NCT00917800|coronary artery disease
443466|NCT00917787|Asthma
443467|NCT00917774|gender specific knee
443468|NCT00917774|osteoarthritis
443469|NCT00917774|total knee arthroplasty
443470|NCT00917761|Hepatitis B, chronic
443471|NCT00917761|Peginterferon alfa-2a
443472|NCT00917761|Entecavir
443473|NCT00917735|Green tea
443474|NCT00917735|Breast cancer
443475|NCT00917735|Prevention
443476|NCT00917735|COMT genotype
443477|NCT00917735|EGCG (Epigallocatechin gallate)
443478|NCT00917735|Mammographic density
443479|NCT00917735|Reproductive hormones
443480|NCT00917735|IGF axis proteins
443481|NCT00917735|Oxidative stress
443482|NCT00917722|Parkinson's Disease
443483|NCT00917722|STN DBS
443484|NCT00917722|Deep Brain Stimulation
443485|NCT00917709|dementia with Lewy bodies
443486|NCT00917709|imaging
443487|NCT00917709|acetylcholine
443488|NCT00917709|dopamine
443489|NCT00917709|IBVM
443490|NCT00917709|DATSCAN
443491|NCT00917670|trabecular meshwork
443492|NCT00917670|electron microscopy
443493|NCT00917657|photorefractive keratectomy
443494|NCT00917657|hyperopia
443495|NCT00917657|radial keratotomy
443496|NCT00917657|refractive surgery
443497|NCT00917644|Bioqeuivalence, Pharmacokinetics, Atorvastatin
443498|NCT00917631|Co-bedding
443499|NCT00917631|Procedural pain
443500|NCT00917631|Twin
443501|NCT00917631|Comfort
443502|NCT00917631|RCT
443503|NCT00917618|osteoarthritis
443504|NCT00917618|knee
443505|NCT00917618|exercise
443506|NCT00917618|cycling
443507|NCT00917592|Diverticulitis
443508|NCT00917579|Bioequivalence, pharmacokinetics, atorvastatin
443509|NCT00917566|Airtraq
443510|NCT00917566|Pediatric
443511|NCT00917553|diabetic retinopathy
443512|NCT00917553|diabetes
443513|NCT00917553|diabetic eye studies
443514|NCT00917527|Subjects with family history of coronary heart disease
443515|NCT00917514|Dosing Tool
443516|NCT00917514|Compliance
443517|NCT00917514|User Friendly
443518|NCT00917514|Crohn's Disease
443519|NCT00917514|Ulcerative Colitis
443520|NCT00917501|Mania
443521|NCT00917501|Adolescents at risk for Mania
443522|NCT00917488|Allergen extract Standardization
443523|NCT00917475|preterm infants
443524|NCT00917462|ESOPHAGUS
443525|NCT00917462|BAY 43-9006 (SORAFENIB)
443526|NCT00917462|09-016
443527|NCT00917462|Nexavar®.
443528|NCT00917449|Metabolic Syndrome
443529|NCT00917449|Impaired glucose tolerance
443530|NCT00917449|Type 2 diabetes mellitus
443531|NCT00917449|Endothelial dysfunction
443532|NCT00917449|L-arginine
443533|NCT00917449|Insulin resistance
443534|NCT00917423|Anorexia Nervosa
443535|NCT00917423|Exercise
443536|NCT00917423|Physical Activity
443537|NCT00917397|Traumatized refugee
443538|NCT00917397|treatment
443539|NCT00917397|antidepressants
443540|NCT00917397|psychotherapy
443541|NCT00917397|PTSD in traumatized refugees
443542|NCT00917384|IMC-1121B
443543|NCT00917384|Monoclonal antibody (MAb)
443544|NCT00917384|Vascular endothelial growth factor (VEGF)
443545|NCT00917384|Human vascular endothelial growth factor receptor-2 (VEGFR-2)
443546|NCT00917384|Platinum resistant
443547|NCT00917384|platinum refractory
443548|NCT00917384|Gastric
443549|NCT00917384|Gastroesophageal Junction Adenocarcinoma
443550|NCT00917384|metastatic
443551|NCT00917384|Angiogenesis
443552|NCT00917371|adults with attention-deficit hyperactivity disorder
443553|NCT00917371|atomoxetine
443554|NCT00917371|neuropsychological functioning
443555|NCT00917371|brain imaging studies
443556|NCT00917358|Hepatitis C
443557|NCT00917358|Dialysis
443558|NCT00917358|Interferon
443559|NCT00917345|ARC
443560|NCT00917345|PRA
443561|NCT00917345|primary aldosteronism
443562|NCT00917345|captopril test
443563|NCT00917345|aldosterone-renin ratio
443564|NCT00917345|Primary aldosteronism (PA) than PRA and establish thresholds for the diagnosis using ARC.
443565|NCT00917332|pain
443566|NCT00917332|childbirth
443567|NCT00917332|relaxation
443568|NCT00917332|guided imagery
443569|NCT00917332|VAS
443570|NCT00917332|epidural
443571|NCT00917306|Peplin
443572|NCT00917306|Actinic keratosis
443573|NCT00917306|PEP005
443574|NCT00917293|Tardive Dyskinesia
443575|NCT00917293|Schizophrenia
443576|NCT00917293|Pyridoxal 5'-phosphate
443577|NCT00917280|Parkinson's Disease
443578|NCT00917267|diabetes
443579|NCT00917267|exenatide
443580|NCT00917267|once weekly
443581|NCT00917267|Byetta
443582|NCT00917267|Amylin
443583|NCT00917267|Lilly
443584|NCT00917254|YM150
443585|NCT00917254|Thrombosis
443586|NCT00917254|VTE
443587|NCT00917254|Knee Replacement
443588|NCT00917254|Anticoagulant
443589|NCT00917254|FXa inhibitor
443590|NCT00917241|Graves' disease
443591|NCT00917241|dexamethasone
443592|NCT00917241|relapse
443593|NCT00917241|methimazole
443594|NCT00917215|Asthma
443595|NCT00917215|Acupuncture
443596|NCT00917215|Pulmonary function
443597|NCT00917215|Quality of life
443598|NCT00917189|VCFS
443599|NCT00917189|Chromosome 22q Deletion Syndrome
443600|NCT00917189|Learning Disorders
443601|NCT00917163|coronary artery disease
443602|NCT00917163|restenosis
443603|NCT00917163|stent thrombosis
443604|NCT00917163|coronary stents
443605|NCT00917163|angioplasty
443606|NCT00917163|drug eluting stents
443607|NCT00917150|chronic obstructive pulmonary disease
443608|NCT00917150|COPD
443609|NCT00917150|emphysema
443610|NCT00917137|Lung cancer
443611|NCT00917137|Lung nodule
443612|NCT00917137|Transbronchial needle aspiration
443613|NCT00917137|Transbronchial lung biopsy
443614|NCT00917137|Bronchoscopy
443615|NCT00917124|cerebral oximetry
443616|NCT00917124|NIRS
443617|NCT00917124|INVOS
443618|NCT00917111|Randomized
443619|NCT00917111|Double-Blind
443620|NCT00917111|Multi-Center
443621|NCT00917111|Placebo-Controlled
443622|NCT00917111|Phase II
443623|NCT00917111|Nasal Carbon Dioxide
443624|NCT00917111|Carbon Dioxide
443625|NCT00917111|Efficacy
443626|NCT00917111|Safety
443627|NCT00917111|Total Nasal Symptom Score
443628|NCT00917098|Behavior Therapy
443629|NCT00917098|Supportive Counseling
443630|NCT00917098|Child
443631|NCT00917098|Adolescent
443632|NCT00917098|Hair Pulling
443633|NCT00917098|CBT
443634|NCT00917085|Preterm infant
443635|NCT00917085|Skin-to-skin contact
443636|NCT00917085|kangaroo care
443637|NCT00917085|temperature
443638|NCT00917085|behavioral state
443639|NCT00917072|Clinical Handoff
443640|NCT00917072|Medical Education
443641|NCT00917072|Simulation
443642|NCT00917072|Residency and Internship
443643|NCT00917059|Major Depressive Disorder
443644|NCT00917059|SSRI
443645|NCT00917059|EEG
443646|NCT00917046|All-cause heart failure patients
443647|NCT00917046|coronary artery disease etiology
443648|NCT00917046|dilated cardiomyopathy etiology
443649|NCT00917020|Randomized
443650|NCT00917020|Double-Blind
443651|NCT00917020|Multi-Center
443652|NCT00917020|Phase II
443653|NCT00917020|Nasal Carbon Dioxide
443654|NCT00917020|Carbon Dioxide
443655|NCT00917020|Efficacy
443656|NCT00917020|Safety
443657|NCT00917020|Total Nasal Symptom Score
443658|NCT00917007|ABO incompatibility
443659|NCT00917007|hemolysis
443660|NCT00917007|jaundice
443661|NCT00917007|hyperbilirubinemia
443662|NCT00917007|newborn
443663|NCT00916994|Rotator Cuff Tear
443664|NCT00916981|pseudarthrosis
443665|NCT00916981|Treatment
443666|NCT00916981|osteoblast grafting
443667|NCT00916981|cell therapy
443668|NCT00916981|nonunion
443669|NCT00916968|Gender specific
443670|NCT00916968|cruciate retaining
443671|NCT00916968|total knee arthroplasty
443672|NCT00916968|Bilateral Osteoarthritis of the knee joint
443673|NCT00916955|22q11.2 deletion syndrome
443674|NCT00916955|velo-cardio-facial syndrome
443675|NCT00916955|congenital anomalies
443676|NCT00916955|mental illness
443677|NCT00916955|congenital heart disease
443678|NCT00916942|Tolerability study
443679|NCT00916916|Acromegaly
443680|NCT00916916|Lanreotide
443681|NCT00916903|Talus
443682|NCT00916903|Neuroserpin
443683|NCT00916903|mental retardation
443684|NCT00916903|epilepsy
443685|NCT00916903|FENIB
443686|NCT00916903|XLMR
443687|NCT00916890|Opioid pharmacogenetics
443688|NCT00916890|Opioid pharmacokinetic
443689|NCT00916890|Long-term opioid treatment
443690|NCT00916890|Cancer pain
443691|NCT00916877|Prophylactic Cranial Irradiation
443692|NCT00916877|Her-2-positive met breast cancer
443693|NCT00916851|attention-deficit hyperactivity disorder
443694|NCT00916851|autism spectrum disorders
443695|NCT00916851|normally developing children and adolescents
443696|NCT00916851|cognitive functions
443697|NCT00916851|emotion/behaviors
443698|NCT00916851|brain imaging
443699|NCT00916851|genotypes
443700|NCT00916838|Type 1 Diabetes Mellitis
443701|NCT00916838|MRI
443702|NCT00916825|breast cancer
443703|NCT00916825|quality of life
443704|NCT00916825|children of somatically ill parents
443705|NCT00916825|psychological adaptation
443706|NCT00916812|Difficult intubation
443707|NCT00916812|Hyomental distance
443708|NCT00916812|Obstetric
443709|NCT00916812|Mallampati classification
443710|NCT00916812|Thyromental distance
443711|NCT00916812|Sternomental distance
443712|NCT00916799|telehealth
443713|NCT00916799|oximetry
443714|NCT00916799|copd
443715|NCT00916786|Attention-deficit/hyperactivity disorder
443716|NCT00916786|pharmacogenetics
443717|NCT00916786|molecular genetics
443718|NCT00916786|medication response
443719|NCT00916773|Obstructive sleep apnea
443720|NCT00916773|Airway inflammation
443721|NCT00916773|Exercise-induced bronchoconstriction
443722|NCT00916773|Continuous positive airway pressure
443723|NCT00916760|allergic, rhinoconjunctivitis, Immunotherapy
443724|NCT00916747|Progeria
443725|NCT00916734|McKenzie
443726|NCT00916734|thrust manipulation
443727|NCT00916734|clinical prediction rule
443728|NCT00916721|Smoking cessation
443729|NCT00916721|propranolol
443730|NCT00916721|memory reconsolidation blockade
443731|NCT00916721|craving
443732|NCT00916708|endometrial cancer
443733|NCT00916708|follow up
443734|NCT00916708|relapse
443735|NCT00916695|Stents
443736|NCT00916695|Angioplasty
443737|NCT00916695|Coronary Artery Disease
443738|NCT00916695|Bifurcation Coronary Lesions
443739|NCT00916669|SCLC
443740|NCT00916669|enoxaparin sodium
443741|NCT00916669|cisplatin
443742|NCT00916669|etoposide
443743|NCT00916656|Congenital fibrinogen deficiency
443744|NCT00916643|Hypercholesterolemia
443745|NCT00916643|FH
443746|NCT00916643|LDL-C
443747|NCT00916643|CHD
443748|NCT00916630|recurrent
443749|NCT00916630|alimta
443750|NCT00916630|pemetrexed
443751|NCT00916630|CNS lymphoma
443752|NCT00916630|Primary CNS lymphoma
443753|NCT00916630|Metastatic lymphoma to brain
443754|NCT00916617|open-label
443755|NCT00916617|safety
443756|NCT00916617|antibody
443757|NCT00916604|AZD1656
443758|NCT00916604|Safety
443759|NCT00916604|Pharmacokinetics
443760|NCT00916604|Pharmacodynamic
443761|NCT00916604|Multiple ascending doses
443762|NCT00916604|Japanese
443763|NCT00916604|T2DM
443764|NCT00916591|gastroesophageal reflux
443765|NCT00916591|respiratory aspiration
443766|NCT00916578|Advanced Inflammatory Breast Cancer
443767|NCT00916578|Non-Inflammatory Breast Cancer
443768|NCT00916578|Capecitabine
443769|NCT00916578|Xeloda
443770|NCT00916578|Concomitant Radiation
443771|NCT00916578|Radiation Therapy
443772|NCT00916578|Radiotherapy
443773|NCT00916578|Women
443774|NCT00916565|optimize nutritional content of infant formula
443775|NCT00916565|Infant
443776|NCT00916552|Erythropoietin
443777|NCT00916552|Epo
443778|NCT00916552|depression
443779|NCT00916552|bipolar disorder
443780|NCT00916552|cognition
443781|NCT00916552|cognitive function
443782|NCT00916552|antidepressant
443783|NCT00916526|Chronic cough
443784|NCT00916526|Inhaled corticosteroid treatment
443785|NCT00916526|Bronchial provocation test with mannitol
443786|NCT00916526|Methacholine
443787|NCT00916513|Diabetes
443788|NCT00916513|Treatment Satisfaction
443789|NCT00916513|Quality of Life
443790|NCT00916513|HbA1c levels and goals
443791|NCT00916513|Healthcare resources consumption
443792|NCT00916500|CERVICAL CANCER, CONCURRENT CHEMORADIATION, CISPLATIN
443793|NCT00916461|First episode psychosis
443794|NCT00916461|Schizophrenia
443795|NCT00916461|Minocycline
443796|NCT00916461|neuroprotection
443797|NCT00916461|First episode non affective psychosis
443798|NCT00916461|With in first five years of illness
443799|NCT00916448|Endotoxin
443800|NCT00916448|Bilirubin
443801|NCT00916448|Inflammation
443802|NCT00916448|Sepsis
443803|NCT00916448|Multi organ dysfunction syndrome
443804|NCT00916448|Oxidative Stress
443805|NCT00916448|Heme oxygenase
443806|NCT00916435|Arrhythmia
443807|NCT00916435|Cardiac Arrest
443808|NCT00916435|Cardiomyopathy
443809|NCT00916435|Heart Failure
443810|NCT00916422|Immunotherapy
443811|NCT00916422|Allergoid
443812|NCT00916422|Depigmented
443813|NCT00916422|Polymerized
443814|NCT00916422|Allergen-extract
443815|NCT00916422|Rhinoconjunctivitis
443816|NCT00916409|Glioblastoma Multiforme
443817|NCT00916409|Glioblastoma
443818|NCT00916409|GBM
443819|NCT00916409|Brain tumor
443820|NCT00916409|Treatment
443821|NCT00916409|Minimal toxicity
443822|NCT00916409|Newly Diagnosed
443823|NCT00916409|TTFields
443824|NCT00916409|Tumor Treating Fields
443825|NCT00916409|NovoCure
443826|NCT00916383|Skin Irritation
443827|NCT00916383|Donepezil Transdermal Patch System
443828|NCT00916383|Elderly
443829|NCT00916383|Alzheimer's subjects
443830|NCT00916383|Skin Irritation in elderly Alzheimer's subjects
443831|NCT00916370|drug eluting stents
443832|NCT00916370|stents
443833|NCT00916370|Angioplasty
443834|NCT00916370|myocardial ischemia
443835|NCT00916370|coronary artery stenosis
443836|NCT00916370|Coronary Disease
443837|NCT00916370|Coronary Artery Disease
443838|NCT00916370|Coronary Restenosis
443839|NCT00916370|Long lesion
443840|NCT00916357|recombinant human hyaluronidase PH20 (rHuPH20)
443841|NCT00916357|Insulin lispro
443842|NCT00916357|Regular human insulin
443843|NCT00916331|total knee replacement arthroplasty
443844|NCT00916331|subcutaneous indwelling
443845|NCT00916331|blood loss
443846|NCT00916331|complications
443847|NCT00916331|functional status
443848|NCT00916305|deafness noise tinnitus hearingloss
443849|NCT00916292|Diabetes
443850|NCT00916292|dermal ulcers
443851|NCT00916279|Bare Metal In-Stent Restenosis
443852|NCT00916279|Paclitaxel Coated Balloon Catheter
443853|NCT00916279|Drug Coated Balloon
443854|NCT00916279|Coronary Artery Disease
443855|NCT00916266|Seizure frequency
443856|NCT00916266|Hippocampal volume
443857|NCT00916266|Adverse effects
443858|NCT00916253|Sleep
443859|NCT00916253|real driving
443860|NCT00916253|simulated driving
443861|NCT00916253|MWT
443862|NCT00916240|Adolescents
443863|NCT00916240|African American
443864|NCT00916227|Low or Intermediate-1 Risk Myelodysplastic Syndrome
443865|NCT00916201|schizophrenia
443866|NCT00916188|Black Tea
443867|NCT00916188|Oxidative Stress
443868|NCT00916188|Blood Lipids
443869|NCT00916188|Insulin Sensitivity
443870|NCT00916175|hyperglycemia
443871|NCT00916175|overweight
443872|NCT00916175|functional food
443873|NCT00916175|aloe vera
443874|NCT00916175|cnidoscolus chayamansa
443875|NCT00916162|aromatase inhibitor
443876|NCT00916149|Epilepsy
443877|NCT00916149|Cognition
443878|NCT00916149|Lamictal
443879|NCT00916149|Lamotrigine
443880|NCT00916149|Keppra
443881|NCT00916149|Levetiracetam
443882|NCT00916136|Pre-operative Traction
443883|NCT00916136|Traction
443884|NCT00916136|Proximal Femur Fracture
443885|NCT00916136|Femoral Fractures
443886|NCT00916136|Femoral Fracture
443887|NCT00916136|Skeletal Traction
443888|NCT00916136|Cutaneous Traction
443889|NCT00916123|castrate-resistant prostate cancer
443890|NCT00916123|CRPC
443891|NCT00916110|healthy subjects
443892|NCT00916071|Bulimia Nervosa
443893|NCT00916071|Eating Disorder NOS
443894|NCT00916071|Attention Deficit Hyperactivity Disorder
443895|NCT00916071|ADHD
443896|NCT00916058|Multiple Myeloma
443897|NCT00916058|Autologous Stem Cell Transplant
443898|NCT00916058|ASCT
443899|NCT00916058|MM
443900|NCT00916019|gene expression
443901|NCT00916019|skeletal muscle
443902|NCT00916019|Healthy men
443903|NCT00916006|Peplin
443904|NCT00916006|Actinic keratosis
443905|NCT00916006|PEP005
443906|NCT00915993|stage IV renal cell cancer
443907|NCT00915993|recurrent renal cell cancer
443908|NCT00915980|Meal-test
443909|NCT00915980|reduced OGTT
443910|NCT00915980|gastric bypass surgery and glucose metabolism
443911|NCT00915980|Glucose metabolism before and after gastric bypass
443912|NCT00915980|Different OGTT
443913|NCT00915980|New meal- test
443914|NCT00915967|Infection
443915|NCT00915967|Vancomycin
443916|NCT00915967|Neurosurgery
443917|NCT00915967|Stimulator
443918|NCT00915967|Pump
443919|NCT00915967|Deep Brain Stimulation
443920|NCT00915967|Intrathecal Pump
443921|NCT00915954|Acromegaly
443922|NCT00915954|Type 2 diabetes mellitus
443923|NCT00915954|recombinant human IGF1
443924|NCT00915954|oral glucose tolerance test
443925|NCT00915915|Female contraception
443926|NCT00915915|Ovulation inhibition
443927|NCT00915889|psychosocial effects of cancer and its treatment
443928|NCT00915889|stage IA cervical cancer
443929|NCT00915889|stage IB cervical cancer
443930|NCT00915889|stage IIA cervical cancer
443931|NCT00915889|stage IIB cervical cancer
443932|NCT00915889|stage III cervical cancer
443933|NCT00915889|cancer survivor
443934|NCT00915876|chronic kidney disease
443935|NCT00915876|Vitamin D
443936|NCT00915863|pancreaticoduodenectomy
443937|NCT00915863|pancreatic fistula
443938|NCT00915863|reconstruction
443939|NCT00915863|isolated Roux-en-Y
443940|NCT00915837|DME
443941|NCT00915824|Drug therapy
443942|NCT00915824|Prescribing
443943|NCT00915824|Appropriateness
443944|NCT00915824|Randomized controlled trial
443945|NCT00915824|STOPP/START criteria
443946|NCT00915824|Appropriateness of prescribing in older patients
443947|NCT00915824|Prescription Drugs
443948|NCT00915811|Myelodysplastic Syndromes
443949|NCT00915811|Leukemia, Myeloid, Acute
443950|NCT00915811|Haematopoietic stem cell transplantation
443951|NCT00915811|Fludarabine
443952|NCT00915811|Busulphan
443953|NCT00915811|Thymoglobuline
443954|NCT00915759|ProKera
443955|NCT00915759|Amniotic membrane
443956|NCT00915759|Photorefractive Keratectomy
443957|NCT00915759|PRK
443958|NCT00915759|time to re-epithelialization
443959|NCT00915746|Phase I
443960|NCT00915746|ketoconazole
443961|NCT00915746|CYP3A4 inhibitor
443962|NCT00915746|drug interaction
443963|NCT00915746|metabolism
443964|NCT00915746|Healthly Volunteer
443965|NCT00915746|JNJ-31001074
443966|NCT00915733|acute myocardial infarction
443967|NCT00915733|inhibition of platelet aggregation
443968|NCT00915733|triple antiplatelet therapy
443969|NCT00915733|high maintenance-dose clopidogrel.
443970|NCT00915733|CYP2C19 polymorphism
443971|NCT00915733|High posttreatment platelet reactivity
443972|NCT00915733|Platelet Aggregation Inhibitors
443973|NCT00915733|CYP2C19, human
443974|NCT00915720|Atrial Fibrillation
443975|NCT00915720|Surgical Ablation
443976|NCT00915720|Implanted loop recorder
443977|NCT00915720|Atrial Fibrillation Ablation
443978|NCT00915707|obesity
443979|NCT00915707|diabetes, risk
443980|NCT00915707|obesity, diabetes risk related to sleep
443981|NCT00915694|adult giant cell glioblastoma
443982|NCT00915694|adult gliosarcoma
443983|NCT00915694|adult glioblastoma
443984|NCT00915681|amatoxin
443985|NCT00915681|amanita
443986|NCT00915681|mushroom poisoning
443987|NCT00915681|hepatic failure
443988|NCT00915681|milk thistle
443989|NCT00915681|Silibinin
443990|NCT00915681|Legalon
443991|NCT00915668|Healthy women
443992|NCT00915668|Non-childbearing potential
443993|NCT00915668|Drug-drug interaction
443994|NCT00915668|Oral contraceptive
443995|NCT00915668|OC
443996|NCT00915668|Ovral-L
443997|NCT00915668|ethinyl estradiol
443998|NCT00915668|EE
443999|NCT00915668|levonorgestrel
444000|NCT00915668|JNJ-31001074
444001|NCT00915655|HIV Infections
444002|NCT00915655|TMC114-TiDP29-C230
444003|NCT00915655|TMC114-C230
444004|NCT00915655|TMC114
444005|NCT00915655|HIV-1
444006|NCT00915655|Darunavir
444007|NCT00915655|Ritonavir
444008|NCT00915655|NRTI
444009|NCT00915655|Treatment Naive
444010|NCT00915642|Obesity
444011|NCT00915642|Weight loss rate
444012|NCT00915642|Sleep
444013|NCT00915642|Vigil
444014|NCT00915642|Metabolism
444015|NCT00915642|Actigraphy
444016|NCT00915642|Normal
444017|NCT00915603|Metastatic Breast Cancer
444018|NCT00915603|Paclitaxel
444019|NCT00915603|Bevacizumab
444020|NCT00915603|Everolimus
444021|NCT00915577|Multiple Sclerosis
444022|NCT00915577|interferon beta-1a
444023|NCT00915577|Avonex
444024|NCT00915577|liquid Avonex
444025|NCT00915564|Hepatitis C
444026|NCT00915564|HCV
444027|NCT00915564|Hepatitis C Virus
444028|NCT00915564|HCV negative
444029|NCT00915564|Protease inhibitor
444030|NCT00915564|Methadone
444031|NCT00915564|TMC435
444032|NCT00915551|Peplin
444033|NCT00915551|Actinic keratosis
444034|NCT00915551|PEP005
444035|NCT00915538|Asthma
444036|NCT00915538|Formoterol
444037|NCT00915538|LABA
444038|NCT00915538|Symbicort
444039|NCT00915538|Aerochamber
444040|NCT00915512|Schizophrenia
444041|NCT00915512|Paliperidone
444042|NCT00915512|Invega
444043|NCT00915486|Diabetic
444044|NCT00915486|ulcer
444045|NCT00915486|topical
444046|NCT00915486|PDGF
444047|NCT00915486|GSoC
444048|NCT00915460|Multiple Sclerosis
444049|NCT00915460|Avonex
444050|NCT00915460|Interferon beta-1a
444051|NCT00915460|patients at high risk to develop multiple sclerosis
444052|NCT00915447|Cat Allergic Rhinitis
444053|NCT00915434|Healthy volunteer
444054|NCT00915434|Phase I
444055|NCT00915434|Non-childbearing potential
444056|NCT00915434|JNJ-31001074
444057|NCT00915434|Food
444058|NCT00915434|Pharmacokinetics
444059|NCT00915421|cardiac arrest
444060|NCT00915421|therapeutic hypothermia
444061|NCT00915421|Postresuscitative disease
444062|NCT00915408|Multiple Myeloma
444063|NCT00915408|Cyclophosphamide
444064|NCT00915408|Dexamethasone
444065|NCT00915408|Lenalidomide
444066|NCT00915356|AZD1305
444067|NCT00915356|intravenous cardioversion of Atrial Fibrillation
444068|NCT00915343|Adrenal insufficiency
444069|NCT00915343|Primary adrenal insufficiency
444070|NCT00915343|Addison's disease
444071|NCT00915343|Hydrocortisone
444072|NCT00915343|Modified release
444073|NCT00915330|Transbronchial needle aspiration
444074|NCT00915330|Bronchoscopy
444075|NCT00915330|Rapid on-site cytopathologic evaluation
444076|NCT00915330|Mediastinal lymphadenopathy
444077|NCT00915330|Hilar Lymphadenopathy
444078|NCT00915304|Clinical Decision Support System
444079|NCT00915304|Automatic reminder
444080|NCT00915304|Primary care
444081|NCT00915304|Evidence-Based Medicine
444082|NCT00915291|medical education
444083|NCT00915291|clinical decisionmaking
444084|NCT00915291|pharmaceutical marketing
444085|NCT00915278|Neoplasms
444086|NCT00915278|monoclonal antibody
444087|NCT00915278|PF-04605412
444088|NCT00915278|advanced metastatic solid tumors
444089|NCT00915265|Epidural analgesia
444090|NCT00915265|Continuous preperitoneal analgesia
444091|NCT00915265|Surgery
444092|NCT00915265|Open colorectal surgery
444093|NCT00915265|Fast-track surgery
444094|NCT00915265|ERAS
444095|NCT00915252|Acute Myeloid Leukemia
444096|NCT00915252|azacitidine
444097|NCT00915252|elderly
444098|NCT00915252|demethylating agent
444099|NCT00915252|flt3
444100|NCT00915252|AML
444101|NCT00915239|volunteers
444102|NCT00915226|Optic disk
444103|NCT00915226|Regional blood flow
444104|NCT00915226|Autoregulation
444105|NCT00915213|E. Coli
444106|NCT00915213|Prostate Biopsy
444107|NCT00915200|Diabetic Nephropathies
444108|NCT00915200|Proteinuria
444109|NCT00915200|Renal Insufficiency, Chronic
444110|NCT00915200|Monocytes
444111|NCT00915200|Oxidative stress
444112|NCT00915200|Inflammation
444113|NCT00915200|Antioxidants
444114|NCT00915200|Glutathione
444115|NCT00915200|Silymarin
444116|NCT00915200|Acetylcysteine
444117|NCT00915200|Dietary Supplements
444118|NCT00915200|Complementary Therapies
444119|NCT00915187|Vaccination, influenza prevention
444120|NCT00915174|drug-drug interaction study
444121|NCT00915161|ventilation
444122|NCT00915161|oxygenation
444123|NCT00915148|Prolonged labor
444124|NCT00915148|Ultrasound
444125|NCT00915148|Caeserian section
444126|NCT00915135|Insomnia
444127|NCT00915135|Sleep Initiation and Maintenance Disorders
444128|NCT00915135|Drug Therapy
444129|NCT00915122|IMRT treatment for Prostate cancer patients
444130|NCT00915122|Radiation treatment for prostate cancer
444131|NCT00915122|cancer of the prostate
444132|NCT00915122|Patients with high risk adenocarcinoma of the prostate
444133|NCT00915109|amputees
444134|NCT00915109|lower limb
444135|NCT00915096|Follicular Lymphoma
444136|NCT00915096|PET
444137|NCT00915096|GELA
444138|NCT00915070|BQ-123
444139|NCT00915070|Optic Nerve Head Blood Flow
444140|NCT00915070|Intraocular Pressure
444141|NCT00915070|Regional Blood Flow
444142|NCT00915070|Ocular Physiology
444143|NCT00915070|Optic Disk
444144|NCT00915044|IBD
444145|NCT00915031|Robotic prostatectomy
444146|NCT00915031|Hypothermia
444147|NCT00915031|Potency
444148|NCT00915018|ErbB-2 positive advanced breast cancer
444149|NCT00915005|Locally-advanced non-small-cell lung carcinoma
444150|NCT00915005|NSCLC
444151|NCT00915005|Lung Cancer
444152|NCT00915005|Image-Guided Adaptive Conformal Photon
444153|NCT00915005|Proton Therapy
444154|NCT00915005|Chemotherapy
444155|NCT00915005|Treatment Related Pneumonitis
444156|NCT00914992|optic disk
444157|NCT00914992|regional blood flow
444158|NCT00914992|autoregulation
444159|NCT00914979|Angiosculpt
444160|NCT00914979|Bifurcation Lesion
444161|NCT00914979|Side branch
444162|NCT00914979|IVUS
444163|NCT00914953|social isolation
444164|NCT00914953|cooperative behavior
444165|NCT00914953|depression
444166|NCT00914953|loneliness
444167|NCT00914953|happiness
444168|NCT00914953|empathy
444169|NCT00914940|graft versus host disease
444170|NCT00914940|adult acute lymphoblastic leukemia in remission
444171|NCT00914940|recurrent adult acute lymphoblastic leukemia
444172|NCT00914940|childhood acute lymphoblastic leukemia in remission
444173|NCT00914940|recurrent childhood acute lymphoblastic leukemia
444174|NCT00914940|adult acute myeloid leukemia in remission
444175|NCT00914940|recurrent adult acute myeloid leukemia
444176|NCT00914940|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
444177|NCT00914940|adult acute myeloid leukemia with inv(16)(p13;q22)
444178|NCT00914940|adult acute myeloid leukemia with t(15;17)(q22;q12)
444179|NCT00914940|adult acute myeloid leukemia with t(16;16)(p13;q22)
444180|NCT00914940|adult acute myeloid leukemia with t(8;21)(q22;q22)
444181|NCT00914940|childhood acute myeloid leukemia in remission
444182|NCT00914940|recurrent childhood acute myeloid leukemia
444183|NCT00914940|childhood myelodysplastic syndromes
444184|NCT00914940|previously treated myelodysplastic syndromes
444185|NCT00914940|refractory anemia with excess blasts
444186|NCT00914940|de novo myelodysplastic syndromes
444187|NCT00914940|secondary myelodysplastic syndromes
444188|NCT00914927|Thrombocytopenia
444189|NCT00914927|chronic liver disease
444190|NCT00914901|Asthma
444191|NCT00914901|Doping
444192|NCT00914901|Salmeterol
444193|NCT00914901|Beta-agonist
444194|NCT00914901|Urine concentrations
444195|NCT00914888|children
444196|NCT00914888|pediatry
444197|NCT00914888|pneumonia
444198|NCT00914888|intra-abdominal
444199|NCT00914888|infection
444200|NCT00914875|kidney function tests
444201|NCT00914875|anti-inflammatory agents, non-steroidal
444202|NCT00914875|laparoscopic cholecystectomy
444203|NCT00914875|adult
444204|NCT00914862|Sleep Initiation and Maintenance Disorders
444205|NCT00914862|Drug Therapy
444206|NCT00914836|shoulder
444207|NCT00914836|subacromion
444208|NCT00914836|corticosteroid
444209|NCT00914836|bursitis
444210|NCT00914836|tendinitis
444211|NCT00914836|calcific tendonitis
444212|NCT00914836|subacromial bursitis
444213|NCT00914836|rotator cuff tendinitis
444214|NCT00914810|Chronic obstructive pulmonary disease
444215|NCT00914810|Vitamin D
444216|NCT00914810|Cholecalciferol
444217|NCT00914810|Skeletal muscle
444218|NCT00914797|Asthma
444219|NCT00914797|Doping
444220|NCT00914797|Beta agonist
444221|NCT00914797|Terbutaline
444222|NCT00914797|Pharmacokinetics
444223|NCT00914784|TRALI
444224|NCT00914784|Transfusion
444225|NCT00914784|dyspnea
444226|NCT00914784|pulmonary infiltrates
444227|NCT00914771|Pandemic Influenza
444228|NCT00914771|H5N1
444229|NCT00914771|Adults and Elderly
444230|NCT00914771|antigen dose
444231|NCT00914758|multiple sclerosis
444232|NCT00914758|cognition
444233|NCT00914758|cognitive functioning
444234|NCT00914758|Campath
444235|NCT00914758|Rebif
444236|NCT00914758|alemtuzumab
444237|NCT00914758|interferon
444238|NCT00914732|IMVAMUNE®, smallpox, vaccine
444239|NCT00914719|sexual risk behavior among adolescents
444240|NCT00914719|alcohol and drug use among adolescents
444241|NCT00914706|Diabetes
444242|NCT00914693|Fertility control
444243|NCT00914693|Contraception
444244|NCT00914667|Overactive Bladder Urgency Frequency
444245|NCT00914654|Asthma
444246|NCT00914654|Doping
444247|NCT00914654|Formoterol
444248|NCT00914654|Urinary concentrations
444249|NCT00914654|Beta-agonists
444250|NCT00914641|formulation; sustained release; modified release; extended release
444251|NCT00914628|high risk acute leukemia
444252|NCT00914628|HSV-TK
444253|NCT00914628|Haploidentical HCT
444254|NCT00914628|GvHD
444255|NCT00914628|GvL
444256|NCT00914628|Immunoreconstitution
444257|NCT00914615|Stereotactic Body Radiation Therapy
444258|NCT00914615|Liver Metastasis from colorectal cancer
444259|NCT00914615|Patients with Liver Metastasis
444260|NCT00914576|Endotoxin, Escherichia Coli
444261|NCT00914576|Retina
444262|NCT00914576|Regional Blood Flow
444263|NCT00914563|Burned shock
444264|NCT00914563|Volume resuscitative patterns
444265|NCT00914563|Non-invasive hemodynamic monitoring
444266|NCT00914550|Pneumonia
444267|NCT00914550|Lung Infiltrates
444268|NCT00914550|Antibiotic discontinuation
444269|NCT00914550|De-escalation therapy
444270|NCT00914537|Anal Cancer
444271|NCT00914537|AIN
444272|NCT00914537|HPV
444273|NCT00914537|Cytology
444274|NCT00914537|HIV
444275|NCT00914537|HIV Positive
444276|NCT00914524|Chronic Glomerulonephritis
444277|NCT00914524|Diabetic Nephropathy
444278|NCT00914524|Angiotensin II Receptor Blocker
444279|NCT00914524|Urinary Protein
444280|NCT00914511|Semen
444281|NCT00914511|Sperm
444282|NCT00914511|Avanafil
444283|NCT00914511|Pharmacokinetics
444284|NCT00914511|Elderly
444285|NCT00914498|Xylocaine
444286|NCT00914498|Casarean section
444287|NCT00914498|Post operative pain
444288|NCT00914498|Scar quality
444289|NCT00914472|Preventing the thrombi formation
444290|NCT00914459|hemophilia A
444291|NCT00914446|Steatohepatitis
444292|NCT00914433|COPD
444293|NCT00914420|OCT
444294|NCT00914420|Reendothelialisation
444295|NCT00914420|Intrepide
444296|NCT00914420|Trapidil
444297|NCT00914420|Taxus
444298|NCT00914407|Ocular physiology
444299|NCT00914394|L-NG-Monomethyl Arginine
444300|NCT00914394|Optic Nerve Head Blood Flow
444301|NCT00914394|Intraocular Pressure
444302|NCT00914394|Regional Blood Flow
444303|NCT00914394|Ocular Physiology
444304|NCT00914394|Optic Disk
444305|NCT00914381|Community reinforcement approach
444306|NCT00914381|Contingency management
444307|NCT00914381|12-step facilitation counseling
444308|NCT00914381|Cocaine dependence
444309|NCT00914381|Women
444310|NCT00914368|Platelet Aggregation Inhibitors
444311|NCT00914368|Aspirin
444312|NCT00914368|Clopidogrel
444313|NCT00914368|Pathologic Processes
444314|NCT00914368|Disease
444315|NCT00914368|Therapeutic Uses
444316|NCT00914368|Syndrome
444317|NCT00914368|Hematologic Agents
444318|NCT00914368|Cardiovascular Diseases
444319|NCT00914368|Pharmacologic Actions
444320|NCT00914355|Hepatocellular Carcinoma
444321|NCT00914355|Stereotactic Body Radiation
444322|NCT00914355|Unresectable liver cancer
444323|NCT00914355|Patients with Hepatocellular Carcinoma
444324|NCT00914342|Gerd
444325|NCT00914342|GerdQ questionnaire
444326|NCT00914342|work productivity
444327|NCT00914342|Greece
444328|NCT00914329|stress provoked
444329|NCT00914329|healthy volunteers
444330|NCT00914329|gelsemium
444331|NCT00914329|homeopathy
444332|NCT00914316|Lower leg claudication
444333|NCT00914316|Poor circulation of the leg muscles
444334|NCT00914316|Cramping or discomfort in the lower legs
444335|NCT00914316|Lower leg pain
444336|NCT00914316|Peripheral arterial disease
444337|NCT00914316|PAD
444338|NCT00914303|Safety
444339|NCT00914303|tolerability
444340|NCT00914303|healthy
444341|NCT00914303|Healthy volunteer study
444342|NCT00914277|Rho-kinase inhibitor
444343|NCT00914277|male impotence
444344|NCT00914264|chronic obstructive airway disease
444345|NCT00914264|obstructive sleep apnea
444346|NCT00914264|continuous positive airway pressure
444347|NCT00914251|endothelial
444348|NCT00914251|metabolic syndrome
444349|NCT00914251|hesperidin
444350|NCT00914238|Randomized clinical trial
444351|NCT00914238|first episode psychosis of schizophrenia and schizotypal disorder
444352|NCT00914238|rehabilitation
444353|NCT00914238|psychosocial
444354|NCT00914238|health service research
444355|NCT00914238|schizotypal Disorder
444356|NCT00914225|Human immunodeficiency virus
444357|NCT00914225|malaria
444358|NCT00914225|plasmodium falciparum
444359|NCT00914225|diarrhea
444360|NCT00914225|helminth
444361|NCT00914225|HIV
444362|NCT00914225|Treatment naive
444363|NCT00914199|PCI
444364|NCT00914199|Bifurcation lesion
444365|NCT00914186|Atopic Dermatitis
444366|NCT00914186|Pruritus
444367|NCT00914160|Anti-inflammatory
444368|NCT00914147|unspecified adult solid tumor, protocol specific
444369|NCT00914134|Parkinson's disease
444370|NCT00914134|Autonomic nervous system
444371|NCT00914134|Levodopa infusion
444372|NCT00914108|Preterm Infants
444373|NCT00914108|Developmental Care
444374|NCT00914108|NIDCAP
444375|NCT00914108|Intrauterine Growth Restriction
444376|NCT00914108|APIB
444377|NCT00914108|EEG
444378|NCT00914108|Neurobehavior
444379|NCT00914095|Parkinson's disease
444380|NCT00914095|Freezing of Gait
444381|NCT00914095|Methylphenidate
444382|NCT00914095|Dopamine transporter inhibitor
444383|NCT00914095|Noradrenaline
444384|NCT00914082|Self hypnosis
444385|NCT00914082|Hypnosis
444386|NCT00914082|mental training
444387|NCT00914082|antenatal training
444388|NCT00914082|pregnancy
444389|NCT00914082|pain control
444390|NCT00914082|Childbirth
444391|NCT00914082|Analgesia
444392|NCT00914043|fatigue
444393|NCT00914043|HER2-negative breast cancer
444394|NCT00914043|stage II breast cancer
444395|NCT00914043|stage IIIA breast cancer
444396|NCT00914043|stage IIIB breast cancer
444397|NCT00914030|Visual perception
444398|NCT00914030|Local/global processing
444399|NCT00914030|Attention
444400|NCT00914030|Visual priming
444401|NCT00914030|Collinearity
444402|NCT00914030|Grouping
444403|NCT00914017|Breast Cancer
444404|NCT00914017|Breast Cancer Prevention
444405|NCT00914017|Mammographic Density
444406|NCT00914017|Breast Density
444407|NCT00914017|Breast Cancer Biomarkers
444408|NCT00914004|Antidepressant
444409|NCT00913991|Nitric Oxide
444410|NCT00913978|Normothermia
444411|NCT00913978|Abdominal Surgery
444412|NCT00913978|Bair Paws
444413|NCT00913952|Antidepressant
444414|NCT00913939|Prostate Cancer
444415|NCT00913939|HDR Brachytherapy
444416|NCT00913939|Prostate Brachytherapy
444417|NCT00913926|Climacteric symptoms
444418|NCT00913913|Renal Cell Carcinoma
444419|NCT00913900|Arterial Occlusive Diseases
444420|NCT00913900|Vascular Disease
444421|NCT00913887|Anti-Inflammatory
444422|NCT00913861|endoscopy
444423|NCT00913861|comfort
444424|NCT00913861|non-pharmacological
444425|NCT00913848|Treatment of Epilepsy and Bipolar Disorder
444426|NCT00913835|Liposomal Doxorubicin
444427|NCT00913835|IMC-3G3
444428|NCT00913835|3G3
444429|NCT00913835|Platinum resistant
444430|NCT00913835|Platinum refractory
444431|NCT00913835|Ovary
444432|NCT00913835|Neoplasm
444433|NCT00913835|PDGFr
444434|NCT00913822|Antidepressant
444435|NCT00913809|Antidepressant
444436|NCT00913796|Renal transplantation
444437|NCT00913796|Metabolic acidosis
444438|NCT00913796|Physical capacity
444439|NCT00913796|Bone histology
444440|NCT00913796|Bone histomorphometry
444441|NCT00913796|Parathyroid function
444442|NCT00913796|Calcium and phosphate metabolism
444443|NCT00913783|Antidepressant
444444|NCT00913770|opioid dependence
444445|NCT00913770|buprenorphine
444446|NCT00913770|brief intervention
444447|NCT00913757|Hepatocellular Carcinoma
444448|NCT00913757|Liver Cancer
444449|NCT00913757|Chronic Liver Disease
444450|NCT00913757|Genome Wide Association Study
444451|NCT00913757|Gene Expression Profiling
444452|NCT00913744|AMD
444453|NCT00913731|Psychotic symptom assessments
444454|NCT00913731|Observational assessments of patients with acute psychotic symptoms
444455|NCT00913705|NATCH
444456|NCT00913705|LUNG
444457|NCT00913705|OPERABLE NSCLC
444458|NCT00913705|SURGERY PLUS ADJUVANT THERAPY
444459|NCT00913705|SURGERY PLUS NEOADJUVANT THERAPY
444460|NCT00913692|Glutamine
444461|NCT00913692|Herpes Labialis
444462|NCT00913692|Herpes Simplex Virus
444463|NCT00913692|Cold Sore
444464|NCT00913679|osteonecrosis
444465|NCT00913679|femoral neck fracture
444466|NCT00913679|implant fixation
444467|NCT00913679|implant failure
444468|NCT00913679|periprosthetic bone mineral density
444469|NCT00913679|gait function
444470|NCT00913679|gait analysis
444471|NCT00913679|patient recovery
444472|NCT00913666|Multiple Sclerosis
444473|NCT00913653|Heart failure
444474|NCT00913653|LCZ696
444475|NCT00913640|Prospective Memory Performance
444476|NCT00913640|Prospective Memory Outcome
444477|NCT00913640|Parkinson's Disease
444478|NCT00913627|Extended-release, ibuprofen
444479|NCT00913614|insomnia pediatric safety
444480|NCT00913601|Idiopathic Fecal Incontinence
444481|NCT00913601|Fecal Incontinence
444482|NCT00913601|Sacral Nerve Stimulation
444483|NCT00913601|Sacral Nerve Neuromodulation
444484|NCT00913575|neuromuscular training
444485|NCT00913575|preoperative exercise
444486|NCT00913575|physiotherapy
444487|NCT00913575|total knee replacement
444488|NCT00913575|knee osteoarthritis
444489|NCT00913562|Ocular Physiology
444490|NCT00913562|Regional Blood Flow
444491|NCT00913549|Antihistamine
444492|NCT00913536|Bladder Cancer
444493|NCT00913536|Cone Beam CT
444494|NCT00913536|On-line image guidance
444495|NCT00913536|Radiation therapy in bladder cancer patients
444496|NCT00913523|tampons
444497|NCT00913523|Glycerol Monolaurate
444498|NCT00913523|vaginal microflora
444499|NCT00913523|microbes
444500|NCT00913523|Vaginal Tampon
444501|NCT00913497|Type 1 diabetes mellitus in children
444502|NCT00913497|insulin glulisine
444503|NCT00913497|insulin aspart
444504|NCT00913497|post prandial
444505|NCT00913484|Disulfiram
444506|NCT00913484|Buprenorphine
444507|NCT00913484|Cocaine dependence
444508|NCT00913484|Opioid dependence
444509|NCT00913484|Dopamine-Beta-Hydroxylase
444510|NCT00913471|Spinal cord injury
444511|NCT00913471|SCI
444512|NCT00913471|Neuropathic pain
444513|NCT00913471|Pain
444514|NCT00913445|Appendicitis
444515|NCT00913445|appendicectomy
444516|NCT00913445|stitches
444517|NCT00913445|wound healing
444518|NCT00913445|cosmetic results
444519|NCT00913432|rheumatoid arthritis
444520|NCT00913432|methotrexate
444521|NCT00913432|DMARD
444522|NCT00913432|c-kit inhibitor
444523|NCT00913419|Antidepressant
444524|NCT00913406|Effect of lutein fortification growth healthy term infants
444525|NCT00913367|Type 2 Diabetes Mellitus
444526|NCT00913354|infertility
444527|NCT00913354|ivf
444528|NCT00913354|acupuncture
444529|NCT00913328|Asthma
444530|NCT00913328|Airway responsiveness
444531|NCT00913328|Dose-response plateau
444532|NCT00913328|Montelukast
444533|NCT00913328|Add-on to inhaled corticosteroids
444534|NCT00913315|prostatitis
444535|NCT00913315|Adrenergic alpha-Antagonists
444536|NCT00913315|tolterodine
444537|NCT00913302|Ankylosing Spondylitis
444538|NCT00913302|Education
444539|NCT00913302|Physical fitness
444540|NCT00913289|Liver Cirrhosis
444541|NCT00913263|Prostate cancer
444542|NCT00913250|Multiple Sclerosis
444543|NCT00913250|Interferon beta-1a
444544|NCT00913237|Antidepressant
444545|NCT00913224|Anti-inflammatory
444546|NCT00913198|Pancreas
444547|NCT00913198|Advanced adenocarcinoma
444548|NCT00913198|CP-4126
444549|NCT00913185|Acne
444550|NCT00913172|TB
444551|NCT00913172|cost
444552|NCT00913172|HEWs
444553|NCT00913172|Cost-effectiveness
444554|NCT00913172|treatment success rate
444555|NCT00913159|Renal stones
444556|NCT00913159|lithotripsy
444557|NCT00913159|stone free rate
444558|NCT00913146|Management of fever
444559|NCT00913146|Malaria
444560|NCT00913146|Malaria rapid diagnostic test
444561|NCT00913146|Clinical trial
444562|NCT00913133|Anticoagulation
444563|NCT00913133|Prophylaxis
444564|NCT00913133|Desirudin
444565|NCT00913133|Direct thrombin inhibitor
444566|NCT00913133|Heparin-induced thrombocytopenia
444567|NCT00913120|YM150
444568|NCT00913120|FXa inhibitor
444569|NCT00913120|Thrombosis
444570|NCT00913120|Anticoagulant
444571|NCT00913120|Venous thromboembolism
444572|NCT00913120|Arthroplasty, replacement, hip
444573|NCT00913107|Trigeminal Neuralgia
444574|NCT00913107|Lamotrigine
444575|NCT00913107|Carbamazepine
444576|NCT00913107|Lamictal®
444577|NCT00913107|Tegretol®
444578|NCT00913094|Hypertension
444579|NCT00913081|Skin
444580|NCT00913081|pharmacology
444581|NCT00913081|metabolism
444582|NCT00913081|lipid
444583|NCT00913068|radical prostatectomy
444584|NCT00913055|S-LAR
444585|NCT00913055|Octreotide
444586|NCT00913055|Implant
444587|NCT00913042|Febrile neutropenia
444588|NCT00913042|Blood culture
444589|NCT00913042|Bacteremia
444590|NCT00913042|Bacterial DNA testing
444591|NCT00913029|primary open angle glaucoma (POAG)
444592|NCT00913029|OAG
444593|NCT00913029|glaucoma
444594|NCT00913016|hormonal therapy(letrozole)
444595|NCT00913016|postmenopausal breast cancer
444596|NCT00913016|quality of life
444597|NCT00913003|Lidocaine
444598|NCT00913003|Mastectomy
444599|NCT00913003|Pain
444600|NCT00912990|Pediatric
444601|NCT00912977|Parkinsons disease
444602|NCT00912977|dyskinesia
444603|NCT00912977|measurement
444604|NCT00912964|Overactive Bladder
444605|NCT00912964|Frequency
444606|NCT00912964|Micturition
444607|NCT00912964|Urgency
444608|NCT00912964|Urinary incontinence
444609|NCT00912964|Urinary urgency incontinence
444610|NCT00912964|Mirabegron
444611|NCT00912964|YM178
444612|NCT00912938|metastatic breast cancer
444613|NCT00912938|bone remodeling markers
444614|NCT00912938|zoledronic acid
444615|NCT00912912|Genitourinary
444616|NCT00912912|Testis
444617|NCT00912912|Refractory Germ Cell Tumors
444618|NCT00912912|Advanced germ cell tumors
444619|NCT00912912|GCTs
444620|NCT00912912|Sunitinib Malate
444621|NCT00912912|Sutent
444622|NCT00912912|SU011248
444623|NCT00912899|Refractory Multiple Myeloma
444624|NCT00912899|CB3304
444625|NCT00912899|Noscapine HCl
444626|NCT00912899|Multiple Myeloma
444627|NCT00912886|alzheimer
444628|NCT00912886|memory
444629|NCT00912886|neurosteroids
444630|NCT00912873|pain
444631|NCT00912873|catheter
444632|NCT00912873|nerve block
444633|NCT00912873|UCSD
444634|NCT00912873|range of motion
444635|NCT00912873|hip surgery
444636|NCT00912873|psoas compartment
444637|NCT00912860|multiple sclerosis
444638|NCT00912860|interferon beta-1a
444639|NCT00912860|avonex
444640|NCT00912847|HBV carriers
444641|NCT00912834|hematuria
444642|NCT00912834|urinary tract infection
444643|NCT00912821|Renal Replacement Therapy
444644|NCT00912821|Peritoneal dialysis
444645|NCT00912808|parkinsons disease
444646|NCT00912808|falling
444647|NCT00912795|Smoking Cessation
444648|NCT00912795|technology
444649|NCT00912795|developing countries
444650|NCT00912782|ESRD
444651|NCT00912782|Vitamin D
444652|NCT00912782|Arteriovenous Fistulae
444653|NCT00912782|Dialysis Vascular Access
444654|NCT00912769|Total knee replacement
444655|NCT00912769|Subvastus
444656|NCT00912769|Midvastus
444657|NCT00912769|Isokinetic
444658|NCT00912769|Quadriceps
444659|NCT00912756|endovascular therapy
444660|NCT00912756|restenosis
444661|NCT00912756|cilostazol
444662|NCT00912756|femoropopliteal artery lesions
444663|NCT00912756|Chronic arteriosclerosis obliterans afflicting the femoropopliteal artery area
444664|NCT00912743|Colorectal cancer
444665|NCT00912743|Olaparib
444666|NCT00912743|MSI status
444667|NCT00912743|Stage IV
444668|NCT00912743|Measurable Colorectal Cancer
444669|NCT00912743|Stratified by MSI Status
444670|NCT00912730|melanoma
444671|NCT00912730|imaging
444672|NCT00912730|sentinel node
444673|NCT00912730|biopsy
444674|NCT00912704|Hemodialysis patients
444675|NCT00912704|Kidney
444676|NCT00912704|Physician attitudes
444677|NCT00912704|Family wishes
444678|NCT00912704|30 numbers require maximum
444679|NCT00912691|Autism
444680|NCT00912678|Kidney transplantation
444681|NCT00912678|Old for old kidney transplantation
444682|NCT00912678|European senior program
444683|NCT00912678|Calcineurin inhibitor free immunosuppression
444684|NCT00912665|Optic Nerve Head Blood Flow
444685|NCT00912665|Intraocular Pressure
444686|NCT00912665|Regional Blood Flow
444687|NCT00912665|Ocular Physiology
444688|NCT00912665|Optic Disk
444689|NCT00912652|obesity
444690|NCT00912652|rural health
444691|NCT00912652|exercise
444692|NCT00912639|recurrent breast cancer
444693|NCT00912639|Genexol-PM
444694|NCT00912626|siblings
444695|NCT00912626|family
444696|NCT00912626|child behavior
444697|NCT00912626|critical illness
444698|NCT00912626|social support
444699|NCT00912613|Critical illness
444700|NCT00912613|ICU Diaries
444701|NCT00912613|Post Traumatic Stress Disorder
444702|NCT00912613|Incidence
444703|NCT00912600|Intensive Care Units
444704|NCT00912600|Triage
444705|NCT00912600|Aged, 80 and over
444706|NCT00912600|Death
444707|NCT00912600|Activities of Daily Living
444708|NCT00912600|Health Services Research
444709|NCT00912600|Health Care Quality, Access, and Evaluation
444710|NCT00912574|Melanoma
444711|NCT00912574|adjuvant
444712|NCT00912574|dendritic cells
444713|NCT00912574|vaccine
444714|NCT00912561|chronic brain ischaemia
444715|NCT00912561|stroke prevention
444716|NCT00912561|exercise
444717|NCT00912561|physical training
444718|NCT00912561|Chronic, extra- or intracranial stenoses of brain supplying arteries
444719|NCT00912548|premenopause
444720|NCT00912548|ovarian function suppression
444721|NCT00912548|tamoxifen
444722|NCT00912535|Primary Anxiety Disorders
444723|NCT00912535|Mood Disorders with Comorbid Anxiety Symptoms
444724|NCT00912522|reward
444725|NCT00912522|TMS
444726|NCT00912522|cognition
444727|NCT00912522|Motivation
444728|NCT00912522|Perception
444729|NCT00912522|Decision making
444730|NCT00912509|infectious keratitis
444731|NCT00912509|cross linking
444732|NCT00912509|corneal ulcer
444733|NCT00912509|corneal infection
444734|NCT00912509|collagen cross linking
444735|NCT00912496|Influenza, H5N1, vaccine, avian influenza
444736|NCT00912483|VTE
444737|NCT00912470|genetic vascular risc factors
444738|NCT00912470|ocular blood flow
444739|NCT00912470|progressive glaucoma
444740|NCT00912457|sleep apnea
444741|NCT00912457|donepezil
444742|NCT00912457|pharmacological
444743|NCT00912457|cholinergic
444744|NCT00912444|Breast Neoplasms
444745|NCT00912444|Neoadjuvant
444746|NCT00912444|Chemotherapy
444747|NCT00912444|Docetaxel
444748|NCT00912444|Cyclophosphamide
444749|NCT00912444|Anthracycline
444750|NCT00912431|Healthy Volunteers
444751|NCT00912418|melanoma
444752|NCT00912418|vaccine
444753|NCT00912418|IL2 low dose
444754|NCT00912405|Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)
444755|NCT00912366|VATS
444756|NCT00912366|Lung cancer
444757|NCT00912366|NSCLC
444758|NCT00912353|Phase I
444759|NCT00912353|Japanese healthy volunteer
444760|NCT00912353|AZD7268
444761|NCT00912340|Breast Cancer
444762|NCT00912327|Colorectal
444763|NCT00912327|KRAS mutation
444764|NCT00912327|Stage IV
444765|NCT00912327|Imprime PGG
444766|NCT00912327|Cetuximab
444767|NCT00912327|Immunotherapy
444768|NCT00912314|OAB
444769|NCT00912314|overactive bladder
444770|NCT00912314|ptns
444771|NCT00912314|posterior tibial nerve stimulation
444772|NCT00912314|percutaneous tibial nerve stimulation
444773|NCT00912301|chenodeoxycholate, IBS, transit, colon, constipation
444774|NCT00912288|Alzheimer disease moderate-to-severe memantine safety and efficacy
444775|NCT00912262|Analgesics
444776|NCT00912262|Capsaicin
444777|NCT00912249|Horticulture Therapy
444778|NCT00912249|Psychiatric Rehabilitation
444779|NCT00912249|Nature-assisted psychotherapy
444780|NCT00912249|Day Care
444781|NCT00912236|Obesity
444782|NCT00912236|HDL
444783|NCT00912236|HDL functionality
444784|NCT00912223|Follicular Non-Hodgkin's Lymphoma
444785|NCT00912223|Hematopoietic Stem Cell Transplant (HSCT)
444786|NCT00912223|Non-Myeloablative Transplant (NST)
444787|NCT00912184|Kidney failure, acute
444788|NCT00912184|Shock
444789|NCT00912184|Toxins, biological
444790|NCT00912184|Hemofiltration
444791|NCT00912184|High cut off/super high flux membranes
444792|NCT00912171|obstructive sleep apnea syndrome
444793|NCT00912171|snoring
444794|NCT00912171|adenotonsillar hypertrophy
444795|NCT00912171|polysomnography
444796|NCT00912171|intranasal steroids
444797|NCT00912171|Anti-leukotrienes
444798|NCT00912158|CPE
444799|NCT00912158|CPAP
444800|NCT00912158|BiPAP
444924|NCT00911612|malabsorption
444801|NCT00912158|non invasive mechanical ventilation
444802|NCT00912132|Fetal Growth
444803|NCT00912132|Pregnancy
444804|NCT00912119|craniofacial surgery
444805|NCT00912119|pharmacokinetics
444806|NCT00912119|cranial vault abnormalities
444807|NCT00912119|homologous blood products
444808|NCT00912119|wide scalp dissections
444809|NCT00912119|transfusion requirements
444810|NCT00912106|osteoarthritis
444811|NCT00912106|HA
444812|NCT00912106|synovial fluid
444813|NCT00912106|lubrication
444814|NCT00912093|HAE
444815|NCT00912093|Type I HAE
444816|NCT00912093|Type II HAE
444817|NCT00912080|genomic signature
444818|NCT00912080|lymph nodes
444819|NCT00912080|no metastases
444820|NCT00912054|OAG
444821|NCT00912054|OH
444822|NCT00912041|Brain computer interface
444823|NCT00912041|Assistive device
444824|NCT00912041|Environmental control
444825|NCT00912041|Communication device
444826|NCT00912041|quadriplegia
444827|NCT00912041|tetraplegia
444828|NCT00911989|Obesity
444829|NCT00911989|Weight Loss
444830|NCT00911976|Coronary artery bypass
444831|NCT00911976|Stents
444832|NCT00911976|Angioplasty, Transluminal, Percutaneous Coronary
444833|NCT00911976|Coronary Restenosis
444834|NCT00911976|Everolimus
444835|NCT00911976|Saphenous vein grafts
444836|NCT00911963|VX-222
444837|NCT00911937|incontinence OAB urgency nocturia
444838|NCT00911924|primary open angle glaucoma (POAG)
444839|NCT00911924|OAG
444840|NCT00911924|glaucoma
444841|NCT00911911|Breast cancer
444842|NCT00911911|Neo-adjuvant chemotherapy
444843|NCT00911911|Proteomic
444844|NCT00911911|Histological response
444845|NCT00911898|Her2 amplified solid tumors
444846|NCT00911898|Breast Cancer
444847|NCT00911898|Her3/ErbB3
444848|NCT00911898|Bispecific Antibody
444849|NCT00911885|Weight
444850|NCT00911885|Diet
444851|NCT00911885|Lipids
444852|NCT00911872|wrinkles
444853|NCT00911872|dermal filler
444854|NCT00911872|collagen
444855|NCT00911872|soft tissue augmentation
444856|NCT00911872|aesthetic
444857|NCT00911859|Multiple Myeloma
444858|NCT00911859|CNTO328
444859|NCT00911859|Interleukin-6 (IL-6)
444860|NCT00911859|Monoclonal antibody
444861|NCT00911859|Anti-IL-6 monoclonal antibody
444862|NCT00911859|Bortezomib
444863|NCT00911859|Velcade
444864|NCT00911859|Melphalan
444865|NCT00911859|Prednisone
444866|NCT00911846|opioid dependence substitution buprenorphine methadone
444867|NCT00911846|"substitution"
444868|NCT00911833|Trust
444869|NCT00911807|Clinical Trial, Phase II
444870|NCT00911807|Randomized Controlled Trial
444871|NCT00911807|Multicenter Study
444872|NCT00911807|Cerebrolysin
444873|NCT00911807|Donepezil
444874|NCT00911794|Dyspnea
444875|NCT00911794|Written Disclosure Therapy
444876|NCT00911794|COPD
444877|NCT00911794|Pulmonary Fibrosis
444878|NCT00911794|Chronic Lung Diseases
444879|NCT00911794|Pulmonary Rehabilitation
444880|NCT00911781|Infantile hemangioma
444881|NCT00911768|Xerostomia
444882|NCT00911768|Panax ginseng(Korean Red Ginseng)
444883|NCT00911768|Visual Analogue Scale
444884|NCT00911768|Salivary Flow Rates
444885|NCT00911755|Laryngoscopy
444886|NCT00911755|Glidescope
444887|NCT00911729|paraganglioma
444888|NCT00911729|pheochromocytoma
444889|NCT00911716|estrogen receptor-negative breast cancer
444890|NCT00911716|estrogen receptor-positive breast cancer
444891|NCT00911716|HER2-negative breast cancer
444892|NCT00911716|stage IA breast cancer
444893|NCT00911716|stage IB breast cancer
444894|NCT00911716|stage II breast cancer
444895|NCT00911716|stage IIIA breast cancer
444896|NCT00911716|male breast cancer
444897|NCT00911690|Dementia
444898|NCT00911690|Alzheimers Disease
444899|NCT00911690|Cognitive Disorders
444900|NCT00911690|Tissue Banking
444901|NCT00911677|Delirium (MeSH Unique ID D003693)
444902|NCT00911677|Cognition Disorders (MeSH Unique ID D003072)
444903|NCT00911677|Postoperative Complications (MeSH Unique ID D011183)
444904|NCT00911677|Apolipoproteins E (MeSH Unique ID D001057)
444905|NCT00911664|Vitamin D
444906|NCT00911664|HIV-Infected children
444907|NCT00911664|CD4 count
444908|NCT00911651|COPD
444909|NCT00911651|salbutamol
444910|NCT00911651|ipratropium bromide
444911|NCT00911651|computational fluid dynamics
444912|NCT00911651|functional imaging
444913|NCT00911651|central and peripheral airways
444914|NCT00911638|Patient decision aids
444915|NCT00911638|Patient preferences
444916|NCT00911638|Osteoarthritis
444917|NCT00911638|Joint replacement
444918|NCT00911638|Waiting times
444919|NCT00911625|glargine
444920|NCT00911625|glulisine
444921|NCT00911625|type 2 diabetes
444922|NCT00911625|renal insufficiency
444923|NCT00911612|bile acid
444925|NCT00911612|permeability
444926|NCT00911612|diarrhea
444927|NCT00911612|IBS
444928|NCT00911612|stool
444929|NCT00911599|Individuals undergoing unilateral total hip replacement.
444930|NCT00911573|pediatry
444931|NCT00911573|children
444932|NCT00911573|skin
444933|NCT00911573|bacteria
444934|NCT00911573|MRSA
444935|NCT00911560|BETA-D-GLUCAN
444936|NCT00911560|OPT-821
444937|NCT00911560|GD2-KLH
444938|NCT00911560|GD3-KLH
444939|NCT00911560|QS 21
444940|NCT00911560|Vaccine
444941|NCT00911560|05-075
444942|NCT00911547|chronic asthma
444943|NCT00911534|Gastroesophageal Reflux Disease
444944|NCT00911534|GERD
444945|NCT00911521|human papillomavirus
444946|NCT00911521|vaccine
444947|NCT00911521|lupus
444948|NCT00911508|Atrial Fibrillation
444949|NCT00911508|Left Atrial Ablation
444950|NCT00911508|Pulmonary Vein Isolation
444951|NCT00911508|Catheter Ablation
444952|NCT00911508|Antiarrhythmic Drug Therapy
444953|NCT00911495|Sickle Cell Disease
444954|NCT00911482|Type 2 Diabetes
444955|NCT00911482|Dyslipidemia
444956|NCT00911482|FFA
444957|NCT00911482|Triglycerides
444958|NCT00911482|Tracers
444959|NCT00911469|Knee osteoarthritis
444960|NCT00911469|fibroblast growth factor 18
444961|NCT00911430|Staphylococcus Aureus (S. Areus)
444962|NCT00911430|Recurrent Staphylococcal Infection
444963|NCT00911430|Atopic Dermatitis
444964|NCT00911430|Immunodeficiency
444965|NCT00911430|Community Associated Staphylococcal Infection
444966|NCT00911430|Staphylococcal Infection
444967|NCT00911430|Invasive Staphylococcal Infection
444968|NCT00911430|Staph Infection
444969|NCT00911417|peripheral arterial disease
444970|NCT00911417|peripheral vascular disease
444971|NCT00911404|Gestational diabetes
444972|NCT00911404|Carbohydrate
444973|NCT00911404|Diet
444974|NCT00911404|Insulin
444975|NCT00911391|Doppler
444976|NCT00911391|Colectomy
444977|NCT00911391|ERAS
444978|NCT00911391|Fluid
444979|NCT00911391|Perioperative Care
444980|NCT00911378|weaning
444981|NCT00911378|mechanical ventilation
444982|NCT00911365|voluntary participants
444983|NCT00911365|75 years old or less
444984|NCT00911352|Cryotherapy
444985|NCT00911352|Hand toxicity
444986|NCT00911352|Nail toxicity
444987|NCT00911352|Infection control
444988|NCT00911326|HNSCC
444989|NCT00911313|Polycystic ovary syndrome
444990|NCT00911313|clomiphene resistance
444991|NCT00911313|letrozole
444992|NCT00911300|Cardioversion, Electric
444993|NCT00911300|Pathological Conditions, Sings and Symptoms
444994|NCT00911300|Cardiovascular Diseases
444995|NCT00911300|Heart Diseases
444996|NCT00911300|Atrial Fibrillation
444997|NCT00911300|Arrhythmias, Cardiac
444998|NCT00911300|Pathologic Processes
444999|NCT00911300|Anticoagulants
445000|NCT00911287|Chronic pain
445001|NCT00911287|Extended Release
445002|NCT00911287|Long-Acting Opioid
445003|NCT00911287|Opioid
445004|NCT00911287|Opioid-Naive
445005|NCT00911287|Oxymorphone
445006|NCT00911274|Bioequivalence
445007|NCT00911274|Healthy Subjects
445008|NCT00911261|Cancer Pain
445009|NCT00911261|Neuropathic Pain
445010|NCT00911261|Extended Release
445011|NCT00911261|Long-Acting Opioid
445012|NCT00911261|Oxymorphone
445013|NCT00911248|Angiogenesis
445014|NCT00911248|Neurofibromatosis
445015|NCT00911248|Post-transcriptional control
445016|NCT00911248|PTC299
445017|NCT00911248|VEGF
445018|NCT00911235|The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
445019|NCT00911222|antiemetic therapy
445020|NCT00911222|emesis
445021|NCT00911222|vomiting
445022|NCT00911222|nausea
445023|NCT00911222|moderately and highly emetogenic chemotherapy
445024|NCT00911222|cisplatin
445025|NCT00911222|carboplatin
445026|NCT00911222|oxaliplatin
445027|NCT00911222|anthracycline
445028|NCT00911222|cyclophosphamid
445029|NCT00911209|Heart Disease
445030|NCT00911209|Obesity
445031|NCT00911196|Prognosis
445032|NCT00911196|Markers
445033|NCT00911196|Expression analysis
445034|NCT00911196|Hepatocellular carcinoma
445035|NCT00911183|contiguous stage II adult diffuse large cell lymphoma
445036|NCT00911183|noncontiguous stage II adult diffuse large cell lymphoma
445037|NCT00911183|stage III adult diffuse large cell lymphoma
445038|NCT00911183|stage IV adult diffuse large cell lymphoma
445039|NCT00911170|adenocarcinoma of the colon or rectum
445040|NCT00911170|febrile neutropenia
445041|NCT00911170|Bevacizumab
445042|NCT00911170|Avastin
445043|NCT00911170|5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX)
445044|NCT00911170|5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
445045|NCT00911157|Pulmonary thromboembolism
445046|NCT00911157|contrast-enhanced MDCT
445047|NCT00911157|Deep Vein Thrombosis
445048|NCT00911157|Fondaparinux sodium
445049|NCT00911144|Safety
445050|NCT00911144|Pneumococcal vaccine
445051|NCT00911144|Immunogenicity
445052|NCT00911144|Pneumococcal disease
445053|NCT00911144|Booster vaccination
445054|NCT00911131|Small grade esophageal varices
445055|NCT00911131|capsule endoscopy
445056|NCT00911131|PillCam ESO
445057|NCT00911131|abdominal binder
445058|NCT00911118|prostate
445059|NCT00911118|radiation
445060|NCT00911118|09-035
445061|NCT00911105|Multiple Myeloma
445062|NCT00911105|Non-interventional study
445063|NCT00911105|Lenalidomide
445064|NCT00911105|Dexamethasone
445065|NCT00911105|Observational
445066|NCT00911105|Time to progression
445067|NCT00911105|Clinical routine
445068|NCT00911105|Germany
445069|NCT00911105|Plasmacytoma
445070|NCT00911092|Oesophageal cancer
445071|NCT00911092|exclusive concomitant radiochemotherapy
445072|NCT00911079|Stage III, IV cervical cancer
445073|NCT00911079|Rising prostate specific antigen (PSA) after local therapy
445074|NCT00911053|melatonin
445075|NCT00911053|sleep
445076|NCT00911053|blindness
445077|NCT00911053|blind individuals
445078|NCT00911027|Prostate
445079|NCT00911027|Cancer
445080|NCT00911027|Biopsy
445081|NCT00911027|Guided
445082|NCT00911027|Contrast
445083|NCT00911027|Enhanced
445084|NCT00911027|SonoVue
445085|NCT00911027|Suspicion of prostate cancer
445086|NCT00911001|Arthroplasty
445087|NCT00911001|Antithrombotic prophylaxis treatment
445088|NCT00911001|Replacement
445089|NCT00911001|Knee
445090|NCT00910988|healthy
445091|NCT00910988|sedentary
445092|NCT00910988|men
445093|NCT00910988|acute effects of antipsychotic
445094|NCT00910988|blood sugar
445095|NCT00910988|insulin sensitivity
445096|NCT00910975|Hepatitis C virus
445097|NCT00910975|Real-time PCR
445098|NCT00910975|Treatment
445099|NCT00910962|NSTEMI, acute coronary syndrome, p38 MAPK inhibitor, GW856553, percutaneous coronary intervention
445100|NCT00910949|persistent pain
445101|NCT00910949|neuropathic pain
445102|NCT00910949|Thoracotomy
445103|NCT00910949|Chronic Pain
445104|NCT00910936|HIV
445105|NCT00910936|Exercise
445106|NCT00910936|Inflammation
445107|NCT00910936|Quality of life
445108|NCT00910936|Lipodystrophia
445109|NCT00910923|Diabetes Mellitus, Type 2
445110|NCT00910897|Newly Diagnosed
445111|NCT00910897|multiple myeloma
445112|NCT00910897|induction
445113|NCT00910897|Thalidomide
445114|NCT00910884|stage I breast cancer
445115|NCT00910884|stage II breast cancer
445116|NCT00910884|stage IIIA breast cancer
445117|NCT00910884|male breast cancer
445118|NCT00910884|stage I uterine sarcoma
445119|NCT00910884|stage II uterine sarcoma
445120|NCT00910884|stage I prostate cancer
445121|NCT00910884|stage II prostate cancer
445122|NCT00910871|Tuberculosis
445123|NCT00910871|TMC207-TiDP13-C209
445124|NCT00910871|TMC207-C209
445125|NCT00910871|TMC207
445126|NCT00910871|TB
445127|NCT00910871|MDR-TB
445128|NCT00910832|Dyschesia treatment
445129|NCT00910832|Rehabilitation
445130|NCT00910832|Dyschesia
445131|NCT00910819|Colorectal Cancer
445132|NCT00910819|Advanced Colorectal Cancer
445133|NCT00910819|Epidemiology
445134|NCT00910819|Health Services Research
445135|NCT00910819|Germany
445136|NCT00910819|Registry
445137|NCT00910819|Palliative Care
445138|NCT00910819|Palliative Treatment
445139|NCT00910819|Adjuvant Drug Therapy
445140|NCT00910819|Nutrition Assessment
445141|NCT00910819|Physical Activity
445142|NCT00910806|TMC207-TiDP13-C117
445143|NCT00910806|TMC207-C110
445144|NCT00910806|TMC207
445145|NCT00910806|drug-drug interaction
445146|NCT00910806|Tuberculosis
445147|NCT00910806|HIV
445148|NCT00910806|nevirapine
445149|NCT00910806|open-label
445150|NCT00910806|Pharmacokinetics
445151|NCT00910793|Asthma
445152|NCT00910793|Formoterol
445153|NCT00910793|Beclomethasone Dipropionate
445154|NCT00910793|Computational Fluid Dynamics
445155|NCT00910793|Functional Imaging
445156|NCT00910793|Central and Peripheral Airways
445157|NCT00910754|Prostate neoplasms
445158|NCT00910754|Metastatic castration resistant prostate cancer
445159|NCT00910754|Abiraterone acetate
445160|NCT00910754|CB7630
445161|NCT00910741|pancreatic cancer
445162|NCT00910741|Gemcitabine
445163|NCT00910728|Primary Myelofibrosis (PMF)
445164|NCT00910728|Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)
445165|NCT00910728|Myeloproliferative diseases
445166|NCT00910728|Phase I
445167|NCT00910728|Phase II
445168|NCT00910728|Bone marrow
445169|NCT00910715|erythema migrans
445170|NCT00910715|Lyme borreliosis
445171|NCT00910715|doxycycline treatment
445172|NCT00910715|outcome
445173|NCT00910715|subjective symptoms
445174|NCT00910702|retinal detachment, vitreous body substitute
445175|NCT00910689|Migraine Headache
445176|NCT00910689|Preventive Therapy
445177|NCT00910689|Beta Blocker Medication
445178|NCT00910689|Behavior Therapy
445179|NCT00910689|Clinical Trial
445180|NCT00910676|EGF-R inhibitors
445181|NCT00910663|Bioequivalence
445182|NCT00910663|Healthy Subjects
445183|NCT00910650|Adoptive transfer therapy
445184|NCT00910650|Dendritic cell vaccines
445185|NCT00910637|Pregnancy prevention
445186|NCT00910637|Female contraception
445187|NCT00910637|Patch
445188|NCT00910611|pediatric
445189|NCT00910611|immunization
445190|NCT00910611|pain
445191|NCT00910611|analgesia
445192|NCT00910611|Immunization pain
445193|NCT00910598|clinically isolated syndrome
445194|NCT00910598|relapsing remitting multiple sclerosis
445195|NCT00910598|glatiramer acetate
445196|NCT00910598|Optical Coherence Tomography
445197|NCT00910585|childhood
445198|NCT00910585|asthma
445199|NCT00910572|Yttrium-90
445200|NCT00910572|Radiation
445201|NCT00910572|Radioembolization
445202|NCT00910572|Hepatoma
445203|NCT00910572|BCLC classification
445204|NCT00910572|Hepatic loco-regional treatments
445205|NCT00910572|Yttrium
445206|NCT00910572|Microspheres
445207|NCT00910559|Autism Spectrum Disorder
445208|NCT00910559|ASD
445209|NCT00910559|Autism
445210|NCT00910559|Asperger Syndrome
445211|NCT00910559|PDD-NOS
445212|NCT00910559|Pervasive Developmental Disorders- Not Otherwise Specified
445213|NCT00910546|Lung Cancer
445214|NCT00910546|Stereotactic radiotherapy
445215|NCT00910546|Image guidance
445216|NCT00910546|breathing adaption
445217|NCT00910546|tumor motion
445218|NCT00910546|implanted marker
445219|NCT00910533|Lyme neuroborreliosis
445220|NCT00910507|Diabetes Mellitus, Type 2
445221|NCT00910507|Exercise
445222|NCT00910507|Counseling
445223|NCT00910507|Behavior
445224|NCT00910494|Rectal neoplasm C04.588.274.476.411.307.790
445225|NCT00910494|Intraoperative Radiotherapy
445226|NCT00910481|Coronary Artery Disease
445227|NCT00910481|Percutaneous Transluminal Coronary Angioplasty
445228|NCT00910481|Intraaortic Balloon Pumping
445229|NCT00910481|Left Ventricular Dysfunction
445230|NCT00910481|High Risk
445231|NCT00910455|Phase 1
445232|NCT00910455|Safety
445233|NCT00910455|Tolerability
445234|NCT00910455|Pharmacokinetics
445235|NCT00910429|Chronic thromboembolic Hypertension
445236|NCT00910429|PH
445237|NCT00910429|soluble Guanylate Cyclase Stimulator
445238|NCT00910429|sGC
445239|NCT00910416|Anesthesia
445240|NCT00910416|Monitoring, Intraoperative
445241|NCT00910416|Electroencephalography/*drug effects
445242|NCT00910403|Presbyopia
445243|NCT00910403|LASIK
445244|NCT00910403|Hyperopes
445245|NCT00910390|IVF
445246|NCT00910390|embryo cryopreservation
445247|NCT00910390|vitrification
445248|NCT00910390|Human Embryo
445249|NCT00910390|Embryonic development
445250|NCT00910390|Pregnancy rate
445251|NCT00910377|breastfeeding
445252|NCT00910377|exclusive breastfeeding
445253|NCT00910377|lactation counseling
445254|NCT00910377|teenagers
445255|NCT00910377|complementary food
445256|NCT00910377|adolescent
445257|NCT00910377|caregivers
445258|NCT00910364|Lower extremity DVT
445259|NCT00910364|Clot
445260|NCT00910364|leg clot
445261|NCT00910364|Deep vein thrombosis
445262|NCT00910364|Thrombosis
445263|NCT00910364|Warfarin
445264|NCT00910351|Cystic Fibrosis
445265|NCT00910351|Pharmacokinetics
445266|NCT00910351|Pediatrics
445267|NCT00910351|Inhalation
445268|NCT00910351|Sputum
445269|NCT00910338|Pelvic Floor Muscle Training
445270|NCT00910338|Extracorporeal Biofeedback
445271|NCT00910325|Female
445272|NCT00910325|Cholelithiasis
445273|NCT00910325|Natural Orifice Surgery
445274|NCT00910325|Laparoscopic- Assisted
445275|NCT00910325|Transvaginal
445276|NCT00910299|Clopidogrel
445277|NCT00910299|VerifyNow
445278|NCT00910299|PRU Measurements
445279|NCT00910299|Drug Eluting Stents (DES)
445280|NCT00910299|Heart Disease
445281|NCT00910299|Percutaneous Coronary Intervention (PCI)
445282|NCT00910299|P2Y12
445283|NCT00910299|Platelets
445284|NCT00910299|Platelet Reactivity
445285|NCT00910286|Pressure support ventilation
445286|NCT00910286|cycling off criteria
445287|NCT00910286|expiratory trigger
445288|NCT00910286|patient-ventilator interaction
445289|NCT00910286|patient comfort
445290|NCT00910273|IMT evaluation in AS patients treated with etanercept
445291|NCT00910260|vitamin D level under phototherapy
445292|NCT00910247|Seizures
445293|NCT00910247|Epilepsy
445294|NCT00910247|Anticonvulsant
445295|NCT00910247|Monotherapy
445296|NCT00910247|Epilepsy with simple or complete partial onset seizures
445297|NCT00910234|Periventricular leukomalacia (PVL)
445298|NCT00910234|Erythropoietin (EPO)
445299|NCT00910234|Retinopathy of prematurity (ROP)
445300|NCT00910234|Hypoxia-ischemia
445301|NCT00910221|Cardiac surgery
445302|NCT00910221|Cardiopulmonary bypass
445303|NCT00910221|Oxidative stress
445304|NCT00910221|Acute renal dysfunction
445305|NCT00910221|Atorvastatin
445306|NCT00910208|Pain
445307|NCT00910208|Analgesia
445308|NCT00910208|Analgesia, Patient-controlled
445309|NCT00910208|Emergency Medicine
445310|NCT00910195|Obstructive sleep apnea
445311|NCT00910195|CPAP
445312|NCT00910195|Bi-Level
445313|NCT00910182|Splenic rupture
445314|NCT00910182|abdominal injuries
445315|NCT00910182|Surgery
445316|NCT00910182|Angiography
445317|NCT00910182|Embolisation
445318|NCT00910182|Computed tomography
445319|NCT00910182|Classification
445320|NCT00910169|Anorexia nervosa
445321|NCT00910169|treatment
445322|NCT00910169|inpatient
445323|NCT00910169|efficacy
445324|NCT00910169|outcome
445325|NCT00910143|Rectal cancer
445326|NCT00910143|Colorectal Surgery
445327|NCT00910143|Surgery
445328|NCT00910143|Local neoplasm recurrence
445329|NCT00910143|survival
445330|NCT00910143|Follow-up Study
445331|NCT00910130|Retinol Binding Protein 4
445332|NCT00910130|Insulin Resistance
445333|NCT00910130|Diabetes
445334|NCT00910130|End Stage Renal Disease
445335|NCT00910130|Dialysis
445336|NCT00910130|Nutrition
445337|NCT00910117|HNSCC
445338|NCT00910117|induction chemotherapy
445339|NCT00910117|nimotuzumab
445340|NCT00910104|PNALD
445341|NCT00910104|Omegaven
445342|NCT00910104|Parenteral Nutrition Associated Liver Disease
445343|NCT00910104|Cholestasis
445344|NCT00910104|Short Bowel Syndrome
445345|NCT00910091|Endometrial cancer
445346|NCT00910091|Antitumour efficacy in women with advanced endometrial cancer
445347|NCT00910078|Total kappa and lambda ratio
445348|NCT00910078|Stem cell transplantation
445349|NCT00910078|Serum immunofixation
445350|NCT00910065|Acute Coronary Syndrome
445351|NCT00910065|ACS
445352|NCT00910065|Aspirin
445353|NCT00910052|randomised
445354|NCT00910052|controlled
445355|NCT00910052|double blinded
445356|NCT00910039|cognitive/functional effects
445357|NCT00910039|tumors metastatic to brain
445358|NCT00910039|unspecified adult solid tumor, protocol specific
445359|NCT00910026|EBC and mechanical ventilation
445360|NCT00910026|low tidal volume ventilation
445361|NCT00910026|high tidal volume ventilation
445362|NCT00910026|inflammatory and oxidative stress EBC biomarkers
445363|NCT00910026|Ventilator induced lung injury
445364|NCT00910013|TKR
445365|NCT00910013|Femoral block
445366|NCT00910013|Ropivacaïne
445367|NCT00910013|intra-articular ropivacaïne
445368|NCT00910013|post-operative analgesia
445369|NCT00910000|carboplatin
445370|NCT00910000|gemcitabine
445371|NCT00910000|vorinostat
445372|NCT00909987|rectum
445373|NCT00909987|intermediate risk cancer rectum
445374|NCT00909987|neoadjuvant
445375|NCT00909974|multiple micronutrients
445376|NCT00909974|energy deficiency
445377|NCT00909961|Osteoporosis
445378|NCT00909961|Bone Mineral Density
445379|NCT00909961|Biomarkers
445380|NCT00909948|Related stem cell transplant,
445381|NCT00909948|TBI,
445382|NCT00909948|Mismatched stem cell transplant
445383|NCT00909948|Fludarabine
445384|NCT00909948|Non-myeloablative
445385|NCT00909948|Lymphoma
445386|NCT00909948|Multiple myeloma
445387|NCT00909935|To determine pharmacokinetics of dexmedetomidine in children
445388|NCT00909922|Amputation
445389|NCT00909922|Amputees
445390|NCT00909922|Artificial Limbs
445391|NCT00909922|Leg Length Inequality
445392|NCT00909922|Lower Extremity
445393|NCT00909922|Pelvis
445394|NCT00909922|Posture
445395|NCT00909922|Prostheses
445396|NCT00909922|Range of Motion
445397|NCT00909922|Trunk Muscles
445398|NCT00909909|ductal breast carcinoma in situ
445399|NCT00909909|invasive ductal breast carcinoma
445400|NCT00909909|invasive lobular breast carcinoma
445401|NCT00909909|medullary ductal breast carcinoma with lymphocytic infiltrate
445402|NCT00909909|mucinous ductal breast carcinoma
445403|NCT00909909|papillary ductal breast carcinoma
445404|NCT00909909|tubular ductal breast carcinoma
445405|NCT00909909|stage I breast cancer
445406|NCT00909909|stage II breast cancer
445407|NCT00909909|stage IIIA breast cancer
445408|NCT00909896|endometrial
445409|NCT00909896|pain
445410|NCT00909883|Idiopathic Parkinson's disease
445411|NCT00909883|Foot (Tiptoe) dystonia
445412|NCT00909883|Botulinum Toxin
445413|NCT00909883|Muscles : Flexor digitorum longus/ Flexor digitorum brevis/ quadratus plantae
445414|NCT00909870|Venous leg ulcer
445415|NCT00909870|randomized trial
445416|NCT00909870|clinical trial
445417|NCT00909870|Dermagraft
445418|NCT00909870|compression therapy
445419|NCT00909870|surgical debridement
445420|NCT00909870|venous stasis
445421|NCT00909870|chronic ulcer
445422|NCT00909870|chronic wound
445423|NCT00909870|fibroblasts
445424|NCT00909857|Primary Dysmenorrhea
445425|NCT00909857|Oral Contraception
445426|NCT00909831|unspecified adult solid tumor, protocol specific
445427|NCT00909805|dermabond glue
445428|NCT00909805|suture
445429|NCT00909805|children
445430|NCT00909779|Chronic obstructive pulmonary disease (COPD)
445431|NCT00909779|respiratory
445432|NCT00909779|long-acting beta agonist (LABA)
445433|NCT00909753|Bioequivalence
445434|NCT00909753|Healthy Subjects
445435|NCT00909740|Solid Tumor
445436|NCT00909740|Cancer
445437|NCT00909727|Fibrosis
445438|NCT00909727|Pancreatic Diseases
445439|NCT00909727|Digestive System Diseases
445440|NCT00909727|Lung Diseases
445441|NCT00909727|Respiratory Tract Diseases
445442|NCT00909727|Genetic Diseases, Inborn
445443|NCT00909727|Infant, Newborn, Diseases
445444|NCT00909727|Pathologic Processes
445445|NCT00909714|stroke
445446|NCT00909714|non-invasive cortical stimulation
445447|NCT00909714|motor recovery
445448|NCT00909714|cortical plasticity
445449|NCT00909714|TDCS
445450|NCT00909701|Dietary supplement
445451|NCT00909701|healthy volunteers
445452|NCT00909701|Anaesthesia for surgery
445453|NCT00909688|Healthy Subjects
445454|NCT00909662|cognitive/functional effects
445455|NCT00909662|long-term effects secondary to cancer therapy in adults
445456|NCT00909662|fatigue
445457|NCT00909662|stage I breast cancer
445458|NCT00909662|stage II breast cancer
445459|NCT00909662|stage IIIA breast cancer
445460|NCT00909662|stage IIIB breast cancer
445461|NCT00909662|stage IIIC breast cancer
445462|NCT00909649|fibrin glue
445463|NCT00909649|seroma
445464|NCT00909649|mastectomy
445465|NCT00909636|multiple ascending doses (MAD)
445466|NCT00909610|Bioequivalence
445467|NCT00909610|Healthy Subjects
445468|NCT00909584|Hematology
445469|NCT00909584|Neutropenia
445470|NCT00909584|SCN
445471|NCT00909584|Severe Chronic Neutropenia
445472|NCT00909584|Idiopathic
445473|NCT00909584|Telintra
445474|NCT00909584|ezatiostat hydrochloride
445475|NCT00909584|ezatiostat
445476|NCT00909584|TLK199
445477|NCT00909584|Glutathione
445478|NCT00909584|Glutathione analog
445479|NCT00909584|Glutathione Transferase
445480|NCT00909584|Glutathione Transferase inhibitor
445481|NCT00909584|Glutathione Transferase P1-1 inhibitor
445482|NCT00909584|GSTp1-1 inhibitor
445483|NCT00909584|Apoptosis
445484|NCT00909584|Differentiation
445485|NCT00909584|Enzyme inhibitor
445486|NCT00909571|FK506E
445487|NCT00909571|MR4
445488|NCT00909571|Prograf
445489|NCT00909571|Tacrolimus
445490|NCT00909571|Living Liver Transplantation
445491|NCT00909558|metastatic malignancies
445492|NCT00909558|tumor markers
445493|NCT00909558|chemotherapy
445494|NCT00909558|cancer
445495|NCT00909558|breast cancer
445496|NCT00909558|glioma
445497|NCT00909558|hepatocellular cancer
445498|NCT00909558|squamous cell lung cancer
445499|NCT00909558|pancreatic cancer
445500|NCT00909558|colon cancer
445501|NCT00909558|prostate cancer
445502|NCT00909545|Early Parkinson disease
445503|NCT00909532|Fibrosis
445504|NCT00909532|Pancreatic Diseases
445505|NCT00909532|Lung Diseases
445506|NCT00909532|Respiratory Tract Diseases
445507|NCT00909532|Genetic Diseases, Inborn
445508|NCT00909532|Infant, Newborn, Diseases
445509|NCT00909532|Pathologic Processes
445510|NCT00909493|Improvement of patient care as measured by self-rated health and improve physician satisfaction with chronic pain management
445511|NCT00909454|Vitamin D deficiency
445512|NCT00909454|Adolescents
445513|NCT00909454|African Americans
445514|NCT00909454|Overweight
445515|NCT00909454|Obesity
445516|NCT00909441|Breast Cancer
445517|NCT00909441|Node Positive Breast Cancer
445518|NCT00909441|Sentinel Lymph Node Biopsy
445519|NCT00909441|Breast Surgery
445520|NCT00909441|Axillary Lymph Node Dissection
445521|NCT00909441|Neoadjuvant Chemotherapy
445522|NCT00909428|overactive bladder syndrome
445523|NCT00909428|lower urinary tract
445524|NCT00909428|urgency
445525|NCT00909428|solifenacin
445526|NCT00909428|pharmacotherapy
445527|NCT00909428|urodynamic testing
445528|NCT00909415|patients with anorectal malformation
445529|NCT00909376|Pregnancy
445530|NCT00909376|Ultrasonography
445531|NCT00909376|outcome
445532|NCT00909376|adverse
445533|NCT00909350|Barrett's esophagus
445534|NCT00909350|BE
445535|NCT00909350|esophageal adenocarcinoma
445536|NCT00909350|Micro-RNA
445537|NCT00909350|miR expression
445538|NCT00909324|Post LASIK dry eye
445539|NCT00909324|Pre LASIK dry eye
445540|NCT00909324|Hypromellose
445541|NCT00909311|Food effect
445542|NCT00909298|Left ventricular assist devices
445543|NCT00909298|Cardiac Disease
445544|NCT00909298|Heart Failure
445545|NCT00909298|Anticoagulant for Left Ventricular Assist Devices
445546|NCT00909285|Alzheimer
445547|NCT00909285|TMS
445548|NCT00909285|cognitive training
445549|NCT00909272|ultrasound
445550|NCT00909272|diagnostic
445551|NCT00909272|lumbar
445552|NCT00909272|median branch
445553|NCT00909272|block
445554|NCT00909272|Lumbar facet joint pain
445555|NCT00909259|Sleep Disordered Breathing
445556|NCT00909259|Periodic Breathing
445557|NCT00909259|Cheyne-Stokes Respiration
445558|NCT00909259|Sleep Apnea
445559|NCT00909233|Erectile dysfunction,
445560|NCT00909233|Phosphodiesterase Inhibitors
445561|NCT00909220|Major Depressive Disorder
445562|NCT00909207|Advanced Cancers
445563|NCT00909207|Hematologic Disorders
445564|NCT00909207|Solid Tumors
445565|NCT00909207|Cognitive Interview
445566|NCT00909207|Patient-Reported Outcomes
445567|NCT00909207|PRO
445568|NCT00909207|Common Terminology Criteria for Adverse Events
445569|NCT00909207|CTCAE
445570|NCT00909207|PRO-CTCAE
445571|NCT00909207|Cancer Symptoms
445572|NCT00909207|Interview
445573|NCT00909194|Juvenile Primary Fibromyalgia
445574|NCT00909194|Adolescents
445575|NCT00909194|Psychiatry
445576|NCT00909168|Induction chemotherapy
445577|NCT00909168|Fludarabine
445578|NCT00909168|Gemtuzumab Ozogamicin
445579|NCT00909155|Major Depressive Disorder
445580|NCT00909142|Breast cancer
445581|NCT00909142|Prostate cancer
445582|NCT00909142|Multiple myeloma
445583|NCT00909129|HIV-1
445584|NCT00909129|Chronic hepatitis C
445585|NCT00909129|Immune activation
445586|NCT00909129|HCV kinetics
445587|NCT00909129|IP-10
445588|NCT00909116|ODS
445589|NCT00909116|chronic constipation
445590|NCT00909116|internal rectal prolapse
445591|NCT00909116|rectocele
445592|NCT00909116|Stapled Transanal Rectal Resection
445593|NCT00909116|Contour Transtar
445594|NCT00909116|STARR
445595|NCT00909103|Endoscopic Ultrasound Elastography
445596|NCT00909103|Pancreatic adenocarcinoma
445597|NCT00909103|Chronic Pancreatitis
445598|NCT00909090|macular pigment
445599|NCT00909090|glare disability
445600|NCT00909090|lutein
445601|NCT00909090|photostress
445602|NCT00909077|ITP-Rituximab-dexamethasone
445603|NCT00909051|Diabetes Mellitus
445604|NCT00909012|phenylketonuria
445605|NCT00909012|docosahexaenoic acid
445606|NCT00909012|visually evoked potential
445607|NCT00909012|choice-reaction time
445608|NCT00908999|anosognosia fMRI amnestic MCI Alzheimer
445609|NCT00908999|anosognosia in AD and MCI
445610|NCT00908986|Lupus Membranous Nephritis
445611|NCT00908973|Obesity
445612|NCT00908973|Gastric bypass
445613|NCT00908973|Gut hormone
445614|NCT00908973|Intestinal transit time
445615|NCT00908960|enoxaparin
445616|NCT00908947|SFA
445617|NCT00908947|Stent
445618|NCT00908947|Popliteal
445619|NCT00908947|infrainguinal
445620|NCT00908947|LifeStent
445621|NCT00908947|Peripheral
445622|NCT00908947|Arterial
445623|NCT00908934|Relative Bioavailability
445624|NCT00908934|AZD9056
445625|NCT00908908|Advanced Solid Tumors
445626|NCT00908908|Failure of Multiple Prior Chemotherapy Regimens
445627|NCT00908895|Radius fractures
445628|NCT00908895|Radio-radial fixator
445629|NCT00908895|Percutaneous pinning
445630|NCT00908895|Grip strength
445631|NCT00908882|Nursing Care
445632|NCT00908882|Veterans
445633|NCT00908869|advanced neoplasm
445634|NCT00908869|adult advanced neoplasm
445635|NCT00908856|stroke cell therapy repair autologous
445636|NCT00908843|Contrast nephropathy
445637|NCT00908843|Renal failure
445638|NCT00908817|postoperative sore throat
445639|NCT00908817|tracheal intubation
445640|NCT00908817|lubrication
445641|NCT00908817|triamcinolone
445642|NCT00908804|acute appendicitis
445643|NCT00908791|Conjugated Linoleic Acid
445644|NCT00908791|Proof of Principle
445645|NCT00908791|Lipogenic Pathway
445646|NCT00908791|Clarinol
445647|NCT00908778|Diabetic Retinopathy
445648|NCT00908765|Exercise Training COPD
445649|NCT00908752|HCC
445650|NCT00908739|stage I renal cell cancer
445651|NCT00908739|stage III renal cell cancer
445652|NCT00908739|recurrent renal cell cancer
445653|NCT00908739|clear cell renal cell carcinoma
445654|NCT00908739|childhood renal cell carcinoma
445655|NCT00908713|Severe CAP
445656|NCT00908713|Adjuvant therapy
445657|NCT00908713|Glucocorticoids
445658|NCT00908713|CAP Fine V with C-reactive protein >= 15 mg/100 mL
445659|NCT00908700|Atrial fibrillation
445660|NCT00908700|Stroke
445661|NCT00908700|left atrial appendage
445662|NCT00908700|Re-exploration for bleeding
445663|NCT00908661|Parastomal, hernia
445664|NCT00908648|screening colonoscopy
445665|NCT00908648|narrow band imaging
445666|NCT00908635|sepsis
445667|NCT00908635|organ failure
445668|NCT00908622|Percutaneous implantation of autologous myoblasts
445669|NCT00908609|Breast Cancer Diagnosis
445670|NCT00908609|Optical Imaging
445671|NCT00908609|Ultrasound Imaging
445672|NCT00908609|Monitoring Neoadjuvant Chemotherapy Response
445673|NCT00908596|Nephrogenic Systemic Fibrosis (NSF)
445674|NCT00908596|Primovist / Eovist
445675|NCT00908583|Alloantibody
445676|NCT00908583|Desensitization
445677|NCT00908583|Kidney Transplantation
445678|NCT00908583|Nephrology
445679|NCT00908583|Plasma Cells
445680|NCT00908583|Translational Research/Science
445681|NCT00908570|estrogen
445682|NCT00908570|estriol
445683|NCT00908570|cream
445684|NCT00908570|vagina
445685|NCT00908570|infection prevention
445686|NCT00908557|Lexicosyntactic readability improvement
445687|NCT00908557|phase II/III trials
445688|NCT00908557|ethic
445689|NCT00908557|Informed consent
445690|NCT00908544|HIV-infection
445691|NCT00908544|Primary HIV-infection
445692|NCT00908544|Proviral DNA
445693|NCT00908544|Eradication
445694|NCT00908544|Multi drug class HAART
445695|NCT00908531|Breast neoplasms
445696|NCT00908531|Randomised trial
445697|NCT00908531|Aromatase Inhibitors
445698|NCT00908531|Preoperative care
445699|NCT00908531|Age 60 or older
445700|NCT00908531|Hormone receptor positive tumor
445701|NCT00908531|Tumor lager than 2 cm
445702|NCT00908531|No distant metastasis
445703|NCT00908518|Cognitive dysfunction
445704|NCT00908518|Cardiac morbidity
445705|NCT00908518|anesthesia
445706|NCT00908505|Cystic fibrosis
445707|NCT00908505|physiotherapy
445708|NCT00908505|pulmonary function test
445709|NCT00908492|Randomized control trial
445710|NCT00908492|Dementia caregivers
445711|NCT00908492|Occupational Therapy
445712|NCT00908492|Caregivers
445713|NCT00908479|Exercise
445714|NCT00908479|Rehabilitation
445715|NCT00908479|leg function
445716|NCT00908479|in patient
445717|NCT00908479|RCT
445718|NCT00908466|Non-infectious
445719|NCT00908466|Uveitis
445720|NCT00908466|Panuveitis
445721|NCT00908453|NPC-06
445722|NCT00908453|fosphenytoin
445723|NCT00908453|phenytoin
445724|NCT00908453|pharmacokinetics
445725|NCT00908453|safety
445726|NCT00908440|Decision Aid
445727|NCT00908440|Posttraumatic Stress Disorder
445728|NCT00908440|evidence-based treatments
445729|NCT00908427|benign prostatic hyperplasia
445730|NCT00908427|KTP laser
445731|NCT00908427|transurethral resection of prostate
445732|NCT00908427|urinary bladder neck obstruction
445733|NCT00908414|PEPI-TiDP23-C104
445734|NCT00908414|PEPI-C104
445735|NCT00908414|PEPI
445736|NCT00908414|TMC589337
445737|NCT00908414|TMC589354
445738|NCT00908414|TMC310911
445739|NCT00908414|Healthy Volunteers
445740|NCT00908401|breastmilk
445741|NCT00908401|oral sucrose
445742|NCT00908401|analgesia
445743|NCT00908401|preterm neonates
445744|NCT00908401|Neonates
445745|NCT00908388|Acute, Complicated Type B Dissection
445746|NCT00908375|Pregabalin
445747|NCT00908375|Radicular pain
445748|NCT00908375|Failed back surgery
445749|NCT00908375|Of greater than 3 months duration
445750|NCT00908362|Dendritic cells
445751|NCT00908362|Airway
445752|NCT00908362|Smoker
445753|NCT00908362|COPD
445754|NCT00908336|Adenocarcinoma
445755|NCT00908336|Carcinoma, Non-Small Cell
445756|NCT00908336|Lung Neoplasms
445757|NCT00908336|Docetaxel
445758|NCT00908336|Erlotinib
445759|NCT00908336|Chemotherapy
445760|NCT00908323|HIV Seronegativity
445761|NCT00908323|HIV Preventive Vaccine
445762|NCT00908310|CKD - Chronic Kidney Disease
445763|NCT00908310|GBCA - Gadolinium-based contrast agent
445764|NCT00908310|GFR - Glomerular Filtration Rate
445765|NCT00908310|MRI - Magnetic Resonance Imaging
445766|NCT00908310|NSF - Nephrogenic Systemic Fibrosis
445767|NCT00908310|Known or suspected CKD with an eGFR greater than or equal to 30mL & less than 60 mL/min/1.73m2 as measured within 30 days prior to the OMNISCAN.
445768|NCT00908297|Cardiovascular disease
445769|NCT00908297|End stage renal disease
445770|NCT00908297|Atherosclerosis
445771|NCT00908297|Oxidative stress
445772|NCT00908297|Antioxidants
445773|NCT00908284|AIDS
445774|NCT00908284|Acquired Immune Deficiency Syndrome Virus
445775|NCT00908284|Human Immunodeficiency Virus
445776|NCT00908284|Exercise Physiology
445777|NCT00908284|Endothelial Dysfunction
445778|NCT00908245|Preconditioning
445779|NCT00908245|Hepatectomy
445780|NCT00908245|Clamping
445781|NCT00908232|multiple myeloma
445782|NCT00908232|bortezomib
445783|NCT00908232|hematology
445784|NCT00908232|bone marrow cancer
445785|NCT00908232|immunoglobulin
445786|NCT00908232|refractory
445787|NCT00908232|progression
445788|NCT00908232|dexamethasone
445789|NCT00908232|lenalidomide
445790|NCT00908232|cyclophosphamide
445791|NCT00908219|malignant ascites
445792|NCT00908219|bevacizumab
445793|NCT00908219|vascular endothelial growth factor (VEGF)
445794|NCT00908219|paracentesis
445795|NCT00908206|Alcoholism
445796|NCT00908206|Craving
445797|NCT00908206|Dependence
445798|NCT00908206|Alcohol
445799|NCT00908193|Treatment of abdominal ruptured
445800|NCT00908193|Digestive system disease
445801|NCT00908193|Coelioscopy
445802|NCT00908193|Assistance robotics
445803|NCT00908193|Medical device
445804|NCT00908193|DA VINCI Robot
445805|NCT00908193|Pain patient
445806|NCT00908193|Morphine consumption
445807|NCT00908193|Comparative Randomized study
445808|NCT00908193|patient over 18 years
445809|NCT00908193|with ruptured abdominal
445810|NCT00908193|with an indication of treatment of ruptured
445811|NCT00908180|recurrent adult Hodgkin lymphoma
445812|NCT00908167|sorafenib
445813|NCT00908167|cytarabine
445814|NCT00908167|clofarabine
445815|NCT00908167|acute myeloid leukemia
445816|NCT00908167|acute promyelocytic leukemia
445817|NCT00908167|acute lymphoblastic leukemia
445818|NCT00908154|sodium channel blocker
445819|NCT00908154|bipolar disorder
445820|NCT00908154|repeat dose
445821|NCT00908141|adenocarcinoma of the prostate
445822|NCT00908141|recurrent prostate cancer
445823|NCT00908128|Bioequivalence
445824|NCT00908128|Healthy Subjects
445825|NCT00908102|low back pain
445826|NCT00908102|recurrent
445827|NCT00908102|subacute
445828|NCT00908102|secondary prevention
445829|NCT00908102|primary care
445830|NCT00908102|occupational health
445831|NCT00908102|back book
445832|NCT00908102|rehabilitation
445833|NCT00908089|rheumatoid arthritis
445834|NCT00908089|methotrexate
445835|NCT00908089|sulfasalazine
445836|NCT00908089|hydroxychloroquine
445837|NCT00908089|infliximab
445838|NCT00908076|constipation
445839|NCT00908076|Parkinson's disease
445840|NCT00908063|TBI
445841|NCT00908063|Traumatic Brain Injury
445842|NCT00908050|bruxism, botulinum toxin, sleep study
445843|NCT00908037|idiopathic thrombocytopenic purpura
445844|NCT00908037|ITP
445845|NCT00908037|pharmacokinetics
445846|NCT00908037|chronic ITP
445847|NCT00908037|eltrombopag
445848|NCT00908037|thrombocytopenia
445849|NCT00908037|pharmacodynamics
445850|NCT00908037|pediatrics
445851|NCT00908011|Hypercholesterolemia
445852|NCT00908011|HIV
445853|NCT00908011|Ezetimibe
445854|NCT00908011|Statin
445855|NCT00908011|Apolipoprotein B100/Apolipoprotein A1 ratio
445856|NCT00907998|Coronary heart disease
445857|NCT00907998|APL180
445858|NCT00907985|Healthy Volunteer
445859|NCT00907985|Resting motor threshold (rMT)
445860|NCT00907985|Transcranial magnetic stimulation (TMS)
445861|NCT00907972|Parkinson's Disease
445862|NCT00907972|Parkinson Disease
445863|NCT00907972|PD
445864|NCT00907972|Movement Disorder
445865|NCT00907946|Renal stones
445866|NCT00907907|Bioequivalence
445867|NCT00907907|Subjects
445868|NCT00907894|Chronic hepatitis B,
445869|NCT00907894|telbivudine,
445870|NCT00907894|pharmacokinetics,
445871|NCT00907894|safety,
445872|NCT00907894|tolerability,
445873|NCT00907894|pediatric
445874|NCT00907868|ductal breast carcinoma in situ
445875|NCT00907855|Ischemic Heart Disease
445876|NCT00907855|Duke Activity Status Index
445877|NCT00907855|Stress Myocardial Perfusion Imaging
445878|NCT00907842|stoma
445879|NCT00907829|stroke
445880|NCT00907829|fingertip force
445881|NCT00907829|muscle coordination
445882|NCT00907816|this study does not look at patient conditions
445883|NCT00907803|Orthopoxvirus
445884|NCT00907803|Smallpox
445885|NCT00907803|This is a safety study only
445886|NCT00907803|ST-246 is being studied for treatment of Orthopoxviruses
445887|NCT00907790|Irritable Bowel Syndrome
445888|NCT00907790|Cognitive Therapy
445889|NCT00907790|Abdominal Pain
445890|NCT00907790|Quality of Life
445891|NCT00907777|Haemophilus influenzae
445892|NCT00907777|Streptococcus pneumoniae
445893|NCT00907777|safety
445894|NCT00907777|Pneumococcal conjugate vaccine
445895|NCT00907777|immunogenicity
445896|NCT00907725|medical abortion
445897|NCT00907725|serum BhCG follow-up
445898|NCT00907725|ultrasonographic follow-up
445899|NCT00907725|follow-up methods
445900|NCT00907712|amputation
445901|NCT00907712|vascular
445902|NCT00907712|below knee
445903|NCT00907712|above knee
445904|NCT00907712|cardiovascular
445905|NCT00907712|echo
445906|NCT00907712|cardiovascular assessment
445907|NCT00907699|recurrent non-small cell lung cancer
445908|NCT00907699|stage IIIB non-small cell lung cancer
445909|NCT00907699|stage IV non-small cell lung cancer
445910|NCT00907686|Transfusion Transmitted Cytomegalovirus (TT-CMV)
445911|NCT00907686|Low birthweight infants (LBWIs)
445912|NCT00907686|Leukoreduction and filter failure
445913|NCT00907686|CMV Seronegative blood products
445914|NCT00907660|Obesity
445915|NCT00907660|Weight loss
445916|NCT00907660|Meal replacements
445917|NCT00907660|Health services research
445918|NCT00907634|cervix
445919|NCT00907634|cervical
445920|NCT00907634|radiation
445921|NCT00907621|Infant Colic
445922|NCT00907621|Acupuncture
445923|NCT00907621|General Practice
445924|NCT00907595|Huntington's chorea
445925|NCT00907595|Huntington's Disease
445926|NCT00907595|Parkinson's Disease
445927|NCT00907595|Parkinsonism
445928|NCT00907595|Dementia
445929|NCT00907595|Dementia with Lewy Bodies
445930|NCT00907595|Actigraphy
445931|NCT00907595|Circadian dysregulation
445932|NCT00907595|Sleep Disorders
445933|NCT00907595|Circadian rhythm
445934|NCT00907582|PCR negative
445935|NCT00907569|Small cell lung cancer
445936|NCT00907569|radiotherapy dose escalation
445937|NCT00907543|esophageal carcinoma
445938|NCT00907543|chemotherapy
445939|NCT00907543|radiation
445940|NCT00907543|surgery
445941|NCT00907543|randomized clinical trial
445942|NCT00907543|Clinical Trial
445943|NCT00907543|Radiotherapy
445944|NCT00907491|Cough
445945|NCT00907491|Wheeze Rate
445946|NCT00907491|Respiratory Function Tests
445947|NCT00907478|Idiopathic Thrombocytopenic Purpura
445948|NCT00907478|Idiopathic Thrombocytopenia Purpura
445949|NCT00907478|Immune Thrombocytopenic Purpura
445950|NCT00907478|Immune Thrombocytopenia
445951|NCT00907478|ITP
445952|NCT00907452|Pharmacogenomics
445953|NCT00907452|prediction response
445954|NCT00907452|prediction adverse event
445955|NCT00907439|Diastole, physiopathology
445956|NCT00907439|coronary artery disease
445957|NCT00907439|volatile anesthetic
445958|NCT00907439|sevoflurane
445959|NCT00907426|eyelashes
445960|NCT00907413|cancer
445961|NCT00907413|bile duct
445962|NCT00907400|Phase 1
445963|NCT00907400|Healthy Volunteer
445964|NCT00907400|Healthy Volunteer Study
445965|NCT00907387|Lateral Canthal Lines
445966|NCT00907387|Crow's Feet
445967|NCT00907387|Facial Wrinkles
445968|NCT00907374|Microalbuminuria
445969|NCT00907374|Carotid intima media thickness
445970|NCT00907374|Endothelial dysfunction
445971|NCT00907374|Renin angiotensin system
445972|NCT00907374|Diabetic nephropathy
445973|NCT00907361|pacemaker
445974|NCT00907361|ICD
445975|NCT00907361|Implantable Cardioverter Defibrillator
445976|NCT00907361|MRI
445977|NCT00907361|Magnetic Resonance Imaging
445978|NCT00907348|NHL
445979|NCT00907348|Non Hodgkin Lymphoma
445980|NCT00907348|Follicular Lymphoma
445981|NCT00907335|acne
445982|NCT00907335|irritation
445983|NCT00907335|objective sensory methods
445984|NCT00907322|oral, single ascending doses; CYP2D6 metabolizer status; healthy subjects; safety, tolerability, pharmacokinetics
445985|NCT00907309|alcohol abuse
445986|NCT00907309|marijuana abuse
445987|NCT00907309|drug abuse
445988|NCT00907309|tobacco use
445989|NCT00907309|tobacco dependence
445990|NCT00907296|Fracture Healing
445991|NCT00907296|Tibial Diaphyseal Fracture
445992|NCT00907283|NBIA
445993|NCT00907283|Iron overload AND brain
445994|NCT00907283|Iron chelation AND neurodegeneration
445995|NCT00907283|Brain iron Overload
445996|NCT00907283|Neurodegeneration
445997|NCT00907283|Brain iron Accumulation
445998|NCT00907257|acne
445999|NCT00907257|irritation
446000|NCT00907257|objective sensory methods
446001|NCT00907218|ADHD
446002|NCT00907218|Attention Deficit Hyperactivity Disorder
446003|NCT00907218|ADHD medication
446004|NCT00907218|Chantix
446005|NCT00907218|varenicline
446006|NCT00907218|smoking
446007|NCT00907218|smoking cessation
446008|NCT00907218|quit smoking
446009|NCT00907205|Advanced Solid Tumors
446010|NCT00907205|Metastatic Solid Tumors
446011|NCT00907205|PI3K
446012|NCT00907205|PI3K Inhibitors
446013|NCT00907205|PI3 Kinase Inhibitors
446014|NCT00907205|mTORC inhibitor
446015|NCT00907205|mTORC1 inhibitor
446016|NCT00907205|mTORC2 inhibitor
446017|NCT00907205|vascular targeted
446018|NCT00907205|conjugate
446019|NCT00907192|Cancer
446020|NCT00907192|Opioid analgesic prescriptions
446021|NCT00907192|Narcotic pain drugs
446022|NCT00907192|Self-report
446023|NCT00907192|Questionnaire
446024|NCT00907192|Interview
446025|NCT00907192|Actual use
446026|NCT00907192|Doctor-prescribed use
446027|NCT00907192|Frequency of deviation
446028|NCT00907166|Cornerstone Pharmaceuticals, Inc.
446029|NCT00907166|CPI-613
446030|NCT00907166|Altered Energy Metabolism Directed Compound
446031|NCT00907166|Phase I
446032|NCT00907166|Phase II
446033|NCT00907166|Cancer
446034|NCT00907166|Carcinoma of the Pancreas
446035|NCT00907166|Pancreatic Cancer
446036|NCT00907166|Pancreatic Carcinoma
446037|NCT00907153|Polycystic Ovary Syndrome
446038|NCT00907153|Vitamin D
446039|NCT00907153|Insulin resistance
446040|NCT00907153|Inflammation
446041|NCT00907140|Cervical Cancer
446042|NCT00907140|Positron Emission Tomography
446043|NCT00907140|Fluorodeoxyglucose
446044|NCT00907127|Metabolic
446045|NCT00907127|Syndrome
446046|NCT00907127|CAN
446047|NCT00907114|proliferative diabetic retinopathy
446048|NCT00907114|macular edema
446049|NCT00907114|panphotocoagulation
446050|NCT00907114|topic ketorolac
446051|NCT00907114|efficacy
446052|NCT00907114|treatment
446053|NCT00907088|Iron depletion
446054|NCT00907088|Children
446055|NCT00907088|Educational intervention
446056|NCT00907088|Office-based
446057|NCT00907075|diabetes
446058|NCT00907075|nutrition
446059|NCT00907075|diet
446060|NCT00907075|foods
446061|NCT00907062|vitiligo
446062|NCT00907062|leucoderma
446063|NCT00907049|quality of sleep
446064|NCT00907049|neck pain
446065|NCT00907049|disability
446066|NCT00907049|catastrophizing
446067|NCT00907049|depression
446068|NCT00907036|recurrent adult Hodgkin lymphoma
446069|NCT00907023|solid organ transplant
446070|NCT00907023|hospital discharge
446071|NCT00907010|Ageing
446072|NCT00907010|Sarcopenia
446073|NCT00907010|Muscular contraction
446074|NCT00906997|Colorectal cancer
446075|NCT00906997|Screening
446076|NCT00906997|Prevention
446077|NCT00906997|Fecal occult blood test
446078|NCT00906997|Colonoscopy
446079|NCT00906997|Colorectal neoplasm
446080|NCT00906997|Randomized clinical trial
446081|NCT00906984|Hepatocellular carcinoma
446082|NCT00906984|Liver cancer
446083|NCT00906984|Primary liver cancer
446084|NCT00906984|Unresectable liver cancer
446085|NCT00906984|Unresectable hepatocellular carcinoma
446086|NCT00906984|TheraSphere
446087|NCT00906971|Physical Therapy
446088|NCT00906971|Chronic Functional Constipation
446089|NCT00906971|Children
446090|NCT00906945|stem cell mobilization
446091|NCT00906945|chemosensitization
446092|NCT00906945|CXCR4
446093|NCT00906945|SDF-1
446094|NCT00906945|CXCL-12
446095|NCT00906932|Fiberoptic intubation
446096|NCT00906932|direct laryngoscopy
446097|NCT00906932|Trachview
446098|NCT00906932|Comparison of a fiberoptic intubating videoscope to direct laryngoscopy.
446099|NCT00906919|self-efficacy
446100|NCT00906919|health behavior
446101|NCT00906919|patient education
446102|NCT00906919|health education
446103|NCT00906893|[18F]-FMISO uptake
446104|NCT00906893|Glioblastoma
446105|NCT00906893|Hypoxia
446106|NCT00906893|tumours
446107|NCT00906880|Human African Trypanosomiasis
446108|NCT00906880|HAT
446109|NCT00906880|sleeping sickness
446110|NCT00906880|combination treatment
446111|NCT00906880|nifurtimox
446112|NCT00906880|eflornithine
446113|NCT00906880|Human African Trypanosomiasis in the meningo-encephalitic phase (stage 2 HAT)
446114|NCT00906867|Vocal cord dysfunction
446115|NCT00906867|Laryngoscopy
446116|NCT00906867|Methacholine challenge
446117|NCT00906867|Pulmonary function testing
446118|NCT00906854|urinary incontinence
446119|NCT00906854|physical exercise
446120|NCT00906841|Disseminated diffuse large B-cell lymphoma
446121|NCT00906841|first line treatment
446122|NCT00906841|R CHOP
446123|NCT00906841|90Y-DOTA-hLL2
446124|NCT00906841|Patients older than 60 years
446125|NCT00906828|Levodopa/carbidopa infusion
446126|NCT00906828|entacapone
446127|NCT00906828|tolcapone
446128|NCT00906828|efficacy
446129|NCT00906828|pharmacokinetic
446130|NCT00906828|pharmacodynamics
446131|NCT00905957|transversus abdominis plane block
446132|NCT00905957|relief
446133|NCT00905944|Left ventricular failure
446134|NCT00905944|chronic heart failure
446135|NCT00905944|Pacemaker
446136|NCT00905944|Resynchronisation therapy
446137|NCT00905944|Exercise
446138|NCT00905944|Endurance exercise
446139|NCT00905931|Aneurysmal subarachnoid hemorrhage (aSAH)
446140|NCT00905931|Cerebral vasospasm
446141|NCT00905931|impaired cerebral autoregulation
446142|NCT00905931|transient hyperaemic response test
446143|NCT00905931|delayed ischaemic neurological deficits
446144|NCT00905918|colon cancer
446145|NCT00905918|rectal cancer
446146|NCT00906802|pancreaticoduodenectomy
446147|NCT00906802|reconstruction
446148|NCT00906789|Lung Cancer
446149|NCT00906789|Chest Radiograph
446150|NCT00906789|Computer-aided Detection
446151|NCT00906789|Image processing
446152|NCT00906763|Parkinson's disease
446153|NCT00906763|Neurodegenerative Disorders
446154|NCT00906763|Biogenic amines
446155|NCT00906763|Chocolate
446156|NCT00906763|Cocoa
446157|NCT00906750|FLuMIST
446158|NCT00906750|Inactivated influenza vaccine
446159|NCT00906750|Study of FluMist versus inactivated influenza vaccine in children with cancer
446160|NCT00906737|Multiple Sclerosis
446161|NCT00906737|Gait
446162|NCT00906737|foot-drop
446163|NCT00906737|Ankle-Bot
446164|NCT00906737|Physical Therapy
446165|NCT00906737|Gait Abnormalities
446166|NCT00906711|Aging
446167|NCT00906711|Postural Balance
446168|NCT00906685|CRVO
446169|NCT00906685|anti-VEGF
446170|NCT00906685|Macular edema
446171|NCT00906672|Dermal substitute Integra®
446172|NCT00906672|Flap
446173|NCT00906672|graft
446174|NCT00906672|traumatic wound
446175|NCT00906672|medico economic costs
446176|NCT00906672|esthetical and functional scar results
446177|NCT00906659|center point thickness
446178|NCT00906659|diabetic retinopathy
446179|NCT00906659|diabetic macular edema
446180|NCT00906659|macular volume
446181|NCT00906659|visual capacity
446182|NCT00906659|visual function
446183|NCT00906646|cardiac
446184|NCT00906646|surgery
446185|NCT00906646|metabolic
446186|NCT00906646|supplements
446187|NCT00906646|antioxidant
446188|NCT00906633|antifungal therapies
446189|NCT00906620|Data on student's healthy and at-risk lifestyles and their relation with health measured by well-being, depression and suicidality
446190|NCT00906607|Urinary Incontinence
446191|NCT00906581|Depression
446192|NCT00906568|Cystic fibrosis
446193|NCT00906568|Sensitization to Aspergillus
446194|NCT00906568|Bronchial allergen challenge
446195|NCT00906568|Induced Sputum
446196|NCT00906568|Bronchial inflammation
446197|NCT00906568|Small airways disease (SAD)
446198|NCT00906542|acute stroke
446199|NCT00906542|ischemic stroke
446200|NCT00906542|pneumonia
446201|NCT00906542|chest infection
446202|NCT00906542|brain lesion
446203|NCT00906542|lesion topology
446204|NCT00906542|dysphagia
446205|NCT00906542|sympathetic activation
446206|NCT00906542|immunosuppression
446207|NCT00906529|Type 2 Diabetes
446208|NCT00906529|Inpatient
446209|NCT00906529|Length of Stay
446210|NCT00906529|Blood Glucose Control
446211|NCT00906516|Recurrent Glioblastoma multiforme (GBM)
446212|NCT00906516|Recurrent Brain Tumor
446213|NCT00906516|Recurrent Brain Disease
446214|NCT00906516|Neuradiab
446215|NCT00906516|Avastin
446216|NCT00906516|Bevacizumab
446217|NCT00906503|pulmonary nodule
446218|NCT00906490|Glucose Monitoring
446219|NCT00906490|Accurate Blood Glucose Monitoring in critical care setting
446220|NCT00906451|myocardial infarction
446221|NCT00906451|inflammation
446222|NCT00906451|endothelial dysfunction
446223|NCT00906425|Dental Implant
446224|NCT00906412|Essential Tremor
446225|NCT00906399|interferon
446226|NCT00906399|injectable
446227|NCT00906399|MS
446228|NCT00906399|SC
446229|NCT00906399|PEGylated
446230|NCT00906399|Interferon beta-1a
446231|NCT00906399|relapsing
446232|NCT00906399|PEG
446233|NCT00906399|multiple sclerosis
446234|NCT00906399|subcutaneous
446235|NCT00906386|Varenicline
446236|NCT00906373|Hepatocellular Carcinoma
446237|NCT00906373|Liver Neoplasms
446238|NCT00906373|Antibodies, Monoclonal
446239|NCT00906347|Labor augmentation
446240|NCT00906347|Oral misoprostol
446241|NCT00906334|Myelodysplastic Syndrome
446242|NCT00906334|Trisomy 8
446243|NCT00906334|Intermediate-2 Risk Group
446244|NCT00906334|High-Risk Group
446245|NCT00906334|azacitidine
446246|NCT00906334|azacytidine
446247|NCT00906334|Vidaza
446248|NCT00906334|decitabine
446249|NCT00906334|Dacogen
446250|NCT00906321|Web-Based Decision Support
446251|NCT00906321|Breast Cancer Risk
446252|NCT00906295|Hemoglobin
446253|NCT00906295|Ambulation
446254|NCT00906282|neoadjuvant NSCLC
446255|NCT00906282|NSCLC
446256|NCT00906282|pemetrexed
446257|NCT00906269|impotence
446258|NCT00906269|prostatic neoplasms
446259|NCT00906269|hyperbaric oxygenation
446260|NCT00906269|Phosphodiesterase Inhibitors
446261|NCT00906256|Hepatitis C
446262|NCT00906256|Pharmacokinetics
446263|NCT00906256|AZD7295
446264|NCT00906256|Healthy volunteers
446265|NCT00906217|colonoscopy
446266|NCT00906217|preparation
446267|NCT00906217|safety
446268|NCT00906217|elderly
446269|NCT00906204|Renal transplantation
446270|NCT00906204|Kidney transplantation
446271|NCT00906178|HIV prevention
446272|NCT00906178|technology
446273|NCT00906178|adolescent
446274|NCT00906178|developing countries
446275|NCT00906152|quality of sleep
446276|NCT00906152|low back pain
446277|NCT00906152|disability
446278|NCT00906152|catastrophizing
446279|NCT00906152|depression
446280|NCT00906139|Propofol
446281|NCT00906139|Midazolam
446282|NCT00906139|Cirrhosis
446283|NCT00906139|Gastrointestinal endoscopy
446284|NCT00906139|Complications
446285|NCT00906139|Sedation
446286|NCT00906126|oral misoprostol
446287|NCT00906126|labor augmentation
446288|NCT00906126|arrest of dilation
446289|NCT00906126|nulliparous
446290|NCT00906113|Retinoblastoma
446291|NCT00906100|Biventricular ICD
446292|NCT00906100|AV delay
446293|NCT00906087|Myocilin gene
446294|NCT00906087|Glaucoma
446295|NCT00906087|dorzolamide and timolol combination eyedrop
446296|NCT00906074|Surgical Wound Infection
446297|NCT00906074|Surgical Site Infection
446298|NCT00906074|Abdominal Surgery
446299|NCT00906061|Carcinoma, Small Cell
446300|NCT00906061|Lung Neoplasms
446301|NCT00906061|Docetaxel
446302|NCT00906061|Gemcitabine
446303|NCT00906061|ECOG 2
446304|NCT00906035|Peripheral Arterial Disease
446305|NCT00906035|PAD
446306|NCT00906035|Claudication
446307|NCT00906035|Peripheral Vascular Disease
446308|NCT00906022|Below the Knee
446309|NCT00906022|Infrapopliteal arteries
446310|NCT00906022|nitinol
446311|NCT00906022|limb ischemia
446312|NCT00906022|claudication
446313|NCT00906022|self-expanding stent
446314|NCT00906022|duplex
446315|NCT00906022|angiography
446316|NCT00905983|Carcinoma, Non-Small-Cell
446317|NCT00905983|Elderly patients
446318|NCT00905983|Docetaxel
446319|NCT00905983|Gemcitabine
446320|NCT00905905|myocardial infarction
446321|NCT00905905|systemic inflammatory activity
446322|NCT00905905|endothelial function
446323|NCT00905892|overfeeding
446324|NCT00905892|stable isotopes
446325|NCT00905892|lipoprotein metabolism
446326|NCT00905892|lipid oxidation
446327|NCT00905892|fat distribution
446328|NCT00905892|gene expression
446329|NCT00905892|endotoxemia
446330|NCT00905892|mass spectrometry/gas chromatography
446331|NCT00905879|Magnetic Resonance Imaging (MRI)
446332|NCT00905879|Observational study
446333|NCT00905879|Gadobutrol
446334|NCT00905866|Quality of life
446335|NCT00905866|Hyperparathyroidism
446336|NCT00905853|Ventricular Tachycardia
446337|NCT00905853|Catheter Ablation
446338|NCT00905853|ICD therapy
446339|NCT00905853|Antiarrhythmic Drug Therapy
446340|NCT00905853|Ischemic Heart Disease
446341|NCT00905827|suicide
446342|NCT00905827|assessment
446343|NCT00905827|management
446344|NCT00905827|Provider Training
446345|NCT00905827|health services
446346|NCT00905814|Bioequivalence
446347|NCT00905801|Non small cell lung cancer
446348|NCT00905801|NSCLC
446349|NCT00905801|CTP
446350|NCT00905801|Perfusion
446351|NCT00905801|Imaging
446352|NCT00905788|Embryo transfer
446353|NCT00905788|IVF/ICSI
446354|NCT00905788|Embryo expulsion
446355|NCT00905775|Isoflurane;
446356|NCT00905775|Propofol
446357|NCT00905775|Renal functions tests
446358|NCT00905775|Cardiovascular tests
446359|NCT00905775|revascularization surgery of the myocardium
446360|NCT00905775|extracorporeal circulation
446361|NCT00905762|pharmacokinetics
446362|NCT00905736|tendon
446363|NCT00905736|healing
446364|NCT00905736|microcurrent
446365|NCT00905736|chronic tennis elbow
446366|NCT00905723|climacterium
446367|NCT00905723|sexual life
446368|NCT00905723|isoflavone
446369|NCT00905723|estrogen
446370|NCT00905723|McCoy's sexual questionnaire
446371|NCT00905723|Kupperman index
446372|NCT00905710|colorectal adenomas
446373|NCT00905710|colorectal cancer
446374|NCT00905710|Lynch syndrome
446375|NCT00905710|chromoendoscopy
446376|NCT00905697|Living donor lung transplantation
446377|NCT00905697|Health-related quality of life
446378|NCT00905697|Prognosis
446379|NCT00905697|Patient reported outcome
446380|NCT00905684|Compliance
446381|NCT00905684|Hormonal Contraception
446382|NCT00905671|Lipid Core Plaque
446383|NCT00905671|LCP
446384|NCT00905671|Bifurcation
446385|NCT00905671|Stenosis
446386|NCT00905671|Lesion
446387|NCT00905671|Angioplasty
446388|NCT00905658|stage IVA cervical cancer
446389|NCT00905658|stage IVB cervical cancer
446390|NCT00905658|fallopian tube cancer
446391|NCT00905658|stage IV ovarian epithelial cancer
446392|NCT00905658|stage IV ovarian germ cell tumor
446393|NCT00905658|ovarian sarcoma
446394|NCT00905658|ovarian stromal cancer
446395|NCT00905658|stage IV endometrial carcinoma
446396|NCT00905658|stage IV uterine sarcoma
446397|NCT00905658|stage IVA vaginal cancer
446398|NCT00905658|stage IVB vaginal cancer
446399|NCT00905658|stage IV vulvar cancer
446400|NCT00905645|Breast Augmentation
446401|NCT00905645|Breast Reconstruction
446402|NCT00905645|Breast Revision
446403|NCT00905645|Silicone breast implants
446404|NCT00905606|Bioequivalence
446405|NCT00905606|Healthy Subjects
446406|NCT00905593|chronic myeloid leukemia,
446407|NCT00905593|blast crisis,
446408|NCT00905593|accelerated phase,
446409|NCT00905593|nilotinib,
446410|NCT00905593|imatinib,
446411|NCT00905593|resistant,
446412|NCT00905593|intolerant,
446413|NCT00905593|chronic phase
446414|NCT00905580|thyroidectomy
446415|NCT00905580|pain, postoperative
446416|NCT00905580|pregabalin
446417|NCT00905567|Bioequivalence
446418|NCT00905567|Healthy Subjects
446419|NCT00905554|sedation
446420|NCT00905554|warm water
446421|NCT00905528|type 2 diabetes mellitus
446422|NCT00905528|endothelial function
446423|NCT00905528|renal hemodynamics
446424|NCT00905515|Kidney Transplantation
446425|NCT00905515|Immunosuppressive Agents
446426|NCT00905502|Obesity
446427|NCT00905502|fluid management
446428|NCT00905502|postoperative complications
446429|NCT00905502|bariatric surgery
446430|NCT00905502|hemostasis
446431|NCT00905476|NPPV
446432|NCT00905476|Prognosis
446433|NCT00905476|Health-related quality of life
446434|NCT00905476|Patient reported outcomes
446435|NCT00905463|Lung transplant candidates
446436|NCT00905463|Health-related quality of life
446437|NCT00905463|patient reported outcome
446438|NCT00905463|Prognosis
446439|NCT00905450|Surgery
446440|NCT00905437|perioperative
446441|NCT00905437|pregabalin
446442|NCT00905437|total hip replacement
446443|NCT00905437|post-operative pain
446444|NCT00905411|Overweight
446445|NCT00905411|blood pressure
446446|NCT00905411|DASH diet
446447|NCT00905411|Pacific
446448|NCT00905411|children
446449|NCT00905398|Leukemia
446450|NCT00905398|Lymphoblastic
446451|NCT00905398|Acute
446452|NCT00905398|Philadelphia
446453|NCT00905398|BCR-ABL
446454|NCT00905398|Nilotinib
446455|NCT00905398|Treatment
446456|NCT00905385|nontypeable Haemophilus influenzae, NTHi
446457|NCT00905346|Bioequivalence
446458|NCT00905346|Healthy Subjects
446459|NCT00905333|pharmacokinetics
446460|NCT00905333|candesartan
446461|NCT00905333|felodipine
446462|NCT00905333|test formulations
446463|NCT00905333|Atacand®
446464|NCT00905333|Splendil®
446465|NCT00905333|healthy volunteers
446466|NCT00905333|blood samples
446467|NCT00905333|after meal intake interaction
446468|NCT00905333|Kinetic interaction amongst test formulations of Candesartan and Felodipine and the brands Atacand® and Splendil® in healthy volunteers after a fasting period.
446469|NCT00905320|Hernia repair
446470|NCT00905307|Schizophrenia
446471|NCT00905307|Relapsed
446472|NCT00905281|Metastatic breast cancer
446473|NCT00905281|Supportive care
446474|NCT00905281|Third or fourth line of chemotherapy
446475|NCT00905281|Quality of life
446476|NCT00905281|Treatment preferences
446477|NCT00905268|FRDA
446478|NCT00905268|idebenone
446479|NCT00905268|FRDA disease
446480|NCT00905255|hyperglycemia
446481|NCT00905255|GLP-1
446482|NCT00905242|Kidney Transplantation
446483|NCT00905242|Gastrointestinal Agents
446484|NCT00905229|hip fracture
446485|NCT00905229|warfarin
446486|NCT00905229|vitamin k
446487|NCT00905229|Phytonadione
446488|NCT00905229|INR level
446489|NCT00905216|heparin
446490|NCT00905203|Postmenopausal women
446491|NCT00905203|Diabetes
446492|NCT00905203|Skin microcirculation
446493|NCT00905203|Exercise capacity
446494|NCT00905203|Skeletal muscle oxygenation
446495|NCT00905203|Dose-response relationship
446496|NCT00905203|postmenopausal diabetic women
446497|NCT00905177|Atrial Fibrillation
446498|NCT00905177|deep vein thrombosis
446499|NCT00905177|anticoagulation
446500|NCT00905177|warfarin
446501|NCT00905177|coumadin
446502|NCT00905164|Bioequivalence
446503|NCT00905164|Healthy Subjects
446504|NCT00905151|HIV positive
446505|NCT00905151|AIDS
446506|NCT00905151|antiretroviral
446507|NCT00905151|Kidney disease
446508|NCT00905151|Antiretroviral Therapy
446509|NCT00905138|Safety
446510|NCT00905138|Tolerability
446511|NCT00905138|Pharmacokinetics
446512|NCT00905125|influenza, trivalent, vaccine, pregnant women
446513|NCT00905112|Pregnancy
446514|NCT00905112|Pain
446515|NCT00905112|Musculoskeletal manipulations
446516|NCT00905112|Exercise
446517|NCT00905086|cognitive/functional effects
446518|NCT00905086|psychosocial effects of cancer and its treatment
446519|NCT00905086|stage I breast cancer
446520|NCT00905086|stage II breast cancer
446521|NCT00905086|stage IIIA breast cancer
446522|NCT00905086|stage IIIB breast cancer
446523|NCT00905086|stage IIIC breast cancer
446524|NCT00905086|stage I colon cancer
446525|NCT00905086|stage II colon cancer
446526|NCT00905086|stage III colon cancer
446527|NCT00905086|stage I rectal cancer
446528|NCT00905086|stage II rectal cancer
446529|NCT00905086|stage III rectal cancer
446530|NCT00905086|stage I non-small cell lung cancer
446531|NCT00905086|stage II non-small cell lung cancer
446532|NCT00905086|stage IIIA non-small cell lung cancer
446533|NCT00905086|stage IIIB non-small cell lung cancer
446534|NCT00905086|stage I prostate cancer
446535|NCT00905086|stage II prostate cancer
446536|NCT00905086|stage III prostate cancer
446537|NCT00905086|extensive stage small cell lung cancer
446538|NCT00905086|limited stage small cell lung cancer
446539|NCT00905073|type 1 diabetes mellitus
446540|NCT00905073|cyclosporin
446541|NCT00905073|methotrexate
446542|NCT00905073|renal function
446543|NCT00905060|Newly Diagnosed Glioblastoma Multiforme, vaccine
446544|NCT00905047|colo-rectal cancer
446545|NCT00905047|advanced
446546|NCT00905047|metastatic
446547|NCT00905047|locally advanced or metastatic colo-rectal cancer
446548|NCT00905034|Acute lymphoblastic leukemia
446549|NCT00905034|ALL
446550|NCT00905034|Leukemia
446551|NCT00905034|Methotrexate
446552|NCT00905034|Vincristine
446553|NCT00905034|PEG-l-asparaginase
446554|NCT00905034|PEG asparaginase
446555|NCT00905034|Pegaspargase
446556|NCT00905034|Oncaspar
446557|NCT00905034|Polyethylene Glycol Conjugated Lasparaginase-H
446558|NCT00905034|Dexamethasone
446559|NCT00905034|Decadron
446560|NCT00905034|Rituximab
446561|NCT00905034|Rituxan
446562|NCT00905021|Breast Cancer
446563|NCT00905021|Metastatic
446564|NCT00905021|Hormone Receptor Positive
446565|NCT00905008|drug-eluting stent
446566|NCT00905008|bare-metal stent
446567|NCT00905008|long-term safety
446568|NCT00905008|mortality
446569|NCT00905008|stent thrombosis
446570|NCT00905008|Angioplasty
446571|NCT00905008|Transluminal
446572|NCT00905008|Percutaneous Coronary
446573|NCT00904995|Leukemia
446574|NCT00904995|Cancer of the blood
446575|NCT00904995|Cancer of the bone marrow
446576|NCT00904995|Hematologic malignancy
446577|NCT00904995|Invasive fungal infection
446578|NCT00904995|Voriconazole
446579|NCT00904995|Vfend
446580|NCT00904995|antifungal prophylaxis
446581|NCT00904982|warfarin
446582|NCT00904982|coumadin
446583|NCT00904982|adherence
446584|NCT00904982|mechanical heart valves
446585|NCT00904969|Urinary Incontinence, Stress
446586|NCT00904969|Intrinsic sphincter deficiency
446587|NCT00904969|Secondary
446588|NCT00904969|TUR
446589|NCT00904969|TURP
446590|NCT00904969|Radical prostatectomy
446591|NCT00904969|Open prostatectomy
446592|NCT00904969|Post-suprapubic prostatectomy
446593|NCT00904956|Latent Tuberculosis Infection
446594|NCT00904956|High Resolution Scanners
446595|NCT00904956|Dynamic Hypothesis of Latent Tuberculosis Infection
446596|NCT00904943|Bioequivalence
446597|NCT00904943|Healthy Subjects
446598|NCT00904930|Tooth mobility assessment
446599|NCT00904930|Splinting
446600|NCT00904930|Splint Rigidity
446601|NCT00904917|African American Mothers
446602|NCT00904917|Children
446603|NCT00904917|African American Families
446604|NCT00904917|Parental Depression
446605|NCT00904917|Preventive Intervention
446606|NCT00904891|Adolescents
446607|NCT00904891|Prevention
446608|NCT00904891|Bibliotherapy
446609|NCT00904878|pregnant IBD patients
446610|NCT00904865|Single port access
446611|NCT00904865|Laparoscopy
446612|NCT00904865|cholecystectomy
446613|NCT00904865|cholangiography
446614|NCT00904865|cosmesis
446615|NCT00904826|NMO
446616|NCT00904826|Devic's disease
446617|NCT00904826|Neuromyelitis optica
446618|NCT00904826|NMO-IgG
446619|NCT00904826|Aquaporin-4 antibody
446620|NCT00904826|Eculizumab
446621|NCT00904826|Complement
446622|NCT00904813|Rectal cancer
446623|NCT00904813|Preoperative radiotherapy
446624|NCT00904813|Timing of Surgery
446625|NCT00904813|Prognosis
446626|NCT00904800|Phase I
446627|NCT00904800|Healthy volunteers
446628|NCT00904787|Leukemia
446629|NCT00904787|Hematologic neoplasms
446630|NCT00904774|bronchopulmonary dysplasia
446631|NCT00904774|neonates
446632|NCT00904774|lung development
446633|NCT00904774|prematurity
446634|NCT00904761|diabetes mellitus
446635|NCT00904761|autonomic neuropathy
446636|NCT00904761|exercise training
446637|NCT00904761|exercise capacity
446638|NCT00904761|heart rate variability
446639|NCT00904748|Sildenafil
446640|NCT00904748|Bio-equivalence
446641|NCT00904735|adult grade I meningioma
446642|NCT00904735|adult grade II meningioma
446643|NCT00904735|adult anaplastic meningioma
446644|NCT00904735|adult papillary meningioma
446645|NCT00904735|recurrent adult brain tumor
446646|NCT00904722|Follicular lymphoma
446647|NCT00904722|Immunotherapy
446648|NCT00904722|CT-011
446649|NCT00904722|Monoclonal Antibody CT-011
446650|NCT00904722|Rituximab
446651|NCT00904722|Rituxan
446652|NCT00904696|Irritable bowel syndrome
446653|NCT00904696|probiotics
446654|NCT00904670|Hyperactivity Attention Deficit Disorder
446655|NCT00904670|ADHD
446656|NCT00904670|Pediatric Patients
446657|NCT00904670|Quillivant
446658|NCT00904670|methylphenidate
446659|NCT00904657|pharmacokinetic/pharmacodynamic modeling
446660|NCT00904657|biomarkers (growth factors) as a possible tool of drug effect
446661|NCT00904644|HIV
446662|NCT00904644|antiretroviral treatment
446663|NCT00904644|Swiss HIV Cohort Study
446664|NCT00904644|drug resistance
446665|NCT00904644|integrase inhibitor
446666|NCT00904644|Treatment
446667|NCT00904618|Suburethral slings
446668|NCT00904618|Urethra
446669|NCT00904618|Urinary incontinence
446670|NCT00904618|Urinary stress incontinence
446671|NCT00904592|diabetic retinopathy
446672|NCT00904592|traditional chinese medicine
446673|NCT00904579|Organ Transplants
446674|NCT00904579|Immunosuppression
446675|NCT00904579|Cancer
446676|NCT00904579|End Stage Renal Disease
446677|NCT00904579|ESRD
446678|NCT00904579|Cancer Risk
446679|NCT00904566|microarray
446680|NCT00904566|gene expression profiling
446681|NCT00904566|MammaPrint
446682|NCT00904566|breast cancer
446683|NCT00904553|Brain
446684|NCT00904553|metastases
446685|NCT00904527|Relaxation (Schultz)
446686|NCT00904527|Migraine
446687|NCT00904527|antipain center
446688|NCT00904514|recurrent adult Hodgkin lymphoma
446689|NCT00904514|stage IV cutaneous T-cell non-Hodgkin lymphoma
446690|NCT00904514|recurrent cutaneous T-cell non-Hodgkin lymphoma
446691|NCT00904514|Waldenström macroglobulinemia
446692|NCT00904514|recurrent adult acute myeloid leukemia
446693|NCT00904514|recurrent adult acute lymphoblastic leukemia
446694|NCT00904514|relapsing chronic myelogenous leukemia
446695|NCT00904514|refractory chronic lymphocytic leukemia
446696|NCT00904514|refractory hairy cell leukemia
446697|NCT00904514|recurrent small lymphocytic lymphoma
446698|NCT00904514|recurrent grade 1 follicular lymphoma
446699|NCT00904514|recurrent grade 2 follicular lymphoma
446700|NCT00904514|recurrent grade 3 follicular lymphoma
446701|NCT00904514|recurrent adult diffuse small cleaved cell lymphoma
446702|NCT00904514|recurrent adult diffuse mixed cell lymphoma
446703|NCT00904514|recurrent adult diffuse large cell lymphoma
446704|NCT00904514|recurrent adult immunoblastic large cell lymphoma
446705|NCT00904514|recurrent adult lymphoblastic lymphoma
446706|NCT00904514|recurrent adult Burkitt lymphoma
446707|NCT00904514|stage I adult T-cell leukemia/lymphoma
446708|NCT00904514|stage II adult T-cell leukemia/lymphoma
446709|NCT00904514|stage III adult T-cell leukemia/lymphoma
446710|NCT00904514|stage IV adult T-cell leukemia/lymphoma
446711|NCT00904514|recurrent adult T-cell leukemia/lymphoma
446712|NCT00904514|prolymphocytic leukemia
446713|NCT00904514|recurrent mantle cell lymphoma
446714|NCT00904514|stage IV mycosis fungoides/Sezary syndrome
446715|NCT00904514|recurrent mycosis fungoides/Sezary syndrome
446716|NCT00904514|recurrent marginal zone lymphoma
446717|NCT00904514|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
446718|NCT00904514|nodal marginal zone B-cell lymphoma
446719|NCT00904514|splenic marginal zone lymphoma
446720|NCT00904514|stage IV colon cancer
446721|NCT00904514|stage IV breast cancer
446722|NCT00904514|recurrent breast cancer
446723|NCT00904514|stage IV gastric cancer
446724|NCT00904514|recurrent gastric cancer
446725|NCT00904514|recurrent non-small cell lung cancer
446726|NCT00904514|recurrent pancreatic cancer
446727|NCT00904514|recurrent colon cancer
446728|NCT00904514|stage IV esophageal cancer
446729|NCT00904514|recurrent esophageal cancer
446730|NCT00904514|recurrent bladder cancer
446731|NCT00904514|stage IV bladder cancer
446732|NCT00904514|recurrent ovarian epithelial cancer
446733|NCT00904514|epithelial mesothelioma
446734|NCT00904514|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
446735|NCT00904514|recurrent salivary gland cancer
446736|NCT00904514|recurrent squamous cell carcinoma of the nasopharynx
446737|NCT00904514|stage III cervical cancer
446738|NCT00904514|recurrent cervical cancer
446739|NCT00904514|stage IVB cervical cancer
446740|NCT00904514|stage IVA cervical cancer
446741|NCT00904514|squamous cell lung cancer
446742|NCT00904514|stage III ovarian epithelial cancer
446743|NCT00904514|stage IV ovarian epithelial cancer
446744|NCT00904514|advanced malignant mesothelioma
446745|NCT00904514|recurrent malignant mesothelioma
446746|NCT00904514|stage IIIA non-small cell lung cancer
446747|NCT00904514|stage IIIB non-small cell lung cancer
446748|NCT00904514|stage IV non-small cell lung cancer
446749|NCT00904514|recurrent metastatic squamous neck cancer with occult primary
446750|NCT00904514|ovarian undifferentiated adenocarcinoma
446751|NCT00904514|ovarian mixed epithelial carcinoma
446862|NCT00904124|eating behaviour
446752|NCT00904514|ovarian serous cystadenocarcinoma
446753|NCT00904514|ovarian endometrioid adenocarcinoma
446754|NCT00904514|ovarian clear cell cystadenocarcinoma
446755|NCT00904514|cervical squamous cell carcinoma
446756|NCT00904514|metastatic squamous neck cancer with occult primary squamous cell carcinoma
446757|NCT00904514|stage III squamous cell carcinoma of the lip and oral cavity
446758|NCT00904514|stage IV squamous cell carcinoma of the lip and oral cavity
446759|NCT00904514|recurrent squamous cell carcinoma of the lip and oral cavity
446760|NCT00904514|stage III squamous cell carcinoma of the oropharynx
446761|NCT00904514|stage IV squamous cell carcinoma of the oropharynx
446762|NCT00904514|recurrent squamous cell carcinoma of the oropharynx
446763|NCT00904514|stage III squamous cell carcinoma of the nasopharynx
446764|NCT00904514|stage IV squamous cell carcinoma of the nasopharynx
446765|NCT00904514|stage III squamous cell carcinoma of the hypopharynx
446766|NCT00904514|stage IV squamous cell carcinoma of the hypopharynx
446767|NCT00904514|recurrent squamous cell carcinoma of the hypopharynx
446768|NCT00904514|stage III squamous cell carcinoma of the larynx
446769|NCT00904514|stage IV squamous cell carcinoma of the larynx
446770|NCT00904514|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
446771|NCT00904514|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
446772|NCT00904514|fallopian tube cancer
446773|NCT00904514|primary peritoneal cavity cancer
446774|NCT00904514|ovarian carcinosarcoma
446775|NCT00904514|Brenner tumor
446776|NCT00904514|untreated metastatic squamous neck cancer with occult primary
446777|NCT00904514|salivary gland squamous cell carcinoma
446778|NCT00904514|stage III salivary gland cancer
446779|NCT00904514|stage IV salivary gland cancer
446780|NCT00904514|stage II pancreatic cancer
446781|NCT00904514|stage III pancreatic cancer
446782|NCT00904514|ovarian mucinous cystadenocarcinoma
446783|NCT00904514|stage IV pancreatic cancer
446784|NCT00904514|recurrent squamous cell carcinoma of the larynx
446785|NCT00904514|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
446786|NCT00904514|adult acute myeloid leukemia with inv(16)(p13;q22)
446787|NCT00904514|adult acute myeloid leukemia with t(15;17)(q22;q12)
446788|NCT00904514|adult acute myeloid leukemia with t(16;16)(p13;q22)
446789|NCT00904514|adult acute myeloid leukemia with t(8;21)(q22;q22)
446790|NCT00904501|Limb ischemia
446791|NCT00904501|Cell Therapy
446792|NCT00904488|Acute Decompensated Heart Failure
446793|NCT00904488|Diuretics
446794|NCT00904436|Tetraplegia
446795|NCT00904436|Breathing Patterns
446796|NCT00904436|Dyspnea
446797|NCT00904410|adenocarcinoma
446798|NCT00904410|breast
446799|NCT00904384|HIV+
446800|NCT00904384|COPD
446801|NCT00904384|emphysema
446802|NCT00904358|internal jugular vein
446803|NCT00904358|cross sectional area
446804|NCT00904358|ultrasound
446805|NCT00904358|central venous pressure
446806|NCT00904345|SCC Head and Neck Cancer
446807|NCT00904332|Transcranial Magnetic Stimulation (TMS)
446808|NCT00904332|Electroencephalogram (EEG)
446809|NCT00904332|Motor Learning
446810|NCT00904332|Health Volunteer
446811|NCT00904332|HV
446812|NCT00904319|osteoarthritis
446813|NCT00904319|knee pain
446814|NCT00904319|power training
446815|NCT00904319|rehabilitation
446816|NCT00904306|binge eating
446817|NCT00904306|chromium
446818|NCT00904306|mood
446819|NCT00904306|glucose
446820|NCT00904306|appetite
446821|NCT00904293|warfarin
446822|NCT00904293|CYP2C9
446823|NCT00904293|VKOR
446824|NCT00904293|Coumadin
446825|NCT00904293|pharmacogenetics
446826|NCT00904293|pharmacogenomics
446827|NCT00904293|anticoagulation
446828|NCT00904293|genotype-guided therapy
446829|NCT00904254|cerebrovascular disorders
446830|NCT00904254|symptomatic carotid artery stenosis
446831|NCT00904254|asymptomatic carotid artery stenosis
446832|NCT00904254|monoclonal antibody
446833|NCT00904254|diagnostics
446834|NCT00904254|molecular target
446835|NCT00904254|immunoglobulin Fab fragments
446836|NCT00904254|physiological effects of drugs
446837|NCT00904254|Tc99m-pertechnetate
446838|NCT00904254|Fab-fragment of Anti-human CD4
446839|NCT00904254|Antibodies, Monoclonal
446840|NCT00904254|Antibodies
446841|NCT00904228|hypothermia
446842|NCT00904228|euthermia
446843|NCT00904228|hyperthermia
446844|NCT00904228|mortality
446845|NCT00904228|morbidity
446846|NCT00904228|sepsis
446847|NCT00904228|bronchopulmonary dysplasia
446848|NCT00904228|intraventricular hemorrhage
446849|NCT00904228|ventilator days
446850|NCT00904150|menstruation
446851|NCT00904150|migraine
446852|NCT00904150|menstrual migraine
446853|NCT00904150|genetics
446854|NCT00904137|Supracondylar fracture
446855|NCT00904137|humerus
446856|NCT00904137|elbow
446857|NCT00904124|Dietary fiber
446858|NCT00904124|guar gum
446859|NCT00904124|alginate
446860|NCT00904124|cellulose
446861|NCT00904124|food intake
446863|NCT00904098|migraine
446864|NCT00904072|CDSS
446865|NCT00904072|prescribing error
446866|NCT00904072|prescribing errors influenced by CDSS
446867|NCT00904072|CPOE
446868|NCT00904046|Uric acid
446869|NCT00904046|Nephrolithiasis
446870|NCT00904007|Educational Technology
446871|NCT00904007|Hypertension
446872|NCT00904007|Education, Professional
446873|NCT00903994|Acute Pain
446874|NCT00903968|refractory
446875|NCT00903968|relapsed
446876|NCT00903968|bortezomib
446877|NCT00903968|AMD3100
446878|NCT00903968|plerixafor
446879|NCT00903955|Mucus
446880|NCT00903955|COPD
446881|NCT00903955|Chronic Bronchitis
446882|NCT00903916|antipsychotic
446883|NCT00903916|ghrelin
446884|NCT00903916|PYY
446885|NCT00903916|appetite
446886|NCT00903916|weight gain
446887|NCT00903903|active synovitis
446888|NCT00903838|Parkinson's disease
446889|NCT00903825|femoral artery puncture
446890|NCT00903825|local anesthesia
446891|NCT00903825|ultrasound guided
446892|NCT00903799|Drug-refractory gastroparesis
446893|NCT00903799|diabetes mellitus induced gastroparesis
446894|NCT00903799|Gastric electrical stimulation
446895|NCT00903799|Long-term multicenter study
446896|NCT00903786|Seizure
446897|NCT00903786|epilepsy
446898|NCT00903773|VX-950-TiDP24-C132
446899|NCT00903773|VX-950-C132
446900|NCT00903773|VX-950
446901|NCT00903773|HCV
446902|NCT00903760|Myelodysplastic Syndrome
446903|NCT00903760|MDS
446904|NCT00903760|Leukemia
446905|NCT00903760|Decitabine
446906|NCT00903760|clofarabine
446907|NCT00903760|Dacogen®
446908|NCT00903760|Clolar®
446909|NCT00903747|Prucalopride
446910|NCT00903747|safety study
446911|NCT00903734|Metastatic Cancer
446912|NCT00903734|Histology-independent
446913|NCT00903734|EGFR Mutation
446914|NCT00903734|EGFR inhibitor-sensitive mutation
446915|NCT00903734|Erlotinib Hydrochloride
446916|NCT00903734|Tarceva
446917|NCT00903734|OSI-774
446918|NCT00903734|Cetuximab
446919|NCT00903734|Bortezomib
446920|NCT00903734|Dasatinib
446921|NCT00903708|Advanced Cancers
446922|NCT00903708|LY2275796
446923|NCT00903708|Eukaryotic initiation factor 4E
446924|NCT00903708|eIF-4E
446925|NCT00903695|Memory XL
446926|NCT00903695|Mild Cognitive Impairment
446927|NCT00903695|cognitive status
446928|NCT00903682|HIV
446929|NCT00903682|Intelence
446930|NCT00903682|etravirine
446931|NCT00903682|ETR
446932|NCT00903682|TMC125
446933|NCT00903682|Sustiva
446934|NCT00903682|efavirenz
446935|NCT00903682|EFV
446936|NCT00903682|Non-nucleoside Reverse Transcriptase Inhibitor
446937|NCT00903682|NNRTI
446938|NCT00903682|treatment-naive
446939|NCT00903669|Facial paralysis
446940|NCT00903669|Muscle tonus
446941|NCT00903669|Rehabilitation
446942|NCT00903669|Myofunctional
446943|NCT00903669|Stomatognathic system
446944|NCT00903656|metastatic breast cancer
446945|NCT00903656|Her2
446946|NCT00903656|Lapatinib
446947|NCT00903656|Caelyx
446948|NCT00903656|cardiotoxic
446949|NCT00903643|Painful Bladder Syndrome
446950|NCT00903643|Urinary Bladder
446951|NCT00903630|recurrent ovarian epithelial cancer
446952|NCT00903630|fallopian tube cancer
446953|NCT00903630|peritoneal cavity cancer
446954|NCT00903617|lipids
446955|NCT00903617|HM74A
446956|NCT00903604|Cardiac surgery
446957|NCT00903604|coronary artery bypass grafting
446958|NCT00903604|valve surgery
446959|NCT00903604|aortic root or ascending aortic aneurysm repair surgery
446960|NCT00903604|Acute kidney injury
446961|NCT00903591|Breast
446962|NCT00903591|cancer
446963|NCT00903591|09-040
446964|NCT00903591|blood sample
446965|NCT00903591|saliva sample
446966|NCT00903591|WECARE
446967|NCT00903591|GWA
446968|NCT00903578|FGF-23
446969|NCT00903578|vitamin D
446970|NCT00903578|phosphate
446971|NCT00903578|allograft dysfunction
446972|NCT00903578|mortality
446973|NCT00903565|genomic profiling
446974|NCT00903565|gene expression
446975|NCT00903565|ColoPrint
446976|NCT00903565|adenocarcinoma colon
446977|NCT00903565|recurrence risk assessment
446978|NCT00903565|prospective
446979|NCT00903539|Peripherally Inserted Central Catheter
446980|NCT00903539|Central Venous Catheter
446981|NCT00903539|Intravenous Catheter
446982|NCT00903539|StatLock
446983|NCT00903539|Patients indicated to have an intravenous catheter placed
446984|NCT00903526|fungal susceptibility
446985|NCT00903474|anxiety disorder
446986|NCT00903474|depression
446987|NCT00903474|cognitive/functional effects
446988|NCT00903474|psychosocial effects of cancer and its treatment
446989|NCT00903474|cancer survivor
446990|NCT00903474|breast cancer
446991|NCT00903448|Normal Healthy Subject Population
446992|NCT00903435|Cystitis
446993|NCT00903435|Urinary
446994|NCT00903435|Bladder
446995|NCT00903422|de novo AML
446996|NCT00903422|sAML/MDS
446997|NCT00903422|Thrombopoietin
446998|NCT00903422|secondary Acute Myeloid Leukemia after MDS
446999|NCT00903422|MDS
447000|NCT00903422|Eltrombopag
447001|NCT00903422|Platelets
447002|NCT00903422|TPO-R agonist
447003|NCT00903422|Advanced Myelodysplastic Syndrome
447004|NCT00903422|Thrombocytopenia
447005|NCT00903422|Thrombopoietin receptor agonist
447006|NCT00903409|High triglycerides
447007|NCT00903409|Lovaza
447008|NCT00903409|simvastatin
447009|NCT00903409|omega-3-acid ethyl esters
447010|NCT00903396|nausea and vomiting
447011|NCT00903396|gastrointestinal carcinoid tumor
447012|NCT00903396|anal cancer
447013|NCT00903396|carcinoma of the appendix
447014|NCT00903396|colon cancer
447015|NCT00903396|rectal cancer
447016|NCT00903396|extrahepatic bile duct cancer
447017|NCT00903396|gallbladder cancer
447018|NCT00903396|gastric cancer
447019|NCT00903396|liver and intrahepatic biliary tract cancer
447020|NCT00903396|pancreatic cancer
447021|NCT00903396|small intestine cancer
447022|NCT00903396|primary peritoneal cavity cancer
447023|NCT00903370|Mitral Valve Regurgitation
447024|NCT00903370|Mitral Valve Surgery
447025|NCT00903370|Mitral Valve Disease
447026|NCT00903370|Ablation, Catheter
447027|NCT00903370|Catheter Ablation, Radiofrequency
447028|NCT00903357|Atopic dermatitis
447029|NCT00903357|Montelukast
447030|NCT00903331|idiopathic pulmonary fibrosis
447031|NCT00903331|MUSIC
447032|NCT00903318|Endocrine
447033|NCT00903318|Environmental Chemicals
447034|NCT00903318|Male:Female Birth Ratio
447035|NCT00903318|Phthalate Exposure
447036|NCT00903318|Generational sex ratio trends
447037|NCT00903318|Mexican American
447038|NCT00903318|Baytown
447039|NCT00903318|Rio Grande Valley
447040|NCT00903318|Hidalgo County
447041|NCT00903318|Texas
447042|NCT00903305|pain
447043|NCT00903305|fatigue
447044|NCT00903305|nausea and vomiting
447045|NCT00903305|stage I breast cancer
447046|NCT00903305|stage II breast cancer
447047|NCT00903305|stage IIIA breast cancer
447048|NCT00903305|stage IIIB breast cancer
447049|NCT00903305|stage IIIC breast cancer
447050|NCT00903292|EGFR
447051|NCT00903292|NSCLC
447052|NCT00903292|EGFR mutation rate
447053|NCT00903279|MRSA colonization
447054|NCT00903279|Orthopedic Surgery
447055|NCT00903279|Altabax
447056|NCT00903279|Placebo
447057|NCT00903266|Aphasia
447058|NCT00903266|Speech Impairment
447059|NCT00903266|Stroke
447060|NCT00903266|Cerebrovascular Accident
447061|NCT00903266|Cerebral Infarction
447062|NCT00903266|Brain Ischemia
447063|NCT00903266|Brain Infarction
447064|NCT00903266|Cerebrovascular Disorder
447065|NCT00903227|Asthma
447066|NCT00903227|Allergic rhinitis
447067|NCT00903227|fluticasone
447068|NCT00903227|methacholine
447069|NCT00903214|stage I breast cancer
447070|NCT00903214|stage II breast cancer
447071|NCT00903214|stage IIIA breast cancer
447072|NCT00903201|cystic fibrosis
447073|NCT00903188|Renal Transplantation
447074|NCT00903188|graft function
447075|NCT00903188|cardiovascular events
447076|NCT00903188|malignancy
447077|NCT00903188|cyclosporin
447078|NCT00903188|steroids
447079|NCT00903188|mycophenolate
447080|NCT00903188|everolimus
447081|NCT00903188|renal biopsies
447082|NCT00903188|pharmacokinetics
447083|NCT00903175|RAD001
447084|NCT00903175|everolimus
447085|NCT00903175|sunitinib
447086|NCT00903175|renal cell carcinoma
447087|NCT00903175|kidney cancer
447088|NCT00903175|metastatic renal cell cancer
447089|NCT00903175|advanced kidney cancer
447090|NCT00903162|hormone-receptor positive
447091|NCT00903162|tamoxifen
447092|NCT00903162|letrozole
447093|NCT00903162|zoledronic acid
447094|NCT00903162|leuprolide
447095|NCT00903149|Premature babies
447096|NCT00903149|Social interaction
447097|NCT00903149|Psychoeducative intervention
447098|NCT00903149|Mother Infant Transaction Program
447099|NCT00903149|Three years follow-up
447100|NCT00903149|Late preterm
447101|NCT00903149|Cognitive development
447102|NCT00903149|Social development
447103|NCT00903149|Emotional development
447104|NCT00903149|Motor development
447105|NCT00903149|Children born preterm and their parents
447106|NCT00903136|Barrett esophagus
447107|NCT00903136|esophageal cancer
447108|NCT00903136|adenocarcinoma of the esophagus
447109|NCT00903084|Pharmacokinetics in Hair
447110|NCT00903084|Tenofovir
447111|NCT00903084|Pharmacokinetics
447112|NCT00903084|Concentrations
447113|NCT00903084|Hair
447114|NCT00903071|Hypertension
447115|NCT00903071|Primary Care
447116|NCT00903071|Physician Learning
447117|NCT00903045|Overactive bladder
447118|NCT00903045|Propiverin
447119|NCT00903032|compliance/adherence
447120|NCT00903019|Homebound
447121|NCT00903019|Older Adults
447122|NCT00903019|Disability
447123|NCT00903019|Videoconferencing
447124|NCT00903006|Breast
447125|NCT00903006|Hormone receptor-positive metastatic breast cancer
447126|NCT00903006|Fulvestrant
447127|NCT00903006|Faslodex
447128|NCT00903006|MK-0646
447129|NCT00903006|Dasatinib
447130|NCT00903006|BMS-354825
447131|NCT00903006|Sprycel
447132|NCT00903006|Adjuvant hormonal therapy
447133|NCT00902993|MAD
447134|NCT00902993|NNR
447135|NCT00902993|to investigate safety and tolerability in a multiple ascending dose study in Healthy subjects
447136|NCT00902993|AZD1446
447137|NCT00902980|Kidney transplantation
447138|NCT00902980|Tacrolimus
447139|NCT00902980|Immunosuppression
447140|NCT00902967|Postoperative pain
447141|NCT00902967|atorvastatin
447142|NCT00902967|analgesic
447143|NCT00902967|antiinflammatory
447144|NCT00902954|Disease free survival
447145|NCT00902954|Distant disease free survival
447146|NCT00902954|Toxicity
447147|NCT00902954|Overall survival
447148|NCT00902941|Parkinson´s disease
447149|NCT00902941|olfaction
447150|NCT00902941|rasagiline
447151|NCT00902941|smell testing
447152|NCT00902928|Elective hip replacement surgery
447153|NCT00902928|Factor Xa
447154|NCT00902928|Venous Thromboembolism
447155|NCT00902928|Thrombosis
447156|NCT00902928|Anticoagulants
447157|NCT00902928|Prevention
447158|NCT00902928|YM150
447159|NCT00902915|multiple myeloma renal insufficiency
447160|NCT00902902|Hepatocellular carcinoma
447161|NCT00902889|Globus pallidus
447162|NCT00902889|Huntington's Disease
447163|NCT00902889|Deep Brain Stimulation
447164|NCT00902889|Movement Disorders
447165|NCT00902876|root coverage
447166|NCT00902876|gingival recession
447167|NCT00902876|keratinized gingiva
447168|NCT00902863|chronic pain
447169|NCT00902863|mindfulness
447170|NCT00902863|yoga
447171|NCT00902863|quality of life
447172|NCT00902863|stress
447173|NCT00902837|randomised
447174|NCT00902837|double-blind
447175|NCT00902837|double-dummy
447176|NCT00902837|parallel-group
447177|NCT00902837|non-inferiority
447178|NCT00902837|pain locomotor function
447179|NCT00902837|improvement in symptoms of constipation
447180|NCT00902837|moderate to severe pain due to osteoarthritis (OA)
447181|NCT00902837|OXN PR
447182|NCT00902837|OxyPR
447183|NCT00902837|Moderate to severe chronic nonmalignant OA
447184|NCT00902824|HIV
447185|NCT00902811|uncomplicated falciparum malaria
447186|NCT00902811|artemisinin combination therapy
447187|NCT00902798|Autism
447188|NCT00902798|Autism Spectrum Disorders
447189|NCT00902798|Asperger's Syndrome
447190|NCT00902798|Pervasive Developmental Disorder
447191|NCT00902798|Cognition
447192|NCT00902798|Social Cognition
447193|NCT00902798|Psychosocial Treatment
447194|NCT00902798|Cognitive Enhancement Therapy
447195|NCT00902798|Enriched Supportive Therapy
447196|NCT00902798|Therapy
447197|NCT00902798|Psychotherapy
447198|NCT00902785|exploratory
447199|NCT00902785|observational
447200|NCT00902785|non-interventional study age-related macular degeneration (AMD) choroidal neovascularization (CNV)
447201|NCT00902772|Recreational CNS depressant
447202|NCT00902772|Abuse liability
447203|NCT00902772|Abuse potential
447204|NCT00902772|Healthy Recreational CNS Depressant Users
447205|NCT00902759|Surgery
447206|NCT00902759|Chemotherapy
447207|NCT00902759|Radiation Therapy
447208|NCT00902759|Pancreatic cancer
447209|NCT00902759|Fatigue
447210|NCT00902733|pain
447211|NCT00902733|fatigue
447212|NCT00902733|nausea and vomiting
447213|NCT00902733|recurrent pancreatic cancer
447214|NCT00902733|stage I pancreatic cancer
447215|NCT00902733|stage II pancreatic cancer
447216|NCT00902733|stage III pancreatic cancer
447217|NCT00902733|stage IV pancreatic cancer
447218|NCT00902720|Ovarian
447219|NCT00902720|Tissue
447220|NCT00902720|Cryopreservation
447221|NCT00902707|healthy nonsmokers
447222|NCT00902694|Serious Mental Illness
447223|NCT00902694|Weight Loss
447224|NCT00902681|Bioequivalence, Pharmacokinetics
447225|NCT00902668|radiation toxicity
447226|NCT00902668|stage IA breast cancer
447227|NCT00902668|stage IB breast cancer
447228|NCT00902668|stage II breast cancer
447229|NCT00902668|breast cancer in situ
447230|NCT00902655|Nocturnal polyuria
447231|NCT00902655|Nocturnal bladder capacity
447232|NCT00902642|Physical therapy,
447233|NCT00902642|musculoskeletal pain,
447234|NCT00902642|psychosocial factors,
447235|NCT00902642|dissimilation,
447236|NCT00902642|evidence based,
447237|NCT00902642|education
447238|NCT00902629|Epiretinal Fibrosis
447239|NCT00902629|Macular Pucker
447240|NCT00902616|Type 2 diabetes
447241|NCT00902616|Peripheral neuropathy
447242|NCT00902616|Microcirculation
447243|NCT00902603|pulmonary arterial hypertension
447244|NCT00902603|Ventavis®
447245|NCT00902603|iloprost
447246|NCT00902590|renal pelvis
447247|NCT00902590|ureter
447248|NCT00902590|bladder
447249|NCT00902590|09-025
447250|NCT00902590|Renal Pelvis, Ureter, Bladder Cancer
447251|NCT00902564|Generalized Anxiety Disorder
447252|NCT00902564|GAD
447253|NCT00902564|Antidepressant
447254|NCT00902564|Anxiolytic
447255|NCT00902551|DNA cytometry
447256|NCT00902551|Cytology
447257|NCT00902551|Diagnosis accuracy
447258|NCT00902538|Add on treatment
447259|NCT00902538|essential hypertension
447260|NCT00902525|two sequential doses of 90Y-Ibritumomab Tiuxetan
447261|NCT00902499|functional magnetic resonance imaging
447262|NCT00902486|Rheumatoid arthritis
447263|NCT00902473|Topiramate fed study
447264|NCT00902460|drug interactions CYP3A4 CYP3A5 midazolam anti-rheumatic agents
447265|NCT00902447|Human Blood Cell Disorders
447266|NCT00902447|lymphoid, myeloid and erythroid proliferative disease
447267|NCT00902434|Non-Hodgkin's Lymphoma
447268|NCT00902421|Overactive bladder
447269|NCT00902421|SSRI
447270|NCT00902421|Antimuscarinics
447271|NCT00902395|Preschool children
447272|NCT00902382|Infertility
447273|NCT00902382|Ovulation stimulation
447274|NCT00902382|Pregnancy
447275|NCT00902369|AK106-001616
447276|NCT00902356|Amgen
447277|NCT00902356|Phase 1
447278|NCT00902356|First in Human
447279|NCT00902356|Postmenopausal
447280|NCT00902343|Liver
447281|NCT00902343|Cancer
447282|NCT00902343|Primary
447283|NCT00902343|Metastatic
447284|NCT00902343|transfusions
447285|NCT00902343|08-158
447286|NCT00902330|depression
447287|NCT00902330|anxiety disorder
447288|NCT00902330|fatigue
447289|NCT00902330|pain
447290|NCT00902330|sleep disorders
447291|NCT00902330|stage IA breast cancer
447292|NCT00902330|stage IB breast cancer
447293|NCT00902330|stage II breast cancer
447294|NCT00902330|stage IIIA breast cancer
447295|NCT00902304|Hypertension
447296|NCT00902304|valsartan
447297|NCT00902291|Clinical Trial, Phase II
447298|NCT00902291|Combination Drug Therapy
447299|NCT00902291|Gemcitabine
447300|NCT00902291|AGS-1C4D4
447301|NCT00902291|Pancreatic Cancer
447302|NCT00902278|influenzavirus A
447303|NCT00902278|influenzavirus B
447304|NCT00902278|human influenza
447305|NCT00902278|T lymphocytes
447306|NCT00902278|influenza vaccines
447307|NCT00902226|Social Anxiety Disorder
447308|NCT00902226|SAD
447309|NCT00902226|Antidepressant
447310|NCT00902226|Anxiolytic
447311|NCT00902200|Glaucoma
447312|NCT00902200|Intraocular pressure
447313|NCT00902187|Bioequivalence
447314|NCT00902174|Pulmonary arterial hypertension
447315|NCT00902174|Imatinib
447316|NCT00902174|6MWD
447317|NCT00902174|Borg scale
447318|NCT00902174|Pulmonary hypertension
447319|NCT00902148|Surgery
447320|NCT00902148|Colectomy
447321|NCT00902148|Proctocolectomy
447322|NCT00902148|Adhesions
447323|NCT00902135|Multiple Sclerosis
447324|NCT00902135|Interferon beta-1b
447325|NCT00902122|p53 gene
447326|NCT00902122|thyroid
447327|NCT00902122|gene therapy
447328|NCT00902122|malignant tumors
447329|NCT00902109|visual field
447330|NCT00902109|perimetry
447331|NCT00902109|progression
447332|NCT00902109|POAG
447333|NCT00902109|glaucoma
447334|NCT00902096|cord blood
447335|NCT00902096|IgE
447336|NCT00902096|prenatal
447337|NCT00902096|predictor
447338|NCT00902083|p53 gene
447339|NCT00902083|Oral and Maxillofacial
447340|NCT00902083|gene therapy
447341|NCT00902083|malignant tumors
447342|NCT00902044|Refractory Sarcoma
447343|NCT00902044|Metastatic Sarcoma
447344|NCT00902044|Sarcoma
447345|NCT00902044|HER2-positive
447346|NCT00902044|Gene Therapy
447347|NCT00902044|HER2-specific T cells
447348|NCT00902031|Docusate
447349|NCT00902031|Constipation
447350|NCT00902031|Colace
447351|NCT00902031|Palliative Care
447352|NCT00902031|Sennoside
447353|NCT00902031|Senokot
447354|NCT00902031|Terminally Ill
447355|NCT00902031|Stool
447356|NCT00902031|Randomized Trial
447357|NCT00902018|ITP
447358|NCT00902005|Endothelial dysfunction
447359|NCT00902005|Bone and cartilage markers
447360|NCT00902005|Inflammatory disease activity
447361|NCT00902005|Rheumatoid arthritis
447362|NCT00902005|Psoriatic arthritis
447363|NCT00902005|Ankylosing Spondylitis
447364|NCT00901992|type 2 diabetes
447365|NCT00901992|education
447366|NCT00901992|self-management
447367|NCT00901992|insulin therapy
447368|NCT00901979|Type 2 Diabetes
447369|NCT00901966|Melanoma
447370|NCT00901966|Sun Exposure History
447371|NCT00901966|Sun Exposure
447372|NCT00901953|migraine
447373|NCT00901953|migrainous vertigo
447374|NCT00901953|vestibular evoked myogenic potentials
447375|NCT00901953|vestibular function test
447376|NCT00901953|vestibular disorders
447377|NCT00901927|Lymphoma
447378|NCT00901927|Non-Hodgkin's Lymphoma
447379|NCT00901927|Untreated High Risk Follicular Lymphoma
447380|NCT00901927|Bendamustine hydrochloride
447381|NCT00901927|Bendamustine HCI
447382|NCT00901927|Bendamustine
447383|NCT00901927|CEP-18083
447384|NCT00901927|SDX-105
447385|NCT00901927|Treanda
447386|NCT00901927|Mitoxantrone
447387|NCT00901927|Novantrone
447388|NCT00901927|Rituximab
447389|NCT00901927|Rituxan
447390|NCT00901914|Hypersensitivity
447391|NCT00901914|Allergy
447392|NCT00901914|Birch, allergy, Sublingual Immunotherapy
447393|NCT00901901|Sorafenib (Nexavar)
447394|NCT00901901|Erlotinib (Tarceva)
447395|NCT00901901|First Line
447396|NCT00901901|HCC
447397|NCT00901888|Renin Angiotensin System
447398|NCT00901875|Buprenorphine
447399|NCT00901875|Naloxone
447400|NCT00901875|Suboxone
447401|NCT00901862|Migraine
447402|NCT00901862|therapy
447403|NCT00901862|magnetic therapy
447404|NCT00901862|prophylaxis
447405|NCT00901862|prevention
447406|NCT00901836|Sarcoma
447407|NCT00901810|Length Determination
447408|NCT00901810|Working Length
447409|NCT00901810|Electronic Apex Locator
447410|NCT00901810|Root Canal Therapy
447411|NCT00901810|Endodontics
447412|NCT00901797|ABD
447413|NCT00901797|ABDuction
447414|NCT00901797|ABR
447415|NCT00901797|Arthroscopic Bankart Repair
447416|NCT00901797|ACJ
447417|NCT00901797|AcromioClavicular Joint
447418|NCT00901797|AD
447419|NCT00901797|Anterior Drawer
447420|NCT00901797|ARIC
447421|NCT00901797|Arthroscopic Rotator Interval Closure
447422|NCT00901797|BL
447423|NCT00901797|Bankart Lesion
447424|NCT00901797|CHL
447425|NCT00901797|CoracoHumeral Ligament
447426|NCT00901797|ER
447427|NCT00901797|External Rotation
447428|NCT00901797|FF
447429|NCT00901797|Forward Flexion
447430|NCT00901797|GHJ
447431|NCT00901797|GlenoHumeral Joint
447432|NCT00901797|HSL
447433|NCT00901797|HillSacs Lesion
447434|NCT00901797|IR
447435|NCT00901797|Internal Rotation
447436|NCT00901797|ISP
447437|NCT00901797|InfraSPinatus
447438|NCT00901797|PD
447439|NCT00901797|Posterior Drawer
447440|NCT00901797|RI
447441|NCT00901797|Rotator Interval
447442|NCT00901797|ROM
447443|NCT00901797|Range Of Motion
447444|NCT00901797|SGHL
447445|NCT00901797|Superior GlenoHumeral Ligament
447446|NCT00901797|SSC
447447|NCT00901797|SubSCapularis
447448|NCT00901797|SSP
447449|NCT00901797|SupraSPinatus
447450|NCT00901784|Topiramate fasting study
447451|NCT00901771|Sleep
447452|NCT00901771|Sleep Apnea, Obstructive
447453|NCT00901771|OSA
447454|NCT00901771|OSAH
447455|NCT00901745|Renin angiotensin system
447456|NCT00901745|Apelin
447457|NCT00901745|Vasodilatation
447458|NCT00901745|Heart disease
447459|NCT00901745|Vascular biology
447460|NCT00901732|Caphosol
447461|NCT00901732|Oral Mucositis
447462|NCT00901732|Eusa Pharma
447463|NCT00901732|Moffitt Cancer Center
447464|NCT00901719|Renin angiotensin system
447465|NCT00901719|Apelin
447466|NCT00901719|Cardiac output
447467|NCT00901719|Vasodilatation
447468|NCT00901706|Self-Neglect
447469|NCT00901706|Comprehensive Geriatric Assessment (CGA)
447470|NCT00901706|Geriatric Syndromes
447471|NCT00901706|Quality of Life
447472|NCT00901706|Basic Activities of Daily Living
447473|NCT00901706|Instrumental Activities of Daily Living
447474|NCT00901693|pink eye
447475|NCT00901693|eye infection
447476|NCT00901693|conjunctivitis
447477|NCT00901680|Tissue Bank
447478|NCT00901654|Vaccination
447479|NCT00901654|Diarrhea
447480|NCT00901654|Traveler's Diarrhea
447481|NCT00901654|ETEC
447482|NCT00901654|Enterotoxigenic E. coli
447483|NCT00901641|cognitive training
447484|NCT00901641|insomnia
447485|NCT00901628|periarticular multimodal drug injection
447486|NCT00901615|lymphoma
447487|NCT00901615|lenalidomide
447488|NCT00901615|gela
447489|NCT00901602|streptococcus pneumoniae
447490|NCT00901602|pneumococcus
447491|NCT00901602|pneumonia
447492|NCT00901602|meningitis
447493|NCT00901602|serotypes
447494|NCT00901602|bacteremia
447495|NCT00901602|sepsis
447496|NCT00901589|n-3 PUFAs
447497|NCT00901589|menopause
447498|NCT00901589|adipose tissue
447499|NCT00901589|estrogens
447500|NCT00901589|Incorporation of fishoil in pre- and postmenopausal women
447501|NCT00901589|Marine n-3 PUFAs influence on female hormones in blood
447502|NCT00901576|Healthy volunteers
447503|NCT00901563|Gap Junctions
447504|NCT00901563|Rotigaptide
447505|NCT00901563|Ischaemia reperfusion
447506|NCT00901563|t-PA
447507|NCT00901563|Fibrinolysis
447508|NCT00901563|Endothelial function
447509|NCT00901563|Venous occlusion plethysmography
447510|NCT00901550|MTX
447511|NCT00901550|anti-TNF
447512|NCT00901550|Early RA
447513|NCT00901537|Non-small Cell Lung Cancer
447514|NCT00901537|Head and Neck Cancer
447515|NCT00901537|Azacitidine
447516|NCT00901537|Vidaza
447517|NCT00901537|Cisplatin
447518|NCT00901524|HCV Genotype 1, 4
447519|NCT00901524|Virological response
447520|NCT00901524|Ribavirin
447521|NCT00901524|PegPegIFN- alpha 2a
447522|NCT00901524|Viral Hepatitis (HCV)
447523|NCT00901511|Whole lung lavage
447524|NCT00901511|Pulmonary surfactant
447525|NCT00901511|GM-CSF
447526|NCT00901511|Autoantibodies anti GM-CSF
447527|NCT00901485|Respiratory insufficiency
447528|NCT00901485|Hypercapnia
447529|NCT00901485|Hypoventilation
447530|NCT00901485|Sleep
447531|NCT00901485|Polysomnography
447532|NCT00901485|Hypoxia
447533|NCT00901485|Titration
447534|NCT00901485|Non Invasive Ventilation
447535|NCT00901472|Type 2 diabetes,
447536|NCT00901472|obstructive sleep apnea
447537|NCT00901459|Repetitive Transcranial Magnetic Stimulation
447538|NCT00901459|Cigarette Smoker
447539|NCT00901459|Cigarette Dependence
447540|NCT00901459|To block cue-elicited craving in dependent cigarette smokers
447541|NCT00901433|Asthma
447542|NCT00901433|Wheeze Rate
447543|NCT00901433|Respiratory Function Tests
447544|NCT00901420|Prostate
447545|NCT00901420|Urodynamic Evaluation
447546|NCT00901420|Prostatectomy
447547|NCT00901420|Salvage prostatectomy
447548|NCT00901420|Bladder compliance
447549|NCT00901420|Radiation Therapy
447550|NCT00901420|External beam radiation therapy
447551|NCT00901420|Quality-of-life
447552|NCT00901407|augmentation
447553|NCT00901407|depression
447554|NCT00901407|resistance
447555|NCT00901394|Nitrous oxide
447556|NCT00901394|cobalamin
447557|NCT00901394|homocysteine
447558|NCT00901394|vitamin B12
447559|NCT00901394|folate
447560|NCT00901394|No specific diseases targeted
447561|NCT00901394|Focus is on all patients receiving general anesthesia with nitrous oxide for elective surgery
447562|NCT00901381|Ischemic stroke
447563|NCT00901381|Stem cells
447564|NCT00901381|Colony-stimulating factors
447565|NCT00901381|Filgrastim
447566|NCT00901381|Randomized controlled trial
447567|NCT00901355|Blood pressure
447568|NCT00901355|Arterial stiffness
447569|NCT00901355|Morbidity
447570|NCT00901355|Mortality
447571|NCT00901355|Elderly
447572|NCT00901342|AIPC
447573|NCT00901342|CRPC
447574|NCT00901342|prostate cancer
447575|NCT00901342|prostate
447576|NCT00901342|immune therapy
447577|NCT00901342|immunotherapy
447578|NCT00901342|vaccine
447579|NCT00901342|dendritic cells
447580|NCT00901342|antigen-presenting cells
447581|NCT00901342|antigen presenting cells
447582|NCT00901342|cancer vaccine
447583|NCT00901342|PSA
447584|NCT00901342|prostatic adenocarcinoma
447585|NCT00901329|TKA
447586|NCT00901329|functional outcome
447587|NCT00901329|pain
447588|NCT00901329|ROM
447589|NCT00901329|gait
447590|NCT00901316|Skin and Soft Tissue Infections
447591|NCT00901316|Abscesses
447592|NCT00901316|Boils
447593|NCT00901316|Clorox Baths
447594|NCT00901316|Colonization
447595|NCT00901316|Staph
447596|NCT00901316|MRSA
447597|NCT00901316|MSSA
447598|NCT00901316|Recurrent Infections
447599|NCT00901316|Prevention CA-SA Infections
447600|NCT00901316|Community-Acquired Staphylococcus in Children
447601|NCT00901290|oral contraceptive
447602|NCT00901277|Post MI
447603|NCT00901264|Chemosensitivity, chemotherapy, all cancers, personalized chemotherapy, personalized cancer treatment
447604|NCT00901264|Cancer Patients for whom chemotherapy is planned.
447605|NCT00901251|OABSS
447606|NCT00901238|retinoblastoma
447607|NCT00901238|intra-arterial chemotherapy
447608|NCT00901238|chemosurgery
447609|NCT00901238|melphalan
447610|NCT00901238|topotecan
447611|NCT00901225|NHL
447612|NCT00901212|Heart Failure
447613|NCT00901212|resynchronisation
447614|NCT00901212|ICD
447615|NCT00901199|Thalassemia
447616|NCT00901199|Chelation
447617|NCT00901199|Iron Overload
447618|NCT00901199|Thalassemia patients with Iron overload
447619|NCT00901186|Diabetic Macular Edema
447620|NCT00901186|Ranibizumab
447621|NCT00901186|Laser Treatment
447622|NCT00901186|Visual impairment
447623|NCT00901173|Case-Control Study
447624|NCT00901173|Esophageal Squamous Cell Carcinoma
447625|NCT00901173|Risk Factors
447626|NCT00901160|thromboelastography
447627|NCT00901160|post-operative complications
447628|NCT00901160|anti-platelet agents
447629|NCT00901160|prospective
447630|NCT00901160|pilot
447631|NCT00901160|patients taking anti-platelet agents
447632|NCT00901147|t-cell lymphoma
447633|NCT00901147|peripheral t-cell lymphoma
447634|NCT00901147|nk/t-cell lymphoma, nasal type
447635|NCT00901147|bortezomib
447636|NCT00901147|velcade
447637|NCT00901147|panobinostat
447638|NCT00901147|LBH589b
447639|NCT00901147|histone deacetylase inhibitor
447640|NCT00901147|proteasome inhibitor
447641|NCT00901134|therapeutic hypothermia after cardiac arrest
447642|NCT00901121|maxillary sinus lift
447643|NCT00901121|Histomorphometric evaluation
447644|NCT00901121|bone graft
447645|NCT00901121|bone augmentation
447646|NCT00901108|open angle glaucoma
447647|NCT00901108|trabectome
447648|NCT00901108|trabeculectomy
447649|NCT00901108|cataract
447650|NCT00901082|chronic pain
447651|NCT00901082|anxiety
447652|NCT00901082|intervention
447653|NCT00901082|information
447654|NCT00901082|relaxation
447655|NCT00901056|ED
447656|NCT00901056|Erectile Dysfunction
447657|NCT00901056|Erectile dysfunction treated with PDE-5 inhibitors
447658|NCT00901030|platelet function
447659|NCT00901030|perioperative complications
447660|NCT00901030|thromboelastography
447661|NCT00901030|coronary stents
447662|NCT00901030|non-cardiac surgery
447663|NCT00901004|Minimal Change
447664|NCT00901004|GERD
447665|NCT00901004|GERDQ
447666|NCT00900991|Pandemic Influenza A Vaccine
447667|NCT00900991|Immunogenictiy
447668|NCT00900991|Safety
447669|NCT00900978|Streptococcus pneumoniae
447670|NCT00900978|carriage
447671|NCT00900978|Resistance
447672|NCT00900978|Serotype
447673|NCT00900978|vaccination
447674|NCT00900978|Colonization of S. pneumoniae
447675|NCT00900965|irritable bowel syndrome
447676|NCT00900965|IBS
447677|NCT00900965|fMRI
447678|NCT00900965|acupuncture
447679|NCT00900965|functional
447680|NCT00900965|brain
447681|NCT00900900|Cigarette Smokers
447682|NCT00900900|DHEA
447683|NCT00900900|dehydroepiandrosterone
447684|NCT00900900|pregnenolone
447685|NCT00900900|Nicotine withdrawal symptoms
447686|NCT00900887|diabetic retinopathy
447687|NCT00900887|clinically significant macular edema
447688|NCT00900887|selective photocoagulation
447689|NCT00900887|topic ketorolac
447690|NCT00900887|topic nepafenac
447691|NCT00900887|efficacy
447692|NCT00900887|treatment
447693|NCT00900874|Formoterol
447694|NCT00900874|Rapid bronchodilation
447695|NCT00900861|asthma control level
447696|NCT00900861|visual analogue scale
447697|NCT00900848|Posterior tibial artery bypass
447698|NCT00900848|Iliofemoral artery injury
447699|NCT00900848|Shock
447700|NCT00900848|Reconstruction
447701|NCT00900835|fatigue
447702|NCT00900835|pain
447703|NCT00900835|recurrent breast cancer
447704|NCT00900835|stage I breast cancer
447705|NCT00900835|stage II breast cancer
447706|NCT00900835|stage IIIA breast cancer
447707|NCT00900835|stage IIIB breast cancer
447708|NCT00900835|stage IIIC breast cancer
447709|NCT00900835|stage IV breast cancer
447710|NCT00900835|recurrent prostate cancer
447711|NCT00900835|stage I prostate cancer
447712|NCT00900835|stage II prostate cancer
447713|NCT00900835|stage III prostate cancer
447714|NCT00900835|stage IV prostate cancer
447715|NCT00900835|recurrent colon cancer
447716|NCT00900835|stage I colon cancer
447717|NCT00900835|stage II colon cancer
447718|NCT00900835|stage III colon cancer
447719|NCT00900835|stage IV colon cancer
447720|NCT00900835|extensive stage small cell lung cancer
447721|NCT00900835|limited stage small cell lung cancer
447722|NCT00900835|recurrent non-small cell lung cancer
447723|NCT00900835|recurrent small cell lung cancer
447724|NCT00900835|stage I non-small cell lung cancer
447725|NCT00900835|stage II non-small cell lung cancer
447726|NCT00900835|stage IIIA non-small cell lung cancer
447727|NCT00900835|stage IIIB non-small cell lung cancer
447728|NCT00900835|stage IV non-small cell lung cancer
447729|NCT00900822|bone grafting
447730|NCT00900822|sinus elevation
447731|NCT00900822|sinus augmentation
447732|NCT00900809|Acute Myeloid Leukemia
447733|NCT00900809|Neukoplast™
447734|NCT00900809|NK-92
447735|NCT00900809|Refractory
447736|NCT00900809|Refractory or Relapsed Acute Myeloid Leukemia
447737|NCT00900796|Ankylosing spondylitis;predictive factors
447738|NCT00900783|herpes zoster
447739|NCT00900783|shingles
447740|NCT00900783|Phase II
447741|NCT00900783|FV-100
447742|NCT00900783|Inhibitex
447743|NCT00900770|dementia
447744|NCT00900770|mild cognitive impairment
447745|NCT00900770|beta amyloid
447746|NCT00900757|Primary Glioma
447747|NCT00900757|Palonosetron
447748|NCT00900757|Standard Radiotherapy
447749|NCT00900757|Temozolomide
447750|NCT00900744|Tamoxifen
447751|NCT00900744|Breast Cancer
447752|NCT00900731|COPD
447753|NCT00900731|indacaterol
447754|NCT00900731|beta 2 agonist
447755|NCT00900731|tiotropium
447756|NCT00900692|Excessive pronation
447757|NCT00900692|CVA
447758|NCT00900692|Forearm
447759|NCT00900692|Excessive pronation following CVA
447760|NCT00900679|transitional care planning
447761|NCT00900679|stage I ovarian epithelial cancer
447762|NCT00900679|stage II ovarian epithelial cancer
447763|NCT00900679|stage III ovarian epithelial cancer
447764|NCT00900679|stage IV ovarian epithelial cancer
447765|NCT00900666|Stiff knee gait
447766|NCT00900666|Gait analysis
447767|NCT00900666|Traumatic Brain Injury
447768|NCT00900666|Acquired Brain Injury
447769|NCT00900653|urinary tract infections
447770|NCT00900653|postmenopause
447771|NCT00900653|lactobacillus
447772|NCT00900653|estriol
447773|NCT00900627|Cancer
447774|NCT00900627|Tumour
447775|NCT00900627|Breast cancer
447776|NCT00900627|Metastatic
447777|NCT00900627|Secondary
447778|NCT00900614|Hematologic malignancy
447779|NCT00900614|Prostate carcinoma
447780|NCT00900614|Hematologic cancer
447781|NCT00900614|Prostate cancer
447782|NCT00900601|Sacroiliac pain
447783|NCT00900601|Sacroiliac instability
447784|NCT00900601|Pelvic girdle pain
447785|NCT00900601|Sacroiliac arthrodesis
447786|NCT00900601|Arthrodesis
447787|NCT00900601|Surgery
447788|NCT00900588|immunogenictiy
447789|NCT00900588|safety
447790|NCT00900588|pandemic influenza A vaccine
447791|NCT00900575|cervical cancer
447792|NCT00900575|LEEP
447793|NCT00900575|colposcopy
447794|NCT00900562|Zalypsis
447795|NCT00900562|Cancer
447796|NCT00900562|Endometrial
447797|NCT00900562|Uterine Cervical
447798|NCT00900562|PharmaMar
447799|NCT00900549|Heart failure
447800|NCT00900549|Cardiac resynchronization therapy
447801|NCT00900549|ICD
447802|NCT00900536|clear cell renal cell carcinoma
447803|NCT00900536|stage I renal cell cancer
447804|NCT00900536|stage II renal cell cancer
447805|NCT00900536|stage III renal cell cancer
447806|NCT00900536|stage IV renal cell cancer
447807|NCT00900536|papillary renal cell carcinoma
447808|NCT00900523|recurrent ovarian epithelial cancer
447809|NCT00900523|stage I ovarian epithelial cancer
447810|NCT00900523|stage II ovarian epithelial cancer
447811|NCT00900523|stage III ovarian epithelial cancer
447812|NCT00900523|stage IV ovarian epithelial cancer
447813|NCT00900510|subcutaneous abscess
447814|NCT00900510|Incision and drainage
447815|NCT00900510|Methicillin-resistant staphylococcus aureus
447816|NCT00900497|granulocytes
447817|NCT00900497|Graft-vs-Host-Disease
447818|NCT00900484|stage I adult diffuse large cell lymphoma
447819|NCT00900484|stage I adult diffuse mixed cell lymphoma
447820|NCT00900484|stage I adult diffuse small cleaved cell lymphoma
447821|NCT00900484|stage II adult diffuse large cell lymphoma
447822|NCT00900484|stage II adult diffuse mixed cell lymphoma
447823|NCT00900484|stage II adult diffuse small cleaved cell lymphoma
447824|NCT00900484|stage III adult diffuse large cell lymphoma
447825|NCT00900484|stage III adult diffuse mixed cell lymphoma
447826|NCT00900484|stage III adult diffuse small cleaved cell lymphoma
447827|NCT00900484|stage IV adult diffuse large cell lymphoma
447828|NCT00900484|stage IV adult diffuse mixed cell lymphoma
447829|NCT00900484|stage IV adult diffuse small cleaved cell lymphoma
447830|NCT00900484|stage I grade 3 follicular lymphoma
447831|NCT00900484|stage II grade 3 follicular lymphoma
447832|NCT00900484|stage III grade 3 follicular lymphoma
447833|NCT00900484|stage IV grade 3 follicular lymphoma
447834|NCT00900484|stage I adult immunoblastic large cell lymphoma
447835|NCT00900484|stage II adult immunoblastic large cell lymphoma
447836|NCT00900484|stage III adult immunoblastic large cell lymphoma
447837|NCT00900484|stage IV adult immunoblastic large cell lymphoma
447838|NCT00900484|stage I adult lymphoblastic lymphoma
447839|NCT00900484|stage II adult lymphoblastic lymphoma
447840|NCT00900484|stage III adult lymphoblastic lymphoma
447841|NCT00900484|stage IV adult lymphoblastic lymphoma
447842|NCT00900484|stage I adult Burkitt lymphoma
447843|NCT00900484|stage II adult Burkitt lymphoma
447844|NCT00900484|stage III adult Burkitt lymphoma
447845|NCT00900484|stage IV adult Burkitt lymphoma
447846|NCT00900471|unspecified adult solid tumor, protocol specific
447847|NCT00900471|unspecified childhood solid tumor, protocol specific
447848|NCT00900458|preeclampsia
447849|NCT00900458|low vs high plasma volume
447850|NCT00900445|childhood acute lymphoblastic leukemia in remission
447851|NCT00900445|untreated childhood acute lymphoblastic leukemia
447852|NCT00900432|recurrent colon cancer
447853|NCT00900432|stage I colon cancer
447854|NCT00900432|stage II colon cancer
447855|NCT00900432|stage III colon cancer
447856|NCT00900432|stage IV colon cancer
447857|NCT00900419|non-small cell lung cancer
447858|NCT00900419|small cell lung cancer
447859|NCT00900419|squamous lung dysplasia
447860|NCT00900419|hypopharyngeal cancer
447861|NCT00900419|laryngeal cancer
447862|NCT00900419|lip and oral cavity cancer
447863|NCT00900419|metastatic squamous neck cancer with occult primary
447864|NCT00900419|nasopharyngeal cancer
447865|NCT00900419|oropharyngeal cancer
447866|NCT00900419|paranasal sinus and nasal cavity cancer
447867|NCT00900419|salivary gland cancer
447868|NCT00900419|esophageal cancer
447869|NCT00900419|pulmonary carcinoid tumor
447870|NCT00900419|tongue cancer
447871|NCT00900380|adult acute monocytic leukemia (M5b)
447872|NCT00900380|adult acute megakaryoblastic leukemia (M7)
447873|NCT00900380|adult acute myeloblastic leukemia with maturation (M2)
447874|NCT00900380|adult acute myeloblastic leukemia without maturation (M1)
447875|NCT00900380|adult acute myelomonocytic leukemia (M4)
447876|NCT00900380|adult acute monoblastic leukemia (M5a)
447877|NCT00900380|secondary acute myeloid leukemia
447878|NCT00900380|untreated adult acute myeloid leukemia
447879|NCT00900380|adult acute minimally differentiated myeloid leukemia (M0)
447880|NCT00900380|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
447881|NCT00900380|adult acute myeloid leukemia with inv(16)(p13;q22)
447882|NCT00900380|adult acute myeloid leukemia with t(16;16)(p13;q22)
447883|NCT00900380|adult acute myeloid leukemia with t(8;21)(q22;q22)
447884|NCT00900380|adult erythroleukemia (M6a)
447885|NCT00900380|adult pure erythroid leukemia (M6b)
447886|NCT00900367|breast cancer
447887|NCT00900354|unspecified childhood solid tumor, protocol specific
447888|NCT00900341|adult soft tissue sarcoma
447889|NCT00900341|childhood soft tissue sarcoma
447890|NCT00900328|adenocarcinoma of the lung
447891|NCT00900328|recurrent non-small cell lung cancer
447892|NCT00900328|stage 0 non-small cell lung cancer
447893|NCT00900328|stage I non-small cell lung cancer
447894|NCT00900328|stage II non-small cell lung cancer
447895|NCT00900328|stage IIIA non-small cell lung cancer
447896|NCT00900328|stage IIIB non-small cell lung cancer
447897|NCT00900328|stage IV non-small cell lung cancer
447898|NCT00900302|male breast cancer
447899|NCT00900302|recurrent breast cancer
447900|NCT00900302|stage IA breast cancer
447901|NCT00900302|stage IB breast cancer
447902|NCT00900302|stage II breast cancer
447903|NCT00900302|stage IIIA breast cancer
447904|NCT00900302|stage IIIB breast cancer
447905|NCT00900302|stage IIIC breast cancer
447906|NCT00900302|stage IV breast cancer
447907|NCT00900302|unspecified adult solid tumor, protocol specific
447908|NCT00900302|unspecified childhood solid tumor, protocol specific
447909|NCT00900302|squamous cell carcinoma of the anus
447910|NCT00900302|squamous cell carcinoma of the bladder
447911|NCT00900302|squamous cell carcinoma of the esophagus
447912|NCT00900302|squamous cell carcinoma of the gallbladder
447913|NCT00900302|squamous cell carcinoma of the skin
447914|NCT00900302|squamous cell carcinoma of the vulva
447915|NCT00900302|squamous cell lung cancer
447916|NCT00900302|vaginal squamous cell carcinoma
447917|NCT00900302|stage I squamous cell carcinoma of the hypopharynx
447918|NCT00900302|stage II squamous cell carcinoma of the hypopharynx
447919|NCT00900302|stage III squamous cell carcinoma of the hypopharynx
447920|NCT00900302|stage IV squamous cell carcinoma of the hypopharynx
447921|NCT00900302|recurrent squamous cell carcinoma of the hypopharynx
447922|NCT00900302|stage I squamous cell carcinoma of the larynx
447923|NCT00900302|stage I verrucous carcinoma of the larynx
447924|NCT00900302|stage II squamous cell carcinoma of the larynx
447925|NCT00900302|stage II verrucous carcinoma of the larynx
447926|NCT00900302|stage III squamous cell carcinoma of the larynx
447927|NCT00900302|stage III verrucous carcinoma of the larynx
447928|NCT00900302|stage IV squamous cell carcinoma of the larynx
447929|NCT00900302|stage IV verrucous carcinoma of the larynx
447930|NCT00900302|recurrent squamous cell carcinoma of the larynx
447931|NCT00900302|recurrent verrucous carcinoma of the larynx
447932|NCT00900302|stage I squamous cell carcinoma of the lip and oral cavity
447933|NCT00900302|stage II squamous cell carcinoma of the lip and oral cavity
447934|NCT00900302|stage III squamous cell carcinoma of the lip and oral cavity
447935|NCT00900302|stage IV squamous cell carcinoma of the lip and oral cavity
447936|NCT00900302|recurrent squamous cell carcinoma of the lip and oral cavity
447937|NCT00900302|stage I verrucous carcinoma of the oral cavity
447938|NCT00900302|stage II verrucous carcinoma of the oral cavity
447939|NCT00900302|stage III verrucous carcinoma of the oral cavity
447940|NCT00900302|stage IV verrucous carcinoma of the oral cavity
447941|NCT00900302|recurrent verrucous carcinoma of the oral cavity
447942|NCT00900302|metastatic squamous neck cancer with occult primary squamous cell carcinoma
447943|NCT00900302|recurrent metastatic squamous neck cancer with occult primary
447944|NCT00900302|untreated metastatic squamous neck cancer with occult primary
447945|NCT00900302|stage I squamous cell carcinoma of the nasopharynx
447946|NCT00900302|stage II squamous cell carcinoma of the nasopharynx
447947|NCT00900302|stage III squamous cell carcinoma of the nasopharynx
447948|NCT00900302|stage IV squamous cell carcinoma of the nasopharynx
447949|NCT00900302|recurrent squamous cell carcinoma of the nasopharynx
447950|NCT00900302|stage I squamous cell carcinoma of the oropharynx
447951|NCT00900302|stage II squamous cell carcinoma of the oropharynx
447952|NCT00900302|stage III squamous cell carcinoma of the oropharynx
447953|NCT00900302|stage IV squamous cell carcinoma of the oropharynx
447954|NCT00900302|recurrent squamous cell carcinoma of the oropharynx
447955|NCT00900302|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
447956|NCT00900302|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
447957|NCT00900302|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
447958|NCT00900302|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
447959|NCT00900302|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
447960|NCT00900302|salivary gland squamous cell carcinoma
447961|NCT00900302|stage I salivary gland cancer
447962|NCT00900302|stage II salivary gland cancer
447963|NCT00900302|stage III salivary gland cancer
447964|NCT00900302|stage IV salivary gland cancer
447965|NCT00900302|recurrent salivary gland cancer
447966|NCT00900302|squamous cell carcinoma of unknown primary
447967|NCT00900302|cervical squamous cell carcinoma
447968|NCT00900302|penile squamous cell carcinoma
447969|NCT00900302|recurrent anal cancer
447970|NCT00900302|stage I anal cancer
447971|NCT00900302|stage II anal cancer
447972|NCT00900302|stage IIIA anal cancer
447973|NCT00900302|stage IIIB anal cancer
447974|NCT00900302|stage IV anal cancer
447975|NCT00900302|recurrent bladder cancer
447976|NCT00900302|stage I bladder cancer
447977|NCT00900302|stage II bladder cancer
447978|NCT00900302|stage III bladder cancer
447979|NCT00900302|stage IV bladder cancer
447980|NCT00900302|recurrent esophageal cancer
447981|NCT00900302|stage I esophageal cancer
447982|NCT00900302|stage II esophageal cancer
447983|NCT00900302|stage III esophageal cancer
447984|NCT00900302|stage IV esophageal cancer
447985|NCT00900302|localized gallbladder cancer
447986|NCT00900302|recurrent gallbladder cancer
447987|NCT00900302|unresectable gallbladder cancer
447988|NCT00900302|recurrent vulvar cancer
447989|NCT00900302|stage I vulvar cancer
447990|NCT00900302|stage II vulvar cancer
447991|NCT00900302|stage III vulvar cancer
447992|NCT00900302|stage IV vulvar cancer
447993|NCT00900302|recurrent cervical cancer
447994|NCT00900302|stage IA cervical cancer
447995|NCT00900302|stage IB cervical cancer
447996|NCT00900302|stage IIA cervical cancer
447997|NCT00900302|stage IIB cervical cancer
447998|NCT00900302|stage III cervical cancer
447999|NCT00900302|stage IVA cervical cancer
448000|NCT00900302|stage IVB cervical cancer
448001|NCT00900302|recurrent non-small cell lung cancer
448002|NCT00900302|stage I non-small cell lung cancer
448003|NCT00900302|stage II non-small cell lung cancer
448004|NCT00900302|stage IIIA non-small cell lung cancer
448005|NCT00900302|stage IIIB non-small cell lung cancer
448006|NCT00900302|stage IV non-small cell lung cancer
448007|NCT00900302|recurrent skin cancer
448008|NCT00900302|newly diagnosed carcinoma of unknown primary
448009|NCT00900302|recurrent carcinoma of unknown primary
448010|NCT00900302|recurrent penile cancer
448011|NCT00900302|stage I penile cancer
448012|NCT00900302|stage II penile cancer
448013|NCT00900302|stage III penile cancer
448014|NCT00900302|stage IV penile cancer
448015|NCT00900302|recurrent melanoma
448016|NCT00900302|stage IA melanoma
448017|NCT00900302|stage IB melanoma
448018|NCT00900302|stage IIA melanoma
448019|NCT00900302|stage IIB melanoma
448020|NCT00900302|stage IIC melanoma
448021|NCT00900302|stage IIIA melanoma
448022|NCT00900302|stage IIIB melanoma
448023|NCT00900302|stage IIIC melanoma
448024|NCT00900302|stage IV melanoma
448025|NCT00900289|stage IC ovarian epithelial cancer
448026|NCT00900289|stage IIA ovarian epithelial cancer
448027|NCT00900289|stage IIB ovarian epithelial cancer
448028|NCT00900289|stage IIC ovarian epithelial cancer
448029|NCT00900289|stage IIIA ovarian epithelial cancer
448030|NCT00900289|stage IIIB ovarian epithelial cancer
448031|NCT00900289|stage IIIC ovarian epithelial cancer
448032|NCT00900289|stage IV ovarian epithelial cancer
448033|NCT00900276|localized transitional cell cancer of the renal pelvis and ureter
448034|NCT00900276|metastatic transitional cell cancer of the renal pelvis and ureter
448035|NCT00900276|recurrent transitional cell cancer of the renal pelvis and ureter
448036|NCT00900276|regional transitional cell cancer of the renal pelvis and ureter
448037|NCT00900276|transitional cell carcinoma of the bladder
448038|NCT00900276|stage I renal cell cancer
448039|NCT00900276|stage II renal cell cancer
448040|NCT00900276|recurrent renal cell cancer
448041|NCT00900276|recurrent bladder cancer
448042|NCT00900276|stage I bladder cancer
448043|NCT00900276|stage II bladder cancer
448044|NCT00900276|stage III bladder cancer
448045|NCT00900276|stage IV bladder cancer
448046|NCT00900276|anterior urethral cancer
448047|NCT00900276|posterior urethral cancer
448048|NCT00900276|recurrent urethral cancer
448049|NCT00900276|urethral cancer associated with invasive bladder cancer
448050|NCT00900263|stage I multiple myeloma
448051|NCT00900263|isolated plasmacytoma of bone
448052|NCT00900263|monoclonal gammopathy of undetermined significance
448053|NCT00900237|Partial
448054|NCT00900237|Epilepsy
448055|NCT00900237|Eslicarbazepine acetate
448056|NCT00900237|Pharmacokinetics
448057|NCT00900237|Tolerability
448058|NCT00900224|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448059|NCT00900224|adult acute myeloid leukemia with inv(16)(p13;q22)
448060|NCT00900224|adult acute myeloid leukemia with t(15;17)(q22;q12)
448061|NCT00900224|adult acute myeloid leukemia with t(16;16)(p13;q22)
448062|NCT00900224|adult acute myeloid leukemia with t(8;21)(q22;q22)
448063|NCT00900224|untreated adult acute myeloid leukemia
448064|NCT00900224|untreated childhood acute myeloid leukemia and other myeloid malignancies
448065|NCT00900224|secondary acute myeloid leukemia
448066|NCT00900211|recurrent adult soft tissue sarcoma
448067|NCT00900211|stage I adult soft tissue sarcoma
448068|NCT00900211|stage II adult soft tissue sarcoma
448069|NCT00900211|stage III adult soft tissue sarcoma
448070|NCT00900211|adult synovial sarcoma
448071|NCT00900211|adult angiosarcoma
448072|NCT00900211|adult epithelioid sarcoma
448073|NCT00900211|adult extraskeletal chondrosarcoma
448074|NCT00900211|adult leiomyosarcoma
448075|NCT00900211|adult liposarcoma
448076|NCT00900211|adult malignant fibrous histiocytoma
448077|NCT00900211|adult malignant hemangiopericytoma
448078|NCT00900211|adult malignant mesenchymoma
448079|NCT00900211|adult fibrosarcoma
448080|NCT00900211|adult neurofibrosarcoma
448081|NCT00900198|Tissue Collection
448082|NCT00900198|Biospecimen
448083|NCT00900198|Assay Development
448084|NCT00900198|Tissue Acquisition
448085|NCT00900198|Tissue Biopsies
448086|NCT00900185|recurrent prostate cancer
448087|NCT00900185|stage I prostate cancer
448088|NCT00900185|stage IIB prostate cancer
448089|NCT00900185|stage IIA prostate cancer
448090|NCT00900185|stage III prostate cancer
448091|NCT00900185|stage IV prostate cancer
448092|NCT00900172|stage IIIB non-small cell lung cancer
448093|NCT00900172|stage IV non-small cell lung cancer
448094|NCT00900172|recurrent non-small cell lung cancer
448095|NCT00900172|adenocarcinoma of the lung
448096|NCT00900172|bronchoalveolar cell lung cancer
448097|NCT00900159|Shift-work
448098|NCT00900159|SWSD
448099|NCT00900159|eszopiclone
448100|NCT00900159|MWT
448101|NCT00900159|shiftworkers
448102|NCT00900146|type 2 diabetes
448103|NCT00900146|canakinumab
448104|NCT00900133|stage I breast cancer
448105|NCT00900133|stage II breast cancer
448106|NCT00900133|stage IIIA breast cancer
448107|NCT00900133|stage IIIB breast cancer
448108|NCT00900133|stage IIIC breast cancer
448109|NCT00900120|aplastic anemia
448110|NCT00900120|myelodysplastic/myeloproliferative neoplasm, unclassifiable
448111|NCT00900120|unspecified adult solid tumor, protocol specific
448112|NCT00900120|unspecified childhood solid tumor, protocol specific
448113|NCT00900120|secondary myelodysplastic syndromes
448114|NCT00900120|accelerated phase chronic myelogenous leukemia
448115|NCT00900120|acute undifferentiated leukemia
448116|NCT00900120|adult acute lymphoblastic leukemia in remission
448117|NCT00900120|adult acute myeloid leukemia in remission
448118|NCT00900120|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448119|NCT00900120|adult acute myeloid leukemia with inv(16)(p13;q22)
448120|NCT00900120|adult acute myeloid leukemia with t(15;17)(q22;q12)
448121|NCT00900120|adult acute myeloid leukemia with t(16;16)(p13;q22)
448122|NCT00900120|adult acute myeloid leukemia with t(8;21)(q22;q22)
448123|NCT00900120|atypical chronic myeloid leukemia, BCR-ABL negative
448124|NCT00900120|blastic phase chronic myelogenous leukemia
448125|NCT00900120|childhood acute lymphoblastic leukemia in remission
448126|NCT00900120|childhood acute myeloid leukemia in remission
448127|NCT00900120|childhood chronic myelogenous leukemia
448128|NCT00900120|chronic myelomonocytic leukemia
448129|NCT00900120|chronic phase chronic myelogenous leukemia
448130|NCT00900120|juvenile myelomonocytic leukemia
448131|NCT00900120|mast cell leukemia
448132|NCT00900120|meningeal chronic myelogenous leukemia
448133|NCT00900120|progressive hairy cell leukemia, initial treatment
448134|NCT00900120|prolymphocytic leukemia
448135|NCT00900120|recurrent adult acute lymphoblastic leukemia
448136|NCT00900120|recurrent adult acute myeloid leukemia
448137|NCT00900120|recurrent adult T-cell leukemia/lymphoma
448138|NCT00900120|recurrent childhood acute lymphoblastic leukemia
448139|NCT00900120|recurrent childhood acute myeloid leukemia
448140|NCT00900120|refractory chronic lymphocytic leukemia
448141|NCT00900120|refractory hairy cell leukemia
448142|NCT00900120|relapsing chronic myelogenous leukemia
448143|NCT00900120|secondary acute myeloid leukemia
448144|NCT00900120|stage 0 chronic lymphocytic leukemia
448145|NCT00900120|stage I adult T-cell leukemia/lymphoma
448146|NCT00900120|stage I chronic lymphocytic leukemia
448147|NCT00900120|stage II adult T-cell leukemia/lymphoma
448148|NCT00900120|stage II chronic lymphocytic leukemia
448149|NCT00900120|stage III adult T-cell leukemia/lymphoma
448150|NCT00900120|stage III chronic lymphocytic leukemia
448151|NCT00900120|stage IV adult T-cell leukemia/lymphoma
448152|NCT00900120|stage IV chronic lymphocytic leukemia
448153|NCT00900120|T-cell large granular lymphocyte leukemia
448154|NCT00900120|untreated adult acute lymphoblastic leukemia
448155|NCT00900120|untreated adult acute myeloid leukemia
448156|NCT00900120|untreated childhood acute lymphoblastic leukemia
448157|NCT00900120|untreated childhood acute myeloid leukemia and other myeloid malignancies
448158|NCT00900120|untreated hairy cell leukemia
448159|NCT00900120|AIDS-related diffuse large cell lymphoma
448160|NCT00900120|AIDS-related diffuse mixed cell lymphoma
448161|NCT00900120|AIDS-related diffuse small cleaved cell lymphoma
448162|NCT00900120|AIDS-related immunoblastic large cell lymphoma
448163|NCT00900120|AIDS-related lymphoblastic lymphoma
448164|NCT00900120|AIDS-related peripheral/systemic lymphoma
448165|NCT00900120|AIDS-related primary CNS lymphoma
448166|NCT00900120|AIDS-related small noncleaved cell lymphoma
448167|NCT00900120|HIV-associated Hodgkin lymphoma
448168|NCT00900120|recurrent adult Hodgkin lymphoma
448169|NCT00900120|recurrent/refractory childhood Hodgkin lymphoma
448170|NCT00900120|stage I adult Hodgkin lymphoma
448171|NCT00900120|stage I childhood Hodgkin lymphoma
448172|NCT00900120|stage II adult Hodgkin lymphoma
448173|NCT00900120|stage II childhood Hodgkin lymphoma
448174|NCT00900120|stage III adult Hodgkin lymphoma
448175|NCT00900120|stage III childhood Hodgkin lymphoma
448176|NCT00900120|stage IV adult Hodgkin lymphoma
448177|NCT00900120|stage IV childhood Hodgkin lymphoma
448178|NCT00900120|anaplastic large cell lymphoma
448179|NCT00900120|angioimmunoblastic T-cell lymphoma
448180|NCT00900120|cutaneous B-cell non-Hodgkin lymphoma
448181|NCT00900120|recurrent cutaneous T-cell non-Hodgkin lymphoma
448182|NCT00900120|stage I cutaneous T-cell non-Hodgkin lymphoma
448183|NCT00900120|stage II cutaneous T-cell non-Hodgkin lymphoma
448184|NCT00900120|stage III cutaneous T-cell non-Hodgkin lymphoma
448185|NCT00900120|stage IV cutaneous T-cell non-Hodgkin lymphoma
448186|NCT00900120|recurrent mycosis fungoides/Sezary syndrome
448187|NCT00900120|stage I mycosis fungoides/Sezary syndrome
448188|NCT00900120|stage II mycosis fungoides/Sezary syndrome
448189|NCT00900120|stage III mycosis fungoides/Sezary syndrome
448190|NCT00900120|stage IV mycosis fungoides/Sezary syndrome
448191|NCT00900120|adult grade III lymphomatoid granulomatosis
448192|NCT00900120|adult nasal type extranodal NK/T-cell lymphoma
448193|NCT00900120|Waldenstrom macroglobulinemia
448194|NCT00900120|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
448195|NCT00900120|nodal marginal zone B-cell lymphoma
448196|NCT00900120|splenic marginal zone lymphoma
448197|NCT00900120|contiguous stage II adult Burkitt lymphoma
448198|NCT00900120|contiguous stage II adult diffuse large cell lymphoma
448199|NCT00900120|contiguous stage II adult diffuse mixed cell lymphoma
448200|NCT00900120|contiguous stage II adult diffuse small cleaved cell lymphoma
448201|NCT00900120|contiguous stage II adult immunoblastic large cell lymphoma
448202|NCT00900120|contiguous stage II adult lymphoblastic lymphoma
448203|NCT00900120|contiguous stage II grade 1 follicular lymphoma
448204|NCT00900120|contiguous stage II grade 2 follicular lymphoma
448205|NCT00900120|contiguous stage II grade 3 follicular lymphoma
448206|NCT00900120|contiguous stage II mantle cell lymphoma
448207|NCT00900120|contiguous stage II marginal zone lymphoma
448208|NCT00900120|contiguous stage II small lymphocytic lymphoma
448209|NCT00900120|stage I adult Burkitt lymphoma
448210|NCT00900120|stage I adult diffuse large cell lymphoma
448211|NCT00900120|stage I adult diffuse mixed cell lymphoma
448212|NCT00900120|stage I adult diffuse small cleaved cell lymphoma
448213|NCT00900120|stage I adult immunoblastic large cell lymphoma
448214|NCT00900120|stage I adult lymphoblastic lymphoma
448215|NCT00900120|stage I grade 1 follicular lymphoma
448216|NCT00900120|stage I grade 2 follicular lymphoma
448217|NCT00900120|stage I grade 3 follicular lymphoma
448218|NCT00900120|stage I mantle cell lymphoma
448219|NCT00900120|stage I marginal zone lymphoma
448220|NCT00900120|stage I small lymphocytic lymphoma
448221|NCT00900120|noncontiguous stage II adult Burkitt lymphoma
448222|NCT00900120|noncontiguous stage II adult diffuse large cell lymphoma
448223|NCT00900120|noncontiguous stage II adult diffuse mixed cell lymphoma
448224|NCT00900120|noncontiguous stage II adult diffuse small cleaved cell lymphoma
448225|NCT00900120|noncontiguous stage II adult immunoblastic large cell lymphoma
448226|NCT00900120|noncontiguous stage II adult lymphoblastic lymphoma
448227|NCT00900120|noncontiguous stage II grade 1 follicular lymphoma
448228|NCT00900120|noncontiguous stage II grade 2 follicular lymphoma
448229|NCT00900120|noncontiguous stage II grade 3 follicular lymphoma
448230|NCT00900120|noncontiguous stage II mantle cell lymphoma
448231|NCT00900120|noncontiguous stage II marginal zone lymphoma
448232|NCT00900120|noncontiguous stage II small lymphocytic lymphoma
448233|NCT00900120|stage I childhood large cell lymphoma
448234|NCT00900120|stage I childhood lymphoblastic lymphoma
448235|NCT00900120|stage I childhood small noncleaved cell lymphoma
449003|NCT00899132|skin cancer
448236|NCT00900120|stage II childhood large cell lymphoma
448237|NCT00900120|stage II childhood lymphoblastic lymphoma
448238|NCT00900120|stage II childhood small noncleaved cell lymphoma
448239|NCT00900120|stage III adult Burkitt lymphoma
448240|NCT00900120|stage III adult diffuse large cell lymphoma
448241|NCT00900120|stage III adult diffuse mixed cell lymphoma
448242|NCT00900120|stage III adult diffuse small cleaved cell lymphoma
448243|NCT00900120|stage III adult immunoblastic large cell lymphoma
448244|NCT00900120|stage III adult lymphoblastic lymphoma
448245|NCT00900120|stage III childhood large cell lymphoma
448246|NCT00900120|stage III childhood lymphoblastic lymphoma
448247|NCT00900120|stage III childhood small noncleaved cell lymphoma
448248|NCT00900120|stage III grade 1 follicular lymphoma
448249|NCT00900120|stage III grade 2 follicular lymphoma
448250|NCT00900120|stage III grade 3 follicular lymphoma
448251|NCT00900120|stage III mantle cell lymphoma
448252|NCT00900120|stage III marginal zone lymphoma
448253|NCT00900120|stage III small lymphocytic lymphoma
448254|NCT00900120|stage IV adult Burkitt lymphoma
448255|NCT00900120|stage IV adult diffuse large cell lymphoma
448256|NCT00900120|stage IV adult diffuse mixed cell lymphoma
448257|NCT00900120|stage IV adult diffuse small cleaved cell lymphoma
448258|NCT00900120|stage IV adult immunoblastic large cell lymphoma
448259|NCT00900120|stage IV adult lymphoblastic lymphoma
448260|NCT00900120|stage IV childhood large cell lymphoma
448261|NCT00900120|stage IV childhood lymphoblastic lymphoma
448262|NCT00900120|stage IV childhood small noncleaved cell lymphoma
448263|NCT00900120|stage IV grade 1 follicular lymphoma
448264|NCT00900120|stage IV grade 2 follicular lymphoma
448265|NCT00900120|stage IV grade 3 follicular lymphoma
448266|NCT00900120|stage IV mantle cell lymphoma
448267|NCT00900120|stage IV marginal zone lymphoma
448268|NCT00900120|stage IV small lymphocytic lymphoma
448269|NCT00900120|recurrent adult Burkitt lymphoma
448270|NCT00900120|recurrent adult diffuse large cell lymphoma
448271|NCT00900120|recurrent adult diffuse mixed cell lymphoma
448272|NCT00900120|recurrent adult diffuse small cleaved cell lymphoma
448273|NCT00900120|recurrent adult grade III lymphomatoid granulomatosis
448274|NCT00900120|recurrent adult immunoblastic large cell lymphoma
448275|NCT00900120|recurrent adult lymphoblastic lymphoma
448276|NCT00900120|recurrent childhood grade III lymphomatoid granulomatosis
448277|NCT00900120|recurrent childhood large cell lymphoma
448278|NCT00900120|recurrent childhood lymphoblastic lymphoma
448279|NCT00900120|recurrent childhood small noncleaved cell lymphoma
448280|NCT00900120|recurrent grade 1 follicular lymphoma
448281|NCT00900120|recurrent grade 2 follicular lymphoma
448282|NCT00900120|recurrent grade 3 follicular lymphoma
448283|NCT00900120|recurrent mantle cell lymphoma
448284|NCT00900120|recurrent marginal zone lymphoma
448285|NCT00900120|recurrent small lymphocytic lymphoma
448286|NCT00900120|Burkitt lymphoma
448287|NCT00900120|childhood diffuse large cell lymphoma
448288|NCT00900120|childhood grade III lymphomatoid granulomatosis
448289|NCT00900120|childhood immunoblastic large cell lymphoma
448290|NCT00900120|childhood nasal type extranodal NK/T-cell lymphoma
448291|NCT00900120|intraocular lymphoma
448292|NCT00900120|primary central nervous system non-Hodgkin lymphoma
448293|NCT00900120|primary central nervous system Hodgkin lymphoma
448294|NCT00900120|post-transplant lymphoproliferative disorder
448295|NCT00900120|chronic eosinophilic leukemia
448296|NCT00900120|chronic neutrophilic leukemia
448297|NCT00900120|primary myelofibrosis
448298|NCT00900120|essential thrombocythemia
448299|NCT00900120|polycythemia vera
448300|NCT00900120|extramedullary plasmacytoma
448301|NCT00900120|isolated plasmacytoma of bone
448302|NCT00900120|stage I multiple myeloma
448303|NCT00900120|stage II multiple myeloma
448304|NCT00900120|stage III multiple myeloma
448305|NCT00900120|primary systemic amyloidosis
448306|NCT00900120|refractory multiple myeloma
448307|NCT00900120|de novo myelodysplastic syndromes
448308|NCT00900120|previously treated myelodysplastic syndromes
448309|NCT00900120|childhood myelodysplastic syndromes
448310|NCT00900120|recurrent childhood anaplastic large cell lymphoma
448311|NCT00900120|stage I childhood anaplastic large cell lymphoma
448312|NCT00900120|stage II childhood anaplastic large cell lymphoma
448313|NCT00900120|stage III childhood anaplastic large cell lymphoma
448314|NCT00900120|stage IV childhood anaplastic large cell lymphoma
448315|NCT00900094|stage I breast cancer
448316|NCT00900094|stage II breast cancer
448317|NCT00900094|stage IIIA breast cancer
448318|NCT00900094|stage IIIB breast cancer
448319|NCT00900094|stage IV breast cancer
448320|NCT00900094|adenocarcinoma of the colon
448321|NCT00900094|stage I colon cancer
448322|NCT00900094|stage II colon cancer
448323|NCT00900094|stage III colon cancer
448324|NCT00900094|stage IV colon cancer
448325|NCT00900094|adenocarcinoma of the esophagus
448326|NCT00900094|squamous cell carcinoma of the esophagus
448327|NCT00900094|stage I esophageal cancer
448328|NCT00900094|stage II esophageal cancer
448329|NCT00900094|stage III esophageal cancer
448330|NCT00900094|stage IV esophageal cancer
448331|NCT00900094|stage I non-small cell lung cancer
448332|NCT00900094|stage II non-small cell lung cancer
448333|NCT00900094|stage IIIA non-small cell lung cancer
448334|NCT00900094|stage IIIB non-small cell lung cancer
448335|NCT00900094|stage IV non-small cell lung cancer
448336|NCT00900094|stage I ovarian epithelial cancer
448337|NCT00900094|stage II ovarian epithelial cancer
448338|NCT00900094|stage III ovarian epithelial cancer
448339|NCT00900094|stage IV ovarian epithelial cancer
448340|NCT00900094|localized unresectable adult primary liver cancer
448341|NCT00900094|advanced adult primary liver cancer
448342|NCT00900094|adenocarcinoma of the pancreas
448343|NCT00900094|stage II pancreatic cancer
448344|NCT00900094|stage III pancreatic cancer
448345|NCT00900094|extensive stage small cell lung cancer
448346|NCT00900094|stage IIIC breast cancer
448347|NCT00900094|stage IV pancreatic cancer
448348|NCT00900094|recurrent breast cancer
448349|NCT00900094|recurrent colon cancer
448350|NCT00900094|recurrent esophageal cancer
448351|NCT00900094|recurrent non-small cell lung cancer
448352|NCT00900094|recurrent ovarian epithelial cancer
448353|NCT00900094|recurrent adult primary liver cancer
448354|NCT00900094|adult primary hepatocellular carcinoma
448355|NCT00900094|recurrent small cell lung cancer
448356|NCT00900081|cervical squamous cell carcinoma
448357|NCT00900081|stage IA cervical cancer
448358|NCT00900081|stage 0 cervical cancer
448359|NCT00900081|cervical intraepithelial neoplasia grade 1
448360|NCT00900081|cervical intraepithelial neoplasia grade 2
448361|NCT00900081|cervical intraepithelial neoplasia grade 3
448362|NCT00900068|nausea and vomiting
448363|NCT00900068|stage III adult Burkitt lymphoma
448364|NCT00900068|stage III adult diffuse large cell lymphoma
448365|NCT00900068|stage III adult diffuse mixed cell lymphoma
448366|NCT00900068|stage III adult diffuse small cleaved cell lymphoma
448367|NCT00900068|stage III adult Hodgkin lymphoma
448368|NCT00900068|stage III adult immunoblastic large cell lymphoma
448369|NCT00900068|stage III adult lymphoblastic lymphoma
448370|NCT00900068|stage III grade 1 follicular lymphoma
448371|NCT00900068|stage III grade 2 follicular lymphoma
448372|NCT00900068|stage III grade 3 follicular lymphoma
448373|NCT00900068|stage III mantle cell lymphoma
448374|NCT00900068|stage III marginal zone lymphoma
448375|NCT00900068|stage III small lymphocytic lymphoma
448376|NCT00900068|stage IV adult Burkitt lymphoma
448377|NCT00900068|stage IV adult diffuse large cell lymphoma
448378|NCT00900068|stage IV adult diffuse mixed cell lymphoma
448379|NCT00900068|stage IV adult diffuse small cleaved cell lymphoma
448380|NCT00900068|stage IV adult Hodgkin lymphoma
448381|NCT00900068|stage IV adult immunoblastic large cell lymphoma
448382|NCT00900068|stage IV adult lymphoblastic lymphoma
448383|NCT00900068|stage IV grade 1 follicular lymphoma
448384|NCT00900068|stage IV grade 2 follicular lymphoma
448385|NCT00900068|stage IV grade 3 follicular lymphoma
448386|NCT00900068|stage IV mantle cell lymphoma
448387|NCT00900068|stage IV marginal zone lymphoma
448388|NCT00900068|stage IV small lymphocytic lymphoma
448389|NCT00900068|recurrent adult Burkitt lymphoma
448390|NCT00900068|recurrent adult diffuse large cell lymphoma
448391|NCT00900068|recurrent adult diffuse mixed cell lymphoma
448392|NCT00900068|recurrent adult diffuse small cleaved cell lymphoma
448393|NCT00900068|recurrent adult Hodgkin lymphoma
448394|NCT00900068|recurrent adult immunoblastic large cell lymphoma
448395|NCT00900068|recurrent adult lymphoblastic lymphoma
448396|NCT00900068|recurrent cutaneous T-cell non-Hodgkin lymphoma
448397|NCT00900068|recurrent grade 1 follicular lymphoma
448398|NCT00900068|recurrent grade 2 follicular lymphoma
448399|NCT00900068|recurrent grade 3 follicular lymphoma
448400|NCT00900068|recurrent mantle cell lymphoma
448401|NCT00900068|recurrent marginal zone lymphoma
448402|NCT00900068|recurrent small lymphocytic lymphoma
448403|NCT00900068|recurrent mycosis fungoides/Sezary syndrome
448404|NCT00900068|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
448405|NCT00900068|nodal marginal zone B-cell lymphoma
448406|NCT00900068|splenic marginal zone lymphoma
448407|NCT00900068|noncontiguous stage II adult Burkitt lymphoma
448408|NCT00900068|noncontiguous stage II adult diffuse large cell lymphoma
448409|NCT00900068|noncontiguous stage II adult diffuse mixed cell lymphoma
448410|NCT00900068|noncontiguous stage II adult diffuse small cleaved cell lymphoma
448411|NCT00900068|noncontiguous stage II adult immunoblastic large cell lymphoma
448412|NCT00900068|noncontiguous stage II adult lymphoblastic lymphoma
448413|NCT00900068|noncontiguous stage II grade 1 follicular lymphoma
448414|NCT00900068|noncontiguous stage II grade 2 follicular lymphoma
448415|NCT00900068|noncontiguous stage II grade 3 follicular lymphoma
448416|NCT00900068|noncontiguous stage II mantle cell lymphoma
448417|NCT00900068|noncontiguous stage II marginal zone lymphoma
448418|NCT00900068|noncontiguous stage II small lymphocytic lymphoma
448419|NCT00900068|accelerated phase chronic myelogenous leukemia
448420|NCT00900068|adult acute lymphoblastic leukemia in remission
448421|NCT00900068|adult acute myeloid leukemia in remission
448422|NCT00900068|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448423|NCT00900068|adult acute myeloid leukemia with inv(16)(p13;q22)
448424|NCT00900068|adult acute myeloid leukemia with t(15;17)(q22;q12)
448425|NCT00900068|adult acute myeloid leukemia with t(16;16)(p13;q22)
448426|NCT00900068|adult acute myeloid leukemia with t(8;21)(q22;q22)
448427|NCT00900068|atypical chronic myeloid leukemia, BCR-ABL negative
448428|NCT00900068|blastic phase chronic myelogenous leukemia
448429|NCT00900068|chronic myelomonocytic leukemia
448430|NCT00900068|chronic phase chronic myelogenous leukemia
448431|NCT00900068|recurrent adult acute lymphoblastic leukemia
448432|NCT00900068|recurrent adult acute myeloid leukemia
448433|NCT00900068|refractory chronic lymphocytic leukemia
448434|NCT00900068|refractory hairy cell leukemia
448435|NCT00900068|relapsing chronic myelogenous leukemia
448436|NCT00900068|secondary acute myeloid leukemia
448437|NCT00900068|stage III chronic lymphocytic leukemia
448438|NCT00900068|stage IV chronic lymphocytic leukemia
448439|NCT00900068|chronic eosinophilic leukemia
448440|NCT00900068|primary myelofibrosis
448441|NCT00900068|chronic neutrophilic leukemia
448442|NCT00900068|de novo myelodysplastic syndromes
448443|NCT00900068|disseminated neuroblastoma
448444|NCT00900068|myelodysplastic/myeloproliferative neoplasm, unclassifiable
448445|NCT00900068|poor prognosis metastatic gestational trophoblastic tumor
448446|NCT00900068|previously treated myelodysplastic syndromes
448447|NCT00900068|recurrent neuroblastoma
448448|NCT00900068|recurrent ovarian epithelial cancer
448449|NCT00900068|recurrent ovarian germ cell tumor
448450|NCT00900068|recurrent malignant testicular germ cell tumor
448451|NCT00900068|secondary myelodysplastic syndromes
448452|NCT00900068|stage I multiple myeloma
448453|NCT00900068|stage II multiple myeloma
448454|NCT00900068|stage III multiple myeloma
448455|NCT00900068|stage II ovarian epithelial cancer
448456|NCT00900068|stage III ovarian epithelial cancer
448457|NCT00900068|stage IV ovarian epithelial cancer
448458|NCT00900068|stage III malignant testicular germ cell tumor
448459|NCT00900068|stage IIIA breast cancer
448460|NCT00900068|stage IIIB breast cancer
448461|NCT00900068|stage IIIC breast cancer
448462|NCT00900068|stage IV breast cancer
448463|NCT00900068|refractory multiple myeloma
448464|NCT00900055|Fanconi anemia
448465|NCT00900055|multiple myeloma and other plasma cell neoplasms
448466|NCT00900055|chronic myeloproliferative disorders
448467|NCT00900055|myelodysplastic/myeloproliferative neoplasms
448468|NCT00900042|stage IV renal cell cancer
448469|NCT00900029|Venous Leg Ulcer
448470|NCT00900029|Venous Stasis Ulcer
448471|NCT00900029|VLU
448472|NCT00900029|VSU
448473|NCT00900029|Leg Ulcer
448474|NCT00900029|Leg Wound
448475|NCT00900016|adenocarcinoma of the pancreas
448476|NCT00900016|recurrent pancreatic cancer
448477|NCT00900016|stage I pancreatic cancer
448478|NCT00900016|stage II pancreatic cancer
448479|NCT00900003|stage I pancreatic cancer
448480|NCT00900003|stage II pancreatic cancer
448481|NCT00900003|stage III pancreatic cancer
448482|NCT00900003|stage IV pancreatic cancer
448483|NCT00899977|refractory hypertension
448484|NCT00899977|hypertension
448485|NCT00899951|unspecified adult solid tumor, protocol specific
448486|NCT00899951|accelerated phase chronic myelogenous leukemia
448487|NCT00899951|acute undifferentiated leukemia
448488|NCT00899951|adult acute lymphoblastic leukemia in remission
448489|NCT00899951|adult acute myeloid leukemia in remission
448490|NCT00899951|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448491|NCT00899951|adult acute myeloid leukemia with inv(16)(p13;q22)
448492|NCT00899951|adult acute myeloid leukemia with t(15;17)(q22;q12)
448493|NCT00899951|adult acute myeloid leukemia with t(16;16)(p13;q22)
448494|NCT00899951|adult acute myeloid leukemia with t(8;21)(q22;q22)
448495|NCT00899951|atypical chronic myeloid leukemia, BCR-ABL1 negative
448496|NCT00899951|blastic phase chronic myelogenous leukemia
448497|NCT00899951|chronic myelomonocytic leukemia
448498|NCT00899951|chronic phase chronic myelogenous leukemia
448499|NCT00899951|mast cell leukemia
448500|NCT00899951|meningeal chronic myelogenous leukemia
448501|NCT00899951|progressive hairy cell leukemia, initial treatment
448502|NCT00899951|prolymphocytic leukemia
448503|NCT00899951|recurrent adult acute lymphoblastic leukemia
448504|NCT00899951|recurrent adult acute myeloid leukemia
448505|NCT00899951|recurrent adult T-cell leukemia/lymphoma
448506|NCT00899951|refractory chronic lymphocytic leukemia
448507|NCT00899951|refractory hairy cell leukemia
448508|NCT00899951|relapsing chronic myelogenous leukemia
448509|NCT00899951|secondary acute myeloid leukemia
448510|NCT00899951|stage 0 chronic lymphocytic leukemia
448511|NCT00899951|stage I adult T-cell leukemia/lymphoma
448512|NCT00899951|stage I chronic lymphocytic leukemia
448513|NCT00899951|stage II adult T-cell leukemia/lymphoma
448514|NCT00899951|stage II chronic lymphocytic leukemia
448515|NCT00899951|stage III adult T-cell leukemia/lymphoma
448516|NCT00899951|stage III chronic lymphocytic leukemia
448517|NCT00899951|stage IV adult T-cell leukemia/lymphoma
448518|NCT00899951|stage IV chronic lymphocytic leukemia
448519|NCT00899951|T-cell large granular lymphocyte leukemia
448520|NCT00899951|recurrent adult Hodgkin lymphoma
448521|NCT00899951|stage I adult Hodgkin lymphoma
448522|NCT00899951|stage II adult Hodgkin lymphoma
448523|NCT00899951|stage III adult Hodgkin lymphoma
448524|NCT00899951|stage IV adult Hodgkin lymphoma
448525|NCT00899951|anaplastic large cell lymphoma
448526|NCT00899951|angioimmunoblastic T-cell lymphoma
448527|NCT00899951|cutaneous B-cell non-Hodgkin lymphoma
448528|NCT00899951|recurrent cutaneous T-cell non-Hodgkin lymphoma
448529|NCT00899951|stage I cutaneous T-cell non-Hodgkin lymphoma
448530|NCT00899951|stage II cutaneous T-cell non-Hodgkin lymphoma
448531|NCT00899951|stage III cutaneous T-cell non-Hodgkin lymphoma
448532|NCT00899951|stage IV cutaneous T-cell non-Hodgkin lymphoma
448533|NCT00899951|recurrent mycosis fungoides/Sezary syndrome
448534|NCT00899951|stage I mycosis fungoides/Sezary syndrome
448535|NCT00899951|stage II mycosis fungoides/Sezary syndrome
448536|NCT00899951|stage III mycosis fungoides/Sezary syndrome
448537|NCT00899951|stage IV mycosis fungoides/Sezary syndrome
448538|NCT00899951|adult grade III lymphomatoid granulomatosis
448539|NCT00899951|adult nasal type extranodal NK/T-cell lymphoma
448540|NCT00899951|Waldenström macroglobulinemia
448541|NCT00899951|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
448542|NCT00899951|nodal marginal zone B-cell lymphoma
448543|NCT00899951|splenic marginal zone lymphoma
448544|NCT00899951|contiguous stage II adult Burkitt lymphoma
448545|NCT00899951|contiguous stage II adult diffuse large cell lymphoma
448546|NCT00899951|contiguous stage II adult diffuse mixed cell lymphoma
448547|NCT00899951|contiguous stage II adult diffuse small cleaved cell lymphoma
448548|NCT00899951|contiguous stage II adult immunoblastic large cell lymphoma
448549|NCT00899951|contiguous stage II adult lymphoblastic lymphoma
448550|NCT00899951|contiguous stage II grade 1 follicular lymphoma
448551|NCT00899951|contiguous stage II grade 2 follicular lymphoma
448552|NCT00899951|contiguous stage II grade 3 follicular lymphoma
448553|NCT00899951|contiguous stage II mantle cell lymphoma
448554|NCT00899951|contiguous stage II marginal zone lymphoma
448555|NCT00899951|contiguous stage II small lymphocytic lymphoma
448556|NCT00899951|stage I adult Burkitt lymphoma
448557|NCT00899951|stage I adult diffuse large cell lymphoma
448558|NCT00899951|stage I adult diffuse mixed cell lymphoma
448559|NCT00899951|stage I adult diffuse small cleaved cell lymphoma
448560|NCT00899951|stage I adult immunoblastic large cell lymphoma
448561|NCT00899951|stage I adult lymphoblastic lymphoma
448562|NCT00899951|stage I grade 1 follicular lymphoma
448563|NCT00899951|stage I grade 2 follicular lymphoma
448564|NCT00899951|stage I grade 3 follicular lymphoma
448565|NCT00899951|stage I mantle cell lymphoma
448566|NCT00899951|stage I marginal zone lymphoma
448567|NCT00899951|stage I small lymphocytic lymphoma
448568|NCT00899951|noncontiguous stage II adult Burkitt lymphoma
448569|NCT00899951|noncontiguous stage II adult diffuse large cell lymphoma
448570|NCT00899951|noncontiguous stage II adult diffuse mixed cell lymphoma
448571|NCT00899951|noncontiguous stage II adult diffuse small cleaved cell lymphoma
448572|NCT00899951|noncontiguous stage II adult immunoblastic large cell lymphoma
448573|NCT00899951|noncontiguous stage II adult lymphoblastic lymphoma
448574|NCT00899951|noncontiguous stage II grade 1 follicular lymphoma
448575|NCT00899951|noncontiguous stage II grade 2 follicular lymphoma
448576|NCT00899951|noncontiguous stage II grade 3 follicular lymphoma
448577|NCT00899951|noncontiguous stage II mantle cell lymphoma
448578|NCT00899951|noncontiguous stage II marginal zone lymphoma
448579|NCT00899951|noncontiguous stage II small lymphocytic lymphoma
448580|NCT00899951|stage III adult Burkitt lymphoma
448581|NCT00899951|stage III adult diffuse large cell lymphoma
448582|NCT00899951|stage III adult diffuse mixed cell lymphoma
448583|NCT00899951|stage III adult diffuse small cleaved cell lymphoma
448584|NCT00899951|stage III adult immunoblastic large cell lymphoma
448585|NCT00899951|stage III adult lymphoblastic lymphoma
448586|NCT00899951|stage III grade 1 follicular lymphoma
448587|NCT00899951|stage III grade 2 follicular lymphoma
448588|NCT00899951|stage III grade 3 follicular lymphoma
448589|NCT00899951|stage III mantle cell lymphoma
448590|NCT00899951|stage III marginal zone lymphoma
448591|NCT00899951|stage III small lymphocytic lymphoma
448592|NCT00899951|stage IV adult Burkitt lymphoma
448593|NCT00899951|stage IV adult diffuse large cell lymphoma
448594|NCT00899951|stage IV adult diffuse mixed cell lymphoma
448595|NCT00899951|stage IV adult diffuse small cleaved cell lymphoma
448596|NCT00899951|stage IV adult immunoblastic large cell lymphoma
448597|NCT00899951|stage IV adult lymphoblastic lymphoma
448598|NCT00899951|stage IV grade 1 follicular lymphoma
448599|NCT00899951|stage IV grade 2 follicular lymphoma
448600|NCT00899951|stage IV grade 3 follicular lymphoma
448601|NCT00899951|stage IV mantle cell lymphoma
448602|NCT00899951|stage IV marginal zone lymphoma
448603|NCT00899951|stage IV small lymphocytic lymphoma
448604|NCT00899951|recurrent adult Burkitt lymphoma
448605|NCT00899951|recurrent adult diffuse large cell lymphoma
448606|NCT00899951|recurrent adult diffuse mixed cell lymphoma
448607|NCT00899951|recurrent adult diffuse small cleaved cell lymphoma
448608|NCT00899951|recurrent adult grade III lymphomatoid granulomatosis
448609|NCT00899951|recurrent adult immunoblastic large cell lymphoma
448610|NCT00899951|recurrent adult lymphoblastic lymphoma
448611|NCT00899951|recurrent grade 1 follicular lymphoma
448612|NCT00899951|recurrent grade 2 follicular lymphoma
448613|NCT00899951|recurrent grade 3 follicular lymphoma
448614|NCT00899951|recurrent mantle cell lymphoma
448615|NCT00899951|recurrent marginal zone lymphoma
448616|NCT00899951|recurrent small lymphocytic lymphoma
448617|NCT00899951|intraocular lymphoma
448618|NCT00899951|primary central nervous system non-Hodgkin lymphoma
448619|NCT00899951|primary central nervous system Hodgkin lymphoma
448620|NCT00899951|post-transplant lymphoproliferative disorder
448621|NCT00899951|chronic eosinophilic leukemia
448622|NCT00899951|chronic neutrophilic leukemia
448623|NCT00899951|primary myelofibrosis
448624|NCT00899951|essential thrombocythemia
448625|NCT00899951|polycythemia vera
448626|NCT00899951|extramedullary plasmacytoma
448627|NCT00899951|isolated plasmacytoma of bone
448628|NCT00899951|monoclonal gammopathy of undetermined significance
448629|NCT00899951|stage I multiple myeloma
448630|NCT00899951|stage II multiple myeloma
448631|NCT00899951|stage III multiple myeloma
448632|NCT00899951|primary systemic amyloidosis
448633|NCT00899951|refractory multiple myeloma
448634|NCT00899951|de novo myelodysplastic syndromes
448635|NCT00899951|previously treated myelodysplastic syndromes
448636|NCT00899951|secondary myelodysplastic syndromes
448637|NCT00899951|myelodysplastic/myeloproliferative neoplasm, unclassifiable
448638|NCT00899951|pain
448639|NCT00899912|stage IIB prostate cancer
448640|NCT00899912|stage IIA prostate cancer
448641|NCT00899912|adenocarcinoma of the prostate
448642|NCT00899899|adult acute lymphoblastic leukemia in remission
448643|NCT00899899|childhood acute lymphoblastic leukemia in remission
448644|NCT00899899|recurrent adult acute lymphoblastic leukemia
448645|NCT00899899|recurrent childhood acute lymphoblastic leukemia
448646|NCT00899873|chronic lymphocytic leukemia
448647|NCT00899860|recurrent renal cell cancer
448648|NCT00899860|stage I renal cell cancer
448649|NCT00899860|stage II renal cell cancer
448650|NCT00899860|stage III renal cell cancer
448651|NCT00899860|stage IV renal cell cancer
448652|NCT00899834|adult brain stem glioma
448653|NCT00899834|childhood brain stem glioma
448654|NCT00899821|recurrent metastatic squamous neck cancer with occult primary
448655|NCT00899821|untreated metastatic squamous neck cancer with occult primary
448656|NCT00899821|stage I squamous cell carcinoma of the hypopharynx
448657|NCT00899821|stage I squamous cell carcinoma of the larynx
448658|NCT00899821|stage I squamous cell carcinoma of the lip and oral cavity
448659|NCT00899821|stage I squamous cell carcinoma of the nasopharynx
448660|NCT00899821|stage I squamous cell carcinoma of the oropharynx
448661|NCT00899821|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
448662|NCT00899821|stage II squamous cell carcinoma of the hypopharynx
448663|NCT00899821|stage II squamous cell carcinoma of the larynx
448664|NCT00899821|stage II squamous cell carcinoma of the lip and oral cavity
448665|NCT00899821|stage II squamous cell carcinoma of the nasopharynx
448666|NCT00899821|stage II squamous cell carcinoma of the oropharynx
448667|NCT00899821|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
448668|NCT00899821|stage III squamous cell carcinoma of the hypopharynx
448669|NCT00899821|stage III squamous cell carcinoma of the larynx
448670|NCT00899821|stage III squamous cell carcinoma of the lip and oral cavity
448671|NCT00899821|stage III squamous cell carcinoma of the nasopharynx
448672|NCT00899821|stage III squamous cell carcinoma of the oropharynx
448673|NCT00899821|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
448674|NCT00899821|stage IV squamous cell carcinoma of the hypopharynx
448675|NCT00899821|stage IV squamous cell carcinoma of the larynx
448676|NCT00899821|stage IV squamous cell carcinoma of the lip and oral cavity
448677|NCT00899821|stage IV squamous cell carcinoma of the nasopharynx
448678|NCT00899821|stage IV squamous cell carcinoma of the oropharynx
448679|NCT00899821|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
448680|NCT00899821|recurrent squamous cell carcinoma of the hypopharynx
448681|NCT00899821|recurrent squamous cell carcinoma of the larynx
448682|NCT00899821|recurrent squamous cell carcinoma of the lip and oral cavity
448683|NCT00899821|recurrent squamous cell carcinoma of the nasopharynx
448684|NCT00899821|recurrent squamous cell carcinoma of the oropharynx
448685|NCT00899821|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
448686|NCT00899821|recurrent salivary gland cancer
448687|NCT00899821|salivary gland squamous cell carcinoma
448688|NCT00899821|stage I salivary gland cancer
448689|NCT00899821|stage II salivary gland cancer
448690|NCT00899821|stage III salivary gland cancer
448691|NCT00899821|stage IV salivary gland cancer
448692|NCT00899808|unspecified adult solid tumor, protocol specific
448693|NCT00899808|unspecified childhood solid tumor, protocol specific
448694|NCT00899808|hematopoietic/lymphoid cancer
448695|NCT00899795|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448696|NCT00899795|adult acute myeloid leukemia with inv(16)(p13;q22)
448697|NCT00899795|adult acute myeloid leukemia with t(15;17)(q22;q12)
448698|NCT00899795|adult acute myeloid leukemia with t(16;16)(p13;q22)
448699|NCT00899795|adult acute myeloid leukemia with t(8;21)(q22;q22)
448700|NCT00899795|de novo myelodysplastic syndromes
448701|NCT00899795|previously treated myelodysplastic syndromes
448702|NCT00899795|recurrent adult acute myeloid leukemia
448703|NCT00899795|secondary acute myeloid leukemia
448704|NCT00899795|secondary myelodysplastic syndromes
448705|NCT00899795|untreated adult acute myeloid leukemia
448706|NCT00899795|childhood myelodysplastic syndromes
448707|NCT00899769|metastatic squamous neck cancer with occult primary squamous cell carcinoma
448708|NCT00899769|recurrent squamous cell carcinoma of the hypopharynx
448709|NCT00899769|recurrent squamous cell carcinoma of the larynx
448710|NCT00899769|recurrent squamous cell carcinoma of the lip and oral cavity
448711|NCT00899769|recurrent squamous cell carcinoma of the nasopharynx
448712|NCT00899769|recurrent squamous cell carcinoma of the oropharynx
448713|NCT00899769|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
448714|NCT00899769|stage I squamous cell carcinoma of the hypopharynx
448715|NCT00899769|stage I squamous cell carcinoma of the larynx
448716|NCT00899769|stage I squamous cell carcinoma of the lip and oral cavity
448717|NCT00899769|stage I squamous cell carcinoma of the nasopharynx
448718|NCT00899769|stage I squamous cell carcinoma of the oropharynx
448719|NCT00899769|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
448720|NCT00899769|stage II squamous cell carcinoma of the hypopharynx
448721|NCT00899769|stage II squamous cell carcinoma of the larynx
448722|NCT00899769|stage II squamous cell carcinoma of the lip and oral cavity
448723|NCT00899769|stage II squamous cell carcinoma of the nasopharynx
448724|NCT00899769|stage II squamous cell carcinoma of the oropharynx
448725|NCT00899769|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
448726|NCT00899769|stage III squamous cell carcinoma of the hypopharynx
448727|NCT00899769|stage III squamous cell carcinoma of the larynx
448728|NCT00899769|stage III squamous cell carcinoma of the lip and oral cavity
448729|NCT00899769|stage III squamous cell carcinoma of the nasopharynx
448730|NCT00899769|stage III squamous cell carcinoma of the oropharynx
448731|NCT00899769|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
448732|NCT00899769|stage IV squamous cell carcinoma of the hypopharynx
448733|NCT00899769|stage IV squamous cell carcinoma of the larynx
448734|NCT00899769|stage IV squamous cell carcinoma of the lip and oral cavity
448735|NCT00899769|stage IV squamous cell carcinoma of the nasopharynx
448736|NCT00899769|stage IV squamous cell carcinoma of the oropharynx
448737|NCT00899769|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
448738|NCT00899769|untreated metastatic squamous neck cancer with occult primary
448739|NCT00899769|recurrent metastatic squamous neck cancer with occult primary
448740|NCT00899769|recurrent salivary gland cancer
448741|NCT00899769|salivary gland squamous cell carcinoma
448742|NCT00899769|stage I salivary gland cancer
448743|NCT00899769|stage II salivary gland cancer
448744|NCT00899769|stage III salivary gland cancer
448745|NCT00899769|stage IV salivary gland cancer
448746|NCT00899756|recurrent non-small cell lung cancer
448747|NCT00899756|stage IIIA non-small cell lung cancer
448748|NCT00899756|stage IIIB non-small cell lung cancer
448749|NCT00899756|stage IV non-small cell lung cancer
448750|NCT00899743|adult erythroleukemia (M6a)
448751|NCT00899743|adult pure erythroid leukemia (M6b)
448752|NCT00899743|adult acute megakaryoblastic leukemia (M7)
448753|NCT00899743|adult acute minimally differentiated myeloid leukemia (M0)
448754|NCT00899743|adult acute monoblastic leukemia (M5a)
448755|NCT00899743|adult acute monocytic leukemia (M5b)
448756|NCT00899743|adult acute myeloblastic leukemia with maturation (M2)
448757|NCT00899743|adult acute myeloblastic leukemia without maturation (M1)
448758|NCT00899743|adult acute myelomonocytic leukemia (M4)
448759|NCT00899743|adult acute myeloid leukemia with t(8;21)(q22;q22)
448760|NCT00899743|adult acute myeloid leukemia with t(16;16)(p13;q22)
448761|NCT00899743|adult acute myeloid leukemia with inv(16)(p13;q22)
448762|NCT00899743|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448763|NCT00899743|untreated adult acute myeloid leukemia
448764|NCT00899717|Temporomandibular Joint Disorders (TMD)
448765|NCT00899717|Orofacial pain
448766|NCT00899717|Limited mouth opening
448767|NCT00899717|Craniomandibular dysfunction syndrome
448768|NCT00899717|Axiography
448769|NCT00899717|Gnatography
448770|NCT00899717|Preferred chewing side
448771|NCT00899717|Occlusal adjustment
448772|NCT00899717|Selective grinding
448773|NCT00899717|Handedness
448774|NCT00899717|Bruxism
448775|NCT00899717|TMD
448776|NCT00899717|Costen's Syndrome
448777|NCT00899717|Myofascial pain
448778|NCT00899717|TMD treatment
448779|NCT00899717|Pain
448780|NCT00899704|stage I squamous cell carcinoma of the lip and oral cavity
448781|NCT00899704|stage II squamous cell carcinoma of the lip and oral cavity
448782|NCT00899704|tongue cancer
448783|NCT00899691|unspecified adult solid tumor, protocol specific
448784|NCT00899678|Certolizumab Pegol
448785|NCT00899678|Cimzia ®
448786|NCT00899678|Crohn's Disease
448787|NCT00899665|stage IV prostate cancer
448788|NCT00899665|bone metastases
448789|NCT00899665|anemia
448790|NCT00899665|monoclonal gammopathy of undetermined significance
448791|NCT00899665|de novo myelodysplastic syndromes
448792|NCT00899665|previously treated myelodysplastic syndromes
448793|NCT00899665|secondary myelodysplastic syndromes
448794|NCT00899652|childhood acute myelomonocytic leukemia (M4)
448795|NCT00899652|childhood acute monocytic leukemia (M5b)
448796|NCT00899652|childhood acute monoblastic leukemia (M5a)
448797|NCT00899652|secondary acute myeloid leukemia
448798|NCT00899652|untreated childhood acute lymphoblastic leukemia
448799|NCT00899652|untreated childhood acute myeloid leukemia and other myeloid malignancies
448800|NCT00899652|recurrent childhood acute lymphoblastic leukemia
448801|NCT00899652|recurrent childhood acute myeloid leukemia
448802|NCT00899639|stage I breast cancer
448803|NCT00899639|stage II breast cancer
448804|NCT00899639|stage IIIA breast cancer
448805|NCT00899639|estrogen receptor-positive breast cancer
448806|NCT00899639|male breast cancer
448807|NCT00899626|colon cancer
448808|NCT00899626|esophageal cancer
448809|NCT00899626|gastric cancer
448810|NCT00899626|pancreatic cancer
448811|NCT00899626|adenomatous polyp
448812|NCT00899613|localized malignant mesothelioma
448813|NCT00899613|lung metastases
448814|NCT00899613|malignant pleural effusion
448815|NCT00899600|chronic pain
448816|NCT00899600|back surgery
448817|NCT00899600|opioid dependent
448818|NCT00899600|NMDA receptor antagonism
448819|NCT00899600|Ketamine
448820|NCT00899600|Central sensitization
448821|NCT00899574|toll-like receptor
448822|NCT00899574|toll-like receptor agonist
448823|NCT00899574|recurrent breast cancer
448824|NCT00899574|breast cancer metastasized to skin and/or chestwall
448825|NCT00899574|immunomodulator
448826|NCT00899561|Chronic rhinosinusitis
448827|NCT00899561|Computed tomography
448828|NCT00899561|Histology
448829|NCT00899561|Middle turbinate
448830|NCT00899561|Morphometry
448831|NCT00899561|osteomyelitis
448832|NCT00899561|polyps
448833|NCT00899548|stage IV breast cancer
448834|NCT00899548|recurrent breast cancer
448835|NCT00899535|adenocarcinoma of the lung
448836|NCT00899535|large cell lung cancer
448837|NCT00899535|squamous cell lung cancer
448838|NCT00899535|stage I non-small cell lung cancer
448839|NCT00899535|stage II non-small cell lung cancer
448840|NCT00899522|Fanconi anemia
448841|NCT00899522|unspecified adult solid tumor, protocol specific
448842|NCT00899522|unspecified childhood solid tumor, protocol specific
448843|NCT00899509|stage II breast cancer
448844|NCT00899509|stage IIIA breast cancer
448845|NCT00899496|stage IV bladder cancer
448846|NCT00899496|stage IV colon cancer
448847|NCT00899496|stage IV non-small cell lung cancer
448848|NCT00899496|stage IV pancreatic cancer
448849|NCT00899496|stage IV rectal cancer
448850|NCT00899496|stage IV renal cell cancer
448851|NCT00899496|stage IV melanoma
448852|NCT00899496|stage III multiple myeloma
448853|NCT00899496|extensive stage small cell lung cancer
448854|NCT00899496|stage IV adult soft tissue sarcoma
448855|NCT00899496|stage III malignant testicular germ cell tumor
448856|NCT00899496|stage IV breast cancer
448857|NCT00899496|stage IV ovarian epithelial cancer
448858|NCT00899496|stage IV prostate cancer
448859|NCT00899496|stage IV endometrial carcinoma
448860|NCT00899496|unspecified adult solid tumor, protocol specific
448861|NCT00899496|metastatic osteosarcoma
448862|NCT00899496|stage IV uterine sarcoma
448863|NCT00899496|stage III ovarian epithelial cancer
448864|NCT00899496|ovarian sarcoma
448865|NCT00899496|stage IV adult Burkitt lymphoma
448866|NCT00899496|stage III adult diffuse large cell lymphoma
448867|NCT00899496|stage III adult diffuse mixed cell lymphoma
448868|NCT00899496|stage III adult diffuse small cleaved cell lymphoma
448869|NCT00899496|stage IV adult diffuse large cell lymphoma
448870|NCT00899496|stage IV adult diffuse mixed cell lymphoma
448871|NCT00899496|stage IV adult diffuse small cleaved cell lymphoma
448872|NCT00899496|stage III adult Burkitt lymphoma
448873|NCT00899496|stage III adult immunoblastic large cell lymphoma
448874|NCT00899496|stage IV adult immunoblastic large cell lymphoma
448875|NCT00899496|stage III adult lymphoblastic lymphoma
448876|NCT00899496|stage IV adult lymphoblastic lymphoma
448877|NCT00899496|stage IV grade 1 follicular lymphoma
448878|NCT00899496|stage IV grade 2 follicular lymphoma
448879|NCT00899496|stage IV grade 3 follicular lymphoma
448880|NCT00899496|stage III mantle cell lymphoma
448881|NCT00899496|stage IV mantle cell lymphoma
448882|NCT00899496|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
448883|NCT00899496|nodal marginal zone B-cell lymphoma
448884|NCT00899496|splenic marginal zone lymphoma
448885|NCT00899496|stage III marginal zone lymphoma
448886|NCT00899496|stage IV marginal zone lymphoma
448887|NCT00899496|stage III small lymphocytic lymphoma
448888|NCT00899496|stage IV small lymphocytic lymphoma
448889|NCT00899496|stage III mycosis fungoides/Sezary syndrome
448890|NCT00899496|stage IV mycosis fungoides/Sezary syndrome
448891|NCT00899496|cutaneous B-cell non-Hodgkin lymphoma
448892|NCT00899496|stage III cutaneous T-cell non-Hodgkin lymphoma
448893|NCT00899496|stage IV cutaneous T-cell non-Hodgkin lymphoma
448894|NCT00899496|stage III adult T-cell leukemia/lymphoma
448895|NCT00899496|stage IV adult T-cell leukemia/lymphoma
448896|NCT00899496|anaplastic large cell lymphoma
448897|NCT00899496|angioimmunoblastic T-cell lymphoma
448898|NCT00899496|adult nasal type extranodal NK/T-cell lymphoma
448899|NCT00899496|Waldenstrom macroglobulinemia
448900|NCT00899496|adult grade III lymphomatoid granulomatosis
448901|NCT00899496|primary central nervous system non-Hodgkin lymphoma
448902|NCT00899496|intraocular lymphoma
448903|NCT00899457|squamous cell lung cancer
448904|NCT00899457|non-small cell lung cancer
448905|NCT00899457|small cell lung cancer
448906|NCT00899457|healthy, no evidence of disease
448907|NCT00899431|Nonmyeloablative Stem Cell Transplantation
448908|NCT00899431|Chronic Lymphocytic Leukemia
448909|NCT00899431|CLL
448910|NCT00899431|Immunomanipulation
448911|NCT00899431|Fludarabine
448912|NCT00899431|Lenalidomide
448913|NCT00899431|Rituximab
448914|NCT00899431|Thymoglobulin
448915|NCT00899431|Stem Cell Transplantation
448916|NCT00899418|recurrent breast cancer
448917|NCT00899418|stage IV breast cancer
448918|NCT00899405|lung cancer
448919|NCT00899392|consent
448920|NCT00899392|Anxiety
448921|NCT00899392|Satisfaction
448922|NCT00899392|Efficiency
448923|NCT00899392|Questions
448924|NCT00899392|Attainment of Informed Consent (Consent-20)
448925|NCT00899392|Procedural State Anxiety (STAI)
448926|NCT00899392|Subject Satisfaction (mGHAA-9)
448927|NCT00899392|Duration in Endoscopy Suite
448928|NCT00899392|Number of questions asked
448929|NCT00899366|T-cell adult acute lymphoblastic leukemia
448930|NCT00899366|T-cell childhood acute lymphoblastic leukemia
448931|NCT00899366|untreated adult acute lymphoblastic leukemia
448932|NCT00899366|untreated childhood acute lymphoblastic leukemia
448933|NCT00899366|recurrent adult acute lymphoblastic leukemia
448934|NCT00899366|recurrent childhood acute lymphoblastic leukemia
448935|NCT00899366|adult acute lymphoblastic leukemia in remission
448936|NCT00899366|childhood acute lymphoblastic leukemia in remission
448937|NCT00899353|ES-CLL
448938|NCT00899353|MGUS
448939|NCT00899353|SMM
448940|NCT00899353|Early Stage - Chronic Lymphocytic Leukemia
448941|NCT00899340|recurrent squamous cell carcinoma of the oropharynx
448942|NCT00899340|stage I squamous cell carcinoma of the oropharynx
448943|NCT00899340|stage II squamous cell carcinoma of the oropharynx
448944|NCT00899340|stage III squamous cell carcinoma of the oropharynx
448945|NCT00899340|stage IV squamous cell carcinoma of the oropharynx
448946|NCT00899327|myelodysplastic syndromes
448947|NCT00899327|acute myeloid leukemia
448948|NCT00899301|breast cancer
448949|NCT00899301|stage IA breast cancer
448950|NCT00899301|stage IB breast cancer
448951|NCT00899301|stage II breast cancer
448952|NCT00899301|stage IIIA breast cancer
448953|NCT00899301|stage IIIB breast cancer
448954|NCT00899301|stage IIIC breast cancer
448955|NCT00899301|stage IV breast cancer
448956|NCT00899288|osteoporosis
448957|NCT00899288|stage I breast cancer
448958|NCT00899288|stage II breast cancer
448959|NCT00899288|stage IIIA breast cancer
448960|NCT00899275|osteosarcoma
448961|NCT00899262|lung cancer
448962|NCT00899262|tobacco use disorder
448963|NCT00899210|liver metastases
448964|NCT00899210|adenocarcinoma of the colon
448965|NCT00899210|stage IV colon cancer
448966|NCT00899210|adenocarcinoma of the rectum
448967|NCT00899210|stage IV rectal cancer
448968|NCT00899210|recurrent colon cancer
448969|NCT00899210|recurrent rectal cancer
448970|NCT00899197|stage I breast cancer
448971|NCT00899197|stage II breast cancer
448972|NCT00899197|stage IIIA breast cancer
448973|NCT00899197|stage IIIB breast cancer
448974|NCT00899184|recurrent prostate cancer
448975|NCT00899184|stage IV prostate cancer
448976|NCT00899184|stage I prostate cancer
448977|NCT00899184|stage IIB prostate cancer
448978|NCT00899184|stage IIA prostate cancer
448979|NCT00899184|stage III prostate cancer
448980|NCT00899171|adult acute myeloid leukemia in remission
448981|NCT00899171|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
448982|NCT00899171|adult acute myeloid leukemia with inv(16)(p13;q22)
448983|NCT00899171|adult acute myeloid leukemia with t(15;17)(q22;q12)
448984|NCT00899171|adult acute myeloid leukemia with t(16;16)(p13;q22)
448985|NCT00899171|adult acute myeloid leukemia with t(8;21)(q22;q22)
448986|NCT00899171|recurrent adult acute myeloid leukemia
448987|NCT00899171|untreated adult acute myeloid leukemia
448988|NCT00899171|adult acute erythroid leukemia (M6)
448989|NCT00899171|adult acute megakaryoblastic leukemia (M7)
448990|NCT00899171|adult acute minimally differentiated myeloid leukemia (M0)
448991|NCT00899171|adult acute monoblastic leukemia (M5a)
448992|NCT00899171|adult acute monocytic leukemia (M5b)
448993|NCT00899171|adult acute myeloblastic leukemia with maturation (M2)
448994|NCT00899171|adult acute myeloblastic leukemia without maturation (M1)
448995|NCT00899171|adult acute myelomonocytic leukemia (M4)
448996|NCT00899171|secondary acute myeloid leukemia
448997|NCT00899158|recurrent pancreatic cancer
448998|NCT00899158|stage I pancreatic cancer
448999|NCT00899158|stage II pancreatic cancer
449000|NCT00899158|stage III pancreatic cancer
449001|NCT00899158|stage IV pancreatic cancer
449002|NCT00899158|cachexia
449004|NCT00899132|small intestine cancer
449005|NCT00899132|pancreatic cancer
449006|NCT00899132|malignant testicular germ cell tumor
449007|NCT00899132|testicular teratoma
449008|NCT00899119|Waldenström macroglobulinemia
449009|NCT00899080|stage I multiple myeloma
449010|NCT00899080|stage II multiple myeloma
449011|NCT00899080|stage III multiple myeloma
449012|NCT00899041|Prosthesis
449013|NCT00899028|stage 0 non-small cell lung cancer
449014|NCT00899028|stage I non-small cell lung cancer
449015|NCT00899028|extensive stage small cell lung cancer
449016|NCT00899028|limited stage small cell lung cancer
449017|NCT00899028|stage II non-small cell lung cancer
449018|NCT00899028|stage IV non-small cell lung cancer
449019|NCT00899028|stage IIIA non-small cell lung cancer
449020|NCT00899028|stage IIIB non-small cell lung cancer
449021|NCT00899015|recurrent childhood acute myeloid leukemia
449022|NCT00899015|childhood acute promyelocytic leukemia (M3)
449023|NCT00899015|recurrent childhood acute lymphoblastic leukemia
449024|NCT00899015|recurrent childhood large cell lymphoma
449025|NCT00899015|recurrent childhood lymphoblastic lymphoma
449026|NCT00899015|recurrent childhood small noncleaved cell lymphoma
449027|NCT00899015|recurrent/refractory childhood Hodgkin lymphoma
449028|NCT00899015|childhood chronic myelogenous leukemia
449029|NCT00899015|atypical chronic myeloid leukemia, BCR-ABL1 negative
449030|NCT00899002|childhood hepatocellular carcinoma
449031|NCT00899002|childhood liver cancer
449032|NCT00899002|adult primary liver cancer
449033|NCT00899002|adult primary hepatocellular carcinoma
449034|NCT00898976|stage I breast cancer
449035|NCT00898976|stage II breast cancer
449036|NCT00898976|stage IV breast cancer
449037|NCT00898976|stage IIIA breast cancer
449038|NCT00898976|breast cancer in situ
449039|NCT00898976|recurrent breast cancer
449040|NCT00898976|stage IIIB breast cancer
449041|NCT00898976|inflammatory breast cancer
449042|NCT00898976|stage IIIC breast cancer
449043|NCT00898963|stage III grade 1 follicular lymphoma
449044|NCT00898963|stage III grade 2 follicular lymphoma
449045|NCT00898963|stage III grade 3 follicular lymphoma
449046|NCT00898963|stage IV grade 1 follicular lymphoma
449047|NCT00898963|stage IV grade 2 follicular lymphoma
449048|NCT00898963|stage IV grade 3 follicular lymphoma
449049|NCT00898950|diabetes
449050|NCT00898950|aspirin
449051|NCT00898950|oxidative stress
449052|NCT00898950|insulin resistance
449053|NCT00898950|endothelial function
449054|NCT00898950|inflammation
449055|NCT00898950|photoplethysmography
449056|NCT00898950|dysglycaemia
449057|NCT00898937|breast cancer
449058|NCT00898924|stage IIIA non-small cell lung cancer
449059|NCT00898924|stage IIIB non-small cell lung cancer
449060|NCT00898911|recurrent squamous cell carcinoma of the hypopharynx
449061|NCT00898911|stage IV squamous cell carcinoma of the hypopharynx
449062|NCT00898911|stage IV squamous cell carcinoma of the larynx
449063|NCT00898911|stage IV verrucous carcinoma of the larynx
449064|NCT00898911|recurrent squamous cell carcinoma of the larynx
449065|NCT00898911|recurrent verrucous carcinoma of the larynx
449066|NCT00898911|recurrent squamous cell carcinoma of the lip and oral cavity
449067|NCT00898911|stage IV squamous cell carcinoma of the lip and oral cavity
449068|NCT00898911|recurrent verrucous carcinoma of the oral cavity
449069|NCT00898911|stage IV verrucous carcinoma of the oral cavity
449070|NCT00898911|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449071|NCT00898911|recurrent metastatic squamous neck cancer with occult primary
449072|NCT00898911|recurrent squamous cell carcinoma of the nasopharynx
449073|NCT00898911|stage IV squamous cell carcinoma of the nasopharynx
449074|NCT00898911|recurrent squamous cell carcinoma of the oropharynx
449075|NCT00898911|stage IV squamous cell carcinoma of the oropharynx
449076|NCT00898911|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
449077|NCT00898911|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449078|NCT00898911|recurrent salivary gland cancer
449079|NCT00898911|salivary gland squamous cell carcinoma
449080|NCT00898911|stage IV salivary gland cancer
449081|NCT00898898|stage IA breast cancer
449082|NCT00898898|stage IB breast cancer
449083|NCT00898898|stage II breast cancer
449084|NCT00898898|stage IIIA breast cancer
449085|NCT00898898|HER2-positive breast cancer
449086|NCT00898885|oral manifestations
449087|NCT00898885|bone marrow transplantation
449088|NCT00898885|adverse effects
449089|NCT00898872|recurrent grade 3 follicular lymphoma
449090|NCT00898872|recurrent adult diffuse small cleaved cell lymphoma
449091|NCT00898872|recurrent adult diffuse mixed cell lymphoma
449092|NCT00898872|recurrent adult diffuse large cell lymphoma
449093|NCT00898872|recurrent adult immunoblastic large cell lymphoma
449094|NCT00898872|recurrent adult lymphoblastic lymphoma
449095|NCT00898872|recurrent adult Burkitt lymphoma
449096|NCT00898872|recurrent adult grade III lymphomatoid granulomatosis
449097|NCT00898872|recurrent grade 1 follicular lymphoma
449098|NCT00898872|recurrent grade 2 follicular lymphoma
449099|NCT00898872|recurrent mantle cell lymphoma
449100|NCT00898872|recurrent marginal zone lymphoma
449101|NCT00898872|recurrent small lymphocytic lymphoma
449102|NCT00898872|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
449103|NCT00898872|nodal marginal zone B-cell lymphoma
449104|NCT00898872|splenic marginal zone lymphoma
449105|NCT00898872|Waldenström macroglobulinemia
449106|NCT00898872|adult nasal type extranodal NK/T-cell lymphoma
449107|NCT00898872|recurrent childhood grade III lymphomatoid granulomatosis
449108|NCT00898872|recurrent childhood large cell lymphoma
449109|NCT00898872|recurrent childhood lymphoblastic lymphoma
449110|NCT00898872|recurrent childhood small noncleaved cell lymphoma
449111|NCT00898872|childhood diffuse large cell lymphoma
449112|NCT00898872|childhood immunoblastic large cell lymphoma
449113|NCT00898872|childhood Burkitt lymphoma
449114|NCT00898872|childhood nasal type extranodal NK/T-cell lymphoma
449115|NCT00898859|ADAM
449116|NCT00898859|epithelial
449117|NCT00898859|COPD
449118|NCT00898846|stage II colon cancer
449119|NCT00898846|stage II rectal cancer
449120|NCT00898846|adenocarcinoma of the colon
449121|NCT00898846|adenocarcinoma of the rectum
449122|NCT00898833|recurrent prostate cancer
449123|NCT00898833|stage III prostate cancer
449124|NCT00898833|stage IV prostate cancer
449125|NCT00898833|adenocarcinoma of the prostate
449126|NCT00898820|stage IIIB non-small cell lung cancer
449127|NCT00898820|stage IV non-small cell lung cancer
449128|NCT00898820|recurrent non-small cell lung cancer
449129|NCT00898807|neuropsychiatric symptoms
449130|NCT00898807|aggression
449131|NCT00898807|mood lability
449132|NCT00898794|unspecified adult solid tumor, protocol specific
449133|NCT00898794|unspecified childhood solid tumor, protocol specific
449134|NCT00898781|male breast cancer
449135|NCT00898781|stage IV breast cancer
449136|NCT00898781|stage IV ovarian epithelial cancer
449137|NCT00898781|stage IV ovarian germ cell tumor
449138|NCT00898781|stage IV pancreatic cancer
449139|NCT00898781|stage IV colon cancer
449140|NCT00898781|ovarian sarcoma
449141|NCT00898768|Lynch syndrome
449142|NCT00898768|HNPCC
449143|NCT00898768|Capsule endoscopy
449144|NCT00898768|Small bowel cancer
449145|NCT00898768|Double balloon endoscopy
449146|NCT00898755|childhood acute lymphoblastic leukemia in remission
449147|NCT00898755|unspecified childhood solid tumor, protocol specific
449148|NCT00898755|childhood acute myeloid leukemia in remission
449149|NCT00898755|childhood central nervous system germ cell tumor
449150|NCT00898755|childhood choroid plexus tumor
449151|NCT00898755|childhood chronic myelogenous leukemia
449152|NCT00898755|childhood craniopharyngioma
449153|NCT00898755|childhood diffuse large cell lymphoma
449154|NCT00898755|childhood extragonadal germ cell tumor
449155|NCT00898755|childhood grade III lymphomatoid granulomatosis
449156|NCT00898755|childhood infratentorial ependymoma
449157|NCT00898755|childhood teratoma
449158|NCT00898755|childhood grade I meningioma
449159|NCT00898755|childhood grade II meningioma
449160|NCT00898755|childhood grade III meningioma
449161|NCT00898755|childhood supratentorial ependymoma
449162|NCT00898755|childhood high-grade cerebral astrocytoma
449163|NCT00898755|childhood low-grade cerebral astrocytoma
449164|NCT00898755|metastatic childhood soft tissue sarcoma
449165|NCT00898755|newly diagnosed childhood ependymoma
449166|NCT00898755|nonmetastatic childhood soft tissue sarcoma
449167|NCT00898755|previously treated childhood rhabdomyosarcoma
449168|NCT00898755|previously untreated childhood rhabdomyosarcoma
449169|NCT00898755|recurrent childhood acute lymphoblastic leukemia
449170|NCT00898755|recurrent childhood acute myeloid leukemia
449171|NCT00898755|recurrent childhood brain stem glioma
449172|NCT00898755|recurrent childhood cerebellar astrocytoma
449173|NCT00898755|recurrent childhood cerebral astrocytoma
449174|NCT00898755|recurrent childhood ependymoma
449175|NCT00898755|recurrent childhood grade III lymphomatoid granulomatosis
449176|NCT00898755|recurrent childhood large cell lymphoma
449177|NCT00898755|recurrent childhood lymphoblastic lymphoma
449178|NCT00898755|recurrent childhood malignant germ cell tumor
449179|NCT00898755|recurrent childhood medulloblastoma
449180|NCT00898755|recurrent childhood rhabdomyosarcoma
449181|NCT00898755|recurrent childhood small noncleaved cell lymphoma
449182|NCT00898755|recurrent childhood soft tissue sarcoma
449183|NCT00898755|recurrent childhood supratentorial primitive neuroectodermal tumor
449184|NCT00898755|recurrent childhood visual pathway and hypothalamic glioma
449185|NCT00898755|recurrent Wilms tumor and other childhood kidney tumors
449186|NCT00898755|recurrent/refractory childhood Hodgkin lymphoma
449187|NCT00898755|stage I childhood Hodgkin lymphoma
449188|NCT00898755|stage I childhood large cell lymphoma
449189|NCT00898755|stage I childhood liver cancer
449190|NCT00898755|stage I childhood lymphoblastic lymphoma
449191|NCT00898755|stage I childhood small noncleaved cell lymphoma
449192|NCT00898755|stage II childhood Hodgkin lymphoma
449193|NCT00898755|stage II childhood large cell lymphoma
449194|NCT00898755|stage II childhood lymphoblastic lymphoma
449195|NCT00898755|stage II childhood small noncleaved cell lymphoma
449196|NCT00898755|stage III childhood Hodgkin lymphoma
449197|NCT00898755|stage III childhood large cell lymphoma
449198|NCT00898755|stage III childhood lymphoblastic lymphoma
449199|NCT00898755|stage III childhood small noncleaved cell lymphoma
449200|NCT00898755|stage IV childhood Hodgkin lymphoma
449201|NCT00898755|stage IV childhood large cell lymphoma
449202|NCT00898755|stage IV childhood lymphoblastic lymphoma
449203|NCT00898755|stage IV childhood small noncleaved cell lymphoma
449204|NCT00898755|untreated childhood acute lymphoblastic leukemia
449205|NCT00898755|untreated childhood acute myeloid leukemia and other myeloid malignancies
449206|NCT00898755|untreated childhood brain stem glioma
449207|NCT00898755|untreated childhood cerebellar astrocytoma
449208|NCT00898755|untreated childhood medulloblastoma
449209|NCT00898755|untreated childhood supratentorial primitive neuroectodermal tumor
449210|NCT00898755|untreated childhood visual pathway and hypothalamic glioma
449211|NCT00898755|childhood hepatoblastoma
449212|NCT00898755|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
449213|NCT00898755|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
449214|NCT00898755|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
449215|NCT00898755|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
449216|NCT00898755|childhood hepatocellular carcinoma
449217|NCT00898755|childhood immunoblastic large cell lymphoma
449218|NCT00898755|childhood malignant ovarian germ cell tumor
449219|NCT00898755|childhood malignant testicular germ cell tumor
449220|NCT00898755|childhood Langerhans cell histiocytosis
449221|NCT00898755|alveolar childhood rhabdomyosarcoma
449222|NCT00898755|childhood Burkitt lymphoma
449223|NCT00898755|de novo myelodysplastic syndromes
449224|NCT00898755|previously treated myelodysplastic syndromes
449225|NCT00898755|secondary myelodysplastic syndromes
449226|NCT00898755|disseminated neuroblastoma
449227|NCT00898755|localized resectable neuroblastoma
449228|NCT00898755|localized unresectable neuroblastoma
449229|NCT00898755|recurrent neuroblastoma
449230|NCT00898755|regional neuroblastoma
449231|NCT00898755|stage 4S neuroblastoma
449232|NCT00898755|childhood germ cell tumor
449233|NCT00898755|recurrent childhood liver cancer
449234|NCT00898755|localized osteosarcoma
449235|NCT00898755|metastatic osteosarcoma
449236|NCT00898755|recurrent osteosarcoma
449237|NCT00898755|extraocular retinoblastoma
449238|NCT00898755|intraocular retinoblastoma
449239|NCT00898755|recurrent retinoblastoma
449240|NCT00898755|stage I Wilms tumor
449241|NCT00898755|stage II Wilms tumor
449242|NCT00898755|stage III Wilms tumor
449243|NCT00898755|stage IV Wilms tumor
449244|NCT00898755|stage II childhood liver cancer
449245|NCT00898755|stage III childhood liver cancer
449246|NCT00898755|stage IV childhood liver cancer
449247|NCT00898755|unusual cancers of childhood
449248|NCT00898755|stage V Wilms tumor
449249|NCT00898755|childhood myelodysplastic syndromes
449250|NCT00898755|childhood atypical teratoid/rhabdoid tumor
449251|NCT00898755|rhabdoid tumor of the kidney
449252|NCT00898755|childhood extracranial germ cell tumor
449253|NCT00898755|childhood central nervous system choriocarcinoma
449254|NCT00898755|childhood central nervous system embryonal tumor
449255|NCT00898755|recurrent childhood central nervous system embryonal tumor
449256|NCT00898755|childhood central nervous system germinoma
449257|NCT00898755|childhood central nervous system mixed germ cell tumor
449258|NCT00898755|childhood central nervous system teratoma
449259|NCT00898755|childhood central nervous system yolk sac tumor
449260|NCT00898742|recurrent squamous cell carcinoma of the hypopharynx
449261|NCT00898742|stage IV squamous cell carcinoma of the hypopharynx
449262|NCT00898742|stage IV squamous cell carcinoma of the larynx
449263|NCT00898742|stage IV verrucous carcinoma of the larynx
449264|NCT00898742|recurrent squamous cell carcinoma of the larynx
449265|NCT00898742|recurrent verrucous carcinoma of the larynx
449266|NCT00898742|recurrent squamous cell carcinoma of the lip and oral cavity
449267|NCT00898742|stage IV squamous cell carcinoma of the lip and oral cavity
449268|NCT00898742|recurrent verrucous carcinoma of the oral cavity
449269|NCT00898742|stage IV verrucous carcinoma of the oral cavity
449270|NCT00898742|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449271|NCT00898742|recurrent metastatic squamous neck cancer with occult primary
449272|NCT00898742|recurrent squamous cell carcinoma of the nasopharynx
449273|NCT00898742|stage IV squamous cell carcinoma of the nasopharynx
449274|NCT00898742|recurrent squamous cell carcinoma of the oropharynx
449275|NCT00898742|stage IV squamous cell carcinoma of the oropharynx
449276|NCT00898742|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
449277|NCT00898742|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449278|NCT00898742|recurrent salivary gland cancer
449279|NCT00898742|salivary gland squamous cell carcinoma
449280|NCT00898742|stage IV salivary gland cancer
449281|NCT00898703|breast cancer
449282|NCT00898690|stage I breast cancer
449283|NCT00898690|stage II breast cancer
449284|NCT00898690|stage IIIA breast cancer
449285|NCT00898690|stage IIIB breast cancer
449286|NCT00898690|stage IIIC breast cancer
449287|NCT00898690|stage IV breast cancer
449288|NCT00898690|recurrent breast cancer
449289|NCT00898664|stage I squamous cell carcinoma of the hypopharynx
449290|NCT00898664|stage II squamous cell carcinoma of the hypopharynx
449291|NCT00898664|stage III squamous cell carcinoma of the hypopharynx
449292|NCT00898664|stage IV squamous cell carcinoma of the hypopharynx
449293|NCT00898664|recurrent squamous cell carcinoma of the hypopharynx
449294|NCT00898664|stage I squamous cell carcinoma of the larynx
449295|NCT00898664|stage II squamous cell carcinoma of the larynx
449296|NCT00898664|stage III squamous cell carcinoma of the larynx
449297|NCT00898664|stage IV squamous cell carcinoma of the larynx
449298|NCT00898664|recurrent squamous cell carcinoma of the larynx
449299|NCT00898664|stage I squamous cell carcinoma of the lip and oral cavity
449300|NCT00898664|stage II squamous cell carcinoma of the lip and oral cavity
449301|NCT00898664|stage III squamous cell carcinoma of the lip and oral cavity
449302|NCT00898664|stage IV squamous cell carcinoma of the lip and oral cavity
449303|NCT00898664|recurrent squamous cell carcinoma of the lip and oral cavity
449304|NCT00898664|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449305|NCT00898664|recurrent metastatic squamous neck cancer with occult primary
449306|NCT00898664|untreated metastatic squamous neck cancer with occult primary
449307|NCT00898664|stage I squamous cell carcinoma of the nasopharynx
449308|NCT00898664|stage II squamous cell carcinoma of the nasopharynx
449309|NCT00898664|stage III squamous cell carcinoma of the nasopharynx
449310|NCT00898664|stage IV squamous cell carcinoma of the nasopharynx
449311|NCT00898664|recurrent squamous cell carcinoma of the nasopharynx
449312|NCT00898664|stage I squamous cell carcinoma of the oropharynx
449313|NCT00898664|stage II squamous cell carcinoma of the oropharynx
449314|NCT00898664|stage III squamous cell carcinoma of the oropharynx
449315|NCT00898664|stage IV squamous cell carcinoma of the oropharynx
449316|NCT00898664|recurrent squamous cell carcinoma of the oropharynx
449317|NCT00898664|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
449318|NCT00898664|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
449319|NCT00898664|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
449320|NCT00898664|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449321|NCT00898664|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
449322|NCT00898664|salivary gland squamous cell carcinoma
449323|NCT00898664|stage I salivary gland cancer
449324|NCT00898664|stage II salivary gland cancer
449325|NCT00898664|stage III salivary gland cancer
449326|NCT00898664|stage IV salivary gland cancer
449327|NCT00898664|recurrent salivary gland cancer
449328|NCT00898638|stage I squamous cell carcinoma of the hypopharynx
449329|NCT00898638|stage II squamous cell carcinoma of the hypopharynx
449330|NCT00898638|stage III squamous cell carcinoma of the hypopharynx
449331|NCT00898638|stage IV squamous cell carcinoma of the hypopharynx
449332|NCT00898638|recurrent squamous cell carcinoma of the hypopharynx
449333|NCT00898638|stage I squamous cell carcinoma of the larynx
449334|NCT00898638|stage I verrucous carcinoma of the larynx
449335|NCT00898638|stage II squamous cell carcinoma of the larynx
449336|NCT00898638|stage II verrucous carcinoma of the larynx
449337|NCT00898638|stage III squamous cell carcinoma of the larynx
449338|NCT00898638|stage III verrucous carcinoma of the larynx
449339|NCT00898638|stage IV squamous cell carcinoma of the larynx
449340|NCT00898638|stage IV verrucous carcinoma of the larynx
449341|NCT00898638|recurrent squamous cell carcinoma of the larynx
449342|NCT00898638|recurrent verrucous carcinoma of the larynx
449343|NCT00898638|stage I adenoid cystic carcinoma of the oral cavity
449344|NCT00898638|stage I basal cell carcinoma of the lip
449345|NCT00898638|stage I mucoepidermoid carcinoma of the oral cavity
449346|NCT00898638|stage I squamous cell carcinoma of the lip and oral cavity
449347|NCT00898638|stage I verrucous carcinoma of the oral cavity
449348|NCT00898638|stage II adenoid cystic carcinoma of the oral cavity
449349|NCT00898638|stage II basal cell carcinoma of the lip
449350|NCT00898638|stage II mucoepidermoid carcinoma of the oral cavity
449351|NCT00898638|stage II squamous cell carcinoma of the lip and oral cavity
449352|NCT00898638|stage II verrucous carcinoma of the oral cavity
449353|NCT00898638|stage III adenoid cystic carcinoma of the oral cavity
449354|NCT00898638|stage III basal cell carcinoma of the lip
449355|NCT00898638|stage III mucoepidermoid carcinoma of the oral cavity
449356|NCT00898638|stage III squamous cell carcinoma of the lip and oral cavity
449357|NCT00898638|stage III verrucous carcinoma of the oral cavity
449358|NCT00898638|stage IV adenoid cystic carcinoma of the oral cavity
449359|NCT00898638|stage IV basal cell carcinoma of the lip
449360|NCT00898638|stage IV mucoepidermoid carcinoma of the oral cavity
449361|NCT00898638|stage IV squamous cell carcinoma of the lip and oral cavity
449362|NCT00898638|stage IV verrucous carcinoma of the oral cavity
449363|NCT00898638|recurrent adenoid cystic carcinoma of the oral cavity
449364|NCT00898638|recurrent basal cell carcinoma of the lip
449365|NCT00898638|recurrent mucoepidermoid carcinoma of the oral cavity
449366|NCT00898638|recurrent squamous cell carcinoma of the lip and oral cavity
449367|NCT00898638|recurrent verrucous carcinoma of the oral cavity
449368|NCT00898638|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449369|NCT00898638|recurrent metastatic squamous neck cancer with occult primary
449370|NCT00898638|untreated metastatic squamous neck cancer with occult primary
449371|NCT00898638|stage I lymphoepithelioma of the nasopharynx
449372|NCT00898638|stage I squamous cell carcinoma of the nasopharynx
449373|NCT00898638|stage II lymphoepithelioma of the nasopharynx
449374|NCT00898638|stage II squamous cell carcinoma of the nasopharynx
449375|NCT00898638|stage III lymphoepithelioma of the nasopharynx
449376|NCT00898638|stage III squamous cell carcinoma of the nasopharynx
449377|NCT00898638|stage IV lymphoepithelioma of the nasopharynx
449378|NCT00898638|stage IV squamous cell carcinoma of the nasopharynx
449379|NCT00898638|recurrent lymphoepithelioma of the nasopharynx
449380|NCT00898638|recurrent squamous cell carcinoma of the nasopharynx
449381|NCT00898638|stage I lymphoepithelioma of the oropharynx
449382|NCT00898638|stage I squamous cell carcinoma of the oropharynx
449383|NCT00898638|stage II lymphoepithelioma of the oropharynx
449384|NCT00898638|stage II squamous cell carcinoma of the oropharynx
449385|NCT00898638|stage III lymphoepithelioma of the oropharynx
449386|NCT00898638|stage III squamous cell carcinoma of the oropharynx
449387|NCT00898638|stage IV lymphoepithelioma of the oropharynx
449388|NCT00898638|stage IV squamous cell carcinoma of the oropharynx
449389|NCT00898638|recurrent lymphoepithelioma of the oropharynx
449390|NCT00898638|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
449391|NCT00898638|stage I inverted papilloma of the paranasal sinus and nasal cavity
449392|NCT00898638|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
449393|NCT00898638|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
449394|NCT00898638|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
449395|NCT00898638|stage II inverted papilloma of the paranasal sinus and nasal cavity
449396|NCT00898638|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
449397|NCT00898638|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
449398|NCT00898638|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
449399|NCT00898638|stage III inverted papilloma of the paranasal sinus and nasal cavity
449400|NCT00898638|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
449401|NCT00898638|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
449402|NCT00898638|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
449403|NCT00898638|stage IV inverted papilloma of the paranasal sinus and nasal cavity
449404|NCT00898638|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
449405|NCT00898638|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449406|NCT00898638|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
449407|NCT00898638|recurrent inverted papilloma of the paranasal sinus and nasal cavity
449408|NCT00898638|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
449409|NCT00898638|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
449410|NCT00898638|stage I salivary gland cancer
449411|NCT00898638|stage II salivary gland cancer
449412|NCT00898638|stage III salivary gland cancer
449413|NCT00898638|stage IV salivary gland cancer
449414|NCT00898638|recurrent salivary gland cancer
449415|NCT00898638|recurrent squamous cell carcinoma of the oropharynx
449416|NCT00898612|stage III adult Burkitt lymphoma
449417|NCT00898612|stage III adult diffuse large cell lymphoma
449418|NCT00898612|stage III adult diffuse mixed cell lymphoma
449419|NCT00898612|stage III adult diffuse small cleaved cell lymphoma
449420|NCT00898612|stage III adult Hodgkin lymphoma
449421|NCT00898612|stage III adult immunoblastic large cell lymphoma
449422|NCT00898612|stage III adult lymphoblastic lymphoma
449423|NCT00898612|stage III grade 1 follicular lymphoma
449424|NCT00898612|stage III grade 2 follicular lymphoma
449425|NCT00898612|stage III grade 3 follicular lymphoma
449426|NCT00898612|stage III mantle cell lymphoma
449427|NCT00898612|stage III marginal zone lymphoma
449428|NCT00898612|stage III small lymphocytic lymphoma
449429|NCT00898612|stage IV adult Burkitt lymphoma
449430|NCT00898612|stage IV adult diffuse large cell lymphoma
449431|NCT00898612|stage IV adult diffuse mixed cell lymphoma
449432|NCT00898612|stage IV adult diffuse small cleaved cell lymphoma
449433|NCT00898612|stage IV adult Hodgkin lymphoma
449434|NCT00898612|stage IV adult immunoblastic large cell lymphoma
449435|NCT00898612|stage IV adult lymphoblastic lymphoma
449436|NCT00898612|stage IV grade 1 follicular lymphoma
449437|NCT00898612|stage IV grade 2 follicular lymphoma
449438|NCT00898612|stage IV grade 3 follicular lymphoma
449439|NCT00898612|stage IV mantle cell lymphoma
449440|NCT00898612|stage IV marginal zone lymphoma
449441|NCT00898612|stage IV small lymphocytic lymphoma
449442|NCT00898612|recurrent adult Burkitt lymphoma
449443|NCT00898612|recurrent adult diffuse large cell lymphoma
449444|NCT00898612|recurrent adult diffuse mixed cell lymphoma
449445|NCT00898612|recurrent adult diffuse small cleaved cell lymphoma
449446|NCT00898612|recurrent adult Hodgkin lymphoma
449447|NCT00898612|recurrent adult immunoblastic large cell lymphoma
449448|NCT00898612|recurrent adult lymphoblastic lymphoma
449449|NCT00898612|recurrent childhood large cell lymphoma
449450|NCT00898612|recurrent childhood lymphoblastic lymphoma
449451|NCT00898612|recurrent childhood small noncleaved cell lymphoma
449452|NCT00898612|recurrent cutaneous T-cell non-Hodgkin lymphoma
449453|NCT00898612|recurrent grade 1 follicular lymphoma
449454|NCT00898612|recurrent grade 2 follicular lymphoma
449455|NCT00898612|recurrent grade 3 follicular lymphoma
449456|NCT00898612|recurrent mantle cell lymphoma
449457|NCT00898612|recurrent marginal zone lymphoma
449458|NCT00898612|recurrent small lymphocytic lymphoma
449459|NCT00898612|recurrent/refractory childhood Hodgkin lymphoma
449460|NCT00898612|recurrent mycosis fungoides/Sezary syndrome
449461|NCT00898612|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
449462|NCT00898612|nodal marginal zone B-cell lymphoma
449463|NCT00898612|splenic marginal zone lymphoma
449464|NCT00898612|noncontiguous stage II adult Burkitt lymphoma
449465|NCT00898612|noncontiguous stage II adult diffuse large cell lymphoma
449466|NCT00898612|noncontiguous stage II adult diffuse mixed cell lymphoma
449467|NCT00898612|noncontiguous stage II adult diffuse small cleaved cell lymphoma
449468|NCT00898612|noncontiguous stage II adult immunoblastic large cell lymphoma
449469|NCT00898612|noncontiguous stage II adult lymphoblastic lymphoma
449470|NCT00898612|noncontiguous stage II grade 1 follicular lymphoma
449471|NCT00898612|noncontiguous stage II grade 2 follicular lymphoma
449472|NCT00898612|noncontiguous stage II grade 3 follicular lymphoma
449473|NCT00898612|noncontiguous stage II mantle cell lymphoma
449474|NCT00898612|noncontiguous stage II marginal zone lymphoma
449475|NCT00898612|noncontiguous stage II small lymphocytic lymphoma
449476|NCT00898612|accelerated phase chronic myelogenous leukemia
449477|NCT00898612|adult acute lymphoblastic leukemia in remission
449478|NCT00898612|adult acute myeloid leukemia in remission
449479|NCT00898612|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
449480|NCT00898612|adult acute myeloid leukemia with inv(16)(p13;q22)
449481|NCT00898612|adult acute myeloid leukemia with t(15;17)(q22;q12)
449482|NCT00898612|adult acute myeloid leukemia with t(16;16)(p13;q22)
449483|NCT00898612|adult acute myeloid leukemia with t(8;21)(q22;q22)
449484|NCT00898612|atypical chronic myeloid leukemia, BCR-ABL negative
449485|NCT00898612|blastic phase chronic myelogenous leukemia
449486|NCT00898612|childhood acute lymphoblastic leukemia in remission
449487|NCT00898612|childhood acute myeloid leukemia in remission
449488|NCT00898612|childhood chronic myelogenous leukemia
449489|NCT00898612|chronic myelomonocytic leukemia
449490|NCT00898612|chronic phase chronic myelogenous leukemia
449491|NCT00898612|juvenile myelomonocytic leukemia
449492|NCT00898612|recurrent adult acute lymphoblastic leukemia
449493|NCT00898612|recurrent adult acute myeloid leukemia
449494|NCT00898612|recurrent childhood acute lymphoblastic leukemia
449495|NCT00898612|recurrent childhood acute myeloid leukemia
449496|NCT00898612|refractory chronic lymphocytic leukemia
449497|NCT00898612|refractory hairy cell leukemia
449498|NCT00898612|relapsing chronic myelogenous leukemia
449499|NCT00898612|secondary acute myeloid leukemia
449500|NCT00898612|stage III chronic lymphocytic leukemia
449501|NCT00898612|stage IV chronic lymphocytic leukemia
449502|NCT00898612|childhood myelodysplastic syndromes
449503|NCT00898612|chronic eosinophilic leukemia
449504|NCT00898612|primary myelofibrosis
449505|NCT00898612|chronic neutrophilic leukemia
449506|NCT00898612|de novo myelodysplastic syndromes
449507|NCT00898612|disseminated neuroblastoma
449508|NCT00898612|myelodysplastic/myeloproliferative neoplasm, unclassifiable
449509|NCT00898612|poor prognosis metastatic gestational trophoblastic tumor
449510|NCT00898612|previously treated childhood rhabdomyosarcoma
449511|NCT00898612|previously treated myelodysplastic syndromes
449512|NCT00898612|recurrent Wilms tumor and other childhood kidney tumors
449513|NCT00898612|recurrent childhood rhabdomyosarcoma
449514|NCT00898612|recurrent neuroblastoma
449515|NCT00898612|recurrent ovarian epithelial cancer
449516|NCT00898612|recurrent ovarian germ cell tumor
449517|NCT00898612|recurrent malignant testicular germ cell tumor
449518|NCT00898612|secondary myelodysplastic syndromes
449519|NCT00898612|stage I multiple myeloma
449520|NCT00898612|stage II multiple myeloma
449521|NCT00898612|stage III multiple myeloma
449522|NCT00898612|stage II ovarian epithelial cancer
449523|NCT00898612|stage III ovarian epithelial cancer
449524|NCT00898612|stage IV ovarian epithelial cancer
449525|NCT00898612|stage III malignant testicular germ cell tumor
449526|NCT00898612|stage IIIA breast cancer
449527|NCT00898612|stage IIIB breast cancer
449528|NCT00898612|stage IIIC breast cancer
449529|NCT00898612|stage IV breast cancer
449530|NCT00898612|refractory multiple myeloma
449531|NCT00898573|breast cancer
449532|NCT00898560|Partial
449533|NCT00898560|Epilepsy
449534|NCT00898560|Eslicarbazepine acetate
449535|NCT00898560|Combined oral contraceptive
449536|NCT00898560|Pharmacokinetics
449537|NCT00898560|Tolerability
449538|NCT00898547|advanced malignant mesothelioma
449539|NCT00898547|recurrent malignant mesothelioma
449540|NCT00898547|epithelial mesothelioma
449541|NCT00898547|sarcomatous mesothelioma
449542|NCT00898534|Pediatrics
449543|NCT00898534|Hemoglobin A1c
449544|NCT00898534|Point of Care testing
449545|NCT00898508|invasive ductal breast carcinoma
449546|NCT00898508|invasive lobular breast carcinoma
449547|NCT00898508|ductal breast carcinoma in situ
449548|NCT00898508|lobular breast carcinoma in situ
449549|NCT00898508|stage I breast cancer
449550|NCT00898508|stage II breast cancer
449551|NCT00898508|stage IIIA breast cancer
449552|NCT00898508|stage IIIB breast cancer
449553|NCT00898508|stage IIIC breast cancer
449554|NCT00898508|stage IV breast cancer
449555|NCT00898495|adenocarcinoma of the esophagus
449556|NCT00898495|stage II esophageal cancer
449557|NCT00898495|stage III esophageal cancer
449558|NCT00898495|stage IV esophageal cancer
449559|NCT00898495|stage I esophageal cancer
449560|NCT00898482|adenocarcinoma of the pancreas
449561|NCT00898482|recurrent pancreatic cancer
449562|NCT00898482|stage I pancreatic cancer
449563|NCT00898482|stage II pancreatic cancer
449564|NCT00898482|stage III pancreatic cancer
449565|NCT00898482|stage IV pancreatic cancer
449566|NCT00898469|childhood acute lymphoblastic leukemia
449567|NCT00898456|adult acute myeloid leukemia
449568|NCT00898456|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
449569|NCT00898456|adult acute myeloid leukemia with inv(16)(p13;q22)
449570|NCT00898456|adult acute myeloid leukemia with t(16;16)(p13;q22)
449571|NCT00898456|adult acute myeloid leukemia with t(8;21)(q22;q22)
449572|NCT00898456|adult acute minimally differentiated myeloid leukemia (M0)
449573|NCT00898456|adult acute myeloblastic leukemia without maturation (M1)
449574|NCT00898456|adult acute myeloblastic leukemia with maturation (M2)
449575|NCT00898456|adult acute myelomonocytic leukemia (M4)
449576|NCT00898456|adult acute monoblastic leukemia (M5a)
449577|NCT00898456|adult acute monocytic leukemia (M5b)
449578|NCT00898456|adult erythroleukemia (M6a)
449579|NCT00898456|adult pure erythroid leukemia (M6b)
449580|NCT00898456|adult acute megakaryoblastic leukemia (M7)
449581|NCT00898456|adult acute basophilic leukemia
449582|NCT00898456|adult acute eosinophilic leukemia
449583|NCT00898430|stage III squamous cell carcinoma of the hypopharynx
449584|NCT00898430|stage IV squamous cell carcinoma of the hypopharynx
449585|NCT00898430|stage III squamous cell carcinoma of the larynx
449586|NCT00898430|stage III verrucous carcinoma of the larynx
449587|NCT00898430|stage IV squamous cell carcinoma of the larynx
449588|NCT00898430|stage IV verrucous carcinoma of the larynx
449589|NCT00898430|stage III squamous cell carcinoma of the lip and oral cavity
449590|NCT00898430|stage IV squamous cell carcinoma of the lip and oral cavity
449591|NCT00898430|stage III verrucous carcinoma of the oral cavity
449592|NCT00898430|stage IV verrucous carcinoma of the oral cavity
449593|NCT00898430|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449594|NCT00898430|untreated metastatic squamous neck cancer with occult primary
449595|NCT00898430|stage III squamous cell carcinoma of the nasopharynx
449596|NCT00898430|stage IV squamous cell carcinoma of the nasopharynx
449597|NCT00898430|stage III squamous cell carcinoma of the oropharynx
449598|NCT00898430|stage IV squamous cell carcinoma of the oropharynx
449599|NCT00898430|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
449600|NCT00898430|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449601|NCT00898430|salivary gland squamous cell carcinoma
449602|NCT00898430|stage III salivary gland cancer
449603|NCT00898430|stage IV salivary gland cancer
449604|NCT00898417|stage IIIB non-small cell lung cancer
449605|NCT00898417|recurrent non-small cell lung cancer
449606|NCT00898417|stage IV non-small cell lung cancer
449607|NCT00898417|adenocarcinoma of the lung
449608|NCT00898417|bronchoalveolar cell lung cancer
449609|NCT00898378|healthy, no evidence of disease
449610|NCT00898378|stage I colon cancer
449611|NCT00898378|stage II colon cancer
449612|NCT00898378|stage III colon cancer
449613|NCT00898378|stage IV colon cancer
449614|NCT00898378|stage I rectal cancer
449615|NCT00898378|stage II rectal cancer
449616|NCT00898378|stage III rectal cancer
449617|NCT00898378|stage IV rectal cancer
449618|NCT00898378|recurrent rectal cancer
449619|NCT00898378|recurrent colon cancer
449620|NCT00898378|adenomatous polyp
449621|NCT00898352|stage III vulvar cancer
449622|NCT00898352|squamous cell carcinoma of the vulva
449623|NCT00898326|stage I prostate cancer
449624|NCT00898326|stage IIB prostate cancer
449625|NCT00898326|stage IIA prostate cancer
449626|NCT00898313|lung cancer
449627|NCT00898300|stage I squamous cell carcinoma of the hypopharynx
449628|NCT00898300|stage II squamous cell carcinoma of the hypopharynx
449629|NCT00898300|stage III squamous cell carcinoma of the hypopharynx
449630|NCT00898300|stage IV squamous cell carcinoma of the hypopharynx
449631|NCT00898300|stage I squamous cell carcinoma of the larynx
449632|NCT00898300|stage II squamous cell carcinoma of the larynx
449633|NCT00898300|stage III squamous cell carcinoma of the larynx
449634|NCT00898300|stage IV squamous cell carcinoma of the larynx
449635|NCT00898300|stage I verrucous carcinoma of the larynx
449636|NCT00898300|stage II verrucous carcinoma of the larynx
449637|NCT00898300|stage III verrucous carcinoma of the larynx
449638|NCT00898300|stage IV verrucous carcinoma of the larynx
449639|NCT00898300|stage I basal cell carcinoma of the lip
449640|NCT00898300|stage II basal cell carcinoma of the lip
449641|NCT00898300|stage III basal cell carcinoma of the lip
449642|NCT00898300|stage IV basal cell carcinoma of the lip
449643|NCT00898300|stage I mucoepidermoid carcinoma of the oral cavity
449644|NCT00898300|stage II mucoepidermoid carcinoma of the oral cavity
449645|NCT00898300|stage III mucoepidermoid carcinoma of the oral cavity
449646|NCT00898300|stage IV mucoepidermoid carcinoma of the oral cavity
449647|NCT00898300|stage I verrucous carcinoma of the oral cavity
449648|NCT00898300|stage II verrucous carcinoma of the oral cavity
449649|NCT00898300|stage III verrucous carcinoma of the oral cavity
449650|NCT00898300|stage IV verrucous carcinoma of the oral cavity
449651|NCT00898300|stage I adenoid cystic carcinoma of the oral cavity
449652|NCT00898300|stage II adenoid cystic carcinoma of the oral cavity
449653|NCT00898300|stage III adenoid cystic carcinoma of the oral cavity
449654|NCT00898300|stage IV adenoid cystic carcinoma of the oral cavity
449655|NCT00898300|stage I squamous cell carcinoma of the lip and oral cavity
449656|NCT00898300|stage II squamous cell carcinoma of the lip and oral cavity
449657|NCT00898300|stage III squamous cell carcinoma of the lip and oral cavity
449658|NCT00898300|stage IV squamous cell carcinoma of the lip and oral cavity
449659|NCT00898300|metastatic squamous neck cancer with occult primary
449660|NCT00898300|stage I lymphoepithelioma of the nasopharynx
449661|NCT00898300|stage II lymphoepithelioma of the nasopharynx
449662|NCT00898300|stage III lymphoepithelioma of the nasopharynx
449663|NCT00898300|stage IV lymphoepithelioma of the nasopharynx
449664|NCT00898300|stage I squamous cell carcinoma of the nasopharynx
449665|NCT00898300|stage II squamous cell carcinoma of the nasopharynx
449666|NCT00898300|stage III squamous cell carcinoma of the nasopharynx
449667|NCT00898300|stage IV squamous cell carcinoma of the nasopharynx
449668|NCT00898300|stage I lymphoepithelioma of the oropharynx
449669|NCT00898300|stage II lymphoepithelioma of the oropharynx
449670|NCT00898300|stage III lymphoepithelioma of the oropharynx
449671|NCT00898300|stage IV lymphoepithelioma of the oropharynx
449672|NCT00898300|stage I squamous cell carcinoma of the oropharynx
449673|NCT00898300|stage II squamous cell carcinoma of the oropharynx
449674|NCT00898300|stage III squamous cell carcinoma of the oropharynx
449675|NCT00898300|stage IV squamous cell carcinoma of the oropharynx
449676|NCT00898300|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
449677|NCT00898300|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
449678|NCT00898300|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
449679|NCT00898300|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
449680|NCT00898300|stage I inverted papilloma of the paranasal sinus and nasal cavity
449681|NCT00898300|stage II inverted papilloma of the paranasal sinus and nasal cavity
449682|NCT00898300|stage III inverted papilloma of the paranasal sinus and nasal cavity
449683|NCT00898300|stage IV inverted papilloma of the paranasal sinus and nasal cavity
449684|NCT00898300|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
449685|NCT00898300|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
449686|NCT00898300|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
449687|NCT00898300|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
449688|NCT00898300|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
449689|NCT00898300|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
449690|NCT00898300|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
449691|NCT00898300|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
449692|NCT00898300|stage I salivary gland cancer
449693|NCT00898300|stage II salivary gland cancer
449694|NCT00898300|stage III salivary gland cancer
449695|NCT00898300|stage IV salivary gland cancer
449696|NCT00898300|recurrent squamous cell carcinoma of the hypopharynx
449697|NCT00898300|recurrent squamous cell carcinoma of the larynx
449698|NCT00898300|recurrent squamous cell carcinoma of the lip and oral cavity
449699|NCT00898300|recurrent squamous cell carcinoma of the nasopharynx
449700|NCT00898300|recurrent squamous cell carcinoma of the oropharynx
449701|NCT00898300|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
449702|NCT00898300|recurrent adenoid cystic carcinoma of the oral cavity
449703|NCT00898300|recurrent basal cell carcinoma of the lip
449704|NCT00898300|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
449705|NCT00898300|recurrent inverted papilloma of the paranasal sinus and nasal cavity
449706|NCT00898300|recurrent lymphoepithelioma of the nasopharynx
449707|NCT00898300|recurrent lymphoepithelioma of the oropharynx
449708|NCT00898300|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
449709|NCT00898300|recurrent mucoepidermoid carcinoma of the oral cavity
449710|NCT00898300|recurrent salivary gland cancer
449711|NCT00898300|recurrent verrucous carcinoma of the larynx
449712|NCT00898300|recurrent verrucous carcinoma of the oral cavity
449713|NCT00898300|recurrent metastatic squamous neck cancer with occult primary
449714|NCT00898287|Locally advanced or metastatic adenocarcinoma of pancreas
449715|NCT00898274|prostate cancer
449716|NCT00898274|high grade prostatic intraepithelial neoplasia
449717|NCT00898261|adult acute lymphoblastic leukemia in remission
449718|NCT00898235|primary systemic amyloidosis
449719|NCT00898222|healthy volunteers
449720|NCT00898222|aspirin
449721|NCT00898222|Normal healthy subjects
449722|NCT00898209|stage I non-small cell lung cancer
449723|NCT00898209|stage II non-small cell lung cancer
449724|NCT00898209|stage IIIA non-small cell lung cancer
449725|NCT00898209|stage IIIB non-small cell lung cancer
449726|NCT00898209|stage IV non-small cell lung cancer
449727|NCT00898183|stage III melanoma
449728|NCT00898183|stage IV melanoma
449729|NCT00898183|recurrent melanoma
449730|NCT00898170|myoma
449731|NCT00898170|hypertension
449732|NCT00898170|erythropoetin
449733|NCT00898170|blood pressure
449734|NCT00898170|erythropoetin level
449735|NCT00898157|contiguous stage II adult diffuse large cell lymphoma
449736|NCT00898157|noncontiguous stage II adult diffuse large cell lymphoma
449737|NCT00898157|recurrent adult diffuse large cell lymphoma
449738|NCT00898157|stage I adult diffuse large cell lymphoma
449739|NCT00898157|stage III adult diffuse large cell lymphoma
449740|NCT00898157|stage IV adult diffuse large cell lymphoma
449741|NCT00898144|cervical cancer
449742|NCT00898144|cervical intraepithelial neoplasia grade 2
449743|NCT00898144|cervical intraepithelial neoplasia grade 3
449744|NCT00898144|cervical adenocarcinoma
449745|NCT00898144|atypical squamous cells of undetermined significance
449746|NCT00898131|breast cancer
449747|NCT00898118|refractory cytopenia with multilineage dysplasia
449748|NCT00898118|childhood myelodysplastic syndromes
449749|NCT00898118|previously treated myelodysplastic syndromes
449750|NCT00898118|secondary myelodysplastic syndromes
449751|NCT00898092|adult acute minimally differentiated myeloid leukemia (M0)
449752|NCT00898092|adult acute myeloblastic leukemia without maturation (M1)
449753|NCT00898092|adult acute myeloblastic leukemia with maturation (M2)
449754|NCT00898092|adult acute myelomonocytic leukemia (M4)
449755|NCT00898092|adult acute monoblastic leukemia (M5a)
449756|NCT00898092|adult acute monocytic leukemia (M5b)
449757|NCT00898092|adult erythroleukemia (M6a)
449758|NCT00898092|adult pure erythroid leukemia (M6b)
449759|NCT00898092|adult acute megakaryoblastic leukemia (M7)
449760|NCT00898092|adult acute eosinophilic leukemia
449761|NCT00898092|adult acute basophilic leukemia
449762|NCT00898092|untreated adult acute myeloid leukemia
449763|NCT00898066|Waldenstrom macroglobulinemia
449764|NCT00898066|monoclonal gammopathy of undetermined significance
449765|NCT00898066|primary systemic amyloidosis
449766|NCT00898066|stage I multiple myeloma
449767|NCT00898066|stage II multiple myeloma
449768|NCT00898066|stage III multiple myeloma
449769|NCT00898040|stage I multiple myeloma
449770|NCT00898040|stage II multiple myeloma
449771|NCT00898040|stage III multiple myeloma
449772|NCT00898040|refractory multiple myeloma
449773|NCT00898027|unspecified adult solid tumor, protocol specific
449774|NCT00898014|stage IV breast cancer
449775|NCT00897988|recurrent squamous cell carcinoma of the oropharynx
449776|NCT00897988|stage I squamous cell carcinoma of the oropharynx
449777|NCT00897988|stage II squamous cell carcinoma of the oropharynx
449778|NCT00897988|stage III squamous cell carcinoma of the oropharynx
449779|NCT00897988|stage IV squamous cell carcinoma of the oropharynx
449780|NCT00897975|statin associated myalgias
449781|NCT00897975|hyperlipidemia
449782|NCT00897975|red yeast rice
449783|NCT00897975|phytosterols
449784|NCT00897975|therapeutic lifestyle changes
449785|NCT00897975|compliance
449786|NCT00897962|stage IV breast cancer
449787|NCT00897936|adult acute myeloid leukemia in remission
449788|NCT00897936|recurrent adult acute myeloid leukemia
449789|NCT00897936|untreated adult acute myeloid leukemia
449790|NCT00897936|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
449791|NCT00897936|adult acute myeloid leukemia with inv(16)(p13;q22)
449792|NCT00897936|adult acute myeloid leukemia with t(15;17)(q22;q12)
449793|NCT00897936|adult acute myeloid leukemia with t(16;16)(p13;q22)
449794|NCT00897936|adult acute myeloid leukemia with t(8;21)(q22;q22)
449795|NCT00897923|AIDS-related peripheral/systemic lymphoma
449796|NCT00897923|AIDS-related primary CNS lymphoma
449797|NCT00897923|anaplastic large cell lymphoma
449798|NCT00897923|angioimmunoblastic T-cell lymphoma
449799|NCT00897923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
449800|NCT00897923|intraocular lymphoma
449801|NCT00897923|nodal marginal zone B-cell lymphoma
449802|NCT00897923|primary central nervous system non-Hodgkin lymphoma
449803|NCT00897923|recurrent adult Burkitt lymphoma
449804|NCT00897923|recurrent adult diffuse large cell lymphoma
449805|NCT00897923|recurrent adult diffuse mixed cell lymphoma
449806|NCT00897923|recurrent adult diffuse small cleaved cell lymphoma
449807|NCT00897923|recurrent adult immunoblastic large cell lymphoma
449808|NCT00897923|recurrent adult lymphoblastic lymphoma
449809|NCT00897923|recurrent adult T-cell leukemia/lymphoma
449810|NCT00897923|recurrent cutaneous T-cell non-Hodgkin lymphoma
449811|NCT00897923|recurrent grade 1 follicular lymphoma
449812|NCT00897923|recurrent grade 2 follicular lymphoma
449813|NCT00897923|recurrent grade 3 follicular lymphoma
449814|NCT00897923|recurrent mantle cell lymphoma
449815|NCT00897923|recurrent marginal zone lymphoma
449816|NCT00897923|recurrent mycosis fungoides/Sezary syndrome
449817|NCT00897923|recurrent small lymphocytic lymphoma
449818|NCT00897923|small intestine lymphoma
449819|NCT00897923|splenic marginal zone lymphoma
449820|NCT00897923|stage III adult Burkitt lymphoma
449821|NCT00897923|stage III adult diffuse large cell lymphoma
449822|NCT00897923|stage III adult diffuse mixed cell lymphoma
449823|NCT00897923|stage III adult diffuse small cleaved cell lymphoma
449824|NCT00897923|stage III adult immunoblastic large cell lymphoma
449825|NCT00897923|stage III adult lymphoblastic lymphoma
449826|NCT00897923|stage III adult T-cell leukemia/lymphoma
449827|NCT00897923|stage III cutaneous T-cell non-Hodgkin lymphoma
449828|NCT00897923|stage III grade 1 follicular lymphoma
449829|NCT00897923|stage III grade 2 follicular lymphoma
449830|NCT00897923|stage III grade 3 follicular lymphoma
449831|NCT00897923|stage III mantle cell lymphoma
449832|NCT00897923|stage III marginal zone lymphoma
449833|NCT00897923|stage III mycosis fungoides/Sezary syndrome
449834|NCT00897923|stage III small lymphocytic lymphoma
449835|NCT00897923|stage IV adult Burkitt lymphoma
449836|NCT00897923|stage IV adult diffuse large cell lymphoma
449837|NCT00897923|stage IV adult diffuse mixed cell lymphoma
449838|NCT00897923|stage IV adult diffuse small cleaved cell lymphoma
449839|NCT00897923|stage IV adult immunoblastic large cell lymphoma
449840|NCT00897923|stage IV adult lymphoblastic lymphoma
449841|NCT00897923|stage IV adult T-cell leukemia/lymphoma
449842|NCT00897923|stage IV cutaneous T-cell non-Hodgkin lymphoma
449843|NCT00897923|stage IV grade 1 follicular lymphoma
449844|NCT00897923|stage IV grade 2 follicular lymphoma
449845|NCT00897923|stage IV grade 3 follicular lymphoma
449846|NCT00897923|stage IV mantle cell lymphoma
449847|NCT00897923|stage IV marginal zone lymphoma
449848|NCT00897923|stage IV mycosis fungoides/Sezary syndrome
449849|NCT00897923|stage IV small lymphocytic lymphoma
449850|NCT00897923|Waldenström macroglobulinemia
449851|NCT00897923|stage I adult Burkitt lymphoma
449852|NCT00897923|stage I adult diffuse large cell lymphoma
449853|NCT00897923|stage I adult diffuse mixed cell lymphoma
449854|NCT00897923|stage I adult diffuse small cleaved cell lymphoma
449855|NCT00897923|stage I adult immunoblastic large cell lymphoma
449856|NCT00897923|stage I adult lymphoblastic lymphoma
449857|NCT00897923|stage I adult T-cell leukemia/lymphoma
449858|NCT00897923|stage I cutaneous T-cell non-Hodgkin lymphoma
449859|NCT00897923|stage I grade 1 follicular lymphoma
449860|NCT00897923|stage I grade 2 follicular lymphoma
449861|NCT00897923|stage I grade 3 follicular lymphoma
449862|NCT00897923|stage I mantle cell lymphoma
449863|NCT00897923|stage I marginal zone lymphoma
449864|NCT00897923|stage I small lymphocytic lymphoma
449865|NCT00897923|stage II adult T-cell leukemia/lymphoma
449866|NCT00897923|adult grade III lymphomatoid granulomatosis
449867|NCT00897923|adult nasal type extranodal NK/T-cell lymphoma
449868|NCT00897923|recurrent adult grade III lymphomatoid granulomatosis
449869|NCT00897923|contiguous stage II adult Burkitt lymphoma
449870|NCT00897923|contiguous stage II adult diffuse large cell lymphoma
449871|NCT00897923|contiguous stage II adult diffuse mixed cell lymphoma
449872|NCT00897923|contiguous stage II adult diffuse small cleaved cell lymphoma
449873|NCT00897923|contiguous stage II adult immunoblastic large cell lymphoma
449874|NCT00897923|contiguous stage II adult lymphoblastic lymphoma
449875|NCT00897923|contiguous stage II grade 1 follicular lymphoma
449876|NCT00897923|contiguous stage II grade 2 follicular lymphoma
449877|NCT00897923|contiguous stage II grade 3 follicular lymphoma
449878|NCT00897923|contiguous stage II mantle cell lymphoma
449879|NCT00897923|contiguous stage II marginal zone lymphoma
449880|NCT00897923|contiguous stage II small lymphocytic lymphoma
449881|NCT00897923|noncontiguous stage II adult Burkitt lymphoma
449882|NCT00897923|noncontiguous stage II adult diffuse large cell lymphoma
449883|NCT00897923|noncontiguous stage II adult diffuse mixed cell lymphoma
449884|NCT00897923|noncontiguous stage II adult diffuse small cleaved cell lymphoma
449885|NCT00897923|noncontiguous stage II adult immunoblastic large cell lymphoma
449886|NCT00897923|noncontiguous stage II adult lymphoblastic lymphoma
449887|NCT00897923|noncontiguous stage II grade 1 follicular lymphoma
449888|NCT00897923|noncontiguous stage II grade 2 follicular lymphoma
449889|NCT00897923|noncontiguous stage II grade 3 follicular lymphoma
449890|NCT00897923|noncontiguous stage II mantle cell lymphoma
449891|NCT00897923|noncontiguous stage II marginal zone lymphoma
449892|NCT00897923|noncontiguous stage II small lymphocytic lymphoma
449893|NCT00897923|stage I mycosis fungoides/Sezary syndrome
449894|NCT00897923|stage II mycosis fungoides/Sezary syndrome
449895|NCT00897923|stage II cutaneous T-cell non-Hodgkin lymphoma
449896|NCT00897910|stage I multiple myeloma
449897|NCT00897910|stage II multiple myeloma
449898|NCT00897910|stage III multiple myeloma
449899|NCT00897910|refractory multiple myeloma
449900|NCT00897897|Uterine Leiomyomas
449901|NCT00897897|Fibroids
449902|NCT00897897|HIFU
449903|NCT00897897|Ablation
449904|NCT00897897|High Intensity Focused Ultrasound
449905|NCT00897884|breast cancer
449906|NCT00897884|metformin
449907|NCT00897884|breast surgery
449908|NCT00897871|unspecified childhood solid tumor, protocol specific
449909|NCT00897858|childhood central nervous system germ cell tumor
449910|NCT00897858|childhood choroid plexus tumor
449911|NCT00897858|childhood grade I meningioma
449912|NCT00897858|childhood grade II meningioma
449913|NCT00897858|childhood grade III meningioma
449914|NCT00897858|childhood atypical teratoid/rhabdoid tumor
449915|NCT00897858|untreated childhood visual pathway glioma
449916|NCT00897858|childhood infratentorial ependymoma
449917|NCT00897858|childhood supratentorial ependymoma
449918|NCT00897858|newly diagnosed childhood ependymoma
449919|NCT00897858|childhood craniopharyngioma
449920|NCT00897858|untreated childhood medulloblastoma
449921|NCT00897858|untreated childhood cerebellar astrocytoma
449922|NCT00897858|untreated childhood supratentorial primitive neuroectodermal tumor
449923|NCT00897858|untreated childhood brain stem glioma
449924|NCT00897858|untreated childhood visual pathway and hypothalamic glioma
449925|NCT00897858|childhood high-grade cerebral astrocytoma
449926|NCT00897858|childhood low-grade cerebral astrocytoma
449927|NCT00897858|childhood central nervous system choriocarcinoma
449928|NCT00897858|childhood central nervous system embryonal tumor
449929|NCT00897858|childhood central nervous system germinoma
449930|NCT00897858|childhood central nervous system mixed germ cell tumor
449931|NCT00897858|childhood central nervous system teratoma
449932|NCT00897858|childhood central nervous system yolk sac tumor
449933|NCT00897845|stage II breast cancer
449934|NCT00897845|stage IIIA breast cancer
449935|NCT00897845|stage IIIB breast cancer
449936|NCT00897832|pancreatic cancer
449937|NCT00897819|recurrent colon cancer
449938|NCT00897819|recurrent rectal cancer
449939|NCT00897819|stage III colon cancer
449940|NCT00897819|stage III rectal cancer
449941|NCT00897819|stage IV colon cancer
449942|NCT00897819|stage IV rectal cancer
449943|NCT00897819|adenocarcinoma of the colon
449944|NCT00897819|adenocarcinoma of the rectum
449945|NCT00897806|stage III ovarian epithelial cancer
449946|NCT00897806|stage IV ovarian epithelial cancer
449947|NCT00897806|peritoneal cavity cancer
449948|NCT00897793|recurrent squamous cell carcinoma of the hypopharynx
449949|NCT00897793|stage I squamous cell carcinoma of the hypopharynx
449950|NCT00897793|stage II squamous cell carcinoma of the hypopharynx
449951|NCT00897793|stage III squamous cell carcinoma of the hypopharynx
449952|NCT00897793|stage IV squamous cell carcinoma of the hypopharynx
449953|NCT00897793|recurrent squamous cell carcinoma of the larynx
449954|NCT00897793|recurrent verrucous carcinoma of the larynx
449955|NCT00897793|stage I squamous cell carcinoma of the larynx
449956|NCT00897793|stage I verrucous carcinoma of the larynx
449957|NCT00897793|stage II squamous cell carcinoma of the larynx
449958|NCT00897793|stage II verrucous carcinoma of the larynx
449959|NCT00897793|stage III squamous cell carcinoma of the larynx
449960|NCT00897793|stage III verrucous carcinoma of the larynx
449961|NCT00897793|stage IV squamous cell carcinoma of the larynx
449962|NCT00897793|stage IV verrucous carcinoma of the larynx
449963|NCT00897793|recurrent adenoid cystic carcinoma of the oral cavity
449964|NCT00897793|recurrent mucoepidermoid carcinoma of the oral cavity
449965|NCT00897793|recurrent verrucous carcinoma of the oral cavity
449966|NCT00897793|stage I adenoid cystic carcinoma of the oral cavity
449967|NCT00897793|stage I mucoepidermoid carcinoma of the oral cavity
449968|NCT00897793|stage I verrucous carcinoma of the oral cavity
449969|NCT00897793|stage II adenoid cystic carcinoma of the oral cavity
449970|NCT00897793|stage II mucoepidermoid carcinoma of the oral cavity
449971|NCT00897793|stage II verrucous carcinoma of the oral cavity
449972|NCT00897793|stage III adenoid cystic carcinoma of the oral cavity
449973|NCT00897793|stage III mucoepidermoid carcinoma of the oral cavity
449974|NCT00897793|stage III verrucous carcinoma of the oral cavity
449975|NCT00897793|stage IV adenoid cystic carcinoma of the oral cavity
449976|NCT00897793|stage IV mucoepidermoid carcinoma of the oral cavity
449977|NCT00897793|stage IV verrucous carcinoma of the oral cavity
449978|NCT00897793|stage I squamous cell carcinoma of the lip and oral cavity
449979|NCT00897793|stage II squamous cell carcinoma of the lip and oral cavity
449980|NCT00897793|stage III squamous cell carcinoma of the lip and oral cavity
449981|NCT00897793|stage IV squamous cell carcinoma of the lip and oral cavity
449982|NCT00897793|recurrent basal cell carcinoma of the lip
449983|NCT00897793|recurrent squamous cell carcinoma of the lip and oral cavity
449984|NCT00897793|stage I basal cell carcinoma of the lip
449985|NCT00897793|stage II basal cell carcinoma of the lip
449986|NCT00897793|stage III basal cell carcinoma of the lip
449987|NCT00897793|stage IV basal cell carcinoma of the lip
449988|NCT00897793|metastatic squamous neck cancer with occult primary squamous cell carcinoma
449989|NCT00897793|recurrent metastatic squamous neck cancer with occult primary
449990|NCT00897793|untreated metastatic squamous neck cancer with occult primary
449991|NCT00897793|recurrent lymphoepithelioma of the nasopharynx
449992|NCT00897793|recurrent squamous cell carcinoma of the nasopharynx
449993|NCT00897793|stage I lymphoepithelioma of the nasopharynx
449994|NCT00897793|stage I squamous cell carcinoma of the nasopharynx
449995|NCT00897793|stage II lymphoepithelioma of the nasopharynx
449996|NCT00897793|stage II squamous cell carcinoma of the nasopharynx
449997|NCT00897793|stage III lymphoepithelioma of the nasopharynx
449998|NCT00897793|stage III squamous cell carcinoma of the nasopharynx
449999|NCT00897793|stage IV lymphoepithelioma of the nasopharynx
450000|NCT00897793|stage IV squamous cell carcinoma of the nasopharynx
450001|NCT00897793|recurrent lymphoepithelioma of the oropharynx
450002|NCT00897793|recurrent squamous cell carcinoma of the oropharynx
450003|NCT00897793|stage I lymphoepithelioma of the oropharynx
450004|NCT00897793|stage I squamous cell carcinoma of the oropharynx
450005|NCT00897793|stage II lymphoepithelioma of the oropharynx
450006|NCT00897793|stage II squamous cell carcinoma of the oropharynx
450007|NCT00897793|stage III lymphoepithelioma of the oropharynx
450008|NCT00897793|stage III squamous cell carcinoma of the oropharynx
450009|NCT00897793|stage IV lymphoepithelioma of the oropharynx
450010|NCT00897793|stage IV squamous cell carcinoma of the oropharynx
450011|NCT00897793|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
450012|NCT00897793|recurrent inverted papilloma of the paranasal sinus and nasal cavity
450013|NCT00897793|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
450014|NCT00897793|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
450015|NCT00897793|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
450016|NCT00897793|stage I inverted papilloma of the paranasal sinus and nasal cavity
450017|NCT00897793|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
450018|NCT00897793|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
450019|NCT00897793|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
450020|NCT00897793|stage II inverted papilloma of the paranasal sinus and nasal cavity
450021|NCT00897793|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
450022|NCT00897793|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
450023|NCT00897793|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
450024|NCT00897793|stage III inverted papilloma of the paranasal sinus and nasal cavity
450025|NCT00897793|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
450026|NCT00897793|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
450027|NCT00897793|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
450028|NCT00897793|stage IV inverted papilloma of the paranasal sinus and nasal cavity
450029|NCT00897793|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
450030|NCT00897793|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
450031|NCT00897793|high-grade salivary gland mucoepidermoid carcinoma
450032|NCT00897793|low-grade salivary gland mucoepidermoid carcinoma
450033|NCT00897793|recurrent salivary gland cancer
450034|NCT00897793|salivary gland acinic cell tumor
450035|NCT00897793|salivary gland adenocarcinoma
450036|NCT00897793|salivary gland adenoid cystic carcinoma
450037|NCT00897793|salivary gland anaplastic carcinoma
450038|NCT00897793|salivary gland malignant mixed cell type tumor
450039|NCT00897793|salivary gland poorly differentiated carcinoma
450040|NCT00897793|salivary gland squamous cell carcinoma
450041|NCT00897793|stage I salivary gland cancer
450042|NCT00897793|stage II salivary gland cancer
450043|NCT00897793|stage III salivary gland cancer
450044|NCT00897793|stage IV salivary gland cancer
450045|NCT00897793|limited stage small cell lung cancer
450046|NCT00897793|recurrent non-small cell lung cancer
450047|NCT00897793|recurrent small cell lung cancer
450048|NCT00897793|stage I non-small cell lung cancer
450049|NCT00897793|stage II non-small cell lung cancer
450050|NCT00897793|stage IIIA non-small cell lung cancer
450051|NCT00897793|stage IIIB non-small cell lung cancer
450052|NCT00897793|stage IV non-small cell lung cancer
450053|NCT00897793|extensive stage small cell lung cancer
450054|NCT00897793|male breast cancer
450055|NCT00897793|recurrent breast cancer
450056|NCT00897793|stage I breast cancer
450057|NCT00897793|stage II breast cancer
450058|NCT00897793|stage IIIA breast cancer
450059|NCT00897793|stage IIIB breast cancer
450060|NCT00897793|stage IIIC breast cancer
450061|NCT00897793|stage IV breast cancer
450062|NCT00897793|recurrent colon cancer
450063|NCT00897793|stage I colon cancer
450064|NCT00897793|stage II colon cancer
450065|NCT00897793|stage III colon cancer
450066|NCT00897793|stage IV colon cancer
450067|NCT00897793|recurrent rectal cancer
450068|NCT00897793|stage I rectal cancer
450069|NCT00897793|stage II rectal cancer
450070|NCT00897793|stage III rectal cancer
450071|NCT00897793|stage IV rectal cancer
450072|NCT00897793|recurrent prostate cancer
450073|NCT00897793|stage I prostate cancer
450074|NCT00897793|stage II prostate cancer
450075|NCT00897793|stage III prostate cancer
450076|NCT00897793|stage IV prostate cancer
450077|NCT00897780|Headache
450078|NCT00897780|Pediatric
450079|NCT00897780|Virtual Reality
450080|NCT00897780|Biofeedback
450081|NCT00897767|accelerated phase chronic myelogenous leukemia
450082|NCT00897767|atypical chronic myeloid leukemia, BCR-ABL1 negative
450083|NCT00897767|blastic phase chronic myelogenous leukemia
450084|NCT00897767|childhood chronic myelogenous leukemia
450085|NCT00897767|chronic myelomonocytic leukemia
450086|NCT00897767|chronic phase chronic myelogenous leukemia
450087|NCT00897767|juvenile myelomonocytic leukemia
450088|NCT00897767|meningeal chronic myelogenous leukemia
450089|NCT00897767|progressive hairy cell leukemia, initial treatment
450090|NCT00897767|recurrent adult acute lymphoblastic leukemia
450091|NCT00897767|recurrent adult acute myeloid leukemia
450092|NCT00897767|recurrent adult T-cell leukemia/lymphoma
450093|NCT00897767|recurrent childhood acute lymphoblastic leukemia
450094|NCT00897767|recurrent childhood acute myeloid leukemia
450095|NCT00897767|refractory chronic lymphocytic leukemia
450096|NCT00897767|refractory hairy cell leukemia
450203|NCT00897455|breast cancer
450097|NCT00897767|relapsing chronic myelogenous leukemia
450098|NCT00897767|stage I adult T-cell leukemia/lymphoma
450099|NCT00897767|stage I chronic lymphocytic leukemia
450100|NCT00897767|stage II adult T-cell leukemia/lymphoma
450101|NCT00897767|stage II chronic lymphocytic leukemia
450102|NCT00897767|stage III adult T-cell leukemia/lymphoma
450103|NCT00897767|stage III chronic lymphocytic leukemia
450104|NCT00897767|stage IV adult T-cell leukemia/lymphoma
450105|NCT00897767|stage IV chronic lymphocytic leukemia
450106|NCT00897767|untreated adult acute lymphoblastic leukemia
450107|NCT00897767|untreated adult acute myeloid leukemia
450108|NCT00897767|untreated childhood acute lymphoblastic leukemia
450109|NCT00897767|untreated childhood acute myeloid leukemia and other myeloid malignancies
450110|NCT00897767|T-cell large granular lymphocyte leukemia
450111|NCT00897767|adult acute myeloid leukemia in remission
450112|NCT00897767|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
450113|NCT00897767|adult acute myeloid leukemia with inv(16)(p13;q22)
450114|NCT00897767|adult acute myeloid leukemia with t(15;17)(q22;q12)
450115|NCT00897767|adult acute myeloid leukemia with t(16;16)(p13;q22)
450116|NCT00897767|adult acute myeloid leukemia with t(8;21)(q22;q22)
450117|NCT00897767|secondary acute myeloid leukemia
450118|NCT00897767|childhood acute myeloid leukemia in remission
450119|NCT00897767|acute undifferentiated leukemia
450120|NCT00897767|mast cell leukemia
450121|NCT00897767|adult acute lymphoblastic leukemia in remission
450122|NCT00897767|childhood acute lymphoblastic leukemia in remission
450123|NCT00897767|prolymphocytic leukemia
450124|NCT00897767|untreated hairy cell leukemia
450125|NCT00897754|adenocarcinoma of the colon
450126|NCT00897754|adenocarcinoma of the rectum
450127|NCT00897754|recurrent rectal cancer
450128|NCT00897754|stage III rectal cancer
450129|NCT00897754|stage IV rectal cancer
450130|NCT00897754|recurrent colon cancer
450131|NCT00897754|stage III colon cancer
450132|NCT00897754|stage IV colon cancer
450133|NCT00897741|recurrent pancreatic cancer
450134|NCT00897741|stage IV pancreatic cancer
450135|NCT00897728|stage IA breast cancer
450136|NCT00897728|stage IB breast cancer
450137|NCT00897728|stage II breast cancer
450138|NCT00897728|stage IIIA breast cancer
450139|NCT00897728|stage IIIB breast cancer
450140|NCT00897728|stage IIIC breast cancer
450141|NCT00897728|HER2-positive breast cancer
450142|NCT00897728|triple-negative breast cancer
450143|NCT00897728|estrogen receptor-negative breast cancer
450144|NCT00897715|CKD
450145|NCT00897715|inflammation
450146|NCT00897715|CVD
450147|NCT00897702|recurrent breast cancer
450148|NCT00897702|male breast cancer
450149|NCT00897702|stage IV breast cancer
450150|NCT00897676|Hyperinsulinism
450151|NCT00897676|Hypoglycemia
450152|NCT00897676|KATP channel
450153|NCT00897663|adult giant cell glioblastoma
450154|NCT00897663|adult gliosarcoma
450155|NCT00897663|adult glioblastoma
450156|NCT00897650|lung cancer
450157|NCT00897624|metastatic intraocular melanoma
450158|NCT00897624|ciliary body and choroid melanoma, medium/large size
450159|NCT00897624|ciliary body and choroid melanoma, small size
450160|NCT00897611|adult anaplastic astrocytoma
450161|NCT00897611|adult anaplastic oligodendroglioma
450162|NCT00897611|adult giant cell glioblastoma
450163|NCT00897611|recurrent adult brain tumor
450164|NCT00897611|adult glioblastoma
450165|NCT00897611|adult gliosarcoma
450166|NCT00897559|adult acute megakaryoblastic leukemia (M7)
450167|NCT00897546|recurrent melanoma
450168|NCT00897546|stage IV melanoma
450169|NCT00897546|stage IA melanoma
450170|NCT00897546|stage IB melanoma
450171|NCT00897546|stage IIA melanoma
450172|NCT00897546|stage IIB melanoma
450173|NCT00897546|stage IIC melanoma
450174|NCT00897546|stage IIIA melanoma
450175|NCT00897546|stage IIIB melanoma
450176|NCT00897546|stage IIIC melanoma
450177|NCT00897533|recurrent non-small cell lung cancer
450178|NCT00897533|stage IIIB non-small cell lung cancer
450179|NCT00897533|stage IV non-small cell lung cancer
450180|NCT00897533|adenocarcinoma of the lung
450181|NCT00897533|squamous cell lung cancer
450182|NCT00897533|bronchoalveolar cell lung cancer
450183|NCT00897520|stage II melanoma
450184|NCT00897520|stage III melanoma
450185|NCT00897520|stage IV melanoma
450186|NCT00897507|childhood acute lymphoblastic leukemia in remission
450187|NCT00897507|recurrent childhood acute lymphoblastic leukemia
450188|NCT00897494|stage I pancreatic cancer
450189|NCT00897494|stage II pancreatic cancer
450190|NCT00897494|stage III pancreatic cancer
450191|NCT00897494|stage IV pancreatic cancer
450192|NCT00897481|stage IV melanoma
450193|NCT00897481|recurrent melanoma
450194|NCT00897481|stage IA melanoma
450195|NCT00897481|stage IB melanoma
450196|NCT00897481|stage IIA melanoma
450197|NCT00897481|stage IIB melanoma
450198|NCT00897481|stage IIC melanoma
450199|NCT00897481|stage IIIA melanoma
450200|NCT00897481|stage IIIB melanoma
450201|NCT00897481|stage IIIC melanoma
450202|NCT00897468|breast cancer
450204|NCT00897455|BRCA1 mutation carrier
450205|NCT00897455|BRCA2 mutation carrier
450206|NCT00897429|stage IIA colon cancer
450207|NCT00897429|stage IIB colon cancer
450208|NCT00897429|stage IIC colon cancer
450209|NCT00897416|breast cancer
450210|NCT00897416|stage I breast cancer
450211|NCT00897416|stage II breast cancer
450212|NCT00897416|stage IIIA breast cancer
450213|NCT00897416|stage IIIB breast cancer
450214|NCT00897416|stage IIIC breast cancer
450215|NCT00897416|stage IV breast cancer
450216|NCT00897403|colon cancer
450217|NCT00897403|health status unknown
450218|NCT00897364|non-small cell lung cancer
450219|NCT00897364|small cell lung cancer
450220|NCT00897364|squamous lung dysplasia
450221|NCT00897351|recurrent prostate cancer
450222|NCT00897338|stage IV breast cancer
450223|NCT00897312|stage IV melanoma
450224|NCT00897312|hepatitis C infection
450225|NCT00897312|melanoma (skin)
450226|NCT00897312|precancerous/nonmalignant condition
450227|NCT00897299|estrogen receptor
450228|NCT00897299|HER-2
450229|NCT00897299|PgR
450230|NCT00897299|stage II breast cancer
450231|NCT00897299|stage IIIA breast cancer
450232|NCT00897299|stage IIIB breast cancer
450233|NCT00897286|childhood atypical teratoid/rhabdoid tumor
450234|NCT00897286|childhood choroid plexus tumor
450235|NCT00897286|childhood medulloblastoma
450236|NCT00897286|recurrent childhood medulloblastoma
450237|NCT00897286|childhood infratentorial ependymoma
450238|NCT00897286|childhood supratentorial ependymoma
450239|NCT00897286|recurrent childhood ependymoma
450240|NCT00897286|recurrent childhood supratentorial primitive neuroectodermal tumor
450241|NCT00897286|untreated childhood supratentorial primitive neuroectodermal tumor
450242|NCT00897286|gliomas
450243|NCT00897273|recurrent squamous cell carcinoma of the oropharynx
450244|NCT00897273|oropharyngeal cancer
450245|NCT00897273|oropharyngeal squamous cell carcinoma
450246|NCT00897273|infection
450247|NCT00897273|precancerous condition
450248|NCT00897273|human papilloma virus infection
450249|NCT00897260|Unrelated Umbilical Cord Blood Transplant
450250|NCT00897260|Multiple cord blood
450251|NCT00897247|malignant mesothelioma
450252|NCT00897247|pulmonary complications
450253|NCT00897234|recurrent non-small cell lung cancer
450254|NCT00897234|stage I non-small cell lung cancer
450255|NCT00897234|stage II non-small cell lung cancer
450256|NCT00897234|stage IIIA non-small cell lung cancer
450257|NCT00897234|stage IIIB non-small cell lung cancer
450258|NCT00897234|stage IV non-small cell lung cancer
450259|NCT00897221|Friedreich's ataxia
450260|NCT00897208|breast cancer
450261|NCT00897208|ductal breast carcinoma in situ
450262|NCT00897208|breast cancer in situ
450263|NCT00897208|stage IA breast cancer
450264|NCT00897208|stage IB breast cancer
450265|NCT00897208|stage II breast cancer
450266|NCT00897182|adult acute myeloid leukemia in remission
450267|NCT00897182|adult acute myeloid leukemia with inv(16)(p13;q22)
450268|NCT00897182|adult acute myeloid leukemia with t(15;17)(q22;q12)
450269|NCT00897182|adult acute myeloid leukemia with t(8;21)(q22;q22)
450270|NCT00897182|childhood acute myeloid leukemia in remission
450271|NCT00897182|recurrent adult acute myeloid leukemia
450272|NCT00897182|recurrent childhood acute myeloid leukemia
450273|NCT00897182|secondary acute myeloid leukemia
450274|NCT00897182|untreated adult acute myeloid leukemia
450275|NCT00897182|untreated childhood acute myeloid leukemia and other myeloid malignancies
450276|NCT00897143|non-small cell lung cancer
450277|NCT00897143|malignant pleural effusion
450278|NCT00897143|small cell lung cancer
450279|NCT00897130|low-risk (IPSS 0-INT1) MDS according to WHO classification
450280|NCT00897117|stage I non-small cell lung cancer
450281|NCT00897117|stage II non-small cell lung cancer
450282|NCT00897091|stage II breast cancer
450283|NCT00897091|stage IIIA breast cancer
450284|NCT00897078|cancer survivor
450285|NCT00897078|healthy, no evidence of disease
450286|NCT00897078|long-term effects secondary to cancer therapy in children
450287|NCT00897078|childhood acute lymphoblastic leukemia in remission
450288|NCT00897065|stage IA breast cancer
450289|NCT00897065|stage IB breast cancer
450290|NCT00897065|stage II breast cancer
450291|NCT00897065|stage IIIA breast cancer
450292|NCT00897065|estrogen receptor-positive breast cancer
450293|NCT00897065|progesterone receptor-positive breast cancer
450294|NCT00897052|stage II squamous cell carcinoma of the lip and oral cavity
450295|NCT00897052|stage III squamous cell carcinoma of the lip and oral cavity
450296|NCT00897052|stage IV squamous cell carcinoma of the lip and oral cavity
450297|NCT00897052|stage II squamous cell carcinoma of the oropharynx
450298|NCT00897052|stage III squamous cell carcinoma of the oropharynx
450299|NCT00897052|stage IV squamous cell carcinoma of the oropharynx
450300|NCT00897052|stage II squamous cell carcinoma of the hypopharynx
450301|NCT00897052|stage III squamous cell carcinoma of the hypopharynx
450302|NCT00897052|stage IV squamous cell carcinoma of the hypopharynx
450303|NCT00897052|stage II squamous cell carcinoma of the larynx
450304|NCT00897052|stage III squamous cell carcinoma of the larynx
450692|NCT00896051|TMC125-C238
450305|NCT00897052|stage IV squamous cell carcinoma of the larynx
450306|NCT00897039|ovarian serous cystadenocarcinoma
450307|NCT00897039|ovarian undifferentiated adenocarcinoma
450308|NCT00897039|recurrent ovarian epithelial cancer
450309|NCT00897039|ovarian clear cell cystadenocarcinoma
450310|NCT00897039|ovarian endometrioid adenocarcinoma
450311|NCT00897039|ovarian mucinous cystadenocarcinoma
450312|NCT00897039|stage IA ovarian epithelial cancer
450313|NCT00897039|stage IB ovarian epithelial cancer
450314|NCT00897039|stage IC ovarian epithelial cancer
450315|NCT00897039|stage IIA ovarian epithelial cancer
450316|NCT00897039|stage IIB ovarian epithelial cancer
450317|NCT00897039|stage IIC ovarian epithelial cancer
450318|NCT00897039|stage IIIA ovarian epithelial cancer
450319|NCT00897039|stage IIIB ovarian epithelial cancer
450320|NCT00897039|stage IIIC ovarian epithelial cancer
450321|NCT00897039|recurrent primary peritoneal cavity cancer
450322|NCT00897039|stage IA primary peritoneal cavity cancer
450323|NCT00897039|stage IB primary peritoneal cavity cancer
450324|NCT00897039|stage IC primary peritoneal cavity cancer
450325|NCT00897039|stage IIA primary peritoneal cavity cancer
450326|NCT00897039|stage IIB primary peritoneal cavity cancer
450327|NCT00897039|stage IIC primary peritoneal cavity cancer
450328|NCT00897039|stage IIIA primary peritoneal cavity cancer
450329|NCT00897039|stage IIIB primary peritoneal cavity cancer
450330|NCT00897039|stage IIIC primary peritoneal cavity cancer
450331|NCT00897039|recurrent fallopian tube cancer
450332|NCT00897039|stage IA fallopian tube cancer
450333|NCT00897039|stage IB fallopian tube cancer
450334|NCT00897039|stage IC fallopian tube cancer
450335|NCT00897039|stage IIA fallopian tube cancer
450336|NCT00897039|stage IIB fallopian tube cancer
450337|NCT00897039|stage IIC fallopian tube cancer
450338|NCT00897039|stage IIIA fallopian tube cancer
450339|NCT00897039|stage IIIB fallopian tube cancer
450340|NCT00897039|stage IIIC fallopian tube cancer
450341|NCT00897026|stage II breast cancer
450342|NCT00897026|stage IIIA breast cancer
450343|NCT00896987|Epilepsy
450344|NCT00896987|lamotrigine
450345|NCT00896987|cognitive function
450346|NCT00896948|head and neck cancer
450347|NCT00896935|cancer
450348|NCT00896922|contiguous stage II grade 1 follicular lymphoma
450349|NCT00896922|contiguous stage II grade 2 follicular lymphoma
450350|NCT00896922|contiguous stage II grade 3 follicular lymphoma
450351|NCT00896922|noncontiguous stage II grade 1 follicular lymphoma
450352|NCT00896922|noncontiguous stage II grade 2 follicular lymphoma
450353|NCT00896922|noncontiguous stage II grade 3 follicular lymphoma
450354|NCT00896922|stage III grade 1 follicular lymphoma
450355|NCT00896922|stage III grade 2 follicular lymphoma
450356|NCT00896922|stage III grade 3 follicular lymphoma
450357|NCT00896922|stage IV grade 1 follicular lymphoma
450358|NCT00896922|stage IV grade 2 follicular lymphoma
450359|NCT00896922|stage IV grade 3 follicular lymphoma
450360|NCT00896909|recurrent non-small cell lung cancer
450361|NCT00896909|stage IIIB non-small cell lung cancer
450362|NCT00896909|stage IV non-small cell lung cancer
450363|NCT00896896|stage I squamous cell carcinoma of the hypopharynx
450364|NCT00896896|stage II squamous cell carcinoma of the hypopharynx
450365|NCT00896896|stage III squamous cell carcinoma of the hypopharynx
450366|NCT00896896|stage IV squamous cell carcinoma of the hypopharynx
450367|NCT00896896|recurrent squamous cell carcinoma of the hypopharynx
450368|NCT00896896|stage I squamous cell carcinoma of the larynx
450369|NCT00896896|stage I verrucous carcinoma of the larynx
450370|NCT00896896|stage II squamous cell carcinoma of the larynx
450371|NCT00896896|stage II verrucous carcinoma of the larynx
450372|NCT00896896|stage III squamous cell carcinoma of the larynx
450373|NCT00896896|stage III verrucous carcinoma of the larynx
450374|NCT00896896|stage IV squamous cell carcinoma of the larynx
450375|NCT00896896|stage IV verrucous carcinoma of the larynx
450376|NCT00896896|recurrent squamous cell carcinoma of the larynx
450377|NCT00896896|recurrent verrucous carcinoma of the larynx
450378|NCT00896896|stage I adenoid cystic carcinoma of the oral cavity
450379|NCT00896896|stage I basal cell carcinoma of the lip
450380|NCT00896896|stage I mucoepidermoid carcinoma of the oral cavity
450381|NCT00896896|stage I squamous cell carcinoma of the lip and oral cavity
450382|NCT00896896|stage I verrucous carcinoma of the oral cavity
450383|NCT00896896|stage II adenoid cystic carcinoma of the oral cavity
450384|NCT00896896|stage II basal cell carcinoma of the lip
450385|NCT00896896|stage II mucoepidermoid carcinoma of the oral cavity
450386|NCT00896896|stage II squamous cell carcinoma of the lip and oral cavity
450387|NCT00896896|stage II verrucous carcinoma of the oral cavity
450388|NCT00896896|stage III adenoid cystic carcinoma of the oral cavity
450389|NCT00896896|stage III basal cell carcinoma of the lip
450390|NCT00896896|stage III mucoepidermoid carcinoma of the oral cavity
450391|NCT00896896|stage III squamous cell carcinoma of the lip and oral cavity
450392|NCT00896896|stage III verrucous carcinoma of the oral cavity
450393|NCT00896896|stage IV adenoid cystic carcinoma of the oral cavity
450394|NCT00896896|stage IV basal cell carcinoma of the lip
450395|NCT00896896|stage IV mucoepidermoid carcinoma of the oral cavity
450396|NCT00896896|stage IV squamous cell carcinoma of the lip and oral cavity
450397|NCT00896896|stage IV verrucous carcinoma of the oral cavity
450398|NCT00896896|recurrent adenoid cystic carcinoma of the oral cavity
450399|NCT00896896|recurrent basal cell carcinoma of the lip
450400|NCT00896896|recurrent mucoepidermoid carcinoma of the oral cavity
450401|NCT00896896|recurrent squamous cell carcinoma of the lip and oral cavity
450402|NCT00896896|recurrent verrucous carcinoma of the oral cavity
450403|NCT00896896|metastatic squamous neck cancer with occult primary squamous cell carcinoma
450404|NCT00896896|recurrent metastatic squamous neck cancer with occult primary
450405|NCT00896896|stage I lymphoepithelioma of the nasopharynx
450406|NCT00896896|stage I squamous cell carcinoma of the nasopharynx
450407|NCT00896896|stage II lymphoepithelioma of the nasopharynx
450408|NCT00896896|stage II squamous cell carcinoma of the nasopharynx
450409|NCT00896896|stage III lymphoepithelioma of the nasopharynx
450410|NCT00896896|stage III squamous cell carcinoma of the nasopharynx
450411|NCT00896896|stage IV lymphoepithelioma of the nasopharynx
450412|NCT00896896|stage IV squamous cell carcinoma of the nasopharynx
450413|NCT00896896|recurrent lymphoepithelioma of the nasopharynx
450414|NCT00896896|recurrent squamous cell carcinoma of the nasopharynx
450415|NCT00896896|stage I lymphoepithelioma of the oropharynx
450416|NCT00896896|stage I squamous cell carcinoma of the oropharynx
450417|NCT00896896|stage II lymphoepithelioma of the oropharynx
450418|NCT00896896|stage II squamous cell carcinoma of the oropharynx
450419|NCT00896896|stage III lymphoepithelioma of the oropharynx
450420|NCT00896896|stage III squamous cell carcinoma of the oropharynx
450421|NCT00896896|stage IV lymphoepithelioma of the oropharynx
450422|NCT00896896|stage IV squamous cell carcinoma of the oropharynx
450423|NCT00896896|recurrent lymphoepithelioma of the oropharynx
450424|NCT00896896|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
450425|NCT00896896|stage I inverted papilloma of the paranasal sinus and nasal cavity
450426|NCT00896896|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
450427|NCT00896896|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
450428|NCT00896896|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
450429|NCT00896896|stage II inverted papilloma of the paranasal sinus and nasal cavity
450430|NCT00896896|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
450431|NCT00896896|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
450432|NCT00896896|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
450433|NCT00896896|stage III inverted papilloma of the paranasal sinus and nasal cavity
450434|NCT00896896|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
450435|NCT00896896|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
450436|NCT00896896|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
450437|NCT00896896|stage IV inverted papilloma of the paranasal sinus and nasal cavity
450438|NCT00896896|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
450439|NCT00896896|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
450440|NCT00896896|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
450441|NCT00896896|recurrent inverted papilloma of the paranasal sinus and nasal cavity
450442|NCT00896896|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
450443|NCT00896896|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
450444|NCT00896896|stage I salivary gland cancer
450445|NCT00896896|stage II salivary gland cancer
450446|NCT00896896|stage III salivary gland cancer
450447|NCT00896896|stage IV salivary gland cancer
450448|NCT00896896|recurrent salivary gland cancer
450449|NCT00896896|recurrent squamous cell carcinoma of the oropharynx
450450|NCT00896896|recurrent colon cancer
450451|NCT00896896|stage IV colon cancer
450452|NCT00896896|recurrent rectal cancer
450453|NCT00896896|stage IV rectal cancer
450454|NCT00896896|adenocarcinoma of the colon
450455|NCT00896883|turbinate
450456|NCT00896883|implant
450457|NCT00896883|sinus surgery
450458|NCT00896883|Turbinates
450459|NCT00896857|breast cancer
450460|NCT00896857|ductal breast carcinoma in situ
450461|NCT00896844|emotional disclosure
450462|NCT00896844|expressive writing
450463|NCT00896844|students
450464|NCT00896831|minimal hepatic encephalopathy
450465|NCT00896831|L-ornithine-L-aspartate
450466|NCT00896831|psychometric test
450467|NCT00896831|critical flicker frequency
450468|NCT00896831|quality of life
450469|NCT00896831|Treatment
450470|NCT00896831|Health-related quality of life
450471|NCT00896818|breast cancer
450472|NCT00896792|unspecified adult solid tumor, protocol specific
450473|NCT00896792|hematopoietic/lymphoid cancer
450474|NCT00896766|childhood acute lymphoblastic leukemia in remission
450475|NCT00896766|B-cell childhood acute lymphoblastic leukemia
450476|NCT00896753|stage IV colon cancer
450477|NCT00896753|liver metastases
450478|NCT00896753|lung metastases
450479|NCT00896753|recurrent colon cancer
450480|NCT00896740|Fanconi anemia
450481|NCT00896727|stage IA breast cancer
450482|NCT00896727|stage IB breast cancer
450483|NCT00896727|stage II breast cancer
450484|NCT00896727|stage IIIA breast cancer
450485|NCT00896701|adult acute myeloid leukemia in remission
450486|NCT00896701|recurrent adult acute myeloid leukemia
450487|NCT00896701|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
450488|NCT00896701|adult acute myeloid leukemia with inv(16)(p13;q22)
450489|NCT00896701|adult acute myeloid leukemia with t(15;17)(q22;q12)
450490|NCT00896701|adult acute myeloid leukemia with t(16;16)(p13;q22)
450491|NCT00896701|adult acute myeloid leukemia with t(8;21)(q22;q22)
450492|NCT00896688|cervical branch block
450493|NCT00896688|fluoroscopic guidance
450494|NCT00896688|ultrasound guidance
450495|NCT00896675|recurrent squamous cell carcinoma of the hypopharynx
450496|NCT00896675|stage IV squamous cell carcinoma of the hypopharynx
450497|NCT00896675|recurrent squamous cell carcinoma of the larynx
450498|NCT00896675|stage IV squamous cell carcinoma of the larynx
450499|NCT00896675|stage IV squamous cell carcinoma of the lip and oral cavity
450500|NCT00896675|recurrent squamous cell carcinoma of the lip and oral cavity
450501|NCT00896675|metastatic squamous neck cancer with occult primary squamous cell carcinoma
450502|NCT00896675|recurrent metastatic squamous neck cancer with occult primary
450503|NCT00896675|recurrent squamous cell carcinoma of the nasopharynx
450504|NCT00896675|stage IV squamous cell carcinoma of the nasopharynx
450505|NCT00896675|recurrent squamous cell carcinoma of the oropharynx
450506|NCT00896675|stage IV squamous cell carcinoma of the oropharynx
450507|NCT00896675|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
450508|NCT00896675|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
450509|NCT00896675|salivary gland squamous cell carcinoma
450510|NCT00896675|stage IV salivary gland cancer
450511|NCT00896675|recurrent salivary gland cancer
450512|NCT00896662|unspecified adult solid tumor, protocol specific
450513|NCT00896662|recurrent adult Burkitt lymphoma
450514|NCT00896662|stage IV adult Burkitt lymphoma
450515|NCT00896662|recurrent adult diffuse large cell lymphoma
450516|NCT00896662|recurrent adult diffuse mixed cell lymphoma
450517|NCT00896662|recurrent adult diffuse small cleaved cell lymphoma
450518|NCT00896662|stage IV adult diffuse large cell lymphoma
450519|NCT00896662|stage IV adult diffuse mixed cell lymphoma
450520|NCT00896662|stage IV adult diffuse small cleaved cell lymphoma
450521|NCT00896662|recurrent adult immunoblastic large cell lymphoma
450522|NCT00896662|stage IV adult immunoblastic large cell lymphoma
450523|NCT00896662|recurrent adult lymphoblastic lymphoma
450524|NCT00896662|stage IV adult lymphoblastic lymphoma
450525|NCT00896662|recurrent grade 1 follicular lymphoma
450526|NCT00896662|recurrent grade 2 follicular lymphoma
450527|NCT00896662|recurrent grade 3 follicular lymphoma
450528|NCT00896662|stage IV grade 1 follicular lymphoma
450529|NCT00896662|stage IV grade 2 follicular lymphoma
450530|NCT00896662|stage IV grade 3 follicular lymphoma
450531|NCT00896662|recurrent mantle cell lymphoma
450532|NCT00896662|stage IV mantle cell lymphoma
450533|NCT00896662|recurrent marginal zone lymphoma
450534|NCT00896662|splenic marginal zone lymphoma
450535|NCT00896662|stage IV marginal zone lymphoma
450536|NCT00896662|nodal marginal zone B-cell lymphoma
450537|NCT00896662|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
450538|NCT00896662|recurrent small lymphocytic lymphoma
450539|NCT00896662|stage IV small lymphocytic lymphoma
450540|NCT00896649|breast cancer
450541|NCT00896636|breast cancer
450542|NCT00896636|healthy, no evidence of disease
450543|NCT00896623|stage I breast cancer
450544|NCT00896623|stage II breast cancer
450545|NCT00896610|Diabetes Mellitus
450546|NCT00896610|Type 1 Diabetes
450547|NCT00896610|Complications
450548|NCT00896610|Anti Beta-Cell Autoantibodies
450549|NCT00896610|T-Lymphocyte Assays
450550|NCT00896610|Type 2 Diabetes
450551|NCT00896610|Autoimmune Diabetes
450552|NCT00896610|At Risk Diabetes
450553|NCT00896584|Chronic obstructive pulmonary disease
450554|NCT00896584|Hypoxemia
450555|NCT00896584|Pre-flight evaluation
450556|NCT00896584|Hypobaria
450557|NCT00896584|COPD
450558|NCT00896584|Pulseoximetry
450559|NCT00896584|Air travel
450560|NCT00896584|Exercise desaturation
450561|NCT00896571|Fertility control
450562|NCT00896571|Contraception
450563|NCT00896558|GSK1322322, repeat dose, healthy subjects, elderly, drug-drug interaction, probe, midazolam, double-blind
450564|NCT00896519|stage III grade 1 follicular lymphoma
450565|NCT00896519|stage III grade 2 follicular lymphoma
450566|NCT00896519|stage III grade 3 follicular lymphoma
450567|NCT00896519|stage IV grade 1 follicular lymphoma
450568|NCT00896519|stage IV grade 2 follicular lymphoma
450569|NCT00896519|stage IV grade 3 follicular lymphoma
450570|NCT00896480|ASCI (Antigen-Specific Cancer Immunotherapeutic)
450571|NCT00896480|Cancer immunotherapeutic
450572|NCT00896480|Malignant melanoma
450573|NCT00896480|MAGE-A3
450574|NCT00896467|anxiety disorder
450575|NCT00896467|depression
450576|NCT00896467|stage IV breast cancer
450577|NCT00896467|stage IV renal cell cancer
450578|NCT00896467|stage IV non-small cell lung cancer
450579|NCT00896467|extensive stage small cell lung cancer
450580|NCT00896467|stage IV gastric cancer
450581|NCT00896467|stage IV anal cancer
450582|NCT00896467|stage IV pancreatic cancer
450583|NCT00896467|stage IV esophageal cancer
450584|NCT00896467|advanced adult primary liver cancer
450585|NCT00896467|unresectable gallbladder cancer
450586|NCT00896467|small intestine cancer
450587|NCT00896454|hypercalcemia
450588|NCT00896454|calcium
450589|NCT00896454|bisphosphonates
450590|NCT00896454|denosumab
450591|NCT00896454|amgen
450592|NCT00896454|malignancy
450593|NCT00896454|20070315
450594|NCT00896454|HMC
450595|NCT00896454|oncology
450596|NCT00896454|hematology
450597|NCT00896428|Asthma
450598|NCT00896428|gallopamil
450599|NCT00896428|airway remodelling
450600|NCT00896428|smooth muscle
450601|NCT00896415|on two models of CT scanner acquire CT images of the abdomen pelvis and midthigh in 20 Postmenopausal female volunteers
450602|NCT00896402|chloraprep
450603|NCT00896402|betadine
450604|NCT00896402|colonization
450605|NCT00896402|femoral catheter
450606|NCT00896389|hypertension
450607|NCT00896389|hydrochlorothiazide
450608|NCT00896389|HCTZ
450609|NCT00896389|salt sensitivity
450610|NCT00896389|Hydrochlorothiazide induced hyperglycemia
450611|NCT00896376|stage IV breast cancer
450612|NCT00896376|HER2-positive breast cancer
450613|NCT00896363|anti-depressant
450614|NCT00896363|Severe Depression
450615|NCT00896363|Efficacy
450616|NCT00896363|Major Depressive Disorder
450617|NCT00896363|Major Depressive Episode
450618|NCT00896350|stage III squamous cell carcinoma of the hypopharynx
450619|NCT00896350|stage III squamous cell carcinoma of the larynx
450620|NCT00896350|stage III squamous cell carcinoma of the lip and oral cavity
450621|NCT00896350|stage III squamous cell carcinoma of the nasopharynx
450622|NCT00896350|stage III squamous cell carcinoma of the oropharynx
450623|NCT00896350|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
450624|NCT00896350|stage IV squamous cell carcinoma of the hypopharynx
450625|NCT00896350|stage IV squamous cell carcinoma of the larynx
450626|NCT00896350|stage IV squamous cell carcinoma of the lip and oral cavity
450627|NCT00896350|stage IV squamous cell carcinoma of the nasopharynx
450628|NCT00896350|stage IV squamous cell carcinoma of the oropharynx
450629|NCT00896350|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
450630|NCT00896350|stage III lymphoepithelioma of the nasopharynx
450631|NCT00896350|stage III lymphoepithelioma of the oropharynx
450632|NCT00896350|stage III verrucous carcinoma of the larynx
450633|NCT00896350|stage IV lymphoepithelioma of the nasopharynx
450634|NCT00896350|stage IV lymphoepithelioma of the oropharynx
450635|NCT00896350|stage IV verrucous carcinoma of the larynx
450636|NCT00896350|stage III basal cell carcinoma of the lip
450637|NCT00896350|stage IV basal cell carcinoma of the lip
450638|NCT00896350|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
450639|NCT00896350|stage III inverted papilloma of the paranasal sinus and nasal cavity
450640|NCT00896350|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
450641|NCT00896350|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
450642|NCT00896350|stage IV inverted papilloma of the paranasal sinus and nasal cavity
450643|NCT00896350|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
450644|NCT00896350|tongue cancer
450645|NCT00896337|iliac artery stenosis
450646|NCT00896337|claudication
450647|NCT00896337|atherosclerotic iliac disease
450648|NCT00896337|peripheral vascular disease
450649|NCT00896324|Quality of life
450650|NCT00896298|Lipodystrophy
450651|NCT00896298|Insulin secretory response
450652|NCT00896285|Pleural malignancy
450653|NCT00896285|pleural effusion
450654|NCT00896285|pleurodesis
450655|NCT00896285|chest tube
450656|NCT00896285|cancer
450657|NCT00896285|cancer pain management
450658|NCT00896272|Klinefelter Syndrome
450659|NCT00896272|47,XXY
450660|NCT00896272|XXY
450661|NCT00896259|Unilateral total hip arthroplasty
450662|NCT00896233|Staging of liver fibrosis prior to clinical trials for treatment of Hepatitis C Virus
450663|NCT00896220|chronic critical illness
450664|NCT00896220|mechanical ventilation
450665|NCT00896220|outcomes
450666|NCT00896220|weakness
450667|NCT00896220|quality of life
450668|NCT00896220|Critically Ill patients and their family caregiver
450669|NCT00896194|Overweight
450670|NCT00896194|Obesity
450671|NCT00896194|Self-Efficacy
450672|NCT00896194|Treatment Adherence
450673|NCT00896168|Arthritis, Rheumatoid
450674|NCT00896168|Infliximab
450675|NCT00896168|Methotrexate
450676|NCT00896155|Breast cancer
450677|NCT00896155|Pulmonary fibrosis
450678|NCT00896155|tamoxifen
450679|NCT00896155|radiotherapy
450680|NCT00896142|ischemic cardiomyopathy
450681|NCT00896142|cardiac resynchronization therapy
450682|NCT00896142|LV structure and function
450683|NCT00896129|Health Outcomes Research
450684|NCT00896129|CML
450685|NCT00896077|healthy subjects
450686|NCT00896064|Pneumococcal vaccine
450687|NCT00896064|Streptococcus pneumoniae
450688|NCT00896064|Young adults
450689|NCT00896051|HIV Infections
450690|NCT00896051|Acquired Immunodeficiency Syndrome
450691|NCT00896051|TMC125-TiDP2-C238
450693|NCT00896051|Etravirine
450694|NCT00896051|Intelence
450695|NCT00896051|HIV
450696|NCT00896051|HIV-1
450697|NCT00896051|Pharmacokinetics
450698|NCT00896038|Alcohol Dependence
450699|NCT00896038|Alcohol Treatment
450700|NCT00896038|Alcoholics
450701|NCT00896038|Alcoholism
450702|NCT00896038|Posttraumatic Stress Disorder
450703|NCT00896038|PTSD
450704|NCT00896025|Liver disease
450705|NCT00896012|Kidney Transplant
450706|NCT00896012|Immunosuppression drugs
450707|NCT00896012|Rapamune
450708|NCT00896012|tacrolimus
450709|NCT00896012|calcineurin inhibitor
450710|NCT00896012|Kidney Biopsy, Needle
450711|NCT00895986|Diabetes
450712|NCT00895986|Education
450713|NCT00895960|Brain
450714|NCT00895960|CNS Disease
450715|NCT00895960|CNS
450716|NCT00895960|Intracranial Supratentorial GBM
450717|NCT00895960|Gliosarcoma
450718|NCT00895960|GS
450719|NCT00895960|Glioblastoma
450720|NCT00895960|GBM
450721|NCT00895960|Dasatinib
450722|NCT00895960|Sprycel
450723|NCT00895960|Temozolomide
450724|NCT00895960|TMZ
450725|NCT00895960|Temodar
450726|NCT00895960|Radiation Therapy
450727|NCT00895960|Radiotherapy
450728|NCT00895960|RT
450729|NCT00895947|Prophylaxis
450730|NCT00895947|Treatment
450731|NCT00895947|Symptoms
450732|NCT00895947|Winter Colds and Flu
450733|NCT00895921|Insulin Resistance
450734|NCT00895921|Antipsychotic Medications
450735|NCT00895908|ADHD
450736|NCT00895908|Psychosocial Intervention
450737|NCT00895908|Social Skills Training
450738|NCT00895869|Screening
450739|NCT00895869|Retinopathy
450740|NCT00895869|Prematurity
450741|NCT00895869|Pain
450742|NCT00895856|Physiotherapy
450743|NCT00895856|Aged
450744|NCT00895856|Functionality
450745|NCT00895856|Physiotherapic assistance
450746|NCT00895856|Functional capacity
450747|NCT00895843|Third molar
450748|NCT00895817|Eosinophilic esophagitis
450749|NCT00895817|acid reflux
450750|NCT00895804|MDMA
450751|NCT00895804|beta adrenergic
450752|NCT00895804|Ecstasy
450753|NCT00895791|coronary bifurcation
450754|NCT00895791|stent implantation
450755|NCT00895791|PCI
450756|NCT00895791|Optical Coherence Tomography
450757|NCT00895778|Neuromuscular blockade
450758|NCT00895778|post-operative pain
450759|NCT00895778|post-operative pulmonary function
450760|NCT00895765|Melamine
450761|NCT00895765|Calculus
450762|NCT00895765|Kidney
450763|NCT00895765|Child
450764|NCT00895739|aplastic anemia
450765|NCT00895726|cachexia
450766|NCT00895726|neoplasms
450767|NCT00895713|Hepatitis B
450768|NCT00895713|HBV
450769|NCT00895713|Anti-hepatitis B antibodies
450770|NCT00895713|Immunoglobulins
450771|NCT00895713|liver transplantation
450772|NCT00895713|Protective levels
450773|NCT00895713|Recurrence
450774|NCT00895713|Intramuscular
450775|NCT00895700|Anxiety
450776|NCT00895700|ICD concerns
450777|NCT00895700|Quality of life
450778|NCT00895687|Metastatic Cancer
450779|NCT00895687|Bortezomib
450780|NCT00895687|Velcade
450781|NCT00895687|Erlotinib
450782|NCT00895687|Erlotinib Hydrochloride
450783|NCT00895687|Tarceva
450784|NCT00895687|EGFR
450785|NCT00895687|EGFR mutations
450786|NCT00895674|Advanced Renal Cell Carcinoma
450787|NCT00895661|rituximab
450788|NCT00895648|Meso
450789|NCT00895648|mesothelioma
450790|NCT00895648|pleura
450791|NCT00895648|pleural
450792|NCT00895635|Claudication
450793|NCT00895635|Peripheral Arterial Disease
450794|NCT00895635|Exercise Rehabilitation
450795|NCT00895635|Cardiovascular Function
450796|NCT00895622|adult grade I meningioma
450797|NCT00895622|adult grade II meningioma
450798|NCT00895622|adult grade III meningioma
450799|NCT00895622|adult anaplastic meningioma
450800|NCT00895622|adult papillary meningioma
450801|NCT00895622|recurrent adult brain tumor
450802|NCT00895609|Residual neuromuscular block
450803|NCT00895609|post-operative residual curarization
450804|NCT00895609|PORC
450805|NCT00895609|sugammadex
450806|NCT00895609|neostigmine
450807|NCT00895609|Shallow neuromuscular block (TOF-ratio of 0.5)
450808|NCT00895596|Chronic hepatitis B
450809|NCT00895596|Lamivudine resistant
450810|NCT00895596|YMDD mutant type
450811|NCT00895583|renal transplant
450812|NCT00895583|immunosuppression
450813|NCT00895583|sirolimus/rapamune
450814|NCT00895583|planned transition
450815|NCT00895570|sleep restriction
450816|NCT00895570|glucose metabolism
450817|NCT00895570|modafinil
450818|NCT00895570|euglycemic clamp
450819|NCT00895570|insulin sensitivity
450820|NCT00895570|insulin release
450821|NCT00895557|varenicline
450822|NCT00895557|cocaine
450823|NCT00895557|brain imaging
450824|NCT00895531|Knee Replacement, Total
450825|NCT00895531|Morphine
450826|NCT00895518|PTSD
450827|NCT00895505|DVT
450828|NCT00895505|Venous thromboembolism
450829|NCT00895505|D-Dimer
450830|NCT00895505|thrombophilia
450831|NCT00895505|secondary prophylaxis
450832|NCT00895505|secondary prophylaxis using oral anticoagulant treatment (OAT)
450833|NCT00895505|higher risk of recurrence in patients showing increased levels
450834|NCT00895505|of D-Dimer after withdrawal of OAT
450835|NCT00895505|D-Dimer-based treatment
450836|NCT00895492|diarrhea
450837|NCT00895492|rotavirus
450838|NCT00895492|genotype
450839|NCT00895492|VP4
450840|NCT00895492|VP7
450841|NCT00895479|End Stage Renal Disease
450842|NCT00895479|ESRD
450843|NCT00895479|Hemodialysis
450844|NCT00895479|Access Graft
450845|NCT00895466|prostatic diseases
450846|NCT00895466|neoplasms
450847|NCT00895466|prostatic neoplasms
450848|NCT00895466|hormones
450849|NCT00895466|androgen antagonists
450850|NCT00895466|vaccines
450851|NCT00895466|peptide vaccines
450852|NCT00895466|adjuvants, immunological
450853|NCT00895453|recurrent vulvovaginal candidiasis
450854|NCT00895453|itraconazole
450855|NCT00895453|classic homeopathy
450856|NCT00895440|Diabetes
450857|NCT00895440|Diabetic neuropathy
450858|NCT00895440|neuropad
450859|NCT00895440|Painless peripheral diabetic neuropathy
450860|NCT00895440|Painful peripheral diabetic neuropathy
450861|NCT00895440|Autonomic peripheral neuropathy
450862|NCT00895440|Charcot neuroarthropathy
450863|NCT00895427|Coronary artery calcification
450864|NCT00895414|stage I breast cancer
450865|NCT00895414|stage II breast cancer
450866|NCT00895414|stage IIIA breast cancer
450867|NCT00895414|stage IIIB breast cancer
450868|NCT00895414|stage IIIC breast cancer
450869|NCT00895414|stage IV breast cancer
450870|NCT00895401|Nutritional supplement
450871|NCT00895401|Malnutrition
450872|NCT00895401|Hemodialysis
450873|NCT00895401|Nepro with Carb Steady
450874|NCT00895388|Urinary function
450875|NCT00895388|Anal function
450876|NCT00895375|Dermatology
450877|NCT00895375|Skin
450878|NCT00895375|Psoriasis
450879|NCT00895375|Sleep
450880|NCT00895375|Wake Forest
450881|NCT00895375|Insomnia
450882|NCT00895362|Advanced Cancer
450883|NCT00895362|EGFR mutation
450884|NCT00895362|Erlotinib
450885|NCT00895362|Erlotinib Hydrochloride
450886|NCT00895362|Tarceva
450887|NCT00895362|OSI-774
450888|NCT00895362|Cetuximab
450889|NCT00895362|C225
450890|NCT00895362|Erbitux
450891|NCT00895362|IMC-C225
450892|NCT00895349|Positron Emission Tomography (PET)
450893|NCT00895349|Diagnostic Intervention
450894|NCT00895349|Locally Advanced Cervical Cancer
450895|NCT00895336|Pediatric Ulcerative Colitis
450896|NCT00895323|stage I colon cancer
450897|NCT00895323|stage II colon cancer
450898|NCT00895323|stage III colon cancer
450899|NCT00895323|stage IV colon cancer
450900|NCT00895323|stage I rectal cancer
450901|NCT00895323|stage II rectal cancer
450902|NCT00895323|stage III rectal cancer
450903|NCT00895323|stage IV rectal cancer
450904|NCT00895323|recurrent colon cancer
450905|NCT00895323|recurrent rectal cancer
450906|NCT00895310|PSA
450907|NCT00895310|Ketoconazole
450908|NCT00895310|Prostate Cancer
450909|NCT00895310|Hormone Refractory
450910|NCT00895310|Chemotherapy Regimen
450911|NCT00895297|Relapsing after allogeneic transplantation
450912|NCT00895297|Dasatinib
450913|NCT00895297|Sprycel
450914|NCT00895297|Philadelphia Chromosomes
450915|NCT00895284|robotic
450916|NCT00895284|laparoscopic surgical procedures
450917|NCT00895271|Primary Immunodeficiency
450918|NCT00895271|Immunodysregulation
450919|NCT00895271|Skin Biopsy
450920|NCT00895271|Induced Pluripotent Stem Cell (iPS)
450921|NCT00895271|Lymphocyte
450922|NCT00895271|Common Variable Immunodeficiency
450923|NCT00895271|Severe Combined Immunodeficiency
450924|NCT00895271|Healthy Volunteer
450925|NCT00895271|HV
450926|NCT00895258|Schizoaffective Disorder
450927|NCT00895258|Major Depressive Disorder
450928|NCT00895258|Supported Employment
450929|NCT00895258|Work
450930|NCT00895258|Rehabilitation
450931|NCT00895258|Severe Mental Illness
450932|NCT00895258|Cognitive Training
450933|NCT00895258|Cognitive Rehabilitation
450934|NCT00895258|Cognitive Remediation
450935|NCT00895219|Hyperventilation
450936|NCT00895219|Dysfunctional breathing
450937|NCT00895219|Physiotherapy
450938|NCT00895219|Musculoskeletal techniques
450939|NCT00895193|Niacin
450940|NCT00895193|Hypercholesterolemia
450941|NCT00895193|Flushing
450942|NCT00895180|recurrent adult brain tumor
450943|NCT00895180|adult glioblastoma
450944|NCT00895180|adult giant cell glioblastoma
450945|NCT00895180|adult gliosarcoma
450946|NCT00895167|Heme Oxygenase
450947|NCT00895167|Genetic Polymorphism
450948|NCT00895167|Healthy Subjects
450949|NCT00895154|Sickle Cell Disease
450950|NCT00895154|Sickle Cell
450951|NCT00895154|Memory
450952|NCT00895154|Learning
450953|NCT00895154|Achievement
450954|NCT00895141|Saturated fat
450955|NCT00895141|LDL size
450956|NCT00895141|Large LDL
450957|NCT00895141|Large HDL
450958|NCT00895128|Advanced Cancer
450959|NCT00895128|EGFR mutations
450960|NCT00895128|Dasatinib
450961|NCT00895128|Sprycel
450962|NCT00895128|Erlotinib
450963|NCT00895128|Erlotinib Hydrochloride
450964|NCT00895128|Tarceva
450965|NCT00895115|prostate cancer
450966|NCT00895102|Bioavailability (BA)
450967|NCT00895102|Single Ascending Dose (SAD)
450968|NCT00895089|liver abscess
450969|NCT00895089|moxifloxacin
450970|NCT00895089|ceftriaxone
450971|NCT00895089|treatment
450972|NCT00895063|Spasmodic Dysphonia
450973|NCT00895063|Botulinum Toxin
450974|NCT00895063|Vocal Exercise
450975|NCT00895024|Caregiver
450976|NCT00895024|Questionnaire
450977|NCT00895024|Home Hospice Care
450978|NCT00895024|Family Evaluation of Hospice Care
450979|NCT00895024|FEHC
450980|NCT00895024|The Texas Revised Inventory of Grief
450981|NCT00895024|TRIG
450982|NCT00895024|Cross-ethnic differences
450983|NCT00895024|Parenteral Hydration
450984|NCT00895024|Grief
450985|NCT00895011|Erectile Dysfunction
450986|NCT00895011|E.D.
450987|NCT00894998|heparin cardiac surgery
450988|NCT00894985|heparin cardiac surgery
450989|NCT00894959|heparin cardiac surgery
450990|NCT00894946|recurrent IVF implantation failure
450991|NCT00894933|Prostate Cancer
450992|NCT00894933|Radical Prostatectomy
450993|NCT00894933|Vesico-Urethral Anastomosis
450994|NCT00894920|biotin
450995|NCT00894920|deficiency
450996|NCT00894920|pregnancy
450997|NCT00894920|lymphocyte propionyl-CoA carboxylase
450998|NCT00894907|Severe pancreatitis
450999|NCT00894907|acute pancreatitis
451000|NCT00894907|haemodynamic monitoring
451001|NCT00894907|PiCCO
451002|NCT00894894|MP470
451003|NCT00894894|MP-470
451004|NCT00894894|SuperGen
451005|NCT00894894|Tyrosine
451006|NCT00894894|Kinase
451007|NCT00894894|Inhibitor
451008|NCT00894894|Solid Malignancies
451009|NCT00894894|Oncology
451010|NCT00894881|colonoscopy
451011|NCT00894881|Healthy individuals before colonoscopy
451012|NCT00894868|Congestive Heart Failure
451013|NCT00894868|CHF, vildagliptin
451014|NCT00894868|metabolic disease
451015|NCT00894868|cardiovascular disease
451016|NCT00894868|T2DM
451017|NCT00894855|skin cancer prevention
451018|NCT00894855|SHADE
451019|NCT00894855|Beach
451020|NCT00894842|Schizophrenia
451021|NCT00894842|Pregnenolone
451022|NCT00894842|Neurocognition
451023|NCT00894829|heparin cardiac surgery
451024|NCT00894816|Prevention
451025|NCT00894816|Probiotics
451026|NCT00894816|Eczema
451027|NCT00894816|Allergy
451028|NCT00894816|Asthma
451029|NCT00894816|Obesity
451030|NCT00894816|Caries
451031|NCT00894816|Gut microbiota
451032|NCT00894803|acute ischemic stroke
451033|NCT00894803|stroke
451034|NCT00894803|rt-PA, thrombolytic
451035|NCT00894803|t-PA
451036|NCT00894803|recombinant tissue plasminogen activator
451037|NCT00894803|Activase
451038|NCT00894803|eptifibatide
451039|NCT00894803|Integrilin
451040|NCT00894803|fibrinolytic agents
451041|NCT00894803|clot dissolving
451042|NCT00894803|blood clot
451043|NCT00894790|Treatment of the acute pain due to cervical
451044|NCT00894790|sprain
451045|NCT00894790|Celecoxib
451046|NCT00894790|NSAID
451047|NCT00894790|Diclofenac
451048|NCT00894777|Psoriasis
451049|NCT00894764|Childhood
451050|NCT00894764|Pneumonia
451051|NCT00894764|Pneumococcal
451052|NCT00894764|pneumococcus
451053|NCT00894764|Carriage
451054|NCT00894751|dexmedetomidine and propofol for MRI
451055|NCT00894751|quality of care between two anesthetic agents for MRI
451056|NCT00894738|pediatric
451057|NCT00894738|mental illness
451058|NCT00894738|antipsychotic
451059|NCT00894738|cardiometabolic risk
451060|NCT00894738|Antipsychotic agents
451061|NCT00894738|Mental disorders diagnosed in childhood
451062|NCT00894725|left colon cancer
451063|NCT00894712|Radiation Therapy
451064|NCT00894699|procedural sedation
451065|NCT00894673|heparin cardiac surgery
451066|NCT00894660|Bioequivalence, Healthy Volunteers
451067|NCT00894647|actinic keratosis
451068|NCT00894647|skin disease
451069|NCT00894621|Shock
451070|NCT00894621|Respiration, artificial
451071|NCT00894621|Norepinephrine
451072|NCT00894608|letrozole
451073|NCT00894608|ovarian stimulation
451074|NCT00894608|PCOS
451075|NCT00894608|IVF-ET
451076|NCT00894595|Incidence of ACL injury
451077|NCT00894595|Risk factors for ACL injury
451078|NCT00894595|Prevention of ACL injury or any acute knee injury
451079|NCT00894582|massive ventral hernia
451080|NCT00894582|abdominal volume
451081|NCT00894582|pulmonary function
451082|NCT00894582|components separation
451083|NCT00894582|abdominal compartments syndrome
451084|NCT00894569|carcinoma of unknown primary
451085|NCT00894569|cancer of unknown primary
451086|NCT00894569|CUP
451087|NCT00894569|carboplatin
451088|NCT00894569|paclitaxel
451089|NCT00894569|cetuximab
451090|NCT00894556|Treatment of acute migraine with or without aura in adults
451091|NCT00894543|Hot flashes
451092|NCT00894543|Menopause
451093|NCT00894543|Vasomotor symptoms
451094|NCT00894504|Metastatic Breast Cancer
451095|NCT00894504|Triple Negative
451096|NCT00894504|Panitumumab
451097|NCT00894504|Vectibix
451098|NCT00894504|Gemcitabine
451099|NCT00894504|Gemzar
451100|NCT00894504|Carboplatin
451101|NCT00894491|alternative medicine
451102|NCT00894491|complementary medicine
451103|NCT00894491|acupuncture
451104|NCT00894491|Chinese herbals
451105|NCT00894478|MRI-Negative
451106|NCT00894478|Diffusion tensor imaging
451107|NCT00894478|Localization-related epilepsy
451108|NCT00894478|Partial Epilepsy
451109|NCT00894478|Children
451110|NCT00894465|Midazolam
451111|NCT00894465|VCUG
451112|NCT00894465|Anxiety
451113|NCT00894452|Methadone
451114|NCT00894452|CYP
451115|NCT00894452|OPRM1
451116|NCT00894452|MDR1
451117|NCT00894452|COMT
451118|NCT00894452|Midazolam challenge
451119|NCT00894426|COPD
451120|NCT00894426|Symptom
451121|NCT00894426|Morning activity
451122|NCT00894426|Questionnaire
451123|NCT00894400|AF
451124|NCT00894400|catheter ablation
451125|NCT00894400|fractionated electrogram
451126|NCT00894400|complex fractionated atrial electrogram (CFAE)
451127|NCT00894387|elevated BNP
451128|NCT00894387|reduced LVEF
451129|NCT00894387|Acute Heart Failure
451130|NCT00894387|Cardiovascular death
451131|NCT00894387|CHF
451132|NCT00894387|hospitalization
451133|NCT00894387|morbi-mortality trial
451134|NCT00894387|outcome study
451135|NCT00894387|endpoint driven
451136|NCT00894387|plasma renin activity
451137|NCT00894387|renin angiotensin
451138|NCT00894387|aldosterone system
451139|NCT00894387|direct renin inhibitors
451140|NCT00894387|BNP
451141|NCT00894387|KCCQ
451142|NCT00894387|eGFR
451143|NCT00894374|Bio-equivalence, Healthy Volunteers
451144|NCT00894361|knee arthritis
451145|NCT00894361|total knee arthroplasty
451146|NCT00894361|total knee replacement
451147|NCT00894361|mobile bearing design
451148|NCT00894361|all-polyethylene tibia
451149|NCT00894348|ERCP
451150|NCT00894348|Positive Biliary Brush Cytology
451151|NCT00894348|To determine factors associated with the positive yield of malignancy on biliary brush cytology obtained by ERCP
451152|NCT00894335|retroperitoneoscopic adrenalectomy
451153|NCT00894335|intraoperative arterial-alveolar Carbon dioxide Difference
451154|NCT00894322|diabetes
451155|NCT00894322|exenatide once weekly
451156|NCT00894322|Byetta
451157|NCT00894322|Amylin
451158|NCT00894322|Lilly
451159|NCT00894296|MEG
451160|NCT00894296|schizophrenia
451161|NCT00894296|negative symptoms
451162|NCT00894283|DVT
451163|NCT00894283|PE
451164|NCT00894283|MRV
451165|NCT00894283|bariatric surgery
451166|NCT00894270|Diabetes
451167|NCT00894270|Injection
451168|NCT00894270|Needle
451169|NCT00894257|HCV infected pregnant women
451170|NCT00894244|None- Normal healthy upper arm skin will be used.
451171|NCT00894205|neuropsychological function
451172|NCT00894205|cognitive function
451173|NCT00894205|exercise
451174|NCT00894205|older adult
451175|NCT00894192|This study tests functional ability of patients with refractive error or normal vision while using different types of eyeglasses.
451176|NCT00894179|coronary artery disease
451177|NCT00894179|stress echocardiography
451178|NCT00894179|regadenoson
451179|NCT00894179|atropine
451180|NCT00894179|coronary angiogram
451181|NCT00894166|Smoking Cessation
451182|NCT00894166|Chantix
451183|NCT00894166|varenicline
451184|NCT00894166|Nicotine Replacement Therapy
451185|NCT00894166|Nicotine Patches
451186|NCT00894166|Zyban
451187|NCT00894166|bupropion
451188|NCT00894166|Quit Smoking
451189|NCT00894153|p53 gene
451190|NCT00894153|head and neck malignent tumors
451191|NCT00894153|gene therapy
451192|NCT00894140|Hip
451193|NCT00894140|Cementless
451194|NCT00894140|Conservative
451195|NCT00894127|Lung Cancer
451196|NCT00894127|Porphyrin
451197|NCT00894127|Fluorescence
451198|NCT00894127|Diagnostic
451199|NCT00894127|Sputum Cytology
451200|NCT00894127|Early Detection
451201|NCT00894075|genetic metabolic disorder
451202|NCT00894075|alkaline phosphatase
451203|NCT00894075|tissue non-specific alkaline phosphatase
451204|NCT00894075|rickets
451205|NCT00894075|osteomalacia
451206|NCT00894036|esbl children Switzerland
451207|NCT00894036|Colonization
451208|NCT00894036|ESBL-producing gram-negative bacilli
451209|NCT00894036|Infection
451210|NCT00894023|Patients with AMI
451211|NCT00894010|Photosensitive epilepsy
451212|NCT00894010|Photosensitivity
451213|NCT00894010|Seizures
451214|NCT00894010|Epilepsy
451215|NCT00893997|myelodysplastic syndrome
451216|NCT00893997|MDS
451217|NCT00893997|PR1 Peptide Vaccine
451218|NCT00893984|Intolerance
451219|NCT00893984|Beta blocker
451220|NCT00893971|Healthy Volunteers
451221|NCT00893932|SIRS leptin outcome sepsis
451222|NCT00893906|influenza
451223|NCT00893906|influenza vaccine
451224|NCT00893906|vaccine effectiveness
451225|NCT00893906|cluster randomized
451226|NCT00893906|Africa
451227|NCT00893893|Obesity
451228|NCT00893893|Lipid metabolism
451229|NCT00893893|VLDL
451230|NCT00893880|Tinea Pedis
451231|NCT00893880|Athletes Foot
451232|NCT00893880|Nitric Oxide
451233|NCT00893867|acute ischemic stroke
451234|NCT00893867|neuroprotective agent
451235|NCT00893841|bipolar
451236|NCT00893841|bipolar depression
451237|NCT00893841|bipolar disorder
451238|NCT00893841|depression
451239|NCT00893841|quetiapine
451240|NCT00893841|pramipexole
451241|NCT00893841|Seroquel XR
451242|NCT00893841|Mirapex
451243|NCT00893815|HIV
451244|NCT00893815|Neurocognitive function
451245|NCT00893802|periodontal disease
451246|NCT00893802|pregnancy
451247|NCT00893802|periodontal treatment
451248|NCT00893763|Nosocomial (Hospital-Acquired) Infections
451249|NCT00893763|Ventilator-Associated Pneumonia
451250|NCT00893763|Mechanical ventilation
451251|NCT00893763|Endotracheal intubation
451252|NCT00893750|Vulnerable Youths in Northern Uganda
451253|NCT00893750|Formerly Abducted Children
451254|NCT00893750|Reintegration and Reconciliation
451255|NCT00893750|Trauma Treatment
451256|NCT00893750|Narrative Exposure Therapy
451257|NCT00893750|Reconciliation
451258|NCT00893750|Revenge Feelings
451259|NCT00893737|Migraine
451260|NCT00893737|Headache, Migraine
451261|NCT00893724|DME
451262|NCT00893724|NAMD
451263|NCT00893724|Oxidative damage
451264|NCT00893724|Nutritional supplements/vitamins
451265|NCT00893724|DNA repair
451266|NCT00893724|NAMD/wet AMD
451267|NCT00893711|infantile colic
451268|NCT00893711|lactobacillus
451269|NCT00893711|gut microflora
451270|NCT00893711|FISH
451271|NCT00893685|Telemedicine
451272|NCT00893672|Radiography, Thoracic
451273|NCT00893672|Intensive Care Units
451274|NCT00893672|Ventilation, mechanical
451275|NCT00893672|Matched-Pair Analysis
451276|NCT00893659|Beta-glucan
451277|NCT00893659|faecal microflora
451278|NCT00893659|polypectomized
451279|NCT00893659|Precancerous Nonmalignant Condition
451280|NCT00893646|abdominal obesity
451281|NCT00893646|weight reduction
451282|NCT00893646|diet
451283|NCT00893646|exercise training
451284|NCT00893646|lifestyle activity
451285|NCT00893646|health-related fitness
451286|NCT00893646|walking
451287|NCT00893646|actigraphy
451288|NCT00893646|lifestyle modification
451289|NCT00893646|sleep
451290|NCT00893646|sleep hygiene
451291|NCT00893646|alertness
451292|NCT00893646|daytime sleepiness
451293|NCT00893646|metabolic syndrome
451294|NCT00893646|counselling
451295|NCT00893646|health education
451296|NCT00893646|truck drivers
451297|NCT00893646|bus drivers
451298|NCT00893646|randomized controlled trial
451299|NCT00893633|neuromuscular diseases
451300|NCT00893633|critical illness
451301|NCT00893633|mechanical ventilation
451302|NCT00893633|phrenic nerve
451303|NCT00893633|nerve conduction studies
451304|NCT00893620|iliac aneurysm
451305|NCT00893620|endovascular repair
451306|NCT00893594|migraine
451307|NCT00893594|migraine with aura
451308|NCT00893594|headache
451309|NCT00893581|mania
451310|NCT00893581|adolescent
451311|NCT00893581|bipolar
451312|NCT00893568|Post traumatic stress disorder PTSD
451313|NCT00893555|Invasive fungal infection
451314|NCT00893555|hematological malignancy
451315|NCT00893555|voriconazole
451316|NCT00893555|therapeutic drug monitoring
451317|NCT00893529|overweight
451318|NCT00893529|children
451319|NCT00893529|intervention
451320|NCT00893529|sugar-sweetened beverages
451321|NCT00893516|non cutaneous peripheral t-cell lymphoma with nodal involvement
451322|NCT00893477|stage II grade 1 follicular lymphoma
451323|NCT00893477|stage II grade 2 follicular lymphoma
451324|NCT00893477|stage II grade 3 follicular lymphoma
451325|NCT00893477|stage III grade 1 follicular lymphoma
451326|NCT00893477|stage III grade 2 follicular lymphoma
451327|NCT00893477|stage III grade 3 follicular lymphoma
451328|NCT00893477|stage IV grade 1 follicular lymphoma
451329|NCT00893477|stage IV grade 2 follicular lymphoma
451330|NCT00893477|stage IV grade 3 follicular lymphoma
451331|NCT00893451|renal disease
451332|NCT00893451|renal impairment
451333|NCT00893451|chronic kidney disease stage 3-4
451334|NCT00893451|25(OH) vitamin D
451335|NCT00893451|cholecalciferol
451336|NCT00893451|vitamin D deficiency
451337|NCT00893451|insulin resistance
451338|NCT00893451|insulin-glucose clamp
451339|NCT00893451|non-diabetic
451340|NCT00893438|Chronic Fatigue Syndrome (CFS)
451341|NCT00893438|Adolescence
451342|NCT00893438|Cognitive behaviour therapy (CBT)
451343|NCT00893438|Web-based
451344|NCT00893438|Internet
451345|NCT00893438|Efficacy
451346|NCT00893425|CD95
451347|NCT00893425|ADMA
451348|NCT00893425|proteinuria
451349|NCT00893425|diabetic nephropathy
451350|NCT00893425|CD95 and ADMA levels
451351|NCT00893412|HSG
451352|NCT00893412|analgesia
451353|NCT00893412|tramadol
451354|NCT00893412|metal cannula
451355|NCT00893412|balloon catheter
451356|NCT00893399|adult patients
451357|NCT00893399|NPM1 mutation
451358|NCT00893386|Extraction
451359|NCT00893386|Removal
451360|NCT00893386|Lead
451361|NCT00893386|Heart Failure
451362|NCT00893373|AML
451363|NCT00893373|sorafenib
451364|NCT00893360|Adult Stem cells
451365|NCT00893360|Cardiosphere derived stem cells
451366|NCT00893360|Myocardial infarction
451367|NCT00893347|Mild traumatic brain injury
451368|NCT00893347|Concussion
451369|NCT00893347|Post-Concussion Syndrome
451370|NCT00893347|Cognitive-Behavioural Therapy
451371|NCT00893334|Duchenne and Becker muscular dystrophy
451372|NCT00893334|muscular dystrophy
451373|NCT00892541|Schizophrenia
451374|NCT00892541|Mood disorders
451375|NCT00892541|Antipsychotic drugs
451376|NCT00892541|Renal secretion
451377|NCT00892541|ER OROS paliperidone
451378|NCT00892515|breast cancer
451379|NCT00892515|healthy, no evidence of disease
451380|NCT00892502|haematology
451381|NCT00892502|haematological
451382|NCT00892502|hematology
451383|NCT00892502|hematological
451384|NCT00892502|malignancy
451385|NCT00892502|lymphoma
451386|NCT00892502|myeloma
451387|NCT00892502|leukemia
451388|NCT00892502|blood diseases
451389|NCT00892502|malignant
451390|NCT00892502|bismuth
451391|NCT00892489|Schizophrenia, Mood disorders, Antipsychotics
451392|NCT00892489|ER OROS Paliperidone
451393|NCT00892476|myopia
451394|NCT00892476|calcium supplementation
451395|NCT00892476|prematurity
451396|NCT00892463|Major Depressive Disorder
451397|NCT00892463|Seroquel XR
451398|NCT00892463|Quetiapine
451399|NCT00892450|Overactive bladder symptoms
451400|NCT00892450|Parkinson's disease
451401|NCT00892450|darifenacin
451402|NCT00892450|oxybutynin
451403|NCT00892450|cognition
451404|NCT00892437|HIV
451405|NCT00892437|HIV-1
451406|NCT00892437|Antiretroviral Treatment-Naive
451407|NCT00892424|Liver metastasis
451408|NCT00892424|sorafenib
451409|NCT00892424|Liver metastasis from cancer
451410|NCT00892411|Neuroplasticity
451411|NCT00892411|Prognosis
451412|NCT00893295|colon cancer
451413|NCT00893295|rectal cancer
451414|NCT00893282|renal
451415|NCT00893282|calculi
451416|NCT00893282|kidney
451417|NCT00893282|stones
451418|NCT00893269|marijuana
451419|NCT00893269|cannabis
451420|NCT00893269|dependence
451421|NCT00893269|withdrawal
451422|NCT00893256|schizophrenia
451423|NCT00893256|risperidone
451424|NCT00893256|citalopram
451425|NCT00893256|secondary negative symptoms
451426|NCT00893230|atopic dermatitis
451427|NCT00893230|chemokines
451428|NCT00893230|probiotics
451429|NCT00893178|eNOS Polymorphism
451430|NCT00893178|TNF alpha polymorphism
451431|NCT00893178|pulmonary pressure
451432|NCT00893178|polymorphism of vasoactive substances
451433|NCT00893165|inflammation
451434|NCT00893165|cardiovascular disease
451435|NCT00893139|Dry Eye
451436|NCT00893126|psoriasis
451437|NCT00893126|coronary arteriosclerosis
451438|NCT00893126|coronary events
451439|NCT00893126|rheumatoid arthritis
451440|NCT00893126|arthritis
451441|NCT00893087|Ventilatory care, children, intensive care, asynchrony, triggering
451442|NCT00893087|Children needing ventilatory care
451443|NCT00893074|withdrawal
451444|NCT00893074|acute effects
451445|NCT00893074|cognitive performance
451446|NCT00893074|Marijuana Use
451447|NCT00893074|Marijuana Abstinence
451448|NCT00893061|stage IA breast cancer
451449|NCT00893061|stage IB breast cancer
451450|NCT00893061|stage II breast cancer
451451|NCT00893061|stage IIIA breast cancer
451452|NCT00893061|stage IIIB breast cancer
451453|NCT00893061|stage IIIC breast cancer
451454|NCT00893061|estrogen receptor-positive breast cancer
451455|NCT00893061|progesterone receptor-positive breast cancer
451456|NCT00893048|prednisone
451457|NCT00893048|cellulitis
451458|NCT00893048|erysipelas
451459|NCT00893048|steroids
451460|NCT00893048|oral
451461|NCT00893035|Radiotherapy
451462|NCT00893035|Late side effects
451463|NCT00893035|Predictive assay
451464|NCT00893009|Forced expiratory volume in one second
451465|NCT00893009|Inspiratory capacity
451466|NCT00893009|endurance time
451467|NCT00893009|residual volume
451468|NCT00892996|Intrathecal morphine
451469|NCT00892996|Cesarean section
451470|NCT00892996|Nausea and vomiting
451471|NCT00892996|Prevention
451472|NCT00892983|Obesity
451473|NCT00892983|Sleep
451474|NCT00892983|Physical activity
451475|NCT00892983|Breast feeding
451476|NCT00892983|Depression
451477|NCT00892957|Vascular Surgery
451478|NCT00892957|Arterio-arterial bypasses
451479|NCT00892957|Arterio-venous (AV) shunts
451480|NCT00892944|Positron Emission Tomography
451481|NCT00892944|Phase 1
451482|NCT00892944|Healthy volunteers
451483|NCT00892944|AZD2516
451484|NCT00892931|Glioblastoma
451485|NCT00892931|Brain Neoplasms
451486|NCT00892931|Recurrence
451487|NCT00892918|pterygium
451488|NCT00892918|gatifloxacin
451489|NCT00892918|moxifloxacin
451490|NCT00892918|corneal epithelial defect
451491|NCT00892905|coagulation
451492|NCT00892905|INR
451493|NCT00892905|aPTT
451494|NCT00892905|point of care
451495|NCT00892905|laboratory
451496|NCT00892905|CABG
451497|NCT00892905|surgery
451498|NCT00892892|sympatholytic treatment
451499|NCT00892892|sympathetic nerve activity
451500|NCT00892853|calcification
451501|NCT00892853|osteoporosis
451502|NCT00892827|Rituximab
451503|NCT00892827|Mabthera
451504|NCT00892827|FFP
451505|NCT00892827|Fresh Frozen Plasma
451506|NCT00892827|CLL
451507|NCT00892827|Complement
451508|NCT00892827|Response
451509|NCT00892827|Overall response rate of FFP+Rituximab combined therapy
451510|NCT00892827|Analysis of complement activation pathways prior to, during and
451511|NCT00892827|after the study treatment.
451512|NCT00892827|Time to disease progression
451513|NCT00892827|Time to re-treatment (See Appendix I).
451514|NCT00892827|Safety of the combination treatment of FFP and RTX.
451515|NCT00892801|tumors metastatic to brain
451516|NCT00892801|recurrent non-small cell lung cancer
451517|NCT00892801|stage IV non-small cell lung cancer
451518|NCT00892788|Overweight
451519|NCT00892788|Obesity
451520|NCT00892788|Contingency Management
451521|NCT00892775|Working seed virus
451522|NCT00892775|Rubella
451523|NCT00892775|Mumps
451524|NCT00892775|Varicella
451525|NCT00892775|Combined measles-mumps-rubella-varicella vaccine
451526|NCT00892775|Pediatric immunization
451527|NCT00892775|Measles
451528|NCT00892762|Open Angle Glaucoma
451529|NCT00892762|Ocular hypertension
451530|NCT00892762|OAG
451531|NCT00892762|OH
451532|NCT00892749|hyperphosphatemia
451533|NCT00892749|hemodialysis
451534|NCT00892749|CKD
451535|NCT00892749|ASP1585
451536|NCT00892723|AZX100
451537|NCT00892723|Patient and Observer Scar Assessment Scale
451538|NCT00892723|POSAS
451539|NCT00892723|Visual Analog Scale
451540|NCT00892723|VAS
451541|NCT00892723|Keloid
451542|NCT00892723|Scarring
451543|NCT00892723|Scar reduction
451544|NCT00892723|Scar prevention
451545|NCT00892710|Non small cell lung cancer
451546|NCT00892710|NSCLC
451547|NCT00892710|Pemetrexed
451548|NCT00892710|Bevacizumab
451549|NCT00892710|Avastin
451550|NCT00892710|Carboplatin
451551|NCT00892710|Stage IIIB/IV
451552|NCT00892697|hepatitis C
451553|NCT00892697|FNA
451554|NCT00892697|intrahepatic
451555|NCT00892684|Randomized
451556|NCT00892684|Placebo controlled
451557|NCT00892684|Double blind
451558|NCT00892684|Omega-3 fatty acids
451559|NCT00892684|Pregnancy
451560|NCT00892684|Childhood allergy
451561|NCT00892684|Cytokines
451562|NCT00892684|Eicosanoids
451563|NCT00892684|Polyunsaturated fatty acids
451564|NCT00892671|Perceived effectiveness
451565|NCT00892658|Sorafenib
451566|NCT00892658|Hepatocellular carcinoma
451567|NCT00892632|Biliary Strictures
451568|NCT00892632|Cholangiocarcinoma
451569|NCT00892632|ERCP
451570|NCT00892619|Epiretinal Membrane
451571|NCT00892619|Vitreomacular traction
451572|NCT00892619|MVR blade
451573|NCT00892619|Tano brush
451574|NCT00892619|ILM forceps
451575|NCT00892619|surgical technique
451576|NCT00892606|Surgery, Orthopedic
451577|NCT00892606|Pain, Postoperative
451578|NCT00892593|colon
451579|NCT00892593|neoplasia
451580|NCT00892593|polyp
451581|NCT00892593|adenoma
451582|NCT00892593|FIT
451583|NCT00892593|cancer
451584|NCT00892580|fragile X syndrome
451585|NCT00892580|biomarkers
451586|NCT00892567|breast cancer
451587|NCT00892567|peptide vaccine
451588|NCT00892567|immunotherapy
451589|NCT00892554|Phenylketonurias
451590|NCT00892554|Docosahexaenoic Acids
451591|NCT00892554|Neuropsychological Tests
451592|NCT00892554|Female
451593|NCT00892554|Adolescent
451594|NCT00892554|Adult
451595|NCT00892398|Trabeculectomy
451596|NCT00892398|Vascular Endothelial Growth Factor A
451597|NCT00892398|Wound Healing
451598|NCT00892398|Angiogenesis Inhibitors
451599|NCT00892385|unspecified adult solid tumor, protocol specific
451600|NCT00892372|body weight
451601|NCT00892372|glycohemoglobin
451602|NCT00892359|pharmacokinetics
451603|NCT00892359|renal replacement therapy
451604|NCT00892359|hemofiltration
451605|NCT00892359|anidulafungin
451606|NCT00892346|autologous hematopoietic stem cell transplantation
451607|NCT00892346|maintenance
451608|NCT00892333|Repair of a large hernia with SurgiMend 3.0, a biologic mesh
451609|NCT00892320|Schizophrenia, mood stabilizers, antipsychotics
451610|NCT00892320|ER OROS paliperidone
451611|NCT00892307|Diagnostic Imaging
451612|NCT00892307|Dual Source Multidetector Computed Tomography
451613|NCT00892307|Computed Tomography
451614|NCT00892307|CT
451615|NCT00892307|Single Photon Emission Computed Tomography
451616|NCT00892307|SPECT
451617|NCT00892307|Myocardial Perfusion
451618|NCT00892307|Atherosclerosis
451619|NCT00892268|menopausal symptoms
451620|NCT00892268|estrogen receptor-positive breast cancer
451621|NCT00892268|progesterone receptor-positive breast cancer
451622|NCT00892268|breast cancer
451623|NCT00892268|pain
451624|NCT00892255|Liver cancer
451625|NCT00892255|Tumors
451626|NCT00892242|Neoadjuvant zoledronic acid in resectable pancreas cancer
451627|NCT00892229|First trimester missed abortion
451628|NCT00892229|Misoprostol
451629|NCT00892229|buccal
451630|NCT00892229|vaginal
451631|NCT00892229|cervical ripening
451632|NCT00892229|first trimester
451633|NCT00892229|missed abortion
451634|NCT00892216|PONV
451635|NCT00892216|NUSS procedure
451636|NCT00892216|Acupressure
451637|NCT00892216|Pectus Excavatum
451638|NCT00892203|Migraine
451639|NCT00892203|Headache
451640|NCT00892190|AML
451641|NCT00892190|Dasatinib
451642|NCT00892190|all trans retinoic acid
451643|NCT00892190|relapsed AML
451644|NCT00892190|refractory AML
451645|NCT00892190|Relapsed/Refractory Acute myelogenous leukemia
451646|NCT00892190|Elderly subjects (age 65 or older) with acute myelogenous leukemia
451647|NCT00892190|Myelodysplastic Syndrome
451648|NCT00892190|MDS
451649|NCT00892177|adult giant cell glioblastoma
451650|NCT00892177|adult glioblastoma
451651|NCT00892177|adult gliosarcoma
451652|NCT00892177|adult mixed glioma
451653|NCT00892177|recurrent adult brain tumor
451654|NCT00892177|adult anaplastic oligodendroglioma
451655|NCT00892177|adult oligodendroglioma
451656|NCT00892177|adult anaplastic astrocytoma
451657|NCT00892164|thyroid surgery
451658|NCT00892164|total thyroidectomy
451659|NCT00892164|harmonic scalpel
451660|NCT00892164|electrothermal bipolar vessel sealer
451661|NCT00892164|hemostatic device
451662|NCT00892138|mindfulness training
451663|NCT00892138|medical students
451664|NCT00892138|psychology students
451665|NCT00892138|stress management
451666|NCT00892138|personal development
451667|NCT00892138|stress
451668|NCT00892125|Schizophrenia
451669|NCT00892125|Bipolar I disorder
451670|NCT00892125|mood disorders
451671|NCT00892125|antipsychotic drugs
451672|NCT00892125|enzyme inducer
451673|NCT00892125|Paliperidone ER
451674|NCT00892112|Immunoglobulins, Intravenous
451675|NCT00892112|Cardiomyopathies
451676|NCT00892112|Parvo B19, Human
451677|NCT00892099|end stage renal disease
451678|NCT00892099|hemodialysis
451679|NCT00892086|geriatric syndrome
451680|NCT00892086|immobility
451681|NCT00892073|Craniopharyngioma surgery
451682|NCT00892073|Hypothalamic Obesity
451683|NCT00892073|Children
451684|NCT00892073|Combined Diazoxide and Metformin
451685|NCT00892047|Depression
451686|NCT00892047|Aripiprazole
451687|NCT00892047|Venlafaxine
451688|NCT00892047|Partial Remission
451689|NCT00892047|Augmentation strategy
451690|NCT00892047|Treatment resistance
451691|NCT00892047|Elderly
451692|NCT00892047|Late-life
451693|NCT00892008|pregabalin
451694|NCT00892008|neuropathic pain
451695|NCT00892008|safety
451696|NCT00891995|Type 1 Diabetes
451697|NCT00891995|Closed Loop Therapy
451698|NCT00891995|Continuous Glucose Monitor
451699|NCT00891982|Acne Vulgaris
451700|NCT00891969|stage I breast cancer
451701|NCT00891969|stage II breast cancer
451702|NCT00891969|stage IIIA breast cancer
451703|NCT00891956|Rett Syndrome
451704|NCT00891943|Obesity
451705|NCT00891943|Overweight
451706|NCT00891943|Randomised controlled trial
451707|NCT00891943|Primary Care
451708|NCT00891943|Weight
451709|NCT00891943|Cardiovascular Risk
451710|NCT00891943|Diabetes
451711|NCT00891943|Quality of life
451712|NCT00891930|wild-type KRAS
451713|NCT00891930|panitumumab
451714|NCT00891930|biomarker
451715|NCT00891930|mechanisms of acquired resistance
451716|NCT00891930|metastatic colorectal cancer
451717|NCT00891917|Down syndrome
451718|NCT00891917|coenzyme Q10
451719|NCT00891917|language function
451720|NCT00891917|behavior
451721|NCT00891904|recurrent squamous cell carcinoma of the hypopharynx
451722|NCT00891904|recurrent squamous cell carcinoma of the larynx
451723|NCT00891904|recurrent squamous cell carcinoma of the lip and oral cavity
451724|NCT00891904|recurrent squamous cell carcinoma of the nasopharynx
451725|NCT00891904|recurrent squamous cell carcinoma of the oropharynx
451726|NCT00891904|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
451727|NCT00891891|Spina Bifida, psychosocial adjustment, adolescence
451728|NCT00891878|adenocarcinoma of the esophagus
451729|NCT00891878|adenocarcinoma of the gastroesophageal junction
451730|NCT00891878|recurrent esophageal cancer
451731|NCT00891878|stage IV esophageal cancer
451732|NCT00891878|stage III esophageal cancer
451733|NCT00891865|lung transplant
451734|NCT00891865|BOS
451735|NCT00891865|OB
451736|NCT00891865|Respiratory Viral Infection (RVI)
451737|NCT00891865|Lung disease
451738|NCT00891826|Bipolar disorders
451739|NCT00891826|Omega-3 fatty acids
451740|NCT00891826|Heart rate
451741|NCT00891800|Cancer
451742|NCT00891800|Breast
451743|NCT00891800|Liver
451744|NCT00891787|Probiotics
451745|NCT00891787|Isoagglutinins
451746|NCT00891787|Anti-A
451747|NCT00891787|Anti-B
451748|NCT00891787|Hemolysis
451749|NCT00891787|Healthy Volunteer
451750|NCT00891787|HV
451751|NCT00891761|cisplatin
451752|NCT00891761|nausea
451753|NCT00891761|vomiting
451754|NCT00891761|cancer
451755|NCT00891761|lung cancer
451756|NCT00891735|Lucentis
451757|NCT00891735|AMD
451758|NCT00891735|Age-related macular degeneration
451759|NCT00891735|Subfoveal neovascular age-related macular degeneration
451760|NCT00891735|Wet AMD
451761|NCT00891735|Macular degeneration
451762|NCT00891735|Ranibizumab
451763|NCT00891722|recurrent childhood brain stem glioma
451764|NCT00891722|untreated childhood brain stem glioma
451765|NCT00891722|recurrent childhood cerebellar astrocytoma
451766|NCT00891722|untreated childhood cerebellar astrocytoma
451767|NCT00891722|childhood low-grade cerebral astrocytoma
451768|NCT00891722|recurrent childhood cerebral astrocytoma
451769|NCT00891722|childhood oligodendroglioma
451770|NCT00891722|recurrent childhood visual pathway and hypothalamic glioma
451771|NCT00891722|untreated childhood visual pathway and hypothalamic glioma
451772|NCT00891722|childhood mixed glioma
451773|NCT00891696|Sarcopenia
451774|NCT00891696|Aging
451775|NCT00891696|Metabolism
451776|NCT00891696|Muscle
451777|NCT00891696|mTOR
451778|NCT00891696|Essential Amino Acids
451779|NCT00891696|Exercise
451780|NCT00891696|Rapamycin
451781|NCT00891683|Diabetic
451782|NCT00891683|peripheral
451783|NCT00891683|neuropathy
451784|NCT00891683|pain
451785|NCT00891683|hyperalgesia
451786|NCT00891683|allodynia
451787|NCT00891670|CYP2C19 polymorphism
451788|NCT00891670|platelet
451789|NCT00891670|Adjunctive cilostazol
451790|NCT00891670|high maintenance dose clopidogrel
451791|NCT00891670|P2Y12 Reaction Unit
451792|NCT00891657|Adhesion
451793|NCT00891657|Fibroid
451794|NCT00891657|Myoma
451795|NCT00891657|Leiomyoma
451796|NCT00891657|Myomectomy
451797|NCT00891644|HIV
451798|NCT00891644|Care-seeking
451799|NCT00891631|tobacco
451800|NCT00891631|alcohol
451801|NCT00891631|marijuana
451802|NCT00891631|drug use
451803|NCT00891631|seat-belt
451804|NCT00891631|weapons
451805|NCT00891631|depression
451806|NCT00891631|suicidality
451807|NCT00891631|sexual risk behaviors
451808|NCT00891618|Lymphoma
451809|NCT00891618|Myeloma
451810|NCT00891618|Multiple Myeloma
451811|NCT00891618|MM
451812|NCT00891618|Non-Hodgkin's Lymphoma
451813|NCT00891618|NHL
451814|NCT00891618|Acupuncture
451815|NCT00891618|Treatment-induced Peripheral Neuropathy
451816|NCT00891618|Thalidomide
451817|NCT00891618|Bortezomib
451818|NCT00891618|Neuropathy
451819|NCT00891618|Peripheral Neuropathy
451820|NCT00891605|Paclitaxel
451821|NCT00891605|Solid Tumors
451822|NCT00891592|AML
451823|NCT00891592|MDS
451824|NCT00891592|ALL
451825|NCT00891592|NHL
451826|NCT00891592|Multiple Myeloma
451827|NCT00891592|Hodgkin's
451828|NCT00891579|NSCLC
451829|NCT00891579|EGFR
451830|NCT00891579|Pemetrexed
451831|NCT00891579|Gefitinib
451832|NCT00891579|without EGFR mutations
451833|NCT00891566|medium to large tear
451834|NCT00891566|rotator cuff tear
451835|NCT00891566|arthroscopic repair
451836|NCT00891566|repair integrity
451837|NCT00891566|immobilization
451838|NCT00891553|bone mineral density
451839|NCT00891553|calcium-sensing receptor antagonist
451840|NCT00891553|ronacaleret
451841|NCT00891553|postmenopausal osteoporosis
451842|NCT00891527|Pulmonary Vein Stenosis,
451843|NCT00891527|Avastin and Gleevec,
451844|NCT00891527|Targeting VEGF and PDGF
451845|NCT00891514|Exercise
451846|NCT00891514|Inflammation
451847|NCT00891514|Insulin Sensitivity
451848|NCT00891501|autologous bone marrow mesenchymal stem cells
451849|NCT00891501|cartilage repair
451850|NCT00891501|osteoarthritis
451851|NCT00891501|osteochondral defects
451852|NCT00891488|VO2 max
451853|NCT00891488|stress
451854|NCT00891488|cortisol
451855|NCT00891488|fitness
451856|NCT00891475|metastatic renal cell carcinoma
451857|NCT00891475|radiofrequency ablation
451858|NCT00891462|COPD
451859|NCT00891462|Chronic Obstructive Pulmonary Disease
451860|NCT00891462|Chronic Bronchitis
451861|NCT00891462|Emphysema
451862|NCT00891462|Airflow Obstruction, Chronic
451863|NCT00891462|Chronic Airflow Obstruction
451864|NCT00891462|Chronic Obstructive Airway Disease
451865|NCT00891462|Chronic Obstructive Lung Disease
451866|NCT00891449|space flight simulation study
451867|NCT00891449|medical research study
451868|NCT00891449|bed rest
451869|NCT00891449|microgravity
451870|NCT00891449|weightlessness
451871|NCT00891449|The effects of long duration microgravity on humans
451872|NCT00891423|Meropenem
451873|NCT00891423|extended infusion
451874|NCT00891423|prolonged infusion
451875|NCT00891423|Time above MIC
451876|NCT00891397|CPRS
451877|NCT00891397|stellate ganglion block
451878|NCT00891397|pregabalin
451879|NCT00891397|pain
451880|NCT00891397|Type I
451881|NCT00891384|Multiple Myeloma
451882|NCT00891384|maintenance therapy
451883|NCT00891384|lenalidomide
451884|NCT00891371|symptomatic treatment of patients with refractory diarrhea
451885|NCT00891358|Adolescent Medicine Trials Network for HIV/AIDS Interventions
451886|NCT00891358|Human Immunodeficiency Virus
451887|NCT00891358|HIV seronegativity
451888|NCT00891345|hormone-refractory prostate cancer
451889|NCT00891345|Immunotherapy
451890|NCT00891319|hand
451891|NCT00891319|stroke
451892|NCT00891319|hemiplegia
451893|NCT00891319|electrical stimulation
451894|NCT00891319|recovery
451895|NCT00891306|LPLD, Lipoprotein Lipase Deficiency
451896|NCT00891306|Chylomicronemia
451897|NCT00891306|Gene therapy
451898|NCT00891306|AAV
451899|NCT00891306|Lipoprotein Lipase
451900|NCT00891306|Alipogene tiparvovec
451901|NCT00891306|AMT-011
451902|NCT00891293|omega-3-acid ethyl esters
451903|NCT00891293|Very high triglycerides
451904|NCT00891293|Lovaza
451905|NCT00891293|fenofibrate
451906|NCT00891280|Inflammatory breast cancer
451907|NCT00891280|Castleman's Disease
451908|NCT00891280|Multiple Myeloma
451909|NCT00891280|Breast cancer
451910|NCT00891280|Solid tumors
451911|NCT00891280|CK2 inhibitor
451912|NCT00891267|Inflammatory markers
451913|NCT00891267|Vascular protection
451914|NCT00891267|OM Effect
451915|NCT00891267|Metabolic syndrome
451916|NCT00891267|Hypertension
451917|NCT00891254|Incisional hernia
451918|NCT00891254|Intraperitoneal mesh repair
451919|NCT00891254|On-lay repair
451920|NCT00891254|Prosthetic mesh
451921|NCT00891254|First repair (no recurrent hernia will be included)
451922|NCT00891254|Recurrence
451923|NCT00891254|Complications
451924|NCT00891241|Heart Failure, PET Imaging, Implantable Cardioverter-Defibrillator, Dosimetry
451925|NCT00891228|Contraception
451926|NCT00891228|Male Contraception
451927|NCT00891228|Suppression of Sperm Production
451928|NCT00891202|Gaucher,
451929|NCT00891202|beta-glucosidase,
451930|NCT00891202|acid ß-glucosidase,
451931|NCT00891202|glucocerebrosidase,
451932|NCT00891202|glucosylceramide,
451933|NCT00891202|D-glucosyl-N-acylsphingosine glucohydrolase,
451934|NCT00891202|substrate reduction therapy
451935|NCT00891189|Circadian Rhythm
451936|NCT00891176|Conjugate vaccines
451937|NCT00891176|Meningococcal serogroup C vaccine
451938|NCT00891176|Antibody persistence
451939|NCT00891176|Pneumococcal vaccine
451940|NCT00891176|Haemophilus Influenzae type b vaccine
451941|NCT00891163|Topical anesthesia
451942|NCT00891163|Analgesia
451943|NCT00891137|adult acute myeloid leukemia 11q23 (MLL) abnormalities
451944|NCT00891137|adult acute myeloid leukemia inv(16)(p13;q22)
451945|NCT00891137|adult acute myeloid leukemia t(15;17)(q22;q12)
451946|NCT00891137|adult acute myeloid leukemia t(16;16)(p13;q22)
451947|NCT00891137|adult acute myeloid leukemia t(8;21)(q22;q22)
451948|NCT00891137|accelerated phase chronic myelogenous leukemia
451949|NCT00891137|adult acute lymphoblastic leukemia in remission
451950|NCT00891137|adult acute myeloid leukemia in remission
451951|NCT00891137|childhood acute lymphoblastic leukemia in remission
451952|NCT00891137|childhood acute myeloid leukemia in remission
451953|NCT00891137|childhood chronic myelogenous leukemia
451954|NCT00891137|blastic phase chronic myelogenous leukemia
451955|NCT00891137|childhood diffuse large cell lymphoma
451956|NCT00891137|childhood immunoblastic large cell lymphoma
451957|NCT00891137|chronic phase chronic myelogenous leukemia
451958|NCT00891137|de novo myelodysplastic syndromes
451959|NCT00891137|extranodal marginal zone B-cell lymphoma
451960|NCT00891137|mucosa-associated lymphoid tissue
451961|NCT00891137|nodal marginal zone B-cell lymphoma
451962|NCT00891137|stage I adult Burkitt lymphoma
451963|NCT00891137|contiguous stage II adult Burkitt lymphoma
451964|NCT00891137|noncontiguous stage II adult Burkitt lymphoma
451965|NCT00891137|Waldenstrom macroglobulinemia
451966|NCT00891137|noncontiguous stage II adult immunoblastic
451967|NCT00891137|contiguous stage II adult immunoblastic
451968|NCT00891137|large cell lymphoma
451969|NCT00891137|stage I adult immunoblastic large cell lymphoma
451970|NCT00891137|previously treated myelodysplastic syndromes
451971|NCT00891137|recurrent adult Burkitt lymphoma
451972|NCT00891137|recurrent adult diffuse large cell lymphoma
451973|NCT00891137|recurrent adult immunoblastic large cell lymphoma
451974|NCT00891137|recurrent adult lymphoblastic lymphoma
451975|NCT00891137|recurrent grade 1 follicular lymphoma
451976|NCT00891137|recurrent grade 2 follicular lymphoma
451977|NCT00891137|recurrent grade 3 follicular lymphoma
451978|NCT00891137|recurrent marginal zone lymphoma
451979|NCT00891137|recurrent small lymphocytic lymphoma
451980|NCT00891137|refractory multiple myeloma
451981|NCT00891137|relapsing chronic myelogenous leukemia
451982|NCT00891137|secondary acute myeloid leukemia
451983|NCT00891137|secondary myelodysplastic syndromes
451984|NCT00891137|splenic marginal zone lymphoma
451985|NCT00891137|stage I multiple myeloma
451986|NCT00891137|stage II multiple myeloma
451987|NCT00891137|stage III multiple myeloma
451988|NCT00891137|stage III adult Burkitt lymphoma
451989|NCT00891137|stage III adult diffuse large cell lymphoma
451990|NCT00891137|stage III adult immunoblastic large cell lymphoma
451991|NCT00891137|stage III adult lymphoblastic lymphoma
451992|NCT00891137|stage IV adult immunoblastic large cell lymphoma
451993|NCT00891137|stage IV adult lymphoblastic lymphoma
451994|NCT00891137|refractory anemia with excess blasts in transformation
451995|NCT00891137|refractory anemia with excess blasts
451996|NCT00891137|refractory anemia
451997|NCT00891137|prolymphocytic leukemia
451998|NCT00891137|contiguous stage II adult diffuse large cell lymphoma
451999|NCT00891137|noncontiguous stage II adult diffuse large cell lymphoma
452000|NCT00891137|refractory chronic lymphocytic leukemia
452001|NCT00891137|stage IV adult Burkitt lymphoma
452002|NCT00891137|stage I childhood small noncleaved cell lymphoma
452003|NCT00891137|stage II childhood small noncleaved cell lymphoma
452004|NCT00891137|stage III childhood small noncleaved cell lymphoma
452005|NCT00891137|stage IV childhood small noncleaved cell lymphoma
452006|NCT00891137|recurrent childhood small noncleaved cell lymphoma
452007|NCT00891137|stage I childhood large cell lymphoma
452008|NCT00891137|stage II childhood large cell lymphoma
452009|NCT00891137|stage III childhood large cell lymphoma
452010|NCT00891137|stage IV childhood large cell lymphoma
452011|NCT00891137|contiguous stage II mantle cell lymphoma
452012|NCT00891137|contiguous stage II adult lymphoblastic lymphoma
452013|NCT00891137|noncontiguous stage II adult lymphoblastic lymphoma
452014|NCT00891137|noncontiguous stage II mantle cell lymphoma
452015|NCT00891137|stage III mantle cell lymphoma
452016|NCT00891137|stage IV mantle cell lymphoma
452017|NCT00891137|stage I mantle cell lymphoma
452018|NCT00891137|stage I adult lymphoblastic lymphoma
452019|NCT00891137|stage I adult diffuse large cell lymphoma
452020|NCT00891137|stage IV adult diffuse large cell lymphoma
452021|NCT00891137|recurrent childhood large cell lymphoma
452022|NCT00891137|stage I childhood lymphoblastic lymphoma
452023|NCT00891137|stage II childhood lymphoblastic lymphoma
452024|NCT00891137|stage III childhood lymphoblastic lymphoma
452025|NCT00891137|stage IV childhood lymphoblastic lymphoma
452026|NCT00891137|recurrent childhood lymphoblastic lymphoma
452027|NCT00891137|childhood myelodysplastic syndromes
452028|NCT00891137|Burkitt lymphoma
452029|NCT00891124|Hypertension
452030|NCT00891124|Type II DM
452031|NCT00891124|Hyperlipidemia
452032|NCT00891124|Glycemia
452033|NCT00891124|ADA 2008 guideline
452034|NCT00891124|Patient Consultation
452035|NCT00891111|Health Risk Assessment
452036|NCT00891111|Incentives
452037|NCT00891111|Preventative Healthcare
452038|NCT00891111|Encouraging Health Risk Assessments
452039|NCT00891085|ventilation
452040|NCT00891085|ards
452041|NCT00891085|ali
452042|NCT00891085|trauma
452043|NCT00891085|Trauma Patients with ISS > 25
452044|NCT00891059|Cognitive Impairment
452045|NCT00891059|Diskus Inhaler
452046|NCT00891059|Nursing Home
452047|NCT00891046|Flare
452048|NCT00891046|arthritis
452049|NCT00891046|IL-1beta antagonist
452050|NCT00891046|systemic juvenile idiopathic arthritis
452051|NCT00891046|CHAQ
452052|NCT00891046|steroids
452053|NCT00891046|ACR pediatric response
452054|NCT00891046|Systemic juvenile idiopathic arthritis with active flare
452055|NCT00891033|cancer
452056|NCT00891007|Measles
452057|NCT00891007|Virus Disease
452058|NCT00891007|Paediatric Diseases
452059|NCT00891007|Paramyoxyviridae
452060|NCT00890994|MBI
452061|NCT00890994|Molecular Breast Imaging
452062|NCT00890994|Breast Cancer
452063|NCT00890994|DCIS
452064|NCT00890994|Breast
452065|NCT00890994|Calcifications
452066|NCT00890994|Microcalcifications
452067|NCT00890968|hand dermatitis
452068|NCT00890968|hand eczema
452069|NCT00890968|triamcinolone acetonide
452070|NCT00890955|Solid tumors
452071|NCT00890942|pruritus
452072|NCT00890942|intrathecal morphine
452073|NCT00890929|Acute myeloid leukemia
452074|NCT00890929|Acute myeloblastic leukemia
452075|NCT00890929|AML
452076|NCT00890916|spinal cord injury
452077|NCT00890916|neuroprosthesis
452078|NCT00890916|functional electrical stimulation
452079|NCT00890916|quadriplegia
452080|NCT00890903|NSCLC
452081|NCT00890903|non small cell lung carcinoma
452082|NCT00890903|metastatic breast cancer
452083|NCT00890903|MBC
452084|NCT00890903|advanced breast cancer
452085|NCT00890903|Navelbine
452086|NCT00890903|Navelbine-ORAL
452087|NCT00890903|Vinorelbine
452088|NCT00890903|Vinorelbine-ORAL
452089|NCT00890903|daily routine
452090|NCT00890903|concomitant antiemetic therapy
452091|NCT00890903|patient compliance
452092|NCT00890903|germany
452093|NCT00890903|non-interventional study
452094|NCT00890903|oral anti cancer therapy
452095|NCT00890903|quality of life
452096|NCT00890877|asthma
452097|NCT00890877|treatment
452098|NCT00890877|placebo
452099|NCT00890877|efficacy
452100|NCT00890877|safety
452101|NCT00890864|Breast screening
452102|NCT00890864|Mammogram
452103|NCT00890864|Routine screening programme
452104|NCT00890851|Radiofrequency
452105|NCT00890851|Mini invasin surgery
452106|NCT00890851|Outpatient treatment
452107|NCT00890851|Men health
452108|NCT00890838|IVFO
452109|NCT00890838|Inflammation
452110|NCT00890838|Valvular surgery
452111|NCT00890838|Inflammatory status
452112|NCT00890838|Infectious complications
452113|NCT00890825|Non small cell lung cancer (NSCLC)
452114|NCT00890825|KRAS mutation
452115|NCT00890812|Acute Ischemic Stroke
452116|NCT00890799|transcatheter closure
452117|NCT00890799|ventricular septal defects
452118|NCT00890760|Malaria
452119|NCT00890760|Vaccine
452120|NCT00890747|HIV Infections
452121|NCT00890747|treatment experienced
452122|NCT00890721|Hemorrhoid
452123|NCT00890721|Hemorrhoidectomy
452124|NCT00890721|Postoperative pain
452125|NCT00890721|Analgesia
452126|NCT00890695|supplementary feeding
452127|NCT00890695|moderate malnutrition
452128|NCT00890695|acute infection
452129|NCT00890695|developing country
452130|NCT00890695|children
452131|NCT00890682|Bunion
452132|NCT00890682|Bunionectomy
452133|NCT00890682|Osteotomy
452134|NCT00890669|treadmill training
452135|NCT00890669|body load
452136|NCT00890669|quality of life
452137|NCT00890669|Parkinson's disease
452138|NCT00890669|Motor Symptoms
452139|NCT00890656|Acute Lymphoblastic Leukemia
452140|NCT00890656|ALL
452141|NCT00890656|Leukemia
452142|NCT00890656|Hyper-CVAD
452143|NCT00890643|Stress disorders, post-traumatic
452144|NCT00890643|Combat Disorders
452145|NCT00890643|prazosin
452146|NCT00890643|cognition
452147|NCT00890643|neurophysiology
452148|NCT00890617|lung metastases
452149|NCT00890617|stage I non-small cell lung cancer
452150|NCT00890591|hypertension
452151|NCT00890591|angiotensin II type 1 receptor blocker
452152|NCT00890591|olmesartan
452153|NCT00890578|Histoacryl
452154|NCT00890578|closure of surgical incisions
452155|NCT00890565|Electrocardiogram
452156|NCT00890565|Effect on electrocardiogram
452157|NCT00890565|Granisetron
452158|NCT00890565|Moxifloxacin
452159|NCT00890565|Pharmacokinetic profile
452160|NCT00890565|Sancuso® patch
452161|NCT00890565|Transdermal
452162|NCT00890526|Tinnitus Retraining Therapy (TRT)
452163|NCT00890474|Breech presentation at 34 to 36 weeks of gestation
452164|NCT00890461|ECG
452165|NCT00890461|ICD
452166|NCT00890448|Alanine Transaminase elevation
452167|NCT00890448|Genetic Markers
452168|NCT00890448|DNA Markers
452169|NCT00890435|unspecified adult solid tumor, protocol specific
452170|NCT00890435|unspecified childhood solid tumor, protocol specific
452171|NCT00890435|recurrent childhood brain stem glioma
452172|NCT00890435|recurrent childhood cerebellar astrocytoma
452173|NCT00890435|recurrent childhood cerebral astrocytoma
452174|NCT00890435|recurrent childhood medulloblastoma
452175|NCT00890435|recurrent childhood supratentorial primitive neuroectodermal tumor
452176|NCT00890435|recurrent childhood ependymoma
452177|NCT00890435|recurrent childhood pineoblastoma
452178|NCT00890435|recurrent childhood subependymal giant cell astrocytoma
452179|NCT00890435|recurrent childhood visual pathway and hypothalamic glioma
452180|NCT00890435|recurrent childhood acute lymphoblastic leukemia
452181|NCT00890435|recurrent childhood acute myeloid leukemia
452182|NCT00890435|childhood choroid plexus tumor
452183|NCT00890435|childhood craniopharyngioma
452184|NCT00890435|childhood ependymoblastoma
452185|NCT00890435|childhood medulloepithelioma
452186|NCT00890435|childhood meningioma
452187|NCT00890435|childhood mixed glioma
452188|NCT00890435|childhood oligodendroglioma
452189|NCT00890435|adult astrocytic tumors
452190|NCT00890435|adult brain stem glioma
452191|NCT00890435|adult choroid plexus tumor
452192|NCT00890435|adult craniopharyngioma
452193|NCT00890435|adult ependymoblastoma
452194|NCT00890435|adult medulloblastoma
452195|NCT00890435|adult supratentorial primitive neuroectodermal tumor (PNET)
452196|NCT00890435|adult ependymal tumors
452197|NCT00890435|adult meningeal tumor
452198|NCT00890435|adult mixed glioma
452199|NCT00890435|adult oligodendroglial tumors
452200|NCT00890435|adult pineal parenchymal tumor
452201|NCT00890435|recurrent adult brain tumor
452202|NCT00890435|relapsing chronic myelogenous leukemia
452203|NCT00890435|recurrent adult acute lymphoblastic leukemia
452204|NCT00890435|recurrent adult acute myeloid leukemia
452205|NCT00890435|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
452206|NCT00890435|adult acute myeloid leukemia with inv(16)(p13;q22)
452207|NCT00890435|adult acute myeloid leukemia with t(15;17)(q22;q12)
452208|NCT00890435|adult acute myeloid leukemia with t(16;16)(p13;q22)
452209|NCT00890435|adult acute myeloid leukemia with t(8;21)(q22;q22)
452210|NCT00890435|secondary acute myeloid leukemia
452211|NCT00890435|acute undifferentiated leukemia
452212|NCT00890435|mast cell leukemia
452213|NCT00890435|atypical chronic myeloid leukemia, BCR-ABL1 negative
452214|NCT00890435|T-cell large granular lymphocyte leukemia
452215|NCT00890435|refractory chronic lymphocytic leukemia
452216|NCT00890435|childhood chronic myelogenous leukemia
452217|NCT00890435|chronic myelomonocytic leukemia
452218|NCT00890435|juvenile myelomonocytic leukemia
452219|NCT00890435|refractory hairy cell leukemia
452220|NCT00890435|prolymphocytic leukemia
452221|NCT00890422|encephalitis
452222|NCT00890422|FSME
452223|NCT00890422|central european encephalitis
452224|NCT00890409|hypothermia
452225|NCT00890409|neonate
452226|NCT00890409|hypoxic-ischemic encephalopathy
452227|NCT00890409|efficacy
452228|NCT00890409|safety
452229|NCT00890396|Sickle Cell Anemia
452230|NCT00890396|Hydroxyurea
452231|NCT00890383|trauma resuscitation
452232|NCT00890383|abdominal hypertension
452233|NCT00890383|abdominal compartment syndrome
452234|NCT00890370|Cystic fibrosis
452235|NCT00890370|Airway clearance
452236|NCT00890344|PeaPod
452237|NCT00890344|BIA
452238|NCT00890344|Anthropometry
452239|NCT00890344|Body Composition
452240|NCT00890344|Fat Mass
452241|NCT00890344|Total Body Water
452242|NCT00890344|Neonatology
452243|NCT00890305|Metastatic colorectal cancer
452244|NCT00890305|FOLFOX chemotherapy
452245|NCT00890292|Attention Deficit Hyperactivity Disorder
452246|NCT00890292|ADHD
452247|NCT00890292|JNJ-31001074
452248|NCT00890279|Autosomal Dominant Polycystic Kidney Disease
452249|NCT00890279|Hypertension
452250|NCT00890279|Angiotensin-II Receptor Blocker
452251|NCT00890279|Calcium Channel Blocker
452252|NCT00890279|Angiotensin converting enzyme inhibitor
452253|NCT00890279|Kidney Volume
452254|NCT00890279|eGFR
452255|NCT00890266|keratoconus
452256|NCT00890266|collagen cross-linking
452257|NCT00890266|riboflavin
452258|NCT00890266|UV light
452259|NCT00890253|Renal impairment
452260|NCT00890253|Liver transplantation
452261|NCT00890253|Chronic Renal Insufficiency
452262|NCT00890240|Attention Deficit Hyperactivity Disorder
452263|NCT00890240|ADHD
452264|NCT00890240|JNJ-31001074
452265|NCT00890227|scoliosis
452266|NCT00890227|kyphosis
452267|NCT00890227|Surgical treatment
452268|NCT00890214|Anticoagulation
452269|NCT00890214|Prostacyclin
452270|NCT00890214|Heparin
452271|NCT00890214|Renal Replacement Therapy
452272|NCT00890214|Kidney failure acute
452273|NCT00890214|Platelet aggregation
452274|NCT00890201|Pancreaticobiliary reflux
452275|NCT00890201|Normal pancreaticobiliary junction
452276|NCT00890201|Gallstones
452277|NCT00890201|Cholelithiasis
452278|NCT00890201|Cholecystectomy
452279|NCT00890188|THALIDOMIDE
452280|NCT00890188|UFUR
452281|NCT00890188|Colorectal cancer
452282|NCT00890188|Oxaliplatin
452283|NCT00890175|Asthma, Staccato loxapine
452284|NCT00890162|Omalizumab
452285|NCT00890162|Idiopathic Anaphylaxis
452286|NCT00890162|Serum Tryptase
452287|NCT00890162|Placebo-Controlled
452288|NCT00890162|Adult
452289|NCT00890162|Anaphylaxis
452290|NCT00890162|Allergic Reaction
452291|NCT00890149|alcohol abuse
452292|NCT00890149|binge drinking
452293|NCT00890149|severe drinking
452294|NCT00890149|alcoholism
452295|NCT00890149|heavy drinking
452296|NCT00890136|Chronic Obstructive Pulmonary Disease (COPD)
452297|NCT00890123|Omega 3 Fatty Acids
452298|NCT00890123|Inflammation
452299|NCT00890123|Hip Surgery
452300|NCT00890123|Inflammatory status
452301|NCT00890123|Infectious complications
452302|NCT00890110|Renal cell cancer
452303|NCT00890110|sunitinib
452304|NCT00890110|autologous vaccine
452305|NCT00890110|metastatic RCC
452306|NCT00890097|Geographic Atrophy
452307|NCT00890097|GA
452308|NCT00890097|Age-Related Macular Degeneration
452309|NCT00890097|AMD
452310|NCT00890071|Fluid responsiveness
452311|NCT00890071|Ultrasound
452312|NCT00890071|Cardiac output
452313|NCT00890058|Arthritis
452314|NCT00890058|Synovitis
452315|NCT00890058|Aromatase Inhibitor
452316|NCT00890058|Arthralgia Syndrome
452317|NCT00890045|Vascular access hemodialysis
452318|NCT00890045|ePTFE graft
452319|NCT00890045|Graft-eligible
452320|NCT00890045|Long-term vascular access for hemodialysis
452321|NCT00890032|adult giant cell glioblastoma
452322|NCT00890032|adult glioblastoma
452323|NCT00890032|adult gliosarcoma
452324|NCT00890032|adult astrocytoma
452325|NCT00890032|recurrent adult brain tumor
452326|NCT00890006|Prostate cancer
452327|NCT00890006|Magnetic resonance imaging
452328|NCT00889993|Food intake
452329|NCT00889993|Gut hormones
452330|NCT00889993|Fiber
452331|NCT00889993|Visual analog scales
452332|NCT00889967|Pseudomonas aeruginosa
452333|NCT00889967|antimicrobial
452334|NCT00889967|inhalation
452335|NCT00889967|ciprofloxacin
452336|NCT00889967|Non-Cystic Fibrosis Bronchiectasis
452337|NCT00889954|EBV+
452338|NCT00889954|Her2
452339|NCT00889954|TGFBeta
452340|NCT00889954|EBV positive
452341|NCT00889954|HER 2 positive malignancy
452342|NCT00889954|cytotoxic T lymphocytes
452343|NCT00889928|gallbladder disease
452344|NCT00889928|cholecystectomy
452345|NCT00889928|gallbladder disease indicated for cholecystectomy
452346|NCT00889915|ADHD
452347|NCT00889915|Methylphenidate
452348|NCT00889915|Amphetamine
452349|NCT00889902|Molecular Markers
452350|NCT00889902|Cervical Cancer
452351|NCT00889902|Screening
452352|NCT00889902|Makov
452353|NCT00889889|Influenza
452354|NCT00889889|Phase II
452355|NCT00889889|Placebo-controlled
452356|NCT00889876|Obesity
452357|NCT00889876|Adolescents
452358|NCT00889876|Nocturnal blood pressure reduction
452359|NCT00889876|Insulin metabolism
452360|NCT00889876|Cardiovascular structure and function
452361|NCT00889876|Treatment
452362|NCT00889876|Exercise
452363|NCT00889876|Metformin
452364|NCT00889876|Insulin
452365|NCT00889876|Blood glucose
452366|NCT00889876|Impaired nocturnal blood pressure reduction
452367|NCT00889863|Flare
452368|NCT00889863|arthritis
452369|NCT00889863|IL-1beta antagonist
452370|NCT00889863|systemic juvenile idiopathic arthritis
452371|NCT00889863|Juvenile rheumatoid
452372|NCT00889850|Healthy
452373|NCT00889850|Bioavailability
452374|NCT00889850|Bioequivalence
452375|NCT00889850|Esomeprazole
452376|NCT00889850|Bioavailability, Therapeutical Indication Not Studied
452377|NCT00889837|Staccato Loxapine
452378|NCT00889837|COPD
452379|NCT00889837|pulmonary safety
452380|NCT00889824|Chronic imbalance
452381|NCT00889824|vestibular disorders
452382|NCT00889824|balance prosthesis
452383|NCT00889811|OPCAB
452384|NCT00889811|RIPC
452385|NCT00889798|Malignant lymphatic disease
452386|NCT00889798|therapy-reality
452387|NCT00889798|observation
452388|NCT00889798|registry
452389|NCT00889798|therapy sequences
452390|NCT00889798|NHL
452391|NCT00889798|CLL
452392|NCT00889798|Germany
452393|NCT00889798|lenalidomide
452394|NCT00889798|alemtuzumab
452395|NCT00889798|rituximab
452396|NCT00889798|bendamustin
452397|NCT00889798|thalidomide
452398|NCT00889798|bortezomib
452399|NCT00889798|ibritumomab-tiuxetan
452400|NCT00889798|G-CSF
452401|NCT00889798|chronic lymphocytic leukaemia
452402|NCT00889798|follicular lymphoma
452403|NCT00889798|gastric MALT lymphoma
452404|NCT00889798|nongastric MALT lymphoma
452405|NCT00889798|nodal marginal zone lymphoma
452406|NCT00889798|splenic marginal zone lymphoma
452407|NCT00889798|mantle cell lymphoma
452408|NCT00889798|diffuse large b-cell lymphoma
452409|NCT00889785|Adolescents
452410|NCT00889785|Type 2 Diabetes
452411|NCT00889785|Behavioral Research
452412|NCT00889772|Respiratory distress, adult
452413|NCT00889772|risk
452414|NCT00889772|emergency room
452415|NCT00889772|high risk surgery
452416|NCT00889772|sepsis
452417|NCT00889772|trauma
452418|NCT00889772|aspiration
452419|NCT00889772|pneumonia
452420|NCT00889759|Tuberculosis
452421|NCT00889759|Outbreaks
452422|NCT00889720|smoking cessation
452423|NCT00889720|varenicline
452424|NCT00889720|elective surgery
452425|NCT00889720|wound infections
452426|NCT00889720|post-operative complications
452427|NCT00889707|Benign Prostatic Hyperplasia
452428|NCT00889707|BPH
452429|NCT00889707|Enlarged Prostate
452430|NCT00889668|Glucose monitoring
452431|NCT00889668|GlucoTrack
452432|NCT00889668|Self glucose monitoring
452433|NCT00889655|efficacy of bowel cleansing
452434|NCT00889655|patient tolerability
452435|NCT00889655|Golytely
452436|NCT00889655|MiraLax
452437|NCT00889655|colonoscopy preparation
452438|NCT00889655|bowel preparation
452439|NCT00889655|screening colonoscopy
452440|NCT00889629|kidney transplantation
452441|NCT00889629|kidney transplant recipients
452442|NCT00889616|Malaria
452443|NCT00889616|Asexual Blood Stafe
452444|NCT00889616|Plasmodium Falciparum
452445|NCT00889616|Immunogenicity
452446|NCT00889616|Safety
452447|NCT00889616|Vaccine
452448|NCT00889603|Aricept® Evess
452449|NCT00889603|non-interventional study
452450|NCT00889603|Alzheimer's Disease
452451|NCT00889603|Vascular Dementia
452452|NCT00889603|efficacy
452453|NCT00889603|tolerability
452454|NCT00889603|safety.
452455|NCT00889590|GCT
452456|NCT00889590|Bisfosfonates
452457|NCT00889564|Vascular access for hemodialysis
452458|NCT00889564|Catheter dependent patients
452459|NCT00889564|Access challenged patients
452460|NCT00889564|Bacteremia
452461|NCT00889564|HeRO Vascular Access Device
452462|NCT00889538|Autism
452463|NCT00889538|Severe Behavior Disorder
452464|NCT00889538|Glutathione
452465|NCT00889538|Antioxidants
452466|NCT00889525|Cabergoline
452467|NCT00889486|gastroparesis
452468|NCT00889486|diabetes mellitus
452469|NCT00889486|delayed gastric emptying
452470|NCT00889473|Celiac Disease
452471|NCT00889473|Gluten
452472|NCT00889460|rBet v 1
452473|NCT00889460|Birch pollen allergy
452474|NCT00889460|Sublingual Immunotherapy
452475|NCT00889447|Chronic Obstructive Pulmonary disease (COPD)
452476|NCT00889434|Cystic fibrosis
452477|NCT00889434|splicing mutations
452478|NCT00889434|molecular therapy
452479|NCT00889434|EGCG
452480|NCT00889434|Tocotrienol
452481|NCT00889434|Splicing-mutation-mediated Cystic Fibrosis
452482|NCT00889421|uveitis
452483|NCT00889421|apremilast
452484|NCT00889408|refractory chronic lymphocytic leukemia
452485|NCT00889408|childhood diffuse large cell lymphoma
452486|NCT00889408|childhood grade III lymphomatoid granulomatosis
452487|NCT00889408|childhood immunoblastic large cell lymphoma
452488|NCT00889408|B-cell adult acute lymphoblastic leukemia
452489|NCT00889408|recurrent adult acute lymphoblastic leukemia
452490|NCT00889408|B-cell childhood acute lymphoblastic leukemia
452491|NCT00889408|recurrent childhood acute lymphoblastic leukemia
452492|NCT00889408|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
452493|NCT00889408|adult acute myeloid leukemia with inv(16)(p13;q22)
452494|NCT00889408|adult acute myeloid leukemia with t(15;17)(q22;q12)
452495|NCT00889408|adult acute myeloid leukemia with t(16;16)(p13;q22)
452496|NCT00889408|adult acute myeloid leukemia with t(8;21)(q22;q22)
452497|NCT00889408|recurrent adult acute myeloid leukemia
452498|NCT00889408|recurrent childhood acute myeloid leukemia
452499|NCT00889408|secondary acute myeloid leukemia
452500|NCT00889408|B-cell chronic lymphocytic leukemia
452501|NCT00889408|relapsing chronic myelogenous leukemia
452502|NCT00889408|childhood chronic myelogenous leukemia
452503|NCT00889408|cutaneous B-cell non-Hodgkin lymphoma
452504|NCT00889408|recurrent adult grade III lymphomatoid granulomatosis
452505|NCT00889408|Waldenström macroglobulinemia
452506|NCT00889408|recurrent adult Burkitt lymphoma
452507|NCT00889408|recurrent adult diffuse large cell lymphoma
452508|NCT00889408|recurrent adult diffuse mixed cell lymphoma
452509|NCT00889408|recurrent adult diffuse small cleaved cell lymphoma
452510|NCT00889408|recurrent adult immunoblastic large cell lymphoma
452511|NCT00889408|recurrent adult lymphoblastic lymphoma
452512|NCT00889408|recurrent grade 1 follicular lymphoma
452513|NCT00889408|recurrent grade 2 follicular lymphoma
452514|NCT00889408|recurrent grade 3 follicular lymphoma
452515|NCT00889408|recurrent mantle cell lymphoma
452516|NCT00889408|recurrent marginal zone lymphoma
452517|NCT00889408|recurrent small lymphocytic lymphoma
452518|NCT00889408|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
452519|NCT00889408|nodal marginal zone B-cell lymphoma
452520|NCT00889408|splenic marginal zone lymphoma
452521|NCT00889408|recurrent childhood grade III lymphomatoid granulomatosis
452522|NCT00889408|recurrent childhood large cell lymphoma
452523|NCT00889408|recurrent childhood lymphoblastic lymphoma
452524|NCT00889408|recurrent childhood small noncleaved cell lymphoma
452525|NCT00889408|childhood Burkitt lymphoma
452526|NCT00889408|intraocular lymphoma
452527|NCT00889408|noncutaneous extranodal lymphoma
452528|NCT00889408|prolymphocytic leukemia
452529|NCT00889395|MISC
452530|NCT00889395|caregivers
452531|NCT00889395|children
452532|NCT00889395|psychosocial gains
452533|NCT00889395|cognitive benefits
452534|NCT00889382|Ovarian Cancer
452535|NCT00889382|Ovarian
452536|NCT00889382|Paclitaxel
452537|NCT00889382|OSI-906
452538|NCT00889382|IGF-1R
452539|NCT00889382|Solid Tumors
452540|NCT00889369|depression
452541|NCT00889369|duloxetine
452542|NCT00889369|menopause
452543|NCT00889369|imaging
452544|NCT00889369|FMRI
452545|NCT00889369|Menopausal staging
452546|NCT00889369|vasomotor symptoms
452547|NCT00889343|Second-line therapy of metastatic colorectal cancer
452548|NCT00889343|Sorafenib
452549|NCT00889343|Colorectal Neoplasms
452550|NCT00889343|palliative therapy
452551|NCT00889343|after progression of firstline therapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab
452552|NCT00889304|HTO, high tibial osteotomy, open wedge, medial arthritis
452553|NCT00889291|End stage renal disease
452554|NCT00889291|Bacteremia
452555|NCT00889291|HeRO Vascular Access Device
452556|NCT00889291|Access challenged
452557|NCT00889291|Catheter dependent
452558|NCT00889291|End stage renal disease requiring vascular access. See HeRO device instructions for use for appropriate patient population
452559|NCT00889278|Lymphoma
452560|NCT00889278|Autologous Peripheral Blood Stem Cell Transplant
452561|NCT00889278|APBSCT
452562|NCT00889278|Pneumococcal Conjugate Vaccine
452563|NCT00889265|Alveolar Bone Augmentation
452564|NCT00889265|Implant Surgery
452565|NCT00889265|Guided Bone Regeneration (GBR)
452566|NCT00889265|Guided Tissue Regeneration (GTR)
452567|NCT00889265|Bone Graft
452568|NCT00889265|Periodontal Surgery
452569|NCT00889239|ceramic
452570|NCT00889239|wear rate
452571|NCT00889239|opposing enamel
452572|NCT00889226|pitavastatin
452573|NCT00889226|PWV
452574|NCT00889226|ESPRIT
452575|NCT00889226|Pitavastatin and Atorvastatin
452576|NCT00889226|Adiponectin
452577|NCT00889226|fasting insulin
452578|NCT00889226|hs-CRP
452579|NCT00889226|baPWV
452580|NCT00889213|pancreatectomy
452581|NCT00889213|fistula
452582|NCT00889213|fibrin glue
452583|NCT00889213|falciform patch
452584|NCT00889213|surgery
452585|NCT00889213|complications
452586|NCT00889187|radiation therapy
452587|NCT00889187|capecitabine
452588|NCT00889174|Genetic Disorders of the White Matter
452589|NCT00889174|Leukodystrophies
452590|NCT00889174|Myelin
452591|NCT00889174|White Matter Disorder
452592|NCT00889174|Genetic Disorder
452593|NCT00889161|Crohn's disease
452594|NCT00889161|ulcerative colitis
452595|NCT00889161|curcumin
452596|NCT00889161|pediatric
452597|NCT00889161|inflammatory bowel disease
452598|NCT00889148|hip
452599|NCT00889148|arthroplasty
452600|NCT00889148|postoperative pain
452601|NCT00889148|gabapentin
452602|NCT00889122|Obesity
452603|NCT00889122|Exergames
452604|NCT00889122|Videogames
452605|NCT00889122|Prevention
452606|NCT00889122|Family
452607|NCT00889122|Dance Dance Revolution
452608|NCT00889122|Pedometer
452609|NCT00889096|memory
452610|NCT00889096|heart rate
452611|NCT00889096|skin conductance
452612|NCT00889096|α-amylase
452613|NCT00889096|propranolol
452614|NCT00889096|tolerability
452615|NCT00889083|Sepsis
452616|NCT00889083|Peritonitis
452617|NCT00889083|Mitochondria
452618|NCT00889083|Liver
452619|NCT00889057|osteosarcoma
452620|NCT00889057|sorafenib
452621|NCT00889057|target therapy
452622|NCT00889031|CLL
452623|NCT00889018|intraocular retinoblastoma
452624|NCT00889018|chemotherapy
452625|NCT00889005|Post-traumatic Stress Disorder
452626|NCT00889005|Acute Stress Disorder
452627|NCT00889005|Cognitive behavioral therapy
452628|NCT00889005|Secondary Prevention
452629|NCT00889005|Anxiety disorders
452630|NCT00889005|Service Delivery
452631|NCT00888992|Smoking
452632|NCT00888992|Cessation
452633|NCT00888992|Quitline
452634|NCT00888992|Counseling
452635|NCT00888979|Smoking Cessation during Pregnancy
452636|NCT00888979|Nicotrol Inhaler
452637|NCT00888966|heart arrest
452638|NCT00888966|oxidative stress
452639|NCT00888966|lactic acid
452640|NCT00888966|outcome
452641|NCT00888953|Falls
452642|NCT00888953|Nursing Homes
452643|NCT00888953|Elderly
452644|NCT00888953|Prevention
452645|NCT00888953|Spain
452646|NCT00888953|Cluster Randomized Clinical Trial
452647|NCT00888927|T-Cell Lymphoma
452648|NCT00888927|PTCL
452649|NCT00888927|CTCL
452650|NCT00888914|Lateral Canthal Lines
452651|NCT00888914|Crow's Feet
452652|NCT00888914|Facial Wrinkles
452653|NCT00888901|ITP
452654|NCT00888901|eltrombopag
452655|NCT00888901|platelet function
452656|NCT00888901|thrombocytopenia
452657|NCT00888901|Platelet function in patients with cAITP on eltrombopag
452658|NCT00888888|Acute appendicitis
452659|NCT00888888|Colonic diverticulitis
452660|NCT00888888|Colonic tumors
452661|NCT00888888|Colonic resections
452662|NCT00888875|i-gel
452663|NCT00888875|Fastrach
452664|NCT00888875|intubation
452665|NCT00888875|fiberoptic
452666|NCT00888875|difficult airway
452667|NCT00888875|Patients undergoing elective surgery requiring tracheal intubation
452668|NCT00888875|Presenting at least one sign of difficult intubation
452669|NCT00888862|depression
452670|NCT00888862|desvenlafaxine
452671|NCT00888862|menopause
452672|NCT00888862|imaging
452673|NCT00888862|FMRI
452674|NCT00888849|Stapling
452675|NCT00888849|hand sutured anastamosis
452676|NCT00888849|colorectal disease
452677|NCT00888836|bariatric surgery
452678|NCT00888836|GBP
452679|NCT00888836|BPD
452680|NCT00888836|type 2 diabetes
452681|NCT00888823|Fractionated stereotactic radiotherapy
452682|NCT00888823|Medically inoperable
452683|NCT00888823|Image-guided radiotherapy
452684|NCT00888810|ovarian - cancer - relapse - topotecan - lapatinib
452685|NCT00888771|Colorectal cancer
452686|NCT00888771|polyps
452687|NCT00888771|colonoscopy
452688|NCT00888771|advanced imaging
452689|NCT00888758|Stents
452690|NCT00888745|RA
452691|NCT00888732|Diabetes
452692|NCT00888680|Migraine
452693|NCT00888680|Headaches
452694|NCT00888680|Migraine headaches
452695|NCT00888680|Head pain
452696|NCT00888667|ICD patients with PVCs and EGM recordings
452697|NCT00888654|adenocarcinoma of the prostate
452698|NCT00888654|stage I prostate cancer
452699|NCT00888654|stage II prostate cancer
452700|NCT00888628|Type I diabetes
452701|NCT00888628|Islet after Kidney Transplant
452702|NCT00888628|Islet transplantation
452703|NCT00888589|MBI
452704|NCT00888589|Molecular Breast Imaging
452705|NCT00888589|Breast
452706|NCT00888589|Breast Cancer
452707|NCT00888589|Molecular Imaging
452708|NCT00888563|Fatigue
452709|NCT00888563|Depression
452710|NCT00888563|Healthy Volunteer
452711|NCT00888563|HV
452712|NCT00888537|Decision aid
452713|NCT00888537|Heart attack
452714|NCT00888537|myocardial infarction
452715|NCT00888524|head out water immersion,
452716|NCT00888524|high intensity exercise,
452717|NCT00888524|evidence-based physiotherapy;
452718|NCT00888524|aquatics;
452719|NCT00888524|hydrotherapy
452720|NCT00888524|aquatics therapy
452721|NCT00888524|exercise therapy
452722|NCT00888511|Lung cancer
452723|NCT00888511|Non-small cell lung cancer
452724|NCT00888511|Tarceva
452725|NCT00888511|Radiotherapy
452726|NCT00888511|Local-regionally advanced non-small cell lung cancer
452727|NCT00888498|Sprains and Strains
452728|NCT00888498|Ankle
452729|NCT00888498|Manual Therapies
452730|NCT00888498|Outcome Studies
452731|NCT00888472|Extracorporeal leukocytapheresis
452732|NCT00888459|tobacco
452733|NCT00888459|chew
452734|NCT00888459|nrt
452735|NCT00888459|nicotine lozenges
452736|NCT00888459|self-help
452737|NCT00888446|HIV
452738|NCT00888446|HIV seronegativity
452739|NCT00888446|preventative vaccine
452740|NCT00888433|hypertension
452741|NCT00888433|renal denervation
452742|NCT00888433|sympathetic nervous system
452743|NCT00888433|RDN
452744|NCT00888420|Chronic Pain
452745|NCT00888407|Asian American Health
452746|NCT00888407|Cancer
452747|NCT00888407|Hepatitis
452748|NCT00888407|Hepatitis B
452749|NCT00888407|Liver Cancer
452750|NCT00888394|chiropody
452751|NCT00888394|podiatry
452752|NCT00888394|insoles
452753|NCT00888394|foot orthesis
452754|NCT00888342|Pulmonary Disease
452755|NCT00888342|Chronic Obstructive
452756|NCT00888342|Hypercapnia
452757|NCT00888342|Hypoxemia
452758|NCT00888342|Arrhythmias, Cardiac
452759|NCT00888342|Polysomnography
452760|NCT00888342|Capnography
452761|NCT00888342|Electrocardiography, Holter
452762|NCT00888329|Elective hysterectomy
452763|NCT00888316|iron overload
452764|NCT00888290|metabolic acidosis
452765|NCT00888290|chronic kidney disease
452766|NCT00888290|Estimated GFR 15-45
452767|NCT00888264|Antipsychotics
452768|NCT00888264|Bipolar Disorder
452769|NCT00888264|Depressive episodes
452770|NCT00888264|Bipolar I or II Disorders
452771|NCT00888251|Obesity
452772|NCT00888251|Meal replacement
452773|NCT00888251|Obesity treatment
452774|NCT00888251|Weight management
452775|NCT00888225|Tennis elbow
452776|NCT00888225|Epicondylitis
452777|NCT00888225|Pain
452778|NCT00888225|Muscle strength
452779|NCT00888225|Quality of life
452780|NCT00888225|RCT
452781|NCT00888225|Tendinitis
452782|NCT00888225|Chronic tennis elbow
452783|NCT00888199|amputation
452784|NCT00888199|amputee
452785|NCT00888199|prosthetic
452786|NCT00888199|foot
452787|NCT00888199|prosthesis
452788|NCT00888199|Tensegrity
452789|NCT00888199|Prosthetics
452790|NCT00888199|K3 Promoter
452791|NCT00888186|Dyskinesias
452792|NCT00888186|Duodenal levodopa infusion
452793|NCT00888186|Dose optimization
452794|NCT00888186|Pharmacokinetics
452795|NCT00888186|Pharmacodynamics
452796|NCT00888147|Tube feeding
452797|NCT00888147|Fiber
452798|NCT00888147|Constipation
452799|NCT00888095|deep brain stimulation
452800|NCT00888095|caudal Zona incerta
452801|NCT00888095|Nucleus subthalamicus
452802|NCT00888095|Parkinson's disease
452803|NCT00888095|randomized
452804|NCT00888095|blinded
452805|NCT00888095|Movement disorder
452806|NCT00888082|adjuvant chemotherapy
452807|NCT00888082|breast cancer
452808|NCT00888082|goserelin acetate
452809|NCT00888082|ovarian function
452810|NCT00888082|Chemotherapy
452811|NCT00888082|Primary invasive breast cancer
452812|NCT00888069|Parathyroid Diseases
452813|NCT00888069|Renal Insufficiency
452814|NCT00888069|Kidney Failure, Chronic
452815|NCT00888069|Hyperparathyroidism, Secondary
452816|NCT00888069|Vitamin D
452817|NCT00888069|Hyperparathyroidism
452818|NCT00888069|Renal Insufficiency, Chronic
452819|NCT00888069|Kidney Diseases
452820|NCT00888069|Kidney Failure
452821|NCT00888043|solid tumors
452822|NCT00888043|avastin
452823|NCT00888043|Phase I
452824|NCT00888043|combination therapy
452825|NCT00888043|bevacizumab
452826|NCT00888030|p-cresol
452827|NCT00888030|indoxyl sulfate
452828|NCT00888030|chronic kidney disease
452829|NCT00888030|outcome
452830|NCT00888017|bone density
452831|NCT00888017|proton pump inhibitors
452832|NCT00888017|premature infants
452833|NCT00888004|Parkinson's
452834|NCT00888004|L-dopa
452835|NCT00888004|dyskinesia
452836|NCT00887991|Randomised trial
452837|NCT00887991|breast pumps
452838|NCT00887991|efficacy
452839|NCT00887991|preterm
452840|NCT00887991|Mothers of preterm infants who plan to express milk for their infants.
452841|NCT00887965|Low Bone Mass
452842|NCT00887965|Low Bone Mineral Density
452843|NCT00887965|Osteoporosis
452844|NCT00887965|Postmenopausal Osteoporosis
452845|NCT00887965|Bone Biopsy
452846|NCT00887965|Transiliac Crest Bone Histology
452847|NCT00887965|Histomorphometry
452848|NCT00887952|Deep caries lesion
452849|NCT00887952|dentine caries removal
452850|NCT00887952|dental restoration
452851|NCT00887952|stepwise excavation
452852|NCT00887939|Physical Urticaria
452853|NCT00887939|Pathogenesis
452854|NCT00887939|Inflammasome
452855|NCT00887939|IL-1
452856|NCT00887939|Mast Cell
452857|NCT00887939|Urticaria
452858|NCT00887926|AML
452859|NCT00887926|Leukemia
452860|NCT00887926|Acute Myeloid Leukemia
452861|NCT00887926|Antibodies, Monoclonal
452862|NCT00887900|lamellar keratoplasty
452863|NCT00887900|keratoconus
452864|NCT00887900|penetrated keratoplasty
452865|NCT00887900|Visual acuity
452866|NCT00887887|liver surgery
452867|NCT00887887|gene polymorphisms
452868|NCT00887887|innate immune response
452869|NCT00887887|infectious complications
452870|NCT00887887|post-resectional liver failure
452871|NCT00887887|mortality
452872|NCT00887861|epilepsy
452873|NCT00887861|seizure
452874|NCT00887861|monotherapy trials
452875|NCT00887861|partial seizure
452876|NCT00887861|Partial seizures and undergoing evaluation for epilepsy surgery
452877|NCT00887848|Child
452878|NCT00887848|Robotic-assisted treadmill training
452879|NCT00887848|Rehabilitation
452880|NCT00887835|PERPOS fusion
452881|NCT00887809|Bevacizumab (avastin)
452882|NCT00887809|Gemcitabine
452883|NCT00887809|Taxotere (docetaxel)
452884|NCT00887809|09-015
452885|NCT00887809|Soft tissue
452886|NCT00887783|Induction chemotherapy
452887|NCT00887783|Non-small cell lung cancer
452888|NCT00887783|Randomized phase II study
452889|NCT00887783|Navelbine Oral (R)
452890|NCT00887783|3D-conformal radiotherapy
452891|NCT00887783|Chemo-radiotherapy
452892|NCT00887783|Local-regionally advanced non-small cell lung cancer
452893|NCT00887770|QTcF
452894|NCT00887770|Crossover
452895|NCT00887770|ICH E14
452896|NCT00887770|QT/QTc prolongation
452897|NCT00887770|Moxifloxacin
452898|NCT00887770|QT/QTc Interval
452899|NCT00887744|Degenerative Lumbar Spinal Stenosis
452900|NCT00887744|Neurogenic Intermittent Claudication
452901|NCT00887744|Interpinous Device
452902|NCT00887744|Percutaneous
452903|NCT00887731|closed loop oxygen controller
452904|NCT00887731|premature infants
452905|NCT00887731|oxygen exposure
452906|NCT00887718|PET scan and Hodgkin's Lymphoma
452907|NCT00887718|PET scan and Non Hodgkin's Lymphoma
452908|NCT00887718|PET scan
452909|NCT00887705|COPD
452910|NCT00887705|Pulmonary Rehabilitation
452911|NCT00887705|ADL-Training
452912|NCT00887705|COPD Rehabilitation
452913|NCT00887679|Escitalopram
452914|NCT00887679|Anxiety Disorder
452915|NCT00887679|HIV and AIDS
452916|NCT00887679|treatment experienced
452917|NCT00887640|metastatic
452918|NCT00887640|Temsirolimus
452919|NCT00887640|prostate
452920|NCT00887640|cancer
452921|NCT00887627|Pharmacokinetics
452922|NCT00887627|Protein Binding
452923|NCT00887627|Conivaptan
452924|NCT00887627|Vaprisol
452925|NCT00887627|Kidney Diseases
452926|NCT00887614|mindfulness
452927|NCT00887614|meditation
452928|NCT00887614|stress
452929|NCT00887614|rumination
452930|NCT00887614|emotion regulation
452931|NCT00887614|sleep quality
452932|NCT00887614|spirituality
452933|NCT00887614|quality of life
452934|NCT00887588|Chronic heart failure
452935|NCT00887588|preserved ejection fraction
452936|NCT00887588|cardiovascular disease
452937|NCT00887588|NT-proBNP
452938|NCT00887588|biomarkers
452939|NCT00887588|Heart failure with preserved left-ventricular ejection
452940|NCT00887588|fraction
452941|NCT00887575|Breast Cancer
452942|NCT00887575|Triple-Negative
452943|NCT00887575|Paclitaxel
452944|NCT00887575|Carboplatin
452945|NCT00887575|Sunitinib
452946|NCT00887575|Sutent
452947|NCT00887575|Neoadjuvant
452948|NCT00887536|National Surgical Adjuvant Breast and Bowel Project (NSABP)
452949|NCT00887536|Taxotere
452950|NCT00887536|Docetaxel
452951|NCT00887536|Doxorubicin
452952|NCT00887536|Cyclophosphamide
452953|NCT00887536|Bevacizumab
452954|NCT00887536|Breast Neoplasms
452955|NCT00887536|Adenocarcinoma
452956|NCT00887536|Breast Diseases
452957|NCT00887536|Carcinoma
452958|NCT00887536|HER2 negative
452959|NCT00887536|Node negative
452960|NCT00887536|High risk node positive
452961|NCT00887536|Adjuvant Therapy
452962|NCT00887510|Metabolic Syndrome
452963|NCT00887510|High Blood Pressure
452964|NCT00887510|Abdominal Obesity
452965|NCT00887510|Impaired Glucose Tolerance
452966|NCT00887484|Acne
452967|NCT00887484|Acne Vulgaris
452968|NCT00887471|Sleep-disordered breathing
452969|NCT00887471|Obstructive sleep apnea
452970|NCT00887471|Polysomnography
452971|NCT00887471|Tonsillectomy
452972|NCT00887471|Microdebrider assisted partial intracapsular tonsillectomy
452973|NCT00887458|metastatic prostate cancer
452974|NCT00887458|castration resistant prostate cancer
452975|NCT00887458|rising PSA
452976|NCT00887445|First in Man
452977|NCT00887445|SLV341
452978|NCT00887445|diabetes
452979|NCT00887419|chronic back pain
452980|NCT00887419|spinal cord stimulator implant
452981|NCT00887406|first time in human study
452982|NCT00887406|COPD
452983|NCT00887406|long-acting bronchodilator
452984|NCT00887393|morbid obesity
452985|NCT00887393|non-alcoholic fatty liver disease
452986|NCT00887393|bariatric surgery
452987|NCT00887393|low fat diet
452988|NCT00887393|low carbohydrate diet
452989|NCT00887380|Breast Cancer
452990|NCT00887380|Timing of Radiotherapy
452991|NCT00887380|Local control
452992|NCT00887367|Healthy volunteers
452993|NCT00887367|Substance dependence
452994|NCT00887367|Alcohol dependence
452995|NCT00887354|Low bone mass
452996|NCT00887354|Recent pertrochanteric hip fracture
452997|NCT00887328|ischemic stroke
452998|NCT00887328|ischemic penumbra
452999|NCT00887328|magnetic resonance imaging
453000|NCT00887328|MRI
453001|NCT00887328|diffusion imaging
453002|NCT00887328|DWI
453003|NCT00887328|perfusion imaging
453004|NCT00887328|PWI
453005|NCT00887328|thrombolysis
453006|NCT00887328|alteplase
453007|NCT00887328|tPA
453008|NCT00887328|EPITHET
453009|NCT00887315|NSCLC
453010|NCT00887315|Metastatic Stage IV NSCLC
453011|NCT00887315|Limited Volume Stage IV Non-small Cell Lung Cancer
453012|NCT00887276|Ampicillin
453013|NCT00887276|Amoxicillin
453014|NCT00887276|Moxifloxacin
453015|NCT00887276|Community-Acquired Pneumonia
453016|NCT00887237|Heart failure
453017|NCT00887237|Cardiac resynchronization
453018|NCT00887237|Triple site ventricular pacing
453019|NCT00887224|Major Depressive Disorder
453020|NCT00887211|stent
453021|NCT00887211|coronary artery disease
453022|NCT00887198|Prostate cancer
453023|NCT00887198|Abiraterone acetate
453024|NCT00887198|CB7630
453025|NCT00887198|CRPC
453026|NCT00887198|Metastatic castration-resistant prostate cancer
453027|NCT00887198|hormone refractory prostate cancer
453028|NCT00887185|Surgical Simulation
453029|NCT00887185|Surgical skills training
453030|NCT00887185|Temporal bone surgery
453031|NCT00887185|Computer simulation
453032|NCT00887172|Acute upper respiratory tract infections
453033|NCT00887146|adult anaplastic astrocytoma
453034|NCT00887146|adult anaplastic oligodendroglioma
453035|NCT00887146|adult mixed glioma
453036|NCT00887120|Second line treatment
453037|NCT00887120|therapeutic drug monitoring
453038|NCT00887120|Asia
453039|NCT00887120|LPV
453040|NCT00887120|children
453041|NCT00887120|pharmacokinetic
453042|NCT00887120|To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in Protease inhibitor (PI)- naive HIV-1 infected Thai patients.
453043|NCT00887120|To study clinical and immunological efficacy after 48-weeks of lopinavir/ritonavir-based antiretroviral therapy in PI naive HIV-1 infected Thai patients.
453044|NCT00887094|Diabetes mellitus
453045|NCT00887094|Exercise
453046|NCT00887094|Endurance
453047|NCT00887094|Resistance
453048|NCT00887094|Continuous glucose monitoring system
453049|NCT00887081|antiviral treatment in hemoglobinopathies
453050|NCT00887081|management of chronic viral hepatitis C infection
453051|NCT00887081|antiviral treatment
453052|NCT00887068|Leukemia
453053|NCT00887068|Acute myelogenous leukemia
453054|NCT00887068|AML
453055|NCT00887068|Myelodysplastic syndrome
453056|NCT00887068|MDS
453057|NCT00887068|Remission
453058|NCT00887068|Allogeneic stem cell transplant
453059|NCT00887068|Allotx
453060|NCT00887068|Azacitidine
453061|NCT00887068|5-Azacitidine
453062|NCT00887068|5-aza
453063|NCT00887068|Vidaza
453064|NCT00887068|5-AZC
453065|NCT00887068|AZA-CR
453066|NCT00887068|Ladakamycin
453067|NCT00887068|NSC-102816
453068|NCT00887042|Acute myeloid leukemia
453069|NCT00887042|Cord blood transplantation
453070|NCT00887042|Pediatric
453071|NCT00887029|Topical prostaglandin analogue
453072|NCT00887029|glaucoma
453073|NCT00887029|POAG
453074|NCT00887029|OHT
453075|NCT00887029|OAG
453076|NCT00887029|ocular hypertension
453077|NCT00887029|fixed combination protaglandin analogue therapy
453078|NCT00887029|DuoTrav
453079|NCT00887029|timolol
453080|NCT00887029|travoprost
453081|NCT00887029|24 hour post dose
453082|NCT00887029|IOP
453083|NCT00887029|dosing preference
453084|NCT00887003|epidural
453085|NCT00887003|volume
453086|NCT00887003|dose
453087|NCT00887003|pain relief
453088|NCT00887003|steroid
453089|NCT00886990|single- and double-boosted PI
453090|NCT00886990|second line regimen
453091|NCT00886990|NNRTI failure
453092|NCT00886990|HIV-infected children
453093|NCT00886990|Compare virological efficacy and safety of single- or double-boosted PI regimens as second line therapy in children with NNRTI-based treatment failure
453094|NCT00886990|treatment experienced
453095|NCT00886977|ALS
453096|NCT00886964|HBV vaccine
453097|NCT00886964|HIV children
453098|NCT00886964|immune recovery
453099|NCT00886964|HBV antibody
453100|NCT00886964|Intradermal
453101|NCT00886964|Intramuscular
453102|NCT00886964|antibody response after HBV vaccine
453103|NCT00886964|treatment experienced
453104|NCT00886938|tinnitus
453105|NCT00886925|Hepatic encephalopathy
453106|NCT00886925|Cirrhosis
453107|NCT00886925|Albumin
453108|NCT00886912|mountain sickness
453109|NCT00886899|CTO
453110|NCT00886899|chronic total occlusion
453111|NCT00886899|CAD
453112|NCT00886899|coronary artery disease
453113|NCT00886899|interventional cardiology
453114|NCT00886899|revascularization
453115|NCT00886899|recanalization
453116|NCT00886886|MDMA
453117|NCT00886886|norepinephrine
453118|NCT00886886|Ecstasy
453119|NCT00886886|stimulant
453120|NCT00886873|Uterine fibroids
453121|NCT00886873|Mifepristone
453122|NCT00886873|Antiprogestins
453123|NCT00886860|Efficacy
453124|NCT00886860|Cervical ripening/Labor induction
453125|NCT00886860|Titrated oral misoprostol/Conventional oral misoprostol
453126|NCT00886860|Term pregnancy
453127|NCT00886847|Lung
453128|NCT00886847|Lymphadenopathy
453129|NCT00886847|Enlarged hilar or/and mediastinal lymph adenopathy
453130|NCT00886847|Benign
453131|NCT00886847|Malignant
453132|NCT00886847|Mediastinal lymph nodes
453133|NCT00886847|Hilar lymph nodes
453134|NCT00886847|Fine Needle Aspiration
453135|NCT00886847|FNA
453136|NCT00886847|Fine Needle Capillary Sampling
453137|NCT00886847|FNC
453138|NCT00886847|Endobronchial Ultrasound-Guided Biopsy
453139|NCT00886847|EBUS
453140|NCT00886847|Tissue Sample
453141|NCT00886847|Suction
453142|NCT00886834|IUD insertion
453143|NCT00886834|Nulliparous women
453144|NCT00886834|Contraception
453145|NCT00886834|Family Planning
453146|NCT00886834|IUD insertion in nulliparous women
453147|NCT00886821|Phase 1 Type 2 diabetes CVX-096 diabetes mellitus
453148|NCT00886821|adult-onset diabetes mellitus
453149|NCT00886821|non-insulin dependent
453150|NCT00886808|DME, Diabetic Retinopathy, Diabetic Macular Edema
453151|NCT00886795|hives
453152|NCT00886795|rash
453153|NCT00886795|pruritis
453154|NCT00886782|Advanced and/or Metastatic solid cancers
453155|NCT00886769|Flare
453156|NCT00886769|arthritis
453157|NCT00886769|IL-1beta antagonist
453158|NCT00886769|systemic juvenile idiopathic arthritis
453159|NCT00886769|Juvenile Rheumatoid
453160|NCT00886769|Systemic juvenile idiopathic arthritis with active flare
453161|NCT00886756|Phase I
453162|NCT00886756|Japanese healthy volunteer
453163|NCT00886756|AZD8529
453164|NCT00886730|Depressive disorder
453165|NCT00886730|Primary care
453166|NCT00886730|Internet
453167|NCT00886730|Social support
453168|NCT00886730|Feasibility
453169|NCT00886717|stage IIIA ovarian epithelial cancer
453170|NCT00886717|stage IIIB ovarian epithelial cancer
453171|NCT00886717|stage IIIC ovarian epithelial cancer
453172|NCT00886717|stage IV ovarian epithelial cancer
453173|NCT00886717|stage IIIA ovarian germ cell tumor
453174|NCT00886717|stage IIIB ovarian germ cell tumor
453175|NCT00886717|stage IIIC ovarian germ cell tumor
453176|NCT00886717|stage IV ovarian germ cell tumor
453177|NCT00886704|Omega-3 fatty acids
453178|NCT00886704|dietary supplementation
453179|NCT00886704|atherosclerosis
453180|NCT00886691|recurrent ovarian epithelial cancer
453181|NCT00886691|recurrent fallopian tube cancer
453182|NCT00886691|recurrent primary peritoneal cavity cancer
453183|NCT00886678|Non-Small Cell Lung Cancer
453184|NCT00886678|pemetrexed
453185|NCT00886678|radiation
453186|NCT00886665|Diabetic Neuropathy
453187|NCT00886665|Nerve Conduction Studies
453188|NCT00886665|Clinical Trial
453189|NCT00886652|Scoliosis
453190|NCT00886652|Muscle Strength
453191|NCT00886652|Respiratory function tests
453192|NCT00886652|Exercise therapy
453193|NCT00886639|COPD III/IV
453194|NCT00886639|Oxygen Supply
453195|NCT00886639|Six-Minute-Walking-Test
453196|NCT00886639|Oxygen Responder
453197|NCT00886626|Obesity
453198|NCT00886626|Impaired Glucose Tolerance
453199|NCT00886626|Children
453200|NCT00886587|eczema
453201|NCT00886574|Cilostazol versus Aspirin
453202|NCT00886574|Anti-PLT drug
453203|NCT00886574|Primary Prevention of Atherosclerotic Events
453204|NCT00886574|Type 2 DM
453205|NCT00886574|Intima media thickness (IMT)
453206|NCT00886561|HIV prevention, female sex workers
453207|NCT00886561|HIV seronegativity
453208|NCT00886535|breast cancer
453209|NCT00886535|hot flashes
453210|NCT00886535|tamoxifen
453211|NCT00886522|Anti-thymocyte globulin Fresenius
453212|NCT00886522|Busulfan
453213|NCT00886522|Cord blood
453214|NCT00886522|Cyclophosphamide
453215|NCT00886522|Fludarabine
453216|NCT00886522|Human Leucocyte Antigen
453217|NCT00886522|Hematopoietic Stem Cell
453218|NCT00886522|Hematopoietic Stem Cell Transplant
453219|NCT00886522|Graft-versus-Host-Disease
453220|NCT00886522|Graft-versus-Host-Disease prophylaxis
453221|NCT00886522|Intrabone infusion
453222|NCT00886522|Thiotepa
453223|NCT00886509|Coronary Artery Disease
453224|NCT00886509|Stable
453225|NCT00886509|Coronary Collaterals
453226|NCT00886509|Therapeutic Collateral Promotion (TCP)
453227|NCT00886496|unspecified childhood solid tumor, protocol specific
453228|NCT00886496|fever, sweats, and hot flashes
453229|NCT00886496|neutropenia
453230|NCT00886496|infection
453231|NCT00886496|recurrent childhood small noncleaved cell lymphoma
453232|NCT00886496|stage I and II childhood small noncleaved cell lymphoma
453233|NCT00886496|stage I childhood small noncleaved cell lymphoma
453234|NCT00886496|stage II childhood small noncleaved cell lymphoma
453235|NCT00886496|stage III and IV childhood small noncleaved cell lymphoma
453236|NCT00886496|stage III childhood small noncleaved cell lymphoma
453237|NCT00886496|stage IV childhood small noncleaved cell lymphoma
453238|NCT00886496|recurrent childhood lymphoblastic lymphoma
453239|NCT00886496|stage I and II childhood lymphoblastic lymphoma
453240|NCT00886496|stage I childhood lymphoblastic lymphoma
453241|NCT00886496|stage II childhood lymphoblastic lymphoma
453242|NCT00886496|stage III and IV childhood lymphoblastic lymphoma
453243|NCT00886496|stage III childhood lymphoblastic lymphoma
453244|NCT00886496|stage IV childhood lymphoblastic lymphoma
453245|NCT00886496|childhood Burkitt lymphoma
453246|NCT00886496|recurrent/refractory childhood Hodgkin lymphoma
453247|NCT00886496|stage I childhood Hodgkin lymphoma
453248|NCT00886496|stage II childhood Hodgkin lymphoma
453249|NCT00886496|stage III childhood Hodgkin lymphoma
453250|NCT00886496|stage IV childhood Hodgkin lymphoma
453251|NCT00886496|childhood acute lymphoblastic leukemia in remission
453252|NCT00886496|recurrent childhood acute lymphoblastic leukemia
453253|NCT00886496|untreated childhood acute lymphoblastic leukemia
453254|NCT00886496|de novo myelodysplastic syndromes
453255|NCT00886496|previously treated myelodysplastic syndromes
453256|NCT00886496|secondary myelodysplastic syndromes
453257|NCT00886496|childhood acute myeloid leukemia in remission
453258|NCT00886496|recurrent childhood acute myeloid leukemia
453259|NCT00886496|untreated childhood acute myeloid leukemia and other myeloid malignancies
453260|NCT00886496|childhood grade III lymphomatoid granulomatosis
453261|NCT00886496|childhood nasal type extranodal NK/T-cell lymphoma
453262|NCT00886496|recurrent childhood grade III lymphomatoid granulomatosis
453263|NCT00886496|childhood diffuse large cell lymphoma
453264|NCT00886496|childhood immunoblastic large cell lymphoma
453265|NCT00886496|recurrent childhood large cell lymphoma
453266|NCT00886496|stage I childhood large cell lymphoma
453267|NCT00886496|stage II childhood large cell lymphoma
453268|NCT00886496|stage III and IV childhood large cell lymphoma
453269|NCT00886496|stage III childhood large cell lymphoma
453270|NCT00886496|stage IV childhood large cell lymphoma
453271|NCT00886483|Neurofeedback
453272|NCT00886470|cytokines
453273|NCT00886470|pain
453274|NCT00886470|scarring
453275|NCT00886470|vascularity
453276|NCT00886457|Biopsy proven cancer, which is metastatic or unresectable
453277|NCT00886431|IVF
453278|NCT00886431|embryo cryopreservation
453279|NCT00886431|vitrification
453280|NCT00886431|slow cooling
453281|NCT00886431|slow freezing
453282|NCT00886431|surplus embryos
453283|NCT00886431|Human Reproduction
453284|NCT00886405|Nitroglycerin
453285|NCT00886405|Locally advanced non small-cell lung cancer
453286|NCT00886405|Vascular endothelial growth factor
453287|NCT00886405|Hypoxia Inducible Factor
453288|NCT00886405|Clinical stage IIIA and/or IIIB (without pleural effusion)
453289|NCT00886392|Clinically Significant Macular Edema
453290|NCT00886392|Diabetic Macular Edema
453291|NCT00886392|Optical Coherence Tomography
453292|NCT00886392|Diabetic Retinopathy
453293|NCT00886392|Severity
453294|NCT00886379|vitamin d
453295|NCT00886379|children
453296|NCT00886379|Mongolia
453297|NCT00886366|Type II Diabetes
453298|NCT00886353|RAS
453299|NCT00886353|ACE2
453300|NCT00886353|Cardiovascular
453301|NCT00886353|Pulmonary
453302|NCT00886353|Angiotensin II
453303|NCT00886353|Angiotensin 1-7
453304|NCT00886340|diabetes prevention, primary care
453305|NCT00886327|Colonic capsule endoscopy
453306|NCT00886327|Crohn's disease
453307|NCT00886327|Capsule endoscopy
453308|NCT00886314|children
453309|NCT00886314|surgery
453310|NCT00886314|anxiety
453311|NCT00886301|overweight
453312|NCT00886301|obesity
453313|NCT00886301|steatohepatitis
453314|NCT00886301|ectopic fat
453315|NCT00886275|Postoperative sedation in intensive care
453316|NCT00886262|liver transplantation
453317|NCT00886262|vasopressin
453318|NCT00886262|renal function
453319|NCT00886262|hypotension
453320|NCT00886262|creatinine
453321|NCT00886262|urine output
453322|NCT00886262|diuretics
453323|NCT00886262|vasopressors
453324|NCT00886262|hemodynamic stability
453325|NCT00886249|Vision
453326|NCT00886249|Eye
453327|NCT00886249|Cataract
453328|NCT00886236|Gastric Bypass
453329|NCT00886236|Gabapentin
453330|NCT00886236|Postoperative Nausea and Vomiting
453331|NCT00886236|Analgesics, Opioids
453332|NCT00886236|Sleep Apnea, Obstructive
453333|NCT00886236|Respiratory Depression
453334|NCT00886236|Oximetry
453335|NCT00886223|vaginal vault prolapse repair
453336|NCT00886223|robot-assisted laparoscopic sacropexy
453337|NCT00886223|robot-assisted laparoscopic sacrocolpopexy
453338|NCT00886223|robotic laparoscopic sacropexy
453339|NCT00886210|drain
453340|NCT00886210|laparoscopic cholecystectomy
453341|NCT00886210|pneumoperitonum
453342|NCT00886197|reflux
453343|NCT00886197|GERD
453344|NCT00886184|Hypothermia
453345|NCT00886184|Cardiac arrest
453346|NCT00886184|Biomarkers
453347|NCT00886184|Pre hospital cardiac arrest
453348|NCT00886171|social skills
453349|NCT00886171|physical activity
453350|NCT00886171|peer relationships
453351|NCT00886171|childhood obesity
453352|NCT00886171|changes in physical activity
453353|NCT00886171|changes in social involvement
453354|NCT00886158|Organ Transplants
453355|NCT00886145|Spinal Cord Injuries
453356|NCT00886145|Mechanical Stimulation
453357|NCT00886145|Vibration Plate
453358|NCT00886132|Phase 2 Study
453359|NCT00886132|Sunitinib
453360|NCT00886132|Recurrent
453361|NCT00886132|Metastatic
453362|NCT00886132|Adenoid Cystic Carcinoma
453363|NCT00886132|Salivary Glands
453364|NCT00886132|Metastasis
453365|NCT00886106|Capsaicin
453366|NCT00886106|Remifentanil
453367|NCT00886106|Hyperalgesia
453368|NCT00886093|pharmacokinetics, single dose, crossover, fed vs fasted state
453369|NCT00886080|Atrial fibrillation
453370|NCT00886080|Health related Quality of Life
453371|NCT00886080|Add-on surgery
453372|NCT00886080|Ablation
453373|NCT00886080|Randomised controlled trial
453374|NCT00886080|SF-36
453375|NCT00886080|EuroQoL
453376|NCT00886080|MFI-20
453377|NCT00886067|AZD1446
453378|NCT00886067|PET examination
453379|NCT00886054|Transcranial Doppler
453380|NCT00886054|Transcranial color-coded duplex sonography
453381|NCT00886054|Neurocritical patients
453382|NCT00886041|laparoscopy
453383|NCT00886041|unexplained infertility
453384|NCT00886028|Malignant pleural mesothelioma
453385|NCT00886028|Liposomal doxorubicin
453386|NCT00886028|Progression free survival
453387|NCT00886028|Patients who received LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles
453388|NCT00886028|Patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM
453389|NCT00886015|Trachoma
453390|NCT00886015|trichiasis
453391|NCT00886015|bilamellar tarsal rotation procedure
453392|NCT00886002|Healthy volunteers
453393|NCT00885989|SLV338
453394|NCT00885989|phase I
453395|NCT00885989|healthy volunteers
453396|NCT00885950|colorectal liver metastases
453397|NCT00885950|neoadjuvant chemotherapy
453398|NCT00885950|oxaliplatin
453399|NCT00885950|sinusoidal obstruction syndrome
453400|NCT00885950|anticoagulants
453401|NCT00885937|Dexpanthenol
453402|NCT00885937|Safety,
453403|NCT00885937|New formulation
453404|NCT00885937|Topical administration
453405|NCT00885924|postoperative Hemorrhage
453406|NCT00885924|Hemorrhage
453407|NCT00885924|Vasopressin
453408|NCT00885924|Blood Loss, Surgical
453409|NCT00885911|Intubating laryngeal airway
453410|NCT00885911|pediatric
453411|NCT00885911|observational study
453412|NCT00885898|Respiratory Insufficiency
453413|NCT00885898|Respiratory Failure
453414|NCT00885885|Colorectal Cancer
453415|NCT00885885|Panitumumab
453416|NCT00885885|FOLFOX-4
453417|NCT00885885|FOLFIRI
453418|NCT00885846|Qigong
453419|NCT00885846|Breathing management
453420|NCT00885846|Glucose
453421|NCT00885833|Wiskott-Aldrich syndrome
453422|NCT00885833|HSCT
453423|NCT00885820|Kidney Transplantation
453424|NCT00885820|Tacrolimus
453425|NCT00885820|Immunosuppression
453426|NCT00885820|Graft Survival
453427|NCT00885807|ADHD
453428|NCT00885807|WFIRS
453429|NCT00885807|WSR
453430|NCT00885794|Clinically Significant Diabetic Macular Edema
453431|NCT00885794|Focal Laser
453432|NCT00885794|GRID-Laser
453433|NCT00885794|Ranibizumab
453434|NCT00885794|Lucentis
453435|NCT00885794|Microperimetry
453436|NCT00885794|High-Definition OCT
453437|NCT00885794|Randomized
453438|NCT00885794|Observer-Blinded
453439|NCT00885794|Ineffective Treatment with Focal Laser or GRID-Laser
453440|NCT00885768|RAS(renal Artery Stenosis)
453441|NCT00885768|Atherosclerosis
453442|NCT00885768|angiography
453443|NCT00885742|Hereditary Factor XIII deficiency
453444|NCT00885742|Factor XIII
453445|NCT00885729|Cartilage defect
453446|NCT00885729|chondrocytes
453447|NCT00885729|mesenchymal stem cells (MSC)
453448|NCT00885729|femoral condyle
453449|NCT00885729|knee
453450|NCT00885703|CM
453451|NCT00885703|HIV
453452|NCT00885703|Meningitis
453453|NCT00885690|Schizophrenia
453454|NCT00885690|Antipsychotic
453455|NCT00885690|Cognition
453456|NCT00885664|HIV
453457|NCT00885664|immune reconstitution
453458|NCT00885664|treatment naive
453459|NCT00885651|SNP
453460|NCT00885651|catecholamines
453461|NCT00885651|metoprolole
453462|NCT00885651|healthy subjects
453463|NCT00885651|physiological stress
453464|NCT00885638|GLP-1
453465|NCT00885638|Insulin secretion
453466|NCT00885638|Macronutrients
453467|NCT00885625|invasive pneumococcal disease
453468|NCT00885625|pneumococcal conjugated vaccine
453469|NCT00885612|CHD-Risk
453470|NCT00885612|Breast Cancer
453471|NCT00885612|Aromatase Inhibitors
453472|NCT00885612|postmenopausal early breast cancer
453473|NCT00885599|gingivitis
453474|NCT00885599|natural remedy
453475|NCT00885599|inflammation
453476|NCT00885599|C-reactive protein
453477|NCT00885599|mouthwash
453478|NCT00885586|herpes zoster
453479|NCT00885586|neuropathic pain
453480|NCT00885586|acupuncture
453481|NCT00885586|randomised controlled trial
453482|NCT00885586|acute herpes zoster
453483|NCT00885573|sleep apnea
453484|NCT00885573|pharyngeal sensitivity
453485|NCT00885573|pharyngeal dilator reflex
453486|NCT00885573|diagnosis algorithm
453487|NCT00885573|patients with suspected sleep apnea syndrome
453488|NCT00885560|ADHD
453489|NCT00885560|SNAP 25
453490|NCT00885560|amphetamine
453491|NCT00885560|methylphenidate
453492|NCT00885534|skin cancer
453493|NCT00885534|CISPLATIN
453494|NCT00885534|TEMOZOLOMIDE
453495|NCT00885534|VINBLASTINE
453496|NCT00885534|09-017
453497|NCT00885508|MDS
453498|NCT00885508|AML
453499|NCT00885508|deletion 5q
453500|NCT00885508|Documented diagnosis of MDS, or CMML
453501|NCT00885508|with WBC < 13,000/mm3 that meets IPSS criteria for intermediate-2
453502|NCT00885508|or high-risk disease, or AML with an associated del 5q[31]
453503|NCT00885508|(the deleted chromosomal region must include 5q[31]),
453504|NCT00885508|with or without additional cytogenetic abnormalities
453505|NCT00885495|HIV
453506|NCT00885495|dyslipidemia
453507|NCT00885495|statins
453508|NCT00885495|protease inhibitors
453509|NCT00885482|HIV/AIDS
453510|NCT00885482|HAART
453511|NCT00885482|Simplification
453512|NCT00885482|Atazanavir
453513|NCT00885482|Lamivudine
453514|NCT00885482|treatment experienced
453515|NCT00885469|known Barrett's Esophagus
453516|NCT00885469|Suspected Barrett's Esophagus
453517|NCT00885469|chronic GERD
453518|NCT00885469|known Barrett's Esophagus or chronic GERD
453519|NCT00885456|stroke
453520|NCT00885456|secondary prevention
453521|NCT00885456|vascular risk
453522|NCT00885456|behavioral change
453523|NCT00885456|exercise
453524|NCT00885456|lifestyle modification
453525|NCT00885443|propofol
453526|NCT00885443|sevoflurane
453527|NCT00885443|pediatric
453528|NCT00885443|emergence delirium
453529|NCT00885443|Induction of sedation
453530|NCT00885430|colonoscopy
453531|NCT00885430|preparation
453532|NCT00885417|Helicobacter pylori
453533|NCT00885417|sequential therapy
453534|NCT00885417|levofloxacin
453535|NCT00885417|clarithromycin
453536|NCT00885417|rescue
453537|NCT00885417|salvage
453538|NCT00885417|treatment failure
453539|NCT00885417|For those who fail from one standard eradication therapy for H. pylori infection
453540|NCT00885404|chloride
453541|NCT00885404|acidosis
453542|NCT00885391|Atrial Fibrillation
453543|NCT00885391|Cardioversion
453544|NCT00885391|Direct Current Cardioversion
453545|NCT00885391|QT Interval
453546|NCT00885365|cystic fibrosis
453547|NCT00885365|P. aeruginosa
453548|NCT00885365|tobramycin
453549|NCT00885339|Colonic Diseases
453550|NCT00885326|recurrent neuroblastoma
453551|NCT00885313|NAFLD
453552|NCT00885313|NASH
453553|NCT00885313|fibrosis
453554|NCT00885287|uncomplicated malaria
453555|NCT00885287|HIV/AIDS
453556|NCT00885287|drug interactions
453557|NCT00885287|antimalarial drug efficacy
453558|NCT00885287|antiretrovirals
453559|NCT00885287|pharmacovigilance
453560|NCT00885287|Tanzania
453561|NCT00885261|chronic pain and metabolic syndrome
453562|NCT00885248|pancreatic cancer
453563|NCT00885248|integrated PET-CT
453564|NCT00885235|Bowel Diseases
453565|NCT00885222|Parkinson's disease
453566|NCT00885222|Major depressive disorder
453567|NCT00885222|Deep brain stimulation
453568|NCT00885209|Colonic Diseases
453569|NCT00885196|Psoriasis
453570|NCT00885196|plaque psoriasis
453571|NCT00885196|inflammatory skin disease
453572|NCT00885196|scaly patches
453573|NCT00885196|AEB071
453574|NCT00885183|breast cancer
453575|NCT00885183|chemotherapy
453576|NCT00885183|adjuvant therapy
453577|NCT00885183|acupuncture
453578|NCT00885183|fatigue
453579|NCT00885183|Early stage breast cancer patients
453580|NCT00885157|Poliomyelitis
453581|NCT00885157|intradermal
453582|NCT00885144|Stunting
453583|NCT00885144|Growth failure
453584|NCT00885144|Malnutrition
453585|NCT00885144|Lipid based nutrient supplement
453586|NCT00885144|LNS
453587|NCT00885144|Prevention
453588|NCT00885144|Malawi
453589|NCT00885144|Sub-Saharan Africa
453590|NCT00885144|Dietary supplementation
453591|NCT00885131|Reward Processing
453592|NCT00885131|Motor Cortex
453593|NCT00885131|HV
453594|NCT00885131|Healthy Volunteer
453595|NCT00885105|Fluzone® vaccine
453596|NCT00885105|Influenza
453597|NCT00885092|Contact lenses
453598|NCT00885092|Disinfecting solutions
453599|NCT00885066|stage III pancreatic cancer
453600|NCT00885066|stage IV pancreatic cancer
453601|NCT00885066|adenocarcinoma of the pancreas
453602|NCT00885066|recurrent pancreatic cancer
453603|NCT00885053|Inflammation
453604|NCT00885053|Fatty acids, Omega 3
453605|NCT00885053|Leukotrienes
453606|NCT00885053|Adiponectin
453607|NCT00885053|Adipose tissue
453608|NCT00885053|RNA, Messenger
453609|NCT00885040|Neurofeedback
453610|NCT00885040|Tourette Syndrome
453611|NCT00885040|Healthy Volunteer
453612|NCT00885040|Movement Disorder
453613|NCT00885040|Brain Activity
453614|NCT00885040|fMRI
453615|NCT00885040|HV
453616|NCT00885014|Depressive disorder
453617|NCT00885014|Behavior therapy
453618|NCT00885014|Workplace
453619|NCT00885014|Subthreshold depression
453620|NCT00884988|ankle fracture
453621|NCT00884988|edema
453622|NCT00884988|surgical repair
453623|NCT00884988|homeopathy
453624|NCT00884988|lymphomyosot
453625|NCT00884975|Chronic obstructive pulmonary disease
453626|NCT00884975|exacerbations
453627|NCT00884975|quality of life
453628|NCT00884975|emphysema
453629|NCT00884962|emphysema
453630|NCT00884962|aeris
453631|NCT00884962|PLVR
453632|NCT00884962|BLVR
453633|NCT00884962|germany
453634|NCT00884962|treatment
453635|NCT00884962|device
453636|NCT00884962|breathing
453637|NCT00884949|Mucopolysaccharidosis IV type A
453638|NCT00884949|MPS IV Type A
453639|NCT00884949|Mucopolysaccharidosis IVA
453640|NCT00884949|MPS IVA
453641|NCT00884949|Morquio A Syndrome
453642|NCT00884949|Lysosomal Storage Disorder
453643|NCT00884949|LSD
453644|NCT00884949|N-acetylgalactosamine-6-sulfatase
453645|NCT00884949|N-acetylgalactosamine-6-sulfate sulfatase
453646|NCT00884949|galactose-6-sulfatase
453647|NCT00884949|GALNS
453648|NCT00884949|enzyme replacement therapy
453649|NCT00884949|ERT
453650|NCT00884936|Skin
453651|NCT00884936|Aging
453652|NCT00884936|Dermogenomics
453653|NCT00884936|Genetic
453654|NCT00884936|Biomarker
453655|NCT00884936|Dermatology
453656|NCT00884910|laryngectomy
453657|NCT00884910|Provox Vega
453658|NCT00884910|voice prosthesis
453659|NCT00884897|Social Cognition
453660|NCT00884897|Schizophrenia
453661|NCT00884897|Oxytocin
453662|NCT00884884|Alcohol dependence
453663|NCT00884884|alcohol abuse
453664|NCT00884884|topiramate
453665|NCT00884884|aripiprazole
453666|NCT00884871|pelvic floor disorders
453667|NCT00884871|weight loss
453668|NCT00884858|HIV-1
453669|NCT00884858|CD4
453670|NCT00884858|INR
453671|NCT00884858|HIV-1 infection
453672|NCT00884858|extreme immunological compromission
453673|NCT00884858|treatment experienced
453674|NCT00884845|PM2734
453675|NCT00884845|Tumors
453676|NCT00884845|PharmaMar
453677|NCT00884845|Erlotinib
453678|NCT00884845|Tarceva
453679|NCT00884832|fecal incontinence
453680|NCT00884832|stool leakage
453681|NCT00884832|incontinence
453682|NCT00884832|FI
453683|NCT00884832|Urge predominant fecal incontinence
453684|NCT00884819|polycystic ovary syndrome
453685|NCT00884819|hepatic adiposity
453686|NCT00884819|diabetes
453687|NCT00884819|hormones
453688|NCT00884819|cardiovascular disease
453689|NCT00884806|Contact lenses
453690|NCT00884806|Disinfecting solutions
453691|NCT00884793|HIV
453692|NCT00884793|persistence
453693|NCT00884793|reservoirs
453694|NCT00884793|residual replication
453695|NCT00884793|gut
453696|NCT00884793|gut-associated lymphoid tissue
453697|NCT00884793|treatment experienced
453698|NCT00884780|Electronic Diary
453699|NCT00884780|Body Map
453700|NCT00884780|Electronic Measure of Pediatric Pain
453701|NCT00884767|neurotoxicity
453702|NCT00884767|chemotherapeutic agent toxicity
453703|NCT00884767|recurrent colon cancer
453704|NCT00884767|stage I colon cancer
453705|NCT00884767|stage II colon cancer
453706|NCT00884767|stage III colon cancer
453707|NCT00884767|stage IV colon cancer
453708|NCT00884767|recurrent rectal cancer
453709|NCT00884767|stage I rectal cancer
453710|NCT00884767|stage II rectal cancer
453711|NCT00884767|stage III rectal cancer
453712|NCT00884767|stage IV rectal cancer
453713|NCT00884728|Scabies
453714|NCT00884728|Impetigo
453715|NCT00884728|Pyoderma
453716|NCT00884728|Streptococcal infections
453717|NCT00884702|Sleep
453718|NCT00884702|14C-Leucine
453719|NCT00884702|Cerebral Protein Synthesis
453720|NCT00884702|Memory
453721|NCT00884702|Positron Emission Tomography (PET)
453722|NCT00884702|HV
453723|NCT00884702|Healthy Volunteer
453724|NCT00884689|Symbicort SMART
453725|NCT00884689|Free Combination GCS/LABA treatment
453726|NCT00884676|unspecified adult solid tumor, protocol specific
453727|NCT00884650|Pain
453728|NCT00884650|Pain management
453729|NCT00884650|Cerebral Palsy
453730|NCT00884637|HMP
453731|NCT00884637|CNV
453732|NCT00884637|AMD
453733|NCT00884637|PHP
453734|NCT00884637|HPHP
453735|NCT00884637|foresee home
453736|NCT00884624|Bowel Diseases
453737|NCT00884598|adult tumors metastatic to brain
453738|NCT00884598|extensive stage small cell lung cancer
453739|NCT00884598|stage IV non-small cell lung cancer
453740|NCT00884559|Leadership
453741|NCT00884559|Team building
453742|NCT00884559|Resuscitation
453743|NCT00884533|QTc
453744|NCT00884533|pharmacokinetics
453745|NCT00884533|rosiglitazone XR
453746|NCT00884533|cardiac conduction
453747|NCT00884533|healthy volunteers
453748|NCT00884520|[F-18]VM4-037
453749|NCT00884520|VM4-037
453750|NCT00884520|hypoxia
453751|NCT00884520|CA-IX
453752|NCT00884520|CAIX
453753|NCT00884520|carbonic anhydrase IX
453754|NCT00884520|hypoxia marker
453755|NCT00884520|lung cancer
453756|NCT00884520|renal carcinoma
453757|NCT00884520|squamous cell carcinoma
453758|NCT00884520|hepatic carcinoma
453759|NCT00884520|head and neck cancer
453760|NCT00884520|advanced stage lung cancer
453761|NCT00884520|exploratory
453762|NCT00884494|Obesity
453763|NCT00884494|Insulin resistance
453764|NCT00884494|Ghrelin
453765|NCT00884468|Anxiety and depression in patients with psoriatic arthritis
453766|NCT00884455|tissue banking, research
453767|NCT00884442|Healthy
453768|NCT00884442|Bioavailability
453769|NCT00884442|Nifedipine
453770|NCT00884429|Chest physiotherapy
453771|NCT00884416|high grade glioma
453772|NCT00884416|glioblastoma
453773|NCT00884416|gliosarcoma
453774|NCT00884416|anaplastic astrocytoma
453775|NCT00884416|anaplastic oligoastrocytoma
453776|NCT00884416|anaplastic oligodendroglioma
453777|NCT00884416|phase I
453778|NCT00884416|first line treatment
453779|NCT00884416|sorafenib
453780|NCT00884416|temozolomide
453781|NCT00884416|radiation therapy
453782|NCT00884416|safety
453783|NCT00884416|tolerability
453784|NCT00884416|protein kinase inhibitors
453785|NCT00884403|abortion
453786|NCT00884403|pregnancy dating
453787|NCT00884403|gestational age
453788|NCT00884403|ultrasound
453789|NCT00884390|Hemophilia A
453790|NCT00884364|Lymphoma
453791|NCT00884364|Leukemia
453792|NCT00884364|Multiple myeloma
453793|NCT00884364|Hodgkin´s disease
453794|NCT00884364|Exercise
453795|NCT00884364|Sport
453796|NCT00884364|Fatigue
453797|NCT00884364|Hematological neoplastic diseases
453798|NCT00884351|Epilepsy
453799|NCT00884351|MEG
453800|NCT00884351|Seizures
453801|NCT00884338|Fatigue
453802|NCT00884338|Cancer
453803|NCT00884338|Cognitive impairment
453804|NCT00884338|Exercise
453805|NCT00884338|Sport
453806|NCT00884338|Peripheral blood stem cell transplantation
453807|NCT00884338|High-dose chemotherapy
453808|NCT00884325|Itching
453809|NCT00884325|Atopic Dermatitis
453810|NCT00884312|Multiple myeloma
453811|NCT00884312|proteasome
453812|NCT00884312|Hematological
453813|NCT00884312|carfilzomib
453814|NCT00884312|PR-171
453815|NCT00884299|Lung function
453816|NCT00884299|Chronic obstructive pulmonary disease
453817|NCT00884299|Antioxidants
453818|NCT00884286|Aplidin
453819|NCT00884286|Aggressive Non Hodgkin Lymphoma
453820|NCT00884286|Leukemia-Lymphoma, Adult T-Cell and B-cell
453821|NCT00884260|Contraception
453822|NCT00884260|Intrauterine contraception system
453823|NCT00884247|GERD
453824|NCT00884247|Quality of life
453825|NCT00884247|Structured treatment
453826|NCT00884234|Lateral Canthal Lines
453827|NCT00884234|Crow's Feet
453828|NCT00884234|Facial Wrinkles
453829|NCT00884234|Lateral Canthal Area
453830|NCT00884195|Obesity
453831|NCT00884182|Influenza
453832|NCT00884182|Orthomyxoviruses
453833|NCT00884182|Split Virion Pandemic Influenza Vaccine
453834|NCT00884182|A/H5N1
453835|NCT00884143|tamoxifen
453836|NCT00884143|arimidex
453837|NCT00884143|adjuvant hormonal therapies
453838|NCT00884143|breast cancer
453839|NCT00884143|post-menopausal
453840|NCT00884143|Adjuvant hormonal therapy in patients post menopausal with breast cancer
453841|NCT00884130|Laparoscopy
453842|NCT00884130|Colorectal surgery
453843|NCT00884130|Quality of life
453844|NCT00884130|economic analysis
453845|NCT00884130|Patients undergoing laparoscopic colorectal surgery
453846|NCT00884104|Solifenacin
453847|NCT00884104|Tamsulosin
453848|NCT00884104|OAB
453849|NCT00884091|Chinese
453850|NCT00884091|Glucagon-like peptide 1
453851|NCT00884091|Glucagon
453852|NCT00884091|Insulin
453853|NCT00884091|Mixed meals
453854|NCT00884091|Healthy Adults
453855|NCT00884078|Self harm in south asian women
453856|NCT00884078|depression
453857|NCT00884078|suicidal ideations
453858|NCT00884078|problem solving training
453859|NCT00884065|Physiotherapy
453860|NCT00884065|Manual therapy
453861|NCT00884065|Painful Shoulder
453862|NCT00884065|Diacutaneous Fibrolysis
453863|NCT00884052|Neonatal seizures
453864|NCT00884039|cornea
453865|NCT00884039|transplant
453866|NCT00884039|intraocular pressure
453867|NCT00884039|steroid response
453868|NCT00884026|Cesarean delivery
453869|NCT00884026|hypotension
453870|NCT00884026|Augmentation Index
453871|NCT00884026|Pulse Wave analysis
453872|NCT00884026|spinal anesthesia
453873|NCT00884026|Hypotension following spinal anesthesia for cesarean delivery
453874|NCT00884013|Pay for Quality
453875|NCT00884013|Provider
453876|NCT00884013|Clinical Decision Support
453877|NCT00884013|Quality Reporting
453878|NCT00884013|Quality Measurement
453879|NCT00883974|preterm bith
453880|NCT00883974|neurodevelopment
453881|NCT00883974|sensitivity training
453882|NCT00883974|magnetic resonance imaging (MRI)
453883|NCT00883974|Infant neurodevelopment following preterm birth
453884|NCT00883961|High-dose chemotherapy
453885|NCT00883961|Hematological neoplasties
453886|NCT00883961|Fatigue
453887|NCT00883961|Cancer
453888|NCT00883961|Exercise
453889|NCT00883961|Sport
453890|NCT00883961|Hematologic neoplastic disorders
453891|NCT00883948|Acute Lung Injury
453892|NCT00883948|Acute Respiratory Distress Syndrome
453893|NCT00883948|Feeding
453894|NCT00883948|Critical Care
453895|NCT00883948|Ventilator
453896|NCT00883935|GSK1349572
453897|NCT00883935|Atazanavir
453898|NCT00883935|Ritonavir
453899|NCT00883935|Reyataz
453900|NCT00883935|Norvir
453901|NCT00883935|healthy
453902|NCT00883935|pharmacokinetic
453903|NCT00883909|Prostate Cancer
453904|NCT00883909|Benign Prostatic Hyperplasia
453905|NCT00883896|Rheumatoid Arthritis
453906|NCT00883896|ACR
453907|NCT00883896|Methotrexate
453908|NCT00883896|Interleukin-22
453909|NCT00883883|Antibiotic
453910|NCT00883870|mesenchymal stem cells
453911|NCT00883870|critical limb ischemia
453912|NCT00883844|Hepatitis B
453913|NCT00883844|sustained response
453914|NCT00883844|peginterferon
453915|NCT00883844|nucleos(t)ide analogues
453916|NCT00883831|Acupuncture
453917|NCT00883831|Hemodialysis
453918|NCT00883831|Symptom
453919|NCT00883831|end stage renal disease
453920|NCT00883831|chronic kidney disease
453921|NCT00883831|supportive care
453922|NCT00883818|Overactive bladder
453923|NCT00883818|Mycoplasma
453924|NCT00883805|Metal Ion Concentration
453925|NCT00883805|Osteolysis
453926|NCT00883766|Polycystic Ovary Syndrome
453927|NCT00883766|GnRH Antagonist
453928|NCT00883766|Long Agonist Protocol
453929|NCT00883766|OHSS
453930|NCT00883740|Fibromyalgia sleep maintenance disturbance pregabalin
453931|NCT00883727|mesenchymal stem cells
453932|NCT00883727|myocardial infarction
453933|NCT00883714|Exercise
453934|NCT00883714|sport
453935|NCT00883714|Allogeneic blood stem cell transplantation
453936|NCT00883714|Blood stem cell transplantation
453937|NCT00883714|Fatigue
453938|NCT00883714|Cancer
453939|NCT00883714|Physical performance
453940|NCT00883714|Mood
453941|NCT00883714|Complications
453942|NCT00883701|Chronic Obstructive Pulmonary Disease
453943|NCT00883701|exacerbations
453944|NCT00883701|perforin
453945|NCT00883701|granzymes
453946|NCT00883688|Brain Tumor
453947|NCT00883688|Recurrent Ependymoma
453948|NCT00883688|Refractory Ependymoma
453949|NCT00883688|Intracranial ependymoma
453950|NCT00883688|Ependymoblastoma
453951|NCT00883688|Subependymoma
453952|NCT00883688|Myxopapillary
453953|NCT00883688|Clear cell
453954|NCT00883688|Anaplastic
453955|NCT00883688|Bevacizumab
453956|NCT00883688|Avastin
453957|NCT00883688|Anti-VEGF Monoclonal Antibody
453958|NCT00883688|rhuMAb-VEGF
453959|NCT00883688|Lapatinib
453960|NCT00883688|Tykerb
453961|NCT00883688|GW572016
453962|NCT00883675|Lung cancer
453963|NCT00883675|Adjuvant therapy
453964|NCT00883649|Keratoconjunctivitis Sicca
453965|NCT00883649|Dry Eyes
453966|NCT00883649|Post-menopausal
453967|NCT00883636|Podocyte Protein
453968|NCT00883636|Podocyte Mutation
453969|NCT00883623|AL-Amyloidosis
453970|NCT00883623|Lenalidomide
453971|NCT00883610|QT Interval
453972|NCT00883610|Dual Chamber Pacemaker
453973|NCT00883610|Atrial Fibrillation
453974|NCT00883584|Proof of Concept
453975|NCT00883584|Inflammatory Markers
453976|NCT00883584|Lung Function
453977|NCT00883584|Chronic Obstructive Pulmonary Disease
453978|NCT00883584|COPD
453979|NCT00883571|anal stenosis
453980|NCT00883571|flaps
453981|NCT00883571|anoplasty
453982|NCT00883558|recombinant human hyaluronidase (rHuPH20)
453983|NCT00883558|Insulin lispro
453984|NCT00883558|regular human insulin
453985|NCT00883545|Adherence to screening colonoscopy in women
453986|NCT00883532|Preterm infant
453987|NCT00883532|Respiratory distress syndrome
453988|NCT00883532|chronic lung disease
453989|NCT00883532|budesonide
453990|NCT00883532|surfactant
453991|NCT00883493|Acute bipolar depression
453992|NCT00883493|Lithium carbonate
453993|NCT00883493|quetiapine fumarate
453994|NCT00883493|MADRS
453995|NCT00883480|NSCLC
453996|NCT00883467|Ischemic Preconditioning
453997|NCT00883467|functional MRI
453998|NCT00883467|BOLD
453999|NCT00883467|Reperfusion
454000|NCT00883454|hepatocellular carcinoma
454001|NCT00883454|liver tumor
454002|NCT00883454|cirrhosis
454003|NCT00883454|liver resection
454004|NCT00883454|tumor staging
454005|NCT00883454|liver disease staging
454006|NCT00883441|IMPLEMENTATION RESEARCH
454007|NCT00883441|AEDES
454008|NCT00883441|VECTOR CONTROL
454009|NCT00883428|low back pain
454010|NCT00883428|pelvic pain
454011|NCT00883428|pregnancy
454012|NCT00883415|metabolism
454013|NCT00883415|myocardium
454014|NCT00883415|chronic kidney disease
454015|NCT00883402|Carotid stenosis
454016|NCT00883402|CEA
454017|NCT00883402|CAS
454018|NCT00883402|Stenting
454019|NCT00883389|patient safety
454020|NCT00883389|chronic kidney disease
454021|NCT00883389|med-alert
454022|NCT00883376|Classification of Stanford for Snoring
454023|NCT00883376|OSAS
454024|NCT00883376|Apnea-Hipopnea Index
454025|NCT00883363|precondition
454026|NCT00883363|ruptured abdominal aortic aneurysm
454027|NCT00883363|myocardial infarction
454028|NCT00883350|Body weight changes
454029|NCT00883350|Overweight
454030|NCT00883350|Obesity
454031|NCT00883337|Relapsing-remitting multiple sclerosis
454032|NCT00883324|fFN
454033|NCT00883324|fetal fibronectin
454034|NCT00883324|non-speculum
454035|NCT00883324|risk of preterm delivery
454036|NCT00883311|Efficacy
454037|NCT00883298|temozolomide
454038|NCT00883298|bevacizumab
454039|NCT00883298|Temodar
454040|NCT00883298|Avastin
454041|NCT00883298|glioblastoma multiforme
454042|NCT00883298|gliosarcoma
454043|NCT00883298|glioma
454044|NCT00883298|GBM
454045|NCT00883298|brain tumor
454046|NCT00883272|Menopause
454047|NCT00883272|Thrombophilia
454048|NCT00883272|factor V Leiden
454049|NCT00883272|Estrogen Replacement Therapy
454050|NCT00883272|Hypercoagulability
454051|NCT00883272|Venous Thrombosis
454052|NCT00883259|High-risk patients
454053|NCT00883259|Metformin
454054|NCT00883259|PCOS
454055|NCT00883259|Pregnancy complications
454056|NCT00883259|Previous gestational DM
454057|NCT00883246|PAD
454058|NCT00883233|Acne
454059|NCT00883220|self management
454060|NCT00883220|chronic condition
454061|NCT00883220|urinary catheter
454062|NCT00883207|Depression
454063|NCT00883207|family therapy
454064|NCT00883207|dialogical processes
454065|NCT00883207|Developing couple therapy for depression
454066|NCT00883194|Experimental Pain Model
454067|NCT00883155|Antidepressant
454068|NCT00883142|Lokomat
454069|NCT00883142|Suspended walking
454070|NCT00883142|Body Weight Supported
454071|NCT00883142|Treadmill Training
454072|NCT00883129|Systemic Sclerosis
454073|NCT00883129|Mycophenolate Mofetil
454074|NCT00883129|Cyclophosphamide
454075|NCT00883129|High Resolution Computerized Tomography
454076|NCT00883129|Pulmonary Function
454077|NCT00883129|Dyspnea
454078|NCT00883129|Health Related Quality of Life
454079|NCT00883103|female urethral catheterization
454080|NCT00883103|Lidocaine
454081|NCT00883103|lubricant
454082|NCT00883103|Q-tip test
454083|NCT00883103|Q tip test
454084|NCT00883103|K-Y jelly
454085|NCT00883103|pain perception
454086|NCT00883103|straight catheterization
454087|NCT00883090|Factor XIII
454088|NCT00883077|permeability
454089|NCT00883077|inflammatory bowel disease
454090|NCT00883077|confocal laser endomicroscopy
454091|NCT00883077|irritable bowel syndrome
454092|NCT00883051|COL-144
454093|NCT00883051|acute treatment
454094|NCT00883051|migraine
454095|NCT00883038|insulin resistance
454096|NCT00883038|vegetarian diet
454097|NCT00883025|Friedman Classification
454098|NCT00883025|Apnea-Hypopnea Index
454099|NCT00883025|Obstructive Sleep Apnea Syndrome
454100|NCT00883012|Viral-confirmed
454101|NCT00882999|Relapsing
454102|NCT00882999|Remitting
454103|NCT00882999|Multiple Sclerosis
454104|NCT00882999|Multiple
454105|NCT00882999|Sclerosis
454106|NCT00882999|MS
454107|NCT00882999|LY2127399
454108|NCT00882986|insulin resistance
454109|NCT00882960|pre-hospital
454110|NCT00882960|intra-nasal fentanyl
454111|NCT00882960|patients requiring analgesia
454112|NCT00882947|Primary Pulmonary Hypertension (PPH)
454113|NCT00882934|Placebo
454114|NCT00882934|Placebo Effect
454115|NCT00882934|Sexual Dysfunction
454116|NCT00882934|Erectile Dysfunction
454117|NCT00882934|Clinical Trial
454118|NCT00882921|Hunter syndrome
454119|NCT00882921|hunters syndrome
454120|NCT00882921|hunter's syndrome
454121|NCT00882921|hunter disease
454122|NCT00882921|hunters disease
454123|NCT00882921|hunter's disease
454124|NCT00882921|MPS II
454125|NCT00882921|MPSII
454126|NCT00882921|MPS2
454127|NCT00882921|MPS 2
454128|NCT00882921|mucopolysaccharides
454129|NCT00882921|lysosomal storage disease
454130|NCT00882921|lysosomal storage disorder
454131|NCT00882921|chronic ear infection
454132|NCT00882921|enlarged adenoids
454133|NCT00882921|mps symptoms
454134|NCT00882921|mps diagnosis
454135|NCT00882921|mps ii therapy
454136|NCT00882921|MPS II treatment
454137|NCT00882921|ert treatment
454138|NCT00882921|elaprase
454139|NCT00882921|idursulfase
454140|NCT00882921|iduronate sulfatase
454141|NCT00882921|iduronate 2 sulfatase
454142|NCT00882921|enzyme replacement therapy
454143|NCT00882921|hunter syndrome treatment
454144|NCT00882921|hunter's syndrome treatment
454145|NCT00882921|hunter syndrome therapy
454146|NCT00882921|hunter's disease treatment
454147|NCT00882921|mps society
454148|NCT00882908|Hepatitis C
454149|NCT00882908|TMC435
454150|NCT00882908|Peginterferon alpha-2a
454151|NCT00882908|PegIFNalpha-2a
454152|NCT00882908|RBV
454153|NCT00882908|Ribavirin
454154|NCT00882908|Placebo
454155|NCT00882895|Lymphoma, Non-Hodgkin
454156|NCT00882895|Transplantation, Autologous
454157|NCT00882895|Transplantation, Homologous
454158|NCT00882895|Total Lymphoid Irradiation
454159|NCT00882895|Anti-thymocyte globulin
454160|NCT00882869|Advanced Hepatocellular carcinoma
454161|NCT00882869|liver
454162|NCT00882869|cancer
454163|NCT00882869|antisense
454164|NCT00882869|sorafenib
454165|NCT00882856|Clozapine
454166|NCT00882856|Sinustachycardia
454167|NCT00882856|Heartrate variability
454168|NCT00882856|Cardiomyopathy
454169|NCT00882843|Vibrating plate
454170|NCT00882843|Mechanical Stimulation
454171|NCT00882843|Osteoporosis
454172|NCT00882830|ICU
454173|NCT00882830|myopathy
454174|NCT00882830|neuropathy
454175|NCT00882830|EMS
454176|NCT00882830|critical illness polyneuromyopathy
454177|NCT00882830|NIRS
454178|NCT00882830|muscle biopsy
454179|NCT00882830|microdialysis
454180|NCT00882830|CIPNM
454181|NCT00882817|ILD
454182|NCT00882804|hemin, heme oxygenase, humans, HO-1
454183|NCT00882791|Skin Cancer
454184|NCT00882791|Basal Cell
454185|NCT00882791|Mohs surgery
454186|NCT00882765|adenocarcinoma of the pancreas
454187|NCT00882765|stage I pancreatic cancer
454188|NCT00882765|stage II pancreatic cancer
454189|NCT00882765|stage III pancreatic cancer
454190|NCT00882752|Ulcerative Colitis (UC)
454191|NCT00882739|angiography
454192|NCT00882739|percutaneous coronary intervention
454193|NCT00882739|Platelet Aggregation Inhibitors
454194|NCT00882739|Platelet Function Tests
454195|NCT00882726|Diabetes Mellitus, Type 2
454196|NCT00882726|CNTO 3649
454197|NCT00882726|safety
454198|NCT00882726|Phase I
454199|NCT00882726|healthy adults
454200|NCT00882726|Type 2 Diabetes Mellitus
454201|NCT00882700|Antibiotic
454202|NCT00882661|Neck Pain
454203|NCT00882661|Arm Pain
454204|NCT00882648|Drug dependence during pregnancy
454205|NCT00882635|STEMI
454206|NCT00882635|acute coronary syndromes
454207|NCT00882635|primary percutaneous coronary intervention
454208|NCT00882622|Ischemic Preconditioning
454209|NCT00882622|Cardiac Surgery
454210|NCT00882609|bone metastasis
454211|NCT00882609|bone metastases
454212|NCT00882609|Sodium Fluoride
454213|NCT00882609|F18 Fluoride
454214|NCT00882609|bone scan
454215|NCT00882596|Contura
454216|NCT00882596|Cancer
454217|NCT00882596|Accelerated
454218|NCT00882596|Partial
454219|NCT00882596|Breast
454220|NCT00882596|Irradiation
454221|NCT00882583|HNSCC
454222|NCT00882583|Dasatinib
454223|NCT00882583|Cetuximab
454224|NCT00882583|Cisplatin
454225|NCT00882570|Antibiotic
454226|NCT00882557|End-stage renal disease
454227|NCT00882557|hemodialysis
454228|NCT00882557|chronic renal failure
454229|NCT00882544|hydronephrosis
454230|NCT00882544|robotic pyeloplasty
454231|NCT00882544|pediatric pyeloplasty
454232|NCT00882518|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
454233|NCT00882518|qualified PANSS assessment
454234|NCT00882492|Cardiac
454235|NCT00882492|Surgery
454236|NCT00882492|Glycemia
454237|NCT00882466|erythropoietin
454238|NCT00882453|Physical Activity
454239|NCT00882453|Fatigue
454240|NCT00882453|RRMS
454241|NCT00882453|CIS
454242|NCT00882427|algorithm
454243|NCT00882427|tight glycemic control
454244|NCT00882427|glucose control
454245|NCT00882427|intensive care
454246|NCT00882427|insulin
454247|NCT00882427|ICU
454248|NCT00882414|ferric carboxymaltose
454249|NCT00882414|platelet
454250|NCT00882414|thrombocyte
454251|NCT00882414|ferritin
454252|NCT00882414|hemoglobin
454253|NCT00882414|transferrin
454254|NCT00882388|celecoxib
454255|NCT00882388|platelet
454256|NCT00882388|thrombosis
454257|NCT00882388|Volunteers
454258|NCT00882375|Smoking Cessation
454259|NCT00882336|Cardiovascular risk management
454260|NCT00882336|Hyperlipidemia
454261|NCT00882336|Hypertension
454262|NCT00882336|Diabetes
454263|NCT00882336|Obesity
454264|NCT00882310|Pancreatic cancer
454265|NCT00882310|Gemzar
454266|NCT00882310|Taxotere
454267|NCT00882310|Xeloda
454268|NCT00882310|GTX
454269|NCT00882297|Ultrasoundography
454270|NCT00882297|catheterization
454271|NCT00882297|central venous subclavian vein methods
454272|NCT00882284|NICHD Neonatal Research Network
454273|NCT00882284|Blood Pressure Management
454274|NCT00882271|Fibromyalgia
454275|NCT00882271|Acupuncture
454276|NCT00882271|Pain
454277|NCT00882258|Uterine fibroids
454278|NCT00882232|prostate
454279|NCT00882232|cancer
454280|NCT00882232|cross-linked
454281|NCT00882232|hyaluronan
454282|NCT00882232|gel
454283|NCT00882232|Hylaform
454284|NCT00882232|rectal
454285|NCT00882232|toxicity
454286|NCT00882219|Drug eluting stent
454287|NCT00882219|Stents
454288|NCT00882219|Angioplasty
454289|NCT00882219|Chronic coronary occlusion
454290|NCT00882219|Stent thrombosis
454291|NCT00882219|Vascular disease
454292|NCT00882219|Myocardial ischemia
454293|NCT00882219|Coronary artery stenosis
454294|NCT00882219|Coronary Disease
454295|NCT00882219|Coronary Artery Disease
454296|NCT00882219|Coronary Restenosis
454297|NCT00882206|recurrent adult lymphoblastic lymphoma
454298|NCT00882206|recurrent childhood lymphoblastic lymphoma
454299|NCT00882206|recurrent adult acute lymphoblastic leukemia
454300|NCT00882206|recurrent childhood acute lymphoblastic leukemia
454301|NCT00882193|Chronic hepatitis C
454302|NCT00882193|Genotype 1
454303|NCT00882193|Nonresponder
454304|NCT00882193|Relapser
454305|NCT00882193|Betaine
454306|NCT00882193|Antiviral therapy
454307|NCT00882180|Liver
454308|NCT00882180|Solid Tumors
454309|NCT00882180|Advanced Solid Tumors with Liver Involvement
454310|NCT00882154|Antibiotic
454311|NCT00882141|Exercise
454312|NCT00882141|Obesity
454313|NCT00882141|Insulin Sensitivity
454314|NCT00882128|Asthma seasonal respiratory symptoms
454315|NCT00882128|Asthmatic patients with increase of respiratory symptoms
454316|NCT00882115|DEP
454317|NCT00882115|Broccoli Sprout Extract
454318|NCT00882115|Allergies
454319|NCT00882102|Acute Myelogenous Leukemia
454320|NCT00882102|High-Risk Myelodysplastic Syndrome
454321|NCT00882102|AML
454322|NCT00882102|MDS
454323|NCT00882102|Leukemia
454324|NCT00882102|Decitabine
454325|NCT00882102|Gemtuzumab Ozogamicin
454326|NCT00882102|Dacogen
454327|NCT00882102|Mylotarg
454328|NCT00882089|Contura
454329|NCT00882089|Cancer
454330|NCT00882089|Accelerated
454331|NCT00882089|Partial
454332|NCT00882089|Breast
454333|NCT00882089|Irradiation
454334|NCT00882076|acute lymphoblastic leukemia
454335|NCT00882076|chronic lymphocytic leukemia
454336|NCT00882063|Multiple Myeloma
454337|NCT00882037|Methamphetamine Dependence
454338|NCT00882037|Substance Abuse Treatment
454339|NCT00882037|Rural and Urban
454340|NCT00882037|Latino and Non-Latino
454341|NCT00882024|Rheumatoid arthritis
454342|NCT00882011|T-lymphoblastic lymphoma
454343|NCT00882011|Intensive chemo/radiotherapy
454344|NCT00882011|Intensive chemotherapy
454345|NCT00882011|Transplant
454346|NCT00882011|Adult patients
454347|NCT00881998|Evaluate early functional outcomes of two anterior approaches to total hip arthroplasty
454348|NCT00881985|obstructive sleep apnea
454349|NCT00881985|resistant hypertension
454350|NCT00881985|refractory hypertension
454351|NCT00881985|continuous positive airway pressure
454352|NCT00881985|blood pressure control
454353|NCT00881959|exposed Root Surface or Tooth
454354|NCT00881959|Tooth Sensitivity Miller Class I
454355|NCT00881959|Miller Class II
454356|NCT00881959|Gingival Margin
454357|NCT00881946|chronic lymphocytic leukemia
454358|NCT00881946|aggressive lymphoma
454359|NCT00881946|non-Hodgkin's lymphoma
454360|NCT00881946|Hodgkin's lymphoma
454361|NCT00881946|chronic myelogenous leukemia
454362|NCT00881946|multiple myeloma
454363|NCT00881946|acute lymphoblastic leukemia
454364|NCT00881946|acute myeloid leukemia
454365|NCT00881933|Fludarabine, Cyclophosphamide, TBI, severe aplastic anemia,
454366|NCT00881933|cord blood transplantation, pediatric
454367|NCT00881920|Lymphocytic
454368|NCT00881920|Leukemia
454369|NCT00881920|B Cell
454370|NCT00881920|Non-Hodgkin
454371|NCT00881920|Multiple Myeloma
454372|NCT00881920|Lymphoma
454373|NCT00881907|Regeneration (revascularization) of dental pulp
454374|NCT00881907|Immature Permanent Tooth With a Diagnosis of Pulpal Necrosis
454375|NCT00881894|Rotigotine
454376|NCT00881894|Neupro®
454377|NCT00881894|Transdermal Patch
454378|NCT00881855|Antibiotics
454379|NCT00881842|Influenza
454380|NCT00881842|Vaccine
454381|NCT00881842|CHMP criteria
454382|NCT00881829|Pulse Oximetry
454383|NCT00881829|Temperature
454384|NCT00881829|Respiratory Rate
454385|NCT00881829|Respiratory Gases
454386|NCT00881829|This study determine the measurement accuracy of the physiological parameters
454387|NCT00881816|Liposomal Paclitaxel
454388|NCT00881816|Capecitabine
454389|NCT00881816|Maximum tolerated dose
454390|NCT00881816|Dose limiting toxicity
454391|NCT00881803|Spinal Cord Injuries
454392|NCT00881803|Ascorbic Acid
454393|NCT00881803|Vitamin C
454394|NCT00881803|Iron
454395|NCT00881803|Dietary Supplements
454396|NCT00881777|Heart Failure
454397|NCT00881777|Cardiomyopathy
454398|NCT00881777|Ventricular Dysfunction
454399|NCT00881777|Heart Disease
454400|NCT00881764|Anesthesia
454401|NCT00881764|New York
454402|NCT00881764|Columbia
454403|NCT00881764|Children
454404|NCT00881764|Neurodevelopment
454405|NCT00881764|Child development
454406|NCT00881764|Pediatric
454407|NCT00881751|adult primary hepatocellular carcinoma
454408|NCT00881751|advanced adult primary liver cancer
454409|NCT00881751|recurrent adult primary liver cancer
454410|NCT00881738|Antibiotic
454411|NCT00881725|Metformin
454412|NCT00881725|Prostate Cancer
454413|NCT00881725|Radical Prostatectomy
454414|NCT00881725|Neoadjuvant Intervention
454415|NCT00881725|PTEN/AKT Pathway
454416|NCT00881725|Tumour Expression
454417|NCT00881725|Ki67 Expression
454418|NCT00881712|Non-small cell lung Cancer
454419|NCT00881712|Proton Radiation
454420|NCT00881712|Stage III
454421|NCT00881699|HIV Information
454422|NCT00881699|HIV Prevention
454423|NCT00881699|Severe Mental Illness
454424|NCT00881699|HIV seronegativity
454425|NCT00881686|Ischemic Preconditioning, Myocardial
454426|NCT00881686|Adenosine
454427|NCT00881673|Conjunctivitis
454428|NCT00881660|Fetal Tracheal Occlusion
454429|NCT00881660|congenital diaphragmatic hernia
454430|NCT00881660|FETO plug-unplug
454431|NCT00881660|Goldvalve balloon
454432|NCT00881660|Severe Congenital Diaphragmatic Hernia
454433|NCT00881660|Extremely Severe Congenital Diaphragmatic Hernia
454434|NCT00881647|PTSD
454435|NCT00881647|Insomnia Disorder
454436|NCT00881647|Insomnia
454437|NCT00881647|CBT
454438|NCT00881621|Pancreas cancer
454439|NCT00881621|lapatinib
454440|NCT00881621|capecitabine
454441|NCT00881608|Menstruation
454442|NCT00881595|Sarcomas
454443|NCT00881595|High-Risk Soft Tissue Sarcomas
454444|NCT00881582|Hepatitis c
454445|NCT00881582|Renal transplantation
454446|NCT00881582|Pegylated interferon
454447|NCT00881556|Allogeneic Stem Cell Transplant
454448|NCT00881556|AlloSCT
454449|NCT00881556|RDEB
454450|NCT00881556|recessive dystrophic epidermolysis bullosa
454451|NCT00881543|Sitagliptin
454452|NCT00881543|Diets
454453|NCT00881543|Diabetes type 2
454454|NCT00881543|Näive patients
454455|NCT00881517|human cytomegalovirus
454456|NCT00881517|immune globulin
454457|NCT00881517|congenital infection
454458|NCT00881517|prevention
454459|NCT00881517|pregnancy
454460|NCT00881504|Biliary
454461|NCT00881504|Oxaliplatin
454462|NCT00881504|Bevacizumab
454463|NCT00881491|Regeneration (revascularization) of dental pulp
454464|NCT00881491|Immature permanent tooth with a diagnosis of
454465|NCT00881478|Obesity
454466|NCT00881478|Children
454467|NCT00881478|Dyslipidemia
454468|NCT00881478|Hypertension
454469|NCT00881465|Obsessive compulsive disorder
454470|NCT00881452|Autism
454471|NCT00881439|Heart failure
454472|NCT00881439|Renal Failure
454473|NCT00881439|Cardiorenal Syndrome
454474|NCT00881439|Renin inhibition
454475|NCT00881439|Aliskiren
454476|NCT00881426|Antibiotic
454477|NCT00881413|Peptic ulcer bleeding
454478|NCT00881413|Proton pump inhibitor
454479|NCT00881413|Esomeprazole
454480|NCT00881413|Pantoprazole
454481|NCT00881413|Recurrent bleeding
454482|NCT00881413|bleeding
454483|NCT00881400|Antibiotic
454484|NCT00881387|recurrent adult Hodgkin lymphoma
454485|NCT00881387|adult lymphocyte depletion Hodgkin lymphoma
454486|NCT00881387|adult lymphocyte predominant Hodgkin lymphoma
454487|NCT00881387|adult mixed cellularity Hodgkin lymphoma
454488|NCT00881387|adult nodular sclerosis Hodgkin lymphoma
454489|NCT00881361|stage II breast cancer
454490|NCT00881361|stage IIIA breast cancer
454491|NCT00881361|stage IIIB breast cancer
454492|NCT00881335|geriatric
454493|NCT00881335|pulmonary disease
454494|NCT00881335|flutter
454495|NCT00881335|sputum
454496|NCT00881335|physical therapy techniques
454497|NCT00881296|Elder Patients
454498|NCT00881296|Non-Small Cell Lung Cancer
454499|NCT00881296|Previously Untreated
454500|NCT00881296|Advanced
454501|NCT00881283|Cushing's disease
454502|NCT00881257|Peripheral Vascular Disease
454503|NCT00881257|Peripheral Artery Disease
454504|NCT00881257|Radiofrequency
454505|NCT00881218|myocardial ischemia, perfusion imaging, cardiac MRI
454506|NCT00881205|Multiple Sclerosis
454507|NCT00881205|Cognition
454508|NCT00881205|Rivastigmine
454509|NCT00881205|Patch
454510|NCT00881192|CABG
454511|NCT00881192|coronary surgery
454512|NCT00881192|intra-aortic balloon pump
454513|NCT00881192|CABG operation
454514|NCT00881179|Antibiotic
454515|NCT00881166|MP-470
454516|NCT00881166|Multi-targeted Tyrosine Kinase Inhibitor
454517|NCT00881166|Malignant disease
454518|NCT00881153|Antibiotic
454519|NCT00881140|oral mifepristone
454520|NCT00881140|vaginal tablets
454521|NCT00881114|Head and neck cancer
454522|NCT00881114|pharmacogenetics
454523|NCT00881114|chemoradiotherapy
454524|NCT00881101|Liposomal Paclitaxel
454525|NCT00881101|Maximum tolerated dose
454526|NCT00881101|Dose limiting toxicity
454527|NCT00881088|Deep vein trombosis
454528|NCT00881088|Profylaxis
454529|NCT00881088|Below knee plaster cast
454530|NCT00881088|Ankle fracture
454531|NCT00881075|Magnetic resonance imaging
454532|NCT00881075|Heart diseases
454533|NCT00881075|myocardial infarction
454534|NCT00881075|contrast agents
454535|NCT00881075|manganese
454536|NCT00881062|ABSORPTION
454537|NCT00881062|METABOLISM
454538|NCT00881062|EXCRETION
454539|NCT00881049|metastatic acral or mucosal melanoma with c-kit mutation or copy number increase
454540|NCT00881036|Hepatitis B
454541|NCT00881010|Breast Cancer
454542|NCT00881010|Pain Intervention
454543|NCT00881010|Underserved minority patients
454544|NCT00881010|African American
454545|NCT00881010|Hispanic
454546|NCT00881010|Automated Telephone System for measuring symptoms
454547|NCT00881010|Interactive voice response
454548|NCT00881010|IVR
454549|NCT00880997|Cocaine Dependence
454550|NCT00880997|Substance Related Disorders
454551|NCT00880984|Colon Anastomosis
454552|NCT00880984|Rectum Anastomosis
454553|NCT00880984|Intestine
454554|NCT00880984|Colorectal Surgery
454555|NCT00880984|Colorectal Anastomosis
454556|NCT00880971|Lung
454557|NCT00880971|Carcinoma
454558|NCT00880971|radiotherapy
454559|NCT00880971|Surgery
454560|NCT00880945|FBS
454561|NCT00880945|coin lesions
454562|NCT00880945|ENB
454563|NCT00880945|ROSE
454564|NCT00880932|warfarin
454565|NCT00880932|NSAID
454566|NCT00880932|The condition is the concomitant prescription of
454567|NCT00880919|Borderline Personality Disorder
454568|NCT00880919|BPD
454569|NCT00880919|Seroquel
454570|NCT00880919|Seroquel XR
454571|NCT00880919|quetiapine
454572|NCT00880919|quetiapine extended-release
454573|NCT00880906|eosinophilic esophagitis
454574|NCT00880906|esophageal food impaction
454575|NCT00880906|dysphagia
454576|NCT00880893|Dengue virus
454577|NCT00880893|Dengue fever
454578|NCT00880893|Dengue hemorrhagic fever
454579|NCT00880893|Dengue diseases
454580|NCT00880893|Sanofi Pasteur's CYD Dengue Vaccine
454581|NCT00880880|urinary incontinence
454582|NCT00880880|fecal incontinence
454583|NCT00880880|communication
454584|NCT00880867|Low Grade Recurrent B and T Cell Lymphoma
454585|NCT00880854|bladder cancer
454586|NCT00880854|BCG-resistant localized transitional cell of the bladder
454587|NCT00880841|healthy normals, phase 1
454588|NCT00880841|phase 1a study for healthy normals
454589|NCT00880828|Cervical Radiculopathy
454590|NCT00880828|Radicular Pain
454591|NCT00880828|Acute neck pain
454592|NCT00880828|Cervicobrachial pain
454593|NCT00880828|Far-infrared ray
454594|NCT00880828|FIR
454595|NCT00880828|Cervical collar
454596|NCT00880828|Cervical device
454597|NCT00880828|FIR Device
454598|NCT00880815|Leukemia
454599|NCT00880815|Lymphoma
454600|NCT00880815|Lymphoid Malignancies
454601|NCT00880815|Non-myeloablative Allogeneic Conditioning
454602|NCT00880815|Non-myeloablative Allogeneic Hematopoietic Transplantation
454603|NCT00880815|Stem Cell Transplant
454604|NCT00880815|SCT
454605|NCT00880815|Bendamustine HCI
454606|NCT00880815|Bendamustine
454607|NCT00880815|Bendamustine Hydrochloride
454608|NCT00880815|CEP-18083
454609|NCT00880815|SDX-105
454610|NCT00880815|Treanda
454611|NCT00880815|Fludarabine
454612|NCT00880815|Fludarabine Phosphate
454613|NCT00880815|Fludara
454614|NCT00880815|Rituximab
454615|NCT00880815|Rituxan
454616|NCT00880815|FBR
454617|NCT00880815|Graft-versus-host disease
454618|NCT00880815|GVHD
454619|NCT00880802|Acute Coronary Syndromes
454620|NCT00880802|Non ST-Segment Elevation Myocardial Infarction
454621|NCT00880802|ST-Segment Elevation Myocardial Infarction
454622|NCT00880802|Unstable Angina
454623|NCT00880789|Cord Blood Transplant
454624|NCT00880789|cytomegalovirus
454625|NCT00880789|CMV
454626|NCT00880789|Adenovirus
454627|NCT00880789|ADV
454628|NCT00880750|End stage Renal disease
454629|NCT00880724|COPD
454630|NCT00880724|Emphysema
454631|NCT00880724|Bronchoscopic Treatment
454632|NCT00880724|Interventional Bronchoscopy
454633|NCT00880711|Fiona
454634|NCT00880711|Faslodex
454635|NCT00880711|Advanced Breast Cancer
454636|NCT00880711|Real life data
454637|NCT00880711|Collect real life data in clinical practice across Austria
454638|NCT00880698|Rotavirus
454639|NCT00880698|Rotavirus vaccine
454640|NCT00880685|Compulsive Stealing
454641|NCT00880685|Compulsive Shoplifting
454642|NCT00880672|prostate, dutasteride
454643|NCT00880672|vascular endothelial growth factor
454644|NCT00880672|hypoxia inducible factor
454645|NCT00880659|Influenza
454646|NCT00880659|secondary transmission
454647|NCT00880659|handwashing
454648|NCT00880633|EUS
454649|NCT00880633|periampullary neoplasms
454650|NCT00880620|Parkinson's disease
454651|NCT00880607|Pain
454652|NCT00880607|Pediatric
454653|NCT00880607|Spinal Fusion
454654|NCT00880607|pain management
454655|NCT00880555|Magnetic Resonance Imaging
454656|NCT00880555|Alzheimer disease
454657|NCT00880555|Mild cognitive impairment
454658|NCT00880555|Continuous arterial spin labeling
454659|NCT00880555|Semantic memory
454660|NCT00880542|localized osteosarcoma
454661|NCT00880542|stage II adult soft tissue sarcoma
454662|NCT00880542|stage III adult soft tissue sarcoma
454663|NCT00880529|rib fractures
454664|NCT00880529|ventilator
454665|NCT00880529|ON-Q
454666|NCT00880529|analgesia
454667|NCT00880503|Multidrug Resistance Molecular Target Analysis
454668|NCT00880490|COPD
454669|NCT00880464|autologous vaccination
454670|NCT00880464|GM-CSF
454671|NCT00880464|adenoviral mediated gene transfer
454672|NCT00880464|Stage IV breast cancer
454673|NCT00880451|Children and Adolescents
454674|NCT00880451|Aging
454675|NCT00880451|Brain Imaging
454676|NCT00880451|MRI (Magnetic Resonance Imaging)
454677|NCT00880412|safety
454678|NCT00880412|efficacy
454679|NCT00880412|Alzheimer's disease
454680|NCT00880412|treatment
454681|NCT00880412|phase II
454682|NCT00880412|study
454683|NCT00880412|cholinesterase inhibitor
454684|NCT00880399|depression
454685|NCT00880399|QIDS-SR
454686|NCT00880399|HAMD-17
454687|NCT00880399|orvepitant
454688|NCT00880399|MDD
454689|NCT00880399|neurokinin-1 antagonist
454690|NCT00880399|double-blind
454691|NCT00880399|Phase II
454692|NCT00880399|randomized
454693|NCT00880399|efficacy
454694|NCT00880399|placebo
454695|NCT00880399|safety
454696|NCT00880386|dyspnea
454697|NCT00880386|stage I non-small cell lung cancer
454698|NCT00880386|stage II non-small cell lung cancer
454699|NCT00880386|stage IIIA non-small cell lung cancer
454700|NCT00880386|stage IIIB non-small cell lung cancer
454701|NCT00880386|pulmonary complications
454702|NCT00880386|radiation fibrosis
454703|NCT00880373|Sickle Cell Disease
454704|NCT00880373|Pain
454705|NCT00880373|Ibuprofen
454706|NCT00880373|Morphine
454707|NCT00880373|Diamorphine
454708|NCT00880373|Patient Controlled Analgesia
454709|NCT00880360|Epithelial Ovarian Cancer
454710|NCT00880360|FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV
454711|NCT00880360|Extraovarian Peritoneal Cancer
454712|NCT00880360|Fallopian Tube Carcinoma Failing
454713|NCT00880347|Alzheimer's disease
454714|NCT00880347|Other dementia
454715|NCT00880347|Vascular dementia
454716|NCT00880347|Mixed dementia
454717|NCT00880347|Parkinson's Disease dementia
454718|NCT00880347|Lewy bodies dementia
454719|NCT00880347|Frontotemporal dementia
454720|NCT00880347|Blood signature
454721|NCT00880347|Diagnosis
454722|NCT00880347|SpliceArray (tm)
454723|NCT00880347|Alzheimer's Disease and other non-AD dementia
454724|NCT00880334|TCC
454725|NCT00880334|Zactima
454726|NCT00880334|docetaxel
454727|NCT00880334|ZD6474
454728|NCT00880334|taxotere
454729|NCT00880321|first time in human
454730|NCT00880321|BRAF inhibitor
454731|NCT00880321|dose escalation
454732|NCT00880308|Advanced tumors
454733|NCT00880308|hedgehog
454734|NCT00880308|smoothened inhibitor
454735|NCT00880269|Acute myeloid leukemia
454736|NCT00880269|AML
454737|NCT00880269|relapsed acute myeloid leukemia
454738|NCT00880269|refractory AML
454739|NCT00880269|refractory de novo AML
454740|NCT00880269|refractory secondary AML
454741|NCT00880269|secondary AML
454742|NCT00880269|AML following myelodysplastic syndrome (MDS)
454743|NCT00880269|AML following antecedent hematological disorder (AHD)
454744|NCT00880269|AML resistant to therapy
454745|NCT00880256|irritable bowel
454746|NCT00880256|mindfulness
454747|NCT00880256|stress
454748|NCT00880256|meditation
454749|NCT00880243|Acute myeloid leukemia
454750|NCT00880243|Priming
454751|NCT00880243|GM-CSF
454752|NCT00880243|Timed-sequential chemotherapy
454753|NCT00880243|Prognosis
454754|NCT00880230|Iliac Artery Stenting
454755|NCT00880230|Peripheral Artery Disease
454756|NCT00880217|Attention Deficit Hyperactivity Disorder
454757|NCT00880217|Attention Deficit Disorders with Hyperactivity
454758|NCT00880217|Adult ADHD
454759|NCT00880217|JNJ-31001074
454760|NCT00880204|Cluster Randomized Trial
454761|NCT00880204|ESS-EMCH
454762|NCT00880204|Neonatal
454763|NCT00880204|Maternal
454764|NCT00880204|Life threatening emergency event
454765|NCT00880191|nausea and vomiting
454766|NCT00880191|unspecified adult solid tumor, protocol specific
454767|NCT00880178|Simvastatin
454768|NCT00880178|Niacin
454769|NCT00880178|Vascular Disease
454770|NCT00880178|Magnetic Resonance Imaging
454771|NCT00880178|High Density Lipoprotein
454772|NCT00880178|Oxidation
454773|NCT00880178|Proteomics
454774|NCT00880178|Stroke
454775|NCT00880178|Cerebrovascular Accident
454776|NCT00880165|Polysomnogram
454777|NCT00880165|Continuous positive airway pressure
454778|NCT00880152|stress
454779|NCT00880152|mindfulness
454780|NCT00880152|trauma
454781|NCT00880139|Diabetes mellitus, type 1
454782|NCT00880139|Inflammation
454783|NCT00880139|Cytokines
454784|NCT00880139|Vascular reactivity
454785|NCT00880126|Individualized Implementation
454786|NCT00880126|Community Development Teams
454787|NCT00880113|CT-perfusion
454788|NCT00880113|CT-angiography
454789|NCT00880100|Steatorrhea
454790|NCT00880100|Malabsorption of fat
454791|NCT00880100|Pancreatic enzymes
454792|NCT00880100|Abdominal pain
454793|NCT00880100|Greasy stools
454794|NCT00880087|Cardiac Arrest
454795|NCT00880087|Cardiopulmonary Arrest
454796|NCT00880087|Pediatric Cardiac Arrest
454797|NCT00880087|VABS
454798|NCT00880087|Vineland Adaptive Behavior Scale
454799|NCT00880087|POPC/PCPC
454800|NCT00880087|hypoxic-ischemic encephalopathy
454801|NCT00880074|Advanced Cancers
454802|NCT00880074|FLT-PET
454803|NCT00880074|Positron Emission Tomography
454804|NCT00880074|PET
454805|NCT00880074|[18F] fluorothymidine
454806|NCT00880074|[F-18]-fluoro-L-thymidine
454807|NCT00880074|FLT
454808|NCT00880061|Diffuse Infiltrating Pontine Glioma
454809|NCT00880061|Supratentorial High Grade Glioma
454810|NCT00880061|Convection-Enhanced Delivery
454811|NCT00880061|Pediatric Brain Tumor
454812|NCT00880061|Brain Tumor
454813|NCT00880061|Glioma
454814|NCT00880048|depression
454815|NCT00880048|safety
454816|NCT00880048|HAMD
454817|NCT00880048|QIDS-SR
454818|NCT00880048|NK-1 antagonist
454819|NCT00880048|efficacy
454820|NCT00880048|orvepitant
454821|NCT00880048|placebo
454822|NCT00880048|MDD
454823|NCT00880048|video-rating
454824|NCT00880035|sedative drug
454825|NCT00880035|stress
454826|NCT00880035|music
454827|NCT00880035|mechanical ventilation
454828|NCT00880035|IL-6
454829|NCT00880035|cortisol
454830|NCT00880035|prolactin
454831|NCT00880035|CRP
454832|NCT00880035|copeptin
454833|NCT00880022|compression
454834|NCT00880022|Flexitouch
454835|NCT00880022|breast cancer
454836|NCT00880022|lymphedema
454837|NCT00879996|Opiate Addiction
454838|NCT00879996|Narcotic Addiction
454839|NCT00879996|Drug Addiction
454840|NCT00879996|Pain
454841|NCT00879983|azithromycin, pharmacokinetics
454842|NCT00879970|Cardiovascular Outcomes
454843|NCT00879957|Infant, Premature
454844|NCT00879957|Infant
454845|NCT00879957|Central venous catheterization
454846|NCT00879957|Anticoagulants
454847|NCT00879944|Psoriasis
454848|NCT00879944|Obesity
454849|NCT00879944|BMI
454850|NCT00879944|Atopic Dermatitis
454851|NCT00879918|Cigarette Smoking in African Americans
454852|NCT00879905|Phase I
454853|NCT00879905|Adults
454854|NCT00879905|HSP990
454855|NCT00879905|Advanced Solid Tumors
454856|NCT00879905|Hsp90 inhibitor
454857|NCT00879905|Cancer
454858|NCT00879892|xenon
454859|NCT00879892|hypothermia
454860|NCT00879892|out-of-hospital cardiac arrest
454861|NCT00879879|precancerous condition
454862|NCT00879866|NSCLC
454863|NCT00879866|immunocytokine
454864|NCT00879866|radiation
454865|NCT00879866|interleukin-2
454866|NCT00879866|immunotherapy
454867|NCT00879866|maintenance therapy
454868|NCT00879853|PTSD
454869|NCT00879853|Depression
454870|NCT00879853|Anger
454871|NCT00879853|Domestic Violence
454872|NCT00879853|Refugee
454873|NCT00879853|Asylum Seeker
454874|NCT00879853|Community Therapist
454875|NCT00879853|Paraprofessional Therapists
454876|NCT00879840|Screening
454877|NCT00879840|Modalities
454878|NCT00879840|Gynecological Cancers
454879|NCT00879801|prevention of diabetes
454880|NCT00879801|susceptibility genes
454881|NCT00879801|type 2 diabetes
454882|NCT00879801|insulin resistance
454883|NCT00879801|beta-cell funtion
454884|NCT00879788|Ramipril fed condition
454885|NCT00879775|Pain
454886|NCT00879775|Cancer patients
454887|NCT00879775|Caffeine
454888|NCT00879775|Adjuvant analgesics
454889|NCT00879775|Sedation
454890|NCT00879775|Confusion
454891|NCT00879775|Quality of life
454892|NCT00879775|Fatigue
454893|NCT00879762|smallpox, vaccine, IMVAMUNE®
454894|NCT00879736|Doctor-patient communication
454895|NCT00879736|Encounters
454896|NCT00879736|Patient education training
454897|NCT00879723|post-burn recovery
454898|NCT00879723|oxidative stress
454899|NCT00879723|micronutrient protocol
454900|NCT00879710|Diabetes Mellitus
454901|NCT00879710|Hypercholesterolemia
454902|NCT00879710|Simvastatin
454903|NCT00879710|Ezetimibe.
454904|NCT00879697|peripheral arterial disease
454905|NCT00879697|exercise
454906|NCT00879697|resistance training
454907|NCT00879697|cardiac rehabilitation
454908|NCT00879684|Phase 1
454909|NCT00879684|Tumors
454910|NCT00879684|CVX-060
454911|NCT00879671|lutein
454912|NCT00879671|nonexudative AMD
454913|NCT00879671|MPOD
454914|NCT00879671|Supplementary Concepts
454915|NCT00879658|Multiple Sclerosis
454916|NCT00879658|Relapsing-Remitting
454917|NCT00879658|Demyelinating Autoimmune Diseases
454918|NCT00879645|Renal Impairment
454919|NCT00879645|Renal Disease
454920|NCT00879645|Sodium Sulfide
454921|NCT00879606|Sepsis
454922|NCT00879606|Acute Lung Injury
454923|NCT00879606|Acute Respiratory Distress Syndrome
454924|NCT00879606|ALI/ARDS
454925|NCT00879606|Lung Disease
454926|NCT00879580|aneurysm
454927|NCT00879580|stent
454928|NCT00879580|intracranial aneurysm
454929|NCT00879580|Ruptured Intracranial Aneurysm
454930|NCT00879554|Phase 1
454931|NCT00879554|Solid Tumors
454932|NCT00879554|CVX-045
454933|NCT00879541|Hemophilia A
454934|NCT00879528|Hodgkin's Lymphoma
454935|NCT00879528|stem cell reinfusion
454936|NCT00879515|Fragile X Premutation
454937|NCT00879515|Fragile X Syndrome
454938|NCT00879515|Down Syndrome
454939|NCT00879502|Fragile X Premutation
454940|NCT00879502|FMR1
454941|NCT00879502|Premutation
454942|NCT00879502|Fragile X
454943|NCT00879502|Brain Function
454944|NCT00879489|Stage IV histologically proven breast cancer
454945|NCT00879476|Bioequivalence ramipril fasting condition
454946|NCT00879463|Blood transfusion in cardiac operations under CPB
454947|NCT00879463|Infrared spectrophotoscopy
454948|NCT00879450|Congenital muscular torticollis
454949|NCT00879437|brain tumor
454950|NCT00879437|bevacizumab
454951|NCT00879437|valproic acid
454952|NCT00879437|radiation therapy
454953|NCT00879424|vitamin D
454954|NCT00879424|atopic dermatitis
454955|NCT00879424|eczema
454956|NCT00879424|winter
454957|NCT00879385|KRAS wild-type
454958|NCT00879385|Colon
454959|NCT00879385|Cancer
454960|NCT00879385|colorectal
454961|NCT00879385|metastatic colorectal
454962|NCT00879385|advanced colorectal
454963|NCT00879372|Bipolar Disorder
454964|NCT00879372|cognitive impairment
454965|NCT00879372|depression
454966|NCT00879346|Healthy Volunteers
454967|NCT00879346|ADME
454968|NCT00879346|Healthy male volunteers
454969|NCT00879333|Gastric cancer,
454970|NCT00879333|advanced gastric cancer,
454971|NCT00879333|stomach neoplasm,
454972|NCT00879333|stomach disease,
454973|NCT00879333|adenocarcinoma of stomach,
454974|NCT00879333|GI neoplasm
454975|NCT00879320|ADHD
454976|NCT00879320|health
454977|NCT00879320|healthy lifestyle
454978|NCT00879294|Perforated appendicitis
454979|NCT00879294|Ruptured appendicitis
454980|NCT00879294|Acute appendicitis with perforation
454981|NCT00879281|COPD
454982|NCT00879281|emphysema
454983|NCT00879281|chronic bronchitis
454984|NCT00879268|Liver Transplantation
454985|NCT00879268|Organ Preservation
454986|NCT00879268|Liver Preservation
454987|NCT00879268|Machine Perfusion
454988|NCT00879268|Vasosol
454989|NCT00879268|Machine Preservation
454990|NCT00879255|cognitive processing therapy
454991|NCT00879255|combat
454992|NCT00879255|veterans
454993|NCT00879255|PTSD
454994|NCT00879255|Telemental Health
454995|NCT00879255|Videoteleconference
454996|NCT00879255|outcome
454997|NCT00879255|Rural
454998|NCT00879255|Remote
454999|NCT00879255|CPT
455000|NCT00879255|VTC
455001|NCT00879242|Thalassemia
455002|NCT00879242|cardiac MRI T2*
455003|NCT00879229|Idiopathic Pulmonary Fibrosis
455004|NCT00879229|Pulmonary Hypertension
455005|NCT00879229|PH
455006|NCT00879229|IPF
455007|NCT00879229|Ambrisentan
455008|NCT00879229|ERA
455009|NCT00879229|Endothelin Receptor Antagonist
455010|NCT00879229|Cardiovascular
455011|NCT00879216|Nocturia
455012|NCT00879216|Hyptotension
455013|NCT00879216|Elderly
455014|NCT00879216|Males
455015|NCT00879203|Type 1 Diabetes Mellitis
455016|NCT00879203|Youth
455017|NCT00879203|Hypoglycemia
455018|NCT00879203|Hyperglycemia
455019|NCT00879203|Cognition
455020|NCT00879203|Memory
455021|NCT00879203|Brain Growth & Development
455022|NCT00879203|Magnetic Resonance Imaging
455023|NCT00879177|smoking
455024|NCT00879177|varenicline
455025|NCT00879177|behavioral therapy
455026|NCT00879177|ABPM
455027|NCT00879177|hypertension
455028|NCT00879164|hot flashes
455029|NCT00879125|Gastric by-pass on patients with T2DM
455030|NCT00879112|Hyperlipidemia
455031|NCT00879099|Interaction
455032|NCT00879099|healthy volunteers
455033|NCT00879099|Interaction study for healthy volunteers
455034|NCT00879086|Breast Cancer
455035|NCT00879086|Oncology
455036|NCT00879073|Brain and Nervous System
455037|NCT00879060|Fibrosis
455038|NCT00879060|Hypertrophic cardiomyopathy
455039|NCT00879060|MRI
455040|NCT00879060|To evaluate the efficacy of spironolactone in decreasing myocardial fibrosis in Hypertrophic cardiomyopathy
455041|NCT00879047|HIV
455042|NCT00879047|Hepatitis C
455043|NCT00879021|The outcome is to prevent Central Neuropathic Pain
455044|NCT00879021|participants will have suffered spinal cord trauma
455045|NCT00879008|Disease Exacerbation
455046|NCT00879008|Acute Exacerbations of Chronic Bronchitis
455047|NCT00879008|AECB
455048|NCT00879008|Avelox
455049|NCT00879008|Bronchitis
455050|NCT00878995|stage IIB cervical cancer
455051|NCT00878995|stage III cervical cancer
455052|NCT00878995|recurrent cervical cancer
455053|NCT00878995|cachexia
455054|NCT00878995|advanced head/neck carcinoma
455055|NCT00878995|recurrent head/neck carcinoma
455056|NCT00878969|Hemodialysis
455057|NCT00878969|fibrinolysis
455058|NCT00878969|oxidative stress
455059|NCT00878969|systemic inflammatory reaction
455060|NCT00878969|endothelial dysfunction
455061|NCT00878969|carotid intima media thickness (IMT
455062|NCT00878969|angiotensin receptor blockade
455063|NCT00878969|angiotensin converting enzyme inhibition
455064|NCT00878956|Cardiac surgery
455065|NCT00878956|Cardiopulmonary bypass
455066|NCT00878956|Oxidative stress
455067|NCT00878956|Acute renal dysfunction
455068|NCT00878956|Sodium bicarbonate
455069|NCT00878943|Open label access
455070|NCT00878943|sildenafil
455071|NCT00878943|pulmonary arterial hypertension
455072|NCT00878930|Breast cancer
455073|NCT00878930|Fulvestrant
455074|NCT00878930|Faslodex
455075|NCT00878930|Acceptability
455076|NCT00878930|Compliance
455077|NCT00878930|Efficacy
455078|NCT00878917|Equivalence Study
455079|NCT00878917|Eye Drops Solution
455080|NCT00878917|Dorzolamide
455081|NCT00878917|Open Angle Glaucoma
455082|NCT00878917|Ocular Hypertension
455083|NCT00878904|unspecified adult solid tumor, protocol specific
455084|NCT00878891|Microdialysis
455085|NCT00878891|realtime
455086|NCT00878891|glucose sensor
455087|NCT00878891|coronary artery bypass
455088|NCT00878878|Pulmonary artery systolic pressure (PASP)
455089|NCT00878878|Pulmonary Vascular Resistance (PVR)
455090|NCT00878878|Right Heart Catheterization
455091|NCT00878878|Pulmonary hemodynamics
455092|NCT00878865|Alprazolam
455093|NCT00878865|bioequivalence
455094|NCT00878839|Cataract
455095|NCT00878839|Toric IOL
455096|NCT00878839|Corneal Aberration
455097|NCT00878839|Astigmatism
455098|NCT00878839|AcrySof
455099|NCT00878813|Copeptin
455100|NCT00878813|Vasopressin
455101|NCT00878813|Stroke
455102|NCT00878813|Transient ischemic attack
455103|NCT00878813|Thrombolytic therapy
455104|NCT00878813|Prognosis
455105|NCT00878813|Complications
455106|NCT00878800|Phase I/II trial
455107|NCT00878800|Solid tumors
455108|NCT00878800|Soft tissue sarcoma
455109|NCT00878800|PXD101
455110|NCT00878800|Doxorubicin
455111|NCT00878774|Ragweed allergy
455112|NCT00878774|Immunotherapy
455113|NCT00878774|Rhinoconjunctivitis
455114|NCT00878774|Toleromune Ragweed
455115|NCT00878761|Renal transplant
455116|NCT00878761|Interstitial fibrosis and tubular atrophy
455117|NCT00878761|Chronic allograft dysfunction
455118|NCT00878761|Chronic allograft nephropathy
455119|NCT00878761|kidney transplant
455120|NCT00878735|Meditation
455121|NCT00878735|Mindfulness
455122|NCT00878735|fMRI
455123|NCT00878735|cancer
455124|NCT00878735|stress
455125|NCT00878735|anxiety
455126|NCT00878735|depression
455127|NCT00878735|attention
455128|NCT00878735|Neuroscience
455129|NCT00878735|Neuroimaging
455130|NCT00878735|Psychobiology
455131|NCT00878735|Healthy volunteers (regular meditators and non-meditators)
455132|NCT00878722|Acute Myeloid Leukemia
455133|NCT00878722|PXD101
455134|NCT00878722|Belinostat
455135|NCT00878722|Idarubicin
455136|NCT00878709|HER-2/erbB-2 positive breast cancer
455137|NCT00878709|breast cancer
455138|NCT00878709|adjuvant therapy
455139|NCT00878709|neratinib
455140|NCT00878709|HKI-272
455141|NCT00878657|adenocarcinoma of the pancreas
455142|NCT00878657|stage III pancreatic cancer
455143|NCT00878644|Cardiac Arrest
455144|NCT00878644|Cardiopulmonary Arrest
455145|NCT00878644|Pediatric Cardiac Arrest
455146|NCT00878644|VABS
455147|NCT00878644|Vineland Adaptive Behavior Survey
455148|NCT00878644|POPC/PCPC
455149|NCT00878644|hypoxic-ichemic encephalopathy
455150|NCT00878631|emergency medical services
455151|NCT00878631|traumatic brain injury
455152|NCT00878631|hypertonic saline with dextran
455153|NCT00878631|fluid resuscitation
455154|NCT00878618|Healthy volunteers
455155|NCT00878605|Diabetes
455156|NCT00878605|Cyclo-Z
455157|NCT00878592|Post liver transplant
455158|NCT00878592|weight reduction classes
455159|NCT00878592|obesity
455160|NCT00878592|weight management
455161|NCT00878592|dietary and lifestyle modification
455162|NCT00878579|back pain
455163|NCT00878579|Spine
455164|NCT00878579|Spinal
455165|NCT00878579|Lower back pain
455166|NCT00878579|Lumbar
455167|NCT00878579|Lumbar Pain
455168|NCT00878579|DDD
455169|NCT00878579|Degenerative Disc Disease
455170|NCT00878566|hypertension
455171|NCT00878566|pharmacists
455172|NCT00878566|rural health
455173|NCT00878566|prescribing
455174|NCT00878553|insomnia
455175|NCT00878553|middle of the night
455176|NCT00878553|sleep maintenance
455177|NCT00878540|mirtazapine
455178|NCT00878540|metabolism
455179|NCT00878540|depression
455180|NCT00878540|Healthy males
455181|NCT00878527|Heart Failure
455182|NCT00878527|Partial Circulatory Assist
455183|NCT00878527|NYHA Class IIIb
455184|NCT00878527|NYHA Class IV
455185|NCT00878527|Ventricular Assist Device
455186|NCT00878527|VAD
455187|NCT00878514|Alprazolam
455188|NCT00878514|Bioequivalence
455189|NCT00878501|Phase II
455190|NCT00878501|Pain
455191|NCT00878475|Quantitative Capnometry
455192|NCT00878475|N-Terminal Pro-Brain Natriuretic Peptide
455193|NCT00878475|Acute Heart Failure
455194|NCT00878475|Diagnostic Accuracy
455195|NCT00878436|histone deacetylase inhibitor
455196|NCT00878436|hormone therapy
455197|NCT00878436|androgen-independent
455198|NCT00878436|PSA
455199|NCT00878436|androgen receptor
455200|NCT00878423|HSP90
455201|NCT00878423|Metastatic solid tumor including lymphoma which are
455202|NCT00878423|refractory to standard therapy
455203|NCT00878397|malaria
455204|NCT00878397|long lasting insecticide nets
455205|NCT00878397|anaemia
455206|NCT00878397|schools
455207|NCT00878384|Atrial Fibrillation
455208|NCT00878384|Heart Failure
455209|NCT00878384|Heart Rate Control
455210|NCT00878384|Catheter Ablation
455211|NCT00878371|morphine
455212|NCT00878371|blood brain barrier
455213|NCT00878371|surgery induced peripheral inflammatory response
455214|NCT00878358|Osteoarthritis
455215|NCT00878358|Total knee replacement
455216|NCT00878345|Pediatric sedation
455217|NCT00878345|Pentobarbital
455218|NCT00878345|Dexmedetomidine
455219|NCT00878345|Procedural sedation in children
455220|NCT00878332|edentulous
455221|NCT00878332|fixed dental rehabilitation
455222|NCT00878332|insufficient bone height
455223|NCT00878332|Partially edentulous patients
455353|NCT00877838|Serotonin
455224|NCT00878332|Patients interested in fixed non removable dental rehabilitation by dental implants.
455225|NCT00878332|The recipient bone with insufficient bone height for dental implant insertion.
455226|NCT00878332|Adult patients
455227|NCT00878319|Humeral
455228|NCT00878319|diaphyseal (mid-shaft)
455229|NCT00878319|fracture
455230|NCT00878319|operative
455231|NCT00878319|non-operative
455232|NCT00878306|Treatment of drug dependency with HIV medications
455233|NCT00878306|HIV
455234|NCT00878293|analgesic
455235|NCT00878293|diabetes mellitus
455236|NCT00878293|chronic neuropathic pain
455237|NCT00878293|painful polyneuropathy caused by diabetes mellitus type I or II
455238|NCT00878267|Cancer
455239|NCT00878267|Computer Program
455240|NCT00878267|Palliative Care
455241|NCT00878267|Patient-Reported Outcomes
455242|NCT00878267|PRO
455243|NCT00878267|Palliative and Hospice Care Practice
455244|NCT00878267|Electronic Health Record
455245|NCT00878267|EHR
455246|NCT00878267|Interview
455247|NCT00878254|Mantle Cell Lymphoma
455248|NCT00878254|Non-Hodgkin's Lymphoma
455249|NCT00878254|MCL
455250|NCT00878254|NHL
455251|NCT00878241|Colon Anastomosis
455252|NCT00878241|Rectum Anastomosis
455253|NCT00878241|Intestine
455254|NCT00878241|Colorectal Surgery
455255|NCT00878241|Colorectal Anastomosis
455256|NCT00878215|Image Guided Liver Surgery
455257|NCT00878189|Phase 1 dose escalation study in advanced solid tumor malignancy and leukemia
455258|NCT00878176|sacral neuromodulation therapy
455259|NCT00878176|urinary retention
455260|NCT00878176|screening
455261|NCT00878176|non obstructive urinary retention
455262|NCT00878150|traumatic brain injury
455263|NCT00878150|TBI
455264|NCT00878150|head injury
455265|NCT00878150|brain injury
455266|NCT00878150|depression
455267|NCT00878150|major depressive disorder
455268|NCT00878150|cognitive behavioral therapy
455269|NCT00878150|CBT
455270|NCT00878150|counseling
455271|NCT00878124|Poor ovarian response
455272|NCT00878124|Chromosomal aberrations
455273|NCT00878124|poor pregnancy outcome
455274|NCT00878124|Late maternal age
455275|NCT00878111|NGR-hTNF
455276|NCT00878111|Solid tumours
455277|NCT00878111|High doses
455278|NCT00878098|DDT
455279|NCT00878098|Malaria
455280|NCT00878098|Pregnancy Outcome
455281|NCT00878098|Spontaneous Abortion
455282|NCT00878098|HIV
455283|NCT00878098|Pregnancy
455284|NCT00878085|Robot Therapy
455285|NCT00878085|Upper Limb
455286|NCT00878085|Stroke
455287|NCT00878085|Rehabilitation
455288|NCT00878085|fMRI
455289|NCT00878085|DTI
455290|NCT00878072|Herpes labialis
455291|NCT00878072|cold sores
455292|NCT00878072|herpes simplex type 1
455293|NCT00878046|Hip
455294|NCT00878046|Cementless
455295|NCT00878046|Conservative
455296|NCT00878007|Anaemia
455297|NCT00878007|Malaria
455298|NCT00878007|Literacy
455299|NCT00878007|Kenya
455300|NCT00877994|Disordered Eating
455301|NCT00877994|Parenting
455302|NCT00877994|Mothers
455303|NCT00877981|hyperparathyroidism
455304|NCT00877981|surgery
455305|NCT00877981|minimal invasive
455306|NCT00877981|videoassited
455307|NCT00877968|Pea flour
455308|NCT00877968|Glycemic response
455309|NCT00877968|Diabetes
455310|NCT00877968|Sensory
455311|NCT00877968|Functional food
455312|NCT00877968|Diabetes control and prevention
455313|NCT00877955|bioequivalence
455314|NCT00877955|pharmacokinetic
455315|NCT00877955|alprazolam
455316|NCT00877955|sublingual
455317|NCT00877903|Acute myocardial infarction
455318|NCT00877903|AMI
455319|NCT00877903|Myocardial infarction
455320|NCT00877903|Heart attack
455321|NCT00877903|Mesenchymal stem cells
455322|NCT00877903|MSC
455323|NCT00877903|Adult human stem cells
455324|NCT00877903|Osiris
455325|NCT00877890|diabetes
455326|NCT00877890|exenatide once weekly
455327|NCT00877890|Byetta
455328|NCT00877890|Amylin
455329|NCT00877890|Lilly
455330|NCT00877890|Bydureon
455331|NCT00877877|HPV vaccine
455332|NCT00877877|cervical cancer
455333|NCT00877864|diabetes
455334|NCT00877864|exercise
455335|NCT00877864|printed materials
455336|NCT00877851|Diet
455337|NCT00877851|Physical activity
455338|NCT00877851|Self management
455339|NCT00877851|Goal setting
455340|NCT00877838|Headache
455341|NCT00877838|Migraine
455342|NCT00877838|Aura
455343|NCT00877838|Acute
455344|NCT00877838|Attack
455345|NCT00877838|Clinical
455346|NCT00877838|Trial
455347|NCT00877838|Intervention
455348|NCT00877838|Nitrogen Oxide
455349|NCT00877838|NOS
455350|NCT00877838|nNOS
455351|NCT00877838|Triptan
455352|NCT00877838|5HT
455354|NCT00877825|Diet Therapy
455355|NCT00877812|Vitamin B6
455356|NCT00877812|Vitamin B6 deficiency
455357|NCT00877812|Amino acids
455358|NCT00877812|pyridoxine
455359|NCT00877799|pain
455360|NCT00877799|acute pain
455361|NCT00877799|visceral pain
455362|NCT00877799|kappa agonist
455363|NCT00877799|opioid analgesics
455364|NCT00877799|peripheral nervous system agents
455365|NCT00877799|physiological effects of drugs
455366|NCT00877799|surgery
455367|NCT00877799|hysterectomy
455368|NCT00877799|post-operative
455369|NCT00877799|post-operative complications
455370|NCT00877773|Advanced cancer
455371|NCT00877773|Advanced Cancer with genetic mutation
455372|NCT00877773|Phosphoinositides 3-kinase
455373|NCT00877773|PI3K
455374|NCT00877773|PIK3 mutations
455375|NCT00877773|Temsirolimus
455376|NCT00877773|CCI-779
455377|NCT00877773|Torisel
455378|NCT00877773|mTOR inhibitor
455379|NCT00877760|Hepatitis B Entecavir pegylated interferon a-2a
455380|NCT00877747|PET
455381|NCT00877734|alcohol dependence
455382|NCT00877734|baclofen
455383|NCT00877734|pharmacotherapy
455384|NCT00877734|women
455385|NCT00877721|Postural Control
455386|NCT00877721|Gait
455387|NCT00877721|Falls
455388|NCT00877721|Elderly
455389|NCT00877721|Old adults (65 years old and older) with low risk of falls
455390|NCT00877708|E. Coli
455391|NCT00877708|isolates
455392|NCT00877695|HIV
455393|NCT00877695|HIV Seronegativity
455394|NCT00877695|prevention
455395|NCT00877695|Hispanic
455396|NCT00877695|Latino
455397|NCT00877695|MSM
455398|NCT00877695|men
455399|NCT00877682|Prostate Cancer
455400|NCT00877682|Prostate Tumor
455401|NCT00877682|Adenocarcinoma of the Prostate
455402|NCT00877682|PCA
455403|NCT00877682|Regional Prostate Cryoablation
455404|NCT00877682|Cryotherapy
455405|NCT00877682|Cryoablation
455406|NCT00877682|Health Related Quality of Life
455407|NCT00877682|HRQOL
455408|NCT00877617|Quality of Life
455409|NCT00877617|QOL
455410|NCT00877617|Questionnaire
455411|NCT00877617|High Risk localized Prostate Cancer
455412|NCT00877617|HRLPC
455413|NCT00877617|Neoadjuvant Investigational Therapy
455414|NCT00877617|Radical Prostatectomy
455415|NCT00877604|ALS
455416|NCT00877604|Therapy
455417|NCT00877604|Tauroursodeoxycholic acid
455418|NCT00877604|TUDCA
455419|NCT00877604|antioxidant
455420|NCT00877604|antiapoptotic drug
455421|NCT00877604|neuroprotective drug
455422|NCT00877591|Interaction of Buprenorphine with HIV and TB Medications
455423|NCT00877578|elderly patient
455424|NCT00877578|malnutrition
455425|NCT00877578|new nutritional support
455426|NCT00877578|micronutrients
455427|NCT00877578|elderly patient malnutrition
455428|NCT00877565|LVF
455429|NCT00877565|Left ventricular systolic function
455430|NCT00877552|Schizophrenia
455431|NCT00877552|brain development
455432|NCT00877552|MRI
455433|NCT00877539|Asthma Allergen Challenge
455434|NCT00877513|Smoking
455435|NCT00877513|Insulin resistance
455436|NCT00877513|Metabolic syndrome
455437|NCT00877513|Body fat distribution
455438|NCT00877513|Cigarette smoking
455439|NCT00877500|HER2/neu-negative Breast Cancer
455440|NCT00877500|Residual Breast Cancer
455441|NCT00877500|Surgery
455442|NCT00877500|Neoadjuvant Systemic Therapy
455443|NCT00877500|NST
455444|NCT00877500|Ixabepilone
455445|NCT00877500|BMS-247550
455446|NCT00877500|Epothilone B analogue
455447|NCT00877487|ADHD
455448|NCT00877474|PM01183
455449|NCT00877474|Solid tumors
455450|NCT00877474|PharmaMar USA
455451|NCT00877448|INFLUENZA
455452|NCT00877448|VACCINE
455453|NCT00877448|UNIVERSAL
455454|NCT00877448|SAFETY
455455|NCT00877422|vitamin deficiency
455456|NCT00877409|Acnase
455457|NCT00877409|Acne Vulgaris
455458|NCT00877409|Safety
455459|NCT00877409|Efficacy
455460|NCT00877383|chronic obstructive pulmonary disease
455461|NCT00877383|COPD
455462|NCT00877383|indacaterol
455463|NCT00877383|tiotropium
455464|NCT00877383|bronchodilation
455465|NCT00877370|ertapenem
455466|NCT00877370|continuous hemodialysis
455467|NCT00877370|pharmacokinetics
455468|NCT00877357|Vaccine
455469|NCT00877357|Prevention
455470|NCT00877357|Diphtheria
455471|NCT00877357|Tetanus
455472|NCT00877357|Pertussis
455473|NCT00877357|Hepatitis B
455474|NCT00877357|Haemophilus influenzae type b
455475|NCT00877357|Lot Consistency
455476|NCT00877357|Long Term Immunogenicity
455477|NCT00877357|Reactogenicity
455478|NCT00877357|Healthy infants
455479|NCT00877344|Pregnancy
455480|NCT00877344|IUC
455481|NCT00877344|abortion
455482|NCT00877344|contraception
455483|NCT00877331|Drug Abuse
455484|NCT00877331|Drug Addiction
455485|NCT00877331|Drug Dependence
455486|NCT00877331|Drug Usage
455487|NCT00877331|Drug Use Disorders
455488|NCT00877331|Substance Abuse
455489|NCT00877331|Substance Addiction
455490|NCT00877331|Substance Dependence
455491|NCT00877331|Substance Use Disorders
455492|NCT00877305|Ischemic Preconditioning
455493|NCT00877305|Cognitive function
455494|NCT00877292|Down Syndrome
455495|NCT00877292|trisomy 21
455496|NCT00877292|prenatal testing
455497|NCT00877292|pregnant women
455498|NCT00877279|Facial wrinkles
455499|NCT00877279|Nasolabial folds
455500|NCT00877266|catheter
455501|NCT00877266|ultrasound guidance
455502|NCT00877266|nerve stimulation
455503|NCT00877266|electrical stimulation
455504|NCT00877266|nerve block
455505|NCT00877266|UCSD
455506|NCT00877266|timed placement
455507|NCT00877266|surgery
455508|NCT00877266|Catheter Placement Time
455509|NCT00877227|CVA
455510|NCT00877227|stroke
455511|NCT00877227|newborns
455512|NCT00877227|homocysteine
455513|NCT00877227|folinic acid
455514|NCT00877214|Bendamustine
455515|NCT00877214|Rituximab
455516|NCT00877214|Significance of maintenance therapy
455517|NCT00877214|Efficacy and safety
455518|NCT00876213|Amylin
455519|NCT00876213|GLP-1
455520|NCT00876213|gastric emptying
455521|NCT00876213|appetite and food intake
455522|NCT00876200|Williams Beuren syndrome
455523|NCT00876200|Cardiovascular abnormalities
455524|NCT00876200|Cardiovascular structure
455525|NCT00876187|randomized controlled trial
455526|NCT00876187|monoclonal antibody
455527|NCT00876187|nerve growth factor
455528|NCT00876187|naproxen
455529|NCT00876174|Chronic hepatitis C
455530|NCT00876174|Genotype 1
455531|NCT00876161|Healthy Adults
455532|NCT00875147|neoadjuvant chemotherapy
455533|NCT00875147|bevacizumab
455534|NCT00875121|Food reinforcement
455535|NCT00875121|social reinforcers
455536|NCT00875121|overweight
455537|NCT00875121|children
455538|NCT00875095|sperm DNA integrity
455539|NCT00875095|Toluidine blue staining
455540|NCT00875082|Asthma
455541|NCT00875082|Children
455542|NCT00875082|Remodelling
455543|NCT00875082|Metalloproteinases
455544|NCT00875082|Montelukast
455545|NCT00875069|Nosocomial infection
455546|NCT00875069|Catheterization
455547|NCT00875069|Central Venous Ethanol
455548|NCT00875069|lock solution
455549|NCT00875069|intensive care units
455550|NCT00875069|Renal replacement therapy in ICU
455551|NCT00875043|ischemic optic neuropathy
455552|NCT00875043|cortical blindness
455553|NCT00875030|Bioequivalence study-artesunate sachets-arsuamoon tablet
455554|NCT00877201|Accommodation
455555|NCT00877201|visual display terminal (VDT)
455556|NCT00877201|antioxidant
455557|NCT00877188|breast cancer
455558|NCT00877188|exercise
455559|NCT00877188|upper extremity function
455560|NCT00877188|quality of life
455561|NCT00877175|preterm infants
455562|NCT00877175|mydriasis
455563|NCT00877175|pupil dilation
455564|NCT00877162|Cognitive and behavioural intervention
455565|NCT00877162|trial
455566|NCT00877162|group
455567|NCT00877162|Behavioral sleep problems
455568|NCT00877149|Chronic HBV
455569|NCT00877136|Liver tumors
455570|NCT00877136|Liver cancer
455571|NCT00877136|Adult primary hepatocellular carcinoma
455572|NCT00877136|HCC
455573|NCT00877136|Hepatoma
455574|NCT00877136|Neoplasms
455575|NCT00877123|fasting glucose
455576|NCT00877123|obesity
455577|NCT00877123|arab women
455578|NCT00877123|interleukin
455579|NCT00877123|diabetes
455580|NCT00877123|impaired fasting glucose (IFG)
455581|NCT00877110|BETA-D-GLUCAN
455582|NCT00877110|CYCLOPHOSPHAMIDE (CYTOXAN)
455583|NCT00877110|MAB 131 I - 3F8
455584|NCT00877110|TOPOTECAN
455585|NCT00877110|VINCRISTINE
455586|NCT00877110|Neuroblastoma
455587|NCT00877110|09-011
455588|NCT00877097|osteoporosis
455589|NCT00877097|Bone mineral density
455590|NCT00877097|clodronate
455591|NCT00877097|HRT
455592|NCT00877097|postmenopausal
455593|NCT00877084|exacerbation
455594|NCT00877084|COPD
455595|NCT00877084|Resistance training
455596|NCT00877084|Muscle force
455597|NCT00877058|Frailty
455598|NCT00877058|health promotion
455599|NCT00877058|prevention
455600|NCT00877058|self management
455601|NCT00877058|intervention
455602|NCT00877045|Gastrointestinal Stromal Tumors
455603|NCT00877045|GIST
455604|NCT00877045|tyrosine kinase inhibitors
455605|NCT00877045|Imatinib
455606|NCT00877045|Gleevec
455607|NCT00877045|Suntinib
455608|NCT00877045|Sutent
455609|NCT00877032|Phase 1
455610|NCT00877032|Dry Age Related Macular Degeneration
455611|NCT00877032|RN6G
455612|NCT00877019|sonic brushes
455613|NCT00877019|time effectiveness
455614|NCT00877019|brush head design
455615|NCT00877019|ADA-toothbrush
455616|NCT00877019|professional brushing
455617|NCT00877019|time dependence
455618|NCT00877019|efficacy
455619|NCT00877019|toothbrush
455620|NCT00876980|Obstructive sleep apnea
455621|NCT00876980|Type II diabetes mellitus
455622|NCT00876980|Randomized controlled trial
455623|NCT00876967|anesthesiology
455624|NCT00876967|randomized
455625|NCT00876967|laryngoscope
455626|NCT00876967|intubation
455627|NCT00876967|laryngeal exposition
455628|NCT00876967|laryngoscope blades
455629|NCT00876967|plastic single use blade
455630|NCT00876967|metallic single use blade
455631|NCT00876967|metallic reusable blade
455632|NCT00876967|success to intubation at first attempt
455633|NCT00876967|Cormack and lehanne modify grade
455634|NCT00876941|Drug
455635|NCT00876941|Drug Use
455636|NCT00876941|Screening
455637|NCT00876941|Brief Intervention
455638|NCT00876941|Primary Care
455639|NCT00876941|Utilization
455640|NCT00876928|pre-diabetes
455641|NCT00876928|minorities
455642|NCT00876928|oral glucose tolerance test
455643|NCT00876928|disposition index
455644|NCT00876928|insulin secretion
455645|NCT00876928|insulin sensitivity
455646|NCT00876928|diabetes
455647|NCT00876915|prevention of VTE and PE in high risk cancer patients
455648|NCT00876902|liver transplantation
455649|NCT00876902|cadaveric liver transplantation
455650|NCT00876902|ischemic reperfusion injury
455651|NCT00876902|primary non-function
455652|NCT00876902|delayed non-Function
455653|NCT00876902|poor early graft function
455654|NCT00876902|YSPSL
455655|NCT00876902|recombinant PSGL-Ig
455656|NCT00876889|spinal cord injury
455657|NCT00876889|riluzole
455658|NCT00876889|pharmacokinetics
455659|NCT00876889|Acute Traumatic Spinal Cord Injury
455660|NCT00876876|hypervolemic hyponatremia
455661|NCT00876876|serum sodium
455662|NCT00876876|fluid overload
455663|NCT00876876|heartfailure
455664|NCT00876876|acute heart failure
455665|NCT00876876|vasopressin antagonist
455666|NCT00876863|Alzheimer's disease
455667|NCT00876863|Dementia
455668|NCT00876863|Memory loss
455669|NCT00876863|Cognitive impairment
455670|NCT00876863|Nerve growth factor
455671|NCT00876863|NGF
455672|NCT00876863|Neurotrophic factors
455673|NCT00876863|Gene therapy
455674|NCT00876850|cSSI
455675|NCT00876850|Abscess
455676|NCT00876850|Would
455677|NCT00876850|Cellulitis
455678|NCT00876850|Complicated Skin and Skin Structure Infections (cSSSI)
455679|NCT00876824|Black Fever
455680|NCT00876824|Kala-Azar
455681|NCT00876824|Amphotericin B lipid emulsion
455682|NCT00876824|Liposomal Amphotericin B
455683|NCT00876811|raspberry
455684|NCT00876811|fruit
455685|NCT00876811|antioxidants
455686|NCT00876811|polyphenols
455687|NCT00876811|oxidative stress
455688|NCT00876811|dietary intervention
455689|NCT00876798|Euvolemic Hyponatremia
455690|NCT00876798|SIADH
455691|NCT00876798|Serum Sodium
455692|NCT00876785|Rye bread satiety breakfast
455693|NCT00876772|ALS
455694|NCT00876772|olanazapine
455695|NCT00876772|Loss of Apptetite
455696|NCT00876772|Appetite Loss
455697|NCT00876772|Malnutrition
455698|NCT00876772|Cachexia
455699|NCT00876772|Zyprexa
455700|NCT00876759|cerebral metastases
455701|NCT00876746|Pain
455702|NCT00876746|surgery
455703|NCT00876746|catheter
455704|NCT00876746|nerve block
455705|NCT00876746|supraclavicular
455706|NCT00876746|infraclavicular
455707|NCT00876746|UCSD
455708|NCT00876746|moderate-to-severe pain
455709|NCT00876746|Supraclavicular catheter
455710|NCT00876746|Infraclavicular catheter
455711|NCT00876720|Tinnitus
455712|NCT00876720|chronic subjective tinnitus
455713|NCT00876720|transcranial magnetic stimulation
455714|NCT00876720|sensation disorders
455715|NCT00876720|hearing disorders
455716|NCT00876707|wavefront
455717|NCT00876707|multifocal IOL
455718|NCT00876707|modulation transfer function
455719|NCT00876707|intraocular lenses
455720|NCT00876707|wavefront data
455721|NCT00876707|Visual performance
455722|NCT00876694|COPD, Chronic Obstructive Pulmonary Disease, Indacaterol, long acting β2-agonist
455723|NCT00876681|Catheter
455724|NCT00876681|Ultrasound-guidance
455725|NCT00876681|Nerve Stimulation
455726|NCT00876681|Electrical stimulation
455727|NCT00876681|nerve block
455728|NCT00876681|UCSD
455729|NCT00876681|Orthopedic surgery
455730|NCT00876681|Foot/ankle pain
455731|NCT00876681|Foot/ankle numbness
455732|NCT00876681|Popliteal-Sciatic Catheters
455733|NCT00876668|Peripheral Vascular diseases
455734|NCT00876668|Microcirculation
455735|NCT00876668|fluorescence angiography
455736|NCT00876642|Radiation dermatitis
455737|NCT00876642|best supportive care
455738|NCT00876642|Aloe vera gel
455739|NCT00876642|phase III study was to assess the effectiveness of aloe vera and vitamin E.
455740|NCT00876629|MR Elastography
455741|NCT00876629|kidney
455742|NCT00876629|fibrosis
455743|NCT00876616|lupus nephritis;multi-target therapy; MMF; FK506
455744|NCT00876603|cervical spondylotic myelopathy
455745|NCT00876603|anterior decompression and fusion
455746|NCT00876603|cervical laminoplasty
455747|NCT00876577|Acute Exacerbations of Chronic Bronchitis
455748|NCT00876577|Avelox
455749|NCT00876577|Bronchitis
455750|NCT00876564|Triage precision
455751|NCT00876551|Negative-Pressure Wound Therapy
455752|NCT00876551|Endoscopic/endoluminal V.A.C. therapy
455753|NCT00876551|Esophagectomy
455754|NCT00876551|Anastomotic leakage
455755|NCT00876551|Anastomosis, Surgical
455756|NCT00876538|Chemotherapy Induced Peripheral Neuropathy
455757|NCT00876538|TR019622
455758|NCT00876538|Trophos
455759|NCT00876525|Heart diseases.
455760|NCT00876525|Aortic valve diseases.
455761|NCT00876525|Aortic valve insufficiency.
455762|NCT00876525|Aortic valve stenosis.
455763|NCT00876512|thienopyridine resistance
455764|NCT00876512|stable effort angina
455765|NCT00876512|platelet activation
455766|NCT00876512|ADAMTS13
455767|NCT00876512|von Willebrand Factor
455768|NCT00876499|Primary Brain Tumor
455769|NCT00876499|PBT
455770|NCT00876499|Brain Cancer
455771|NCT00876499|Primary glioma
455772|NCT00876499|Astrocytoma
455773|NCT00876499|Oligodendroglioma
455774|NCT00876499|Oligo-astrocytoma
455775|NCT00876499|Ependymoma
455776|NCT00876499|Anaplastic astrocytoma
455777|NCT00876499|Anaplastic oligodendroglioma
455778|NCT00876499|Anaplastic oligo-astrocytoma
455779|NCT00876499|Anaplastic ependymoma
455780|NCT00876499|Fatigue
455781|NCT00876499|Cytokines
455782|NCT00876499|Questionnaires
455783|NCT00876499|Actigraphy
455784|NCT00876499|Sleep Disturbance
455785|NCT00876499|Radiation Therapy
455786|NCT00876473|CPAP
455787|NCT00876473|Acute Respiratory Failure
455788|NCT00876434|Sirolimus
455789|NCT00876434|Anterior Uveitis
455790|NCT00876434|Autoimmune Disease
455791|NCT00876434|Uveitis
455792|NCT00876421|ONO-8539
455793|NCT00876421|Overactive bladder
455794|NCT00876421|OAB
455795|NCT00876408|RT-PCR molecular profiling assay
455796|NCT00876408|Molecular Profiling-Real Time Polymerase Chain Reaction
455797|NCT00876408|Unknown Primary
455798|NCT00876408|UPC
455799|NCT00876408|CUP
455800|NCT00876395|Breast Cancer
455801|NCT00876395|HER2+
455802|NCT00876395|mTOR
455803|NCT00876395|everolimus
455804|NCT00876395|RAD001
455805|NCT00876395|first line
455806|NCT00876395|metastatic
455807|NCT00876395|locally advanced
455808|NCT00876382|advanced renal cell carcinoma
455809|NCT00876382|renal cancer
455810|NCT00876382|renal cell
455811|NCT00876382|Sorafenib
455812|NCT00876382|Nexavar
455813|NCT00876382|Bevacizumab
455814|NCT00876382|Avastin
455815|NCT00876382|Sunitinib
455816|NCT00876382|Sutent
455817|NCT00876369|urticaria
455818|NCT00876369|angioedema
455819|NCT00876369|vitamin D
455820|NCT00876369|allergy
455821|NCT00876356|Asthma
455822|NCT00876356|Conjugated Linoleic Acid (CLA)
455823|NCT00876356|dietary supplement
455824|NCT00876330|Clinical Decision Support Systems
455825|NCT00876330|Hyperlipidemia
455826|NCT00876330|Hypertension
455827|NCT00876317|Tenosynovitis
455828|NCT00876317|Bursitis
455829|NCT00876304|PF-04802540 multiple dose safety study
455830|NCT00876278|Cataract
455831|NCT00876278|Intraocular Lens (IOL)
455832|NCT00876278|Mesotest II
455833|NCT00876278|Evaluation of usability of Mesotest II for assessment of night driving capacity of pseudo-phakic patients
455834|NCT00876265|Facial wrinkles
455835|NCT00876265|Nasolabial fold
455836|NCT00876226|Citalopram
455837|NCT00876226|Pharmacokinetics
455838|NCT00876226|Short Bowel Syndrome
455839|NCT00876148|Incidence of hepatitis B after allografting
455840|NCT00876148|Risk of hepatitis B reactivation
455841|NCT00876148|Lamivudine prophylaxis
455842|NCT00876122|NHL
455843|NCT00876122|Metastatic Solid Tumors
455844|NCT00876122|PI3K Inhibitors
455845|NCT00876122|PI3K
455846|NCT00876109|Metastatic Solid Tumors
455847|NCT00876109|PI3K
455848|NCT00876109|PI3K Inhibitors
455849|NCT00876096|Diagnosis, Differential
455850|NCT00876083|Drug utilization review
455851|NCT00876070|Metastatic Breast Cancer
455852|NCT00876070|Breast Cancer
455853|NCT00876070|MBC
455854|NCT00876070|Abraxane
455855|NCT00876070|Paclitaxel
455856|NCT00876070|Taxol
455857|NCT00876070|Docetaxel
455858|NCT00876070|Taxotere
455859|NCT00876057|psychological well-being
455860|NCT00876057|recovery
455861|NCT00876057|time in hospital
455862|NCT00876057|sick-leave
455863|NCT00876057|complications
455864|NCT00876057|Sexual well-being
455865|NCT00876031|pediatric soft tissue sarcoma
455866|NCT00876031|rhabdomyosarcoma
455867|NCT00876031|extraosseous Ewing family tumours
455868|NCT00876031|synovial sarcoma
455869|NCT00876031|undifferentiated sarcoma
455870|NCT00876018|physical performance
455871|NCT00876018|micronutrients
455872|NCT00876018|physical fitness
455873|NCT00876018|healthy children
455874|NCT00876005|Wound infection
455875|NCT00875979|MBC
455876|NCT00875979|Breast Cancer
455877|NCT00875979|HER2+
455878|NCT00875979|HER2+ breast cancer
455879|NCT00875979|HER2 positive breast cancer
455880|NCT00875979|herceptin
455881|NCT00875979|Trastuzumab emtansine
455882|NCT00875953|squamous cell carcinoma
455883|NCT00875953|head and neck cancer
455884|NCT00875953|neck dissection
455885|NCT00875927|Halitosis
455886|NCT00875914|AV-node reentry tachycardia
455887|NCT00875914|radiofrequency ablation
455888|NCT00875914|magnetic navigation system
455889|NCT00875901|Lung Cancer
455890|NCT00875901|Stage I Non-Small Cell Lung Cancer
455891|NCT00875901|Proton Radiation
455892|NCT00875901|HypoIGRT
455893|NCT00875875|Diarrhea, travelers
455894|NCT00875875|Acute travelers' diarrhea
455895|NCT00875862|UCSD
455896|NCT00875862|pain
455897|NCT00875862|quality-of-life
455898|NCT00875862|range-of-motion
455899|NCT00875862|interscalene catheter
455900|NCT00875862|nerve block
455901|NCT00875862|shoulder
455902|NCT00875862|Shoulder Manipulation
455903|NCT00875849|recurrent squamous cell carcinoma of the hypopharynx
455904|NCT00875849|stage I squamous cell carcinoma of the hypopharynx
455905|NCT00875849|stage II squamous cell carcinoma of the hypopharynx
455906|NCT00875849|stage III squamous cell carcinoma of the hypopharynx
455907|NCT00875849|recurrent squamous cell carcinoma of the larynx
455908|NCT00875849|stage I squamous cell carcinoma of the larynx
455909|NCT00875849|stage II squamous cell carcinoma of the larynx
455910|NCT00875849|stage III squamous cell carcinoma of the larynx
455911|NCT00875849|stage I squamous cell carcinoma of the lip and oral cavity
455912|NCT00875849|stage II squamous cell carcinoma of the lip and oral cavity
455913|NCT00875849|stage III squamous cell carcinoma of the lip and oral cavity
455914|NCT00875849|recurrent squamous cell carcinoma of the lip and oral cavity
455915|NCT00875849|recurrent squamous cell carcinoma of the oropharynx
455916|NCT00875849|stage I squamous cell carcinoma of the oropharynx
455917|NCT00875849|stage II squamous cell carcinoma of the oropharynx
455918|NCT00875849|stage III squamous cell carcinoma of the oropharynx
455919|NCT00875849|tongue cancer
455920|NCT00875836|Marijuana
455921|NCT00875836|Buspirone
455922|NCT00875836|Contingency management
455923|NCT00875836|Motivational enhancement therapy
455924|NCT00875823|PH
455925|NCT00875823|Primary Hyperoxaluria
455926|NCT00875823|Type I
455927|NCT00875823|Type II
455928|NCT00875823|NonI-NonII
455929|NCT00875823|Kidney stones
455930|NCT00875823|oxalate
455931|NCT00875823|oxalosis
455932|NCT00875797|enteral
455933|NCT00875797|parenteral
455934|NCT00875797|glutamine
455935|NCT00875797|intestinal permeability
455936|NCT00875797|infection
455937|NCT00875784|Sumatriptan exposure
455938|NCT00875771|metastatic colorectal cancer
455939|NCT00875771|BEVACIZUMAB
455940|NCT00875771|CAPECITABINE
455941|NCT00875771|IRINOTECAN
455942|NCT00875758|preterm infants
455943|NCT00875758|IVH
455944|NCT00875758|germinal matrix
455945|NCT00875758|intraventricular hemorrhage
455946|NCT00875758|hydrocephalus
455947|NCT00875732|Resynchronization
455948|NCT00875732|Device
455949|NCT00875732|Bradycardia
455950|NCT00875732|atrioventricular block
455951|NCT00875732|Cardiac Resynchronization
455952|NCT00875719|COPD patients with respiratory failure
455953|NCT00875706|Nursing Homes
455954|NCT00875706|Implementation of innovative programs
455955|NCT00875706|Nursing staff
455956|NCT00875706|Nurses' aides
455957|NCT00875706|Educational models
455958|NCT00875693|AML
455959|NCT00875693|leukemia
455960|NCT00875693|MDS
455961|NCT00875667|Mantle Cell Lymphoma
455962|NCT00875667|Relapsed Mantle Cell Lymphoma
455963|NCT00875667|Refractory Mantle Cell Lymphoma
455964|NCT00875667|Lymphoma
455965|NCT00875667|MCL
455966|NCT00875654|Cell therapy
455967|NCT00875654|Stroke
455968|NCT00875654|Neuronal Plasticity
455969|NCT00875654|Recovery
455970|NCT00875654|Mesenchymal Stem Cells
455971|NCT00875654|Transplantation
455972|NCT00875628|Japanese Healthy volunteers HCV pharmacokinetics PF-00868554 filibuvir
455973|NCT00875615|adult primary hepatocellular carcinoma
455974|NCT00875615|localized unresectable adult primary liver cancer
455975|NCT00875615|advanced adult primary liver cancer
455976|NCT00875602|All hospitalized patients in a general Med/ Surg unit
455977|NCT00875589|Traumatic Brain Injury
455978|NCT00875589|Eye movement recording
455979|NCT00875576|social influences
455980|NCT00875576|meals
455981|NCT00875576|obesity
455982|NCT00875576|amount of food consumed
455983|NCT00875550|Intubated and mechanically ventilated PICU subjects
455984|NCT00875537|Burning mouth syndrome
455985|NCT00875537|neuropathy
455986|NCT00875537|inflammation
455987|NCT00875537|tongue mucosa
455988|NCT00875537|tongue innervation
455989|NCT00875537|dysgeusia
455990|NCT00875524|Dengue virus
455991|NCT00875524|Dengue fever
455992|NCT00875524|Dengue hemorrhagic fever
455993|NCT00875524|Dengue diseases
455994|NCT00875524|Dengue vaccine
455995|NCT00875511|peer rejection
455996|NCT00875511|obesity
455997|NCT00875511|amount of food chosen
455998|NCT00875511|amount of social time chosen
455999|NCT00875498|iTBS
456000|NCT00875498|Negative Symptoms
456001|NCT00875485|Monovalent Hepatitis A
456002|NCT00875485|hepatitis B vaccine
456003|NCT00875485|Belgium and Czech Republic
456004|NCT00875472|social influences
456005|NCT00875472|food purchases
456006|NCT00875472|childhood obesity
456007|NCT00875472|amount of energy dense food and beverage items purchased
456008|NCT00875472|amount of nutrient dense food and beverage items purchased
456009|NCT00875420|hot flashes
456010|NCT00875420|hot flushes
456011|NCT00875420|vasomotor symptoms
456012|NCT00875420|postmenopausal
456013|NCT00875381|Melanocytes
456014|NCT00875368|HIV-1
456015|NCT00875368|HAART
456016|NCT00875368|CD4 cell
456017|NCT00875368|Immunologic non-responders
456018|NCT00875368|Immunology
456019|NCT00875368|treatment experienced
456020|NCT00875355|tumors metastatic to brain
456021|NCT00875355|stage IV breast cancer
456022|NCT00875342|Traumatic Event
456023|NCT00875342|Trauma Survivor
456024|NCT00875342|Exposure Therapy
456025|NCT00875342|PTSD DCS
456026|NCT00875342|Telemedicine
456027|NCT00875342|Telepsychiatry
456028|NCT00875342|Telemental health
456029|NCT00875329|Brain Injury
456030|NCT00875316|Parkinson's disease
456031|NCT00875316|Phase I
456032|NCT00875303|Parents' plans to discipline their children
456033|NCT00875290|Diabetes Mellitus, Type I
456034|NCT00875290|Children
456035|NCT00875290|Insulin pump therapy
456036|NCT00875290|Continuous glucose monitor
456037|NCT00875264|CEP-11981
456038|NCT00875264|TIE-2
456039|NCT00875264|VEGF-R
456040|NCT00875251|body composition
456041|NCT00875251|preterm infant
456042|NCT00875251|anthropometry
456043|NCT00875238|cardiac toxicity
456044|NCT00875238|cardiovascular complications
456045|NCT00875238|stage I breast cancer
456046|NCT00875238|stage II breast cancer
456047|NCT00875238|stage IIIA breast cancer
456048|NCT00875238|stage IIIB breast cancer
456049|NCT00875238|stage IIIC breast cancer
456050|NCT00875225|Hypertension
456051|NCT00875225|Adherence to medications
456052|NCT00875212|Calcium glycerophosphate
456053|NCT00875212|Fluoride
456054|NCT00875212|Dentifrice
456055|NCT00875212|Biofilm
456056|NCT00875212|Dental caries
456057|NCT00875199|Overweight
456058|NCT00875199|Obesity
456059|NCT00875199|Contingency Management
456060|NCT00875186|bariatric surgery
456061|NCT00875186|co-morbidities
456062|NCT00875186|aerobic physical exercise
456063|NCT00875173|Selenium
456064|NCT00875173|Chagas disease
456065|NCT00875173|Chagasic cardiopathy
456066|NCT00875004|anemia
456067|NCT00875004|unspecified adult solid tumor, protocol specific
456068|NCT00874991|Cardiac deformation
456069|NCT00874991|Cardiopulmonary bypass
456070|NCT00874991|TEE
456071|NCT00874991|Cardiac Surgery
456072|NCT00874991|Left ventricular function
456073|NCT00874991|Pulmonary Artery catheter
456074|NCT00874991|Tissue Doppler
456075|NCT00874991|Left ventricular function in cardiac surgery
456076|NCT00874978|Lenalidomide
456077|NCT00874978|myelodysplastic syndromes
456078|NCT00874965|Chronic Obstructive Pulmonary Disease (COPD)
456079|NCT00874965|Electrostimulation
456080|NCT00874965|Muscle function
456081|NCT00874965|Exercise ventilation
456082|NCT00874965|Anabolism/catabolism pathway
456083|NCT00874952|Metabolic syndrome
456084|NCT00874952|Lipids
456085|NCT00874952|Waist Circumference
456086|NCT00874952|HDL
456087|NCT00874952|hypertension
456088|NCT00874926|Octocog alfa
456089|NCT00874926|Haemophilia A
456090|NCT00874913|blood flow
456091|NCT00874913|obstructive sleep apnea syndrome
456092|NCT00874913|normal tension glaucoma
456093|NCT00874874|stage III adult soft tissue sarcoma
456094|NCT00874874|stage IV adult soft tissue sarcoma
456095|NCT00874874|recurrent adult soft tissue sarcoma
456096|NCT00874874|adult angiosarcoma
456097|NCT00874861|cancer
456098|NCT00874861|brain
456099|NCT00874861|tumor
456100|NCT00874861|vaccine
456101|NCT00874848|Imprime PGG
456102|NCT00874848|NSCLC
456103|NCT00874848|Cetuximab
456104|NCT00874835|Endothelial Keratoplasty
456105|NCT00874835|EK
456106|NCT00874835|Descemet Stripping Endothelial Keratoplasty
456107|NCT00874835|Corneal Transplantation
456108|NCT00874835|Keratoplasty
456109|NCT00874835|DSEK
456110|NCT00874835|DSAEK
456111|NCT00874809|insulin pump
456112|NCT00874809|DM Type 2
456113|NCT00874809|CGMS
456114|NCT00874809|basal rate
456115|NCT00874796|apoptosis
456116|NCT00874796|liver inflammation
456117|NCT00874796|hepatitis C
456118|NCT00874783|Amyotrophic Lateral Sclerosis
456119|NCT00874783|Familial Dysautonomia
456120|NCT00874783|Parkinson's Disease
456121|NCT00874783|Alzheimer's Disease
456122|NCT00874783|Age Related Macular Degeneration
456123|NCT00874783|Retinitis Pigmentosa
456124|NCT00874783|Huntington's Disease
456125|NCT00874783|Machado - Joseph Disease
456126|NCT00874783|SMA - Spinal Muscular Atrophy
456127|NCT00874783|Ataxia Telangiectasia
456128|NCT00874770|Antivirals
456129|NCT00874757|Statins, anti-inflammatory
456130|NCT00874757|Healthy subjects study
456131|NCT00874744|Diabetic macular edema
456132|NCT00874744|intravitreal injection
456133|NCT00874744|Pharmacological treatment
456134|NCT00874718|repetitive strain injury
456135|NCT00874718|quality of life
456136|NCT00874718|functional capacity
456137|NCT00874718|workers
456138|NCT00874692|tap water temperature
456139|NCT00874692|social housing
456140|NCT00874692|scald reduction
456141|NCT00874692|Temperature (degrees Celsius) of hot tap water at point of delivery.
456142|NCT00874666|garlic
456143|NCT00874666|allicin
456144|NCT00874666|allyl methyl sulfide
456145|NCT00874666|healthy persons
456146|NCT00874640|Drug utilization review
456147|NCT00874627|children > 5 years old
456148|NCT00874627|IgE-mediated
456149|NCT00874627|cow milk allergy
456150|NCT00874627|IgE-mediated cow milk allergy persisting after 5 years
456151|NCT00874614|radiotherapy
456152|NCT00874614|MIBG
456153|NCT00874614|Azedra
456154|NCT00874614|neuroendocrine tumors
456155|NCT00874614|Iobenguane I 131
456156|NCT00874614|progenics
456157|NCT00874601|acute ischemic stroke
456158|NCT00874601|blood pressure
456159|NCT00874601|valsartan
456160|NCT00874601|death
456161|NCT00874601|dependancy
456162|NCT00874575|HMB
456163|NCT00874575|Vitamin D
456164|NCT00874575|Older Adults
456165|NCT00874562|rapamycin
456166|NCT00874562|corticosteroid
456167|NCT00874562|ALL
456168|NCT00874549|Meningococcal Vaccine
456169|NCT00874549|Menactra®
456170|NCT00874549|Menomune®
456171|NCT00874536|ADHD
456172|NCT00874536|methylphenidate
456173|NCT00874536|omega-3
456174|NCT00874523|raltegravir
456175|NCT00874523|atazanavir
456176|NCT00874523|HIV infections
456177|NCT00874523|pharmacokinetics
456178|NCT00874523|antiretroviral agents
456179|NCT00874523|treatment experienced
456180|NCT00874510|sleep deprivation
456181|NCT00874510|fatigue
456182|NCT00874458|ductal breast carcinoma in situ
456183|NCT00874432|cardiovascular disease
456184|NCT00874432|angiotensin converting enzyme inhibitors
456185|NCT00874432|chronic kidney disease
456186|NCT00874432|cardiovascular disease in elderly patients with CKD
456187|NCT00874419|EGFR mutation
456188|NCT00874419|EGFR-TKI
456189|NCT00874419|Chemotherapy
456190|NCT00874406|colorectal cancer
456191|NCT00874406|liver metastasis
456192|NCT00874406|neoadjuvant chemotherapy
456193|NCT00874393|NICHD Neonatal Research Network
456194|NCT00874393|Very Low Birth Weight (VLBW)
456195|NCT00874393|Extremely Low Birth Weight (ELBW)
456196|NCT00874393|Prematurity
456197|NCT00874393|Blood Pressure Management
456198|NCT00874393|Dopamine
456199|NCT00874393|Hydrocortisone
456200|NCT00874380|Fiber
456201|NCT00874380|Dialysis
456202|NCT00874380|Renal Replacement Therapy
456203|NCT00874380|Food Frequency Questionnaire
456204|NCT00874380|FFQ
456205|NCT00874380|Dietary counseling
456206|NCT00874367|NICHD Neonatal Research Network
456207|NCT00874367|Very Low Birth Weight (VLBW)
456208|NCT00874367|Extremely Low Birth Weight (ELBW)
456209|NCT00874367|Prematurity
456210|NCT00874367|Early Onset Sepsis
456211|NCT00874354|Myocardial Infarction
456212|NCT00874354|Heart Attack
456213|NCT00874354|Infarct
456214|NCT00874354|Stem Cells
456215|NCT00874354|Bone Marrow Derived Mononuclear Cells
456216|NCT00874354|CHF
456217|NCT00874354|Congestive Heart Failure
456218|NCT00874354|Stent
456219|NCT00874354|PCI
456220|NCT00874354|Percutaneous Coronary Intervention
456221|NCT00874341|Fruit
456222|NCT00874341|Vegetables
456223|NCT00874341|Intervention
456224|NCT00874341|Insulin resistance
456225|NCT00874341|Cardiovascular disease risk
456226|NCT00874341|Dose response
456227|NCT00874341|High risk of cardiovascular disease
456228|NCT00874328|Non small cell lung cancer
456229|NCT00874328|Irinotecan plus Cisplatin plus S-1
456230|NCT00874328|Phase I/II trial
456231|NCT00874315|recurrent or refractory neuroblastoma
456232|NCT00874302|Uterine fibroids
456233|NCT00874289|NGAL
456234|NCT00874289|Heart failure
456235|NCT00874276|DCA
456236|NCT00874276|Dichloroacetate
456237|NCT00874276|Trichloroacetate
456238|NCT00874263|Probe-based imaging of GI pre-malignant or malignant lesions
456239|NCT00874237|Staccato loxapine
456240|NCT00874237|QTc
456241|NCT00874237|healthy volunteers
456242|NCT00874224|Colorectal cancer liver metastasis
456243|NCT00874224|Benign liver disease
456244|NCT00874211|bone metastases
456245|NCT00874211|unspecified adult solid tumor, protocol specific
456246|NCT00874211|refractory multiple myeloma
456247|NCT00874211|stage I multiple myeloma
456248|NCT00874211|stage II multiple myeloma
456249|NCT00874211|stage III multiple myeloma
456250|NCT00874211|male breast cancer
456251|NCT00874211|recurrent breast cancer
456252|NCT00874211|stage IA breast cancer
456253|NCT00874211|stage IB breast cancer
456254|NCT00874211|stage II breast cancer
456255|NCT00874211|stage IIIA breast cancer
456256|NCT00874211|stage IIIB breast cancer
456257|NCT00874211|stage IIIC breast cancer
456258|NCT00874211|stage IV breast cancer
456259|NCT00874211|recurrent prostate cancer
456260|NCT00874211|stage I prostate cancer
456261|NCT00874211|stage IIB prostate cancer
456262|NCT00874211|stage IIA prostate cancer
456263|NCT00874211|stage III prostate cancer
456264|NCT00874211|stage IV prostate cancer
456265|NCT00874211|recurrent non-small cell lung cancer
456266|NCT00874211|stage I non-small cell lung cancer
456267|NCT00874211|stage II non-small cell lung cancer
456268|NCT00874211|stage IIIA non-small cell lung cancer
456269|NCT00874211|stage IIIB non-small cell lung cancer
456270|NCT00874211|stage IV non-small cell lung cancer
456271|NCT00874211|extensive stage small cell lung cancer
456272|NCT00874211|limited stage small cell lung cancer
456273|NCT00874211|recurrent small cell lung cancer
456274|NCT00874198|normal pressure hydrocephalus
456275|NCT00874198|cerebrospinal fluid dynamic test
456276|NCT00874198|cerebrospinal fluid outflow resistance
456277|NCT00874198|cerebrospinal compliance
456278|NCT00874198|outcome
456279|NCT00874198|shunt surgery
456280|NCT00874198|normal pressure hydrocephalus guidelines
456281|NCT00874198|biomarkers
456282|NCT00874198|shunt surgery selection
456283|NCT00874198|Outcome measures
456284|NCT00874198|Outcomes assessment
456285|NCT00874198|Outcome and process assessment
456286|NCT00874185|satisfaction
456287|NCT00874172|Anemia
456288|NCT00874172|Sickle Cell
456289|NCT00874172|Analgesic
456290|NCT00874172|Pain
456291|NCT00874172|Emergency treatment
456292|NCT00874172|Quality of life
456293|NCT00874107|NSCLC
456294|NCT00874107|Phase 2
456295|NCT00874107|Randomized
456296|NCT00874107|Efficacy
456297|NCT00874107|Safety
456298|NCT00874107|Imprime PGG
456299|NCT00874107|Bevacizumab
456300|NCT00874094|nasolabial folds
456301|NCT00874094|platelet rich plasma
456302|NCT00874094|fibrin matrix
456303|NCT00874094|facial rhytids
456304|NCT00874094|dermal filler
456305|NCT00874068|term infants
456306|NCT00874068|preterm infants
456307|NCT00874068|bone strength
456308|NCT00874068|Speed of sound (SOS)
456309|NCT00874068|Ultrasound
456310|NCT00874055|social influence
456311|NCT00874055|friends
456312|NCT00874055|eating behavior
456313|NCT00874055|childhood overweight
456314|NCT00874042|dose escalation
456315|NCT00874042|safety
456316|NCT00874042|tolerability
456317|NCT00874042|tumor
456318|NCT00874042|PK
456319|NCT00874029|Uterine Fibroids
456320|NCT00874029|Myomas
456321|NCT00874016|intubation
456322|NCT00874016|Airtraq
456323|NCT00874016|pediatric
456324|NCT00874016|airway
456325|NCT00874003|alcohol dependence
456326|NCT00874003|anti-depressant
456327|NCT00874003|5-HT
456328|NCT00874003|NE
456329|NCT00873990|fissure sealant
456330|NCT00873990|self etch
456331|NCT00873990|total etch
456332|NCT00873977|Adherence
456333|NCT00873977|Continuous Positive Airway Pressure
456334|NCT00873964|Metabolic Syndrome
456335|NCT00873964|Obesity
456336|NCT00873964|Elderly
456337|NCT00873964|Insulin Resistance
456338|NCT00873938|Artesunate-Amodiaquine
456339|NCT00873938|Compliance
456340|NCT00873938|Malaria
456341|NCT00873925|Type 1 Diabetes
456342|NCT00873912|influenza
456343|NCT00873912|FluMist
456344|NCT00873899|Heart Failure
456345|NCT00873899|Implantable defibrillator
456346|NCT00873899|Remote Monitoring
456347|NCT00873873|Asthma Progression
456348|NCT00873873|Airway Wall Thickness
456349|NCT00873873|Corticosteroid Resistance
456350|NCT00873873|Biomarkers
456351|NCT00873873|Pulmonary Physiology
456352|NCT00873860|Interleukin
456353|NCT00873860|Adult
456354|NCT00873847|NICHD Neonatal Research Network
456355|NCT00873847|Very Low Birth Weight (VLBW)
456356|NCT00873847|Extremely Low Birth Weight (ELBW)
456357|NCT00873847|Prematurity
456358|NCT00873847|Amplitude-integrated Electroencephalography (aEEG)
456359|NCT00873834|autism
456360|NCT00873834|fluoxetine
456361|NCT00873834|Comparative
456362|NCT00873834|double blind
456363|NCT00873834|placebo
456364|NCT00873834|controlled trial
456365|NCT00873834|anatomy-functional imaging
456366|NCT00873834|children
456367|NCT00873834|DSM-IV-R criteria for autism and CARS score (of 30 or above)
456368|NCT00873808|breast cancer
456369|NCT00873795|efficacy
456370|NCT00873795|tolerability
456371|NCT00873795|combination of aripiprazole and SSRI(sertraline)
456372|NCT00873782|Limb Perfusion
456373|NCT00873782|Gene Therapy
456374|NCT00873769|Staccato Loxapine
456375|NCT00873769|pharmacokinetics
456376|NCT00873769|smokers
456377|NCT00873769|non-smokers
456378|NCT00873756|CRC
456379|NCT00873756|Colon Cancer
456380|NCT00873756|Avastin
456381|NCT00873756|Apo2L/TRAIL
456382|NCT00873743|lower pain intensity with combination drug after cesarian section in first 48h postoperatively
456383|NCT00873730|Effect of etanercept in subjects with ankylosing spondylitis
456384|NCT00873717|elderly
456385|NCT00873717|long-term facilities
456386|NCT00873717|nutritional status
456387|NCT00873691|Patients indicated for an ICD/ CRT-D
456388|NCT00873678|Molar tooth
456389|NCT00873678|AHI1 gene
456390|NCT00873678|CEP290 gene
456391|NCT00873678|ciliopathies
456392|NCT00873652|Hepatitis B vaccine
456393|NCT00873652|Booster dose
456394|NCT00873652|Persistence
456395|NCT00873652|Immune response
456396|NCT00873652|Healthy children
456397|NCT00873626|Urinary tract infection
456398|NCT00873626|treatment duration
456399|NCT00873626|acute pyelonephritis
456400|NCT00873626|good use of antibiotics
456401|NCT00873600|cognitive/functional effects
456402|NCT00873600|psychosocial effects of cancer and its treatment
456403|NCT00873600|stage I breast cancer
456404|NCT00873600|stage II breast cancer
456405|NCT00873600|stage IIIA breast cancer
456406|NCT00873600|stage IIIB breast cancer
456407|NCT00873600|stage IIIC breast cancer
456408|NCT00873600|adenocarcinoma of the colon
456409|NCT00873600|stage I colon cancer
456410|NCT00873600|stage II colon cancer
456411|NCT00873600|stage III colon cancer
456412|NCT00873587|Thoracotomy
456413|NCT00873587|Inspiration
456414|NCT00873587|Expiration
456415|NCT00873587|Chest Tube
456416|NCT00873587|pneumothorax
456417|NCT00873587|Method of chest tube removal
456418|NCT00873574|Familial myeloproliferative disorders
456419|NCT00873574|JAK-STAT
456420|NCT00873574|V617
456421|NCT00873574|JAK2
456422|NCT00873561|diabetes
456423|NCT00873561|type 1
456424|NCT00873561|adult
456425|NCT00873561|adolescent
456426|NCT00873561|new onset
456427|NCT00873535|Nicotine
456428|NCT00873535|Nicotine dependence
456429|NCT00873535|Smoking cessation
456430|NCT00873535|Alcohol
456431|NCT00873535|Alcohol dependence
456432|NCT00873535|Alcohol cessation
456433|NCT00873535|Treatment
456434|NCT00873535|Smoking
456435|NCT00873535|Cigarette
456436|NCT00873535|Heavy drinkers
456437|NCT00873535|Social drinkers
456438|NCT00873535|Co-morbidity of alcohol and nicotine dependence
456439|NCT00873535|Nicotine receptor
456440|NCT00873535|Nicotinic receptor
456441|NCT00873535|Nicotinic acetycholine receptor
456442|NCT00873535|Alpha-4-beta-2 nicotinic acetycholine receptor
456443|NCT00873535|Cholinergic receptor
456444|NCT00873535|Dopamine
456445|NCT00873535|Craving
456446|NCT00873535|Diary
456447|NCT00873535|Cue induced
456448|NCT00873535|Pharmacotherapy
456449|NCT00873535|Varenicline
456450|NCT00873535|Chantix
456451|NCT00873535|Champix
456452|NCT00873522|pneumonia
456453|NCT00873509|Autism
456454|NCT00873496|Sjögren's Syndrome
456455|NCT00873496|hyposalivation
456456|NCT00873496|mouth dryness
456457|NCT00873496|complications
456458|NCT00873483|Pregnancy prevention
456459|NCT00873483|female contraception
456460|NCT00873483|patch
456461|NCT00873457|B-Cell Chronic Lymphocytic Leukemia
456462|NCT00873457|Leukemia
456463|NCT00873444|Hip
456464|NCT00873444|Cementless
456465|NCT00873444|Ceramic-on-Metal
456466|NCT00873444|Metal-on-Metal
456467|NCT00873431|Prevention of pneumococcal infections
456468|NCT00873418|Heart Failure
456469|NCT00873418|Intervention
456470|NCT00873418|Cognitive Behavior Therapy
456471|NCT00873418|Quality of Life
456472|NCT00873405|Type 2 diabetes mellitus
456473|NCT00873405|Metabolic control
456474|NCT00873405|Bariatric Surgery
456475|NCT00873405|Weight Loss
456476|NCT00873405|Sleeve gastrectomy
456477|NCT00873405|BMI reduction
456478|NCT00873405|Waist circumference reduction
456479|NCT00873405|Percentage of excess BMI loss
456480|NCT00873405|Glucose homeostasis
456481|NCT00873392|Parkinson's disease
456482|NCT00873392|Motor fluctuation
456483|NCT00873392|Nicotine
456484|NCT00873392|Drug treatment
456485|NCT00873392|neuroprotection
456486|NCT00873366|stage I breast cancer
456487|NCT00873366|stage II breast cancer
456488|NCT00873366|stage IIIA breast cancer
456489|NCT00873366|stage IIIB breast cancer
456490|NCT00873366|stage IIIC breast cancer
456491|NCT00873353|Metastatic Adenocarcinoma of the Pancreas
456492|NCT00873340|MS
456493|NCT00873340|Multiple Sclerosis
456494|NCT00873340|Betaferon
456495|NCT00873340|Colombia
456496|NCT00873327|presumed sepsis
456497|NCT00873301|vulvodynia
456498|NCT00873301|vestibulectomy
456499|NCT00873301|surgery
456500|NCT00873301|vestibulitis
456501|NCT00873288|cervical intraepithelial neoplasia
456502|NCT00873288|atypical squamous cells of undetermined significance
456503|NCT00873288|high-grade squamous intraepithelial lesion
456504|NCT00873288|low-grade squamous intraepithelial lesion
456505|NCT00873275|stage IV colon cancer
456506|NCT00873275|stage IV rectal cancer
456507|NCT00873275|recurrent colon cancer
456508|NCT00873275|recurrent rectal cancer
456509|NCT00873275|adenocarcinoma of the colon
456510|NCT00873275|adenocarcinoma of the rectum
456511|NCT00873262|PreMenstrual Syndrome
456512|NCT00873262|Hormones
456513|NCT00873262|Skin tests
456514|NCT00873262|Desensitization
456515|NCT00873262|Allergen Immunotherapy
456516|NCT00873249|Schizophrenia
456517|NCT00873249|Therapeutic adherence
456518|NCT00873249|Short message system
456519|NCT00873249|Mobile phone
456520|NCT00873236|stage III renal cell cancer
456521|NCT00873236|stage IV renal cell cancer
456522|NCT00873210|renal cell carcinoma
456523|NCT00873210|sunitinib malate
456524|NCT00873197|Co-administration of transdermal and intravenous granisetron
456525|NCT00873197|Granisetron
456526|NCT00873197|Healthy subjects
456527|NCT00873197|Intravenous
456528|NCT00873197|Pharmacokinetic profile
456529|NCT00873197|Sancuso® patch
456530|NCT00873197|Transdermal
456531|NCT00873197|Pharmacokinetics
456532|NCT00873184|massage therapy in patients with brain tumors
456533|NCT00873171|Osteopathic Manipulation
456534|NCT00873158|Adhesive Capsulitis
456535|NCT00873158|ROM
456536|NCT00873158|Dynasplint
456537|NCT00873145|Survival
456538|NCT00873145|Function
456539|NCT00873145|Infection
456540|NCT00873145|Revision
456541|NCT00873145|Loosening
456542|NCT00873119|Belinostat
456543|NCT00873119|PXD101
456544|NCT00873119|Carboplatin
456545|NCT00873119|Paclitaxel
456546|NCT00873119|CUP
456547|NCT00873119|Carcinoma of unknown primary
456548|NCT00873119|Occult primary
456549|NCT00873080|reliability
456550|NCT00873080|photogrammetry
456551|NCT00873067|Atrial fibrillation
456552|NCT00873067|Complex fractionated electrograms
456553|NCT00873067|CFAE
456554|NCT00873041|Thalassemia
456555|NCT00873041|thalassemia intermedia
456556|NCT00873041|alpha-thalassemia
456557|NCT00873041|beta-thalassemia
456558|NCT00873041|deferasirox
456559|NCT00873041|iron overload
456560|NCT00873041|non-transfusion dependent
456561|NCT00873028|Physical therapy
456562|NCT00873028|Inspiratory muscles
456563|NCT00873028|Exercise
456564|NCT00873015|Cerebral aneurysm
456565|NCT00873015|Subarachnoid hemorrhage
456566|NCT00873015|Nitrite
456567|NCT00873002|adult primary hepatocellular carcinoma
456568|NCT00873002|advanced adult primary liver cancer
456569|NCT00873002|recurrent adult primary liver cancer
456570|NCT00873002|localized unresectable adult primary liver cancer
456571|NCT00872989|recurrent ovarian epithelial cancer
456572|NCT00872989|recurrent fallopian tube cancer
456573|NCT00872989|recurrent primary peritoneal cavity cancer
456574|NCT00872963|malaria vaccine
456575|NCT00872963|RTS,S,
456576|NCT00872950|LEMS
456577|NCT00872950|CMS
456578|NCT00872950|3,4 DIAMINOPYRIDINE
456579|NCT00872950|3,4 DAP
456580|NCT00872924|Bioequivalence
456581|NCT00872911|Sarcopenia
456582|NCT00872911|nutrition
456583|NCT00872911|aging
456584|NCT00872911|metabolism
456585|NCT00872911|exercise
456586|NCT00872898|autism
456587|NCT00872898|memantine
456588|NCT00872898|pediatric
456589|NCT00872898|Forest Laboratories
456590|NCT00872898|Autism in pediatric patients
456591|NCT00872885|analgesic
456592|NCT00872885|bunionectomy
456593|NCT00872885|surgery
456594|NCT00872885|post operative pain
456595|NCT00872885|single Hallux valgus repair
456596|NCT00872872|NVP
456597|NCT00872872|PMTCT
456598|NCT00872872|pregnancy
456599|NCT00872872|resistance
456600|NCT00872859|Breast Cancer
456601|NCT00872859|Cancer of Breast
456602|NCT00872859|Reconstructive Surgery
456603|NCT00872846|Body weight
456604|NCT00872846|Signs and symptoms
456605|NCT00872846|Obesity
456606|NCT00872846|Metabolic disease
456607|NCT00872846|Diabetes mellitus type 2
456608|NCT00872846|Diabetes mellitus
456609|NCT00872846|Nutrition disorder
456610|NCT00872846|Endocrine system diseases
456611|NCT00872846|Overweight
456612|NCT00872846|Overnutrition
456613|NCT00872846|Glucose metabolic disorder
456614|NCT00872833|Transfusion-Dependant Thalassemia
456615|NCT00872833|Pain
456616|NCT00872833|Mild Pain
456617|NCT00872820|Social Anxiety
456618|NCT00872820|Social Anxiety Treatment
456619|NCT00872820|Cognitive Therapy
456620|NCT00872820|Mindfulness
456621|NCT00872820|Social Phobia
456622|NCT00872820|Social Phobia Treatment
456623|NCT00872807|childhood
456624|NCT00872807|therapy
456625|NCT00872807|life style
456626|NCT00872807|motor activity
456627|NCT00872807|obesity
456628|NCT00872807|overweight
456629|NCT00872807|body mass index
456630|NCT00872807|treatment
456631|NCT00872794|Hip
456632|NCT00872794|Conservative
456633|NCT00872794|Metal on Metal
456634|NCT00872794|Resurfacing
456635|NCT00872781|Bioequivalence fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
456636|NCT00872742|Impulse Control Disorders
456637|NCT00872742|Behavior Therapy
456638|NCT00872742|Acceptance
456639|NCT00872742|Habit Reversal
456640|NCT00872729|cystinosis
456641|NCT00872729|cysteamine
456642|NCT00872729|inheritable disease
456643|NCT00872729|orphan disease
456644|NCT00872729|CTNS protein, human
456645|NCT00872729|nephropathic cystinosis
456646|NCT00872716|specific phobia
456647|NCT00872716|simple phobia
456648|NCT00872716|anxiety disorder
456649|NCT00872703|CMV
456650|NCT00872703|Prenatal Diagnosis
456651|NCT00872703|Ultrasound
456652|NCT00872703|MRI
456653|NCT00872690|Multiple Trauma
456654|NCT00872690|Blast Injuries
456655|NCT00872690|Brain Injuries
456656|NCT00872690|Rehabilitation, Vocational
456657|NCT00872690|Consumer participation
456658|NCT00872677|weight changes
456659|NCT00872677|obesity
456660|NCT00872677|stage I breast cancer
456661|NCT00872677|stage II breast cancer
456662|NCT00872677|stage IIIA breast cancer
456663|NCT00872664|ROP
456664|NCT00872664|anti-oxidants
456665|NCT00872664|carotenoids
456666|NCT00872651|Glaucoma
456667|NCT00872651|intraocular pressure
456668|NCT00872651|travoprost/timolol
456669|NCT00872651|timolol
456670|NCT00872638|wound edge eversion
456671|NCT00872638|cosmetic outcomes
456672|NCT00872638|surgical incisions
456673|NCT00872625|stage IA breast cancer
456674|NCT00872625|stage IB breast cancer
456675|NCT00872625|stage II breast cancer
456676|NCT00872625|stage IIIA breast cancer
456677|NCT00872625|stage IIIB breast cancer
456678|NCT00872625|stage IIIC breast cancer
456679|NCT00872625|recurrent breast cancer
456680|NCT00872612|Sarcoidosis
456681|NCT00872612|Diagnosis
456682|NCT00872612|Non-caseating granulomas
456683|NCT00872612|BAL
456684|NCT00872612|EUS-FNA
456685|NCT00872612|EBUS-TBNA
456686|NCT00872612|TBLB
456687|NCT00872599|Hypertension
456688|NCT00872599|Phenotyping
456689|NCT00872599|High Salt intake
456690|NCT00872599|frequently sampled IV glucose tolerance test(FSIVGTT)
456691|NCT00872599|fenofibrate
456692|NCT00872599|epoxyeicosatrienoic acids
456693|NCT00872599|hydroxyeicosatetraenoic acids
456694|NCT00872599|dihydroxyeicosatrienoic acid
456695|NCT00872599|PPAR Alpha Agonist
456696|NCT00872599|CYP Monooxygenase Activity
456697|NCT00872573|Hip
456698|NCT00872573|Cemented
456699|NCT00872547|Hip
456700|NCT00872547|Resurfacing
456701|NCT00872547|Metal-on-Metal
456702|NCT00872547|Large Heads
456703|NCT00872547|XL Head
456704|NCT00872547|ASR - osteoarthritis (primary)
456705|NCT00872534|To evaluate the acute gastrointestinal safety of PL-2100.
456706|NCT00872521|Multiple Myeloma
456707|NCT00872521|transplant eligible
456708|NCT00872521|doxorubicin
456709|NCT00872521|dexamethasone
456710|NCT00872521|bortezomib
456711|NCT00872521|bortezomib resistance
456712|NCT00872521|PAD induction
456713|NCT00872521|PIMMS Trial
456714|NCT00872495|Urothelial Cancer
456715|NCT00872495|Cancer
456716|NCT00872495|Bladder Neoplasms
456717|NCT00872495|Urinary Bladder Cancer
456718|NCT00872482|non-small cell lung cancer
456719|NCT00872482|NSCLC
456720|NCT00872482|Brain metastases
456721|NCT00872482|nimotuzumab
456722|NCT00872482|TheraCIM
456723|NCT00872482|h-R3
456724|NCT00872482|Radiation
456725|NCT00872469|Postpartum haemorrhage
456726|NCT00872469|randomised controlled trial
456727|NCT00872469|tranexamic acid
456728|NCT00872469|antifibrinolytic
456729|NCT00872456|Diabetes Mellitus
456730|NCT00872456|Cardiovascular Disease
456731|NCT00872456|Haptoglobin
456732|NCT00872430|constipation
456733|NCT00872430|RCT
456734|NCT00872430|phytotherapy
456735|NCT00872417|HIV/AIDS
456736|NCT00872417|antiretroviral therapy
456737|NCT00872417|immune reconstitution
456738|NCT00872404|CP-751,871
456739|NCT00872404|squamous cell carcinoma
456740|NCT00872404|recurrent or metastatic
456741|NCT00872404|after 1st line chemotherapy
456742|NCT00872378|Morbid Obesity
456743|NCT00872378|LAP Band
456744|NCT00872378|Adjustable Gastric Band
456745|NCT00872378|Exenatide
456746|NCT00872378|Byetta
456747|NCT00872378|Weight Loss
456748|NCT00872378|Bariatric Surgery
456749|NCT00872365|Pregnancy
456750|NCT00872365|Exercise
456751|NCT00872365|Nutrition
456752|NCT00872365|Micronutrients
456753|NCT00872365|non-transmissible chronic diseases
456754|NCT00872365|Endothelium
456755|NCT00872352|Multiple Myeloma
456756|NCT00872352|Bortezomib
456757|NCT00872352|Peripheral Neuropathy
456758|NCT00872352|evaluation
456759|NCT00872352|evaluation of electrophysiological changes related to the dose and time of bortezomib administration
456760|NCT00872352|investigation of correlation between the incidence of BIPN and the subtype of myeloma
456761|NCT00872339|Transfusion-Dependent Thalassemia
456762|NCT00872339|Non-Transfusion-Dependent Thalassemia
456763|NCT00872326|Diabetes Complications
456764|NCT00872326|Lower limb ischemia
456765|NCT00872326|Adult stem cells
456766|NCT00872313|Labor
456767|NCT00872313|Psychology
456768|NCT00872313|Postpartum Psychology
456769|NCT00872287|minimally invasive surgery
456770|NCT00872287|scarless cholecystectomy
456771|NCT00872287|new techniques in laparoscopy
456772|NCT00872287|invisible scar
456773|NCT00872287|single port access
456774|NCT00872287|abdominal pain
456775|NCT00872287|shoulder pain
456776|NCT00872274|Bioequivalence
456777|NCT00872261|Clinical Trials as Topic
456778|NCT00872261|Adolescent Psychology
456779|NCT00872261|Patient Acceptance of Health Care
456780|NCT00872261|HIV Risk Behaviors
456781|NCT00872261|Adolescents
456782|NCT00872261|Clinical Trial Recruitment
456783|NCT00872261|Microbicide Acceptability
456784|NCT00872261|Ethics
456785|NCT00872261|Mixed Methods
456786|NCT00872261|HIV
456787|NCT00872248|Restless leg syndrome
456788|NCT00872248|Spinal anesthesia
456789|NCT00872248|Epidural anesthesia
456790|NCT00872248|Neuraxial block
456791|NCT00872235|Bioequivalence fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
456792|NCT00872222|Hip
456793|NCT00872222|Cementless
456794|NCT00872222|Ceramic-on-Ceramic
456795|NCT00872209|swimmer's ear
456796|NCT00872209|ear drops
456797|NCT00872209|ear foam
456798|NCT00872209|otic foam
456799|NCT00872209|ear infection
456800|NCT00872209|ear pain
456801|NCT00872209|ear inflammation
456802|NCT00872183|Motor Learning
456803|NCT00872183|Mirror Neurons
456804|NCT00872183|Healthy Volunteer
456805|NCT00872183|HV
456806|NCT00872170|Pulmonary Hypertension
456807|NCT00872157|Castrate-Resistant Prostate Cancer
456808|NCT00872157|Prostate
456809|NCT00872157|High-Volume Osseous Metastases
456810|NCT00872157|BMTP-11
456811|NCT00872157|Prostate State Antigen
456812|NCT00872157|PSA
456813|NCT00872131|Anxiety
456814|NCT00872131|Social Phobia
456815|NCT00872131|Generalized Social Anxiety Disorder
456816|NCT00872118|alcohol consumption
456817|NCT00872118|social anxiety
456818|NCT00872118|brief intervention
456819|NCT00872118|motivational interviewing
456820|NCT00872118|cognitive behavioral
456821|NCT00872105|clavicle
456822|NCT00872105|fractures
456823|NCT00872105|distal
456824|NCT00872092|small bowel
456825|NCT00872092|bacterial overgrowth
456826|NCT00872079|warfarin
456827|NCT00872079|pharmacokinetics
456828|NCT00872079|pharmacodynamics
456829|NCT00872066|Hip
456830|NCT00872066|Bone Cement
456831|NCT00872053|robot
456832|NCT00872053|treadmill
456833|NCT00872053|foot drop
456834|NCT00872053|rehabilitation
456835|NCT00872053|gait
456836|NCT00872040|Sexual function
456837|NCT00872040|Pelvic floor disorders
456838|NCT00872040|Delivery mode
456839|NCT00872027|Critical Illness
456840|NCT00872027|Intensive Care Unit
456841|NCT00872027|Acute Respiratory Failure
456842|NCT00872027|Prolonged Mechanical Ventilation
456843|NCT00871975|LUTS
456844|NCT00871975|OAB
456845|NCT00871962|long-term oxygen therapy
456846|NCT00871962|COPD patients on necessity of long-term oxygen therapy
456847|NCT00871949|Safety tolerability pharmacokinetics PK first in human FIH
456848|NCT00871923|Non-small cell lung cancer
456849|NCT00871923|NSCLC
456850|NCT00871923|Brain Metastases
456851|NCT00871923|Brain Cancer
456852|NCT00871923|Lung Cancer
456853|NCT00871923|Tarceva
456854|NCT00871923|Erlotinib Hydrochloride
456855|NCT00871923|OSI-774
456856|NCT00871923|Radiation Therapy
456857|NCT00871923|Whole Brain Radiation Therapy
456858|NCT00871923|WBRT
456859|NCT00871897|Neuropsychology
456860|NCT00871897|Cardiac Rehabilitation
456861|NCT00871884|Post Concussion Syndrome
456862|NCT00871884|Cognitive Behavioral Therapy
456863|NCT00871884|Anxiety Sensitivity
456864|NCT00871884|Mild Head Injury
456865|NCT00871884|Psychotherapy
456866|NCT00871884|Chronic Post Concussion Symptoms
456867|NCT00871858|stage II breast cancer
456868|NCT00871858|stage IIIA breast cancer
456869|NCT00871858|stage IIIB breast cancer
456870|NCT00871858|estrogen receptor-positive breast cancer
456871|NCT00871858|progesterone receptor-positive breast cancer
456872|NCT00871845|obesity
456873|NCT00871845|hepatitis C
456874|NCT00871845|insulin resistance
456875|NCT00871845|metabolic syndrome
456876|NCT00871832|hyperglycemia
456877|NCT00871832|HgA1c
456878|NCT00871832|mortality
456879|NCT00871819|Spinal Cord Stimulation
456880|NCT00871806|Pharmacokinetics
456881|NCT00871806|eletriptan
456882|NCT00871806|bioavailability
456883|NCT00871806|oral disintegrating tablet
456884|NCT00871780|TYSABRI naive
456885|NCT00871780|Relapsing-remitting multiple sclerosis (RRMS)
456886|NCT00871767|AZD5672
456887|NCT00871767|relative bioavailability
456888|NCT00871767|rheumatoid arthritis (RA)
456889|NCT00871754|Bladder Cancer
456890|NCT00871754|Cancer, bladder
456891|NCT00871754|Urinary Bladder Cancer
456892|NCT00871741|Combined vaccine
456893|NCT00871741|Primary vaccination
456894|NCT00871728|Onychomycosis, Toe
456895|NCT00871728|Itraconazole
456896|NCT00871728|Sporanox
456897|NCT00871715|stroke
456898|NCT00871715|hemiparesis
456899|NCT00871715|physical therapy
456900|NCT00871715|occupational therapy
456901|NCT00871715|neurorehabilitation
456902|NCT00871715|patient focused
456903|NCT00871715|motor learning
456904|NCT00871715|motor control
456905|NCT00871715|skill acquisition
456906|NCT00871715|skill training
456907|NCT00871715|motor recovery
456908|NCT00871715|task oriented training
456909|NCT00871715|task specific training
456910|NCT00871715|arm function
456911|NCT00871715|hand function
456912|NCT00871715|upper extremity
456913|NCT00871715|arm therapy
456914|NCT00871715|physical rehabilitation
456915|NCT00871715|arm rehabilitation
456916|NCT00871715|motor function
456917|NCT00871702|Leukemia
456918|NCT00871702|Lymphoma, Non-Hodgkin
456919|NCT00871702|Hodgkin Disease
456920|NCT00871702|Myelodysplastic Syndromes
456921|NCT00871702|Multiple Myeloma
456922|NCT00871689|recurrent adult acute myeloid leukemia
456923|NCT00871689|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
456924|NCT00871689|adult acute myeloid leukemia with inv(16)(p13;q22)
456925|NCT00871689|adult acute myeloid leukemia with t(15;17)(q22;q12)
456926|NCT00871689|adult acute myeloid leukemia with t(16;16)(p13;q22)
456927|NCT00871689|adult acute myeloid leukemia with t(8;21)(q22;q22)
456928|NCT00871689|recurrent childhood acute myeloid leukemia
456929|NCT00871689|secondary acute myeloid leukemia
456930|NCT00871689|childhood acute myeloid leukemia with 11q23 (MLL) abnormalities
456931|NCT00871689|childhood acute myeloid leukemia with inv(16)(p13;q22)
456932|NCT00871689|childhood acute myeloid leukemia with t(15;17)(q22;q12)
456933|NCT00871689|childhood acute myeloid leukemia with t(16;16)(p13;q22)
456934|NCT00871689|childhood acute myeloid leukemia with t(8;21)(q22;q22)
456935|NCT00871650|Post Traumatic Stress Disorder
456936|NCT00871650|PTSD
456937|NCT00871650|Brain
456938|NCT00871650|Imaging
456939|NCT00871650|PET
456940|NCT00871650|Neural
456941|NCT00871650|Sleep
456942|NCT00871650|REM Sleep
456943|NCT00871637|Pulmonary disease, chronic obstructive
456944|NCT00871637|Airway macrophages
456945|NCT00871637|Sputum milieu
456946|NCT00871637|Airway inflammation
456947|NCT00871637|Occupational diseases
456948|NCT00871611|Hereditary
456949|NCT00871611|Anderson-Fabry
456950|NCT00871611|prevalence
456951|NCT00871611|heart
456952|NCT00871611|hypertrophy
456953|NCT00871611|urine
456954|NCT00871611|globotriaosylceramide
456955|NCT00871611|isoforms
456956|NCT00871611|α - Galactosidase
456957|NCT00871598|plaque psoriasis
456958|NCT00871598|BTT1023
456959|NCT00871598|safety
456960|NCT00871598|pharmacokinetics
456961|NCT00871585|bicalutamide
456962|NCT00871585|PSA
456963|NCT00871585|advanced prostate cancer
456964|NCT00871572|Diabetes Mellitus, Type 2
456965|NCT00871533|Biochemical Marker
456966|NCT00871533|Biochemical Markers
456967|NCT00871533|Biologic Marker
456968|NCT00871533|Biologic Markers
456969|NCT00871533|Biomarkers
456970|NCT00871533|Clinical Marker
456971|NCT00871533|Clinical Markers
456972|NCT00871533|Immune Marker
456973|NCT00871533|Immune Markers
456974|NCT00871533|Immunologic Marker
456975|NCT00871533|Immunologic Markers
456976|NCT00871533|Laboratory Marker
456977|NCT00871533|Laboratory Markers
456978|NCT00871533|Marker, Biochemical
456979|NCT00871533|Marker, Biological
456980|NCT00871533|Marker, Clinical
456981|NCT00871533|Marker, Immunologic
456982|NCT00871533|Marker, Laboratory
456983|NCT00871533|Marker, Serum
456984|NCT00871533|Marker, Surrogate
456985|NCT00871533|Markers, Biochemical
456986|NCT00871533|Markers, Biological
456987|NCT00871533|Markers, Clinical
456988|NCT00871533|Markers, Immunologic
456989|NCT00871533|Markers, Laboratory
456990|NCT00871533|Markers, Serum
456991|NCT00871533|Markers, Surrogate
456992|NCT00871533|Markers, Viral
456993|NCT00871533|Serum Marker
456994|NCT00871533|Serum Markers
456995|NCT00871533|Surrogate End Point
456996|NCT00871533|Surrogate End Points
456997|NCT00871533|Surrogate Endpoint
456998|NCT00871533|Surrogate Endpoints
456999|NCT00871533|Surrogate Marker
457000|NCT00871533|Surrogate Markers
457001|NCT00871533|Viral Marker
457002|NCT00871533|Viral Markers
457003|NCT00871520|Palliative Care
457004|NCT00871520|Predictive Value of Tests
457005|NCT00871520|Prospective Studies
457006|NCT00871520|Survival Analysis
457007|NCT00871520|Survival prediction
457008|NCT00871507|Diabetes Mellitus, Type 2
457009|NCT00871455|Spinal Cord Injury
457010|NCT00871455|Baclofen
457011|NCT00871455|Growth Hormone, Pituitary
457012|NCT00871455|Insulin-Like Growth Factor I
457013|NCT00871442|PCEA
457014|NCT00871442|labor and delivery
457015|NCT00871442|pain
457016|NCT00871442|epidural
457017|NCT00871442|anesthesia
457018|NCT00871442|pregnant women
457019|NCT00871429|skin toxicity
457020|NCT00871429|cancer patients
457021|NCT00871429|adverse effects
457022|NCT00871403|GW786034
457023|NCT00871403|pazopanib
457024|NCT00871403|pemetrexed
457025|NCT00871403|cisplatin
457026|NCT00871403|non-small cell lung cancer
457027|NCT00871403|NSCLC
457028|NCT00871390|Paroxysmal Atrial Fibrillation
457029|NCT00871390|Permanent/Persistent Atrial Fibrillation
457030|NCT00871377|epilepsy
457031|NCT00871377|cardiac risk factors
457032|NCT00871377|memory
457033|NCT00871377|cognition
457034|NCT00871377|n-3 fatty acids
457035|NCT00871377|fish oil
457036|NCT00871377|EPA
457037|NCT00871377|DHA
457038|NCT00871377|seizures
457039|NCT00871364|Bioequivalence
457040|NCT00871364|venlafaxine
457041|NCT00871364|Healthy subjects
457042|NCT00871338|combined
457043|NCT00871338|Vaccines
457044|NCT00871325|Gastric emptying
457045|NCT00871325|Small bowel transit
457046|NCT00871325|Colonic transit
457047|NCT00871325|Whole gut transit
457048|NCT00871325|Postoperative Ileus
457049|NCT00871312|diabetes
457050|NCT00871312|diabetic
457051|NCT00871312|wound
457052|NCT00871312|ulcer
457053|NCT00871312|lower extremity
457054|NCT00871312|foot
457055|NCT00871312|oxygen
457056|NCT00871312|hyperbaric
457057|NCT00871312|topical wound oxygen
457058|NCT00871299|Treatment-resistant depression, meditation, mindfulness
457059|NCT00871286|Chronic rhinosinusitis
457060|NCT00871286|Chronic sinusitis
457061|NCT00871286|CRS
457062|NCT00871273|capecitabine
457063|NCT00871273|total gastrectomy
457064|NCT00871273|pharmacokinetic
457065|NCT00871260|Coronary Disease
457066|NCT00871260|Stress Testing
457067|NCT00871260|Lexiscan (regadenoson)
457068|NCT00871260|Cardiac Magnetic Resonance Imaging
457069|NCT00871247|Bioequivalence
457070|NCT00871247|finasteride
457071|NCT00871247|Healthy subjects
457072|NCT00871234|HIV
457073|NCT00871234|Endothelial function
457074|NCT00871234|Etravirine
457075|NCT00871208|Atopic Dermatitis
457076|NCT00871208|pruritus
457077|NCT00871208|quality of life
457078|NCT00871195|Rhesus D
457079|NCT00871195|RHD
457080|NCT00871195|genotype
457081|NCT00871195|phenotype
457082|NCT00871195|neonatal
457083|NCT00871195|noninvasive
457084|NCT00871195|fetal
457085|NCT00871195|MassARRAY
457086|NCT00871195|DNA
457087|NCT00871182|COPD
457088|NCT00871182|obstructive lung diseases
457089|NCT00871182|Tiotropium
457090|NCT00871169|Irinotecan
457091|NCT00871169|Oxaliplatin
457092|NCT00871169|Cetuximab
457093|NCT00871169|Advanced or metastatic pancreatic cancer
457094|NCT00871156|Drug-Drug Interaction
457095|NCT00871143|CBT
457096|NCT00871143|BDD
457097|NCT00871130|Thyroid gland
457098|NCT00871130|bariatric surgery
457099|NCT00871130|weight loss
457100|NCT00871130|thyroid hormones
457101|NCT00871130|adult
457102|NCT00871130|morbid obesity
457103|NCT00871130|cohort
457104|NCT00871117|Co-administration
457105|NCT00871117|Immunization
457106|NCT00871117|Preschool
457107|NCT00871117|Booster
457108|NCT00871104|Infective endocarditis
457109|NCT00871091|CAD/CAM
457110|NCT00871091|orthodontics
457111|NCT00871091|fixed appliance
457112|NCT00871091|tooth movement
457113|NCT00871065|Cerebral Vasospasm
457114|NCT00871065|Vasospasm
457115|NCT00871065|Subarachnoid Hemorrhage
457116|NCT00871065|Sildenafil citrate
457117|NCT00871065|Aneurysm
457118|NCT00871065|Intracranial aneurysm
457119|NCT00871052|Polymorphic light eruption
457120|NCT00871052|UV radiation
457121|NCT00871052|Vitamin D
457122|NCT00871052|Immune suppression
457123|NCT00871052|Prevention
457124|NCT00871039|Alcoholism
457125|NCT00871039|Mechanical ventilation
457126|NCT00871026|CAD/CAM
457127|NCT00871026|orthodontics
457128|NCT00871026|fixed appliance
457129|NCT00871026|tooth movement
457130|NCT00871026|Adverse Effects
457131|NCT00871026|Time Factors
457132|NCT00871026|Treatment Outcome
457133|NCT00871013|This study is being done in an attempt to improve the remission rate and the survival time for participants with high-risk myeloma
457134|NCT00871000|Boostrix Polio
457135|NCT00871000|dTpa-IPV
457136|NCT00870987|Malaria
457137|NCT00870987|Vaccine
457138|NCT00870974|Parkinson
457139|NCT00870974|Huntington's
457140|NCT00870974|Fragile X
457141|NCT00870974|Autistic Spectrum
457142|NCT00870974|Alzheimer's
457143|NCT00870974|MCI
457144|NCT00870961|colon cancer
457145|NCT00870961|rectal cancer
457146|NCT00870961|adenomatous polyp
457147|NCT00870948|Open Label
457148|NCT00870948|Healthy Volunteers
457149|NCT00870935|Balloon catheter
457150|NCT00870935|Cervical vacuum cup
457151|NCT00870935|Hysterosalpingography
457152|NCT00870935|Infertility
457153|NCT00870935|Pain
457154|NCT00870935|Fallopian Tube Patency Tests
457155|NCT00870935|Female Infertility
457156|NCT00870896|capsaicin
457157|NCT00870896|COPD
457158|NCT00870896|COPD with chronic bronchitis
457159|NCT00870870|Tumors
457160|NCT00870870|Antibodies, Monoclonal
457161|NCT00870870|Stage IIIb Metastatic Non-Small Cell Lung Cancer
457162|NCT00870870|Stage IV Metastatic Non-Small Cell Lung Cancer
457163|NCT00870857|Lungs
457164|NCT00870857|antiretrovirals
457165|NCT00870857|HIV
457166|NCT00870857|COPD
457167|NCT00870844|Acute ischemic stroke
457168|NCT00870844|Erythropoietin
457169|NCT00870844|Carbamylated
457170|NCT00870844|Neuroprotection
457171|NCT00870831|diabetes
457172|NCT00870818|Teplizumab
457173|NCT00870818|Protege
457174|NCT00870818|MGA031
457175|NCT00870818|Monoclonal antibody
457176|NCT00870818|Type 1 Diabetes Mellitus
457177|NCT00870818|T1DM
457178|NCT00870818|MacroGenics
457179|NCT00870792|HIV
457180|NCT00870792|antiretroviral therapy
457181|NCT00870792|medication adherence
457182|NCT00870792|Treatment Experienced
457183|NCT00870779|Fluorescence
457184|NCT00870779|Brain Tumor
457185|NCT00870779|Malignant Glioma
457186|NCT00870779|Pituitary Tumor
457187|NCT00870779|Skull Base Tumor
457188|NCT00870779|Brain Lesions
457189|NCT00870779|Brain Metastases
457190|NCT00870779|Meningioma
457191|NCT00870753|Eating disorders
457192|NCT00870753|yoga
457193|NCT00870753|body awareness
457194|NCT00870753|depression
457195|NCT00870753|anxiety
457196|NCT00870740|MS
457197|NCT00870740|Multiple Sclerosis
457198|NCT00870727|PDD NOS
457199|NCT00870714|Prostate Cancer
457200|NCT00870714|Neoadjuvant
457201|NCT00870701|sarcoma
457202|NCT00870701|soft tissue
457203|NCT00870701|members
457204|NCT00870701|radiotherapy
457205|NCT00870701|absence of radiotherapy
457206|NCT00870688|valproate
457207|NCT00870688|epilepsy
457208|NCT00870688|compliance
457209|NCT00870688|sustained released minitablet
457210|NCT00870688|Orfiril long
457211|NCT00870675|Ventriculomegaly
457212|NCT00870675|ultrasound
457213|NCT00870675|MRI
457214|NCT00870675|fetus
457215|NCT00870649|Schistosomiasis vaccine
457216|NCT00870649|therapeutic vaccine
457217|NCT00870649|Bilhvax
457218|NCT00870636|Pan-Vascular Endothelial Growth Factor Blockade
457219|NCT00870636|Safety
457220|NCT00870636|ROP
457221|NCT00870636|Bevacizumab
457222|NCT00870636|Avastin
457223|NCT00870610|jugular venous oxygen saturation
457224|NCT00870610|hypothermia
457225|NCT00870597|Floaters
457226|NCT00870597|multifocal IOL
457227|NCT00870597|visual complaints
457228|NCT00870597|vitrectomy
457229|NCT00870584|Asthma; asthma management; asthma impairment ; Xolair ; omalizumab
457230|NCT00870571|Bioequivalence
457231|NCT00870571|amlodipine besylate
457232|NCT00870571|amlodipine
457233|NCT00870571|Healthy subjects
457234|NCT00870558|adult primary hepatocellular carcinoma
457235|NCT00870558|advanced adult primary liver cancer
457236|NCT00870558|localized resectable adult primary liver cancer
457237|NCT00870558|localized unresectable adult primary liver cancer
457238|NCT00870545|spouses
457239|NCT00870545|social support
457240|NCT00870545|reintegration
457241|NCT00870545|families
457242|NCT00870545|military
457243|NCT00870545|post deployment
457244|NCT00870545|OEF/OIF
457245|NCT00870532|Phase I
457246|NCT00870532|Combination
457247|NCT00870532|Anti-angiogenic
457248|NCT00870532|Sorafenib
457249|NCT00870532|Metronomic oral vinorelbine
457250|NCT00870519|Alzheimer disease
457251|NCT00870506|Randomized Controlled Trial
457252|NCT00870506|Healthcare Disparities
457253|NCT00870493|proteinuria
457254|NCT00870493|renal failure
457255|NCT00870493|glomerulonephritis
457256|NCT00870480|Bioequivalence
457257|NCT00870480|finasteride
457258|NCT00870480|Healthy subjects
457259|NCT00870467|Rheumatoid Arthritis
457260|NCT00870454|Diabetic neuropathies
457261|NCT00870454|Diabetic neuropathy, painful
457262|NCT00870454|Carisbamate
457263|NCT00870454|Neurotherapeutic agents
457264|NCT00870441|ASP2151
457265|NCT00870441|Valacyclovir
457266|NCT00870441|Healthy Volunteers
457267|NCT00870428|Preeclampsia
457268|NCT00870428|proteinuria
457269|NCT00870415|stage IA breast cancer
457270|NCT00870415|stage IB breast cancer
457271|NCT00870415|stage II breast cancer
457272|NCT00870415|stage IIIA breast cancer
457273|NCT00870415|stage IIIC breast cancer
457274|NCT00870415|ductal breast carcinoma
457275|NCT00870415|invasive ductal breast carcinoma
457276|NCT00870402|aldosterone
457277|NCT00870402|albuminuria
457278|NCT00870402|diastolic disfunction
457279|NCT00870402|hyperkalemia
457280|NCT00870376|lower urinary tract symptoms
457281|NCT00870376|biomarkers
457282|NCT00870376|urodynamic studies
457283|NCT00870363|HIV
457284|NCT00870363|HIV positive
457285|NCT00870363|Gastrointestinal Associated Lymphoid Tissue (GALT)
457286|NCT00870363|GALT Immune Reconstruction
457287|NCT00870363|treatment naive
457288|NCT00870350|immunogenicity
457289|NCT00870350|safety
457290|NCT00870350|tetanus
457291|NCT00870350|diphtheria
457292|NCT00870350|acellular
457293|NCT00870350|pertussis
457294|NCT00870350|vaccine
457295|NCT00870350|booster
457296|NCT00870350|adverse event
457297|NCT00870350|adverse reaction
457298|NCT00870350|DT1aP
457299|NCT00870350|DT5ap
457300|NCT00870350|FHA
457301|NCT00870350|fimbriae
457302|NCT00870350|pertactin
457303|NCT00870350|SMI
457304|NCT00870350|Smittskyddsinstitutet
457305|NCT00870350|Immune response and safety profile to a Tdap booster
457306|NCT00870337|recurrent endometrial carcinoma
457307|NCT00870337|stage IV endometrial carcinoma
457308|NCT00870337|endometrial adenocarcinoma
457309|NCT00870324|ICD
457310|NCT00870324|Tachyarrhythmias
457311|NCT00870324|Atrial Fibrillation
457312|NCT00870324|Patients who meets current ICD or CRT-D implant indications
457313|NCT00870311|Lithium
457314|NCT00870311|Neuroprotection
457315|NCT00870311|Neurotrophic
457316|NCT00870311|bcl2
457317|NCT00870311|gsk3
457318|NCT00870311|pkc
457319|NCT00870311|MRI
457320|NCT00870311|myoinositol
457321|NCT00870311|MRS
457322|NCT00870311|Alzheimers Disease
457323|NCT00870298|drug orders
457324|NCT00870285|Psoriasis
457325|NCT00870285|Biologic
457326|NCT00870285|Ustekinumab
457327|NCT00870285|UVB-311nm narrowband
457328|NCT00870285|phototherapy
457329|NCT00870285|half-side comparison
457330|NCT00870272|Medical Abortion
457331|NCT00870272|Mifepristone
457332|NCT00870272|Misoprostol
457333|NCT00870272|Sublingual administration
457334|NCT00870272|Buccal administration
457335|NCT00870259|Weight loss
457336|NCT00870259|Weight maintenance
457337|NCT00870246|COPD
457338|NCT00870246|pulmonary emphysema
457339|NCT00870233|Gynecologic cancers
457340|NCT00870233|Quality of Life
457341|NCT00870233|08-155
457342|NCT00870233|Surgery
457343|NCT00870220|Turner's Syndrome
457344|NCT00870207|Feasibility of implementing TSSC in worksite environment
457345|NCT00870194|diabetes
457346|NCT00870194|exenatide
457347|NCT00870194|Byetta
457348|NCT00870194|sitagliptin
457349|NCT00870194|Januvia
457350|NCT00870194|Amylin
457351|NCT00870194|Lilly
457352|NCT00870168|stage IV breast cancer
457353|NCT00870168|estrogen receptor-negative breast cancer
457354|NCT00870168|progesterone receptor-negative breast cancer
457355|NCT00870142|Bioequivalence
457356|NCT00870142|amlodipine besylate
457357|NCT00870142|amlodipine
457358|NCT00870142|Healthy subjects
457359|NCT00870129|brain tumor
457360|NCT00870129|radiation
457361|NCT00870129|MRI
457362|NCT00870129|09-009
457363|NCT00870116|SBRT
457364|NCT00870116|non-operated
457365|NCT00870116|non-metastatic
457366|NCT00870116|non-small-cell lung cancer
457367|NCT00870116|conformational radiotherapy
457368|NCT00870116|non-operated non-metastatic non-small-cell lung cancer
457369|NCT00870103|Cataract
457370|NCT00870077|Intrahepatic fat
457371|NCT00870077|obesity
457372|NCT00870077|body fat
457373|NCT00870077|impaired glucose tolerance
457374|NCT00870064|Surgical Procedures, Operative
457375|NCT00870064|Fractures, Open
457376|NCT00870064|Fracture Fixation
457377|NCT00870051|Endurant
457378|NCT00870051|Stent Graft
457379|NCT00870051|Abdominal Aortic Aneurysm
457380|NCT00870038|PCI
457381|NCT00870038|stent
457382|NCT00870038|drug eluting stent
457383|NCT00870038|reendothelialization
457384|NCT00870038|restenosis
457385|NCT00870038|Percutaneous Coronary Angioplasty
457386|NCT00870025|androgens
457387|NCT00870025|hCG
457388|NCT00870025|low response
457389|NCT00870025|IVF
457390|NCT00870025|Ovarian response in women with previous low response
457391|NCT00869999|rituximab
457392|NCT00869999|everolimus
457393|NCT00869999|DLBCL
457394|NCT00869999|mTOR
457395|NCT00869973|aprepitant
457396|NCT00869973|delayed emesis
457397|NCT00869973|cyclophosphamide plus anthracyclines
457398|NCT00869973|breast cancer
457399|NCT00869973|antiemetic
457400|NCT00869960|Healthy Volunteers
457401|NCT00869947|Unilateral below the knee amputation
457402|NCT00869934|Insomnia
457403|NCT00869934|Sleep disorders
457404|NCT00869934|Treatment
457405|NCT00869934|Sleep disturbances
457406|NCT00869895|Advanced solid tumors
457407|NCT00869882|Spondylolisthesis
457408|NCT00869882|degeneration
457409|NCT00869882|spinal fusion
457410|NCT00869869|Heart Failure
457411|NCT00869869|Sleep Disorders
457412|NCT00869869|Melatonin
457413|NCT00869869|Antioxidants
457414|NCT00869869|Molecular Mechanisms of Pharmacological Action
457415|NCT00869869|Nervous System Diseases
457416|NCT00869869|Physiological Effects of Drugs
457417|NCT00869869|Vascular Diseases
457418|NCT00869869|Central Nervous System Depressants
457419|NCT00869869|Protective Agents
457420|NCT00869869|Pharmacologic Actions
457421|NCT00869869|Signs and Symptoms
457422|NCT00869869|Mental Disorders
457423|NCT00869869|Therapeutic Uses
457424|NCT00869869|Neurologic Manifestations
457425|NCT00869869|Cardiovascular Diseases
457426|NCT00869869|Central Nervous System Agents
457427|NCT00869856|Treatment associated with CRI
457428|NCT00869843|Metastatic colorectal cancer
457429|NCT00869830|Biofeedback
457430|NCT00869830|constipation
457431|NCT00869830|Parkinson's disease
457432|NCT00869817|Alzheimer's disease
457433|NCT00869817|antecedent biomarkers
457434|NCT00869817|Amyloid Precursor Protein (APP) mutation
457435|NCT00869817|presenilin I (PS1) mutation
457436|NCT00869817|presenilin 2 (PS2) mutation
457437|NCT00869817|Autosomal Dominant Alzheimer's Disease
457438|NCT00869804|breast cancer
457439|NCT00869804|chemotherapy-induced peripheral neuropathy
457440|NCT00869804|exercise
457441|NCT00869791|Parkinson's
457442|NCT00869778|Chronic Hepatitis B
457443|NCT00869778|HBeAg positive
457444|NCT00869778|Therapeutic HBV Vaccine
457445|NCT00869778|HBV-specific Cytotoxic T Lymphocyte
457446|NCT00869765|Depression
457447|NCT00869765|Treatment
457448|NCT00869765|Transcranial direct current stimulation
457449|NCT00869765|D-cycloserine
457450|NCT00869752|combined type small cell lung cancer
457451|NCT00869752|fusiform type small cell lung cancer
457452|NCT00869752|polygonal type small cell lung cancer
457453|NCT00869752|lymphocyte-like type small cell lung cancer
457454|NCT00869752|extensive stage small cell lung cancer
457455|NCT00869739|cancer survivor
457456|NCT00869739|depression
457457|NCT00869739|psychosocial effects of cancer and its treatment
457458|NCT00869739|male erectile disorder
457459|NCT00869739|urinary complications
457460|NCT00869739|gastrointestinal complications
457461|NCT00869739|stage I prostate cancer
457462|NCT00869739|stage IIB prostate cancer
457463|NCT00869739|stage IIA prostate cancer
457464|NCT00869739|stage III prostate cancer
457465|NCT00869713|Hemorrhagic Fever
457466|NCT00869713|Viral Infections
457467|NCT00869713|Neurologic diseases
457468|NCT00869713|Arbovirus Infections
457469|NCT00869713|RVF
457470|NCT00869700|HIV
457471|NCT00869700|Malaria
457472|NCT00869700|Pharmacokinetics
457473|NCT00869700|Treatment Experienced
457474|NCT00869674|GeneSearch
457475|NCT00869674|Breast cancer
457476|NCT00869648|Airway
457477|NCT00869648|Anaesthesia
457478|NCT00869648|Resuscitation
457479|NCT00869648|Ventilation
457480|NCT00869635|Cholangiocarcinoma
457481|NCT00869635|Photodynamic therapy
457482|NCT00869635|S-1
457483|NCT00869622|osteoporosis
457484|NCT00869622|bone mineral density
457485|NCT00869622|fracture
457486|NCT00869622|antiepileptic drug
457487|NCT00869622|seizure
457488|NCT00869622|Prevention of bone loss
457489|NCT00869622|Prevention of osteoporosis
457490|NCT00869622|Prevention of Fractures
457491|NCT00869609|Diabetes Prevention
457492|NCT00869609|CVD Risk Reduction
457493|NCT00869609|Lifestyle Intervention
457494|NCT00869596|Sputum inflammatory biomarkers
457495|NCT00869583|Women
457496|NCT00869583|Physical Activity
457497|NCT00869583|Hispanic
457498|NCT00869583|Overweight
457499|NCT00869570|adenocarcinoma of the rectum
457500|NCT00869570|stage II rectal cancer
457501|NCT00869570|stage III rectal cancer
457502|NCT00869557|HIV
457503|NCT00869557|HIV-1
457504|NCT00869557|Antiretroviral Treatment-Naive
457505|NCT00869557|treatment naive
457506|NCT00869544|HIV
457507|NCT00869544|smoker
457508|NCT00869544|emphysema
457509|NCT00869544|antiretrovirals
457510|NCT00869544|COPD
457511|NCT00869531|Obesity
457512|NCT00869531|wholegrain
457513|NCT00869531|wheat
457514|NCT00869531|cardiovascular disease
457515|NCT00869518|Staphylococcus aureus
457516|NCT00869518|colonization
457517|NCT00869518|eradication
457518|NCT00869518|HIV
457519|NCT00869518|rifabutin
457520|NCT00869505|To evaluate the effectiveness of memantine as an augmenting agent for standard intensive residential treatment of severe obsessive-compulsive disorder (OCD)
457521|NCT00869492|Acne
457522|NCT00869492|Nadifloxacin
457523|NCT00869492|benzoyl peroxide
457524|NCT00869479|Nephrogenic Systemic Fibrosis
457525|NCT00869479|Screening
457526|NCT00869466|weight changes
457527|NCT00869466|stage IA breast cancer
457528|NCT00869466|stage IB breast cancer
457529|NCT00869466|stage II breast cancer
457530|NCT00869466|stage IIIA breast cancer
457531|NCT00869466|stage IIIB breast cancer
457532|NCT00869466|stage IIIC breast cancer
457533|NCT00869453|Gut hormone
457534|NCT00869453|hyperglycaemic clamp
457535|NCT00869453|glucose turnver
457536|NCT00869440|CNS 7056
457537|NCT00869440|Procedural Sedation
457538|NCT00869440|Sedation
457539|NCT00869440|Endoscopy
457540|NCT00869427|UVI
457541|NCT00869427|Spinal cord injury
457542|NCT00869427|Prevention
457543|NCT00869427|Vitamin C
457544|NCT00869414|hypoglycemia
457545|NCT00869414|type 1 diabetes
457546|NCT00869414|split dosing insulin glargine
457547|NCT00869414|continuous glucose monitoring
457548|NCT00869401|adult giant cell glioblastoma
457549|NCT00869401|adult glioblastoma
457550|NCT00869401|adult gliosarcoma
457551|NCT00869388|malignant
457552|NCT00869388|resistant
457553|NCT00869388|solid tumor
457554|NCT00869375|acute or critical limb ischemia with angiographic thrombus
457555|NCT00869349|Rheumatoid Arthritis
457556|NCT00869349|IFS
457557|NCT00869349|psychosocial
457558|NCT00869349|social support
457559|NCT00869336|Tinea Pedis
457560|NCT00869336|Athlete's Foot
457561|NCT00869323|post-transplant lymphoproliferative disorder
457562|NCT00869310|aprepitant
457563|NCT00869310|delayed emesis
457564|NCT00869310|cisplatin
457565|NCT00869310|antiemetic
457566|NCT00869284|High-dose chemotherapy
457567|NCT00869284|aggressive NHL
457568|NCT00869284|high-risk
457569|NCT00869284|PBSC
457570|NCT00869271|liver metastasis
457571|NCT00869271|colorectal cancer
457572|NCT00869258|Pancreatic cancer
457573|NCT00869258|Gemcitabine
457574|NCT00869258|Docetaxel
457575|NCT00869258|Capecitabine
457576|NCT00869245|ACS
457577|NCT00869245|Acute Coronary Syndrome
457578|NCT00869245|Chest pain
457579|NCT00869245|Cardiac MRI
457580|NCT00869245|CMR
457581|NCT00869245|Risk Stratification
457582|NCT00869245|Emergency Department
457583|NCT00869232|Multiple Myeloma
457584|NCT00869219|Pain
457585|NCT00869219|Pain after eyedrops
457586|NCT00869206|pain
457587|NCT00869206|Prostate Adenocarcinoma
457588|NCT00869206|urinary complications
457589|NCT00869206|stage IV breast cancer
457590|NCT00869206|Recurrent Breast Carcinoma
457591|NCT00869206|stage IV prostate cancer
457592|NCT00869206|recurrent prostate cancer
457593|NCT00869206|Recurrent Prostate Carcinoma
457594|NCT00869206|stage I multiple myeloma
457595|NCT00869206|stage II multiple myeloma
457596|NCT00869206|Refractory Plasma Cell Myeloma
457597|NCT00869206|bone metastases
457598|NCT00869193|Blood pressure
457599|NCT00869193|Grape seed
457600|NCT00869180|diclofenac
457601|NCT00869180|ankle sprain
457602|NCT00869180|acute pain
457603|NCT00869180|topical
457604|NCT00869180|patch
457605|NCT00869180|Acute Pain due to Mild to Moderate Ankle Sprain
457606|NCT00869154|Mild TBI
457607|NCT00869154|TBI (Traumatic Brain Injury)
457608|NCT00869154|Traumatic Brain Injury
457609|NCT00869154|Injury, Brain, Traumatic
457610|NCT00869154|Injuries, Acute Brain
457611|NCT00869154|Brain Injuries, Traumatic
457612|NCT00869154|Acute Brain Injuries
457613|NCT00869141|Glaucoma tube shunt procedure
457614|NCT00869128|melatonin
457615|NCT00869128|insomnia
457616|NCT00869128|diabetes
457617|NCT00869128|sleep
457618|NCT00869115|Digoxin
457619|NCT00869115|Inotropes
457620|NCT00869115|Lusitropic agents
457621|NCT00869115|Istaroxime
457622|NCT00869115|Debio 0614
457623|NCT00869102|IGT
457624|NCT00869102|IFG
457625|NCT00869089|PN
457626|NCT00869076|Diabetes Mellitus
457627|NCT00869076|Pharmacist
457628|NCT00869063|wrist
457629|NCT00869063|sprain
457630|NCT00869063|strain
457631|NCT00869063|contusion
457632|NCT00869063|diclofenac
457633|NCT00869063|patch
457634|NCT00869063|acute pain
457635|NCT00869063|acute pain due to mild to moderate wrist sprain, strain or contusion
457636|NCT00869050|Pancreatic cancer
457637|NCT00869050|Neuroendocrine tumors
457638|NCT00869050|Carcinoid tumors
457639|NCT00869050|Pheochromocytomas
457640|NCT00869050|Gastrinomas
457641|NCT00869050|Zollinger-Ellison syndrome
457642|NCT00869050|MEN Type I/II
457643|NCT00869050|Somatostatinomas
457644|NCT00869050|VIPomas
457645|NCT00869050|Merkel cell tumors
457646|NCT00869050|medullary thyroid carcinoma
457647|NCT00869037|Randomized controlled study
457648|NCT00869037|Total knee arthroplasty
457649|NCT00869037|Post operative pain
457650|NCT00869037|Continuous Femoral Nerve Block
457651|NCT00869037|Posterior Capsular injection
457652|NCT00869037|Periarticular injection
457653|NCT00869024|Heart failure
457654|NCT00869024|Left ventricular assist device
457655|NCT00869024|Stem cells
457656|NCT00869011|Cancer
457657|NCT00869011|renal cell carcinoma
457658|NCT00869011|fatigue
457659|NCT00869011|exercise
457660|NCT00868998|Biliary Cancer
457661|NCT00868972|Renal Artery Obstruction
457662|NCT00868972|renovascular hypertension
457663|NCT00868972|stent
457664|NCT00868972|Kidney Failure
457665|NCT00868972|embolic protection
457666|NCT00868959|Bipolar
457667|NCT00868959|Depression
457668|NCT00868959|Lurasidone
457669|NCT00868959|Latuda
457670|NCT00868946|Ribavirin
457671|NCT00868946|Hemorrhagic Fever with Renal Syndrome
457672|NCT00868946|Dobrava Virus
457673|NCT00868946|Puumala Virus
457674|NCT00868881|Hypertension
457675|NCT00868881|Therapeutic diagnostic attitude
457676|NCT00868881|Blood pressure
457677|NCT00868868|Pedometer
457678|NCT00868868|Prostate
457679|NCT00868868|Cancer
457680|NCT00868868|Hormonotherapy
457681|NCT00868868|Exercise
457682|NCT00868855|Coronary Artery Disease
457683|NCT00868842|Penicillin
457684|NCT00868842|Allergy
457685|NCT00868842|Prevention
457686|NCT00868842|Anaphylaxis
457687|NCT00868842|Clinically proven history of penicillin allergy
457688|NCT00868842|preventing anaphylaxis
457689|NCT00868829|Stent
457690|NCT00868829|FireBird2
457691|NCT00868829|Coronary Heart Disease
457692|NCT00868816|oxaliplatine
457693|NCT00868816|colorectal cancer
457694|NCT00868816|chemotherapy
457695|NCT00868803|prostate cancer
457696|NCT00868777|Implant site development
457697|NCT00868777|Bone grafting
457698|NCT00868777|Dental implants
457699|NCT00868764|Effect of age
457700|NCT00868764|Effect of body fat
457701|NCT00868764|Granisetron
457702|NCT00868764|Pharmacokinetic profile
457703|NCT00868764|Sancuso® patch
457704|NCT00868764|Transdermal
457705|NCT00868751|Antibodies, Monoclonal
457706|NCT00868751|Interleukin 6
457707|NCT00868738|Calcium
457708|NCT00868738|Vitamin D
457709|NCT00868738|Magnesium
457710|NCT00868738|Zinc
457711|NCT00868725|oral cavity
457712|NCT00868725|carcinoma
457713|NCT00868725|thermal imaging
457714|NCT00868712|coronary calcification
457715|NCT00868712|vitamin K dependent proteins
457716|NCT00868712|warfarin
457717|NCT00868699|Bipolar I, Depression
457718|NCT00868673|Role of Fructose in overweight and obesity
457719|NCT00868673|Fructose and metabolic syndrome
457720|NCT00868673|Low fructose diet study
457721|NCT00868673|Effects of fructose in blood pressure and hypertension
457722|NCT00868673|Somatometry changes observed in fructose diets
457723|NCT00868673|Fructose induced overweight and obesity
457724|NCT00868673|Fructose induced metabolic syndrome
457725|NCT00868673|Fructose induced hyperuricemia
457726|NCT00868608|Refractory Indolent NHL
457727|NCT00868608|lymphoma
457728|NCT00868582|Patients with proven or suspected cancer referred for NaF-18 PET to identify bone metastasis
457729|NCT00868569|liver metastasis
457730|NCT00868569|colorectal cancer
457731|NCT00868569|oxaliplatine
457732|NCT00868569|transartery chemotherapy
457733|NCT00868569|embolision
457734|NCT00868569|Unresectable Liver Metastasis of Colorectal Cancer
457735|NCT00868556|fMRI scans
457736|NCT00868556|episodic migraine sufferers
457737|NCT00868556|chronic migraine sufferers
457738|NCT00868556|non migraine sufferers (controls)
457739|NCT00868543|Gastric bypass
457740|NCT00868543|obesity
457741|NCT00868543|superobese
457742|NCT00868530|On-demand treatment; Hemostatic Efficacy Assessments; Factor VIII recovery; Factor VIII Inhibitor; Chinese
457743|NCT00868517|Veterans
457744|NCT00868517|Operation Iraqi Freedom
457745|NCT00868517|Operation Enduring Freedom
457746|NCT00868517|Combat Disorders
457747|NCT00868517|Acupuncture
457748|NCT00868517|Complementary Therapies
457749|NCT00868504|GI tract
457750|NCT00868504|Tumors
457751|NCT00868504|Temperatures
457752|NCT00868491|head and neck cancer
457753|NCT00868491|inoperable
457754|NCT00868491|induction chemotherapy
457755|NCT00868491|concomitant radiochemotherapy
457756|NCT00868491|biological agent
457757|NCT00868491|efficacy
457758|NCT00868491|toxicity
457759|NCT00868478|humanized monoclonal antibody
457760|NCT00868452|Bipolar I
457761|NCT00868452|Latuda
457762|NCT00868452|Lurasidone
457763|NCT00868439|HF
457764|NCT00868439|Heart failure
457765|NCT00868439|hyperkalemia
457766|NCT00868439|chronic kidney disease
457767|NCT00868439|prevention of hyperkalemia in heart failure participants
457768|NCT00868426|Healthy volunteer study
457769|NCT00868400|Preoperative care
457770|NCT00868400|colorectal surgery
457771|NCT00868400|carbohydrate
457772|NCT00868400|fasting
457773|NCT00868387|weight reduction
457774|NCT00868387|low-carbohydrate
457775|NCT00868387|body fat
457776|NCT00868387|telemedicine
457777|NCT00868387|cardiovascular risk markers
457778|NCT00868361|Mass Balance
457779|NCT00868361|Talampanel
457780|NCT00868361|Pharmacokinetics
457781|NCT00868361|Metabolism
457782|NCT00868361|Metabolites
457783|NCT00868361|Healthy Volunteers
457784|NCT00868348|Total Knee Arthroplasty
457785|NCT00868335|Cervical degenerative disc disease
457786|NCT00868335|Anterior cervical discectomy
457787|NCT00868335|Cervical disc prosthesis
457788|NCT00868335|Activ-C
457789|NCT00868335|Mobility
457790|NCT00868335|Movement
457791|NCT00868309|Snake Bite
457792|NCT00868309|Venom and antivenom kinetics
457793|NCT00868296|Safety
457794|NCT00868257|AIDS
457795|NCT00868257|Adherence to Antiretroviral Therapy
457796|NCT00868257|Pediatric
457797|NCT00868257|Resource Limited Setting
457798|NCT00868257|Treatment experienced
457799|NCT00868244|facial patterns
457800|NCT00868244|bruxism
457801|NCT00868244|masticatory muscles
457802|NCT00868231|COPD
457803|NCT00868231|Antimuscarinic
457804|NCT00868218|Influenza A
457805|NCT00868218|pandemic
457806|NCT00868218|vaccine
457807|NCT00868218|immunogenicity
457808|NCT00868218|Virus
457809|NCT00868218|H5N1
457810|NCT00868205|oxidative stress
457811|NCT00868205|Comet assay
457812|NCT00868205|antioxidants
457813|NCT00868179|Thrombosis
457814|NCT00868179|total knee replacement
457815|NCT00868166|Amyotrophic Lateral Sclerosis
457816|NCT00868166|TRO19622
457817|NCT00868166|Trophos
457818|NCT00868127|Hyperlipidemia
457819|NCT00868127|Drug Therapy
457820|NCT00868127|Dyslipidemia
457821|NCT00868114|Inoperable pancreatic cancer
457822|NCT00868114|Dendritic Cell Vaccine
457823|NCT00868114|Locally advanced or low volume metatstatic pancreatic cancer
457824|NCT00868101|ischemic
457825|NCT00868101|preconditioning
457826|NCT00868101|congenital heart disease
457827|NCT00868088|AC
457828|NCT00868088|SCC
457829|NCT00868088|SCC-is
457830|NCT00868088|PDT
457831|NCT00868088|Mohs
457832|NCT00868075|Physiotherapy
457833|NCT00868075|Rehabilitation
457834|NCT00868075|Bronchiectasis
457835|NCT00868062|The responses of patients to 1L infusions of Gelofusine (succinylated gelatine 40g/L) and Voluven (6% hydroxyethyl starch in 0.9% saline) intraoperatively.
457836|NCT00868049|chewing
457837|NCT00868049|deglutition
457838|NCT00868049|orofacial motricity
457839|NCT00868049|obesity
457840|NCT00868036|urticaria
457841|NCT00868036|hives
457842|NCT00868036|dermatitis
457843|NCT00868036|rash
457844|NCT00868036|contact dermatitis
457845|NCT00868036|contact
457846|NCT00868036|contact sensitization
457847|NCT00868036|allergy
457848|NCT00868036|allergen
457849|NCT00868036|patch testing
457850|NCT00868036|IgG
457851|NCT00868036|delayed-hypersensitivity reaction
457852|NCT00868036|hypersensitivity
457853|NCT00868010|stroke
457854|NCT00868010|donepezil
457855|NCT00868010|recovery
457856|NCT00867997|Noncarious Cervical Lesions
457857|NCT00867997|Hypersensitivity
457858|NCT00867997|Teeth
457859|NCT00867997|Dentistry
457860|NCT00867997|Practice-based research network
457861|NCT00867984|CRT, resynchronization,
457862|NCT00867958|Colon Anastomosis
457863|NCT00867958|Rectum Anastomosis
457864|NCT00867958|Intestine
457865|NCT00867958|Colorectal Surgery
457866|NCT00867958|Colorectal Anastomosis
457867|NCT00867932|Paroxysmal Nocturnal Hemoglobinuria (PNH)
457868|NCT00867906|Cat allergy
457869|NCT00867906|Immunotherapy
457870|NCT00867906|Cat-PAD
457871|NCT00867880|To evaluate the Pharmacokinetic Profile of IVIb
457872|NCT00867867|Iron deficiency anemia
457873|NCT00867867|Helicobacter pylori
457874|NCT00867867|Iron absorption
457875|NCT00867867|Iron fortification
457876|NCT00867867|ferrous sulphate
457877|NCT00867867|ferrous fumarate
457878|NCT00867854|de-intensification
457879|NCT00867854|HAART
457880|NCT00867854|monotherapy
457881|NCT00867854|persistent low-level viremia (LLV)
457882|NCT00867854|treatment experienced
457883|NCT00867841|pneumonia, community-acquired
457884|NCT00867841|polymerase chain reaction
457885|NCT00867841|pneumococcus
457886|NCT00867841|mycoplasma
457887|NCT00867841|chlamydophila
457888|NCT00867841|anti-bacterial agents
457889|NCT00867828|Decline of global cognitive function
457890|NCT00867828|Neuropsychological Test Battery (NTB)
457891|NCT00867828|Early stage Alzheimer's disease
457892|NCT00867815|Non-arteritic Anterior Ischemic Optic Neuropathy
457893|NCT00867815|NAION
457894|NCT00867815|PDE5 inhibitors
457895|NCT00867815|vardenafil
457896|NCT00867815|Levitra
457897|NCT00867815|sildenafil
457898|NCT00867815|Viagra
457899|NCT00867815|Tadalafil
457900|NCT00867815|Cialis
457901|NCT00867815|acute vision loss
457902|NCT00867815|vision loss
457903|NCT00867815|blurred vision
457904|NCT00867815|optic neuropathy
457905|NCT00867815|erectile dysfunction.
457906|NCT00867802|MICAS
457907|NCT00867802|MBSR
457908|NCT00867789|abscess
457909|NCT00867789|outcomes
457910|NCT00867789|antibiotics
457911|NCT00867789|incision and drainage
457912|NCT00867789|skin abscess
457913|NCT00867776|Depression
457914|NCT00867776|African Americans
457915|NCT00867776|Exercise
457916|NCT00867776|Culturally tailored intervention
457917|NCT00867776|Health disparities
457918|NCT00867763|Polycystic ovaries,
457919|NCT00867763|Tubal occlusion
457920|NCT00867763|Unexplained infertility
457921|NCT00867763|Low ovarian reserve
457922|NCT00867763|Male factor infertility
457923|NCT00867750|HCC
457924|NCT00867750|RE
457925|NCT00867750|Yttrium-90
457926|NCT00867750|SIR-Spheres microspheres
457927|NCT00867750|TACE
457928|NCT00867750|Radioembolisation
457929|NCT00867750|Transarterial Chemoembolisation
457930|NCT00867737|Asthma
457931|NCT00867737|Forced Oscillation
457932|NCT00867737|Impulse Oscillometry
457933|NCT00867737|Electrical-equivalent respiratory system model
457934|NCT00867724|polyp
457935|NCT00867698|Hepatic encephalopathy
457936|NCT00867698|Mild hepatic encephalopathy
457937|NCT00867698|HE
457938|NCT00867698|MHE
457939|NCT00867698|Cognitive impairment
457940|NCT00867698|Cognitive dysfunction
457941|NCT00867698|Liver Disease
457942|NCT00867698|Cirrhosis
457943|NCT00867685|Healthy Volunteers
457944|NCT00867672|Acute Myeloid Leukemia
457945|NCT00867672|Low-dose Decitabine
457946|NCT00867672|Valproic acid
457947|NCT00867672|All-trans retinoic acid
457948|NCT00867672|Older Patients
457949|NCT00867659|ovarian hyperstimulation syndrome
457950|NCT00867659|cetrotide acetate
457951|NCT00867659|GnRH antagonist
457952|NCT00867659|oocyte donors
457953|NCT00867646|PT
457954|NCT00867646|DVT
457955|NCT00867633|urothelial carinoma
457956|NCT00867633|aristolochic acid
457957|NCT00867633|DNA
457958|NCT00867633|adduct
457959|NCT00867607|Contact dermatitis
457960|NCT00867607|Eczema
457961|NCT00867581|middle cerebral artery
457962|NCT00867581|infarction
457963|NCT00867581|chronic stage
457964|NCT00867581|hippocampal volume
457965|NCT00867581|MRI
457966|NCT00867581|MRS
457967|NCT00867581|neuropsychologic assessment
457968|NCT00867568|Relapsed Neuroblastoma
457969|NCT00867568|Refractory Neuroblastoma
457970|NCT00867568|Relapsed Medulloblastoma
457971|NCT00867568|Refractory Medulloblastoma
457972|NCT00867542|past IUGR
457973|NCT00867542|ECC
457974|NCT00867542|oral findings in children with past IUGR
457975|NCT00867503|ovarian cancer
457976|NCT00867503|bendamustine
457977|NCT00867490|Hypertension
457978|NCT00867490|aliskiren
457979|NCT00867490|cardiovascular diseases
457980|NCT00867477|Cancer of esophagus
457981|NCT00867477|Gastrointestine
457982|NCT00867477|esophagus cancer
457983|NCT00867477|Positron emission tomography
457984|NCT00867477|PET scan
457985|NCT00867477|Nitric oxide
457986|NCT00867477|NO
457987|NCT00867477|NO Breathing Test
457988|NCT00867477|Respiratory symptoms questionnaire
457989|NCT00867464|Vaccine Efficacy
457990|NCT00867464|Long-Term Protection
457991|NCT00867464|Immune Response
457992|NCT00867464|Human Papillomavirus
457993|NCT00867464|HPV
457994|NCT00867464|Vaccine
457995|NCT00867451|Attention Deficit Hyperactivity Disorder (ADHD)
457996|NCT00867438|ulcerative colitis
457997|NCT00867438|Left-sided, mild to moderate ulcerative colitis
457998|NCT00867425|Diabetes
457999|NCT00867425|Internet
458000|NCT00867425|Obesity
458001|NCT00867425|Obesity with high cardiovascular risks
458002|NCT00867412|NSCLC
458003|NCT00867412|PET/CT
458004|NCT00867412|Surgery
458005|NCT00867412|FDG
458006|NCT00867412|staging
458007|NCT00867373|Obesity
458008|NCT00867373|Weight perceptions
458009|NCT00867347|transitional cell carcinoma of the bladder
458010|NCT00867347|stage II bladder cancer
458011|NCT00867347|stage III bladder cancer
458012|NCT00867334|colorectal neoplasm
458013|NCT00867334|colorectal cancer
458014|NCT00867334|imatinib mesylate
458015|NCT00867334|Gleevec
458016|NCT00867334|Physiological Effects of Drugs
458017|NCT00867334|panitumumab
458018|NCT00867334|Vectibix
458019|NCT00867334|c-kit receptor
458020|NCT00867334|Receptor
458021|NCT00867334|Platelet-Derived Growth Factor alpha
458022|NCT00867321|adult primary hepatocellular carcinoma
458023|NCT00867321|advanced adult primary liver cancer
458024|NCT00867321|localized unresectable adult primary liver cancer
458025|NCT00867321|recurrent adult primary liver cancer
458026|NCT00867308|IPSS Int-2
458027|NCT00867308|high risk myelodysplastic syndrome
458028|NCT00867308|MDS)
458029|NCT00867308|5q31.1 deletions
458030|NCT00867295|implantable catheters
458031|NCT00867295|Indwelling Catheters
458032|NCT00867295|infection
458033|NCT00867295|cefazolin sodium
458034|NCT00867295|prophylactic
458035|NCT00867295|antibiotic
458036|NCT00867295|totally implantable venous access device
458037|NCT00867295|cancer patients
458038|NCT00867269|Idiopathic Lymphocytopenia
458039|NCT00867269|Opportunistic Infection
458040|NCT00867269|Immunodeficiency Syndrome
458041|NCT00867269|Autoimmune Disease
458042|NCT00867269|CD4+ Lymphocytes
458043|NCT00867269|Idiopathic CD4 Lymphocytopenia
458044|NCT00867243|Hepatitis C virus
458045|NCT00867243|HCV
458046|NCT00867243|Hepatitis C (and cirrhosis)
458047|NCT00867243|Liver cirrhosis not due to HCV infection
458048|NCT00867230|Myelodysplastic Syndrome
458049|NCT00867230|Chronic Myelomonocytic Leukemia
458050|NCT00867230|Acute Myeloid Leukemia
458051|NCT00867230|Acute Lymphocytic Leukemia
458052|NCT00867230|Chronic Lymphocytic Leukemia
458053|NCT00867230|Chronic Myelogenous Leukemia
458054|NCT00867230|Agnogenic Myeloid Metaplasia
458055|NCT00867230|FTS
458056|NCT00867230|S-Trans, Trans-Farnesylthiosalicylic Acid
458057|NCT00867204|ERCP
458058|NCT00867204|Study focus was to compare the performance of the ERCP short-wire device versus the Long-wire device.
458059|NCT00867165|heterozygous familial hypercholesterolemia
458060|NCT00867165|nonfamilial hypercholesterolemia
458061|NCT00867152|ritonavir
458062|NCT00867152|GSK1349572
458063|NCT00867152|integrase
458064|NCT00867152|lopinavir
458065|NCT00867152|darunavir
458066|NCT00867152|etravirine
458067|NCT00867139|Influenza
458068|NCT00867139|Immunocompromised
458069|NCT00867139|Antiviral
458070|NCT00867126|stage IV pancreatic cancer
458071|NCT00867126|adenocarcinoma of the pancreas
458072|NCT00867126|recurrent pancreatic cancer
458073|NCT00867113|Imatinib
458074|NCT00867113|Protein Kinase Inhibitors
458075|NCT00867113|Gastrointestinal Stromal Tumors
458076|NCT00867113|Digestive System Diseases
458077|NCT00867113|Digestive System Neoplasms
458204|NCT00866645|Agitation
458078|NCT00867113|Gastrointestinal Diseases
458079|NCT00867113|Gastrointestinal Neoplasms
458080|NCT00867113|Adjuvant
458081|NCT00867113|PERSIST
458082|NCT00867113|PERSIS-5
458083|NCT00867087|Diffuse large b-cell lymphoma
458084|NCT00867087|inotuzumab ozogamicin
458085|NCT00867087|autologous stem cell transplant
458086|NCT00867061|Myelodysplastic
458087|NCT00867061|IPSS Intermediate 1
458088|NCT00867061|IPSS Intermediate 2
458089|NCT00867061|IPSS High risk
458090|NCT00867048|highly active antiretroviral therapy (HAART)
458091|NCT00867048|CD4 Count
458092|NCT00867048|Early Intervention
458093|NCT00867048|HIV
458094|NCT00867048|HIV Infection
458095|NCT00867048|HIV Infections
458096|NCT00867048|treatment naive
458097|NCT00867022|Inflammatory factors
458098|NCT00867022|Coagulation factors
458099|NCT00867022|Sympathetic activity
458100|NCT00866996|Attention deficit hyperactivity disorder
458101|NCT00866996|Methylphenidate
458102|NCT00866996|Atomoxetine
458103|NCT00866996|Concerta
458104|NCT00866983|Open label
458105|NCT00866983|sildenafil
458106|NCT00866983|PAH
458107|NCT00866983|Brazil
458108|NCT00866970|Lung Cancer
458109|NCT00866970|Fatigue
458110|NCT00866970|Cachexia
458111|NCT00866944|Colorectal carcinoma
458112|NCT00866944|Liver metastases (only)
458113|NCT00866944|R0 resection
458114|NCT00866944|R0 resection of liver metastases from colorectal cancer
458115|NCT00866905|Breast Cancer
458116|NCT00866905|Ixabepilone
458117|NCT00866905|Ixempra
458118|NCT00866905|Cyclophosphamide
458119|NCT00866905|Cytoxan
458120|NCT00866905|Neoadjuvant Therapy
458121|NCT00866879|Sirolimus
458122|NCT00866879|Rapamune
458123|NCT00866879|Immunosuppression
458124|NCT00866879|Renal allograft function
458125|NCT00866879|Lymphocytes function
458126|NCT00866853|TMC435350
458127|NCT00866853|HCV
458128|NCT00866853|Hepatitis C
458129|NCT00866853|TMC435
458130|NCT00866853|protease inhibitor
458131|NCT00866853|CYP
458132|NCT00866853|Cooperstown 5+1 cocktail
458133|NCT00866840|stage III melanoma
458134|NCT00866840|stage IV melanoma
458135|NCT00866840|recurrent melanoma
458136|NCT00866827|Airway
458137|NCT00866827|Hemangiomas
458138|NCT00866827|Venous Malformations
458139|NCT00866827|Lymphatic Malformations
458140|NCT00866814|hernia
458141|NCT00866814|open
458142|NCT00866801|coronary blood flow
458143|NCT00866801|coronary flow reserve
458144|NCT00866801|cardiac sympathetic innervation
458145|NCT00866801|general anesthesia
458146|NCT00866801|thoracic epidural
458147|NCT00866801|autonomic dysfunction
458148|NCT00866801|autonomic neuropathy
458149|NCT00866788|Xolair
458150|NCT00866788|CIU
458151|NCT00866775|Seizure
458152|NCT00866775|Epilepsy
458153|NCT00866775|Anticonvulsant
458154|NCT00866775|Historical Control
458155|NCT00866775|Monotherapy
458156|NCT00866762|Polycythaemia Vera
458157|NCT00866762|Polycythemia Vera
458158|NCT00866762|Essential Thrombocythaemia
458159|NCT00866762|Essential Thrombocythemia
458160|NCT00866762|HDAC-inhibitor
458161|NCT00866762|Haematology
458162|NCT00866762|Hematology
458163|NCT00866762|Haematological disorder
458164|NCT00866762|Haematological disease
458165|NCT00866762|Hematological disorder
458166|NCT00866762|Hematological disease
458167|NCT00866749|acute lymphoblastic leukemia
458168|NCT00866749|acute lymphoblastic lymphoma
458169|NCT00866749|Leukemia
458170|NCT00866749|ALL
458171|NCT00866749|6-Thioguanine
458172|NCT00866749|Cyclophosphamide
458173|NCT00866749|Cytarabine
458174|NCT00866749|Daunorubicin
458175|NCT00866749|Doxorubicin
458176|NCT00866749|Methotrexate
458177|NCT00866749|PEG-L-Asparaginase
458178|NCT00866749|Vincristine
458179|NCT00866749|Intrathecal Methotrexate
458180|NCT00866749|Mercaptopurine
458181|NCT00866736|chronic myeloid leukemia
458182|NCT00866736|dasatinib
458183|NCT00866736|chronic phase myeloid leukemia
458184|NCT00866723|Avastin
458185|NCT00866723|bevacizumab
458186|NCT00866697|fallopian tube cancer
458187|NCT00866697|pazopanib
458188|NCT00866697|anti-angiogenesis
458189|NCT00866697|ovarian cancer
458190|NCT00866697|primary peritoneal cancer
458191|NCT00866697|tyrosine kinase inhibitors
458192|NCT00866697|gynecologic cancer
458193|NCT00866684|renal transplant-patients with high-risk for skin cancer
458194|NCT00866671|T-ALL
458195|NCT00866671|Safety
458196|NCT00866671|Post Authorisation Safety Study
458197|NCT00866671|T-LBL
458198|NCT00866671|Lymphoblastic Lymphoma
458199|NCT00866671|Acute Lymphoblastic Leukemia
458200|NCT00866658|hyperglycemia
458201|NCT00866658|GLP-1
458202|NCT00866658|sulfonylurea
458203|NCT00866658|insulin
458205|NCT00866645|Schizophrenia
458206|NCT00866645|Randomized
458207|NCT00866645|Blind
458208|NCT00866645|Parallel
458209|NCT00866645|Intramuscular Haloperidol
458210|NCT00866645|Controlled
458211|NCT00866645|Multicenter
458212|NCT00866645|Clinical Trial
458213|NCT00866645|Efficacy
458214|NCT00866645|Safety
458215|NCT00866645|Intramuscular Levosulpiride
458216|NCT00866645|Chinese
458217|NCT00866645|PANSS-EC
458218|NCT00866645|ACES
458219|NCT00866645|CGI
458220|NCT00866645|BPRS
458221|NCT00866645|PANSS
458222|NCT00866645|RSESE
458223|NCT00866645|BAS
458224|NCT00866632|Depression
458225|NCT00866632|Anxiety
458226|NCT00866632|Brain Injury
458227|NCT00866632|Cognitive Therapy
458228|NCT00866632|Coping Skills
458229|NCT00866606|On-demand treatment
458230|NCT00866606|Hemostatic efficacy
458231|NCT00866606|Factor IX activity
458232|NCT00866606|Factor IX recovery
458233|NCT00866606|Factor IX inhibitor
458234|NCT00866606|Chinese
458235|NCT00866593|major depressive disorder(MDD)
458236|NCT00866593|depression
458237|NCT00866593|antidepressant
458238|NCT00866593|escitalpram oxalate
458239|NCT00866593|generic
458240|NCT00866593|innovator
458241|NCT00866593|Lexapro
458242|NCT00866593|efficacy
458243|NCT00866593|safety
458244|NCT00866593|multicenter
458245|NCT00866593|double-blind
458246|NCT00866593|randomized
458247|NCT00866593|chinese
458248|NCT00866593|HAMD
458249|NCT00866593|MADRS
458250|NCT00866593|HAMA
458251|NCT00866593|VAS-PI
458252|NCT00866593|SDS
458253|NCT00866593|CGI
458254|NCT00866580|Pandemic influenza
458255|NCT00866567|prematurity
458256|NCT00866567|VLBW
458257|NCT00866567|sepsis
458258|NCT00866567|innate immunity
458259|NCT00866554|Prostate
458260|NCT00866554|Brachytherapy
458261|NCT00866554|Cytoreduction
458262|NCT00866554|Sexual function
458263|NCT00866554|Toxicity
458264|NCT00866541|resistance
458265|NCT00866541|flow proportional pressure support
458266|NCT00866541|pressure support ventilation
458267|NCT00866541|volunteers
458268|NCT00866541|assistant breathing
458269|NCT00866541|breathing comfort and objective breathing data
458270|NCT00866528|NSCLC
458271|NCT00866528|non-small cell lung cancer
458272|NCT00866528|GW786034
458273|NCT00866528|pazopanib
458274|NCT00866528|Advanced Non-Small Cell Lung Cancer
458275|NCT00866528|Advanced Solid Tumor
458276|NCT00866528|Metastatic Non-Small Cell Lung Cancer
458277|NCT00866528|paclitaxel
458278|NCT00866515|Healthy volunteer
458279|NCT00866515|pharmacodynamics
458280|NCT00866515|Ketoconazole
458281|NCT00866515|Drug Interaction
458282|NCT00866515|pharmacokinetcs
458283|NCT00866515|GW642444M
458284|NCT00866515|pharmacokinetics
458285|NCT00866502|Parkinson
458286|NCT00866502|Safety
458287|NCT00866502|PDGF
458288|NCT00866502|Intracerebroventricular
458289|NCT00866502|Infusion
458290|NCT00866502|Device
458291|NCT00866489|Experimental
458292|NCT00866476|Shigella
458293|NCT00866476|Vaccine
458294|NCT00866476|Mucosal immunity
458295|NCT00866463|Sildenafil, Pharmacokinetics, Healthy Volunteer
458296|NCT00866437|PMS
458297|NCT00866437|Hormones
458298|NCT00866437|Skin tests
458299|NCT00866437|Allergen Immunotherapy
458300|NCT00866424|trigeminal neuralgia
458301|NCT00866424|pain
458302|NCT00866424|HBO
458303|NCT00866424|VAS
458304|NCT00866424|MGPQ
458305|NCT00866411|cranial electrotherapy stimulation
458306|NCT00866411|anxiety
458307|NCT00866411|depression
458308|NCT00866411|pain
458309|NCT00866411|sleep disturbance
458310|NCT00866411|combat exposure
458311|NCT00866411|post traumatic stress
458312|NCT00866411|health status
458313|NCT00866411|medication use
458314|NCT00866411|soldiers
458315|NCT00866398|coronary heart disease
458316|NCT00866398|chd
458317|NCT00866398|stent
458318|NCT00866385|Healthy Volunteer
458319|NCT00866385|AZD8566
458320|NCT00866385|Food Effect
458321|NCT00866385|Microtracer
458322|NCT00866346|Chronic Myelogenous Leukemia
458323|NCT00866346|CML
458324|NCT00866346|Allogeneic Hematopoietic Transplantation
458325|NCT00866346|Bone Marrow Transplant
458326|NCT00866346|PR1-Specific Cytotoxic T-Lymphocyte Infusion
458327|NCT00866333|Hodgkin's Lymphoma
458328|NCT00866333|Relapsed Hodgkin's Lymphoma
458329|NCT00866333|Refractory Hodgkin's Lymphoma
458330|NCT00866320|clear cell renal cell carcinoma
458331|NCT00866320|recurrent renal cell cancer
458332|NCT00866320|stage IV renal cell cancer
458333|NCT00866294|Immediate-release formulation of paroxetine (paroxetine IR)
458334|NCT00866294|HAM-D (17 items)
458335|NCT00866294|Controlled-release formulation of paroxetine (paroxetine CR)
458336|NCT00866281|Acute Myeloid Leukemia
458337|NCT00866281|AML
458338|NCT00866281|Acute Lymphoblastic Leukemia
458339|NCT00866281|ALL
458340|NCT00866281|midostaurin
458341|NCT00866281|PKC412
458342|NCT00866281|Pediatric relapsed or refractory FLT3 positive Acute Myeloid Leukemia
458343|NCT00866281|Pediatric relapsed or refractory Mixed-lineage leukemia gene rearranged Acute Lymphoblastic leukemia
458344|NCT00866268|Blood loss
458345|NCT00866268|Total knee arthroplasty
458346|NCT00866268|Adults
458347|NCT00866268|Drain
458348|NCT00866268|Drainage system
458349|NCT00866255|endotracheal tube
458350|NCT00866255|endotracheal pressure
458351|NCT00866255|airway pressure
458352|NCT00866255|pressure drop
458353|NCT00866255|calculation
458354|NCT00866255|continuous calculation
458355|NCT00866242|Shigella
458356|NCT00866242|Vaccine
458357|NCT00866242|Mucosal immunity
458358|NCT00866190|Mycobacterium tuberculosis, SQ109
458359|NCT00866164|back pain
458360|NCT00866164|intractable pain
458361|NCT00866164|implantable infusion pump
458362|NCT00866164|morphine
458363|NCT00866151|genetic biomarker
458364|NCT00866151|biomarker
458365|NCT00866151|molecular diagnostics
458366|NCT00866151|genes
458367|NCT00866151|genetics
458368|NCT00866151|overweight management
458369|NCT00866151|weight management
458370|NCT00866151|weight reduction
458371|NCT00866151|SNPs
458372|NCT00866151|single nucleotide polymorphisms
458373|NCT00866138|multiple myeloma
458374|NCT00866138|t(4/14)
458375|NCT00866138|relapsing
458376|NCT00866138|refractory
458377|NCT00866125|Polymyositis
458378|NCT00866125|Dermatomyositis
458379|NCT00866125|Grip force
458380|NCT00866125|Quality of life
458381|NCT00866125|Activity performance
458382|NCT00866112|Wheelchair use
458383|NCT00866112|Spinal cord injury
458384|NCT00866112|Multiple sclerosis
458385|NCT00866112|Muscular dystrophy
458386|NCT00866112|Cerebral palsy
458387|NCT00866112|Spina bifida
458388|NCT00866112|Amputation
458389|NCT00866112|Arthritis
458390|NCT00866112|Stroke
458391|NCT00866099|Dementia
458392|NCT00866099|primary care
458393|NCT00866099|early diagnosis
458394|NCT00866099|psychosocial interventions
458395|NCT00866099|cholinesterase inhibitors
458396|NCT00866086|stage I non-small cell lung cancer
458397|NCT00866086|stage II non-small cell lung cancer
458398|NCT00866086|stage IIIA non-small cell lung cancer
458399|NCT00866086|stage IIIB non-small cell lung cancer
458400|NCT00866086|stage IV non-small cell lung cancer
458401|NCT00866086|recurrent non-small cell lung cancer
458402|NCT00866086|pulmonary carcinoid tumor
458403|NCT00866086|extensive stage small cell lung cancer
458404|NCT00866086|limited stage small cell lung cancer
458405|NCT00866086|recurrent small cell lung cancer
458406|NCT00866073|AML
458407|NCT00866073|Acute myeloid leukemia
458408|NCT00866073|Decitabine
458409|NCT00866060|donepezil
458410|NCT00866060|memantine
458411|NCT00866060|moderately severe Alzheimer's disease
458412|NCT00866060|severe Alzheimer's disease
458413|NCT00866047|Antigens, CD30
458414|NCT00866047|Antibody-Drug Conjugate
458415|NCT00866047|Antibodies, Monoclonal
458416|NCT00866047|Lymphoma, Non-Hodgkin
458417|NCT00866047|Lymphoma, Large-Cell, Anaplastic
458418|NCT00866047|monomethyl auristatin E
458419|NCT00866047|Drug Therapy
458420|NCT00866047|Immunotherapy
458421|NCT00866047|Hematologic Diseases
458422|NCT00866047|Lymphoma
458423|NCT00866034|Cetrotide
458424|NCT00866034|IVF
458425|NCT00866034|ICSI
458426|NCT00866034|Treatment protocol
458427|NCT00866021|HIV infection
458428|NCT00866021|HCV infection
458429|NCT00866021|treatment experienced
458430|NCT00866008|IVF
458431|NCT00866008|In vitro implantation
458432|NCT00866008|Preimplantation genetic screening
458433|NCT00866008|Aneuploidy
458434|NCT00865995|pepsin
458435|NCT00865995|aspiration
458436|NCT00865995|GE reflux
458437|NCT00865982|adenocarcinoma of the stomach, gastro-esophageal junction or distal esophagus
458438|NCT00865982|gastric cancer
458439|NCT00865982|esophageal cancer
458440|NCT00865982|gastro-esophageal junction
458441|NCT00865982|docetaxel
458442|NCT00865982|capecitabine
458443|NCT00865982|cisplatin
458444|NCT00865982|perioperative chemotherapy
458445|NCT00865969|Belinostat
458446|NCT00865969|peripheral T-cell lymphoma
458447|NCT00865969|PXD101
458448|NCT00865969|PTCL
458449|NCT00865969|HDAC inhibitor
458450|NCT00865969|histone deacetylase inhibitor
458451|NCT00865956|disease management
458452|NCT00865956|substance use disorders
458453|NCT00865956|behavioral incentives
458454|NCT00865943|Bioequivalence
458455|NCT00865943|Citalopram
458456|NCT00865943|Healthy subjects
458457|NCT00865917|POTS
458458|NCT00865904|∆F508
458459|NCT00865904|F508del
458460|NCT00865904|Cystic Fibrosis Transmembrane Conductance Regulator
458461|NCT00865904|CFTR
458462|NCT00865904|Pancreatic diseases
458463|NCT00865904|Lung diseases
458464|NCT00865904|Genetic disease, inborn
458465|NCT00865904|Infant, newborn, diseases
458466|NCT00865891|Bioequivalence
458467|NCT00865891|Nifedipine
458468|NCT00865891|Healthy subjects
458469|NCT00865878|Actinic Keratoses
458470|NCT00865878|Skin Neoplasms
458471|NCT00865878|Photodynamic Therapy
458472|NCT00865878|Transplants
458473|NCT00865865|Knee
458474|NCT00865865|Computer
458475|NCT00865865|Gap
458476|NCT00865865|Soft tissue
458477|NCT00865865|Balancing
458478|NCT00865865|Replacement
458479|NCT00865865|Arthroplasty
458480|NCT00865852|Bioequivalence
458481|NCT00865852|Metformin
458482|NCT00865852|Healthy subjects
458483|NCT00865839|Bioequivalence
458484|NCT00865839|Metformin
458485|NCT00865839|Healthy subjects
458486|NCT00865826|Pulmonary Tuberculosis
458487|NCT00865826|Myobacterium Infections
458488|NCT00865813|Punch biopsy,
458489|NCT00865813|periocular
458490|NCT00865813|tumors.
458491|NCT00865774|Trauma
458492|NCT00865774|Alcohol
458493|NCT00865774|Brief Intervention
458494|NCT00865761|Bioequivalence
458495|NCT00865761|Alprazolam
458496|NCT00865761|Healthy subjects
458497|NCT00865748|Bioequivalence
458498|NCT00865748|Metformin
458499|NCT00865748|Healthy subjects
458500|NCT00865722|Remote Postconditioning
458501|NCT00865722|Myocardial reperfusion Injury
458502|NCT00865722|Myocardial Infarction
458503|NCT00865722|Primary PCI
458504|NCT00865709|Colorectal Cancer
458505|NCT00865709|Metastasis
458506|NCT00865709|Stage IV
458507|NCT00865709|Liver Metastasis
458508|NCT00865696|Bioequivalence
458509|NCT00865696|Mirtazapine
458510|NCT00865696|Healthy subjects
458511|NCT00865683|Gestational Diabetes
458512|NCT00865683|Pregnancy
458513|NCT00865683|Docosahexaenoic Acid
458514|NCT00865683|DHA
458515|NCT00865683|Maternal-Fetal Exchange
458516|NCT00865657|Bioequivalence
458517|NCT00865657|Alprazolam
458518|NCT00865657|Healthy subjects
458519|NCT00865644|imiquimod 5% cream
458520|NCT00865631|Bioequivalence
458521|NCT00865631|Gabapentin
458522|NCT00865631|Healthy subjects
458523|NCT00865605|bioequivalence
458524|NCT00865605|Vasoconstriction
458525|NCT00865605|Halobetasol
458526|NCT00865605|Healthy subjects
458527|NCT00865592|diabetes
458528|NCT00865592|DPP4 inhibitor
458529|NCT00865592|dutogliptin
458530|NCT00865592|PHX1149
458531|NCT00865579|MAO inhibitors
458532|NCT00865579|motor fluctuations
458533|NCT00865579|dyskinesia
458534|NCT00865579|Parkinson's Disease
458535|NCT00865566|HIV Seronegativity
458536|NCT00865566|HIV Preventive Vaccine
458537|NCT00865566|HIV Treatment Vaccine
458538|NCT00865566|Adenovirus
458539|NCT00865553|tobacco use disorder
458540|NCT00865540|cataract
458541|NCT00865540|pupillary dilation
458542|NCT00865540|anti-inflammatory
458543|NCT00865540|therapeutic use
458544|NCT00865527|Colorectal cancer
458545|NCT00865527|Colon cancer
458546|NCT00865527|Adenomatous polyps
458547|NCT00865527|Screening
458548|NCT00865527|Fecal occult blood test
458549|NCT00865527|Computed tomographic colonography
458550|NCT00865527|Colonoscopy
458551|NCT00865514|dichloroacetate
458552|NCT00865514|tyrosine
458553|NCT00865514|maleylacetoacetate
458554|NCT00865514|trichloroethylene
458555|NCT00865514|leucine
458556|NCT00865514|haplotype
458557|NCT00865501|primary hypertension
458558|NCT00865501|aldosterone
458559|NCT00865501|left ventricular hypertrophy
458560|NCT00865475|HIV infection
458561|NCT00865475|Treatment Experienced
458562|NCT00865462|Bioequivalence
458563|NCT00865462|Bupropion
458564|NCT00865462|Healthy subjects
458565|NCT00865449|spironolactone
458566|NCT00865449|peritoneal fibrosis
458567|NCT00865449|peritoneal dialysis
458568|NCT00865436|Bioequivalence
458569|NCT00865436|Metformin
458570|NCT00865436|Glyburide
458571|NCT00865436|Healthy subjects
458572|NCT00865423|Bioequivalence
458573|NCT00865423|Gabapentin
458574|NCT00865423|Healthy subjects
458575|NCT00865410|Bioequivalence
458576|NCT00865410|Bupropion
458577|NCT00865410|Healthy subjects
458578|NCT00865384|Bioequivalence
458579|NCT00865384|Mirtazapine
458580|NCT00865384|Healthy subjects
458581|NCT00865371|Bioequivalence
458582|NCT00865371|Bupropion
458583|NCT00865371|Healthy subjects
458584|NCT00865358|yoga
458585|NCT00865358|complementary alternative medicine
458586|NCT00865358|low back pain
458587|NCT00865358|minority health
458588|NCT00865358|health care disparities
458589|NCT00865358|community health centers
458590|NCT00865345|blood sugar
458591|NCT00865345|glucose
458592|NCT00865345|sensor
458593|NCT00865332|PET
458594|NCT00865332|fMRI
458595|NCT00865332|D-Amphetamine
458596|NCT00865332|Cocaine Addiction
458597|NCT00865332|Methylphenidate
458598|NCT00865319|Non Small Cell Lung Cancer
458599|NCT00865319|Spect CT Imaging
458600|NCT00865319|PET CT Imaging as Comparator
458601|NCT00865306|Cognitive behavioral therapy
458602|NCT00865306|Anxiety
458603|NCT00865306|Preschoolers
458604|NCT00865306|Young Children
458605|NCT00865306|Parents
458606|NCT00865306|At-risk
458607|NCT00865306|Behavioral Inhibition
458608|NCT00865293|Obesity
458609|NCT00865293|expiratory flow limitation
458610|NCT00865293|EFL
458611|NCT00865293|posture
458612|NCT00865293|small airways obstruction
458613|NCT00865293|FOT
458614|NCT00865280|CSSI
458615|NCT00865280|Abscess
458616|NCT00865280|Wound
458617|NCT00865280|Cellulitis
458618|NCT00865280|Complicated Skin and Skin Structure Infections (cSSSI)
458619|NCT00865267|Vasoconstriction
458620|NCT00865267|Halobetasol
458621|NCT00865267|Healthy adult subjects
458622|NCT00865254|Nicotine Dependence
458623|NCT00865254|Smoking
458624|NCT00865254|Smoking Cessation
458625|NCT00865254|Contingency Management
458626|NCT00865241|Bioequivalence
458627|NCT00865241|Metformin
458628|NCT00865241|Glyburide
458629|NCT00865241|Healthy subjects
458630|NCT00865228|Hyperlipidemia
458631|NCT00865228|Dyslipidemia
458632|NCT00865228|High Cholesterol
458633|NCT00865228|Drug Therapy
458634|NCT00865215|Bioequivalence
458635|NCT00865215|Propranolol
458636|NCT00865215|Healthy subjects
458637|NCT00865202|delirium
458638|NCT00865202|surgery
458639|NCT00865202|operation
458640|NCT00865202|geriatric
458641|NCT00865202|complication
458642|NCT00865163|Percutaneous Coronary Intervention
458643|NCT00865163|anticoagulation
458644|NCT00865163|PCI
458645|NCT00865150|Prematurity
458646|NCT00865150|Neonatal screening
458647|NCT00865150|Parenteral nutrition
458648|NCT00865150|Amino acids
458649|NCT00865150|Acylcarnitine
458650|NCT00865137|Kidney Transplantation
458651|NCT00865137|Pharmacokinetics
458652|NCT00865137|Tacrolimus modified release
458653|NCT00865137|FK506E
458654|NCT00865111|Bioequivalence
458655|NCT00865111|Bupropion
458656|NCT00865111|Healthy subjects
458657|NCT00865098|Newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN)
458658|NCT00865085|Bioequivalence
458659|NCT00865085|Citalopram
458660|NCT00865085|Healthy subjects
458661|NCT00865072|Bioequivalence
458662|NCT00865072|Metformin
458663|NCT00865072|Healthy subjects
458664|NCT00865059|Bioequivalence
458665|NCT00865059|Gabapentin
458666|NCT00865059|Healthy subjects
458667|NCT00865046|acupuncture
458668|NCT00865020|Hypertension
458669|NCT00865020|ABPM
458670|NCT00865020|systolic blood pressure
458671|NCT00865020|diastolic blood pressure
458672|NCT00865020|cardiovascular disease
458673|NCT00865020|aliskiren
458674|NCT00865020|telmisartan
458675|NCT00865007|Lipodystrophy
458676|NCT00865007|treatment experienced
458677|NCT00864994|COPD
458678|NCT00864994|Inflammation
458679|NCT00864994|Smoking
458680|NCT00864994|Multiorgan pathology
458681|NCT00864994|Extra pulmonary manifestations
458682|NCT00864968|Bioequivalence
458683|NCT00864968|Nabumetone
458684|NCT00864968|Healthy subjects
458685|NCT00864955|UV-A irradiation
458686|NCT00864955|Cyclobutane-Pyrimidine Dimer
458687|NCT00864955|Oxidative lesions
458688|NCT00864955|cutaneous phototype
458689|NCT00864955|UV-B irradiation
458690|NCT00864955|DNA damages
458691|NCT00864942|CLL
458692|NCT00864942|NHL
458693|NCT00864942|lymphoma
458694|NCT00864929|Non-interventional study
458695|NCT00864929|Vietnam
458696|NCT00864929|inappropriate treatment
458697|NCT00864929|nosocomial infection
458698|NCT00864916|Endothelial Function
458699|NCT00864916|Pentoxifylline
458700|NCT00864916|Antiretroviral Therapy
458701|NCT00864916|Inflammation
458702|NCT00864903|enterovirus
458703|NCT00864903|aseptic meningitis
458704|NCT00864903|real time PCR
458705|NCT00864903|diagnostics
458706|NCT00864890|Bioequivalence
458707|NCT00864890|Citalopram
458708|NCT00864890|Healthy subjects
458709|NCT00864877|retrospective
458710|NCT00864877|comparison
458711|NCT00864877|biodegradable
458712|NCT00864877|implant
458713|NCT00864877|ankle fracture
458714|NCT00864864|sunitinib
458715|NCT00864838|intraocular pressure
458716|NCT00864838|bevacizumab
458717|NCT00864838|acetazolamide
458718|NCT00864838|brimonidine
458719|NCT00864838|anterior chamber paracentesis
458720|NCT00864825|Schizophrenia
458721|NCT00864825|Allopurinol
458722|NCT00864825|Add-on-treatment
458723|NCT00864799|Abortion
458724|NCT00864799|Misoprostol
458725|NCT00864799|Mifepristone
458726|NCT00864799|Pregnancy
458727|NCT00864799|Fetus
458728|NCT00864786|Multiple dose safety and pharmacokinetics study
458729|NCT00864760|Bioequivalence
458730|NCT00864760|Gabapentin
458731|NCT00864760|Healthy subjects
458732|NCT00864747|Bioequivalence
458733|NCT00864747|Propranolol
458734|NCT00864747|Healthy subjects
458735|NCT00864734|Bioequivalence
458736|NCT00864734|Metformin
458737|NCT00864734|Glyburide
458738|NCT00864734|Healthy subjects
458739|NCT00864721|Untreated NSCLC in patients > 70
458740|NCT00864708|Functional Electrical Stimulation
458741|NCT00864695|Anesthesia
458742|NCT00864695|Ethics
458743|NCT00864695|Trends
458744|NCT00864695|Manpower
458745|NCT00864695|Perioperative care
458746|NCT00864682|propofol
458747|NCT00864682|lidocaine
458748|NCT00864682|injection pain
458749|NCT00864669|Bioequivalence
458750|NCT00864669|Metformin
458751|NCT00864669|Healthy subjects
458752|NCT00864656|adrenergic alpha-agonists
458753|NCT00864656|phenylephrine
458754|NCT00864656|drug effects
458755|NCT00864656|diagnostic use
458756|NCT00864643|Hyperlipidemia
458757|NCT00864643|Drug Therapy
458758|NCT00864643|Dyslipidemia
458759|NCT00864617|Bioequivalence
458760|NCT00864617|Nifedipine
458761|NCT00864617|Healthy subjects
458762|NCT00864604|Bioequivalence
458763|NCT00864604|Nabumetone
458764|NCT00864604|Healthy subjects
458765|NCT00864591|SPECT Imaging
458766|NCT00864591|Stress adenosine CMR
458767|NCT00864578|POAG
458768|NCT00864578|IOP
458769|NCT00864578|Forskolin
458770|NCT00864578|Food supplement
458771|NCT00864565|Bioequivalence
458772|NCT00864565|Fentanyl
458773|NCT00864565|Healthy subjects
458774|NCT00864552|Hemophilia A
458775|NCT00864552|Recombinant Factor VIII
458776|NCT00864539|vitamin D fortification
458777|NCT00864539|milk
458778|NCT00864539|orange juice
458779|NCT00864539|supplement
458780|NCT00864539|efficacy
458781|NCT00864526|Bioequivalence
458782|NCT00864526|Oxycodone
458783|NCT00864526|Ibuprofen
458784|NCT00864526|Healthy subjects
458785|NCT00864513|pancreas
458786|NCT00864513|metastatic
458787|NCT00864513|recurrent
458788|NCT00864500|Bio-Equivalence
458789|NCT00864500|Vasoconstriction
458790|NCT00864500|Clobetasol
458791|NCT00864500|Healthy adult females
458792|NCT00864461|Down syndrome
458793|NCT00864461|Metabolis syndrome X
458794|NCT00864461|Insulin resistance
458795|NCT00864448|Bioequivalence
458796|NCT00864448|Ramipril
458797|NCT00864448|Healthy subjects
458798|NCT00864435|Bioequivalence
458799|NCT00864435|Carvedilol
458800|NCT00864435|Healthy subjects
458801|NCT00864422|low back pain
458802|NCT00864422|motor training
458803|NCT00864422|motor cortex
458804|NCT00864422|brain plasticity
458805|NCT00864409|postoperative pain
458806|NCT00864409|total hip arthroplasty
458807|NCT00864396|Laryngopharyngeal reflux
458808|NCT00864396|Gastroesophageal reflux disease
458809|NCT00864396|GERD
458810|NCT00864370|Psychiatry
458811|NCT00864370|Pregnancy
458812|NCT00864370|Bipolar Disorder
458813|NCT00864357|Bioequivalence
458814|NCT00864357|Oxycodone
458815|NCT00864357|Ibuprofen
458816|NCT00864357|Healthy subjects
458817|NCT00864344|Bioequivalence
458818|NCT00864344|Sertralin
458819|NCT00864344|Healthy subjectse
458820|NCT00864331|lung cancer
458821|NCT00864331|nonsmall cell lung cancer
458822|NCT00864331|radiation therapy
458823|NCT00864331|chemotherapy
458824|NCT00864331|Locally advanced and metastatic nonsmall cell lung cancer
458825|NCT00864318|refractory
458826|NCT00864318|germ cell tumors
458827|NCT00864318|relapse
458828|NCT00864318|bad prognosis
458829|NCT00864318|Refractory germ cell tumors with relapse and bad prognosis
458830|NCT00864305|Bioequivalence
458831|NCT00864305|Gabapentin
458832|NCT00864305|Healthy subjects
458833|NCT00864279|Bioequivalence
458834|NCT00864279|Cetirizine
458835|NCT00864279|Healthy subjects
458836|NCT00864266|Non small cell lung carcinoma
458837|NCT00864266|Chemotherapy
458838|NCT00864266|Response prediction
458839|NCT00864253|Melanoma
458840|NCT00864253|Malignant
458841|NCT00864253|Abraxane
458842|NCT00864253|ABI-007
458843|NCT00864253|Dacarbazine
458844|NCT00864253|Dtic-Dome
458845|NCT00864240|Vasoconstriction
458846|NCT00864240|Clobetasol
458847|NCT00864240|Healthy adult females
458848|NCT00864227|Acute Lymphoblastic Leukemia/Lymphoma
458849|NCT00864227|Acute Myelogenous Leukemia
458850|NCT00864227|Mantel-Cell Lymphoma
458851|NCT00864227|Hematopoietic Transplant
458852|NCT00864227|Umbilical Cord Blood (UCB)
458853|NCT00864227|Non-Myeloablative Transplant
458854|NCT00864214|bioidentical hormone
458855|NCT00864214|menopause
458856|NCT00864214|estrogen
458857|NCT00864214|progesterone
458858|NCT00864188|skin health
458859|NCT00864188|probiotics
458860|NCT00864188|dairy
458861|NCT00864188|oral
458862|NCT00864162|Bioequivalence
458863|NCT00864162|Ramipril
458864|NCT00864162|Healthy subjects
458865|NCT00864149|Bioequivalence
458866|NCT00864149|Carvedilol
458867|NCT00864149|Healthy subjects
458868|NCT00864123|Obsessive-compulsive disorder
458869|NCT00864110|Non small cell lung cancer
458870|NCT00864110|SPECT CT imaging
458871|NCT00864110|Pharmacokinetic
458872|NCT00864110|Radiation Dosimetry
458873|NCT00864110|PET CT comparison
458874|NCT00864097|Arthritis monoclonal antibody nerve growth factor (NGF) anti-NGF tanezumab PF-04383119 RN-624 OA
458875|NCT00864071|Bioequivalence
458876|NCT00864071|Griseofulvin
458877|NCT00864071|Healthy subjects
458878|NCT00864058|Bioequivalence
458879|NCT00864058|Gabapentin
458880|NCT00864058|Healthy subjects
458881|NCT00864032|Soft tissue sarcoma of the extremity and body wall
458882|NCT00864019|Bioequivalence
458883|NCT00864019|Sertraline
458884|NCT00864019|Healthy subjects
458885|NCT00863980|angiotensin
458886|NCT00863980|receptor
458887|NCT00863980|vulnerable plaque
458888|NCT00863980|coronary artery
458889|NCT00863967|physical examination
458890|NCT00863967|diagnostic techniques and procedures
458891|NCT00863967|diagnosis
458892|NCT00863967|immunologic tests
458893|NCT00863967|diagnostic tests
458894|NCT00863967|causality
458895|NCT00863967|genetic test
458896|NCT00863967|biomarker
458897|NCT00863941|Bioequivalence
458898|NCT00863941|Bupropion
458899|NCT00863941|Healthy subjects
458900|NCT00863915|Bioequivalence
458901|NCT00863915|Ramipril
458902|NCT00863915|Healthy subjects
458903|NCT00863902|Bioequivalence
458904|NCT00863902|Cetirizine
458905|NCT00863902|Healthy subjects
458906|NCT00863876|wavefront measurements of the entire eye
458907|NCT00863863|Bioequivalence
458908|NCT00863863|Griseofulvin
458909|NCT00863863|Healthy subjects
458910|NCT00863837|Acute variceal bleeding
458911|NCT00863837|banding ligation
458912|NCT00863837|vasoconstrictor
458913|NCT00863837|proton pump inhibitor
458914|NCT00863824|NNAL
458915|NCT00863824|Cotinine
458916|NCT00863824|Second hand smoke
458917|NCT00863824|NNAL is a known lung carcinogen. So, we are studying an agent that can potentially cause lung cancer.
458918|NCT00863811|POAG
458919|NCT00863811|IOP
458920|NCT00863811|Forskolin
458921|NCT00863811|beta-blockers
458922|NCT00863811|prostaglandins
458923|NCT00863798|Major Depressive Disorder
458924|NCT00863785|Acute Alcoholic Hepatitis
458925|NCT00863785|Cirrhosis
458926|NCT00863785|Alcohol
458927|NCT00863785|Alcoholic Liver disease
458928|NCT00863759|intra-ocular lenses
458929|NCT00863759|comparative study
458930|NCT00863759|Ocular aberrations
458931|NCT00863759|Contrast Sensitivity
458932|NCT00863746|Non-Small Cell Lung Cancer (NSCLC)
458933|NCT00863746|Sorafenib
458934|NCT00863707|regadenoson
458935|NCT00863707|chronic kidney disease stage III
458936|NCT00863707|chronic kidney disease stage IV
458937|NCT00863707|renal impairment
458938|NCT00863707|coronary artery disease
458939|NCT00863694|cystic fibrosis
458940|NCT00863694|calprotectin
458941|NCT00863694|elastase
458942|NCT00863681|Pulmonary arterial hypertension
458943|NCT00863681|PH
458944|NCT00863681|Stimulator
458945|NCT00863668|Infection
458946|NCT00863668|HIV 1
458947|NCT00863668|HIV
458948|NCT00863668|treatment naive
458949|NCT00863655|Breast Cancer
458950|NCT00863655|Estrogen Receptor positive
458951|NCT00863655|ER+
458952|NCT00863655|exemestane
458953|NCT00863655|mTOR
458954|NCT00863655|everolimus
458955|NCT00863655|refractory
458956|NCT00863655|NSAI
458957|NCT00863642|Early cholecystectomy
458958|NCT00863642|gallstone pancreatitis
458959|NCT00863629|myocardial infarction
458960|NCT00863629|oxidative stress
458961|NCT00863629|stem cells
458962|NCT00863629|glycemic control
458963|NCT00863616|COPD
458964|NCT00863616|Mucus hypersecretion
458965|NCT00863616|HRQL
458966|NCT00863616|ESWT
458967|NCT00863616|HFCWO
458968|NCT00863603|Supplemental oxygen
458969|NCT00863603|Intimal hyperplasia
458970|NCT00863603|Graft patency
458971|NCT00863577|Healthy volunteers
458972|NCT00863564|Postprandial Period
458973|NCT00863564|Postprandial Lipaemia
458974|NCT00863564|Incretins
458975|NCT00863564|Subclinical Inflammation
458976|NCT00863564|Obesity
458977|NCT00863564|Atherosclerosis
458978|NCT00863564|Triglyceride
458979|NCT00863564|Lipoproteins
458980|NCT00863564|Postprandial inflammation
458981|NCT00863538|Spinocerebellar degeneration
458982|NCT00863538|Thyrotropin-Releasing Hormone (TRH)
458983|NCT00863538|SCD
458984|NCT00863512|stage IA non-small cell lung cancer
458985|NCT00863512|stage IB non-small cell lung cancer
458986|NCT00863512|stage IIA non-small cell lung cancer
458987|NCT00863512|adenocarcinoma of the lung
458988|NCT00863512|adenosquamous cell lung cancer
458989|NCT00863512|bronchoalveolar cell lung cancer
458990|NCT00863512|large cell lung cancer
458991|NCT00863512|squamous cell lung cancer
458992|NCT00863499|Attention Deficit/Hyperactivity Disorder
458993|NCT00863499|Attention Deficit Disorder
458994|NCT00863499|ADHD
458995|NCT00863499|ADD
458996|NCT00863499|iSPOT
458997|NCT00863473|Proximal Humerus Fracture in elderly
458998|NCT00863421|Sleep disordered breathing
458999|NCT00863421|Prevalence
459000|NCT00863421|Chronic heart failure
459001|NCT00863421|Incidence
459002|NCT00863421|Sleep apnea
459003|NCT00863421|Cheyne-Stokes-Breathing
459004|NCT00863408|Mosquito
459005|NCT00863408|Human Landing Collection
459006|NCT00863408|Malaria
459007|NCT00863395|pruritis
459008|NCT00863395|itch
459009|NCT00863395|CTCL
459010|NCT00863382|atrial fibrillation
459011|NCT00863369|recurrent adult Burkitt lymphoma
459012|NCT00863369|recurrent adult diffuse large cell lymphoma
459013|NCT00863369|recurrent adult diffuse mixed cell lymphoma
459014|NCT00863369|recurrent adult diffuse small cleaved cell lymphoma
459015|NCT00863369|recurrent adult grade III lymphomatoid granulomatosis
459016|NCT00863369|recurrent adult immunoblastic large cell lymphoma
459017|NCT00863369|recurrent adult lymphoblastic lymphoma
459018|NCT00863369|recurrent grade 3 follicular lymphoma
459019|NCT00863369|recurrent mantle cell lymphoma
459020|NCT00863369|adult grade III lymphomatoid granulomatosis
459021|NCT00863356|Epistaxis
459022|NCT00863356|Chitosan
459023|NCT00863356|Hemostatic
459024|NCT00863356|Nose bleed
459025|NCT00863356|Nasal bleeding
459026|NCT00863356|Nasal pack
459027|NCT00863356|Sealant
459028|NCT00863356|ChitoFlex®
459029|NCT00863356|HemCon
459030|NCT00863356|HemCon® ChitoFlex Surgical Dressing
459031|NCT00863356|HemCon® Nasal Plugs
459032|NCT00863356|Biocompatible dressing
459033|NCT00863343|Influenza infections
459034|NCT00863343|Orthomyxoviridae infections
459035|NCT00863330|stage IV melanoma
459036|NCT00863330|recurrent melanoma
459037|NCT00863317|Bronchiolitis
459038|NCT00863317|montelukast
459039|NCT00863317|leukotriene inhibitor
459040|NCT00863304|monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth factor OA pain arthritis
459041|NCT00863291|Depression
459042|NCT00863291|suicidality
459043|NCT00863291|buprenorphine
459044|NCT00863265|Phytosterols
459045|NCT00863265|Ezetimibe
459046|NCT00863265|Cholesterol Excretion
459047|NCT00863265|Cholesterol Absorption
459048|NCT00863265|Diet
459049|NCT00863265|Mass Spectrometry
459050|NCT00863265|Deuterium
459051|NCT00863252|proteinuria
459052|NCT00863252|creatinine
459053|NCT00863252|kidney survival
459054|NCT00863252|ESRD
459055|NCT00863239|treatment naive
459056|NCT00863239|genotype 1
459057|NCT00863226|Quality of Life issues in Parkinson's disease
459058|NCT00863213|Catheter Ablation, Radiofrequency
459059|NCT00863213|Atrial fibrillation
459060|NCT00863213|Antiarrhythmic Drugs
459061|NCT00863200|Depression
459062|NCT00863200|Cancer
459063|NCT00863200|African Americans
459064|NCT00863200|Latinos
459065|NCT00863200|Hispanics
459066|NCT00863200|Interactive voice response
459067|NCT00863200|IVR
459068|NCT00863200|Behavioral Intervention
459069|NCT00863174|Multiple myeloma
459070|NCT00863174|Bio-equivalence
459071|NCT00863161|Safety
459072|NCT00863161|tolerability
459073|NCT00863161|exposure
459074|NCT00863161|healthy
459075|NCT00863161|renally impaired subjects
459076|NCT00863148|MDS
459077|NCT00863148|AML
459078|NCT00863148|ALL
459079|NCT00863148|RIC
459080|NCT00863148|clofarabine
459081|NCT00863148|allo-HSCT
459082|NCT00863148|high-risk MDS/AML
459083|NCT00863135|obstructive sleep apnea
459084|NCT00863135|refractory arterial hypertension
459085|NCT00863135|continuous positive airways pressure
459086|NCT00863122|Lapatinib
459087|NCT00863122|Tykerb
459088|NCT00863122|EGFR inhibitor
459089|NCT00863122|ErbB2 inhibitor
459090|NCT00863122|Pharmacokinetics
459091|NCT00863096|HPV
459092|NCT00863096|acceptability
459093|NCT00863083|pediatric obesity
459094|NCT00863083|pediatric overweight
459095|NCT00863083|multi-family group weight management intervention
459096|NCT00863083|financial rewards
459097|NCT00863070|Bladder exstrophy
459098|NCT00863070|Abnormal gait
459099|NCT00863070|anatomy
459100|NCT00863070|urinary bladder disease
459101|NCT00863070|urogenital abnormalities
459102|NCT00863057|HIV Infections
459103|NCT00863057|Neuropathy
459104|NCT00863057|Pain
459105|NCT00863044|off pump coronary bypass
459106|NCT00863044|high frequency ventilation
459107|NCT00863044|cerebral oxygen saturation
459108|NCT00863044|vasopressors used
459109|NCT00863044|right and left ventricular function
459110|NCT00863044|arterial blood pressure
459111|NCT00863044|heart rate
459112|NCT00863031|mental health
459113|NCT00863031|problem-solving therapy
459114|NCT00863031|elderly
459115|NCT00863031|health-related quality of life
459116|NCT00863031|primary care
459117|NCT00863031|Chinese
459118|NCT00863018|Corneal endothelial cell
459119|NCT00863018|Specular microscopy
459120|NCT00863018|Glaucoma implant surgery
459121|NCT00863018|Ahmed glaucoma valve
459122|NCT00863018|Trabeculectomy
459123|NCT00862992|schizophrenia
459124|NCT00862992|antipsychotics
459125|NCT00862992|dopamine D3/D2 antagonist
459126|NCT00862979|Heart Transplantation
459127|NCT00862979|Cardiac Transplantation
459128|NCT00862979|CNI-sparing
459129|NCT00862979|renal function
459130|NCT00862979|CNI
459131|NCT00862979|Cyclosporine A
459132|NCT00862979|Everolimus
459133|NCT00862979|enteric coated mycophenolic acid
459134|NCT00862953|low carbohydrate
459135|NCT00862953|high protein diet
459136|NCT00862940|Memantine
459137|NCT00862940|Neuroimaging
459138|NCT00862940|MRI
459139|NCT00862940|Brain atrophy
459140|NCT00862927|Smoking Cessation
459141|NCT00862927|Cigarette Smoking
459142|NCT00862927|Tobacco Smoking
459143|NCT00862927|Cue Reactivity
459144|NCT00862927|Virtual Reality
459145|NCT00862927|VR
459146|NCT00862927|Contextual Cues
459147|NCT00862927|Explicit Smoking Cues
459148|NCT00862927|Craving
459149|NCT00862927|Physiological Arousal
459150|NCT00862927|Nicotine Dependence
459151|NCT00862927|Breath Sample
459152|NCT00862927|Saliva Test
459153|NCT00862927|Questionnaire
459154|NCT00862914|Skin
459155|NCT00862914|MicroRNA
459156|NCT00862914|miRNA
459157|NCT00862914|Dicer
459158|NCT00862914|Malignant Melanoma
459159|NCT00862901|cancer
459160|NCT00862901|skin metastases
459161|NCT00862901|chest wall progression of breast cancer
459162|NCT00862901|malignant melanoma
459163|NCT00862901|photodynamic therapy
459164|NCT00862901|photophrin
459165|NCT00862901|satellite and in-transit metastases of malignant melanoma
459166|NCT00862901|skin cancer
459167|NCT00862875|Insulin initiation
459168|NCT00862875|oral therapy failure
459169|NCT00862862|infection
459170|NCT00862862|staphylococcus aureus
459171|NCT00862862|vancomycin
459172|NCT00862862|pharmacodynammics
459173|NCT00862849|rHuPH20
459174|NCT00862849|Recombinant Human Hyaluronidase
459175|NCT00862849|Insulin Lispro
459176|NCT00862849|Regular Human Insulin
459177|NCT00862836|ZD6474
459178|NCT00862836|Vandetanib
459179|NCT00862836|Zactima
459180|NCT00862836|Ovarian Cancer
459181|NCT00862836|Phase I
459182|NCT00862836|Phase II
459183|NCT00862836|Randomized
459184|NCT00862836|Safety
459185|NCT00862823|Healthy Volunteers
459186|NCT00862810|Human papillomavirus
459187|NCT00862810|Cervical cancer
459188|NCT00862810|Genital warts
459189|NCT00862810|Vaccine
459190|NCT00862810|Immunogenicity
459191|NCT00862797|endotracheal tube
459192|NCT00862797|swallowing
459193|NCT00862797|aspiration
459194|NCT00862797|cuff pressure
459195|NCT00862797|pneumonia
459196|NCT00862784|Colorectal carcinoma
459197|NCT00862784|CRC
459198|NCT00862784|Colon Cancer
459199|NCT00862758|juvenile idiopathic arthritis
459200|NCT00862732|active suicidal ideation
459201|NCT00862732|cognitive behavioural therapy
459202|NCT00862732|Sri Lanka
459203|NCT00862732|RCT
459204|NCT00862706|Chronic HBV
459205|NCT00862693|Immunoglobulin A
459206|NCT00862693|Antibodies
459207|NCT00862693|treatment
459208|NCT00862680|Lung Colorectum
459209|NCT00862680|Colorectal cancer
459210|NCT00862680|Lung Cancer
459211|NCT00862680|Liver Cancer
459212|NCT00862680|Non-small cell lung cancer
459213|NCT00862680|NSCLC
459214|NCT00862680|4D PET/CT Imaging
459215|NCT00862680|Positron emission tomography/computed tomography
459216|NCT00862680|PET/CT scan
459217|NCT00862680|Breathing motion
459218|NCT00862667|Pharmacokinetics
459219|NCT00862641|regadenoson
459220|NCT00862641|CVT 3146
459221|NCT00862641|asthma
459222|NCT00862641|coronary artery disease
459223|NCT00862641|pulmonary disease, chronic obstructive
459224|NCT00862615|Ageing
459225|NCT00862615|Inflammation
459226|NCT00862615|Muscle protein synthesis
459227|NCT00862615|Osteopenia
459228|NCT00862615|Sarcopenia
459229|NCT00862602|GDM
459230|NCT00862602|gestational diabetes
459231|NCT00862602|pregnancy
459232|NCT00862602|diabetes
459233|NCT00862602|walking
459234|NCT00862602|exercise
459235|NCT00862602|pedometer
459236|NCT00862602|online
459237|NCT00862589|glucagon
459238|NCT00862589|GLP-1
459239|NCT00862589|hyperglycemia
459240|NCT00862576|Burning Mouth Syndrome
459241|NCT00862576|Sleep
459242|NCT00862576|Neuropathic pain
459243|NCT00862576|Glossodynia
459244|NCT00862576|Chronic pain
459245|NCT00862576|Orofacial pain
459246|NCT00862563|Alcoholism
459247|NCT00862563|Alcohol Dependence
459248|NCT00862563|Alcohol Abuse
459249|NCT00862563|Substance Abuse
459250|NCT00862563|Alcoholic Intoxication
459251|NCT00862550|Head and Neck Cancer
459252|NCT00862550|HNC
459253|NCT00862550|Nasopharyngeal carcinoma
459254|NCT00862550|Acupuncture
459255|NCT00862550|Radiation-Induced Xerostomia
459256|NCT00862550|Xerostomia
459257|NCT00862550|Dry Mouth
459258|NCT00862550|Radiation
459259|NCT00862511|metal ion concentration
459260|NCT00862511|total knee arthroplasty
459261|NCT00862511|metal hypersensitivity
459262|NCT00862498|PTSD
459263|NCT00862498|Written Disclosure
459264|NCT00862498|Written Emotional Disclosure
459265|NCT00862498|Narrative Exposure
459266|NCT00862498|Narrative Writing
459267|NCT00862498|Motor Vehicle Accident
459268|NCT00862472|open-angle glaucoma
459269|NCT00862472|ocular hypertension
459270|NCT00862472|open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)
459271|NCT00862459|Contrast Agents
459272|NCT00862446|Parenteral nutrition associate liver disease
459273|NCT00862446|TPN cholestasis
459274|NCT00862446|TPN Associated Liver Disease
459275|NCT00862433|Vitamin C
459276|NCT00862433|Antioxidant
459277|NCT00862433|Lipid Peroxidation
459278|NCT00862433|Non-Insulin Requiring Diabetics
459279|NCT00862433|Alpha-Tocopherol
459280|NCT00862433|Health Volunteer
459281|NCT00862433|HV
459282|NCT00862433|Normal Weight
459283|NCT00862433|Overweight
459284|NCT00862433|Type 2 Diabetes
459285|NCT00862420|Platelet aggregation inhibitors
459286|NCT00862420|Peripheral arterial disease (PAD)
459287|NCT00862407|Cardiopulmonary bypass
459288|NCT00862407|Non-pulsatile perfusion
459289|NCT00862407|Pulsatile perfusion
459290|NCT00862407|plasma proteins
459291|NCT00862381|shock
459292|NCT00862381|Tracheal Intubation
459293|NCT00862381|reanimation
459294|NCT00862381|suprarenal insufficiency
459295|NCT00862381|Etomidate
459296|NCT00862381|Adrenocorticotropic Hormone
459297|NCT00862381|hydrocortisone
459298|NCT00862368|Motivational Interviewing
459299|NCT00862368|Pediatric Asthma
459300|NCT00862368|Smoking Cessation
459301|NCT00862368|Environmental Tobacco Smoke
459302|NCT00862368|Second hand smoke
459303|NCT00862368|Biomarker
459304|NCT00862368|Asthma
459305|NCT00862368|Asthma Education
459306|NCT00862368|Family Intervention
459307|NCT00862368|Smoking
459308|NCT00862368|Nicotine Patch
459309|NCT00862368|Parents
459310|NCT00862368|Caregivers
459311|NCT00862368|Child Wellness
459312|NCT00862355|Carcinoma
459313|NCT00862355|Ovary
459314|NCT00862355|Carcinoma Ovary
459315|NCT00862342|colorectal cancer
459316|NCT00862342|Bevacizumab
459317|NCT00862329|Healthy subjects
459318|NCT00862316|Eligible for Unicompartmental Knee Arthritis
459319|NCT00862303|autologous cytokine induced killer cells
459320|NCT00862303|dendritic cell
459321|NCT00862303|vaccine
459322|NCT00862303|renal cell carcinoma
459323|NCT00862290|sepsis
459324|NCT00862290|microRNA
459325|NCT00862277|Menactra®
459326|NCT00862277|Menomune®
459327|NCT00862277|Meningitis
459328|NCT00862277|Meningococcal Infections
459329|NCT00862251|cardiovascular disorder
459330|NCT00862225|rhinomanometry
459331|NCT00862225|mode of action
459332|NCT00862225|grass pollen
459333|NCT00862212|anxiety
459334|NCT00862212|social anxiety
459335|NCT00862212|social anxiety disorder
459336|NCT00862212|coping behaviors
459337|NCT00862212|alcohol abuse
459338|NCT00862186|Neoplasms
459339|NCT00862186|Fatigue
459340|NCT00862186|Self Care
459341|NCT00862173|Gene-expression profile
459342|NCT00862173|Central nervous system metastasis
459343|NCT00862173|Non-small-cell lung cancer
459344|NCT00862160|coronary artery bypass surgery
459345|NCT00862160|cardiopulmonary bypass
459346|NCT00862160|heart lung machine
459347|NCT00862160|acute cerebrovascular event
459348|NCT00862160|intracranial embolism
459349|NCT00862160|embolism, air
459350|NCT00862160|outcome assessment (health care)
459351|NCT00862160|neuropsychological tests
459352|NCT00862160|magnetic resonance imaging
459353|NCT00862160|saccadic eye movement test
459354|NCT00862147|Child psychosocial Functioning
459355|NCT00862108|Attention Deficit Hyperactivity Disorder
459356|NCT00862108|Polymorphism, Single Nucleotide
459357|NCT00862108|SLC6A2 protein, human
459358|NCT00862108|ADRA2A protein, human
459359|NCT00862056|asymptomatic
459360|NCT00862056|coronary artery disease
459361|NCT00862043|Secondary Pulmonary Hypertension
459362|NCT00862043|Valvular Heart Disease
459363|NCT00862043|Phosphodiesterase-Inhibitors
459364|NCT00862043|Sildenafil
459365|NCT00862043|Outcomes Research
459366|NCT00862030|Palliative radiotherapy
459367|NCT00862030|Treatment planning
459368|NCT00862030|Non-small cell lung cancer
459369|NCT00862017|Physiology
459370|NCT00862004|video-assisted thoracoscopic surgery (VATS)
459371|NCT00862004|systematic node dissection (SND)
459372|NCT00862004|stage IIIA non-small cell lung cancer
459373|NCT00861991|medical communication
459374|NCT00861991|empathy
459375|NCT00861991|medical education
459376|NCT00861991|standardized patients
459377|NCT00861991|"enhancing patient satisfaction"
459378|NCT00861978|mild to moderate depression with atypical features according to DSM-IV
459379|NCT00861965|Leukemia
459380|NCT00861965|Lymphoma
459381|NCT00861965|Multiple Myeloma
459382|NCT00861952|Diabetic peripheral neuropathies
459383|NCT00861952|Neuralgia
459384|NCT00861952|Complementary medicine
459385|NCT00861952|Analgesia
459386|NCT00861926|Maintenance and Reliever Treatments
459387|NCT00861887|Clostridium difficile
459388|NCT00861887|colitis
459389|NCT00861887|recurrence
459390|NCT00861887|relapse
459391|NCT00861887|Vancomycin
459392|NCT00861861|Pitavastatin
459393|NCT00861861|Atorvastatin
459394|NCT00861861|CAD
459395|NCT00861861|HDL-C
459396|NCT00861861|Adiponectin
459397|NCT00861822|Anemia
459398|NCT00861822|Cardiac surgery
459399|NCT00861822|RBC transfusion
459400|NCT00861822|Acute Kidney Injury
459401|NCT00861822|Cardiac surgery with cardiopulmonary bypass
459402|NCT00861809|single dose
459403|NCT00861809|gut motility
459404|NCT00861809|Type I Diabetes Mellitus patients
459405|NCT00861809|tolerability
459406|NCT00861809|phase II
459407|NCT00861809|13C octanoic acid breath test
459408|NCT00861809|pharmacodynamics
459409|NCT00861809|gastric emtpying
459410|NCT00861809|pharmacokinetics
459411|NCT00861783|oxaliplatin
459412|NCT00861783|diaminocyclohexane oxalatoplatinum
459413|NCT00861783|oxalatoplatin
459414|NCT00861783|oxalatoplatinum
459415|NCT00861783|Eloxatin
459416|NCT00861770|Congestive Heart Failure
459417|NCT00861770|Ultrafiltration
459418|NCT00861770|Blood Volume Measurement
459419|NCT00861744|Measles, Mumps, Rubella, Varicella Vaccine
459420|NCT00861744|Children
459421|NCT00861744|Immunogenicity
459422|NCT00861744|Safety
459423|NCT00861744|Humans
459424|NCT00861744|Combined Vaccine
459425|NCT00861744|Vaccines
459426|NCT00861731|chronic renal failure
459427|NCT00861731|proteinuria
459428|NCT00861731|apolipoprotein
459429|NCT00861731|c reactive protein
459430|NCT00861718|Phase 1
459431|NCT00861718|Healthy Volunteer
459432|NCT00861692|Argatroban
459433|NCT00861692|heparin induced thrombocytopenia (HIT)
459434|NCT00861692|direct thrombin inhibitor (DTI)
459435|NCT00861679|HSCT
459436|NCT00861679|ALL
459437|NCT00861679|GvHD
459438|NCT00861666|Forgiveness
459439|NCT00861666|Writing
459440|NCT00861666|PTSD
459441|NCT00861666|OEF
459442|NCT00861666|OIF
459443|NCT00861666|Veterans
459444|NCT00861653|Atherosclerosis
459445|NCT00861653|Subjects diagnosed with atherosclerosis
459446|NCT00861640|rabeprazole
459447|NCT00861640|omeprazole
459448|NCT00861640|upper gastrointestinal bleeding
459449|NCT00861627|REOLYSIN
459450|NCT00861627|reovirus
459451|NCT00861627|non-small cell lung cancer
459452|NCT00861627|carcinoma
459453|NCT00861627|oncolytics virus
459454|NCT00861627|chemotherapy
459455|NCT00861627|paclitaxel
459456|NCT00861627|carboplatin
459457|NCT00861588|complementary & alternative medicine
459458|NCT00861588|randomized control trial
459459|NCT00861588|uroflowmetry
459460|NCT00861588|quality of life
459461|NCT00861588|benign prostate hyperplasia
459462|NCT00861575|Cardiovascular
459463|NCT00861562|constipation
459464|NCT00861562|hemorrhoids
459465|NCT00861562|water smartweed
459466|NCT00861562|RCT
459467|NCT00861549|Bioavailability
459468|NCT00861549|Pharmacokinetics
459469|NCT00861549|Safety Evaluation
459470|NCT00861536|risk factors
459471|NCT00861536|immunology
459472|NCT00861523|nausea
459473|NCT00861523|vomiting
459474|NCT00861523|pregnancy
459475|NCT00861523|thiamine
459476|NCT00861523|promethazine
459477|NCT00861523|nausea and vomiting in pregnancy
459478|NCT00861510|Small Lymphocytic Lymphoma (SLL)
459479|NCT00861510|Prolymphocytic Lymphoma (PLL)
459480|NCT00861510|Hairy Cell Leukemia (HCL)
459481|NCT00861510|Mantle Cell Lymphoma
459482|NCT00861510|MCL
459483|NCT00861510|Chronic Lymphocytic Leukemia
459484|NCT00861510|CLL
459485|NCT00861510|Multiple Myeloma
459486|NCT00861510|MM
459487|NCT00861497|Open-label
459488|NCT00861497|Flexible-dose
459489|NCT00861497|Extension
459490|NCT00861497|Safety study
459491|NCT00861471|hormone refractory prostate cancer
459492|NCT00861471|tyrosine kinase inhibitor
459493|NCT00861471|Gleevec
459494|NCT00861471|PSA
459495|NCT00861471|prostate specific antigen
459496|NCT00861471|growth factor receptor inhibitor
459497|NCT00861471|androgen independent
459498|NCT00861445|Lacosamide, Vimpat®
459499|NCT00861432|Life quality
459500|NCT00861432|questionnaire
459501|NCT00861432|tumor patients
459502|NCT00861419|AMG 386
459503|NCT00861419|AMG 706
459504|NCT00861419|Bevacizumab
459505|NCT00861419|Sorafenib
459506|NCT00861419|Angiogenesis Inhibitors
459507|NCT00861419|Combination Therapy
459508|NCT00861419|Peptibody
459509|NCT00861419|Sunitinib
459510|NCT00861406|Melanoma
459511|NCT00861406|Stage II melanoma
459512|NCT00861406|Pegylated Interferon-alfa 2b
459513|NCT00861406|PEG Interferon alfa-2b
459514|NCT00861406|PEG Intron
459515|NCT00861406|Melanoma Peptide Vaccine
459516|NCT00861406|GP100 Vaccine
459517|NCT00861406|gp100
459518|NCT00861406|peptide vaccine
459519|NCT00861406|Leukapheresis
459520|NCT00861406|Immune-cell response
459521|NCT00861380|Pneumococcal conjugate vaccine
459522|NCT00861380|Invasive disease
459523|NCT00861380|Respiratory tract infections
459524|NCT00861380|Haemophilus influenzae
459525|NCT00861380|Streptococcus pneumoniae
459526|NCT00861380|Acute otitis media
459527|NCT00861380|Pneumonia
459528|NCT00861367|aspirin
459529|NCT00861367|blood loss
459530|NCT00861367|transurethral surgery
459531|NCT00861354|atrial fibrillation
459532|NCT00861354|home blood pressure monitoring
459533|NCT00861341|Pioglitazone
459534|NCT00861341|Thiazolidinediones
459535|NCT00861341|Platelet Function
459536|NCT00861341|Platelet aggregation
459537|NCT00861341|Diabetic
459538|NCT00861341|Aspirin.
459539|NCT00861328|Phase 1
459540|NCT00861328|maximum tolerated dose
459541|NCT00861328|oxaliplatin
459542|NCT00861328|irinotecan
459543|NCT00861328|ON 01910.Na
459544|NCT00861315|Pneumonia
459545|NCT00861315|Nebulization
459546|NCT00861315|Amikacin
459547|NCT00861276|Smoking Cessation
459548|NCT00861276|Nicotine
459549|NCT00861276|Administration and dosage
459550|NCT00861276|Randomized Controlled Trial
459551|NCT00861250|Bortezomib plus dexamethasone induction therapy
459552|NCT00861250|Autologous stem cell transplantation
459553|NCT00861250|Molecular remission
459554|NCT00861237|Nux vomica
459555|NCT00861237|homeopathy
459556|NCT00861237|heart lung machine
459557|NCT00861237|heart surgery
459558|NCT00861237|postoperatively studied
459559|NCT00861211|asthma
459560|NCT00861211|inflammation
459561|NCT00861211|bronchoconstriction
459562|NCT00861211|allergen challenge
459563|NCT00861211|KCa3.1
459564|NCT00861185|bronchospasm
459565|NCT00861185|exercise asthma
459566|NCT00861185|inflammation
459567|NCT00861185|KCa3.1
459568|NCT00861172|Multiple sclerosis
459569|NCT00861172|Active plaque
459570|NCT00861172|Multimodal analysis
459571|NCT00861172|3T MRI
459572|NCT00861172|Weekly follow-up
459573|NCT00861172|Physiopathology
459574|NCT00861172|Physiopathology of active lesions formation in Multiple Sclerosis using multimodal MR sequences
459575|NCT00861159|RLIP76 Auto Antibodies
459576|NCT00861146|nicotine dependence
459577|NCT00861146|tobacco dependence
459578|NCT00861146|smoking cessation
459579|NCT00861146|alcoholism
459580|NCT00861146|self-efficacy
459581|NCT00861146|relapse
459582|NCT00861133|cardiac monitor
459583|NCT00861133|loop recorder
459584|NCT00861133|stroke
459585|NCT00861133|ECG
459586|NCT00861133|Implantable Loop Recorder
459587|NCT00861133|cryptogenic
459588|NCT00861133|ILR
459589|NCT00861120|Ovarian cancer
459590|NCT00861120|KRAS wildtype
459591|NCT00861120|Platinum resistant
459592|NCT00861107|Colorectal cancer
459593|NCT00861107|Breast Cancer
459594|NCT00861107|Melanoma
459595|NCT00861107|GI cancer
459596|NCT00861107|Prostate cancer
459597|NCT00861107|Kidney cancer
459598|NCT00861107|Lung cancer
459599|NCT00861107|all types metastatic cancer where at least one tumor lesion is accessable for percutaneous cryoablation
459600|NCT00861094|adenocarcinoma of the esophagus
459601|NCT00861094|squamous cell carcinoma of the esophagus
459602|NCT00861094|stage IIA esophageal cancer
459603|NCT00861094|stage IIB esophageal cancer
459604|NCT00861094|stage IIIA esophageal cancer
459605|NCT00861094|stage IIIB esophageal cancer
459606|NCT00861094|stage IIIC esophageal cancer
459607|NCT00861094|stage IV esophageal cancer
459608|NCT00861081|Group Clinics
459609|NCT00861081|Self Management
459610|NCT00861068|Lacosamide, Vimpat®
459611|NCT00861042|Lacosamide, Vimpat®
459612|NCT00861029|GW786034, pazopanib, moxifloxacin, ECG intervals and morphology, QTc, Holter monitor, pharmacokinetics, safety, cancer
459613|NCT00861016|Post marketing study
459614|NCT00861003|schizophrenia
459615|NCT00861003|adherence
459616|NCT00860977|HIV
459617|NCT00860977|Herpes simplex virus type II
459618|NCT00860977|Genital herpes
459619|NCT00860977|Treatment Naive
459620|NCT00860964|estradiol valerate
459621|NCT00860964|Medroxyprogesterone
459622|NCT00860964|menopause
459623|NCT00860964|Lipid
459624|NCT00860964|Bone mineral density
459625|NCT00860964|Body Composition
459626|NCT00860951|Normal
459627|NCT00860938|Inhaled corticosteroids
459628|NCT00860938|COPD
459629|NCT00860938|mannitol
459630|NCT00860925|Randomized Controlled Trial
459631|NCT00860925|Blinded
459632|NCT00860925|Clonidine
459633|NCT00860925|acetyl-salicylic acid (ASA)
459634|NCT00860925|Perioperative vascular complications
459635|NCT00860925|Noncardiac surgery
459636|NCT00860912|Veritas
459637|NCT00860912|Cystocele
459638|NCT00860912|Prolapse
459639|NCT00860899|clonidine
459640|NCT00860899|levobupivacaine
459641|NCT00860899|preoperative analgesia
459642|NCT00860899|postoperative pain
459643|NCT00860899|systemic inflammatory stress response
459644|NCT00860899|epidural analgesia
459645|NCT00860899|Anesthetics, Local
459646|NCT00860886|Mongolia
459647|NCT00860886|Asia
459648|NCT00860886|GROWTH FACTORS
459649|NCT00860886|Hormones
459650|NCT00860886|Premenopausal
459651|NCT00860886|Breast Cancer
459652|NCT00860860|radioimmunotherapy
459653|NCT00860860|pretargeting
459654|NCT00860860|bispecific antibody
459655|NCT00860860|lutetium 177
459656|NCT00860860|phase I clinical trial
459657|NCT00860847|Progression of Atherosclerosis
459658|NCT00860847|Aged garlic extract
459659|NCT00860847|Biomarkers of inflammation
459660|NCT00860847|Coronary Plaque Volume and coronary Stenosis
459661|NCT00860847|Vascular function
459662|NCT00860834|Consumer Participation
459663|NCT00860834|Telephone Coaching Program
459664|NCT00860821|Healthy subjects
459665|NCT00860821|LPS
459666|NCT00860821|Effect
459667|NCT00860821|Intranasally
459668|NCT00860808|tinnitus
459669|NCT00860795|Echinacea
459670|NCT00860795|prevention
459671|NCT00860795|immune modulation
459672|NCT00860782|Sickle Cell Disease
459673|NCT00860782|Educational Outcomes
459674|NCT00860782|Neurodevelopmental Functioning
459675|NCT00860756|sleep
459676|NCT00860756|disturbance
459677|NCT00860756|deployment
459678|NCT00860756|intervention
459679|NCT00860756|actigraph
459680|NCT00860743|intermittent hypoxia
459681|NCT00860743|ventilatory long-term facilitation
459682|NCT00860743|autonomic nervous system plasticity
459683|NCT00860730|Aortic valve replacement
459684|NCT00860730|Aortic stenosis
459685|NCT00860730|Biological valve
459686|NCT00860730|Sutureless valve
459687|NCT00860730|Stented valve
459688|NCT00860730|Aortic Valve Disease
459689|NCT00860717|Leprosy
459690|NCT00860717|Ulcers
459691|NCT00860717|Laser
459692|NCT00860704|goal directed fluid therapy
459693|NCT00860704|lean patients
459694|NCT00860704|obese patients
459695|NCT00860704|crystalloids
459696|NCT00860704|Esophageal Doppler
459697|NCT00860704|tissue oxygenation
459698|NCT00860704|Fluid management during surgery
459699|NCT00860704|Fluid management
459700|NCT00860691|Curative surgical resection
459701|NCT00860691|Laparoscopic technique
459702|NCT00860665|colorectal cancer
459703|NCT00860665|prevention
459704|NCT00860665|colonoscopy
459705|NCT00860665|screening
459706|NCT00860665|quality assessment
459707|NCT00860665|colorectal cancer prevention
459708|NCT00860652|Oncology
459709|NCT00860652|Prostate Cancer
459710|NCT00860652|Radiotherapy
459711|NCT00860652|Radical Prostatectomy
459712|NCT00860652|Prior Radical Prostatectomy (RP)
459713|NCT00860652|Histological Confirmation of adenocarcinoma of the prostate
459714|NCT00860652|Positive margins and/or extraprostatic extension (EPE)
459715|NCT00860639|AML
459716|NCT00860639|gemtuzumab ozogamycin
459717|NCT00860613|gestational diabetes
459718|NCT00860613|medical nutrition therapy program
459719|NCT00860613|glucose monitoring
459720|NCT00860613|metabolic control
459721|NCT00860613|nutritional status
459722|NCT00860613|cost effectiveness
459723|NCT00860600|Idiopathic Thrombocytopenic Purpura (ITP)
459724|NCT00860600|Platelet Response
459725|NCT00860600|PG2 Treatment
459726|NCT00860600|Quality of Life
459727|NCT00860600|Fatigue
459728|NCT00860600|WHO Bleeding score
459729|NCT00860587|Antibiotic resistance
459730|NCT00860587|Antibiotic treatment
459731|NCT00860561|Efficacy profile
459732|NCT00860561|Safety profile
459733|NCT00860561|Faslodex
459734|NCT00860522|relapsed leukemia
459735|NCT00860522|refractory leukemia
459736|NCT00860509|phytosterols
459737|NCT00860509|cholesterol excretion
459738|NCT00860509|cholesterol absorption
459739|NCT00860509|diet
459740|NCT00860509|mass spectrometry
459741|NCT00860509|deuterium
459742|NCT00860496|Immunosuppression, JAK3 inhibitor, calcineurin inhibitors, tacrolimus, cyclosporine, pharmacokinetics, safety, tolerability
459743|NCT00860483|Comparison of experienced and novice laparoscopic surgeons
459744|NCT00860470|micronutrients
459745|NCT00860470|deficiency
459746|NCT00860470|pregnancy
459747|NCT00860470|birth outcomes
459748|NCT00860470|infant mortality
459749|NCT00860470|neonatal mortality
459750|NCT00860470|malnutrition
459751|NCT00860470|antenatal
459752|NCT00860457|Leukemia
459753|NCT00860444|Primary Care
459754|NCT00860444|Diet
459755|NCT00860444|Physical Activity
459756|NCT00860418|asthma
459757|NCT00860418|feedback
459758|NCT00860418|anti-inflammatory
459759|NCT00860418|ED visits
459760|NCT00860366|Acute ischemic stroke
459761|NCT00860366|thrombolysis
459762|NCT00860366|alteplase
459763|NCT00860366|uric acid
459764|NCT00860366|neuroprotection
459765|NCT00860366|oxidative stress
459766|NCT00860353|Healthy Volunteer
459767|NCT00860353|Single Ascending Dose
459768|NCT00860353|Safety
459769|NCT00860353|Tolerability
459770|NCT00860353|AZD2551
459771|NCT00860353|Healthy Volunteer Study
459772|NCT00860340|Congestive Heart Failure
459773|NCT00860340|Hemodynamics
459774|NCT00860340|Echocardiographs
459775|NCT00860327|Pediatric Heart Disease
459776|NCT00860327|Congenital Heart Disease
459777|NCT00860327|Congenital Heart Defects
459778|NCT00860327|Developmental Biology
459779|NCT00860327|Contractile Function
459780|NCT00860314|external electrical cardioversion
459781|NCT00860314|typical atrial flutter
459782|NCT00860314|electrode position
459783|NCT00860314|antero-lateral
459784|NCT00860314|antero-posterior
459785|NCT00860314|biphasic cardioversion
459786|NCT00860314|step-up protocol
459787|NCT00860301|infantile colic
459788|NCT00860288|Type 2 Diabetes
459789|NCT00860288|vildagliptin
459790|NCT00860249|education
459791|NCT00860249|preventive service
459792|NCT00860249|screening
459793|NCT00860249|Colorectal Cancer Screening
459794|NCT00860249|Prevention & Control
459795|NCT00860236|CFS
459796|NCT00860236|Giardia
459797|NCT00860236|Fatigue
459798|NCT00860236|Cognitive behavioural therapy
459799|NCT00860236|CBT
459800|NCT00860236|Chronic fatigue syndrome
459801|NCT00860223|Healthy Subjects
459802|NCT00860197|Coffee
459803|NCT00860197|Elderly
459804|NCT00860197|Immune response
459805|NCT00860197|Inflammatory status
459806|NCT00860184|carotid artery
459807|NCT00860184|atherosclerosis
459808|NCT00860184|stroke
459809|NCT00860184|transient ischemic attack
459810|NCT00860184|MRI
459811|NCT00860184|software
459812|NCT00860184|risk
459813|NCT00860145|epilepsy
459814|NCT00860145|radiosurgery
459815|NCT00860145|temporal lobectomy
459816|NCT00860132|hip fracture elderly orthogeriatric
459817|NCT00860132|cost effectiveness of hip fracture patients
459818|NCT00860119|Bioequivalence, Pharmacokinetics, Alprazolam, Sublingual
459819|NCT00860106|VTE
459820|NCT00860106|VKA treatment
459821|NCT00860106|VKA treatment cessation
459822|NCT00860093|Kidney Calculi
459823|NCT00860093|Urolithiasis
459824|NCT00860093|Lithotripsy
459825|NCT00860093|potassium compounds
459826|NCT00860093|magnesium compounds
459827|NCT00860080|post-surgery adhesion formation
459828|NCT00860067|influenza, FluMist, adults, vaccine
459829|NCT00860054|phytosterols
459830|NCT00860054|cholesterol excretion
459831|NCT00860054|cholesterol absorption
459832|NCT00860054|diet
459833|NCT00860054|mass spectrometry
459834|NCT00860054|deuterium
459835|NCT00860041|pain
459836|NCT00860041|neurotoxicity
459837|NCT00860041|chemotherapeutic agent toxicity
459838|NCT00860041|unspecified adult solid tumor, protocol specific
459839|NCT00860028|Smoking cessation
459840|NCT00860028|Smoking
459841|NCT00860028|Tobacco
459842|NCT00860028|Varenicline
459843|NCT00860028|Alcohol
459844|NCT00860002|myomectomy
459845|NCT00860002|uterine artery occlusion
459846|NCT00860002|uterine vessel occlusion
459847|NCT00860002|fibroids
459848|NCT00860002|leiomyomas
459849|NCT00860002|Surgical technique, patient suffering and outcomes
459850|NCT00859989|breast cancer
459851|NCT00859989|weight changes
459852|NCT00859989|obesity
459853|NCT00859976|BoneMaster
459854|NCT00859976|Total Hip Replacement
459855|NCT00859976|Bone Density
459856|NCT00859976|Patients suitable for Total Hip Replacement
459857|NCT00859963|Press fit tibial tray
459858|NCT00859950|Sleep Apnea
459859|NCT00859950|Vascular Occlusion
459860|NCT00859950|Nocturnal Polysomnography
459861|NCT00859950|Continuous Positive Airway Pressure
459862|NCT00859911|micronutrients
459863|NCT00859898|Diabetes Mellitus, Type 2
459864|NCT00859898|Diabetes Mellitus
459865|NCT00859898|Endocrine System Diseases
459866|NCT00859898|Glucose Metabolism Disorders
459867|NCT00859898|Metabolic Diseases
459868|NCT00859898|Metformin
459869|NCT00859898|Dapagliflozin
459870|NCT00859898|Hypoglycemic Agents
459871|NCT00859898|Pharmacologic Actions
459872|NCT00859898|Physiological Effects of Drugs
459873|NCT00859885|patent foramen ovale
459874|NCT00859885|ischemic stroke
459875|NCT00859885|transient ischemic attack
459876|NCT00859885|secondary prevention
459877|NCT00859885|medical treatment
459878|NCT00859885|percutaneous device closure
459879|NCT00859872|acute psychotic agitation
459880|NCT00859872|schizophrenia
459881|NCT00859872|risperidone oral solution
459882|NCT00859872|clonazepam
459883|NCT00859872|haloperidol
459884|NCT00859846|Arterial line
459885|NCT00859846|Ultrasound
459886|NCT00859846|Anesthesia
459887|NCT00859846|Pediatric
459888|NCT00859833|adenosine
459889|NCT00859833|regadenoson
459890|NCT00859833|adenosine receptor subtypes
459891|NCT00859807|Amodiaquine suspension
459892|NCT00859807|Flavoquine tablets
459893|NCT00859807|Bioequivalence study
459894|NCT00859794|Epilepsy
459895|NCT00859794|fMRI
459896|NCT00859794|Electrophysiology
459897|NCT00859794|Cortical Mapping
459898|NCT00859794|Neurosurgery
459899|NCT00859781|Prostate
459900|NCT00859768|Cancer
459901|NCT00859729|DNA
459902|NCT00859729|Vaccine
459903|NCT00859729|Electroporation
459904|NCT00859729|xenogenic
459905|NCT00859729|PSA
459906|NCT00859716|Vaccination
459907|NCT00859716|Diarrhea
459908|NCT00859716|Traveler's Diarrhea
459909|NCT00859716|Campylobacter jejuni
459910|NCT00859716|C. jejuni
459911|NCT00859716|Campylobacter
459912|NCT00859716|Campy
459913|NCT00859703|Aromatase inhibitor treatment
459914|NCT00859703|osteoporosis
459915|NCT00859703|breast cancer
459916|NCT00859703|bisphosphonates
459917|NCT00859690|Obstructive Sleep Apnea
459918|NCT00859690|Thrombosis
459919|NCT00859690|Adenosine Deaminase
459920|NCT00859690|Sleep Disorder
459921|NCT00859677|HIV
459922|NCT00859677|Methicillin-resistant Staphylococcus aureus (MRSA)
459923|NCT00859677|HIV and Staphylococcus aureus infection
459924|NCT00859651|breast cancer chemoprevention
459925|NCT00859651|vitamin D
459926|NCT00859651|breast density
459927|NCT00859625|colonoscopy
459928|NCT00859625|adenoma detection rate
459929|NCT00859599|Monochromatic Phototherapy
459930|NCT00859599|Diabetic Foot Ulcers
459931|NCT00859599|Wound healing
459932|NCT00859599|Bacterial colonisation
459933|NCT00859586|Acute Myelogenous Leukemia (AML)
459934|NCT00859586|Acute Lymphoblastic Leukemia (ALL)
459935|NCT00859586|Chronic Lymphocytic Leukemia
459936|NCT00859586|Myelodysplastic Syndrome (MDS)
459937|NCT00859586|Acute Myelogenous Leukemia
459938|NCT00859586|AML
459939|NCT00859586|Acute Lymphoblastic Leukemia
459940|NCT00859586|ALL
459941|NCT00859586|Myelodysplastic Syndrome
459942|NCT00859586|MDS
459943|NCT00859560|Breast cancer
459944|NCT00859560|post-menopausal women
459945|NCT00859560|Arimidex
459946|NCT00859560|bone fracture
459947|NCT00859534|Solar Urticaria
459948|NCT00859521|Bioequivalence
459949|NCT00859521|Healthy Subjects
459950|NCT00859508|dura repair following cranial surgery
459951|NCT00859482|natalizumab
459952|NCT00859482|multiple sclerosis
459953|NCT00859469|Mesothelioma
459954|NCT00859430|Bioequivalence
459955|NCT00859430|Healthy Subjects
459956|NCT00859417|correction of anterior prolapse
459957|NCT00859417|prosthetic trans-obturator way kit
459958|NCT00859417|randomized study
459959|NCT00859404|Mild to moderate persistent asthma
459960|NCT00859391|Celiac Disease
459961|NCT00859378|Hip
459962|NCT00859378|Hip endoprosthesis
459963|NCT00859378|Hip fracture
459964|NCT00859378|Femoral fracture
459965|NCT00859378|Bone cement
459966|NCT00859378|Non-cemented
459967|NCT00859365|back pain
459968|NCT00859365|neck pain
459969|NCT00859365|anxiety
459970|NCT00859365|range of motion
459971|NCT00859339|TCC
459972|NCT00859300|myocardial infarction
459973|NCT00859300|ventricular fibrillation
459974|NCT00859300|sudden death
459975|NCT00859300|polymorphism
459976|NCT00859287|Reflux esophagitis
459977|NCT00859287|Omepral®
459978|NCT00859287|QOLRAD
459979|NCT00859235|Percutaneous endoscopic gastrostomy
459980|NCT00859235|peristomal wound infection
459981|NCT00859235|antibiotic mouth wash solution
459982|NCT00859235|prophylaxis prior Percutaneous endoscopic gastrostomy (PEG)
459983|NCT00859222|LBH589
459984|NCT00859222|bevacizumab
459985|NCT00859222|Avastin
459986|NCT00859222|Panobinostat
459987|NCT00859209|HVF
459988|NCT00859209|Premature infants
459989|NCT00859209|ETCO2
459990|NCT00859196|Wound healing
459991|NCT00859196|Cell proliferation
459992|NCT00859196|Gene expression
459993|NCT00859183|in-stent restenosis
459994|NCT00859183|stents
459995|NCT00859183|sirolimus
459996|NCT00859170|kidney stones
459997|NCT00859170|ureter
459998|NCT00859170|laser lithotripsy
459999|NCT00859157|perioperative/postoperative complications
460000|NCT00859157|pain
460001|NCT00859157|ductal breast carcinoma in situ
460002|NCT00859157|invasive ductal breast carcinoma
460003|NCT00859157|invasive lobular breast carcinoma
460004|NCT00859157|stage IA breast cancer
460005|NCT00859157|stage IB breast cancer
460006|NCT00859157|stage II breast cancer
460007|NCT00859157|stage IIIA breast cancer
460008|NCT00859157|stage IIIB breast cancer
460009|NCT00859144|HIV Prevention
460010|NCT00859144|Youth
460011|NCT00859144|Adolescent
460012|NCT00859144|Community Collaboration
460013|NCT00859144|Community Mentorship
460014|NCT00859144|Minority
460015|NCT00859144|Urban
460016|NCT00859144|Sexual Risk Behaviors
460017|NCT00859144|HIV seronegativity
460018|NCT00859079|diabetes mellitus type 2, GLP-1, insulin infusion
460019|NCT00859040|recurrent intracranial meningioma(s)
460020|NCT00859040|progressive intracranial meningioma(s)
460021|NCT00859027|Non-metastatic
460022|NCT00858975|renal tumor
460023|NCT00858975|cryotherapy
460024|NCT00858975|cytokine
460025|NCT00858962|HIV
460026|NCT00858962|Pharmacokinetics
460027|NCT00858962|Pharmacodynamics
460028|NCT00858962|Buprenorphine
460029|NCT00858962|Raltegravir
460030|NCT00858962|HIV seronegativity
460031|NCT00858962|Interaction
460032|NCT00858949|Outpatient surgery
460033|NCT00858949|Postoperative nausea and vomiting
460034|NCT00858949|Costs
460035|NCT00858949|Observational
460036|NCT00858936|CABG(coronary artery bypass graft)
460037|NCT00858936|Ischemia
460038|NCT00858936|Heart surgery
460039|NCT00858936|Heart damage
460040|NCT00858923|Extracorporeal Photophoresis
460041|NCT00858923|immuno-therapy
460042|NCT00858923|treatment naive
460043|NCT00858910|Motor imagery
460044|NCT00858910|Motor skill
460045|NCT00858910|Performance improvement
460046|NCT00858897|Glutathione
460047|NCT00858884|Systemic lupus erythematosus
460048|NCT00858884|Libman-Sacks endocarditis
460049|NCT00858884|Stroke
460050|NCT00858884|Transient ischemic attack
460051|NCT00858884|Neuropsychiatric systemic lupus erythematosus
460052|NCT00858884|Transesophageal echocardiography
460053|NCT00858884|Magnetic resonance imaging
460054|NCT00858845|Leg Weakness
460055|NCT00858845|Skeletal Myopathy
460056|NCT00858845|Sympathetic Nerve Activity
460057|NCT00858819|Osteoporosis
460058|NCT00858819|Fractures
460059|NCT00858819|Bone Mineral Density
460060|NCT00858819|Quantitative Computed Tomography
460061|NCT00858793|AIDS
460062|NCT00858793|HIV
460063|NCT00858793|Lymphoma
460064|NCT00858793|Stem Cell Transplantation
460065|NCT00858793|gene-modified Stem Cells
460066|NCT00858793|treatment experienced
460067|NCT00858767|vitamin K2
460068|NCT00858767|absorption
460069|NCT00858767|efficacy
460070|NCT00858754|opioid induced constipation
460071|NCT00858754|Cancer patients
460072|NCT00858754|methylnaltrexone
460073|NCT00858741|bone metastases from any histological subtype.
460074|NCT00858728|Natural killer cell cytotoxicity
460075|NCT00858728|Antibody response
460076|NCT00858728|Tetanus toxoid vaccination
460077|NCT00858728|Pneumovax II vaccination
460078|NCT00858728|Total serum immunoglobulins
460079|NCT00858728|IgG subclasses
460080|NCT00858715|Clopidogrel
460081|NCT00858715|Aspirin
460082|NCT00858715|Antithrombotic therapy
460083|NCT00858715|Platelet function testing
460084|NCT00858702|Essential hypertension
460085|NCT00858702|Combination therapy
460086|NCT00858689|Clinical Drug Trial
460087|NCT00858676|acarbose
460088|NCT00858676|diabetes mellitus
460089|NCT00858676|impaired glucose tolerance
460090|NCT00858676|coronary artery disease
460091|NCT00858663|RAD001(Everolimus)
460092|NCT00858663|Cisplatin
460093|NCT00858663|08-138
460094|NCT00858650|registry
460095|NCT00858650|natural history
460096|NCT00858637|Chronic Kidney Disease
460097|NCT00858637|Dialysis
460098|NCT00858637|Dyslipidemia
460099|NCT00858637|Bile acid sequestrant
460100|NCT00858624|Cough
460101|NCT00858624|Cough reflex
460102|NCT00858624|NMDA receptor
460103|NCT00858624|central sensitisation
460104|NCT00858611|Influenza
460105|NCT00858611|Healthy
460106|NCT00858611|Immunity
460107|NCT00858611|Preventive
460108|NCT00858611|Flu
460109|NCT00858611|Healthy Volunteer
460110|NCT00858611|HV
460111|NCT00858598|Total Knee Arthroplasty
460112|NCT00858598|Revision
460113|NCT00858598|Tibial
460114|NCT00858598|Void
460115|NCT00858598|Bone Filler
460116|NCT00858585|Bone metastasis, SNP concordance
460117|NCT00858572|Synta
460118|NCT00858572|STA-9090
460119|NCT00858572|AML
460120|NCT00858572|CML
460121|NCT00858572|MDS
460122|NCT00858572|myeloproliferative disorder
460123|NCT00858572|hematologic malignancy
460124|NCT00858572|ganetespib
460125|NCT00858559|Implantable cardioverter defibrillator
460126|NCT00858559|Remote monitoring
460127|NCT00858559|Follow-up
460128|NCT00858533|early intervention
460129|NCT00858533|sickness absence
460130|NCT00858533|return to work
460131|NCT00858533|primary care
460132|NCT00858520|COPD
460133|NCT00858520|Lung cancer
460134|NCT00858520|genes
460135|NCT00858520|DNA
460136|NCT00858494|upper respiratory tract infection
460137|NCT00858494|children
460138|NCT00858494|homeopathic
460139|NCT00858481|Pediculosis capitis
460140|NCT00858481|Head Lice
460141|NCT00858468|Influenza
460142|NCT00858468|Influenza vaccine
460143|NCT00858455|Healthy Volunteers
460144|NCT00858455|Drug interation, Pharmacokinetics
460145|NCT00858442|Burn sequelae
460146|NCT00858442|PRP
460147|NCT00858442|Children
460148|NCT00858429|advanced adult primary liver cancer
460149|NCT00858429|liver metastases
460150|NCT00858429|adult primary cholangiocellular carcinoma
460151|NCT00858403|Advanced Non-small Cell Lung Cancer
460152|NCT00858377|Amgen
460153|NCT00858377|Phase 1
460154|NCT00858377|First in Human
460155|NCT00858377|Advanced Solid Tumors
460156|NCT00858377|Clinical Trial
460157|NCT00858377|Aurora kinase inhibitor
460158|NCT00858377|Open-label
460159|NCT00858377|Oncology
460160|NCT00858364|darbepoetin alfa
460161|NCT00858364|non-small cell lung cancer
460162|NCT00858364|Aranesp
460163|NCT00858364|chemotherapy
460164|NCT00858364|chemotherapy induce anemia
460165|NCT00858364|advanced lung cancer
460166|NCT00858364|malignant pleural effusion
460167|NCT00858364|metastatic lung cancer
460168|NCT00858364|NSCLC
460169|NCT00858364|anemia
460170|NCT00858364|lung cancer
460171|NCT00858364|pleural effusion
460172|NCT00858364|Stage IIIB lung cancer
460173|NCT00858364|Stage IV lung cancer
460174|NCT00858351|Diabetes
460175|NCT00858351|Neuropathy
460176|NCT00858351|Peripheral
460177|NCT00858351|Painful
460178|NCT00858351|Thermal
460179|NCT00858351|Temperature
460180|NCT00858351|Biofeedback
460181|NCT00858351|Relaxation
460182|NCT00858351|Diabetic
460183|NCT00858338|stomach cancer
460184|NCT00858338|gastroesophageal junction cancer
460185|NCT00858338|GEJ cancer
460186|NCT00858338|intraperitoneal
460187|NCT00858338|adjuvant chemoradiation therapy
460188|NCT00858338|resection of advanced stomach cancer
460189|NCT00858338|locally advanced stomach cancer
460190|NCT00858325|Cubicin
460191|NCT00858325|PK
460192|NCT00858325|China Registration
460193|NCT00858325|Pharmacokinetics
460194|NCT00858312|dairy foods
460195|NCT00858312|weight loss
460196|NCT00858312|fat loss
460197|NCT00858312|metabolic regulation
460198|NCT00858299|proteinuria
460199|NCT00858299|chronic kidney disease
460200|NCT00858299|renin-angiotensin system
460201|NCT00858299|angiotensinogen
460202|NCT00858273|Glutathione
460203|NCT00858260|Klotho
460204|NCT00858260|calcium
460205|NCT00858260|phosphate
460206|NCT00858260|parathormone
460207|NCT00858260|survival
460208|NCT00858260|dialysis
460209|NCT00858260|Adult patients undergoing maintenance dialysis since at leat three months
460210|NCT00858247|vitamin D
460211|NCT00858247|Obesity
460212|NCT00858247|Insulin sensitivity
460213|NCT00858247|Adolescent Obesity
460214|NCT00858221|obesity
460215|NCT00858221|genes
460216|NCT00858221|polymorphisms
460217|NCT00858221|weight loss
460218|NCT00858221|haplotype
460219|NCT00858221|diplotype
460220|NCT00858208|efficacy and safety of Macugen in routine clinical practice
460221|NCT00858195|Anti-inflammatory
460222|NCT00858182|L-Carnitine
460223|NCT00858182|Xylitol
460224|NCT00858182|Peritoneal Dialysis
460225|NCT00858169|three-dimensional power Doppler ultrasonography
460226|NCT00858169|wrist
460227|NCT00858169|knee
460228|NCT00858169|rheumatoid arthritis
460229|NCT00858156|Pharmacokinetics
460230|NCT00858143|Open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study
460231|NCT00858130|Veinoplus
460232|NCT00858130|post thrombotic syndrome
460233|NCT00858130|deep vein thrombosis
460234|NCT00858130|electrical muscle stimulator
460235|NCT00858130|Venous stasis syndrome
460236|NCT00858130|venous insufficiency syndrome
460237|NCT00858130|Postphlebitic syndrome
460238|NCT00858130|history of deep vein thrombosis
460239|NCT00858117|B-cell chronic lymphocytic leukemia
460240|NCT00858117|stage I chronic lymphocytic leukemia
460241|NCT00858117|stage II chronic lymphocytic leukemia
460242|NCT00858117|stage III chronic lymphocytic leukemia
460243|NCT00858117|stage IV chronic lymphocytic leukemia
460244|NCT00858078|Qualitative Research
460245|NCT00858078|Semi-Structured Telephone Interview
460246|NCT00858078|BRCA 1/2
460247|NCT00858078|Psychosocial/Behavioral Research
460248|NCT00858078|Hereditary Cancer Risk
460249|NCT00858078|BRCA
460250|NCT00858078|BRCA1 Gene
460251|NCT00858078|BRCA2 Gene
460252|NCT00858065|Adolescent alcohol and other drug use
460253|NCT00858065|Choice
460254|NCT00858065|Family-based
460255|NCT00858065|Prevention
460256|NCT00858052|breast implants
460257|NCT00858052|saline
460258|NCT00858026|weaning
460259|NCT00858026|breastfeeding
460260|NCT00858026|infant formula
460261|NCT00858026|fermented formula
460262|NCT00858013|Type 2 Diabetes Mellitus
460263|NCT00858013|Nateglinide
460264|NCT00858013|Pancreatic beta cell function
460265|NCT00858000|markers
460266|NCT00858000|expression analysis
460267|NCT00857987|IRA, Guaifenesin, Etaphedrine, Doxilamine
460268|NCT00857974|Physical Activity
460269|NCT00857974|Renal Transplant Candidate
460270|NCT00857974|Physical Function
460271|NCT00857974|Body Composition
460272|NCT00857948|head lice
460273|NCT00857948|Pediculus humanus capitis
460274|NCT00857948|ivermectin
460275|NCT00857935|Pediculosis Capitis
460276|NCT00857935|Head Lice
460277|NCT00857922|Neurological
460278|NCT00857922|Neurosurgical
460279|NCT00857896|Study of fesoterodine in pediatric overactive bladder patients
460280|NCT00857883|Obesity
460281|NCT00857883|Food Effect
460282|NCT00857883|Pharmacokinetics
460283|NCT00857883|First-Time-In-Humans
460284|NCT00857883|Pharmacodynamics
460285|NCT00857883|Healthy Volunteers
460286|NCT00857857|asthma
460287|NCT00857857|late phase response
460288|NCT00857857|allergen
460289|NCT00857857|challenge
460290|NCT00857857|GW870086X
460291|NCT00857844|Chronic Nephrotoxicity
460292|NCT00857844|Kidney dysfunction post liver transplant
460293|NCT00857844|Urinary biomarkers of chronic nephrotoxicity from CI
460294|NCT00857831|spinal cord injury
460295|NCT00857831|Vitamin D deficiency
460296|NCT00857831|Functional Electrical Stimulation
460297|NCT00857805|Transarterial chemoembolization
460298|NCT00857805|Carcinoma, Hepatocellular
460299|NCT00857805|Proton Beam Radiotherapy
460300|NCT00857792|Coronary Disease
460301|NCT00857792|Cardiac CT Imaging
460302|NCT00857792|Stress Testing
460303|NCT00857792|Lexiscan (regadenoson)
460304|NCT00857779|allergen immunotherapy
460305|NCT00857779|allergy to grass pollen
460306|NCT00857766|Chronic Obstructive Pulmonary Disease
460307|NCT00857766|arterial stiffness
460308|NCT00857766|Computed Tomography
460309|NCT00857766|pulse wave velocity
460310|NCT00857766|Pulse wave analysis
460311|NCT00857727|Dexmedetomidine
460312|NCT00857727|Emergence Delirium
460313|NCT00857727|Agitation
460314|NCT00857727|Pediatric
460315|NCT00857727|Anesthesia
460316|NCT00857714|DCIS
460317|NCT00857714|breast
460318|NCT00857701|total knee arthroplasty
460319|NCT00857701|Dynamic Splinting
460320|NCT00857701|Knee extension
460321|NCT00857701|knee
460322|NCT00857701|Reduced knee flexion after total knee arthroscopy
460323|NCT00857688|aphtous
460324|NCT00857688|bismuth
460325|NCT00857688|procain
460326|NCT00857688|neomycin
460327|NCT00857688|Efficacy of the Association in Treatment of Aphtous
460328|NCT00857675|HBV DNA suppression
460329|NCT00857675|ALT normalisation
460330|NCT00857675|Viral resistance
460331|NCT00857675|HBeAg seroconversion
460332|NCT00857662|US Multicenter
460333|NCT00857662|Randomized
460334|NCT00857662|Onyx
460335|NCT00857662|Brain Arteriovenous Malformation (BAVMs)
460336|NCT00857649|Alzheimer's Disease
460337|NCT00857636|Ethnic minority women
460338|NCT00857636|Cancer screening
460339|NCT00857636|Health literacy
460340|NCT00857636|Behavioral intervention
460341|NCT00857636|Breast Cancer screening
460342|NCT00857636|Cervical Cancer screening
460343|NCT00857623|Pain
460344|NCT00857623|Diabetic Neuropathy
460345|NCT00857623|PDN
460346|NCT00857623|Analgesia
460347|NCT00857623|Efficacy
460348|NCT00857610|Aged skin
460349|NCT00857610|Photoaged skin
460350|NCT00857610|Retinol
460351|NCT00857610|Topical retinoids
460352|NCT00857597|GERD
460353|NCT00857597|endoscopic
460354|NCT00857597|fundoplication
460355|NCT00857597|Proton Pump Inhibitors
460356|NCT00857597|heartburn
460357|NCT00857597|anti-reflux surgery
460358|NCT00857584|Bipolar disorder
460359|NCT00857584|Bipolar depression
460360|NCT00857584|quetiapine
460361|NCT00857584|sertraline
460362|NCT00857571|Dose Response Bioavailability Study
460363|NCT00857532|amyloid burden
460364|NCT00857532|Parkinson's disease
460365|NCT00857532|florbetapir PET
460366|NCT00857532|amyloid PET imaging
460367|NCT00857519|retinoblastoma
460368|NCT00857519|Intraarterial
460369|NCT00857519|Chemotherapy
460370|NCT00857519|Melphalan
460371|NCT00857519|Carboplatin
460372|NCT00857506|Cognitive outcome
460373|NCT00857506|18F-AV-45 PET scan
460374|NCT00857506|Amyloid PET scan
460375|NCT00857506|Florbetapir F 18 amyloid PET scan
460376|NCT00857506|Normal cognition
460377|NCT00857506|Change in cognitive status in relation to brain amyloid on PET
460378|NCT00857415|florbetapir F 18 PET
460379|NCT00857415|amyloid imaging
460380|NCT00857415|Amyloid pathology in the brain
460381|NCT00857402|Arginine
460382|NCT00857402|Nitric oxide
460383|NCT00857402|Peanuts
460384|NCT00857402|Sedimentation rate
460385|NCT00857389|Cancer
460386|NCT00857389|Blood And Marrow Transplantation
460387|NCT00857389|Stem Cell
460388|NCT00857389|Leukemia
460389|NCT00857389|Lymphoma
460390|NCT00857389|Pediatrics
460391|NCT00857389|Bone marrow
460392|NCT00857389|Lymph node system
460393|NCT00857389|Allogeneic Stem Cell Transplant
460394|NCT00857389|ASCT
460395|NCT00857389|Busulfan
460396|NCT00857389|Busulfex
460397|NCT00857389|Myleran
460398|NCT00857389|Clofarabine
460399|NCT00857389|Clofarex
460400|NCT00857389|Clolar
460401|NCT00857389|Thiotepa
460402|NCT00857389|Antithymocyte globulin
460403|NCT00857389|ATG
460404|NCT00857389|Thymoglobulin
460405|NCT00857389|G-CSF
460406|NCT00857389|Filgrastim
460407|NCT00857389|Neupogen
460408|NCT00857389|Cyclophosphamide
460409|NCT00857389|Cytoxan
460410|NCT00857389|Neosar
460411|NCT00857389|Mesna
460412|NCT00857389|Mesnex
460413|NCT00857389|Tacrolimus
460414|NCT00857389|Prograf
460415|NCT00857389|Methotrexate
460416|NCT00857376|Heart disease risk factors
460417|NCT00857376|Risk factor management
460418|NCT00857376|Pre-Diabetes
460419|NCT00857376|Hypertension
460420|NCT00857376|obesity
460421|NCT00857376|glucose intolerance
460422|NCT00857376|high cholesterol
460423|NCT00857376|abdominal obesity
460424|NCT00857376|enlarged waist
460425|NCT00857363|capsule
460426|NCT00857363|constipation
460427|NCT00857363|whole gut transit
460428|NCT00857363|colonic transit
460429|NCT00857363|gastric emptying
460430|NCT00857363|small bowel transit
460431|NCT00857350|HIV
460432|NCT00857350|resistance
460433|NCT00857350|opioid dependence
460434|NCT00857324|Refractory or relapsed patients
460435|NCT00857324|dose-finding
460436|NCT00857324|Vorinostat
460437|NCT00857298|HIV
460438|NCT00857298|Metabolic Syndrome
460439|NCT00857298|Obesity
460440|NCT00857298|Treatment Experienced
460441|NCT00857272|colonoscopy
460442|NCT00857272|bowel preparation
460443|NCT00857259|AMD
460444|NCT00857259|macular degeneration
460445|NCT00857259|Everolimus
460446|NCT00857259|Lucentis
460447|NCT00857259|Ranibizumab
460448|NCT00857259|Choroidal Neo-Vascular (CNV) age-onset macular degeneration
460449|NCT00857259|Age-related Macular Degeneration (AMD)
460450|NCT00857246|stomach cancer
460451|NCT00857246|biologics
460452|NCT00857246|antibody
460453|NCT00857246|chemotherapy
460454|NCT00857246|chemoradiation
460455|NCT00857246|adjuvant therapy
460456|NCT00857246|neoadjuvant therapy
460457|NCT00857246|epidermal growth factor receptor
460458|NCT00857246|combination therapy
460459|NCT00857233|Alzheimer's Disease
460460|NCT00857220|Hypnotic
460461|NCT00857220|Eszopiclone
460462|NCT00857220|Attention Deficit Hyperactivity Disorder
460463|NCT00857220|Insomnia
460464|NCT00857220|Children
460465|NCT00857220|Adolescent
460466|NCT00857207|Cognitive Therapy
460467|NCT00857207|Outcomes Assessment
460468|NCT00857194|Coronary Heart Disease
460469|NCT00857194|spinal cord injury
460470|NCT00857194|risk factor
460471|NCT00857194|postprandial lipemia
460472|NCT00857181|Liver Cirrhosis
460473|NCT00857181|Infection
460474|NCT00857181|Inflammation
460475|NCT00857181|Cytokines
460476|NCT00857155|Coronary Artery Disease
460477|NCT00857155|CABG
460478|NCT00857155|Clopidogrel
460479|NCT00857155|Aspirin
460480|NCT00857155|Point of Care devices
460481|NCT00857129|"normal birth"
460482|NCT00857129|"birth outcome"
460483|NCT00857129|"low risk birth"
460484|NCT00857129|"low risk units"
460485|NCT00857129|If type of birth care unit have effect on birth outcome
460486|NCT00857129|Apgar score
460487|NCT00857129|breast feeding frequency
460488|NCT00857129|patient satisfaction
460489|NCT00857116|Deworming
460490|NCT00857116|Tuberculosis
460491|NCT00857116|TB-score
460492|NCT00857116|Albendazole
460493|NCT00857116|Helminths
460494|NCT00857103|computer support
460495|NCT00857103|patient-provider communication
460496|NCT00857103|patient-centered care
460497|NCT00857103|cancer
460498|NCT00857090|Urinary Calculi
460499|NCT00857090|Urinary Stones
460500|NCT00857090|Urinary Tract Stones
460501|NCT00857090|Renal Calculi
460502|NCT00857090|Kidney Stones
460503|NCT00857090|Calculi
460504|NCT00857090|Urolithotomy
460505|NCT00857090|Ureteroscopy
460506|NCT00857077|incidence of anaemia
460507|NCT00857064|Schizophrenia
460508|NCT00857064|antipsychotics
460509|NCT00857064|social functioning
460510|NCT00857064|subjective well being
460511|NCT00857064|Patients suffering from Schizophrenia
460512|NCT00857051|Stress
460513|NCT00857038|COPD
460514|NCT00857038|Inflammation
460515|NCT00857038|Neutrophilic
460516|NCT00857038|Myeloperoxidase
460517|NCT00857038|Doxycycline
460518|NCT00857025|stage IIIA non-small cell lung cancer
460519|NCT00857025|stage IIIB non-small cell lung cancer
460520|NCT00857025|stage IV non-small cell lung cancer
460521|NCT00857025|recurrent non-small cell lung cancer
460522|NCT00857012|Primary early MCa
460523|NCT00857012|Arimidex
460524|NCT00856999|Glabellar lines of moderate severity at maximum frown
460525|NCT00856973|Hypnotic
460526|NCT00856973|Eszopiclone
460527|NCT00856973|Attention Deficit/Hyperactivity Disorder
460528|NCT00856973|Insomnia
460529|NCT00856973|Children
460530|NCT00856973|Adolescent
460531|NCT00856973|Polysomnography
460532|NCT00856973|Actigraphy
460533|NCT00856947|wheeze
460534|NCT00856947|infections
460535|NCT00856947|allergy
460536|NCT00856947|eczema
460537|NCT00856947|vitamin D
460538|NCT00856934|Skin graft donor site healing
460539|NCT00856934|skin
460540|NCT00856934|wound
460541|NCT00856934|platelet concentrate
460542|NCT00856934|keratinocytes
460543|NCT00856934|burns
460544|NCT00856921|Relationship between achalasia and AAAS gene
460545|NCT00856908|Type II Diabetes
460546|NCT00856895|Improved Life Quality
460547|NCT00856856|Bioabsorbable
460548|NCT00856856|Coronary Stent
460549|NCT00856856|Everolimus
460550|NCT00856856|drug eluting stents
460551|NCT00856856|stents
460552|NCT00856856|angioplasty
460553|NCT00856856|coronary artery disease
460554|NCT00856856|total coronary occlusion
460555|NCT00856856|coronary artery restenosis
460556|NCT00856856|stent thrombosis
460557|NCT00856856|vascular disease
460558|NCT00856856|myocardial ischemia
460559|NCT00856856|coronary artery stenosis
460560|NCT00856856|CAD
460561|NCT00856856|CAOD
460562|NCT00856843|colonoscopy
460563|NCT00856843|bowel preparation
460564|NCT00856830|Small cell lung cancer
460565|NCT00856830|Chemonaive
460566|NCT00856830|Bendamustine
460567|NCT00856830|Irinotecan
460568|NCT00856830|Etoposide
460569|NCT00856830|Carboplatin
460570|NCT00856804|Thalidomide
460571|NCT00856804|Hepatitis C
460572|NCT00856804|Interferon resistance
460573|NCT00856804|Immunomodulators
460574|NCT00856791|Ovarian
460575|NCT00856791|Cancer
460576|NCT00856791|Cisplatin
460577|NCT00856791|Carboplatin
460578|NCT00856778|Male sling
460579|NCT00856778|stress urinary incontinence
460580|NCT00856778|urinary incontinence
460581|NCT00856739|obesity
460582|NCT00856739|arthritis
460583|NCT00856700|GLP-1
460584|NCT00856700|Endothelial Function
460585|NCT00856700|Metabolic Syndrome
460586|NCT00856687|Asthma Allergen Challenge
460587|NCT00856674|IgA nephropathy
460588|NCT00856674|chemokine fusion protein
460589|NCT00856674|leukocyte population modulator
460590|NCT00856674|phase-1
460591|NCT00856661|Acute ischemic stroke
460592|NCT00856661|Angiography
460593|NCT00856661|Desmoteplase
460594|NCT00856661|Thrombolytic
460595|NCT00856622|open-angle glaucoma ocular hypertension glaucoma
460596|NCT00856609|Weight Loss
460597|NCT00856609|Byetta (Exenatide)
460598|NCT00856609|Energy Expenditure
460599|NCT00856609|Obesity
460600|NCT00856609|Food Intake
460601|NCT00856596|Tinea pedis
460602|NCT00856596|Fungus
460603|NCT00856596|Pruritus
460604|NCT00856596|Dermatophyte
460605|NCT00856596|Athlete's foot
460606|NCT00856596|Dermatomycosis
460607|NCT00856596|Skin manifestation
460608|NCT00856596|Infectious skin disease
460609|NCT00856596|Foot diseases
460610|NCT00856570|YM178
460611|NCT00856570|Mirabegron
460612|NCT00856570|DDI
460613|NCT00856570|Phase I
460614|NCT00856570|Warfarin
460615|NCT00856570|Pharmacokinetics
460616|NCT00856557|Patients with complex psychosocial needs
460617|NCT00856544|Arthritis
460618|NCT00856544|Rheumatoid
460619|NCT00856544|Antirheumatic Agents
460620|NCT00856544|Clinical Trial
460621|NCT00856531|Möbius syndrome
460622|NCT00856531|Language
460623|NCT00856531|Speech, Language and Hearing Sciences
460624|NCT00856518|Multiple Sclerosis
460625|NCT00856518|Parkinson's disease
460626|NCT00856518|Dysphagia
460627|NCT00856505|Hematopoietic Stem Cell Transplantation
460628|NCT00856505|Drug Therapy, Combination
460629|NCT00856505|Immunosuppression
460630|NCT00856492|inflammatory breast cancer
460631|NCT00856492|stage II breast cancer
460632|NCT00856492|stage IIIA breast cancer
460633|NCT00856492|stage IIIB breast cancer
460634|NCT00856492|HER2-negative breast cancer
460635|NCT00856492|estrogen receptor-negative breast cancer
460636|NCT00856492|estrogen receptor-positive breast cancer
460637|NCT00856492|progesterone receptor-negative breast cancer
460638|NCT00856492|progesterone receptor-positive breast cancer
460639|NCT00856492|stage IIIC breast cancer
460640|NCT00856479|Infuse
460641|NCT00856479|cost analysis
460642|NCT00856479|Non union diaphyseal fracture
460643|NCT00856479|The efficacy of Infuse BMP 2 in Non union diaphyseal fractures. Also the cost analysis with the amount of time spent in hospital post op.
460644|NCT00856453|fatigue
460645|NCT00856453|depression
460646|NCT00856453|recurrent ovarian epithelial cancer
460647|NCT00856453|recurrent ovarian germ cell tumor
460648|NCT00856453|stage I ovarian epithelial cancer
460649|NCT00856453|stage I ovarian germ cell tumor
460650|NCT00856453|stage II ovarian epithelial cancer
460651|NCT00856453|stage II ovarian germ cell tumor
460652|NCT00856453|stage III ovarian epithelial cancer
460653|NCT00856453|stage III ovarian germ cell tumor
460654|NCT00856453|stage IV ovarian epithelial cancer
460655|NCT00856453|stage IV ovarian germ cell tumor
460656|NCT00856440|SCI
460657|NCT00856427|stage IIIA non-small cell lung cancer
460658|NCT00856427|stage IIIB non-small cell lung cancer
460659|NCT00856427|stage IA non-small cell lung cancer
460660|NCT00856427|stage IB non-small cell lung cancer
460661|NCT00856427|stage IIA non-small cell lung cancer
460662|NCT00856427|stage IIB non-small cell lung cancer
460663|NCT00856401|hypoparathyroidism
460664|NCT00856401|hypopara
460665|NCT00856401|PTH
460666|NCT00856401|parathyroid hormone
460667|NCT00856401|CL-11-040
460668|NCT00856401|CL1-11 Study
460669|NCT00856401|NPSP 558
460670|NCT00856401|RELAY
460671|NCT00856401|RACE
460672|NCT00856401|REPLACE
460673|NCT00856401|HEXT
460674|NCT00856401|c10-007
460675|NCT00856401|c10-008
460676|NCT00856401|NPSP558
460677|NCT00856401|Columbia study
460678|NCT00856401|Columbia studies
460679|NCT00856401|HPTH
460680|NCT00856401|PTH1-84
460681|NCT00856375|colorectal cancer
460682|NCT00856375|Colorectal cancer, second line
460683|NCT00856362|Healthy Subjects
460684|NCT00856349|Implantable Cardioverter Defibrillator (ICD)
460685|NCT00856349|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
460686|NCT00856349|Lead Integrity Alert (LIA)
460687|NCT00856349|Therapy Programming Report (TPR)
460688|NCT00856323|Methamphetamine
460689|NCT00856323|HIV
460690|NCT00856323|Post-exposure prophylaxis
460691|NCT00856323|HIV seronegativity
460692|NCT00856310|Healthy volunteers
460693|NCT00856297|Meningococcal
460694|NCT00856297|ACWY
460695|NCT00856297|Conjugate Vaccine
460696|NCT00856297|Meningitis
460697|NCT00856297|Adolescents
460698|NCT00856297|Persistence
460699|NCT00856284|Diabetes Mellitus
460700|NCT00856284|Drug Therapy
460701|NCT00856284|Hyperinsulinism
460702|NCT00856284|Hyperglycemia
460703|NCT00856284|Glucose Intolerance
460704|NCT00856258|Multiple dose in healthy volunteers
460705|NCT00856245|non-Hodgkins
460706|NCT00856245|lymphoma
460707|NCT00856245|stem cell transplant
460708|NCT00856232|Headache
460709|NCT00856232|Cephalgia
460710|NCT00856232|Migraine
460711|NCT00856219|Immune System
460712|NCT00856206|Metabolism, Inborn Errors
460713|NCT00856206|Allopurinol
460714|NCT00856206|Metabolic Disease
460715|NCT00856206|Genetic Diseases, Inborn
460716|NCT00856206|Musculoskeletal Diseases
460717|NCT00856206|Joint Diseases
460718|NCT00856206|Arthritis
460719|NCT00856206|Rheumatic Diseases
460720|NCT00856206|Metabolic disorder
460721|NCT00856206|Purine Pyrimidine Metabolism, Inborn Errors
460722|NCT00856206|Gout
460723|NCT00856206|Intercritical Gout
460724|NCT00856193|COPD
460725|NCT00856193|Bronchodilator
460726|NCT00856180|avastin
460727|NCT00856180|bevacizumab
460728|NCT00856180|cyclophosphamide
460729|NCT00856180|cytoxan
460730|NCT00856180|mullerian malignancies
460731|NCT00856167|temporomandibular dysfunction
460732|NCT00856167|TMD
460733|NCT00856167|TMJ
460734|NCT00856167|Traditional Chinese Medicine
460735|NCT00856167|TCM
460736|NCT00856154|HIV-1
460737|NCT00856154|HLA-A2
460738|NCT00856154|Therapeutic
460739|NCT00856154|Vaccine
460740|NCT00856154|treatment vaccine
460741|NCT00856154|treatment naive
460742|NCT00856141|IOP measurement
460743|NCT00856141|IOP fluctuation
460744|NCT00856141|in-vivo IOP measuring device
460745|NCT00856141|intraocular pressure measurement
460746|NCT00856115|stage I colon cancer
460747|NCT00856115|stage II colon cancer
460748|NCT00856115|stage III colon cancer
460749|NCT00856115|stage IV colon cancer
460750|NCT00856115|stage I rectal cancer
460751|NCT00856115|stage II rectal cancer
460752|NCT00856115|stage III rectal cancer
460753|NCT00856115|stage IV rectal cancer
460754|NCT00856076|Venous thromboembolism
460755|NCT00856076|Intrauterine fetal death
460756|NCT00856076|Risk factor
460757|NCT00856076|Thrombophilia
460758|NCT00856076|Venous thromboembolism (in pregnancy)
460759|NCT00856063|Attention Deficit Hyperactivity Disorder
460760|NCT00856063|Atomoxetine
460761|NCT00856063|Electrodermal Response
460762|NCT00856063|Impulsivity
460763|NCT00856063|Preschool Children
460764|NCT00856050|estrogen receptor positive
460765|NCT00856050|progesterone receptor positive
460766|NCT00856050|letrozole
460767|NCT00855998|Thymidine Kinase 1
460768|NCT00855998|BRCA1 and BRCA2 mutations
460769|NCT00855998|hereditary breast/ovarian cancer
460770|NCT00855985|Pancreatic anastomosis
460771|NCT00855985|Whipple operation
460772|NCT00855959|Asthma
460773|NCT00855959|Pulmicort Respules
460774|NCT00855946|tumor response
460775|NCT00855946|rectal adenocarcinoma
460776|NCT00855946|preoperative radiochemotherapy
460777|NCT00855946|Proteomic analysis
460778|NCT00855946|MALDI-TOF-TOF
460779|NCT00855946|rectal adenocarcinoma, tumor response after preoperative radiochemotherapy
460780|NCT00855920|Metabolism, Inborn Errors
460781|NCT00855920|Allopurinol
460782|NCT00855920|Metabolic Diseases
460783|NCT00855920|Genetic Diseases, Inborn
460784|NCT00855920|Musculoskeletal Diseases
460785|NCT00855920|Joint Diseases
460786|NCT00855920|Arthritis
460787|NCT00855920|Rheumatic Diseases
460788|NCT00855920|Metabolic disorder
460789|NCT00855920|Purine-Pyrimidine Metabolism, Inborn Errors
460790|NCT00855920|Gout
460791|NCT00855920|Flare
460792|NCT00855907|IBD
460793|NCT00855907|inflammatory bowel disease
460794|NCT00855907|fatty liver
460795|NCT00855894|Tarceva
460796|NCT00855894|NSCLC
460797|NCT00855881|adjuvant chemotherapy for head and neck cancer
460798|NCT00855868|Amyloid imaging
460799|NCT00855868|Positron Emission Tomography
460800|NCT00855868|18F-AV-45
460801|NCT00855868|florbetapir F 18
460802|NCT00855868|Diagnostic imaging
460803|NCT00855855|Diphtheria
460804|NCT00855855|Tetanus
460805|NCT00855855|Pertussis
460806|NCT00855855|Poliovirus types 1-3
460807|NCT00855855|Haemophilus influenzae type b
460808|NCT00855855|Pentacel®
460809|NCT00855842|second trimester abortion
460810|NCT00855842|labor induction abortion
460811|NCT00855842|second trimester medical abortion
460812|NCT00855842|pregnancy
460813|NCT00855803|spinal cord metastases
460814|NCT00855803|unspecified adult solid tumor, protocol specific
460815|NCT00855803|pain
460816|NCT00855790|evaluate the effectiveness of one bite polypectomy with the RJ3 biopsy forcep versus the RJ4 biopsy forcep
460817|NCT00855777|third molar extraction
460818|NCT00855777|etoricoxib
460819|NCT00855777|ibuprofen
460820|NCT00855777|analgesic efficacy
460821|NCT00855777|pain
460822|NCT00855738|epilepsy antiepileptic biotherapy
460823|NCT00855725|Epilepsy
460824|NCT00855725|Depression
460825|NCT00855725|Neurology
460826|NCT00855725|fMRI
460827|NCT00855725|Healthy Controls
460828|NCT00855712|Heart Failure
460829|NCT00855712|Transplant
460830|NCT00855712|Warm Perfusion
460831|NCT00855712|Organ Care
460832|NCT00855712|Resting Mode
460833|NCT00855699|Alcohol detoxification
460834|NCT00855686|Memantine
460835|NCT00855686|Cognition
460836|NCT00855686|Parkinson's Disease Dementia
460837|NCT00855686|Dementia With Lewy Bodies
460838|NCT00855673|Claudication
460839|NCT00855673|Peripheral Arterial Disease
460840|NCT00855673|Intermittent Compression
460841|NCT00855673|Mechanical Compression
460842|NCT00855673|Flowmedic
460843|NCT00855660|Bone Metabolism
460844|NCT00855634|Pancreatic cancer
460845|NCT00855634|metastasis
460846|NCT00855634|venous infiltration
460847|NCT00855634|Pancreatic cancer with minimal metastatic disease or venous infiltration
460848|NCT00855621|deep brain stimulation
460849|NCT00855621|subthalamic nucleus
460850|NCT00855608|choroidal neovascularization
460851|NCT00855608|diabetic retinopathy
460852|NCT00855608|uveitis
460853|NCT00855608|refractory cases of uveitis
460854|NCT00855595|Rosacea
460855|NCT00855582|Erectile Dysfunction
460856|NCT00855582|Benign Prostatic Hyperplasia
460857|NCT00855569|allografting
460858|NCT00855530|Depression
460859|NCT00855504|preeclampsia
460860|NCT00855504|periodontitis
460861|NCT00855504|cytokines
460862|NCT00855491|PCO
460863|NCT00855491|POCO
460864|NCT00855465|Chronic thromboembolic pulmonary hypertension
460865|NCT00855465|PH
460866|NCT00855465|soluble Guanylate Cyclase Stimulator
460867|NCT00855465|sGC
460868|NCT00855452|GVL
460869|NCT00855452|rIL-2(LAK)
460870|NCT00855452|GVHD
460871|NCT00855452|MST
460872|NCT00855452|alloCT
460873|NCT00855452|alloBMT
460874|NCT00855439|Diabetes
460875|NCT00855439|Neuropathy
460876|NCT00855439|Glucose
460877|NCT00855439|Control
460878|NCT00855439|Peripheral
460879|NCT00855439|Autonomic
460880|NCT00855413|Acute HIV
460881|NCT00855413|HIV
460882|NCT00855413|Treatment Naive
460883|NCT00855413|Acute Infections
460884|NCT00855400|Amyotrophic Lateral Sclerosis
460885|NCT00855400|Bone marrow
460886|NCT00855400|Stem cells
460887|NCT00855400|Autologous
460888|NCT00855400|Safety
460889|NCT00855387|Clinical outcome (complications), in-hospital costs
460890|NCT00855387|The influence and impact of postoperative complications on in-hospital costs
460891|NCT00855361|Gastroesophageal Reflux
460892|NCT00855361|Erosive Gastroesophageal Reflux Disease
460893|NCT00855361|Ulcerative Gastroesophageal Reflux Disease
460894|NCT00855361|Endoscopy
460895|NCT00855361|Pediatrics
460896|NCT00855361|GERD
460897|NCT00855361|Rabeprazole, Rabeprazole sodium
460898|NCT00855361|AcipHex
460899|NCT00855348|colorectal cancer
460900|NCT00855348|early detection
460901|NCT00855348|methylation, biomarker
460902|NCT00855335|HIV-1
460903|NCT00855335|HIV
460904|NCT00855335|Pregnancy
460905|NCT00855335|Postpartum
460906|NCT00855335|Human immunodeficiency virus
460907|NCT00855335|PREZISTA
460908|NCT00855335|INTELENCE
460909|NCT00855335|NORVIR
460910|NCT00855335|TMC114
460911|NCT00855335|TMC125
460912|NCT00855335|darunavir
460913|NCT00855335|ritonavir
460914|NCT00855335|etravirine
460915|NCT00855335|rilpivirine
460916|NCT00855335|TMC278
460917|NCT00855335|Cobicistat
460918|NCT00855335|treatment experienced
460919|NCT00855322|Arthritis, Rheumatoid
460920|NCT00855322|Exercise
460921|NCT00855322|Biological Therapy
460922|NCT00855309|chemotherapeutic agent toxicity
460923|NCT00855309|renal toxicity
460924|NCT00855309|infection
460925|NCT00855309|neutropenia
460926|NCT00855270|PTSD
460927|NCT00855257|Acid nicotinique
460928|NCT00855257|FLOW MEDIATED DILATATION (FMD)
460929|NCT00855257|HDL-C< 0.4 G/L
460930|NCT00855244|Bone marrow transplantation
460931|NCT00855231|Acute coronary syndrome
460932|NCT00855231|Coronary artery disease
460933|NCT00855231|cardiac imaging
460934|NCT00855231|computed tomography
460935|NCT00855218|Sorafenib
460936|NCT00855218|TACE
460937|NCT00855218|DC bead
460938|NCT00855218|Combination
460939|NCT00855205|pulmonary sarcoidosis
460940|NCT00855192|anxiety
460941|NCT00855192|depression
460942|NCT00855192|pregnancy
460943|NCT00855192|antenatal
460944|NCT00855192|prenatal
460945|NCT00855192|mindfulness-based therapy
460946|NCT00855192|interpersonal therapy
460947|NCT00855192|support groups
460948|NCT00855166|Dapagliflozin
460949|NCT00855166|Metformin
460950|NCT00855166|Type 2 diabetes
460951|NCT00855166|body weight
460952|NCT00855153|PTSD
460953|NCT00855153|burns
460954|NCT00855153|virtual reality exposure
460955|NCT00855153|D-Cycloserine
460956|NCT00855153|Combat related psychological trauma in burned servicemembers
460957|NCT00855140|Insomnia
460958|NCT00855140|Primary insomnia
460959|NCT00855140|Insomnia disorder
460960|NCT00855140|Acupuncture
460961|NCT00855127|Biological Markers
460962|NCT00855127|Renal Replacement Therapy
460963|NCT00855127|Mortality
460964|NCT00855114|stage II breast cancer
460965|NCT00855114|stage III breast cancer
460966|NCT00855114|stage IIIA breast cancer
460967|NCT00855101|Pharmacokinetics and safety of voriconazole intravenous oral adults
460968|NCT00855088|HIV seronegativity
460969|NCT00855075|Sedation
460970|NCT00855075|Analgesia
460971|NCT00855075|Mechanical ventilation
460972|NCT00855075|Cerebral State Monitor
460973|NCT00855075|Cerebral State Index
460974|NCT00855062|Human immunodeficiency virus (HIV)
460975|NCT00855062|HIV associated cognitive impairment
460976|NCT00855062|HIV dementia
460977|NCT00855062|Uganda
460978|NCT00855062|Acquired immune deficiency syndrome (AIDS)
460979|NCT00855062|Treatment Naive
460980|NCT00855049|Pharmacokinetics
460981|NCT00855049|Acetaminophen
460982|NCT00855049|Intranasal
460983|NCT00855049|Absorption
460984|NCT00855036|blunt renal injury
460985|NCT00855036|kidney laceration
460986|NCT00855023|anterior cruciate ligament
460987|NCT00855023|Knee Joint
460988|NCT00855010|Pioglitazone
460989|NCT00855010|prediabetes
460990|NCT00855010|diabetes
460991|NCT00855010|obesity
460992|NCT00855010|Pancreatic fat
460993|NCT00854997|Obstructive sleep apnea; myocardial infarction
460994|NCT00854984|Depression
460995|NCT00854984|diabetes
460996|NCT00854984|Coronary heart disease
460997|NCT00854984|CBT
460998|NCT00854984|Cognitive behavioural therapy
460999|NCT00854971|NKCell
461000|NCT00854971|FOLFOX-4
461001|NCT00854971|advanced or unresectable colorectal cancer
461002|NCT00854958|Oral
461003|NCT00854958|Allergy
461004|NCT00854958|Syndrome
461005|NCT00854958|Food
461006|NCT00854958|Pollen
461007|NCT00854945|Myelodysplastic Syndrome
461008|NCT00854945|Refractory Cytopenia
461009|NCT00854945|Refractory Anemia
461010|NCT00854945|Dysplasia
461011|NCT00854945|Acute Myeloid Leukemia
461012|NCT00854932|procalcitonin
461013|NCT00854932|sepsis
461014|NCT00854932|newborn
461015|NCT00854932|intervention study
461016|NCT00854919|obsessive-compulsive disorder
461017|NCT00854919|augmentation treatment
461018|NCT00854919|SSRI-refractory
461019|NCT00854906|dry eye
461020|NCT00854906|keratometer
461021|NCT00854906|fluorescein
461022|NCT00854893|stroke
461023|NCT00854893|aphasia
461024|NCT00854893|aging
461025|NCT00854893|language learning
461026|NCT00854880|Erosive Gastritis
461027|NCT00854867|Solid tumour neoplastic meningitis
461028|NCT00854867|STNM
461029|NCT00854867|leptomeningeal metastases
461030|NCT00854867|DepoCyte
461031|NCT00854867|WBRT
461032|NCT00854867|Whole Brain Radiotherapy
461033|NCT00854867|Liposomal cytarabine intrathecal
461034|NCT00854867|Solid Tumour Neoplastic Meningitis with or without brain metastasis
461035|NCT00854854|NKCell
461036|NCT00854854|FOLFOX-4
461037|NCT00854854|gastric cancer
461038|NCT00854841|CML
461039|NCT00854841|suboptimal response
461040|NCT00854841|dasatinib
461041|NCT00854841|imatinib
461042|NCT00854828|Symptomatic 40-80 y/o w/lumbar Cobb of 30 degrees
461043|NCT00854828|All Participants must be reasonable surgical candidate at enrollment
461044|NCT00854815|Perforated appendicitis
461045|NCT00854815|laparoscopic appendectomy
461046|NCT00854815|children
461047|NCT00854815|irrigation
461048|NCT00854802|Hepatitis
461049|NCT00854802|Hepatitis C
461050|NCT00854789|Breast cancer
461051|NCT00854776|aspirin
461052|NCT00854776|clopidogrel
461053|NCT00854776|proton pump inhibitor
461054|NCT00854776|peptic ulcer
461055|NCT00854776|ulcer complications
461056|NCT00854750|Multiple Sclerosis, hx of unilateral ON, evidence of thermal sensitivity, and no evidence of an ocular motor syndrome
461057|NCT00854750|Multiple Sclerosis, no evidence of ON, and evidence of thermal sensitivity
461058|NCT00854750|Healthy age/gender matched controls
461059|NCT00854737|bipolar disorder
461060|NCT00854737|bipolar depression
461061|NCT00854737|bipolar mania
461062|NCT00854737|manic depression
461063|NCT00854737|depression
461064|NCT00854737|mania
461065|NCT00854737|hypomania
461066|NCT00854711|ST elevated Myocardical infraction
461192|NCT00854152|Tumors
461067|NCT00854698|THE LEFT VENTRICULAR REMODELING AFTER MECHANICAL AORTIC VALVE REPLACEMENT
461068|NCT00854698|exercise training
461069|NCT00854672|Sarcoidosis
461070|NCT00854672|muscle strength
461071|NCT00854672|exercise intolerance
461072|NCT00854672|QOL
461073|NCT00854646|ON 01910.Na
461074|NCT00854646|refractory
461075|NCT00854646|leukemia
461076|NCT00854646|myelodysplastic
461077|NCT00854646|cell cycle
461078|NCT00854633|Pre-term infants
461079|NCT00854633|Pre-term infants 750 to 1500 grams
461080|NCT00854594|Diabetes
461081|NCT00854594|Telemedicine
461082|NCT00854594|Shared Medical Appointments
461083|NCT00854581|recurrent adult T-cell leukemia/lymphoma
461084|NCT00854581|stage I adult T-cell leukemia/lymphoma
461085|NCT00854581|stage II adult T-cell leukemia/lymphoma
461086|NCT00854581|stage III adult T-cell leukemia/lymphoma
461087|NCT00854581|stage IV adult T-cell leukemia/lymphoma
461088|NCT00854581|HTLV-1 infection
461089|NCT00854568|B-cell lymphoma
461090|NCT00854568|CHOP
461091|NCT00854568|CEOP
461092|NCT00854568|Cardiotoxicity
461093|NCT00854555|incomplete spinal cord injury
461094|NCT00854555|locomotor activity
461095|NCT00854555|walking function
461096|NCT00854555|gait
461097|NCT00854542|Telepsychiatry
461098|NCT00854542|Culturally Sensitive Collaborative Treatment
461099|NCT00854542|Chinese Americans
461100|NCT00854542|Depression
461101|NCT00854529|bevacizumab
461102|NCT00854529|subconjunctival injection
461103|NCT00854529|trabeculectomy
461104|NCT00854529|bleb
461105|NCT00854529|mitomycin c
461106|NCT00854516|compression therapy
461107|NCT00854516|3M
461108|NCT00854503|Statins administration in diabetic dyslipidemia
461109|NCT00854477|capecitabine
461110|NCT00854477|Post whipples
461111|NCT00854477|pancreatico-duodenectomy
461112|NCT00854477|pancreatic adenocarcinoma
461113|NCT00854477|pharmacokinetic
461114|NCT00854464|Arsenic Methylation Capability
461115|NCT00854464|Arsenic Methylation Enzymes
461116|NCT00854464|Cigarette Metabolites
461117|NCT00854464|Cigarette Metabolic Enzymes
461118|NCT00854464|DNA Repair Enzymes
461119|NCT00854464|Inflammatory Factors
461120|NCT00854464|Urothelial Carcinoma
461121|NCT00854451|Helicobacter pylori
461122|NCT00854451|CYP2C19 genotype
461123|NCT00854451|intragastric pH
461124|NCT00854451|dual therapy
461125|NCT00854451|antibiotic resistance
461126|NCT00854438|anticholinergic drugs
461127|NCT00854438|adverse events
461128|NCT00854438|elderly
461129|NCT00854438|clinical pharmacist
461130|NCT00854438|Evaluate the clinical effects of reducing anticholinergic in elderly
461131|NCT00854412|Obesity
461132|NCT00854412|Weight loss
461133|NCT00854412|Very low-calorie diet
461134|NCT00854412|Mannose-binding lectin
461135|NCT00854412|Insulin resistance
461136|NCT00854386|fluid management
461137|NCT00854386|VATS
461138|NCT00854386|ALI
461139|NCT00854386|ARDS
461140|NCT00854373|Infertility
461141|NCT00854373|Pregnancy
461142|NCT00854373|in vitro fertilization
461143|NCT00854360|Seasonal Allergic Rhinitis
461144|NCT00854360|Hayfever
461145|NCT00854347|hyperglycemia
461146|NCT00854347|diabetes
461147|NCT00854347|intensive care
461148|NCT00854347|prevalence
461149|NCT00854334|Sleep
461150|NCT00854334|Overweight
461151|NCT00854334|Physical activity
461152|NCT00854334|Appetite
461153|NCT00854334|NEAT
461154|NCT00854321|rheumatoid arthritis
461155|NCT00854321|rituximab
461156|NCT00854321|therapy
461157|NCT00854308|Tarceva
461158|NCT00854308|Lung Cancer
461159|NCT00854308|NSCLC
461160|NCT00854295|arthritis
461161|NCT00854295|osteoarthritis
461162|NCT00854295|degenerative knee disease
461163|NCT00854295|avascular necrosis
461164|NCT00854295|total knee replacement
461165|NCT00854295|TKA
461166|NCT00854256|glaucoma
461167|NCT00854230|HIV
461168|NCT00854230|alcohol
461169|NCT00854230|naltrexone
461170|NCT00854230|Treatment Experienced
461171|NCT00854204|Innovation-TiFP4-C101
461172|NCT00854204|Innovation-C101
461173|NCT00854204|Innovation
461174|NCT00854204|TMC114/TMC41629
461175|NCT00854204|controlled-release coformulations
461176|NCT00854204|immediate-release coformulation
461177|NCT00854204|Pharmacokinetics
461178|NCT00854191|mechanical simulator
461179|NCT00854191|ERCP
461180|NCT00854191|training
461181|NCT00854178|isoflurane
461182|NCT00854178|propofol
461183|NCT00854178|genotoxicity
461184|NCT00854178|gene expression
461185|NCT00854178|cytokines
461186|NCT00854178|apoptosis
461187|NCT00854165|lung transplantation
461188|NCT00854165|respiratory failure
461189|NCT00854165|ECMO
461190|NCT00854165|Lung transplants in respiratory failure patients
461191|NCT00854152|NHL
461193|NCT00854152|Carcinogenic Tumors
461194|NCT00854139|Multiple myeloma
461195|NCT00854139|Renal failure
461196|NCT00854139|Kidney transplant
461197|NCT00854126|NHL
461198|NCT00854126|Solid Tumors
461199|NCT00854126|Carcinogenic Tumors
461200|NCT00854113|Diabetes Mellitus Type 2
461201|NCT00854100|Adjunctive
461202|NCT00854100|Depression
461203|NCT00854100|Major Depressive Disorder (MDD)
461204|NCT00854087|Hepatitis C Virus
461205|NCT00854087|HCV
461206|NCT00854087|Herbal treatment
461207|NCT00854087|Herbs
461208|NCT00854087|San Diego
461209|NCT00854087|Non responder
461210|NCT00854087|Relapser
461211|NCT00854087|Treatment failure
461212|NCT00854087|Antifibrotic
461213|NCT00854087|Anti-fibrotic
461214|NCT00854087|Fibrosis
461215|NCT00854087|Failure of previous Interferon based therapy
461216|NCT00854087|Refuse Interferon based therapy
461217|NCT00854087|Intolerance to Interferon
461218|NCT00854087|Male or female 18-70 years of age
461219|NCT00854074|Post-operative Paralytic Ileus
461220|NCT00854074|Neuromodulation
461221|NCT00854074|Neurostimulation
461222|NCT00854074|Extended loss of functional bowel motility
461223|NCT00854048|Pediatric
461224|NCT00854048|Oxygen Saturation
461225|NCT00854048|Cardiopulmonary bypass
461226|NCT00854035|MK-0431/ONO-5435
461227|NCT00854035|Type 2 diabetes mellitus
461228|NCT00854009|Healthy Subjects
461229|NCT00853983|Healthy Volunteers
461230|NCT00853983|ADME
461231|NCT00853970|Pain and Inflammation as a function of cataract surgery
461232|NCT00853957|Hypertension
461233|NCT00853957|African Americans
461234|NCT00853957|Aliskiren
461235|NCT00853957|Amlodipine
461236|NCT00853957|Systolic blood pressure
461237|NCT00853957|Diastolic blood pressure
461238|NCT00853957|Stage II
461239|NCT00853957|Combination
461240|NCT00853944|islet transplantation
461241|NCT00853944|type 1 diabetes
461242|NCT00853944|incretin
461243|NCT00853931|KRAS wild type
461244|NCT00853931|metastatic colorectal cancer
461245|NCT00853931|KRAS wild type metastatic colorectal cancer with no prior exposure to EGFR inhibitors
461246|NCT00853918|Physician survey
461247|NCT00853918|Mail survey
461248|NCT00853918|Response rate
461249|NCT00853905|open angle glaucoma (POAG)
461250|NCT00853905|angle closure glaucoma (PACG)
461251|NCT00853905|pigmentary glaucoma
461252|NCT00853905|pseudoexfoliation glaucoma
461253|NCT00853905|neovascular glaucoma
461254|NCT00853905|traumatic glaucoma
461255|NCT00853892|Healthy Subjects
461256|NCT00853892|Bioequivalence
461257|NCT00853866|stroke
461258|NCT00853866|reboxetine
461259|NCT00853866|noradrenaline
461260|NCT00853866|motor cortex
461261|NCT00853866|transcranial direct current stimulation
461262|NCT00853866|motor function
461263|NCT00853866|rehabilitation
461264|NCT00853866|Jebsen Taylor test
461265|NCT00853853|Hemorrhoidectomy
461266|NCT00853853|Hemorrhoids
461267|NCT00853840|pharmacodynamics. maraviroc, vardenafil, blood pressure
461268|NCT00853827|CAD
461269|NCT00853827|coronary artery disease
461270|NCT00853827|coronary atherosclerosis
461271|NCT00853827|coronary angiography
461272|NCT00853827|IVUS
461273|NCT00853827|intravascular ultrasound
461274|NCT00853827|plasma renin activity
461275|NCT00853827|renin angiotensin aldosterone system,
461276|NCT00853827|direct renin inhibitors
461277|NCT00853827|coronary atheroma
461278|NCT00853814|adolescence
461279|NCT00853814|obesity
461280|NCT00853814|physical activity
461281|NCT00853814|built environment
461282|NCT00853814|neighborhood environment
461283|NCT00853814|children
461284|NCT00853814|youth
461285|NCT00853814|increasing physical activity
461286|NCT00853814|changing dietary intake
461287|NCT00853814|reducing zBMI
461288|NCT00853801|Pre-Diabetes
461289|NCT00853801|Metabolic Syndrome
461290|NCT00853801|Type 2 Diabetes
461291|NCT00853801|Diabetes Prevention
461292|NCT00853801|Lifestyle Modification
461293|NCT00853801|Diet Therapy
461294|NCT00853801|Provider Education
461295|NCT00853788|systemic sclerosis
461296|NCT00853788|biomarkers
461297|NCT00853788|microarray
461298|NCT00853775|heart disease
461299|NCT00853775|cardiovascular disease
461300|NCT00853775|lipoproteins
461301|NCT00853775|lipoprotein(a)
461302|NCT00853775|Lp(a)
461303|NCT00853775|apolipoprotein(a)
461304|NCT00853775|apo(a)
461305|NCT00853775|fats
461306|NCT00853775|proteins
461307|NCT00853775|metabolism
461308|NCT00853749|Immune response
461309|NCT00853749|pneumococcal conjugate vaccine
461310|NCT00853749|polysaccharide
461311|NCT00853736|Healthy Subjects
461312|NCT00853736|Bioequivalence
461313|NCT00853723|osteoporosis
461314|NCT00853723|post-menopausal
461315|NCT00853723|bone anabolic agents
461316|NCT00853710|Prostate-Specific Antigen
461317|NCT00853710|Prostate Cancer
461318|NCT00853710|Cancer
461319|NCT00853710|Assay
461320|NCT00853697|Prostate
461321|NCT00853697|DUTASTERIDE
461322|NCT00853697|TESTOSTERONE
461323|NCT00853697|09-008
461324|NCT00853697|Consortium Protocol LOI# c09-028
461325|NCT00853684|Advanced Colorectal Cancer
461326|NCT00853684|Oxaliplatin
461327|NCT00853684|Capecitabine
461328|NCT00853684|Endostar
461329|NCT00853684|efficacy
461330|NCT00853671|Coronary Artery Disease
461331|NCT00853671|Multidetector Computed Tomography
461332|NCT00853671|Myocardial Perfusion Imaging
461333|NCT00853658|Chronic Heart Failure
461334|NCT00853658|Cardiovascular death
461335|NCT00853658|CHF hospitalization
461336|NCT00853658|morbi-mortality trial
461337|NCT00853658|outcome study
461338|NCT00853658|endpoint driven
461339|NCT00853658|plasma renin activity
461340|NCT00853658|renin angiotensin aldosterone system
461341|NCT00853658|direct renin inhibitors
461342|NCT00853658|BNP
461343|NCT00853658|KCCQ
461344|NCT00853658|eGFR
461345|NCT00853658|(NYHA class II to IV) with elevated
461346|NCT00853658|BNP and reduced LVEF
461347|NCT00853632|Mitral valve
461348|NCT00853632|pericardial bioprostheses
461349|NCT00853632|PERIMOUNT
461350|NCT00853632|bovine pericardial leaflets
461351|NCT00853632|mitral valve replacement
461352|NCT00853632|mitral valve regurgitation
461353|NCT00853632|Heart valve disease
461354|NCT00853619|clinical decision support
461355|NCT00853619|knowledge management
461356|NCT00853619|knowledge representation
461357|NCT00853619|clinical guidelines
461358|NCT00853619|coronary artery disease
461359|NCT00853619|myocardial ischemia
461360|NCT00853619|diabetes mellitus
461361|NCT00853619|hypertension
461362|NCT00853606|ED
461363|NCT00853606|Erectile Dysfunction
461364|NCT00853606|Dysfunction
461365|NCT00853606|Erectile
461366|NCT00853593|heart failure
461367|NCT00853593|cardiac pacing
461368|NCT00853593|cardiac resynchronization therapy
461369|NCT00853593|left ventricular lead
461370|NCT00853580|Neurofibromatosis Type 1, Neurocognitive, Phase II
461371|NCT00853567|Uterine Fibroids
461372|NCT00853554|Healthy Subjects
461373|NCT00853554|Bioequivalence
461374|NCT00853541|renal impairment
461375|NCT00853541|heart failure
461376|NCT00853541|hyperphosphatemia
461377|NCT00853541|coronary artery calcification
461378|NCT00853528|spinal cord metastases
461379|NCT00853502|anorexia nervosa
461380|NCT00853502|testosterone
461381|NCT00853502|disordered eating
461382|NCT00853502|hypogonadism
461383|NCT00853502|bone
461384|NCT00853489|Open tibia fractures
461385|NCT00853489|rhBMP-2
461386|NCT00853489|critical size defects
461387|NCT00853489|bone grafting
461388|NCT00853463|Pulmonary Embolism
461389|NCT00853463|Deep Vein Thrombosis
461390|NCT00853463|Prophylaxis
461391|NCT00853463|Venous thromboembolism
461392|NCT00853463|Prevention
461393|NCT00853463|Medical patients
461394|NCT00853450|Antiplatelet
461395|NCT00853437|Comparison of CO by new method to clinician's estimate and implied CO from the measurement of arteriovenous oxygen content difference.
461396|NCT00853424|diabetic retinopathy
461397|NCT00853424|diabetic macular edema
461398|NCT00853424|type 1 diabetes
461399|NCT00853424|intensive medical therapy
461400|NCT00853424|islet cell transplantation
461401|NCT00853424|visual acuity
461402|NCT00853424|diabetic eye disease
461403|NCT00853411|Moderate to severe asthma
461404|NCT00853398|Primary Osteoarthritis of the knee.
461405|NCT00853385|oral DMARD
461406|NCT00853385|JAK inhibitor
461407|NCT00853385|clinical trial
461408|NCT00853346|Depression
461409|NCT00853346|Parkinson's Disease
461410|NCT00853346|Major Depression
461411|NCT00853346|Cognitive Behavioral Therapy
461412|NCT00853333|Pain
461413|NCT00853333|Propofol
461414|NCT00853333|Dexmedetomidine
461415|NCT00853333|Midazolam
461416|NCT00853333|Effects of sedation on pain perception.
461417|NCT00853320|Healthy Subjects
461418|NCT00853320|Bioequivalence
461419|NCT00853294|Healthy Subjects
461420|NCT00853294|Bioequivalence
461421|NCT00853281|Forest malaria prevention
461422|NCT00853281|Long-lasting insecticidal hammocks
461423|NCT00853281|Cluster randomized trial
461424|NCT00853281|Central Vietnam
461425|NCT00853268|Healthy Subjects
461426|NCT00853268|Bioequivalence
461427|NCT00853255|Bird Flu
461428|NCT00853242|Chronic Kidney Disease
461429|NCT00853242|Phosphate Binder
461430|NCT00853242|Phosphate
461431|NCT00853242|Hyperphosphatemia
461432|NCT00853229|vulvodynia
461433|NCT00853229|vulvar vestibulitis
461434|NCT00853229|chronic vulvar pain
461435|NCT00853229|generalized vulvodynia
461436|NCT00853229|localized vulvodynia
461437|NCT00853216|Healthy Subjects
461438|NCT00853216|Bioequivalence
461439|NCT00853203|Colorectal Cancer
461440|NCT00853203|Rectal Cancer
461441|NCT00853203|Psychosocial
461442|NCT00853203|Expressive Disclosure
461443|NCT00853203|Questionnaires
461444|NCT00853203|Quality of life
461445|NCT00853203|QOL
461446|NCT00853203|Electronically Activated Recorder
461447|NCT00853203|EAR
461448|NCT00853190|Healthy Subjects
461449|NCT00853177|Oocyte retrieval
461450|NCT00853177|pain
461451|NCT00853177|surgery
461452|NCT00853177|anaesthesiology
461453|NCT00853177|Assisted Reproductive Technologies
461454|NCT00853164|prostate cancer
461455|NCT00853164|aerobic exercise
461456|NCT00853164|resistance training
461457|NCT00853138|cognitive-behavioral therapy
461458|NCT00853138|chronic pain
461459|NCT00853138|randomized controlled trial
461460|NCT00853138|pediatrics
461461|NCT00853125|clear cell renal cell carcinoma
461462|NCT00853125|stage IV renal cell cancer
461463|NCT00853112|PAH pulmonary hypertension pulmonary arterial hypertension
461464|NCT00853099|Ulcerative Colitis
461465|NCT00853073|failing blebs
461466|NCT00853073|failing express shunt
461467|NCT00853073|avastin
461468|NCT00853073|bevacizumab
461469|NCT00853073|glaucoma
461470|NCT00853073|prior trabeculectomy
461471|NCT00853073|Express shunt placed under a scleral flap
461472|NCT00853073|subsequent filtration failure
461473|NCT00853060|energy expenditure
461474|NCT00853060|mechanical ventilation
461475|NCT00853060|weaning
461476|NCT00853060|pressure support ventilation
461477|NCT00853060|T-tube
461478|NCT00853034|gastrointestinal effects
461479|NCT00853034|prebiotic
461480|NCT00853021|clear cell renal cell carcinoma
461481|NCT00853021|recurrent renal cell cancer
461482|NCT00853021|stage IV renal cell cancer
461483|NCT00853008|Acute Lymphoblastic Leukemia
461484|NCT00853008|High-Risk (HR)
461485|NCT00853008|Philadelphia Chromosome-Negative
461486|NCT00852995|Venous Leg Ulcer (VLU)
461487|NCT00852995|Venous Stasis Ulcer (VSU)
461488|NCT00852995|VLU
461489|NCT00852995|VSU
461490|NCT00852995|Leg Ulcer
461491|NCT00852995|Leg Wound
461492|NCT00852982|Exercise
461493|NCT00852982|Risk factors
461494|NCT00852982|Primary health care
461495|NCT00852969|Chronic Kidney Disease
461496|NCT00852969|Niacin
461497|NCT00852969|HDL
461498|NCT00852969|Endothelial Function
461499|NCT00852956|Betahistine
461500|NCT00852956|Olanzapine
461501|NCT00852956|Safety of co-administration of Betahistien and Olanzapine
461502|NCT00852943|Mast Cells
461503|NCT00852943|Piebaldism
461504|NCT00852943|Anaphylaxis
461505|NCT00852943|Allergy
461506|NCT00852943|Genetics
461507|NCT00852930|lymphedema
461508|NCT00852930|quality of life
461509|NCT00852930|breast cancer
461510|NCT00852930|symptoms
461511|NCT00852930|lymphedema in breast cancer survivors
461512|NCT00852917|Pain due to Osteoarthritis of the Knee
461513|NCT00852904|Childhood Growth and Development
461514|NCT00852904|Genetics
461515|NCT00852904|Children
461516|NCT00852904|Environment
461517|NCT00852904|Longitudinal Study
461518|NCT00852904|National Children's Study
461519|NCT00852891|weaning
461520|NCT00852891|echocardiogram
461521|NCT00852891|diastolic dysfunction
461522|NCT00852891|Mechanical ventilation
461523|NCT00852878|Recurrent Abdominal Pain
461524|NCT00852878|Biofeedback
461525|NCT00852878|Heart Rate Variability
461526|NCT00852865|Inflammation
461527|NCT00852865|Pain
461528|NCT00852852|ESRA-C 2
461529|NCT00852852|computerized assessment
461530|NCT00852839|Dry mouth
461531|NCT00852839|Sjogren's syndrome
461532|NCT00852839|Xerostomia
461533|NCT00852826|axillary seroma
461534|NCT00852826|axillary lymphadenectomy
461535|NCT00852826|morbidity
461536|NCT00852826|morbidity postlymphadenectomy
461537|NCT00852826|Lymphadenectomy
461538|NCT00852813|tolerance
461539|NCT00852813|prebiotic
461540|NCT00852813|gastrointestinal effects
461541|NCT00852800|spontaneous bacterial peritonitis
461542|NCT00852800|albumin
461543|NCT00852800|renal impairment
461544|NCT00852800|mortality
461545|NCT00852787|Digoxin like substances
461546|NCT00852787|digibind
461547|NCT00852787|digoxin immune fab
461548|NCT00852787|end-stage-renal-disease
461549|NCT00852787|marinobufagenin
461550|NCT00852761|Psoriasis
461551|NCT00851786|Herpes Zoster Vaccine
461552|NCT00851786|Herpes Zoster Virus
461553|NCT00851786|HIV
461554|NCT00851721|Hemophilia A
461555|NCT00851721|Factor VIII Inhibitor
461556|NCT00851721|Factor IX Inhibitor
461557|NCT00851721|Hemophilia B
461558|NCT00851708|kidney
461559|NCT00851708|deceased kidney transplant
461560|NCT00851708|oxidative stress
461561|NCT00851708|renal function measurements
461562|NCT00851695|Lung Function Decline
461563|NCT00851695|Lung Function
461564|NCT00851695|Allergy
461565|NCT00851695|COPD
461566|NCT00851695|Vitamin D
461567|NCT00851682|Prostate Cancer
461568|NCT00851682|Dynamic Contrast Enhanced MRI
461569|NCT00851682|Non-invasive Prostate Cancer Detection
461570|NCT00851669|depression
461571|NCT00851669|alcohol dependence
461572|NCT00851669|women
461573|NCT00851669|psychotherapy
461574|NCT00851669|men
461575|NCT00851630|HIV
461576|NCT00851630|Tuberculosis
461577|NCT00851630|Treatment Naive
461578|NCT00852748|headache
461579|NCT00852735|Cardiovascular diseases
461580|NCT00852735|Rapeseed oil
461581|NCT00852735|Micronutriments
461582|NCT00852735|HDL cholesterol
461583|NCT00852735|Oxidative stress
461584|NCT00852735|Tocopherols
461585|NCT00852735|Sterols
461586|NCT00852735|Prevention of cardiovascular diseases
461587|NCT00852722|Multiple sclerosis
461588|NCT00852722|Diet
461589|NCT00852709|Myelodysplastic syndrome that has transformed to AML (AML/MDS)
461590|NCT00852709|Treatment-related AML
461591|NCT00852709|AML evolving from myeloproliferative disorders (MPD)
461592|NCT00852709|Acute lymphocytic leukemia (ALL)
461593|NCT00852709|Acute promyelocytic leukemia (APL) refractory to arsenic therapy or retinoic acid therapy
461594|NCT00852709|Relapsed and/or refractory acute leukemia with progressive disease since last therapy
461595|NCT00852709|Chronic myelogenous leukemia (CML) in accelerated phase or blast crisis refractory to imatinib
461596|NCT00852709|High-risk MPD including myelofibrosis, chronic myelomonocytic leukemia (CMML, and relapsed or refractory juvenile myelomonocytic leukemia (JMML).
461597|NCT00852696|Overactive Bladder
461598|NCT00852696|Incontinence
461599|NCT00852696|Solifenacin
461600|NCT00852696|Women
461601|NCT00852696|Postoperative
461602|NCT00852657|Rotator cuff tear
461603|NCT00852657|surgical repair
461604|NCT00852657|Physiotherapy
461605|NCT00852657|Treatment benefit
461606|NCT00852657|Surgery
461607|NCT00852644|stage I non-small cell lung cancer
461608|NCT00852644|stage II non-small cell lung cancer
461609|NCT00852631|Quetiapine efficacy in schizophrenia
461610|NCT00852618|HIV Integrase Inhibitors
461611|NCT00852618|HIV Nucleoside Reverse Transcriptase Inhibitors
461612|NCT00852618|Treatment Naive
461613|NCT00852618|Viral Load
461614|NCT00852605|Acute Lung Injury after allogeneic transplantation
461615|NCT00852592|Bipolar Disorder Depression Midday Light Therapy
461616|NCT00852592|Bipolar Disorder Type I or II
461617|NCT00852579|Asthma
461618|NCT00852579|Smoker
461619|NCT00852579|Macrolide
461620|NCT00852566|Chronic myeloid leukemia
461621|NCT00852566|tyrosine kinase inhibitor
461622|NCT00852566|stem cell
461623|NCT00852566|Philadelphia chromosome
461624|NCT00852566|dasatinib
461625|NCT00852553|intestinal
461626|NCT00852553|smooth
461627|NCT00852553|muscle
461628|NCT00852553|GI
461629|NCT00852553|motility
461630|NCT00852540|impetigo
461631|NCT00852540|methicillin-resistant Staphylococcus aureus
461632|NCT00852540|linezolid
461633|NCT00852540|secondarily-infected traumatic lesion
461634|NCT00852540|uncomplicated skin infection
461635|NCT00852540|retapamulin
461636|NCT00852527|Traumatic Brain Injury
461637|NCT00852527|Screening
461638|NCT00852527|Diagnosis
461639|NCT00852527|Rehabilitation Outcome
461640|NCT00852514|Bioimpedance
461641|NCT00852514|ultrafiltration
461642|NCT00852514|blood pressure
461643|NCT00852514|pulse pressure
461644|NCT00852501|Non-functioning pituitary adenoma
461645|NCT00852501|RTPCR
461646|NCT00852501|Hormonal receptors
461647|NCT00852475|MUFA
461648|NCT00852475|PUFA
461649|NCT00852475|MOVE! program
461650|NCT00852462|SAMI
461651|NCT00852462|Symptom Assessment and Management Intervention Program
461652|NCT00852449|Intraoperative fluid
461653|NCT00852449|Monitoring
461654|NCT00852449|Oesophageal Doppler
461655|NCT00852449|Abdominal surgery
461656|NCT00852449|major abdominal surgery
461657|NCT00852436|neuropathic pain
461658|NCT00852436|orofacial pain
461659|NCT00852436|clinical trials
461660|NCT00852436|pregabalin
461661|NCT00852436|randomized controlled trial
461662|NCT00852423|Malaria in pregnancy
461663|NCT00852423|Sub-saharan Africa
461664|NCT00852423|Treatment
461665|NCT00852423|Artemisinin containing Therapy
461666|NCT00852423|Efficacy
461667|NCT00852423|Safety
461668|NCT00852410|Endoscopic sinus surgery
461669|NCT00852384|Anesthesia induction
461670|NCT00852384|Obese patients
461671|NCT00852384|Noninvasive ventilation
461672|NCT00852384|Alveolar recruitment
461673|NCT00852371|Malaria
461674|NCT00852371|Intermittent preventive treatment
461675|NCT00852371|Efficacy
461676|NCT00852371|Safety
461677|NCT00852371|Tolerability
461678|NCT00852371|Schoolchildren
461679|NCT00852371|Uganda
461680|NCT00852358|mucopolysaccharidosis
461681|NCT00852358|Hurler-Scheie
461682|NCT00852358|Scheie
461683|NCT00852358|laronidase
461684|NCT00852358|cognitive decline
461685|NCT00852358|central nervous system
461686|NCT00852358|enzyme replacement therapy
461687|NCT00852358|intrathecal
461688|NCT00852358|LA Biomed
461689|NCT00852345|multibacillary leprosy
461690|NCT00852345|leprosy
461691|NCT00852345|clofazamine
461692|NCT00852332|male breast cancer
461693|NCT00852332|stage IIIB breast cancer
461694|NCT00852332|stage IIIC breast cancer
461695|NCT00852332|stage IV breast cancer
461696|NCT00852332|recurrent breast cancer
461697|NCT00852332|stage IIIA breast cancer
461698|NCT00852332|HER2-negative breast cancer
461699|NCT00852319|Interpregnancy Care
461700|NCT00852319|Preconceptual Care
461701|NCT00852319|Premature Birth
461702|NCT00852319|Preterm Delivery
461703|NCT00852306|oocyte freezing
461704|NCT00852306|vitrification
461705|NCT00852306|slow freeze
461706|NCT00852306|fertility preservation
461707|NCT00852293|liver disease
461708|NCT00852293|Chitinase 3 like-1 protein
461709|NCT00852280|scars
461710|NCT00852280|late effect of burn
461711|NCT00852280|burn
461712|NCT00852280|pulsed-dye laser
461713|NCT00852267|cholesterol
461714|NCT00852267|diet
461715|NCT00852267|protein
461716|NCT00852267|carbohydrate
461717|NCT00852267|saturated fat
461718|NCT00852267|LDL subclass
461719|NCT00852267|healthy volunteers
461720|NCT00852254|Cardiac Index
461721|NCT00852254|Ultrasound Dilution
461722|NCT00852254|Accuracy of ultrasound dilution cardiac index.
461723|NCT00852228|colorectal cancer
461724|NCT00852228|unresectable metastases
461725|NCT00852228|neo-adjuvant chemotherapy
461726|NCT00852228|liver metastases
461727|NCT00852228|chronotherapy
461728|NCT00852228|cetuximab
461729|NCT00852228|irinotecan
461730|NCT00852228|oxaliplatin
461731|NCT00852228|5-fluorouracil
461732|NCT00852228|hepatic artery infusion
461733|NCT00852228|Unresectable hepatic lesions
461734|NCT00852228|1 to 3 prior chemotherapy regimens
461735|NCT00852215|Angioplasty, Transluminal, Percutaneous Coronary
461736|NCT00852215|Paclitaxel-eluting stent
461737|NCT00852215|Vision stent
461738|NCT00852202|bipolar
461739|NCT00852202|depression
461740|NCT00852189|Cancer
461741|NCT00852189|Phase 1
461742|NCT00852189|EC0489
461743|NCT00852189|EC20
461744|NCT00852189|Refractory
461745|NCT00852189|Metastatic
461746|NCT00852189|Experimental
461747|NCT00852176|Coronary brachytherapy
461748|NCT00852176|Coronary restenosis
461749|NCT00852176|Coronary in stent restenosis
461750|NCT00852163|conditioning, preparative
461751|NCT00852163|clofarabine; transplant
461752|NCT00852163|Busulfan
461753|NCT00852163|leukemia
461754|NCT00852163|myelodysplastic syndrome
461755|NCT00852150|gastritis
461756|NCT00852150|duodenitis
461757|NCT00852150|inter-rater reliability
461758|NCT00852150|intra-rater reliablity
461759|NCT00852150|gastroscopy
461760|NCT00852150|duodenoscopy
461761|NCT00852137|Peplin
461762|NCT00852137|PEP005
461763|NCT00852137|Actinic Keratosis
461764|NCT00852124|Asthma
461765|NCT00852124|Probiotic
461766|NCT00852124|VSL#3
461767|NCT00852111|Fatigue
461768|NCT00852111|Radiotherapy
461769|NCT00852111|Cancer Therapy
461770|NCT00852111|Cancer
461771|NCT00852098|Fundoplication
461772|NCT00852098|gastroesophageal reflux
461773|NCT00852098|gastric vessels
461774|NCT00852098|surgery
461775|NCT00852085|Counseling
461776|NCT00852085|Crime
461777|NCT00852085|Adolescent
461778|NCT00852072|common bile duct stones
461779|NCT00852072|mechanical lithotripsy
461780|NCT00852072|balloon sphincteroplasty
461781|NCT00852059|ADHD
461782|NCT00852059|children
461783|NCT00852059|adolescents
461784|NCT00852059|methylphenidate
461785|NCT00852059|adherence
461786|NCT00852059|immediate release
461787|NCT00852059|extended release
461788|NCT00852059|efficacy
461789|NCT00852046|Mechanical ventilation
461790|NCT00852033|alcoholism
461791|NCT00852033|alcohol abuse
461792|NCT00852033|prevention
461793|NCT00852033|behavior modification
461794|NCT00852033|parent offspring interaction
461795|NCT00852033|university student
461796|NCT00852033|substance abuse related behavior
461797|NCT00852033|adolescence
461798|NCT00852007|prostate cancer
461799|NCT00852007|dendritic cells
461800|NCT00852007|MUC-1
461801|NCT00852007|immune therapy
461802|NCT00851994|Patients having surgery
461803|NCT00851981|Alcohol Liver Disease
461804|NCT00851968|hepatectomy
461805|NCT00851968|Selective HepaticVascular Clamping
461806|NCT00851942|Volunteer
461807|NCT00851942|Hypoadrenalism
461808|NCT00851942|Hypopituitarism
461809|NCT00851942|Healthy volunteers
461810|NCT00851929|sarcoidosis
461811|NCT00851929|pulmonary hypertension
461812|NCT00851929|dyspnea
461813|NCT00851929|sarcoidosis associated pulmonary hypertension
461814|NCT00851877|stage III squamous cell carcinoma of the oropharynx
461815|NCT00851877|stage IV squamous cell carcinoma of the oropharynx
461816|NCT00851877|stage III squamous cell carcinoma of the hypopharynx
461817|NCT00851877|stage IV squamous cell carcinoma of the hypopharynx
461818|NCT00851877|stage II squamous cell carcinoma of the larynx
461819|NCT00851877|stage IV squamous cell carcinoma of the larynx
461820|NCT00851877|tongue cancer
461821|NCT00851864|anticoagulation
461822|NCT00851864|pregnancy
461823|NCT00851851|Surgical patients
461824|NCT00851838|Peritoneal dialysis
461825|NCT00851838|L-carnitine
461826|NCT00851825|autonomic modulation
461827|NCT00851825|heart rate
461828|NCT00851825|pressure support ventilation
461829|NCT00851825|T-tube
461830|NCT00851825|Mechanical ventilation
461831|NCT00851812|Exercise
461832|NCT00851812|Breast cancer
461833|NCT00851812|fatigue
461834|NCT00851799|ART
461835|NCT00851799|Antiretroviral therapy
461836|NCT00851799|Treatment naive
461837|NCT00851799|Highly active antiretroviral therapy (HAART)
461838|NCT00851617|Mechanical ventilator weaning
461839|NCT00851617|Respiratory Muscle Training
461840|NCT00851617|Ventilator dependent
461841|NCT00851604|ProGRP
461842|NCT00851604|CgA
461843|NCT00851604|NSE
461844|NCT00851604|TUM2-PK
461845|NCT00851604|Neuroendocrine Tumors
461846|NCT00851591|fenugreek
461847|NCT00851591|galactogogue
461848|NCT00851591|breastmilk
461849|NCT00851591|Trigonella foenum-graecum
461850|NCT00851591|Bird's Foot
461851|NCT00851591|Greek Clover
461852|NCT00851591|Greek Hay
461853|NCT00851591|Hu Lu Ba
461854|NCT00851591|Trigonella
461855|NCT00851578|AF
461856|NCT00851578|atrial fibrillation
461857|NCT00851578|LAA occlusion
461858|NCT00851552|recurrent adult diffuse large cell lymphoma
461859|NCT00851552|recurrent adult immunoblastic large cell lymphoma
461860|NCT00851552|anaplastic large cell lymphoma
461861|NCT00851539|HIV
461862|NCT00851539|Teenagers
461863|NCT00851539|Adolescent
461864|NCT00851539|HIV Testing
461865|NCT00851539|HIV Seronegativity
461866|NCT00851526|Coronary bifurcation lesion
461867|NCT00851526|Drug-eluting stent
461868|NCT00851513|Pudendal neuralgia
461869|NCT00851513|pudendal nerve
461870|NCT00851513|Alcock's canal syndrome
461871|NCT00851513|Canal syndrome
461872|NCT00851513|neuropathic pain
461873|NCT00851513|infiltration
461874|NCT00851513|randomized protocol
461875|NCT00851513|pain scales
461876|NCT00851500|atherosclerosis
461877|NCT00851500|carotid artery disease
461878|NCT00851487|ARI
461879|NCT00851487|LRTI
461880|NCT00851474|COstatus(R)
461881|NCT00851474|Ultrasound Dilution
461882|NCT00851474|Cardiac Output
461883|NCT00851474|Blood Volumes
461884|NCT00851474|Comparison of COstatus(R) cardiac output with other methods
461885|NCT00851461|Spinobulbar muscular atrophy
461886|NCT00851461|Kennedy's disease
461887|NCT00851461|Goserelin
461888|NCT00851461|Electrophysiologic study
461889|NCT00851461|Inclusion body
461890|NCT00851435|Pneumonia
461891|NCT00851435|Nosocomial pneumonia
461892|NCT00851435|Pseudomonas aeruginosa
461893|NCT00851435|Monoclonal antibody
461894|NCT00851435|Hospital-Acquired Pneumonia
461895|NCT00851422|Ultrasound Dilution
461896|NCT00851422|Cardiac Output
461897|NCT00851422|Validation of measured ultrasound dilution cardiac output
461898|NCT00851396|Vitamin D deficiency
461899|NCT00851396|Insulin resistance
461900|NCT00851396|Glucose- Insulin dynamics
461901|NCT00851396|Obese adolescents
461902|NCT00851383|HIV
461903|NCT00851383|Human Immunodeficiency Virus
461904|NCT00851383|HIV Seronegativity
461905|NCT00851383|Preventive Vaccine
461906|NCT00851370|COPD
461907|NCT00851370|Exacerbation
461908|NCT00851357|Nicotine Replacement Therapy
461909|NCT00851357|Nicotine Patch
461910|NCT00851357|Smoking cessation
461911|NCT00851357|Telephone
461912|NCT00851357|Tobacco cessation
461913|NCT00851357|Counseling
461914|NCT00851357|Nicotine
461915|NCT00851357|Self-Help
461916|NCT00851357|Smoking abstinence
461917|NCT00851357|Tobacco Use Disorder
461918|NCT00851344|Proof-of-Concept
461919|NCT00851344|Allergic Rhinitis
461920|NCT00851331|Benign childhood epilepsy
461921|NCT00851318|Rheumatoid Arthritis
461922|NCT00851318|Certolizumab Pegol
461923|NCT00851318|Cimzia
461924|NCT00851305|Stomach
461925|NCT00851305|endoscopy
461926|NCT00851305|neoplasms
461927|NCT00851292|prostate cancer
461928|NCT00851292|biopsy
461929|NCT00851292|TRUS
461930|NCT00851292|diagnosis
461931|NCT00851279|arrhythmia
461932|NCT00851279|ventricular tachycardia
461933|NCT00851279|ablation
461934|NCT00851279|mapping
461935|NCT00851279|electrophysiology
461936|NCT00851253|recurrent adenoid cystic carcinoma of the oral cavity
461937|NCT00851253|recurrent mucoepidermoid carcinoma of the oral cavity
461938|NCT00851253|recurrent verrucous carcinoma of the oral cavity
461939|NCT00851253|stage II adenoid cystic carcinoma of the oral cavity
461940|NCT00851253|stage II mucoepidermoid carcinoma of the oral cavity
461941|NCT00851253|stage II verrucous carcinoma of the oral cavity
461942|NCT00851253|stage III adenoid cystic carcinoma of the oral cavity
461943|NCT00851253|stage III mucoepidermoid carcinoma of the oral cavity
461944|NCT00851253|stage III verrucous carcinoma of the oral cavity
461945|NCT00851253|stage II squamous cell carcinoma of the lip and oral cavity
461946|NCT00851253|stage III squamous cell carcinoma of the lip and oral cavity
461947|NCT00851253|recurrent basal cell carcinoma of the lip
461948|NCT00851253|recurrent squamous cell carcinoma of the lip and oral cavity
461949|NCT00851253|stage II basal cell carcinoma of the lip
461950|NCT00851253|stage III basal cell carcinoma of the lip
461951|NCT00851253|recurrent lymphoepithelioma of the nasopharynx
461952|NCT00851253|recurrent squamous cell carcinoma of the nasopharynx
461953|NCT00851253|stage II lymphoepithelioma of the nasopharynx
461954|NCT00851253|stage II squamous cell carcinoma of the nasopharynx
461955|NCT00851253|stage III lymphoepithelioma of the nasopharynx
461956|NCT00851253|stage III squamous cell carcinoma of the nasopharynx
461957|NCT00851253|recurrent lymphoepithelioma of the oropharynx
461958|NCT00851253|recurrent squamous cell carcinoma of the oropharynx
461959|NCT00851253|stage II lymphoepithelioma of the oropharynx
461960|NCT00851253|stage II squamous cell carcinoma of the oropharynx
461961|NCT00851253|stage III lymphoepithelioma of the oropharynx
461962|NCT00851253|stage III squamous cell carcinoma of the oropharynx
461963|NCT00851253|high-grade salivary gland mucoepidermoid carcinoma
461964|NCT00851253|low-grade salivary gland mucoepidermoid carcinoma
461965|NCT00851253|recurrent salivary gland cancer
461966|NCT00851253|salivary gland acinic cell tumor
461967|NCT00851253|salivary gland adenocarcinoma
461968|NCT00851253|salivary gland adenoid cystic carcinoma
461969|NCT00851253|salivary gland anaplastic carcinoma
461970|NCT00851253|salivary gland malignant mixed cell type tumor
461971|NCT00851253|salivary gland poorly differentiated carcinoma
461972|NCT00851253|salivary gland squamous cell carcinoma
461973|NCT00851253|stage II salivary gland cancer
461974|NCT00851253|stage III salivary gland cancer
461975|NCT00851253|stage IV adenoid cystic carcinoma of the oral cavity
461976|NCT00851253|stage IV mucoepidermoid carcinoma of the oral cavity
461977|NCT00851253|stage IV squamous cell carcinoma of the lip and oral cavity
461978|NCT00851253|stage IV verrucous carcinoma of the oral cavity
461979|NCT00851253|stage IV salivary gland cancer
461980|NCT00851253|stage IV lymphoepithelioma of the nasopharynx
461981|NCT00851253|stage IV lymphoepithelioma of the oropharynx
461982|NCT00851253|stage IV squamous cell carcinoma of the nasopharynx
461983|NCT00851253|stage IV squamous cell carcinoma of the oropharynx
461984|NCT00851253|stage IV basal cell carcinoma of the lip
461985|NCT00851240|rheumatoid arthritis
461986|NCT00851240|safety
461987|NCT00851227|Pharmacokinetics
461988|NCT00851227|Protein Binding
461989|NCT00851227|Conivaptan
461990|NCT00851227|Vaprisol
461991|NCT00851227|Liver Disease
461992|NCT00851214|Non-invasive hemodynamic monitoring
461993|NCT00851214|Emergency Department patients
461994|NCT00851214|trauma with an ISS>15
461995|NCT00851214|Non-invasive continuous hemodynamic monitoring
461996|NCT00851201|children
461997|NCT00851201|obesity
461998|NCT00851201|weight loss
461999|NCT00851201|prevention
462000|NCT00851201|diabetes risk
462001|NCT00851201|cardiometabolic
462002|NCT00851162|Bone defect
462003|NCT00851162|Benign bone lesions
462004|NCT00851162|Stem cells
462005|NCT00851149|aorta
462006|NCT00851149|disease
462007|NCT00851149|abdominal
462008|NCT00851149|surgery
462009|NCT00851149|Osteoarthritis, Hip
462010|NCT00851149|replacement
462011|NCT00851149|blood
462012|NCT00851149|autolog
462013|NCT00851149|transfusion
462014|NCT00851149|cytokines
462015|NCT00851136|CRC
462016|NCT00851136|Colon cancer
462017|NCT00851136|Avastin
462018|NCT00851136|APM4566g
462019|NCT00851123|Stroke
462020|NCT00851123|arm paresis
462021|NCT00851123|mCIMT
462022|NCT00851123|bimanual training
462023|NCT00851123|rehabilitation
462024|NCT00851110|high dose
462025|NCT00851110|breast cancer
462026|NCT00851110|adjuvant
462027|NCT00851084|Angiogenesis
462028|NCT00851084|Colon cancer
462029|NCT00851084|Rectal cancer
462030|NCT00851084|Oxaliplatin
462031|NCT00851071|Anxiety
462032|NCT00851071|Implantable Cardioverter Defibrillator (ICD)
462033|NCT00851071|Defibrillators, Implantable
462034|NCT00851058|Behavioral research
462035|NCT00851058|Motivational counseling
462036|NCT00851058|Group Counseling
462037|NCT00851058|Motivational Interviewing
462038|NCT00851058|Vicarious Learning
462039|NCT00851058|Risky alcohol use
462040|NCT00851058|Recidivism
462041|NCT00851058|Motor Vehicles
462042|NCT00851058|Crime
462043|NCT00851032|Advanced Cancer
462044|NCT00851032|Initiative for Molecular Profiling in Advanced Cancer Therapy
462045|NCT00851032|IMPACT
462046|NCT00851032|Molecular Profile-Based Study
462047|NCT00851032|Investigational Cancer Therapeutics Program
462048|NCT00851032|Molecular profiling
462049|NCT00851032|Phase I Therapies
462050|NCT00851032|Tissue Bank
462051|NCT00851019|Exercise
462052|NCT00851019|Video game
462053|NCT00851019|Type 2 diabetes
462054|NCT00851019|Dance
462055|NCT00851006|Depression
462056|NCT00851006|Females
462057|NCT00851006|Adolescents
462058|NCT00850993|Hemolysis
462059|NCT00850954|Lung Cancer
462060|NCT00850954|Cancer
462061|NCT00850954|Smoke
462062|NCT00850954|Mexican American
462063|NCT00850954|Indoor Air Policy
462064|NCT00850954|Secondhand smoke
462065|NCT00850954|SHS
462066|NCT00850954|Smoking cessation programs
462067|NCT00850954|Smokers
462068|NCT00850954|Tobacco
462069|NCT00850954|Nicotine
462070|NCT00850954|Chronic diseases
462071|NCT00850954|Transtheoretical model of change
462072|NCT00850954|TTM
462073|NCT00850941|Registry
462074|NCT00850941|Research Database
462075|NCT00850941|Prostate cancer
462076|NCT00850941|Casodex
462077|NCT00850941|Flutamide
462078|NCT00850941|Goserelin Acetate
462079|NCT00850941|Leuprolide Acetate
462080|NCT00850941|Radiation
462081|NCT00850941|PSA
462082|NCT00850941|Post-prostatectomy
462083|NCT00850941|Radiation Therapy
462084|NCT00850941|Prostate Specific Antigen
462085|NCT00850941|Adenocarcinoma
462086|NCT00850941|Radical Prostatectomy
462087|NCT00850941|Bicalutamide
462088|NCT00850941|Zoladex
462089|NCT00850941|Lupron Depot
462090|NCT00850941|Tissue banking
462091|NCT00850941|Hormones
462092|NCT00850928|Postoperative Cognitive Dysfunction
462093|NCT00850928|MCI
462094|NCT00850928|Mild Cognitive Impairment
462095|NCT00850928|Aβ40
462096|NCT00850928|Aβ42
462097|NCT00850928|Apolipoprotein E
462098|NCT00850928|Inflammatory Markers
462099|NCT00850928|Apolipoprotein E Profile
462100|NCT00850928|Serum Beta Amyloid Profile
462101|NCT00850928|Inflammatory Markers Profile
462102|NCT00850915|tuberculosis
462103|NCT00850915|community IPT
462104|NCT00850915|isoniazid adverse events
462105|NCT00850915|tuberculosis incidence
462106|NCT00850902|ELBW
462107|NCT00850902|Humidity
462108|NCT00850902|BPD
462109|NCT00850889|Aesthetic correction of nasolabial folds
462110|NCT00850863|COPD
462111|NCT00850863|Inflammation
462112|NCT00850863|Smoking
462113|NCT00850863|Susceptibility
462114|NCT00850850|PACU
462115|NCT00850850|Physostigmine
462116|NCT00850850|Recovery
462117|NCT00850850|Postanesthesia Nursing
462118|NCT00850850|Wakefulness
462119|NCT00850850|General anesthesia
462120|NCT00850850|General Anesthetics
462121|NCT00850850|Postoperative Period
462122|NCT00850837|Microbicide
462123|NCT00850837|HIV Seronegativity
462124|NCT00850824|T2DM
462125|NCT00850811|Peplin
462126|NCT00850811|PEP005
462127|NCT00850798|Type 2 diabetes
462128|NCT00850798|Elder patients
462129|NCT00850798|Glycemic control
462130|NCT00850798|Men or women aged ≥80 years at time of randomization. There is no upper age limit.
462131|NCT00850798|Be able to walk by themselves
462132|NCT00850798|They had their first diagnosis of type 2 diabetes mellitus at age 30 years or older.
462133|NCT00850772|Enteral nutrition
462134|NCT00850772|Ovarian cancer
462135|NCT00850772|Peritoneal cancer
462136|NCT00850772|Fallopian tube cancer
462137|NCT00850772|Malnutrition
462138|NCT00850772|Surgery
462139|NCT00850772|Gynecological Cancer
462140|NCT00850772|Suspected advanced epithelial ovarian cancer
462141|NCT00850759|pedestrian safety
462142|NCT00850759|street-crossing ability
462143|NCT00850759|road-crossing
462144|NCT00850759|children
462145|NCT00850759|injury prevention
462146|NCT00850746|QT interval
462147|NCT00850746|Cardiac Repolarization
462148|NCT00850746|Cardiac Conduction
462149|NCT00850746|Healthy Subjects
462150|NCT00850746|YM443 (Z-338, acotiamide hydrochloride)
462151|NCT00850746|Evaluation of QT Interval
462152|NCT00850720|Biological Response Modifiers
462153|NCT00850720|Bypass Surgery
462154|NCT00850720|Cardiology
462155|NCT00850720|Congenital Heart Disease
462156|NCT00850720|Endocrinology
462157|NCT00850720|Hormone Dysfunction
462158|NCT00850720|Hormones
462159|NCT00850720|Neuroendocrinology
462160|NCT00850720|Pediatric Surgery
462161|NCT00850707|AVF
462162|NCT00850707|AVG
462163|NCT00850707|TCC
462164|NCT00850707|inflammation
462165|NCT00850707|monocite senescence
462166|NCT00850694|Vitamin D deficiency
462167|NCT00850694|Obesity
462168|NCT00850694|Insulin resistance
462169|NCT00850694|Glucose tolerance
462170|NCT00850681|Peplin
462171|NCT00850681|PEP005
462172|NCT00850668|Food Allergy
462173|NCT00850668|Peanut Allergy
462174|NCT00850642|Sputum cell counts
462175|NCT00850642|Neutrophils
462176|NCT00850642|Severe Asthma
462177|NCT00850642|ICS
462178|NCT00850642|Inhaled corticosteroids
462179|NCT00850629|weight regain
462180|NCT00850629|endocrine counterregulation
462181|NCT00850616|HIV
462182|NCT00850616|HIV Seronegativity
462183|NCT00850616|Preventive Vaccine
462184|NCT00850603|Menomune® - A/C/Y/W-135
462185|NCT00850603|Meningococcal Infections
462186|NCT00850603|Meningitis
462187|NCT00850564|growth hormone releasing hormone
462188|NCT00850551|Early Intervention
462189|NCT00850551|Pulmonary Exacerbation
462190|NCT00850551|Cystic Fibrosis
462191|NCT00850551|Lung Function
462192|NCT00850551|Spirometry
462193|NCT00850551|Phillips Telemonitor
462194|NCT00850551|Home Spirometry
462195|NCT00850551|PiKo-6
462196|NCT00850551|Home Monitoring
462197|NCT00850538|Bone Marrow Lesion
462198|NCT00850538|BML
462199|NCT00850538|Arthroplasty
462200|NCT00850538|Replacement
462201|NCT00850538|Knee
462202|NCT00850538|Discarded tissue
462203|NCT00850486|women
462204|NCT00850486|ischemic heart disease
462205|NCT00850486|high frequency ECG
462206|NCT00850486|exercise stress testing
462207|NCT00850486|signal processing
462208|NCT00850486|ischemic heart disease in women
462209|NCT00850473|PET
462210|NCT00850473|CT
462211|NCT00850473|Heart Attack
462212|NCT00850473|Coronary Artery disease
462213|NCT00850473|Cardiac Catheterization
462214|NCT00850447|Posttraumatic stress disorder
462215|NCT00850447|Cognition
462216|NCT00850447|Neuropsychological Tests
462217|NCT00849589|Screening
462218|NCT00849589|Brief intervention
462219|NCT00849589|Underage drinking
462220|NCT00849563|predictive genomics
462221|NCT00849563|personalized medicine
462222|NCT00849563|personal genomics
462223|NCT00849563|genetic knowledge
462224|NCT00849563|genetic attitudes
462225|NCT00849563|prevention
462226|NCT00849563|health outcomes
462227|NCT00849563|behavioral
462228|NCT00849550|Advanced Solid Tumors
462229|NCT00849550|Cancer
462230|NCT00849550|Capecitabine
462231|NCT00849550|XELOX
462232|NCT00849550|Neoplasms
462233|NCT00849550|Oxaliplatin
462234|NCT00849550|Bevacizumab
462235|NCT00849550|RAD001
462236|NCT00849537|Triamcinolon
462237|NCT00849537|Cataract
462238|NCT00849537|Diabetic retinopathy
462239|NCT00849537|non-proliferative retinopathy
462240|NCT00849511|Migraine prevention
462241|NCT00849511|Crossover
462242|NCT00849511|Melatonin
462243|NCT00849485|Bioequivalence
462244|NCT00849485|Healthy Subjects
462245|NCT00850421|migraine headache
462246|NCT00850421|Botulinum Toxin Type A
462247|NCT00850421|BOTOX
462248|NCT00850421|BTX-A
462249|NCT00850408|Stroke
462250|NCT00850408|rTMS
462251|NCT00850408|TMS
462252|NCT00850408|Rehabilitation
462253|NCT00850408|Upper Extremity
462254|NCT00850395|HIV-1
462255|NCT00850395|non-interventional
462256|NCT00850395|CCR-5 tropic virus
462257|NCT00850395|therapy experienced patients
462258|NCT00850382|CBF AML
462259|NCT00850382|Dasatinib
462260|NCT00850382|Core Binding Factor (CBF)
462261|NCT00850369|Pulmonary hypertension
462262|NCT00850369|Sickle cell disease
462263|NCT00850356|Bariatric Surgery
462264|NCT00850356|Body Weight
462265|NCT00850356|Health care costs
462266|NCT00850356|Obesity
462267|NCT00850356|Obesity Complications
462268|NCT00850356|Prolonged wait times
462269|NCT00850356|Quality of Life
462270|NCT00850343|Rheumatoid Arthritis
462271|NCT00850343|Certolizumab Pegol
462272|NCT00850343|Cimzia
462273|NCT00850330|Drug interactions
462274|NCT00850330|Drug interaction software
462275|NCT00850330|Older patients
462276|NCT00850330|Hospitalization
462277|NCT00850317|Fanconi Anemia
462278|NCT00850317|FA
462279|NCT00850317|Stem Cell Transplant
462280|NCT00850317|T-Cell
462281|NCT00850304|AML
462282|NCT00850291|Partial duodenopancreatectomy using electrosurgical vessel sealing device
462283|NCT00850278|Brain tumor
462284|NCT00850278|[18F]FLT
462285|NCT00850278|[11C]MET
462286|NCT00850278|TEP-imaging
462287|NCT00850278|tumor cell proliferation
462288|NCT00850265|Asthma
462289|NCT00850265|Formoterol
462290|NCT00850265|Beclomethasone
462291|NCT00850265|Extrafine formulation
462292|NCT00850265|Spacer
462293|NCT00850265|Moderate
462294|NCT00850265|Severe
462295|NCT00850265|Stable
462296|NCT00850252|Lifeline
462297|NCT00850252|Tissue engineered blood vessel
462298|NCT00850252|A-V shunt
462299|NCT00850239|diabetes
462300|NCT00850239|DPP4 inhibitor
462301|NCT00850239|dutogliptin
462302|NCT00850226|test anxiety
462303|NCT00850200|Hodgkin Lymphoma, Proton Radiation
462304|NCT00850187|Knee cartilage diseases
462305|NCT00850174|Bioequivalence
462306|NCT00850174|Healthy Subjects
462307|NCT00850161|Type 1 Diabetes
462308|NCT00850161|Nasal Insulin
462309|NCT00850161|Insulin Deficiency
462310|NCT00850161|Insulin-Dependent
462311|NCT00850148|Anwar
462312|NCT00850148|Melles
462313|NCT00850148|Keratoconus
462314|NCT00850096|Phase 2 Study for novel insulin delivery of type 2 diabetes
462315|NCT00850083|Fever
462316|NCT00850083|Children
462317|NCT00850070|autism
462318|NCT00850044|FIH
462319|NCT00850044|SAD
462320|NCT00850031|Presbyopia
462321|NCT00850031|Accommodation
462322|NCT00850031|Near visual acuity
462323|NCT00850031|LASIK
462324|NCT00850018|Sickle Cell Disease
462325|NCT00850018|Sickle Cell Anemia
462326|NCT00850018|Hemoglobin SS
462327|NCT00850018|Hemoglobin SB0
462328|NCT00850005|neuropathic pain
462329|NCT00850005|resistant
462330|NCT00850005|neuroinflammation
462331|NCT00850005|neuroinflammatory markers
462332|NCT00850005|Neuropathic pain that has not responded to standard therapy
462333|NCT00849992|Actinic cheilitis
462334|NCT00849992|Imiquimod 5%
462335|NCT00849992|Photodynamic therapy
462336|NCT00849979|Colorectal
462337|NCT00849979|Gastric
462338|NCT00849979|Gastrointestinal
462339|NCT00849979|GI
462340|NCT00849979|Liver
462341|NCT00849979|Pancreas
462342|NCT00849979|Gastrointestinal Cancers
462343|NCT00849979|Gastro-Intestinal Chemotherapy
462344|NCT00849979|M.D. Anderson Symptom Inventory
462345|NCT00849979|MDASI-GI
462346|NCT00849979|Medical Oncology
462347|NCT00849966|Celebrex
462348|NCT00849966|celecoxib
462349|NCT00849966|Cyclooxygenase Inhibitors
462350|NCT00849966|Anti-Inflammatory Agents Non-Steroidal
462351|NCT00849966|Adverse drug events
462352|NCT00849966|quality of life
462353|NCT00849966|Pain Postoperative
462354|NCT00849966|Tonsillectomy
462355|NCT00849966|Adenotonsillectomy
462356|NCT00849966|Otologic Surgical Procedures
462357|NCT00849940|Spectroscopy
462358|NCT00849940|Near infrared
462359|NCT00849940|Oximetry
462360|NCT00849940|Hypoxemia
462361|NCT00849940|Tissue oxygenation
462362|NCT00849940|Pediatric
462363|NCT00849927|shoulder instability
462364|NCT00849927|labral lesions
462365|NCT00849927|arthroscopic labral repair
462366|NCT00849927|SLAP
462367|NCT00849927|triple labrum
462368|NCT00849927|circumferential labrum
462369|NCT00849927|Pan-labral lesion
462370|NCT00849888|Thymus Transplantation
462371|NCT00849888|DiGeorge Anomaly
462372|NCT00849888|Athymia
462373|NCT00849888|Low T cell numbers
462374|NCT00849888|Immunoreconstitution
462375|NCT00849888|Immunodeficiency
462376|NCT00849875|ASCI
462377|NCT00849875|Malignant melanoma
462378|NCT00849875|Dacarbazine
462379|NCT00849875|Cancer immunotherapeutic
462380|NCT00849875|MAGE-A3
462381|NCT00849862|Bioequivalence
462382|NCT00849862|Healthy Subjects
462383|NCT00849849|postgestational diabetes
462384|NCT00849849|diabetes mellitus
462385|NCT00849849|OGTT
462386|NCT00849849|insulin sensitivity
462387|NCT00849849|insulin secretion
462388|NCT00849823|African American
462389|NCT00849823|Men
462390|NCT00849823|Condoms
462391|NCT00849823|Randomization
462392|NCT00849823|Brief Intervention
462393|NCT00849823|HIV
462394|NCT00849823|HIV Seronegativity
462395|NCT00849810|Hypertension
462396|NCT00849810|Beta-blockers
462397|NCT00849810|Ambulatory blood pressure
462398|NCT00849810|Basal metabolic rate
462399|NCT00849810|Quality of life
462400|NCT00849797|Bioequivalence
462401|NCT00849797|Healthy Subjects
462402|NCT00849771|Displaced Scapula Fracture
462403|NCT00849771|Scapula Fracture
462404|NCT00849771|Extraarticular Scapula Fractures
462405|NCT00849771|Clavicle
462406|NCT00849758|breast cancer
462407|NCT00849758|elderly
462408|NCT00849758|biomarker
462409|NCT00849745|severe autoimmune diseases
462410|NCT00849745|allogeneic stem cell transplant
462411|NCT00849732|HIV Seronegativity
462412|NCT00849732|Preventive Vaccine
462413|NCT00849719|visual analog scale
462414|NCT00849719|patient controlled analgesia
462415|NCT00849719|post operative pain
462416|NCT00849719|rescue drug
462417|NCT00849706|sleep deprivation
462418|NCT00849706|workload
462419|NCT00849706|increased workload
462420|NCT00849680|HIV Seronegativity
462421|NCT00849680|Preventive Vaccine
462422|NCT00849667|ovarian cancer
462423|NCT00849667|relapsed ovarian cancer
462424|NCT00849667|Platinum-sensitive Ovarian Cancer
462425|NCT00849654|PCI-32765
462426|NCT00849654|Lymphoma
462427|NCT00849654|Lymphoma, Non-Hodgkin
462428|NCT00849654|Lymphoma, B-Cell
462429|NCT00849654|Burkitt Lymphoma
462430|NCT00849654|Lymphoma, B-Cell, Marginal Zone
462431|NCT00849654|Lymphoma, B-Cell, Diffuse
462432|NCT00849654|Lymphoma, Follicular
462433|NCT00849654|Lymphoma, Mantle Cell
462434|NCT00849654|Leukemia, Lymphoid
462435|NCT00849654|Leukemia, B-Cell
462436|NCT00849654|Waldenstrom macroglobulinemia
462437|NCT00849654|Bruton's Tyrosine Kinase
462438|NCT00849641|decompensation
462439|NCT00849641|septic shock
462440|NCT00849641|tissue oxygenation
462441|NCT00849641|near infrared spectroscopy
462442|NCT00849628|Aged
462443|NCT00849628|Polypharmacy
462444|NCT00849628|Adverse effects
462445|NCT00849628|Nursing homes
462446|NCT00849472|Neoadjuvant Breast Cancer
462447|NCT00849472|Pazopanib (GW786034)
462448|NCT00849472|NSABP Foundation, Inc.
462449|NCT00849472|cyclophosphamide
462450|NCT00849472|Paclitaxel
462451|NCT00849472|Doxorubicin
462452|NCT00849459|recurrent breast cancer
462453|NCT00849459|stage IV breast cancer
462454|NCT00849433|Inflammation
462455|NCT00849433|epithelial
462456|NCT00849433|integrity
462457|NCT00849433|ECIS
462458|NCT00849394|bevacizumab
462459|NCT00849394|proteinuria
462460|NCT00849381|HPV
462461|NCT00849381|HPV vaccine
462462|NCT00849381|papillomavirus
462463|NCT00849381|cervical cancer
462464|NCT00849381|human papillomavirus
462465|NCT00849329|lapatinib (GW572016), subject, pharmacokinetic, esomeprazole, proton-pump inhibitor, drug interaction, Phase 1
462466|NCT00849303|stroke
462467|NCT00849303|rehabilitation
462468|NCT00849303|gait
462469|NCT00849303|timing
462470|NCT00849303|transcranial magnetic stimulation
462471|NCT00849277|Respiratory Tract Infections
462472|NCT00849277|Influenza, Human
462473|NCT00849277|Probiotics
462474|NCT00849264|hepatocellular carcinoma
462475|NCT00849264|portal vein tumor thrombus
462476|NCT00849264|surgical comprehensive treatment
462477|NCT00849212|Seizures
462478|NCT00849212|epilepsy
462479|NCT00849199|screening
462480|NCT00849199|early detection
462481|NCT00849199|prevention
462482|NCT00849199|cancer
462483|NCT00849199|high risk
462484|NCT00849199|ovarian cancer
462485|NCT00849199|breast cancer
462486|NCT00849186|stage I renal cell cancer
462487|NCT00849186|stage II renal cell cancer
462488|NCT00849186|stage III renal cell cancer
462489|NCT00849186|stage IV renal cell cancer
462490|NCT00849173|Endometriosis
462491|NCT00849173|Infertility
462492|NCT00849173|Tubal Ligation
462493|NCT00849173|Chronic Pelvic Pain
462494|NCT00849173|Quality of Life
462495|NCT00849160|Treatment Experienced
462496|NCT00849147|Acute Lymphoblastic Leukemia/Lymphoma
462497|NCT00849147|Acute Myelogenous Leukemia
462498|NCT00849147|Mantel-Cell Lymphoma
462499|NCT00849147|Hematopoietic Transplant
462500|NCT00849147|Haplo-Identical Transplant
462501|NCT00849147|Non-Myeloablative Transplant
462502|NCT00849134|First-Time-in-Human
462503|NCT00849134|Tolerability
462504|NCT00849134|Pharmacodynamics
462505|NCT00849134|Safety
462506|NCT00849134|Food Effect
462507|NCT00849134|Pharmacokinetics
462508|NCT00849134|Healthy Volunteers
462509|NCT00849121|Vaccine
462510|NCT00849121|pTVG-HP
462511|NCT00849121|Prostate Cancer
462512|NCT00849121|Castrate Resistant
462513|NCT00849108|Myocardial Perfusion
462514|NCT00849108|PET imaging
462515|NCT00849108|SPECT imaging
462516|NCT00849108|Coronary artery disease
462517|NCT00849108|Subjects that are male and nonpregnant female patients
462518|NCT00849108|presenting with reversible ischemia as characterized by a
462519|NCT00849108|rest/stress SPECT imaging study using
462520|NCT00849108|Technetium(99mTc)-labeled tracers
462521|NCT00849095|Adult
462522|NCT00849095|Asthma
462523|NCT00849095|Bronchodilator Agents
462524|NCT00849095|Budesonide
462525|NCT00849095|Double-Blind Method
462526|NCT00849095|Drug Therapy, Combination
462527|NCT00849095|Ethanolamines
462528|NCT00849095|Female
462529|NCT00849095|Forced Expiratory Volume
462530|NCT00849095|Humans
462531|NCT00849095|Male
462532|NCT00849095|Terbutaline
462533|NCT00849082|stage IIB prostate cancer
462534|NCT00849082|stage IIA prostate cancer
462535|NCT00849082|stage III prostate cancer
462536|NCT00849082|stage IV prostate cancer
462537|NCT00849069|Streptococcus pneumoniae
462538|NCT00849069|Vaccine
462539|NCT00849069|Non-typable Haemophilus influenza
462540|NCT00849069|Adults and Elderly Adults
462541|NCT00849056|diabetes
462542|NCT00849043|obstructive sleep apnea hypopnea
462543|NCT00849043|OSA
462544|NCT00849043|OSAH
462545|NCT00849017|placebo
462546|NCT00849017|albiglutide
462547|NCT00849017|monotherapy
462548|NCT00849017|diabetes
462549|NCT00849004|keloid
462550|NCT00849004|silicone sheet
462551|NCT00849004|silicone gel
462552|NCT00849004|paper tape
462553|NCT00849004|steri-strip
462554|NCT00848991|precedex
462555|NCT00848991|propofol
462556|NCT00848978|Functional capacity
462557|NCT00848978|Quality of life
462558|NCT00848978|Depression
462559|NCT00848978|Falls
462560|NCT00848978|Body composition
462561|NCT00848978|Physical activity
462562|NCT00848965|fluticasone propionate
462563|NCT00848965|Vienna Challenge Chamber
462564|NCT00848965|glucocorticosteroids
462565|NCT00848965|allergic rhinitis
462566|NCT00848939|systemic sclerosis
462567|NCT00848939|scleroderma
462568|NCT00848939|pharmacokinetics
462569|NCT00848939|treprostinil diethanolamine
462570|NCT00848926|Antigens, CD30
462571|NCT00848926|Antibody-Drug Conjugate
462572|NCT00848926|Antibodies, Monoclonal
462573|NCT00848926|Disease, Hodgkin
462574|NCT00848926|Hematologic Diseases
462575|NCT00848926|Lymphoma
462576|NCT00848926|monomethylauristatin E
462577|NCT00848926|Drug Therapy
462578|NCT00848926|Immunotherapy
462579|NCT00848913|strength deficit
462580|NCT00848913|physical function
462581|NCT00848887|Influenza
462582|NCT00848887|Flu
462583|NCT00848887|Vaccine
462584|NCT00848887|Adjuvant
462585|NCT00848861|propofol sedation
462586|NCT00848861|colonoscopy
462587|NCT00848861|recovery time
462588|NCT00848861|recovery time after sedation for colonoscopy
462589|NCT00848848|Influenza
462590|NCT00848848|Flu
462591|NCT00848848|Vaccine
462592|NCT00848848|Intradermal
462593|NCT00848848|Adjuvant
462594|NCT00848835|defibrillator
462595|NCT00848822|Pediatrics
462596|NCT00848822|Sleep
462597|NCT00848822|Glucose regulation
462598|NCT00848822|Type 1 Diabetes Mellitus
462599|NCT00848809|Acute kidney injury
462600|NCT00848809|Vancomycin therapy
462601|NCT00848809|Slow-low efficiency daily dialysis
462602|NCT00848809|Intermittent Hemodialysis
462603|NCT00848809|Kidney
462604|NCT00848809|Vancomycin
462605|NCT00848809|Hemofiltration
462606|NCT00848796|Heparin Leo
462607|NCT00848796|Hepalean
462608|NCT00848796|CPB Cardiopuilmonary Bypass
462609|NCT00848796|CABG Coronary Artery Bypass Grafting
462610|NCT00848796|Anticoagulation efficacy
462611|NCT00848783|gastric cancer
462612|NCT00848783|gastroesophageal junction
462613|NCT00848783|stomach cancer
462614|NCT00848783|intraperitoneal infusion
462615|NCT00848783|capecitabine
462616|NCT00848783|irinotecan
462617|NCT00848783|cisplatin
462618|NCT00848783|floxuridine
462619|NCT00848770|Stroke, Acute
462620|NCT00848770|Systolic Pressure of Blood
462621|NCT00848757|Diabetes
462622|NCT00848757|Lifestyle Intervention
462623|NCT00848744|Acne
462624|NCT00848731|pulmonary hypertension
462625|NCT00848731|venous thromboembolism
462626|NCT00848718|Tumors, cancer
462627|NCT00848705|type 1 diabetes, adolescent, self-management
462628|NCT00848692|Chronic Fatigue Syndrome
462629|NCT00848692|CFS
462630|NCT00848692|Myalgic Encephalomyelitis
462631|NCT00848692|Rituximab
462632|NCT00848692|B-lymphocyte depletion
462633|NCT00848692|B-cell depletion
462634|NCT00848679|Pre-eclampsia
462635|NCT00848679|Pregnancy
462636|NCT00848679|Uteroplacental blood flow
462637|NCT00848679|Epidural
462638|NCT00848679|Anesthesia
462639|NCT00848627|Bladder cancer
462640|NCT00848627|Smokers
462641|NCT00848627|Hematuria
462642|NCT00848601|SGI-1776
462643|NCT00848601|PIM
462644|NCT00848601|Hormone & Docetaxel refractory Prostate Cancer
462645|NCT00848601|Refractory non-Hodgkin's Lymphoma
462646|NCT00848588|agonal breathing
462647|NCT00848588|cardiac arrest
462648|NCT00848588|9-1-1 call taker
462649|NCT00848588|survey
462650|NCT00848562|sudden cardiac death
462651|NCT00848549|Epilepsy
462652|NCT00848549|Monotherapy
462653|NCT00848536|OAG
462654|NCT00848536|OHT
462655|NCT00848523|LBH859
462656|NCT00848523|Panobinostat
462657|NCT00848523|GBM
462658|NCT00848523|Glioma
462659|NCT00848523|Glioblastoma
462660|NCT00848523|Astrocytoma
462661|NCT00848523|oligodendroglioma
462662|NCT00848523|oligoastrocytoma
462663|NCT00848523|gliosarcoma
462664|NCT00848523|anaplastic
462793|NCT00847938|train of four
462665|NCT00848497|hormone replacement therapy
462666|NCT00848497|radical prostatectomy
462667|NCT00848497|erectile dysfunctions
462668|NCT00848497|scheduled for removal of prostate gland
462669|NCT00848471|Indirect calorimeter
462670|NCT00848471|Validation
462671|NCT00848471|Energy expenditure
462672|NCT00848471|Healthy volunteers
462673|NCT00848458|Azelaic Acid
462674|NCT00848458|Iontophoresis
462675|NCT00848432|Schizophrenia
462676|NCT00848432|Risperidone
462677|NCT00848432|Maintenance treatment
462678|NCT00848432|Relapse
462679|NCT00848419|Epidural
462680|NCT00848419|Analgesia
462681|NCT00848419|Methadone
462682|NCT00848419|Morphine
462683|NCT00848419|Pharmacokinetic-pharmacodynamic
462684|NCT00848419|Experimental pain - analgesic response
462685|NCT00848406|bronchial
462686|NCT00848406|COPD
462687|NCT00848406|Asthma
462688|NCT00848406|sputum
462689|NCT00848406|biopsies
462690|NCT00848393|pediatric cardiac surgery
462691|NCT00848393|stress response
462692|NCT00848393|early extubation
462693|NCT00848393|Dexmedetomidine
462694|NCT00848393|TOF
462695|NCT00848393|VSD
462696|NCT00848393|AVSD
462697|NCT00848380|Hypertension
462698|NCT00848380|hyperlipidemia
462699|NCT00848354|enbrel
462700|NCT00848354|moderate arthritis
462701|NCT00848354|severe arthritis
462702|NCT00848354|rheumatoid arthritis
462703|NCT00848328|recurrent small lymphocytic lymphoma
462704|NCT00848328|recurrent grade 1 follicular lymphoma
462705|NCT00848328|recurrent grade 2 follicular lymphoma
462706|NCT00848328|recurrent grade 3 follicular lymphoma
462707|NCT00848315|cognitive behavioral intervention
462708|NCT00848315|low literate/illiterate Hispanic patients
462709|NCT00848302|peripheral vascular disease
462710|NCT00848302|endothelial dysfunction
462711|NCT00848302|intravascular ultrasound
462712|NCT00848302|L-Arginine
462713|NCT00848289|Bladder cancer
462714|NCT00848289|Genetic susceptibility
462715|NCT00848289|Increased Risk
462716|NCT00848276|PCSK9
462717|NCT00848276|Lipoprotein metabolism
462718|NCT00848276|testosterone
462719|NCT00848276|estradiol
462720|NCT00848263|Fracture
462721|NCT00848263|Radius
462722|NCT00848263|Surgery
462723|NCT00848263|Osteosynthesis
462724|NCT00848250|Cardiopulmonary Bypass
462725|NCT00848250|ACE inhibitor
462726|NCT00848250|Pediatrics
462727|NCT00848237|Barrett's Esophagus
462728|NCT00848237|Dysplasia
462729|NCT00848237|Intestinal Metaplasia
462730|NCT00848224|coronary heart disease
462731|NCT00848224|lipid lowering medication
462732|NCT00848224|NCEP guidelines
462733|NCT00848211|HIV
462734|NCT00848211|vaccine
462735|NCT00848211|lipopeptide
462736|NCT00848211|Tat
462737|NCT00848211|TUTI-16
462738|NCT00848211|THYMON
462739|NCT00848211|Treatment Naive
462740|NCT00848198|Dry Eye Disease
462741|NCT00848198|Dry Eye Syndrome
462742|NCT00848198|Dry Eye
462743|NCT00848185|VEGF
462744|NCT00848185|Trigger
462745|NCT00848185|OHSS
462746|NCT00848172|Essential Tremor
462747|NCT00848172|Octanol
462748|NCT00848172|Octanoic Acid
462749|NCT00848172|Ethanol
462750|NCT00848172|Accelerometry
462751|NCT00848159|Osteoporosis
462752|NCT00848159|kyphosis
462753|NCT00848159|photogrammetry
462754|NCT00848107|systemic sclerosis
462755|NCT00848107|scleroderma
462756|NCT00848107|digital ulcers
462757|NCT00848107|vasculopathy
462758|NCT00848094|hepatocellular carcinoma
462759|NCT00848094|radiation therapy
462760|NCT00848094|3-dimensional conformal radiation therapy (3-DCRT)
462761|NCT00848094|intensity modulated radiation therapy (IMRT)
462762|NCT00848094|active breathing control
462763|NCT00848081|Prostate
462764|NCT00848081|BPH
462765|NCT00848081|Benign Prostatic Hyperplasia
462766|NCT00848081|BPH-LUTS
462767|NCT00848081|LUTS
462768|NCT00848081|Phosphodiesterase Inhibitors
462769|NCT00848081|tadalafil
462770|NCT00848081|alpha blockers
462771|NCT00848068|lipid layer thickness
462772|NCT00848042|cancer
462773|NCT00848042|head and neck
462774|NCT00848042|laser
462775|NCT00848042|ablation
462776|NCT00848029|Influenza vaccine
462777|NCT00848003|Probiotics
462778|NCT00848003|BB-12
462779|NCT00848003|Yogurt
462780|NCT00848003|Antibiotics
462781|NCT00847990|Down syndrome
462782|NCT00847990|aneuploidy
462783|NCT00847990|chromosome abnormality
462784|NCT00847990|amniocentesis
462785|NCT00847990|chorionic villus sampling
462786|NCT00847990|Laboratory Developed Test (LDT)
462787|NCT00847977|Acute head trauma
462788|NCT00847964|Heart Failure
462789|NCT00847951|renal
462790|NCT00847951|neonates
462791|NCT00847938|neostigmine
462792|NCT00847938|neuromuscular blocking agent
462794|NCT00847938|anesthesia
462795|NCT00847912|NMSC
462796|NCT00847912|nonmelanoma skin cancer
462797|NCT00847912|topical 5-FU 5% cream
462798|NCT00847912|Neoplasms
462799|NCT00847912|Antineoplastic Agents
462800|NCT00847912|Therapeutic Uses
462801|NCT00847912|Dermatologic Agents
462802|NCT00847912|Neoplasms by Site
462803|NCT00847912|carcinoma, basal cell
462804|NCT00847912|carcinoma, squamous cell
462805|NCT00847899|hypertension
462806|NCT00847899|impaired glucose tolerance
462807|NCT00847899|s-EH enzyme inhibition
462808|NCT00847899|pre-diabetes
462809|NCT00847873|intimate partner violence
462810|NCT00847873|domestic violence
462811|NCT00847873|alcohol abuse
462812|NCT00847873|alcohol dependence
462813|NCT00847873|drug abuse
462814|NCT00847873|drug dependence
462815|NCT00847873|addiction
462816|NCT00847860|cognition
462817|NCT00847847|ALS
462818|NCT00847847|Motor neuron
462819|NCT00847847|Pathophysiology
462820|NCT00847847|Neuromuscular junction
462821|NCT00847847|Neuromuscular transmission
462822|NCT00847847|Microelectrodes
462823|NCT00847808|Esophageal Reflux
462824|NCT00847808|Gastro-Esophageal Reflux
462825|NCT00847808|Gastroesophageal Reflux Disease
462826|NCT00847808|GERD
462827|NCT00847808|Regurgitation, Gastric
462828|NCT00847808|Heartburn
462829|NCT00847808|Drug Therapy
462830|NCT00847769|Ankle Sprain
462831|NCT00847756|Otitis media
462832|NCT00847756|demography
462833|NCT00847756|Streptococcus pneumoniae
462834|NCT00847756|Haemophilus influenzae
462835|NCT00847756|Moraxella catarrhalis
462836|NCT00847756|rhinovirus
462837|NCT00847756|children, 0-5 years of age
462838|NCT00847756|diagnosed rAOM, COME or CSOM by an otorhinolaryngologist
462839|NCT00847756|primary and secondary hospital Nijmegen, the Netherlands
462840|NCT00847743|oxidative stress
462841|NCT00847743|aging
462842|NCT00847743|ischemia-reperfusion
462843|NCT00847730|Ease of dressing application, dressing conformability and ease of dressing removal on diabetic foot ulcers using the ActiVAC therapy
462844|NCT00847717|Oral
462845|NCT00847717|cancer
462846|NCT00847717|surgery
462847|NCT00847717|neck dissection
462848|NCT00847717|spinal accessory nerve
462849|NCT00847704|Stroke
462850|NCT00847704|Rehabilitation
462851|NCT00847704|Robotics
462852|NCT00847691|economic evaluation
462853|NCT00847691|diagnostics
462854|NCT00847691|sarcoma
462855|NCT00847678|Cryptococcal Meningitis
462856|NCT00847665|Pressure ulcers
462857|NCT00847665|Repositioning
462858|NCT00847665|Prevention
462859|NCT00847665|Mechanical Ventilation
462860|NCT00847665|Critical care
462861|NCT00847639|Multiple Myeloma
462862|NCT00847639|lenalidomide
462863|NCT00847639|Revlimid
462864|NCT00847639|Allogeneic Hematopoietic Cell Transplantation
462865|NCT00847626|Hypertensive
462866|NCT00847626|Blood Pressure, High
462867|NCT00847626|Vascular Disease
462868|NCT00847626|Cardiovascular Disease
462869|NCT00847626|Drug Therapy
462870|NCT00847613|double-blind placebo-controlled investigational drug oral therapy safety and efficacy hand and feet x-rays
462871|NCT00847600|Schizophrenia
462872|NCT00847600|Neurosteroids
462873|NCT00847600|Pregnenolone
462874|NCT00847600|Augmentation
462875|NCT00847587|Contraceptive
462876|NCT00847587|Implant
462877|NCT00847587|Postpartum period
462878|NCT00847587|etonogestrel-releasing
462879|NCT00847587|lactogenesis
462880|NCT00847587|Breastfeeding
462881|NCT00847574|Weight loss
462882|NCT00847574|Weight maintenance
462883|NCT00847574|Weight management
462884|NCT00847574|Cardiovascular disease risk
462885|NCT00847574|Dietary Guidelines
462886|NCT00847574|Diet and exercise
462887|NCT00847574|Prevention
462888|NCT00847561|Anxiety
462889|NCT00847548|intimate partner violence
462890|NCT00847548|domestic violence
462891|NCT00847548|substance abuse
462892|NCT00847548|alcohol abuse
462893|NCT00847548|drug abuse
462894|NCT00847548|addiction
462895|NCT00847522|melanoma
462896|NCT00847522|skin cancer
462897|NCT00847522|lymph node
462898|NCT00847522|sentinel lymph node
462899|NCT00847522|malignant melanoma
462900|NCT00847522|mapping
462901|NCT00847509|lung cancer
462902|NCT00847509|head and neck cancer
462903|NCT00847509|radiotherapy
462904|NCT00847509|chemoradiotherapy
462905|NCT00847509|radiation
462906|NCT00847509|chemoradiation
462907|NCT00847509|FLT
462908|NCT00847509|[F-18]FLT
462909|NCT00847509|FDG
462910|NCT00847509|[F-18]FDG
462911|NCT00847496|Partial Thickness burn
462912|NCT00847496|Biological Dressing
462913|NCT00847483|glaucoma
462914|NCT00847483|ocular hypertension
462915|NCT00847483|latanoprost
462916|NCT00847483|travoprost
462917|NCT00847483|bimatoprost
462918|NCT00847470|Dental caries
462919|NCT00847470|Assessments
462920|NCT00847470|dental materials
462921|NCT00847457|Exercise
462922|NCT00847457|Stretching
462923|NCT00847457|Adolescents
462924|NCT00847431|Subthalamic Nucleus
462925|NCT00847431|Deep Brain Stimulation
462926|NCT00847431|Depression
462927|NCT00847431|Anxiety
462928|NCT00847431|Parkinson's Disease
462929|NCT00847418|pharmacokinetics
462930|NCT00847418|ketamine
462931|NCT00847418|Anesthetics, Dissociative
462932|NCT00847405|Bioequivalence
462933|NCT00847405|Healthy Subjects
462934|NCT00847392|Urethral catheterization
462935|NCT00847392|Emergency Department
462936|NCT00847392|Ultrasound
462937|NCT00847392|Urinary tract infection
462938|NCT00847392|Pediatric
462939|NCT00847379|Duchenne muscular dystrophy
462940|NCT00847379|Becker muscular dystrophy
462941|NCT00847379|Nonsense mutation
462942|NCT00847379|Premature stop codon
462943|NCT00847379|DMD
462944|NCT00847379|BMD
462945|NCT00847379|Ataluren
462946|NCT00847379|PTC124
462947|NCT00847366|Perifosine
462948|NCT00847353|high frequency ECG
462949|NCT00847353|normal values
462950|NCT00847353|asymptomatic
462951|NCT00847353|obese
462952|NCT00847340|Genital warts
462953|NCT00847340|HPV typing
462954|NCT00847340|HPV infections
462955|NCT00847340|Condyloma Acuminata
462956|NCT00847327|Type 1 Diabetes
462957|NCT00847327|Parenting
462958|NCT00847327|Young Children
462959|NCT00847314|Hypogonadism
462960|NCT00847314|Abdominal obesity
462961|NCT00847314|Physical exercise
462962|NCT00847314|Testosterone
462963|NCT00847288|Heart Failure
462964|NCT00847288|Implantable Cardioverter Defibrillator (ICD)
462965|NCT00847288|Cardiac Resynchronization Therapy with Defibrillator (CRT D)
462966|NCT00847288|OptiVol®
462967|NCT00847275|Elderly patients
462968|NCT00847275|renal insufficiency
462969|NCT00847275|gerontologic evaluation
462970|NCT00847262|Hypertension
462971|NCT00847262|Abdominal obesity
462972|NCT00847262|Diabetes
462973|NCT00847262|Treatment
462974|NCT00847249|safety
462975|NCT00847249|tolerability
462976|NCT00847249|healthy
462977|NCT00847249|inhalation
462978|NCT00847249|Healthy males
462979|NCT00847236|Polymyalgia Rheumatica
462980|NCT00847236|Rheumatoid Arthritis
462981|NCT00847236|Rheumatic Disease
462982|NCT00847236|PMR
462983|NCT00847223|Mantle cell lymphoma
462984|NCT00847223|Lymphoma
462985|NCT00847223|relapsed, refractory or progressive MCL
462986|NCT00847223|Mantle cell lymphoma (relapsed, refractory or progressive)
462987|NCT00847210|Esophageal Reflux
462988|NCT00847210|Gastro-Esophageal Reflux
462989|NCT00847210|Gastroesophageal Reflux Disease
462990|NCT00847210|GERD
462991|NCT00847210|Regurgitation, Gastric
462992|NCT00847210|Heartburn
462993|NCT00847210|Drug Therapy
462994|NCT00847210|Adolescent
462995|NCT00847184|nasal intubation
462996|NCT00847184|Aitraq
462997|NCT00847184|difficult intubation
462998|NCT00847171|male breast cancer
462999|NCT00847171|stage II breast cancer
463000|NCT00847171|stage IIIA breast cancer
463001|NCT00847171|stage IIIB breast cancer
463002|NCT00847171|stage IIIC breast cancer
463003|NCT00847171|stage IV breast cancer
463004|NCT00847171|HER2-positive breast cancer
463005|NCT00847158|POAG
463006|NCT00847158|Combination glaucoma & cataract procedure
463007|NCT00847158|trabecular micro-bypass stent
463008|NCT00847158|iStent
463009|NCT00847145|toddler
463010|NCT00847145|Meningococcal disease
463011|NCT00847145|prevention
463012|NCT00847145|vaccination
463013|NCT00847132|Collaborative Care
463014|NCT00847119|rectum
463015|NCT00847119|adenocarcinoma
463016|NCT00847119|neoadjuvant
463017|NCT00847119|bevacizumab
463018|NCT00847119|capecitabine
463019|NCT00847119|radiotherapy
463020|NCT00847119|locally
463021|NCT00847119|advanced
463022|NCT00847119|resectable
463023|NCT00847119|resectable locally advanced adenocarcinoma of the rectum
463024|NCT00847119|xeberecto
463025|NCT00847106|Dendritic Cells
463026|NCT00847106|Regulatory T cells
463027|NCT00847106|CD25
463028|NCT00847106|Melanoma
463029|NCT00847106|Immunotherapy
463030|NCT00847106|Daclizumab
463031|NCT00847106|Stage IV Melanoma
463032|NCT00847080|Reactive hypoglycemia
463033|NCT00847080|Sitagliptin
463034|NCT00847080|Glucagon-Like Peptide 1
463035|NCT00847080|Incretins
463036|NCT00847080|Prediabetes
463037|NCT00847054|Solid Tumor
463038|NCT00847054|Endosialin
463039|NCT00845598|Allergic Rhinitis
463040|NCT00845585|arterial reconstruction
463041|NCT00845585|bypass
463042|NCT00845585|below knee
463043|NCT00845585|PZFE
463044|NCT00845585|Ovine graft
463045|NCT00845585|Omniflow II
463046|NCT00845585|graft patency
463047|NCT00845572|Schizophrenia
463048|NCT00845572|Schizoaffective
463049|NCT00845572|Risperdal Consta
463050|NCT00845572|Medication Adherence
463051|NCT00845572|Antipsychotic
463052|NCT00845559|Childhood Obesity
463053|NCT00845559|Insulin resistance
463054|NCT00845559|Impaired Glucose Tolerance
463055|NCT00845559|Cardiovascular Disease
463056|NCT00845559|Type 2 Diabetes Mellitus
463057|NCT00845559|Continuous Glucose Monitoring (CGMS)
463058|NCT00845559|Exenatide
463059|NCT00845559|Oral Glucose Tolerance Test
463060|NCT00845546|Bioequivalence 10 mg Loratadine 240 mg Pseudoephedrine Sulfate Extended Release Tablets
463061|NCT00845494|Medication history
463062|NCT00845494|medication errors
463063|NCT00845494|Reduction of admission medication history errors
463064|NCT00845468|coronary flow reserve
463065|NCT00845468|diabetes mellitus
463066|NCT00845468|acute myocardial infarction
463067|NCT00845468|transthoracic echocardiography
463068|NCT00845442|Bilateral vocal cord paralyses
463069|NCT00845442|Implanted laryngeal stimulator
463070|NCT00845442|vocal cord opening
463071|NCT00845442|pulmonary function tests
463072|NCT00847028|Newborn
463073|NCT00847028|Pain
463074|NCT00847028|glucose solution
463075|NCT00847028|venipuncture
463076|NCT00847028|non-pharmacologic pain relief.
463077|NCT00847015|Bladder
463078|NCT00847015|Urinary
463079|NCT00847015|CISPLATIN
463080|NCT00847015|GEMCITABINE
463081|NCT00847015|SU011248 (Sunitinib Malate)
463082|NCT00847015|08-159
463083|NCT00847002|Flexitouch system
463084|NCT00847002|FarrowWrap
463085|NCT00847002|venous stasis ulcer
463086|NCT00846989|glaucoma,
463087|NCT00846989|primary open-angle glaucoma (POAG),
463088|NCT00846989|ocular hypertension (OH),
463089|NCT00846989|intraocular pressure (IOP)
463090|NCT00846976|Safety
463091|NCT00846963|parenteral nutrition associated cholestasis in neonates
463092|NCT00846963|parenteral nutrition induced cholestasis in preterms
463093|NCT00846963|Bile duct obstruction
463094|NCT00846963|biliary stasis
463095|NCT00846950|H1-antagonist
463096|NCT00846950|Event Related Potentials
463097|NCT00846950|Memory
463098|NCT00846950|Information processing
463099|NCT00846950|The effects of an H1 antagonist (dexchlorpheniramine) on human cognition
463100|NCT00846937|Cholesterol
463101|NCT00846937|Plant stanolester
463102|NCT00846937|Beverage
463103|NCT00846937|Ileostoma
463104|NCT00846937|Serum cholesterol level
463105|NCT00846937|serum LDL-cholesterol level
463106|NCT00846937|Intestinal cholesterol absorption efficiency
463107|NCT00846924|Stroke
463108|NCT00846924|Transient Ischemic Attack
463109|NCT00846924|Atrial fibrillation
463110|NCT00846924|Atrial flutter
463111|NCT00846911|Acute Exacerbation of Chronic Bronchitis (AECB) patients
463112|NCT00846898|blood sugar
463113|NCT00846898|cholesterol
463114|NCT00846898|cinnamon
463115|NCT00846898|HbA1c
463116|NCT00846885|Bioequivalence
463117|NCT00846885|Healthy Subjects
463118|NCT00846872|GHRP-3
463119|NCT00846872|Insulin Resistance
463120|NCT00846872|Markers of inflammation
463121|NCT00846872|Endothelial Dysfunction
463122|NCT00846872|Flow Mediated Dilation
463123|NCT00846872|GH/IGF-1 axis
463124|NCT00846872|Post menopausal
463125|NCT00846859|alcohol dependence
463126|NCT00846859|nicotine dependence
463127|NCT00846859|alcohol abuse
463128|NCT00846859|varenicline
463129|NCT00846859|Champix
463130|NCT00846859|Chantix
463131|NCT00846859|smoking
463132|NCT00846859|drinking
463133|NCT00846859|snuffing
463134|NCT00846859|diary
463135|NCT00846859|phosphatidyl ethanol
463136|NCT00846859|PEth
463137|NCT00846833|Melanoma, Experimental
463138|NCT00846755|Thyroid
463139|NCT00846755|Pregnancy
463140|NCT00846742|Hodgkin Lymphoma
463141|NCT00846716|Type 2 Diabetes Mellitus
463142|NCT00846716|Diabetic Nephropathy
463143|NCT00846716|Diabetic Retinopathy
463144|NCT00846716|pioglitazone
463145|NCT00846690|topical anesthetics
463146|NCT00846690|topical anesthesia
463147|NCT00846690|20% benzocaine
463148|NCT00846690|TAC alternate gel
463149|NCT00846690|combination topical anesthetics
463150|NCT00846690|dental anesthesia
463151|NCT00846677|Healthy
463152|NCT00846677|Infants
463153|NCT00846677|Vitamin D
463154|NCT00846651|spinal anesthesia
463155|NCT00846651|cesarean section
463156|NCT00846638|Risk drinking
463157|NCT00846638|Women
463158|NCT00846638|Medical problems
463159|NCT00846625|Biomedical research
463160|NCT00846625|Macular Edema
463161|NCT00846625|Uveitis
463162|NCT00846625|Ranibizumab
463163|NCT00846625|Steroids
463164|NCT00846612|refractory
463165|NCT00846612|avastin
463166|NCT00846612|doxil
463167|NCT00846612|relapsed
463168|NCT00846612|ovarian cancer
463169|NCT00846612|platinum-resistant
463170|NCT00846599|brachial artery ultrasound
463171|NCT00846599|brachial artery reactivity
463172|NCT00846599|HIV
463173|NCT00846599|human immunodeficiency virus
463174|NCT00846599|cardiovascular risk
463175|NCT00846599|omega three
463176|NCT00846599|saturated fat
463177|NCT00846599|sustiva
463178|NCT00846599|atripla
463179|NCT00846599|kaletra
463180|NCT00846599|treatment naive
463181|NCT00846586|chronic obstructive pulmonary disease
463182|NCT00846586|COPD
463183|NCT00846586|indacaterol
463184|NCT00846586|tiotropium
463185|NCT00846586|bronchodilation
463186|NCT00846573|Helium
463187|NCT00846573|MRI
463188|NCT00846573|Hyperpolarized Helium
463189|NCT00846573|Hyperpolarized Noble Gas
463190|NCT00845507|weight gain
463191|NCT00846547|Autism
463192|NCT00846547|Autism Spectrum Disorders
463193|NCT00846547|irritability
463194|NCT00846547|aberrant behavior
463195|NCT00846534|Oxidative stress markers
463196|NCT00846534|Cardiac surgery
463197|NCT00846534|Atrial Fibrillation
463198|NCT00846521|Pediatric Obesity
463199|NCT00846521|Insulin Resistance
463200|NCT00846521|Glucose Tolerance
463201|NCT00846521|Adolescents
463202|NCT00846521|Acarbose
463203|NCT00846521|Continuous Glucose Monitoring (CGMS)
463204|NCT00846521|Endothelial Dysfunction
463205|NCT00846508|cervical cancer
463206|NCT00846508|Cisplatin
463207|NCT00846508|chemoradiation
463208|NCT00846495|Migraine
463209|NCT00846495|Migraine prevention
463210|NCT00846495|Prodrome
463211|NCT00846495|Premonitory phase
463212|NCT00846495|Preemptive therapy
463213|NCT00846482|Colorectal cancer
463214|NCT00846482|Oxaliplatin
463215|NCT00846482|ERCC-1
463216|NCT00846456|Tumor setm cell
463217|NCT00846443|non-small cell lung cancer
463218|NCT00846430|Neurofibromas
463219|NCT00846430|Neurofibromatosis 1
463220|NCT00846430|Celecoxib
463221|NCT00846430|Celebrex
463222|NCT00846430|Peg-Interferon alpha-2b
463223|NCT00846430|PEG-Intron
463224|NCT00846430|Temozolomide
463225|NCT00846430|Temodar
463226|NCT00846430|Vincristine Sulfate
463227|NCT00846430|Oncovin
463228|NCT00846417|myocardial infarction
463229|NCT00846417|heart failure
463230|NCT00846417|arrhythmia
463231|NCT00846404|heart failure
463232|NCT00846404|cardiomyopathy
463233|NCT00846404|diastolic dysfunction
463234|NCT00846378|ST segment elevation myocardial infarction (STEMI)
463235|NCT00846378|timed balloon inflations
463236|NCT00846378|post conditioning
463237|NCT00846365|Essential Hypertension
463238|NCT00846365|Hypertensive
463239|NCT00846365|Blood Pressure, High
463240|NCT00846365|Vascular Disease
463241|NCT00846365|Cardiovascular Disease
463242|NCT00846365|Drug Therapy
463243|NCT00846352|Bone Marrow Transplantation
463244|NCT00846352|Hematopoietic Stem Cell Transplantation
463245|NCT00846352|Bronchoscopy
463246|NCT00846339|Smoking cessation
463247|NCT00846339|Bupropion
463248|NCT00846326|allergic rhinitis
463249|NCT00846326|rhinitis medicamentosa
463250|NCT00846326|imidazolines
463251|NCT00846326|corticosteroid
463252|NCT00846313|Dietary intake
463253|NCT00846313|Dietary counseling
463254|NCT00846313|Weight loss
463255|NCT00846313|Body composition
463256|NCT00846313|Resting energy expenditure
463257|NCT00846313|Quality of life
463258|NCT00846300|Patient compliance
463259|NCT00846300|Hispanics
463260|NCT00846300|Health Behavior
463261|NCT00846300|Family Physicians
463262|NCT00846300|Primary Healthcare
463263|NCT00846287|COPD
463264|NCT00846287|aformoterol
463265|NCT00846287|Helium
463266|NCT00846287|Hyperpolarized helium
463267|NCT00846287|Hyperpolarized Noble Gas
463268|NCT00846287|MRI
463269|NCT00846274|Healthy Male subjects
463270|NCT00846261|infected
463271|NCT00846261|Ilizarov
463272|NCT00846248|diabetes
463273|NCT00846248|insulin resistance
463274|NCT00846248|chromium
463275|NCT00846248|healthy volunteers
463276|NCT00846235|Dermatitis
463277|NCT00846235|Atopic
463278|NCT00846235|Moisturising cream
463279|NCT00846235|Skin
463280|NCT00846209|prescription drug
463281|NCT00846209|warnings
463282|NCT00846209|health literacy
463283|NCT00846209|enhanced language
463284|NCT00846183|local injury
463285|NCT00846183|implantation rate
463286|NCT00846183|endometrial receptivity
463287|NCT00846183|IVF
463288|NCT00846170|Irritable bowel syndrome probiotics
463289|NCT00846157|natural killer cell
463290|NCT00846157|DLBCL (Diffuse Large B Cell Lymphoma)
463291|NCT00846144|Glucose stimulated insulin secretion
463292|NCT00846144|copper
463293|NCT00846144|cytokines
463294|NCT00846144|diabetes
463295|NCT00846144|Reduction in insulin secretion
463296|NCT00846131|Subjects with primary hepatocellular carcinoma, intended for liver transplantation.
463297|NCT00846118|Pitavastatin
463298|NCT00846118|Hemodialysis
463299|NCT00846118|Mortality
463300|NCT00846118|Cardiovascular disease
463301|NCT00846105|methicillin resistant Staphylococcus aureus
463302|NCT00846105|MRSA
463303|NCT00846105|cross-infection
463304|NCT00846105|staphylococcal infection
463305|NCT00846105|infection control
463306|NCT00846092|Diabetic Retinopathy
463307|NCT00846092|Diabetic Macular Edema
463308|NCT00846092|NIR
463309|NCT00846092|Near-infrared Light Therapy
463310|NCT00846079|coronary artery disease
463311|NCT00846079|stress testing
463312|NCT00846066|educational research,
463313|NCT00846066|instructional methods,
463314|NCT00846066|Hands on training,
463315|NCT00846066|Web based training,
463316|NCT00846066|pediatric residents
463317|NCT00846066|preventive oral health,
463318|NCT00846066|dental caries,
463319|NCT00846066|Instructional strategies in Preventive Oral health
463320|NCT00846066|Web-based training on Preventive Oral Health
463321|NCT00846066|Hands on Training on Preventive Oral Health
463322|NCT00846040|Obesity
463323|NCT00846040|Weight Loss
463324|NCT00846040|Carbohydrate
463325|NCT00846040|Fat
463326|NCT00846040|Macronutrient Balance
463327|NCT00846040|Healthy Volunteer
463328|NCT00846014|asthma
463329|NCT00846014|exacerbation
463330|NCT00846014|Helium
463331|NCT00846014|MRI
463332|NCT00846014|Lung imaging
463333|NCT00846001|Resynchronization Therapy
463334|NCT00845988|Bipolar disorder
463335|NCT00845988|metabolic complication
463336|NCT00845988|Aripiprazole
463337|NCT00845988|Weight gain
463338|NCT00845988|Clinical Trial
463339|NCT00845988|Antipsychotic
463340|NCT00845988|Metabolic syndrome
463341|NCT00845988|Psychopharmacology
463342|NCT00845988|Open Label
463343|NCT00845962|bupivacaine
463344|NCT00845962|chloroprocaine
463345|NCT00845962|spinal
463346|NCT00845962|anesthesia
463347|NCT00845962|elective surgery
463348|NCT00845962|ambulatory surgery
463349|NCT00845949|chemokines synovium
463350|NCT00845936|Atypical antipsychotics
463351|NCT00845936|Weight
463352|NCT00845936|adolecsents
463353|NCT00845936|pediatric
463354|NCT00845936|Metformin
463355|NCT00845923|Postherpetic neuralgia of at least 6 months
463356|NCT00845897|Diabetes mellitus
463357|NCT00845897|plantar ulcers
463358|NCT00845897|peripheral neuropathy
463359|NCT00845884|Gastric
463360|NCT00845884|Cancer
463361|NCT00845884|Advanced
463362|NCT00845884|Docetaxel
463363|NCT00845884|Cisplatin
463364|NCT00845884|Capecitabine
463365|NCT00845884|Bevacizumab
463366|NCT00845871|Exjade
463367|NCT00845871|deferasirox
463368|NCT00845871|palatability
463369|NCT00845871|tolerability
463370|NCT00845871|food
463371|NCT00845871|iron overload
463372|NCT00845871|Serum Iron overload due to transfusions
463373|NCT00845858|Gastroparesis
463374|NCT00845858|Diabetic Gastroparesis
463375|NCT00845858|Diabetes
463376|NCT00845858|Diabetes Mellitus
463377|NCT00845858|Delayed Gastric Emptying
463378|NCT00845845|Non-alcoholic steatohepatitis
463379|NCT00845845|Omega-3 fatty acids
463380|NCT00845845|MRI
463381|NCT00845845|NASH
463382|NCT00845819|oral mucositis
463383|NCT00845819|intensive chemotherapy
463384|NCT00845819|stem cell transplantation
463385|NCT00845819|epidermal growth factor
463386|NCT00845806|Diacritics
463387|NCT00845806|Neuronal Processing
463388|NCT00845806|fMRI
463389|NCT00845806|Arabic
463390|NCT00845793|Type 2 diabetes
463391|NCT00845793|Nutrition
463392|NCT00845793|Lifestyle modifications
463393|NCT00845780|persistent atrial fibrillation
463394|NCT00845780|amiodarone
463395|NCT00845780|late recurrence atrial fibrillation
463396|NCT00845780|adverse events
463397|NCT00845767|Nitric Oxide
463398|NCT00845767|Nitric Oxide Synthase
463399|NCT00845767|Air Pollution
463400|NCT00845767|Endothelial Dysfunction
463401|NCT00845767|Diesel Exhaust
463402|NCT00845754|Post-operative febrile morbidity
463403|NCT00845754|Post-operative pain management
463404|NCT00845728|Indacaterol
463405|NCT00845728|Tiotropium
463406|NCT00845728|COPD
463407|NCT00845715|rotator cuff
463408|NCT00845715|rehabilitation
463409|NCT00845715|range of motion
463410|NCT00845702|Renal artery stenosis
463411|NCT00845702|Contrast agent
463412|NCT00845702|MRA
463413|NCT00845689|liver surgery
463414|NCT00845676|Hepatitis C virus
463415|NCT00845676|Acute hepatitis C infection
463416|NCT00845676|HIV
463417|NCT00845676|HCV
463418|NCT00845663|certolizumab pegol
463419|NCT00845663|Cimzia
463420|NCT00845663|bioequivalence
463421|NCT00845663|Comparison Bioequivalence Study
463422|NCT00845650|Anthrax
463423|NCT00845650|Human Anthrax Immune Globulin Intravenous
463424|NCT00845650|Safety
463425|NCT00845650|Pharmacokinetics
463426|NCT00845637|eggplant
463427|NCT00845637|dyslipidemia
463428|NCT00845637|postprandial lipemia
463429|NCT00845624|oxygen saturation
463430|NCT00845624|retinopathy of prematurity
463431|NCT00845624|long term outcomes
463432|NCT00845624|hypoxia
463433|NCT00845624|hyperoxia
463434|NCT00845611|peptide vaccine
463435|NCT00845611|URLC10
463436|NCT00845429|Influenza
463437|NCT00845429|Orthomyxoviruses
463438|NCT00845429|Split-virion inactivated influenza vaccine
463439|NCT00845429|cell-based vaccine
463440|NCT00845429|Adults
463441|NCT00845416|TREC
463442|NCT00845416|T cell
463443|NCT00845416|Primary Immunodeficiency
463444|NCT00845416|PID
463445|NCT00845416|Navajo
463446|NCT00845416|SCID
463447|NCT00845403|Hepatitis B carrier
463448|NCT00845377|Depression
463449|NCT00845377|Aging
463450|NCT00845377|Psychological well-being
463451|NCT00845377|Psychosocial intervention
463452|NCT00845364|Perhexiline
463453|NCT00845364|Coronary artery bypass
463454|NCT00845364|Myocardial reperfusion injury
463455|NCT00845364|Cardiac output, low
463456|NCT00845364|Troponin
463457|NCT00845351|Cushing's
463458|NCT00845338|Darifenacin
463459|NCT00845338|Multiple Sclerosis
463460|NCT00845338|Open Label Study
463461|NCT00845325|Carpal tunnel release
463462|NCT00845325|Rehabilitation
463463|NCT00845325|Early motion
463464|NCT00845312|Age
463465|NCT00845312|Mortality
463466|NCT00845299|glaucoma
463467|NCT00845299|ocular hypertension
463468|NCT00845286|exercise, myocardial dysfunction, endothelial dysfunction,
463469|NCT00845286|polymorphism
463470|NCT00845273|Subfoveal choroidal neovascularization secondary to age-related macular degeneration
463471|NCT00845247|Case Management
463472|NCT00845234|behavioral intervention
463473|NCT00845234|implantable cardioverter defibrillator
463474|NCT00845234|psychosocial education
463475|NCT00845234|anxiety
463476|NCT00845234|depression
463477|NCT00845208|Network Support
463478|NCT00845208|AA
463479|NCT00845208|Contingency Management
463480|NCT00845195|Rhinitis
463481|NCT00845195|Allergy
463482|NCT00845195|Nasal Spray
463483|NCT00845195|Antihistamine
463484|NCT00845195|Intranasal Corticosteroid
463485|NCT00845182|Type 2 diabetes pathogenesis, thiazolidinediones
463486|NCT00845182|impaired glucose tolerance
463487|NCT00845182|Incretins
463488|NCT00845182|Insulin secretion
463489|NCT00845169|Air Pollution
463490|NCT00845169|Nitric Oxide
463491|NCT00845169|Nitric Oxide Synthase
463492|NCT00845169|Diesel exhaust
463493|NCT00845169|endothelial dysfunction
463494|NCT00845156|Diabetes
463495|NCT00845156|Insulin resistance
463496|NCT00845156|healthy controls
463497|NCT00845156|anti oxidants
463498|NCT00845143|Non-small cell lung cancer
463499|NCT00845143|surgery
463500|NCT00845143|lung function
463501|NCT00845130|Diabetes
463502|NCT00845130|MR imaging
463503|NCT00845130|Vitamin C
463504|NCT00845117|Aniridia,
463505|NCT00845117|Steven Johnsons Syndrome,
463506|NCT00845117|Ocular burns,
463507|NCT00845117|Pterygium
463508|NCT00845091|Parasympathetic activity
463509|NCT00845091|Exercise
463510|NCT00845091|Education
463511|NCT00845091|Arrhythmias
463512|NCT00845091|Defibrillators, Implantable
463513|NCT00845078|Breast
463514|NCT00845078|Radiotherapy
463515|NCT00845078|Esthetics
463516|NCT00845078|Treatment Outcome
463517|NCT00845078|Reconstructive Surgical Procedures
463518|NCT00845052|Housestaff
463519|NCT00845052|Patient Safety
463520|NCT00845052|Patient Care
463521|NCT00845052|Focus of Study: To assess safety climate amongst housestaff
463522|NCT00845039|Tumors
463523|NCT00845039|Antibodies, Monoclonal
463524|NCT00845039|Colorectal Neoplasms
463525|NCT00845039|Metastatic K-RAS Wild-Type Carcinoma of the Colon or Rectum
463526|NCT00845013|HIV infection
463527|NCT00845013|pulmonary hypertension
463528|NCT00845013|endothelial function
463529|NCT00845013|antiretroviral medication
463530|NCT00845013|Treatment Experienced
463531|NCT00844987|PDGF
463532|NCT00844987|HGF
463533|NCT00844987|VEGF
463534|NCT00844987|ACS
463535|NCT00844987|markers of myocardial injury
463536|NCT00844987|Vascular Endothelial Growth Factor
463537|NCT00844987|Hepatocyte Growth Factor
463538|NCT00844987|Platelet Derived Growth Factor
463539|NCT00844987|Strategies in ACS
463540|NCT00844961|IBS
463541|NCT00844961|CBT
463542|NCT00844961|Internet treatment
463543|NCT00844961|Cognitive behavior therapy
463544|NCT00844948|Depression
463545|NCT00844935|Heart rate variability, mechanical ventilation, weaning,
463546|NCT00844935|spontaneous breathing trial
463547|NCT00844909|CNTO 136
463548|NCT00844909|safety
463549|NCT00844909|pharmacokinetics
463550|NCT00844909|healthy Japanese
463551|NCT00844909|healthy Caucasian
463552|NCT00844909|Phase I
463553|NCT00844909|antibody
463554|NCT00844909|male.
463555|NCT00844896|Pathological stress & PTSD in preschool children & parents
463556|NCT00844896|Child and parent resilience after burn trauma
463557|NCT00844883|primary liver cancer
463558|NCT00844883|sorafenib
463559|NCT00844883|Nexavar
463560|NCT00844883|doxorubicin
463561|NCT00844883|drug eluting beads
463562|NCT00844883|transarterial chemoembolization
463563|NCT00844870|rehabilitation, reaching, stroke
463564|NCT00844857|Bipolar I Depression
463565|NCT00844844|aHUS
463566|NCT00844831|Constipation
463567|NCT00844831|small intestinal bacterial overgrowth
463568|NCT00844831|stool bacteria
463569|NCT00844818|smoking cessation
463570|NCT00844818|parents
463571|NCT00844792|Male Urogenital Diseases
463572|NCT00844792|Antioxidants
463573|NCT00844792|Vitamin E
463574|NCT00844792|Vitamin D
463575|NCT00844792|Lycopene
463576|NCT00844792|Selenium
463577|NCT00844779|Metabolic syndrome- hepatic steatosis- steatohepatitis - gene expression
463578|NCT00844779|Non alcoholic fatty liver disease (NFALD)
463579|NCT00844766|Lactose intolerance
463580|NCT00844766|Lactose
463581|NCT00844766|Home-screening test
463582|NCT00844766|Validate
463583|NCT00844753|Autism
463584|NCT00844753|PDD NOS
463585|NCT00844753|Attention Deficit Hyperactivity Disorder
463586|NCT00844753|Parent Management Training
463587|NCT00844740|Familial hypophosphatemic rickets
463588|NCT00844740|Cinacalcet
463589|NCT00844740|hyperparathyroidism
463590|NCT00844714|endothelial function
463591|NCT00844714|rheumatoid arthritis
463592|NCT00844714|cardiovascular risk
463593|NCT00844714|rituxan therapy
463594|NCT00844701|nicotine
463595|NCT00844701|addiction
463596|NCT00844701|fMRI
463597|NCT00844701|neuroimaging
463598|NCT00844701|neurobiology
463599|NCT00844701|craving
463600|NCT00844688|Hepatocellular Carcinoma
463601|NCT00844688|Sorafenib
463602|NCT00844688|Gemcitabine
463603|NCT00844675|endoscopic mucosal resection
463604|NCT00844675|Proton Pump Inhibitor
463605|NCT00844675|gastrointestinal hemorrhage
463606|NCT00844675|rabeprazole
463607|NCT00844662|Hyperphosphataemia
463608|NCT00844662|phosphate binder
463609|NCT00844636|Needlestick injuries
463610|NCT00844636|Glove perforations
463611|NCT00844636|Blunt Needles
463612|NCT00844636|Glove perforations of surgeons, assistants
463613|NCT00844636|Needlestick injuries of same
463614|NCT00844623|primary liver cancer, hepatoma
463615|NCT00844584|Atrial fibrillation
463616|NCT00844584|radiofrequency
463617|NCT00844584|totally thoracoscope
463618|NCT00844584|epicardial
463619|NCT00844571|child abuse and neglect
463620|NCT00844571|child maltreatment
463621|NCT00844571|non accidental injury
463622|NCT00844571|training
463623|NCT00844571|educational program
463624|NCT00844558|osteoarthritis
463625|NCT00844558|knee pain
463626|NCT00844558|gait training
463627|NCT00844558|power training
463628|NCT00844558|rehabilitation
463629|NCT00844558|physical therapy
463630|NCT00844545|aHUS
463631|NCT00844532|Atherosclerosis
463632|NCT00844532|Peripheral artery disease
463633|NCT00844532|Peripheral vascular disease
463634|NCT00844532|PAD
463635|NCT00844532|Claudication
463636|NCT00844532|Peripheral Arterial Occlusive Disease
463637|NCT00844532|Stent
463638|NCT00844532|PAOD
463639|NCT00844532|PVD
463640|NCT00844519|Treatment Experienced
463641|NCT00844519|CCR5 receptor
463642|NCT00844519|maraviroc
463643|NCT00844506|Ovarian cancer patients with recurrent disease
463644|NCT00844493|diarrhea
463645|NCT00844493|vaccine
463646|NCT00844493|enterotoxigenic E coli
463647|NCT00844493|colonization factor antigen
463648|NCT00844493|volunteer study
463649|NCT00844480|spinal cord injury
463650|NCT00844480|osteoporosis
463651|NCT00844480|bone loss
463652|NCT00844480|zoledronic acid
463653|NCT00844480|bisphosphonate
463654|NCT00844467|Risk factors
463655|NCT00844467|Case fatality
463656|NCT00844467|disease burden
463657|NCT00844467|Resistance
463658|NCT00844467|Benefits of pneumococcal vaccination
463659|NCT00844454|hepatocellular carcinoma
463660|NCT00844454|PEI
463661|NCT00844454|RF ablation
463662|NCT00844454|tumor ablation
463663|NCT00844441|de novo myelodysplastic syndromes
463664|NCT00844441|previously treated myelodysplastic syndromes
463665|NCT00844441|secondary myelodysplastic syndromes
463666|NCT00844441|recurrent adult acute myeloid leukemia
463667|NCT00844441|untreated adult acute myeloid leukemia
463668|NCT00844441|adult acute myeloid leukemia with inv(16)(p13;q22)
463669|NCT00844441|adult acute myeloid leukemia with t(16;16)(p13;q22)
463670|NCT00844441|adult acute myeloid leukemia with t(8;21)(q22;q22)
463671|NCT00844441|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
463672|NCT00844441|adult acute minimally differentiated myeloid leukemia (M0)
463673|NCT00844441|adult acute myeloblastic leukemia without maturation (M1)
463674|NCT00844441|adult acute myeloblastic leukemia with maturation (M2)
463675|NCT00844441|adult acute myelomonocytic leukemia (M4)
463676|NCT00844441|adult acute monoblastic leukemia (M5a)
463677|NCT00844441|adult acute eosinophilic leukemia
463678|NCT00844441|adult acute monocytic leukemia (M5b)
463679|NCT00844441|adult acute megakaryoblastic leukemia (M7)
463680|NCT00844441|adult acute basophilic leukemia
463681|NCT00844441|acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
463682|NCT00844441|adult erythroleukemia (M6a)
463683|NCT00844441|adult pure erythroid leukemia (M6b)
463684|NCT00844402|Cholestasis
463685|NCT00844402|Atherosclerosis
463686|NCT00844402|Statins
463687|NCT00844402|Vascular function
463688|NCT00844389|Open Angle Glaucoma
463689|NCT00844389|Biophotomodulation
463690|NCT00844389|Near to Infrared light stimulation
463691|NCT00844389|Neuroprotection
463692|NCT00844376|Cardiovascular Diseases
463693|NCT00844350|Oxytocin
463694|NCT00844350|Letrozole
463695|NCT00844350|Induction of ovulation
463696|NCT00844337|antibiotic regimens
463697|NCT00844337|sepsis
463698|NCT00844337|young infants
463699|NCT00844337|Bangladeshi
463700|NCT00844337|outpatient treatment
463701|NCT00844337|Suspected sepsis in young infants
463702|NCT00844324|Candesartan
463703|NCT00844324|Bioequivalence
463704|NCT00844311|hCG
463705|NCT00844311|human chorionic gonadotropin
463706|NCT00844298|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
463707|NCT00844298|untreated adult acute lymphoblastic leukemia
463708|NCT00844285|Certolizumab Pegol, Cimzia ®
463709|NCT00844285|Crohn's Disease
463710|NCT00844272|Opiate Dependence
463711|NCT00844272|Chronic Hepatitis C
463712|NCT00844259|Down syndrome
463713|NCT00844259|Pragmatics
463714|NCT00844259|Language Development
463715|NCT00844246|Developmental delays
463716|NCT00844246|Early intervention services
463717|NCT00844220|Suspected coronary artery disease
463718|NCT00844207|Bioavailability
463719|NCT00844155|Prevention or treatment of influenza in ventilated patients
463720|NCT00844142|ankylosing spondylitis
463721|NCT00844142|axial spondyloarthritis
463722|NCT00844142|magnetic resonance imaging
463723|NCT00844142|etanercept
463724|NCT00844142|sulfasalazine
463725|NCT00844129|neurofibromatosis type 1
463726|NCT00844129|spinal abnormalities
463727|NCT00844129|scoliosis
463728|NCT00844116|COPD
463729|NCT00844116|spirometry
463730|NCT00844116|Telematic spirometry
463731|NCT00844103|Volunteer
463732|NCT00844103|Safety
463733|NCT00844103|Tolerability
463734|NCT00844103|AZD8566
463735|NCT00844090|Apathy
463736|NCT00844090|Diabetes
463737|NCT00844090|Self-care behaviors
463738|NCT00844077|Barrett's Intestinal Metaplasia
463739|NCT00844064|Pancreatic cancer
463740|NCT00844064|Metastatic melanoma
463741|NCT00844064|Advanced tumor
463742|NCT00844064|Targeted therapy
463743|NCT00844064|Antisense
463744|NCT00844064|Transforming Growth Factor beta 2
463745|NCT00844064|Dose escalation
463746|NCT00844051|Influenza
463747|NCT00844051|influenza vaccination
463748|NCT00844051|school-based vaccination
463749|NCT00844038|Steven-Johnson syndrome
463750|NCT00844038|erythema multiform
463751|NCT00844038|autoimmune disease
463752|NCT00844025|Adverse drug reaction
463753|NCT00844025|Inappropriate medication
463754|NCT00844025|Pharmacist
463755|NCT00844025|Pharmaceutical care
463756|NCT00843986|hyponatremia
463757|NCT00843986|euvolemic hyponatremia
463758|NCT00843986|hypervolemic hyponatremia
463759|NCT00843986|acute decompensated heart failure
463760|NCT00843986|conivaptan
463761|NCT00843986|Vaprisol
463762|NCT00843973|Iliac Crest Bone Graft
463763|NCT00843973|Reamer Irrigator Aspirator
463764|NCT00843934|Carcinoma, Hepatocellular
463765|NCT00843934|Trans arterial chemoembolization
463766|NCT00843934|Epirubicin
463767|NCT00843934|Cisplatin
463768|NCT00843921|Hyperammonemia
463769|NCT00843908|Stress incontinence
463770|NCT00843908|Surgical Treatments
463771|NCT00843908|Minislings
463772|NCT00843895|Laboratory based study
463773|NCT00843895|antibiotic susceptibilty
463774|NCT00843895|invasive strains
463775|NCT00843843|Circadian Rhythms
463776|NCT00843817|cystic fibrosis
463777|NCT00843804|nosocomial infection
463778|NCT00843804|bloodstream infection
463779|NCT00843804|central venous catheter
463780|NCT00843804|invasive Aspergillosis
463781|NCT00843804|Clostridium difficile associated disease
463782|NCT00843791|obesity
463783|NCT00843778|Rheumatoid Arthritis
463784|NCT00843778|Moderate to Low Disease Activity
463785|NCT00843778|Certolizumab Pegol
463786|NCT00843765|Stroke
463787|NCT00843765|Traditional Chinese Medicine
463788|NCT00843765|Rehabilitation
463789|NCT00843739|Breathing
463790|NCT00843739|Cough
463791|NCT00843739|Speech
463792|NCT00843739|Swallow
463793|NCT00843739|Parkinson's disease
463794|NCT00843726|stage I non-small cell lung cancer
463795|NCT00843726|stage II non-small cell lung cancer
463796|NCT00843713|HIV
463797|NCT00843713|endothelium
463798|NCT00843713|inflammation
463799|NCT00843713|Treatment Experienced
463800|NCT00843687|Schizophrenia
463801|NCT00843687|Risperidone
463802|NCT00843687|Long-acting injectable
463803|NCT00843687|Intramuscular injection
463804|NCT00843687|Pharmacokinetics
463805|NCT00843661|Treatment Experienced
463806|NCT00843648|antibody immune profile
463807|NCT00843648|preterm
463808|NCT00843648|c-section
463809|NCT00843648|breastfeeding
463810|NCT00843635|stage I squamous cell carcinoma of the lip and oral cavity
463811|NCT00843635|stage I squamous cell carcinoma of the oropharynx
463812|NCT00843635|stage II squamous cell carcinoma of the lip and oral cavity
463813|NCT00843635|stage II squamous cell carcinoma of the oropharynx
463814|NCT00843635|stage III squamous cell carcinoma of the oropharynx
463815|NCT00843635|stage III squamous cell carcinoma of the lip and oral cavity
463816|NCT00843635|stage IV squamous cell carcinoma of the oropharynx
463817|NCT00843635|stage IV squamous cell carcinoma of the lip and oral cavity
463818|NCT00843635|stage I verrucous carcinoma of the oral cavity
463819|NCT00843635|stage II verrucous carcinoma of the oral cavity
463820|NCT00843635|stage III verrucous carcinoma of the oral cavity
463821|NCT00843635|stage IV verrucous carcinoma of the oral cavity
463822|NCT00843622|Smoking
463823|NCT00843622|Smoking cessation
463824|NCT00843622|Smokeless tobacco
463825|NCT00843622|Snus
463826|NCT00843609|diabetes mellitus, type 1
463827|NCT00843609|hypoglycemia
463828|NCT00843609|continuous glucose monitoring
463829|NCT00843609|HbA1c
463830|NCT00843609|glycemic variability
463831|NCT00843596|cardiac surgery requiring ECC
463832|NCT00843583|prevalence
463833|NCT00843583|obstructive sleep apnea
463834|NCT00843583|resistant hypertension
463835|NCT00843570|IVF
463836|NCT00843570|Frozen Embryo Replacement
463837|NCT00843557|critical illness
463838|NCT00843557|intensive care
463839|NCT00843557|nosocomial infection
463840|NCT00843531|neuroendocrine
463841|NCT00843531|islet cell
463842|NCT00843531|carcinoid
463843|NCT00843531|pancreatic neuroendocrine
463844|NCT00843531|paraganglioma
463845|NCT00843531|pheochromocytoma
463846|NCT00843531|RAD001
463847|NCT00843531|everolimus
463848|NCT00843531|erlotinib
463849|NCT00843531|Tarceva
463850|NCT00843518|Agitation and Aggression
463851|NCT00843505|Smoking Cessation
463852|NCT00843505|Motivational Interviewing
463853|NCT00843505|Quitline
463854|NCT00843505|Telemedicine
463855|NCT00843505|Stop Smoking Medication
463856|NCT00843492|deep vein thrombosis
463857|NCT00843492|immobilization
463858|NCT00843492|nadroparin
463859|NCT00843492|isolated lower-extremity injuries distal to the knee
463860|NCT00843492|plaster cast
463861|NCT00843492|non-surgical leg injury
463862|NCT00843492|venous thromboembolism
463863|NCT00843492|bleeding events
463864|NCT00843492|fondaparinux
463865|NCT00843479|diabetes mellitus, type 2
463866|NCT00843479|Insulin resistance
463867|NCT00843479|Aging
463868|NCT00843479|Incretins
463869|NCT00843479|DPP-IV protein, human
463870|NCT00843479|Glucagon-Like Peptide 1
463871|NCT00843479|Gastric Inhibitory Polypeptide
463872|NCT00843479|insulin
463873|NCT00843479|glucagon
463874|NCT00843479|ghrelin
463875|NCT00843466|Hand dermatitis
463876|NCT00843453|vitamin B12 deficiency
463877|NCT00843453|cyanocobalamin deficiency
463878|NCT00843453|proton pump inhibitors
463879|NCT00843453|omeprazole
463880|NCT00843440|Antiangiogenic therapies
463881|NCT00843440|Bevacuzimab
463882|NCT00843440|Hemorrhagic Hereditary Telangiectasia (HHT) with severe liver involvement
463883|NCT00843427|aphasia
463884|NCT00843427|stroke
463885|NCT00843427|functional magnetic resonance imaging
463886|NCT00843427|fMRI
463887|NCT00843427|language recovery after stroke
463888|NCT00843427|constraint-induced aphasia therapy
463889|NCT00843427|CIAT
463890|NCT00843414|Emphysema
463891|NCT00843414|Sarcoidosis
463892|NCT00843414|Interstitial Pulmonary Fibrosis
463893|NCT00843401|Low oxygen saturation
463894|NCT00843401|Anticipated need for pulse oximetry monitoring
463895|NCT00843401|Arterial line in place as indicated per patient's clinical management needs
464020|NCT00842855|GERD
463896|NCT00843401|Availability to analyze arterial blood saturation by Co-Oximeter or
463897|NCT00843401|Blood Gas Analyzer
463898|NCT00843349|Phosphorus
463899|NCT00843349|Fibroblast Growth Factor-23
463900|NCT00843349|Kidney Disease
463901|NCT00843336|fertility monitoring
463902|NCT00843336|contraception
463903|NCT00843310|multiple myeloma
463904|NCT00843310|frontline treatment
463905|NCT00843310|first-line treatment
463906|NCT00843297|Sudden Cardiac Arrest
463907|NCT00843297|Hypothermia
463908|NCT00843297|Outcome, neurological
463909|NCT00843297|Coolgard
463910|NCT00843297|ArcticSun
463911|NCT00843284|neuropathic, pain, pregabalin, Lyrica
463912|NCT00843271|COPD MESA LUNG BIOMARKERS
463913|NCT00843258|therapy
463914|NCT00843258|ultrasound
463915|NCT00843258|mild dysplasia
463916|NCT00843245|Heart Failure
463917|NCT00843245|Electric bioimpedance
463918|NCT00843245|Body composition
463919|NCT00843245|Diagnosis
463920|NCT00843245|monitoring
463921|NCT00843245|Prognosis
463922|NCT00843245|Total body water
463923|NCT00843232|diabetes mellitus, type 2
463924|NCT00843232|Insulin resistance
463925|NCT00843232|Aging
463926|NCT00843232|Incretins
463927|NCT00843232|DPP-IV protein, human
463928|NCT00843232|Glucagon-Like Peptide 1
463929|NCT00843232|Gastric Inhibitory Polypeptide
463930|NCT00843232|insulin
463931|NCT00843232|glucagon
463932|NCT00843232|ghrelin
463933|NCT00843219|Lung
463934|NCT00843219|Lung Cancer
463935|NCT00843219|Non-small cell Lung Cancer
463936|NCT00843219|NSCLC
463937|NCT00843219|Motion Correction
463938|NCT00843219|PET/CT Scan
463939|NCT00843219|PET
463940|NCT00843219|Positron Emission Tomography
463941|NCT00843219|CT
463942|NCT00843219|Computed Tomography
463943|NCT00843219|Amplitude Gating
463944|NCT00843193|Asthma
463945|NCT00843193|Asthma control questionnaire
463946|NCT00843180|Bone Marrow Transplant
463947|NCT00843180|Massage
463948|NCT00843180|Pediatric Oncology
463949|NCT00843180|children undergoing bone marrow transplantation
463950|NCT00843167|mammography
463951|NCT00843167|biopsy
463952|NCT00843167|ductal breast carcinoma in situ
463953|NCT00843167|atypical ductal breast hyperplasia
463954|NCT00843154|Natriuretic Peptide, Brain
463955|NCT00843154|Biological Markers
463956|NCT00843154|Biomarkers
463957|NCT00843154|Cardiac Failure
463958|NCT00843154|Congestive Heart Failure
463959|NCT00843154|Heart Decompensation
463960|NCT00843154|Drug Therapy
463961|NCT00843141|ADHD
463962|NCT00843141|Executive functions
463963|NCT00843141|Quality of life
463964|NCT00843115|Alzheimer's Disease, naturalistic study
463965|NCT00843102|atherosclerosis
463966|NCT00843102|pulmonary hypertension
463967|NCT00843089|coronary artery disease
463968|NCT00843089|CABG
463969|NCT00843063|pantoprazole
463970|NCT00843063|famotidine
463971|NCT00843063|aspirin
463972|NCT00843063|dyspepsia
463973|NCT00843063|gastrointestinal bleeding
463974|NCT00843063|peptic ulcer / erosion
463975|NCT00843050|CKD inhibitor
463976|NCT00843050|Mantle Cell Lymphoma
463977|NCT00843037|PARAGANGLIOMA
463978|NCT00843037|PHEOCHROMOCYTOMA
463979|NCT00843037|SUNITINIB
463980|NCT00843037|PHASE II
463981|NCT00843037|Metastatic or locally advanced malignant paraganglioma
463982|NCT00843037|Metastatic or locally advanced malignant pheochromocytoma
463983|NCT00843024|Migraine with or without aura
463984|NCT00843024|Migraine efficacy
463985|NCT00843024|Migraine
463986|NCT00843024|Migraine headache
463987|NCT00843024|Adolescent migraine
463988|NCT00843024|TREXIMET
463989|NCT00843024|Sumatriptan succinate
463990|NCT00843024|Naproxen sodium
463991|NCT00843024|Migraine, acute
463992|NCT00843011|NK1 antagonist
463993|NCT00843011|effect of food
463994|NCT00843011|safety and tolerability
463995|NCT00843011|pharmacokinetics
463996|NCT00843011|formulation
463997|NCT00842998|breast cancer
463998|NCT00842998|HER2
463999|NCT00842998|Trastuzumab
464000|NCT00842998|Lapatinib
464001|NCT00842998|HER2 gene-amplification
464002|NCT00842985|Cannabis Abuse
464003|NCT00842985|Cannabis Dependence
464004|NCT00842985|Cannabis-Related Disorder
464005|NCT00842985|Marijuana Dependence
464006|NCT00842985|Marihuana Abuse
464007|NCT00842959|Improvement of adjustment accuracy of intraocular lenses and imaging quality
464008|NCT00842933|Septic shock
464009|NCT00842933|Acute adrenal insufficiency
464010|NCT00842920|amnestic MCI
464011|NCT00842907|Brazil
464012|NCT00842907|isotretinoin
464013|NCT00842907|photodamage
464014|NCT00842907|photoaging
464015|NCT00842881|Healingstone
464016|NCT00842868|atherosclerosis
464017|NCT00842868|contrast induced nephropathy
464018|NCT00842868|renal impairment
464019|NCT00842868|catheterization
464021|NCT00842855|PPI
464022|NCT00842855|partial responders
464023|NCT00842842|surgical fixation devices
464024|NCT00842842|postoperative pain
464025|NCT00842842|ventral hernia
464026|NCT00842842|fibrin tissue adhesive
464027|NCT00842842|laparoscopy
464028|NCT00842842|quality of life
464029|NCT00842842|fatigue
464030|NCT00842829|Breakthrough Cancer Pain
464031|NCT00842816|Dementia
464032|NCT00842816|Alzheimer Type Senile Dementia
464033|NCT00842816|Cognitive impairment
464034|NCT00842803|Liver
464035|NCT00842803|transplant
464036|NCT00842803|albumin
464037|NCT00842803|outcome
464038|NCT00842803|Liver transplant recipients canadian transplant status 1 or 2
464039|NCT00842790|Carcinoma, Renal Cell [C04.557.470.200.025.390]
464040|NCT00842790|Angiogenesis Inhibitors [D27.505.954.248.025]
464041|NCT00842790|Tomography Scanners, X-Ray Computed [E07.913]
464042|NCT00842790|Magnetic Resonance Imaging [E01.370.350.825.500]
464043|NCT00842790|Diffusion Magnetic Resonance Imaging [E01.370.350.825.500.150]
464044|NCT00842790|Perfusion [E05.680]
464045|NCT00842777|Childhood obesity
464046|NCT00842777|Quality of life
464047|NCT00842777|Self-esteem
464048|NCT00842777|BMI
464049|NCT00842777|parental group treatment
464050|NCT00842777|Body image
464051|NCT00842764|eyelid fat pads
464052|NCT00842751|5α-reductase
464053|NCT00842751|androgen
464054|NCT00842751|dihydrotestosterone (DHT)
464055|NCT00842751|drug delivery
464056|NCT00842751|oestradiol
464057|NCT00842738|Screening
464058|NCT00842738|Cervical cancer
464059|NCT00842738|Cervical dysplasia
464060|NCT00842738|Adverse psychosocial effects
464061|NCT00842738|Alternative treatment
464062|NCT00842712|First-line treatment for subjects with advanced NSCLC,
464063|NCT00842712|integrin receptor antagonist, EGFR chimerized monoclonal antibody, chemotherapy
464064|NCT00842712|safety run-in + randomization part, MTD, PFS, Overall survival time, best overall response
464065|NCT00842686|rectal cancer
464066|NCT00842686|capecitabine
464067|NCT00842686|bevacizumab
464068|NCT00842686|radiotherapy
464069|NCT00842673|Dementia
464070|NCT00842673|Alzheimer Type Senile Dementia
464071|NCT00842673|Cognitive impairment
464072|NCT00842660|Cervical cancer
464073|NCT00842660|concurrent chemoradiotherapy
464074|NCT00842660|gemcitabine
464075|NCT00842647|Sensitivity
464076|NCT00842647|specificity
464077|NCT00842647|positive rate
464078|NCT00842647|negative rate
464079|NCT00842634|HIV
464080|NCT00842634|Treatment Experienced
464081|NCT00842621|Sickle Cell Disease, Hemolytic Anemia
464082|NCT00842621|Hemolysis
464083|NCT00842608|confusion
464084|NCT00842608|dementia
464085|NCT00842595|relapsed aggressive B-cell lymphoma
464086|NCT00842595|Chemotherapy
464087|NCT00842582|Ovarian cancer
464088|NCT00842582|chemotherapy
464089|NCT00842582|azacitidine
464090|NCT00842569|obesity
464091|NCT00842569|cognitive process
464092|NCT00842569|reward
464093|NCT00842569|P300
464094|NCT00842569|ERP
464095|NCT00842569|Event-related potential during oddball paradigm
464096|NCT00842569|brain electrophysiological patterns
464097|NCT00842569|externalizing factor
464098|NCT00842543|Nutrition
464099|NCT00842543|Oxidative Stress
464100|NCT00842543|Insulin Resistance
464101|NCT00842543|Whole Food Supplement
464102|NCT00842543|Pediatric
464103|NCT00842543|Retinoids
464104|NCT00842543|Antioxidants
464105|NCT00842543|Dietary Supplements
464106|NCT00842530|Dengue virus
464107|NCT00842530|Dengue fever
464108|NCT00842530|Dengue hemorrhagic fever
464109|NCT00842530|Dengue diseases
464110|NCT00842530|Dengue vaccine
464111|NCT00842517|Cocaine Dependence
464112|NCT00842517|Cocaine Abuse
464113|NCT00842517|Substance Abuse
464114|NCT00842517|Contingency Management
464115|NCT00842517|Drug Treatment
464116|NCT00842504|Anti-fungal
464117|NCT00842504|Immunocompromised
464118|NCT00842504|Pharmacokinetic
464119|NCT00842504|Prophylaxis
464120|NCT00842504|Pharmacokinetics
464121|NCT00842465|Breast diseases,
464122|NCT00842465|human mutation,
464123|NCT00842465|prolactin receptor;
464124|NCT00842465|breast cancer
464125|NCT00842452|recurrent ovarian epithelial cancer
464126|NCT00842452|stage III ovarian epithelial cancer
464127|NCT00842452|stage IV ovarian epithelial cancer
464128|NCT00842452|recurrent ovarian germ cell tumor
464129|NCT00842452|stage III ovarian germ cell tumor
464130|NCT00842452|stage IV ovarian germ cell tumor
464131|NCT00842452|recurrent endometrial carcinoma
464132|NCT00842452|stage III endometrial carcinoma
464133|NCT00842452|stage IV endometrial carcinoma
464134|NCT00842452|recurrent uterine sarcoma
464135|NCT00842452|stage III uterine sarcoma
464136|NCT00842452|stage IV uterine sarcoma
464137|NCT00842452|recurrent vaginal cancer
464138|NCT00842452|stage III vaginal cancer
464139|NCT00842452|stage IVA vaginal cancer
464140|NCT00842452|stage IVB vaginal cancer
464141|NCT00842452|recurrent vulvar cancer
464142|NCT00842452|stage III vulvar cancer
464143|NCT00842452|stage IV vulvar cancer
464144|NCT00842452|recurrent cervical cancer
464145|NCT00842452|stage III cervical cancer
464146|NCT00842452|stage IVA cervical cancer
464147|NCT00842452|stage IVB cervical cancer
464148|NCT00842452|fallopian tube cancer
464149|NCT00842452|ovarian sarcoma
464150|NCT00842452|ovarian stromal cancer
464151|NCT00842439|aggression
464152|NCT00842439|Prevention and treatment of youth aggression
464153|NCT00842426|Diabetes
464154|NCT00842426|Cardiovascular disease
464155|NCT00842426|Metabolic syndrome
464156|NCT00842426|Cardiometabolic
464157|NCT00842413|Prefrontal cortex
464158|NCT00842413|visual consciousness
464159|NCT00842413|focal lesions
464160|NCT00842413|action perception
464161|NCT00842400|Obesity
464162|NCT00842387|gastroesophageal reflux disease
464163|NCT00842387|reflux, heartburn
464164|NCT00842387|regurgitation
464165|NCT00842387|acid control
464166|NCT00842387|PPI
464167|NCT00842387|antiacid
464168|NCT00842387|primary care
464169|NCT00842387|esophagitis
464170|NCT00842348|Lanreotide
464171|NCT00842348|Somatuline
464172|NCT00842348|Neuroendocrine tumour
464173|NCT00842348|NET
464174|NCT00842335|solid tumors
464175|NCT00842335|angiogenesis inhibitor
464176|NCT00842335|dose escalation
464177|NCT00842335|maximum tolerated dose
464178|NCT00842335|JI-101
464179|NCT00842322|chronic kidney disease
464180|NCT00842322|transplantation
464181|NCT00842322|kidney function
464182|NCT00842322|fluid intake
464183|NCT00842322|osmolarity
464184|NCT00842296|GSV
464185|NCT00842296|RadioFrequency
464186|NCT00842283|dermatologic diseases
464187|NCT00842270|severe asthma
464188|NCT00842270|corticosteroids dependent
464189|NCT00842270|asthma exacerbation
464190|NCT00842270|weaning
464191|NCT00842270|tyrosine kinase inhibitor
464192|NCT00842270|severe persistent corticosteroid dependent asthma
464193|NCT00842257|panitumumab
464194|NCT00842257|cetuximab
464195|NCT00842257|KRAS wild-type
464196|NCT00842231|Corneal astigmatism
464197|NCT00842231|post-cataract surgery
464198|NCT00842231|visual performance
464199|NCT00842231|Corneal astigmatism 0.5-0.75 Diopter
464200|NCT00842218|Gait
464201|NCT00842218|scoliosis
464202|NCT00842218|energy
464203|NCT00842218|mechanics
464204|NCT00842205|hepatitis C
464205|NCT00842205|NASH
464206|NCT00842205|Hem Oxygenase
464207|NCT00842205|Gene polymorphism
464208|NCT00842179|Perclose
464209|NCT00842153|Psoriasis
464210|NCT00842153|Plaque Type Psoriasis
464211|NCT00842140|Polycystic ovary syndrome
464212|NCT00842140|Oral Contraceptives, Hormonal
464213|NCT00842140|Cardiovascular Disease
464214|NCT00842140|Endothelium
464215|NCT00842127|Methylphenidate
464216|NCT00842127|ADHD
464217|NCT00842127|Multidrug resistance(MDR)polymorphism
464218|NCT00842127|OROS methylphenidate
464219|NCT00842114|Intermediate-high FLIPI score
464220|NCT00842114|Follicular Lymphoma
464221|NCT00842114|Progression free survival
464222|NCT00842101|Intramedullary nails
464223|NCT00842101|Compartmental syndrome
464224|NCT00842101|Fractures
464225|NCT00842075|type 1 diabetes
464226|NCT00842075|adolescents
464227|NCT00842075|post prandial glucose
464228|NCT00842049|Subarachnoid haemorrhage
464229|NCT00842049|Aneurysm
464230|NCT00842049|Cerebrospinal fluid drainage
464231|NCT00842036|Family Therapy
464232|NCT00842036|Relationship Dysfunction
464233|NCT00842036|Family Dysfunction
464234|NCT00842036|Family Relations
464235|NCT00842036|Stimulant Dependence
464236|NCT00842036|Opiate Dependence
464237|NCT00842036|Alcohol Dependence
464238|NCT00842036|Behavior Therapy
464239|NCT00842036|Drug Treatment
464240|NCT00842036|Substance Abuse
464241|NCT00842036|Drug Addiction
464242|NCT00842023|Natriuretic peptides
464243|NCT00842023|BNP
464244|NCT00842023|Heart Failure
464245|NCT00842023|Nitoglycerin
464246|NCT00842023|Biomarkers
464247|NCT00842010|Diabetes
464248|NCT00842010|Inpatient
464249|NCT00842010|Hospital
464250|NCT00842010|Hyperglycemia
464251|NCT00841984|Magnetic resonance spectroscopy
464252|NCT00841984|neurological diseases
464253|NCT00841984|metabolic
464254|NCT00841984|inborn errors of metabolism
464255|NCT00841984|Complex neurological diseases of unknown cause
464256|NCT00841945|Diffuse B larg cell lymphoma
464257|NCT00841945|Chemotherapy
464258|NCT00841945|Radiotherapy
464259|NCT00841932|Fractional Flow Reserve
464260|NCT00841932|Without anticoagulation
464261|NCT00841919|Diabetes
464262|NCT00841919|Inpatient
464263|NCT00841919|Insulin
464264|NCT00841919|Insulin pen
464265|NCT00841893|Thermogenesis
464266|NCT00841893|Meal-induced thermogenesis
464267|NCT00841893|Energy expenditure
464268|NCT00841893|Fat oxidation
464269|NCT00841893|Carbohydrate oxidation
464270|NCT00841893|Bioactive ingredient
464271|NCT00841893|Spice
464272|NCT00841867|Impaired Glucose Tolerance
464273|NCT00841867|Diabetes
464274|NCT00841854|Helicobacter pylori
464275|NCT00841854|Bismuth
464276|NCT00841854|Salvage treatment
464277|NCT00841854|Metronidazole
464278|NCT00841841|Analgesia
464279|NCT00841841|molar third
464280|NCT00841841|acetaminophen
464281|NCT00841841|dipyrone
464282|NCT00841815|Bioequivalence
464283|NCT00841815|Healthy Subjects
464284|NCT00841802|Chronic sinusitis
464285|NCT00841802|Chronic rhinosinusitis
464286|NCT00841802|Nasal polyps
464287|NCT00841789|Etanercept
464288|NCT00841776|Acne Vulgaris
464289|NCT00841776|Acne
464290|NCT00841763|virus
464291|NCT00841763|pandemic influenza
464292|NCT00841763|vaccine
464293|NCT00841750|Chest Tubes
464294|NCT00841750|Thoracic Surgery, Video-Assisted
464295|NCT00841750|Lung Diseases, Interstitial
464296|NCT00841750|Pulmonary Nodule, Solitary
464297|NCT00841737|Depressive Disorders;
464298|NCT00841737|Primary Health Care;
464299|NCT00841737|Nurses;
464300|NCT00841737|Health education.
464301|NCT00841724|Allogeneic stem cell transplantation
464302|NCT00841724|Reduced-intensity conditioning
464303|NCT00841724|Reduced-toxicity conditioning
464304|NCT00841724|Hematological malignancies
464305|NCT00841724|IV Busulfan
464306|NCT00841711|HIV
464307|NCT00841711|AIDS
464308|NCT00841711|Buprenorphine
464309|NCT00841711|Intensive Case Management
464310|NCT00841711|Money Management
464311|NCT00841711|Rapid Testing
464312|NCT00841711|Substance Abuse
464313|NCT00841711|Opioid Dependance
464314|NCT00841711|Inmate Population
464315|NCT00841698|Bioequivalence
464316|NCT00841698|Healthy Subjects
464317|NCT00841672|Hypertension
464318|NCT00841672|systolic blood pressure
464319|NCT00841672|cardiovascular disease
464320|NCT00841672|aliskiren
464321|NCT00841672|amlodipine
464322|NCT00841659|Bioequivalence
464323|NCT00841659|Healthy Subjects
464324|NCT00841646|Influenza vaccine
464325|NCT00841633|subarachnoid hemorrhage
464326|NCT00841633|ischemia
464327|NCT00841633|vasospasm
464328|NCT00841633|CT
464329|NCT00841633|perfusion
464330|NCT00841633|induced hypertension
464331|NCT00841633|delayed cerebral ischemia
464332|NCT00841620|Symptoms
464333|NCT00841620|Postoperative pain
464334|NCT00841620|Postoperative complications
464335|NCT00841620|Milligan
464336|NCT00841620|Anopxy
464337|NCT00841607|whipple
464338|NCT00841607|pancreas
464339|NCT00841607|reconstruction
464340|NCT00841607|leak
464341|NCT00841607|fistula
464342|NCT00841594|healthy volunteers
464343|NCT00841581|Age Related Macular Degeneration
464344|NCT00841581|Pigment Epithelial Detachment
464345|NCT00841581|Intravitreal Detachment
464346|NCT00841581|Anti-VEGF
464347|NCT00841568|ADPKD
464348|NCT00841568|Tolvaptan
464349|NCT00841555|adult giant cell glioblastoma
464350|NCT00841555|adult gliosarcoma
464351|NCT00841555|adult anaplastic astrocytoma
464352|NCT00841555|adult glioblastoma
464353|NCT00841555|GBM/AA
464354|NCT00841542|Bioequivalence
464355|NCT00841542|Healthy Subjects
464356|NCT00841529|left atrial appendage
464357|NCT00841529|LAA
464358|NCT00841529|atrial fibrillation
464359|NCT00841529|AF
464360|NCT00841516|Specific immunotherapy
464361|NCT00841516|SIT
464362|NCT00841516|SCIT
464363|NCT00841516|recombinant
464364|NCT00841516|Type 1 - Allergy
464365|NCT00841503|functional food study
464366|NCT00841490|Helicobacter pylori
464367|NCT00841490|Oral Health
464368|NCT00841490|Intellectually & Developmentally Disabled
464369|NCT00841477|druguser,HB vaccine adherence, HBV, HCV, HIV incidence
464370|NCT00841464|Parkinson's disease
464371|NCT00841464|Transcranial Magnetic Stimulation
464372|NCT00841451|Atrial Fibrillation
464373|NCT00841451|Persistent
464374|NCT00841451|Paroxysmal
464375|NCT00841451|Pulmonary Vein isolation
464376|NCT00841451|Omega three fatty acids
464377|NCT00841451|Fish Oils
464378|NCT00841438|Angioplasty
464379|NCT00841438|Transluminal
464380|NCT00841438|Percutaneous Coronary
464381|NCT00841412|Usual Care Control Group
464382|NCT00841399|Breast cancer
464383|NCT00841386|Cornea
464384|NCT00841386|Keratoconus
464385|NCT00841386|Ectasia
464386|NCT00841386|Riboflavin
464387|NCT00841386|Collagen cross-linking
464388|NCT00841373|Retinal ischemia: Iris/Angle Neovascularization
464389|NCT00841360|Social network
464390|NCT00841360|Asymptomatic HIV
464391|NCT00841347|Obesity
464392|NCT00841347|Glucose metabolism disorders
464393|NCT00841347|Appetite regulation
464394|NCT00841347|Sleep
464395|NCT00841347|Adolescent
464396|NCT00841347|Randomized controlled trials
464397|NCT00841334|Adolescent
464398|NCT00841334|Overweight
464399|NCT00841334|Obesity
464400|NCT00841334|Weight loss
464401|NCT00841334|Nutrition
464402|NCT00841334|Physical activity
464403|NCT00841334|Community-based participatory research
464404|NCT00841334|School-based
464405|NCT00841334|Primary Care
464406|NCT00841334|Motivational interviewing
464407|NCT00841321|Ginkgo biloba
464408|NCT00841321|Multiple Sclerosis
464409|NCT00841321|Cognition
464410|NCT00841321|Neuropsychological Tests
464411|NCT00841321|Neurobehavioral Manifestations
464412|NCT00841321|Quality of life
464413|NCT00841321|Randomized Controlled Trials
464414|NCT00841321|Placebos
464415|NCT00841321|Double-Blind Method
464416|NCT00841282|Colorectal cancer screening
464417|NCT00841282|Optical colonoscopy
464418|NCT00841282|Water method
464419|NCT00841282|Sedation
464420|NCT00841269|Bipolar Manic Depression
464421|NCT00841256|specific immunotherapy
464422|NCT00841256|SIT
464423|NCT00841256|SLIT
464424|NCT00841256|sublingual
464425|NCT00841243|Hepatitis C
464426|NCT00841243|Antiviral therapy
464427|NCT00841243|weight loss
464428|NCT00841243|dietary support
464429|NCT00841243|dietary advise
464430|NCT00841230|Tinnitus
464431|NCT00841217|Drug treatment
464432|NCT00841191|Resistant to anti-EGFR
464433|NCT00841191|Interleukin-6
464434|NCT00841191|Neoplasms by Histologic Type
464435|NCT00841191|Immunologic Factors
464436|NCT00841191|Mol Physiological Effects of Drugs
464437|NCT00841191|KRAS protein, human
464438|NCT00841191|CNTO 328
464439|NCT00841178|Randomised controlled trial
464440|NCT00841178|Venous insufficiency
464441|NCT00841178|Varicose veins
464442|NCT00841178|Quality of Life
464443|NCT00841178|Clinical effectiveness
464444|NCT00841178|Cost effectiveness
464445|NCT00841165|Carbon Monoxide Toxicity
464446|NCT00841165|Carbon
464447|NCT00841165|Monoxide
464448|NCT00841165|Poisoning
464449|NCT00841165|Toxicity
464450|NCT00841165|Treatment
464451|NCT00841165|CPAP
464452|NCT00841165|Hyperbaric
464453|NCT00841165|Oxygen
464454|NCT00841152|Bone tumors
464455|NCT00841152|Surgery
464456|NCT00841152|Bone graft substitutes
464457|NCT00841152|Bioactive glass
464458|NCT00841152|Bioceramics
464459|NCT00841152|Bone autograft
464460|NCT00841152|Bone allograft
464461|NCT00841139|perhexiline
464462|NCT00841139|idiopathic dilated cardiomyopathy
464463|NCT00841139|magnetic resonance spectroscopy
464464|NCT00841139|cardiac energetics
464465|NCT00841126|Hyperphosphatemia
464466|NCT00841126|Phosphate binder
464467|NCT00841113|Prostate cancer
464468|NCT00841113|Advanced
464469|NCT00841113|Metastatic
464470|NCT00841100|PKU
464471|NCT00841100|Kuvan
464472|NCT00841100|BH4
464473|NCT00841100|tetrahydrobiopterin
464474|NCT00841074|Pneumonia
464475|NCT00841074|Elderly
464476|NCT00841074|Chlorhexidine
464477|NCT00841074|Respiratory pathogens
464478|NCT00841048|Safety and tolerability
464479|NCT00841035|Pancreatic
464480|NCT00841035|Cancer
464481|NCT00841035|Assay
464482|NCT00841035|Biomarkers
464483|NCT00841022|anxiety
464484|NCT00841022|anaesthesia
464485|NCT00841022|child
464486|NCT00841022|RCT
464487|NCT00841022|Elective surgery
464488|NCT00841009|gastric bypass
464489|NCT00841009|obesity
464490|NCT00840996|Spine Surgery
464491|NCT00840996|Intraocular pressure
464492|NCT00840996|Lidocaine
464493|NCT00840996|Epidural Anesthetic
464494|NCT00840983|delayed cord clamping
464495|NCT00840983|very low birthweight infant
464496|NCT00840983|bronchopulmonary dysplasia
464497|NCT00840983|intraventricular hemorrhage
464498|NCT00840983|motor function
464499|NCT00840944|gonadotropin releasing hormone agonist
464500|NCT00840944|growth hormone
464501|NCT00840944|final height
464502|NCT00840944|bone density
464503|NCT00840944|puberty
464504|NCT00840931|Myeloid
464505|NCT00840931|Monocytic
464506|NCT00840931|Immunotherapy
464507|NCT00840931|Vaccine
464508|NCT00840931|MDS
464509|NCT00840931|High Risk Myelodysplastic Syndrome
464510|NCT00840918|Cardiac surgery
464511|NCT00840918|Lidocaine
464512|NCT00840918|Quality of life
464513|NCT00840905|HPV
464514|NCT00840879|Bioequivalence
464515|NCT00840879|Healthy Subjects
464516|NCT00840866|Bioequivalence
464517|NCT00840866|Healthy Subjects
464518|NCT00840853|Stem cell transplant
464519|NCT00840853|Acute Lymphoblastic Leukemia (ALL)
464520|NCT00840853|Chronic Lymphocytic Leukemia (CLL)
464521|NCT00840853|Non Hodgkin's Lymphoma
464522|NCT00840853|Cytotoxic T lymphocytes
464523|NCT00840853|CTL
464524|NCT00840853|CD-19
464525|NCT00840853|chimeric receptor
464526|NCT00840840|Bioequivalence
464527|NCT00840840|Healthy Subjects
464528|NCT00840827|stage (IPSS low and INT-1)
464529|NCT00840827|RBC transfusion-dependent
464530|NCT00840827|non-del 5q MDS
464531|NCT00840814|lymphedema
464532|NCT00840814|stage I squamous cell carcinoma of the hypopharynx
464533|NCT00840814|stage II squamous cell carcinoma of the hypopharynx
464534|NCT00840814|stage III squamous cell carcinoma of the hypopharynx
464535|NCT00840814|stage I squamous cell carcinoma of the larynx
464536|NCT00840814|stage I verrucous carcinoma of the larynx
464537|NCT00840814|stage II squamous cell carcinoma of the larynx
464538|NCT00840814|stage II verrucous carcinoma of the larynx
464539|NCT00840814|stage III squamous cell carcinoma of the larynx
464540|NCT00840814|stage III verrucous carcinoma of the larynx
464541|NCT00840814|stage I squamous cell carcinoma of the lip and oral cavity
464542|NCT00840814|stage II squamous cell carcinoma of the lip and oral cavity
464543|NCT00840814|stage III squamous cell carcinoma of the lip and oral cavity
464544|NCT00840814|stage I verrucous carcinoma of the oral cavity
464545|NCT00840814|stage II verrucous carcinoma of the oral cavity
464546|NCT00840814|stage III verrucous carcinoma of the oral cavity
464547|NCT00840814|stage I squamous cell carcinoma of the nasopharynx
464548|NCT00840814|stage II squamous cell carcinoma of the nasopharynx
464549|NCT00840814|stage III squamous cell carcinoma of the nasopharynx
464550|NCT00840814|stage I squamous cell carcinoma of the oropharynx
464551|NCT00840814|stage II squamous cell carcinoma of the oropharynx
464552|NCT00840814|stage III squamous cell carcinoma of the oropharynx
464553|NCT00840814|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
464554|NCT00840814|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
464555|NCT00840814|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
464556|NCT00840814|salivary gland squamous cell carcinoma
464557|NCT00840814|stage I salivary gland cancer
464558|NCT00840814|stage II salivary gland cancer
464559|NCT00840814|stage III salivary gland cancer
464560|NCT00840788|skin adhesive
464561|NCT00840788|tissue adhesive
464562|NCT00840788|mediolateral episiotomy
464563|NCT00840788|perineal repair
464564|NCT00840788|labor and delivery
464565|NCT00840788|repair
464566|NCT00840775|Stent
464567|NCT00840775|interventional cardiology
464568|NCT00840775|catheterization
464569|NCT00840775|symptomatic ischemic heart disease
464570|NCT00840762|HIV-1
464571|NCT00840762|HIV
464572|NCT00840762|HIV Genotypic testing
464573|NCT00840762|resistance
464574|NCT00840749|STARS
464575|NCT00840749|Early Stage Non Small Cell Lung Cancer
464576|NCT00840749|NSCLC
464577|NCT00840749|CyberKnife
464578|NCT00840749|Surgery
464579|NCT00840749|Accuray
464580|NCT00840736|VBG
464581|NCT00840736|LAGB
464582|NCT00840736|long term results
464583|NCT00840736|Weight loss
464584|NCT00840736|Complications
464585|NCT00840736|Reoperations
464586|NCT00840736|Conversion
464587|NCT00840723|Healthy smokers
464588|NCT00840723|Current cigarette smokers
464589|NCT00840723|No lung disease
464590|NCT00840710|women in active labor
464591|NCT00840697|low back pain
464592|NCT00840697|neck pain
464593|NCT00840697|return to work
464594|NCT00840697|exercises
464595|NCT00840697|cognitive intervention
464596|NCT00840684|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
464597|NCT00840684|untreated adult acute myeloid leukemia
464598|NCT00840671|Cerebrolysin
464599|NCT00840671|Alteplase
464600|NCT00840671|Ischemic Stroke
464601|NCT00840671|Modified Rankin Scale
464602|NCT00840671|NIH Stroke Scale
464603|NCT00840671|Barthel Index
464604|NCT00840671|Glasgow Outcome Score
464605|NCT00840658|HIV
464606|NCT00840658|Injection drug users
464607|NCT00840658|Female sex workers
464608|NCT00840658|STIs
464609|NCT00840658|HIV Seronegativity
464610|NCT00840645|YM178
464611|NCT00840645|Urinary Bladder, Overactive
464612|NCT00840645|Mirabegron
464613|NCT00840632|Bioequivalence
464614|NCT00840632|Healthy Subjects
464615|NCT00840606|Bioequivalence
464616|NCT00840606|Healthy Subjects
464617|NCT00840593|Acromioclavicular Joint
464618|NCT00840593|Dislocation
464619|NCT00840593|Trials, Randomized Clinical
464620|NCT00840593|Surgical Procedures, Operative
464621|NCT00840580|Cataract, Cornea, Vigamox, Cravit
464622|NCT00840567|Stem cells
464623|NCT00840554|Fatigue
464624|NCT00840554|Cancer-related fatigue
464625|NCT00840554|High grade glioma
464626|NCT00840554|Quality of life
464627|NCT00840554|Exercise
464628|NCT00840554|Physical Therapy
464629|NCT00840554|HGG
464630|NCT00840554|QOL
464631|NCT00840528|ozone
464632|NCT00840502|malaria
464633|NCT00840502|ultrasound
464634|NCT00840502|pregnancy
464635|NCT00840502|Pregnant women (infected with malaria and without)
464636|NCT00840476|Bioequivalence
464637|NCT00840476|Healthy Subjects
464638|NCT00840463|Pulmonary Hypertension
464639|NCT00840463|Diastolic Heart Failure
464640|NCT00840450|ovarian cancer
464641|NCT00840450|recurrent
464642|NCT00840450|Gleevec
464643|NCT00840450|Paclitaxel
464644|NCT00840450|Taxane
464645|NCT00840450|mullerian
464646|NCT00840437|angina
464647|NCT00840437|health related quality of life
464648|NCT00840411|Bioequivalence
464649|NCT00840411|Healthy Subjects
464650|NCT00840398|Bioequivalence
464651|NCT00840398|Healthy Subjects
464652|NCT00840385|Peripheral T-cell lymphomas (PTCL)
464653|NCT00840385|Fludarabine
464654|NCT00840372|Blunt needles
464655|NCT00840372|Semi-blunt needles
464656|NCT00840372|Buttonhole cannulation method
464657|NCT00840359|Cutaneous leishmaniasis
464658|NCT00840359|Photodynamic therapy
464659|NCT00840346|Acute Myeloblastic Leukaemia (AML)
464660|NCT00840346|Panobinostat
464661|NCT00840320|Safety
464662|NCT00840320|tolerability
464663|NCT00840307|Obesity
464664|NCT00840307|Type 2 Diabetes
464665|NCT00840307|Gastric Banding
464666|NCT00840294|Men with Elevated PSA
464667|NCT00840281|Bioequivalence
464668|NCT00840281|Healthy Subjects
464669|NCT00840268|OSDI
464670|NCT00840268|corneal staining
464671|NCT00840268|Dry Eye
464672|NCT00840268|Dry Eye Signs and Symptoms in Dry Eye Patients
464673|NCT00840255|Chronic Insomnia lasting more than 1 month
464674|NCT00840229|adhesive capsulitis
464675|NCT00840229|corticosteroids
464676|NCT00840229|injection
464677|NCT00840229|pain
464678|NCT00840216|Bioequivalence
464679|NCT00840216|Healthy Subjects
464680|NCT00840203|Bioequivalence
464681|NCT00840203|Healthy Subjects
464682|NCT00840177|recurrent adult acute myeloid leukemia
464683|NCT00840177|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
464684|NCT00840177|adult acute myeloid leukemia with inv(16)(p13;q22)
464685|NCT00840177|adult acute myeloid leukemia with t(15;17)(q22;q12)
464686|NCT00840177|adult acute myeloid leukemia with t(16;16)(p13;q22)
464687|NCT00840177|adult acute myeloid leukemia with t(8;21)(q22;q22)
464688|NCT00840164|small-fiber sensory neuropathy
464689|NCT00840164|nerve pathology
464690|NCT00840164|vasculature pathology
464691|NCT00840164|amputation
464692|NCT00840164|diabetic foot wound
464693|NCT00840164|sensory neuropathy
464694|NCT00840164|below knee amputation
464695|NCT00840151|Substance Abuse
464696|NCT00840151|Contingency Management
464697|NCT00840125|NSCLC
464698|NCT00840125|ERLOTINIB
464699|NCT00840125|DOCETAXEL
464700|NCT00840125|first line treatment
464701|NCT00840125|Stage IIIB /IV
464702|NCT00840125|not previously treated
464703|NCT00840125|ECOG PS 2 or age over 65
464704|NCT00840112|Long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD)
464705|NCT00840112|Mitochondrial trifunctional protein (TFP)
464706|NCT00840112|LCHAD/TFP deficiency with peripheral neuropathy
464707|NCT00840099|Bioequivalence
464708|NCT00840099|Healthy Subjects
464709|NCT00840073|Bioequivalence
464710|NCT00840073|Healthy Subjects
464711|NCT00840047|Pediatric brain tumor
464712|NCT00840047|Pediatric solid tumor
464713|NCT00840047|Pediatric solid neoplasms
464714|NCT00840008|peptic ulcer bleeding
464715|NCT00840008|upper GI hemorrhage
464716|NCT00840008|adherence to guidelines
464717|NCT00840008|knowledge transfer
464718|NCT00839995|To determine the efficacy of ROTEM on assessing coagulation profiles.
464719|NCT00839969|overactive bladder syndrome
464720|NCT00839969|voiding
464721|NCT00839969|pressure flow studies
464722|NCT00839969|urethral dilatation
464723|NCT00839943|ozone
464724|NCT00839943|clean air
464725|NCT00839930|Bioequivalence
464726|NCT00839930|Healthy Subjects
464727|NCT00839917|Measles
464728|NCT00839917|Mumps
464729|NCT00839917|Rubella
464730|NCT00839917|Varicella
464731|NCT00839904|children
464732|NCT00839904|cancer
464733|NCT00839904|exercise
464734|NCT00839904|fitness
464735|NCT00839904|body composition
464736|NCT00839891|TQT, QTc
464737|NCT00839865|Evidence-based evaluation
464738|NCT00839865|Multi-center randomized controlled clinical trials
464739|NCT00839865|Traditional Chinese Medicine
464740|NCT00839865|therapy
464741|NCT00839865|diabetic foot ulcer
464742|NCT00839865|clinical trails
464743|NCT00839839|infertility
464744|NCT00839839|egg freezing
464745|NCT00839839|fertility preservation
464746|NCT00839826|Prevention of Thromboembolism after total hip replacement
464747|NCT00839813|Yoga
464748|NCT00839813|Posttraumatic Stress Disorder
464749|NCT00839813|PTSD
464750|NCT00839813|women's health
464751|NCT00839800|Asthma
464752|NCT00839800|Symbicort Turbuhaler
464753|NCT00839774|Peas
464754|NCT00839774|Cardiovascular
464755|NCT00839774|Diabetes
464756|NCT00839774|Insulin
464757|NCT00839774|Insulin resistance
464758|NCT00839774|Abdominal fat
464759|NCT00839748|asthma
464760|NCT00839748|registry for future asthmatic studies
464761|NCT00839748|questionnaires
464762|NCT00839748|lung function tests
464763|NCT00839735|COPD
464764|NCT00839722|Uterine embolization
464765|NCT00839722|leiomyomas
464766|NCT00839722|fertility
464767|NCT00839722|myomectomies
464768|NCT00839709|liver disease
464769|NCT00839709|liver transplantation
464770|NCT00839709|depletion immunosuppression
464771|NCT00839709|non-depletion immunosuppression
464772|NCT00839696|Breast
464773|NCT00839696|Estrogens
464774|NCT00839696|Mammography
464775|NCT00839670|1- Constraint induced therapy
464776|NCT00839670|2- Stroke
464777|NCT00839670|3- Upper limb
464778|NCT00839670|4- Rehabilitation
464779|NCT00839670|5- Motor training
464780|NCT00839670|1- First time clinical ischemic or hemorrhagic stroke
464781|NCT00839670|2- At least 10° of active wrist extension
464782|NCT00839670|3- At least 10° of thumb abduction/ extension
464783|NCT00839670|4- At least 10° of extension in at least 2 additional digits
464784|NCT00839670|3- Adequate balance while wearing the restraint.
464785|NCT00839657|Embolism
464786|NCT00839657|Thrombosis
464787|NCT00839644|cystic fibrosis
464788|NCT00839644|Chest Wall Oscillation
464789|NCT00839644|drainage, postural
464790|NCT00839644|Medication Adherence
464791|NCT00839644|patient dropouts
464792|NCT00839631|subjects with advanced solid tumors refractory to standard therapy or for whom no effective therapy is available.
464793|NCT00839605|Thoracic surgery one lung ventilation
464794|NCT00839605|airway reconstruction
464795|NCT00839592|Insomnia
464796|NCT00839592|Acupuncture
464797|NCT00839592|Electroacupuncture
464798|NCT00839592|Randomized Clinical Trial
464799|NCT00839592|Traditional Chinese Medicine
464800|NCT00839579|slightly overweight
464801|NCT00839579|males 35-45 years
464802|NCT00839566|Atrial Fibrillation
464803|NCT00839566|Heart Failure
464804|NCT00839540|candidemia
464805|NCT00839540|echinocandin
464806|NCT00839540|micafungin
464807|NCT00839540|caspofungin
464808|NCT00839527|diabetes
464809|NCT00839514|Parkinson's disease
464810|NCT00839514|Trichloroethylene
464811|NCT00839488|pantoprazole
464812|NCT00839488|famotidine
464813|NCT00839488|stomach ulcer
464814|NCT00839488|digestive system surgical procedure
464815|NCT00839475|colposcopy
464816|NCT00839475|Cervical intraepithelial neoplasia
464817|NCT00839475|cervical cancer
464818|NCT00839475|cervical precancer
464819|NCT00839462|Thermal Erythema
464820|NCT00839462|Dexpanthenol
464821|NCT00839462|Erythema
464822|NCT00839462|Efficacy
464823|NCT00839449|subarachnoid hemorrhage
464824|NCT00839449|cerebral vasospasm
464825|NCT00839449|eicosapentaenoic acid
464826|NCT00839436|Idiopathic CD4+ T-Lymphocytopenia
464827|NCT00839436|Interleukin-7
464828|NCT00839436|Clinical Trial
464829|NCT00839436|T-Lymphocytes
464830|NCT00839436|Idiopathic CD4 Lymphocytopenia (ICL)
464831|NCT00839436|ICL
464832|NCT00839423|Major depressive disorder
464833|NCT00839423|Placebo-controlled
464834|NCT00839423|Active reference
464835|NCT00839423|Multicenter study
464836|NCT00839423|Randomised study
464837|NCT00839423|Acute treatment
464838|NCT00839410|skin cancer
464839|NCT00839410|melanoma
464840|NCT00839410|sentinel lymph node biopsy
464841|NCT00839410|bio bank
464842|NCT00839410|genetic polymorphism
464843|NCT00839410|prospective cohort
464844|NCT00839410|cohort
464845|NCT00839410|sentinel lymph nodes
464846|NCT00839410|tissue samples
464847|NCT00839371|bispectral analysis
464848|NCT00839371|bronchoscopy
464849|NCT00839371|midazolam
464850|NCT00839371|propofol
464851|NCT00839371|recovery
464852|NCT00839371|sedation
464853|NCT00839358|cirrhosis
464854|NCT00839358|renal failure
464855|NCT00839358|midodrine
464856|NCT00839358|albumine
464857|NCT00839345|platelet
464858|NCT00839345|clopidogrel
464859|NCT00839345|VerifyNow
464860|NCT00839345|ticlopidine
464861|NCT00839345|thrombosis
464862|NCT00839332|Pancreas
464863|NCT00839332|metastatic cancer
464864|NCT00839332|advanced cancer
464865|NCT00839332|Pancreatic cancer
464866|NCT00839319|hCG
464867|NCT00839319|testosterone
464868|NCT00839319|Acyline
464869|NCT00839319|Intratesticular hormone
464870|NCT00839306|Gastroesophageal
464871|NCT00839306|Reflux
464872|NCT00839306|Disease
464873|NCT00839306|GERD
464874|NCT00839293|Bioavailability
464875|NCT00839280|Dry skin
464876|NCT00839280|Dexpanthenol
464877|NCT00839280|Moisturizing effect
464878|NCT00839267|platelet
464879|NCT00839267|VASP
464880|NCT00839267|clopidogrel
464881|NCT00839267|cardiogenic shock
464882|NCT00839267|myocardial infarction
464883|NCT00839267|percutaneous coronary intervention
464884|NCT00839254|Streptococcus pneumoniae
464885|NCT00839254|acute otitis media
464886|NCT00839254|Pneumococcal conjugate vaccine
464887|NCT00839254|nasopharyngeal carriage
464888|NCT00839254|Haemophilus influenzae
464889|NCT00839254|immunogenicity
464890|NCT00839254|invasive disease
464891|NCT00839228|diastolic dysfunction
464892|NCT00839228|cardiac energetics
464893|NCT00839228|perhexiline
464894|NCT00839228|magnetic resonance spectroscopy
464895|NCT00839202|factor VIII
464896|NCT00839202|hemophilia A
464897|NCT00839202|assay
464898|NCT00839189|CCRE
464899|NCT00839189|endotoxin
464900|NCT00839189|LPS
464901|NCT00839189|asthma
464902|NCT00839189|allergies
464903|NCT00839189|allergic rhinitis
464904|NCT00839176|Major Depressive Disorder (MDD)
464905|NCT00839176|Serdaxin
464906|NCT00839176|Rexahn
464907|NCT00839163|Embolism and Thrombosis
464908|NCT00839163|Pulmonary embolism
464909|NCT00839163|Embolism
464910|NCT00839163|Thrombosis
464911|NCT00839150|Diabetic retinopathy
464912|NCT00839150|Color vision
464913|NCT00839150|Contrast sensitivity
464914|NCT00839150|Electroretinogram
464915|NCT00839150|Flicker-induced vasodilatation
464916|NCT00839150|Dynamic Vessel Analyzer
464917|NCT00839137|asthma
464918|NCT00839137|exercise therapy
464919|NCT00839124|normal volunteer
464920|NCT00839124|healthy control volunteer
464921|NCT00839124|healthy subjects
464922|NCT00839124|asthma
464923|NCT00839124|allergy
464924|NCT00839124|allergic asthma
464925|NCT00839111|Progression free survival
464926|NCT00839111|Toxicity
464927|NCT00839111|Response rate
464928|NCT00839111|overall survival
464929|NCT00839098|power wheelchairs
464930|NCT00839098|assistive technology
464931|NCT00839098|rehabilitation
464932|NCT00839085|CABG
464933|NCT00839085|on pump
464934|NCT00839085|Grape seed extract
464935|NCT00839085|Vit C
464936|NCT00839085|Oxidative stress
464937|NCT00839072|bioavailability
464938|NCT00839072|pharmacokinetics
464939|NCT00839072|healthy
464940|NCT00839072|crossover
464941|NCT00839072|trazodone
464942|NCT00839059|AML
464943|NCT00839059|lenalidomide
464944|NCT00839046|Pediatric Asthma
464945|NCT00839046|Air Filters
464946|NCT00839046|Indoor Particulate Matter
464947|NCT00839033|Cough assisted device
464948|NCT00839033|Neuromuscular disease
464949|NCT00839033|Respiratory exacerbation
464950|NCT00839033|Invasive ventilation,
464951|NCT00839033|Chest physiotherapy
464952|NCT00839033|Congenital myopathies
464953|NCT00839020|Surgical Procedures, Minimally Invasive
464954|NCT00839020|Range of Motion
464955|NCT00839020|Articular Arthroplasty, Replacement, Knee
464956|NCT00839007|ADHF
464957|NCT00839007|AHF
464958|NCT00839007|HF
464959|NCT00838994|Insomnia
464960|NCT00838994|Depression
464961|NCT00838994|Electroacupuncture
464962|NCT00838994|Acupuncture
464963|NCT00838994|Randomized Clinical Trial
464964|NCT00838994|Traditional Chinese Medicine
464965|NCT00838981|Treatment for addiction
464966|NCT00838981|Methadone given for opioid dependence
464967|NCT00838981|Cocaine
464968|NCT00838981|Opiates
464969|NCT00838968|hepatocellular carcinoma
464970|NCT00838968|interferon-alpha
464971|NCT00838968|p48
464972|NCT00838955|Hodgkin's lymphoma
464973|NCT00838955|relapsed Hodgkin's lymphoma
464974|NCT00838955|refractory Hodgkin's lymphoma
464975|NCT00838955|Temsirolimus
464976|NCT00838942|Eyes disease and dementia.
464977|NCT00838942|Cataract surgery in the patient with dementia.
464978|NCT00838942|Visual hallucinations
464979|NCT00838942|Visual acuity,
464980|NCT00838942|Specific eye pathologies in Alzheimer's disease.
464981|NCT00838942|Improvement of behaviour,
464982|NCT00838942|Improvement of autonomy
464983|NCT00838942|Improvement of mood
464984|NCT00838942|Cataract extraction in Alzheimer disease patient
464985|NCT00838929|brain metastases
464986|NCT00838929|radiation
464987|NCT00838929|vorinostat
464988|NCT00838929|lung cancer
464989|NCT00838929|breast cancer
464990|NCT00838916|diabetes
464991|NCT00838903|diabetes
464992|NCT00838877|Alzheimer's Disease
464993|NCT00838877|PET
464994|NCT00838877|Phase 1
464995|NCT00838877|Positron Emission Tomography
464996|NCT00838864|variceal bleeding
464997|NCT00838864|antibiotic prophylaxis
464998|NCT00838864|ceftrioxone
464999|NCT00838851|endotoxin
465000|NCT00838851|CCRE
465001|NCT00838851|LPS
465002|NCT00838838|Testosterone replacement therapy
465003|NCT00838838|Hypogonadism
465004|NCT00838838|Osteoporosis
465005|NCT00838838|Immobilisation
465006|NCT00838838|Paraplegia
465007|NCT00838838|Testosterone
465008|NCT00838825|diabetes
465009|NCT00838825|chronic care management
465010|NCT00838825|resource utilization
465011|NCT00838825|outcome
465012|NCT00838825|glycohemoglobin
465013|NCT00838825|hospitalization
465014|NCT00838812|clindamycin
465015|NCT00838812|tretinoin
465016|NCT00838812|acne vulgaris
465017|NCT00838812|Acne vulgaris mild to moderate
465018|NCT00838799|diabetic
465019|NCT00838799|peripheral
465020|NCT00838799|neuropathic
465021|NCT00838799|pain
465022|NCT00838799|chronic
465023|NCT00838799|diabetes
465024|NCT00838760|PEPI-TiDP23-C103
465025|NCT00838760|PEPI-C103
465026|NCT00838760|PEPI
465027|NCT00838760|TMC558445
465028|NCT00838760|TMC310911
465029|NCT00838760|Darunavir, Healthy volunteers
465030|NCT00838760|Pharmacokinetics
465031|NCT00838760|HIV Infections
465032|NCT00838747|folate receptor
465033|NCT00838747|blood samples
465034|NCT00838747|ovarian cancer
465035|NCT00838747|development of measure of folate receptor in blood samples
465036|NCT00838747|possible selection of patients for treatment with FR targeted agents
465037|NCT00838734|CORNEAL TOPOGRAPHY
465038|NCT00838734|KERATOPLASTY
465039|NCT00838721|Open Angle Glaucoma
465040|NCT00838721|Ocular Hypertension
465041|NCT00838721|Laser Trabeculoplasty
465042|NCT00838695|Hand vein sensitivity
465043|NCT00838695|phenylephrine
465044|NCT00838695|nitroglycerin
465045|NCT00838682|peptic ulcer bleeding
465046|NCT00838682|rabeprazole
465047|NCT00838682|proton pump inhibitor
465048|NCT00838669|Schizophrenia
465049|NCT00838669|Mood disorders
465050|NCT00838669|Antipsychotic drugs
465051|NCT00838669|Extended release OROS paliperidone
465052|NCT00838656|ovarian carcinosarcoma
465053|NCT00838656|stage IIIA ovarian epithelial cancer
465054|NCT00838656|stage IIIB ovarian epithelial cancer
465055|NCT00838656|stage IIIC ovarian epithelial cancer
465056|NCT00838656|stage IV ovarian epithelial cancer
465057|NCT00838656|stage IIIA primary peritoneal cavity cancer
465058|NCT00838656|stage IIIB primary peritoneal cavity cancer
465059|NCT00838656|stage IIIC primary peritoneal cavity cancer
465060|NCT00838656|stage IV primary peritoneal cavity cancer
465061|NCT00838656|stage IIIA fallopian tube cancer
465062|NCT00838656|stage IIIB fallopian tube cancer
465063|NCT00838656|stage IIIC fallopian tube cancer
465064|NCT00838656|stage IV fallopian tube cancer
465065|NCT00838643|allogeneic transplantation
465066|NCT00838643|Invasive aspergillosis
465067|NCT00838630|Bioequivalence
465068|NCT00838630|Healthy Subjects
465069|NCT00838617|Amyotrophic Lateral Sclerosis
465070|NCT00838617|Ultrasonography
465071|NCT00838617|Atrophy
465072|NCT00838591|MN-221
465073|NCT00838591|Asthma
465074|NCT00838591|Acute
465075|NCT00838591|Exacerbation
465076|NCT00838578|KRN330
465077|NCT00838578|Colorectal Cancer
465078|NCT00838578|Antimetabolites
465079|NCT00838578|Antimetabolites, Antineoplastic
465080|NCT00838578|Digestive System Neoplasms
465081|NCT00838578|Immunologic Factors
465082|NCT00838578|Molecular Mechanisms of Pharmacological Action
465083|NCT00838578|Antineoplastic Agents
465084|NCT00838578|Gastrointestinal Diseases
465085|NCT00838578|Physiological Effects of Drugs
465086|NCT00838578|Colonic Diseases
465087|NCT00838578|Irinotecan
465088|NCT00838578|Enzyme Inhibitors
465089|NCT00838578|Intestinal Diseases
465090|NCT00838578|Immunosuppressive Agents
465091|NCT00838578|Rectal Diseases
465092|NCT00838578|Pharmacologic Actions
465093|NCT00838578|Intestinal Neoplasms
465094|NCT00838578|Neoplasms by Site
465095|NCT00838578|Digestive System Diseases
465096|NCT00838578|Therapeutic Uses
465097|NCT00838578|Fluorouracil
465098|NCT00838578|Neoplasms
465099|NCT00838578|Gastrointestinal Neoplasms
465100|NCT00838578|Antineoplastic Agents, Phytogenic
465101|NCT00838578|Colorectal Neoplasms
465102|NCT00838565|Safety and tolerability Pharmacokinetics Pharmacodynamics PF-04236921
465103|NCT00838552|asthma inflammation bronchoscopy
465104|NCT00838539|Neratinib in combination with Temsirolimus
465105|NCT00838539|solid tumors
465106|NCT00838539|phase 1
465107|NCT00838539|dose finding study
465108|NCT00838526|Gastroesophageal
465109|NCT00838526|Reflux
465110|NCT00838526|Disease
465111|NCT00838526|GERD
465112|NCT00838513|aHUS
465113|NCT00838500|Venous insufficiency
465114|NCT00838500|Leg ulcer
465115|NCT00838500|balneology
465116|NCT00838500|hydrotherapy
465117|NCT00838500|Modified Rutherford score
465118|NCT00838500|Euroquol EQ 5d scale
465119|NCT00838500|CIVIQ2 scale
465120|NCT00838500|Visual analogic Scale
465121|NCT00838500|SPA treatment
465122|NCT00838487|chondroitin
465123|NCT00838487|glucosamine
465124|NCT00838487|osteoarthritis
465125|NCT00838474|metabolic rate
465126|NCT00838474|music
465127|NCT00838474|preterm infants
465128|NCT00838474|energy expenditure
465129|NCT00838474|NIDCA
465130|NCT00838448|exercise
465131|NCT00838448|cannabis use
465132|NCT00838448|visual cues
465133|NCT00838435|Phenylketonuria
465134|NCT00838435|PKU
465135|NCT00838435|Kuvan
465136|NCT00838435|Phenoptin
465137|NCT00838435|Biopten
465138|NCT00838435|Neurocognitive Function
465139|NCT00838435|Phenylalanine
465140|NCT00838383|multi-center, placebo-controlled, randomized study of sitaxsentan administered to subjects post-cross-clamp release and 12 hours post-CPB
465141|NCT00838370|Pharmacogenetics
465142|NCT00838370|cost-benefit analysis
465143|NCT00838370|toxicity
465144|NCT00838370|antineoplastic drugs
465145|NCT00838370|Dihydropyrimidine Dehydrogenase
465146|NCT00838357|Mobilisation stem cells
465147|NCT00838357|G-CSF Mobilisation Regimen
465148|NCT00838357|Lymphoma
465149|NCT00838357|Multiple Myeloma
465150|NCT00838344|medication adherence
465151|NCT00838344|medication persistence
465152|NCT00838344|pharmacist interventions
465153|NCT00838344|diabetes
465154|NCT00838344|persistence
465155|NCT00838344|adherence
465156|NCT00838331|Blood Transfusions
465157|NCT00838318|Colorectal CancerScreening
465158|NCT00838318|CRC
465159|NCT00838318|Hispanic
465160|NCT00838318|CRC Patients
465161|NCT00838318|First-Degree Relatives
465162|NCT00838318|FDRs
465163|NCT00838318|Interviews
465164|NCT00838318|Colorectal cancer screening
465165|NCT00838318|CRCS
465166|NCT00838318|Key Informants
465167|NCT00838305|MDMA
465168|NCT00838305|citalopram
465169|NCT00838305|serotonin
465170|NCT00838305|psychedelic
465171|NCT00838292|food supplementation
465172|NCT00838292|HIV
465173|NCT00838292|malnutrition
465174|NCT00838279|Bioequivalence
465175|NCT00838279|Healthy Subjects
465176|NCT00838266|mouthrinse
465177|NCT00838266|grape seed extract
465178|NCT00838266|fluor
465179|NCT00838266|plaque index
465180|NCT00838253|Acute Heart Failure
465181|NCT00838253|Inotropes
465182|NCT00838253|Lusitropic agents
465183|NCT00838253|Istaroxime
465184|NCT00838253|Debio 0614
465185|NCT00838240|adult acute minimally differentiated myeloid leukemia (M0)
465186|NCT00838240|adult acute myeloblastic leukemia without maturation (M1)
465187|NCT00838240|adult acute myeloblastic leukemia with maturation (M2)
465188|NCT00838240|adult acute myelomonocytic leukemia (M4)
465189|NCT00838240|adult acute monoblastic leukemia (M5a)
465190|NCT00838240|adult acute monocytic leukemia (M5b)
465191|NCT00838240|adult erythroleukemia (M6a)
465192|NCT00838240|adult pure erythroid leukemia (M6b)
465193|NCT00838240|adult acute megakaryoblastic leukemia (M7)
465194|NCT00838240|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
465195|NCT00838240|adult acute myeloid leukemia with t(16;16)(p13;q22)
465196|NCT00838240|adult acute myeloid leukemia with t(8;21)(q22;q22)
465197|NCT00838240|adult acute myeloid leukemia with inv(16)(p13;q22)
465198|NCT00838240|untreated adult acute myeloid leukemia
465199|NCT00838240|de novo myelodysplastic syndromes
465200|NCT00838240|secondary acute myeloid leukemia
465201|NCT00838227|Schizophrenia
465202|NCT00838227|Cognition
465203|NCT00838227|Obesity
465204|NCT00838227|Sedation
465205|NCT00838201|Androgen deprivation therapy for non-metastatic prostate cancer
465206|NCT00838188|Metabolic rate
465207|NCT00838188|indirect calorimetry
465208|NCT00838188|oral feeding
465209|NCT00838175|Peripheral Venous Catheterization
465210|NCT00838162|Human immunodeficiency virus type 1
465211|NCT00838162|HIV-1
465212|NCT00838162|HIV-1 treatment-naive
465213|NCT00838162|TMC310911
465214|NCT00838162|Protease inhibitor
465215|NCT00838162|Ritonavir
465216|NCT00838162|Antiviral Activity
465217|NCT00838162|HIV Infections
465218|NCT00838162|Treatment Naive
465219|NCT00838136|Bioequivalence
465220|NCT00838136|Healthy Subjects
465221|NCT00838110|Alzheimer's Disease
465222|NCT00838110|Dimebon
465223|NCT00838110|Safety
465224|NCT00838110|Tolerability
465225|NCT00838097|CKD
465226|NCT00838097|Paediatric
465227|NCT00838097|Darbepoetin Alfa
465228|NCT00838071|Hepatitis B
465229|NCT00838071|HBV
465230|NCT00838071|Anti-hepatitis B antibodies
465231|NCT00838071|Immunoglobulins
465232|NCT00838071|liver transplantation
465233|NCT00838071|Protective levels
465234|NCT00838071|Recurrence
465235|NCT00838071|Intravenous
465236|NCT00838058|pharmacology formulation normal healthy volunteers food effect
465237|NCT00838032|acute schizophrenic patients
465238|NCT00838006|post-traumatic stress disorder
465239|NCT00838006|post-deployment
465240|NCT00838006|prediction
465241|NCT00838006|prevention
465242|NCT00837993|Advanced Stage Serous Carcinoma of the Ovary
465243|NCT00837993|serous ovarian carcinoma
465244|NCT00837993|Ovary
465245|NCT00837993|GOG Protocol 158
465246|NCT00837993|Survival Analysis
465247|NCT00837993|Pathology Slides
465248|NCT00837993|Two-tier Grading System
465249|NCT00837993|Ancillary Study
465250|NCT00837980|head and neck cancer
465251|NCT00837980|DW MRI
465252|NCT00837980|PET
465253|NCT00837980|DCE MRI
465254|NCT00837980|functional imaging
465255|NCT00837980|IMRT
465256|NCT00837967|Asthma
465257|NCT00837967|Symbicort Turbuhaler
465258|NCT00837954|PTFE Graft
465259|NCT00837954|Suture Hole Bleeding
465260|NCT00837954|Hemostasis
465261|NCT00837928|unspecified adult solid tumor, protocol specific
465262|NCT00837928|tumors metastatic to brain
465263|NCT00837915|Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets
465264|NCT00837902|Atenolol
465265|NCT00837902|Exercise
465266|NCT00837902|Genotype
465267|NCT00837902|Healthy volunteers
465268|NCT00837889|cognition
465269|NCT00837889|decompensation
465270|NCT00837889|heart failure
465271|NCT00837889|recompensation
465272|NCT00837876|recurrent pancreatic cancer
465273|NCT00837876|stage III pancreatic cancer
465274|NCT00837876|stage IV pancreatic cancer
465275|NCT00837876|adenocarcinoma of the pancreas
465276|NCT00837850|total hip arthroplasty
465277|NCT00837850|Charnley stem
465278|NCT00837850|RSA
465279|NCT00837850|non-inflammatory arthritis
465280|NCT00837837|pharmacokinetics
465281|NCT00837837|children
465282|NCT00837837|adolescents
465283|NCT00837837|antihistamine
465284|NCT00837824|Fabry Disease patients with Severe Renal Disease
465285|NCT00837811|Arthritis
465286|NCT00837772|Alignment
465287|NCT00837759|Type I Diabetes
465288|NCT00837759|Preserve Beta Cell Function
465289|NCT00837759|Sitagliptin
465290|NCT00837759|Lansoprazole
465291|NCT00837759|GAD65 (Diamyd)
465292|NCT00837759|Diabetes
465293|NCT00837759|Type 1 Diabetes
465294|NCT00837759|T1DM
465295|NCT00837733|Endometrial biopsy
465296|NCT00837733|IVF/ICSI
465297|NCT00837733|Pregnancy outcome
465298|NCT00837733|Recurrent implantation failure
465299|NCT00837720|hypertension
465300|NCT00837720|blood pressure
465301|NCT00837720|Atacand®
465302|NCT00837720|candesartan
465303|NCT00837707|aripiprazole
465304|NCT00837707|Tardive Dyskinesia
465305|NCT00837694|BMI
465306|NCT00837694|obesity
465307|NCT00837694|sensitization
465308|NCT00837694|food reinforcement
465309|NCT00837694|snack food
465310|NCT00837694|Portion size of daily snacks
465311|NCT00837694|Weight status
465312|NCT00837681|Bone Marrow Transplant
465313|NCT00837681|hematopoietic stem cell transplantation
465314|NCT00837668|sarcoidosis
465315|NCT00837668|stromal gene expression
465316|NCT00837668|pulmonary sarcoidosis
465317|NCT00837668|bronchoscopy
465318|NCT00837655|Chronic kidney disease
465319|NCT00837655|End-stage renal disease
465320|NCT00837655|phosphate binder
465321|NCT00837655|insulin resistance
465322|NCT00837655|glucose intolerance
465323|NCT00837655|sevelamer
465324|NCT00837642|Vascular function in offspring of ART
465325|NCT00837629|chronic obstructive pulmonary disease
465326|NCT00837629|COPD
465327|NCT00837629|Symbicort Turbuhaler
465328|NCT00837616|Turner Syndrome
465329|NCT00837616|Hypogonadism
465330|NCT00837616|GH
465331|NCT00837616|Estrogen
465332|NCT00837616|Estrogen Patches
465333|NCT00837616|IGF-I
465334|NCT00837616|Body Composition
465335|NCT00837616|Protein Metabolism
465336|NCT00837616|Lipid Oxidation
465337|NCT00837616|Estradiol assay by LCMSMS
465338|NCT00837616|Recombinant Cell Bioassay
465339|NCT00837603|tga
465340|NCT00837603|atrial switch
465341|NCT00837603|training
465342|NCT00837590|Vascular function
465343|NCT00837590|Glucose tolerance
465344|NCT00837590|Obesity
465345|NCT00837590|Pre-diabetes
465346|NCT00837564|chronic depression
465347|NCT00837564|CBASP
465348|NCT00837564|Escitalopram
465349|NCT00837564|depression
465350|NCT00837564|trauma
465351|NCT00837551|Non-steroid
465352|NCT00837551|Small molecule
465353|NCT00837551|Topical cream
465354|NCT00837551|Inflammatory disease
465355|NCT00837551|Skin
465356|NCT00837538|Spinal sagittal range of motion
465357|NCT00837538|Intersegmental range of motion
465358|NCT00837538|Spinal Mouse
465359|NCT00837512|microneedle continuous subcutaneous insulin infusion
465360|NCT00837499|Breast
465361|NCT00837499|Breast Cancer
465362|NCT00837499|Risk Factors
465363|NCT00837499|Mexican Women
465364|NCT00837499|Mexican-American Women
465365|NCT00837499|African-American Women
465366|NCT00837499|Epidemiological
465367|NCT00837499|Questionnaire
465368|NCT00837499|Survey
465369|NCT00837499|Interview
465370|NCT00837486|Treatment Resistant Depression
465371|NCT00837486|Treatment Refractory Depression
465372|NCT00837486|Deep Brain Stimulation
465373|NCT00837486|Depression
465374|NCT00837473|Bone Void Filler
465375|NCT00837473|Iliac Crest Bone Void Filler
465376|NCT00837473|Back Surgery and Autograft Bone
465377|NCT00837473|Autograft Bone
465378|NCT00837473|Allograft Bone
465379|NCT00837460|Hand
465380|NCT00837460|Rehabilitation
465381|NCT00837434|tumor necrosis factor (TNF) blockade
465382|NCT00837434|inflammatory autoimmune disorder
465383|NCT00837421|sepsis
465384|NCT00837421|registry
465385|NCT00837408|Diabetes
465386|NCT00837408|Genetics
465387|NCT00837408|Asians
465388|NCT00837408|Type 2 Diabetes
465389|NCT00837395|premenstrual increase in asthma symptoms
465390|NCT00837369|Stress echocardiography
465391|NCT00837369|SPECT
465392|NCT00837369|Myocardial perfusion imaging
465393|NCT00837343|Bipolar disorder
465394|NCT00837330|polypoidal choroidal vasculopathy
465395|NCT00837330|choroidal neovascularization
465396|NCT00837330|ranibizumab
465397|NCT00837330|Lucentis
465398|NCT00837317|Phenols
465399|NCT00837317|Laser-Doppler
465400|NCT00837317|Olive Oil
465401|NCT00837317|Sunflower Oil
465402|NCT00837317|Dimethylpolysiloxane
465403|NCT00837317|Postprandial
465404|NCT00837317|Inflammation
465405|NCT00837317|Oxidative Stress
465406|NCT00837291|osteoarthritis
465407|NCT00837291|knee
465408|NCT00837291|CF101
465409|NCT00837278|IVF
465410|NCT00837278|angiogenic factors
465411|NCT00837278|cytokines
465412|NCT00837265|Breast Cancer Supportive Care Neutropenia
465413|NCT00837252|Central Serous Chorioretinopathy
465414|NCT00837252|Finasteride
465415|NCT00837252|Proscar
465416|NCT00837252|Retinal Eye Disease
465417|NCT00837239|HuaChanSu
465418|NCT00837239|HCS
465419|NCT00837239|Gastrointestinal
465420|NCT00837239|Gastrointestinal Disease
465421|NCT00837239|Metastases
465422|NCT00837239|Cancer
465423|NCT00837239|Pancreatic cancer
465424|NCT00837239|Placebo
465425|NCT00837239|Gemcitabine
465426|NCT00837239|Gemcitabine Hydrocholoride
465427|NCT00837239|Gemzar
465428|NCT00837239|Fudan UniversityCancer Hospital
465429|NCT00837213|Acne
465430|NCT00837200|lymphoma
465431|NCT00837200|myeloma
465432|NCT00837187|dexmedetomidine
465433|NCT00837187|intranasal
465434|NCT00837187|pharmacokinetics
465435|NCT00837187|pharmacodynamics
465436|NCT00837174|non-Hodgkin Lymphoma
465437|NCT00837174|aggressive lymphoma
465438|NCT00837174|indolent lymphoma
465439|NCT00837174|B cell lymphoma
465440|NCT00837174|T cell lymphoma
465441|NCT00837174|Diffuse large B cell lymphoma
465442|NCT00837174|anaplastic large B cell lymphoma
465443|NCT00837174|lymphoblastic lymphoma
465444|NCT00837174|Burkitt's lymphoma
465445|NCT00837174|transformed follicular center cell lymphoma
465446|NCT00837174|transformed marginal zone lymphoma
465447|NCT00837174|transformed small lymphocytic lymphoma
465448|NCT00837174|grade 3 follicular center cell lymphoma
465449|NCT00837174|blastic form marginal zone lymphoma
465450|NCT00837174|transformed cutaneous T cell lymphoma
465451|NCT00837174|mycosis fungoides stage IV
465452|NCT00837174|angioimmunoblastic lymphadenopathy-like T-cell lymphoma
465453|NCT00837174|nasal NK/T cell lymphoma
465454|NCT00837174|peripheral T-cell lymphoma
465455|NCT00837174|small lymphocytic lymphoma
465456|NCT00837174|lymphoplasmacytic lymphoma
465457|NCT00837174|follicular center cell lymphoma grade 1
465458|NCT00837174|follicular center cell lymphoma grade 2
465459|NCT00837174|mantle cell lymphoma
465460|NCT00837174|marginal zone lymphoma
465461|NCT00837174|mycosis fungoides
465462|NCT00837161|High Intensity Focused Ultrasound Ablation
465463|NCT00837161|Uterine Fibroids
465464|NCT00837161|Leiomyomata
465465|NCT00837161|Non-Invasive Treatment of Uterine Fibroids
465466|NCT00837161|MRI-Guided
465467|NCT00837161|Fibroids
465468|NCT00837161|Uterine Leiomyomata
465469|NCT00837148|Sarcoma
465470|NCT00837148|Bone
465471|NCT00837148|BAY 43-9006 (SORAFENIB)
465472|NCT00837148|DACARBAZINE
465473|NCT00837148|08-068
465474|NCT00837135|Pancreatic Cancer
465475|NCT00837122|Diabetes
465476|NCT00837122|Genetics
465477|NCT00837122|Type 2 Diabetes
465478|NCT00837083|hypercholesterolemia
465479|NCT00837083|cholesterol
465480|NCT00837083|LDL-cholesterol
465481|NCT00837083|rosuvastatin
465482|NCT00837083|Crestor
465483|NCT00837070|Zygapophyseal
465484|NCT00837070|joint
465485|NCT00837070|cyst
465486|NCT00837070|Fluoroscopy
465487|NCT00837070|guided
465488|NCT00837070|percutaneous
465489|NCT00837070|Lumbar
465490|NCT00837031|Pancreatic
465491|NCT00837031|Pancreatic Cancer
465492|NCT00837031|Lenalidomide
465493|NCT00837031|Revlimid
465494|NCT00837031|Gemcitabine
465495|NCT00837018|OSAS
465496|NCT00837018|exercise
465497|NCT00837018|metabolic
465498|NCT00837018|cardio-vascular
465499|NCT00837005|dobutamine stress
465500|NCT00837005|inducible ischemia
465501|NCT00837005|CAD
465502|NCT00836992|anal cancer
465503|NCT00836992|colon cancer
465504|NCT00836992|rectal cancer
465505|NCT00836992|esophageal cancer
465506|NCT00836992|extrahepatic bile duct cancer
465507|NCT00836992|gallbladder cancer
465508|NCT00836992|gastric cancer
465509|NCT00836992|adult primary liver cancer
465510|NCT00836992|pancreatic cancer
465511|NCT00836992|small intestine cancer
465512|NCT00836992|non-small cell lung cancer
465513|NCT00836992|small cell lung cancer
465514|NCT00836992|head and neck cancer
465515|NCT00836979|Urinary Incontinence
465516|NCT00836979|Incontinence
465517|NCT00836979|bladder problems
465518|NCT00836979|bladder dysfunction
465519|NCT00836953|Influenza
465520|NCT00836953|Fluzone®
465521|NCT00836953|Children
465522|NCT00836940|Type 2 diabetes mellitus
465523|NCT00836940|GRC 8200
465524|NCT00836914|Allergic Rhinitis
465525|NCT00836914|Allergy
465526|NCT00836914|Phosphatidylinositol 3-kinase
465527|NCT00836901|Bioequivalence
465528|NCT00836901|Healthy Subjects
465529|NCT00836888|ONO-4538
465530|NCT00836888|MDX-1106
465531|NCT00836888|solid tumors
465532|NCT00836875|Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized
465533|NCT00836862|Hemodialysis
465534|NCT00836862|Vascular access
465535|NCT00836862|Arteriovenous fistula
465536|NCT00836849|Bioequivalence
465537|NCT00836849|Healthy Subjects
465538|NCT00836836|Childhood epilepsy
465539|NCT00836836|ketogenic diet
465540|NCT00836823|Patient-reported most bothersome symptom
465541|NCT00836823|Patient-reported symptom-specific goal achievement
465542|NCT00836823|Medical treatment
465543|NCT00836810|Circadian variations of cytokines in PMR
465544|NCT00836810|effect of TRT Prednisone in cytokines
465545|NCT00836797|Alveolar Bone Loss
465546|NCT00836797|Alveolar ridge
465547|NCT00836797|Alveolar Process
465548|NCT00836784|Old tooth brush
465549|NCT00836784|Plaque removal
465550|NCT00836771|Infant formula
465551|NCT00836771|Probiotic microorganisms
465552|NCT00836771|prebiotic
465553|NCT00836745|Advanced renal cell Cancer
465554|NCT00836745|Non interventional study
465555|NCT00836745|Renal Cancer
465556|NCT00836745|Sutent
465557|NCT00836745|Metastatic
465558|NCT00836745|Advanced Renal Cell Carcinoma
465559|NCT00836732|celle therapy
465560|NCT00836732|cell culture
465561|NCT00836732|mesenchymal stem cells
465562|NCT00836719|Multiple sclerosis
465563|NCT00836719|safety
465564|NCT00836719|open label
465565|NCT00836719|Polyphenon E
465566|NCT00836719|EGCG
465567|NCT00836719|NAA
465568|NCT00836719|N-acetyl-aspartate
465569|NCT00836719|MRI
465570|NCT00836706|Bioequivalence
465571|NCT00836706|Healthy Subjects
465572|NCT00836693|Erectile Dysfunction
465573|NCT00836667|Bioequivalence
465574|NCT00836667|Healthy Subjects
465575|NCT00836654|EpCAM positive tumor
465576|NCT00836654|malignant ascites
465577|NCT00836654|intraperitoneal
465578|NCT00836641|preschool asthma
465579|NCT00836641|sequential pneumococcal immunization
465580|NCT00836641|immunogenicity
465581|NCT00836641|safety
465582|NCT00836589|Long-term safety and reliability of ICD leads
465583|NCT00836576|Bioequivalence
465584|NCT00836576|Healthy Subjects
465585|NCT00836563|Hemodialysis
465586|NCT00836563|Arteriovenous Graft
465587|NCT00836550|HIV
465588|NCT00836550|HIV knowledge measure
465589|NCT00836550|Teen HIV testing
465590|NCT00836550|HIV Seronegativity
465591|NCT00836537|Bioequivalence
465592|NCT00836537|Healthy Subjects
465593|NCT00836524|IUGR
465594|NCT00836524|Preeclampsia
465595|NCT00836524|ultrasound
465596|NCT00836524|YKL-40
465597|NCT00836472|Bioequivalence
465598|NCT00836472|Healthy Subjects
465599|NCT00836459|Humans
465600|NCT00836459|Middle Aged
465601|NCT00836459|Behavior Therapy
465602|NCT00836459|Directive Counseling
465603|NCT00836459|Health Behavior
465604|NCT00836459|Interview, Psychological
465605|NCT00836459|Motivation
465606|NCT00836459|Exercise
465607|NCT00836459|Physical Fitness
465608|NCT00836459|Self Efficacy
465609|NCT00836459|Life Style
465610|NCT00836459|Health Promotion
465611|NCT00836459|Health Knowledge, Attitudes, Practice
465612|NCT00836459|Body Mass Index
465613|NCT00836459|Monitoring, Ambulatory
465614|NCT00836459|Walking
465615|NCT00836446|school-aged
465616|NCT00836446|children
465617|NCT00836446|obesity
465618|NCT00836446|cardiovascular risk
465619|NCT00836446|physical activity
465620|NCT00836433|staff education
465621|NCT00836433|complexity science
465622|NCT00836433|social constructivist theory
465623|NCT00836420|ammonia
465624|NCT00836420|acute liver failure
465625|NCT00836420|brain edema
465626|NCT00836420|oxidative metabolism
465627|NCT00836420|intracranial pressure
465628|NCT00836407|pancreatic cancer
465629|NCT00836407|vaccine
465630|NCT00836407|immunotherapy
465631|NCT00836407|antibody
465632|NCT00836407|CTLA-4
465633|NCT00836394|arthritis
465634|NCT00836394|juvenile idiopathic arthritis
465635|NCT00836394|pediatric
465636|NCT00836394|intervention
465637|NCT00836394|vibration therapy
465638|NCT00836394|JIA
465639|NCT00836381|Overactive bladder
465640|NCT00836381|Antimuscarinics
465641|NCT00836381|Patient-reported goal achievement
465642|NCT00836368|Asthma
465643|NCT00836368|Asthmatic
465644|NCT00836368|Allergy
465645|NCT00836368|Allergic
465646|NCT00836368|Gamma-tocopherol
465647|NCT00836368|Vitamin
465648|NCT00836368|Vitamin E
465649|NCT00836355|stroke
465650|NCT00836355|magnetic resonance imaging
465651|NCT00836355|enoxaparin
465652|NCT00836355|minocycline
465653|NCT00836355|NIH stroke scale
465654|NCT00836355|modified Rankin scale
465655|NCT00836355|neuroprotection
465656|NCT00836342|Non-melanoma skin cancer
465657|NCT00836342|Basal cell carcinoma
465658|NCT00836342|Squamous cell carcinoma
465659|NCT00836329|Neurologic
465660|NCT00836329|Diabetes
465661|NCT00836329|Cardiac Surgery
465662|NCT00836329|Stroke
465663|NCT00836316|laparoscopic cholecystectomy
465664|NCT00836290|risk reduction
465665|NCT00836290|HIV prevention
465666|NCT00836290|HIV education
465667|NCT00836290|HIV Seronegativity
465668|NCT00836277|Panitumumab
465669|NCT00836277|Irinotecan
465670|NCT00836277|Esophageal Adenocarcinoma
465671|NCT00836277|Phase II
465672|NCT00836264|Morphine
465673|NCT00836264|Phenotype
465674|NCT00836264|Genotype
465675|NCT00836264|Tonsillectomy
465676|NCT00836264|Adenoidectomy
465677|NCT00836264|Opioid Receptors
465678|NCT00836264|Genome-Wide Association
465679|NCT00836264|Pharmacokinetics
465680|NCT00836251|energy expenditure
465681|NCT00836251|schizophrenia
465682|NCT00836238|Prostate Cancer
465683|NCT00836238|Neural Functioning Assessment
465684|NCT00836238|Physical Assessment
465685|NCT00836238|Questionnaire
465686|NCT00836238|Objective Measures of Functional Status
465687|NCT00836238|Physical Function
465688|NCT00836238|Symptom Assessment Interview
465689|NCT00836238|Elderly
465690|NCT00836225|diabetes
465691|NCT00836225|SGLT2 inhibitor
465692|NCT00836212|HIV
465693|NCT00836212|Adjusting Antiretroviral Therapy
465694|NCT00836212|Dosage using Therapeutic Drug Monitoring
465695|NCT00836212|Swiss HIV Cohort Study
465696|NCT00836212|HIV Geneva
465697|NCT00836212|lopinavir
465698|NCT00836212|efavirenz
465699|NCT00836212|Treatment Experienced
465700|NCT00836199|smoking cessation
465701|NCT00836199|NicVAX
465702|NCT00836199|smoking vaccine
465703|NCT00836199|smoking abstinence
465704|NCT00836199|smoking
465705|NCT00836199|tobacco cessation
465706|NCT00836173|CARBOPLATIN
465707|NCT00836173|DEXAMETHASONE
465708|NCT00836173|DIFFUSE LARGE B-CELL LYMPHOMA
465709|NCT00836173|ETOPOSIDE
465710|NCT00836173|GALLIUM NITRATE
465711|NCT00836173|IFOSFAMIDE
465712|NCT00836173|PHASE II
465713|NCT00836173|RELAPSED OR REFRACTORY
465714|NCT00836173|RITUXIMAB
465715|NCT00836160|EGFR-TKI therapy
465716|NCT00836160|NSCLC
465717|NCT00836160|Efficacy
465718|NCT00836134|pain relief after umbilical hernia repair
465719|NCT00836134|morphine consumption
465720|NCT00836134|plasma bupivacaine levels
465721|NCT00836121|Teratoma
465722|NCT00836121|Mediastinum
465723|NCT00836108|Lung Diseases, Obstructive
465724|NCT00836108|Breathing Exercises
465725|NCT00836108|Exercise Tolerance
465726|NCT00836108|Dyspnea
465727|NCT00836108|Arm Exercise
465728|NCT00836095|laryngeal mask, proseal
465729|NCT00836082|Healthy volunteers
465730|NCT00836069|Generalized Anxiety Disorder
465731|NCT00836056|Bioequivalence
465732|NCT00836056|Healthy Subjects
465733|NCT00836043|CLL
465734|NCT00836043|alemtuzumab
465735|NCT00836004|Bioequivalence
465736|NCT00836004|Healthy Subjects
465737|NCT00835991|Bioequivalence
465738|NCT00835991|Healthy Subjects
465739|NCT00835978|axitinib or AG-013736 dose titration (increase) renal cell carcinoma
465740|NCT00835978|kidney cancer
465741|NCT00835965|Laparoscopic
465742|NCT00835965|Surgery
465743|NCT00835965|Postoperative
465744|NCT00835965|Nausea
465745|NCT00835965|Vomiting
465746|NCT00835965|Aprepitant
465747|NCT00835965|Dexamethasone
465748|NCT00835965|Postoperative Nausea, Postoperative Vomiting
465749|NCT00835939|Achilles
465750|NCT00835939|Tendinopathy
465751|NCT00835939|Sclerotherapy
465752|NCT00835939|Neovascularisation
465753|NCT00835939|sports medicine
465754|NCT00835939|interventional radiology
465755|NCT00835926|Influenza
465756|NCT00835926|Fluzone®
465757|NCT00835913|Autonomic nervous system
465758|NCT00835913|Sepsis shock
465759|NCT00835913|severe sepsis
465760|NCT00835913|sinusal change
465761|NCT00835913|Myocardiac fixing
465762|NCT00835913|NTproBNP
465763|NCT00835913|Patient in intensive care unit with sepsis shock or severe
465764|NCT00835913|Sepsis
465765|NCT00835900|smoking cessation
465766|NCT00835900|varenicline
465767|NCT00835900|smoking cessation treatment
465768|NCT00835874|probiotic
465769|NCT00835874|preterm
465770|NCT00835874|lactation
465771|NCT00835874|breast feeding
465772|NCT00835874|necrotizing enterocolitis
465773|NCT00835874|sepsis
465774|NCT00835874|bacterial cultures
465775|NCT00835874|lactating mother
465776|NCT00835874|breast feeding of at least 50% of enteric feeding volume
465777|NCT00835874|Infant, very low birth weight
465778|NCT00835861|Non Insulin Dependent Diabetes
465779|NCT00835861|Pregnancy
465780|NCT00835848|ST-segment elevation myocardial infarction
465781|NCT00835848|Primary PCI
465782|NCT00835848|Postconditioning
465783|NCT00835835|Multiple Sclerosis
465784|NCT00835835|gait
465785|NCT00835835|falls
465786|NCT00835835|lokomat
465787|NCT00835835|body-weight support treadmill training
465788|NCT00835822|Chronic Venous Insufficiency, Venocur Triplex®
465789|NCT00835809|Acute respiratory insufficiency respiratory
465790|NCT00835809|Biomarkers
465791|NCT00835809|Emergency
465792|NCT00835809|Intensive care unit
465793|NCT00835809|Prospective
465794|NCT00835809|Patient hospitalize in emergency or in intensive care unit
465795|NCT00835809|for acute respiratory insufficiency
465796|NCT00835796|Bioequivalence
465797|NCT00835796|Healthy Subjects
465798|NCT00835770|relapsing
465799|NCT00835770|multiple sclerosis
465800|NCT00835770|remitting
465801|NCT00835770|oral
465802|NCT00835744|ovulation induction
465803|NCT00835744|clomiphene citrate
465804|NCT00835744|gonadotropins
465805|NCT00835731|induced abortion
465806|NCT00835731|misoprostol
465807|NCT00835731|cervical ripening
465808|NCT00835731|second trimester abortion
465809|NCT00835731|Dilapan-S
465810|NCT00835705|Bioequivalence
465811|NCT00835705|Healthy Subjects
465812|NCT00835692|Bioequivalence
465813|NCT00835692|Healthy Subjects
465814|NCT00835666|Bioequivalence
465815|NCT00835666|Healthy Subjects
465816|NCT00835640|Bioequivalence
465817|NCT00835640|Healthy Subjects
465818|NCT00835627|Treatment
465819|NCT00835627|Cognitive Behavior Therapy
465820|NCT00835627|pharmacotherapy
465821|NCT00835627|psychogenic nonepileptic seizures
465822|NCT00835627|pseudoseizures
465823|NCT00835627|dissociative seizures
465824|NCT00835627|conversion disorder
465825|NCT00835614|Bioequivalence
465826|NCT00835614|Healthy Subjects
465827|NCT00835588|Bioequivalence
465828|NCT00835588|Healthy Subjects
465829|NCT00835575|Bioequivalence
465830|NCT00835575|Healthy Subjects
465831|NCT00835562|Shoulder fractures
465832|NCT00835562|Proximal humeral fractures
465833|NCT00835562|Randomised clinical trial
465834|NCT00835562|elderly
465835|NCT00835562|Displaced four-part fractures of the proximal humerus
465836|NCT00835549|Bioequivalence
465837|NCT00835549|Healthy Subjects
465838|NCT00835536|Bioequivalence
465839|NCT00835536|Healthy Subjects
465840|NCT00835523|frozen-thawed embryo replacement
465841|NCT00835523|GnRH agonist
465842|NCT00835523|GnRH antagonist
465843|NCT00835523|ovarian hyperstimulation
465844|NCT00835510|Tinea pedis
465845|NCT00835497|Bioequivalence
465846|NCT00835497|Healthy Subjects
465847|NCT00835484|Bioequivalence
465848|NCT00835484|Healthy Subjects
465849|NCT00835471|Lung cancer
465850|NCT00835471|non-small-cell
465851|NCT00835471|erlotinib
465852|NCT00835471|chemotherapy
465853|NCT00835458|gastric fistula
465854|NCT00835458|perforation
465855|NCT00835458|endoscopy
465856|NCT00835458|closure
465857|NCT00835458|endolumenal
465858|NCT00835432|Lateral augmentation
465859|NCT00835432|GBR
465860|NCT00835432|BoneCeramic
465861|NCT00835432|collagen membrane
465862|NCT00835432|histomorphometry
465863|NCT00835432|morphometry
465864|NCT00835432|reentry
465865|NCT00835432|biopsy
465866|NCT00835419|metastatic malignant melanoma with cyclin D1 positivity
465867|NCT00835406|Bioequivalence
465868|NCT00835406|Healthy Subjects
465869|NCT00835393|Bioequivalence
465870|NCT00835393|Healthy Subjects
465871|NCT00835367|Bioequivalence
465872|NCT00835367|Healthy Subjects
465873|NCT00835354|Bioequivalence
465874|NCT00835354|Healthy Subjects
465875|NCT00835341|oral epithelial dysplasia
465876|NCT00835341|p16 methylation
465877|NCT00835341|prognosis
465878|NCT00835341|malignant transformation
465879|NCT00835341|oral squamous cell carcinoma
465880|NCT00835328|hyperinsulinism
465881|NCT00835328|hypoglycemia
465882|NCT00835328|ATP- sensitive potassium channel (KATP)
465883|NCT00835315|interdigital psoriasis (psoriasis alba)
465884|NCT00835302|Cervical
465885|NCT00835302|Thoracic
465886|NCT00835302|Manipulation
465887|NCT00835302|Mobilization
465888|NCT00835302|Clinical prediction rule
465889|NCT00835302|Shoulder pain.
465890|NCT00835289|Clinical Trials, Randomized
465891|NCT00835276|Bioequivalence
465892|NCT00835276|Healthy Subjects
465893|NCT00835263|Bioequivalence
465894|NCT00835263|Healthy Subjects
465895|NCT00835250|Transvaginal cholecystectomy
465896|NCT00835250|NOTES
465897|NCT00835250|Minilaparoscopy
465898|NCT00835250|Endoscopic surgery
465899|NCT00835250|Cholecystectomy
465900|NCT00835250|Surgical translumenal endoscopic surgery
465901|NCT00835250|Transvaginal translumenal endoscopic surgery
465902|NCT00835237|Boostrix®
465903|NCT00835237|adults
465904|NCT00835224|Spinal Cord Injury
465905|NCT00835224|Orthostatic Hypotension
465906|NCT00835224|Blood Pressure
465907|NCT00835224|Midodrine Hydrochloride
465908|NCT00835224|L-NAME
465909|NCT00835211|Bioequivalence
465910|NCT00835211|Healthy Subjects
465911|NCT00835185|Antibodies, Monoclonal
465912|NCT00835185|Colorectal Neoplasms
465913|NCT00835172|Bioequivalence
465914|NCT00835172|Healthy Subjects
465915|NCT00835159|Postoperative Delirium
465916|NCT00835159|Postoperative Cognitive Dysfunction
465917|NCT00835159|Rivastigmine
465918|NCT00835159|Exelon
465919|NCT00835159|Memory impairment
465920|NCT00835159|Delirium
465921|NCT00835159|Cognitive function
465922|NCT00835146|Bioequivalence
465923|NCT00835146|Healthy Subjects
465924|NCT00835133|family
465925|NCT00835133|history
465926|NCT00835133|pancreas
465927|NCT00835133|cancer
465928|NCT00835133|melanoma
465929|NCT00835133|genetic
465930|NCT00835107|Bipolar Depression
465931|NCT00835107|Sleep
465932|NCT00835107|Polysomnograph
465933|NCT00835107|Slow Wave Sleep
465934|NCT00835107|Ziprasidone
465935|NCT00835107|Antipsychotic
465936|NCT00835107|Placebo
465937|NCT00835081|Bioequivalence
465938|NCT00835081|Healthy Subjects
465939|NCT00835068|Hemophilia B
465940|NCT00835068|observational
465941|NCT00835068|post marketing study
465942|NCT00835055|rectal cancer with neoadjuvant treatment
465943|NCT00835055|standardized clinical tests
465944|NCT00835055|tumor markers on tumor tissue
465945|NCT00835042|Bioequivalence
465946|NCT00835042|Healthy Subjects
465947|NCT00835029|oral
465948|NCT00835029|candida
465949|NCT00835029|denture
465950|NCT00835029|clotrimazole
465951|NCT00835029|slow releases
465952|NCT00835016|Early psychosocial stimulation, RCT, Depressed mother
465953|NCT00835003|Neonatal admission
465954|NCT00835003|Elective Caesarean Section
465955|NCT00835003|Timing
465956|NCT00835003|Choice behavior
465957|NCT00835003|Intraoperative complications
465958|NCT00835003|Postoperative complications
465959|NCT00834990|Bioequivalence
465960|NCT00834990|Healthy Subjects
465961|NCT00834977|Bioequivalence
465962|NCT00834977|Healthy Subjects
465963|NCT00834964|Bioequivalence
465964|NCT00834964|Healthy Subjects
465965|NCT00834951|Diffuse large B-cell lymphoma
465966|NCT00834951|Elderly patients
465967|NCT00834951|Low dose total body irradiation
465968|NCT00834951|RCHOP14
465969|NCT00834938|diabetes mellitus, type 2
465970|NCT00834938|Insulin resistance
465971|NCT00834938|bariatric surgery
465972|NCT00834938|Glucagon-Like Peptide 1
465973|NCT00834938|Gastric Inhibitory Polypeptide
465974|NCT00834938|insulin
465975|NCT00834938|glucagon
465976|NCT00834938|ghrelin
465977|NCT00834938|adiponectin
465978|NCT00834938|Cytokines
465979|NCT00834938|gastric bypass
465980|NCT00834938|Obesity
465981|NCT00834925|atrial fibrillation with rapid ventricular response
465982|NCT00834912|Healthy Subjects
465983|NCT00834899|Sickle cell disease
465984|NCT00834899|Pain crisis
465985|NCT00834899|Acute pain episode
465986|NCT00834899|Eptifibatide
465987|NCT00834899|Antiplatelet therapy
465988|NCT00834899|Safety
465989|NCT00834899|Treatment
465990|NCT00834873|Bioequivalence
465991|NCT00834873|Healthy Subjects
465992|NCT00834860|chronic hepatitis C
465993|NCT00834860|sustained virological response
465994|NCT00834860|peginterferon
465995|NCT00834860|ribavirin
465996|NCT00834860|neoplasm
465997|NCT00834847|Bioequivalence
465998|NCT00834847|Healthy Subjects
465999|NCT00834834|Suicidal and Self-Injurious Behavior
466000|NCT00834821|Attention Deficit Hyperactivity Disorder
466001|NCT00834821|ADHD, Predominantly Inattentive Type
466002|NCT00834821|Inattention
466003|NCT00834821|Psychosocial Intervention
466004|NCT00834821|Behavioral Intervention
466005|NCT00834808|Healthy volunteers
466006|NCT00834795|Bioequivalence
466007|NCT00834795|Healthy Subjects
466008|NCT00834782|PK
466009|NCT00834782|IOP
466010|NCT00833807|Melanoma
466011|NCT00833807|Metastatic Melanoma to the Liver
466012|NCT00833807|Liver metastasis
466013|NCT00833807|Nab-paclitaxel
466014|NCT00833807|Abraxane
466015|NCT00833807|Paclitaxel (protein-bound)
466016|NCT00833807|intraarterial intrahepatic administration
466017|NCT00833807|Hepatic Artery
466018|NCT00833807|Hepatic Arterial Infusion
466019|NCT00833807|Hepatic Administration
466020|NCT00833781|HIV vaccine
466021|NCT00833781|Dendritic cells
466022|NCT00833781|treatment experienced
466023|NCT00833755|Pain
466024|NCT00833755|Chronic pain
466025|NCT00833755|Opioid induced hyperalgesia
466026|NCT00833755|Opioid therapy
466027|NCT00833742|somatization
466028|NCT00833742|psychosomatic
466029|NCT00833742|short-term
466030|NCT00833742|dynamic
466031|NCT00833742|psychotherapy
466032|NCT00833729|psoriasis
466033|NCT00833729|etanercept
466034|NCT00833729|adalimumab
466035|NCT00833729|moderate to severe plaque psoriasis
466036|NCT00833703|cyanotic congenital heart disease
466037|NCT00833703|shunt palliation
466038|NCT00833703|thrombosis
466039|NCT00833703|clopidogrel
466040|NCT00833690|Parkinson's disease
466041|NCT00833690|Parkinson disease
466042|NCT00833690|PD
466043|NCT00833690|inosine
466044|NCT00833690|urate
466045|NCT00833690|uric acid
466046|NCT00833690|cerebrospinal fluid
466047|NCT00833677|Coping skills
466048|NCT00833677|Chinese
466049|NCT00833677|Immigrant
466050|NCT00833677|Type 2 Diabetes Mellitus
466051|NCT00833677|Family research
466052|NCT00833664|Bioequivalence
466053|NCT00833664|Healthy Subjects
466054|NCT00833651|Transplant
466055|NCT00833651|Immunology
466056|NCT00833651|Immunosuppression
466057|NCT00833638|Erectile Dysfunction
466058|NCT00833625|Gastrointestinal
466059|NCT00833625|Esophagus
466060|NCT00833625|Cancer of the esophagus
466061|NCT00833625|Biopsy
466062|NCT00833625|EGD
466063|NCT00833625|Esophagogastroduodenoscopy
466064|NCT00833625|PET/CT
466065|NCT00833625|Positive Emission Tomography/Computerized Tomography
466066|NCT00833625|Esophageal Cancer
466067|NCT00833625|Chemoradiation
466068|NCT00833625|Chemotherapy
466069|NCT00833625|Radiation Therapy
466070|NCT00833612|IABC
466071|NCT00833612|AMI
466072|NCT00833599|Lymphedema
466073|NCT00833599|Genetic
466074|NCT00833599|Lymphatic Disorder
466075|NCT00833599|Lipedema
466076|NCT00833599|Vascular Malformation
466077|NCT00833599|Vascular Anomaly
466078|NCT00833586|Bioequivalence
466079|NCT00833586|Healthy Subjects
466080|NCT00833573|GERD digestive expression
466081|NCT00833573|ages
466082|NCT00833560|Multiple Myeloma
466083|NCT00833560|Untreated multiple myeloma
466084|NCT00833560|Bortezomib
466085|NCT00833560|VELCADE
466086|NCT00833560|Cyclophosphamide
466087|NCT00833560|Dexamethasone
466088|NCT00833560|Chemotherapy
466089|NCT00833560|Remission therapy
466090|NCT00833560|Induction therapy
466091|NCT00833560|Stem Cell Transplantation
466092|NCT00833547|sleep
466093|NCT00833547|schizophrenia
466094|NCT00833547|procedural learning
466095|NCT00833547|motor skill
466096|NCT00833534|stage I chronic lymphocytic leukemia
466097|NCT00833534|stage II chronic lymphocytic leukemia
466098|NCT00833534|stage III chronic lymphocytic leukemia
466099|NCT00833534|stage IV chronic lymphocytic leukemia
466100|NCT00833534|stage I small lymphocytic lymphoma
466101|NCT00833534|stage III small lymphocytic lymphoma
466102|NCT00833534|stage IV small lymphocytic lymphoma
466103|NCT00833534|contiguous stage II small lymphocytic lymphoma
466104|NCT00833534|noncontiguous stage II small lymphocytic lymphoma
466105|NCT00834756|Bioequivalence
466106|NCT00834756|Healthy Subjects
466107|NCT00834743|Bioequivalence
466108|NCT00834743|Healthy Subjects
466109|NCT00834717|Bioequivalence
466110|NCT00834717|Healthy Subjects
466111|NCT00834704|PEGPH20
466112|NCT00834704|PEGylated recombinant human hyaluronidase
466113|NCT00834704|Metastatic or locally advanced solid tumor
466114|NCT00834691|Inflammation
466115|NCT00834691|Oxidative stress
466116|NCT00834691|Estimated glomerular filtration rate
466117|NCT00834678|male breast cancer
466118|NCT00834678|recurrent breast cancer
466119|NCT00834678|stage IIIB breast cancer
466120|NCT00834678|stage IIIC breast cancer
466121|NCT00834678|stage IV breast cancer
466122|NCT00834678|estrogen receptor-negative breast cancer
466123|NCT00834678|HER2-negative breast cancer
466124|NCT00834678|progesterone receptor-negative breast cancer
466125|NCT00834678|triple-negative breast cancer
466126|NCT00834652|Metabolic Diseases
466127|NCT00834652|Depressive Disorder, Major
466128|NCT00834652|Depressive Disorder
466129|NCT00834652|Glucose Metabolism Disorders
466130|NCT00834652|Depression Recurrence
466131|NCT00834639|Bioequivalence
466132|NCT00834639|Healthy Subjects
466133|NCT00834626|Ileal Interposition
466134|NCT00834626|Sleeve Gastrectomy
466135|NCT00834626|Type-2 Diabetes
466136|NCT00834613|Bioequivalence
466137|NCT00834613|Healthy Subjects
466138|NCT00834587|Bioequivalence
466139|NCT00834587|Healthy Subjects
466140|NCT00834574|Bioequivalence
466141|NCT00834574|Healthy Subjects
466142|NCT00834561|Bioequivalence
466143|NCT00834561|Healthy Subjects
466144|NCT00834548|Magnetic resonance
466145|NCT00834548|whole body
466146|NCT00834548|angiography
466147|NCT00834548|hybrid protocol
466148|NCT00834548|MRI
466149|NCT00834535|Bioequivalence
466150|NCT00834535|Healthy Subjects
466151|NCT00834522|Bioequivalence
466152|NCT00834522|Healthy Subjects
466153|NCT00834483|Safety
466154|NCT00834483|Efficacy
466155|NCT00834483|Cost-savings
466156|NCT00834483|Cosmesis
466157|NCT00834483|Safety and efficacy of wound closure
466158|NCT00834483|Cost-savings potential
466159|NCT00834483|Cosmesis of the wound/scar
466160|NCT00834457|AIDS-related Kaposi's sarcoma
466161|NCT00834457|antiretroviral therapy
466162|NCT00834444|Bioequivalence
466163|NCT00834444|Healthy Subjects
466164|NCT00834431|Bioequivalence
466165|NCT00834431|Healthy Subjects
466166|NCT00834418|Bioequivalence
466167|NCT00834418|Healthy Subjects
466168|NCT00834405|Bioequivalence
466169|NCT00834405|Healthy Subjects
466170|NCT00834379|Bioequivalence
466171|NCT00834379|Healthy Subjects
466172|NCT00834366|Healthy volunteers
466173|NCT00834340|Bioequivalence
466174|NCT00834340|Healthy Subjects
466175|NCT00834327|Restless Legs Syndrome
466176|NCT00834301|End Stage Renal Disease
466177|NCT00834301|Inflammation
466178|NCT00834288|Healthy subjects
466179|NCT00834288|Pharmacokinetics
466180|NCT00834288|Bioavailability
466181|NCT00834275|Bioequivalence
466182|NCT00834275|Healthy Subjects
466183|NCT00834249|Bioequivalence
466184|NCT00834249|Healthy Subjects
466185|NCT00834236|gastric cancer
466186|NCT00834236|proteomics
466187|NCT00834236|gastric juice
466188|NCT00834223|refractory chronic forms of open angle glaucoma (OAG)
466189|NCT00834223|OAG
466190|NCT00834223|glaucoma
466191|NCT00834197|Bioequivalence
466192|NCT00834197|Healthy Subjects
466193|NCT00834184|nikkomycin Z
466194|NCT00834184|evaluate safety, tolerance and pharmacokinetics of nikkomycin Z
466195|NCT00834158|Hepatocellular Carcinoma
466196|NCT00834158|Hepatitis B
466197|NCT00834158|Transarterial chemoembolization (TACE)
466198|NCT00834158|Portal vein embolization (PVE)
466199|NCT00834158|Surgical resection
466200|NCT00834158|Disease-free survival
466201|NCT00834158|Overall survival
466202|NCT00834145|Edema
466203|NCT00834145|Right heart failure
466204|NCT00834145|Cor pulmonale
466205|NCT00834145|Pump
466206|NCT00834145|Leg compression
466207|NCT00834132|Bioequivalence
466208|NCT00834132|Healthy Subjects
466209|NCT00834106|HPV 6/11/16/18 Infection
466210|NCT00834093|Epstein-Barr Virus
466211|NCT00834093|NPC
466212|NCT00834093|EBV
466213|NCT00834093|immunotherapy
466214|NCT00834080|opioid dependence
466215|NCT00834080|VIVITROL
466216|NCT00834080|opioid-related disorders
466217|NCT00834067|Bioequivalence
466218|NCT00834067|Healthy Subjects
466219|NCT00834041|aliskiren
466220|NCT00834041|pediatric
466221|NCT00834041|hypertension
466222|NCT00834041|pharmacokinetics (PK)
466223|NCT00834041|pharmacodynamics (PD)
466224|NCT00834041|plasma renin activity
466225|NCT00834041|mini-tablet formulation
466226|NCT00834028|hepatocellular carcinoma
466227|NCT00834028|vascular endothelial growth factor
466228|NCT00834028|angiopoietin
466229|NCT00834028|cathepsin
466230|NCT00834015|spinal fusion
466231|NCT00834015|pain
466232|NCT00834015|disability
466233|NCT00834015|muscle strength
466234|NCT00834015|mobility
466235|NCT00834015|quality of life
466236|NCT00834015|lumbar
466237|NCT00834015|isthmic or degenerative spondylolisthesis
466238|NCT00834002|AML in remission
466239|NCT00833963|Herceptin
466240|NCT00833963|MBC
466241|NCT00833963|BC
466242|NCT00833963|Pregnancy
466243|NCT00833963|childbirth
466244|NCT00833963|Perjeta
466245|NCT00833963|Kadcyla
466246|NCT00833963|pertuzumab
466247|NCT00833963|ado-trastuzumab emtansine
466248|NCT00833950|Tinnitus
466249|NCT00833950|Phase Out
466250|NCT00833937|Bioequivalence
466251|NCT00833937|Healthy Subjects
466252|NCT00833924|Low Profile
466253|NCT00833924|Abdominal Aortic Aneurysms
466254|NCT00833924|Endovascular
466255|NCT00833911|Moderate to severe symptomatic osteoarthritis of the knee
466256|NCT00833898|depression
466257|NCT00833898|stress
466258|NCT00833898|caregiving
466259|NCT00833898|anxiety
466260|NCT00833898|psychoeducation intervention
466261|NCT00833898|psycho-oncology
466262|NCT00833885|Non pharmaceutical measures
466263|NCT00833859|stereotactic radiosurgery
466264|NCT00833859|borderline resectable pancreatic cancer
466265|NCT00833859|gastrointestinal
466266|NCT00833859|pancreas
466267|NCT00833846|Mitochondria in Platelets
466268|NCT00833846|Mitochondria in Diabetes
466269|NCT00833846|Insulin Resistance and Mitochondria
466270|NCT00833846|Diabetes
466271|NCT00833846|Insulin Resistance
466272|NCT00833820|ALS
466273|NCT00833820|transcranial brain stimulation
466274|NCT00833521|Bioequivalence
466275|NCT00833521|Healthy Subjects
466276|NCT00833508|Exercise capacity
466277|NCT00833508|Chemoradiotherapy
466278|NCT00833508|Colorectal cancer
466279|NCT00833469|women
466280|NCT00833469|postpartum depression
466281|NCT00833469|anxiety
466282|NCT00833456|schizophrenia
466283|NCT00833456|Seroquel SR
466284|NCT00833456|atypical antipsychotics
466285|NCT00833456|assessment of functioning
466286|NCT00833456|GAF scale
466287|NCT00833443|Methamphetamine
466288|NCT00833443|Addiction
466289|NCT00833443|Pharmacogenomics
466290|NCT00833443|Amphetamine
466291|NCT00833443|Bupropion
466292|NCT00833443|Meth
466293|NCT00833443|Crank
466294|NCT00833443|Crystal
466295|NCT00833430|AVN
466296|NCT00833430|Femoral Head Collapse
466297|NCT00833417|BCC
466298|NCT00833417|Hedgehog Pathway Inhibitor
466299|NCT00833417|Hedgehog
466300|NCT00833417|Basal Cell Cancer
466301|NCT00833404|Smoking
466302|NCT00833404|Smoking Cessation
466303|NCT00833404|Quit Smoking
466304|NCT00833404|Stop Smoking
466305|NCT00833404|Nicotine Patch
466306|NCT00833404|Nicotine Replacement Therapy
466307|NCT00833404|Sexual Functioning
466308|NCT00833404|Erectile Functioning
466309|NCT00833404|Sexual Health
466310|NCT00833391|healthy volunteer
466311|NCT00833391|formulations
466312|NCT00833391|bioavailability
466313|NCT00833391|pharmacokinetics
466314|NCT00833378|Drug interaction, SB-497115 (eltrombopag), Kaletra (Lopinavir, Ritonavir),thrombocytopenia, pharmacokinetics
466315|NCT00833365|premature infants
466316|NCT00833365|PDA
466317|NCT00833365|ibuprofen
466318|NCT00833313|Atrial fibrillation
466319|NCT00833313|Gene expression
466320|NCT00833313|Genetic
466321|NCT00833300|Delirium
466322|NCT00833300|Agitation
466323|NCT00833300|Intensive Care
466324|NCT00833300|Critical Care
466325|NCT00833300|Antipsychotics
466326|NCT00833300|Olanzapine
466327|NCT00833300|Haloperidol
466328|NCT00833287|immunoregulatory
466329|NCT00833287|dysfunction
466330|NCT00833287|obesity
466331|NCT00833261|recurrent squamous cell carcinoma of the hypopharynx
466332|NCT00833261|recurrent squamous cell carcinoma of the larynx
466333|NCT00833261|recurrent verrucous carcinoma of the larynx
466334|NCT00833261|recurrent squamous cell carcinoma of the lip and oral cavity
466335|NCT00833261|recurrent verrucous carcinoma of the oral cavity
466336|NCT00833261|recurrent metastatic squamous neck cancer with occult primary
466337|NCT00833261|recurrent squamous cell carcinoma of the oropharynx
466338|NCT00833261|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
466339|NCT00833261|tongue cancer
466340|NCT00833222|premature birth
466341|NCT00833209|Orbitofrontal cortex
466342|NCT00833209|Medication Overuse Headache
466343|NCT00833209|Chronic headache
466344|NCT00833209|withdrawal
466345|NCT00833170|pediatric inflammatory bowel disease
466346|NCT00833170|multiple site study
466347|NCT00833157|Knee Osteoarthritis
466348|NCT00833157|exercise
466349|NCT00833157|strength training
466350|NCT00833157|Glucosamine
466351|NCT00833157|Dietary supplement
466352|NCT00833157|Ibuprofen
466353|NCT00833157|NSAID
466354|NCT00833144|heart failure
466355|NCT00833144|dyspnea
466356|NCT00833144|ultrasound
466357|NCT00833131|Rectal cancer
466358|NCT00833131|Preoperative radiotherapy and consolidating chemotherapy
466359|NCT00833118|Surgery
466360|NCT00833118|General Anesthesia
466361|NCT00833118|Intubation
466362|NCT00833105|Incomplete Spinal Cord Injury
466363|NCT00833105|Rehabilitation
466364|NCT00833105|Upper Extremity
466365|NCT00833105|AMES device
466366|NCT00833105|Incomplete SCI
466367|NCT00833105|Quadriplegia
466368|NCT00833092|magnesium
466369|NCT00833092|Nutritional Requirements
466370|NCT00833092|Sleep
466371|NCT00833079|Atopic Dermatitis
466372|NCT00833066|hay fever
466373|NCT00833066|grass pollen allergy
466374|NCT00833040|Cancer breakthrough pain
466375|NCT00833001|Anterior vaginal prolapse (medial, lateral,apical cystocele)
466376|NCT00833001|Posterior vaginal prolapse (rectocele and/or enterocele)
466377|NCT00833001|Vault prolapse (enterocele, uterine/vaginal vault prolapse)
466378|NCT00832988|pacing thresholds
466379|NCT00832988|sensing
466380|NCT00832988|impedance
466381|NCT00832962|Rhesus D
466382|NCT00832962|Anti-D allo-immunization
466383|NCT00832962|Fetal RHD genotyping
466384|NCT00832962|anti-D immunoglobulins
466385|NCT00832962|anti-D prophylaxis
466386|NCT00832949|Mixed methods research (qualitative and quantitative)
466387|NCT00832949|Peer support
466388|NCT00832949|Early inflammatory arthritis
466389|NCT00832949|Self-management
466390|NCT00832949|Patient education
466391|NCT00832923|parental empowerment
466392|NCT00832923|parent self-efficacy
466393|NCT00832910|Body image
466394|NCT00832910|Rheumatoid Arthritis
466395|NCT00832897|Keratoconus
466396|NCT00832897|riboflavin
466397|NCT00832897|cornea
466398|NCT00832897|crosslinking
466399|NCT00832884|partial
466400|NCT00832884|onset
466401|NCT00832884|epilepsy
466402|NCT00832884|pediatric
466403|NCT00832884|lacosamide
466404|NCT00832884|partial onset epilepsy
466405|NCT00832884|vimpat
466406|NCT00832871|Mifepristone
466407|NCT00832871|RU-486
466408|NCT00832871|Compassionate Use
466409|NCT00832871|Antiprogesterone
466410|NCT00832845|Late-life schizophrenia (LLS)
466411|NCT00832845|Cognitive Behavioural Social Skills Training (CBSST)
466412|NCT00832845|Randomized
466413|NCT00832832|Glaucoma
466414|NCT00832832|Eye drop
466415|NCT00832832|Intraocular pressure
466416|NCT00832832|Eyelid closure
466417|NCT00832819|Cancer
466418|NCT00832819|Lung Cancer
466419|NCT00832806|smoking
466420|NCT00832806|Champix
466421|NCT00832806|Integrated Voice Response technology
466422|NCT00832793|Mixed methods research (qualitative and quantitative)
466423|NCT00832793|Peer support
466424|NCT00832793|Early inflammatory arthritis
466425|NCT00832793|Self-management
466426|NCT00832793|Patient education
466427|NCT00832780|Lung cancer
466428|NCT00832780|radiation therapy
466429|NCT00832780|SBRT
466430|NCT00832780|Stereotactic Body Radiation Therapy
466431|NCT00832780|Tomotherapy
466432|NCT00832780|other solid tumors
466433|NCT00832767|Laparoscopic Cholecystectomy
466434|NCT00832767|Single Incision Laparoscopic Surgery
466435|NCT00832767|Surgical Procedures, Minimally Invasive
466436|NCT00832754|malaria
466437|NCT00832754|rapid diagnostic test
466438|NCT00832754|artemisinin
466439|NCT00832754|Ghana
466440|NCT00832741|GLP-1
466441|NCT00832741|Type 1 diabetes
466442|NCT00832741|Glycemic control
466443|NCT00832741|Incretin hormone
466444|NCT00832715|Lung
466445|NCT00832715|Lung Cancer
466446|NCT00832715|NSCLC
466447|NCT00832715|Non Small Cell Lung Cancer
466448|NCT00832715|Squamous Cell
466449|NCT00832715|Adenocarcinoma
466450|NCT00832715|Large Cell
466451|NCT00832715|Endobronchial Ultrasound Transbronchial Needle Aspiration
466452|NCT00832715|Mediastinal lymph node negative disease
466453|NCT00832715|Mediastinal Nodal Metastasis
466454|NCT00832715|EBUS-FNA
466455|NCT00832715|Endobronchial Ultrasound Fine Needle Aspiration
466456|NCT00832715|EBUS guided needle mediastinal lymph node biopsy
466457|NCT00832715|Biopsy
466458|NCT00832715|PET scan
466459|NCT00832715|Positron Emission Tomography
466460|NCT00832715|CT Scans
466461|NCT00832715|Computed Tomography Scans
466462|NCT00832715|Lymph node
466463|NCT00832715|Mediastinoscopy
466464|NCT00832715|Bronchoscope
466465|NCT00832702|Cardiac
466466|NCT00832702|MRI
466467|NCT00832702|Coronary Vascular Dysfunction
466468|NCT00832689|toxicity
466469|NCT00832676|Mixed methods research (qualitative and quantitative)
466470|NCT00832676|Peer support
466471|NCT00832676|Early inflammatory arthritis
466472|NCT00832676|Self-management
466473|NCT00832676|Patient education
466474|NCT00832663|Muscle regeneration
466475|NCT00832663|Satellite cells
466476|NCT00832663|electrical stimulation
466477|NCT00832663|eccentric contractions
466478|NCT00832663|myogenic precursor cells
466479|NCT00832650|Healthy; Fesoterodine; Solifenacin
466480|NCT00832637|Liver
466481|NCT00832637|Gallbladder
466482|NCT00832637|Bile duct
466483|NCT00832637|Gemzar
466484|NCT00832637|Eloxatin
466485|NCT00832637|Tarceva
466486|NCT00832637|erlotinib
466487|NCT00832637|Gem-ox
466488|NCT00832611|Lung Disease
466489|NCT00832611|Chronic Airflow Obstruction
466490|NCT00832611|Chronic Bronchitis
466491|NCT00832611|Chronic Emphysema
466492|NCT00832598|18F-FACBC
466493|NCT00832598|PET scan imaging
466494|NCT00832598|08-142
466495|NCT00832585|Atopic
466496|NCT00832585|Dermatitis
466497|NCT00832585|chronic
466498|NCT00832585|skin
466499|NCT00832572|Coronary Artery Disease
466500|NCT00832572|Pain
466501|NCT00832572|Peripheral Neuropathy
466502|NCT00832572|Polyneuropathy
466503|NCT00832559|CAVATAK
466504|NCT00832559|Coxsackievirus A21
466505|NCT00832559|CVA21
466506|NCT00832559|Oncolytic virotherapy
466507|NCT00832533|Vitamin D
466508|NCT00832533|Serum 25-Hydroxyvitamin D
466509|NCT00832533|UV exposure
466510|NCT00832533|Ultraviolet Light Exposure
466511|NCT00832533|Skin Melanoma Advanced
466512|NCT00832520|Advanced cancer
466513|NCT00832520|weight loss
466514|NCT00832520|Remeron
466515|NCT00832520|body weight
466516|NCT00832507|PAH
466517|NCT00832507|pulmonary hypertension
466518|NCT00832507|cicletanine
466519|NCT00832507|cicletanine HCL
466520|NCT00832507|cardiovascular
466521|NCT00832507|endothelin receptor antagonist
466522|NCT00832507|ERA
466523|NCT00832507|monotherapy
466524|NCT00832507|combination therapy
466525|NCT00832507|phosphodiesterase type-5 inhibitor
466526|NCT00832507|PDE5i
466527|NCT00832507|parenteral prostanoid
466528|NCT00832507|PH
466529|NCT00832507|pulmonary
466530|NCT00832481|Repaglinide
466531|NCT00832481|Metformin
466532|NCT00832468|insomnia
466533|NCT00832468|ear acupressure
466534|NCT00832442|Beta blocker
466535|NCT00832442|Heart Failure
466536|NCT00832442|Meta analysis
466537|NCT00832442|Individual patient data
466538|NCT00832429|Sebaceous Gland Carcinoma of the Eyelid
466539|NCT00832429|Eyelid Sebaceous Gland Carcinoma
466540|NCT00832429|Cancer of the eyelid
466541|NCT00832429|Eye Cancer
466542|NCT00832429|Tumors of the Eye
466543|NCT00832429|Sentinel Lymph Node Localization and Biopsy
466544|NCT00832429|SLN
466545|NCT00832429|Metastatic Disease
466546|NCT00832429|Metastatic Cancer of the Eyelid
466547|NCT00832429|Lymphatic Mapping
466548|NCT00832429|SLN Mapping/Biopsy
466549|NCT00832429|SLN Biopsy Procedure
466550|NCT00832429|SLN Biopsy
466551|NCT00832429|Lymph Nodes
466552|NCT00832429|Tc99m-Sulfur Colloid
466553|NCT00832429|Single Photon Emission Computed Tomography
466554|NCT00832429|Computed Tomography
466555|NCT00832429|SPECT/CT
466556|NCT00832403|atrophic rhinitis
466557|NCT00832403|implants
466558|NCT00832403|Polytetrafluoroethylene
466559|NCT00832364|Psoriasis
466560|NCT00832364|Moderate to Severe Plaque Psoriasis
466561|NCT00832351|Stroke
466562|NCT00832351|Brain infarction
466563|NCT00832351|Intracerebral hemorrhage
466564|NCT00832351|Early Mobilisation
466565|NCT00832338|Breast cancer
466566|NCT00832338|Tumors, Breast
466567|NCT00832338|Cancer of the breast
466568|NCT00832325|Childhood Survivor
466569|NCT00832325|survivors
466570|NCT00832325|Young Adult Cancer Survivors
466571|NCT00832325|Childhood cancers
466572|NCT00832325|09-001
466573|NCT00832312|Osteoarthritis
466574|NCT00832312|Knee
466575|NCT00832312|Pain management
466576|NCT00832312|Ozone therapy
466577|NCT00832312|Intraarticular injection
466578|NCT00832286|genomic techniques,intestinal microbiome
466579|NCT00832273|Expanded access to ELAD® in patients with liver failure
466580|NCT00832247|Hepatitis C
466581|NCT00832247|Cirrhosis
466582|NCT00832247|Stem cell
466583|NCT00832234|Morbus Waldenstrom
466584|NCT00832234|Waldenstroms Macroglobulinemia
466585|NCT00832234|Therapy
466586|NCT00832234|Rituximab
466587|NCT00832234|Dexamethasone
466588|NCT00832234|Bortezomib
466589|NCT00832221|PET
466590|NCT00832221|Phase 1
466591|NCT00832221|Depression
466592|NCT00832221|SEROQUEL
466593|NCT00832221|Positron Emission Tomography
466594|NCT00832221|Drug profile comparison
466595|NCT00832195|running
466596|NCT00832195|injury
466597|NCT00832195|pronation
466598|NCT00832195|footwear.
466599|NCT00832169|Pain
466600|NCT00832156|Burns
466601|NCT00832156|Cultured autologous keratinocytes
466602|NCT00832156|Wound healing
466603|NCT00832156|Wound closure
466604|NCT00832156|Scar quality
466605|NCT00832143|neonatal illness
466606|NCT00832143|qualified care seeking
466607|NCT00832143|Behaviour change
466608|NCT00832143|Urban slums
466609|NCT00832143|India
466610|NCT00832143|Neonatal morbidity
466611|NCT00832143|Care seeking for neonatal illnesses
466612|NCT00832143|Qualified medical care seeking
466613|NCT00832143|Integrated management of neonatal and childhood illnesses (IMNCI)
466614|NCT00832117|Lung Cancer (NSCLC)
466615|NCT00832091|Venous Stasis Ulcers
466616|NCT00832091|venous insufficiency
466617|NCT00832091|leg ulcers
466618|NCT00832091|Thymosin Beta 4
466619|NCT00832091|Laminin-5
466620|NCT00832065|Sleep Apnea Syndrome
466621|NCT00832065|Sleep Apnea
466622|NCT00832065|CPAP
466623|NCT00832065|Low testosterone
466624|NCT00832065|Sexual Dysfunction
466625|NCT00832052|elderly, multi-dose, safety, efficacy
466626|NCT00832039|sepsis
466627|NCT00832039|adjunctive therapy
466628|NCT00832039|sodium-selenite
466629|NCT00832039|procalcitonin
466630|NCT00832026|sleep apnea
466631|NCT00832026|snoring
466632|NCT00832026|sleep apnea treatment
466633|NCT00832026|TNI
466634|NCT00832026|Trans nasal insuflation
466635|NCT00832026|Open CPAP
466636|NCT00832013|Propofol
466637|NCT00832013|sedation
466638|NCT00832013|pediatric
466639|NCT00832013|Induction of sedation
466640|NCT00831987|Fluzone®
466641|NCT00831987|Influenza
466642|NCT00831987|Adults
466643|NCT00831974|mastocytosis
466644|NCT00831974|indolent
466645|NCT00831974|handicap
466646|NCT00831974|wild-type
466647|NCT00831974|systemic
466648|NCT00831974|not D816V mutated
466649|NCT00831961|Antibiotic resistance, Conjunctival flora, Intravitreal injections
466650|NCT00831935|Acoustic properties of voice in depression
466651|NCT00831922|Rheumatoid Arthritis
466652|NCT00831922|DMARD failure
466653|NCT00831922|ACR
466654|NCT00831909|Lung Cancer
466655|NCT00831909|NSCLC management
466656|NCT00831909|NSCLC use of health care resources
466657|NCT00831883|Adolescent
466658|NCT00831883|Adolescent behavior
466659|NCT00831883|Health behavior
466660|NCT00831883|Sexual Behavior
466661|NCT00831883|Incarceration
466662|NCT00831883|Behavioral Intervention
466663|NCT00831883|Risk Reduction Behavior
466664|NCT00831870|EndoSure Sensor
466665|NCT00831870|s2 Sensor
466666|NCT00831870|abdominal aortic aneurysm
466667|NCT00831831|perinatal
466668|NCT00831831|intimate partner violence
466669|NCT00831831|randomized controlled trial
466670|NCT00831831|preterm
466671|NCT00831831|hemorrhage
466672|NCT00831831|safety
466673|NCT00831818|breastfeeding
466674|NCT00831818|ghrelin
466675|NCT00831818|PYY
466676|NCT00831818|appetite-regulation
466677|NCT00831805|geriatrics
466678|NCT00831805|psycho-cognitive troubles
466679|NCT00831805|elderly
466680|NCT00831805|mobile unit
466681|NCT00831805|elderly patients
466682|NCT00831792|Prostate Cancer
466683|NCT00831792|Advanced Prostate Cancer
466684|NCT00831792|Castrate Resistant Prostate Cancer
466685|NCT00831792|Prostate Specific Antigen
466686|NCT00831792|PSA
466687|NCT00831792|Castration-Resistant Prostate Cancer Patients
466688|NCT00831792|TK1258
466689|NCT00831792|CHIR-258
466690|NCT00831766|Hematopoietic
466691|NCT00831766|Myeloid and Monocytic Leukemia
466692|NCT00831766|AML
466693|NCT00831753|Diphtheria
466694|NCT00831753|Tetanus
466695|NCT00831753|Pertussis
466696|NCT00831753|whooping cough
466697|NCT00831753|Haemophilus influenzae type b
466698|NCT00831753|Hepatitis B
466699|NCT00831753|Poliomyelitis
466700|NCT00831740|Stroke
466701|NCT00831740|Communication
466702|NCT00831740|Speech and Language Therapy
466703|NCT00831727|expressive writing
466704|NCT00831727|trauma
466705|NCT00831727|intervention
466706|NCT00831727|posttraumatic stress
466707|NCT00831714|Prophylaxis of Venous Thromboembolism
466708|NCT00831701|Adrenergic alpha antagonists
466709|NCT00831701|drug therapy
466710|NCT00831701|tamsulosin
466711|NCT00831701|ureter
466712|NCT00831688|Meniere
466713|NCT00831688|vertigo
466714|NCT00831688|overpressure treatment
466715|NCT00831688|caloric irrigation
466716|NCT00831688|hearing levels
466717|NCT00831688|vertigo severity
466718|NCT00831688|functional disability scale
466719|NCT00831675|Influenza
466720|NCT00831675|Fluzone® vaccine
466721|NCT00831675|Infants
466722|NCT00831675|Toddlers
466723|NCT00831636|CP-4055
466724|NCT00831636|Cancer
466725|NCT00831636|Metastatic
466726|NCT00831636|Solid tumors
466727|NCT00831636|advanced ovarian cancer
466728|NCT00831636|stage III and IV ovarian cancer
466729|NCT00831636|advanced epithelian ovarian cancer
466730|NCT00831623|hypofractionation
466731|NCT00831623|proton beam radiation
466732|NCT00831610|bariatric surgery
466733|NCT00831610|plastic surgery
466734|NCT00831610|abdominal wall
466735|NCT00831610|skin
466736|NCT00831610|sensation
466737|NCT00831610|abdominoplasty
466738|NCT00831597|Lymphoma
466739|NCT00831597|B-Cell
466740|NCT00831571|oxaliplatin
466741|NCT00831571|hypersensitivity
466742|NCT00831532|Dimebon Hepatic Impairment
466743|NCT00831506|digoxin dimebon drug-drug interaction study
466744|NCT00831493|Pancreas
466745|NCT00831493|Pancreatic Cancer
466746|NCT00831493|Locally Advanced Pancreatic Cancer
466747|NCT00831493|LAPC
466748|NCT00831493|Non-Metastatic
466749|NCT00831493|Unresectable
466750|NCT00831493|Vorinostat
466751|NCT00831493|XRT
466752|NCT00831493|RT
466753|NCT00831493|Radiation Therapy
466754|NCT00831493|SAHA
466755|NCT00831493|Suberoylanilide Hydroxamic Acid
466756|NCT00831493|MSK-390
466757|NCT00831480|Renal cell carcinoma
466758|NCT00831480|Everolimus
466759|NCT00831480|Neoadjuvant
466760|NCT00831480|advanced kidney cancer
466761|NCT00831467|Hormonal refractory prostate cancer
466762|NCT00831467|RNA vaccine
466763|NCT00831441|NOS
466764|NCT00831428|asthma
466765|NCT00831428|rhinitis
466766|NCT00831428|swimmers
466767|NCT00831428|mannitol
466768|NCT00831415|Open-label Long-term extension study
466769|NCT00831402|woman
466770|NCT00831376|Asthma
466771|NCT00831376|Genotype
466772|NCT00831376|Beta2adrenoreceptor
466773|NCT00831376|Levosalbutamol
466774|NCT00831363|gait analysis
466775|NCT00831363|minimal invasive approach
466776|NCT00831363|transgluteal approach
466777|NCT00831363|THA
466778|NCT00831350|RVO
466779|NCT00831350|PVD
466780|NCT00831337|VSL3
466781|NCT00831337|Probiotics
466782|NCT00831337|Gut microbiota
466783|NCT00831337|Cytokines
466784|NCT00831337|Portal hypertension
466785|NCT00831337|Chemokines
466786|NCT00831337|Liver cirrhosis
466787|NCT00831324|adult diffuse astrocytoma
466788|NCT00831324|adult pineal gland astrocytoma
466789|NCT00831324|adult subependymal giant cell astrocytoma
466790|NCT00831324|adult mixed glioma
466791|NCT00831324|adult anaplastic oligodendroglioma
466792|NCT00831324|adult oligodendroglioma
466793|NCT00831324|recurrent adult brain tumor
466794|NCT00831311|Diphtheria
466795|NCT00831311|Tetanus
466796|NCT00831311|Pertussis
466797|NCT00831311|Whooping cough
466798|NCT00831311|Hepatitis B
466799|NCT00831311|Poliomyelitis
466800|NCT00831311|Haemophilus influenzae type b
466801|NCT00831298|alzheimer disease
466802|NCT00831298|sleep disturbance
466803|NCT00831298|apathy
466804|NCT00831298|memory loss
466805|NCT00831285|Healthy volunteers
466806|NCT00831259|stroke
466807|NCT00831259|PFO
466808|NCT00831259|embolism
466809|NCT00831246|Ileus,
466810|NCT00831246|Gynecologic surgery,
466811|NCT00831246|Post-operative,
466812|NCT00831246|Flatus
466813|NCT00831220|COPD
466814|NCT00831220|exacerbations
466815|NCT00831220|EPCs
466816|NCT00831220|Erythropoietin
466817|NCT00831220|C-RP
466818|NCT00831220|COPD and endothelial dysfunction
466819|NCT00831207|B-2 microglobulin
466820|NCT00831207|Serum cytokines
466821|NCT00831207|HIV-1
466822|NCT00831207|Resistance
466823|NCT00831207|HAART
466824|NCT00831207|Therapeutic failure
466825|NCT00831207|Genotyping.
466826|NCT00831194|Type 2 Diabetes
466827|NCT00831194|Obesity
466828|NCT00831194|Weight loss
466829|NCT00831194|PDA
466830|NCT00831194|Stress
466831|NCT00831194|Dietary lapse
466832|NCT00831194|salivary alpha amylase
466833|NCT00831181|stage II rectal cancer
466834|NCT00831181|stage III rectal cancer
466835|NCT00831181|adenocarcinoma of the rectum
466836|NCT00831168|neonatal
466837|NCT00831168|premature babies
466838|NCT00831168|healthcare research
466839|NCT00831168|Babies born before 27 weeks gestation
466840|NCT00831155|smoking
466841|NCT00831155|nicotine patches
466842|NCT00831155|extinction based treatment
466843|NCT00831142|Prostate Cancer
466844|NCT00831142|MRI
466845|NCT00831142|Prostatectomy
466846|NCT00831116|near infrared spectroscopy
466847|NCT00831116|LipiScan
466848|NCT00831116|lipid core
466849|NCT00831116|percutaneous coronary intervention
466850|NCT00831116|myocardial infarction
466851|NCT00831116|NIRS
466852|NCT00831116|intravascular imaging
466853|NCT00831103|EPB348
466854|NCT00831103|Valomaciclovir Stearate
466855|NCT00831103|Valacyclovir
466856|NCT00831103|Herpes Zoster
466857|NCT00831103|Shingles
466858|NCT00831077|Healthy volunteers
466859|NCT00831064|bowel preparation quality
466860|NCT00831064|colonoscopy
466861|NCT00831051|Bunionectomy
466862|NCT00831038|pulmonary function tests
466863|NCT00831038|infants
466864|NCT00831038|chronic lung disease
466865|NCT00831038|dysphagia
466866|NCT00831038|chronic aspiration
466867|NCT00831025|Immunotherapy
466868|NCT00831025|Allergoid
466869|NCT00831025|Depigmented
466870|NCT00831025|Polymerized
466871|NCT00831025|Allergen-extract
466872|NCT00831025|Rhinoconjunctivitis
466873|NCT00831012|Dengue Vaccine
466874|NCT00831012|Dengue Virus
466875|NCT00831012|Dengue Hemorrhagic Fever
466876|NCT00831012|Dengue Shock Syndrome
466877|NCT00830999|fat metabolism
466878|NCT00830999|exercise
466879|NCT00830999|liver
466880|NCT00830999|lipoproteins
466881|NCT00830999|triglycerides
466882|NCT00830986|Mental Cognition Change
466883|NCT00830986|Fat Embolism
466884|NCT00830986|Bone Marrow Debris Emboli
466885|NCT00830986|Computer Assisted Total Knee Arthroplasty
466886|NCT00830986|Conventional Instrumented Total Knee Arthroplasty
466887|NCT00830973|Estrogen Antagonists
466888|NCT00830973|Antineoplastic Agents, Hormonal
466889|NCT00830973|Hormone Antagonists
466890|NCT00830973|Hormones
466891|NCT00830973|Hormone Substitutes
466892|NCT00830973|Selective Estrogen Receptor Modulators
466893|NCT00830973|Estrogen Receptor Modulators
466894|NCT00830973|Neoplasms
466895|NCT00830973|Neoplasms by Site
466896|NCT00830947|Orthodontic
466897|NCT00830947|Extraction
466898|NCT00830947|Device
466899|NCT00830947|Space Closure
466900|NCT00830947|Orthodontic malocclusion
466901|NCT00830934|pelvic girdle pain
466902|NCT00830934|symphysio pubic dysfunction
466903|NCT00830934|group care
466904|NCT00830934|individual care
466905|NCT00830921|Histocytologically proven thoracic malignancy
466906|NCT00830908|seborrheic dermatitis
466907|NCT00830895|Renal cell carcinoma
466908|NCT00830895|Non-clear cell
466909|NCT00830895|RAD001
466910|NCT00830895|Metastatic, non-clear cell, renal cell carcinoma
466911|NCT00830882|asthma
466912|NCT00830882|levosalbutamol
466913|NCT00830882|genotype
466914|NCT00830882|bronchoprotection
466915|NCT00830856|Cryptococcal Meningitis
466916|NCT00830856|HIV
466917|NCT00830856|Fluconazole
466918|NCT00830856|Antiretroviral therapy
466919|NCT00830856|Africa
466920|NCT00830856|treatment naive
466921|NCT00830843|SAH
466922|NCT00830843|sedation
466923|NCT00830843|anesthesia
466924|NCT00830817|Topical cream application
466925|NCT00830817|Mild to moderate psoriasis
466926|NCT00830804|Treatment Naive
466927|NCT00830778|pancreas
466928|NCT00830778|surgery
466929|NCT00830778|cancer
466930|NCT00830778|pancreaticoduodenectomy (PD)
466931|NCT00830778|peri-ampullary tumours (ampulla, duodenum, distal bile duct, and miscellaneous tumours)
466932|NCT00830778|pancreatic tumors
466933|NCT00830778|peri-ampullary tumors
466934|NCT00830752|alexithymia
466935|NCT00830739|Smoking Cessation
466936|NCT00830739|Dopamine
466937|NCT00830739|Cognitive Control
466938|NCT00830739|Reward Processing
466939|NCT00830739|Varenicline
466940|NCT00830726|Aquaporin
466941|NCT00830726|Epithelial Sodium Channels
466942|NCT00830726|Heart Failure
466943|NCT00830726|Valvular heart disease
466944|NCT00830726|Ischemic heart disease
466945|NCT00830713|vitiligo
466946|NCT00830713|skin transplantation
466947|NCT00830713|non-cultured
466948|NCT00830713|melanocyte
466949|NCT00830713|surgery
466950|NCT00830700|ADHD
466951|NCT00830700|telemental health
466952|NCT00830700|TMH
466953|NCT00830700|telepsychiatry
466954|NCT00830700|rural mental health services for children
466955|NCT00830687|subcapital femoral fractures
466956|NCT00830687|transcervical femoral fractures
466957|NCT00830687|TARGON FN
466958|NCT00830674|XLH
466959|NCT00830661|transsphincteric anal fistula
466960|NCT00830661|cryptoglandular origin
466961|NCT00830661|anal fistula repair
466962|NCT00830661|Ligation of Intersphincteric Fistula Track (LIFT) procedure
466963|NCT00830661|anal fistula plug (Plug)
466964|NCT00830661|surgical repair
466965|NCT00830648|varicella-zoster virus
466966|NCT00830648|varicella
466967|NCT00830635|long-term effects of cancer treatment
466968|NCT00830635|psychosocial effects of cancer and its treatment
466969|NCT00830635|depression
466970|NCT00830635|stage IA breast cancer
466971|NCT00830635|stage IB breast cancer
466972|NCT00830635|stage II breast cancer
466973|NCT00830635|stage I prostate cancer
466974|NCT00830635|stage II prostate cancer
466975|NCT00830622|HIV/AIDS
466976|NCT00830622|Adherence
466977|NCT00830622|Antiretroviral Therapy, ART, ARV
466978|NCT00830622|Mobile phone, cell phone, telephone
466979|NCT00830622|Text message, SMS
466980|NCT00830622|Telemedicine
466981|NCT00830622|Africa
466982|NCT00830622|Resource-limited setting
466983|NCT00830622|Counseling, support
466984|NCT00830622|treatment experienced
466985|NCT00830609|Chronic Hepatitis C
466986|NCT00830609|Genotype 3
466987|NCT00830609|High viral load
466988|NCT00830570|CYP2C9
466989|NCT00830570|VKORC1
466990|NCT00830570|polymorphism
466991|NCT00830570|warfarin
466992|NCT00830570|Coumadin
466993|NCT00830557|recurrent pancreatic cancer
466994|NCT00830557|stage I pancreatic cancer
466995|NCT00830557|stage II pancreatic cancer
466996|NCT00830557|stage III pancreatic cancer
466997|NCT00830557|stage IV pancreatic cancer
466998|NCT00830557|recurrent islet cell carcinoma
466999|NCT00830557|pancreatic alpha cell carcinoma
467000|NCT00830557|pancreatic beta islet cell carcinoma
467001|NCT00830557|pancreatic delta cell carcinoma
467002|NCT00830557|pancreatic G-cell carcinoma
467003|NCT00830544|neoadjuvant chemotherapy breast cancer
467004|NCT00830544|Breast cancer patients with tumors over one cm
467005|NCT00830531|Hypoxic-ischemic encephalopathy
467006|NCT00830531|Neonatal stroke
467007|NCT00830531|Intracranial hemorrhage
467008|NCT00830531|Perinatal asphyxia
467009|NCT00830531|Neonatal Seizures
467010|NCT00830505|fluticasone
467011|NCT00830505|salmeterol
467012|NCT00830505|bronchoprotection
467013|NCT00830492|clomiphene citrate
467014|NCT00830492|GnRH agonist
467015|NCT00830492|GnRH antagonist
467016|NCT00830492|in vitro fertilization
467017|NCT00830492|clinical pregnancy
467018|NCT00830492|pregnancy
467019|NCT00830466|port wine stain
467020|NCT00830453|Brain injury with sequelae from stroke, anoxia, or trauma
467021|NCT00830427|asthma bronchial diseases
467022|NCT00830414|Bioequivalence
467023|NCT00830414|Healthy Subjects
467024|NCT00830401|intra-uterine abnormalities
467025|NCT00830401|intracavitary pathology
467026|NCT00830401|hysteroscopy
467027|NCT00830401|IVF
467028|NCT00830401|ICSI
467029|NCT00830401|polyp
467030|NCT00830401|myoma
467031|NCT00830401|adhesion
467032|NCT00830401|septum
467033|NCT00830401|endometritis
467034|NCT00830388|tinea versicolor
467035|NCT00830388|ketoconazole
467036|NCT00830375|Buying
467037|NCT00830375|Shopping
467038|NCT00830375|Impulse Control
467039|NCT00830362|cocaine
467040|NCT00830362|cocaine-dependent
467041|NCT00830362|propranolol
467042|NCT00830362|craving
467043|NCT00830362|beta-blockade
467044|NCT00830362|cue exposure
467045|NCT00830362|drug
467046|NCT00830362|addiction
467047|NCT00830362|memory
467048|NCT00830362|addictive behavior
467049|NCT00830349|Bioequivalence
467050|NCT00830349|Healthy Subjects
467051|NCT00830336|Bioequivalence
467052|NCT00830336|Healthy Subjects
467053|NCT00830310|Patient Non-Adherence
467054|NCT00830310|Patient Non-Compliance
467055|NCT00830310|Patient Nonadherence
467056|NCT00830310|Patient Noncompliance
467057|NCT00830310|Patient Refusal of Treatment
467058|NCT00830310|Refusal of Treatment
467059|NCT00830310|Treatment Refusal
467060|NCT00830297|TIP
467061|NCT00830297|NODAT
467062|NCT00830297|hyperglycemia
467063|NCT00830297|long-acting insulin
467064|NCT00830297|post-transplant hyperglycemia
467065|NCT00830284|Pediatric Acute Respiratory Distress Syndrome (ARDS)
467066|NCT00830284|Pediatric Acute Lung Injury (ALI)
467067|NCT00830271|surgical site infection
467068|NCT00830271|wound complications
467069|NCT00830271|suture
467070|NCT00830271|antiseptic
467071|NCT00830271|wound closure
467072|NCT00830258|Bioequivalence
467073|NCT00830258|Healthy Subjects
467074|NCT00830245|EGFR mutation
467075|NCT00830245|Erlotinib
467076|NCT00830245|Lung cancer
467077|NCT00830245|leptomeningeal carcinomatosis in EGFR mutation positive non-small cell lung cancer
467078|NCT00830232|Stroke
467079|NCT00830232|Carotid stenosis
467080|NCT00830232|stents
467081|NCT00830219|Bioequivalence
467082|NCT00830219|Healthy Subjects
467083|NCT00830206|Bioequivalence
467084|NCT00830206|Healthy Subjects
467085|NCT00830193|N-acetylcysteine
467086|NCT00830193|prevention
467087|NCT00830193|contrast-induced nephropathy
467088|NCT00830193|critically ill adults
467089|NCT00830180|Cancer pain
467090|NCT00830180|NGF
467091|NCT00830180|open-label extension
467092|NCT00830154|stutter
467093|NCT00830154|stuttering
467094|NCT00830154|Adults with a history of stuttering
467095|NCT00830141|Ghrelin
467096|NCT00830141|obesity
467097|NCT00830141|idiopathic short stature (ISS)
467098|NCT00830115|PPI therapy
467099|NCT00830115|Pantoprazole
467100|NCT00830115|eGERD (Erosive Gastroesophageal Reflux Disease)
467101|NCT00830115|NERD (Non-Erosive Reflux Disease)
467102|NCT00830102|Mild to Moderate Asthma
467103|NCT00830089|Transversus abdominis plane block
467104|NCT00830089|Laparoscopic colorectal surgery
467105|NCT00830089|Analgesia
467106|NCT00830063|monoclonal antibody
467107|NCT00830063|RN624
467108|NCT00830063|PF-04383119
467109|NCT00830063|nerve growth factor
467110|NCT00830063|anti-nerve growth factor
467111|NCT00830063|OA
467112|NCT00830063|pain
467113|NCT00830050|fMRI functional magnetic resonance imaging Pain
467114|NCT00830037|anemia
467115|NCT00830037|iron
467116|NCT00830037|kidney disease
467117|NCT00830037|progression
467118|NCT00830037|glomerular filtration rate
467119|NCT00830024|Bioequivalence
467120|NCT00830024|Healthy Subjects
467121|NCT00830011|diabetes
467122|NCT00830011|neuropathy
467123|NCT00830011|chronic pain
467124|NCT00830011|Cognitive behavioral therapy
467125|NCT00829998|Bioequivalence
467126|NCT00829998|Healthy Subjects
467127|NCT00829985|Rhinitis, Allergic, Perennial
467128|NCT00829985|Rhinitis, Allergic, Seasonal
467129|NCT00829985|Immunotherapy
467130|NCT00829985|Asthma
467131|NCT00829985|Nasal Allergies
467132|NCT00829985|Hypersensitivity
467133|NCT00829959|Ovary, Cancer
467134|NCT00829959|Ovarian Cancer
467135|NCT00829959|Breast Cancer
467136|NCT00829959|Hereditary Breast and Ovarian Cancer Syndrome
467137|NCT00829959|HBOC
467138|NCT00829959|Genetic testing
467139|NCT00829959|Pregnancy
467140|NCT00829959|Fertility
467141|NCT00829959|Prenatal diagnostic testing
467142|NCT00829946|Strength training
467143|NCT00829946|Anorexia
467144|NCT00829946|Girls
467145|NCT00829946|Quality of life
467146|NCT00829946|Functional mobility
467147|NCT00829933|Atrial fibrillation
467148|NCT00829933|Factor Xa inhibition
467149|NCT00829920|Bladder cancer
467150|NCT00829907|Healthy volunteer study
467151|NCT00829894|Bioequivalence
467152|NCT00829894|Healthy Subjects
467153|NCT00829881|Attention
467154|NCT00829868|Bioequivalence
467155|NCT00829868|Healthy Subjects
467156|NCT00829855|pulmonary edema
467157|NCT00829855|hypertension
467158|NCT00829855|echocardiography
467159|NCT00829842|chlorexidine
467160|NCT00829842|ventilator-associated pneumonia
467161|NCT00829842|nosocomial pneumonia
467162|NCT00829842|heart surgery
467163|NCT00829842|oral hygiene
467164|NCT00829829|Metabolism, Inborn Errors
467165|NCT00829829|Allopurinol
467166|NCT00829829|Metabolic Diseases
467167|NCT00829829|Genetic Diseases, Inborn
467168|NCT00829829|Musculoskeletal Diseases
467169|NCT00829829|Joint Diseases
467170|NCT00829829|Arthritis
467171|NCT00829829|Rheumatic Diseases
467172|NCT00829829|Metabolic disorder
467173|NCT00829829|Purine-Pyrimidine Metabolism, Inborn Errors
467174|NCT00829829|Gout
467175|NCT00829816|Alzheimers disease
467176|NCT00829816|donepezil
467177|NCT00829816|memantine
467178|NCT00829803|To acquire developmental data to prospectively support SNAP
467179|NCT00829803|II index ranges at the studied anesthetic states.
467180|NCT00829790|Bioequivalence
467181|NCT00829790|Healthy Subjects
467182|NCT00829777|Naloxone
467183|NCT00829777|6β-Naltrexol
467184|NCT00829777|Opioid-dependent
467185|NCT00829777|Pharmacokinetics
467186|NCT00829777|peripheral effects of withdrawal
467187|NCT00829777|central effects of withdrawal
467188|NCT00829764|Bioequivalence
467189|NCT00829764|Healthy Subjects
467190|NCT00829751|staining
467191|NCT00829751|toxicity
467192|NCT00829751|fluorometry
467193|NCT00829751|dye diffusion
467194|NCT00829751|anterior chamber
467195|NCT00829738|PPI therapy
467196|NCT00829738|pantoprazole
467197|NCT00829738|GERD (Erosive Gastroesophageal Reflux Disease)
467198|NCT00829725|subcapital femoral fractures
467199|NCT00829725|transcervical femoral fractures
467200|NCT00829725|TARGON FN
467201|NCT00829712|Bioequivalence
467202|NCT00829712|Healthy Subjects
467203|NCT00829699|endothelial function
467204|NCT00829699|fibrinolytic balance
467205|NCT00829686|abscess
467206|NCT00829686|cellulitis
467207|NCT00829686|antibiotics
467208|NCT00829686|MRSA
467209|NCT00829673|Bioequivalence
467210|NCT00829673|Healthy Subjects
467211|NCT00829660|Acarbose
467212|NCT00829647|CLL
467213|NCT00829647|dasatinib
467214|NCT00829647|lenalidomide
467215|NCT00829647|sprycel
467216|NCT00829647|revlimid
467217|NCT00829647|CLL relapsed or refractory to fludarabine
467218|NCT00829634|methamphetamine
467219|NCT00829634|inpatient
467220|NCT00829634|d-MA
467221|NCT00829634|l-MA
467222|NCT00829634|APRL
467223|NCT00829634|San Francisco
467224|NCT00829634|metabolism
467225|NCT00829634|Metabolism of methamphetamine
467226|NCT00829621|BMP-2
467227|NCT00829621|Incisional Vacuum Assisted Closure (IVAC)
467228|NCT00829608|RRP
467229|NCT00829608|Recurrent Respiratory Papillomatosis
467230|NCT00829608|HPV vaccine
467231|NCT00829608|HPV
467232|NCT00829595|inflammatory bowel disease
467233|NCT00829595|Crohn disease
467234|NCT00829595|ulcerative colitis
467235|NCT00829595|immunosuppression
467236|NCT00829595|anti tumor necrosis alpha
467237|NCT00829595|pneumovax
467238|NCT00829595|pneumococcal vaccine
467239|NCT00829569|Intralipid
467240|NCT00829569|Omegaven
467241|NCT00829569|fish oil
467242|NCT00829569|hyperinsulinemic isoglycemic clamps
467243|NCT00829569|C-peptide glucagon test
467244|NCT00829569|indirect calorimetry
467245|NCT00829569|F2-isoprostanes
467246|NCT00829543|Spodyloarthropathy
467247|NCT00829543|Guide-free sacroiliac injection
467248|NCT00829530|Bioequivalence
467249|NCT00829530|Healthy Subjects
467250|NCT00829517|Contraception
467251|NCT00829517|sexually transmitted diseases
467252|NCT00829504|Bioequivalence
467253|NCT00829504|Healthy Subjects
467254|NCT00829491|Cardiovascular Disease Prevention
467255|NCT00829491|Behavior change
467256|NCT00829491|Risk Reduction
467257|NCT00829478|Atrial fibrillation
467258|NCT00829478|Cerebrovascular accident
467259|NCT00829478|Anticoagulation
467260|NCT00829478|Decision-making
467261|NCT00829452|Bioequivalence
467262|NCT00829452|Healthy Subjects
467263|NCT00829439|Angelman syndrome
467264|NCT00829439|Levodopa
467265|NCT00829439|Carbidopa
467266|NCT00829439|L-dopa
467267|NCT00829426|Bioequivalence
467268|NCT00829426|Healthy Subjects
467269|NCT00829400|Neuropsychology
467270|NCT00829400|Cognitive Remediation
467271|NCT00829400|Vocational Rehabilitation
467272|NCT00829400|Schizophrenia
467273|NCT00829400|Severe and persistent mental illness
467274|NCT00829400|Chronic and disabling mental illness
467275|NCT00829387|Diabetes
467276|NCT00829387|Pain
467277|NCT00829387|Neuropathic Pain
467278|NCT00829374|Alzheimer's disease
467279|NCT00829374|clinical trial
467280|NCT00829374|mitochondria
467281|NCT00829374|memory loss
467282|NCT00829374|neurodegenerative disease
467283|NCT00829374|dementia
467284|NCT00829374|investigational drug
467285|NCT00829361|Telemedicine
467286|NCT00829361|Acute stroke
467287|NCT00829361|Rural
467288|NCT00829361|thrombosis
467289|NCT00829361|consultation
467290|NCT00829361|Stroke
467291|NCT00829361|Cerebral Infarction
467292|NCT00829361|Vascular diseases
467293|NCT00829361|brain ischemia
467294|NCT00829361|brain infarction
467295|NCT00829361|brain diseases
467296|NCT00829361|cerebrovascular disorders
467297|NCT00829348|Compliance
467298|NCT00829348|Chronic
467299|NCT00829348|Pharmacotherapy
467300|NCT00829348|Statins
467301|NCT00829335|Intraoperative ultrasound
467302|NCT00829335|Segmentectomy
467303|NCT00829335|HCC
467304|NCT00829309|Bioequivalence
467305|NCT00829309|Healthy Subjects
467306|NCT00829296|diabetes
467307|NCT00829296|hypertension
467308|NCT00829296|aortic impedance
467309|NCT00829283|Experimental
467310|NCT00829283|Comparator
467311|NCT00829244|Infertility
467312|NCT00829244|Assisted reproductive technology
467313|NCT00829231|Liver disease
467314|NCT00829218|Irritable Bowel Syndrome
467315|NCT00829218|Fibromyalgia
467316|NCT00829218|Glutamate
467317|NCT00829218|Diet
467318|NCT00829218|Food additives
467319|NCT00829205|recurrent adult diffuse large cell lymphoma
467320|NCT00829192|Actinic keratoses (AK)
467321|NCT00829192|Squamous cell carcinomas (SCC)
467322|NCT00829192|CUV1647
467323|NCT00829192|Afamelanotide
467324|NCT00829192|Clinuvel
467325|NCT00829192|Photoprotection
467326|NCT00829192|Organ transplant
467327|NCT00829179|Asthma
467328|NCT00829153|Fistula patency
467329|NCT00829127|volunteers
467330|NCT00829114|AE
467331|NCT00829114|AIDS
467332|NCT00829114|ALT
467333|NCT00829114|ART
467334|NCT00829114|AST
467335|NCT00829114|DCF
467336|NCT00829114|DMC
467337|NCT00829114|FDA
467338|NCT00829114|GCP
467339|NCT00829114|HB sAg
467340|NCT00829114|ICH
467341|NCT00829114|IND
467342|NCT00829114|IRB
467343|NCT00829114|IU
467344|NCT00829114|mg
467345|NCT00829114|mm3
467346|NCT00829114|PCR
467347|NCT00829114|SAE
467348|NCT00829114|ULN
467349|NCT00829114|WB
467350|NCT00829114|COC
467351|NCT00829114|Combined Oral Contraceptives
467352|NCT00829101|unilateral cleft lip and palate
467353|NCT00829101|primary palatal surgery
467354|NCT00829101|articulation
467355|NCT00829101|phonology
467356|NCT00829101|one stage palatal repair
467357|NCT00829101|two stage palatal repair
467358|NCT00829088|Mass balance
467359|NCT00829088|AZD2066
467360|NCT00829088|Pain
467361|NCT00829088|Pain conditions
467362|NCT00829062|Type 1 diabetes
467363|NCT00829062|Insulin pump
467364|NCT00829062|Glycemic variability
467365|NCT00829036|Rehabilitation
467366|NCT00829036|Sensory Aid
467367|NCT00829023|Positive aerobic or anaerobic cultures
467368|NCT00829010|Human Immunodeficiency Virus
467369|NCT00829010|Booster vaccination
467370|NCT00829010|Safety
467371|NCT00829010|Primary vaccination
467372|NCT00829010|Pneumococcal vaccine
467373|NCT00829010|Immunogenicity
467374|NCT00829010|Pneumococcal disease
467375|NCT00828997|rheumatoid arthritis
467376|NCT00828997|spondylarthropathy
467377|NCT00828997|immunological response following vaccination with Prevenar
467378|NCT00828971|Complicated skin and skin structure infections
467379|NCT00828971|cSSSI
467380|NCT00828958|schizophrenia
467381|NCT00828958|Risperidone
467382|NCT00828958|Long acting injectable
467383|NCT00828958|Intradeltoidal injection
467384|NCT00828919|VEGFR inhibitor
467385|NCT00828919|angi-angiogenic
467386|NCT00828919|tyrosine kinase inhibitor
467387|NCT00828906|Glaucoma
467388|NCT00828906|IOP
467389|NCT00828906|DuoTrav
467390|NCT00828893|drain under scanner
467391|NCT00828867|healthy subjects
467392|NCT00828867|FTIH, single dose, food effect, healthy subjects, double-blind
467393|NCT00828854|breast cancer
467394|NCT00828854|estrogen receptor postive
467395|NCT00828828|Influenza Vaccine
467396|NCT00828828|Sarcoidosis
467397|NCT00828828|Antibody
467398|NCT00828815|HIV-negative
467399|NCT00828815|buprenorphine/nalaxone
467400|NCT00828815|norbuprenorphine
467401|NCT00828815|opioid-dependent
467402|NCT00828815|TMC125-TiDP2-C188
467403|NCT00828815|TMC125-C188
467404|NCT00828815|TMC125
467405|NCT00828815|HIV Infections
467406|NCT00828802|Myelodysplastic Syndromes
467407|NCT00828802|MDS
467408|NCT00828789|Hepatitis C
467409|NCT00828789|HCV
467410|NCT00828789|HIV
467411|NCT00828789|AIDS
467412|NCT00828789|Telaprevir
467413|NCT00828789|Efavirenz
467414|NCT00828789|Tenofovir disproxil fumarate
467415|NCT00828789|Healthy volunteer
467416|NCT00828789|VX-950-C134
467417|NCT00828789|VX-950-TiDP24-C134
467418|NCT00828789|HIV Infections
467419|NCT00828776|TTPa
467420|NCT00828776|Anti-Xa
467421|NCT00828776|Adverse Reactions
467422|NCT00828763|healthy volunteer
467423|NCT00828763|radiolabelled
467424|NCT00828750|eltrombopag
467425|NCT00828750|thrombopoietin receptor agonist
467426|NCT00828750|ITP
467427|NCT00828750|blood platelet
467428|NCT00828711|Misoprostol vaginal insert
467429|NCT00828711|Induction of labor
467430|NCT00828711|Cervical ripening
467431|NCT00828711|Rate of cesarean section
467432|NCT00828698|Death, sudden
467433|NCT00828698|All cause mortality
467434|NCT00828685|Return to Work
467435|NCT00828685|CRPP
467436|NCT00828685|ORIF
467437|NCT00828685|Distal Radius
467438|NCT00828672|assess activity
467439|NCT00828672|bevacizumab
467440|NCT00828672|capecitabine
467441|NCT00828672|radiation therapy
467442|NCT00828672|oxaliplatin
467443|NCT00828672|pre-operative treatment
467444|NCT00828672|TME (total mesorectal excision).
467445|NCT00828659|Abuse potential
467446|NCT00828646|Healthy Subjects
467447|NCT00828633|stage I prostate cancer
467448|NCT00828633|stage II prostate cancer
467449|NCT00828607|Contrast Enhanced Ultrasound (CEUS)
467450|NCT00828607|Liver tumors
467451|NCT00828607|Hepatocellular carcinoma
467452|NCT00828607|Hemangioma
467453|NCT00828607|Focal Nodular Hyperplasia
467454|NCT00828607|Hepatic metastases
467455|NCT00828594|Hepatocellular carcinoma
467456|NCT00828594|dose-finding study
467457|NCT00828594|randomized trial
467458|NCT00828594|medical treatment
467459|NCT00828594|RAD001
467460|NCT00828594|sorafenib
467461|NCT00828594|Advanced hepatocellular cancer (HCC)
467462|NCT00828568|Actinic Keratosis
467463|NCT00828555|HPV vaccine
467464|NCT00828555|Tdap vaccine
467465|NCT00828542|Adverse Effects
467466|NCT00828542|Etonogestrel
467467|NCT00828542|Postpartum period
467468|NCT00828542|Contraception
467469|NCT00828542|Hemostasis
467470|NCT00828542|Metabolism
467471|NCT00828529|TMC207-TiDP13-C110
467472|NCT00828529|TMC207-C110
467473|NCT00828529|TMC207
467474|NCT00828529|Drug-drug interaction
467475|NCT00828529|Tuberculosis
467476|NCT00828529|HIV
467477|NCT00828529|Kaletra
467478|NCT00828529|Lopinavir
467479|NCT00828529|Ritonavir
467480|NCT00828529|Open-label
467481|NCT00828529|HIV Infections
467482|NCT00828516|lymphedema
467483|NCT00828516|male breast cancer
467484|NCT00828516|stage IA breast cancer
467485|NCT00828516|stage IB breast cancer
467486|NCT00828516|stage II breast cancer
467487|NCT00828516|recurrent breast cancer
467488|NCT00828516|recurrent squamous cell carcinoma of the hypopharynx
467489|NCT00828516|stage I squamous cell carcinoma of the hypopharynx
467490|NCT00828516|stage II squamous cell carcinoma of the hypopharynx
467491|NCT00828516|recurrent squamous cell carcinoma of the larynx
467492|NCT00828516|recurrent verrucous carcinoma of the larynx
467493|NCT00828516|stage I squamous cell carcinoma of the larynx
467494|NCT00828516|stage I verrucous carcinoma of the larynx
467495|NCT00828516|stage II squamous cell carcinoma of the larynx
467496|NCT00828516|stage II verrucous carcinoma of the larynx
467497|NCT00828516|recurrent adenoid cystic carcinoma of the oral cavity
467498|NCT00828516|recurrent mucoepidermoid carcinoma of the oral cavity
467499|NCT00828516|recurrent verrucous carcinoma of the oral cavity
467500|NCT00828516|stage I adenoid cystic carcinoma of the oral cavity
467501|NCT00828516|stage I mucoepidermoid carcinoma of the oral cavity
467502|NCT00828516|stage I verrucous carcinoma of the oral cavity
467503|NCT00828516|stage II adenoid cystic carcinoma of the oral cavity
467504|NCT00828516|stage II mucoepidermoid carcinoma of the oral cavity
467505|NCT00828516|stage II verrucous carcinoma of the oral cavity
467506|NCT00828516|stage I squamous cell carcinoma of the lip and oral cavity
467507|NCT00828516|stage II squamous cell carcinoma of the lip and oral cavity
467508|NCT00828516|recurrent basal cell carcinoma of the lip
467509|NCT00828516|recurrent squamous cell carcinoma of the lip and oral cavity
467510|NCT00828516|stage I basal cell carcinoma of the lip
467511|NCT00828516|stage II basal cell carcinoma of the lip
467512|NCT00828516|recurrent metastatic squamous neck cancer with occult primary
467513|NCT00828516|recurrent lymphoepithelioma of the nasopharynx
467514|NCT00828516|recurrent squamous cell carcinoma of the nasopharynx
467515|NCT00828516|stage I lymphoepithelioma of the nasopharynx
467516|NCT00828516|stage I squamous cell carcinoma of the nasopharynx
467517|NCT00828516|stage II lymphoepithelioma of the nasopharynx
467518|NCT00828516|stage II squamous cell carcinoma of the nasopharynx
467519|NCT00828516|recurrent lymphoepithelioma of the oropharynx
467520|NCT00828516|recurrent squamous cell carcinoma of the oropharynx
467521|NCT00828516|stage I lymphoepithelioma of the oropharynx
467522|NCT00828516|stage I squamous cell carcinoma of the oropharynx
467523|NCT00828516|stage II lymphoepithelioma of the oropharynx
467524|NCT00828516|stage II squamous cell carcinoma of the oropharynx
467525|NCT00828516|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
467526|NCT00828516|recurrent inverted papilloma of the paranasal sinus and nasal cavity
467527|NCT00828516|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
467528|NCT00828516|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
467529|NCT00828516|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
467530|NCT00828516|stage I inverted papilloma of the paranasal sinus and nasal cavity
467531|NCT00828516|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
467532|NCT00828516|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
467533|NCT00828516|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
467534|NCT00828516|stage II inverted papilloma of the paranasal sinus and nasal cavity
467535|NCT00828516|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
467536|NCT00828516|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
467537|NCT00828516|low-grade salivary gland mucoepidermoid carcinoma
467538|NCT00828516|recurrent salivary gland cancer
467539|NCT00828516|salivary gland acinic cell tumor
467540|NCT00828516|salivary gland adenocarcinoma
467541|NCT00828516|salivary gland adenoid cystic carcinoma
467542|NCT00828516|salivary gland anaplastic carcinoma
467543|NCT00828516|salivary gland malignant mixed cell type tumor
467544|NCT00828516|salivary gland poorly differentiated carcinoma
467545|NCT00828516|salivary gland squamous cell carcinoma
467546|NCT00828516|stage I salivary gland cancer
467547|NCT00828516|stage II salivary gland cancer
467548|NCT00828516|tongue cancer
467549|NCT00828503|Certi-CMV
467550|NCT00828503|immunosuppressive switch (to Certican)
467551|NCT00828503|renal transplant
467552|NCT00828490|Fraud and Abuse
467553|NCT00828490|opioids
467554|NCT00828464|Dermatosis, Dermatitis, Dry skin, Irritated skin
467555|NCT00828451|newborn
467556|NCT00828451|necrotizing enterocolitis
467557|NCT00828451|genetics
467558|NCT00828451|growth factors
467559|NCT00828451|metabolism
467560|NCT00828425|Diabetes Mellitus
467561|NCT00828425|retinopathy
467562|NCT00828425|Management of diabetic patients with retinopathy
467563|NCT00828399|Radiotherapy
467564|NCT00828399|Diarrhoea
467565|NCT00828399|Glutamine
467566|NCT00828399|Oxydative stress
467567|NCT00828399|Calprotectin
467568|NCT00828399|Citrulline
467569|NCT00828386|Nasopharyngeal cancers
467570|NCT00828386|induction chemotherapy
467571|NCT00828386|radiochemotherapy
467572|NCT00828360|Heart Failure
467573|NCT00828360|CRT
467574|NCT00828360|Dobutamine echocardiography
467575|NCT00828321|Bioequivalency
467576|NCT00828321|Healthy Volunteers
467577|NCT00828308|localized
467578|NCT00828308|high risk
467579|NCT00828308|prostate cancer
467580|NCT00828308|neoadjuvant treatment
467581|NCT00828295|Postoperative Nausea and Vomiting
467582|NCT00828295|palonosetron
467583|NCT00828295|pediatric
467584|NCT00828282|Chronic Lymphocytic Leukemia
467585|NCT00828282|Simvastatin
467586|NCT00828282|Zocor
467587|NCT00828269|Patients with Chronic Hepatitis C
467588|NCT00828256|arthroscopic repair
467589|NCT00828256|rotator cuff
467590|NCT00828256|tears
467591|NCT00828256|shoulder
467592|NCT00828256|chronic tear of rotator cuff
467593|NCT00828243|Pulmonary surfactants
467594|NCT00828243|Pulmonary surfactant associated protein B
467595|NCT00828243|Pulmonary surfactant associated protein C
467596|NCT00828243|ATP-binding cassette protein sub member family A3
467597|NCT00828230|budesonide
467598|NCT00828230|placebo
467599|NCT00828230|acute radiation proctitis
467600|NCT00828230|late radiation proctitis
467601|NCT00828230|Prevention of acute radiation proctitis
467602|NCT00828230|Prevention of late radiation proctitis
467603|NCT00828217|adapted physical activity
467604|NCT00828217|hospital
467605|NCT00828217|health-related quality of life
467606|NCT00828217|satisfaction with care
467607|NCT00828217|child
467608|NCT00828217|adolescent
467609|NCT00828217|randomized controlled trial
467610|NCT00828217|physical activity
467611|NCT00828217|quality of life
467612|NCT00828191|Luteal support in IVF
467613|NCT00828178|SLE
467614|NCT00828178|atherosclerosis
467615|NCT00828178|omega-3
467616|NCT00828126|Metastatic Melanoma
467617|NCT00828126|AJCC Stage III Melanoma
467618|NCT00828126|AJCC stage IV Melanoma
467619|NCT00828126|PET-CT
467620|NCT00828126|Positron Emission Tomography-Computed Tomography
467621|NCT00828126|Contrast-enhanced Computed Tomography Scan
467622|NCT00828126|CT
467623|NCT00828126|Conventional Imaging
467624|NCT00828126|False Positive Rate
467625|NCT00828126|Fluorodeoxyglucose
467626|NCT00828126|FDG
467627|NCT00828126|Surgery
467628|NCT00828113|smoking
467629|NCT00828113|relapse
467630|NCT00828113|withdrawal
467631|NCT00828087|acute myocardial infarction
467632|NCT00828087|primary percutaneous coronary intervention
467633|NCT00828087|drug-eluting stent
467634|NCT00828074|stage IV breast cancer
467635|NCT00828074|recurrent breast cancer
467636|NCT00828035|robotics
467637|NCT00828035|laparoscopy
467638|NCT00828035|surgery
467639|NCT00828035|computer assisted
467640|NCT00828022|measles-positive NSCLC
467641|NCT00828022|measles vaccine
467642|NCT00828022|consolidation
467643|NCT00828022|Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission
467644|NCT00828009|stage IIIA non-small cell lung cancer
467645|NCT00828009|stage IIIB non-small cell lung cancer
467646|NCT00828009|adenocarcinoma of the lung
467647|NCT00828009|bronchoalveolar cell lung cancer
467648|NCT00828009|large cell lung cancer
467649|NCT00827996|Apocrine glands
467650|NCT00827996|abcesses
467651|NCT00827983|Luteal Phase Support in IVF patients
467652|NCT00827970|mass screening
467653|NCT00827957|Hypothermia
467654|NCT00827957|Internal cooling
467655|NCT00827957|External cooling
467656|NCT00827957|Cardiac arrest
467657|NCT00827944|Uncomplicated primary inguinal hernias
467658|NCT00827931|tranexamic acid
467659|NCT00827931|major abdominal surgery
467660|NCT00827931|blood loss
467661|NCT00827918|Acute Exacerbation of Schizophrenia
467662|NCT00827905|Non-Contact
467663|NCT00827905|Radar
467664|NCT00827905|Respiratory
467665|NCT00827905|Respiration
467666|NCT00827905|Breathing
467667|NCT00827905|Rate
467668|NCT00827905|Frequency
467669|NCT00827905|Respiratory Mechanics
467670|NCT00827905|Respiratory Rate Measurement
467671|NCT00827892|Intracerebral Hemorrhage
467672|NCT00827892|Treatment
467673|NCT00827892|MRI
467674|NCT00827879|Intimate partner aggression
467675|NCT00827879|Couples intervention
467676|NCT00827879|PTSD
467677|NCT00827879|Veterans
467678|NCT00827879|Prevention
467679|NCT00827879|Violence Prevention
467680|NCT00827879|Prevention of pertetration of intimate partner aggression.
467681|NCT00827866|Tobacco quitline
467682|NCT00827866|Childhood cancer survivors
467683|NCT00827866|Adult-onset cancer survivors
467684|NCT00827853|Diabetes
467685|NCT00827853|Peripheral Vascular Disease (PVD)
467686|NCT00827853|Superficial Femoral Artery (SFA)
467687|NCT00827853|Cryoplasty
467688|NCT00827853|Restenosis
467689|NCT00827827|Stroke
467690|NCT00827827|Exercise
467691|NCT00827827|Strength Training
467692|NCT00827827|Skeletal Muscle
467693|NCT00827827|Insulin Sensitivity
467694|NCT00827801|Cancer
467695|NCT00827801|Heart Failure
467696|NCT00827801|HF
467697|NCT00827801|Cancer and Concurrent Heart Failure
467698|NCT00827801|MDASI-HF Symptom Management Program
467699|NCT00827801|MDASI-HF
467700|NCT00827801|MDASI-HF questionnaire
467701|NCT00827801|M. D. Anderson Symptom Inventory - Heart Failure
467702|NCT00827801|Questionnaire
467703|NCT00827801|Symptom Management Gap
467704|NCT00827788|contrast media
467705|NCT00827788|angiography
467706|NCT00827788|percutaneous coronary intervention
467707|NCT00827775|Hypertension
467708|NCT00827775|Hemodialysis
467709|NCT00827762|phenylketonuria
467710|NCT00827762|Kuvan
467711|NCT00827762|sapropterin
467712|NCT00827762|behavior
467713|NCT00827762|cognition
467714|NCT00827762|executive abilities
467715|NCT00827762|attention
467716|NCT00827749|swallowing disorders
467717|NCT00827749|geriatrics
467718|NCT00827736|anal fissure
467719|NCT00827736|fissura ani
467720|NCT00827736|botox
467721|NCT00827736|ISDN
467722|NCT00827736|Nitric oxide donor
467723|NCT00827723|Hepatic functional reserve
467724|NCT00827723|Hepatocellular carcinoma (HCC)
467725|NCT00827723|Indocyanine Green retention rate at 15 minutes (ICG-R15')
467726|NCT00827723|Portal Pressure (PP)
467727|NCT00827723|Hepatic Portal Venous Gradient (HPVG)
467728|NCT00827723|Alcoholic and Viral Cirrhosis
467729|NCT00827723|Makuuchi criteria
467730|NCT00827723|Barcelona Clinic of Liver Cancer (BCLC)
467731|NCT00827723|Hepatic resection
467732|NCT00827710|diabetes
467733|NCT00827710|registry
467734|NCT00827710|computer
467735|NCT00827710|self management
467736|NCT00827697|Gonorrhea
467737|NCT00827697|Chlamydia
467738|NCT00827697|Rectal
467739|NCT00827684|KRAS mutation
467740|NCT00827658|anesthesia, local
467741|NCT00827658|ulnar nerve
467742|NCT00827658|hand
467743|NCT00827658|surgery, plastic
467744|NCT00827658|blinded
467745|NCT00827658|randomized
467746|NCT00827658|prospective
467747|NCT00827658|local anesthesia
467748|NCT00827658|volar wrist block
467749|NCT00827658|hypothenar palm block
467750|NCT00827658|hand surgery
467751|NCT00827632|Ovarian Suppression
467752|NCT00827632|Oral Contraceptives
467753|NCT00827632|Obese and Normal BMI
467754|NCT00827619|Peripheral Arterial Disease
467755|NCT00827606|pediatric heterozygous familial hypercholesterolemia
467756|NCT00827580|HFS
467757|NCT00827580|patients with breast or colon cancer receiving capecitabine
467758|NCT00827567|Breast cancer
467759|NCT00827567|metastatic breast
467760|NCT00827567|triple negative
467761|NCT00827567|ER/PR negative
467762|NCT00827567|Her2 Neu negative
467763|NCT00827554|Liver Neoplasms
467764|NCT00827554|Liver Diseases
467765|NCT00827554|Digestive System Diseases
467766|NCT00827554|Digestive System Neoplasms
467767|NCT00827554|Carcinoma, Hepatocellular
467768|NCT00827554|Gastrointestinal Neoplasms
467769|NCT00827554|Adenocarcinoma
467770|NCT00827554|Hepatocellular carcinoma
467771|NCT00827554|Neoplasms
467772|NCT00827554|Transarterial chemoembolization
467773|NCT00827554|Nadroparin
467774|NCT00827554|low-molecular-weight heparin
467775|NCT00827554|chemoembolization
467776|NCT00827541|tigecycline
467777|NCT00827541|complicated intra-abdominal infections (cIAI)
467778|NCT00827541|complicated skin and soft tissue infections (cSSTI).
467779|NCT00827528|Pelvic Organ Prolapse
467780|NCT00827528|Surgical Treatment
467781|NCT00827515|Relative Bioavailability Effect of food
467782|NCT00827502|TRULIMAX (AZITHROMYCIN ) NON-INTERVENTIONAL STUDY
467783|NCT00827489|schizophrenia
467784|NCT00827476|ovary
467785|NCT00827476|human
467786|NCT00827476|transplantaion
467787|NCT00827476|ovarian failure
467788|NCT00827463|aneamia
467789|NCT00827463|aneamia during the maternity
467790|NCT00827450|hepatic steatosis
467791|NCT00827450|coffee
467792|NCT00827450|fructose
467793|NCT00827450|lipids
467794|NCT00827424|physical activity (PA)
467795|NCT00827424|obesity
467796|NCT00827424|life style modification
467797|NCT00827424|physical activity
467798|NCT00827424|diet
467799|NCT00827424|BMI reduction
467800|NCT00827424|clinical and metabolic measure
467801|NCT00827424|health expenditure
467802|NCT00827424|improvement of patient readiness for lifestyle change
467803|NCT00827411|Drug Eluting Stent
467804|NCT00827411|Percutaneous coronary intervention
467805|NCT00827411|Oral antiplatelet therapy
467806|NCT00827411|Clopidogrel/Aspirin
467807|NCT00827411|Acute Coronary Syndrome
467808|NCT00827398|MSC
467809|NCT00827398|GVHD
467810|NCT00827398|Adults
467811|NCT00827398|Children
467812|NCT00827398|steroid refractory acute GVHD occurring after allogeneic stem cell transplantation
467813|NCT00827359|everolimus
467814|NCT00827333|recurrent non-small cell lung cancer
467815|NCT00827333|stage I non-small cell lung cancer
467816|NCT00827333|stage II non-small cell lung cancer
467817|NCT00827333|stage IIIA non-small cell lung cancer
467818|NCT00827333|stage IIIB non-small cell lung cancer
467819|NCT00827333|stage IV non-small cell lung cancer
467820|NCT00827307|breast carcinoma; goserelin; Mammographic density
467821|NCT00827294|Phantom limb pain
467822|NCT00827294|Mirror therapy
467823|NCT00827294|amputation
467824|NCT00827294|Limb loss
467825|NCT00827294|treatment
467826|NCT00827281|DCS
467827|NCT00827281|CBT
467828|NCT00827281|smoking
467829|NCT00827281|tobacco
467830|NCT00827268|Dyslexia
467831|NCT00827268|Reading
467832|NCT00827268|Aphasia
467833|NCT00827268|Stroke
467834|NCT00827242|Signs and Symptoms
467835|NCT00827242|Prostatic Hyperplasia
467836|NCT00827242|Hyperplasia
467837|NCT00827242|Genital Diseases, Male
467838|NCT00827242|Prostatic Diseases
467839|NCT00827242|BPH-LUTS
467840|NCT00827229|Active labor
467841|NCT00827229|Term pregnancy
467842|NCT00827229|Vertex presentation
467843|NCT00827229|Single fetus
467844|NCT00827216|Gastric emptying
467845|NCT00827216|emergency anesthesia
467846|NCT00827216|intravenous erythromycin
467847|NCT00827203|cancer
467848|NCT00827203|metastatic
467849|NCT00827203|Elesclomol Sodium
467850|NCT00827203|tumor
467851|NCT00827203|Advanced solid tumors that are metastatic and unresectable
467852|NCT00827190|Acute Ischemic Stroke
467853|NCT00827177|dose escalation
467854|NCT00827177|safety
467855|NCT00827177|tolerability
467856|NCT00827177|tumor
467857|NCT00827177|PK
467858|NCT00827177|hepatocellular carcinoma
467859|NCT00827177|renal cell carcinoma
467860|NCT00827177|melanoma
467861|NCT00827177|non-small cell lung cancer
467862|NCT00827177|breast cancer
467863|NCT00827164|head and neck cancer
467864|NCT00827164|resistance training
467865|NCT00827164|nutrition counseling
467866|NCT00827164|radiation therapy
467867|NCT00827164|pharyngeal or laryngeal cancer
467868|NCT00827151|amenorrhea
467869|NCT00827151|athletes
467870|NCT00827151|bone loss
467871|NCT00827151|eumenorrhea
467872|NCT00827125|active stage
467873|NCT00827125|labor
467874|NCT00827125|progression
467875|NCT00827125|pregnant woman during active phases of labor
467876|NCT00827112|CCR5-tropic HIV-1 virus
467877|NCT00827099|accelerated phase cml
467878|NCT00827099|adult ALL in remission
467879|NCT00827099|adult AML in remission
467880|NCT00827099|adult AML with 11q23 (MLL) abnormalities
467881|NCT00827099|adult AML with inv(16)(p13;q22)
467882|NCT00827099|adult acute myeloid leukemia with t(15;17)(q22;q12)
467883|NCT00827099|adult acute myeloid leukemia with t(16;16)(p13;q22)
467884|NCT00827099|adult acute myeloid leukemia with t(8;21)(q22;q22)
467885|NCT00827099|blastic phase chronic myelogenous leukemia
467886|NCT00827099|chronic myelomonocytic leukemia
467887|NCT00827099|chronic phase chronic myelogenous leukemia
467888|NCT00827099|prolymphocytic leukemia
467889|NCT00827099|recurrent adult T-cell leukemia/lymphoma
467890|NCT00827099|relapsing chronic myelogenous leukemia
467891|NCT00827099|secondary acute myeloid leukemia
467892|NCT00827099|refractory chronic lymphocytic leukemia
467893|NCT00827099|stage I chronic lymphocytic leukemia
467894|NCT00827099|stage II chronic lymphocytic leukemia
467895|NCT00827099|stage III chronic lymphocytic leukemia
467896|NCT00827099|stage IV chronic lymphocytic leukemia
467897|NCT00827099|recurrent adult Hodgkin lymphoma
467898|NCT00827099|anaplastic large cell lymphoma
467899|NCT00827099|angioimmunoblastic T-cell lymphoma
467900|NCT00827099|cutaneous B-cell non-Hodgkin lymphoma
467901|NCT00827099|recurrent cutaneous T-cell non-Hodgkin lymphoma
467902|NCT00827099|recurrent mycosis fungoides/Sezary syndrome
467903|NCT00827099|adult grade III lymphomatoid granulomatosis
467904|NCT00827099|adult nasal type extranodal NK/T-cell lymphoma
467905|NCT00827099|Waldenstrom macroglobulinemia
467906|NCT00827099|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
467907|NCT00827099|nodal marginal zone B-cell lymphoma
467908|NCT00827099|splenic marginal zone lymphoma
467909|NCT00827099|recurrent adult diffuse large cell lymphoma
467910|NCT00827099|recurrent adult diffuse mixed cell lymphoma
467911|NCT00827099|recurrent adult diffuse small cleaved cell lymphoma
467912|NCT00827099|recurrent adult grade III lymphomatoid granulomatosis
467913|NCT00827099|recurrent grade 1 follicular lymphoma
467914|NCT00827099|recurrent grade 2 follicular lymphoma
467915|NCT00827099|recurrent grade 3 follicular lymphoma
467916|NCT00827099|recurrent mantle cell lymphoma
467917|NCT00827099|recurrent marginal zone lymphoma
467918|NCT00827099|recurrent small lymphocytic lymphoma
467919|NCT00827099|chronic idiopathic myelofibrosis
467920|NCT00827099|stage I multiple myeloma
467921|NCT00827099|stage II multiple myeloma
467922|NCT00827099|stage III multiple myeloma
467923|NCT00827099|refractory multiple myeloma
467924|NCT00827099|de novo myelodysplastic syndromes
467925|NCT00827099|previously treated myelodysplastic syndromes
467926|NCT00827099|secondary myelodysplastic syndromes
467927|NCT00827086|influencing factors (smoking, nutrition, education)
467928|NCT00827060|primary care
467929|NCT00827060|procalcitonin
467930|NCT00827060|acute respiratory tract infection
467931|NCT00827047|hepatocellular carcinoma
467932|NCT00827047|Surgical resection
467933|NCT00827047|total hemihepatic vascular exclusion
467934|NCT00827047|occlusion
467935|NCT00827047|bleeding
467936|NCT00827047|overall survival
467937|NCT00827034|Dimebon Warfarin Drug-Drug Interaction
467938|NCT00826995|patient Education
467939|NCT00826995|dermatology Patient Education
467940|NCT00826995|melanoma
467941|NCT00826995|melanoma education
467942|NCT00826995|malignant melanoma
467943|NCT00826995|melanoma detection
467944|NCT00826969|Asthma
467945|NCT00826969|Ciclesonide
467946|NCT00826943|Allergic Rhinitis
467947|NCT00826930|High Grade Glioma
467948|NCT00826930|Brain Tumor
467949|NCT00826930|Solid Tumor
467950|NCT00826930|Partial Debulking
467951|NCT00826930|Tumor Resection
467952|NCT00826930|Tumor Tissue Hypoxia
467953|NCT00826930|Radiation Sensitizer
467954|NCT00826930|Cancerous Tumor
467955|NCT00826917|3D, 2D, ultrasound, volumetry, multiplanar, VOCALTM, XI VOCALTM, fetal, gestational sac, placenta
467956|NCT00826904|Fetal programming
467957|NCT00826904|Fetal macrosomia
467958|NCT00826904|Fetal health
467959|NCT00826904|Gestational diabetes
467960|NCT00826904|Maternal health
467961|NCT00826904|Maternal obesity
467962|NCT00826878|tivozanib
467963|NCT00826878|AV-951
467964|NCT00826839|In vitro fertilization
467965|NCT00826839|Poor responder patients
467966|NCT00826839|Randomized clinical trial
467967|NCT00826839|Estrogen patch
467968|NCT00826839|Gonadotropin-releasing hormone antagonist
467969|NCT00826839|Oral contraceptive pill
467970|NCT00826839|Microdose lupron
467971|NCT00826826|Atrial fibrillation
467972|NCT00826826|Amiodarone
467973|NCT00826826|Arrhythmias, Cardiac
467974|NCT00826826|Catheter ablation
467975|NCT00826813|Dysphagia
467976|NCT00826813|esophageal cancer
467977|NCT00826813|stent
467978|NCT00826813|brachytherapy
467979|NCT00826800|BEVACIZUMAB (AVASTIN)
467980|NCT00826800|FLUOROURACIL
467981|NCT00826800|LEUCOVORIN
467982|NCT00826800|OXALIPLATIN
467983|NCT00826800|Chemotherapy
467984|NCT00826774|Body Weight
467985|NCT00826774|Overweight
467986|NCT00826774|Hypertension
467987|NCT00826774|Hyperglycemia
467988|NCT00826748|COPD
467989|NCT00826748|inhaled steroids
467990|NCT00826748|gene expression
467991|NCT00826748|smoker's lungs
467992|NCT00826735|third stage of labor
467993|NCT00826735|bleeding
467994|NCT00826735|guided imagery
467995|NCT00826735|childbirth
467996|NCT00826696|preeclampsia
467997|NCT00826683|Non-small cell lung cancer
467998|NCT00826683|Endothelial cell progenitor
467999|NCT00826683|Angiogenesis
468000|NCT00826683|Vascular endothelial cell growth factor
468001|NCT00826683|Healthy control
468002|NCT00826683|COPD patients
468003|NCT00826683|NSCLC patients
468004|NCT00826670|Antibiotic resistance
468005|NCT00826670|ESBL carriage
468006|NCT00826657|B12 deficiency
468007|NCT00826657|methylmalonic acid
468008|NCT00826657|homocystein
468009|NCT00826657|vitamin B12 supplementation intervention
468010|NCT00826644|Small cell lung cancer
468011|NCT00826644|Camptothecin
468012|NCT00826644|Response rate
468013|NCT00826631|weight
468014|NCT00826631|metabolism
468015|NCT00826631|cholesterol
468016|NCT00826631|insulin
468017|NCT00826618|Uveitis
468018|NCT00826618|Cystoid Macular Edema
468019|NCT00826605|Weight loss, urobilinogen
468020|NCT00826592|patient education
468021|NCT00826592|dermatology patient education
468022|NCT00826592|atopic dermatitis
468023|NCT00826592|atopic dermatitis education
468024|NCT00826592|atopic eczema
468025|NCT00826592|infantile eczema
468026|NCT00826592|hand eczema
468027|NCT00826579|Sentinel lymph node
468028|NCT00826579|Lymph node analysis
468029|NCT00826579|Bone marrow analysis
468030|NCT00826566|COPD
468031|NCT00826566|caffeine
468032|NCT00826566|chronic systemic inflammation
468033|NCT00826566|oxidative stress
468034|NCT00826566|supplementation
468035|NCT00826566|stable COPD GOLD stage II with CRP levels ≥ 3 mg/l
468036|NCT00826553|sedative
468037|NCT00826553|GABA
468038|NCT00826553|alpha 2 agonist
468039|NCT00826553|propofol
468040|NCT00826553|midazolam
468041|NCT00826553|lorazepam
468042|NCT00826553|dexmedetomidine
468043|NCT00826553|sleep
468044|NCT00826553|electroencephalogram
468045|NCT00826553|polysomnogram
468046|NCT00826553|ICU
468047|NCT00826514|Chronic Prostatis
468048|NCT00826488|Breast Cancer
468049|NCT00826488|Mammography
468050|NCT00826488|Benign masses
468051|NCT00826488|Breast Lump
468052|NCT00826488|Breast Biopsy
468053|NCT00826488|Breast Mass
468054|NCT00826475|Migraine
468055|NCT00826475|Headache
468056|NCT00826462|Randomised
468057|NCT00826462|Placebo-controlled
468058|NCT00826462|double blind
468059|NCT00826462|Intervention study
468060|NCT00826462|Primary health care
468061|NCT00826449|Advanced Solid Tumors
468062|NCT00826449|Advanced Cancer
468063|NCT00826449|Non-Small Cell Lung Cancer
468064|NCT00826449|NSCLC
468065|NCT00826449|Solid Tumor Malignancy
468066|NCT00826449|Dasatinib
468067|NCT00826449|BMS-354825
468068|NCT00826449|Sprycel®
468069|NCT00826449|Erlotinib
468070|NCT00826449|Erlotinib hydrochloride
468071|NCT00826449|Tarceva
468072|NCT00826449|OSI-774
468073|NCT00826423|treatment with Triple antibiotic therapy
468074|NCT00826410|Laparotomy
468075|NCT00826410|Surgical site infection
468076|NCT00826410|Drainage
468077|NCT00826397|aromatase inhibitors
468078|NCT00826397|joint pain
468079|NCT00826397|symptoms control
468080|NCT00826384|hepatocellular carcinoma
468081|NCT00826384|transcatheter arterial chemoembolization
468082|NCT00826384|overall survival
468083|NCT00826371|AMD
468084|NCT00826371|Ranibizumab
468085|NCT00826358|Adverse events
468086|NCT00826358|Pharmacokinetic
468087|NCT00826345|Peripheral Neuropathy
468088|NCT00826345|Neuropathy
468089|NCT00826345|HIV
468090|NCT00826345|AIDS
468091|NCT00826345|DSP
468092|NCT00826345|alternative therapies
468093|NCT00826332|ultrasound
468094|NCT00826332|IVF
468095|NCT00826332|Embryo transfer
468096|NCT00826332|Pregnancy rate
468097|NCT00826332|female patient undergoing IVF
468098|NCT00826319|Chronic Kidney Disease
468099|NCT00826319|Renal Insufficiency
468100|NCT00826319|Biomarkers
468101|NCT00826319|Observational
468102|NCT00826306|patient education
468103|NCT00826306|dermatology patient education
468104|NCT00826306|sunscreen
468105|NCT00826306|sunscreen education
468106|NCT00826306|skin cancer
468107|NCT00826280|coronary artery disease (CAD)
468108|NCT00826280|ischemia
468109|NCT00826280|pharmacologic stress
468110|NCT00826254|vitamin K
468111|NCT00826254|Bone Mineral Density
468112|NCT00826254|undercarboxylated osteocalcin
468113|NCT00826241|Brain Tumor
468114|NCT00826241|Central Nervous System
468115|NCT00826241|CNS
468116|NCT00826241|Spinal Cord Tumor
468117|NCT00826241|Anaplastic Ependymoma
468118|NCT00826241|Supratentorial Ependymoma
468119|NCT00826241|Infratentorial Ependymoma
468120|NCT00826241|Spinal Cord Ependymoma
468121|NCT00826241|Lapatinib
468122|NCT00826241|GW572016
468123|NCT00826241|Temozolomide
468124|NCT00826241|Temodar
468125|NCT00826215|mechanical
468126|NCT00826215|neck pain
468127|NCT00826215|chronic
468128|NCT00826215|acupuncture
468129|NCT00826215|chronic mechanical neck pain
468130|NCT00826202|schizophrenia
468131|NCT00826202|d-serine
468132|NCT00826202|prodrome
468133|NCT00826189|Probiotics
468134|NCT00826189|Asthma
468135|NCT00826189|Allergic Rhinitis
468136|NCT00826150|ovarian cancer
468137|NCT00826150|H19 gene
468138|NCT00826150|plasmid
468139|NCT00826137|prebiotics
468140|NCT00826137|Antibiotic-associated diarrhea
468141|NCT00826124|low back pain
468142|NCT00826124|radiculopathy
468143|NCT00826124|sciatica
468144|NCT00826111|Magnetic Resonance Spectroscopy
468145|NCT00826111|Glutamate
468146|NCT00826111|Glutamine
468147|NCT00826111|GABA
468148|NCT00826111|Lexapro
468149|NCT00826111|Lunesta
468150|NCT00826111|Escitalopram
468151|NCT00826111|Eszopiclone
468152|NCT00826098|Total knee replacement
468153|NCT00826098|Platelet Rich Plasma
468154|NCT00826098|PRP
468155|NCT00826098|Biologic
468156|NCT00826098|Randomized
468157|NCT00826085|Breast Cancer
468158|NCT00826085|Recurrent Chest Wall Cancer
468159|NCT00826085|Loco-regional Recurrent Breast Cancer
468160|NCT00826085|Breast Cancer Recurrence at the Chest Wall
468161|NCT00826072|Single Nucleotide Polymorphism
468162|NCT00826072|cardiopulmonary bypass
468163|NCT00826072|cardiac surgery
468164|NCT00826059|acute ischemic stroke
468165|NCT00826059|randomized clinical trial
468166|NCT00826059|effectiveness
468167|NCT00826059|safety
468168|NCT00826046|GVHD
468169|NCT00826046|Prochymal
468170|NCT00826046|Graft vs Host Disease
468171|NCT00826033|Fluorine-18-α-methyltyrosine
468172|NCT00826033|Positron emission tomography
468173|NCT00826033|Lung cancer
468174|NCT00826033|chemotherapy
468175|NCT00826033|monitoring
468176|NCT00826020|PN
468177|NCT00826020|parenteral nutrition
468178|NCT00826020|fat emulsions
468179|NCT00826020|omega-6 fatty acid
468180|NCT00826020|liver disease
468181|NCT00826020|fatty acid deficiency
468182|NCT00826007|perioperative hypoglycemia diabetes surgery
468183|NCT00826007|surgery
468184|NCT00825994|menopause
468185|NCT00825994|perimenopause
468186|NCT00825994|postmenopause
468187|NCT00825994|depression
468188|NCT00825994|mood
468189|NCT00825994|sleep
468190|NCT00825994|hot flashes
468191|NCT00825968|Electrophysiological
468192|NCT00825968|Heart Disease
468193|NCT00825968|Cardiology
468194|NCT00825968|Atrial Fibrillation
468195|NCT00825968|Risk Factors
468196|NCT00825968|Follow-up
468197|NCT00825968|Outcomes
468198|NCT00825942|Asteroid hyalosis
468199|NCT00825942|Opthalmic Study
468200|NCT00825929|pharmacokinetics
468201|NCT00825929|pregnancy
468202|NCT00825929|antiretrovirals
468203|NCT00825929|neonates
468204|NCT00825929|HIV
468205|NCT00825929|treatment experienced
468206|NCT00825916|AZX100
468207|NCT00825916|Patient and Observer Scar Assessment Scale
468208|NCT00825916|POSAS
468209|NCT00825916|Visual Analog Scale
468210|NCT00825916|VAS
468211|NCT00825916|Keloid
468212|NCT00825916|Scarring
468213|NCT00825916|Scar reduction
468214|NCT00825916|Scar prevention
468215|NCT00825903|aquatic exercise
468216|NCT00825903|asthma
468217|NCT00825890|high cup disc ratio
468218|NCT00825890|glaucoma suspect
468219|NCT00825877|Hepatitis C
468220|NCT00825877|Sustained Virological Response
468221|NCT00825877|HALT-C
468222|NCT00825877|Peginterferon and Ribavirin
468223|NCT00825877|HCV RNA
468224|NCT00825838|Body weight
468225|NCT00825838|Body composition
468226|NCT00825838|Resting metabolic rate and fat oxidation in men
468227|NCT00825838|class I obese
468228|NCT00825825|Citalopram
468229|NCT00825825|Escitalopram
468230|NCT00825825|Celexa
468231|NCT00825825|Lexapro
468232|NCT00825825|fMRI
468233|NCT00825825|antidepressant
468234|NCT00825825|healthy volunteers
468235|NCT00825799|biomarker
468236|NCT00825799|depression
468237|NCT00825799|blood test
468238|NCT00825786|surgery for arm hand or elbow
468239|NCT00825786|mepivacaine
468240|NCT00825786|ropivacaine
468241|NCT00825786|hand surgery
468242|NCT00825786|elbow surgery
468243|NCT00825786|forearm surgery
468244|NCT00825773|TVF
468245|NCT00825773|TLF
468246|NCT00825773|MACE
468247|NCT00825773|Ischemia-driven Target Vessel Failure (TVF) at 12 months.
468248|NCT00825773|Ischemia-driven Target Lesion Failure (TLF) at 12 months defined as a
468249|NCT00825773|composite of cardiac death that can not be clearly attributed to a vessel
468250|NCT00825773|other than the target vessel, target vessel MI (Q and Non-Q wave) and
468251|NCT00825773|ischemia-driven TLR.
468252|NCT00825773|Rates of stent thrombosis, defined (per ARC definition) as definite or probable
468253|NCT00825773|and categorized as early, late or very late.
468254|NCT00825773|Major Adverse Cardiac Events (MACE) defined as cardiac death, target
468255|NCT00825773|vessel MI (Q and Non-Q wave), or target lesion revascularization (TLR) at 30
468256|NCT00825773|days, 6 months, 12 months and 2 to 5 years annually.
468257|NCT00825760|Antimicrobial Photodynamic Therapy
468258|NCT00825760|Photodynamic Therapy
468259|NCT00825760|PDT
468260|NCT00825760|Red light
468261|NCT00825760|Visible light
468262|NCT00825760|Antimicrobial
468263|NCT00825760|Antibacterial
468264|NCT00825760|Wound healing
468265|NCT00825760|Wound management
468266|NCT00825760|Leg ulcer
468267|NCT00825760|Chronic venous leg ulcer
468268|NCT00825760|Chronic wound
468269|NCT00825760|Wound therapy
468270|NCT00825760|Antimicrobial therapy
468271|NCT00825747|Cataract
468272|NCT00825747|Cataract surgery
468273|NCT00825747|intraocular lens
468274|NCT00825747|Aspheric lens
468275|NCT00825734|Metastatic Breast Cancer
468276|NCT00825734|Sorafenib
468277|NCT00825734|Nexavar
468278|NCT00825734|Ixabepilone
468279|NCT00825734|Ixempra
468280|NCT00825721|Cataract Study
468281|NCT00825721|Ophthalmic Study
468282|NCT00825721|Agerelated cataract
468283|NCT00825721|Nuclear Cataract
468284|NCT00825721|Low grade nuclear cataracts
468285|NCT00825708|ADHD
468286|NCT00825682|Breast cancer
468287|NCT00825682|Radiation therapy
468288|NCT00825682|Reflexology
468289|NCT00825682|Fatigue
468290|NCT00825682|Quality of life
468291|NCT00825682|Sleep disturbance
468292|NCT00825669|hepatocellular carcinoma
468293|NCT00825669|Portal vein tumor thrombus
468294|NCT00825669|laser ablation
468295|NCT00825656|Allergic Rhinitis
468296|NCT00825656|Capsaicin
468297|NCT00825656|Homeopathic
468298|NCT00825656|Sinol
468299|NCT00825656|Sinol-M
468300|NCT00825630|HP
468301|NCT00825630|UBT
468302|NCT00825630|PPI
468303|NCT00825617|TS
468304|NCT00825617|HRT
468305|NCT00825617|Liver function tests
468306|NCT00825604|stable coronary artery disease
468307|NCT00825604|quality of life
468308|NCT00825604|target achievement
468309|NCT00825604|physical training
468310|NCT00825604|percutaneous coronary intervention
468311|NCT00825591|optic nerve hypoplasia
468312|NCT00825591|septo-optic dysplasia
468313|NCT00825591|melatonin
468314|NCT00825591|circadian rhythm
468315|NCT00825578|intrabronchial valve
468316|NCT00825578|heterogeneous emphysema
468317|NCT00825578|non-upper lobe
468318|NCT00825565|Epidermolysis bullosa
468319|NCT00825552|Risperidone
468320|NCT00825552|Severe mood dysregulation
468321|NCT00825552|bipolar
468322|NCT00825552|children
468323|NCT00825539|Schizophrenia
468324|NCT00825539|Manic depression
468325|NCT00825539|anxiety
468326|NCT00825526|Mindfulness Based Stress Reduction (MBSR)
468327|NCT00825526|Stress Reduction
468328|NCT00825526|hypertension
468329|NCT00825526|high blood pressure
468330|NCT00825526|ambulatory blood pressure monitoring
468331|NCT00825500|Migraine headache
468332|NCT00825500|Loxapine
468333|NCT00825500|Staccato
468334|NCT00825487|metastatic
468335|NCT00825487|hematologic
468336|NCT00825487|malignancy
468337|NCT00825487|multiple
468338|NCT00825487|myeloma
468339|NCT00825487|malignant
468340|NCT00825487|lymphoma
468341|NCT00825487|chronic
468342|NCT00825487|lymphocytic
468343|NCT00825487|leukemia
468344|NCT00825487|acute
468345|NCT00825487|myelogenous
468346|NCT00825487|promyelocytic
468347|NCT00825487|dose escalation
468348|NCT00825487|safety
468349|NCT00825487|tolerability
468350|NCT00825487|pharmacodynamics
468351|NCT00825487|tumor
468352|NCT00825487|PK
468353|NCT00825474|small hepatocellular carcinoma
468354|NCT00825474|partial hepatectomy
468355|NCT00825474|TACE plus PEI
468356|NCT00825461|Anorexia Nervosa
468357|NCT00825448|alcohol addiction
468358|NCT00825435|Coronary CT angiogram
468359|NCT00825435|Cardiac imaging
468360|NCT00825435|Cost analysis
468361|NCT00825435|acute chest pain
468362|NCT00825435|risk stratification
468363|NCT00825435|cumulative costs over 90-days of providing treatment services
468364|NCT00825422|Posterior lumbar arthrodesis
468365|NCT00825422|Degenerative spine
468366|NCT00825422|Postoperative analgesia
468367|NCT00825422|Local anesthesic
468368|NCT00825422|Continuous wound infusion catheter
468369|NCT00825422|Pain
468370|NCT00825422|lumbar vertebrae
468371|NCT00825422|Spinal fusion
468372|NCT00825383|Diabetes
468373|NCT00825383|lipids
468374|NCT00825383|fiber
468375|NCT00825370|Hydromorphone
468376|NCT00825370|acute pain
468377|NCT00825370|Protocolized
468378|NCT00825370|Efficacy
468379|NCT00825370|Safety
468380|NCT00825357|biological markers
468381|NCT00825357|sepsis
468382|NCT00825357|acute lung injury
468383|NCT00825344|postoperative pain
468384|NCT00825344|inguinal hernia
468385|NCT00825344|chronic postsurgical pain
468386|NCT00825344|cytokine
468387|NCT00825344|preemptive analgesia
468388|NCT00825344|patients with inguinal hernia scheduled for surgery
468389|NCT00825331|guide wire
468390|NCT00825331|cardiac catheterization
468391|NCT00825331|ultrasound-guided examination of the access site
468392|NCT00825331|graduated scheme
468393|NCT00825331|elective and non elective cardiac catheterization
468394|NCT00825318|End-stage renal disease
468395|NCT00825318|Chronic kidney disease
468396|NCT00825318|Hemodialysis
468397|NCT00825305|vaccine
468398|NCT00825305|prevention
468399|NCT00825305|rabies
468400|NCT00825305|Rabies disease
468401|NCT00825292|colon polyps, colon adenomas
468402|NCT00825279|Biodegradable polymer
468403|NCT00825279|Drug Eluting Stent
468404|NCT00825279|In stent restenosis
468405|NCT00825279|stent thrombosis
468406|NCT00825279|Bare Metal Stent
468407|NCT00825266|pulmonary hypertension & insulin resistance
468408|NCT00825240|Colorectal Cancer
468409|NCT00825240|Cancer Survivorship Study
468410|NCT00825240|Questionnaires
468411|NCT00825240|Survivorship
468412|NCT00825240|Survivor Health
468413|NCT00825240|Health Promotion
468414|NCT00825240|Behavior Changes
468415|NCT00825240|Computer-assisted intervention program
468416|NCT00825227|Cancer
468417|NCT00825227|Fatigue
468418|NCT00825227|Taxanes
468419|NCT00825201|peritoneal carcinomatosis
468420|NCT00825201|peritoneal cavity cancer
468421|NCT00825201|stage IV ovarian epithelial cancer
468422|NCT00825201|recurrent ovarian epithelial cancer
468423|NCT00825201|unspecified adult solid tumor, protocol specific
468424|NCT00825175|Down syndrome
468425|NCT00825175|Gait
468426|NCT00825175|Motor Development
468427|NCT00825175|Orthoses
468428|NCT00825136|Panic Disorder
468429|NCT00825136|Temperature Biofeedback
468430|NCT00825136|Internet
468431|NCT00825123|healthy individuals
468432|NCT00825110|colorectal
468433|NCT00825110|cancer
468434|NCT00825110|gene expression
468435|NCT00825110|biomarker
468436|NCT00825110|genomic mismatch repair
468437|NCT00825097|Spastic equinovarus foot
468438|NCT00825097|Stroke
468439|NCT00825097|Tibial neurotomy
468440|NCT00825097|Botulinum toxin type A
468441|NCT00825097|Selective tibial neurotomy
468442|NCT00825084|Dimebon, Japanese and Western population, pharmacokinetics
468443|NCT00825071|Postoperative Nausea and Vomiting
468444|NCT00825071|Ondansetron
468445|NCT00825071|Dexamethasone
468446|NCT00825058|Depression
468447|NCT00825045|dopamine
468448|NCT00825045|D2
468449|NCT00825045|D3
468450|NCT00825045|caudate
468451|NCT00825045|putamen
468452|NCT00825045|globus pallidus
468453|NCT00825045|antipsychotic
468454|NCT00825045|risperidone
468455|NCT00825045|geriatric
468456|NCT00825045|Brief Psychiatric Rating Scale
468457|NCT00825045|PET
468458|NCT00825045|radiotracer
468459|NCT00825045|[11C]-(+)-PHNO
468460|NCT00825045|[11C]-raclopride
468461|NCT00825032|Pulmonary disease, chronic obstructive
468462|NCT00825032|Upper extremity
468463|NCT00825032|Exercise therapy
468464|NCT00825019|Depression
468465|NCT00825006|Cardiac resynchronization therapy
468466|NCT00825006|Anodal stimulation
468467|NCT00824993|Blood Cancer
468468|NCT00824993|Calcium
468469|NCT00824993|Vitamin D
468470|NCT00824993|Ibandronate
468471|NCT00824993|Boniva
468472|NCT00824993|Hematological Malignancies
468473|NCT00824993|Bone Marrow Transplantation
468474|NCT00824993|BMT
468475|NCT00824993|Osteoporosis
468476|NCT00824993|Bone Loss
468477|NCT00824993|Allogeneic Bone Marrow Transplantation
468478|NCT00824954|0 to 30 years
468479|NCT00824954|Refractory Acute GVHD
468480|NCT00824941|Abdominal Pain
468481|NCT00824941|Women's Health and Disease
468482|NCT00824941|Gut
468483|NCT00824941|Symptoms
468484|NCT00824941|Brain
468485|NCT00824941|Chronic Abdominal Pain
468486|NCT00824928|Prostate Cancer
468487|NCT00824928|Recurrent Prostate Cancer
468488|NCT00824928|Prostate Cancer Recurrence
468489|NCT00824928|Radiation Failure
468490|NCT00824928|Salvage Cryotherapy
468491|NCT00824915|Lead Integrity Algorithm
468492|NCT00824902|Prostate Cancer
468493|NCT00824902|Prostate
468494|NCT00824902|Radical Prostatectomy
468495|NCT00824902|Tissue Elastography
468496|NCT00824902|Tissue Elastography Imaging
468497|NCT00824902|Software Program Measuring Prostate Elasticity
468498|NCT00824902|Elasticity/Tissue Strain-Hardening Imaging
468499|NCT00824902|Ultrasound
468500|NCT00824876|Mammae cancer patients
468501|NCT00824863|pityrosporum folliculitis
468502|NCT00824863|ketoconazole 2% foam
468503|NCT00824850|Single site
468504|NCT00824850|single dose
468505|NCT00824850|Participated in Wyeth D118-P8
468506|NCT00824837|beta 2 microglobulin
468507|NCT00824837|haemodialysis
468508|NCT00824837|albumin
468509|NCT00824824|Retinal Vascular Autoregulation
468510|NCT00824811|Epiphora
468511|NCT00824811|Breast Cancer
468512|NCT00824811|Lung Cancer
468513|NCT00824811|Prostate Cancer
468514|NCT00824811|Non-small cell lung cancer
468515|NCT00824811|Bladder Cancer
468516|NCT00824811|Esophageal Cancer
468517|NCT00824811|Head and Neck Cancer
468518|NCT00824811|HNC
468519|NCT00824811|Small Cell Lung Cancer
468520|NCT00824811|SCLC
468521|NCT00824811|Ovarian Cancer
468522|NCT00824811|Stomach Cancer
468523|NCT00824811|Canalicular Stenosis
468524|NCT00824811|Excessive tearing
468525|NCT00824811|Eye inflammation
468526|NCT00824811|Cyclosporine Ophthalmic Emulsion 0.05%
468527|NCT00824811|Docetaxel
468528|NCT00824811|Taxotere
468529|NCT00824811|Restasis®
468530|NCT00824811|Cyclosporine
468531|NCT00824811|Cyclosporine eye drops
468532|NCT00824811|FML Forte®
468533|NCT00824811|Fluorometholone 0.25% ophthalmic suspension
468534|NCT00824811|Fluorometholone eye drops
468535|NCT00824811|Fluorometholone
468536|NCT00824811|Refresh Endura™
468537|NCT00824811|Lubricant eye drops
468538|NCT00824811|Eye drops
468539|NCT00824798|gait
468540|NCT00824798|haemophilia
468541|NCT00824798|arthropathy
468542|NCT00824785|epirubicin
468543|NCT00824785|oxaliplatin
468544|NCT00824785|capecitabine
468545|NCT00824785|panitumumab
468546|NCT00824772|pharmacogenetics
468547|NCT00824759|Healthy subjects
468548|NCT00824759|CABG
468549|NCT00824759|Patients undergoing coronary artery bypass graft under cardiopulmonary bypass
468550|NCT00824746|Gefitinib
468551|NCT00824746|Recurrence
468552|NCT00824746|Carcinoma, Non-Small-Cell Lung
468553|NCT00824733|recurrent breast cancer
468554|NCT00824733|stage IV breast cancer
468555|NCT00824733|stage IIIA breast cancer
468556|NCT00824733|stage IIIB breast cancer
468557|NCT00824733|stage IIIC breast cancer
468558|NCT00824733|HER2-positive breast cancer
468559|NCT00824733|male breast cancer
468560|NCT00824707|primary liver cancer
468561|NCT00824707|hepatitis B virus
468562|NCT00824707|anti-virus therapy
468563|NCT00824694|Glucose
468564|NCT00824694|Diabetes Mellitus, Type 2
468565|NCT00824694|HbA1c
468566|NCT00824681|Psychological adjustment of family
468567|NCT00824681|family of patients
468568|NCT00824681|children of patients
468569|NCT00824681|intensive care unit
468570|NCT00824681|burn
468571|NCT00824681|music therapy
468572|NCT00824681|music
468573|NCT00824681|music program
468574|NCT00824681|anxiety
468575|NCT00824681|coping
468576|NCT00824681|adjustment
468577|NCT00824681|psychological stressor
468578|NCT00824681|emotional stressor
468579|NCT00824655|Healthy Subjects
468580|NCT00824655|Vaccines
468581|NCT00824655|Pneumococcal
468582|NCT00824642|Asthma
468583|NCT00824642|Exercise training
468584|NCT00824642|TENS
468585|NCT00824642|Acupuncture
468586|NCT00824642|FEV1
468587|NCT00824629|Embryo transfer
468588|NCT00824629|IVF
468589|NCT00824629|Ultrasound embryo transfer
468590|NCT00824590|Dimebon
468591|NCT00824590|renal impairment
468592|NCT00824590|pharmacokinetics
468593|NCT00824577|heart rate variability
468594|NCT00824577|autonomic function
468595|NCT00824577|heart function
468596|NCT00824564|Tranexamic Acid
468597|NCT00824564|Blood Loss
468598|NCT00824564|Long Bone Fracture Surgery
468599|NCT00824551|Acute Thermal Burns
468600|NCT00824551|Hyperbaric Oxygen Therapy
468601|NCT00824551|Burns conversion
468602|NCT00824538|stage IA breast cancer
468603|NCT00824538|stage IB breast cancer
468604|NCT00824538|stage II breast cancer
468605|NCT00824538|stage IIIA breast cancer
468606|NCT00824538|stage IIIB breast cancer
468607|NCT00824538|stage IIIC breast cancer
468608|NCT00824486|child
468609|NCT00824486|injury prevention
468610|NCT00824460|Hemodialysis
468611|NCT00824447|randomised
468612|NCT00824447|double-blind
468613|NCT00824447|placebo-controlled
468614|NCT00824447|long-term efficacy and safety
468615|NCT00824447|Oralgen® Grass Pollen
468616|NCT00824447|allergic rhinoconjunctivitis
468617|NCT00824447|Allergy
468618|NCT00824447|Rhinoconjunctivitis
468619|NCT00824447|Immunotherapy
468620|NCT00824447|Grass pollen extract
468621|NCT00824434|Atherosclerosis
468622|NCT00824434|Coronary Artery Disease
468623|NCT00824421|HIV-1. Treatment Naive
468624|NCT00824421|HIV Infections
468625|NCT00824421|treatment naive
468626|NCT00824395|diabetes
468627|NCT00824395|type 1
468628|NCT00824395|type 2
468629|NCT00824395|metabolic syndrome
468630|NCT00824395|mitochondria
468631|NCT00824369|HIV-1
468632|NCT00824369|Rollover
468633|NCT00824369|Safety.
468634|NCT00824369|HIV Infections
468635|NCT00824369|treatment experienced
468636|NCT00824356|Allergic Rhinitis
468637|NCT00824356|Proof-of-Concept
468638|NCT00824330|Aging
468639|NCT00824330|Type 2 diabetes
468640|NCT00824330|exercise
468641|NCT00824330|walking
468642|NCT00824330|glucose metabolism
468643|NCT00824330|arterial baroreceptors
468644|NCT00824330|heart rate variability
468645|NCT00824330|cerebral autoregulation
468646|NCT00824330|tilt table study
468647|NCT00824330|transcranial Doppler
468648|NCT00824330|autonomic nervous system
468649|NCT00824304|cognitive performance
468650|NCT00824304|growth
468651|NCT00824304|iron
468652|NCT00824304|zinc
468653|NCT00824291|Major Depressive Disorder
468654|NCT00824278|Pediatrics
468655|NCT00824278|Distresss Screening
468656|NCT00824278|Cancer
468657|NCT00824278|Neurofibromatosis
468658|NCT00824278|HIV
468659|NCT00824278|Pediatric Cancer
468660|NCT00824278|Distress Screening
468661|NCT00824265|Relapsed
468662|NCT00824265|Oncology
468663|NCT00824265|Safety
468664|NCT00824265|Chronic Lymphocytic Leukemia
468665|NCT00824265|Ofatumumab
468666|NCT00824265|Efficacy
468667|NCT00824252|Head And Neck Cancer
468668|NCT00824252|HNC
468669|NCT00824252|Radiation Therapy
468670|NCT00824252|Spousal Support
468671|NCT00824252|Emotional Disclosure
468672|NCT00824252|Observational
468673|NCT00824252|Social Constraints
468674|NCT00824252|Questionnaires
468675|NCT00824252|Videotaped Interview
468676|NCT00824252|Quality of Life
468677|NCT00824239|critical care
468678|NCT00824239|sedation
468679|NCT00824239|Mechanically ventilated patients
468680|NCT00824226|primary hypoparathyroidism
468681|NCT00824226|secondary hypoparathyroidism
468682|NCT00824226|magnesium
468683|NCT00824213|Whole Body SPECT imaging
468684|NCT00824200|Sleep
468685|NCT00824200|Quality of life
468686|NCT00824200|nocturia
468687|NCT00824187|Premenstrual Dysphoric Disorder ( PMDD)
468688|NCT00824187|Oral contraceptive
468689|NCT00824174|Questionnaire
468690|NCT00824174|Head and Neck Cancer
468691|NCT00824174|Skin Cancer
468692|NCT00824174|Body Image
468693|NCT00824174|Surgical Treatment
468694|NCT00824174|Oral Cavity Cancer
468695|NCT00824174|Cutaneous Cancer
468696|NCT00824148|Real-time glucose monitoring system
468697|NCT00824148|HbA1c
468698|NCT00824148|Quality of life
468699|NCT00824148|Hypoglycemia
468700|NCT00824135|Stem Cell Transplantation, Hematopoietic
468701|NCT00824135|Peripheral Blood Stem Cell Transplantation
468702|NCT00824135|Maximal Tolerated Dose
468703|NCT00824135|Clofarabine
468704|NCT00824135|Hematological Malignancies
468705|NCT00824135|Apheresis
468706|NCT00824109|Aneurysmal disease of the abdominal aorta
468707|NCT00824109|Occlusive disease of the abdominal aorta
468708|NCT00824096|endotracheal intubation
468709|NCT00824096|cuff-leak test
468710|NCT00824096|post-extubation stridor
468711|NCT00824096|bronchoscopy
468712|NCT00824096|corticosteroids
468713|NCT00824096|Cuff-leak volume less than 24%
468714|NCT00824083|bone tumors
468715|NCT00824083|long-term function
468716|NCT00824083|daily activity
468717|NCT00824083|late sequelae
468718|NCT00824070|Bioavailability
468719|NCT00824057|Phase I
468720|NCT00824044|Major Depressive Disorder (MDD)
468721|NCT00824044|Cognitive Behavioral Therapy (CBT)
468722|NCT00824044|Escitalopram
468723|NCT00824044|Quantitative EEG (QEEG)
468724|NCT00824031|schizophrenia
468725|NCT00824031|medical mental care
468726|NCT00824031|caregiver
468727|NCT00824031|Sapin
468728|NCT00823264|Anticonvulsants
468729|NCT00823264|Toxicology
468730|NCT00823264|multidose charcoal
468731|NCT00823264|phenytoin
468732|NCT00822198|peripheral neuropathy
468733|NCT00822198|diabetes
468734|NCT00822198|plantar vibration
468735|NCT00822172|Peripheral Vascular Disease
468736|NCT00822172|Peripheral Arterial Disease
468737|NCT00822172|Intermittent Claudication
468738|NCT00822172|Peak Walking Time
468739|NCT00822172|Claudication Onset Time
468740|NCT00822172|Cilostazol
468741|NCT00822172|Carnitine
468742|NCT00822159|Fixation failure
468743|NCT00822159|Bone strength
468744|NCT00822159|DensiProbe
468745|NCT00822146|CRT
468746|NCT00822133|ketamine
468747|NCT00822133|preemption
468748|NCT00822133|postoperative
468749|NCT00822133|pain
468750|NCT00822133|safety
468751|NCT00822120|stage III adult Hodgkin lymphoma
468752|NCT00822120|stage IV adult Hodgkin lymphoma
468753|NCT00822120|adult lymphocyte depletion Hodgkin lymphoma
468754|NCT00822120|adult lymphocyte predominant Hodgkin lymphoma
468755|NCT00822120|adult mixed cellularity Hodgkin lymphoma
468756|NCT00822120|adult nodular sclerosis Hodgkin lymphoma
468757|NCT00822120|HIV infection
468758|NCT00822107|Hypokalemia
468759|NCT00822107|Bartter Syndrome
468760|NCT00822107|Salt Wasting
468761|NCT00822094|Acute
468762|NCT00822094|Myeloid
468763|NCT00822094|Leukemia
468764|NCT00822094|Adult
468765|NCT00822094|First
468766|NCT00822094|Relapse
468767|NCT00822094|AML
468768|NCT00822094|Acute Myelogenous leukemia
468769|NCT00822094|Leukemia, Myeloid
468770|NCT00822094|Leukemia, Myeloid, Acute
468771|NCT00822094|Acute myelocytic leukemia
468772|NCT00822068|stroke
468773|NCT00822068|aphasia
468774|NCT00822068|rehabilitation
468775|NCT00822068|transcranial direct current stimulation
468776|NCT00822068|intensive training
468777|NCT00822068|chronic aphasia after stroke
468778|NCT00822042|Lipodystrophy
468779|NCT00822042|Adipokines
468780|NCT00822042|Glucocorticoids
468781|NCT00822042|Patients with glucocorticoids
468782|NCT00822016|Best Supportive Care
468783|NCT00822016|Protocol of Standard Practice
468784|NCT00822016|Carcinoma of the Lung
468785|NCT00822003|GLP-1
468786|NCT00822003|insulin
468787|NCT00822003|glucose
468788|NCT00824005|Congestive Heart Failure
468789|NCT00824005|Regional Wall Motion
468790|NCT00824005|Perfusion Defects
468791|NCT00823979|HIV-1 NNRTI Treatment Experienced
468792|NCT00823979|may have Protease inhibitor experience
468793|NCT00823953|diabetes type 2
468794|NCT00823940|FTIH
468795|NCT00823940|Glucagon
468796|NCT00823940|Safety
468797|NCT00823940|GSK1362885
468798|NCT00823940|Pharmacokinetics
468799|NCT00823940|Tolerability
468800|NCT00823940|Pharmacodynamics
468801|NCT00823927|lung damage
468802|NCT00823927|cigarette smoking
468803|NCT00823927|HIV-seropositive
468804|NCT00823927|emphysema
468805|NCT00823914|Psoriasis
468806|NCT00823914|Quality of Life
468807|NCT00823901|rosacea
468808|NCT00823901|clindamycin
468809|NCT00823901|tretinoin
468810|NCT00823901|clinical study
468811|NCT00823901|treatment
468812|NCT00823888|Knee Osteoarthritis
468813|NCT00823888|pneumatic bracing
468814|NCT00823862|HCV
468815|NCT00823862|Immunostimulatory sequence (ISS)
468816|NCT00823862|TLR9 (toll-like receptor 9)
468817|NCT00823862|interferon (IFN)
468818|NCT00823862|ribavirin
468819|NCT00823849|type 2 diabetes mellitus, with Arteriosclerosis obliterans
468820|NCT00823836|Ropinirole, advanced Parkinson's disease, L-dopa adjunctive therapy
468821|NCT00823823|Casting techniques
468822|NCT00823823|Bivalved cast
468823|NCT00823823|Circumferential cast
468824|NCT00823823|Displaced distal radius fracture
468825|NCT00823823|Children
468826|NCT00823810|Colorectal cancer
468827|NCT00823810|Response to treatment
468828|NCT00823810|FDG PET/CT
468829|NCT00823784|hemorrhoids
468830|NCT00823784|stapler
468831|NCT00823784|Doppler
468832|NCT00823784|artery ligation
468833|NCT00823784|outcome
468834|NCT00823784|recurrence
468835|NCT00823758|Acetaminophen
468836|NCT00823758|Liver
468837|NCT00823758|Centers for Education and Research on Therapeutics
468838|NCT00823758|CERTS
468839|NCT00823758|Over-the-counter Acetaminophen
468840|NCT00823758|OTC
468841|NCT00823758|Self-administration
468842|NCT00823758|Parental administration
468843|NCT00823758|Houston
468844|NCT00823758|Texas
468845|NCT00823758|Liver toxicity
468846|NCT00823758|Qualitative study
468847|NCT00823758|Pharmacists
468848|NCT00823758|Adolescents
468849|NCT00823758|Primary care physicians
468850|NCT00823758|Family Practitioners
468851|NCT00823758|General Internist
468852|NCT00823732|stage IIIB non-small cell lung cancer
468853|NCT00823732|stage IV non-small cell lung cancer
468854|NCT00823732|recurrent non-small cell lung cancer
468855|NCT00823719|Salvage chemotherapy
468856|NCT00823719|relapsed
468857|NCT00823719|grade 3B follicular lymphoma
468858|NCT00823719|efficacy
468859|NCT00823719|safety
468860|NCT00823719|DHAP
468861|NCT00823719|ofatumumab
468862|NCT00823719|refractory
468863|NCT00823719|Non-Hodgkin's Lymphoma
468864|NCT00823719|Diffuse Large B Cell Lymphoma (DLBCL)
468865|NCT00823719|Oncology
468866|NCT00823719|ICE
468867|NCT00823719|Transformed follicular lymphoma
468868|NCT00823706|chronic angle closure hyperopia
468869|NCT00823667|stage I non-small cell lung cancer
468870|NCT00823667|stage II non-small cell lung cancer
468871|NCT00823667|stage IIIA non-small cell lung cancer
468872|NCT00823654|Breast
468873|NCT00823654|Questionaires
468874|NCT00823654|Blood draw
468875|NCT00823654|BRCA1
468876|NCT00823654|BRCA2
468877|NCT00823654|08-156
468878|NCT00823641|HAM/TSP
468879|NCT00823641|HTLV-I
468880|NCT00823602|GnRH antagonist
468881|NCT00823602|GnRH agonist
468882|NCT00823602|pregnancy rate
468883|NCT00823602|Ovarian stimulation
468884|NCT00823589|ELDERLY POPULATION
468885|NCT00823576|Arthodeses rachis lombar
468886|NCT00823576|Spinal Surgery
468887|NCT00823550|Chronic hepatitis B
468888|NCT00823550|Advanced fibrosis
468889|NCT00823550|Lamivudine
468890|NCT00823550|Entecavir
468891|NCT00823524|accelerated phase chronic myelogenous leukemia
468892|NCT00823524|acute undifferentiated leukemia
468893|NCT00823524|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
468894|NCT00823524|adult acute myeloid leukemia with inv(16)(p13;q22)
468895|NCT00823524|adult acute myeloid leukemia with t(15;17)(q22;q12)
468896|NCT00823524|adult acute myeloid leukemia with t(16;16)(p13;q22)
468897|NCT00823524|adult acute myeloid leukemia with t(8;21)(q22;q22)
468898|NCT00823524|atypical chronic myeloid leukemia, BCR-ABL1 negative
468899|NCT00823524|blastic phase chronic myelogenous leukemia
468900|NCT00823524|chronic myelomonocytic leukemia
468901|NCT00823524|chronic phase chronic myelogenous leukemia
468902|NCT00823524|mast cell leukemia
468903|NCT00823524|meningeal chronic myelogenous leukemia
468904|NCT00823524|progressive hairy cell leukemia, initial treatment
468905|NCT00823524|prolymphocytic leukemia
468906|NCT00823524|recurrent adult acute lymphoblastic leukemia
468907|NCT00823524|recurrent adult acute myeloid leukemia
468908|NCT00823524|recurrent adult T-cell leukemia/lymphoma
468909|NCT00823524|refractory chronic lymphocytic leukemia
468910|NCT00823524|refractory hairy cell leukemia
468911|NCT00823524|relapsing chronic myelogenous leukemia
468912|NCT00823524|secondary acute myeloid leukemia
468913|NCT00823524|stage III adult T-cell leukemia/lymphoma
468914|NCT00823524|stage III chronic lymphocytic leukemia
468915|NCT00823524|stage IV adult T-cell leukemia/lymphoma
468916|NCT00823524|stage IV chronic lymphocytic leukemia
468917|NCT00823524|T-cell large granular lymphocyte leukemia
468918|NCT00823524|adult grade III lymphomatoid granulomatosis
468919|NCT00823524|adult nasal type extranodal NK/T-cell lymphoma
468920|NCT00823524|anaplastic large cell lymphoma
468921|NCT00823524|angioimmunoblastic T-cell lymphoma
468922|NCT00823524|splenic marginal zone lymphoma
468923|NCT00823524|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
468924|NCT00823524|nodal marginal zone B-cell lymphoma
468925|NCT00823524|stage III adult Burkitt lymphoma
468926|NCT00823524|stage III adult diffuse large cell lymphoma
468927|NCT00823524|stage III adult diffuse mixed cell lymphoma
468928|NCT00823524|stage III adult diffuse small cleaved cell lymphoma
468929|NCT00823524|stage III adult Hodgkin lymphoma
468930|NCT00823524|stage III adult immunoblastic large cell lymphoma
468931|NCT00823524|stage III adult lymphoblastic lymphoma
468932|NCT00823524|stage III cutaneous T-cell non-Hodgkin lymphoma
468933|NCT00823524|stage III mycosis fungoides/Sezary syndrome
468934|NCT00823524|stage III grade 1 follicular lymphoma
468935|NCT00823524|stage III grade 2 follicular lymphoma
468936|NCT00823524|stage III grade 3 follicular lymphoma
468937|NCT00823524|stage III mantle cell lymphoma
468938|NCT00823524|stage III marginal zone lymphoma
468939|NCT00823524|stage III small lymphocytic lymphoma
468940|NCT00823524|stage IV adult Burkitt lymphoma
468941|NCT00823524|stage IV adult diffuse large cell lymphoma
468942|NCT00823524|stage IV adult diffuse mixed cell lymphoma
468943|NCT00823524|stage IV adult diffuse small cleaved cell lymphoma
468944|NCT00823524|stage IV adult Hodgkin lymphoma
468945|NCT00823524|stage IV adult immunoblastic large cell lymphoma
468946|NCT00823524|stage IV adult lymphoblastic lymphoma
468947|NCT00823524|stage IV cutaneous T-cell non-Hodgkin lymphoma
468948|NCT00823524|stage IV mycosis fungoides/Sezary syndrome
468949|NCT00823524|stage IV grade 1 follicular lymphoma
468950|NCT00823524|stage IV grade 2 follicular lymphoma
468951|NCT00823524|stage IV grade 3 follicular lymphoma
468952|NCT00823524|stage IV mantle cell lymphoma
468953|NCT00823524|stage IV marginal zone lymphoma
468954|NCT00823524|stage IV small lymphocytic lymphoma
468955|NCT00823524|recurrent adult Hodgkin lymphoma
468956|NCT00823524|recurrent adult Burkitt lymphoma
468957|NCT00823524|recurrent adult diffuse large cell lymphoma
468958|NCT00823524|recurrent adult diffuse mixed cell lymphoma
468959|NCT00823524|recurrent adult diffuse small cleaved cell lymphoma
468960|NCT00823524|recurrent adult grade III lymphomatoid granulomatosis
468961|NCT00823524|recurrent adult immunoblastic large cell lymphoma
468962|NCT00823524|recurrent adult lymphoblastic lymphoma
468963|NCT00823524|recurrent cutaneous T-cell non-Hodgkin lymphoma
468964|NCT00823524|recurrent mycosis fungoides/Sezary syndrome
468965|NCT00823524|recurrent grade 1 follicular lymphoma
468966|NCT00823524|recurrent grade 2 follicular lymphoma
468967|NCT00823524|recurrent grade 3 follicular lymphoma
468968|NCT00823524|recurrent mantle cell lymphoma
468969|NCT00823524|recurrent marginal zone lymphoma
468970|NCT00823524|recurrent small lymphocytic lymphoma
468971|NCT00823524|intraocular lymphoma
468972|NCT00823524|primary central nervous system non-Hodgkin lymphoma
468973|NCT00823524|primary central nervous system Hodgkin lymphoma
468974|NCT00823524|post-transplant lymphoproliferative disorder
468975|NCT00823524|chronic eosinophilic leukemia
468976|NCT00823524|chronic neutrophilic leukemia
468977|NCT00823524|primary myelofibrosis
468978|NCT00823524|essential thrombocythemia
468979|NCT00823524|polycythemia vera
468980|NCT00823524|extramedullary plasmacytoma
468981|NCT00823524|isolated plasmacytoma of bone
468982|NCT00823524|stage II multiple myeloma
468983|NCT00823524|stage III multiple myeloma
468984|NCT00823524|primary systemic amyloidosis
468985|NCT00823524|refractory multiple myeloma
468986|NCT00823524|de novo myelodysplastic syndromes
468987|NCT00823524|previously treated myelodysplastic syndromes
468988|NCT00823524|secondary myelodysplastic syndromes
468989|NCT00823524|myelodysplastic/myeloproliferative neoplasm, unclassifiable
468990|NCT00823524|cutaneous B-cell non-Hodgkin lymphoma
468991|NCT00823524|Waldenström macroglobulinemia
468992|NCT00823524|unspecified adult solid tumor, protocol specific
468993|NCT00823511|HPV
468994|NCT00823511|Human Papillomavirus Infection
468995|NCT00823511|Cervix Uteri
468996|NCT00823511|Cancer Control
468997|NCT00823511|Risk Assessment, Detection & Intervention
468998|NCT00823511|Sexually Transmitted
468999|NCT00823511|Neoplasia
469000|NCT00823511|Carcinogenesis
469001|NCT00823511|Cervix
469002|NCT00823498|Cancer Prevention
469003|NCT00823498|African American
469004|NCT00823498|African American Parents
469005|NCT00823498|African American Youth
469006|NCT00823498|Public Housing
469007|NCT00823498|Physical Activity
469008|NCT00823498|Focus Groups
469009|NCT00823498|Housing Developments
469010|NCT00823498|Houston Public Housing
469011|NCT00823498|Photovoice Project
469012|NCT00823498|Prevention
469013|NCT00823472|embryonic structures
469014|NCT00823472|sperm injections, intracytoplasmic
469015|NCT00823472|IVF
469016|NCT00823472|GnRH antagonist
469017|NCT00823472|ovarian stimulation
469018|NCT00823472|cycle day 2 versus cycle day 5
469019|NCT00823459|Low-grade glioma
469020|NCT00823459|astrocytoma
469021|NCT00823459|oligodendroglioma
469022|NCT00823459|mixed oligoastrocytoma
469023|NCT00823433|Penicillin
469024|NCT00823433|Group B Streptococcus
469025|NCT00823433|Pregnancy
469026|NCT00823433|Labor
469027|NCT00823420|PCOS and normal ovulatory patients
469028|NCT00823420|aneuploidy
469029|NCT00823420|in-vitro maturation of oocytes
469030|NCT00823407|MDA
469031|NCT00823407|MDMA
469032|NCT00823407|Ecstasy
469033|NCT00823407|entactogen
469034|NCT00823407|pharmacokinetics
469035|NCT00823407|pharmacodynamics
469036|NCT00823407|Pharmacokinetics and pharmacodynamics of MDA studies in healthy volunteers
469037|NCT00823394|African American
469038|NCT00823394|Adults
469039|NCT00823394|African American Cancer Prevention Project
469040|NCT00823394|Health Disparities
469041|NCT00823394|Questionnaire
469042|NCT00823394|Body Measurements
469043|NCT00823394|Self-help
469044|NCT00823394|Cancer Rates
469045|NCT00823394|Prevention
469046|NCT00823381|obesity
469047|NCT00823381|metabolic syndrome
469048|NCT00823381|diabetes
469049|NCT00823381|aging
469050|NCT00823381|calorie restriction
469051|NCT00823381|resveratrol
469052|NCT00823381|antioxidant
469053|NCT00823368|fragile X syndrome
469054|NCT00823368|biomarkers
469055|NCT00823342|HBe, Hepatitis, Vireda (TENOFOVIR, CLEVUDINE), HBV, HBe Ag negative
469056|NCT00823329|measurement of energy expenditure of physical activity
469057|NCT00823329|analysis of body composition and hydration status
469058|NCT00823316|Mesenchymal Stem Cells
469059|NCT00823316|Allogeneic Transplantation
469060|NCT00823316|Engraftment
469061|NCT00823316|GvHD
469062|NCT00823316|Childhood
469063|NCT00823316|unrelated HSCT
469064|NCT00823303|PTH
469065|NCT00823303|Active Vitamin D
469066|NCT00823303|hypercalcemia
469067|NCT00823303|Chronic Kidney Disease
469068|NCT00823290|HCC
469069|NCT00823290|sorafenib
469070|NCT00823290|HDAC
469071|NCT00823290|LBH589
469072|NCT00823290|Panobinostat
469073|NCT00823225|Diabetes
469074|NCT00823225|urokinase
469075|NCT00823225|ulcer healing
469076|NCT00823225|major amputation
469077|NCT00823225|survival
469078|NCT00823212|drug-eluting stents
469079|NCT00823212|DES
469080|NCT00823212|atherosclerotic
469081|NCT00823186|cervical carcinoma
469082|NCT00823186|neoadjuvant chemotherapy
469083|NCT00823173|Uveitis
469084|NCT00823173|TNF-alpha
469085|NCT00823173|Topical
469086|NCT00823173|ESBA105
469087|NCT00823173|scFv antibody fragment
469088|NCT00823173|ocular inflammation
469089|NCT00823160|Pericardial window
469090|NCT00823160|Sternotomy
469091|NCT00823160|Haemopericardium
469092|NCT00823147|Pain
469093|NCT00823147|Systemic Inflammation
469094|NCT00823147|Pain Catastrophizing
469095|NCT00823121|Fresh embryo transfer
469096|NCT00823121|frozen- thawed embryo transfer
469097|NCT00823121|vitrification
469098|NCT00823121|endometrial receptivity
469099|NCT00823121|implantation rate
469100|NCT00823121|pregnancy
469101|NCT00823121|ART
469102|NCT00823108|GIK, septic shock, sepsis
469103|NCT00823095|chronic cutaneous ulcers
469104|NCT00823095|Nitric Oxide
469105|NCT00823095|topically applied
469106|NCT00823095|Biofilm
469107|NCT00823095|Colonized chronic non-healing ulcers
469108|NCT00823082|antithrombin
469109|NCT00823082|ATIII
469110|NCT00823082|acquired deficiency
469111|NCT00823082|anticoagulants
469112|NCT00823082|cardiopulmonary bypass
469113|NCT00823082|surgery
469114|NCT00823082|complications
469115|NCT00823082|postoperative outcomes
469116|NCT00823069|Correction of Nasolabial Folds
469117|NCT00823056|Probiotics
469118|NCT00823056|Infections
469119|NCT00823056|Children
469120|NCT00823030|Interstitial Cystitis
469121|NCT00823030|Intravesical Lidocaine
469122|NCT00823017|ICU environment
469123|NCT00823017|Auditory stimulation
469124|NCT00823017|Properties of relaxation music
469125|NCT00823017|music
469126|NCT00823017|music therapy
469127|NCT00823017|pain
469128|NCT00823017|anxiety
469129|NCT00823017|cortisol
469130|NCT00823017|IgA
469131|NCT00823017|biomarkers
469132|NCT00823017|relaxation music
469133|NCT00823004|controlled ovarian hyperstimulation
469134|NCT00823004|pregnancy rate
469135|NCT00823004|Poor responders
469136|NCT00823004|GnRH antagonist
469137|NCT00823004|GnRH agonist
469138|NCT00823004|letrozole
469139|NCT00823004|in vitro fertilization
469140|NCT00822991|Sonazoid
469141|NCT00822991|Early detection
469142|NCT00822991|Hepatocellular carcinoma
469143|NCT00822991|Liver cirrhosis
469144|NCT00822978|healthy
469145|NCT00822978|volunteers
469146|NCT00822978|subjects
469147|NCT00822965|Pacemakers
469148|NCT00822965|PM
469149|NCT00822965|Implantable cardioverter-defibrillators
469150|NCT00822965|ICD
469151|NCT00822965|Implantable pulse generators
469152|NCT00822965|Educational Interventions
469153|NCT00822913|Botulinum A toxin
469154|NCT00822913|Parkinson's disease
469155|NCT00822900|Trauma
469156|NCT00822900|Brain Injury
469157|NCT00822887|malignant
469158|NCT00822887|gliomas
469159|NCT00822874|PCOS and normal ovulatory patients
469160|NCT00822874|aneuploidy
469161|NCT00822874|in-vitro maturation of oocytes
469162|NCT00822848|stage II adult soft tissue sarcoma
469163|NCT00822848|stage III adult soft tissue sarcoma
469164|NCT00822822|Questionnaire
469165|NCT00822822|Electronic Health History
469166|NCT00822809|Cancer
469167|NCT00822809|Neoplasms
469168|NCT00822809|Carcinoma
469169|NCT00822809|Malignant Ascites
469170|NCT00822809|Drug therapy
469171|NCT00822809|Antineoplastic Protocols
469172|NCT00822809|Immunotherapy
469173|NCT00822809|Phase III
469174|NCT00822809|trifunctional antibody
469175|NCT00822809|monoclonal antibody
469176|NCT00822809|EpCAM
469177|NCT00822796|Hypothermia
469178|NCT00822796|Severe burns
469179|NCT00822796|Warming catheter
469180|NCT00822796|Thermogard™
469181|NCT00822796|Coagulopathy
469182|NCT00822783|Serum IgE levels
469183|NCT00822783|inflammatory cells in the skin
469184|NCT00822783|inflammatory cells in the blood
469185|NCT00822783|IgE
469186|NCT00822783|IgE depletion
469187|NCT00822783|atopic dermatitis
469188|NCT00822783|atopic eczema
469189|NCT00822783|Omalizumab
469190|NCT00822770|Blood Stem Cell Transplantation
469191|NCT00822770|Bone Marrow Transplantation
469192|NCT00822770|Bone Marrow Cell Transplantation
469193|NCT00822770|Stem Cell Transplantation
469194|NCT00822770|Allogeneic Hematopoietic Transplantation
469195|NCT00822770|Advanced Myeloid Leukemia
469196|NCT00822770|Acute Myeloid Leukemia
469197|NCT00822770|AML
469198|NCT00822770|Myelodysplastic syndrome
469199|NCT00822770|MDS
469200|NCT00822770|Chronic Myeloid Leukemia
469201|NCT00822770|CML
469202|NCT00822770|Graft Versus Host Disease
469203|NCT00822770|GVHD
469204|NCT00822770|ATG
469205|NCT00822770|Busulfan
469206|NCT00822770|Busulfex™
469207|NCT00822770|Myleran®
469208|NCT00822770|Filgrastim
469209|NCT00822770|Neupogen
469210|NCT00822770|Fludarabine
469211|NCT00822770|Fludarabine Phosphate
469212|NCT00822770|Fludara™
469213|NCT00822770|G-CSF
469214|NCT00822770|Plerixafor
469215|NCT00822770|Antithymocyte globulin
469216|NCT00822770|Thymoglobulin
469217|NCT00822757|study in healthy subjects
469218|NCT00822744|Depression
469219|NCT00822744|Major Depressive Episode
469220|NCT00822744|Antidepressant
469221|NCT00822731|Lymphoma
469222|NCT00822731|prognosis
469223|NCT00822731|morbidity
469224|NCT00822718|obestatin
469225|NCT00822718|ghrelin
469226|NCT00822718|stomach cancer
469227|NCT00822718|distal gastrectomy
469228|NCT00822705|Appetite, energy consumption, gastrointestinal hormones
469229|NCT00822692|Abscess
469230|NCT00822692|Cellulitis
469231|NCT00822692|Antibiotics
469232|NCT00822692|MRSA
469233|NCT00822679|Acute Coronary Syndrome
469234|NCT00822679|cytokines
469235|NCT00822679|pro-coagulant mediators
469236|NCT00822679|sleep disorders
469237|NCT00822666|Platelet aggregation
469238|NCT00822666|Platelet
469239|NCT00822666|Thrombosis
469240|NCT00822666|Clopidogrel
469241|NCT00822653|hemodialysis treatment
469242|NCT00822653|pump stimulation
469243|NCT00822653|reduce hypotensive episodes
469244|NCT00822640|Prosthesis Design
469245|NCT00822640|Range of Motion, Articular
469246|NCT00822640|Arthroplasty, Replacement, Knee
469247|NCT00822627|Influenza
469248|NCT00822627|vaccination
469249|NCT00822627|Emergency Department
469250|NCT00822614|Pain
469251|NCT00822601|Repetitive Transcranial Magnetic Stimulation
469252|NCT00822601|Supplementary Motor Area
469253|NCT00822601|Obsessive-Compulsive Disorder
469254|NCT00822601|Sham rTMS
469255|NCT00822601|Placebo-controlled
469256|NCT00822601|Randomized
469257|NCT00822601|Double-blind
469258|NCT00822601|fMRI
469259|NCT00822601|DSM-IV Obsessive-Compulsive Disorder
469260|NCT00822575|mosquito bites
469261|NCT00822575|itching
469262|NCT00822562|hepatocellular carcinoma
469263|NCT00822562|surgery
469264|NCT00822549|Morphine titration
469265|NCT00822549|Sub acute pain
469266|NCT00822549|Major orthopaedic surgery
469267|NCT00822549|Pharmacokinetics
469268|NCT00822549|Pharmacodynamics
469269|NCT00822549|Genetic polymorphism
469270|NCT00822549|PACU
469271|NCT00822549|Patients undergoing major scheduled orthopaedic surgery
469272|NCT00822536|Drug-eluting stent
469273|NCT00822536|Clopidogrel
469274|NCT00822536|Stent thrombosis
469275|NCT00822536|Myocardial infarction
469276|NCT00822510|Psychosocial Intervention
469277|NCT00822510|Men with Prostate Cancer & Partners
469278|NCT00822497|music therapy
469279|NCT00822497|pain
469280|NCT00822497|anxiety
469281|NCT00822497|muscle tension
469282|NCT00822471|Diabetes
469283|NCT00822471|Self-Management Education
469284|NCT00822471|Library
469285|NCT00822471|Emergency Department Visits
469286|NCT00822471|African American
469287|NCT00822471|CVD prevention
469288|NCT00822471|Prevention
469289|NCT00822471|Uncontrolled diabetes
469290|NCT00822445|Biomarker
469291|NCT00822445|S100 protein
469292|NCT00822445|Traumatic brain injury
469293|NCT00822445|Craniocerebral tomodensitometry
469294|NCT00822445|Neurological sequelae
469295|NCT00822432|biomarkers
469296|NCT00822432|ABC transporters
469297|NCT00822432|MRP2
469298|NCT00822432|MTX pharmacokinetics
469299|NCT00822419|sternotomy pain
469300|NCT00822406|allergy
469301|NCT00822406|rhinitis
469302|NCT00822406|homeopathy
469303|NCT00822406|double-blind
469304|NCT00822393|Treosulfan
469305|NCT00822393|Busulfan
469306|NCT00822393|Conditioning
469307|NCT00822393|Allogeneic
469308|NCT00822393|Transplantation
469309|NCT00822380|Anemia
469310|NCT00822380|Iron
469311|NCT00822380|Children
469312|NCT00822380|Micronutrients
469313|NCT00822354|Secondary Raynaud's Phenomenon
469314|NCT00822328|Probiotics
469315|NCT00822328|Lactobacillus
469316|NCT00822328|Intestine
469317|NCT00822328|Flora
469318|NCT00822315|HIV
469319|NCT00822315|Tuberculosis
469320|NCT00822315|Pharmacokinetics
469321|NCT00822315|Raltegravir
469322|NCT00822315|France
469323|NCT00822315|Brazil
469324|NCT00822315|treatment naive
469325|NCT00822302|atherosclerosis
469326|NCT00822302|stroke
469327|NCT00822302|ischaemia
469328|NCT00822289|radioactive iodine
469329|NCT00822289|Helicobacter pylori
469330|NCT00822289|Thyroid diseases
469331|NCT00822289|CagA
469332|NCT00822276|Methicillin-resistant Staphylococcus aureus
469333|NCT00822276|MRSA
469334|NCT00822276|Methicillin-sensitive Staphylococcus aureus
469335|NCT00822276|MSSA
469336|NCT00822276|Atopic Dermatitis
469337|NCT00822276|Eczema Herpeticum
469338|NCT00822263|mild traumatic brain injury
469339|NCT00822263|anti-oxidant
469340|NCT00822263|early treatment
469341|NCT00822224|acute pain
469342|NCT00822224|MEOPA
469343|NCT00822224|Dementia
469344|NCT00822211|Diabetes Mellitus
469345|NCT00822211|HbA1c reduction
469346|NCT00822211|vildagliptin
469347|NCT00822211|add-on to metformin
469348|NCT00822211|Chinese patients
469349|NCT00821990|Failed after previous chemotherapy
469350|NCT00821977|Type 2 Diabetes
469351|NCT00821977|Vildagliptin
469352|NCT00821964|Breast Cancer
469353|NCT00821964|Stage IV
469354|NCT00821964|cream
469355|NCT00821964|topical
469356|NCT00821938|Narrow QRS
469357|NCT00821938|CRT
469358|NCT00821925|osteoporosis
469359|NCT00821899|diabetes type 1
469360|NCT00821899|bone marrow transplantation
469361|NCT00821886|Breast Cancer
469362|NCT00821886|Neoadjuvant
469363|NCT00821886|Ixabepilone
469364|NCT00821886|Carboplatin
469365|NCT00821886|Trastuzumab
469366|NCT00821873|Cartilage injury
469367|NCT00821873|OATS
469368|NCT00821873|Knee injury
469369|NCT00821873|allograft
469370|NCT00821873|autograft
469371|NCT00821860|epithelial mesothelioma
469372|NCT00821860|recurrent malignant mesothelioma
469373|NCT00821860|sarcomatous mesothelioma
469374|NCT00821860|malignant pleural effusion
469375|NCT00821860|stage IA malignant mesothelioma
469376|NCT00821860|stage IB malignant mesothelioma
469377|NCT00821860|stage II malignant mesothelioma
469378|NCT00821860|stage III malignant mesothelioma
469379|NCT00821860|stage IV malignant mesothelioma
469380|NCT00821847|HIV
469381|NCT00821847|glomerular filtration rate
469382|NCT00821847|cockcroft
469383|NCT00821847|MDRD formula
469384|NCT00821847|creatinine
469385|NCT00821847|cystatin C
469386|NCT00821847|isotopic clearance
469387|NCT00821847|EDTA-51Cr
469388|NCT00821847|DEXA scan
469389|NCT00821834|Old Myocardial infarction
469390|NCT00821834|Platelet Aggregation Inhibitors
469391|NCT00821834|Angioplasty
469392|NCT00821834|Transluminal
469393|NCT00821834|Percutaneous Coronary
469394|NCT00821834|Stents
469395|NCT00821795|Diabetes Mellitus, Type 2
469396|NCT00821795|insulin
469397|NCT00821795|therapy
469398|NCT00821782|Bacteria
469399|NCT00821782|Oral flora bacteria
469400|NCT00821782|Resistance
469401|NCT00821756|Suicidal behaviour
469402|NCT00821756|Attempted suicide
469403|NCT00821756|Self harm
469404|NCT00821756|Suicide
469405|NCT00821756|Health system contacts
469406|NCT00821756|Contacts with health system
469407|NCT00821730|Mixed methods research (qualitative and quantitative)
469408|NCT00821730|Peer support
469409|NCT00821730|Early inflammatory arthritis
469410|NCT00821730|Self-management
469411|NCT00821730|Patient education
469412|NCT00821717|Chronic Heart Failure
469413|NCT00821717|Iron deficiency
469414|NCT00821717|Iron deficiency anaemia
469415|NCT00821717|Anaemia
469416|NCT00821717|Heart disease
469417|NCT00821691|cerebral infarction
469418|NCT00821678|telemedicine
469419|NCT00821678|rural
469420|NCT00821678|veterans
469421|NCT00821678|care management
469422|NCT00821678|psychotherapy
469423|NCT00821665|Type 2 diabetes
469424|NCT00821665|Glycemic control
469425|NCT00821665|(postprandial) Hyperglycemia
469426|NCT00821665|Sucrose
469427|NCT00821652|Tumor
469428|NCT00821652|NY-ESO-1 expression
469429|NCT00821652|Tumors that often express NY-ESO-1.
469430|NCT00821626|Influenza
469431|NCT00821626|Rapid flu test
469432|NCT00821626|Returning travelers with fever
469433|NCT00821600|Risperidone
469434|NCT00821600|Antipsychotic
469435|NCT00821600|Pharmacokinetic
469436|NCT00821600|Long-acting Injectable
469437|NCT00821587|Hepatitis C Post Liver Transplant
469438|NCT00821574|Hypertension, dyslipidemia
469439|NCT00821561|Persistent
469440|NCT00821561|cornea
469441|NCT00821561|defect
469442|NCT00821561|Nexagon
469443|NCT00821561|Coda
469444|NCT00821548|facioscapulohumeral muscular dystrophy
469445|NCT00821548|electrostimulation
469446|NCT00821548|training
469447|NCT00821535|pharmacokinetics, Japanese, healthy volunteer, maraviroc
469448|NCT00821522|Acute Kidney Insufficiency
469449|NCT00821522|Acute Renal Insufficiency
469450|NCT00821522|Acute Kidney Injury
469451|NCT00821522|Cardiac Surgical Procedures
469452|NCT00821522|Ischemic Preconditioning
469453|NCT00821509|virus infection
469454|NCT00821509|hygiene
469455|NCT00821509|transmission
469456|NCT00821509|intervention
469457|NCT00821496|Multiple dose administration
469458|NCT00821496|Oral Contraceptives
469459|NCT00821470|osteonecrosis
469460|NCT00821470|bone marrow
469461|NCT00821470|core decompression
469462|NCT00821470|femoral head
469463|NCT00821457|existing scars the are two to six months old
469464|NCT00821444|schizophrenia, pharmacokinetics, bioavailability, food effect
469465|NCT00821405|Number : 250~300 patients
469466|NCT00821405|Correlation between PET, glucose loading and peritoneal thickness/calcification
469467|NCT00821379|PCOS
469468|NCT00821379|Polycystic Ovary Syndrome
469469|NCT00821379|Pregnancy Complications
469470|NCT00821379|Gestational Diabetes
469471|NCT00821379|Pre eclampsia
469472|NCT00821379|Prediction Model
469473|NCT00821379|Pre conceptional
469474|NCT00821366|HIV/AIDS
469475|NCT00821366|Food security
469476|NCT00821366|treatment experienced
469477|NCT00821353|Atrial fibrillation
469478|NCT00821353|Hypertrophic cardiomyopathy
469479|NCT00821353|RF ablation
469480|NCT00821353|Antiarrhythmic drugs
469481|NCT00821340|Leber congenital amaurosis
469482|NCT00821340|LCA
469483|NCT00821340|RPE65
469484|NCT00821340|RPE65-associated Leber congenital amaurosis
469485|NCT00821340|Retinal disease due to RPE65 mutations
469486|NCT00821301|Multiple myeloma
469487|NCT00821288|cancer survivorship
469488|NCT00821288|survivorship prescription
469489|NCT00821288|cancer related anxiety
469490|NCT00821275|Uterine Artery Embolization
469491|NCT00821275|Leiomyoma
469492|NCT00821275|myomectomy
469493|NCT00821275|hysterectomy
469494|NCT00821275|pregnancy
469495|NCT00821275|complication
469496|NCT00821275|ovarian function
469497|NCT00821275|quality of life
469498|NCT00821262|Sevoflurane
469499|NCT00821262|Anesthesia
469500|NCT00821262|Troponin
469501|NCT00821262|Myocardial Preconditioning
469502|NCT00821262|Surgery, Cardiac
469503|NCT00821262|Stents
469504|NCT00821262|Non-cardiac Surgery
469505|NCT00821262|Surgery
469506|NCT00821249|plasma cell dyscrasia
469507|NCT00821249|plasmacytoma
469508|NCT00821249|kinesin spindle protein
469509|NCT00821249|anti-mitotic
469510|NCT00821236|Myopia
469511|NCT00821236|LASIK
469512|NCT00821236|Astigmatism
469513|NCT00821236|Laser Vision Correction
469514|NCT00821236|Excimer Laser
469515|NCT00821223|phacoemulsification
469516|NCT00821223|manual small incision cataract surgery
469517|NCT00821223|visual acuity
469518|NCT00821223|contrast sensitivity
469519|NCT00821223|quality of vision
469520|NCT00821210|Obstructive sleep apnea
469521|NCT00821210|myocardial infarction
469522|NCT00821197|obesity
469523|NCT00821197|laparoscopy
469524|NCT00821197|bariatric
469525|NCT00821197|super obesity
469526|NCT00821184|urinary incontinence
469527|NCT00821184|overactive bladder
469528|NCT00821184|urinary frequency
469529|NCT00821145|abdominal aortic aneurysms
469530|NCT00821132|FALS
469531|NCT00821132|ALS
469532|NCT00821132|ALS/FTD
469533|NCT00821132|SALS
469534|NCT00821132|MND
469535|NCT00821132|PLS
469536|NCT00821119|non invasive ventilation
469537|NCT00821119|mechanical ventilation
469538|NCT00821119|pulmonary morbidity
469539|NCT00821119|preterm infant
469540|NCT00821119|Respiratory distress syndrome
469541|NCT00821119|nasal intermittent positive pressure
469542|NCT00821119|nasal continuous positive pressure
469543|NCT00821119|bronchopulmonary dysplasia
469544|NCT00821106|Coronary angiography
469545|NCT00821106|percutaneous coronary intervention
469546|NCT00821106|Transradial approach
469547|NCT00821093|respiratory
469548|NCT00821093|dyspnea
469549|NCT00821093|breathlessness
469550|NCT00821093|COPD
469551|NCT00821093|indacaterol
469552|NCT00821093|long-acting β2-agonist
469553|NCT00821080|vandetanib
469554|NCT00821080|sirolimus
469555|NCT00821080|recurrent glioblastoma
469556|NCT00821054|Phase I Food Effect
469557|NCT00821041|insomnia
469558|NCT00821041|online systems
469559|NCT00821028|atherosclerosis
469560|NCT00821028|angioplasty
469561|NCT00821028|peripheral arterial disease
469562|NCT00821015|cryoablation
469563|NCT00821015|recurring arrhythmia
469564|NCT00821015|stroke
469565|NCT00821015|RF ablation
469566|NCT00821015|LA ablation
469567|NCT00821015|nodal ablation
469568|NCT00821015|catheter ablation
469569|NCT00821002|Glaucoma
469570|NCT00820989|Healthy Immune System
469571|NCT00820976|G-CSF
469572|NCT00820976|AML
469573|NCT00820976|survival
469574|NCT00820963|adult giant cell glioblastoma
469575|NCT00820963|adult glioblastoma
469576|NCT00820963|adult gliosarcoma
469577|NCT00820924|HER-2
469578|NCT00820924|Circulating Tumour Cell (CTC)
469579|NCT00820924|EGFR
469580|NCT00820924|Lapatinib (GW572016)
469581|NCT00820924|Breast Cancer
469582|NCT00820911|Kidney transplant
469583|NCT00820911|AEB071
469584|NCT00820872|male breast cancer
469585|NCT00820872|stage I breast cancer
469586|NCT00820872|stage II breast cancer
469587|NCT00820872|stage IIIA breast cancer
469588|NCT00820872|stage IIIB breast cancer
469589|NCT00820859|Cognition disorder
469590|NCT00820859|nursing home residents
469591|NCT00820859|agitation
469592|NCT00820859|behavior disorder
469593|NCT00820846|HIV Seronegativity
469594|NCT00820846|HIV Preventive Vaccine
469595|NCT00820833|infant formula
469596|NCT00820833|obesity
469597|NCT00820833|growth
469598|NCT00820820|Atopic Dermatitis
469599|NCT00820820|immunosuppression
469600|NCT00820820|Measles vaccine
469601|NCT00820820|T lymphocytes
469602|NCT00820820|Atopic Dermatitis in adults
469603|NCT00820807|dietary fiber
469604|NCT00820807|fiber
469605|NCT00820807|insulin sensitivity
469606|NCT00820807|insulin resistance
469607|NCT00820807|glucose metabolism
469608|NCT00820794|Drug-drug interaction, lithium, PD 0332334, pharmacokinetics
469609|NCT00820781|bleeding gastric varices
469610|NCT00820781|cirrhosis of the liver
469611|NCT00820781|portacaval shunt
469612|NCT00820781|endoscopic variceal sclerotherapy
469613|NCT00820781|endoscopic variceal ligation
469614|NCT00820781|Bleeding gastric varices due to cirrhosis of the liver
469615|NCT00820742|A5751025
469616|NCT00820729|interstitial lung disease
469617|NCT00820729|pulmonary hypertension
469618|NCT00820729|biomarkers
469619|NCT00820729|NT-pro-BNP
469620|NCT00820729|von Willebrand factor
469621|NCT00820729|D-dimer
469622|NCT00820729|Exhaled NO
469623|NCT00820729|Troponin-t
469624|NCT00820716|Asthma
469625|NCT00820716|Asthmatic subjects
469626|NCT00820716|Exercise training
469627|NCT00820716|Constant load
469628|NCT00820716|Alternate load
469629|NCT00820703|Nexagon
469630|NCT00820703|CoDa
469631|NCT00820703|ulcer
469632|NCT00820703|diabetic
469633|NCT00820703|foot
469634|NCT00820690|neoadjuvant chemotherapy
469635|NCT00820690|advanced breast cancer
469636|NCT00820690|microarray
469637|NCT00820690|correlation analysis
469638|NCT00820690|oncoplastic surgery
469639|NCT00820651|Nonalcoholic steatohepatitis
469640|NCT00820651|Insulinresistance
469641|NCT00820651|Diet and exercise
469642|NCT00820651|Nutritional supplement
469643|NCT00820651|Nonalcoholic fatty liver disease
469644|NCT00820651|Lifestyle modifications
469645|NCT00820638|neurorobotics
469646|NCT00820638|occupational therapy
469647|NCT00820599|Sapien Valve
469648|NCT00820599|Cardiovascular Diseases
469649|NCT00820599|Valvular Heart Disease
469650|NCT00820599|Aortic Stenosis
469651|NCT00820599|Heart Valve Therapy
469652|NCT00820599|Transfemoral
469653|NCT00820599|Transcatheter
469654|NCT00820586|Intramyocardial
469655|NCT00820586|Autologous
469656|NCT00820586|Bone
469657|NCT00820586|Marrow
469658|NCT00820586|Randomized
469659|NCT00820586|Percutaneous
469660|NCT00820586|CD34+
469661|NCT00820586|Refractory
469662|NCT00820586|Angina
469663|NCT00820586|Pectoris.
469664|NCT00820573|Diabetes
469665|NCT00820547|inflammatory breast cancer
469666|NCT00820547|stage IIIA breast cancer
469667|NCT00820547|stage IIIB breast cancer
469668|NCT00820547|stage IIIC breast cancer
469669|NCT00820547|male breast cancer
469670|NCT00820547|HER2-negative breast cancer
469671|NCT00820534|cold sore
469672|NCT00820508|Haematological disease
469673|NCT00820508|Lymphoid malignancy
469674|NCT00820508|Histone deacetylase inhibitor
469675|NCT00820508|dose escalation
469676|NCT00820495|Smokeless tobacco
469677|NCT00820495|Chewing Tobacco
469678|NCT00820495|Internet
469679|NCT00820495|Adolescent
469680|NCT00820469|Rituximab
469681|NCT00820469|Plasma exchange
469682|NCT00820469|Autoimmune diseases
469683|NCT00820456|colorectal cancer
469684|NCT00820456|colorectal neoplasm
469685|NCT00820456|colorectal neoplasms
469686|NCT00820456|metastasis
469687|NCT00820456|metastases
469688|NCT00820456|liver
469689|NCT00820456|hepatic metastasis
469690|NCT00820456|liver metastasis
469691|NCT00820456|perfusion imaging
469692|NCT00820456|MRI
469693|NCT00820456|magnetic resonance imaging
469694|NCT00820456|dynamic contrast enhanced MRI
469695|NCT00820456|dynamic contrast enhanced magnetic resonance imaging
469696|NCT00820430|osteoarthritis
469697|NCT00820430|knee
469698|NCT00820430|magnetic resonance imaging
469699|NCT00820430|knee cartilage
469700|NCT00820430|reproducibility
469701|NCT00820417|cetuximab
469702|NCT00820417|monoclonal
469703|NCT00820417|antibody
469704|NCT00820417|epidermal
469705|NCT00820417|growth
469706|NCT00820417|factor
469707|NCT00820417|receptor
469708|NCT00820417|EGFR
469709|NCT00820417|Gefitinib
469710|NCT00820417|tyrosine
469711|NCT00820417|kinase
469712|NCT00820417|inhibitor
469713|NCT00820417|advanced
469714|NCT00820417|cancer
469715|NCT00820391|Post-traumatic Stress disorder (PTSD)
469716|NCT00820378|Aortic dimension
469717|NCT00820378|Atherosclerosis
469718|NCT00820378|Vascular disease
469719|NCT00820378|Risk factors
469720|NCT00820365|Inflammatory Bowel Disease (IBD)
469721|NCT00820365|Crohn's Disease
469722|NCT00820365|Ulcerative Colitis
469723|NCT00820365|SC12267
469724|NCT00820365|4SC-101
469725|NCT00820365|Phase II
469726|NCT00820352|HFNEF
469727|NCT00820352|HFPEF
469728|NCT00820352|Secondary Pulmonary Hypertension
469729|NCT00820352|Endothelin Receptor Blockade
469730|NCT00820339|hepatocellular carcinoma
469731|NCT00820339|hepatic vein
469732|NCT00820339|Surgical resection
469733|NCT00820339|occlusion
469734|NCT00820339|time to recurrence
469735|NCT00820339|overall survival
469736|NCT00820313|Coronary Heart Disease
469737|NCT00820313|Biomarkers of Cardiovascular Disease
469738|NCT00820313|Health Related Quality of Life
469739|NCT00820313|Diabetes
469740|NCT00820313|Diet
469741|NCT00820287|Testicular cancer
469742|NCT00820287|incidence
469743|NCT00820287|young men
469744|NCT00820261|Genotypes
469745|NCT00820261|Epidemiology
469746|NCT00820261|Diarrhea
469747|NCT00820248|stage III squamous cell carcinoma of the hypopharynx
469748|NCT00820248|stage III squamous cell carcinoma of the larynx
469749|NCT00820248|stage III verrucous carcinoma of the larynx
469750|NCT00820248|stage III squamous cell carcinoma of the oropharynx
469751|NCT00820248|stage IV squamous cell carcinoma of the hypopharynx
469752|NCT00820248|stage IV squamous cell carcinoma of the larynx
469753|NCT00820248|stage IV verrucous carcinoma of the larynx
469754|NCT00820248|stage IV squamous cell carcinoma of the oropharynx
469755|NCT00820248|stage III verrucous carcinoma of the oral cavity
469756|NCT00820248|stage III squamous cell carcinoma of the lip and oral cavity
469757|NCT00820248|stage IV verrucous carcinoma of the oral cavity
469758|NCT00820248|stage IV squamous cell carcinoma of the lip and oral cavity
469759|NCT00820222|ErbB2
469760|NCT00820222|HERCEPTIN
469761|NCT00820222|XELODA
469762|NCT00820222|ErbB1
469763|NCT00820222|TYKERB
469764|NCT00820222|metastatic breast cancer
469765|NCT00820222|trastuzumab
469766|NCT00820222|breast cancer
469767|NCT00820222|capecitabine
469768|NCT00820222|lapatinib
469769|NCT00820222|brain metastases
469770|NCT00820222|HER2 positive
469771|NCT00820222|TYVERB
469772|NCT00820196|Venous ulcer
469773|NCT00820196|Nexagon
469774|NCT00820196|CoDa
469775|NCT00820183|Hypertension
469776|NCT00820183|Intervention
469777|NCT00820183|Primary Care
469778|NCT00820183|Quality improvement
469779|NCT00820170|Breast
469780|NCT00820170|Cancer
469781|NCT00820170|DASATINIB
469782|NCT00820170|TAXOL (PACLITAXEL)
469783|NCT00820170|08-122
469784|NCT00820157|Carcinoma, Hepatocellular
469785|NCT00820157|Chemoembolization, Therapeutic
469786|NCT00820157|Cytoreductive
469787|NCT00820144|immune response
469788|NCT00820144|b-subunit of cholera toxin
469789|NCT00820144|mucosal way
469790|NCT00820144|healthy volonteers
469791|NCT00820144|vaccine
469792|NCT00820118|ANTIRETROVIRAL THERAPY
469793|NCT00820118|STRUCTURED TREATMENT INTERRUPTIONS
469794|NCT00820118|treatment naive
469795|NCT00820105|Migraine
469796|NCT00820105|Aura
469797|NCT00820105|Migraine headache
469798|NCT00820092|Xerecept
469799|NCT00820092|Pharmacokinetics
469800|NCT00820092|Japanese versus Caucasians
469801|NCT00820079|Gastroesophageal reflux
469802|NCT00820079|Heartburn
469803|NCT00820079|Regurgitation
469804|NCT00820053|hepatocellular carcinoma
469805|NCT00820053|adjuvant therapy
469806|NCT00820053|TACE
469807|NCT00820053|time to recurrence
469808|NCT00820053|overall survival
469809|NCT00819208|fatigue
469810|NCT00819208|sleep disorders
469811|NCT00819208|depression
469812|NCT00819208|anxiety disorder
469813|NCT00819208|psychosocial effects of cancer and its treatment
469814|NCT00819208|cognitive/functional effects
469815|NCT00819208|stage II colon cancer
469816|NCT00819208|stage III colon cancer
469817|NCT00819208|adenocarcinoma of the colon
469818|NCT00819195|relapsing-remitting
469819|NCT00819195|multiple sclerosis
469820|NCT00819195|Copaxone
469821|NCT00819195|glatiramer acetate
469822|NCT00819195|MS
469823|NCT00819182|Menopause
469824|NCT00819182|Breast Cancer
469825|NCT00819182|Hot Flash
469826|NCT00819182|Night Sweats
469827|NCT00819169|AMG 655
469828|NCT00819169|AMG 479
469829|NCT00819169|Apoptosis
469830|NCT00819169|Monoclonal Antibody
469831|NCT00819169|Tumor Necrosis Factor
469832|NCT00819169|Insulin-like Growth Factor
469833|NCT00819143|Tissue Procurement
469834|NCT00819143|Sample Collection
469835|NCT00819143|Chronic Myelogenous Leukemia
469836|NCT00819143|Laboratory Research
469837|NCT00820014|ESBA105
469838|NCT00820014|scFv antibody fragment
469839|NCT00820014|cataract surgery
469840|NCT00820014|pharmacokinetics
469841|NCT00820014|biodistribution
469842|NCT00820014|Irvine-Gass syndrome
469843|NCT00820001|Cognitive Behavioral Therapy
469844|NCT00820001|Multimodal Treatment
469845|NCT00820001|Physiological Parameters
469846|NCT00820001|Hormone Concentration in pubertal development
469847|NCT00820001|Treatment as usual comparison
469848|NCT00819988|Postoperative
469849|NCT00819988|Perioperative
469850|NCT00819988|Orthopedic surgery
469851|NCT00819988|Vascular surgery
469852|NCT00819988|Gabapentinoid
469853|NCT00819975|Casein
469854|NCT00819975|Whey
469855|NCT00819975|postprandial
469856|NCT00819975|Triglyceride
469857|NCT00819975|Free fatty acids
469858|NCT00819975|Retinyl palmitate
469859|NCT00819975|Incretins
469860|NCT00819975|Type 2 Diabetes
469861|NCT00819949|Robot
469862|NCT00819949|Treadmill
469863|NCT00819949|Rehabilitation
469864|NCT00819949|Freezing of gait
469865|NCT00819936|abdominal aorta surgery
469866|NCT00819936|Physical Training
469867|NCT00819936|backward walking
469868|NCT00819936|physiotherapy
469869|NCT00819923|Titanium
469870|NCT00819923|everolimus
469871|NCT00819923|drug eluting stent
469872|NCT00819923|stent thrombosis
469873|NCT00819923|restenosis
469874|NCT00819923|percutaneous coronary intervention
469875|NCT00819923|acute coronary syndrome
469876|NCT00819910|Type 4 hyperlipidemia
469877|NCT00819910|Rosiglitazone
469878|NCT00819910|Fenofibrate
469879|NCT00819897|MS
469880|NCT00819897|CIS
469881|NCT00819897|IFN
469882|NCT00819897|MRI
469883|NCT00819897|OCT
469884|NCT00819897|QOL
469885|NCT00819884|Type II Diabetes
469886|NCT00819884|24 hour glucose profile
469887|NCT00819858|weight loss
469888|NCT00819858|weight gain
469889|NCT00819858|malnutrition
469890|NCT00819858|convalescence
469891|NCT00819858|malaria
469892|NCT00819858|RUTF
469893|NCT00819858|RUF
469894|NCT00819858|supplementation
469895|NCT00819858|nutrition
469896|NCT00819845|Duchenne
469897|NCT00819845|Becker muscular dystrophy
469898|NCT00819845|cardioprotective therapy
469899|NCT00819845|cardiac magnetic resonance
469900|NCT00819845|ultrasound tissue characterization
469901|NCT00819832|vertebral compression fractures
469902|NCT00819832|VCF
469903|NCT00819832|Spinal
469904|NCT00819832|Broken spinal bones
469905|NCT00819832|Kyphoplasty
469906|NCT00819832|vertebroplasty
469907|NCT00819832|Cavity SpineWand
469908|NCT00819832|Circulating Tumor Cell Burden
469909|NCT00819832|CTCB
469910|NCT00819832|Spine pain
469911|NCT00819832|Coblation
469912|NCT00819832|plasma radiofrequency ablation
469913|NCT00819832|Plasma-mediated ablation technology
469914|NCT00819832|precise molecular dissociation (ablation) process
469915|NCT00819832|medical cement
469916|NCT00819793|Cardiac Dysfunction
469917|NCT00819793|Failure-to-wean from CPB
469918|NCT00819793|CentriMag
469919|NCT00819793|Levitronix
469920|NCT00819793|Thoratec Corporation
469921|NCT00819780|Colon Cancer
469922|NCT00819780|Colorectal Cancer
469923|NCT00819780|Rectal Cancer
469924|NCT00819780|Panitumumab
469925|NCT00819780|Vectibix
469926|NCT00819780|modified FOLFOX 6
469927|NCT00819780|mFOLFOX 6
469928|NCT00819780|FOLFOX
469929|NCT00819780|Bevacizumab
469930|NCT00819780|Avastin
469931|NCT00819780|First-Line
469932|NCT00819780|metastatic
469933|NCT00819767|hypertension
469934|NCT00819767|systolic blood pressure
469935|NCT00819767|exercise test
469936|NCT00819767|cardiovascular disease
469937|NCT00819767|aliskiren
469938|NCT00819767|valsartan
469939|NCT00819715|Preterm infants
469940|NCT00819715|small for gestational age
469941|NCT00819715|electrogastrography
469942|NCT00819702|child abuse prevention
469943|NCT00819702|primary care
469944|NCT00819702|professional education in primary care
469945|NCT00819650|hepatocellular carcinoma
469946|NCT00819650|adjuvant therapy
469947|NCT00819650|Licartin
469948|NCT00819650|time to recurrence
469949|NCT00819650|overall survival
469950|NCT00819637|Acute asthma
469951|NCT00819637|Arformoterol
469952|NCT00819637|Long acting beta agonists
469953|NCT00819624|fibromyalgia methodology pain sleep fatigue
469954|NCT00819611|Attention deficit disorder with hyperactivity
469955|NCT00819611|Working memory training
469956|NCT00819611|Placebo
469957|NCT00819611|Behavioral symptoms
469958|NCT00819611|Neuropsychology
469959|NCT00819611|Electropsychophysiology
469960|NCT00819585|Gout
469961|NCT00819585|Chronic Gout
469962|NCT00819585|Gouty arthritis
469963|NCT00819585|Gout flares
469964|NCT00819572|Osteoarthritis
469965|NCT00819572|TNF-alpha
469966|NCT00819572|DLX105
469967|NCT00819572|scFv antibody fragment
469968|NCT00819572|pain
469969|NCT00819572|fragment
469970|NCT00819572|antibody fragment
469971|NCT00819559|Rectal neoplasm
469972|NCT00819559|Clinical stage
469973|NCT00819559|T3N0
469974|NCT00819559|Preoperative chemoradiotherapy
469975|NCT00819559|Laparoscopic
469976|NCT00819559|Open resection
469977|NCT00819546|AML
469978|NCT00819546|MDS
469979|NCT00819520|pediculosis capitis
469980|NCT00819520|pediculus
469981|NCT00819507|Skin barrier
469982|NCT00819507|Atopic Dermatitis
469983|NCT00819507|Corticosteroid
469984|NCT00819507|Effects on skin severity and barrier function
469985|NCT00819494|Contrast media skin test
469986|NCT00819494|Skin test
469987|NCT00819494|hypersensitivity
469988|NCT00819494|contrast media
469989|NCT00819481|Total knee replacement
469990|NCT00819455|Diabetes
469991|NCT00819455|Prevention of Diabetes
469992|NCT00819455|Lifestyle Modification
469993|NCT00819455|Text messages
469994|NCT00819442|heart failure
469995|NCT00819442|desmin
469996|NCT00819442|ubiquitin
469997|NCT00819429|Attention Deficit Hyperactivity Disorder
469998|NCT00819429|Conduct Disorder
469999|NCT00819429|Oppositional Defiant Disorder
470000|NCT00819429|Omega 3 Supplements
470001|NCT00819429|Social Skills Training
470002|NCT00819429|Dietary Intake
470003|NCT00819429|Aggression
470004|NCT00819429|Nutrition
470005|NCT00819429|Disruptive Behaviors Disorder
470006|NCT00819416|randomized controlled trial
470007|NCT00819416|clinical trial
470008|NCT00819403|triglycerides
470009|NCT00819403|hypertension
470010|NCT00819403|low hdl
470011|NCT00819403|obesity
470012|NCT00819377|Valvular surgery
470013|NCT00819377|pulmonary artery pressure
470014|NCT00819364|Autism
470015|NCT00819364|early intervention
470016|NCT00819364|BCRI model
470017|NCT00819351|acute lymphoblastic leukemia
470018|NCT00819351|child
470019|NCT00819351|PEG-Asparaginase
470020|NCT00819351|EFS
470021|NCT00819351|efficacy
470022|NCT00819351|childhood acute lymphoblastic leukemia
470023|NCT00819338|Non-alcoholic fatty liver disease
470024|NCT00819338|Polyunsaturated fatty acids
470025|NCT00819338|Omega-3
470026|NCT00819325|diabetes
470027|NCT00819325|stents
470028|NCT00819325|restenosis
470029|NCT00819325|thiazolidinediones
470030|NCT00819325|coronary atherosclerosis
470031|NCT00819312|Contraceptives,
470032|NCT00819312|Oral Hormonal;
470033|NCT00819312|Contraceptive Methods;
470034|NCT00819312|Female
470035|NCT00819286|open heart surgery
470036|NCT00819273|hsCRP
470037|NCT00819260|Mammaplasty
470038|NCT00819260|Electrocoagulation
470039|NCT00819260|Breast
470040|NCT00819234|Leptin
470041|NCT00819234|Pramlintide
470042|NCT00819234|Obese
470043|NCT00819234|Symlin
470044|NCT00819234|Amylin
470045|NCT00819221|advanced tumors
470046|NCT00819221|solid tumors
470047|NCT00819221|dose escalation
470048|NCT00819221|combination
470049|NCT00819221|AZD2281
470050|NCT00819221|liposomal doxorubicin
470051|NCT00819221|pharmacology
470052|NCT00819221|phase I
470053|NCT00819221|multicenter
470054|NCT00819117|Epicardial leads
470055|NCT00819117|Cardiac Resynchronization Therapy
470056|NCT00819104|Primary hypertension
470057|NCT00819104|Metoprolol XL
470058|NCT00819104|Amlodipine
470059|NCT00819078|adolescent
470060|NCT00819078|bupropion
470061|NCT00819078|smoking
470062|NCT00819078|cessation
470063|NCT00819078|depression
470064|NCT00819065|Botulinum toxin A
470065|NCT00819065|Spasticity
470066|NCT00819065|Randomized Clinical Trial
470067|NCT00819000|Specialty Pharmacy
470068|NCT00819000|Therapy Management
470069|NCT00819000|Medication Compliance
470070|NCT00819000|Medication Adherence
470071|NCT00819000|Medication Persistence
470072|NCT00819000|Health Outcomes
470073|NCT00818987|Operative
470074|NCT00818987|Non operative
470075|NCT00818961|accelerated phase chronic myelogenous leukemia
470076|NCT00818961|adult acute lymphoblastic leukemia in remission
470077|NCT00818961|adult acute myeloid leukemia in remission
470078|NCT00818961|adult AML with 11q23 (MLL) abnormalities
470079|NCT00818961|blastic phase chronic myelogenous leukemia
470080|NCT00818961|chronic myelomonocytic leukemia
470081|NCT00818961|chronic phase chronic myelogenous leukemia
470082|NCT00818961|prolymphocytic leukemia
470083|NCT00818961|recurrent adult T-cell leukemia/lymphoma
470084|NCT00818961|refractory chronic lymphocytic leukemia
470085|NCT00818961|relapsing chronic myelogenous leukemia
470086|NCT00818961|secondary acute myeloid leukemia
470087|NCT00818961|stage I adult T-cell leukemia/lymphoma
470088|NCT00818961|stage I chronic lymphocytic leukemia
470089|NCT00818961|stage II adult T-cell leukemia/lymphoma
470090|NCT00818961|stage II chronic lymphocytic leukemia
470091|NCT00818961|stage III adult T-cell leukemia/lymphoma
470092|NCT00818961|stage III chronic lymphocytic leukemia
470093|NCT00818961|stage IV adult T-cell leukemia/lymphoma
470094|NCT00818961|stage IV chronic lymphocytic leukemia
470095|NCT00818961|recurrent adult Hodgkin lymphoma
470096|NCT00818961|anaplastic large cell lymphoma
470097|NCT00818961|angioimmunoblastic T-cell lymphoma
470098|NCT00818961|cutaneous B-cell non-Hodgkin lymphoma
470099|NCT00818961|recurrent cutaneous T-cell NHL
470100|NCT00818961|stage I cutaneous T-cell NHL
470101|NCT00818961|stage II cutaneous T-cell NHL
470102|NCT00818961|stage III cutaneous T-cell NHL
470103|NCT00818961|stage IV cutaneous T-cell NHL
470104|NCT00818961|extranodal marginal zone B-cell lymphoma of mucosal tissue
470105|NCT00818961|nodal marginal zone B-cell lymphoma
470106|NCT00818961|splenic marginal zone lymphoma
470107|NCT00818961|contiguous st II adult diffuse large cell lymphoma
470108|NCT00818961|contiguous st II adult diffuse mixed cell lymphoma
470109|NCT00818961|contiguous st II adult diffuse sm cleaved cell lymphoma
470110|NCT00818961|contiguous st II grade 1 follicular lymphoma
470111|NCT00818961|contiguous st II grade 2 follicular lymphoma
470112|NCT00818961|contiguous st II grade 3 follicular lymphoma
470113|NCT00818961|contiguous st II mantle cell lymphoma
470114|NCT00818961|contiguous st II marginal zone lymphoma
470115|NCT00818961|contiguous st II small lymphocytic lymphoma
470116|NCT00818961|stage I adult diffuse large cell lymphoma
470117|NCT00818961|stage I adult diffuse mixed cell lymphoma
470118|NCT00818961|stage I adult diffuse small cleaved cell lymphoma
470119|NCT00818961|stage I grade 1 follicular lymphoma
470120|NCT00818961|stage I grade 2 follicular lymphoma
470121|NCT00818961|stage I grade 3 follicular lymphoma
470122|NCT00818961|stage I mantle cell lymphoma
470123|NCT00818961|stage I marginal zone lymphoma
470124|NCT00818961|stage I small lymphocytic lymphoma
470125|NCT00818961|noncontiguous st II adult diffuse large cell lymphoma
470126|NCT00818961|noncontiguous st II adult diffuse mixed cell lymphoma
470127|NCT00818961|noncontiguous st II adult diffuse sm cleaved cell lymphoma
470128|NCT00818961|noncontiguous st II grade 1 follicular lymphoma
470129|NCT00818961|noncontiguous st II grade 2 follicular lymphoma
470130|NCT00818961|noncontiguous st II grade 3 follicular lymphoma
470131|NCT00818961|noncontiguous st II mantle cell lymphoma
470132|NCT00818961|noncontiguous st II marginal zone lymphoma
470133|NCT00818961|noncontiguous st II small lymphocytic lymphoma
470134|NCT00818961|stage III adult diffuse large cell lymphoma
470135|NCT00818961|stage III adult diffuse mixed cell lymphoma
470136|NCT00818961|stage III adult diffuse small cleaved cell lymphoma
470137|NCT00818961|stage III grade 1 follicular lymphoma
470138|NCT00818961|stage III grade 2 follicular lymphoma
470139|NCT00818961|stage III grade 3 follicular lymphoma
470140|NCT00818961|stage III mantle cell lymphoma
470141|NCT00818961|stage III marginal zone lymphoma
470142|NCT00818961|stage III small lymphocytic lymphoma
470143|NCT00818961|stage IV adult diffuse large cell lymphoma
470144|NCT00818961|stage IV adult diffuse mixed cell lymphoma
470145|NCT00818961|stage IV adult diffuse small cleaved cell lymphoma
470146|NCT00818961|stage IV grade 1 follicular lymphoma
470147|NCT00818961|stage IV grade 2 follicular lymphoma
470148|NCT00818961|stage IV grade 3 follicular lymphoma
470149|NCT00818961|stage IV mantle cell lymphoma
470150|NCT00818961|stage IV marginal zone lymphoma
470151|NCT00818961|stage IV small lymphocytic lymphoma
470152|NCT00818961|recurrent adult diffuse large cell lymphoma
470153|NCT00818961|recurrent adult diffuse mixed cell lymphoma
470154|NCT00818961|recurrent adult diffuse small cleaved cell lymphoma
470155|NCT00818961|recurrent adult gr III lymphomatoid granulomatosis
470156|NCT00818961|recurrent grade 1 follicular lymphoma
470157|NCT00818961|recurrent grade 2 follicular lymphoma
470158|NCT00818961|recurrent grade 3 follicular lymphoma
470159|NCT00818961|recurrent mantle cell lymphoma
470160|NCT00818961|recurrent marginal zone lymphoma
470161|NCT00818961|recurrent small lymphocytic lymphoma
470162|NCT00818961|de novo MDS
470163|NCT00818961|previously treated MDS
470164|NCT00818961|secondary myelodysplastic syndromes
470165|NCT00818961|Waldenstrom macroglobulinemia
470166|NCT00818961|myelodysplastic/myeloproliferative disease
470167|NCT00818948|Lupus
470168|NCT00818948|Nephritis
470169|NCT00818909|Dry eye
470170|NCT00818909|Systane
470171|NCT00818909|Moderate to severe dry eye
470172|NCT00818896|thyroid deficiency
470173|NCT00818896|pregnancy
470174|NCT00818896|post-partum thyroid dysfunction
470175|NCT00818896|permanent hypothyroidism
470176|NCT00818883|Essential Hypertension
470177|NCT00818883|Hypertensive
470178|NCT00818883|Blood Pressure, High
470179|NCT00818883|Vascular Disease
470180|NCT00818883|Cardiovascular Disease
470181|NCT00818883|Drug Therapy
470182|NCT00818870|Gastroesophageal Reflux
470183|NCT00818870|GERD
470184|NCT00818870|Nocturnal GERD
470185|NCT00818870|Heartburn
470186|NCT00818870|Nighttime Heartburn
470187|NCT00818870|Nocturnal Heartburn
470188|NCT00818857|cancer screening
470189|NCT00818857|screening disparities
470190|NCT00818857|underserved populations
470191|NCT00818844|Nepafenac
470192|NCT00818844|vitrectomy surgery
470193|NCT00818844|Epiretinal membrane surgery
470194|NCT00818831|Advanced, refractory solid tumors
470195|NCT00818818|Leishmaniasis
470196|NCT00818818|Cutaneous leishmaniasis
470197|NCT00818818|Leishmania braziliensis
470198|NCT00818818|Pentavalent antimonial
470199|NCT00818818|Glucantime
470200|NCT00818805|conjunctivitis
470201|NCT00818792|Percutaneous coronary intervention
470202|NCT00818792|Drug-eluting stent
470203|NCT00818792|Chronic kidney disease
470204|NCT00818792|Restenosis
470205|NCT00818779|diabetes
470206|NCT00818779|heart disease
470207|NCT00818779|atherosclerosis
470208|NCT00818766|Thoracic Surgery
470209|NCT00818766|Antibiotic Prophylaxis
470210|NCT00818766|Chest Tube
470211|NCT00817752|stress
470212|NCT00817752|inflammation
470213|NCT00817752|natural remedy
470214|NCT00817752|cytokines
470215|NCT00817752|interleukin
470216|NCT00817752|inflammatory conditions
470217|NCT00817752|auto-immune disorders
470218|NCT00817739|Drug therapy
470219|NCT00817726|Rapid Eye Movement Sleep Behavior Disorder
470220|NCT00817726|Parkinson's Disease
470221|NCT00817726|Parkinsonian Syndromes
470222|NCT00817726|Atypical Parkinson's
470223|NCT00817726|RBD
470224|NCT00817726|PD
470225|NCT00817726|fMRI
470226|NCT00817726|PSP
470227|NCT00817726|MSA
470228|NCT00817713|Human Immunodeficiency Virus
470229|NCT00817713|Helminthiasis
470230|NCT00817713|treatment naive
470231|NCT00817713|co-infection
470232|NCT00817713|immune modulation
470233|NCT00817700|Sleep
470234|NCT00817700|young adults
470235|NCT00817700|middle-age adults
470236|NCT00817700|older adults
470237|NCT00817674|CKD
470238|NCT00817674|Kidney Disease
470239|NCT00817674|poor sleep
470240|NCT00817674|CKD progression
470241|NCT00817661|vitamin A
470242|NCT00817661|influenza vaccine
470243|NCT00817661|passive immunity
470244|NCT00817661|pregnant mothers
470245|NCT00817661|vitamin A suplementation
470246|NCT00817661|Influenza vaccination
470247|NCT00817661|Infant immune responses
470248|NCT00817648|schizophrenia
470249|NCT00817648|antipsychotics
470250|NCT00817648|quetiapine
470251|NCT00817648|risperidone
470252|NCT00817648|efficacy
470253|NCT00817648|safety
470254|NCT00817648|multicenter
470255|NCT00817648|rater-blind
470256|NCT00817648|randomized
470257|NCT00817648|chinese
470258|NCT00817648|han
470259|NCT00817635|Blood Pressure
470260|NCT00817635|Hypertension
470261|NCT00817635|Resistant Hypertension
470262|NCT00818727|Bone density
470263|NCT00818727|SSRI
470264|NCT00818727|newborn infants
470265|NCT00818714|IIIA, selected IIIB
470266|NCT00818714|(T1N2-3M0, T2N2-3M0, T3N1-3M0)
470267|NCT00818701|Congestive Heart Failure
470268|NCT00818701|Congestive Heart Failure with a NYHF Class 2-3
470269|NCT00818701|Ejection Fraction of 35 or less
470270|NCT00818688|Superficial thrombophlebitis (ST)
470271|NCT00818688|Deep-vein thrombosis
470272|NCT00818688|Symptomatic pulmonary embolism
470273|NCT00818688|Symptomatic Superficial Thrombophlebitis of the lower limbs
470274|NCT00818662|Alzheimer´s
470275|NCT00818662|Dementia
470276|NCT00818662|Dementia of Alzheimer Type
470277|NCT00818662|Immunoglobulins
470278|NCT00818662|Gammaglobulins
470279|NCT00818662|Immune Globulin Intravenous (IGIV)
470280|NCT00818662|Intravenous Immune Globulin (IVIG)
470281|NCT00818662|Antibodies
470282|NCT00818662|Amyloid
470283|NCT00818662|Immunotherapy
470284|NCT00818649|de novo myelodysplastic syndromes
470285|NCT00818649|previously treated myelodysplastic syndromes
470286|NCT00818649|secondary myelodysplastic syndromes
470287|NCT00818649|refractory anemia with excess blasts
470288|NCT00818649|adult acute myeloblastic leukemia with maturation (M2)
470289|NCT00818649|adult acute myeloblastic leukemia without maturation (M1)
470290|NCT00818649|adult acute minimally differentiated myeloid leukemia (M0)
470291|NCT00818649|adult acute myelomonocytic leukemia (M4)
470292|NCT00818649|adult acute monoblastic leukemia (M5a)
470293|NCT00818649|adult acute monocytic leukemia (M5b)
470294|NCT00818649|adult erythroleukemia (M6a)
470295|NCT00818649|adult pure erythroid leukemia (M6b)
470296|NCT00818649|adult acute megakaryoblastic leukemia (M7)
470297|NCT00818649|recurrent adult acute myeloid leukemia
470298|NCT00818649|untreated adult acute myeloid leukemia
470299|NCT00818649|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
470300|NCT00818649|adult acute myeloid leukemia with inv(16)(p13;q22)
470301|NCT00818649|adult acute myeloid leukemia with t(16;16)(p13;q22)
470302|NCT00818649|adult acute myeloid leukemia with t(8;21)(q22;q22)
470303|NCT00818636|expressive writing
470304|NCT00818636|ruminating
470305|NCT00818636|ruminative thinking
470306|NCT00818636|experiential avoidance
470307|NCT00818636|depression
470308|NCT00818636|alcohol
470309|NCT00818636|drinking
470310|NCT00818636|emotional processing
470311|NCT00818610|Community-acquired infections
470312|NCT00818610|Pneumonia
470313|NCT00818610|Clinical Stability
470314|NCT00818610|Antibiotics
470315|NCT00818610|Combination therapy
470316|NCT00818610|Atypical bacteria
470317|NCT00818597|septic shock
470318|NCT00818597|immunoparalysis
470319|NCT00818597|extracorporeal
470320|NCT00818597|granulocyte bioreactor
470321|NCT00818597|plasmapheresis
470322|NCT00818584|Micafungin
470323|NCT00818584|Candida
470324|NCT00818584|Neonates
470325|NCT00818584|Mycamine
470326|NCT00818584|FK463
470327|NCT00818571|Renal impairment
470328|NCT00818571|Diabetes
470329|NCT00818571|vildagliptin
470330|NCT00818571|Galvus
470331|NCT00818571|Eucreas
470332|NCT00818558|non small cell lung cancer
470333|NCT00818545|aging
470334|NCT00818545|barrier function
470335|NCT00818545|transcriptomic
470336|NCT00818532|Corneal astigmatism
470337|NCT00818532|Low diopter
470338|NCT00818532|Corneal measurement
470339|NCT00818532|Corneal astigmatism < 1 Diopter
470340|NCT00818519|Moderate Acne Vulgaris
470341|NCT00818519|Oral contraceptive
470342|NCT00818519|Female
470343|NCT00818506|Depression
470344|NCT00818506|Major depressive disorder
470345|NCT00818506|Coronary artery disease
470346|NCT00818506|White Matter Hyperintensities
470347|NCT00818506|White Matter Lesions
470348|NCT00818506|Coronary artery calcification
470349|NCT00818493|total knee arthroplasty
470350|NCT00818493|total hip arthroplasty
470351|NCT00818480|prostate cancer
470352|NCT00818480|melanoma
470353|NCT00818480|lymphoma
470354|NCT00818480|YM155
470355|NCT00818467|Skin tone
470356|NCT00818467|Vitamin D
470357|NCT00818441|lung cancer adenocarcinoma HER2
470358|NCT00818428|Phonological Awareness
470359|NCT00818428|Speech Articulation Disorder
470360|NCT00818428|Development Articulation Disorder
470361|NCT00818428|Phonological Impairment
470362|NCT00818428|Dyslexia
470363|NCT00818428|Speech Therapy
470364|NCT00818428|School Transition
470365|NCT00818402|Quality of life
470366|NCT00818402|symptoms
470367|NCT00818389|Amyotrophic lateral sclerosis
470368|NCT00818389|ALS
470369|NCT00818389|Lou Gehrig's disease
470370|NCT00818389|riluzole
470371|NCT00818389|lithium
470372|NCT00818389|neurodegeneration
470373|NCT00818376|Chlorhexidine
470374|NCT00818376|adverse effects
470375|NCT00818376|staining
470376|NCT00818376|dental calculus
470377|NCT00818376|dental plaque
470378|NCT00818363|Postoperative pain
470379|NCT00818363|shoulder surgery
470380|NCT00818363|opioid
470381|NCT00818311|Light emitting diode
470382|NCT00818311|tolerance
470383|NCT00818311|photomodulation
470384|NCT00818298|schizophrenia
470385|NCT00818298|schizoaffective disorder
470386|NCT00818298|PET Scan
470387|NCT00818298|ziprasidone
470388|NCT00818298|dopamine
470389|NCT00818298|D2
470390|NCT00818298|receptor
470391|NCT00818298|antagonist
470392|NCT00818298|occupancy
470393|NCT00818298|dissociation
470394|NCT00818298|affinity
470395|NCT00818298|constant
470396|NCT00818298|Ki
470397|NCT00818298|ligand
470398|NCT00818298|raclopride
470399|NCT00818298|half-life
470400|NCT00818298|striatal
470401|NCT00818298|plasma dynamics
470402|NCT00818298|central dynamics
470403|NCT00818298|plasma drug level
470404|NCT00818298|compliance
470405|NCT00818298|antipsychotic
470406|NCT00818298|pharmacotherapy
470407|NCT00818298|twice daily dosing
470408|NCT00818298|BID dosing
470409|NCT00818298|once daily dosing
470410|NCT00818298|od dosing
470411|NCT00818298|qd dosing
470412|NCT00818298|dosing schedule
470413|NCT00818233|dynamic contour tonometry
470414|NCT00818233|variability
470415|NCT00818233|pulse amplitude
470416|NCT00818233|Ocular pulse amplitude
470417|NCT00818220|intraventricular hemorrhage
470418|NCT00818220|sepsis
470419|NCT00818220|motor function
470420|NCT00818220|motor functioning at 7 months corrected age
470421|NCT00818220|cytokines in cord blood and at 6 and 20 hours of age
470422|NCT00818220|stem cells in cord blood and at 20 hours of age
470423|NCT00818207|Smoking cessation
470424|NCT00818207|quit rates
470425|NCT00818207|reimbursement
470426|NCT00818207|drug coverage
470427|NCT00818207|effectiveness
470428|NCT00818207|cost-effectiveness
470429|NCT00818207|health policy
470430|NCT00818207|drug utilization
470431|NCT00818207|adherence
470432|NCT00818207|urine cotinine.
470433|NCT00818194|Tacrolimus
470434|NCT00818194|cyclosporine A
470435|NCT00818194|renal plasma flow
470436|NCT00818194|glomerular filtration rate
470437|NCT00818194|human
470438|NCT00818194|pharmacodynamics
470439|NCT00818194|pharmacokinetics
470440|NCT00818194|Pharmacodynamics of tacrolimus
470441|NCT00818181|Type I - Allergy, rhinoconjunctivitis
470442|NCT00818129|Phase I
470443|NCT00818129|Japan
470444|NCT00818129|Japanese
470445|NCT00818129|oral solution
470446|NCT00818116|Cataract
470447|NCT00818116|visual acuity
470448|NCT00818116|AcrySof ReSTOR Aspheric Intraoculare Lens
470449|NCT00818116|Bilateral cataract
470450|NCT00818103|Multiple Sclerosis,Genetics,Pathogenesis,Pathology,Therapy
470451|NCT00818090|thymic epithelial tumor
470452|NCT00818090|paclitaxel
470453|NCT00818090|cisplatin
470454|NCT00818090|thymic carcinoma
470455|NCT00818090|invasive thymoma
470456|NCT00818051|stage IA breast cancer
470457|NCT00818051|stage IB breast cancer
470458|NCT00818051|stage II breast cancer
470459|NCT00818051|stage IIIA breast cancer
470460|NCT00818038|RRMS
470461|NCT00818038|Relapsing Remitting
470462|NCT00818038|MS
470463|NCT00818025|Transplantation
470464|NCT00818025|Self-care agency
470465|NCT00818025|Self-care behaviors
470466|NCT00818025|Hand-held device
470467|NCT00818012|atrial fibrillation
470468|NCT00818012|atrial electromechanical interval
470469|NCT00818012|direct current cardioversion
470470|NCT00818012|pulse wave velocity
470471|NCT00817999|Platelet Aggregation Inhibition
470472|NCT00817986|Acute back pain in the lumbar region
470473|NCT00817973|Whey protein
470474|NCT00817973|gluten
470475|NCT00817973|casein
470476|NCT00817973|cod protein
470477|NCT00817973|GLP-1
470478|NCT00817973|postprandial
470479|NCT00817973|triglyceride
470480|NCT00817973|free fatty acids
470481|NCT00817973|chylomicrons
470482|NCT00817973|retinyl palmitate
470483|NCT00817973|type 2 diabetes
470484|NCT00817973|GIP
470485|NCT00817973|Postprandial incretins
470486|NCT00817960|Dual tasking
470487|NCT00817960|Postural Control
470488|NCT00817960|Methylphenidate (Ritalin)
470489|NCT00817960|old adults
470490|NCT00817947|Airway clearance
470491|NCT00817947|Cystic fibrosis
470492|NCT00817947|High frequency chest wall oscillation
470493|NCT00817934|Efficacy
470494|NCT00817934|patient's tolerance
470495|NCT00817934|patient's safety
470496|NCT00817921|premature renal function
470497|NCT00817921|ibuprofen
470498|NCT00817921|blood pressure
470499|NCT00817921|Renal function
470500|NCT00817908|liver transplant
470501|NCT00817908|lung transplant
470502|NCT00817908|kidney transplant
470503|NCT00817908|heart transplant
470504|NCT00817908|CMV CMI
470505|NCT00817908|Transplant
470506|NCT00817895|hepatocellular carcinoma
470507|NCT00817895|liver resection
470508|NCT00817895|intraoperative chemotherapy
470509|NCT00817882|vocational
470510|NCT00817882|rehabilitation
470511|NCT00817882|work
470512|NCT00817882|ability
470513|NCT00817882|low back pain
470514|NCT00817869|Floors and Floorcoverings
470515|NCT00817869|Health Services for the Aged
470516|NCT00817869|Fractures, bone
470517|NCT00817869|Delirium, Dementia, Amnestic, Cognitive Disorders
470518|NCT00817869|Frail Elderly
470519|NCT00817869|Aged, 80 and over
470520|NCT00817843|Postprandial hypertriglyceridemia
470521|NCT00817843|Metabolic syndrome
470522|NCT00817843|Endothelial function
470523|NCT00817843|Flow mediated dilatation
470524|NCT00817843|EndoPAT
470525|NCT00817843|Simvastatin
470526|NCT00817843|Ezetimibe
470527|NCT00817830|Coronaropathy
470528|NCT00817830|lodenafil carbonate
470529|NCT00817830|Erectile dysfunction
470530|NCT00817830|Treatment
470531|NCT00817830|QT interval
470532|NCT00817830|Phosphodiesterase inhibitors
470533|NCT00817830|Cardiac arrhythmia
470534|NCT00817830|Effort testPhosphodiesterase 5 inhibitors
470535|NCT00817830|Cardiovascular test
470536|NCT00817804|noninvasive ventilation
470537|NCT00817791|CABG
470538|NCT00817791|hyperbaric oxygen
470539|NCT00817791|preconditioning
470540|NCT00817791|S100B
470541|NCT00817791|NSE
470542|NCT00817791|Troponin I
470543|NCT00817791|CABG surgery
470544|NCT00817791|neuroprotection
470545|NCT00817778|Type II Diabetes
470546|NCT00817765|interaction
470547|NCT00817765|pharmacokinetics
470548|NCT00817765|boosting
470549|NCT00817765|drug-drug interaction
470550|NCT00817765|safety
470551|NCT00817622|diabetes mellitus type 2
470552|NCT00817622|EPA
470553|NCT00817622|leptin
470554|NCT00817622|adiponectin
470555|NCT00817609|Angongniuhuang Pill
470556|NCT00817609|consciousness level of patients who suffered from a stroke
470557|NCT00817583|Phase 2 Clinical Trial
470558|NCT00817583|NPC
470559|NCT00817583|neoadjuvant chemotherapy
470560|NCT00817583|concurrent chemoradiation
470561|NCT00817570|Trans Femoral Amputees Balance Reactions
470562|NCT00817557|Contact lenses
470563|NCT00817557|Loteprednol
470564|NCT00817557|Effect on CL dryness
470565|NCT00817544|3098004
470566|NCT00817544|Healthy volunteers
470567|NCT00817531|Breast Cancer
470568|NCT00817505|Type I diabetes
470569|NCT00817505|bioavailability
470570|NCT00817492|Sleep
470571|NCT00817492|CKD
470572|NCT00817492|kidney
470573|NCT00817492|PSG
470574|NCT00817492|polysomnography
470575|NCT00817492|Decreased sleep time
470576|NCT00817492|Decreased sleep quality
470577|NCT00817479|Subject has intraabdominal disease either proven or strongly
470578|NCT00817479|suspected to be ovarian or primary peritoneal cancer
470579|NCT00817466|bronchiolitis
470580|NCT00817466|infants
470581|NCT00817466|racemic adrenaline
470582|NCT00817466|inhalations
470583|NCT00817466|treatment
470584|NCT00817453|Parkinson's Disease
470585|NCT00817440|growth hormone insulin signaltransduction signalpathways
470586|NCT00817440|growth hormone and insulin signalpathways
470587|NCT00817427|Chronic Kidney Disease
470588|NCT00817427|Poor sleep
470589|NCT00817427|CKD
470590|NCT00817427|Kidney Failure
470591|NCT00817414|Blood Pressure
470592|NCT00817414|Hypertension
470593|NCT00817414|Cortisol
470594|NCT00817401|asphyxia
470595|NCT00817401|hypothermia
470596|NCT00817401|hypoxic-ischemic encephalopathy
470597|NCT00817401|neonates
470598|NCT00817388|Interstitial cystitis
470599|NCT00817388|pelvic pain
470600|NCT00817375|Pharmacogenomics
470601|NCT00817375|Prediction of Antidepressant Response
470602|NCT00817375|Depressed Patients
470603|NCT00817362|Breast Cancer
470604|NCT00817362|Advanced Breast Cancer
470605|NCT00817362|Metastatic Breast Cancer
470606|NCT00817362|HER2 Positive Breast Cancer
470607|NCT00817362|Cancer of the breast
470608|NCT00817362|Trastuzumab
470609|NCT00817362|Herceptin
470610|NCT00817349|Angio-Seal
470611|NCT00817349|Peripheral vascular disease
470612|NCT00817349|Vascular closure device
470613|NCT00817349|Arterial closure
470614|NCT00817349|Coronary artery disease
470615|NCT00817349|Arterial hemostasis
470616|NCT00817349|Coronary cardiac catheterization
470617|NCT00817349|Percutaneous coronary intervention
470618|NCT00817349|Interventional catheterization
470619|NCT00817349|Diagnostic catheterization
470620|NCT00817349|Common femoral artery
470621|NCT00817349|Manual compression
470622|NCT00817349|Vascular intervention
470623|NCT00817349|Angiogram
470624|NCT00817349|Coronary intervention
470625|NCT00817349|Coronary angioplasty
470626|NCT00817349|Angiography
470627|NCT00817349|Arteriotomy
470628|NCT00817349|Vascular access
470629|NCT00817336|biomarker
470630|NCT00817336|EEG
470631|NCT00817336|schizophrenia
470632|NCT00817336|NMDA
470633|NCT00817336|D-serine
470634|NCT00817323|bipolar depression
470635|NCT00817323|atypical antipsychotic
470636|NCT00817323|remission
470637|NCT00817323|depletion
470638|NCT00817323|mood
470639|NCT00817284|Newly diagnosed patients with glioblastoma multiforme.
470640|NCT00817284|Performance status 0-2.
470641|NCT00817271|Type II Diabetes
470642|NCT00817271|Counter-regulatory response
470643|NCT00817271|Hypoglycemia
470644|NCT00817258|Phase 2 Clinical Trial
470645|NCT00817258|NPC
470646|NCT00817258|radiation therapy
470647|NCT00817258|chemotherapy
470648|NCT00817245|CSR
470649|NCT00817245|Helicobacter pylori
470650|NCT00817232|tennis elbow
470651|NCT00817232|microcurrent
470652|NCT00817232|tissue healing
470653|NCT00817206|kidney transplantation
470654|NCT00817206|renal transplantation
470655|NCT00817206|maintenance immunosuppression
470656|NCT00817206|tacrolimus
470657|NCT00817206|Prevention of acute allograft rejection
470658|NCT00817193|Clinical trial
470659|NCT00817193|Short Physical Performance Battery
470660|NCT00817193|Disability
470661|NCT00817193|Senior Housing
470662|NCT00817193|Aging
470663|NCT00817180|physiotherapy
470664|NCT00817180|airway clearance techniques
470665|NCT00817180|Positive Expiratory Pressure Technique
470666|NCT00817180|high frequency Chest Wall Oscillation
470667|NCT00817180|vest
470668|NCT00817167|Known or suspected lung disease
470669|NCT00817167|Candidates for non-emergency bronchoscopy
470670|NCT00817154|Older persons with SMI
470671|NCT00817128|Complex Regional Pain Syndrome Type I
470672|NCT00817128|Sympathetic Reflex Dystrophy
470673|NCT00817128|Pain Exposure Physical Therapy
470674|NCT00817128|Pharmacological treatment
470675|NCT00817128|Functional recovery
470676|NCT00817115|Region-of-Interest Imaging
470677|NCT00817115|X-ray Fovea Imaging
470678|NCT00817115|Cardiovascular Diseases
470679|NCT00817115|Radiation Dosage
470680|NCT00817115|Radiographic Image Enhancement
470681|NCT00817115|Radiography, Interventional
470682|NCT00817102|coronary artery stenoses
470683|NCT00817063|retinoid treatment
470684|NCT00817063|fingertip dermatitis
470685|NCT00817063|hyperkeratotic hand eczema
470686|NCT00817063|vesicular hand eczema
470687|NCT00817063|pompholyx
470688|NCT00817037|Chronic kidney disease
470689|NCT00817037|Proteinuria
470690|NCT00817037|Blood pressure
470691|NCT00817037|Arterial stiffness
470692|NCT00817037|Endothelin antagonist
470693|NCT00817037|Sitaxsentan
470694|NCT00817024|Coronary Heart Disease
470695|NCT00817024|PCI
470696|NCT00817024|Traditional Chinese Medicine
470697|NCT00817024|Quality of Life
470698|NCT00817011|depression
470699|NCT00817011|pharmacogenomics
470700|NCT00817011|antidepressant response
470701|NCT00817011|biological markers
470702|NCT00817011|clinical variables
470703|NCT00816998|Radius fractures
470704|NCT00816985|Female
470705|NCT00816985|Lymphedema
470706|NCT00816959|Lymphocytic Predominant Hodgkin's Lymphoma
470707|NCT00816959|Late, widespread and recurrent LPHD
470708|NCT00816946|malnutrition
470709|NCT00816946|growth
470710|NCT00816933|pain
470711|NCT00816933|operative times
470712|NCT00816933|complication
470713|NCT00816933|time to return for normal life
470714|NCT00816933|pain using VAS score
470715|NCT00816920|distal DVT
470716|NCT00816920|calf DVT
470717|NCT00816920|DVT diagnosis
470718|NCT00816920|management of patients with suspected leg DVT
470719|NCT00816907|Schizoaffective Disorder
470720|NCT00816894|schizophrenia
470721|NCT00816894|treatment resistance
470722|NCT00816894|D-serine
470723|NCT00816894|Olanzapine
470724|NCT00816894|treatment refractory schizophrenia
470725|NCT00816881|Pulmonary Disease, Chronic Obstructive
470726|NCT00816881|flutter
470727|NCT00816881|airway clearance
470728|NCT00816881|sputum
470729|NCT00816881|Physical Therapy Techniques
470730|NCT00816868|stage IIIB/IV adenocarcinoma non-small cell lung cancer
470731|NCT00816855|Phase 2 Clinical Trial
470732|NCT00816855|NPC
470733|NCT00816855|neoadjuvant chemotherapy
470734|NCT00816855|concurrent chemoradiation
470735|NCT00816842|citrulline
470736|NCT00816842|malabsorption
470737|NCT00816842|Villous atrophy
470738|NCT00816842|enteropathy
470739|NCT00816829|Dyslipidemia
470740|NCT00816829|Sleep Apnea Syndromes
470741|NCT00816829|Fenofibrate
470742|NCT00816829|Obese
470743|NCT00816829|Overweight or obese patients
470744|NCT00816816|Phase 2 Clinical Trial
470745|NCT00816816|NPC
470746|NCT00816816|neoadjuvant chemotherapy
470747|NCT00816816|concurrent chemoradiation
470748|NCT00816803|Spinal cord injury
470749|NCT00816790|Septic shock
470750|NCT00816790|Acute Renal Failure
470751|NCT00816790|Antimicrobial
470752|NCT00816790|Drug Dosing
470753|NCT00816790|Feasibility Study
470754|NCT00816777|Cancer
470755|NCT00816777|Carcinoma
470756|NCT00816777|Colon Cancer
470757|NCT00816777|Colorectal Cancer
470758|NCT00816777|Gastric Cancer
470759|NCT00816777|Gastrointestinal Cancer
470760|NCT00816777|Metastases
470761|NCT00816777|Metastatic Cancer
470762|NCT00816777|Metastatic Colorectal Cancer
470763|NCT00816777|Oncology
470764|NCT00816777|Rectal Cancer
470765|NCT00816764|clinical trial, phase 1
470766|NCT00816764|carcinoma
470767|NCT00816764|pharmacokinetics
470768|NCT00816764|safety
470769|NCT00816764|ovarian
470770|NCT00816751|Local anesthesia
470771|NCT00816751|Paracervical
470772|NCT00816751|Intracervical
470773|NCT00816751|Abortion
470774|NCT00816751|Pain
470775|NCT00816751|Local anesthesia for elective first trimester abortion
470776|NCT00816738|Nd: YAG laser
470777|NCT00816738|recurrent corneal erosions
470778|NCT00816738|trauma
470779|NCT00816738|anterior stromal puncture
470780|NCT00816725|Postnatal Depression
470781|NCT00816725|Cognitive Behavioral Therapy
470782|NCT00816725|Mood Management
470783|NCT00816725|Self-help
470784|NCT00816725|Internet
470785|NCT00816712|Males with low-normal serum total testosterone levels.
470786|NCT00816699|Anxiety
470787|NCT00816699|preprint anesthetic risk information
470788|NCT00816686|clinical trial, phase 1
470789|NCT00816686|carcinoma, advanced renal cell
470790|NCT00816686|kidney
470791|NCT00816686|pharmacokinetics
470792|NCT00816686|safety
470793|NCT00816686|AGS-16M18
470794|NCT00816673|Insomnia
470795|NCT00816673|Primary insomnia
470796|NCT00816673|sleep latency
470797|NCT00816673|non restorative sleep
470798|NCT00816673|sleep quality
470799|NCT00816673|Double-Blind
470800|NCT00816673|Placebo Controlled
470801|NCT00816673|Parallel-Group
470802|NCT00816673|Sleep Laboratory Study
470803|NCT00816647|Patella
470804|NCT00816647|Dislocation
470805|NCT00816647|Knee
470806|NCT00816647|Medial Patellofemoral Ligament
470807|NCT00816634|First line chemotherapy
470808|NCT00816634|Advanced or recurrent esophageal squamous cell carcinoma
470809|NCT00816621|Internationally Adopted Children
470810|NCT00816621|Adoption
470811|NCT00816621|Attachment
470812|NCT00816621|Inattention
470813|NCT00816621|Prevention
470814|NCT00816608|diabetes
470815|NCT00816608|prediabetes
470816|NCT00816608|impaired fasting glucose (IFG)
470817|NCT00816608|impaired glucose tolerance (IGT)
470818|NCT00816608|body weight
470819|NCT00816595|B-cell chronic lymphocytic leukemia
470820|NCT00816595|stage 0 chronic lymphocytic leukemia
470821|NCT00816595|stage I chronic lymphocytic leukemia
470822|NCT00816595|stage II chronic lymphocytic leukemia
470823|NCT00816595|stage III chronic lymphocytic leukemia
470824|NCT00816595|stage IV chronic lymphocytic leukemia
470825|NCT00816595|stage I small lymphocytic lymphoma
470826|NCT00816595|stage III small lymphocytic lymphoma
470827|NCT00816595|stage IV small lymphocytic lymphoma
470828|NCT00816595|contiguous stage II small lymphocytic lymphoma
470829|NCT00816595|noncontiguous stage II small lymphocytic lymphoma
470830|NCT00816582|Post-menopausal hormone receptor positive recurrent/metastatic breast cancer.
470831|NCT00816582|PET/CT
470832|NCT00816582|Recurrent or metastatic
470833|NCT00816569|Orthokeratology
470834|NCT00816569|Keratoconus
470835|NCT00816530|breast
470836|NCT00816530|breast cancer
470837|NCT00816530|breast screening
470838|NCT00816530|breast cancer screening
470839|NCT00816530|ultrasound
470840|NCT00816530|ultrasonography
470841|NCT00816530|mammogram
470842|NCT00816530|mammography
470843|NCT00816530|breast density
470844|NCT00816530|dense breasts
470845|NCT00816530|early detection
470846|NCT00816530|somo v
470847|NCT00816530|somo•v
470848|NCT00816530|U-Systems
470849|NCT00816530|Automated Breast Ultrasound
470850|NCT00816530|Ultrasonography, Mammary
470851|NCT00816530|Breast Neoplasms
470852|NCT00816530|Breast Density > 50% (BI-RADS III & IV)
470853|NCT00816517|Psoriasis
470854|NCT00816517|Botulinum toxin
470855|NCT00816504|FSGS
470856|NCT00816504|Permeability factor
470857|NCT00816504|Galactose
470858|NCT00816504|Primary FSGS, resistant to immunosuppressive medication
470859|NCT00816491|patient with long-standing UC
470860|NCT00816478|FSGS
470861|NCT00816478|Permeability factor
470862|NCT00816478|Galactose
470863|NCT00816478|Primary FSGS, resistant to immunosuppressive medication
470864|NCT00816465|Hoodia gordoni
470865|NCT00816465|NASH
470866|NCT00816465|NAFLD
470867|NCT00816452|Osteoporosis
470868|NCT00816452|Prostate Cancer
470869|NCT00816452|Osteoporosis in male with Prostate Cancer
470870|NCT00816439|Positron Emission Tomography
470871|NCT00816439|Brain Imaging
470872|NCT00816439|Alcoholism
470873|NCT00816426|Tuberculosis
470874|NCT00816426|Lesions
470875|NCT00816426|Pharmacokinetics
470876|NCT00816426|Maldistribution
470877|NCT00816426|Histopathology
470878|NCT00816413|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
470879|NCT00816413|adult acute myeloid leukemia with inv(16)(p13;q22)
470880|NCT00816413|adult acute myeloid leukemia with t(15;17)(q22;q12)
470881|NCT00816413|adult acute myeloid leukemia with t(16;16)(p13;q22)
470882|NCT00816413|adult acute myeloid leukemia with t(8;21)(q22;q22)
470883|NCT00816413|adult acute myeloid leukemia in remission
470884|NCT00816413|recurrent adult acute myeloid leukemia
470885|NCT00816413|secondary acute myeloid leukemia
470886|NCT00816413|adult acute lymphoblastic leukemia in remission
470887|NCT00816413|recurrent adult acute lymphoblastic leukemia
470888|NCT00816413|accelerated phase chronic myelogenous leukemia
470889|NCT00816413|blastic phase chronic myelogenous leukemia
470890|NCT00816413|chronic phase chronic myelogenous leukemia
470891|NCT00816413|relapsing chronic myelogenous leukemia
470892|NCT00816413|chronic myelomonocytic leukemia
470893|NCT00816413|de novo myelodysplastic syndromes
470894|NCT00816413|previously treated myelodysplastic syndromes
470895|NCT00816413|secondary myelodysplastic syndromes
470896|NCT00816413|essential thrombocythemia
470897|NCT00816413|polycythemia vera
470898|NCT00816413|primary myelofibrosis
470899|NCT00816413|stage III mantle cell lymphoma
470900|NCT00816413|stage IV mantle cell lymphoma
470901|NCT00816413|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
470902|NCT00816413|nodal marginal zone B-cell lymphoma
470903|NCT00816413|splenic marginal zone lymphoma
470904|NCT00816413|stage III adult lymphoblastic lymphoma
470905|NCT00816413|stage IV adult lymphoblastic lymphoma
470906|NCT00816413|aplastic anemia
470907|NCT00816413|chronic eosinophilic leukemia
470908|NCT00816413|chronic neutrophilic leukemia
470909|NCT00816413|contiguous stage II adult diffuse small cleaved cell lymphoma
470910|NCT00816413|noncontiguous stage II adult diffuse small cleaved cell lymphoma
470911|NCT00816413|stage I adult diffuse small cleaved cell lymphoma
470912|NCT00816413|stage III adult diffuse small cleaved cell lymphoma
470913|NCT00816413|stage IV adult diffuse small cleaved cell lymphoma
470914|NCT00816413|contiguous stage II grade 1 follicular lymphoma
470915|NCT00816413|contiguous stage II grade 2 follicular lymphoma
470916|NCT00816413|noncontiguous stage II grade 1 follicular lymphoma
470917|NCT00816413|noncontiguous stage II grade 2 follicular lymphoma
470918|NCT00816413|stage I grade 1 follicular lymphoma
470919|NCT00816413|stage I grade 2 follicular lymphoma
470920|NCT00816413|stage III grade 1 follicular lymphoma
470921|NCT00816413|stage III grade 2 follicular lymphoma
470922|NCT00816413|stage IV grade 1 follicular lymphoma
470923|NCT00816413|stage IV grade 2 follicular lymphoma
470924|NCT00816413|contiguous stage II marginal zone lymphoma
470925|NCT00816413|noncontiguous stage II marginal zone lymphoma
470926|NCT00816413|stage I marginal zone lymphoma
470927|NCT00816413|stage III marginal zone lymphoma
470928|NCT00816413|stage IV marginal zone lymphoma
470929|NCT00816413|contiguous stage II small lymphocytic lymphoma
470930|NCT00816413|noncontiguous stage II small lymphocytic lymphoma
470931|NCT00816413|stage I small lymphocytic lymphoma
470932|NCT00816413|stage III small lymphocytic lymphoma
470933|NCT00816413|stage IV small lymphocytic lymphoma
470934|NCT00816413|contiguous stage II mantle cell lymphoma
470935|NCT00816413|noncontiguous stage II mantle cell lymphoma
470936|NCT00816413|stage I mantle cell lymphoma
470937|NCT00816413|contiguous stage II adult lymphoblastic lymphoma
470938|NCT00816413|noncontiguous stage II adult lymphoblastic lymphoma
470939|NCT00816413|stage I adult lymphoblastic lymphoma
470940|NCT00816413|stage I chronic lymphocytic leukemia
470941|NCT00816413|stage II chronic lymphocytic leukemia
470942|NCT00816413|stage III chronic lymphocytic leukemia
470943|NCT00816413|stage IV chronic lymphocytic leukemia
470944|NCT00816374|cutaneous malignant melanoma
470945|NCT00816374|CMM
470946|NCT00816374|total cutaneous examination
470947|NCT00816374|TCE
470948|NCT00816374|skin self-examination
470949|NCT00816374|SSE
470950|NCT00816374|first degree relatives
470951|NCT00816374|FDR
470952|NCT00816374|skin cancer protection
470953|NCT00816374|skin cancer screening
470954|NCT00816348|Cholestasis
470955|NCT00816348|Parenteral Nutrition Associated Liver Disease
470956|NCT00816335|unspecified adult solid tumor, protocol specific
470957|NCT00816309|physiotherapy
470958|NCT00816309|bronchiectasis
470959|NCT00816296|NAFLD
470960|NCT00816296|Obesity
470961|NCT00816296|Microbiome
470962|NCT00816283|accelerated phase chronic myelogenous leukemia
470963|NCT00816283|blastic phase chronic myelogenous leukemia
470964|NCT00816283|relapsing chronic myelogenous leukemia
470965|NCT00816283|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
470966|NCT00816283|recurrent adult acute lymphoblastic leukemia
470967|NCT00816283|untreated adult acute lymphoblastic leukemia
470968|NCT00816270|Blepharoptosis
470969|NCT00816270|Dermatochalasis
470970|NCT00816270|octyl 2-cyanoacrylate
470971|NCT00816270|Suture Techniques
470972|NCT00816270|Tissue Adhesive
470973|NCT00816257|lung tissue repository
470974|NCT00816244|Breast cancer
470975|NCT00816244|Postmenopausal
470976|NCT00816244|Neo-adjuvant
470977|NCT00816244|Tumor proliferation
470978|NCT00816244|Statin
470979|NCT00816244|Atorvastatin
470980|NCT00816244|Ki67
470981|NCT00816244|Translational research
470982|NCT00816244|Cell cycle regulators
470983|NCT00816244|Gene expression
470984|NCT00816244|Genomic profiling
470985|NCT00816244|Apoptosis
470986|NCT00816244|Window-of-opportunity
470987|NCT00816231|Prevention Intervention
470988|NCT00816231|Alcohol
470989|NCT00816231|Tobacco
470990|NCT00816231|Nicotine
470991|NCT00816231|Craving
470992|NCT00816231|Cue Reactivity
470993|NCT00816231|Cross Cue Reactions
470994|NCT00816192|FA
470995|NCT00816192|Atrial fibrillation
470996|NCT00816192|Catheter
470997|NCT00816192|Ablation
470998|NCT00816192|RF
470999|NCT00816179|Pancreatic head mass
471000|NCT00816179|Pancreatic cancer
471001|NCT00816179|NOTES
471002|NCT00816179|Endoscopic peritoneoscopy
471003|NCT00816179|Whipple
471004|NCT00816179|palliative gastrojejunostomy
471005|NCT00816166|Ischemic stroke
471006|NCT00816166|Transient Ischemic Attack
471007|NCT00816166|Intracranial Stenting
471008|NCT00816153|Pleth variability Index
471009|NCT00816153|Fluid management
471010|NCT00816153|Fluid management during surgery
471011|NCT00816140|Helicobacter pylori
471012|NCT00816140|levofloxacin
471013|NCT00816140|clarithromycin
471014|NCT00816140|ERADICATION RATE
471015|NCT00816127|liver cirrhosis
471016|NCT00816127|coagulopathy
471017|NCT00816127|desmopressin
471018|NCT00816127|blood transfusion
471019|NCT00816114|Imatinib
471020|NCT00816114|Gleevec
471021|NCT00816114|Chronic Myelogenous Leukemia
471022|NCT00816114|CML
471023|NCT00816101|Curettage and electrodesiccation
471024|NCT00816101|acute wounds
471025|NCT00816101|partial thickness wounds
471026|NCT00816088|chemotherapy
471027|NCT00816088|Stem cell transplantation
471028|NCT00816075|distilled water
471029|NCT00816075|recurrent
471030|NCT00816075|bladder
471031|NCT00816075|mitomycin
471032|NCT00816062|Aortic Aneurysm
471033|NCT00816062|Aneurysm
471034|NCT00816062|Abdominal Aortic Aneurysm
471035|NCT00816062|Talent
471036|NCT00816062|Medtronic
471037|NCT00816049|acute lymphoblastic leukemia
471038|NCT00816049|child
471039|NCT00816049|6-mercaptopurine
471040|NCT00816049|minimal residual disease
471041|NCT00816049|efficacy
471042|NCT00816049|childhood acute lymphoblastic leukemia
471043|NCT00816036|Smoking Cessation
471044|NCT00816036|Practice Guidelines
471045|NCT00816036|Inpatient
471046|NCT00816036|Effectiveness Trial
471047|NCT00816036|Veterans Administration
471048|NCT00816036|Relapse prevention
471049|NCT00816010|drug compliance
471050|NCT00816010|lifestyle modification
471051|NCT00815997|radial artery
471052|NCT00815997|transradial intervention
471053|NCT00815997|stent
471054|NCT00815984|Asthma
471055|NCT00815984|Allergic Rhinitis
471056|NCT00815984|Atopic Dermatitis
471057|NCT00815984|Children
471058|NCT00815984|lung function
471059|NCT00815984|skin prick tests
471060|NCT00815984|FeNO
471061|NCT00815971|EGFR mutations
471062|NCT00815971|EGFR inhibitor
471063|NCT00815971|erlotinib
471064|NCT00815958|knee replacement surgery
471065|NCT00815958|Reamer-Irrigator-Aspirator
471066|NCT00815958|femoral reaming
471067|NCT00815958|fat embolism
471068|NCT00815945|leiomyosarcoma
471069|NCT00815945|carcinosarcoma
471070|NCT00815945|mixed epithelial mesenchymal tumor
471071|NCT00815945|endometrial stroma sarcomas
471072|NCT00815945|Müllerian mixed tumors
471073|NCT00815945|carcinosarcoma of the uterus
471074|NCT00815945|mesenchymal tumors of the ovary or uterus
471075|NCT00815945|mixed epithelial mesenchymal tumors of the ovary or uterus
471076|NCT00815919|cGVHD
471077|NCT00815919|Velcade
471078|NCT00815919|bortezomib
471079|NCT00815893|Dexmedetomidine
471080|NCT00815893|Fiberoptic nasal intubation
471081|NCT00815893|satisfaction
471082|NCT00815880|Heart Failure
471083|NCT00815880|Device
471084|NCT00815880|Implantable
471085|NCT00815880|Active
471086|NCT00815880|Class III and Class IV
471087|NCT00815880|Counterpulsation
471088|NCT00815867|kidney failure
471089|NCT00815867|kidney transplant
471090|NCT00815867|graft function
471091|NCT00815867|haemoglobin
471092|NCT00815867|epoetin
471093|NCT00815854|Antipsychotic
471094|NCT00815854|Metabolic Syndrome
471095|NCT00815854|Insulin Resistance
471096|NCT00815854|Endothelial Function
471097|NCT00815841|Determine the effect of MPH on a diagnostic continuous performance task that assesses attention and on a decision making test in young healthy adults
471098|NCT00815828|Gestational Diabetes
471099|NCT00815828|Resistance Exercise
471100|NCT00815828|Pregnancy
471101|NCT00815828|Insulin
471102|NCT00815815|Anorexia Nervosa
471103|NCT00815802|Children in day care centers
471104|NCT00815802|cytomegalovirus excretion
471105|NCT00815776|Temporomandibular disorders
471106|NCT00815763|randomized trial
471107|NCT00815763|ischemic stroke
471108|NCT00815763|Ginsenoside-Rd
471109|NCT00815750|Prostate Cancer
471110|NCT00815737|Lung Infection After Cerebral Hemorrhage
471111|NCT00815737|Prevention of Pneumonia
471112|NCT00815737|Rhubarb
471113|NCT00815724|Daily Inhaled Corticosteroids
471114|NCT00815724|Distributed Learning
471115|NCT00815724|E-learning
471116|NCT00815711|IPF
471117|NCT00815698|pain
471118|NCT00815685|n-3 fatty acids
471119|NCT00815685|nutritional treatment
471120|NCT00815685|molecular pathogenesis
471121|NCT00815672|Exercise
471122|NCT00815672|Prostate cancer
471123|NCT00815672|Fatigue
471124|NCT00815659|plasma lipid profile
471125|NCT00815659|metabolic syndrome
471126|NCT00815646|Immersion pulmonary edema
471127|NCT00815646|Diving
471128|NCT00815646|Swimming
471129|NCT00815646|Pulmonary edema
471130|NCT00815646|Cold water immersion
471131|NCT00815633|PRP
471132|NCT00815633|Pityriasis Rubra Pilaris
471133|NCT00815633|Amevive
471134|NCT00815633|Alefacept
471135|NCT00815633|Biologic
471136|NCT00815633|Immunosuppressant
471137|NCT00815633|Severe skin disease
471138|NCT00815620|neuroendocrine tumors
471139|NCT00815620|transcatheter arterial chemoembolization
471140|NCT00815620|selective internal radiotherapy
471141|NCT00815620|surgery
471142|NCT00815620|radio-frequency ablation
471143|NCT00815620|peptide-receptor radiotherapy
471144|NCT00815620|progression-free survival
471145|NCT00815620|quality of life
471146|NCT00815620|overall survival
471147|NCT00815620|weight
471148|NCT00815620|time of hospitalization
471149|NCT00815607|melanoma
471150|NCT00815607|biologic
471151|NCT00815607|immunotherapy
471152|NCT00815607|cancer
471153|NCT00815594|bleb
471154|NCT00815594|vascular change
471155|NCT00815594|bevacizumab
471156|NCT00815594|trabeculectomy
471157|NCT00815594|Bleb vascularity associated with increased scarring activity
471158|NCT00815594|Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery
471159|NCT00815594|the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
471160|NCT00814905|chorioamnionitis
471161|NCT00814905|antibiotics
471162|NCT00814905|cesarean
471163|NCT00814905|vaginal delivery
471164|NCT00814892|adenocarcinoma of the prostate
471165|NCT00814892|recurrent prostate cancer
471166|NCT00814892|stage I prostate cancer
471167|NCT00814892|stage IIB prostate cancer
471168|NCT00814892|stage IIA prostate cancer
471169|NCT00814892|stage III prostate cancer
471170|NCT00814892|stage IV prostate cancer
471171|NCT00814879|Acquired Immune Deficiency Syndrome
471172|NCT00814879|AIDS
471173|NCT00814879|Anti-Infective Agents
471174|NCT00814879|Antiretroviral
471175|NCT00814879|Antiviral Agents
471176|NCT00814879|Atazanavir
471177|NCT00814879|Human Immunodeficiency Virus
471178|NCT00814879|HIV
471179|NCT00814879|HIV Protease Inhibitors
471180|NCT00814879|NRTI
471181|NCT00814879|Nucleoside Reverse Transcriptase Inhibitors
471182|NCT00814879|Raltegravir
471183|NCT00814879|Resistance
471184|NCT00814879|treatment experienced
471185|NCT00814866|Rheumatoid arthritis
471186|NCT00814866|arthritis
471187|NCT00814866|osteoclasts
471188|NCT00814866|bone
471189|NCT00814853|Extubation
471190|NCT00814853|testing
471191|NCT00814853|ventilator weaning
471192|NCT00814853|Pediatric extubation
471193|NCT00814840|Heart failure
471194|NCT00814840|Dyssynchrony
471195|NCT00814840|Cardiac resynchronization
471196|NCT00814840|Triple-site pacing
471197|NCT00814827|Interferon-Gamma
471198|NCT00814827|Autoantibodies
471199|NCT00814827|Mycobacteria
471200|NCT00814827|Opportunistic Infections
471201|NCT00814827|Immunodeficiency
471202|NCT00814801|Alzheimer's Disease
471203|NCT00814801|Cognitive dysfunction
471204|NCT00814801|Dementia
471205|NCT00814801|Galantamine
471206|NCT00814801|R113675
471207|NCT00814788|stage IV prostate cancer
471208|NCT00814788|adenocarcinoma of the prostate
471209|NCT00814788|recurrent prostate cancer
471210|NCT00814775|Laryngeal mask
471211|NCT00814775|Difficult intubation
471212|NCT00814762|immunogenicity
471213|NCT00814762|HIV
471214|NCT00814762|reactogenicity
471215|NCT00814762|safety
471216|NCT00814762|vaccine
471217|NCT00814762|HIV Infections
471218|NCT00814749|stress urinary incontinence
471219|NCT00814749|urodynamics
471220|NCT00814749|randomized clinical trial
471221|NCT00814749|surgery
471222|NCT00814710|Pneumococcal disease
471223|NCT00814710|Pneumococcal vaccine
471224|NCT00814710|Safety
471225|NCT00814710|Primary vaccination
471226|NCT00814710|Immunogenicity
471227|NCT00814697|Alzheimer
471228|NCT00814697|Language
471229|NCT00814697|Treatment
471230|NCT00814697|TMS
471231|NCT00814697|rTMS
471232|NCT00814671|Tuberculosis
471233|NCT00814671|Pharmacokinetics
471234|NCT00814658|Dementia
471235|NCT00814658|Mixed Dementia
471236|NCT00814658|Galantamine
471237|NCT00814658|Reminyl ER
471238|NCT00814658|Nimodipine
471239|NCT00815581|children between 1 to 10 years old
471240|NCT00815581|amblyopy
471241|NCT00815568|fludarabine
471242|NCT00815568|busulfan
471243|NCT00815568|total body irradiation
471244|NCT00815568|conditioning regimen
471245|NCT00815555|receptor positive breast cancer
471246|NCT00815555|Tamoxifen treatment
471247|NCT00815555|CYP2D6 status
471248|NCT00815555|relapse
471249|NCT00815529|Acupuncture
471250|NCT00815529|Chronic low back pain
471251|NCT00815529|Qualitative study
471252|NCT00815516|candidiasis
471253|NCT00815516|candida
471254|NCT00815516|Neonate
471255|NCT00815516|candidemia
471256|NCT00815516|Micafungin
471257|NCT00815516|Mycamine
471258|NCT00815516|amphotericin B deoxycholate
471259|NCT00815503|Anesthetics
471260|NCT00815503|Local infiltration
471261|NCT00815503|Periacetabular osteotomy
471262|NCT00815490|Spectroscopy, near infrared
471263|NCT00815490|Oximetry
471264|NCT00815490|Hypoxemia
471265|NCT00815490|Tissue oxygenation
471266|NCT00815464|Chronic Hepatitis B
471267|NCT00815464|Liquid Acupuncture(Herb Acupoint Injection)
471268|NCT00815464|Therapeutics
471269|NCT00815464|Herbalist
471270|NCT00815464|Acupoint
471271|NCT00815438|Transvaginal
471272|NCT00815438|Cholecystectomy
471273|NCT00815438|NOTES
471274|NCT00815438|Endoscopic
471275|NCT00815425|African American
471276|NCT00815386|mitral valve
471277|NCT00815386|heart failure
471278|NCT00815386|mitral regurgitation
471279|NCT00815386|annuloplasty
471280|NCT00815386|coronary sinus
471281|NCT00815373|Ocular Blood flow
471282|NCT00815373|Ocular hypertension
471283|NCT00815373|POAG
471284|NCT00815373|Ocular hemodynamics
471285|NCT00815373|Xalacom
471286|NCT00815373|Cosopt
471287|NCT00815360|diabetic macular edema
471288|NCT00815347|Asthma
471289|NCT00815334|vesicoureteral reflux
471290|NCT00815334|low compliant bladder
471291|NCT00815321|chronic myeloid leukemia
471292|NCT00815321|autologous cytokine induced killer cells
471293|NCT00815321|Chronic myeloid leukemia in blast crisis treated with chemotherapy or kinase inhibitors
471294|NCT00815321|Chronic myeloid leukemia with mutation resistant to kinase inhibitors
471295|NCT00815321|chronic myeloid leukemia with good response to kinase inhibitor and stable persistence of residual disease
471296|NCT00815308|Therapeutic
471297|NCT00815308|Drug Therapy, combination
471298|NCT00815308|Radiotherapy
471299|NCT00815295|squamous cell cancer, head and neck
471300|NCT00815269|Inhalant anesthetic
471301|NCT00815269|Vasodilation
471302|NCT00815269|General anesthesia
471303|NCT00815269|Ultrasonography
471304|NCT00815256|Cornea degeneration
471305|NCT00815256|keratoconus
471306|NCT00815256|collagen cross linking
471307|NCT00815256|CXL
471308|NCT00815256|Riboflavin
471309|NCT00815243|fracture
471310|NCT00815243|coxarthrosis
471311|NCT00815243|complication
471312|NCT00815243|congenital abnormalities
471313|NCT00815243|bone
471314|NCT00815243|joint
471315|NCT00815243|telemedicine
471316|NCT00815243|transportation
471317|NCT00815243|decision making
471318|NCT00815243|outcomes
471319|NCT00815230|radiation injury
471320|NCT00815230|computed tomography
471321|NCT00815230|reactive oxygen species
471322|NCT00815230|free radicals
471323|NCT00815217|Lipoaspirate
471324|NCT00815217|Diabetes Mellitus
471325|NCT00815217|Mesenchymal Stem cells
471326|NCT00815217|Fat grafts
471327|NCT00815217|venous stasis
471328|NCT00815204|PTSD
471329|NCT00815204|HPA axis
471330|NCT00815204|Pituitary volume
471331|NCT00815191|temperature
471332|NCT00815191|surgery
471333|NCT00815191|heating device
471334|NCT00815178|inspiratory muscle weakness
471335|NCT00815178|autonomic modulation
471336|NCT00815178|diabetes mellitus
471337|NCT00815178|heart rate variability
471338|NCT00815178|functional capacity
471339|NCT00815165|cytomegalovirus, CMV, cell-mediated immunity, children, sub-study
471340|NCT00815152|high grade glioma
471341|NCT00815152|Coping skills intervention
471342|NCT00815152|caregivers
471343|NCT00815139|Coronary artery disease, stent
471344|NCT00815113|Gastric cancer
471345|NCT00815113|screening
471346|NCT00815113|high-risk
471347|NCT00815113|relatives
471348|NCT00815113|gastroscopy
471349|NCT00815100|Ivabradine
471350|NCT00815100|Acute coronary syndrome.
471351|NCT00815100|Inflammation
471352|NCT00815100|C-reactive protein
471353|NCT00815100|Atherosclerosis
471354|NCT00815087|Nasopharyngeal carcinoma
471355|NCT00815087|functional electrical stimulation
471356|NCT00815074|Military Women
471357|NCT00815074|Women's Health
471358|NCT00815074|Genitourinary Symptoms
471359|NCT00815074|Illness Behaviors
471360|NCT00815074|To determine how women manage genitourinary symptoms while deployed.
471361|NCT00815061|prevalence
471362|NCT00815061|Incidence
471363|NCT00815061|crohn's disease
471364|NCT00815061|ulcerative colitis
471365|NCT00815061|Epidemiology
471366|NCT00815048|Remifentanil
471367|NCT00815048|Endotracheal intubation
471368|NCT00815048|Premedication
471369|NCT00815048|Sedation
471370|NCT00815048|Endotracheal Intubation in Neonates
471371|NCT00815035|Peanut Allergy
471372|NCT00815022|Temperature
471373|NCT00815022|Spinal anesthesia
471374|NCT00815022|Cesarean section
471375|NCT00815022|Cephalad sensory blockade
471376|NCT00815022|Regional anesthesia
471377|NCT00815009|NAFLD
471378|NCT00815009|NASH
471379|NCT00814983|myeloablative
471380|NCT00814983|stem cell
471381|NCT00814983|naive T-cell depleted
471382|NCT00814983|allogeneic
471383|NCT00814970|PAD
471384|NCT00814970|peripheral arterial disease
471385|NCT00814970|stent
471386|NCT00814970|SFA
471387|NCT00814970|PPA
471388|NCT00814957|positron emission tomography
471389|NCT00814957|addiction
471390|NCT00814944|dry eye
471391|NCT00814944|sirolimus
471392|NCT00814944|rapamycin
471393|NCT00814918|acne vulgaris
471394|NCT00814918|acne
471395|NCT00814918|dermatalogy
471396|NCT00814632|vulvodynia
471397|NCT00814632|pelvic pain
471398|NCT00814632|vulvar pain
471399|NCT00814619|adenocarcinoma of the rectum
471400|NCT00814619|stage III rectal cancer
471401|NCT00814619|stage II rectal cancer
471402|NCT00814606|genotype 1 hepatitis C
471403|NCT00814606|hepatitis C
471404|NCT00814606|HCV
471405|NCT00814606|liver
471406|NCT00814593|adult giant cell glioblastoma
471407|NCT00814593|adult gliosarcoma
471408|NCT00814593|adult glioblastoma
471409|NCT00814580|analgesia
471410|NCT00814580|postoperative pain
471411|NCT00814580|opioid
471412|NCT00814580|rotator cuff repair
471413|NCT00814580|labral tear repair
471414|NCT00814580|Bankart procedure
471415|NCT00814580|oxycodone
471416|NCT00814580|tapentadol
471417|NCT00814580|arthroscopic shoulder surgery
471418|NCT00814567|recurrent breast cancer
471419|NCT00814567|stage IA breast cancer
471420|NCT00814567|stage II breast cancer
471421|NCT00814567|invasive ductal breast carcinoma
471422|NCT00814567|invasive ductal breast carcinoma with predominant intraductal component
471423|NCT00814554|obesity
471424|NCT00814554|nutrition
471425|NCT00814554|cluster randomized trial
471426|NCT00814554|high school
471427|NCT00814554|primary prevention
471428|NCT00814541|refractory multiple myeloma
471429|NCT00814541|stage I multiple myeloma
471430|NCT00814541|stage II multiple myeloma
471431|NCT00814541|stage III multiple myeloma
471432|NCT00814528|actinic keratosis
471433|NCT00814528|skin lesions
471434|NCT00814528|5-ALA
471435|NCT00814528|AK
471436|NCT00814528|Blu-Light
471437|NCT00814515|Moderate
471438|NCT00814515|Severe
471439|NCT00814515|Dry
471440|NCT00814515|Eye
471441|NCT00814515|Ciclosporin
471442|NCT00814515|Cyclosporine
471443|NCT00814502|Alzheimer disease
471444|NCT00814502|Dementia, vascular
471445|NCT00814502|Actigraphy
471446|NCT00814502|Circadian dysregulation
471447|NCT00814502|Sleep Disorders
471448|NCT00814502|Circadian rhythm
471449|NCT00814489|Non-typable Haemophilus influenzae
471450|NCT00814489|protein vaccine
471451|NCT00814489|Streptococcus pneumoniae
471452|NCT00814489|young adults
471453|NCT00814476|Medtronic CareLink
471454|NCT00814476|therapy management
471455|NCT00814476|diabetes
471456|NCT00814476|insulin pump
471457|NCT00814476|Blood glucose monitor
471458|NCT00814463|tumors metastatic to brain
471459|NCT00814463|unspecified adult solid tumor, protocol specific
471460|NCT00814450|Biopsy
471461|NCT00814450|Fine needle aspiration
471462|NCT00814424|EtCO2
471463|NCT00814424|supplemental oxygen delivery
471464|NCT00814424|ERCP
471465|NCT00814411|contraception
471466|NCT00814411|noninferiority
471467|NCT00814411|intention
471468|NCT00814411|family planning counseling
471469|NCT00814411|post abortion care
471470|NCT00814411|Family planning intention among women with unmet need
471471|NCT00814398|Infertility
471472|NCT00814398|IVF
471473|NCT00814398|SET
471474|NCT00814398|DET
471475|NCT00814398|Blastocyst
471476|NCT00814359|mucositis
471477|NCT00814359|radiation
471478|NCT00814359|magic mouthwash
471479|NCT00814359|sucralfate
471480|NCT00814359|benzydamine
471481|NCT00814359|diphenhydramine
471482|NCT00814359|dexamethasone
471483|NCT00814359|nystatin
471484|NCT00814346|Mild Alzheimer's disease (AD) patients
471485|NCT00814346|Memory complaint patients with cognitive impairment (MC)
471486|NCT00814346|Memory complaint patients cognitively normal (CNE)
471487|NCT00814333|epistaxis
471488|NCT00814307|Antirheumatic Agents Clinical Trial
471489|NCT00814294|Type 2
471490|NCT00814281|particulate air pollution
471491|NCT00814281|leukotriene
471492|NCT00814281|asthma
471493|NCT00814281|montelukast
471494|NCT00814281|vascular endothelial dysfunction
471495|NCT00814281|nitric oxide(NO)endothelin (ET) system
471496|NCT00814255|Primary FSGS
471497|NCT00814255|Steroid Resistant
471498|NCT00814255|Rosiglitazone
471499|NCT00814255|Adalimumab
471500|NCT00814255|Resistant primary FSGS
471501|NCT00814255|GALACTOSE
471502|NCT00814242|Hepatocellular Carcinoma
471503|NCT00814242|Adjacent to Major Blood Vessels
471504|NCT00814242|Surgical resection
471505|NCT00814242|Ppercutaneous radiationfrequency ablation
471506|NCT00814242|Time to recurrence
471507|NCT00814242|Disease-free survival
471508|NCT00814242|Overall survival
471509|NCT00814229|influenza
471510|NCT00814229|H9N2
471511|NCT00814229|vaccine
471512|NCT00814216|Efficacy
471513|NCT00814216|safety
471514|NCT00814216|QAV680
471515|NCT00814216|pharmacokinetics
471516|NCT00814216|corticosteroid
471517|NCT00814216|asthma
471518|NCT00814203|COPD
471519|NCT00814190|Type 2 Diabetes
471520|NCT00814190|Internet Therapeutic Intervention
471521|NCT00814177|warfarin
471522|NCT00814177|dosing
471523|NCT00814177|prothrombin time
471524|NCT00814177|Heart valve prosthesis
471525|NCT00814164|adult erythroleukemia (M6a)
471526|NCT00814164|adult pure erythroid leukemia (M6b)
471527|NCT00814164|adult acute megakaryoblastic leukemia (M7)
471528|NCT00814164|adult acute minimally differentiated myeloid leukemia (M0)
471529|NCT00814164|adult acute monoblastic leukemia (M5a)
471530|NCT00814164|adult acute monocytic leukemia (M5b)
471531|NCT00814164|adult acute myeloblastic leukemia with maturation (M2)
471532|NCT00814164|adult acute myeloblastic leukemia without maturation (M1)
471533|NCT00814164|adult acute myelomonocytic leukemia (M4)
471534|NCT00814164|untreated adult acute myeloid leukemia
471535|NCT00814164|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
471536|NCT00814164|adult acute myeloid leukemia with inv(16)(p13;q22)
471537|NCT00814164|adult acute myeloid leukemia with t(16;16)(p13;q22)
471538|NCT00814164|adult acute myeloid leukemia with t(8;21)(q22;q22)
471539|NCT00814164|secondary acute myeloid leukemia
471540|NCT00814151|Blood culture
471541|NCT00814151|Staphylococcus aureus
471542|NCT00814151|Bacteremia
471543|NCT00814151|MRSA
471544|NCT00814151|MSSA
471545|NCT00814151|MicroPhage
471546|NCT00814138|myasthenia gravis
471547|NCT00814125|Endometrial
471548|NCT00814125|Endometrial histological findings
471549|NCT00814099|Acute Respiratory Failure
471550|NCT00814099|Acute Lung Injury
471551|NCT00814073|Mastocytosis with handicap
471552|NCT00814073|Mastocytosis
471553|NCT00814073|Smouldering systemic mastocytosis
471554|NCT00814073|Indolent systemic mastocytosis
471555|NCT00814073|Cutaneous mastocytosis
471556|NCT00814073|Mast cell
471557|NCT00814073|Mast cell infiltration
471558|NCT00814073|Skin
471559|NCT00814073|Bone marrow
471560|NCT00814073|Pruritus
471561|NCT00814073|Flushes
471562|NCT00814073|c-kit
471563|NCT00814073|c-kit mutation
471564|NCT00814073|Wild Type
471565|NCT00814073|Mutation Asp-816-Val(D816V)
471566|NCT00814047|ultrasonography
471567|NCT00814034|Aromatase Inhibitors
471568|NCT00814034|Coagulation parameters
471569|NCT00814034|Tamoxifen
471570|NCT00814021|recurrent renal cell cancer
471571|NCT00814021|stage IV renal cell cancer
471572|NCT00814021|tumors metastatic to brain
471573|NCT00813969|Mesenchymal Stem Cell
471574|NCT00813969|MSC
471575|NCT00813969|Autologous
471576|NCT00813969|Multiple Sclerosis
471577|NCT00813956|triple negative breast cancer
471578|NCT00813943|Newly diagnosed Glioblastoma (WHO Grade IV)
471579|NCT00813943|Cilengitide
471580|NCT00813943|Temozolomide
471581|NCT00813943|Radiotherapy
471582|NCT00813930|Diabetes
471583|NCT00813930|Lifestyle Intervention
471584|NCT00813930|Cardiovascular risk reduction
471585|NCT00813891|ranibizumab
471586|NCT00813891|verteporfin
471587|NCT00813878|breast cancer
471588|NCT00813878|breast cancer in situ
471589|NCT00813852|obstructive sleep apnea
471590|NCT00813852|skeletal muscle
471591|NCT00813852|magnetic stimulation
471592|NCT00813852|magnetic resonance spectroscopy
471593|NCT00813852|inflammatory markers
471594|NCT00813852|exercise
471595|NCT00813839|SmartCare
471596|NCT00813839|Spontaneous Breathing Trials
471597|NCT00813839|Mechanical Ventilation
471598|NCT00813839|Weaning
471599|NCT00813839|Patients requiring prolonged mechanical ventilation (>72 hours)
471600|NCT00813826|PHN
471601|NCT00813826|Pain after Shingles
471602|NCT00813800|Smoking
471603|NCT00813800|Bipolar Disorder
471604|NCT00813800|Depression
471605|NCT00813787|Magnetic Resonance Imaging
471606|NCT00813787|Glioma
471607|NCT00813774|Cimzia
471608|NCT00813774|certolizumab pegol
471609|NCT00813774|Bioavailability
471610|NCT00813774|Healthy volunteers
471611|NCT00813748|Asthma
471612|NCT00813748|Anaphylaxis
471613|NCT00813735|Insomnia
471614|NCT00813735|Major Depression
471615|NCT00813735|Geriatric
471616|NCT00813722|adherence
471617|NCT00813722|blood pressure
471618|NCT00813722|hypertension
471619|NCT00813722|compliance
471620|NCT00813722|atenolol
471621|NCT00813722|hydrochlorothiazide
471622|NCT00813722|amlodipine
471623|NCT00813722|losartan
471624|NCT00813709|Interferon 1-beta
471625|NCT00813709|Clinical Definite Multiple Sclerosis
471626|NCT00813696|chemotherapy
471627|NCT00813696|advanced cancer
471628|NCT00813696|inoperable
471629|NCT00813696|Stage II, III, IV
471630|NCT00813683|Acupuncture, moxybustion,
471631|NCT00813683|Cephalic version,
471632|NCT00813683|Breech presentation
471633|NCT00813631|Malignant fungating wound
471634|NCT00813631|Head and neck
471635|NCT00813631|Ionic silver-releasing dressing
471636|NCT00813631|Wound care
471637|NCT00813631|RCT
471638|NCT00813618|Acute GvHD of at least Grade II severity
471639|NCT00813605|AMG 655
471640|NCT00813605|AMG 479
471641|NCT00813605|Colon Cancer
471642|NCT00813605|Rectal Cancer
471643|NCT00813605|Monoclonal Antibody
471644|NCT00813605|Clinical Trial
471645|NCT00813605|Colorectal Cancer
471646|NCT00813605|metastatic colorectal cancer
471647|NCT00813605|metastatic cancer
471648|NCT00813605|antibody-2nd line
471649|NCT00813605|KRAS
471650|NCT00813605|adenocarcinoma
471651|NCT00813592|meningioma
471652|NCT00813592|brain
471653|NCT00813579|assess the safety of living kidney donation
471654|NCT00813566|cancer
471655|NCT00813566|imaging
471656|NCT00813566|PET scanning
471657|NCT00813553|physical fitness
471658|NCT00813553|exercise
471659|NCT00813553|amino acid
471660|NCT00813540|Colonic Neoplasms
471661|NCT00813540|Aerobic Exercise
471662|NCT00813540|Weight Lifting
471663|NCT00813540|Body Composition
471664|NCT00813527|Drug Therapy
471665|NCT00813527|Lipid Metabolism Disorders
471666|NCT00813527|Hyperlipidemias
471667|NCT00813527|Hypercholesterolemia
471668|NCT00813527|Hypertriglyceridemia
471669|NCT00813514|AMD
471670|NCT00813514|VEGF genotyping
471671|NCT00813514|complement H gene polymorphism
471672|NCT00813514|Vascular Endothelial Growth Factor A
471673|NCT00813501|graft versus host disease
471674|NCT00813501|infection
471675|NCT00813501|therapy-related toxicity
471676|NCT00813501|stage III adult Burkitt lymphoma
471677|NCT00813501|stage III adult diffuse large cell lymphoma
471678|NCT00813501|stage III adult diffuse mixed cell lymphoma
471679|NCT00813501|stage III adult diffuse small cleaved cell lymphoma
471680|NCT00813501|stage III adult Hodgkin lymphoma
471681|NCT00813501|stage III adult immunoblastic large cell lymphoma
471682|NCT00813501|stage III adult lymphoblastic lymphoma
471683|NCT00813501|stage III grade 1 follicular lymphoma
471684|NCT00813501|stage III grade 2 follicular lymphoma
471685|NCT00813501|stage III grade 3 follicular lymphoma
471686|NCT00813501|stage III mantle cell lymphoma
471687|NCT00813501|stage III marginal zone lymphoma
471688|NCT00813501|stage III small lymphocytic lymphoma
471689|NCT00813501|stage IV adult Burkitt lymphoma
471690|NCT00813501|stage IV adult diffuse large cell lymphoma
471691|NCT00813501|stage IV adult diffuse mixed cell lymphoma
471692|NCT00813501|stage IV adult diffuse small cleaved cell lymphoma
471693|NCT00813501|stage IV adult Hodgkin lymphoma
471694|NCT00813501|stage IV adult immunoblastic large cell lymphoma
471695|NCT00813501|stage IV adult lymphoblastic lymphoma
471696|NCT00813501|stage IV grade 1 follicular lymphoma
471697|NCT00813501|stage IV grade 2 follicular lymphoma
471698|NCT00813501|stage IV grade 3 follicular lymphoma
471699|NCT00813501|stage IV mantle cell lymphoma
471700|NCT00813501|stage IV marginal zone lymphoma
471701|NCT00813501|stage IV small lymphocytic lymphoma
471702|NCT00813501|recurrent adult Burkitt lymphoma
471703|NCT00813501|recurrent adult diffuse large cell lymphoma
471704|NCT00813501|recurrent adult diffuse mixed cell lymphoma
471705|NCT00813501|recurrent adult diffuse small cleaved cell lymphoma
471706|NCT00813501|recurrent adult Hodgkin lymphoma
471707|NCT00813501|recurrent adult immunoblastic large cell lymphoma
471708|NCT00813501|recurrent adult lymphoblastic lymphoma
471709|NCT00813501|recurrent cutaneous T-cell non-Hodgkin lymphoma
471710|NCT00813501|recurrent grade 1 follicular lymphoma
471711|NCT00813501|recurrent grade 2 follicular lymphoma
471712|NCT00813501|recurrent grade 3 follicular lymphoma
471713|NCT00813501|recurrent mantle cell lymphoma
471714|NCT00813501|recurrent marginal zone lymphoma
471715|NCT00813501|recurrent small lymphocytic lymphoma
471716|NCT00813501|recurrent mycosis fungoides/Sezary syndrome
471717|NCT00813501|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
471718|NCT00813501|nodal marginal zone B-cell lymphoma
471719|NCT00813501|splenic marginal zone lymphoma
471720|NCT00813501|noncontiguous stage II adult Burkitt lymphoma
471721|NCT00813501|noncontiguous stage II adult diffuse large cell lymphoma
471722|NCT00813501|noncontiguous stage II adult diffuse mixed cell lymphoma
471723|NCT00813501|noncontiguous stage II adult diffuse small cleaved cell lymphoma
471724|NCT00813501|noncontiguous stage II adult immunoblastic large cell lymphoma
471725|NCT00813501|noncontiguous stage II adult lymphoblastic lymphoma
471726|NCT00813501|noncontiguous stage II grade 1 follicular lymphoma
471727|NCT00813501|noncontiguous stage II grade 2 follicular lymphoma
471728|NCT00813501|noncontiguous stage II grade 3 follicular lymphoma
471729|NCT00813501|noncontiguous stage II mantle cell lymphoma
471730|NCT00813501|noncontiguous stage II marginal zone lymphoma
471731|NCT00813501|noncontiguous stage II small lymphocytic lymphoma
471732|NCT00813501|accelerated phase chronic myelogenous leukemia
471733|NCT00813501|adult acute lymphoblastic leukemia in remission
471734|NCT00813501|adult acute myeloid leukemia in remission
471735|NCT00813501|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
471736|NCT00813501|adult acute myeloid leukemia with inv(16)(p13;q22)
471737|NCT00813501|adult acute myeloid leukemia with t(15;17)(q22;q12)
471738|NCT00813501|adult acute myeloid leukemia with t(16;16)(p13;q22)
471739|NCT00813501|adult acute myeloid leukemia with t(8;21)(q22;q22)
471740|NCT00813501|atypical chronic myeloid leukemia, BCR-ABL negative
471741|NCT00813501|blastic phase chronic myelogenous leukemia
471742|NCT00813501|chronic myelomonocytic leukemia
471743|NCT00813501|chronic phase chronic myelogenous leukemia
471744|NCT00813501|recurrent adult acute lymphoblastic leukemia
471745|NCT00813501|recurrent adult acute myeloid leukemia
471746|NCT00813501|refractory chronic lymphocytic leukemia
471747|NCT00813501|refractory hairy cell leukemia
471748|NCT00813501|relapsing chronic myelogenous leukemia
471749|NCT00813501|secondary acute myeloid leukemia
471750|NCT00813501|stage III chronic lymphocytic leukemia
471751|NCT00813501|stage IV chronic lymphocytic leukemia
471752|NCT00813501|chronic eosinophilic leukemia
471753|NCT00813501|primary myelofibrosis
471754|NCT00813501|chronic neutrophilic leukemia
471755|NCT00813501|de novo myelodysplastic syndromes
471756|NCT00813501|disseminated neuroblastoma
471757|NCT00813501|myelodysplastic/myeloproliferative neoplasm, unclassifiable
471758|NCT00813501|previously treated myelodysplastic syndromes
471759|NCT00813501|secondary myelodysplastic syndromes
471760|NCT00813501|stage I multiple myeloma
471761|NCT00813501|stage II multiple myeloma
471762|NCT00813501|stage III multiple myeloma
471763|NCT00813501|refractory multiple myeloma
471764|NCT00813488|Breakthrough Pain
471765|NCT00813488|Opioid-tolerant
471766|NCT00813488|Chronic Pain
471767|NCT00813475|cardio vascular outcome
471768|NCT00813449|Endostar
471769|NCT00813449|advanced melanoma
471770|NCT00813449|combined chemotherapy
471771|NCT00813436|ToM
471772|NCT00813436|Theory of Mind
471773|NCT00813436|Simulation
471774|NCT00813436|Empathy
471775|NCT00813436|Oxytocin
471776|NCT00813436|Schizophrenia
471777|NCT00813384|Cancer
471778|NCT00813384|Solid Tumors
471779|NCT00813384|Phase 1
471780|NCT00813384|C-met inhibitor
471781|NCT00813384|Clinical Trial
471782|NCT00813371|Acute Respiratory Distress Syndrome
471783|NCT00813371|acute lung injury
471784|NCT00813371|Airway Pressure Release Ventilation
471785|NCT00813371|ARDSnet
471786|NCT00813371|Bi-level
471787|NCT00813371|respiratory failure
471788|NCT00813371|trauma
471789|NCT00813371|APRV
471790|NCT00813358|Endovascular Aneurysm Repair
471791|NCT00813358|Aortic Aneurysm
471792|NCT00813358|Thoracic
471793|NCT00813345|anesthesia propofol ambulatory rhythm
471794|NCT00813332|Endostar
471795|NCT00813332|NSCLC
471796|NCT00813332|Docetaxel
471797|NCT00813332|Combined therapy
471798|NCT00813332|second-line chemotherapy
471799|NCT00813319|GARDASIL
471800|NCT00813319|HPV
471801|NCT00813319|Vaccination
471802|NCT00813306|GERD
471803|NCT00813306|TLESR
471804|NCT00813306|reflux
471805|NCT00813293|Hepatocellular Cancer
471806|NCT00813293|HCC
471807|NCT00813293|Liver Cancer
471808|NCT00813293|radiofrequency ablation
471809|NCT00813293|RFA
471810|NCT00813293|sorafenib
471811|NCT00813293|nexavaar
471812|NCT00813293|liver directed therapy
471813|NCT00813293|interventional radiology
471814|NCT00813267|Mesenchymal Stem Cells
471815|NCT00813267|Osteonecrosis of the Femoral Head
471816|NCT00813254|Platinum-Resistant Ovarian Cancer
471817|NCT00813254|Platinum-based chemotherapy
471818|NCT00813254|Ovarian Cancer
471819|NCT00813254|Ovary
471820|NCT00813254|Epithelial ovarian cancer
471821|NCT00813254|Quality of Life
471822|NCT00813254|Cost Utility Analysis
471823|NCT00813254|Sexual functioning
471824|NCT00813254|Questionnaire
471825|NCT00813254|Caregiver
471826|NCT00813241|Ankylosing spondylitis,Rheumatoid Arthritis,Adenomatous Polyposis Coli,Osteoarthritis,Dysmenorrhoea,pharmacokinetic study
471827|NCT00813228|Immune Function
471828|NCT00813228|DDP-4
471829|NCT00813228|Sitagliptin
471830|NCT00813228|GLP-1
471831|NCT00813228|TGF Beta
471832|NCT00813215|Type 2 diabetes mellitus
471833|NCT00813215|Postprandial dysmetabolism
471834|NCT00813215|Postprandial inflammation
471835|NCT00813215|Relatives
471836|NCT00813215|Meal challenge
471837|NCT00813202|Nesiritide
471838|NCT00813202|Natrecor
471839|NCT00813202|Quanke
471840|NCT00813202|Acute Decompensated Heart Failure
471841|NCT00813189|glucocorticoid therapy
471842|NCT00813189|muscle function
471843|NCT00813189|growth hormone treatment
471844|NCT00813176|Obesity
471845|NCT00813176|One-Lung Ventilation
471846|NCT00813176|Anesthesia
471847|NCT00813176|Thoracic
471848|NCT00813176|One-lung ventilation in the morbidly obese patient
471849|NCT00813163|Phase II study
471850|NCT00813163|Second line
471851|NCT00813163|Pancreatic cancer
471852|NCT00813163|Metastatic
471853|NCT00813150|Multiple myeloma
471854|NCT00813150|Bortezomib
471855|NCT00813150|Dexamethasone
471856|NCT00813150|Cyclophosphamide
471857|NCT00813150|Oncology
471858|NCT00813137|Colorectal Cancer
471859|NCT00813137|chemotherapy
471860|NCT00813137|recombinant human endostatin
471861|NCT00813124|Chronic Myelogenous Leukemia
471862|NCT00813124|CML
471863|NCT00813124|Donor stem cell transplant
471864|NCT00813124|Allogeneic stem cell transplantation
471865|NCT00813124|Stem cell transplant
471866|NCT00813124|ATG
471867|NCT00813124|Antithymocyte globulin
471868|NCT00813124|Vidaza
471869|NCT00813124|Azacitidine
471870|NCT00813124|5-Azacitidine
471871|NCT00813124|5-Aza
471872|NCT00813124|5-AZC
471873|NCT00813124|Ladakamycin
471874|NCT00813124|NSC-102816
471875|NCT00813124|allotx
471876|NCT00813124|Busulfan
471877|NCT00813124|Busulfex
471878|NCT00813124|Myleran
471879|NCT00813124|Fludarabine
471880|NCT00813124|Fludarabine Phosphate
471881|NCT00813124|Tacrolimus
471882|NCT00813124|Methotrexate
471883|NCT00813124|Azacitidine maintenance therapy
471884|NCT00813124|molecular remission
471885|NCT00813124|HLA compatible donor
471886|NCT00813124|Engraftment
471887|NCT00813124|Chimerism
471888|NCT00813124|Graft vs host disease
471889|NCT00813124|GVHD
471890|NCT00813111|Postsurgical pain
471891|NCT00813111|Analgesia
471892|NCT00813111|Breast augmentation
471893|NCT00813085|Diabetes
471894|NCT00813085|Computerized clinical decision support
471895|NCT00813085|shared care
471896|NCT00813085|patient self-monitoring
471897|NCT00813085|quality of care
471898|NCT00813085|complex interventions
471899|NCT00813085|composite outcomes
471900|NCT00813072|Gastric Cancer
471901|NCT00813072|Stomach Cancer
471902|NCT00813072|Gastroesophageal
471903|NCT00813072|Gastroesophageal Junction
471904|NCT00813072|Esophageal Cancer
471905|NCT00813072|phase II
471906|NCT00813072|PEP02
471907|NCT00813072|randomization
471908|NCT00813072|randomisation
471909|NCT00813072|adenocarcinoma
471910|NCT00813072|locally advanced
471911|NCT00813072|metastatic
471912|NCT00813072|simon's two
471913|NCT00813059|NAION
471914|NCT00813059|bevacizumab
471915|NCT00813033|create a patient decision aid for endoscopy
471916|NCT00813033|evaluate efficacy of a patient decision aid for endoscopy
471917|NCT00813007|Cervical Cancer
471918|NCT00813007|Cervix
471919|NCT00813007|Questionnaire
471920|NCT00813007|Adenocarcinoma of uterine cervix
471921|NCT00813007|Squamous cell carcinoma of uterine cervix
471922|NCT00813007|Adenosquamous carcinoma of uterine cervix
471923|NCT00813007|Abdominal radical trachelectomy
471924|NCT00813007|Trachelectomy
471925|NCT00813007|Quality of life
471926|NCT00813007|Sexual functioning
471927|NCT00812994|Depression
471928|NCT00812994|BDNF
471929|NCT00812994|neurotrophic factor
471930|NCT00812994|neurosetroid
471931|NCT00812994|allopregnanolone
471932|NCT00812981|Pandemic influenza
471933|NCT00812968|Myelodysplastic Syndromes
471934|NCT00812968|Lenalidomide
471935|NCT00812955|Dyslipidemia
471936|NCT00812955|Hypercholesterolemia
471937|NCT00812955|Hypertriglyceridemia
471938|NCT00812942|average-risk subjects for
471939|NCT00812929|Asthma, Exercise Induced Asthma, Exercise Induced Bronchospasm
471940|NCT00812916|Persistent or longstanding persistent atrial fibrillation
471941|NCT00812903|Neck
471942|NCT00812903|Pain
471943|NCT00812903|Exercise
471944|NCT00812903|Pilots
471945|NCT00812903|Crew
471946|NCT00812877|pulp capping
471947|NCT00812877|MTA
471948|NCT00812877|CaOH
471949|NCT00812877|Mineral Trioxide Aggregate
471950|NCT00812877|Calcium Hydroxide
471951|NCT00812864|Capecitabine
471952|NCT00812864|pharmacocinetics
471953|NCT00812864|Breast metastatic cancer
471954|NCT00812864|colorectal metastatic cancer
471955|NCT00812864|Elderly patients
471956|NCT00812851|ALS
471957|NCT00812851|cramps
471958|NCT00812851|THC
471959|NCT00812851|Dronabinol
471960|NCT00812825|Safety Tolerability Pharmacokinetics/pharmacodynamics
471961|NCT00812812|paroxetine
471962|NCT00812812|selective serotonin reuptake inhibitor
471963|NCT00812812|CDRS-R
471964|NCT00812812|children and adolescents
471965|NCT00812799|randomised
471966|NCT00812799|double-blind
471967|NCT00812799|placebo-controlled
471968|NCT00812799|efficacy and safety
471969|NCT00812799|Oralgen® Grass Pollen
471970|NCT00812799|allergic rhinoconjunctivitis
471971|NCT00812799|allergy
471972|NCT00812799|rhinoconjunctivitis
471973|NCT00812799|immunotherapy
471974|NCT00812799|grass pollen extract
471975|NCT00812786|heart transplantation
471976|NCT00812786|immunosuppressive drugs
471977|NCT00812786|individual dose adjustment
471978|NCT00812786|harmacokinetics
471979|NCT00812786|modelling
471980|NCT00812773|GSK2190915
471981|NCT00812773|Repeat
471982|NCT00812773|Oral
471983|NCT00812773|Dose
471984|NCT00812773|Challenge
471985|NCT00812773|Asthma
471986|NCT00812773|Allergen
471987|NCT00812760|Electroretinography
471988|NCT00812760|levodopa
471989|NCT00812747|surgical wound infection
471990|NCT00812747|risk factor
471991|NCT00812734|Neuropathic pain
471992|NCT00812734|chronic pain
471993|NCT00812734|postoperative
471994|NCT00812734|surgery
471995|NCT00812734|anesthesiology
471996|NCT00812734|Scheduled surgery
471997|NCT00812721|higher order aberrations
471998|NCT00812721|tear blur
471999|NCT00812708|aniridia
472000|NCT00812708|Morcher iris diaphragms
472001|NCT00812708|modified capsule tension ring
472002|NCT00812708|artificial iris
472003|NCT00812708|iris reconstruction lens
472004|NCT00812708|glare sensitivity
472005|NCT00812708|photophobia
472006|NCT00812695|Obstructive sleep apnea
472007|NCT00812695|Refractory hypertension
472008|NCT00812695|Heart remodeling
472009|NCT00812695|Arterial stiffness
472010|NCT00812695|CPAP
472011|NCT00812682|SYMBICORT AMD
472012|NCT00812669|B-cell chronic lymphocytic leukemia
472013|NCT00812669|refractory chronic lymphocytic leukemia
472014|NCT00812669|stage I chronic lymphocytic leukemia
472015|NCT00812669|stage II chronic lymphocytic leukemia
472016|NCT00812669|stage III chronic lymphocytic leukemia
472017|NCT00812669|stage IV chronic lymphocytic leukemia
472018|NCT00812643|pharmacokinetics
472019|NCT00812630|male hormonal contraception
472020|NCT00812630|Blood pressure, sperm concentration
472021|NCT00812578|Type 2 diabetes
472022|NCT00812578|Vitamin D insufficiency
472023|NCT00812578|Insulin secretion
472024|NCT00812578|Insulin sensitivity
472025|NCT00812578|Pulsatility
472026|NCT00812539|Diabetes
472027|NCT00812539|Blood glucose monitoring
472028|NCT00812539|Internet
472029|NCT00812526|Choroid
472030|NCT00812526|Regional blood flow
472031|NCT00812526|Autoregulation
472032|NCT00812526|Laser Doppler flowmetry
472033|NCT00812513|rhPDGF-BB
472034|NCT00812513|Platelet derived growth factor
472035|NCT00812513|Burns
472036|NCT00812513|Thermal burns
472037|NCT00812513|Electric burns
472038|NCT00812500|assess the effect of age on the EAR and RDA for protein
472039|NCT00812487|congestive heart failure
472040|NCT00812487|diabetes mellitus
472041|NCT00812487|hyperglycemia
472042|NCT00812474|cerebral blood flow
472043|NCT00812461|Pharmacologic Actions
472044|NCT00812461|Alcohol-Related Disorders
472045|NCT00812461|Alcoholism
472046|NCT00812461|Mental Disorders
472047|NCT00812461|Central Nervous System Agents
472048|NCT00812448|prophylaxis
472049|NCT00812448|influenza infection
472050|NCT00812448|catechins
472051|NCT00812448|prophylaxis of influenza infection
472052|NCT00812435|STEMI
472053|NCT00812435|Patients
472054|NCT00812435|male or female
472055|NCT00812435|greater than 18 years of age
472056|NCT00812435|presenting with ST elevation myocardial infarction
472057|NCT00812422|Fever due to acute upper respiratory tract infection
472058|NCT00812409|Measuring markers of metabolic syndrome in overweight and obese adults.
472059|NCT00812396|Biomarkers of muscle anabolism
472060|NCT00812370|DVT
472061|NCT00812370|Deep Venous Thrombosis
472062|NCT00812370|UNBLOCK
472063|NCT00812370|Bivalirudin
472064|NCT00812370|Angiomax
472065|NCT00812357|Symbicort Turbuhaler
472066|NCT00812357|asthma
472067|NCT00812357|cohort study
472068|NCT00812357|France
472069|NCT00812344|pharmacokinetics
472070|NCT00812331|Hepatitis C
472071|NCT00812331|TMC435
472072|NCT00812318|HIV infected subjects
472073|NCT00812318|Healthy volunteer
472074|NCT00812318|GSK1265744.
472075|NCT00812292|TMC278
472076|NCT00812292|TMC278-C145
472077|NCT00812292|TMC278-TiDP38-C145
472078|NCT00812292|concept pediatric formulations of TMC278
472079|NCT00812292|HIV Infections
472080|NCT00812279|Smokers with acceptable health conditions
472081|NCT00812266|SCLC
472082|NCT00812266|Extensive disease
472083|NCT00812266|topotecan
472084|NCT00812253|Heart failure
472085|NCT00812253|Hyperglycemia
472086|NCT00812253|Hospital
472087|NCT00812253|Diabetes Mellitus
472088|NCT00812240|Gastro-Intestinal Stromal Tumour
472089|NCT00812240|GIST
472090|NCT00812240|non resectable
472091|NCT00812240|recurrent post-surgery
472092|NCT00812240|first line of treatment
472093|NCT00812240|metastatic
472094|NCT00812240|locally advanced
472095|NCT00812227|Depression
472096|NCT00812227|Psychotherapy
472097|NCT00812227|Neuroimaging
472098|NCT00812227|Subjects with Major Depressive Disorder (MDD)
472099|NCT00812214|insomnia
472100|NCT00812214|migraine
472101|NCT00812214|eszopiclone
472102|NCT00812214|insomnia in migraineurs
472103|NCT00812201|Heart failure
472104|NCT00812201|auto threshold
472105|NCT00812201|pacing
472106|NCT00812201|CRT-P or CRT-D recipients, threshold measurements
472107|NCT00812188|Morphea
472108|NCT00812188|Plaque morphea
472109|NCT00812188|Localized Scleroderma
472110|NCT00812175|Hepatocellular Carcinoma
472111|NCT00812175|HCC
472112|NCT00812175|Sorafenib
472113|NCT00812149|Type-2 Deiodinase
472114|NCT00812149|Genetic Polymorphism
472115|NCT00812149|Triiodothyronine (T3)
472116|NCT00812149|Thyrotropin Releasing Hormone (TRH) Test
472117|NCT00812136|Using Parent Mentors to Improve Asthma Care for Urban Minority Children
472118|NCT00812123|kidney transplantation
472119|NCT00812123|calcineurin inhibitor free
472120|NCT00812123|protocol biopsy
472121|NCT00812123|Cyclosporin A
472122|NCT00812123|Sirolimus
472123|NCT00812110|Influenza prevention
472124|NCT00812097|Breast Augmentation
472125|NCT00812097|Breast Reconstruction
472126|NCT00812097|Breast Revision
472127|NCT00812097|Silicone gel
472128|NCT00812097|Contour Profile Gel
472129|NCT00812097|Siltex®
472130|NCT00812084|Quality of life
472131|NCT00812084|health resources
472132|NCT00812084|costs
472133|NCT00812084|community-acquired pneumonia
472134|NCT00812071|volunteers
472135|NCT00812058|Bipolar Depression
472136|NCT00812058|Bipolar Disease
472137|NCT00812058|Bipolar Disorder
472138|NCT00812058|Bipolar
472139|NCT00812058|Manic Depression
472140|NCT00812058|Manic Depressive Disorder
472141|NCT00812045|Induced sputum
472142|NCT00812045|cystic fibrosis
472143|NCT00812045|biomarker
472144|NCT00812045|CYBER
472145|NCT00812032|NIDDM
472146|NCT00812032|Aspirin
472147|NCT00812032|platelet inhibition
472148|NCT00812032|Aspirin treatment
472149|NCT00812019|H5N1 Influenza
472150|NCT00812019|Pandemic Flu
472151|NCT00812019|MF59 Adjuvant
472152|NCT00812019|Cell Culture-Derived
472153|NCT00812019|Safety
472154|NCT00812019|Immunogenicity
472155|NCT00812019|Vaccination
472156|NCT00812019|H5N1 influenza pandemic
472157|NCT00811954|Treatment naive
472158|NCT00811954|Treatment inexperienced
472159|NCT00811941|Pharmacologic Actions
472160|NCT00811941|Alcohol-Related Disorders
472161|NCT00811941|Alcoholism
472162|NCT00811941|Mental Disorders
472163|NCT00811941|Central Nervous System Agents
472164|NCT00811928|high-risk leukopenic patients
472165|NCT00811915|Sirolimus
472166|NCT00811915|Tacrolimus
472167|NCT00811915|Kidney transplantation
472168|NCT00811915|Kidney Transplant Recipients
472169|NCT00811902|Multiple sclerosis
472170|NCT00811876|Prostate cancer
472171|NCT00811863|Nephrogenic Systemic Fibrosis
472172|NCT00811863|Renal Insufficiency
472173|NCT00811863|Gadoversetamide
472174|NCT00811863|OptiMARK
472175|NCT00811863|Magnetic Resonance Imaging
472176|NCT00811837|Sunburn
472177|NCT00811837|Remifentanil
472178|NCT00811837|Hyperalgesia
472179|NCT00811824|Weight loss
472180|NCT00811824|Physical activity
472181|NCT00811824|Dietary change
472182|NCT00811811|Hypertension
472183|NCT00811811|Biofeedback
472184|NCT00811811|Relaxation training
472185|NCT00811798|Hong Kong
472186|NCT00811798|Human papillomavirus
472187|NCT00811798|Safety
472188|NCT00811785|Copper Deficiency
472189|NCT00811785|Menkes Disease
472190|NCT00811785|Neurodevelopment
472191|NCT00811785|Occipital Horn Syndrome
472192|NCT00811772|Randomized controlled trial
472193|NCT00811772|Bare metal stent
472194|NCT00811772|Drug eluting stent
472195|NCT00811759|stage IV melanoma
472196|NCT00811759|stage III melanoma
472197|NCT00811759|recurrent melanoma
472198|NCT00811746|obstructive sleep apnea
472199|NCT00811746|eszopiclone
472200|NCT00811746|ramelteon
472201|NCT00811746|polysomnography
472202|NCT00811733|Waldenstrom's Macroglobulinemia
472203|NCT00811733|Ofatumumab
472204|NCT00811720|Alcohol-Related Disorders
472205|NCT00811720|Alcoholism
472206|NCT00811720|Mental Disorders
472207|NCT00811720|Central Nervous System Agents
472208|NCT00811707|ultrasound image
472209|NCT00811707|epidural space
472210|NCT00811694|glaucoma
472211|NCT00811694|ficker stimulation
472212|NCT00811694|ocular blood flow
472213|NCT00811681|Friedreich's ataxia
472214|NCT00811681|Pioglitazone
472215|NCT00811668|Sleep Apnea Syndromes
472216|NCT00811668|heart diseases
472217|NCT00811655|tumors metastatic to brain
472218|NCT00811655|unspecified adult solid tumor, protocol specific
472219|NCT00811642|refractory or first line medication intolerable invasive fungal infection
472220|NCT00811629|Receptor for advanced glycation end products (RAGE)
472221|NCT00811629|Soluble RAGE (sRAGE)
472222|NCT00811629|Acute Lung Injury (ALI)
472223|NCT00811629|Acute respiratory distress syndrome (ARDS)
472224|NCT00811629|Severe sepsis
472225|NCT00811629|Septic shock
472226|NCT00811629|Alveolar epithelium
472227|NCT00811629|Mechanical ventilation
472228|NCT00811629|Intensive Care Unit (ICU)
472229|NCT00811616|Coronary artery disease
472230|NCT00811616|Supralimus-Core™
472231|NCT00811616|de novo native coronary artery lesion
472232|NCT00811603|Antibiotic
472233|NCT00811603|Prophylaxis
472234|NCT00811603|Cesarean
472235|NCT00811603|Infection
472236|NCT00811603|Antibiotic prophylaxis
472237|NCT00811590|Cancer
472238|NCT00811590|Polyps
472239|NCT00811577|AZX100
472240|NCT00811577|Patient and Observer Scar Assessment Scale
472241|NCT00811577|POSAS
472242|NCT00811577|Visual Analog Scale
472243|NCT00811577|VAS
472244|NCT00811577|Trocar
472245|NCT00811577|Scarring
472246|NCT00811577|Scar reduction
472247|NCT00811577|Scar prevention
472248|NCT00811551|Heart Failure
472249|NCT00811551|Impedance Monitoring
472250|NCT00811551|Wedge Pressure
472251|NCT00811538|ischemic stroke
472252|NCT00811538|endovascular treatment
472253|NCT00811538|Thrombolysis
472254|NCT00811538|outcome
472255|NCT00811525|Breast Augmentation
472256|NCT00811525|Breast Reconstruction
472257|NCT00811525|Breast Revision
472258|NCT00811525|Silicone gel
472259|NCT00811525|Contour Profile Gel
472260|NCT00811525|Siltex
472261|NCT00811512|retina
472262|NCT00811512|fold
472263|NCT00811512|fovea
472264|NCT00811473|Bipolar Depression
472265|NCT00811473|Depression
472266|NCT00811473|Children
472267|NCT00811473|Adolescents
472268|NCT00811473|Seroquel
472269|NCT00811473|Bipolar Depression in Children and Adolescents
472270|NCT00811434|encephalopathy
472271|NCT00811434|pediatric liver disease
472272|NCT00811434|pediatric cirrhosis
472273|NCT00811434|serum ammonia levels
472274|NCT00811421|Malaria
472275|NCT00811421|Pregnancy
472276|NCT00811421|HIV
472277|NCT00811421|Prevention
472278|NCT00811421|Malaria prevention
472279|NCT00811408|human papilloma virus infection
472280|NCT00811408|cervical squamous cell carcinoma
472281|NCT00811408|cervical adenocarcinoma
472282|NCT00811408|stage IB cervical cancer
472283|NCT00811408|stage II cervical cancer
472284|NCT00811408|stage III cervical cancer
472285|NCT00811408|stage IVA cervical cancer
472286|NCT00811382|cardiac resynchronization therapy
472287|NCT00811382|therapy of atrial fibrillation
472288|NCT00811382|telecardiology
472289|NCT00811382|home monitoring
472290|NCT00811382|cardiovascular hospitalization
472291|NCT00811382|cardiovascular mortality
472292|NCT00811369|Breast Cancer
472293|NCT00811369|Bone Metastases
472294|NCT00811369|Telopeptide
472295|NCT00811369|Zactima
472296|NCT00811369|Fulvestrant
472297|NCT00811356|Food Effect
472298|NCT00811356|Drug-Drug Interaction
472299|NCT00811356|Antimalarial
472300|NCT00811356|First Time In Human
472301|NCT00811356|Single Dose
472302|NCT00811356|Repeat Dose
472303|NCT00811343|anti TNF Therapy
472304|NCT00811343|Tuberculosis
472305|NCT00811343|Tuberculin test
472306|NCT00811343|QFTB-G
472307|NCT00811343|T-SPOT.TB
472308|NCT00811343|Need anti TNF Therapy
472309|NCT00811330|Left ventricular hypertrophy
472310|NCT00811330|Aortic valve stenosis
472311|NCT00811330|Aortic valve replacement
472312|NCT00811330|Cardiopulmonary bypass
472313|NCT00811330|Statins
472314|NCT00811330|Myocardial preconditioning
472315|NCT00811330|Left ventricular reverse remodeling
472316|NCT00811317|diabetes
472317|NCT00811317|glucose
472318|NCT00811317|hyperglycemia
472319|NCT00811317|hypoglycemia
472320|NCT00811317|insulin
472321|NCT00811317|glucagon
472322|NCT00811317|counter-regulation
472323|NCT00811317|closed-loop
472324|NCT00811317|feedback
472325|NCT00811317|control
472326|NCT00811317|dual-infusion
472327|NCT00811317|subcutaneous
472328|NCT00811317|automated
472329|NCT00811317|artificial pancreas
472330|NCT00811317|intensive insulin therapy
472331|NCT00811304|ultrasound
472332|NCT00811304|labor epidural
472333|NCT00811304|failed epidural
472334|NCT00811304|outcome
472335|NCT00811304|Epidural insertion under realtime ultrasound guidance
472336|NCT00811291|B-vitamins
472337|NCT00811291|Folic-Acid
472338|NCT00811291|kindergarten kids
472339|NCT00811291|cognitive tests
472340|NCT00811291|Healthy kids
472341|NCT00811291|second part low urine vitamine-B-metabolites
472342|NCT00811278|inhaled corticosteroids
472343|NCT00811265|ExAblate MRgFUS
472344|NCT00811265|Focused ultrasound
472345|NCT00811265|Magnetic resonance imaging
472346|NCT00811265|Prostate cancer
472347|NCT00811265|Radical prostatectomy candidate
472348|NCT00811252|Depression
472349|NCT00811252|Elderly
472350|NCT00811252|Acute treatment
472351|NCT00811239|antivenom
472352|NCT00811239|snake bite
472353|NCT00811239|Bungarus multicinctus
472354|NCT00811239|Vietnam
472355|NCT00811226|Hypertension Stage I
472356|NCT00811226|Hypertension Stage II
472357|NCT00811200|radiation
472358|NCT00811200|retinopathy
472359|NCT00811200|maculopathy
472360|NCT00811200|choroidopathy
472361|NCT00811200|uveal
472362|NCT00811200|melanoma
472363|NCT00811200|lucentis
472364|NCT00811200|ranibizumab
472365|NCT00811200|kenalog
472366|NCT00811200|triamcinolone acetonide
472367|NCT00811200|radiation retinopathy after irradiation of uveal melanoma
472368|NCT00811200|radiation maculopathy after irradiation of uveal melanoma
472369|NCT00811200|radiation choroidopathy after irradiation of uveal melanoma
472370|NCT00811187|Hysteroscopy
472371|NCT00811187|Pain medication
472372|NCT00811187|Lidocaine
472373|NCT00811187|Office Procedures
472374|NCT00811161|Remodeling
472375|NCT00811161|Airgent
472376|NCT00811161|Hyaluronic acid
472377|NCT00811161|Collagen formation
472378|NCT00811148|Brain Neoplasms
472379|NCT00811148|Central Nervous System Diseases
472380|NCT00811148|Central Nervous System Neoplasms
472381|NCT00811148|Brain Diseases
472382|NCT00811148|Nervous System Neoplasms
472383|NCT00811122|Alzheimer's disease
472384|NCT00811122|AD
472385|NCT00811122|Frontotemporal dementia
472386|NCT00811122|FTD
472387|NCT00811109|Acute Kidney Injury
472388|NCT00811109|Critical care
472389|NCT00811109|Hypotension
472390|NCT00811109|Renal replacement therapy
472391|NCT00811109|Efficacy
472392|NCT00811109|Tolerance
472393|NCT00811109|Outcome
472394|NCT00811096|Malaria, Vivax/*drug therapy
472395|NCT00811096|Tinidazole/pharmacology/*therapeutic use
472396|NCT00811096|Recurrence
472397|NCT00811096|Plasmodium vivax/*drug effects
472398|NCT00811083|autism
472399|NCT00811083|toxic metals
472400|NCT00811083|DMSA
472401|NCT00811083|dimercaptosuccinic acid
472402|NCT00811083|chelation
472403|NCT00811070|CML. Chronic myelocytic leukemia. Philadelphia Chromosome. Japanese. SKI-606. Bosutinib. Imatinib resistant. Imatinib intolerant
472404|NCT00811057|Preterm Labor in Pregnancy
472405|NCT00811044|diabetes
472406|NCT00811044|genetics
472407|NCT00811044|oral glucose tolerance testing
472408|NCT00811044|family history of diabetes
472409|NCT00811044|gestational diabetes
472410|NCT00811031|Prostate
472411|NCT00811031|prostate gland
472412|NCT00811031|prostate cancer markers
472413|NCT00811031|Taxotere®
472414|NCT00811031|Docetaxel
472415|NCT00811031|Prednisone
472416|NCT00811031|Castration Resistant Prostate Cancer
472417|NCT00811031|adenocarcinoma of the prostate
472418|NCT00811018|Open-label study
472419|NCT00811005|acitretin
472420|NCT00811005|fumaric acid ester
472421|NCT00811005|pustular palmoplantar psoriasis
472422|NCT00811005|PUVA
472423|NCT00810992|dietary, behavior
472424|NCT00810992|IDF criteria
472425|NCT00810992|coronary artery disease
472426|NCT00810992|Traditional Tibetan Medicine
472427|NCT00810992|coronary artery disease in patients, who have an increased cardiovascular risk profile according to the criteria by the International Diabetes Federation (IDF)
472428|NCT00810940|TBI
472429|NCT00810940|closed head injury
472430|NCT00810940|severe head trauma
472431|NCT00810940|traumatic brain injury
472432|NCT00810914|Patient controlled epidural anesthesia
472433|NCT00810914|Pain control in labor
472434|NCT00810901|ethnic minority adolescents
472435|NCT00810901|designated organ donor
472436|NCT00810888|intracerebral hemorrhage
472437|NCT00810888|ICH
472438|NCT00810888|computed tomography angiography
472439|NCT00810888|CTA
472440|NCT00810888|recombinant activated factor seven
472441|NCT00810888|rFVIIa
472442|NCT00810888|NovoSeven
472443|NCT00810888|recombinant activated factor VII
472444|NCT00810875|pregnancy
472445|NCT00810875|immunity
472446|NCT00810875|cord blood
472447|NCT00810875|influenza vaccines
472448|NCT00810875|disease transmission, vertical
472449|NCT00810862|African American children
472450|NCT00810849|Tuberculosis, pericardium
472451|NCT00810823|Diabetes
472452|NCT00810823|gastric bypass
472453|NCT00810823|type 2 diabetes and gastric bypass
472454|NCT00810810|Blood Component Transfusion
472455|NCT00810810|Leukoreduction
472456|NCT00810810|HLA antibody
472457|NCT00810810|Immunosuppression
472458|NCT00810797|recurrent breast cancer
472459|NCT00810797|stage IV breast cancer
472460|NCT00810784|Venous Thromboembolism
472461|NCT00810784|Prevention
472462|NCT00810784|Quality Improvement
472463|NCT00810784|Education
472464|NCT00810784|Compliance with VTE prophylaxis
472465|NCT00810771|Hospitals, Veterans
472466|NCT00810771|Mass Screening/utilization
472467|NCT00810771|Patient Preference
472468|NCT00810771|Prevention & Control
472469|NCT00810771|Epidemiology
472470|NCT00810758|HCV
472471|NCT00810758|Toll-like receptor 7
472472|NCT00810758|Multiple oral dose escalation study of PF-04878691
472473|NCT00810745|ODS
472474|NCT00810745|stapled transanal rectal resection
472475|NCT00810732|This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
472476|NCT00810732|B1321005
472477|NCT00810719|recurrent pancreatic cancer
472478|NCT00810719|stage IV pancreatic cancer
472479|NCT00810706|Breast Cancer
472480|NCT00810706|Aromatase inhibitors
472481|NCT00810706|Exemestane
472482|NCT00810706|Tamoxifen
472483|NCT00810706|Lipids
472484|NCT00810693|Pulmonary arterial hypertension
472485|NCT00810693|PH
472486|NCT00810693|Stimulator
472487|NCT00810680|chronic lymphocytic leukemia
472488|NCT00810680|relapsed
472489|NCT00810680|refractory
472490|NCT00810680|valproic acid
472491|NCT00810680|valproate
472492|NCT00810667|Schizophrenia
472493|NCT00810667|Cognition
472494|NCT00810667|BACS
472495|NCT00810667|Risperidone
472496|NCT00810667|Augmentation therapy
472497|NCT00810667|Add-on therapy
472498|NCT00810667|Lu AE58054
472499|NCT00810654|Celiac disease
472500|NCT00810654|Coeliac disease
472501|NCT00810654|treatment
472502|NCT00810654|AN-PEP
472503|NCT00810654|prolyl endoprotease
472504|NCT00810654|gluten
472505|NCT00810641|BPPV(benign paroxysmal positional vertigo)
472506|NCT00810641|HC-BPPV(BPPV involving the horizontal semicircular canal)
472507|NCT00810641|Nystagmus
472508|NCT00810641|Treatment outcome
472509|NCT00810641|Horizontal Canal Benign Paroxysmal Positional Vertigo
472510|NCT00810628|Parkinson's disease
472511|NCT00810628|depression
472512|NCT00810628|Parkinson's disease with mild to moderate depression.
472513|NCT00810615|chronic TBI
472514|NCT00810615|cognitive function
472515|NCT00810615|PTSD
472516|NCT00810615|HBO
472517|NCT00810615|hyperbaric
472518|NCT00810615|oxygen
472519|NCT00810615|chronic brain injury
472520|NCT00810576|Relapsed T-Cell Non-Hodgkin's Lymphoma
472521|NCT00810576|Refractory T-Cell Non-Hodgkin's Lymphoma
472522|NCT00810576|NHL
472523|NCT00810576|T-cell NHL
472524|NCT00810576|vorinostat
472525|NCT00810576|SAHA
472526|NCT00810576|Suberoylanilide Hydroxamic Acid
472527|NCT00810576|MSK-390
472528|NCT00810576|Zolinza
472529|NCT00810576|Bortezomib
472530|NCT00810576|Velcade
472531|NCT00810576|LDP-341
472532|NCT00810576|MLN341
472533|NCT00810576|PS-341
472534|NCT00810576|Peripheral T-cell lymphoma
472535|NCT00810576|CD 30 + anaplastic large cell lymphoma
472536|NCT00810576|Angioimmunoblastic T-cell lymphoma
472537|NCT00810576|Angiocentric/nasal type T/NK-cell lymphoma
472538|NCT00810576|Intestinal T-cell lymphoma
472539|NCT00810576|Hepatosplenic gamma delta T-cell lymphoma
472540|NCT00810576|Subcutaneous panniculitic T-cell lymphoma
472541|NCT00810576|Transformed Mycosis fungoides
472542|NCT00810563|pain
472543|NCT00810563|tubal ligation
472544|NCT00810563|bupivacaine
472545|NCT00810563|laparoscopy
472546|NCT00810524|Chronic hepatitis B
472547|NCT00810524|antiviral treatment
472548|NCT00810524|long term prognosis
472549|NCT00810485|Gastroesophageal reflux
472550|NCT00810485|Proton pump inhibitor
472551|NCT00810485|Heartburn
472552|NCT00810485|Regurgitation
472553|NCT00810472|Penetrating keratoplasty
472554|NCT00810472|HLA matching
472555|NCT00810472|Corneal diseases that require penetrating keratoplasty
472556|NCT00810420|Hypoglycemia
472557|NCT00810420|EEG
472558|NCT00810420|type 1 diabetes
472559|NCT00810420|neuroglycopenia
472560|NCT00810420|Hypoglycemia is a potential dangerous condition
472561|NCT00810420|EEG is changed during hypoglycemia
472562|NCT00810420|A hypoglycemia alarm based on EEG-measures may prevent development of severe hypoglycemia
472563|NCT00810394|unspecified adult solid tumor, protocol specific
472564|NCT00810381|Nitrovasodilators
472565|NCT00810381|ONH blood flow
472566|NCT00810381|Choroidal blood flow
472567|NCT00810381|Nitroglycerin
472568|NCT00810381|Isosorbide Dinitrate
472569|NCT00810381|Sodium nitroprusside
472570|NCT00810381|Laser-Doppler Flowmetry
472571|NCT00810381|Regional Blood Flow
472572|NCT00810368|Carnosine
472573|NCT00810368|antioxidant
472574|NCT00810368|Persian Gulf War
472575|NCT00810368|Gulf War Syndrome
472576|NCT00810368|GWI
472577|NCT00810368|Gulf War Illness
472578|NCT00810368|Exercise
472579|NCT00810368|Chronic Fatigue
472580|NCT00810368|Fibromyalgia
472581|NCT00810368|Veterans
472582|NCT00810368|Irritable Bowel Syndrome
472583|NCT00810368|Migraine headaches
472584|NCT00810368|Neuropathy
472585|NCT00810368|Multiple Chemical Sensitivity
472586|NCT00810355|Schizophrenia Spectrum Disorders
472587|NCT00810355|Cognitive Behavior Therapy
472588|NCT00810355|work
472589|NCT00810342|physical activity standard
472590|NCT00810342|exercise
472591|NCT00810329|CFS,FM,CSF,Proteomics,Pain,Fatigue,GWI,IBS,IC,MCS.
472592|NCT00810316|Alprazolam
472593|NCT00810316|Alprazolam extended release
472594|NCT00810316|Clonazepam
472595|NCT00810316|Pharmacokinetics
472596|NCT00810316|Mexican population
472597|NCT00810316|Healthy
472598|NCT00810290|Metabolic syndrome
472599|NCT00810290|Latino health
472600|NCT00810290|Community participatory research
472601|NCT00810290|Translational Research
472602|NCT00810264|Long-term safety and reliability of a bipolar left ventricular lead on congestive heart failure patients
472603|NCT00810251|rib fracture
472604|NCT00810251|flail chest
472605|NCT00810251|plate
472606|NCT00810251|chest trauma
472607|NCT00810251|osteosynthesis
472608|NCT00810251|mechanical ventilation
472609|NCT00810251|respirator
472610|NCT00810238|Heart failure
472611|NCT00810238|Cell therapy
472612|NCT00810225|CNDP1
472613|NCT00810225|carnosine dipeptidase 1
472614|NCT00810225|Persian Gulf War
472615|NCT00810225|Gulf War Syndrome
472616|NCT00810225|GWI
472617|NCT00810225|Gulf War Illness
472618|NCT00810225|Exercise
472619|NCT00810225|Chronic Fatigue
472620|NCT00810225|Fibromyalgia
472621|NCT00810225|Veterans
472622|NCT00810225|Irritable Bowel Syndrome
472623|NCT00810225|Migraine headaches
472624|NCT00810225|Neuropathy
472625|NCT00810225|Multiple Chemical Sensitivity
472626|NCT00810212|Degenerative disc disease
472627|NCT00810212|Spondylolisthesis
472628|NCT00810212|Spinal stenosis
472629|NCT00810212|Stem cell
472630|NCT00810212|Spinal Fusion
472631|NCT00810173|type 2 diabetes
472632|NCT00810173|physical activity
472633|NCT00810173|behavior change
472634|NCT00810173|profile personality
472635|NCT00810173|phone call support
472636|NCT00810160|probiotic
472637|NCT00810160|prebiotic
472638|NCT00810160|oligosaccharides
472639|NCT00810160|GOS
472640|NCT00810160|galacto oligosaccharides
472641|NCT00810160|Bifidobacterium infantis
472642|NCT00810160|Bifidobacterium animalis
472643|NCT00810134|Superficial femoral artery occlusion (TASC II B or C)
472644|NCT00810108|HIV/AIDS
472645|NCT00810108|pediatrics
472646|NCT00810108|resource-limited settings
472647|NCT00810108|lopinavir
472648|NCT00810108|ritonavir
472649|NCT00810108|Kaletra®
472650|NCT00810108|antiretroviral treatment
472651|NCT00810108|crushed tablets
472652|NCT00810108|treatment experienced
472653|NCT00810095|Cerebral Infarction
472654|NCT00810095|Stroke
472655|NCT00810095|Vascular Diseases
472656|NCT00810095|Central Nervous System Diseases
472657|NCT00810095|Penumbra
472658|NCT00810095|Functional Outcome
472659|NCT00810095|Aphasia
472660|NCT00810095|Hemiplegia
472661|NCT00810095|Left sided weakness
472662|NCT00810095|Right Sided weakness
472663|NCT00810069|Major Depressive Disorder
472664|NCT00810069|MDD
472665|NCT00810069|Depression
472666|NCT00810056|Child abuse and neglect
472667|NCT00810056|Out-of-home care
472668|NCT00810056|Mentoring
472669|NCT00810056|Skills groups
472670|NCT00810056|Assessment
472671|NCT00810030|ferric carboxymaltose
472672|NCT00810030|iron sucrose
472673|NCT00810030|Iron-Deficiency Anemia
472674|NCT00810030|Crohn's Disease
472675|NCT00810030|Ulcerative Colitis
472676|NCT00810030|Ferritin
472677|NCT00810030|Transferrin
472678|NCT00810017|Her2 Positive
472679|NCT00810017|Breast Cancer
472680|NCT00810017|Metastatic
472681|NCT00809991|Prostate Cancer
472682|NCT00809965|Rivaroxaban
472683|NCT00809965|Acute Coronary Syndrome
472684|NCT00809965|ACS
472685|NCT00809965|Aspirin
472686|NCT00809965|Thienopyridine
472687|NCT00809965|Unstable Angina
472688|NCT00809965|Myocardial Infarction
472689|NCT00809965|Anticoagulation
472690|NCT00809965|Clopidogrel (Plavix)
472691|NCT00809939|preterm delivery
472692|NCT00809939|short cervical length
472693|NCT00809939|progesterone
472694|NCT00809926|Hypertension, aliskiren and valsartan
472695|NCT00809913|Urinary Tract Infection
472696|NCT00809913|Fever
472697|NCT00809913|Acute Pyelonephritis
472698|NCT00809913|Treatment duration
472699|NCT00809913|Febrile Urinary Tract Infection Treatment Duration
472700|NCT00809887|catheter fungal infections, antimicrobial lock therapy, micafungin, central venous catheter
472701|NCT00809874|Postprandial Period
472702|NCT00809874|Postprandial Lipaemia
472703|NCT00809874|Incretins
472704|NCT00809874|Subclinical Inflammation
472705|NCT00809874|Obesity
472706|NCT00809874|Atherosclerosis
472707|NCT00809874|Triglyceride
472708|NCT00809874|Lipoproteins
472709|NCT00809835|Cocaine
472710|NCT00809835|Methadone
472711|NCT00809835|CBT
472712|NCT00809822|IVIG in pemphigoid
472713|NCT00809822|Patients with bullous pemphigoid unresponsive to corticosteroids
472714|NCT00809809|Cold sores
472715|NCT00809809|Zinc
472716|NCT00809809|HSL
472717|NCT00809809|Herpes simple labialis
472718|NCT00809783|Tanezumab OA arthritis
472719|NCT00809770|stimulant abuse
472720|NCT00809770|drug abuse
472721|NCT00809770|schizophrenia
472722|NCT00809770|bipolar disorder
472723|NCT00809770|major depressive disorder
472724|NCT00809770|contingency management
472725|NCT00809770|psychosocial treatment
472726|NCT00809757|Asthma
472727|NCT00809731|Schizophrenia remission status by 8-item PANSS
472728|NCT00809718|Raltegravir
472729|NCT00809718|Pharmacokinetics
472730|NCT00809718|Rifapentine
472731|NCT00809718|Drug Kinetics
472732|NCT00809692|histamine biotransformation
472733|NCT00809692|laser Doppler flowimetry
472734|NCT00809692|pediatric pharmacology
472735|NCT00809679|Postherpetic neuralgia
472736|NCT00809679|Varicella Zoster
472737|NCT00809679|Shingles
472738|NCT00809679|Neuropathic pain
472739|NCT00809679|Analgesia
472740|NCT00809679|Pain
472741|NCT00809666|pregnancy
472742|NCT00809666|hypertension
472743|NCT00809666|mercury sphygmomanometry
472744|NCT00809666|blood pressure
472745|NCT00809666|automated blood pressure
472746|NCT00809666|pre eclampsia
472747|NCT00809666|Hypertension in pregnancy
472748|NCT00809653|Air pollution
472749|NCT00809653|Face mask
472750|NCT00809653|Myocardial ischaemia
472751|NCT00809653|Heart rate variability
472752|NCT00809653|Angina pectoris
472753|NCT00809653|Coronary heart disease
472754|NCT00809640|low back pain
472755|NCT00809640|prevention
472756|NCT00809640|schoolchildren
472757|NCT00809640|education campaign
472758|NCT00809627|headache
472759|NCT00809627|caffeine
472760|NCT00809627|pain
472761|NCT00809614|Psoriatic arthritis
472762|NCT00809614|IgG1K monoclonal antibody
472763|NCT00809614|Interleukin -17A neutralizing
472764|NCT00809588|vaccination
472765|NCT00809588|GM-CSF
472766|NCT00809588|autologous
472767|NCT00809588|irradiated
472768|NCT00809575|adult
472769|NCT00809575|de novo myelodysplastic syndromes
472770|NCT00809575|Quality of life
472771|NCT00809575|Patient reported outcomes
472772|NCT00809549|Stroke
472773|NCT00809549|GCSF
472774|NCT00809549|Hematopoeitic
472775|NCT00809549|Neupogen
472776|NCT00809549|Filgrastim
472777|NCT00809536|metformin, PD 0332334, organic cation transporter, OCT2, pharmacokinetics
472778|NCT00809523|SAD
472779|NCT00809523|winter depression
472780|NCT00809497|PLC for treatment of peripheral arterial diseases
472781|NCT00809484|Arimidex
472782|NCT00809484|Bone Mineral density
472783|NCT00809484|Bisphosphonates
472784|NCT00809484|Aromatase Inhibitors
472785|NCT00809471|ED
472786|NCT00809471|Erectile Dysfunction
472787|NCT00809471|Dysfunction
472788|NCT00809471|Diabetic
472789|NCT00809471|Erectile
472790|NCT00809458|Vitamin E
472791|NCT00809458|Prostate Cancer
472792|NCT00809458|Alpha-tocopherol (α-tocopherol)
472793|NCT00809432|Air pollution
472794|NCT00809432|Heart rate
472795|NCT00809432|Heart rate variability
472796|NCT00809432|Blood pressure
472797|NCT00809432|Face mask
472798|NCT00809419|Brachytherapy
472799|NCT00809419|EpiRad
472800|NCT00809419|Macular Degeneration
472801|NCT00809419|Ranibizumab
472802|NCT00809393|Antifibrinolytic
472803|NCT00809393|Tranexamic acid
472804|NCT00809393|Cardiopulmonary bypass
472805|NCT00809393|Transfusion
472806|NCT00809393|Hemorrhage
472807|NCT00809380|Conscious sedation
472808|NCT00809380|Parental presence
472809|NCT00809380|Invasive procedure
472810|NCT00809380|Children
472811|NCT00809380|Anxiety
472812|NCT00809367|MDS
472813|NCT00809367|AML
472814|NCT00809367|banking study
472815|NCT00809354|monoclonal antibody
472816|NCT00809354|nerve growth factor (NGF)
472817|NCT00809354|anti-NGF
472818|NCT00809354|tanezumab
472819|NCT00809354|PF-04383119
472820|NCT00809354|RN624
472821|NCT00809354|osteoarthritis (OA)
472822|NCT00809341|B-Cell
472823|NCT00809341|non-Hodgkin's
472824|NCT00809341|Lymphoma
472825|NCT00809315|Child abuse and neglect
472826|NCT00809315|Out-of-home care
472827|NCT00809315|Mentoring
472828|NCT00809315|Skills groups
472829|NCT00809315|Assessment
472830|NCT00809315|Functioning as a result of maltreatment and placement in out-of-home care
472831|NCT00809289|Thorough QT/QTc study
472832|NCT00809276|Acute lymphocytic leukemia (ALL)
472833|NCT00809276|Acute myeloid leukemia (AML)
472834|NCT00809276|Acute Leukemia
472835|NCT00809276|Refractory or Relapsed AML
472836|NCT00809276|Myelodysplastic syndrome (MDS)
472837|NCT00809276|Chronic myeloid leukemia (CML)
472838|NCT00809276|Chronic myelomonocytic leukemia
472839|NCT00809276|Hodgkin's Lymphoma
472840|NCT00809276|Non-Hodgkin's lymphoma
472841|NCT00809276|Philadelphia-negative myeloproliferative disorder
472842|NCT00809276|Hematologic Malignancies
472843|NCT00809276|Transplantation
472844|NCT00809276|Busulfan
472845|NCT00809276|Fludarabine
472846|NCT00809276|Cytoxan
472847|NCT00809276|Bone Marrow
472848|NCT00809276|Allogeneic
472849|NCT00809276|Related donor
472850|NCT00809276|unrelated donor
472851|NCT00809263|homeopathy
472852|NCT00809263|homeopathic drug proving
472853|NCT00809263|Document symptoms associated with administration of a homeopathic remedy.
472854|NCT00809250|vaccination
472855|NCT00809250|AML
472856|NCT00809250|CMML
472857|NCT00809250|MDS-RAEB
472858|NCT00809237|Non-small cell lung cancer
472859|NCT00809237|Gefitinib
472860|NCT00809237|Hydroxychloroquine
472861|NCT00809224|ALS
472862|NCT00809224|amyotrophic lateral sclerosis
472863|NCT00809224|brain-computer interface
472864|NCT00809224|functional magnetic resonance imaging
472865|NCT00809224|radiology
472866|NCT00809224|fMRI
472867|NCT00809211|chronic myelogenous leukemia, BCR-ABL1 positive
472868|NCT00809211|chronic phase chronic myelogenous leukemia
472869|NCT00809198|Sodium Hyaluronate, Kynex, Carboxymethylcellulose sodium
472870|NCT00809198|Refresh Plus
472871|NCT00809198|Dry Eye
472872|NCT00809198|Cornea Staining
472873|NCT00809198|TBUT
472874|NCT00809185|de novo myelodysplastic syndromes
472875|NCT00809185|secondary myelodysplastic syndromes
472876|NCT00809185|previously treated myelodysplastic syndromes
472877|NCT00809172|Atopic-dermatitis
472878|NCT00809172|scorad
472879|NCT00809172|methotrexate
472880|NCT00809172|ciclosporin
472881|NCT00809159|ankylosing spondylitis
472882|NCT00809146|Status Epilepticus
472883|NCT00809146|Emergency Medical Services
472884|NCT00809146|Anticonvulsants
472885|NCT00809146|Drug Administration Routes
472886|NCT00809146|Seizures
472887|NCT00809120|Electrostimulation
472888|NCT00809120|COPD
472889|NCT00809120|Tolerance
472890|NCT00809120|Muscle fatigue
472891|NCT00809120|Cardio-respiratory response
472892|NCT00809107|natural cycle
472893|NCT00809107|FET
472894|NCT00809107|spontaneous LH pic
472895|NCT00809107|HCG
472896|NCT00809081|periampullar carcinoma
472897|NCT00809081|Pancreaticoduodenectomy
472898|NCT00809081|Enteral feeding
472899|NCT00809081|Total Parenteral Support
472900|NCT00809068|Menopause
472901|NCT00809068|menopausal symptoms
472902|NCT00809068|tibolone
472903|NCT00809068|HDL-C
472904|NCT00809068|fenofibrate
472905|NCT00809042|Hydroxyurea
472906|NCT00809042|magnesium chloride
472907|NCT00809042|L-carnitine
472908|NCT00809042|β-thalassemia intermedia
472909|NCT00809029|GIP
472910|NCT00809029|OBESITY
472911|NCT00809029|HSL
472912|NCT00809029|LPL
472913|NCT00809029|ADIPOCYTOKINES
472914|NCT00809029|BARIATRIC SURGERY
472915|NCT00809016|recurrent squamous cell carcinoma of the hypopharynx
472916|NCT00809016|stage III squamous cell carcinoma of the hypopharynx
472917|NCT00809016|stage IV squamous cell carcinoma of the hypopharynx
472918|NCT00809016|recurrent squamous cell carcinoma of the larynx
472919|NCT00809016|stage III squamous cell carcinoma of the larynx
472920|NCT00809016|stage IV squamous cell carcinoma of the larynx
472921|NCT00809016|recurrent verrucous carcinoma of the larynx
472922|NCT00809016|stage III verrucous carcinoma of the larynx
472923|NCT00809016|stage IV verrucous carcinoma of the larynx
472924|NCT00809016|recurrent adenoid cystic carcinoma of the oral cavity
472925|NCT00809016|recurrent mucoepidermoid carcinoma of the oral cavity
472926|NCT00809016|recurrent verrucous carcinoma of the oral cavity
472927|NCT00809016|stage III adenoid cystic carcinoma of the oral cavity
472928|NCT00809016|stage III mucoepidermoid carcinoma of the oral cavity
472929|NCT00809016|stage III verrucous carcinoma of the oral cavity
472930|NCT00809016|stage IV adenoid cystic carcinoma of the oral cavity
472931|NCT00809016|stage IV mucoepidermoid carcinoma of the oral cavity
472932|NCT00809016|stage IV verrucous carcinoma of the oral cavity
472933|NCT00809016|recurrent basal cell carcinoma of the lip
472934|NCT00809016|recurrent squamous cell carcinoma of the lip and oral cavity
472935|NCT00809016|stage III basal cell carcinoma of the lip
472936|NCT00809016|stage III squamous cell carcinoma of the lip and oral cavity
472937|NCT00809016|stage IV basal cell carcinoma of the lip
472938|NCT00809016|stage IV squamous cell carcinoma of the lip and oral cavity
472939|NCT00809016|metastatic squamous neck cancer with occult primary squamous cell carcinoma
472940|NCT00809016|recurrent metastatic squamous neck cancer with occult primary
472941|NCT00809016|untreated metastatic squamous neck cancer with occult primary
472942|NCT00809016|recurrent lymphoepithelioma of the oropharynx
472943|NCT00809016|recurrent squamous cell carcinoma of the oropharynx
472944|NCT00809016|stage III lymphoepithelioma of the oropharynx
472945|NCT00809016|stage III squamous cell carcinoma of the oropharynx
472946|NCT00809016|stage IV lymphoepithelioma of the oropharynx
472947|NCT00809016|stage IV squamous cell carcinoma of the oropharynx
472948|NCT00809016|high-grade salivary gland mucoepidermoid carcinoma
472949|NCT00809016|low-grade salivary gland mucoepidermoid carcinoma
472950|NCT00809016|recurrent salivary gland cancer
472951|NCT00809016|salivary gland acinic cell tumor
472952|NCT00809016|salivary gland adenocarcinoma
472953|NCT00809016|salivary gland adenoid cystic carcinoma
472954|NCT00809016|salivary gland anaplastic carcinoma
472955|NCT00809016|salivary gland malignant mixed cell type tumor
472956|NCT00809016|salivary gland poorly differentiated carcinoma
472957|NCT00809016|salivary gland squamous cell carcinoma
472958|NCT00809016|stage III salivary gland cancer
472959|NCT00809016|stage IV salivary gland cancer
472960|NCT00809003|Non dry eyed(normals)
472961|NCT00808990|Non Alcoholic Fatty Liver Disease
472962|NCT00808990|Non Alcoholic SteatoHepatitis
472963|NCT00808990|Small bowel bacterial overgrowth
472964|NCT00808990|Probiotics
472965|NCT00808990|Patients with Non Alcoholic Fatty Liver Disease
472966|NCT00808964|CABG
472967|NCT00808964|anticoagulant
472968|NCT00808964|Off-Pump CABG
472969|NCT00808951|Uncomplicated malaria
472970|NCT00808951|P falciparum
472971|NCT00808951|Children
472972|NCT00808951|National treatment protocol
472973|NCT00808951|Burkina Faso
472974|NCT00808951|Artemether-lumefantrine
472975|NCT00808951|Artesunate-amodiaquine
472976|NCT00808951|In vivo efficacy
472977|NCT00808951|In vitro efficacy
472978|NCT00808925|acclimation
472979|NCT00808925|heat
472980|NCT00808925|cytokines
472981|NCT00808925|stress
472982|NCT00808925|inflammation
472983|NCT00808912|phosphodiesterase
472984|NCT00808912|sildenafil
472985|NCT00808912|pulmonary hypertension
472986|NCT00808912|exercise performance
472987|NCT00808912|air pollution
472988|NCT00808899|Neuroblastoma
472989|NCT00808886|cataract
472990|NCT00808886|locs3
472991|NCT00808886|pentacam
472992|NCT00808873|attempted suicide
472993|NCT00808873|socio-educational intervention
472994|NCT00808873|follow up study
472995|NCT00808860|Herbal medicine
472996|NCT00808860|Type 2 diabetes
472997|NCT00808860|Gynostemma pentaphyllum Tea
472998|NCT00808860|Insulin sensitivity
472999|NCT00808860|add-on
473000|NCT00808808|FluMist, TIV, vaccination rates
473001|NCT00808795|Acute kidney injury
473002|NCT00808795|contrast-induced nephropathy
473003|NCT00808795|Chronic kidney disease
473004|NCT00808795|Diabetes mellitus
473005|NCT00808795|N-acetylcysteine
473006|NCT00808782|Pervasive Developmental Disorders
473007|NCT00808782|Asperger Syndrome
473008|NCT00808782|Autism
473009|NCT00808756|Carbohydrates
473010|NCT00808756|Infant
473011|NCT00808756|Intestine
473012|NCT00808756|Faeces
473013|NCT00808756|Growth
473014|NCT00808756|Diet
473015|NCT00808743|Familial adenomatous polyposis
473016|NCT00808743|Adenomatous Polyposis Coli
473017|NCT00808743|Digestive System Neoplasms
473018|NCT00808743|Gastrointestinal Disease
473019|NCT00808743|Intestinal disease
473020|NCT00808743|Intestinal neoplasms
473021|NCT00808743|Gastrointestinal neoplasms
473022|NCT00808743|Polyps
473023|NCT00808743|Adenoma
473024|NCT00808743|Adenomatous Polyps
473025|NCT00808743|Neoplastic Syndromes, Hereditary
473026|NCT00808743|Digestive System Diseases
473027|NCT00808743|Genetic Diseases, Inborn
473028|NCT00808743|Chemoprevention
473029|NCT00808743|Celecoxib
473030|NCT00808743|Ursodeoxycholic acid
473031|NCT00808743|Anti-Inflammatory agents, Non-Steroidal
473032|NCT00808743|Cyclooxygenase Inhibitors
473033|NCT00808730|Asthma, airway remodelling, smooth muscle, mitochondria
473034|NCT00808717|Myocardial Infarction
473035|NCT00808717|Coronary Angioplasty
473036|NCT00808717|Myocardial infarction, Angioplasty, Transluminal, Percutaneous Coronary
473037|NCT00808704|asphyxia
473038|NCT00808704|erythropoietin
473039|NCT00808704|neonates
473040|NCT00808678|Adverse Events
473041|NCT00808665|Lumbar Fusion
473042|NCT00808665|Inflammation
473043|NCT00808665|Dexmedetomidine
473044|NCT00808665|Length of Hospital Stay
473045|NCT00808665|General Anesthesia
473046|NCT00808665|Anti-inflammatory
473047|NCT00808665|GPCR
473048|NCT00808665|Cytokine
473049|NCT00808665|Immune Response
473050|NCT00808639|pegfilgrastim
473051|NCT00808639|MVAC
473052|NCT00808600|lung transplantation
473053|NCT00808600|heart-lung transplantation
473054|NCT00808600|rehabilitation
473055|NCT00808600|resource-activating training
473056|NCT00808600|anaerobic exercise training
473057|NCT00808587|Genomic Scan
473058|NCT00808587|Personalized Medicine
473059|NCT00808587|Gene testing
473060|NCT00808574|Obstructive sleep apnea
473061|NCT00808574|Internet
473062|NCT00808574|Screening
473063|NCT00808574|Health belief model
473064|NCT00808548|stress
473065|NCT00808548|carer's experiences
473066|NCT00808548|Prader-willi syndrome
473067|NCT00808548|personal experiences
473068|NCT00808535|Endothelial dysfunction
473069|NCT00808535|Cardiac Perfusion MRI
473070|NCT00808535|Vasomotor Stress
473071|NCT00808535|Cold Pressor Test
473072|NCT00808535|Adenosine Stress
473073|NCT00808522|Breast Cancer
473074|NCT00808522|Chemoprevention
473075|NCT00808522|Tamoxifen
473076|NCT00808522|Breast density
473077|NCT00808522|Hcg
473078|NCT00808509|adalimumab,Remission,drug discontinuation
473079|NCT00808496|Magnetic resonance imaging
473080|NCT00808496|Radiography
473081|NCT00808496|Randomized controlled trial
473082|NCT00808496|Antirheumatic agents
473083|NCT00808483|total hip arthroplasty
473084|NCT00808483|physical functioning
473085|NCT00808483|training program
473086|NCT00808483|self-efficacy
473087|NCT00808483|exercise therapy
473088|NCT00808483|walking
473089|NCT00808470|Noise
473090|NCT00808470|Hearing Loss
473091|NCT00808470|Tinnitus
473092|NCT00808470|Antioxidant
473093|NCT00808470|Vasodilator
473094|NCT00808470|Beta-Carotene
473095|NCT00808470|Vitamin C
473096|NCT00808470|Vitamin E
473097|NCT00808470|Magnesium
473098|NCT00808457|chest ultrasound
473099|NCT00808457|pneumonia
473100|NCT00808457|X-ray
473101|NCT00808457|CT
473102|NCT00808457|Sensitivity and specificity of chest ultrasound in diagnosing pneumonia
473103|NCT00808444|Pneumococcal vaccine
473104|NCT00808444|Immunogenicity
473105|NCT00808444|Primary vaccination
473106|NCT00808444|Safety
473107|NCT00808444|Pneumococcal disease
473108|NCT00808431|Obesity
473109|NCT00808431|Diabetes
473110|NCT00808431|Physical Activity
473111|NCT00808431|Child Feeding
473112|NCT00808431|Growth Trajectories
473113|NCT00808431|Family based
473114|NCT00808418|prostate
473115|NCT00808418|cancer
473116|NCT00808418|metastatic
473117|NCT00808418|castration
473118|NCT00808418|refractory
473119|NCT00808418|elesclomol
473120|NCT00808418|sodium
473121|NCT00808418|docetaxel
473122|NCT00808418|prednisone
473123|NCT00808405|herpes simplex virus
473124|NCT00808405|acyclovir
473125|NCT00808405|HSV shedding
473126|NCT00808405|women
473127|NCT00808405|Africa
473128|NCT00808392|vaccine
473129|NCT00808392|prevention
473130|NCT00808392|haemophilus influenzae type b
473131|NCT00808392|children
473132|NCT00808379|Unresectable rectal cancers
473133|NCT00808353|CVD
473134|NCT00808327|Cesarean section
473135|NCT00808327|Spinal
473136|NCT00808314|Lexiscan(TM)
473137|NCT00808314|Dipyridamole
473138|NCT00808314|Myocardial Perfusion
473139|NCT00808314|Positron Emission Computed Tomography
473140|NCT00808301|Coeliac disease
473141|NCT00808301|Oat
473142|NCT00808288|COPD Respiratory Long acting beta agonist
473143|NCT00808275|dietary calcium
473144|NCT00808275|weight loss
473145|NCT00808262|anti-TNFa
473146|NCT00808262|immunization
473147|NCT00808262|kinoid
473148|NCT00808262|crohn's disease
473149|NCT00808249|Generalized Anxiety Disorder
473150|NCT00808249|GAD
473151|NCT00808249|Anxiety
473152|NCT00808236|Cardiac Arrest
473153|NCT00808236|Pre-hospital
473154|NCT00808236|Mild hypothermia
473155|NCT00808236|Resuscitation
473156|NCT00808223|alefacept
473157|NCT00808223|adolescent
473158|NCT00808223|psoriasis
473159|NCT00808210|RA
473160|NCT00808210|Arthritis
473161|NCT00808197|AMD
473162|NCT00808197|choroidal blood flow
473163|NCT00808197|fellow eye in patients with unilateral choroidal neovascularisation
473164|NCT00808184|Histologically or cytologically proven solid tumour for which CPT-11 given by the Folfiri regimen
473165|NCT00808171|lumbar punction
473166|NCT00808171|myelogram
473167|NCT00808171|pain assessment
473168|NCT00808171|nitrous oxide and EMLA
473169|NCT00808171|Leukemia and non Hodgkin lymphoma
473170|NCT00808145|Treatment of advanced liver cancer
473171|NCT00808132|Postmenopausal Women
473172|NCT00808132|Bazedoxifene/Conjugated Estrogens
473173|NCT00808106|Albinism
473174|NCT00808106|Oculocutaneous Albinism
473175|NCT00808106|Pigmentation
473176|NCT00808106|Natural History
473177|NCT00808106|Vesical Biology
473178|NCT00808093|Food Effect
473179|NCT00808093|GSK256073F
473180|NCT00808093|TRIS Salt
473181|NCT00808080|AML
473182|NCT00808054|Pain
473183|NCT00808054|preterm neonate
473184|NCT00808054|pain assessment
473185|NCT00808054|EMLA
473186|NCT00808054|oral glucose
473187|NCT00808041|Neoadjuvant Treatment
473188|NCT00808041|Therapy Response
473189|NCT00808041|Breast Computed Tomography
473190|NCT00808015|Observational non-interventional trial
473191|NCT00808002|Maraviroc
473192|NCT00808002|CCR5 antagonists
473193|NCT00808002|Primary HIV Infection
473194|NCT00808002|HIV-1 reservoir
473195|NCT00808002|eradication
473196|NCT00808002|treatment naive
473197|NCT00807976|Diabetes mellitus
473198|NCT00807976|Elderly
473199|NCT00807976|Orthostatic hypotension
473200|NCT00807963|Pharmacokinetics
473201|NCT00807963|rHuPH20
473202|NCT00807937|Generalized Anxiety Disorder
473203|NCT00807937|GAD
473204|NCT00807937|Anxiety
473205|NCT00807924|Fibroadenomas
473206|NCT00807924|Papillomas
473207|NCT00807924|Breast
473208|NCT00807924|Minimally invasive
473209|NCT00807924|Interstitial laser therapy
473210|NCT00807924|Laser ablation
473211|NCT00807924|Benign
473212|NCT00807924|Non-cancerous
473213|NCT00807924|Breast lesion
473214|NCT00807924|Breast tumor
473215|NCT00807911|rectal cancer
473216|NCT00807911|adjuvant chemotherapy
473217|NCT00807911|FOLFOX
473218|NCT00807898|Gardasil
473219|NCT00807898|HPV vaccine
473220|NCT00807898|decision making
473221|NCT00807898|mother
473222|NCT00807898|daughter
473223|NCT00807885|dehydration
473224|NCT00807885|fluid therapy
473225|NCT00807885|hyaluronoglucosaminidase
473226|NCT00807885|hyaluronidase
473227|NCT00807885|hypodermoclysis
473228|NCT00807885|clysis
473229|NCT00807885|subcutaneous hydration
473230|NCT00807885|subcutaneous rehydration
473231|NCT00807885|hyaluronan
473232|NCT00807885|rHuPH20
473233|NCT00807872|Radioimmunoimaging
473234|NCT00807872|AL Amyloidosis
473235|NCT00807872|PET/CT
473236|NCT00807859|AMG 386
473237|NCT00807859|Paclitaxel
473238|NCT00807859|Trastuzumab
473239|NCT00807859|Capecitabine
473240|NCT00807859|Lapatinib
473241|NCT00807859|HER2-positive
473242|NCT00807859|metastatic breast cancer
473243|NCT00807859|locally recurrent breast cancer
473244|NCT00807859|Taxol
473245|NCT00807859|Herceptin
473246|NCT00807859|Xeloda
473247|NCT00807859|Tykerb
473248|NCT00807859|anti-angiogenic therapy
473249|NCT00807846|Juvenile Arthritis; Juvenile Rheumatoid Arthritis;Blood Pressure;Juvenile Idiopathic Arthritis
473250|NCT00807833|SAH
473251|NCT00807833|TBI
473252|NCT00807820|Prostate Cancer
473253|NCT00807807|Plasma Homocysteine Concentration
473254|NCT00807807|Folate
473255|NCT00807807|Homocysteine
473256|NCT00807807|Supplements
473257|NCT00807807|Folic Acid
473258|NCT00807755|unspecified adult solid tumor, protocol specific
473259|NCT00807755|extensive stage small cell lung cancer
473260|NCT00807755|recurrent small cell lung cancer
473261|NCT00807742|Contingency management for smoking for substance abusers
473262|NCT00807742|Contingency reinforcement for smoking abstinence
473263|NCT00807742|Contingency Management
473264|NCT00807742|Noncontingent Reinforcement
473265|NCT00807729|Laparoscopy
473266|NCT00807729|Endoscopic retrograde cholangiopancreatography
473267|NCT00807729|Sphincterotomy
473268|NCT00807729|Common bile duct stones
473269|NCT00807729|Laparoscoopic common bile duct exploration
473270|NCT00807729|Cost efficiency
473271|NCT00807729|Examination of efficacy, safety, cost of intervention for patients with choleclithiasis and likely common bile duct stones
473272|NCT00807716|physiotherapy
473273|NCT00807716|functional outcome
473274|NCT00807716|activity level
473275|NCT00807716|self efficacy
473276|NCT00807716|task oriented exercises
473277|NCT00807703|Parkinson
473278|NCT00807703|deep brain stimulation (DBS)
473279|NCT00807703|subthalamic nucleus (STN)
473280|NCT00807703|Parkinson patients
473281|NCT00807690|vitiligo
473282|NCT00807690|tacrolimus ointment 0.1%
473283|NCT00807690|narrowband UVB (TL01)
473284|NCT00807677|Chronic myelogenous leukemia (CML) in chronic phase, accelerated phase, or blast crisis
473285|NCT00807677|Intermediate or high risk myelodysplastic syndrome
473286|NCT00807677|Philadelphia chromosome-negative CML (including blast phase)
473287|NCT00807677|All subtypes of myeloid metaplasia with myelofibrosis; advanced polycythemia
473288|NCT00807651|Diabetes Mellitus
473289|NCT00807651|Stem cells
473290|NCT00807651|Autologous stem cell transplantation
473291|NCT00807651|Autoimmune diseases
473292|NCT00807625|HIV/AIDS
473293|NCT00807625|Contraception
473294|NCT00807625|Birth control
473295|NCT00807625|CD4+
473296|NCT00807625|Viral Load
473297|NCT00807625|T-cell activation
473298|NCT00807625|B-cell activation
473299|NCT00807625|Hormonal
473300|NCT00807625|Intrauterine device
473301|NCT00807625|Depo Provera
473302|NCT00807625|Women
473303|NCT00807625|IUCD
473304|NCT00807625|treatment naive
473305|NCT00807612|AMG 479
473306|NCT00807612|IGF-1R
473307|NCT00807612|Apoptosis
473308|NCT00807612|Monoclonal Antibody
473309|NCT00807612|Advanced Squamous Non-Small Cell Lung Cancer
473310|NCT00807612|antibody 1st-line
473311|NCT00807599|CYCLOPHOSPHAMIDE (CYTOXAN)
473312|NCT00807599|DEXAMETHASONE
473313|NCT00807599|G-CSF
473314|NCT00807599|Lenalidomide
473315|NCT00807599|MELPHALAN
473316|NCT00807599|PEG-FILGRASTIM (NEULASTA)
473317|NCT00807599|08-121
473318|NCT00807586|Atrial Fibrillation
473319|NCT00807586|Corticosteroid
473320|NCT00807586|Radiofrequency catheter ablation for atrial fibrillation
473321|NCT00807573|BEVACIZUMAB (AVASTIN)
473322|NCT00807573|PEMETREXED (ALTIMA)
473323|NCT00807573|TAXOL (PACLITAXEL)
473324|NCT00807573|08-109
473325|NCT00807560|Overweight
473326|NCT00807560|Obesity
473327|NCT00807560|Adolescents
473328|NCT00807560|Family Therapy
473329|NCT00807534|Chronic Obstructive Pulmonary Disease (COPD)
473330|NCT00807534|Exercise
473331|NCT00807534|3-min constant rate stepping test
473332|NCT00807534|3-min constant rate walking test
473333|NCT00807534|Bronchodilation
473334|NCT00807534|Ipratropium bromide
473335|NCT00807495|MLN8237
473336|NCT00807495|alisertib
473337|NCT00807482|Primary Ciliary Dyskinesia
473338|NCT00807482|Mucociliary Clearance
473339|NCT00807482|Genetic Mutation
473340|NCT00807469|COPD
473341|NCT00807469|smoking
473342|NCT00807469|susceptibility
473343|NCT00807469|inflammation
473344|NCT00807469|genetic
473345|NCT00807443|HIV-1
473346|NCT00807443|integrase inhibitor (raltegravir)
473347|NCT00807443|the cell reservoir of HIV-1
473348|NCT00807443|treatment experienced
473349|NCT00807430|Bruxism
473350|NCT00807430|EMG
473351|NCT00807430|Biofeedback
473352|NCT00807404|ductal intraepithelial neoplasia
473353|NCT00807391|lung cancer
473354|NCT00807391|transbronchial biopsy
473355|NCT00807391|transbronchial catheter aspiration
473356|NCT00807391|transbronchial needle aspiration
473357|NCT00807391|peripheral pulmonary lesion
473358|NCT00807391|bronchoscopy
473359|NCT00807378|CNS viral infection
473360|NCT00807378|PCR
473361|NCT00807378|HYBRIDIZATION
473362|NCT00807365|Growth Hormone-Releasing Hormone
473363|NCT00807365|Growth Hormone Insufficiency
473364|NCT00807365|Aging
473365|NCT00807365|Growth Hormone
473366|NCT00807365|Physiological Effects of Drugs
473367|NCT00807365|Hormones, Hormone Substitutes, and Hormone Antagonists
473368|NCT00807365|Hormones
473369|NCT00807352|Triage
473370|NCT00807352|Pediatrics
473371|NCT00807352|Emergency Department
473372|NCT00807339|CyberKnife
473373|NCT00807326|Antidiarrheals
473374|NCT00807313|Oligometastatic disease
473375|NCT00807313|Colorectal cancer
473376|NCT00807313|Stereotactic body radiotherapy
473377|NCT00807313|Tomotherapy
473378|NCT00807313|Metabolic response
473379|NCT00807313|Stage IV
473380|NCT00807300|percutaneous treatment
473381|NCT00807287|jejunal tube placement
473382|NCT00807274|Adult congenital heart disease
473383|NCT00807274|Heart failure
473384|NCT00807274|Renal failure
473385|NCT00807274|Proteinuria
473386|NCT00807235|Lucinactant
473387|NCT00807235|Nasal continuous positive airway pressure (nCPAP)
473388|NCT00807235|Respiratory distress syndrome (RDS)
473389|NCT00807235|Pediatric
473390|NCT00807235|Premature
473391|NCT00807222|ADHD
473392|NCT00807222|Vyvanse
473393|NCT00807222|lisdexamfetamine dimesylate
473394|NCT00807222|LDX
473395|NCT00807222|sleep
473396|NCT00807209|Pain
473397|NCT00807209|postoperative
473398|NCT00807209|thoracotomy
473399|NCT00807196|Allogeneic Stem Cell Transplantation
473400|NCT00807196|Zevalin
473401|NCT00807196|Non-Hodgkins Lymphoma
473402|NCT00807170|Non-small Cell Lung Cancer (NSCLC)
473403|NCT00807170|Whole Brain Radiotherapy
473404|NCT00807170|metastasis
473405|NCT00807157|PROBIOSTICK®
473406|NCT00807157|Probiotic
473407|NCT00807157|Anxiety
473408|NCT00807157|Daily stress
473409|NCT00807144|Kidney transplant
473410|NCT00807144|Rejection
473411|NCT00807144|Adherence
473412|NCT00807144|Quality of life
473413|NCT00807131|pharmacy care
473414|NCT00807131|hypertension
473415|NCT00807131|primary care
473416|NCT00807131|adherence
473417|NCT00807118|bioequivalence, food effect
473418|NCT00807105|MOOD EVALUATION
473419|NCT00807079|recurrent cervical cancer
473420|NCT00807079|stage IVB cervical cancer
473421|NCT00807079|stage IVA cervical cancer
473422|NCT00807079|cervical adenocarcinoma
473423|NCT00807079|cervical adenosquamous cell carcinoma
473424|NCT00807079|cervical squamous cell carcinoma
473425|NCT00807066|QUALITY OF LIFE
473426|NCT00807053|Seasonal Allergic Rhinitis
473427|NCT00807053|Ciclesonide
473428|NCT00807053|SAR
473429|NCT00807040|Ischemic Mitral Regurgitation
473430|NCT00807040|Mitral Valve Disease
473431|NCT00807040|Severe Mitral Regurgitation
473432|NCT00807027|Glioblastoma
473433|NCT00807027|Newly diagnosed Glioblastoma
473434|NCT00807014|Differin
473435|NCT00807014|quality of life
473436|NCT00807014|Acne
473437|NCT00807014|Duac
473438|NCT00807014|Acne Vulgaris
473439|NCT00807001|Hepatitis C, HCV, treatment-naive
473440|NCT00806988|Ischemic Mitral Regurgitation
473441|NCT00806988|Mitral Valve Regurgitation
473442|NCT00806910|Heart Failure
473443|NCT00806910|conivaptan
473444|NCT00806910|Diuresis
473445|NCT00806884|Cystic Fibrosis
473446|NCT00806884|Musculoskeletal Physiotherapy
473447|NCT00806884|Manual therapy
473448|NCT00806884|Posture
473449|NCT00806884|Pain
473450|NCT00806845|HIV
473451|NCT00806845|B-lymphocyte
473452|NCT00806832|Medical clowns
473453|NCT00806832|Cataract surgery
473454|NCT00806832|Blood pressure
473455|NCT00806832|Heart rate
473456|NCT00806806|pain management
473457|NCT00806806|postoperative
473458|NCT00806780|gallstones
473459|NCT00806780|cholangiography
473460|NCT00806767|stage III adult Burkitt lymphoma
473461|NCT00806767|stage III adult diffuse large cell lymphoma
473462|NCT00806767|stage III adult diffuse mixed cell lymphoma
473463|NCT00806767|stage III adult diffuse small cleaved cell lymphoma
473464|NCT00806767|stage III adult Hodgkin lymphoma
473465|NCT00806767|stage III adult immunoblastic large cell lymphoma
473466|NCT00806767|stage III adult lymphoblastic lymphoma
473467|NCT00806767|stage III grade 1 follicular lymphoma
473468|NCT00806767|stage III grade 2 follicular lymphoma
473469|NCT00806767|stage III grade 3 follicular lymphoma
473470|NCT00806767|stage III mantle cell lymphoma
473471|NCT00806767|stage III marginal zone lymphoma
473472|NCT00806767|stage III small lymphocytic lymphoma
473473|NCT00806767|stage IV adult Burkitt lymphoma
473474|NCT00806767|stage IV adult diffuse large cell lymphoma
473475|NCT00806767|stage IV adult diffuse mixed cell lymphoma
473476|NCT00806767|stage IV adult diffuse small cleaved cell lymphoma
473477|NCT00806767|stage IV adult Hodgkin lymphoma
473478|NCT00806767|stage IV adult immunoblastic large cell lymphoma
473479|NCT00806767|stage IV adult lymphoblastic lymphoma
473480|NCT00806767|stage IV grade 1 follicular lymphoma
473481|NCT00806767|stage IV grade 2 follicular lymphoma
473482|NCT00806767|stage IV grade 3 follicular lymphoma
473483|NCT00806767|stage IV mantle cell lymphoma
473484|NCT00806767|stage IV marginal zone lymphoma
473485|NCT00806767|stage IV small lymphocytic lymphoma
473486|NCT00806767|recurrent adult Burkitt lymphoma
473487|NCT00806767|recurrent adult diffuse large cell lymphoma
473488|NCT00806767|recurrent adult diffuse mixed cell lymphoma
473489|NCT00806767|recurrent adult diffuse small cleaved cell lymphoma
473490|NCT00806767|recurrent adult Hodgkin lymphoma
473491|NCT00806767|recurrent adult immunoblastic large cell lymphoma
473492|NCT00806767|recurrent adult lymphoblastic lymphoma
473493|NCT00806767|recurrent cutaneous T-cell non-Hodgkin lymphoma
473494|NCT00806767|recurrent grade 1 follicular lymphoma
473495|NCT00806767|recurrent grade 2 follicular lymphoma
473496|NCT00806767|recurrent grade 3 follicular lymphoma
473497|NCT00806767|recurrent mantle cell lymphoma
473498|NCT00806767|recurrent marginal zone lymphoma
473499|NCT00806767|recurrent small lymphocytic lymphoma
473500|NCT00806767|recurrent mycosis fungoides/Sezary syndrome
473501|NCT00806767|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
473502|NCT00806767|nodal marginal zone B-cell lymphoma
473503|NCT00806767|splenic marginal zone lymphoma
473504|NCT00806767|noncontiguous stage II adult Burkitt lymphoma
473505|NCT00806767|noncontiguous stage II adult diffuse large cell lymphoma
473506|NCT00806767|noncontiguous stage II adult diffuse mixed cell lymphoma
473507|NCT00806767|noncontiguous stage II adult diffuse small cleaved cell lymphoma
473508|NCT00806767|noncontiguous stage II adult immunoblastic large cell lymphoma
473509|NCT00806767|noncontiguous stage II adult lymphoblastic lymphoma
473510|NCT00806767|noncontiguous stage II grade 1 follicular lymphoma
473511|NCT00806767|noncontiguous stage II grade 2 follicular lymphoma
473512|NCT00806767|noncontiguous stage II grade 3 follicular lymphoma
473513|NCT00806767|noncontiguous stage II mantle cell lymphoma
473514|NCT00806767|noncontiguous stage II marginal zone lymphoma
473515|NCT00806767|noncontiguous stage II small lymphocytic lymphoma
473516|NCT00806767|accelerated phase chronic myelogenous leukemia
473517|NCT00806767|adult acute lymphoblastic leukemia in remission
473518|NCT00806767|adult acute myeloid leukemia in remission
473519|NCT00806767|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
473520|NCT00806767|adult acute myeloid leukemia with inv(16)(p13;q22)
473521|NCT00806767|adult acute myeloid leukemia with t(15;17)(q22;q12)
473522|NCT00806767|adult acute myeloid leukemia with t(16;16)(p13;q22)
473523|NCT00806767|adult acute myeloid leukemia with t(8;21)(q22;q22)
473524|NCT00806767|atypical chronic myeloid leukemia, BCR-ABL1 negative
473525|NCT00806767|blastic phase chronic myelogenous leukemia
473526|NCT00806767|chronic myelomonocytic leukemia
473527|NCT00806767|chronic phase chronic myelogenous leukemia
473528|NCT00806767|recurrent adult acute lymphoblastic leukemia
473529|NCT00806767|recurrent adult acute myeloid leukemia
473530|NCT00806767|recurrent childhood acute lymphoblastic leukemia
473531|NCT00806767|recurrent childhood acute myeloid leukemia
473532|NCT00806767|refractory chronic lymphocytic leukemia
473533|NCT00806767|refractory hairy cell leukemia
473534|NCT00806767|relapsing chronic myelogenous leukemia
473535|NCT00806767|secondary acute myeloid leukemia
473536|NCT00806767|stage III chronic lymphocytic leukemia
473537|NCT00806767|stage IV chronic lymphocytic leukemia
473538|NCT00806767|chronic eosinophilic leukemia
473539|NCT00806767|primary myelofibrosis
473540|NCT00806767|chronic neutrophilic leukemia
473541|NCT00806767|de novo myelodysplastic syndromes
473542|NCT00806767|myelodysplastic/myeloproliferative neoplasm, unclassifiable
473543|NCT00806767|previously treated myelodysplastic syndromes
473544|NCT00806767|secondary myelodysplastic syndromes
473545|NCT00806767|stage I multiple myeloma
473546|NCT00806767|stage II multiple myeloma
473547|NCT00806767|stage III multiple myeloma
473548|NCT00806767|refractory multiple myeloma
473549|NCT00806754|Perennial Allergic Rhinitis
473550|NCT00806754|Ciclesonide
473551|NCT00806754|PAR
473552|NCT00806741|L-NG-Monomethyl Arginine
473553|NCT00806741|Optic Nerve Head blood flow
473554|NCT00806741|Intraocular Pressure
473555|NCT00806741|Regional blood flow
473556|NCT00806741|Ocular Physiology
473557|NCT00806741|Optic Disk
473558|NCT00806715|hemochromatosis
473559|NCT00806715|Iron overload
473560|NCT00806715|Stem cell transplant
473561|NCT00806715|Pediatrics
473562|NCT00806715|Pediatric Stem cell transplant
473563|NCT00806689|heart rhythm surveillance
473564|NCT00806689|follow-up
473565|NCT00806689|atrial fibrillation success
473566|NCT00806676|chronic kidney disease
473567|NCT00806676|children
473568|NCT00806676|dialysis
473569|NCT00806676|kidney transplant
473570|NCT00806676|human papilloma virus
473571|NCT00806676|Gardasil
473572|NCT00806676|Chronic kidney disease (non-dialysis, dialysis, and kidney transplant) secondary to any cause.
473573|NCT00806663|mCRC
473574|NCT00806663|colorectal cancer
473575|NCT00806663|FOLFIRI
473576|NCT00806663|sunitinib
473577|NCT00806663|DCE-MRI
473578|NCT00806663|DCE-USI
473579|NCT00806650|stage I renal cell cancer
473580|NCT00806650|stage II renal cell cancer
473581|NCT00806650|stage III renal cell cancer
473582|NCT00806650|stage IV renal cell cancer
473583|NCT00806637|Vessel sealing system
473584|NCT00806637|uvulopalatoplasty
473585|NCT00806637|UPPP
473586|NCT00806637|uvulopalatal flap
473587|NCT00806637|bleeding
473588|NCT00806637|operative time
473589|NCT00806637|adverse effects
473590|NCT00806611|pancreatic cancer
473591|NCT00806611|periampullary cancer
473592|NCT00806611|resectable
473593|NCT00806611|unresectable
473594|NCT00806611|celiac plexus neurolysis
473595|NCT00806611|surgery
473596|NCT00806598|Myelodysplastic Syndrome
473597|NCT00806598|Aplastic Anemia
473598|NCT00806598|Thymoglobulin
473599|NCT00806598|Cyclosporine
473600|NCT00806598|Methylprednisolone
473601|NCT00806598|G-CSF
473602|NCT00806572|Diabetes, juvenile diabetes, teplizumab
473603|NCT00806559|effects clinical space
473604|NCT00806559|follow-up appointments
473605|NCT00806520|Continuous Glucose Monitoring
473606|NCT00806520|Exenatide Once Weekly or
473607|NCT00806520|Januvia or
473608|NCT00806520|Actos
473609|NCT00806507|Tissue Doppler Imaging
473610|NCT00806507|B-type natriuretic peptide
473611|NCT00806507|Advia Centaur immunoassay system
473612|NCT00806507|GE Vivid ultrasound machine
473613|NCT00806507|Roche 2010 system
473614|NCT00806507|Echocardiography
473615|NCT00806507|Herceptin
473616|NCT00806494|Fesoterodine
473617|NCT00806494|Open Label
473618|NCT00806494|Flexible Dose
473619|NCT00806494|OAB
473620|NCT00806481|Phosphate
473621|NCT00806468|nycturia
473622|NCT00806468|Parkinson syndrome
473623|NCT00806468|desmopressin
473624|NCT00806468|Nocturnal polyuria in patients with Parkinson syndrome
473625|NCT00806455|to determine how often exercise-induced bronchospasm
473626|NCT00806455|occurs in cystic fibrosis
473627|NCT00806455|Exercise-induced bronchospasm in cystic fibrosis
473628|NCT00806442|Asthma
473629|NCT00806442|Fatty acids
473630|NCT00806442|Leukotrienes
473631|NCT00806442|Diet
473632|NCT00806429|appendicitis
473633|NCT00806429|surgery
473634|NCT00806429|laparoscopy
473635|NCT00806429|natural orifice transluminal surgery
473636|NCT00806403|thrombolysis
473637|NCT00806403|primary PCI
473638|NCT00806403|abciximab
473639|NCT00806403|ST-segment resolution
473640|NCT00806403|TIMI flow
473641|NCT00806390|ejection fraction
473642|NCT00806390|anthracyclines
473643|NCT00806390|beta-adrenergic blockade
473644|NCT00806390|Patients receiving anthracyclines
473645|NCT00806377|Electromagnetic field
473646|NCT00806377|Oversensing
473647|NCT00806377|Non-thoracic surgery
473648|NCT00806364|Healthy Volunteers
473649|NCT00806364|Allergy
473650|NCT00806364|Bone Marrow
473651|NCT00806364|Buccal Mucosa
473652|NCT00806364|HV
473653|NCT00806364|Healthy Volunteer
473654|NCT00806351|Candidiasis; Invasive Candidiasis; Candida; Candidemia; Fungal Infection; Neutropenia
473655|NCT00806325|Severe Sepsis
473656|NCT00806325|Acute Myeloid Leukemia
473657|NCT00806325|Sepsis in patients being treated for Acute Myeloid Leukemia
473658|NCT00806312|MiRNA
473659|NCT00806312|pulmonary arterial hypertension
473660|NCT00806273|debridement
473661|NCT00806273|root canal
473662|NCT00806260|Overweight
473663|NCT00806260|Obesity
473664|NCT00806260|coordination
473665|NCT00806260|psychomotor
473666|NCT00806247|Tapentadol
473667|NCT00806247|Bunionectomy
473668|NCT00806247|Analgesia
473669|NCT00806247|Acute pain
473670|NCT00806247|Postsurgical pain
473671|NCT00806234|Weight Gain
473672|NCT00806234|Obesity
473673|NCT00806234|IMPACT
473674|NCT00806234|Antipsychotic Treatment
473675|NCT00806234|Excessive Weight Gain Associated With Antipsychotic Treatment
473676|NCT00806234|Hybrid Efficacy/Effectiveness Design
473677|NCT00806234|Reducing Weight Gain
473678|NCT00806234|Improving Metabolic Parameters
473679|NCT00806234|Aripiprazole
473680|NCT00806234|Metformin
473681|NCT00806234|Risperdal
473682|NCT00806234|Seroquel
473683|NCT00806234|Quetiapine
473684|NCT00806234|Olanzapine
473685|NCT00806234|Zyprexa
473686|NCT00806234|Geodon
473687|NCT00806234|Risperidone
473688|NCT00806234|Abilify
473689|NCT00806234|Trilafon
473690|NCT00806234|Perphenazine
473691|NCT00806234|Glucophage
473692|NCT00806234|Paliperidone
473693|NCT00806234|Olanzapine/fluoxetine
473694|NCT00806221|Atopic Dermatitis
473695|NCT00806221|Prevention
473696|NCT00806221|Skin Barrier
473697|NCT00806195|vaccine
473698|NCT00806195|infants
473699|NCT00806195|healthy
473700|NCT00806195|meningitis
473701|NCT00806195|meningococcal
473702|NCT00806182|paraneoplastic
473703|NCT00806182|neuroblastoma
473704|NCT00806182|Kinsbourne syndrome
473705|NCT00806182|autoimmune disease
473706|NCT00806182|immunotherapy
473707|NCT00806182|ataxia
473708|NCT00806169|combined therapy
473709|NCT00806169|DRP
473710|NCT00806169|efficacy
473711|NCT00806169|safety
473712|NCT00806169|sustainability
473713|NCT00806169|macular edema due to DRP
473714|NCT00806143|Depression
473715|NCT00806143|TMS
473716|NCT00804440|bioequivalency
473717|NCT00804440|ibuprofen
473718|NCT00804414|Diabetes
473719|NCT00804414|Diabetic ulcer
473720|NCT00804414|Chronic ulcer
473721|NCT00804414|SBG
473722|NCT00804401|bioequivalency
473723|NCT00804401|Naproxen
473724|NCT00804388|Vitamine E
473725|NCT00804388|E-poly
473726|NCT00804388|Hip
473727|NCT00804388|Degenerative joint disease
473728|NCT00804375|stump pain
473729|NCT00804349|Heart Decompensation
473730|NCT00804349|Heart Failure, Congestive
473731|NCT00804349|Heart Failure, Left-Sided
473732|NCT00804349|Heart Failure, Right-Sided
473733|NCT00804349|Apnea, Sleep
473734|NCT00804349|Sleep Apnea, Mixed Central and Obstructive
473735|NCT00804349|Sleep Hypopnea
473736|NCT00804349|Sleep-Disordered Breathing
473737|NCT00804336|pasireotide
473738|NCT00804336|SOM230
473739|NCT00804336|RAD001
473740|NCT00804310|unspecified adult solid tumor, protocol specific
473741|NCT00804297|Hypoglycemia
473742|NCT00804297|Diabetes Mellitus
473743|NCT00804297|Octreotide
473744|NCT00804284|DAPTACEL®
473745|NCT00804284|PENTACEL®
473746|NCT00804284|Diphtheria
473747|NCT00804284|Tetanus
473748|NCT00804284|Pertussis
473749|NCT00804284|Haemophilus influenzae type b
473750|NCT00804258|recurrent ovarian epithelial cancer
473751|NCT00804258|recurrent ovarian germ cell tumor
473752|NCT00804258|stage I ovarian epithelial cancer
473753|NCT00804258|stage I ovarian germ cell tumor
473754|NCT00804258|stage II ovarian epithelial cancer
473755|NCT00804258|stage II ovarian germ cell tumor
473756|NCT00804258|stage III ovarian epithelial cancer
473757|NCT00804258|stage III ovarian germ cell tumor
473758|NCT00804258|stage IV ovarian epithelial cancer
473759|NCT00804258|stage IV ovarian germ cell tumor
473760|NCT00804245|adenocarcinoma of the prostate
473761|NCT00804245|stage I prostate cancer
473762|NCT00804245|stage II prostate cancer
473763|NCT00804245|stage III prostate cancer
473764|NCT00804245|stage IV prostate cancer
473765|NCT00804232|Diabetes type1; children
473766|NCT00804219|low responsiveness after vaccination
473767|NCT00804206|Intravitreal injection of Bevacizumab
473768|NCT00804206|Visual acuity
473769|NCT00804206|central retinal thickness
473770|NCT00804206|color studies, Farnsworth-Munsell
473771|NCT00804206|electroretinogram studies
473772|NCT00806117|Cervical cancer
473773|NCT00806117|Concurrent chemoradiation
473774|NCT00806117|Randomized controlled clinical trials
473775|NCT00806091|AM proteomes will be compared between smokers with and without COPD
473776|NCT00806078|Healthy
473777|NCT00806078|Bioequivalence
473778|NCT00806078|Pharmacokinetics
473779|NCT00806039|Kidney Failure, Acute
473780|NCT00806039|Renal Insufficiency, Acute
473781|NCT00806039|Kidney Failure
473782|NCT00806039|Renal Insufficiency
473783|NCT00806026|RLS
473784|NCT00806013|genotype
473785|NCT00806000|Prevalence of Exercised induced asthma in athletes
473786|NCT00805974|diapasom
473787|NCT00805974|sleep quality
473788|NCT00805974|type I diabete
473789|NCT00805974|blood pressure
473790|NCT00805974|plasma glucose
473791|NCT00805974|daytime and nighttime variations
473792|NCT00805961|Glioblastoma Multiforme
473793|NCT00805961|Radiation Therapy
473794|NCT00805961|Temozolomide
473795|NCT00805961|Bevacizumab
473796|NCT00805961|Everolimus
473797|NCT00805948|thoracic aneurysm
473798|NCT00805948|thoracic aortic aneurysms
473799|NCT00805948|Thoracic Endovascular Aneurysm Repair (TEVAR)
473800|NCT00805948|Talent Thoracic Stent Graft
473801|NCT00805935|pre-menopausal women
473802|NCT00805935|PCOS
473803|NCT00805935|polycystic ovarian syndrome
473804|NCT00805935|infertility
473805|NCT00805935|IVF
473806|NCT00805935|in vitro fertilization
473807|NCT00805883|Prostate Neoplasm
473808|NCT00805883|Localized
473809|NCT00805883|Photothermal
473810|NCT00805883|Radical Prostatectomy
473811|NCT00805844|Spine
473812|NCT00805844|Motor Evoked Potentials
473813|NCT00805831|sutureless vascular bypass
473814|NCT00805805|Copper
473815|NCT00805805|ceruloplasmin
473816|NCT00805805|tetrathiomolybdate
473817|NCT00805792|Ischemic stroke
473818|NCT00805792|treatment
473819|NCT00805792|recovery
473820|NCT00805792|donepezil
473821|NCT00805792|Aricept
473822|NCT00805779|Overactive Bladder
473823|NCT00805779|Overactive Urinary Bladder
473824|NCT00805779|Bladder, Overactive
473825|NCT00805779|Overactive Detrusor
473826|NCT00805779|Detrusor, Overactive
473827|NCT00805779|Overactive Detrusor Function
473828|NCT00805779|Detrusor Function, Overactive
473829|NCT00805766|Infliximab
473830|NCT00805766|REMICADE
473831|NCT00805766|Crohn's disease
473832|NCT00805740|Candidiasis; Invasive Candidiasis; Deep Tissue Candidiasis; Candida; Candidemia; Fungal Infection
473833|NCT00805714|Hydroxymethylglutaryl-CoA Reductase Inhibitors
473834|NCT00805701|prostate
473835|NCT00805701|cancer
473836|NCT00805701|avodart
473837|NCT00805701|dutasteride
473838|NCT00805701|mitcheson
473839|NCT00805688|Questionnaire
473840|NCT00805688|Pancreas
473841|NCT00805688|Pancreatic Cancer
473842|NCT00805688|Metastatic Disease
473843|NCT00805688|symptom outcomes
473844|NCT00805688|Biomarkers
473845|NCT00805688|Pedometer
473846|NCT00805688|MDASI-GI symptom assessment
473847|NCT00805688|interactive voice response telephone system
473848|NCT00805688|IVRS
473849|NCT00805675|Chronic HBV
473850|NCT00805675|Asian adult subjects with chronic HBV, in immune tolerant phase, and positive for hepatitis B e antigen (HBeAg)
473851|NCT00805662|IUI
473852|NCT00805662|oxytocin
473853|NCT00805649|ARMD
473854|NCT00805649|combined therapy
473855|NCT00805649|efficacy
473856|NCT00805649|safety
473857|NCT00805636|cell death
473858|NCT00805636|PET imaging
473859|NCT00805636|brain metastases
473860|NCT00805636|stereotactic radiosurgery
473861|NCT00805623|sucrose
473862|NCT00805623|sucking
473863|NCT00805623|pain relief
473864|NCT00805623|infant
473865|NCT00805623|require venous puncture
473866|NCT00805610|Liver Failure
473867|NCT00805610|Hepatocyte Transplantation
473868|NCT00805610|Liver Transplantation
473869|NCT00805597|breast cancer
473870|NCT00805597|mastectomy
473871|NCT00805597|one to three positive nodes
473872|NCT00805597|radiotherapy
473873|NCT00805571|Rejection
473874|NCT00805571|Infection
473875|NCT00805571|Side effect of immunosuppressive drug (nephrotoxicity)
473876|NCT00805558|Chronic Periodontitis
473877|NCT00805558|antibiotics
473878|NCT00805532|PTSD
473879|NCT00805532|depression
473880|NCT00805532|behavior therapy
473881|NCT00805532|veterans
473882|NCT00805532|behavioral activation
473883|NCT00805532|usual care
473884|NCT00805519|Osteoarthritis of the Knee
473885|NCT00805519|Glucosamine Chondroitin sulfate
473886|NCT00805519|Prednisolone
473887|NCT00805519|Chloroquine
473888|NCT00805506|continuous glucose monitoring accuracy
473889|NCT00805493|Mania
473890|NCT00805493|Bipolar
473891|NCT00805493|Bipolar Disorder
473892|NCT00805493|Bipolar Manic-Depressive Illness
473893|NCT00805493|Bipolar Mood Disorder
473894|NCT00805480|Plaque
473895|NCT00805480|psoriasis
473896|NCT00805480|inflammatory skin disease
473897|NCT00805480|skin condition, thickening
473898|NCT00805480|flaking
473899|NCT00805480|scaly patches
473900|NCT00805480|skin disease
473901|NCT00805467|RA
473902|NCT00805454|Healthy Volunteers
473903|NCT00805454|Phase I
473904|NCT00805454|Pet Scan
473905|NCT00805441|Alcoholic
473906|NCT00804193|Tinea Pedis
473907|NCT00804193|Ciclopirox Olamine
473908|NCT00804180|anxiety
473909|NCT00804180|injection
473910|NCT00804180|needle
473911|NCT00804180|pediatric
473912|NCT00804180|youth
473913|NCT00804180|children
473914|NCT00804180|adolescents
473915|NCT00804180|cognitive behavioral
473916|NCT00804180|behavioral
473917|NCT00804180|exposure
473918|NCT00804180|group
473919|NCT00804180|treatment
473920|NCT00804180|chronic illness
473921|NCT00804180|adherence
473922|NCT00804167|Hypertensive patients aged of 75 years and older
473923|NCT00804167|renal damage
473924|NCT00804167|Clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage
473925|NCT00804154|Pain
473926|NCT00804154|Vanilloid
473927|NCT00804154|Capsaicin
473928|NCT00804154|Cancer Pain
473929|NCT00804154|Resiniferatoxin
473930|NCT00804141|treatment for opioid-induced constipation
473931|NCT00805415|Oral Contraceptive
473932|NCT00805415|Ovulation Inhibition
473933|NCT00805389|Adjuvant Systems
473934|NCT00805389|Hepatitis B
473935|NCT00805376|Brain
473936|NCT00805376|Brain Cancer
473937|NCT00805376|Central Nervous System Diseases
473938|NCT00805376|CNS
473939|NCT00805376|Conditionally Replication-Competent Adenovirus
473940|NCT00805376|Delta-24-RGD
473941|NCT00805376|DNX-2401
473942|NCT00805376|Recurrent Malignant Gliomas
473943|NCT00805376|malignant brain tumor
473944|NCT00805350|Insomnia
473945|NCT00805350|Sleep Maintenance
473946|NCT00805350|Polysomnography
473947|NCT00805337|Cancer amplitude-modulated electromagnetic fields
473948|NCT00805311|Internal Carotid Artery Stenosis
473949|NCT00805311|Carotid Endarterectomy
473950|NCT00805311|Stroke
473951|NCT00805311|Cerebrovascular
473952|NCT00805311|Atherosclerosis
473953|NCT00805298|third molar
473954|NCT00805298|postoperative pain
473955|NCT00805298|thermography
473956|NCT00805298|postoperative inflammation
473957|NCT00805298|methylprednisolone
473958|NCT00805298|local anaesthetic
473959|NCT00805298|postoperative pain after removal of lower third molars
473960|NCT00805298|inflammation after removal of lower third molars
473961|NCT00805285|Inflammatory Bowel Disease
473962|NCT00805285|Ulcerative Colitis
473963|NCT00805285|Budesonide
473964|NCT00805285|Corticosteroids
473965|NCT00805272|HIV
473966|NCT00805272|tuberculosis
473967|NCT00805272|IGRA
473968|NCT00805272|diagnosis
473969|NCT00805272|treatment naive
473970|NCT00805259|cognitive function
473971|NCT00805259|elderly
473972|NCT00805259|technology
473973|NCT00805259|financial incentives
473974|NCT00805259|General maintenance of cognitive function
473975|NCT00805246|Pulmonary embolism
473976|NCT00805246|PE
473977|NCT00805246|CT
473978|NCT00805246|Biomarker
473979|NCT00805246|Prognosis
473980|NCT00805246|Risk Prediction
473981|NCT00805233|Neovascular
473982|NCT00805233|AMD
473983|NCT00805233|Treatment
473984|NCT00805233|Lucentis
473985|NCT00805233|Bromfenac
473986|NCT00805220|frail elderly walking capacity walk training Nordic Walking
473987|NCT00805207|PCOS
473988|NCT00805207|sleep apnea
473989|NCT00805207|obese
473990|NCT00805207|VLDL metabolism
473991|NCT00805207|isotope tracer
473992|NCT00805207|women
473993|NCT00805168|Gram-negative Pneumonia
473994|NCT00805168|Pneumonia
473995|NCT00805168|Intubation
473996|NCT00805168|Mechanical ventilation
473997|NCT00805168|Amikacin
473998|NCT00805155|Bioequivalence
473999|NCT00805155|Mometasone Furoate
474000|NCT00805142|Pain
474001|NCT00805142|Cancer
474002|NCT00805142|Tapentadol
474003|NCT00805129|URETER
474004|NCT00805129|URINARY BLADDER
474005|NCT00805129|RAD001
474006|NCT00805129|Everolimus
474007|NCT00805129|Urothelium
474008|NCT00805129|08-123
474009|NCT00805103|Brain Metastases
474010|NCT00805103|Stereotactic radiosurgery (SRS)
474011|NCT00805103|Hypofractionated stereotactic radiotherapy (HSRT)
474012|NCT00805103|Recurrent Brain Metastases
474013|NCT00805090|Renal
474014|NCT00805090|Hepatic
474015|NCT00805090|Healthy
474016|NCT00805077|interoperative care
474017|NCT00805077|Tidal volume
474018|NCT00805077|Postoperative complications
474019|NCT00805077|Pneumonectomy
474020|NCT00805077|Lobectomy
474021|NCT00805077|Mechanical ventilation
474022|NCT00805051|Aortic stenosis
474023|NCT00805051|aortic valve replacement
474024|NCT00805051|von Willebrand disease
474025|NCT00805051|blood loss
474026|NCT00805012|S-1
474027|NCT00805012|docetaxel
474028|NCT00805012|head and neck cancer
474029|NCT00805012|Recurrent or metastatic head and neck squamous cell carcinoma
474030|NCT00804999|confocal microscopy
474031|NCT00804999|contact lens wear
474032|NCT00804999|contact lens solutions
474033|NCT00804999|sodium fluorescein
474034|NCT00804973|Migraine
474035|NCT00804973|Headache
474036|NCT00804960|Cost of Infertility Treatment
474037|NCT00804960|Ovulation Induction
474038|NCT00804960|Letrozole
474039|NCT00804960|In Vitro Fertilization
474040|NCT00804947|Autologous transplantation
474041|NCT00804947|Multiple Myeloma
474042|NCT00804947|Intravenous Busulfan
474043|NCT00804921|bevacizumab
474044|NCT00804921|intra-ocular pressure
474045|NCT00804921|acetazolamide
474046|NCT00804921|anterior chamber paracentesis
474047|NCT00804921|brimonidine
474048|NCT00804921|macular edema secondary to diabetic retinopathy or macular degeneration
474049|NCT00804908|Temozolomide
474050|NCT00804908|MM
474051|NCT00804908|Metastatic Melanoma
474052|NCT00804908|ABT-888
474053|NCT00804908|Skin cancer
474054|NCT00804908|Melanoma
474055|NCT00804895|cluster headache
474056|NCT00804895|greater occipital nerve block
474057|NCT00804895|cortivazol
474058|NCT00804882|Metabolic syndrome
474059|NCT00804882|Heart failure
474060|NCT00804882|Mexican Americans
474061|NCT00804882|Ethnic differences
474062|NCT00804882|Echocardiography
474063|NCT00804830|adjuvant
474064|NCT00804830|Anaplastic thyroid cancer
474065|NCT00804817|self management
474066|NCT00804817|adherence
474067|NCT00804817|activity enhancement
474068|NCT00804817|oral mucositis prevention
474069|NCT00804817|and mal nutrition prevention
474070|NCT00804817|cancer
474071|NCT00804817|hematopoietic stem cell transplantation (HSCT)
474072|NCT00804817|loss of activity
474073|NCT00804804|Sleep
474074|NCT00804804|aging
474075|NCT00804804|cognitives processes
474076|NCT00804804|constant routine
474077|NCT00804791|dry eye
474078|NCT00804791|autofluorescence
474079|NCT00804791|residence time
474080|NCT00804778|CAD
474081|NCT00804778|CABG
474082|NCT00804778|CO
474083|NCT00804778|CI
474084|NCT00804778|thermodilution
474085|NCT00804778|USCOM
474086|NCT00804765|Prevention
474087|NCT00804765|child obesity
474088|NCT00804765|pregnancy
474089|NCT00804765|overweight women
474090|NCT00804765|obese women
474091|NCT00804752|Patients with Chronic Hepatitis C
474092|NCT00804739|Major Depression
474093|NCT00804739|Postpartum Depression
474094|NCT00804739|Perinatal Depression
474095|NCT00804739|Treatment Feasibility
474096|NCT00804739|Treatment Engagement
474097|NCT00804739|Treatment Adherence
474098|NCT00804739|Postpartum
474099|NCT00804739|Interpersonal Psychotherapy
474100|NCT00804739|IPT
474101|NCT00804739|Sertraline
474102|NCT00804739|Zoloft
474103|NCT00804726|Cataract extraction
474104|NCT00804726|Phacoemulsification
474105|NCT00804713|TB
474106|NCT00804713|tuberculosis diagnosis
474107|NCT00804713|TB screening
474108|NCT00804700|synchronous
474109|NCT00804700|exercise
474110|NCT00804700|music
474111|NCT00804700|heartbeat
474112|NCT00804700|tunes
474113|NCT00804687|Allergy
474114|NCT00804687|Rhinitis
474115|NCT00804687|Allergic Rhinitis
474116|NCT00804687|JNJ-39220675
474117|NCT00804687|Pseudoephedrine
474118|NCT00804674|bupivacain
474119|NCT00804674|breast
474120|NCT00804674|reconstruction
474121|NCT00804674|diep
474122|NCT00804674|pain
474123|NCT00804674|postoperative
474124|NCT00804674|catheter
474125|NCT00804674|anesthesia
474126|NCT00804661|sleep
474127|NCT00804661|nocturnal hypoventilation
474128|NCT00804661|sleep quality
474129|NCT00804661|lung function
474130|NCT00804622|HBeAg positive compensated chronic hepatitis B
474131|NCT00804583|Cystic Fibrosis
474132|NCT00804583|Liver Disease
474133|NCT00804583|Genetic Modifiers
474134|NCT00804557|Male Urinary Disorders
474135|NCT00804557|Urinary catheterization
474136|NCT00804557|Urinary retention
474137|NCT00804544|Integrated SPECT/CT
474138|NCT00804544|99mTc-sestMIBI
474139|NCT00804544|Chemosensitivity
474140|NCT00804531|Low back pain
474141|NCT00804531|steroid injection
474142|NCT00804531|inter-vertebral disc
474143|NCT00804531|randomized trial
474144|NCT00804531|Lack of efficacy of usual recommended treatments
474145|NCT00804531|More than 40 on the pain numeric scale (0-100)
474146|NCT00804531|Inflammatory discopathy (MODIC I) on MRI
474147|NCT00804518|Aging
474148|NCT00804518|Diastolic dysfunction
474149|NCT00804518|Systolic function
474150|NCT00804518|Exercise
474151|NCT00804518|Echocardiography
474152|NCT00804518|tissue Doppler imaging
474153|NCT00804518|Cardiac function
474154|NCT00804505|Substantial equivalence to control device
474155|NCT00804492|To organize a multidisciplinary team for integrated falls prevention
474156|NCT00804492|To draft a guideline for falls prevention in the elderly
474157|NCT00804492|To set up a multidisciplinary fall clinic
474158|NCT00804492|To set up a falls prevention classroom
474159|NCT00804492|To enhance cooperate between hospitals and primary care units for falls prevention
474160|NCT00804466|Human Papillomavirus
474161|NCT00804466|Natural History
474162|NCT00804466|Cervical Cancer
474163|NCT00804466|Screening
474164|NCT00804453|Chronic Kidney Failure
474165|NCT00804453|Hemodialysis
474166|NCT00804453|Biocompatibility
474167|NCT00804128|ductal breast carcinoma in situ
474168|NCT00804115|Exfoliation Syndrome
474169|NCT00804115|Latanoprost
474170|NCT00804115|Timolol
474171|NCT00804115|Pilocarpine
474172|NCT00804102|Retinitis pigmentosa
474173|NCT00804102|Macula off
474174|NCT00804102|Primary open angle Glaucoma
474175|NCT00804102|Hereditary Macular Degeneration
474176|NCT00804102|Treated Retina detachment
474177|NCT00804102|Retinal Artery Occlusion
474178|NCT00804102|Retinal Vein Occlusion,
474179|NCT00804102|Non-Arthritic-Anterior-Ischemic Optic-Neuropathy
474180|NCT00804102|Hereditary autosomal dominant Optic atrophy
474181|NCT00804102|dry Age-related Macular Degeneration
474182|NCT00804102|Ischemic Macula edema
474183|NCT00804089|Low Back Pain, Chronic
474184|NCT00804089|Acupuncture
474185|NCT00804089|Dry Needling
474186|NCT00804089|Acupressure
474187|NCT00804089|Acupuncture Points
474188|NCT00804089|Trigger Points, Myofascial
474189|NCT00804076|gene therapy
474190|NCT00804076|replication defective HSV vector
474191|NCT00804076|pain
474192|NCT00804076|enkephalin
474193|NCT00804076|intradermal
474194|NCT00804063|glaucoma
474195|NCT00804063|citrate
474196|NCT00804050|Myelodysplastic Syndromes
474197|NCT00804050|Erythropoietin
474198|NCT00804050|Acid 13-Cis-Retinoic
474199|NCT00804050|Dihydroxyvitamin D3
474200|NCT00804050|low or intermediate-1 IPSS
474201|NCT00804050|MDS low risk
474202|NCT00804037|Snoring and Mild Apnea
474203|NCT00804024|Heart Diseases. Vascular Diseases.
474204|NCT00804011|Snakebite
474205|NCT00804011|Weaning
474206|NCT00804011|Mechanical ventilation
474207|NCT00803985|Inguinal hernia
474208|NCT00803985|TEP
474209|NCT00803985|Lichtenstein
474210|NCT00803985|mesh
474211|NCT00803985|Randomized
474212|NCT00803985|Chronic pain
474213|NCT00803985|Sexual dysfunction
474214|NCT00803972|Humalog
474215|NCT00803972|Humulin R
474216|NCT00803972|rHuPH20
474217|NCT00803972|Hylenex
474218|NCT00803959|Stress urinary incontinence, Mixed, Urge
474219|NCT00803946|bioequivalency
474220|NCT00803946|ibuprofen
474221|NCT00803933|first stage
474222|NCT00803933|Trypanosoma brucei gambiense
474223|NCT00803933|T. b. gambiense
474224|NCT00803933|sleeping sickness
474225|NCT00803933|First stage T. b. gambiense sleeping sickness
474226|NCT00803920|exenatide twice daily or once weekly
474227|NCT00803920|continuous glucose monitoring
474228|NCT00803907|immunomodulator
474229|NCT00803907|Carcinoma, Basal Cell
474230|NCT00803894|Biomarkers of Notch inhibition
474231|NCT00803855|single dose
474232|NCT00803855|pharmacokinetics
474233|NCT00803855|safety
474234|NCT00803855|healthy volunteers
474235|NCT00803855|food interaction
474236|NCT00803855|AZD1446
474237|NCT00803842|erlotinib
474238|NCT00803842|rash
474239|NCT00803842|supportive care
474240|NCT00803816|endogoneous
474241|NCT00803816|posterior
474242|NCT00803816|intermediate
474243|NCT00803803|Pilocarpine
474244|NCT00803803|POAG
474245|NCT00803803|IOP
474246|NCT00803803|Concentration
474247|NCT00803803|Frequency
474248|NCT00803803|Primary open-angle glaucoma
474249|NCT00803803|Primary open-angle glaucoma suspect
474250|NCT00803764|bioequivalency
474251|NCT00803764|naproxen
474252|NCT00803751|Laryngoscopy [E04.580.373]
474253|NCT00803738|Vulvovaginal Candidiasis
474254|NCT00803738|Terconazole
474255|NCT00803725|spinal anesthesia
474256|NCT00803725|mepivacaine
474257|NCT00803725|fentanyl
474258|NCT00803725|duration of anesthesia
474259|NCT00803725|knee arthroscopy
474260|NCT00803725|regional anesthesia
474261|NCT00803725|Spinal anesthesia for knee arthroscopy
474262|NCT00803699|selenium
474263|NCT00803673|Healthy volunteers
474264|NCT00803673|New formulation
474265|NCT00803660|hypertension
474266|NCT00803660|BP
474267|NCT00803660|diabetes
474268|NCT00803660|anti-hypertensive treatment
474269|NCT00803660|ACE-I
474270|NCT00803660|ARB
474271|NCT00803647|NSABP
474272|NCT00803647|Cetuximab
474273|NCT00803647|FOLFOX7
474274|NCT00803647|Oxaliplatin
474275|NCT00803647|Leucovorin
474276|NCT00803647|5-FU
474277|NCT00803647|colorectal cancer
474278|NCT00803647|KRAS wild type
474279|NCT00803647|metastatic colorectal cancer
474280|NCT00803647|Erbitux
474281|NCT00803647|Eloxatin
474282|NCT00803647|Liver resection
474283|NCT00803647|Liver ablation
474284|NCT00803647|Metastasectomy
474285|NCT00803634|Hypertension
474286|NCT00803634|Antihypertensive Agent
474287|NCT00803634|Calcium Channel Blocker
474288|NCT00803608|Plantar
474289|NCT00803608|Ulcer
474290|NCT00803608|Diabetes
474291|NCT00803595|Influenza
474292|NCT00803595|Neuraminidase inhibitor
474293|NCT00803569|recurrent ovarian epithelial cancer
474294|NCT00803569|stage II ovarian epithelial cancer
474295|NCT00803569|stage III ovarian epithelial cancer
474296|NCT00803569|stage IV ovarian epithelial cancer
474297|NCT00803569|fallopian tube cancer
474298|NCT00803569|peritoneal cavity cancer
474299|NCT00803543|HSV-2
474300|NCT00803543|Herpes Simplex
474301|NCT00803543|HSV Type 2
474302|NCT00803543|HIV
474303|NCT00803543|HIV/HSV
474304|NCT00803543|treatment experienced
474305|NCT00803530|myelodysplastic syndromes
474306|NCT00803530|arsenic trioxide
474307|NCT00803530|ascorbic acid
474308|NCT00803517|chronic central serous chorioretinopathy
474309|NCT00803517|multifocal electroretinogram
474310|NCT00803517|central retinal function after treatment in chronic serous chorioretinopathy
474311|NCT00803504|optic disc morphology
474312|NCT00803504|ocular blood flow
474313|NCT00803504|retina
474314|NCT00803504|ocular physiology
474315|NCT00803491|Rheumatic diseases
474316|NCT00803491|Problem based learning
474317|NCT00803491|Health-related quality of life
474318|NCT00803491|Empowerment
474319|NCT00803491|Self-care
474320|NCT00803478|IntraLase LASIK for primary myopia
474321|NCT00803465|Bioequivalence
474322|NCT00803465|Fluticasone Propionate
474323|NCT00803452|Meibomian gland dysfunction
474324|NCT00803452|Lid margin disease
474325|NCT00803452|doxycycline
474326|NCT00803452|azithromycin
474327|NCT00803452|essential fatty acid
474328|NCT00803439|Bioequivalence
474329|NCT00803439|Clobetasol Propionate
474330|NCT00803426|ultrasound-guided regional anesthesia
474331|NCT00803426|nerve block
474332|NCT00803426|popliteal fossa
474333|NCT00803426|sciatic nerve
474334|NCT00803426|common peroneal nerve
474335|NCT00803426|tibial nerve
474336|NCT00803426|onset time
474337|NCT00803426|ankle surgery
474338|NCT00803426|foot surgery
474339|NCT00803413|Chronic low back pain
474340|NCT00803413|Back School
474341|NCT00803413|Walking
474342|NCT00803413|Physical activity
474343|NCT00803400|Panic disorder
474344|NCT00803400|Exercise
474345|NCT00803400|Alprazolam
474346|NCT00803400|Aerobic
474347|NCT00803387|ocular dryness
474348|NCT00803387|ocular irritation
474349|NCT00803387|open-angle glaucoma
474350|NCT00803387|ocular hypertension
474351|NCT00803387|TravatanZ
474352|NCT00803387|Xalatan
474353|NCT00803361|anxiety
474354|NCT00803348|continuous femoral nerve blockade
474355|NCT00803348|knee arthroplasty
474356|NCT00803348|knee replacement
474357|NCT00803348|regional anesthesia
474358|NCT00803348|readiness to discharge
474359|NCT00803348|Femoral nerve blockade for total knee arthroplasty
474360|NCT00803335|pelvic organ prolapse
474361|NCT00803335|vaginal atrophy
474362|NCT00803335|atrophic vaginitis
474363|NCT00803335|postmenopausal
474364|NCT00803335|posthysterectomy
474365|NCT00803335|vaginal health
474366|NCT00803335|vaginal cytology
474367|NCT00803335|vaginal maturity index
474368|NCT00803335|vaginal histology
474369|NCT00803335|quality of life questionnaires
474370|NCT00803322|TB
474371|NCT00803322|community
474372|NCT00803322|community health workers
474373|NCT00803322|Ethiopia
474374|NCT00803322|identify suspects of pulmonary tuberculosis
474375|NCT00803322|collect sputum specimen for examination
474376|NCT00803322|treat smear positive cases in the community
474377|NCT00803309|Chronic HCV-genotype 2/3
474378|NCT00803309|Efficacy of treatment extension
474379|NCT00803309|PegIntron
474380|NCT00803309|pegylated interferon alpha-2b
474381|NCT00803309|Rebetol
474382|NCT00803309|ribavirin
474383|NCT00803283|Pain
474384|NCT00803283|Hydromorphone hydrochloride OROS
474385|NCT00803283|Morphine
474386|NCT00803270|Stress urinary incontinence, Mixed, Urge
474387|NCT00803257|Carpal Tunnel Syndrome
474388|NCT00803257|Splint
474389|NCT00803257|Hand exercises
474390|NCT00803244|allergic rhinoconjunctivitis
474391|NCT00803218|Bioequivalence
474392|NCT00803218|Fluticasone Propionate
474393|NCT00803205|Cystic fibrosis
474394|NCT00803205|Nonsense mutation
474395|NCT00803205|Premature stop codon
474396|NCT00803205|PTC124
474397|NCT00803205|Ataluren
474398|NCT00803192|bioavailability
474399|NCT00803192|famotidine
474400|NCT00803179|CF
474401|NCT00803166|Bioequivalence
474402|NCT00803166|Halobetasol Propionate
474403|NCT00803153|Panretinal photocoagulation
474404|NCT00803153|Bruch rupture
474405|NCT00803153|Choroidal detachment
474406|NCT00803153|complication rates
474407|NCT00803140|scarring
474408|NCT00803127|vaginal infection, color appearance
474409|NCT00803114|Postpartum perineal pain
474410|NCT00803114|Epidural morphine
474411|NCT00803114|Randomised clinical trial
474412|NCT00803101|Anticoagulant reversal
474413|NCT00803101|Prothrombin Complex Concentrate
474414|NCT00803101|Coagulopathy
474415|NCT00803101|Coumarin derivatives
474416|NCT00803101|Emergency surgery
474417|NCT00803101|Invasive procedures
474418|NCT00803101|Vitamin K
474419|NCT00803101|Reversal of coagulopathy induced by coumarin derivatives
474420|NCT00803101|Kcentra
474421|NCT00803049|Multiple Sclerosis
474422|NCT00803049|Oral treatment
474423|NCT00803036|spreading cortical depression
474424|NCT00803036|electroencephalography
474425|NCT00803036|traumatic brain injury
474426|NCT00803036|intensive care
474427|NCT00803036|vascular hypotension
474428|NCT00803036|intracranial hypertension
474429|NCT00803010|Acute Graft Versus Host Disease (aGVHD)
474430|NCT00803010|GVHD
474431|NCT00803010|graft-versus-host disease
474432|NCT00803010|tacrolimus
474433|NCT00803010|sirolimus
474434|NCT00803010|methotrexate
474435|NCT00803010|combination therapy
474436|NCT00803010|GVHD prophylaxis
474437|NCT00802971|Reactive hypoglycaemia
474438|NCT00802971|Fiber
474439|NCT00802971|Prevalence
474440|NCT00802971|Randomised controlled trial
474441|NCT00802971|Idiopathic reactive hypoglycemia
474442|NCT00802958|Bioequivalence
474443|NCT00802958|Halobetasol Propionate
474444|NCT00802932|breast cancer
474445|NCT00802932|female
474446|NCT00802932|metallic markers
474447|NCT00802932|image guided radiation therapy
474448|NCT00802932|IGRT
474449|NCT00802919|schizophrenia
474450|NCT00802919|smoking
474451|NCT00802919|nicotine
474452|NCT00802919|cognitive deficits
474453|NCT00802919|DNMT1 mRNA
474454|NCT00802919|nicotinic receptors
474455|NCT00802919|Cognitive Deficits in Schizophrenia
474456|NCT00802906|micropulselaserphotocoagulation
474457|NCT00802906|bevacizumab
474458|NCT00802906|CSC
474459|NCT00802893|Isolated Systolic Hypertension with Endothelial Dysfunction
474460|NCT00802867|DAPTACEL®
474461|NCT00802867|PENTACEL™
474462|NCT00802867|Diphtheria
474463|NCT00802867|Tetanus
474464|NCT00802867|Pertussis
474465|NCT00802867|Haemophilus influenzae type b
474466|NCT00802854|anidulafungin
474467|NCT00802854|safety
474468|NCT00802854|efficacy
474469|NCT00802841|Chronic
474470|NCT00802841|Myelogenous
474471|NCT00802841|Leukemia
474472|NCT00802841|CML
474473|NCT00802841|Chronic Phase
474474|NCT00802841|Suboptimal Response
474475|NCT00802828|bioavailability
474476|NCT00802828|famotidine
474477|NCT00802763|VAGINAL INFECTION
474478|NCT00802763|COLOR APPEARANCE
474479|NCT00802763|ELEVATED Ph
474480|NCT00802737|Maintenance
474481|NCT00802737|Retreatment
474482|NCT00802737|Chronic lymphocytic leukemia
474483|NCT00802737|B-Cell Chronic Lymphocytic Leukemia
474484|NCT00802737|Ofatumumab
474485|NCT00802724|low back pain
474486|NCT00802724|classification
474487|NCT00802724|spine
474488|NCT00802711|stage IA breast cancer
474489|NCT00802711|stage IB breast cancer
474490|NCT00802711|stage II breast cancer
474491|NCT00802711|invasive ductal breast carcinoma
474492|NCT00802698|Biphasic waveform
474493|NCT00802698|Central retinal artery occlusion
474494|NCT00802698|To describe the effect of Transcorneal Electrical Stimulation (TES) with a non conventional biphasic bipolar waveform
474495|NCT00802698|in central retinal artery occlusion
474496|NCT00802685|Patent ductus arteriosus
474497|NCT00802685|Respiratory outcome
474498|NCT00802672|Tinea Pedis
474499|NCT00802672|Ciclopirox Olamine
474500|NCT00802646|first-time mother
474501|NCT00802646|epidural request
474502|NCT00802646|vaginal childbirth
474503|NCT00802633|Tissue sealing device
474504|NCT00802633|Articulating stapling device
474505|NCT00802633|Radical cystectomy
474506|NCT00802620|Amniotic membrane
474507|NCT00802620|Conjunctival autograft
474508|NCT00802620|Recurrent pterygia
474509|NCT00802620|compare amniotic membrane associated with conjunctival autograft versus conjunctival autograft alone in the treatment of recurrent pterygia
474510|NCT00802607|Bone Diseases
474511|NCT00802607|Connective Tissue Diseases
474512|NCT00802594|first stage
474513|NCT00802594|T.b. gambiense
474514|NCT00802594|sleeping sickness
474515|NCT00802594|Patients with first stage T.b. gambiense sleeping sickness
474516|NCT00802581|sciatic nerve block
474517|NCT00802581|local anesthetic
474518|NCT00802581|lidocaine
474519|NCT00802581|ankle surgery
474520|NCT00802581|foot surgery
474521|NCT00802581|ultrasound-guided regional anesthesia
474522|NCT00802581|circumferential spread
474523|NCT00802581|anesthetic infiltration
474524|NCT00802568|stage I multiple myeloma
474525|NCT00802568|stage II multiple myeloma
474526|NCT00802568|stage III multiple myeloma
474527|NCT00802568|refractory multiple myeloma
474528|NCT00802568|osteolytic lesions of multiple myeloma
474529|NCT00802555|HCC
474530|NCT00802555|Cirrhotic Patients with Hepatocellular Carcinoma
474531|NCT00802542|Hypertension
474532|NCT00802542|blood pressure
474533|NCT00802542|Atacand
474534|NCT00802529|Meniere's disease
474535|NCT00802529|transtympanic steroids
474536|NCT00802529|Randomised controlled trial
474537|NCT00802503|Critically ill
474538|NCT00802503|nutrition
474539|NCT00802503|randomised controlled clinical trial
474540|NCT00802503|human
474541|NCT00802503|adult
474542|NCT00802503|Supplemental parenteral nutrition
474543|NCT00802490|Attention Deficit Hyperactivity Disorder
474544|NCT00802490|Electroencephalogram biofeedback
474545|NCT00802490|Inattention
474546|NCT00802490|Brain-Computer Interface System
474547|NCT00802477|mastectomy
474548|NCT00802477|seroma
474549|NCT00802477|lymph node dissection
474550|NCT00802464|Cytokine
474551|NCT00802464|Vaccine
474552|NCT00802464|Herpes Zoster (HZ)
474553|NCT00802464|Cell mediated immunity (CMI)
474554|NCT00802464|Antibody response
474555|NCT00802464|Varicella Zoster Virus (VZV)
474556|NCT00802464|Shingles
474557|NCT00802451|Bioavailability
474558|NCT00802451|Mesalamine
474559|NCT00802438|asthma
474560|NCT00802438|allergic inflammation
474561|NCT00802438|interleukin-5
474562|NCT00802425|Sudden hearing loss
474563|NCT00802425|Sudden deafness
474564|NCT00802425|Acoustic trauma
474565|NCT00802425|Noise trauma
474566|NCT00802412|tobacco use disorders
474567|NCT00802412|alcoholism
474568|NCT00802399|Cornea
474569|NCT00802399|Dry eye
474570|NCT00802399|lacrimal punctual occlusion
474571|NCT00802399|lacrimal film
474572|NCT00802399|ocular surface
474573|NCT00802386|BACTERIAL VAGINOSIS
474574|NCT00802386|IUD INSERTION
474575|NCT00802373|Overactive Bladder
474576|NCT00802360|Healthy, pre-menopausal women, age 18-42 with a history of infertility and requiring IVF
474577|NCT00802347|Delayed Graft Function
474578|NCT00802347|Kidney Transplant
474579|NCT00802347|Renal Transplant
474580|NCT00802347|small interfering ribonucleic acid (siRNA)
474581|NCT00802334|generic lopinavir/ritonavir
474582|NCT00802334|therapeutic drug monitoring
474583|NCT00802334|safety and efficacy
474584|NCT00802321|steroid 5AReductase
474585|NCT00802321|genetic polymorphism
474586|NCT00802321|GABA receptor
474587|NCT00802295|Ovarian
474588|NCT00802295|hyperstimulation
474589|NCT00802295|Embryo
474590|NCT00802295|Aneuploidy
474591|NCT00802295|Ovarian hyperstimulation and Embryo Aneuploidy Rates
474592|NCT00802282|healthy volunteers
474593|NCT00802282|spirituality
474594|NCT00802282|psilocybin
474595|NCT00802282|meditation
474596|NCT00802269|Proliferative diabetic retinopathy
474597|NCT00802269|Laser photocoagulation
474598|NCT00802269|Pain
474599|NCT00802256|pulpotomy
474600|NCT00802256|primary molar teeth
474601|NCT00802256|MTA
474602|NCT00802256|NEC
474603|NCT00802256|CEM
474604|NCT00802256|Primary Molar Teeth Which Require Pulpotomy Treatment
474605|NCT00802243|Bullous pemphigoid
474606|NCT00802243|leflunomide
474607|NCT00802243|corticosteroid treatment reduction
474608|NCT00802243|Patients are screened by: the physicians in different departments of the hospital, the liberal dermatologists and the general practicioners.
474609|NCT00802243|Phase I: Patients will be referred to the investigators of Dupuytren Hospital Dermatology Department.
474610|NCT00802243|Phase II: Patients will be referred to the investigators of Purpan (Toulouse), Haut Leveque (Pessac) and Dupuytren (Limoges) Hospitals.
474611|NCT00802217|Pharmacokinetics
474612|NCT00802217|Safety
474613|NCT00802217|Tolerability
474614|NCT00802217|Healthy Volunteers
474615|NCT00802204|Obesity
474616|NCT00802204|Insulin Resistance
474617|NCT00802204|Neuroendocrine regulation
474618|NCT00802204|Eating behaviors
474619|NCT00802204|Dopamine signaling
474620|NCT00802165|Asymptomatic normals
474621|NCT00802152|Diabetes
474622|NCT00802152|Hypertension
474623|NCT00802139|iron deficiency anemia
474624|NCT00802139|pregnant women with iron deficiency anemia
474625|NCT00802113|Autologous Stem Cell Transplant
474626|NCT00802113|Cord Blood Transplant
474627|NCT00802113|Allogeneic Stem Cell Transplant
474628|NCT00802113|Relapsed Lymphoma
474629|NCT00802100|Schizoaffective Disorder
474630|NCT00802087|Hydrocodone
474631|NCT00802087|Pharmacokinetics
474632|NCT00802087|Safety & Tolerability
474633|NCT00802074|Healthy Subjects
474634|NCT00802074|Pharmacokinetics study
474635|NCT00802074|Pharmacokinetics of medications
474636|NCT00802061|progressive glaucoma despite controlled IOP
474637|NCT00802048|Sternotomy
474638|NCT00802048|Postoperative hyperalgesia
474639|NCT00802048|Intralesional anesthetic infusion
474640|NCT00802048|Ropivacaïne
474641|NCT00802048|Chronic
474642|NCT00802048|Postoperative pain
474643|NCT00802048|Cardiac surgery
474644|NCT00802048|Sternum
474645|NCT00802048|Cardiac surgical procedures
474646|NCT00802035|ALK29
474647|NCT00802035|Alcohol Dependence
474648|NCT00802035|Pharmacokinetics
474649|NCT00802022|diabetic neuropathies
474650|NCT00802022|electric stimulation therapy
474651|NCT00802009|ultrasound-guided regional anesthesia
474652|NCT00802009|nerve block
474653|NCT00802009|brachial plexus
474654|NCT00802009|mepivicaine
474655|NCT00802009|dexamethasone
474656|NCT00802009|hand wrist surgery
474657|NCT00802009|duration
474658|NCT00802009|anesthetic duration following brachial plexus/nerve block for hand/wrist surgery
474659|NCT00801996|prostate cancer
474660|NCT00801996|genetics
474661|NCT00801970|Fear of childbirth
474662|NCT00801970|Tokophobia
474663|NCT00801970|Anxiety
474664|NCT00801970|Labor
474665|NCT00801970|Pregnancy
474666|NCT00801970|Cognitive-behavioral
474667|NCT00801970|Psychoanalysis
474668|NCT00801970|Group Therapy
474669|NCT00801970|etiology
474670|NCT00801957|atopic dermatitis
474671|NCT00801957|meningitis
474672|NCT00801957|vaccination
474673|NCT00801957|tacrolimus
474674|NCT00801957|steroids
474675|NCT00801957|equivalence response
474676|NCT00801957|meningococcal vaccine
474677|NCT00801944|Overactive Bladder
474678|NCT00801931|Cord Blood Transplant
474679|NCT00801931|Allogeneic Stem Cell Transplant
474680|NCT00801918|lymphoma
474681|NCT00801918|pediatric
474682|NCT00801918|adolescent
474683|NCT00801918|relapsed
474684|NCT00801918|refractory
474685|NCT00801918|denileukin diftitox
474686|NCT00801918|Ontak
474687|NCT00801905|Macular thickening
474688|NCT00801905|Macular edema
474689|NCT00801905|Pan-retinal photocoagulation
474690|NCT00801905|Nepafenac
474691|NCT00801905|Topical non-steroidal anti inflammatory agents
474692|NCT00801892|daytime sleepiness
474693|NCT00801892|obstructive sleep apnea
474694|NCT00801892|type 2 diabetes mellitus
474695|NCT00801892|diabetes management
474696|NCT00801879|mupirocin
474697|NCT00801879|Staphylococcus aureus
474698|NCT00801879|colonization
474699|NCT00801879|infection
474700|NCT00801879|HIV
474701|NCT00801866|Panretinal Photocoagulation
474702|NCT00801866|Macular Edema
474703|NCT00801866|Intravitreal Bevacizumab
474704|NCT00801853|asthma
474705|NCT00801853|allergy
474706|NCT00801853|atopy
474707|NCT00801853|atopic
474708|NCT00801853|wheeze
474709|NCT00801827|Obesity
474710|NCT00801827|Addiction
474711|NCT00801827|PET imaging
474712|NCT00801814|viscous
474713|NCT00801814|fibre
474714|NCT00801814|polysaccharide
474715|NCT00801814|blood glucose
474716|NCT00801814|post prandial
474717|NCT00801775|calorimetry
474718|NCT00801736|Recurrent non-small cell lung cancer
474719|NCT00801736|Stage IIIB non-small cell lung cancer
474720|NCT00801736|Stage IV non-small cell lung cancer
474721|NCT00801723|Ulcerative Colitis
474722|NCT00801697|HIV Seronegativity
474723|NCT00801697|HIV Preventive Vaccine
474724|NCT00801697|Adenovirus
474725|NCT00801684|COPD
474726|NCT00801684|pulmonary
474727|NCT00801684|inhalation
474728|NCT00801671|obstructive sleep apnea
474729|NCT00801671|obstructive sleep apnea syndrome
474730|NCT00801671|hypertension
474731|NCT00801671|systemic hypertension
474732|NCT00801671|ambulatory blood pressure monitoring
474733|NCT00801658|glaucoma
474734|NCT00801658|SLT
474735|NCT00801658|Laser treatment
474736|NCT00801658|IOP
474737|NCT00801658|glaucoma treated with eye drops but IOP not controlled
474738|NCT00801645|Obesity
474739|NCT00801645|Cardiovascular disease
474740|NCT00801645|Endothelial function
474741|NCT00801645|Blood pressure
474742|NCT00801645|Exercise
474743|NCT00801645|Physical activity
474744|NCT00801645|Metabolic syndrome
474745|NCT00801645|Children
474746|NCT00801645|Pediatric
474747|NCT00801632|renal allograft tolerance
474748|NCT00801632|mixed chimerism
474749|NCT00801632|kidney transplant
474750|NCT00801632|bone marrow transplant
474751|NCT00801632|antirejection
474752|NCT00801632|immunosuppression
474753|NCT00801606|Micronutrient
474754|NCT00801606|Childhood Tuberculosis
474755|NCT00801593|JIA
474756|NCT00801580|relapsed ALL
474757|NCT00801580|refractory ALL
474758|NCT00801580|relapsed adult acute lymphoid leukemia
474759|NCT00801567|Bipolar disorder
474760|NCT00801567|Schizophrenia
474761|NCT00801567|Healthy volunteer
474762|NCT00801567|Brain imaging
474763|NCT00801567|Photic stimulation
474764|NCT00801554|Autism Spectrum Disorder
474765|NCT00801554|ASD
474766|NCT00801554|Autism
474767|NCT00801554|Asperger's Syndrome
474768|NCT00801554|PDD-NOS
474769|NCT00801554|Pervasive Developmental Disorders- Not Otherwise Specified
474770|NCT00801554|Adults
474771|NCT00801554|Children
474772|NCT00801541|AMD
474773|NCT00801528|ropivacaine
474774|NCT00801528|diclofenac
474775|NCT00801528|local anesthetic instillation
474776|NCT00801515|Compassionate
474777|NCT00801515|HIV
474778|NCT00801515|CCR5
474779|NCT00801502|Omega-3
474780|NCT00801502|Oily fish
474781|NCT00801502|Antioxidant
474782|NCT00801502|Selenium
474783|NCT00801502|Atopic disease
474784|NCT00801502|Pregnancy
474785|NCT00801502|Nutrient status
474786|NCT00801489|Leukemia
474787|NCT00801489|Acute Myelogenous Leukemia
474788|NCT00801489|AML
474789|NCT00801476|Breast Cancer
474790|NCT00801476|Magnetic Resonance Imaging
474791|NCT00801476|Preoperative MRI
474792|NCT00801463|Focal Segmental Glomerulosclerosis
474793|NCT00801463|Prednisone
474794|NCT00801463|Tripterygium Wilfordii
474795|NCT00801450|diabetes
474796|NCT00801450|macular edema
474797|NCT00801450|triamcinolone
474798|NCT00801450|cataract
474799|NCT00801450|refractory diabetic macular edema
474800|NCT00801437|glaucoma, open-angle, non-interventional study, safety, tolerability
474801|NCT00801424|abdominal surgery
474802|NCT00801424|hypothermia
474803|NCT00801424|wound dessication
474804|NCT00801424|warming
474805|NCT00801411|stage II breast cancer
474806|NCT00801398|Opioid tolerant
474807|NCT00801398|Pediatric
474808|NCT00801398|Pain
474809|NCT00801398|Non malignant
474810|NCT00801398|Malignant
474811|NCT00801385|recurrent non-small cell lung cancer
474812|NCT00801385|stage IIIB non-small cell lung cancer
474813|NCT00801385|stage IV non-small cell lung cancer
474814|NCT00801372|pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.
474815|NCT00801372|pregnant healthy couples older than 18 who signed an informed consent for a c-section.
474816|NCT00801372|healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.
474817|NCT00801359|cataract
474818|NCT00801359|phacoemulsification
474819|NCT00801359|irrigation solution
474820|NCT00801359|endothelial cell density
474821|NCT00801359|corneal thickness
474822|NCT00801346|fatigue
474823|NCT00801346|long-term effects secondary to cancer therapy in children
474824|NCT00801346|childhood acute lymphoblastic leukemia in remission
474825|NCT00801346|B-cell childhood acute lymphoblastic leukemia
474826|NCT00801346|T-cell childhood acute lymphoblastic leukemia
474827|NCT00801333|ALS
474828|NCT00801320|tumor harvest
474829|NCT00801320|tumor collection
474830|NCT00801320|tumor storage
474831|NCT00801307|evaluate Inspiratory Capacity (IC) measured by spirometry
474832|NCT00801281|Lymphoma
474833|NCT00801281|Immunochemotherapy
474834|NCT00801281|Induction therapy
474835|NCT00801281|Maintenance therapy
474836|NCT00801281|Follicular lymphoma grade 1,2,3a
474837|NCT00801281|Marginal zone lymphoma, including MALT type
474838|NCT00801281|Small lymphocytic lymphoma (BM inv. <30%)
474839|NCT00801268|polycystic kidney disease
474840|NCT00801268|tripterygium wilfordii
474841|NCT00801229|ADHD
474842|NCT00801229|young adults
474843|NCT00801229|driving
474844|NCT00801229|Vyvanse
474845|NCT00801229|lisdexamfetamine
474846|NCT00801216|B-cell lymphomas
474847|NCT00801216|lymphomatous meningitis
474848|NCT00801216|liposomal cytarabine
474849|NCT00801216|autologous transplant
474850|NCT00801216|CNS involvement
474851|NCT00801216|Secondary CNS lymphomas
474852|NCT00801203|Stress Urinary Incontinence
474853|NCT00801190|colloid
474854|NCT00801190|CABG
474855|NCT00801190|cardiopulmonary bypass
474856|NCT00801190|bleeding
474857|NCT00801177|Tumors
474858|NCT00801177|Antibodies, Monoclonal
474859|NCT00801164|Diabetes Type 2
474860|NCT00801164|Periodontitis
474861|NCT00801138|interscalene nerve block
474862|NCT00801138|analgesia
474863|NCT00801112|Bioimpedance
474864|NCT00801112|Fluid status
474865|NCT00801112|Peritoneal Dialysis
474866|NCT00801112|Extra-cellular fluid volume
474867|NCT00801099|Postoperative wound infection
474868|NCT00801099|surgical site infection
474869|NCT00801099|antimicrobial prophylaxis
474870|NCT00801099|developing countries
474871|NCT00801099|Sub-Saharan Africa
474872|NCT00801099|reduction of SSI using preoperative antibiotics
474873|NCT00801086|Alopecia
474874|NCT00801086|Hair loss
474875|NCT00801086|Radiation
474876|NCT00801086|Whole brain radiotherapy
474877|NCT00801086|Radiation-induced alopecia
474878|NCT00801073|Amniotic membrane
474879|NCT00801073|Cornea
474880|NCT00801073|Scleral thinning
474881|NCT00801060|Fludara
474882|NCT00801060|CD23
474883|NCT00801060|Cyclophosphamide
474884|NCT00801060|Antibody
474885|NCT00801060|Fludarabine
474886|NCT00801060|CLL
474887|NCT00801060|Rituximab
474888|NCT00801060|Mabthera
474889|NCT00801060|Biogen Idec
474890|NCT00801060|Lumiliximab
474891|NCT00801060|Rituxan
474892|NCT00801060|Cytoxan
474893|NCT00801060|Chronic Lymphocytic Leukemia
474894|NCT00801047|Epidural
474895|NCT00801047|Labor
474896|NCT00801047|Remifentanil
474897|NCT00801034|hypertension
474898|NCT00801034|potassium
474899|NCT00801034|blood pressure
474900|NCT00801021|Cystitis
474901|NCT00801021|Urinary Tract Infections
474902|NCT00801008|young adult
474903|NCT00801008|cancer
474904|NCT00801008|exercise
474905|NCT00801008|relaxation
474906|NCT00800995|ARMD
474907|NCT00800995|SOD
474908|NCT00800982|Obese patients (BMI>30)
474909|NCT00800982|Patients with moderate to severe psoriasis
474910|NCT00800969|Adenocarcinoma of the stomach and esophagogastric junction
474911|NCT00800956|Radiolabel ADME study Healthy volunteers
474912|NCT00800943|Leukemia
474913|NCT00800943|Chronic
474914|NCT00800943|Chronic Lymphocytic Leukemia
474915|NCT00800943|CAMPATH
474916|NCT00800943|Alemtuzumab
474917|NCT00800943|MabCampath
474918|NCT00800943|Subcutaneous
474919|NCT00800943|CLL
474920|NCT00800943|C-CLL
474921|NCT00800943|Residual
474922|NCT00800930|Shigellosis
474923|NCT00800930|sodium butyrate
474924|NCT00800930|antimicrobial peptides
474925|NCT00800930|LL-37
474926|NCT00800930|innate immunity
474927|NCT00800930|The aims are to assess efficacy of sodium butyrate enema in
474928|NCT00800930|marked improvement in clinical features
474929|NCT00800930|endoscopic findings
474930|NCT00800930|histological features
474931|NCT00800930|Induction of LL-37 in the rectum.
474932|NCT00800904|Asthma
474933|NCT00800904|Inhaled corticosteroid
474934|NCT00800904|Thai patient eligibility
474935|NCT00800904|Persistent asthma
474936|NCT00799188|Cardiac Transplantation
474937|NCT00799188|Skin cancer
474938|NCT00799188|Everolimus
474939|NCT00799175|Postoperative pain
474940|NCT00799175|Local infiltration analgesia
474941|NCT00799175|Knee arthroplasty
474942|NCT00799149|Post-operative pain
474943|NCT00799149|Knee arthroscopy
474944|NCT00799149|Gabapentin
474945|NCT00799149|Etoricoxib
474946|NCT00799149|Elective ambulatory knee arthroscopy
474947|NCT00799136|Lymphoma Large B Cell Diffuse
474948|NCT00799136|Acquired Immunodeficiency
474949|NCT00799123|NT-proBNP
474950|NCT00799110|dendritic cells
474951|NCT00799110|fusion vaccines
474952|NCT00799110|GM-CSF
474953|NCT00799110|imiquimod
474954|NCT00799084|symptom management
474955|NCT00799084|cancer
474956|NCT00799084|chemotherapy treatment
474957|NCT00799084|Behavioral Research
474958|NCT00799084|Physiological Effects of Drugs
474959|NCT00799084|Clinical Trial, Phase II
474960|NCT00799071|prophylaxis
474961|NCT00799071|CGD
474962|NCT00799071|pharmacokinetics
474963|NCT00799058|HIV-1 infections
474964|NCT00799045|Migraine
474965|NCT00799045|atrial septal defects
474966|NCT00799045|transcatheter
474967|NCT00799045|clopidogrel
474968|NCT00800878|Chronic Kidney Disease
474969|NCT00800878|Renal insufficiency
474970|NCT00800852|adiponectin
474971|NCT00800852|adiponectin receptor
474972|NCT00800852|Prader-Willi syndrome
474973|NCT00800839|Post-allogeneic transplantation
474974|NCT00800839|Graft-versus-Host Disease Prophylaxis
474975|NCT00800839|Graft-versus-Host Disease
474976|NCT00800839|GVHD
474977|NCT00800839|Hematologic malignancies
474978|NCT00800839|Leukemia
474979|NCT00800839|Lymphoma
474980|NCT00800839|Myeloma
474981|NCT00800839|Human Leukocyte Antigen
474982|NCT00800839|HLA
474983|NCT00800839|Busulfan
474984|NCT00800839|Cyclophosphamide
474985|NCT00800839|Fludarabine
474986|NCT00800839|Mesna
474987|NCT00800839|Cytoxan®
474988|NCT00800839|Neosar®
474989|NCT00800839|Busulfex
474990|NCT00800839|Myleran®
474991|NCT00800839|Fludarabine Phosphate
474992|NCT00800813|Prostate
474993|NCT00800813|Erectile function
474994|NCT00800813|Peyronie's Plaque
474995|NCT00800813|08-135
474996|NCT00800800|progression of aortic stenosis
474997|NCT00800787|Chronic hepatitis B liver disease
474998|NCT00800774|LASIK
474999|NCT00800774|safety
475000|NCT00800774|efficacy
475001|NCT00800774|stability
475002|NCT00800774|high anisometropia
475003|NCT00800774|patients 8 to 15 years old
475004|NCT00800774|conventional treatments have failed
475005|NCT00800722|hypervascular anomalies
475006|NCT00800709|Alzheimer's Disease
475007|NCT00800709|tau protein
475008|NCT00800709|PET
475009|NCT00800709|Memantine
475010|NCT00800696|antibiotics
475011|NCT00800696|Hospitalization
475012|NCT00800696|oral care
475013|NCT00800670|tuberculosis
475014|NCT00800670|vaccine
475015|NCT00800670|adenovirus
475016|NCT00800657|Cardiac Resynchronization
475017|NCT00800657|Dilated Cardiomyopathy
475018|NCT00800657|Stem Cells Therapy
475019|NCT00800657|Heart Failure
475020|NCT00800657|Stem Cells/Cardiac Pacing, Artificial
475021|NCT00800644|Cervical Cancer
475022|NCT00800644|Endometrial Cancer
475023|NCT00800644|Vaginal Cancer
475024|NCT00800644|Cervix
475025|NCT00800644|Endometrial
475026|NCT00800644|X-ray
475027|NCT00800644|Computed tomography
475028|NCT00800644|Magnetic resonance imaging
475029|NCT00800644|Vagina
475030|NCT00800644|Pelvic radiation therapy
475031|NCT00800644|Bone density
475032|NCT00800644|Bone mineral density test
475033|NCT00800644|Pelvic fractures
475034|NCT00800644|Gynecologic Oncology
475035|NCT00800644|Bone turnover
475036|NCT00800592|Sildenafil, Revatio, PAH, IV, Bolus
475037|NCT00800579|cystic fibrosis
475038|NCT00800579|CF
475039|NCT00800579|mucociliary clearance
475040|NCT00800579|amiloride
475041|NCT00800579|ENaC
475042|NCT00800579|ENaC Inhibitor
475043|NCT00800579|airway hydration
475044|NCT00800579|epithelial sodium channel inhibitor
475045|NCT00800566|Clofarabine
475046|NCT00800566|Leukemia
475047|NCT00800566|Chronic Lymphocytic Leukemia
475048|NCT00800553|sleep deprivation
475049|NCT00800553|fMRI
475050|NCT00800553|double blind crossover study
475051|NCT00800540|glaucoma
475052|NCT00800540|ocular perfusion pressure
475053|NCT00800540|ocular blood flow
475054|NCT00800540|open angle glaucoma requiring more than one IOP-lowering medication
475055|NCT00800527|sternotomy
475056|NCT00800527|pain
475057|NCT00800527|paresthesia
475058|NCT00800527|Poststernotomy chest pain
475059|NCT00800527|Poststernotomy chest paresthesia
475060|NCT00800514|perception of time, traumatic brain injury, amantadine
475061|NCT00800501|ALS
475062|NCT00800501|VEGF165
475063|NCT00800501|Safety
475064|NCT00800501|Intracerebroventricular
475065|NCT00800501|Infusion
475066|NCT00800501|Implantable
475067|NCT00800488|Fever
475068|NCT00800488|Infant
475069|NCT00800488|Procalcitonin
475070|NCT00800488|Serious Bacterial Infection
475071|NCT00800475|bioavailability
475072|NCT00800475|Gemfibrozil
475073|NCT00800449|Haptoglobin
475074|NCT00800449|sepsis
475075|NCT00800449|premature babies
475076|NCT00800423|corneal edema
475077|NCT00800423|postoperative corneal edema
475078|NCT00800423|central corneal thickness
475079|NCT00800423|visual acuity
475080|NCT00800423|postoperative
475081|NCT00800423|brimonidine
475082|NCT00800423|timolol
475083|NCT00800423|cataract surgery
475084|NCT00800410|Randomized Controlled Trial
475085|NCT00800371|JIA
475086|NCT00800358|Secondary hyperparathyroidism
475087|NCT00800358|End stage renal disease
475088|NCT00800358|Haemodialysis
475089|NCT00800358|Peritoneal dialysis
475090|NCT00800358|Paricalcitol (Zemplar)
475091|NCT00800358|Calcitriol
475092|NCT00800345|Gynecologic tumors
475093|NCT00800332|Rhinoconjunctivitis due to house dust mite allergy
475094|NCT00800319|Alcohol dependence
475095|NCT00800319|Opioid antagonist
475096|NCT00800319|RDC-0313
475097|NCT00800306|sepsis
475098|NCT00800306|septic shock
475099|NCT00800306|microcirculation
475100|NCT00800306|levosimendan
475101|NCT00800306|dobutamine
475102|NCT00800306|inotropes
475103|NCT00800306|inhaled nitric oxide
475104|NCT00800293|bioequivalence
475105|NCT00800293|betamethasone dipropionate
475106|NCT00800293|Bioequivalency
475107|NCT00800280|cimetidine, PD 0332334, organic cation transporter, OCT2, pharmacokinetics
475108|NCT00800267|glaucoma
475109|NCT00800267|ocular hypertension
475110|NCT00800267|Fixed combination latanoprost-timolol
475111|NCT00800267|latanoprost
475112|NCT00800267|timolol
475113|NCT00800254|electrical stimulation
475114|NCT00800254|total knee arthroplasty
475115|NCT00800254|quadriceps
475116|NCT00800254|muscle
475117|NCT00800254|arthroscopy
475118|NCT00800241|Asthma
475119|NCT00800241|Symbicort SMART
475120|NCT00800241|Thai patient eligibility
475121|NCT00800241|Persistent asthma
475122|NCT00800228|salt
475123|NCT00800228|blood pressure
475124|NCT00800228|breathing
475125|NCT00800215|Epilepsy
475126|NCT00800150|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
475127|NCT00800150|adult acute myeloid leukemia with inv(16)(p13;q22)
475128|NCT00800150|adult acute myeloid leukemia with t(15;17)(q22;q12)
475129|NCT00800150|adult acute myeloid leukemia with t(16;16)(p13;q22)
475130|NCT00800150|adult acute myeloid leukemia with t(8;21)(q22;q22)
475131|NCT00800150|recurrent adult acute lymphoblastic leukemia
475132|NCT00800150|recurrent adult acute myeloid leukemia
475133|NCT00800150|recurrent adult T-cell leukemia/lymphoma
475134|NCT00800150|secondary acute myeloid leukemia
475135|NCT00800150|stage III adult T-cell leukemia/lymphoma
475136|NCT00800150|stage IV adult T-cell leukemia/lymphoma
475137|NCT00800150|adult grade III lymphomatoid granulomatosis
475138|NCT00800150|adult nasal type extranodal NK/T-cell lymphoma
475139|NCT00800150|anaplastic large cell lymphoma
475140|NCT00800150|angioimmunoblastic T-cell lymphoma
475141|NCT00800150|splenic marginal zone lymphoma
475142|NCT00800150|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
475143|NCT00800150|nodal marginal zone B-cell lymphoma
475144|NCT00800150|stage III adult Burkitt lymphoma
475145|NCT00800150|stage III adult diffuse large cell lymphoma
475146|NCT00800150|stage III adult diffuse mixed cell lymphoma
475147|NCT00800150|stage III adult diffuse small cleaved cell lymphoma
475148|NCT00800150|stage III adult immunoblastic large cell lymphoma
475149|NCT00800150|stage III adult lymphoblastic lymphoma
475150|NCT00800150|stage III cutaneous T-cell non-Hodgkin lymphoma
475151|NCT00800150|stage III mycosis fungoides/Sezary syndrome
475152|NCT00800150|stage III grade 1 follicular lymphoma
475153|NCT00800150|stage III grade 2 follicular lymphoma
475154|NCT00800150|stage III grade 3 follicular lymphoma
475155|NCT00800150|stage III mantle cell lymphoma
475156|NCT00800150|stage III marginal zone lymphoma
475157|NCT00800150|stage III small lymphocytic lymphoma
475158|NCT00800150|stage IV adult Burkitt lymphoma
475159|NCT00800150|stage IV adult diffuse large cell lymphoma
475160|NCT00800150|stage IV adult diffuse mixed cell lymphoma
475161|NCT00800150|stage IV adult diffuse small cleaved cell lymphoma
475162|NCT00800150|stage IV adult immunoblastic large cell lymphoma
475163|NCT00800150|stage IV adult lymphoblastic lymphoma
475164|NCT00800150|stage IV cutaneous T-cell non-Hodgkin lymphoma
475165|NCT00800150|stage IV mycosis fungoides/Sezary syndrome
475166|NCT00800150|stage IV grade 1 follicular lymphoma
475167|NCT00800150|stage IV grade 2 follicular lymphoma
475168|NCT00800150|stage IV grade 3 follicular lymphoma
475169|NCT00800150|stage IV mantle cell lymphoma
475170|NCT00800150|stage IV marginal zone lymphoma
475171|NCT00800150|stage IV small lymphocytic lymphoma
475172|NCT00800150|recurrent adult Burkitt lymphoma
475173|NCT00800150|recurrent adult diffuse large cell lymphoma
475174|NCT00800150|recurrent adult diffuse mixed cell lymphoma
475175|NCT00800150|recurrent adult diffuse small cleaved cell lymphoma
475176|NCT00800150|recurrent adult grade III lymphomatoid granulomatosis
475177|NCT00800150|recurrent adult immunoblastic large cell lymphoma
475178|NCT00800150|recurrent adult lymphoblastic lymphoma
475179|NCT00800150|recurrent cutaneous T-cell non-Hodgkin lymphoma
475180|NCT00800150|recurrent mycosis fungoides/Sezary syndrome
475181|NCT00800150|recurrent grade 1 follicular lymphoma
475182|NCT00800150|recurrent grade 2 follicular lymphoma
475183|NCT00800150|recurrent grade 3 follicular lymphoma
475184|NCT00800150|recurrent mantle cell lymphoma
475185|NCT00800150|recurrent marginal zone lymphoma
475186|NCT00800150|recurrent small lymphocytic lymphoma
475187|NCT00800150|intraocular lymphoma
475188|NCT00800150|primary central nervous system non-Hodgkin lymphoma
475189|NCT00800150|primary myelofibrosis
475190|NCT00800150|stage II multiple myeloma
475191|NCT00800150|stage III multiple myeloma
475192|NCT00800150|refractory multiple myeloma
475193|NCT00800150|de novo myelodysplastic syndromes
475194|NCT00800150|previously treated myelodysplastic syndromes
475195|NCT00800150|secondary myelodysplastic syndromes
475196|NCT00800150|myelodysplastic/myeloproliferative neoplasm, unclassifiable
475197|NCT00800150|cutaneous B-cell non-Hodgkin lymphoma
475198|NCT00800150|Waldenstrom macroglobulinemia
475199|NCT00800137|coumadin
475200|NCT00800137|device surgery
475201|NCT00800137|pocket hematoma
475202|NCT00800137|Pocket hematoma and device surgery
475203|NCT00800124|hip fracture
475204|NCT00800124|hemiprosthesis
475205|NCT00800124|bone cement
475206|NCT00800124|clinical outcome
475207|NCT00800111|failed penetrating keratoplasty
475208|NCT00800085|first degree relatives of type 1 diabetes patients
475209|NCT00800085|hyperglycemic clamp test
475210|NCT00800072|to verify accurrancy of data collected by the NOWOX
475211|NCT00800059|Relapse
475212|NCT00800059|Refractory
475213|NCT00799032|Coronary Stent
475214|NCT00799019|EPO antibody mediated PRCA
475215|NCT00799019|Erythropoiesis stimulating agents
475216|NCT00799006|Single Ascending Dose Study in Overweight subjects
475217|NCT00798993|Chronic kidney failure
475218|NCT00798993|25 hydroxyvitamin D
475219|NCT00798993|falls
475220|NCT00798993|exercise
475221|NCT00798993|quadriceps strength
475222|NCT00798980|Mirena
475223|NCT00798980|Nulliparous
475224|NCT00798980|Intrauterine Devices
475225|NCT00798967|SBS
475226|NCT00798967|short bowel syndrome
475227|NCT00798967|TPN
475228|NCT00798967|parenteral nutrition
475229|NCT00798967|PN
475230|NCT00798915|Diabetes
475231|NCT00798915|Blood Sugar
475232|NCT00798915|Xenin-25
475233|NCT00798915|GIP
475234|NCT00798915|Insulin
475235|NCT00798902|DDD
475236|NCT00798902|Spondylolisthesis
475237|NCT00798902|Spine Fusion
475238|NCT00798902|Lumbar Spine
475239|NCT00798902|Bone Graft
475240|NCT00798889|Solid tumors
475241|NCT00798863|submandibular gland
475242|NCT00798863|video assisted neck surgery
475243|NCT00798850|Claudication
475244|NCT00798850|Vascular claudication
475245|NCT00798850|Peripheral Vascular Disease
475246|NCT00798850|Peripheral arterial disease
475247|NCT00798850|Peripheral arterial occlusive disease
475248|NCT00798850|Angioplasty
475249|NCT00798850|Femoral angioplasty
475250|NCT00798850|Superficial femoral artery
475251|NCT00798850|Femoral arterial disease
475252|NCT00798850|Exercise
475253|NCT00798850|Supervised exercise
475254|NCT00798850|Exercise therapy
475255|NCT00798850|Exercise programme
475256|NCT00798850|Infrainuginal
475257|NCT00798850|Quality of life
475258|NCT00798850|SF36
475259|NCT00798850|Questionnaire
475260|NCT00798850|VascuQol
475261|NCT00798850|Randomised
475262|NCT00798850|Randomised trial
475263|NCT00798850|Combination therapy
475264|NCT00798850|Intermittent Claudication due to Femoropopliteal Disease
475265|NCT00798837|prostate
475266|NCT00798837|cancer
475267|NCT00798837|IMRT
475268|NCT00798837|radiation
475269|NCT00800033|metabolic syndrome
475270|NCT00800033|lipids
475271|NCT00800033|blood pressure
475272|NCT00800033|body composition
475273|NCT00800007|Hepatitis C, HCV, ANZ-521, Listeria
475274|NCT00799994|glaucoma
475275|NCT00799994|intraocular pressure
475276|NCT00799994|multifocal visually evoked potentials
475277|NCT00799968|Thrombolytic therapy
475278|NCT00799968|Urokinase
475279|NCT00799968|Efficacy
475280|NCT00799968|Safety
475281|NCT00799955|Cesarean delivery
475282|NCT00799955|post-operative analgesia
475283|NCT00799955|TAP block
475284|NCT00799955|ultrasound
475285|NCT00799942|Nystagmus, congenital idiopathic
475286|NCT00799929|IVF Research Study
475287|NCT00799929|Infertility Sudy
475288|NCT00799929|in vitro fertilization
475289|NCT00799929|Mini IVF
475290|NCT00799929|Conventional IVF
475291|NCT00799916|Sepsis
475292|NCT00799916|Fluid resuscitation
475293|NCT00799916|Voluven
475294|NCT00799916|Colloids
475295|NCT00799916|Saline solution
475296|NCT00799916|Crystalloids
475297|NCT00799916|Sublingual microcirculation
475298|NCT00799903|heart disease
475299|NCT00799903|Lp-PLA2 inhibitor
475300|NCT00799903|cardiovascular disease
475301|NCT00799903|coronary heart disease
475302|NCT00799903|CV risk
475303|NCT00799903|Atherosclerosis
475304|NCT00799890|primary or secondary chronic-progressive
475305|NCT00799890|sunphenon egcg
475306|NCT00799890|brain atrophy
475307|NCT00799890|T2 lesions
475308|NCT00799877|Chronic Plaque Psoriasis
475309|NCT00799877|Severe Chronic Plaque Psoriasis
475310|NCT00799877|Registry
475311|NCT00799877|Psoriasis
475312|NCT00799877|Severe Psoriasis
475313|NCT00799877|Moderate Psoriasis
475314|NCT00799864|HIV Infection
475315|NCT00799864|Antiretroviral
475316|NCT00799864|HIV-1
475317|NCT00799864|AIDS
475318|NCT00799864|Children
475319|NCT00799864|Rilpivirine (TMC278)
475320|NCT00799864|Pediatric
475321|NCT00799851|advanced liver disease
475322|NCT00799851|esophageal varices
475323|NCT00799851|band ligation
475324|NCT00799851|cyanoacrylate injection
475325|NCT00799825|papillomavirus
475326|NCT00799825|HPV vaccine
475327|NCT00799825|cervical cancer
475328|NCT00799825|HPV
475329|NCT00799825|human papillomavirus
475330|NCT00799812|antimicrobial
475331|NCT00799812|antisepsis
475332|NCT00799799|Nk cells infusion
475333|NCT00799799|minimal residual disease in AML patients
475334|NCT00799799|trafficking of NK cells after infusion
475335|NCT00799799|cytolytic effects on leukemic cells
475336|NCT00799773|TTP
475337|NCT00799773|Rituximab
475338|NCT00799773|Plasma Exchange
475339|NCT00799760|influenza A
475340|NCT00799760|neuraminidase inhibitor
475341|NCT00799760|oseltamivir
475342|NCT00799760|zanamivir
475343|NCT00799760|treatment outcome
475344|NCT00799760|resistance
475345|NCT00799760|mutation
475346|NCT00799760|combination therapy
475347|NCT00799760|monotherapy
475348|NCT00799760|pandemic
475349|NCT00799760|primary care
475350|NCT00799760|randomized controlled trials
475351|NCT00799760|antiviral agent
475352|NCT00799747|safety
475353|NCT00799747|tolerability
475354|NCT00799747|pharmacokinetics
475355|NCT00799747|AZD4017Japanese
475356|NCT00799734|hot flushes
475357|NCT00799734|night sweats
475358|NCT00799734|menopausal symptoms
475359|NCT00799734|osteoporosis
475360|NCT00799734|complementary and alternative medicine
475361|NCT00799721|ROP
475362|NCT00799721|VLBW
475363|NCT00799721|Epo
475364|NCT00799721|IUGR
475365|NCT00799721|VEGF
475366|NCT00799721|sFLT-1
475367|NCT00799721|very low birth weight infants
475368|NCT00799721|retinopathy of prematurity
475369|NCT00799721|erythropoietin therapy and risk of ROP
475370|NCT00799708|Biomarkers of estrogen receptor beta activation
475371|NCT00799695|diabetic retinopathy
475372|NCT00799695|screening
475373|NCT00799695|annual
475374|NCT00799682|Dry Eye
475375|NCT00799682|Monotherapy for Ocular Hypertension, Glaucoma
475376|NCT00799682|Ocular Hypertension
475377|NCT00799682|Chronic Open-Angle Glaucoma
475378|NCT00799682|Chronic Angle-Closure Glaucoma
475379|NCT00799682|Iridotomy
475380|NCT00799682|Iridectomy
475381|NCT00799682|Pseudo Exfoliate
475382|NCT00799682|Pigmentary Glaucoma
475383|NCT00799682|Systemic Non-Glaucoma Medications
475384|NCT00799682|Hyperemia
475385|NCT00799669|hypopharyngeal cancer
475386|NCT00799669|laryngeal cancer
475387|NCT00799669|lip and oral cavity cancer
475388|NCT00799669|nasopharyngeal cancer
475389|NCT00799669|oropharyngeal cancer
475390|NCT00799669|paranasal sinus and nasal cavity cancer
475391|NCT00799669|tobacco use disorder
475392|NCT00799656|Diabetic neuropathy
475393|NCT00799656|painful pain
475394|NCT00799656|postoperative
475395|NCT00799643|Type 2 Diabetes Mellitus (T2D)
475396|NCT00799643|Inflammation
475397|NCT00799643|Obesity
475398|NCT00799643|Metabolic Syndrome
475399|NCT00799643|Salicylates
475400|NCT00799630|energy drink
475401|NCT00799630|exercise
475402|NCT00799630|BCAA
475403|NCT00799630|peripheral and central fatigue
475404|NCT00799617|Testosterone
475405|NCT00799617|Mobility disability
475406|NCT00799617|Decreased libido
475407|NCT00799617|Age associated memory impairment
475408|NCT00799617|Low vitality
475409|NCT00799617|Anemia
475410|NCT00799604|Hypertension
475411|NCT00799604|Antihypertensive Agent
475412|NCT00799604|Calcium Channel Blocker
475413|NCT00799591|Registre MONTRAVERS
475414|NCT00799578|NASH, NAFLD,nonalcoholic steatohepatitis
475415|NCT00799565|Mitral Valve prolapse
475416|NCT00799565|echography
475417|NCT00799565|genetic study
475418|NCT00799565|study case-witness
475419|NCT00799565|Patients with a Mitral Valve Prolapse
475420|NCT00799552|Keratoconjunctivitis Sicca
475421|NCT00799552|Dry eye
475422|NCT00799552|Resolvin
475423|NCT00799539|Prednisone
475424|NCT00799539|Bortezomib
475425|NCT00799539|Melphalan
475426|NCT00799526|Ex Vivo Conjunctival Epithelial Cell
475427|NCT00799526|Transplantation
475428|NCT00799513|Lenalidomide
475429|NCT00799513|revlimid
475430|NCT00799513|large B-cell lymphoma
475431|NCT00799513|relapse
475432|NCT00799487|ADHD
475433|NCT00799487|Attention Deficit Hyperactivity Disorder
475434|NCT00799435|Diabetes
475435|NCT00799435|Diastolic Heart Failure
475436|NCT00799435|Aortic Stiffness
475437|NCT00799435|Exenatide
475438|NCT00799422|Conjunctival Staining
475439|NCT00799422|lens parameters
475440|NCT00799422|lens fit
475441|NCT00799409|ADHD
475442|NCT00799409|Attention Deficit Hyperactivity Disorder
475443|NCT00799383|Risperidone
475444|NCT00799383|hyperprolactinemia
475445|NCT00799383|children
475446|NCT00799383|adolescents
475447|NCT00799383|antipsychotics
475448|NCT00799383|prevention
475449|NCT00799383|calcium
475450|NCT00799383|vitamin D
475451|NCT00799383|Risperidone-induced hyperprolactinemia
475452|NCT00799370|Osteotomy
475453|NCT00799370|Weight bearing
475454|NCT00799370|Opening wedge
475455|NCT00799357|ultrasound
475456|NCT00799344|Coronary Stent
475457|NCT00799331|Healthy volunteers
475458|NCT00799279|smoking
475459|NCT00799279|cessation
475460|NCT00799279|family medicine
475461|NCT00799279|evidence-based
475462|NCT00799279|knowledge translation
475463|NCT00799279|smoking cessation, primary care
475464|NCT00799266|Osteoporosis, children and adolescents, zoledronic acid, chronic inflammation, Duchenne muscular dystrophy, glucocorticoids
475465|NCT00799240|lung cancer
475466|NCT00799240|stage IIIb
475467|NCT00799240|pleural effusion
475468|NCT00799240|stage IV
475469|NCT00799240|metastatic lung cancer
475470|NCT00799240|non squamous lung cancer
475471|NCT00799240|IGF-1R
475472|NCT00799240|Pemetrexed
475473|NCT00799240|Cisplatin
475474|NCT00799214|bacterial vaginosis
475475|NCT00799214|intravaginal
475476|NCT00799214|boric acid
475477|NCT00799214|metronidazole
475478|NCT00799214|placebo controlled
475479|NCT00799214|double-blind
475480|NCT00799214|randomized
475481|NCT00799214|multicenter
475482|NCT00799214|non-inferiority
475483|NCT00799201|Enteral nutrition
475484|NCT00799201|Constipation
475485|NCT00799201|Gastrointestinal motility
475486|NCT00799201|Naloxone
475487|NCT00799201|Docusate
475488|NCT00799201|Bowel stimulant
475489|NCT00799201|Stool softener
475490|NCT00798824|tube feeding
475491|NCT00798824|premature infant
475492|NCT00798811|brain tumor
475493|NCT00798811|high-dose chemotherapy
475494|NCT00798811|autologous stem cell transplantation
475495|NCT00798811|infant
475496|NCT00798785|diabetes mellitus type 1
475497|NCT00798785|pancreatic beta cell
475498|NCT00798785|transplantation
475499|NCT00798772|HIV infection
475500|NCT00798772|Micronutrients
475501|NCT00798772|Antioxidants
475502|NCT00798759|Open-angle glaucoma
475503|NCT00798759|Ocular hypertension
475504|NCT00798746|Esophageal cancer
475505|NCT00798746|pyloric drainage
475506|NCT00798746|pyloric drainage procedure
475507|NCT00798746|reflux
475508|NCT00798746|reflux symptoms
475509|NCT00798746|esophagectomy
475510|NCT00798746|Quality of Life
475511|NCT00798746|Health-related quality of life
475512|NCT00798746|HRQL
475513|NCT00798720|non small cell lung cancer
475514|NCT00798720|HDAC
475515|NCT00798720|proteasome inhibitor
475516|NCT00798707|Major Depressive Disorder
475517|NCT00798694|glaucoma
475518|NCT00798694|impression cytology
475519|NCT00798694|ocular surface changes
475520|NCT00798694|prostaglandins
475521|NCT00798681|parenteral nutrition
475522|NCT00798681|ready-to-use
475523|NCT00798681|customized nutrition formulation
475524|NCT00798681|olive oil
475525|NCT00798681|soybean oil
475526|NCT00798681|LCT/MCT
475527|NCT00798681|Clinoleic
475528|NCT00798681|oliclinomel
475529|NCT00798681|number of infections associated with TPN delivery system
475530|NCT00798681|BSI
475531|NCT00798681|Infection rates
475532|NCT00798668|Endocrine and Gastrointestinal Response to Food
475533|NCT00798655|panitumumab
475534|NCT00798655|cisplatin
475535|NCT00798655|radiation
475536|NCT00798642|Hypnotherapy
475537|NCT00798642|Ulcerative Colitis
475538|NCT00798642|Inflammatory Bowel Disease
475539|NCT00798642|Gastrointestinal Diseases
475540|NCT00798642|Digestive System Diseases
475541|NCT00798642|Intestinal Diseases
475542|NCT00798642|Colonic Diseases
475543|NCT00798629|stage III melanoma
475544|NCT00798629|stage IV melanoma
475545|NCT00798629|recurrent melanoma
475546|NCT00798629|mucosal melanoma
475547|NCT00798616|bronchiolitis
475548|NCT00798616|steroids
475549|NCT00798616|corticosteroids
475550|NCT00798616|albuterol
475551|NCT00798616|child
475552|NCT00798616|infant
475553|NCT00798616|pediatric
475554|NCT00798603|stage IIIB non-small cell lung cancer
475555|NCT00798603|stage IV non-small cell lung cancer
475556|NCT00798603|recurrent non-small cell lung cancer
475557|NCT00798603|adenocarcinoma of the lung
475558|NCT00798603|adenosquamous cell lung cancer
475559|NCT00798590|Intensive insulin therapy (IIT)
475560|NCT00798590|Insulin infusion
475561|NCT00798590|Tight glycemic control
475562|NCT00798590|Intensive Care Units
475563|NCT00798577|Bacterial Conjunctivitis
475564|NCT00798564|Exercise
475565|NCT00798564|Mannitol
475566|NCT00798538|Buprenorphine
475567|NCT00798538|HIV
475568|NCT00798538|Drug Abuse
475569|NCT00798538|Drug Addiction
475570|NCT00798538|Drug Dependence
475571|NCT00798538|Drug Use Disorders
475572|NCT00798538|Drug Use Disorder
475573|NCT00798538|Substance Abuse
475574|NCT00798538|Opiate Addiction
475575|NCT00798538|Substance-related disorders
475576|NCT00798525|thrombocytopenia
475577|NCT00798525|Heparin
475578|NCT00798525|Lepirudin
475579|NCT00798525|Argatroban
475580|NCT00798525|critically ill patients
475581|NCT00798512|carotid artery stenting
475582|NCT00798512|cerebral protection
475583|NCT00798512|stroke
475584|NCT00798512|ischemic lesion
475585|NCT00798512|DW-MRI
475586|NCT00798499|haemophilia
475587|NCT00798499|patients with haemophilia
475588|NCT00798473|Crohn's disease
475589|NCT00798473|Osteopenia
475590|NCT00798473|Osteoporosis
475591|NCT00798473|Bisphosphonates
475592|NCT00798473|Zoledronate
475593|NCT00798460|Chronic hepatitis B
475594|NCT00798460|lamivudine resistance
475595|NCT00798460|clevudine
475596|NCT00798447|post OP
475597|NCT00798434|Overactive bladder syndrome
475598|NCT00798434|fesoterodine
475599|NCT00798434|elderly
475600|NCT00798434|flexible dose regimen
475601|NCT00798434|urgency
475602|NCT00798434|frequency
475603|NCT00798434|urge urinary incontinence
475604|NCT00798434|anticholinergic
475605|NCT00798434|antimuscarinic
475606|NCT00798421|Influenza, transmission
475607|NCT00798408|Evaluate the effects of energy-yielding fluids and solids endocrine and metabolic response to food in the elderly
475608|NCT00798369|Acute flares
475609|NCT00798369|Gout
475610|NCT00798369|Anti-interleukin-1β monoclonal antibody
475611|NCT00798369|Colchicine
475612|NCT00798369|Triamcinolone acetonide
475613|NCT00798356|atrial fibrillation, yoga
475614|NCT00798343|Influenza, heterosubtypic immune responses
475615|NCT00798330|Cancer
475616|NCT00798330|Blood stream infections
475617|NCT00798330|Bacteremia
475618|NCT00798330|Dental procedure
475619|NCT00798330|Central venous catheters
475620|NCT00798330|Mediport
475621|NCT00798330|PICC line
475622|NCT00798304|Meningococcal B vaccine
475623|NCT00798304|infants
475624|NCT00798304|safety
475625|NCT00798304|immunogenicity
475626|NCT00798278|Empyema
475627|NCT00798278|Urokinase
475628|NCT00798278|Thoracoscopic
475629|NCT00798278|Childhood
475630|NCT00798265|HPV Vaccination
475631|NCT00798265|HPV Immunogenicity
475632|NCT00798265|HIV Infection
475633|NCT00798265|HIV Negative
475634|NCT00798265|Adolescents and Young Adults
475635|NCT00798265|Healthy Volunteer
475636|NCT00798265|HV
475637|NCT00798265|Adolescent
475638|NCT00798252|metastatic, chemotherapy combination
475639|NCT00798239|DDD
475640|NCT00798239|Spondylolisthesis
475641|NCT00798239|Spine Fusion
475642|NCT00798239|Lumbar Spine
475643|NCT00798239|Bone Graft
475644|NCT00798226|Asthma
475645|NCT00798226|Eczema
475646|NCT00798226|Sensitization
475647|NCT00798226|Allergy
475648|NCT00798200|Cancer
475649|NCT00798200|Oncology
475650|NCT00798200|Rehabilitation
475651|NCT00798200|Endurance
475652|NCT00798200|Strength
475653|NCT00798187|Prostate Cancer
475654|NCT00798187|Breast Cancer
475655|NCT00798187|Behavioral Intervention
475656|NCT00798187|Cancer Support Programs
475657|NCT00798187|Social Comparison
475658|NCT00798187|Heterogeneous support group
475659|NCT00798187|Homogeneous support group
475660|NCT00798174|DFT
475661|NCT00798174|CHF
475662|NCT00798174|ICD
475663|NCT00798148|Neuroblastoma
475664|NCT00798148|MIBG
475665|NCT00798148|Autologous Peripheral Stem Cell Transplantation
475666|NCT00798122|sex
475667|NCT00798122|acute coronary syndromes
475668|NCT00798122|normal angiogram
475669|NCT00798122|no obstruction at angiography
475670|NCT00798122|women
475671|NCT00798109|Schizophrenia
475672|NCT00798109|Cannabis misuse comorbidity
475673|NCT00798109|Motivational interview
475674|NCT00798109|Randomised open trial
475675|NCT00798096|T Cell Lymphoma
475676|NCT00798096|Lymphoma
475677|NCT00798070|Lymph node positive or high risk lymph node negative breast
475678|NCT00798070|cancer
475679|NCT00798057|Pituitary tumor
475680|NCT00798057|Outcomes
475681|NCT00798057|Proton radiation
475682|NCT00798044|quality improvement
475683|NCT00798044|feedback
475684|NCT00798044|substance use disorders
475685|NCT00798031|dental implant
475686|NCT00798031|upper jaw
475687|NCT00798031|posterior tooth loss
475688|NCT00798031|short dental implant
475689|NCT00798031|Adults, 18 years of age and older
475690|NCT00798031|Missing a minimum of two posterior teeth in their upper jaw
475691|NCT00798031|Subjects in need of dental implants
475692|NCT00798031|the research study is survival and function of the implants
475693|NCT00798018|lidocaine
475694|NCT00798018|tetracaine
475695|NCT00798018|tracheal intubation
475696|NCT00798018|pharyngitis
475697|NCT00798005|NV1FGF
475698|NCT00798005|PAOD
475699|NCT00798005|CLI
475700|NCT00797992|Bevacizumab
475701|NCT00797992|Myopia
475702|NCT00797992|Complications
475703|NCT00797992|Neovascularization
475704|NCT00797992|OCT
475705|NCT00797979|Craniotomy
475706|NCT00797979|Skull fixation
475707|NCT00797979|Skull Grip
475708|NCT00797979|Reconstructive cranial surgery
475709|NCT00797966|OPC-34712, Major Depressive Disorder, Adjunctive Treatment
475710|NCT00797953|Angina Pectoris Treatment
475711|NCT00797940|GBM
475712|NCT00797940|Glioblastoma
475713|NCT00797940|Glioblastoma Multiforme
475714|NCT00797940|Brain Tumor
475715|NCT00797940|Brain Cancer
475716|NCT00797940|Glioma
475717|NCT00797927|schizophrenia
475718|NCT00797927|quetiapine
475719|NCT00797927|conventional antipsychotics
475720|NCT00797927|magnetic resonance spectroscopy
475721|NCT00797914|Colonoscopy
475722|NCT00797914|Instrumentation
475723|NCT00797914|Force Monitoring
475724|NCT00797914|Quality Control
475725|NCT00797914|Training
475726|NCT00797888|diabetes
475727|NCT00797888|behavioral intervention
475728|NCT00797888|HbA1c
475729|NCT00797888|health disparities
475730|NCT00797875|proprioceptive neuromuscular facilitation stretching technique, total knee arthroplasty, range of motion
475731|NCT00797862|Aliskiren
475732|NCT00797862|Amlodipine
475733|NCT00797862|Hypertension
475734|NCT00797862|SPA1000
475735|NCT00797862|Norvasc
475736|NCT00797849|phantom limb pain
475737|NCT00797849|amputees
475738|NCT00797849|Farabloc
475739|NCT00797849|Phantom limb pain in the missing limb of Veteran amputees
475740|NCT00797836|Occupational Diseases
475741|NCT00797836|Tuberculosis
475742|NCT00797836|Tuberculin Test
475743|NCT00797836|Immunoassay
475744|NCT00797823|diabetes
475745|NCT00797823|pancreas
475746|NCT00797823|beta cell
475747|NCT00797823|glucagon
475748|NCT00797823|insulin
475749|NCT00797823|hypoglycemia
475750|NCT00797810|Acute lymphoblastic leukemia of the mature B-cell type
475751|NCT00797810|High-grade non-Hodgkin's lymphoma
475752|NCT00797797|fibromyalgia
475753|NCT00797797|milnacipran
475754|NCT00797797|pregabalin
475755|NCT00797797|treatment
475756|NCT00797797|Forest Research Institute
475757|NCT00797771|Insulin delivery
475758|NCT00797758|Cord blood transplantation
475759|NCT00797758|Conditioning regimen
475760|NCT00797758|Acute myeloid leukaemia
475761|NCT00797758|SORROR comorbidity index
475762|NCT00797758|Quality of life
475763|NCT00797758|Innate immunity
475764|NCT00797758|Immune reconstitution post transplant
475765|NCT00797758|Umbilical Cord Blood Stem Cell Transplantation
475766|NCT00797758|Hematopoietic Stem Cell Transplantation
475767|NCT00797745|genotype 1 infection
475768|NCT00797732|acupuncture
475769|NCT00797732|dysphagia
475770|NCT00797732|chemoradiation related effects
475771|NCT00797732|squamous cell carcinoma of the head and neck
475772|NCT00797732|nasopharyngeal cancer
475773|NCT00797732|oropharynx cancer
475774|NCT00797732|hypopharynx cancer
475775|NCT00797732|larynx cancer
475776|NCT00797719|MPM
475777|NCT00797719|Short hemithoracic IMRT
475778|NCT00797693|First trimester
475779|NCT00797693|missed abortion
475780|NCT00797693|misoprostol
475781|NCT00797693|cervical ripening
475782|NCT00797693|oral
475783|NCT00797693|vaginal
475784|NCT00797693|first trimester missed abortion
475785|NCT00797680|Pediatric cardiac arrest
475786|NCT00797654|Sexual Risks for HIV
475787|NCT00797654|Psychosocial Sequelae Relating to Childhood Sexual Abuse
475788|NCT00797641|bleeding
475789|NCT00797641|ulcer
475790|NCT00797641|hemorrhage
475791|NCT00797641|gastrointestinal diseases
475792|NCT00797641|digestive system disease
475793|NCT00797641|peptic ulcer
475794|NCT00797641|proton pump inhibitor
475795|NCT00797602|Chordomas
475796|NCT00797602|Chondrosarcomas
475797|NCT00797602|Cancer
475798|NCT00797602|Outcomes
475799|NCT00797602|Proton radiation
475800|NCT00797589|aorta valve
475801|NCT00797589|mitral valve
475802|NCT00797589|coronary artery bypass grafting surgery
475803|NCT00797589|perfusion
475804|NCT00797589|priming
475805|NCT00797576|left atrial appendage thrombi
475806|NCT00797576|transesophageal echocardiogram
475807|NCT00797576|cardiac magnetic resonance imaging
475808|NCT00797576|atrial fibrillation
475809|NCT00797576|cardioversion
475810|NCT00797550|posterolateral spine fusion
475811|NCT00797550|bone graft
475812|NCT00797537|Inflammation of bone and cartilage
475813|NCT00797511|Diphtheria
475814|NCT00797511|Tetanus
475815|NCT00797511|Pertussis
475816|NCT00797511|Poliomyelitis
475817|NCT00797498|Nasal Cavity
475818|NCT00797498|Paranasal Sinuses
475819|NCT00797498|Proton Radiation
475820|NCT00797498|Outcomes
475821|NCT00797485|stage IV colon cancer
475822|NCT00797485|stage IV rectal cancer
475823|NCT00797472|Hodgkin's Lymphoma
475824|NCT00797472|R-mabHD
475825|NCT00797472|ABVD treatment
475826|NCT00797472|Hodgkin's Disease
475827|NCT00797459|Correction of Nasolabial Folds
475828|NCT00797446|Oropharyngeal
475829|NCT00797446|cancer
475830|NCT00797446|proton
475831|NCT00797446|radiation
475832|NCT00797446|outcomes
475833|NCT00797433|testosterone
475834|NCT00797433|mechanical ventilation
475835|NCT00797420|fluconazole
475836|NCT00797420|pharmacokinetic
475837|NCT00797420|candidiasis
475838|NCT00797420|sepsis
475839|NCT00797420|pediatric
475840|NCT00797420|infants
475841|NCT00797420|antifungal
475842|NCT00797420|candidemia
475843|NCT00797420|fungemia
475844|NCT00797420|loading dose
475845|NCT00797407|Hydroxymethylglutaryl-CoA Reductase Inhibitors
475846|NCT00797407|Creatine
475847|NCT00797407|Adverse Effects
475848|NCT00797407|Muscle Toxicity
475849|NCT00797394|prostate
475850|NCT00797394|dietary supplements
475851|NCT00797394|saw palmetto
475852|NCT00797394|canada
475853|NCT00797381|MK-0518
475854|NCT00797381|HIV
475855|NCT00797381|AIDS
475856|NCT00797381|hemophilia
475857|NCT00797381|treatment experienced
475858|NCT00797368|ankle sprain
475859|NCT00797368|manual therapy
475860|NCT00797368|exercise
475861|NCT00797368|physical therapy
475862|NCT00797368|Patients who have sustained an inversion ankle sprain
475863|NCT00797342|rheumatoid arthritis First in human safety pharmacokinetics pharmacodynamics
475864|NCT00797329|psychiatric patients with violent behavior
475865|NCT00797316|Hypertension
475866|NCT00797316|Metabolic Syndrome
475867|NCT00797316|aliskiren
475868|NCT00797316|hydrochlorothiazide
475869|NCT00797316|systolic blood pressure
475870|NCT00797316|diastolic blood pressure
475871|NCT00797316|stage 2
475872|NCT00797303|bevacizumab
475873|NCT00797303|cornea
475874|NCT00797303|neovascularization
475875|NCT00797290|Nasopharynx Cancer, Proton Radiation, Outcomes
475876|NCT00797277|schizophrenia
475877|NCT00797277|schizoaffective disorder
475878|NCT00797277|olanzapine
475879|NCT00797277|haloperidol
475880|NCT00797277|lorazepam
475881|NCT00797277|agitation
475882|NCT00797264|Ketamine
475883|NCT00797264|Morphine
475884|NCT00797264|PCA
475885|NCT00797264|Hyperalgesia
475886|NCT00797264|Nor-ketamine
475887|NCT00797251|Colorectal liver metastasis
475888|NCT00797251|hepatocellular carcinoma
475889|NCT00797251|liver surgery
475890|NCT00797251|intraoperative ultrasound
475891|NCT00797251|finger-compression
475892|NCT00797238|Gene Expression
475893|NCT00797238|Carcinoma, Non-Small-Cell Lung
475894|NCT00797238|Chemotherapy
475895|NCT00797225|bone mineral density
475896|NCT00797225|Endometriosis
475897|NCT00797225|Pelvic Pain
475898|NCT00797199|Breast Cancer Risk
475899|NCT00797199|Hormone Replacement Therapy
475900|NCT00797199|Optical Transillumination Spectroscopy
475901|NCT00797199|Optical Breast Spectroscopy
475902|NCT00797199|Transillumination Breast Spectroscopy
475903|NCT00797186|diabetes
475904|NCT00797186|dyslipidemia
475905|NCT00797186|microvascular dysfunction
475906|NCT00797186|imaging
475907|NCT00797160|propofol
475908|NCT00797160|midazolam
475909|NCT00797160|neonate
475910|NCT00797160|tracheal intubation
475911|NCT00797121|Cholangiocarcinoma
475912|NCT00797121|Drainage
475913|NCT00797095|Adolescence
475914|NCT00797095|Obesity
475915|NCT00797095|Substance use
475916|NCT00797095|Prevalence
475917|NCT00797095|Social and Environmental Contexts
475918|NCT00797095|Survey
475919|NCT00797082|Diabetic
475920|NCT00797082|Coronary disease
475921|NCT00797082|Atherosclerosis
475922|NCT00797082|Magnetic resonance imaging
475923|NCT00797082|Myocardial Perfusion Scintigraphy
475924|NCT00797082|Coronary angiography
475925|NCT00797056|G-CSF
475926|NCT00797056|angiogenesis
475927|NCT00797056|endothelial progenitor cell
475928|NCT00797056|limb ischemia
475929|NCT00797056|revascularization
475930|NCT00797043|Carcinoma of the skin of the head and neck
475931|NCT00797043|Proton radiation
475932|NCT00797043|Outcomes
475933|NCT00797030|dry eye syndromes
475934|NCT00797030|keratoconjuntivitis sicca / drug therapy
475935|NCT00797030|cyclosporine
475936|NCT00797030|ophthalmic solutions
475937|NCT00797030|HIV seropositivity
475938|NCT00797017|Chronic Pain
475939|NCT00797017|Fentanyl Matrix
475940|NCT00797017|Spinal disorder-related pain
475941|NCT00797004|olfactory dysfunction
475942|NCT00796991|Untreated Advanced Melanoma
475943|NCT00796978|stage I breast cancer
475944|NCT00796978|stage II breast cancer
475945|NCT00796978|stage IIIA breast cancer
475946|NCT00796978|stage IIIB breast cancer
475947|NCT00796978|stage IIIC breast cancer
475948|NCT00796978|HER2-positive breast cancer
475949|NCT00796965|Phase 1
475950|NCT00796952|Head/ neck cancer
475951|NCT00796952|Swallowing
475952|NCT00796952|behavioral treatment
475953|NCT00796939|Delayed Sleep Phase Syndrome
475954|NCT00796939|Sleep
475955|NCT00796900|Hyperthermia
475956|NCT00796900|subarachnoidal hemorrhage
475957|NCT00796900|placebo controlled
475958|NCT00796900|double blinded
475959|NCT00796900|Dantrolene
475960|NCT00796887|Ischemic Stroke
475961|NCT00796887|Recovery of Function
475962|NCT00796887|Extended-release niacin
475963|NCT00796874|stage I prostate cancer
475964|NCT00796874|stage II prostate cancer
475965|NCT00796861|malignant ascites
475966|NCT00796835|Schizophrenia
475967|NCT00796835|Mood disorders
475968|NCT00796835|Antipsychotic drugs
475969|NCT00796835|ER OROS Paliperidone
475970|NCT00796822|Endothelial Function
475971|NCT00796822|Inflammation
475972|NCT00796809|TNF inhibitors
475973|NCT00796809|Biologic agents
475974|NCT00796809|coccidioidomycosis
475975|NCT00796809|Rheumatoid arthritis
475976|NCT00796796|Non-small cell lung cancer
475977|NCT00796796|temsirolimus
475978|NCT00796796|radiation therapy
475979|NCT00796783|Cushing's Disease
475980|NCT00796783|Cushing's Syndrome
475981|NCT00796783|Cushings
475982|NCT00796783|Pituitary
475983|NCT00796783|ACTH
475984|NCT00796783|Adrenocorticotropic hormone
475985|NCT00796783|Ectopic
475986|NCT00796783|Adrenal adenoma
475987|NCT00796783|Adrenal carcinoma
475988|NCT00796783|Adrenal autonomy
475989|NCT00796783|Cortisol
475990|NCT00796783|Hypercortisolemia
475991|NCT00796783|Cushinoid
475992|NCT00796783|Moon facies
475993|NCT00796783|Dorsalcervical fat
475994|NCT00796783|Plethora
475995|NCT00796783|Hirsutism
475996|NCT00796783|Violaceous striae
475997|NCT00796783|Hormone
475998|NCT00796783|Contraceptive
475999|NCT00796783|Endocrine
476000|NCT00796783|Cushing Syndrome
476001|NCT00796783|Ectopic ACTH Secretion
476002|NCT00796770|HIV
476003|NCT00796770|Vaccine
476004|NCT00796770|HAART
476005|NCT00796770|HIV-1
476006|NCT00796770|AIDS
476007|NCT00796770|Dendritic Cells
476008|NCT00796770|DALIA
476009|NCT00796744|Diabetes mellitus
476010|NCT00796744|Diabetic neuropathy
476011|NCT00796744|Peripheral vascular disease
476012|NCT00796744|Infection
476013|NCT00796744|Topical application
476014|NCT00796744|plantar foot ulcers
476015|NCT00796731|B-cell lymphoma
476016|NCT00796731|NHL
476017|NCT00796692|Heparin
476018|NCT00796692|Low molecular weight heparin
476019|NCT00796692|Safety
476020|NCT00796692|Efficacy
476021|NCT00796692|Cost effective
476022|NCT00796679|paricalcitol
476023|NCT00796679|chronic kidney disease
476024|NCT00796679|cardiac hypertrophy
476025|NCT00796666|endothelin receptor antagonist (ETRA)
476026|NCT00796666|Sitaxsentan
476027|NCT00796640|Schizophrenia
476028|NCT00796640|Mood disorders
476029|NCT00796640|Antipsychotic drugs
476030|NCT00796640|ER Paliperidone
476031|NCT00796627|Wound Healing
476032|NCT00796627|Burns
476033|NCT00796627|HIF-1
476034|NCT00796627|EPC
476035|NCT00796614|tamsulosin
476036|NCT00796614|pediatric
476037|NCT00796614|neurogenic bladder
476038|NCT00796601|double-blind placebo-controlled maintenance of efficacy
476039|NCT00796588|preconditioning
476040|NCT00796588|remote
476041|NCT00796575|multiple ascending dose healthy volunteers
476042|NCT00796575|pharmacokinetics
476043|NCT00796575|pharmacodynamics
476044|NCT00796562|Leukemia
476045|NCT00796562|Lymphoma
476046|NCT00796562|Hematologic malignancies
476047|NCT00796562|ALL
476048|NCT00796562|AML
476049|NCT00796562|MDS
476050|NCT00796562|Transplantation
476051|NCT00796562|Mismatched
476052|NCT00796562|Haploidentical
476053|NCT00796562|Busulfan
476054|NCT00796562|Cyclophosphamide
476055|NCT00796562|Cellcept
476056|NCT00796562|Tacrolimus
476057|NCT00796562|TBI
476058|NCT00796562|CMMOL
476059|NCT00796562|CML
476060|NCT00796562|JMML
476061|NCT00796536|Acute Pain
476062|NCT00796536|Low Back Pain
476063|NCT00796536|Back Pain
476064|NCT00796536|Functional Magnetic Resonance Imaging (fMRI)
476065|NCT00796536|Cognitive Behavioral Therapy
476066|NCT00796536|Pain Education
476067|NCT00796523|colic
476068|NCT00796523|crying
476069|NCT00796523|clinical trial
476070|NCT00796510|endothelin receptor antagonist (ETRA)
476071|NCT00796510|sitaxsentan
476072|NCT00796497|Obsessive Compulsive Disorder
476073|NCT00796497|5-ht3
476074|NCT00796497|ondansetron
476075|NCT00796484|Cancer
476076|NCT00796484|Solid Tumors
476077|NCT00796471|Schizophrenia
476078|NCT00796471|Mood Disorders
476079|NCT00796471|Antipsychotic drugs
476080|NCT00796471|Paliperidone ER
476081|NCT00796458|pain
476082|NCT00796458|adenocarcinoma of the prostate
476083|NCT00796458|recurrent prostate cancer
476084|NCT00796458|stage IV prostate cancer
476085|NCT00796458|stage III prostate cancer
476086|NCT00796445|DERMA
476087|NCT00796445|Tumor antigen
476088|NCT00796445|Immunotherapeutic
476089|NCT00796445|Adjuvant cancer therapy
476090|NCT00796445|Melanoma
476091|NCT00796445|ASCI
476092|NCT00796432|Schizophrenia
476093|NCT00796432|mood disorders
476094|NCT00796432|antipsychotic drugs
476095|NCT00796432|dopamine
476096|NCT00796432|receptor occupancy
476097|NCT00796432|OROS paliperidone
476098|NCT00796419|Acute lung injury (ALI)
476099|NCT00796419|Acute respiratory distress syndrome (ARDS)
476100|NCT00796419|Respiratory failure
476101|NCT00796367|Obesity
476102|NCT00796354|Constipation
476103|NCT00796354|Irritable Bowel Syndrome
476104|NCT00796341|invitro-fertilization ,embryo transfer,endometrial injury
476105|NCT00796315|Pharmacokinetic study
476106|NCT00796302|Conduct Disorder
476107|NCT00796302|Attention Deficit and Disruptive Behavior Disorders
476108|NCT00796289|anovulatory/oligoovulatory infertility
476109|NCT00796276|Schizophrenia
476110|NCT00796276|Mood disorders
476111|NCT00796276|Antipsychotics
476112|NCT00796276|Pharmacokinetics
476113|NCT00796276|Enantiomer
476114|NCT00796276|IR OROS Paliperidone
476115|NCT00796276|ER OROS Paliperidone
476116|NCT00796263|Acute HIV infection
476117|NCT00796237|stroke
476118|NCT00796237|bone
476119|NCT00796237|gait
476120|NCT00796237|muscle
476121|NCT00796237|vibration
476122|NCT00796237|motor balance
476123|NCT00796224|azithromycin, pharmacokinetics, pediatrics
476124|NCT00796211|Psoriasis
476125|NCT00796211|CRx-197
476126|NCT00796211|nortriptyline
476127|NCT00796211|loratadine
476128|NCT00796211|CombinatoRx
476129|NCT00796211|Dermatology
476130|NCT00796211|Erythema
476131|NCT00796211|Pruritus
476132|NCT00796198|Glaucoma
476133|NCT00796198|Intraocular pressure
476134|NCT00796198|Ocular diastolic perfusion pressure
476135|NCT00796198|Dorzolamide/timolol Fixed combination
476136|NCT00796198|Heidelberg Retina Flowmeter
476137|NCT00796185|Schizophrenia
476138|NCT00796185|Schizoaffective Disorder
476139|NCT00796185|Mood Disorders
476140|NCT00796185|Antipsychotic drugs
476141|NCT00796185|Paliperidone ER
476142|NCT00796172|Hypertension
476143|NCT00796172|High Blood Pressure
476144|NCT00796172|Blood Lipid Management
476145|NCT00796159|Efficacy; Tolerability; Safety; Essential Hypertension
476146|NCT00796133|NES/E2
476147|NCT00796133|transdermal gel delivery
476148|NCT00796133|contraception
476149|NCT00796133|ovulation
476150|NCT00796133|bleeding patterns
476151|NCT00796120|Sarcomas
476152|NCT00796120|Trabectedin
476153|NCT00796120|Doxorubicin
476154|NCT00796120|Ifosfamide
476155|NCT00796120|YONDELIS
476156|NCT00796081|Schizophrenia
476157|NCT00796081|Schizoaffective disorder
476158|NCT00796081|Schizophreniform disorders
476159|NCT00796081|Mood disorders
476160|NCT00796081|Antipshychotic drugs
476161|NCT00796081|Pediatrics
476162|NCT00796081|ER OROS Paliperidone, Paliperidone ER
476163|NCT00796042|Pressure Ulcer
476164|NCT00796042|Bed Sores
476165|NCT00796042|Bedsore
476166|NCT00796042|Decubitus Ulcer
476167|NCT00796042|Pressure Sore
476168|NCT00796042|Best rest
476169|NCT00796042|mobility
476170|NCT00796042|pressure management
476171|NCT00796029|Schizophrenia
476172|NCT00796029|Mood disorders
476173|NCT00796029|Antipsychotic drugs: 14C-paliperidone
476174|NCT00796003|Myelodysplastic syndrome
476175|NCT00796003|MDS
476176|NCT00796003|Decitabine
476177|NCT00796003|JNJ-30979754
476178|NCT00795990|Efficacy of early vs late use of ibuprofen for PDA closure
476179|NCT00795977|preoperative
476180|NCT00795977|intratumor
476181|NCT00795977|dendritic cells
476182|NCT00795977|pancreatic cancer
476183|NCT00795977|OK-432
476184|NCT00795964|tidal volume
476185|NCT00795964|predicted body weight
476186|NCT00795964|lung function
476187|NCT00795964|respiratory outcome
476188|NCT00795964|Respiratory Function Tests
476189|NCT00795964|surgery
476190|NCT00795951|allergic
476191|NCT00795951|contact dermatitis
476192|NCT00795951|contact allergy
476193|NCT00795951|Type IV
476194|NCT00795951|Children
476195|NCT00795951|TRUE TEST
476196|NCT00795925|propiverine
476197|NCT00795925|anticholinergics
476198|NCT00795925|urinary incontinence
476199|NCT00795925|overactive bladder
476200|NCT00795925|children
476201|NCT00795925|dose-finding in children aged 5-10 years
476202|NCT00795912|Systolic heart failure
476203|NCT00795912|HMG CoA reductase inhibitors
476204|NCT00795912|B-type natriuretic peptide
476205|NCT00795912|Inflammation
476206|NCT00795912|Myocardial collagen turnover
476207|NCT00795899|Safety and efficacy of experimental treatment
476208|NCT00795886|ALL
476209|NCT00795886|Cancer
476210|NCT00795886|Stem Cell Transplant
476211|NCT00795873|Heart failure
476212|NCT00795873|cardiac resynchronization therapy
476213|NCT00795860|Insulin sensitivity
476214|NCT00795860|fat metabolism
476215|NCT00795860|inflammation
476216|NCT00795847|Hypertensive patients with morning hypertension
476217|NCT00795834|polyphenolics
476218|NCT00795834|flavonols
476219|NCT00795834|lipids
476220|NCT00795834|endothelial function
476221|NCT00795834|vascular risk factors
476222|NCT00795808|Polycystic ovary syndrome
476223|NCT00795808|PCOS
476224|NCT00795808|Anovulation
476225|NCT00795808|Infertility
476226|NCT00795808|Anovulatory polycystic ovary syndrome (PCOS)
476227|NCT00795795|Chromosomal abnormalities in preimplantation embryos
476228|NCT00795782|Papillary thyroid carcinoma
476229|NCT00795782|Lymph node dissection
476230|NCT00795782|Lymph node metastasis
476231|NCT00795782|Prophylactic node dissection
476232|NCT00795782|Central lymph node metastasis
476233|NCT00795756|Adults
476234|NCT00795756|Central nervous system prophylaxis
476235|NCT00795756|Minimal residual disease
476236|NCT00795743|Central Venous Catheterization
476237|NCT00795743|coagulopathy
476238|NCT00795743|thromboelastography
476239|NCT00795730|Alzheimer's Disease
476240|NCT00795730|schizophrenia
476241|NCT00795717|HIV
476242|NCT00795717|cardiovascular risk
476243|NCT00795717|atherogenic lipid profile
476244|NCT00795717|brachial artery reactivity
476245|NCT00795717|omega three fatty acids
476246|NCT00795704|Herbal Supplement
476247|NCT00795704|Type 2 Diabetes
476248|NCT00795704|Mulberry
476249|NCT00795704|Hemoglobin A1C
476250|NCT00795691|diabetes
476251|NCT00795691|low-carbohydrate diet
476252|NCT00795691|weight loss
476253|NCT00795691|obesity
476254|NCT00795691|dietary intervention
476255|NCT00795678|tumors metastatic to brain
476256|NCT00795678|stage IV breast cancer
476257|NCT00795665|adult anaplastic astrocytoma
476258|NCT00795665|adult glioblastoma
476259|NCT00795665|adult gliosarcoma
476260|NCT00795665|adult giant cell glioblastoma
476261|NCT00795665|adult anaplastic oligodendroglioma
476262|NCT00795665|adult mixed glioma
476263|NCT00795665|recurrent adult brain tumor
476264|NCT00795652|Postpartum depression
476265|NCT00795652|Distance therapy
476266|NCT00795652|depression
476267|NCT00795652|Distance Treatment
476268|NCT00795652|Barriers to care
476269|NCT00795639|Sitaxsentan
476270|NCT00795639|endothelin receptor antagonist
476271|NCT00795626|nursing education
476272|NCT00795626|cardiovascular risk factors
476273|NCT00795626|coronary heart disease
476274|NCT00795613|PET
476275|NCT00795574|Hidradenitis Suppurativa
476276|NCT00795561|Hyperemesis gravidarum
476277|NCT00795561|nausea
476278|NCT00795561|vomiting
476279|NCT00795561|pregnancy
476280|NCT00795561|day care
476281|NCT00795561|inpatient management
476282|NCT00795561|Nausea and vomiting of pregnancy
476283|NCT00795548|Myelodysplastic syndrome (MDS)
476284|NCT00795548|Acute myeloid leukemia (AML)
476285|NCT00795548|Stem cell transplantation
476286|NCT00795548|5-Azacitidine
476287|NCT00795548|Donor lymphocyte infusion
476288|NCT00795548|MDS or AML relapsed after stem cell transplantation
476289|NCT00795535|Injury
476290|NCT00795496|Atopic dermatitis
476291|NCT00795496|Bronchial hyperreactivity
476292|NCT00795496|Skin prick tests
476293|NCT00795496|Serum IgE
476294|NCT00795496|Mantoux test
476295|NCT00795483|Osteoporosis
476296|NCT00795483|HIV infection
476297|NCT00795483|Bisphosphonates
476298|NCT00795483|Zoledronic acid
476299|NCT00795470|urinary tract infection
476300|NCT00795470|critically ill
476301|NCT00795470|ICU
476302|NCT00795470|antimicrobial
476303|NCT00795470|Catheter associated urinary tract infections
476304|NCT00795457|vaccine
476305|NCT00795457|WHO Grade II Astrocytoma
476306|NCT00795457|WHO Grade II Oligo-Astrocytoma
476307|NCT00795444|HIV-1
476308|NCT00795444|CCR5 coreceptor antagonist (Maraviroc)
476309|NCT00795444|the cell reservoir of HIV-1
476310|NCT00795418|Active immunization
476311|NCT00795418|Alzheimer's disease
476312|NCT00795418|Antibody
476313|NCT00795418|Vaccine
476314|NCT00795418|Central Nervous System Diseases
476315|NCT00795418|Neurodegenerative diseases
476316|NCT00795405|sporting events
476317|NCT00795405|stress
476318|NCT00795405|myocardial ischemia
476319|NCT00795405|ST-segment depression
476320|NCT00795405|blood pressure
476321|NCT00795392|Psychology
476322|NCT00795392|Postoperative outcome
476323|NCT00795392|Surgical Operation
476324|NCT00795379|Psychotherapy
476325|NCT00795366|TBI, trauma, brain
476326|NCT00795353|plaque psoriasis
476327|NCT00795353|psoriasis
476328|NCT00795353|alefacept
476329|NCT00795353|Amevive
476330|NCT00795340|stage IIIB non-small cell lung cancer
476331|NCT00795340|stage IV non-small cell lung cancer
476332|NCT00795340|recurrent non-small cell lung cancer
476333|NCT00795314|Opioids
476334|NCT00795314|General anesthesia
476335|NCT00795301|tumor
476336|NCT00795288|subarachnoid hemorrhage
476337|NCT00795288|vasospasm
476338|NCT00795288|cerebral blood flow
476339|NCT00795288|cerebral metabolism
476340|NCT00795288|autoregulation
476341|NCT00795288|statin
476342|NCT00795288|Vasospasm associated with Subarachnoid hemorrhage
476343|NCT00795275|pre-diabetes
476344|NCT00795275|isotopes
476345|NCT00795275|insulin secretion
476346|NCT00795275|insulin action
476347|NCT00795275|GLP-1
476348|NCT00795275|simple obesity
476349|NCT00795275|impaired fasting glucose
476350|NCT00795262|brachial artery reactivity
476351|NCT00795236|melatonin
476352|NCT00795210|HIV lipodystrophy
476353|NCT00795210|growth hormone
476354|NCT00795210|growth hormone releasing hormone
476355|NCT00795197|Gaucher Disease,
476356|NCT00795197|acid B-glucosidase,
476357|NCT00795197|gluco cerebrosidase,
476358|NCT00795197|glucosylceramide,
476359|NCT00795184|Barrett's Esophagus
476360|NCT00795184|EsoGastroDuodenoscopy
476361|NCT00795184|Barrett's Carcinoma
476362|NCT00795184|adenocarcinoma
476363|NCT00795184|Cellvizio
476364|NCT00795184|endomicroscopy
476365|NCT00795184|random biopsy
476366|NCT00795145|Linezolid, QTc interval, pharmacokinetics, therapeutic dose, supra-therapeutic dose
476367|NCT00795132|cancer
476368|NCT00795132|Hematologic Malignancies
476369|NCT00795132|Hematopoietic Cell Transplantation
476370|NCT00795119|Near Infrared Spectroscopy
476371|NCT00795119|Diagnosis
476372|NCT00795119|Children
476373|NCT00795106|Capsaicin
476374|NCT00795106|hydrogel
476375|NCT00795106|myofascial pain syndrome
476376|NCT00795106|neck pain
476377|NCT00795093|GERD
476378|NCT00795093|PPI
476379|NCT00795093|partial responders
476380|NCT00795080|CVJ malformations
476381|NCT00795054|Stem cell transplantation
476382|NCT00795054|Financial impact
476383|NCT00795041|vitrification
476384|NCT00795041|ovarian stimulation
476385|NCT00795041|reproductive medicine
476386|NCT00795028|older women
476387|NCT00795028|hip fracture
476388|NCT00795028|exercise intervention
476389|NCT00795015|postoperative blood glucose control
476390|NCT00795015|IV insulin infusion
476391|NCT00794989|breast cancer
476392|NCT00794989|atypical ductal breast hyperplasia
476393|NCT00794989|lobular breast carcinoma in situ
476394|NCT00794989|ductal breast carcinoma in situ
476395|NCT00794989|breast cancer prevention
476396|NCT00794989|high risk breast cancer
476397|NCT00794950|Bladder Cancer
476524|NCT00794391|IDU
476398|NCT00794950|High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
476399|NCT00794924|probiotics
476400|NCT00794924|elderly
476401|NCT00794924|motility
476402|NCT00794924|diarrhea
476403|NCT00794911|Liver Transplantation
476404|NCT00794911|Quality of Life
476405|NCT00794911|Chronic HCV
476406|NCT00794911|Hepatitis C Virus
476407|NCT00794911|Cirrhosis
476408|NCT00794911|Liver disease
476409|NCT00794885|hypertension
476410|NCT00794885|stroke
476411|NCT00794885|cardiovascular events
476412|NCT00794885|enalapril
476413|NCT00794885|folic acid
476414|NCT00794885|randomized controlled trial
476415|NCT00794885|MTHFR C677T genotype
476416|NCT00794872|Cardiovascular autonomic neuropathy
476417|NCT00794872|Chemoreflex sensitivity
476418|NCT00794872|Chronic kidney disease
476419|NCT00794872|Sudden cardiac arrest
476420|NCT00794820|Chronic Lymphocytic Leukemia
476421|NCT00794820|CLL
476422|NCT00794820|Leukemia
476423|NCT00794820|Fludarabine phosphate
476424|NCT00794820|Cyclophosphamide
476425|NCT00794820|Rituximab
476426|NCT00794820|FCR
476427|NCT00794820|Cytoxan®
476428|NCT00794820|Neosar®
476429|NCT00794820|Rituxan®
476430|NCT00794807|Alefacept
476431|NCT00794807|Skin Diseases
476432|NCT00794807|Psoriasis
476433|NCT00794807|Skin Diseases, Papulosquamos
476434|NCT00794807|Therapeutic Uses
476435|NCT00794807|Dermatologic Agents
476436|NCT00794781|Cancer
476437|NCT00794781|solid tumors
476438|NCT00794755|Vitamin K
476439|NCT00794755|Vitamin K1 (Phytonadione)
476440|NCT00794755|Unstable INR
476441|NCT00794755|VTE or Thrombosis
476442|NCT00794755|Warfarin
476443|NCT00794755|Anticoagulation Control
476444|NCT00794755|Patients on warfarin with unstable anticoagulation control
476445|NCT00794742|Burn
476446|NCT00794742|Antimicrobial
476447|NCT00794742|Bacteria
476448|NCT00794742|Resistance
476449|NCT00794742|Biofilm
476450|NCT00794742|Pathogen
476451|NCT00794729|Healthy Volunteers
476452|NCT00794729|Consents
476453|NCT00794703|Antifungal
476454|NCT00794703|micafungin
476455|NCT00794703|itraconazole
476456|NCT00794690|cimicifuga racemosa
476457|NCT00794690|liver blood flow and functions
476458|NCT00794677|Hypercholesterolemia
476459|NCT00794677|Oxysterol
476460|NCT00794677|Ezetimibe
476461|NCT00794677|Zetia
476462|NCT00794651|osteoarthritis
476463|NCT00794651|testing kit
476464|NCT00794651|knee
476465|NCT00794638|Non-Hodgkin's Lymphoma
476466|NCT00794638|Diffuse Large B-Cell Lymphoma
476467|NCT00794638|Mantle cell Lymphoma
476468|NCT00794638|Transformed lymphoma, transformed to diffuse large B-cell lymphoma
476469|NCT00794638|Follicular Lymphoma
476470|NCT00794625|Attention-Deficit/Hyperactivity Disorder
476471|NCT00794625|Aggressive Behavior
476472|NCT00794625|Oppositional Defiant Disorder
476473|NCT00794625|Conduct Disorder
476474|NCT00794586|cystic fibrosis
476475|NCT00794586|CF
476476|NCT00794586|inhaled antibiotic
476477|NCT00794586|antipseudomonal antibiotic
476478|NCT00794586|tobramycin
476479|NCT00794586|fosfomycin
476480|NCT00794586|lung infection
476481|NCT00794586|pseudomonal infection
476482|NCT00794586|FTI
476483|NCT00794573|Smoking Cessation
476484|NCT00794573|Cardiac Population
476485|NCT00794573|Acute Coronary Syndrome
476486|NCT00794573|Varenicline
476487|NCT00794573|Champix
476488|NCT00794560|Heparin, Low-Molecular-Weight
476489|NCT00794560|compliance
476490|NCT00794560|drug safety
476491|NCT00794560|self-administration
476492|NCT00794560|ambulatory Care
476493|NCT00794560|Pharmaceutical Services
476494|NCT00794547|lung cancer; nsclc
476495|NCT00794508|Severe Combined Immune Deficiency
476496|NCT00794508|Adenosine Deaminase Deficiency
476497|NCT00794508|Gene Therapy
476498|NCT00794508|Hematopoietic Stem Cells
476499|NCT00794508|Retroviral Vector
476500|NCT00794508|ADA-deficient SCID
476501|NCT00794469|Resting metabolic rate
476502|NCT00794456|Passiflora
476503|NCT00794456|Crataegus
476504|NCT00794456|Herbal
476505|NCT00794456|Valeriana
476506|NCT00794456|anxiety
476507|NCT00794443|ONO-5920
476508|NCT00794443|YM529
476509|NCT00794443|Bone mineral density
476510|NCT00794443|Minodronic acid
476511|NCT00794430|Safety
476512|NCT00794430|Tolerability
476513|NCT00794430|Efficacy
476514|NCT00794430|Patients
476515|NCT00794430|Diabetic peripheral neuropathic pain.
476516|NCT00794417|advanced cancer
476517|NCT00794417|lung cancer
476518|NCT00794417|NSCLC
476519|NCT00794417|Non-small Cell Lung Cancer
476520|NCT00794417|aflibercept
476521|NCT00794417|chemotherapy
476522|NCT00794391|Vulnerable Populations
476523|NCT00794391|Injecting drug users
476525|NCT00794391|Risky injecting practices
476526|NCT00794391|Psychotherapy, brief
476527|NCT00794391|Motivational interviewing
476528|NCT00794391|Educational activities
476529|NCT00794391|Clinical trial
476530|NCT00794391|Risk behavior
476531|NCT00794391|risk reduction behavior
476532|NCT00794365|Smoking; smoking cessation; Philippines; Varenicline
476533|NCT00794352|Inflammation
476534|NCT00794352|Multiple Sclerosis
476535|NCT00794352|Neuroimmunology
476536|NCT00794352|Immune Disorder
476537|NCT00794352|Neuroimaging
476538|NCT00794352|Central Nervous System Disease
476539|NCT00794352|Healthy Volunteers
476540|NCT00794352|HV
476541|NCT00794339|cervical squamous cell carcinoma
476542|NCT00794339|stage IIB cervical cancer
476543|NCT00794339|stage III cervical cancer
476544|NCT00794339|stage IV cervical cancer
476545|NCT00794339|stage IVA cervical cancer
476546|NCT00794339|stage IB cervical cancer
476547|NCT00794339|stage IIA cervical cancer
476548|NCT00794326|Chronic Kidney Failure
476549|NCT00794326|Peritoneal Dialysis
476550|NCT00794326|Low sodium solution
476551|NCT00794326|Hypertension
476552|NCT00794326|Total Body Water
476553|NCT00794313|Parkinsons disease
476554|NCT00794313|dyskinesia
476555|NCT00794313|amantadine
476556|NCT00794313|efficacy
476557|NCT00794300|reproducibility
476558|NCT00794300|contrast agent
476559|NCT00794300|magnetic resonance imaging
476560|NCT00794300|infarct size
476561|NCT00794300|myocardial salvage index
476562|NCT00794300|myocardial salvage assessment
476563|NCT00794274|Sarcodiosis
476564|NCT00794274|tumor necrosis factor
476565|NCT00794261|Myeloma
476566|NCT00794261|lymphoma
476567|NCT00794261|high-dose chemotherapy
476568|NCT00794261|PSC infusion, autologous
476569|NCT00794261|neutropenia
476570|NCT00794261|thrombocytopenia
476571|NCT00794261|hospital stay
476572|NCT00794261|infection
476573|NCT00794261|Autologous PSC transplantation for patients with lymphoma or myeloma treated with high-dose chemotherapy
476574|NCT00794222|Cellular phones
476575|NCT00794222|mental health
476576|NCT00794222|Early intervention
476577|NCT00794222|prevention
476578|NCT00794222|momentary sampling
476579|NCT00794222|Adolescent
476580|NCT00794209|AeroLEF, fentanyl, liposome encapsulated, opioid
476581|NCT00794196|Medication adherence
476582|NCT00794196|Antidepressive agents
476583|NCT00794196|Primary care
476584|NCT00794196|Pharmaceutical care
476585|NCT00794183|heart failure
476586|NCT00794183|CRT
476587|NCT00794183|CHF
476588|NCT00794170|Treatment Compliance
476589|NCT00794157|COPD
476590|NCT00794157|chronic obstructive pulmonary disease
476591|NCT00794157|indacaterol
476592|NCT00794157|long acting β2-agonist
476593|NCT00794144|Allergic Rhinitis
476594|NCT00794144|Pediatric
476595|NCT00794144|PATANASE
476596|NCT00794131|cancer
476597|NCT00794131|vaccinia virus
476598|NCT00794131|vaccinia
476599|NCT00794131|oncolytic
476600|NCT00794131|oncolytic virus
476601|NCT00794131|biological
476602|NCT00794131|imaging
476603|NCT00794105|Gas
476604|NCT00794105|Middle ear
476605|NCT00794079|Healthy volunteers
476606|NCT00794079|young adults
476607|NCT00794079|Aged
476608|NCT00794066|PAD
476609|NCT00794066|Stroke
476610|NCT00794066|ICH
476611|NCT00794066|prevalence
476612|NCT00794053|Sentinel lymph node
476613|NCT00794053|thyroid cancer
476614|NCT00794053|neck dissection
476615|NCT00794040|Irritability
476616|NCT00794040|Attention Deficit Hyperactivity Disorder
476617|NCT00794040|Explosive
476618|NCT00794040|Tantrums
476619|NCT00794040|Bipolar Mood Disorder
476620|NCT00794040|Mood Disorder
476621|NCT00794040|Childhood Mood Disorder
476622|NCT00794040|ADHD
476623|NCT00794027|heart failure
476624|NCT00794027|yoga
476625|NCT00794027|quality of life
476626|NCT00794014|Angioplasty, Transluminal, Percutaneous Coronary
476627|NCT00794001|myocardial infarction
476628|NCT00794001|angioplasty
476629|NCT00794001|data feedback
476630|NCT00794001|continuous quality improvement
476631|NCT00794001|STEMI
476632|NCT00794001|Feedback
476633|NCT00794001|Quality Assurance, Health Care
476634|NCT00794001|Emergency service hospital
476635|NCT00793988|vibration
476636|NCT00793988|local anaesthesia
476637|NCT00793988|ptosis surgery
476638|NCT00793988|blepharoplasty
476639|NCT00793988|Upper eyelid surgery
476640|NCT00793988|dermatochalasis +/- blepharoptosis
476641|NCT00793975|Tumors
476642|NCT00793975|Antibodies, Monoclonal
476643|NCT00793962|breast cancer
476644|NCT00793962|mastectomy
476645|NCT00793962|radiotherapy
476646|NCT00793962|fractionation
476647|NCT00793936|Right Double Lumen Tube
476648|NCT00793923|Exudative Age Related Macular Degeneration
476649|NCT00793910|Gabapentin
476650|NCT00793910|PRK
476651|NCT00793910|pain
476652|NCT00793897|Subjects with Advanced or Metastatic Solid Tumors or Neoplasms
476653|NCT00793884|Diabetes
476654|NCT00793884|Latino population
476655|NCT00793871|sunitinib
476656|NCT00793871|Phase IV
476657|NCT00793871|gastrointestinal stomal tumor
476658|NCT00793871|imatinib resistant or intolerant
476659|NCT00793871|Chinese
476660|NCT00793845|tandem high-dose chemotherapy for high-risk neuroblastoma
476661|NCT00793832|weight loss
476662|NCT00793819|nocturia
476663|NCT00793819|BPH
476664|NCT00793819|benign prostate hyperplasia
476665|NCT00793819|nocturia in men with benign prostate hyperplasia
476666|NCT00793806|chronic kidney disease
476667|NCT00793780|obesity
476668|NCT00793780|schizophrenia
476669|NCT00793780|schizoaffective disorder
476670|NCT00793780|weight loss
476671|NCT00793767|Erythropoietin
476672|NCT00793767|human muscle tissue
476673|NCT00793767|insulin sensitivity
476674|NCT00793767|substrate metabolism
476675|NCT00793741|Type 1 diabetes
476676|NCT00793741|Hypoglycemia unawareness
476677|NCT00793741|Islet transplant
476678|NCT00793728|Morbid obesity
476679|NCT00793728|High risk
476680|NCT00793715|acute pancreatitis
476681|NCT00793715|abdominal compartment syndrome
476682|NCT00793715|decompressive laparotomy
476683|NCT00793715|percutaneous abdominal puncture
476684|NCT00793715|Mortality of patients treated in both arms
476685|NCT00793702|tuberculosis
476686|NCT00793702|diagnosis
476687|NCT00793702|ESAT-6
476688|NCT00793702|CFP-10
476689|NCT00793702|skin test
476690|NCT00793702|Skin test for the diagnosis of tuberculosis infection
476691|NCT00793689|parathyroid
476692|NCT00793689|thyroidectomy
476693|NCT00793689|hypoparathyroidism
476694|NCT00793689|Parathyroid function after total thyroidectomy
476695|NCT00793676|GPCR expression
476696|NCT00793676|transcriptomic
476697|NCT00793676|white blood cells
476698|NCT00793676|diagnostic
476699|NCT00793676|Control
476700|NCT00793663|Xenon
476701|NCT00793663|Sevoflurane
476702|NCT00793663|Postoperative Nausea and vomiting
476703|NCT00793663|Depth of anaesthesia
476704|NCT00793650|Cancer
476705|NCT00793650|Multiple Myeloma
476706|NCT00793650|Peripheral Blood Stem Cell Transplant
476707|NCT00793637|Angular stable locking system
476708|NCT00793637|Handling test
476709|NCT00793637|Complications
476710|NCT00793611|Overactive Bladder
476711|NCT00793611|Hypnotherapy
476712|NCT00793598|CMX001
476713|NCT00793598|Kidney transplant
476714|NCT00793598|HSCT transplant
476715|NCT00793598|BK Virus
476716|NCT00793598|Post kidney transplant patients with BK virus viruria > 10^4
476717|NCT00793598|Post HSCT transplant patients with BK virus viruria > 10^4
476718|NCT00793585|IgA nephropathy
476719|NCT00793559|septic shock refractory to catecholamines
476720|NCT00793546|Bosutinib
476721|NCT00793546|Exemestane
476722|NCT00793546|postmenopausal
476723|NCT00793546|breast cancer
476724|NCT00793520|fibromyalgia
476725|NCT00793520|milnacipran
476726|NCT00793520|Forest Laboratories
476727|NCT00793507|childhood caries
476728|NCT00793494|Irritable bowel syndrome
476729|NCT00793494|Children
476730|NCT00793494|Pediatrics
476731|NCT00793494|Probiotics
476732|NCT00793481|Metabolic Syndrome
476733|NCT00793468|nicotine dependence
476734|NCT00793468|smoking
476735|NCT00793468|pharmacological treatment
476736|NCT00793468|relapse prevention
476737|NCT00793455|education
476738|NCT00793455|preventive service
476739|NCT00793455|screening
476740|NCT00793442|sepsis
476741|NCT00793442|severe sepsis
476742|NCT00793442|septic shock
476743|NCT00793442|endothelium
476744|NCT00793442|microcirculation
476745|NCT00793442|biomarkers
476746|NCT00793429|electrocardiographic safety
476747|NCT00793429|pharmacokinetics
476748|NCT00793416|Normal Pressure Hydrocephalus
476749|NCT00793416|Valve Adjustment
476750|NCT00793416|Blocked Shunt in NPH patients
476751|NCT00793416|Diagnosis of blockage
476752|NCT00793403|Observational cohort
476753|NCT00793403|prospectives
476754|NCT00793403|multicentre
476755|NCT00793403|the Italian study RA patient CLARA and PRO-CLARA
476756|NCT00793390|Case-Control
476757|NCT00793390|Inflammatory Breast Cancer
476758|NCT00793390|North Africa
476759|NCT00793390|IBC
476760|NCT00793364|Cholesterol, stanol-ester, mediterranean diet, cardiac risk
476761|NCT00793351|reduced intensity stem cell transplantation for neuroblastoma
476762|NCT00793351|relapsed neuroblastoma after high-dose chemotherapy and autologous stem cell rescue
476763|NCT00793338|Heart failure
476764|NCT00793338|Sildenafil
476765|NCT00793338|Cardiopulmonary exercise test
476766|NCT00793338|quality of life
476767|NCT00793338|6 minute walk test
476768|NCT00793286|inguinal hernia
476769|NCT00793286|laparoscopy
476770|NCT00793286|mesh
476771|NCT00793234|TKR
476772|NCT00793234|VTE
476773|NCT00793234|DVT
476774|NCT00793221|Coronary stent.
476775|NCT00793221|Restenosis.
476776|NCT00793221|Coronary artery disease.
476777|NCT00793221|Chronic total occlusion.
476778|NCT00793208|Lung cancer
476779|NCT00793208|non small cell
476780|NCT00793208|vaccine
476781|NCT00793208|carcinoma
476782|NCT00793208|immunization
476783|NCT00793208|autologous Tumor
476784|NCT00793208|vaccination
476785|NCT00793195|Neonates
476786|NCT00793195|Short Bowel Syndrome
476787|NCT00793195|Intestinal Failure
476788|NCT00793195|Liver Failure
476789|NCT00793195|Parenteral Nutrition
476790|NCT00793195|Intralipid
476791|NCT00793195|SMOF
476792|NCT00793182|Renal
476793|NCT00793182|Kidney
476794|NCT00793182|Contrast Induced Nephropathy
476795|NCT00793169|squamous cell carcinoma of the head or neck
476796|NCT00793156|uremic pruritus
476797|NCT00793143|morbid obesity
476798|NCT00793143|laparoscopic sleeve gastrectomy
476799|NCT00793143|LSG
476800|NCT00793143|laparoscopic gastric bypass
476801|NCT00793143|LGB
476802|NCT00793143|comorbidities
476803|NCT00793143|diabetes
476804|NCT00793143|excessive weight loss
476805|NCT00793143|weight loss
476806|NCT00793130|Ulcerative
476807|NCT00793130|Colitis
476808|NCT00793130|Coltect
476809|NCT00793130|Curcumin
476810|NCT00793130|Green tea
476811|NCT00793130|Selenium
476812|NCT00793130|inflammation
476813|NCT00793130|bowel
476814|NCT00793117|chronic sinusitis
476815|NCT00793117|FESS
476816|NCT00793117|packing
476817|NCT00793104|allograft
476818|NCT00793104|knee injury
476819|NCT00793104|cartilage injury
476820|NCT00793104|Osteochondral defects in the articular femoral cartilage
476821|NCT00793078|sepsis
476822|NCT00793078|arterial blood pressure
476823|NCT00793078|complexity
476824|NCT00793078|variability
476825|NCT00793065|electronic health records
476826|NCT00793065|health information technology
476827|NCT00793065|physician incentives
476828|NCT00793065|quality of health care
476829|NCT00793052|trismus
476830|NCT00793052|Edema
476831|NCT00793052|pain
476832|NCT00793013|Acute Lung Injury
476833|NCT00793013|Adult Respiratory Distress Syndrome
476834|NCT00793013|Airway Pressure Release Ventilation
476835|NCT00793013|Acute Kidney Injury
476836|NCT00793013|Pressure Trial
476837|NCT00793000|Safety tolerability pharmacokinetics PK first in human FIH
476838|NCT00792974|Cognitive behavioral education
476839|NCT00792974|COPD (Chronic Obstructive Pulmonary Disease), GOLD II-IV
476840|NCT00792961|Prostate cancer
476841|NCT00792961|Robotic surgery
476842|NCT00792961|Endomicroscopy
476843|NCT00792922|Trachoma
476844|NCT00792922|Azithromycin
476845|NCT00792922|Mass treatment
476846|NCT00792909|Pneumococcal vaccine
476847|NCT00792909|Pneumococcal disease
476848|NCT00792909|Safety
476849|NCT00792909|Immunogenicity
476850|NCT00792883|PICU
476851|NCT00792883|BIA
476852|NCT00792883|Phase angle
476853|NCT00792883|RQ
476854|NCT00792883|EEM
476855|NCT00792883|Compliance
476856|NCT00792883|Resistance
476857|NCT00792883|Curves
476858|NCT00792883|Polymorphisms
476859|NCT00792883|NF-kappa B
476860|NCT00792883|Scores
476861|NCT00792883|PIM 2
476862|NCT00792883|PRISM I
476863|NCT00792870|Obesity
476864|NCT00792870|Weight loss
476865|NCT00792870|Internet
476866|NCT00792857|Parathyroid Diseases
476867|NCT00792857|Renal Insufficiency
476868|NCT00792857|Kidney Failure, Chronic
476869|NCT00792857|Hyperparathyroidism, Secondary
476870|NCT00792857|Vitamin D
476871|NCT00792857|Hyperparathyroidism
476872|NCT00792857|Renal Insufficiency, Chronic
476873|NCT00792857|Kidney Diseases
476874|NCT00792857|Kidney Failure
476875|NCT00792818|Osteoarthritis, Knee, Curcumin, Multicenter, RCT
476876|NCT00792805|COPD
476877|NCT00792805|indacaterol
476878|NCT00792805|long-acting β2-agonist
476879|NCT00792805|adults
476880|NCT00792792|tissue transfer
476881|NCT00792779|Morbid obesity
476882|NCT00792779|General anaesthesia
476883|NCT00792779|Propofol
476884|NCT00792779|Sevoflurane
476885|NCT00792766|Tuberous Sclerosis Complex (TSC)
476886|NCT00792766|Angiolipoma
476887|NCT00792766|mTOR
476888|NCT00792766|Everolimus
476889|NCT00792753|Coronary Artery Disease
476890|NCT00792727|Pain
476891|NCT00792727|Knee
476892|NCT00792727|Arthritis
476893|NCT00792727|Knee pain
476894|NCT00792701|stage I non-small cell lung cancer
476895|NCT00792688|burn wounds
476896|NCT00792688|wound healing
476897|NCT00792675|exercise
476898|NCT00792675|disease activity
476899|NCT00792675|inflammation
476900|NCT00792675|resistance training
476901|NCT00792675|rehabilitation
476902|NCT00792662|Diabetes Mellitus
476903|NCT00792662|Alzheimer's Disease
476904|NCT00792662|Apathy
476905|NCT00792662|Methylphenidate
476906|NCT00792662|Dementia
476907|NCT00792636|sumatriptan and naproxen sodium
476908|NCT00792636|migraine with or without aura
476909|NCT00792636|naproxen sodium
476910|NCT00792636|sumatriptan
476911|NCT00792636|blood pressure
476912|NCT00792636|migraine headaches
476913|NCT00792623|Varicella
476914|NCT00792623|VarilrixTM
476915|NCT00792610|youth
476916|NCT00792610|hepatitis B
476917|NCT00792610|vaccination
476918|NCT00792610|booster
476919|NCT00792610|immunity response
476920|NCT00792584|etravirine
476921|NCT00792584|efavirenz
476922|NCT00792584|anxiety
476923|NCT00792584|depression
476924|NCT00792584|sleep quality
476925|NCT00792584|HIV
476926|NCT00792584|NNRTI
476927|NCT00792584|Tritherapy
476928|NCT00792584|compliance
476929|NCT00792584|stocrin
476930|NCT00792584|To replace efavirenz in long-term users with etravirine
476931|NCT00792584|To investigate effect of such replacement on patient preference, sleep quality, daytime sleepiness, and anxiety
476932|NCT00792519|alcohol use
476933|NCT00792519|HIV
476934|NCT00792519|cognitive behavioral treatment
476935|NCT00792519|Kenya
476936|NCT00792519|hazardous/binge drinking
476937|NCT00792519|alcohol abuse/dependence
476938|NCT00792493|Healthy volunteer study
476939|NCT00792480|Obesity
476940|NCT00792480|Pregnancy
476941|NCT00792480|Exercise
476942|NCT00792480|Nutrition
476943|NCT00792480|obesity in pregnancy
476944|NCT00792454|Chronic kidney disease
476945|NCT00792454|End stage renal disease
476946|NCT00792454|Exercise
476947|NCT00792454|Cardiovascular disease
476948|NCT00792441|Specific inspiratory muscle training(SIMT)
476949|NCT00792441|Loaded deep breathing
476950|NCT00792441|Weaning
476951|NCT00792441|Mechanical ventilation
476952|NCT00792441|Respiratory muscle
476953|NCT00792428|Stroke
476954|NCT00792428|Ischemia
476955|NCT00792428|Infarction
476956|NCT00792428|Cerebrovascular Disorder
476957|NCT00792428|Central Nervous System Diseases
476958|NCT00792428|Brain Infarction
476959|NCT00792428|Brain Ischemia
476960|NCT00792428|Rehabilitation
476961|NCT00792428|Recovery
476962|NCT00792428|Neurorehabilitation
476963|NCT00792428|Plasticity
476964|NCT00792415|Abstinence syndrome symptoms
476965|NCT00792415|Withdrawal symptoms
476966|NCT00792415|Opioid dependence
476967|NCT00792402|chronic heart failure
476968|NCT00792402|Computerized clinical guidelines
476969|NCT00792402|Primary care
476970|NCT00792389|Gallstones
476971|NCT00792389|Gallbladder
476972|NCT00792389|Cholecystectomy
476973|NCT00792389|Gallstone disease
476974|NCT00792376|NSAID
476975|NCT00792376|tendon
476976|NCT00792376|pain
476977|NCT00792376|stiffness
476978|NCT00792376|Achilles
476979|NCT00792363|KRAS
476980|NCT00792350|Carcinoma, Hepatocellular
476981|NCT00792350|Sorafenib
476982|NCT00792311|Tsui test
476983|NCT00792311|Epidural Analgesia
476984|NCT00792285|Colon cancer
476985|NCT00792285|Prevention
476986|NCT00792285|Screening
476987|NCT00792285|Telephone
476988|NCT00792272|aspirin resistance
476989|NCT00792272|aspirin resistance in hemodialysis patients
476990|NCT00792246|pharmacokinetics
476991|NCT00792246|pediatric
476992|NCT00792246|bioavailability
476993|NCT00792233|Poly JIA
476994|NCT00792233|TNF
476995|NCT00792233|Remission
476996|NCT00792220|stroke
476997|NCT00792220|mobile stroke unit
476998|NCT00792220|thrombolysis
476999|NCT00792220|stroke management
477000|NCT00792220|computerized tomography
477001|NCT00792194|Cystic fibrosis
477002|NCT00792194|Exercise training
477003|NCT00792194|Home training
477004|NCT00792194|Aerobic capacity
477005|NCT00792181|The focus is the pain reduce in the first 15 minutes for patients suffering an acute myocardial infarction, treated by caregivers in Ambulance service.
477006|NCT00792155|PKD
477007|NCT00792142|neurotoxicity
477008|NCT00792142|stage I multiple myeloma
477009|NCT00792142|stage II multiple myeloma
477010|NCT00792142|stage III multiple myeloma
477011|NCT00792129|MIS
477012|NCT00792129|Minimally invasive
477013|NCT00792129|Atavi
477014|NCT00792129|Flex Posure
477015|NCT00792129|retractor
477016|NCT00792129|Patients with chronic low back and/or leg pain who are candidates for elective lumbar interbody fusion through a posterior unilateral approach,
477017|NCT00792129|for inclusion in the study.
477018|NCT00792129|If the patient meets all of the eligibility criteria,
477139|NCT00791622|Cardiovascular
477019|NCT00792129|they will be enrolled into the study and have either the MiLIF or open procedure depending on the surgeon they present to
477020|NCT00792129|(i.e., what group their surgeon agreed to participate in.)
477021|NCT00792090|allergy
477022|NCT00792090|cow's milk
477023|NCT00792090|sensibilisation
477024|NCT00792090|fermented milk
477025|NCT00792090|infant formula
477026|NCT00792077|Leukemia
477027|NCT00792077|Lenalidomide
477028|NCT00792077|Actigraph
477029|NCT00792077|Sleep Test Study
477030|NCT00792077|Chronic Lymphocytic Leukemia
477031|NCT00792077|CC-5013
477032|NCT00792077|Revlimid
477033|NCT00792064|quality of life
477034|NCT00792064|adverse effects
477035|NCT00792051|influenza
477036|NCT00792051|vaccination
477037|NCT00792051|children
477038|NCT00792051|Influenza-like illness
477039|NCT00792038|Psychological tests
477040|NCT00792038|Magnetic Resonance Imaging
477041|NCT00792038|Cognitive therapy
477042|NCT00792025|metastatic transitional cell cancer of the renal pelvis and ureter
477043|NCT00792025|recurrent transitional cell cancer of the renal pelvis and ureter
477044|NCT00792025|regional transitional cell cancer of the renal pelvis and ureter
477045|NCT00792025|stage III bladder cancer
477046|NCT00792025|stage IV bladder cancer
477047|NCT00792025|transitional cell carcinoma of the bladder
477048|NCT00792025|recurrent bladder cancer
477049|NCT00792012|Glioblastoma Multiforme
477050|NCT00791999|Rheumatoid Arthritis
477051|NCT00791999|Certolizumab Pegol
477052|NCT00791999|Cimzia
477053|NCT00791986|Breathing exercise
477054|NCT00791986|blood pressure
477055|NCT00791986|hypertension
477056|NCT00791960|Cesarean Section
477057|NCT00791960|Dimenhydrinate
477058|NCT00791960|Gravol
477059|NCT00791960|Antiemetics
477060|NCT00791921|Rheumatoid Arthritis
477061|NCT00791921|Certolizumab Pegol
477062|NCT00791921|Cimzia
477063|NCT00791869|bupropion
477064|NCT00791869|smoking
477065|NCT00791869|pharmacokinetics
477066|NCT00791869|Pharmacokinetics of bupropion
477067|NCT00791843|CHF
477068|NCT00791830|Residual renal function
477069|NCT00791830|Haemodialysis
477070|NCT00791830|Applanation tonometry
477071|NCT00791830|Cardiac output
477072|NCT00791830|Quality of life
477073|NCT00791830|Angiotensin II Type 1 Receptor Blockers
477074|NCT00791817|pharmacokinetics study
477075|NCT00791804|Pain
477076|NCT00791804|Post Op pain
477077|NCT00791804|Fentanyl
477078|NCT00791804|Pain Control
477079|NCT00791804|Surgery
477080|NCT00791791|Anesthesia General
477081|NCT00791791|Anesthetics Inhalation
477082|NCT00791791|Stress measurement
477083|NCT00791791|Surgical Stress
477084|NCT00791791|Diagnostic Techniques and Procedures
477085|NCT00791778|Peritoneal Neoplasma
477086|NCT00791765|Scalp
477087|NCT00791765|Psoriasis
477088|NCT00791765|Plaque Psoriasis
477089|NCT00791765|Skin Diseases
477090|NCT00791765|Moderate to severe plaque psoriasis
477091|NCT00791765|etanercept
477092|NCT00791752|Safety and Tolerability
477093|NCT00791739|fibromyalgia
477094|NCT00791739|trazodone
477095|NCT00791739|pregabalin
477096|NCT00791739|Fibromyalgia Impact Questionnaire (FIQ)
477097|NCT00791739|Pittsburgh Sleep Quality Inventory (PSQI)
477098|NCT00791739|Brief Pain Inventory (BPI)
477099|NCT00791726|microperimetry
477100|NCT00791726|macular edema
477101|NCT00791726|uveitis
477102|NCT00791726|Retinal sensitivity as measured with fundus related microperimetry
477103|NCT00791713|Paliperidone ER
477104|NCT00791713|Antipsychotic drugs
477105|NCT00791713|Selective serotonin reuptake inhibitors
477106|NCT00791713|Mood disorders
477107|NCT00791713|Schizophrenia
477108|NCT00791700|Open label pharmacokinetic safety and efficacy in HIV-1 infected pediatrics
477109|NCT00791687|Antioxidant enzymes
477110|NCT00791687|Glutathione
477111|NCT00791687|Oxidative stress
477112|NCT00791687|Prematurity
477113|NCT00791687|Respiratory distress
477114|NCT00791687|Non enzymatic antioxidant defense system
477115|NCT00791687|Enzymatic antioxidant defense system
477116|NCT00791674|Opiates
477117|NCT00791674|sleep apnea
477118|NCT00791674|ventilatory failure
477119|NCT00791648|aki
477120|NCT00791648|delirium
477121|NCT00791648|statin
477122|NCT00791648|short-term
477123|NCT00791648|cardiac
477124|NCT00791635|Cervical Cancer
477125|NCT00791635|Vaginal Cancer
477126|NCT00791635|Endometrial Cancer
477127|NCT00791635|Cervix
477128|NCT00791635|Endometrial
477129|NCT00791635|Pelvic Exenteration
477130|NCT00791635|Pelvic Exenteration Surgery
477131|NCT00791635|Questionnaire
477132|NCT00791635|Gynecologic Cancer
477133|NCT00791635|Vagina
477134|NCT00791635|Vulva
477135|NCT00791635|Gynecologic Malignancy
477136|NCT00791622|Paliperidone ER
477137|NCT00791622|Schizophernia
477138|NCT00791622|Mood Disorders, Antipsychotic drugs
477140|NCT00791622|Schizoaffective Disorder
477141|NCT00791609|cancer
477142|NCT00791596|Ergonomic intervention
477143|NCT00791596|Musculoskeletal disorders
477144|NCT00791596|Low back pain
477145|NCT00791596|Posture
477146|NCT00791596|Video display terminal
477147|NCT00791583|Emergency Medicine (EM)
477148|NCT00791583|Central Venous Catheter (CVC)
477149|NCT00791583|Maximal Barrier Precaution (MBP)
477150|NCT00791583|Precaution Technique during Central Venous Cathether Placement
477151|NCT00791544|monoclonal antibody, anti IGF1R
477152|NCT00791531|Methotrexate
477153|NCT00791531|Malaria
477154|NCT00791518|Chronic Obstructive Pulmonary Disease (COPD)
477155|NCT00791518|Spirometry
477156|NCT00791505|chronic obstructive pulmonary disease
477157|NCT00791505|pulmonary infection
477158|NCT00791505|antibiotic
477159|NCT00791492|FAP
477160|NCT00791492|Familial Amyloid Polyneuropathy
477161|NCT00791492|ATTR-PN
477162|NCT00791492|transthyretin
477163|NCT00791492|TTR
477164|NCT00791492|amyloid
477165|NCT00791492|polyneuropathy
477166|NCT00791492|familial
477167|NCT00791492|hereditary
477168|NCT00791492|amyloidosis
477169|NCT00791492|FoldRx
477170|NCT00791479|Diabetes, type 2 diabetes
477171|NCT00791466|Iodine deficiency
477172|NCT00791466|Pregnancy
477173|NCT00791466|Thyroid function
477174|NCT00791466|Infant development
477175|NCT00791466|Growth
477176|NCT00791453|Diabetic patients at the Clarksdale Diabetes
477177|NCT00791453|and Metabolism Clinic and must be between the
477178|NCT00791453|ages of 18 and 64 years of age.
477179|NCT00791440|Schizophrenia
477180|NCT00791440|Schizoaffective
477181|NCT00791440|Schizophreniform
477182|NCT00791440|Psychosis
477183|NCT00791440|Psychotic
477184|NCT00791440|Hallucinations
477185|NCT00791440|Delusions
477186|NCT00791440|Paranoia
477187|NCT00791440|Paranoid
477188|NCT00791440|Voices
477189|NCT00791440|CBT
477190|NCT00791440|Cognitive Behavior Therapy
477191|NCT00791440|Cognitive Therapy
477192|NCT00790582|ALS
477193|NCT00790582|Amyotrophic Lateral Sclerosis
477194|NCT00790582|Lou Gehrig's Disease
477195|NCT00790582|Lithium
477196|NCT00790582|Lithium Carbonate
477197|NCT00790569|bladder cancer
477198|NCT00790569|cervical cancer
477199|NCT00790569|esophageal cancer
477200|NCT00790569|gastric cancer
477201|NCT00790569|renal cell carcinoma
477202|NCT00790569|adult primary liver cancer
477203|NCT00790569|non-small cell lung cancer
477204|NCT00790569|small cell lung cancer
477205|NCT00790569|pancreatic cancer
477206|NCT00790569|hypopharyngeal cancer
477207|NCT00790569|laryngeal cancer
477208|NCT00790569|lip and oral cavity cancer
477209|NCT00790569|nasopharyngeal cancer
477210|NCT00790569|oropharyngeal cancer
477211|NCT00790569|paranasal sinus and nasal cavity cancer
477212|NCT00790569|adult acute myeloid leukemia
477213|NCT00790569|tobacco use disorder
477214|NCT00790543|Crohn's Disease
477215|NCT00790543|Inflammatory Bowel Disease
477216|NCT00790530|Diabetes
477217|NCT00790530|Information Technology
477218|NCT00790530|Health Plans
477219|NCT00790517|Weight loss
477220|NCT00790517|Diabetes prevention
477221|NCT00790517|Serious mental illness
477222|NCT00790517|Antipsychotic medications
477223|NCT00790517|Lifestyle intervention
477224|NCT00790517|Antipsychotic Agents
477225|NCT00790504|Pelvic floor
477226|NCT00790504|Transperineal ultrasound
477227|NCT00790504|Multiple pregnancy
477228|NCT00790504|Singleton pregnancy
477229|NCT00790504|Female pelvic floor
477230|NCT00790491|reduction in risk of heart disease and diabetes
477231|NCT00790478|Ulcerative Colitis
477232|NCT00790478|Melatonin
477233|NCT00790478|Gastrointestinal
477234|NCT00790478|Irritable Bowel syndrome
477235|NCT00790478|Sleep
477236|NCT00790478|Pilot Study
477237|NCT00791401|Schizophrenia
477238|NCT00791401|Mood disorders
477239|NCT00791401|Antipsychotic drugs
477240|NCT00791401|ER OROS Paliperidone
477241|NCT00791388|Pharmacokinetics
477242|NCT00791375|young adult
477243|NCT00791375|cancer
477244|NCT00791375|exercise
477245|NCT00791375|physical activity
477246|NCT00791362|accreditation
477247|NCT00791362|cardiovascular disease
477248|NCT00791362|primary care
477249|NCT00791349|Schizophrenia
477250|NCT00791349|Schizoaffective Disorder
477251|NCT00791349|Mood Disorders
477252|NCT00791349|Antipsychotic drugs
477253|NCT00791349|Cardiovascular
477254|NCT00791349|Immediate release (IR) Paliperidone
477255|NCT00791336|NSCLC
477256|NCT00791336|chemotherapy
477257|NCT00791336|radiation therapy
477258|NCT00791336|nelfinavir
477259|NCT00791336|NFV
477260|NCT00791310|Medical ICU
477261|NCT00791310|Severe sepsis
477262|NCT00791297|CDB-2914
477385|NCT00790868|Panic Disorder
477263|NCT00791297|Contraceptive Vaginal Rings
477264|NCT00791297|ovulation
477265|NCT00791297|endometrial changes
477266|NCT00791297|bleeding patterns
477267|NCT00791297|normal cycling women
477268|NCT00791297|Inhibition of ovulation, endometrial changes and bleeding patterns in normal cycling women
477269|NCT00791284|Schizophrenia
477270|NCT00791284|Mood disorders
477271|NCT00791284|Antipsychotic drugs
477272|NCT00791284|intermediate release (IR) Paliperidone
477273|NCT00791271|Melanoma
477274|NCT00791271|Malignant melanoma
477275|NCT00791271|Unresectable
477276|NCT00791271|Decitabine
477277|NCT00791271|PEG Interferon Alpha-2b
477278|NCT00791271|PEG Intron
477279|NCT00791271|5-Aza-Deoxycytidine
477280|NCT00791271|Dacogen
477281|NCT00791245|ISTO Technologies, Inc
477282|NCT00791245|cartilage repair
477283|NCT00791245|arthroscopy
477284|NCT00791245|361 HCT/P
477285|NCT00791245|human tissue
477286|NCT00791245|biologic
477287|NCT00791245|knee
477288|NCT00791232|Extended-release paliperidone
477289|NCT00791232|Schizophrenia, Mood disorders, Antipsychotic drugs
477290|NCT00791232|ER OROS paliperidone
477291|NCT00791219|Onychomycosis
477292|NCT00791206|exercise
477293|NCT00791206|ischemia
477294|NCT00791206|MRI
477295|NCT00791206|MRI spectroscopy
477296|NCT00791206|Ischemia preconditioning
477297|NCT00791193|Paliperidone ER
477298|NCT00791193|Antipsychotic drugs
477299|NCT00791193|Schizophrenia
477300|NCT00791193|Mood disorders
477301|NCT00791180|dynamic stabilization
477302|NCT00791180|Dynesys
477303|NCT00791180|fusion success
477304|NCT00791180|Immobilization of spinal segments as an adjunct to fusion in the treatment of the following:
477305|NCT00791180|acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine
477306|NCT00791180|degenerative spondylolisthesis with objective evidence of neurologic impairment
477307|NCT00791180|failed previous fusion (pseudarthrosis).
477308|NCT00791167|Mood Disorders, Antipsychotic drugs
477309|NCT00791167|Schizophrenia
477310|NCT00791167|Paliperidone ER
477311|NCT00791154|Extensive disease
477312|NCT00791154|Extrathoracic metasasis
477313|NCT00791154|Malignant pericardial effusion
477314|NCT00791154|Malignant pleural effusion
477315|NCT00791154|Contralateral hilar adenopathy
477316|NCT00791141|Head and Neck Cancer
477317|NCT00791141|Radiation therapy
477318|NCT00791141|Chemotherapy
477319|NCT00791141|Chemoradiotherapy
477320|NCT00791141|adjuvant cetuximab administration
477321|NCT00791128|Type 2 Diabetes
477322|NCT00791115|Prostate cancer
477323|NCT00791115|prostatectomy
477324|NCT00791115|radiotherapy
477325|NCT00791115|prostatectomy after radiotherapy
477326|NCT00791089|Radiofrequency Ablation
477327|NCT00791089|atrial fibrillation
477328|NCT00791076|Insulin pump therapy
477329|NCT00791076|Type 1 diabetic
477330|NCT00791076|Chronic pancreatitis
477331|NCT00791076|Pancreatic resection
477332|NCT00791076|Pancreatic polypeptide
477333|NCT00791063|cell death
477334|NCT00791063|Apoptosis
477335|NCT00791063|PET imaging
477336|NCT00791063|brain metastases
477337|NCT00791063|whole brain radiation therapy
477338|NCT00791050|Hypothermia/complications/etiology
477339|NCT00791050|coronary artery bypass/adverse effects
477340|NCT00791024|Analgesia Tests
477341|NCT00791024|Analog Pain Scale
477342|NCT00791024|Pain Measurement
477343|NCT00791011|Lymphoma
477344|NCT00791011|AMG 655
477345|NCT00791011|Trail receptor
477346|NCT00791011|Apoptosis
477347|NCT00791011|Vorinostat
477348|NCT00791011|Bortezomib
477349|NCT00791011|SAHA
477350|NCT00791011|Velcade
477351|NCT00790998|onchocerciasis
477352|NCT00790998|river blindness
477353|NCT00790998|onchocerca volvulus
477354|NCT00790998|moxidectin
477355|NCT00790998|ivermectin
477356|NCT00790972|MRSA
477357|NCT00790972|sinofresh
477358|NCT00790972|nasal spray
477359|NCT00790959|Intimate Partner Violence
477360|NCT00790959|HIV/AIDS
477361|NCT00790959|Gender
477362|NCT00790959|Prevention
477363|NCT00790959|Community mobilisation
477364|NCT00790959|Uganda
477365|NCT00790946|valsartan
477366|NCT00790946|Metabolic syndrome
477367|NCT00790920|Acute ischemic stroke
477368|NCT00790920|Angiography
477369|NCT00790920|Desmoteplase
477370|NCT00790920|Thrombolytic
477371|NCT00790907|Unstable angina
477372|NCT00790907|Non ST elevation myocardial infarction
477373|NCT00790907|PCI
477374|NCT00790907|unfractionated heparin
477375|NCT00790907|fondaparinux
477376|NCT00790907|acute coronary syndrome
477377|NCT00790881|malaria
477378|NCT00790881|HIV
477379|NCT00790881|AIDS
477380|NCT00790881|nevirapine
477381|NCT00790881|lumefantrine
477382|NCT00790881|artemether
477383|NCT00790881|drug interaction
477384|NCT00790881|pharmacokinetics
477386|NCT00790868|Anxiety
477387|NCT00790868|D-cycloserine
477388|NCT00790868|DCS
477389|NCT00790868|Cognitive Behavioral Therapy
477390|NCT00790868|CBT
477391|NCT00790855|Bendamustine
477392|NCT00790855|Acute Leukemia
477393|NCT00790855|Leukemia
477394|NCT00790855|Acute myeloid leukemia
477395|NCT00790855|Myelodysplastic Syndrome
477396|NCT00790855|Acute lymphoblastic leukemia
477397|NCT00790855|Chronic myeloid leukemia
477398|NCT00790855|MDS
477399|NCT00790855|ALL
477400|NCT00790855|AML
477401|NCT00790855|CML
477402|NCT00790842|Refractory Multiple Myeloma
477403|NCT00790842|Relapsed Multiple Myeloma
477404|NCT00790842|Multiple Myeloma with Renal Dysfunction
477405|NCT00790842|Stage I Multiple Myeloma
477406|NCT00790842|Stage II Multiple Myeloma
477407|NCT00790842|Stage III Multiple Myeloma
477408|NCT00790829|preemptive
477409|NCT00790829|Nicotine Patch
477410|NCT00790829|Open Abdominal Surgery
477411|NCT00790816|Cancer
477412|NCT00790816|lapatinib
477413|NCT00790816|Combination therapy
477414|NCT00790816|Chronic administration
477415|NCT00790803|uveitis
477416|NCT00790803|cystoid macular edema
477417|NCT00790777|Paliperidone ER
477418|NCT00790777|Schizophrenia, Mood disorders, Antipsychotic drugs
477419|NCT00790751|ED
477420|NCT00790751|Erectile Dysfunction
477421|NCT00790751|Dysfunction
477422|NCT00790751|Erectile
477423|NCT00790738|bipolar disorder
477424|NCT00790738|depression
477425|NCT00790738|treatment
477426|NCT00790738|randomized controlled trial
477427|NCT00790699|diabetes
477428|NCT00790699|Symlin
477429|NCT00790699|pramlintide acetate
477430|NCT00790699|insulin
477431|NCT00790699|multiple injection port
477432|NCT00790699|I-PORT
477433|NCT00790686|Ureteral obstruction
477434|NCT00790686|Urologic surgical procedure
477435|NCT00790686|Stents
477436|NCT00790686|Endoscopy
477437|NCT00790686|Urology
477438|NCT00790673|Hepatitis C
477439|NCT00790673|Viral hepatitis
477440|NCT00790660|Type 2 Diabetes Mellitus
477441|NCT00790660|ASP1941
477442|NCT00790647|primary systemic amyloidosis
477443|NCT00790595|Prostatectomy
477444|NCT00790465|achalasia
477445|NCT00790465|lower esophageal sphincter
477446|NCT00790465|nitric oxide
477447|NCT00790465|dark chocolate
477448|NCT00790465|flavanols
477449|NCT00790452|Brain
477450|NCT00790452|Hematologic Disorder
477451|NCT00790452|Venous Thromboembolism
477452|NCT00790452|Glioblastoma
477453|NCT00790452|Aspirin
477454|NCT00790452|Placebo
477455|NCT00790452|VTE
477456|NCT00790452|ASA
477457|NCT00790452|DVT
477458|NCT00790439|Insulin dependence
477459|NCT00790426|Advanced urothelial cancer
477460|NCT00790413|Radiotherapy
477461|NCT00790413|Immunotherapy
477462|NCT00790413|Hematopoietic Stem Cell Transplantation
477463|NCT00790400|Angiomyolipoma
477464|NCT00790400|AML
477465|NCT00790400|Tuberous Sclerosis Complex
477466|NCT00790400|TSC
477467|NCT00790400|mTOR
477468|NCT00790400|RAD001
477469|NCT00790400|Mammalian Target of Rapamycin
477470|NCT00790400|Everolimus
477471|NCT00790400|Afinitor
477472|NCT00790400|SEGA
477473|NCT00790400|Subependymal Giant Cell Astrocytoma
477474|NCT00790400|Seizures
477475|NCT00790400|Tuberous sclerosis complex (TSC)
477476|NCT00790400|Tuberous sclerosis
477477|NCT00790400|benign tumors of brain
477478|NCT00790400|kidney
477479|NCT00790400|heart
477480|NCT00790400|eyes
477481|NCT00790400|lungs
477482|NCT00790400|skinTSC1
477483|NCT00790400|TSC2
477484|NCT00790400|hamaratin
477485|NCT00790400|tuberin, tumor growth suppressors
477486|NCT00790400|gyri
477487|NCT00790400|tubers
477488|NCT00790400|Sporadic Lymphangioleiomyomatosis.
477489|NCT00790400|Lymphangioleiomyomatosis (LAM)
477490|NCT00790400|rare lung disease
477491|NCT00790387|enoxaparin
477492|NCT00790387|tirofiban
477493|NCT00790387|percutaneous intervention
477494|NCT00790387|platelet inhibition
477495|NCT00790387|CD40L
477496|NCT00790387|Mac-1
477497|NCT00790387|prothrombin fragment 1+2.
477498|NCT00790374|Pharmacodynamic profile and safety of BN83495
477499|NCT00790361|cervical spondylotic myelopathy
477500|NCT00790361|spinal cord compression
477501|NCT00790361|magnetic resonance spectroscopy
477502|NCT00790361|functional magnetic resonance imaging
477503|NCT00790361|brain plasticity
477504|NCT00790335|deep vein thrombosis
477505|NCT00790335|deep venous thrombosis
477506|NCT00790335|post thrombotic syndrome
477507|NCT00790335|blood clot
477508|NCT00790335|thrombolysis
477509|NCT00790335|tissue plasminogen activator
477510|NCT00790335|rt-PA
477511|NCT00790335|Activase
477512|NCT00790335|mechanical thrombectomy
477513|NCT00790335|pharmacomechanical
477514|NCT00790335|ATTRACT
477515|NCT00790322|Cancer
477516|NCT00790322|Radiation therapy
477517|NCT00790322|Radiotherapy
477518|NCT00790322|Oral Mucositis
477519|NCT00790322|SBG
477520|NCT00790309|Obesity
477521|NCT00790309|Diabetes
477522|NCT00790309|Bariatric surgery
477523|NCT00790296|cancer fatigue
477524|NCT00790283|Treatment of de novo lesions in native coronary arteries
477525|NCT00790270|Cervical strain
477526|NCT00790270|whiplash
477527|NCT00790270|ibuprofen
477528|NCT00790270|cyclobenzaprine
477529|NCT00790257|Diabetes
477530|NCT00790257|Islets transplantation
477531|NCT00790257|Encapsulation
477532|NCT00790244|Soft-tissue sarcomas
477533|NCT00790244|prognostic factors
477534|NCT00790244|adjuvant
477535|NCT00790244|chemotherapy
477536|NCT00790244|radiotherapy
477537|NCT00790244|metastases-free survival
477538|NCT00790244|toxicity
477539|NCT00790244|High malignancy grade
477540|NCT00790244|High-risk for metastases
477541|NCT00790244|Adult
477542|NCT00790231|urinary bladder
477543|NCT00790231|thoracic epidural analgesia
477544|NCT00790231|urodynamics
477545|NCT00790231|open kidney surgery with lumbotomy
477546|NCT00790218|Hepatocellular carcinoma
477547|NCT00790218|Hepatoma
477548|NCT00790218|HCC
477549|NCT00790192|Schizophrenia
477550|NCT00790192|SM-13496
477551|NCT00790192|Latuda
477552|NCT00790192|Lurasidone
477553|NCT00790179|Continuous lumbar plexus,Femoral,hydromorphone
477554|NCT00790153|Type 2 diabetes, hormonal response
477555|NCT00790140|Esophageal Cancer
477556|NCT00790140|esophagectomy
477557|NCT00790140|enteral feeding
477558|NCT00790140|body composition
477559|NCT00790140|immunology
477560|NCT00790114|Phase I
477561|NCT00790088|Diabetes Mellitus, Type 1
477562|NCT00790088|continuous glucose monitoring
477563|NCT00790088|sensor-augmented pump therapy
477564|NCT00790075|agitation
477565|NCT00790075|Episodes of agitation regardless of diagnosis
477566|NCT00790062|Uterine atony
477567|NCT00790062|Postpartum hemorrhage
477568|NCT00790062|clinical trial
477569|NCT00790062|Prophylactic oxytocin
477570|NCT00790036|Diffuse large B cell lymphoma
477571|NCT00790036|poor risk
477572|NCT00790036|R-IPI 3-5
477573|NCT00790036|adjuvant therapy
477574|NCT00790036|after R-CHOP or R-EPOCH
477575|NCT00790036|after R-CHOP
477576|NCT00790023|SAR
477577|NCT00790010|bevacizumab
477578|NCT00790010|ipilimumab
477579|NCT00790010|unresectable stage III melanoma
477580|NCT00790010|unresectable stage IV melanoma
477581|NCT00789997|COPD Exacerbation
477582|NCT00789997|Etanercept
477583|NCT00789997|TNF alpha
477584|NCT00789997|Randomized
477585|NCT00789984|Keratic precipitates
477586|NCT00789971|orbital floor triamcinolone
477587|NCT00789971|phacoemulsification
477588|NCT00789971|post op inflammation
477589|NCT00789971|cmo
477590|NCT00789958|cholangiocarcinoma of the extrahepatic bile duct
477591|NCT00789958|cholangiocarcinoma of the gallbladder
477592|NCT00789958|localized extrahepatic bile duct cancer
477593|NCT00789958|localized gallbladder cancer
477594|NCT00789958|unresectable extrahepatic bile duct cancer
477595|NCT00789958|unresectable gallbladder cancer
477596|NCT00789958|metastatic extrahepatic bile duct cancer
477597|NCT00789958|metastatic gallbladder cancer
477598|NCT00789945|type 1 diabetes
477599|NCT00789945|continuous glucose monitoring
477600|NCT00789945|Intensive Insulin therapy
477601|NCT00789919|Mild Preeclampsia
477602|NCT00789906|Computerized Neuropsychological Assessment
477603|NCT00789906|Development of Population Norms of the Computerized Neuropsychological Assessment
477604|NCT00789893|external beam pelvic radiation
477605|NCT00789893|brachytherapy
477606|NCT00789880|Vitamin D3
477607|NCT00789880|Atopic Dermatitis
477608|NCT00789880|Antimicrobial Peptide Expression
477609|NCT00789867|Single dose
477610|NCT00789867|Pilot
477611|NCT00789867|Safety
477612|NCT00789867|Gene expression
477613|NCT00789867|Tolerability
477614|NCT00789867|CFTR gene
477615|NCT00789867|Cystic fibrosis
477616|NCT00789867|Non-viral
477617|NCT00789854|Depression
477618|NCT00789854|MDD
477619|NCT00789854|TRD
477620|NCT00789841|Neuroendocrine tumor
477621|NCT00789841|Carcinoid syndrome
477622|NCT00789841|Motility
477623|NCT00789841|Transit time
477624|NCT00789828|SEGA
477625|NCT00789828|Tuberous Sclerosis
477626|NCT00789828|Subependymal Giant Cell Astrocytoma
477627|NCT00789828|mTOR
477628|NCT00789828|RAD001
477629|NCT00789828|Mamalian Target Rapamycin
477630|NCT00789828|Everolimus
477631|NCT00789828|TSC
477632|NCT00789815|flexible bronchoscopy
477633|NCT00789815|sedation
477634|NCT00789815|bispectral index
477635|NCT00789802|contraception
477636|NCT00789802|progestin contraception
477637|NCT00789802|intrauterine contraception
477638|NCT00789802|unscheduled bleeding
477639|NCT00789802|placebo
477640|NCT00789789|Cohort
477641|NCT00789789|HIV uninfected volunteers
477642|NCT00789789|HIV preventive vaccine
477643|NCT00789789|Long term safety
477644|NCT00789763|pancreatic cancer
477645|NCT00789763|Pancreatic cancer locally advanced
477646|NCT00789724|acute myocardial infarction
477647|NCT00789698|Schizophrenia
477648|NCT00789698|SM-13496
477649|NCT00789698|Latuda
477650|NCT00789698|Lurasidone
477651|NCT00789685|Open label
477652|NCT00789672|Amblyopia
477653|NCT00789672|Patching
477654|NCT00789672|Levodopa
477655|NCT00789659|Fracture fixation, internal
477656|NCT00789659|Obesity
477657|NCT00789659|Pelvis
477658|NCT00789659|Negative pressure wound therapy
477659|NCT00789659|Vacuum-assisted closure
477660|NCT00789646|corneal ulcer
477661|NCT00789646|painless
477662|NCT00789646|subconjunctival injection
477663|NCT00789646|antibiotics
477664|NCT00789646|antifungal
477665|NCT00789646|lidocaine
477666|NCT00789633|Pancreatic cancer
477667|NCT00789633|Advanced pancreatic cancer
477668|NCT00789633|Metastatic pancreatic cancer
477669|NCT00789633|Gemcitabine
477670|NCT00789633|Chemo-naive
477671|NCT00789620|intravenous lidocaine
477672|NCT00789620|laparoscopic urological surgery
477673|NCT00789620|hospital stay
477674|NCT00789620|pain
477675|NCT00789620|fatigue
477676|NCT00789620|length of stay
477677|NCT00789607|prostate cancer
477678|NCT00789607|individualized radiotherapy
477679|NCT00789607|fiducial markers
477680|NCT00789607|MRI
477681|NCT00789607|ultrasound
477682|NCT00789607|High-Risk Localized Prostate Cancer
477683|NCT00789594|Monitoring
477684|NCT00789594|Testing
477685|NCT00789594|Medications
477686|NCT00789594|Patients receiving medications and having laboratory tests
477687|NCT00789581|Breast Cancer
477688|NCT00789581|Adjuvant
477689|NCT00789581|Doxorubicin
477690|NCT00789581|Cyclophosphamide
477691|NCT00789581|Paclitaxel
477692|NCT00789581|Ixabepilone
477693|NCT00789581|TITAN
477694|NCT00789568|Hyperphenylalanemia due to Phenylketonuria
477695|NCT00789555|nasal allergy
477696|NCT00789555|nasal spray
477697|NCT00789555|seasonal allergy
477698|NCT00789555|perennial allergy
477699|NCT00789542|stroke
477700|NCT00789542|deep vein thrombosis
477701|NCT00789542|doppler
477702|NCT00789529|Contact lenses, wettability, Contact Lens Disinfectant Solutions, pre-lens tear film
477703|NCT00789516|Coagulation markers, thalassemia disease post SCT
477704|NCT00789503|dietary fortification
477705|NCT00789503|Vitamin D3
477706|NCT00789503|Osteomalacia
477707|NCT00789503|bread
477708|NCT00789503|bone mineral density
477709|NCT00789503|geriatrics
477710|NCT00789503|cholecalciferol
477711|NCT00789503|calcidiol
477712|NCT00789503|osteoporosis
477713|NCT00789503|dual-energy photon absorptiometry
477714|NCT00789503|bread fortification
477715|NCT00789490|pregnancy
477716|NCT00789490|relative bioavailability
477717|NCT00789490|iron
477718|NCT00789490|folic acid
477719|NCT00789490|ferric pyrophosphate
477720|NCT00789490|Study focus is to compare the relative bioavailability of SuppleFem Sprinkles to the current tradtional tablet Materna in pregnant women
477721|NCT00789464|Urinary Tract Infection
477722|NCT00789464|Probiotics
477723|NCT00789464|Dietary Supplements
477724|NCT00789464|Bacteriuria
477725|NCT00789451|Ischaemia reperfusion
477726|NCT00789451|t-PA
477727|NCT00789451|Fibrinolysis
477728|NCT00789451|Endothelial function
477729|NCT00789438|Analgesia
477730|NCT00789438|Sedation
477731|NCT00789438|Spinal
477732|NCT00789438|Stress
477733|NCT00789438|Surgical
477734|NCT00789438|Surgical Stress
477735|NCT00789438|Pain
477736|NCT00789425|osteoporosis
477737|NCT00789425|osteopenia
477738|NCT00789425|olive extract
477739|NCT00789425|oleuropein
477740|NCT00789412|Analgesia
477741|NCT00789412|Sedation
477742|NCT00789412|Critical Illness
477743|NCT00789412|Intensive Care
477744|NCT00789399|deep vein thrombosis
477745|NCT00789399|coronary artery bypass surgery
477746|NCT00789399|Venous thromboembolism
477747|NCT00789386|Capsaicin
477748|NCT00789386|Remifentanil
477749|NCT00789386|Hyperalgesia
477750|NCT00789360|Healthy volunteers
477751|NCT00789347|Neuropathic pain
477752|NCT00789347|Cortical excitability
477753|NCT00789347|Transcranial magnetic stimulation
477754|NCT00789347|Contact Heat evoked potential
477755|NCT00789347|peripheral nerve stimulation
477756|NCT00789347|neurotrophic factors
477757|NCT00787852|dasatinib
477758|NCT00787852|radiation
477759|NCT00787852|paclitaxel
477760|NCT00787852|carboplatin
477761|NCT00787852|NSCLC
477762|NCT00787852|safety addition of dasatinib to chemo RT stage III NSCLC
477763|NCT00787839|type 2 diabetes mellitus
477764|NCT00787839|prediabetic state
477765|NCT00787839|mass screening
477766|NCT00787839|glucose tolerance test
477767|NCT00787826|Live Vaccine Strain (LVS)
477768|NCT00787813|N-acetyl cysteine (NAC)
477769|NCT00787813|Cervical cerclage
477770|NCT00787813|cervical cerclage for cervical insufficiency
477771|NCT00787800|Shock prevention
477772|NCT00787800|Single vs. Dual Chamber
477773|NCT00787800|Reduce ventricular pacing
477774|NCT00787800|Atrial Fibrillation
477775|NCT00787800|Remote Monitoring
477776|NCT00787800|ICD
477777|NCT00787800|Implantable Cardioverter Defibrillator
477778|NCT00787774|HIV
477779|NCT00787774|resistance
477780|NCT00787774|integrase
477781|NCT00787761|accelerated phase CML
477782|NCT00787761|blastic phase CML
477783|NCT00787761|Philadelphia chromosome positive CML
477784|NCT00787761|stage I CLL
477785|NCT00787761|stage II CLL
477786|NCT00787761|stage III CLL
477787|NCT00787761|stage IV CLL
477788|NCT00787761|stage I multiple myeloma
477789|NCT00787761|stage II multiple myeloma
477790|NCT00787761|stage III multiple myeloma
477791|NCT00787761|adult AML with 11q23 (MLL) abnormalities
477792|NCT00787761|adult CML in remission
477793|NCT00787761|adult ALL in remission
477794|NCT00787761|stage IV renal cell cancer
477795|NCT00787761|de novo MDS
477796|NCT00787761|previously treated MDS
477797|NCT00787761|secondary MDS
477798|NCT00787761|atypical CML, BCR-ABL negative
477799|NCT00787761|chronic myelomonocytic leukemia
477800|NCT00787761|MDS/myeloproliferative neoplasm, unclassifiable
477801|NCT00787761|primary myelofibrosis
477802|NCT00787761|chronic neutrophilic leukemia
477803|NCT00787761|recurrent adult Hodgkin lymphoma
477804|NCT00787761|clear cell renal cell carcinoma
477805|NCT00787761|adult AML with inv(16)(p13;q22)
477806|NCT00787761|adult AML with t(15;17)(q22;q12)
477807|NCT00787761|adult AML with t(16;16)(p13;q22)
477808|NCT00787761|adult AML with t(8;21)(q22;q22)
477809|NCT00787761|adult nasal type extranodal NK/T-cell lymphoma
477810|NCT00787761|AML/transient myeloproliferative disorder
477811|NCT00787761|Burkitt lymphoma
477812|NCT00787761|chronic phase CML
477813|NCT00787761|extranodal marginal zone B-cell lymphoma of mucosa tissue
477814|NCT00787761|nodal marginal zone B-cell lymphoma
477815|NCT00787761|stage III adult Burkitt lymphoma
477816|NCT00787761|stage IV adult Burkitt lymphoma
477817|NCT00787761|recurrent adult Burkitt lymphoma
477818|NCT00787761|stage III adult diffuse large cell lymphoma
477819|NCT00787761|stage III adult diffuse mixed cell lymphoma
477820|NCT00787761|recurrent adult diffuse large cell lymphoma
477821|NCT00787761|stage IV adult diffuse large cell lymphoma
477822|NCT00787761|stage IV adult diffuse mixed cell lymphoma
477823|NCT00787761|recurrent adult diffuse mixed cell lymphoma
477824|NCT00787761|stage III adult immunoblastic large cell lymphoma
477825|NCT00787761|stage IV adult immunoblastic large cell lymphoma
477826|NCT00787761|stage III adult lymphoblastic lymphoma
477827|NCT00787761|stage IV adult lymphoblastic lymphoma
477828|NCT00787761|recurrent adult immunoblastic large cell lymphoma
477829|NCT00787761|recurrent adult lymphoblastic lymphoma
477830|NCT00787761|recurrent grade 3 follicular lymphoma
477831|NCT00787761|stage III grade 3 follicular lymphoma
477832|NCT00787761|stage IV grade 3 follicular lymphoma
477833|NCT00787761|recurrent mantle cell lymphoma
477834|NCT00787761|stage III mantle cell lymphoma
477835|NCT00787761|stage IV mantle cell lymphoma
477836|NCT00787761|contiguous st II adult diffuse small cleaved cell lymphoma
477837|NCT00787761|noncontiguous st II diffuse small cleaved cell lymphoma
477838|NCT00787761|recurrent adult diffuse small cleaved cell lymphoma
477839|NCT00787761|stage III adult diffuse small cleaved cell lymphoma
477840|NCT00787761|stage IV adult diffuse small cleaved cell lymphoma
477841|NCT00787761|contiguous stage II grade 1 follicular lymphoma
477842|NCT00787761|contiguous stage II grade 2 follicular lymphoma
477843|NCT00787761|noncontiguous stage II grade 1 follicular lymphoma
477844|NCT00787761|noncontiguous stage II grade 2 follicular lymphoma
477845|NCT00787761|recurrent grade 1 follicular lymphoma
477846|NCT00787761|recurrent grade 2 follicular lymphoma
477847|NCT00787761|stage III grade 1 follicular lymphoma
477848|NCT00787761|stage III grade 2 follicular lymphoma
477849|NCT00787761|stage IV grade 1 follicular lymphoma
477850|NCT00787761|stage IV grade 2 follicular lymphoma
477851|NCT00787761|contiguous stage II marginal zone lymphoma
477852|NCT00787761|noncontiguous stage II marginal zone lymphoma
477853|NCT00787761|recurrent marginal zone lymphoma
477854|NCT00787761|stage III marginal zone lymphoma
477855|NCT00787761|stage IV marginal zone lymphoma
477856|NCT00787761|contiguous stage II small lymphocytic lymphoma
477857|NCT00787761|noncontiguous stage II small lymphocytic lymphoma
477858|NCT00787761|recurrent small lymphocytic lymphoma
477859|NCT00787761|stage III small lymphocytic lymphoma
477860|NCT00787761|stage IV small lymphocytic lymphoma
477861|NCT00787761|recurrent adult grade III lymphomatoid granulomatosis
477862|NCT00787761|relapsing chronic myelogenous leukemia
477863|NCT00787761|refractory chronic lymphocytic leukemia
477864|NCT00787761|splenic marginal zone lymphoma
477865|NCT00787761|Waldenstrom macroglobulinemia
477866|NCT00787761|recurrent adult T-cell leukemia/lymphoma
477867|NCT00787761|stage III adult T-cell leukemia/lymphoma
477868|NCT00787761|stage IV adult T-cell leukemia/lymphoma
477869|NCT00787761|anaplastic large cell lymphoma
477870|NCT00787761|angioimmunoblastic T-cell lymphoma
477871|NCT00787748|Cardiovascular
477872|NCT00787748|COPD
477873|NCT00787748|Population
477874|NCT00787748|Prevalence
477875|NCT00787748|Underdiagnosis
477876|NCT00789308|Insulin dependence
477877|NCT00789295|Mediterranean diet
477878|NCT00789295|Postprandial lipids
477879|NCT00789295|Postprandial glucose
477880|NCT00789295|High fibre diet
477881|NCT00789295|Low- CHO diet
477882|NCT00789295|High MUFA diet
477883|NCT00789295|Dietary approach
477884|NCT00789282|chronic disease
477885|NCT00789282|Family Physician
477886|NCT00789282|primary care network
477887|NCT00789282|practice-based model
477888|NCT00789282|type 2 diabetes
477889|NCT00789282|complications
477890|NCT00789282|sequelae
477891|NCT00789269|lung infection after ischemic Stroke
477892|NCT00789269|prevention of pneumonia
477893|NCT00789269|rhubarb
477894|NCT00789256|Acute Myelogenous Leukemia
477895|NCT00789256|AML
477896|NCT00789256|Myelodysplastic Syndromes
477897|NCT00789256|MDS
477898|NCT00789256|Melphalan
477899|NCT00789256|Bortezomib
477900|NCT00789256|Velcade
477901|NCT00789243|Ischaemia reperfusion
477902|NCT00789243|t-PA
477903|NCT00789243|Fibrinolysis
477904|NCT00789243|Endothelial function
477905|NCT00789243|Local and remote ischaemic preconditioning
477906|NCT00789230|umbilical
477907|NCT00789230|hernia
477908|NCT00789230|mesh
477909|NCT00789217|Penicillin
477910|NCT00789217|Beta-Lactams
477911|NCT00789217|Allergy
477912|NCT00789217|Hypersensitivity
477913|NCT00789204|exercise
477914|NCT00789204|low back pain
477915|NCT00789204|posture
477916|NCT00789204|rehabilitation
477917|NCT00789178|memory disturbances
477918|NCT00789165|Brugada syndrome
477919|NCT00789165|quinidine
477920|NCT00789165|Asymptomatic Brugada Syndrome
477921|NCT00789113|lamotrigine
477922|NCT00789113|epilepsy
477923|NCT00789113|metabolism
477924|NCT00789113|bipolar disorder
477925|NCT00789113|bipolar depression
477926|NCT00789113|glucuronidation
477927|NCT00789100|telehealth
477928|NCT00789100|telemonitor
477929|NCT00789100|telemedicine
477930|NCT00789100|Co-morbidities
477931|NCT00789087|Pleural Effusion.
477932|NCT00789087|Talc.
477933|NCT00789087|Pleurodesis.
477934|NCT00789087|Quality of Life.
477935|NCT00789087|Thoracoscopy.
477936|NCT00789074|Smoking cessation
477937|NCT00789074|Tobacco dependence
477938|NCT00789074|Varenicline
477939|NCT00789074|Preloading
477940|NCT00789061|Acute hearing loss in patients with SLC26A4 mutations
477941|NCT00789048|hip
477942|NCT00789048|arthroplasty
477943|NCT00789048|radiograph
477944|NCT00789022|First-Psychotic-Episode (FPE)
477945|NCT00789022|Glutamatergic system
477946|NCT00789022|Glycine
477947|NCT00789022|D-Serine
477948|NCT00789022|Oxytocin
477949|NCT00789022|Estrogen
477950|NCT00789009|HIV
477951|NCT00789009|Natural History
477952|NCT00789009|Stored Sample
477953|NCT00789009|AIDS
477954|NCT00788996|Tobacco Smoke Pollution/prevention and control
477955|NCT00788996|Parent-Child Relations
477956|NCT00788996|Environmental Tobacco Smoke (ETS)
477957|NCT00788983|Induced hypoxia
477958|NCT00788983|Pulse oximeter
477959|NCT00788983|Nonin Medical
477960|NCT00788983|Verification of SpO2 accuracy
477961|NCT00788970|Acupressure
477962|NCT00788970|Shiatsu
477963|NCT00788970|Schizophrenia
477964|NCT00788957|panitumumab
477965|NCT00788957|vectibix
477966|NCT00788957|AMG 102
477967|NCT00788957|AMG 479
477968|NCT00788957|colon cancer
477969|NCT00788957|rectal cancer
477970|NCT00788957|colorectal cancer
477971|NCT00788957|metastatic colorectal cancer
477972|NCT00788957|EGFR inhibitor
477973|NCT00788957|IGF inhibitor
477974|NCT00788957|c-MET inhibitor
477975|NCT00788931|Breast Cancer
477976|NCT00788931|HER2 positive
477977|NCT00788931|adult-female
477978|NCT00788931|LBH589
477979|NCT00788931|HDAC inhibitor
477980|NCT00788931|panobinostat
477981|NCT00788931|metastatic breast
477982|NCT00788931|adult female patients
477983|NCT00788918|Chronic Hepatitis C
477984|NCT00788918|cognitive dysfunction
477985|NCT00788918|MRI
477986|NCT00788918|MR spectroscopy
477987|NCT00788918|interferon
477988|NCT00788918|ribavirin
477989|NCT00788918|sustained virologic response, major depressive disorder
477990|NCT00788905|Hemodialysis
477991|NCT00788892|Acute
477992|NCT00788892|Myeloid
477993|NCT00788892|Leukemia
477994|NCT00788892|elderly
477995|NCT00788892|Newly
477996|NCT00788892|Diagnosed
477997|NCT00788879|Behavioral Journalism
477998|NCT00788879|Mexican-Americans
477999|NCT00788879|Obesity
478000|NCT00788879|Nutrition
478001|NCT00788879|Physical Activity
478002|NCT00788879|Border Health
478003|NCT00788866|Neuroprotection
478004|NCT00788866|Antioxidants
478005|NCT00788866|Neonatal brain injury
478006|NCT00788866|Pomegranate juice
478007|NCT00788853|DiabCare Asia 2008, Cross-sectional survey, Glycemic control, Psychosocial well-being, Diabetic complications, Quality of life.
478008|NCT00788827|diabetes type I
478009|NCT00788827|diabetes type 2
478010|NCT00788827|renal transplant
478011|NCT00788827|stem cells
478012|NCT00788827|successful renal transplant
478013|NCT00788788|Airway obstruction
478014|NCT00788788|Heliox
478015|NCT00788788|Different Helium content
478016|NCT00788775|nilotinib
478017|NCT00788762|glaucoma
478018|NCT00788762|myocilin
478019|NCT00788749|chronic rhinosinusitis
478020|NCT00788749|nasal polyps
478021|NCT00788749|oral steroid
478022|NCT00788749|intranasal steroid
478023|NCT00788749|medical polypectomy
478024|NCT00788736|venous thromboembolism
478025|NCT00788736|long-term oral anticoagulant therapy
478026|NCT00788736|warfarin
478027|NCT00788736|bleeding risk
478028|NCT00788736|clinical prediction rule
478029|NCT00788736|predictors
478030|NCT00788736|deep vein thrombosis
478031|NCT00788736|pulmonary embolism
478032|NCT00788736|vitamin k antagonist
478033|NCT00788736|side effect
478034|NCT00788723|Severe Brain Injury
478035|NCT00788723|Excitability
478036|NCT00788723|Transcranial Magnetic Stimulation
478037|NCT00788684|Navitoclax
478038|NCT00788684|Rituximab
478039|NCT00788684|CD20-Positive Lymphoid Malignancies
478040|NCT00788684|ABT-263
478041|NCT00788684|Chronic Lymphoid Leukemia
478042|NCT00788684|Non-Hodgkin's Lymphoma
478043|NCT00788684|Hematological Malignancies
478044|NCT00788671|Endometrioid Endometrial Carcinoma
478045|NCT00788671|Complex Atypical Hyperplasia
478046|NCT00788671|Levonorgestrel Intrauterine Device
478047|NCT00788671|Endometrial Biopsy
478048|NCT00788671|Endometrium
478049|NCT00788671|Hyperplasia of lining of the uterus (womb)
478050|NCT00788671|Questionnaires
478051|NCT00788671|Progesterone
478052|NCT00788671|Estrogen
478053|NCT00788671|Postmenopausal
478054|NCT00788671|Endometrial
478055|NCT00788671|Mirena
478056|NCT00788671|Intrauterine Device
478057|NCT00788671|Birth control
478058|NCT00788671|IUD
478059|NCT00788671|LIUD
478060|NCT00788671|CAH
478061|NCT00788671|G1EEC
478062|NCT00788671|Grade 1 endometrial cancer
478063|NCT00788671|Early endometrial cancer
478064|NCT00788658|Obstructed constipation
478065|NCT00788658|Quality of life
478066|NCT00788645|Smoking
478067|NCT00788645|COPD
478068|NCT00788645|Chronic Obstructive Lung Disease
478069|NCT00788645|COPD Exacerbations
478070|NCT00788645|Viruses and Bacteria associated with COPD exacerbations
478071|NCT00788632|Osteoporosis
478072|NCT00788632|BMD
478073|NCT00788632|Bisphosphonates
478074|NCT00788632|Educational materials
478075|NCT00788632|Patient Stories
478076|NCT00788619|Infertility
478077|NCT00788619|Assisted reproductive technology
478078|NCT00788619|Nitric oxide
478079|NCT00788606|diffused large B cell lymphoma, DLBCL, R-Chop, bevacizumab
478080|NCT00788606|Diffuse large B-cell non-Hodgkin's lymphoma.
478081|NCT00788593|Chronic Pancreatitis
478082|NCT00788593|Exocrine Pancreatic Insufficiency
478083|NCT00788580|unspecified adult solid tumor, protocol specific
478084|NCT00788554|groin
478085|NCT00788554|inguinal
478086|NCT00788554|hernia
478087|NCT00788554|lichtenstein
478088|NCT00788554|TEP
478089|NCT00788541|Open-Angle Glaucoma
478090|NCT00788541|Intraocular Pressure
478091|NCT00788541|Anecortave Acetate
478092|NCT00788528|Obesity
478093|NCT00788515|insomnia
478094|NCT00788515|sleep maintenance
478095|NCT00788489|breast cancer
478096|NCT00788489|FDG-PET
478097|NCT00788489|MRI
478098|NCT00788489|chemotherapy
478099|NCT00788489|ultrasonography
478100|NCT00788476|Needs Assessment Survey
478101|NCT00788476|Childhood Cancer Survivors
478102|NCT00788476|Parents
478103|NCT00788476|Primary Caregiver
478104|NCT00788476|Survey
478105|NCT00788463|administration, intranasal
478106|NCT00788463|aerosol
478107|NCT00788463|beclomethasone
478108|NCT00788463|QVAR
478109|NCT00788463|corticosteroids
478110|NCT00788463|nasal polyps
478111|NCT00788463|rhinomanometry
478112|NCT00788463|Rhinitis Quality of Life Questionnaire
478113|NCT00788463|Quality of Life
478114|NCT00787722|High dose immunosuppressive therapy
478115|NCT00787722|Hematopoietic stem cell support
478116|NCT00787709|Obesity prevention
478117|NCT00787709|Health promotion
478118|NCT00787709|School based curriculum
478119|NCT00787696|HIV prevention
478120|NCT00787696|female adolescent offenders
478121|NCT00787696|sexual risk reduction
478122|NCT00787696|alcohol and other drug abuse
478123|NCT00787683|Patients with ventricular arrhythmias and the prevention of sudden cardiac death
478124|NCT00787670|Obese
478125|NCT00787670|Type 2 Diabetes Mellitus
478126|NCT00787670|Gastric Bypass surgery
478127|NCT00787670|Risk of cardiovascular diseases
478128|NCT00787657|Clinically Isolated Syndrome (CIS)
478129|NCT00787644|Asthma
478130|NCT00787644|Adipose Tissue
478131|NCT00787644|Asthmatics
478132|NCT00787644|Pioglitazone
478133|NCT00787644|Actos
478134|NCT00787644|Obesity
478135|NCT00787644|Exacerbation
478136|NCT00787644|Fat
478137|NCT00787644|Overweight
478138|NCT00787644|Leptin
478139|NCT00787644|Adiponectin
478140|NCT00787644|Wheezing
478141|NCT00787644|Vermont
478142|NCT00787644|Pulmonary
478143|NCT00787644|Lung
478144|NCT00787631|birch pollen pollen allergy
478145|NCT00787631|oral allergy syndrome to apple
478146|NCT00787631|cross reactivity
478147|NCT00787631|bet v 1
478148|NCT00787631|mal d 1
478149|NCT00787618|Renal impairment
478150|NCT00787605|Hypertension, diabetes mellitus, aliskiren, hydrochlorothiazide, systolic blood pressure, diastolic blood pressure, amlodipine, stage 2
478151|NCT00787592|Burns
478152|NCT00787592|children
478153|NCT00787592|collagenase
478154|NCT00787592|silver sulfadiazine
478155|NCT00787592|Childhood burns
478156|NCT00788424|AS101 Psoriasis
478157|NCT00788385|Hydrocephalus
478158|NCT00788385|High Pressure
478159|NCT00788385|Shunt Blockage
478160|NCT00788372|Chronic pain
478161|NCT00788372|Fentanyl Patch
478162|NCT00788359|cystic fibrosis
478163|NCT00788359|pulmonary exacerbation
478164|NCT00788359|biomarkers
478165|NCT00788346|Heavily marketed medications
478166|NCT00788346|Prescribing
478167|NCT00788346|Health information technology
478168|NCT00788346|Education
478169|NCT00788333|Advanced or Metastatic Her-2-positive Breast Cancer
478170|NCT00788320|Tuberculosis
478171|NCT00788320|vitamin D
478172|NCT00788320|immune system
478173|NCT00788307|adenocarcinoma of the prostate
478174|NCT00788307|recurrent prostate cancer
478175|NCT00788307|stage I prostate cancer
478176|NCT00788307|stage II prostate cancer
478177|NCT00788294|Pharmacokinetics tanezumab subcutaneous bioavailability intravenous Japanese subjects
478178|NCT00788242|Cardiac surgery
478179|NCT00788242|Cardioprotection
478180|NCT00788242|Aortocoronary bypass graft
478181|NCT00788242|Aortic stenosis
478182|NCT00788229|Dry Eye Syndromes
478183|NCT00788229|Keratoconjunctivitis Sicca
478184|NCT00788229|artificial tears
478185|NCT00788229|carboxymethylcellulose sodium
478186|NCT00788229|sodium hyaluronate
478187|NCT00788216|Radical hysterectomy
478188|NCT00788216|Whole pelvic radiation
478189|NCT00788216|Brachytherapy
478190|NCT00788216|Chemoradiation
478191|NCT00788216|Complications
478192|NCT00788216|Quality of Life
478193|NCT00788190|Distal Radius Fracture
478194|NCT00788190|Elderly
478195|NCT00788190|Prospective randomized trial
478196|NCT00788190|Outcomes
478197|NCT00788190|Pain and Function
478198|NCT00788190|Surgical Vs. conservative management
478199|NCT00788190|Fractures with borderline alignment
478200|NCT00788177|age-related macular degeneration
478201|NCT00788177|subretinal injection
478202|NCT00788177|Pegaptanib
478203|NCT00788177|Macugen
478204|NCT00788164|cervical cancer
478205|NCT00788164|cervical intraepithelial neoplasia grade 3
478206|NCT00788164|therapeutic vaccine
478207|NCT00788164|treatment
478208|NCT00788164|CIN
478209|NCT00788164|HPV
478210|NCT00788164|vaccine
478211|NCT00788164|Hopkins
478212|NCT00788164|Trimble
478213|NCT00788151|Dengue virus
478214|NCT00788151|Dengue fever
478215|NCT00788151|Dengue hemorrhagic fever
478216|NCT00788151|Dengue diseases
478217|NCT00788151|Dengue vaccine
478218|NCT00788138|Cystic Fibrosis
478219|NCT00788138|Vitamin D
478220|NCT00788138|Anti-microbial peptides
478221|NCT00788125|previously treated childhood rhabdomyosarcoma
478222|NCT00788125|metastatic childhood soft tissue sarcoma
478223|NCT00788125|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
478224|NCT00788125|metastatic osteosarcoma
478225|NCT00788125|recurrent childhood rhabdomyosarcoma
478226|NCT00788125|recurrent childhood soft tissue sarcoma
478227|NCT00788125|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
478228|NCT00788125|recurrent osteosarcoma
478229|NCT00788125|unspecified childhood solid tumor, protocol specific
478230|NCT00788125|recurrent Wilms tumor and other childhood kidney tumors
478231|NCT00788125|recurrent neuroblastoma
478232|NCT00788125|stage 4S neuroblastoma
478233|NCT00788125|childhood extracranial germ cell tumor
478234|NCT00788125|childhood malignant ovarian germ cell tumor
478235|NCT00788125|childhood malignant testicular germ cell tumor
478236|NCT00788125|childhood teratoma
478237|NCT00788125|clear cell sarcoma of the kidney
478238|NCT00788125|childhood renal cell carcinoma
478239|NCT00788125|recurrent renal cell cancer
478240|NCT00788125|congenital mesoblastic nephroma
478241|NCT00788125|cystic nephroma
478242|NCT00788125|peripheral primitive neuroectodermal tumor of the kidney
478243|NCT00788125|rhabdoid tumor of the kidney
478244|NCT00788125|disseminated neuroblastoma
478245|NCT00788125|recurrent malignant testicular germ cell tumor
478246|NCT00788125|recurrent ovarian germ cell tumor
478247|NCT00788125|recurrent childhood liver cancer
478248|NCT00788125|stage IV childhood liver cancer
478249|NCT00788125|angioimmunoblastic T-cell lymphoma
478250|NCT00788125|stage IV childhood Hodgkin lymphoma
478251|NCT00788125|stage IV childhood large cell lymphoma
478252|NCT00788125|stage IV childhood lymphoblastic lymphoma
478253|NCT00788125|stage IV childhood small noncleaved cell lymphoma
478254|NCT00788125|recurrent childhood grade III lymphomatoid granulomatosis
478255|NCT00788125|recurrent childhood large cell lymphoma
478256|NCT00788125|recurrent childhood lymphoblastic lymphoma
478257|NCT00788125|recurrent childhood small noncleaved cell lymphoma
478258|NCT00788125|recurrent/refractory childhood Hodgkin lymphoma
478259|NCT00788125|childhood diffuse large cell lymphoma
478260|NCT00788125|childhood grade III lymphomatoid granulomatosis
478261|NCT00788125|childhood immunoblastic large cell lymphoma
478262|NCT00788125|childhood nasal type extranodal NK/T-cell lymphoma
478263|NCT00788125|Burkitt lymphoma
478264|NCT00788125|primary central nervous system non-Hodgkin lymphoma
478265|NCT00788125|recurrent childhood anaplastic large cell lymphoma
478266|NCT00788125|stage IV childhood anaplastic large cell lymphoma
478267|NCT00788125|childhood central nervous system choriocarcinoma
478268|NCT00788125|childhood central nervous system embryonal tumor
478269|NCT00788125|childhood central nervous system germ cell tumor
478270|NCT00788125|childhood central nervous system germinoma
478271|NCT00788125|childhood central nervous system mixed germ cell tumor
478272|NCT00788125|childhood central nervous system teratoma
478273|NCT00788125|childhood central nervous system yolk sac tumor
478274|NCT00788125|recurrent childhood central nervous system embryonal tumor
478275|NCT00788125|childhood choroid plexus tumor
478276|NCT00788125|childhood craniopharyngioma
478277|NCT00788125|childhood ependymoblastoma
478278|NCT00788125|childhood medulloepithelioma
478279|NCT00788125|childhood infratentorial ependymoma
478280|NCT00788125|childhood supratentorial ependymoma
478281|NCT00788125|childhood oligodendroglioma
478282|NCT00788125|childhood pineal parenchymal tumor
478283|NCT00788125|childhood grade I meningioma
478284|NCT00788125|childhood grade II meningioma
478285|NCT00788125|childhood grade III meningioma
478286|NCT00788125|recurrent childhood cerebellar astrocytoma
478287|NCT00788125|recurrent childhood cerebral astrocytoma
478288|NCT00788125|recurrent childhood ependymoma
478289|NCT00788125|recurrent childhood medulloblastoma
478290|NCT00788125|recurrent childhood pineoblastoma
478291|NCT00788125|recurrent childhood supratentorial primitive neuroectodermal tumor
478292|NCT00788125|recurrent childhood visual pathway and hypothalamic glioma
478293|NCT00788125|recurrent uterine sarcoma
478294|NCT00788125|childhood high-grade cerebellar astrocytoma
478295|NCT00788125|childhood high-grade cerebral astrocytoma
478296|NCT00788125|childhood low-grade cerebellar astrocytoma
478297|NCT00788125|childhood low-grade cerebral astrocytoma
478298|NCT00788125|childhood atypical teratoid/rhabdoid tumor
478299|NCT00788125|primary central nervous system Hodgkin lymphoma
478300|NCT00788125|childhood extragonadal germ cell tumor
478301|NCT00788125|recurrent childhood malignant germ cell tumor
478302|NCT00788125|recurrent childhood brain stem glioma
478303|NCT00788125|recurrent childhood subependymal giant cell astrocytoma
478304|NCT00788125|recurrent childhood brain tumor
478305|NCT00788125|recurrent childhood spinal cord neoplasm
478306|NCT00788112|ductal breast carcinoma in situ
478307|NCT00788099|Aplidin
478308|NCT00788099|Plitidepsin
478309|NCT00788099|Tumors
478310|NCT00788099|Lymphomas
478311|NCT00788073|fragile X syndrome
478312|NCT00788073|irritability
478313|NCT00788073|behavior problems
478314|NCT00788060|Renal Cell Carcinoma
478315|NCT00788060|Rad001
478316|NCT00788060|Sutent
478317|NCT00788034|Relapse prevention
478318|NCT00788034|GAD
478319|NCT00788034|Maintenance
478320|NCT00788034|Double-blind
478321|NCT00788034|Multicentre
478322|NCT00788021|Transplant
478323|NCT00788021|Immunity
478324|NCT00788021|Immunosuppression
478325|NCT00788008|spinal, joint
478326|NCT00787995|Mucopolysaccharidosis IV type A
478327|NCT00787995|MPS IV Type A
478572|NCT00786812|Leukemia
478328|NCT00787995|Mucopolysaccharidosis IVA
478329|NCT00787995|MPS IVA
478330|NCT00787995|Morquio A Syndrome
478331|NCT00787995|Lysosomal Storage Disorder
478332|NCT00787995|LSD
478333|NCT00787995|N-acetylgalactosamine-6-sulfatase
478334|NCT00787995|galactose-6-sulfatase
478335|NCT00787995|GALNS
478336|NCT00787995|enzyme replacement therapy
478337|NCT00787995|ERT
478338|NCT00787982|brain
478339|NCT00787982|metastasis
478340|NCT00787982|neoplasm
478341|NCT00787982|tumor
478342|NCT00787982|Patients with secondary brain neoplasms
478343|NCT00787982|laser therapy
478344|NCT00787982|laser interstitial thermal therapy
478345|NCT00787969|stage I mantle cell lymphoma
478346|NCT00787969|Stage II Contiguous Mantle Cell Lymphoma
478347|NCT00787969|Stage II Non-Contiguous Mantle Cell Lymphoma
478348|NCT00787969|Stage III Mantle Cell Lymphoma
478349|NCT00787969|Stage IV Mantle Cell Lymphoma
478350|NCT00787943|Acne
478351|NCT00787930|BPD
478352|NCT00787917|Cystic Fibrosis
478353|NCT00787917|Allergic Bronchopulmonary Aspergillosis
478354|NCT00787917|omalizumab
478355|NCT00787917|oral corticosteroid use
478356|NCT00787917|anti-immunoglobulin E
478357|NCT00787904|Osteoporosis, T-cells
478358|NCT00787891|Gastroesophageal Reflux Disease (GERD)
478359|NCT00787891|Erosive Gastroesophageal Reflux Disease
478360|NCT00787891|Ulcerative Gastroesophageal Reflux Disease
478361|NCT00787891|Endoscopy
478362|NCT00787891|Pediatrics
478363|NCT00787891|Rabeprazole
478364|NCT00787865|Diffusion Tensor Imaging
478365|NCT00787865|DTI
478366|NCT00787865|Newborn
478367|NCT00787865|Krabbe Disease
478368|NCT00787865|Motor Development
478369|NCT00787865|Motor Disability
478370|NCT00787579|Myopia, bifocal, children
478371|NCT00787566|Highly emetogenic chemotherapy induced nausea and vomiting
478372|NCT00787553|hysterectomy
478373|NCT00787553|antibiotic prophylaxis
478374|NCT00787553|bacterial vaginosis
478375|NCT00787553|tinidazole
478376|NCT00787553|cefazolin
478377|NCT00787540|Coronary disease
478378|NCT00787540|Psychosocial
478379|NCT00787540|Nursing
478380|NCT00787527|Lymphoma
478381|NCT00787527|Non-Hodgkin's Lymphoma
478382|NCT00787527|SAHA
478383|NCT00787527|Vorinostat
478384|NCT00787527|Suberoylanilide Hydroxamic Acid
478385|NCT00787527|MSK-390
478386|NCT00787527|CHOP
478387|NCT00787527|Cyclophosphamide
478388|NCT00787527|Doxorubicin
478389|NCT00787527|AD
478390|NCT00787527|Hydroxydaunomycin hydrochloride
478391|NCT00787527|Cytoxan
478392|NCT00787527|Neosar
478393|NCT00787527|Vincristine
478394|NCT00787527|Prednisone
478395|NCT00787527|Untreated T-cell
478396|NCT00787527|T-cell NHL
478397|NCT00787527|Peripheral T-cell lymphoma
478398|NCT00787527|PTCL
478399|NCT00787527|CD 30
478400|NCT00787527|Anaplastic large cell lymphoma
478401|NCT00787527|Angioimmunoblastic T-cell lymphoma
478402|NCT00787527|Intestinal T-cell lymphoma
478403|NCT00787527|Subcutaneous panniculitic T-cell lymphoma
478404|NCT00787514|ovarian cancer, folate receptor, plasma
478405|NCT00787501|Major Depressive Disorder
478406|NCT00787501|Depression
478407|NCT00787501|Selective Serotonin Reuptake Inhibitors
478408|NCT00787501|Cognitive Behavior Therapy
478409|NCT00787501|Cognitive Therapy
478410|NCT00787501|antidepressant medications
478411|NCT00787488|Ovarian
478412|NCT00787488|debulked
478413|NCT00787488|recurrent
478414|NCT00787488|Stage III
478415|NCT00787488|Stage IV
478416|NCT00787475|Diabetes
478417|NCT00787475|Community health worker
478418|NCT00787475|Community outreach
478419|NCT00787462|Neuropathic
478420|NCT00787462|Neuropathic pain
478421|NCT00787462|Nerve pain
478422|NCT00787462|Pain
478423|NCT00787462|Chronic pain
478424|NCT00787462|Pregabalin
478425|NCT00787462|Lyrica
478426|NCT00787462|Small fiber neuropathy
478427|NCT00787462|Neuropathy
478428|NCT00787436|portal hypertension
478429|NCT00787436|Gastroesophageal
478430|NCT00787436|Varices
478431|NCT00787436|Liver disease
478432|NCT00787436|cirrhosis
478433|NCT00787423|Field Tools
478434|NCT00787423|Drug Use
478435|NCT00787423|Psychological Stress
478436|NCT00787423|Ecological Momentary Assessment
478437|NCT00787423|Global Positioning Units
478438|NCT00787410|malignant mesothelioma
478439|NCT00787410|IRESSA
478440|NCT00787410|ZD1839
478441|NCT00787397|Sleep difficulties in pediatric anxiety disorder
478442|NCT00787397|Neural correlates of pediatric anxiety disorder
478443|NCT00787397|Social correlates of pediatric anxiety disorder
478444|NCT00787397|Generalized Anxiety Disorder in pediatric populations
478445|NCT00787397|Separation Anxiety Disorder in pediatric populations
478446|NCT00787397|Social Phobia in pediatric populations
478447|NCT00787384|Hypereosinophilic syndrome (HES)
478697|NCT00786383|1121B
478448|NCT00787384|chronic eosinophilic leukaemia (CEL)
478449|NCT00787384|chronic idiopathic hypereosinophilia (CIH)
478450|NCT00787384|Imatinib
478451|NCT00787384|Response
478452|NCT00787384|Timing to response
478453|NCT00787371|alanine transaminase
478454|NCT00787358|osteoporosis
478455|NCT00787358|intertrochanteric
478456|NCT00787358|hip fracture
478457|NCT00787358|compression hip screw
478458|NCT00787358|surgical fixation
478459|NCT00787345|precaution technique during central venous catheter placement.
478460|NCT00787332|Suspected Heparin Induced Thrombocytopenia (HIT)
478461|NCT00787319|Ophthalmology
478462|NCT00787319|Age-related macular degeneration
478463|NCT00787319|outpatients
478464|NCT00787306|chronic disease management
478465|NCT00787306|decision aids
478466|NCT00787306|cardiovascular risk factors
478467|NCT00787293|Heart Failure
478468|NCT00787293|Mitral Regurgitation
478469|NCT00787293|Percutaneous
478470|NCT00787293|Coronary sinus
478471|NCT00787280|obese
478472|NCT00787280|overweight
478473|NCT00787280|fMRI
478474|NCT00787280|Diet
478475|NCT00787267|NSCLC
478476|NCT00787267|Lung Cancer
478477|NCT00787267|Dasatinib
478478|NCT00787267|Genomics
478479|NCT00787267|Genomics analysis
478480|NCT00787267|Genomic signature
478481|NCT00787254|Curling Ulcer
478482|NCT00787254|Gastric Ulcer
478483|NCT00787254|Nonsteroid anti-inflammatory drug
478484|NCT00787254|Drug Therapy
478485|NCT00787241|Platelets
478486|NCT00787241|Labor
478487|NCT00787241|Preeclampsia
478488|NCT00787215|oral glucose tolerance test
478489|NCT00787215|Hong Kong Chinese
478490|NCT00787202|treatment of ulcerative colitis; CP 690 550
478491|NCT00787189|sensorineural hearing loss
478492|NCT00787189|tinnitus
478493|NCT00787189|word recognition
478494|NCT00787176|Oxytocin
478495|NCT00787176|Labor, Obstetric
478496|NCT00787176|Non-reassuring fetal heart rate
478497|NCT00787176|epidural
478498|NCT00787163|pPROM
478499|NCT00787163|oligohydramnios
478500|NCT00787163|amnioinfusion
478501|NCT00787163|prematurity
478502|NCT00787163|Early premature rupture of membranes in pregnancy
478503|NCT00787111|Drug: Fluoxetine
478504|NCT00787098|therapeutic mobility
478505|NCT00787098|acute care
478506|NCT00787098|nursing
478507|NCT00787098|inflammatory markers
478508|NCT00787085|Funguria
478509|NCT00787085|Epidemiology
478510|NCT00787085|Urinary Tract Infections
478511|NCT00787059|Adenylyl Cyclase
478512|NCT00787059|AC6
478513|NCT00787059|adenovirus
478514|NCT00787059|gene therapy
478515|NCT00787059|congestive heart failure
478516|NCT00787059|intracoronary
478517|NCT00787059|nitroprusside
478518|NCT00787033|Focal Adhesion Kinase; Advanced Non-Hematologic Malignancies
478519|NCT00787020|Cerebrospinal Fluid
478520|NCT00787020|Ventriculostomy
478521|NCT00787020|Subarachnoid hemorrhage
478522|NCT00787020|vasospasm
478523|NCT00787020|Human Subjects
478524|NCT00787007|healthy volunteers
478525|NCT00787007|pharmacokinetics
478526|NCT00786994|Actinic Keratoses
478527|NCT00786968|mucopolysaccharidosis
478528|NCT00786968|Hurler-Scheie
478529|NCT00786968|Scheie
478530|NCT00786968|laronidase
478531|NCT00786968|spinal cord compression
478532|NCT00786968|central nervous system
478533|NCT00786968|enzyme replacement therapy
478534|NCT00786968|intrathecal
478535|NCT00786942|osteotomy
478536|NCT00786942|knee
478537|NCT00786942|varus deformity
478538|NCT00786942|bone graft
478539|NCT00786929|Conversion to more aggressive treatment of recurrent fluid collection
478540|NCT00786916|pain
478541|NCT00786916|propofol
478542|NCT00786916|lidocaine
478543|NCT00786916|sedation
478544|NCT00786916|pediatric
478545|NCT00786890|Prediabetes (IFG, IGT)
478546|NCT00786890|Hong Kong Chinese
478547|NCT00786890|Cardiovascular risk factors
478548|NCT00786877|pneumonia
478549|NCT00786864|Randomised controlled trial
478550|NCT00786864|low back pain
478551|NCT00786864|exercise
478552|NCT00786864|children
478553|NCT00786864|school-based
478554|NCT00786864|prevalence
478555|NCT00786864|intensity
478556|NCT00786851|MANTLE CELL LYMPHOMA (MCL)
478557|NCT00786851|Lenalidomide (Len)
478558|NCT00786851|Dexamethasone (Dex)
478559|NCT00786838|Solid tumor
478560|NCT00786838|Advanced solid tumor
478561|NCT00786838|Malignant tumors
478562|NCT00786838|Sarcoma
478563|NCT00786838|Breast tumor
478564|NCT00786838|Ovarian tumor
478565|NCT00786838|QT interval
478566|NCT00786838|Trabectedin
478567|NCT00786838|Yondelis
478568|NCT00786838|Ecteinascidin 743
478569|NCT00786838|ET743
478570|NCT00786825|Type 1 diabetes
478571|NCT00786825|Hypoglycemia unawareness
478573|NCT00786812|adult chronic myeloid leukemia
478574|NCT00786812|imatinib
478575|NCT00786812|nilotinib
478576|NCT00786786|Any person with a spinal cord injury
478577|NCT00786786|at least 18 years of age
478578|NCT00786773|GERD
478579|NCT00786773|reflux symptom
478580|NCT00786773|heartburn
478581|NCT00786773|acid regurgitation
478582|NCT00786773|PPI
478583|NCT00786773|H2RA
478584|NCT00786773|antacid
478585|NCT00786760|HPV
478586|NCT00786760|Papillomavirus
478587|NCT00786760|Infection
478588|NCT00786760|Sexually transmitted disease
478589|NCT00786760|STD
478590|NCT00786747|Computer-assisted instruction
478591|NCT00786747|Health knowledge, attitudes, practice
478592|NCT00786747|Mass screening
478593|NCT00786747|Patient acceptance of health care
478594|NCT00786747|Patient education as topic
478595|NCT00786747|Primary health care
478596|NCT00786747|Self-efficacy
478597|NCT00786734|pitavastatin
478598|NCT00786734|PCI
478599|NCT00786734|stable angina
478600|NCT00786721|Mitochondria and Metabolic Syndrome
478601|NCT00786708|renal
478602|NCT00786708|kidney
478603|NCT00786708|lipocalin
478604|NCT00786708|urine
478605|NCT00786708|biomarker
478606|NCT00786708|Azotemia
478607|NCT00786708|Renal insufficiency, chronic
478608|NCT00786708|Renal failure, acute
478609|NCT00786708|Hydronephrosis
478610|NCT00786695|noncardiac chest pain
478611|NCT00786695|gastroesophageal reflux disease
478612|NCT00786695|diagnostic test
478613|NCT00786695|proton pump inhibitor
478614|NCT00786695|esomeprazole
478615|NCT00786682|stage IV prostate cancer
478616|NCT00786682|recurrent prostate cancer
478617|NCT00786656|Navigation
478618|NCT00786656|Coordination
478619|NCT00786656|Cancer Care
478620|NCT00786656|Patient Experience
478621|NCT00786656|Cancer
478622|NCT00786656|Patient Survey
478623|NCT00786643|Gamma Interferon
478624|NCT00786643|5-FU
478625|NCT00786643|LV
478626|NCT00786630|Drug treatment entry and retention
478627|NCT00786630|Drug injection frequency
478628|NCT00786630|HIV risk behaviors
478629|NCT00786630|Hepatitis C risk behaviors
478630|NCT00786591|Acute pancreatitis
478631|NCT00786591|biological markers
478632|NCT00786591|substance P
478633|NCT00786591|hydrogen sulfide
478634|NCT00786591|disease severity index
478635|NCT00786578|training
478636|NCT00786578|intramyocellular lipid
478637|NCT00786578|insulin resistance
478638|NCT00786552|recurrent/advanced thyroid cancer
478639|NCT00786552|papillary or anaplastic thyroid cancer
478640|NCT00786539|mitochondrial
478641|NCT00786526|Mechanical ventilation
478642|NCT00786526|Ventilator induced diaphragmatic dysfunction
478643|NCT00786526|Weaning
478644|NCT00786526|Neuromuscular diseases- Respiratory function tests
478645|NCT00786526|Intubated patients in intensive care unit
478646|NCT00786513|Cystic fibrosis
478647|NCT00786513|Pseudomonas aeruginosa
478648|NCT00786513|biofilm
478649|NCT00786513|antibiotic susceptibility testing
478650|NCT00786513|pediatrics
478651|NCT00786500|Herbal medicine
478652|NCT00786500|Type 2 diabetes
478653|NCT00786500|Insulin sensitivity
478654|NCT00786500|Insulin secretion
478655|NCT00786487|insulin resistance
478656|NCT00786487|lipid metabolism
478657|NCT00786487|lipid infusion
478658|NCT00786487|glycerol infusion
478659|NCT00786487|skeletal muscle
478660|NCT00786487|diabetes
478661|NCT00786474|Bridging Anticoagulation
478662|NCT00786461|silver nitrate
478663|NCT00786461|marsupialisation
478664|NCT00786448|Overactive Bladder
478665|NCT00786422|Embolism and Thrombosis
478666|NCT00786422|Pulmonary Embolism
478667|NCT00786422|Embolism
478668|NCT00786422|Venous Thrombosis
478669|NCT00786422|Thrombosis
478670|NCT00786422|Enzyme Inducers
478671|NCT00786422|CYP Inducers
478672|NCT00786422|Cohort Study
478673|NCT00786422|Pharmacologic Actions
478674|NCT00786422|Respiratory Tract Diseases
478675|NCT00786422|Lung Diseases
478676|NCT00786422|Vascular Diseases
478677|NCT00786422|Human Immunodeficiency Virus (HIV)
478678|NCT00786422|Neurologic disease
478679|NCT00786422|Additional relevant MeSH terms:
478680|NCT00786422|Fibrin Modulating Agents
478681|NCT00786422|Anticoagulants
478682|NCT00786422|Therapeutic Uses
478683|NCT00786422|Hematologic Agents
478684|NCT00786422|Enzyme Inhibitors
478685|NCT00786422|Cardiovascular Diseases
478686|NCT00786422|Cardiovascular Agents
478687|NCT00786409|Lupus
478688|NCT00786396|HIV
478689|NCT00786396|AIDS
478690|NCT00786396|substance abuse
478691|NCT00786396|directly administered antiretroviral therapy
478692|NCT00786396|adherence
478693|NCT00786396|Substance Abuse and Dependency
478694|NCT00786383|Phase I
478695|NCT00786383|cancer
478696|NCT00786383|solid tumors
478698|NCT00786383|VEGFR-2
478699|NCT00786383|Anti-Vascular Endothelial Growth Factor Receptor 2
478700|NCT00786370|propofol
478701|NCT00786370|dexmedetomidine
478702|NCT00786370|cataract
478703|NCT00786370|respiratory
478704|NCT00786370|blood pressure
478705|NCT00786370|Cataract surgery
478706|NCT00786357|shift-work
478707|NCT00786357|sleep
478708|NCT00786357|nurse
478709|NCT00786357|relaxation
478710|NCT00786344|Health Promotion: Wellness Programs
478711|NCT00786344|Occupational Therapy
478712|NCT00786344|Quality of Life
478713|NCT00786344|Health
478714|NCT00786344|Biomarkers
478715|NCT00786331|second line treatment
478716|NCT00786331|pemetrexed
478717|NCT00786331|carboplatin
478718|NCT00786318|Psychosis
478719|NCT00786318|Agitation
478720|NCT00786318|Delirium
478721|NCT00786305|Nebulization
478722|NCT00786305|ceftazidime
478723|NCT00786305|amikacin
478724|NCT00786305|pneumonia
478725|NCT00786305|Pseudomonas aeruginosa
478726|NCT00786305|mechanical ventilation
478727|NCT00786305|Ventilator-associated pneumonia
478728|NCT00786305|treatment
478729|NCT00786279|atherosclerosis
478730|NCT00786266|shift-work
478731|NCT00786266|sleep
478732|NCT00786266|nurse
478733|NCT00786266|relaxation
478734|NCT00786253|Erectile dysfunction
478735|NCT00786253|Vardenafil
478736|NCT00786240|Bioequivalence
478737|NCT00786240|Therapeutic Equivalency
478738|NCT00786214|Functional Dyspepsia
478739|NCT00786214|Acupuncture
478740|NCT00786214|Traditional Chinese Medicine
478741|NCT00786201|CNTO 888
478742|NCT00786201|Idiopathic Pulmonary Fibrosis
478743|NCT00786201|IPF
478744|NCT00786188|Menopause
478745|NCT00786188|Vasomotor Symptoms
478746|NCT00786188|Hot flash
478747|NCT00786188|Perimenopause
478748|NCT00786188|Nonhormonal therapies
478749|NCT00786188|Climacteric symptoms
478750|NCT00786188|Mesafem
478751|NCT00786188|Low-Dose Mesylate salt of Paroxetine (LDMP)
478752|NCT00786149|Underserved populations
478753|NCT00786149|Homelessness
478754|NCT00786149|Nicotine replacement therapy
478755|NCT00786149|Counseling
478756|NCT00786149|Cancer Prevention and control
478757|NCT00786136|diabetes mellitus
478758|NCT00786136|chronic kidney disease
478759|NCT00786136|contrast induced acute kidney injury
478760|NCT00786136|angiography
478761|NCT00786123|irritable bowel syndrome
478762|NCT00786123|rectal hypersensitivity
478763|NCT00786123|probiotics
478764|NCT00786123|melatonin
478765|NCT00786123|brain-gut axis
478766|NCT00786110|Sorafenib
478767|NCT00786110|Paclitaxel
478768|NCT00786110|Disease free survival
478769|NCT00786084|Hiatal hernia
478770|NCT00786084|PEH
478771|NCT00786084|paraesophageal hernia
478772|NCT00786084|synthetic mesh
478773|NCT00786084|small intestine submucosa
478774|NCT00786071|Rett syndrome.
478775|NCT00786071|Nutritional status.
478776|NCT00786071|Metabolic alterations.
478777|NCT00786058|refractory pancreatic cancer
478778|NCT00786058|gemcitabine
478779|NCT00786058|phase III
478780|NCT00786058|second line
478781|NCT00786045|stroke
478782|NCT00786045|rehabilitation
478783|NCT00786045|walking
478784|NCT00786032|Amyotrophic Lateral Sclerosis
478785|NCT00786032|Brain Computer Interface (BCI)
478786|NCT00786032|Lou Gehrig's disease
478787|NCT00786019|Type
478788|NCT00786019|2
478789|NCT00786019|Diabetes
478790|NCT00786019|Blood
478791|NCT00786019|Vessel
478792|NCT00786019|Function
478793|NCT00786019|Exercise
478794|NCT00786019|Program
478795|NCT00786019|Intervention
478796|NCT00786019|Vitamin
478797|NCT00786019|C
478798|NCT00786019|Men
478799|NCT00786019|Women
478800|NCT00786019|Blood vessel function
478801|NCT00786006|pancreatic cancer
478802|NCT00786006|gemcitabine
478803|NCT00786006|oxaliplatin
478804|NCT00786006|irinotecan
478805|NCT00786006|fluorouracil
478806|NCT00786006|Failure to gemcitabine chemotherapy
478807|NCT00785993|Egg banking, clinical outcome
478808|NCT00785980|quinine sulfate
478809|NCT00785980|ciprofloxacin
478810|NCT00785980|drug interactions
478811|NCT00785980|cytochrome p450
478812|NCT00785980|male
478813|NCT00785980|female
478814|NCT00785980|adult
478815|NCT00785980|pharmacokinetics
478816|NCT00785967|V(D)J recombination; RAG-1/2 recombinase function
478817|NCT00785954|Heart Diseases
478818|NCT00785954|Myocardial Ischemia
478819|NCT00785954|Infarction
478820|NCT00785954|Myocardial Infarction
478821|NCT00785941|Tumors
478822|NCT00785941|Antibodies, Monoclonal
478823|NCT00785928|Arthritis
478824|NCT00785915|AZD6765
478825|NCT00785915|Japanese and Caucasian Healthy Volunteers
478826|NCT00785915|Phase I study
478827|NCT00785915|Single and multiple Ascending Dose
478828|NCT00785915|Japanese volunteers
478829|NCT00785889|Colorectal cancer screening
478830|NCT00785889|optical colonoscopy
478831|NCT00785889|water method
478832|NCT00785889|sedation
478833|NCT00785876|Paediatric
478834|NCT00785876|Emergency Department
478835|NCT00785876|Ankle
478836|NCT00785876|Injury
478837|NCT00785876|Low risk ankle rule
478838|NCT00785863|hyperalgesia
478839|NCT00785863|remifentanil
478840|NCT00785863|ketorolac
478841|NCT00785863|parecoxib
478842|NCT00785863|COX-1 inhibitor
478843|NCT00785863|COX-2 inhibitor
478844|NCT00785837|Hydrotherapy
478845|NCT00785837|Perinatal Care
478846|NCT00785837|Neonatology
478847|NCT00785824|Lactation
478848|NCT00785824|Endocrine System Diseases
478849|NCT00785824|Musculoskeletal System Disease
478850|NCT00785824|Hormone
478851|NCT00785824|Physiological Properties
478852|NCT00785798|Relapsed Lymphomas
478853|NCT00785798|Refractory Lymphomas
478854|NCT00785785|Unresectable GIST
478855|NCT00785785|metastatic GIST
478856|NCT00785785|nilotinib
478857|NCT00785785|AMN107
478858|NCT00785785|imatinib
478859|NCT00785785|STI571
478860|NCT00785772|Gabapentin Pharmacokinetics
478861|NCT00785759|Alzheimer's Disease
478862|NCT00785746|elderly, balance, core, strength
478863|NCT00785733|asthma
478864|NCT00785707|sensorineural hearing loss
478865|NCT00785707|cochlear implant
478866|NCT00785668|Asthma
478867|NCT00785668|Allergy
478868|NCT00785668|Interleukin-4
478869|NCT00785668|Interleukin-13
478870|NCT00785668|IL-4
478871|NCT00785668|IL-13
478872|NCT00785668|Pharmacokinetics
478873|NCT00785668|Safety
478874|NCT00785668|Tolerability
478875|NCT00785668|Aerovance
478876|NCT00785668|dry powder
478877|NCT00785629|phosphorus
478878|NCT00785629|secondary hyperparathyroidism
478879|NCT00785629|vascular calcification
478880|NCT00785616|HIV
478881|NCT00785616|Adherence
478882|NCT00785616|MEMS
478883|NCT00785603|Depression
478884|NCT00785603|pain
478885|NCT00785603|CYP2D6
478886|NCT00785603|interactions
478887|NCT00785603|Pupillometry
478888|NCT00785603|Tramadol
478889|NCT00785603|Paroxetine
478890|NCT00785603|MR-ratio
478891|NCT00785564|T-wave memory
478892|NCT00785564|Sick Sinus Syndrome
478893|NCT00785551|male
478894|NCT00785551|female
478895|NCT00785551|pharmacokinetics
478896|NCT00785551|normal and impaired renal function
478897|NCT00785538|Tumors
478898|NCT00785538|Antibodies, Monoclonal
478899|NCT00785525|Healthy Unrelated Stem Cell Donors
478900|NCT00785512|nebivolol
478901|NCT00785512|Bystolic®
478902|NCT00785512|Hypertension
478903|NCT00785512|blood pressure
478904|NCT00785512|withdrawal
478905|NCT00785499|obesity
478906|NCT00785499|metabolic syndrome
478907|NCT00785499|milk components
478908|NCT00785499|casein
478909|NCT00785499|whey
478910|NCT00785499|children
478911|NCT00785499|adolescent
478912|NCT00785486|midazolam
478913|NCT00785486|drug interactions
478914|NCT00785486|cytochrome p450
478915|NCT00785447|Cardiopulmonary Resuscitation
478916|NCT00785447|Respiratory Physiology
478917|NCT00785447|Mouth to mouth ventilation
478918|NCT00785447|Mouth to nose ventilation
478919|NCT00785434|MDD
478920|NCT00785434|escitalopram
478921|NCT00785421|heparin
478922|NCT00785421|LMWH
478923|NCT00785421|pancreatic cancer
478924|NCT00785408|obesity
478925|NCT00785408|overweight
478926|NCT00785408|weight loss
478927|NCT00785408|Amylin
478928|NCT00785408|AC2307
478929|NCT00785382|Pain, Pregabalin, Lyrica, Breast surgery
478930|NCT00785369|skin disorders
478931|NCT00785369|skin cancer
478932|NCT00785369|melanoma
478933|NCT00785369|lentigo maligna
478934|NCT00785356|Uterine fibroids
478935|NCT00785356|Anemia
478936|NCT00785343|stroke
478937|NCT00785343|acute
478938|NCT00785343|arm
478939|NCT00785343|robot
478940|NCT00785343|therapy
478941|NCT00785343|arm paresis
478942|NCT00785330|rituximab
478943|NCT00785330|Non-Hodgkin's lymphoma
478944|NCT00785330|diffuse large B cell lymphoma
478945|NCT00785330|peripheral t cell lymphoma
478946|NCT00785330|graft-versus-host disease
478947|NCT00785330|graft-versus-lymphoma effect
478948|NCT00785330|allogeneic haematopoietic stem cell transplantation
478949|NCT00785330|relapsed or primary progressive aggressive Non-Hodgkin's lymphoma
478950|NCT00785317|Postmenopausal Hormone Replacement Therapy
478951|NCT00785278|Wheelchair Set-Up
478952|NCT00785278|Shoulder Joint Forces
478953|NCT00785278|Manual Wheelchair Users
478954|NCT00785278|Paraplegia
478955|NCT00785278|Upper Limb Pain
478956|NCT00785278|Secondary Injury to Spinal Cord Injury
478957|NCT00785278|Biomechanics
478958|NCT00785265|Live Donor Kidney Transplantation
478959|NCT00785265|LDKT
478960|NCT00785265|African Americans
478961|NCT00785265|Disparity
478962|NCT00785265|Education
478963|NCT00785252|Catheters, Indwelling
478964|NCT00785239|Malignant Airway Disease
478965|NCT00785239|Benign Airway Disease
478966|NCT00785239|Lung Cancer
478967|NCT00785239|Emphysema
478968|NCT00785239|Chronic Bronchitis
478969|NCT00785239|COPD
478970|NCT00785239|Asthma
478971|NCT00785239|Sarcoidosis
478972|NCT00785239|Mesothelioma
478973|NCT00785239|CryoSpray Ablation
478974|NCT00785239|Cryotherapy
478975|NCT00785239|Cryospray
478976|NCT00785239|Cryo
478977|NCT00785213|rosiglitazone
478978|NCT00785213|quinine sulfate
478979|NCT00785213|drug interactions
478980|NCT00785213|cytochrome p450
478981|NCT00785200|MRSA
478982|NCT00785200|Methicillin-resistant Staphylococcus aureus
478983|NCT00785200|Chlorhexidine
478984|NCT00785200|Asymptomatic colonization
478985|NCT00785200|Asymptomatic colonization, MRSA
478986|NCT00785200|Skin and soft tissue infections
478987|NCT00785187|UVB induced skin erythema
478988|NCT00785174|noninvasive ventilation, continuous posi
478989|NCT00785161|Penumbra System
478990|NCT00785161|Mechanical Thrombectomy
478991|NCT00785161|Ischemic Stroke
478992|NCT00785161|Intervention
478993|NCT00785161|Neurovascular
478994|NCT00785161|Thrombus
478995|NCT00785161|Imaging
478996|NCT00785161|Ischemic Penumbra
478997|NCT00785161|Functional Outcome
478998|NCT00785135|vision, binocular
478999|NCT00785135|vision disparity
479000|NCT00785135|headache
479001|NCT00785135|dizziness
479002|NCT00785135|anxiety
479003|NCT00785135|neck pain
479004|NCT00785135|learning disorders
479005|NCT00785135|asthenopia
479006|NCT00785135|motion sickness
479007|NCT00785135|depth perception
479008|NCT00785135|gait disorder
479009|NCT00785135|diplopia
479010|NCT00785135|photophobia
479011|NCT00785135|agoraphobia
479012|NCT00785135|panic disorder
479013|NCT00785122|cancer vaccine
479014|NCT00785109|aortic valve calcification
479015|NCT00785109|vitamin K supplementation
479016|NCT00785096|Perception, surgical complications, patients, nurses and physicians
479017|NCT00785083|Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume
479018|NCT00785070|Perioperative
479019|NCT00785070|Obstructive Sleep Apnea
479020|NCT00785070|Screening
479021|NCT00785070|Home Sleep Testing
479022|NCT00785057|Hypertension
479023|NCT00785057|Stroke
479024|NCT00785057|Neurology
479025|NCT00785057|JNC7
479026|NCT00785057|2007 ESH-ESC guidelines
479027|NCT00785057|survey
479028|NCT00785044|Heart Failure
479029|NCT00785044|MIBG
479030|NCT00785044|Meta-Iodobenzylguanidine
479031|NCT00785031|risk management
479032|NCT00785031|Self Management
479033|NCT00785031|Self-Efficacy
479034|NCT00785031|Disease management
479035|NCT00785031|nurse practitioner
479036|NCT00785031|internet
479037|NCT00785031|risk factors
479038|NCT00785031|vascular diseases
479039|NCT00785031|economic evaluation
479040|NCT00785018|Endotoxin
479041|NCT00785018|C1-inhibitor
479042|NCT00785018|Inflammation
479043|NCT00785018|Sepsis
479044|NCT00785018|Multi organ dysfunction syndrome
479045|NCT00785018|Complement activation
479046|NCT00785005|Diabetes
479047|NCT00785005|Exercise
479048|NCT00785005|Women
479049|NCT00785005|Research
479050|NCT00785005|Bike
479051|NCT00785005|Type
479052|NCT00785005|Control
479053|NCT00785005|Healthy
479054|NCT00784992|NLDO
479055|NCT00784992|DCR
479056|NCT00784992|silicone tubes
479057|NCT00784992|stent
479058|NCT00784979|Renal
479059|NCT00784979|Transplant
479060|NCT00784979|PRA
479061|NCT00784966|Islet transplantation
479062|NCT00784966|Type 1 Diabetes Mellitus
479063|NCT00784966|Kidney Transplantation
479064|NCT00784953|Symbicort SMART
479065|NCT00784953|budesonide
479066|NCT00784953|formoterol
479067|NCT00784953|ICS/LABA
479068|NCT00784953|Asthma Control Questionnaire
479069|NCT00784953|Not optimally controlled asthma
479070|NCT00784927|stage I grade 1 follicular lymphoma
479071|NCT00784927|contiguous stage II grade 1 follicular lymphoma
479072|NCT00784927|noncontiguous stage II grade 1 follicular lymphoma
479073|NCT00784927|stage III grade 1 follicular lymphoma
479074|NCT00784927|stage IV grade 1 follicular lymphoma
479075|NCT00784927|stage I grade 2 follicular lymphoma
479076|NCT00784927|contiguous stage II grade 2 follicular lymphoma
479077|NCT00784927|noncontiguous stage II grade 2 follicular lymphoma
479078|NCT00784927|stage III grade 2 follicular lymphoma
479079|NCT00784927|stage IV grade 2 follicular lymphoma
479080|NCT00784927|stage I small lymphocytic lymphoma
479081|NCT00784927|contiguous stage II small lymphocytic lymphoma
479082|NCT00784927|noncontiguous stage II small lymphocytic lymphoma
479083|NCT00784927|stage III small lymphocytic lymphoma
479084|NCT00784927|stage IV small lymphocytic lymphoma
479085|NCT00784927|Waldenstrom macroglobulinemia
479086|NCT00784927|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
479087|NCT00784927|nodal marginal zone B-cell lymphoma
479088|NCT00784927|splenic marginal zone lymphoma
479089|NCT00784927|stage I marginal zone lymphoma
479090|NCT00784927|contiguous stage II marginal zone lymphoma
479091|NCT00784927|noncontiguous stage II marginal zone lymphoma
479092|NCT00784927|stage III marginal zone lymphoma
479093|NCT00784927|stage IV marginal zone lymphoma
479094|NCT00784914|adult anaplastic astrocytoma
479095|NCT00784914|adult diffuse astrocytoma
479096|NCT00784914|adult craniopharyngioma
479097|NCT00784914|adult choroid plexus tumor
479098|NCT00784914|adult brain stem glioma
479099|NCT00784914|tumors metastatic to brain
479100|NCT00784914|recurrent adult brain tumor
479101|NCT00784914|adult gliosarcoma
479102|NCT00784914|adult giant cell glioblastoma
479103|NCT00784914|adult ependymoblastoma
479104|NCT00784914|adult medulloblastoma
479105|NCT00784914|adult supratentorial primitive neuroectodermal tumor (PNET)
479106|NCT00784914|adult anaplastic ependymoma
479107|NCT00784914|adult ependymoma
479108|NCT00784914|adult myxopapillary ependymoma
479109|NCT00784914|adult subependymoma
479110|NCT00784914|adult mixed glioma
479111|NCT00784914|meningeal melanocytoma
479112|NCT00784914|adult meningeal hemangiopericytoma
479113|NCT00784914|adult grade I meningioma
479114|NCT00784914|adult grade II meningioma
479115|NCT00784914|adult grade III meningioma
479116|NCT00784914|adult anaplastic oligodendroglioma
479117|NCT00784914|adult oligodendroglioma
479118|NCT00784914|adult pineoblastoma
479119|NCT00784914|adult pineocytoma
479120|NCT00784901|Macular Thickness Analyzed by Optical Coherence Tomography in Retinitis Pigmemtosa
479121|NCT00784888|aromatase inhibitor
479122|NCT00784888|quality of life
479123|NCT00784888|safety
479124|NCT00784888|postmenopausal breast cancer
479125|NCT00784849|Breast cancer
479126|NCT00784849|diagnostic
479127|NCT00784849|lymph nodes
479128|NCT00784836|Multiple Sclerosis - Relapsing
479129|NCT00784810|Efficacy, tolerability, moderate/severe, oxycodone/naloxone
479130|NCT00784810|codeine/paracetamol, chronic low back pain, osteoarthritis
479131|NCT00784784|antiviral drugs
479132|NCT00784784|influenza vaccines
479133|NCT00784771|Hypnotherapy
479134|NCT00784771|Hypnosis
479135|NCT00784771|PTSD
479136|NCT00784758|Asthma
479137|NCT00784758|Lung Diseases
479138|NCT00784758|Respiratory Tract Diseases
479139|NCT00784745|incretin effect
479140|NCT00784745|type 2 diabetes
479141|NCT00784745|GLP-1
479142|NCT00784745|GIP
479143|NCT00784745|dexamethasone
479144|NCT00784732|Seasonal Allergic Rhinitis
479145|NCT00784732|Environmental Exposure Chamber
479146|NCT00784732|nasal lavage
479147|NCT00784719|Dry eye
479148|NCT00784706|stroke rehabilitation
479149|NCT00784706|perceptual deficits
479150|NCT00784706|kinematic analysis
479151|NCT00784693|Endometriosis
479152|NCT00784693|pain
479153|NCT00784693|tanezumab
479154|NCT00784693|nerve growth factor
479155|NCT00784693|questionnaires
479156|NCT00784667|Colorectal neoplasm
479157|NCT00784667|Metastasis
479158|NCT00784615|Phenotypes of Polycystic Ovary Syndrome
479159|NCT00784615|Cardiovascular risk factors
479160|NCT00784615|Adiponectin
479161|NCT00784615|C Reactive Protein
479162|NCT00784602|prolapse
479163|NCT00784602|pelvic organ prolapse
479164|NCT00784589|Corticothérapy
479165|NCT00784589|Rituximab
479166|NCT00784589|therapeutic efficacity
479167|NCT00784589|therapeutic tolerance
479168|NCT00784576|Delirium
479169|NCT00784576|Cardiac Surgery
479170|NCT00784576|Depression
479171|NCT00784576|Cognitive Impairment
479172|NCT00784576|Diagnostic Criteria for Delirium
479173|NCT00784576|Memorial Delirium Assessment Scale
479174|NCT00784576|Delirium Index
479175|NCT00784563|Parkinson Disease
479176|NCT00784563|Exercise/*physiology
479177|NCT00784563|*Physical Fitness
479178|NCT00784563|Rehabilitation
479179|NCT00784563|Cognition
479180|NCT00784550|Spirometry
479181|NCT00784550|COPD
479182|NCT00784537|Hodgkin's lymphoma
479183|NCT00784537|ABVD
479184|NCT00784537|FDG-PET (18-Fluoro-deoxy-D-glucose Positron Emission Tomography)
479185|NCT00784537|Radiotherapy
479186|NCT00784524|stage IV breast cancer
479187|NCT00784524|recurrent breast cancer
479188|NCT00784524|metastatic breast cancer
479189|NCT00784511|diabetes
479190|NCT00784511|vitamin D
479191|NCT00784511|African Americans
479192|NCT00784511|overweight
479193|NCT00784511|insulin sensitivity
479194|NCT00784511|glucose control
479195|NCT00784498|Procedural sedation and analgesia
479196|NCT00784498|Emergency Department
479197|NCT00784498|propofol versus ketamine and midazolam
479198|NCT00784498|painful orthopedic manipulations
479199|NCT00784485|Asthma
479200|NCT00784485|Respiratory Tract Diseases
479201|NCT00784485|Lung Diseases
479202|NCT00784485|Dyspnea
479203|NCT00784472|PCNL
479204|NCT00784472|oxycodone
479205|NCT00784472|morphine
479206|NCT00784472|visceral pain
479207|NCT00784459|Asthma
479208|NCT00784459|Allergy
479209|NCT00784446|AIO
479210|NCT00784446|colorectal cancer
479211|NCT00784446|0205
479212|NCT00784446|Capecitabine
479213|NCT00784446|Oxaliplatin
479214|NCT00784446|Bevacizumab
479215|NCT00784446|Imatinib
479216|NCT00784433|alcohol diabetes CVD
479217|NCT00784420|Drug Interaction, Pharmacokinetics
479218|NCT00784407|thyroid surgery
479219|NCT00784407|total thyroidectomy
479220|NCT00784407|harmonic scalpel
479221|NCT00784381|Renal failure
479222|NCT00784381|Elderly
479223|NCT00784381|Drug Therapy Computer-Assisted
479224|NCT00784381|Quality of care
479225|NCT00784381|Patients With Impaired Renal Function
479226|NCT00784381|Inappropriateness of target drug prescribed
479227|NCT00784368|Mycoses
479228|NCT00784368|Candidiasis
479229|NCT00784368|Aspergillosis
479230|NCT00784368|Cryptococcosis
479231|NCT00784368|Blastomycosis
479232|NCT00784368|Histoplasmosis
479233|NCT00784368|Neutropenia
479234|NCT00784368|Itraconazole
479235|NCT00784368|JK1211
479236|NCT00784355|recurrence of idiopathic pancreatitis
479237|NCT00784355|laparoscopic cholecystectomy
479238|NCT00784355|etiology of pancreatitis
479239|NCT00784342|COPD
479240|NCT00784329|Lung Cancer
479241|NCT00784329|Squamous Cell Lung Cancer
479242|NCT00784329|Bronchial carcinoma in situ
479243|NCT00784329|Central Airway Diseases
479244|NCT00784316|Prevention
479245|NCT00784303|Thyroid Cancer
479246|NCT00784277|Pain medication
479247|NCT00784277|Arthritis
479248|NCT00784277|Joint pain
479249|NCT00784277|Analgesia
479250|NCT00784277|Analgesics
479251|NCT00784277|tapentadol
479252|NCT00784277|CG5503
479253|NCT00784277|Nucynta
479254|NCT00784264|Asymptomatic atherosclerosis
479255|NCT00784264|Intima media thickness (IMT)
479256|NCT00784264|central obesity
479257|NCT00784264|cardiovascular disease
479258|NCT00784251|Pain
479259|NCT00784251|Leg pain
479260|NCT00784251|Back pain
479261|NCT00784251|PROMIS
479262|NCT00784238|Schizophrenia
479263|NCT00784238|Paliperidone Extended-release
479264|NCT00784238|Paliperidone
479265|NCT00784238|R076477
479266|NCT00784225|cataract
479267|NCT00784225|advanced macular degeneration
479268|NCT00784212|Photosensitive Epilepsy, photic stimulation, electroencephalogram
479269|NCT00784199|MDD
479270|NCT00784199|Depression
479271|NCT00784186|Pregnancy termination
479272|NCT00784186|abortion
479273|NCT00784186|medical abortion
479274|NCT00784186|2nd trimester
479275|NCT00784186|mifepristone
479276|NCT00784186|misoprostol
479277|NCT00784173|Syndrome
479278|NCT00784173|Velocardiofacial
479279|NCT00784173|Middle ear
479280|NCT00784173|Inner ear
479281|NCT00784173|Malformation
479282|NCT00784147|HIV
479283|NCT00784147|CD4
479284|NCT00784147|experienced
479285|NCT00784147|resistant
479286|NCT00784147|resistance
479287|NCT00784147|monoclonal
479288|NCT00784147|antibody
479289|NCT00784147|infusion
479290|NCT00784147|ibalizumab
479291|NCT00784147|TNX355
479292|NCT00784147|TNX-355
479293|NCT00784147|TMB355
479294|NCT00784147|TMB-355
479295|NCT00784134|intraventricular hemorrhage thrombolysis
479296|NCT00784095|quality of life
479297|NCT00784082|Sickle cell disease, hydroxyurea, inflammation
479298|NCT00784043|Cochlear implant
479299|NCT00784043|hearing loss
479300|NCT00784030|Autosomal Dominant Polycystic Kidney Disease
479301|NCT00784030|Polycystic Kidney Disease
479302|NCT00784030|Water Loading
479303|NCT00784030|Biomarkers
479304|NCT00784017|Children with previously untreated acute lymphoblastic leukemia
479305|NCT00784004|breathing patterns,
479306|NCT00784004|unidirectional breathing,
479307|NCT00784004|mask ventilation,
479308|NCT00784004|respiratory physiology
479309|NCT00783991|IVF
479310|NCT00783991|PDA
479311|NCT00783991|PC
479312|NCT00783991|CAT
479313|NCT00783991|COPD
479314|NCT00783991|MDD
479315|NCT00783991|RA
479316|NCT00783978|Surfactant protein C
479317|NCT00783978|Interstitial
479318|NCT00783978|lung
479319|NCT00783978|Children
479320|NCT00783965|nevoid basal cell carcinoma syndrome
479321|NCT00783965|basal cell carcinoma of the skin
479322|NCT00783952|Mixed venous oxygen saturation
479323|NCT00783952|Tissue oxygenation
479324|NCT00783952|Near infrared spectroscopy
479325|NCT00783913|Direct Current Stimulation
479326|NCT00783913|Rehabilitation
479327|NCT00783913|Motor Learning
479328|NCT00783913|Stroke
479329|NCT00783900|Prevention
479330|NCT00783887|Cilia
479331|NCT00783887|Axoneme
479332|NCT00783887|Dynein
479333|NCT00783887|Gene
479334|NCT00783887|Ultrastructure
479335|NCT00783887|Linkage analysis
479336|NCT00783848|CHF
479337|NCT00783835|Attention Deficit Hyperactivity Disorder
479338|NCT00783835|Methylphenidate
479339|NCT00783835|Concerta
479340|NCT00783835|CONQoL
479341|NCT00783822|breast neoplasms
479342|NCT00783822|genetic counseling
479343|NCT00783809|intracranial pressure
479344|NCT00783809|intracranial hypertension
479345|NCT00783809|ultrasound
479346|NCT00783809|emergency
479347|NCT00783809|traumatic brain injury
479348|NCT00783809|ocular ultrasound
479349|NCT00783796|Coronary artery disease
479350|NCT00783796|Atherosclerosis
479351|NCT00783796|Myocardial ischemia
479352|NCT00783783|Psychiatric disorders
479353|NCT00783783|Neurodevelopmental disorders
479354|NCT00783783|Autism
479355|NCT00783783|Risperidone
479356|NCT00783783|Pharmacogenetics
479357|NCT00783783|Pharmacokinetics
479358|NCT00783770|Breastfeeding
479359|NCT00783770|Infant
479360|NCT00783770|Preterm
479361|NCT00783770|Nutrition
479362|NCT00783757|neo-adjuvant chemotherapy
479363|NCT00783757|TOBI
479364|NCT00783757|breast imaging
479365|NCT00783757|optical imaging
479366|NCT00783731|intubation
479367|NCT00783679|Cardiac output
479368|NCT00783679|Noninvasive cardiac output measurement
479369|NCT00783679|Thermodilution
479370|NCT00783653|AML
479371|NCT00783653|FLT3
479372|NCT00783653|acute myeloid leukemia
479373|NCT00783653|FLT 3 inhibitor
479374|NCT00783653|FLT3 mutated AML
479375|NCT00783627|Endothelium
479376|NCT00783627|progenitors
479377|NCT00783627|stem cells
479378|NCT00783627|sickle cell
479379|NCT00783614|HIV
479380|NCT00783614|Cardiovascular Disease
479381|NCT00783614|Endothelial Dysfunction
479382|NCT00783601|Chronic Asthma
479383|NCT00783588|Chronic lymphocytic leukemia
479384|NCT00783588|CLL
479385|NCT00783588|Leukemia
479386|NCT00783588|Leukemia, Lymphocytic, Chronic, B-Cell
479387|NCT00783588|Leukemia, B-Cell
479388|NCT00783588|Immune System Diseases
479389|NCT00783588|ISF35
479390|NCT00783588|Ad-ISF35
479391|NCT00783588|Immunotherapy
479392|NCT00783588|Immune therapy
479393|NCT00783588|Active immune therapy
479394|NCT00783575|Crohn's disease
479395|NCT00783575|Ulcerative colitis
479396|NCT00783575|Inflammatory bowel disease
479397|NCT00783575|NOD2,CARD 15 mutations
479398|NCT00783562|Low back pain
479399|NCT00783562|Neck pain
479400|NCT00783562|Functional disability
479401|NCT00783562|Nursery school teachers
479402|NCT00783562|Exercise program
479403|NCT00783562|Prevention
479404|NCT00783549|tolerability
479405|NCT00783549|pharmacodynamics
479406|NCT00783549|pharmacokinetics
479407|NCT00783549|safety
479408|NCT00783536|An randomized, open label, multicenter study to compare the ef
479409|NCT00783510|Polyarticular JIA
479410|NCT00783510|Juvenile Arthritis
479411|NCT00783510|Juvenile Idiopathic Arthritis
479412|NCT00783510|JIA
479413|NCT00783510|Polyarticular-course JIA
479414|NCT00783497|High Blood Pressure
479415|NCT00783497|Stress
479416|NCT00783484|First in Human (FIH), PF-03716539, PK enhancer
479417|NCT00783445|Metabolic Cardiovascular Syndrome
479418|NCT00783445|Metabolic Syndrome
479419|NCT00783445|Obesity
479420|NCT00783445|Hyperglycemia
479421|NCT00783419|tubo-ovarian abscess, pelvic-inflammatory disease
479422|NCT00783406|COPD
479423|NCT00783380|Influenza vaccination
479424|NCT00783380|Subunit
479425|NCT00783380|Virosomal
479426|NCT00783380|HIV/AIDS
479427|NCT00783380|Renal Dialysis
479428|NCT00783380|Kidney transplantation
479429|NCT00783380|Rheumatologic diseases
479430|NCT00783380|Immunogenicity
479431|NCT00783380|Reactogenicity
479432|NCT00783367|Revlimid
479433|NCT00783367|Celgene brand of lenalidomide
479434|NCT00783367|lenalidomide
479435|NCT00783367|Rituxan
479436|NCT00783367|CD20 antibody, rituximab
479437|NCT00783367|rituximab
479438|NCT00783367|Follicular Lymphoma
479439|NCT00783367|Marginal Zone B-Cell Lymphoma
479440|NCT00783367|Lymphoma, Small Lymphocytic
479441|NCT00783367|Waldenstrom Macroglobulinemia
479442|NCT00783367|Mantle-Cell Lymphoma
479443|NCT00783367|Antigens, CD20
479444|NCT00783367|refractory
479569|NCT00782743|Need for new anticoagulation treatment
479445|NCT00783367|resistantRefractory/progressive lymphoma less than 6 months from first rituximab dose of previous rituximab-containing regimen
479446|NCT00783367|Previously treated
479447|NCT00783367|Treated with rituximab
479448|NCT00783328|solid tumor
479449|NCT00783315|Hypertension
479450|NCT00783315|Diabetes
479451|NCT00783315|Hypercholesterolemia
479452|NCT00783302|CAD
479453|NCT00783302|Visipaque
479454|NCT00783302|CCTA
479455|NCT00783250|COPD
479456|NCT00783250|Respiratory Mechanics
479457|NCT00783250|Bronchodilators
479458|NCT00783250|COPD patients with poor reversibility
479459|NCT00783185|psychotic disorders
479460|NCT00783185|cannabis
479461|NCT00783185|intervention
479462|NCT00783172|pancreas
479463|NCT00783172|pancreatic cancer
479464|NCT00783172|cancer
479465|NCT00783172|Opioid Growth Factor
479466|NCT00783172|OGF
479467|NCT00783172|gemcitabine
479468|NCT00783172|chemotherapy
479469|NCT00783159|Muscle power
479470|NCT00783159|Frailty
479471|NCT00783159|Exercise
479472|NCT00783159|Vitamin D
479473|NCT00783120|schizophrenia, negative symptoms, TMS, magnetic stimulation
479474|NCT00783107|Gold Stage III COPD
479475|NCT00783081|Intermittent Claudication
479476|NCT00783081|Peripheral Arterial Disease
479477|NCT00783068|Endotoxin
479478|NCT00783068|GTS-21
479479|NCT00783068|Vagal activity
479480|NCT00783068|Autonomic balance
479481|NCT00783055|Autonomy
479482|NCT00783055|Older people
479483|NCT00783055|Physically frail
479484|NCT00783055|Nursing home
479485|NCT00783055|Intervention study
479486|NCT00783042|TTDE-CFR
479487|NCT00783042|coronary artery function
479488|NCT00783042|cardiovascular biomarkers
479489|NCT00783042|rosuvastatin
479490|NCT00783042|Crestor
479491|NCT00783029|Vasodilation
479492|NCT00783029|Vessel Reactivity
479493|NCT00783029|Dynamic Vessel Analyzer
479494|NCT00783029|Retina
479495|NCT00783016|appendicitis
479496|NCT00783016|diagnosis
479497|NCT00783003|Tolerability
479498|NCT00783003|Muscarinic Receptor Antagonist, Anticholinergic
479499|NCT00783003|Safety
479500|NCT00783003|Anticholinergic
479501|NCT00783003|ß2 agonist
479502|NCT00783003|Pharmacokinetics
479503|NCT00782990|stress urinary incontinence
479504|NCT00782990|female incontinence
479505|NCT00782990|surgical treatment
479506|NCT00782990|Female stress urinary incontinence
479507|NCT00782977|Apneic oxygenation
479508|NCT00782977|Apneic diffusion oxygenation
479509|NCT00782964|Depression
479510|NCT00782964|Major Depressive Disorder
479511|NCT00782964|SSRI resistant depression
479512|NCT00782964|strategies in depression
479513|NCT00782925|Low back pain
479514|NCT00782925|recurrence
479515|NCT00782925|chronic low back pain
479516|NCT00782925|educational program
479517|NCT00782925|physical therapy
479518|NCT00782925|home exercise
479519|NCT00782925|compliance
479520|NCT00782912|postpartum anemia, postpartum depression
479521|NCT00782899|Schizophrenia
479522|NCT00782899|subjective well-being
479523|NCT00782899|depressive symptoms
479524|NCT00782899|schizophrenia course
479525|NCT00782886|Pathfinder
479526|NCT00782886|Liver
479527|NCT00782886|Resection
479528|NCT00782886|Surgery
479529|NCT00782886|To evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.
479530|NCT00782886|Completeness of resection and the accuracy of the resection, as determined by preoperative predicted RLV
479531|NCT00782873|propofol
479532|NCT00782873|sedation
479533|NCT00782873|safety
479534|NCT00782873|obesity
479535|NCT00782860|Early pregnancy failure
479536|NCT00782860|Misoprostol
479537|NCT00782860|Gestational sac volume
479538|NCT00782847|diabetes mellitus
479539|NCT00782847|diabetic nephropathy
479540|NCT00782847|hypertension
479541|NCT00782834|GIST
479542|NCT00782834|Nilotinib
479543|NCT00782821|Kidney
479544|NCT00782821|Renal
479545|NCT00782821|Rejection
479546|NCT00782821|High risk
479547|NCT00782821|Induction
479548|NCT00782821|Immunology
479549|NCT00782821|Transplantation
479550|NCT00782821|B Cell
479551|NCT00782821|Allograft
479552|NCT00782821|Desensitization
479553|NCT00782808|HIV DNA in Monocytes
479554|NCT00782795|Chronic pancreatitis
479555|NCT00782795|Insulin resistance
479556|NCT00782756|Radiation
479557|NCT00782756|BEVACIZUMAB
479558|NCT00782756|AVASTIN
479559|NCT00782756|TEMOZOLOMIDE
479560|NCT00782756|newly diagnosed
479561|NCT00782756|Glioblastoma
479562|NCT00782756|GBM
479563|NCT00782756|malignant glioma
479564|NCT00782756|Radiotherapy
479565|NCT00782756|08-126
479566|NCT00782743|phenprocoumon
479567|NCT00782743|anticoagulation
479568|NCT00782743|acetylic salicylic acid
479570|NCT00782730|bladder volume measurement
479571|NCT00782730|pregnancy
479572|NCT00782730|bladder function
479573|NCT00782730|Postvoid residual volume assessment
479574|NCT00782730|Bladder volumes
479575|NCT00782717|diabetic retinopathy
479576|NCT00782717|cystoid macular edema;
479577|NCT00782704|A self-administered questionnaire to collect data from patients, physicians and nurses about the severity of postoperative surgical complications.
479578|NCT00782704|Based on this questionnaire we will develop the morbidity index
479579|NCT00782691|FDG-PET segmentation tools
479580|NCT00782691|Head-and-neck cancer
479581|NCT00782691|Histological validation
479582|NCT00782665|postoperative
479583|NCT00782665|infection
479584|NCT00782665|c-section
479585|NCT00782652|myocaridal infarction
479586|NCT00782652|right ventricular infarction
479587|NCT00782652|cardiogenic shock
479588|NCT00782652|RVAD
479589|NCT00782652|Right ventricular assist device
479590|NCT00782652|cardiac disease
479591|NCT00782652|right ventricle
479592|NCT00782652|cardiac shock
479593|NCT00782652|heart dysfunction
479594|NCT00782626|RAD001
479595|NCT00782613|Psoriasis
479596|NCT00782613|The primary objective of this study will be to evaluate the
479597|NCT00782613|efficacy of topical ALT-2074 applied twice daily for 28
479598|NCT00782613|days for treatment of chronic plaque psoriasis in adult
479599|NCT00782613|subjects.
479600|NCT00782613|The secondary objective will be to evaluate the safety
479601|NCT00782613|of topical ALT-2074 applied twice daily for 28 days for
479602|NCT00782613|treatment of chronic plaque psoriasis in adult subjects.
479603|NCT00782613|Tertiary objectives will be to provide visual documentation
479604|NCT00782613|of the improvement of psoriatic plaques treated with
479605|NCT00782613|ALT-2074 using digital photography, and to determine the
479606|NCT00782613|extent of systemic absorption of topically applied ALT-2074
479607|NCT00782613|based on a pharmacokinetic measurement of blood
479608|NCT00782613|concentration.
479609|NCT00782600|Pharmacokinetics Immediate Release Oral Suspension Controlled Release Formulation
479610|NCT00782587|Non-Muscle-Invasive Bladder Cancer
479611|NCT00782587|Superficial Bladder Cancer
479612|NCT00782587|recombinant human hyaluronidase
479613|NCT00782587|rHuPH20
479614|NCT00782587|Chemophase®
479615|NCT00782587|Mitomycin
479616|NCT00782574|Advanced solid tumours
479617|NCT00782574|Poly(ADP ribose) polymerases
479618|NCT00782574|homologous deficiency
479619|NCT00782574|BRCA1
479620|NCT00782561|steroid resistant focal segmental glomerulosclerosis
479621|NCT00782561|FSGS
479622|NCT00782561|adolescent focal segmental glomerulosclerosis
479623|NCT00782561|focal segmental glomerulosclerosis
479624|NCT00782548|KADIAN
479625|NCT00782548|morphine
479626|NCT00782548|Avinza
479627|NCT00782548|30 mg
479628|NCT00782548|bioequivalence
479629|NCT00782548|fed
479630|NCT00782483|Diagnosis
479631|NCT00782483|Port Wine Stain
479632|NCT00782483|PWS
479633|NCT00782405|antidepressant action
479634|NCT00782405|clinical psychopharmacology
479635|NCT00782392|Nutrition
479636|NCT00782392|Infant Formula
479637|NCT00782379|stage III adult diffuse large cell lymphoma
479638|NCT00782379|stage III adult diffuse mixed cell lymphoma
479639|NCT00782379|stage III adult diffuse small cleaved cell lymphoma
479640|NCT00782379|stage III adult Hodgkin lymphoma
479641|NCT00782379|stage III adult lymphoblastic lymphoma
479642|NCT00782379|stage III grade 1 follicular lymphoma
479643|NCT00782379|stage III grade 2 follicular lymphoma
479644|NCT00782379|stage III grade 3 follicular lymphoma
479645|NCT00782379|stage III mantle cell lymphoma
479646|NCT00782379|stage IV adult diffuse large cell lymphoma
479647|NCT00782379|stage IV adult diffuse mixed cell lymphoma
479648|NCT00782379|stage IV adult diffuse small cleaved cell lymphoma
479649|NCT00782379|stage IV adult Hodgkin lymphoma
479650|NCT00782379|stage IV adult lymphoblastic lymphoma
479651|NCT00782379|stage IV grade 1 follicular lymphoma
479652|NCT00782379|stage IV grade 2 follicular lymphoma
479653|NCT00782379|stage IV grade 3 follicular lymphoma
479654|NCT00782379|stage IV mantle cell lymphoma
479655|NCT00782379|recurrent adult diffuse large cell lymphoma
479656|NCT00782379|recurrent adult diffuse mixed cell lymphoma
479657|NCT00782379|recurrent adult diffuse small cleaved cell lymphoma
479658|NCT00782379|recurrent adult Hodgkin lymphoma
479659|NCT00782379|recurrent grade 1 follicular lymphoma
479660|NCT00782379|recurrent grade 2 follicular lymphoma
479661|NCT00782379|recurrent grade 3 follicular lymphoma
479662|NCT00782379|recurrent mantle cell lymphoma
479663|NCT00782379|noncontiguous stage II adult diffuse large cell lymphoma
479664|NCT00782379|noncontiguous stage II adult diffuse mixed cell lymphoma
479665|NCT00782379|noncontiguous stage II adult diffuse small cleaved cell lymphoma
479666|NCT00782379|noncontiguous stage II adult lymphoblastic lymphoma
479667|NCT00782379|noncontiguous stage II grade 1 follicular lymphoma
479668|NCT00782379|noncontiguous stage II grade 2 follicular lymphoma
479669|NCT00782379|noncontiguous stage II grade 3 follicular lymphoma
479670|NCT00782379|noncontiguous stage II mantle cell lymphoma
479903|NCT00781573|Drug Eluting Stent
479671|NCT00782379|accelerated phase chronic myelogenous leukemia
479672|NCT00782379|adult acute lymphoblastic leukemia in remission
479673|NCT00782379|adult acute myeloid leukemia in remission
479674|NCT00782379|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
479675|NCT00782379|adult acute myeloid leukemia with inv(16)(p13;q22)
479676|NCT00782379|adult acute myeloid leukemia with t(15;17)(q22;q12)
479677|NCT00782379|adult acute myeloid leukemia with t(16;16)(p13;q22)
479678|NCT00782379|adult acute myeloid leukemia with t(8;21)(q22;q22)
479679|NCT00782379|chronic myelomonocytic leukemia
479680|NCT00782379|chronic phase chronic myelogenous leukemia
479681|NCT00782379|recurrent adult acute myeloid leukemia
479682|NCT00782379|refractory chronic lymphocytic leukemia
479683|NCT00782379|relapsing chronic myelogenous leukemia
479684|NCT00782379|secondary acute myeloid leukemia
479685|NCT00782379|stage III chronic lymphocytic leukemia
479686|NCT00782379|stage IV chronic lymphocytic leukemia
479687|NCT00782379|de novo myelodysplastic syndromes
479688|NCT00782379|previously treated myelodysplastic syndromes
479689|NCT00782379|secondary myelodysplastic syndromes
479690|NCT00782379|prolymphocytic leukemia
479691|NCT00782366|predictive genomics
479692|NCT00782366|personalized medicine
479693|NCT00782366|personal genomics
479694|NCT00782366|direct-to-consumer genetic testing
479695|NCT00782366|genetic knowledge
479696|NCT00782366|genetic attitudes
479697|NCT00782353|HCV
479698|NCT00782340|NOH
479699|NCT00782340|Neurogenic Orthostatic Hypotension
479700|NCT00782340|Orthostatic hypotension
479701|NCT00782340|PAF
479702|NCT00782340|Pure Autonomic Failure
479703|NCT00782340|MSA
479704|NCT00782340|Multiple System Atrophy
479705|NCT00782340|Neuropathy
479706|NCT00782340|Autonomic Failure
479707|NCT00782340|Parkinson
479708|NCT00782340|Dopamine Deficiency
479709|NCT00782340|Dopamine
479710|NCT00782340|Droxidopa
479711|NCT00782314|asthma
479712|NCT00782314|SMART
479713|NCT00782314|Symbicort Turbuhaler
479714|NCT00782314|asthma control
479715|NCT00782301|HIV and Hepatitis co-infection
479716|NCT00782288|digitoxin
479717|NCT00782288|inflammatory markers
479718|NCT00782288|cytokines
479719|NCT00782288|gene expression
479720|NCT00782275|RCC
479721|NCT00782275|avastin
479722|NCT00782275|temsirolimus
479723|NCT00782223|hips, spine, lower limb, digital radiograph measurements, TraumaCad, digital software
479724|NCT00782223|Measurements of orthopaedic parameters on digital X-rays using particular software
479725|NCT00782197|osteoarthritis
479726|NCT00782197|knee
479727|NCT00782197|PRGF
479728|NCT00782197|autologous plasma
479729|NCT00782197|plasma preparations
479730|NCT00782197|treatment
479731|NCT00782171|Dental implants
479732|NCT00782158|HIV
479733|NCT00782158|Hepatitis B
479734|NCT00782158|Coinfection
479735|NCT00782158|Liver Fibrosis
479736|NCT00782158|Transient Elastography
479737|NCT00782145|psychosocial effects of cancer and its treatment
479738|NCT00782145|recurrent childhood large cell lymphoma
479739|NCT00782145|recurrent childhood lymphoblastic lymphoma
479740|NCT00782145|recurrent childhood small noncleaved cell lymphoma
479741|NCT00782145|recurrent/refractory childhood Hodgkin lymphoma
479742|NCT00782145|accelerated phase chronic myelogenous leukemia
479743|NCT00782145|atypical chronic myeloid leukemia, BCR-ABL negative
479744|NCT00782145|blastic phase chronic myelogenous leukemia
479745|NCT00782145|childhood acute lymphoblastic leukemia in remission
479746|NCT00782145|childhood acute myeloid leukemia in remission
479747|NCT00782145|childhood chronic myelogenous leukemia
479748|NCT00782145|chronic myelomonocytic leukemia
479749|NCT00782145|chronic phase chronic myelogenous leukemia
479750|NCT00782145|juvenile myelomonocytic leukemia
479751|NCT00782145|recurrent childhood acute lymphoblastic leukemia
479752|NCT00782145|recurrent childhood acute myeloid leukemia
479753|NCT00782145|relapsing chronic myelogenous leukemia
479754|NCT00782145|secondary acute myeloid leukemia
479755|NCT00782145|childhood myelodysplastic syndromes
479756|NCT00782145|primary myelofibrosis
479757|NCT00782145|de novo myelodysplastic syndromes
479758|NCT00782145|disseminated neuroblastoma
479759|NCT00782145|myelodysplastic/myeloproliferative neoplasm, unclassifiable
479760|NCT00782145|previously treated childhood rhabdomyosarcoma
479761|NCT00782145|previously treated myelodysplastic syndromes
479762|NCT00782145|recurrent childhood rhabdomyosarcoma
479763|NCT00782145|recurrent neuroblastoma
479764|NCT00782145|recurrent ovarian germ cell tumor
479765|NCT00782145|secondary myelodysplastic syndromes
479766|NCT00782132|Infertility Services, HIV, pregnancy planning
479767|NCT00782093|AMD
479768|NCT00782080|ADHD
479769|NCT00782080|children
479770|NCT00782080|adolescents
479771|NCT00782080|St. John`s Wort
479772|NCT00782080|Valerian extract
479773|NCT00782080|Safety
479774|NCT00782080|Efficacy
479775|NCT00782067|Aggressive systemic mastocytosis
479776|NCT00782067|mast cell leukemia
479777|NCT00782067|C-Findings
479778|NCT00782067|tyrosine kinase inhibitor
479779|NCT00782067|KIT mutation
479780|NCT00782067|AHNMD
479781|NCT00782067|Systemic
479782|NCT00782067|Aggressive
479783|NCT00782054|pruritus
479784|NCT00782054|itch
479785|NCT00782054|burn
479786|NCT00782054|endopeptidase
479787|NCT00782054|moisturizer
479788|NCT00782054|randomized controlled
479789|NCT00782028|primary care, high-risk families, maternal depression
479790|NCT00782015|almonds
479791|NCT00782015|heart disease
479792|NCT00782015|vascular reactivity
479793|NCT00782015|inflammation
479794|NCT00782015|dyslipidemia
479795|NCT00782015|oxidative stress
479796|NCT00782002|Solid Tumors
479797|NCT00782002|VEGF-A
479798|NCT00782002|stromal cells
479799|NCT00782002|endothelial cells
479800|NCT00782002|malignant cells
479801|NCT00781989|early rheumatoid arthritis
479802|NCT00781989|biomarkers
479803|NCT00781989|ultrasound
479804|NCT00781963|cognitive behavior therapy
479805|NCT00781963|insomnia
479806|NCT00781950|PAD
479807|NCT00781950|Peripheral Arterial Disease
479808|NCT00781950|Diabetes
479809|NCT00781950|Atherosclerosis
479810|NCT00781950|Flax
479811|NCT00781950|Flaxseeds
479812|NCT00781950|Functional Foods
479813|NCT00781950|Essential Fatty Acids
479814|NCT00781950|Winnipeg
479815|NCT00781911|Islet Cell
479816|NCT00781911|CARCINOMA, ISLET CELL
479817|NCT00781911|Octreotide
479818|NCT00781911|depot octreotide acetate
479819|NCT00781911|Insulin-Like Growth Factor (IGF) 1
479820|NCT00781911|Metastatic, Carcinoid or Islet Cell
479821|NCT00781911|Neuroendocrine Tumors
479822|NCT00781898|Depot naltrexone
479823|NCT00781898|Parolees
479824|NCT00781898|Opioid addiction prevention
479825|NCT00781898|Medication Treatment Alternatives
479826|NCT00781898|Prevention of Relapse to Opioid Addiction
479827|NCT00781872|multiple sclerosis (MS)
479828|NCT00781872|bone marrow stromal cells
479829|NCT00781872|stem cells
479830|NCT00781833|Therapeutic Electric Stimulation
479831|NCT00781833|Functional Electric Stimulation
479832|NCT00781833|Implantable Stimulator
479833|NCT00781833|Muscle Strength
479834|NCT00781833|Muscle Spasticity
479835|NCT00781820|Bifonazole
479836|NCT00781820|Placebo
479837|NCT00781820|Urea
479838|NCT00781820|Nail fungus
479839|NCT00781807|Heart-Assist-Devices
479840|NCT00781807|Rehabilitation
479841|NCT00781807|Outcome Assessment (Health Care)
479842|NCT00781807|Exercise Capacity
479843|NCT00781807|Ergometry
479844|NCT00781807|Social Support
479845|NCT00781807|Quality of Life
479846|NCT00781807|Nutrition Assessment
479847|NCT00781807|Nutrition Therapy
479848|NCT00781807|Neuropsychological Tests
479849|NCT00781781|Myeloid and Lymphoid malignances
479850|NCT00781768|Bone Marrow Transplant
479851|NCT00781768|Nausea
479852|NCT00781768|Vomiting
479853|NCT00781768|NK-1 antagonist
479854|NCT00781768|Nausea and vommitting in the stem cell/marrow transplant population.
479855|NCT00781755|smoking cessation
479856|NCT00781755|varenicline
479857|NCT00781755|schizophrenia
479858|NCT00781755|serious mental illness
479859|NCT00781755|Nicotine addiction
479860|NCT00781755|Smoking Behavior
479861|NCT00781742|Depression
479862|NCT00781742|Depressive Disorder
479863|NCT00781742|MDD
479864|NCT00781729|Kyphosis
479865|NCT00781729|Yoga
479866|NCT00781729|Aging
479867|NCT00781729|Physical performance
479868|NCT00781729|Quality of Life
479869|NCT00781716|ST elevation myocardial infarction
479870|NCT00781716|Drug eluting stents
479871|NCT00781690|Chronic kidney failure
479872|NCT00781690|Heparin
479873|NCT00781690|Hemodialysis
479874|NCT00781690|Biocompatibility
479875|NCT00781677|Major Depressive Disorder
479876|NCT00781677|Depression
479877|NCT00781677|Anxiety
479878|NCT00780793|Rheumatoid arthritis
479879|NCT00780793|Remission
479880|NCT00780793|Therapeutic strategy
479881|NCT00780793|DMARDs
479882|NCT00780793|Biological agents
479883|NCT00780780|triamcinolone
479884|NCT00780780|nepafenac
479885|NCT00780780|DME
479886|NCT00780780|edema macular
479887|NCT00781638|Pediatric UC, Adacolumn apheresis
479888|NCT00781625|probiotics
479889|NCT00781625|QoL
479890|NCT00781625|inflammation
479891|NCT00781625|nutritional factors
479892|NCT00781625|prophylactic aid
479893|NCT00781625|Lactobacillus rhamnosus GR-1
479894|NCT00781625|Lactobacillus reuteri RC-14
479895|NCT00781625|Recurrent lower UTI in women
479896|NCT00781599|African american
479897|NCT00781599|smokers
479898|NCT00781599|smoking cessation
479899|NCT00781599|African American smokers
479900|NCT00781586|Energy expenditure
479901|NCT00781586|Nutritional
479902|NCT00781586|Weight control
479904|NCT00781573|Clopidogrel
479905|NCT00781573|Optimal duration of clopidogrel post DES stent implantation
479906|NCT00781560|Hyperlipidemia
479907|NCT00781560|Chinese National Adult Lipid Treatment Guideline (2007)
479908|NCT00781560|Crestor®
479909|NCT00781547|growth hormone
479910|NCT00781547|obesity
479911|NCT00781547|abdominal obesity
479912|NCT00781534|Health Supplements
479913|NCT00781534|Ginseng
479914|NCT00781534|Diabetes
479915|NCT00781508|heart failure, left sided
479916|NCT00781508|ventricular dysfunction
479917|NCT00781508|diastolic dysfunction
479918|NCT00781508|sildenafil
479919|NCT00781495|insulin
479920|NCT00781482|Positron Emission Tomography
479921|NCT00781482|GABA receptor binding
479922|NCT00781482|Hypnotic Drugs
479923|NCT00781482|Eszopiclone
479924|NCT00781482|Zolpidem
479925|NCT00781482|[11-C] Flumazenil
479926|NCT00781482|Molecular imaging of the brain
479927|NCT00781469|Rheumatoid arthritis
479928|NCT00781469|RNA
479929|NCT00781469|Synovium
479930|NCT00781469|Peripheral blood mononuclear cells
479931|NCT00781456|Migraine headache
479932|NCT00781456|menstrual
479933|NCT00781456|oral contraceptive
479934|NCT00781456|Menstrually-Related Migraine Headache
479935|NCT00781443|Asthma
479936|NCT00781417|vitamin D
479937|NCT00781417|Chronic Kidney Disease
479938|NCT00781417|parathyroid hormone
479939|NCT00781417|Chronic kidney disease Stage II and III
479940|NCT00781404|adenosine
479941|NCT00781404|angioplasty
479942|NCT00781404|acute myocardial infarction
479943|NCT00781404|acute coronary syndrome with ST segment elevation
479944|NCT00781404|infarct size
479945|NCT00781404|rescued myocardium
479946|NCT00781391|Systemic embolic events
479947|NCT00781378|Thrombolytic therapy
479948|NCT00781378|Recombinant tissue plasminogen activator
479949|NCT00781378|Efficacy
479950|NCT00781378|Safety
479951|NCT00781365|Hypertension
479952|NCT00781365|Telemonitoring
479953|NCT00781365|Pharmacy management
479954|NCT00781352|nitrous oxide
479955|NCT00781352|cancer recurrence
479956|NCT00781352|colorectal surgery
479957|NCT00781339|Bacteriuria
479958|NCT00781339|Catheterized
479959|NCT00781339|Chronically Catheterized
479960|NCT00781326|Depressive Disorder, Major
479961|NCT00781326|Cerebrovascular Disorders
479962|NCT00781326|Risk Factors
479963|NCT00781326|Nimodipine
479964|NCT00781300|Intraocular pressure
479965|NCT00781300|Pterygium
479966|NCT00781300|Surgery
479967|NCT00781300|Steroids
479968|NCT00781300|Glaucoma
479969|NCT00781287|human immunodeficiency virus
479970|NCT00781287|raltegravir
479971|NCT00781287|primary HIV infection
479972|NCT00781287|HIV-1
479973|NCT00781261|hip
479974|NCT00781261|collapse femoral head
479975|NCT00781261|bisphosphonates
479976|NCT00781261|osteonecrosis
479977|NCT00781248|enteral feeding
479978|NCT00781248|Subject who requires nasogastric tube
479979|NCT00781209|irradiation
479980|NCT00781209|stereotactic radiosurgery
479981|NCT00781209|posterior fossa
479982|NCT00781209|cerebellar metastases
479983|NCT00781196|phenytoin
479984|NCT00781196|gum hyperplasia
479985|NCT00781196|phenytoin induced gingival overgrowth
479986|NCT00781196|plaque index
479987|NCT00781196|gingival overgrowth grade
479988|NCT00781183|COPD
479989|NCT00781183|rehabilitation
479990|NCT00781183|walking
479991|NCT00781170|Multiple Myeloma
479992|NCT00781170|Plasmocytoma
479993|NCT00781170|Stem Cell Transplantation
479994|NCT00781157|Spinal induced hypotension in cesarean delivery
479995|NCT00781118|Acute Myocardial Infarction (MI)
479996|NCT00781118|ST Shift
479997|NCT00781118|Coronary Occlusion
479998|NCT00781118|Acute Coronary Syndrome
479999|NCT00781105|Chronic hepatitis B
480000|NCT00781105|Adult
480001|NCT00781105|HBV DNA suppression
480002|NCT00781105|Telbivudine
480003|NCT00781092|Dry Eyes
480004|NCT00781092|LASIK
480005|NCT00781092|Laser Vision Correction
480006|NCT00781079|Organization Innovation
480007|NCT00781079|Opinion Leaders
480008|NCT00781079|Schizophrenia
480009|NCT00781066|POSTPARTUM HEMORRHAGE
480010|NCT00781066|PREVENTION
480011|NCT00781066|CORD TRACTION
480012|NCT00781066|THIRD STAGE LABOR
480013|NCT00781053|skin fibrosis
480014|NCT00781053|systemic scleroderma
480015|NCT00781053|systemic sclerosis
480016|NCT00781053|p144
480017|NCT00781053|orphan drug
480018|NCT00781040|Severe sepsis in neutropenic haematological patients
480019|NCT00781001|neuropathic pain
480020|NCT00781001|diabetic neuropathy
480021|NCT00781001|cannabis
480022|NCT00781001|marijuana
480023|NCT00780975|Aplidin
480024|NCT00780975|Plitidepsin
480025|NCT00780975|Prostate
480026|NCT00780975|Cancer
480027|NCT00780962|NAC
480028|NCT00780962|Radiocontrast Nephropathy
480029|NCT00780962|N-Acetycysteine
480030|NCT00780962|RCN
480031|NCT00780962|RCIN
480032|NCT00780962|Creatinine
480033|NCT00780962|Computerized Tomography
480034|NCT00780962|CT
480035|NCT00780962|Emergency Department
480036|NCT00780962|ED
480037|NCT00780962|Safety of IV N-Acetylcysteine
480038|NCT00780949|Crohn's Disease, inflammatory bowel disease, Peyer's patches
480039|NCT00780897|PREMATURE OVARIAN FAILURE (POF)
480040|NCT00780897|GENETIC ANALYSIS
480041|NCT00780897|PHYSIOPATHOLOGIC ANALYSIS
480042|NCT00780884|acupuncture
480043|NCT00780884|schizophrenia
480044|NCT00780884|insomnia
480045|NCT00780858|GnRH antagonist
480046|NCT00780858|IUI
480047|NCT00780845|Acute Kidney failure
480048|NCT00780845|Clinical outcomes
480049|NCT00780845|On-pump
480050|NCT00780845|Coronary artery bypass grafting
480051|NCT00780845|Morbidity
480052|NCT00780845|Mortality
480053|NCT00780832|overactive bladder
480054|NCT00780832|dietary caffeine
480055|NCT00780832|anticholinergic medication
480056|NCT00780832|lifestyle modification
480057|NCT00780832|incontinence
480058|NCT00780832|urinary frequency
480059|NCT00780806|MnB
480060|NCT00780806|rLP2086
480061|NCT00780806|blood collection
480062|NCT00780806|vaccination
480063|NCT00780767|angiojet
480064|NCT00780767|massive pulmonary embolism
480065|NCT00780767|RHEOLYTIC THROMBECTOMY
480066|NCT00780767|patients presenting with massive pulmonary embolism
480067|NCT00780754|prostate cancer
480068|NCT00780754|chemoprevention
480069|NCT00780754|dutasteride
480070|NCT00780741|Nasolacrimal duct obstruction
480071|NCT00780741|Simple probing
480072|NCT00780715|Diabetes therapies
480073|NCT00780715|Pharmacogenetics
480074|NCT00780702|Cocaine
480075|NCT00780702|Treatment
480076|NCT00780702|Airpiprazole
480077|NCT00780702|Methadone
480078|NCT00780702|Relapse
480079|NCT00780702|HIV
480080|NCT00780702|Ecological Momentary Assessment (EMA)
480081|NCT00780702|Contingency Management
480082|NCT00780676|Dasatinib
480083|NCT00780676|Metastatic Breast Cancer
480084|NCT00780676|Sprycel
480085|NCT00780676|BMS-354825
480086|NCT00780676|Genetic testing
480087|NCT00780676|AZD6244
480088|NCT00780676|Selumetinib
480089|NCT00780663|Neuroendocrine
480090|NCT00780663|Carcinoid
480091|NCT00780663|NET
480092|NCT00780663|MEN-1
480093|NCT00780663|Islet cell
480094|NCT00780637|Heart Transplant
480095|NCT00780637|Endothelial Function
480096|NCT00780637|Fibrinolysis
480097|NCT00780637|Transplant recipients at baseline
480098|NCT00780624|RDS
480099|NCT00780624|Infant, newborn
480100|NCT00780624|NIPPV
480101|NCT00780624|CPAP
480102|NCT00780598|Acute Myeloid Leukemia
480103|NCT00780598|AML
480104|NCT00780598|Cancer
480105|NCT00780598|Hematological malignancies
480106|NCT00780598|Elderly
480107|NCT00780598|Refractory
480108|NCT00780598|Relapsed
480109|NCT00780598|Blood disorder
480110|NCT00780572|Safety Management
480111|NCT00780572|Risk Management
480112|NCT00780572|surveillance
480113|NCT00780572|triggers
480114|NCT00780559|Neuropathy
480115|NCT00780559|diabetes
480116|NCT00780546|tuberculosis
480117|NCT00780546|spatial epidemiology
480118|NCT00780546|geographic information system
480119|NCT00780520|glutamine inflammation HSP70 sepsis
480120|NCT00780481|Obesity
480121|NCT00780481|Endothelial Function
480122|NCT00780481|Fibrinolytic Balance
480123|NCT00780481|Baseline
480124|NCT00780468|Weight loss
480125|NCT00780468|Diet
480126|NCT00780468|Obesity
480127|NCT00780455|KineSEP
480128|NCT00780455|Rehabilitation
480129|NCT00780455|Betaferon
480130|NCT00780442|substance related disorders
480131|NCT00780429|kidney
480132|NCT00780429|transplant
480133|NCT00780429|Mycophenolic acid
480134|NCT00780429|Inosine monophosphate dehydrogenase
480135|NCT00780416|Chronic Hepatitis C
480136|NCT00780416|Protease Inhibitor
480137|NCT00780416|Telaprevir
480138|NCT00780416|Peginterferon Alfa-2b
480139|NCT00780416|Ribavirin
480140|NCT00780390|RSD
480141|NCT00780390|SCS
480142|NCT00780390|CRPS
480143|NCT00780390|Complex regional pain syndrome patients before undergoing spinal cord stimulator implant and under other treatments
480144|NCT00780377|Heart Transplant
480145|NCT00780377|Fibrinolysis
480146|NCT00780377|Resting conditions
480147|NCT00780364|stroke; sour taste; cold temperature; pharyngeal swallowing
480148|NCT00780351|vancomycin, SLEDD-f
480149|NCT00780325|Cyclooxygenase-2
480150|NCT00780325|Carbonic anhydrase
480151|NCT00780325|Eicosanoids
480152|NCT00780325|Healthy volunteers
480153|NCT00780312|radiotherapy
480154|NCT00780312|trismus
480155|NCT00780312|physiotherapy
480156|NCT00780312|lymphoedema
480157|NCT00780312|late side effects
480158|NCT00780312|fibrosis
480159|NCT00780312|decreased cervical range of motion
480160|NCT00780312|quality of life
480161|NCT00780299|Plasma epuration
480162|NCT00780299|Hemofiltration
480163|NCT00780299|Cardiac arrest
480164|NCT00780299|Shock
480165|NCT00780299|Inflammatory mediators
480166|NCT00780273|subjects with edentulous mandible
480167|NCT00780260|HIV/AIDS
480168|NCT00780260|African Americans
480169|NCT00780260|Women
480170|NCT00780260|Case Management
480171|NCT00780247|Vitamin D
480172|NCT00780247|Sun
480173|NCT00780247|Latitude
480174|NCT00780247|Vitamin D status
480175|NCT00780234|chemoprevention
480176|NCT00780234|lung cancer
480177|NCT00780234|pioglitazone
480178|NCT00780221|CRP
480179|NCT00780221|coronary artery disease
480180|NCT00780221|polymorphisms
480181|NCT00780208|Attention Deficit Hyperactivity ADHD
480182|NCT00780195|hypoglycemia
480183|NCT00780195|African Americans
480184|NCT00780182|Bioavailability
480185|NCT00780156|Drug eluting stent
480186|NCT00780156|Dual antiplatelet therapy
480187|NCT00780156|bleeding
480188|NCT00780156|stent thrombosis
480189|NCT00780156|follow-up of the drug eluting stent
480190|NCT00780143|Tumor
480191|NCT00780143|Leukemia
480192|NCT00780143|Plitidepsin
480193|NCT00780143|Aplidin
480194|NCT00780117|CURRARINO syndrome
480195|NCT00780117|Sacrococcygeal teratoma
480196|NCT00780117|HLXB9 (MNX1) gene
480197|NCT00780117|Alpha foeto protein
480198|NCT00780117|Prognosis factors
480199|NCT00780104|Advanced myeloid leukemias
480200|NCT00780104|AML
480201|NCT00780104|Leukemia
480202|NCT00780104|Relapsed myeloid leukemias
480203|NCT00780104|Refractory myeloid leukemias
480204|NCT00780104|MEC
480205|NCT00780104|Rapamycin
480206|NCT00780104|Sirolimus
480207|NCT00780091|optimization
480208|NCT00780091|risk scale
480209|NCT00780091|non inferiority
480210|NCT00780091|cluster randomization
480211|NCT00780091|monitoring strategies
480212|NCT00780078|Intensive care unit
480213|NCT00780078|Extubation failure
480214|NCT00780078|Physiotherapist
480215|NCT00780078|Pre-extubation bedside tests
480216|NCT00780078|Swallowing disorders
480217|NCT00779246|Methicillin resistance
480218|NCT00779246|Infection control
480219|NCT00779246|Staphylococcus aureus
480220|NCT00779246|Cross infection
480221|NCT00779246|Epidemiology
480222|NCT00779246|Chlorhexidine
480223|NCT00779233|Bioequivalence
480224|NCT00779207|obesity
480225|NCT00779207|aging
480226|NCT00779207|exercise
480227|NCT00779207|diet
480228|NCT00779207|weight loss
480229|NCT00779207|physical function
480230|NCT00779207|Obesity in the Elderly
480231|NCT00779181|Hypertension
480232|NCT00779181|High blood pressure
480233|NCT00779181|Htn
480234|NCT00779181|Addrenex
480235|NCT00780052|Hematologic Malignancies
480236|NCT00780052|c-myb
480237|NCT00780052|c-myb AS ODN
480238|NCT00780026|liver
480239|NCT00780026|transplant
480240|NCT00780026|blood sugar
480241|NCT00780013|Bioequivalence metformin hydrochloride
480242|NCT00779987|Dry eye
480243|NCT00779987|Autologous serum
480244|NCT00779987|Ocular Surface Disease Index
480245|NCT00779974|Total Shoulder Arthroplasty
480246|NCT00779974|Osteoarthritis
480247|NCT00779961|pediatric
480248|NCT00779961|cleft palate
480249|NCT00779961|plastic surgery
480250|NCT00779961|palatoplasty
480251|NCT00779961|pharyngoplasty
480252|NCT00779948|Femoral Neck Fracture
480253|NCT00779948|Internal Fixation
480254|NCT00779948|Dynamic Hip Screw
480255|NCT00779922|Multiple Myeloma
480256|NCT00779922|impaired renal function
480257|NCT00779909|vitamin D
480258|NCT00779909|gingivitis
480259|NCT00779909|periodontal disease
480260|NCT00779909|inflammation
480261|NCT00779896|To evaluate therapeutic potential of tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study
480262|NCT00779896|Stage I-IIA disease CTCL
480263|NCT00779883|Chronic lymphocytic leukemia
480264|NCT00779883|CLL
480265|NCT00779883|Leukemia
480266|NCT00779883|Leukemia, Lymphocytic, Chronic, B-Cell
480267|NCT00779883|Leukemia, B-Cell
480268|NCT00779883|Immune System Diseases
480269|NCT00779883|ISF35
480270|NCT00779883|Ad-ISF35
480271|NCT00779883|Immunotherapy
480272|NCT00779883|Immune therapy
480273|NCT00779883|Active immune therapy
480274|NCT00779870|asthma severity
480275|NCT00779870|airway smooth muscle
480276|NCT00779870|oxidative stress
480277|NCT00779857|left atrial appendage
480278|NCT00779857|laa
480279|NCT00779857|atrial fibrillation
480280|NCT00779857|afib
480281|NCT00779857|af
480282|NCT00779857|stroke
480283|NCT00779857|tia
480284|NCT00779844|Anesthesia
480285|NCT00779844|Obesity
480286|NCT00779831|Bioequivalence Pseudoephedrine hydrochloride 120 mg extended release tablets
480287|NCT00779805|Bioequivalence Pseudoephedrine hydrochloride 120 mg ER tablets
480288|NCT00779792|Irritant contact dermatitis
480289|NCT00779792|experimental contact dermatitis
480290|NCT00779792|treatment
480291|NCT00779792|efficacy
480292|NCT00779792|topical steroids
480293|NCT00779792|topical immune modulators
480294|NCT00779792|glycerol
480295|NCT00779779|Gastroenteritis
480296|NCT00779766|Human papillomavirus
480297|NCT00779766|vaccine
480298|NCT00779766|cervical cancer
480299|NCT00779766|cervical infection
480300|NCT00779753|Parenteral Feeding
480301|NCT00779753|Neonate
480302|NCT00779753|Lysine
480303|NCT00779727|women
480304|NCT00779727|increased
480305|NCT00779727|risk
480306|NCT00779714|metastatic (AJCC stage IV)
480307|NCT00779714|first-line chemotherapy
480308|NCT00779714|ex-vivo chemosensitivity profiling
480309|NCT00779714|evaluation of biomarkers
480310|NCT00779701|Hyperglycemia
480311|NCT00779701|Glycemic control
480312|NCT00779688|Endoscopic Retrograde Cholangiopancreatography
480313|NCT00779688|ERCP
480314|NCT00779688|bile duct cancer
480315|NCT00779688|pancreatic duct cancer
480316|NCT00779688|gall bladder
480317|NCT00779688|pancreas
480318|NCT00779688|duodenoscope
480319|NCT00779688|Cellvizio
480320|NCT00779688|endomicroscopy
480321|NCT00779688|cholangiopancreatoscopy
480322|NCT00779688|Biliary Tract Neoplasms (suspected)
480323|NCT00779688|Biliary Tract Mass (suspected)
480324|NCT00779688|Biliary Tract Stricture (suspected)
480325|NCT00779688|Pancreatic Duct Neoplasms (suspected)
480326|NCT00779688|Pancreatic Duct Mass (suspected)
480327|NCT00779688|Pancreatic Duct Stricture (suspected)
480328|NCT00779662|Rheumatic Heart Disease
480329|NCT00779662|Streptococcus
480330|NCT00779662|Fiji
480331|NCT00779649|Colonoscopy,
480332|NCT00779649|Prep
480333|NCT00779649|MoviPrep
480334|NCT00779649|HalfLytely
480335|NCT00779649|The effectiveness of colonoscopy preps
480336|NCT00779597|self care
480337|NCT00779597|symptom management
480338|NCT00779597|pain
480339|NCT00779597|cancer
480340|NCT00779597|nurse coaching
480341|NCT00779597|patient education
480342|NCT00779571|Polycystic Ovary Syndrome
480343|NCT00779571|Morbid Obesity
480344|NCT00779571|Type 2 DM
480345|NCT00779571|Coronary heart disease
480346|NCT00779532|Electrocardiography
480347|NCT00779532|Pharmacokinetics
480348|NCT00779519|Obesity
480349|NCT00779519|Class 1
480350|NCT00779519|Class 2
480351|NCT00779519|Weight Loss
480352|NCT00779519|AgRP
480353|NCT00779519|TTP435
480354|NCT00779519|alphaMSH
480355|NCT00779519|Agouti-Related Protein
480356|NCT00779519|alpha-melanocyte stimulating hormone
480357|NCT00779506|Acute schizophrenia
480358|NCT00779506|PANSS
480359|NCT00779493|irritable bowel syndrome
480360|NCT00779493|constipation
480361|NCT00779493|diarrhea
480362|NCT00779493|gas
480363|NCT00779493|bloating
480364|NCT00779493|abdominal pain
480365|NCT00779493|disturbance of defecation
480366|NCT00779493|irritable colon
480367|NCT00779480|Acute Myelogenous Leukemia
480368|NCT00779480|Safety
480369|NCT00779480|Dose Tolerance
480370|NCT00779480|Pharmacokinetics/Pharmacodynamics
480371|NCT00779480|FLT-3
480372|NCT00779467|non narcotic
480373|NCT00779467|epidural
480374|NCT00779467|labor pain
480375|NCT00779467|Non narcotic treatment of labor pain
480376|NCT00779454|KRAS wild-type
480377|NCT00779454|Cholangiocarcinoma
480378|NCT00779454|Inoperable
480379|NCT00779441|Bioequivalence zolpidem 10mg tablets
480380|NCT00779428|This is an open-label continuing treatment protocol in patients with advanced malignancies who will receive Tanespimycin
480381|NCT00779415|Partial Thickness
480382|NCT00779415|Rotator Cuff
480383|NCT00779402|cancer
480384|NCT00779402|prostate cancer
480385|NCT00779402|prostatectomy
480386|NCT00779402|PSA
480387|NCT00779389|Head and Neck cancer
480388|NCT00779376|Bioequivalence
480389|NCT00779363|obese,
480390|NCT00779363|Diabetes
480391|NCT00779350|Bioequivalence sertraline 100 mg tablets fasting conditions
480392|NCT00779337|Epstein-Barr virus
480393|NCT00779337|lymphoma
480394|NCT00779337|immunotherapy
480395|NCT00779324|traumatic brain injury
480396|NCT00779324|irritability
480397|NCT00779324|aggression
480398|NCT00779324|amantadine
480399|NCT00779324|behavior
480400|NCT00779311|Metastatic Colorectal Cancer
480401|NCT00779298|rye whole-meal bread
480402|NCT00779298|white-wheat bread
480403|NCT00779298|gastric emptying rate
480404|NCT00779298|postprandial glucose response
480405|NCT00779298|healthy subjects
480406|NCT00779272|neoadjuvant chemotherapy
480407|NCT00779272|clinically postoperative outcome
480408|NCT00779272|liver regeneration after liver resection
480409|NCT00779259|quinine sulfate
480410|NCT00779259|theophylline
480411|NCT00779259|drug interactions
480412|NCT00779259|cytochrome p450
480413|NCT00779259|humans
480414|NCT00779259|male
480415|NCT00779259|adult
480416|NCT00779168|recurrent prostate cancer
480417|NCT00779168|adenocarcinoma of the prostate
480418|NCT00779142|resistant diabetic macular edema
480419|NCT00779103|puberty
480420|NCT00779103|precocious puberty
480421|NCT00779103|early puberty
480422|NCT00779103|early onset puberty
480423|NCT00779103|histrelin
480424|NCT00779103|histrelin subcutaneous implant
480425|NCT00779103|implant therapy
480426|NCT00779077|device characteristics
480427|NCT00779064|Atrial Fibrillation
480428|NCT00779051|Bioequivalence Zolpidem 10mg tablets
480429|NCT00779038|IONSYS
480430|NCT00779038|Fentanyl Iontophoretic Transdermal System
480431|NCT00779038|Postoperative pain
480432|NCT00778986|heart failure
480433|NCT00778986|remote patient monitoring
480434|NCT00778986|telemonitoring
480435|NCT00778986|home monitoring
480436|NCT00778986|randomized controlled trial
480437|NCT00778986|self care
480438|NCT00778973|Bioequivalence sertraline 100 mg tablets under fed conditions
480439|NCT00778947|Breast Reconstruction
480440|NCT00778947|Halmonic Scalpel
480441|NCT00778947|diathermy
480442|NCT00778947|Free Tissue Transfer
480443|NCT00778921|Aliskiren
480444|NCT00778921|Amlodipine
480445|NCT00778921|Non-responder to Amlodipine
480446|NCT00778908|Nasopharyngeal carcinoma
480447|NCT00778908|Locally advanced disease
480448|NCT00778908|Intensity-modulated radiation therapy
480449|NCT00778908|Accelerated hyperfractionation
480450|NCT00778908|Concomitant boost radiation therapy
480451|NCT00778908|Concurrent chemotherapy
480452|NCT00778895|Flu
480453|NCT00778895|Safety
480454|NCT00778895|Immunogenicity
480455|NCT00778895|Flu vaccine
480456|NCT00778895|Influenza
480457|NCT00778895|Virus
480458|NCT00778882|Chronic Granulomatous Disease
480459|NCT00778882|Retroviral Vector
480460|NCT00778882|Gene Therapy
480461|NCT00778843|Chronic hepatitis C
480462|NCT00778843|Oxidative stress
480463|NCT00778843|Antioxidant
480464|NCT00778843|Cytokines
480465|NCT00778843|Nutritional supplement
480466|NCT00778830|mCRC
480467|NCT00778804|CVD risk
480468|NCT00778804|self monitoring
480469|NCT00778804|Internet
480470|NCT00778804|telemedicine
480471|NCT00778791|Bioequivalence metformin HC1 750 mg extended-release tablets
480472|NCT00778778|Bioequivalence cefprozil 500mg tablets fasting conditions
480473|NCT00778765|Bioequivalence gabapentin fed conditions
480474|NCT00778752|Multiple Myeloma
480475|NCT00778752|Stem Cell Transplantation
480476|NCT00778752|Revlimid
480477|NCT00778752|Lenalidomide
480478|NCT00778739|bioequivalence 1) CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL fed conditions
480479|NCT00778726|Bioequivalence benazepril and hydrochlorothiazide tablets
480480|NCT00778713|Bioequivalence
480481|NCT00778674|Bioequivalence Benazepril HCl Hydrochlorothiazide Tablets
480482|NCT00778661|Bioequivalence
480483|NCT00778648|Common cold
480484|NCT00778648|prevention
480485|NCT00778648|dietary supplement
480486|NCT00778609|Combined Oral Contraceptives
480487|NCT00778609|Pelvic Pain
480488|NCT00778609|Headache
480489|NCT00778596|Hepatitis B
480490|NCT00778596|Telbivudine
480491|NCT00778596|Prednisolone
480492|NCT00778583|Bioequivalence Nitrofurantoin capsules
480493|NCT00778557|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL, Bioequivalence fasting conditions
480494|NCT00778544|Bioequivalence amoxicillin-clavulanic acid 600 mg 42.9 mg per 5 mL oral suspension
480495|NCT00778531|injectable implant
480496|NCT00778531|nasolabial folds
480497|NCT00778531|Correction of nasolabial folds
480498|NCT00778518|growth hormone
480499|NCT00778518|growth hormone deficiency
480500|NCT00778518|GHD
480501|NCT00778518|PEG
480502|NCT00778518|pegylated
480503|NCT00778518|IGF-1
480504|NCT00778505|Anesthesia
480505|NCT00778492|Thrombelastogram
480506|NCT00778492|Microvascular bleeding
480507|NCT00778492|antiplatelet medication
480508|NCT00778492|cardiac surgery
480509|NCT00778492|consumption of blood products
480510|NCT00778492|preoperative platelet mapping derived from modified TEG
480511|NCT00778492|postoperative bleeding
480512|NCT00778466|Bioequivalence metformin hydrochloride 1000 mg tablets fed conditions
480513|NCT00778453|stroke rehabilitation
480514|NCT00778453|kinematic analysis
480515|NCT00778453|upper extremity training
480516|NCT00778453|predictors
480517|NCT00778440|Injuries
480518|NCT00778440|Traffic Injuries
480519|NCT00778440|Preventive medicine
480520|NCT00778440|Observational studies
480521|NCT00778440|Primary care
480522|NCT00778427|Bioequivalence metformin hydrochloride 1000 mg tablets fasting conditions
480523|NCT00778414|Bioequivalence Amoxicillin Clavulanic acid 600mg 42.9 mg per 5 mL oral suspension
480524|NCT00778401|Bioequivalence Gabapentin tablets 800 mg fasting conditions
480525|NCT00778388|Pseudomonas Aeruginosa
480526|NCT00778375|Leukemia
480527|NCT00778375|Acute Myeloid Leukemia
480528|NCT00778375|Myelodysplastic Syndrome
480529|NCT00778375|AML
480530|NCT00778375|MDS
480531|NCT00778375|Clofarabine
480532|NCT00778375|Ara-C
480533|NCT00778375|Cytarabine
480534|NCT00778375|Decitabine
480535|NCT00778362|OPSI
480536|NCT00778362|Splenectomy
480537|NCT00778349|Bioavailability Metformin solution 100 mg/mL
480538|NCT00778336|Peripheral Thrombosis
480539|NCT00778336|DVT
480540|NCT00778336|Limb Ischemia
480541|NCT00778336|AV Access
480542|NCT00778336|AngioJet
480543|NCT00778336|Thrombectomy
480544|NCT00778323|remote ischemic preconditioning
480545|NCT00778323|cervical compression myelopathy
480546|NCT00778323|spinal cord
480547|NCT00778323|neuron-specific enolase
480548|NCT00778323|s-100B
480549|NCT00778310|Attention Deficit Disorder with Hyperactivity
480550|NCT00778310|Attention Deficit Hyperactivity Disorder
480551|NCT00778310|ADHD
480552|NCT00778297|prevention
480553|NCT00778297|influenza
480554|NCT00778297|infection
480555|NCT00778297|vaccine
480556|NCT00778297|Influenza vaccine
480557|NCT00778297|Influenza in humans
480558|NCT00778284|Bioequivalence
480559|NCT00778271|Bioequivalence gabapentin 400mg capsules fasting conditions
480560|NCT00778258|Food Allergy
480561|NCT00778258|Milk Allergy
480562|NCT00778245|Bioequivalence cefprozil 500mg tablets fed conditions
480563|NCT00778232|Bioequivalence Gabapentin tablets 800 mg fed conditions
480564|NCT00778219|heart rate variability, tracheal intubation
480565|NCT00778206|Phenylketonuria
480566|NCT00778206|Hyperphenylalaninemia
480567|NCT00778206|PKU
480568|NCT00778206|Phenylalanine
480569|NCT00778193|NSAID
480570|NCT00778193|ulcer
480571|NCT00778193|gastroduodenal ulcer
480572|NCT00778193|naproxen
480573|NCT00778193|aspirin
480574|NCT00778193|ASA
480575|NCT00778193|celecoxib
480576|NCT00778193|clopidogrel
480577|NCT00778193|healing
480578|NCT00778193|Cyclooxygenase 2 Inhibitors
480579|NCT00778193|Anti-Inflammatory Agents, Non-Steroidal
480580|NCT00778193|Platelet Aggregation Inhibitors
480581|NCT00778193|Wound Healing
480582|NCT00778180|Bioequivalence furosemide 80 mg tablets
480583|NCT00778141|Bioequivalecne metformin HC1 750 mg extended-release tablets
480584|NCT00778128|CP-4126
480585|NCT00778128|Cancer
480586|NCT00778128|Metastatic
480587|NCT00778128|Solid tumours
480588|NCT00778128|Gemzitabine
480589|NCT00778128|Gemzar
480590|NCT00778115|Bioequivalence Loperamide HCl 2 mg and simethicone 125 mg tablets
480591|NCT00778089|skin test
480592|NCT00778089|ArteFill
480593|NCT00778089|Skin test prior to administration of ArteFill® implant
480594|NCT00778076|Knee OA, Hyaluronic acid, Gait, Pain, Synovial fluid
480595|NCT00778063|dexmedetomidine
480596|NCT00778063|pressure equalization tubes in the ear
480597|NCT00778063|myringotomy
480598|NCT00778063|sevoflurane
480599|NCT00778050|Bioequivalence, amoxicillin 600mg fasting conditions
480600|NCT00778037|Bioequivalence Cyclobenzaprine hydrochloride 10 mg tablet fasting conditions
480601|NCT00778024|Bioequivalence fluoxetine HCL 40 mg capsules fasting conditions
480602|NCT00778011|Nausea
480603|NCT00778011|Vomiting
480604|NCT00778011|Ondansetron
480605|NCT00778011|Metoclopramide
480606|NCT00778011|Randomized
480607|NCT00778011|Double-Blind
480608|NCT00778011|nausea and vomiting in the emergency department
480609|NCT00777998|Multiple Myeloma
480610|NCT00777998|Stem Cell Transplantation
480611|NCT00777998|Thalidomide
480612|NCT00777998|DLI
480613|NCT00777985|Cardiovascular system
480614|NCT00777985|Sleep
480615|NCT00777985|Endothelial function
480616|NCT00777985|Endothelin system
480617|NCT00777972|Bioequivalence Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets fasting conditions
480618|NCT00777946|Aliskiren, Amlodipine, Non-responder to aliskiren
480619|NCT00777907|neurovascular embolization
480620|NCT00777907|therapeutic embolization
480621|NCT00777894|advanced adult primary liver cancer
480622|NCT00777894|localized unresectable adult primary liver cancer
480623|NCT00777894|adult primary hepatocellular carcinoma
480624|NCT00777855|warfarin
480625|NCT00777855|pharmacokinetics
480626|NCT00777855|drug transporter
480627|NCT00777855|healthy volunteer
480628|NCT00777855|drug interaction
480629|NCT00777855|rifampin
480630|NCT00777829|Nap
480631|NCT00777829|Pharmacology
480632|NCT00777829|Memory
480633|NCT00777829|Visual Learning
480634|NCT00777829|Verbal Memory
480635|NCT00777829|Motor Learning
480636|NCT00777816|Rheumatoid
480637|NCT00777816|Arthritis
480638|NCT00777790|Meningitis
480639|NCT00777790|Meningococcemia
480640|NCT00777790|Neisseria meningitidis
480641|NCT00777777|multi-vessel, therapy, surgery, CABG
480642|NCT00777764|Xolair
480643|NCT00777764|Asthma
480644|NCT00777764|Skin Tests
480645|NCT00777751|Chest Tumor
480646|NCT00777751|Heart
480647|NCT00777751|Lung Cancer
480648|NCT00777751|Esophageal Cancer
480649|NCT00777751|Thymoma
480650|NCT00777751|Radiation dose to the heart
480651|NCT00777751|Cardiac Enzymes
480652|NCT00777751|Cardiac Biomarkers
480653|NCT00777751|Radiation Therapy
480654|NCT00777751|RT
480655|NCT00777751|Electrocardiograms
480656|NCT00777751|ECG
480657|NCT00777738|Advanced Waldenström's macroglobulinemia
480658|NCT00777738|Bortezomib
480659|NCT00777738|Dexamethasone
480660|NCT00777738|Safety
480661|NCT00777738|Efficacy
480662|NCT00777712|Wound healing
480663|NCT00777712|diabetes
480664|NCT00777712|inflammatory cell
480665|NCT00777712|monocyte
480666|NCT00777712|leukocyte
480667|NCT00777712|macrophage
480668|NCT00777699|Cancer
480669|NCT00777699|Solid Tumors
480670|NCT00777699|NSCLC
480671|NCT00777686|Intracranial Glioblastoma
480672|NCT00777686|Intracranial Gliosarcoma
480673|NCT00777686|glioblastoma
480674|NCT00777686|recurrent glioblastoma
480675|NCT00777686|gliosarcoma
480676|NCT00777686|brain cancer
480677|NCT00777686|magnetic resonance spectroscopy
480678|NCT00777686|MRS
480679|NCT00777686|magnetic resonance imaging
480680|NCT00777686|MRI
480681|NCT00777686|MRI/MRS
480682|NCT00777686|Recurrent Glioblastoma Treated with Antiangiogenic agents
480683|NCT00777686|contrast enhanced MRI
480684|NCT00777686|DCE-MRI
480685|NCT00777686|diffusion-weighted MRI
480686|NCT00777686|DSC
480687|NCT00777686|DW-MRI
480688|NCT00777673|Breast Cancer
480689|NCT00777673|Triple Negative
480690|NCT00777673|Neoadjuvant
480691|NCT00777673|Neoadjuvant therapy
480692|NCT00777673|ER, PR and HER2 Negative
480693|NCT00777634|Binge Eating Disorder
480694|NCT00777634|Eating Disorder
480695|NCT00777595|QTc
480696|NCT00777595|CHF 4226 HFA
480697|NCT00777595|pMDI
480698|NCT00777595|Carmoterol
480699|NCT00777582|Poly (ADP ribose) polymerases
480700|NCT00777582|Homologous Recombination Deficiency (HRD)
480701|NCT00777582|Advanced solid tumours
480702|NCT00777569|Smoking
480703|NCT00777569|PREPS
480704|NCT00777569|Harm reduction
480705|NCT00777569|Biomarkers of tobacco exposure
480706|NCT00777569|Compensatory smoking
480707|NCT00777543|Bioavailability
480708|NCT00777543|Ferulic acid
480709|NCT00777543|Phenolic compounds
480710|NCT00777543|Colonic metabolites
480711|NCT00777543|Immunomodulatory effects
480712|NCT00777543|No disease
480713|NCT00777517|Cardiovascular Diseases
480714|NCT00777504|angiogenesis
480715|NCT00777504|inhibitor
480716|NCT00777504|duration of therapy
480717|NCT00777504|GIST
480718|NCT00777491|stage II bladder cancer
480719|NCT00777491|stage III bladder cancer
480720|NCT00777491|transitional cell carcinoma of the bladder
480721|NCT00777478|Sunitinib
480722|NCT00777478|Capecitabine
480723|NCT00777478|Irinotecan
480724|NCT00777478|colorectal cancer
480725|NCT00777465|Acute kidney injury
480726|NCT00777465|Kidney failure
480727|NCT00777465|Risk factors
480728|NCT00777465|Clinical outcomes
480729|NCT00777465|Cardiac valve surgery
480730|NCT00777465|Coronary artery bypass grafting
480731|NCT00777465|Morbidity
480732|NCT00777465|Mortality
480733|NCT00777452|quality of life
480734|NCT00777452|localized prostate cancer
480735|NCT00777452|FACT-P
480736|NCT00777439|Dopamine
480737|NCT00777439|Domperidone
480738|NCT00777439|Gastroparesis
480739|NCT00777439|Gastrointestinal Diseases
480740|NCT00777439|Neurologic Manifestations
480741|NCT00777439|Stomach Diseases
480742|NCT00777439|Digestive System Diseases
480743|NCT00777439|Esophagitis
480744|NCT00777439|Esophageal Disorders
480745|NCT00777439|Paralysis
480746|NCT00777426|HIV positive with HAD
480747|NCT00777413|Bioequiavlence Minocycline Tablets
480748|NCT00777400|Kidney transplant
480749|NCT00777400|T regulatory cells
480750|NCT00777400|Efalizumab
480751|NCT00777400|Rejection
480752|NCT00777400|Safely convert renal transplant from mycophenolate mofetil and Calcineurin inhibitor to efalizumab and sirolimus
480753|NCT00777387|human oocyte cryopreservation
480754|NCT00777387|slow-freeze
480755|NCT00777387|vitrification
480756|NCT00777361|Mass balance
480757|NCT00777361|AZD3480, Pharmacokinetics, Healthy volunteers
480758|NCT00777322|keratoconus
480759|NCT00777322|pellucid marginal degeneration
480760|NCT00777322|corneal ectasia
480761|NCT00777322|collagen cross-linking
480762|NCT00777322|riboflavin
480763|NCT00777322|UV light
480764|NCT00777322|excimer laser
480765|NCT00777322|Topography-Computer Assisted Treatment (T-Cat)
480766|NCT00777322|Wavelight Allegretto laser
480767|NCT00777309|NSCLC
480768|NCT00777296|Cystic Fibrosis
480769|NCT00777296|Respiratory Infections
480770|NCT00777296|Pulmonary Cystic Fibrosis
480771|NCT00777296|CFTR
480772|NCT00777270|episiotomy
480773|NCT00777270|perineal lesion
480774|NCT00777270|vaginal trauma
480775|NCT00777257|Meningitis
480776|NCT00777257|Meningococcemia
480777|NCT00777257|Pertussis
480778|NCT00777257|Neisseria meningitidis
480779|NCT00777257|Tetanus
480780|NCT00777257|Diphtheria
480781|NCT00777244|mitotane
480782|NCT00777244|adjuvant therapy
480783|NCT00777244|disease free survival
480784|NCT00777231|Sickle Cell
480785|NCT00777231|Stem Cell
480786|NCT00777231|Tolerance
480787|NCT00777231|Bone Marrow Transplant
480788|NCT00777231|Total Body Irradiation (TBI)
480789|NCT00777231|Apheresis
480790|NCT00777231|Aplastic Anemia
480791|NCT00777231|Hemoglobinopathies
480792|NCT00777231|Non Malignant
480793|NCT00777218|migraine
480794|NCT00777205|Peer Support
480795|NCT00777205|Quality of Life
480796|NCT00777205|Telephone
480797|NCT00777192|colon cancer
480798|NCT00777192|Cancers of the colon and rectum
480799|NCT00777192|Oxaliplatin
480800|NCT00777192|oxaliplatin chemotherapy
480801|NCT00777192|inflammatory cytokines
480802|NCT00777192|neurocognitive symptoms
480803|NCT00777192|neuropsychiatric symptoms
480804|NCT00777179|Vandetanib, NSCLC, Maintenance, Phase II
480805|NCT00777166|oxytocin
480806|NCT00777166|ST depression
480807|NCT00777166|cesarean section
480808|NCT00777166|blood loss
480809|NCT00777153|Cancer
480810|NCT00777153|Tumour
480811|NCT00777153|Advanced Solid Tumour
480812|NCT00777153|GBM
480813|NCT00777153|Glioblastoma
480814|NCT00777140|Stroke
480815|NCT00777140|Ischemic Stroke
480816|NCT00777140|Thrombolytic treatment
480817|NCT00777140|Middle cerebral artery occlusion
480818|NCT00777140|Deferoxamine
480819|NCT00777140|Iron chelator
480820|NCT00777140|Acute Ischemic Stroke treated with Intravenous Thrombolytic
480821|NCT00777127|actinic keratosis
480822|NCT00777127|invasive SCC
480823|NCT00777127|in situ SCC
480824|NCT00777127|histological classification
480825|NCT00777127|histological progression
480826|NCT00777127|clinical clearance
480827|NCT00777127|cryotherapy
480828|NCT00777114|relapsed non-Hodgkin's lymphoma
480829|NCT00777101|HER2
480830|NCT00777101|ErbB2
480831|NCT00777101|metastatic
480832|NCT00777101|neratinib
480833|NCT00777101|lapatinib
480834|NCT00777101|capecitabine
480835|NCT00777101|HKI-272
480836|NCT00777101|Tykerb
480837|NCT00777101|Tyverb
480838|NCT00777101|Xeloda
480839|NCT00777088|neurovascular embolization
480840|NCT00777088|therapeutic embolization
480841|NCT00777075|nitrate
480842|NCT00777075|nitric oxide
480843|NCT00777075|asymmetric dimethylarginine
480844|NCT00777075|blood pressure
480845|NCT00777075|NOS
480846|NCT00777075|IIEF
480847|NCT00777062|alcohol
480848|NCT00777062|cocaine
480849|NCT00777062|addiction
480850|NCT00777062|alcoholism
480851|NCT00777062|substance dependence
480852|NCT00777062|substance abuse
480853|NCT00777036|Leukemia, Pediatric
480854|NCT00777023|Hot Flashes
480855|NCT00777023|Hot Flushes
480856|NCT00777023|Postmenopausal symptoms
480857|NCT00777023|Vasomotor symptoms
480858|NCT00777010|memory loss
480859|NCT00777010|mild cognitive impairment
480860|NCT00777010|forgetfulness
480861|NCT00776997|Gastroesophageal Reflux
480862|NCT00776958|A Lynne Cohen Consortium Project
480863|NCT00776958|Multi-Center Database Registry
480864|NCT00776958|High Risk
480865|NCT00776958|Cancer
480866|NCT00776958|Breast
480867|NCT00776958|BRCA1 or BRCA2 gene
480868|NCT00776958|Ovary
480869|NCT00776958|Questionnaire
480870|NCT00776919|Acne Vulgaris
480871|NCT00776919|Acne
480872|NCT00776373|ALL
480873|NCT00776373|Burkitt's Lymphoma
480874|NCT00776373|Adult T-Cell leukemia/lymphoma
480875|NCT00776373|Lymphoblastic leukemia
480876|NCT00776373|CML in lymphoid blast crisis patients
480877|NCT00776373|HiVAC
480878|NCT00776373|Rapamycin
480879|NCT00776360|oxytocin
480880|NCT00776360|gastroparesis
480881|NCT00776360|diabetics
480882|NCT00776360|The effect of oxytocin on gastric emptying
480883|NCT00776347|Dementia with Lewy bodies (DLB)
480884|NCT00776347|FDG-PET
480885|NCT00776334|bioequivalence Fosinopril Tablets
480886|NCT00776321|hypercholesterolemia
480887|NCT00776321|dyslipidemia
480888|NCT00776321|thyroid
480889|NCT00776321|safety
480890|NCT00776880|Surgical operation
480891|NCT00776867|Pediatric
480892|NCT00776867|solid tumors
480893|NCT00776867|Pediatric solid tumors
480894|NCT00776867|08-091
480895|NCT00776841|Phase-I
480896|NCT00776841|Hypercholesterolemia
480897|NCT00776841|Obesity
480898|NCT00776841|fatty liver
480899|NCT00776841|Part A: Healthy male volunteers Part B: Mildly overweight, otherwise healthy hypercholesterolemic male volunteers
480900|NCT00776828|cilostazol
480901|NCT00776828|clopidogrel
480902|NCT00776828|statin
480903|NCT00776828|drug-eluting stent
480904|NCT00776802|GCS-100
480905|NCT00776802|Diffuse Large B-cell Lymphoma
480906|NCT00776802|DLBCL
480907|NCT00776802|Relapsed or refractory DLBCL
480908|NCT00776802|Etoposide; Dexamethasone
480909|NCT00776789|Skin to skin contact
480910|NCT00776789|Salivary cortisol
480911|NCT00776789|Breast feeding Behavior
480912|NCT00776776|BMI > 40
480913|NCT00776776|Obesity
480914|NCT00776776|Adolescents
480915|NCT00776776|Weight Loss Surgery
480916|NCT00776737|Attention Deficit Disorder
480917|NCT00776737|Attention Deficit Hyperactivity Disorder
480918|NCT00776737|Computer Aided Learning
480919|NCT00776737|Attention Deficits
480920|NCT00776737|Healthy Volunteer
480921|NCT00776737|HV
480922|NCT00776724|breast ca
480923|NCT00776724|phase III
480924|NCT00776724|Tailored neoadjuvant chemotherapy
480925|NCT00776724|stage II/III
480926|NCT00776711|Healthy
480927|NCT00776711|Avian Influenza
480928|NCT00776711|Immunity
480929|NCT00776711|Preventive
480930|NCT00776711|Bird Flu
480931|NCT00776711|Healthy Volunteer
480932|NCT00776711|HV
480933|NCT00776711|Influenza
480934|NCT00776672|Bioequivalence Fosinopril Tablets
480935|NCT00776659|An Observational Study of Indian Breast Cancer Patients Receiving Adjuvant Therapy with Aromasin
480936|NCT00776659|Antineoplastic Hormonal Drugs
480937|NCT00776659|Aromasin
480938|NCT00776646|bioequivalence hydrochlorothiazide 50 mg tablet fasting conditions
480939|NCT00776633|aspirin
480940|NCT00776633|clopidogrel
480941|NCT00776633|oral anticoagulation
480942|NCT00776633|warfarin
480943|NCT00776633|drug eluting stent
480944|NCT00776633|phenprocoumon
480945|NCT00776620|Bioequivalence Glimepiride Tablets
480946|NCT00776607|LADA
480947|NCT00776607|Latent autoimmune diabetes in adults
480948|NCT00776607|Type 1.5
480949|NCT00776607|Slowly progressive type 1 diabetes
480950|NCT00776594|Androgen deprivation therapy
480951|NCT00776594|ADT
480952|NCT00776594|bevacizumab
480953|NCT00776581|Combined spinal-epidural analgesia
480954|NCT00776581|Patient-controlled analgesia
480955|NCT00776581|Epidural analgesia
480956|NCT00776555|Not required
480957|NCT00776542|bioequivalence Minocycline Tablets
480958|NCT00776529|sensorimotor training
480959|NCT00776529|Strengthening
480960|NCT00776529|Balance
480961|NCT00776516|Healthy volunteer subjects
480962|NCT00776516|CYP3A4 inducer
480963|NCT00776516|rifampin
480964|NCT00776516|drug interaction
480965|NCT00776516|pharmacokinetics
480966|NCT00776516|YM178
480967|NCT00776516|mirabegron
480968|NCT00776503|Epigenetic
480969|NCT00776503|Myelodysplasia
480970|NCT00776503|Cytarabine
480971|NCT00776490|Bioequivalence Glimepiride Tablets
480972|NCT00776451|AMD
480973|NCT00776438|Influenza
480974|NCT00776438|Orthomyxoviruses
480975|NCT00776438|Myxovirus Infection
480976|NCT00776438|Inactivated Split-virion influenza vaccine
480977|NCT00776438|Adults
480978|NCT00776438|Elderly
480979|NCT00776412|Immunologic Non-Responder
480980|NCT00776412|Cardiovascular Disease
480981|NCT00776412|D-dimer
480982|NCT00776412|Antiretroviral
480983|NCT00776412|Mortality
480984|NCT00776412|HIV Positive
480985|NCT00776412|HIV Negative
480986|NCT00776412|Healthy Volunteer
480987|NCT00776412|HV
480988|NCT00776399|Colorectal cancer
480989|NCT00776399|lung metastasis
480990|NCT00776399|radiofrequency ablation
480991|NCT00776399|metastasectomy
480992|NCT00776399|Lung metastasis from colorectal cancer
480993|NCT00776308|molecular breast imaging
480994|NCT00776308|breast cancer
480995|NCT00776308|mammography
480996|NCT00776295|Small Cell Lung Cancer
480997|NCT00776295|SCLC
480998|NCT00776295|Limited Stage Small Cell Lung Cancer
480999|NCT00776282|bioequivalence loratadine 10 mg orally disintegrating
481000|NCT00776282|tablets fed conditions
481001|NCT00776269|Argon laser
481002|NCT00776269|Trichiasis
481003|NCT00776269|Radiofrequency
481004|NCT00776269|Patients with trichiasis
481005|NCT00776256|satiety
481006|NCT00776256|food intake
481007|NCT00776243|incretin
481008|NCT00776243|GLP-1
481009|NCT00776243|GIP
481010|NCT00776243|intensive insulin therapy
481011|NCT00776217|bioequivalence loratadine 10 mg orally disintegrating tablets fasting
481012|NCT00776204|Coronary Artery Disease
481013|NCT00776204|Drug eluting stent
481014|NCT00776204|Percutaneous Coronary Interventions
481015|NCT00776204|Optical Coherence Tomography
481016|NCT00776191|Physioneal 35
481017|NCT00776191|Physioneal 40
481018|NCT00776191|children
481019|NCT00776191|chronic peritoneal dialysis
481020|NCT00776178|Survival Study
481021|NCT00776178|Bladder Cancer
481022|NCT00776178|Cancer Recurrence
481023|NCT00776178|Tumor Markers/Heterogeneity
481024|NCT00776139|Cetirizine Hydrochloride 10 mg tablet fasting conditions
481025|NCT00776126|Breast
481026|NCT00776126|3D Digital Mammography
481027|NCT00776126|Digital Breast Tomosynthesis
481028|NCT00776113|Bioequivalence Carvedilol fasting
481029|NCT00776100|stage IV non-small cell lung cancer
481030|NCT00776100|adenosquamous cell lung cancer
481031|NCT00776100|squamous cell lung cancer
481032|NCT00776100|large cell lung cancer
481033|NCT00776100|adenocarcinoma of the lung
481034|NCT00776100|bronchoalveolar cell lung cancer
481035|NCT00776087|Medical costs
481036|NCT00776087|Telemonitoring
481037|NCT00776087|Implantable cardioverter-defibrillator
481038|NCT00776074|Leiomyoma
481039|NCT00776074|Uterine Fibroids
481040|NCT00776074|Drug Therapy
481041|NCT00776074|Uterine Neoplasms
481042|NCT00776074|Fibroid Tumor
481043|NCT00776035|Obesity
481044|NCT00776035|Heart
481045|NCT00776035|Failure
481046|NCT00776035|PET
481047|NCT00776035|radiation
481048|NCT00776035|metabolism
481049|NCT00776022|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
481050|NCT00776009|ADHD, children, subjects, laboratory classroom
481051|NCT00775996|bioequivalence Clorazepate Tablets
481052|NCT00775970|Obesity
481053|NCT00775970|Weight loss maintenance
481054|NCT00775970|Spontaneous physical activity
481055|NCT00775970|Lipid oxydation
481056|NCT00775970|Walking
481057|NCT00775944|Tobacco
481058|NCT00775944|Cigarette
481059|NCT00775944|Smoking
481060|NCT00775944|Counselling
481061|NCT00775944|Nicotine Replacement Therapy
481062|NCT00775944|Telephone
481063|NCT00775944|Quitline
481064|NCT00775944|Helpline
481065|NCT00775931|osteopetrosis
481066|NCT00775918|Bioequivalence Doxycycline monohydrate 100mg tablets fed conditions
481067|NCT00775905|Bioequivalence amlodipine tablets fasting
481068|NCT00775892|ACL
481069|NCT00775892|Ligament
481070|NCT00775879|Général anesthesia
481071|NCT00775879|Gynecology
481072|NCT00775866|prostate cancer, magnetic resonance imaging, guided imagery
481073|NCT00775853|Biomarkers
481074|NCT00775853|Catecholamines
481075|NCT00775853|18F-Fluoro-L-dopa
481076|NCT00775853|Fluorodopamine
481077|NCT00775853|Parkinson's Disease
481078|NCT00775853|Parkinson Disease
481079|NCT00775853|PD
481080|NCT00775840|Cardiac Failure
481081|NCT00775840|Congestive Heart Failure
481082|NCT00775840|Drug Therapy
481083|NCT00775840|Hypertension
481084|NCT00775840|Diabetes Mellitus
481085|NCT00775827|bioequivalence fenofibrate tablets
481086|NCT00775814|Hypertension
481087|NCT00775814|Drug Therapy
481088|NCT00775814|Blood Pressure
481089|NCT00775814|Insulin, Resistant
481090|NCT00775788|Fat Injection to Breast
481091|NCT00775788|Fat Grafting to Breast
481092|NCT00775762|Symptomatic Polyvascular disease
481093|NCT00775762|Multiple recurrent cardiovascular events
481094|NCT00775749|post operative nausea and vomiting
481095|NCT00775749|gynecological surgery
481096|NCT00775749|outpatient surgery
481097|NCT00775749|nicotine patch
481098|NCT00775749|laparoscopic surgery
481099|NCT00775723|6sulphatoxymelatonin
481100|NCT00775723|preterm infants
481101|NCT00775723|melatonin is low in preterm infants at least until the age of 6 months
481102|NCT00775697|wheezing
481103|NCT00775697|children
481104|NCT00775697|montelukast
481105|NCT00775697|bronchodilators
481106|NCT00775697|lung function
481107|NCT00775697|Rint
481108|NCT00775684|Exenatide
481109|NCT00775684|Sitagliptin
481110|NCT00775684|Glimepiride
481111|NCT00775684|Glucagon-Like Peptide-1
481112|NCT00775684|Impaired Fasting Glucose
481113|NCT00775684|Type 2 Diabetes
481114|NCT00775684|Beta-cell Function
481115|NCT00775684|Beta-cell Secretory Capacity
481116|NCT00775684|Glucose-potentiated arginine
481117|NCT00775658|allergy
481118|NCT00775658|skin testing
481119|NCT00775658|eye drops
481120|NCT00775658|antihistamines
481121|NCT00775645|neurotoxicity
481122|NCT00775645|chemotherapeutic agent toxicity
481123|NCT00775645|fatigue
481124|NCT00775645|neuropathy
481125|NCT00775645|stage IA breast cancer
481126|NCT00775645|stage IB breast cancer
481127|NCT00775645|stage II breast cancer
481128|NCT00775645|stage IIIA breast cancer
481129|NCT00775645|stage IIIB breast cancer
481130|NCT00775645|stage IIIC breast cancer
481131|NCT00775632|Graft Versus Host Disease
481132|NCT00775632|Alemtuzumab
481133|NCT00775632|Campath
481134|NCT00775632|Bone Marrow Transplants
481135|NCT00775619|bioequivalence Carvedilol 12.5 mg tablets fed conditions
481136|NCT00775606|AIDS, HIV
481137|NCT00775593|recurrent adult acute myeloid leukemia
481138|NCT00775593|adult acute basophilic leukemia
481139|NCT00775593|adult acute eosinophilic leukemia
481140|NCT00775593|adult erythroleukemia (M6a)
481141|NCT00775593|adult pure erythroid leukemia (M6b)
481142|NCT00775593|adult acute megakaryoblastic leukemia (M7)
481143|NCT00775593|adult acute minimally differentiated myeloid leukemia (M0)
481144|NCT00775593|adult acute monoblastic leukemia (M5a)
481145|NCT00775593|adult acute monocytic leukemia (M5b)
481146|NCT00775593|adult acute myeloblastic leukemia with maturation (M2)
481147|NCT00775593|adult acute myeloblastic leukemia without maturation (M1)
481148|NCT00775593|adult acute myelomonocytic leukemia (M4)
481149|NCT00775593|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
481150|NCT00775593|adult acute myeloid leukemia with t(16;16)(p13;q22)
481151|NCT00775593|adult acute myeloid leukemia with t(8;21)(q22;q22)
481152|NCT00775593|adult acute myeloid leukemia with inv(16)(p13;q22)
481153|NCT00775580|bioequivalence Atenolol Tablets
481154|NCT00775567|Fructose
481155|NCT00775567|Intolerance
481156|NCT00775567|Adaptation
481157|NCT00775567|Prebiotic
481158|NCT00775567|Healthy men or women 18-40
481159|NCT00775541|Diabetes
481160|NCT00775541|Type 2 Diabetes
481161|NCT00775528|Cystic Fibrosis
481162|NCT00775528|Pancreatic Exocrine Insufficiency
481163|NCT00775515|chronic
481164|NCT00775515|prostatitis
481165|NCT00775515|prostate
481166|NCT00775515|pain
481167|NCT00775515|pelvic
481168|NCT00775515|pelvis
481169|NCT00775515|inflamation
481170|NCT00775502|Multiple myeloma
481171|NCT00775502|GM-2 ganglioside
481172|NCT00775502|monoclonal antibody
481173|NCT00775502|Potelligent design
481174|NCT00775502|Treatment of subjects who have failed previous treatment
481175|NCT00775489|glaucoma, steroid, nasal
481176|NCT00775476|Systemic lupus erythematosus (SLE), an autoimmune disease
481177|NCT00775463|Scleroderma, Diffuse
481178|NCT00775463|Scleroderma, Limited
481179|NCT00775463|Scleroderma, Systemic
481180|NCT00775463|Ulcer
481181|NCT00775463|prostacyclin
481182|NCT00775450|Influenza
481183|NCT00775450|Orthomyxovirus Infection
481184|NCT00775450|Inactivated Split-virion influenza vaccine
481185|NCT00775450|Elderly
481186|NCT00775437|juvenile idiopathic arthritis
481187|NCT00775437|compassionate use
481188|NCT00775437|open label
481189|NCT00775424|HIV infection
481190|NCT00775424|DNA vaccine
481191|NCT00775424|IL-12 adjuvant
481192|NCT00775424|IL-15 adjuvant
481193|NCT00775398|Hemostasis
481194|NCT00775398|Thrombin-JMI
481195|NCT00775398|Thrombin
481196|NCT00775398|Blood Coagulation
481197|NCT00775385|Chemotherapy, Adjuvant
481198|NCT00775372|Bioequivalence study of clarithromycin 250mg/5mL powdder
481199|NCT00775359|bioequivalence fenofibrate tablets
481200|NCT00775333|Carpal Tunnel Syndrome
481201|NCT00775333|Diabetes
481202|NCT00775333|APB strength
481203|NCT00775333|Sensory Function
481204|NCT00775333|Pillar Pain
481205|NCT00775333|Cold Intolerance
481206|NCT00775333|Patient Satisfaction
481207|NCT00775320|Brain scan
481208|NCT00775307|Non-small cell lung cancer
481209|NCT00775307|Stage I
481210|NCT00775307|adjuvant therapy
481211|NCT00775307|Adjuvant Drug Therapy
481212|NCT00775281|Tachykinin receptors
481213|NCT00775281|Protein expression
481214|NCT00775281|Contractile proteins
481215|NCT00775281|Inflammatory proteins
481216|NCT00775268|18F Fluorothymidine
481217|NCT00775268|PET/CT
481218|NCT00775268|FLT
481219|NCT00775268|Lymphoma
481220|NCT00775268|FDG
481221|NCT00775255|Bioequiavelnce clarithromycin
481222|NCT00775242|Menopause
481223|NCT00775242|Hormone Replacement Therapy
481224|NCT00775242|Microspheres
481225|NCT00775242|Progesterone
481226|NCT00775242|Estradiol
481227|NCT00775242|Hot flashes
481228|NCT00775229|hair pulling
481229|NCT00775203|Unipolar
481230|NCT00775190|birth control pills
481231|NCT00775190|oral contraceptives
481232|NCT00775190|brand name
481233|NCT00775190|generic
481234|NCT00775190|side effects
481235|NCT00775190|oral contraceptive side effects
481236|NCT00775190|dysfunctional uterine bleeding
481237|NCT00775190|pre-menstrual symptoms
481238|NCT00775177|Bioequivalence Doxycycline monohydrate 100mg tablets fed conditions
481239|NCT00775164|Obese children with insulin resistance
481240|NCT00775151|Bioequivalence amlodipine 10 mg tablet under fed conditions
481241|NCT00775138|Bronchiectasis
481242|NCT00775138|Respiratory Infections
481243|NCT00775138|Amikacin
481244|NCT00775138|Genetic Diseases, Inborn
481245|NCT00775138|Respiratory Tract Diseases
481246|NCT00775138|Cystic Fibrosis
481247|NCT00775138|Respiratory Tract Infections
481248|NCT00775138|Lung Diseases
481249|NCT00775138|Infant, Newborn, Diseases
481250|NCT00775138|Pancreatic Diseases
481251|NCT00775125|VX-950-TiDP24-C124
481252|NCT00775125|VX-950-C124
481253|NCT00775125|HCV
481254|NCT00775125|DDI
481255|NCT00775125|telaprevir
481256|NCT00775125|darunavir
481257|NCT00775125|ritonavir
481258|NCT00775125|fosamprenavir
481259|NCT00775125|interaction
481260|NCT00775125|pharmacokinetics
481261|NCT00775125|steady-state
481262|NCT00775112|supportive care
481263|NCT00775112|lumbar puncture
481264|NCT00775112|childhood disease
481265|NCT00775112|pediatric hemato-oncology
481266|NCT00775099|Air Pollution
481267|NCT00775099|Particles
481268|NCT00775099|Particulate Matter
481269|NCT00775099|Vascular function
481270|NCT00775099|Endothelial function
481271|NCT00775099|Thrombosis
481272|NCT00775086|ORTHO EVRA
481273|NCT00775086|contraception
481274|NCT00775086|NGMN
481275|NCT00775086|contraceptive patch
481276|NCT00775086|bioequivalence
481277|NCT00775086|EE
481278|NCT00775086|norelgestromin
481279|NCT00775086|ethinyl estradiol
481280|NCT00775073|Liver cancer
481281|NCT00775073|HCC
481282|NCT00775047|depo medroxyprogesterone acetate
481283|NCT00775047|Depo Provera
481284|NCT00775047|contraceptive compliance
481285|NCT00775047|pharmacists
481286|NCT00775047|Compliance in receiving additional Depo Provera injections
481287|NCT00775047|Satisfaction in receiving Depo Provera injections at a pharmacy compared with usual clinic
481288|NCT00775008|weight loss, health information, e-health
481289|NCT00774995|Engerix-B
481290|NCT00774995|Hepatitis B
481291|NCT00774982|Crohns Disease
481292|NCT00774982|Pharmacokinetics
481293|NCT00774982|Local Targeted Delivery to the Ileum
481294|NCT00774982|Delayed Release
481295|NCT00774982|Immunology Measurements
481296|NCT00774982|Pharmacokinetics in Crohns Disease Patients
481297|NCT00774943|Systemic lupus erythematosus
481298|NCT00774943|ICOSL
481299|NCT00774943|B7RP-1
481300|NCT00774943|Costimulation
481301|NCT00774930|Carcinoid tumor
481302|NCT00774930|Somatuline Depot
481303|NCT00774930|Lanreotide Autogel
481304|NCT00774930|Neuroendocrine tumor
481305|NCT00774930|NET
481306|NCT00774930|Diarrhea
481307|NCT00774930|Flushing
481308|NCT00774930|Carcinoid tumour
481309|NCT00774930|Neuroendocrine tumour
481310|NCT00774930|Diarrhoea
481311|NCT00774917|numen
481312|NCT00774917|hyperplasia
481313|NCT00774904|Type 2 Diabetes
481314|NCT00774904|Diabetic Nephropathy
481315|NCT00774904|Glucose Metabolism
481316|NCT00774904|Angiotensin II Type 1 Receptor Blockers
481317|NCT00774891|Echocardiography- exercise
481318|NCT00774891|Echocardiography- dobutamine
481319|NCT00774891|Wall stress
481320|NCT00774891|Ventricular volume-left
481321|NCT00774891|Ischemia
481322|NCT00774891|Angina
481323|NCT00774891|Heart diseases
481324|NCT00774891|Stress echocardiography
481325|NCT00774891|Ventricular volume
481326|NCT00774891|Vascular diseases
481327|NCT00774878|Breast cancer
481328|NCT00774878|Breast Tumors
481329|NCT00774878|Anti IGF-1R
481330|NCT00774878|Hormonosensitivity
481331|NCT00774865|Robotic
481332|NCT00774865|CABG
481333|NCT00774865|LITA
481334|NCT00774865|Patency
481335|NCT00774865|Long
481336|NCT00774865|Term
481337|NCT00774852|lupus
481338|NCT00774852|systemic lupus erythematosus
481339|NCT00774852|lupus nephritis
481340|NCT00774852|SLE
481341|NCT00774852|abatacept
481342|NCT00774852|CTLA4
481343|NCT00774852|CTLA4Ig
481344|NCT00774852|glomerulonephritis
481345|NCT00774839|Newly Diagnosed
481346|NCT00774839|Colon
481347|NCT00774839|Stage II
481348|NCT00774839|Stage III
481349|NCT00774826|Follicular lymphoma
481350|NCT00774826|Rituximab
481351|NCT00774813|Depression
481352|NCT00774813|Mild
481353|NCT00774813|Moderate
481354|NCT00774813|Anxiety
481355|NCT00774813|Kalaco Scientific, Inc.
481356|NCT00774800|Recombinant Hyaluronidase
481357|NCT00774800|Type 1 Diabetes Mellitus
481358|NCT00774800|Humalog
481359|NCT00774800|Humulin R
481360|NCT00774800|rHuPH20
481361|NCT00774800|Hylenex
481362|NCT00774787|Combination treatment
481363|NCT00774787|Imiquimod
481364|NCT00774787|Cryotherapy
481365|NCT00774774|Influenza, human
481366|NCT00774774|Masks
481367|NCT00774774|Disease Transmission, Horizontal
481368|NCT00774761|Chronic
481369|NCT00774761|Obstructive
481370|NCT00774761|Pulmonary
481371|NCT00774761|Disease
481372|NCT00774761|COPD
481373|NCT00774761|Pharmacodynamic
481374|NCT00774761|Pharmacokinetic
481375|NCT00774748|low molecular weight heparin
481376|NCT00774748|enoxaparin
481377|NCT00774748|Lovenox
481378|NCT00774748|Insuflon
481379|NCT00774748|subcutaneous catheter
481380|NCT00774748|once or twice daily dosing of subcutaneous enoxaparin
481381|NCT00774735|healthy volunteer
481382|NCT00774735|darunavir
481383|NCT00774735|lopinavir
481384|NCT00774735|ritonavir
481385|NCT00774735|GSK1349572
481386|NCT00774735|integrase
481387|NCT00774735|pharmacokinetics
481388|NCT00774709|Heart failure
481389|NCT00774709|Preserved ejection fraction
481390|NCT00774709|Diastolic dysfunction
481391|NCT00774709|Dyssynchrony
481392|NCT00774709|Echocardiography
481393|NCT00774709|Patients with acute heart failure clinically
481394|NCT00774709|diagnosed
481395|NCT00774709|BNP level > 100 ng / l or NT-proBNP > 300 ng /l
481396|NCT00774709|Preserved left ventricular ejection fraction(LVEF
481397|NCT00774709|≥ 45%)
481398|NCT00774696|Bioequivalence study of clarithromycin
481399|NCT00774683|Pilot
481400|NCT00774683|Pharmacokinetics
481401|NCT00774683|Raltegravir
481402|NCT00774683|Cervicovaginal
481403|NCT00774683|HIV
481404|NCT00774683|Women
481405|NCT00774657|Aortic Stenosis
481406|NCT00774657|Valvular heart disease
481407|NCT00774657|Heart disease
481408|NCT00774657|Cardiovascular disease
481409|NCT00774657|Two dimensional echocardiography
481410|NCT00774657|Three dimensional echocardiography
481411|NCT00774631|Meningitis
481412|NCT00774631|Hypothermia
481413|NCT00774631|Intensive care
481414|NCT00774618|Rib Fracture
481415|NCT00774618|Thoracic Injuries
481416|NCT00774618|Flail Chest
481417|NCT00774618|Rib Fracture Repair
481418|NCT00774618|Rib Fracture ORIF
481419|NCT00774618|Chronic rib fractures
481420|NCT00774618|Non-healing rib fractures
481421|NCT00774618|Rib Fracture Non-union
481422|NCT00774605|percutaneous, transcutaneous, topical, varenicline, transdermal, transdermal delivery system, patch
481423|NCT00774592|Adolescent Risk Reduction
481424|NCT00774592|HIV/AIDS Prevention
481425|NCT00774592|Behavioral Change
481426|NCT00774592|HIV
481427|NCT00774579|growth hormone
481428|NCT00774579|growth hormone deficiency
481429|NCT00774579|liver fat
481430|NCT00774579|liver steatosis
481431|NCT00774579|growth hormone replacement
481432|NCT00774566|catheter ablation
481433|NCT00774566|randomized
481434|NCT00774566|cryo
481435|NCT00774566|radiofrequency
481436|NCT00774566|atrial fibrillation
481437|NCT00774566|cryo-balloon
481438|NCT00774566|PV-Isolation
481439|NCT00774553|Type 2 diabetes
481440|NCT00774540|Acute pain
481441|NCT00774540|Inflammatory pain
481442|NCT00774540|Inflammatory mediators
481443|NCT00774540|Pain relief
481444|NCT00774540|Microdialysis
481445|NCT00774514|Air Pollution
481446|NCT00774514|Nitrogen Dioxide
481447|NCT00774514|NO2
481448|NCT00774514|Endothelial dysfunction
481449|NCT00774501|Anesthesia
481450|NCT00774501|suspended ventilation
481451|NCT00774488|Euglycemic-hyperinsulinemic clamp
481452|NCT00774488|fat biopsies
481453|NCT00774488|microarray analysis
481454|NCT00774488|quantitative real time PCR
481455|NCT00774488|overnutrition
481456|NCT00774488|low grade-inflammation
481457|NCT00774475|Clopidogrel therapy
481458|NCT00774475|platelet function inhibition
481459|NCT00774462|Myositis
481460|NCT00774462|Anti-synthetase
481461|NCT00774462|Anti-SRP
481462|NCT00774462|Myasthenia gravis
481463|NCT00774462|Rituximab
481464|NCT00774449|lung transplantation
481465|NCT00774449|bronchiolitis obliterans syndrome
481466|NCT00774449|broncholaveolar lavage
481467|NCT00774449|high-resolution computertomography
481468|NCT00774449|quality of life
481469|NCT00774436|focal cryotherapy
481470|NCT00774436|low-risk prostate cancer
481471|NCT00774423|Spinal muscular atrophies (SMA)
481472|NCT00774423|Degeneration of the motor neurons
481473|NCT00774423|Anterior horn of the spinal cord
481474|NCT00774423|Riluzole
481475|NCT00774384|Neisseria meningitidis
481476|NCT00774384|Mucosal
481477|NCT00774384|Vaccination
481478|NCT00774384|Immunity
481479|NCT00774384|T cells
481480|NCT00774384|T regulatory cells
481481|NCT00774371|Overweight
481482|NCT00774371|Obese
481483|NCT00774371|Breast cancer survivors
481484|NCT00774371|Weight loss
481485|NCT00774371|Physical activity
481486|NCT00774371|Exercise
481487|NCT00774371|Cognitive behavioral therapy
481488|NCT00774358|Primary Immunodeficiency
481489|NCT00774319|HNSCC
481490|NCT00774319|neo Adjuvant
481491|NCT00774319|Chemoradiation therapy
481492|NCT00774319|TPF
481493|NCT00774306|vascular risk
481494|NCT00774306|lipid fractions
481495|NCT00774306|lipoprotein(a)
481496|NCT00774306|C-reactive protein
481497|NCT00774306|subarachnoid hemorrhage
481498|NCT00774306|antiepileptic drug
481499|NCT00774306|randomized
481500|NCT00774306|seizure
481501|NCT00774306|cholesterol
481502|NCT00774293|Homoeopathic treatment,
481503|NCT00774293|heart surgery,
481504|NCT00774293|randomized clinical trial
481505|NCT00774254|Health Disparities
481506|NCT00774254|Risk Communication
481507|NCT00774254|Numeracy
481508|NCT00774254|Doctor-Patient Communication
481509|NCT00774254|Virtual Reality Technology
481510|NCT00774254|Communication
481511|NCT00774228|Cataract or intraocular lens placement surgery
481512|NCT00774215|Pelvic Organ Prolapse
481513|NCT00774215|Cystocele
481514|NCT00774215|Rectocele
481515|NCT00774215|Enterocele
481516|NCT00774215|Synthetic Mesh
481517|NCT00774215|Vaginal Mesh
481518|NCT00774215|Transobturator
481519|NCT00774202|Pts w/ Chronic ITP who have fail/relap after Rituxan rx
481520|NCT00774189|Bioequivalence clarithromycin 250mg tablets fasting
481521|NCT00774176|Chronic Obstructive Pulmonary Disease
481522|NCT00774176|COPD
481523|NCT00774176|COPD Exacerbation
481524|NCT00774176|Genetic markers COPD
481525|NCT00774176|Gene expression in COPD exacerbations
481526|NCT00774176|COPD Exacerbation Symptom Reporting
481527|NCT00774176|COPD Exacerbation Disease Management
481528|NCT00774176|COPD Treatment
481529|NCT00774176|Breathing disorders
481530|NCT00774176|Emphysema
481531|NCT00774176|COPD with Healthy Control comparators for genetic association studies.
481532|NCT00774163|probiotics
481533|NCT00774163|lactobacillus
481534|NCT00774163|reuteri
481535|NCT00774163|none (safety only)
481536|NCT00774150|Neural correlates of pediatric anxiety disorder
481537|NCT00774150|Social correlates of pediatric anxiety disorder
481538|NCT00774150|Generalized Anxiety Disorder in pediatric populations
481539|NCT00774150|Separation Anxiety Disorder in pediatric populations
481540|NCT00774150|Social Phobia in pediatric populations
481541|NCT00774137|Acute Kidney Injury
481542|NCT00774137|IL-18
481543|NCT00774137|NGAL
481544|NCT00774137|Cystatin C
481545|NCT00774137|Biomarkers
481546|NCT00774137|Dialysis
481547|NCT00774124|GDM, pregnancy, macrosomia
481548|NCT00774111|healthy volunteer
481549|NCT00774111|pharmacokinetics
481550|NCT00774111|GSK1349572
481551|NCT00774111|integrase
481552|NCT00774111|etravirine
481553|NCT00774098|all adult patients (>18 years) planned to undergo a major liver resection
481554|NCT00774085|Schizophrenia
481555|NCT00774085|Risperidone
481556|NCT00774085|Risperdal Consta
481557|NCT00774085|Propective
481558|NCT00774085|Retrospective
481559|NCT00774085|Mental disorders
481560|NCT00774085|Observational
481561|NCT00774072|subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
481562|NCT00774059|Breast ptosis, Breast lift
481563|NCT00774046|Therapy-related myelodysplastic syndrome/ Therapy -related Acute myeloid leukemia
481564|NCT00774046|Myelodysplastic syndrome
481565|NCT00774046|Acute myeloid leukemia
481566|NCT00774033|Keratinocytes
481567|NCT00774033|Cell spray
481568|NCT00774033|Deep partial thickness burns
481569|NCT00774033|Full thickness burns
481570|NCT00774020|Paget's Disease of Bone
481571|NCT00774020|Serum Alkaline Phosphatase
481572|NCT00774007|Irritable bowel syndrome, abdominal pain, abdominal bloating, immune cells, mast cells
481573|NCT00773994|anterior palatal eminence
481574|NCT00773994|palatal elevation above the maxillary plane
481575|NCT00773994|anterior uvular prolapse
481576|NCT00773994|"inverted-V present in base view."
481577|NCT00773981|anastomotic leakage
481578|NCT00773942|Medication therapy management
481579|NCT00773942|Pharmacist
481580|NCT00773942|Chronic care
481581|NCT00773942|Medicare
481582|NCT00773942|Medicaid
481583|NCT00773942|Medication reconciliation
481584|NCT00773942|Adverse drug events
481585|NCT00773942|Drug related problems
481586|NCT00773916|Attention Deficit Disorder
481587|NCT00773916|Attention Deficit Disorders with Hyperactivity
481588|NCT00773916|Hyperkinetic Syndrome
481589|NCT00773916|Family Function
481590|NCT00773916|Adverse Factors
481591|NCT00773916|Parental Psychopathology
481592|NCT00773877|RNFL thickness
481593|NCT00773864|Healthcare employees who work in the rehabilitation center
481594|NCT00773851|ventral hernia
481595|NCT00773851|laparoscopy
481596|NCT00773851|mesh
481597|NCT00773851|recurrence
481598|NCT00773825|Genomic imprinting
481599|NCT00773825|Reproductive techniques, assisted
481600|NCT00773825|Beckwith-Wiedemann syndrome
481601|NCT00773825|Angelman syndrome
481602|NCT00773812|Autistic Disorder
481603|NCT00773812|Autism
481604|NCT00773812|Mecamylamine
481605|NCT00773812|Pervasive Developmental Disorder-Not Otherwise Specified
481606|NCT00773799|To define activities and patient characteristics likely to lead to dissemination of resistant bacteria in rehabilitation centers and
481607|NCT00773799|To define specific risk factors for acquisition of resistant bacteria (ESBL producers and MRSA) in rehabilitation centers.
481608|NCT00773799|ESBL producers
481609|NCT00773799|MRSA
481610|NCT00773786|COPD
481611|NCT00773786|Bronchodilator
481612|NCT00773786|arformoterol
481613|NCT00773786|tiotropium
481614|NCT00773773|Biomarkers - PSA, hK2 and solubilized
481615|NCT00773773|urokinase-receptor forms (su-PAR)
481616|NCT00773773|08-114
481617|NCT00773760|opioids
481618|NCT00773760|COMT
481619|NCT00773760|SNP
481620|NCT00773760|analgesia
481621|NCT00773760|postoperative pain
481622|NCT00773747|Neoplasms, Plasma Cell
481623|NCT00773747|Neoplasms by Histologic Type
481624|NCT00773747|Neoplasms
481625|NCT00773747|Hemostatic Disorders
481626|NCT00773747|Vascular Diseases
481627|NCT00773747|Cardiovascular Diseases
481628|NCT00773747|Paraproteinemias
481629|NCT00773747|Blood Protein Disorders
481630|NCT00773747|Hematologic Diseases
481631|NCT00773747|Hemorrhagic Disorders
481632|NCT00773747|Lymphoproliferative Disorders
481633|NCT00773747|Immunoproliferative Disorders
481634|NCT00773747|Immune System Diseases
481635|NCT00773747|Vorinostat
481636|NCT00773747|Bortezomib
481637|NCT00773747|Anti-Inflammatory Agents, Non-Steroidal
481638|NCT00773747|Analgesics, Non-Narcotic
481639|NCT00773747|Analgesics
481640|NCT00773747|Sensory System Agents
481641|NCT00773747|Peripheral Nervous System Agents
481642|NCT00773747|Physiological Effects of Drugs
481643|NCT00773747|Pharmacologic Actions
481644|NCT00773747|Anti-Inflammatory Agents
481645|NCT00773747|Therapeutic Uses
481646|NCT00773747|Antirheumatic Agents
481647|NCT00773747|Antineoplastic Agents
481648|NCT00773747|Enzyme Inhibitors
481649|NCT00773747|Molecular Mechanisms of Pharmacological Action
481650|NCT00773747|Anticarcinogenic Agents
481651|NCT00773734|moderate-to-severe plaque-type psoriasis
481652|NCT00773708|HIV infection
481653|NCT00773708|Discordant patient
481654|NCT00773708|CD4 recovery
481655|NCT00773708|intensification antiretroviral therapy
481656|NCT00773708|raltegravir
481657|NCT00773708|"HIV-1 infected patient classified as discordant who showed high level of CD8+HLADR+CD38+ and cell death values at the screening"
481658|NCT00773682|osteoarthritis
481659|NCT00773682|hands
481660|NCT00773682|mud-packs therapy
481661|NCT00773682|balneotherapy
481662|NCT00773682|Osteoarthritis of the hands
481663|NCT00773669|male breast cancer
481664|NCT00773669|Male breast cancer patients diagnosed and/or
481665|NCT00773669|treated at Summa Health System/Akron City Hospital
481666|NCT00773669|from the reference year of 1995 through 2007.
481667|NCT00773656|Radiotherapy
481668|NCT00773656|Biologically effective dose
481669|NCT00773656|Radiation injury
481670|NCT00773643|to procure human temporalis muscle, subcutaneous adipose (fat), and bone tissue samples from children with craniosynostosis,
481671|NCT00773643|to grow cells from these tissues in vitro
481672|NCT00773643|to evaluate the osteogenic potentials of these cell types.
481673|NCT00773617|Bulimia Nervosa
481674|NCT00773617|Treatment Efficacy
481675|NCT00773617|Integrative Cognitive Affective Therapy
481676|NCT00773617|Cognitive Behavior Therapy
481677|NCT00773604|blepharospasm
481678|NCT00773604|Deep brain Stimulation
481679|NCT00773604|cervical dystonia
481680|NCT00773604|cranial dystonia
481681|NCT00773604|generalized dystonia
481682|NCT00773604|subthalamic nucleus
481683|NCT00773604|DBS
481684|NCT00773591|Sleep-related breathing disorders
481685|NCT00773591|Snoring
481686|NCT00773578|Children
481687|NCT00773578|Tobacco smoke exposure
481688|NCT00773578|Exhaled nitric oxide
481689|NCT00773578|Nasal lavage
481690|NCT00773578|Cytokines
481691|NCT00773565|patients with obesity (BMI > 30 kg/m2)
481692|NCT00773552|OAB
481693|NCT00773552|overactive bladder
481694|NCT00773552|urinary urge
481695|NCT00773552|urge incontinence
481696|NCT00773552|urge
481697|NCT00773539|atrial fibrillation
481698|NCT00773539|pulmonary veins
481699|NCT00773539|ablation
481700|NCT00773500|Medication Errors
481701|NCT00773487|Asthma GINA 1
481702|NCT00773487|Mild intermittant asthma
481703|NCT00773448|Cancer
481704|NCT00773448|Screening
481705|NCT00773435|Upper respiratory tract infections
481706|NCT00773435|Children
481707|NCT00773435|Echinacea
481708|NCT00773435|Prevention
481709|NCT00773435|Immune modulation
481710|NCT00773422|smoking lapse behavior
481711|NCT00773422|smoking cessation
481712|NCT00773422|varenicline
481713|NCT00773422|naltrexone
481714|NCT00773422|medication effect on smoking lapse behavior
481715|NCT00773370|stroke
481716|NCT00773370|exercise
481717|NCT00773357|smoking lapse behavior
481718|NCT00773357|smoking cessation
481719|NCT00773357|guanfacine
481720|NCT00773357|carvedilol
481721|NCT00773357|medication effect on smoking lapse behavior
481722|NCT00773357|medication effect on smoking cessation
481723|NCT00773357|stress
481724|NCT00773357|gender differences
481725|NCT00773344|Solid Tumors (dose escalation/Phase 1)
481726|NCT00773344|Breast Cancer (recommended dose phase/Phase 2)
481727|NCT00773318|LM/SL
481728|NCT00773318|SPECT/low-dose multislice CT
481729|NCT00773305|seed implantation
481730|NCT00773292|HAM/TSP
481731|NCT00773266|Aphakia
481732|NCT00773266|Secondary IOL-Implantation
481733|NCT00773266|Iris-Fixated IOL
481734|NCT00773266|Artisan
481735|NCT00773266|Anterior Segment OCT
481736|NCT00773266|Aphakia - secondary iris-fixated IOL position
481737|NCT00773253|dystonia
481738|NCT00773253|cervical dystonia
481739|NCT00773253|Botox
481740|NCT00773253|idiopathic primary cervical dystonia
481741|NCT00773227|Oculopharyngeal muscular dystrophy
481742|NCT00773227|Swallowing disorders, dysphagia
481743|NCT00773227|Pharyngeal propulsion
481744|NCT00773227|Upper oesophageal sphincter
481745|NCT00773227|Cricopharyngeal muscle
481746|NCT00773227|Autologous myoblasts
481747|NCT00773227|Autograft
481748|NCT00773227|Myotomy of the upper oesophageal sphincter
481749|NCT00773227|Fibroscopy of swallowing
481750|NCT00773227|Videofluoroscopy of swallowing
481751|NCT00773214|Obesity
481752|NCT00773214|Appetite
481753|NCT00773214|Body composition
481754|NCT00773214|Energy compensation
481755|NCT00773201|Long QT syndrome
481756|NCT00773201|Cardiac repolarisation
481757|NCT00773201|Genome-wide association
481758|NCT00773201|Electrophysiology
481759|NCT00773201|Drugs/adverse effects
481760|NCT00773175|pediatric
481761|NCT00773175|hylenex
481762|NCT00773175|subcutaneous infusion
481763|NCT00773175|hyaluronidase
481764|NCT00773175|rHuPH20
481765|NCT00773175|recombinant human hyaluronidase
481766|NCT00773149|Adult Acute Lymphocytic Leukemia
481767|NCT00773149|Alemtuzumab
481768|NCT00773136|Bimatoprost
481769|NCT00773136|Eyelash lengthening
481770|NCT00773136|Prostaglandin Analogs
481771|NCT00773136|Cosmetics
481772|NCT00773123|RT-View
481773|NCT00773123|Spectral domain OCT
481774|NCT00773123|Ganglion cell layer
481775|NCT00773123|RNFL
481776|NCT00773123|Visual field defect
481777|NCT00773110|hemolysis
481778|NCT00773110|systemic inflammatory response syndrome
481779|NCT00773110|cardiopulmonary bypass
481780|NCT00773110|albumin
481781|NCT00773097|Prevention
481782|NCT00773097|Colorectal Cancer
481783|NCT00773084|Diastolic Heart Failure
481784|NCT00773084|Hispanic Americans
481785|NCT00773084|Aliskiren
481786|NCT00773084|Spironolactone
481787|NCT00773084|Lisinopril
481788|NCT00773084|Diastolic Heart Failure in Hispanic Americans
481789|NCT00773071|Cervical cancer, vulvar cancer, LM/SL, SPECT/CT
481790|NCT00773058|acute respiratory distress syndrome
481791|NCT00773058|glucocorticoid
481792|NCT00773058|adrenal insufficiency
481793|NCT00773045|pain scores
481794|NCT00773045|critically ill patients
481795|NCT00773045|ICU
481796|NCT00773045|pain management
481797|NCT00773045|pain measurement
481798|NCT00773019|infusion pump
481799|NCT00773019|implantable
481800|NCT00773019|performance
481801|NCT00773006|coronary artery disease
481802|NCT00773006|percutaneous coronary intervention
481803|NCT00773006|anticoagulation
481804|NCT00772993|glaucoma
481805|NCT00772993|myopia
481806|NCT00772993|myopia with glaucoma
481807|NCT00772993|normal control
481808|NCT00772954|Clostridium difficile diarrhea
481809|NCT00772954|Clostridium difficile toxoid vaccine
481810|NCT00772928|Pertussis
481811|NCT00772928|Whooping cough
481812|NCT00772928|Diphtheria
481813|NCT00772928|Tetanus
481814|NCT00772928|Haemophilus influenzae
481815|NCT00772928|Poliovirus Types 1, 2, and 3.
481816|NCT00772915|stage I multiple myeloma
481817|NCT00772915|stage II multiple myeloma
481818|NCT00772915|stage III multiple myeloma
481819|NCT00772902|HIV-1
481820|NCT00772902|LDL
481821|NCT00772902|HDL
481822|NCT00772902|non-HDL cholesterol
481823|NCT00772902|triglycerides
481824|NCT00772902|cholesterol
481825|NCT00772889|Elderly
481826|NCT00772889|Vaccine
481827|NCT00772889|Influenza
481828|NCT00772876|P1446A-05
481829|NCT00772876|Advanced refractory malignancies
481830|NCT00772876|Phase I
481831|NCT00772850|Humeral fracture; Antegrade nailing; Rotator cuff
481832|NCT00772837|Functional Dyspepsia
481833|NCT00772837|Helicobacter Pylori eradication
481834|NCT00772837|Quality of Life
481835|NCT00772837|Dyspeptic Symptoms
481836|NCT00772824|Breast cancer
481837|NCT00772824|Chemotherapy
481838|NCT00772824|Epirubicin
481839|NCT00772824|Glutamine
481840|NCT00772824|FEC chemotherapy
481841|NCT00772798|ovarian cancer
481842|NCT00772798|HDAC inhibitor
481843|NCT00772798|vorinostat
481844|NCT00772785|opioid dependence
481845|NCT00772785|opioid addiction
481846|NCT00772785|buprenorphine
481847|NCT00772785|methadone
481848|NCT00772785|heroin
481849|NCT00772785|implant
481850|NCT00772785|opioid withdrawal
481851|NCT00772785|opioid pain medication
481852|NCT00772785|suboxone
481853|NCT00772772|Vitamin D3 repletion
481854|NCT00772772|levels of endotoxin
481855|NCT00772772|intestinal permeability
481856|NCT00772772|accelerated atherosclerosis
481857|NCT00772759|AZD3199
481858|NCT00772759|Japanese Healthy Volunteers
481859|NCT00772759|Phase I study
481860|NCT00772759|Single and Multiple Ascending Dose
481861|NCT00772759|safety
481862|NCT00772759|tolerability
481863|NCT00772759|PK
481864|NCT00772746|panic
481865|NCT00772746|respiration
481866|NCT00772746|anxiety
481867|NCT00772746|exercise
481868|NCT00772746|cognition
481869|NCT00772733|Quality assurance
481870|NCT00772733|rehabilitation
481871|NCT00772733|chronic care model
481872|NCT00772733|COPD
481873|NCT00772707|contact lens solution
481874|NCT00772707|OPTI-FREE RepleniSH
481875|NCT00772707|contact lenses
481876|NCT00772694|testicular cancer
481877|NCT00772694|germ cell cancer
481878|NCT00772694|sorafenib
481879|NCT00772668|stage III grade 1 follicular lymphoma
481880|NCT00772668|stage IV grade 1 follicular lymphoma
481881|NCT00772668|stage III grade 2 follicular lymphoma
481882|NCT00772668|stage IV grade 2 follicular lymphoma
481883|NCT00772668|stage III marginal zone lymphoma
481884|NCT00772668|stage IV marginal zone lymphoma
481885|NCT00772655|Follicular Lymphoma
481886|NCT00772655|First line therapy
481887|NCT00772655|Zevalin
481888|NCT00772655|90Yttrium-Ibritumomab Tiuxetan
481889|NCT00772655|Yttrium
481890|NCT00772655|Rituximab
481891|NCT00772655|Radio-immuno therapy
481892|NCT00772642|Cross-Sectional
481893|NCT00772642|Plasmodium Falciparum Malaria
481894|NCT00772642|Cord Blood
481895|NCT00772642|Immunology
481896|NCT00772642|Mali
481897|NCT00772642|Malaria
481898|NCT00772629|Menactra®
481899|NCT00772629|Meningitis
481900|NCT00772629|Meningococcemia
481901|NCT00772629|Neisseria meningitidis
481902|NCT00772616|Anesthesia
481903|NCT00772616|Analgesia
481904|NCT00772616|Patient-Controlled Analgesia
481905|NCT00772616|Hyperalgesia
481906|NCT00772603|Partial onset epilepsy
481907|NCT00772603|Partial onset seizures
481908|NCT00772590|HIV
481909|NCT00772590|antiretroviral therapy intensification
481910|NCT00772590|suboptimal CD4+ T cell response
481911|NCT00772590|virological suppression
481912|NCT00772590|bovine colostrum
481913|NCT00772590|raltegravir
481914|NCT00772577|Hypertension, Obese, aliskiren, hydrochlorothiazide, systolic blood pressure, diastolic blood pressure, ramipril, stage 2
481915|NCT00772564|Acute ST Elevation Myocardial Infarction
481916|NCT00772525|Visual acuity
481917|NCT00772525|Contrast sensitivity
481918|NCT00772525|Visual Evoked Potentials
481919|NCT00772525|Optical Coherence Tomography
481920|NCT00772512|PF-04802540, polysomnography, REM, cross over
481921|NCT00772486|Chronic lymphocytic leukemia
481922|NCT00772486|Leukemia
481923|NCT00772486|Leukemia, Lymphocytic, Chronic, B-Cell
481924|NCT00772486|Leukemia, B-Cell
481925|NCT00772486|Immune System Diseases
481926|NCT00772486|Rituximab
481927|NCT00772486|Fludarabine
481928|NCT00772486|Cyclophosphamide
481929|NCT00772486|ISF35
481930|NCT00772486|Ad-ISF35
481931|NCT00772486|Refractory
481932|NCT00772486|Resistant
481933|NCT00772486|17p-
481934|NCT00772486|del 17p
481935|NCT00772486|17p
481936|NCT00772486|Resistant CLL
481937|NCT00772486|Refractory CLL
481938|NCT00772486|17p- CLL
481939|NCT00772486|CLL
481940|NCT00772460|patient warming
481941|NCT00772460|convective warming
481942|NCT00772460|conductive warming
481943|NCT00772460|intraoperative normothermia
481944|NCT00772460|accidental hypothermia
481945|NCT00772460|intraoperative hypothermia
481946|NCT00772447|Skin Infections
481947|NCT00772447|Complicated Bacterial Skin and Skin Structure Infection due to Gram-positive Pathogens
481948|NCT00772421|Epilepsy
481949|NCT00772421|Recruitment rhythm
481950|NCT00772421|DBS
481951|NCT00772408|pulmonary tuberculosis
481952|NCT00772408|Toll-like receptor 2 gene polymorphisms
481953|NCT00772408|blood lymphocyte subsets
481954|NCT00772408|systemic symptoms
481955|NCT00772408|pleural effusion
481956|NCT00772395|Periprosthetic bone loss risedronate bisphosphonates
481957|NCT00772382|Chronic Kidney Disease
481958|NCT00772382|Dialysis
481959|NCT00772382|Hyperphosphatemia
481960|NCT00772382|Phosphate binder
481961|NCT00772369|Pertussis
481962|NCT00772369|Whooping cough
481963|NCT00772369|Diphtheria
481964|NCT00772369|Tetanus
481965|NCT00772369|Haemophilus influenzae
481966|NCT00772369|Poliovirus Types 1, 2, and 3.
481967|NCT00772343|Diarrhea
481968|NCT00772343|Clostridium difficile infection
481969|NCT00772343|Clostridium difficile toxoid
481970|NCT00772317|Recurrent
481971|NCT00772317|prostate cancer
481972|NCT00772317|ebrt
481973|NCT00772317|hifu
481974|NCT00772304|rhinitis
481975|NCT00772291|inguinal
481976|NCT00772291|hernia
481977|NCT00772291|chronic
481978|NCT00772291|pain
481979|NCT00772291|pregabalin
481980|NCT00772291|chronic pain after inguinal herniorraphy
481981|NCT00772278|carotid stenosis
481982|NCT00772278|asymptomatic
481983|NCT00772278|carotid stenting
481984|NCT00772278|carotid endarterectomy
481985|NCT00772265|Bioequivalence
481986|NCT00772265|pharmacokinetic
481987|NCT00772265|Pharmacodynamic
481988|NCT00772265|Isophane insulin
481989|NCT00772252|Liver support treatment
481990|NCT00772239|Coagulation Management
481991|NCT00772239|Cardiac surgery
481992|NCT00772239|Bleeding
481993|NCT00772239|Rotem
481994|NCT00772226|laparoscopic cholecystectomy
481995|NCT00772226|pain
481996|NCT00772226|PONV
481997|NCT00772226|music
481998|NCT00772226|therapy
481999|NCT00772226|fatigue after elective laparoscopic cholecystectomy
482000|NCT00772213|multiple trauma
482001|NCT00772213|outcome and process assessment
482002|NCT00772187|Laparoscopic surgery (general surgery).
482003|NCT00772174|Glucose Metabolism Disorder
482004|NCT00772174|Dysmetabolic Syndrome
482005|NCT00772174|Type II Diabetes
482006|NCT00772174|Diabetes Mellitus, Lipoatrophic
482007|NCT00772174|Dyslipidemia
482008|NCT00772174|Drug Therapy
482009|NCT00772161|ADHD
482010|NCT00772161|Attention Deficit Disorder
482011|NCT00772161|Attention Deficit an Disruptive Behavior Disorders
482012|NCT00772161|Children
482013|NCT00772161|Central Nervous System Stimulants
482014|NCT00772161|Methylphenidate
482015|NCT00772161|Pharmacokinetics
482016|NCT00772161|Area Under Curve
482017|NCT00772161|Therapeutic Equivalency
482018|NCT00772161|Psychopharmacology
482019|NCT00772148|Liver
482020|NCT00772148|Hepatic
482021|NCT00772148|Transplantation
482022|NCT00772148|Immunosuppression
482023|NCT00772148|Tacrolimus
482024|NCT00772148|Prograf
482025|NCT00772135|pulmonary hypertension
482026|NCT00772135|congenital heart defects
482027|NCT00772135|exercise
482028|NCT00772135|phosphodiesterase inhibitors
482029|NCT00772135|Exercise induced pulmonary arterial hypertensive response in congenital heart disease
482030|NCT00772122|Recurrent Miscarriage
482031|NCT00772122|G-CSF
482032|NCT00772122|pregnancy outcome
482033|NCT00772122|pregnancy outcome of pregnancies treated with G-CSF
482034|NCT00772122|treatment of recurrent miscarriage
482035|NCT00772109|Influenza
482036|NCT00772109|Orthomyxoviruses
482037|NCT00772109|Inactivated Split-virion influenza vaccine
482038|NCT00772109|Fluzone®
482039|NCT00772109|Adults
482040|NCT00772070|Menactra®
482041|NCT00772070|Menomune®
482042|NCT00772070|Meningitis
482043|NCT00772070|Meningococcemia
482044|NCT00772070|Neisseria meningitidis
482045|NCT00772044|OSA
482046|NCT00772044|sleep apnea
482047|NCT00772044|apnea
482048|NCT00772044|AHI
482049|NCT00772031|chronic migraine, migraine prevention, chronic headache
482050|NCT00772018|stage 0 bladder cancer
482051|NCT00771992|Asthma GINA 1
482052|NCT00771979|Healthy Volunteers
482053|NCT00771979|Relative Bioavailability
482054|NCT00771966|patients with cancer in the prostate
482055|NCT00771953|apricoxib
482056|NCT00771953|docetaxel
482057|NCT00771953|pemetrexed
482058|NCT00771953|Stage IIIb or Stage IV
482059|NCT00771927|Vimpat®
482060|NCT00771927|Lacosamide
482061|NCT00771927|LCM
482062|NCT00771927|epilepsy
482063|NCT00771927|epilepsies
482064|NCT00771927|seizure
482065|NCT00771927|partial seizure
482066|NCT00771927|partial onset
482067|NCT00771927|seizure disorder
482068|NCT00771927|single seizure
482069|NCT00771927|motor seizure
482070|NCT00771927|convulsions
482071|NCT00771927|add-on
482072|NCT00771927|AED
482073|NCT00771927|anti-epileptic
482074|NCT00771927|anti-epileptic drug
482075|NCT00771927|seizure control
482076|NCT00771927|open-label
482077|NCT00771927|post authorization
482078|NCT00771927|PASS
482079|NCT00771927|late stage
482080|NCT00771927|trial
482081|NCT00771927|study
482082|NCT00771927|phase 4
482083|NCT00771927|phase IV
482084|NCT00771914|aspirin
482085|NCT00771914|omega 3 fatty acids
482086|NCT00771914|Lovaza
482087|NCT00771914|myocardial infarction
482088|NCT00771914|aspirin resistance
482089|NCT00771914|cardiovascular disease
482090|NCT00771901|obesity
482091|NCT00771901|insulin resistance
482092|NCT00771901|type II diabetes
482093|NCT00771862|pain
482094|NCT00771862|amputation
482095|NCT00771862|phantom limb
482096|NCT00771862|stump pain
482097|NCT00771862|catheter
482098|NCT00771862|nerve block
482099|NCT00771862|peripheral nerve block
482100|NCT00771862|ucsd
482101|NCT00771862|post-amputation phantom limb or stump pain
482102|NCT00771849|Meningitis
482103|NCT00771849|Meningococcemia
482104|NCT00771849|Neisseria meningitidis
482105|NCT00771836|Stem cell transplantation
482106|NCT00771836|Airway hyper-reactivity
482107|NCT00771836|methacholine
482108|NCT00771836|pediatric
482109|NCT00771810|Ovarian Cancer
482110|NCT00771810|Thrombocytopenia
482111|NCT00771810|Cytopenia
482112|NCT00771810|Chemotherapy
482113|NCT00771797|PAOD
482114|NCT00771797|diabetis
482115|NCT00771797|vascular function
482116|NCT00771797|in diabetics with PAOD
482117|NCT00771784|Endotracheal intubation
482118|NCT00771784|tracheostomy
482119|NCT00771784|laryngeal mask
482120|NCT00771771|Stroke
482121|NCT00771771|Rehabilitation
482122|NCT00771771|Early Supported Discharge
482123|NCT00771771|ESD
482124|NCT00771771|RCT
482125|NCT00771758|Vertebral compression fracture
482126|NCT00771758|Osteoporosis
482127|NCT00771758|Acute pain
482128|NCT00771758|Analgesic
482129|NCT00771758|Oxycodone
482130|NCT00771758|Tapentadol
482131|NCT00771732|toe nail fungus
482132|NCT00771719|VAP
482133|NCT00771706|Pediatric Cough, Quality of Life
482134|NCT00771706|Drug (including placebo)
482135|NCT00771693|NIDDM
482136|NCT00771693|Platelet Activation
482137|NCT00771693|Postprandial hyperglycemia
482138|NCT00771693|insulin
482139|NCT00771667|Interleukin-12
482140|NCT00771667|Inflammation
482141|NCT00771667|Research study
482142|NCT00771667|Ustekinumab
482143|NCT00771667|CNTO1275
482144|NCT00771667|Interleukin-23
482145|NCT00771641|stage III squamous cell carcinoma of the lip and oral cavity
482146|NCT00771641|stage IV squamous cell carcinoma of the lip and oral cavity
482147|NCT00771641|stage II squamous cell carcinoma of the oropharynx
482148|NCT00771641|stage II lymphoepithelioma of the oropharynx
482149|NCT00771641|stage III squamous cell carcinoma of the oropharynx
482150|NCT00771641|stage III lymphoepithelioma of the oropharynx
482151|NCT00771641|stage IV squamous cell carcinoma of the oropharynx
482152|NCT00771641|stage IV lymphoepithelioma of the oropharynx
482153|NCT00771641|stage II squamous cell carcinoma of the hypopharynx
482154|NCT00771641|stage III squamous cell carcinoma of the hypopharynx
482155|NCT00771641|stage IV squamous cell carcinoma of the hypopharynx
482156|NCT00771641|stage III squamous cell carcinoma of the larynx
482157|NCT00771641|stage IV squamous cell carcinoma of the larynx
482158|NCT00771628|Intubation, Flex-It, stylet, GlideScope
482159|NCT00771615|human
482160|NCT00771615|Avian
482161|NCT00771615|safety
482162|NCT00771615|vaccines
482163|NCT00771615|influenza
482164|NCT00771615|pandemic
482165|NCT00771615|immunogenicity
482166|NCT00771615|H5N1
482167|NCT00771602|Chronic Lymphocytic Leukemia
482168|NCT00771602|Leukemia
482169|NCT00771602|CLL
482170|NCT00771602|PLL
482171|NCT00771602|SLL
482172|NCT00771602|Rituximab
482173|NCT00771602|Rituxan
482174|NCT00771602|Alemtuzumab
482175|NCT00771602|Campath
482176|NCT00771563|Non-Small Cell Lung Cancer
482177|NCT00771563|chemotherapy
482178|NCT00771563|Low Molecular Weight Heparin
482179|NCT00771537|HIV Testing
482180|NCT00771537|Persuasion
482181|NCT00771537|Health Communication
482182|NCT00771537|Clinical Trials Participation
482183|NCT00771537|Attitudes toward Health
482184|NCT00771537|Diagnostic Tests
482185|NCT00771537|Behavioral Research
482186|NCT00771537|Intervention Studies
482187|NCT00771524|Pharmacokinetics
482188|NCT00771524|Hip replacement
482189|NCT00771524|Ceftobiprole
482190|NCT00771498|rifampin
482191|NCT00771498|lopinavir
482192|NCT00771498|drug interaction
482193|NCT00771498|pharmacokinetic
482194|NCT00771459|Local infiltration analgesia
482195|NCT00771459|postoperative pain
482196|NCT00771459|ropivacaine
482197|NCT00771446|Hepatitis, acute
482198|NCT00771446|Acute Hepatitis OR Chronic Hepatitis
482199|NCT00771433|neutropenia
482200|NCT00771433|chemotherapeutic agent toxicity
482201|NCT00771433|recurrent breast cancer
482202|NCT00771433|stage I breast cancer
482203|NCT00771433|stage II breast cancer
482204|NCT00771433|stage IIIA breast cancer
482205|NCT00771433|stage IIIB breast cancer
482206|NCT00771433|stage IIIC breast cancer
482207|NCT00771433|stage IV breast cancer
482208|NCT00771407|Ostomy creation
482209|NCT00771407|Parastomal hernia
482210|NCT00771394|Vesicare
482211|NCT00771394|Solifenacin succinate
482212|NCT00771394|Tamsulosin
482213|NCT00771394|Overactive Bladder
482214|NCT00771394|BPH
482215|NCT00771381|18F-FAZA
482216|NCT00771381|18F-FDG
482217|NCT00771381|Positron Emission Tomography
482218|NCT00771381|Cell Hypoxia
482219|NCT00771303|Pregnancy
482220|NCT00771303|Pulmonary embolism
482221|NCT00771303|MSCT
482222|NCT00771290|Rectal sparing
482223|NCT00771290|Colon cancer
482224|NCT00771277|Brain Injuries
482225|NCT00771277|Caregivers
482226|NCT00771277|Volunteer Workers
482227|NCT00771277|Social Networks
482228|NCT00771264|Overactive Bladder
482229|NCT00771251|Rheumatoid arthritis
482230|NCT00771251|Fully Human anti-TNFa monoclonal antibody
482231|NCT00771251|CNTO148
482232|NCT00771251|Golimumab
482233|NCT00771238|pressure ulcers
482234|NCT00771238|Therapy mattresses
482235|NCT00771238|Incidence of pressure ulcers
482236|NCT00771225|genital prolapse
482237|NCT00771225|surgery
482238|NCT00771225|fascial repair
482239|NCT00771225|mesh
482240|NCT00771225|prolift
482241|NCT00771212|Pain
482242|NCT00771212|Observational
482243|NCT00771212|Taiwan
482244|NCT00771199|Cancer pain
482245|NCT00771199|Pain
482246|NCT00771199|Fentanyl
482247|NCT00771199|Durogesic
482248|NCT00771199|Cancer
482249|NCT00771199|Transdermal
482250|NCT00771186|pediatric
482251|NCT00771186|Laryngeal EMG
482252|NCT00771173|Phenazopyrdine
482253|NCT00771173|post operative bladder catheritization
482254|NCT00771173|VAS scores
482255|NCT00771173|Bladder pain related to indwelling foley catheters.
482256|NCT00771173|Bladder irritaion related to indwelling foley catheters.
482257|NCT00771147|Advanced Renal Cell Carcinoma ( RCC)
482258|NCT00771134|Depression
482259|NCT00771134|Bipolar I Disorder
482260|NCT00771134|Bipolar II Disorder
482261|NCT00771134|Placebo-controlled
482262|NCT00771134|Double-blind
482263|NCT00771134|Randomised controlled
482264|NCT00771134|Multicenter
482265|NCT00771134|Clinical study
482266|NCT00771134|Mania
482267|NCT00771108|NAFLD
482268|NCT00771108|Obesity
482269|NCT00771108|Metabolic Syndrome
482270|NCT00771108|Nonalcoholic Fatty Liver Disease
482271|NCT00771095|weight loss
482272|NCT00771095|elaboration
482273|NCT00771095|self efficacy
482274|NCT00771082|inflammatory markers
482275|NCT00771082|bone markers
482276|NCT00771082|OA
482277|NCT00771069|Hypertension
482278|NCT00771069|Type II DM
482279|NCT00771069|DM related complication
482280|NCT00771069|JNC7
482281|NCT00771069|2007 ESH-ESC guidelines
482282|NCT00771069|survey
482283|NCT00771056|untreated
482284|NCT00771017|adenocarcinoma of the prostate
482285|NCT00771017|recurrent prostate cancer
482286|NCT00771017|stage II prostate cancer
482287|NCT00771017|stage III prostate cancer
482288|NCT00771017|stage I prostate cancer
482289|NCT00771004|drug effects
482290|NCT00771004|Type II Diabetes
482291|NCT00771004|Angioplasty, Transluminal, Percutaneous Coronary
482292|NCT00771004|Drug Therapy
482293|NCT00771004|Heart
482294|NCT00771004|physiology
482295|NCT00771004|function
482296|NCT00770991|Polyp, Familial Adenomatous Polyposis, Prevention
482297|NCT00770978|ICU
482298|NCT00770965|Plaque psoriasis, skin condition, thickening, flaking, skin disease, autoimmune disease
482299|NCT00770952|Glucose Metabolism Disorder
482300|NCT00770952|Dysmetabolic Syndrome
482301|NCT00770952|Type II Diabetes
482302|NCT00770952|Diabetes Mellitus, Lipoatrophic
482303|NCT00770952|Dyslipidemia
482304|NCT00770952|Drug Therapy
482305|NCT00770939|Complete healing of chronic diabetic foot ulcers
482306|NCT00770939|Platelet Rich Fibrin
482307|NCT00770939|Vivostat
482308|NCT00770939|Growth factor treatment
482309|NCT00770939|Treatment of chronic diabetic foot ulcers
482310|NCT00770926|risk reduction
482311|NCT00770926|minority
482312|NCT00770926|diabetes prevention
482313|NCT00770926|lifestyle program
482314|NCT00770926|behavior change
482315|NCT00770913|reflux esophagitis
482316|NCT00770913|rabeprazole
482317|NCT00770913|GERD
482318|NCT00770913|Japan
482319|NCT00770887|Undesired fertility
482320|NCT00770861|nebivolol
482321|NCT00770861|Bystolic ™
482322|NCT00770861|Hypertension
482323|NCT00770861|Hispanic
482324|NCT00770861|Hypertension in Hispanic patients
482325|NCT00770848|CRPC
482326|NCT00770835|Glucose Metabolism Disorder
482327|NCT00770835|Dysmetabolic Syndrome
482328|NCT00770835|Type II Diabetes
482329|NCT00770835|Diabetes Mellitus, Lipoatrophic
482330|NCT00770835|Dyslipidemia
482331|NCT00770835|Drug Therapy
482332|NCT00770822|Primary
482333|NCT00770822|Prostate
482334|NCT00770822|Cancer
482335|NCT00770822|Primary T1c/T2a organ confined prostate cancer
482336|NCT00770822|organ-confined
482337|NCT00770796|Contrast induced nephropathy
482338|NCT00770770|Macular edema secondary to RVO
482339|NCT00770744|Schizophrenia
482340|NCT00770744|Antipsychotic
482341|NCT00770744|Olanzapine
482342|NCT00770744|Lu 31-130
482343|NCT00770731|Torisel
482344|NCT00770731|Temsirolimus
482345|NCT00770731|Hycamtin
482346|NCT00770731|Topotecan hydrochloride
482347|NCT00770731|Velcade
482348|NCT00770731|Bortezomib
482349|NCT00770731|FDG-PET Scans
482350|NCT00770731|18F-Fluoro-2-Deoxyglucose Positron Emission Tomography
482351|NCT00770718|intracranial hemorrhage
482352|NCT00770718|warfarin
482353|NCT00770718|anticoagulant
482354|NCT00770718|Factor VII
482355|NCT00770718|Prothrombin
482356|NCT00770692|insomnia
482357|NCT00770692|primary insomnia
482358|NCT00770692|insomnia associated with psychiatric or physical disorder(s)
482359|NCT00770666|Tobacco dependence treatment
482360|NCT00770653|Glucose Metabolism Disorder
482361|NCT00770653|Dysmetabolic Syndrome
482362|NCT00770653|Type II Diabetes
482363|NCT00770653|Diabetes Mellitus, Lipoatrophic
482364|NCT00770653|Dyslipidemia
482365|NCT00770653|Hyperlipidemias
482366|NCT00770653|Drug Therapy
482367|NCT00770640|Glucose Metabolism Disorder
482368|NCT00770640|Dysmetabolic Syndrome
482369|NCT00770640|Type II Diabetes
482370|NCT00770640|Diabetes Mellitus, Lipoatrophic
482371|NCT00770640|Dyslipidemia
482372|NCT00770640|Drug Therapy
482373|NCT00770627|160 children
482374|NCT00770627|parallel group
482375|NCT00770614|Contrast Induced Nephropathy
482376|NCT00770601|NOMID
482377|NCT00770601|CINCA Syndrome
482378|NCT00770601|Canakinumab
482379|NCT00770588|non-small cell lung cancer (NSCLC)
482380|NCT00770588|Gefitinib
482381|NCT00770575|Biological Markers
482382|NCT00770575|Biochemical Markers
482383|NCT00770575|Carotid Artery, Internal
482384|NCT00770575|Carotid Artery, Common
482385|NCT00770575|Marker, Surrogate
482386|NCT00770575|Vascular Diseases
482387|NCT00770575|Diabetes Mellitus
482388|NCT00770575|Drug Therapy
482389|NCT00770536|fallopian tube cancer
482390|NCT00770536|Gynecological Malignancy
482391|NCT00770536|primary peritoneal cancer of predominantly epithelial origin
482392|NCT00770536|Stage II to IV ovarian cancer
482393|NCT00770523|patients without comorbidity
482394|NCT00770510|Primary insomnia
482395|NCT00770497|drug effects
482396|NCT00770497|Hypertension
482397|NCT00770497|Vascular Resistance
482398|NCT00770497|Drug Therapy
482399|NCT00770497|physiopathology, vascular
482400|NCT00770484|Exercise
482401|NCT00770484|Propanolol
482402|NCT00770484|Beta blockers
482403|NCT00770471|adult glioblastoma
482404|NCT00770471|adult gliosarcoma
482405|NCT00770471|adult giant cell glioblastoma
482406|NCT00770458|Down Syndrome
482407|NCT00770445|Glucose Metabolism Disorder
482408|NCT00770445|Dysmetabolic Syndrome
482409|NCT00770445|Type II Diabetes
482410|NCT00770445|Diabetes Mellitus, Lipoatrophic
482411|NCT00770445|Dyslipidemia
482412|NCT00770445|Drug Therapy
482413|NCT00770432|Human Experimentation
482414|NCT00770419|depression
482415|NCT00770419|psychosocial effects of cancer and its treatment
482416|NCT00770419|unspecified adult solid tumor, protocol specific
482417|NCT00770419|acute undifferentiated leukemia
482418|NCT00770419|adult acute lymphoblastic leukemia in remission
482419|NCT00770419|adult acute myeloid leukemia in remission
482420|NCT00770419|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
482421|NCT00770419|adult acute myeloid leukemia with inv(16)(p13;q22)
482422|NCT00770419|adult acute myeloid leukemia with t(15;17)(q22;q12)
482423|NCT00770419|adult acute myeloid leukemia with t(16;16)(p13;q22)
482424|NCT00770419|adult acute myeloid leukemia with t(8;21)(q22;q22)
482425|NCT00770419|atypical chronic myeloid leukemia, BCR-ABL negative
482426|NCT00770419|chronic myelomonocytic leukemia
482427|NCT00770419|mast cell leukemia
482428|NCT00770419|meningeal chronic myelogenous leukemia
482429|NCT00770419|prolymphocytic leukemia
482430|NCT00770419|recurrent adult acute lymphoblastic leukemia
482431|NCT00770419|recurrent adult acute myeloid leukemia
482432|NCT00770419|recurrent adult T-cell leukemia/lymphoma
482433|NCT00770419|refractory chronic lymphocytic leukemia
482434|NCT00770419|refractory hairy cell leukemia
482435|NCT00770419|relapsing chronic myelogenous leukemia
482436|NCT00770419|secondary acute myeloid leukemia
482437|NCT00770419|T-cell large granular lymphocyte leukemia
482438|NCT00770419|AIDS-related diffuse large cell lymphoma
482439|NCT00770419|AIDS-related diffuse mixed cell lymphoma
482440|NCT00770419|AIDS-related diffuse small cleaved cell lymphoma
482441|NCT00770419|AIDS-related immunoblastic large cell lymphoma
482442|NCT00770419|AIDS-related lymphoblastic lymphoma
482443|NCT00770419|AIDS-related peripheral/systemic lymphoma
482444|NCT00770419|AIDS-related primary CNS lymphoma
482445|NCT00770419|AIDS-related small noncleaved cell lymphoma
482446|NCT00770419|HIV-associated Hodgkin lymphoma
482447|NCT00770419|recurrent adult Hodgkin lymphoma
482448|NCT00770419|anaplastic large cell lymphoma
482449|NCT00770419|angioimmunoblastic T-cell lymphoma
482450|NCT00770419|cutaneous B-cell non-Hodgkin lymphoma
482451|NCT00770419|recurrent cutaneous T-cell non-Hodgkin lymphoma
482452|NCT00770419|recurrent mycosis fungoides/Sezary syndrome
482453|NCT00770419|adult grade III lymphomatoid granulomatosis
482454|NCT00770419|adult nasal type extranodal NK/T-cell lymphoma
482455|NCT00770419|Waldenstrom macroglobulinemia
482456|NCT00770419|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
482457|NCT00770419|nodal marginal zone B-cell lymphoma
482458|NCT00770419|splenic marginal zone lymphoma
482459|NCT00770419|recurrent adult Burkitt lymphoma
482460|NCT00770419|recurrent adult diffuse large cell lymphoma
482461|NCT00770419|recurrent adult diffuse mixed cell lymphoma
482462|NCT00770419|recurrent adult diffuse small cleaved cell lymphoma
482463|NCT00770419|recurrent adult grade III lymphomatoid granulomatosis
482464|NCT00770419|recurrent adult immunoblastic large cell lymphoma
482465|NCT00770419|recurrent adult lymphoblastic lymphoma
482466|NCT00770419|recurrent grade 1 follicular lymphoma
482467|NCT00770419|recurrent grade 2 follicular lymphoma
482468|NCT00770419|recurrent grade 3 follicular lymphoma
482469|NCT00770419|recurrent mantle cell lymphoma
482470|NCT00770419|recurrent marginal zone lymphoma
482471|NCT00770419|recurrent small lymphocytic lymphoma
482472|NCT00770419|intraocular lymphoma
482473|NCT00770419|primary central nervous system non-Hodgkin lymphoma
482474|NCT00770419|primary central nervous system Hodgkin lymphoma
482475|NCT00770419|chronic eosinophilic leukemia
482476|NCT00770419|chronic neutrophilic leukemia
482477|NCT00770419|primary myelofibrosis
482478|NCT00770419|primary systemic amyloidosis
482479|NCT00770419|refractory multiple myeloma
482480|NCT00770419|previously treated myelodysplastic syndromes
482481|NCT00770419|secondary myelodysplastic syndromes
482482|NCT00770419|myelodysplastic/myeloproliferative neoplasm, unclassifiable
482483|NCT00770393|squamous cell carcinoma of the pyriform sinus
482484|NCT00770393|laryngeal preservation
482485|NCT00770393|patients with biopsy-proven previously untreated resectable T3 with fixed cord involvement squamous cell carcinoma of the pyriform sinus
482486|NCT00770380|smoking
482487|NCT00770367|Cardiovascular risk
482488|NCT00770367|biological markers
482489|NCT00770354|Breast cancer
482490|NCT00770328|Plasma PAI-1 level at 0, 4, 8 weeks
482491|NCT00770328|Plasma hsCRP level at 0, 4, 8 weeks
482492|NCT00770328|Plasma TNF-a level at 0, 4, 8 weeks
482493|NCT00770302|DPP-4 inhibitors
482494|NCT00770302|HBA1c
482495|NCT00770302|Incretins
482496|NCT00770302|Pharmacokinetics
482497|NCT00770276|obesity WHO I-III
482498|NCT00770276|metabolic syndrome
482499|NCT00770276|Framingham risk score
482500|NCT00770276|subclinical atherosclerosis
482501|NCT00770276|endothelial dysfunction
482502|NCT00770263|any solid tumors
482503|NCT00770250|asthma symptoms
482504|NCT00770250|words used by patients and physicians
482505|NCT00770250|express asthma symptoms
482506|NCT00770237|Smoking
482507|NCT00770237|Nicotine
482508|NCT00770237|Schizophrenia
482509|NCT00770224|contiguous stage II grade 1 follicular lymphoma
482510|NCT00770224|contiguous stage II grade 2 follicular lymphoma
482511|NCT00770224|contiguous stage II grade 3 follicular lymphoma
482512|NCT00770224|noncontiguous stage II grade 1 follicular lymphoma
482513|NCT00770224|noncontiguous stage II grade 2 follicular lymphoma
482514|NCT00770224|noncontiguous stage II grade 3 follicular lymphoma
482515|NCT00770224|stage III grade 1 follicular lymphoma
482516|NCT00770224|stage III grade 2 follicular lymphoma
482517|NCT00770224|stage III grade 3 follicular lymphoma
482518|NCT00770224|stage IV grade 1 follicular lymphoma
482519|NCT00770224|stage IV grade 2 follicular lymphoma
482520|NCT00770224|stage IV grade 3 follicular lymphoma
482521|NCT00770198|liver
482522|NCT00770198|alcohol
482523|NCT00770198|HCV
482524|NCT00770185|endometrial adenocarcinoma
482525|NCT00770185|endometrial adenosquamous cell carcinoma
482526|NCT00770185|endometrial clear cell carcinoma
482527|NCT00770185|endometrial papillary carcinoma
482528|NCT00770185|recurrent endometrial carcinoma
482529|NCT00770185|stage III endometrial carcinoma
482530|NCT00770185|stage IV endometrial carcinoma
482531|NCT00770172|chemotherapeutic agent toxicity
482532|NCT00770172|neutropenia
482533|NCT00770172|unspecified adult solid tumor, protocol specific
482534|NCT00770120|recurrent malignant mesothelioma
482535|NCT00770120|stage II malignant mesothelioma
482536|NCT00770120|stage III malignant mesothelioma
482537|NCT00770120|stage IV malignant mesothelioma
482538|NCT00770094|LASIK
482539|NCT00770094|Laser Vision correction
482540|NCT00770094|Myopia
482541|NCT00770094|Myopia with astigmatism
482542|NCT00770094|Nearsighted
482543|NCT00770081|Type 2 diabetes
482544|NCT00770081|vildagliptin
482545|NCT00770068|Mood Disorders
482546|NCT00770068|Major Depressive Disorder
482547|NCT00770068|Bipolar Disorder
482548|NCT00770068|Tree Pollen
482549|NCT00770068|Ragweed Pollen
482550|NCT00770068|Rhinitis
482551|NCT00770068|Allergic
482552|NCT00770068|Seasonal
482553|NCT00770068|Allergens
482554|NCT00770055|stage IV breast cancer
482555|NCT00770055|recurrent breast cancer
482556|NCT00770016|insulin sensitivity
482557|NCT00770016|Substrate metabolism
482558|NCT00770016|Fatty liver
482559|NCT00770016|intramyocellular lipid
482560|NCT00770016|intracellular signaling
482561|NCT00770003|patients
482562|NCT00770003|allergic rhinitis
482563|NCT00770003|tolerability
482564|NCT00770003|safety
482565|NCT00770003|nasal symptoms
482566|NCT00769990|bone metastases
482567|NCT00769990|pain
482568|NCT00769990|recurrent breast cancer
482569|NCT00769990|stage IV breast cancer
482570|NCT00769990|recurrent prostate cancer
482571|NCT00769990|stage IV prostate cancer
482572|NCT00769990|recurrent melanoma
482573|NCT00769990|stage IV melanoma
482574|NCT00769990|recurrent renal cell cancer
482575|NCT00769990|stage IV renal cell cancer
482576|NCT00769990|recurrent non-small cell lung cancer
482577|NCT00769990|stage IV non-small cell lung cancer
482578|NCT00769990|extensive stage small cell lung cancer
482579|NCT00769990|recurrent small cell lung cancer
482580|NCT00769964|Healthy (Dysmenorrhea)
482581|NCT00769951|pain
482582|NCT00769951|depression
482583|NCT00769951|weight changes
482584|NCT00769951|cognitive/functional effects
482585|NCT00769951|malnutrition
482586|NCT00769951|psychosocial effects of cancer and its treatment
482587|NCT00769951|unspecified adult solid tumor, protocol specific
482588|NCT00769951|hematopoietic/lymphoid cancer
482589|NCT00769938|Atrial fibrillation
482590|NCT00769938|Percutaneous coronary stenting
482591|NCT00769938|Bleeding complications
482592|NCT00769938|Triple therapy
482593|NCT00769925|Generalized Anxiety
482594|NCT00769925|Social Phobia
482595|NCT00769925|Separation Anxiety
482596|NCT00769925|Phobia
482597|NCT00769899|AZD7325
482598|NCT00769899|Japanese Healthy Volunteers
482599|NCT00769899|Phase I study
482600|NCT00769899|Single Ascending Dose
482601|NCT00769873|anticoagulation
482602|NCT00769873|thrombosis
482603|NCT00769873|portal vein thrombosis
482604|NCT00769873|splenic vein thrombosis
482605|NCT00769873|splenectomy
482606|NCT00769873|randomized
482607|NCT00769873|laparoscopic splenectomy
482608|NCT00769873|lovenox
482609|NCT00769860|myositis
482610|NCT00769860|IBM
482611|NCT00769860|inclusion body myositis
482612|NCT00769847|Endoscopic, craniosynostosis, sagittal, synostosis
482613|NCT00769834|chronic kidney disease
482614|NCT00769834|chronic renal insufficiency
482615|NCT00769834|uremia
482616|NCT00769834|disc edema
482617|NCT00769834|papilledema
482618|NCT00769834|idiopathic intracranial hypertension
482619|NCT00769834|pseudotumor cerebri
482620|NCT00769821|lymphedema
482621|NCT00769821|perioperative/postoperative complications
482622|NCT00769821|cancer survivor
482623|NCT00769821|stage I breast cancer
482624|NCT00769821|stage II breast cancer
482625|NCT00769821|stage IIIA breast cancer
482626|NCT00769821|stage IIIB breast cancer
482627|NCT00769821|stage IIIC breast cancer
482628|NCT00769821|stage IV breast cancer
482629|NCT00769795|prostate cancer
482630|NCT00769795|prostatic neoplasm
482631|NCT00769795|androgen deprivation therapy
482632|NCT00769795|insulin-like growth factor receptor I
482633|NCT00769795|neoadjuvant
482634|NCT00769795|prostatectomy
482635|NCT00769782|gastrointestinal stromal tumor
482636|NCT00769782|liver metastases
482637|NCT00769769|Health Status
482638|NCT00769756|Different Strategies to Fight Obesity in Families
482639|NCT00769730|hepatocellular carcinoma
482640|NCT00769730|hepatitis B virus
482641|NCT00769730|transcatheter arterial chemoembolization
482642|NCT00769717|obesity
482643|NCT00769717|wellness
482644|NCT00769717|cardiovascular disease prevention
482645|NCT00769717|health at every size
482646|NCT00769717|weight loss
482647|NCT00769704|Melanoma
482648|NCT00769704|OncoVEX^GM-CSF
482649|NCT00769704|GM-CSF
482650|NCT00769704|Stage IIIb, IIIc and IV Disease
482651|NCT00769704|oncolytic
482652|NCT00769704|OncoVex
482653|NCT00769704|T-Vec
482654|NCT00769704|talimogene laherparepvec
482655|NCT00769691|Cardiac surgery
482656|NCT00769691|Cerebral blood flow autoregulation
482657|NCT00769678|Biventricular Pacing
482658|NCT00769665|Dry Eye
482659|NCT00769665|re-wetting drops
482660|NCT00769652|malnutrition
482661|NCT00769652|non-small cell lung cancer
482662|NCT00769652|small cell lung cancer
482663|NCT00769652|stage III prostate cancer
482664|NCT00769652|stage IV prostate cancer
482665|NCT00769652|pancreatic cancer
482666|NCT00769652|weight changes
482667|NCT00769626|Low Back Pain
482668|NCT00769626|Clinical Practice Guidelines
482669|NCT00769626|Spinal Manipulation
482670|NCT00769626|Physical Therapy Techniques
482671|NCT00769613|stage III adult Burkitt lymphoma
482672|NCT00769613|stage III adult diffuse large cell lymphoma
482673|NCT00769613|stage III adult diffuse mixed cell lymphoma
482674|NCT00769613|stage III adult diffuse small cleaved cell lymphoma
482675|NCT00769613|stage III adult Hodgkin lymphoma
482676|NCT00769613|stage III adult immunoblastic large cell lymphoma
482677|NCT00769613|stage III adult lymphoblastic lymphoma
482678|NCT00769613|stage III grade 1 follicular lymphoma
482679|NCT00769613|stage III grade 2 follicular lymphoma
482680|NCT00769613|stage III grade 3 follicular lymphoma
482681|NCT00769613|stage III mantle cell lymphoma
482682|NCT00769613|stage III marginal zone lymphoma
482683|NCT00769613|stage III small lymphocytic lymphoma
482684|NCT00769613|stage IV adult Burkitt lymphoma
482685|NCT00769613|stage IV adult diffuse large cell lymphoma
482686|NCT00769613|stage IV adult diffuse mixed cell lymphoma
482687|NCT00769613|stage IV adult diffuse small cleaved cell lymphoma
482688|NCT00769613|stage IV adult Hodgkin lymphoma
482689|NCT00769613|stage IV adult immunoblastic large cell lymphoma
482690|NCT00769613|stage IV adult lymphoblastic lymphoma
482691|NCT00769613|stage IV grade 1 follicular lymphoma
482692|NCT00769613|stage IV grade 2 follicular lymphoma
482693|NCT00769613|stage IV grade 3 follicular lymphoma
482694|NCT00769613|stage IV mantle cell lymphoma
482695|NCT00769613|stage IV marginal zone lymphoma
482696|NCT00769613|stage IV small lymphocytic lymphoma
482697|NCT00769613|recurrent adult Burkitt lymphoma
482698|NCT00769613|recurrent adult diffuse large cell lymphoma
482699|NCT00769613|recurrent adult diffuse mixed cell lymphoma
482700|NCT00769613|recurrent adult diffuse small cleaved cell lymphoma
482701|NCT00769613|recurrent adult Hodgkin lymphoma
482702|NCT00769613|recurrent adult immunoblastic large cell lymphoma
482703|NCT00769613|recurrent adult lymphoblastic lymphoma
482704|NCT00769613|recurrent childhood large cell lymphoma
482705|NCT00769613|recurrent childhood lymphoblastic lymphoma
482706|NCT00769613|recurrent childhood small noncleaved cell lymphoma
482707|NCT00769613|recurrent cutaneous T-cell non-Hodgkin lymphoma
482708|NCT00769613|recurrent grade 1 follicular lymphoma
482709|NCT00769613|recurrent grade 2 follicular lymphoma
482710|NCT00769613|recurrent grade 3 follicular lymphoma
482711|NCT00769613|recurrent mantle cell lymphoma
482712|NCT00769613|recurrent marginal zone lymphoma
482713|NCT00769613|recurrent small lymphocytic lymphoma
482714|NCT00769613|recurrent/refractory childhood Hodgkin lymphoma
482715|NCT00769613|recurrent mycosis fungoides/Sezary syndrome
482716|NCT00769613|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
482717|NCT00769613|nodal marginal zone B-cell lymphoma
482718|NCT00769613|splenic marginal zone lymphoma
482719|NCT00769613|noncontiguous stage II adult Burkitt lymphoma
482720|NCT00769613|noncontiguous stage II adult diffuse large cell lymphoma
482721|NCT00769613|noncontiguous stage II adult diffuse mixed cell lymphoma
482722|NCT00769613|noncontiguous stage II adult diffuse small cleaved cell lymphoma
482723|NCT00769613|noncontiguous stage II adult immunoblastic large cell lymphoma
482724|NCT00769613|noncontiguous stage II adult lymphoblastic lymphoma
482725|NCT00769613|noncontiguous stage II grade 1 follicular lymphoma
482726|NCT00769613|noncontiguous stage II grade 2 follicular lymphoma
482727|NCT00769613|noncontiguous stage II grade 3 follicular lymphoma
482728|NCT00769613|noncontiguous stage II mantle cell lymphoma
482729|NCT00769613|noncontiguous stage II marginal zone lymphoma
482730|NCT00769613|noncontiguous stage II small lymphocytic lymphoma
482731|NCT00769613|accelerated phase chronic myelogenous leukemia
482732|NCT00769613|adult acute lymphoblastic leukemia in remission
482733|NCT00769613|adult acute myeloid leukemia in remission
482734|NCT00769613|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
482735|NCT00769613|adult acute myeloid leukemia with inv(16)(p13;q22)
482736|NCT00769613|adult acute myeloid leukemia with t(15;17)(q22;q12)
482737|NCT00769613|adult acute myeloid leukemia with t(16;16)(p13;q22)
482738|NCT00769613|adult acute myeloid leukemia with t(8;21)(q22;q22)
482739|NCT00769613|atypical chronic myeloid leukemia, BCR-ABL1 negative
482740|NCT00769613|blastic phase chronic myelogenous leukemia
482741|NCT00769613|childhood acute lymphoblastic leukemia in remission
482742|NCT00769613|childhood acute myeloid leukemia in remission
482743|NCT00769613|childhood chronic myelogenous leukemia
482744|NCT00769613|chronic myelomonocytic leukemia
482745|NCT00769613|chronic phase chronic myelogenous leukemia
482746|NCT00769613|juvenile myelomonocytic leukemia
482747|NCT00769613|recurrent adult acute lymphoblastic leukemia
482748|NCT00769613|recurrent adult acute myeloid leukemia
482749|NCT00769613|recurrent childhood acute lymphoblastic leukemia
482750|NCT00769613|recurrent childhood acute myeloid leukemia
482751|NCT00769613|refractory chronic lymphocytic leukemia
482752|NCT00769613|refractory hairy cell leukemia
482753|NCT00769613|relapsing chronic myelogenous leukemia
482754|NCT00769613|secondary acute myeloid leukemia
482755|NCT00769613|stage III chronic lymphocytic leukemia
482756|NCT00769613|stage IV chronic lymphocytic leukemia
482757|NCT00769613|childhood myelodysplastic syndromes
482758|NCT00769613|chronic eosinophilic leukemia
482759|NCT00769613|primary myelofibrosis
482760|NCT00769613|chronic neutrophilic leukemia
482761|NCT00769613|de novo myelodysplastic syndromes
482991|NCT00768677|adolescents
482762|NCT00769613|disseminated neuroblastoma
482763|NCT00769613|myelodysplastic/myeloproliferative neoplasm, unclassifiable
482764|NCT00769613|high risk metastatic gestational trophoblastic tumor
482765|NCT00769613|previously treated childhood rhabdomyosarcoma
482766|NCT00769613|previously treated myelodysplastic syndromes
482767|NCT00769613|recurrent Wilms tumor and other childhood kidney tumors
482768|NCT00769613|recurrent childhood rhabdomyosarcoma
482769|NCT00769613|recurrent neuroblastoma
482770|NCT00769613|recurrent ovarian epithelial cancer
482771|NCT00769613|recurrent ovarian germ cell tumor
482772|NCT00769613|recurrent malignant testicular germ cell tumor
482773|NCT00769613|secondary myelodysplastic syndromes
482774|NCT00769613|stage I multiple myeloma
482775|NCT00769613|stage II multiple myeloma
482776|NCT00769613|stage III multiple myeloma
482777|NCT00769613|stage II ovarian epithelial cancer
482778|NCT00769613|stage III ovarian epithelial cancer
482779|NCT00769613|stage IV ovarian epithelial cancer
482780|NCT00769613|stage III malignant testicular germ cell tumor
482781|NCT00769613|stage IIIA breast cancer
482782|NCT00769613|stage IIIB breast cancer
482783|NCT00769613|stage IIIC breast cancer
482784|NCT00769613|stage IV breast cancer
482785|NCT00769613|refractory multiple myeloma
482786|NCT00769613|cytomegalovirus infection
482787|NCT00769600|Recurrent Non-Small Cell Lung Cancer
482788|NCT00769587|aggressive systemic mastocytosis
482789|NCT00769587|smoldering systemic mastocytosis
482790|NCT00769561|Temporomandibular disorders
482791|NCT00769561|Biofeedback
482792|NCT00769561|Cognitive behavioral therapy
482793|NCT00769561|Pain
482794|NCT00769548|adenocarcinoma of the prostate
482795|NCT00769548|stage I prostate cancer
482796|NCT00769548|stage IIB prostate cancer
482797|NCT00769548|stage IIA prostate cancer
482798|NCT00769548|stage III prostate cancer
482799|NCT00769548|stage IV prostate cancer
482800|NCT00769535|heat shock protein70
482801|NCT00769535|tumor necrosis factor-alpha promoter
482802|NCT00769535|polymorphism
482803|NCT00769522|B-cell chronic lymphocytic leukemia
482804|NCT00769522|stage 0 chronic lymphocytic leukemia
482805|NCT00769522|stage I chronic lymphocytic leukemia
482806|NCT00769522|stage II chronic lymphocytic leukemia
482807|NCT00769522|stage III chronic lymphocytic leukemia
482808|NCT00769522|stage IV chronic lymphocytic leukemia
482809|NCT00769509|energy expenditure
482810|NCT00769509|indirect calorimetry
482811|NCT00769509|human milk
482812|NCT00769509|preterm formula
482813|NCT00769509|premature infant
482814|NCT00769483|Pancreas
482815|NCT00769483|Pancreatic Cancer
482816|NCT00769483|Advanced cancer of the pancreas
482817|NCT00769483|Pancreatic Adenocarcinoma
482818|NCT00769483|MK-0646
482819|NCT00769483|Gemcitabine
482820|NCT00769483|Gemzar
482821|NCT00769483|Erlotinib hydrochloride
482822|NCT00769483|Erlotinib
482823|NCT00769483|OSI-774
482824|NCT00769483|Tarceva
482825|NCT00769470|stage I breast cancer
482826|NCT00769470|stage II breast cancer
482827|NCT00769470|stage IIIA breast cancer
482828|NCT00769470|stage IIIB breast cancer
482829|NCT00769470|stage IIIC breast cancer
482830|NCT00769470|HER2-positive breast cancer
482831|NCT00769431|stage I prostate cancer
482832|NCT00769431|stage IIB prostate cancer
482833|NCT00769431|stage IIA prostate cancer
482834|NCT00769405|recurrent colon cancer
482835|NCT00769405|stage IV colon cancer
482836|NCT00769405|recurrent rectal cancer
482837|NCT00769405|stage IV rectal cancer
482838|NCT00769405|peritoneal carcinomatosis
482839|NCT00769392|Macular Degeneration
482840|NCT00769392|Intravitreal injections
482841|NCT00769392|Eye anesthesia-Topical/subconjunctival
482842|NCT00769392|Eye-surgical procedures
482843|NCT00769392|Ophthalmologic anesthesia methods
482844|NCT00769327|chronic myelogenous leukemia, BCR-ABL1 positive
482845|NCT00769327|chronic phase chronic myelogenous leukemia
482846|NCT00769301|Symptoms
482847|NCT00769301|pain
482848|NCT00769301|fatigue
482849|NCT00769301|depression
482850|NCT00769301|sleeplessness
482851|NCT00769301|genetic markers
482852|NCT00769301|caregiver burden.
482853|NCT00769275|silent ischemia
482854|NCT00769275|type 2 diabetes mellitus
482855|NCT00769275|screening
482856|NCT00769275|cardiac outcome
482857|NCT00769275|Prevalence silent myocardial ischemia
482858|NCT00769275|Cardiac outcome in screened and not-screened subjects
482859|NCT00769262|Premature neonates
482860|NCT00769262|Thermoregulation
482861|NCT00769262|Isolette
482862|NCT00769262|Feeding status
482863|NCT00769249|psychosocial effects of cancer and its treatment
482864|NCT00769249|unspecified adult solid tumor, protocol specific
482865|NCT00769223|radiation toxicity
482866|NCT00769223|recurrent prostate cancer
482867|NCT00769223|stage IIB prostate cancer
482868|NCT00769223|stage IIA prostate cancer
482869|NCT00769223|stage III prostate cancer
482870|NCT00769223|stage I prostate cancer
482871|NCT00769223|stage IV prostate cancer
482872|NCT00769223|adenocarcinoma of the prostate
482873|NCT00769197|optic disc cupping
482874|NCT00769197|cerebral palsy
482875|NCT00769197|static encephalopathy
482876|NCT00769197|optic disc
482877|NCT00769197|optic nerve
482878|NCT00769197|periventricular Leukomalacia
482879|NCT00769184|chronic plaque psoriasis
482880|NCT00769171|Complicated Intra-Abdominal Infections
482881|NCT00769158|Alcohol
482882|NCT00769158|Alcoholism
482883|NCT00769158|Alcohol Dependence
482884|NCT00769145|Corneal neovascularization
482885|NCT00769145|Ranibizumab
482886|NCT00769145|Corneal transplantation
482887|NCT00769119|bronchiectasis
482888|NCT00769119|Phase II
482889|NCT00769106|hepatocellular carcinoma
482890|NCT00769106|recurrent
482891|NCT00769106|cytokine-induced killer cell
482892|NCT00769093|ferumoxytol
482893|NCT00769093|diagnostic imaging
482894|NCT00769080|PSP
482895|NCT00769080|Standard Treatment
482896|NCT00769080|Standard Treatment plus PSP
482897|NCT00769067|Lung cancer
482898|NCT00769067|advanced
482899|NCT00769067|second or third line
482900|NCT00769054|Postoperative pain
482901|NCT00769054|PONV
482902|NCT00769028|Systemic sclerosis
482903|NCT00769028|Diffuse cutaneous systemic sclerosis
482904|NCT00769028|Scleroderma
482905|NCT00769028|Biological
482906|NCT00769028|Hyperimmune caprine serum
482907|NCT00769028|Goat Serum
482908|NCT00769015|age-related macular degeneration
482909|NCT00769015|depression
482910|NCT00769015|vision loss
482911|NCT00769002|influenza
482912|NCT00769002|flu
482913|NCT00769002|vaccine
482914|NCT00769002|vaccination
482915|NCT00769002|immune response
482916|NCT00769002|FluShield
482917|NCT00769002|FluMist
482918|NCT00769002|PET-CT
482919|NCT00769002|Healthy Volunteers
482920|NCT00768989|Combination Therapy
482921|NCT00768976|Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
482922|NCT00768976|Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
482923|NCT00768963|ranibizumab
482924|NCT00768963|pterygium
482925|NCT00768950|Seronegative spondyloarthropathies
482926|NCT00768950|Endoscopic capsule examination
482927|NCT00768950|Small bowel and colon lesions
482928|NCT00768950|Nonsteroidal anti-inflammatory drugs
482929|NCT00768950|Anti TNF Alpha Drugs
482930|NCT00768937|hepatocellular carcinoma
482931|NCT00768937|sorafenib
482932|NCT00768937|transarterial chemoembolization
482933|NCT00768937|tumor angiogenesis
482934|NCT00768937|angiogenic factors
482935|NCT00768924|Bone Void Filler
482936|NCT00768924|Post-Harvest Iliac Crest
482937|NCT00768924|Ability of CopiOs to fill the post-harvest iliac crest bone void created by a surgeon during spinal fusion.
482938|NCT00768911|glioblastoma
482939|NCT00768911|Glioblastoma multiforme (newly diagnosed)
482940|NCT00768898|conjunctival
482941|NCT00768898|staining
482942|NCT00768872|activity, spinal cord stimulation, pain
482943|NCT00768859|breast cancer
482944|NCT00768859|HER2 positive
482945|NCT00768859|neo-adjuvant
482946|NCT00768859|trastuzumab
482947|NCT00768859|paclitaxel
482948|NCT00768859|carboplatin
482949|NCT00768846|PCI
482950|NCT00768846|Stent
482951|NCT00768846|DES
482952|NCT00768846|CAD
482953|NCT00768833|S.pneumoniae healthy subjects
482954|NCT00768833|Healthy subjects
482955|NCT00768820|Velocardiofacial syndrome
482956|NCT00768820|Williams syndrome
482957|NCT00768820|fragile X syndrome
482958|NCT00768820|cognitive phenotype
482959|NCT00768820|psychiatric phenotype
482960|NCT00768794|thrush
482961|NCT00768781|insomnia
482962|NCT00768781|hyperarousal
482963|NCT00768781|mindfulness meditation
482964|NCT00768781|complementary and alternative medicine
482965|NCT00768781|cognitive-behavioral therapy
482966|NCT00768768|iontophoresis
482967|NCT00768768|terbinafine
482968|NCT00768768|onychomycosis
482969|NCT00768755|non-squamous NSCLC
482970|NCT00768755|axitinib
482971|NCT00768755|pemetrexed/cisplatin
482972|NCT00768742|Uterine Fibroid RF Ablation
482973|NCT00768742|Intrauterine Ultrasound
482974|NCT00768742|VizAblate
482975|NCT00768729|End stage renal disease
482976|NCT00768729|Kidney transplantation
482977|NCT00768729|Renal transplantation
482978|NCT00768729|Kidney failure
482979|NCT00768729|Children
482980|NCT00768729|Adolescents
482981|NCT00768729|Sirolimus
482982|NCT00768729|Rapamycin
482983|NCT00768729|CellCept
482984|NCT00768729|Mycophenolate mofetil (MMF)
482985|NCT00768729|Azathioprine
482986|NCT00768703|Congenital diaphragmatic hernia
482987|NCT00768703|lung-head ratio
482988|NCT00768703|percutaneous tracheal occlusion
482989|NCT00768703|fetal intervention
482990|NCT00768677|binge eating behavior
482992|NCT00768664|recurrent or metastatic squamous cell cancer of the Head and Neck; no prior systemic therapy for recurrence
482993|NCT00768638|Chronic kidney disease
482994|NCT00768612|Acute, Schizophrenia, Phase2a, Vabicaserin
482995|NCT00768599|Econazole
482996|NCT00768599|Foam
482997|NCT00768599|Quinnova
482998|NCT00768573|taste test
482999|NCT00768534|Acute Otitis Media
483000|NCT00768534|Serotype distribution
483001|NCT00768508|Alcohol
483002|NCT00768508|Alcohol Dependence
483003|NCT00768508|Alcoholism
483004|NCT00768495|revascularization
483005|NCT00768495|claudication
483006|NCT00768495|hyperspectral
483007|NCT00768495|oxygenation
483008|NCT00768495|limb ischemia
483009|NCT00768482|opioid dependence
483010|NCT00768482|opioid addiction
483011|NCT00768482|buprenorphine
483012|NCT00768482|methadone
483013|NCT00768482|heroin
483014|NCT00768482|implant
483015|NCT00768482|opioid withdrawal
483016|NCT00768482|opioid pain medication
483017|NCT00768482|suboxone
483018|NCT00768469|HKI-272
483019|NCT00768469|Paclitaxel
483020|NCT00768469|Combination
483021|NCT00768469|Solid Tumor
483022|NCT00768443|GERD
483023|NCT00768443|PPI
483024|NCT00768417|Nuts
483025|NCT00768417|Lipids
483026|NCT00768417|Mastication
483027|NCT00768417|Bioaccessibility
483028|NCT00768417|Satiety
483029|NCT00768417|Hormones
483030|NCT00768417|Human
483031|NCT00768391|Tumors
483032|NCT00768391|Lymphoma
483033|NCT00768391|Antibodies, Monoclonal
483034|NCT00768378|Physical Therapy (Specialty)
483035|NCT00768378|Balance dysfunction or disorder
483036|NCT00768378|Vestibular
483037|NCT00768378|Rehabilitation
483038|NCT00768365|adrenal incidentaloma
483039|NCT00768365|cardiovascular risk
483040|NCT00768352|Pediatric
483041|NCT00768352|Resident
483042|NCT00768352|Depression
483043|NCT00768352|Screening
483044|NCT00768352|Substance Abuse
483045|NCT00768352|Pediatric Resident knowledge of mental health topics
483046|NCT00768352|Pediatric Resident current practices for screening and treating mental health disorders
483047|NCT00768352|Pediatric Resident mental health care competency
483048|NCT00768339|antisense
483049|NCT00768339|AEG35156
483050|NCT00768339|lymphocytic
483051|NCT00768339|lymphoma
483052|NCT00768339|leukemia
483053|NCT00768339|B-cell
483054|NCT00768326|Schizophrenia
483055|NCT00768326|Antipsychotic
483056|NCT00768326|Lu 31-130
483057|NCT00768313|scoliosis correction rod strength adolescent
483058|NCT00768300|idiopathic pulmonary fibrosis
483059|NCT00768300|interstitial lung disease
483060|NCT00768300|ambrisentan
483061|NCT00768274|Cholesterol
483062|NCT00768274|High density lipoprotein
483063|NCT00768274|Dyslipidemia
483064|NCT00768274|Atherosclerosis
483065|NCT00768274|Apolipoprotein A-I
483066|NCT00768261|Dementia of the Alzheimer type
483067|NCT00768248|pain
483068|NCT00768248|phantom limb
483069|NCT00768248|stump pain
483070|NCT00768248|catheter
483071|NCT00768248|nerve block
483072|NCT00768248|peripheral nerve block
483073|NCT00768248|NMCSD
483074|NCT00768248|Post-Amputation Phantom Limb or Stump Pain
483075|NCT00768235|Sedentary elderly women that had medical assignment
483076|NCT00768222|wound healing
483077|NCT00768209|Pharmacokinetics
483078|NCT00768196|GERD
483079|NCT00768196|Korea
483080|NCT00768196|typical symptom
483081|NCT00768196|quality of life
483082|NCT00768196|Naturalistic
483083|NCT00768196|epidemiological
483084|NCT00768183|KADIAN
483085|NCT00768183|morphine
483086|NCT00768183|alcohol
483087|NCT00768183|water
483088|NCT00768183|Ethanol
483089|NCT00768183|solution
483090|NCT00768183|fed
483091|NCT00768183|fasting
483092|NCT00768157|hepatocellular carcinoma
483093|NCT00768157|hepatitis B virus
483094|NCT00768157|surgery
483095|NCT00768157|anti-virus
483096|NCT00768157|recurrence
483097|NCT00768144|Sutent
483098|NCT00768144|sunitinib
483099|NCT00768118|healthy, no evidence of disease
483100|NCT00768105|Type 2 diabetes
483101|NCT00768079|Benralizumab
483102|NCT00768079|MEDI-563
483103|NCT00768079|Asthma
483104|NCT00768066|Chronic Ischemic Left Ventricular Dysfunction
483105|NCT00768053|EULAR-RAID
483106|NCT00768053|active rheumatoid arthritis
483107|NCT00768053|etanercept
483108|NCT00768040|Diabetes
483109|NCT00768040|Macular edema
483110|NCT00768040|Aliskiren
483111|NCT00768040|Diabetic retinopathy
483112|NCT00768040|Diabetes mellitus type 1
483113|NCT00768040|Diabetes mellitus type 2
483114|NCT00768027|hyperspectral imaging
483115|NCT00768027|tissue oxygenation
483116|NCT00768027|wounds
483117|NCT00768027|wound healing
483118|NCT00768027|prevention
483119|NCT00768027|hyperbaric
483120|NCT00767988|Probiotics
483121|NCT00767988|Spina Bifida
483122|NCT00767988|Dietary Supplements
483123|NCT00767988|Bacteriuria
483124|NCT00767988|Urinary Tract Infection (UTI)
483125|NCT00767962|recurrent primary spontaneous pneumothorax
483126|NCT00767949|wet
483127|NCT00767949|AMD
483128|NCT00767923|hyperspectral imaging
483129|NCT00767923|tissue oxygenation
483130|NCT00767923|foot amputation
483131|NCT00767923|critical limb ischemia
483132|NCT00767923|tissue necrosis
483133|NCT00767897|Dose response relationship
483134|NCT00767897|immunity
483135|NCT00767884|panretinal photocoagulation
483136|NCT00767884|diabetic retinopathy
483137|NCT00767884|optic nerve head changes
483138|NCT00767871|Panic disorder
483139|NCT00767871|PET
483140|NCT00767871|Escitaopram
483141|NCT00767858|Genetic
483142|NCT00767858|Genetic Literacy
483143|NCT00767858|Human Genetic Research
483144|NCT00767858|Cultural Congruence
483145|NCT00767858|Interview
483146|NCT00767845|psychosocial effects of cancer and its treatment
483147|NCT00767845|stage I prostate cancer
483148|NCT00767845|stage II prostate cancer
483149|NCT00767845|stage III prostate cancer
483150|NCT00767819|progressive GIST
483151|NCT00767819|progressive sarcoma
483152|NCT00767767|To investigate the effects of anesthetic drugs on associative memory processes involving fear
483153|NCT00767754|panic disorder
483154|NCT00767754|paroxetine
483155|NCT00767754|PET
483156|NCT00767741|diabetes
483157|NCT00767741|post prandial glucose level
483158|NCT00767741|insulin
483159|NCT00767741|pharmacokinetics
483160|NCT00767741|pharmacodynamics
483161|NCT00767728|UC
483162|NCT00767728|ulcerative colitis
483163|NCT00767728|IBD
483164|NCT00767728|Inflammatory Bowel Disease
483165|NCT00767702|Genetic/Genomic Researchers
483166|NCT00767702|Human Genetic Variation
483167|NCT00767702|Interviews
483168|NCT00767702|Research Design
483169|NCT00767702|Race/Ethnicity
483170|NCT00767702|Interview
483171|NCT00767676|Contact sensitization
483172|NCT00767676|Healthy Adult Volunteers
483173|NCT00767650|Aplastic Anemia
483174|NCT00767650|Cyclosporine
483175|NCT00767650|Campath
483176|NCT00767650|Neurophyschological Side Effect
483177|NCT00767611|Infertility
483178|NCT00767611|Sperm
483179|NCT00767611|Embryo Development
483180|NCT00767611|In Vitro Fertilization
483181|NCT00767598|CYP3A5
483182|NCT00767598|sildenafil
483183|NCT00767598|udenafil
483184|NCT00767598|vardenafil
483185|NCT00767585|breast cancer
483186|NCT00767585|aromatase inhibitors
483187|NCT00767585|bone mineral density
483188|NCT00767585|osteoporosis
483189|NCT00767572|Coarctation of the aorta
483190|NCT00767572|cross over design
483191|NCT00767572|atorvastatin
483192|NCT00767572|endothelial function
483193|NCT00767559|Deep Vein Thrombosis, anticoagulants, surgery, pulmonary embolus, warfarin, fondaparinox
483194|NCT00767546|seborrhic dermatitis
483195|NCT00767546|parkinson's disease
483196|NCT00767546|Parkinson disease parkinsonism and seborrhic dermatitis
483197|NCT00767520|Advanced Estrogen Receptor Positive Breast Cancer
483198|NCT00767494|OAG
483199|NCT00767494|OH
483200|NCT00767494|Open-angle glaucoma or ocular hypertension
483201|NCT00767481|glaucoma
483202|NCT00767481|Patients with open-angle glaucoma or ocular hypertension
483203|NCT00767468|adult primary hepatocellular carcinoma
483204|NCT00767468|advanced adult primary liver cancer
483205|NCT00767468|localized unresectable adult primary liver cancer
483206|NCT00767468|recurrent adult primary liver cancer
483207|NCT00767455|cumulative irritation
483208|NCT00767455|healthy adult volunteers
483209|NCT00767429|accelerometer
483210|NCT00767429|fall risk
483211|NCT00767429|target group
483212|NCT00767429|field measurements
483213|NCT00767416|MEDI-559
483214|NCT00767416|Respiratory Syncytial Virus
483215|NCT00767416|RSV
483216|NCT00767416|Pediatric
483217|NCT00767416|Vaccine
483218|NCT00767416|respiratory syncytial virus, RSV, pediatric, vaccine
483219|NCT00767390|ACL Patch Placement
483220|NCT00767377|Time to Progression
483221|NCT00767377|Overall survival
483222|NCT00767377|Response rate
483223|NCT00767377|Quality of Live
483224|NCT00767377|Toxicities
483225|NCT00767364|Infant
483226|NCT00767338|Infertility
483227|NCT00767338|Pregnancy
483228|NCT00767338|Men
483229|NCT00767338|Palpable varicocele
483230|NCT00767338|Abnormal semen analysis
483231|NCT00767338|Intrauterine insemination
483232|NCT00767338|Microsurgical varicocelectomy
483233|NCT00767312|HIV
483234|NCT00767312|Antiretrovial Therapy
483235|NCT00767312|Viremia
483236|NCT00767312|Genetic Analysis
483237|NCT00767312|Single Copy Assay
483238|NCT00767286|stage IIB prostate cancer
483239|NCT00767286|stage IIA prostate cancer
483240|NCT00767286|stage III prostate cancer
483241|NCT00767286|stage IV prostate cancer
483242|NCT00767260|type 2 diabetes mellitus
483243|NCT00767260|bone marrow mononuclear cell
483244|NCT00767260|hyperbaric oxygen therapy
483245|NCT00767247|Arterial Hypertension
483246|NCT00767208|type 2 diabetic subjects
483247|NCT00767195|pulmonary edema
483248|NCT00767195|cardiogenic
483249|NCT00767195|non-cardiogenic
483250|NCT00767195|mortality
483251|NCT00767195|length of stay
483252|NCT00767182|preeclampsia
483253|NCT00767182|eclampsia
483254|NCT00767182|retroplacental hematoma
483255|NCT00767182|vascular IUGR
483256|NCT00767182|IUFD
483257|NCT00767182|placental volume
483258|NCT00767169|Edentatio (Toothlessness)
483259|NCT00767156|Sea buckthorn oil, Oral and topical treatment, Skin aging
483260|NCT00767130|single nucleotide polymorphisms, SNP, LDL cholesterol, statin myopathy, atorvastatin, simvastatin, rosuvastatin
483261|NCT00767117|TMC125-C197
483262|NCT00767117|TMC125-TiDP2-C197
483263|NCT00767117|HIV
483264|NCT00767117|DDI
483265|NCT00767117|Lopinavir
483266|NCT00767117|Intelence
483267|NCT00767117|Kaletra
483268|NCT00767117|Ritonavir
483269|NCT00767117|Etravirine
483270|NCT00767117|Interaction
483271|NCT00767117|Pharmacokinetics
483272|NCT00767117|Steady-state
483273|NCT00767091|Parkinson's disease
483274|NCT00767091|Apathy
483275|NCT00767091|Rivastigmine
483276|NCT00767091|transdermal patch
483277|NCT00767091|anticholinesterasic
483278|NCT00767091|acetylcholine
483279|NCT00767052|Healthy Volunteer
483280|NCT00767052|Safety
483281|NCT00767052|Tolerability
483282|NCT00767052|Pharmacokinetics
483283|NCT00767052|AZD1236
483284|NCT00767039|Very Premature
483285|NCT00767039|RDS
483286|NCT00767039|Surfactant
483287|NCT00767026|Epilepsy
483288|NCT00767026|Caregiver Burden
483289|NCT00767026|Parenting a Child with a Chronic Illness
483290|NCT00767013|DSCT, coronary artery disease, aortic valve stenosis
483291|NCT00766987|coronary artery disease
483292|NCT00766987|FDG PET viability imaging
483293|NCT00766987|morbidity and mortality
483294|NCT00766987|revascularization
483295|NCT00766987|resource utilization
483296|NCT00766974|Chronic Venous Disease
483297|NCT00766974|C3
483298|NCT00766974|Edema
483299|NCT00766974|Compression Garments
483300|NCT00766974|Compression Stockings
483301|NCT00766974|Bioimpedance
483302|NCT00766961|Peptic ulcer bleeding uncontrolled by endoscopic therapy.
483303|NCT00766935|Lymphedema
483304|NCT00766935|Bioimpedance
483305|NCT00766909|Insulin pulsatility
483306|NCT00766909|Insulin secretion
483307|NCT00766909|Insulin sensitivity
483308|NCT00766909|Calcineurin inhibitor
483309|NCT00766909|Cyclosporine
483310|NCT00766909|Tacrolimus
483311|NCT00766896|Stroke
483312|NCT00766896|Cerebral Infarction
483313|NCT00766896|Acute Coronary Syndrome
483314|NCT00766896|Cardiovascular Diseases
483315|NCT00766896|Vascular Diseases
483316|NCT00766896|Platelet Activation
483317|NCT00766896|Platelets
483318|NCT00766896|Platelet Function Tests
483319|NCT00766896|Aspirin
483320|NCT00766896|Atherosclerosis
483321|NCT00766896|Ischemia
483322|NCT00766896|Thrombosis
483323|NCT00766883|Allogeneic HSCT
483324|NCT00766883|Psychosocial Distress
483325|NCT00766883|Coping
483326|NCT00766883|Cognitive Behavior Therapy
483327|NCT00766883|Self Efficacy
483328|NCT00766883|Allogeneic Stem Cell Transplant
483329|NCT00766870|Efficacy
483330|NCT00766870|Safety
483331|NCT00766870|Depression
483332|NCT00766870|Interventional
483333|NCT00766870|Placebo
483334|NCT00766870|Short-term
483335|NCT00766870|Major Depressive Disorder
483336|NCT00766870|Major Depressive Episode
483337|NCT00766857|Exenatide
483338|NCT00766857|Type 2 diabetes mellitus
483339|NCT00766857|Congestive heart failure
483340|NCT00766857|Incretin hormones
483341|NCT00766857|GLP-1 agonist
483342|NCT00766857|Cardiac metabolism
483343|NCT00766857|Insulin resistance
483344|NCT00766857|Cardiac MRI
483345|NCT00766844|vasospasm
483346|NCT00766844|spinal cord stimulation
483347|NCT00766844|aneurysm
483348|NCT00766844|subarachnoid hemorrhage
483349|NCT00766831|Cancer pain
483350|NCT00766831|Hydromorphone OROS
483351|NCT00766831|Jurnista
483352|NCT00766779|hematopoietic cell transplantation
483353|NCT00766779|Acute Myeloid Leukemia
483354|NCT00766779|first Complete Remission
483355|NCT00766766|Environmental Tobacco Exposure
483356|NCT00766753|HLA-A2 positive
483357|NCT00766753|Malignant Gliomas
483358|NCT00766753|Vaccine
483359|NCT00766740|ST elevation myocardial infarction
483360|NCT00766740|thrombectomy
483361|NCT00766740|primary PCI
483362|NCT00766675|Pain
483363|NCT00766675|Fibromyalgia
483364|NCT00766675|Ultracet
483365|NCT00766675|Tramadol Hydrochloride
483366|NCT00766675|Acetaminophen
483367|NCT00766662|Malaria
483368|NCT00766662|Intermittent Preventive Treatment
483369|NCT00766662|EPI vaccine coverage
483370|NCT00766662|Resistance of P. falciparum to Sulfadoxine- Pyrimethamine
483371|NCT00766649|Age Related Macular Degeneration (AMD)
483372|NCT00766649|Geographic Atrophy
483373|NCT00766649|Sirolimus
483374|NCT00766649|Age-Related Macular Degeneration
483375|NCT00766649|AMD
483376|NCT00766636|Adenocarcinoma of the pancreatic head
483377|NCT00766636|Pancreaticoduodenectomy
483378|NCT00766636|Preoperative chemotherapy
483379|NCT00766636|Chemoradiation
483380|NCT00766636|Resectable pancreatic cancer
483381|NCT00766636|Surgical removal of the pancreas and duodenum
483382|NCT00766636|External-beam radiation therapy
483383|NCT00766636|EBRT
483384|NCT00766636|Gemcitabine
483385|NCT00766636|Erlotinib
483386|NCT00766623|endothelium,
483387|NCT00766623|postprandial
483388|NCT00766623|microvascular
483389|NCT00766623|macrovascular
483390|NCT00766597|Treatment Experienced
483391|NCT00766584|Aging
483392|NCT00766584|Autonomic nervous system
483393|NCT00766584|stroke
483394|NCT00766584|Myocardiac infarction
483395|NCT00766584|Prospective cohort
483396|NCT00766584|Sleep apnea/hypopnea
483397|NCT00766571|VACTERL Association
483398|NCT00766571|VATER Association
483399|NCT00766571|Multiple Congenital Anomalies
483400|NCT00766571|VACTERL
483401|NCT00766571|Congenital Defects
483402|NCT00766571|Birth Defects
483403|NCT00766571|Congenital Abnormalities
483404|NCT00766558|anorexia
483405|NCT00766558|bulimia
483406|NCT00766558|eating disorder not otherwise specified
483407|NCT00766519|fluid responsiveness
483408|NCT00766519|monitoring
483409|NCT00766519|arterial pulse pressure
483410|NCT00766506|IONSYS
483411|NCT00766506|Fentanyl
483412|NCT00766506|Morphine
483413|NCT00766506|PCA
483414|NCT00766506|Postoperative pain
483415|NCT00766506|Mobilization
483416|NCT00766493|carotid artery stenosis
483417|NCT00766493|embolic protection device
483418|NCT00766493|distal embolic filter
483419|NCT00766493|minimizing risks of carotid artery stenting
483420|NCT00766480|squamous cell carcinoma of the esophagus
483421|NCT00766480|stage IIA esophageal cancer
483422|NCT00766480|stage IIB esophageal cancer
483423|NCT00766480|stage IIIA esophageal cancer
483424|NCT00766480|stage IIIB esophageal cancer
483425|NCT00766480|stage IIIC esophageal cancer
483426|NCT00766467|armodafinil
483427|NCT00766467|Nuvigil
483428|NCT00766467|fatigue
483429|NCT00766454|breast cancer
483430|NCT00766441|diabetes
483431|NCT00766441|hypoglycemia
483432|NCT00766441|ramadan
483433|NCT00766441|fasting
483434|NCT00766415|COPD
483435|NCT00766415|Moderate to severe COPD
483436|NCT00766402|Spondylitis, ankylosing
483437|NCT00766402|Pain
483438|NCT00766402|Ultracet
483439|NCT00766402|Diclofenac
483440|NCT00766402|Voltaren
483441|NCT00766402|Tramadol/acetaminophen
483442|NCT00766389|Glaucoma
483443|NCT00766389|Retinal nerve fiber layer
483444|NCT00766389|Cirrus OCT
483445|NCT00766389|Stratus OCT
483446|NCT00766363|Alzheimer's Disease
483447|NCT00766363|Central Nervous System Diseases
483448|NCT00766363|Pharmacokinetics
483449|NCT00766363|Cognition
483450|NCT00766350|fibromyalgia
483451|NCT00766350|quetiapine
483452|NCT00766350|amitriptyline
483453|NCT00766337|wet AMD
483454|NCT00766298|Exercise
483455|NCT00766298|Weight Loss
483456|NCT00766298|Physical Activity
483457|NCT00766298|Type 2 Diabetes Mellitus
483458|NCT00766285|Baculovirus, influenza, stem cell transplant
483459|NCT00766272|Rehabilitation
483460|NCT00766272|Treadmill
483461|NCT00766272|MS
483462|NCT00766272|Gait
483463|NCT00766272|Robot
483464|NCT00766259|methicillin-resistant Staphylococcus
483465|NCT00766259|colonization
483466|NCT00766246|Non-Small Cell Lung Cancer
483467|NCT00766246|Advanced Non-Small Cell Lung Cancer
483468|NCT00766246|Lung Cancer
483469|NCT00766233|Hyperthermia
483470|NCT00766233|superficial tumor treatment
483471|NCT00766233|superficial tumors
483472|NCT00766220|Colon
483473|NCT00766220|Liver
483474|NCT00766220|Colorectal cancer
483475|NCT00766220|Colorectal cancer metastases to the liver
483476|NCT00766220|Metastases to the liver
483477|NCT00766220|Colorectal cancer mets to liver
483478|NCT00766220|Colon cancer metastasized to liver
483479|NCT00766220|Yttrium microspheres
483480|NCT00766220|SIR-Spheres
483481|NCT00766220|Yttrium-90
483482|NCT00766220|Cetuximab
483483|NCT00766220|C225
483484|NCT00766220|Erbitux
483485|NCT00766220|IMC-C225
483486|NCT00766220|Irinotecan
483487|NCT00766220|CPT-11
483488|NCT00766220|Liver directed therapy
483489|NCT00766207|Teratogens
483490|NCT00766207|Abnormalities, Drug-Induced
483491|NCT00766207|Contraception
483492|NCT00766181|IV placement; Parent satisfaction level
483493|NCT00766168|contact lens
483494|NCT00766168|rigid gas permeable
483495|NCT00766168|refractive index
483496|NCT00766155|stage II rectal cancer
483497|NCT00766155|stage III rectal cancer
483498|NCT00766155|adenocarcinoma of the rectum
483499|NCT00766142|adenocarcinoma of the colon
483500|NCT00766142|recurrent colon cancer
483501|NCT00766142|stage IV colon cancer
483502|NCT00766142|adenocarcinoma of the rectum
483503|NCT00766142|recurrent rectal cancer
483504|NCT00766142|stage IV rectal cancer
483505|NCT00766142|peritoneal carcinomatosis
483506|NCT00766129|saphenous vein graft, TAXUS stent, Chopin stent
483507|NCT00766116|AML
483508|NCT00766103|Cerebral metabolism, perfusion, induced hypothermia
483509|NCT00766064|posttraumatic stress disorder
483510|NCT00766051|Neurophysiologically Based Occupational Therapy Intervention (NBOTI)
483511|NCT00766051|NBOTI
483512|NCT00766051|NICU
483513|NCT00766051|NCCU
483514|NCT00766051|Developmental Biology
483515|NCT00766051|Critical Period
483516|NCT00766051|Brain Development
483517|NCT00766051|Sensory Integration
483518|NCT00766051|Neurodevelopment
483519|NCT00766051|Sensitive Period
483520|NCT00766038|Mood disorders
483521|NCT00766038|Cognitive disorders
483522|NCT00766038|Fatigue
483523|NCT00766038|Metabolic disorders
483524|NCT00766025|Taiwanese Subjects
483525|NCT00766025|CYP2C19
483526|NCT00766025|Poor Metabolizers
483527|NCT00766025|Extensive Metabolizers
483528|NCT00766025|Taiwanese Subjects identified as CYP2C19 Poor or Extensive Metabolizers
483529|NCT00766012|safety
483530|NCT00766012|tolerability
483531|NCT00766012|pharmacokinetics
483532|NCT00766012|AZD2066
483533|NCT00766012|Japanese
483534|NCT00765999|Constipation
483535|NCT00765999|Chronic Constipation
483536|NCT00765999|Irritable Bowel Syndrome With Constipation
483537|NCT00765999|Linaclotide
483538|NCT00765986|18F-FAZA
483539|NCT00765986|18F-FDG
483540|NCT00765986|Positron Emission Tomography
483541|NCT00765973|Other Advanced Solid Tumors
483542|NCT00765960|Vision
483543|NCT00765947|Essential Hypertension ( mild to moderate)
483544|NCT00765934|Healthy
483545|NCT00765921|glaucoma, neovascular
483546|NCT00765921|macular edema
483547|NCT00765921|eye enucleation
483548|NCT00765921|antibodies, monoclonal
483549|NCT00765921|radiation oncology
483550|NCT00765895|idiopathic gastroparesis
483551|NCT00765882|Constipation
483552|NCT00765882|Chronic Constipation
483553|NCT00765882|Linaclotide
483554|NCT00765869|Decision support techniques
483555|NCT00765856|Opioid tolerant
483556|NCT00765856|Pediatric
483557|NCT00765856|Male 6-17 years of age
483558|NCT00765856|Female 6-17 years of age
483559|NCT00765856|Pain
483560|NCT00765856|Non malignant
483561|NCT00765856|Malignant
483562|NCT00765843|heel pain
483563|NCT00765830|Type 2 diabetes, vildagliptin
483564|NCT00765817|diabetes
483565|NCT00765817|exenatide
483566|NCT00765817|Amylin
483567|NCT00765817|Lilly
483568|NCT00765817|metformin
483569|NCT00765817|pioglitazone
483570|NCT00765817|insulin glargine
483571|NCT00765804|Dry Eye
483572|NCT00765804|Iontophoresis
483573|NCT00765804|Ophthalmic Delivery
483574|NCT00765791|head and neck cancer
483575|NCT00765791|oral cancer
483576|NCT00765791|oropharyngeal cancer
483577|NCT00765791|laryngeal cancer
483578|NCT00765791|selective neck dissection
483579|NCT00765791|submuscular recess
483580|NCT00765791|level 2b
483581|NCT00765778|resistant bacteria rehabilitation centers
483582|NCT00765765|stage IV breast cancer
483583|NCT00765765|recurrent breast cancer
483584|NCT00765765|male breast cancer
483585|NCT00765752|Insomnia
483586|NCT00765752|depression
483587|NCT00765752|GABA
483588|NCT00765752|magnetic resonance spectroscopy
483589|NCT00765752|MRS
483590|NCT00765752|Sleep
483591|NCT00765752|antidepressant medication use
483592|NCT00765739|muscle fibers
483593|NCT00765739|aging
483594|NCT00765726|hemophilia
483595|NCT00765726|hemophilia A
483596|NCT00765726|ReFacto
483597|NCT00765726|Xyntha
483598|NCT00765726|moroctocog alfa
483599|NCT00765726|bleeding disorder
483600|NCT00765713|Sleep apnea
483601|NCT00765713|CPAP
483602|NCT00765713|Ventricular arrhythmias
483603|NCT00765713|Defibrillator therapies
483604|NCT00765700|Sprain
483605|NCT00765700|Strain
483606|NCT00765700|Pain
483607|NCT00765700|Ankle Pain
483608|NCT00765700|Shoulder Pain
483609|NCT00765700|Elbow Pain
483610|NCT00765700|Tennis Elbow
483611|NCT00765700|Knee pain
483612|NCT00765700|Wrist Pain
483613|NCT00765700|Hand Pain
483614|NCT00765700|Muscle, Bone and Cartilage Disorders
483615|NCT00765674|aliskiren
483616|NCT00765674|antihypertensive
483617|NCT00765674|hypertension
483618|NCT00765674|renin inhibitor
483619|NCT00765674|moderate-severe hypertension
483620|NCT00765661|Kidney
483621|NCT00765661|Transplantation
483622|NCT00765661|Immunosuppression
483623|NCT00765661|Tacrolimus
483624|NCT00765661|Prograf
483625|NCT00765648|hypertension
483626|NCT00765648|emergency department
483627|NCT00765648|Nicardipine
483628|NCT00765648|Labetalol
483629|NCT00765648|hypertensive emergency
483630|NCT00765648|hypertensive urgency
483631|NCT00765635|complete occlusion of the ear canal due to cerumen
483632|NCT00765622|Urinary incontinence
483633|NCT00765622|pelvic floor
483634|NCT00765622|functional evaluation
483635|NCT00765609|Paediatric
483636|NCT00765609|Analgesic
483637|NCT00765609|Prescribing
483638|NCT00765609|Parents
483639|NCT00765596|Obesity
483640|NCT00765596|Insulin resistance
483641|NCT00765596|Gastric tube
483642|NCT00765596|Ghrelin
483643|NCT00765583|Wrinkles (Nasolabial Folds)
483644|NCT00765570|large tumors in the head & neck, lung, abdomen or pelvis
483645|NCT00765557|To determine if laxative therapy can resolve Urge Syndrome, and if so, in which patients.
483646|NCT00765557|To determine usefulness of KUB, an abdominal X-ray of the kidneys, ureters, and bladder.
483647|NCT00765557|To predict the bowel activity of children with Urge Syndrome, who are most likely to respond to laxatives, with the use of the Bowel/Bladder questionnaire.
483648|NCT00765544|MS
483649|NCT00765544|Rehabilitation
483650|NCT00765544|Treadmill
483651|NCT00765544|Robot
483652|NCT00765544|Foot-drop
483653|NCT00765531|To determine the prevalence of genetic mutations in a population.
483654|NCT00765531|To identify stone formers with significant family history of stones.
483655|NCT00765531|To follow a cohort of pediatric stone formers an their families to report the long-term recurrence rats and therapeutic outcomes.
483656|NCT00765518|Ischemic Dilated Cardiomyopathy
483657|NCT00765518|Non-Ischemic Dilated Cardiomyopathy
483658|NCT00765518|ixmyelocel-T
483659|NCT00765505|Insulin Resistance
483660|NCT00765505|Obesity
483661|NCT00765505|Exercise Training
483662|NCT00765505|Physical Activity
483663|NCT00765492|Phase I
483664|NCT00765479|stage IIB prostate cancer
483665|NCT00765479|stage IIA prostate cancer
483666|NCT00765466|Explore the effect of AVR118 4.0 mL, given subcutaneously on appetite
483667|NCT00765453|Heart attack
483668|NCT00765453|Anterior Myocardial infarction (MI)
483669|NCT00765453|adult stem cells
483670|NCT00765453|bone marrow progenitor cells
483671|NCT00765453|bone marrow stem cells
483672|NCT00765453|autologous
483673|NCT00765453|left ventricular function
483674|NCT00765453|intracoronary injection
483675|NCT00765440|infection
483676|NCT00765440|malnutrition
483677|NCT00765440|stage I adenoid cystic carcinoma of the oral cavity
483678|NCT00765440|stage I mucoepidermoid carcinoma of the oral cavity
483679|NCT00765440|stage I verrucous carcinoma of the oral cavity
483680|NCT00765440|stage II adenoid cystic carcinoma of the oral cavity
483681|NCT00765440|stage II mucoepidermoid carcinoma of the oral cavity
483682|NCT00765440|stage II verrucous carcinoma of the oral cavity
483683|NCT00765440|stage III adenoid cystic carcinoma of the oral cavity
483684|NCT00765440|stage III mucoepidermoid carcinoma of the oral cavity
483685|NCT00765440|stage III verrucous carcinoma of the oral cavity
483686|NCT00765440|stage IV adenoid cystic carcinoma of the oral cavity
483687|NCT00765440|stage IV mucoepidermoid carcinoma of the oral cavity
483688|NCT00765440|stage IV verrucous carcinoma of the oral cavity
483689|NCT00765440|stage I squamous cell carcinoma of the larynx
483690|NCT00765440|stage I verrucous carcinoma of the larynx
483691|NCT00765440|stage II squamous cell carcinoma of the larynx
483692|NCT00765440|stage II verrucous carcinoma of the larynx
483693|NCT00765440|stage III squamous cell carcinoma of the larynx
483694|NCT00765440|stage III verrucous carcinoma of the larynx
483695|NCT00765440|stage IV squamous cell carcinoma of the larynx
483696|NCT00765440|stage IV verrucous carcinoma of the larynx
483697|NCT00765440|stage I lymphoepithelioma of the oropharynx
483698|NCT00765440|stage I squamous cell carcinoma of the oropharynx
483699|NCT00765440|stage II lymphoepithelioma of the oropharynx
483700|NCT00765440|stage II squamous cell carcinoma of the oropharynx
483701|NCT00765440|stage III lymphoepithelioma of the oropharynx
483702|NCT00765440|stage III squamous cell carcinoma of the oropharynx
483703|NCT00765440|stage IV lymphoepithelioma of the oropharynx
483704|NCT00765440|stage IV squamous cell carcinoma of the oropharynx
483705|NCT00765440|stage I squamous cell carcinoma of the hypopharynx
483706|NCT00765440|stage II squamous cell carcinoma of the hypopharynx
483707|NCT00765440|stage III squamous cell carcinoma of the hypopharynx
483708|NCT00765440|stage IV squamous cell carcinoma of the hypopharynx
483709|NCT00765440|tongue cancer
483710|NCT00765401|Abdominal Pain
483711|NCT00765401|Cystic Fibrosis
483712|NCT00765401|H. pylori
483713|NCT00765401|Children
483714|NCT00765388|urostomy, 1-piece, cross-over, randomised, preference
483715|NCT00765375|acne
483716|NCT00765375|Botox
483717|NCT00765375|cosmetic treatments
483718|NCT00765336|Spermatogenesis in Healthy Males
483719|NCT00765323|Octreotide
483720|NCT00765323|Sandostatin LAR
483721|NCT00765323|Growth hormone
483722|NCT00765323|IGF-1
483723|NCT00765310|atherosclerosis
483724|NCT00765310|lipoic acid
483725|NCT00765310|thioctic acid
483726|NCT00765310|triglycerides
483727|NCT00765310|overweight
483728|NCT00765310|obesity
483729|NCT00765310|oxidative stress
483730|NCT00765310|inflammation
483731|NCT00765297|fall risk
483732|NCT00765297|movement characteristics
483733|NCT00765297|stumble detection
483734|NCT00765297|accelerometry
483735|NCT00765284|HDL
483736|NCT00765284|RCT
483737|NCT00765284|Cholesterol
483738|NCT00765245|stage I adult diffuse large cell lymphoma
483739|NCT00765245|contiguous stage II adult diffuse large cell lymphoma
483740|NCT00765245|noncontiguous stage II adult diffuse large cell lymphoma
483741|NCT00765245|stage III adult diffuse large cell lymphoma
483742|NCT00765245|stage IV adult diffuse large cell lymphoma
483743|NCT00765232|laparoscopic
483744|NCT00765232|donor
483745|NCT00765232|nephrectomy
483746|NCT00765219|Generalized Anxiety Disorder
483747|NCT00765219|Geriatric
483748|NCT00765180|colonoscopy
483749|NCT00765180|hood
483750|NCT00765180|NBI
483751|NCT00765141|wound debridement
483752|NCT00765141|removed orthopedic implants
483753|NCT00765141|removed catheters or shunts
483754|NCT00765141|excised tonsils
483755|NCT00765141|amputated tissue
483756|NCT00765141|sputum, stool
483757|NCT00765141|or other excretions.
483758|NCT00765128|Percutaneous
483759|NCT00765128|Nephrolithotomy
483760|NCT00765128|Kidney stones
483761|NCT00765102|Multiple Myelonoma
483762|NCT00765102|Romidepsin
483763|NCT00765102|Bortezomib
483764|NCT00765076|Vaccine
483765|NCT00765076|Elderly
483766|NCT00765076|Influenza
483767|NCT00765063|Diabetic Foot Ulcers Neuroischaemic
483768|NCT00765050|Cellular therapy
483769|NCT00765050|CD133+
483770|NCT00765024|strongyloidiasis, ivermectin, albendazole
483771|NCT00765011|Head and Neck Cancer
483772|NCT00764998|Influenza
483773|NCT00764998|HIV
483774|NCT00764998|Influenza Vaccine
483775|NCT00764998|Efficacy
483776|NCT00764985|Syncope
483777|NCT00764985|Pre-Syncope
483778|NCT00764985|Fainting
483779|NCT00764972|To evaluate the use of sorafenib added to vinorelbine chemotherapy, to find out which are the doses of two drugs can be safely combined
483780|NCT00764933|information programme
483781|NCT00764933|anxiety reduction
483782|NCT00764933|multicenter trial
483783|NCT00764933|intensive care
483784|NCT00764933|critical care
483785|NCT00764920|human skin
483786|NCT00764907|T-cell childhood acute lymphoblastic leukemia
483787|NCT00764907|B-cell childhood acute lymphoblastic leukemia
483788|NCT00764907|untreated childhood acute lymphoblastic leukemia
483789|NCT00764881|Oral contraceptive
483790|NCT00764881|Sexual dysfunction
483791|NCT00764881|Libido
483792|NCT00764829|hematopoietic stem cell transplantation
483793|NCT00764829|fludarabine
483794|NCT00764829|mycophenolate mofetil
483795|NCT00764829|mycophenolic acid
483796|NCT00764829|biomarkers
483797|NCT00764816|Chronic kidney disease, stages 3 and 4
483798|NCT00764816|phosphaturia
483799|NCT00764816|phosphorus
483800|NCT00764816|PTH
483801|NCT00764816|FGF23
483802|NCT00764816|Dietary protein source
483803|NCT00764777|Peripheral Vascular Disease
483804|NCT00764777|Intermittent Claudication
483805|NCT00764777|Critical limb Ischemia
483806|NCT00764777|TASC A
483807|NCT00764777|TASC B
483808|NCT00764777|TASC C
483809|NCT00764777|TASC D
483810|NCT00764777|balloon-expandable stent
483811|NCT00764777|Self-expanding stent
483812|NCT00764777|TASC
483813|NCT00764764|shoulder pain
483814|NCT00764764|rotator cuff
483815|NCT00764764|impingement
483816|NCT00764764|cervical referred pain
483817|NCT00764764|neural tension
483818|NCT00764738|ARMD
483819|NCT00764738|AMD
483820|NCT00764738|exudative AMD
483821|NCT00764712|Tight glycemia control
483822|NCT00764712|cardiac surgery patients
483823|NCT00764699|poor growth
483824|NCT00764699|inflammatory bowel disease
483825|NCT00764686|Exercise
483826|NCT00764686|Education
483827|NCT00764686|Hydrotherapy
483828|NCT00764686|Physical Therapy Modalities
483829|NCT00764647|family caregivers
483830|NCT00764647|caregiver education
483831|NCT00764647|caregiver burden
483832|NCT00764647|caregiver hardiness
483833|NCT00764647|caregiver depressive symptoms
483953|NCT00764192|nictric oxide
483834|NCT00764621|Gadolinium ethoxybenzyl DTPA
483835|NCT00764621|Contrast media
483836|NCT00764621|Outcome Assessment (Health Care)
483837|NCT00764621|Magnetic Resonance Imaging
483838|NCT00764621|Tomography, X-Ray Computed
483839|NCT00764621|Liver
483840|NCT00764595|gastrointestinal stromal tumor
483841|NCT00764595|liver metastases
483842|NCT00764582|Corneal penetration of levofloxacin and moxifloxacin
483843|NCT00764569|oral tissue
483844|NCT00764556|Glucose
483845|NCT00764556|Insulin
483846|NCT00764556|COPD
483847|NCT00764556|Exacerbations
483848|NCT00764556|Tight glycaemic control
483849|NCT00764556|Acute hospital ward
483850|NCT00764543|To measure 24-hour ambulatory blood pressure in children who have unilateral hydronephrosis or multicystic-dysplastic kidneys
483851|NCT00764543|To compare these blood pressure measurements between the children who require surgical correction and those who do not need surgical correction.
483852|NCT00763685|preoperative pain prophylaxis
483853|NCT00763685|postoperative pain
483854|NCT00763672|Preeclampsia
483855|NCT00763672|Hypertension
483856|NCT00763672|Intra uterine growth retardation
483857|NCT00763672|Antiangiogenic factor
483858|NCT00763672|Prevention
483859|NCT00763646|Gastric or Gastroesophageal Junction Adenocarcinoma
483860|NCT00763633|nausea
483861|NCT00763633|vomiting
483862|NCT00763633|pregnancy
483863|NCT00763633|B6
483864|NCT00763620|Community acquired pneumonia
483865|NCT00763620|Nosocomial pneumonia
483866|NCT00763620|Mini bronchoalveolar lavage
483867|NCT00763620|Endotracheal aspirates
483868|NCT00763620|Expectorated sputum
483869|NCT00763607|non small cell lung cancer patients
483870|NCT00763594|Major Depression
483871|NCT00763594|Interpersonal Psychotherapy
483872|NCT00763594|Brief Relational Therapy
483873|NCT00763594|Outcome research
483874|NCT00763581|Patient Non-Adherence
483875|NCT00763581|Patient Non-Compliance
483876|NCT00763581|Patient Nonadherence
483877|NCT00763581|Patient Noncompliance
483878|NCT00763581|Patient Refusal of Treatment
483879|NCT00763581|Treatment Refusal
483880|NCT00763581|Refusal of Treatment
483881|NCT00763568|Chronic hepatitis C
483882|NCT00763568|Viral hepatitis
483883|NCT00763555|psoriasis
483884|NCT00763555|spray
483885|NCT00763555|calcitriol
483886|NCT00764465|Healthy Subjects
483887|NCT00764465|Pharmacokinetics study
483888|NCT00764465|Pharmacokinetics of medications
483889|NCT00764426|alcoholic beverages
483890|NCT00764426|non-alcoholic beverages
483891|NCT00764426|inflammation
483892|NCT00764426|Serum concentration of inflammatory markers before and after intervention
483893|NCT00764413|EDSS
483894|NCT00764413|methylprednisolone
483895|NCT00764413|circadian rhythms
483896|NCT00764413|MSFC
483897|NCT00764400|aphasia
483898|NCT00764400|anomia
483899|NCT00764400|speech therapy
483900|NCT00764400|rehabilitation
483901|NCT00764387|Neoplastic CNS lesions
483902|NCT00764387|Contrast enhanced MRI
483903|NCT00764387|Comparison
483904|NCT00764374|YM443
483905|NCT00764374|Z-338
483906|NCT00764374|Acotiamide
483907|NCT00764374|Rome III
483908|NCT00764374|Signs and symptoms, digestive
483909|NCT00764361|Diabetic
483910|NCT00764361|Ulcer
483911|NCT00764361|Wound
483912|NCT00764348|Acute and Chronic Wounds
483913|NCT00764322|menopausal symptoms
483914|NCT00764322|recurrent breast cancer
483915|NCT00764322|stage I breast cancer
483916|NCT00764322|stage II breast cancer
483917|NCT00764322|stage IIIA breast cancer
483918|NCT00764322|stage IIIB breast cancer
483919|NCT00764322|stage IIIC breast cancer
483920|NCT00764322|stage IV breast cancer
483921|NCT00764322|ductal breast carcinoma in situ
483922|NCT00764322|breast cancer in situ
483923|NCT00764296|acute wounds and chronic wounds
483924|NCT00764270|atherosclerosis
483925|NCT00764270|lipoic acid
483926|NCT00764270|thioctic acid
483927|NCT00764270|triglycerides
483928|NCT00764270|overweight
483929|NCT00764270|obesity
483930|NCT00764270|oxidative stress
483931|NCT00764270|inflammation
483932|NCT00764244|Diabetes
483933|NCT00764244|Macular edema
483934|NCT00764244|Optical Coherence tomography
483935|NCT00764244|VitrectomyLaser therapy
483936|NCT00764244|Intravitreal triamcinolone injection
483937|NCT00764231|acute myeloid leukemia
483938|NCT00764231|exercise
483939|NCT00764231|fatigue
483940|NCT00764231|quality of life
483941|NCT00764231|home-based
483942|NCT00764231|AML
483943|NCT00764218|Obstructive sleep apnea syndrome
483944|NCT00764218|Hypertension
483945|NCT00764218|Cardiovascular phenotype
483946|NCT00764205|ACS
483947|NCT00764205|non STEMI
483948|NCT00764205|ECG troponin
483949|NCT00764205|iSTAT
483950|NCT00764205|Acute coronary syndrome without ST-segment elevation
483951|NCT00764192|hemodialysis
483952|NCT00764192|Flow-mediated dilation
483954|NCT00764192|endothelial function
483955|NCT00764179|Neonates with intra-uterine growth delay
483956|NCT00764166|PSA (biochemical)
483957|NCT00764166|Progression- free Survival
483958|NCT00764166|Clinical progress
483959|NCT00764166|Overall survival
483960|NCT00764166|Tolerance to the treatment
483961|NCT00764166|Quality of Live
483962|NCT00764153|Displaced Femoral Neck Fractures
483963|NCT00764153|Treatment
483964|NCT00764153|Function
483965|NCT00764153|Pain
483966|NCT00764153|Quality of life
483967|NCT00764153|Complications
483968|NCT00764153|Reoperations
483969|NCT00764153|Internal Fixation
483970|NCT00764153|Hemiarthroplasty
483971|NCT00764153|Activities of Daily Living
483972|NCT00764140|tumor growth factor
483973|NCT00764127|adolescent
483974|NCT00764127|obesity
483975|NCT00764127|bariatric surgery
483976|NCT00764127|eating
483977|NCT00764114|Spondylodiscitis
483978|NCT00764114|Duration treatment
483979|NCT00764114|Antibiotic
483980|NCT00764114|men or women more than 18 years
483981|NCT00764114|proved bacterial spondylodiscitis
483982|NCT00764114|patient for which is decided a treatment antibiotic
483983|NCT00764114|the diagnosis on clinical
483984|NCT00764114|Radiological
483985|NCT00764114|microbiological criteria
483986|NCT00764088|full Thickness wounds
483987|NCT00764075|heart failure; EF<35%; NYHA II, III or IV
483988|NCT00764062|Amoxicillin
483989|NCT00764062|Drug resistance, microbial
483990|NCT00764062|Streptococcus
483991|NCT00764062|Surgery, oral
483992|NCT00764049|Albumin dialysis
483993|NCT00764049|Artificial liver support
483994|NCT00764049|Acute on chronic liver failure
483995|NCT00764036|phase I
483996|NCT00764036|safety
483997|NCT00764023|wound debridement
483998|NCT00764023|removed orthopedic implants
483999|NCT00764023|removed catheters or shunts
484000|NCT00764023|excised tonsils, amputated tissue
484001|NCT00764023|sputum
484002|NCT00764023|stool
484003|NCT00764023|other excretions.
484004|NCT00763997|dipyrone
484005|NCT00763997|platelet aggregation
484006|NCT00763997|neuraxial blockage
484007|NCT00763997|ibuprofen
484008|NCT00763997|platelet aggregation under dipyrone compared to ibuprofen, acetaminophen and parecoxib/valdecoxib
484009|NCT00763997|neuraxial blockage in patients receiving ibuprofen is critical in special circumstances, but traditionally not fpr dipyrone
484010|NCT00763984|Bladder Control for Women
484011|NCT00763984|Exercising Your Pelvic Muscles
484012|NCT00763984|Kegel Exercises: How to Strengthen Pelvic Floor Muscles
484013|NCT00763984|Kegel Exercises for Your Pelvic Muscles
484014|NCT00763984|Pelvic Floor Disorders
484015|NCT00763984|Pelvic Support Problems
484016|NCT00763984|Pregnancy
484017|NCT00763984|Pregnancy Childbirth and Bladder Control
484018|NCT00763984|Urinary Incontinence
484019|NCT00763984|Urinary Incontinence: Embarrassing but Treatable
484020|NCT00763958|opiates
484021|NCT00763958|HIV
484022|NCT00763945|Acute coronary Syndrome
484023|NCT00763945|STEMI
484024|NCT00763945|NSTEMI
484025|NCT00763945|Registry
484026|NCT00763919|Patient Non-Adherence
484027|NCT00763919|Patient Non-Compliance
484028|NCT00763919|Patient Nonadherence
484029|NCT00763919|Patient Noncompliance
484030|NCT00763919|Patient Refusal of Treatment
484031|NCT00763919|Refusal of Treatment
484032|NCT00763919|Treatment Refusal
484033|NCT00763906|septic shock
484034|NCT00763906|fuzzy logic
484035|NCT00763906|norepinephrine weaning
484036|NCT00763893|Marfan syndrome
484037|NCT00763893|Angiotensin II Type 1 Receptor Blockers
484038|NCT00763893|Aortic Aneurysm, Thoracic
484039|NCT00763880|Hematoma block
484040|NCT00763880|Lidocaine
484041|NCT00763880|Forearm fracture
484042|NCT00763880|Radius fracture
484043|NCT00763880|Ulna fracture
484044|NCT00763880|Ketamine
484045|NCT00763880|Midazolam
484046|NCT00763880|Procedural sedation
484047|NCT00763867|Heart Failure, Diastolic
484048|NCT00763867|Decompensated Heart Failure
484049|NCT00763867|Sildenafil
484050|NCT00763867|Exercise Capacity
484051|NCT00763841|Auditory hallucinations
484052|NCT00763828|Myocardial Infarction
484053|NCT00763828|Hypothermia, Induced
484054|NCT00763815|hyperglycemia GLP-1 pioglitazone
484055|NCT00763789|conscious sedation
484056|NCT00763789|remifentanil
484057|NCT00763789|hysteroscopic surgery
484058|NCT00763789|anesthesia recovery period
484059|NCT00763789|ambulatory surgery
484060|NCT00763789|patient satisfaction
484061|NCT00763789|length of stay
484062|NCT00763776|Liver cirrhosis
484063|NCT00763776|Hepatectomy
484064|NCT00763776|Liver parenchyma transection
484065|NCT00763776|Randomized controlled trial
484066|NCT00763763|Imatinib mesylate
484067|NCT00763763|Combination therapy
484068|NCT00763763|Leukemia, Lymphocytic, Acute
484069|NCT00763763|Philadelphia Chromosome
484070|NCT00763763|Blast Crisis
484071|NCT00763763|Leukemia, Myeloid, Chronic
484072|NCT00763750|glioblastoma multiforme or anaplastic glioma
484073|NCT00763737|congenital diaphragmatic hernia
484074|NCT00763737|fetal surgery
484075|NCT00763737|pulmonary hypoplasia
484076|NCT00763737|observed/expected lung to head ratio
484077|NCT00763737|liver position
484078|NCT00763737|feto
484079|NCT00763737|fetoscopic endoluminal tracheal occlusion
484080|NCT00763737|standardized neonatal care
484081|NCT00763711|Urinary Incontinence
484082|NCT00763711|ISD
484083|NCT00763698|Left heart pacing lead
484084|NCT00763698|Cardiac resynchronization therapy (CRT)
484085|NCT00763698|Heart failure
484086|NCT00763698|ICD
484087|NCT00763516|Pancreatic Cancer
484088|NCT00763516|Proton radiation
484089|NCT00763516|Chemotherapy
484090|NCT00763516|Xeloda
484091|NCT00763516|Gemzar
484092|NCT00763516|Resectable
484093|NCT00763516|Surgery
484094|NCT00763503|psoriasis
484095|NCT00763503|PK
484096|NCT00763503|calcitriol
484097|NCT00763490|umbilical cord blood
484098|NCT00763490|stem cell transplant
484099|NCT00763490|leukemia
484100|NCT00763490|multiple myeloma
484101|NCT00763490|lymphoma
484102|NCT00763477|Cystic fibrosis
484103|NCT00763477|Weight
484104|NCT00763477|Appetite
484105|NCT00763477|Ghrelin
484106|NCT00763477|Cystic fibrosis with low BMI
484107|NCT00763464|Coronary Artery Disease
484108|NCT00763464|ischemia diagnostic
484109|NCT00763451|hyperglycemia, GLP-1
484110|NCT00763438|Schizophrenia
484111|NCT00763438|Sertindole
484112|NCT00763438|Safety study
484113|NCT00763425|polypectomy
484114|NCT00763425|colonic polyp
484115|NCT00763425|colorectal polyp
484116|NCT00763425|colorectal cancer prevention
484117|NCT00763412|Cystic Fibrosis
484118|NCT00763412|Diabetes
484119|NCT00763412|Cystic Fibrosis Related Diabetes
484120|NCT00763412|Pre-diabetes
484121|NCT00763412|oral hypoglycemic agents
484122|NCT00763412|Repaglinide
484123|NCT00763412|treatment
484124|NCT00763412|inflammatory markers
484125|NCT00763412|Lung function
484126|NCT00763412|nutrition
484127|NCT00763399|probiotics
484128|NCT00763386|Total Knee Arthroplasty
484129|NCT00763386|Osteoarthritis
484130|NCT00763386|Knee
484131|NCT00763373|Lower respiratory infection
484132|NCT00763373|Upper respiratory infection
484133|NCT00763373|Urinary tract infection
484134|NCT00763373|Soft tissue infection
484135|NCT00763373|Hepatobiliary infection
484136|NCT00763360|Cataract
484137|NCT00763347|Glucose Metabolism Disorder
484138|NCT00763347|Dysmetabolic Syndrome
484139|NCT00763347|Type II Diabetes
484140|NCT00763347|Diabetes Mellitus, Lipoatrophic
484141|NCT00763347|Dyslipidemia
484142|NCT00763347|Drug Therapy
484143|NCT00763321|Effect on sleep interference by pain
484144|NCT00763308|Weight
484145|NCT00763308|Blood Pressure
484146|NCT00763308|Smoking Status
484147|NCT00763308|Cardiovascular Risk Profile
484148|NCT00763295|latent tuberculosis
484149|NCT00763295|HIV
484150|NCT00763295|IFN-γ based assay
484151|NCT00763282|Spinal cord injuries
484152|NCT00763282|Pressure ulcers
484153|NCT00763282|Health behavior
484154|NCT00763282|self management
484155|NCT00763282|Rehabilitation
484156|NCT00763282|Outcome assessment
484157|NCT00763282|QUERI
484158|NCT00763282|Veterans
484159|NCT00763243|profound bilateral hearing loss with cochlear implants
484160|NCT00763230|Depression
484161|NCT00763230|Treatment
484162|NCT00763230|Transcranial direct current stimulation
484163|NCT00763217|inflammation
484164|NCT00763217|coagulation
484165|NCT00763217|neuroprotection
484166|NCT00763217|drugs
484167|NCT00763217|clinical neurology
484168|NCT00763217|pharmacology
484169|NCT00763217|biological factors
484170|NCT00763204|Plaque Type Psoriasis
484171|NCT00763204|Topical
484172|NCT00763178|PTSD
484173|NCT00763152|prostate
484174|NCT00763152|prostate bed
484175|NCT00763152|periprostatic
484176|NCT00763139|RA
484177|NCT00763139|Rheumatoid Arthritis
484178|NCT00763126|parturient
484179|NCT00763126|epidural analgesia
484180|NCT00763126|labor
484181|NCT00763126|spouse
484182|NCT00763126|Stress levels
484183|NCT00763126|Salivary amylase
484184|NCT00763100|Breast cancer
484185|NCT00763100|Three dimensional versus two dimensional
484186|NCT00763100|Breast cancer surveillance
484187|NCT00763100|Tomosynthesis
484188|NCT00763087|diabetes mellitus
484189|NCT00763087|peripheral neuropathy
484190|NCT00763087|exercise
484191|NCT00763074|Intra-Abdominal Fat
484192|NCT00763074|Adipokines
484193|NCT00763074|Exercise
484194|NCT00763074|Diet therapy
484195|NCT00763061|Glaucoma
484196|NCT00763035|Coronary Artery Disease
484197|NCT00763035|Coronary Vessels
484198|NCT00763035|Myocardial Ischemia
484199|NCT00763035|Coronary Disease
484200|NCT00763035|Ischemic heart disease
484201|NCT00763035|asthma
484202|NCT00763035|copd
484203|NCT00763022|Glucose Metabolism Disorder
484204|NCT00763022|Dysmetabolic Syndrome
484205|NCT00763022|Type II Diabetes
484206|NCT00763022|Diabetes Mellitus, Lipoatrophic
484207|NCT00763022|Dyslipidemia
484208|NCT00763022|Drug Therapy
484209|NCT00762957|Glucose Metabolism Disorder
484210|NCT00762957|Dysmetabolic Syndrome
484211|NCT00762957|Type II Diabetes
484212|NCT00762957|Diabetes Mellitus, Lipoatrophic
484213|NCT00762957|Dyslipidemia
484214|NCT00762957|Drug Therapy
484215|NCT00762944|Patients requiring total joint reconstruction due to:
484216|NCT00762944|Arthritis (osteo-, rheumatoid, traumatic) malignancy
484217|NCT00762944|Ankylosis functional deformity
484218|NCT00762944|Avascular necrosis revisions
484219|NCT00762944|Benign neoplasms fracture
484220|NCT00762944|Multiple operated joints
484221|NCT00762931|bronchoconstriction
484222|NCT00762931|neuromodulation
484223|NCT00762931|neurostimulation
484224|NCT00762931|vagus nerve stimulation
484225|NCT00762931|vagal nerve stimulation
484226|NCT00762931|nVNS
484227|NCT00762931|VNS
484228|NCT00762931|non invasive
484229|NCT00762931|gammacore
484230|NCT00762918|cystic fibrosis
484231|NCT00762918|vitamin d
484232|NCT00762918|inflammation
484233|NCT00762905|cyanoacrylate
484234|NCT00762905|LiquiBand Laparoscopic
484235|NCT00762905|Dermabond
484236|NCT00762905|The rate of complete dermal apposition
484237|NCT00762905|The rate of wound infections and wound dehiscence
484238|NCT00762905|The rate of optimal cosmesis
484239|NCT00762892|Raltegravir
484240|NCT00762892|Integrase inhibitor
484241|NCT00762892|Protease inhibitor
484242|NCT00762892|Naive patients
484243|NCT00762892|HIV disease
484244|NCT00762892|Lipids
484245|NCT00762892|Treatment Naïve
484246|NCT00762879|Juvenile Idiopathic Arthritis
484247|NCT00762879|JIA
484248|NCT00762879|Arthritis
484249|NCT00762879|Osteoporosis
484250|NCT00762879|Osteoporosis in Children
484251|NCT00762866|Major Depressive Disorder
484252|NCT00762866|Depression
484253|NCT00762866|Bipolar I Disorder
484254|NCT00762866|Bipolar II Disorder
484255|NCT00762866|Bipolar Disorder NOS
484256|NCT00762866|Psychotic Disorder
484257|NCT00762866|Schizophrenia
484258|NCT00762866|Schizoaffective Disorder
484259|NCT00762840|Periapical lesions
484260|NCT00762840|Apical Periodontitis
484261|NCT00762840|endodontic procedure
484262|NCT00762840|root canal treatment
484263|NCT00762827|Excess body weight
484264|NCT00762827|High blood pressure
484265|NCT00762827|High levels of cholesterol
484266|NCT00762827|High blood sugar levels
484267|NCT00762814|Parkinson disease
484268|NCT00762814|Individuals
484269|NCT00762814|frequent
484270|NCT00762814|freezing
484271|NCT00762814|during
484272|NCT00762814|gait
484273|NCT00762801|RLIP76
484274|NCT00762801|Cancer
484275|NCT00762801|apoptosis
484276|NCT00762775|Bone resorption
484277|NCT00762775|Calcium homeostasis
484278|NCT00762775|Bone markers
484279|NCT00762775|Calcium and Vitamin D supplementation
484280|NCT00762775|Parathyroid hormone levels
484281|NCT00762775|Interaction between calcium and vitamin D supplementation
484282|NCT00762736|Glucose Metabolism Disorder
484283|NCT00762736|Dysmetabolic Syndrome
484284|NCT00762736|Type II Diabetes
484285|NCT00762736|Diabetes Mellitus, Lipoatrophic
484286|NCT00762736|Dyslipidemia
484287|NCT00762736|Drug Therapy
484288|NCT00762723|Degenerative Disc Disease
484289|NCT00762723|Spinal Stenosis
484290|NCT00762723|Spondylolisthesis
484291|NCT00762723|ALIF
484292|NCT00762723|fusion success
484293|NCT00762723|Anterior Lumbar Plate
484294|NCT00762723|fixed versus variable screw configurations
484295|NCT00762723|Anterior Lumbar Interbody Fusion to treat spinal instability
484296|NCT00762710|Alcohol
484297|NCT00762710|Abuse
484298|NCT00762710|Use
484299|NCT00762710|Disorder
484300|NCT00762710|Dependence
484301|NCT00762710|Symptoms
484302|NCT00762710|Alcoholic
484303|NCT00762710|Alcoholism
484304|NCT00762710|Prazosin
484305|NCT00762710|Drug
484306|NCT00762710|Medicine
484307|NCT00762710|Medication
484308|NCT00762710|Treatment
484309|NCT00762710|Study
484310|NCT00762710|Placebo
484311|NCT00762710|Medical
484312|NCT00762710|Management
484313|NCT00762710|Craving
484314|NCT00762710|Consumption
484315|NCT00762710|Binge
484316|NCT00762710|Drinking
484317|NCT00762710|Drink
484318|NCT00762710|Heavy
484319|NCT00762697|diabetic, venous insufficiency
484320|NCT00762684|Glucose Metabolism Disorder
484321|NCT00762684|Dysmetabolic Syndrome
484322|NCT00762684|Type II Diabetes
484323|NCT00762684|Diabetes Mellitus, Lipoatrophic
484324|NCT00762684|Dyslipidemia
484325|NCT00762658|Plaque Type Psoriasis
484326|NCT00762658|Topical
484327|NCT00762645|IOP lowering efficacy
484328|NCT00762645|CACG
484329|NCT00762632|patients with c-kit+ AML
484330|NCT00762606|Cataract
484331|NCT00762593|urinary stress incontinence
484332|NCT00762593|urinary stress incontinence in women
484333|NCT00762580|rotator cuff
484334|NCT00762580|rehabilitation
484335|NCT00762554|analgesia
484336|NCT00762554|cesarean section
484337|NCT00762554|fentanyl
484338|NCT00762554|Depodur
484339|NCT00762554|Post-cesarean section analgesia
484340|NCT00762541|Myopia
484341|NCT00762541|Laser In Situ Keratomileusis
484342|NCT00762541|Laser Therapy
484343|NCT00762541|Laser Corneal Surgery
484344|NCT00762541|Refractive Surgical Procedures
484345|NCT00762541|Ophthalmologic Surgical Procedure
484346|NCT00762541|Operative Surgical Procedures
484347|NCT00762541|Therapeutics
484348|NCT00762489|Temporal artery thermometry
484349|NCT00762489|Rectal temperature
484350|NCT00762489|Axillary temperature
484351|NCT00762489|Newborns
484352|NCT00762489|Temperature measurement
484353|NCT00762476|cold, common
484354|NCT00762476|rhinovirus
484355|NCT00762424|Kidney stone
484356|NCT00762424|Ureterolithiasis
484357|NCT00762424|Tamsulosin
484358|NCT00762424|Flowmax
484359|NCT00762424|Emergency Department
484360|NCT00762411|Alzheimer's Disease
484361|NCT00762398|Major surgery, excpected blood loss, arterial line
484362|NCT00762372|anesthesia
484363|NCT00762372|desflurane
484364|NCT00762359|Curling Ulcer
484365|NCT00762359|Gastric Ulcer
484366|NCT00762359|Aspirin
484367|NCT00762359|Acetylsalicylic Acid
484368|NCT00762359|Drug Therapy
484369|NCT00762346|non small cell lung cancer
484370|NCT00762346|NTX
484371|NCT00762346|zometa
484372|NCT00762320|HIV
484373|NCT00762320|Kaletra
484374|NCT00762320|treatment Experienced
484375|NCT00762294|breast cancer
484376|NCT00762294|arimidex
484377|NCT00762294|femara
484378|NCT00762294|bone health
484379|NCT00762281|Hyperopia
484380|NCT00762281|Laser In Situ Keratomileusis
484381|NCT00762281|Laser Therapy
484382|NCT00762281|Laser Corneal Surgery
484383|NCT00762281|Refractive Surgical Procedures
484384|NCT00762281|Ophthalmologic Surgical Procedure
484385|NCT00762281|Operative Surgical Procedures
484386|NCT00762281|Therapeutics
484387|NCT00762268|SAMe
484388|NCT00762268|alternative treatments
484389|NCT00762268|bipolar disorder
484390|NCT00762268|depression
484391|NCT00762268|bipolar depression
484392|NCT00762268|treatment-resistant depression
484393|NCT00762255|recurrent glioblastoma
484394|NCT00762255|multiple agents
484395|NCT00762255|immunotherapy
484396|NCT00762255|chemotherapy
484397|NCT00762255|brain and nervous system
484398|NCT00762242|metabolomics
484399|NCT00762242|flow-mediated vasodilation
484400|NCT00762229|Cholesterol
484401|NCT00762229|Ezetimibe
484402|NCT00762216|Cataract
484403|NCT00762190|Glucose Metabolism Disorder
484404|NCT00762190|Dysmetabolic Syndrome
484405|NCT00762190|Type II Diabetes
484406|NCT00762190|Diabetes Mellitus, Lipoatrophic
484407|NCT00762190|Dyslipidemia
484408|NCT00762190|Drug Therapy
484409|NCT00762164|Hypercholesterolemia
484410|NCT00762164|Statins
484411|NCT00762164|Ezetimibe
484412|NCT00762151|Dental Plaque
484413|NCT00762138|Platelet rich plasma
484414|NCT00762138|wounds
484415|NCT00762138|leg ulcers
484416|NCT00762138|pressure ulcers
484417|NCT00762138|diabetic ulcers
484418|NCT00762138|management of mechanically or surgically-debrided wounds
484419|NCT00762125|Fibromyalgia Syndrome
484420|NCT00762125|FMS
484421|NCT00762125|Physical Therapy
484422|NCT00762125|Psychotherapy
484423|NCT00762125|Group Counseling
484424|NCT00762125|Individual Counseling
484425|NCT00762125|Chronic Pain
484426|NCT00762112|Glucose Metabolism Disorder
484427|NCT00762112|Dysmetabolic Syndrome
484428|NCT00762112|Type II Diabetes
484429|NCT00762112|Diabetes Mellitus, Lipoatrophic
484430|NCT00762112|Dyslipidemia
484431|NCT00762112|Drug Therapy.
484432|NCT00762099|Arthroplasty, Hip
484433|NCT00762099|Hip replacement
484434|NCT00762099|Pain Management
484435|NCT00762099|Functional Rehabilitation
484436|NCT00762099|Anxiety
484437|NCT00762099|Perioperative
484438|NCT00762099|Pregabalin
484439|NCT00762099|Arthroplasty
484440|NCT00762086|Peripheral Arterial Disease
484441|NCT00762086|intermittent pneumatic compression treatment
484442|NCT00762086|Initial claudication
484443|NCT00762073|eosinophilic esophagitis
484444|NCT00762060|colorectal surgery
484445|NCT00762047|Fecal Incontinence
484446|NCT00762021|cataract
484447|NCT00762008|biomarkers
484448|NCT00761995|Raised IOP
484449|NCT00761969|peripheral arterial disease
484450|NCT00761969|secondary prevention
484451|NCT00761969|cardiovascular /atherothrombotic events
484452|NCT00761969|European guidelines
484453|NCT00761969|Cardiovascular disease prevention
484454|NCT00761956|Total Knee Arthroplasty
484455|NCT00761956|Osteoarthritis
484456|NCT00761956|Knee
484457|NCT00761943|Adhesive Capsulitis
484458|NCT00761943|Bursitis
484459|NCT00761943|Frozen Shoulder
484460|NCT00761904|hypertension
484461|NCT00761904|hyperlipidemia
484462|NCT00761904|free generic samples
484463|NCT00761891|aspirin
484464|NCT00761891|cyclooxygenase-1
484465|NCT00761891|aspirin resistance
484466|NCT00761891|aspirin nonresponse
484467|NCT00761891|platelet
484468|NCT00761891|Normal volunteers
484469|NCT00761878|Skin aging
484470|NCT00761878|Skin wrinkling
484471|NCT00761865|Lateral Ankle Sprin
484472|NCT00761865|Air Cast Stirrup Brace
484473|NCT00761865|High Tide Fracture Boot
484474|NCT00761839|wound healing
484475|NCT00761839|self-management
484476|NCT00761839|patient education
484477|NCT00761826|Mixed Astigmatism
484478|NCT00761826|Laser In Situ Keratomileusis
484479|NCT00761826|Laser Therapy
484480|NCT00761826|Laser Corneal Surgery
484481|NCT00761826|Refractive Surgical Procedures
484482|NCT00761826|Ophthalmologic Surgical Procedure
484483|NCT00761826|Operative Surgical Procedures
484484|NCT00761826|Therapeutics
484485|NCT00761813|Sliding Hip Screw Fixation
484486|NCT00761813|Cannulated Screw Fixation
484487|NCT00761787|allograft
484488|NCT00761787|rejection
484489|NCT00761787|biopsy
484490|NCT00761787|gene
484491|NCT00761787|expression
484492|NCT00761787|cardiology
484493|NCT00761787|heart
484494|NCT00761787|transplant
484495|NCT00761774|Epilepsy
484496|NCT00761774|Monotherapy
484497|NCT00761774|Partial Onset Seizures
484498|NCT00761761|Sensoril
484499|NCT00761761|Bipolar Illness
484500|NCT00761761|Cognitive enhancement
484501|NCT00761748|Urostomy,
484502|NCT00761748|2-piece,
484503|NCT00761748|preference,
484504|NCT00761722|Acute Myeloid Leukemia
484505|NCT00761722|Myelodysplastic Syndromes
484506|NCT00761722|Lymphoma
484507|NCT00761722|Multiple Myeloma
484508|NCT00761722|Chronic Myelomonocytic Leukemia (CMML)
484509|NCT00761709|Open Angle Glaucoma
484510|NCT00761709|Ocular Hypertension
484511|NCT00761696|solid tumor malignancies
484512|NCT00761683|Endometriosis
484513|NCT00761657|Kidney
484514|NCT00761657|Chronic Kidney Disease
484515|NCT00761657|CKD
484516|NCT00761657|Stage 3 or 4 Chronic Kidney Disease
484517|NCT00761657|Renal
484518|NCT00761657|Anemia
484519|NCT00761657|Oral anemia treatment
484520|NCT00761657|Hemoglobin levels
484521|NCT00761657|Blood count
484522|NCT00761657|Erythropoietin
484523|NCT00761644|Metastatic cancer
484524|NCT00761644|Doxil
484525|NCT00761644|Liposomal doxorubicin
484526|NCT00761644|Doxorubicin hydrochloride (liposomal)
484527|NCT00761644|Avastin
484528|NCT00761644|Bevacizumab
484529|NCT00761644|Anti-VEGF monoclonal antibody
484530|NCT00761644|rhuMAb-VEGF
484531|NCT00761644|Torisel
484532|NCT00761644|Temsirolimus
484533|NCT00761644|CCI-779
484534|NCT00761644|Dynamic contrast-enhanced magnetic resonance imaging
484535|NCT00761644|DCE-MRI scan
484536|NCT00761618|Intrapleural catheter
484537|NCT00761618|IPC
484538|NCT00761618|Pleurodesis
484539|NCT00761618|PD
484540|NCT00761618|Pleural effusion
484541|NCT00761618|Fluid in the chest cavity
484542|NCT00761618|Recurrent malignant pleural effusion
484543|NCT00761618|MPE
484544|NCT00761618|Pleural inflammatory response
484545|NCT00761605|Schizophrenia
484546|NCT00761605|Paliperidone
484547|NCT00761605|Paliperidone extended-release
484548|NCT00761605|Antipsychotics Agents
484549|NCT00761579|Schizophrenia
484550|NCT00761579|Paliperidone
484551|NCT00761579|Antipsychotics Agents
484552|NCT00761566|Elite swimmers
484553|NCT00761566|Exercise
484554|NCT00761566|Preconditioning
484555|NCT00761553|The study is designed to determine the effects of food supplements and strength training.
484556|NCT00761501|Phase I
484557|NCT00761501|Healthy Volunteer
484558|NCT00761488|Visual acuity,
484559|NCT00761488|corneal and
484560|NCT00761488|refractive
484561|NCT00761488|cylinder
484562|NCT00761488|following
484563|NCT00761488|implantation of the
484564|NCT00761488|AcrySof® Toric
484565|NCT00761475|incisional hernia
484566|NCT00761462|Pediatrics
484567|NCT00761462|Safety
484568|NCT00761462|Musculoskeletal System
484569|NCT00761462|Neurologic Manifestations
484570|NCT00761462|Joint Diseases
484571|NCT00761462|Joint Deformities, Acquired
484572|NCT00761449|MDS
484573|NCT00761449|AML
484574|NCT00761449|Lenalidomide
484575|NCT00761449|monosomy 5
484576|NCT00761449|del5q
484577|NCT00761410|Arthroplasty
484578|NCT00761410|Knee
484579|NCT00761410|Replacement
484580|NCT00761410|High Flexion
484581|NCT00761410|PFC Sigma RP-F
484582|NCT00761397|Oropharyngeal cancer
484583|NCT00761397|Dysphagic
484584|NCT00761397|Swallowing exercises
484585|NCT00761397|Swallowing rehabilitative regimens
484586|NCT00761397|PREPARE
484587|NCT00761397|Patients' Radiation Expectations
484588|NCT00761397|Prevention, Adherence, Rehabilitative Exercises
484589|NCT00761384|B-cell lymphoma
484590|NCT00761384|Refractory
484591|NCT00761384|Recurrent
484592|NCT00761384|90Y-ibritumomab
484593|NCT00761384|Stem cells support
484594|NCT00761384|Dosimetry study
484595|NCT00761371|external genital and perianal warts
484596|NCT00761358|Acotiamide
484597|NCT00761345|pancreatic cancer
484598|NCT00761345|locally advanced
484599|NCT00761345|unresectable
484600|NCT00761345|metastatic pancreatic cancer
484601|NCT00761319|Open-angle glaucoma
484602|NCT00761319|ocular hypertension
484603|NCT00761306|Major Depressive Disorder
484604|NCT00761306|Long-term
484605|NCT00761306|Safety
484606|NCT00761306|Open-label
484607|NCT00761280|Anaplastic astrocytoma
484608|NCT00761280|Glioblastoma
484609|NCT00761280|Antisense
484610|NCT00761280|Cancer
484611|NCT00761280|Transforming Growth Factor beta 2
484612|NCT00761280|Targeted therapy
484613|NCT00761280|Brain tumor
484614|NCT00761280|Glioma
484615|NCT00761280|Central Nervous System (CNS)
484616|NCT00761280|Convection Enhanced Delivery (CED)
484617|NCT00761280|Intratumoral administration
484618|NCT00761267|Anidulafungin
484619|NCT00761267|pediatrics
484620|NCT00761267|candidemia
484621|NCT00761267|invasive candidiasis
484622|NCT00761267|safety
484623|NCT00761254|Domperidone
484624|NCT00761254|Gastroparesis
484625|NCT00761241|pancreas cancer
484626|NCT00761241|combined modality therapy
484627|NCT00761228|Vegetative State
484628|NCT00761228|Minimally Conscious State
484629|NCT00761228|Coma
484630|NCT00761228|Traumatic Brain Injury
484631|NCT00761215|Skin
484632|NCT00761215|Infection
484633|NCT00761215|Complicated Skin and Skin Structure Infection
484634|NCT00761189|Paliperidone
484635|NCT00761189|R076477
484636|NCT00761189|Schizophrenia
484637|NCT00761176|Diabetes
484638|NCT00761176|Ulcers
484639|NCT00761176|Wounds
484640|NCT00761163|The purpose of this study is to identify the body's response to aerobic vs. resistance exercise
484641|NCT00761150|Effect on sleep interference by pain
484642|NCT00761137|sialorrhea
484643|NCT00761137|drooling
484644|NCT00761137|excessive salivation
484645|NCT00761137|parkinson's disease
484646|NCT00761124|PSA screening
484647|NCT00761124|Prostate cancer and Latino men
484648|NCT00761111|information booklet
484649|NCT00761111|low back beliefs
484650|NCT00761111|education
484651|NCT00761111|disc hernia
484652|NCT00761111|discectomy
484653|NCT00761111|A common monoradicular sciatica
484654|NCT00761111|on a slipped disc
484655|NCT00761111|with a clinical radio
484656|NCT00761111|agreement requiring a surgical treatment
484657|NCT00761111|carried out
484658|NCT00761111|one duration
484659|NCT00761111|of evolution higher
484660|NCT00761111|than four weeks
484661|NCT00761111|at naive subjects
484662|NCT00761111|of any rachidian interventional treatment
484663|NCT00761111|after failure of an good ambulatory
484664|NCT00761098|Cirrhosis
484665|NCT00761098|SBP
484666|NCT00761072|Propofol
484667|NCT00761072|Remifentanil
484668|NCT00761072|Total Intravenous Anesthesia
484669|NCT00761059|analgesia
484670|NCT00761059|infant, premature
484671|NCT00761059|glucose
484672|NCT00761059|nasopharyngeal suctioning
484673|NCT00760279|Bacterial infection
484674|NCT00760279|Azithromycin
484675|NCT00760266|Hypertension
484676|NCT00760266|older population
484677|NCT00760266|aliskiren
484678|NCT00760266|hydrochlorothiazide
484679|NCT00760266|systolic blood pressure
484680|NCT00760266|diastolic blood pressure
484681|NCT00760266|amlodipine, stage 2
484682|NCT00760253|target control infusion
484683|NCT00760253|alfentanyl
484684|NCT00760253|propofol
484685|NCT00760253|BIS
484686|NCT00760240|compliance
484687|NCT00760240|eyedrop instillation
484688|NCT00760240|How patients with low vision due to glaucoma or retinal pathology instill eyedrops into their own eyes.
484689|NCT00760214|Essential Hypertension
484690|NCT00760214|Hypertension
484691|NCT00760214|Drug Therapy
484692|NCT00760214|Blood Pressure, High
484693|NCT00760214|Vascular Disease
484694|NCT00760214|Cardiovascular Disease
484695|NCT00761033|children undergoing intravenous placement in the pediatric emergency department
484696|NCT00761020|Malaria
484697|NCT00761020|Diagnosis
484698|NCT00761020|Biomarker
484699|NCT00761007|Irritable Bowel Syndrome
484700|NCT00761007|Bowel disease
484701|NCT00760994|Alcohol
484702|NCT00760994|Alcoholic
484703|NCT00760994|Alcoholism
484704|NCT00760994|Post-traumatic stress disorder
484705|NCT00760994|PTSD
484706|NCT00760994|Experiential acceptance
484707|NCT00760994|Mindfulness
484708|NCT00760994|Meditation
484709|NCT00760994|Meditate
484710|NCT00760994|Cognitive restructuring
484711|NCT00760994|Cognitive
484712|NCT00760994|Behavioral
484713|NCT00760994|Therapy
484714|NCT00760994|Treatment
484715|NCT00760994|Study
484716|NCT00760994|Intervention
484717|NCT00760968|Rheumatoid Arthritis
484718|NCT00760968|Drug Therapy
484719|NCT00760955|Asymmetric Diabetic Proximal Motor Neuropathy
484720|NCT00760955|Diabetic Amyotrophy
484721|NCT00760955|Diabetic Autonomic Neuropathy
484722|NCT00760955|Diabetic Polyneuropathy
484723|NCT00760955|Neuralgia, Diabetic
484724|NCT00760955|Symmetric Diabetic Proximal Motor Neuropathy
484725|NCT00760955|Drug Therapy
484726|NCT00760942|Low birth weight
484727|NCT00760942|neonates
484728|NCT00760942|premature infants
484729|NCT00760942|nutrition
484730|NCT00760942|human milk fortification
484731|NCT00760942|Infant
484732|NCT00760916|Pulmonary Arterial Hypertension
484733|NCT00760903|Moderate brain trauma
484734|NCT00760890|Iron, breastfed infant
484735|NCT00760877|MYELOGENOUS
484736|NCT00760877|LEUKEMIA
484737|NCT00760877|Chronic Phase
484738|NCT00760877|CML
484739|NCT00760864|Rheumatoid Arthritis
484740|NCT00760864|Drug Therapy
484741|NCT00760851|Probiotics
484742|NCT00760851|Child, preschool
484743|NCT00760851|Child Day Care Centers
484744|NCT00760851|Health
484745|NCT00760851|Immune system
484746|NCT00760838|Inadequately controlled severe asthma
484747|NCT00760825|cholera
484748|NCT00760825|vibrios
484749|NCT00760825|oral cholera vaccine
484750|NCT00760812|Autism
484751|NCT00760812|Autism Spectrum Disorders
484752|NCT00760812|Pervasive Developmental Disorders
484753|NCT00760812|Toddlers
484754|NCT00760812|Intervention
484755|NCT00760799|Lumbar Disc Herniation
484756|NCT00760786|IVUS-VH
484757|NCT00760786|Plaque characterization
484758|NCT00760786|Omega3-fatty acid
484759|NCT00760786|Atorvastatin
484760|NCT00760773|Probiotic treatment
484761|NCT00760773|Daycare attendance
484762|NCT00760773|Pediatric
484763|NCT00760773|Emergency department
484764|NCT00760747|ADHD
484765|NCT00760747|Children
484766|NCT00760747|Stimulant
484767|NCT00760747|Atomoxetine
484768|NCT00760747|Adolescents
484769|NCT00760734|Chronic traumatic brain injury
484770|NCT00760734|Post concussion syndrome
484771|NCT00760734|Post traumatic stress disorder
484772|NCT00760734|Chronic post traumatic stress disorder
484773|NCT00760721|Hepatitis B Screening
484774|NCT00760721|Korean Americans
484775|NCT00760708|nucleosides
484776|NCT00760708|neurotransmitter
484777|NCT00760708|myocardial ischemia
484778|NCT00760708|Adenosine
484779|NCT00760695|anorexia nervosa
484780|NCT00760695|chronic
484781|NCT00760695|dronabinol
484782|NCT00760695|weight gain
484783|NCT00760695|EDI
484784|NCT00760682|osteoradionecrosis
484785|NCT00760682|hyperbaric oxygen
484786|NCT00760682|sequestrectomy
484787|NCT00760669|Spondylitis, Ankylosing
484788|NCT00760669|Arthritis, Rheumatoid
484789|NCT00760669|Psoriasis
484790|NCT00760669|Arthritis, Psoriatic
484791|NCT00760669|Infliximab
484792|NCT00760669|Remicade
484793|NCT00760656|Health outcomes in adults who survived pediatric cancer
484794|NCT00760656|Survivors of Pediatric Cancer
484795|NCT00760630|abnormal stress test
484796|NCT00760630|fractional flow reserve
484797|NCT00760630|pressure drop coefficient
484798|NCT00760630|lesion flow coefficient
484799|NCT00760617|Influenza
484800|NCT00760617|Elderly
484801|NCT00760604|Esophageal neoplasms
484802|NCT00760604|Esophagectomy
484803|NCT00760591|Acute kidney failure
484804|NCT00760591|Colonoscopy
484805|NCT00760591|Neutrophil gelatinase-associated lipocalin
484806|NCT00760552|Hypertension
484807|NCT00760552|Adherence
484808|NCT00760552|Pharmacist
484809|NCT00760552|Interdisciplinary
484810|NCT00760552|Randomized Controlled
484811|NCT00760552|Primary Care
484812|NCT00760539|Glaucoma
484813|NCT00760539|Hypertension
484814|NCT00760526|Continuous Glucose Monitor
484815|NCT00760513|non alcoholic fatty liver disease
484816|NCT00760513|NAFLD
484817|NCT00760513|fish oil
484818|NCT00760513|intervention
484819|NCT00760513|RCT
484820|NCT00760513|biomarkers
484821|NCT00760487|Cataract AcrySof Toric IOL
484822|NCT00760487|Bilateral cataract
484823|NCT00760474|Fibromyalgia; fMRI; pain; pregabalin; Lyrica; imaging
484824|NCT00760435|Kawasaki disease
484825|NCT00760435|Infliximab
484826|NCT00760435|Remicade
484827|NCT00760435|Pediatrics
484828|NCT00760409|recurrent tumor
484829|NCT00760396|healthy volunteers
484830|NCT00760383|Total Knee Arthroplasty
484831|NCT00760383|Osteoarthritis
484832|NCT00760383|Muscle Metabolism
484833|NCT00760383|Rehabilitation
484834|NCT00760383|Physical Therapy
484835|NCT00760370|bone marker
484836|NCT00760370|bisphosphonate
484837|NCT00760370|Zometa
484838|NCT00760370|retention
484839|NCT00760370|breast cancer
484840|NCT00760370|multiple myeloma
484841|NCT00760370|CTX
484842|NCT00760370|bone specific ALP
484843|NCT00760357|Critical Ischemia
484844|NCT00760344|Glucose Metabolism Disorder
484845|NCT00760344|Dysmetabolic Syndrome
484846|NCT00760344|Type II Diabetes
484847|NCT00760344|Diabetes Mellitus, Lipoatrophic
484848|NCT00760344|Dyslipidemia
484849|NCT00760344|Drug Therapy
484850|NCT00760331|HNF1B
484851|NCT00760331|TCF2
484852|NCT00760331|MODY-5
484853|NCT00760331|CAKUT
484854|NCT00760331|Anomaly of renal development
484855|NCT00760318|cervical dystonia, keppra, botox, spasmodic torticollis
484856|NCT00760305|cancer pain
484857|NCT00760305|bone metastasis
484858|NCT00760305|patient education
484859|NCT00760305|psychoeducational education
484860|NCT00760305|side effects
484861|NCT00760305|analgesics
484862|NCT00760292|Type 2 Diabetes Mellitus
484863|NCT00760292|Genetic Variants
484864|NCT00760292|SNP
484865|NCT00760292|DNA microarray
484866|NCT00760201|executive
484867|NCT00760201|administrator
484868|NCT00760201|perceptions
484869|NCT00760201|legal counsel
484870|NCT00760201|end of life
484871|NCT00760188|knee replacement
484872|NCT00760175|Lung transplant Recipients
484873|NCT00760175|Vaxigrip
484874|NCT00760162|Chronic Kidney failure stage three and four
484875|NCT00760162|Probiotics
484876|NCT00760162|Kibow Biotics
484877|NCT00760162|Enteric Dialysis
484878|NCT00760162|Gut based removal uremic toxin removal
484879|NCT00760149|tuberculosis
484880|NCT00760149|rifampicin
484881|NCT00760149|pharmacokinetics
484882|NCT00760149|pharmacodynamics
484883|NCT00760136|patellofemoral pain
484884|NCT00760136|quadriceps contraction
484885|NCT00760123|Lymphedema
484886|NCT00760123|Prevention
484887|NCT00760123|Breast cancer
484888|NCT00760123|Physical therapy
484889|NCT00760110|Morning BP
484890|NCT00760110|Clinic BP
484891|NCT00760110|micro- and macrovascular complications
484892|NCT00760084|Acute Myelogenous Leukemia
484893|NCT00760084|Myelodysplastic Syndrome
484894|NCT00760084|Dacogen
484895|NCT00760084|Decitabine
484896|NCT00760071|cystic fibrosis,
484897|NCT00760071|lung disease,
484898|NCT00760071|MRI,
484899|NCT00760071|morphology,
484900|NCT00760071|function
484901|NCT00760071|morphological MRI
484902|NCT00760071|functional MRI
484903|NCT00760071|correlation to clinical data
484904|NCT00760058|cataract, intraocular lens
484905|NCT00760032|Cirrhosis
484906|NCT00760032|Ascites
484907|NCT00760032|Lipopolysaccharide binding protein
484908|NCT00760032|Infections
484909|NCT00760032|Cytokines
484910|NCT00760032|Ciprofloxacin
484911|NCT00760019|vascular inflammation
484912|NCT00760019|endothelium-dependent flow-mediated blood vessel function
484913|NCT00760006|cleft secondary palate
484914|NCT00760006|Patients undergoing primary closure of a cleft secondary palate
484915|NCT00759993|weight gain
484916|NCT00759993|Obesity
484917|NCT00759993|Psychiatry
484918|NCT00759993|Medication
484919|NCT00759993|Induced
484920|NCT00759980|Thrombocytopenia
484921|NCT00759980|Platelet transfusion
484922|NCT00759967|Randomized
484923|NCT00759967|Cross-Over
484924|NCT00759967|Conventional
484925|NCT00759967|Daily
484926|NCT00759967|Hemodialysis
484927|NCT00759954|bioequivalence
484928|NCT00759954|morphine sulfate sustained release capsules
484929|NCT00759954|KADIAN capsules
484930|NCT00759954|200 mg
484931|NCT00759954|applesauce
484932|NCT00759941|Glaucoma
484933|NCT00759928|Refractory Solid Tumors
484934|NCT00759928|Unresectable Stage III/IV
484935|NCT00759928|Sorafenib
484936|NCT00759928|Erlotinib
484937|NCT00759928|Pharmacokinetics
484938|NCT00759915|10 mg
484939|NCT00759915|KADIAN capsules
484940|NCT00759915|20 mg
484941|NCT00759915|fed conditions
484942|NCT00759915|bioequivalence
484943|NCT00759902|bioequivalence
484944|NCT00759902|10 mg
484945|NCT00759902|KADIAN capsules
484946|NCT00759902|20 mg
484947|NCT00759902|under fasted conditions
484948|NCT00759889|venous leg ulcer
484949|NCT00759876|Duchenne muscular dystrophy
484950|NCT00759876|Nonsense mutation
484951|NCT00759876|Premature stop codon
484952|NCT00759876|DMD
484953|NCT00759876|PTC124
484954|NCT00759876|Ataluren
484955|NCT00759850|Acute Myocardial Infarction
484956|NCT00759850|Drug Eluting Stent
484957|NCT00759850|Primary PCI
484958|NCT00759824|Small cell lung carcinoma
484959|NCT00759824|Valproic acid
484960|NCT00759824|Adriamycin
484961|NCT00759824|Cyclophosphamide
484962|NCT00759824|Vindesine
484963|NCT00759824|Second-line chemotherapy
484964|NCT00759811|Heart Failure
484965|NCT00759811|Myocardial Ischemia
484966|NCT00759811|Methotrexate
484967|NCT00759811|Inflammation
484968|NCT00759811|Anti-Inflammatory Agents
484969|NCT00759811|Inflammation Mediators
484970|NCT00759798|Chronic Lymphocytic Leukemia
484971|NCT00759798|Leukemia
484972|NCT00759798|FCR
484973|NCT00759798|Fludarabine
484974|NCT00759798|Cyclophosphamide
484975|NCT00759798|Rituximab
484976|NCT00759772|Anorexia Nervosa
484977|NCT00759772|Disordered Eating
484978|NCT00759772|Osteoporosis
484979|NCT00759772|Parathyroid Hormone
484980|NCT00759772|Bone
484981|NCT00759759|bioequivalence
484982|NCT00759759|morphine sulfate sustained release capsules
484983|NCT00759759|KADIAN capsules
484984|NCT00759759|200 mg
484985|NCT00759746|Weight loss maintenance
484986|NCT00759733|pregnancy
484987|NCT00759733|heart disease
484988|NCT00759733|heart function testing
484989|NCT00759733|echocardiography
484990|NCT00759733|B-type natriuretic peptide
484991|NCT00759733|obstetrical care
484992|NCT00759720|Glucose Metabolism Disorder
484993|NCT00759720|Dysmetabolic Syndrome
484994|NCT00759720|Type II Diabetes
484995|NCT00759720|Diabetes Mellitus, Lipoatrophic
484996|NCT00759720|Dyslipidemia
484997|NCT00759720|Drug Therapy
484998|NCT00759707|saphenous vein bypass grafts
484999|NCT00759707|flow-mediated vasodilation
485000|NCT00759681|Arterial Surgery
485001|NCT00759681|Open vascular Surgery
485002|NCT00759681|Sealant
485003|NCT00759655|hemophilia A
485004|NCT00759655|Xyntha
485005|NCT00759655|ReFacto
485006|NCT00759655|moroctocog alfa
485007|NCT00759655|bleeding disorder
485008|NCT00759642|breast cancer
485009|NCT00759642|hormone receptor positive
485010|NCT00759642|HER-2 negative
485011|NCT00759616|Knee Replacement
485012|NCT00759603|Leukemia
485013|NCT00759603|CLL
485014|NCT00759603|Chronic Lymphocytic Leukemia
485015|NCT00759603|SLL
485016|NCT00759603|Small Lymphocytic Lymphoma
485017|NCT00759603|Lenalidomide
485018|NCT00759603|Revlimid
485019|NCT00759603|Rituximab
485020|NCT00759603|Rituxan
485021|NCT00759551|Blood Pressure
485022|NCT00759551|Drug Therapy
485023|NCT00759551|Systolic Pressure
485024|NCT00759551|Diastolic Pressure
485025|NCT00759551|Vascular Diseases
485026|NCT00759538|Lung Transplantation
485027|NCT00759538|Pulmonary Rehabilitation
485028|NCT00759538|Exercise tolerance
485029|NCT00759538|Quality of Life
485030|NCT00759499|study of debridement tissue for research purposes.
485031|NCT00759499|open wound
485032|NCT00759486|craniofacial fracture
485033|NCT00759486|Subjects who are in the active phase of craniofacial skeletal growth, and have sustained a craniofacial fracture
485034|NCT00759473|substance-related disorders
485035|NCT00759460|Schizophrenia
485036|NCT00759434|Varicose veins
485037|NCT00759434|Chronic venous insufficiency
485038|NCT00759434|Venous ulceration
485039|NCT00759434|Surgery
485040|NCT00759434|Endovenous Laser
485041|NCT00759421|Schizophrenia
485042|NCT00759408|primary pulmonary hypertension
485043|NCT00759408|secondary pulmonary hypertension due to left heart failure
485044|NCT00759408|secondary pulmonary hypertension due to other causes
485045|NCT00759408|patients without pulmonary disease or pulmonary hypertension
485046|NCT00759395|Anxious Major Depressive Disorder
485047|NCT00759382|Non small cell lung carcinoma
485048|NCT00759382|PET scan
485049|NCT00759382|Observational study
485050|NCT00759382|Non metastatic
485051|NCT00759382|treated
485052|NCT00759382|curative intent
485053|NCT00759369|ADPKD
485054|NCT00759356|bioavailability
485055|NCT00759356|KADIAN
485056|NCT00759356|200 mg
485057|NCT00759356|morphine sulfate sustained release capsules
485058|NCT00759356|100 mg
485059|NCT00759356|fed conditions
485060|NCT00759343|Kidney stones
485061|NCT00759343|urinary stone disease
485062|NCT00759343|urinary stones
485063|NCT00759343|urine
485064|NCT00759343|serum
485065|NCT00759330|Flurbiprofen, low back pain, chronic low back pain
485066|NCT00759317|normal controls
485067|NCT00759304|Aging
485068|NCT00759304|cardiovascular risk factors
485069|NCT00759304|Autonomic nervous system
485070|NCT00759304|stroke
485071|NCT00759304|Myocardiac infarction
485072|NCT00759304|Neuropsychological evaluation
485073|NCT00759304|Prospective cohort
485074|NCT00759291|free fatty acids
485075|NCT00759291|insulin-mediated
485076|NCT00759291|endothelium-dependent vasodilation
485077|NCT00759291|metabolic syndrome
485078|NCT00759278|pregnancy
485079|NCT00759278|umbilical artery systolic to diastolic flow ratio
485080|NCT00759278|middle cerebral artery peak systolic flow
485081|NCT00759278|antihypertensive medication
485082|NCT00759265|Muscle strength
485083|NCT00759265|Physical activity
485084|NCT00759265|Mobility
485085|NCT00759265|Gait analysis
485086|NCT00759252|diagnosis of dementia
485087|NCT00759252|perceptions of risk
485088|NCT00759252|dementia screening
485089|NCT00759239|Open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension
485090|NCT00759226|esophageal cancer
485091|NCT00759226|Gemcitabine
485092|NCT00759226|Cisplatin
485093|NCT00759226|5-FU
485094|NCT00759226|Folinic Acid
485095|NCT00759226|inoperable esophageal cancer
485096|NCT00759213|Discharge planning
485097|NCT00759213|Family needs
485098|NCT00759213|Family concerns
485099|NCT00759213|NICU
485100|NCT00759213|Infants
485101|NCT00759200|Chronic hepatitis C
485102|NCT00759200|genotype 2
485103|NCT00759200|genotype 3
485104|NCT00759200|albumin interferon alfa-2b
485105|NCT00759200|alb-interferon
485106|NCT00759174|Optic Neuropathy Acute NAION PDE5 Inhibitor
485107|NCT00759161|Plaque Type Psoriasis
485108|NCT00759161|Topical
485109|NCT00759148|pink eye
485110|NCT00759148|conjunctivitis
485111|NCT00759148|moxifloxacin
485112|NCT00759148|fluoroquinolone
485113|NCT00759135|Benign Prostatic Hyperplasia
485114|NCT00759135|BPH
485115|NCT00759135|Enlarged Prostate
485116|NCT00759122|mdd
485117|NCT00759122|major depressive disorder
485118|NCT00759122|depression
485119|NCT00759096|bilateral implantation
485120|NCT00759096|ReSTOR Aspheric IOL
485121|NCT00759096|uniocular unaided distance
485122|NCT00759096|binocular unaided distance
485123|NCT00759096|intermediate visual acuity
485124|NCT00759096|near visual acuity
485125|NCT00759083|HIT
485126|NCT00759083|HITTS
485127|NCT00759070|Treatment Naïve
485128|NCT00759057|Spinal Stenosis
485129|NCT00759057|Spinal Instability
485130|NCT00759057|Leg Pain
485131|NCT00759018|GVHD
485132|NCT00759018|Prochymal
485133|NCT00759018|Graft vs Host Disease
485134|NCT00758992|gene transfer
485135|NCT00758966|OCD,
485136|NCT00758966|naltrexone,
485137|NCT00758966|fluoxetine,
485138|NCT00758966|obsessive-compulsive disorder
485139|NCT00758940|Clinical
485140|NCT00758940|assessment
485141|NCT00758940|of visual
485142|NCT00758940|function
485143|NCT00758940|with the Acrysof ReSTOR
485144|NCT00758940|multifocal IOL
485145|NCT00758927|diabetes mellitus
485146|NCT00758927|combined hyperlipidemia
485147|NCT00758927|OMACOR
485148|NCT00758927|small dense LDL
485149|NCT00758927|HDL subfraction
485150|NCT00758914|Vitamin E
485151|NCT00758849|NOH
485152|NCT00758849|Orthostatic hypotension
485153|NCT00758849|PAF
485154|NCT00758849|MSA
485155|NCT00758849|Shy-Drager syndrome
485156|NCT00758849|Olivopontocerebellar atrophy
485157|NCT00758849|Striatonigral degeneration
485158|NCT00758849|Autonomic Failure
485159|NCT00758849|Parkinson
485160|NCT00758849|Fipamezole
485161|NCT00758849|JP-1730
485162|NCT00758823|head lice
485163|NCT00758810|Health Education
485164|NCT00758810|Myocardial Infarction
485165|NCT00758810|Acute Coronary Syndrome
485166|NCT00758810|Quality of Life
485167|NCT00758797|metastatic melanoma
485168|NCT00758758|Anterior Cervical Discectomy and Fusion,
485169|NCT00758758|Degenerative Disc Disease,
485170|NCT00758758|Cervical Spine,
485171|NCT00758758|Herniated Disc
485172|NCT00758745|Cataract
485173|NCT00758745|Patients
485174|NCT00758745|bilateral
485175|NCT00758745|age related
485176|NCT00758745|undergoing
485177|NCT00758745|phacoemulsification
485178|NCT00758732|Cancer
485179|NCT00758732|Ovarian cancer
485180|NCT00758732|Chemotherapy
485181|NCT00758732|Docetaxel
485182|NCT00758732|Carboplatin
485183|NCT00758732|Pegylated doxorubicin
485184|NCT00758732|Platinum sensitive
485185|NCT00758719|Spinal Fusion
485186|NCT00758719|DDD
485187|NCT00758706|COPD
485188|NCT00758693|Chronic Lymphocytic Leukemia
485189|NCT00758693|Bendamustine
485190|NCT00758693|Treanda
485191|NCT00758693|Rituximab
485192|NCT00758693|Rituxan
485193|NCT00758667|capsular contracture
485194|NCT00758667|capsulectomy
485195|NCT00758667|mesna
485196|NCT00758667|Capsular contracture after breast implant placement
485197|NCT00758654|myocardial strain
485198|NCT00758654|Strain-Encoded MRI
485199|NCT00758654|dobutamine stress MRI
485200|NCT00758654|ischemia
485201|NCT00758654|strain rate reserve
485202|NCT00758641|plantar fasciitis
485203|NCT00758641|platelet rich plasma
485204|NCT00758641|GPS
485205|NCT00758615|Obesity
485206|NCT00758615|Physical activity
485207|NCT00758615|Injury Prevention
485208|NCT00758615|Pedestrian safety
485209|NCT00758615|Self efficacy
485210|NCT00758615|School
485211|NCT00758615|Walking School Bus
485212|NCT00758615|Safe Routes to School
485213|NCT00758589|Asthma
485214|NCT00758576|Cataract
485215|NCT00758550|Visual function;
485216|NCT00758550|Refractive cylinder;
485217|NCT00758550|AcrySof® Toric;
485218|NCT00758550|AcrySof® Natural
485219|NCT00758537|Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease
485220|NCT00758524|Essential hypertension
485221|NCT00758524|phase 2 study
485222|NCT00758524|antihypertensive agent
485223|NCT00758511|cortisol
485224|NCT00758511|pain
485225|NCT00758511|pain management
485226|NCT00758511|preterm infants
485227|NCT00758511|sucrose
485228|NCT00758511|facilitated tucking
485229|NCT00758459|COPD
485230|NCT00758433|Adverse Events
485231|NCT00758433|Erythema Rating
485232|NCT00758433|Pharmacokinetics
485233|NCT00758433|Civamide
485234|NCT00758433|Phase 1
485235|NCT00758433|Pain
485236|NCT00758433|Patch
485237|NCT00758420|Varicose Veins
485238|NCT00758407|Fatigue, Cancer, Methylphenidate,
485239|NCT00758381|pancreatic cancer
485240|NCT00758381|advanced or metastatic
485241|NCT00758381|sorafenib
485242|NCT00758368|Parkinson's disease
485243|NCT00758368|PD
485244|NCT00758368|pulsatile apomorphine
485245|NCT00758368|dyskinesia
485246|NCT00758368|apomorphine
485247|NCT00758368|continuous dopaminergic stimulation
485248|NCT00758342|IOP lowering efficacy and safety of Azopt plus Travatan
485249|NCT00758316|Malignant
485250|NCT00758316|Pleural
485251|NCT00758316|Effusions
485252|NCT00758316|Thoracoscopy
485253|NCT00758316|Catheter
485254|NCT00758303|Triglycerides
485255|NCT00758303|Cholesterol
485256|NCT00758277|prevention of alcohol relapse
485257|NCT00758264|Safety
485258|NCT00758264|Routine infancy vaccination
485259|NCT00758264|Meningococcal vaccine
485260|NCT00758264|Immunogenicity
485261|NCT00758264|Pneumococcal vaccine
485262|NCT00758251|Schizophrenia
485263|NCT00758251|Seroquel XR
485264|NCT00758251|CGI
485265|NCT00758238|hypertension
485266|NCT00758238|self-management
485267|NCT00758238|e-health
485268|NCT00758225|Duchenne Muscular Dystrophy
485269|NCT00758225|DMD
485270|NCT00758225|Duchenne
485271|NCT00758225|Idebenone
485272|NCT00758212|Influenza in Humans
485273|NCT00758212|Acquired Immune Deficiency Syndrome
485274|NCT00758212|Immunization, Active
485275|NCT00758186|Colorectal cancer
485276|NCT00758186|Endoscopic stent
485277|NCT00758186|Intestinal obstruction
485278|NCT00758186|Laparoscopy
485279|NCT00758173|prostate cancer
485280|NCT00758160|Attention Deficit Disorder With Hyperactivity
485281|NCT00758160|Methylphenidate
485282|NCT00758160|Concerta
485283|NCT00758147|force feedback joystick
485284|NCT00758147|stroke
485285|NCT00758147|haptics
485286|NCT00758147|kinematics
485287|NCT00758147|rehabilitation
485288|NCT00758147|robotics
485289|NCT00758147|Force feedback joystick in stroke rehabilitation
485290|NCT00758108|Genotype/Phenotype Correlation
485291|NCT00758108|Energy Homeostasis
485292|NCT00758108|Nociception
485293|NCT00758108|Obesity
485294|NCT00758108|Behavior and Neurocognition
485295|NCT00758108|WAGR Syndrome
485296|NCT00758108|Wilm's Tumor
485297|NCT00758108|Aniridia
485298|NCT00758108|Mental Retardation
485299|NCT00758108|Urogenital Abnormalities
485300|NCT00758108|Healthy Volunteer
485301|NCT00758082|type 1 diabetes
485302|NCT00758082|PDA phone (Personal Digital Assistant)
485303|NCT00758082|HbA1c
485304|NCT00758056|endometrial cancer
485305|NCT00758043|Genotype 1
485306|NCT00758030|Schizophrenia
485307|NCT00758030|Paliperidone
485308|NCT00758017|low back pain
485309|NCT00758017|acupuncture
485310|NCT00758004|Cardiovascular Diseases
485311|NCT00757991|healthy, no evidence of disease
485312|NCT00757978|Schizophrenia
485313|NCT00757978|negative symptoms
485314|NCT00757978|clozapine
485315|NCT00757965|colon cancer
485316|NCT00757965|rectal cancer
485317|NCT00757952|ovarian epithelial cancer
485318|NCT00757939|Alzheimer's Disease, MRI, PET
485319|NCT00757900|influenza, human
485320|NCT00757887|malaria
485321|NCT00757887|plasmodium
485322|NCT00757887|falciparum
485323|NCT00757887|human
485324|NCT00757887|experimental infection
485325|NCT00757874|Female urogenital disease
485326|NCT00757874|skin disease
485327|NCT00757848|cystic fibrosis
485328|NCT00757835|24-hour IOP
485329|NCT00757835|exfoliative glaucoma
485330|NCT00757835|travoprost/timolol
485331|NCT00757835|latanoprost/timolol
485332|NCT00757835|fixed combinations
485333|NCT00757783|HIV
485334|NCT00757783|AIDS
485335|NCT00757783|Immunodeficiency Virus, Human
485336|NCT00757783|PREZISTA
485337|NCT00757783|darunavir
485338|NCT00757783|TMC114
485339|NCT00757783|Protease Inhibitor
485340|NCT00757783|Truvada
485341|NCT00757783|Atazanavir
485342|NCT00757783|REYATAZ
485343|NCT00757783|HIV Infections
485344|NCT00757783|Treatment Naïve
485345|NCT00757770|Gastroenteritis
485346|NCT00757757|Prostate cancer
485347|NCT00757757|bone metastases
485348|NCT00757757|anti-M-CSF
485349|NCT00757757|M-CSF antibody
485350|NCT00757757|M-CSF
485351|NCT00757757|Prostate Cancer with bone metastases
485352|NCT00757744|drug counseling
485353|NCT00757744|HIV risks
485354|NCT00757744|methadone maintenance
485355|NCT00757744|HIV Seronegativity
485356|NCT00757718|Sleep Disordered Breathing
485357|NCT00757718|Obstructive Sleep Apnea
485358|NCT00757718|Gestational Hypertension
485359|NCT00757718|Preeclampsia
485360|NCT00757705|Schizophrenia
485361|NCT00757705|Paliperidone Extended-Release
485362|NCT00757692|Vandetanib (ZD6474)
485363|NCT00757692|Hormone
485364|NCT00757692|Refractory
485365|NCT00757692|Prostate Cancer
485366|NCT00757692|Chemotherapy
485367|NCT00757692|Naïve
485368|NCT00757666|Pacemaker
485369|NCT00757640|gastric cancer, surgery, prophylactic cholecystectomy
485370|NCT00757614|AIDS-related lymphoma
485371|NCT00757614|cutaneous lymphoma
485372|NCT00757614|adult Hodgkin lymphoma
485373|NCT00757614|adult non-Hodgkin lymphoma
485374|NCT00757614|intraocular lymphoma
485375|NCT00757614|adult T-cell leukemia/lymphoma
485376|NCT00757614|primary central nervous system non-Hodgkin lymphoma
485377|NCT00757614|primary central nervous system Hodgkin lymphoma
485378|NCT00757614|noncutaneous extranodal lymphoma
485379|NCT00757614|adult astrocytic tumors
485380|NCT00757614|adult brain stem glioma
485381|NCT00757614|adult choroid plexus tumor
485382|NCT00757614|adult craniopharyngioma
485383|NCT00757614|adult embryonal tumor
485384|NCT00757614|adult ependymal tumors
485385|NCT00757614|adult meningeal tumor
485386|NCT00757614|adult oligodendroglial tumors
485387|NCT00757614|adult pineal parenchymal tumor
485388|NCT00757614|adult brain tumor
485389|NCT00757614|intraocular melanoma
485390|NCT00757614|bladder cancer
485391|NCT00757614|clear cell sarcoma of the kidney
485392|NCT00757614|congenital mesoblastic nephroma
485393|NCT00757614|esophageal cancer
485394|NCT00757614|melanoma
485395|NCT00757614|pancreatic cancer
485396|NCT00757614|peripheral primitive neuroectodermal tumor of the kidney
485397|NCT00757614|renal cell carcinoma
485398|NCT00757614|rhabdoid tumor of the kidney
485399|NCT00757614|transitional cell cancer of the renal pelvis and ureter
485400|NCT00757575|PNEUMONET JAPAN STUDY
485401|NCT00757549|recurrent squamous cell carcinoma of the hypopharynx
485402|NCT00757549|recurrent squamous cell carcinoma of the larynx
485403|NCT00757549|recurrent squamous cell carcinoma of the oropharynx
485404|NCT00757549|stage III squamous cell carcinoma of the hypopharynx
485405|NCT00757549|stage III squamous cell carcinoma of the larynx
485406|NCT00757549|stage III squamous cell carcinoma of the oropharynx
485407|NCT00757549|stage IV squamous cell carcinoma of the hypopharynx
485408|NCT00757549|stage IV squamous cell carcinoma of the larynx
485409|NCT00757549|stage IV squamous cell carcinoma of the oropharynx
485410|NCT00757536|Rhegmatogenous retinal detachment
485411|NCT00757536|primary vitrectomy
485412|NCT00757536|encircling band
485413|NCT00757536|endolaser treatment
485414|NCT00757523|Acne
485415|NCT00757523|Acne Vulgaris
485416|NCT00757523|Akne
485417|NCT00757523|Akne Vulgaris
485418|NCT00757510|Congenital Heart Disease
485419|NCT00757497|Treatment Study
485420|NCT00757497|Psychosis
485421|NCT00757497|Electrical Stimulation
485422|NCT00757497|Refractory
485423|NCT00757497|Novel
485424|NCT00757497|Childhood Onset Psychotic Disorders
485425|NCT00757497|Schizophrenia
485426|NCT00757471|Macular hole surgery
485427|NCT00757471|membranepeeling
485428|NCT00757471|closure rate
485429|NCT00757471|vitreoretinal dyes
485430|NCT00757458|Propofol
485431|NCT00757458|Bacterial growth
485432|NCT00757458|Fungal growth
485433|NCT00757458|EDTA
485434|NCT00757458|Target controlled infusion
485435|NCT00757445|Antibiotic therapy
485436|NCT00757445|Microbiological diagnosis
485437|NCT00757419|Safety
485438|NCT00757419|tolerability
485439|NCT00757419|healthy subjects
485440|NCT00757406|Lymphedema
485441|NCT00757406|Bioimpedance
485442|NCT00757393|Growth hormone
485443|NCT00757393|Pediatrics
485444|NCT00757393|Vitamin D
485445|NCT00757393|Calcium
485446|NCT00757393|Exercise
485447|NCT00757380|epiretinal membranes
485448|NCT00757380|vitreoretinal dyes
485449|NCT00757380|membranepeeling
485450|NCT00757367|Healthy subjects
485451|NCT00757367|insulin
485452|NCT00757367|bronchoscope
485453|NCT00757367|serum insulin
485454|NCT00757367|serum C-Peptide
485455|NCT00757367|BAL fluid
485456|NCT00757367|FDKP
485457|NCT00757328|Bipolar depression Treatment
485458|NCT00757315|acne keloidalis nuchae
485459|NCT00757315|NdYag laser
485460|NCT00757315|AKN
485461|NCT00757315|acne keloidalis
485462|NCT00757315|AK
485463|NCT00757315|dermatitis papillaris capillitii
485464|NCT00757315|folliculitis keloidalis nuchae
485465|NCT00757315|sycosis nuchae
485466|NCT00757315|acne keloid
485467|NCT00757315|keloidal folliculitis
485468|NCT00757315|lichen keloidalis nuchae
485469|NCT00757315|folliculitis nuchae scleroticans
485470|NCT00757315|sycosis framboesiformis
485471|NCT00757302|breast cancer
485472|NCT00757302|CarolIReS
485473|NCT00757302|intraoperative gamma camera
485474|NCT00757302|lymphoscintigraphy
485475|NCT00757302|sentinel lymph node
485476|NCT00757302|Hundred and ten patients with infiltrative breast cancer or ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.
485477|NCT00757289|Tennis Elbow
485478|NCT00757276|Copeptin
485479|NCT00757276|Diabetes insipidus
485480|NCT00757276|diagnostic marker
485481|NCT00757276|Vasopressin
485482|NCT00757276|antidiuretic hormone (ADH)
485483|NCT00757263|ovarian epithelial cancer
485484|NCT00757263|ovarian germ cell tumor
485485|NCT00757263|ovarian sarcoma
485486|NCT00757263|ovarian stromal cancer
485487|NCT00757250|HIV
485488|NCT00757250|AIDS
485489|NCT00757250|Human Immunodeficiency Virus
485490|NCT00757250|CD4+ T-lymphocytes
485491|NCT00757250|treatment Experienced
485492|NCT00757237|aztreonam lysine
485493|NCT00757237|tobramycin inhalation solution
485494|NCT00757237|tobramycin nebuliser solution
485495|NCT00757237|cystic fibrosis
485496|NCT00757237|pseudomonas aeruginosa
485497|NCT00757237|lung infection
485498|NCT00757237|CFQ-R
485499|NCT00757237|inhaled antibiotic
485500|NCT00757211|breast cancer
485501|NCT00757211|male breast cancer
485502|NCT00757198|pain, postoperative, opioid, PCA, cardiac surgery
485503|NCT00757185|skin blood flow
485504|NCT00757185|microcirculation
485505|NCT00757172|adenocarcinoma of the esophagus
485506|NCT00757172|adenocarcinoma of the gastroesophageal junction
485507|NCT00757172|stage II esophageal cancer
485508|NCT00757172|stage III esophageal cancer
485509|NCT00757172|stage IV esophageal cancer
485510|NCT00757159|Periodontal disease
485511|NCT00757159|Hydroxyapatite
485512|NCT00757159|Enamel matrix protein
485513|NCT00757159|Regeneration
485514|NCT00757159|Human
485515|NCT00757146|chronic lung disease
485516|NCT00757146|bronchopulmonary dysplasia
485517|NCT00757146|inhaled nitric oxide
485518|NCT00757146|premature infants
485519|NCT00757120|COPD
485520|NCT00757120|Cigarette Smoke-Induced Inflammation
485521|NCT00757120|EMMPRIN
485522|NCT00757120|Matrix Metalloproteinase
485523|NCT00757107|Short femoral stem
485524|NCT00757107|Stress shielding
485525|NCT00757107|Stem migration
485526|NCT00757107|Implant Survival
485527|NCT00757107|DEXA
485528|NCT00757107|Radiostereometric analysis
485529|NCT00757094|Fasting
485530|NCT00757094|Chemotherapy
485531|NCT00757094|Cancer
485532|NCT00757068|Non-smoking
485533|NCT00757068|Women
485534|NCT00757068|Pregnancy
485535|NCT00757068|Treatment
485536|NCT00757068|Mood
485537|NCT00757068|Weight
485538|NCT00757068|Supportive
485539|NCT00757068|Adjustment
485540|NCT00757055|Heart failure
485541|NCT00757055|Diastolic heart failure
485542|NCT00757055|Heart failure with preserved systolic function
485543|NCT00757055|Heart failure with normal ejection fraction
485544|NCT00757055|Ivabradine
485545|NCT00757055|Diastolic dysfunction
485546|NCT00757042|atopic dermatitis
485547|NCT00757042|skin diseases
485548|NCT00757042|healthy volunteer
485549|NCT00757029|ADHD,
485550|NCT00757029|norepinephrine transporter
485551|NCT00757029|pharmacogenetics
485552|NCT00757016|low back pain
485553|NCT00757016|randomised controlled trial
485554|NCT00757016|slow release corticosteroid
485555|NCT00757016|injection treatment
485556|NCT00756977|Colonoscopy
485557|NCT00756977|screening
485558|NCT00756964|cardiac surgery
485559|NCT00756964|hyperuricemia
485560|NCT00756951|SCV-07
485561|NCT00756951|Oral Mucositis
485562|NCT00756925|CRH
485563|NCT00756925|cocaine
485564|NCT00756925|functional magnetic resonance imaging
485565|NCT00756925|gender differences
485566|NCT00756912|ANC
485567|NCT00756912|BMT
485568|NCT00756912|graft versus leukemia
485569|NCT00756912|graft vs. host disease
485570|NCT00756912|MD2 (endotoxin binding-protein)
485571|NCT00756912|undergo allogeneic BMT
485572|NCT00756912|myeloablative
485573|NCT00756912|conditioning
485574|NCT00756912|therapy
485575|NCT00756899|Vitamin D deficiency, insulin resistance, obesity, bone
485576|NCT00756873|Elective tonsillectomy
485577|NCT00756847|Solid Tumors
485578|NCT00756847|NSCLC
485579|NCT00756847|Ovarian Cancer
485580|NCT00756847|Endometrial Cancer
485581|NCT00756821|Spinal Muscular Atrophy
485582|NCT00756821|Blood Biomarkers
485583|NCT00756821|Urine Biomarkers
485584|NCT00756821|Type I Spinal Muscular Atrophy
485585|NCT00756821|Type II Spinal Muscular Atrophy
485586|NCT00756821|Type III Spinal Muscular Atrophy
485587|NCT00756821|Modified Hammersmith Functional Motor Scale
485588|NCT00756821|Disease severity
485589|NCT00756821|Biomarkers
485590|NCT00756808|latent tuberculosis in elderly
485591|NCT00756782|hepatocellular carcinoma
485592|NCT00756756|G-CSF
485593|NCT00756756|Myocardial infarction
485594|NCT00756743|PF-04802540 multiple dose safety study
485595|NCT00756730|lopinavir
485596|NCT00756730|ritonavir
485597|NCT00756730|atazanavir
485598|NCT00756730|fosamprenavir
485599|NCT00756730|darunavir
485600|NCT00756730|anti-retroviral
485601|NCT00756730|AIDS
485602|NCT00756730|HIV
485603|NCT00756730|LARD
485604|NCT00756730|triglyceride
485605|NCT00756730|protease inhibitors
485606|NCT00756730|treatment Experienced
485607|NCT00756717|MK-0752
485608|NCT00756717|Tamoxifen
485609|NCT00756717|Letroxole
485610|NCT00756704|Smoking Cessation
485611|NCT00756704|Emergency Medicine
485612|NCT00756704|Emergency Nursing
485613|NCT00756704|Effectiveness Trial
485614|NCT00756704|Implementation
485615|NCT00756704|Relapse prevention
485616|NCT00756691|18F-FAZA
485617|NCT00756691|Positron Emission Tomography
485618|NCT00756691|Radiation dosimetry
485619|NCT00756691|Pharmacokinetics
485620|NCT00756665|prostate
485621|NCT00756665|cancer
485622|NCT00756639|small cell carcinoma of the bladder
485623|NCT00756639|urothelial carcinoma
485624|NCT00756639|genitourinary bladder
485625|NCT00756639|urothelium
485626|NCT00756639|bladder
485627|NCT00756639|bladder cancer
485628|NCT00756639|prophylactic cranial irradiation
485629|NCT00756639|PCI
485630|NCT00756639|brain metastasis
485631|NCT00756639|genitourinary
485632|NCT00756639|radiation
485633|NCT00756639|TCC
485634|NCT00756639|adenocarcinoma
485635|NCT00756626|Bottle Weaning
485636|NCT00756626|Bottle Feeding
485637|NCT00756626|Overweight in toddlers
485638|NCT00756626|Bottle use
485639|NCT00756626|excess weight for length
485640|NCT00756600|Infants
485641|NCT00756600|scheduled
485642|NCT00756600|unilateral
485643|NCT00756600|bilateral
485644|NCT00756600|repair
485645|NCT00756587|Cup Feeding
485646|NCT00756587|late Preterm
485647|NCT00756574|N95
485648|NCT00756574|Respirator
485649|NCT00756574|mask
485650|NCT00756574|influenza
485651|NCT00756574|efficacy
485652|NCT00756561|Fine Needle Aspiration
485653|NCT00756561|Male Health
485654|NCT00756561|Male Contraception
485655|NCT00756548|colonoscopy
485656|NCT00756548|screening
485657|NCT00756535|Exercise Therapy
485658|NCT00756535|Length of Stay
485659|NCT00756535|Disability Evaluation
485660|NCT00756522|COPD
485661|NCT00756509|unresectable or metastatic GIST
485662|NCT00756509|1st. line treatment
485663|NCT00756483|Resistance
485664|NCT00756483|Exercise
485665|NCT00756470|Breast Cancer
485666|NCT00756470|Inflammatory Breast Cancer
485667|NCT00756470|IBC
485668|NCT00756470|ErbB2 overexpression
485669|NCT00756470|Lapatinib
485670|NCT00756470|Paclitaxel
485671|NCT00756470|5-Fluorouracil
485672|NCT00756470|Epirubicin
485673|NCT00756470|Cyclophosphamide
485674|NCT00756470|Neoadjuvant Chemotherapy
485675|NCT00756457|PTTD
485676|NCT00756457|Tendinopathy
485677|NCT00756457|Tendon Injuries
485678|NCT00756457|Muscular Diseases
485679|NCT00756457|Foot Diseases
485680|NCT00756444|PK Study, Metastatic Recurrent
485681|NCT00756392|3T MR Spectroscopy
485682|NCT00756392|Prostate Imaging
485683|NCT00756379|Cardiovascular disease
485684|NCT00756379|Atherosclerosis
485685|NCT00756379|Coronary artery disease
485686|NCT00756379|Coronary perfusion defect
485687|NCT00756379|Absolute coronary flow
485688|NCT00756379|Lifestyle management
485689|NCT00756379|Cardiovascular rehabilitation
485690|NCT00756379|Cardiovascular dietary guidelines
485691|NCT00756366|positron emission tomography
485692|NCT00756366|myocardial energetics
485693|NCT00756366|sympathetic nerve function
485694|NCT00756353|Heroin
485695|NCT00756353|Buprenorphine use
485696|NCT00756327|pediatric eyes
485697|NCT00756327|bilateral cataract
485698|NCT00756327|IOL implantation
485699|NCT00756327|Aqualase capsule wash
485700|NCT00756327|posterior capsule opacification
485701|NCT00756314|Ambulatory Care Facilities
485702|NCT00756314|abortion care
485703|NCT00756314|contraception
485704|NCT00756314|counseling
485705|NCT00756314|outpatient clinic
485706|NCT00756288|Actinic Keratoses
485707|NCT00756288|Blue light therapy
485708|NCT00756288|photosensitizer
485709|NCT00756288|Retinoid
485710|NCT00756275|Tobacco Smoking
485711|NCT00756275|Smoking Cessation
485712|NCT00756275|Nicotine Dependence
485713|NCT00756275|Tobacco Use Disorder
485714|NCT00756262|Vancomycin Resistant enterococcal colonization
485715|NCT00756262|Probiotics
485716|NCT00756262|LGG
485717|NCT00756262|Lactobacillus rhamnosus
485718|NCT00756249|Acute ischemic stroke
485719|NCT00756249|Erythropoietin
485720|NCT00756249|Carbamylated
485721|NCT00756249|Neuroprotection
485722|NCT00756197|Radiation Proctitis
485723|NCT00756197|Radiation Induced Proctitis
485724|NCT00756184|Glaucoma
485725|NCT00756184|Adherence
485726|NCT00756184|Teaching
485727|NCT00756171|Cholestatic
485728|NCT00756171|pruritus
485729|NCT00756171|of any cause
485730|NCT00756158|Attention Deficit Hyperactivity Disorder
485731|NCT00756158|dopaminergic
485732|NCT00756158|noradrenergic
485733|NCT00756158|endophenotype
485734|NCT00756158|molecular genetics
485735|NCT00756158|candidate gene
485736|NCT00756158|Family-based Association study
485737|NCT00756145|stage V
485738|NCT00756145|treated
485739|NCT00756145|hemodiafiltration
485740|NCT00756132|Breast
485741|NCT00756132|Neoplasm
485742|NCT00756132|Locally Advanced
485743|NCT00756132|Stage IV
485744|NCT00756132|Stage III
485745|NCT00756132|Cognitive Function
485746|NCT00756132|Cytokines
485747|NCT00756132|Inflammatory
485748|NCT00756132|Node positive
485749|NCT00756106|adult glioblastoma
485750|NCT00756106|adult giant cell glioblastoma
485751|NCT00756106|adult gliosarcoma
485752|NCT00756106|adult anaplastic astrocytoma
485753|NCT00756106|adult anaplastic ependymoma
485754|NCT00756106|adult anaplastic oligodendroglioma
485755|NCT00756106|adult mixed glioma
485756|NCT00756093|Dry Eye, Artificial Tears,
485757|NCT00756067|Streptococcus pneumoniae
485758|NCT00756067|pneumococcal vaccine
485759|NCT00756041|Diabetic Mononeuropathy
485760|NCT00756041|Diabetic Neuralgia
485761|NCT00756041|Mononeuropathy, Diabetic
485762|NCT00756041|Neuralgia, Diabetic
485763|NCT00756041|Diabetic Polyneuropathy
485764|NCT00756041|Drug Therapy
485765|NCT00756028|OHSS
485766|NCT00756028|quality of life
485767|NCT00756028|IVF
485768|NCT00756028|ICSI
485769|NCT00756028|GnRH-agonist
485770|NCT00756028|GnRH-antagonist
485771|NCT00756015|rotator cuff
485772|NCT00756015|post-operative immobilization protocol
485773|NCT00756015|post-operative early motion protocol
485774|NCT00756015|physical therapy
485775|NCT00756015|cuff repair integrity
485776|NCT00756015|ultrasound
485777|NCT00756002|Chronic Insomnia
485778|NCT00756002|DIMS (Disorders of Initiating and Maintaining Sleep)
485779|NCT00756002|Disorders of Initiating and Maintaining Sleep
485780|NCT00756002|Insomnia Disorder Sleep Initiation Dysfunction
485781|NCT00756002|Transient Insomnia
485782|NCT00756002|Drug Therapy
485783|NCT00756002|Sleep Disorders, Intrinsic
485784|NCT00755976|stage IV melanoma
485785|NCT00755950|Acute
485786|NCT00755950|Hepatitis
485787|NCT00755950|Silymarin
485788|NCT00755950|Global Health
485789|NCT00755911|dental
485790|NCT00755911|tooth
485791|NCT00755911|implant
485792|NCT00755911|extraction
485793|NCT00755911|Oral
485794|NCT00755911|Surgical
485795|NCT00755911|Procedures
485796|NCT00755898|cancer
485797|NCT00755898|diagnostic test
485798|NCT00755898|urine
485799|NCT00755898|amantadine acetylation
485800|NCT00755885|stage IIIA breast cancer
485801|NCT00755885|stage IIIB breast cancer
485802|NCT00755885|stage IIIC breast cancer
485803|NCT00755885|stage IV breast cancer
485804|NCT00755885|recurrent breast cancer
485805|NCT00755885|estrogen receptor-positive breast cancer
485806|NCT00755885|progesterone receptor-positive breast cancer
485807|NCT00755859|IgA nephropathy
485808|NCT00755859|steroids
485809|NCT00755859|azathioprine
485810|NCT00755859|chronic kidney disease progression
485811|NCT00755859|proteinuria
485812|NCT00755846|Diabetes Mellitus
485813|NCT00755846|Drug Therapy
485814|NCT00755846|Diabetes Mellitus, Type II
485815|NCT00755846|Type 2 Diabetes Mellitus
485816|NCT00755846|Hyperinsulinism
485817|NCT00755846|Insulin Resistance
485818|NCT00755807|Central Neuropathic Pain
485819|NCT00755807|Multiple Sclerosis
485820|NCT00755781|lung transplant
485821|NCT00755781|lung transplant recipient
485822|NCT00755781|bronchiolitis obliterans syndrome
485823|NCT00755781|bronchiolitis obliterans
485824|NCT00755781|single lung transplant
485825|NCT00755781|double lung transplant
485826|NCT00755781|heart-lung transplant
485827|NCT00755781|Aerosol
485828|NCT00755768|hemodialysis
485829|NCT00755768|phosphate
485830|NCT00755768|calcium phosphate product
485831|NCT00755768|dietician
485832|NCT00755768|dietetic advice
485833|NCT00755742|obesity
485834|NCT00755742|insulin resistance
485835|NCT00755742|metabolic syndrome
485836|NCT00755742|hepatitis C
485837|NCT00755742|adipokine
485838|NCT00755742|TNF
485839|NCT00755742|leptin
485840|NCT00755742|adiponectin
485841|NCT00755742|fatigue
485842|NCT00755742|mood
485843|NCT00755742|depression
485844|NCT00755742|exercise
485845|NCT00755742|diet
485846|NCT00755742|counseling
485847|NCT00755742|behavior modification
485848|NCT00755729|Preoperative oral carbohydrate
485849|NCT00755729|Insulin resistance
485850|NCT00755729|phosphatidylinositol-3-kinase
485851|NCT00755716|nicotine patch
485852|NCT00755716|smoking
485853|NCT00755716|topiramate
485854|NCT00755703|Influenza
485855|NCT00755703|Vaccine
485856|NCT00755703|Pandemic
485857|NCT00755703|Avian influenza
485858|NCT00755703|Adenovirus strain 5
485859|NCT00755703|Vectored vaccine
485860|NCT00755703|Intranasal
485861|NCT00755703|Tissue-culture derived
485862|NCT00755703|Non-replicating
485863|NCT00755690|Chronic Kidney Disease
485864|NCT00755690|CKD
485865|NCT00755690|Diet
485866|NCT00755690|Dietary Phosphate
485867|NCT00755690|Mineral Metabolism
485868|NCT00755690|FGF-23
485869|NCT00755664|homocysteine
485870|NCT00755664|folate acid,
485871|NCT00755664|vitamin B
485872|NCT00755664|random controlled trail
485873|NCT00755651|Menorrhagia
485874|NCT00755651|Uterine fibroids
485875|NCT00755651|Endometrial polyps
485876|NCT00755651|Endometrial cancer
485877|NCT00755599|Papanicolaou Smear
485878|NCT00755599|Vaginitis
485879|NCT00755599|Patient Satisfaction
485880|NCT00755586|Brachial plexus
485881|NCT00755586|Muscle denervation
485882|NCT00755586|Stem cell transplantation
485883|NCT00755586|Bone marrow cells
485884|NCT00755586|Satellite cells
485885|NCT00755586|Fibrosis
485886|NCT00755573|Pain
485887|NCT00755573|Neuropathic pain
485888|NCT00755560|Toxocara
485889|NCT00755560|Pediatrics
485890|NCT00755560|Albendazole
485891|NCT00755560|eosinophilia
485892|NCT00755560|parasitology
485893|NCT00755560|pediatric clinical pharmacology
485894|NCT00755547|Childhood
485895|NCT00755547|insulin sensitivity
485896|NCT00755547|steatosis, spectroscopy
485897|NCT00755534|Metastatic colorectal cancer
485898|NCT00755534|Second line
485899|NCT00755534|Irinotecan
485900|NCT00755534|Cetuximab (Erbitux)
485901|NCT00755534|Capecitabine (Xeloda)
485902|NCT00755521|Fibromyalgia
485903|NCT00755521|tenderness
485904|NCT00755521|widespread pain
485905|NCT00755521|comrbidity
485906|NCT00755508|Chronic Insomnia
485907|NCT00755508|DIMS (Disorders of Initiating and Maintaining Sleep)
485908|NCT00755508|Disorders of Initiating and Maintaining Sleep
485909|NCT00755508|Insomnia Disorder Sleep Initiation Dysfunction
485910|NCT00755508|Transient Insomnia
485911|NCT00755508|Drug Therapy
485912|NCT00755508|Sleep Disorders, Intrinsic
485913|NCT00755495|Chronic Insomnia
485914|NCT00755495|DIMS (Disorders of Initiating and Maintaining Sleep)
485915|NCT00755495|Disorders of Initiating and Maintaining Sleep
485916|NCT00755495|Insomnia Disorder Sleep Initiation Dysfunction
485917|NCT00755495|Transient Insomnia
485918|NCT00755495|Drug Therapy
485919|NCT00755495|Sleep Disorders, Intrinsic
485920|NCT00755482|Osteoarthritis
485921|NCT00755482|Clinical trial
485922|NCT00755482|Aquamin F
485923|NCT00755482|NSAID
485924|NCT00755469|Reperfusion injury
485925|NCT00755469|Post-Conditioning
485926|NCT00755469|Infarct size
485927|NCT00755456|Peritoneal dialysis
485928|NCT00755456|L-carnitine
485929|NCT00755456|Insulin resistance
485930|NCT00755456|Glucose homeostasis
485931|NCT00755456|Dyslipidemia
485932|NCT00755430|autism spectrum disorders (ASD)
485933|NCT00755430|structural and functional connectivity
485934|NCT00755430|diffusion spectrum imaging (DSI)
485935|NCT00755430|functional magnetic resonance imaging (fMRI)
485936|NCT00755430|siblings
485937|NCT00755430|repeated follow-up measurement
485938|NCT00755417|Hot flashes
485939|NCT00755417|Hot flushes
485940|NCT00755417|Postmenopausal symptoms
485941|NCT00755417|Vasomotor symptoms
485942|NCT00755404|Peritoneal dialysis
485943|NCT00755404|L-carnitine
485944|NCT00755404|Diabetes
485945|NCT00755404|Glucose homeostasis
485946|NCT00755404|Dyslipidemia
485947|NCT00755391|BN and subthreshold BN
485948|NCT00755378|Phase I
485949|NCT00755365|pelvic fractures
485950|NCT00755365|angioembolism
485951|NCT00755365|Treatment at Hershey Medical Center
485952|NCT00755365|Angioembolization in Operating Room
485953|NCT00755339|Repetitive TMS (rTMS)
485954|NCT00755339|Magnetoencephalogram
485955|NCT00755339|Transcranial Magnetic Stimulation (TMS)
485956|NCT00755339|Tourette Syndrome
485957|NCT00755339|Tic Disorder
485958|NCT00755339|Tourete Syndrome
485959|NCT00755326|OA
485960|NCT00755313|cognitive/functional effects
485961|NCT00755313|fatigue
485962|NCT00755313|long-term effects secondary to cancer therapy in adults
485963|NCT00755313|psychosocial effects of cancer and its treatment
485964|NCT00755313|chemotherapeutic agent toxicity
485965|NCT00755313|neurotoxicity
485966|NCT00755313|stage IA breast cancer
485967|NCT00755313|stage IB breast cancer
485968|NCT00755313|stage II breast cancer
485969|NCT00755313|stage IIIA breast cancer
485970|NCT00755313|stage IIIB breast cancer
485971|NCT00755313|stage IIIC breast cancer
485972|NCT00755313|estrogen receptor-negative breast cancer
485973|NCT00755313|estrogen receptor-positive breast cancer
485974|NCT00755313|progesterone receptor-negative breast cancer
485975|NCT00755313|progesterone receptor-positive breast cancer
485976|NCT00755300|Total knee replacement
485977|NCT00755300|esophageal echocardiography
485978|NCT00755274|Influenza
485979|NCT00755274|Orthomyxoviruses
485980|NCT00755274|Orthomyxoviridae Infections
485981|NCT00755274|Influenza vaccine
485982|NCT00755261|STS
485983|NCT00755248|Coronary Artery Bypass Grafting (CABG)
485984|NCT00755248|outcome
485985|NCT00755248|saphenous graft patency
485986|NCT00755248|biochemical factors
485987|NCT00755248|genomics
485988|NCT00755235|Depression
485989|NCT00755235|Primary care
485990|NCT00755235|Effectiveness
485991|NCT00755235|Care management
485992|NCT00755222|Peyronie's disease
485993|NCT00755222|penile plaque
485994|NCT00755222|penile curvature
485995|NCT00755209|Traumatic brain injury (TBI)
485996|NCT00755209|Adults
485997|NCT00755209|Moderately severe TBI
485998|NCT00755209|Delayed traumatic intracranial haemorrhage
485999|NCT00755209|Expanding traumatic intracranial haemorrhage
486000|NCT00755209|Progressive intracranial haemorrhage (PIH)
486001|NCT00755209|Antifibrinolytic agent
486002|NCT00755209|Tranexamic acid (TXA)
486003|NCT00755209|Randomised, placebo-controlled trial
486004|NCT00755209|Human
486005|NCT00755196|Plaque Type Psoriasis
486006|NCT00755196|Topical
486007|NCT00755183|Meibomian Gland Dysfunction
486008|NCT00755183|Dry Eye Syndrome
486009|NCT00755170|Vinorelbine
486010|NCT00755170|Bevacizumab
486011|NCT00755170|Chemotherapy
486012|NCT00755157|Cancer
486013|NCT00755157|SCLC
486014|NCT00755157|Docetaxel
486015|NCT00755157|Bevacizumab
486016|NCT00755157|Chemotherapy
486017|NCT00755131|Cardiac Rehabilitation
486018|NCT00755131|High Mobility Group Box proteins
486019|NCT00755131|Inflammatory markers
486020|NCT00755131|Cardiopulmonary Functional Capacity
486021|NCT00755131|Maximal Oxygen Consumption
486022|NCT00755131|Echocardiography
486023|NCT00755131|Left Ventricular Ejection Fraction
486024|NCT00755131|Left Ventricular Chambers Dilation
486025|NCT00755131|Left Ventricular Remodeling
486026|NCT00755131|Left Atrium Remodeling
486027|NCT00755131|Cardiac Remodeling
486028|NCT00755131|Exercise Training
486029|NCT00755118|Metastatic colorectal cancer
486030|NCT00755118|Second line
486031|NCT00755118|Irinotecan
486032|NCT00755118|Cetuximab
486033|NCT00755118|Bevacizumab
486034|NCT00755105|body iron excretion
486035|NCT00755105|Iron isotopes
486036|NCT00755092|Doula
486037|NCT00755092|Psychological care
486038|NCT00755092|Labor analgesia
486039|NCT00755079|spinal cord injury
486040|NCT00755079|beta-2 agonist
486041|NCT00755079|respiratory muscle strength
486042|NCT00755079|pulmonary function test
486043|NCT00755053|Clotrimazole
486044|NCT00755053|Ovule
486045|NCT00755053|Tablet
486046|NCT00755053|Vulvovaginal candidiasis
486047|NCT00755053|Non-inferiority
486048|NCT00755040|graft versus host disease
486049|NCT00755040|stage III adult Burkitt lymphoma
486050|NCT00755040|stage III adult diffuse large cell lymphoma
486268|NCT00754182|thyroidectomy
486051|NCT00755040|stage III adult diffuse mixed cell lymphoma
486052|NCT00755040|stage III adult diffuse small cleaved cell lymphoma
486053|NCT00755040|stage III adult Hodgkin lymphoma
486054|NCT00755040|stage III adult immunoblastic large cell lymphoma
486055|NCT00755040|stage III adult lymphoblastic lymphoma
486056|NCT00755040|stage III grade 1 follicular lymphoma
486057|NCT00755040|stage III grade 2 follicular lymphoma
486058|NCT00755040|stage III grade 3 follicular lymphoma
486059|NCT00755040|stage III mantle cell lymphoma
486060|NCT00755040|stage III marginal zone lymphoma
486061|NCT00755040|stage III small lymphocytic lymphoma
486062|NCT00755040|stage IV adult Burkitt lymphoma
486063|NCT00755040|stage IV adult diffuse large cell lymphoma
486064|NCT00755040|stage IV adult diffuse mixed cell lymphoma
486065|NCT00755040|stage IV adult diffuse small cleaved cell lymphoma
486066|NCT00755040|stage IV adult Hodgkin lymphoma
486067|NCT00755040|stage IV adult immunoblastic large cell lymphoma
486068|NCT00755040|stage IV adult lymphoblastic lymphoma
486069|NCT00755040|stage IV grade 1 follicular lymphoma
486070|NCT00755040|stage IV grade 2 follicular lymphoma
486071|NCT00755040|stage IV grade 3 follicular lymphoma
486072|NCT00755040|stage IV mantle cell lymphoma
486073|NCT00755040|stage IV marginal zone lymphoma
486074|NCT00755040|stage IV small lymphocytic lymphoma
486075|NCT00755040|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
486076|NCT00755040|nodal marginal zone B-cell lymphoma
486077|NCT00755040|splenic marginal zone lymphoma
486078|NCT00755040|noncontiguous stage II adult Burkitt lymphoma
486079|NCT00755040|noncontiguous stage II adult diffuse large cell lymphoma
486080|NCT00755040|noncontiguous stage II adult diffuse mixed cell lymphoma
486081|NCT00755040|noncontiguous stage II adult diffuse small cleaved cell lymphoma
486082|NCT00755040|noncontiguous stage II adult immunoblastic large cell lymphoma
486083|NCT00755040|noncontiguous stage II adult lymphoblastic lymphoma
486084|NCT00755040|noncontiguous stage II grade 1 follicular lymphoma
486085|NCT00755040|noncontiguous stage II grade 2 follicular lymphoma
486086|NCT00755040|noncontiguous stage II grade 3 follicular lymphoma
486087|NCT00755040|noncontiguous stage II mantle cell lymphoma
486088|NCT00755040|noncontiguous stage II marginal zone lymphoma
486089|NCT00755040|noncontiguous stage II small lymphocytic lymphoma
486090|NCT00755040|accelerated phase chronic myelogenous leukemia
486091|NCT00755040|adult acute lymphoblastic leukemia in remission
486092|NCT00755040|adult acute myeloid leukemia in remission
486093|NCT00755040|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
486094|NCT00755040|adult acute myeloid leukemia with inv(16)(p13;q22)
486095|NCT00755040|adult acute myeloid leukemia with t(15;17)(q22;q12)
486096|NCT00755040|adult acute myeloid leukemia with t(16;16)(p13;q22)
486097|NCT00755040|adult acute myeloid leukemia with t(8;21)(q22;q22)
486098|NCT00755040|atypical chronic myeloid leukemia, BCR-ABL negative
486099|NCT00755040|blastic phase chronic myelogenous leukemia
486100|NCT00755040|chronic myelomonocytic leukemia
486101|NCT00755040|chronic phase chronic myelogenous leukemia
486102|NCT00755040|secondary acute myeloid leukemia
486103|NCT00755040|stage III chronic lymphocytic leukemia
486104|NCT00755040|stage IV chronic lymphocytic leukemia
486105|NCT00755040|chronic eosinophilic leukemia
486106|NCT00755040|primary myelofibrosis
486107|NCT00755040|chronic neutrophilic leukemia
486108|NCT00755040|de novo myelodysplastic syndromes
486109|NCT00755040|myelodysplastic/myeloproliferative neoplasm, unclassifiable
486110|NCT00755040|previously treated myelodysplastic syndromes
486111|NCT00755040|secondary myelodysplastic syndromes
486112|NCT00755040|stage I multiple myeloma
486113|NCT00755040|stage II multiple myeloma
486114|NCT00755040|stage III multiple myeloma
486115|NCT00755027|Parkinson's disease
486116|NCT00755027|Apathy
486117|NCT00755027|Rasagiline
486118|NCT00755001|Total Hip Replacement
486119|NCT00754949|Blepharoconjunctivitis,
486120|NCT00754949|Ophthalmology
486121|NCT00754936|Depression
486122|NCT00754923|recurrent non-small cell lung cancer
486123|NCT00754923|stage IIIB non-small cell lung cancer
486124|NCT00754923|stage IV non-small cell lung cancer
486125|NCT00754923|adenocarcinoma of the lung
486126|NCT00754923|bronchoalveolar cell lung cancer
486127|NCT00754923|large cell lung cancer
486128|NCT00754910|stage I non-small cell lung cancer
486129|NCT00754910|stage II non-small cell lung cancer
486130|NCT00754910|stage IIIA non-small cell lung cancer
486131|NCT00754910|stage IIIB non-small cell lung cancer
486132|NCT00754910|stage IV non-small cell lung cancer
486133|NCT00754910|recurrent non-small cell lung cancer
486134|NCT00754897|Phone Interview
486135|NCT00754897|Anesthesia
486136|NCT00754897|Siblings
486137|NCT00754897|Inguinal Hernia
486138|NCT00754897|Neurologic Examination
486139|NCT00754897|Developmental Delay Disorders
486140|NCT00754884|salmon calcitonin
486141|NCT00754884|endorphins
486142|NCT00754884|treatment
486143|NCT00754884|fibromyalgia
486144|NCT00754858|extensive stage small cell lung cancer
486145|NCT00754845|stage I breast cancer
486146|NCT00754845|stage II breast cancer
486147|NCT00754845|stage IIIA breast cancer
486148|NCT00754845|stage IIIB breast cancer
486149|NCT00754845|stage IIIC breast cancer
486150|NCT00754832|Multiple sclerosis
486151|NCT00754832|fatigue
486152|NCT00754832|ginseng
486153|NCT00754806|HALS
486154|NCT00754806|open splenectomy
486155|NCT00754806|splenomegaly
486156|NCT00754806|HALS as a hybrid approach of pure laparoscopy and open surgery has some definite advantages over open surgery
486157|NCT00754806|In the HALS group, incision length is significantly shorter
486158|NCT00754806|In the HALS group, postoperative pain is less than with open surgery
486159|NCT00754806|In the HALS group, postoperative hospital stay is shorter than with open surgery
486160|NCT00754780|NF1
486161|NCT00754780|plexiform neurofibroma
486162|NCT00754767|neurotoxicity
486163|NCT00754767|chemotherapeutic agent toxicity
486164|NCT00754767|stage IV breast cancer
486165|NCT00754767|recurrent breast cancer
486166|NCT00754754|brain
486167|NCT00754754|surgery
486168|NCT00754754|retraction
486169|NCT00754754|injury
486170|NCT00754754|monitoring
486171|NCT00754741|medication adherence
486172|NCT00754741|motivational interviewing
486173|NCT00754715|Multiple dosing study,
486174|NCT00754715|safety
486175|NCT00754702|Vinorelbine metronomic-lapatinib
486176|NCT00754702|Chemotherapy
486177|NCT00754702|Targeted therapy
486178|NCT00754689|Rimonabant/metformin combination
486179|NCT00754663|exercise
486180|NCT00754663|implantable cardioverter-defibrillator
486181|NCT00754663|arrhythmia
486182|NCT00754637|Joint
486183|NCT00754637|Osteoarthritis
486184|NCT00754637|Avascular Necrosis
486185|NCT00754546|exercise;
486186|NCT00754546|treadmill;
486187|NCT00754546|cycle ergometer;
486188|NCT00754546|breathlessness;
486189|NCT00754546|leg discomfort
486190|NCT00754533|cardiac rehabilitation
486191|NCT00754533|coronary heart disease
486192|NCT00754533|interval training
486193|NCT00754533|continuous training
486194|NCT00754533|ventilatory threshold
486195|NCT00752804|ICU patients with acute renal failure after cardiac surgery
486196|NCT00752791|Anemia
486197|NCT00752791|Drug Therapy
486198|NCT00752791|Peritoneal Dialysis.
486199|NCT00752778|MRI, PET scan
486200|NCT00752765|knee osteoarthritis
486201|NCT00752765|bariatric surgery
486202|NCT00752765|weight loss
486203|NCT00752765|knee pain
486204|NCT00752752|Marathon Running
486205|NCT00752752|Cardiac Ischemia
486206|NCT00752752|Magnetic Resonance Imaging
486207|NCT00752739|adenocarcinoma of the prostate
486208|NCT00752739|stage I prostate cancer
486209|NCT00752739|stage II prostate cancer
486210|NCT00752739|stage III prostate cancer
486211|NCT00752739|stage IV prostate cancer
486212|NCT00754481|Paediatrics
486213|NCT00754468|Barrett's Esophagus
486214|NCT00754468|Esophageal Cancer
486215|NCT00754468|Esophageal Dysplasia
486216|NCT00754468|Low Grade Dysplasia
486217|NCT00754468|High Grade Dysplasia
486218|NCT00754442|hyperparathyroidism
486219|NCT00754442|parathyroid
486220|NCT00754442|vitamin D
486221|NCT00754442|vitamin D deficiency
486222|NCT00754416|Shoulder Replacement
486223|NCT00754403|Glucose Metabolism Disorder
486224|NCT00754403|Dysmetabolic Syndrome
486225|NCT00754403|Type II Diabetes
486226|NCT00754403|Diabetes Mellitus, Lipoatrophic
486227|NCT00754403|Dyslipidemia
486228|NCT00754403|Drug Therapy
486229|NCT00754390|dietary zinc absorption
486230|NCT00754390|dietary phytic acid
486231|NCT00754390|dietary calcium
486232|NCT00754377|Education
486233|NCT00754377|Program Evaluation
486234|NCT00754377|Quality of Health Care
486235|NCT00754377|Medical Residents
486236|NCT00754351|docetaxel
486237|NCT00754351|gemcitabine
486238|NCT00754351|bevacizumab
486239|NCT00754351|chemotherapy
486240|NCT00754338|comfort
486241|NCT00754338|wetability
486242|NCT00754338|protein deposit
486243|NCT00754338|lipid deposit
486244|NCT00754312|breast cancer
486245|NCT00754299|nonunion/malunion osseous fractures
486246|NCT00754299|nicotine dependent
486247|NCT00754299|chronic osseous infection
486248|NCT00754299|infected osseous nonunions
486249|NCT00754299|Fracture nonunion or infection
486250|NCT00754286|Aromatherapy
486251|NCT00754247|Keloid
486252|NCT00754247|Hypertrophic scar
486253|NCT00754247|Hydrocortisone, silicone, vitamin E lotion
486254|NCT00754247|HSE
486255|NCT00754247|Onion extract gel
486256|NCT00754247|OE
486257|NCT00754247|Cetearyl alcohol lotion
486258|NCT00754247|CEA
486259|NCT00754234|iron absorption
486260|NCT00754234|iron requirements
486261|NCT00754234|dietary guidelines
486262|NCT00754234|MyPyramid
486263|NCT00754221|Phase 3, safety study, [S,S]-Reboxetine, Fibromyalgia
486264|NCT00754208|Attention Deficit Hyperactivity Disorder
486265|NCT00754208|Stimulant Treatment
486266|NCT00754208|Young Children
486267|NCT00754195|Thoracotomy
486269|NCT00754182|surgery
486270|NCT00754182|synthetic glue
486271|NCT00754182|subcuticular suture
486272|NCT00754169|Traumatic Brain Injury
486273|NCT00754169|Brain Imaging
486274|NCT00754169|Brain Plasticity
486275|NCT00754169|Neuroplasticity
486276|NCT00754169|Neuropsychological Testing
486277|NCT00754169|Head Injury
486278|NCT00754169|Healthy Volunteer
486279|NCT00754156|Closure, Wounds
486280|NCT00754143|Type 1 or Type 2 diabetes
486281|NCT00754143|proteinuria
486282|NCT00754117|diffuse large b cell lymphoma
486283|NCT00754117|newly diagnosed
486284|NCT00754078|tomotherapy
486285|NCT00754065|Oral contraceptive
486286|NCT00754065|Estradiol valerate and dienogest
486287|NCT00754065|EV/DNG
486288|NCT00754065|comparative tolerability
486289|NCT00754052|Pediatric
486290|NCT00754052|Down syndrome
486291|NCT00754052|Downs
486292|NCT00754052|Cognitive Dysfunction of Down syndrome
486293|NCT00754039|Mixed hyperlipidemia
486294|NCT00754026|Shoulder surgery
486295|NCT00754013|pediatric
486296|NCT00754013|Down syndrome
486297|NCT00754013|cognitive dysfunction
486298|NCT00754013|Downs
486299|NCT00754013|Aricept
486300|NCT00754013|children with Down syndrome
486301|NCT00753987|Cystic Fibrosis
486302|NCT00753987|Hypertonic Saline
486303|NCT00753987|Infants
486304|NCT00753961|Shiftworkers
486305|NCT00753961|volunteers
486306|NCT00753948|Tetraplegia
486307|NCT00753948|Mild asthma
486308|NCT00753948|Exhaled Nitric Oxide
486309|NCT00753948|NOS inhibitor
486310|NCT00753948|Spinal cord injury
486311|NCT00753948|Pulmonary Function
486312|NCT00753935|aspirin
486313|NCT00753935|aspirin resistance
486314|NCT00753935|aspirin nonresponse
486315|NCT00753935|cyclooxygenase
486316|NCT00753935|thromboxane
486317|NCT00753935|oxidative stress
486318|NCT00753922|Breast Reconstruction
486319|NCT00753922|Breast Augmentation
486320|NCT00753922|Revision
486321|NCT00753922|Silicone breast implants
486322|NCT00753922|Round low-bleed
486323|NCT00753909|Non Small Cell Lung Cancer
486324|NCT00753909|Paclitaxel
486325|NCT00753909|Carboplatin
486326|NCT00753909|Bevacizumab
486327|NCT00753896|Amylin
486328|NCT00753896|Lilly
486329|NCT00753896|exenatide once weekly
486330|NCT00753896|thiazolidinedione
486331|NCT00753896|metformin
486332|NCT00753870|current
486333|NCT00753870|no health problems
486334|NCT00753870|no daily cough from smoking
486335|NCT00753857|risk communication
486336|NCT00753857|probability sample by random digit dialing
486337|NCT00753844|peptide vaccine
486338|NCT00753844|URLC10
486339|NCT00753831|Blepharoptosis
486340|NCT00753831|Ophthalmoplegia
486341|NCT00753831|Blepharospasm
486342|NCT00752726|overweight, orlistat, body composition
486343|NCT00752713|AMI,
486344|NCT00752713|Reperfusion
486345|NCT00752713|successful
486346|NCT00752700|Patients
486347|NCT00752700|radically
486348|NCT00752700|treated
486349|NCT00752687|Phase 1
486350|NCT00752674|Low back pain
486351|NCT00752674|physical therapy
486352|NCT00752674|pain
486353|NCT00752661|osteoarthritis
486354|NCT00752661|low back pain
486355|NCT00752661|oral drug
486356|NCT00752661|tramadol
486357|NCT00752648|TMC435350-TiDP16-C106
486358|NCT00752648|TMC435350-C106
486359|NCT00752648|Bioavailability
486360|NCT00752648|Pharmacokinetics
486361|NCT00752635|TriCilest
486362|NCT00752635|acne vulgaris
486363|NCT00753818|infant formula
486364|NCT00753818|visual development
486365|NCT00753805|mare's milk
486366|NCT00753805|atopic dermatitis
486367|NCT00753805|endogenous eczema
486368|NCT00753805|SCORAD
486369|NCT00753805|Bifidobacteria
486370|NCT00753792|multiple sclerosis
486371|NCT00753792|relapse
486372|NCT00753792|methylprednisolone
486373|NCT00753766|A1c
486374|NCT00753766|Blood Glucose Management
486375|NCT00753766|Blood Pressure
486376|NCT00753766|Case Management
486377|NCT00753766|Diabetes Mellitus
486378|NCT00753766|Intervention study
486379|NCT00753766|Multifactorial
486380|NCT00753766|Peri-operative complications
486381|NCT00753766|Pre-operative
486382|NCT00753753|stent thrombosis
486383|NCT00753753|clopidogrel
486384|NCT00753753|aspirin
486385|NCT00753753|bleeding
486386|NCT00753753|coronary
486387|NCT00753753|angioplasty
486388|NCT00753740|Cancer
486389|NCT00753740|Neoplasms
486390|NCT00753740|Solid Tumor
486391|NCT00753740|Ovarian Cancer
486392|NCT00753740|Solid Malignancies
486393|NCT00753727|soft tissue
486394|NCT00753727|Sarcoma
486395|NCT00753727|Sunitinib
486396|NCT00753727|neoadjuvant
486397|NCT00753727|radiotherapy
486398|NCT00753714|ZD6474
486399|NCT00753714|VANDETANIB
486400|NCT00753714|ZACTIMA
486401|NCT00753714|ADVANCED
486402|NCT00753714|NSCLC
486403|NCT00753714|LUNG CANCER
486404|NCT00753714|ELDERLY PATIENTS
486405|NCT00753714|GEMCITABINE
486406|NCT00753714|PHASE II
486407|NCT00753714|RANDOMIZED
486408|NCT00753714|DOUBLE-BLIND
486409|NCT00753714|histologically or cytologically-confirmed advanced (stage IIIB with supraclavicular lymph node metastases or pleural effusion or stage IV) NSCLC
486410|NCT00753688|metastatic soft-tissue sarcoma
486411|NCT00753688|pazopanib
486412|NCT00753688|Soft Tissue Sarcoma
486413|NCT00753688|placebo
486414|NCT00753675|Intrahepatic
486415|NCT00753675|Cholangiocarcinoma
486416|NCT00753675|Vandetanib
486417|NCT00753675|Zactima
486418|NCT00753675|Advanced
486419|NCT00753675|Biliary
486420|NCT00753675|Tract
486421|NCT00753675|Gallbladder
486422|NCT00753675|Extrahepatic Bile Duct
486423|NCT00753675|Intrahepatic Cholangiocarcinoma
486424|NCT00753675|Ampullary Carcinoma
486425|NCT00753662|TMS AD H2 coil
486426|NCT00753649|Infant
486427|NCT00753649|First nation
486428|NCT00753649|Aboriginal
486429|NCT00753649|Canada
486430|NCT00753636|Parkinson's disease
486431|NCT00753636|Isradipine
486432|NCT00753636|Neuroprotection
486433|NCT00753623|Pain
486434|NCT00753623|Neuropathic pain
486435|NCT00753623|Pain scores
486436|NCT00753610|EPC
486437|NCT00753610|CCRT
486438|NCT00753610|Cervical cancer
486439|NCT00753597|B cell depletion
486440|NCT00753597|steroidogenesis
486441|NCT00753571|Amyotrophic Lateral Sclerosis
486442|NCT00753571|Cistanche Total Glycosides
486443|NCT00753571|Randomized Control Trial Study
486444|NCT00753545|Serous,
486445|NCT00753545|Ovarian cancer,
486446|NCT00753545|PARP,
486447|NCT00753545|BRCA1,
486448|NCT00753545|BRCA2,
486449|NCT00753545|Poly(ADP ribose) polymerases,
486450|NCT00753545|Platinum sensitive,
486451|NCT00753545|Homologous Recombination Deficiency (HRD)
486452|NCT00753532|Carotid artery stenoses
486453|NCT00753532|Brain ischaemia
486454|NCT00753532|stroke
486455|NCT00753532|Lipid abnormalities
486456|NCT00753532|Fatty Liver
486457|NCT00753519|Parkinson's Disease
486458|NCT00753519|Brain Stimulation
486459|NCT00753519|Motor Cortex
486460|NCT00753519|Bradykinesia
486461|NCT00753519|Parkinson Disease
486462|NCT00753519|PD
486463|NCT00753480|EOC
486464|NCT00753480|PPC
486465|NCT00753480|FTC
486466|NCT00753467|HBV
486467|NCT00753467|Treatment
486468|NCT00753467|Interferon-gamma
486469|NCT00753467|combination
486470|NCT00753467|Hepsera
486471|NCT00753467|Actimmune
486472|NCT00753467|HBV DNA
486473|NCT00753454|Rheumatoid Arthritis
486474|NCT00753454|Joint Disease
486475|NCT00753454|Arthritis
486476|NCT00753454|Certolizumab pegol
486477|NCT00753454|Cimzia
486478|NCT00753441|Pancreatic cancer
486479|NCT00753441|Bile duct obstruction
486480|NCT00753441|Stent
486481|NCT00753441|Bypass
486482|NCT00753428|HIV-free survival
486483|NCT00753428|Community based evaluation
486484|NCT00753428|Pregnancy
486485|NCT00753428|Under 2 child survival
486486|NCT00753428|PMTCT
486487|NCT00753428|Pediatric HIV infection
486488|NCT00753428|HAART
486489|NCT00753428|Routine ART
486490|NCT00753428|HIV Seronegativity
486491|NCT00753415|Urinary Bladder Neoplasms
486492|NCT00753415|Breast Neoplasms
486493|NCT00753415|Renal Cell carcinoma
486494|NCT00753415|Melanoma
486495|NCT00753415|Prostatic Neoplasms
486496|NCT00753415|Colonic Neoplasms
486497|NCT00753415|Urologic Neoplasms
486498|NCT00753415|Urogenital Neoplasms
486499|NCT00753415|Urinary Bladder Diseases
486500|NCT00753415|Urologic Diseases
486501|NCT00753415|Breast Diseases
486502|NCT00753415|Skin Diseases
486503|NCT00753415|Neoplasms
486504|NCT00753415|Glandular and Epithelial Neoplasms by Histologic Type
486505|NCT00753415|Adenocarcinoma
486506|NCT00753415|Kidney Neoplasms
486507|NCT00753415|Kidney Diseases
486508|NCT00753415|Neuroendocrine Tumors
486509|NCT00753415|Neuroectodermal Tumors
486510|NCT00753415|Neoplasms, Germ Cell and Embryonal
486511|NCT00753415|Neoplasms, Nerve Tissue
486512|NCT00753415|Nevi and Melanomas
486513|NCT00753415|Genital Neoplasms
486514|NCT00753415|Male Genital Diseases
486515|NCT00753415|Male, Prostatic Diseases
486516|NCT00753415|Colorectal Neoplasms
486517|NCT00753415|Intestinal Neoplasms
486518|NCT00753389|Postoperative residual curarization,
486519|NCT00753389|muscle relaxants,
486520|NCT00753389|morbidity mortality
486521|NCT00753363|Glucose Metabolism
486522|NCT00753350|obesity
486523|NCT00753324|PMTCT
486524|NCT00753324|HAART
486525|NCT00753324|Pregnancy
486526|NCT00753324|HIV Infection
486527|NCT00753324|HIV Transmission
486528|NCT00753324|HIV Seronegativity
486529|NCT00753311|migraine
486530|NCT00753311|rizatriptan
486531|NCT00753311|unilateral trigeminal autonomic symptoms
486532|NCT00753311|Migraine with or without aura
486533|NCT00753272|Efficacy
486534|NCT00753272|Influenza Vaccines
486535|NCT00753272|Influenza
486536|NCT00753272|Vaccine
486537|NCT00753272|Elderly
486538|NCT00753259|atrial fibrillation
486539|NCT00753259|disease management program
486540|NCT00753259|integrated chronic care program
486541|NCT00753259|guideline
486542|NCT00753259|stroke
486543|NCT00753259|heart failure
486544|NCT00753259|quality of life
486545|NCT00753259|costs
486546|NCT00753246|glioblastoma multiforma
486547|NCT00753233|Hypertrophic Cardiomyopathy
486548|NCT00753233|Children
486549|NCT00753233|Sudden Death
486550|NCT00753233|Arrhythmias
486551|NCT00753233|Electrophysiology Study
486552|NCT00753220|Metastatic
486553|NCT00753220|Androgen
486554|NCT00753220|Independent
486555|NCT00753220|Prostate Cancer
486556|NCT00753220|(AIPC),
486557|NCT00753220|Hormone-refractory
486558|NCT00753220|(HRPC),
486559|NCT00753220|cryotherapy,
486560|NCT00753220|dendritic cell,
486561|NCT00753220|immunotherapy
486562|NCT00753220|Chemo-naïve
486563|NCT00753220|lymph nodes
486564|NCT00753220|bone
486565|NCT00753207|stage IV breast cancer
486566|NCT00753207|recurrent breast cancer
486567|NCT00753194|hearing
486568|NCT00753194|newborn
486569|NCT00753194|otoacoustic emissions
486570|NCT00753168|glaucoma, open angle, ocular hypertension, beta blocker, beta adrenergic, intraocular pressure
486571|NCT00753155|HRQoL;
486572|NCT00753155|exercise
486573|NCT00753155|capacity
486574|NCT00753142|Hyperglycemia
486575|NCT00753129|Prone position
486576|NCT00753129|ALI/ARDS
486577|NCT00753129|Head elevation
486578|NCT00753103|Infliximab
486579|NCT00753103|Vasculitis
486580|NCT00753103|antitnf monoclonal antibody
486581|NCT00753064|Red Scorpion envenomation
486582|NCT00753064|Composite clinical scoring system
486583|NCT00753064|AScVS
486584|NCT00753064|Prazosin
486585|NCT00753064|Superiority
486586|NCT00753051|clozapine-resistant schizophrenics
486587|NCT00753051|haloperidol augmenting clozapine
486588|NCT00753051|electroconvulsive therapy augmenting clozapine
486589|NCT00753038|carcinoma
486590|NCT00753038|squamous cell
486591|NCT00753038|head
486592|NCT00753038|neck
486593|NCT00753038|REOLYSIN
486594|NCT00753038|chemotherapy
486595|NCT00753038|Carboplatin
486596|NCT00753038|Paclitaxel
486597|NCT00753025|lower extremity ischemia
486598|NCT00753025|Bone marrow
486599|NCT00753025|Progenitor cells
486600|NCT00753025|Neoangiogenesis
486601|NCT00753012|cardiovascular testing
486602|NCT00753012|home blood pressure monitoring
486603|NCT00753012|office home blood pressure monitoring
486604|NCT00753012|cardiopulmonary exercise testing
486605|NCT00753012|transthoracic echocardiography
486606|NCT00753012|Lisdexamfetamine
486607|NCT00753012|Vyvanse
486608|NCT00753012|normotensive and hypertensive adults with ADHD
486609|NCT00753012|ADHD medication.
486610|NCT00752999|SLE
486611|NCT00752999|Lupus
486612|NCT00752986|ZD6474
486613|NCT00752986|Vandetanib
486614|NCT00752986|Zactima
486615|NCT00752986|Fulvestrant
486616|NCT00752986|Faslodex
486617|NCT00752986|Breast Cancer
486618|NCT00752986|Advanced, Metastatic
486619|NCT00752986|Hormone Receptor Positive
486620|NCT00752986|Post-Menopausal Patients
486621|NCT00752986|post-menopausal women with hormone receptor positive advanced breast cancer
486622|NCT00752973|Head Lice
486623|NCT00752960|single nucleotide polymorphism, SNP, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, metabolic syndrome
486624|NCT00752934|nursing homes
486625|NCT00752934|children
486626|NCT00752934|ages 1-18 years
486627|NCT00752934|spastic quadriplegia
486628|NCT00752921|Etoricoxib, Fasting Headache, Headache, Yom Kippur
486629|NCT00752895|stage I chronic lymphocytic leukemia
486630|NCT00752895|stage II chronic lymphocytic leukemia
486631|NCT00752895|stage III chronic lymphocytic leukemia
486632|NCT00752895|stage IV chronic lymphocytic leukemia
486633|NCT00752882|Ceftazidime
486634|NCT00752882|Pharmacokinetics
486635|NCT00752882|Pseudomonas
486636|NCT00752882|aeruginosa
486637|NCT00752882|Meningitis
486638|NCT00752882|Patients
486639|NCT00752882|hospitalised
486640|NCT00752882|cerebrolesion
486641|NCT00752882|acquired
486642|NCT00752882|pneumopathy
486643|NCT00752882|mechanic
486644|NCT00752882|ventilation
486645|NCT00752869|low testosterone
486646|NCT00752856|HIV treatment
486647|NCT00752856|Treatment-naive
486648|NCT00752856|Adult
486649|NCT00752843|mifepristone
486650|NCT00752843|CORLUX
486651|NCT00752843|fluvastatin
486652|NCT00752843|Lescol
486653|NCT00752843|drug-drug interaction
486654|NCT00752843|DDI
486655|NCT00752843|pharmacokinetics
486656|NCT00752830|AZD0328
486657|NCT00752830|Food Effect
486658|NCT00752817|Virtual Reality
486659|NCT00752817|Simulator
486660|NCT00752817|Proficiency
486661|NCT00752817|Laparoscopic
486662|NCT00752817|Colectomy
486663|NCT00752817|Education
486664|NCT00752817|Surgical Training
486665|NCT00752609|Anemia
486666|NCT00752609|Drug Therapy
486667|NCT00752609|Hemodialysis
486668|NCT00752609|Kidney Failure
486669|NCT00752596|patients
486670|NCT00752596|with ICD
486671|NCT00752583|Chronic renal insufficiency (patients under dialysis)
486672|NCT00752570|Metastatic Colorectal Cancer
486673|NCT00752570|colorectal cancer
486674|NCT00752570|colon cancer
486675|NCT00752557|Bone mineral density
486676|NCT00752557|bone morphogenetic protein
486677|NCT00752557|osteoporosis
486678|NCT00752544|TMC435350
486679|NCT00752544|HCV
486680|NCT00752544|Hepatitis C
486681|NCT00752544|TMC435350-TiDP16-C109
486682|NCT00752544|TMC435350-C109
486683|NCT00752531|Chronic Obstructive Pulmonary Disease
486684|NCT00752531|COPD
486685|NCT00752518|bolus
486686|NCT00752518|intravenous
486687|NCT00752518|proteasome inhibitor
486688|NCT00752518|multiple myeloma
486689|NCT00752518|refractory
486690|NCT00752518|relapse
486691|NCT00752505|Fibromyalgia
486692|NCT00752492|Isocapnic hyperpnoea
486693|NCT00752492|obesity
486694|NCT00752492|isoflurane
486695|NCT00752492|Recovery of obese patient from isoflurane anesthesia
486696|NCT00752479|living
486697|NCT00752479|related
486698|NCT00752466|Healthy volunteers
486699|NCT00752466|drug interaction
486700|NCT00752466|Flunarizine
486701|NCT00752466|Topiramate
486702|NCT00752466|Migraine
486703|NCT00752453|ICU
486704|NCT00752453|patients
486705|NCT00752453|lactate
486706|NCT00752453|acidosis
486707|NCT00752440|Diabetes Mellitus
486708|NCT00752440|Autonomic Neuropathy
486709|NCT00752440|Inspiratory Muscle training
486710|NCT00752427|Schizophrenia: paliperidone
486711|NCT00752414|COPD
486712|NCT00752414|Patients
486713|NCT00752401|Vitamin D
486714|NCT00752401|Cholecalciferol
486715|NCT00752401|Vitamin D3
486716|NCT00752401|25-hydroxyvitamin D3
486717|NCT00752401|Immunomodulation
486718|NCT00752401|Vitamin D deficiency
486719|NCT00752401|Kidney transplantation
486720|NCT00752401|Renal transplantation
486721|NCT00752401|Graft function
486722|NCT00752401|Acute rejection
486723|NCT00752401|Renal osteodystrophy
486724|NCT00752401|Posttransplant bone loss
486725|NCT00752375|pyelonephritis
486726|NCT00752375|pediatric pyelonephritis
486727|NCT00752375|vesicoureteral reflux
486728|NCT00752375|DMSA scan
486729|NCT00752362|Supralimus®,
486730|NCT00752362|Infinnium®,
486731|NCT00752362|Matrix®,
486732|NCT00752362|Restenosis
486733|NCT00752362|Percutaneous
486734|NCT00752362|Revascularization
486735|NCT00752362|Techniques
486736|NCT00752362|Metallic
486737|NCT00752362|Platform
486738|NCT00752362|Agents
486739|NCT00752362|Antiproliferative
486740|NCT00752362|Properties
486741|NCT00752349|Videofluoroscopic
486742|NCT00752349|swallowing
486743|NCT00752349|study
486744|NCT00752349|(VFSS)
486745|NCT00752349|ultrasound
486746|NCT00752336|HRQoL
486747|NCT00752336|exercise capacity
486748|NCT00752323|adult giant cell glioblastoma
486749|NCT00752323|adult glioblastoma
486750|NCT00752323|adult gliosarcoma
486751|NCT00752323|recurrent adult brain tumor
486752|NCT00752310|TMC114-TiDP29-C169
486753|NCT00752310|TMC114-C169
486754|NCT00752310|Darunavir (suspension formulation)
486755|NCT00752297|Botulinum Toxin Type A
486756|NCT00752297|Botulinum Toxin
486757|NCT00752297|Glabellar Rhytides
486758|NCT00752297|Rhytides
486759|NCT00752297|Frown Lines
486760|NCT00752297|Neuromuscular Agents
486761|NCT00752297|Neurotoxin
486762|NCT00752297|Forehead
486763|NCT00752297|Eyebrow
486764|NCT00752297|Wrinkle
486765|NCT00752284|coronectomy
486766|NCT00752284|neurosensory deficit
486767|NCT00752284|third molar surgery
486768|NCT00752271|Arthroscopic
486769|NCT00752258|Botulinum Toxin Type A
486770|NCT00752258|Botulinum Toxin
486771|NCT00752258|Glabellar Rhytides
486772|NCT00752258|Rhytides
486773|NCT00752258|Frown Lines
486774|NCT00752258|Neuromuscular Agents
486775|NCT00752258|Neurotoxin
486776|NCT00752258|Forehead
486777|NCT00752258|Eyebrow
486778|NCT00752258|Wrinkle
486779|NCT00752258|Frown Lines Between the Eyebrows
486780|NCT00752245|ICU patients with acute renal failure with sepsis/multi-organ failure
486781|NCT00752232|Phase IIa
486782|NCT00752232|multiple ascending dose study of ACC-001
486783|NCT00752206|AZD0530
486784|NCT00752206|Saracatinib
486785|NCT00752206|Osteosarcoma
486786|NCT00752206|Recurrent
486787|NCT00752206|Localized
486788|NCT00752206|to the Lung
486789|NCT00752180|pharmacokinetics
486790|NCT00752180|pharmacodynamics
486791|NCT00752180|type 1 diabetics
486792|NCT00752180|recombinant human insulin
486793|NCT00752167|exercise induced bronchospasm
486794|NCT00752167|asthma
486795|NCT00752167|athlete
486796|NCT00752167|sports
486797|NCT00752167|eucapnic voluntary hyperventilation
486798|NCT00752167|albuterol
486799|NCT00752154|Subjects
486800|NCT00752154|active
486801|NCT00752154|Rheumatoid
486802|NCT00752154|Arthritis
486803|NCT00752154|revised
486804|NCT00752154|American
486805|NCT00752154|College
486806|NCT00752154|Rheumatology
486807|NCT00752154|Criteria
486808|NCT00752128|Drug Eluting Stent
486809|NCT00752128|Interventional Cardiology
486810|NCT00752128|Percutaneous Coronary Intervention
486811|NCT00752115|non-small cell lung cancer
486812|NCT00752115|previously untreated
486813|NCT00752102|Secondary Hyperparathryoidism
486814|NCT00752102|Chronic Kidney Disease
486815|NCT00752102|Vitamin D
486816|NCT00752102|Coronary Calcification
486817|NCT00752102|Bone metabolism
486818|NCT00752089|enamel fluoride uptake
486819|NCT00752089|erosion
486820|NCT00752089|enamel remineralization
486821|NCT00752076|EGFR mutation
486822|NCT00752076|NSCLC cell line
486823|NCT00752076|Malignant pleural effusion
486824|NCT00752063|Sorafenib
486825|NCT00752063|Capecitabine
486826|NCT00752063|Oxaliplatin
486827|NCT00752063|Advanced Hepatocellular Carcinoma
486828|NCT00752063|Metastatic Hepatocellular Carcinoma
486829|NCT00752050|Botulinum Toxin Type A
486830|NCT00752050|Botulinum Toxin
486831|NCT00752050|Glabellar Rhytides
486832|NCT00752050|Rhytides
486833|NCT00752050|Frown Lines
486834|NCT00752050|Neuromuscular Agents
486835|NCT00752050|Neurotoxin
486836|NCT00752050|Forehead
486837|NCT00752050|Eyebrow
486838|NCT00752050|Wrinkle
486839|NCT00752037|HIV
486840|NCT00752037|Protease Inhibitor
486841|NCT00752037|Integrase Inhibitor
486842|NCT00752037|Treatment Experienced
486843|NCT00752037|Naive
486844|NCT00752024|HICH
486845|NCT00752024|Suction drainages
486846|NCT00752024|TTAC
486847|NCT00752011|Cancer
486848|NCT00752011|Solid Tumors
486849|NCT00752011|Advanced Cancer
486850|NCT00752011|Carboplatin
486851|NCT00752011|Paraplatin
486852|NCT00752011|TAS-106
486853|NCT00752011|Antitumor Activity
486854|NCT00752011|Biomarkers
486855|NCT00751998|biliary
486856|NCT00751998|ERCP
486857|NCT00751998|cholangioscopy
486858|NCT00751998|pancreatic
486859|NCT00751985|Heavy drinking
486860|NCT00751985|Ultra-brief intervention
486861|NCT00751985|Brief intervention
486862|NCT00751985|Alcohol prevention
486863|NCT00751985|Randomized trial
486864|NCT00751985|Personal normative feedback
486865|NCT00751985|Self-help material
486866|NCT00751985|Web-based
486867|NCT00751985|Intervention Studies
486868|NCT00751985|prevention & control
486869|NCT00751959|Continuous positive airway pressure (CPAP)
486870|NCT00751959|extremely preterm infant
486871|NCT00751959|Idiopathic respiratory distress syndrome (IRDS)
486872|NCT00751959|Surfactant
486873|NCT00751946|Posttraumatic Stress Disorder
486874|NCT00751946|PTSD
486875|NCT00751946|psychotherapy
486876|NCT00751946|adolescents
486877|NCT00751946|clinical trial
486878|NCT00751933|Ulcerative colitis
486879|NCT00751933|Vaccines
486880|NCT00751933|Oats
486881|NCT00751920|Magnetic Resonance Imaging
486882|NCT00751920|Pediatrics
486883|NCT00751920|Multi-Detector Computed Tomography
486884|NCT00751920|Computed Tomography
486885|NCT00751920|Detection
486886|NCT00751907|Cerebral blood flow
486887|NCT00751894|Children
486888|NCT00751894|cancer
486889|NCT00751894|Bone marrow transplantation
486890|NCT00751894|Stem cell mobilization
486891|NCT00751894|G-CSF
486892|NCT00751894|Children with solid malignancies
486893|NCT00751881|relapsing multiple sclerosis
486894|NCT00751868|breast cancer
486895|NCT00751842|Diabetes
486896|NCT00751842|Juvenile Diabetes
486897|NCT00751842|Diabetes type 1
486898|NCT00751842|Autoimmune Diabetes
486899|NCT00751842|Insulin dependent Diabetes
486900|NCT00751842|Type 1 diabetes
486901|NCT00751842|Type 1 diabetes mellitus
486902|NCT00751842|Diamyd
486903|NCT00751842|rhGAD65
486904|NCT00751842|GAD
486905|NCT00751842|GAD-alum
486906|NCT00751816|musculoskeletal complications
486907|NCT00751816|stage I squamous cell carcinoma of the hypopharynx
486908|NCT00751816|stage II squamous cell carcinoma of the hypopharynx
486909|NCT00751816|stage III squamous cell carcinoma of the hypopharynx
486910|NCT00751816|stage IV squamous cell carcinoma of the hypopharynx
486911|NCT00751816|stage I squamous cell carcinoma of the larynx
486912|NCT00751816|stage I verrucous carcinoma of the larynx
486913|NCT00751816|stage II squamous cell carcinoma of the larynx
486914|NCT00751816|stage II verrucous carcinoma of the larynx
486915|NCT00751816|stage III squamous cell carcinoma of the larynx
486916|NCT00751816|stage III verrucous carcinoma of the larynx
486917|NCT00751816|stage IV squamous cell carcinoma of the larynx
486918|NCT00751816|stage IV verrucous carcinoma of the larynx
486919|NCT00751816|stage I adenoid cystic carcinoma of the oral cavity
486920|NCT00751816|stage I mucoepidermoid carcinoma of the oral cavity
486921|NCT00751816|stage I verrucous carcinoma of the oral cavity
486922|NCT00751816|stage II adenoid cystic carcinoma of the oral cavity
486923|NCT00751816|stage II mucoepidermoid carcinoma of the oral cavity
486924|NCT00751816|stage II verrucous carcinoma of the oral cavity
486925|NCT00751816|stage III adenoid cystic carcinoma of the oral cavity
486926|NCT00751816|stage III mucoepidermoid carcinoma of the oral cavity
486927|NCT00751816|stage III verrucous carcinoma of the oral cavity
486928|NCT00751816|stage IV adenoid cystic carcinoma of the oral cavity
486929|NCT00751816|stage IV mucoepidermoid carcinoma of the oral cavity
486930|NCT00751816|stage IV verrucous carcinoma of the oral cavity
486931|NCT00751816|stage I squamous cell carcinoma of the lip and oral cavity
486932|NCT00751816|stage II squamous cell carcinoma of the lip and oral cavity
486933|NCT00751816|stage III squamous cell carcinoma of the lip and oral cavity
486934|NCT00751816|stage IV squamous cell carcinoma of the lip and oral cavity
486935|NCT00751816|stage I basal cell carcinoma of the lip
486936|NCT00751816|stage II basal cell carcinoma of the lip
486937|NCT00751816|stage III basal cell carcinoma of the lip
486938|NCT00751816|stage IV basal cell carcinoma of the lip
486939|NCT00751816|stage I lymphoepithelioma of the nasopharynx
486940|NCT00751816|stage I squamous cell carcinoma of the nasopharynx
486941|NCT00751816|stage II lymphoepithelioma of the nasopharynx
486942|NCT00751816|stage II squamous cell carcinoma of the nasopharynx
486943|NCT00751816|stage III lymphoepithelioma of the nasopharynx
486944|NCT00751816|stage III squamous cell carcinoma of the nasopharynx
486945|NCT00751816|stage IV lymphoepithelioma of the nasopharynx
486946|NCT00751816|stage IV squamous cell carcinoma of the nasopharynx
486947|NCT00751816|stage I lymphoepithelioma of the oropharynx
486948|NCT00751816|stage I squamous cell carcinoma of the oropharynx
486949|NCT00751816|stage II lymphoepithelioma of the oropharynx
486950|NCT00751816|stage II squamous cell carcinoma of the oropharynx
486951|NCT00751816|stage III lymphoepithelioma of the oropharynx
486952|NCT00751816|stage III squamous cell carcinoma of the oropharynx
486953|NCT00751816|stage IV lymphoepithelioma of the oropharynx
486954|NCT00751816|stage IV squamous cell carcinoma of the oropharynx
486955|NCT00751816|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
486956|NCT00751816|stage I inverted papilloma of the paranasal sinus and nasal cavity
486957|NCT00751816|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
486958|NCT00751816|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
486959|NCT00751816|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
486960|NCT00751816|stage II inverted papilloma of the paranasal sinus and nasal cavity
486961|NCT00751816|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
486962|NCT00751816|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
486963|NCT00751816|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
486964|NCT00751816|stage III inverted papilloma of the paranasal sinus and nasal cavity
486965|NCT00751816|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
486966|NCT00751816|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
486967|NCT00751816|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
486968|NCT00751816|stage IV inverted papilloma of the paranasal sinus and nasal cavity
486969|NCT00751816|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
486970|NCT00751816|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
486971|NCT00751816|high-grade salivary gland mucoepidermoid carcinoma
486972|NCT00751816|low-grade salivary gland mucoepidermoid carcinoma
486973|NCT00751816|salivary gland acinic cell tumor
486974|NCT00751816|salivary gland adenocarcinoma
486975|NCT00751816|salivary gland adenoid cystic carcinoma
486976|NCT00751816|salivary gland anaplastic carcinoma
486977|NCT00751816|salivary gland malignant mixed cell type tumor
486978|NCT00751816|salivary gland poorly differentiated carcinoma
486979|NCT00751816|salivary gland squamous cell carcinoma
486980|NCT00751816|stage I salivary gland cancer
486981|NCT00751816|stage II salivary gland cancer
486982|NCT00751816|stage III salivary gland cancer
486983|NCT00751816|stage IV salivary gland cancer
486984|NCT00751790|triptorelin, 6-month formulation, advanced prostate cancer
486985|NCT00751712|Aortic Arch
486986|NCT00751699|Pharmacokinetics
486987|NCT00751686|Gastroenteritis
486988|NCT00751686|Burden
486989|NCT00751686|Rotavirus
486990|NCT00751686|< 5 years
486991|NCT00751686|Greece
486992|NCT00751686|Children
486993|NCT00751660|small cell lung cancer
486994|NCT00751660|non-small cell lung cancer
486995|NCT00751660|tobacco use disorder
486996|NCT00751647|CF
486997|NCT00751634|subarachnoid hemorrhage
486998|NCT00751634|intracerebral hemorrhage
486999|NCT00751634|fever
487000|NCT00751621|Immune globulin subcutaneous
487001|NCT00751621|SCIG
487002|NCT00751621|primary immunodeficiency
487003|NCT00751621|PID
487004|NCT00751608|Familial hypercholesterolemia, endothelial function, venous occlusion plethysmography, forearm blood flow, ApoAI-mimetic, endothelial dependent vasodilation
487005|NCT00751595|HIV
487006|NCT00751595|Tat protein
487007|NCT00751595|Therapeutic vaccine
487008|NCT00751595|HAART
487009|NCT00751595|HIV Therapeutic Vaccine
487010|NCT00751595|Treatment Experienced
487011|NCT00751582|nutrition
487012|NCT00751582|education
487013|NCT00751582|supplementation
487014|NCT00751569|umbilical cord blood
487015|NCT00751556|Naproxen Sodium
487016|NCT00751556|Bioavailability
487017|NCT00751543|To evaluate the longitudinal change of tumor perfusion in the course of radiation therapy in adenocarcinoma and squamous cell carcinoma using perfusion MDCT
487018|NCT00751543|Comparison between adenocarcinoma and squamous cell carcinoma will be evaluated according to the derived perfusion parameter obtained from perfusion MDCT
487019|NCT00751530|HIV
487020|NCT00751530|AIDS
487021|NCT00751530|raltegravir
487022|NCT00751530|BRAVO
487023|NCT00751530|protease inhibitor
487024|NCT00751530|treatment Experienced
487025|NCT00751517|Vasculitis
487026|NCT00751517|Cyclophosphamide
487027|NCT00751517|Methotrexate
487028|NCT00751517|Systemic Necrotizing Vasculitides
487029|NCT00751504|Quetiapine
487030|NCT00751504|Psychotic depression
487031|NCT00751491|Stable angina
487032|NCT00751491|Percutaneous Coronary Intervention
487033|NCT00751491|Myonecrosis
487034|NCT00751478|ALO-01
487035|NCT00751478|morphine
487036|NCT00751478|Determination of the relative pharmacodynamic effects
487037|NCT00751478|(including drug-liking), pharmacokinetics, and safety of
487038|NCT00751478|ALO-01 when administered whole or crushed and compared to
487039|NCT00751478|equivalent doses of immediate release morphine and placebo
487040|NCT00751465|Social Anxiety Disorder
487041|NCT00751465|Social Phobia
487042|NCT00751465|Fear of blushing
487043|NCT00751465|attention
487044|NCT00751465|attention training
487045|NCT00751465|cognitive behavior therapy
487046|NCT00751452|Children
487047|NCT00751452|Allogeneic bone marrow transplantation
487048|NCT00751452|Intestinal damage
487049|NCT00751452|Citrulline
487050|NCT00751452|Graft versus Host Disease
487051|NCT00751452|0 to 18 years old
487052|NCT00751439|Oximeter
487053|NCT00751439|Arterial blood gas
487054|NCT00751439|comparison
487055|NCT00751426|Interferon-alpha
487056|NCT00751426|hepatitis c
487057|NCT00751426|Drug addiction
487058|NCT00751426|methadone
487059|NCT00751426|psychiatric disorder
487060|NCT00751426|Safety and efficacy of Interferon-alpha i patients with a psychiatric disorder.
487061|NCT00751400|Non-prescription
487062|NCT00751361|Rheopheresis
487063|NCT00751361|Dry Age Related Macular Degeneration
487064|NCT00751361|AMD
487065|NCT00751361|apheresis
487066|NCT00751361|microcirculation
487067|NCT00751348|second year of life
487068|NCT00751348|one-dose schedule
487069|NCT00751348|varicella
487070|NCT00751348|rubella
487071|NCT00751348|measles
487072|NCT00751348|mumps
487073|NCT00751335|Obstructive Sleep Apnea
487074|NCT00751335|Humidification
487075|NCT00751335|Continuous Positive Airway Pressure
487076|NCT00751322|Pulmonary
487077|NCT00751322|Protein
487078|NCT00751309|allograft
487079|NCT00751309|rejection
487080|NCT00751309|biopsy
487081|NCT00751309|gene
487082|NCT00751309|expression
487083|NCT00751309|pulmonary
487084|NCT00751309|lung
487085|NCT00751309|transplant
487086|NCT00751296|Lenalidomide
487087|NCT00751296|immunomodulatory drug (IMiD®)
487088|NCT00751296|Thalidomide analogues
487089|NCT00751270|Immunotherapy
487090|NCT00751270|Gene therapy
487091|NCT00751270|Tumor Vaccine
487092|NCT00751270|Cytotoxicity
487093|NCT00751270|Radiation
487094|NCT00751257|Nicotine
487095|NCT00751257|N-acetylcysteine
487096|NCT00751257|smoking reduction
487097|NCT00751244|women
487098|NCT00751244|posttraumatic stress disorder
487099|NCT00751244|PTSD
487100|NCT00751244|psychotherapy
487101|NCT00751244|clinical trial
487102|NCT00751244|emotion regulation
487103|NCT00751231|PCI
487104|NCT00751231|percutaneous coronary intervention
487105|NCT00751205|Peripheral Neuropathy
487106|NCT00751205|Prostate Carcinoma
487107|NCT00751205|Ovarian Carcinoma
487108|NCT00751192|Men who have sex with men
487109|NCT00751192|Peru
487110|NCT00751192|HIV testing
487111|NCT00751192|video
487112|NCT00751192|online
487113|NCT00751192|Internet
487114|NCT00751192|HIV Seronegativity
487115|NCT00751153|drug substitution
487116|NCT00751153|Raltegravir
487117|NCT00751153|Atazanavir
487118|NCT00751153|treatment Experienced
487119|NCT00751140|surgical candidates
487120|NCT00751140|upper urinary tract
487121|NCT00751140|urothelial carcinoma
487122|NCT00751140|lymph node dissection
487123|NCT00751127|open angle glaucoma
487124|NCT00751127|ocular hypertension
487125|NCT00751101|palmar-plantar erythrodysesthesia
487126|NCT00751101|chemotherapeutic agent toxicity
487127|NCT00751101|stage IV breast cancer
487128|NCT00751101|recurrent breast cancer
487129|NCT00751088|single-incision
487130|NCT00751088|sling
487131|NCT00751088|stress incontinence
487132|NCT00751088|surgery
487133|NCT00751088|treatment
487134|NCT00751088|Female urinary stress incontinence
487135|NCT00751062|open angle glaucoma ocular hypertension
487136|NCT00751049|open angle glaucoma ocular hypertension
487137|NCT00751036|GIST
487138|NCT00751023|Methamphetamine
487139|NCT00751023|Modafinil
487140|NCT00751023|Addiction
487141|NCT00751023|Craving
487142|NCT00751023|Cognitive
487143|NCT00751010|Vulvar pain
487144|NCT00751010|Vulvodynia
487145|NCT00751010|Interstitial cystitis
487146|NCT00750971|ASSIST
487147|NCT00750971|SLE
487148|NCT00750971|Stem Cell Transplantation
487149|NCT00750971|Tolerance
487150|NCT00750958|cardiac rhythm changes
487151|NCT00750945|Parkinson's disease
487152|NCT00750945|Cueing training
487153|NCT00750945|Treadmill training
487154|NCT00750945|Music
487155|NCT00750893|Gastroenteritis
487156|NCT00750867|multiple system atrophy, MSA,
487157|NCT00750867|intravenous immunoglobulin, IVIg
487158|NCT00750854|arthritis
487159|NCT00750854|osteoarthritis
487160|NCT00750854|fibromyalgia
487161|NCT00750854|connective tissue disorder
487162|NCT00750841|advanced cancer
487163|NCT00750841|metastatic
487164|NCT00750841|rifampicin
487165|NCT00750841|pharmacokinetics
487166|NCT00750841|Phase I
487167|NCT00750841|Advanced solid tumours
487168|NCT00750828|Saliva
487169|NCT00750828|Sjögren's Syndrome
487170|NCT00750828|GCF
487171|NCT00750828|Oral Mucosal Wetness
487172|NCT00750815|B Cell
487173|NCT00750815|hematologic malignancy
487174|NCT00750815|plasma
487175|NCT00750815|bone marrow
487176|NCT00750802|Phase I
487177|NCT00750776|Quality assurance
487178|NCT00750776|medical treatment
487179|NCT00750776|Patient satisfaction
487180|NCT00750763|Mucosal inflammation
487181|NCT00750763|Fleet
487182|NCT00750763|Picoprep
487183|NCT00750763|Colonlytely
487184|NCT00750763|Colonoscopy
487185|NCT00750763|tolerability
487186|NCT00750763|efficacy
487187|NCT00750737|Hematologic Malignancies
487188|NCT00750737|Blood Cancer
487189|NCT00750737|Lymphatic Cancer
487190|NCT00750737|Amphotericin B Lipid Complex
487191|NCT00750737|Amphotericin B
487192|NCT00750737|ABLC
487193|NCT00750737|Fungizone
487194|NCT00750737|Noxafil
487195|NCT00750737|SCH56592
487196|NCT00750737|Posaconazole
487197|NCT00750737|Invasive fungal infections
487198|NCT00750737|IFI
487199|NCT00750737|Hematopoietic Stem Cell Transplant
487200|NCT00750737|HSCT
487201|NCT00750737|Bone Marrow Transplant
487202|NCT00750737|Allogeneic hematopoietic stem cell transplant
487203|NCT00750724|Hyaluronic acid,
487204|NCT00750724|OA knee,
487205|NCT00750724|MRI
487206|NCT00750698|lung cancer
487207|NCT00750698|non small cell lung cancer
487208|NCT00750685|Primary Breast Reconstruction
487209|NCT00750672|Endometrial neoplasia
487210|NCT00750672|Follow-up care
487211|NCT00750672|survivorship
487212|NCT00750672|Primary care provider
487213|NCT00750659|Chronic myeloid leukemia
487214|NCT00750659|Ph+ acute lymphoblastic leukemia
487215|NCT00750659|stem cell transplantation
487216|NCT00750659|nilotinib
487217|NCT00750646|compliance
487218|NCT00750646|eye drop administration
487219|NCT00750646|MEMS
487220|NCT00750646|adherence
487221|NCT00750633|swimmer's ear
487222|NCT00750633|ear drops
487223|NCT00750633|ear infection
487224|NCT00750633|ear pain
487225|NCT00750633|ear inflammation
487226|NCT00750620|mild, moderate, and severe renal impaired subjects
487227|NCT00750620|normal renal function subjects
487228|NCT00750620|Glomerular filtration rate (GFR)
487229|NCT00750620|Modification of Diet in Renal Disease (MDRD) formula
487230|NCT00750620|YM178
487231|NCT00750620|pharmacokinetics
487232|NCT00750594|Children
487233|NCT00750594|Migraine headaches
487234|NCT00750581|Patent Ductus Arteriosus
487235|NCT00750568|Bronchial asthma
487236|NCT00750568|Asthma, bronchial
487237|NCT00750568|Status Asthmaticus
487238|NCT00750568|Terbutaline sulfate
487239|NCT00750555|squamous cell cancer of head and neck
487240|NCT00750555|SCCHN
487241|NCT00750529|sleep
487242|NCT00750529|Alzheimer
487243|NCT00750529|old patients
487244|NCT00750516|Lactic acid
487245|NCT00750516|hypotension
487246|NCT00750516|sepsis
487247|NCT00750503|tobacco cessation
487248|NCT00750503|behavioral therapy
487249|NCT00750503|pharmacotherapy
487250|NCT00750503|workplace
487251|NCT00750503|oral cancer screening
487252|NCT00750503|Tobacco Quit rates
487253|NCT00750477|osteoarthritis
487254|NCT00750477|arthritis
487255|NCT00750477|knee
487256|NCT00750477|eggshell
487257|NCT00750477|membrane
487258|NCT00750477|OPTION
487259|NCT00750451|fertilization in vitro
487260|NCT00750451|assisted reproduction
487261|NCT00750451|recurrent implantation failure
487262|NCT00750451|low molecular weight heparin
487263|NCT00750451|heparin
487264|NCT00750451|luteal phase
487265|NCT00750438|Obesity
487266|NCT00750438|Short chain fatty acids
487267|NCT00750438|Appetite
487268|NCT00750438|Body weight
487269|NCT00750438|Insulin sensitivity
487270|NCT00750438|Propionate
487271|NCT00750438|Propionate ester
487272|NCT00750425|advanced cancer,
487273|NCT00750425|metastatic
487274|NCT00750425|ketoconazole
487275|NCT00750425|pharmacokinetics
487276|NCT00750425|Phase I
487277|NCT00750412|TeenScreen
487278|NCT00750412|Mental Health
487279|NCT00750412|Adolescent Mental Health
487280|NCT00750412|Social Work
487281|NCT00750399|radiation
487282|NCT00750399|retinopathy
487283|NCT00750399|ranibizumab
487284|NCT00750399|melanoma
487285|NCT00750399|choroid
487286|NCT00750386|Cancer
487287|NCT00750386|Ovarian cancer
487288|NCT00750386|Dose-dense chemotherapy
487289|NCT00750373|Endocarditis
487290|NCT00750360|Influenza
487291|NCT00750360|Korea
487292|NCT00750360|FluarixTM
487293|NCT00750347|pain,
487294|NCT00750347|analgesia
487295|NCT00750347|Healthy volunteers
487296|NCT00750334|Oral Clofarabine,
487297|NCT00750334|relapsed/refractory MDS,
487298|NCT00750334|Myelodysplastic
487299|NCT00750295|Chronic kidney disease,
487300|NCT00750295|hemodialysis,
487301|NCT00750295|serum phosphorus,
487302|NCT00750295|phosphate binders
487303|NCT00750282|Alzheimer Disease
487304|NCT00750282|Amyloid beta-Protein
487305|NCT00750269|stage I non-small cell lung cancer
487306|NCT00750256|Safety
487307|NCT00750256|pharmacokinetics
487308|NCT00750256|tolerability
487309|NCT00750230|arthritis
487310|NCT00750230|osteoarthritis
487311|NCT00750230|fibromyalgia
487312|NCT00750230|connective tissue disorder
487313|NCT00750217|transfer methadone buprenorphine patch heroin addiction
487314|NCT00750204|Acute Lung Injury
487315|NCT00750204|ALI
487316|NCT00750204|Acute Respiratory Distress Syndrome
487317|NCT00750204|ARDS
487318|NCT00750204|Mechanical Ventilation
487319|NCT00750204|Sedation
487320|NCT00750204|Critical Illness
487321|NCT00750204|Ventilator Induced Lung Injury
487322|NCT00750204|VILI
487323|NCT00750204|Cytokines
487324|NCT00750204|Protective Ventilation
487325|NCT00750204|Airway Pressure Release Ventilation
487326|NCT00750204|APRV
487327|NCT00750204|Breathing Comfort
487328|NCT00750204|Dyssynchrony
487329|NCT00750204|Asynchrony
487330|NCT00750191|Lower Back Pain
487331|NCT00750165|Obstructive Sleep Apnea
487332|NCT00750165|Humidification
487333|NCT00750165|Continuous Positive Airway Pressure
487334|NCT00750152|tinea cruris
487335|NCT00750152|jock itch
487336|NCT00750139|Tinea Pedis
487337|NCT00750139|Athlete's foot
487338|NCT00750126|Allograft
487339|NCT00750126|Children
487340|NCT00750126|malignancy
487341|NCT00750126|Reduced Intensity Conditioning
487342|NCT00750126|Fludarabin
487343|NCT00750126|Busulfex
487344|NCT00750126|Thymoglobulin
487345|NCT00750100|infertility
487346|NCT00750100|IVF
487347|NCT00750100|hCG
487348|NCT00750100|primary infertility
487349|NCT00750100|secondary infertility
487350|NCT00750100|patients requiring in-vitro fertilisation
487351|NCT00750087|Schizophrenia
487352|NCT00750074|mechanical ventilation
487353|NCT00750061|Spinal Cord Injury
487354|NCT00750048|pain,
487355|NCT00750048|sensitization,
487356|NCT00750048|analgesia
487357|NCT00750035|Total hysterectomy
487358|NCT00750035|subtotal hysterectomy
487359|NCT00750035|urinary function
487360|NCT00750035|bowel function
487361|NCT00750035|sexual function
487362|NCT00750035|Quality of life
487363|NCT00750035|Psychological function
487364|NCT00750009|unspecified adult solid tumor, protocol specific
487365|NCT00750009|accelerated phase chronic myelogenous leukemia
487366|NCT00750009|acute undifferentiated leukemia
487367|NCT00750009|adult acute lymphoblastic leukemia in remission
487368|NCT00750009|adult acute myeloid leukemia in remission
487369|NCT00750009|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
487370|NCT00750009|adult acute myeloid leukemia with inv(16)(p13;q22)
487371|NCT00750009|adult acute myeloid leukemia with t(15;17)(q22;q12)
487372|NCT00750009|adult acute myeloid leukemia with t(16;16)(p13;q22)
487373|NCT00750009|adult acute myeloid leukemia with t(8;21)(q22;q22)
487374|NCT00750009|atypical chronic myeloid leukemia, BCR-ABL1 negative
487375|NCT00750009|blastic phase chronic myelogenous leukemia
487376|NCT00750009|childhood acute lymphoblastic leukemia in remission
487377|NCT00750009|childhood acute myeloid leukemia in remission
487378|NCT00750009|childhood chronic myelogenous leukemia
487379|NCT00750009|chronic myelomonocytic leukemia
487380|NCT00750009|chronic phase chronic myelogenous leukemia
487381|NCT00750009|juvenile myelomonocytic leukemia
487382|NCT00750009|mast cell leukemia
487383|NCT00750009|meningeal chronic myelogenous leukemia
487384|NCT00750009|progressive hairy cell leukemia, initial treatment
487385|NCT00750009|prolymphocytic leukemia
487386|NCT00750009|recurrent adult acute lymphoblastic leukemia
487387|NCT00750009|recurrent adult acute myeloid leukemia
487388|NCT00750009|recurrent adult T-cell leukemia/lymphoma
487389|NCT00750009|recurrent childhood acute lymphoblastic leukemia
487390|NCT00750009|recurrent childhood acute myeloid leukemia
487391|NCT00750009|refractory chronic lymphocytic leukemia
487392|NCT00750009|refractory hairy cell leukemia
487393|NCT00750009|relapsing chronic myelogenous leukemia
487394|NCT00750009|secondary acute myeloid leukemia
487395|NCT00750009|stage 0 chronic lymphocytic leukemia
487396|NCT00750009|stage I adult T-cell leukemia/lymphoma
487397|NCT00750009|stage I chronic lymphocytic leukemia
487398|NCT00750009|stage II adult T-cell leukemia/lymphoma
487399|NCT00750009|stage II chronic lymphocytic leukemia
487400|NCT00750009|stage III adult T-cell leukemia/lymphoma
487401|NCT00750009|stage III chronic lymphocytic leukemia
487402|NCT00750009|stage IV adult T-cell leukemia/lymphoma
487403|NCT00750009|stage IV chronic lymphocytic leukemia
487404|NCT00750009|T-cell large granular lymphocyte leukemia
487405|NCT00750009|untreated adult acute lymphoblastic leukemia
487406|NCT00750009|untreated adult acute myeloid leukemia
487407|NCT00750009|untreated childhood acute lymphoblastic leukemia
487408|NCT00750009|untreated childhood acute myeloid leukemia and other myeloid malignancies
487409|NCT00750009|untreated hairy cell leukemia
487410|NCT00750009|AIDS-related diffuse large cell lymphoma
487411|NCT00750009|AIDS-related diffuse mixed cell lymphoma
487412|NCT00750009|AIDS-related diffuse small cleaved cell lymphoma
487413|NCT00750009|AIDS-related immunoblastic large cell lymphoma
487414|NCT00750009|AIDS-related lymphoblastic lymphoma
487415|NCT00750009|AIDS-related peripheral/systemic lymphoma
487416|NCT00750009|AIDS-related primary CNS lymphoma
487417|NCT00750009|AIDS-related small noncleaved cell lymphoma
487418|NCT00750009|HIV-associated Hodgkin lymphoma
487419|NCT00750009|recurrent adult Hodgkin lymphoma
487420|NCT00750009|recurrent/refractory childhood Hodgkin lymphoma
487421|NCT00750009|stage I adult Hodgkin lymphoma
487422|NCT00750009|stage I childhood Hodgkin lymphoma
487423|NCT00750009|stage II adult Hodgkin lymphoma
487424|NCT00750009|stage II childhood Hodgkin lymphoma
487425|NCT00750009|stage III adult Hodgkin lymphoma
487426|NCT00750009|stage III childhood Hodgkin lymphoma
487427|NCT00750009|stage IV adult Hodgkin lymphoma
487428|NCT00750009|stage IV childhood Hodgkin lymphoma
487429|NCT00750009|anaplastic large cell lymphoma
487430|NCT00750009|angioimmunoblastic T-cell lymphoma
487431|NCT00750009|cutaneous B-cell non-Hodgkin lymphoma
487432|NCT00750009|recurrent cutaneous T-cell non-Hodgkin lymphoma
487433|NCT00750009|stage I cutaneous T-cell non-Hodgkin lymphoma
487434|NCT00750009|stage II cutaneous T-cell non-Hodgkin lymphoma
487435|NCT00750009|stage III cutaneous T-cell non-Hodgkin lymphoma
487436|NCT00750009|stage IV cutaneous T-cell non-Hodgkin lymphoma
487437|NCT00750009|recurrent mycosis fungoides/Sezary syndrome
487438|NCT00750009|stage I mycosis fungoides/Sezary syndrome
487439|NCT00750009|stage II mycosis fungoides/Sezary syndrome
487440|NCT00750009|stage III mycosis fungoides/Sezary syndrome
487441|NCT00750009|stage IV mycosis fungoides/Sezary syndrome
487442|NCT00750009|adult grade III lymphomatoid granulomatosis
487443|NCT00750009|adult nasal type extranodal NK/T-cell lymphoma
487444|NCT00750009|Waldenstrom macroglobulinemia
487445|NCT00750009|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
487446|NCT00750009|nodal marginal zone B-cell lymphoma
487447|NCT00750009|splenic marginal zone lymphoma
487448|NCT00750009|contiguous stage II adult Burkitt lymphoma
487449|NCT00750009|contiguous stage II adult diffuse large cell lymphoma
487450|NCT00750009|contiguous stage II adult diffuse mixed cell lymphoma
487451|NCT00750009|contiguous stage II adult diffuse small cleaved cell lymphoma
487452|NCT00750009|contiguous stage II adult immunoblastic large cell lymphoma
487662|NCT00749658|Bupropion
487453|NCT00750009|contiguous stage II adult lymphoblastic lymphoma
487454|NCT00750009|contiguous stage II grade 1 follicular lymphoma
487455|NCT00750009|contiguous stage II grade 2 follicular lymphoma
487456|NCT00750009|contiguous stage II grade 3 follicular lymphoma
487457|NCT00750009|contiguous stage II mantle cell lymphoma
487458|NCT00750009|contiguous stage II marginal zone lymphoma
487459|NCT00750009|contiguous stage II small lymphocytic lymphoma
487460|NCT00750009|stage I adult Burkitt lymphoma
487461|NCT00750009|stage I adult diffuse large cell lymphoma
487462|NCT00750009|stage I adult diffuse mixed cell lymphoma
487463|NCT00750009|stage I adult diffuse small cleaved cell lymphoma
487464|NCT00750009|stage I adult immunoblastic large cell lymphoma
487465|NCT00750009|stage I adult lymphoblastic lymphoma
487466|NCT00750009|stage I grade 1 follicular lymphoma
487467|NCT00750009|stage I grade 2 follicular lymphoma
487468|NCT00750009|stage I grade 3 follicular lymphoma
487469|NCT00750009|stage I mantle cell lymphoma
487470|NCT00750009|stage I marginal zone lymphoma
487471|NCT00750009|stage I small lymphocytic lymphoma
487472|NCT00750009|noncontiguous stage II adult Burkitt lymphoma
487473|NCT00750009|noncontiguous stage II adult diffuse large cell lymphoma
487474|NCT00750009|noncontiguous stage II adult diffuse mixed cell lymphoma
487475|NCT00750009|noncontiguous stage II adult diffuse small cleaved cell lymphoma
487476|NCT00750009|noncontiguous stage II adult immunoblastic large cell lymphoma
487477|NCT00750009|noncontiguous stage II adult lymphoblastic lymphoma
487478|NCT00750009|noncontiguous stage II grade 1 follicular lymphoma
487479|NCT00750009|noncontiguous stage II grade 2 follicular lymphoma
487480|NCT00750009|noncontiguous stage II grade 3 follicular lymphoma
487481|NCT00750009|noncontiguous stage II mantle cell lymphoma
487482|NCT00750009|noncontiguous stage II marginal zone lymphoma
487483|NCT00750009|noncontiguous stage II small lymphocytic lymphoma
487484|NCT00750009|stage I childhood large cell lymphoma
487485|NCT00750009|stage I childhood lymphoblastic lymphoma
487486|NCT00750009|stage I childhood small noncleaved cell lymphoma
487487|NCT00750009|stage II childhood large cell lymphoma
487488|NCT00750009|stage II childhood lymphoblastic lymphoma
487489|NCT00750009|stage II childhood small noncleaved cell lymphoma
487490|NCT00750009|stage III adult Burkitt lymphoma
487491|NCT00750009|stage III adult diffuse large cell lymphoma
487492|NCT00750009|stage III adult diffuse mixed cell lymphoma
487493|NCT00750009|stage III adult diffuse small cleaved cell lymphoma
487494|NCT00750009|stage III adult immunoblastic large cell lymphoma
487495|NCT00750009|stage III adult lymphoblastic lymphoma
487496|NCT00750009|stage III childhood large cell lymphoma
487497|NCT00750009|stage III childhood lymphoblastic lymphoma
487498|NCT00750009|stage III childhood small noncleaved cell lymphoma
487499|NCT00750009|stage III grade 1 follicular lymphoma
487500|NCT00750009|stage III grade 2 follicular lymphoma
487501|NCT00750009|stage III grade 3 follicular lymphoma
487502|NCT00750009|stage III mantle cell lymphoma
487503|NCT00750009|stage III marginal zone lymphoma
487504|NCT00750009|stage III small lymphocytic lymphoma
487505|NCT00750009|stage IV adult Burkitt lymphoma
487506|NCT00750009|stage IV adult diffuse large cell lymphoma
487507|NCT00750009|stage IV adult diffuse mixed cell lymphoma
487508|NCT00750009|stage IV adult diffuse small cleaved cell lymphoma
487509|NCT00750009|stage IV adult immunoblastic large cell lymphoma
487510|NCT00750009|stage IV adult lymphoblastic lymphoma
487511|NCT00750009|stage IV childhood large cell lymphoma
487512|NCT00750009|stage IV childhood lymphoblastic lymphoma
487513|NCT00750009|stage IV childhood small noncleaved cell lymphoma
487514|NCT00750009|stage IV grade 1 follicular lymphoma
487515|NCT00750009|stage IV grade 2 follicular lymphoma
487516|NCT00750009|stage IV grade 3 follicular lymphoma
487517|NCT00750009|stage IV mantle cell lymphoma
487518|NCT00750009|stage IV marginal zone lymphoma
487519|NCT00750009|stage IV small lymphocytic lymphoma
487520|NCT00750009|recurrent adult Burkitt lymphoma
487521|NCT00750009|recurrent adult diffuse large cell lymphoma
487522|NCT00750009|recurrent adult diffuse mixed cell lymphoma
487523|NCT00750009|recurrent adult diffuse small cleaved cell lymphoma
487524|NCT00750009|recurrent adult grade III lymphomatoid granulomatosis
487525|NCT00750009|recurrent adult immunoblastic large cell lymphoma
487526|NCT00750009|recurrent adult lymphoblastic lymphoma
487527|NCT00750009|recurrent childhood grade III lymphomatoid granulomatosis
487528|NCT00750009|recurrent childhood large cell lymphoma
487529|NCT00750009|recurrent childhood lymphoblastic lymphoma
487530|NCT00750009|recurrent childhood small noncleaved cell lymphoma
487531|NCT00750009|recurrent grade 1 follicular lymphoma
487532|NCT00750009|recurrent grade 2 follicular lymphoma
487533|NCT00750009|recurrent grade 3 follicular lymphoma
487534|NCT00750009|recurrent mantle cell lymphoma
487535|NCT00750009|recurrent marginal zone lymphoma
487536|NCT00750009|recurrent small lymphocytic lymphoma
487537|NCT00750009|Burkitt lymphoma
487538|NCT00750009|childhood diffuse large cell lymphoma
487539|NCT00750009|childhood grade III lymphomatoid granulomatosis
487540|NCT00750009|childhood immunoblastic large cell lymphoma
487541|NCT00750009|childhood nasal type extranodal NK/T-cell lymphoma
487542|NCT00750009|intraocular lymphoma
487543|NCT00750009|primary central nervous system non-Hodgkin lymphoma
487544|NCT00750009|primary central nervous system Hodgkin lymphoma
487545|NCT00750009|post-transplant lymphoproliferative disorder
487546|NCT00750009|chronic eosinophilic leukemia
487547|NCT00750009|chronic neutrophilic leukemia
487548|NCT00750009|primary myelofibrosis
487549|NCT00750009|essential thrombocythemia
487550|NCT00750009|polycythemia vera
487551|NCT00750009|extramedullary plasmacytoma
487552|NCT00750009|isolated plasmacytoma of bone
487553|NCT00750009|stage I multiple myeloma
487554|NCT00750009|stage II multiple myeloma
487555|NCT00750009|stage III multiple myeloma
487556|NCT00750009|primary systemic amyloidosis
487557|NCT00750009|refractory multiple myeloma
487558|NCT00750009|de novo myelodysplastic syndromes
487559|NCT00750009|previously treated myelodysplastic syndromes
487560|NCT00750009|secondary myelodysplastic syndromes
487561|NCT00750009|myelodysplastic/myeloproliferative neoplasm, unclassifiable
487562|NCT00750009|childhood myelodysplastic syndromes
487563|NCT00750009|recurrent childhood anaplastic large cell lymphoma
487564|NCT00750009|stage I childhood anaplastic large cell lymphoma
487565|NCT00750009|stage II childhood anaplastic large cell lymphoma
487566|NCT00750009|stage III childhood anaplastic large cell lymphoma
487567|NCT00750009|stage IV childhood anaplastic large cell lymphoma
487568|NCT00749970|schizophrenia
487569|NCT00749970|subjective well-being
487570|NCT00749970|psychometric validation
487571|NCT00749957|AAV
487572|NCT00749957|adeno-associated virus
487573|NCT00749957|RPE65
487574|NCT00749957|Leber congenital amaurosis
487575|NCT00749957|LCA
487576|NCT00749957|gene therapy
487577|NCT00749957|human gene transfer
487578|NCT00749944|nicotine withdrawal, smoking cessation, varenicline
487579|NCT00749931|IDC, DCIS, ILC
487580|NCT00749918|vitamin D
487581|NCT00749918|Cholecalciferol
487582|NCT00749918|Insulin sensitivity
487583|NCT00749918|MinMod Millennium
487584|NCT00749918|FSIGT
487585|NCT00749918|modified frequently sampled IV glucose tolerance test
487586|NCT00749892|Transitional Cell Carcinoma
487587|NCT00749892|Bladder Cancer
487588|NCT00749892|Urothelial Cancer
487589|NCT00749892|Erlotinib Hydrochloride
487590|NCT00749892|Tarceva
487591|NCT00749892|OSI-774
487592|NCT00749892|TCC
487593|NCT00749879|PK
487594|NCT00749879|Pharmacokinetics
487595|NCT00749866|Nebulised antibiotics
487596|NCT00749866|Non cystic fibrosis bronchiectasis
487597|NCT00749866|Bacterial Load
487598|NCT00749866|Inflammation
487599|NCT00749866|Quality of Life
487600|NCT00749866|Side Effects
487601|NCT00749853|ovarian stimulation
487602|NCT00749853|FSH
487603|NCT00749853|genotyping
487604|NCT00749853|polymorphism
487605|NCT00749840|Acquired Immune Deficiency Syndrome
487606|NCT00749840|Human Immunodeficiency Virus
487607|NCT00749840|Questionnaire
487608|NCT00749840|AIDS
487609|NCT00749840|HIV
487610|NCT00749840|Highly Active Antiretroviral Therapy
487611|NCT00749840|HAART
487612|NCT00749840|Steps of HIV Care
487613|NCT00749840|CDC
487614|NCT00749827|Contrast Induced Nephropathy, fluid prophylaxis
487615|NCT00749814|sleep patterns in children in the night prior to surgery and post surgery.
487616|NCT00749814|the influence of melatonin on sleep patterns
487617|NCT00749801|drug naive
487618|NCT00749801|Dyslipidemic
487619|NCT00749801|nattokinase
487620|NCT00749801|fibrinolytic
487621|NCT00749775|Eplerenone
487622|NCT00749775|Selara
487623|NCT00749775|Hypertension
487624|NCT00749775|Good post-marketing study Practice
487625|NCT00749775|Drug use Investigation
487626|NCT00749775|Regulatory Post Marketing Commitment Plan
487627|NCT00749775|ESSENCE
487628|NCT00749762|DURING
487629|NCT00749762|PRONE
487630|NCT00749762|SUPINE
487631|NCT00749762|POSITIONING
487632|NCT00749749|Abdominal Hysterectomy
487633|NCT00749749|Postoperative pain
487634|NCT00749736|vitamin D
487635|NCT00749736|determine
487636|NCT00749736|normal
487637|NCT00749736|intrapatient
487638|NCT00749736|interpatient
487639|NCT00749736|variability
487640|NCT00749736|measures
487641|NCT00749736|immune system
487642|NCT00749723|brain tumor
487643|NCT00749723|relapse
487644|NCT00749723|children
487645|NCT00749723|etoposide
487646|NCT00749723|intraventricular
487647|NCT00749723|temozolomide
487648|NCT00749710|femoral neck fractures
487649|NCT00749710|pertrochanteric fractures
487650|NCT00749710|antiaggregant therapy
487651|NCT00749710|clopidogrel
487652|NCT00749710|plavix
487653|NCT00749697|radioiodine
487654|NCT00749697|differentiated thyroid cancers
487655|NCT00749697|dosimetry
487656|NCT00749697|metastases
487657|NCT00749684|interferon-alpha
487658|NCT00749658|Tobacco
487659|NCT00749658|Nicotine
487660|NCT00749658|Smoking
487661|NCT00749658|Varenicline
487663|NCT00749658|Human laboratory study
487664|NCT00749658|Stress tolerance
487665|NCT00749658|Startle response
487666|NCT00749658|Cognitive assessment
487667|NCT00749658|Progressive ratio
487668|NCT00749658|Motivation
487669|NCT00749645|Arthritis, Rheumatoid, Andrographolides treatment, Efficacy.
487670|NCT00749632|urinary incontinence, urge
487671|NCT00749632|urinary urge incontinence
487672|NCT00749632|urge incontinence
487673|NCT00749632|over active bladder
487674|NCT00749619|Tunneled Cuffed Catheter
487675|NCT00749619|Catheter Lock Solution
487676|NCT00749619|Catheter Related Bacteremia
487677|NCT00749606|Obesity
487678|NCT00749606|Metabolic syndrome
487679|NCT00749606|Weight loss
487680|NCT00749606|Diabetes prevention
487681|NCT00749593|Congenital Adrenal Hyperplasia
487682|NCT00749593|Quality of Life
487683|NCT00749593|Genotype
487684|NCT00749593|Metabolic outcomes
487685|NCT00749580|Safety
487686|NCT00749567|NSCLC
487687|NCT00749567|TKI's
487688|NCT00749567|Anti-VEGF
487689|NCT00749554|Cooled Radiofrequency
487690|NCT00749554|Disc biacuplasty
487691|NCT00749554|TransDiscal system
487692|NCT00749554|Discogenic pain
487693|NCT00749541|vitamin d coronary catheterization
487694|NCT00749528|Wheezing
487695|NCT00749528|Hair trace elements
487696|NCT00749528|Hair toxic metals
487697|NCT00749528|Oxidative stress
487698|NCT00749515|Thalassemia
487699|NCT00749515|Iron
487700|NCT00749515|Chelation
487701|NCT00749502|Neoplasms
487702|NCT00749502|Ovarian neoplasms
487703|NCT00749502|Prostatic neoplasms
487704|NCT00749502|Endocrine gland neoplasms
487705|NCT00749502|Ovarian diseases
487706|NCT00749502|Adnexal diseases
487707|NCT00749502|Genital diseases, female
487708|NCT00749502|Genital diseases, male
487709|NCT00749502|Genital neoplasms, female
487710|NCT00749502|Urogenital neoplasms
487711|NCT00749502|Endocrine system diseases
487712|NCT00749502|Gonadal disorders
487713|NCT00749502|Genital neoplasms, male
487714|NCT00749502|Prostatic diseases
487715|NCT00749489|Pain
487716|NCT00749489|Hip Fractures
487717|NCT00749489|Femoral Fractures
487718|NCT00749489|Analgesics
487719|NCT00749489|Opioid
487720|NCT00749489|Nerve Block
487721|NCT00749489|Geriatric
487722|NCT00749489|Nerve Stimulation
487723|NCT00749463|nicotine dependence, smoking cessation, NRT
487724|NCT00749450|stage II colon cancer
487725|NCT00749450|stage III colon cancer
487726|NCT00749450|stage II rectal cancer
487727|NCT00749450|stage III rectal cancer
487728|NCT00749437|stage I breast cancer
487729|NCT00749437|stage II breast cancer
487730|NCT00749437|ductal breast carcinoma in situ
487731|NCT00749437|invasive ductal breast carcinoma
487732|NCT00749437|medullary ductal breast carcinoma with lymphocytic infiltrate
487733|NCT00749437|papillary ductal breast carcinoma
487734|NCT00749437|tubular ductal breast carcinoma
487735|NCT00749437|mucinous ductal breast carcinoma
487736|NCT00749437|breast cancer in situ
487737|NCT00749411|COPD
487738|NCT00749411|long-acting beta agonist
487739|NCT00749411|Emphysema
487740|NCT00749411|Chronic Bronchitis
487741|NCT00749411|Chronic Obstructive Pulmonary Disease (COPD)
487742|NCT00749411|bronchodilator
487743|NCT00749411|long acting muscarinic antagonist
487744|NCT00749359|healthy volunteers
487745|NCT00749359|paroxetine
487746|NCT00749346|TTFields
487747|NCT00749346|NSCLC
487748|NCT00749346|Alimta
487749|NCT00749346|Pemetrexed
487750|NCT00749333|Healthy Volunteer
487751|NCT00749333|Safety
487752|NCT00749333|Tolerability
487753|NCT00749333|AZD8566
487754|NCT00749333|study
487755|NCT00749320|MRI
487756|NCT00749320|Sunitinib
487757|NCT00749320|Pazopanib
487758|NCT00749307|Heart rate variability
487759|NCT00749307|Docosahexaenoic acid
487760|NCT00749307|DHA
487761|NCT00749307|Long chain fatty acids
487762|NCT00749307|Long chain polyunsaturated fatty acids
487763|NCT00749307|Algal fatty acids
487764|NCT00749307|Schizochytrium
487765|NCT00749307|Omega 3
487766|NCT00749307|Death, Sudden, Cardiac
487767|NCT00749307|Arrhythmias, Cardiac
487768|NCT00749281|atherosclerosis
487769|NCT00749281|ngal
487770|NCT00749281|coronary artery disease
487771|NCT00749268|hernia
487772|NCT00749255|Breast Cancer
487773|NCT00749255|Digital archiver software
487774|NCT00749242|Traumatic vertebral fracture
487775|NCT00749242|Vertebroplasty
487776|NCT00749242|Balloon kyphoplasty
487777|NCT00749242|Bohler bracing
487778|NCT00749229|Traumatic vertebral fracture
487779|NCT00749229|Balloon Kyphoplasty
487780|NCT00749229|type A3.2, or A3.3 or B1 or C1 in the MAGERL CLASSIFICATION
487781|NCT00749203|Stress Disorders, Post-Traumatic
487782|NCT00749203|PTSD
487783|NCT00749203|anxiety disorder
487784|NCT00749203|ketamine
487785|NCT00749203|depression
487786|NCT00749203|depressed mood
487787|NCT00749177|traditional healing
487788|NCT00749177|anxiety
487789|NCT00749177|depression
487790|NCT00749177|aboriginal
487791|NCT00749177|children
487792|NCT00749177|youth
487793|NCT00749164|Mesenchymal stem cells
487794|NCT00749164|Umbilical cord
487795|NCT00749164|graft-vs-host disease
487796|NCT00749164|Steroid resistant
487797|NCT00749151|smoking cessation
487798|NCT00749151|telephone help line
487799|NCT00749138|hepatitis C, tamoxifen
487800|NCT00749125|Emotional Circuitry
487801|NCT00749125|fMRI
487802|NCT00749112|Idiopathic Thrombocytopenic Purpura
487803|NCT00749112|Anemia
487804|NCT00749112|Hemolytic
487805|NCT00749112|Autoimmune
487806|NCT00749112|Alemtuzumab
487807|NCT00749112|Rituximab
487808|NCT00749086|Osteoporosis
487809|NCT00749086|Non-traumatic vertebral fracture
487810|NCT00749086|Vertebral compression
487811|NCT00749086|Balloon kyphoplasty
487812|NCT00749086|Vertebroplasty
487813|NCT00749073|Spinal Stenosis
487814|NCT00749073|Lumbar Spinal Stenosis
487815|NCT00749073|Laminotomy
487816|NCT00749073|Laminectomy
487817|NCT00749073|Spine Surgery
487818|NCT00749060|osteoporosis
487819|NCT00749060|non-traumatic vertebral fracture
487820|NCT00749060|vertebral compression
487821|NCT00749060|Balloon kyphoplasty
487822|NCT00749060|vertebroplasty
487823|NCT00749047|Pioglitazone
487824|NCT00749047|Open study
487825|NCT00749047|Proteinuria
487826|NCT00749047|Glomerular selectivity indices
487827|NCT00749034|Safety
487828|NCT00749034|Immunogenicity
487829|NCT00749034|Tuberculosis
487830|NCT00749034|Vaccination
487831|NCT00749034|Vaccination against tuberculosis
487832|NCT00749034|Safety and immunogenicity of VPM1002 in comparison with BCG
487833|NCT00749021|choroidal neovascularization
487834|NCT00749021|vascularized
487835|NCT00749008|Cerebral palsy
487836|NCT00749008|Generalized movements
487837|NCT00749008|Fidgety movements
487838|NCT00749008|Prechtl
487839|NCT00748982|AZD1305
487840|NCT00748982|anti-arrhythmics
487841|NCT00748982|safety
487842|NCT00748969|MPS I
487843|NCT00748969|MPS II
487844|NCT00748969|MPS VI
487845|NCT00748969|growth hormone
487846|NCT00748969|short stature
487847|NCT00748956|Mood Disorder
487848|NCT00748956|Anxiety Disorders
487849|NCT00748943|chlorine
487850|NCT00748943|dioxide
487851|NCT00748943|mouthwash
487852|NCT00748943|halitosis
487853|NCT00748943|bacteria
487854|NCT00748943|saliva
487855|NCT00746525|stroke
487856|NCT00746525|motor learning
487857|NCT00746525|rehabilitation of upper extremity
487858|NCT00746525|functional electrical stimulation
487859|NCT00746525|FES
487860|NCT00746525|brain computer interface
487861|NCT00746525|BCI
487862|NCT00746525|coordination
487863|NCT00746525|motor control
487864|NCT00746460|primary prevention
487865|NCT00746460|patient knowledge
487866|NCT00746460|nurse
487867|NCT00746460|exercise
487868|NCT00746460|smoking cessation
487869|NCT00746460|weight loss
487870|NCT00746447|maintenance
487871|NCT00746447|5-ASA
487872|NCT00746447|mesalamine
487873|NCT00746447|mesalazine
487874|NCT00746447|ulcerative colitis
487875|NCT00746434|Mild plaque psoriasis,
487876|NCT00746434|Moderate plaque psoriasis,
487877|NCT00746434|0.5% Roflumilast cream
487878|NCT00746421|Cognition
487879|NCT00746421|attention
487880|NCT00746421|bipolar
487881|NCT00746421|disability
487882|NCT00746408|Internet
487883|NCT00746408|Information supply
487884|NCT00746408|Tailoring
487885|NCT00746408|Patient empowerment
487886|NCT00746408|Headaches
487887|NCT00746408|Consumer Health Information
487888|NCT00746408|Information Services
487889|NCT00746408|Information Storage and Retrieval
487890|NCT00746408|Information Systems
487891|NCT00748904|cirrhosis of liver and progressive renal failure
487892|NCT00748891|Cancer
487893|NCT00748891|tumour
487894|NCT00748891|advanced sold tumour
487895|NCT00748891|imaging
487896|NCT00748891|DCE-CT Scan
487897|NCT00748891|DCE-MRI scan
487898|NCT00748891|Cediranib
487899|NCT00748891|Recentin
487900|NCT00748878|To better understand platelet function during ECMO
487901|NCT00748865|Dry Eye
487902|NCT00748865|Artificial Tears
487903|NCT00748839|HIT
487904|NCT00748839|Heparin-induced thrombocytopenia
487905|NCT00748839|heparin treatment
487906|NCT00748839|venous thrombosis
487907|NCT00748839|arterial thrombosis
487908|NCT00748839|predictive clinical score
487909|NCT00748839|biological test
487910|NCT00748839|anti-H-PF4 antibodies
487911|NCT00748813|Influenza vaccine
487912|NCT00748800|HIV prevention
487913|NCT00748800|HIV seronegativity
487914|NCT00748774|Primary Brain Tumor
487915|NCT00748774|Caregivers
487916|NCT00748774|Symptom Severity
487917|NCT00748774|Questionnaire
487918|NCT00748774|M.D. Anderson Symptom Inventory-Brain Tumor
487919|NCT00748774|MDASI-BT
487920|NCT00748761|Obsessive-Compulsive Disorder
487921|NCT00748761|OCD
487922|NCT00748761|Cognitive-Behavioral Therapy
487923|NCT00748761|CBT
487924|NCT00748761|MRSI
487925|NCT00748761|Glutamate
487926|NCT00748735|cardiac resynchronization therapy
487927|NCT00748735|echocardiography
487928|NCT00748735|heart failure
487929|NCT00748735|left ventricular function
487930|NCT00748735|pacing
487931|NCT00748735|myocardial deformation imaging
487932|NCT00748735|Optimal Definition of Left Ventricular Lead Position in Cardiac Resynchronization Therapy
487933|NCT00748722|Breast reconstruction
487934|NCT00748722|Perforator flaps
487935|NCT00748722|CT Angiography
487936|NCT00748696|sarcopenia
487937|NCT00748696|elderly
487938|NCT00748696|resistance training
487939|NCT00748696|oral nutritional supplement
487940|NCT00748683|elderly
487941|NCT00748683|longterm care
487942|NCT00748644|Wegener's granulomatosis,
487943|NCT00748644|microscopic polyangiitis,
487944|NCT00748644|ANCA-associated vasculitis,
487945|NCT00748644|rituximab,
487946|NCT00748644|azathioprine
487947|NCT00748631|Vertebral fracture
487948|NCT00748631|Vertebral compression fracture
487949|NCT00748631|Multiple Myeloma Bone marrow diseases
487950|NCT00748631|Vertebral metastases
487951|NCT00748631|Balloon Kyphoplasty
487952|NCT00748618|Kidney transplantation (KTX)
487953|NCT00748618|Vitamin D deficiency
487954|NCT00748618|Cardiovascular Disease (CVD)
487955|NCT00748618|Vascular risk
487956|NCT00748618|Parathyroid hormone (PTH)
487957|NCT00748618|Carotid intima media thickness (CIMT)
487958|NCT00748618|Insulin resistance (IR)
487959|NCT00748605|Obesity
487960|NCT00748592|Insomnia, Primary Insomnia, Chronic Insomnia, DIMS (Disorders of Initiating and Maintaining Sleep), Disorders of Initiating and Maintaining Sleep
487961|NCT00748566|Ziprasidone
487962|NCT00748566|metabolic syndrome
487963|NCT00748566|risk factors
487964|NCT00748566|schizophrenia
487965|NCT00748566|psychotic disorders.
487966|NCT00748540|sensorineural hearing loss
487967|NCT00748540|conductive hearing loss
487968|NCT00748540|mixed hearing loss
487969|NCT00748527|fallopian tube cancer
487970|NCT00748527|stage III ovarian epithelial cancer
487971|NCT00748527|stage IV ovarian epithelial cancer
487972|NCT00748527|recurrent ovarian epithelial cancer
487973|NCT00748527|peritoneal cavity cancer
487974|NCT00748514|capsular incision
487975|NCT00748514|biochemical recurrence
487976|NCT00748514|radical perineal prostatectomy
487977|NCT00748501|Amyotrophic Lateral Sclerosis,
487978|NCT00748501|ALS,
487979|NCT00748501|Lou Gehrig's Disease
487980|NCT00748488|Parkinson
487981|NCT00748488|Physical Therapy
487982|NCT00748488|Physical Activity
487983|NCT00748462|Acne scar, Wrinkle, Pigmentation, Fractional CO2 laser
487984|NCT00748449|Colorectal advanced adenoma
487985|NCT00748449|Colorectal cancer polypectomy (endoscopic)
487986|NCT00748449|Colectomy
487987|NCT00748449|Colonoscopy with anaesthesia
487988|NCT00748449|CT-colonography
487989|NCT00748436|Obese females
487990|NCT00748436|Weight loss
487991|NCT00748436|Betahistine
487992|NCT00748423|Inhaled drug
487993|NCT00748423|Acute lung injury
487994|NCT00748423|Nitric oxide
487995|NCT00748423|Sickle cell
487996|NCT00748410|CD11b
487997|NCT00748410|Ulcerative colitis
487998|NCT00748410|99mTc-HMPAO-labelled leukocyte scintigraphy
487999|NCT00748384|HMP, CNV, AMD, PHP, HPHP, foresee
488000|NCT00748371|platelet aggregation
488001|NCT00748371|granule secretion
488002|NCT00748371|thromboxane production
488003|NCT00748371|prostacyclin production
488004|NCT00748358|metastatic prostate carcinoma
488005|NCT00748358|sunitinib [Substance Name]
488006|NCT00748358|Clinical Trial, Phase II [Publication Type]
488007|NCT00748345|Caspofungin,
488008|NCT00748345|burn patients,
488009|NCT00748345|pharmacokinetics,
488010|NCT00748345|optimal dose,
488011|NCT00748345|antifungal treatment
488012|NCT00748319|Receptors KIR
488013|NCT00748319|Polymerase chain reaction
488014|NCT00748319|Diagnosis
488015|NCT00748319|Lymphoma T-cell cutaneous
488016|NCT00748319|Mycosis fungicides
488017|NCT00748319|Sezary syndrome
488018|NCT00748319|Differential diagnosis from dermatitis
488019|NCT00748306|challenge
488020|NCT00748306|early asthmatic response
488021|NCT00748306|mild asthmatics
488022|NCT00748306|Allergen
488023|NCT00748306|methacholine
488024|NCT00748293|Colonoscopy
488025|NCT00748293|Colon cleansing
488026|NCT00748293|Low-reside diet
488027|NCT00748293|Compliance
488028|NCT00748293|PEG-ELS
488029|NCT00748280|Endodontics
488030|NCT00748280|CEM cement
488031|NCT00748280|Calcium enriched mixture
488032|NCT00748280|MTA
488033|NCT00748280|Root Canal Therapy
488034|NCT00748280|Pain
488035|NCT00748280|Pulpotomy
488036|NCT00748280|Human
488037|NCT00748280|Permanent
488038|NCT00748280|Molar teeth
488039|NCT00748267|anxiety disorder
488040|NCT00748267|pain
488041|NCT00748267|nausea and vomiting
488042|NCT00748267|breast cancer
488043|NCT00748254|Rheumatoid arthritis
488044|NCT00748215|diarrhea
488045|NCT00748215|chemotherapeutic agent toxicity
488046|NCT00748215|recurrent colon cancer
488047|NCT00748215|recurrent rectal cancer
488048|NCT00748215|stage IV colon cancer
488049|NCT00748215|stage IV rectal cancer
488050|NCT00748202|Hereditary angioedema
488051|NCT00748202|C1-Esterase inhibitor
488052|NCT00748202|intravenous
488053|NCT00748202|subcutaneous
488054|NCT00748202|pharmacokinetic
488055|NCT00748189|Safety
488056|NCT00748189|Untreated
488057|NCT00748189|Efficacy
488058|NCT00748189|Chronic Lymphocytic Leukemia
488059|NCT00748189|Chronic Lymphocytic Leukemia (CLL), untreated
488060|NCT00748189|Ofatumumab
488061|NCT00748189|Oncology
488062|NCT00748163|stage IV non-small cell lung cancer
488063|NCT00748150|flu
488064|NCT00748150|influenza
488065|NCT00748150|influenza vaccine antigen
488066|NCT00748150|immunogenicity
488067|NCT00748150|antibody response
488068|NCT00748150|intra muscular
488069|NCT00748150|elderly
488070|NCT00748150|non-elderly
488071|NCT00748137|Type 1 Diabetes
488072|NCT00748137|Youth
488073|NCT00748137|Insulin dose
488074|NCT00748111|Sudden death
488075|NCT00748111|Out of hospital cardiac arrest
488076|NCT00748111|Acute myocardial infarction
488077|NCT00748111|Acute coronary syndrome
488078|NCT00748098|PSG
488079|NCT00748098|Restless Legs Syndrome
488080|NCT00748098|gabapentin enacarbil
488081|NCT00748098|XP13512
488082|NCT00748098|GSK1838262
488083|NCT00748098|sleep disturbance
488084|NCT00748098|RLS
488085|NCT00748098|polysomnography
488086|NCT00748085|Malignant Airway Disease
488087|NCT00748085|Lung Cancer
488088|NCT00748085|Inoperable Lung Cancer
488089|NCT00748085|Mesothelioma
488090|NCT00748085|Endoluminal Tumor
488091|NCT00748072|Vasopressin
488092|NCT00748072|bleeding
488093|NCT00748072|biopsy
488094|NCT00748072|ultrasonography
488095|NCT00748059|autonomic nervous system diseases
488096|NCT00748059|blood pressure
488097|NCT00748059|congenital
488098|NCT00748059|orthostasis
488099|NCT00748059|catecholamines
488100|NCT00748046|Biodistribution
488101|NCT00748046|Radiation dosimetry
488102|NCT00748046|Pharmacokinetics
488103|NCT00748046|Safety
488104|NCT00746395|capsule
488105|NCT00746395|endoscopy
488106|NCT00746395|prokinetic
488107|NCT00746395|lubiprostone
488108|NCT00746395|Normal
488109|NCT00746395|volunteers
488110|NCT00746382|Mild atopic dermatitis, Roflumilast cream 0.5%
488111|NCT00746369|HIV
488112|NCT00746369|Prevention
488113|NCT00746369|Adolescents
488114|NCT00746369|HIV Seronegativity
488115|NCT00746356|heart failure
488116|NCT00746356|cardiac resynchronization therapy
488117|NCT00746356|autocapture
488118|NCT00746356|Current RF
488119|NCT00746356|Promote RF
488120|NCT00746343|Bipolar I Disorder
488121|NCT00746343|Medical Risks
488122|NCT00746343|Integrated Risk Reduction Intervention
488123|NCT00746343|Currently in Remission
488124|NCT00746343|BMI
488125|NCT00746330|Asthma
488126|NCT00746330|Children
488127|NCT00746330|Persistent asthma
488128|NCT00746304|botulinum
488129|NCT00746304|esotropia
488130|NCT00746278|Ovarian Cysts
488131|NCT00746278|Electrocoagulation
488132|NCT00746278|Ovarian Function Tests
488133|NCT00746278|Laparoscopy
488134|NCT00746265|behavioral interventions for weight loss
488135|NCT00746252|bipolar
488136|NCT00746252|children
488137|NCT00746252|antipsychotic
488138|NCT00746252|side effect
488139|NCT00748007|Down syndrome, cholinesterase inhibitor, Rivastigmine
488140|NCT00747994|Paget's disease of bone
488141|NCT00747994|Relatives
488142|NCT00747994|Mutations screening
488143|NCT00747994|Haplotypes analysis
488144|NCT00747994|Linkage analysis
488145|NCT00747994|< 55 years
488146|NCT00747994|4 > or = WAFFECTED Bones
488147|NCT00747994|bone deformity
488148|NCT00747981|CT Scan
488149|NCT00747981|Endoscopy
488150|NCT00747981|Aspiration
488151|NCT00747981|Foreign Bodies
488152|NCT00747955|Human Performance
488153|NCT00747955|Physical Disability
488154|NCT00747955|Functional Outcome Measures
488155|NCT00747955|Health Volunteer
488156|NCT00747955|HV
488157|NCT00747942|overweight
488158|NCT00747942|physical inactivity
488159|NCT00747942|physical fitness
488160|NCT00747942|lifestyle change
488161|NCT00747929|Obesity
488162|NCT00747916|Parietal pleura
488163|NCT00747916|Neoplasms
488164|NCT00747916|Pleural Surface
488165|NCT00747916|Pleural Neoplasms
488166|NCT00747916|Lung Cancer
488167|NCT00747903|basal cell carcinoma of the skin
488168|NCT00747903|recurrent skin cancer
488169|NCT00747877|stage II multiple myeloma
488170|NCT00747877|stage III multiple myeloma
488171|NCT00747877|refractory multiple myeloma
488172|NCT00747877|stage I multiple myeloma
488173|NCT00747864|Gestational Age
488174|NCT00747864|Urine
488175|NCT00747864|Concentration
488176|NCT00747864|of S100B
488177|NCT00747851|protein
488178|NCT00747851|synthesis
488179|NCT00747851|response
488180|NCT00747851|PAF-stimulated
488181|NCT00747851|PMNs
488182|NCT00747851|collected
488183|NCT00747838|Afib
488184|NCT00747838|Atrial Fibrillation
488185|NCT00747838|Maze
488186|NCT00747838|Mini-Maze
488187|NCT00747825|cancer
488188|NCT00747825|oncology
488189|NCT00747825|melanoma
488190|NCT00747825|tumor
488191|NCT00747812|Headache
488192|NCT00747812|Migraine
488193|NCT00747812|Refractory
488194|NCT00747812|Chronic
488195|NCT00747812|Pain
488196|NCT00747799|recurrent or metastatic Nasopharyngeal Neoplasms
488197|NCT00747773|Lung Cancer
488198|NCT00747773|CryoPsray Ablation
488199|NCT00747773|CSA therapy
488200|NCT00747773|CSA treatment
488201|NCT00747773|Lobectomy
488202|NCT00747773|lung resection
488203|NCT00747760|TSH Receptor, resistance TSH, Hyperthyrortropinemia
488204|NCT00747747|Sinusitis
488205|NCT00747734|Neuropilin-1
488206|NCT00747734|NRP1
488207|NCT00747734|anti-NRP1
488208|NCT00747734|anti-angiogenic
488209|NCT00747708|heart failure
488210|NCT00747708|coronary heart disease
488211|NCT00747708|adult stem cells
488212|NCT00747708|bone marrow progenitor cells
488213|NCT00747708|bone marrow stem cells
488214|NCT00747708|autologous
488215|NCT00747708|granulocyte-colony stimulating factor
488216|NCT00747708|left ventricular function
488217|NCT00747708|intracoronary injection
488218|NCT00747708|intramyocardial injection
488219|NCT00747695|Pediatric Pharmacokinetics
488220|NCT00747695|Pediatric Pharmacodynamics
488221|NCT00747695|Rabeprazole
488222|NCT00747695|Pediatric GERD
488223|NCT00747695|Aciphex
488224|NCT00747682|Cerebral Perfusion,
488225|NCT00747682|Oxygenation,
488226|NCT00747682|Electrical
488227|NCT00747682|Activity
488228|NCT00747656|Electrocardiography
488229|NCT00747656|Emergency medical services
488230|NCT00747656|Emergency medicine
488231|NCT00747656|Health services
488232|NCT00747656|Cost effectiveness
488233|NCT00747643|tobacco
488234|NCT00747643|nicotine
488235|NCT00747643|smoking
488236|NCT00747643|reward
488237|NCT00747643|reinforcement
488238|NCT00747643|craving
488239|NCT00747643|cues
488240|NCT00747643|conditioned stimuli
488241|NCT00747643|cue reactivity
488242|NCT00747630|Fetal Alcohol Syndrome
488243|NCT00747630|Teen pregnancy
488244|NCT00747617|polycystic ovary syndrome
488245|NCT00747617|androgens
488246|NCT00747617|ovary
488247|NCT00747617|LH
488248|NCT00747604|Growth Hormone (GH) Insensitivity Syndrome
488249|NCT00747604|Insulin-like Growth Factor Deficiency (IGFD)
488250|NCT00747604|Short Stature
488251|NCT00747604|Insulin-like Growth Factor (IGF-1)
488252|NCT00747604|Growth
488253|NCT00747591|urine
488254|NCT00747591|concentration
488255|NCT00747591|of S100B
488256|NCT00747578|ankylosing spondylitis (AS), costs,
488257|NCT00747578|rheumatoid arthritis (RA),
488258|NCT00747578|systemic lupus erythematosus (SLE),
488259|NCT00747578|health-related
488260|NCT00747578|quality of life (HRQOL)
488261|NCT00747578|compare
488262|NCT00747578|utility
488263|NCT00747578|patients
488264|NCT00747565|cataract, tecnis, multifocal, intraocular lens
488265|NCT00747552|IAP measurements
488266|NCT00747552|Abdominal compartment syndrome
488267|NCT00747552|NICU patients
488268|NCT00747552|Intra-abdominal Hypertension
488269|NCT00747539|Hepatitis C Virus
488270|NCT00747539|HCV
488271|NCT00747539|Human Immunodeficiency Virus
488272|NCT00747539|Coinfection
488273|NCT00747526|Gastroesophageal Reflux Disease (GERD)
488274|NCT00747526|Pediatrics
488275|NCT00747526|Pharmacokinetics
488276|NCT00747526|Pharmacodynamics
488277|NCT00747526|Rabeprazole
488278|NCT00747526|GERD
488279|NCT00747526|Aciphex
488280|NCT00747513|school
488281|NCT00747513|prevention
488282|NCT00747513|overweight
488283|NCT00747513|children
488284|NCT00747513|diet
488285|NCT00747513|physical activity
488286|NCT00747513|fitness
488287|NCT00747487|Leber
488288|NCT00747487|LHON
488289|NCT00747487|Leber's Hereditary Optic Neuropathy
488290|NCT00747487|Idebenone
488291|NCT00747461|Benign Airway Disease
488292|NCT00747461|Airway Injury
488293|NCT00747461|Sarcoidosis
488294|NCT00747461|Wegener's Granulomatosis
488295|NCT00747461|Rhinoscleroma
488296|NCT00747461|Recurrent Respiratory Papillomatosis(RRP)
488297|NCT00747448|Barrett's Esophagus
488298|NCT00747448|High Grade Dysplasia
488299|NCT00747448|Low Grade Dysplasia
488300|NCT00747448|Squamous Dysplasia
488301|NCT00747448|Esophageal Cancer
488302|NCT00747448|CryoSpray Ablation
488303|NCT00747448|Cryotherapy
488304|NCT00747448|Cryospray
488305|NCT00747409|postprandial glucose, diastolic function, analogue insulins
488306|NCT00747396|Romania,
488307|NCT00747396|children,
488308|NCT00747396|foster care,
488309|NCT00747396|institutionalization,
488310|NCT00747396|brain function,
488311|NCT00747396|MRI,
488312|NCT00747396|attachment,
488313|NCT00747396|language,
488314|NCT00747396|growth,
488315|NCT00747396|IQ,
488316|NCT00747396|psychiatric symptomatology
488317|NCT00747396|early intervention
488318|NCT00747383|Diabetes Mellitus
488319|NCT00747383|GLP1
488320|NCT00747383|DPP4
488321|NCT00747370|stress urinary incontinence
488322|NCT00747370|Tension free vaginal tape
488323|NCT00747370|tension free vaginal tape obturator
488324|NCT00747370|genital prolapse
488325|NCT00747344|Psoriasis
488326|NCT00747344|Psoriatic Arthritis
488327|NCT00747344|Ustekinumab
488328|NCT00747344|CNTO 1275
488329|NCT00747331|Cardiopulmonary bypass
488330|NCT00747331|Lactic acidosis
488331|NCT00747331|Oxygen delivery
488332|NCT00747331|Acute renal failure
488333|NCT00747331|outcome
488334|NCT00747331|cardiac
488335|NCT00747331|surgery
488336|NCT00747318|Moderate to Severe
488337|NCT00747305|stage IV renal cell cancer
488338|NCT00747305|clear cell renal cell carcinoma
488339|NCT00747305|recurrent renal cell cancer
488340|NCT00747292|laparoscopic
488341|NCT00747292|colon
488342|NCT00747292|analgesia
488343|NCT00747292|fluid optimised
488344|NCT00746239|insomnia
488345|NCT00746239|sleep difficulty
488346|NCT00746239|panic disorder
488347|NCT00746239|nocturnal panic attacks
488348|NCT00746239|anxiety
488349|NCT00746226|birch pollen
488350|NCT00746213|Thoracotomy
488351|NCT00746213|Chronic Pain
488352|NCT00746200|chronic constipation
488353|NCT00746200|electroacupuncture
488354|NCT00746200|randomized controlled trial
488355|NCT00747253|laser interstitial thermal therapy
488356|NCT00747253|laser therapy
488357|NCT00747253|thermal therapy
488358|NCT00747253|brain tumors
488359|NCT00747253|recurrent brain tumor
488360|NCT00747253|progressive brain tumor
488361|NCT00747253|glioblastoma multiforme tumor
488362|NCT00747240|Ile198Thr
488363|NCT00747240|Ala379Val
488364|NCT00747240|variants
488365|NCT00747240|PAF-AH
488366|NCT00747227|cataract
488367|NCT00747227|monofocal
488368|NCT00747227|intraocular lens
488369|NCT00747227|acrylic
488370|NCT00747214|Rheumatoid Arthritis
488371|NCT00747214|RA
488372|NCT00747214|DMARD
488373|NCT00747214|CRP
488374|NCT00747201|Replicating Effective Programs
488375|NCT00747201|Care Management
488376|NCT00747201|Implementation
488377|NCT00747201|Intervention
488378|NCT00747188|Problem-based learning (PBL)
488379|NCT00747188|lecture
488380|NCT00747188|nursing
488381|NCT00747188|education
488382|NCT00747188|none of students had any prior exposure to PBL
488383|NCT00747175|Type 2 diabetes
488384|NCT00747162|Compartment Syndrome
488385|NCT00747162|Muscle Oxygenation
488386|NCT00747162|Skin Pigmentation
488387|NCT00747149|diabetes
488388|NCT00747149|type 2
488389|NCT00747136|Barrett's
488390|NCT00747136|Dysplasia
488391|NCT00747136|esophageal cancer
488392|NCT00747136|Patients
488393|NCT00747110|5-ASA
488394|NCT00747110|mesalamine
488395|NCT00747110|mesalazine
488396|NCT00747110|budesonide
488397|NCT00747110|ulcerative colitis
488398|NCT00747084|unsedated colonoscopy
488399|NCT00747071|Clostridium difficile
488400|NCT00747071|diarrhea
488401|NCT00747071|colostrum
488402|NCT00747058|phase 1, human study, healthy volunteers
488403|NCT00747045|Chronic Thromboembolic Pulmonary Hypertension
488404|NCT00747045|Lung Injury
488405|NCT00747045|Ventilation Strategies
488406|NCT00746993|Contraception
488407|NCT00746993|Counseling
488408|NCT00746980|alopecia
488409|NCT00746980|areata
488410|NCT00746980|universalis
488411|NCT00746980|severe
488412|NCT00746980|ophiasis
488413|NCT00746980|variants
488414|NCT00746954|buspirone
488415|NCT00746954|acetazolamide
488416|NCT00746941|PML
488417|NCT00746941|Human Polyomavirus JC
488418|NCT00746941|HIV
488419|NCT00746941|Central Nervous System Disease
488420|NCT00746941|Mefloquine
488421|NCT00746941|JC Virus
488422|NCT00746928|Blood pressure
488423|NCT00746928|Hypertension
488424|NCT00746928|sympathetic control
488425|NCT00746928|chemosensitivity
488426|NCT00746928|baroreflex
488427|NCT00746915|Patients undergoing elective pain relief treatment of lumbar epidural steroid injection under fluoroscopy
488428|NCT00746902|Refractory hypertension
488429|NCT00746902|Obstructive sleep apnea syndrome
488430|NCT00746902|Obesity
488431|NCT00746902|Leptinemia
488432|NCT00746902|RHOOSAS study
488433|NCT00746889|osteoarthritis
488434|NCT00746889|knee
488435|NCT00746889|corticosteroids
488436|NCT00746889|ultrasound
488437|NCT00746876|Hip
488438|NCT00746876|Fracture
488439|NCT00746876|Femoral neck
488440|NCT00746876|Hemiarthroplasty
488441|NCT00746876|Bipolar
488442|NCT00746876|Unipolar
488443|NCT00746876|Displaced femoral neck fractures
488444|NCT00746863|mid-urethral sling
488445|NCT00746863|pubovaginal sling
488446|NCT00746863|postoperative pain
488447|NCT00746863|visual analog scale
488448|NCT00746863|suprapubic approach
488449|NCT00746863|SPARC sling
488450|NCT00746850|acute cholecystitis
488451|NCT00746850|laparoscopic cholecystectomy
488452|NCT00746850|conversion rate
488453|NCT00746850|morbidity
488454|NCT00746850|mortality
488455|NCT00746850|postoperative pain
488456|NCT00746850|hospital stay
488457|NCT00746837|AZD5672
488458|NCT00746824|Obesity
488459|NCT00746824|weight loss
488460|NCT00746824|7TM Pharma
488461|NCT00746824|TM30339
488462|NCT00746824|Y4 receptor antagonist
488463|NCT00746811|cholesterol
488464|NCT00746811|hypercholesterolemia
488465|NCT00746811|omega 3
488466|NCT00746798|West Nile Fever
488467|NCT00746798|ChimeriVax
488468|NCT00746798|West Nile Virus Vaccine
488469|NCT00746785|Olanzapine
488470|NCT00746772|antioxidant
488471|NCT00746772|oral lichen planus
488472|NCT00746772|treatment
488473|NCT00746772|purslane
488474|NCT00746759|Lung Cancer
488475|NCT00746759|Smoker
488476|NCT00746759|Former Smoker
488477|NCT00746759|Gene Expression
488478|NCT00746759|Bronchoscopy
488479|NCT00746746|Advanced Melanoma
488480|NCT00746733|Drug
488481|NCT00746733|Interaction
488482|NCT00746733|Study
488483|NCT00746720|hip replacement
488484|NCT00746720|osteoarthritis
488485|NCT00746720|etoricoxib
488486|NCT00746720|pain
488487|NCT00746720|cerebrospinal fluid
488488|NCT00746720|pharmacokinetics
488489|NCT00746707|adhesive glue, perineal tear, suture
488490|NCT00746668|Reading
488491|NCT00746668|Macular Degeneration
488492|NCT00746668|Rehabilitation
488493|NCT00746668|Vision, Low
488494|NCT00746655|Hepatocellular
488495|NCT00746642|glucose measurements
488496|NCT00746616|Total Hip Arthroplasty,
488497|NCT00746616|Acetabular Cup,
488498|NCT00746616|Hip Resurfacing
488499|NCT00746616|Young,
488500|NCT00746616|active
488501|NCT00746616|patients
488502|NCT00746590|hepatocellular carcinoma
488503|NCT00746590|liver cancer
488504|NCT00746590|Prolarix
488505|NCT00746590|tretazicar
488506|NCT00746590|caricotamide
488507|NCT00746590|Phase 2
488508|NCT00746590|tumor
488509|NCT00746590|chemotherapy
488510|NCT00746564|Implantable Cardiac Monitor
488511|NCT00746564|Arrhythmias
488512|NCT00746564|Atrial Fibrillation
488513|NCT00746551|iron deficiency anemia
488514|NCT00746551|pregnancy
488515|NCT00746551|third trimester
488516|NCT00746551|intravenous iron
488517|NCT00746551|efficacy
488518|NCT00746551|a randomized trial
488519|NCT00746551|Female
488520|NCT00746551|Ferric Compounds/therapeutic use*
488521|NCT00746551|Infusions, Intravenous
488522|NCT00746551|Hematologic/therapy*
488523|NCT00746538|Hilar cholangiocarcinoma
488524|NCT00746538|biliary stent
488525|NCT00746538|plastic stent
488526|NCT00746538|metallic stent
488527|NCT00746538|quality of life
488528|NCT00746174|insulin sensitivity
488529|NCT00746174|magnetic resonance spectroscopy (MRS)
488530|NCT00746174|lipotoxicity
488531|NCT00746174|lipid oxidation
488532|NCT00746174|thiazolidinediones
488533|NCT00746174|intracellular
488534|NCT00746174|triglyceride
488535|NCT00746174|content
488536|NCT00746161|total gastrectomy
488537|NCT00746161|double tract reconstruction
488538|NCT00746161|gastric cancer
488539|NCT00746161|Total gastrectomy in patients with gastric cancer
488540|NCT00746148|Polycystic Ovary Syndrome
488541|NCT00746148|Reflexology
488542|NCT00746148|Complementary and Alternative Medicine
488543|NCT00746148|Endocrinopathy
488544|NCT00746148|Oligo
488545|NCT00746148|Amenorrhoea
488546|NCT00746135|Heart failure (NYHA class III and IV)
488547|NCT00746135|Ventricular Dyssynchrony
488548|NCT00746109|randomized
488549|NCT00746109|clinical trial
488550|NCT00746109|ultrasound
488551|NCT00746109|prospective
488552|NCT00746109|abscess
488553|NCT00746109|packing
488554|NCT00746109|incision and drainage
488555|NCT00746109|superficial soft tissue infection
488556|NCT00746083|pediatric
488557|NCT00746083|obesity
488558|NCT00746083|African American
488559|NCT00746083|adolescents
488560|NCT00746083|intervention
488561|NCT00746083|home-based
488562|NCT00746083|community-based
488563|NCT00746070|cardiovascular disease, endothelium function, aldosterone
488564|NCT00746057|Renal graft
488565|NCT00746057|chronic rejection
488566|NCT00746057|tolerance
488567|NCT00746057|DNA chip
488568|NCT00746057|biopsy
488569|NCT00746044|Healthy
488570|NCT00746031|MTI
488571|NCT00746031|Fibroids
488572|NCT00746031|Novel
488573|NCT00746031|MR imaging
488574|NCT00746031|techniques
488575|NCT00746018|ovary
488576|NCT00746018|uterus
488577|NCT00746018|cervix
488578|NCT00746018|08-092
488579|NCT00746005|mild cognitive impairment
488580|NCT00745992|Voriconazole
488581|NCT00745992|Antifungal Agents
488582|NCT00745992|Invasive fungal infections
488583|NCT00745992|Therapeutic drug monitoring
488584|NCT00745992|CYP Genetic polymorphism
488585|NCT00745966|Bipolar
488586|NCT00745966|atypical antipsychotics
488587|NCT00745966|quality of life
488588|NCT00745966|observational
488589|NCT00745953|Metabolic syndrome
488590|NCT00745953|Lipotoxicity
488591|NCT00745953|Insulin sensitivity
488592|NCT00745953|Myocardial triglyceride levels
488593|NCT00745953|Hepatic triglyceride levels
488594|NCT00745953|Magnetic resonance spectroscopy
488595|NCT00745940|Mindfulness-Based Cognitive Therapy
488596|NCT00745940|MBCT
488597|NCT00745940|Depression
488598|NCT00745940|Traumatic Brain Injury
488599|NCT00745940|TBI
488600|NCT00745927|Colorectal neoplasm
488601|NCT00745927|Colorectal cancer
488602|NCT00745927|Screening colonoscopy
488603|NCT00745927|CO2 insufflations
488604|NCT00745927|Colonoscopy
488605|NCT00745914|PPAR-gamma, diabetic, kidney disease, atherosclerosis
488606|NCT00745901|contraception
488607|NCT00745901|bleeding
488608|NCT00745901|cycle control
488609|NCT00745888|oxidative stress
488610|NCT00745888|intensive care
488611|NCT00745888|Postoperative intensive care
488612|NCT00745875|NSCLC
488613|NCT00745875|Phase II
488614|NCT00745875|ZD4054
488615|NCT00745875|Pemetrexed
488616|NCT00745875|Lung Cancer
488617|NCT00745862|Skin
488618|NCT00745849|non-allergic rhinitis, laryngopharyngeal reflux
488619|NCT00745836|insulin sensitivity
488620|NCT00745823|HIV Infections
488621|NCT00745823|Treatment Naïve
488622|NCT00745810|cardiopulmonary bypass
488623|NCT00745810|oxidative injuries
488624|NCT00745797|nonsmall cell lung cancer
488625|NCT00745797|brain metastasis
488626|NCT00745797|prophylactic cranial irradiation
488627|NCT00745784|Young Bereaved Spouses
488628|NCT00745771|pharmacokinetics
488629|NCT00745771|of Diractin®
488630|NCT00745771|safety
488631|NCT00745771|efficacy
488632|NCT00745771|exercise
488633|NCT00745758|SAH, vasospasm, ADMA
488634|NCT00745732|Non-Small Cell Lung Cancer
488635|NCT00745732|Lung Cancer
488636|NCT00745732|NSCLC
488637|NCT00745732|ZD6474
488638|NCT00745732|ZACTIMA
488639|NCT00745732|Vandetanib
488640|NCT00745732|Inoperable NSCLC
488641|NCT00745732|Unresectable NSCLC
488642|NCT00745732|Radiation Therapy
488643|NCT00745732|Palliative radiation therapy
488644|NCT00745732|Angiogenesis
488645|NCT00745719|parathyroidectomy
488646|NCT00745719|cardiovascular
488647|NCT00745719|bone
488648|NCT00745719|endstage renal disease
488649|NCT00745693|Endothelin
488650|NCT00745693|Air pollution
488651|NCT00745693|Diesel exhaust
488652|NCT00745693|Vascular function
488653|NCT00745693|exposure
488654|NCT00745680|Left ventricular remodeling, acute myocardial infarction
488655|NCT00745667|laparoscopic
488656|NCT00745667|peptic ulcer
488657|NCT00745654|Lung Transplantation
488658|NCT00745654|Chronic pain
488659|NCT00745654|Thoracotomy
488660|NCT00745641|radiation injury
488661|NCT00745641|computed tomography
488662|NCT00745641|reactive oxygen species
488663|NCT00745641|free radicals
488664|NCT00745628|coronary heart disease
488665|NCT00745628|secondary prevention
488666|NCT00745602|direct current cardioversion, cerebral blood flow
488667|NCT00745589|vascular,
488668|NCT00745589|valvular calcification,
488669|NCT00745589|phosphate binder,
488670|NCT00745589|sevelamer,
488671|NCT00745589|endstage renal disease
488672|NCT00745589|peritoneal dialysis
488673|NCT00745563|infertility
488674|NCT00745563|insemination
488675|NCT00745563|slow release
488676|NCT00745550|SB1518
488677|NCT00745550|Chronic Idiopathic Myelofibrosis
488678|NCT00745550|Myeloproliferative disorders
488679|NCT00745550|Polycythemia Vera
488680|NCT00745550|Essential Thrombocythemia
488681|NCT00745550|JAK2 inhibitor
488682|NCT00745537|postpartum major depression
488683|NCT00745537|adolescent mothers
488684|NCT00745537|telephone depression care management
488685|NCT00745537|barriers to depression care
488686|NCT00745524|Attention-deficit hyperactivity disorder
488687|NCT00745524|adolescent
488688|NCT00745524|adult
488689|NCT00745524|high risk population
488690|NCT00745524|functional impairment
488691|NCT00745524|quality of life
488692|NCT00745511|AMD
488693|NCT00745511|Avastin
488694|NCT00745511|ORA102
488695|NCT00745511|macular degeneration
488696|NCT00745511|neo-vascular age related macular degeneration (AMD)
488697|NCT00745498|Proliferative diabetic retinopathy
488698|NCT00745498|vitrectomy
488699|NCT00745498|bevacizumab
488700|NCT00745498|vitreous hemorrhage
488701|NCT00745485|Osteoporosis
488702|NCT00745485|zoledronic acid
488703|NCT00745485|postmenopausal women
488704|NCT00745472|AEP
488705|NCT00745472|experimental pain
488706|NCT00745472|healthy volunteers
488707|NCT00745459|Patients
488708|NCT00745459|undergoing
488709|NCT00745459|gastric
488710|NCT00745459|endoscopy
488711|NCT00745446|Air pollution
488712|NCT00745446|Diesel exhaust
488713|NCT00745446|Endothelial function
488714|NCT00745446|Vascular function
488715|NCT00745446|Particle trap
488716|NCT00745446|Thrombosis
488717|NCT00745446|effects
488718|NCT00745446|inhalation
488719|NCT00745420|Sickle Cell Disease
488720|NCT00745420|Sickle Cell Anemia
488721|NCT00744380|Analgesia
488722|NCT00744380|Mechanical ventilation
488723|NCT00744354|refractory multiple myeloma
488724|NCT00744354|stage I multiple myeloma
488725|NCT00744354|stage II multiple myeloma
488726|NCT00744354|stage III multiple myeloma
488727|NCT00744341|SLV320; Acute Decompensated Heart Failure (ADHF); chronic heart failure; renal failure; I.V. doses; hospitalization
488728|NCT00744328|Postpartum depression
488729|NCT00744328|estradiol
488730|NCT00744328|Postpartum major depressive disorder
488731|NCT00744315|myocardial revascularization
488732|NCT00744315|myocardial ischemia
488733|NCT00744315|genetics, medical
488734|NCT00744315|Angiogenesis Inducing Agents
488735|NCT00744302|Dialysate calcium
488736|NCT00744302|Mineral metabolism
488737|NCT00744302|Parathyroid hormone
488738|NCT00744302|Calcification
488739|NCT00744302|Cardiovascular disease
488740|NCT00744302|Haemodialysis
488741|NCT00744289|Hepatitis B
488742|NCT00744289|People who inject drugs
488743|NCT00744289|Financial incentive
488744|NCT00744289|Vaccine completion
488745|NCT00744276|fibrocystic breast disease
488746|NCT00744276|fibrocystic disease of breast
488747|NCT00744276|breast pain
488748|NCT00744276|mastalgia
488749|NCT00744276|cyclic mastalgia
488750|NCT00744276|cystic breast disease
488751|NCT00744250|Exocrine Pancreatic Insufficiency
488752|NCT00744250|Chronic Pancreatitis
488753|NCT00744250|Cystic fibrosis
488754|NCT00744250|Pancrelipase
488755|NCT00744250|Pancrecarb
488756|NCT00744250|Intraduodenal aspiration
488757|NCT00744250|Bioavailability
488758|NCT00744237|nebivolol
488759|NCT00744237|Bystolic ™
488760|NCT00744237|Hypertension
488761|NCT00744237|Diabetes
488762|NCT00744198|Autologous
488763|NCT00744198|Biological
488764|NCT00744198|Mesh
488765|NCT00744198|Polypropylene
488766|NCT00744198|Sling
488767|NCT00744198|Synthetic
488768|NCT00744198|Stress incontinence
488769|NCT00744198|Surgery
488770|NCT00744198|TOT
488771|NCT00744198|Treatment
488772|NCT00744185|infantile capillary hemangiomas
488773|NCT00744185|propranolol
488774|NCT00744185|ultrasonography
488775|NCT00744172|hysterectomy
488776|NCT00744172|vaginal
488777|NCT00744172|laparoscopy
488778|NCT00744172|abdominal
488779|NCT00744172|complication
488780|NCT00744172|quality of life
488781|NCT00744172|cost-effectiveness
488782|NCT00744172|Morbidity of three types of hysterectomy
488783|NCT00745407|adipocytokines
488784|NCT00745407|insulin sensitivity
488785|NCT00745407|hypertriglyceridemic patients
488786|NCT00745394|NIRS
488787|NCT00745394|bypass
488788|NCT00745394|cardiopulmonary
488789|NCT00745394|CPB
488790|NCT00745394|monitoring
488791|NCT00745394|system
488792|NCT00745381|PANCREAS
488793|NCT00745381|STOMACH
488794|NCT00745381|Questionnaire
488795|NCT00745381|08-105
488796|NCT00745368|HIV
488797|NCT00745368|Raltegravir
488798|NCT00745368|pharmacokinetics
488799|NCT00745368|Treatment Experienced
488800|NCT00745355|Quality of Life
488801|NCT00745355|Questionnaires
488802|NCT00745355|08-076
488803|NCT00745342|type 1 diabetes
488804|NCT00745342|glycemic control
488805|NCT00745342|family conflict
488806|NCT00745342|quality of life
488807|NCT00745342|parental involvement
488808|NCT00745316|Heart Failure
488809|NCT00745316|Renal Insufficiency
488810|NCT00745316|Congestive Heart Failure
488811|NCT00745303|Tai Chi Chuan; Lipid; Cytokine
488812|NCT00745290|Total knee arthroplasty
488813|NCT00745290|Pain
488814|NCT00745290|Analgesia
488815|NCT00745277|carbidopa
488816|NCT00745277|levodopa
488817|NCT00745277|Parkinson's disease
488818|NCT00745264|heat
488819|NCT00745264|exercise
488820|NCT00745251|Sleep apnea; obesity
488821|NCT00745238|endothelial function
488822|NCT00745238|peripheral arterial tone
488823|NCT00745238|systemic inflammation
488824|NCT00745238|oxidative stress
488825|NCT00745238|respiratory and peripheral muscular function
488826|NCT00745225|peritoneal dialysis, cardiovascular, PPAR-gamma
488827|NCT00745212|venous thromboembolism diseases
488828|NCT00745212|placental vascular pathologies
488829|NCT00745212|antithrombotic treatment
488830|NCT00745212|symptomatic thromboembolic events
488831|NCT00745212|pregnant women
488832|NCT00745212|score
488833|NCT00745212|therapeutic strategies
488834|NCT00745212|heparin
488835|NCT00745212|aspirin
488836|NCT00745212|pregnancy pathology
488837|NCT00745199|End Stage Renal Disease
488838|NCT00745199|Cromolyn Sodium
488839|NCT00745199|Pruritus
488840|NCT00745199|Tryptase
488841|NCT00745160|Questionaires
488842|NCT00745147|constipation
488843|NCT00745147|traditional Chinese medicine
488844|NCT00745147|Chinese herbal formula
488845|NCT00745147|lactulose
488846|NCT00745147|cost-effective
488847|NCT00745147|long-term care
488848|NCT00745134|Rectum
488849|NCT00745134|Rectal Cancer
488850|NCT00745134|Colon Cancer
488851|NCT00745134|Curcumin
488852|NCT00745134|Diferuloylmethane
488853|NCT00745134|Capecitabine
488854|NCT00745134|Radiation Therapy
488855|NCT00745134|RT
488856|NCT00745134|XRT
488857|NCT00745134|Surgery for Rectal Cancer
488858|NCT00745095|Safety
488859|NCT00745095|Efficacy
488860|NCT00745095|Colonoscopy
488861|NCT00745095|PIEE
488862|NCT00745095|MoviPrep
488863|NCT00745095|Neostigmine
488864|NCT00745095|Glycopyrrolate
488865|NCT00745069|Tapentadol
488866|NCT00745069|Osteoarthritis
488867|NCT00745069|Analgesia
488868|NCT00745069|Chronic pain
488869|NCT00745056|Cognition
488870|NCT00745056|Memory
488871|NCT00745056|Hormone Therapy
488872|NCT00745056|HT
488873|NCT00745043|COPD
488874|NCT00745043|Betablockers
488875|NCT00745043|bronchodilator
488876|NCT00745043|exercise capacity
488877|NCT00745043|methacholine challenge
488878|NCT00745030|Parkinson's disease
488879|NCT00745030|Multiple Systems Atrophy
488880|NCT00745030|Lewy Body Dementia
488881|NCT00745017|recurrent depression
488882|NCT00745017|major depressive disorder
488883|NCT00745017|interpersonal therapy
488884|NCT00745017|cognitive behavioral therapy
488885|NCT00745017|antidepressant therapies
488886|NCT00745017|outome predictors
488887|NCT00745017|personality dimensions
488888|NCT00745004|IBS D
488889|NCT00744978|Efficacy
488890|NCT00744978|Safety
488891|NCT00744978|Pharmacokinetics
488892|NCT00744978|Alzheimer's disease
488893|NCT00744952|Large-vessel vasculitis
488894|NCT00744939|Gadolinium
488895|NCT00744939|NSF
488896|NCT00744939|Renal Impairment
488897|NCT00744939|chemically induced
488898|NCT00744939|adverse effects
488899|NCT00744939|Contrast Media
488900|NCT00744939|complications
488901|NCT00744913|Pregnancy
488902|NCT00744913|Women
488903|NCT00744913|Nicotine replacement therapy
488904|NCT00744913|Smoking cessation
488905|NCT00744900|Pemetrexed, Non-Small Cell Lung Cancer, brain metastasis
488906|NCT00744887|TMC114-TiDP3-C181
488907|NCT00744887|TMC114-C181, health volunteers, Darunavir, ritonavir oral solution
488908|NCT00744874|atrial fibrillation
488909|NCT00744861|Lumbar Fusion
488910|NCT00744861|exospine
488911|NCT00744861|Exo-Spine
488912|NCT00744848|hemorrhoids
488913|NCT00744835|atrial fibrillation
488914|NCT00744822|Lung Transplantation
488915|NCT00744822|Infections
488916|NCT00744822|Graft Rejection
488917|NCT00744809|TMC278-C152
488918|NCT00744809|TMC278-TiDP6-C152
488919|NCT00744809|Healthy Volunteers
488920|NCT00744809|QT/QTc interval
488921|NCT00744796|Endothelial Dystrophy
488922|NCT00744796|Fuchs' Endothelial Corneal Dystrophy
488923|NCT00744770|TMC278-TiDP6-C121
488924|NCT00744770|TMC278-C121
488925|NCT00744770|open-label
488926|NCT00744770|drug-drug interaction
488927|NCT00744770|methadone
488928|NCT00744770|TMC278
488929|NCT00744757|5-aza-2'-deoxycytidine
488930|NCT00744757|decitabine
488931|NCT00744757|dacogen
488932|NCT00744757|Myelodysplastic Syndrome
488933|NCT00744744|stage 0 bladder cancer
488934|NCT00744731|Partial-onset Seizures
488935|NCT00744731|Simple Partial Seizures
488936|NCT00744731|Complex Partial Seizures
488937|NCT00744705|Retinal nerve fiber layer
488938|NCT00744705|Glaucoma
488939|NCT00744705|Myopia
488940|NCT00744692|Immunodeficiencies
488941|NCT00744692|Congenital Marrow Failures
488942|NCT00744692|Hemoglobinopathies
488943|NCT00744692|Inborn Errors of Metabolism
488944|NCT00744692|SCIDS
488945|NCT00744692|Wiskott Aldrich
488946|NCT00744692|FEL
488947|NCT00744692|HLH
488948|NCT00744692|IPEX
488949|NCT00744692|LAD
488950|NCT00744692|Sickle Cell
488951|NCT00744692|Thalassemia
488952|NCT00744692|Omenn's Syndrome
488953|NCT00744692|Hurler's Syndrome
488954|NCT00744692|MLD
488955|NCT00744692|ALD
488956|NCT00744692|Sanfilippo
488957|NCT00744692|Krabbe
488958|NCT00744692|Hunter's syndrome
488959|NCT00744692|TaySachs
488960|NCT00744692|Diamond Blackfan Anemia
488961|NCT00744692|transplant
488962|NCT00744692|MPS
488963|NCT00744692|Gaucher
488964|NCT00744679|MS
488965|NCT00744679|Multiple Sclerosis
488966|NCT00744666|Intravitreal triamcinolone acetonide
488967|NCT00744666|Side-effects
488968|NCT00744666|Ocular hypertension
488969|NCT00744666|Glaucoma
488970|NCT00744666|Prevention
488971|NCT00744666|Vitreoretinal diseases requiring IVTA for treatment
488972|NCT00744653|Breast Cancer
488973|NCT00744653|Recurrence
488974|NCT00744640|advanced pancreatic cancer
488975|NCT00744640|palliative chemotherapy
488976|NCT00744640|first-line therapy
488977|NCT00744640|capecitabine
488978|NCT00744640|oxaliplatin
488979|NCT00744640|gemcitabine
488980|NCT00744640|dose-finding study
488981|NCT00744640|Phase II
488982|NCT00744627|Generalized Anxiety Disorder
488983|NCT00744627|Anxiety Disorders
488984|NCT00744627|Drug Therapy
488985|NCT00744614|PC02
488986|NCT00744614|Respiratory Rate
488987|NCT00744614|Arterial blood gas
488988|NCT00744614|Intubation
488989|NCT00744614|Capnography
488990|NCT00744601|impulsivity
488991|NCT00744601|cocaine dependence
488992|NCT00744601|relapse
488993|NCT00744601|neuroimaging
488994|NCT00744601|functional magnetic resonance imaging (fMRI)
488995|NCT00744601|single photon emission computed tomography (SPECT)
488996|NCT00744588|substance abuse
488997|NCT00744588|alcohol dependence
488998|NCT00744588|hypothalamic-pituitary-adrenal (HPA) system
488999|NCT00744588|cosyntropin
489000|NCT00744588|corticotropin-releasing Hormone (CRH)
489001|NCT00744588|pituitary-adrenal system
489002|NCT00744588|stress
489003|NCT00744588|trauma
489004|NCT00744588|neurosteroids
489005|NCT00744588|cortisol
489006|NCT00744588|relapse
489007|NCT00744575|back pain
489008|NCT00744575|eeg
489009|NCT00744575|chronic pain
489010|NCT00744562|Phase 1,
489011|NCT00744562|dose escalation,
489012|NCT00744562|histologically
489013|NCT00744562|confirmed
489014|NCT00744562|malignancy
489015|NCT00744562|metastatic
489016|NCT00744549|Male Urogenital Diseases
489017|NCT00744549|Antioxidants
489018|NCT00744549|Vitamin E
489019|NCT00744549|Vitamin D
489020|NCT00744549|Lycopene
489021|NCT00744549|Selenium
489022|NCT00744536|Myelodysplastic syndrome
489023|NCT00744536|Chronic myelomonocytic leukemia
489024|NCT00744536|High intermediate risk and high risk IPSS score
489025|NCT00744536|Angiogenesis
489026|NCT00744536|Metronomic chemotherapy
489027|NCT00744536|Myelodysplastic Myeloproliferative Diseases
489028|NCT00744523|carotid artery stenting
489029|NCT00744523|stroke
489030|NCT00744523|cerebral protection
489031|NCT00744523|high surgical risk
489032|NCT00744510|Polycystic Ovary Syndrome
489033|NCT00744510|Reflexology
489034|NCT00744510|Complementary and Alternative Medicine
489035|NCT00744510|Endocrinopathy
489036|NCT00744510|Oligo
489037|NCT00744510|Amenorrhoea
489038|NCT00744484|Chronic Obstructive Pulmonary Disease
489039|NCT00744484|COPD
489040|NCT00744484|Physical group training
489041|NCT00744484|Water exercise
489042|NCT00744484|Cardiorespiratory fitness
489043|NCT00744484|Functional exercise capacity
489044|NCT00744484|Health related quality of life
489045|NCT00744471|monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth OA
489046|NCT00744458|Primary Health care in rural Africa
489047|NCT00744458|Chronic non-communicable diseases
489048|NCT00744458|Patient Compliance
489049|NCT00744458|Treatment adherence
489050|NCT00744445|hemodialysis
489051|NCT00744445|erythropoietin
489052|NCT00744419|GERD
489053|NCT00744419|pharmacokinetics
489054|NCT00744419|pantoprazole
489055|NCT00744419|neonates
489056|NCT00744419|infants
489057|NCT00744406|recurrent depression
489058|NCT00744406|major depressive disorder
489059|NCT00744406|interpersonal therapy
489060|NCT00744406|cognitive behavioral therapy
489061|NCT00744406|antidepressant treatment
489062|NCT00744406|outcome predictors
489063|NCT00744406|personality dimensions
489064|NCT00744393|sleep
489065|NCT00744393|critically ill
489066|NCT00744393|mechanical ventilation
489067|NCT00744159|colon cancer
489068|NCT00744159|laparoscopic colorectal surgery
489069|NCT00744159|cellular immunity
489070|NCT00744159|HLA-DR expression on monocyte
489071|NCT00744133|Plasmodium falciparum, NF54, Anopheles stephensi, mosquito, malaria
489072|NCT00744120|cancer
489073|NCT00744107|Ischemic coronary artery disease in native coronary arteries
489074|NCT00744107|Single stent
489075|NCT00744107|RVD 2.5- 4.0mm
489076|NCT00744107|Lesion length up to 26mm
489077|NCT00744107|de novo or previously unstented lesions
489078|NCT00744094|resistance training
489079|NCT00744094|protein supplementation
489080|NCT00744094|hypertrophy
489081|NCT00744068|Stimulant
489082|NCT00744068|Drug treatment
489083|NCT00744068|Continuing care
489084|NCT00744068|Telephone support
489085|NCT00744068|Aftercare
489086|NCT00744055|alcohol dependence
489087|NCT00744055|post traumatic stress disorder
489088|NCT00744055|treatment
489089|NCT00744055|prazosin
489090|NCT00744042|Hypophosphatasia
489091|NCT00744042|HPP
489092|NCT00744042|Bone Disease
489093|NCT00744042|Soft Bones
489094|NCT00744042|Low Alkaline Phosphatase
489095|NCT00744042|genetic metabolic disorder
489096|NCT00744042|alkaline phosphatase
489097|NCT00744042|tissue non-specific alkaline phosphatase
489098|NCT00744042|rickets
489099|NCT00744042|osteomalacia
489100|NCT00744029|prehospital delays
489101|NCT00744029|intervention
489102|NCT00744029|population-based
489103|NCT00744029|stroke
489104|NCT00744016|UC
489105|NCT00744016|Ulcerative colitis
489106|NCT00744016|IBD
489107|NCT00744016|Inflammatory bowel disease
489108|NCT00743990|Cough symptoms
489109|NCT00743990|Cold symptoms
489110|NCT00743990|Congestion
489111|NCT00743990|Children
489112|NCT00743990|URI
489113|NCT00743990|Alternative cough symptom treatment
489114|NCT00743951|patient decision aids
489115|NCT00743951|patient preferences
489116|NCT00743951|osteoarthritis
489117|NCT00743951|joint replacement
489118|NCT00743951|waiting times
489119|NCT00743925|Unstable Angina
489120|NCT00743925|STEMI
489121|NCT00743925|NSTEMI
489122|NCT00743925|ACS
489123|NCT00743925|Acute Coronary Syndrome
489124|NCT00743925|C14.280.647.124
489125|NCT00743925|C14.280.647.500
489126|NCT00743912|rifaximin
489127|NCT00743912|midazolam
489128|NCT00743912|pharmacokinetics
489129|NCT00743899|Angioplasty, Transluminal, Percutaneous Coronary
489130|NCT00743899|Everolimus-eluting stent
489131|NCT00743873|medial retinaculum tear s/p patella dislocation
489132|NCT00743860|darapladib
489133|NCT00743860|pharmacokinetics
489134|NCT00743860|metabolite
489135|NCT00743860|SB-480848
489136|NCT00743847|schizophrenia, treatment, cognition
489137|NCT00743808|hypertension
489138|NCT00743808|diabetes
489139|NCT00743808|quality improvement
489140|NCT00743808|blood pressure
489141|NCT00743795|Hepatitis C
489142|NCT00743795|HCV
489143|NCT00743795|Rapid Virologic Response
489144|NCT00743795|Sustained Virologic Response
489145|NCT00743795|HCV RNA
489146|NCT00743795|Polymerase inhibitor
489147|NCT00743795|GS-9190
489148|NCT00743782|Hypoparathyroidism
489149|NCT00743782|Parathyroid Hormone 1-34
489150|NCT00743769|Myocardial Infarction
489151|NCT00743769|Myocardial Ischemia
489152|NCT00743769|Myocardial Diseases
489153|NCT00743769|Infarction
489154|NCT00743756|obesity
489155|NCT00743756|diabetes
489156|NCT00743756|endothelial function
489157|NCT00743756|insulin sensitivity
489158|NCT00743743|dementia
489159|NCT00743743|Alzheimer disease
489160|NCT00743743|cognition
489161|NCT00743743|function
489162|NCT00743743|behavior
489163|NCT00743743|treatment
489164|NCT00743730|developmental delay
489165|NCT00743730|cognitive impairment
489166|NCT00743730|pain control
489167|NCT00743730|post operative pain
489168|NCT00743730|opioid
489169|NCT00743730|pain assessment
489170|NCT00743730|Parent Nurse controlled Analgesic
489171|NCT00743730|patient controlled analgesic
489172|NCT00743730|children
489173|NCT00743730|pain
489174|NCT00743730|analgesic
489175|NCT00743730|safety
489176|NCT00743730|parent satisfaction
489177|NCT00743730|nurse satisfaction
489178|NCT00743730|Pediatric
489179|NCT00743717|total knee arthroplasty
489180|NCT00743717|osteoarthritis
489181|NCT00743717|ceramic bearing
489182|NCT00743717|zirconia
489183|NCT00743691|Ethiopia
489184|NCT00743691|Community
489185|NCT00743691|Community based
489186|NCT00743691|Health extension Worker
489187|NCT00743691|Health Extension Program
489188|NCT00743678|Colorectal Cancer
489189|NCT00743678|Unresectable liver metastasis
489190|NCT00743678|FOLFOX6
489191|NCT00743678|Cetuximab
489192|NCT00743678|Neoadjuvant therapy
489193|NCT00743665|Youth
489194|NCT00743665|consensus
489195|NCT00743665|criteria
489196|NCT00743665|CVS
489197|NCT00743652|13 valent Pneumococcal Conjugate Vaccine
489198|NCT00743652|Antibody Response
489199|NCT00743652|safety
489200|NCT00743652|Alaskan Native Children
489201|NCT00743639|Cardiomyopathy
489202|NCT00743639|stem cell
489203|NCT00743639|cardiac failure
489204|NCT00743626|Pap test
489205|NCT00743626|HPV
489206|NCT00743626|Healthy patients screened for cervical cancer tests.
489207|NCT00743613|Erectile Dysfunction
489208|NCT00743613|ED
489209|NCT00743613|Peripheral Arterial Disease
489210|NCT00743613|PAD
489211|NCT00743613|Ankle-Brachial Index
489212|NCT00743613|ABI
489213|NCT00743600|ultrasound
489214|NCT00743600|rotator cuff
489215|NCT00743561|MSA
489216|NCT00743561|sleep apnea
489217|NCT00743561|ambulatory polygraphy
489218|NCT00743561|polysomnography
489219|NCT00743548|interdental self-care aids
489220|NCT00743548|plaque
489221|NCT00743548|bleeding gums
489222|NCT00743535|Cystocele
489223|NCT00743535|Mesh
489224|NCT00743535|Prolapse
489225|NCT00743535|Sling
489226|NCT00743535|Stress incontinence
489227|NCT00743535|Surgery
489228|NCT00743535|TOT
489229|NCT00743535|TVT
489230|NCT00743535|Treatment
489231|NCT00743522|Reducing shocks
489232|NCT00743509|sarcoma
489233|NCT00743509|Cyclophosphamide
489234|NCT00743509|Sirolimus
489235|NCT00743509|Progressive or recurrent, advanced (unresectable or metastatic) high-grade osteosarcoma, Ewing's or soft tissue sarcoma previously treated with chemotherapy.
489236|NCT00743483|cystic fibrosis
489237|NCT00743483|pancreatic insufficiency
489238|NCT00743483|bucelipase alfa
489239|NCT00743483|bile salt stimulating lipase
489240|NCT00743483|BSSL
489241|NCT00743483|coefficient of fat absorption
489242|NCT00743470|HIV co-infected with tuberculosis
489243|NCT00743457|Possible VPS failure with symptom such as headache
489244|NCT00743457|vomiting
489245|NCT00743457|lethargy
489246|NCT00743457|VPS failure
489247|NCT00743444|GERD
489248|NCT00743444|transient lower esophageal sphincter relaxations (TLESRs)
489249|NCT00743444|reflux
489250|NCT00743405|M1 receptor agonist
489251|NCT00743405|schizophrenia
489252|NCT00743405|GSK1034702
489253|NCT00743405|safety
489254|NCT00743405|pharmacokinetics
489255|NCT00743379|Phase 1/2
489256|NCT00743379|Advanced Solid Tumors
489257|NCT00743379|Hypoxia
489258|NCT00743379|Prodrug
489259|NCT00743379|Dose-Escalation
489260|NCT00743379|Evofosfamide
489261|NCT00743366|quetiapine
489262|NCT00743366|smoked marijuana
489263|NCT00743366|marijuana use
489264|NCT00743353|laryngeal
489265|NCT00743353|squamous cell
489266|NCT00743353|anaplastic astrocytoma
489267|NCT00743353|oligodendroglioma
489268|NCT00743353|glioblastoma multiforme
489269|NCT00743340|HIV-1 infection
489270|NCT00743340|emtricitabine
489271|NCT00743340|pediatrics
489272|NCT00743340|pediatric patients
489273|NCT00743327|hormone therapy
489274|NCT00743314|lymphedema
489275|NCT00743314|stage I breast cancer
489276|NCT00743314|stage II breast cancer
489277|NCT00743301|CVD
489278|NCT00743301|Palm olein
489279|NCT00743301|Olive oil
489280|NCT00743301|Lard
489281|NCT00743301|healthy men
489282|NCT00743301|metabolic syndrome
489283|NCT00743301|Risk of cardiovascular disease and metabolic syndrome
489284|NCT00743288|stage I multiple myeloma
489285|NCT00743288|stage II multiple myeloma
489286|NCT00743288|stage III multiple myeloma
489287|NCT00743288|refractory multiple myeloma
489288|NCT00743275|Influenza
489289|NCT00743262|laryngectomy
489290|NCT00743262|larynx cancer
489291|NCT00743249|Dry eye
489292|NCT00743249|Tear duct
489293|NCT00743249|Punctal plug
489294|NCT00743236|perioperative/postoperative complications
489295|NCT00743236|urinary complications
489296|NCT00743236|long-term effects secondary to cancer therapy in adults
489297|NCT00743236|stage I renal cell cancer
489298|NCT00743223|temporomandibular disorder
489299|NCT00743223|orofacial pain
489300|NCT00743223|posture of the head
489301|NCT00743210|pregnancy
489302|NCT00743210|obesity
489303|NCT00743210|asymmetric dimethylarginine
489304|NCT00743210|L-arginine
489305|NCT00743210|L-citrulline
489306|NCT00743197|coronary artery disease (CAD)
489307|NCT00743197|chest pain
489308|NCT00743197|myocardial ischemia
489309|NCT00743197|endothelial function
489310|NCT00743184|BPH
489311|NCT00743184|LUTS
489312|NCT00743184|Lower urinary tract symptoms (LUTS)
489313|NCT00743171|Lung transplantation
489314|NCT00743171|Home spirometry
489315|NCT00743171|non-adherence
489316|NCT00743171|outcomes
489317|NCT00743171|bronchiolitis obliterans
489318|NCT00742170|opioid dependence
489319|NCT00742170|opioid detoxification
489320|NCT00742170|electroacupuncture
489321|NCT00742170|adjunctive treatment
489322|NCT00742170|alternative/complementary medicine
489323|NCT00742157|Growth Hormone
489324|NCT00742157|TPN
489325|NCT00742157|Total Parenteral Nutrition
489326|NCT00742157|Glutamine
489327|NCT00742157|Short Bowel Syndrome
489328|NCT00742157|Increase in absorption of small bowel.
489329|NCT00742144|CD20 positive
489330|NCT00742144|Chronic lymphocytic leukemia
489331|NCT00742144|Follicular lymphoma
489332|NCT00742144|GSK1841157
489333|NCT00742144|Japanese patient
489334|NCT00742144|Ofatumumab
489335|NCT00742131|MET inhibitor
489336|NCT00742131|c-Met
489337|NCT00742131|XL880
489338|NCT00742131|GSK1363089
489339|NCT00742131|Solid Tumors
489340|NCT00742105|PI3K
489341|NCT00742105|mTOR
489342|NCT00742105|Advanced solid tumor
489343|NCT00742105|Adult
489344|NCT00742079|Paranoid Schizophrenia
489345|NCT00742079|Paranoid Delusions
489346|NCT00742079|CBT
489347|NCT00742079|D-Cycloserine
489348|NCT00742066|Hypertension
489349|NCT00742066|Insulin resistance
489350|NCT00742066|Microcirculation
489351|NCT00742066|Angiotensin II receptor blocker
489352|NCT00742053|ECG PICC
489353|NCT00742053|Patients undergoing PICC placement
489354|NCT00742040|up-titration
489355|NCT00742040|captopril
489356|NCT00742040|pediatric
489357|NCT00742040|cardiac patients
489358|NCT00742027|Classical Hodgkin Lymphoma
489359|NCT00742027|Classical Hodgkin's Lymphoma
489360|NCT00742027|Hodgkin Lymphoma
489361|NCT00742027|Hodgkin's Lymphoma
489362|NCT00742027|Nodular sclerosing
489363|NCT00742027|Mixed-cellularity
489364|NCT00742027|Lymphocyte-rich
489365|NCT00742027|Lymphocyte depleted
489366|NCT00742027|HL
489367|NCT00742027|Classical HL
489368|NCT00742027|Refractory Hodgkin's Lymphoma
489369|NCT00742027|Refractory Hodgkin Lymphoma
489370|NCT00742027|Refractory HL
489371|NCT00742014|Pulmonary arterial hypertension
489372|NCT00742014|Pediatrics
489373|NCT00742014|Sildenafil
489374|NCT00742014|Catheterization
489375|NCT00742014|Right ventricular contractility
489376|NCT00742001|red blood cells
489377|NCT00742001|transfusion
489378|NCT00742001|recovery
489379|NCT00742001|feasibility
489380|NCT00742001|white blood cell inactivation
489381|NCT00741988|Non-Small Cell Lung Cancer
489382|NCT00741988|Advanced Disease
489383|NCT00741988|Untreated
489384|NCT00741988|Ixabepilone
489385|NCT00741988|Carboplatin
489386|NCT00741988|Bevacizumab
489387|NCT00741975|HIV prevention
489388|NCT00741949|Respiratory failure
489389|NCT00741949|Target Controlled Infusion
489390|NCT00741949|TCI
489391|NCT00741949|Propofol
489392|NCT00741949|Noninvasive ventilation
489393|NCT00741949|Broncho-alveolar lavage
489394|NCT00741936|Functional Constipation
489395|NCT00741936|Chinese Herbal Medicine
489396|NCT00741936|MaZiRenWan
489397|NCT00741936|Hemp Seed Pill
489398|NCT00741936|Traditional Chinese Medicine
489399|NCT00741936|Herbal Medicine
489400|NCT00743158|ztr
489401|NCT00743158|transfer impedance
489402|NCT00743158|cystic fibrosis
489403|NCT00743158|pulmonary function test
489404|NCT00743158|pft
489405|NCT00743145|naltrexone
489406|NCT00743145|smoked marijuana
489407|NCT00743145|marijuana use
489408|NCT00743132|evaluation
489409|NCT00743132|incidence
489410|NCT00743132|liver surgery
489411|NCT00743132|resection
489412|NCT00743132|impact
489413|NCT00743132|postoperative
489414|NCT00743132|mortality
489415|NCT00743119|oral thc
489416|NCT00743119|smoked marijuana
489417|NCT00743119|pain
489418|NCT00743119|analgesic effects
489419|NCT00743106|nephrectomy
489420|NCT00743106|fenoldopam
489421|NCT00743106|atrophic minimally functioning kidney
489422|NCT00743093|acetaminophen
489423|NCT00743093|protein adducts
489424|NCT00743093|drug safety
489425|NCT00743093|alanine aminotransferase
489426|NCT00743093|Alanine Amino Transferase
489427|NCT00743080|laparoscopy
489428|NCT00743080|myomectomy
489429|NCT00743080|myomas
489430|NCT00743080|morcellator
489431|NCT00743080|supracervical hysterectomy
489432|NCT00743080|surgery
489433|NCT00743080|symptomatic uterine myomas
489434|NCT00743067|XL880
489435|NCT00743067|MET inhibitor
489436|NCT00743067|GSK1363089
489437|NCT00743067|Solid Tumors
489438|NCT00743067|c-Met
489439|NCT00743054|Carcinoma, Renal Cell
489440|NCT00743054|MicroRNAs
489441|NCT00743041|PTSD, EFT, depression, anxiety, telephone
489442|NCT00743028|Other hematological and non-hematological malignancies
489443|NCT00743002|TT223
489444|NCT00742989|osteopathic
489445|NCT00742989|lymphatic
489446|NCT00742989|treatment
489447|NCT00742989|OLT
489448|NCT00742989|normal
489449|NCT00742976|Weight gain in insulin treated type 2 diabetes
489450|NCT00742976|extracellular volume
489451|NCT00742976|insulin treatment
489452|NCT00742976|sodium retention
489453|NCT00742963|TH-302
489454|NCT00742963|Advanced Soft Tissue Sarcoma
489455|NCT00742963|Doxorubicin
489456|NCT00742963|Phase 1/2
489457|NCT00742950|Corneal incision
489458|NCT00742950|Cataract surgery
489459|NCT00742950|Phacoemulsification
489460|NCT00742950|Surgically induced astigmatism
489461|NCT00742950|Corneal Topography
489462|NCT00742937|Hypovitaminosis A
489463|NCT00742924|metastatic osteosarcoma
489464|NCT00742911|Solid Tumors, Liver
489465|NCT00742898|Quasi-experimental design
489466|NCT00742898|Non-targeted opt-out rapid HIV screening
489467|NCT00742898|Diagnostic rapid HIV testing
489468|NCT00742898|Emergency department
489469|NCT00742898|Effectiveness
489470|NCT00742898|Efficiency
489471|NCT00742898|Health services research
489472|NCT00742898|Program evaluation
489473|NCT00742898|Effectiveness and efficiency of non-targeted rapid HIV screening in the ED
489474|NCT00742885|Immunogenicity
489475|NCT00742885|Safety
489476|NCT00742885|Pandemic Influenza
489477|NCT00742872|Mosapride
489478|NCT00742872|Irritable Bowel Syndrome
489479|NCT00742872|Constipation
489480|NCT00742859|Atrial Fibrillation
489481|NCT00742859|Betrixaban
489482|NCT00742859|Factor Xa inhibitor
489483|NCT00742859|Warfarin
489484|NCT00742846|Adhesive Capsulitis
489485|NCT00742846|Subacromial injection
489486|NCT00742846|Intraarticular injection
489487|NCT00742833|Overactive bladder
489488|NCT00742833|Frequency
489489|NCT00742833|Micturition
489490|NCT00742833|Urgency
489491|NCT00742833|Urge urinary incontinence
489492|NCT00742833|β3-agonist
489493|NCT00742820|bioequivalence
489494|NCT00742807|sensation
489495|NCT00742807|relief
489496|NCT00742807|during
489497|NCT00742807|surgery
489498|NCT00742781|Crohn's
489499|NCT00742781|vitamin D
489500|NCT00742768|absorption
489501|NCT00742768|encapsulation
489502|NCT00742768|menaquinone
489503|NCT00742768|Bio-availability
489504|NCT00742755|Follow-up of breast abnormalities
489505|NCT00742755|Korean American immigrants
489506|NCT00742742|Walnut
489507|NCT00742742|Lipids
489508|NCT00742742|Blood Glucose
489509|NCT00742729|Colorectal cancer screening
489510|NCT00742729|Fecal occult blood test
489511|NCT00742729|Endoscopies
489512|NCT00742729|Filipino American immigrants
489513|NCT00742729|Community based organizations and churches
489514|NCT00742716|Parathyroid Diseases
489515|NCT00742716|Renal Insufficiency
489516|NCT00742716|Kidney Failure, Chronic
489517|NCT00742716|Hyperparathyroidism, Secondary
489518|NCT00742716|Vitamin D
489519|NCT00742716|Hyperparathyroidism
489520|NCT00742716|Renal Insufficiency, Chronic
489521|NCT00742716|Kidney Diseases
489522|NCT00742716|Kidney Failure
489523|NCT00742690|cirrhosis
489524|NCT00742690|type 1 hepatorenal syndrome
489525|NCT00742690|terlipressin
489526|NCT00742690|albumin
489527|NCT00742690|effective circulating volume
489528|NCT00742690|Patients
489529|NCT00742690|with
489530|NCT00742677|female reproductive cancer
489531|NCT00742664|Prader-Willi Syndrome
489532|NCT00742664|Compulsive behavior
489533|NCT00742664|Hoarding
489534|NCT00742664|Obsessive-compulsive disorder
489535|NCT00742664|Children
489536|NCT00742664|Treatment
489537|NCT00742664|genetically
489538|NCT00742664|confirmed
489539|NCT00742664|diagnosis
489540|NCT00742638|CCMD-3,
489541|NCT00742638|CRF,
489542|NCT00742638|EPS,
489543|NCT00742638|GCP,
489544|NCT00742638|ICH,
489545|NCT00742638|ITT,
489546|NCT00742638|LOCF,
489547|NCT00742638|MADRS,
489548|NCT00742638|PANSS,
489549|NCT00742638|YMRS.
489550|NCT00742638|Acute
489551|NCT00742638|manic
489552|NCT00742638|patients
489553|NCT00742638|with
489554|NCT00742638|bipolar
489555|NCT00742638|disorder
489556|NCT00742612|Carotid Endarterectomy
489557|NCT00742612|von Willebrand Factor
489558|NCT00742612|Microembolic Signal
489559|NCT00742599|Stomach Diseases
489560|NCT00742586|Gene Expression Changes in Blood Cells
489561|NCT00742586|RNA
489562|NCT00742586|Pure Autonomic Failure
489563|NCT00742586|Multiply System Atrophy
489564|NCT00742586|Parkinson's Plus
489565|NCT00742573|Major Depressive Disorder
489566|NCT00742573|Mood Disorders
489567|NCT00742573|Hispanic
489568|NCT00742560|Multiple Myeloma
489569|NCT00742547|prevention
489570|NCT00742547|health services research
489571|NCT00742534|Bronchopulmonary Dysplasia
489572|NCT00742534|Prematurity
489573|NCT00742534|Lung Disease
489574|NCT00742534|preterm infants
489575|NCT00742521|cortisol
489576|NCT00742521|catecholamines
489577|NCT00742521|Type 1 DM
489578|NCT00742508|carvedilol phosphate
489579|NCT00742508|ß-blocker
489580|NCT00742508|SK&F-105517-D
489581|NCT00742508|Chronic heart failure(CHF)
489582|NCT00742469|TD
489583|NCT00742469|traveller's diarrhea
489584|NCT00742469|campylobacter
489585|NCT00742469|shigella
489586|NCT00742469|salmonella
489587|NCT00742469|E. coli
489588|NCT00742469|diarrhea
489589|NCT00742456|Microcirculation
489590|NCT00742456|Insulin
489591|NCT00742456|Hypertension
489592|NCT00742456|Obesity
489593|NCT00742443|Scar Revision
489594|NCT00742430|aspirin resistance
489595|NCT00742430|coronary artery disease
489596|NCT00742430|clopidogrel resistance
489597|NCT00742430|major adverse cardiac events
489598|NCT00742430|multiplate platelet function analyser
489599|NCT00742430|percutaneous coronary intervention
489600|NCT00742417|Alzheimer's
489601|NCT00742417|Dementia
489602|NCT00742417|Senile
489603|NCT00742417|Loss of cognitive abilities
489604|NCT00742417|Old age
489605|NCT00742417|Elderly
489606|NCT00742417|Aging
489607|NCT00742417|Albumin
489608|NCT00742417|Caregiver
489609|NCT00742417|amyloid
489610|NCT00742417|beta amyloid
489611|NCT00742417|Central Nervous System Diseases
489612|NCT00742417|Brain Disease
489613|NCT00742417|Mental Disorders
489614|NCT00742417|Plasma Exchange
489615|NCT00742404|stage I multiple myeloma
489616|NCT00742404|stage II multiple myeloma
489617|NCT00742404|stage III multiple myeloma
489618|NCT00742391|Peplin
489619|NCT00742391|Actinic keratosis
489620|NCT00742391|PEP005
489621|NCT00742378|Glaucoma
489622|NCT00742378|Retinal nerve fiber layer
489623|NCT00742378|Cirrus OCT
489624|NCT00742365|Seasonal Affective Disorder
489625|NCT00742365|Light Therapy
489626|NCT00742365|Seasonal Depression
489627|NCT00742365|Psychiatric Disorder
489628|NCT00742365|Bright Light
489629|NCT00742365|Major Depressive Disorder
489630|NCT00742365|Bipolar Disorder
489631|NCT00742339|cirrhosis
489632|NCT00742339|hepatorenal syndrome
489633|NCT00742339|terlipressin
489634|NCT00742339|midodrine
489635|NCT00742339|octreotide
489636|NCT00742339|human albumin
489637|NCT00742339|effective circulating volume
489638|NCT00742339|The criteria which will be used for the diagnosis of HRS will be the criteria which were recently published by the International Ascites Club
489639|NCT00742339|Patients with cirrhosis and type 2 HRS only with serum creatinine value > 2.5 mg/dl
489640|NCT00742339|All patients with cirrhosis and type 1 HRS
489641|NCT00742326|HIV
489642|NCT00742326|Hepatitis C
489643|NCT00742326|Liver Disease
489644|NCT00742326|Fatty Liver
489645|NCT00742326|Steatosis
489646|NCT00742313|Endoscopic
489647|NCT00742313|saphenous
489648|NCT00742313|vein
489649|NCT00742313|harvest
489650|NCT00742300|ASCT
489651|NCT00742300|Tolerance induction
489652|NCT00742300|SLE
489653|NCT00742300|Transplantation
489654|NCT00742300|Autoimmune diseases
489655|NCT00742287|smoking
489656|NCT00742287|oligomeric proanthocyanidins
489657|NCT00742287|polyphenols
489658|NCT00742287|supplementation
489659|NCT00742287|vascular function
489660|NCT00742287|oxidative stress
489661|NCT00742287|inflammation
489662|NCT00742261|Pharmacokinetics
489663|NCT00742261|Safety
489664|NCT00742261|MET
489665|NCT00742261|Bioavailability
489666|NCT00742261|Patients
489667|NCT00742261|GSK1363089A
489668|NCT00742261|GSK1363089G
489669|NCT00742261|GSK1363089
489670|NCT00742261|Relative
489671|NCT00742248|COPD
489672|NCT00742222|Electronic brachytherapy registry
489673|NCT00742222|Multi-society registry
489674|NCT00742222|Breast cancer registry
489675|NCT00742209|migraine
489676|NCT00742209|prophylaxis
489677|NCT00742209|prevention
489678|NCT00742196|Parapapillary atrophy
489679|NCT00742196|Retinal nerve fiber layer thickness
489680|NCT00742196|Glaucoma
489681|NCT00742196|Cirrus OCT
489682|NCT00741923|beans
489683|NCT00741923|pulses
489684|NCT00741923|satiety
489685|NCT00741923|appetite
489686|NCT00741923|obesity
489687|NCT00741923|overweight
489688|NCT00741923|diabetes
489689|NCT00741923|metabolic syndrome
489690|NCT00741923|hypertension
489691|NCT00741923|blood glucose
489692|NCT00741923|insulin
489693|NCT00741923|cholesterol
489694|NCT00741923|HDL
489695|NCT00741923|LDL
489696|NCT00741923|leptin
489697|NCT00741923|GLP-1
489698|NCT00741923|adiponectin
489699|NCT00741923|Peptide YY
489700|NCT00741923|diet
489701|NCT00741910|Crohn's Disease
489702|NCT00741910|TNF-alpha inhibitor
489703|NCT00741910|MAP Kinase inhibitor
489704|NCT00741910|CNI-1493
489705|NCT00741871|Lymphoid malignancies
489706|NCT00741871|Hodgkin's Lymphoma
489707|NCT00741871|Diffuse large B cell lymphoma
489708|NCT00741858|Chiari malformation;
489709|NCT00741858|Duraplasty;
489710|NCT00741858|Posterior fossa decompression;
489711|NCT00741858|Duragen;
489712|NCT00741858|Duraguard
489713|NCT00741832|chronic obstructive pulmonary disease
489714|NCT00741832|dynamic hyperinflation
489715|NCT00741832|dyspnea
489716|NCT00741832|recovery
489717|NCT00741832|positive expiratory pressure
489718|NCT00741832|exercise
489719|NCT00741819|pulmonary arterial hypertension
489720|NCT00741819|PAH
489721|NCT00741819|treprostinil sodium
489722|NCT00741819|inhalation
489723|NCT00741819|ventavis
489724|NCT00741819|iloprost
489725|NCT00741806|vaccination
489726|NCT00741806|avian
489727|NCT00741793|Rheumatoid arthritis; psoriatic arthritis; axial spondyloarthritis
489728|NCT00741793|Remicade®
489729|NCT00741793|Simponi®
489730|NCT00741793|Simponi® I.V
489731|NCT00741793|Stelara®
489732|NCT00741793|Registry
489733|NCT00741793|BioTRAC
489734|NCT00741767|Chronic Obstructive Pulmonary Disease
489735|NCT00741767|COPD
489736|NCT00741767|Sleep
489737|NCT00741767|Sleep quality
489738|NCT00741767|Lung hyperinflation
489739|NCT00741754|salivary flow
489740|NCT00741754|oral neoplasm
489741|NCT00741754|calcium hydroxide
489742|NCT00741754|sodium dodecylsulphate
489743|NCT00741754|radiotherapy.
489744|NCT00741741|TMC278-C150
489745|NCT00741741|TMC278-TiDP15-C150
489746|NCT00741741|HIV-1 infected patients
489747|NCT00741741|Intramuscular or subcutaneous injection
489748|NCT00741741|Nanosuspension
489749|NCT00741741|Therapy
489750|NCT00741741|Prevention
489751|NCT00741741|Healthy volunteers
489752|NCT00741741|HIV Infections
489753|NCT00741728|epidemiology
489754|NCT00741728|risk factors
489755|NCT00741728|heart rate
489756|NCT00741728|baroreflex sensitivity
489757|NCT00741728|sudden death
489758|NCT00741715|primary hypercholesterolemia
489759|NCT00741702|Hypertension
489760|NCT00741702|Type 2 diabetes
489761|NCT00741702|First Nations populations
489762|NCT00741689|Japanese
489763|NCT00741689|healthy
489764|NCT00741689|volunteers
489765|NCT00741663|cirrhosis
489766|NCT00741663|ascites
489767|NCT00741663|diuretic therapy
489768|NCT00741663|potassium canrenoate
489769|NCT00741663|furosemide
489770|NCT00741663|hyperkalemia
489771|NCT00741663|plasma renin activity
489772|NCT00741663|nitric oxide
489773|NCT00741663|serum sodium concentration
489774|NCT00741663|refractory ascites
489775|NCT00741663|Nonazotemic patients with cirrhosis and moderate ascites
489776|NCT00741650|Musculoskeletal pain
489777|NCT00741650|Brief cognitive intervention
489778|NCT00741650|Cognitive behavior therapy
489779|NCT00741650|Intervention Study
489780|NCT00741650|Health prevention
489781|NCT00741650|workplace intervention
489782|NCT00741637|Vibrio Cholerae
489783|NCT00741637|Diarrhea
489784|NCT00741637|Live oral Vaccines
489785|NCT00741637|Immunogenicity
489786|NCT00741637|Safety
489787|NCT00741637|HIV
489788|NCT00741624|refractive surgery
489789|NCT00741585|Ambulatory blood pressure monitoring
489790|NCT00741585|Chronotherapy
489791|NCT00741585|Circadian
489792|NCT00741585|Non-dipper
489793|NCT00741585|Type 2 diabetes
489794|NCT00741585|Resistant hypertension
489795|NCT00741585|Total mortality
489796|NCT00741572|sarcoidosis
489797|NCT00741572|fibrosis
489798|NCT00741572|oxidative stress
489799|NCT00741572|inflammation
489800|NCT00741572|triggers
489801|NCT00741572|individual sensitivity
489802|NCT00741559|epilepsy
489803|NCT00741559|pediatrics
489804|NCT00741559|magnetoencephalography
489805|NCT00741559|electroencephalography
489806|NCT00741559|positron emission tomography
489807|NCT00741546|Vitamin D
489808|NCT00741546|malnutrition
489809|NCT00741546|cardiac surgery
489810|NCT00741546|study
489811|NCT00741546|emphasize
489812|NCT00741546|importance
489813|NCT00741546|significant
489814|NCT00741546|high risk patient
489815|NCT00741520|Obstructive Sleep Apnea
489816|NCT00741520|Blood Pressure
489817|NCT00741520|PreHypertension
489818|NCT00741520|Masked Hypertension
489819|NCT00741507|Anesthetics
489820|NCT00741507|Sedatives
489821|NCT00741507|Analgesics
489822|NCT00741494|infertility
489823|NCT00741494|ICSI
489824|NCT00741494|hyaluronan binding
489825|NCT00741494|sperm
489826|NCT00741494|sperm selection
489827|NCT00741494|male factor
489828|NCT00741494|hyaluronan
489829|NCT00741494|sperm maturity
489830|NCT00741494|clinical pregnancy rates
489831|NCT00741494|hyaluronan binding assay
489832|NCT00741494|HBA
489833|NCT00741494|PICSI
489834|NCT00741481|metastatic colorectal cancer
489835|NCT00741481|fdg pet
489836|NCT00741481|response evaluation
489837|NCT00741468|Drug-drug interactions
489838|NCT00741468|DDI
489839|NCT00741455|Non-myeloablative transplant
489840|NCT00741455|Chronic Myelogenous Leukemia
489841|NCT00741455|Acute Myelogenous Leukemia
489842|NCT00741455|Acute Lymphoblastic Leukemia
489843|NCT00741455|Multiple Myeloma
489844|NCT00741455|Non-Hodgkin's Lymphoma
489845|NCT00741455|Myelodysplastic syndrome
489846|NCT00741455|Chronic Lymphocytic Leukemia
489847|NCT00741455|Hodgkin's Disease
489848|NCT00741416|Heart Disease
489849|NCT00741416|Biorepository
489850|NCT00741416|Biobank
489851|NCT00741403|Phase I
489852|NCT00741403|malignancies
489853|NCT00741403|refractory
489854|NCT00741403|relapsed
489855|NCT00741390|Diabetes
489856|NCT00741390|Lancets
489857|NCT00741390|Pain
489858|NCT00741377|Multiple myeloma
489859|NCT00741377|bone disease
489860|NCT00741377|antibody
489861|NCT00741364|vitamin D
489862|NCT00741364|prostate cancer
489863|NCT00741364|prostatectomy
489864|NCT00741364|pathology
489865|NCT00741364|immunohistochemistry
489866|NCT00741351|Anesthesia
489867|NCT00741351|Craniotomy
489868|NCT00741351|Neurosurgery
489869|NCT00741338|MPS I, Mucopolysaccharidosis, Hurler syndrome
489870|NCT00741312|pregnancy
489871|NCT00741312|preeclampsia
489872|NCT00741312|exercise
489873|NCT00741299|bipolar affective disorder, Smoking
489874|NCT00741286|Cerebral infarction
489875|NCT00741286|Cilostazol
489876|NCT00741286|Aspirin
489877|NCT00741286|Transcranial Doppler
489878|NCT00741286|Pulsatile Index
489879|NCT00741260|solid tumor
489880|NCT00741260|erbB2+ breast cancer
489881|NCT00741260|prior Herceptin
489882|NCT00741260|metastatic
489883|NCT00741247|staging
489884|NCT00741247|Endobronchial ultrasound
489885|NCT00741247|Endoscopic ultrasound
489886|NCT00741234|SB939
489887|NCT00741234|Myelodysplastic Syndrome
489888|NCT00741234|Combination with azacitidine
489889|NCT00741234|Solid malignancies
489890|NCT00741234|Hematologic malignancies
489891|NCT00741234|HDAC inhibitor
489892|NCT00741234|Refractory to standard therapy
489893|NCT00741221|Cancer
489894|NCT00741221|NSCLC
489895|NCT00741221|Docetaxel
489896|NCT00741221|Bevacizumab
489897|NCT00741208|asthma
489898|NCT00741208|soy isoflavone
489899|NCT00741208|genistein
489900|NCT00741208|soy
489901|NCT00741195|Cancer
489902|NCT00741195|NSCLC
489903|NCT00741195|Docetaxel
489904|NCT00741195|Bevacizumab
489905|NCT00741182|Fracture
489906|NCT00741182|Osteoporosis
489907|NCT00741182|Forsteo
489908|NCT00741182|Teriparatide
489909|NCT00741182|Fracture healing
489910|NCT00741169|TMC435350-TiDP16-C105
489911|NCT00741169|TMC435350-C105
489912|NCT00741169|Hepatitis C
489913|NCT00741169|HCV
489914|NCT00741169|Rifampin
489915|NCT00741156|pediatric
489916|NCT00741156|hypertension
489917|NCT00741156|congestive cardiomyopathy
489918|NCT00741156|angiotensin-converting enzyme inhibitor
489919|NCT00741156|cardiac catheterization
489920|NCT00741143|Food Fortification
489921|NCT00741143|Iron deficiency
489922|NCT00741143|NaFeEdta
489923|NCT00741143|Iron deficiency anemia
489924|NCT00741143|Cognition
490052|NCT00740662|gastric bypass
489925|NCT00741130|retinal nerve fiber layer
489926|NCT00741130|optic nerve head
489927|NCT00741130|Cirrus OCT
489928|NCT00741117|Pulse Oximetry
489929|NCT00741117|Blood Gas Analysis
489930|NCT00741117|Liver Disease
489931|NCT00741117|Hyperbilirubinemia
489932|NCT00741091|Cerebrovascular Disease
489933|NCT00741091|Carotid Stent
489934|NCT00741091|Stent
489935|NCT00741091|Carotid Endarterectomy (CEA)
489936|NCT00741078|endothelial
489937|NCT00741078|function
489938|NCT00741078|insulin
489939|NCT00741078|sensitivity
489940|NCT00741065|Coronary Artery Bypass Grafting
489941|NCT00741065|Myocardial Regeneration
489942|NCT00741052|V. cholerae,
489943|NCT00741052|ciprofloxacin,
489944|NCT00741052|azithromycin,
489945|NCT00741052|randomized
489946|NCT00741039|Breast
489947|NCT00741039|Lung
489948|NCT00741039|Prostate
489949|NCT00741039|Vaccine
489950|NCT00741026|Insulin Resistance
489951|NCT00741026|Diabetes mellitus
489952|NCT00741026|Antipsychotic
489953|NCT00741013|randomized
489954|NCT00741013|positron emission tomography
489955|NCT00741013|lung inflammation
489956|NCT00741013|lovastatin
489957|NCT00741013|recombinant human activated protein C
489958|NCT00741013|endotoxin
489959|NCT00741013|fluorodeoxyglucose
489960|NCT00740987|Mechanical device
489961|NCT00740987|Intermittent pneumatic compression
489962|NCT00740987|Venous thromboembolism prophylaxis
489963|NCT00740987|Intensive care unit
489964|NCT00740987|Hospitalization
489965|NCT00740987|Intensive
489966|NCT00740987|Care
489967|NCT00740987|Unit
489968|NCT00739986|Crohn's Disease
489969|NCT00739986|TNF-alpha
489970|NCT00739986|IL-6
489971|NCT00739986|MAP Kinase
489972|NCT00739986|CNI-1493
489973|NCT00739973|Hypertension, Aliskiren, Amlodipine
489974|NCT00740961|psychosocial effects of cancer and its treatment
489975|NCT00740961|cognitive/functional effects
489976|NCT00740961|breast cancer
489977|NCT00740961|colon cancer
489978|NCT00740948|Sjogren's disease
489979|NCT00740948|Rituximab
489980|NCT00740948|Treatment
489981|NCT00740948|anti CD20
489982|NCT00740935|prevention
489983|NCT00740935|rotavirus vaccine
489984|NCT00740935|gastroenteritis
489985|NCT00740935|systematic vaccination
489986|NCT00740935|infants
489987|NCT00740935|aged 6 to 12 weeks
489988|NCT00740922|Becaplermin gel
489989|NCT00740922|Target Ulcer
489990|NCT00740922|Retrospective Studies
489991|NCT00740922|Diabetic Foot
489992|NCT00740922|Neoplasms
489993|NCT00740922|Long-Term Safety
489994|NCT00740922|Topical Administration
489995|NCT00740909|Trich
489996|NCT00740909|Hair Pulling
489997|NCT00740909|Cognitive Behavioral Therapy
489998|NCT00740909|Behavioral Therapy
489999|NCT00740896|Cigarette Smoking
490000|NCT00740896|Airway dendritic cells
490001|NCT00740883|venous thromboembolism
490002|NCT00740883|warfarin
490003|NCT00740883|duration of anticoagulation
490004|NCT00740883|recurrent venous thromboembolism
490005|NCT00740883|anticoagulant-related bleeding
490006|NCT00740870|RVOT
490007|NCT00740870|Dysfunctional
490008|NCT00740870|conduit
490009|NCT00740870|Indications
490010|NCT00740870|Invasive
490011|NCT00740870|intervention
490012|NCT00740870|Tetralogy of Fallot
490013|NCT00740870|Right Ventricular Outflow Tract
490014|NCT00740857|Dental pain analgesia
490015|NCT00740844|Intermittent pneumatic compression
490016|NCT00740844|Hospitalization
490017|NCT00740844|Intensive care unit
490018|NCT00740844|High bleeding risk
490019|NCT00740844|Venous thromboembolism prophylaxis
490020|NCT00740831|Uterine Myomas
490021|NCT00740779|prostatitis, chronic pelvic pain
490022|NCT00740766|Perinatal Outcomes
490023|NCT00740766|Obesity
490024|NCT00740766|Pregnant women
490025|NCT00740753|liver tumor
490026|NCT00740753|cancer
490027|NCT00740753|hepatoma
490028|NCT00740753|yttrium
490029|NCT00740740|Aneurysm
490030|NCT00740740|Rupture
490031|NCT00740727|Disaster
490032|NCT00740727|Mass casualty incident
490033|NCT00740727|Prehospital
490034|NCT00740727|Rehydration
490035|NCT00740727|Intravascular access
490036|NCT00740714|Parkinson disease
490037|NCT00740714|PD
490038|NCT00740714|Coenzyme Q10
490039|NCT00740714|CoQ
490040|NCT00740701|TMS
490041|NCT00740701|fMRI
490042|NCT00740701|verbal working memory
490043|NCT00740701|classical conditioning
490044|NCT00740701|eyeblink
490045|NCT00740701|classical eyeblink conditioning
490046|NCT00740701|Healthy subjects
490047|NCT00740701|Memory
490048|NCT00740675|adverse drug events
490049|NCT00740675|outpatient
490050|NCT00740662|morbid obesity
490051|NCT00740662|small bowel
490053|NCT00740662|weight loss
490054|NCT00740636|TEMOZOLOMIDE
490055|NCT00740636|Lung
490056|NCT00740623|Partial Onset Seizures
490057|NCT00740623|Simple Partial Seizures
490058|NCT00740623|Complex Partial Seizures
490059|NCT00740597|recurrent adult soft tissue sarcoma
490060|NCT00740597|stage I adult soft tissue sarcoma
490061|NCT00740597|stage II adult soft tissue sarcoma
490062|NCT00740597|stage III adult soft tissue sarcoma
490063|NCT00740597|adult alveolar soft-part sarcoma
490064|NCT00740597|adult epithelioid sarcoma
490065|NCT00740597|adult extraskeletal chondrosarcoma
490066|NCT00740597|adult extraskeletal osteosarcoma
490067|NCT00740597|adult fibrosarcoma
490068|NCT00740597|adult malignant fibrous histiocytoma
490069|NCT00740597|adult malignant hemangiopericytoma
490070|NCT00740597|adult malignant mesenchymoma
490071|NCT00740597|adult neurofibrosarcoma
490072|NCT00740597|adult rhabdomyosarcoma
490073|NCT00740597|dermatofibrosarcoma protuberans
490074|NCT00740584|Prevention
490075|NCT00740571|neuralgia
490076|NCT00740571|off-label
490077|NCT00740571|cancer
490078|NCT00740558|HRV
490079|NCT00740558|Activator
490080|NCT00740558|Chiropractic
490081|NCT00740558|VLF
490082|NCT00740558|HF
490083|NCT00740558|LF
490084|NCT00740558|LF/HF
490085|NCT00740532|EGFR, HER-2, HER-3, MET, KRAS
490086|NCT00740506|Behavioral
490087|NCT00740506|Environmental
490088|NCT00740506|Delivery
490089|NCT00740506|Pregnancy
490090|NCT00740493|recurrent venous thromboembolism
490091|NCT00740493|idiopathic deep vein thrombosis
490092|NCT00740493|optimal duration of anticoagulation
490093|NCT00740480|Evaluation
490094|NCT00740480|ENTact™
490095|NCT00740480|Septal
490096|NCT00740480|Staple
490097|NCT00740480|System
490098|NCT00740480|tissue
490099|NCT00740480|approximation
490100|NCT00740480|during
490101|NCT00740480|septoplasties
490102|NCT00740467|graft versus host disease
490103|NCT00740467|adult acute myeloid leukemia in remission
490104|NCT00740467|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
490105|NCT00740467|adult acute myeloid leukemia with inv(16)(p13;q22)
490106|NCT00740467|adult acute myeloid leukemia with t(15;17)(q22;q12)
490107|NCT00740467|adult acute myeloid leukemia with t(16;16)(p13;q22)
490108|NCT00740467|adult acute myeloid leukemia with t(8;21)(q22;q22)
490109|NCT00740467|recurrent adult acute myeloid leukemia
490110|NCT00740467|adult acute lymphoblastic leukemia in remission
490111|NCT00740467|recurrent adult acute lymphoblastic leukemia
490112|NCT00740467|accelerated phase chronic myelogenous leukemia
490113|NCT00740467|chronic phase chronic myelogenous leukemia
490114|NCT00740467|refractory multiple myeloma
490115|NCT00740467|relapsing chronic myelogenous leukemia
490116|NCT00740467|recurrent adult Hodgkin lymphoma
490117|NCT00740467|adult nasal type extranodal NK/T-cell lymphoma
490118|NCT00740467|anaplastic large cell lymphoma
490119|NCT00740467|angioimmunoblastic T-cell lymphoma
490120|NCT00740467|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
490121|NCT00740467|nodal marginal zone B-cell lymphoma
490122|NCT00740467|recurrent adult Burkitt lymphoma
490123|NCT00740467|recurrent adult diffuse large cell lymphoma
490124|NCT00740467|recurrent adult diffuse mixed cell lymphoma
490125|NCT00740467|recurrent adult diffuse small cleaved cell lymphoma
490126|NCT00740467|recurrent adult grade III lymphomatoid granulomatosis
490127|NCT00740467|recurrent adult immunoblastic large cell lymphoma
490128|NCT00740467|recurrent adult lymphoblastic lymphoma
490129|NCT00740467|recurrent adult T-cell leukemia/lymphoma
490130|NCT00740467|recurrent cutaneous T-cell non-Hodgkin lymphoma
490131|NCT00740467|recurrent grade 1 follicular lymphoma
490132|NCT00740467|recurrent grade 2 follicular lymphoma
490133|NCT00740467|recurrent grade 3 follicular lymphoma
490134|NCT00740467|recurrent grade I lymphomatoid granulomatosis
490135|NCT00740467|recurrent grade II lymphomatoid granulomatosis
490136|NCT00740467|recurrent mantle cell lymphoma
490137|NCT00740467|recurrent marginal zone lymphoma
490138|NCT00740467|recurrent small lymphocytic lymphoma
490139|NCT00740467|splenic marginal zone lymphoma
490140|NCT00740467|refractory chronic lymphocytic leukemia
490141|NCT00740454|pregnancy
490142|NCT00740454|postpartum
490143|NCT00740454|deep vein thrombosis
490144|NCT00740454|venous thromboembolism
490145|NCT00740454|diagnosis
490146|NCT00740454|compression ultrasonography
490147|NCT00740441|renal cell carcinoma
490148|NCT00740441|rcc
490149|NCT00740441|kidney cancer
490150|NCT00740428|Pelvic floor,
490151|NCT00740428|muscular dysfunction,
490152|NCT00740428|urinary incontinence
490153|NCT00740415|contiguous stage II mantle cell lymphoma
490154|NCT00740415|noncontiguous stage II mantle cell lymphoma
490155|NCT00740415|stage III mantle cell lymphoma
490156|NCT00740415|stage IV mantle cell lymphoma
490157|NCT00740389|TMC125-C187
490158|NCT00740389|TMC125-TiDP2-C187
490159|NCT00740389|HIV
490160|NCT00740389|AIDS
490161|NCT00740389|Fungal Infection
490162|NCT00740389|Pharmacokinetics
490163|NCT00740376|osteoarthritis
490164|NCT00740363|renal transplantation
490165|NCT00740363|diabetes
490166|NCT00740363|glucose intolerance
490167|NCT00740363|impaired glucose tolerance
490168|NCT00740337|Chronic Obstructive Pulmonary Disease
490169|NCT00740337|COPD
490170|NCT00740337|Emphysema
490171|NCT00740337|Natural Killer T-cell
490172|NCT00740337|Interleukin-13
490173|NCT00740337|Innate Immune Signaling
490174|NCT00740324|During
490175|NCT00740324|Endoscopy
490176|NCT00740324|Gastric
490177|NCT00740324|Peristalsis
490178|NCT00740311|Prevention of the reduction of the alveolar crest
490179|NCT00740298|infants
490180|NCT00740298|undergoing
490181|NCT00740298|vaccinations
490182|NCT00740285|scleroderma
490183|NCT00740285|scleroderma - limited or diffuse types
490184|NCT00740285|lidocaine
490185|NCT00740285|effectiveness
490186|NCT00740272|brady-tachy syndrome
490187|NCT00740272|AF ablation
490188|NCT00740259|flunarizine
490189|NCT00740259|schizophrenia
490190|NCT00740259|antipsychotic
490191|NCT00740233|fibromyalgia
490192|NCT00740233|irritable bowel syndrome
490193|NCT00740233|interstitial cystitis
490194|NCT00740233|chronic fatigue syndrome
490195|NCT00740233|vulvodynia
490196|NCT00740233|chronic stress
490197|NCT00740233|chronic pain
490198|NCT00740233|stress-related conditions
490199|NCT00740233|functional GI disorders
490200|NCT00740220|hypoxemia
490201|NCT00740220|anoxia
490202|NCT00740220|oxygen
490203|NCT00740220|dyspnea
490204|NCT00740220|pulmonary disease
490205|NCT00740220|chronic obstructive
490206|NCT00740194|Physiology
490207|NCT00740194|males
490208|NCT00740181|myelodysplasia
490209|NCT00740181|refractory leukemia
490210|NCT00740181|acute leukemia
490211|NCT00740168|bevacizumab
490212|NCT00740168|cancer
490213|NCT00740155|Dengue virus
490214|NCT00740155|Dengue fever
490215|NCT00740155|Dengue hemorrhagic fever
490216|NCT00740155|Dengue diseases
490217|NCT00740142|L ornithine L aspartate
490218|NCT00740142|Lactulose
490219|NCT00740142|Hepatic encephalopathy
490220|NCT00740142|LOLA
490221|NCT00740129|Paget's Disease
490222|NCT00740129|Zoledronic acid
490223|NCT00740129|Reclast®/Aclasta®
490224|NCT00740129|infusion
490225|NCT00740129|re-treatment
490226|NCT00740129|re-lapse
490227|NCT00740116|Tumor of ovary
490228|NCT00740116|Surgical blood loss
490229|NCT00740116|Postoperative blood loss
490230|NCT00740116|Preventive therapy
490231|NCT00740116|Thromboembolism
490232|NCT00740103|Semapimod
490233|NCT00740103|Crohn's Disease
490234|NCT00740103|TNF-alpha inhibitor
490235|NCT00740103|MAP Kinase inhibitor
490236|NCT00740103|CNI-1493
490237|NCT00740090|Malaria
490238|NCT00740090|Reactogenicity, Safety, Immunogenicity
490239|NCT00740090|Maleria Endemic
490240|NCT00740090|Plasmodium Falciparum
490241|NCT00740090|Dose Escalating
490242|NCT00740077|cranberry
490243|NCT00740077|flavonoid
490244|NCT00740077|phenolic acid
490245|NCT00740077|phytochemical
490246|NCT00740077|bioavailability
490247|NCT00740064|HIV infections
490248|NCT00740038|Stress Management
490249|NCT00740038|Quality of Life
490250|NCT00740038|Exercise
490251|NCT00740038|Cancer
490252|NCT00740038|Chemotherapy
490253|NCT00740025|QD dose
490254|NCT00740025|BID dosing
490255|NCT00740025|peak estradiol
490256|NCT00740025|oocytes
490257|NCT00740025|implantation rate
490258|NCT00740025|pregnancy rate
490259|NCT00740012|Nocturnal glucose profiles
490260|NCT00740012|continuous glucose profiles
490261|NCT00739999|heterozygous familial hypercholesterolemia (HeFH); atorvastatin; pediatric
490262|NCT00739947|Observational
490263|NCT00739947|rotator cuff tear
490264|NCT00739947|arthroscopic
490265|NCT00739947|surgical
490266|NCT00739947|outcome study
490267|NCT00739934|Open-Label
490268|NCT00739934|Pharmacokinetics
490269|NCT00739934|Intravenous to oral switch
490270|NCT00739934|Safety
490271|NCT00739934|Voriconazole
490272|NCT00739934|Immunocompromise
490273|NCT00739934|Children
490274|NCT00739934|High Risk For Systemic Fungal Infection.
490275|NCT00739921|PCR Analysis
490276|NCT00739921|Allergic fungal sinusitis
490277|NCT00739921|Chronic rhinosinusitis
490278|NCT00739921|Nasal Polyps
490279|NCT00739908|MDD
490280|NCT00739895|athletes
490281|NCT00739882|Efalizumab,
490282|NCT00739882|Chronic plaque psoriasis
490283|NCT00739882|moderate to severe
490284|NCT00739882|involving
490285|NCT00739882|hands
490286|NCT00739882|feet
490287|NCT00739869|Silent Infarcts
490288|NCT00739869|Magnetic Resonance Imaging
490289|NCT00739869|MRI
490290|NCT00739869|Subclinical Cerebrovascular Disease
490291|NCT00739869|White Matter Grade Abnormalities
490292|NCT00739869|Total Brain Volume
490293|NCT00739869|Ventricular and Hippocampal Volume
490294|NCT00739869|Subclinical Vascular Abnormalities
490295|NCT00739869|Cerebrovascular Disease
490296|NCT00739869|CVD
490297|NCT00739869|Subclinical CVD
490298|NCT00739856|posttraumatic stress disorder
490299|NCT00739856|electroconvulsive therapy
490300|NCT00739856|medication refractoriness
490301|NCT00739843|Dementia,
490302|NCT00739843|Cognitive Disorders,
490303|NCT00739843|Hemodialysis
490304|NCT00739791|adenocarcinoma of the prostate
490305|NCT00739791|stage I prostate cancer
490306|NCT00739791|stage IIB prostate cancer
490307|NCT00739791|stage IIA prostate cancer
490308|NCT00739765|Trauma
490309|NCT00739765|Psychotherapy
490310|NCT00739765|Anxiety
490311|NCT00739752|Attitude to Health
490312|NCT00739752|Communication
490313|NCT00739752|Intervention Studies
490314|NCT00739752|Health Promotion
490315|NCT00739752|Psychology, Medical
490316|NCT00739752|Sexual Behavior
490317|NCT00739752|Behavioral Research
490318|NCT00739752|Vaccination
490319|NCT00739713|dry eye
490320|NCT00739713|sea buckthorn
490321|NCT00739713|Hippophaë
490322|NCT00739700|hemodynamics
490323|NCT00739700|blood pressure
490324|NCT00739700|blood pressure monitors
490325|NCT00739687|Chronic Heart Failure
490326|NCT00739661|Systemic Hedgehog
490327|NCT00739661|Hedgehog Pathway Inhibitor
490328|NCT00739648|COPD
490329|NCT00739648|Patients
490330|NCT00739622|TMC278-TiDP6-C136
490331|NCT00739622|TMC278-C136
490332|NCT00739622|Healthy Volunteer
490333|NCT00739596|Hypertension
490334|NCT00739596|African American
490335|NCT00739596|aliskiren
490336|NCT00739596|hydrochlorothiazide
490337|NCT00739596|systolic blood pressure
490338|NCT00739596|diastolic blood pressure
490339|NCT00739596|amlodipine
490340|NCT00739596|stage 2
490341|NCT00739583|Skin preparation
490342|NCT00739583|Skin marking
490343|NCT00739583|site marking
490344|NCT00739583|Site identification
490345|NCT00739570|Activator
490346|NCT00739570|EMG
490347|NCT00739570|Thermography
490348|NCT00739570|Diagnostic
490349|NCT00739570|X-Rays
490350|NCT00739557|elective TAAA repair
490351|NCT00739544|Reference Values
490352|NCT00739544|Sensory Thresholds
490353|NCT00739544|Pain Threshold
490354|NCT00739544|Breast Neoplasms
490355|NCT00739531|Asthma
490356|NCT00739531|nitric oxide
490357|NCT00739531|eNO
490358|NCT00739531|FENO
490359|NCT00739531|Apieron INSIGHT
490360|NCT00739531|Aerocrine NIOX
490361|NCT00739518|Neurological
490362|NCT00739518|MRI
490363|NCT00739505|Hypophosphatasia
490364|NCT00739505|Bone Disease
490365|NCT00739505|Soft Bones
490366|NCT00739505|Low Alkaline Phosphatase
490367|NCT00739505|genetic metabolic disorder
490368|NCT00739505|alkaline phosphatase
490369|NCT00739505|tissue non-specific alkaline phosphatase
490370|NCT00739505|rickets
490371|NCT00739505|osteomalacia
490372|NCT00739492|weight loss, obesity, financial incentives
490373|NCT00739479|Metabolic Syndrome
490374|NCT00739479|METS
490375|NCT00739479|Obesity
490376|NCT00739479|Partially Hydrolyzed Whey Protein
490377|NCT00739479|Partially Hydrolyzed Gelatin
490378|NCT00739479|PHWP
490379|NCT00739479|PHG
490380|NCT00739479|Weight Loss
490381|NCT00739466|Liposomal Alendronate
490382|NCT00739466|Percutaneous coronary intervention
490383|NCT00739466|Coronary stenting
490384|NCT00739466|de novo stenotic lesions
490385|NCT00739466|Native coronary arteries
490386|NCT00739466|Restenosis
490387|NCT00739466|Bare metal stent
490388|NCT00739466|Presillion CoCr coronary stent
490389|NCT00739453|Advanced cancer
490390|NCT00739453|Non-small cell lung cancer
490391|NCT00739453|Pancreatic cancer
490392|NCT00739453|Colorectal cancer
490393|NCT00739453|Prostate cancer
490394|NCT00739414|Histone Deacetylases
490395|NCT00739414|HDAC inhibitor
490396|NCT00739414|LBH589
490397|NCT00739414|Advanced solid tumor
490398|NCT00739414|Adult
490399|NCT00739401|AAA
490400|NCT00739401|Aneurysm
490401|NCT00739401|Suprarenal
490402|NCT00739401|Proximal
490403|NCT00739401|Cuff
490404|NCT00739401|Extension
490405|NCT00739401|Endograft
490406|NCT00739401|Endovascular repair
490407|NCT00739401|EVAR
490408|NCT00739401|Endoleak
490409|NCT00739401|Type I
490410|NCT00739388|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
490411|NCT00739388|adult acute myeloid leukemia with inv(16)(p13;q22)
490412|NCT00739388|adult acute myeloid leukemia with t(16;16)(p13;q22)
490413|NCT00739388|adult acute myeloid leukemia with t(8;21)(q22;q22)
490414|NCT00739388|secondary acute myeloid leukemia
490415|NCT00739388|untreated adult acute myeloid leukemia
490416|NCT00739388|adult acute myeloblastic leukemia without maturation (M1)
490417|NCT00739388|adult acute myeloblastic leukemia with maturation (M2)
490418|NCT00739388|adult acute myelomonocytic leukemia (M4)
490419|NCT00739388|adult acute monoblastic leukemia (M5a)
490420|NCT00739388|adult acute monocytic leukemia (M5b)
490421|NCT00739388|adult erythroleukemia (M6a)
490422|NCT00739388|adult pure erythroid leukemia (M6b)
490423|NCT00739388|adult acute megakaryoblastic leukemia (M7)
490424|NCT00739375|Influence
490425|NCT00739375|of av access
490426|NCT00739375|flow
490427|NCT00739375|development
490428|NCT00739362|Behavioral Weight Loss Treatment
490429|NCT00739362|Obesity
490430|NCT00739362|Appetite Control
490431|NCT00739362|Weight Loss
490432|NCT00739362|Transcranial Direct Current Stimulation (TDCS)
490433|NCT00739349|Dry Eye
490434|NCT00739349|Cyclosporine
490435|NCT00739336|diabetes mellitus
490436|NCT00739336|obesity
490437|NCT00739336|prevention
490438|NCT00739310|High Frequency Chest Wall Oscillation
490439|NCT00739310|Cerebral Palsy
490440|NCT00739310|Restrictive lung disease
490441|NCT00739297|Chronic asthma
490442|NCT00739284|preferred
490443|NCT00739284|procedure
490444|NCT00739284|drainage
490445|NCT00739284|obstructed
490446|NCT00739284|kidney
490447|NCT00739284|stone
490448|NCT00739258|HIV-infected person
490449|NCT00739258|Entamoeba
490450|NCT00739258|Cryptosporidium
490451|NCT00739258|Giardia
490452|NCT00739258|ELISA
490453|NCT00739258|PCR
490454|NCT00739258|IDU
490455|NCT00739258|Gonorrhea
490456|NCT00739258|Chlamydial trachomatis
490457|NCT00739258|Syphilis
490458|NCT00739258|Genital warts
490459|NCT00739258|Herpes simplex virus
490460|NCT00739232|Safety and tolerability of HSD-016
490461|NCT00739219|Asthma
490462|NCT00739219|inflammation
490463|NCT00739219|nitric oxide
490464|NCT00739219|eNO
490465|NCT00739219|FENO
490466|NCT00739206|uncomplicated
490467|NCT00739206|severe
490468|NCT00739206|treatment
490469|NCT00739206|Plasmodium Falciparum
490470|NCT00739193|Blood Pressure
490471|NCT00739180|Childhood obesity
490472|NCT00739180|Abdominal obesity
490473|NCT00739180|Visceral fat
490474|NCT00739180|Insulin resistance
490475|NCT00739180|Liver fat
490476|NCT00739180|Skeletal muscle lipid
490477|NCT00739180|Fitness
490478|NCT00739167|adult primary hepatocellular carcinoma
490479|NCT00739167|advanced adult primary liver cancer
490480|NCT00739167|liver metastases
490481|NCT00739167|recurrent adult primary liver cancer
490482|NCT00739154|glaucoma
490483|NCT00739154|Phenytoin
490484|NCT00739154|retinal nerve fiber layer
490485|NCT00739154|corrected pattern standard deviation
490486|NCT00739154|visual acuity
490487|NCT00739154|optic disc cupping
490488|NCT00739141|CYCLOPHOSPHAMIDE (CYTOXAN)
490489|NCT00739141|CYCLOSPORINE A
490490|NCT00739141|FLUDARABINE
490491|NCT00739141|G-CSF
490492|NCT00739141|MYCOPHENOLATE MOFETIL (MMF)
490493|NCT00739141|THI0TEPA
490494|NCT00739141|UMBILICAL CORD BLOOD (UCB)
490495|NCT00739141|08-087
490496|NCT00739128|celiac disease
490497|NCT00739128|hepatitis B vaccine
490498|NCT00739115|Respiratory
490499|NCT00739115|Distress
490500|NCT00739115|Prematurity
490501|NCT00739115|Heliox
490502|NCT00739115|CPAP
490503|NCT00739102|Superficial Femoral Artery
490504|NCT00739102|Nitinol Self-Expandable Stent System
490505|NCT00739089|hemodynamics
490506|NCT00739089|oxygen
490507|NCT00739089|renal dialysis
490508|NCT00739089|shock
490509|NCT00739089|sepsis
490510|NCT00739089|hypotension
490511|NCT00739089|lactic acidosis
490512|NCT00739063|Breast cancer
490513|NCT00739063|Carcinoma of the breast
490514|NCT00739063|Stage IV
490515|NCT00739063|Triple receptor-negative
490516|NCT00739063|Triple receptor-negative breast cancer
490517|NCT00739063|Metastatic triple receptor-negative breast cancer
490518|NCT00739063|Epidermal growth factor receptor
490519|NCT00739063|EGFR
490520|NCT00739063|EGFR-overexpressing
490521|NCT00739063|GFR inhibitor erlotinib
490522|NCT00739063|Erlotinib hydrochloride
490523|NCT00739063|Erlotinib
490524|NCT00739063|Tarceva
490525|NCT00739063|OSI-774
490526|NCT00739024|Migraine
490527|NCT00739024|Headache
490528|NCT00738998|Breast Cancer
490529|NCT00738998|Aromatase Inhibitors
490530|NCT00738998|Symptom Assessment
490531|NCT00738998|Questionnaire
490532|NCT00738998|Survey
490533|NCT00738998|Phone Call
490534|NCT00738998|Arimidex
490535|NCT00738998|Anastrozole
490536|NCT00738959|AZD0328
490537|NCT00738959|Japanese
490538|NCT00738959|Caucasian
490539|NCT00738959|pharmacokinetics
490540|NCT00738959|safety
490541|NCT00738959|tolerability
490542|NCT00738946|Intermittent Preventive treatment
490543|NCT00738946|insecticide treated bednets
490544|NCT00738946|malaria
490545|NCT00738933|Atherosclerosis
490546|NCT00738933|Plant sterols
490547|NCT00738933|Plant stanols
490548|NCT00738933|Aortic valve
490549|NCT00738907|Type 1 diabetes
490550|NCT00738894|cryptogenic
490551|NCT00738894|stroke
490552|NCT00738894|transient ischemic attack
490553|NCT00738894|TIA
490554|NCT00738894|PFO
490555|NCT00738894|Patent foramen ovale
490556|NCT00738894|HELEX
490557|NCT00738894|Septal Occluder
490558|NCT00738894|PFO Occluder
490559|NCT00738868|recurrent squamous cell carcinoma of the hypopharynx
490560|NCT00738868|stage III squamous cell carcinoma of the hypopharynx
490561|NCT00738868|stage III squamous cell carcinoma of the larynx
490562|NCT00738868|stage III verrucous carcinoma of the larynx
490563|NCT00738868|recurrent squamous cell carcinoma of the larynx
490564|NCT00738868|recurrent verrucous carcinoma of the larynx
490565|NCT00738868|recurrent squamous cell carcinoma of the lip and oral cavity
490566|NCT00738868|stage III squamous cell carcinoma of the lip and oral cavity
490567|NCT00738868|recurrent verrucous carcinoma of the oral cavity
490568|NCT00738868|stage III verrucous carcinoma of the oral cavity
490569|NCT00738868|recurrent squamous cell carcinoma of the nasopharynx
490570|NCT00738868|stage III squamous cell carcinoma of the nasopharynx
490571|NCT00738868|recurrent squamous cell carcinoma of the oropharynx
490572|NCT00738868|stage III squamous cell carcinoma of the oropharynx
490573|NCT00738868|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
490574|NCT00738868|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
490575|NCT00738868|recurrent salivary gland cancer
490576|NCT00738868|salivary gland squamous cell carcinoma
490577|NCT00738868|stage III salivary gland cancer
490578|NCT00738855|Adhesions
490579|NCT00738855|Oral contrast
490580|NCT00738855|Exploration
490581|NCT00738842|Uric
490582|NCT00738842|Acid
490583|NCT00738842|Level
490584|NCT00738829|CLL
490585|NCT00738829|untreated
490586|NCT00738829|immune therapy
490587|NCT00738829|dose escalation
490588|NCT00738829|maximum tolerated dose
490589|NCT00738829|maintenance therapy
490590|NCT00738829|Lenalidomide
490591|NCT00738829|Rituximab
490592|NCT00738829|Fludarabine
490593|NCT00738816|Medication review
490594|NCT00738816|Patient
490595|NCT00738816|Safety
490596|NCT00738816|Drug
490597|NCT00738816|Prescriptions
490598|NCT00738816|Drug-use
490599|NCT00738803|leg length
490600|NCT00738803|hip arthroplasty
490601|NCT00738803|offset
490602|NCT00738790|rectal cancer
490603|NCT00738790|preoperative radiotherapy and local excision
490604|NCT00738777|pre-operative
490605|NCT00738777|endocrine treatment
490606|NCT00738777|drug resistance
490607|NCT00738764|cancer
490608|NCT00738764|antibody
490609|NCT00738764|Phase 1 Clinical Trial
490610|NCT00738751|NSCLC
490611|NCT00738751|Metastatic
490612|NCT00738751|erlotinib
490613|NCT00738751|aerodigestive tract cancers
490614|NCT00738751|non-small cell lung cancer
490615|NCT00738751|H&N cancer
490616|NCT00738738|Generalized Anxiety Disorder Elderly
490617|NCT00738725|High risk plaque
490618|NCT00738725|High-risk plaque
490619|NCT00738725|Vulnerable plaque
490620|NCT00738725|Atherosclerotic Disease
490621|NCT00738725|Heart Disease
490622|NCT00738725|Stroke
490623|NCT00738712|Vascular MRI
490624|NCT00738712|Abdominal MRI
490625|NCT00738712|Pelvic MRI
490626|NCT00738712|Breast MRI
490627|NCT00738712|Magnetic Resonance Imaging (MRI)
490628|NCT00738699|ovarian cancer
490629|NCT00738699|relapsed ovarian cancer
490630|NCT00738699|refractory ovarian cancer
490631|NCT00738686|coronary artery disease
490632|NCT00738686|drug-eluting stent
490633|NCT00738686|percutaneous coronary intervention
490634|NCT00738686|major adverse cardiac event
490635|NCT00738686|in-stent restenosis
490636|NCT00738686|stent thrombosis
490637|NCT00738673|Hormone refractory prostate cancer
490638|NCT00738673|Agonist treatment failure
490639|NCT00738660|type1 DM
490640|NCT00738660|microalbuminuria
490641|NCT00738660|nephropathy
490642|NCT00738660|albumin excretion rate
490643|NCT00738660|dual blockade
490644|NCT00738660|ACEI
490645|NCT00738660|ARB
490646|NCT00738647|Filling materials
490647|NCT00738647|Restorative materials
490648|NCT00738647|clinical trial
490649|NCT00738647|Resin based composite
490650|NCT00738634|Depression
490651|NCT00738634|Motor Activity
490652|NCT00738634|Adolescent
490653|NCT00738621|PONV
490654|NCT00738621|breast surgery
490655|NCT00738621|prevention
490656|NCT00738621|antiemetics
490657|NCT00738608|morphine
490658|NCT00738608|consumption
490659|NCT00738608|postoperative
490660|NCT00738608|pain
490661|NCT00738608|Pain during 24h postoperative
490662|NCT00738608|Morphine consumption in 24h postoperative
490663|NCT00738595|Smoking Cessation
490664|NCT00738569|Chronic inflammation
490665|NCT00738569|memory cells
490666|NCT00738569|activated t-lymphocytes
490667|NCT00738543|Antiseptics
490668|NCT00738543|Administration, cutaneous
490669|NCT00738543|Iodophors
490670|NCT00738543|Chlorine compounds
490671|NCT00738543|Anti-infecting agents, local
490672|NCT00738517|heart failure
490673|NCT00738517|coronary heart disease
490674|NCT00738517|autoantibodies
490675|NCT00738517|immunoadsorption
490676|NCT00738517|immunoglobulin substitution
490677|NCT00738504|Intensive insulin therapy
490678|NCT00738504|Carbohydrate restrictive strategy
490679|NCT00738504|RIFLE Criteria
490680|NCT00738504|Acute Kidney Injury
490681|NCT00738504|Critically ill patients
490682|NCT00738504|Acute
490683|NCT00738491|Angina pectoris
490684|NCT00738491|Exercise capacity
490685|NCT00738491|Myocardial ischaemia
490686|NCT00738491|Air pollution
490687|NCT00738478|distal gastrectomy
490688|NCT00738478|quality of life
490689|NCT00738452|recurrent non-small cell lung cancer
490690|NCT00738452|stage II non-small cell lung cancer
490691|NCT00738452|stage IIIA non-small cell lung cancer
490692|NCT00738452|stage IIIB non-small cell lung cancer
490693|NCT00738439|scoliosis
490694|NCT00738439|kyphosis
490695|NCT00738439|treatment outcomes
490696|NCT00738439|spinal deformity
490697|NCT00738426|non-invasive body contouring of waists hips and thighs
490698|NCT00738413|Iron chelation
490699|NCT00738413|Iron balance
490700|NCT00738413|Secondary iron overload
490701|NCT00738413|deferoxamine
490702|NCT00738413|deferasirox
490703|NCT00738400|Vardenafil
490704|NCT00738400|Erectile Dysfunction
490705|NCT00738400|Double-blind study
490706|NCT00738387|Tumor vascular disrupting agent
490707|NCT00738387|VDA
490708|NCT00738387|ASA404
490709|NCT00738387|non-small cell lung cancer
490710|NCT00738387|NSCLC
490711|NCT00738361|ciliary body and choroid melanoma, medium/large size
490712|NCT00738361|iris melanoma
490713|NCT00738361|metastatic intraocular melanoma
490714|NCT00738361|recurrent intraocular melanoma
490715|NCT00738361|extraocular extension melanoma
490716|NCT00738348|surgery
490717|NCT00738335|stage IV non-small cell lung cancer
490718|NCT00738335|tumors metastatic to brain
490719|NCT00738335|recurrent non-small cell lung cancer
490720|NCT00738322|AZD1305
490721|NCT00738322|safety
490722|NCT00738322|pharmacokinetics
490723|NCT00738322|single ascending doses
490724|NCT00738322|Japanese
490725|NCT00738322|male
490726|NCT00738309|Treatment Outcomes
490727|NCT00738309|Spinal Deformity
490728|NCT00738309|Scheuermann's Kyphosis
490729|NCT00738283|Zinc
490730|NCT00738283|Copper
490731|NCT00738283|Neonate
490732|NCT00738257|Renal
490733|NCT00738257|transplant,
490734|NCT00738257|pamidronate,
490735|NCT00738257|ciclosporin,
490736|NCT00738257|Ciclosporin A,
490737|NCT00738257|steroids,
490738|NCT00738257|bone mineral density,
490739|NCT00738257|fracture rates
490740|NCT00738257|immunosuppressive
490741|NCT00738257|regimen
490742|NCT00738244|hearing aid algorithm
490743|NCT00738244|wind-noise suppression
490744|NCT00738231|risk factors; coronary arterial hearth disease
490745|NCT00738218|Coronary Artery Disease
490746|NCT00738218|Computed Tomography
490747|NCT00738218|Angiography
490748|NCT00738205|Electronic device
490749|NCT00738205|Growth hormone treatment
490750|NCT00738192|Postoperative analgesia
490751|NCT00738192|Opioids
490752|NCT00738192|Laparoscopic surgery
490753|NCT00738179|Continuous Positive Airway Pressure (CPAP)
490754|NCT00738179|Obstructive Sleep Apnea (OSA)
490755|NCT00738179|Cardiovascular (CV)
490756|NCT00738179|Cardiovascular Disease
490757|NCT00738179|Clinical Trial
490758|NCT00738166|diet, organic, health
490759|NCT00738166|healthy people
490760|NCT00738140|insulin sensitivity
490761|NCT00738140|Diabetes Prevention Program
490762|NCT00738140|lifestyle intervention
490763|NCT00738127|Acute trans-scaphoid perilunate dislocations
490764|NCT00738127|Open reduction and internal fixation
490765|NCT00738127|Kirschner-wire
490766|NCT00738127|Range of motion
490767|NCT00738114|non-cardiac
490768|NCT00738114|surgery
490769|NCT00738114|mortality
490770|NCT00738114|morbidity
490771|NCT00738114|perioperative
490772|NCT00738114|period
490773|NCT00738101|Omega-3
490774|NCT00738101|Omegaven
490775|NCT00738101|Cholestasis
490776|NCT00738101|Liver damage
490777|NCT00738088|Sulphonylurea
490778|NCT00738088|Pharmacogenetics
490779|NCT00738062|NOH
490780|NCT00738062|Neurogenic Orthostatic Hypotension
490781|NCT00738062|Orthostatic hypotension
490782|NCT00738062|PAF
490783|NCT00738062|Pure Autonomic Failure
490784|NCT00738062|MSA
490785|NCT00738062|Multiple System Atrophy
490786|NCT00738062|Neuropathy
490787|NCT00738062|Autonomic Failure
490788|NCT00738062|Parkinson
490789|NCT00738062|Dopamine Deficiency
490790|NCT00738062|Dopamine
490791|NCT00738062|Droxidopa
490792|NCT00738049|atherosclerosis
490793|NCT00738049|coronary artery disease
490794|NCT00738049|myocardial perfusion defect
490795|NCT00738049|endothelial dysfunction
490796|NCT00738049|endothelin receptor blockade
490797|NCT00738036|Analgesics
490798|NCT00738036|Opioid
490799|NCT00738036|Opioid maintenance therapy
490800|NCT00738036|Acute pain
490801|NCT00738023|diabetes,
490802|NCT00738023|hypertension,
490803|NCT00738023|free-fatty acids
490804|NCT00738010|NMES
490805|NCT00738010|ACL
490806|NCT00738010|Atrophy Prevention
490807|NCT00738010|Accelerated Recovery
490808|NCT00738010|Knee Surgery
490809|NCT00737997|Pediatrics
490810|NCT00737997|Scoliosis
490811|NCT00737997|Morphine
490812|NCT00737997|Surgery
490813|NCT00737997|Analgesia
490814|NCT00737984|Infertility
490815|NCT00737984|Clinical pregnancy rate
490816|NCT00737971|avastin
490817|NCT00737971|bevacizumab
490818|NCT00737971|triamcinolone
490819|NCT00737971|diabetic macular edema
490820|NCT00737971|macular edema
490821|NCT00737971|intravitreal injection
490822|NCT00737958|Angina pectoris
490823|NCT00737958|Air pollution
490824|NCT00737958|Diesel exhaust
490825|NCT00737958|Myocardial ischaemia
490826|NCT00737958|Exercise capacity
490827|NCT00737919|Cholesterol
490828|NCT00737919|Plant sterols
490829|NCT00737919|Atherosclerotic carotid plaques
490830|NCT00737906|Chronic rhinitis
490831|NCT00737906|Nasal Obstruction
490832|NCT00737906|Nasal Obstruction Symptoms
490833|NCT00737906|Failed Medical Management for Nasal Obstruction
490834|NCT00737906|Inflammation of the nasal mucosa
490835|NCT00737906|Pediatric Turbinate reduction
490836|NCT00737906|Coblation
490837|NCT00737906|Arthrocare
490838|NCT00737906|ENT
490839|NCT00737906|Failed Medical Management for Chronic Sinusitis
490840|NCT00737906|Turbinate
490841|NCT00737906|Inferior Turbinate Hypertrophy
490842|NCT00737906|Bilateral Inferior Turbinate Hypertrophy
490843|NCT00737906|Turbinate Hypertrophy
490844|NCT00737906|Inferior Turbinate
490845|NCT00737906|Bilateral Inferior Turbinate
490846|NCT00737893|Erythropoietin
490847|NCT00737893|Radical Prostatectomy
490848|NCT00737893|Erectile Dysfunction
490849|NCT00737893|Prostate Cancer
490850|NCT00737880|Pancreas Clinical, Donor
490851|NCT00737880|Pancreas Clinical, Preservation Solutions
490852|NCT00737880|Organ Preservation and Procurement, Surgery
490853|NCT00737880|Organ Procurement, Ischemia reperfusion Injury
490854|NCT00737880|Organ Preservation and Procurement
490855|NCT00737867|lung cancer
490856|NCT00737867|chemotherapy
490857|NCT00737867|vinorelbine
490858|NCT00737867|gemcitabine
490859|NCT00737867|carboplatin
490860|NCT00737867|advanced lung cancer
490861|NCT00737867|non-small cell lung cancer
490862|NCT00737854|OLP
490863|NCT00737854|Free Soft Tissue Graft
490864|NCT00737854|Treatment
490865|NCT00737841|stress
490866|NCT00737841|brain-gut interactions
490867|NCT00737841|visceral perception
490868|NCT00737841|gastrointestinal motility
490869|NCT00737841|emotion
490870|NCT00737828|Cardiopulmonary exercise test
490871|NCT00737828|CPX
490872|NCT00737828|CPEX
490873|NCT00737828|surgical outcome
490874|NCT00737828|colorectal surgery
490875|NCT00737828|risk stratification
490876|NCT00737815|Randomized Controlled Trial
490877|NCT00737815|Magnesium
490878|NCT00737815|Diabetes Mellitus, Type 2
490879|NCT00737815|Inflammation
490880|NCT00737802|GERD
490881|NCT00737802|Heartburn
490882|NCT00737802|Esophageal reflux
490883|NCT00737802|Barretts esophagus
490884|NCT00737802|Normal subjects
490885|NCT00737763|efalizumab
490886|NCT00737763|Raptiva
490887|NCT00737763|Diabetes
490888|NCT00737763|Type 1 Diabetes Mellitus
490889|NCT00737750|Neuromuscular electrical stimulation (NMES)
490890|NCT00737750|Knee Surgery
490891|NCT00737750|Anterior cruciate ligament
490892|NCT00737750|Atrophy Prevention
490893|NCT00737750|Accelerated Recovery
490894|NCT00737737|Analgesia
490895|NCT00737737|Chronic Pain
490896|NCT00737737|Neuroendocrine Axis
490897|NCT00737737|Degenerative Diseases
490898|NCT00737724|Enzyme-Linked ImmunoSpot
490899|NCT00737724|Deferred treatment
490900|NCT00737724|Immune Recovery Inflammatory Syndrome
490901|NCT00737698|COPD
490902|NCT00737698|exercise
490903|NCT00737698|repetitive magnetic stimulation
490904|NCT00737698|quadriceps strength
490905|NCT00737685|Pediatric
490906|NCT00737685|UBMT
490907|NCT00737685|Severe
490908|NCT00737672|Hemodialysis
490909|NCT00737672|Stent Graft
490910|NCT00737672|Venous Anastomosis
490911|NCT00737672|Arteriovenous Grafts
490912|NCT00737659|Renal Transplant
490913|NCT00737659|Renal
490914|NCT00737659|Transplant
490915|NCT00737659|MMF
490916|NCT00737659|MPA
490917|NCT00737659|Recipients
490918|NCT00737646|Cancer
490919|NCT00737646|Colorectal cancer
490920|NCT00737646|Patient education
490921|NCT00737646|Physician education
490922|NCT00737633|Diabetes
490923|NCT00737633|Type 2 Diabetes
490924|NCT00737633|Diabetes Mellitus
490925|NCT00737633|Metabolic Diseases
490926|NCT00737633|Glucose Metabolism Disorders
490927|NCT00737633|Glycemic Control
490928|NCT00737620|Renal Failure, End Stage
490929|NCT00737620|Blood Vessel Grafting
490930|NCT00737620|Hemodialysis
490931|NCT00737620|Surgical Arteriovenous Shunt
490932|NCT00737607|outcome
490933|NCT00737607|surgery
490934|NCT00737607|lumbar spinal stenosis
490935|NCT00737607|minimally invasive
490936|NCT00737581|Subject's
490937|NCT00737581|response
490938|NCT00737581|changes
490939|NCT00737581|in spinal
490940|NCT00737581|cord
490941|NCT00737581|stimulation
490942|NCT00737581|during
490943|NCT00737581|postural
490944|NCT00737568|Tenofovir DF
490945|NCT00737568|Emtricitabine
490946|NCT00737568|Chronic hepatitis B
490947|NCT00737568|Combination therapy
490948|NCT00737555|Solid tumour
490949|NCT00737555|Solid tumor
490950|NCT00737555|Pharmacokinetic
490951|NCT00737555|Interaction
490952|NCT00737555|dose escalation
490953|NCT00737555|cancer
490954|NCT00737555|paclitaxel
490955|NCT00737542|management
490956|NCT00737542|post
490957|NCT00737529|Mantle Cell Lymphoma
490958|NCT00737529|Non-Hodgkin's Lymphoma
490959|NCT00737529|CC-5013
490960|NCT00737529|Revlimid
490961|NCT00737529|Lenalidomide
490962|NCT00737516|Registry
490963|NCT00737516|Unrelated Umbilical Cord Blood donor
490964|NCT00737516|Hematopoietic Reconstitution
490965|NCT00737516|Center for Cord Blood
490966|NCT00737516|Bone Marrow Transplantation
490967|NCT00737503|vaccine effectiveness, rotavirus, diarrhoea, Bangladesh
490968|NCT00737451|urticaria
490969|NCT00737451|goiter
490970|NCT00737438|BEVACIZUMAB (AVASTIN)
490971|NCT00737438|CAPECITABINE (ORAL)
490972|NCT00737438|CISPLATIN
490973|NCT00737438|EPIRUBICIN
490974|NCT00737438|IRINOTECAN (CPT-11) CAMPTOSAR
490975|NCT00737438|TAXOTERE (DOCETAXEL)
490976|NCT00737438|ESOPHAGUS
490977|NCT00737438|STOMACH
490978|NCT00737438|08-081
490979|NCT00737425|laparoscopic-assisted surgery
490980|NCT00737425|abdominal
490981|NCT00737425|pain relief
490982|NCT00737425|wound healing
490983|NCT00737425|low intensity ultrasound
490984|NCT00737412|Bio-K+CL1285
490985|NCT00737412|Probiotics
490986|NCT00737412|Traveler's Diarrhea
490987|NCT00737412|Lactobacillus Acidophilus
490988|NCT00737412|Lactobacillus Casei
490989|NCT00737399|depression
490990|NCT00737399|anxiety
490991|NCT00737399|pain
490992|NCT00737399|insomnia
490993|NCT00737399|cancer
490994|NCT00737399|cholangiocarcinoma
490995|NCT00737399|EFT (Emotional Freedom Techniques)
490996|NCT00737386|Leishmania tropica
490997|NCT00737386|Hyrax
490998|NCT00737386|Sandfly
490999|NCT00737347|type 2 diabetes
491000|NCT00737347|obesity
491001|NCT00737347|weight gain
491002|NCT00737347|thiazolidinediones
491003|NCT00737334|Carotid stenosis
491004|NCT00737334|EEGo
491005|NCT00737334|nonlinear EEG
491006|NCT00737334|BIS
491007|NCT00737334|cerebral oximetry
491008|NCT00737334|FORE-SIGHT cerebral oximeter
491009|NCT00737334|cerebral monitoring
491010|NCT00737334|arterial jugular venous lactate difference
491011|NCT00737334|cerebral ischemia
491012|NCT00737334|carotid endarterectomy
491013|NCT00737321|Impact of ischemia
491014|NCT00737321|Impact of stress and
491015|NCT00737321|Identify patterns of gene expression
491016|NCT00737308|crowns
491017|NCT00737308|ceramics
491018|NCT00737295|Biliary
491019|NCT00737295|Dyskinesia
491020|NCT00737295|Gallbladder
491021|NCT00737295|Cholecystitis
491022|NCT00737282|Uterine Fibroids
491023|NCT00737269|Complicated Skin and Soft-Tissue Infection
491024|NCT00737269|Skin Infection
491025|NCT00737269|Skin Infection Registry
491026|NCT00737269|cSSTI Registry
491027|NCT00737243|Carcinoma of Unknown Primary Site
491028|NCT00737243|Molecular profiling assay
491029|NCT00737243|Bevacizumab
491030|NCT00737243|Erlotinib
491031|NCT00737243|Paclitaxel
491032|NCT00737243|Carboplatin
491033|NCT00737230|long-term effects secondary to cancer therapy in adults
491034|NCT00737230|long-term effects secondary to cancer therapy in children
491035|NCT00737230|gastrointestinal complications
491036|NCT00737230|radiation toxicity
491037|NCT00737230|prostate cancer
491038|NCT00737230|bladder cancer
491039|NCT00737230|vulvar cancer
491040|NCT00737230|vaginal cancer
491041|NCT00737230|cervical cancer
491042|NCT00737230|endometrial cancer
491043|NCT00737230|anal cancer
491044|NCT00737230|rectal cancer
491045|NCT00737230|malignant testicular germ cell tumor
491046|NCT00737204|HIV
491047|NCT00737204|AIDS
491048|NCT00737204|Armodafinil
491049|NCT00737204|Depression
491050|NCT00737191|unspecified adult solid tumor, protocol specific
491051|NCT00737191|hematopoietic/lymphoid cancer
491052|NCT00737191|pain
491053|NCT00737178|IUD
491054|NCT00737178|Intrauterine device
491055|NCT00737178|Intrauterine contraception
491056|NCT00737178|Medication abortion
491057|NCT00737178|Medical abortion
491058|NCT00737165|Suicide, Prevention
491059|NCT00737165|Community
491060|NCT00737152|RAS 130
491061|NCT00737152|Exercise
491062|NCT00737152|Diabetes Mellitus
491063|NCT00737152|Type II Diabetes
491064|NCT00737152|Diabetes
491065|NCT00737152|Aerobic
491066|NCT00737139|Hip
491067|NCT00737139|Knee
491068|NCT00737139|Arthroplasty
491069|NCT00737139|Epinephrine
491070|NCT00737139|Hemostasis
491071|NCT00737126|Diabetic nephropathies
491072|NCT00737126|Hyperhomocysteinemia
491073|NCT00737126|Folic acid
491074|NCT00737126|Endothelial dysfunction
491075|NCT00737113|allogeneic stem cell transplantation
491076|NCT00737113|Engrafted
491077|NCT00737113|subjects
491078|NCT00737087|total shoulder replacement
491079|NCT00737087|rotator cuff
491080|NCT00737087|osteoarthritis
491081|NCT00737087|rheumatoid arthritis
491082|NCT00737087|Delta Extend
491083|NCT00737074|Fibrovascular proliferation
491084|NCT00737074|Internal limiting membrane peeling
491085|NCT00737074|Macular detachment
491086|NCT00737074|Macular hole
491087|NCT00737074|Proliferative diabetic retinopathy.
491088|NCT00737061|Female
491089|NCT00737061|Sterilization
491090|NCT00737048|Pain
491091|NCT00737048|Tooth extraction
491092|NCT00737048|Oral surgery
491093|NCT00737048|Postoperative pain
491094|NCT00737048|JNS013
491095|NCT00737048|Tramadol hydrochloride
491096|NCT00737048|Acetaminophen
491097|NCT00737035|Intimate Partner Homicide
491098|NCT00737035|Parental Homicide
491099|NCT00737035|Guardians of Child Survivors of Parental Homicide
491100|NCT00737035|Post-Traumatic Stress Disorder
491101|NCT00737035|Uxoricide Project
491102|NCT00737022|Diabetic vitrectomy
491103|NCT00737022|Epiretinal membrane (ERM)
491104|NCT00737022|Macular appearance
491105|NCT00737022|Optical coherence tomography (OCT)
491106|NCT00737022|Visual function
491107|NCT00737009|Breast cancer
491108|NCT00737009|adherence
491109|NCT00737009|anastrozole
491110|NCT00737009|post-menopausal women
491111|NCT00736996|Metabolic Syndrome
491112|NCT00736996|Mild Cognitive Impairment
491113|NCT00736996|Insulin Resistance
491114|NCT00736996|Endurance Exercise
491115|NCT00736983|Perianal fistulas
491116|NCT00736983|Crohn's disease
491117|NCT00736970|ridaforolimus
491118|NCT00736970|deforolimus
491119|NCT00736970|AP23573
491120|NCT00736970|breast cancer
491121|NCT00736957|Chronic Pain
491122|NCT00736957|Acetaminophen
491123|NCT00736957|Tramadol
491124|NCT00736957|JNS013
491125|NCT00736931|Brivaracetam
491126|NCT00736931|Cognitive neurophysiological tests (CNT)
491127|NCT00736931|Neuropsychological assessments
491128|NCT00736918|Suicide Attempt
491129|NCT00736905|TMC278-TiDP6-C130
491130|NCT00736905|TMC278-C130
491131|NCT00736905|healthy volunteer
491132|NCT00736905|hepatic impairment
491133|NCT00736905|HIV Infections
491134|NCT00736892|Acute lung injury
491135|NCT00736892|Acute respiratory distress syndrome
491136|NCT00736892|Mechanical ventilation
491137|NCT00736892|Prognosis
491138|NCT00736892|Definitions
491139|NCT00736879|Diabetes Mellitus, Type 2
491140|NCT00736879|Diabetes Mellitus
491141|NCT00736879|Endocrine System Diseases
491142|NCT00736879|Glucose Metabolism Disorders
491143|NCT00736879|Metabolic Diseases
491144|NCT00736866|acetylcysteine
491145|NCT00736866|contrast-induced nephropathy
491146|NCT00736866|angiography
491147|NCT00736866|angioplasty with or without Stent
491148|NCT00736853|Chronic pain
491149|NCT00736853|Acetoaminophen
491150|NCT00736853|Tramadol
491151|NCT00736853|Osteoarthritis of the knee
491152|NCT00736853|Low back pain
491153|NCT00736840|Methacetin
491154|NCT00736840|Breath
491155|NCT00736840|Test
491156|NCT00736840|Cirrhosis
491157|NCT00736827|BK virus
491158|NCT00736827|acute renal failure
491159|NCT00736827|hemodiafiltration
491160|NCT00736827|humans
491161|NCT00736827|patients
491162|NCT00736827|polytrauma
491163|NCT00736827|surgery
491164|NCT00736827|complement
491165|NCT00736827|inflammation
491166|NCT00736827|inflammatory response
491167|NCT00736827|biomarkers
491168|NCT00736827|cytokines
491169|NCT00736827|cell surface markers
491170|NCT00736827|functional polymorphisms
491171|NCT00736827|infections
491172|NCT00736827|systemic inflammatory response syndrome
491173|NCT00736827|SIRS
491174|NCT00736827|sepsis
491175|NCT00736827|severe sepsis
491176|NCT00736827|shock
491177|NCT00736827|organ dysfunctions
491178|NCT00736827|SOFA
491179|NCT00736827|severity of disease
491180|NCT00736827|APACHEII
491181|NCT00736827|SAPSII
491182|NCT00736827|SPAPS3
491183|NCT00736827|length of stay
491184|NCT00736827|outcome
491185|NCT00736827|mortality
491186|NCT00736814|stage IIIB non-small cell lung cancer
491187|NCT00736814|stage IV non-small cell lung cancer
491188|NCT00736801|Airway hyperresponsiveness
491189|NCT00736788|AZD1704,
491190|NCT00736788|Japanese
491191|NCT00736788|Healthy
491192|NCT00736788|Volunteers,
491193|NCT00736788|Phase I study,
491194|NCT00736788|Single Ascending Dose
491195|NCT00736788|Safety,
491196|NCT00736788|Tolerability
491197|NCT00736788|Pharmacokinetics
491198|NCT00736775|AD
491199|NCT00736775|Alzheimer's
491200|NCT00736775|Alzheimers
491201|NCT00736762|Global postural re-education
491202|NCT00736762|Balance
491203|NCT00736762|Physical therapy
491204|NCT00736762|older people
491205|NCT00736723|NT-proBNP
491206|NCT00736723|myocardial dysfunction
491207|NCT00736723|humans
491208|NCT00736723|patients
491209|NCT00736723|polytrauma
491210|NCT00736723|complement
491211|NCT00736723|inflammation
491212|NCT00736723|inflammatory response
491213|NCT00736723|biomarkers
491214|NCT00736723|cytokines
491215|NCT00736723|cell surface markers
491216|NCT00736723|functional polymorphisms
491217|NCT00736723|infections
491218|NCT00736723|systemic inflammatory response syndrome
491219|NCT00736723|SIRS
491220|NCT00736723|sepsis
491221|NCT00736723|severe sepsis
491222|NCT00736723|shock
491223|NCT00736723|organ dysfunctions
491224|NCT00736723|SOFA
491225|NCT00736723|severity of disease
491226|NCT00736723|APACHEII
491227|NCT00736723|SAPSII
491228|NCT00736723|SPAPS3
491229|NCT00736723|length of stay
491230|NCT00736723|outcome
491231|NCT00736723|mortality
491232|NCT00736710|Repetitive Transcranial Magnetic Stimulation
491233|NCT00736710|Cigarette smoking
491234|NCT00736710|Schizophrenia
491235|NCT00736710|Randomized
491236|NCT00736710|Double-blind
491237|NCT00736710|Placebo-controlled
491238|NCT00736710|longitudinal
491239|NCT00736710|nicotine patch
491240|NCT00736684|Femoral fractures [MeSH]
491241|NCT00736684|hip fractures [MeSH]
491242|NCT00736684|trochanteric fractures (femoral neck fractures [MeSH])
491243|NCT00736684|intramedullary nailing (fracture fixation, intramedullary [MeSH])
491244|NCT00736684|complex femoral fractures
491245|NCT00736684|femoral nail
491246|NCT00736684|surgical treatment (surgical procedures, operative [MeSH])
491247|NCT00736684|complications
491248|NCT00736658|Japanese
491249|NCT00736658|MAD
491250|NCT00736658|Multiple ascending dose
491251|NCT00736658|Chronic pain
491252|NCT00736645|adenocarcinoma of the prostate
491253|NCT00736645|stage I prostate cancer
491254|NCT00736645|stage II prostate cancer
491255|NCT00736632|Vitamin D
491256|NCT00736632|Insulin Resistance
491257|NCT00736632|Type 2 Diabetes Mellitus
491258|NCT00736632|Cardiovascular Disease
491259|NCT00736619|MAB C225(CETUXIMAB)(ANTI-EGFR)
491260|NCT00736619|TAXOL (PACLITAXEL)
491261|NCT00736619|Radiation Therapy
491262|NCT00736619|08-084
491263|NCT00736606|simvastatin
491264|NCT00736606|AZD5672
491265|NCT00736593|Wound
491266|NCT00736593|Healing
491267|NCT00736580|Cesarean delivery
491268|NCT00736580|Surgical Needles
491269|NCT00736580|blunt-tip needles
491270|NCT00736580|surgical glove perforation
491271|NCT00736567|Diarrhea
491272|NCT00736567|Diagnostic
491273|NCT00736567|Pediatric
491274|NCT00736554|Staphylococcus aureus
491275|NCT00736554|CA-MRSA
491276|NCT00736554|skin and soft tissue infections
491277|NCT00736554|resistance
491278|NCT00736554|emergency department
491279|NCT00736541|ARF
491280|NCT00736541|OLT
491281|NCT00736541|NAC
491282|NCT00736541|I/R injury
491283|NCT00736528|safety, tolerability, pharmacokinetics, cognition
491284|NCT00736515|combination therapy,monotherapy,gliclazide MR,insulin,CGMS
491285|NCT00736489|Asthma
491286|NCT00736489|airway obstruction
491287|NCT00736489|beta2-agonist
491288|NCT00736489|efficacy
491289|NCT00736489|inhalation
491290|NCT00736476|helicobacter pylori infection
491291|NCT00736476|vaccination
491292|NCT00736476|adults
491293|NCT00736463|HDL cholesterol
491294|NCT00736463|statin
491295|NCT00736463|inflammation
491296|NCT00736463|atherosclerosis
491297|NCT00736463|prevention
491298|NCT00736463|patients with low baseline HDL cholesterol
491299|NCT00736437|UV-induced
491300|NCT00736437|Herpes labialis
491301|NCT00736437|time to healing
491302|NCT00736424|Epilepsy
491303|NCT00736424|SUDEP
491304|NCT00736424|DBS
491305|NCT00736411|infertility
491306|NCT00736411|IVF
491307|NCT00736411|acupuncture
491308|NCT00736385|nonalcoholic fatty liver disease
491309|NCT00736372|cancer
491310|NCT00736372|metastatic cancer
491311|NCT00736372|advanced or metastatic cancer
491312|NCT00736346|Panic Disorder
491313|NCT00736346|anxiety
491314|NCT00736346|chest pain
491315|NCT00736346|emergency department
491316|NCT00736346|cognitive-behavioral treatment
491317|NCT00736320|Hodgkin Lymphoma
491318|NCT00736320|early stage
491319|NCT00736320|PET
491320|NCT00736307|limbal stem cell deficiency
491321|NCT00736294|Catheter Ablation, Radiofrequency
491322|NCT00736294|Angiotensin-Converting Enzyme Inhibitors
491323|NCT00736281|Sublingual Immunotherapy for Food Allergy
491324|NCT00736281|Food Drops for Food Allergy
491325|NCT00736268|Lung Disease
491326|NCT00736268|Chronic Bronchitis
491327|NCT00736268|Emphysema
491328|NCT00736268|Caregiver stress
491329|NCT00736268|COPD
491330|NCT00736268|Chronic Obstructive Pulmonary Disease
491331|NCT00736255|ADHD
491332|NCT00736255|Smoking
491333|NCT00736242|HIV
491334|NCT00736229|hyperglycemia
491335|NCT00736229|acute coronary syndromes
491336|NCT00736229|myocardial infarction
491337|NCT00736216|cervical cancer
491338|NCT00736216|human papilloma virus infection
491339|NCT00736203|fMRI
491340|NCT00736203|non-smokers
491341|NCT00736190|Hepatitis B
491342|NCT00736190|Hepatitis
491343|NCT00736190|Tenofovir disoproxil fumarate
491344|NCT00736190|Tenofovir DF
491345|NCT00736190|Asian-American
491346|NCT00736177|IVF
491347|NCT00736177|blastocyst transfer
491348|NCT00736177|endometrium
491349|NCT00736177|embryo cryopreservation
491350|NCT00736164|stage I prostate cancer
491351|NCT00736164|stage II prostate cancer
491352|NCT00736164|adenocarcinoma of the prostate
491353|NCT00736125|postoperative cognitive dysfunction
491354|NCT00736125|total knee arthroplasty
491355|NCT00736125|cerebral emboli
491356|NCT00736125|carbon dioxide lavage
491357|NCT00736125|pulsatile saline lavage
491358|NCT00736112|Food Allergy in Children
491359|NCT00736112|Otitis Media with Effusion (OME)
491360|NCT00736112|Recurrent Middle Ear Infections
491361|NCT00736112|Middle Ear Fluid
491362|NCT00736112|Food Allergy and Otitis Media with Effusion
491363|NCT00736112|Recurrent middle ear fluid in children <4 years old
491364|NCT00736112|Chronic ear infections in children <4 years old
491365|NCT00736086|femoral artery
491366|NCT00736086|post-percutaneous cardiac catheterization
491367|NCT00736086|post-percutaneous peripheral vascular catheterization
491368|NCT00736086|post-percutaneous diagnostic catheterization
491369|NCT00736086|early ambulation
491370|NCT00736086|vascular closure
491371|NCT00736073|pancreatitis
491372|NCT00736060|Fever
491373|NCT00736060|Blood cultures
491374|NCT00736047|Smokers
491375|NCT00736047|smoking cessation
491376|NCT00736047|vaccine
491377|NCT00736047|antibodies
491378|NCT00736047|anti-nicotine
491379|NCT00736034|Age Associated Memory Impairment
491380|NCT00736021|PTSD
491381|NCT00736021|Pharmacological Treatment
491382|NCT00736021|SSRI
491383|NCT00736021|Escitalopram
491384|NCT00736021|Anxiety Disorders
491385|NCT00736008|Factor V Leiden
491386|NCT00736008|Prothrombin Mutation
491387|NCT00736008|Hypercoagulability
491388|NCT00736008|Pediatrics
491389|NCT00735969|Non-Responder
491390|NCT00735969|Relapser
491391|NCT00735969|High Dose Ribavirin
491392|NCT00735969|Peginterferon
491393|NCT00735969|Chronic Hepatitis C
491394|NCT00735956|Screening
491395|NCT00735956|Brief Intervention
491396|NCT00735943|Pegaptanib
491397|NCT00735943|macular degeneration
491398|NCT00735943|vascular endothelial growth factor
491399|NCT00735904|AG-013736
491400|NCT00735904|axitinib
491401|NCT00735904|cisplatin
491402|NCT00735904|gemcitabine
491403|NCT00735904|NSCLC
491404|NCT00735904|squamous cell
491405|NCT00735904|lung cancer
491406|NCT00735891|Stage IIIB non small cell lung cancer
491407|NCT00735891|Stage IV non small cell lung cancer
491408|NCT00735878|Lung Cancer
491409|NCT00735878|Advanced Lung Cancer
491410|NCT00735878|NSCLC
491411|NCT00735865|Dry Eye Syndrome
491412|NCT00735865|Punctal Occlusion
491413|NCT00735865|Punctal Plugs
491414|NCT00735865|Tear Drainage duct blockage
491415|NCT00735852|endometriosis
491416|NCT00735852|chronic cyclical pelvic pain
491417|NCT00735826|resectable
491418|NCT00735826|stage I-III
491419|NCT00735826|NSCLC
491420|NCT00735826|non-small cell lung cancer
491421|NCT00735826|vorinostat
491422|NCT00735826|proof of principle
491423|NCT00735826|resectable stage I to III NSCLC
491424|NCT00735813|Catheterization, Central
491425|NCT00735813|Catheterization, Peripheral
491426|NCT00735813|Infection
491427|NCT00735813|Methods
491428|NCT00735813|Sepsis
491429|NCT00735813|Microscopy, Electron, Scanning
491430|NCT00735813|Sonication
491431|NCT00735813|Taurolidine
491432|NCT00735813|Catheters, Indwelling
491433|NCT00735813|Pediatrics
491434|NCT00735800|Dementia
491435|NCT00735800|Caregivers
491436|NCT00735800|Alzheimer's disease
491437|NCT00735774|Healthy volunteer study
491438|NCT00735748|Patients who will undergo a general anesthesia for a procedure in short stay
491439|NCT00735735|low back pain
491440|NCT00735735|chronic
491441|NCT00735735|Substance P
491442|NCT00735722|AF
491443|NCT00735722|CAD
491444|NCT00735709|Depression
491445|NCT00735709|Depressive Disorder
491446|NCT00735709|Mood Disorder
491447|NCT00735709|Mental Disorder
491448|NCT00735709|Melancholia, Involutional
491449|NCT00735709|Paraphrenia, Involutional
491450|NCT00735709|Drug Therapy
491451|NCT00735696|Non Small Cell Lung Cancer
491452|NCT00735696|Lung
491453|NCT00735696|NSCLC
491454|NCT00735683|Weight loss
491455|NCT00735683|Weight-loss drugs
491456|NCT00735683|Obesity
491457|NCT00735683|Overweight
491458|NCT00735683|Body weight
491459|NCT00735683|Diet
491460|NCT00735683|Metabolic Disorder
491461|NCT00735683|Nutrition Disorder
491462|NCT00735670|SCI
491463|NCT00735657|Efficiency
491464|NCT00735657|Pars
491465|NCT00735657|Plana
491466|NCT00735657|Vitrectomy
491467|NCT00735644|Japanese encephalitis, Hepatitis A, Inactivated Mouse-Brain
491468|NCT00735631|Patients entering the post-operative cardiac intensive care unit following coronary artery reconstruction surgery.
491469|NCT00735618|Advanced Cancer
491470|NCT00735618|Cancer Patients
491471|NCT00735618|Relaxation Therapy
491472|NCT00735618|Relaxation and Heart Rate Variability
491473|NCT00735618|Guided Relaxation
491474|NCT00735618|HRV
491475|NCT00735618|Stress, Anxiety, and Panic Disorder
491476|NCT00735605|obstructed defecation
491477|NCT00735605|constipation
491478|NCT00735605|puborectalis
491479|NCT00735592|X rays findings
491480|NCT00735579|major abdominal surgery
491481|NCT00735579|coagulation
491482|NCT00735579|extracellular matrix proteins
491483|NCT00735579|wound healing after major abdominal surgery
491484|NCT00735566|gastric cancer
491485|NCT00735566|antiangiogenic factors
491486|NCT00735566|TNM stage
491487|NCT00735553|Uterine Fibroids
491488|NCT00735527|seizures
491489|NCT00735527|status epilepticus
491490|NCT00735527|lorazepam
491491|NCT00735527|intra-nasal
491492|NCT00735514|radiation toxicity
491493|NCT00735514|sexuality and reproductive issues
491494|NCT00735514|stage I endometrial carcinoma
491495|NCT00735514|stage II endometrial carcinoma
491496|NCT00735514|stage IB cervical cancer
491497|NCT00735514|stage IIA cervical cancer
491498|NCT00735514|stage IIB cervical cancer
491499|NCT00735514|stage III cervical cancer
491500|NCT00735488|Thalassemia
491501|NCT00735488|Sickle cell anemia
491502|NCT00735488|Carrier detection
491503|NCT00735488|Prenatal Diagnosis
491504|NCT00735488|Genetic counseling
491505|NCT00735462|external genital warts
491506|NCT00735462|perianal warts
491507|NCT00735462|condylomata acuminata
491508|NCT00735462|human papilloma virus
491509|NCT00735462|HPV types 6 and 11
491510|NCT00735436|Malignant glioma
491511|NCT00735436|Glioblastoma multiforme
491512|NCT00735436|GBM
491513|NCT00735436|Gliosarcoma
491514|NCT00735436|Gliadel
491515|NCT00735436|Carmustine
491516|NCT00735436|Irinotecan
491517|NCT00735436|CPT-11
491518|NCT00735436|Camptosar
491519|NCT00735436|Avastin
491520|NCT00735436|Bevacizumab
491521|NCT00735423|Healthy children
491522|NCT00735423|Brain Function
491523|NCT00735423|Diet
491524|NCT00735423|Nutrition
491525|NCT00735423|Language
491526|NCT00735423|fMRI
491527|NCT00735423|ERP
491528|NCT00735423|Behavior
491529|NCT00735410|Influenza vaccine
491530|NCT00735410|Seasonal
491531|NCT00735410|Split
491532|NCT00735397|Partial onset seizures
491533|NCT00735384|sepsis
491534|NCT00735384|critical illness
491535|NCT00735384|muscle, skeletal
491536|NCT00735384|myopathy
491537|NCT00735384|isometric contraction
491538|NCT00735384|intensive care units
491539|NCT00735384|torque
491540|NCT00735384|muscular atrophy
491541|NCT00735384|malignant hyperthermia
491542|NCT00735384|skin resistance
491543|NCT00735358|gastric variceal bleeding
491544|NCT00735358|cyanoacrylate
491545|NCT00735358|rebleeding
491546|NCT00735358|complication
491547|NCT00735358|survival
491548|NCT00735358|acute gastric variceal bleeding
491549|NCT00735345|Esophageal cancer
491550|NCT00735345|Pre-operative
491551|NCT00735345|Chemo-immunotherapy
491552|NCT00735345|Radiochemo-immunotherapy
491553|NCT00735345|EGFR
491554|NCT00735345|Radiosensitivity
491555|NCT00735345|Resection
491556|NCT00735332|Melanoma
491557|NCT00735332|Metastatic Melanoma
491558|NCT00735332|Phase II
491559|NCT00735332|Skin Cancer
491560|NCT00735319|Neonatal Jaundice
491561|NCT00735319|Physiological Neonatal Jaundice
491562|NCT00735319|Neonatal Hyperbilirubinemia
491563|NCT00735319|Transcutaneous Bilirubinometer
491564|NCT00735306|Locally advanced
491565|NCT00735306|Unresectable
491566|NCT00735293|hyperhidrosis
491567|NCT00735293|bromidrosis
491568|NCT00735293|bromhidrosis
491569|NCT00735293|osmidrosis
491570|NCT00735293|hircismus
491571|NCT00735293|excessive
491572|NCT00735293|underarm
491573|NCT00735293|sweat
491574|NCT00735293|perspiration
491575|NCT00735293|Body Odor
491576|NCT00735280|Coronary artery disease, stent, heparin
491577|NCT00735267|Generalized Anxiety Disorder
491578|NCT00735254|post
491579|NCT00735254|surgical
491580|NCT00735241|colon cancer
491581|NCT00735241|colorectal cancer
491582|NCT00735241|liver metastases
491583|NCT00735241|SIR-Spheres Microspheres
491584|NCT00735241|yttrium-90
491585|NCT00735241|FOLFOX
491586|NCT00735241|Bevacizumab
491587|NCT00735241|chemo-radiation
491588|NCT00735228|surgery
491589|NCT00735228|artificial pancreas
491590|NCT00735228|tight glycemic control
491591|NCT00735228|Liver
491592|NCT00735215|Breast cancer,
491593|NCT00735215|fulvestrant,
491594|NCT00735215|postmenopausal,
491595|NCT00735215|women
491596|NCT00735215|locally advanced,
491597|NCT00735215|hormone receptor-positive.
491598|NCT00735189|warfarin
491599|NCT00735189|anticoagulation
491600|NCT00735189|anticoagulation clinics
491601|NCT00735176|Radiculopathy, cervical
491602|NCT00735176|Nerve Root Compression
491603|NCT00735176|Disc, intervertebral
491604|NCT00735176|Intervertebral Disk Displacement
491605|NCT00735176|Spondylosis
491606|NCT00735176|Spinal Osteophytosis
491607|NCT00735176|Arthroplasty, replacement
491608|NCT00735176|Diskectomy
491609|NCT00735176|Spinal Fusion
491610|NCT00735163|algorithm
491611|NCT00735163|tight glycemic control
491612|NCT00735163|glucose control
491613|NCT00735163|intensive care
491614|NCT00735163|insulin
491615|NCT00735163|ICU
491616|NCT00735150|Breast
491617|NCT00735150|Ovary
491618|NCT00735150|Mutation carrier
491619|NCT00735137|Twins
491620|NCT00735137|Short cervix
491621|NCT00735137|Preterm birth
491622|NCT00735137|Vaginal pessary
491623|NCT00735124|analgesia requirement and post operative pain
491624|NCT00735111|QOL
491625|NCT00735111|Quality of Life
491626|NCT00735111|KPS
491627|NCT00735111|Karnofsky Performance Status
491628|NCT00735111|Cancer
491629|NCT00735098|Knee Osteoarthritis
491630|NCT00735098|arthritis
491631|NCT00735085|Brain Injury
491632|NCT00735072|HIV infection
491633|NCT00735072|T cell activation
491634|NCT00735072|Antiretroviral Therapy
491635|NCT00735072|CCR5
491636|NCT00735072|Maraviroc
491637|NCT00735059|dialysis membrane
491638|NCT00735059|Polynephron
491639|NCT00735059|Elisio H
491640|NCT00735059|Polyethersulfone
491641|NCT00735059|Diapes
491642|NCT00735059|PES-DS
491643|NCT00735059|online post-dilution hemodiafiltration
491644|NCT00735059|hemodialysis
491645|NCT00735059|protein-bound toxins
491646|NCT00735059|beta-2-microglobulin
491647|NCT00735059|hemodialysis patients
491648|NCT00735046|Early dementia in Alzheimer's disease (MMSE ≥ 21)
491649|NCT00735033|Physical therapy
491650|NCT00735033|Physical therapy modalities
491651|NCT00735033|Cerebral Vascular Accident (CVA)
491652|NCT00735020|influenza
491653|NCT00735020|vaccine
491654|NCT00735020|adjuvants
491655|NCT00735020|flu
491656|NCT00735007|Multiple Sclerosis
491657|NCT00734968|Urinary tract infection (UTI)
491658|NCT00734968|suburethral sling
491659|NCT00734968|Prevention
491660|NCT00734968|Nitrofurantoin
491661|NCT00734968|Prophylaxis
491662|NCT00734955|Partial Mastectomy
491663|NCT00734955|Lumpectomy
491664|NCT00734955|Mastectomy
491665|NCT00734942|young carers
491666|NCT00734942|family support
491667|NCT00734942|children (up to the age of 18) of chronically ill parents
491668|NCT00734929|PONV
491669|NCT00734929|nausea
491670|NCT00734929|emesis
491671|NCT00734929|antiemetics
491672|NCT00734929|aprepitant
491673|NCT00734929|ondansetron
491674|NCT00734929|dexamethasone
491675|NCT00734916|total parenteral nutrition
491676|NCT00734916|infections
491677|NCT00734916|Infectious complications related to parenteral nutrition
491678|NCT00734903|Women
491679|NCT00734903|Substance Use Disorders
491680|NCT00734903|Treatment Efficacy
491681|NCT00734903|Women's Health
491682|NCT00734903|Outcome Assessment (Health Care)
491683|NCT00734890|unspecified adult solid tumor, protocol specific
491684|NCT00734890|AIDS-related diffuse large cell lymphoma
491685|NCT00734890|AIDS-related diffuse mixed cell lymphoma
491686|NCT00734890|AIDS-related diffuse small cleaved cell lymphoma
491687|NCT00734890|AIDS-related immunoblastic large cell lymphoma
491688|NCT00734890|AIDS-related lymphoblastic lymphoma
491689|NCT00734890|AIDS-related peripheral/systemic lymphoma
491690|NCT00734890|AIDS-related small noncleaved cell lymphoma
491691|NCT00734890|HIV-associated Hodgkin lymphoma
491692|NCT00734890|recurrent adult Burkitt lymphoma
491693|NCT00734890|recurrent adult diffuse large cell lymphoma
491694|NCT00734890|recurrent adult diffuse mixed cell lymphoma
491695|NCT00734890|recurrent adult diffuse small cleaved cell lymphoma
491696|NCT00734890|recurrent adult grade III lymphomatoid granulomatosis
491697|NCT00734890|recurrent adult Hodgkin lymphoma
491698|NCT00734890|recurrent adult immunoblastic large cell lymphoma
491699|NCT00734890|recurrent adult lymphoblastic lymphoma
491700|NCT00734890|recurrent adult T-cell leukemia/lymphoma
491701|NCT00734890|recurrent cutaneous T-cell non-Hodgkin lymphoma
491702|NCT00734890|recurrent grade 1 follicular lymphoma
491703|NCT00734890|recurrent grade 2 follicular lymphoma
491704|NCT00734890|recurrent grade 3 follicular lymphoma
491705|NCT00734890|recurrent mantle cell lymphoma
491706|NCT00734890|recurrent marginal zone lymphoma
491707|NCT00734890|recurrent small lymphocytic lymphoma
491708|NCT00734890|anaplastic large cell lymphoma
491709|NCT00734890|angioimmunoblastic T-cell lymphoma
491710|NCT00734890|recurrent mycosis fungoides/Sezary syndrome
491711|NCT00734890|adult nasal type extranodal NK/T-cell lymphoma
491712|NCT00734890|Waldenström macroglobulinemia
491713|NCT00734890|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
491714|NCT00734890|nodal marginal zone B-cell lymphoma
491715|NCT00734890|splenic marginal zone lymphoma
491716|NCT00734890|intraocular lymphoma
491717|NCT00734890|post-transplant lymphoproliferative disorder
491718|NCT00734890|cutaneous B-cell non-Hodgkin lymphoma
491719|NCT00734890|small intestine lymphoma
491720|NCT00734890|adenocarcinoma of the lung
491721|NCT00734890|bronchoalveolar cell lung cancer
491722|NCT00734890|large cell lung cancer
491723|NCT00734890|adenosquamous cell lung cancer
491724|NCT00734890|recurrent non-small cell lung cancer
491725|NCT00734890|stage IIIA non-small cell lung cancer
491726|NCT00734890|stage IIIB non-small cell lung cancer
491727|NCT00734890|stage IV non-small cell lung cancer
491728|NCT00734890|stage III adult Burkitt lymphoma
491729|NCT00734890|stage III adult diffuse large cell lymphoma
491730|NCT00734890|stage III adult diffuse mixed cell lymphoma
491731|NCT00734890|stage III adult diffuse small cleaved cell lymphoma
491732|NCT00734890|stage III adult Hodgkin lymphoma
491733|NCT00734890|stage III adult immunoblastic large cell lymphoma
491734|NCT00734890|stage III adult lymphoblastic lymphoma
491735|NCT00734890|stage III adult T-cell leukemia/lymphoma
491736|NCT00734890|stage III cutaneous T-cell non-Hodgkin lymphoma
491737|NCT00734890|stage III grade 1 follicular lymphoma
491738|NCT00734890|stage III grade 2 follicular lymphoma
491739|NCT00734890|stage III grade 3 follicular lymphoma
491740|NCT00734890|stage III mantle cell lymphoma
491741|NCT00734890|stage III marginal zone lymphoma
491742|NCT00734890|stage III mycosis fungoides/Sezary syndrome
491743|NCT00734890|stage III small lymphocytic lymphoma
491744|NCT00734890|stage IV adult Burkitt lymphoma
491745|NCT00734890|stage IV adult diffuse large cell lymphoma
491746|NCT00734890|stage IV adult diffuse mixed cell lymphoma
491747|NCT00734890|stage IV adult diffuse small cleaved cell lymphoma
491748|NCT00734890|stage IV adult Hodgkin lymphoma
491749|NCT00734890|stage IV adult immunoblastic large cell lymphoma
491750|NCT00734890|stage IV adult lymphoblastic lymphoma
491751|NCT00734890|stage IV adult T-cell leukemia/lymphoma
491752|NCT00734890|stage IV cutaneous T-cell non-Hodgkin lymphoma
491753|NCT00734890|stage IV grade 1 follicular lymphoma
491754|NCT00734890|stage IV grade 2 follicular lymphoma
491755|NCT00734890|stage IV grade 3 follicular lymphoma
491756|NCT00734890|stage IV mantle cell lymphoma
491757|NCT00734890|stage IV marginal zone lymphoma
491758|NCT00734890|stage IV mycosis fungoides/Sezary syndrome
491759|NCT00734890|stage IV small lymphocytic lymphoma
491760|NCT00734864|Dasatinib
491761|NCT00734864|Sprycel
491762|NCT00734864|Temozolomide
491763|NCT00734864|Temodar
491764|NCT00734864|Recurrent Malignant Glioma
491765|NCT00734864|Malignant Glioma
491766|NCT00734864|glioblastoma multiforme
491767|NCT00734864|gliosarcoma
491768|NCT00734864|anaplastic astrocytoma
491769|NCT00734864|anaplastic oligodendroglioma
491770|NCT00734864|anaplastic mixed glioma
491771|NCT00734864|glioma
491772|NCT00734851|prostate cancer
491773|NCT00734851|sunitinib
491774|NCT00734851|docetaxel
491775|NCT00734851|PSA
491776|NCT00734851|radiation
491777|NCT00734851|PSA recurrence
491778|NCT00734851|No metastatic disease
491779|NCT00734838|Breast Cancer
491780|NCT00734838|Breast Biopsy
491781|NCT00734838|Reduction mammoplasty
491782|NCT00734825|Appendicitis
491783|NCT00734825|IV Contrast
491784|NCT00734825|Oral Contrast
491785|NCT00734825|CT scan
491786|NCT00734812|Hysterectomy
491787|NCT00734812|Laparoscopic
491788|NCT00734799|Posttraumatic Stress Disorder
491789|NCT00734799|Insomnia,
491790|NCT00734799|Imagery Rehearsal Therapy,
491791|NCT00734799|IRT,
491792|NCT00734799|Cognitive Behavioral Therapy for Insomnia,
491793|NCT00734799|CBTI.
491794|NCT00734786|gonyautoxin
491795|NCT00734773|neurotoxicity
491796|NCT00734773|primary central nervous system non-Hodgkin lymphoma
491797|NCT00734773|primary central nervous system Hodgkin lymphoma
491798|NCT00734760|patient education
491799|NCT00734760|acute coronary syndrome
491800|NCT00734760|prehospital delay to treatment
491801|NCT00734747|GERD
491802|NCT00734747|Gastroesophageal Reflux
491803|NCT00734747|Fundoplication
491804|NCT00734747|Endoluminal
491805|NCT00734747|Gastroesophageal Flap Valve
491806|NCT00734734|Prophylaxis of Influenza
491807|NCT00734734|Influenza Vaccines
491808|NCT00734734|MF59C.1
491809|NCT00734721|intravitreal injection
491810|NCT00734695|BURN
491811|NCT00734695|EYE
491812|NCT00734695|VITAMIN C
491813|NCT00734695|ASCORBIC ACID
491814|NCT00734682|Glioblastoma
491815|NCT00734682|Gliosarcoma
491816|NCT00734682|Anaplastic Astrocytoma
491817|NCT00734682|Anaplastic Oligodendroglioma
491818|NCT00734682|Anaplastic Mixed Oligoastrocytoma
491819|NCT00734682|Malignant Astrocytoma NOS
491820|NCT00734682|Nanoliposomal CPT-11
491821|NCT00734682|liposomal irinotecan
491822|NCT00734669|Diabetes
491823|NCT00734669|Hypoglycemia
491824|NCT00734656|steroid 5Alpha Reductase
491825|NCT00734656|dutasteride
491826|NCT00734656|neuroactive steroid
491827|NCT00734643|Hypoplastic Left Heart Syndrome
491828|NCT00734643|Family coping
491829|NCT00734643|Complex Congenital Heart Disease
491830|NCT00734630|nebivolol
491831|NCT00734630|Bystolic ™
491832|NCT00734630|lisinopril
491833|NCT00734630|losartan
491834|NCT00734630|Hypertension
491835|NCT00734617|Cigarette
491836|NCT00734617|Nicotine
491837|NCT00734591|Observational Study Exubera
491838|NCT00734565|vaccine
491839|NCT00734565|prevention
491840|NCT00734565|haemophilus influenzae type b
491841|NCT00734565|children
491842|NCT00734552|Continuous Ambulatory Peritoneal Dialysis
491843|NCT00734552|α-Keto Acid
491844|NCT00734552|Low Protein Diet
491845|NCT00734552|Residual Renal Function
491846|NCT00734539|Candida
491847|NCT00734539|Neonate
491848|NCT00734539|Fluconazole
491849|NCT00734539|Prophylaxis
491850|NCT00734539|Colonization
491851|NCT00734539|Resistance
491852|NCT00734526|Glioblastoma
491853|NCT00734526|Gliosarcoma
491854|NCT00734526|Brain Cancer
491855|NCT00734526|Sorafenib
491856|NCT00734526|Temozolomide
491857|NCT00734526|Radiation
491858|NCT00734526|Radiotherapy
491859|NCT00734526|XRT
491860|NCT00734513|GI Cancer
491861|NCT00734513|Emotional Disclosure
491862|NCT00734513|Behavioral Intervention
491863|NCT00734513|Partner
491864|NCT00734513|Couples
491865|NCT00734487|Spectral Domain Optical Coherence Tomography
491866|NCT00734487|Optical Coherence Tomography
491867|NCT00734487|AREDS2
491868|NCT00734487|AMD
491869|NCT00734487|Age-related macular degeneration
491870|NCT00734487|Drusen
491871|NCT00734474|Diabetes, type 2 diabetes
491872|NCT00734461|Non-physically dependent subjects
491873|NCT00734461|history of opioid abuse
491874|NCT00734448|gestational diabetes mellitus
491875|NCT00734448|carbohydrate intolerance
491876|NCT00734448|myo-inositol
491877|NCT00734448|insulin resistance
491878|NCT00734435|schizophrenia
491879|NCT00734435|schizophreniform
491880|NCT00734435|schizoaffective disorder
491881|NCT00734435|Zyprexa
491882|NCT00734435|olanzapine
491883|NCT00734422|Phobic Disorders (Fear of Flying)
491884|NCT00734422|Virtual Reality Exposure Therapy
491885|NCT00734422|Fear extinction
491886|NCT00734422|Yohimbine
491887|NCT00734409|Mechanical ventilation
491888|NCT00734409|Human
491889|NCT00734409|conscious sedation
491890|NCT00734409|bispectral index
491891|NCT00734409|monitoring
491892|NCT00734409|critical care
491893|NCT00734409|propofol
491894|NCT00734396|Mesenchymal stem cells
491895|NCT00734396|Allograft rejection
491896|NCT00734396|Subclinical rejection
491897|NCT00734383|coronary artery bypass surgery
491898|NCT00734383|coronary artery bypass grafting
491899|NCT00734383|cardiopulmonary bypass
491900|NCT00734383|diabetes
491901|NCT00734383|myocardial injury markers,
491902|NCT00734383|sex differences
491903|NCT00734383|cardiac anesthesia
491904|NCT00734383|inhalational anesthetics
491905|NCT00734370|Panic Disorder and Agoraphobia
491906|NCT00734370|Virtual Reality Exposure Therapy
491907|NCT00734357|contrast
491908|NCT00734357|ct
491909|NCT00734357|cat scan
491910|NCT00734357|kidney
491911|NCT00734357|nephrotoxicity
491912|NCT00734357|Computerized Emission Tomography
491913|NCT00734331|inflammatory bowel disease
491914|NCT00734331|micro RNA
491915|NCT00734331|cholinergic tone
491916|NCT00734331|inflammation
491917|NCT00734318|Severe asthma
491918|NCT00734318|Fluticasone
491919|NCT00734318|Formoterol
491920|NCT00734305|cancer, solid tumors, oncology, Phase I, ErbB3, HER3
491921|NCT00734305|(erbB-3, HER-3)
491922|NCT00734292|Asthma
491923|NCT00734292|Asthma Mild to Moderate
491924|NCT00734279|Puberty
491925|NCT00734279|Delayed
491926|NCT00734279|Early
491927|NCT00734279|Precocious
491928|NCT00734279|Peripubertal
491929|NCT00734279|Gonadotropin
491930|NCT00734279|FSH
491931|NCT00734279|LH
491932|NCT00734266|COPD
491933|NCT00734266|CPB
491934|NCT00734266|Leukotrienes
491935|NCT00734253|Nephropathy
491936|NCT00734253|Kidney Disease
491937|NCT00734253|Diabetes
491938|NCT00734253|Pyridoxamine
491939|NCT00734253|Pyridorin
491940|NCT00734253|NephroGenex
491941|NCT00734253|PYR-210
491942|NCT00734227|Survival and control of hemorrhage
491943|NCT00734214|Parenteral Fluids
491944|NCT00734214|Isotonic
491945|NCT00734214|Hypotonic
491946|NCT00734214|Pediatric
491947|NCT00734214|Fluid overload
491948|NCT00734201|Study effects on blood pressure and weight in obese subjects
491949|NCT00734175|Vaccine
491950|NCT00734175|Influenza
491951|NCT00734162|tenofovir
491952|NCT00734162|adolescents
491953|NCT00734162|chronic hepatitis B
491954|NCT00734149|Multiple myeloma
491955|NCT00734136|Angiogenic Factors
491956|NCT00734136|Hepatorenal Syndrome
491957|NCT00734136|Liver Disease
491958|NCT00734136|Renal Failure
491959|NCT00734136|Liver Cirrhosis
491960|NCT00734136|Ascites
491961|NCT00734123|Atherosclerosis
491962|NCT00734123|Cardiovascular Prevention
491963|NCT00734123|Carotid Intima-Media Thickness
491964|NCT00734123|Ankle-Brachial Index
491965|NCT00734110|Arthroplasty, Replacement, Knee, P.F.C. Sigma RPF, Sigma RP
491966|NCT00734097|heartburn
491967|NCT00734097|reflux
491968|NCT00734097|proton
491969|NCT00734097|pump
491970|NCT00734097|inhibitor
491971|NCT00734084|Arthroplasty
491972|NCT00734084|Knee
491973|NCT00734084|UKA
491974|NCT00734084|Partial
491975|NCT00734084|Preservation
491976|NCT00734071|Generalized Anxiety Disorder
491977|NCT00734071|Mood Disorder
491978|NCT00734071|Affective Disorder
491979|NCT00734071|Anxiety Disorder
491980|NCT00734071|Drug Therapy
491981|NCT00734058|Ablation
491982|NCT00734058|AF
491983|NCT00734058|Atrial Fibrillation
491984|NCT00734058|Cardiac
491985|NCT00734058|Endocardial
491986|NCT00734058|Endocardium
491987|NCT00734058|EP
491988|NCT00734058|Electrophysiology
491989|NCT00734058|Epicardial
491990|NCT00734058|Epicardium
491991|NCT00734058|Heart
491992|NCT00734058|Interventional
491993|NCT00734058|Lesion
491994|NCT00734058|PVI
491995|NCT00734058|Pulmonary Vein
491996|NCT00734058|MAZE
491997|NCT00734058|Surgery
491998|NCT00734058|Surgical
491999|NCT00734058|Treatment
492000|NCT00734058|Patients with persistent AF with 3 months duration
492001|NCT00734058|Requiring concomitant open heart surgery
492002|NCT00734045|Congestive Heart Failure (CHF)
492003|NCT00734045|NT-proBNP
492004|NCT00734032|SB-480848
492005|NCT00734032|Dyslipidaemia
492006|NCT00734019|Arthroplasty, Replacement, Knee, TKR, PFC Sigma
492007|NCT00734006|Cortico-cortical
492008|NCT00734006|connectivity
492009|NCT00734006|Transcranial
492010|NCT00734006|Magnetic
492011|NCT00734006|Stimulation
492012|NCT00733993|substance abuse
492013|NCT00733993|cocaine
492014|NCT00733993|caffeine
492015|NCT00733993|impulsivity
492016|NCT00733980|Depressive Disorder, Major
492017|NCT00733967|Methamphetamine
492018|NCT00733967|Chantix
492019|NCT00733967|Varenicline
492020|NCT00733941|Exercise test
492021|NCT00733941|Running
492022|NCT00733941|Arterial diameter
492023|NCT00733941|Monitoring, physiologic
492024|NCT00733941|Oxygen Consumption
492025|NCT00733928|Arthroplasty,
492026|NCT00733928|Replacement,
492027|NCT00733928|Knee,
492028|NCT00733928|P.F.C.
492029|NCT00733928|Sigma
492030|NCT00733928|all-polyethylene
492031|NCT00733915|Arthroplasty, knee, TKA, TKR, Duofix, Porocoat, LCS
492032|NCT00733902|monoclonal antibody
492033|NCT00733902|RN624
492034|NCT00733902|PF-04383119
492035|NCT00733902|nerve growth factor
492036|NCT00733902|anti-nerve growth factor
492037|NCT00733902|OA
492038|NCT00733902|pain
492039|NCT00733889|esophageal carcinoma
492040|NCT00733889|cetuximab
492041|NCT00733889|docetaxel
492042|NCT00733889|cisplatin
492043|NCT00733889|5-fluorouracil
492044|NCT00733876|Acute Renal Failure Cardiac Surgery Stem Cell
492045|NCT00733863|Active immunization
492046|NCT00733863|Alzheimer disease
492047|NCT00733863|Antibody
492048|NCT00733863|Central Nervous System Diseases
492049|NCT00733863|Neurodegenerative diseases
492050|NCT00733863|Vaccine
492051|NCT00733824|Plerixafor
492052|NCT00733824|Lymphoma
492053|NCT00733824|Hematopoietic Stem Cell Mobilization
492054|NCT00733824|Transplantation, Autologous
492055|NCT00733824|Receptors, CXCR4
492056|NCT00733811|thalassemia major
492057|NCT00733811|chelation treatment
492058|NCT00733811|secondary hemochromatosis
492059|NCT00733798|Melanoma
492060|NCT00733798|Malignant melanoma
492061|NCT00733798|metastatic melanoma
492062|NCT00733798|Phase 1
492063|NCT00733798|Phase 2
492064|NCT00733785|Rosiglitazone XR
492065|NCT00733785|Pharmacokinetics
492066|NCT00733785|Strength Equivalence.
492067|NCT00733785|Alzheimers Disease
492068|NCT00733785|Repeat dose
492069|NCT00733785|Dose proportionality
492070|NCT00733772|flaxseed
492071|NCT00733772|lignans
492072|NCT00733772|alpha-Linolenic Acid
492073|NCT00733772|LDL Cholesterol
492074|NCT00733746|adenocarcinoma of the pancreas
492075|NCT00733746|stage I pancreatic cancer
492076|NCT00733746|stage II pancreatic cancer
492077|NCT00733733|kidney
492078|NCT00733733|transplantation
492079|NCT00733733|non-heart-beating donor
492080|NCT00733733|delayed graft function
492081|NCT00733733|Antithymocyte globulin
492082|NCT00733733|ischemia-reperfusion damage
492083|NCT00733707|adherence
492084|NCT00733707|oral contraceptive pills
492085|NCT00733707|contraception
492086|NCT00733707|text messaging
492087|NCT00733694|Arthroplasty, Replacement, Knee,LCS
492088|NCT00733681|Arthroplasty, Replacement, Knee
492089|NCT00733681|Prosthesis Failure
492090|NCT00733681|Revision surgery
492091|NCT00733668|considered
492092|NCT00733668|entry
492093|NCT00733668|into
492094|NCT00733668|the study
492095|NCT00733668|SSRI
492096|NCT00733668|Seroquel
492097|NCT00733668|Quetiapine
492098|NCT00733668|fumarate
492099|NCT00733668|antipsychotic
492100|NCT00733642|antibody amyloid Alzheimer's Disease AD
492101|NCT00733616|advanced gastric adenocarcinoma
492102|NCT00733616|docetaxel
492103|NCT00733616|oxaliplatin
492104|NCT00733616|capecitabine
492105|NCT00733616|intermediate general status
492106|NCT00733603|Interstitial Cystitis
492107|NCT00733603|IC
492108|NCT00733603|Painful Bladder Syndrome
492109|NCT00733603|PBS
492110|NCT00733603|Bladder Pain
492111|NCT00733603|Pelvic Pain
492112|NCT00733590|defibrillator, implanted
492113|NCT00733590|genomics
492114|NCT00733590|electrocardiography
492115|NCT00733590|electrophysiological study
492116|NCT00733590|proteomics
492117|NCT00733577|diabetes
492118|NCT00733577|pharmacodynamics
492119|NCT00733577|safety
492120|NCT00733577|pharmacokinetics
492121|NCT00733564|Local anesthetic
492122|NCT00733564|Propofol
492123|NCT00733564|Sevoflurane
492124|NCT00733551|motilin
492125|NCT00733551|gastric emptying
492126|NCT00733551|GSK962040
492127|NCT00733551|oral dose
492128|NCT00733538|stage I multiple myeloma
492129|NCT00733525|Bulimia Nervosa
492130|NCT00733512|ReSTOR Aspheric +4 IOL
492131|NCT00733499|Arthroplasty, replacement, Knee, LCS Duofix, Porocoat
492132|NCT00733486|Arthroplasty, Replacement, Knee, LCS Complete APG (MeSH);
492133|NCT00733473|Wheezing
492134|NCT00733473|Acute asthma
492135|NCT00733473|Children
492136|NCT00733460|BFPET
492137|NCT00733460|Coronary Artery Disease
492138|NCT00733460|Myocardial Perfusion Imaging
492139|NCT00733460|Radiation Dosimetry
492140|NCT00733447|Biventricular failure
492141|NCT00733434|Microsurgery
492142|NCT00733434|Head and neck
492143|NCT00733434|Prostaglandin E1
492144|NCT00733434|Thrombosis
492145|NCT00733434|Complication
492146|NCT00733421|Day surgery
492147|NCT00733421|Hallux Valgus
492148|NCT00733421|Pain
492149|NCT00733421|Analgesics
492150|NCT00733395|Muscle pain
492151|NCT00733382|migraine
492152|NCT00733382|dexamethasone
492153|NCT00733382|dihydroergotamine
492154|NCT00733369|Arthroplasty
492155|NCT00733369|Replacement
492156|NCT00733369|Knee
492157|NCT00733369|PFC Sigma RPF
492158|NCT00733369|PFC Sigma RP
492159|NCT00733356|Attention Deficit Hyperactivity Disorder
492160|NCT00733356|ADHD
492161|NCT00733356|ADD
492162|NCT00733356|reading
492163|NCT00733356|brain hemodynamics
492164|NCT00733356|brain imaging
492165|NCT00733356|attention
492166|NCT00733356|Near-Infrared Spectroscopy
492167|NCT00733356|NIRS
492168|NCT00733356|MSIT
492169|NCT00733343|heart failure
492170|NCT00733343|sleep disordered breathing
492171|NCT00733343|sleep apnea
492172|NCT00733343|left ventricular systolic dysfunction
492173|NCT00733343|SBAS
492174|NCT00733343|HF
492175|NCT00733330|Arthroplasty, Knee, TKA, TKR, CAS, minimally invasive
492176|NCT00733317|Wheezing
492177|NCT00733317|Acute asthma
492178|NCT00733317|Children
492179|NCT00733317|Budesonide
492180|NCT00733317|Emergency room
492181|NCT00733304|vascular endothelial growth factor (VEGF)
492182|NCT00733304|choroidal neovascularization (CNV)
492183|NCT00733304|age-related macular degeneration (AMD)
492184|NCT00733304|pazopanib
492185|NCT00733304|angiogenesis
492186|NCT00733291|Daily disposable contact lenses
492187|NCT00733291|Multi-purpose disinfecting solutions
492188|NCT00733278|Postpartum contraception
492189|NCT00733278|Copper IUD
492190|NCT00733265|Renal Impairment
492191|NCT00733252|non-small cell lung cancer
492192|NCT00733252|small cell lung cancer
492193|NCT00733252|benign respiratory tract neoplasm
492194|NCT00733252|lung papilloma
492195|NCT00733252|recurrent respiratory papillomatosis
492196|NCT00733252|squamous lung dysplasia
492197|NCT00733252|malignant mesothelioma
492198|NCT00733252|pulmonary carcinoid tumor
492199|NCT00733252|lung metastases
492200|NCT00733239|methadone
492201|NCT00733239|opioid dependence
492202|NCT00733239|opioid
492203|NCT00733226|wheezing
492204|NCT00733226|asthma
492205|NCT00733226|childhood
492206|NCT00733226|OM-85 BV
492207|NCT00733226|Broncho-Vaxom
492208|NCT00733213|Prostate Cancer, Treatment alternatives, Metastasis
492209|NCT00733200|Minor Liver Resection
492210|NCT00733200|Major Liver Resection
492211|NCT00733200|Hilar
492212|NCT00733174|IGT
492213|NCT00733161|passive leg exercise
492214|NCT00733161|congestive heart failure
492215|NCT00733161|endothelium-derived factors
492216|NCT00733161|elderly
492217|NCT00733148|glucose, interstitial, intensive care
492218|NCT00733135|peripheral vascular disease
492219|NCT00733135|atherectomy
492220|NCT00733135|atherosclerosis
492221|NCT00733135|calcified lesions
492222|NCT00733109|CIN2
492223|NCT00733109|management
492224|NCT00733096|radiculopathy
492225|NCT00733096|sciatica
492226|NCT00733096|low back pain
492227|NCT00733083|tonsillectomy
492228|NCT00733083|paediatric
492229|NCT00733083|pain
492230|NCT00733083|child
492231|NCT00733083|opiates
492232|NCT00733083|pre-emptive
492233|NCT00733083|oxycodone
492234|NCT00733083|morphine
492235|NCT00733083|dexamethasone
492236|NCT00733070|CTO
492237|NCT00733070|Chronic Total Occlusion
492238|NCT00733070|Revascularization
492239|NCT00733057|Minocycline
492240|NCT00733057|Schizophrenia
492241|NCT00733057|Negative symptoms
492242|NCT00733057|Cognitive
492243|NCT00733044|Objective tinnitus
492244|NCT00733044|Tinnitus
492245|NCT00733044|RCT
492246|NCT00733044|Specialised treatment
492247|NCT00733044|Usual care
492248|NCT00733044|Cost-effectiveness
492249|NCT00733031|Phase I,
492250|NCT00733031|cancer,
492251|NCT00733031|solid tumors,
492252|NCT00733031|advanced solid malignancies,
492253|NCT00733031|dose escalation,
492254|NCT00733031|combination treatment,
492255|NCT00733031|TRK inhibitor
492256|NCT00733018|Nutrigenomics
492257|NCT00733018|Gene Expression
492258|NCT00733018|Diet, Carbohydrate-Restricted
492259|NCT00733018|Life Style
492260|NCT00733018|Health Behavior
492261|NCT00732992|Solid tumor
492262|NCT00732992|malignancy
492263|NCT00732992|sunitinib
492264|NCT00732992|pemetrexed
492265|NCT00732992|phase 1
492266|NCT00732992|neoplasms
492267|NCT00732979|Elective
492268|NCT00732979|hepatic
492269|NCT00732979|resection
492270|NCT00732979|due to any
492271|NCT00732979|reason.
492272|NCT00732966|cyp2c9
492273|NCT00732966|losartan
492274|NCT00732966|pharmacogenetics
492275|NCT00732966|pharmacokinetics
492276|NCT00732966|pharmacodynamics
492277|NCT00732953|patients with coronary artery disease
492278|NCT00732953|percutaneous coronary intervention
492279|NCT00732953|stent implantation
492280|NCT00732953|paclitaxel eluting balloon
492281|NCT00732953|angiographic follow-up
492282|NCT00732953|clinical follow-up
492283|NCT00732940|SLE
492284|NCT00732940|Lupus
492285|NCT00732940|Systemic Lupus Erythematosus
492286|NCT00732940|Antibodies
492287|NCT00732940|Autoimmune Diseases
492288|NCT00732940|Belimumab
492289|NCT00732927|thrombosis, vein, retina
492290|NCT00732914|Renal Cell Carcinoma
492291|NCT00732914|Sunitinib
492292|NCT00732914|Sorafenib
492293|NCT00732914|Sequential
492294|NCT00732901|substance abuse
492295|NCT00732901|cocaine
492296|NCT00732901|impulsivity
492297|NCT00732901|serotonin
492298|NCT00732901|Remeron
492299|NCT00732901|Mirtzapine
492300|NCT00732901|Lexapro
492301|NCT00732901|Escatilopram
492302|NCT00732888|Pharmacokinetics
492303|NCT00732888|Healthy volunteers
492304|NCT00732888|No condition
492305|NCT00732888|Pharmacokinetics study
492306|NCT00732862|Type 2 diabetes
492307|NCT00732862|intensive therapy
492308|NCT00732849|immunonutrition
492309|NCT00732849|surgical patients
492310|NCT00732849|postoperative period
492311|NCT00732836|Liver Cancer
492312|NCT00732836|Solid Cancer
492313|NCT00732836|Abraxane
492314|NCT00732836|nab paclitaxel
492315|NCT00732836|HAI abraxane
492316|NCT00732836|HAI
492317|NCT00732836|hepatic arterial infusion
492318|NCT00732836|hepatic metastases
492319|NCT00732797|Dizziness
492320|NCT00732797|Self-management
492321|NCT00732797|booklet-based
492322|NCT00732797|vestibular rehabilitation
492323|NCT00732784|Pharmacokinetics
492324|NCT00732784|Healthy volunteers
492325|NCT00732784|No condition
492326|NCT00732784|Pharmacokinetics study
492327|NCT00732771|primary hyperaldosteronism
492328|NCT00732771|hypokalemia
492329|NCT00732771|hypertension
492330|NCT00732771|aldosterone synthase inhibitor
492331|NCT00732758|Vitamin D Deficiency
492332|NCT00732758|Vitamin D Insufficiency
492333|NCT00732758|Child
492334|NCT00732758|Adolescent
492335|NCT00732758|African American
492336|NCT00732758|Caucasian
492337|NCT00732758|Definition
492338|NCT00732758|Preadolescent
492339|NCT00732745|adenocarcinoma of the esophagus
492340|NCT00732745|adenocarcinoma of the gastroesophageal junction
492341|NCT00732745|squamous cell carcinoma of the esophagus
492342|NCT00732745|stage III esophageal cancer
492343|NCT00732745|stage IV esophageal cancer
492344|NCT00732745|recurrent esophageal cancer
492345|NCT00732732|diarrhea
492346|NCT00732732|Plantain
492347|NCT00732732|Green banana
492348|NCT00732732|Infants
492349|NCT00732732|Children
492350|NCT00732706|FNB
492351|NCT00732706|Femoral Nerve
492352|NCT00732706|Sartorius Twitch
492353|NCT00732706|Quadriceps Twitch
492354|NCT00732706|Analgesia
492355|NCT00732706|Anesthesia
492356|NCT00732693|Premature ovarian failure
492357|NCT00732693|Sex hormone replacement
492358|NCT00732693|HRT
492359|NCT00732693|Blood pressure
492360|NCT00732693|Bone mineral density
492361|NCT00732693|Bone metabolism
492362|NCT00732693|Uterine function
492363|NCT00732680|Empty nose syndrome
492364|NCT00732680|Over resection of turbinate
492365|NCT00732680|Atrophic rhinitis
492366|NCT00732654|Food Allergy
492367|NCT00732654|Oral Immunotherapy
492368|NCT00732654|Immunoglobulin E
492369|NCT00732615|Hypoparathyroidism
492370|NCT00732602|Glucagon
492371|NCT00732602|Glucose-dependent Insulinotropic Polypeptide
492372|NCT00732602|Glucagon-Like peptide 2
492373|NCT00732589|suprascapular nerve block
492374|NCT00732589|shoulder pain
492375|NCT00732589|hemiplegia
492376|NCT00732576|Cardiovascular
492377|NCT00732576|Calcification
492378|NCT00732563|stage I non-small cell lung cancer
492379|NCT00732563|stage II non-small cell lung cancer
492380|NCT00732550|cholelithiasis
492381|NCT00732550|cholecystitis
492382|NCT00732537|Hypoxia
492383|NCT00732537|Respiratory failure
492384|NCT00732537|Infant, term
492385|NCT00732537|Nitric oxide
492386|NCT00732524|Hyperglycemia
492387|NCT00732524|Glucose toxicity
492388|NCT00732524|Glargine
492389|NCT00732524|Glipizide
492390|NCT00732511|Endothelial dysfunction
492391|NCT00732511|Blood vessel stiffness
492392|NCT00732511|Nitric oxide
492393|NCT00732511|Oxidative stress
492394|NCT00732498|contiguous stage II grade 1 follicular lymphoma
492395|NCT00732498|contiguous stage II grade 2 follicular lymphoma
492396|NCT00732498|contiguous stage II grade 3 follicular lymphoma
492397|NCT00732498|noncontiguous stage II grade 1 follicular lymphoma
492398|NCT00732498|noncontiguous stage II grade 2 follicular lymphoma
492399|NCT00732498|noncontiguous stage II grade 3 follicular lymphoma
492400|NCT00732498|recurrent grade 1 follicular lymphoma
492401|NCT00732498|recurrent grade 2 follicular lymphoma
492402|NCT00732498|recurrent grade 3 follicular lymphoma
492403|NCT00732498|stage III grade 1 follicular lymphoma
492404|NCT00732498|stage III grade 2 follicular lymphoma
492405|NCT00732498|stage III grade 3 follicular lymphoma
492406|NCT00732498|stage IV grade 1 follicular lymphoma
492407|NCT00732498|stage IV grade 2 follicular lymphoma
492408|NCT00732498|stage IV grade 3 follicular lymphoma
492409|NCT00732485|Burn injury
492410|NCT00732485|Fenofibrate
492411|NCT00732485|Insulin resistance
492412|NCT00732485|Mitochondrial function
492413|NCT00732485|Fat oxidation
492414|NCT00732485|PPAR
492415|NCT00732485|Protein
492416|NCT00732485|Glucose
492417|NCT00732485|Wound
492418|NCT00732472|Chronic Obstructive Pulmonary Disease (COPD)
492419|NCT00732472|Magnesium stearate
492420|NCT00732472|GSK573719
492421|NCT00732459|myocardial protection
492422|NCT00732459|cardiac surgery
492423|NCT00732459|heart valve replacement
492424|NCT00732446|moxifloxacin
492425|NCT00732446|dexamethasone
492426|NCT00732446|ocular inflammation
492427|NCT00732446|ocular infection
492428|NCT00732420|pazopanib
492429|NCT00732420|Phase I
492430|NCT00732420|topotecan
492431|NCT00732420|Advanced Solid Tumors
492432|NCT00732407|aliskiren
492433|NCT00732407|arteial stiffness
492434|NCT00732407|platelet function
492435|NCT00732407|diabetes mellitus
492436|NCT00732355|syphilis
492437|NCT00732342|Alcohol Abuse
492438|NCT00732342|Contingency Management
492439|NCT00732342|Treatment Duration
492440|NCT00732316|accelerated phase chronic myelogenous leukemia
492441|NCT00732316|adult acute lymphoblastic leukemia in remission
492442|NCT00732316|adult acute myeloid leukemia in remission
492443|NCT00732316|acute undifferentiated leukemia
492444|NCT00732316|blastic phase chronic myelogenous leukemia
492445|NCT00732316|childhood acute lymphoblastic leukemia in remission
492446|NCT00732316|childhood acute myeloid leukemia in remission
492447|NCT00732316|childhood chronic myelogenous leukemia
492448|NCT00732316|childhood myelodysplastic syndromes
492449|NCT00732316|chronic phase chronic myelogenous leukemia
492450|NCT00732316|chronic myelomonocytic leukemia
492451|NCT00732316|de novo myelodysplastic syndromes
492452|NCT00732316|previously treated myelodysplastic syndromes
492453|NCT00732316|recurrent childhood acute lymphoblastic leukemia
492454|NCT00732316|recurrent childhood acute myeloid leukemia
492455|NCT00732316|recurrent adult acute lymphoblastic leukemia
492456|NCT00732316|recurrent adult acute myeloid leukemia
492457|NCT00732316|refractory anemia with excess blasts
492458|NCT00732316|refractory anemia with excess blasts in transformation
492459|NCT00732316|relapsing chronic myelogenous leukemia
492460|NCT00732316|secondary myelodysplastic syndromes
492461|NCT00732290|Healthy volunteer
492462|NCT00732290|Pharmacokinetic
492463|NCT00732290|pharmacodynamic
492464|NCT00732290|Polymorphism, Genetic
492465|NCT00732277|sepsis
492466|NCT00732277|septicaemia
492467|NCT00732277|septicemia
492468|NCT00732277|paediatric
492469|NCT00732277|pediatric
492470|NCT00732277|children
492471|NCT00732251|Bipolar Disorder
492472|NCT00732251|Stable Bipolar Disorder
492473|NCT00732251|Mania
492474|NCT00732251|Mixed mania
492475|NCT00732251|Allopurinol
492476|NCT00732238|Spinal Cord Injury
492477|NCT00732238|Urinary Tract Infection
492478|NCT00732238|Catheter Dependent
492479|NCT00732225|DisCoVisc OVD
492480|NCT00732225|Ophthalmic Viscosurgical Device
492481|NCT00732212|UGI Bleeding
492482|NCT00732212|Ulcer or variceal hemorrhage
492483|NCT00732212|Stigmata of recent hemorrhage
492484|NCT00732212|Endoscopy
492485|NCT00732212|Randomized Controlled Trial
492486|NCT00732212|Non-variceal UGI hemorrhage
492487|NCT00732212|Variceal hemorrhage
492488|NCT00732199|Sleep apnea syndromes
492489|NCT00732199|central apnea
492490|NCT00732199|hypoxia
492491|NCT00732199|aging
492492|NCT00732173|stage I endometrial carcinoma
492493|NCT00732173|stage II endometrial carcinoma
492494|NCT00732160|Glucose
492495|NCT00732160|Insulin
492496|NCT00732147|triglycerides
492497|NCT00732147|endogenous
492498|NCT00732147|glucose
492499|NCT00732147|production
492500|NCT00732121|Type 2 Diabetes
492501|NCT00732108|migraine
492502|NCT00732108|headache
492503|NCT00732108|dizziness
492504|NCT00732108|vertigo
492505|NCT00732108|topiramate
492506|NCT00732108|Topamax
492507|NCT00732095|Self-change
492508|NCT00732095|Natural recovery
492509|NCT00732095|Alcohol Drinking
492510|NCT00732095|Mechanisms of Change
492511|NCT00732095|Advertisements
492512|NCT00732082|LAG-3 and gemcitabine treatment for advanced pancreas cancer
492513|NCT00732069|hemodialysis
492514|NCT00732069|oxidative stress
492515|NCT00732069|inflammation
492516|NCT00732069|kallikrein-kinin
492517|NCT00732069|angiotensin receptor blockade
492518|NCT00732069|angiotensin converting enzyme inhibition
492519|NCT00732069|RAAS
492520|NCT00732069|fibrinolysis
492521|NCT00732069|endothelial dysfunction
492522|NCT00732056|Metastatic Breast Cancer
492523|NCT00732056|Recurrent Breast Cancer
492524|NCT00732043|prostate cancer
492525|NCT00732043|prostate-specific antigen
492526|NCT00732043|PSA
492527|NCT00732043|pomegranate
492528|NCT00732030|Toric IOL
492529|NCT00732017|Sprain
492530|NCT00732017|Electric stimulation
492531|NCT00732017|Physical trauma
492532|NCT00732017|Inflammation
492533|NCT00731991|Muscle
492534|NCT00731978|Near-Infrared Spectroscopy
492535|NCT00731978|Intraoperative Care
492536|NCT00731965|Arthritis, Juvenile Rheumatoid
492537|NCT00731965|Measles-Mumps-Rubella Vaccine
492538|NCT00731965|Serology
492539|NCT00731965|Lymphocytes
492540|NCT00731952|surgically resectable
492541|NCT00731939|Erectile Dysfunction
492542|NCT00731939|Penile implant
492543|NCT00731939|Titan
492544|NCT00731913|Surgical wounds
492545|NCT00731913|Sutures
492546|NCT00731900|pharmacogenetic
492547|NCT00731900|study
492548|NCT00731900|Topirmate
492549|NCT00731900|induced
492550|NCT00731887|Burn injury
492551|NCT00731887|Burn recovery
492552|NCT00731874|Kidney transplantation
492553|NCT00731874|Immunosuppression
492554|NCT00731874|Minimization
492555|NCT00731874|Tacrolimus
492556|NCT00731874|Prograf
492557|NCT00731874|Thymoglobulin
492558|NCT00731848|prostate cancer
492559|NCT00731848|prostate-specific antigens
492560|NCT00731848|PSA
492561|NCT00731835|Vascular
492562|NCT00731822|Chronic Obstructive Pulmonary Disease
492563|NCT00731822|Novel Dry Powder Inhaler
492564|NCT00731822|Chronic Obstructive Pulmonary Disease (COPD)
492565|NCT00731822|GW685698/GW642444
492566|NCT00731809|Crohn's disease
492567|NCT00731796|Stroke
492568|NCT00731796|Retrochiasmatic
492569|NCT00731796|Vision
492570|NCT00731796|VFD
492571|NCT00731783|Abscesses
492572|NCT00731783|Furunculosis
492573|NCT00731783|Staphylococcus aureus colonization
492574|NCT00731783|Staphylococcal Skin Infections
492575|NCT00731783|MRSA
492576|NCT00731770|COPD
492577|NCT00731770|sleep
492578|NCT00731770|daytime somnolence
492579|NCT00731718|Head Lice
492580|NCT00731692|FTY720, primary progressive multiple sclerosis,PPMS
492581|NCT00731679|IBS
492582|NCT00731679|Abdominal pain
492583|NCT00731679|Bloating
492584|NCT00731679|Diarrhea
492585|NCT00731679|Rifaximin
492586|NCT00731666|penile length
492587|NCT00731666|IPP
492588|NCT00731666|Erectile dysfunction
492589|NCT00731653|depression
492590|NCT00731653|combination
492591|NCT00731640|AcrySof
492592|NCT00731640|ReSTOR
492593|NCT00731640|Multifocal
492594|NCT00731640|Intraocular Lens
492595|NCT00731627|intracranial aneurysm
492596|NCT00731614|cognitive therapy
492597|NCT00731614|mirror training
492598|NCT00731614|nondirective therapy
492599|NCT00731614|veterans
492600|NCT00731614|amputees
492601|NCT00731601|shock
492602|NCT00731601|peptic ulcer bleeding
492603|NCT00731601|rebleeding
492604|NCT00731575|asthma
492605|NCT00731575|child
492606|NCT00731575|pathogenesis
492607|NCT00731575|rhinovirus
492608|NCT00731575|prednisolone
492609|NCT00731575|Prevention
492610|NCT00731575|pediatric
492611|NCT00731562|food, varenicline, pharmacokinetics, bioavailability
492612|NCT00731549|Aripiprazole
492613|NCT00731549|IM Depot
492614|NCT00731549|Schizophrenia
492615|NCT00731549|Intramuscular
492616|NCT00731536|Hepatosplenic T-cell Lymphoma
492617|NCT00731536|Remicade
492618|NCT00731536|Infliximab
492619|NCT00731536|Dutch national database of pathology
492620|NCT00731536|PALGA
492621|NCT00731536|Autoimmune disease
492622|NCT00731536|Non-Hodgkin lymphoma
492623|NCT00731523|FTY720, Pharmacokinetics, Renal insufficiency
492624|NCT00731510|Acute mountain sickness
492625|NCT00731510|Body composition,Hypoxia
492626|NCT00731510|Carbohydrate supplementation
492627|NCT00731510|Expedition,
492628|NCT00731510|Hydration,
492629|NCT00731510|Hypoxia
492630|NCT00731510|Performance
492631|NCT00731497|SODIS
492632|NCT00731497|Drinking Water
492633|NCT00731497|Disinfection
492634|NCT00731497|Intervention Trial
492635|NCT00731484|Dry Eye Disease
492636|NCT00731484|Tear Osmolarity
492637|NCT00731484|Tear Osmolality
492638|NCT00731458|OCT;
492639|NCT00731458|Cirrus;
492640|NCT00731458|Stratus;
492641|NCT00731458|macular thickness
492642|NCT00731445|Z-208
492643|NCT00731432|gingivitis, diabetes mellitus, herbal, oral inflammation
492644|NCT00731419|biliary
492645|NCT00731419|obstruction
492646|NCT00731419|malignant
492647|NCT00731419|stent
492648|NCT00731419|palliation
492649|NCT00731393|Thiomersal-free influenza split vaccine 2003/2004
492650|NCT00731393|Influsplit SSW®/Fluarix™ 2003/2004
492651|NCT00731393|Influenza
492652|NCT00731380|Abraxane
492653|NCT00731380|Head and Neck Cancer
492654|NCT00731380|Determine
492655|NCT00731380|Maximum
492656|NCT00731380|Tolerated dose
492657|NCT00731380|ABI-007
492658|NCT00731380|Combination
492659|NCT00731380|Cisplatin
492660|NCT00731380|5-Fluorouracil
492661|NCT00731380|Patients
492662|NCT00731354|lipoplasty
492663|NCT00731354|liposuction
492664|NCT00731354|VASER
492665|NCT00731354|body contouring
492666|NCT00731354|body sculpting
492667|NCT00731354|Any patient
492668|NCT00731354|expressing
492669|NCT00731354|interest
492670|NCT00731354|in elective surgery
492671|NCT00731341|Uterine fibroids
492672|NCT00731341|Leiomyoma
492673|NCT00731341|Menorrhagia
492674|NCT00731341|Hysteroscopic cryoablation
492675|NCT00731341|Minimally invasive
492676|NCT00731328|refractory anemia
492677|NCT00731328|refractory anemia with ringed sideroblasts
492678|NCT00731328|refractory cytopenia with multilineage dysplasia
492679|NCT00731328|childhood myelodysplastic syndromes
492680|NCT00731328|de novo myelodysplastic syndromes
492681|NCT00731328|previously treated myelodysplastic syndromes
492682|NCT00731328|secondary myelodysplastic syndromes
492683|NCT00731328|aplastic anemia
492684|NCT00731328|paroxysmal nocturnal hemoglobinuria
492685|NCT00731315|UTI
492686|NCT00731315|Kiosk
492687|NCT00731315|Computer Assisted Care
492688|NCT00731315|cystitis
492689|NCT00731289|Osteoarthritis
492690|NCT00731289|Knee
492691|NCT00731289|Hyaluronan
492692|NCT00731289|Gait Analysis
492693|NCT00731276|unspecified adult solid tumor, protocol specific
492694|NCT00731263|Cancer
492695|NCT00731263|Advance solid tumours
492696|NCT00731263|Dose Escalation
492697|NCT00731263|Preliminary efficacy
492698|NCT00731263|AZD8055
492699|NCT00731263|Tor kinase inhibitor
492700|NCT00731263|Oral administration
492701|NCT00731250|Capsaicin challenge
492702|NCT00731237|Drug Eluting Stent
492703|NCT00731237|Percutaneous Coronary Intervention
492704|NCT00731237|Everolimus
492705|NCT00731224|Alzheimer's disease, rivastigmine, patch
492706|NCT00731211|Renal Cell Carcinoma
492707|NCT00731211|Metastatic
492708|NCT00731211|Pazopanib
492709|NCT00731211|Previously-treated
492710|NCT00731198|ERCP
492711|NCT00731198|Drotaverine hydrochloride
492712|NCT00731198|Hyoscine-N-butylbromide
492713|NCT00731185|functional
492714|NCT00731185|endoscopic
492715|NCT00731185|sinus
492716|NCT00731185|surgery
492717|NCT00731172|crohns disease
492718|NCT00731146|Interscalene Brachial Plexus Block
492719|NCT00731146|Regional Anesthesia
492720|NCT00731146|Ultrasound guided peripheral nerve block
492721|NCT00731146|Minimum Effective Anesthetic Volume
492722|NCT00731146|Nerve Stimulator guided peripheral nerve block
492723|NCT00731133|disulfiram
492724|NCT00731133|methamphetamine dependence
492725|NCT00731133|open label
492726|NCT00731120|Generalized Anxiety Disorder
492727|NCT00731120|Mood Disorder
492728|NCT00731120|Affective Disorder
492729|NCT00731120|Anxiety Disorder
492730|NCT00731120|Drug Therapy
492731|NCT00731107|Veress Needle
492732|NCT00731107|XCEL bladeless trocar
492733|NCT00731107|Laparoscopic entry techniques
492734|NCT00731094|overweight
492735|NCT00731094|sedentary lifestyle
492736|NCT00731094|exercise
492737|NCT00731094|primary health care
492738|NCT00731094|controlled clinical trials, randomized
492739|NCT00731068|Achilles tendon
492740|NCT00731042|Skin health
492741|NCT00731029|Influenza
492742|NCT00731029|Thiomersal-free influenza split vaccine 2002/2003
492743|NCT00731029|Influsplit SSW®/Fluarix™ 2002/2003
492744|NCT00731003|serotonin
492745|NCT00731003|gut permeability
492746|NCT00731003|visceral sensitivity
492747|NCT00731003|irritable bowel syndrome
492748|NCT00730990|Positron Emission Tomography study in healthy volunteers for ligand qualification and receptor occupancy determination.
492749|NCT00730964|Surveillance
492750|NCT00730964|Optison
492751|NCT00730964|Perflutren
492752|NCT00730964|Echocardiography
492753|NCT00730964|Subjects receive Optison during enhanced echocardiography
492754|NCT00730938|fibrin
492755|NCT00730938|endophthalmitis
492756|NCT00730938|cataract extraction
492757|NCT00730938|Lens
492758|NCT00730938|implantation,
492759|NCT00730938|intraocular
492760|NCT00730886|Uterine Fibroids
492761|NCT00730886|Unexplained Infertility
492762|NCT00730886|MRgFUS
492763|NCT00730886|ExAblate
492764|NCT00730886|Focused Ultrasound
492765|NCT00730886|Myomectomy
492766|NCT00730860|radiofrequency ablation
492767|NCT00730860|Cancer of Liver
492768|NCT00730860|postoperative
492769|NCT00730860|transhepatic arterial chemoembolization
492770|NCT00730860|prospective
492771|NCT00730847|PMS
492772|NCT00730847|Post-marketing surveillance
492773|NCT00730847|Safety
492774|NCT00730847|Prescribing Information
492775|NCT00730847|Philippines
492776|NCT00730847|HPV
492777|NCT00730847|Human papillomavirus
492778|NCT00730834|tinnitus
492779|NCT00730834|ringing in the ears
492780|NCT00730834|buzzing
492781|NCT00730834|static
492782|NCT00730834|hyperacusis
492783|NCT00730834|loudness discomfort
492784|NCT00730834|Clinically
492785|NCT00730834|significant
492786|NCT00730834|discomfort
492787|NCT00730808|Enteral nutritional regimen prior to surgery
492788|NCT00730795|Tuberculosis vaccine
492789|NCT00730769|Valganciclovir
492790|NCT00730769|Ganciclovir
492791|NCT00730769|Pharmacokinetics
492792|NCT00730769|Solid organ transplantation
492793|NCT00730769|Transplant
492794|NCT00730756|Adolescents
492795|NCT00730756|Irritant(non-allergic)rhinitis
492796|NCT00730756|Adults
492797|NCT00730756|GW685698
492798|NCT00730756|Air Pollution
492799|NCT00730730|Iliac Artery, Peripheral Vascular Disease (PVD)
492800|NCT00730704|Human Papilloma Virus vaccines
492801|NCT00730704|HPV
492802|NCT00730704|Gardasil
492803|NCT00730704|Post partum
492804|NCT00730691|Generalized Anxiety Disorder
492805|NCT00730691|Mood Disorder
492806|NCT00730691|Affective Disorder
492807|NCT00730691|Anxiety Disorder
492808|NCT00730691|Drug Therapy
492809|NCT00730678|Metabolism
492810|NCT00730678|Pharmacogenetic testing
492811|NCT00730665|PPI partial responders with non-erosive GERD.
492812|NCT00730652|Medarex Inc.
492813|NCT00730626|Probiotics
492814|NCT00730626|Immunity
492815|NCT00730626|Immune response
492816|NCT00730626|Intestinal microflora
492817|NCT00730626|Blood lipids
492818|NCT00730626|Phagocytosis activity
492819|NCT00730613|adult anaplastic astrocytoma
492820|NCT00730613|adult diffuse astrocytoma
492821|NCT00730613|adult pilocytic astrocytoma
492822|NCT00730613|adult subependymal giant cell astrocytoma
492823|NCT00730613|adult anaplastic ependymoma
492824|NCT00730613|adult ependymoma
492825|NCT00730613|adult myxopapillary ependymoma
492826|NCT00730613|adult subependymoma
492827|NCT00730613|adult anaplastic oligodendroglioma
492828|NCT00730613|adult oligodendroglioma
492829|NCT00730613|adult brain stem glioma
492830|NCT00730613|adult giant cell glioblastoma
492831|NCT00730613|adult glioblastoma
492832|NCT00730613|recurrent adult brain tumor
492833|NCT00730613|adult gliosarcoma
492834|NCT00730613|adult mixed glioma
492835|NCT00730613|adult pineal gland astrocytoma
492836|NCT00730600|Thai Traditional massage
492837|NCT00730600|Bone Formation
492838|NCT00730600|Bone Resorption
492839|NCT00730587|Nutrition
492840|NCT00730587|Body Fat
492841|NCT00730587|Infant
492842|NCT00730587|Healthy Babies
492843|NCT00730561|nerve conduction velocity
492844|NCT00730561|hematopoietic stem cell transplantation
492845|NCT00730535|Overactive bladder, Tolterodine,Symptoms Relapse, Predictor
492846|NCT00730522|Methamphetamine
492847|NCT00730522|Dependency
492848|NCT00730522|Addiction
492849|NCT00730522|vigabatrin
492850|NCT00730509|cystic fibrosis
492851|NCT00730509|folate
492852|NCT00730509|vitamin B12
492853|NCT00730496|Embryo culture supernatant
492854|NCT00730496|injection
492855|NCT00730496|embryo transfer
492856|NCT00730496|embryo implantation rate
492857|NCT00730483|liver metastases
492858|NCT00730483|metastatic gastrointestinal carcinoid tumor
492859|NCT00730483|regional gastrointestinal carcinoid tumor
492860|NCT00730483|islet cell carcinoma
492861|NCT00730483|gastrinoma
492862|NCT00730483|insulinoma
492863|NCT00730483|glucagonoma
492864|NCT00730483|pancreatic polypeptide tumor
492865|NCT00730483|somatostatinoma
492866|NCT00730470|Human Epidermal Growth Factor Receptor 3
492867|NCT00730470|HER3
492868|NCT00730470|Heregulin
492869|NCT00730470|erb B3
492870|NCT00730470|Solid Tumors
492871|NCT00730470|Phase I Clinical Study
492872|NCT00730457|influenza
492873|NCT00730457|recombinant
492874|NCT00730457|hemagglutinin
492875|NCT00730457|vaccine
492876|NCT00730444|Neuroblastoma
492877|NCT00730444|Nuclear medicine
492878|NCT00730444|Diagnostic scintigraphy
492879|NCT00730444|Known and suspected neuroblastoma
492880|NCT00730431|Hepatitis C, healthy volunteers
492881|NCT00730418|Benign Prostatic Hyperplasia
492882|NCT00730418|alpha Adrenergic Blockers
492883|NCT00730418|alpha-1 Adrenergic Receptor
492884|NCT00730405|Distal, Subungual onychomycosis
492885|NCT00730405|onychomycosis
492886|NCT00730405|nail fungus
492887|NCT00730405|Toenail fungus
492888|NCT00730392|Type 1 diabetes, Etanercept, honeymoon period
492889|NCT00730366|Malaria
492890|NCT00730366|Pregnancy
492891|NCT00730366|Intermittent Preventive Treatment
492892|NCT00730340|Tonsillectomy, tonsillar fossa, wound closure
492893|NCT00730314|unrelated
492894|NCT00730314|BMT
492895|NCT00730314|HSCT
492896|NCT00730314|bone marrow transplantation
492897|NCT00730314|sickle cell disease
492898|NCT00730314|thalassemia
492899|NCT00730314|CGD
492900|NCT00730314|HLH
492901|NCT00730314|Blackfan-Diamond anemia
492902|NCT00730314|Hurler
492903|NCT00730314|leukodystrophy
492904|NCT00730314|LAD I
492905|NCT00730314|Genetic diseases
492906|NCT00730314|Red blood cell defects
492907|NCT00730314|Leukocyte defects and immune deficiencies
492908|NCT00730314|Hereditary Lymphohistiocytosis
492909|NCT00730314|chronic granulomatous disease
492910|NCT00730314|Wiskott-Aldrich syndrome
492911|NCT00730314|Chediak Higashi syndrome
492912|NCT00730314|CD40 ligand deficiency
492913|NCT00730314|Hyper IgM syndrome
492914|NCT00730314|leucocytes adhesion defect type 1
492915|NCT00730314|Osteopetrosis
492916|NCT00730314|congenital neutropenia
492917|NCT00730314|X-linked lymphoproliferative disease
492918|NCT00730314|Platelets defects
492919|NCT00730314|Congenital amegakaryocytic thrombocytopenia
492920|NCT00730314|Metabolic and storage disorders
492921|NCT00730314|Hurler disease
492922|NCT00730314|leukodystrophies
492923|NCT00730314|Niemann-Pick disease
492924|NCT00730314|Fucosidosis
492925|NCT00730314|Stem cell defects
492926|NCT00730314|reticular agenesis
492927|NCT00730301|Emphysema
492928|NCT00730301|Chronic obstructive pulmonary disease
492929|NCT00730301|Lung volume reduction
492930|NCT00730301|Lung function
492931|NCT00730288|Dengue
492932|NCT00730288|Dengue fever
492933|NCT00730288|Dengue hemorrhagic fever
492934|NCT00730288|Dengue virus
492935|NCT00730262|Glioblastoma Multiforme (GBM)
492936|NCT00730262|Phase II
492937|NCT00730262|Brain Cancer
492938|NCT00730249|ADHD
492939|NCT00730249|Attention Deficit Hyperactivity Disorder
492940|NCT00730249|adult
492941|NCT00730249|methylphenidate hydrochloride
492942|NCT00730249|Medikinet retard
492943|NCT00730249|controlled clinical trial
492944|NCT00730249|safety
492945|NCT00730249|randomized, double-blind, placebo-controlled trial
492946|NCT00730249|treatment
492947|NCT00730249|central nervous system stimulants
492948|NCT00730249|therapeutic uses
492949|NCT00730223|Nevirapine
492950|NCT00730223|Efavirenz
492951|NCT00730223|pharmacokinetics
492952|NCT00730223|healthy
492953|NCT00730223|CYP2B6
492954|NCT00730223|HIV/AIDS
492955|NCT00730210|Hypoparathyroidism
492956|NCT00730210|HypoPTH
492957|NCT00730210|PTH
492958|NCT00730184|acid-base
492959|NCT00730184|potassium
492960|NCT00730184|acidosis
492961|NCT00730184|osteoporosis
492962|NCT00730184|sarcopenia
492963|NCT00730184|calcium absorption
492964|NCT00730184|dietary protein
492965|NCT00730145|pharmacokinetics, PD-0332334, hemodialysis, renal dialysis
492966|NCT00730119|Non-invasive Blood Pressure (NIBP)
492967|NCT00730119|GE Monitor
492968|NCT00730119|Temperature
492969|NCT00730119|SpO2
492970|NCT00730119|Respiration, ECG
492971|NCT00730106|Gastroesophageal reflux disease
492972|NCT00730106|Alarm symptoms
492973|NCT00730106|Gastrointestinal endoscopy
492974|NCT00730093|Vitamin B12 absorption
492975|NCT00730093|Pregnancy
492976|NCT00730080|phenylketonuria
492977|NCT00730080|sapropterin
492978|NCT00730080|Kuvan
492979|NCT00730080|cognition
492980|NCT00730080|executive abilities
492981|NCT00730080|brain
492982|NCT00730067|COPD
492983|NCT00730067|Pulmonary hypertension
492984|NCT00730067|Sildenafil
492985|NCT00730067|NT-pro BNP
492986|NCT00730067|apelin
492987|NCT00730054|Remifentanil
492988|NCT00730054|clonidine
492989|NCT00730054|acute pain
492990|NCT00730054|respiration
492991|NCT00730054|sedation
492992|NCT00730054|cognitive function
492993|NCT00730041|obstructive sleep apnea
492994|NCT00730041|continuous positive air pressure
492995|NCT00730028|Methicillin-resistant Staphylococcus aureus (MRSA), cellulitis, abscess, children, elderly
492996|NCT00730002|Lupus
492997|NCT00729989|Meconium Aspiration
492998|NCT00729989|Respiratory Distress
492999|NCT00729989|Meconium Stained Amniotic Fluid
493000|NCT00729976|Ibuprofen
493001|NCT00729976|Suppository
493002|NCT00729976|febrile children
493003|NCT00729937|Methicillin, Staphylococcus aureus, MRSA
493004|NCT00729924|Raltegravir
493005|NCT00729924|CSF
493006|NCT00729924|ABCB1 SNP
493007|NCT00729924|HIV/AIDS
493008|NCT00729911|Atrial fibrillation Ablation
493009|NCT00729885|Vertigo
493010|NCT00729885|Benign Paroxysmal Positional Vertigo
493011|NCT00729885|BPPV
493012|NCT00729885|Positional Vertigo
493013|NCT00729872|AG011
493014|NCT00729872|Ulcerative Colitis
493015|NCT00729872|human Interleukin-10
493016|NCT00729859|HDL
493017|NCT00729859|Insulin sensitivity
493018|NCT00729859|testosterone
493019|NCT00729859|estradiol
493020|NCT00729859|cholesterol
493021|NCT00729846|choroidal neovascularization
493022|NCT00729846|macular degeneration
493023|NCT00729846|macular edema
493024|NCT00729846|intravitreal bevacizumab
493025|NCT00729846|vegf
493026|NCT00729846|verteporfin PDT
493027|NCT00729820|PERSONALITY
493028|NCT00729820|COGNITIVE PERFORMANCE
493029|NCT00729820|the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior
493030|NCT00729807|recurrent melanoma
493031|NCT00729794|Vasopressin
493032|NCT00729794|Epinephrine
493033|NCT00729794|Adrenal Cortex Hormones
493034|NCT00729794|Heart Arrest
493035|NCT00729781|nasal obstruction
493036|NCT00729781|airway resistance
493037|NCT00729781|soft tissue collapse
493038|NCT00729781|cosmetic contour deformity
493039|NCT00729768|Renal transplant
493040|NCT00729768|Raptiva
493041|NCT00729755|Creatine
493042|NCT00729755|Augmentation
493043|NCT00729755|Major Depressive Disorder
493044|NCT00729755|Efficacy
493045|NCT00729755|Brain Energy Metabolism
493046|NCT00729729|Comparative
493047|NCT00729729|bioavailability
493048|NCT00729729|of PCA
493049|NCT00729729|formulations
493050|NCT00729716|Microfracture
493051|NCT00729716|Cartilage repair
493052|NCT00729716|Autologous chondrocyte implantation
493053|NCT00729703|ICD
493054|NCT00729703|Minimized
493055|NCT00729703|ventricular
493056|NCT00729703|pacing
493057|NCT00729703|indication
493058|NCT00729703|Clinical outcome
493059|NCT00729703|Inappropriate shock
493060|NCT00729690|Pregabalin
493061|NCT00729690|CSF
493062|NCT00729690|Neurotransmitter
493063|NCT00729677|nausea and vomiting
493064|NCT00729677|colon cancer
493065|NCT00729677|rectal cancer
493066|NCT00729638|relapsed multiple myeloma
493067|NCT00729638|refractory multiple myeloma
493068|NCT00729638|RAD001
493069|NCT00729638|lenalidomide
493070|NCT00729625|stroke, rehabilitation, robotics
493071|NCT00729612|stage IIIB non-small cell lung cancer
493072|NCT00729612|stage IV non-small cell lung cancer
493073|NCT00729612|recurrent non-small cell lung cancer
493074|NCT00729612|squamous cell lung cancer
493075|NCT00729573|Microbicide
493076|NCT00729573|HIV Seronegativity
493077|NCT00729573|Bone Mineral Density
493078|NCT00729560|PCOS
493079|NCT00729547|Depression
493080|NCT00729547|Biofeedback
493081|NCT00729547|Psychophysiology
493082|NCT00729534|Perception
493083|NCT00729534|Focus Group
493084|NCT00729534|Perception of Clinical Research Participation
493085|NCT00729521|Fall injury hospitalization
493086|NCT00729521|Fall injury emergency department visit
493087|NCT00729521|Fall injury death
493088|NCT00729508|Cat allergy
493089|NCT00729508|Immunotherapy
493090|NCT00729508|Cat-PAD
493091|NCT00729508|Environmental Exposure Chamber
493092|NCT00729495|Phase I,
493093|NCT00729495|Healthy
493094|NCT00729495|Volunteer
493095|NCT00729495|Study
493096|NCT00729482|RAD001 (everolimus)
493097|NCT00729482|second-line treatment
493098|NCT00729482|advanced gastric cancer
493099|NCT00729469|Vulvar and vaginal atrophy in postmenopausal women
493100|NCT00729469|Menopausal symptoms
493101|NCT00729469|Vaginal atrophy
493102|NCT00729469|Urogenital atrophy
493103|NCT00729456|Diabetes
493104|NCT00729456|Education
493105|NCT00729456|Ulcer
493106|NCT00729456|Foot
493107|NCT00729456|Behaviour
493108|NCT00729443|Single dose
493109|NCT00729443|Phase 1
493110|NCT00729443|Safety of AZD3241
493111|NCT00729443|tolerability of AZD3241
493112|NCT00729430|Heart Attack
493113|NCT00729430|Sudden Cardiac Death
493114|NCT00729430|Peri-infarct Zone
493115|NCT00729430|Omega-3 Fatty Acids
493116|NCT00729430|Biological Markers
493117|NCT00729430|Cytogenetic Analysis
493118|NCT00729430|Cardiac Arrest
493119|NCT00729417|incontinence
493120|NCT00729417|obstetric risk factors
493121|NCT00729417|women
493122|NCT00729417|of age 18
493123|NCT00729417|above
493124|NCT00729404|Female Contraception
493125|NCT00729404|Ovulation Inhibition
493126|NCT00729391|HIV
493127|NCT00729391|Sexual Risk
493128|NCT00729391|Substance Abuse
493129|NCT00729391|Victimization
493130|NCT00729391|Violence
493131|NCT00729391|Voluntary Counseling and Testing (VCT)
493132|NCT00729365|Urine albumin excretion rates
493133|NCT00729365|Nighttime and daytime blood pressure
493134|NCT00729365|Endothelial Dysfunction
493135|NCT00729352|NQO1, ozone, airway mucociliary clearance.
493136|NCT00729339|Gastroesophageal reflux disease
493137|NCT00729339|Mosapride
493138|NCT00729339|Lansoprazole
493139|NCT00729326|diabetes
493140|NCT00729326|exenatide
493141|NCT00729326|sitagliptin
493142|NCT00729326|Amylin
493143|NCT00729326|Lilly
493144|NCT00729326|metformin
493145|NCT00729326|thiazolidinedione
493146|NCT00729313|Treatment
493147|NCT00729300|cocaine
493148|NCT00729300|disulfiram
493149|NCT00729300|antabuse
493150|NCT00729300|addiction
493151|NCT00729300|stimulant
493152|NCT00729287|stage 0 bladder cancer
493153|NCT00729287|stage I bladder cancer
493154|NCT00729287|transitional cell carcinoma of the bladder
493155|NCT00729261|mechanical ventilation
493156|NCT00729261|extubation
493157|NCT00729261|outcomes
493158|NCT00729261|brain injury
493159|NCT00729248|Transplants
493160|NCT00729248|Kidney Transplantation
493161|NCT00729248|Immunosuppression
493162|NCT00729248|Assay
493163|NCT00729248|Graft Rejection
493164|NCT00729235|Slow VT, CRT-D, ATP therapy
493165|NCT00729235|Incidence
493166|NCT00729235|of slow VTs
493167|NCT00729235|in CRT-D patients
493168|NCT00729235|Clinical
493169|NCT00729235|relevance
493170|NCT00729235|treatment
493171|NCT00729235|VTs
493172|NCT00729235|during
493173|NCT00729235|2-years
493174|NCT00729235|follow-up
493175|NCT00729196|Obesity
493176|NCT00729196|Type 2 Diabetes
493177|NCT00729196|Glycemic Load
493178|NCT00729196|Weight Loss
493179|NCT00729196|Glycated Hemoglobin
493180|NCT00729170|Milk
493181|NCT00729170|Calcium
493182|NCT00729170|Weight loss
493183|NCT00729170|Bone density
493184|NCT00729170|Appetite
493185|NCT00729144|fecal incontinence
493186|NCT00729144|bowel incontinence
493187|NCT00729144|pelvic floor disorder
493188|NCT00729131|Ozone, TNF, TNF promoter polymorphism, airway hyperresponsiveness.
493189|NCT00729118|stage I multiple myeloma
493190|NCT00729118|stage II multiple myeloma
493191|NCT00729118|stage III multiple myeloma
493192|NCT00729118|refractory multiple myeloma
493193|NCT00729092|PET SCAN
493194|NCT00729092|PAIN LEVELS
493195|NCT00729079|Diabetes Prevention
493196|NCT00729079|Pre-Diabetes
493197|NCT00729079|Exercise
493198|NCT00729079|Fat Intake
493199|NCT00729079|Fasting blood sugar
493200|NCT00729079|tobacco cessation
493201|NCT00729053|renal
493202|NCT00729053|cell
493203|NCT00729053|renal carcinoma
493204|NCT00729053|metastatic
493205|NCT00729053|recurrent
493206|NCT00729053|treatment naive
493207|NCT00729040|heart
493208|NCT00729040|weight
493209|NCT00729040|Overweight
493210|NCT00729040|bmi
493211|NCT00729040|diabetes
493212|NCT00729040|type 2
493213|NCT00729040|diabetic
493214|NCT00729040|walk
493215|NCT00729040|walk*
493216|NCT00729040|diab*
493217|NCT00729040|obese
493218|NCT00729040|exercise
493219|NCT00729040|activity
493220|NCT00729040|coronary
493221|NCT00729040|pedometer
493222|NCT00729027|hypercholesterolemia
493223|NCT00729014|herbal nephropathy
493224|NCT00729014|Chinese herbal nephropathy
493225|NCT00729014|nephrotoxicity
493226|NCT00729014|renal disease
493227|NCT00729014|adverse drug reaction
493228|NCT00729014|Chinese herbal medicine
493229|NCT00729001|Rotavirus Gastroenteritis
493230|NCT00729001|Human rotavirus vaccine
493231|NCT00728988|Asia Lipitor Pre-treatment in Acute Coronary Syndrome
493232|NCT00728975|constipation
493233|NCT00728975|cancer
493234|NCT00728975|palliative care
493235|NCT00728975|terminal
493236|NCT00728975|bowel
493237|NCT00728962|dental implants
493238|NCT00728962|Osseotite Certain Prevail
493239|NCT00728962|multicenter
493240|NCT00728962|observational
493241|NCT00728962|clinical study
493242|NCT00728962|partial edentulism
493243|NCT00728962|single stage
493244|NCT00728962|immediate occlusal loading
493245|NCT00728962|crestal bone level
493246|NCT00728962|short fixed bridge
493247|NCT00728949|breast cancer
493248|NCT00728949|Postmenopausal
493249|NCT00728949|Hormones
493250|NCT00728949|Antiestrogen
493251|NCT00728936|Hepatitis C
493252|NCT00728936|unresponsive to pegylated interferon and ribavirin therapy
493253|NCT00728936|HCV
493254|NCT00728923|OCD
493255|NCT00728910|Low HDL cholesterol
493256|NCT00728910|High triglycerides
493257|NCT00728910|niacin
493258|NCT00728910|fibrate
493259|NCT00728897|Healthy volunteer
493260|NCT00728897|relative bioavailability.
493261|NCT00728884|dental implants
493262|NCT00728884|Certain Prevail
493263|NCT00728884|multicenter
493264|NCT00728884|clinical study
493265|NCT00728884|partial edentulism
493266|NCT00728884|total edentulism
493267|NCT00728884|platform switching
493268|NCT00728884|single stage
493269|NCT00728884|early loading
493270|NCT00728884|crestal bone level
493271|NCT00728884|single tooth replacements
493272|NCT00728884|short or long fixed bridges
493273|NCT00728884|overdenture
493274|NCT00728884|fixed denture
493275|NCT00728871|cervical cancer, HPV, immunity
493276|NCT00728858|Hypertension
493277|NCT00728858|SNP
493278|NCT00728858|Nifedipine
493279|NCT00728858|Barnidipine
493280|NCT00728845|adenocarcinoma of the lung
493281|NCT00728845|large cell lung cancer
493282|NCT00728845|recurrent non-small cell lung cancer
493283|NCT00728845|stage IIIB non-small cell lung cancer
493284|NCT00728845|stage IV non-small cell lung cancer
493285|NCT00728832|extended release epidural morphine
493286|NCT00728832|morphine
493287|NCT00728832|thoracic epidural
493288|NCT00728832|pharmacokinetics
493289|NCT00728832|pharmacodynamics
493290|NCT00728832|postoperative pain
493291|NCT00728832|upper abdominal surgery
493292|NCT00728819|Inpatients
493293|NCT00728819|Requiring
493294|NCT00728819|DL PICC
493295|NCT00728819|Access
493296|NCT00728819|Medications
493297|NCT00728819|Blood
493298|NCT00728806|Continuous Ambulatory Peritoneal Dialysis
493299|NCT00728806|Ultrafiltration failure
493300|NCT00728806|Biomarker
493301|NCT00728806|Proteomics
493302|NCT00728793|Advanced Solid Tumors
493303|NCT00728793|EGFR
493304|NCT00728793|HDAC
493305|NCT00728793|Her2
493306|NCT00728793|Open-Label
493307|NCT00728793|Dose-Escalation
493308|NCT00728780|Adverse events
493309|NCT00728780|Pharmacokinetic variables
493310|NCT00728767|Heavy drinking
493311|NCT00728767|Brief intervention
493312|NCT00728767|Alcohol prevention
493313|NCT00728767|Randomized trial
493314|NCT00728767|Motivational interviewing
493315|NCT00728767|Intervention Studies
493316|NCT00728767|prevention & control
493317|NCT00728754|dental implants
493318|NCT00728754|Osseotite Certain Prevail
493319|NCT00728754|Lateralized
493320|NCT00728754|non-lateralized
493321|NCT00728754|Osseotite Certain
493322|NCT00728754|multicenter
493323|NCT00728754|randomized
493324|NCT00728754|clinical study
493325|NCT00728754|partial edentulism
493326|NCT00728754|single stage
493327|NCT00728754|early loading
493328|NCT00728754|crestal bone level
493329|NCT00728754|short fixed bridge
493330|NCT00728741|Neural Networks
493331|NCT00728741|Cortical Activation
493332|NCT00728741|Strategy
493333|NCT00728741|fMRI
493334|NCT00728741|Healthy Volunteer
493335|NCT00728741|HV
493336|NCT00728728|pregnenolone
493337|NCT00728728|schizophrenia
493338|NCT00728728|cognitive
493339|NCT00728728|positive symptom
493340|NCT00728728|negative symptom
493341|NCT00728728|placebo control
493342|NCT00728715|Budesonide
493343|NCT00728715|Formoterol
493344|NCT00728715|Non cystic fibrosis bronchiectasis
493345|NCT00728689|Orthopoxviral
493346|NCT00728689|Smallpox
493347|NCT00728689|Monkey pox
493348|NCT00728676|PKU,
493349|NCT00728676|Phe,
493350|NCT00728676|PAH,
493351|NCT00728676|Kuvan,
493352|NCT00728676|Trp,
493353|NCT00728676|Tyr
493354|NCT00728663|adenocarcinoma of the prostate
493355|NCT00728663|recurrent prostate cancer
493356|NCT00728663|stage IV prostate cancer
493357|NCT00728650|hepatocellular carcinoma
493358|NCT00728650|colorectal carcinoma metastatic to liver
493359|NCT00728650|primary liver cancer
493360|NCT00728637|Prevention
493361|NCT00728624|Antibiotic susceptibility; beta lactamase; ESBLs
493362|NCT00728598|Proliferative diabetic retinopathy
493363|NCT00728598|Angiogenesis
493364|NCT00728598|Vitreous levels
493365|NCT00728598|Vascular endothelial growth factor
493366|NCT00728598|Fractalkine
493367|NCT00728598|Growth factor
493368|NCT00728585|mucositis
493369|NCT00728585|graft versus host disease
493370|NCT00728585|recurrent childhood large cell lymphoma
493371|NCT00728585|recurrent childhood lymphoblastic lymphoma
493372|NCT00728585|recurrent childhood small noncleaved cell lymphoma
493487|NCT00728221|Flow Mediated Dilation
493373|NCT00728585|recurrent/refractory childhood Hodgkin lymphoma
493374|NCT00728585|accelerated phase chronic myelogenous leukemia
493375|NCT00728585|blastic phase chronic myelogenous leukemia
493376|NCT00728585|childhood acute lymphoblastic leukemia in remission
493377|NCT00728585|childhood acute myeloid leukemia in remission
493378|NCT00728585|childhood chronic myelogenous leukemia
493379|NCT00728585|chronic phase chronic myelogenous leukemia
493380|NCT00728585|juvenile myelomonocytic leukemia
493381|NCT00728585|recurrent childhood acute lymphoblastic leukemia
493382|NCT00728585|recurrent childhood acute myeloid leukemia
493383|NCT00728585|secondary acute myeloid leukemia
493384|NCT00728585|childhood myelodysplastic syndromes
493385|NCT00728585|de novo myelodysplastic syndromes
493386|NCT00728585|disseminated neuroblastoma
493387|NCT00728585|previously treated childhood rhabdomyosarcoma
493388|NCT00728585|previously treated myelodysplastic syndromes
493389|NCT00728585|recurrent Wilms tumor and other childhood kidney tumors
493390|NCT00728585|recurrent childhood rhabdomyosarcoma
493391|NCT00728585|recurrent neuroblastoma
493392|NCT00728585|recurrent malignant testicular germ cell tumor
493393|NCT00728585|secondary myelodysplastic syndromes
493394|NCT00728585|stage I multiple myeloma
493395|NCT00728585|stage II multiple myeloma
493396|NCT00728585|stage III multiple myeloma
493397|NCT00728585|refractory multiple myeloma
493398|NCT00728585|stage I ovarian epithelial cancer
493399|NCT00728585|stage II ovarian epithelial cancer
493400|NCT00728585|stage III ovarian epithelial cancer
493401|NCT00728585|stage IV ovarian epithelial cancer
493402|NCT00728585|recurrent ovarian epithelial cancer
493403|NCT00728585|recurrent ovarian germ cell tumor
493404|NCT00728585|stage IIIA breast cancer
493405|NCT00728585|stage IIIB breast cancer
493406|NCT00728585|stage IIIC breast cancer
493407|NCT00728585|stage IV breast cancer
493408|NCT00728585|recurrent breast cancer
493409|NCT00728559|laparoscopy
493410|NCT00728559|preemptive
493411|NCT00728559|postoperative
493412|NCT00728559|pain
493413|NCT00728559|trocar
493414|NCT00728559|site
493415|NCT00728546|tuberculosis
493416|NCT00728546|isoniazid
493417|NCT00728546|Arylamine N-acetyl transferase
493418|NCT00728546|genotyping
493419|NCT00728546|hepatotoxicity
493420|NCT00728546|pharmacogenetics
493421|NCT00728533|Prostate Cancer requiring Androgen Ablation Therapy
493422|NCT00728520|Leukemia
493423|NCT00728520|Azacitidine
493424|NCT00728520|Untreated
493425|NCT00728520|Elderly
493426|NCT00728507|Tuberculosis
493427|NCT00728507|Moxifloxacin
493428|NCT00728507|Rifapentine
493429|NCT00728468|Phase 1
493430|NCT00728468|PF-00299804
493431|NCT00728468|Dextromethorphan
493432|NCT00728468|CYP2D6 Inhibition
493433|NCT00728468|Cancer Patients
493434|NCT00728442|Clinical practice guidelines
493435|NCT00728442|Guideline adherence
493436|NCT00728442|Clinical decision support systems
493437|NCT00728442|Randomized controlled trial
493438|NCT00728442|Intervention study
493439|NCT00728429|cardiac toxicity
493440|NCT00728429|chemotherapeutic agent toxicity
493441|NCT00728429|unspecified adult solid tumor, protocol specific
493442|NCT00728390|advanced cancer refractory advanced non-small cell lung cancer
493443|NCT00728377|gestational diabetes
493444|NCT00728377|physical activity
493445|NCT00728377|behavior change
493446|NCT00728377|glucose tolerance
493447|NCT00728377|pregnancy
493448|NCT00728364|Anderson Fabry disease
493449|NCT00728364|chronic kidney disease
493450|NCT00728364|prevalence
493451|NCT00728351|Type 2 diabetes, vildagliptin
493452|NCT00728338|docosahexenoic acid (DHA)
493453|NCT00728338|dietary supplement
493454|NCT00728338|n-3 polyunsaturated fatty acid
493455|NCT00728338|cardiovascular disease
493456|NCT00728325|PTSD
493457|NCT00728325|Vocational Rehabilitation
493458|NCT00728325|Supported Employment
493459|NCT00728312|Methamphetamine
493460|NCT00728312|Therapeutics
493461|NCT00728312|Psychopharmacology
493462|NCT00728312|Amphetamine
493463|NCT00728299|Coronary artery disease, carotid intima-media thickness
493464|NCT00728286|Type 2 Diabetes Mellitus
493465|NCT00728286|Acute Coronary Syndrome
493466|NCT00728286|Platelet dependent thrombogenicity
493467|NCT00728273|Efficacy
493468|NCT00728273|Vietnam
493469|NCT00728273|school children
493470|NCT00728273|anemia
493471|NCT00728273|fortification
493472|NCT00728273|micronutrient
493473|NCT00728260|Meningitis
493474|NCT00728260|Meningococcal disease
493475|NCT00728260|Menactra vaccine
493476|NCT00728247|Cervical Spine
493477|NCT00728247|Kinematics
493478|NCT00728247|Manipulation
493479|NCT00728247|Biomechanics
493480|NCT00728234|aEEG
493481|NCT00728234|preterm infants
493482|NCT00728234|predictive value
493483|NCT00728234|outcome
493484|NCT00728221|Ginseng
493485|NCT00728221|Korean Red Ginseng
493486|NCT00728221|Ginsenoside
493488|NCT00728221|Endothelial Function
493489|NCT00728221|Hypertension
493490|NCT00728208|Young
493491|NCT00728208|Elderly
493492|NCT00728208|Randomised
493493|NCT00728208|GSK372475
493494|NCT00728195|Schizophrenia
493495|NCT00728195|Central Nervous System
493496|NCT00728195|JNJ-37822681
493497|NCT00728182|Stroke
493498|NCT00728182|Vascular cognitive impairment
493499|NCT00728182|Coiling
493500|NCT00728182|Endovascular repair
493501|NCT00728182|Brain aneurysm
493502|NCT00728182|NA-1
493503|NCT00728169|Asthma
493504|NCT00728169|Focus Group
493505|NCT00728169|Community Based Participatory Research
493506|NCT00728156|Type 2 Diabetes mellitus
493507|NCT00728156|Coronary artery disease
493508|NCT00728156|Platelet dependent thrombogenicity
493509|NCT00728156|Aspirin
493510|NCT00728156|Clopidogrel
493511|NCT00728156|Badimon Chamber
493512|NCT00728130|carcinoma
493513|NCT00728130|upper
493514|NCT00728130|aerodigestive
493515|NCT00728130|tract
493516|NCT00728130|submandibular
493517|NCT00728130|gland
493518|NCT00728117|indomethacin
493519|NCT00728117|ibuprofen
493520|NCT00728117|preterm infant
493521|NCT00728104|Learn
493522|NCT00728104|L-Carnitine
493523|NCT00728104|Co-enzyme Q10
493524|NCT00728104|Effective
493525|NCT00728104|These supplements
493526|NCT00728104|Compared
493527|NCT00728104|Standard
493528|NCT00728091|aquaretic
493529|NCT00728091|SIADH
493530|NCT00728078|hepatocellular carcinoma
493531|NCT00728078|liver cancer
493532|NCT00728078|radiofrequency ablation
493533|NCT00728078|thalidomide
493534|NCT00728052|single
493535|NCT00728052|Tolerability
493536|NCT00728052|dose escalation
493537|NCT00728052|Pharmacodynamics
493538|NCT00728052|GSK598809
493539|NCT00728052|placebo
493540|NCT00728052|Safety
493541|NCT00728052|Smokers
493542|NCT00728052|Pharmacokinetics
493543|NCT00728039|Youth
493544|NCT00728039|Consensus
493545|NCT00728039|Criteria
493546|NCT00728039|CVS
493547|NCT00728026|Chart must reveal the following procedures:
493548|NCT00728026|Heart rate variability,
493549|NCT00728026|Deep Breathing Test,
493550|NCT00728026|Valsalva maneuver,
493551|NCT00728026|Table test,
493552|NCT00728026|Thermoregulatory Sweat Testing,
493553|NCT00728026|Quantitative Sudomotor Axon Reflex Test (QSART),
493554|NCT00728026|Vital signs,
493555|NCT00728026|postural changes in heart rate and blood pressure,
493556|NCT00728026|composite autonomic score
493557|NCT00728013|Acute coronary syndrome
493558|NCT00728013|intensive lipid-lowering
493559|NCT00728013|statins
493560|NCT00728000|Pancreatic Cancer
493561|NCT00727987|Rheumatoid arthritis
493562|NCT00727987|Fully Human anti-TNFa monoclonal antibody
493563|NCT00727987|CNTO148
493564|NCT00727987|Golimumab
493565|NCT00727974|Genome Wide Scan (GWS)
493566|NCT00727974|Mitochondrial scan
493567|NCT00727974|Family trios
493568|NCT00727948|Breast cancer
493569|NCT00727948|Angiogenesis
493570|NCT00727948|Aspirin
493571|NCT00727948|Tamoxifen
493572|NCT00727935|Women
493573|NCT00727935|parturients
493574|NCT00727935|with
493575|NCT00727935|realization
493576|NCT00727935|episiotomy
493577|NCT00727922|Neuropathy
493578|NCT00727922|Oxaliplatin
493579|NCT00727922|Mangafodipir
493580|NCT00727909|Hearing loss
493581|NCT00727909|Hearing Aids
493582|NCT00727909|Speech Perception
493583|NCT00727909|Persons with Hearing Impairment
493584|NCT00727896|Life style modification,
493585|NCT00727896|Type 2 diabetes,
493586|NCT00727896|SMS,
493587|NCT00727896|Patient adherence
493588|NCT00727883|Breast Cancer
493589|NCT00727883|Adjuvant TAM
493590|NCT00727883|post-menopausal
493591|NCT00727883|women
493592|NCT00727870|Shave Biopsy management
493593|NCT00727870|"Biopsy/adverse effects[Mesh]"
493594|NCT00727870|"Biopsy/complications[Mesh])"
493595|NCT00727857|Glucose Metabolism Disorder
493596|NCT00727857|Dysmetabolic Syndrome
493597|NCT00727857|Type II Diabetes
493598|NCT00727857|Diabetes Mellitus, Lipoatrophic
493599|NCT00727857|Dyslipidemia
493600|NCT00727857|Drug Therapy
493601|NCT00727844|XDR-TB
493602|NCT00727844|Linezolid
493603|NCT00727844|Drug Resistance
493604|NCT00727844|Computed Tomography
493605|NCT00727844|Pharmacokinetics
493606|NCT00727844|Tuberculosis
493607|NCT00727844|Drug Resistance Tuberculosis
493608|NCT00727844|MDR-TB
493609|NCT00727831|neurotoxicity
493610|NCT00727831|chemotherapeutic agent toxicity
493611|NCT00727831|mucositis
493612|NCT00727831|primary central nervous system non-Hodgkin lymphoma
493613|NCT00727831|contiguous stage II adult diffuse large cell lymphoma
493614|NCT00727831|noncontiguous stage II adult diffuse large cell lymphoma
493615|NCT00727831|stage I adult diffuse large cell lymphoma
493616|NCT00727831|stage III adult diffuse large cell lymphoma
493617|NCT00727831|stage IV adult diffuse large cell lymphoma
493618|NCT00727792|participants
493619|NCT00727792|scheduled
493620|NCT00727792|clinically
493621|NCT00727792|ordered
493622|NCT00727792|MRI
493623|NCT00727779|diabetes, metabolic syndrome, type 2 diabetes
493624|NCT00727766|Clofarabine
493625|NCT00727766|Clolar
493626|NCT00727766|AML
493627|NCT00727766|Consolidation
493628|NCT00727753|Macular Degeneration
493629|NCT00727753|Age-Related Maculopathies
493630|NCT00727740|Cholangiopancreatography, Endoscopic Retrograde
493631|NCT00727740|Pancreatitis
493632|NCT00727740|Indomethacin
493633|NCT00727727|Piribedil (trade name: Clarium)
493634|NCT00727727|non-ergot dopamine agonist
493635|NCT00727727|Morbus Parkinson
493636|NCT00727727|Tolerability
493637|NCT00727727|Efficacy
493638|NCT00727727|Post Marketing Surveillance
493639|NCT00727714|Cement dust exposure
493640|NCT00727714|Cross-shift study
493641|NCT00727714|Lung function indices
493642|NCT00727714|Exhaled nitric oxide
493643|NCT00727714|Serum inflammatory markers
493644|NCT00727701|varicose ulcer
493645|NCT00727701|veteran
493646|NCT00727701|recurrence
493647|NCT00727701|aftercare
493648|NCT00726648|CDP323
493649|NCT00726648|Relapsing multiple sclerosis
493650|NCT00726648|Blood biomarkers
493651|NCT00726622|rectal cancer
493652|NCT00726622|adenocarcinoma of the rectum
493653|NCT00726596|recurrent prostate cancer
493654|NCT00726596|stage IV prostate cancer
493655|NCT00726596|Prostate-Specific Antigen
493656|NCT00727675|chronic pain
493657|NCT00727675|opioid dependence
493658|NCT00727675|Cognitive Behavioral Therapy (CBT)
493659|NCT00727662|Breast Cancer
493660|NCT00727662|Fatigue
493661|NCT00727662|Proinflammatory Cytokines
493662|NCT00727662|Physical functioning
493663|NCT00727662|Quality of life
493664|NCT00727649|fecal incontinence
493665|NCT00727649|adults
493666|NCT00727649|diarrhea
493667|NCT00727636|inflammatory bowel disease (IBD)
493668|NCT00727636|immunogenicity
493669|NCT00727636|safety
493670|NCT00727636|HPV
493671|NCT00727636|Gardasil
493672|NCT00727636|vaccine
493673|NCT00727623|acute coronary syndrome
493674|NCT00727623|myocardial infarction
493675|NCT00727623|predictors of mortality
493676|NCT00727623|reperfusion therapy
493677|NCT00727610|Adverse drug event
493678|NCT00727610|harm
493679|NCT00727610|patient safety
493680|NCT00727610|clinical decision support
493681|NCT00727610|Adverse drug related event
493682|NCT00727584|spinal cord compression
493683|NCT00727584|unspecified adult solid tumor, protocol specific
493684|NCT00727571|Anemia
493685|NCT00727571|Chronic Kidney Disease
493686|NCT00727571|Quality of Life
493687|NCT00727571|CKD
493688|NCT00727571|Chronic Renal Insufficiency
493689|NCT00727558|refractive error
493690|NCT00727532|clear cell renal cell carcinoma
493691|NCT00727532|hereditary clear cell renal cell carcinoma
493692|NCT00727532|recurrent renal cell cancer
493693|NCT00727532|stage I renal cell cancer
493694|NCT00727532|stage II renal cell cancer
493695|NCT00727532|stage III renal cell cancer
493696|NCT00727532|stage IV renal cell cancer
493697|NCT00727519|Hemodialysis
493698|NCT00727519|Nephrology
493699|NCT00727519|Pomegranate Juice
493700|NCT00727519|Israel
493701|NCT00727493|osteoporosis,
493702|NCT00727493|bisphosphonate
493703|NCT00727493|therapy
493704|NCT00727493|dental implant
493705|NCT00727480|vascularity
493706|NCT00727480|fingertips
493707|NCT00727467|auditory cueing device
493708|NCT00727467|Parkinson's disease
493709|NCT00727467|freezing
493710|NCT00727467|gait
493711|NCT00727467|mobility
493712|NCT00727454|Obstructive sleep apnea
493713|NCT00727454|CPAP
493714|NCT00727454|Heart remodeling
493715|NCT00727454|Cardiovascular disease
493716|NCT00727454|MRI
493717|NCT00727441|adenocarcinoma of the pancreas
493718|NCT00727441|stage I pancreatic cancer
493719|NCT00727441|stage II pancreatic cancer
493720|NCT00727428|FluLaval® TF
493721|NCT00727428|Safety
493722|NCT00727428|Immunogenicity
493723|NCT00727428|Influenza
493724|NCT00727415|advanced or progressive chronic lymphocytic leukemia
493725|NCT00727415|Lenalidomide
493726|NCT00727415|Fludarabine
493727|NCT00727389|Prevention
493728|NCT00727389|Quality of Health Care
493729|NCT00727389|Health Care Evaluation Mechanisms
493730|NCT00727376|esophageal
493731|NCT00727376|stenting
493732|NCT00727363|probiotics
493733|NCT00727363|lactobacillus reuteri
493734|NCT00727363|preterm infants
493735|NCT00727363|nosocomial infection
493736|NCT00727363|necrotizing enterocolitis
493737|NCT00727350|NSCLC
493738|NCT00727350|Novalis
493739|NCT00727350|Stereotactic
493740|NCT00727350|SBRT
493741|NCT00727350|T1, T2 or T3NO NSCLC
493742|NCT00727337|auditory perception
493743|NCT00727337|rehabilitation of hearing impaired
493744|NCT00727324|Ulcerative Colitis
493745|NCT00727324|UC
493746|NCT00727324|moderate
493747|NCT00727324|severe
493748|NCT00727324|LPS
493749|NCT00727324|Alkaline Phosphatase
493750|NCT00727324|AP
493751|NCT00727324|BIAP
493752|NCT00727324|Mucositis
493753|NCT00727285|Cystic Fibrosis
493754|NCT00727285|pulmonary exacerbation
493755|NCT00727285|gene expression
493756|NCT00727285|biomarker
493757|NCT00727285|inflammation
493758|NCT00727285|CF pulmonary exacerbation
493759|NCT00727272|Bioavailability
493760|NCT00727246|Traumatic Brain Injury
493761|NCT00727246|FMRI
493762|NCT00727246|Memory
493763|NCT00727246|Cognition
493764|NCT00727246|Neuropsychology
493765|NCT00727233|Neuroblastosis Type I
493766|NCT00727233|Plexiform Neurofibromas
493767|NCT00727233|Angiogenesis Inhibitor
493768|NCT00727233|Kinase Inhibitor
493769|NCT00727233|Neurofibromatosis Type 1
493770|NCT00727233|NF1
493771|NCT00727233|Plexiform Neurofibroma
493772|NCT00727220|type 1 diabetes
493773|NCT00727220|continuous glucose sensor monitoring
493774|NCT00727207|recurrent mantle cell lymphoma
493775|NCT00727207|contiguous stage II mantle cell lymphoma
493776|NCT00727207|noncontiguous stage II mantle cell lymphoma
493777|NCT00727207|stage I mantle cell lymphoma
493778|NCT00727207|stage III mantle cell lymphoma
493779|NCT00727207|stage IV mantle cell lymphoma
493780|NCT00727181|aortic valve
493781|NCT00727181|heart valve
493782|NCT00727181|tissue valve
493783|NCT00727181|bioprosthesis
493784|NCT00727181|valve disorder
493785|NCT00727181|valve disease
493786|NCT00727181|cardiac surgery
493787|NCT00727181|aortic valve stenosis
493788|NCT00727181|aortic valve regurgitation
493789|NCT00727168|prevalence study
493790|NCT00727168|glaucoma
493791|NCT00727142|NPH
493792|NCT00727142|Hydrocephalus
493793|NCT00727142|Shunt
493794|NCT00727129|vasomotor symptoms
493795|NCT00727129|estrogen
493796|NCT00727129|estradiol
493797|NCT00727129|hot flashes
493798|NCT00727103|Varenicline
493799|NCT00727103|Smoking cessation
493800|NCT00727103|Schizophrenia
493801|NCT00727103|Schizoaffective disorder
493802|NCT00727103|Alcohol dependence
493803|NCT00727103|Nicotine dependence
493804|NCT00727064|Healthy Subjects
493805|NCT00727051|invasive coronary angiography
493806|NCT00727051|multidetector coronary CTA
493807|NCT00727051|coronary artery disease
493808|NCT00727051|detecting coronary artery disease
493809|NCT00727038|glaucoma
493810|NCT00727038|neovascular glaucoma
493811|NCT00727038|new onset glaucoma
493812|NCT00727038|retinal ischemia
493813|NCT00727038|central retinal vein occlusion
493814|NCT00727038|proliferative diabetic retinopathy
493815|NCT00727038|ocular ischemic syndrome
493816|NCT00727038|carotid stenosis
493817|NCT00727038|vascular endothelial growth factor
493818|NCT00727038|neovascular
493819|NCT00727025|skin closure devices
493820|NCT00727025|linear scars
493821|NCT00727012|mitral valve
493822|NCT00727012|heart valve
493823|NCT00727012|valve repair
493824|NCT00727012|valve disorder
493825|NCT00727012|valve disease
493826|NCT00727012|cardiac surgery
493827|NCT00726999|Gabapentin
493828|NCT00726999|Pediatric Spinal Fusion
493829|NCT00726999|Narcotic Use
493830|NCT00726986|extensive stage small cell lung cancer
493831|NCT00726973|Macular edema
493832|NCT00726960|Heroin abuse
493833|NCT00726960|Opioids
493834|NCT00726960|Opiates
493835|NCT00726960|Substance abuse
493836|NCT00726960|Addiction
493837|NCT00726934|Neutropenic Diet
493838|NCT00726934|Food Safety Guidelines
493839|NCT00726934|child
493840|NCT00726934|cancer
493841|NCT00726908|Obesity
493842|NCT00726908|diet
493843|NCT00726908|carbohydrate
493844|NCT00726908|insulin
493845|NCT00726895|Bioavailability
493846|NCT00726882|HCV Infection
493847|NCT00726869|Patients After One to three Prior Therapies
493848|NCT00726843|Headache
493849|NCT00726843|Complementary and Alternative Medicine
493850|NCT00726843|Pediatric
493851|NCT00726843|Yoga
493852|NCT00726830|pain
493853|NCT00726830|unspecified adult solid tumor, protocol specific
493854|NCT00726830|accelerated phase chronic myelogenous leukemia
493855|NCT00726830|acute undifferentiated leukemia
493856|NCT00726830|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
493857|NCT00726830|adult acute myeloid leukemia with inv(16)(p13;q22)
493858|NCT00726830|adult acute myeloid leukemia with t(15;17)(q22;q12)
493859|NCT00726830|adult acute myeloid leukemia with t(16;16)(p13;q22)
493954|NCT00726830|polycythemia vera
493860|NCT00726830|adult acute myeloid leukemia with t(8;21)(q22;q22)
493861|NCT00726830|atypical chronic myeloid leukemia, BCR-ABL1 negative
493862|NCT00726830|blastic phase chronic myelogenous leukemia
493863|NCT00726830|chronic myelomonocytic leukemia
493864|NCT00726830|chronic phase chronic myelogenous leukemia
493865|NCT00726830|mast cell leukemia
493866|NCT00726830|meningeal chronic myelogenous leukemia
493867|NCT00726830|progressive hairy cell leukemia, initial treatment
493868|NCT00726830|prolymphocytic leukemia
493869|NCT00726830|recurrent adult acute lymphoblastic leukemia
493870|NCT00726830|recurrent adult acute myeloid leukemia
493871|NCT00726830|recurrent adult T-cell leukemia/lymphoma
493872|NCT00726830|refractory chronic lymphocytic leukemia
493873|NCT00726830|refractory hairy cell leukemia
493874|NCT00726830|relapsing chronic myelogenous leukemia
493875|NCT00726830|secondary acute myeloid leukemia
493876|NCT00726830|stage III adult T-cell leukemia/lymphoma
493877|NCT00726830|stage III chronic lymphocytic leukemia
493878|NCT00726830|stage IV adult T-cell leukemia/lymphoma
493879|NCT00726830|stage IV chronic lymphocytic leukemia
493880|NCT00726830|T-cell large granular lymphocyte leukemia
493881|NCT00726830|untreated adult acute lymphoblastic leukemia
493882|NCT00726830|untreated adult acute myeloid leukemia
493883|NCT00726830|untreated hairy cell leukemia
493884|NCT00726830|adult grade III lymphomatoid granulomatosis
493885|NCT00726830|adult nasal type extranodal NK/T-cell lymphoma
493886|NCT00726830|AIDS-related diffuse large cell lymphoma
493887|NCT00726830|AIDS-related diffuse mixed cell lymphoma
493888|NCT00726830|AIDS-related diffuse small cleaved cell lymphoma
493889|NCT00726830|AIDS-related immunoblastic large cell lymphoma
493890|NCT00726830|AIDS-related peripheral/systemic lymphoma
493891|NCT00726830|AIDS-related primary CNS lymphoma
493892|NCT00726830|AIDS-related small noncleaved cell lymphoma
493893|NCT00726830|AIDS-related lymphoblastic lymphoma
493894|NCT00726830|anaplastic large cell lymphoma
493895|NCT00726830|angioimmunoblastic T-cell lymphoma
493896|NCT00726830|splenic marginal zone lymphoma
493897|NCT00726830|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
493898|NCT00726830|nodal marginal zone B-cell lymphoma
493899|NCT00726830|stage III adult Burkitt lymphoma
493900|NCT00726830|stage III adult diffuse large cell lymphoma
493901|NCT00726830|stage III adult diffuse mixed cell lymphoma
493902|NCT00726830|stage III adult diffuse small cleaved cell lymphoma
493903|NCT00726830|stage III adult Hodgkin lymphoma
493904|NCT00726830|stage III adult immunoblastic large cell lymphoma
493905|NCT00726830|stage III adult lymphoblastic lymphoma
493906|NCT00726830|stage III cutaneous T-cell non-Hodgkin lymphoma
493907|NCT00726830|stage III mycosis fungoides/Sezary syndrome
493908|NCT00726830|stage III grade 1 follicular lymphoma
493909|NCT00726830|stage III grade 2 follicular lymphoma
493910|NCT00726830|stage III grade 3 follicular lymphoma
493911|NCT00726830|stage III mantle cell lymphoma
493912|NCT00726830|stage III marginal zone lymphoma
493913|NCT00726830|stage III small lymphocytic lymphoma
493914|NCT00726830|stage IV adult Burkitt lymphoma
493915|NCT00726830|stage IV adult diffuse large cell lymphoma
493916|NCT00726830|stage IV adult diffuse mixed cell lymphoma
493917|NCT00726830|stage IV adult diffuse small cleaved cell lymphoma
493918|NCT00726830|stage IV adult Hodgkin lymphoma
493919|NCT00726830|stage IV adult immunoblastic large cell lymphoma
493920|NCT00726830|stage IV adult lymphoblastic lymphoma
493921|NCT00726830|stage IV cutaneous T-cell non-Hodgkin lymphoma
493922|NCT00726830|stage IV mycosis fungoides/Sezary syndrome
493923|NCT00726830|stage IV grade 1 follicular lymphoma
493924|NCT00726830|stage IV grade 2 follicular lymphoma
493925|NCT00726830|stage IV grade 3 follicular lymphoma
493926|NCT00726830|stage IV mantle cell lymphoma
493927|NCT00726830|stage IV marginal zone lymphoma
493928|NCT00726830|stage IV small lymphocytic lymphoma
493929|NCT00726830|HIV-associated Hodgkin lymphoma
493930|NCT00726830|recurrent adult Hodgkin lymphoma
493931|NCT00726830|recurrent adult Burkitt lymphoma
493932|NCT00726830|recurrent adult diffuse large cell lymphoma
493933|NCT00726830|recurrent adult diffuse mixed cell lymphoma
493934|NCT00726830|recurrent adult diffuse small cleaved cell lymphoma
493935|NCT00726830|recurrent adult grade III lymphomatoid granulomatosis
493936|NCT00726830|recurrent adult immunoblastic large cell lymphoma
493937|NCT00726830|recurrent adult lymphoblastic lymphoma
493938|NCT00726830|recurrent cutaneous T-cell non-Hodgkin lymphoma
493939|NCT00726830|recurrent mycosis fungoides/Sezary syndrome
493940|NCT00726830|recurrent grade 1 follicular lymphoma
493941|NCT00726830|recurrent grade 2 follicular lymphoma
493942|NCT00726830|recurrent grade 3 follicular lymphoma
493943|NCT00726830|recurrent mantle cell lymphoma
493944|NCT00726830|recurrent marginal zone lymphoma
493945|NCT00726830|recurrent small lymphocytic lymphoma
493946|NCT00726830|intraocular lymphoma
493947|NCT00726830|primary central nervous system non-Hodgkin lymphoma
493948|NCT00726830|primary central nervous system Hodgkin lymphoma
493949|NCT00726830|post-transplant lymphoproliferative disorder
493950|NCT00726830|chronic eosinophilic leukemia
493951|NCT00726830|chronic neutrophilic leukemia
493952|NCT00726830|primary myelofibrosis
493953|NCT00726830|essential thrombocythemia
493955|NCT00726830|extramedullary plasmacytoma
493956|NCT00726830|isolated plasmacytoma of bone
493957|NCT00726830|monoclonal gammopathy of undetermined significance
493958|NCT00726830|stage II multiple myeloma
493959|NCT00726830|stage III multiple myeloma
493960|NCT00726830|primary systemic amyloidosis
493961|NCT00726830|refractory multiple myeloma
493962|NCT00726830|de novo myelodysplastic syndromes
493963|NCT00726830|previously treated myelodysplastic syndromes
493964|NCT00726830|secondary myelodysplastic syndromes
493965|NCT00726830|myelodysplastic/myeloproliferative neoplasm, unclassifiable
493966|NCT00726830|cutaneous B-cell non-Hodgkin lymphoma
493967|NCT00726830|Waldenström macroglobulinemia
493968|NCT00726817|butyrate, visceral perception, compliance
493969|NCT00726791|chronic pain
493970|NCT00726791|pain disorder
493971|NCT00726778|race/ethnicity
493972|NCT00726778|insulin senistivity
493973|NCT00726778|genetic admixture
493974|NCT00726778|type 2 diabetes
493975|NCT00726778|obesity
493976|NCT00726778|body composition
493977|NCT00726778|Insulin dynamics
493978|NCT00726778|Racial/ethnic differences
493979|NCT00726752|solid tumor
493980|NCT00726752|Axitinib
493981|NCT00726752|Pharmacokinetics
493982|NCT00726752|Phase 1
493983|NCT00726739|recurrent melanoma
493984|NCT00726713|Metanx
493985|NCT00726713|diabetes
493986|NCT00726713|neuropathy
493987|NCT00726713|folic acid
493988|NCT00726713|folate
493989|NCT00726713|L-methylfolate
493990|NCT00726713|vitamin B6
493991|NCT00726713|Pyridoxal 5'-phosphate
493992|NCT00726713|vitamin B12
493993|NCT00726713|methylcobalamin
493994|NCT00726700|stage III grade 3 follicular lymphoma
493995|NCT00726700|stage I adult lymphoblastic lymphoma
493996|NCT00726700|stage III adult lymphoblastic lymphoma
493997|NCT00726700|stage IV adult lymphoblastic lymphoma
493998|NCT00726700|contiguous stage II adult lymphoblastic lymphoma
493999|NCT00726700|noncontiguous stage II adult lymphoblastic lymphoma
494000|NCT00726700|anaplastic large cell lymphoma
494001|NCT00726700|stage III adult diffuse large cell lymphoma
494002|NCT00726700|stage I adult diffuse large cell lymphoma
494003|NCT00726700|stage IV adult diffuse large cell lymphoma
494004|NCT00726700|contiguous stage II adult diffuse large cell lymphoma
494005|NCT00726700|contiguous stage II adult immunoblastic large cell lymphoma
494006|NCT00726700|noncontiguous stage II adult diffuse large cell lymphoma
494007|NCT00726700|noncontiguous stage II adult immunoblastic large cell lymphoma
494008|NCT00726700|stage III adult immunoblastic large cell lymphoma
494009|NCT00726700|stage I adult immunoblastic large cell lymphoma
494010|NCT00726700|stage IV adult immunoblastic large cell lymphoma
494011|NCT00726700|stage III adult Burkitt lymphoma
494012|NCT00726700|stage IV adult Burkitt lymphoma
494013|NCT00726700|stage III mantle cell lymphoma
494014|NCT00726700|stage I mantle cell lymphoma
494015|NCT00726700|contiguous stage II mantle cell lymphoma
494016|NCT00726700|noncontiguous stage II mantle cell lymphoma
494017|NCT00726700|stage I adult Burkitt lymphoma
494018|NCT00726700|contiguous stage II adult Burkitt lymphoma
494019|NCT00726700|noncontiguous stage II adult Burkitt lymphoma
494020|NCT00726700|stage III marginal zone lymphoma
494021|NCT00726700|stage IV marginal zone lymphoma
494022|NCT00726700|stage I marginal zone lymphoma
494023|NCT00726700|contiguous stage II marginal zone lymphoma
494024|NCT00726700|noncontiguous stage II marginal zone lymphoma
494025|NCT00726687|Cancer
494026|NCT00726687|Indibulin
494027|NCT00726687|Capecitabine
494028|NCT00726687|Xeloda
494029|NCT00726674|Diabetes HbA1C
494030|NCT00726661|Metastatic Breast Cancer
494031|NCT00726661|Locally Recurrent Breast Cancer
494032|NCT00726661|Avastin
494033|NCT00726583|Cancer
494034|NCT00726583|Solid Tumors
494035|NCT00726583|Carcinoma
494036|NCT00726583|PI-3K
494037|NCT00726583|PI3 kinase
494038|NCT00726583|PI3K
494039|NCT00726570|Disorders, Blood coagulation
494040|NCT00726570|Deep Vein Thrombosis
494041|NCT00726570|Perioperative Care
494042|NCT00726570|Digestive System Surgical Procedures
494043|NCT00726544|thrombocytopenia
494044|NCT00726544|microangiopathic hemolytic anemia
494045|NCT00726544|von Willebrand Factor
494046|NCT00726544|ADAMTS13
494047|NCT00726531|Falls prevention
494048|NCT00726531|Exercise promotion
494049|NCT00726531|Older people
494050|NCT00726466|Age Related Macular Degeneration
494051|NCT00726466|AMD
494052|NCT00726466|CNV
494053|NCT00726453|TARGET VESSEL REVASCULARIZATION (TVR)
494054|NCT00726453|MYOCARDIAL INFARCTION (MI)
494055|NCT00726453|TARGET VESSEL FAILURE (TVF)
494056|NCT00726453|TARGET LESION REVASCULARIZATION (TLR)
494057|NCT00726453|TARGET LESION FAILURE (TLF)
494058|NCT00726453|STENT THROMBOSIS
494059|NCT00726453|RESTENOTIC LESION
494060|NCT00726453|PERCUTANEOUS CORONARY INTERVENTION (PCI)
494061|NCT00726440|Type 1 Diabetes
494062|NCT00726440|Real Time Continuous Glucose Monitoring System
494063|NCT00726440|HbA1c
494064|NCT00726440|Navigator®
494065|NCT00726427|pharmacokinetics
494066|NCT00726427|pharmacodynamics
494067|NCT00726427|AZD1656
494068|NCT00726427|safety
494069|NCT00726427|tolerability
494070|NCT00726427|Healthy Volunteers
494071|NCT00726414|Bioavailability
494072|NCT00726401|Allergies
494073|NCT00726401|Nasal
494074|NCT00726401|Congestion
494075|NCT00726401|Sneezing
494076|NCT00726401|Pruritus
494077|NCT00726401|Teary
494078|NCT00726401|Eyes
494079|NCT00726388|safety
494080|NCT00726388|diclofenac
494081|NCT00726388|pain, postoperative
494082|NCT00726375|(GVHD)
494083|NCT00726362|Statin
494084|NCT00726362|LDL-C
494085|NCT00726336|healthy volunteer
494086|NCT00726336|pharmacokinetics
494087|NCT00726336|GSK1349572
494088|NCT00726336|integrase
494089|NCT00726323|c-Met
494090|NCT00726323|Papillary Renal Cell Carcinoma(PRC)
494091|NCT00726323|Sporadic papillary renal cell carcinoma,
494092|NCT00726323|Clear cell renal carcinoma
494093|NCT00726323|Hereditary papillary renal cell carcinoma,
494094|NCT00726310|Spondylolisthesis
494095|NCT00726310|Instability
494096|NCT00726284|HNP
494097|NCT00726271|obesity
494098|NCT00726271|appetite set point
494099|NCT00726219|Major
494100|NCT00726219|knee
494101|NCT00726219|surgery
494102|NCT00726180|Breast cancer
494103|NCT00726180|Women
494104|NCT00726180|w/Her2
494105|NCT00726180|positive
494106|NCT00726180|ERnegative
494107|NCT00726180|not metastasized
494108|NCT00726167|Ventilator associated Pneumonia
494109|NCT00726167|mechanically ventilated
494110|NCT00726167|procalcitonin
494111|NCT00726167|pneumonia scores
494112|NCT00726154|Bipolar Disorder
494113|NCT00726154|Circadian Rhythm
494114|NCT00726154|Moderators
494115|NCT00726154|Lithium
494116|NCT00726154|Quetiapine
494117|NCT00726141|Brief Intervention
494118|NCT00726141|Smoking Cessation
494119|NCT00726141|Motivational Interviewing
494120|NCT00726141|Expert System
494121|NCT00726141|Readiness to Change
494122|NCT00726141|Hormonal Contraceptive
494123|NCT00726141|Adolescents
494124|NCT00726128|DDD
494125|NCT00726102|Zinc nutrition
494126|NCT00726102|Growth
494127|NCT00726102|Development
494128|NCT00726102|China
494129|NCT00726102|Infants
494130|NCT00726102|Toddlers
494131|NCT00726076|Epilepsy
494132|NCT00726076|Medication
494133|NCT00726076|Stress
494134|NCT00726076|Sleep
494135|NCT00726076|Lifestyle Management
494136|NCT00726063|dental implants
494137|NCT00726063|Nanotite implant
494138|NCT00726063|Osseotite implants
494139|NCT00726063|multicenter
494140|NCT00726063|randomized
494141|NCT00726063|clinical study
494142|NCT00726063|partial edentulism
494143|NCT00726063|prosthesis
494144|NCT00726050|Theta Burst Stimulation
494145|NCT00726050|Somatosensory Stimulation
494146|NCT00726050|Somatosensory Cortex
494147|NCT00726050|Tactile Discrimination
494148|NCT00726050|Healthy Volunteer
494149|NCT00726050|HV
494150|NCT00726037|Denileukin diftitox
494151|NCT00726037|Metastatic Pancreatic Cancer
494152|NCT00726037|Ontak
494153|NCT00726037|Regulatory T-cell
494154|NCT00726011|due
494155|NCT00726011|cancer treatment
494156|NCT00725998|Cochlear Implantation.
494157|NCT00725998|Cochlear nerve.
494158|NCT00725998|Child.
494159|NCT00725998|study
494160|NCT00725998|ECAP
494161|NCT00725998|During
494162|NCT00725998|First year
494163|NCT00725985|Clinically Isolated Syndrome (CIS)
494164|NCT00725985|Early MS
494165|NCT00725985|Multiple Sclerosis
494166|NCT00725972|Improve
494167|NCT00725972|Patient care
494168|NCT00725972|Applying
494169|NCT00725972|Systematic
494170|NCT00725972|Fashion
494171|NCT00725972|Proven
494172|NCT00725972|Resuscitation
494173|NCT00725972|Algorithms
494174|NCT00725972|High risk
494175|NCT00725972|Surgical
494176|NCT00725959|HIV Prevention
494177|NCT00725959|Social Networking
494178|NCT00725959|Technology Based Intervention
494179|NCT00725920|PTSD,
494180|NCT00725920|posttraumatic
494181|NCT00725920|stress
494182|NCT00725920|disorder,
494183|NCT00725920|randomization,
494184|NCT00725920|placebo,
494185|NCT00725920|controlled
494186|NCT00725907|PRP
494187|NCT00725907|ATFL
494188|NCT00725881|PAD
494189|NCT00725881|Peripheral arterial disease
494190|NCT00725881|Peripheral artery disease
494191|NCT00725881|Intermittent claudication
494192|NCT00725881|IC
494193|NCT00725881|atherosclerosis
494194|NCT00725881|leg pain
494195|NCT00725881|walking pain
494196|NCT00725868|Major adverse
494197|NCT00725855|Schizophrenia
494198|NCT00725855|P50 Sensory Gating
494199|NCT00725855|Mismatched Negativity
494200|NCT00725829|coagulation
494201|NCT00725829|cholesterol
494202|NCT00725829|acute ischemia
494203|NCT00725829|fibrin clot
494204|NCT00724997|live attenuated flu vaccines
494205|NCT00724997|Influenza A (H1N1)
494206|NCT00724997|intranasally application
494207|NCT00724997|replication-deficient influenza virus
494208|NCT00724984|PCI-24781
494209|NCT00724984|Lymphoma
494210|NCT00724984|Hodgkin Disease
494211|NCT00724984|Lymphoma, Non-Hodgkin
494212|NCT00724984|Lymphoma, Large B-Cell, Diffuse
494213|NCT00724984|Lymphoma, Follicular
494214|NCT00724984|Lymphoma, B-Cell, Marginal Zone
494215|NCT00724984|Leukemia, Lymphocytic, Chronic, B-Cell
494216|NCT00724984|Lymphoma, Mantle Cell
494217|NCT00724984|Lymphoma, T-Cell, Cutaneous
494218|NCT00724984|Lymphoma, T-Cell, Peripheral
494219|NCT00724971|B-cell Non-Hodgkin's Lymphoma
494220|NCT00724971|NHL
494221|NCT00725803|Hepatitis C
494222|NCT00725803|HCV
494223|NCT00725803|Fibrosis
494224|NCT00725803|Apoptosis
494225|NCT00725803|GS-9450
494226|NCT00725790|Erectile Dysfunction
494227|NCT00725790|Spinal Cord Injury
494228|NCT00725764|VEGFR2
494229|NCT00725764|XL880
494230|NCT00725764|foretinib
494231|NCT00725764|Squamous Cell Cancer of the Head and Neck
494232|NCT00725764|MET
494233|NCT00725764|GSK1363089
494234|NCT00725738|Myocardial
494235|NCT00725738|Infarction,
494236|NCT00725738|Stem
494237|NCT00725738|Cell
494238|NCT00725738|Therapy
494239|NCT00725712|c-Met
494240|NCT00725712|Metastatic Gastric Carcinoma
494241|NCT00725712|adenocarcinoma
494242|NCT00725712|Gastric cancer
494243|NCT00725712|GSK1363089
494244|NCT00725712|XL880
494245|NCT00725712|MET inhibitor
494246|NCT00725686|"Choroidal Neovascularization (CNV) WET AMD"
494247|NCT00725673|COPD
494248|NCT00725673|Osteoporosis
494249|NCT00725673|BMD
494250|NCT00725673|DEXA-scan
494251|NCT00725660|pre eclampsia
494252|NCT00725660|doppler
494253|NCT00725660|uterine
494254|NCT00725660|arteries
494255|NCT00725660|angiogenic
494256|NCT00725660|factors
494257|NCT00725647|N terminal B type natriuretic peptide
494258|NCT00725647|echocardiography
494259|NCT00725647|diagnosis
494260|NCT00725647|atrial natriuretic peptides
494261|NCT00725647|preterm infant
494262|NCT00725634|Neoplasms,
494263|NCT00725634|Lymphoma,
494264|NCT00725634|Multiple Myeloma,
494265|NCT00725634|Neoplasms, Plasma Cell,
494266|NCT00725634|Neoplasms by Histologic Type,
494267|NCT00725634|Lymphoproliferative Disorders,
494268|NCT00725634|Lymphatic Diseases, Immunoproliferative Disorders
494269|NCT00725634|Immune System Diseases Hemostatic Disorders
494270|NCT00725634|Vascular Diseases
494271|NCT00725634|Cardiovascular Diseases
494272|NCT00725634|Paraproteinemias
494273|NCT00725634|Blood Protein Disorders
494274|NCT00725634|Hematologic Diseases
494275|NCT00725634|Hemorrhagic Disorders
494276|NCT00725634|Erlotinib
494277|NCT00725634|Protein Kinase Inhibitors
494278|NCT00725634|Enzyme Inhibitors,
494279|NCT00725634|Molecular Mechanisms of Pharmacological Action
494280|NCT00725634|Pharmacologic Actions
494281|NCT00725608|Suboxone
494282|NCT00725608|Subutex
494283|NCT00725608|Buprenorphine
494284|NCT00725608|Naloxone
494285|NCT00725595|Cheyne Stocks respiration
494286|NCT00725595|heart failure
494287|NCT00725595|sleep apnea
494288|NCT00725595|ventilator
494289|NCT00725569|Caesarian Section
494290|NCT00725569|Homeopathy
494291|NCT00725569|Pain
494292|NCT00725569|Analgesia
494293|NCT00725556|Autism
494294|NCT00725556|Asperger Syndrome
494295|NCT00725530|Lens deposits
494296|NCT00725530|Soft contact lens wearers
494297|NCT00725517|Icodextrin
494298|NCT00725517|ultrafiltration
494299|NCT00725517|creatinine clearance
494300|NCT00725517|urea nitrogen clearance
494301|NCT00725491|Reproductive
494302|NCT00725491|techniques
494303|NCT00725491|assisted
494304|NCT00725478|Piribedil (trade name: CLARIUM)
494305|NCT00725478|non-ergot dopamine agonist
494306|NCT00725478|Morbus Parkinson
494307|NCT00725478|Tolerability
494308|NCT00725478|Efficacy
494309|NCT00725478|Post Marketing Surveillance
494310|NCT00725465|laparoscopy
494311|NCT00725465|CO2 colonoscopy
494312|NCT00725465|intraoperative CO2 colonoscopy
494313|NCT00725465|combined Lap-CO2 procedure
494314|NCT00725465|to evaluate simultaneous CO2 laparoscopy and colonoscopy safety and physiologic effects on patients from the additional CO2 insufflation
494315|NCT00725426|healthy subjects
494316|NCT00725400|Colorectal Cancer
494317|NCT00725400|Erbitux
494318|NCT00725400|Cetuximab
494319|NCT00725400|Surgery
494320|NCT00725400|Radiation
494321|NCT00725348|Psoriasis
494322|NCT00725335|ischemia
494323|NCT00725335|liver cancer
494324|NCT00725335|radical excision
494325|NCT00725335|prognosis
494326|NCT00725309|Chronic Obstructive Pulmonary Disease
494327|NCT00725309|COPD
494328|NCT00725309|Elastin
494329|NCT00725309|ELN
494330|NCT00725283|Leukemia
494331|NCT00725283|ASCI
494332|NCT00725283|Complete remission
494333|NCT00725283|Immunotherapy
494334|NCT00725283|adult
494335|NCT00725283|Acute Myeloid Leukemia
494336|NCT00725283|Tumor antigen
494337|NCT00725283|WT1
494338|NCT00725244|Radiation Injuries
494339|NCT00725244|Telangiectasis
494340|NCT00725244|Bipolar Eletrocoagulation
494341|NCT00725244|Argon Plasma Coagulation
494342|NCT00725231|T cell lymphoma
494343|NCT00725218|NSAIDs
494344|NCT00725218|Postoperative pain
494345|NCT00725218|Analgesia
494346|NCT00725218|Abortion
494347|NCT00725192|PTSD
494348|NCT00725192|Posttraumatic Stress Disorder
494349|NCT00725192|Physical Assault
494350|NCT00725192|Physical Abuse
494351|NCT00725192|Sexual Assault
494352|NCT00725192|Sexual Abuse
494353|NCT00725192|Interpersonal Assault
494354|NCT00725192|Cognitive Processing Therapy
494355|NCT00725192|Sleep Impairment
494356|NCT00725192|Insomnia
494357|NCT00725192|Hypnosis
494358|NCT00725179|acetaminophen toxicity
494359|NCT00725179|n-acetylcysteine
494360|NCT00725179|liver toxicity
494361|NCT00725166|Aging
494362|NCT00725166|Biopsy
494363|NCT00725166|Skeletal muscle
494364|NCT00725166|Molecular biology
494365|NCT00725166|Genetic markers
494366|NCT00725166|Gene expression regulation
494367|NCT00725166|Young and old men
494368|NCT00725166|Healthy volunteers
494369|NCT00725153|Contact lens deposits
494370|NCT00725153|Soft contact lenses
494371|NCT00725153|Myopia
494372|NCT00725140|Migraine
494373|NCT00725140|Early intervention
494374|NCT00725140|Primary Care
494375|NCT00725140|Almotriptan
494376|NCT00725127|Aspirin
494377|NCT00725127|Chronotherapy
494378|NCT00725127|Primary prevention
494379|NCT00725127|Impaired fasting glucose
494380|NCT00725127|Type 2 diabetes
494381|NCT00725127|Total mortality
494382|NCT00725127|Myocardial infarction
494383|NCT00725127|Stroke
494384|NCT00725127|Angina pectoris
494385|NCT00725127|Chronic kidney disease
494386|NCT00725114|due
494387|NCT00725114|cancer
494388|NCT00725114|treatment
494389|NCT00725088|ST-Elevated Myocardial Infarction
494390|NCT00725088|Exercise Training
494391|NCT00725088|Rehabilitation
494392|NCT00725075|Negative symptoms
494393|NCT00725075|Glycine Uptake inhibitor
494394|NCT00725075|Add-on treatment
494395|NCT00725075|Second Generation Antipsychotic
494396|NCT00725062|graft versus host disease
494397|NCT00725062|adult acute lymphoblastic leukemia in remission
494398|NCT00725062|adult acute myeloid leukemia in remission
494399|NCT00725062|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
494400|NCT00725062|adult acute myeloid leukemia with inv(16)(p13;q22)
494401|NCT00725062|adult acute myeloid leukemia with t(15;17)(q22;q12)
494402|NCT00725062|adult acute myeloid leukemia with t(16;16)(p13;q22)
494403|NCT00725062|adult acute myeloid leukemia with t(8;21)(q22;q22)
494404|NCT00725062|chronic phase chronic myelogenous leukemia
494405|NCT00725062|accelerated phase chronic myelogenous leukemia
494406|NCT00725062|relapsing chronic myelogenous leukemia
494407|NCT00725062|de novo myelodysplastic syndromes
494408|NCT00725062|previously treated myelodysplastic syndromes
494409|NCT00725062|secondary myelodysplastic syndromes
494410|NCT00725062|stage I multiple myeloma
494411|NCT00725062|stage II multiple myeloma
494412|NCT00725062|stage III multiple myeloma
494413|NCT00725062|refractory multiple myeloma
494414|NCT00725062|stage III adult Burkitt lymphoma
494415|NCT00725062|stage III adult diffuse large cell lymphoma
494416|NCT00725062|stage III adult diffuse mixed cell lymphoma
494417|NCT00725062|stage III adult diffuse small cleaved cell lymphoma
494418|NCT00725062|stage III adult immunoblastic large cell lymphoma
494419|NCT00725062|stage III adult lymphoblastic lymphoma
494420|NCT00725062|stage III grade 1 follicular lymphoma
494421|NCT00725062|stage III grade 2 follicular lymphoma
494422|NCT00725062|stage III grade 3 follicular lymphoma
494423|NCT00725062|stage III mantle cell lymphoma
494424|NCT00725062|stage III marginal zone lymphoma
494425|NCT00725062|stage III small lymphocytic lymphoma
494426|NCT00725062|stage IV adult Burkitt lymphoma
494427|NCT00725062|stage IV adult diffuse large cell lymphoma
494428|NCT00725062|stage IV adult diffuse mixed cell lymphoma
494429|NCT00725062|stage IV adult diffuse small cleaved cell lymphoma
494430|NCT00725062|stage IV adult immunoblastic large cell lymphoma
494431|NCT00725062|stage IV adult lymphoblastic lymphoma
494432|NCT00725062|stage IV grade 1 follicular lymphoma
494433|NCT00725062|stage IV grade 2 follicular lymphoma
494434|NCT00725062|stage IV grade 3 follicular lymphoma
494435|NCT00725062|stage IV mantle cell lymphoma
494436|NCT00725062|stage IV marginal zone lymphoma
494437|NCT00725062|stage IV small lymphocytic lymphoma
494438|NCT00725062|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
494439|NCT00725062|nodal marginal zone B-cell lymphoma
494440|NCT00725062|splenic marginal zone lymphoma
494441|NCT00725062|recurrent adult acute lymphoblastic leukemia
494442|NCT00725062|recurrent childhood acute myeloid leukemia
494443|NCT00725062|recurrent adult Burkitt lymphoma
494444|NCT00725062|recurrent adult diffuse large cell lymphoma
494445|NCT00725062|recurrent adult diffuse mixed cell lymphoma
494446|NCT00725062|recurrent adult diffuse small cleaved cell lymphoma
494447|NCT00725062|recurrent adult immunoblastic large cell lymphoma
494448|NCT00725062|recurrent adult lymphoblastic lymphoma
494449|NCT00725062|recurrent grade 1 follicular lymphoma
494450|NCT00725062|recurrent grade 2 follicular lymphoma
494451|NCT00725062|recurrent grade 3 follicular lymphoma
494452|NCT00725062|recurrent mantle cell lymphoma
494453|NCT00725062|recurrent marginal zone lymphoma
494454|NCT00725062|recurrent small lymphocytic lymphoma
494455|NCT00725049|dental implants
494456|NCT00725049|Nanotite Certain implant
494457|NCT00725049|Osseotite
494458|NCT00725049|multicenter
494459|NCT00725049|randomized
494460|NCT00725049|clinical study
494461|NCT00725049|partial edentulism
494462|NCT00725049|crestal bone level
494463|NCT00725049|short fixed bridge
494464|NCT00725049|cost analysis
494465|NCT00725023|Pain, chronic pain, tennis elbow, lateral epicondylitis
494466|NCT00724919|ESBL
494467|NCT00724906|Essential Tremor
494468|NCT00724906|Parkinsonian Tremor
494469|NCT00724906|Parkinson Disease
494470|NCT00724906|Upper Extremity Tremor with duration of less than 2 years
494471|NCT00724906|Diagnosis
494472|NCT00724906|Subjects
494473|NCT00724906|Upper
494474|NCT00724906|Extremity
494475|NCT00724906|Tremor
494476|NCT00724906|Less
494477|NCT00724906|Than 2 years
494478|NCT00724880|coronary artery bypass grafting
494479|NCT00724880|clopidogrel
494480|NCT00724880|post-operative bleeding
494481|NCT00724867|Systemic Lupus Erythematosus
494482|NCT00724867|Belimumab
494483|NCT00724867|SLE
494484|NCT00724867|Antibodies
494485|NCT00724867|Lupus
494486|NCT00724867|Autoimmune Diseases
494487|NCT00724828|Bacterial otitis media
494488|NCT00724828|pneumoniae
494489|NCT00724828|sepsis
494490|NCT00724828|bacteremia
494491|NCT00724828|meningitis
494492|NCT00724828|Streptococcus pneumoniae carriage rate
494493|NCT00724802|babies with canavan disease
494494|NCT00724789|Neonatal outcome
494495|NCT00724789|Congenital malformations
494496|NCT00724789|In-Vitro fertilization
494497|NCT00724789|Controlled ovarian stimulation
494498|NCT00724789|Follow-up
494499|NCT00724776|Chronic hepatitis C, Albinterferon alfa 2b, phase I, Japan
494500|NCT00724763|acupuncture, high blood pressure, HRV
494501|NCT00724724|Stroke
494502|NCT00724724|Transient Ischemic Attack
494503|NCT00724711|HIV
494504|NCT00724711|HIV 1
494505|NCT00724685|Ropivacaine
494506|NCT00724685|elastomeric pump
494507|NCT00724685|patient controlled analgesia
494508|NCT00724685|morphine consumption
494509|NCT00724659|Arthrogram
494510|NCT00724659|Contrast
494511|NCT00724659|Joint
494512|NCT00724659|Ultrasound
494513|NCT00724646|parents
494514|NCT00724646|medically fragile
494515|NCT00724646|death
494516|NCT00724646|end-of-life care
494517|NCT00724646|surveys
494518|NCT00724633|dialysate
494519|NCT00724633|sodium
494520|NCT00724633|hemodialysis
494521|NCT00724633|blood pressure
494522|NCT00724633|thirst
494523|NCT00724633|intradialytic symptoms
494524|NCT00724633|interdialytic weight gain
494525|NCT00724633|extracellular fluid balance
494526|NCT00724633|mechanisms
494527|NCT00724607|Concussion, traumatic brain injury
494528|NCT00724607|Screening
494529|NCT00724607|neuroimaging
494530|NCT00724607|Posttraumatic stress disorder
494531|NCT00724594|chorioamnionitis
494532|NCT00724594|maternal chorioamnionitis
494533|NCT00724594|neonatal white matter injury
494534|NCT00724594|N-acetylcysteine
494535|NCT00724594|NAC
494536|NCT00724594|anti-oxidant treatment
494537|NCT00724581|Atrial fibrillation, amiodarone
494538|NCT00724568|Newly Diagnosed Multiple Myeloma
494539|NCT00724555|stroke
494540|NCT00724555|tissue plasminogen activator
494541|NCT00724555|tPA
494542|NCT00724529|Crohn's Disease
494543|NCT00724529|Ankylosing Spondylitis
494544|NCT00724516|Mammogram
494545|NCT00724516|Biopsy
494546|NCT00724516|Needle
494547|NCT00724516|Wire
494548|NCT00724516|Localization
494549|NCT00724516|Compression
494550|NCT00724516|Paddle
494551|NCT00724503|colon cancer
494552|NCT00724503|Colorectal carcinoma
494553|NCT00724503|liver metastases
494554|NCT00724503|SIR-Spheres microspheres
494555|NCT00724503|yttrium-90
494556|NCT00724503|FOLFOX
494557|NCT00724503|bevacizumab
494558|NCT00724503|metastatic colorectal cancer
494559|NCT00724490|Deep Brain Stimulation
494560|NCT00724490|Obsessive Compulsive Disorder
494561|NCT00724490|Nucleus Accumbens
494562|NCT00724438|Contraception
494563|NCT00724438|Implanon
494564|NCT00724438|Obesity
494565|NCT00724438|Blood spots
494566|NCT00724438|Implant
494567|NCT00724438|Pharmacokinetics
494568|NCT00724412|Dry Eye
494569|NCT00724412|Corneal Staining
494570|NCT00724360|relapsed/refractory
494571|NCT00724360|HER2
494572|NCT00724360|positive
494573|NCT00724360|B-ALL
494574|NCT00724360|trastuzumab
494575|NCT00724347|Auditory Perception
494576|NCT00724347|Hearing Loss
494577|NCT00724347|Presbycusis
494578|NCT00724347|Perceptual Learning
494579|NCT00724347|Hearing Prosthesis
494580|NCT00724347|Speech Discrimination
494581|NCT00724347|Delayed Treatment
494582|NCT00724334|myelofibrosis
494583|NCT00724321|iloprost
494584|NCT00724321|hypoxic
494585|NCT00724321|pulmonary
494586|NCT00724321|vasoconstriction
494587|NCT00724321|altitude
494588|NCT00724308|Smoking
494589|NCT00724308|Smoking Cessation
494590|NCT00724308|Tobacco
494591|NCT00724308|Mental Health
494592|NCT00724282|sleep
494593|NCT00724282|eszopiclone
494594|NCT00724282|insulin secretion
494595|NCT00724282|insulin action
494596|NCT00724282|glucose tolerance
494597|NCT00724269|Contact lens wear
494598|NCT00724269|multi-purpose solution
494599|NCT00724269|corneal staining
494600|NCT00724256|Pyelonephritis.
494601|NCT00724256|Urinary Tract Infections.
494602|NCT00724256|Children.
494603|NCT00724256|Randomised controlled trial.
494604|NCT00724256|Therapy.
494605|NCT00724256|Ceftibuten.
494606|NCT00724204|probiotics
494607|NCT00724204|safety
494608|NCT00724204|fecal microbiota
494609|NCT00724204|infections
494610|NCT00724178|Pediatric HIV infection, bone mineral content, bone mineral density, Vitamin D, calcium Dual x-ray absorptiometry
494611|NCT00724165|physical activity
494612|NCT00724165|Latinas
494613|NCT00724152|coping skills
494614|NCT00724152|psychology
494615|NCT00724152|audiology
494616|NCT00724152|veterans
494617|NCT00724152|tinnitus
494618|NCT00724152|adult
494619|NCT00724152|intervention studies
494620|NCT00724152|tinnitus, noise induced
494621|NCT00724152|noise
494622|NCT00724152|auditory perception
494623|NCT00724126|Diarrhea
494624|NCT00724126|Rifaximin
494625|NCT00724126|IBS
494626|NCT00724126|Abdominal pain
494627|NCT00724126|Bloating
494628|NCT00724113|Shoulder capsulitis
494629|NCT00724113|ARTHRO distension
494630|NCT00724113|Mobilisation
494631|NCT00724113|Randomised clinical trial
494632|NCT00724100|Malignancy
494633|NCT00724100|Solid tumor
494634|NCT00724100|Tubulin inhibitor
494635|NCT00724087|short sleep duration
494636|NCT00724087|energy expenditure
494637|NCT00724087|insulin secretion
494638|NCT00724087|insulin action
494639|NCT00724087|lipid turnover
494640|NCT00724087|free fatty acids
494641|NCT00724074|Arthritis of the knee
494642|NCT00724074|Knee replacement
494643|NCT00724074|Osteoarthritis, knee
494644|NCT00724074|Arthroplasty, knee
494645|NCT00724061|recurrent mycosis fungoides/Sezary syndrome
494646|NCT00724061|stage I mycosis fungoides/Sezary syndrome
494647|NCT00724061|stage II mycosis fungoides/Sezary syndrome
494648|NCT00724061|stage III mycosis fungoides/Sezary syndrome
494649|NCT00724061|stage IV mycosis fungoides/Sezary syndrome
494650|NCT00724061|recurrent cutaneous T-cell non-Hodgkin lymphoma
494651|NCT00724061|stage I cutaneous T-cell non-Hodgkin lymphoma
494652|NCT00724061|stage II cutaneous T-cell non-Hodgkin lymphoma
494653|NCT00724061|stage III cutaneous T-cell non-Hodgkin lymphoma
494654|NCT00724061|stage IV cutaneous T-cell non-Hodgkin lymphoma
494655|NCT00724048|Huntington Disease
494656|NCT00724035|Anesthesia
494657|NCT00724035|Upper extremity
494658|NCT00724035|Nerve block
494659|NCT00724035|Ultrasound
494660|NCT00724035|Brachial plexus
494661|NCT00724022|Kidney transplant status
494662|NCT00724022|Steroid free
494663|NCT00724022|Reduced
494664|NCT00724022|Calcineurin
494665|NCT00724022|Inhibitor
494666|NCT00724022|Immunosuppression
494667|NCT00723970|Major Depressive Disorder
494668|NCT00723970|Insomnia
494669|NCT00723970|Hot Flashes
494670|NCT00723970|Menopause
494671|NCT00723970|Quetiapine
494672|NCT00723944|dental implants
494673|NCT00723944|Osseotite Certain Prevail
494674|NCT00723944|Lateralized
494675|NCT00723944|non-lateralized
494676|NCT00723944|Osseotite Certain
494677|NCT00723944|multicenter
494678|NCT00723944|randomized
494679|NCT00723944|clinical study
494680|NCT00723944|partial edentulism
494681|NCT00723944|single stage
494682|NCT00723944|early loading
494683|NCT00723944|crestal bone level
494684|NCT00723944|short fixed bridge
494685|NCT00723918|HIV-associated neuropathy
494686|NCT00723918|HIV
494687|NCT00723918|AIDS
494688|NCT00723918|cannabinoid
494689|NCT00723918|Cannabis
494690|NCT00723918|methadone
494691|NCT00723918|distal sensory polyneuropathy
494692|NCT00723918|polyneuropathy
494693|NCT00723905|Crohn's Disease, Rheumatoid Arthritis
494694|NCT00723866|Botulinum toxin, Spasticity, Stroke, Rehabilitation.
494695|NCT00723853|Obesity
494696|NCT00723853|Type 2 diabetes
494697|NCT00723853|African American children
494698|NCT00723853|African American youth
494699|NCT00723853|Community based
494700|NCT00723853|Family oriented
494701|NCT00723853|Obesity & Risk of type 2 diabetes
494702|NCT00723840|EuroQOL (EQ-5D)
494703|NCT00722800|YAZ
494704|NCT00722800|oral contraceptive
494705|NCT00722800|hidradenitis suppurativa
494706|NCT00722774|Vaccine
494707|NCT00722774|Influenza
494708|NCT00722761|YAZ
494709|NCT00722761|oral contraceptive
494710|NCT00722761|Acne vulgaris
494711|NCT00722748|Genebank
494712|NCT00722748|Gene registry
494713|NCT00722748|Cardiac Arrythmia Disease
494714|NCT00722735|uncomplicated Urinary Tract Infection in Women
494715|NCT00722735|Antibacterial Chemotherapy
494716|NCT00722735|Proof-of-Concept
494717|NCT00722709|Pain
494718|NCT00722709|Fatigue
494719|NCT00722709|Colon
494720|NCT00722709|Surgery
494721|NCT00722709|ERAS
494722|NCT00722709|Fastrack
494723|NCT00722709|Local anaesthetic
494724|NCT00722709|Peritoneum
494725|NCT00722709|Metabolic
494726|NCT00722709|Endocrine
494727|NCT00722709|Post surgical metabolic response
494728|NCT00722709|Complications
494729|NCT00722709|Time to passage of flatus
494730|NCT00722709|Time to passage of stool
494731|NCT00722709|Time to discharge from facility
494732|NCT00722709|Re-admission rate
494733|NCT00722696|Metabolism
494734|NCT00722696|Muscles
494735|NCT00722696|Exercise
494736|NCT00722670|risk reduction
494737|NCT00722670|prevention
494738|NCT00722670|HIV prevention
494739|NCT00722657|asthma
494740|NCT00722657|epidemiology
494741|NCT00723814|normal
494742|NCT00723801|Marfan syndrome
494743|NCT00723801|Losartan
494744|NCT00723801|Atenolol
494745|NCT00723801|Diastolic Function
494746|NCT00723801|Aortic Stiffness
494747|NCT00723788|Appendicitis
494748|NCT00723788|Children
494749|NCT00723788|Magnetic Resonance Imaging
494750|NCT00723775|KALETRA
494751|NCT00723775|GSK706769
494752|NCT00723775|HIV
494753|NCT00723775|healthy volunteers
494754|NCT00723762|Valproic acid
494755|NCT00723762|Urea cycle
494756|NCT00723762|Ornithine
494757|NCT00723762|Valproate
494758|NCT00723762|Side effect
494759|NCT00723749|Suboxone
494760|NCT00723749|Subutex
494761|NCT00723749|Buprenorphine
494762|NCT00723749|Naloxone
494763|NCT00723697|Subutex
494764|NCT00723684|ADHD
494765|NCT00723684|Children
494766|NCT00723684|EEG-Neurofeedback
494767|NCT00723658|Waldenström macroglobulinemia
494768|NCT00723619|asthma
494769|NCT00723619|spirometry
494770|NCT00723619|FENO
494771|NCT00723619|normal values for spirometry in childhood
494772|NCT00723619|normal values for FENO in childhood
494773|NCT00723606|Intramuscular ziprasidone, agitation, efficacy and safety
494774|NCT00723593|Graft-Versus-Host Disease
494775|NCT00723593|Gastrointestinal
494776|NCT00723593|Apoptotic Assay
494777|NCT00723593|Serum Proteomic Pattern Analysis
494778|NCT00723593|Mucosal Biopsy
494779|NCT00723593|Graft Versus Host Disease
494780|NCT00723593|GVHD
494781|NCT00723580|Kabuki Syndrome
494782|NCT00723580|Actigraphy
494783|NCT00723580|Treatment Response Measurement
494784|NCT00723567|Spectrin Gene
494785|NCT00723567|Hereditary Elliptocytosis (HE)
494786|NCT00723567|Hereditary Pyropoikilocytosis (HPP)
494787|NCT00723567|Genetics
494788|NCT00723554|pulmonary arterial hypertension
494789|NCT00723554|inhaled therapy
494790|NCT00723554|power disc-15
494791|NCT00723528|Psoriasis
494792|NCT00723528|Ustekinumab
494793|NCT00723528|CNTO 1275
494794|NCT00723515|White spot lesion
494795|NCT00723515|Tooth remineralization
494796|NCT00723515|Fluoride varnishes
494797|NCT00723502|Helicobacter pylori
494798|NCT00723502|Eradication
494799|NCT00723502|Dyspepsia
494800|NCT00723489|Yellow Fever Vaccine
494801|NCT00723489|Scarification Method
494802|NCT00723489|Atopic Dermatitis
494803|NCT00723489|IgG antibodies
494804|NCT00723476|Quality of Life
494805|NCT00723476|Adolescent
494806|NCT00723476|Advance Care Planning
494807|NCT00723476|Palliative Care
494808|NCT00723476|End-of-Life Care
494809|NCT00723476|HIV/AIDS
494810|NCT00723476|Psychological Adjustment
494811|NCT00723450|Bipolar I pediatric lamictal adolescent
494812|NCT00723437|nail, psoriasis, NAPSI,acitretin
494813|NCT00723424|AZD5672
494814|NCT00723424|digoxin
494815|NCT00723411|Diabetes
494816|NCT00723411|Juvenile Diabetes
494817|NCT00723411|Diabetes type 1
494818|NCT00723411|Autoimmune Diabetes
494819|NCT00723411|Insulin dependent Diabetes
494820|NCT00723411|Type 1 diabetes
494821|NCT00723411|Type 1 diabetes mellitus
494822|NCT00723411|Diamyd
494823|NCT00723411|rhGAD65
494824|NCT00723411|GAD
494825|NCT00723411|GAD-alum
494826|NCT00723398|omega-3 fatty acids
494827|NCT00723398|antiestrogens
494828|NCT00723398|breast cancer prevention
494829|NCT00723398|breast density
494830|NCT00723398|biomarkers of mammary carcinogenesis
494831|NCT00723385|cholesterol
494832|NCT00723385|LDL-cholesterol
494833|NCT00723385|cholecalciferol
494834|NCT00723385|lipids
494835|NCT00723385|C-reactive protein
494836|NCT00723359|Multiple Myeloma
494837|NCT00723359|Refractory
494838|NCT00723359|Relapsed
494839|NCT00723346|Relapse
494840|NCT00723346|Lymphoma lymphoblastic
494841|NCT00723333|Bone Marrow Transplant
494842|NCT00723333|Myelofibrosis
494843|NCT00723333|Stem Cell Transplant
494844|NCT00723333|Allogenic Transplant
494845|NCT00723320|Atherosclerosis
494846|NCT00723320|Atorvastatin
494847|NCT00723320|Therapeutic lifestyle change
494848|NCT00723320|CIMT
494849|NCT00723320|ABI
494850|NCT00723320|PWV
494851|NCT00723307|No diabetes mellitus
494852|NCT00723307|Elevated waist circumference
494853|NCT00723294|invasive ductal breast carcinoma
494854|NCT00723294|male breast cancer
494855|NCT00723294|stage IA breast cancer
494856|NCT00723294|stage IB breast cancer
494857|NCT00723294|stage II breast cancer
494858|NCT00723281|transplant coronary artery disease
494859|NCT00723281|CT angiography
494860|NCT00723281|conventional angiography
494861|NCT00723281|intravascular ultrasound
494862|NCT00723281|Heart transplant patients with known transplant coronary artery disease
494863|NCT00723268|Oral ulcers
494864|NCT00723216|Prevention
494865|NCT00723216|venous thromboembolism
494866|NCT00723216|curative surgery
494867|NCT00723203|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
494868|NCT00723203|recurrent adult acute lymphoblastic leukemia
494869|NCT00723203|recurrent adult acute myeloid leukemia
494870|NCT00723190|CLONICEL
494871|NCT00723190|Attention Deficit Hyperactivity Disorder
494872|NCT00723190|clonidine HCl sustained release
494873|NCT00723177|opioid withdrawal, analgesia
494874|NCT00723164|Sevoflurane induction
494875|NCT00723164|Premedication
494876|NCT00723164|laryngeal mask airway
494877|NCT00723164|Anesthesia, inhalation [E03.155.197.197]
494878|NCT00723125|Breast Cancer
494879|NCT00723112|Myelodysplastic Syndrome
494880|NCT00723112|Erythropoiesis
494881|NCT00723112|Ineffective Hematopoiesis
494882|NCT00723112|Erythroid Progenitors
494883|NCT00723112|Dyserythropoiesis
494884|NCT00723086|docetaxel, prednisolone, drug combination
494885|NCT00723073|micafungin, caspofungin, febrile neutropenia
494886|NCT00723047|Patients
494887|NCT00723047|CD complicated
494888|NCT00723047|least
494889|NCT00723047|One perianal fistula
494890|NCT00723047|Draining
494891|NCT00723047|2 months duration
494892|NCT00723021|Bronchodilator
494893|NCT00723008|anxiety
494894|NCT00723008|insomnia
494895|NCT00723008|pain
494896|NCT00723008|Alpha Stim
494897|NCT00723008|Cranial electrotherapy stimulation
494898|NCT00722995|Morbid obesity
494899|NCT00722995|Sleeve gastrectomy
494900|NCT00722995|Gastric bypass
494901|NCT00722995|Complications
494902|NCT00722995|Efficacity
494903|NCT00722995|Safety
494904|NCT00722995|Compare
494905|NCT00722982|coxarthrosis
494906|NCT00722982|hip
494907|NCT00722982|RSA
494908|NCT00722982|DXA
494909|NCT00722982|C-stem AMT
494910|NCT00722982|Marathon
494911|NCT00722969|non-small cell lung cancer
494912|NCT00722969|erlotinib
494913|NCT00722969|sorafenib
494914|NCT00722956|atorvastatin
494915|NCT00722956|AZD5672
494916|NCT00722943|infant
494917|NCT00722943|premature
494918|NCT00722943|message
494919|NCT00722943|therapy
494920|NCT00722943|NICU
494921|NCT00722943|neonatal intensive care unit
494922|NCT00722943|cortisol level
494923|NCT00722943|stress
494924|NCT00722943|postnatal
494925|NCT00722943|weight gain
494926|NCT00722943|DMT
494927|NCT00722943|Development Message Therapy
494928|NCT00722943|growth
494929|NCT00722930|Follicular Lymphoma
494930|NCT00722930|High-risk FLIPI
494931|NCT00722930|R-CHOP
494932|NCT00722930|GOTEL
494933|NCT00722930|Partial
494934|NCT00722930|Complete
494935|NCT00722930|Response
494936|NCT00722930|Induction
494937|NCT00722930|Chemotherapy
494938|NCT00722917|Glucose Metabolism Disorder
494939|NCT00722917|Dysmetabolic Syndrome
494940|NCT00722917|Type II Diabetes
494941|NCT00722917|Diabetes Mellitus, Lipoatrophic
494942|NCT00722917|Dyslipidemia
494943|NCT00722917|Drug Therapy
494944|NCT00722904|post-intervention surveillance of aortic coarctation
494945|NCT00722904|MRA and 2D phase contrast imaging
494946|NCT00722904|4D Flow velocity mapping
494947|NCT00722904|Patients undergoing routine post-intervention surveillance of aortic coarctation
494948|NCT00722904|Healthy volunteers
494949|NCT00722891|Eye Diseases
494950|NCT00722878|Primary Ciliary Dyskinesia
494951|NCT00722865|Avastin
494952|NCT00722865|bevacizumab
494953|NCT00722865|ABVD
494954|NCT00722865|angiogenesis
494955|NCT00722865|antiangiogenic
494956|NCT00722865|Hodgkin
494957|NCT00722839|cytomegalovirus infection
494958|NCT00722826|Pulmonary Regurgitation
494959|NCT00722826|Tetralogy of Fallot
494960|NCT00722644|HIV
494961|NCT00722644|Medication Adherence
494962|NCT00722644|Stress Management
494963|NCT00722644|CD4/Viral Loads
494964|NCT00722644|Cognitive Behavioral Treatment
494965|NCT00722618|Infertility
494966|NCT00722605|lung
494967|NCT00722605|esophageal
494968|NCT00722605|cone beam ct scan
494969|NCT00722592|cancer
494970|NCT00722592|ovarian
494971|NCT00722592|platinum-resistant
494972|NCT00722592|Phase II
494973|NCT00722592|EC145
494974|NCT00722592|EC20
494975|NCT00722579|Coronary Artery Disease
494976|NCT00722553|Transitional Cell Carcinoma of the Urinary Bladder
494977|NCT00722553|Transitional Cell Carcinoma
494978|NCT00722553|Bladder Cancer
494979|NCT00722553|Urinary Bladder Cancer
494980|NCT00722553|Bladder
494981|NCT00722553|Carcinoma
494982|NCT00722553|Urinary
494983|NCT00722553|Metastatic
494984|NCT00722553|Relapsed
494985|NCT00722527|Primary Familial and Congenital Polycythemia
494986|NCT00722527|Polycythemia
494987|NCT00722527|Molecular Biology
494988|NCT00722527|Genetics
494989|NCT00722527|Erythropoiesis
494990|NCT00722527|EPOR mutation
494991|NCT00722527|Thrombocytosis
494992|NCT00722527|Hypoxia
494993|NCT00722475|recurrent miscarriage
494994|NCT00722475|immunology
494995|NCT00722475|intravenous immunoglobulin
494996|NCT00722475|miscarriage
494997|NCT00722462|Infertility
494998|NCT00722462|IVF
494999|NCT00722462|Acupuncture
495000|NCT00722436|antifibrinolytic, tranexamic acid
495001|NCT00722423|Hepatitis C
495002|NCT00722423|integrated care
495003|NCT00722423|alpha interferon
495004|NCT00722423|mental health
495005|NCT00722410|Carbapenem
495006|NCT00722410|resistant
495007|NCT00722410|Klebsiella pneumoniae
495008|NCT00722410|Carpapenemases
495009|NCT00722410|Probiotics
495010|NCT00722410|VSL3
495011|NCT00722397|genetics, pediatrics
495012|NCT00722384|AMD
495013|NCT00722384|Macular Degeneration
495014|NCT00722384|Opko Health
495015|NCT00722384|Acuity Pharmaceuticals
495016|NCT00722384|bevasiranib
495017|NCT00722384|Cand5
495018|NCT00722384|Age-Related
495019|NCT00722345|Obesity
495020|NCT00722345|Physical activity
495021|NCT00722345|Adolescents
495022|NCT00722345|Exercise counseling intervention
495023|NCT00722332|HBIG (Hepatitis B Immune Globulin)
495024|NCT00722332|Chronic Hepatitis B Recurrence
495025|NCT00722332|Liver Transplant
495026|NCT00722319|oral anticoagulation
495027|NCT00722319|warfarin
495028|NCT00722319|percutaneous coronary intervention
495029|NCT00722319|stent
495030|NCT00722319|antiplatelet agents
495031|NCT00722306|non-restorative
495032|NCT00722306|sleep
495033|NCT00722293|Solid tumors
495034|NCT00722293|Cancer
495035|NCT00722293|Neoplasms, Ovarian
495036|NCT00722293|doxorubicin
495037|NCT00722293|epirubicin
495038|NCT00722293|anti-angiogenesis
495039|NCT00722293|pharmacodynamics
495040|NCT00722293|pazopanib (GW786034)
495041|NCT00722293|pharmacokinetics
495042|NCT00722293|Soft Tissue
495043|NCT00722293|Sarcoma
495044|NCT00722280|Amputation, upper limb, composite tissue, immunosuppression
495045|NCT00722267|severe COPD
495046|NCT00722267|COPD symptoms
495047|NCT00722267|variability of symptoms
495048|NCT00722267|patient's perception
495049|NCT00722254|Myeloproliferative Disorder
495050|NCT00722254|Primary Myelofibrosis
495051|NCT00722254|Primary Pulmonary Hypertension
495052|NCT00722254|Secondary Myelofibrosis
495053|NCT00722254|Pulmonary Arterial Hypertension
495054|NCT00722254|Flolan
495055|NCT00722254|Clonality
495056|NCT00722254|CD34+ cells
495057|NCT00722254|Hematologic abnormalities
495058|NCT00722241|Continuous Glucose Monitoring
495059|NCT00722241|Interstitial Fluid
495060|NCT00722241|Diabetes Mellitus
495061|NCT00722215|Endothelin antagonist
495062|NCT00722215|Chronic kidney disease
495063|NCT00722215|Proteinuria
495064|NCT00722215|Cardiovascular disease
495065|NCT00722215|Blood pressure
495066|NCT00722215|Arterial stiffness
495067|NCT00722215|Endothelial function
495068|NCT00722189|Mycoses
495069|NCT00722176|Schizophrenia
495070|NCT00722163|Cognitive Behavioural therapy
495071|NCT00722163|Psychosis
495072|NCT00722150|Artesunate
495073|NCT00722150|Plasmodium Falciparum
495074|NCT00722150|Cambodia
495075|NCT00722124|tobacco use
495076|NCT00722124|cigarettes
495077|NCT00722124|smokers
495078|NCT00722111|tongue
495079|NCT00722111|pressure
495080|NCT00722098|Melanoma
495081|NCT00722098|Dendritic Cell
495082|NCT00722098|Vaccine
495083|NCT00722098|Immunotherapy
495084|NCT00722098|Cyclophosphamide
495085|NCT00722085|Amniotic Fluid Sludge
495086|NCT00722085|Cerclage
495087|NCT00722085|Ultrasound
495088|NCT00722085|Preterm Delivery
495089|NCT00722085|Neonatal
495090|NCT00722072|male breast cancer
495091|NCT00722072|stage IIIA breast cancer
495092|NCT00722072|stage IIIB breast cancer
495093|NCT00722072|stage IIIC breast cancer
495094|NCT00722072|stage IV breast cancer
495095|NCT00722072|recurrent breast cancer
495096|NCT00722046|Alzheimer's disease
495097|NCT00722046|antibody
495098|NCT00722046|amyloid
495099|NCT00722033|preterm
495100|NCT00722033|aEEG
495101|NCT00722033|apneas
495102|NCT00722033|surfactant
495103|NCT00722033|indomethacin
495104|NCT00722033|aminophyline
495105|NCT00722020|Asthma
495106|NCT00722020|Bronchial Disease
495107|NCT00722020|Status Asthmaticus
495108|NCT00722020|High Frequency Chest Wall Oscillation
495109|NCT00722020|the Vest
495110|NCT00722020|HFCWO
495111|NCT00722007|hip resurfacing
495112|NCT00722007|osteoarthritis
495113|NCT00722007|avascular necrosis
495114|NCT00722007|rheumatoid arthritis
495115|NCT00721994|hip resurfacing
495116|NCT00721994|osteoarthritis
495117|NCT00721994|avascular necrosis
495118|NCT00721994|rheumatoid arthritis
495119|NCT00721981|patient preference
495120|NCT00721981|oncology
495121|NCT00721981|chemotherapy
495122|NCT00721981|NSCLC
495123|NCT00721968|Open angle
495124|NCT00721968|Glaucoma
495125|NCT00721968|Cataract
495126|NCT00721968|Surgery
495127|NCT00721955|Bipolar 1 disorder,
495128|NCT00721955|agitation,
495129|NCT00721955|acute,
495130|NCT00721955|treatment
495131|NCT00721929|adrenal glands, adrenal masses
495132|NCT00721890|chemoprevention
495133|NCT00721890|green tea
495134|NCT00721890|relapse free-survival
495135|NCT00721890|proteases
495136|NCT00721864|Paroxysmal Nocturnal Hemoglobinuria
495137|NCT00721864|PIG-A Mutation
495138|NCT00721864|Prion Protein
495139|NCT00721864|Hematopoietic stem cells
495140|NCT00721864|Clonal disorder
495141|NCT00721838|adolescent obesity
495142|NCT00721838|eating behavior
495143|NCT00721838|dietary intake
495144|NCT00721825|Stroke
495145|NCT00721825|Cerebral infarct
495146|NCT00721825|Rehabilitation
495147|NCT00721825|Double blind Randomized
495148|NCT00721825|Placebo controlled
495149|NCT00721825|Traditional Chinese Medicine
495150|NCT00721825|Neuroaid
495151|NCT00721812|IBD
495152|NCT00721812|first time in humans
495153|NCT00721812|Phase 1
495154|NCT00721812|human volunteers
495155|NCT00721812|safety
495156|NCT00721812|pharmacokinetics
495157|NCT00721799|Positron-Emission Tomography
495158|NCT00721786|Smoking cessation
495159|NCT00721786|Cigarette smoking
495160|NCT00721786|Tobacco smoking
495161|NCT00721786|Internet interventions
495162|NCT00721786|Spanish-speaking
495163|NCT00721773|Continuous Ambulatory Peritoneal Dialysis
495164|NCT00721773|Angiotensin-converting Enzyme Inhibitor
495165|NCT00721773|Angiotensin II Receptor Blocker
495166|NCT00721773|Renin angiotensin system inhibitor
495167|NCT00721773|Residual Renal Function
495168|NCT00721760|Hip fractures
495169|NCT00721760|Heparin Low-Molecular-Weight
495170|NCT00721760|Randomized Controlled Trial
495171|NCT00721747|breast cancer patients her2 negative pathological responses
495172|NCT00721734|Myeloma
495173|NCT00721734|Renal Insufficiency
495174|NCT00721734|Proteasome
495175|NCT00721734|Hematological
495176|NCT00721734|carfilzomib
495177|NCT00721734|PR-171
495178|NCT00721721|Dietary Sodium
495179|NCT00721721|Dietary Potassium
495180|NCT00721721|Genes
495181|NCT00721721|Genomics
495182|NCT00721708|histidine dipeptides
495183|NCT00721708|carnosine
495184|NCT00721708|anserine
495185|NCT00721695|Cataract
495186|NCT00721695|Cataract Extraction
495187|NCT00721695|Lens Implantation
495188|NCT00721695|Phacoemulsification
495189|NCT00721682|Pediatry
495190|NCT00721682|Ill-treatment
495191|NCT00721682|Pain
495192|NCT00721682|maltreated children
495193|NCT00721669|solid tumor
495194|NCT00721656|Dry eye syndromes
495195|NCT00721656|Corneal diseases
495196|NCT00721656|Conjunctival Diseases
495197|NCT00721643|Angelica keiskei
495198|NCT00721643|absorption kinetics
495199|NCT00721643|quercetin
495200|NCT00721630|CAPECITABINE
495201|NCT00721630|LAPATINIB
495202|NCT00721604|shock
495203|NCT00721604|fluid responsiveness
495204|NCT00721604|volume expansion
495205|NCT00721591|Recurrent Pregnancy Loss
495206|NCT00721591|Habitual abortion
495207|NCT00721591|Fetal demise
495208|NCT00721591|Antiphospholipid antibodies
495209|NCT00721591|Inherited thrombophilia
495210|NCT00721578|Observational study
495211|NCT00721578|Effectiveness
495212|NCT00721578|Safety
495213|NCT00721578|Tolerability
495214|NCT00721578|Systemic Fungal Infection
495215|NCT00721565|Breast Cancer
495216|NCT00721565|Exercise
495217|NCT00721565|Social Cognitive Theory
495218|NCT00721565|Adherence
495219|NCT00721565|Symptoms
495220|NCT00721565|Body Composition
495221|NCT00721552|beta-cell function
495222|NCT00721552|glucocorticoid-induced diabetes
495223|NCT00721552|glucocorticoid
495224|NCT00721552|DPP-4 inhibitors
495225|NCT00721552|sitagliptin
495226|NCT00721552|diabetes mellitus
495227|NCT00721552|steroid diabetes
495228|NCT00721552|insulin resistance
495229|NCT00721552|insulin sensitivity
495230|NCT00721526|alcohol dependence
495231|NCT00721526|alcoholism
495232|NCT00721526|anxiety disorder
495233|NCT00721526|pharmacotherapy
495234|NCT00721526|disulfiram
495235|NCT00721526|lorazepam
495236|NCT00721513|stage III squamous cell carcinoma of the oropharynx
495237|NCT00721513|stage IV squamous cell carcinoma of the oropharynx
495238|NCT00721513|stage III squamous cell carcinoma of the hypopharynx
495239|NCT00721513|stage IV squamous cell carcinoma of the hypopharynx
495240|NCT00721513|stage III squamous cell carcinoma of the larynx
495241|NCT00721513|stage III verrucous carcinoma of the larynx
495242|NCT00721513|stage IV squamous cell carcinoma of the larynx
495243|NCT00721513|stage IV verrucous carcinoma of the larynx
495244|NCT00721487|C. albicans
495245|NCT00721487|fluconazole
495246|NCT00721461|Assess
495247|NCT00721461|Tolerability
495248|NCT00721461|MedPulser DDS device
495249|NCT00721448|Pharmacokinetics
495250|NCT00721422|Pharmacokinetics of PD 0332334 in subjects with renal insufficiency
495251|NCT00721409|hormone-receptor positive advanced breast cancer
495252|NCT00721396|Meningococcal disease,
495253|NCT00721396|Neisseria meningitidis serogroup B,
495254|NCT00721396|Prevention,
495255|NCT00721396|Vaccination,
495256|NCT00721396|Infants
495257|NCT00721383|caregiving, Alzheimer's disease, physical activity
495258|NCT00721370|sentinel lymph node mapping
495259|NCT00721370|breast cancer
495260|NCT00721370|near infrared imaging
495261|NCT00721357|muscles
495262|NCT00721357|work
495263|NCT00721357|Magnetic Resonance Imaging
495264|NCT00721357|control groups
495265|NCT00721344|Healthy males and females
495266|NCT00721331|CombinatoRx
495267|NCT00721331|Atopic
495268|NCT00721331|Dermatitis
495269|NCT00721331|Topical
495270|NCT00721331|CRx-197
495271|NCT00721331|Normal Healthy Volunteers
495272|NCT00721318|chronic widespread pain
495273|NCT00721318|fibromyalgia
495274|NCT00721318|rheumatoid arthritis
495275|NCT00721318|Estonia
495276|NCT00721305|Type 1 human immunodeficiency virus infection
495277|NCT00721305|Lovastatin
495278|NCT00721305|Adaptive Immunity
495279|NCT00721305|Cellular cholesterol
495280|NCT00721305|Rho GTPases
495281|NCT00721305|Lymphocyte function-associated antigen-1
495282|NCT00721253|ReSTOR
495283|NCT00721240|responder
495284|NCT00721240|leucotriene antagonist
495285|NCT00721214|Myelodysplastic Syndrome
495286|NCT00721214|5-azacytidine
495287|NCT00721214|allogeneic stem cell transplantation
495288|NCT00721201|subclinical Cushing's
495289|NCT00721175|biliary stent
495290|NCT00721175|plastic stent
495291|NCT00721175|metallic stent
495292|NCT00721175|Complex hilar cholangiocarcinoma (Bismuth type II,III,IV)
495293|NCT00721162|Ovarian Cancer,
495294|NCT00721162|Fallopian Tube Cancer
495295|NCT00721162|Primary Peritoneal Carcinoma
495296|NCT00721149|Atrial Fibrillation
495297|NCT00721149|Paroxysmal Atrial Fibrillation
495298|NCT00721149|Ablation
495299|NCT00721149|Non-randomized
495300|NCT00721136|bleeding
495301|NCT00721136|anticoagulation
495302|NCT00721136|pacemaker
495303|NCT00721136|implantable cardioverter-defibrillator
495304|NCT00721136|"patients undergoing implantation of a pacemaker or defibrillator (ICD)"
495305|NCT00721110|pain control
495306|NCT00721110|nausea
495307|NCT00721110|surgery recovery
495308|NCT00721097|Severe asthma
495309|NCT00721097|exacerbation
495310|NCT00721097|predictive factors
495311|NCT00721097|Severe
495312|NCT00721084|short sleep duration
495313|NCT00721084|maximal aerobic capacity
495314|NCT00721084|body fat
495315|NCT00721084|visceral adiposity
495316|NCT00721084|activity-related energy expenditure
495317|NCT00721084|energy metabolism
495318|NCT00721071|Pediatrics
495319|NCT00721071|Cystic Fibrosis
495320|NCT00721071|Hypertonic Saline
495321|NCT00721071|Induced Sputum
495322|NCT00721071|Expectorated Sputum
495323|NCT00721058|Eligible
495324|NCT00721058|Operable
495325|NCT00721058|Disease
495326|NCT00721058|Conserving
495327|NCT00721058|Therapy
495328|NCT00721058|Visible mass on mammography
495329|NCT00721058|Ultrasound > 0.5 cm
495330|NCT00721058|Histologically
495331|NCT00721058|Proven
495332|NCT00721045|Heart Failure
495333|NCT00721045|Congestive Heart Failure
495334|NCT00721032|Ventricular tachycardia (VT)
495335|NCT00721032|Implantable cardioverter-defibrillator (ICD)
495336|NCT00721032|Ablation
495337|NCT00721032|Cardiomyopathy
495338|NCT00721032|Electrophysiology study
495339|NCT00721019|short sleep duration
495340|NCT00721019|glucose clamp technique
495341|NCT00721019|insulin secretion
495342|NCT00721019|insulin action
495343|NCT00721019|lipid turnover
495344|NCT00721019|free fatty acids
495345|NCT00721006|peripheral artery disease
495346|NCT00721006|peripheral vascular disease
495347|NCT00721006|PAD
495348|NCT00721006|PVD
495349|NCT00720993|Colorectal cancer screening
495350|NCT00720993|Gene expression
495351|NCT00720993|RTPCR
495352|NCT00720980|granuloma annulare, ROM
495353|NCT00720967|Renal dysfunction
495354|NCT00720967|Hemodialysis
495355|NCT00720967|Modified ultrafiltration
495356|NCT00720967|Open heart surgery
495357|NCT00720954|Thoracoscopy
495358|NCT00720954|Pleural needle biopsy
495359|NCT00720954|Malignant pleural diseases
495360|NCT00720954|Mesothelioma
495361|NCT00720954|Diagnosis
495362|NCT00720954|Pleurisy tuberculosis
495363|NCT00720954|Patients with pleural diseases and pleural effusion should have been included in the study.
495364|NCT00720941|SUTENT
495365|NCT00720941|Locally advanced and/or metastatic renal cell carcinoma
495366|NCT00720941|Pazopanib
495367|NCT00720941|Sunitinib
495368|NCT00720941|GW786034
495369|NCT00720941|Renal cell carcinoma
495370|NCT00720928|Behcet's disease
495371|NCT00720928|posterior uveitis
495372|NCT00720928|flucinolone acetonide
495373|NCT00720928|RETISERT
495374|NCT00720915|unprovoked deep vein thrombosis
495375|NCT00720915|unprovoked pulmonary embolism
495376|NCT00720915|anticoagulant therapy
495377|NCT00720889|short sleep duration
495378|NCT00720889|glucose clamp technique
495379|NCT00720889|insulin secretion
495380|NCT00720889|insulin action
495381|NCT00720889|lipid turnover
495382|NCT00720889|free fatty acids
495383|NCT00720876|contiguous stage II grade 1 follicular lymphoma
495384|NCT00720876|contiguous stage II grade 2 follicular lymphoma
495385|NCT00720876|contiguous stage II grade 3 follicular lymphoma
495386|NCT00720876|noncontiguous stage II grade 1 follicular lymphoma
495387|NCT00720876|noncontiguous stage II grade 2 follicular lymphoma
495388|NCT00720876|noncontiguous stage II grade 3 follicular lymphoma
495389|NCT00720876|recurrent grade 1 follicular lymphoma
495390|NCT00720876|recurrent grade 2 follicular lymphoma
495391|NCT00720876|recurrent grade 3 follicular lymphoma
495392|NCT00720876|stage I grade 1 follicular lymphoma
495393|NCT00720876|stage I grade 2 follicular lymphoma
495394|NCT00720876|stage I grade 3 follicular lymphoma
495395|NCT00720876|stage III grade 1 follicular lymphoma
495396|NCT00720876|stage III grade 2 follicular lymphoma
495397|NCT00720876|stage III grade 3 follicular lymphoma
495398|NCT00720876|stage IV grade 1 follicular lymphoma
495399|NCT00720876|stage IV grade 2 follicular lymphoma
495400|NCT00720876|stage IV grade 3 follicular lymphoma
495401|NCT00720876|contiguous stage II marginal zone lymphoma
495402|NCT00720876|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
495403|NCT00720876|nodal marginal zone B-cell lymphoma
495404|NCT00720876|noncontiguous stage II marginal zone lymphoma
495405|NCT00720876|recurrent marginal zone lymphoma
495406|NCT00720876|splenic marginal zone lymphoma
495407|NCT00720876|stage I marginal zone lymphoma
495408|NCT00720876|stage III marginal zone lymphoma
495409|NCT00720876|stage IV marginal zone lymphoma
495410|NCT00720876|contiguous stage II mantle cell lymphoma
495411|NCT00720876|noncontiguous stage II mantle cell lymphoma
495412|NCT00720876|recurrent mantle cell lymphoma
495413|NCT00720876|stage I mantle cell lymphoma
495414|NCT00720876|stage III mantle cell lymphoma
495415|NCT00720876|stage IV mantle cell lymphoma
495416|NCT00720850|MDS
495417|NCT00720850|AML
495418|NCT00720850|Lenalidomide
495419|NCT00720850|monosomy 5
495420|NCT00720850|monosomy del5q
495421|NCT00720837|Brain Tumor
495422|NCT00720837|Brain Cancer
495423|NCT00720837|MR-guided laser thermal ablation of brain tumors
495424|NCT00720837|Visualase® Thermal Therapy System
495425|NCT00720837|Magnetic Resonance Thermal Imaging
495426|NCT00720837|MRTI
495427|NCT00720837|Visualase Cooled Laser Application System
495428|NCT00720837|Laser Interstitial Thermal Therapy
495429|NCT00720837|LITT
495430|NCT00720824|Immunizations
495431|NCT00720824|Children
495432|NCT00720824|Injections
495433|NCT00720824|aged 4-6 Years
495434|NCT00720824|Hypnosis
495435|NCT00720811|Malaria ACT
495436|NCT00720811|Rapid
495437|NCT00720811|Diagnosis
495438|NCT00720811|Community
495439|NCT00720811|health
495440|NCT00720811|worker
495441|NCT00720811|Artemesinin
495442|NCT00720811|based
495443|NCT00720811|Combination
495444|NCT00720811|Therapy
495445|NCT00720811|Anti Malarial
495446|NCT00720811|Treatment
495447|NCT00720811|antibiotics
495448|NCT00720785|Metastatic Solid Tumor
495449|NCT00720785|Chronic Myelogenous Leukemia (CML)
495450|NCT00720785|Small Lymphocytic Lymphoma (SLL)
495451|NCT00720785|Tumor Cytotoxicity
495452|NCT00720785|Chronic Lymphocytic Leukemia (CLL)
495453|NCT00720785|Lung Cancer
495454|NCT00720785|Prostate Cancer
495455|NCT00720785|Colon Cancer
495456|NCT00720785|Kidney Cancer
495457|NCT00720785|Pancreatic Cancer
495458|NCT00720785|Leukemia
495459|NCT00720785|Chronic Myelogenous Leukemia
495460|NCT00720785|CML
495461|NCT00720785|Small Lymphocytic Lymphoma
495462|NCT00720785|SLL
495463|NCT00720785|Chronic Lymphocytic Leukemia
495464|NCT00720785|CLL
495465|NCT00720772|coronary calcification
495466|NCT00720772|vascular calcification
495467|NCT00720772|sodium thiosulfate
495468|NCT00720759|stroke
495469|NCT00720759|hemiparesis
495470|NCT00720759|randomized controlled trial
495471|NCT00720759|d-cycloserine
495472|NCT00720759|distributed practice
495473|NCT00720759|constraint induced movement therapy
495474|NCT00720733|HIV
495475|NCT00720733|Mood
495476|NCT00720733|Emotion
495477|NCT00720733|Coping
495478|NCT00720733|Aids
495479|NCT00720733|Affect
495480|NCT00720733|Adults
495481|NCT00720733|Diagnosed
495482|NCT00720707|Coronally advanced flap
495483|NCT00720707|gingival recession
495484|NCT00720707|enamel matrix protein
495485|NCT00720707|acellular dermal matrix
495486|NCT00720707|root coverage
495487|NCT00720668|hepatitis B
495488|NCT00720668|hepatocellular carcinoma
495489|NCT00720668|radiofrequency ablation
495490|NCT00720668|reactivation
495491|NCT00720655|coronary heart disease
495492|NCT00720629|graft versus host disease
495493|NCT00720629|GVHD
495494|NCT00720629|allogeneic transplant
495495|NCT00720629|GVHD prevention
495496|NCT00720629|unrelated donors
495497|NCT00720629|mismatched unrelated donors
495498|NCT00720629|hematological malignancies
495499|NCT00720629|Leukemia
495500|NCT00720629|Lymphoma
495501|NCT00720629|Myelodysplastic Syndrome
495502|NCT00720629|Myelofibrosis
495503|NCT00720629|Aplastic Anemia
495504|NCT00720629|Multiple Myeloma
495505|NCT00720616|Growth hormone
495506|NCT00720616|Metabolic syndrome
495507|NCT00720616|Insulin sensitivity
495508|NCT00720603|Autologous Stem Cell Transplant
495509|NCT00720577|Peripheral Arterial Disease
495510|NCT00720577|PAD
495511|NCT00720577|Lower extremity peripheral arterial atherosclerotic plaque
495512|NCT00720577|RNA Expression
495513|NCT00720577|Lipid Biomarkers
495514|NCT00720564|adult glioblastoma
495515|NCT00720564|adult anaplastic astrocytoma
495516|NCT00720564|adult anaplastic oligodendroglioma
495517|NCT00720564|adult gliosarcoma
495518|NCT00720564|adult mixed glioma
495519|NCT00720551|STISIM
495520|NCT00720551|Alcohol
495521|NCT00720538|Inflammatory bowel diseases.
495522|NCT00720538|Crohn disease.
495523|NCT00720538|Ulcerative, colitis.
495524|NCT00720538|Randomised controlled trial.
495525|NCT00720538|Therapy.
495526|NCT00720538|Thalidomide.
495527|NCT00720538|Children.
495528|NCT00720525|arterial stiffness
495529|NCT00720525|arterial wave reflections
495530|NCT00720525|diastolic heart failure
495531|NCT00720512|adenocarcinoma of the colon
495532|NCT00720512|adenocarcinoma of the rectum
495533|NCT00720512|recurrent colon cancer
495534|NCT00720512|recurrent rectal cancer
495535|NCT00720512|stage IV colon cancer
495536|NCT00720512|stage IV rectal cancer
495537|NCT00720512|stage III rectal cancer
495538|NCT00720512|stage III colon cancer
495539|NCT00720473|Bipolar depression
495540|NCT00720473|Elderly
495541|NCT00720473|Lamotrigine
495542|NCT00720473|Brain energy metabolism
495543|NCT00720460|Magnetic Resonance Imaging
495544|NCT00720460|Minimally Invasive Therapy
495545|NCT00720460|Heart Catheterization
495546|NCT00720460|Healthy Volunteers
495547|NCT00720460|Gadolinium Contrast
495548|NCT00720460|Healthy Volunteer
495549|NCT00720460|HV
495550|NCT00720447|stage III mantle cell lymphoma
495551|NCT00720447|stage IV mantle cell lymphoma
495552|NCT00720421|Phase I
495553|NCT00720421|pharmacodynamic study
495554|NCT00720408|Immunosuppressant
495555|NCT00720408|Graft loss
495556|NCT00720408|Combination drug therapy
495557|NCT00720408|Randomized controlled trial
495558|NCT00720408|Open level method
495559|NCT00720395|Psychiatry
495560|NCT00720395|Pregnancy
495561|NCT00720369|Bipolar depression
495562|NCT00720369|elderly
495563|NCT00720369|Coenzyme Q10
495564|NCT00720369|Magnetic resonance spectroscopy
495565|NCT00720356|adult glioblastoma
495566|NCT00720356|adult gliosarcoma
495567|NCT00720330|Inguinal Herniorrhaphy
495568|NCT00720330|Pain assessment
495569|NCT00720330|Outcomes
495570|NCT00720317|Diabetic Retinopathy
495571|NCT00720317|Sickle Cell Trait
495572|NCT00720317|Vision Loss
495573|NCT00720317|Eye disease
495574|NCT00720304|stage III squamous cell carcinoma of the hypopharynx
495575|NCT00720304|stage IV squamous cell carcinoma of the hypopharynx
495576|NCT00720304|stage III squamous cell carcinoma of the larynx
495577|NCT00720304|stage III verrucous carcinoma of the larynx
495578|NCT00720304|stage IV squamous cell carcinoma of the larynx
495579|NCT00720304|stage IV verrucous carcinoma of the larynx
495580|NCT00720304|stage III squamous cell carcinoma of the lip and oral cavity
495581|NCT00720304|stage IV squamous cell carcinoma of the lip and oral cavity
495582|NCT00720304|stage III verrucous carcinoma of the oral cavity
495583|NCT00720304|stage IV verrucous carcinoma of the oral cavity
495584|NCT00720304|metastatic squamous neck cancer with occult primary squamous cell carcinoma
495585|NCT00720304|stage III squamous cell carcinoma of the nasopharynx
495586|NCT00720304|stage IV squamous cell carcinoma of the nasopharynx
495587|NCT00720304|stage III squamous cell carcinoma of the oropharynx
495588|NCT00720304|stage IV squamous cell carcinoma of the oropharynx
495589|NCT00720291|Metronidazole
495590|NCT00720291|BV
495591|NCT00720291|Pregnancy
495592|NCT00720265|Organ Transplantation
495593|NCT00720265|Tacrolimus
495594|NCT00720265|Prograf
495595|NCT00720265|FK506MR
495596|NCT00720226|COPD
495597|NCT00720226|emphysema
495598|NCT00720226|angiotensin receptor blocker
495599|NCT00720200|Communication
495600|NCT00720200|Intensive Care Units
495601|NCT00720200|Palliative Care
495602|NCT00720200|End-of-Life Issues
495603|NCT00720200|Talking with Your Doctor
495604|NCT00720200|Coping with Chronic Illness
495605|NCT00720161|metformin, spina bifida, duchenne, insulin resistance
495606|NCT00720148|Solid tumors
495607|NCT00720122|Bone density
495608|NCT00720122|Bone turnover markers
495609|NCT00720122|rhIGF-1
495610|NCT00720122|Bone structure
495611|NCT00720122|Anorexia nervosa
495612|NCT00720096|Persistent Ovarian Cancer
495613|NCT00720096|Genomic directed salvage chemotherapy
495614|NCT00720096|Genomic Microarray
495615|NCT00720083|stage III squamous cell carcinoma of the hypopharynx
495616|NCT00720083|stage IV squamous cell carcinoma of the hypopharynx
495617|NCT00720083|stage III squamous cell carcinoma of the larynx
495618|NCT00720083|stage IV squamous cell carcinoma of the larynx
495619|NCT00720083|stage III verrucous carcinoma of the oral cavity
495620|NCT00720083|stage IV verrucous carcinoma of the oral cavity
495621|NCT00720083|stage III squamous cell carcinoma of the oropharynx
495622|NCT00720083|stage IV squamous cell carcinoma of the oropharynx
495623|NCT00720070|stage I squamous cell carcinoma of the oropharynx
495624|NCT00720070|stage II squamous cell carcinoma of the oropharynx
495625|NCT00720070|stage III squamous cell carcinoma of the oropharynx
495626|NCT00720070|stage I squamous cell carcinoma of the larynx
495627|NCT00720070|stage I verrucous carcinoma of the larynx
495628|NCT00720070|stage II squamous cell carcinoma of the larynx
495629|NCT00720070|stage II verrucous carcinoma of the larynx
495630|NCT00720070|stage III squamous cell carcinoma of the larynx
495631|NCT00720070|stage III verrucous carcinoma of the larynx
495632|NCT00720070|stage I squamous cell carcinoma of the lip and oral cavity
495633|NCT00720070|stage I verrucous carcinoma of the oral cavity
495634|NCT00720070|stage II squamous cell carcinoma of the lip and oral cavity
495635|NCT00720070|stage II verrucous carcinoma of the oral cavity
495636|NCT00720070|stage III squamous cell carcinoma of the lip and oral cavity
495637|NCT00720070|stage III verrucous carcinoma of the oral cavity
495638|NCT00720070|stage I squamous cell carcinoma of the hypopharynx
495639|NCT00720070|stage II squamous cell carcinoma of the hypopharynx
495640|NCT00720070|stage III squamous cell carcinoma of the hypopharynx
495641|NCT00720070|tongue cancer
495642|NCT00720057|Dental Pain
495643|NCT00720057|Analgesia
495644|NCT00720031|Melanoma,
495645|NCT00720031|Melan-A tumor reactive T cell clones,
495646|NCT00720031|immunotherapy
495647|NCT00720031|HLA-A2 melanoma patients with
495648|NCT00720031|either loco-regional or lymphnode metastasis
495649|NCT00720031|transit nodules not surgically resectable
495650|NCT00720031|-measurable cutaneous or visceral metastasis .
495651|NCT00720031|Patients' tumor express Melan-A/MART-1 antigen.
495652|NCT00720005|Cataract
495653|NCT00720005|cataract extraction
495654|NCT00720005|intraocular lens
495655|NCT00720005|age related
495656|NCT00719992|Exercise tolerance test
495657|NCT00719992|HS-CRP
495658|NCT00719992|Coronary angiography
495659|NCT00719992|Patients
495660|NCT00719979|Major Depressive Disorder
495661|NCT00719979|Cognitive Behavior Therapy
495662|NCT00719979|Technology Assisted
495663|NCT00719979|Internet
495664|NCT00719979|Primary Care
495665|NCT00719966|stage IA breast cancer
495666|NCT00719966|stage IB breast cancer
495667|NCT00719966|stage II breast cancer
495668|NCT00719966|stage IIIA breast cancer
495669|NCT00719966|stage IIIB breast cancer
495670|NCT00719966|stage IIIC breast cancer
495671|NCT00719966|stage IV breast cancer
495672|NCT00719966|ductal breast carcinoma in situ
495673|NCT00719953|Cognitex
495674|NCT00719953|subjects
495675|NCT00719940|tinnitus, cognitive behavioral therapy, CBT
495676|NCT00719927|Social Support
495677|NCT00719914|eptifibatide
495678|NCT00719914|Integrilin
495679|NCT00719914|ST-Elevation Myocardial Infarction
495680|NCT00719914|Acute Myocardial Infarction
495681|NCT00719849|chronic myelogenous leukemia
495682|NCT00719849|acute lymphoblastic leukemia
495683|NCT00719849|acute myeloid leukemia
495684|NCT00719849|atypical chronic myeloid leukemia
495685|NCT00719849|chronic myelomonocytic leukemia
495686|NCT00719849|anaplastic large cell lymphoma
495687|NCT00719849|splenic marginal zone lymphoma
495688|NCT00719849|nodal marginal zone B-cell lymphoma
495689|NCT00719849|recurrent adult Hodgkin lymphoma
495690|NCT00719849|recurrent adult diffuse large cell lymphoma
495691|NCT00719849|recurrent adult immunoblastic large cell lymphoma
495692|NCT00719849|recurrent childhood large cell lymphoma
495693|NCT00719849|recurrent mycosis fungoides/Sezary syndrome
495694|NCT00719849|recurrent grade 1 follicular lymphoma
495695|NCT00719849|recurrent grade 2 follicular lymphoma
495696|NCT00719849|recurrent grade 3 follicular lymphoma
495697|NCT00719849|recurrent mantle cell lymphoma
495698|NCT00719849|recurrent marginal zone lymphoma
495699|NCT00719849|recurrent small lymphocytic lymphoma
495700|NCT00719849|recurrent/refractory childhood Hodgkin lymphoma
495701|NCT00719849|childhood diffuse large cell lymphoma
495702|NCT00719849|childhood immunoblastic large cell lymphoma
495703|NCT00719849|refractory multiple myeloma
495704|NCT00719849|de novo myelodysplastic syndromes
495705|NCT00719849|previously treated myelodysplastic syndromes
495706|NCT00719849|secondary myelodysplastic syndromes
495707|NCT00719849|myelodysplastic/myeloproliferative disease
495708|NCT00719849|childhood myelodysplastic syndromes
495709|NCT00719849|recurrent childhood anaplastic large cell lymphoma
495710|NCT00719849|refractory anemia
495711|NCT00719849|refractory anemia with excess blasts
495712|NCT00719849|refractory anemia with ringed sideroblasts
495713|NCT00719849|refractory cytopenia with multilineage dysplasia
495714|NCT00719849|stage III adult diffuse large cell lymphoma
495715|NCT00719849|stage IV adult diffuse large cell lymphoma
495716|NCT00719849|stage III adult immunoblastic large cell lymphoma
495717|NCT00719849|stage IV adult immunoblastic large cell lymphoma
495718|NCT00719849|stage III childhood anaplastic large cell lymphoma
495719|NCT00719849|stage III childhood large cell lymphoma
495720|NCT00719849|stage IV childhood anaplastic large cell lymphoma
495721|NCT00719849|stage IV childhood large cell lymphoma
495722|NCT00719849|stage III adult Hodgkin lymphoma
495723|NCT00719849|stage III childhood Hodgkin lymphoma
495724|NCT00719849|stage IV adult Hodgkin lymphoma
495725|NCT00719849|stage IV childhood Hodgkin lymphoma
495726|NCT00719849|stage II multiple myeloma
495727|NCT00719849|stage III multiple myeloma
495728|NCT00719849|stage III chronic lymphocytic leukemia
495729|NCT00719849|stage IV chronic lymphocytic leukemia
495730|NCT00719849|stage III small lymphocytic lymphoma
495731|NCT00719849|stage IV small lymphocytic lymphoma
495732|NCT00719849|stage III marginal zone lymphoma
495733|NCT00719849|stage IV marginal zone lymphoma
495734|NCT00719849|stage III grade 1 follicular lymphoma
495735|NCT00719849|stage III grade 2 follicular lymphoma
495736|NCT00719849|stage III grade 3 follicular lymphoma
495737|NCT00719849|stage IV grade 1 follicular lymphoma
495738|NCT00719849|stage IV grade 2 follicular lymphoma
495739|NCT00719849|stage IV grade 3 follicular lymphoma
495740|NCT00719849|Waldenstrom macroglobulinemia
495741|NCT00719849|stage III mantle cell lymphoma
495742|NCT00719849|stage IV mantle cell lymphoma
495743|NCT00719849|stage III mycosis fungoides/Sezary syndrome
496071|NCT00719095|buprenorphine
495744|NCT00719849|stage IV mycosis fungoides/Sezary syndrome
495745|NCT00719849|juvenile myelomonocytic leukemia
495746|NCT00719849|chronic eosinophilic leukemia
495747|NCT00719849|chronic idiopathic myelofibrosis
495748|NCT00719849|chronic neutrophilic leukemia
495749|NCT00719849|essential thrombocythemia
495750|NCT00719849|polycythemia vera
495751|NCT00719836|SB1518
495752|NCT00719836|Chronic Idiopathic Myelofibrosis
495753|NCT00719836|JAK2 Inhibitor
495754|NCT00719823|Maraviroc Compassionate Use
495755|NCT00719810|complicated
495756|NCT00719810|skin
495757|NCT00719797|stage IV rectal cancer
495758|NCT00719797|stage IV colon cancer
495759|NCT00719797|stage III rectal cancer
495760|NCT00719797|stage III colon cancer
495761|NCT00719784|Respiratory
495762|NCT00719784|Pulmonary
495763|NCT00719784|Thoracic
495764|NCT00719784|Chest
495765|NCT00719784|Lung
495766|NCT00719771|Osteoarthritis
495767|NCT00719771|Glenohumeral joint
495768|NCT00719771|Glenoid
495769|NCT00719771|Shoulder arthroplasty
495770|NCT00719758|TRK-100STP,
495771|NCT00719758|beraprost sodium,
495772|NCT00719758|Careload LA
495773|NCT00719758|AST-120
495774|NCT00719758|Spherical carbon adsorbent
495775|NCT00719758|Drug-drug interaction
495776|NCT00719745|Organ transplantation
495777|NCT00719745|Tacrolimus
495778|NCT00719745|Prograf
495779|NCT00719745|MR4
495780|NCT00719732|ReSTOR Aspheric +3 IOL
495781|NCT00719719|Mast Cell
495782|NCT00719719|Tryptase
495783|NCT00719719|Bone Marrow
495784|NCT00719719|Hives
495785|NCT00719719|Adult
495786|NCT00719719|Anaphylaxis
495787|NCT00719706|Bipolar disorder
495788|NCT00719706|Bipolar depression
495789|NCT00719706|Natural substances
495790|NCT00719706|Depression
495791|NCT00719693|Food effect, phase I
495792|NCT00719693|adverse events
495793|NCT00719680|CVID
495794|NCT00719680|XLA
495795|NCT00719667|OPCAB
495796|NCT00719667|coronary
495797|NCT00719667|bypass
495798|NCT00719667|grafting
495799|NCT00719667|off pump
495800|NCT00719654|Preeclampsia
495801|NCT00719654|Proteome
495802|NCT00719654|Pregnancy
495803|NCT00719641|Colonoscopy
495804|NCT00719641|Looping
495805|NCT00719641|Prevent Looping
495806|NCT00719641|Colon Cancer Screening
495807|NCT00719641|Segmental Stiffening Wire
495808|NCT00719628|Postoperative
495809|NCT00719628|Cognitive
495810|NCT00719628|Dysfunction
495811|NCT00719615|Thyroid Cancer
495812|NCT00719615|Thyroid Nodules
495813|NCT00719615|Vitamin D
495814|NCT00719602|Coinfection
495815|NCT00719589|Voiding Dysfunction
495816|NCT00719589|Interstim
495817|NCT00719576|Cartilage legions,
495818|NCT00719576|symptomatic focal cartilage defects,
495819|NCT00719576|microfracture,
495820|NCT00719576|MACI,
495821|NCT00719576|autologous chondrocyte
495822|NCT00719563|fatigue
495823|NCT00719563|unspecified adult solid tumor, protocol specific
495824|NCT00719563|accelerated phase chronic myelogenous leukemia
495825|NCT00719563|acute undifferentiated leukemia
495826|NCT00719563|adult acute lymphoblastic leukemia in remission
495827|NCT00719563|adult acute myeloid leukemia in remission
495828|NCT00719563|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
495829|NCT00719563|adult acute myeloid leukemia with inv(16)(p13;q22)
495830|NCT00719563|adult acute myeloid leukemia with t(15;17)(q22;q12)
495831|NCT00719563|adult acute myeloid leukemia with t(16;16)(p13;q22)
495832|NCT00719563|adult acute myeloid leukemia with t(8;21)(q22;q22)
495833|NCT00719563|atypical chronic myeloid leukemia, BCR-ABL1 negative
495834|NCT00719563|blastic phase chronic myelogenous leukemia
495835|NCT00719563|chronic myelomonocytic leukemia
495836|NCT00719563|chronic phase chronic myelogenous leukemia
495837|NCT00719563|mast cell leukemia
495838|NCT00719563|progressive hairy cell leukemia, initial treatment
495839|NCT00719563|prolymphocytic leukemia
495840|NCT00719563|recurrent adult acute lymphoblastic leukemia
495841|NCT00719563|recurrent adult acute myeloid leukemia
495842|NCT00719563|recurrent adult T-cell leukemia/lymphoma
495843|NCT00719563|refractory chronic lymphocytic leukemia
495844|NCT00719563|refractory hairy cell leukemia
495845|NCT00719563|relapsing chronic myelogenous leukemia
495846|NCT00719563|secondary acute myeloid leukemia
495847|NCT00719563|stage 0 chronic lymphocytic leukemia
495848|NCT00719563|stage I adult T-cell leukemia/lymphoma
495849|NCT00719563|stage I chronic lymphocytic leukemia
495850|NCT00719563|stage II adult T-cell leukemia/lymphoma
495851|NCT00719563|stage II chronic lymphocytic leukemia
495852|NCT00719563|stage III adult T-cell leukemia/lymphoma
495853|NCT00719563|stage III chronic lymphocytic leukemia
495854|NCT00719563|stage IV adult T-cell leukemia/lymphoma
495855|NCT00719563|stage IV chronic lymphocytic leukemia
495856|NCT00719563|T-cell large granular lymphocyte leukemia
495857|NCT00719563|untreated adult acute lymphoblastic leukemia
495858|NCT00719563|recurrent adult Hodgkin lymphoma
495859|NCT00719563|stage I adult Hodgkin lymphoma
495860|NCT00719563|stage II adult Hodgkin lymphoma
495861|NCT00719563|stage III adult Hodgkin lymphoma
495862|NCT00719563|stage IV adult Hodgkin lymphoma
495863|NCT00719563|anaplastic large cell lymphoma
495864|NCT00719563|angioimmunoblastic T-cell lymphoma
495865|NCT00719563|cutaneous B-cell non-Hodgkin lymphoma
495866|NCT00719563|recurrent cutaneous T-cell non-Hodgkin lymphoma
495867|NCT00719563|stage I cutaneous T-cell non-Hodgkin lymphoma
495868|NCT00719563|stage II cutaneous T-cell non-Hodgkin lymphoma
495869|NCT00719563|stage III cutaneous T-cell non-Hodgkin lymphoma
495870|NCT00719563|stage IV cutaneous T-cell non-Hodgkin lymphoma
495871|NCT00719563|recurrent mycosis fungoides/Sezary syndrome
495872|NCT00719563|stage I mycosis fungoides/Sezary syndrome
495873|NCT00719563|stage II mycosis fungoides/Sezary syndrome
495874|NCT00719563|stage III mycosis fungoides/Sezary syndrome
495875|NCT00719563|stage IV mycosis fungoides/Sezary syndrome
495876|NCT00719563|adult grade III lymphomatoid granulomatosis
495877|NCT00719563|adult nasal type extranodal NK/T-cell lymphoma
495878|NCT00719563|Waldenström macroglobulinemia
495879|NCT00719563|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
495880|NCT00719563|nodal marginal zone B-cell lymphoma
495881|NCT00719563|splenic marginal zone lymphoma
495882|NCT00719563|contiguous stage II adult Burkitt lymphoma
495883|NCT00719563|contiguous stage II adult diffuse large cell lymphoma
495884|NCT00719563|contiguous stage II adult diffuse mixed cell lymphoma
495885|NCT00719563|contiguous stage II adult diffuse small cleaved cell lymphoma
495886|NCT00719563|contiguous stage II adult immunoblastic large cell lymphoma
495887|NCT00719563|contiguous stage II adult lymphoblastic lymphoma
495888|NCT00719563|contiguous stage II grade 1 follicular lymphoma
495889|NCT00719563|contiguous stage II grade 2 follicular lymphoma
495890|NCT00719563|contiguous stage II grade 3 follicular lymphoma
495891|NCT00719563|contiguous stage II mantle cell lymphoma
495892|NCT00719563|contiguous stage II marginal zone lymphoma
495893|NCT00719563|contiguous stage II small lymphocytic lymphoma
495894|NCT00719563|stage I adult Burkitt lymphoma
495895|NCT00719563|stage I adult diffuse large cell lymphoma
495896|NCT00719563|stage I adult diffuse mixed cell lymphoma
495897|NCT00719563|stage I adult diffuse small cleaved cell lymphoma
495898|NCT00719563|stage I adult immunoblastic large cell lymphoma
495899|NCT00719563|stage I adult lymphoblastic lymphoma
495900|NCT00719563|stage I grade 1 follicular lymphoma
495901|NCT00719563|stage I grade 2 follicular lymphoma
495902|NCT00719563|stage I grade 3 follicular lymphoma
495903|NCT00719563|stage I mantle cell lymphoma
495904|NCT00719563|stage I marginal zone lymphoma
495905|NCT00719563|stage I small lymphocytic lymphoma
495906|NCT00719563|noncontiguous stage II adult Burkitt lymphoma
495907|NCT00719563|noncontiguous stage II adult diffuse large cell lymphoma
495908|NCT00719563|noncontiguous stage II adult diffuse mixed cell lymphoma
495909|NCT00719563|noncontiguous stage II adult diffuse small cleaved cell lymphoma
495910|NCT00719563|noncontiguous stage II adult immunoblastic large cell lymphoma
495911|NCT00719563|noncontiguous stage II adult lymphoblastic lymphoma
495912|NCT00719563|noncontiguous stage II grade 1 follicular lymphoma
495913|NCT00719563|noncontiguous stage II grade 2 follicular lymphoma
495914|NCT00719563|noncontiguous stage II grade 3 follicular lymphoma
495915|NCT00719563|noncontiguous stage II mantle cell lymphoma
495916|NCT00719563|noncontiguous stage II marginal zone lymphoma
495917|NCT00719563|noncontiguous stage II small lymphocytic lymphoma
495918|NCT00719563|stage III adult Burkitt lymphoma
495919|NCT00719563|stage III adult diffuse large cell lymphoma
495920|NCT00719563|stage III adult diffuse mixed cell lymphoma
495921|NCT00719563|stage III adult diffuse small cleaved cell lymphoma
495922|NCT00719563|stage III adult immunoblastic large cell lymphoma
495923|NCT00719563|stage III adult lymphoblastic lymphoma
495924|NCT00719563|stage III grade 1 follicular lymphoma
495925|NCT00719563|stage III grade 2 follicular lymphoma
495926|NCT00719563|stage III grade 3 follicular lymphoma
495927|NCT00719563|stage III mantle cell lymphoma
495928|NCT00719563|stage III marginal zone lymphoma
495929|NCT00719563|stage III small lymphocytic lymphoma
495930|NCT00719563|stage IV adult Burkitt lymphoma
495931|NCT00719563|stage IV adult diffuse large cell lymphoma
495932|NCT00719563|stage IV adult diffuse mixed cell lymphoma
495933|NCT00719563|stage IV adult diffuse small cleaved cell lymphoma
495934|NCT00719563|stage IV adult immunoblastic large cell lymphoma
495935|NCT00719563|stage IV adult lymphoblastic lymphoma
495936|NCT00719563|stage IV grade 1 follicular lymphoma
495937|NCT00719563|stage IV grade 2 follicular lymphoma
495938|NCT00719563|stage IV grade 3 follicular lymphoma
495939|NCT00719563|stage IV mantle cell lymphoma
495940|NCT00719563|stage IV marginal zone lymphoma
495941|NCT00719563|stage IV small lymphocytic lymphoma
495942|NCT00719563|recurrent adult Burkitt lymphoma
495943|NCT00719563|recurrent adult diffuse large cell lymphoma
495944|NCT00719563|recurrent adult diffuse mixed cell lymphoma
495945|NCT00719563|recurrent adult diffuse small cleaved cell lymphoma
495946|NCT00719563|recurrent adult grade III lymphomatoid granulomatosis
495947|NCT00719563|recurrent adult immunoblastic large cell lymphoma
495948|NCT00719563|recurrent adult lymphoblastic lymphoma
495949|NCT00719563|recurrent grade 1 follicular lymphoma
495950|NCT00719563|recurrent grade 2 follicular lymphoma
495951|NCT00719563|recurrent grade 3 follicular lymphoma
495952|NCT00719563|recurrent mantle cell lymphoma
495953|NCT00719563|recurrent marginal zone lymphoma
495954|NCT00719563|recurrent small lymphocytic lymphoma
495955|NCT00719563|intraocular lymphoma
495956|NCT00719563|post-transplant lymphoproliferative disorder
495957|NCT00719563|chronic eosinophilic leukemia
495958|NCT00719563|chronic neutrophilic leukemia
495959|NCT00719563|primary myelofibrosis
495960|NCT00719563|essential thrombocythemia
495961|NCT00719563|polycythemia vera
495962|NCT00719563|extramedullary plasmacytoma
495963|NCT00719563|isolated plasmacytoma of bone
495964|NCT00719563|monoclonal gammopathy of undetermined significance
495965|NCT00719563|stage I multiple myeloma
495966|NCT00719563|stage II multiple myeloma
495967|NCT00719563|stage III multiple myeloma
495968|NCT00719563|primary systemic amyloidosis
495969|NCT00719563|refractory multiple myeloma
495970|NCT00719563|de novo myelodysplastic syndromes
495971|NCT00719563|previously treated myelodysplastic syndromes
495972|NCT00719563|secondary myelodysplastic syndromes
495973|NCT00719563|myelodysplastic/myeloproliferative neoplasm, unclassifiable
495974|NCT00719550|Locally Advanced
495975|NCT00719550|Metastatic
495976|NCT00719537|preeclampsia
495977|NCT00719537|progesterone
495978|NCT00719537|aspirin
495979|NCT00719537|prevent
495980|NCT00719537|sFlt-1
495981|NCT00719537|PlGF
495982|NCT00719537|risk
495983|NCT00719524|Neoplasms
495984|NCT00719524|Antineoplastic Combined Chemotherapy Protocol
495985|NCT00719511|Rhinoconjunctivitis
495986|NCT00719511|Allergic
495987|NCT00719498|Epo-alpha
495988|NCT00719498|Cardiac arrest
495989|NCT00719498|Mild hypothermia
495990|NCT00719485|lumbar decompression
495991|NCT00719472|Follicular NHL
495992|NCT00719472|NHL
495993|NCT00719472|Large B-Cell NHL
495994|NCT00719446|Acute Lung Injury
495995|NCT00719433|stroke
495996|NCT00719433|chronic
495997|NCT00719433|rehabilitation
495998|NCT00719433|robot therapy
495999|NCT00719433|arm therapy
496000|NCT00719420|Randomized clinical trial
496001|NCT00719420|Helicobacter pylori
496002|NCT00719420|clarithromycin
496003|NCT00719420|metronidazole
496004|NCT00719420|amoxicillin
496005|NCT00719420|proton pump inhibitor
496006|NCT00719420|Colombia
496007|NCT00719407|birth asphyxia
496008|NCT00719407|neonatal encephalopathy
496009|NCT00719407|hypoxic-ischemic encephalopathy
496010|NCT00719407|neuroprotection
496011|NCT00719407|neonate
496012|NCT00719394|alzheimer Disease
496013|NCT00719368|Groin hernia
496014|NCT00719368|pain
496015|NCT00719368|chronic
496016|NCT00719368|quantitative sensory testing
496017|NCT00719368|Persistent postoperative pain
496018|NCT00719342|Retinal vessel diameter
496019|NCT00719342|Flicker-induced vasodilatation
496020|NCT00719342|Optic nerve head blood flow
496021|NCT00719342|Ocular Physiology
496022|NCT00719342|Regional Blood Flow
496023|NCT00719329|chlorhexidine
496024|NCT00719329|umbilical cord
496025|NCT00719316|Renin inhibitor
496026|NCT00719316|Patients
496027|NCT00719316|ACE inhibitor or ARB
496028|NCT00719316|Chronic Kidney Disease
496029|NCT00719316|Hypertension
496030|NCT00719290|Primary Angle Closure Glaucoma
496031|NCT00719290|Phacoemulsification
496032|NCT00719290|Goniosynechialysis
496033|NCT00719290|Outflow facility
496034|NCT00719277|cardiac arrhythmia
496035|NCT00719277|syncope
496036|NCT00719277|ECG
496037|NCT00719277|implantable ECG monitor
496038|NCT00719277|ILR
496039|NCT00719264|Renal cell carcinoma,
496040|NCT00719264|Adults,
496041|NCT00719264|Bevacizumab,
496042|NCT00719264|RAD001
496043|NCT00719264|Everolimus,
496044|NCT00719264|Interferon
496045|NCT00719264|Clear
496046|NCT00719264|Roferon
496047|NCT00719264|Avastin
496048|NCT00719264|Nephrectomy
496049|NCT00719264|newly diagnosed
496050|NCT00719251|Complications of Diabetes Mellitus
496051|NCT00719251|Electric stimulation
496052|NCT00719251|Low-Level Laser Therapy
496053|NCT00719199|Colorectal cancer
496054|NCT00719199|metastatic cancer
496055|NCT00719199|prior therapy
496056|NCT00719199|1b
496057|NCT00719186|Polycystic Ovary Syndrome
496058|NCT00719186|Infertility
496059|NCT00719186|Pregnancy
496060|NCT00719186|Women
496061|NCT00719173|nausea and vomiting
496062|NCT00719173|breast cancer
496063|NCT00719160|Gastric acid
496064|NCT00719160|Dietary protein
496065|NCT00719160|Calcium
496066|NCT00719160|Intestinal absorption
496067|NCT00719160|Calcium sensing receptor
496068|NCT00719108|Diabetes, Healthy Volunteers
496069|NCT00719095|prescription opioid
496070|NCT00719095|opioid detoxification
496072|NCT00719095|naltrexone
496073|NCT00719095|community reinforcement approach
496074|NCT00719095|prescription opioid abuse
496075|NCT00719082|Human Stability
496076|NCT00719082|Geriatric
496077|NCT00719082|Posturography
496078|NCT00719069|healthy subjects who smoke
496079|NCT00719069|healthy subjects
496080|NCT00719056|teicoplanin
496081|NCT00719056|prophylaxis
496082|NCT00719056|arthroplasty
496083|NCT00719056|surgical site infections
496084|NCT00719043|Influenza
496085|NCT00719043|H5N1
496086|NCT00719043|Avian
496087|NCT00719043|Vaccines
496088|NCT00719043|Safety
496089|NCT00719043|Immunogenicity
496090|NCT00719043|Pandemic
496091|NCT00719043|Human
496092|NCT00719017|Brachytherapy
496093|NCT00719017|Early stage edometrial cancer
496094|NCT00719017|Quality of life
496095|NCT00719017|Recurrence
496096|NCT00719017|Treatment
496097|NCT00719017|Vaginectomy
496098|NCT00719004|Anatomy
496099|NCT00719004|Foot
496100|NCT00719004|Sonography
496101|NCT00719004|Medical
496102|NCT00718991|CLI
496103|NCT00718991|excimer laser
496104|NCT00718991|debulking
496105|NCT00718978|bioengineered
496106|NCT00718978|ski
496107|NCT00718978|keratinocytes
496108|NCT00718978|fibroblasts
496109|NCT00718978|skin
496110|NCT00718978|culture
496111|NCT00718978|autologous
496112|NCT00718978|CSS
496113|NCT00718978|full-thickness loss of substance from:
496114|NCT00718978|burns
496115|NCT00718978|ulcers
496116|NCT00718978|giant nevi
496117|NCT00718978|cicatricial outcomes
496118|NCT00718965|Primary hypercholesterolemia
496119|NCT00718952|Pulmonary Hypertension
496120|NCT00718939|Diastolic Heart Failure
496121|NCT00718939|Cardiac dysfunction
496122|NCT00718939|Heart Failure
496123|NCT00718926|dry eye
496124|NCT00718926|Thiol redox
496125|NCT00718926|Oxidative stress
496126|NCT00718913|Adjuvant Gastric Cancer
496127|NCT00718913|Adjuvant chemotherapy
496128|NCT00718913|Adjuvant chemo-radiation
496129|NCT00718913|Capecitabine
496130|NCT00718874|obesity, puberty, diabetes,insulin dynamics
496131|NCT00718861|Osteoporosis
496132|NCT00718861|zoledronic acid
496133|NCT00718861|post-menopausal
496134|NCT00718848|hemodialysis
496135|NCT00718848|left ventricular hypertrophy
496136|NCT00718848|left ventricular systolic function
496137|NCT00718835|smoking cessation
496138|NCT00718835|behavioral treatment
496139|NCT00718835|contingency management
496140|NCT00718835|opioid maintenance
496141|NCT00718835|methadone
496142|NCT00718835|buprenorphine
496143|NCT00718822|clinical outcome
496144|NCT00718822|ICSI cycles
496145|NCT00718822|low oxygen
496146|NCT00718822|poor responders
496147|NCT00718822|pregnancy rate
496148|NCT00718822|prospective randomized study
496149|NCT00718796|cardiovascular disease
496150|NCT00718796|naturopathic medicine
496151|NCT00718796|natural health products
496152|NCT00718796|lifestyle intervention
496153|NCT00718796|dietary advice
496154|NCT00718796|coronary heart disease
496155|NCT00718770|Not respond
496156|NCT00718770|Radioactive iodine
496157|NCT00718770|Therapy
496158|NCT00718770|Shows signs
496159|NCT00718770|Aggressive behavior
496160|NCT00718744|Allergen-extract
496161|NCT00718744|Standardization
496162|NCT00718731|Alzheimer Disease
496163|NCT00718718|Arthritis, Rheumatoid
496164|NCT00718718|Rheumatoid Arthritis
496165|NCT00718718|Active Rheumatoid Arthritis
496166|NCT00718718|CNTO 136
496167|NCT00718718|Interleukin-6
496168|NCT00718718|Anti-interleukin-6 monoclonal antibody
496169|NCT00718718|Methotrexate
496170|NCT00718718|Placebo
496171|NCT00718705|Prematurity
496172|NCT00718705|Ureaplasma spp
496173|NCT00718705|Mycoplasma Hominis
496174|NCT00718705|Amniotic fluid
496175|NCT00718705|Josamycine
496176|NCT00718692|Idiopathic
496177|NCT00718692|ITP
496178|NCT00718666|Safety
496179|NCT00718666|Vaccines, conjugate
496180|NCT00718666|Immunogenicity
496181|NCT00718666|Meningococcal vaccine
496182|NCT00718666|Booster vaccination
496183|NCT00718666|Primary vaccination
496184|NCT00718666|Neisseria meningitides
496185|NCT00718666|Toddlers
496186|NCT00718666|Humans
496187|NCT00718666|Meningococcal disease
496188|NCT00718653|Macular pigment, lutein, green tea extract, antioxidant
496189|NCT00718640|Multiple Myeloma
496190|NCT00718640|Velcade
496191|NCT00718640|Bortezomib
496192|NCT00718640|Dexamethasone
496193|NCT00718627|Urea cycle Disorders
496194|NCT00718627|Carbamoylphosphate synthetase I deficiency
496195|NCT00718627|Ornithine transcarbamoylase deficiency
496196|NCT00718627|Argininosuccinate synthase deficiency
496197|NCT00718627|Citrullinemia
496198|NCT00718627|newborns
496199|NCT00718627|infants
496200|NCT00718627|liver cell transplantation
496201|NCT00718627|liver cell infusion
496202|NCT00718614|Choroidal blood flow
496203|NCT00718614|Laser Doppler flowmetry
496204|NCT00718614|Diabetic Retinopathy
496205|NCT00718614|Diabetic Neuropathy
496206|NCT00718601|Myeloma
496207|NCT00718601|Multiple Myeloma
496208|NCT00718601|Relapsed Multiple Myeloma
496209|NCT00718601|Refractory Multiple Myeloma
496210|NCT00718601|Relapsed or Refractory Multiple Myeloma
496211|NCT00718588|RA
496212|NCT00718575|Liver Disease
496213|NCT00718575|Transplantation
496214|NCT00718562|nilotinib
496215|NCT00718562|AMN107
496216|NCT00718562|Sunitinib
496217|NCT00718562|Sunitinib malate
496218|NCT00718562|Imatinib
496219|NCT00718562|Imatinib mesylate
496220|NCT00718562|Tyrosine
496221|NCT00718536|Atazanavir
496222|NCT00718536|Raltegravir
496223|NCT00718536|once-daily
496224|NCT00718536|pharmacokinetics
496225|NCT00718536|HIV
496226|NCT00718497|Amyotrophic Lateral Sclerosis
496227|NCT00718497|Cerebrospinal Fluid
496228|NCT00718497|Neurodegenerative Disease
496229|NCT00718497|Motor Neuron Disease
496230|NCT00718497|Autonomic Nervous System
496231|NCT00718497|Neurodegenerative Diseases
496232|NCT00718497|Movement Disorders
496233|NCT00718484|Sarcoma
496234|NCT00718484|Soft Tissue Sarcoma
496235|NCT00718484|Doxorubicin
496236|NCT00718484|anthracyclin
496237|NCT00718484|Palifosfamide
496238|NCT00718484|IFOS
496239|NCT00718471|STEMI
496240|NCT00718471|Primary PCI
496241|NCT00718471|Anticoagulation
496242|NCT00718458|Amyotrophic Lateral Sclerosis
496243|NCT00718458|Cerebrospinal Fluid
496244|NCT00718458|Neurodegenerative Disease
496245|NCT00718458|Motor Neuron Disease
496246|NCT00718458|Autonomic Nervous System
496247|NCT00718458|Neurodegenerative Diseases
496248|NCT00718458|Movement Disorders
496249|NCT00718445|Amyotrophic Lateral Sclerosis
496250|NCT00718445|Cerebrospinal Fluid
496251|NCT00718445|Neurodegenerative Disease
496252|NCT00718445|Motor Neuron Disease
496253|NCT00718445|Autonomic Nervous System
496254|NCT00718445|Neurodegenerative Diseases
496255|NCT00718445|Movement Disorders
496256|NCT00718432|Frailty
496257|NCT00718432|Osteoporosis
496258|NCT00718432|Depression
496259|NCT00718419|Waldenstrom's Macroglobulinemia
496260|NCT00718419|Multiple Myeloma
496261|NCT00718406|Acute coronary syndrome
496262|NCT00718406|Chest pain
496263|NCT00718406|Betablockers
496264|NCT00718406|Morphine
496265|NCT00718406|Prehospital phase
496266|NCT00718393|Amyotrophic Lateral Sclerosis
496267|NCT00718393|Cerebrospinal Fluid
496268|NCT00718393|Neurodegenerative Disease
496269|NCT00718393|Motor Neuron Disease
496270|NCT00718393|Autonomic Nervous System
496271|NCT00718393|Neurodegenerative Diseases
496272|NCT00718393|Movement Disorders
496273|NCT00718354|Bleeding events
496274|NCT00718341|Fragile X Syndrome, adults, efficacy
496275|NCT00718328|Intracerebral
496276|NCT00718328|Hemorrhage
496277|NCT00718328|Edema
496278|NCT00718328|Statins
496279|NCT00718302|Ankle Fractures
496280|NCT00718302|Displaced Lateral Malleolus Fractures
496281|NCT00718302|Antiglide Plating
496282|NCT00718302|Lateral Plating
496283|NCT00718289|Citric acid
496284|NCT00718289|citrate
496285|NCT00718289|acetic acid
496286|NCT00718289|acetate
496287|NCT00718289|haemodialysis
496288|NCT00718289|calcium
496289|NCT00718289|hypotension
496290|NCT00718289|haemodynamics
496291|NCT00718289|Dialysate for Haemodialysis
496292|NCT00718276|Healthy postmenopausal women
496293|NCT00718250|Acute myeloid leukaemia
496294|NCT00718250|Cancer vaccines
496295|NCT00718250|Immunotherapy
496296|NCT00718237|Gastroenteritis
496297|NCT00718237|Rotavirus
496298|NCT00718224|Knee surgery
496299|NCT00718224|VTE prevention
496300|NCT00718198|Inpatient
496301|NCT00718198|Computer Physician Order Entry
496302|NCT00718198|Diabetes Mellitus
496303|NCT00718185|Sildenafil
496304|NCT00718185|Pediatrics
496305|NCT00718172|Ribavirin Pretreatment
496306|NCT00718172|Gene Expression
496307|NCT00718172|Peginterferon
496308|NCT00718172|Hepatitis C
496309|NCT00718172|Liver Biopsy
496310|NCT00718172|HCV
496311|NCT00718159|Acute Myeloid Leukemia
496312|NCT00718159|Myeloid Leukemia
496313|NCT00718159|Relapsed
496314|NCT00718159|Refractory
496315|NCT00718146|Influenza
496316|NCT00718146|Orthomyxoviridae Infections
496317|NCT00718146|Orthomyxoviruses
496318|NCT00718146|Split-virion influenza vaccine
496319|NCT00718133|Asthma
496320|NCT00718133|Allergy
496321|NCT00718133|Respiratory
496322|NCT00718133|Pollution
496323|NCT00718133|Children
496324|NCT00718133|Air pollution
496325|NCT00718120|Fluviral
496326|NCT00718120|Influenza
496327|NCT00718107|Amyotrophic Lateral Sclerosis
496328|NCT00718107|Cerebrospinal Fluid
496329|NCT00718107|Neurodegenerative Disease
496330|NCT00718107|Motor Neuron Disease
496331|NCT00718107|Autonomic Nervous System
496332|NCT00718107|Neurodegenerative Diseases
496333|NCT00718107|Movement Disorders
496334|NCT00718107|Quality of Life
496335|NCT00718094|Ulcerative colitis
496336|NCT00718094|EGCG
496337|NCT00718094|Green tea polyphenols
496338|NCT00718094|Inflammatory bowel disease
496339|NCT00718094|Colitis
496340|NCT00718094|IBD
496341|NCT00718094|Green tea
496342|NCT00718068|Potassium chloride
496343|NCT00718068|Preparations, Pharmaceutical
496344|NCT00718068|Hypokalemia
496345|NCT00718068|Critical Care
496346|NCT00718068|Adult
496347|NCT00718068|Randomized Controlled Trial
496348|NCT00718055|MRI
496349|NCT00718055|liverspecific
496350|NCT00718055|contrast
496351|NCT00718055|colorectal
496352|NCT00718055|metastases
496353|NCT00718042|healthy donors
496354|NCT00718029|Human Immunodeficiency Virus
496355|NCT00718029|Cerebrospinal Fluid
496356|NCT00718029|Raltegravir
496357|NCT00718029|Drug Concentrations
496358|NCT00718016|Amyotrophic Lateral Sclerosis
496359|NCT00718016|Cerebrospinal Fluid
496360|NCT00718016|Neurodegenerative Disease
496361|NCT00718016|Motor Neuron Disease
496362|NCT00718016|Autonomic Nervous System
496363|NCT00718016|Neurodegenerative Diseases
496364|NCT00718016|Movement Disorders
496365|NCT00718003|Amyotrophic Lateral Sclerosis
496366|NCT00718003|Cerebrospinal Fluid
496367|NCT00718003|Neurodegenerative Disease
496368|NCT00718003|Motor Neuron Disease
496369|NCT00718003|Autonomic Nervous System
496370|NCT00718003|Neurodegenerative Diseases
496371|NCT00718003|Movement Disorders
496372|NCT00717990|Colorectal cancer
496373|NCT00717990|Bevacizumab
496374|NCT00717990|XELIRI
496375|NCT00717951|advanced breast cancer
496376|NCT00717951|docetaxol
496377|NCT00717951|capecitabine
496378|NCT00717951|cisplatin
496379|NCT00717925|B-cell Non-Hodgkin's Lymphoma
496380|NCT00717925|NHL
496381|NCT00717912|BLOOD GLUCOSE
496382|NCT00717912|glycemic index
496383|NCT00717912|rates of digestion and absorption of food
496384|NCT00717899|Asthma
496385|NCT00717899|Allergy
496386|NCT00717899|Respiratory
496387|NCT00717899|Pollution
496388|NCT00717899|Children
496389|NCT00717899|Air pollution
496390|NCT00717886|Breast
496391|NCT00717886|Lymph Nodes
496392|NCT00717873|Mucus Clearance
496393|NCT00717873|Secretion Clearance
496394|NCT00717873|HFCWO
496395|NCT00717808|Tranilast
496396|NCT00717808|Rheumatoid Arthritis
496397|NCT00717808|Pharmacokinetics
496398|NCT00717808|Methotrexate
496399|NCT00717795|Survivor
496400|NCT00717795|Physical Activity
496401|NCT00717795|NED
496402|NCT00717795|08-067
496403|NCT00717782|botulinum toxin
496404|NCT00717782|thrombosed external haemorrhoids
496405|NCT00717782|pain
496406|NCT00717769|Atopic Dermatitis
496407|NCT00717756|liver cancer, second line
496408|NCT00717743|RCC
496409|NCT00717743|patients
496410|NCT00717743|scheduled
496411|NCT00717743|nephrectomy
496412|NCT00717730|Nutrition
496413|NCT00717730|Children
496414|NCT00717730|Folate
496415|NCT00717730|Vitamin B12
496416|NCT00717730|India
496417|NCT00717730|Homocysteine
496418|NCT00717730|Methyl Malonic Acid
496419|NCT00717717|Cancer Survivor
496420|NCT00717717|Physical Activity
496421|NCT00717717|Health Behavior
496422|NCT00717717|Psychosocial Well-being
496423|NCT00717717|Coaching
496424|NCT00717717|Long Term
496425|NCT00717717|Consequences
496426|NCT00717717|Chemotherapy
496427|NCT00717717|Motivation
496428|NCT00717704|Malignant solid tumor
496429|NCT00717704|Phase 1
496430|NCT00717704|Dose escalation
496431|NCT00717704|Metastatic or locally advanced/unresectable
496432|NCT00717704|Disease progression through standard therapy
496433|NCT00717691|Hallux Limitus
496434|NCT00717691|Dynamic Splinting
496435|NCT00717691|Dynasplint
496436|NCT00717678|Immunosuppressant
496437|NCT00717678|Combination drug therapy
496438|NCT00717678|Graft loss
496439|NCT00717678|Randomized controlled trial
496440|NCT00717678|Open level method
496441|NCT00717665|Hypertension
496442|NCT00717665|Telemanagement
496443|NCT00717665|Home blood pressure monitoring
496444|NCT00717665|Self care
496445|NCT00717639|diagnostic accuracy
496446|NCT00717639|magnetic resonance angiography
496447|NCT00717639|steady state
496448|NCT00717639|digital subtraction angiography
496449|NCT00717639|peripheral arteries
496450|NCT00717626|Hemophilia
496451|NCT00717626|Prophylaxis
496452|NCT00717626|Youth
496453|NCT00717626|Young Adults
496454|NCT00717626|Feasibility
496455|NCT00717600|bacteriuria
496456|NCT00717600|urinary tract infection
496457|NCT00717600|probiotics
496458|NCT00717600|lactobacillus
496459|NCT00717600|vagina
496460|NCT00717600|bladder
496461|NCT00717600|neurogenic bladder
496462|NCT00717600|spina bifida
496463|NCT00717600|myelomeningocele
496464|NCT00717600|neuropathic bladder
496465|NCT00717587|stage IV renal cell cancer
496466|NCT00717587|recurrent renal cell cancer
496467|NCT00717574|depth of sedation
496468|NCT00717574|nitrous oxide
496469|NCT00717574|general anesthesia
496470|NCT00717574|anesthesia indices
496471|NCT00717561|CAP
496472|NCT00717561|Community-acquired pneumonia
496473|NCT00717548|Somatic Complaints
496474|NCT00717535|health status unknown
496475|NCT00717522|Soft Tissue Sarcoma
496476|NCT00717522|CC-4047
496477|NCT00717522|Pomalidomide
496478|NCT00717509|schizophrenia
496479|NCT00717509|metabolic side effect
496480|NCT00717509|clozapine
496481|NCT00717509|genetic polymorphism
496482|NCT00717496|Breastfeeding
496483|NCT00717496|Telephone Support
496484|NCT00717496|Latino
496485|NCT00717470|Kidney
496486|NCT00717470|Transplant
496487|NCT00717470|Immunosuppression
496488|NCT00717470|Advagraf
496489|NCT00717470|Prograf
496490|NCT00717470|FK506
496491|NCT00717444|Substance Abuse
496492|NCT00717444|HIV
496493|NCT00717444|Contingency Management
496494|NCT00717444|Physical Activity
496495|NCT00717431|Deep Brain Stimulation
496496|NCT00717431|Seizures
496497|NCT00717431|Epilepsy
496498|NCT00717392|ADHD
496499|NCT00717392|ASD
496500|NCT00717379|Organ Transplantation
496501|NCT00717379|Tacrolimus
496502|NCT00717379|Prograf
496503|NCT00717379|Kidney
496504|NCT00717379|Immunosuppression
496505|NCT00717340|tivozanib
496506|NCT00717340|AV-951
496507|NCT00717327|MRL
496508|NCT00717327|Adolescents
496509|NCT00717327|Health Literacy
496510|NCT00717301|TBI, traumatic brain injury, S100B, head CT scan
496511|NCT00717288|diabetes
496512|NCT00717288|hyperglycemia
496513|NCT00717288|open heart surgery
496514|NCT00717288|cardiothoracic surgery
496515|NCT00717288|detemir
496516|NCT00717288|insulin infusion
496517|NCT00717288|intravenous insulin
496518|NCT00717275|Brain Metastases
496519|NCT00717275|Temozolomide
496520|NCT00717275|Temodar
496521|NCT00717275|TMZ
496522|NCT00717275|Stereotactic Radiosurgery
496523|NCT00717275|SRS
496524|NCT00717236|Certolizumab pegol
496525|NCT00717236|Cimzia
496526|NCT00717236|Rheumatoid Arthritis
496527|NCT00717236|Joint Disease
496528|NCT00717236|Chronic Arthritis
496529|NCT00717223|Diabetes
496530|NCT00717223|Type 1 diabetes mellitus
496531|NCT00717223|Type 2 diabetes mellitus
496532|NCT00717223|Literacy
496533|NCT00717223|Glycemic control
496534|NCT00717210|1p/19q loss
496535|NCT00717210|MGMT
496536|NCT00717210|prognostic factors
496537|NCT00717210|PCV
496538|NCT00717210|temozolomide
496539|NCT00717197|HGG
496540|NCT00717197|anaplastic astrocytoma
496541|NCT00717197|anaplastic oligodendroglioma
496542|NCT00717197|anaplastic mixed glioma
496543|NCT00717197|glioblastoma multiforme
496544|NCT00717197|GBM
496545|NCT00717197|Xeloda
496546|NCT00717197|capecitabine
496547|NCT00717171|electrical stimulation
496548|NCT00717171|pain
496549|NCT00717171|medication
496550|NCT00717171|edema
496551|NCT00717171|interferential
496552|NCT00717171|neuromuscular
496553|NCT00717171|high voltage pulsed current
496554|NCT00717171|knee
496555|NCT00717158|Health Behavior
496556|NCT00717158|Lifestyle
496557|NCT00717158|health care costs
496558|NCT00717158|quality of life
496559|NCT00717145|bioequivalence
496560|NCT00717132|weight
496561|NCT00717132|cost effectiveness
496562|NCT00717132|obesity
496563|NCT00717132|family based behavioral treatment
496564|NCT00717119|GI
496565|NCT00717119|NSAID
496566|NCT00717119|Complications
496567|NCT00717119|Treated
496568|NCT00717119|Patients
496569|NCT00717106|ILR
496570|NCT00717106|ECG monitoring
496571|NCT00717106|cardiac arrhythmia
496572|NCT00717106|syncope
496573|NCT00717106|presyncope
496574|NCT00717106|fainting
496575|NCT00717080|Retinitis Pigmentosa
496576|NCT00717080|Cataract
496577|NCT00717067|maraviroc, pharmacokinetics, renal impairment
496578|NCT00717054|postoperative nausea and vomiting
496579|NCT00717041|Depression
496580|NCT00717041|Anxiety
496581|NCT00717041|Cognitive Impairment
496582|NCT00717041|Emergency medicine
496583|NCT00717041|prehospital care
496584|NCT00717028|Cerebral palsy
496585|NCT00717028|Dysphagia
496586|NCT00717028|Deglutition
496587|NCT00717028|Endoscopy
496588|NCT00717015|Hormone Receptor Positive Breast Cancer
496589|NCT00716989|Cutaneous immune system
496590|NCT00716989|innate immunity
496591|NCT00716989|tuberculin skin tests
496592|NCT00716989|intradermal vaccination
496593|NCT00716989|pathophysiology
496594|NCT00716989|Healthy subjects
496595|NCT00716989|Immunosuppressed patients
496596|NCT00716976|ototoxicity
496597|NCT00716976|childhood central nervous system germ cell tumor
496598|NCT00716976|childhood extracranial germ cell tumor
496599|NCT00716976|childhood extragonadal germ cell tumor
496600|NCT00716976|childhood malignant testicular germ cell tumor
496601|NCT00716976|childhood malignant ovarian germ cell tumor
496602|NCT00716976|childhood teratoma
496603|NCT00716976|childhood medulloblastoma
496604|NCT00716976|disseminated neuroblastoma
496605|NCT00716976|regional neuroblastoma
496606|NCT00716976|localized resectable neuroblastoma
496607|NCT00716976|localized unresectable neuroblastoma
496608|NCT00716976|stage 4S neuroblastoma
496609|NCT00716976|localized osteosarcoma
496610|NCT00716976|metastatic osteosarcoma
496611|NCT00716976|childhood hepatoblastoma
496612|NCT00716976|stage I childhood liver cancer
496613|NCT00716976|stage II childhood liver cancer
496614|NCT00716976|stage III childhood liver cancer
496615|NCT00716976|stage IV childhood liver cancer
496616|NCT00716963|late allergic response
496617|NCT00716963|fluticasone propionate
496618|NCT00716937|pilonidal sinus
496619|NCT00716937|karydakis
496620|NCT00716937|laying open
496621|NCT00716911|cytomegalovirus infection
496622|NCT00716911|accelerated phase chronic myelogenous leukemia
496623|NCT00716911|atypical chronic myeloid leukemia, BCR-ABL negative
496624|NCT00716911|blastic phase chronic myelogenous leukemia
496625|NCT00716911|chronic myelomonocytic leukemia
496626|NCT00716911|chronic phase chronic myelogenous leukemia
496627|NCT00716911|recurrent adult acute lymphoblastic leukemia
496628|NCT00716911|recurrent adult acute myeloid leukemia
496629|NCT00716911|refractory chronic lymphocytic leukemia
496630|NCT00716911|refractory hairy cell leukemia
496631|NCT00716911|relapsing chronic myelogenous leukemia
496632|NCT00716911|secondary acute myeloid leukemia
496633|NCT00716911|stage III chronic lymphocytic leukemia
496634|NCT00716911|stage IV chronic lymphocytic leukemia
496635|NCT00716911|splenic marginal zone lymphoma
496636|NCT00716911|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
496637|NCT00716911|nodal marginal zone B-cell lymphoma
496638|NCT00716911|stage III adult Burkitt lymphoma
496639|NCT00716911|stage III adult diffuse large cell lymphoma
496640|NCT00716911|stage III adult diffuse mixed cell lymphoma
496641|NCT00716911|stage III adult diffuse small cleaved cell lymphoma
496642|NCT00716911|stage III adult immunoblastic large cell lymphoma
496643|NCT00716911|stage III adult lymphoblastic lymphoma
496644|NCT00716911|stage III grade 1 follicular lymphoma
496645|NCT00716911|stage III grade 2 follicular lymphoma
496646|NCT00716911|stage III grade 3 follicular lymphoma
496647|NCT00716911|stage III mantle cell lymphoma
496648|NCT00716911|stage III marginal zone lymphoma
496649|NCT00716911|stage III small lymphocytic lymphoma
496650|NCT00716911|stage IV adult Burkitt lymphoma
496651|NCT00716911|stage IV adult diffuse large cell lymphoma
496652|NCT00716911|stage IV adult diffuse mixed cell lymphoma
496653|NCT00716911|stage IV adult diffuse small cleaved cell lymphoma
496654|NCT00716911|stage IV adult immunoblastic large cell lymphoma
496655|NCT00716911|stage IV adult lymphoblastic lymphoma
496656|NCT00716911|stage IV grade 1 follicular lymphoma
496657|NCT00716911|stage IV grade 2 follicular lymphoma
496658|NCT00716911|stage IV grade 3 follicular lymphoma
496659|NCT00716911|stage IV mantle cell lymphoma
496660|NCT00716911|stage IV marginal zone lymphoma
496661|NCT00716911|stage IV small lymphocytic lymphoma
496662|NCT00716911|recurrent adult Hodgkin lymphoma
496663|NCT00716911|recurrent adult Burkitt lymphoma
496664|NCT00716911|recurrent adult diffuse large cell lymphoma
496665|NCT00716911|recurrent adult diffuse mixed cell lymphoma
496666|NCT00716911|recurrent adult diffuse small cleaved cell lymphoma
496667|NCT00716911|recurrent adult immunoblastic large cell lymphoma
496668|NCT00716911|recurrent adult lymphoblastic lymphoma
496669|NCT00716911|recurrent cutaneous T-cell non-Hodgkin lymphoma
496670|NCT00716911|recurrent mycosis fungoides/Sezary syndrome
496671|NCT00716911|recurrent grade 1 follicular lymphoma
496672|NCT00716911|recurrent grade 2 follicular lymphoma
496673|NCT00716911|recurrent grade 3 follicular lymphoma
496674|NCT00716911|recurrent mantle cell lymphoma
496675|NCT00716911|recurrent marginal zone lymphoma
496676|NCT00716911|recurrent small lymphocytic lymphoma
496677|NCT00716911|chronic eosinophilic leukemia
496678|NCT00716911|chronic neutrophilic leukemia
496679|NCT00716911|primary myelofibrosis
496680|NCT00716911|stage II multiple myeloma
496681|NCT00716911|stage III multiple myeloma
496682|NCT00716911|refractory multiple myeloma
496683|NCT00716911|de novo myelodysplastic syndromes
496684|NCT00716911|previously treated myelodysplastic syndromes
496685|NCT00716911|secondary myelodysplastic syndromes
496686|NCT00716911|myelodysplastic/myeloproliferative neoplasm, unclassifiable
496687|NCT00716911|stage I multiple myeloma
496688|NCT00716898|Condition
496689|NCT00716898|Cancer
496690|NCT00716898|Patients
496691|NCT00716898|Thrombosis
496692|NCT00716898|Unstable
496693|NCT00716898|Angina
496694|NCT00716898|Pectoris
496695|NCT00716885|Heart failure
496696|NCT00716885|Oxidative stress
496697|NCT00716885|Endothelial Progenitor Cells
496698|NCT00716885|White blood cells
496699|NCT00716872|cancer
496700|NCT00716872|sleep
496701|NCT00716872|insomnia
496702|NCT00716872|Internet
496703|NCT00716872|SHUTi
496704|NCT00716833|pain
496705|NCT00716833|coxibe
496706|NCT00716833|preemptive
496707|NCT00716833|abdominothoracic
496708|NCT00716833|sensibilisation
496709|NCT00716833|Analgesia
496710|NCT00716807|BMS
496711|NCT00716807|TMD
496712|NCT00716794|Prostate cancer
496713|NCT00716794|HE3235
496714|NCT00716794|Apoptone
496715|NCT00716781|Group B streptococcus
496716|NCT00716781|Sepsis
496717|NCT00716781|Infants
496718|NCT00716781|Diagnosis
496719|NCT00716781|Physical examination
496720|NCT00716781|Laboratory tests
496721|NCT00716768|Laparoscopic
496722|NCT00716768|Inguinal Hernia
496723|NCT00716768|Infants
496724|NCT00716755|Positron emission tomography
496725|NCT00716755|antipsychotics
496726|NCT00716755|risperidone
496727|NCT00716755|olanzapine
496728|NCT00716755|Dopamine
496729|NCT00716755|D2 receptor
496730|NCT00716755|elderly
496731|NCT00716755|schizophrenia
496732|NCT00716755|schizoaffective disorder
496733|NCT00716755|schizophreniform disorder
496734|NCT00716755|delusional disorder
496735|NCT00716755|psychotic disorder NOS
496736|NCT00716729|Questionnaire
496737|NCT00716729|Hip
496738|NCT00716729|Groin
496739|NCT00716729|Disability
496740|NCT00716729|Strength
496741|NCT00716729|To develop two new outcome measures for patients with hip and groin disability
496742|NCT00716716|Hemophilia B severe, previously treated patients
496743|NCT00716703|Appendicitis
496744|NCT00716703|Computed tomography
496745|NCT00716703|pediatric
496746|NCT00716703|child
496747|NCT00716703|sensitivity
496748|NCT00716703|specificity
496749|NCT00716703|contrast administration route
496750|NCT00716703|time factors
496751|NCT00716690|Stem cell transplantation
496752|NCT00716690|GVHD
496753|NCT00716677|difficult asthma
496754|NCT00716677|respiratory inductance plethysmography
496755|NCT00716664|cystic fibrosis
496756|NCT00716664|musculoskeletal
496757|NCT00716664|exercise capacity
496758|NCT00716664|posture
496759|NCT00716664|lung function
496760|NCT00716664|physical functioning
496761|NCT00716612|Coenzyme Q 10
496762|NCT00716612|Statin
496763|NCT00716612|Myalgia
496764|NCT00716599|malaria
496765|NCT00716599|diagnosis
496766|NCT00716599|rapid diagnostic test
496767|NCT00716599|rapid diagnostic tests
496768|NCT00716599|fever case management
496769|NCT00716599|training
496770|NCT00716599|fever case management in malaria-endemic areas
496771|NCT00716573|Cardiac transplantation
496772|NCT00716573|Chronic renal insufficiency
496773|NCT00716573|Everolimus
496774|NCT00716521|mobile actigraphy inpatient polysomnography actigraphy ambien
496775|NCT00716508|Patella tendon rupute, suture anchors, repair patella tendon
496776|NCT00716482|breast
496777|NCT00716482|lesion
496778|NCT00716482|ultrasound
496779|NCT00716482|BI-RADS
496780|NCT00716482|malignancy
496781|NCT00716482|women
496782|NCT00716469|Neurofibroma
496783|NCT00716469|Plexiform
496784|NCT00716469|NF1
496785|NCT00716469|Photo dynamic therapy
496786|NCT00716456|MAB C225(CETUXIMAB)(ANTI-EGFR)
496787|NCT00716456|OSI-774, TARCEVA (ERLOTINIB)
496788|NCT00716456|Lung
496789|NCT00716456|Adenocarcinoma
496790|NCT00716456|Lung cancer
496791|NCT00716443|Nasolabial folds
496792|NCT00716443|wrinkles
496793|NCT00716443|topical anesthetic
496794|NCT00716430|acute coronary syndromes
496795|NCT00716430|quality improvement
496796|NCT00716404|FlowMedica
496797|NCT00716404|Benephit
496798|NCT00716404|TRT
496799|NCT00716404|Patients
496800|NCT00716404|Components
496801|NCT00716404|Benephit Infusion System
496802|NCT00716404|Planned
496803|NCT00716404|To be used
496804|NCT00716391|Head and Neck Cancer
496805|NCT00716378|Simulated Driving
496806|NCT00716378|Risky Driving Behavior
496807|NCT00716378|Social Influences
496808|NCT00716365|angiography
496809|NCT00716365|hemostasis
496810|NCT00716365|femoral artery
496811|NCT00716365|duplex
496812|NCT00716352|non-ST elevation acute coronary syndrome
496813|NCT00716352|educational intervention
496814|NCT00716352|evidence based practice
496815|NCT00716352|guidelines
496816|NCT00716339|pseudophakic accommodation
496817|NCT00716326|Transcutaneous Electrical Nerve Stimulation
496818|NCT00716326|Chronic pain
496819|NCT00716326|Neuropathic pain
496820|NCT00716326|Short-term efficacy
496821|NCT00716326|Long-term efficacy
496822|NCT00716300|obesity
496823|NCT00716300|CVD
496824|NCT00716300|HDL kinetics
496825|NCT00716300|Anti-inflammatory and anti-oxidation studies
496826|NCT00716300|30 subjects recruited (15 MetS and 15 lean controls)
496827|NCT00716261|Parkinson's disease
496828|NCT00716261|Audio feedback
496829|NCT00716261|postural control
496830|NCT00716235|ADHD
496831|NCT00716235|ASD
496832|NCT00716235|PDD
496833|NCT00716235|DCD
496834|NCT00716235|Executive Functions
496835|NCT00716196|thin prep
496836|NCT00716196|EUS
496837|NCT00716183|mastitis
496838|NCT00716183|Staphylococcus
496839|NCT00716183|Streptococcus
496840|NCT00716183|lactation
496841|NCT00716183|breastfeeding
496842|NCT00716170|Diabetes Mellitus
496843|NCT00716170|Glucagon
496844|NCT00716170|Insulin
496845|NCT00716170|Incretin hormones
496846|NCT00716170|Glucose-dependent insulinotropic polypeptide
496847|NCT00716170|Glucagon-like peptide-1
496848|NCT00716170|Glucagon-like peptide-2
496849|NCT00716144|Psoriasis
496850|NCT00716131|Amyotrophic Lateral Sclerosis
496851|NCT00716131|Cerebrospinal Fluid
496852|NCT00716131|Neurodegenerative Disease
496853|NCT00716131|Motor Neuron Disease
496854|NCT00716131|Autonomic Nervous System
496855|NCT00716131|Neurodegenerative Diseases
496856|NCT00716131|Movement Disorders
496857|NCT00716118|Oocyte Cryopreservation
496858|NCT00716118|Slow-Freeze
496859|NCT00716118|Egg Freezing
496860|NCT00716118|Meiotic Spindle
496861|NCT00716118|Mitochondria
496862|NCT00716118|Human Oocytes Freezing.
496863|NCT00716105|Infant formula
496864|NCT00716105|Protein metabolism
496865|NCT00716079|Cerebral Hemorrhage
496866|NCT00716079|Stroke
496867|NCT00716079|antihypertensive drugs
496868|NCT00716079|blood pressure
496869|NCT00716079|disability
496870|NCT00716079|clinical trial
496871|NCT00716079|outcomes
496872|NCT00716053|emphysema
496873|NCT00716053|chronic obstructive pulmonary disease
496874|NCT00716053|COPD
496875|NCT00716053|lung volume reduction
496876|NCT00716053|LVRS
496877|NCT00716053|BLVR
496878|NCT00716053|Aeris
496879|NCT00716040|AIDS treatment
496880|NCT00716040|HAART adherence
496881|NCT00716040|intervention
496882|NCT00716014|Pachyonychia Congenita
496883|NCT00716014|siRNA
496884|NCT00716001|patients with chronic renal failure undergoing elective percutaneous coronary intervention
496885|NCT00715988|Methadone
496886|NCT00715988|analgesia
496887|NCT00715988|newborns
496888|NCT00715988|QT prolongation
496889|NCT00715988|Young Infants
496890|NCT00715975|clobetasol
496891|NCT00715975|halobetasol
496892|NCT00715975|psoriasis
496893|NCT00715975|evaluating the efficacy and tolerability of the drug Halobetasol propionate
496894|NCT00715962|Hospitalization
496895|NCT00715962|Aged
496896|NCT00715949|traumatic brain injury
496897|NCT00715949|pediatric
496898|NCT00715949|neurocognitive
496899|NCT00715949|concussion
496900|NCT00715936|Early childhood development
496901|NCT00715936|Psychosocial stimulation
496902|NCT00715936|Care for child development
496903|NCT00715923|informed consent document
496904|NCT00715923|ethics
496905|NCT00715910|Meningococcal vaccine
496906|NCT00715910|Booster vaccination
496907|NCT00715910|Immunogenicity
496908|NCT00715910|Meningococcal disease
496909|NCT00715910|Safety
496910|NCT00715897|chronic neurological deficient due to stroke
496911|NCT00715884|Atherosclerosis
496912|NCT00715884|de novo native coronary lesion
496913|NCT00715871|smoking
496914|NCT00715871|smoke cessation
496915|NCT00715871|stop smoking
496916|NCT00715871|quit smoking
496917|NCT00715871|nicotine replacement therapy
496918|NCT00715871|Smoke Break
496919|NCT00715871|liquid cigarette
496920|NCT00715871|liquid nicotine cigarette
496921|NCT00715858|Alzheimer's disease
496922|NCT00715858|dementia
496923|NCT00715858|inflammation
496924|NCT00715858|cytokine
496925|NCT00715858|biomarker
496926|NCT00715858|cerebrospinal fluid
496927|NCT00715858|serum
496928|NCT00715858|doxycycline
496929|NCT00715858|rifampin
496930|NCT00715845|cardiovascular disease
496931|NCT00715845|embolism
496932|NCT00715845|microemboli
496933|NCT00715845|cognitive decline
496934|NCT00715845|mitral valve repair
496935|NCT00715845|cerebral microemboli
496936|NCT00715845|coronary artery bypass graft
496937|NCT00715845|CABG
496938|NCT00715845|transcranial doppler
496939|NCT00715845|transesophageal echocardiogram
496940|NCT00715845|magnetic resonance imaging
496941|NCT00715845|carbon dioxide
496942|NCT00715832|Breast cancer
496943|NCT00715832|Dendritic cell vaccine
496944|NCT00715832|OFA/iLRP
496945|NCT00715832|Patients
496946|NCT00715832|Line
496947|NCT00715832|Chemotherapy
496948|NCT00715832|Setting
496949|NCT00715832|Four different lines
496950|NCT00715806|claustrophobia
496951|NCT00715806|magnetic resonance imaging
496952|NCT00715806|MRI
496953|NCT00715806|anxiety
496954|NCT00715806|open design
496955|NCT00715806|severely anxious patients
496956|NCT00715793|Decitabine
496957|NCT00715793|Temozolomide
496958|NCT00715793|Metastatic
496959|NCT00715793|Melanoma
496960|NCT00715793|Non-resectable
496961|NCT00715793|Stage IIIB melanoma
496962|NCT00715793|stage IV melanoma
496963|NCT00715793|TMZ
496964|NCT00715793|DTIC
496965|NCT00715793|promoter methylation
496966|NCT00715793|skin cancer
496967|NCT00715793|chemotherapy
496968|NCT00715767|BLS training
496969|NCT00715767|CPR
496970|NCT00715767|post graduate education
496971|NCT00715767|resource-limited settings
496972|NCT00715767|medical education
496973|NCT00715767|CPR retention
496974|NCT00715767|cultural barriers
496975|NCT00715741|atelectasis
496976|NCT00715741|oxygen
496977|NCT00715741|saturation
496978|NCT00715728|Plastic surgery
496979|NCT00715728|Warming
496980|NCT00715728|Core temperature
496981|NCT00715728|Bair Hugger
496982|NCT00715728|Hot Dog heating system
496983|NCT00715715|Hepatitis B e Antigen
496984|NCT00715715|HBeAg-positive chronic hepatitis B
496985|NCT00715702|AZD5672
496986|NCT00715676|Osteoporosis
496987|NCT00715676|2-methylene-19-nor-(20S)-1a, 25-dihydroxyvitamin D3
496988|NCT00715676|Vitamin D
496989|NCT00715676|Bone Density Conservation Agents
496990|NCT00715676|Bone Regeneration
496991|NCT00715650|Rehabilitation, Vocational
496992|NCT00715650|Compensation and Redress
496993|NCT00715650|disability evaluation
496994|NCT00715637|AML
496995|NCT00715637|Leukemia
496996|NCT00715637|MDS
496997|NCT00715637|Amonafide
496998|NCT00715637|Cytarabine
496999|NCT00715637|Daunorubicin
497000|NCT00715637|Lymphatic disorders
497001|NCT00715624|hyperglycemia, GLP-1, metformin, insulin
497002|NCT00715611|pemetrexed
497003|NCT00715611|cisplatin
497004|NCT00715611|IMRT
497005|NCT00715611|PLEURA
497006|NCT00715611|Malignant
497007|NCT00715611|08-053
497008|NCT00715598|Pain Assessment
497009|NCT00715598|Measurement
497010|NCT00715585|diabetes
497011|NCT00715585|education
497012|NCT00715585|health literacy
497013|NCT00715572|hypothyroidism, treatment, thyroxine, triiodothyronine
497014|NCT00715559|Major depressive disorder, depression
497015|NCT00715559|neurotrophic
497016|NCT00715559|brain-derived neurotrophic factor
497017|NCT00715559|antidepressant
497018|NCT00715559|cysteamine
497019|NCT00715546|Adipose-derived stem cell
497020|NCT00715546|Lipodystrophy
497021|NCT00715533|acute (< 24 hours) stroke
497022|NCT00715533|stroke
497023|NCT00715533|TIA
497024|NCT00715533|MRI
497025|NCT00715533|imaging
497026|NCT00715533|acute
497027|NCT00715520|Transcranial Magnetic Stimulation
497028|NCT00715520|Rehabilitation
497029|NCT00715520|Stroke
497030|NCT00715520|Plasticity
497031|NCT00715507|decision making
497032|NCT00715507|graphic display
497033|NCT00715494|brain injuries, dementia, myopathies, muscle disorders
497034|NCT00715481|Type 2 diabetes
497035|NCT00715481|Cardiovascular disease
497036|NCT00715481|Diabetic Nephropathy
497037|NCT00715481|Glomerular filtration rate
497038|NCT00715481|Albuminuria
497039|NCT00715455|CAD
497040|NCT00715455|PCI
497041|NCT00715455|ANTICOAGULANT
497042|NCT00715442|Kidney
497043|NCT00715442|Renal Cell Carcinoma
497044|NCT00715442|RCC
497045|NCT00715442|Sutent
497046|NCT00715442|Sunitinib malate
497047|NCT00715442|Clear cell
497048|NCT00715442|SU011248
497049|NCT00715442|Nephrectomy
497050|NCT00715442|Surgical removal of kidney
497051|NCT00715442|Cytoreductive nephrectomy
497052|NCT00715429|leg cramps
497053|NCT00715429|vitamin D deficiency
497054|NCT00715416|peripheral vascular diseases
497055|NCT00715416|Intermittent Claudication
497056|NCT00715416|Angioplasty
497057|NCT00715390|Children
497058|NCT00715390|Cardiac Arrhythmia
497059|NCT00715390|General Anesthesia
497060|NCT00715377|benztropine
497061|NCT00715377|Anticholinergic antiparkinsonian agents
497062|NCT00715377|antipsychotics
497063|NCT00715377|elderly population
497064|NCT00715377|side-effects
497065|NCT00715338|Exhaled Breath Condensate
497066|NCT00715338|elective surgery
497067|NCT00715338|mechanical ventilation
497068|NCT00715338|Isofurans
497069|NCT00715338|thrombomodulin
497070|NCT00715338|requiring
497071|NCT00715338|mechanical
497072|NCT00715338|ventilation
497073|NCT00715325|colonoscopy
497074|NCT00715325|disposable
497075|NCT00715325|single use
497076|NCT00715312|Inflammation
497077|NCT00715312|LDL
497078|NCT00715312|Oleic acid
497079|NCT00715312|Palmitic acid
497080|NCT00715312|trans fatty acid
497081|NCT00715312|C-reactive protein
497082|NCT00715286|epithelial ovarian cancer
497083|NCT00715286|neoadjuvant chemotherapy
497084|NCT00715286|randomized study
497085|NCT00715273|Magnetic Resonance Imaging
497086|NCT00715273|Atherosclerotic Plaque
497087|NCT00715273|Lipid Lowering Therapy
497088|NCT00715247|Myeloproliferative Disorders
497089|NCT00715247|Hematological Malignancies
497090|NCT00715247|Polycythemia Vera
497091|NCT00715247|Essential Thrombocythemia
497092|NCT00715247|Myelofibrosis
497093|NCT00715247|Genetics
497094|NCT00715247|Chronic Leukemia
497095|NCT00715234|adolescent reminder/recall
497096|NCT00715234|adolescent vaccines
497097|NCT00715234|Tdap
497098|NCT00715234|Meningococcal
497099|NCT00715234|HPV
497100|NCT00715234|Reminder cards
497101|NCT00715234|Recall messages
497102|NCT00715234|vaccine
497103|NCT00715234|conjugate
497104|NCT00715221|Diabetes
497105|NCT00715195|Cognitive behavioral
497106|NCT00715195|Long-term study
497107|NCT00715195|Education
497108|NCT00715182|Renal Cell Cancer
497109|NCT00715156|allergy, peach, birch
497110|NCT00715156|recombinants allergens diagnosis
497111|NCT00715156|OAS
497112|NCT00715156|LTP
497113|NCT00715156|systemic reactions
497114|NCT00715156|subjects with severe reaction to other fruits
497115|NCT00715143|hip
497116|NCT00715143|replacement
497117|NCT00715143|ceramic
497118|NCT00715143|orthopaedic
497119|NCT00715143|joint
497120|NCT00715143|degenerative
497121|NCT00715143|non-inflammatory
497122|NCT00715143|osteoarthritis
497123|NCT00715143|avascular necrosis
497124|NCT00715143|congenital hip dysplasia
497125|NCT00715143|traumatic arthritis
497126|NCT00715130|Energy
497127|NCT00715130|Obesity
497128|NCT00715130|Energy Balance
497129|NCT00715130|Physical Activity
497130|NCT00715130|Dietary Intake
497131|NCT00715130|Overweight
497132|NCT00715130|Sedentary
497133|NCT00715130|Worksite
497134|NCT00715130|Body Mass Index
497135|NCT00715130|Weight Maintenance
497136|NCT00715117|children
497137|NCT00715117|pediatric
497138|NCT00715117|Crohn's Disease
497139|NCT00715117|naltrexone
497140|NCT00715117|LDN
497141|NCT00715117|IBD
497142|NCT00715117|Inflammatory bowel disease
497143|NCT00715091|NSAIDS
497144|NCT00715091|ankylosing spondylitis
497145|NCT00715091|SpA
497146|NCT00715091|Spondyloarthritis
497147|NCT00715091|radiographic changes
497148|NCT00715078|prostate cancer
497149|NCT00715078|prostate
497150|NCT00715078|immune therapy
497151|NCT00715078|immunotherapy
497152|NCT00715078|vaccine
497153|NCT00715078|dendritic cells
497154|NCT00715078|antigen-presenting cells
497155|NCT00715078|antigen presenting cells
497156|NCT00715078|cancer vaccine
497157|NCT00715078|prostate specific antigen (PSA)
497158|NCT00715078|prostatic adenocarcinoma
497159|NCT00715065|syncope
497160|NCT00715065|faint
497161|NCT00715065|blood
497162|NCT00715065|blood injury phobia
497163|NCT00715065|phobia
497164|NCT00715052|neurologic deficiency due traumatic brain injury
497165|NCT00715039|generalized anxiety disorder
497166|NCT00715039|onset of efficacy
497167|NCT00715039|Daily Assessment of Symptoms-Anxiety (DAS-A)
497168|NCT00715039|Methods
497169|NCT00715026|Arthritis
497170|NCT00715026|Total Hip
497171|NCT00715026|Ceramic
497172|NCT00715026|Hip Replacement
497173|NCT00715026|Total Hip Arthroplasty (THA)
497174|NCT00715026|Joint Disease
497175|NCT00715013|recurrent Glioblastoma
497176|NCT00715000|Preterm babies hydration
497177|NCT00715000|Oral rehydration solution
497178|NCT00715000|Continuous gastric drip
497179|NCT00715000|Fluid therapy
497180|NCT00715000|Premature babies comfort
497181|NCT00715000|Infant care
497182|NCT00715000|Technical challenge for the nurses/doctors in charge
497183|NCT00714987|ARDS
497184|NCT00714987|Mechanical ventilation
497185|NCT00714987|PEEP with low level
497186|NCT00714987|PEEP with high level
497187|NCT00714987|EVLW
497188|NCT00714987|Picco® system
497189|NCT00714987|PaO2/FiO2 ratio
497190|NCT00714974|Neuromuscular blocking agents
497191|NCT00714974|Bispectral analysis
497192|NCT00714948|Bladder
497193|NCT00714948|Urinary
497194|NCT00714948|SORAFENIB
497195|NCT00714948|CISPLATIN
497196|NCT00714948|GEMCITABINE
497197|NCT00714935|Risk Factors
497198|NCT00714935|Risk Reduction Behavior
497199|NCT00714935|Counseling
497200|NCT00714909|Breast cancer
497201|NCT00714909|Catheter related thrombosis
497202|NCT00714909|Diagnosis
497203|NCT00714909|Echography doppler
497204|NCT00714909|Risk factors
497205|NCT00714896|smoking cessation
497206|NCT00714896|nicotine dependence
497207|NCT00714896|stage-based intervention
497208|NCT00714896|nicotine replacement medications
497209|NCT00714896|counseling
497210|NCT00714896|substance abuse treatment
497211|NCT00714883|drug-eluting stents
497212|NCT00714883|Percutaneous coronary intervention (PCI)
497213|NCT00714870|BMI
497214|NCT00714870|Quality of life
497215|NCT00714857|ICU patients
497216|NCT00714857|Dexmedetomidine
497217|NCT00714857|Sedation
497218|NCT00714857|Judged
497219|NCT00714857|Attending
497220|NCT00714857|Physician
497221|NCT00714844|insulin therapy
497222|NCT00714844|insulin detemir
497223|NCT00714844|waist circumference
497224|NCT00714831|Physical activity promotion
497225|NCT00714831|Primary health care
497226|NCT00714831|Adherence
497227|NCT00714818|Schizophrenia
497228|NCT00714818|Bipolar Disorder
497229|NCT00714818|Schizoaffective disorder
497230|NCT00714818|Genetic Counseling
497231|NCT00714818|Risk perception
497232|NCT00714818|Stigma
497233|NCT00714818|Control
497234|NCT00714818|Knowledge
497235|NCT00714818|family members
497236|NCT00714818|Sibling parent or child with schizophrenia
497237|NCT00714818|Sibling parent or child with bipolar disorder
497238|NCT00714818|Sibling parent or child with schizoaffective disorder
497239|NCT00714805|Amyotrophic Lateral Sclerosis
497240|NCT00714805|Gastric Motility
497241|NCT00714805|Autonomic Nervous System
497242|NCT00714805|Neurodegenerative Diseases
497243|NCT00714805|Movement Disorders
497244|NCT00714805|Gastrointestinal Motility
497245|NCT00714779|Major depressive Disorder
497246|NCT00714779|fluoxetine
497247|NCT00714779|short-term psychodynamic psychotherapy
497248|NCT00714779|PET
497249|NCT00714753|stage I prostate cancer
497250|NCT00714753|stage II prostate cancer
497251|NCT00714753|adenocarcinoma of the prostate
497252|NCT00714740|apnea, sleep, altitude, hypoxia
497253|NCT00714727|migraine
497254|NCT00714727|headache
497255|NCT00714727|acupuncture
497256|NCT00714714|acne
497257|NCT00714714|irritation
497258|NCT00714714|objective sensory methods
497259|NCT00714688|Adult
497260|NCT00714688|ADHD
497261|NCT00714688|Concerta
497262|NCT00714675|citrulline
497263|NCT00714675|protein-energy malnutrition
497264|NCT00714675|aged
497265|NCT00714675|protein biosynthesis
497266|NCT00714675|amino acid
497267|NCT00714662|high flux hemodialysis
497268|NCT00714649|Head and Neck Squamous Cell Carcinoma treated with surgery
497269|NCT00714649|and/or radiotherapy
497270|NCT00714636|Amyotrophic Lateral Sclerosis
497271|NCT00714636|Cerebrospinal Fluid
497272|NCT00714636|Neurodegenerative Disease
497273|NCT00714636|Motor Neuron Disease
497274|NCT00714636|Autonomic Nervous System
497275|NCT00714636|Neurodegenerative Diseases
497276|NCT00714636|Movement Disorders
497277|NCT00714623|Coronary Artery Disease
497278|NCT00714623|Coronary Restenosis
497279|NCT00714623|Coronary Thrombosis
497280|NCT00714623|Drug-Eluting Stents
497281|NCT00714623|Angioplasty, Transluminal, Percutaneous Coronary
497282|NCT00714610|Serum metal ion concentration
497283|NCT00714597|Venous thrombosis
497284|NCT00714597|Primary prevention
497285|NCT00714584|Infusions, Intravenous
497286|NCT00714584|Safety
497287|NCT00714584|Pharmacokinetics
497288|NCT00714584|Naltrexone
497289|NCT00714584|Administration, Oral
497290|NCT00714571|cognitive rehabilitation
497291|NCT00714571|explicit memory training
497292|NCT00714571|mild cognitive impairment
497293|NCT00714571|Alzheimer's disease
497294|NCT00714571|traumatic brain injury
497295|NCT00714571|veterans
497296|NCT00714558|Pharmacokinetics
497297|NCT00714558|Administration, Oral
497298|NCT00714558|Naltrexone
497299|NCT00714558|Biological Availability
497300|NCT00714558|Infusions, Intravenous
497301|NCT00714558|Fentanyl
497302|NCT00714558|Safety
497303|NCT00714558|Naloxone
497304|NCT00714545|Coronary Artery Disease
497305|NCT00714545|Coronary Restenosis
497306|NCT00714545|Brachytherapy
497307|NCT00714532|smoking cessation
497308|NCT00714532|Asian American
497309|NCT00714532|Chinese American
497310|NCT00714532|smoking reduction
497311|NCT00714532|stage-based intervention
497312|NCT00714532|expert system
497313|NCT00714532|nicotine replacement
497314|NCT00714532|counseling
497315|NCT00714519|Xenaderm
497316|NCT00714519|partial
497317|NCT00714519|thickness
497318|NCT00714519|wounds
497319|NCT00714519|Nursing Homes
497320|NCT00714506|obesity
497321|NCT00714506|physical activity
497322|NCT00714506|older adults
497323|NCT00714506|functional disability
497324|NCT00714493|rheumatoid arthritis
497325|NCT00714493|remicade
497326|NCT00714493|infliximab
497327|NCT00714493|Centocor
497328|NCT00714493|etanercept
497329|NCT00714493|enbrel
497330|NCT00714493|adalimumab
497331|NCT00714493|humira
497332|NCT00714493|restart
497333|NCT00714493|swollen joints
497334|NCT00714493|tender joints.
497335|NCT00714480|Thymoglobulin
497336|NCT00714480|Renal Transplant
497337|NCT00714480|Kidney Transplant
497338|NCT00714480|Immunosuppression
497339|NCT00714480|Induction therapy
497340|NCT00714467|smoking cessation
497341|NCT00714467|Asian
497342|NCT00714467|Chinese American
497343|NCT00714467|family support
497344|NCT00714467|social support
497345|NCT00714467|stage-based intervention
497346|NCT00714441|Diabetes Type 2
497347|NCT00714441|Distress
497348|NCT00714441|Problem Solving Therapy
497349|NCT00714441|Computer Automated Self-Management (CASM)
497350|NCT00714428|Traumatic Brain Injury
497351|NCT00714428|Quality of Life
497352|NCT00714402|UTI
497353|NCT00714389|Urogynecology
497354|NCT00714376|Prostate cancer
497355|NCT00714376|High-risk prostate cancer
497356|NCT00714376|Radical prostatectomy
497357|NCT00714376|Early rising PSA
497358|NCT00714376|Taxotere
497359|NCT00714376|Docetaxel
497360|NCT00714350|Information Display
497361|NCT00714350|situational awareness
497362|NCT00714350|Create intuitive visualization
497363|NCT00714337|Formulation
497364|NCT00714337|pharmacokinetics
497365|NCT00714324|Nutrition
497366|NCT00714324|Screening
497367|NCT00714311|borderline personality disorder
497368|NCT00714311|randomized controlled trial
497369|NCT00714311|Transference-Focused Psychotherapy
497370|NCT00714311|treatment by experienced community psychotherapists
497371|NCT00714298|biological markers
497372|NCT00714298|emergency service hospital
497373|NCT00714298|heart fatty acid binding protein
497374|NCT00714298|ischemia modified albumin
497375|NCT00714285|Primary study
497376|NCT00714285|immunogenicity
497377|NCT00714285|safety
497378|NCT00714259|Low Grade B Cell Malignancies
497379|NCT00714259|nonmyeloablative transplant
497380|NCT00714259|allogeneic
497381|NCT00714246|advanced non small cell lung cancer
497382|NCT00714233|Polycystic Ovary Syndrome
497383|NCT00714233|Overweight Adolescent Girls
497384|NCT00714233|Irregular Menstrual Cycles
497385|NCT00714220|Amyotrophic Lateral Sclerosis
497386|NCT00714220|Gastric Motility
497387|NCT00714220|Autonomic Nervous System
497388|NCT00714220|Neurodegenerative Diseases
497389|NCT00714220|Movement Disorders
497390|NCT00714220|Substrate Utilization
497391|NCT00714207|adolescents
497392|NCT00714207|smoking
497393|NCT00714207|smoking cessation
497394|NCT00714207|tobacco use
497395|NCT00714194|sedation
497396|NCT00714194|delirium
497397|NCT00714194|sleep
497398|NCT00714194|sedation withdrawal
497399|NCT00714194|ICU patients
497400|NCT00714181|unspecified adult solid tumor, protocol specific
497401|NCT00714168|Weight Loss
497402|NCT00714168|Weight Control
497403|NCT00714155|Colpocleisis
497404|NCT00714142|Renal blood flow
497405|NCT00714142|PET imaging
497406|NCT00714129|Steatosis
497407|NCT00714129|Diabetes
497408|NCT00714116|safety
497409|NCT00714116|pharmacokinetics
497410|NCT00714103|Leukemia
497411|NCT00714103|Chronic Lymphocytic Leukemia
497412|NCT00714103|CLL
497413|NCT00714103|8-Chloro-Adenosine
497414|NCT00714103|purine analogues
497415|NCT00714103|Cancer
497416|NCT00714090|repetitive Transcranial Magnetic Stimulation (rTMS)
497417|NCT00714090|Major depressive disorders
497418|NCT00714090|Depression
497419|NCT00714090|Venlafaxine
497420|NCT00714077|rectal cancer
497421|NCT00714077|concurrent chemoradiotherapy
497422|NCT00714077|adjuvant therapy
497423|NCT00714077|phase III study
497424|NCT00714038|Quality development project
497425|NCT00714038|primary care nurses
497426|NCT00714038|asthma
497427|NCT00714038|patient compliance
497428|NCT00714038|follow-up
497429|NCT00714025|RAD001
497430|NCT00714025|TCC
497431|NCT00714025|Palliative treatment
497432|NCT00714025|advance or metastatic TCC
497433|NCT00714025|Failure after Platinum-based chemotherapy
497434|NCT00714012|Display development
497435|NCT00714012|Intuitive display use
497436|NCT00714012|visualizations are intuitive
497437|NCT00713999|Sexually transmitted infections
497438|NCT00713999|Urogenital schistosomiasis
497439|NCT00713999|Schistosoma haematobium
497440|NCT00713999|Reproductive health
497441|NCT00713999|Pelvic examination
497442|NCT00713999|Ultrasonography
497443|NCT00713999|Questionnaire
497444|NCT00713999|Madagascar
497445|NCT00713986|Pain
497446|NCT00713986|Newborn Infant
497447|NCT00713986|Analgesia
497448|NCT00713960|Quality development project
497449|NCT00713960|primary care nurses
497450|NCT00713960|cardiovascular disease
497451|NCT00713960|secondary prevention
497452|NCT00713960|follow-up
497453|NCT00713947|Gastric lesions induced by low dose of aspirin
497454|NCT00713947|Helicobacter pylori
497455|NCT00713934|Autologous Bone marrow stem cells
497456|NCT00713934|Cirrhosis
497457|NCT00713921|Female
497458|NCT00713921|Diabetics
497459|NCT00713921|Stroke
497460|NCT00713908|Voiding dysfunction following TVT placement
497461|NCT00713895|smoking cessation
497462|NCT00713895|randomized trial
497463|NCT00713895|Asian
497464|NCT00713895|Chinese American
497465|NCT00713895|stages of change
497466|NCT00713882|Survivors
497467|NCT00713882|Quality of Life
497468|NCT00713869|Oocyte cryopreservation
497469|NCT00713869|Slow freeze
497470|NCT00713843|Neck Pain
497471|NCT00713843|Manuel Therapy Utrecht
497472|NCT00713843|Physiotherapy
497473|NCT00713830|hyperglycemia, GLP-1
497474|NCT00713817|Pain
497475|NCT00713817|Peripheral Neuropathy
497476|NCT00713804|Schizophrenia
497477|NCT00713804|Bipolar Disorder
497478|NCT00713804|Schizoaffective disorder
497479|NCT00713804|Genetic Counseling
497480|NCT00713804|Risk perception
497481|NCT00713804|Stigma
497482|NCT00713804|Control
497483|NCT00713804|Knowledge
497484|NCT00713791|Healthy Volunteers
497485|NCT00713791|ZD4054
497486|NCT00713778|Ovarian Cysts
497487|NCT00713778|Electrocoagulation
497488|NCT00713778|Ovarian Function Tests
497489|NCT00713778|Laparoscopy
497490|NCT00713765|Healthy volunteers
497491|NCT00713752|HIV-negative
497492|NCT00713739|kidney stones
497493|NCT00713739|ureteral stones
497494|NCT00713739|medical expulsion therapy
497495|NCT00713726|Pain
497496|NCT00713726|Analgesia
497497|NCT00713726|Newborn Infant
497498|NCT00713726|Opioids
497499|NCT00713726|Side-effects
497500|NCT00713726|Intensive care
497501|NCT00713726|Postoperative
497502|NCT00713713|Respiratory Distress Syndrome, Adult
497503|NCT00713713|Tidal volume
497504|NCT00713713|cardiac output
497505|NCT00713713|Respiration, Artificial
497506|NCT00713713|Protective ventilation
497507|NCT00713700|patent ductus arteriosus
497508|NCT00713700|PDA
497509|NCT00713687|photodynamic therapy
497510|NCT00713687|PDT
497511|NCT00713687|gemcitabine
497512|NCT00713687|oxaliplatin
497513|NCT00713687|cholangiocarcinoma
497514|NCT00713674|Methicillin resistance
497515|NCT00713661|Colorectal Anastomosis
497516|NCT00713661|Colorectal Resection
497517|NCT00713661|Tachosil
497518|NCT00713635|Congenital Heart Disease
497519|NCT00713622|Partial
497520|NCT00713622|onset
497521|NCT00713622|seizures
497522|NCT00713609|Acne
497523|NCT00713609|Acne Vulgaris
497524|NCT00713609|Pimples
497525|NCT00713596|Nasal Surgery
497526|NCT00713596|Septorhinoplasty
497527|NCT00713596|fibrin glue
497528|NCT00713596|fibrinogen
497529|NCT00713596|Swelling
497530|NCT00713596|fibrin
497531|NCT00713596|tisseel
497532|NCT00713583|Cocaine, levodopa, contingency management
497533|NCT00713570|intellectual functioning
497534|NCT00713570|memory,visual-spatial and perceptual functions
497535|NCT00713570|cognitive abilities
497536|NCT00713570|COMT
497537|NCT00713570|BDNF
497538|NCT00713570|neuron biological systemic pathway candidate genes
497539|NCT00713570|Chinese
497540|NCT00713570|Taiwan
497541|NCT00713570|Healthy subjects
497542|NCT00713557|coronary angioplasty
497543|NCT00713544|Rheumatoid Arthritis
497544|NCT00713544|RA
497545|NCT00713544|AZD5672
497546|NCT00713531|HIV-negative
497547|NCT00713531|male and female clients
497548|NCT00713531|ages 18-50 years
497549|NCT00713531|seeking HIV counseling
497550|NCT00713531|testing at TRCARC
497551|NCT00713518|AMD Age Related Macular Degeneration Choroidal Neovascularization Monet
497552|NCT00713505|psychosocial effects of cancer and its treatment
497553|NCT00713505|long-term effects secondary to cancer therapy in children
497554|NCT00713505|cancer survivor
497555|NCT00713505|cognitive/functional effects
497556|NCT00713505|childhood acute lymphoblastic leukemia
497557|NCT00713505|childhood acute myeloid leukemia in remission
497558|NCT00713505|childhood anaplastic large cell lymphoma
497559|NCT00713505|childhood large cell lymphoma
497560|NCT00713505|childhood lymphoblastic lymphoma
497561|NCT00713505|childhood small noncleaved cell lymphoma
497562|NCT00713505|childhood nasal type extranodal NK/T-cell lymphoma
497563|NCT00713505|childhood grade III lymphomatoid granulomatosis
497564|NCT00713505|childhood chronic myelogenous leukemia
497565|NCT00713492|Alcohol
497566|NCT00713492|Self -Administration
497567|NCT00713492|Intoxication
497568|NCT00713492|Healthy Volunteer
497569|NCT00713492|HV
497570|NCT00713479|methamphetamine
497571|NCT00713479|varenicline
497572|NCT00713479|Chantix
497573|NCT00713479|stimulant
497574|NCT00713479|crystal meth
497575|NCT00713466|CLIPP cases
497576|NCT00713466|Pediatric clerkship
497577|NCT00713466|Standardizing
497578|NCT00713466|Students' exposure
497579|NCT00713466|Essential
497580|NCT00713466|Enhancing
497581|NCT00713466|Experience
497582|NCT00713453|Pompe disease
497583|NCT00713453|muscle
497584|NCT00713453|enzyme replacement therapy
497585|NCT00713440|Incretin Effect
497586|NCT00713440|Steroids
497587|NCT00713440|Glucagon-Like Peptide 1
497588|NCT00713440|Gastric Inhibitory Peptide
497589|NCT00713440|Glucose-dependent Insulinotropic Polypeptide
497590|NCT00713440|Insulin
497591|NCT00713440|C-peptide
497592|NCT00713440|Glucagon
497593|NCT00713427|Biliary
497594|NCT00713427|Strictures
497595|NCT00713427|Malignant
497596|NCT00713427|Neoplasm
497597|NCT00713427|Palliation
497598|NCT00713414|Spasmodic Dysphonia
497599|NCT00713414|Dystonia
497600|NCT00713414|Basal Ganglia
497601|NCT00713414|PET Imaging
497602|NCT00713414|fMRI
497603|NCT00713414|Voice Disorder
497604|NCT00713414|Healthy Volunteer
497605|NCT00713414|HV
497606|NCT00713375|Autonomic Nervous System
497607|NCT00713375|Subarachnoid Hemorrhage
497608|NCT00713375|Intracranial Hemorrhages
497609|NCT00713375|Cerebral Hemorrhage
497610|NCT00713362|Aspiration, chest tube, pneumothorax, thoracoscopic surgery
497611|NCT00713349|White
497612|NCT00713349|Petrolatum
497613|NCT00713349|Xenaderm
497614|NCT00713349|Vehicle
497615|NCT00713349|Partial thickness wounds
497616|NCT00713349|Healing
497617|NCT00713349|Cryo-surgery
497618|NCT00713336|ZD4054
497619|NCT00713336|Healthy Volunteers
497620|NCT00713336|QT interval
497621|NCT00713323|Pain
497622|NCT00713323|Peripheral Neuropathy
497623|NCT00713297|medication errors
497624|NCT00713297|computerized physician order entry
497625|NCT00713297|pharmaceutical care
497626|NCT00713297|chemotherapeutic agents
497627|NCT00713297|reengineering
497628|NCT00713284|Kidney transplantation
497629|NCT00713284|Sirolimus
497630|NCT00713284|Immunosuppression
497631|NCT00713284|Tacrolimus
497632|NCT00713271|Healthy male
497633|NCT00713271|tolerability
497634|NCT00713271|safety
497635|NCT00713271|inhalation
497636|NCT00713258|Postmenopausal women
497637|NCT00713258|Back pain
497638|NCT00713258|Osteoporosis related fracture
497639|NCT00713245|Pompe disease
497640|NCT00713245|late onset
497641|NCT00713232|naming test
497642|NCT00713219|IMRT
497643|NCT00713219|cetuximab
497644|NCT00713219|docetaxel
497645|NCT00713206|Dental implants, maxilla, sinus lift, augmentation
497646|NCT00713193|Idiopathic TTP
497647|NCT00713193|Treatment
497648|NCT00713193|Exacerbation
497649|NCT00713193|Relapse
497650|NCT00713193|Plasma Exchange
497651|NCT00713167|Grape Seed Extract
497652|NCT00713167|Hyperlipidemia
497653|NCT00713154|Radiotherapy
497654|NCT00713154|induced
497655|NCT00713128|nausea vomiting colorectal cancer
497656|NCT00713115|laparoscopy, needlescopy, adrenalectomy
497657|NCT00713102|in-flight emergency
497658|NCT00713089|Eczema
497659|NCT00713089|Asthma
497660|NCT00713089|Allergic rhinitis
497661|NCT00713089|Singapore
497662|NCT00713089|Indonesia
497663|NCT00713089|Gastrointestinal Flora
497664|NCT00713076|multi-purpose solution
497665|NCT00713076|contact lens wearers
497666|NCT00713076|Contact lense wearers
497667|NCT00713063|smoking cessation
497668|NCT00713063|exercise
497669|NCT00713063|physical activity
497670|NCT00713063|health education
497671|NCT00713050|stroke
497672|NCT00713050|aphasia
497673|NCT00713050|imitation
497674|NCT00713050|mirror neuron
497675|NCT00713037|fluoromisonidazole
497676|NCT00713037|PET scan
497677|NCT00713037|Hypoxia-PET
497678|NCT00713037|IMPT
497679|NCT00713024|Pain; Functional neuroimaging; Neuropathy; Thermal sensation
497680|NCT00713011|Adalat XL
497681|NCT00713011|Diltiazem
497682|NCT00713011|Tiazac XC
497683|NCT00713011|Proteinuria
497684|NCT00712998|radiation injuries
497685|NCT00712998|free radicals
497686|NCT00712998|reactive oxygen species
497687|NCT00712998|radiation injury from X-ray computed tomography
497688|NCT00712998|free radical production
497689|NCT00712998|blood reactive oxygen species level
497690|NCT00712985|Breast cancer
497691|NCT00712985|aromatase inhibitors
497692|NCT00712972|knee injection
497693|NCT00712972|parapatellar
497694|NCT00712959|Pertussis
497695|NCT00712959|Tetanus
497696|NCT00712959|Diphtheria
497697|NCT00712959|Acellular pertussis
497698|NCT00712959|ADACEL®,
497699|NCT00712959|Tdap vaccine
497700|NCT00712933|SLE
497701|NCT00712933|Belimumab
497702|NCT00712933|Antibodies
497703|NCT00712933|Systemic Lupus Erythematosus
497704|NCT00712933|Lupus
497705|NCT00712933|Autoimmune Diseases
497706|NCT00712907|vitamin C
497707|NCT00712907|retinal blood flow
497708|NCT00712907|intraocular pressure
497709|NCT00712907|retinal vessel diameter
497710|NCT00712894|Acute myocardial infarction
497711|NCT00712894|Percutaneous coronary intervention
497712|NCT00712894|No-reflow phenomenon
497713|NCT00712894|Vasodilator agents
497714|NCT00712855|Liver Cancer
497715|NCT00712842|Diabetes
497716|NCT00712842|ocular blood flow
497717|NCT00712829|Prostate cancer
497718|NCT00712829|Imaging
497719|NCT00712816|osteoarthritis
497720|NCT00712816|total knee arthroplasty
497721|NCT00712816|cryotherapy
497722|NCT00712790|First line treatment for Hepatocellular Carcinoma
497723|NCT00712777|Brimonidine
497724|NCT00712777|alpha 2 receptor polymorphism
497725|NCT00712777|Intraocular Pressure
497726|NCT00712764|Adenosine
497727|NCT00712764|Choroidal blood flow
497728|NCT00712764|Suction cup
497729|NCT00712751|Rectum
497730|NCT00712751|Quality of Life
497731|NCT00712751|Sexual Health
497732|NCT00712751|08-073
497733|NCT00712738|Nifedipine
497734|NCT00712738|Thalassemia
497735|NCT00712738|Hemochromatosis
497736|NCT00712738|Iron Overload
497737|NCT00712738|Iron Excretion
497738|NCT00712712|bone metastases
497739|NCT00712712|unspecified adult solid tumor, protocol specific
497740|NCT00712712|pain
497741|NCT00712699|Preschool
497742|NCT00712699|Children
497743|NCT00712699|ADHD
497744|NCT00712699|Medication
497745|NCT00712699|Controlled Study
497746|NCT00712699|Placebo
497747|NCT00712699|Mixed Amphetamine Salts
497748|NCT00712673|hyperglycemia, GLP-1, metformin
497749|NCT00712660|prevention
497750|NCT00712660|relapse
497751|NCT00712660|schizophrenia
497752|NCT00712634|cytomegalovirus infection
497753|NCT00712621|Genetics Home Reference related topics
497754|NCT00712621|breast cancer
497755|NCT00712621|breast cancer related to depression
497756|NCT00712621|Condition
497757|NCT00712621|Stage I-IV Carcinoma of Breast
497758|NCT00712608|Term
497759|NCT00712608|Infant
497760|NCT00712608|Formula
497761|NCT00712595|Uterine fibroids
497762|NCT00712595|mifepristone
497763|NCT00712595|antiprogestins
497764|NCT00712582|Non-Hodgkin
497765|NCT00712582|Lymphoma
497766|NCT00712582|Rituximab
497767|NCT00712582|Cyclophosphamide
497768|NCT00712582|Doxorubicin
497769|NCT00712582|Vincristine
497770|NCT00712582|ifosfamide
497771|NCT00712582|etoposide
497772|NCT00712582|carboplatin
497773|NCT00712582|stem cell transplant
497774|NCT00712582|08-026
497775|NCT00712569|Communication
497776|NCT00712569|Internet
497777|NCT00712569|Physician
497778|NCT00712569|Patient
497779|NCT00712569|08-079
497780|NCT00712556|stage III adult Burkitt lymphoma
497781|NCT00712556|stage III adult diffuse large cell lymphoma
497782|NCT00712556|stage III adult diffuse mixed cell lymphoma
497783|NCT00712556|stage III adult diffuse small cleaved cell lymphoma
497784|NCT00712556|stage III adult immunoblastic large cell lymphoma
497785|NCT00712556|stage III adult lymphoblastic lymphoma
497786|NCT00712556|stage III grade 1 follicular lymphoma
497787|NCT00712556|stage III grade 2 follicular lymphoma
497788|NCT00712556|stage III grade 3 follicular lymphoma
497789|NCT00712556|stage III mantle cell lymphoma
497790|NCT00712556|stage III marginal zone lymphoma
497791|NCT00712556|stage III small lymphocytic lymphoma
497792|NCT00712556|stage IV adult Burkitt lymphoma
497793|NCT00712556|stage IV adult diffuse large cell lymphoma
497794|NCT00712556|stage IV adult diffuse mixed cell lymphoma
497795|NCT00712556|stage IV adult diffuse small cleaved cell lymphoma
497796|NCT00712556|stage IV adult immunoblastic large cell lymphoma
497797|NCT00712556|stage IV adult lymphoblastic lymphoma
497798|NCT00712556|stage IV grade 1 follicular lymphoma
497799|NCT00712556|stage IV grade 2 follicular lymphoma
497800|NCT00712556|stage IV grade 3 follicular lymphoma
497801|NCT00712556|stage IV mantle cell lymphoma
497802|NCT00712556|stage IV marginal zone lymphoma
498289|NCT00710853|Tai chi
497803|NCT00712556|stage IV small lymphocytic lymphoma
497804|NCT00712556|recurrent adult Burkitt lymphoma
497805|NCT00712556|recurrent adult diffuse large cell lymphoma
497806|NCT00712556|recurrent adult diffuse mixed cell lymphoma
497807|NCT00712556|recurrent adult diffuse small cleaved cell lymphoma
497808|NCT00712556|recurrent adult immunoblastic large cell lymphoma
497809|NCT00712556|recurrent adult lymphoblastic lymphoma
497810|NCT00712556|recurrent childhood large cell lymphoma
497811|NCT00712556|recurrent childhood lymphoblastic lymphoma
497812|NCT00712556|recurrent childhood small noncleaved cell lymphoma
497813|NCT00712556|recurrent cutaneous T-cell non-Hodgkin lymphoma
497814|NCT00712556|recurrent grade 1 follicular lymphoma
497815|NCT00712556|recurrent grade 2 follicular lymphoma
497816|NCT00712556|recurrent grade 3 follicular lymphoma
497817|NCT00712556|recurrent mantle cell lymphoma
497818|NCT00712556|recurrent marginal zone lymphoma
497819|NCT00712556|recurrent small lymphocytic lymphoma
497820|NCT00712556|recurrent mycosis fungoides/Sezary syndrome
497821|NCT00712556|nodal marginal zone B-cell lymphoma
497822|NCT00712556|splenic marginal zone lymphoma
497823|NCT00712556|NC stage II adult immunoblastic large cell lymphoma
497824|NCT00712556|NC stage II adult lymphoblastic lymphoma
497825|NCT00712556|NC stage II grade 1 follicular lymphoma
497826|NCT00712556|NC stage II grade 2 follicular lymphoma
497827|NCT00712556|NC stage II grade 3 follicular lymphoma
497828|NCT00712556|NC stage II mantle cell lymphoma
497829|NCT00712556|NC stage II marginal zone lymphoma
497830|NCT00712556|NC stage II small lymphocytic lymphoma
497831|NCT00712543|constipation
497832|NCT00712543|laxative
497833|NCT00712543|lactulose
497834|NCT00712543|Kristalose®
497835|NCT00712530|HIV
497836|NCT00712530|Vaccine
497837|NCT00712530|Immune Therapy
497838|NCT00712530|DermaVir
497839|NCT00712517|postoperative pain
497840|NCT00712517|Piritramid
497841|NCT00712517|propofol
497842|NCT00712517|sevoflurane
497843|NCT00712517|varicose vein
497844|NCT00712517|Anesthesia
497845|NCT00712504|advanced solid tumors, non small cell lung cancer, pulmonary neoplasms, sunitinib (SUTENT), docetaxel (Taxotere), Angiogenesis Inhibitors
497846|NCT00712491|wet AMD
497847|NCT00712491|CNV
497848|NCT00712465|Atrial fibrillation
497849|NCT00712465|interaction
497850|NCT00712465|pharmacokinetic
497851|NCT00712452|fertility
497852|NCT00712452|chemotherapy
497853|NCT00712439|DPN,
497854|NCT00712439|Diabetic
497855|NCT00712439|Peripheral
497856|NCT00712439|Neuropathy
497857|NCT00712439|Painful
497858|NCT00712426|Huntington's disease
497859|NCT00712426|Creatine
497860|NCT00712426|Mitochondrial Dysfunction
497861|NCT00712426|Total Functional Capacity
497862|NCT00712426|UHDRS
497863|NCT00712413|Helicobacter pylori infection
497864|NCT00712413|Quadruple therapy
497865|NCT00712413|Safety
497866|NCT00712413|Efficacy
497867|NCT00712413|Tolerability
497868|NCT00712413|BID dosing
497869|NCT00712400|Latanoprost
497870|NCT00712400|Choroidal Blood Flow
497871|NCT00712400|Intraocular Pressure
497872|NCT00712374|Malaria
497873|NCT00712374|All causes mortality
497874|NCT00712374|Cost effectiveness
497875|NCT00712361|Invasive
497876|NCT00712361|Non-Invasive
497877|NCT00712361|Peripheral blood parameters
497878|NCT00712361|Finger mounted device
497879|NCT00712361|Blood tissue
497880|NCT00712361|Tissue color distribution
497881|NCT00712361|Accuracy
497882|NCT00712361|Tissue pigmentation
497883|NCT00712361|pH
497884|NCT00712361|Hemoglobin
497885|NCT00712361|Hematocrit
497886|NCT00712361|SpO2
497887|NCT00712361|Blood pressure
497888|NCT00712361|Pulse
497889|NCT00712361|CO2
497890|NCT00712348|Gaucher disease
497891|NCT00712348|imiglucerase
497892|NCT00712348|glucocerebrosidase
497893|NCT00712348|enzyme replacement therapy
497894|NCT00712348|lysosomal storage disorder
497895|NCT00712335|asthmatics
497896|NCT00712335|smokers
497897|NCT00712335|inhaled corticosteroids
497898|NCT00712335|leukotriene receptor antagonists
497899|NCT00712322|Pediatric, Children, Urodynamics, Oral Suspension, Overactive bladder, Dose-finding, Neurogenic Detrusor Overactivity, Meningomyelocele, Spinal cord injury
497900|NCT00712309|atherosclerotic
497901|NCT00712309|lesions
497902|NCT00712296|Asthma
497903|NCT00712296|alternative medicine
497904|NCT00712296|complementary medicine
497905|NCT00712296|herbal therapy
497906|NCT00712283|fitness to drive
497907|NCT00712283|operate machines
497908|NCT00712283|To determine the fitness to drive and operate machines.
497909|NCT00712270|Schizophrenia
497910|NCT00712270|Antipsychotic drug treatment response
497911|NCT00712270|Risperidone
497912|NCT00712270|Aripiprazole
497913|NCT00712270|Fallypride
497914|NCT00712270|Positron emission tomography
497915|NCT00712270|Magnetic Resonance Imaging
497916|NCT00712270|Dopamine D2 Receptors
497917|NCT00712257|treatment of superficial femoral artery instent restenosis
497918|NCT00712244|Discovisc
497919|NCT00712244|Ophthalmic Viscosurgical Device
497920|NCT00712231|pseudophakic
497921|NCT00712231|anterior chamber depth
497922|NCT00712231|Pentacam
497923|NCT00712218|Ovarian cancer, FIGO stage IIB-IV
497924|NCT00712205|Asthma
497925|NCT00712205|Vitamin D
497926|NCT00712192|coronary artery bypass grafting
497927|NCT00712192|endoscopic vein harvest
497928|NCT00712192|saphenous vein
497929|NCT00712192|endothelial cells
497930|NCT00712192|eNOS
497931|NCT00712192|ET-1
497932|NCT00712179|Stroke
497933|NCT00712179|walking
497934|NCT00712179|Treadmill
497935|NCT00712179|body weight support system
497936|NCT00712166|cystic fibrosis
497937|NCT00712166|pseudomonas aeruginosa
497938|NCT00712166|lung infection
497939|NCT00712166|CFQ-R
497940|NCT00712166|inhaled antibiotic
497941|NCT00712166|aztreonam lysine
497942|NCT00712153|multislice computed tomography
497943|NCT00712153|coronary artery bypass grafting
497944|NCT00712153|Patients
497945|NCT00712153|underwent
497946|NCT00712153|surgeries
497947|NCT00712140|stage IA breast cancer
497948|NCT00712140|stage IB breast cancer
497949|NCT00712140|stage II breast cancer
497950|NCT00712140|stage IIIA breast cancer
497951|NCT00712140|HER2-positive breast cancer
497952|NCT00712127|Body Fat
497953|NCT00712127|Exercise
497954|NCT00712127|Metabolic syndrome
497955|NCT00712127|Obesity
497956|NCT00712127|Nutrition
497957|NCT00712127|Physical Activity
497958|NCT00712127|Weight Loss
497959|NCT00712114|phase I
497960|NCT00712114|safety
497961|NCT00712114|tolerance
497962|NCT00712114|rheumatoid arthritis
497963|NCT00712114|pharmacokinetics
497964|NCT00712114|methotrexate
497965|NCT00712114|anti-inflammatory
497966|NCT00712101|infarction
497967|NCT00712101|intervention
497968|NCT00712101|stent
497969|NCT00712101|abciximab
497970|NCT00712101|platelets
497971|NCT00712088|HIV
497972|NCT00712088|Unsafe Sex
497973|NCT00712088|High Risk Sex
497974|NCT00712088|HIV Prevention
497975|NCT00712088|African-American
497976|NCT00712088|gay
497977|NCT00712088|bisexual
497978|NCT00712088|intervention trial
497979|NCT00712075|Cognitive Behavioral Therapy
497980|NCT00712075|Social Skills Training
497981|NCT00712075|Experience Sampling Method
497982|NCT00712075|Computer-assisted therapy
497983|NCT00712075|schizophrenia
497984|NCT00712062|PCNSL
497985|NCT00712062|Pemetrexed
497986|NCT00712062|Alimta
497987|NCT00712062|Recurrent
497988|NCT00712062|Progressive
497989|NCT00712049|intima-media-thickness
497990|NCT00712049|dyslipidemia
497991|NCT00712049|progression of atherosclerosis
497992|NCT00712049|peripheral artery disease
497993|NCT00712049|major cardiovascular events
497994|NCT00712036|Heroin dependence
497995|NCT00712036|Interim Methadone Treatment
497996|NCT00712036|Counseling
497997|NCT00712023|Hypothermia
497998|NCT00712023|Vascular surgery
497999|NCT00712023|Forced-air warming mattress
498000|NCT00712023|Circulating-water mattress
498001|NCT00712010|Glucose
498002|NCT00712010|Insulin
498003|NCT00711997|H19 gene, plasmid, diphtheria toxin, pancreatic cancer
498004|NCT00711984|renal artery stenosis
498005|NCT00711984|stent
498006|NCT00711984|comparison of treatments
498007|NCT00711984|progression
498008|NCT00711984|atherosclerosis
498009|NCT00711984|peripheral artery disease
498010|NCT00711984|major cardiovascular events
498011|NCT00711958|Chemotherapy associated anemia in cancer patients
498012|NCT00711945|Crohn's disease
498013|NCT00711945|Relapse
498014|NCT00711945|outcomes
498015|NCT00711945|growth
498016|NCT00711932|Ovarian Cancer
498017|NCT00711932|TRA-8
498018|NCT00711932|Monoclonal Antibody
498019|NCT00711932|Tissue Slice Technology
498020|NCT00711906|Malaria
498021|NCT00711906|Pregnancy
498022|NCT00711906|HIV
498023|NCT00711906|Intermittent Preventive Treatment
498024|NCT00711906|Safety
498025|NCT00711906|Efficacy
498026|NCT00711880|Pain
498027|NCT00711880|Peripheral Neuropathy
498028|NCT00711854|Staphylococcal infection
498029|NCT00711841|HELLP syndrome
498030|NCT00711841|dexamethasone
498031|NCT00711841|postpartum period
498032|NCT00711841|class I HELLP syndrome
498033|NCT00711815|Women of the state of Alabama
498034|NCT00711815|CIN 1
498035|NCT00711815|negative biopsy
498036|NCT00711815|normal colposcopy
498037|NCT00711815|HPV
498038|NCT00711802|Complicated
498039|NCT00711802|Skin
498040|NCT00711802|Structure
498041|NCT00711789|Acute renal failure
498042|NCT00711789|Septic shock
498043|NCT00711789|angiotensin II
498044|NCT00711789|neutrophil gelatinase associated lipocalin (NGAL)
498045|NCT00711789|cystatin C
498046|NCT00711776|Aciclovir cream 5%
498047|NCT00711776|Volunteer
498048|NCT00711776|Japanese
498049|NCT00711776|Male
498050|NCT00711776|Bioequivalence
498051|NCT00711763|Preterm Infant
498052|NCT00711763|Parenteral nutrition cycling
498053|NCT00711763|TPN cycling
498054|NCT00711763|Hypercalcuria
498055|NCT00711750|underwent
498056|NCT00711750|specific
498057|NCT00711750|creation
498058|NCT00711750|hospital
498059|NCT00711750|November 2003
498060|NCT00711750|October 2005
498061|NCT00711737|metabolic parameters
498062|NCT00711737|escitalopram
498063|NCT00711737|metabolic syndrome
498064|NCT00711737|antidepressant
498065|NCT00711724|Attention Deficit Hyperactivity Disorder (ADHD)
498066|NCT00711724|Adolescent
498067|NCT00711711|Physical Therapy - Therapeutics - Edema
498068|NCT00711711|Arthroplasty replacement knee
498069|NCT00711711|Treatment outcome
498070|NCT00711685|Topical vancomycin
498071|NCT00711685|mediastinitis
498072|NCT00711685|coronary
498073|NCT00711685|artery
498074|NCT00711685|bypass
498075|NCT00711685|graft
498076|NCT00711685|Patients
498077|NCT00711672|Personal Communication
498078|NCT00711672|Doctor Patient Relations
498079|NCT00711672|Narrative Medicine
498080|NCT00711659|Physical exam
498081|NCT00711659|Pediatric clerkship
498082|NCT00711659|Medical students
498083|NCT00711646|Spasticity
498084|NCT00711646|Multiple Sclerosis
498085|NCT00711633|Premature birth,
498086|NCT00711633|infant,
498087|NCT00711633|infant formula,
498088|NCT00711633|bacterial colonization,
498089|NCT00711633|Bifidobacterium,
498090|NCT00711633|calprotectin
498091|NCT00711620|sepsis
498092|NCT00711620|Immunotherapy
498093|NCT00711620|Thymosin
498094|NCT00711607|pharmacokinetics (PK)
498095|NCT00711607|combined oral contraceptive
498096|NCT00711607|nomegestrol acetate
498097|NCT00711607|estradiol
498098|NCT00711607|NOMAC
498099|NCT00711607|E2
498100|NCT00711607|NOMAC-E2
498101|NCT00711607|pharmacokinetics
498102|NCT00711581|Cholecystectomy
498103|NCT00711581|Cholecystectomy, Laparoscopic
498104|NCT00711581|Laparoscopy
498105|NCT00711568|depression
498106|NCT00711568|magnetic stimulation
498107|NCT00711555|nausea
498108|NCT00711555|vomiting
498109|NCT00711555|multiple days
498110|NCT00711555|chemotherapy
498111|NCT00711555|serotonin receptor antagonist
498112|NCT00711555|quality of life
498113|NCT00711555|therapy
498114|NCT00711555|corticosteroids
498115|NCT00711555|aprepitant
498116|NCT00711555|rescue therapy
498117|NCT00711542|intracoronary progenitor cell therapy
498118|NCT00711542|NSTEMI
498119|NCT00711542|coronary flow reserve
498120|NCT00711542|randomized doubleblind Placebo-controlled trial
498121|NCT00711529|hot flashes
498122|NCT00711529|breast cancer
498123|NCT00711529|Hypnotherapy
498124|NCT00711529|Quality of Life
498125|NCT00711529|Gabapentin
498126|NCT00711503|endogenous insulin production
498127|NCT00711503|C-peptide level
498128|NCT00711503|insulin requirement
498129|NCT00711490|Diabetic Macular Edema
498130|NCT00711490|Diabetic Retinopathy
498131|NCT00711490|Rapamycin
498132|NCT00711490|Sirolimus
498133|NCT00711490|Diabetes
498134|NCT00711477|obesity
498135|NCT00711477|overweight
498136|NCT00711477|magnetic resonance imaging
498137|NCT00711477|naltrexone
498138|NCT00711477|bupropion
498139|NCT00711464|cognition, pharmacology, memory, attention
498140|NCT00711451|systemic vascular resistance
498141|NCT00711451|pregnancy
498142|NCT00711451|scheduled cesarean delivery
498143|NCT00711451|syncytiotrophoblast apoptosis
498144|NCT00711451|continuous wave Doppler
498145|NCT00711438|Breathlessness
498146|NCT00711438|Dyspnoea
498147|NCT00711438|Dyspnea
498148|NCT00711438|Palliative care
498149|NCT00711438|RCT
498150|NCT00711438|Randomised controlled trial
498151|NCT00711438|COPD
498152|NCT00711438|Chronic respiratory disease
498153|NCT00711425|Jaw, Edentulous, Partially (posterior mandible)
498154|NCT00711412|adenocarcinoma of the esophagus
498155|NCT00711412|stage I esophageal cancer
498156|NCT00711412|stage II esophageal cancer
498157|NCT00711412|stage III esophageal cancer
498158|NCT00711412|stage IV esophageal cancer
498159|NCT00711399|Respiratory sounds
498160|NCT00711399|Wheeze
498161|NCT00711399|Cough
498162|NCT00711386|GSK706769,
498163|NCT00711386|CCR5
498164|NCT00711386|Healthy volunteers
498165|NCT00711373|VCA
498166|NCT00711373|composite tissue allotransplantation
498167|NCT00711373|amputation
498168|NCT00711373|Hand
498169|NCT00711360|heart failure
498170|NCT00711360|implantable cardioverter-defibrillator
498171|NCT00711360|intrathoracic impedance
498172|NCT00711360|cardiac resynchronization therapy
498173|NCT00711360|home monitoring
498174|NCT00711347|Discovisc
498175|NCT00711347|Ophthalmic Visco Surgical Device
498176|NCT00711321|Alzheimer
498177|NCT00711321|Morbus Alzheimer
498178|NCT00711321|Vaccine
498179|NCT00711321|Alzheimer Vaccine
498180|NCT00711321|A-beta immunotherapy
498181|NCT00711308|pulmonary embolism
498182|NCT00711308|low molecular weight heparin
498183|NCT00711308|vitamin K antagonist
498184|NCT00711308|Longterm
498185|NCT00711295|Influenza (Pandemic)
498186|NCT00711282|Replacement of non-restorable single tooth/teeth
498187|NCT00711256|Sunscreen
498188|NCT00711256|Application
498189|NCT00711256|Vitamin D
498190|NCT00711256|Sun protection factor
498191|NCT00711256|Clothing
498192|NCT00711243|unspecified adult solid tumor, protocol specific
498193|NCT00711243|adenocarcinoma of the stomach
498194|NCT00711243|stage III gastric cancer
498195|NCT00711243|stage IV gastric cancer
498196|NCT00711230|HIV
498197|NCT00711230|Vaccine
498198|NCT00711230|Immune Therapy
498199|NCT00711230|DermaVir
498200|NCT00711204|Severe
498201|NCT00711204|Alzheimer's Disease
498202|NCT00711191|pancreas cancer; cancer of the pancreas; gemcitabine; chemotherapy; monoclonal antibody; immunotherapy; CD40
498203|NCT00711165|Asthma
498204|NCT00711165|Nitric Oxide
498205|NCT00711165|Exhaled Breath Condensate
498206|NCT00711165|Methacholine Challenge
498207|NCT00711152|diabetes
498208|NCT00711152|protocol-driven structured care
498209|NCT00711152|web-based
498210|NCT00711152|joint asia diabetes evaluation
498211|NCT00711139|Alzheimer
498212|NCT00711139|Morbus Alzheimer
498213|NCT00711139|Alzheimer Vaccine
498214|NCT00711139|Vaccine
498215|NCT00711139|AD
498216|NCT00711139|A-beta immunotherapy
498217|NCT00711126|intravenous,
498218|NCT00711126|tolerability
498219|NCT00711126|pharmacokinetics,
498220|NCT00711126|oral,
498221|NCT00711126|pharmacodynamics,
498222|NCT00711126|safety,
498223|NCT00711126|GW642444,
498224|NCT00711126|inhaled,
498225|NCT00711113|Jaw, Edentulous, Partially (posterior maxilla)
498226|NCT00711100|Smoking cessation
498227|NCT00711100|Oral tobacco products
498228|NCT00711087|Spinal Cord Injury
498229|NCT00711087|Bladder
498230|NCT00711087|Botulinum toxin (BOTOX-A
498231|NCT00711087|Detrusor External Sphincter Dyssynergia
498232|NCT00711074|pharmacokinetics
498233|NCT00711074|mass balance
498234|NCT00711074|radiolabel
498235|NCT00711074|AZD5672
498236|NCT00711048|GERD
498237|NCT00711048|healthy volunteer
498238|NCT00711048|esophagus
498239|NCT00711048|pain
498240|NCT00711035|CMV
498241|NCT00711035|Adenovirus
498242|NCT00711035|EBV
498243|NCT00711035|non-myeloablative transplants
498244|NCT00711035|Prior allogeneic hematopoietic stem cell transplant
498245|NCT00711022|Jaw, Edentulous (maxilla, with poor bone quality and quantity)
498246|NCT00711009|Human Immunodeficiency Virus infection
498247|NCT00710996|AcrySof IQ IOL
498248|NCT00710983|Mortality
498249|NCT00710983|Morbidity
498250|NCT00710983|Growth
498251|NCT00710983|Immunology
498252|NCT00710970|Urinary Bladder Neoplasms
498253|NCT00710970|Previous Chemotherapy
498254|NCT00710970|Tamoxifen
498255|NCT00710970|Anti-tumor activity
498256|NCT00710957|Vitamin D
498257|NCT00710957|Physical Function
498258|NCT00710957|Falls
498259|NCT00710957|Aging
498260|NCT00710957|CHS
498261|NCT00710944|Jaw, Edentulous, Partially (missing/extracted/avulsed teeth in the maxilla within zone 15(4)-25(13))
498262|NCT00710931|Bilateral Cataract
498263|NCT00710931|IOL
498264|NCT00710931|ReSTOR
498265|NCT00710931|Aspheric
498266|NCT00710905|Cataract IOL ReSTOR Aspheric
498267|NCT00710905|Bilateral cataract
498268|NCT00710892|suicide gene-modified allodepleted donor lymphocytes
498269|NCT00710892|given to recipients of haploidentical stem cell transplants
498270|NCT00710892|Stage III
498271|NCT00710892|Stage IV
498272|NCT00710892|Myelodysplastic syndrome
498273|NCT00710892|AML after first relapse
498274|NCT00710892|primary refractory disease
498275|NCT00710892|CML
498276|NCT00710892|Hemophagocytic lymphohistiocytosis (HLH)
498277|NCT00710892|familial hemophagocytic lymphohistiocytosis (FLH)
498278|NCT00710892|viral-associated hemophagocytic syndrome (VAHS)
498279|NCT00710892|Severe chronic active Epstein Barr virus infection (SCAEBV)
498280|NCT00710892|T or NK cell malignancy
498281|NCT00710892|X-linked lymphoproliferative disease (XLP)
498282|NCT00710879|Efficacy
498283|NCT00710866|Influenza Vaccines
498284|NCT00710866|Infant
498285|NCT00710866|Dose-Response Relationship, Immunologic
498286|NCT00710853|Geriatric
498287|NCT00710853|Qi gong
498288|NCT00710853|Yoga
498290|NCT00710853|Geriatric Assessment
498291|NCT00710840|Knee Replacement
498292|NCT00710840|Knee OA
498293|NCT00710840|OA
498294|NCT00710827|NEBIDO,
498295|NCT00710827|Hypogonadism,
498296|NCT00710827|Symptomatic late onset,
498297|NCT00710827|Testosterone deficiency
498298|NCT00710814|Roux-en-Y gastric bypass
498299|NCT00710814|Leptin
498300|NCT00710814|Bariatric surgery
498301|NCT00710814|Overweight after Roux-en-Y gastric bypass surgery
498302|NCT00710801|Hepatitis C Virus
498303|NCT00710801|HCV
498304|NCT00710801|Liver Transplant
498305|NCT00710801|Cyclosporine
498306|NCT00710801|Tacrolimus
498307|NCT00710801|Myfortic
498308|NCT00710788|QT interval
498309|NCT00710788|QT dispersion
498310|NCT00710788|arrhythmias
498311|NCT00710788|death
498312|NCT00710788|TC score
498313|NCT00710775|Aortic valve stenosis
498314|NCT00710775|Heart surgery
498315|NCT00710775|Endovascular techniques
498316|NCT00710749|Lower urinary tract symptoms leading to lower flow rates
498317|NCT00710697|Bladder Cancer
498318|NCT00710697|Breast Cancer
498319|NCT00710697|Colorectal Cancer
498320|NCT00710697|Gastrointestinal Neoplasm
498321|NCT00710697|Head and Neck Cancer
498322|NCT00710697|Lung Cancer
498323|NCT00710697|Ovarian Cancer
498324|NCT00710697|Pancreatic Cancer
498325|NCT00710697|Prostrate Cancer
498326|NCT00710684|Alzheimer's disease cognition SB-742457
498327|NCT00710671|HIV positive
498328|NCT00710671|YMSM
498329|NCT00710671|risk factors
498330|NCT00710671|coping
498331|NCT00710671|identity development
498332|NCT00710671|psychosocial needs
498333|NCT00710658|Internet support
498334|NCT00710658|Tailored information
498335|NCT00710658|Self-management
498336|NCT00710658|Quality of life
498337|NCT00710658|Online messaging
498338|NCT00710658|Online discussion groups
498339|NCT00710645|Multiple Sclerosis
498340|NCT00710645|Spasticity
498341|NCT00710632|cachexia
498342|NCT00710632|lung cancer
498343|NCT00710632|gastrointestinal cancer
498344|NCT00710632|unspecified adult solid tumor, protocol specific
498345|NCT00710632|hematopoietic/lymphoid cancer
498346|NCT00710606|contraceptive ring
498347|NCT00710606|obesity
498348|NCT00710606|pharmacokinetics
498349|NCT00710606|pharmacodynamics
498350|NCT00710606|Pharmacokinetics of the contraceptive ring in obese women.
498351|NCT00710593|Adolescent Medicine Trials Network for HIV/AIDS Interventions
498352|NCT00710593|Highly-active antiretroviral therapy
498353|NCT00710593|Human papillomavirus
498354|NCT00710593|HPV vaccine
498355|NCT00710593|Reaching for Excellence in Adolescent Care and Health
498356|NCT00710593|Merck Research Laboratory
498357|NCT00710593|Telephone Response System
498358|NCT00710567|Heart Failure
498359|NCT00710567|LVAS
498360|NCT00710567|LVAD
498361|NCT00710567|Rotary Pump
498362|NCT00710554|Pain
498363|NCT00710554|Peripheral Neuropathy
498364|NCT00710554|Allodynia
498365|NCT00710541|non invasive ventilation
498366|NCT00710541|COPD
498367|NCT00710541|hypercapnia
498368|NCT00710541|GOLD stage IV
498369|NCT00710528|CLL
498370|NCT00710528|NHL
498371|NCT00710528|AML
498372|NCT00710528|MM
498373|NCT00710528|Phosphatidylinositol 3-kinase
498374|NCT00710515|Melanoma
498375|NCT00710515|Phase I
498376|NCT00710515|AZD6244
498377|NCT00710502|Transvaginal
498378|NCT00710502|NOTES
498379|NCT00710502|Cholecystectomy
498380|NCT00710502|Laparoscopic
498381|NCT00710489|Acne
498382|NCT00710489|Actinic Keratosis
498383|NCT00710489|Dysplastic Nevi
498384|NCT00710489|Eczema
498385|NCT00710489|Psoriasis
498386|NCT00710489|Vitiligo
498387|NCT00710489|Skin Cancer
498388|NCT00710489|Rosacea
498389|NCT00710489|Leg or Foot Ulcers
498390|NCT00710489|Atopic Dermatosis
498391|NCT00710463|COPD
498392|NCT00710463|non invasive ventilation
498393|NCT00710463|pulmonary rehabilitation
498394|NCT00710450|IL13
498395|NCT00710450|leukotriene
498396|NCT00710450|histamine
498397|NCT00710450|IL4
498398|NCT00710450|Must be allergic asthma or allergic rhinitis
498399|NCT00710437|Dexmedetomidine
498400|NCT00710437|Carotid Endarterectomy
498401|NCT00710437|Electroencephalogram
498402|NCT00710424|Pain
498403|NCT00710424|diabetic neuropathy
498404|NCT00710411|humans
498405|NCT00710411|patients
498406|NCT00710411|polytrauma
498407|NCT00710411|complement
498408|NCT00710411|inflammation
498409|NCT00710411|inflammatory response
498410|NCT00710411|biomarkers
498411|NCT00710411|cytokines
498412|NCT00710411|cell surface markers
498413|NCT00710411|apoptosis
498414|NCT00710411|NF-kappaB
498415|NCT00710411|functional polymorphisms
498416|NCT00710411|mesenchymal stem cell
498417|NCT00710411|severity of injury
498418|NCT00710411|ISS
498419|NCT00710411|infections
498420|NCT00710411|systemic inflammatory response syndrome
498421|NCT00710411|SIRS
498422|NCT00710411|sepsis
498423|NCT00710411|severe sepsis
498424|NCT00710411|shock
498425|NCT00710411|organ dysfunctions
498426|NCT00710411|SOFA
498427|NCT00710411|severity of disease
498428|NCT00710411|APACHEII
498429|NCT00710411|SAPSII
498430|NCT00710411|SPAPS3
498431|NCT00710411|length of stay
498432|NCT00710411|wound healing
498433|NCT00710411|outcome
498434|NCT00710411|mortality
498435|NCT00710398|Dairy Products
498436|NCT00710398|Dietary Protein
498437|NCT00710398|Body Composition
498438|NCT00710398|Fat mass loss
498439|NCT00710398|Lean mass gain
498440|NCT00710398|Pre-menopausal Women
498441|NCT00710359|Cobalamin deficiency
498442|NCT00710359|Infant
498443|NCT00710359|Nutrition
498444|NCT00710359|Cobalamin supplementation
498445|NCT00710359|Feeding problems
498446|NCT00710359|Gastrointestinal symptoms
498447|NCT00710346|Leiomyoma
498448|NCT00710346|Uterus
498449|NCT00710346|Fibroids
498450|NCT00710346|Surgical
498451|NCT00710320|Children core temperature,
498452|NCT00710320|Pediatric surgery,
498453|NCT00710320|Anesthesia induction
498454|NCT00710294|Refractory Hypertension
498455|NCT00710294|High Blood Pressure
498456|NCT00710294|Uncontrolled Blood Pressure
498457|NCT00710281|Intracranial Aneurysm
498458|NCT00710281|Subarachnoid arterial aneurysm
498459|NCT00710281|Aneurysm
498460|NCT00710281|Brain Aneurysm
498461|NCT00710281|Cerebral Aneurysm
498462|NCT00710281|Wall Shear Stress(WSS)
498463|NCT00710281|Hemodynamic Stress
498464|NCT00710281|Subarachnoid Hemorrhage(SAH)
498465|NCT00710268|Bevacizumab
498466|NCT00710268|Poly(ADP ribose) polymerases
498467|NCT00710268|Metastatic Solid Tumours
498468|NCT00710268|PARP inhibitor
498469|NCT00710255|Asthma
498470|NCT00710255|Exercise induced bronchospasm
498471|NCT00710255|Hyperpnea induced bronchospasm
498472|NCT00710255|leukotrienes
498473|NCT00710255|adenosine
498474|NCT00710255|exhaled breath condensate
498475|NCT00710242|prolonged labor
498476|NCT00710229|age related macular degeneration
498477|NCT00710229|Ranibizumab-Lucentis
498478|NCT00710229|Bevacizumab-Avastin
498479|NCT00710216|Viral kinetics
498480|NCT00710216|Viral dynamics
498481|NCT00710216|Telbivudine
498482|NCT00710216|Lamivudine
498483|NCT00710203|Dermatosis Papulosa Nigra
498484|NCT00710203|seborrheic keratoses
498485|NCT00710190|Drug Resistant Hypertension
498486|NCT00710190|Refractory Hypertension
498487|NCT00710190|High Blood Pressure
498488|NCT00710190|Baroreflex Hypertension Therapy
498489|NCT00710177|PPHN
498490|NCT00710177|PTGS1
498491|NCT00710177|NSAID
498492|NCT00710151|neurotoxicity
498493|NCT00710151|cognition in survivors
498494|NCT00710151|diagnostic imaging
498495|NCT00710138|Cobalamin deficiency
498496|NCT00710138|Infant
498497|NCT00710138|Nutrition
498498|NCT00710138|Cobalamin supplementation
498499|NCT00710138|Neurodevelopment
498500|NCT00710138|Neurological symptoms
498501|NCT00710112|CLD
498502|NCT00710112|VLBW infants
498503|NCT00710112|Toll like Receptors
498504|NCT00710112|Biomarkers
498505|NCT00710099|iontophoresis
498506|NCT00710099|cutaneous microcirculation
498507|NCT00710099|sildenafil
498508|NCT00710099|Healthy volunteers
498509|NCT00710086|Remifentanil
498510|NCT00710086|Patient-controlled analgesia
498511|NCT00710086|Intravenous analgesia
498512|NCT00710073|Chronic pelvic pain syndrome
498513|NCT00710073|Neuromodulation
498514|NCT00710060|HIV
498515|NCT00710060|Popular Opinion Leader
498516|NCT00710060|POL
498517|NCT00710060|Behavioral Intervention
498518|NCT00710060|STD
498519|NCT00710060|STI
498520|NCT00710060|Community
498521|NCT00710060|Prevention
498522|NCT00710060|International
498523|NCT00710060|Global
498524|NCT00710047|ZD4054
498525|NCT00710047|Zibotentan
498526|NCT00710047|Healthy Volunteers
498527|NCT00710034|Oral Tobacco Products
498528|NCT00710034|Snus
498529|NCT00710034|Smoking Substitution
498530|NCT00710034|Harm Reduction
498531|NCT00710034|Biomarkers of Tobacco Exposure
498532|NCT00710021|Systemic lupus erythematosus
498533|NCT00710021|SLE
498534|NCT00710021|Vitamin D3
498535|NCT00710021|Vitamin D deficiency
498536|NCT00710021|IFN alpha expression
498537|NCT00710008|type 2 diabetes,
498538|NCT00710008|exercise training,
498539|NCT00710008|ATP-synthesis,
498540|NCT00710008|intramyocellular lipids,
498541|NCT00710008|hepatocellular lipids
498542|NCT00710008|first degree relatives of
498543|NCT00710008|patients
498544|NCT00709982|Norgestimate
498545|NCT00709982|Contraceptives, Oral
498546|NCT00709982|Ortho-Cyclen
498547|NCT00709982|Folic Acid
498548|NCT00709982|Ethinyl Estradiol
498549|NCT00709969|Malaria
498550|NCT00709969|co-artemether
498551|NCT00709969|auditory
498552|NCT00709969|Plasmodium falciparum
498553|NCT00709969|marsh fever
498554|NCT00709969|remittent fever
498555|NCT00709969|artemether
498556|NCT00709969|artemisinins
498557|NCT00709969|lumefantrine
498558|NCT00709969|child
498559|NCT00709969|infant
498560|NCT00709969|Africa
498561|NCT00709956|Ventavis
498562|NCT00709956|iloprost
498563|NCT00709956|inhaled treatment
498564|NCT00709956|pulmonary arterial hypertension
498565|NCT00709904|venous thromboprophylaxis
498566|NCT00709904|primary prevention
498567|NCT00709904|orthopedic surgery
498568|NCT00709878|skin rash, lapatinib, cetuximab, erlotinib, panitumumab
498569|NCT00709865|renal insufficiency
498570|NCT00709865|diuretic
498571|NCT00709865|congestive heart failure
498572|NCT00709865|acute decompensated heart failure
498573|NCT00709852|Patients referred for a contrast-enhanced MRI of the CNS
498574|NCT00709852|CNS Imaging
498575|NCT00709839|glucocorticoid
498576|NCT00709839|hydrocortisone
498577|NCT00709839|carbohydrate metabolism
498578|NCT00709839|appetite-regulatory hormones
498579|NCT00709813|Symptom management
498580|NCT00709813|Cancer
498581|NCT00709813|Patient-centered care
498582|NCT00709800|Pandemic Influenza
498583|NCT00709800|Avian Influenza
498584|NCT00709800|DNA Vaccines
498585|NCT00709800|Antibody
498586|NCT00709800|T Cells
498587|NCT00709800|HA/NP/M2
498588|NCT00709787|Epidemiology, hypertension, risk factors, coronary heart disease, patient management, compliance with medication
498589|NCT00708760|web based learning
498590|NCT00708760|moderate sedation
498591|NCT00708747|Immunoglobulins
498592|NCT00708747|inhibitor proteins
498593|NCT00708747|human albumin
498594|NCT00708747|systemic inflammatory response syndrome
498595|NCT00708747|interleukins
498596|NCT00708747|standardized serum-protein solution
498597|NCT00708734|exercise
498598|NCT00708721|hypomethylating therapy
498599|NCT00708721|CML
498600|NCT00708721|myelodysplastic syndromes
498601|NCT00708708|Plaque-type psoriasis
498602|NCT00708695|nurse
498603|NCT00708695|home visits
498604|NCT00708695|pregnancy
498605|NCT00708695|welfare
498606|NCT00708695|child development
498607|NCT00708695|Child Rearing
498608|NCT00708695|Reproductive Behavior
498609|NCT00708695|Risk Reduction Behavior
498610|NCT00708656|IBD
498611|NCT00708656|Colitis
498612|NCT00708656|UC
498613|NCT00708630|yellow fever vaccine
498614|NCT00708630|patient information
498615|NCT00708630|symptom reports
498616|NCT00708630|patient satisfaction
498617|NCT00708617|Liver fibrosis
498618|NCT00708617|Alcoholic liver disease
498619|NCT00708617|Non invasive diagnostic methods
498620|NCT00708617|Transient elastography
498621|NCT00708617|Fibrotest
498622|NCT00708604|Diabetes Mellitus
498623|NCT00708604|Kidney Transplantation
498624|NCT00708604|Islet Transplantation
498625|NCT00708604|Sirolimus/Tacrolimus/MMF-based Immunosuppressive Regimen
498626|NCT00708565|To study the effects of iloprost on hypoxic pulmonary vasoconstriction at high altitude
498627|NCT00708552|Alzheimer's disease
498628|NCT00708552|Cognition
498629|NCT00708552|SB-742457
498630|NCT00709761|Erbb2
498631|NCT00709761|ABRAXANE
498632|NCT00709761|MBC
498633|NCT00709761|first or second line therapy
498634|NCT00709761|Metastatic Breast Cancer
498635|NCT00709761|TYKERB
498636|NCT00709748|Transcutaneous electrical nerve stimulation
498637|NCT00709748|TENS
498638|NCT00709748|Empi
498639|NCT00709748|Electrotherapy
498640|NCT00709748|Back pain
498641|NCT00709748|Lower back pain
498642|NCT00709748|Chronic lower back pain
498643|NCT00709735|stress disorders, post-traumatic; memory; propranolol; psychophysiology
498644|NCT00709722|Lupus nephritis
498645|NCT00709722|Deoxyspergualin
498646|NCT00709722|Immunosuppression
498647|NCT00709709|stenosis
498648|NCT00709709|coronaropathy
498649|NCT00709709|stent
498650|NCT00709709|bypass surgery
498651|NCT00709709|suspect
498652|NCT00709709|known
498653|NCT00709696|Tobacco
498654|NCT00709696|nicotine
498655|NCT00709696|smoking
498656|NCT00709696|varenicline
498657|NCT00709696|human laboratory study
498658|NCT00709696|stress tolerance
498659|NCT00709696|startle response
498660|NCT00709696|cognitive assessment
498661|NCT00709696|progressive ratio
498662|NCT00709670|MSCT
498663|NCT00709670|Echocardiography
498664|NCT00709670|Coronarography
498665|NCT00709670|Acute coronary syndrome without ST segment elevation
498666|NCT00709670|normal ECG
498667|NCT00709670|normal troponin
498668|NCT00709670|Acute
498669|NCT00709657|Age-related macular degeneration
498670|NCT00709657|anti-VEGF
498671|NCT00709644|Ortho Tri-Cyclen Lo
498672|NCT00709644|Contraceptives, Oral
498673|NCT00709644|Norgestimate
498674|NCT00709644|Ethinyl Estradiol
498675|NCT00709644|Folic Acid
498676|NCT00709644|Female Contraception
498677|NCT00709631|Malignant transformation of leg ulcer
498678|NCT00709631|MARJOLIN's ulcer
498679|NCT00709631|Biopsy
498680|NCT00709631|Leg ulcer
498681|NCT00709631|Chronic wound
498682|NCT00709631|Squamous cell carcinoma
498683|NCT00709631|Basal cell carcinoma
498684|NCT00709618|Erbb2
498685|NCT00709618|MBC
498686|NCT00709618|First or Second line therapy
498687|NCT00709618|Metastatic Breast Cancer
498688|NCT00709618|Vinorelbine
498689|NCT00709618|Tykerb
498690|NCT00709605|HIV Negative
498691|NCT00709605|Healthy
498692|NCT00709605|Immunity
498693|NCT00709605|Preventive
498694|NCT00709605|Virus
498695|NCT00709605|Healthy Volunteer
498696|NCT00709605|HV
498697|NCT00709592|total body irradiation
498698|NCT00709592|Allogeneic Peripheral Blood Stem Cell Transplantation
498699|NCT00709592|thymoglobulin
498700|NCT00709579|Patients needing an oral corticotherapy
498701|NCT00709579|Patients needing a topical corticotherapy
498702|NCT00709579|Corticotherapy
498703|NCT00709566|Hip
498704|NCT00709566|osteoarthritis
498705|NCT00709566|exercise
498706|NCT00709566|manual therapy
498707|NCT00709553|ZD4054
498708|NCT00709553|Healthy Volunteers
498709|NCT00709527|AMD
498710|NCT00709514|Oneness
498711|NCT00709514|DCB-WH1
498712|NCT00709514|DCB-WH1-CP001
498713|NCT00709514|chronic
498714|NCT00709514|diabetic
498715|NCT00709514|foot ulcers
498716|NCT00709514|topical ointment
498717|NCT00709501|weight loss
498718|NCT00709501|obesity
498719|NCT00709501|overweight
498720|NCT00709488|Litx™ BPH System
498721|NCT00709488|LS11
498722|NCT00709488|Talaporfin sodium
498723|NCT00709462|Breast cancer
498724|NCT00709462|Colorectal cancer
498725|NCT00709462|Pancreatic cancer
498726|NCT00709462|Bladder cancer
498727|NCT00709462|Ovarian cancer
498728|NCT00709462|Metastatic cancer
498729|NCT00709462|Locally advanced cancer
498730|NCT00709462|Cancer Vaccine
498731|NCT00709462|Vaccine
498732|NCT00709449|Age-related macular degeneration
498733|NCT00709449|Glaucoma
498734|NCT00709436|orthopedic
498735|NCT00709436|ketamine
498736|NCT00709436|pain
498737|NCT00709410|Cholera, Diarrhea, Vaccination, Vaccines
498738|NCT00709397|HIV-1
498739|NCT00709397|drug resistance
498740|NCT00709397|raltegravir
498741|NCT00709397|integrase inhibitor
498742|NCT00709371|obesity
498743|NCT00709371|zonisamide
498744|NCT00709371|bupropion
498745|NCT00709358|bacteria
498746|NCT00709358|fungi
498747|NCT00709358|real time PCR
498748|NCT00709358|adequate antimicrobial therapy
498749|NCT00709358|microbial DNA
498750|NCT00709358|microbial diagnosis
498751|NCT00709345|Antipsychotic Medications
498752|NCT00709345|Behavioral Interventions
498753|NCT00709332|Norgestimate
498754|NCT00709332|Folic Acid
498755|NCT00709332|Ortho-Cyclen
498756|NCT00709332|Female contraception
498757|NCT00709332|Ethinyl Estradiol
498758|NCT00709332|Drug Interactions
498759|NCT00709332|Pharmacokinetics
498760|NCT00709332|Contraceptives, Oral
498761|NCT00709319|Diabetic retinopathy
498762|NCT00709319|Diabetic macular edema
498763|NCT00709319|dme
498764|NCT00709319|vitrectomy
498765|NCT00709293|Ischemia Reperfusion Injury
498766|NCT00709293|Pediatric Heart Transplant
498767|NCT00709293|ATG
498768|NCT00709293|Induction Therapy
498769|NCT00709280|Cystic Fibrosis
498770|NCT00709280|hypertonic saline
498771|NCT00709280|inhaled saline
498772|NCT00709267|Folic Acid
498773|NCT00709267|Chemistry, Analytical
498774|NCT00709267|Administration, Oral
498775|NCT00709267|Infusions, Intravenous
498776|NCT00709267|Biological Availability
498777|NCT00709267|Safety
498778|NCT00709254|AeroLEF
498779|NCT00709254|fentanyl
498780|NCT00709254|pharmacokinetics
498781|NCT00709254|liposome
498782|NCT00709254|encapsulated
498783|NCT00709241|Heart failure
498784|NCT00709241|Psychosocial factors
498785|NCT00709241|Depression
498786|NCT00709241|Patient compliance
498787|NCT00709215|refractory TdT-positive leukemia
498788|NCT00709215|ALL
498789|NCT00709215|AML
498790|NCT00709215|blastic CML
498791|NCT00709189|Pharmacokinetics
498792|NCT00709189|Ethinyl Estradiol
498793|NCT00709189|Drug Interactions
498794|NCT00709189|Norgestimate
498795|NCT00709189|Contraceptives, Oral
498796|NCT00709189|Ortho-Cyclen
498797|NCT00709189|Folic Acid
498798|NCT00709176|Quality of Life
498799|NCT00709176|Randomized Clinical Trial
498800|NCT00709176|Advanced Cancer
498801|NCT00709176|Breast Cancer
498802|NCT00709176|Colorectal Cancer
498803|NCT00709176|Lung Cancer
498804|NCT00709176|Prostate Cancer
498805|NCT00709176|Family caregiver
498806|NCT00709176|cancer survivorship
498807|NCT00709176|coping
498808|NCT00709176|communication
498809|NCT00709176|uncertainty
498810|NCT00709176|support
498811|NCT00709176|depression
498812|NCT00709176|self-efficacy
498813|NCT00709176|benefits of illness
498814|NCT00709176|Caregivers
498815|NCT00709163|Pediatric
498816|NCT00709163|Dilated Cardiomyopathy
498817|NCT00709163|Nesiritide
498818|NCT00709150|Major Depression
498819|NCT00709150|Diabetes
498820|NCT00709150|Hispanics
498821|NCT00709150|Collaborative Depression Care Management
498822|NCT00709137|resistant hypertensions
498823|NCT00709137|spironolactone
498824|NCT00709137|amiloride
498825|NCT00709137|ambulatory blood pressure monitoring
498826|NCT00709124|Respiration, Artificial
498827|NCT00709124|Critical Illness
498828|NCT00709124|Intensive Care Units
498829|NCT00709124|Electric Stimulation Therapy
498830|NCT00709124|Muscle Weakness
498831|NCT00709124|Paresis
498832|NCT00709124|Mechanically
498833|NCT00709124|Ventilated
498834|NCT00709124|Patients
498835|NCT00709124|Admitted
498836|NCT00709124|Medical
498837|NCT00709111|CCR5 antagonist
498838|NCT00709111|CD4 T-cell count
498839|NCT00709111|immune activation
498840|NCT00709111|treatment experienced
498841|NCT00709098|pulmonary arterial hypertension
498842|NCT00709098|inhaled treatment
498843|NCT00709098|inhalation solution
498844|NCT00709098|iloprost
498845|NCT00709098|Ventavis
498846|NCT00709085|single nucleotide polymorphism
498847|NCT00709072|stuttering
498848|NCT00709072|relapse
498849|NCT00709072|Lidcombe Program
498850|NCT00709072|Preschool children
498851|NCT00709059|hepatitis C
498852|NCT00709046|Endoscopic treatment
498853|NCT00709046|Peptic ulcer
498854|NCT00709046|Bleeding
498855|NCT00709046|Thermocoagulation
498856|NCT00709046|Proton pump inhibitors
498857|NCT00709033|refractory
498858|NCT00709033|relapsed
498859|NCT00709033|low
498860|NCT00709033|intermediate-grade
498861|NCT00709033|Non-Hodgkin lymphoma
498862|NCT00709033|Chronic Lymphocytic Leukemia
498863|NCT00709020|cancer survivor
498864|NCT00709020|breast cancer
498865|NCT00708981|Diabetic Nephropathy
498866|NCT00708968|randomized clinical trial
498867|NCT00708968|coping
498868|NCT00708968|quality of life
498869|NCT00708968|family
498870|NCT00708968|family caregiver
498871|NCT00708968|cancer survivorship
498872|NCT00708968|communication
498873|NCT00708968|uncertainty
498874|NCT00708968|support
498875|NCT00708968|family education
498876|NCT00708968|Caregivers
498877|NCT00708955|Evaluation and Treatment
498878|NCT00708955|Eye Diseases
498879|NCT00708942|Cervical intraepithelial neoplasia (CIN)
498880|NCT00708929|Age-related macular degeneration
498881|NCT00708929|Complement factor H
498882|NCT00708929|Choroidal blood flow
498883|NCT00708916|Cutaneous lupus
498884|NCT00708916|Intervention
498885|NCT00708916|Discoid lupus
498886|NCT00708916|Phosphodiesterase 5 inhibitor
498887|NCT00708903|Thorough QTc study
498888|NCT00708890|Substance use disorders
498889|NCT00708890|Self-help groups
498890|NCT00708890|Twelve Step groups
498891|NCT00708877|cancer
498892|NCT00708877|cholangiocarcinoma
498893|NCT00708851|psoriasis
498894|NCT00708812|Non-small Cell Lung Cancer
498895|NCT00708812|Endostar
498896|NCT00708812|Paclitaxel
498897|NCT00708812|Carboplatin
498898|NCT00708526|hypercapnia
498899|NCT00708526|hyperpnoea
498900|NCT00708526|accelerated recovery
498901|NCT00708513|Cell Saver
498902|NCT00708513|Liver Tumors
498903|NCT00708513|Liver Cancer
498904|NCT00708513|Surgical Oncology
498905|NCT00708513|Whipple
498906|NCT00708513|Blood Transfusion
498907|NCT00708513|Blood salvage
498908|NCT00708513|cancer surgery
498909|NCT00708513|blood loss
498910|NCT00708500|Treatment failure
498911|NCT00708487|in vitro fertilization
498912|NCT00708487|oxygen concentration
498913|NCT00708487|blastocyst
498914|NCT00708487|live birth
498915|NCT00708487|embryo
498916|NCT00708474|Bone graft
498917|NCT00708474|Bone void filler
498918|NCT00708474|Bone plug
498919|NCT00708474|OsseoFit™
498920|NCT00708474|knee
498921|NCT00708474|bone graft sites in the knee
498922|NCT00708461|obesity
498923|NCT00708461|obesity prevention
498924|NCT00708461|worksite
498925|NCT00708461|environment
498926|NCT00708461|intervention
498927|NCT00708448|NSCLC
498928|NCT00708435|Anticoagulant reversal
498929|NCT00708435|Prothrombin
498930|NCT00708435|Complex
498931|NCT00708435|Concentrate
498932|NCT00708435|Coagulopathy
498933|NCT00708435|induced by
498934|NCT00708435|coumarin
498935|NCT00708435|derivatives
498936|NCT00708435|Kcentra
498937|NCT00708422|Ocular surface health
498938|NCT00708422|OSDI
498939|NCT00708422|TFBUT
498940|NCT00708422|Glaucoma
498941|NCT00708422|Ocular hypertension
498942|NCT00708422|Corneal staining
498943|NCT00708409|Ross operation
498944|NCT00708409|autograft procedure
498945|NCT00708409|pulmonary homograft
498946|NCT00708409|root replacement technique
498947|NCT00708409|subcoronary implantation technique
498948|NCT00708396|Patients
498949|NCT00708396|suffer
498950|NCT00708396|from
498951|NCT00708383|embryo development
498952|NCT00708383|embryo quality
498953|NCT00708383|implantation
498954|NCT00708383|IVF/ICSI outcome
498955|NCT00708383|multiple pregnancy
498956|NCT00708370|Interventional
498957|NCT00708370|Non-drug
498958|NCT00708370|Disease Management Program
498959|NCT00708370|Cardiovascular Risk Control
498960|NCT00708370|Dyslipidemias
498961|NCT00708370|Primary Care Centers
498962|NCT00708357|eNOS Gene Polymorphism
498963|NCT00708357|ocular blood flow
498964|NCT00708331|Cataract
498965|NCT00708331|Extraction
498966|NCT00708331|Intraocular Lens
498967|NCT00708331|Hydrophilic Acrylic
498968|NCT00708318|AeroLEF
498969|NCT00708318|fentanyl
498970|NCT00708318|pharmacokinetic
498971|NCT00708318|liposome
498972|NCT00708318|encapsulated
498973|NCT00708305|toothpaste
498974|NCT00708305|plaque fluid
498975|NCT00708305|fluoride
498976|NCT00708292|AUY922
498977|NCT00708292|Multiple Myeloma
498978|NCT00708292|HSP90 inhibitors
498979|NCT00708292|Phase I/II
498980|NCT00708279|angina pectoris, osteopathic manipulation
498981|NCT00708266|Obesity
498982|NCT00708266|Diabetes
498983|NCT00708266|Non-esterified fatty acids
498984|NCT00708266|Cytokines
498985|NCT00708266|Inflammation
498986|NCT00708266|Subcutaneous fat
498987|NCT00708266|Adipose tissue
498988|NCT00708253|balloon assisted enteroscopy
498989|NCT00708253|single balloon enteroscopy
498990|NCT00708253|double balloon enteroscopy
498991|NCT00708253|insertion depth
498992|NCT00708227|Asthma
498993|NCT00708227|Pharmacogenetics
498994|NCT00708227|Salmeterol
498995|NCT00708227|African American
498996|NCT00708227|White
498997|NCT00708201|ileus
498998|NCT00708201|POI
498999|NCT00708188|Stroke, ischemic, etiology, TOAST, CT, multidetector
499000|NCT00708175|Glucose Metabolism Disorder
499001|NCT00708175|Dysmetabolic Syndrome
499002|NCT00708175|Type II Diabetes
499003|NCT00708175|Diabetes Mellitus
499004|NCT00708175|Lipoatrophic
499005|NCT00708175|Postmenopausal
499006|NCT00708162|HIV
499007|NCT00708162|HIV I
499008|NCT00708162|Treatment Experienced
499009|NCT00708149|lansoprazole, weaning,stress ulcer prophylaxis
499010|NCT00708136|Falls
499011|NCT00708136|elderly
499012|NCT00708136|Balance
499013|NCT00708136|speed of stepping
499014|NCT00708136|Stability
499015|NCT00708136|ELDERLY FALLERS
499016|NCT00708123|remineralization
499017|NCT00708123|enamel
499018|NCT00708123|fluoride
499019|NCT00708123|caries
499020|NCT00708123|in situ
499021|NCT00708110|dose-ranging study
499022|NCT00708110|phase IIa
499023|NCT00708110|integrase inhibitor
499024|NCT00708110|HIV-1 infection
499025|NCT00708097|fluoride
499026|NCT00708097|in situ
499027|NCT00708097|remineralization
499028|NCT00708097|enamel
499029|NCT00708097|caries
499030|NCT00708084|Rabies post-exposure prophylaxis
499031|NCT00708084|Monoclonal antibody
499032|NCT00708058|Implanted cardiac defibrillators
499033|NCT00708058|Congestive Heart Failure
499034|NCT00708058|Emergency Department
499035|NCT00708045|Breast Cancer
499036|NCT00708019|cancer pain
499037|NCT00708019|bone metastasis
499038|NCT00708019|psychoeducational intervention
499039|NCT00708019|nurse coaching
499040|NCT00708019|patient education
499041|NCT00708019|breast cancer
499042|NCT00707993|Glucose Metabolism Disorder
499043|NCT00707993|Dysmetabolic Syndrome
499044|NCT00707993|Type II Diabetes
499045|NCT00707993|Diabetes Mellitus
499046|NCT00707993|Lipoatrophic
499047|NCT00707993|Dyslipidemia
499048|NCT00707993|Drug Therapy
499049|NCT00707980|Major Depressive Disorder
499050|NCT00707980|Depression
499051|NCT00707980|Melancholia
499052|NCT00707980|Mood Disorder
499053|NCT00707980|Dysthymic Disorder
499054|NCT00707980|Drug Therapy
499055|NCT00707967|Tuberculosis vaccine
499056|NCT00707954|Diabetes
499057|NCT00707954|TA-7284
499058|NCT00707941|Influenza like illness
499059|NCT00707941|Pneumonia
499060|NCT00707941|Bronchiolitis
499061|NCT00707941|Upper respiratory tract illness
499062|NCT00707941|Otitis media
499063|NCT00707941|Viral shedding
499064|NCT00707941|Nasopharyngeal wash
499065|NCT00707941|Viral culture
499066|NCT00707941|PCR
499067|NCT00707928|retained placenta
499068|NCT00707915|aged
499069|NCT00707915|benzodiazepines
499070|NCT00707915|hypnotics
499071|NCT00707915|cognition
499072|NCT00707915|posture
499073|NCT00707902|Sore throats,
499074|NCT00707902|Pharyngitis
499075|NCT00707902|Acute
499076|NCT00707876|Peripheral arterial disease (PAD); Magnetic Resonance Angiography (MRA); Magnetic Resonance Imaging (MRI), imaging agent or biomarker
499077|NCT00707863|Escitalopram
499078|NCT00707863|Lexapro
499079|NCT00707863|fMRI
499080|NCT00707863|pictures
499081|NCT00707850|Hepatitis C
499082|NCT00707850|Thalassemia
499083|NCT00707850|Pegasys
499084|NCT00707850|Ribavirin
499085|NCT00707824|pruritus
499086|NCT00707824|epidural morphine
499087|NCT00707811|Dyspnea
499088|NCT00707811|Shortness of Breath
499089|NCT00707811|Trouble Breathing
499090|NCT00707811|ST2
499091|NCT00707811|IL-33
499092|NCT00707798|Young adults
499093|NCT00707798|Pneumococcal vaccine,
499094|NCT00707798|Streptococcus pneumoniae,
499095|NCT00707785|vitamin A
499096|NCT00707785|Treatment
499097|NCT00707785|neonates
499098|NCT00707785|newborn
499099|NCT00707785|sepsis
499100|NCT00707785|necrotizing enterocolitis
499101|NCT00707785|meningitis
499102|NCT00707785|pneumonia
499103|NCT00707772|Hepatitis C
499104|NCT00707772|Hemophilia
499105|NCT00707772|Pegasys
499106|NCT00707772|Ribavirin
499107|NCT00707759|Pediatric renal transplantation,Bone metabolism (DXA-pQCT)
499108|NCT00707759|mRNAFOXP3/IL-17,Steroid withdrawal
499109|NCT00707746|statin intolerant
499110|NCT00707746|hypercholesterolemia
499111|NCT00707707|breast cancer
499112|NCT00707707|triple negative
499113|NCT00707707|metastatic
499114|NCT00707694|95 years of age and older
499115|NCT00707681|microbio, MS-20, Hepatoma, Advanced Hepatocellular Carcinoma
499116|NCT00707668|Diabetes
499117|NCT00707668|metabolic syndrome
499118|NCT00707668|dyslipidemia
499119|NCT00707668|osteoporosis
499120|NCT00707642|West Nile Virus
499121|NCT00707642|West Nile Vaccine
499122|NCT00707642|West Nile virus disease
499123|NCT00707642|Hawaii Biotech
499124|NCT00707629|type 1 diabetes
499125|NCT00707629|neurocognitive measures
499126|NCT00707629|behavioral measures
499127|NCT00707603|Insulin resistance
499128|NCT00707603|Liver fat
499129|NCT00707603|Muscle fat
499130|NCT00707603|Abdominal fat
499131|NCT00707603|Cytokines
499132|NCT00707577|Worksite Wellness
499133|NCT00707577|Weight loss and maintenance
499134|NCT00707577|Physical Activity
499135|NCT00707577|Health and Fitness interventions
499136|NCT00707577|Healthy eating
499137|NCT00707577|Weight loss
499138|NCT00707577|Maintenance programs
499139|NCT00707564|hemostasis
499140|NCT00707564|tooth extractions
499141|NCT00707551|AZD1305
499142|NCT00707551|Verapamil
499143|NCT00707551|Ketoconazole
499144|NCT00707551|pharmacokinetics
499145|NCT00707525|aneuploidies, natural cycle, stimulated cycle, preimplantation genetic diagnosis
499146|NCT00707486|Hemostasis, tooth extractions, third molar
499147|NCT00707473|Carcinoma of Paranasal Sinuses
499148|NCT00707473|Paranasal Sinuses
499149|NCT00707473|Nasal Sinuses
499150|NCT00707473|Nasal Cavity
499151|NCT00707473|Squamous Cell Carcinoma
499152|NCT00707473|Undifferentiated Carcinoma
499153|NCT00707473|Poorly Differentiated Carcinoma
499154|NCT00707473|Docetaxel
499155|NCT00707473|5-Fluorouracil
499156|NCT00707473|Cisplatin
499157|NCT00707473|Platinol®
499158|NCT00707473|Platinol®-AQ
499159|NCT00707460|Diabetes
499160|NCT00707460|Cardiovascular
499161|NCT00707460|Obesity
499162|NCT00707460|First.Nation
499163|NCT00707460|Aboriginal (Health)
499164|NCT00707460|Dietary
499165|NCT00707460|Intervention
499166|NCT00707460|Nutrition
499167|NCT00707460|Traditional (Diet)
499168|NCT00707460|Sandy Lake (Health & Diabetes Project)
499169|NCT00707460|(High) protein
499170|NCT00707460|(High) fibre (er)
499171|NCT00707460|(Low) carbohydrate
499172|NCT00707447|diabetes-prevention
499173|NCT00707447|lifestyle modification
499174|NCT00707447|behavior therapy
499175|NCT00707447|self-management
499176|NCT00707434|Continuous Glucose Monitor
499177|NCT00707434|Medtronic Guardian
499178|NCT00707434|Guardian® blood-sugar monitoring device
499179|NCT00707434|Glucose Monitoring
499180|NCT00707434|Critically Ill
499181|NCT00707434|ICU
499182|NCT00707434|Intensive Care Unit
499183|NCT00707434|Glycemic Excursions
499184|NCT00707434|Glucose Control
499185|NCT00707434|Glucose Testing
499186|NCT00707434|Hyperglycemia
499187|NCT00707434|Hypoglycemia
499188|NCT00707434|Insulin Infusion
499189|NCT00707382|Pharmacogenetics
499190|NCT00707382|Compliance
499191|NCT00707382|Antipsychotic drugs
499192|NCT00707382|Schizophrenia
499193|NCT00707369|Periodontitis
499194|NCT00707369|Mechanical Debridement
499195|NCT00707369|Antibiotics
499196|NCT00707369|Attachment loss
499197|NCT00707369|Randomized controlled trial
499198|NCT00707356|Prostatic disease
499199|NCT00707356|genital neoplasm, male
499200|NCT00707356|Urogenital neoplasm
499201|NCT00707356|Genital disease
499202|NCT00707356|male
499203|NCT00707356|Male urogenital disease
499204|NCT00707356|Neoplasms
499205|NCT00707356|Neoplasm by site
499206|NCT00707356|prostatic neoplasm
499207|NCT00707356|Carcinoma
499208|NCT00707330|oxidative stress
499209|NCT00707330|8-oxo-deoxyguanine
499210|NCT00707330|8-oxodG
499211|NCT00707330|clarithromycin
499212|NCT00707330|malondialdehyde
499213|NCT00707330|mda
499214|NCT00707330|vitamine C
499215|NCT00707330|ascorbic acid
499216|NCT00707317|M. tuberculosis
499217|NCT00707317|latent tuberculosis infection
499218|NCT00707317|Quantiferon assay
499219|NCT00707317|ELISPOT assay
499220|NCT00707317|tuberculin skin test
499221|NCT00707317|immunocompromised patients
499222|NCT00707304|Non Small Cell Lung Cancer
499223|NCT00707304|Talactoferrin
499224|NCT00707304|Dendritic Cell Recruiter and Activator
499225|NCT00707304|Immunomodulatory agent
499226|NCT00707291|contact lens
499227|NCT00707291|normal
499228|NCT00707252|Non-small cell lung cancer
499229|NCT00707252|Erlotinib
499230|NCT00707252|Polyphenon E
499231|NCT00707252|Tarceva
499232|NCT00707252|Advanced Non-small Cell Lung Cancer Stage IIIb or IV
499233|NCT00707239|Hospital-acquired pneumonia
499234|NCT00707239|Ventilator-associated pneumonia
499235|NCT00707226|Laser Doppler flowmetry
499236|NCT00707226|Choroidal blood flow
499237|NCT00707226|Fundus pulsation amplitude
499238|NCT00707226|Intraocular Pressure
499239|NCT00707200|severe malarial anemia (SMA)
499240|NCT00707200|cerebral malarial (CM)
499241|NCT00707200|lactic acidosis
499242|NCT00707200|hyperparasitemia
499243|NCT00707200|respiratory distress
499244|NCT00707200|hypoxia
499245|NCT00707200|death
499246|NCT00707200|transfusion
499247|NCT00707187|systemic sclerosis
499248|NCT00707187|scleroderma
499249|NCT00707187|raynaud phenomenon
499250|NCT00707174|Lentigo Maligna
499251|NCT00707148|pertussis, diptheria, tetanus, vaccine, Tdap
499252|NCT00707122|serum albumin, severe sepsis, septic shock, fluid therapy, hypoalbuminemia, critically ill
499253|NCT00707083|untreated childhood acute lymphoblastic leukemia
499254|NCT00707083|childhood acute lymphoblastic leukemia in remission
499255|NCT00707083|B-cell childhood acute lymphoblastic leukemia
499256|NCT00707083|T-cell childhood acute lymphoblastic leukemia
499257|NCT00707070|psoriasis
499258|NCT00707070|acitretin
499259|NCT00707070|efalizumab
499260|NCT00707031|hyperglycemia, GLP-1, metformin
499261|NCT00707005|antibiotic susceptibility
499262|NCT00707005|bacterial flora
499263|NCT00707005|fluoroquinolone
499264|NCT00707005|LASIK
499265|NCT00707005|refractive surgery
499266|NCT00706992|MART-1 Peptide
499267|NCT00706992|Melanoma
499268|NCT00706992|Adjuvant Therapy
499269|NCT00706992|Gene Therapy
499270|NCT00706992|T Cell Persistence
499271|NCT00706979|smoking
499272|NCT00706979|smoking cessation
499273|NCT00706979|nicotine replacement therapy
499274|NCT00706966|adenocarcinoma of the prostate
499275|NCT00706966|stage IIB prostate cancer
499276|NCT00706966|stage IIA prostate cancer
499277|NCT00706966|benign prostatic hyperplasia
499278|NCT00706953|pegylated liposomal doxorubicin
499279|NCT00706953|VELCADE
499280|NCT00706953|DOXIL
499281|NCT00706953|relapsed
499282|NCT00706953|Multiple Myeloma
499283|NCT00706940|dry eye
499284|NCT00706940|Optical coherence tomography
499285|NCT00706927|xalacom
499286|NCT00706927|combigan
499287|NCT00706927|ocular blood flow
499288|NCT00706914|Airflow Obstruction, Chronic
499289|NCT00706914|Chronic Airflow Obstruction
499290|NCT00706914|Chronic Obstructive Pulmonary Disease
499291|NCT00706914|Chronic Obstructive Airway Disease
499292|NCT00706914|Chronic Obstructive Lung Disease
499293|NCT00706914|COPD
499294|NCT00706914|COAD
499295|NCT00706901|MI
499296|NCT00706901|IHMD
499297|NCT00706888|Reduction of cardiovascular factor of risk
499298|NCT00706875|GTD survivors
499299|NCT00706875|questionnaires
499300|NCT00706875|GTD
499301|NCT00706862|Non small cell lung cancer
499302|NCT00706862|Talactoferrin
499303|NCT00706862|Dendritic cell recruiter and activator
499304|NCT00706862|DCRA
499305|NCT00706862|Immunomodulatory agent
499306|NCT00706862|Lactoferrin
499307|NCT00706849|familial hypercholesterolemia
499308|NCT00706836|anxiety
499309|NCT00706836|functional magnetic resonance imaging
499310|NCT00706836|fMRI
499311|NCT00706836|pregabalin
499312|NCT00706836|Lyrica
499313|NCT00706823|Endotracheal Intubation
499314|NCT00706823|Supraglottic Airway
499315|NCT00706810|Cancer
499316|NCT00706810|Brain cancer
499317|NCT00706810|Meningioma
499318|NCT00706797|Moderate Rheumatoid Arthritis
499319|NCT00706784|Healthy women 18-40 years of age
499320|NCT00706771|sodium bicarbonate
499321|NCT00706771|serum neutrophil gelatinase associated lipocalin
499322|NCT00706771|renal impairment
499323|NCT00706771|renal failure
499324|NCT00706771|systemic inflammatory response syndrome
499325|NCT00706771|defined
499326|NCT00706771|by serum NGAL ≥ 100 ng/ml.
499327|NCT00706758|Irritable bowel syndrome
499328|NCT00706758|Patient education
499329|NCT00706745|atherosclerosis
499330|NCT00706745|dietary supplements
499331|NCT00706745|randomised controlled trial
499332|NCT00706745|arterial stiffness
499333|NCT00706745|linoleic acid
499334|NCT00706732|Influenza
499335|NCT00706732|Flu
499336|NCT00706732|A/Wyoming/03/2003
499337|NCT00706732|Alphavirus
499338|NCT00706719|Adult Onset Idiopathic Hypothalamic Hypogonadism (AIHH)
499339|NCT00706719|Secondary hypogonadism
499340|NCT00706719|Semen volume
499341|NCT00706719|Sperm count
499342|NCT00706719|Sperm motility
499343|NCT00706706|sunitinib Phase IV metastatic renal cell carcinoma Chinese
499344|NCT00706693|hypoglycemia
499345|NCT00706693|treatment
499346|NCT00706693|glucose
499347|NCT00706693|sucrose
499348|NCT00706693|fructose
499349|NCT00706654|Aripiprazole
499350|NCT00706654|Intramuscular (IM) depot
499351|NCT00706654|Schizophrenia
499352|NCT00706615|stage IV breast cancer
499353|NCT00706615|recurrent breast cancer
499354|NCT00706602|COPD
499355|NCT00706602|prognosis
499356|NCT00706602|prediction rule
499357|NCT00706602|health-related quality of life
499358|NCT00706602|risk factors
499359|NCT00706602|derivation
499360|NCT00706602|validation
499361|NCT00706602|exacerbation
499362|NCT00706602|mortality
499363|NCT00706602|primary care
499364|NCT00706602|treatment
499365|NCT00706602|decision making
499366|NCT00706589|Chronic Motor Tic disorder
499367|NCT00706589|Chronic Phonic Tic disorder
499368|NCT00706589|Tourette's disorder
499369|NCT00706589|Aripiprazole
499370|NCT00706589|Abilify
499371|NCT00706589|Children
499372|NCT00706589|Adolescent
499373|NCT00706576|Hepatocellular cancer
499374|NCT00706576|HCC
499375|NCT00706576|Opioid growth factor
499376|NCT00706576|OGF
499377|NCT00706576|Cirrhosis
499378|NCT00706550|pneumococcal polysaccharide vaccine
499379|NCT00706537|Pharmacokinetic safety NASH patients
499380|NCT00706511|OSA
499381|NCT00706511|Diabetes
499382|NCT00706511|Metabolism
499383|NCT00706511|Gender
499384|NCT00706485|Y-90 plaque applicator
499385|NCT00706485|dural brachytherapy
499386|NCT00706446|Asthma
499387|NCT00706446|Pharmacogenetics
499388|NCT00706446|Beta agonists
499389|NCT00706446|salmeterol
499390|NCT00706446|formoterol
499391|NCT00706446|tiotropium
499392|NCT00706446|beta adrenergic receptor
499393|NCT00706446|single nucleotide polymorphism
499394|NCT00706433|Photodynamic Therapy
499395|NCT00706420|Diabetes Mellitus
499396|NCT00706420|Islet Transplantation Alone
499397|NCT00706420|Glucocorticoid-free Immunosuppressive Regimen
499398|NCT00706394|Powerlink
499399|NCT00706394|34mm
499400|NCT00706394|Abdominal Aortic Aneurysm
499401|NCT00706394|EVAR
499402|NCT00706381|Deiodinase
499403|NCT00706381|Bile Acids
499404|NCT00706381|Cholecystokinin
499405|NCT00706381|Thyroid Hormones
499406|NCT00706381|Energy Expenditure
499407|NCT00706381|Health Volunteer
499408|NCT00706381|HV
499409|NCT00706368|Sexually transmitted infections
499410|NCT00706368|Acceptability
499411|NCT00706368|Adolescent vaginitis
499412|NCT00706342|Adult Refractory Immune Thrombocytopenic Purpura (ITP)
499413|NCT00706329|Minimally invasive surgery
499414|NCT00706329|Umbilical hernia
499415|NCT00706329|Infant
499416|NCT00706316|Nasopharygneal Cancer
499417|NCT00706316|Epstein Barr Virus
499418|NCT00706316|(EBV)-Specific Cytotoxic T-Lymphocytes
499419|NCT00706316|Recurrent
499420|NCT00706316|Metastatic
499421|NCT00706316|EBV-Positive Nasopharygneal Cancer
499422|NCT00706303|COPD
499423|NCT00706303|self management
499424|NCT00706290|anxiety
499425|NCT00706290|depression
499426|NCT00706290|quality of life
499427|NCT00706290|psychosocial effects of cancer and its treatment
499428|NCT00706290|advanced cancer
499429|NCT00706290|metastatic cancer
499430|NCT00706290|stage IV cancer
499431|NCT00706290|cognitive behavioral therapy
499432|NCT00706277|forced vital capacity
499433|NCT00706277|forced expired volume in 1 s
499434|NCT00706264|Short cervix
499435|NCT00706264|preterm birth
499436|NCT00706264|arabin pessary
499437|NCT00706238|metastatic,
499438|NCT00706238|Melanoma,
499439|NCT00706238|Antigen-Specific Cancer Immunotherapeutic,
499440|NCT00706238|ASCI
499441|NCT00706238|MAGE-A3
499442|NCT00706238|tumor antigen,
499443|NCT00706199|bone marrow
499444|NCT00706199|volunteers
499445|NCT00706199|antigen expression
499446|NCT00706186|Mild Alzheimer's
499447|NCT00706186|Disease
499448|NCT00706173|Post-traumatic stress disorder
499449|NCT00706173|PTSD
499450|NCT00706173|Cortisol
499451|NCT00706173|hydrocortisone
499452|NCT00706173|pharmacological treatment
499453|NCT00706160|Epilepsy
499454|NCT00706160|Language
499455|NCT00706160|fMRI
499456|NCT00706160|Magnetoencephalogram
499457|NCT00706160|Temporal Lobe Epilepsy
499458|NCT00706160|Partial Epilepsy
499459|NCT00706160|Healthy Volunteer
499460|NCT00706160|HV
499461|NCT00706147|Hereditary ALS
499462|NCT00706147|Hereditary neurological disease
499463|NCT00706147|Lou Gehrig's Disease
499464|NCT00706147|Motor Neuron Disease
499465|NCT00706147|Amyotrophic Lateral Sclerosis (ALS)
499466|NCT00706147|Familial ALS
499467|NCT00706147|Neuromuscular disease
499468|NCT00706147|SOD1 mutation
499469|NCT00706147|Superoxide dismutase
499470|NCT00706147|SOD1 positive ALS
499471|NCT00706147|inherited ALS
499472|NCT00706134|Hypertension
499473|NCT00706134|≥ 65 years
499474|NCT00706134|aliskiren
499475|NCT00706134|placebo
499476|NCT00706134|light meal
499477|NCT00706121|colon cancer
499478|NCT00706121|rectal cancer
499479|NCT00706121|adenomatous polyp
499480|NCT00706095|Cancer
499481|NCT00706095|advanced solid tumors
499482|NCT00706069|Metastatic Breast Cancer
499483|NCT00706069|Vinorelbine oral
499484|NCT00706069|Capecitabine
499485|NCT00706043|Low back pain
499486|NCT00706030|Metastatic breast cancer
499487|NCT00706004|constipation
499488|NCT00706004|cystic fibrosis
499489|NCT00706004|lubiprostone
499490|NCT00706004|Constipation in adults with cystic fibrosis
499491|NCT00705978|Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis
499492|NCT00705965|Coronary artery disease
499493|NCT00705965|depression
499494|NCT00705965|psychotherapy
499495|NCT00705965|randomized controlled trial
499496|NCT00705952|No diabetes medications
499497|NCT00705952|New onset
499498|NCT00705939|Gaucher Disease
499499|NCT00705939|Enzyme replacement therapy
499500|NCT00705926|Acute Infection
499501|NCT00705926|HIV
499502|NCT00705926|HAART
499503|NCT00705926|Treatment Naive
499504|NCT00705913|aortic valve
499505|NCT00705913|heart valve
499506|NCT00705913|valve replacement
499507|NCT00705913|valve disease
499508|NCT00705900|psoriasis
499509|NCT00705887|Ultraviolet Rays
499510|NCT00705887|Motivation
499511|NCT00705887|Health Education
499512|NCT00705887|Randomized Controlled Trial
499513|NCT00705887|Health Knowledge, Attitudes, Practice
499514|NCT00705874|cancer
499515|NCT00705874|advanced cancer
499516|NCT00705874|solid tumors
499517|NCT00705874|lymphoma
499518|NCT00705874|CGC-11047
499519|NCT00705861|Erectile dysfunction
499520|NCT00705861|Diabetes Mellitus
499521|NCT00705861|SK3530
499522|NCT00705848|trachea
499523|NCT00705848|malacia
499524|NCT00705848|stenosis
499525|NCT00705835|Prostate
499526|NCT00705835|ALHYDROGEL
499527|NCT00705835|RS-PSMA
499528|NCT00705809|Epidemiology
499529|NCT00705809|Peripheral T-Cell Lymphoma
499530|NCT00705796|Hypogonadism
499531|NCT00705796|Spermatogenesis
499532|NCT00705796|Quality of Life
499533|NCT00705783|Aripiprazole
499534|NCT00705783|Intramuscular (IM) depot
499535|NCT00705783|Schizophrenia
499536|NCT00705770|Open-Angle Glaucoma
499537|NCT00705770|Intraocular Pressure
499538|NCT00705770|Anecortave Acetate
499539|NCT00705757|periocular skin pigmentation
499540|NCT00705757|Lumigan
499541|NCT00705757|Travatan
499542|NCT00705757|Xalatan
499543|NCT00705757|latanoprost
499544|NCT00705757|bimatoprost
499545|NCT00705757|travoprost
499546|NCT00705731|Colorectal cancer (CRC)
499547|NCT00705731|Colorectal cancer screening
499548|NCT00705731|Colonoscopy
499549|NCT00705731|Fecal occult blood test (FOBT)
499550|NCT00705731|Cost-effectiveness
499551|NCT00705718|Endurant Stent Graft System
499552|NCT00705718|Abdominal Aortic Aneurysms
499553|NCT00705718|Endovascular Treatment
499554|NCT00705705|High-Risk Behavior
499555|NCT00705705|Men Who Have Sex With Men
499556|NCT00705705|HIV Seronegativity
499557|NCT00705692|Tetanus
499558|NCT00705692|Vaccines
499559|NCT00705692|Renal Dialysis
499560|NCT00705692|Levamisole
499561|NCT00705679|Microbicide
499562|NCT00705679|HIV Seronegativity
499563|NCT00705653|cancer
499564|NCT00705653|advanced cancer
499565|NCT00705653|solid tumors
499566|NCT00705653|CGC-11047
499567|NCT00705653|PG-11047
499568|NCT00705640|stage II melanoma
499569|NCT00705640|stage III melanoma
499570|NCT00705640|stage IV melanoma
499571|NCT00705640|ciliary body and choroid melanoma, medium/large size
499572|NCT00705640|ciliary body and choroid melanoma, small size
499573|NCT00705640|conjunctival melanoma
499574|NCT00705640|extraocular extension melanoma
499575|NCT00705640|iris melanoma
499576|NCT00705640|metastatic intraocular melanoma
499577|NCT00705640|recurrent intraocular melanoma
499578|NCT00705627|nasopharyngeal carcinoma
499579|NCT00705627|neoadjuvant chemotherapy
499580|NCT00705627|concurrent chemotherapy
499581|NCT00705627|randomized controlled clinical trials
499582|NCT00705601|Nonrestorative Sleep, Restorative Sleep Questionnaire Refinement
499583|NCT00705575|Essential Hypertension
499584|NCT00705575|Stage II
499585|NCT00705549|Advanced
499586|NCT00705549|NSCLC
499587|NCT00705549|ERCC1
499588|NCT00705549|RRM1
499589|NCT00705549|BCRA1
499590|NCT00705549|Alimta
499591|NCT00705549|Gemcitabine
499592|NCT00705536|rHuPH20
499593|NCT00705536|Hyaluronidase
499594|NCT00705536|Insulin
499595|NCT00705523|alcohol
499596|NCT00705523|treatment
499597|NCT00705523|nicotinic acetylcholine receptors
499598|NCT00705523|pharmacotherapy
499599|NCT00705523|outpatient
499600|NCT00705510|Cyclosporine
499601|NCT00705510|Unstable tear film
499602|NCT00705510|Meibomian gland
499603|NCT00705510|Meibomian gland dysfunction
499604|NCT00705497|Radiofrequency tumor ablation
499605|NCT00705497|RFA
499606|NCT00705458|stress myocardial perfusion imaging
499607|NCT00705458|coronary computed tomography angiography
499608|NCT00705445|Malnutrition
499609|NCT00705445|Diarrhea
499610|NCT00705445|Pneumonia
499611|NCT00705445|Growth
499612|NCT00705445|Zinc Supplements
499613|NCT00705445|Microbiome
499614|NCT00705419|Treatment Experienced
499615|NCT00705354|Sinusitis
499616|NCT00705354|Chronic Sinusitis
499617|NCT00705354|Nasal Surgery
499618|NCT00705354|Functional Endoscopic Sinus Surgery (FESS)
499619|NCT00705354|Enoscopic Sinus Surgery (ESS)
499620|NCT00705341|Normal Controls
499621|NCT00705328|low-income families
499622|NCT00705328|children
499623|NCT00705328|recreation
499624|NCT00705328|family healthy lifestyle
499625|NCT00705328|linkages to community resources
499626|NCT00705328|Families with low incomes
499627|NCT00705328|working poor
499628|NCT00705328|welfare recipients
499629|NCT00705315|breast cancer
499630|NCT00705315|chemotherapy
499631|NCT00705315|biological therapy
499632|NCT00705302|Chronic Obstructive Pulmonary Disease
499633|NCT00705302|Outpatient
499634|NCT00705302|Patient education
499635|NCT00705302|Pulmonary rehabilitation
499636|NCT00705302|Self-management
499637|NCT00705250|Bendamustine HCL
499638|NCT00705237|sinusitis
499639|NCT00705185|Major Depressive Disorder
499640|NCT00705185|Blood Test
499641|NCT00705159|Blepharokeratoconjunctivitis
499642|NCT00705146|Osteoarthritis, carpometacarpal joint
499643|NCT00705146|Thumb splints
499644|NCT00705146|AUSCAN-HI 3.1
499645|NCT00705146|Grip and pinch strength
499646|NCT00705133|pulmonary hypertension
499647|NCT00705133|pulmonary fibrosis
499648|NCT00705133|interstitial lung disease
499649|NCT00705120|Osteogenesis Imperfecta
499650|NCT00705120|Bone Marrow Cell Transplantation
499651|NCT00705120|Mesenchymal Stem Cells
499652|NCT00705120|Stem Cell Transplantation, Mesenchymal
499653|NCT00705094|cardiovascular risk factors
499654|NCT00705094|cardiac function
499655|NCT00705094|VO2peak
499656|NCT00705094|Chemotherapy
499657|NCT00705055|Anthropometry
499658|NCT00705055|face recognition
499659|NCT00705055|genetic disease
499660|NCT00705055|newborn infant
499661|NCT00705016|Randomized treatment
499662|NCT00705016|open-label
499663|NCT00705016|controlled
499664|NCT00705016|recurrent
499665|NCT00705016|metastatic
499666|NCT00705016|SCCHN
499667|NCT00705016|suitable
499668|NCT00705016|for local therapy
499669|NCT00705003|depression
499670|NCT00704990|Attention Deficit Disorder
499671|NCT00704990|Pediatrics
499672|NCT00704990|Attention
499673|NCT00704990|Impulsivity
499674|NCT00704990|Complementary Therapies
499675|NCT00704938|recurrent renal cell cancer
499676|NCT00704938|stage IV renal cell cancer
499677|NCT00704938|recurrent melanoma
499678|NCT00704938|stage IV melanoma
499679|NCT00704938|unspecified adult solid tumor, protocol specific
499680|NCT00704925|Lambert Eaton Myasthenic Syndrome
499681|NCT00704925|3,4 DAP
499682|NCT00704925|3,4 Diaminopyridine
499683|NCT00704912|Polycystic Ovary Syndrome
499684|NCT00704886|dementia
499685|NCT00704860|healthy volunteers treatment resistant major depression hippocampus atrophy MRI serotonin genotyping
499686|NCT00704847|Osteoarthritis, oral salmon calcitonin, treatment, efficacy,
499687|NCT00704847|tolerability
499688|NCT00704834|Multiple Sclerosis
499689|NCT00704834|Relapsing Remitting Multiple Sclerosis
499690|NCT00704834|Chronic Progressive Multiple Sclerosis
499691|NCT00704834|Clinically Isolated Syndrome
499692|NCT00704834|Normal Controls
499693|NCT00704834|Blood Draw
499694|NCT00704821|Cancer
499695|NCT00704821|PTC299
499696|NCT00704821|VEGF
499697|NCT00704821|Angiogenesis
499698|NCT00704821|Post-transcriptional control
499699|NCT00704821|Docetaxel
499700|NCT00704743|Colles fracture treatment
499701|NCT00704743|Displaced fracture of distal radius
499702|NCT00704743|distal radius fracture treatment
499703|NCT00704743|RCT
499704|NCT00704743|Emergency Department
499705|NCT00704743|cast
499706|NCT00704743|splint
499707|NCT00704743|treatment
499708|NCT00704730|Medullary Thyroid Cancer
499709|NCT00704730|MTC
499710|NCT00704704|high risk MDS
499711|NCT00704704|IPSS
499712|NCT00704704|5-AZA-Cytidine
499713|NCT00704704|Thalidomide
499714|NCT00704704|response rate
499715|NCT00704704|cytogenetic response
499716|NCT00704704|QOL questionaries
499717|NCT00704704|INT-2 or High risk MDS
499718|NCT00704678|Chronic Kidney Disease
499719|NCT00704678|hemodialysis
499720|NCT00704678|hyperphosphatemia
499721|NCT00704678|Asian
499722|NCT00704678|patients
499723|NCT00704665|Diffuse Scleroderma
499724|NCT00704665|Skin score
499725|NCT00704639|Head and Neck
499726|NCT00704639|Cetuximab
499727|NCT00704639|Carboplatin
499728|NCT00704639|Radiotherapy
499729|NCT00704626|Multiple Sclerosis
499730|NCT00704626|Autoimmune disease
499731|NCT00704626|Inflammatory disease
499732|NCT00704626|Myasthenia Gravis
499733|NCT00704626|Transverse Myelitis
499734|NCT00704600|Locally advanced rectal cancer
499735|NCT00704600|nelfinavir
499736|NCT00704600|radiosensitivity
499737|NCT00704600|chemoradiation
499738|NCT00704587|cancer occurence
499739|NCT00704587|cancer recurrence
499740|NCT00704587|neo-adjuvant treatment response measurement
499741|NCT00704561|Acute Myocardial Infarction
499742|NCT00704561|Percutaneous Coronary Interventions
499743|NCT00704561|Optical Coherence Tomography
499744|NCT00704561|Thrombus
499745|NCT00704509|Schizophrenia
499746|NCT00704509|Antipsychotic
499747|NCT00704509|Bifeprunox
499748|NCT00704496|Sleep, Pseudoephedrine
499749|NCT00704483|Chronic Kidney Disease
499750|NCT00704483|hemodialysis
499751|NCT00704483|hyperphosphatemia
499752|NCT00704483|hemodiafiltration
499753|NCT00704470|Patient Simulation
499754|NCT00704470|Education, Medical, Continuing
499755|NCT00704470|Education, Medical, Graduate
499756|NCT00704470|Stress
499757|NCT00704457|Interstitial Cystitis
499758|NCT00704457|IC
499759|NCT00704457|Sacral Nerve Stimulation
499760|NCT00704431|SB-480848
499761|NCT00704431|darapladib
499762|NCT00704431|tolerability
499763|NCT00704418|Cataract extraction
499764|NCT00704418|intraocular lens implantation
499765|NCT00704405|hepatitis C
499766|NCT00704392|Solid tumors
499767|NCT00704392|NSCLC
499768|NCT00704379|traumatic brain injury
499769|NCT00704379|TBI
499770|NCT00704379|mood disorders
499771|NCT00704379|anxiety disorders
499772|NCT00704379|community reintegration
499773|NCT00704379|executive function
499774|NCT00704379|sertraline
499775|NCT00704379|diffusion tensor imaging
499776|NCT00704366|Advanced carcinoma
499777|NCT00704327|Cognitive Functions
499778|NCT00704327|Brain Ischemia
499779|NCT00704327|Cerebral Atrophy
499780|NCT00704327|Dementia
499781|NCT00704327|Intracranial atherosclerosis
499782|NCT00704327|Memory impairment
499783|NCT00704314|Insulin resistance
499784|NCT00704314|Statins
499785|NCT00704314|Muscle and liver triglycerides
499786|NCT00704301|Delirium
499787|NCT00704301|Confusion
499788|NCT00704288|GBM
499789|NCT00704288|Malignant gliomas
499790|NCT00704275|dry eye
499791|NCT00704249|HIV infection
499792|NCT00704249|nevirapine
499793|NCT00704249|Treatment Experienced
499794|NCT00704236|Traditional Chinese Treatment
499795|NCT00704210|Low Back Pain
499796|NCT00704171|Elective pulmonary resection via open thoracotomy.
499797|NCT00704158|CR011-vcMMAE
499798|NCT00704158|locally advanced breast cancer
499799|NCT00704158|metastatic breast cancer
499800|NCT00704158|breast cancer
499801|NCT00704158|CuraGen
499802|NCT00704145|Drug Eluting Stents
499803|NCT00704145|Percutaneous Coronary Interventions
499804|NCT00704145|Optical Coherence Tomography
499805|NCT00704119|Rhudex
499806|NCT00704119|pharmacokinetic study
499807|NCT00704106|Hepatitis B
499808|NCT00704106|HBV
499809|NCT00704106|Treatment
499810|NCT00704093|pacing
499811|NCT00704093|perfusion
499812|NCT00704093|oxidative metabolism
499813|NCT00704093|efficiency
499814|NCT00704080|GBM
499815|NCT00704080|Anaplastic glioma
499816|NCT00704067|vocational rehabilitation
499817|NCT00704067|supported employment
499818|NCT00704067|cognitive training
499819|NCT00704067|cognitive remediation
499820|NCT00704067|cognitive rehabilitation
499821|NCT00704067|veterans
499822|NCT00704054|Pediatric
499823|NCT00704054|Solid Tumor
499824|NCT00704054|CNS Tumor
499825|NCT00704054|Lymphoma
499826|NCT00704041|squamous cell carcinoma
499827|NCT00704041|head and neck cancer
499828|NCT00704041|vaccine
499829|NCT00704015|Smoking cessation
499830|NCT00704015|Acute injury
499831|NCT00704015|Musculoskeletal
499832|NCT00704015|Postoperative complications
499833|NCT00704002|neck fracture of the fifth metacarpal
499834|NCT00704002|displacement
499835|NCT00704002|antegrade intramedullary splinting
499836|NCT00704002|conservative treatment
499837|NCT00703989|hyperglycemia
499838|NCT00703989|diabetic complications
499839|NCT00703989|advanced glycation endproducts
499840|NCT00703989|hexosamine pathway
499841|NCT00703989|prostacyclin synthase
499842|NCT00703989|reactive oxygen species
499843|NCT00703976|head and neck cancers
499844|NCT00703963|International normalized ratio (INR)
499845|NCT00703950|Sucking patterns
499846|NCT00703950|preterm infants
499847|NCT00703950|breastfeeding
499848|NCT00703924|cutaneous leishmaniasis topical treatment safety efficacy
499849|NCT00703898|HIV
499850|NCT00703898|nevirapine
499851|NCT00703898|durability
499852|NCT00703898|AIDS
499853|NCT00703898|Treatment Naïve
499854|NCT00703885|functional magnetic resonance imaging
499855|NCT00703885|fMRI
499856|NCT00703885|alprazolam
499857|NCT00703885|anxiety disorders
499858|NCT00703872|Chronic Hepatitis C
499859|NCT00703872|Naive
499860|NCT00703872|Nonresponders
499861|NCT00703872|Interferon
499862|NCT00703872|Patients with Chronic Hepatitis C
499863|NCT00703859|Radiotherapy plus temozolomide plus DCA
499864|NCT00703859|PK profile of DCA
499865|NCT00703859|MGMT promoter methylation status
499866|NCT00703859|Newly diagnosed Glioblastoma multiform tumours
499867|NCT00703846|Phase 4
499868|NCT00703846|Seborrheic
499869|NCT00703846|Ketoconazole
499870|NCT00703846|Dermatitis
499871|NCT00703794|ev3 Neurovascular
499872|NCT00703794|aneurysms
499873|NCT00703794|cerebrovascular
499874|NCT00703794|endovascular
499875|NCT00703794|neurovascular therapies
499876|NCT00703794|RACER
499877|NCT00703794|AXIUM
499878|NCT00703794|The AXIUM Progressive Coil System
499879|NCT00703794|ev3
499880|NCT00703794|MTI
499881|NCT00703794|Micro Therapeutics
499882|NCT00703794|FX detachable coil system
499883|NCT00703794|K060747
499884|NCT00703794|brain diseases
499885|NCT00703781|Cataract extraction with intraocular lens implantation
499886|NCT00703768|Quality of Life
499887|NCT00703768|Androgen Deprivation Therapy
499888|NCT00703768|Goserelin
499889|NCT00703755|Diabetes
499890|NCT00703755|Hypertriglyceridaemia
499891|NCT00703755|Metabolic Syndrome
499892|NCT00703716|mini-invasive
499893|NCT00703716|dynamic screw-plate
499894|NCT00703716|Surfix
499895|NCT00703716|Lock-screw
499896|NCT00703703|Heart rate, overactive bladder
499897|NCT00703677|progressive supranuclear palsy
499898|NCT00703677|corticobasal degeneration
499899|NCT00703677|PSP
499900|NCT00703677|CBD
499901|NCT00703677|lithium
499902|NCT00703677|tau
499903|NCT00703651|Influenza
499904|NCT00703651|Orthomyxoviridae Infection
499905|NCT00703651|Inactivated, Split-virion influenza vaccine
499906|NCT00703651|Intradermal injection
499907|NCT00703651|Adults.
499908|NCT00703612|Diabetes Mellitus
499909|NCT00703612|Adipose-derived stem cells
499910|NCT00703612|Adipose stromal vascular fraction
499911|NCT00703612|Autologous
499912|NCT00703612|Hyperglycemia
499913|NCT00703599|Diabetes Mellitus
499914|NCT00703599|Adipose-derived stem cells
499915|NCT00703599|Adipose stromal vascular fraction
499916|NCT00703599|Autologous
499917|NCT00703599|Insulin-dependence
499918|NCT00703586|Maraviroc
499919|NCT00703586|Treatment Experienced
499920|NCT00703573|Atopic Dermatitis
499921|NCT00703560|HCV
499922|NCT00703560|Genotype 1
499923|NCT00703560|HIV co-infection
499924|NCT00703560|viral kinetics
499925|NCT00703560|HCV quasi-species
499926|NCT00703560|Hepatitis C genotype 1
499927|NCT00703560|HIV Infections
499928|NCT00703547|Depression
499929|NCT00703534|GERD
499930|NCT00703534|Acid Reflux
499931|NCT00703534|Heartburn
499932|NCT00703534|Regurgitation
499933|NCT00703534|non-acid reflux
499934|NCT00703534|PRO measures
499935|NCT00703521|rabies vaccination
499936|NCT00703521|pre-exposure prophylaxis
499937|NCT00703521|rabies virus neutralizing antibody
499938|NCT00703521|Antibody response
499939|NCT00703521|immunologic memory of rabies vaccination
499940|NCT00703521|Safety of rabies vaccination administered in pre-exposure regimens both intramuscular and intradermal routes
499941|NCT00703508|PCOS
499942|NCT00703495|traumatic
499943|NCT00703495|brain injury
499944|NCT00703495|brain regional oxygen saturation (rSO2)
499945|NCT00703495|brain tissue oxygenation (PbtO2)
499946|NCT00703495|cerebral perfusion pressure (CPP)
499947|NCT00703482|Ventricular diastolic Function
499948|NCT00703482|Diabetes
499949|NCT00703469|Hep C
499950|NCT00703456|Functional ankle instability
499951|NCT00703456|Balance training
499952|NCT00703443|Genetics
499953|NCT00703443|Dilated Cardiomyopathy
499954|NCT00703443|Hypertrophic Cardiomyopathy
499955|NCT00703443|Mitochondrial Cardiomyopathy
499956|NCT00703443|Noncompaction Cardiomyopathy
499957|NCT00703443|Restrictive Cardiomyopathy
499958|NCT00703443|Heart Failure
499959|NCT00703430|Alzheimer's disease, agitation, aggression, dementia
499960|NCT00703417|osteoporosis
499961|NCT00703417|diabetes
499962|NCT00703404|Anti-Retroviral Therapy
499963|NCT00703404|HIV
499964|NCT00703404|Virologic Response
499965|NCT00703404|Treatment Naïve
499966|NCT00703391|Chronic
499967|NCT00703391|obstructive
499968|NCT00703391|pulmonary
499969|NCT00703391|lung
499970|NCT00703391|respiratory disease
499971|NCT00703391|tolerability
499972|NCT00703391|placebo-controlled
499973|NCT00703391|pharmacokinetics
499974|NCT00703391|COPD
499975|NCT00703365|Hepatocellular Carcinoma (HCC)
499976|NCT00703352|Transposition of the great arteries.
499977|NCT00703352|Transposition of the great vessels.
499978|NCT00703352|Mustard.
499979|NCT00703352|Senning.
499980|NCT00703339|fibrosis, pulmonary
499981|NCT00703339|hypertension, pulmonary
499982|NCT00703339|exercise, aerobic
499983|NCT00703326|Metastatic breast cancer
499984|NCT00703326|HER2 negative breast cancer
499985|NCT00703326|locally recurrent breast cancer
499986|NCT00703313|Study drug concentration in human tears
499987|NCT00703274|ischemic stroke
499988|NCT00703274|stroke
499989|NCT00703274|cerebrovascular stroke
499990|NCT00703274|cerebrovascular accident
499991|NCT00703274|CVA
499992|NCT00703274|community health services
499993|NCT00703274|community health workers
499994|NCT00703274|navigators
499995|NCT00703274|health education
499996|NCT00703274|barriers to care
499997|NCT00703274|healthcare access
499998|NCT00703274|healthcare disparities
499999|NCT00703248|Human Immunodeficiency Virus (HIV)
500000|NCT00703248|complementary therapies
500001|NCT00703222|high-risk neuroblastoma
500002|NCT00703222|single autologous stem cell rescue
500003|NCT00703209|symptomatic diabetic neuropathy
500004|NCT00703209|diabetes
500005|NCT00703209|burning feet
500006|NCT00703209|Diabetic Neuropathy
500007|NCT00703209|Loss of sensation in the foot
500008|NCT00703209|Neuropathy
500009|NCT00703209|Painful Diabetic Neuropathy
500010|NCT00703196|cervical cancer
500011|NCT00703196|human papilloma virus infection
500012|NCT00703196|low-grade squamous intraepithelial lesion
500013|NCT00703196|high-grade squamous intraepithelial lesion
500014|NCT00703196|atypical squamous cells of undetermined significance
500015|NCT00703196|cervical intraepithelial neoplasia grade 1
500016|NCT00703196|cervical intraepithelial neoplasia grade 2
500017|NCT00703196|cervical intraepithelial neoplasia grade 3
500018|NCT00703144|Pharmacokinetics
500019|NCT00703144|piperacillin/tazobactam.
500020|NCT00703144|Septic patients
500021|NCT00703144|oliguric renal failure
500022|NCT00703144|continuous veno-venous hemodiafiltration.
500023|NCT00703131|fistula
500024|NCT00703131|anal fistula
500025|NCT00703118|Hepatitis C, Chronic
500026|NCT00703118|Telaprevir
500027|NCT00703118|Peg-IFN-alfa-2a
500028|NCT00703118|Ribavirin
500029|NCT00703105|ovarian cancer
500030|NCT00703105|Tregs
500031|NCT00703105|vaccine
500158|NCT00702637|Fatigue
500032|NCT00703105|Recurrent Ovarian Cancer
500033|NCT00703079|Acromegaly
500034|NCT00703079|GH
500035|NCT00703079|IGF-I
500036|NCT00703079|Octreotide-LAR
500037|NCT00703079|Lanreotide
500038|NCT00703079|Transsphenoidal surgery
500039|NCT00703066|Malaria
500040|NCT00703066|Vaccine
500041|NCT00703066|GMZ2
500042|NCT00703066|Safety
500043|NCT00703066|African
500044|NCT00703066|immunogenicity
500045|NCT00703053|influenza, H5N1, vaccine, avian influenza, parent protocol
500046|NCT00703040|Care engagement
500047|NCT00703040|Linkage to care
500048|NCT00703040|HIV Infections
500049|NCT00703027|diabetes mellitus
500050|NCT00703027|care decision
500051|NCT00703027|data mining
500052|NCT00703014|Neonatal outcome
500053|NCT00703014|Congenital malformations
500054|NCT00703014|In-Vitro fertilization
500055|NCT00703014|Controlled ovarian stimulation
500056|NCT00703014|Follow-up
500057|NCT00702988|Neonatal outcome
500058|NCT00702988|Congenital malformations
500059|NCT00702988|In-Vitro Fertilization
500060|NCT00702988|Controlled ovarian stimulation
500061|NCT00702988|Follow-up
500062|NCT00702975|phase II
500063|NCT00702975|NSCLC
500064|NCT00702975|bevacizumab
500065|NCT00702975|erlotinib
500066|NCT00702975|metastatic NSCLC
500067|NCT00702962|lung cancer
500068|NCT00702962|small cell lung cancer
500069|NCT00702949|breast cancer
500070|NCT00702949|hot flashes
500071|NCT00702923|Stage D0 Prostate Cancer
500072|NCT00702923|Rising PSA
500073|NCT00702923|Casodex
500074|NCT00702923|Tremelimumab
500075|NCT00702910|Asthma patients
500076|NCT00702910|Magnesium stearate
500077|NCT00702910|Tolerability
500078|NCT00702910|Safety
500079|NCT00702910|Lactose
500080|NCT00702910|GW642444M
500081|NCT00702910|Pharmacodynamics
500082|NCT00702910|Efficacy
500083|NCT00702910|Pharmacokinetics
500084|NCT00702884|recurrent esophageal cancer
500085|NCT00702884|stage IIIA esophageal cancer
500086|NCT00702884|stage IIIB esophageal cancer
500087|NCT00702884|stage IIIC esophageal cancer
500088|NCT00702884|stage IV esophageal cancer
500089|NCT00702871|Ventilator Associated Pneumonia
500090|NCT00702871|antimicrobial susceptibility pattern
500091|NCT00702871|stress ulcer prophylaxis
500092|NCT00702858|Breast Cancer
500093|NCT00702858|Joint Pain
500094|NCT00702858|Aromatase Inhibitors
500095|NCT00702845|In vitro fertilization
500096|NCT00702845|Pharmacological effects of drugs
500097|NCT00702845|Hormones
500098|NCT00702845|Hormone Substitutes and Hormone Antagonists
500099|NCT00702845|Pharmacological Actions
500100|NCT00702845|Randomized
500101|NCT00702845|Multi-center
500102|NCT00702845|Multi-national
500103|NCT00702845|Double-blind
500104|NCT00702845|Active-controlled
500105|NCT00702845|Equivalence
500106|NCT00702832|Vestibular rehabilitation
500107|NCT00702832|acute vestibular injury
500108|NCT00702832|Dizziness
500109|NCT00702832|Nausea
500110|NCT00702832|Nystagmus
500111|NCT00702832|Daily life activities
500112|NCT00702832|Balance
500113|NCT00702832|physiotherapy
500114|NCT00702819|Pan-Vascular Endothelial Growth Factor Blockade
500115|NCT00702819|Safety
500116|NCT00702806|Pharmacological effects of drugs
500117|NCT00702806|Hormones
500118|NCT00702806|Hormone substitutes and Hormone Antagonists
500119|NCT00702806|Pharmacological Actions
500120|NCT00702806|Randomized
500121|NCT00702806|Multi-center
500122|NCT00702806|Multi-national
500123|NCT00702793|Smoking cessation
500124|NCT00702793|schizophrenia
500125|NCT00702793|schizoaffective
500126|NCT00702793|psychosis
500127|NCT00702793|varenicline
500128|NCT00702793|champix
500129|NCT00702793|chantix
500130|NCT00702793|nicotine dependence
500131|NCT00702780|Alzheimer's disease
500132|NCT00702780|escitalopram
500133|NCT00702780|MRI
500134|NCT00702767|This study was completed in October 2006
500135|NCT00702741|Knee
500136|NCT00702741|Meniscus
500137|NCT00702741|Meniscectomy
500138|NCT00702741|Mesenchymal Stem Cells
500139|NCT00702741|MSCs
500140|NCT00702741|Adult Human Stem Cells
500141|NCT00702741|Osiris
500142|NCT00702741|Chondrogen
500143|NCT00702728|Contrast induced nephropathy
500144|NCT00702728|Furosemide
500145|NCT00702728|Percutaneous coronary interventions
500146|NCT00702728|Saline hydration
500147|NCT00702702|Uterine fibroids
500148|NCT00702702|Anemia
500149|NCT00702689|Skin Sclerosis
500150|NCT00702689|Graft Versus Host Disease
500151|NCT00702676|Healthy Volunteers
500152|NCT00702663|Hepatitis B
500153|NCT00702663|Hepatitis B vaccination
500154|NCT00702663|booster effect
500155|NCT00702663|Taiwan
500156|NCT00702663|young adults
500157|NCT00702637|Traumatic Brain Injury
500159|NCT00702637|Modafinil
500160|NCT00702637|Somnolence
500161|NCT00702624|Neonatal outcome
500162|NCT00702624|Congenital malformations
500163|NCT00702624|In-Vitro fertilization
500164|NCT00702624|Controlled ovarian stimulation
500165|NCT00702624|Follow-up
500166|NCT00702611|Ulcerative Colitis
500167|NCT00702611|Inflammatory Bowel disease
500168|NCT00702611|Steroid dependent
500169|NCT00702611|Adacolumn
500170|NCT00702611|Apheresis
500171|NCT00702611|Granulocyte Monocyte apheresis
500172|NCT00702611|GMA apheresis
500173|NCT00702611|Granulocytapheresis
500174|NCT00702598|Depression
500175|NCT00702598|occupational function
500176|NCT00702598|rating scales
500177|NCT00702598|RCT
500178|NCT00702598|cognitive behaviour therapy
500179|NCT00702598|CBT
500180|NCT00702598|escitalopram
500181|NCT00702598|antidepressants
500182|NCT00702585|Ovulation Induction
500183|NCT00702585|Pharmacological effects of drugs
500184|NCT00702585|Hormones
500185|NCT00702585|Hormone substitutes and Hormone Antagonists
500186|NCT00702585|Pharmacological Actions
500187|NCT00702585|Randomized
500188|NCT00702585|Multi-center
500189|NCT00702585|Multi-national
500190|NCT00702572|Phase I
500191|NCT00702572|Advanced non-small cell lung cancer
500192|NCT00702546|In-vitro fertilization
500193|NCT00702546|Controlled Ovarian Stimulation
500194|NCT00702546|Cumulative pregnancy data
500195|NCT00702546|Follow-up
500196|NCT00702533|Hyper/Hyposecretion
500197|NCT00702533|Gastric Analysis
500198|NCT00702533|Gastric pH
500199|NCT00702533|SmartPill
500200|NCT00702533|ph Monitoring
500201|NCT00702533|Gastric Secretion
500202|NCT00702533|Gastric Acid Output
500203|NCT00702533|Healthy Volunteer
500204|NCT00702533|HV
500205|NCT00702520|Neonatal outcome
500206|NCT00702520|Congenital malformations
500207|NCT00702520|In-Vitro fertilization
500208|NCT00702520|Controlled ovarian stimulation
500209|NCT00702520|Follow-up
500210|NCT00702507|Diaper dermatitis complicated by candidiasis
500211|NCT00702494|placental growth factor
500212|NCT00702494|monoclonal antibody
500213|NCT00702494|Phase I
500214|NCT00702494|solid tumors
500215|NCT00702494|Patients with solid tumors
500216|NCT00702481|Head and Neck Squamous Cell Cancer
500217|NCT00702481|Chemoradiation
500218|NCT00702481|EGFR monoclonal antibody
500219|NCT00702468|Spasticity
500220|NCT00702468|Multiple Sclerosis
500221|NCT00702455|Weight loss maintenance.
500222|NCT00702455|Interactive phone and mail-based intervention.
500223|NCT00702442|Nausea, Vomiting
500224|NCT00702442|Vomiting episodes
500225|NCT00702416|Analgesia, Patient-controlled
500226|NCT00702416|Anesthesia, Regional
500227|NCT00702416|Ultrasound
500228|NCT00702416|Postoperative Pain
500229|NCT00702416|Brachial Plexus
500230|NCT00702364|Attention
500231|NCT00702364|Traumatic Brain INjury
500232|NCT00702364|Atomoxetine
500233|NCT00702364|Strattera
500234|NCT00702351|Infertility
500235|NCT00702351|Pharmacological effects of drugs
500236|NCT00702351|Drug therapy
500237|NCT00702351|Hormones
500238|NCT00702351|GnRH agonist
500239|NCT00702351|RecFSH
500240|NCT00702351|Corifollitropin alfa
500241|NCT00702351|Open-label
500242|NCT00702338|Neonatal outcome
500243|NCT00702338|Congenital malformations
500244|NCT00702338|Ovulation Induction
500245|NCT00702338|Follow-up
500246|NCT00702325|Asthma
500247|NCT00702312|Blood pressure
500248|NCT00702299|stage III ovarian epithelial cancer
500249|NCT00702299|recurrent ovarian epithelial cancer
500250|NCT00702299|peritoneal cavity cancer
500251|NCT00702299|fallopian tube cancer
500252|NCT00702286|Surface acoustic ultrasound
500253|NCT00702286|biofilm formation
500254|NCT00702286|percoutaneous nephrostomy tube
500255|NCT00702286|Patients requiring per coetaneous drainage due to urinary
500256|NCT00702286|tract obstruction
500257|NCT00702286|To evaluate the efficacy of surface acoustic wave in
500258|NCT00702286|reducing pain and improving drainage
500259|NCT00702273|In-vitro fertilization
500260|NCT00702273|Controlled Ovarian Stimulation
500261|NCT00702273|Cumulative pregnancy data
500262|NCT00702273|Follow-up
500263|NCT00702247|Multiple Myeloma - Nonmyeloablative transplantation - Autologous Transplant - Graft versus myeloma
500264|NCT00702247|Newly diagnosed multiple myeloma
500265|NCT00702247|Tandem Auto-Allo Transplant
500266|NCT00702247|Overall survival
500267|NCT00702247|Event free survival
500268|NCT00702247|Disease response
500269|NCT00702234|Neonatal outcome
500270|NCT00702234|Congenital malformations
500271|NCT00702234|In-Vitro fertilization
500272|NCT00702234|Controlled ovarian stimulation
500273|NCT00702234|Follow-up
500274|NCT00702221|high blood pressure
500275|NCT00702221|vaccines
500276|NCT00702208|cervical cytology
500277|NCT00702208|Pap smear
500278|NCT00702208|self-sampling
500279|NCT00702208|abnormal
500280|NCT00702208|normal
500281|NCT00702195|Neonatal outcome
500282|NCT00702195|Congenital malformations
500283|NCT00702195|In-Vitro Fertilization
500284|NCT00702195|Controlled ovarian stimulation
500285|NCT00702195|Follow-up
500286|NCT00702195|Ovulation Induction
500287|NCT00702195|Neonates
500288|NCT00702182|Lung Cancer
500289|NCT00702182|Vinorelbine
500290|NCT00702182|Erlotinib
500291|NCT00702182|Phase 1
500292|NCT00702169|high frequency ventilation monitoring
500293|NCT00702169|lung disease
500294|NCT00702169|Respiratory distress syndrome
500295|NCT00702169|lung barotrauma
500296|NCT00702169|mechanical ventilation
500297|NCT00702169|endotracheal tube displacement
500298|NCT00702169|endotracheal tube occlusion
500299|NCT00702169|one lung intubation
500300|NCT00702156|Heart Failure
500301|NCT00702156|Chronic Obstructive Pulmonary Disease
500302|NCT00702156|Beta-blockers
500303|NCT00702156|Pulmonary Function
500304|NCT00702130|Ventilator Associated Pneumonia
500305|NCT00702104|prostate cancer
500306|NCT00702078|COPD
500307|NCT00702078|home-based treatment
500308|NCT00702078|early intervention
500309|NCT00702065|Multiple Sclerosis Quality of life
500310|NCT00702052|Mantle Cell Lymphoma
500311|NCT00702052|Lymphoma
500312|NCT00702052|B-Cell Lymphoma
500313|NCT00702052|Mantle Zone Lymphoma
500314|NCT00702052|Refractory Lymphoma
500315|NCT00702052|Aggressive Lymphoma
500316|NCT00702052|PILLAR-1
500317|NCT00702026|Irritable Bowel Syndrome
500318|NCT00702026|Hypersensitivity
500319|NCT00702026|Probiotics
500320|NCT00702026|Multispecies
500321|NCT00702013|P-glycoprotein
500322|NCT00702013|lymphocyte
500323|NCT00702013|HIV
500324|NCT00702013|children
500325|NCT00702013|ontogenesis
500326|NCT00702013|Ontogenesis P-gp in human lymphocytes
500327|NCT00702013|Study of the influence of HIV infection
500328|NCT00702013|Antiretroviral treatments on P-gp activity
500329|NCT00702013|Expression in human lymphocytes
500330|NCT00702000|ICU acquired paresis
500331|NCT00701987|Cutaneous Metastatic Melanoma
500332|NCT00701974|Non-inferiority based on efficiency
500333|NCT00701961|Mefloquine-artesunate
500334|NCT00701961|Malaria
500335|NCT00701961|Pregnancy
500336|NCT00701961|Pharmacokinetics
500337|NCT00701961|Sub-Saharan Africa
500338|NCT00701961|P falciparum malaria infection in pregnancy
500339|NCT00701948|Late onset neonatal sepsis
500340|NCT00701948|Nosocomial bacterial infection
500341|NCT00701948|Inflammatory markers
500342|NCT00701948|multiplex dosage
500343|NCT00701935|diabetes mellitus
500344|NCT00701935|Amylin
500345|NCT00701935|Lilly
500346|NCT00701922|lung transplantation
500347|NCT00701922|Bronchiolitis Obliterans
500348|NCT00701922|Epstein-Barr Virus Infections
500349|NCT00701922|Paramyxoviridae Infections
500350|NCT00701922|Herpesviridae
500351|NCT00701909|wound care
500352|NCT00701909|procedural pain intensity
500353|NCT00701909|procedural hyperalgesia
500354|NCT00701909|wound care pain intensity
500355|NCT00701909|wound care hyperalgesia
500356|NCT00701909|Wound care pain quality
500357|NCT00701909|Level of drowsiness
500358|NCT00701909|level of nausea
500359|NCT00701909|Level of vomiting
500360|NCT00701909|Level of hallucinations
500361|NCT00701909|Level of dysphoria
500362|NCT00701896|HIV
500363|NCT00701896|Positive
500364|NCT00701896|Smokers
500365|NCT00701896|Varenicline
500366|NCT00701883|Cholesterol
500367|NCT00701883|Hyperlipidemia
500368|NCT00701883|HDL
500369|NCT00701883|LDL
500370|NCT00701883|Triglycerides
500371|NCT00701883|Dyslipidemia
500372|NCT00701870|NSCLC
500373|NCT00701870|Chemotherapy induced neutropenia
500374|NCT00701870|CIN
500375|NCT00701857|stage III esophageal cancer
500376|NCT00701857|stage IV esophageal cancer
500377|NCT00701844|Aplastic Anemia
500378|NCT00701844|Lymphatic Diseases
500379|NCT00701844|Leukemia
500380|NCT00701844|Leukemia, Lymphoid
500381|NCT00701844|Immunoproliferative Disorders
500382|NCT00701844|Precursor Cell Lymphoblastic Leukemia-Lymphoma
500383|NCT00701844|Anemia
500384|NCT00701844|Quality of Life
500385|NCT00701844|Lymphoproliferative Disorders
500386|NCT00701844|Lymphoma
500387|NCT00701844|Multiple Myeloma
500388|NCT00701805|Secondary hyperparathyroidism
500389|NCT00701805|Hemodialysis
500390|NCT00701805|paricalcitol
500391|NCT00701792|cirrhosis transplantation
500392|NCT00701779|Benign Prostatic Hyperplasia
500393|NCT00701779|Dutasteride
500394|NCT00701779|Tamsulosin
500395|NCT00701753|Pharmacogenetic
500396|NCT00701753|DNA
500397|NCT00701753|RNA
500398|NCT00701753|Antipsychotic
500399|NCT00701753|Olanzapine
500400|NCT00701753|Risperidone
500401|NCT00701753|Quetiapine
500402|NCT00701753|Personalized medicine
500403|NCT00701740|photoaging
500404|NCT00701740|isotretinoin
500405|NCT00701740|profilometry
500406|NCT00701740|digital analysis
500407|NCT00701727|metabolic diseases
500408|NCT00701727|metabolic disorder
500409|NCT00701727|dyslipidemias
500410|NCT00701727|lipid metabolism disorders
500411|NCT00701714|Treatment
500412|NCT00701714|associated
500413|NCT00701714|with CRI
500414|NCT00701688|Mucositis, Oral
500415|NCT00701688|Hematopoietic Stem Cell Transplantation
500416|NCT00701688|Allogeneic Transplantation
500417|NCT00701688|Pharmacokinetics
500418|NCT00701688|Maximum Tolerated Dose
500419|NCT00701675|sertraline
500420|NCT00701675|pharmacotherapy
500421|NCT00701675|geriatric
500422|NCT00701649|mild essential hypertension
500423|NCT00701649|moderate essential hypertension
500424|NCT00701636|Daptomycin
500425|NCT00701636|Antibiotic Prophylaxis
500426|NCT00701636|Pharmacokinetics
500427|NCT00701636|Surgical Wound Infection
500428|NCT00701636|Staphylococcus aureus
500429|NCT00701636|Cardiopulmonary Bypass Surgery
500430|NCT00701623|The intention of this work is to verify the effectiveness and safety of sodium heparin in the treatment of burns of the skin.
500431|NCT00701610|Von Willebramd Factor (VWF)
500432|NCT00701610|All infants born in our hospital since August 2007 ill august 2009 will enter.
500433|NCT00701610|Therombocytopenia, maternal aspirin will be excluded
500434|NCT00701597|ocular blood flow dysregulation, glaucoma, endothelin-1
500435|NCT00701584|Phytoestrogens
500436|NCT00701584|Isoflavones
500437|NCT00701584|Lignans
500438|NCT00701584|Breast cancer survival
500439|NCT00701584|breast cancer recurrence
500440|NCT00701571|Virtual Reality
500441|NCT00701571|Oncology
500442|NCT00701571|Lumbar puncture
500443|NCT00701545|von Willebrand disease
500444|NCT00701545|VWD, Humate-P®
500445|NCT00701545|Infusion volume reduced
500446|NCT00701545|ivr
500447|NCT00701532|Cocaine
500448|NCT00701532|Substance abuse
500449|NCT00701532|Addiction
500450|NCT00701532|Dependence
500451|NCT00701532|Modafinil
500452|NCT00701532|Brain imaging
500453|NCT00701519|CHF,
500454|NCT00701519|Sleep apnea,
500455|NCT00701519|Obstructive sleep apnea,
500456|NCT00701519|Heart failure
500457|NCT00701506|Knee
500458|NCT00701506|Osteoarthritis
500459|NCT00701506|Treatment
500460|NCT00701506|Electrostimulation
500461|NCT00701493|Topiramate
500462|NCT00701493|Topiramate oral liquid
500463|NCT00701493|TOPAMAX Sprinkle capsule
500464|NCT00701493|topiramate capsules
500465|NCT00701480|acne
500466|NCT00701480|skin cleanser
500467|NCT00701480|Hibiscus sabdariffa
500468|NCT00701480|Roselle
500469|NCT00701480|safety
500470|NCT00701480|efficacy
500471|NCT00701467|ICD
500472|NCT00701467|ICD implanted patients
500473|NCT00701454|Thai-muslim
500474|NCT00701454|Thai-HALAL
500475|NCT00701454|Diabetes
500476|NCT00701454|Hypertension
500477|NCT00701454|Hyperlipidemia
500478|NCT00701454|Metabolic syndrome
500479|NCT00701441|sleep apnea,
500480|NCT00701441|oxidative stress
500481|NCT00701428|Hypertension
500482|NCT00701428|Sleep Apnea
500483|NCT00701428|Angiotensin II antagonist
500484|NCT00701428|CPAP
500485|NCT00701415|α-GAL, α-Galactosidase-A, r-hαGAL
500486|NCT00701402|time to lipid-lowering drug implementation
500487|NCT00701402|dyslipidemic patients
500488|NCT00701376|Gastric Bypass surgery
500489|NCT00701376|Hepatic disease
500490|NCT00701376|Hepatic function
500491|NCT00701350|Pregnancy
500492|NCT00701350|Intra-amniotic Infection
500493|NCT00701350|Preterm Birth
500494|NCT00701350|Preterm Premature Rupture of Membranes
500495|NCT00701337|Estrogen Replacement Therapy
500496|NCT00701337|menopausal women
500497|NCT00701311|Prostatitis
500498|NCT00701311|Pelvic pain
500499|NCT00701285|heart failure
500500|NCT00701285|pitavastatin
500501|NCT00701285|pravastatin
500502|NCT00701285|statin
500503|NCT00701259|Frequent heartburn, proton pump inhibitor, lansoprazole
500504|NCT00701259|Treatment of
500505|NCT00701259|over 14 days
500506|NCT00701246|Anemia
500507|NCT00701246|Iron deficiency anemia
500508|NCT00701246|Infants
500509|NCT00701246|Children
500510|NCT00701246|Clinical trials
500511|NCT00701246|Ferrous sulfate
500512|NCT00701246|Folic acid
500513|NCT00701246|Daycare centers
500514|NCT00701246|Anaemia in children
500515|NCT00701246|born at term
500516|NCT00701246|non-twins
500517|NCT00701246|with parental approval for participation in the study
500518|NCT00701246|growth
500519|NCT00701220|Cardiovascular Disease
500520|NCT00701220|Cardiomyopathy
500521|NCT00701220|Heart Disease
500522|NCT00701220|Myocardial Disease
500523|NCT00701220|Myocardial Ischemia
500524|NCT00701207|To determine if nicotine treatment reduces lung inflammation
500525|NCT00701194|placement instability
500526|NCT00701194|disruptive behavior disorders
500527|NCT00701194|school readiness
500528|NCT00701194|developmental delays
500529|NCT00701194|cortisol
500530|NCT00701194|executive functioning
500531|NCT00701194|therapeutic foster care
500532|NCT00701194|prevention
500533|NCT00701194|early intervention
500534|NCT00701181|Phase II
500535|NCT00701181|Prospective
500536|NCT00701181|Randomized
500537|NCT00701181|Diabetic Macular Edema
500538|NCT00701181|PF-04523655
500539|NCT00701181|Laser
500540|NCT00701129|Glycogenesis 2
500541|NCT00701129|Acid
500542|NCT00701129|Maltase
500543|NCT00701129|Deficiency
500544|NCT00701090|Type 2 Diabetes Mellitus
500545|NCT00701090|Non Insulin Dependent
500546|NCT00701077|Brugada syndrome
500547|NCT00701077|Electrophysiological study
500548|NCT00701077|Ion channel blockade
500549|NCT00701064|posttraumatic stress disorder
500550|NCT00701064|phototherapy
500551|NCT00701064|anxiety
500552|NCT00701064|depression
500553|NCT00701064|sleep
500554|NCT00701064|negative ion generator
500555|NCT00701038|Sleep apnea,
500556|NCT00701038|obstructive sleep apnea,
500557|NCT00701038|heart failure,
500558|NCT00701038|CHF
500559|NCT00701025|inflammation in asthmatic and non-asthmatic participants
500560|NCT00701012|low or high ligation
500561|NCT00700986|Electroretinography
500562|NCT00700986|Rheumatoid Arthritis
500563|NCT00700986|Anti-TNF
500564|NCT00700986|Disease Modifying Anti-Rheumatic Drugs (DMARD)
500565|NCT00700973|anger
500566|NCT00700973|psychotherapy, brief
500567|NCT00700973|diagnosis, dual
500568|NCT00700947|Heart Disease
500569|NCT00700947|Mitral Regurgitation
500570|NCT00700947|Heart Valve Disease
500571|NCT00700947|Mitral Valve Insufficiency
500572|NCT00700947|Heart Surgery
500573|NCT00700947|Heart Valve Surgery
500574|NCT00700934|FEV1
500575|NCT00700934|mortality
500576|NCT00700934|Quality of life
500577|NCT00700908|type 2 diabetes
500578|NCT00700908|telephone intervention
500579|NCT00700908|automated
500580|NCT00700882|stage IV melanoma
500581|NCT00700882|acral lentiginous malignant melanoma
500582|NCT00700882|mucosal melanoma
500583|NCT00700882|recurrent melanoma
500584|NCT00700882|stage IIIA melanoma
500585|NCT00700882|stage IIIB melanoma
500586|NCT00700882|stage IIIC melanoma
500587|NCT00700869|Altered level of consciousness
500588|NCT00700869|Tracheal tube withdrawal
500589|NCT00700869|Respiration
500590|NCT00700869|Artificial Respiration
500591|NCT00700869|Physiology
500592|NCT00700856|diabetes
500593|NCT00700856|cardiovascular disease
500594|NCT00700856|pioglitazone
500595|NCT00700856|sulphonylurea
500596|NCT00700856|metformin monotherapy
500597|NCT00700856|hypoglycemic therapy
500598|NCT00700843|bariatric surgery
500599|NCT00700843|long term follow up
500600|NCT00700843|gastric partitioning surgery
500601|NCT00700843|Roux-en-Y gastric bypass surgery
500602|NCT00700843|obesity
500603|NCT00700804|Calcium retention
500604|NCT00700804|dietary protein
500605|NCT00700804|dietary calcium
500606|NCT00700791|Single and bilateral body contouring surgical sites.
500607|NCT00700778|breast cancer
500608|NCT00700778|BRCA1 mutation carrier
500609|NCT00700739|Cervical
500610|NCT00700739|Disc
500611|NCT00700739|Arthroplasty
500612|NCT00700739|Spinal
500613|NCT00700726|blood test
500614|NCT00700726|asthma
500615|NCT00700726|skin test
500616|NCT00700713|Meningitis
500617|NCT00700713|Meningococcemia
500618|NCT00700713|Neisseria meningitidis
500619|NCT00700713|Menactra®
500620|NCT00700700|Congestive Heart Failure
500621|NCT00700700|Cardiac Resynchronization Therapy
500622|NCT00700700|Dyspnea
500623|NCT00700700|Exercise Tolerance
500624|NCT00700687|cardiovascular prophylactic therapy
500625|NCT00700674|EEG entropy
500626|NCT00700674|Elderly
500627|NCT00700674|Decreases
500628|NCT00700674|POCD
500629|NCT00700674|Use of EEG entropy
500630|NCT00700674|Geriatric
500631|NCT00700635|Meningitis; Meningococcal infection, Neisseria meningitidis
500632|NCT00700609|Depression
500633|NCT00700609|Family Therapy
500634|NCT00700609|Adolescents
500635|NCT00700596|Salvia
500636|NCT00700596|SA
500637|NCT00700596|Salvinorin
500638|NCT00700596|Psychotomimetic Effects
500639|NCT00700583|nocturia
500640|NCT00700583|bladder
500641|NCT00700583|urination disorders
500642|NCT00700583|hydrochlorothiazide
500643|NCT00700583|terazosin
500644|NCT00700557|Antibiotic Associated Diarrhea
500645|NCT00700557|probiotics
500646|NCT00700557|treatment
500647|NCT00700544|AML
500648|NCT00700544|elderly patients
500649|NCT00700544|Treatment outcome
500650|NCT00700531|Hemodialysis
500651|NCT00700531|Multiple myeloma
500652|NCT00700531|Cast nephropathy
500653|NCT00700531|Kidney failure
500654|NCT00700518|Raynaud's Syndrome
500655|NCT00700518|Raynaud's Disease
500656|NCT00700518|RP
500657|NCT00700505|Benign Prostatic Hyperplasia
500658|NCT00700505|BPH
500659|NCT00700505|Benign Prostatic Hypertrophy
500660|NCT00700505|Urinary Retention
500661|NCT00700505|Shy Bladder
500662|NCT00700505|Urinary Hesitancy
500663|NCT00700505|Bashful Bladder
500664|NCT00700505|Paruresis
500665|NCT00700492|subfertility
500666|NCT00700492|pregnancy rate
500667|NCT00700492|miscarriage
500668|NCT00700479|vascular endothelium
500669|NCT00700479|nitric oxide
500670|NCT00700479|aldosterone
500671|NCT00700479|vascular biology
500672|NCT00700466|Outcome assessment, patients;
500673|NCT00700466|autonomic nervous system;
500674|NCT00700466|perioperative care;
500675|NCT00700466|adrenergic beta antagonist
500676|NCT00700466|Autonomic regulation
500677|NCT00700466|Perioperative beta-blockade
500678|NCT00700466|outcome
500679|NCT00700440|Radiotherapy
500680|NCT00700440|chemotherapy
500681|NCT00700440|Drug Targeting
500682|NCT00700440|loco-regionally advanced nasopharyngeal carcinoma
500683|NCT00700440|Safety.
500684|NCT00700440|efficacy
500685|NCT00700427|ADHD
500686|NCT00700427|Adult
500687|NCT00700427|long term
500688|NCT00700427|maintenance of response
500689|NCT00700427|Attention Deficit Hyperactivity Disorder
500690|NCT00700388|Chronic bronchitis
500691|NCT00700388|COPD
500692|NCT00700388|Bronchiectasis
500693|NCT00700375|Patients undergoing an emergent coronary procedure
500694|NCT00700362|Complications
500695|NCT00700362|Hyperglycemia
500696|NCT00700362|Insulin infusion
500697|NCT00700349|depression
500698|NCT00700349|stress
500699|NCT00700349|microcredit
500700|NCT00700349|poverty
500701|NCT00700349|South Africa
500702|NCT00700336|malignant pleural mesothelioma
500703|NCT00700336|solid tumors
500704|NCT00700323|ADHD
500705|NCT00700323|ADHD diagnosed children
500706|NCT00700310|Partial onset seizures
500707|NCT00700310|E2007
500708|NCT00700310|perampanel
500709|NCT00700310|refractory partial seizures
500710|NCT00700310|adjunctive therapy
500711|NCT00700310|seizure frequency
500712|NCT00700310|reduction in seizure frequency
500713|NCT00700310|safety
500714|NCT00700310|concomitant AED(s)
500715|NCT00700297|Oral aphthosis
500716|NCT00700297|Genital aphthosis
500717|NCT00700297|Psuedofolliculitis
500718|NCT00700297|Erythem nodusom
500719|NCT00700297|Joint manifestations
500720|NCT00700297|Colchicine
500721|NCT00700284|HIV-I
500722|NCT00700284|Reverse transcriptase inhibitors
500723|NCT00700284|HIV Seronegativity
500724|NCT00700271|Hypertension
500725|NCT00700271|ambulatory blood pressure monitoring
500726|NCT00700245|Obese
500727|NCT00700245|Adults
500728|NCT00700232|genetics
500729|NCT00700232|gene expression
500730|NCT00700232|MDR3
500731|NCT00700232|estrogens
500732|NCT00700232|cholestasis
500733|NCT00700232|pregnancy
500734|NCT00700232|controls
500735|NCT00700219|Preterm Labor
500736|NCT00700219|Preterm Birth
500737|NCT00700219|Intra-amniotic Infection
500738|NCT00700219|Pregnancy
500739|NCT00700219|Women
500740|NCT00700206|Hematology
500741|NCT00700206|MDS
500742|NCT00700206|Myelodysplastic Syndrome
500743|NCT00700206|Low Risk MDS
500744|NCT00700206|Intermediate-1 risk MDS
500745|NCT00700206|Int-1 risk MDS
500746|NCT00700206|Telintra
500747|NCT00700206|ezatiostat hydrochloride
500748|NCT00700206|ezatiostat
500749|NCT00700206|TLK199
500750|NCT00700206|Glutathione
500751|NCT00700206|Glutathione analog
500752|NCT00700206|Glutathione Transferase
500753|NCT00700206|Glutathione Transferase inhibitor
500754|NCT00700206|Glutathione Transferase P1-1 inhibitor
500755|NCT00700206|GSTp1-1 inhibitor
500756|NCT00700206|Apoptosis
500757|NCT00700206|Differentiation
500758|NCT00700206|Enzyme inhibitor
500759|NCT00700167|ANTIGENBEARING DENDRITIC CELLS
500760|NCT00700167|98-098
500761|NCT00700154|Vascular Surgery
500762|NCT00700154|Complications
500763|NCT00700154|Hyperglycemia
500764|NCT00700154|Insulin infusion
500765|NCT00700154|Diabetic ulcers
500766|NCT00700154|Infection
500767|NCT00700141|Tachosil
500768|NCT00700141|thyroid
500769|NCT00700141|parathyroid
500770|NCT00700141|fleece-bound hemostasispathologic processes
500771|NCT00700141|hemorrhage
500772|NCT00700141|thyroid surgery
500773|NCT00700128|headaches
500774|NCT00700128|migraines
500775|NCT00700128|breakthrough bleeding
500776|NCT00700128|breakthrough spotting
500777|NCT00700128|menstrually associated migraines
500778|NCT00700128|breakthrough bleeding or breakthrough spotting
500779|NCT00700115|HAART
500780|NCT00700115|lopinavir/ritonavir
500781|NCT00700115|raltegravir
500782|NCT00700115|HIV/AIDS patients on HAART
500783|NCT00700115|Treatment Experienced
500784|NCT00700089|Attempted suicide
500785|NCT00700089|Assertive intervention
500786|NCT00700089|Prevention
500787|NCT00700089|Treatment
500788|NCT00700076|ORG 25935
500789|NCT00700076|Ketamine
500790|NCT00700076|healthy subjects
500791|NCT00700063|Peplin
500792|NCT00700063|Actinic keratosis
500793|NCT00700063|PEP005
500794|NCT00700050|Cystic Fibrosis
500795|NCT00700050|Sex hormones
500796|NCT00700050|Pseudomonas aeruginosa
500797|NCT00700050|Paediatrics
500798|NCT00700024|Body composition
500799|NCT00700024|Physical activity
500800|NCT00700024|Metabolic syndrome
500801|NCT00700011|Myelodysplastic Syndromes
500802|NCT00699998|ACS
500803|NCT00699985|Psychological Symptoms
500804|NCT00699985|Behcet's Disease
500805|NCT00699972|E2007
500806|NCT00699972|perampanel
500807|NCT00699972|refractory partial seizures
500808|NCT00699972|adjunctive therapy
500809|NCT00699972|seizure frequency
500810|NCT00699972|partial onset seizures
500811|NCT00699972|reduction in seizure frequency
500812|NCT00699972|safety
500813|NCT00699972|concomitant AED(s)
500814|NCT00699959|Coronary patients
500815|NCT00699959|heart failure
500816|NCT00699959|dyslipidemia
500817|NCT00699946|delirium, atypical antipsychotics, olanzapine, orthopedic
500818|NCT00699933|acute pancreatitis
500819|NCT00699933|interventional therapy
500820|NCT00699933|CT-guided drainage therapy
500821|NCT00699933|percutaneous necrosectomy
500822|NCT00699933|Comparison of different diagnostic procedures: MRI, CT, Ultrasound
500823|NCT00699933|Evaluation of interventional therapy including percutaneous drainage techniques und necrosectomies
500824|NCT00699907|ovarian epithelial cancer
500825|NCT00699894|PONV
500826|NCT00699894|prevention of postoperative nausea and vomiting
500827|NCT00699894|aprepitant
500828|NCT00699894|ondansetron
500829|NCT00699894|orthognathic surgery
500830|NCT00699881|Time to Progression
500831|NCT00699881|Toxicity
500832|NCT00699881|Overall survival
500833|NCT00699881|Response rate
500834|NCT00699881|Quality of live
500835|NCT00699855|Growth Hormon Deficiency and
500836|NCT00699855|Turner Syndrome in pre-pubertal children
500837|NCT00699855|Long term follow-up of predictive markers
500838|NCT00699842|Myelodysplastic Syndrome
500839|NCT00699842|MDS
500840|NCT00699842|Low to Intermediate-1 MDS
500841|NCT00699842|Non-deletion 5q
500842|NCT00699842|Lenalidomide
500843|NCT00699790|Diabetes
500844|NCT00699790|NOS
500845|NCT00699764|Herpes simplex candidate vaccine
500846|NCT00699764|Herpes simplex
500847|NCT00699751|Hormone Refractory Prostate Cancer
500848|NCT00699751|Bone Metastases
500849|NCT00699751|Radium-223
500850|NCT00699738|Healthy women during pregnancy and in the postpartum period
500851|NCT00699725|Compliance
500852|NCT00699725|gastroprotector therapy
500853|NCT00699725|NSAID
500854|NCT00699725|risk factors
500855|NCT00699712|ADHF
500856|NCT00699712|AHF
500857|NCT00699712|HF
500858|NCT00699699|Chronic Obstructive Pulmonary Disease (COPD)
500859|NCT00699686|Diabetes
500860|NCT00699686|Insulin
500861|NCT00699686|Endothelium
500862|NCT00699686|Cardiovascular disease
500863|NCT00699686|Stem cells
500864|NCT00699673|Brain natriuretic peptide
500865|NCT00699673|EuroScore
500866|NCT00699673|Cardiac surgery
500867|NCT00699673|Cardiopulmonary bypass
500868|NCT00699673|Coronary artery disease
500869|NCT00699673|Valvular disease
500870|NCT00699673|Risk stratification in cardiac surgery
500871|NCT00699660|Disability Examination
500872|NCT00699660|Clinician Administered PTSD Scale
500873|NCT00699660|Quality of Care
500874|NCT00699634|Neuropathic
500875|NCT00699634|Pain
500876|NCT00699634|Phantom
500877|NCT00699634|Limb
500878|NCT00699621|Intracerebral hemorrhage
500879|NCT00699621|Hematoma enlargement
500880|NCT00699621|Antiplatelet agent
500881|NCT00699621|Platelet transfusion
500882|NCT00699621|Outcome
500883|NCT00699608|Zopiclone
500884|NCT00699608|Hypnotic
500885|NCT00699608|Residual effects
500886|NCT00699608|Eszopiclone
500887|NCT00699582|E2007 (perampanel)
500888|NCT00699582|refractory partial seizures
500889|NCT00699582|adjunctive therapy
500890|NCT00699582|seizure frequency
500891|NCT00699582|reduction in seizure frequency
500892|NCT00699582|partial onset seizures
500893|NCT00699582|safety
500894|NCT00699582|concomitant AED(s)
500895|NCT00699569|hyperimmune colostrum
500896|NCT00699569|mucositis
500897|NCT00699556|alcohol
500898|NCT00699556|nicotine
500899|NCT00699556|smoking cessation
500900|NCT00699556|smoking cessation medications
500901|NCT00699530|Prolactin
500902|NCT00699530|Insulin resistance
500903|NCT00699530|Glucose tolerance
500904|NCT00699530|Body Composition
500905|NCT00699530|Substrate metabolism
500906|NCT00699517|tubulin modulator
500907|NCT00699517|endothelium
500908|NCT00699517|combretastatin
500909|NCT00699517|cisplatin
500910|NCT00699504|ECG
500911|NCT00699504|QT
500912|NCT00699504|Effect of study drug on healthy volunteers
500913|NCT00699478|vitamin B12 deficiency
500914|NCT00699478|post total gastrectomy
500915|NCT00699478|stomach cancer
500916|NCT00699465|Thromboprophylaxis
500917|NCT00699465|Prevention of venous thromboembolism after ICH
500918|NCT00699465|Enoxaparin
500919|NCT00699465|Intermittent pneumatic compression
500920|NCT00699452|aortic stenosis
500921|NCT00699452|valve
500922|NCT00699452|candesartan
500923|NCT00699439|Medical Informatics
500924|NCT00699439|Asthma
500925|NCT00699439|Emergency Service, Hospital
500926|NCT00699439|Bayesian Method
500927|NCT00699387|Chagas disease
500928|NCT00699387|Pediatrics
500929|NCT00699387|benznidazole
500930|NCT00699387|population pharmacokinetics
500931|NCT00699387|neglected diseases
500932|NCT00699387|parasitology
500933|NCT00699387|pediatric clinical pharmacology
500934|NCT00699374|sunitinib
500935|NCT00699374|phase 3
500936|NCT00699374|randomized
500937|NCT00699374|hepatocellular
500938|NCT00699374|liver
500939|NCT00699361|Pantoprazole
500940|NCT00699361|congestive heart failure
500941|NCT00699335|pain
500942|NCT00699335|fentanyl
500943|NCT00699335|transdermal patch
500944|NCT00699322|glucose variability
500945|NCT00699322|oxidative stress
500946|NCT00699322|sitagliptin
500947|NCT00699322|glimepiride
500948|NCT00699309|Total Hip Replacement
500949|NCT00699309|Total Hip Arthroplasty
500950|NCT00699309|Minimally Invasive
500951|NCT00699309|Microplasty
500952|NCT00699309|Hip Arthritis
500953|NCT00699296|LBH589
500954|NCT00699296|HDAC inhibitor
500955|NCT00699296|cutaneous T-ceII lymphoma
500956|NCT00699296|adult T-cell leukemia
500957|NCT00699283|Epilepsy; Monotherapy
500958|NCT00699283|Partial Onset Seizures
500959|NCT00699283|Adults and Adolescents
500960|NCT00699270|Total Shoulder Arthroplasty
500961|NCT00699270|Total Shoulder Replacement
500962|NCT00699270|Shoulder Arthritis
500963|NCT00699257|Partial Knee Arthroplasty
500964|NCT00699257|Partial Knee Replacement
500965|NCT00699257|Arthritis of Medial Compartment of the Knee
500966|NCT00699257|Oxford Knee
500967|NCT00699244|forearm
500968|NCT00699244|hand
500969|NCT00699244|elbow
500970|NCT00699244|wrist
500971|NCT00699244|brachial plexus
500972|NCT00699244|infraclavicular block
500973|NCT00699231|Hepatitis B
500974|NCT00699231|Engerix™-B
500975|NCT00699231|Recombinant hepatitis B vaccine
500976|NCT00699231|Adjuvant
500977|NCT00699218|Bipolar
500978|NCT00699218|Depression
500979|NCT00699218|TMS
500980|NCT00699218|repetitive Transcranial Magnetic Stimulation
500981|NCT00699218|treatment
500982|NCT00699218|Efficacy
500983|NCT00699218|Safety
500984|NCT00699192|Blood pressure
500985|NCT00699192|hypertension
500986|NCT00699192|elderly
500987|NCT00699166|IBS
500988|NCT00699166|Diarrhea
500989|NCT00699166|gastrointestinal functional disorder
500990|NCT00699166|IBS-D
500991|NCT00699127|anxiety
500992|NCT00699127|parents
500993|NCT00699127|NICU
500994|NCT00699127|prematurity
500995|NCT00699127|Anxiety of parents to NICU infants
500996|NCT00699114|Pain
500997|NCT00699114|Analgesics
500998|NCT00699114|Molar
500999|NCT00699114|Third
501000|NCT00699114|Acetaminophen
501001|NCT00699114|Paracetamol
501002|NCT00699114|Ibuprofen
501003|NCT00699114|Codeine
501004|NCT00699114|Placebo
501005|NCT00699101|Breast Cancer
501006|NCT00699101|Conture®
501007|NCT00699101|Brachytherapy
501008|NCT00699088|Total Hip Arthroplasty
501009|NCT00699088|Total Hip Replacement
501010|NCT00699088|Minimally Invasive
501011|NCT00699088|Microplasty
501012|NCT00699062|antileukotriene
501013|NCT00699062|small airway
501014|NCT00699062|airway remodeling
501015|NCT00699062|HRCT
501016|NCT00699049|Alpha blocker
501017|NCT00699049|Tamsulosin
501018|NCT00699049|Solifenacin
501019|NCT00699049|Overactive Bladder
501020|NCT00699049|Urgency incontinence
501021|NCT00699036|nonalcoholic steatohepatitis (NASH)
501022|NCT00699036|fatty liver
501023|NCT00699036|insulin resistance
501024|NCT00699023|postprandial lipemia
501025|NCT00699023|type 2 diabetes
501026|NCT00699023|ezetimibe
501027|NCT00699023|hypercholesterolemia
501028|NCT00699010|Abuse Liability
501029|NCT00699010|Abuse Prevention
501030|NCT00699010|Abuse Resistance
501031|NCT00699010|Abuse Deterrence
501032|NCT00698997|autism
501033|NCT00698997|autism spectrum disorder
501034|NCT00698997|intensive intervention for toddlers with autism
501035|NCT00698997|PDD NOS
501036|NCT00698997|early steps study
501037|NCT00698997|early start denver model
501038|NCT00698997|early intervention for infants and toddlers with autism
501039|NCT00698997|toddler treatment
501040|NCT00698997|Sally Rogers
501041|NCT00698997|University of California, Davis
501042|NCT00698997|University of Michigan
501043|NCT00698997|MIND Institute
501044|NCT00698984|Soy Isoflavones, Bone Mineral Density, Bone Mineral Content, postmenopausal Women, Bone Markers, Bone Health, Phytoestrogens
501045|NCT00698958|Respiratory insufficiency
501046|NCT00698958|Hypercapnic chronic respiratory failure secondary to neuromuscular diseases or alterations of thoracic cage
501047|NCT00698932|DPP-4 inhibitors
501048|NCT00698932|HBA1c
501049|NCT00698932|Incretins
501050|NCT00698919|Bacterial DNA
501051|NCT00698919|Systemic inflammatory response syndrome
501052|NCT00698919|Infection
501053|NCT00698919|Intensive Care Unit
501054|NCT00698906|Hepatitis B
501055|NCT00698906|HBV-MPL
501056|NCT00698906|Recombinant Hepatitis B vaccine
501057|NCT00698893|Herpes simplex
501058|NCT00698893|Herpes simplex candidate (gD) vaccine
501059|NCT00698880|Portal vein embolization
501060|NCT00698880|Hepatic vein embolization
501061|NCT00698880|Liver regeneration
501062|NCT00698867|Total Elbow Arthroplasty
501063|NCT00698867|Total Elbow Replacement
501064|NCT00698867|Osteoarthritis
501065|NCT00698867|Elbow arthritis
501066|NCT00698854|Total Knee Arthroplasty
501067|NCT00698854|Total Knee Replacement
501068|NCT00698854|Knee Arthritis
501069|NCT00698828|Cachexia, COPD, Chronic Obstructive Pulmonary Disease
501070|NCT00698763|An ischaemic cerebrovascular event (stroke or TIA)
501071|NCT00698750|Fractured Humeral Head
501072|NCT00698750|Traumatic Arthritis
501073|NCT00698750|Resurfacing Shoulder
501074|NCT00698750|Shoulder Replacement
501075|NCT00698750|Shoulder Arthritis
501076|NCT00698737|Opioid
501077|NCT00698737|Cocaine
501078|NCT00698711|Prostate cancer
501079|NCT00698711|MUC-2-KLH
501080|NCT00698711|QS 21
501081|NCT00698698|tear proteins
501082|NCT00698698|diabetic retinopathy
501083|NCT00698698|HPLC
501084|NCT00698698|Mass spectroscopy
501085|NCT00698685|Allogeneic Hematopoietic Cell Transplantation
501086|NCT00698685|Preparative Regimen
501087|NCT00698685|Pentostatin
501088|NCT00698685|Alemtuzumab
501089|NCT00698685|Hodgkin Disease and Lymphoma, non-Hodgkin
501090|NCT00698685|leukemia, myeloid, acute
501091|NCT00698685|leukemia, lymphocytic, acute
501092|NCT00698685|leukemia, myeloid, chronic
501093|NCT00698685|leukemia, lymphocytic, chronic
501094|NCT00698685|Multiple Myeloma
501095|NCT00698685|Myelodysplastic Syndromes
501096|NCT00698685|Carcinoma, Renal Cell
501097|NCT00698672|RSA
501098|NCT00698646|Systolic blood pressure
501099|NCT00698646|Diastolic blood pressure
501100|NCT00698646|Valsartan
501101|NCT00698646|Hydrochlorothiazide
501102|NCT00698633|Hip arthroplasty
501103|NCT00698607|Everolimus
501104|NCT00698607|Sirolimus
501105|NCT00698607|drug eluting stent
501106|NCT00698607|Clopidogrel
501107|NCT00698581|Epilepsy; Monotherapy
501108|NCT00698581|Partial Onset Seizures
501109|NCT00698581|Adults and Adolescents
501110|NCT00698568|Herpes simplex, Herpes simplex candidate vaccine
501111|NCT00698555|Hepatitis B
501112|NCT00698555|HBV-MPL
501113|NCT00698555|Recombinant hepatitis B vaccine
501114|NCT00698542|PSST
501115|NCT00698542|sepsis
501116|NCT00698542|Neuro Care Unit
501117|NCT00698542|Surviving Sepsis Campaign
501118|NCT00698542|SSC
501119|NCT00698529|Technology Transfer
501120|NCT00698529|HIV Seronegativity
501121|NCT00698516|Bevacizumab
501122|NCT00698516|Small Cell Lung Cancer (SCLC)
501123|NCT00698516|Topotecan
501124|NCT00698503|Metal on Metal
501125|NCT00698503|Total Hip Arthroplasty
501126|NCT00698503|Total Hip Replacement
501127|NCT00698490|Herpes simplex
501128|NCT00698490|Herpes simplex candidate vaccine
501129|NCT00698464|Pasireotide
501130|NCT00698464|PK profile,
501131|NCT00698464|Single dose
501132|NCT00698464|Pasireotide subcutaneous injection
501133|NCT00698464|Safety
501134|NCT00698464|Mild hepatic impaired patients
501135|NCT00698464|Moderate hepatic impaired patients
501136|NCT00698464|Severe hepatic impaired patients
501137|NCT00698451|Ovarian cancer
501138|NCT00698451|fallopian tube cancer
501139|NCT00698451|primary peritoneal cancer
501140|NCT00698451|DOXIL
501141|NCT00698451|carboplatin
501142|NCT00698451|bevacizumab
501143|NCT00698438|At least 18 years of age
501144|NCT00698438|Open-angle glaucoma
501145|NCT00698425|Iontophoresis
501146|NCT00698425|Ophthalmology
501147|NCT00698412|Knee osteoarthritis
501148|NCT00698412|Daily cane use
501149|NCT00698412|Pain
501150|NCT00698412|Function
501151|NCT00698412|Quality of life
501152|NCT00698412|Energy consumption during the gait
501153|NCT00698399|liver
501154|NCT00698399|transplant
501155|NCT00698399|TMAO
501156|NCT00698399|NGAL
501157|NCT00698399|cystatin-C
501158|NCT00698399|Ischemia Reperfusion Injury
501159|NCT00698399|Liver Transplant
501160|NCT00698399|LTx
501161|NCT00698399|allantion
501162|NCT00698386|Micronutrient Zinc
501163|NCT00698386|Category I PTB
501164|NCT00698386|RNTCP
501165|NCT00698386|DOTS
501166|NCT00698386|Sputum smear conversion
501167|NCT00698386|Reduced relapse
501168|NCT00698386|Immunopathogenesis
501169|NCT00698386|Category-I
501170|NCT00698373|Fluorine-18-α-methyltyrosine,
501171|NCT00698373|Positron emission tomography,
501172|NCT00698373|Fluorine-18-fluorodeoxyglucose,
501173|NCT00698373|Lung cancer,
501174|NCT00698360|chronic kidney disease
501175|NCT00698360|melatonin
501176|NCT00698360|erythropoietin
501177|NCT00698360|circadian rhythm
501178|NCT00698347|Total Knee Replacement
501179|NCT00698347|Total Knee Arthroplasty
501180|NCT00698347|Hip Arthritis
501181|NCT00698334|HIV infection
501182|NCT00698334|Acquired immunodeficiency syndrome
501183|NCT00698334|Tuberculosis
501184|NCT00698321|HIV/STD Prevention
501185|NCT00698321|HIV Seronegativity
501186|NCT00698295|schizophrenia
501187|NCT00698295|atypical antipsychotics
501188|NCT00698295|EEG
501189|NCT00698243|OSI-027
501190|NCT00698243|Solid tumor
501191|NCT00698243|Lymphoma
501192|NCT00698204|Mucositis
501193|NCT00698204|Head and Neck Cancer
501194|NCT00698204|Head and Neck Neoplasms
501195|NCT00698204|Stomatitis
501196|NCT00698191|Lupus Erythematosus,Systemic
501197|NCT00698191|Lupus Nephritis
501198|NCT00698191|Mesenchymal Stem Cells
501199|NCT00698191|Transplantation
501200|NCT00698178|Gastroesophageal reflux disease
501201|NCT00698178|Waist circumference
501202|NCT00698178|Body mass index
501203|NCT00698178|Obesity
501204|NCT00698152|Total Hip Arthroplasty
501205|NCT00698152|Total Hip Replacement
501206|NCT00698152|Hip Arthritis
501207|NCT00698152|Polyethylene
501208|NCT00698139|heart failure
501209|NCT00698139|chronotropic incompetence
501210|NCT00698113|anxiety
501211|NCT00698113|depression
501212|NCT00698113|stress
501213|NCT00698113|cancer symptoms
501214|NCT00698113|pediatric cancer
501215|NCT00698113|massage
501216|NCT00698113|parent delivered massage
501217|NCT00698100|DNA
501218|NCT00698100|HU & MOUSE
501219|NCT00698100|TYROSINASE
501220|NCT00698087|Hepatitis B
501221|NCT00698087|Engerix™-B
501222|NCT00698087|Adjuvanted recombinant hepatitis B vaccine
501223|NCT00698061|Hepatitis B
501224|NCT00698061|Adjuvanted vaccine
501225|NCT00698048|Sepsis
501226|NCT00698048|Septic Shock
501227|NCT00698048|Vasopressin
501228|NCT00698048|Copeptin
501229|NCT00698048|Paediatrics
501230|NCT00698035|Vaginal Testosterone Cream
501231|NCT00698035|ESTRING
501232|NCT00698022|healthy
501233|NCT00698022|weight gain
501234|NCT00698022|anti-psychotic
501235|NCT00698022|risperidone
501236|NCT00698022|mifepristone
501237|NCT00698022|mitigation
501238|NCT00698022|weight loss
501239|NCT00698009|Neuroblastoma
501240|NCT00698009|Natural Killer Cell
501241|NCT00698009|NK Cell Infusion
501242|NCT00698009|Haploidentical Natural Killer (NK) Cells
501243|NCT00698009|Fludarabine
501244|NCT00698009|Fludarabine Phosphate
501245|NCT00698009|Fludara
501246|NCT00698009|Cyclophosphamide
501247|NCT00698009|Cytoxan
501248|NCT00698009|Neosar
501249|NCT00698009|Interleukin-2
501250|NCT00698009|IL-2
501251|NCT00698009|Proleukin
501252|NCT00698009|Mesna
501253|NCT00698009|Mesnex
501254|NCT00698009|Infusion of NK cells
501255|NCT00698009|Pediatric NK Cell Infusion
501256|NCT00698009|Pediatric Neuroblastoma
501257|NCT00698009|Pediatric NK
501258|NCT00698009|Pediatric
501259|NCT00697983|Osteoporosis
501260|NCT00697983|ATP
501261|NCT00697983|Purinergic receptors
501262|NCT00697983|Bone mineral density
501263|NCT00697983|Single nucleotide polymorphism
501264|NCT00697970|Hepatitis B
501265|NCT00697970|Engerix™-B
501266|NCT00697970|Recombinant Hepatitis B vaccine
501267|NCT00697970|Adjuvant
501268|NCT00697957|acceleration
501269|NCT00697957|bone density
501270|NCT00697957|cardiovascular diseases
501271|NCT00697957|exercise
501272|NCT00697957|female
501273|NCT00697957|fragility fractures
501274|NCT00697957|impact intensity
501275|NCT00697957|intervention studies
501276|NCT00697957|osteoporosis
501277|NCT00697957|premenopause
501278|NCT00697944|FUNGAL INFECTION
501279|NCT00697944|SEPSIS
501280|NCT00697944|INTENSIVE CARE
501281|NCT00697944|AMBISOME
501282|NCT00697944|PREEMPTIVE TREATMENT
501283|NCT00697944|Sepsis with candida colonisation
501284|NCT00697931|Hepatitis B
501285|NCT00697931|Engerix™-B
501286|NCT00697931|Recombinant Hepatitis B vaccine
501287|NCT00697931|Adjuvant
501288|NCT00697918|Partial onset seizure
501289|NCT00697918|Adjunctive therapy
501290|NCT00697905|nasopharyngeal carcinoma
501291|NCT00697905|Gemcitabine-Carboplatin
501292|NCT00697892|Human Immunodeficiency Virus
501293|NCT00697892|Drug Interactions
501294|NCT00697879|tumour
501295|NCT00697879|Solid tumour
501296|NCT00697879|histone deacetylase inhibitor
501297|NCT00697879|dose escalation
501298|NCT00697879|cancer
501299|NCT00697866|Adjuvanted hepatitis B vaccine
501300|NCT00697866|Hepatitis B
501301|NCT00697866|Recombinant hepatitis B vaccine
501302|NCT00697853|Hepatitis B
501303|NCT00697853|Adjuvanted hepatitis B vaccine
501304|NCT00697853|Recombinant hepatitis B vaccine
501305|NCT00697840|Hepatitis B
501306|NCT00697840|Engerix™-B
501307|NCT00697840|Recombinant hepatitis B vaccine
501308|NCT00697840|Adjuvant
501309|NCT00697814|Hypogonadotropic hypogonadism
501310|NCT00697814|Prolactinoma
501311|NCT00697788|pediatric
501312|NCT00697788|burn
501313|NCT00697788|sedation
501314|NCT00697775|Hepatitis B
501315|NCT00697775|Recombinant hepatitis B vaccine
501316|NCT00697775|Adjuvant
501317|NCT00697762|Partial onset seizure
501318|NCT00697762|Adjunctive therapy
501319|NCT00697749|Recombinant hepatitis B vaccine
501320|NCT00697749|Adjuvanted hepatitis B vaccine
501321|NCT00697749|Hepatitis B
501322|NCT00697736|Systemic Scleroderma
501323|NCT00697736|Echocardiography
501324|NCT00697723|Coronary artery bypass graft
501325|NCT00697723|Intra-aortic balloon pump
501326|NCT00697723|transit-time flowmetry
501327|NCT00697710|Atopic Dermatitis
501328|NCT00697697|asthmatic children
501329|NCT00697684|Reduced Intensity Allogeneic Stem Cell Transplant
501330|NCT00697684|Clofarabine
501331|NCT00697684|Rabbit Antithymocyte Globulin
501332|NCT00697684|Total Lymphoid Radiation
501333|NCT00697671|NK cell infusion
501334|NCT00697671|Immunotherapy
501335|NCT00697671|hematologic malignancy
501336|NCT00697671|Miltenyi Biotec device
501337|NCT00697671|haploidentical donor
501338|NCT00697658|Paliperidone ER
501339|NCT00697658|Schizophrenia
501340|NCT00697645|Stroke,
501341|NCT00697645|Cerebrovascular disease,
501342|NCT00697645|Transcranial magnetic stimulation,
501343|NCT00697645|rehabilitation
501344|NCT00697632|MET
501345|NCT00697632|AXL
501346|NCT00697632|VEGFR
501347|NCT00697632|NSCLC
501348|NCT00697632|HNSCC (Head and neck squamous cell carcinoma)
501349|NCT00697632|Tumor
501350|NCT00697632|Safety
501351|NCT00697632|Phase 1
501352|NCT00697632|Solid tumor
501353|NCT00697606|Seprafilm®
501354|NCT00697606|cesarean
501355|NCT00697606|adhesions
501356|NCT00697606|primary
501357|NCT00697606|repeat
501358|NCT00697593|Efalizumab
501359|NCT00697593|Chronic Plaque Psoriasis
501360|NCT00697593|Transition from systemic therapies on to Efalizumab
501361|NCT00697580|Obesity
501362|NCT00697580|Type 2 Diabetes
501363|NCT00697580|Cardiovascular risk
501364|NCT00697580|Cancer
501365|NCT00697580|Latino
501366|NCT00697580|Adolescents
501367|NCT00697580|Strength Training
501368|NCT00697580|Circuit Training
501369|NCT00697580|Nutrition
501370|NCT00697567|Herpes simplex
501371|NCT00697567|Herpes simplex vaccine
501372|NCT00697554|Hepatitis B
501373|NCT00697554|Adjuvanted hepatitis B vaccine
501374|NCT00697541|erythematous rosacea
501375|NCT00697541|facial gel
501376|NCT00697541|brimonidine
501377|NCT00697541|ophthalmic solution
501378|NCT00697528|Graves
501379|NCT00697528|Color Doppler Imaging
501380|NCT00697528|Graves' Ophthalmopathy
501381|NCT00697528|Orbital Venous Flow
501382|NCT00697489|Pelvic organ prolapse
501383|NCT00697489|Urinary incontinence
501384|NCT00697489|Mesh
501385|NCT00697476|second line chemotherapy
501386|NCT00697463|Teriparatide
501387|NCT00697463|Forteo
501388|NCT00697463|Osteopenia
501389|NCT00697463|Osteoporosis
501390|NCT00697463|Fracture
501391|NCT00697463|Low Bone Density
501392|NCT00697463|Premenopausal women
501393|NCT00697411|Aicardi syndrome
501394|NCT00697411|Microphthalmia with linear skin defects (MLS) syndrome
501395|NCT00697411|X-linked disorders
501644|NCT00696358|Vitiligo
501396|NCT00697372|Angioplasty, Transluminal, Percutaneous Coronary
501397|NCT00697372|Drug-Eluting Stents
501398|NCT00697359|Atrial fibrillation
501399|NCT00697359|Monitoring
501400|NCT00697359|Pulmonary vein isolation
501401|NCT00697359|Implantable loop recorder
501402|NCT00697333|NSCLC
501403|NCT00697333|FDG-PET
501404|NCT00697333|Radiotherapy
501405|NCT00697333|planning
501406|NCT00697333|target volumes
501407|NCT00697307|bioequivalence
501408|NCT00697307|contraception
501409|NCT00697307|contraceptive patch
501410|NCT00697307|ORTHO EVRA
501411|NCT00697307|norelgestromin
501412|NCT00697307|NGMN
501413|NCT00697307|ethinyl estradiol
501414|NCT00697307|EE
501415|NCT00697294|Vitamin D deficiency
501416|NCT00697294|Infants
501417|NCT00697294|Breast feeding
501418|NCT00697281|allergic rhinitis
501419|NCT00697281|human
501420|NCT00697281|clinical trial
501421|NCT00697281|efficacy
501422|NCT00697281|safety
501423|NCT00697281|challenge test
501424|NCT00697268|Depression
501425|NCT00697268|Depression Treatment
501426|NCT00697268|Unipolar Depression
501427|NCT00697268|Citalopram
501428|NCT00697268|Serotonin
501429|NCT00697268|Major Depression
501430|NCT00697268|Healthy Volunteer
501431|NCT00697268|HV
501432|NCT00697255|Pharmacological effects of drugs
501433|NCT00697255|Hormones
501434|NCT00697255|Hormone Substitutes and Hormone Antagonists
501435|NCT00697255|Pharmacological Actions
501436|NCT00697255|Monofollicular growth
501437|NCT00697255|Randomized
501438|NCT00697255|Open-label
501439|NCT00697255|Active-controlled
501440|NCT00697242|Hepatitis B
501441|NCT00697242|Engerix™-B
501442|NCT00697242|Recombinant Hepatitis B vaccine
501443|NCT00697229|Hepatitis B
501444|NCT00697229|Engerix™-B
501445|NCT00697229|Recombinant hepatitis B vaccine
501446|NCT00697216|Hepatitis B
501447|NCT00697216|Recombinant hepatitis B vaccine
501448|NCT00697216|Adjuvanted hepatitis B vaccine
501449|NCT00697177|Gastro-oesophageal reflux
501450|NCT00697177|24 hour oesophageal pH monitoring
501451|NCT00697177|Physiotherapy Airway clearance techniques
501452|NCT00697177|Exercise
501453|NCT00697164|Malaria
501454|NCT00697164|Treatment
501455|NCT00697164|Adjunctive
501456|NCT00697164|Erythropoietin
501457|NCT00697164|Survival
501458|NCT00697151|cerebrovascular diseases
501459|NCT00697151|ischemic stroke
501460|NCT00697151|patent foramen ovale
501461|NCT00697151|warfarin
501462|NCT00697151|aspirin
501463|NCT00697151|transesophageal echocardiography
501464|NCT00697138|Cocaine
501465|NCT00697138|Dependence
501466|NCT00697138|Pharmacotherapies
501467|NCT00697125|Hepatitis B
501468|NCT00697125|Engerix™-B
501469|NCT00697125|Recombinant hepatitis B vaccine
501470|NCT00697099|VTE prevention
501471|NCT00697099|Total Hip Replacement
501472|NCT00697099|Heparin Low-Molecular-Weight
501473|NCT00697086|Heart disease
501474|NCT00697073|Friedreich's Ataxia
501475|NCT00697073|Idebenone
501476|NCT00697073|ICARS
501477|NCT00697060|Metastatic
501478|NCT00697060|Previously treated
501479|NCT00697047|Colorectal Neoplasms
501480|NCT00697047|Mass Screening
501481|NCT00697047|Population Surveillance
501482|NCT00697047|Randomized controlled trial
501483|NCT00697047|Occult Blood
501484|NCT00697047|Colonoscopy
501485|NCT00697047|Sigmoidoscopy
501486|NCT00697047|Health Behavior
501487|NCT00697047|Colorectal Screening
501488|NCT00697021|Thromboelastography
501489|NCT00697021|Aspirin
501490|NCT00697021|Clopidogrel
501491|NCT00697021|Plavix
501492|NCT00697021|Resistance
501493|NCT00697021|Platelet
501494|NCT00697021|Coronary Stenting
501495|NCT00697021|Bare Metal Stent
501496|NCT00697021|Dual antiplatelet therapy
501497|NCT00697021|Overreactivity
501498|NCT00697021|Primary Coronary Intervention
501499|NCT00697008|GERD
501500|NCT00697008|CLINICAL GUIDELINE
501501|NCT00697008|Symptoms
501502|NCT00697008|clinical outcome
501503|NCT00696982|Arterial stiffness
501504|NCT00696982|Augmentation index
501505|NCT00696982|diabetes mellitus
501506|NCT00696956|local drug delivery
501507|NCT00696956|balloon angioplasty
501508|NCT00696956|safety and tolerance of paclitaxel coated PTA balloons
501509|NCT00696956|in inhibiting restenosis of below the knee arteries
501510|NCT00696956|Efficacy of paclitaxel coated PTA balloons
501511|NCT00696956|in inhibiting restenosis of below the knee arteries (late lumen loss)
501512|NCT00696943|cell death
501513|NCT00696943|PET imaging
501514|NCT00696943|brain metastases
501515|NCT00696943|stereotactic radiosurgery
501516|NCT00696930|Malignant Carcinoid Tumors
501517|NCT00696917|Hepatitis B
501518|NCT00696917|Adjuvanted Hepatitis B vaccine
501519|NCT00696917|Recombinant Hepatitis B vaccine
501520|NCT00696891|Adjuvanted hepatitis B vaccine, hepatitis B, Engerix™-B
501521|NCT00696878|Infertility
501522|NCT00696878|Pharmacological effects of drugs
501523|NCT00696878|Hormones, Hormone Substitutes and Hormone Antagonists
501524|NCT00696878|Pharmacological Actions
501525|NCT00696878|Multi-center
501526|NCT00696865|Safety
501527|NCT00696865|Tolerability
501528|NCT00696865|Phase I
501529|NCT00696852|Mindfulness
501530|NCT00696852|Meditation
501531|NCT00696852|Yoga
501532|NCT00696852|Inflammatory Markers
501533|NCT00696839|Behavior Therapy
501534|NCT00696839|Anti-Retroviral Agents
501535|NCT00696839|Relaxation
501536|NCT00696839|Clinical Nursing Research
501537|NCT00696839|Complementary Therapies
501538|NCT00696813|Registry
501539|NCT00696813|Healthcare Utilization
501540|NCT00696813|Outcome
501541|NCT00696813|Safety
501542|NCT00696813|Efficacy
501543|NCT00696813|Cost-effectiveness
501544|NCT00696813|Paliperidone ER
501545|NCT00696813|Invega®
501546|NCT00696813|Oral antipsychotics
501547|NCT00696800|Infertility
501548|NCT00696800|Pharmacological effect of drugs
501549|NCT00696800|Hormones
501550|NCT00696800|Hormone substitutes and hormone antagonists
501551|NCT00696800|Pharmacological actions
501552|NCT00696800|Randomized
501553|NCT00696800|Multi-center
501554|NCT00696800|Multi-national
501555|NCT00696800|Double-blind
501556|NCT00696800|Active-controlled
501557|NCT00696800|Non-inferiority
501558|NCT00696761|LUTS
501559|NCT00696761|BPH
501560|NCT00696761|bladder outlet obstruction
501561|NCT00696761|bladder contractility
501562|NCT00696748|metabolic syndrome
501563|NCT00696748|hypogonadism
501564|NCT00696748|testosterone undecanoate
501565|NCT00696735|Phase III study patients with follicular lymphoma
501566|NCT00696709|Herpes Zoster (Shingles)
501567|NCT00696696|Pancreatic adenocarcinoma
501568|NCT00696696|metastatic
501569|NCT00696696|EGRF inhibitor
501570|NCT00696696|targeted therapy
501571|NCT00696696|combined cancer therapy
501572|NCT00696696|kinase inhibitor
501573|NCT00696696|VEGF-R inhibitor
501574|NCT00696683|scorpion
501575|NCT00696683|sting
501576|NCT00696683|envenomation
501577|NCT00696683|antivenom
501578|NCT00696631|Heart disease
501579|NCT00696631|morbidity
501580|NCT00696618|HIV prevention
501581|NCT00696618|MSM
501582|NCT00696618|Enema
501583|NCT00696618|HIV Seronegativity
501584|NCT00696605|Hypoosmolality
501585|NCT00696605|Hyperosmolality
501586|NCT00696605|Copeptin
501587|NCT00696605|Vasopressin
501588|NCT00696592|Age-Related Macular Degeneration
501589|NCT00696592|Choroidal Neovascularization
501590|NCT00696592|Bevacizumab
501591|NCT00696592|Photodynamic Therapy
501592|NCT00696579|BCG
501593|NCT00696579|Gemcitabine
501594|NCT00696579|Intravesical
501595|NCT00696579|Therapy
501596|NCT00696579|Superficial
501597|NCT00696579|Transitional
501598|NCT00696579|Cell carcinoma
501599|NCT00696566|Thrombosis
501600|NCT00696566|Platelet aggregation inhibitor
501601|NCT00696566|Blood platelets
501602|NCT00696566|P2 receptor
501603|NCT00696566|Cytochrome P450
501604|NCT00696540|Bronchiolitis, respiratory distress, hypertonic saline
501605|NCT00696527|Infiltrative breast cancer-Clinical practice
501606|NCT00696527|Women with infiltrative breast cancer
501607|NCT00696514|fracture
501608|NCT00696514|cognition
501609|NCT00696501|Neuromuscular mapping
501610|NCT00696501|Spinal surgery
501611|NCT00696501|Neurodiagnostics
501612|NCT00696501|Segmental root innervation
501613|NCT00696501|Dermatomal innervation
501614|NCT00696501|Myotomal innervation
501615|NCT00696501|Nerve roots
501616|NCT00696501|Sensory
501617|NCT00696501|Signs and Symptoms
501618|NCT00696462|forced-air warming
501619|NCT00696462|Bair Hugger
501620|NCT00696462|cesarean section
501621|NCT00696462|postoperative infection
501622|NCT00696462|surgical site infections
501623|NCT00696436|Essential Hypertension
501624|NCT00696436|Cardiovascular Disease
501625|NCT00696436|High Blood Pressure
501626|NCT00696436|Drug Therapy
501627|NCT00696423|Infanrix/Hib
501628|NCT00696423|Chinese children
501629|NCT00696410|Heart Failure
501630|NCT00696410|Cardiomyopathy
501631|NCT00696410|Remodeling
501632|NCT00696410|Antioxidant
501633|NCT00696410|Zinc
501634|NCT00696410|Copper
501635|NCT00696384|Essential Hypertension
501636|NCT00696384|Cardiovascular Disease
501637|NCT00696384|High Blood Pressure
501638|NCT00696384|Drug Therapy
501639|NCT00696371|Neuroinflammation
501640|NCT00696371|PBR28
501641|NCT00696371|PET Imaging
501642|NCT00696371|Health Volunteer
501643|NCT00696371|HV
501645|NCT00696345|colorectal cancer
501646|NCT00696345|screening
501647|NCT00696345|biomarker
501648|NCT00696345|plasma
501649|NCT00696345|blood
501650|NCT00696332|ALS
501651|NCT00696319|Rupture of the anterior cruciate ligament of the knee
501652|NCT00696306|Acute Ischemic Stroke
501653|NCT00696306|Stroke
501654|NCT00696306|MRI
501655|NCT00696306|DTI
501656|NCT00696306|Diffusion Tensor Imaging
501657|NCT00696306|SWI
501658|NCT00696306|Susceptibility Weighted Imaging
501659|NCT00696306|Outcome
501660|NCT00696306|Axonal Injury
501661|NCT00696280|nausea
501662|NCT00696280|vomiting
501663|NCT00696280|Carboplatin
501664|NCT00696280|cancer
501665|NCT00696280|delayed emesis following treatment with carboplatin
501666|NCT00696241|Essential Hypertension
501667|NCT00696241|Cardiovascular Disease
501668|NCT00696241|High Blood Pressure
501669|NCT00696241|Drug Therapy
501670|NCT00696215|Parkinson's disease
501671|NCT00696215|rasagiline
501672|NCT00696215|cognition
501673|NCT00696215|MAO-B
501674|NCT00696202|Mirena
501675|NCT00696202|Levonorgestrel
501676|NCT00696202|Intrauterine device
501677|NCT00696202|Efficacy
501678|NCT00696202|Tolerability
501679|NCT00696202|First year of use
501680|NCT00696189|Post operative visual loss (POVL)
501681|NCT00696189|Intraocular pressure (IOP)
501682|NCT00696189|Nitrous oxide
501683|NCT00696176|STAT 3 DECOY
501684|NCT00696150|ultrasound
501685|NCT00696150|hip
501686|NCT00696150|pain
501687|NCT00696124|lower leg ischemia
501688|NCT00696124|peripheral artery disease
501689|NCT00696111|PCOS
501690|NCT00696111|OSA
501691|NCT00696111|Metabolism
501692|NCT00696111|Diabetes
501693|NCT00696085|fetal alcohol exposure
501694|NCT00696085|blood markers of alcohol use
501695|NCT00696085|brief intervention
501696|NCT00696059|Rheumatoid arthritis
501697|NCT00696059|Computed tomography
501698|NCT00696059|Magnetic resonance imaging
501699|NCT00696059|Radiography
501700|NCT00696059|Tumor necrosis factor alpha antagonists
501701|NCT00696046|CORD BLOOD CELLS
501702|NCT00696046|INTRA BONE MARROW INJECTION
501703|NCT00696046|ENGRAFTMENT
501704|NCT00696046|transplants
501705|NCT00696033|Benzodiazepines
501706|NCT00696033|Lorazepam
501707|NCT00696033|Diazepam
501708|NCT00696033|Memory
501709|NCT00696033|Perceptual priming
501710|NCT00696033|Functional brain imaging
501711|NCT00696033|FMRI
501712|NCT00696007|Upper GU Tract Transitional Cell Carinoma
501713|NCT00696007|Nephroureterectomy
501714|NCT00696007|Chemotherapy
501715|NCT00696007|Gemcitabine
501716|NCT00696007|Cisplatin
501717|NCT00695981|Rotator cuff
501718|NCT00695981|Arthroscopic surgery
501719|NCT00695981|Open surgery
501720|NCT00695981|Physiotherapy
501721|NCT00695981|Physical therapy
501722|NCT00695981|Effectiveness
501723|NCT00695981|RCT
501724|NCT00695981|cost-effectiveness
501725|NCT00695955|Essential Hypertension
501726|NCT00695955|Cardiovascular Disease
501727|NCT00695955|High Blood Pressure
501728|NCT00695955|Drug Therapy
501729|NCT00695942|preeclampsia
501730|NCT00695942|eclampsia
501731|NCT00695942|retroplacental hematoma
501732|NCT00695942|vascular IUGR
501733|NCT00695942|IUFD
501734|NCT00695942|VTE
501735|NCT00695929|cardiac surgery with cardiopulmonary bypass
501736|NCT00695903|Gram-positive bacterial infections
501737|NCT00695903|Staph Aureus
501738|NCT00695903|Bacteremia
501739|NCT00695903|MRSA
501740|NCT00695903|Infective Endocarditis
501741|NCT00695903|Right-sided Infective endocarditis
501742|NCT00695903|SABIE
501743|NCT00695903|SAIE
501744|NCT00695903|RIE
501745|NCT00695890|Pupillometry
501746|NCT00695890|Sevoflorane
501747|NCT00695890|Propofol
501748|NCT00695877|HIV Seronegativity
501749|NCT00695877|HIV Preventive Vaccine
501750|NCT00695851|PCK3145
501751|NCT00695851|Prostate
501752|NCT00695838|GERD symptoms- Waist circumference
501753|NCT00695838|Patients with symptomatic GERD
501754|NCT00695812|Neurodevelopmental disorders
501755|NCT00695812|Autism Spectrum Disorders
501756|NCT00695812|Broader autism phenotype
501757|NCT00695812|Siblings
501758|NCT00695812|Cognitive language and social emotional development
501759|NCT00695812|to identify siblings who manifest any autism or broader autism phenotype characteristics
501760|NCT00695799|Propofol
501761|NCT00695799|Anesthesia care provider
501762|NCT00695799|Pollution
501763|NCT00695799|Operating room
501764|NCT00695799|Environment
501765|NCT00695786|Non-Hodgkin's Lymphoma
501766|NCT00695786|Lymphoma
501767|NCT00695786|Lenalidomide
501768|NCT00695786|Revlimid
501769|NCT00695786|Rituximab
501770|NCT00695786|Rituxan
501771|NCT00695773|Prostate Cancer Surgery
501772|NCT00695773|Laparoscopic surgery for Prostate Cancer
501773|NCT00695773|Prostatectomy
501774|NCT00695773|Urologic Surgical Procedures
501775|NCT00695747|Glaucoma
501776|NCT00695747|Cataracts
501777|NCT00695747|Phacoemulsification(IOL)
501778|NCT00695747|Trabeculectomy
501779|NCT00695734|hemodialysis
501780|NCT00695734|end stage renal failure
501781|NCT00695734|tuberculosis
501782|NCT00695734|latent tuberculosis infection
501783|NCT00695734|Patients under hemodialysis for end stage renal failure
501784|NCT00695708|schizophrenia
501785|NCT00695708|neuroplasticity
501786|NCT00695708|sensory gating
501787|NCT00695708|cognitive impairment
501788|NCT00695708|MEG
501789|NCT00695708|Disorders with Psychotic Features
501790|NCT00695695|Parents
501791|NCT00695695|Down Syndrome
501792|NCT00695695|Hope
501793|NCT00695695|Uncertainty
501794|NCT00695695|Adaptation
501795|NCT00695695|DS
501796|NCT00695695|Survey
501797|NCT00695682|Remicade
501798|NCT00695682|Infliximab
501799|NCT00695682|CSME
501800|NCT00695682|BDR
501801|NCT00695682|CNV
501802|NCT00695682|AMD
501803|NCT00695669|H5N1
501804|NCT00695669|immunogenicity
501805|NCT00695669|influenza
501806|NCT00695669|Avian
501807|NCT00695669|pandemic
501808|NCT00695669|vaccines
501809|NCT00695669|human
501810|NCT00695669|safety
501811|NCT00695656|Hypertension
501812|NCT00695656|general practitioner consultation
501813|NCT00695656|Patients with hypertension
501814|NCT00695630|conscious sedation
501815|NCT00695630|dental anxiety/drug therapy
501816|NCT00695630|behavior/drug effects
501817|NCT00695617|MARS treatment
501818|NCT00695617|Citrate anticoagulation
501819|NCT00695604|Acute asthma
501820|NCT00695604|fluticasone
501821|NCT00695604|inhaled corticosteroids
501822|NCT00695591|Home sleep testing neuromuscular disease
501823|NCT00695591|Neuromuscular disease patients with FEV1<50% of predicted
501824|NCT00695552|Major depression, exercise
501825|NCT00695539|Rosuvastatin
501826|NCT00695539|hypercholesterolaemia
501827|NCT00695526|cranberry
501828|NCT00695526|total to HDL cholesterol ratio
501829|NCT00695526|type 2 diabetes
501830|NCT00695513|Food supplement
501831|NCT00695513|Haemodialysis
501832|NCT00695500|Varenicline
501833|NCT00695500|Alcohol
501834|NCT00695500|Alcohol Use
501835|NCT00695487|Anesthesia
501836|NCT00695487|THC
501837|NCT00695487|Postoperative Nausea
501838|NCT00695474|Hypovitaminosis D
501839|NCT00695474|Type 2 diabetes
501840|NCT00695474|Glycemic control
501841|NCT00695474|Inflammation
501842|NCT00695474|Blood pressure
501843|NCT00695461|Colorectal surgery
501844|NCT00695461|Probiotics
501845|NCT00695461|Lactobacillus
501846|NCT00695461|Bacterial translocation
501847|NCT00695461|Postoperative complications
501848|NCT00695461|Inflammatory reaction
501849|NCT00695448|Phosphoinositide 3-kinase inhibitor
501850|NCT00695448|solid tumors
501851|NCT00695435|normal volunteers
501852|NCT00695435|anti-infective
501853|NCT00695435|tobramycin
501854|NCT00695422|high-grade squamous intraepithelial lesion
501855|NCT00695422|low-grade squamous intraepithelial lesion
501856|NCT00695422|human papilloma virus infection
501857|NCT00695422|AIDS-related diffuse large cell lymphoma
501858|NCT00695422|AIDS-related diffuse mixed cell lymphoma
501859|NCT00695422|AIDS-related diffuse small cleaved cell lymphoma
501860|NCT00695422|AIDS-related immunoblastic large cell lymphoma
501861|NCT00695422|AIDS-related Kaposi sarcoma
501862|NCT00695422|AIDS-related lymphoblastic lymphoma
501863|NCT00695422|AIDS-related malignancies
501864|NCT00695422|AIDS-related peripheral/systemic lymphoma
501865|NCT00695422|AIDS-related primary CNS lymphoma
501866|NCT00695422|AIDS-related small noncleaved cell lymphoma
501867|NCT00695422|multicentric Castleman disease
501868|NCT00695422|HIV Infections
501869|NCT00695409|recurrent mantle cell lymphoma
501870|NCT00695409|stage III mantle cell lymphoma
501871|NCT00695409|stage IV mantle cell lymphoma
501872|NCT00695409|recurrent adult diffuse large cell lymphoma
501873|NCT00695409|stage III adult diffuse large cell lymphoma
501874|NCT00695409|stage IV adult diffuse large cell lymphoma
501875|NCT00695409|recurrent grade 1 follicular lymphoma
501876|NCT00695409|recurrent grade 2 follicular lymphoma
501877|NCT00695409|recurrent grade 3 follicular lymphoma
501878|NCT00695409|stage III grade 1 follicular lymphoma
501879|NCT00695409|stage III grade 2 follicular lymphoma
501880|NCT00695409|stage III grade 3 follicular lymphoma
501881|NCT00695409|stage IV grade 1 follicular lymphoma
501882|NCT00695409|stage IV grade 2 follicular lymphoma
501883|NCT00695409|stage IV grade 3 follicular lymphoma
501884|NCT00695409|stage III adult immunoblastic large cell lymphoma
501885|NCT00695409|stage IV adult immunoblastic large cell lymphoma
501886|NCT00695409|recurrent adult immunoblastic large cell lymphoma
501887|NCT00695396|MDS
501888|NCT00695396|Myelodysplastic syndromes
501889|NCT00695396|Anemia
501890|NCT00695396|Epoetin alfa
501891|NCT00695396|EPO
501892|NCT00695383|Exercise therapy
501893|NCT00695383|Physiotherapy
501894|NCT00695383|Critical illness
501895|NCT00695383|Intensive care
501896|NCT00695383|Muscle weakness
501897|NCT00695383|Mechanical ventilation
501898|NCT00695370|Children
501899|NCT00695370|cancer
501900|NCT00695370|Bone marrow transplantation
501901|NCT00695370|Mobilization
501902|NCT00695370|G-CSF
501903|NCT00695370|Children with solid malignancies
501904|NCT00695357|Asthma treatment
501905|NCT00695357|GINA 2006
501906|NCT00695357|patient perception
501907|NCT00695344|Effect of everolimus in graft vascular cardiac illness
501908|NCT00695331|Labor Augmentation
501909|NCT00695331|Misoprostol
501910|NCT00695331|Oxytocin
501911|NCT00695318|AMD
501912|NCT00695318|Age-Related Macular Degeneration
501913|NCT00695318|Geographic Atrophy
501914|NCT00695318|GA
501915|NCT00695305|rilapladib,
501916|NCT00695305|Lp-PLA2,
501917|NCT00695305|atherosclerosis
501918|NCT00695305|SB-659032,
501919|NCT00695305|FDG-PET,
501920|NCT00695292|Small Cell Lung Cancer
501921|NCT00695292|Extensive Stage
501922|NCT00695292|irinotecan
501923|NCT00695292|carboplatin
501924|NCT00695292|sunitinib
501925|NCT00695279|Gene therapy
501926|NCT00695253|AAA
501927|NCT00695240|Continuous bupivacaine infusion
501928|NCT00695240|Analgesia
501929|NCT00695227|laryngopharyngeal reflux
501930|NCT00695227|extraesophageal reflux symptoms
501931|NCT00695214|Obstructive Sleep Apnea
501932|NCT00695214|Propofol
501933|NCT00695214|Sleep Endoscopy
501934|NCT00695201|DEXAMETHASONE
501935|NCT00695201|FLOXURIDINE
501936|NCT00695201|IRINOTECAN (CPT-11) CAMPTOSAR
501937|NCT00695201|OXALIPLATIN
501938|NCT00695188|rheumatoid arthritis
501939|NCT00695188|MTX polyglutamates
501940|NCT00695188|clinical outcome
501941|NCT00695175|Hypertension
501942|NCT00695175|Private cardiology consultation
501943|NCT00695175|Patients with hypertension
501944|NCT00695162|noise
501945|NCT00695162|speech intelligibility
501946|NCT00695162|cognition
501947|NCT00695149|Spinal cord Injury
501948|NCT00695149|Central nervous system
501949|NCT00695149|Regeneration
501950|NCT00695149|Bone marrow stromal cells
501951|NCT00695149|Transplantation
501952|NCT00695136|Autism
501953|NCT00695136|Cognitive Disorder
501954|NCT00695136|Sleep
501955|NCT00695136|Autism Spectrum Disorder
501956|NCT00695136|ASD
501957|NCT00695123|Bone Marrow Transplant
501958|NCT00695123|Sickle Cell Disease
501959|NCT00695123|G-CSF
501960|NCT00695123|Apheresis
501961|NCT00695123|SD
501962|NCT00695123|Healthy Volunteer
501963|NCT00695123|HV
501964|NCT00695110|testosterone
501965|NCT00695110|male hypogonadism
501966|NCT00695110|low testosterone
501967|NCT00695097|Rituximab
501968|NCT00695097|Renal Transplant Rejection
501969|NCT00695097|B cells
501970|NCT00695097|Patients with biopsy proven acute rejection cellular infiltrate, B cells
501971|NCT00695084|multiple sclerosis
501972|NCT00695071|Healthy Volunteers
501973|NCT00695058|Stress incontinence
501974|NCT00695058|urge incontinence
501975|NCT00695058|overactive bladder syndrome
501976|NCT00695058|vibration
501977|NCT00695058|nerve stimulation
501978|NCT00695045|Pain, Postoperative
501979|NCT00695045|Arthroplasty, Replacement, Knee
501980|NCT00695045|Morphine
501981|NCT00695045|Injections, Intrathecal
501982|NCT00695032|renal toxicity
501983|NCT00695032|chemotherapeutic agent toxicity
501984|NCT00695032|unspecified adult solid tumor, protocol specific
501985|NCT00695019|Prevention of Relapse
501986|NCT00695019|HCV genotype 1b
501987|NCT00695019|Recurrence
501988|NCT00695006|manual therapy, cervical traction, cervical radiculopathy
501989|NCT00694993|first time in human
501990|NCT00694993|Allergic rhinitis,
501991|NCT00694980|UC
501992|NCT00694980|Ulcerative Colitis
501993|NCT00694967|short cervix, cervical funneling, spontaneous preterm birth, cerclage, progesterone
501994|NCT00694954|Iron deficiency anemia
501995|NCT00694954|Wireless capsule endoscopy
501996|NCT00694954|Obscure-occult gastrointestinal bleeding
501997|NCT00694941|ONO-2506PO
501998|NCT00694941|Amyotrophic Lateral Sclerosis
501999|NCT00694941|ALS
502000|NCT00694915|STCC (Superficial Transitional Cell Carcinoma)
502001|NCT00694902|Healthy Volunteers
502002|NCT00694889|Psychosis
502003|NCT00694889|First Episode
502004|NCT00694889|Schizophrenia
502005|NCT00694889|Cognitive Remediation
502006|NCT00694876|Health Literacy
502007|NCT00694876|Patient Nonadherence
502008|NCT00694876|Patient Noncompliance
502009|NCT00694876|Follow Up
502010|NCT00694876|India
502011|NCT00694876|Glaucoma
502012|NCT00694863|high risk for ESRD
502013|NCT00694863|immunosuppressive treatment
502014|NCT00694863|membranous nephropathy
502015|NCT00694863|ACTH
502016|NCT00694850|Interstitial lung disease associated pulmonary hypertension
502017|NCT00694837|glioblastoma
502018|NCT00694837|nelfinavir
502019|NCT00694837|functional imaging
502020|NCT00694837|AKT pathway
502021|NCT00694824|Coronary artery calcification
502022|NCT00694824|calcium score
502023|NCT00694824|(TGF) b1,
502024|NCT00694824|fetuin A
502025|NCT00694824|osteoprotegerin (OPG)
502026|NCT00694824|fibroblast growth factor (FGF) 23,
502027|NCT00694824|matrix gla protein (MGP)
502028|NCT00694824|hemodialysis patients
502029|NCT00694811|Obesity
502030|NCT00694811|Weight loss
502031|NCT00694811|Diet
502032|NCT00694811|Very-low-energy diet
502033|NCT00694811|Predictive factors
502034|NCT00694811|Re-feeding
502035|NCT00694798|STCC
502036|NCT00694798|Superficial Transitional Cell Carcinoma- BCG refractor
502037|NCT00694772|Obstructive sleep apnea
502038|NCT00694772|OSA
502039|NCT00694772|Apnea hypopnea index
502040|NCT00694772|AHI
502041|NCT00694772|Coblation
502042|NCT00694772|Electrocautery
502043|NCT00694772|Tonsillectomy
502044|NCT00694772|Tonsillotomy
502045|NCT00694759|Polycystic ovary syndrome
502046|NCT00694759|insulin
502047|NCT00694759|PCOS
502048|NCT00694759|cortisol regulation
502049|NCT00694759|regulation
502050|NCT00694746|ALT
502051|NCT00694746|Non-Alcoholic Fatty Liver Disease
502052|NCT00694746|Adolescents
502053|NCT00694746|Overweight
502054|NCT00694746|Treatment
502055|NCT00694733|Obesity
502056|NCT00694733|Menopausal Syndrome
502057|NCT00694733|Cortisol
502058|NCT00694720|Cheyne-stokes breathing
502059|NCT00694694|Malaria
502060|NCT00694694|Africa
502061|NCT00694694|Child
502062|NCT00694681|Telephonic care management
502063|NCT00694668|Deliberate Self-Harm
502064|NCT00694668|Self-Injurious Behaviour
502065|NCT00694668|Suicidal Behaviour
502066|NCT00694668|Cognitive behavioural therapy
502067|NCT00694668|Mindfulness Based cognitive therapy
502068|NCT00694655|Yellow Fever
502069|NCT00694655|Vaccine
502070|NCT00694655|Immunity
502071|NCT00694655|yellow fever vaccine
502072|NCT00694655|CD8 T cell responses
502073|NCT00694642|Refractory angina
502074|NCT00694629|pulmonary tuberculosis
502075|NCT00694629|treatment
502076|NCT00694616|Obstructive sleep apnea
502077|NCT00694616|Metabolic syndrome
502078|NCT00694616|Insulin resistance
502079|NCT00694616|Hypertension
502080|NCT00694616|Dyslipidemia
502081|NCT00694616|Continuous positive airway pressure (CPAP)
502082|NCT00694603|cetuximab
502083|NCT00694603|tyrosine kinase inhibitor
502084|NCT00694590|AMD3100
502085|NCT00694590|Rituximab
502086|NCT00694590|Chronic Lymphocytic Leukemia
502087|NCT00694590|CLL
502088|NCT00694590|Small Lymphocytic Lymphoma
502089|NCT00694590|SLL
502090|NCT00694577|non-invasive breast cancer
502091|NCT00694577|early invasive breast cancer
502092|NCT00694577|radiation
502093|NCT00694577|PBI
502094|NCT00694564|abdominal pain
502095|NCT00694564|children
502096|NCT00694551|vaccine
502097|NCT00694551|PSMA
502098|NCT00694551|TARP
502099|NCT00694551|immunology
502100|NCT00694551|PSA
502101|NCT00694538|Interferential laser therapy
502102|NCT00694525|21OHD
502103|NCT00694525|21-hydroxylase deficiency
502104|NCT00694525|CAH
502105|NCT00694499|Morbidity
502106|NCT00694499|Mortality
502107|NCT00694486|otitis
502108|NCT00694486|Eustachian tube function
502109|NCT00694486|Normal middle ear status
502110|NCT00694473|hyperglycemia
502111|NCT00694473|hypoglycemia
502112|NCT00694473|insulin
502113|NCT00694473|critical illness
502114|NCT00694473|intensive insulin therapy
502115|NCT00694473|continuous glucose monitoring
502116|NCT00694473|CGM
502117|NCT00694473|interstitial fluid glucose
502118|NCT00694473|intensive care unit
502119|NCT00694473|Blood glucose
502120|NCT00694460|rabies vaccination
502121|NCT00694460|pre-exposure prophylaxis
502122|NCT00694460|rabies virus neutralizing antibody
502123|NCT00694434|Cryopreservation
502124|NCT00694434|Frozen embryo transfer
502125|NCT00694434|Graduated Embryo Score
502126|NCT00694421|otitis
502127|NCT00694421|Eustachian tube
502128|NCT00694421|virus
502129|NCT00694421|Middle ear disease
502130|NCT00694408|End stage liver disease
502131|NCT00694408|Paediatric liver transplantation
502132|NCT00694408|Steroid free immunosuppression
502133|NCT00694395|Qualitative study
502134|NCT00694395|stroke
502135|NCT00694395|20 patients, Family or caregivers
502136|NCT00694395|acute ischemic stroke
502137|NCT00694395|delayed to receive thrombolytic therapy.
502138|NCT00694382|chemotherapy
502139|NCT00694369|Postoperative Dental Pain
502140|NCT00694343|Cesarean section
502141|NCT00694343|spinal anesthesia
502142|NCT00694343|hypotension
502143|NCT00694330|vaccine
502144|NCT00694330|GM-K562
502145|NCT00694330|malignant glioma
502146|NCT00694304|Major Depressive Disorder
502147|NCT00694304|Long-term
502148|NCT00694304|Safety
502149|NCT00694304|Open-label
502150|NCT00694291|Rising PSA
502151|NCT00694265|Carpal Tunnel Syndrome
502152|NCT00694265|Median Nerve
502153|NCT00694265|Ultrasonography
502154|NCT00694265|Prospective cohort study
502155|NCT00694252|Breast cancer
502156|NCT00694252|Tykerb
502157|NCT00694252|CTCs
502158|NCT00694239|hypertension
502159|NCT00694239|compliance
502160|NCT00694226|Adolescent
502161|NCT00694226|Substance use
502162|NCT00694226|Brief intervention
502163|NCT00694226|Child psychiatry
502164|NCT00694213|Pandemic Influenza
502165|NCT00694213|Avian Influenza
502166|NCT00694213|DNA Vaccines
502167|NCT00694213|Antibody
502168|NCT00694213|T Cells
502169|NCT00694213|HA/NP/M2
502170|NCT00694213|Biojector
502171|NCT00694200|breast cancer
502172|NCT00694200|chemotherapy
502173|NCT00694200|anti-angiogenesis therapy
502174|NCT00694174|Procedural Pain in Newborn Infants
502175|NCT00694174|newborn infant
502176|NCT00694174|acute procedural pain
502177|NCT00694174|skin blood flow changes
502178|NCT00694174|sucrose analgesia
502179|NCT00694174|laser doppler imager
502180|NCT00694174|neonatal infant pain scale
502181|NCT00694161|Transthyretin
502182|NCT00694161|TTR
502183|NCT00694161|ATTR
502184|NCT00694161|TTR amyloidosis
502185|NCT00694161|cardiomyopathy
502186|NCT00694161|V122I
502187|NCT00694161|wild-type TTR
502188|NCT00694161|SSA
502189|NCT00694161|Patients with V122I or wild-type TTR amyloid cardiomyopathy
502190|NCT00694148|Treatment of glabellar frown lines
502191|NCT00694135|Iontophoresis
502192|NCT00694135|Non-Infectious Acute Anterior Segment Uveitis
502193|NCT00694135|Ophthalmology
502194|NCT00694122|glucose
502195|NCT00694122|cortisol
502196|NCT00694122|growth hormone
502197|NCT00694122|glucagon
502198|NCT00694122|insulin
502199|NCT00694109|Familial Hypercholesterolemia
502200|NCT00694109|FH
502201|NCT00694109|Heterozygous Familial Hypercholesterolemia
502202|NCT00694109|HeFH
502203|NCT00694109|Homozygous Familial Hypercholesterolemia
502204|NCT00694109|HoFH
502205|NCT00694057|Type 2 Diabetes Mellitus
502206|NCT00694057|Metformin
502207|NCT00694057|HbA1c
502208|NCT00694044|Safety, Tolerability, Pharmacokinetics, Cognition
502209|NCT00694031|Mortality
502210|NCT00694031|Convective therapies
502211|NCT00694031|On-line Hemodiafiltration
502212|NCT00694031|Dialysis Adequacy
502213|NCT00694031|Age 18 or older
502214|NCT00694031|Undergoing hemodialysis
502215|NCT00694018|randomized trial
502216|NCT00694018|walking
502217|NCT00694005|stent
502218|NCT00694005|bifurcation
502219|NCT00694005|balloon angioplasty
502220|NCT00693966|HPV, Vaccine
502221|NCT00693953|Evoked Potentials
502222|NCT00693953|Evoked Potentials, Auditory
502223|NCT00693953|Evoked Potentials, Visual
502224|NCT00693953|Electroencephalography
502225|NCT00693953|Brain Mapping
502226|NCT00693940|Peripheral Arterial Disease
502227|NCT00693940|PAD
502228|NCT00693927|Hematopoietic cell transplantation
502229|NCT00693927|Allogeneic
502230|NCT00693927|Nonmyeloablative
502231|NCT00693927|CD8-depletion
502232|NCT00693927|PBSC
502233|NCT00693927|GVHD
502234|NCT00693927|Hematological malignancies and renal cell carcinoma
502235|NCT00693914|Brain Tumor
502236|NCT00693914|Cognitive Late Effects
502237|NCT00693914|Radiation Therapy
502238|NCT00693914|Working Memory
502239|NCT00693888|dementia
502240|NCT00693888|system of care
502241|NCT00693888|level of care
502242|NCT00693888|interventional study
502243|NCT00693888|evaluation
502244|NCT00693888|dementia diagnostic
502245|NCT00693888|Evaluation of the care study
502246|NCT00693875|incidence
502247|NCT00693875|awareness
502248|NCT00693875|general anesthesia
502249|NCT00693875|relevant factor
502250|NCT00693875|the incidence of intra-operative awareness in China
502251|NCT00693875|the relevant factors
502252|NCT00693862|Focus of the study is pharmacokinetics of the study drug
502253|NCT00693849|depression
502254|NCT00693849|CNS
502255|NCT00693849|iSPOT
502256|NCT00693849|MDD
502257|NCT00693836|stage I non-small cell lung cancer
502258|NCT00693836|stage II non-small cell lung cancer
502259|NCT00693836|stage IIIA non-small cell lung cancer
502260|NCT00693836|stage IIIB non-small cell lung cancer
502261|NCT00693836|stage IV non-small cell lung cancer
502262|NCT00693836|recurrent non-small cell lung cancer
502263|NCT00693836|extensive stage small cell lung cancer
502264|NCT00693836|limited stage small cell lung cancer
502265|NCT00693836|recurrent small cell lung cancer
502266|NCT00693823|atherosclerosis
502267|NCT00693823|stent
502268|NCT00693823|angioplasty
502269|NCT00693823|covered stent
502270|NCT00693797|ventricular hypertrophy
502271|NCT00693797|collagen
502272|NCT00693797|aortic stenosis
502273|NCT00693784|Intervertebral Disk
502274|NCT00693784|chronic low back pain
502275|NCT00693784|internal disc disruption
502276|NCT00693784|degenerative disc disease
502277|NCT00693758|MRI
502278|NCT00693758|coronary reactivity
502279|NCT00693758|coronary physiology
502280|NCT00693745|Acutely
502281|NCT00693719|recurrent breast cancer
502282|NCT00693719|stage IIIA breast cancer
502283|NCT00693719|stage IIIB breast cancer
502284|NCT00693719|stage IIIC breast cancer
502285|NCT00693719|stage IV breast cancer
502286|NCT00693706|cell culture
502287|NCT00693706|Safety
502288|NCT00693706|Influenza
502289|NCT00693706|Humans
502290|NCT00693706|Adults
502291|NCT00693706|Immunogenicity
502292|NCT00693706|Influenza vaccine
502293|NCT00693706|Vaccine
502294|NCT00693680|depression
502295|NCT00693680|antidepressant treatment
502296|NCT00693680|zinc
502297|NCT00693680|placebo
502298|NCT00693667|osteoporosis
502299|NCT00693667|postmenopausal women
502300|NCT00693667|botanical drug
502301|NCT00693654|Uremic Pruritis
502302|NCT00693641|Jellyfish
502303|NCT00693641|Cyanea sp
502304|NCT00693641|Safe Sea
502305|NCT00693641|Prevention
502306|NCT00693641|treatment
502307|NCT00693641|Pain relief
502308|NCT00693641|Prevention of pain
502309|NCT00693628|volume
502310|NCT00693628|healing
502311|NCT00693628|shrinker
502312|NCT00693628|transtibial amputation
502313|NCT00693628|individuals who have undergone transtibial amputation
502314|NCT00693615|HPV, Vaccine
502315|NCT00693589|endothelial function
502316|NCT00693589|flow mediated dilatation
502317|NCT00693589|rosuvastatin
502318|NCT00693589|folic acid
502319|NCT00693589|B vitamins
502320|NCT00693576|renal transplant
502321|NCT00693576|panel reactive antibody
502322|NCT00693576|sensitization
502323|NCT00693576|simvastatin
502324|NCT00693576|immunological
502325|NCT00693563|Spinal Cord Injury
502326|NCT00693550|lip and oral cavity squamous cell carcinoma
502327|NCT00693550|oropharyngeal squamous cell carcinoma
502328|NCT00693524|liver allograft transplantation
502329|NCT00693524|sequential therapy
502330|NCT00693524|tacrolimus
502331|NCT00693511|obesity
502332|NCT00693511|adolescents
502333|NCT00693511|adiposity
502334|NCT00693511|insulin sensitivity
502335|NCT00693511|type 2 diabetes
502336|NCT00693511|Latino
502337|NCT00693511|circuit training
502338|NCT00693511|physical activity
502339|NCT00693511|motivational interviewing
502340|NCT00693498|pediatrics
502341|NCT00693498|congenital heart disease
502342|NCT00693472|Antipsychotic Agents
502343|NCT00693459|Hemorrhoids
502344|NCT00693446|Pancreas-kidney allograft
502345|NCT00693446|tacrolimus
502346|NCT00693446|sirolimus
502347|NCT00693446|Pancreas-kidney allograft recipients
502348|NCT00693381|Transplantation
502349|NCT00693381|Graft Rejection
502350|NCT00693381|Renal Transplantation
502351|NCT00693355|gut health
502352|NCT00693342|stage IA primary peritoneal cavity cancer
502353|NCT00693342|stage IB primary peritoneal cavity cancer
502354|NCT00693342|stage IC primary peritoneal cavity cancer
502355|NCT00693342|stage IIA primary peritoneal cavity cancer
502356|NCT00693342|stage IIB primary peritoneal cavity cancer
502357|NCT00693342|stage IIC primary peritoneal cavity cancer
502358|NCT00693342|stage IIIA primary peritoneal cavity cancer
502359|NCT00693342|stage IIIB primary peritoneal cavity cancer
502360|NCT00693342|stage IIIC primary peritoneal cavity cancer
502361|NCT00693342|stage IV primary peritoneal cavity cancer
502362|NCT00693342|stage IA fallopian tube cancer
502363|NCT00693342|stage IB fallopian tube cancer
502364|NCT00693342|stage IC fallopian tube cancer
502365|NCT00693342|stage IIA fallopian tube cancer
502366|NCT00693342|stage IIB fallopian tube cancer
502367|NCT00693342|stage IIC fallopian tube cancer
502368|NCT00693342|stage IIIA fallopian tube cancer
502369|NCT00693342|stage IIIB fallopian tube cancer
502370|NCT00693342|stage IIIC fallopian tube cancer
502371|NCT00693342|stage IV fallopian tube cancer
502372|NCT00693342|stage IA ovarian epithelial cancer
502373|NCT00693342|stage IB ovarian epithelial cancer
502374|NCT00693342|stage IC ovarian epithelial cancer
502375|NCT00693342|stage IIA ovarian epithelial cancer
502376|NCT00693342|stage IIB ovarian epithelial cancer
502377|NCT00693342|stage IIC ovarian epithelial cancer
502378|NCT00693342|stage IIIA ovarian epithelial cancer
502379|NCT00693342|stage IIIB ovarian epithelial cancer
502380|NCT00693342|stage IIIC ovarian epithelial cancer
502381|NCT00693342|stage IV ovarian epithelial cancer
502382|NCT00693329|Contrast Induced Nephrophathy (CIN)
502383|NCT00693329|Kidney
502384|NCT00693329|NGAL
502385|NCT00693316|Healthy volunteer study
502386|NCT00693303|single subject
502387|NCT00693303|quantitative
502388|NCT00693290|Colonoscopy
502389|NCT00693290|Colorectal screening
502390|NCT00693290|Colon preparation
502391|NCT00693277|none - entry made in error
502392|NCT00693264|Human Volunteers
502393|NCT00693264|Hoodia
502394|NCT00693264|Safety
502395|NCT00693251|stent
502396|NCT00693251|bifurcation
502397|NCT00693251|coronary artery stenosis
502398|NCT00693251|balloon angioplasty
502399|NCT00693238|Prostate Cancer
502400|NCT00693238|Proton Radiation
502401|NCT00693225|Erosive Esophagitis
502402|NCT00693225|Reflux Esophagitis
502403|NCT00693225|Gastroesophageal reflux disease
502404|NCT00693225|GERD
502405|NCT00693225|proton pump inhibitor
502406|NCT00693225|omeprazole/sodium bicarbonate
502407|NCT00693212|ADHD
502408|NCT00693212|Adult
502409|NCT00693212|crossover
502410|NCT00693212|randomized
502411|NCT00693212|Long-term
502412|NCT00693212|Open-label
502413|NCT00693212|methylphenidate
502414|NCT00693212|Social adjustment
502415|NCT00693199|Amlodipine
502416|NCT00693199|Terazosin
502417|NCT00693199|Lower Urinary Tract Symptoms (LUTS)
502418|NCT00693199|Essential hypertension
502419|NCT00693199|International Prostate Symptom Score (IPSS)
502420|NCT00693199|Quality Of Life (QOL)
502421|NCT00693173|anal
502422|NCT00693173|cancer
502423|NCT00693173|rectal
502424|NCT00693173|IMRT
502425|NCT00693173|genital
502426|NCT00693173|sparing
502427|NCT00693173|drop
502428|NCT00693173|technique
502429|NCT00693160|healthy volunteers
502430|NCT00693160|analgesia
502431|NCT00693160|pain
502432|NCT00693160|Healthy subjects
502433|NCT00693147|Goiter [C19.874.283]
502434|NCT00693147|Thyroid Neoplasms [C19.874.788]
502435|NCT00693121|Traumatic Brain Injury
502436|NCT00693121|Posttraumatic Confusional State
502437|NCT00693121|Delirium
502438|NCT00693121|Amantadine
502439|NCT00693121|Clinical trial
502440|NCT00693108|Poor
502441|NCT00693108|Response
502442|NCT00693108|Ovarian
502443|NCT00693108|Stimulation
502444|NCT00693108|IVF
502445|NCT00693108|Patients
502446|NCT00693095|Grade IV Glioblastoma Multiforme
502447|NCT00693095|Newly-diagnosed
502448|NCT00693095|CMV positive
502449|NCT00693082|PCOS
502450|NCT00693082|flaxseed
502451|NCT00693069|angioplasty
502452|NCT00693069|clopidogrel
502453|NCT00693069|coronary artery disease
502454|NCT00693069|platelets
502455|NCT00693069|Percutaneous coronary intervention
502456|NCT00693056|Erectile Dysfunctions
502457|NCT00693056|ED
502458|NCT00693043|Pain control
502459|NCT00693030|Coronary Artery Disease
502460|NCT00693030|Percutaneous Coronary Interventions
502461|NCT00693030|Drug-Eluting stents
502462|NCT00693030|Optical Coherence Tomography
502463|NCT00693030|Thrombosis
502464|NCT00693030|Long lesions in native vessel requiring stents in overlap
502465|NCT00692991|Microvascular Obstruction
502466|NCT00692991|Cardiac MRI
502467|NCT00692991|Alcohol Ablation
502468|NCT00692991|Diagnostic PCI
502469|NCT00692978|Monodisperse aerosols
502470|NCT00692978|Healthy Volunteers
502471|NCT00692978|Asthmatics
502472|NCT00692978|Pharmacokinetics
502473|NCT00692978|Randomized
502474|NCT00692965|HIV
502475|NCT00692965|Sleep Quality
502476|NCT00692965|Sleep apnea
502477|NCT00692965|Berlin Questionnaire
502478|NCT00692965|Pittsburgh Sleep Quality Index
502479|NCT00692952|contraceptive efficacy
502480|NCT00692939|Stem cell transplantation
502481|NCT00692939|Crohn's Disease
502482|NCT00692926|ALDHbr
502483|NCT00692926|Umbilical Cord Blood
502484|NCT00692926|Transplantation
502485|NCT00692926|Hematological malignancy
502486|NCT00692926|MDS
502487|NCT00692926|severe aplastic anemia
502488|NCT00692926|inborn error of metabolism
502489|NCT00692926|congenital marrow failure or congenital immunodeficiency syndrome
502490|NCT00692926|Hurler's Disease
502491|NCT00692926|Tay Sach's
502492|NCT00692926|PMD
502493|NCT00692926|Hunter's Syndrome
502494|NCT00692926|Krabbe
502495|NCT00692926|MLD
502496|NCT00692926|ALD
502497|NCT00692926|ALL
502498|NCT00692926|AML
502499|NCT00692887|AMD
502500|NCT00692874|Quality of Life
502501|NCT00692861|Celiac Disease
502502|NCT00692861|Ataxia
502503|NCT00692861|Adults
502504|NCT00692861|Health Volunteer
502505|NCT00692861|HV
502506|NCT00692848|Procalcitonin
502507|NCT00692848|Antibiotic
502508|NCT00692848|Fever without source
502509|NCT00692848|Fever without focus
502510|NCT00692848|bacteremia
502511|NCT00692848|Urinary tract infection
502512|NCT00692835|Goiter [C19.874.283]
502513|NCT00692835|Thyroid Neoplasms [C19.874.788]
502514|NCT00692822|Neisseria gonorrheae
502515|NCT00692822|Antimicrobial Susceptibility
502516|NCT00692822|Quinolone Resistance
502517|NCT00692822|Sexually transmitted diseases
502518|NCT00692809|Latent tuberculosis infection
502519|NCT00692809|Human immunodeficiency virus
502520|NCT00692809|Tuberculosis
502521|NCT00692809|Natural Killer T Cells
502522|NCT00692809|Invariant Natural Killer T Cells
502523|NCT00692809|Regulatory T cells
502524|NCT00692809|Interferon-gamma
502525|NCT00692796|Pulmonary fibrosis
502526|NCT00692796|Pulmonary rehabilitation
502527|NCT00692796|Dyspnea
502528|NCT00692796|Quality of life
502529|NCT00692783|candida
502530|NCT00692783|dubliniensis
502531|NCT00692783|candidiasis
502532|NCT00692783|HIV
502533|NCT00692783|AIDS
502534|NCT00692783|azole resistance.
502535|NCT00692770|Hepatocellular carcinoma
502536|NCT00692770|Sorafenib
502537|NCT00692770|Adjuvant
502538|NCT00692770|Surgical resection
502539|NCT00692770|Ablation
502540|NCT00692770|Nexavar
502541|NCT00692770|Adjuvant therapy
502542|NCT00692770|Liver cancer
502543|NCT00692770|HCC
502544|NCT00692770|STORM
502545|NCT00692757|Hypochlorous Acid
502546|NCT00692757|Colony forming units
502547|NCT00692757|surgical site infection
502548|NCT00692757|nosocomial infection
502549|NCT00692757|bacterial bioburden
502550|NCT00692757|wound healing
502551|NCT00692744|Subarachnoid hemorrhage
502552|NCT00692744|Cerebral aneurysm
502553|NCT00692744|Elderly
502554|NCT00692731|green tea,
502555|NCT00692731|polyphenols,
502556|NCT00692731|weight loss,
502557|NCT00692731|body fat
502558|NCT00692705|Alzheimer´s Disease
502559|NCT00692705|amyloid deposits
502560|NCT00692705|Positron Emission Tomography
502561|NCT00692705|phase I
502562|NCT00692653|Localized prostate cancer
502563|NCT00692653|Treatment decision making
502564|NCT00692653|Tailored decision aid
502565|NCT00692640|Cancer
502566|NCT00692640|Solid Tumors
502567|NCT00692640|NSCLC
502568|NCT00692627|Falciparum
502569|NCT00692627|malaria
502570|NCT00692627|volume
502571|NCT00692627|haemodynamics
502572|NCT00692601|Acute Exercise protocol
502573|NCT00692601|Crossover design
502574|NCT00692601|Oxygen consumption (VO2)
502575|NCT00692601|Respiratory Exchange Ratio (RER)
502576|NCT00692601|Adrenergic System Agonism
502577|NCT00692601|Capsiate Natura
502578|NCT00692601|Young
502579|NCT00692601|Male
502580|NCT00692588|Alzheimer's Disease
502581|NCT00692588|Magnetic Resonance Imaging
502582|NCT00692588|Magnetic Resonance Spectroscopy
502583|NCT00692588|Diffusion Tensor Imaging
502584|NCT00692588|Susceptibility Weighted Imaging
502585|NCT00692588|Doxycycline
502586|NCT00692588|Rifampicin
502587|NCT00692575|Brain Injuries, Traumatic
502588|NCT00692575|Caregivers
502589|NCT00692562|Islets of Langerhans Transplantation
502590|NCT00692562|Kidney Transplantation
502591|NCT00692562|Type 1 Diabetes Mellitus
502592|NCT00692562|alemtuzumab
502593|NCT00692549|ultrasound
502594|NCT00692549|iv access
502595|NCT00692549|Patients with difficult iv access in emergency departments.
502596|NCT00692536|Obesity
502597|NCT00692536|Postmenopausal
502598|NCT00692536|Diet intervention
502599|NCT00692523|Stroke
502600|NCT00692523|rehabilitation
502601|NCT00692523|Nintendo Wii
502602|NCT00692510|AZD3480
502603|NCT00692510|Cocktail
502604|NCT00692510|caffeine
502605|NCT00692510|bupropion
502606|NCT00692510|omeprazole
502607|NCT00692510|midazolam
502608|NCT00692510|rosiglitazone
502609|NCT00692510|metabolism
502610|NCT00692510|Drug Drug Interaction
502611|NCT00692497|One-Stop
502612|NCT00692497|Public Health Research
502613|NCT00692497|Delivery of Health Care/*standards
502614|NCT00692497|Evaluation Studies
502615|NCT00692497|Referral
502616|NCT00692497|Surgery, Outpatient
502617|NCT00692497|Surgery, Day
502618|NCT00692497|Telemedicine
502619|NCT00692484|Antimicrobial
502620|NCT00692484|Antisepsis
502621|NCT00692484|Topical antisepsis
502622|NCT00692471|Sleep
502623|NCT00692471|Orthostatic tachycardia
502624|NCT00692471|POTS
502625|NCT00692445|depression
502626|NCT00692432|Macrophage Migration Inhibitory Factor
502627|NCT00692432|MIF
502628|NCT00692432|Cardiopulmonary bypass
502629|NCT00692432|CPB
502630|NCT00692432|inflammation
502631|NCT00692432|inflammatory marker
502632|NCT00692432|myocardial depression
502633|NCT00692432|myocardial depressant factor
502634|NCT00692419|pain
502635|NCT00692419|sexual dysfunction
502636|NCT00692419|depression
502637|NCT00692419|symptoms
502638|NCT00692380|gated IMRT
502639|NCT00692367|Body fat
502640|NCT00692367|Exercise
502641|NCT00692367|Fatty acids
502642|NCT00692367|Impaired glucose tolerance
502643|NCT00692367|Insulin resistance
502644|NCT00692367|Insulin Sensitivity
502645|NCT00692367|Metabolic syndrome
502646|NCT00692367|Obesity
502647|NCT00692367|Physical activity
502648|NCT00692367|Weight Loss
502649|NCT00692354|Advanced
502650|NCT00692354|Solid
502651|NCT00692354|Tumour
502652|NCT00692354|Tumor
502653|NCT00692354|Oral
502654|NCT00692341|hepatic impairment
502655|NCT00692328|fatigue; TMS; MEP
502656|NCT00692315|glutathione
502657|NCT00692315|methionine
502658|NCT00692315|folinic acid
502659|NCT00692315|redox
502660|NCT00692315|oxidative stress
502661|NCT00692315|behavior
502662|NCT00692302|Suicide Attempts
502663|NCT00692302|Adolescents
502664|NCT00692302|Suicidal
502665|NCT00692302|Adolescent Suicide Attempters
502666|NCT00692289|Quality of Life
502667|NCT00692263|Healthy subjects
502668|NCT00692250|Familial Hypercholesterolemia
502669|NCT00692237|Type 2 diabetes mellitus
502670|NCT00692237|Endothelial dysfunction
502671|NCT00692237|Sildenafil
502672|NCT00692224|neonatal jaundice
502673|NCT00692224|zinc
502674|NCT00692224|hyperbilirubinemia
502675|NCT00692224|enterohepatic circulation
502676|NCT00692224|bilirubin
502677|NCT00692211|screening
502678|NCT00692198|COPD
502679|NCT00692185|Anorexia Nervosa
502680|NCT00692172|psoriasis
502681|NCT00692172|alefacept
502682|NCT00692172|intramuscular
502683|NCT00692159|TRC102
502684|NCT00692159|Methoxyamine HCL
502685|NCT00692159|Pemetrexed
502686|NCT00692159|Alimta
502687|NCT00692159|Tracon
502688|NCT00692159|Phase 1
502689|NCT00692159|Cancer
502690|NCT00692159|BER
502691|NCT00692159|Base Excision Repair
502692|NCT00692159|Small Molecule
502693|NCT00692159|Anti-folate
502694|NCT00692159|Solid Tumor
502695|NCT00692159|Neoplastic Processes
502696|NCT00692159|Pathologic Processes
502697|NCT00692159|Pathological Conditions, Signs and Symptoms
502698|NCT00692146|Proof of Mechanism
502699|NCT00692146|Capsaicin evoked pain
502700|NCT00692133|schizophrenia
502701|NCT00692133|bipolar disorder
502702|NCT00692133|antipsychotic treatment
502703|NCT00692133|patients´preferences
502704|NCT00692107|Radiotherapy
502705|NCT00692107|Dose
502706|NCT00692094|melatonin
502707|NCT00692094|circadian rhythms
502708|NCT00692094|sleep
502709|NCT00692081|adolescents
502710|NCT00692081|borderline intellectual functioning
502711|NCT00692081|social competence training
502712|NCT00692081|vocational training
502713|NCT00692081|group intervention
502714|NCT00692081|cognitive behavioral therapy
502715|NCT00692081|Adolescents with borderline intellectual functioning
502716|NCT00692068|residual renal function
502717|NCT00692068|oxidative stress
502718|NCT00692068|carbonyl stress
502719|NCT00692068|peritoneal dialysis
502720|NCT00692042|Safety
502721|NCT00692042|tolerability
502722|NCT00692029|Normal
502723|NCT00692029|Healthy Volunteers
502724|NCT00692016|Naproxen Sodium
502725|NCT00691990|Goiter [C19.874.283]
502726|NCT00691990|Thyroid Neoplasms [C19.874.788]
502727|NCT00691977|Radiation Therapy
502728|NCT00691938|LBH589
502729|NCT00691938|Decitabine
502730|NCT00691938|panobinostat
502731|NCT00691938|histone deacetylase
502732|NCT00691938|methylation
502733|NCT00691938|hypomethylation
502734|NCT00691925|refractive surgery
502735|NCT00691886|sedation
502736|NCT00691873|Allergic
502737|NCT00691873|Asthma
502738|NCT00691873|Immunotherapy
502739|NCT00691860|Parastomal hernias
502740|NCT00691860|Tolerance of lightweight meshes
502741|NCT00691860|Paracolostomy hernias
502742|NCT00691860|Peristomal hernias
502743|NCT00691847|Refractive surgery
502744|NCT00691834|Magnetic resonance Imaging
502745|NCT00691821|Negative-Pressure Wound Therapy
502746|NCT00691821|Bandages
502747|NCT00691821|Community Health Services
502748|NCT00691795|Analgesia
502749|NCT00691795|Epidural
502750|NCT00691795|Pregnancy
502751|NCT00691795|Labor
502752|NCT00691795|Clonidine
502753|NCT00691795|Fentanyl
502754|NCT00691795|Bupivacaine
502755|NCT00691795|Childbirth
502756|NCT00691782|African American females between the ages of 21 and 60
502757|NCT00691769|alopecia
502758|NCT00691769|lupus
502759|NCT00691756|renal failure
502760|NCT00691756|thoracoabdominal aortic aneurysm repair
502761|NCT00691756|cold crystalloid
502762|NCT00691756|cold blood
502763|NCT00691756|renal perfusion
502764|NCT00691743|Upper GI Symptoms
502765|NCT00691743|GERD
502766|NCT00691743|NSAIDs
502767|NCT00691717|Anecortave acetate
502768|NCT00691717|Open-angle glaucoma
502769|NCT00691717|IOP
502770|NCT00691717|OHT
502771|NCT00691704|Multiple Myeloma
502772|NCT00691691|Liver malignancy
502773|NCT00691691|Stereotactic Body Radiation Therapy
502774|NCT00691691|Efficacy of SBRT in liver tumors
502775|NCT00691691|Hepatic toxicity with SBRT
502776|NCT00691678|breast cancer
502777|NCT00691678|aromatase inhibitor
502778|NCT00691678|supportive care
502779|NCT00691665|Rhinitis
502780|NCT00691665|Seasonal Allergic Rhinitis
502781|NCT00691665|allergies
502782|NCT00691652|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
502783|NCT00691652|nodal marginal zone B-cell lymphoma
502784|NCT00691652|splenic marginal zone lymphoma
502785|NCT00691652|recurrent adult Burkitt lymphoma
502786|NCT00691652|recurrent adult diffuse large cell lymphoma
502787|NCT00691652|recurrent adult diffuse mixed cell lymphoma
502788|NCT00691652|recurrent adult diffuse small cleaved cell lymphoma
502789|NCT00691652|recurrent adult grade III lymphomatoid granulomatosis
502790|NCT00691652|recurrent adult immunoblastic large cell lymphoma
502791|NCT00691652|recurrent adult lymphoblastic lymphoma
502792|NCT00691652|recurrent grade 1 follicular lymphoma
502793|NCT00691652|recurrent grade 2 follicular lymphoma
502794|NCT00691652|recurrent grade 3 follicular lymphoma
502795|NCT00691652|recurrent mantle cell lymphoma
502796|NCT00691652|recurrent marginal zone lymphoma
502797|NCT00691652|recurrent small lymphocytic lymphoma
502798|NCT00691652|cutaneous B-cell non-Hodgkin lymphoma
502799|NCT00691639|Open-angle glaucoma
502800|NCT00691639|IOP
502801|NCT00691626|posttraumatic stress
502802|NCT00691626|nightmares
502803|NCT00691626|sleep
502804|NCT00691626|psychotherapy
502805|NCT00691626|imagery rehearsal
502806|NCT00691626|insomnia
502807|NCT00691626|behavioral treatment
502808|NCT00691626|veterans
502809|NCT00691626|Operation Iraqi Freedom
502810|NCT00691626|Operation Enduring Freedom
502811|NCT00691613|Apoptosis
502812|NCT00691613|Annexin
502813|NCT00691613|Hypoxia
502814|NCT00691613|Ischemia-Reperfusion Injury
502815|NCT00691600|abscess
502816|NCT00691600|Abscesses in the pediatric emergency population
502817|NCT00691587|mechanical ventilation
502818|NCT00691587|mechanically ventilated
502819|NCT00691587|Pseudomonas aeruginosa
502820|NCT00691587|ventilator associated pneumonia
502821|NCT00691574|Smith-Magenis Syndrome
502822|NCT00691574|melatonin
502823|NCT00691574|circadian rhythm
502824|NCT00691574|sleep
502825|NCT00691561|HIV Prevention
502826|NCT00691561|African American
502827|NCT00691561|Black
502828|NCT00691561|gay
502829|NCT00691561|Men who have sex men
502830|NCT00691561|HIV Seronegativity
502831|NCT00691548|Stage IV cancer
502832|NCT00691522|PERITUMORAL BRAIN EDEMA
502833|NCT00691522|PRIMARY MALIGNANT BRAIN TUMORS
502834|NCT00691522|METASTATIC BRAIN TUMORS
502835|NCT00691509|breast cancer
502836|NCT00691496|HIV Prevention
502837|NCT00691496|African-American
502838|NCT00691496|gay
502839|NCT00691496|bisexual
502840|NCT00691496|intervention trial
502841|NCT00691496|HIV Seronegativity
502842|NCT00691483|smoking cessation
502843|NCT00691483|smoking treatment
502844|NCT00691483|patient self-selected quit date
502845|NCT00691470|Anticoagulation
502846|NCT00691470|Vitamin K-dependent clotting factor inhibitor
502847|NCT00691470|Coumadin
502848|NCT00691470|Warfarin
502849|NCT00691470|Atrial fibrillation
502850|NCT00691470|Prosthetic heart valve
502851|NCT00691470|Venous thromboembolic disease
502852|NCT00691470|Myocardial infarction or cardiomyopathy
502853|NCT00691470|Patients with one or more of the following indications for chronic warfarin anticoagulation:
502854|NCT00691470|Atrial fibrillation (paroxysmal, persistent or permanent, not due to a reversible cause, documented by ECG) or atrial flutter;
502855|NCT00691470|A prosthetic heart valve in the aortic or mitral position that requires chronic anticoagulation;
502856|NCT00691470|A history of venous thromboembolic disease (DVT and/or PE) requiring long term anticoagulation (> 6 months);
502857|NCT00691470|A history of myocardial infarction or cardiomyopathy requiring anticoagulation.
502858|NCT00691470|Currently receiving chronic warfarin therapy for another indication not listed, with Sponsor approval.
502859|NCT00691457|Contact lens
502860|NCT00691457|solution
502861|NCT00691457|confocal microscope
502862|NCT00691444|melatonin
502863|NCT00691444|circadian rhythms
502864|NCT00691444|sleep
502865|NCT00691418|perinatal
502866|NCT00691418|premature
502867|NCT00691418|pregnancy
502868|NCT00691418|gestation
502869|NCT00691405|Arformoterol
502870|NCT00691405|(R,R)-formoterol
502871|NCT00691392|Multi-Drug Resistant Tuberculosis
502872|NCT00691392|Extensively Drug Resistant Tuberculosis
502873|NCT00691392|MDR TB
502874|NCT00691392|XDR TB
502875|NCT00691392|MDR
502876|NCT00691392|XDR
502877|NCT00691379|Breast cancer
502878|NCT00691379|Triple negative
502879|NCT00691379|Chemotherapy
502880|NCT00691379|Anti-angiogenesis therapy
502881|NCT00691353|Bipolar Disorder
502882|NCT00691353|antipsychotics
502883|NCT00691353|social functioning
502884|NCT00691353|mood stabilizers
502885|NCT00691353|Bipolar Disorder Type I
502886|NCT00691353|atypical antipsychotics
502887|NCT00691353|monotherapy
502888|NCT00691353|cotherapy
502889|NCT00691340|POAG
502890|NCT00691340|Alzheimer's disease
502891|NCT00691340|cellular proteome
502892|NCT00691340|human leucocytes
502893|NCT00691340|vasospasm
502894|NCT00691340|Healthy subjects
502895|NCT00691327|Revision of augmentation or reconstruction
502896|NCT00691314|Stroke
502897|NCT00691314|Transietn Ischemic Attack
502898|NCT00691314|Stents
502899|NCT00691314|Stenosis
502900|NCT00691301|cervical squamous cell carcinoma
502901|NCT00691301|recurrent cervical cancer
502902|NCT00691301|stage III cervical cancer
502903|NCT00691301|stage IVA cervical cancer
502904|NCT00691301|stage IVB cervical cancer
502905|NCT00691288|omega-3 fatty acid
502906|NCT00691288|hypertriglyceridemia
502907|NCT00691288|HIV
502908|NCT00691288|pediatric
502909|NCT00691288|HAART
502910|NCT00691275|dehydration
502911|NCT00691275|acute gastroenteritis
502912|NCT00691275|ondansetron
502913|NCT00691275|rehydration
502914|NCT00691262|Atopic dermatitis
502915|NCT00691262|Prograf
502916|NCT00691262|Tacrolimus
502917|NCT00691262|FK506
502918|NCT00691262|Tacrolimus ointment
502919|NCT00691249|Diabetes
502920|NCT00691249|Diet
502921|NCT00691249|Fiber
502922|NCT00691236|osteosarcoma
502923|NCT00691236|zoledronic acid
502924|NCT00691236|bisphosphonates
502925|NCT00691236|adjuvant to chemotherapy
502926|NCT00691223|Focal dermal hypoplasia
502927|NCT00691223|Goltz syndrome
502928|NCT00691223|X linked disorders
502929|NCT00691223|PORCN
502930|NCT00691223|Wnt signaling
502931|NCT00691210|Hodgkin's Disease
502932|NCT00691210|Non-Hodgkin's Lymphoma
502933|NCT00691184|Onychomycosis, Toenail fungal infection, Terbinafine HCl, Pharmacokinetics
502934|NCT00691171|gastroesophageal reflux disease
502935|NCT00691171|GERD
502936|NCT00691171|nonsteroidal anti-inflammatory drugs
502937|NCT00691171|peptic ulcer
502938|NCT00691171|Diagnosed GERD
502939|NCT00691171|Atypical GERD symptoms
502940|NCT00691171|chronic NSAID therapy
502941|NCT00691171|Risk for ulcer
502942|NCT00691145|Atopic dermatitis
502943|NCT00691145|Tacrolimus ointment
502944|NCT00691132|non-small cell lung cancer
502945|NCT00691132|small cell lung cancer
502946|NCT00691132|tobacco use disorder
502947|NCT00691119|breast cancer
502948|NCT00691119|radiation
502949|NCT00691119|Relaxation and Visualization Therapy
502950|NCT00691119|relaxation
502951|NCT00691119|visualization
502952|NCT00691119|RVT
502953|NCT00691119|complementary and alternative medicine
502954|NCT00691119|CAM
502955|NCT00691119|alternative medicine
502956|NCT00691093|observational
502957|NCT00691080|Melatonin
502958|NCT00691080|Sleep
502959|NCT00691080|Autism
502960|NCT00691080|ASD
502961|NCT00691080|Sleep problems in children with autism spectrum disorder
502962|NCT00691054|recurrent pancreatic cancer
502963|NCT00691054|stage III pancreatic cancer
502964|NCT00691054|stage IV pancreatic cancer
502965|NCT00691041|HIV Prevention
502966|NCT00691041|Men who have sex with men
502967|NCT00691041|African American
502968|NCT00691041|Unprotected sex
502969|NCT00691041|HIV Seronegativity
502970|NCT00691028|Rheumatoid Arthritis
502971|NCT00691028|RA
502972|NCT00691028|Infliximab
502973|NCT00691028|TA-650
502974|NCT00691028|Remicade
502975|NCT00691015|stage III adult Burkitt lymphoma
502976|NCT00691015|stage III adult diffuse large cell lymphoma
502977|NCT00691015|stage III adult diffuse mixed cell lymphoma
502978|NCT00691015|stage III adult diffuse small cleaved cell lymphoma
502979|NCT00691015|stage III adult Hodgkin lymphoma
502980|NCT00691015|stage III adult immunoblastic large cell lymphoma
502981|NCT00691015|stage III adult lymphoblastic lymphoma
502982|NCT00691015|stage III grade 1 follicular lymphoma
502983|NCT00691015|stage III grade 2 follicular lymphoma
502984|NCT00691015|stage III grade 3 follicular lymphoma
502985|NCT00691015|stage III mantle cell lymphoma
502986|NCT00691015|stage III marginal zone lymphoma
502987|NCT00691015|stage III small lymphocytic lymphoma
502988|NCT00691015|stage IV adult Burkitt lymphoma
502989|NCT00691015|stage IV adult diffuse large cell lymphoma
502990|NCT00691015|stage IV adult diffuse mixed cell lymphoma
502991|NCT00691015|stage IV adult diffuse small cleaved cell lymphoma
502992|NCT00691015|stage IV adult Hodgkin lymphoma
502993|NCT00691015|stage IV adult immunoblastic large cell lymphoma
502994|NCT00691015|stage IV adult lymphoblastic lymphoma
502995|NCT00691015|stage IV grade 1 follicular lymphoma
502996|NCT00691015|stage IV grade 2 follicular lymphoma
502997|NCT00691015|stage IV grade 3 follicular lymphoma
502998|NCT00691015|stage IV mantle cell lymphoma
502999|NCT00691015|stage IV marginal zone lymphoma
503000|NCT00691015|stage IV small lymphocytic lymphoma
503001|NCT00691015|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
503002|NCT00691015|nodal marginal zone B-cell lymphoma
503003|NCT00691015|splenic marginal zone lymphoma
503004|NCT00691015|noncontiguous stage II adult Burkitt lymphoma
503005|NCT00691015|noncontiguous stage II adult diffuse large cell lymphoma
503006|NCT00691015|noncontiguous stage II adult diffuse mixed cell lymphoma
503007|NCT00691015|noncontiguous stage II adult diffuse small cleaved cell lymphoma
503008|NCT00691015|noncontiguous stage II adult immunoblastic large cell lymphoma
503009|NCT00691015|noncontiguous stage II adult lymphoblastic lymphoma
503010|NCT00691015|noncontiguous stage II grade 1 follicular lymphoma
503011|NCT00691015|noncontiguous stage II grade 2 follicular lymphoma
503012|NCT00691015|noncontiguous stage II grade 3 follicular lymphoma
503013|NCT00691015|noncontiguous stage II mantle cell lymphoma
503014|NCT00691015|noncontiguous stage II marginal zone lymphoma
503015|NCT00691015|noncontiguous stage II small lymphocytic lymphoma
503016|NCT00691015|accelerated phase chronic myelogenous leukemia
503017|NCT00691015|adult acute lymphoblastic leukemia in remission
503018|NCT00691015|adult acute myeloid leukemia in remission
503019|NCT00691015|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
503020|NCT00691015|adult acute myeloid leukemia with inv(16)(p13;q22)
503021|NCT00691015|adult acute myeloid leukemia with t(15;17)(q22;q12)
503022|NCT00691015|adult acute myeloid leukemia with t(16;16)(p13;q22)
503023|NCT00691015|adult acute myeloid leukemia with t(8;21)(q22;q22)
503024|NCT00691015|chronic phase chronic myelogenous leukemia
503025|NCT00691015|recurrent adult acute lymphoblastic leukemia
503026|NCT00691015|recurrent adult acute myeloid leukemia
503027|NCT00691015|secondary acute myeloid leukemia
503028|NCT00691015|stage III chronic lymphocytic leukemia
503029|NCT00691015|stage IV chronic lymphocytic leukemia
503030|NCT00691015|de novo myelodysplastic syndromes
503031|NCT00691015|myelodysplastic/myeloproliferative neoplasm, unclassifiable
503032|NCT00691015|previously treated myelodysplastic syndromes
503033|NCT00691015|secondary myelodysplastic syndromes
503034|NCT00691015|stage I multiple myeloma
503035|NCT00691015|stage II multiple myeloma
503036|NCT00691015|stage III multiple myeloma
503037|NCT00691015|primary myelofibrosis
503038|NCT00691015|atypical chronic myeloid leukemia, BCR-ABL negative
503039|NCT00691015|chronic eosinophilic leukemia
503040|NCT00691015|chronic myelomonocytic leukemia
503041|NCT00691015|chronic neutrophilic leukemia
503042|NCT00690989|Headache
503043|NCT00690989|Adherence
503044|NCT00690989|Followup
503045|NCT00690976|HIV Seronegativity
503046|NCT00690976|HIV risk behavior
503047|NCT00690976|Unprotected sex
503048|NCT00690976|men who have sex with men
503049|NCT00690976|gay
503050|NCT00690976|Latino
503051|NCT00690976|Unsafe Sex
503052|NCT00690963|Radiotherapy
503053|NCT00690963|Intensity-Modulated
503054|NCT00690963|Dose Fractionation
503055|NCT00690950|BPH
503056|NCT00690937|hypercholesterolemia, bile acid sequestrant, LDL-cholesterol
503057|NCT00690924|lung cancer
503058|NCT00690924|tobacco use disorder
503059|NCT00690924|squamous lung dysplasia
503060|NCT00690885|chronic cough
503061|NCT00690885|COPD
503062|NCT00690885|IPF
503063|NCT00690885|interferon alpha
503064|NCT00690872|recurrent lymphoepithelioma of the nasopharynx
503065|NCT00690872|recurrent squamous cell carcinoma of the nasopharynx
503066|NCT00690872|stage IV lymphoepithelioma of the nasopharynx
503067|NCT00690872|stage IV squamous cell carcinoma of the nasopharynx
503068|NCT00690859|Bipolar disorders
503069|NCT00690859|Predictors of recurrence
503070|NCT00690820|Cystic Fibrosis
503071|NCT00690820|Pancreatic Exocrine Insufficiency
503072|NCT00690807|eczema
503073|NCT00690781|casein
503074|NCT00690781|milk soluble proteins
503075|NCT00690781|protein feeding pattern
503076|NCT00690781|overweight
503077|NCT00690781|obesity
503078|NCT00690781|energy restriction
503079|NCT00690781|protein metabolism
503080|NCT00690781|lean body mass
503081|NCT00690781|body composition
503082|NCT00690781|nitrogen balance
503083|NCT00690781|protein synthesis
503084|NCT00690781|proteolysis
503085|NCT00690781|spread
503086|NCT00690781|pulse
503087|NCT00690768|Diabetic Retinopathy
503088|NCT00690768|Retinal detachment
503089|NCT00690768|Vitreous Hemorrhage
503090|NCT00690768|Bevacizumab
503091|NCT00690768|preoperative
503092|NCT00690768|pars plana vitrectomy
503093|NCT00690755|Diabetic
503094|NCT00690716|Nasal CO2
503095|NCT00690716|Phase II
503096|NCT00690716|Adaptive
503097|NCT00690716|Randomized
503098|NCT00690716|Double-Blind
503099|NCT00690716|Placebo-Controlled
503100|NCT00690716|Multiple-Dose
503101|NCT00690716|Multi-center
503102|NCT00690716|Safety
503103|NCT00690716|Efficacy
503104|NCT00690716|Mild Headache
503105|NCT00690716|Migraineur
503106|NCT00690703|non small cell lung cancer
503107|NCT00690703|pulmonary metastases
503108|NCT00690703|radiofrequency ablation
503109|NCT00690690|HIV Seronegativity
503110|NCT00690690|HIV risk behavior
503111|NCT00690690|Unprotected sex
503112|NCT00690690|men who have sex with men
503113|NCT00690690|gay
503114|NCT00690690|Latino
503115|NCT00690690|unsafe sex
503116|NCT00690690|high risk sex
503117|NCT00690677|LBH589
503118|NCT00690677|Metastatic Colorectal Cancer
503119|NCT00690677|Refractory Colorectal Cancer
503120|NCT00690664|Hair characteristics
503121|NCT00690651|ankle
503122|NCT00690651|fracture
503123|NCT00690651|mobilisation
503124|NCT00690651|bed rest
503125|NCT00690651|internal fixation
503126|NCT00690638|dutogliptin
503127|NCT00690638|PHX1149
503128|NCT00690638|DPP4 inhibitor
503129|NCT00690625|Myofacial pain
503130|NCT00690625|Omega 3 fatty acids
503131|NCT00690612|pediatric
503132|NCT00690612|renal disease
503133|NCT00690612|high blood pressure
503134|NCT00690599|Patient satisfaction
503135|NCT00690599|Dentist-Patient relations
503136|NCT00690599|Answering services
503137|NCT00690586|Nephrotic syndrome
503138|NCT00690586|Underfill and overfill theory
503139|NCT00690586|Steroid resistance
503140|NCT00690586|Urine proteomics
503141|NCT00690586|AVP
503142|NCT00690586|ANP
503143|NCT00690586|Angiotensin II
503144|NCT00690586|Renin and Aldosterone
503145|NCT00690573|Juvenile Rheumatoid Arthritis
503146|NCT00690560|contiguous stage II adult diffuse large cell lymphoma
503147|NCT00690560|noncontiguous stage II adult diffuse large cell lymphoma
503148|NCT00690560|stage I adult diffuse large cell lymphoma
503149|NCT00690560|stage III adult diffuse large cell lymphoma
503150|NCT00690560|stage IV adult diffuse large cell lymphoma
503151|NCT00690547|Functionality
503152|NCT00690547|Deliberately
503153|NCT00690547|Activated
503154|NCT00690547|Quadriceps
503155|NCT00690547|Femoris
503156|NCT00690547|During
503157|NCT00690547|After
503158|NCT00690547|Active
503159|NCT00690547|Extension
503160|NCT00690534|sarcopenia
503161|NCT00690534|aging
503162|NCT00690534|muscle metabolism
503163|NCT00690521|congestive heart failure
503164|NCT00690521|diuretics
503165|NCT00690521|combination
503166|NCT00690508|Intubation, Trachea, Sternum,
503167|NCT00690508|Tube tip, Tube placement, Tube tip palpation,
503168|NCT00690508|Validate
503169|NCT00690508|use
503170|NCT00690508|SSTTP
503171|NCT00690508|corrrect
503172|NCT00690508|placement
503173|NCT00690495|Anesthesia
503174|NCT00690495|Induction
503175|NCT00690495|Pain
503176|NCT00690482|COPD
503177|NCT00690456|Randomized Controlled Trial
503178|NCT00690456|Metformin
503179|NCT00690443|Hyperlipidemia
503180|NCT00690430|Carcinoid
503181|NCT00690430|neuroendocrine
503182|NCT00690430|gastroenteropancreatic
503183|NCT00690430|somatostatin analogue
503184|NCT00690430|Symptomatic Refractory Resistant Carcinoid Disease
503185|NCT00690404|formulation
503186|NCT00690404|pharmacokinetic
503187|NCT00690404|crossover formulation
503188|NCT00690404|food effect
503189|NCT00690404|oral solution
503190|NCT00690404|healthy volunteers
503191|NCT00690391|surgery
503192|NCT00690391|prognostic
503193|NCT00690391|palliation
503194|NCT00690365|Switching
503195|NCT00690365|Quetiapine
503196|NCT00690365|schizophrenia
503197|NCT00690365|unsuccessfully treated
503198|NCT00690365|antipsychotics
503199|NCT00690352|Specialized Substance Abuse Supervision
503200|NCT00690352|SSAS
503201|NCT00690352|substance use disorder
503202|NCT00690352|felony drug offender
503203|NCT00690352|probation
503204|NCT00690352|parole
503205|NCT00690352|cognitive behavioral therapy
503206|NCT00690352|CBT
503207|NCT00690326|physical activity
503208|NCT00690326|Diabetes mellitus
503209|NCT00690326|Behavioral change communication
503210|NCT00690326|Household physical activity
503211|NCT00690313|Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis
503212|NCT00690300|adenocarcinoma of the pancreas
503213|NCT00690300|pancreatic cancer
503214|NCT00690300|pancreas carcinoma
503215|NCT00690300|advanced pancreatic cancer
503216|NCT00690300|metastatic pancreatic cancer
503217|NCT00690300|second line
503218|NCT00690300|palliative
503219|NCT00690300|Oxaliplatin
503220|NCT00690300|Docetaxel
503221|NCT00690300|Taxotere
503222|NCT00690300|Eloxatin
503223|NCT00690300|Cancer of pancreas
503224|NCT00690300|Pancreas cancer
503225|NCT00690287|Type 2 diabetes
503226|NCT00690274|schizophrenia
503227|NCT00690274|cognitive deficients
503228|NCT00690274|cognitive enhancing
503229|NCT00690274|antipsychotics
503230|NCT00690261|tumor associated macrophage
503231|NCT00690261|lung cancer
503232|NCT00690261|outcome
503233|NCT00690248|Acute mania
503234|NCT00690248|Bipolar disorder
503235|NCT00690248|depressive symptoms
503236|NCT00690248|mixed mania
503237|NCT00690235|Schizophrenia
503238|NCT00690235|Schizoaffective
503239|NCT00690235|Olanzapine
503240|NCT00690235|Zyprexa
503241|NCT00690235|Clozapine
503242|NCT00690235|Clozaril
503243|NCT00690235|Pramlintide
503244|NCT00690235|Diabetes
503245|NCT00690235|Weight Gain
503246|NCT00690235|Obesity
503247|NCT00690235|Metabolic Syndrome
503248|NCT00690222|cataract surgery
503249|NCT00690222|phacoemulsification
503250|NCT00690222|pupil
503251|NCT00690222|dilation
503252|NCT00690222|mydriasis
503253|NCT00690222|intracameral
503254|NCT00690222|topical
503255|NCT00690222|pseudoexfoliation syndrome
503256|NCT00690209|Chronic ischemic cardiomyopathy with residual viability
503257|NCT00690209|surgical coronary revascularization
503258|NCT00690209|stem cell therapy
503259|NCT00690209|Chronic ischemic heart disease
503260|NCT00690209|severe impairment of global contractility left ventricular dilation
503261|NCT00690209|residual viability
503262|NCT00690183|physical activity
503263|NCT00690183|stem cells
503264|NCT00690183|lifestyle
503265|NCT00690170|ketamine
503266|NCT00690170|nicotine
503267|NCT00690170|schizophrenia
503268|NCT00690170|cognitive deficits
503269|NCT00690170|P300 oddball paradigm
503270|NCT00690170|Mismatch Negativity
503271|NCT00690170|P50 gating
503272|NCT00690157|heart failure, prognosis, markers,heart transplantation
503273|NCT00690144|simulation
503274|NCT00690144|medical education
503275|NCT00690144|performance of clinical reasoning and skills
503276|NCT00690131|Smoking cessation, severe mental illness, behavioral treatment
503277|NCT00690118|amyotrophic lateral sclerosis
503278|NCT00690118|survival time
503279|NCT00690118|ALS functioning Rating Scale
503280|NCT00690118|quality of life
503281|NCT00690118|non-invasive ventilation
503282|NCT00690118|clinical tolerability
503283|NCT00690118|survival
503284|NCT00690105|Dermatitis, Atopic
503285|NCT00690105|Dermatologic Agents
503286|NCT00690105|Topical Drug Administration
503287|NCT00690105|Tacrolimus
503288|NCT00690105|Calcineurin
503289|NCT00690105|Corticosteroid
503290|NCT00690105|Fluticasone propionate
503291|NCT00690105|Face
503292|NCT00690092|Coccidioidin
503293|NCT00690092|Coccidioidin SD
503294|NCT00690092|Spherule-derived coccidioidin
503295|NCT00690092|Coccidioidomycosis
503296|NCT00690092|Valley Fever
503297|NCT00690092|Coccidioides immitis
503298|NCT00690079|MAD
503299|NCT00690079|Multiple ascending dose
503300|NCT00690079|Chronic pain
503301|NCT00690079|pain
503302|NCT00690066|T1DM
503303|NCT00690066|Type 1 Diabetes Mellitus
503304|NCT00690066|Type 1 Diabetes
503305|NCT00690066|Diabetes Mellitus, Insulin-Dependent
503306|NCT00690066|Juvenile Diabetes
503307|NCT00690066|Adult Human Stem Cells
503308|NCT00690066|Mesenchymal Stem Cells
503309|NCT00690066|MSCs
503310|NCT00690066|Insulin
503311|NCT00690066|Osiris
503312|NCT00690066|Prochymal
503313|NCT00690053|Toxicity
503314|NCT00690053|PET
503315|NCT00690053|HX-4
503316|NCT00690053|cancer
503317|NCT00690040|Induction of labor
503318|NCT00690040|Ripening
503319|NCT00690040|Single balloon catheter
503320|NCT00690040|Double balloon catheter
503321|NCT00690014|OAT
503322|NCT00690014|GFR
503323|NCT00690014|renal function
503324|NCT00690014|PAH
503325|NCT00690001|HIV-1 infection
503326|NCT00690001|Treatment Experienced
503327|NCT00689988|Down syndrome
503328|NCT00689988|communication AIDS for disabled
503329|NCT00689988|language development disorders
503330|NCT00689988|vocabulary
503331|NCT00689988|gestures
503332|NCT00689988|language tests
503333|NCT00689988|child
503334|NCT00689975|stage IA breast cancer
503335|NCT00689975|stage IB breast cancer
503336|NCT00689975|stage II breast cancer
503337|NCT00689975|stage IIIA breast cancer
503338|NCT00689975|stage IIIB breast cancer
503339|NCT00689975|stage IIIC breast cancer
503340|NCT00689962|Lisfranc
503341|NCT00689962|fracture
503342|NCT00689962|dislocation
503343|NCT00689962|bioabsorbable
503344|NCT00689949|folic acid
503345|NCT00689949|folate
503346|NCT00689949|p-aminobenzoylglutamate
503347|NCT00689949|formiminoglutamate
503348|NCT00689949|homocysteine
503349|NCT00689949|experimental validation of a new biomarker
503350|NCT00689936|newly diagnosed multiple myeloma
503351|NCT00689936|Lenalidomide
503352|NCT00689936|Revlimid
503353|NCT00689936|phase III
503354|NCT00689910|pharmacokinetics
503355|NCT00689910|pregnancy
503356|NCT00689910|Raltegravir
503357|NCT00689910|HIV
503358|NCT00689910|antiretroviral
503359|NCT00689910|Treatment of HIV in pregnant women with Raltegravir
503360|NCT00689897|Primary Dysmenorrhea
503361|NCT00689897|Deqi
503362|NCT00689897|acupuncture
503363|NCT00689897|psychology
503364|NCT00689858|Healthy volunteers
503365|NCT00689845|contiguous stage II adult diffuse large cell lymphoma
503366|NCT00689845|noncontiguous stage II adult diffuse large cell lymphoma
503367|NCT00689845|stage I adult diffuse large cell lymphoma
503368|NCT00689845|stage III adult diffuse large cell lymphoma
503369|NCT00689845|stage IV adult diffuse large cell lymphoma
503370|NCT00689832|Dermatitis, Atopic
503371|NCT00689832|Dermatologic Agents
503372|NCT00689832|Topical Drug Administration
503373|NCT00689832|Tacrolimus
503374|NCT00689832|Calcineurin
503375|NCT00689832|Corticosteroid
503376|NCT00689832|Fluticasone propionate
503377|NCT00689832|Child
503378|NCT00689819|Hypertension
503379|NCT00689819|High blood pressure
503380|NCT00689819|Pre-clinical cardiac dysfunction
503381|NCT00689806|Asthma
503382|NCT00689793|Fatigue
503383|NCT00689793|Blood donation
503384|NCT00689793|Iron deficiency
503385|NCT00689793|Ferrous sulphate
503386|NCT00689793|Donation
503387|NCT00689793|Donors
503388|NCT00689793|Iron
503389|NCT00689793|Ferritin
503390|NCT00689793|Hemoglobin
503391|NCT00689793|Anemia
503392|NCT00689793|Anaemia
503393|NCT00689793|Haemoglobin
503394|NCT00689793|Don
503395|NCT00689793|Women blood donors
503396|NCT00689780|Pain
503397|NCT00689780|safety
503398|NCT00689780|chronic low back pain
503399|NCT00689767|drug eluting stent
503400|NCT00689754|gastrointestinal hemorrhage
503401|NCT00689754|gastrointestinal intubation
503402|NCT00689754|endoscopy
503403|NCT00689741|HPV
503404|NCT00689741|vaccine
503405|NCT00689715|Cystic tumor
503406|NCT00689715|Pancreas
503407|NCT00689715|EUS
503408|NCT00689702|cetuximab
503409|NCT00689702|capecitabine
503410|NCT00689702|radiotherapy
503411|NCT00689702|rectal cancer
503412|NCT00689676|expressive language
503413|NCT00689676|cognition
503414|NCT00689676|early development
503415|NCT00689676|very low birt weight
503416|NCT00689676|prematurity
503417|NCT00689663|cholecystectomy
503418|NCT00689637|AZD3480
503419|NCT00689637|Warfarin
503420|NCT00689637|Drug interaction
503421|NCT00689624|Colorectal Cancer
503422|NCT00689624|Cetuximab
503423|NCT00689624|FOLFOXIRI
503424|NCT00689611|Acute coronary syndrome
503425|NCT00689611|Myocardial infarction
503426|NCT00689611|Smoking cessation
503427|NCT00689611|Zyban
503428|NCT00689611|Secondary intervention post-ACS
503429|NCT00689598|Atrial fibrillation, spironolactone
503430|NCT00689585|Complex Regional Pain Syndrome
503431|NCT00689585|Reflex Sympathetic Dystrophy
503432|NCT00689585|RSD
503433|NCT00689585|Chronic Pain
503434|NCT00689585|Ethosuximide
503435|NCT00689585|Zarontin
503436|NCT00689585|Anticonvulsant
503437|NCT00689572|cocaine dependence
503438|NCT00689572|cocaine abuse
503439|NCT00689572|cocaine
503440|NCT00689572|crack
503441|NCT00689559|Alzheimer's disease
503442|NCT00689559|AZD3480
503443|NCT00689559|Aripiprazole
503444|NCT00689533|VEPTR
503445|NCT00689533|TIS
503446|NCT00689533|scoliosis
503447|NCT00689533|juvenile
503448|NCT00689520|Venous thromboembolism
503449|NCT00689520|low molecular weight heparin
503450|NCT00689520|Vitamin K antagonist
503451|NCT00689520|Longterm
503452|NCT00689507|Multiple Myeloma
503453|NCT00689507|Relapsed
503454|NCT00689507|Refractory
503455|NCT00689507|Bortezomib
503456|NCT00689507|Velcade
503457|NCT00689494|Nanopaz device
503458|NCT00689494|Blood progesterone measure in using the device
503459|NCT00689494|Delivery progesterone
503460|NCT00689494|Progesterone levonorgestrel
503461|NCT00689481|Plaque-type Psoriasis
503462|NCT00689481|psoriasis
503463|NCT00689468|Otitis media
503464|NCT00689468|Echinacea
503465|NCT00689468|Osteopathic Medicine
503466|NCT00689455|Metabolic Syndrome
503467|NCT00689455|Lipids
503468|NCT00689455|Waist Circumference
503469|NCT00689429|Pilon Fractures
503470|NCT00689416|imaging biomarkers
503471|NCT00689416|MRI
503472|NCT00689416|FDG-PET/CT scanning
503473|NCT00689416|Crestor
503474|NCT00689403|AZD1305
503475|NCT00689403|pharmacokinetics
503476|NCT00689403|Properties of different ER formulations
503477|NCT00689377|Peripheral Arterial Disease (PAD)
503478|NCT00689377|Cardiovascular Disease (CVD)
503479|NCT00689377|Atherosclerotic cardiovascular disease
503480|NCT00689377|Atherosclerosis
503481|NCT00689377|Primary CVD prevention
503482|NCT00689364|Cohort Study
503483|NCT00689364|Colorectal Cancer
503484|NCT00689364|Traditional Chinese Medicine
503485|NCT00689364|Risk of recurrence and metastasis
503486|NCT00689351|Prevention
503487|NCT00689351|against
503488|NCT00689351|pneumococcal
503489|NCT00689351|disease
503490|NCT00689351|Vaccine
503491|NCT00689338|Candida
503492|NCT00689338|Candidemia
503493|NCT00689338|Systemic Candidiasis
503494|NCT00689338|ICU
503495|NCT00689338|Intensive Care Unit
503496|NCT00689338|Critical Care Unit
503497|NCT00689338|Anidulafungin
503498|NCT00689338|Ecalta
503499|NCT00689338|Eraxis
503500|NCT00689338|Fluconazole
503501|NCT00689338|Voriconazole
503502|NCT00689325|Schizophrenia
503503|NCT00689325|remission
503504|NCT00689325|subjective well-being and effectiveness
503505|NCT00689325|Quality of Life
503506|NCT00689312|Gastroenteritis
503507|NCT00689312|Pediatrics
503508|NCT00689312|Rehydration therapy
503509|NCT00689299|Sublingual Immunotherapy (SLIT)
503510|NCT00689299|Non-seasonal allergic rhinitis
503511|NCT00689299|Immunotherapy
503512|NCT00689299|Allergic rhinitis
503513|NCT00689299|Cat
503514|NCT00689299|Perennial allergy
503515|NCT00689299|Non-seasonal allergy
503516|NCT00689286|Knee Osteoarthritis
503517|NCT00689286|Neuromuscular stimulator
503518|NCT00689273|PF-04136309 CCR2 osteoarthritic pain knee, phase 2 placebo multicenter double-blind placebo-controlled
503519|NCT00689247|AZD1305
503520|NCT00689247|ADME
503521|NCT00689247|pharmacokinetic
503522|NCT00689247|Absorption
503523|NCT00689247|distribution
503524|NCT00689247|metabolism
503525|NCT00689247|excretion
503526|NCT00689221|newly diagnosed Glioblastoma (WHO Grade IV)
503527|NCT00689221|Cilengitide
503528|NCT00689221|Temozolomide
503529|NCT00689221|Radiotherapy
503530|NCT00689208|Clamp
503531|NCT00689195|Curcumin
503532|NCT00689195|Ashwagandha
503533|NCT00689195|osteosarcoma
503534|NCT00689195|Pharmacokinetics of curcumin and ashwagandha formulation
503535|NCT00689195|response
503536|NCT00689182|iron reduction
503537|NCT00689182|iron overload
503538|NCT00689182|phlebotomy
503539|NCT00689182|hematopoietic stem cell transplant
503540|NCT00689169|Lymphoma
503541|NCT00689169|Lymphoma Diffuse
503542|NCT00689169|B-Cell lymphoma
503543|NCT00689169|Aggressive lymphoma
503544|NCT00689156|Epirubicin
503545|NCT00689156|docetaxel
503546|NCT00689156|Adjuvant chemotherapy
503547|NCT00689156|DNA Topoisomerases, Type II
503548|NCT00689130|Analgesia
503549|NCT00689130|Bispectral Index
503550|NCT00689130|BIS Variability
503551|NCT00689130|Electroencephalography
503552|NCT00689130|Electromyography
503553|NCT00689130|Monitoring, Intraoperative
503554|NCT00689130|Movement
503555|NCT00689130|Pain, Postoperative
503556|NCT00689130|Somatic Events
503557|NCT00689130|Patients under general anesthesia undergoing a moderately painful procedure.
503558|NCT00689117|Acne Vulgaris
503559|NCT00689117|Acne
503560|NCT00689104|Overactive bladder (OAB)
503561|NCT00689104|Frequency
503562|NCT00689104|Micturition
503563|NCT00689104|Urgency
503564|NCT00689104|Urinary incontinence
503565|NCT00689104|Urinary urge incontinence
503566|NCT00689104|YM178
503567|NCT00689091|Awareness
503568|NCT00689091|BIS Monitor
503569|NCT00689091|electronic alerts
503570|NCT00689091|minimum
503571|NCT00689091|alveolar
503572|NCT00689091|concentration
503573|NCT00689078|Allergic conjunctivitis
503574|NCT00689065|siRNA
503575|NCT00689065|RNA interference (RNAi)
503576|NCT00689065|Cyclodextrin
503577|NCT00689065|Cancer
503578|NCT00689065|Neoplasms
503579|NCT00689065|Solid Tumor
503580|NCT00689065|Ovarian Cancer
503581|NCT00689065|Lung Cancer
503582|NCT00689065|Non Small Cell Lung Cancer
503583|NCT00689065|Pancreatic Cancer
503584|NCT00689065|Breast Cancer
503585|NCT00689065|Colon Cancer
503586|NCT00689065|Endometrial Cancer
503587|NCT00689065|Kidney (Renal Cell) Cancer
503588|NCT00689065|Melanoma
503589|NCT00689065|Prostate Cancer
503590|NCT00689065|Skin Cancer
503591|NCT00689065|Thyroid Cancer
503592|NCT00689065|Solid Malignancies
503593|NCT00689039|AZD1305
503594|NCT00689039|safety
503595|NCT00689039|pharmacokinetics
503596|NCT00689039|multiple ascending doses
503597|NCT00689039|Safety and pharmacokinetics
503598|NCT00689026|Colonoscopy
503599|NCT00689026|Diabetes Mellitus, Type 1
503600|NCT00689026|Diabetes Mellitus, Type 2
503601|NCT00689026|Cleansing
503602|NCT00689026|Preparation
503603|NCT00689026|PEG
503604|NCT00689026|Quality
503605|NCT00689013|Herpes Zoster
503606|NCT00689013|Prevention & control
503607|NCT00689013|Pharmacists
503608|NCT00689013|Pharmacy
503609|NCT00689013|Pharmacies
503610|NCT00689013|Aged
503611|NCT00689013|Immunization
503612|NCT00689013|Vaccination
503613|NCT00689000|Leukemia
503614|NCT00689000|AML
503615|NCT00689000|MDS
503616|NCT00689000|MM
503617|NCT00689000|Acute Myeloid Leukemia
503618|NCT00689000|Myelodysplastic Syndrome
503619|NCT00689000|Multiple Myeloma
503620|NCT00689000|Cancer
503621|NCT00689000|Hematological malignancies
503622|NCT00689000|Elderly
503623|NCT00689000|Refractory
503624|NCT00689000|Blood
503625|NCT00688974|type 2 diabetes
503626|NCT00688974|obesity
503627|NCT00688974|gastric bypass
503628|NCT00688974|adjustable gastric banding
503629|NCT00688974|BMI > 35.
503630|NCT00688974|obesity for more than 5 years
503631|NCT00688961|omega-3 fatty acids
503632|NCT00688961|aspirin
503633|NCT00688961|platelet aggregation
503634|NCT00688961|Healthy volunteers; no disease
503635|NCT00688948|pilot clinical trial
503636|NCT00688935|melatonin
503637|NCT00688935|circadian rhythms
503638|NCT00688935|sleep
503639|NCT00688935|sleep disorders
503640|NCT00688909|breast cancer
503641|NCT00688909|adjuvant treatment in post menopausal women
503642|NCT00688909|letrozole
503643|NCT00688909|arthralgia-myalgia
503644|NCT00688883|Fludarabine
503645|NCT00688883|Purine analog
503646|NCT00688883|Indolent lymphoma
503647|NCT00688870|Prevention against pneumococcal disease
503648|NCT00688844|PKU
503649|NCT00688844|Phenylketonuria
503650|NCT00688844|BH4
503651|NCT00688844|Kuvan
503652|NCT00688844|Tetrahydrobiopterin
503653|NCT00688844|Sapropterin Dihydrochloride
503654|NCT00688844|Nutrition
503655|NCT00688844|PHE
503656|NCT00688844|Phenylalanine
503657|NCT00688844|PAH
503658|NCT00688844|Phenylalanine hydroxylase
503659|NCT00688844|Neurotransmitters
503660|NCT00688844|Serotonin
503661|NCT00688844|Catecholamines
503662|NCT00688844|Diet
503663|NCT00688844|Body Fat
503664|NCT00688844|Bone Density
503665|NCT00688831|AZD1305
503666|NCT00688831|SAD
503667|NCT00688831|safety
503668|NCT00688831|pharmcokinetics
503669|NCT00688831|Safety and tolerability
503670|NCT00688818|Co-morbid depressive and anxiety disorders
503671|NCT00688818|Quetiapine
503672|NCT00688818|Randomized
503673|NCT00688818|Placebo-controlled
503674|NCT00688818|Double-blind
503675|NCT00688818|Major depressive disorder
503676|NCT00688818|Dysthymic disorder
503677|NCT00688818|Anxiety disorders
503678|NCT00688818|Generalized anxiety disorder
503679|NCT00688818|Social anxiety disorder
503680|NCT00688818|Panic disorder
503681|NCT00688818|Post-traumatic stress disorder
503682|NCT00688805|Propanolol
503683|NCT00688805|Substance Abuse
503684|NCT00688805|Craving
503685|NCT00688805|Imagery
503686|NCT00688805|Drug Cues
503687|NCT00688805|Cocaine
503688|NCT00688792|Asthma
503689|NCT00688792|Children
503690|NCT00688792|Adherence
503691|NCT00688792|Maternal factors
503692|NCT00688779|Healthy male
503693|NCT00688779|allergic rhinitis
503694|NCT00688779|tolerability
503695|NCT00688779|safety
503696|NCT00688779|intranasally
503697|NCT00688779|Healthy subjects
503698|NCT00688766|GIST
503699|NCT00688766|Metastatic and/or Unresectable Gastrointestinal Stromal
503700|NCT00688753|renal cell carcinoma
503701|NCT00688753|non clear cell carcinoma
503702|NCT00688753|papillary cell renal carcinoma
503703|NCT00688753|adults
503704|NCT00688753|everolimus
503705|NCT00688740|adjuvant treatment
503706|NCT00688727|non epileptic seizures
503707|NCT00688727|cognitive behavioural therapy
503708|NCT00688727|dissociative disorders
503709|NCT00688727|Seizure disorders
503710|NCT00688727|randomised controlled trial
503711|NCT00688714|Antiplatelet
503712|NCT00688701|hyperglycemia, GLP-1
503713|NCT00688688|Overactive Bladder
503714|NCT00688688|Frequency
503715|NCT00688688|Micturition
503716|NCT00688688|Urgency
503717|NCT00688688|Urinary incontinence
503718|NCT00688688|Urinary urge incontinence
503719|NCT00688675|GERD
503720|NCT00688675|Pharmacoepidemiology
503721|NCT00688662|Sphincter of Oddi Dysfunction
503722|NCT00688662|Pancreatitis
503723|NCT00688662|Sphincterotomy
503724|NCT00688623|Neuroendocrine tumors
503725|NCT00688623|non-functioning neuroendocrine tumors carcinoids
503726|NCT00688623|non-functioning carcinoids
503727|NCT00688623|adults
503728|NCT00688623|everolimus
503729|NCT00688610|primary care
503730|NCT00688610|procalcitonin
503731|NCT00688610|antibiotic prescription
503732|NCT00688597|Pompe Disease
503733|NCT00688584|problem drinking
503734|NCT00688584|randomized control trial
503735|NCT00688584|Pamphlet-based personalized alcohol feedback (PAF)
503736|NCT00688571|Pulmonary Valve
503737|NCT00688571|Congenital Heart Disease
503738|NCT00688545|Celecoxib
503739|NCT00688545|COX-2
503740|NCT00688545|NSAIDs
503741|NCT00688545|observational study
503742|NCT00688545|noninterventional study
503743|NCT00688545|cohort study
503744|NCT00688545|registry
503745|NCT00688545|epidemiologic study
503746|NCT00688545|pediatrics
503747|NCT00688545|rheumatology
503748|NCT00688545|phase iv study
503749|NCT00688532|Prostate cancer
503750|NCT00688532|pharmacoepidemiology study
503751|NCT00688519|Plaque-type Psoriasis
503752|NCT00688519|Psoriasis
503753|NCT00688506|Chronic pelvic pain syndrome
503754|NCT00688506|Neuromodulation
503755|NCT00688506|Brain effects
503756|NCT00688506|Neuroimaging
503757|NCT00688493|QT
503758|NCT00688493|Healthy volunteers
503759|NCT00688480|CKD
503760|NCT00688480|LVH
503761|NCT00688480|Echo LVH
503762|NCT00688480|Chronic Stage 3
503763|NCT00688467|Neutrophilic Asthma
503764|NCT00688454|Hyperlipidemia
503765|NCT00688454|Rosuvastatin
503766|NCT00688454|Efficacy
503767|NCT00688454|tolerability
503768|NCT00688454|CRESTOR therapy
503769|NCT00688441|Randomized
503770|NCT00688441|Double-Blind
503771|NCT00688441|Multi-Center
503772|NCT00688441|Placebo-Controlled
503773|NCT00688441|Phase II
503774|NCT00688441|Nasal Carbon Dioxide
503775|NCT00688441|Carbon Dioxide
503776|NCT00688441|Efficacy
503777|NCT00688441|Safety
503778|NCT00688441|Total Nasal Symptom Score
503779|NCT00688441|RQLQ
503780|NCT00688428|esomeprazole
503781|NCT00688428|upper gi symptoms
503782|NCT00688428|low dose Aspirin treatment
503783|NCT00688402|Reflux Inhibitor
503784|NCT00688402|GERD
503785|NCT00688402|formulations
503786|NCT00688389|Dengue fever, CLEC5A, Mannose receptor, DC-SIGN, NALP,
503787|NCT00688389|decoy receptor 3 (DcR3), Toll-like receptors(TLRs),
503788|NCT00688389|(Nod)-like receptors (NLRs)
503789|NCT00688376|Attention
503790|NCT00688376|cancer
503791|NCT00688376|chemotherapy
503792|NCT00688376|donepezil
503793|NCT00688376|acetylcholinesterase
503794|NCT00688376|inhibitor
503795|NCT00688363|Diabetes control
503796|NCT00688363|glycated haemoglobin
503797|NCT00688363|blood-glucose-self-monitoring
503798|NCT00688363|type 2-diabetes
503799|NCT00688363|conventional insulin therapy
503800|NCT00688350|Hypertension
503801|NCT00688350|Aging
503802|NCT00688350|Medication adherence
503803|NCT00688350|Medication compliance
503804|NCT00688337|Breast cancer
503805|NCT00688337|lymph nodes
503806|NCT00688337|gene-expression
503807|NCT00688337|oncotype
503808|NCT00688337|Age over 18
503809|NCT00688337|Newly diagnosed breast cancer prior to surgery or treatment.
503810|NCT00688337|No evidence of clinical nodal disease
503811|NCT00688324|schizophrenia
503812|NCT00688324|schizoaffective disorder
503813|NCT00688324|glutamate
503814|NCT00688324|NMDA receptor
503815|NCT00688324|magnetic resonance spectroscopy
503816|NCT00688324|acamprosate
503817|NCT00688311|HIV
503818|NCT00688311|synbiotic
503819|NCT00688311|probiotic
503820|NCT00688311|immune activation
503821|NCT00688311|blood CD4 count
503822|NCT00688311|bacterial translocation
503823|NCT00688311|Human Immunodeficiency Virus
503824|NCT00688285|chronic kidney disease
503825|NCT00688285|clinical alerts
503826|NCT00688285|late referral
503827|NCT00688285|electronic medical record
503828|NCT00688285|Computerized clinical decision support systems (CDSS)
503829|NCT00688272|Safety
503830|NCT00688272|Photoirritant
503831|NCT00688272|Placebo control
503832|NCT00688272|Photosensitivity
503833|NCT00688272|Ciprofloxacin
503834|NCT00688272|Eltrombopag
503835|NCT00688259|clinical trials
503836|NCT00688259|psychotherapy
503837|NCT00688246|osteoporosis
503838|NCT00688246|breast cancer
503839|NCT00688233|Seifi's Functional, Class II/1, Mandibular Retrognathism
503840|NCT00688220|Arthritis
503841|NCT00688220|Carpel tunnel syndrome
503842|NCT00688220|Epicondylitis
503843|NCT00688207|PPAR agonist,
503844|NCT00688207|Rosiglitazone XR,
503845|NCT00688207|BRL-049653.
503846|NCT00688207|Alzheimer's disease,
503847|NCT00688194|stage IV breast cancer
503848|NCT00688194|recurrent breast cancer
503849|NCT00688168|Multiple Myeloma
503850|NCT00688168|Phone Call
503851|NCT00688168|Treatment Naive
503852|NCT00688168|Inflammatory Cytokines
503853|NCT00688168|Questionnaire
503854|NCT00688168|Survey
503855|NCT00688168|Interactive Voice Response
503856|NCT00688168|Symptom Production
503857|NCT00688168|Pain
503858|NCT00688168|IVR
503859|NCT00688168|MM
503860|NCT00688129|school readiness
503861|NCT00688129|foster care
503862|NCT00688129|maltreatment
503863|NCT00688129|literacy
503864|NCT00688129|social emotional skills
503865|NCT00688129|self regulation
503866|NCT00688129|caregiver involvement
503867|NCT00688116|metastatic cancer
503868|NCT00688116|solid tumor
503869|NCT00688116|histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable
503870|NCT00688116|STA-9090
503871|NCT00688116|ganetespib
503872|NCT00688090|Immunotherapy, Melanoma, Cancer Vaccine
503873|NCT00688077|Fibroblast growth factor - 23
503874|NCT00688077|Calcitonin
503875|NCT00688064|Acne
503876|NCT00688051|Cystic Fibrosis
503877|NCT00688051|Adherence to treatment
503878|NCT00688038|Advanced Cancer
503879|NCT00688038|Bone Metastases
503880|NCT00688038|Laser Ablation
503881|NCT00688038|Magnetic Resonance Thermal Imaging
503882|NCT00688038|Laser Induced Thermal Therapy
503883|NCT00688038|MRTI
503884|NCT00688038|LITT
503885|NCT00688012|antisense
503886|NCT00688012|microRna antagonist
503887|NCT00688012|anti-miR-122
503888|NCT00688012|Safety in healthy volunteers
503889|NCT00688012|Hepatitis C
503890|NCT00687999|Chronic hepatitis C
503891|NCT00687999|diabetes
503892|NCT00687999|Insulin resistance
503893|NCT00687999|combination therapy
503894|NCT00687986|surgery
503895|NCT00687986|stereotactic radiotherapy
503896|NCT00687986|tumor control
503897|NCT00687986|quality of life
503898|NCT00687960|Diabetes
503899|NCT00687960|Diet
503900|NCT00687960|Fiber
503901|NCT00687960|Age
503902|NCT00687947|FHM
503903|NCT00687947|MA
503904|NCT00687947|healthy controls
503905|NCT00687947|CGRP
503906|NCT00687934|metastatic cancer
503907|NCT00687934|solid tumor
503908|NCT00687934|histologically or cytologically confirmed non-hematological
503909|NCT00687934|malignancy that is metastatic or unresectable for which no
503910|NCT00687934|standard therapy exists
503911|NCT00687934|STA-9090
503912|NCT00687934|ganetespib
503913|NCT00687921|Knee trauma
503914|NCT00687921|MRI
503915|NCT00687921|arthroscopy
503916|NCT00687921|Patients over the age of 18 who had knee trauma intent to or had MRI assessment scheduled for arthroscopy
503917|NCT00687908|Acne
503918|NCT00687895|malaria microscopy primary health care children
503919|NCT00687882|Venous Thromboembolism
503920|NCT00687882|Postthrombotic Syndrome
503921|NCT00687882|Antithrombotic Therapy
503922|NCT00687882|Duration of Therapy
503923|NCT00687882|Children
503924|NCT00687869|stroke
503925|NCT00687869|rehabilitation
503926|NCT00687869|patient care management
503927|NCT00687869|patient participation
503928|NCT00687856|Left Ventricular Assist Device
503929|NCT00687843|Gastric Cancer
503930|NCT00687843|TS-1
503931|NCT00687843|PSK
503932|NCT00687843|Relapse-free survival
503933|NCT00687830|Afternoon colonoscopy
503934|NCT00687830|Morning
503935|NCT00687830|Evening
503936|NCT00687830|Bowel Preparation
503937|NCT00687830|Efficacy
503938|NCT00687830|Satisfaction
503939|NCT00687817|NSCLC
503940|NCT00687804|DME
503941|NCT00687804|Diabetic
503942|NCT00687804|macula
503943|NCT00687804|edema
503944|NCT00687804|ranibizumab
503945|NCT00687804|RESTORE
503946|NCT00687791|patients with cataract and glaucoma
503947|NCT00687791|ologen
503948|NCT00687791|oculusgen
503949|NCT00687791|collagen matrix
503950|NCT00687791|Phacotrabeculectomy
503951|NCT00687791|Aeon Astron
503952|NCT00687791|trabeculectomy
503953|NCT00687791|tissue engineering
503954|NCT00687791|mitomycin-C
503955|NCT00687778|C11-Acetate
503956|NCT00687778|FDG
503957|NCT00687778|sarcoma
503958|NCT00687778|Measurement of C11-Acetate uptake in tumors which are often non-FDG avid.
503959|NCT00687778|Soft tissue sarcomas
503960|NCT00687778|well-differentiated thyroid cancer
503961|NCT00687778|well-differentiated and bronchoalveolar lung cancer
503962|NCT00687778|indolent lymphomas, neuroendocrine tumors
503963|NCT00687778|GIST
503964|NCT00687778|uterine malignancies
503965|NCT00687778|mucin-producing cancer
503966|NCT00687778|teratoma, hepatoma
503967|NCT00687778|HCC
503968|NCT00687778|lobular breast carcinoma
503969|NCT00687765|patients with newly diagnosed glioblastoma
503970|NCT00687752|fetal deglutition
503971|NCT00687752|larynx
503972|NCT00687752|fetal CNS pathology
503973|NCT00687752|sonography
503974|NCT00687752|hydramnios
503975|NCT00687739|hormone therapy
503976|NCT00687739|obesity
503977|NCT00687739|postmenopause
503978|NCT00687739|disease /disorder proneness /risk
503979|NCT00687739|insulin sensitivity /resistance
503980|NCT00687739|metabolic syndrome
503981|NCT00687739|women's health
503982|NCT00687726|osteoarthritis
503983|NCT00687726|knee
503984|NCT00687726|exercise
503985|NCT00687726|balance
503986|NCT00687700|propranolol
503987|NCT00687700|B2-agonist,
503988|NCT00687700|B-antagonist,
503989|NCT00687687|Patients must have advanced (stage III or IV), persistent or recurrent uterine carcinosarcoma with documented disease progression.
503990|NCT00687674|refractory multiple myeloma
503991|NCT00687661|Chronic Kidney Failure
503992|NCT00687661|Vascular Calcification
503993|NCT00687661|Bisphosphonates
503994|NCT00687648|stage IV breast cancer
503995|NCT00687648|recurrent breast cancer
503996|NCT00687648|HER2-negative breast cancer
503997|NCT00687648|estrogen receptor-positive breast cancer
503998|NCT00687648|progesterone receptor-positive breast cancer
503999|NCT00687622|GSK1120212
504000|NCT00687622|Oncology
504001|NCT00687622|melanoma
504002|NCT00687622|MEK inhibitor
504003|NCT00687622|solid tumors
504004|NCT00687622|First Time in Human
504005|NCT00687609|Attention Deficit Hyperactivity Disorder with Cannabis Abuse
504006|NCT00687609|Marihuana Abuse
504007|NCT00687609|Comorbid Cannabis Abuse
504008|NCT00687583|pediatrics
504009|NCT00687583|anesthesia
504010|NCT00687583|head movements
504011|NCT00687583|endotracheal tube
504012|NCT00687570|patients with rectal cancer undergoing surgery
504013|NCT00687570|Bowel purity degree
504014|NCT00687570|Bowel preparation
504015|NCT00687570|Rectal cancer
504016|NCT00687570|Nutritional status
504017|NCT00687570|complications with traditional bowel preparation
504018|NCT00687570|Complications
504019|NCT00687570|Physiological status
504020|NCT00687544|HIV
504021|NCT00687492|hypercholesterolemia
504022|NCT00687492|NCEP ATP III guidelines
504023|NCT00687492|survey
504024|NCT00687479|insulin sensitivity
504025|NCT00687479|insulin secretion
504026|NCT00687479|infant outcome
504027|NCT00687466|Cystic Fibrosis
504028|NCT00687466|Glucose Intolerance
504029|NCT00687453|Glargine
504030|NCT00687453|Type 2 diabetes
504031|NCT00687453|Basal insulin
504032|NCT00687414|gene expression
504033|NCT00687414|gene sequencing
504034|NCT00687414|gene encoding
504035|NCT00687414|MPD
504036|NCT00687414|MDS
504037|NCT00687414|AML
504038|NCT00687414|mDia
504039|NCT00687388|Cyclooxygenase 2 Inhibitors
504040|NCT00687388|Alpha Blockers
504041|NCT00687388|Treatment Outcome
504042|NCT00687375|Inguinal
504043|NCT00687375|Groin hernia
504044|NCT00687375|TAPP
504045|NCT00687375|TEP
504046|NCT00687375|Comparing
504047|NCT00687375|Two
504048|NCT00687375|Techniques
504049|NCT00687349|End-of-Life issues
504050|NCT00687349|Talking with your doctor
504051|NCT00687349|Coping with chronic illness
504052|NCT00687336|Helicobacter pylori
504053|NCT00687336|Treatment
504054|NCT00687336|Upper gastrointestinal bleeding
504055|NCT00687310|Asthma education
504056|NCT00687310|satisfaction adherence
504057|NCT00687310|Quality of Life
504058|NCT00687310|PIKO meter cluster
504059|NCT00687310|Symbicort® Turbuhaler®
504060|NCT00687297|Stage IIIB Non Small Cell Lung Cancer
504061|NCT00687297|Stage IV Non Small Cell Lung Cancer
504062|NCT00687297|Vandetanib
504063|NCT00687297|Docetaxel plus carboplatin
504064|NCT00687258|Anemia
504065|NCT00687258|Oxidative Stress
504066|NCT00687258|Erythropoietin
504067|NCT00687258|dialyser membrane
504068|NCT00687258|Vitamin E
504069|NCT00687258|Erythropoietin responsiveness
504070|NCT00687258|Erythropoietin resistance
504071|NCT00687258|hemodialysis
504072|NCT00687245|children
504073|NCT00687245|reflux
504074|NCT00687245|GERD
504075|NCT00687245|pediatric
504076|NCT00687232|Phase I
504077|NCT00687232|Japan
504078|NCT00687232|Japanese
504079|NCT00687232|inhalation
504080|NCT00687219|hepatitis C
504081|NCT00687193|Phase 2 monotherapy in Japan
504082|NCT00687180|Prednisolone dosage
504083|NCT00687167|Therapeutic Equivalency
504084|NCT00687154|DME
504085|NCT00687154|Laser
504086|NCT00687154|macular edema
504087|NCT00687154|retinopathy
504088|NCT00687154|scatter photocoagulation
504089|NCT00687141|Safety
504090|NCT00687141|tolerability
504091|NCT00687141|AZD0328
504092|NCT00687128|Insulin resistance
504093|NCT00687128|Metabolic syndrome
504094|NCT00687128|Aerobic exercise
504095|NCT00687128|Exercise behavior
504096|NCT00687115|24 Hour Energy Expenditure
504097|NCT00687115|Respiratory Chamber
504098|NCT00687115|Obesity
504099|NCT00687115|Weight Loss
504100|NCT00687115|Overfeeding
504101|NCT00687102|breast cancer
504102|NCT00687102|Tamoxifen
504103|NCT00687102|Raloxifene
504104|NCT00687102|hormone therapy
504105|NCT00687089|Opiates
504106|NCT00687089|Subutex
504107|NCT00687089|Buprenorphine
504108|NCT00687089|Patients who addicted to opiates
504109|NCT00687076|Endovascular Intervention
504110|NCT00687076|MRI
504111|NCT00687076|Ultrasound
504112|NCT00687076|Cholesterol Medications
504113|NCT00687076|High Cholesterol
504114|NCT00687076|Peripheral Arterial disease
504115|NCT00687076|Claudication
504116|NCT00687076|Leg Pain
504117|NCT00687076|Niaspan
504118|NCT00687076|Extended Release Niacin
504119|NCT00687076|Zetia
504120|NCT00687076|Ezetimibe
504121|NCT00687076|Simvastatin
504122|NCT00687076|Zocor
504123|NCT00687076|Atorvastatin
504124|NCT00687076|Lipitor
504125|NCT00687050|end-stage renal disease
504126|NCT00687050|chronic kidney disease
504127|NCT00687037|oral hygiene
504128|NCT00687024|Epilepsy
504129|NCT00687024|Magnetic Resonance Imaging
504130|NCT00687024|Magnetoencephalography
504131|NCT00687011|Antiemetic
504132|NCT00686998|Schizophrenia
504133|NCT00686985|Docetaxel
504134|NCT00686985|Carboplatin
504135|NCT00686985|chemotherapy
504136|NCT00686985|relapse SCLC
504137|NCT00686972|Bariatric Surgery
504138|NCT00686972|Glucose Regulation
504139|NCT00686972|Cardiac Function
504140|NCT00686972|Body Composition
504141|NCT00686946|Severe mental illness
504142|NCT00686946|Antipsychotic medications
504143|NCT00686946|Pregnancy
504144|NCT00686946|Evidence-based guidelines
504145|NCT00686946|Maternal and infant health and wellbeing
504146|NCT00686933|Attention-Deficit/Hyperactivity Disorder
504147|NCT00686907|melatonin, circadian rhythms, sleep
504148|NCT00686881|hepatitis C
504149|NCT00686868|GSK1841157;
504150|NCT00686868|rheumatoid arthritis,
504151|NCT00686868|B-cell depletion
504152|NCT00686868|anti-CD20 monoclonal antibody,
504153|NCT00686855|tacrolimus
504154|NCT00686855|dexamethasone
504155|NCT00686855|oral rinse
504156|NCT00686842|HIV infection
504157|NCT00686842|AIDS-related Kaposi sarcoma
504158|NCT00686842|recurrent Kaposi sarcoma
504159|NCT00686842|Treatment Experienced
504160|NCT00686829|HIV
504161|NCT00686829|Treatment Experienced
504162|NCT00686816|pre-diabetic
504163|NCT00686816|obese
504164|NCT00686803|hypertension
504165|NCT00686803|controlled hypertension
504166|NCT00686803|hypertensives
504167|NCT00686790|Hepatitis D
504168|NCT00686790|Hepatitis B
504169|NCT00686777|hepatitis C
504170|NCT00686764|trans-femoral amputation
504171|NCT00686738|osteosarcoma
504172|NCT00686738|transforming growth factor-beta 1
504173|NCT00686738|nuclear factor-kappa B
504174|NCT00686738|positron emission tomography/computed tomography
504175|NCT00686738|magnetic resonance spectroscopy
504176|NCT00686738|predicting response to neoadjuvant chemotherapy
504177|NCT00686712|Glargine
504178|NCT00686712|Type 2 diabetes
504179|NCT00686712|Basal insulin
504180|NCT00686699|Anti-Dyskinesia Agents
504181|NCT00686699|Antipsychotic Agents
504182|NCT00686673|DECISION AIDS
504183|NCT00686660|copd
504184|NCT00686660|rehabilitation
504185|NCT00686660|quality of life
504186|NCT00686660|inflammation
504187|NCT00686647|Coronary Angioplasty
504188|NCT00686647|Coronary Stents
504189|NCT00686647|Scoring Balloons
504190|NCT00686647|Coronary Artery Bifurcation Lesions
504191|NCT00686634|sitagliptin
504192|NCT00686634|type 2 diabetes
504193|NCT00686634|combination therapy
504194|NCT00686608|Obesity
504195|NCT00686556|recurrent adult acute lymphoblastic leukemia
504196|NCT00686556|recurrent childhood acute lymphoblastic leukemia
504197|NCT00686556|recurrent adult acute myeloid leukemia
504198|NCT00686556|recurrent childhood acute myeloid leukemia
504199|NCT00686556|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
504200|NCT00686556|adult acute myeloid leukemia with inv(16)(p13;q22)
504201|NCT00686556|adult acute myeloid leukemia with t(15;17)(q22;q12)
504202|NCT00686556|adult acute myeloid leukemia with t(16;16)(p13;q22)
504203|NCT00686556|adult acute myeloid leukemia with t(8;21)(q22;q22)
504204|NCT00686556|ALL
504205|NCT00686556|MDS
504206|NCT00686543|Antifungal Agents
504207|NCT00686543|Anti-Infective Agents
504208|NCT00686530|Fetal Death
504209|NCT00686530|Magnetic Resonance Imaging
504210|NCT00686530|Autopsy
504211|NCT00686530|Telencephalon
504212|NCT00686530|Pyramidal Tracts
504213|NCT00686504|Pain
504214|NCT00686504|PET
504215|NCT00686504|Phase 1
504216|NCT00686504|Analgesia
504217|NCT00686504|Positron Emission Tomography
504218|NCT00686504|mGlu5 receptor
504219|NCT00686504|Dose finding
504220|NCT00686504|Analgesia/Pain
504221|NCT00686491|Asthma
504222|NCT00686491|Environment
504223|NCT00686491|Type of sport
504224|NCT00686491|Cardiovascular disease
504225|NCT00686491|Athletes
504226|NCT00686478|burn
504227|NCT00686478|hypertrophic scar
504228|NCT00686478|fibroproliferative disorder
504229|NCT00686465|recurrent cancer
504230|NCT00686465|PET/CT
504231|NCT00686465|FDG
504232|NCT00686465|planned management
504233|NCT00686465|actual treatment
504234|NCT00686452|Asthma
504235|NCT00686452|Airway hyperresponsiveness
504236|NCT00686452|Swimmers
504237|NCT00686452|Airway inflammation
504238|NCT00686452|Airway remodelling
504239|NCT00686439|osteoarthritis
504240|NCT00686439|adalimumab
504241|NCT00686439|mri
504242|NCT00686426|Obesity
504243|NCT00686426|Weight gain
504244|NCT00686426|regain
504245|NCT00686426|dairy
504246|NCT00686426|calcium
504247|NCT00686413|PET
504248|NCT00686413|AZD3480
504249|NCT00686413|PET examination
504250|NCT00686400|schizophrenia
504251|NCT00686400|first-episode
504252|NCT00686400|infection
504253|NCT00686400|Toxoplasma gondii
504254|NCT00686400|levels of IgG antibodies to TG
504255|NCT00686387|Tissue Bank
504256|NCT00686387|Glioblastoma Multiforme
504257|NCT00686387|NAT2
504258|NCT00686387|EGFR
504259|NCT00686387|MGMT
504260|NCT00686387|Brain and Spinal TumorGliomas
504261|NCT00686374|Crohn's Disease
504262|NCT00686374|adalimumab
504263|NCT00686361|Cystic Fibrosis
504264|NCT00686361|choline nutrition
504265|NCT00686361|choline and methyl metabolism
504266|NCT00686361|CF and oxidative stress
504267|NCT00686348|acromegaly
504268|NCT00686335|asthma
504269|NCT00686335|nocturnal asthma
504270|NCT00686335|glucocorticoid dependent persistent asthma
504271|NCT00686335|signs and symptoms
504272|NCT00686335|lung function
504273|NCT00686335|prednisone
504274|NCT00686322|chemotherapy
504275|NCT00686322|radiotherapy
504276|NCT00686322|lung cancer
504277|NCT00686309|exhaled NO
504278|NCT00686309|off line
504279|NCT00686309|on line
504280|NCT00686309|comparison
504281|NCT00686309|Bland altman method
504282|NCT00686296|soft tissue abscess requiring incision and drainage
504283|NCT00686283|Adolescents
504284|NCT00686283|Diabetes
504285|NCT00686283|Exercise
504286|NCT00686270|HIV-1 infection
504287|NCT00686270|NRTI resistance
504288|NCT00686270|M184V mutation
504289|NCT00686270|reverse transcriptase
504290|NCT00686270|apricitabine
504291|NCT00686270|drug resistance
504292|NCT00686270|safety and tolerability
504293|NCT00686270|therapy failure
504294|NCT00686270|Treatment Experienced
504295|NCT00686257|acute respiratory insufficiency
504296|NCT00686257|noninvasive ventilation
504297|NCT00686257|oronasal face mask
504298|NCT00686257|total face mask
504299|NCT00686244|metabolic syndrome
504300|NCT00686244|physical activity
504301|NCT00686244|overweight
504302|NCT00686244|malnutrition
504303|NCT00686244|prevention
504304|NCT00686231|To determine if topical nitroglycerin acts to vasodilate the radial artery by a direct local action, or by systemic vasodilation
504305|NCT00686231|To determine if topical nitroglycerin dilates the radial artery in the presence of local anesthetic agents used in cardiac catheterization
504306|NCT00686218|chronic phase chronic myelogenous leukemia
504307|NCT00686205|healthy donors
504308|NCT00686205|HIV positives
504309|NCT00686192|Obesity
504310|NCT00686192|Calcium carbonate
504311|NCT00686192|Dietary Supplements
504312|NCT00686192|Lipolysis
504313|NCT00686179|TQT
504314|NCT00686179|ECG
504315|NCT00686179|QT
504316|NCT00686179|QTc
504317|NCT00686179|AZD3480
504318|NCT00686179|ECG(QTc effects)
504319|NCT00686166|adenocarcinoma of the rectum
504320|NCT00686166|stage IIA rectal cancer
504321|NCT00686166|stage IIB rectal cancer
504322|NCT00686166|stage IIC rectal cancer
504323|NCT00686166|stage IIIA rectal cancer
504324|NCT00686166|stage IIIB rectal cancer
504325|NCT00686166|stage IIIC rectal cancer
504326|NCT00686140|Schizophrenia
504327|NCT00686140|clinical trial
504328|NCT00686140|risperidone
504329|NCT00686140|immune
504330|NCT00686140|celecoxib
504331|NCT00686127|breast cancer
504332|NCT00686127|neuropathic pain
504333|NCT00686127|topical lidocaine
504334|NCT00686127|postmastectomy pain
504335|NCT00686127|breast symptoms
504336|NCT00686127|breast pain
504337|NCT00686114|Esophageal cancer
504338|NCT00686114|chemoradiation
504339|NCT00686114|radiosensitivity
504340|NCT00686114|EGFR inhibition
504341|NCT00686101|Perception of risk
504342|NCT00686101|Smoking risks
504343|NCT00686101|Smoking consequences
504344|NCT00686101|Quitting smoking
504469|NCT00685581|fat milk
504345|NCT00686101|Motivation to quit smoking
504346|NCT00686101|Schizophrenia
504347|NCT00686088|prostate cancer
504348|NCT00686088|locally recurrent
504349|NCT00686088|PRX302
504350|NCT00686075|Respiratory Syncytial Virus (RSV)
504351|NCT00686075|Parainfluenza Virus Type 3 (PIV3)
504352|NCT00686075|MEDI-534
504353|NCT00686062|Prenatal testing
504354|NCT00686062|Amniocentesis
504355|NCT00686062|Decision making
504356|NCT00686062|Down syndrome
504357|NCT00686049|HIV Treatment Readiness Measure (HTRM)
504358|NCT00686049|Highly Active Antiretroviral Treatment (HAART)
504359|NCT00686049|Adherence
504360|NCT00686049|Treatment readiness
504361|NCT00686049|HIV
504362|NCT00686036|prostate cancer
504363|NCT00686036|hormone treatment
504364|NCT00686023|pertrochanteric femur fracture
504365|NCT00686023|DHS
504366|NCT00686023|IMN
504367|NCT00686010|CETP Inhibitor
504368|NCT00686010|HDL-C
504369|NCT00686010|LDL-C
504370|NCT00686010|Apolipoprotein
504371|NCT00685997|Malignant lymphoma
504372|NCT00685997|Hodgkin's disease
504373|NCT00685997|Non-Hodgkin's lymphoma
504374|NCT00685997|Imaging
504375|NCT00685997|Whole-Body MRI
504376|NCT00685997|CT
504377|NCT00685997|Radiation
504378|NCT00685984|Type 2 diabetes
504379|NCT00685984|silent myocardial ischemia
504380|NCT00685984|endothelial function
504381|NCT00685971|Cystic Fibrosis
504382|NCT00685971|Vitamin D deficiency
504383|NCT00685958|Blood thinner
504384|NCT00685958|enoxaparin
504385|NCT00685958|hip fracture surgery
504386|NCT00685958|bleeding
504387|NCT00685958|thromboembolism
504388|NCT00685945|Bradykinin
504389|NCT00685945|Obesity
504390|NCT00685945|Nitric Oxide Donor
504391|NCT00685945|tissue type plasminogen activator
504392|NCT00685945|isosorbide dinitrate
504393|NCT00685945|phosphodiesterase inhibitor
504394|NCT00685945|Renin-Angiotensin Aldosterone System
504395|NCT00685945|Fibrinolysis
504396|NCT00685945|Angiotensin converting enzyme
504397|NCT00685932|Cesarean section
504398|NCT00685932|Postpartum pain
504399|NCT00685932|Post-cesarean pain
504400|NCT00685932|Surgical retractor
504401|NCT00685932|Elastic retractor
504402|NCT00685919|Dopamine
504403|NCT00685919|Natriuresis
504404|NCT00685919|Catecholamines
504405|NCT00685906|oral contraceptive
504406|NCT00685906|birth control
504407|NCT00685906|Healthy volunteers
504408|NCT00685893|End-of-life issues
504409|NCT00685893|Talking with your doctor
504410|NCT00685893|Coping with chronic illness
504411|NCT00685880|thumb carpo metacarpal joint osteoarthritis
504412|NCT00685880|prolotherapy
504413|NCT00685880|intra articular steroid
504414|NCT00685880|hand therapy
504415|NCT00685867|Staphylococcus aureus
504416|NCT00685867|Resistance
504417|NCT00685867|Prevention
504418|NCT00685854|Macular Telangiectasia
504419|NCT00685854|Vascular Endothelial Growth Factor
504420|NCT00685854|Ranibizumab
504421|NCT00685841|Chronic obstructive pulmonary disease
504422|NCT00685828|gastrointestinal stromal tumor
504423|NCT00685815|IV Iron
504424|NCT00685815|Restless Legs Syndrome
504425|NCT00685815|RLS
504426|NCT00685815|Iron
504427|NCT00685789|Bell's palsy，deqi，acupuncture, neuropsychology
504428|NCT00685776|CHD/CHD risk-equivalent disease
504429|NCT00685776|Coronary Heart Disease (CHD)
504430|NCT00685763|Pancreatic cancer
504431|NCT00685763|Unresectable
504432|NCT00685763|Proton radiation
504433|NCT00685763|Chemotherapy
504434|NCT00685750|tumor antigen
504435|NCT00685750|biomarkers
504436|NCT00685737|Hyperlipidemia
504437|NCT00685724|pathological gambling
504438|NCT00685724|cognitive-behavioral therapy
504439|NCT00685724|motivational enhancement therapy
504440|NCT00685711|Cat allergy
504441|NCT00685711|Immunotherapy
504442|NCT00685711|Cat-PAD
504443|NCT00685698|Diabetic Foot Infections, DFI, Nemonoxacin
504444|NCT00685685|Therapeutic Equivalency
504445|NCT00685672|labor analgesia
504446|NCT00685672|fentanyl
504447|NCT00685672|epinephrine
504448|NCT00685659|cocaine dependence
504449|NCT00685659|treatment
504450|NCT00685659|continuing care
504451|NCT00685659|outcomes
504452|NCT00685659|incentives
504453|NCT00685659|adaptive
504454|NCT00685646|bone metastases
504455|NCT00685646|stage IV prostate cancer
504456|NCT00685633|stage I prostate cancer
504457|NCT00685633|stage II prostate cancer
504458|NCT00685633|stage III prostate cancer
504459|NCT00685633|recurrent prostate cancer
504460|NCT00685607|Pilot Study
504461|NCT00685607|Outcome Measures
504462|NCT00685594|diabetes
504463|NCT00685594|vitamin D
504464|NCT00685594|cholecalciferol
504465|NCT00685594|glucose tolerance
504466|NCT00685581|TFA
504467|NCT00685581|SFA
504468|NCT00685581|Clinical trial
504470|NCT00685568|colon cancer
504471|NCT00685568|rectal cancer
504472|NCT00685568|familial adenomatous polyposis
504473|NCT00685555|Screen time
504474|NCT00685555|Fruits and Vegetable Consumption
504475|NCT00685555|Physical Activity
504476|NCT00685555|Obesity
504477|NCT00685555|Overweight
504478|NCT00685542|diacerein
504479|NCT00685542|osteoarthritis
504480|NCT00685542|hand
504481|NCT00685529|COPD
504482|NCT00685529|Arformoterol
504483|NCT00685529|formoterol
504484|NCT00685516|adenocarcinoma of the prostate
504485|NCT00685516|recurrent prostate cancer
504486|NCT00685516|stage I prostate cancer
504487|NCT00685516|stage II prostate cancer
504488|NCT00685516|stage III prostate cancer
504489|NCT00685516|stage IV prostate cancer
504490|NCT00685503|Macular Telangiectasia
504491|NCT00685503|Vascular Endothelial Growth Factor
504492|NCT00685503|Ranibizumab
504493|NCT00685503|Neovascularization
504494|NCT00685490|branch retinal vein occlusion
504495|NCT00685490|internal limiting membrane
504496|NCT00685490|macular edema
504497|NCT00685490|vitrectomy
504498|NCT00685477|CCK infusion
504499|NCT00685477|Gallbladder ejection fraction
504500|NCT00685477|Normal volunteers
504501|NCT00685464|Abciximab
504502|NCT00685464|Reo-Pro
504503|NCT00685464|Intracoronary
504504|NCT00685464|PCI
504505|NCT00685451|cognitive behavior therapy
504506|NCT00685451|addiction
504507|NCT00685451|PTSD
504508|NCT00685438|Environmental Medicine
504509|NCT00685438|Altitude
504510|NCT00685438|Ultraviolet Rays
504511|NCT00685438|Antioxidants
504512|NCT00685438|Oxidative Stress
504513|NCT00685438|Erythema
504514|NCT00685425|Asthma
504515|NCT00685425|Exercised induced bronchoconstriction
504516|NCT00685412|CIN 2 or 3
504517|NCT00685412|cervical cancer
504518|NCT00685399|Uveitis,
504519|NCT00685399|eye,
504520|NCT00685399|IL-17,
504521|NCT00685399|IL-17A,
504522|NCT00685399|IL17,
504523|NCT00685399|AIN457,
504524|NCT00685399|Vogt-Koyanagi-Harada,
504525|NCT00685399|Behcet's,
504526|NCT00685399|Behcet,
504527|NCT00685399|Sympathetic ophthalmia,
504528|NCT00685399|Multifocal choroiditis,
504529|NCT00685399|Birdshot,
504530|NCT00685399|HLA-B27,
504531|NCT00685399|Birdshot retinochoroiditis,
504532|NCT00685399|Retinal vasculitis,
504533|NCT00685399|Sarcoidosis,
504534|NCT00685399|Intermediate uveitis,
504535|NCT00685399|Panuveitis,
504536|NCT00685399|Posterior uveitis
504537|NCT00685386|endoscopic retrograde cholangiopancreatography
504538|NCT00685386|carbon dioxide
504539|NCT00685386|randomized controlled clinical trial
504540|NCT00685373|Cryopyrin-associated periodic syndromes (CAPS):
504541|NCT00685373|Familial Cold Autoinflammatory Syndrome (FCAS),
504542|NCT00685373|Muckle-Wells Syndrome (MWS),
504543|NCT00685373|MWS with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease (NOMID) or Neonatal Onset Multisystem Inflammatory Disease (NOMID),
504544|NCT00685373|children,
504545|NCT00685373|systemic autoinflammatory disease,
504546|NCT00685373|CIAS-1 gene,
504547|NCT00685373|NALP-3,
504548|NCT00685373|ACZ885,
504549|NCT00685373|human monoclonal anti-human interleukin-1beta (IL-1beta),
504550|NCT00685373|antibody,
504551|NCT00685373|autosomal dominant,
504552|NCT00685373|familial autoinflammatory syndrome
504553|NCT00685360|Tuberculosis
504554|NCT00685360|Pulmonary
504555|NCT00685360|Multidrug resistant
504556|NCT00685360|Antitubercular Agents
504557|NCT00685360|OPC 67683
504558|NCT00685347|Asthma
504559|NCT00685347|Exercised induced bronchoconstriction
504560|NCT00685334|Atypical Antipsychotics
504561|NCT00685334|Anorexia Nervosa
504562|NCT00685321|schizophrenia
504563|NCT00685321|TMS
504564|NCT00685321|brain stimulation
504565|NCT00685321|negative symptoms
504566|NCT00685321|clinical improvement
504567|NCT00685321|cognitive improvement
504568|NCT00685308|Atherosclerosis
504569|NCT00685308|Intracranial artery
504570|NCT00685308|Angioplasty
504571|NCT00685308|Stent
504572|NCT00685295|Emergency Department
504573|NCT00685295|acute
504574|NCT00685269|Obstructive Sleep Apnea Syndrome
504575|NCT00685269|OSAS
504576|NCT00685256|breast cancer
504577|NCT00685256|hereditary breast/ovarian cancer (BRCA1, BRCA2)
504578|NCT00685243|Fraxel
504579|NCT00685243|Pulsed dye laser
504580|NCT00685243|Surgical scars
504581|NCT00685230|scorpion sting
504582|NCT00685230|envenomation
504583|NCT00685230|alacramyn
504584|NCT00685191|Raltegravir
504585|NCT00685191|HIV
504586|NCT00685191|dynamics
504587|NCT00685191|viral load
504588|NCT00685191|Treatment Experienced
504589|NCT00685178|addiction
504590|NCT00685178|drug dependence
504591|NCT00685178|stimulant
504592|NCT00685139|Therapeutic Equivalency
504593|NCT00685126|RAD
504594|NCT00685126|Reactive Airways Disease
504595|NCT00685126|Levalbuterol
504596|NCT00685126|Racemic albuterol
504597|NCT00685100|IVTA; CNV; age-related macular degeneration; PDT
504598|NCT00685087|To define the natural history and the clinical, laboratory and histomorphometric features of chronic pancreatitis (CP).
504599|NCT00685087|To identify clinical and laboratory parameters that correlate with the pathophysiologic state in patients with CP.
504600|NCT00685087|To quantify the behavioral abnormalities associated with CP.
504601|NCT00685087|To determine psychological and behavioral correlates of CP disease progression and outcomes.
504602|NCT00685074|Motivational Interview
504603|NCT00685074|Computer based intervention
504604|NCT00685074|Substance abuse
504605|NCT00685074|post-partum
504606|NCT00685061|Adult, primary deceased donor kidney transplant recipients
504607|NCT00685048|Gambling
504608|NCT00685048|Brief Therapies
504609|NCT00685048|Substance Abuse
504610|NCT00685035|high frequency chest wall oscillation, cystic fibrosis
504611|NCT00685022|Asthma
504612|NCT00685022|Racemic albuterol
504613|NCT00685009|Cognition
504614|NCT00685009|Memory
504615|NCT00685009|Hormone Therapy
504616|NCT00684983|IGF-1R
504617|NCT00684983|IMC-A12
504618|NCT00684970|CRPC
504619|NCT00684970|HRPC
504620|NCT00684970|metastatic prostate cancer
504621|NCT00684931|Attention
504622|NCT00684931|Deficit
504623|NCT00684931|Disorder
504624|NCT00684931|Hyperactivity
504625|NCT00684931|cerebellum
504626|NCT00684931|alteration
504627|NCT00684931|fronto-cerebello-frontal loops
504628|NCT00684918|AML, obatoclax
504629|NCT00684905|adenocarcinoma of the prostate
504630|NCT00684905|recurrent prostate cancer
504631|NCT00684905|stage I prostate cancer
504632|NCT00684905|stage II prostate cancer
504633|NCT00684905|stage III prostate cancer
504634|NCT00684892|Emphysema
504635|NCT00684892|Endobronchial Lung Volume Reduction
504636|NCT00684879|Hereditary Hemorrhagic Telangiectasia
504637|NCT00684879|Health Belief Model
504638|NCT00684879|Illness Perceptions
504639|NCT00684879|Screening
504640|NCT00684879|HHT
504641|NCT00684866|Asthma
504642|NCT00684866|Levalbuterol
504643|NCT00684866|Racemic Albuterol
504644|NCT00684853|AMD
504645|NCT00684853|PDT
504646|NCT00684853|Avastin
504647|NCT00684853|Bevacizumab
504648|NCT00684853|Full fluence
504649|NCT00684853|exudative
504650|NCT00684853|CNV
504651|NCT00684853|Drusen
504652|NCT00684853|ARMD
504653|NCT00684853|Vetaporfin
504654|NCT00684853|efficacy
504655|NCT00684853|treatment
504656|NCT00684840|Behavioral Economics
504657|NCT00684840|Drug self administration
504658|NCT00684840|Opioid
504659|NCT00684827|Asthma
504660|NCT00684827|Racemic albuterol
504661|NCT00684814|equivalency
504662|NCT00684814|Therapeutic equivalency
504663|NCT00684801|recurrent non-small cell lung cancer
504664|NCT00684801|recurrent small cell lung cancer
504665|NCT00684801|stage IIIA non-small cell lung cancer
504666|NCT00684801|stage IIIB non-small cell lung cancer
504667|NCT00684801|stage IV non-small cell lung cancer
504668|NCT00684801|extensive stage small cell lung cancer
504669|NCT00684801|recurrent pancreatic cancer
504670|NCT00684801|stage III pancreatic cancer
504671|NCT00684801|stage IV pancreatic cancer
504672|NCT00684801|recurrent ovarian epithelial cancer
504673|NCT00684801|recurrent ovarian germ cell tumor
504674|NCT00684801|stage III ovarian epithelial cancer
504675|NCT00684801|stage III ovarian germ cell tumor
504676|NCT00684801|stage IV ovarian epithelial cancer
504677|NCT00684801|stage IV ovarian germ cell tumor
504678|NCT00684801|recurrent colon cancer
504679|NCT00684801|stage III colon cancer
504680|NCT00684801|stage IV colon cancer
504681|NCT00684801|recurrent rectal cancer
504682|NCT00684801|stage III rectal cancer
504683|NCT00684801|stage IV rectal cancer
504684|NCT00684788|opiate dependence
504685|NCT00684788|naltrexone
504686|NCT00684788|reinforcement
504687|NCT00684788|behavior therapy
504688|NCT00684788|cocaine dependence
504689|NCT00684788|risk reduction behavior
504690|NCT00684749|Mentor BodyLogic TM System
504691|NCT00684749|Breast augmentation
504692|NCT00684749|Breast implant choice
504693|NCT00684749|Reoperation rates
504694|NCT00684736|septic shock
504695|NCT00684736|shock
504696|NCT00684736|serotonin
504697|NCT00684736|kynurenine
504698|NCT00684736|tryptophan
504699|NCT00684723|Therapeutic Equivalency
504700|NCT00684710|Alzheimer Disease
504701|NCT00684697|premature infants iron neurodevelopment
504702|NCT00684684|Bronchoscopy
504703|NCT00684684|Clinically indicated for routine diagnostic bronchoscopy
504704|NCT00684671|Immune memory
504705|NCT00684671|Combined hepatitis A and B vaccine
504706|NCT00684671|> 41 years old
504707|NCT00684658|Type 1 Diabetes
504708|NCT00684658|Children and Teenagers
504709|NCT00684658|Coping with Chronic Illness
504710|NCT00684658|Adolescence
504711|NCT00684658|Internet psychosocial program
504712|NCT00684658|Coping Skills Training
504713|NCT00684645|Safety and tolerability of SUTENT® in patients with metastatic or advanced renal cell carcinoma after failure of cytokines in real-life setting.
504714|NCT00684632|Pain, cancer
504715|NCT00684606|Induction of Labor
504716|NCT00684606|Low Bishop Score
504717|NCT00684606|Transcervical Foley Catheter.
504718|NCT00684606|IV Oxytocin
504719|NCT00684580|St. Jude Alumni
504720|NCT00684580|St. Jude Life Participants
504721|NCT00684554|Heroin Dependence
504722|NCT00684554|Opioid Dependence
504723|NCT00684554|Primary Care
504724|NCT00684554|Buprenorphine
504725|NCT00684541|Social Anxiety
504726|NCT00684541|Information Processing
504727|NCT00684541|Interpretation
504728|NCT00684528|DM 2
504729|NCT00684528|Metformin
504730|NCT00684528|Januvia
504731|NCT00684528|Community setting
504732|NCT00684528|newly diagnosed diadetics, or diabetes patients not treated during the last year
504733|NCT00684502|Safety
504734|NCT00684502|tolerability
504735|NCT00684502|AZD2066
504736|NCT00684502|Pain conditions
504737|NCT00684489|hypertension
504738|NCT00684489|renin-guided therapeutics
504739|NCT00684463|Antiemetic
504740|NCT00684450|titration of protamine
504741|NCT00684450|exact dose
504742|NCT00684450|protamine
504743|NCT00684450|neutralize heparin
504744|NCT00684437|Health Literacy
504745|NCT00684437|Smoking Risk
504746|NCT00684437|Focus Group
504747|NCT00684437|Questionnaire
504748|NCT00684437|Survey
504749|NCT00684411|T NHL
504750|NCT00684411|Gleevec
504751|NCT00684411|imatinib mesylate
504752|NCT00684398|Neurofibromatosis Type 1
504753|NCT00684398|Quality of Life
504754|NCT00684398|Adaptation
504755|NCT00684398|Stress and Coping Model
504756|NCT00684398|NF1
504757|NCT00684398|Survey
504758|NCT00684359|Patients having PCI with a drug eluting stent
504759|NCT00684346|18FDG-PET imaging
504760|NCT00684346|airway inflammation
504761|NCT00684346|cystic fibrosis
504762|NCT00684346|pediatric
504763|NCT00684346|pulmonary exacerbation
504764|NCT00684333|painless Injections
504765|NCT00684333|Subcutaneous Injections
504766|NCT00684333|Subcutaneous Injections to healthy volunteers
504767|NCT00684320|Social Anxiety Disorder
504768|NCT00684320|Information Processing
504769|NCT00684320|Attention Bias
504770|NCT00684307|Anticoagulant Treatment
504771|NCT00684307|Risk Factors For Stroke
504772|NCT00684294|cancer
504773|NCT00684294|oncology
504774|NCT00684294|solid tumor
504775|NCT00684268|silibinin
504776|NCT00684268|chronic hepatitis C
504777|NCT00684268|peginterferon
504778|NCT00684268|ribavirin
504779|NCT00684268|nonresponders
504780|NCT00684268|efficacy of iv. silibinin
504781|NCT00684268|safety
504782|NCT00684255|Autoimmune Disease
504783|NCT00684255|Reduced Intensity Transplant
504784|NCT00684242|Advanced Cancer
504785|NCT00684242|Refractory Cancer Pain
504786|NCT00684242|Lenalidomide
504787|NCT00684242|Revlimid
504788|NCT00684242|CC-5103
504789|NCT00684229|Anesthesia; regional
504790|NCT00684229|Cancer recurrence
504791|NCT00684229|Anesthesia; inhalational
504792|NCT00684229|Analgesia; opioid
504793|NCT00684216|metastatic
504794|NCT00684216|ER positive
504795|NCT00684216|PD during/after first line hormonal treatment
504796|NCT00684190|Reflux Inhibitor
504797|NCT00684190|GERD
504798|NCT00684190|PPI Interaction
504799|NCT00684177|infection
504800|NCT00684177|retapamulin
504801|NCT00684177|secondarily-infected traumatic lesions
504802|NCT00684177|placebo
504803|NCT00684164|Euvolemic Hyponatremia
504804|NCT00684164|Hypervolemic Hyponatremia
504805|NCT00684164|Neurological injury
504806|NCT00684151|Lipid-lowering
504807|NCT00684138|cataract
504808|NCT00684138|cataract surgery
504809|NCT00684138|IOL
504810|NCT00684138|intraocular lens
504811|NCT00684138|ReSTOR
504812|NCT00684138|Replacement of cataract
504813|NCT00684125|late cardiac tamponade
504814|NCT00684112|pediatrics
504815|NCT00684112|Scoliosis
504816|NCT00684112|Gabapentin
504817|NCT00684099|NSCLC
504818|NCT00684099|Pemetrexed
504819|NCT00684099|Docetaxel
504820|NCT00684073|Suboxone
504821|NCT00684073|Subutex
504822|NCT00684073|Buprenorphine
504823|NCT00684073|Naloxone
504824|NCT00684060|Acute Myocardial Infarction
504825|NCT00684060|Global Left Ventricular Ejection Fraction
504826|NCT00684060|Regional Left Ventricular Ejection Fraction
504827|NCT00684060|Left Ventricular Mass
504828|NCT00684060|Infarct Size
504829|NCT00684060|End Systolic Volume
504830|NCT00684060|End Diastolic Volume
504831|NCT00684047|Fibrin Sealant
504832|NCT00684047|Hemostasis
504833|NCT00684047|Peripheral Vascular Surgery
504834|NCT00684034|Redox state in the course of chronic renal insufficiency and hemodialysis.
504835|NCT00684021|Acute Myocardial Infarction
504836|NCT00684021|Global Left Ventricular Ejection Fraction
504837|NCT00684021|Regional Left Ventricular Ejection Fraction
504838|NCT00684021|Left Ventricular Mass
504839|NCT00684021|Infarct Size
504840|NCT00684021|End Systolic Volume
504841|NCT00684021|End Diastolic Volume
504842|NCT00684008|interleukin-7
504843|NCT00684008|immune based therapies
504844|NCT00684008|graft vs host disease
504845|NCT00684008|immune reconstitution
504846|NCT00684008|infection
504847|NCT00684008|lymphopenia
504848|NCT00684008|hematopoetic stem cell transplantation
504849|NCT00684008|bone marrow transplantation
504850|NCT00684008|peripheral blood stem cell transplant
504851|NCT00684008|immunosuppression
504852|NCT00683995|Pain, Cancer
504853|NCT00683982|nitazoxanide
504854|NCT00683982|Probiotics
504855|NCT00683982|Diarrhea
504856|NCT00683982|Rotavirus
504857|NCT00683982|Children
504858|NCT00683943|Spinocerebellar Ataxia
504859|NCT00683943|Lithium
504860|NCT00683917|Uterine fibroids
504861|NCT00683917|Fibroids
504862|NCT00683891|FOCUS
504863|NCT00683891|Weight gain
504864|NCT00683891|Sialorrhea
504865|NCT00683891|Treatment refractory schizophrenia
504866|NCT00683891|FazaClo
504867|NCT00683891|Treatment resistant schizophrenia
504868|NCT00683891|clozapine
504869|NCT00683891|Hypersalivation
504870|NCT00683865|Antibiotic treatment
504871|NCT00683865|Pelvic infection
504872|NCT00683865|Interventional study
504873|NCT00683865|Female
504874|NCT00683852|Depression
504875|NCT00683839|Tobacco
504876|NCT00683839|Smoking
504877|NCT00683839|Smokeless
504878|NCT00683839|Cessation
504879|NCT00683839|Public health clinic
504880|NCT00683839|Dental patients
504881|NCT00683839|5 As
504882|NCT00683839|NRT
504883|NCT00683839|Tobacco Quit Line
504884|NCT00683839|Smokeless tobacco
504885|NCT00683826|Leucine
504886|NCT00683826|Weight Loss
504887|NCT00683813|cardiac rehabilitation
504888|NCT00683813|telehealth
504889|NCT00683813|Internet
504890|NCT00683800|Menopause
504891|NCT00683800|Hot Flush
504892|NCT00683800|Hot Flash
504893|NCT00683800|Desvenlafaxine succinate Sustained Release
504894|NCT00683787|recurrent gastric cancer
504895|NCT00683787|stage IV gastric cancer
504896|NCT00683787|adenocarcinoma of the stomach
504897|NCT00683761|High grade recurrent glioma
504898|NCT00683761|Phase 2
504899|NCT00683761|Phase 1
504900|NCT00683761|Multi-center
504901|NCT00683761|Open label
504902|NCT00683761|Multiple dose
504903|NCT00683761|Brain Cancer
504904|NCT00683761|Brain Tumor
504905|NCT00683761|GBM
504906|NCT00683761|glioma
504907|NCT00683761|glioblastoma
504908|NCT00683761|astrocytoma
504909|NCT00683761|oligodendroglioma
504910|NCT00683761|131I-TM601
504911|NCT00683761|TM601
504912|NCT00683748|Transplantation
504913|NCT00683748|Immunological monitoring
504914|NCT00683748|Immunological risk
504915|NCT00683748|T cell reactivity
504916|NCT00683748|Cellular immunity
504917|NCT00683735|Incretin, DPP-4, metformin, sitagliptin, insulin secretion
504918|NCT00683722|COPD
504919|NCT00683722|Airflow Obstruction, Chronic
504920|NCT00683722|Chronic Airflow Obstruction
504921|NCT00683722|Chronic Obstructive Airway Disease
504922|NCT00683722|Chronic Obstructive Lung Disease
504923|NCT00683722|Chronic Obstructive Pulmonary Disease
504924|NCT00683722|Pulmonary Emphysema
504925|NCT00683722|Chronic Bronchitis
504926|NCT00683722|Mesenchymal Stem Cells
504927|NCT00683722|MSCs
504928|NCT00683722|Adult Human Stem Cells
504929|NCT00683722|Osiris
504930|NCT00683722|Prochymal
504931|NCT00683709|Bipolar and Schizoaffective Disorder
504932|NCT00683709|Clozapine
504933|NCT00683709|Metabolic Side Effects
504934|NCT00683709|Diet & Exercise
504935|NCT00683709|BMI
504936|NCT00683696|Cardiac Resynchronization Therapy
504937|NCT00683696|Heart Failure
504938|NCT00683696|Ventricular Dyssynchrony
504939|NCT00683696|Mechanical Dyssynchrony
504940|NCT00683696|Intraventricular Dyssynchrony
504941|NCT00683696|Echocardiography
504942|NCT00683696|Normal QRS
504943|NCT00683696|Heart Disease
504944|NCT00683696|EchoCRT
504945|NCT00683683|cardiac arrest, hypothermia, knowledge translation
504946|NCT00683631|liver cancer
504947|NCT00683631|liver tumor
504948|NCT00683631|HCC
504949|NCT00683631|hepatocellular carcinoma
504950|NCT00683631|hepatoma
504951|NCT00683618|HMG-CoA
504952|NCT00683618|LDL-C
504953|NCT00683618|CHD
504954|NCT00683579|HAART
504955|NCT00683579|DHHS guidelines
504956|NCT00683579|Treatment Naive
504957|NCT00683566|parkinson
504958|NCT00683553|Acute Renal Failure
504959|NCT00683553|Acute Kidney Injury
504960|NCT00683540|implementation
504961|NCT00683540|evaluation
504962|NCT00683540|research methodology
504963|NCT00683540|intervention
504964|NCT00683527|Iron supplementation
504965|NCT00683527|Timing
504966|NCT00683527|Serum ferritin
504967|NCT00683527|Very low birth weight infants
504968|NCT00683514|Untreated locally advanced inoperable stage IIIA or stage IIIB NSCLC amenable to radical radiotherapy to a dose of 66 Gy
504969|NCT00683501|ocular hypertension
504970|NCT00683501|elevated IOP
504971|NCT00683501|glaucoma
504972|NCT00683501|neuroprotection
504973|NCT00683488|Substance Abuse
504974|NCT00683488|Adolescent community reinforcement approach
504975|NCT00683488|Adolescent Risk Behavior Assessment
504976|NCT00683488|Child and Adolescent Services Assessment
504977|NCT00683488|Cognitive behavioral therapy
504978|NCT00683488|Cognitive Therapy Rating Scale
504979|NCT00683488|Individual behavior therapy
504980|NCT00683488|Individual cognitive problem solving
504981|NCT00683488|Motivational enhancement therapy
504982|NCT00683488|HIV-Positive Youth With Substance Abuse
504983|NCT00683488|Complementary Therapies
504984|NCT00683475|Prostate Cancer
504985|NCT00683449|Asthma
504986|NCT00683449|Dose-Escalation
504987|NCT00683449|Controlled
504988|NCT00683449|MN-221
504989|NCT00683436|insomnia
504990|NCT00683397|assess
504991|NCT00683397|prevalence
504992|NCT00683397|thrombophilia
504993|NCT00683397|common
504994|NCT00683397|VTE
504995|NCT00683397|risk factors
504996|NCT00683397|patients
504997|NCT00683384|Arthritis
504998|NCT00683384|psoriatic
504999|NCT00683371|Chronic Rhinosinusitis
505000|NCT00683371|Sinus Disease
505001|NCT00683371|Allergy
505002|NCT00683371|Maxillary Sinus
505003|NCT00683371|Microarray
505004|NCT00683358|cancer
505005|NCT00683358|pancreas
505006|NCT00683358|advanced
505007|NCT00683358|peptide
505008|NCT00683358|vaccination
505009|NCT00683358|VEGFR1
505010|NCT00683358|HLA
505011|NCT00683358|gemcitabine
505012|NCT00683358|IFA
505013|NCT00683358|Cancer of Pancreas
505014|NCT00683358|Neoplasms, Pancreatic
505015|NCT00683358|Pancreas Cancer
505016|NCT00683332|Observational study
505017|NCT00683332|Tigecycline
505018|NCT00683332|infection
505019|NCT00683332|skin
505020|NCT00683332|abdominal
505021|NCT00683319|long-term effects secondary to cancer therapy in children
505022|NCT00683319|cognitive/functional effects
505023|NCT00683319|ototoxicity
505024|NCT00683319|childhood infratentorial ependymoma
505025|NCT00683319|childhood supratentorial ependymoma
505026|NCT00683293|Laparoscopic Hysterectomy
505027|NCT00683293|Robot-assisted Laparoscopic Hysterectomy
505028|NCT00683293|Robot-assisted Surgery
505029|NCT00683280|Contingency Management
505030|NCT00683280|Cigarette Smoking Cessation
505031|NCT00683280|varenicline
505032|NCT00683267|THA, Total hip arthroplasty, total hip replacement
505033|NCT00683254|nasal obstruction
505034|NCT00683254|nasal stent
505035|NCT00683241|Vaccine
505036|NCT00683241|Ovarian
505037|NCT00683241|Peritoneal
505038|NCT00683228|Second hand Smoke
505039|NCT00683202|Assisted reproduction
505040|NCT00683202|Ovarian response
505041|NCT00683202|Uteroplacental hemodynamics
505042|NCT00683202|Doppler ultrasonography
505043|NCT00683202|Implantation rate
505044|NCT00683202|Pregnancy rate
505045|NCT00683202|Live birth rate
505046|NCT00683189|MLD
505047|NCT00683176|Diabetic Macular Edema
505048|NCT00683176|OCT
505049|NCT00683163|Combination of PTH and ibandronate
505050|NCT00683163|Bone marker formation
505051|NCT00683163|Postmenopausal
505052|NCT00683163|Trabecular spine BMD
505053|NCT00683150|Endothelial Function
505054|NCT00683150|Abdominal Surgery
505055|NCT00683150|Thoracic Surgery
505056|NCT00683150|Vendy's-DTM Machine
505057|NCT00683150|Digital Thermal Monitoring
505058|NCT00683150|DTM
505059|NCT00683124|Marfan Syndrome
505060|NCT00683124|Losartan
505061|NCT00683124|Nebivolol
505062|NCT00683124|Transforming Growth Factor Beta
505063|NCT00683124|Aortic Root Dilation
505064|NCT00683111|acute coronary syndrome
505065|NCT00683111|acute myocardial infarction
505066|NCT00683111|aspirin
505067|NCT00683111|clopidogrel
505068|NCT00683111|heparin
505069|NCT00683111|thrombolytic
505070|NCT00683111|famotidine
505071|NCT00683111|esomeprazole
505072|NCT00683098|recurrent hernia
505073|NCT00683098|endoscopic total extraperitoneal repair
505074|NCT00683098|inguinal pain
505075|NCT00683098|questionnaire
505076|NCT00683085|cancer
505077|NCT00683085|pancreas
505078|NCT00683085|advanced
505079|NCT00683085|peptide
505080|NCT00683085|vaccination
505081|NCT00683085|VEGFR1
505082|NCT00683085|HLA
505083|NCT00683085|gemcitabine
505084|NCT00683085|IFA
505085|NCT00683085|Cancer of Pancreas
505086|NCT00683085|Neoplasms, Pancreas
505087|NCT00683085|Pancreas Cancer
505088|NCT00683072|Ventilator
505089|NCT00683072|patient-ventilator asynchrony
505090|NCT00683046|Relapsed or refractory acute myelogenous or lymphoid leukemia.
505091|NCT00683046|Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis.
505092|NCT00683046|Chronic myelogenous leukemia in chronic phase
505093|NCT00683046|Chronic myelogenous leukemia in accelerated phase or blast-crisis
505094|NCT00683046|Recurrent or refractory malignant lymphoma or Hodgkin's disease.
505095|NCT00683046|Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
505096|NCT00683046|Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
505097|NCT00683046|Severe aplastic anemia after failure of immunosuppressive therapy.
505098|NCT00683046|Myelodysplastic syndromes (including PNH)
505099|NCT00683046|Multiple myeloma at high risk for disease recurrence.
505100|NCT00683033|Contingency Management
505101|NCT00683033|Cigarette Smoking Cessation
505102|NCT00683033|Substance Abusers
505103|NCT00683020|Chronic Diseases
505104|NCT00683020|Diabetes
505105|NCT00683020|Vulnerable population
505106|NCT00683020|Urban populations
505107|NCT00683020|Disease Management
505108|NCT00683020|Health Information Technology
505109|NCT00683020|Safety
505110|NCT00683020|Health Literacy
505111|NCT00683020|Level of English Proficiency
505112|NCT00683007|TE echo
505113|NCT00683007|hemodilution
505114|NCT00683007|hypertonic
505115|NCT00683007|saline
505116|NCT00683007|Arterial Pressure Cardiac Output
505117|NCT00682994|Advanced Cancer
505118|NCT00682994|Family Member
505119|NCT00682994|Palliative Care
505120|NCT00682994|Decision Making
505121|NCT00682994|Information Disclosure
505122|NCT00682994|Interview
505123|NCT00682994|Survey
505124|NCT00682994|Questionnaire
505125|NCT00682981|ES-SCLC
505126|NCT00682981|Obatoclax
505127|NCT00682968|patient non-adherence
505128|NCT00682968|antihypertensive agents
505129|NCT00682968|hypertension
505130|NCT00682955|Diarrhea
505131|NCT00682955|Zinc Sulphate
505132|NCT00682955|Efficacy
505133|NCT00682929|cannabis
505134|NCT00682929|marijuana
505135|NCT00682929|Multiple Sclerosis
505136|NCT00682929|spasticity
505137|NCT00682916|Obesity
505138|NCT00682916|Diabetes
505139|NCT00682916|Soluble Fiber
505140|NCT00682916|Overweight
505141|NCT00682903|glucose
505142|NCT00682903|diabetes
505143|NCT00682903|glycemia
505144|NCT00682877|gastroparesis
505145|NCT00682877|Digestive
505146|NCT00682877|Gastrointestinal
505147|NCT00682877|Stomach
505148|NCT00682877|Motility
505149|NCT00682877|Non-Invasive
505150|NCT00682877|Capsule
505151|NCT00682877|GI
505152|NCT00682877|Device
505153|NCT00682877|Digestive System Diseases
505154|NCT00682838|Treatment compliance
505155|NCT00682838|Self-management
505156|NCT00682838|Telemedicine
505157|NCT00682825|Anesthesia
505158|NCT00682825|Awareness
505159|NCT00682825|Bispectral
505160|NCT00682825|BIS
505161|NCT00682825|Recall
505162|NCT00682799|RC
505163|NCT00682799|RIC
505164|NCT00682799|MDS
505165|NCT00682799|SCT
505166|NCT00682786|rectal
505167|NCT00682786|rectum
505168|NCT00682786|cancer
505169|NCT00682786|carcinoma
505170|NCT00682760|Botulinum Toxin Type A
505171|NCT00682760|Blepharospasm
505172|NCT00682747|xerostomia
505173|NCT00682747|hyperbaric oxygenation
505174|NCT00682747|radiotherapy
505175|NCT00682721|Bacterial Vaginosis
505176|NCT00682721|Herpes Simplex Virus Type II
505177|NCT00682708|malnutrition
505178|NCT00682708|ready to use food
505179|NCT00682708|Niger
505180|NCT00682695|stroke
505181|NCT00682695|brain attack
505182|NCT00682695|hemorrhagic stroke
505183|NCT00682695|risk factors
505184|NCT00682682|Pain distraction
505185|NCT00682682|Analgesic interventions
505186|NCT00682682|Burn patients
505187|NCT00682669|Asthma
505188|NCT00682669|Mindfulness-based stress reduction
505189|NCT00682669|Peak expiratory flow rate
505190|NCT00682669|Spirometry
505191|NCT00682669|Quality of life
505192|NCT00682656|cutaneous leishmaniasis
505193|NCT00682656|azithromycin
505194|NCT00682656|N- methyl glucamine
505195|NCT00682643|Perennial Allergic Rhinitis
505196|NCT00682643|fluticasone furoate
505197|NCT00682643|ocular safety
505198|NCT00682630|Malaria
505199|NCT00682630|anti-malarial
505200|NCT00682630|pyronaridine
505201|NCT00682630|ACT
505202|NCT00682617|hip
505203|NCT00682617|osteoarthritis
505204|NCT00682617|exercise
505205|NCT00682617|disability
505206|NCT00682617|physical function
505207|NCT00682604|Family Health Program; Food consumption; Nutritional status
505208|NCT00682591|hepatitis C
505209|NCT00682591|drug substitution
505210|NCT00682591|neurocognitive
505211|NCT00682591|patients with stable drug substitution therapy
505212|NCT00682591|patients with interferon-based antiviral therapy
505213|NCT00682578|falciparum malaria
505214|NCT00682578|vivax malaria
505215|NCT00682578|dihydroartemisinin-piperaquine
505216|NCT00682539|diabetic retinopathy
505217|NCT00682539|macular edema
505218|NCT00682539|intravitreal Avastin/ Triamcinolone / Lucentis
505219|NCT00682526|EMS patients with intention to treat with coronary reperfusion therapy (PCI or thrombolytics) based on their initial presentation
505220|NCT00682513|dystonia
505221|NCT00682513|parkinsonism
505222|NCT00682513|rapid-onset dystonia-parkinsonism
505223|NCT00682513|RDP
505224|NCT00682513|Alternating Hemiplegia of Childhood
505225|NCT00682513|AHC
505226|NCT00682500|Pneumonia
505227|NCT00682500|Aspiration
505228|NCT00682500|Drowning
505229|NCT00682500|inhalation
505230|NCT00682487|Myocardial infarction
505231|NCT00682487|Stress
505232|NCT00682487|Hair Cortisol
505233|NCT00682474|Cigarette smoking
505234|NCT00682474|Nicotine dependence
505235|NCT00682474|Adolescents
505236|NCT00682474|Youth
505237|NCT00682474|School health
505238|NCT00682474|Randomized controlled trial
505239|NCT00682461|Nicotine Tolerability NRT
505240|NCT00682448|Olanzapine
505241|NCT00682448|Zyprexa
505242|NCT00682448|Weight Gain
505243|NCT00682448|Antipsychotics
505244|NCT00682448|Metformin
505245|NCT00682448|Glucophage
505246|NCT00682448|Bipolar Disorder
505247|NCT00682448|Schizophrenia
505248|NCT00682448|Depression
505249|NCT00682448|Diabetes
505250|NCT00682448|Side effects
505251|NCT00682448|Metabolic complications
505252|NCT00682448|Prevention
505253|NCT00682448|Treatment
505254|NCT00682448|Metabolic side effects of olanzapine
505255|NCT00682435|Nonedlerly patients with acute moderate to severe pain
505256|NCT00682422|pediatrics, overweight, obese, behavioral intervention
505257|NCT00682383|Advanced NSCLC
505258|NCT00682383|Lung Cancer
505259|NCT00682383|Mount Sinai Medical Center CCOP
505260|NCT00682357|Osteoarthritis, intra articular steroids
505261|NCT00682318|Fish oil
505262|NCT00682318|red wine
505263|NCT00682318|alcohol
505264|NCT00682318|oxidative stress
505265|NCT00682318|Healthy volunteers
505266|NCT00682305|Acute Lymphoblastic Leukemia
505267|NCT00682305|Hematopoeitic Stem Cell Transplantation
505268|NCT00682292|Renal transplantation
505269|NCT00682292|Immunisation
505270|NCT00682292|Acute rejection
505271|NCT00682292|Induction therapy
505272|NCT00682292|Thymoglobulin
505273|NCT00682292|Daclizumab
505274|NCT00682292|Rejection in sensitized renal transplant recipients
505275|NCT00682279|lapatinib
505276|NCT00682279|GW572016
505277|NCT00682279|topotecan
505278|NCT00682279|oral topotecan
505279|NCT00682279|SK&F-104864
505280|NCT00682279|EGFR
505281|NCT00682279|ErbB1
505282|NCT00682279|HER-2/neu
505283|NCT00682279|ErbB2
505284|NCT00682279|BCRP
505285|NCT00682266|Adolescent
505286|NCT00682266|Overweight
505287|NCT00682266|Exercise
505288|NCT00682266|multidisciplinary approach
505289|NCT00682266|Oxygen uptake
505290|NCT00682266|Flow mediated dilatation
505291|NCT00682266|Cardiovascular Risk Factors
505292|NCT00682253|SPECT/CT
505293|NCT00682253|MRI
505294|NCT00682253|Breast neoplasms
505295|NCT00682240|retinal morphology
505296|NCT00682240|laser treatment
505297|NCT00682240|pascal laser
505298|NCT00682240|HD-OCT
505299|NCT00682227|Epitope peptide, CTL, Esophageal cancer, Vaccination
505300|NCT00682214|25(OH)D, muscle strength
505301|NCT00682201|Pregnancy
505302|NCT00682201|Blood pressure
505303|NCT00682201|Cardiac output
505304|NCT00682188|Overweight
505305|NCT00682188|Obesity
505306|NCT00682188|Adolescents
505307|NCT00682188|Youth
505308|NCT00682188|School health
505309|NCT00682188|Randomized controlled trial
505310|NCT00682188|Intervention study
505311|NCT00682175|Congestive Heart Failure
505312|NCT00682162|acupuncture
505313|NCT00682162|randomised controlled trial
505314|NCT00682162|placebo
505315|NCT00682162|sham laser
505316|NCT00682162|vasomotor rhinitis
505317|NCT00682149|Oxidative stress
505318|NCT00682149|malondialdehyde
505319|NCT00682149|glutathione
505320|NCT00682149|diabetes
505321|NCT00682149|polyphenol containing antioxidants
505322|NCT00682149|diet rich in vegetables
505323|NCT00682149|weekly aerobic exercise
505324|NCT00682136|postoperative analgesia
505325|NCT00682136|abdominal surgery
505326|NCT00682136|ropivacaine
505327|NCT00682136|local anaesthesia
505328|NCT00682136|tap block
505329|NCT00682136|pain management
505330|NCT00682123|19-norandrostenedione
505331|NCT00682123|steroids
505332|NCT00682123|drugs in sport
505333|NCT00682123|World Anti-Doping Agency
505334|NCT00682110|End-stage liver disease
505335|NCT00682110|Hemodynamic measurements
505336|NCT00682110|Hyperdynamic circulation
505337|NCT00682110|Pulmonary artery catheter
505338|NCT00682110|Cardiac output
505339|NCT00682084|Cushing's syndrome
505340|NCT00682084|Glucose tolerance
505341|NCT00682084|Insulin sensitivity
505342|NCT00682084|Substrate metabolism
505343|NCT00682084|Body composition
505344|NCT00682071|Ultrasound-guided
505345|NCT00682071|embryo transfer
505346|NCT00682071|in-vitro fertilization
505347|NCT00682058|body composition
505348|NCT00682058|weight loss
505349|NCT00682058|fat
505350|NCT00682058|fat distribution
505351|NCT00682058|fat free mass
505352|NCT00682058|organ
505353|NCT00682058|resting energy expenditure
505354|NCT00682045|tuberculosis
505355|NCT00682045|transplantation
505356|NCT00682032|NSCLC
505357|NCT00682019|Erectile Dysfunction
505358|NCT00682019|Vardenafil
505359|NCT00682006|Omphalitis
505360|NCT00682006|4% Chlorhexidine
505361|NCT00682006|Newborns
505362|NCT00681993|cosmetic
505363|NCT00681993|effect
505364|NCT00681993|breast
505365|NCT00681993|irradiation
505366|NCT00681993|concurrent
505367|NCT00681993|chemotherapy
505368|NCT00681993|potential acute
505369|NCT00681993|late skin
505370|NCT00681993|subcutaneous toxicities
505371|NCT00681980|TSP/HAM, HTLV-1, treatment
505372|NCT00681967|squamous cell cancer of the head & neck
505373|NCT00681967|Gefitinib
505374|NCT00681967|IRESSA
505375|NCT00681967|EGFR Inhibitor
505376|NCT00681967|EGFR-tyrosine kinase inhibitor
505377|NCT00681967|Subjects with histologically proven squamous cell cancer of the head & neck
505378|NCT00681967|Cohort 1:qualifying for postoperative radiotherapy
505379|NCT00681967|(pT3, pT4, pN2b, pN2c, pN3).
505380|NCT00681967|Cohort 2:qualifying for definite chemoradiotherapy
505381|NCT00681967|(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;
505382|NCT00681967|Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,
505383|NCT00681967|glottic and supraglottic larynx; Any TN1-3, T3-4 any N;
505384|NCT00681967|Hypopharynx: T1N1-3, T2-4 and N)
505385|NCT00681954|TRALI
505386|NCT00681954|Randomized Autologous Transfusion
505387|NCT00681954|Intra-Operative Testing of Pulmonary Function
505388|NCT00681928|stage I breast cancer
505389|NCT00681928|stage II breast cancer
505390|NCT00681928|stage IIIA breast cancer
505391|NCT00681928|stage IIIB breast cancer
505392|NCT00681928|stage IIIC breast cancer
505393|NCT00681915|Phase I
505394|NCT00681915|Pharmacokinetics
505395|NCT00681902|Pediatric
505396|NCT00681902|Pain
505397|NCT00681902|Needle
505398|NCT00681902|Emergency
505399|NCT00681902|Phlebotomy
505400|NCT00681902|Intravenous
505401|NCT00681902|Lidocaine
505402|NCT00681902|Local
505403|NCT00681902|Anesthesia
505404|NCT00681876|Metastatic colorectal cancer
505405|NCT00681876|Second line
505406|NCT00681876|Irinotecan
505407|NCT00681876|Erbitux (Cetuximab)
505408|NCT00681876|Avastin (Bevacizumab)
505409|NCT00681850|Diabetes
505410|NCT00681850|Benchmarking
505411|NCT00681850|quality of patient care
505412|NCT00681850|Diabetic Population
505413|NCT00681837|gastroesophageal reflux
505414|NCT00681837|prevalence
505415|NCT00681837|childhood
505416|NCT00681837|France
505417|NCT00681811|Metazyme
505418|NCT00681811|Late Infantile Metachromatic Leukodystrophy
505419|NCT00681798|pancreatic cancer
505420|NCT00681798|pancreatic adenocarcinoma
505421|NCT00681798|pancreas cancer
505422|NCT00681798|dose escalation study
505423|NCT00681798|locally advanced unresectable pancreatic adenocarcinoma
505424|NCT00681798|Zactima
505425|NCT00681798|Vandetanib
505426|NCT00681798|ZD6474
505427|NCT00681785|thrombophylaxis and transurethral surgery
505428|NCT00681772|Erectile Dysfunction
505429|NCT00681772|Vardenafil
505430|NCT00681759|Low Dose Aspirin (LDA)
505431|NCT00681759|Cardiovascular disease
505432|NCT00681759|Low Dose Aspirin (LDA) use in in subjects with cardiovascular risk or disease
505433|NCT00681746|Anxiety
505434|NCT00681746|GABA receptors
505435|NCT00681746|Positron Emission Tomography
505436|NCT00681746|PET
505437|NCT00681746|phase I
505438|NCT00681733|NASH Pentoxifylline Pioglitazone
505439|NCT00681720|Anxiety
505440|NCT00681720|GABA receptors
505441|NCT00681720|Positron Emission Tomography
505442|NCT00681720|PET
505443|NCT00681720|phase I
505444|NCT00681707|Hypertension
505445|NCT00681707|Post stroke
505446|NCT00681707|JNC7
505447|NCT00681707|2007 ESH-ESC guidelines
505448|NCT00681707|survey
505449|NCT00681694|brachytherapy
505450|NCT00681694|radioactive seed implants
505451|NCT00681681|stroke
505452|NCT00681681|vascular marker
505453|NCT00681681|stroke risk
505454|NCT00681681|risk factors
505455|NCT00681681|sex differences
505456|NCT00681668|Postpartum Depression
505457|NCT00681668|Quetiapine
505458|NCT00681668|Psychotic Symptoms
505459|NCT00681642|Corneal epithelial wound
505460|NCT00681642|Human autoserum
505461|NCT00681642|Cord blood
505462|NCT00681629|Schizophrenia
505463|NCT00681629|Integrated Care
505464|NCT00681629|Quetiapine
505465|NCT00681616|Anterior compartment syndrome
505466|NCT00681616|Tibia
505467|NCT00681616|Trauma
505468|NCT00681616|Blood circulation
505469|NCT00681616|Nerve compression syndromes
505470|NCT00681603|corneal neovascularization
505471|NCT00681603|lipid keratopathy
505472|NCT00681603|penetrating keratopathy
505473|NCT00681603|bevacizumab
505474|NCT00681603|Avastin
505475|NCT00681603|subconjunctival injection
505476|NCT00681590|vitamin D
505477|NCT00681590|deficiency
505478|NCT00681590|elderly
505479|NCT00681577|Peptide Vaccine
505480|NCT00681577|URLC10
505481|NCT00681577|KOC1
505482|NCT00681577|VEGFR1
505483|NCT00681577|VEGFR2
505484|NCT00681564|Periodontitis
505485|NCT00681564|Oral health
505486|NCT00681564|Cardiovascular disease
505487|NCT00681551|Detection of brain metastasis by MRI
505488|NCT00681551|Magnevist
505489|NCT00681551|Brain metastasis
505490|NCT00681551|Meglumine gadopentetate
505491|NCT00681538|Spasticity
505492|NCT00681538|Multiple Sclerosis
505493|NCT00681512|NSCLC
505494|NCT00681512|lung cancer
505495|NCT00681512|non small cell lung cancer
505496|NCT00681512|lung carcinoma
505497|NCT00681499|Quality of Life
505498|NCT00681499|Liver Neoplasms
505499|NCT00681499|Surgical procedures, Operative
505500|NCT00681486|Ghrelin
505501|NCT00681486|Nutrition
505502|NCT00681486|Cancer patients
505503|NCT00681486|Survival
505504|NCT00681473|proton radiation therapy
505505|NCT00681473|photon radiation therapy
505506|NCT00681460|gestational diabetes
505507|NCT00681460|birth weight
505508|NCT00681460|fetal growth
505509|NCT00681460|insulin resistance
505510|NCT00681460|oxidative stress
505511|NCT00681460|inflammatory reaction
505512|NCT00681460|Fetal Development
505513|NCT00681447|lumbar disc herniation
505514|NCT00681447|discogenic pain
505515|NCT00681447|lumbar interlaminar epidural
505516|NCT00681447|injections
505517|NCT00681434|stroke
505518|NCT00681434|upper extremity
505519|NCT00681434|hemiparesis
505520|NCT00681421|Peptide Vaccine
505521|NCT00681421|URLC10
505522|NCT00681421|VEGFR1
505523|NCT00681421|VEGFR2
505524|NCT00681408|Steatohepatitis
505525|NCT00681408|NASH
505526|NCT00681408|NAFLD
505527|NCT00681408|omega 3 fatty acids
505528|NCT00681408|Exercise conditioning
505529|NCT00681382|Asthma
505530|NCT00681382|use of asthma medication
505531|NCT00681382|asthma control
505532|NCT00681382|telephone survey
505533|NCT00681382|patient's perception
505534|NCT00681369|breast cancer
505535|NCT00681369|fulvestrant
505536|NCT00681369|longitudinal study
505537|NCT00681369|France
505538|NCT00681356|TKA
505539|NCT00681356|Total knee arthroplasty
505540|NCT00681356|Total knee replacement
505541|NCT00681356|Knee surgery
505542|NCT00681343|Randomized
505543|NCT00681343|study
505544|NCT00681343|effectiveness/toxicity
505545|NCT00681343|induction therapy
505546|NCT00681343|recipients
505547|NCT00681330|Peptide Vaccine
505548|NCT00681330|URLC10
505549|NCT00681330|TTK
505550|NCT00681330|KOC1
505551|NCT00681317|Phase I
505552|NCT00681317|Pharmacokinetics
505553|NCT00681304|Resected Breast Cancer
505554|NCT00681304|Breast Cancer
505555|NCT00681291|surgical mesh
505556|NCT00681291|inguinal hernia repair
505557|NCT00681291|chronic groin pain
505558|NCT00681278|Hypertension
505559|NCT00681278|Type II DM
505560|NCT00681278|JNC7
505561|NCT00681278|2007 ESH-ESC guidelines
505562|NCT00681278|survey
505563|NCT00681265|ocular lubricants
505564|NCT00681252|Peptide Vaccine
505565|NCT00681252|URLC10
505566|NCT00681252|VEGFR1
505567|NCT00681252|VEGFR2
505568|NCT00681239|childhood
505569|NCT00681239|epilepsy
505570|NCT00681239|intractable
505571|NCT00681239|seizures
505572|NCT00681239|Atkins
505573|NCT00681239|ketogenic
505574|NCT00681226|peripheral arterial disease
505575|NCT00681226|angiotensin converting enzyme inhibitors
505576|NCT00681226|exercise
505577|NCT00681200|Blood Pressure Reduction
505578|NCT00681200|Stress Reactivity and Recovery
505579|NCT00681200|Meditation
505580|NCT00681200|Transcendental Meditation
505581|NCT00681200|Stress Reduction
505582|NCT00681200|Stress Management
505583|NCT00681174|Care, Postoperative
505584|NCT00681174|Analgesia
505585|NCT00681174|Analgesics, Opioid
505586|NCT00681174|Morphine
505587|NCT00681174|Remifentanil
505588|NCT00681174|Oxycodone
505589|NCT00681174|Anesthesia, Regional
505590|NCT00681174|Anesthesia, Intravenous
505591|NCT00681174|Preanesthetic Medication
505592|NCT00681174|Analgesia, Patient-Controlled
505593|NCT00681161|obstructive sleep apnea
505594|NCT00681161|OSA
505595|NCT00681161|diabetes
505596|NCT00681161|pre-diabetic condition
505597|NCT00681161|obesity
505598|NCT00681161|blood glucose
505599|NCT00681161|continuous positive airway pressure
505600|NCT00681161|CPAP
505601|NCT00681148|Prostate specific antigen (PSA)
505602|NCT00681148|Prostate cancer
505603|NCT00681148|Lower urinary tract symptoms
505604|NCT00681148|Radioactive seed implantation
505605|NCT00681135|orthodontics
505606|NCT00681135|toothbrush
505607|NCT00681135|interdental brush
505608|NCT00681135|oral hygiene
505609|NCT00681122|Breast Cancer
505610|NCT00681122|hormone therapy
505611|NCT00681122|aromatase inhibitor
505612|NCT00681096|Low back pain in nurses
505613|NCT00681083|Obstructive Sleep Apnea
505614|NCT00681083|Humidification
505615|NCT00681083|Continuous Positive Airway Pressure
505616|NCT00681070|laceration
505617|NCT00681070|wound management
505618|NCT00681070|absorbable sutures
505619|NCT00681070|cosmetic outcomes
505620|NCT00680225|Choroidal melanoma
505621|NCT00680225|Lucentis
505622|NCT00680225|TTT-ICG
505623|NCT00680212|dietary beta-carotene
505624|NCT00680212|vitamin A status
505625|NCT00680212|intrinsically labeled plant foods
505626|NCT00680199|Insomnia
505627|NCT00680199|Primary Insomnia
505628|NCT00680199|Good Sleepers
505629|NCT00680199|ERP
505630|NCT00681044|monoclonal immunoglobulin deposition disease
505631|NCT00681044|light chain deposition disease
505632|NCT00681018|premature
505633|NCT00681018|infants
505634|NCT00681005|PPI test
505635|NCT00681005|gastroesophageal reflux disease
505636|NCT00681005|CYP2C19
505637|NCT00681005|rabeprazole
505638|NCT00681005|pantoprazole
505639|NCT00680992|Giant Cell Tumor of Bone
505640|NCT00680979|Prevention
505641|NCT00680979|Obesity
505642|NCT00680979|Binge Eating
505643|NCT00680979|Adolescents
505644|NCT00680979|Overweight
505645|NCT00680979|Weight Gain
505646|NCT00680966|Treatment efficacy
505647|NCT00680966|Family therapy
505648|NCT00680966|Teens
505649|NCT00680966|Substance abuse
505650|NCT00680966|Substance dependence
505651|NCT00680940|NSCLC
505652|NCT00680927|Atrial Fibrillation
505653|NCT00680927|Risk of cardiac arrhythmias
505654|NCT00680927|Loop recorder
505655|NCT00680914|Streptococcus pneumoniae
505656|NCT00680914|pneumococcal conjugate vaccine
505657|NCT00680901|unresectable
505658|NCT00680901|HER2
505659|NCT00680901|TYVERB
505660|NCT00680901|ErbB2
505661|NCT00680901|TYKERB
505662|NCT00680901|capecitabine
505663|NCT00680901|CapeOx
505664|NCT00680901|gastric/esophageal cancer
505665|NCT00680901|GE junction
505666|NCT00680901|metastatic
505667|NCT00680901|lapatinib
505668|NCT00680901|oxaliplatin
505669|NCT00680888|Psychosis
505670|NCT00680888|adolescents
505671|NCT00680888|adherence
505672|NCT00680888|quetiapine
505673|NCT00680875|School Based Services
505674|NCT00680875|Prevention
505675|NCT00680875|Children
505676|NCT00680862|HIV
505677|NCT00680862|screening
505678|NCT00680849|Type 2 Diabetes Mellitus
505679|NCT00680849|Coronary Disease
505680|NCT00680836|Irritable Bowel Syndrome
505681|NCT00680836|Diarrhea
505682|NCT00680836|Gulf War
505683|NCT00680836|Veterans
505684|NCT00680836|Small intestinal bacterial overgrowth (SIBO)
505685|NCT00680823|Headache
505686|NCT00680823|Migraine
505687|NCT00680823|Ropivacaine
505688|NCT00680797|Aging
505689|NCT00680797|Hormones
505690|NCT00680797|Insulin resistance
505691|NCT00680784|sprain
505692|NCT00680784|ankle
505693|NCT00680784|pain
505694|NCT00680771|Primary Insomnia
505695|NCT00680771|Insomnia
505696|NCT00680771|Good Sleepers
505697|NCT00680771|Hep B
505698|NCT00680771|Vaccine
505699|NCT00680758|male breast cancer
505700|NCT00680758|stage IV breast cancer
505701|NCT00680745|Dapagliflozin
505702|NCT00680745|efficacy
505703|NCT00680745|safety
505704|NCT00680745|sulphonylurea
505705|NCT00680745|Type 2 diabetes
505706|NCT00680732|Malaria
505707|NCT00680732|Pregnancy
505708|NCT00680732|Prevention
505709|NCT00680732|Chloroquine
505710|NCT00680732|Sulphadoxine pyrimethamine
505711|NCT00680732|Maternal anaemia
505712|NCT00680732|Birth weight
505713|NCT00680732|Foetal anaemia
505714|NCT00680719|substance abuse
505715|NCT00680719|HIV risk
505716|NCT00680719|Behavior and Mental Disorders
505717|NCT00680719|HIV Seronegativity
505718|NCT00680693|IBS, functional gastrointestinal disease
505719|NCT00680680|Urinary retention secondary to benign prostatic hyperplasia
505720|NCT00680667|ductal breast carcinoma
505721|NCT00680667|stage I breast cancer
505722|NCT00680667|stage II breast cancer
505723|NCT00680667|stage IIIA breast cancer
505724|NCT00680667|stage IIIB breast cancer
505725|NCT00680667|stage IIIC breast cancer
505726|NCT00680667|estrogen receptor-negative breast cancer
505727|NCT00680667|progesterone receptor-negative breast cancer
505728|NCT00680654|Pulmonary hypertension
505729|NCT00680641|COPD
505730|NCT00680641|Emphysema
505731|NCT00680641|Simvastatin
505732|NCT00680628|Pulmonary Embolism
505733|NCT00680628|Tenecteplase
505734|NCT00680628|Enoxaparin
505735|NCT00680628|Thrombosis
505736|NCT00680628|Fibrinolytics
505737|NCT00680615|Smokeless tobacco
505738|NCT00680602|behavior therapy
505739|NCT00680602|group therapy
505740|NCT00680602|psychopharmacology
505741|NCT00680589|TYRP2 DNA Vaccine
505742|NCT00680576|adolescent substance abuse
505743|NCT00680550|Atrial Fibrillation
505744|NCT00680550|Risk of cardiac Arrhythmias
505745|NCT00680550|Loop recorder
505746|NCT00680537|physical therapy program
505747|NCT00680524|telephone-based intervention for PTSD
505748|NCT00680511|methamphetamine abuse
505749|NCT00680498|Age-Related Macular Degeneration
505750|NCT00680498|Ranibizumab
505751|NCT00680498|Lucentis
505752|NCT00680498|Photodynamic Therapy
505753|NCT00680498|Verteporfin
505754|NCT00680498|Visudyne
505755|NCT00680485|GSK580416
505756|NCT00680485|ketoconazole interaction
505757|NCT00680485|pleuromutilin
505758|NCT00680485|oral dose
505759|NCT00680472|Shoulder pain
505760|NCT00680472|Pain
505761|NCT00680472|Ketoprofen
505762|NCT00680472|Topical Patch
505763|NCT00680459|central line infection
505764|NCT00680459|70% ethanol
505765|NCT00680459|Sepsis
505766|NCT00680446|Primary Immune Deficiency
505767|NCT00680446|Subcutaneous
505768|NCT00680446|Immunoglobulin G
505769|NCT00680420|pancreas cancer
505770|NCT00680420|pancreas cyst
505771|NCT00680420|DNA microarray
505772|NCT00680407|NASH
505773|NCT00680407|non-alcoholic steatohepatitis
505774|NCT00680394|abortion
505775|NCT00680394|medical abortion
505776|NCT00680394|mifepristone
505777|NCT00680394|misoprostol
505778|NCT00680381|adolescent substance abuse
505779|NCT00680368|Feasibility
505780|NCT00680368|Supervision
505781|NCT00680368|Assessing
505782|NCT00680355|golden rice carotenoids
505783|NCT00680355|healthy volunteers
505784|NCT00680355|retinol equivalence
505785|NCT00680342|hepatitis C
505786|NCT00680329|Adherence
505787|NCT00680329|Compliance
505788|NCT00680329|Glaucoma
505789|NCT00680329|Ocular Hypertension
505790|NCT00680316|Pulmozyme
505791|NCT00680316|CF
505792|NCT00680303|Early Stuttering
505793|NCT00680303|Lidcombe Program
505794|NCT00680303|Stuttering Treatment
505795|NCT00680303|Efficiency
505796|NCT00680303|Efficacy
505797|NCT00680303|Service Delivery
505798|NCT00680303|Models of intervention
505799|NCT00680290|exercise, quality of life, cpx
505800|NCT00680277|spirulina
505801|NCT00680277|carotenoids
505802|NCT00680264|Treatment Outcomes
505803|NCT00680264|Scoliosis
505804|NCT00680264|Cerebral Palsy
505805|NCT00680238|Pregnancy
505806|NCT00680238|implantation
505807|NCT00680238|miscarriage
505808|NCT00680238|sHLA-G
505809|NCT00680173|Chronic Hepatitis C
505810|NCT00680173|Single nucleotide polymorphisms
505811|NCT00680173|Sustained virological response
505812|NCT00680173|Peginterferon
505813|NCT00680173|Ribavirin
505814|NCT00680160|Onychomycosis
505815|NCT00680160|Fungal Nail
505816|NCT00680147|HPV
505817|NCT00680147|Gardasil
505818|NCT00680147|African-American
505819|NCT00680147|adolescent
505820|NCT00680147|health behavior
505821|NCT00680147|sexually transmitted infections
505822|NCT00680147|This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.
505823|NCT00680134|Onychomycosis
505824|NCT00680134|Fungal Nail
505825|NCT00680121|Alcoholism
505826|NCT00680121|Benfotiamine
505827|NCT00680121|Thiamine
505828|NCT00680095|Onychomycosis
505829|NCT00680095|Fungal Nail
505830|NCT00680082|statins
505831|NCT00680082|rosuvastatin
505832|NCT00680082|cross sectional study
505833|NCT00680082|France
505834|NCT00680082|CV risk factors
505835|NCT00680069|avian influenza,H5N1,Influenza,parent protocol
505836|NCT00680056|Pulmonary Disease, Chronic Obstructive
505837|NCT00680056|Tiotropium
505838|NCT00680056|Formoterol
505839|NCT00680056|Bronchodilator Agents
505840|NCT00680056|Exercise Tolerance
505841|NCT00680056|Randomized Controlled Trial [Publication Type]
505842|NCT00680056|COPD
505843|NCT00680043|anemia
505844|NCT00680043|chronic kidney disease
505845|NCT00680043|CKD
505846|NCT00680043|chronic renal failure
505847|NCT00680043|CRF
505848|NCT00680043|erythropoietin
505849|NCT00680043|EPO
505850|NCT00680043|erythropoiesis stimulating agent
505851|NCT00680043|ESA
505852|NCT00680043|Hematide™
505853|NCT00680043|hemoglobin
505854|NCT00680043|Hb
505855|NCT00680043|Hgb
505856|NCT00680043|Omontys
505857|NCT00680043|peginesatide
505858|NCT00680043|red blood cell
505859|NCT00680043|red blood cell production
505860|NCT00680030|impedance
505861|NCT00680030|manometry
505862|NCT00680030|motility disorders
505863|NCT00680030|ineffective motility
505864|NCT00680030|diffuse esophageal spasms
505865|NCT00680030|achlasia-like dysmotility
505866|NCT00680017|Dyslipidemia
505867|NCT00680017|Kidney Disease
505868|NCT00680004|Dynamic CTA
505869|NCT00680004|follow-up
505870|NCT00680004|EVAR
505871|NCT00679991|arteriovenous fistula
505872|NCT00679991|AVF
505873|NCT00679991|hemodialysis
505874|NCT00679991|vascular access
505875|NCT00679991|PRT 201
505876|NCT00679991|dose escalation
505877|NCT00679991|dialysis
505878|NCT00679991|fistula
505879|NCT00679991|access
505880|NCT00679991|vonapanitase
505881|NCT00679991|kidney
505882|NCT00679991|renal
505883|NCT00679978|osteoporosis
505884|NCT00679978|glucocorticoid
505885|NCT00679978|bone mineral density
505886|NCT00679978|osteonecrosis of the femoral head
505887|NCT00679965|Onychomycosis
505888|NCT00679965|Fungal Nail
505889|NCT00679952|Pancreatic fistula
505890|NCT00679952|Pancreatic duct stent
505891|NCT00679952|Closed suction drainage
505892|NCT00679939|Type 2 diabetes mellitus
505893|NCT00679939|bone
505894|NCT00679939|x-ray absorptiometry
505895|NCT00679939|bone biomarkers
505896|NCT00679939|dual-energy
505897|NCT00679939|bone mineral density
505898|NCT00679926|HIV
505899|NCT00679926|AIDS
505900|NCT00679926|HIV/AIDS
505901|NCT00679926|Treatment Naive
505902|NCT00679913|Pancreatic cancer
505903|NCT00679913|Pancreaticoduodenectomy
505904|NCT00679913|Extended lymphadenectomy
505905|NCT00679900|Primary Insomnia
505906|NCT00679900|Sleep Maintenance Difficulties
505907|NCT00679887|chiropractic
505908|NCT00679887|myofascial trigger points
505909|NCT00679887|ischemic compression
505910|NCT00679887|shoulder pain
505911|NCT00679874|Cardiovascular Magnetic Resonance Imaging
505912|NCT00679874|Cardiotoxicity
505913|NCT00679874|Anthracyclines
505914|NCT00679874|Trastuzumab
505915|NCT00679874|Breast cancer
505916|NCT00679874|Toxicity
505917|NCT00679861|primary medical care
505918|NCT00679861|computer expert system
505919|NCT00679861|motivational interviewing
505920|NCT00679861|health behavior change counselling
505921|NCT00679861|stages of change
505922|NCT00679848|Weight Loss
505923|NCT00679848|Transoral Suturing
505924|NCT00679848|Experimental
505925|NCT00679822|OSA
505926|NCT00679822|sleep apnea
505927|NCT00679822|heart failure
505928|NCT00679822|CHF
505929|NCT00679822|heart clinic
505930|NCT00679822|clinic
505931|NCT00679822|obstructive sleep apnea
505932|NCT00679809|Resident
505933|NCT00679809|Safety
505934|NCT00679809|Fatigue
505935|NCT00679809|Continuity
505936|NCT00679809|ICU
505937|NCT00679796|varicella
505938|NCT00679796|case-control
505939|NCT00679783|Breast cancer
505940|NCT00679783|Ovarian cancer
505941|NCT00679783|BRCA
505942|NCT00679783|Triple negative
505943|NCT00679783|Poly(ADP ribose) polymerases
505944|NCT00679783|Known BRCA or Recurrent High Grade Serious/ Undifferentiated Tubo- Ovarian Carcinoma
505945|NCT00679783|Known BRCA or Triple Negative Breast Cancer
505946|NCT00679770|Onychomycosis
505947|NCT00679770|Fungal Nail
505948|NCT00679757|Sleep apnea
505949|NCT00679757|Obstructive sleep apnea
505950|NCT00679757|Wound healing
505951|NCT00679757|Non-healing wounds
505952|NCT00679744|Tay-Sachs disease.
505953|NCT00679744|Sandhoff disease.
505954|NCT00679744|GM2 Gangliosidosis.
505955|NCT00679744|β-hexosaminidase deficiency.
505956|NCT00679744|Hexosaminidase
505957|NCT00679744|Phase I clinical trial.
505958|NCT00679731|Psoriasis
505959|NCT00679705|Hemodynamics and arterial function of healthy females
505960|NCT00679692|GH,IGF-1, IGFBP-3
505961|NCT00679679|Polycystic ovary syndrome
505962|NCT00679679|Treatment
505963|NCT00679679|Metformin
505964|NCT00679666|keratoconus
505965|NCT00679666|ectasia
505966|NCT00679666|cross-linking
505967|NCT00679666|riboflavin
505968|NCT00679666|UVA light
505969|NCT00679666|cornea
505970|NCT00679640|candesartan
505971|NCT00679640|heart failure
505972|NCT00679640|cohort study
505973|NCT00679640|France
505974|NCT00679627|Alzheimer's Disease
505975|NCT00679627|Galantamine
505976|NCT00679627|Dementia, Alzheimer type
505977|NCT00679627|Memory loss
505978|NCT00679614|Tramacet
505979|NCT00679614|naloxone
505980|NCT00679614|morphine
505981|NCT00679614|analgesia
505982|NCT00679614|elderly
505983|NCT00679614|elderly patients
505984|NCT00679601|Onychomycosis
505985|NCT00679601|Fungal Nail
505986|NCT00679588|Digestive System Surgical Procedure
505987|NCT00679588|Urologic Surgical Procedure
505988|NCT00679588|Prevention of venous thromboembolism
505989|NCT00679588|Abdominal surgery
505990|NCT00679575|statins
505991|NCT00679575|myocardial infarction
505992|NCT00679575|case-referent study
505993|NCT00679575|France
505994|NCT00679549|Heart Failure
505995|NCT00679549|Obstructive Sleep Apnea
505996|NCT00679549|OSA
505997|NCT00679549|CHF
505998|NCT00679549|Sleep apnea
505999|NCT00679549|CHD
506000|NCT00679536|Reduced Toxicity
506001|NCT00679536|Toxicity
506002|NCT00679536|Event Free Survival
506003|NCT00679536|Graft vs Host Disease
506004|NCT00679523|Onychomycosis
506005|NCT00679523|Fungal Nail
506006|NCT00679510|Rheumatoid Arthritis
506007|NCT00679510|Rosuvastatin
506008|NCT00679510|Cardiovascular
506009|NCT00679510|Intima media thickness
506010|NCT00679497|Low risk HIV infection
506011|NCT00679497|HIV Seronegativity
506012|NCT00679497|HIV Preventive Vaccine
506013|NCT00679471|pre-term infants
506014|NCT00679471|full-term infants
506015|NCT00679471|MRI
506016|NCT00679471|brain structure development
506017|NCT00679471|pre term
506018|NCT00679471|full term
506019|NCT00679458|analgesia
506020|NCT00679458|pain
506021|NCT00679458|buprenorphine
506022|NCT00679458|opioid
506023|NCT00679458|naloxone
506024|NCT00679445|Macular
506025|NCT00679445|Degeneration
506026|NCT00679445|AMD
506027|NCT00679445|Wet Age-related macular degeneration
506028|NCT00679432|Ulcerative colitis
506029|NCT00679406|Chronic Insomnia lasting more than 1 month
506030|NCT00679393|Calcaneus
506031|NCT00679393|Intra-articular fracture
506032|NCT00679393|open reduction internal fixation
506033|NCT00679393|primary subtalar fusion
506034|NCT00679380|Ulcerative colitis
506035|NCT00679367|primary systemic amyloidosis
506036|NCT00679341|HER2-positive breast cancer
506037|NCT00679341|HER2
506038|NCT00679341|Herceptin
506039|NCT00679341|Taxotere
506040|NCT00679341|MBC
506041|NCT00679341|Breast cancer
506042|NCT00679341|TDM1
506043|NCT00679341|TDM-1
506044|NCT00679341|HER2-positive
506045|NCT00679341|HER2+
506046|NCT00679341|HER2 positive breast cancer
506047|NCT00679341|HER2+ breast cancer
506048|NCT00679341|Armed Herceptin
506049|NCT00679341|Trastuzumab emtansine
506050|NCT00679341|Trastuzumab DM1
506051|NCT00679315|female voiding dysfunction
506052|NCT00679315|alpha adrenoreceptor antagonists
506053|NCT00679315|IPSS or American Urological Association symptom index
506054|NCT00679302|skin abscess
506055|NCT00679302|CA-MRSA
506056|NCT00679289|KW2871
506057|NCT00679289|ecromeximab
506058|NCT00679289|anti-ganglioside
506059|NCT00679289|antibody
506060|NCT00679289|interferon alpha
506061|NCT00679289|Metastatic melanoma
506062|NCT00679276|vaginal prolapse
506063|NCT00679263|asthma
506064|NCT00679263|randomized
506065|NCT00679263|placebo controlled
506066|NCT00679263|dose escalation
506067|NCT00679263|safety
506068|NCT00679263|efficacy
506069|NCT00679263|single blind
506070|NCT00679263|MN-221
506071|NCT00679250|allergic rhinitis
506072|NCT00679250|levocetirizine
506073|NCT00679250|nasal provocation testing
506074|NCT00679250|nasal allergen challenge
506075|NCT00679250|nasal adenosine monophosphate challenge
506076|NCT00679224|Pulmonary Arterial Hypertesion
506077|NCT00679224|observational safety
506078|NCT00679211|HER2-positive breast cancer
506079|NCT00679211|HER2
506080|NCT00679211|MBC
506081|NCT00679211|Trastuzumab emtansine
506082|NCT00679198|osteoporosis
506083|NCT00679198|fracture
506084|NCT00679198|communication
506085|NCT00679198|prescription medication
506086|NCT00679185|fatigue
506087|NCT00679185|stage I breast cancer
506088|NCT00679185|stage II breast cancer
506089|NCT00679185|stage IIIA breast cancer
506090|NCT00679185|stage IIIB breast cancer
506091|NCT00679185|stage IIIC breast cancer
506092|NCT00679185|lymphedema
506093|NCT00679133|c-Met
506094|NCT00679133|VEGFR
506095|NCT00679133|Ron
506096|NCT00679133|Cancer
506097|NCT00679133|Tumor
506098|NCT00679133|Safety
506099|NCT00679133|Phase 1
506100|NCT00679120|Unicompartmental osteoarthrosis
506101|NCT00679120|RSA
506102|NCT00679120|Bone-remodelling
506103|NCT00679107|Degenerative Disc Disease
506104|NCT00679068|respiratory mechanics
506105|NCT00679068|bosentan
506106|NCT00679068|exercise capacity
506107|NCT00679042|Diabetes Mellitus Type 1
506108|NCT00679042|Type 1 Diabetes Mellitus
506109|NCT00679042|Islets of Langerhans Transplantation
506110|NCT00679042|Allogeneic Islet transplantation
506111|NCT00679003|Crohn's disease
506112|NCT00679003|Ulcerative colitis
506113|NCT00679003|Inflammatory bowel disease
506114|NCT00679003|Illness behavior
506115|NCT00679003|Cognitive behavioral therapy
506116|NCT00678990|Islets of Langerhans
506117|NCT00678990|islets
506118|NCT00678990|heparin
506119|NCT00678977|pharmacokinetics
506120|NCT00678977|cisplatin
506121|NCT00678977|pazopanib (GW786034)
506122|NCT00678977|Solid tumors
506123|NCT00678977|anti-angiogenesis
506124|NCT00678977|gemcitabine
506125|NCT00678964|NSCLC
506126|NCT00678964|Elderly patients
506127|NCT00678938|smoking reduction
506128|NCT00678938|smoking cessation
506129|NCT00678938|stages of change
506130|NCT00678938|expert system interventions
506131|NCT00678912|mechanical ventilation
506132|NCT00678912|automated weaning
506133|NCT00678912|children
506134|NCT00678899|High frequency severe to profound
506135|NCT00678886|Type 1 diabetes
506136|NCT00678886|new onset type 1 diabetes
506137|NCT00678886|T1DM
506138|NCT00678886|Type l diabetes
506139|NCT00678886|juvenile diabetes
506140|NCT00678873|Single Incision
506141|NCT00678873|Single Access
506142|NCT00678873|Surgery
506143|NCT00678873|Cholecystectomy
506144|NCT00678860|Questionnaire
506145|NCT00678860|Computer Assisted Interface
506146|NCT00678860|Quality of Life
506147|NCT00678860|Dry Eye
506148|NCT00678860|Ocular Surface Disease
506149|NCT00678860|Healthy Volunteer
506150|NCT00678860|HV
506151|NCT00678847|bio-electrical stimulation therapy
506152|NCT00678847|chronic venous ulcers
506153|NCT00678847|microcurrent
506154|NCT00678847|chronic wounds
506155|NCT00678847|complete healing
506156|NCT00678821|Exercise
506157|NCT00678821|Pulmonary Hypertension
506158|NCT00678821|Pulmonary Rehabilitation
506159|NCT00678821|Interstitial Lung Disease
506160|NCT00678795|Detrusor overactivity
506161|NCT00678795|Multiple Sclerosis
506162|NCT00678782|knee
506163|NCT00678782|synovitis
506164|NCT00678782|arthritis
506165|NCT00678782|rheumatoid arthritis
506166|NCT00678782|psoriatic arthritis
506167|NCT00678782|spondyloarthropathies
506168|NCT00678782|intraarticular
506169|NCT00678782|etanercept
506170|NCT00678756|Psoriasis vulgaris,
506171|NCT00678756|vitamin D, UVB-phototherapy, ketokonazol,
506172|NCT00678756|Optical Coherence Tomography,
506173|NCT00678756|local PASI, Nizoral
506174|NCT00678743|cholesterol
506175|NCT00678743|dyslipidemia
506176|NCT00678743|omega 3
506177|NCT00678730|THC
506178|NCT00678730|COMT gene polymorphism
506179|NCT00678730|schizophrenia
506180|NCT00678730|cannabis use
506181|NCT00678717|abdominal
506182|NCT00678717|Pelvic
506183|NCT00678717|Pain
506184|NCT00678717|SCS
506185|NCT00678717|Healthy and Chronic Visceral Pain patients
506186|NCT00678717|Chronic Visceral Pain and spinal cord stimulator
506187|NCT00678704|Vardenafil
506188|NCT00678704|PDE5 inhibitor
506189|NCT00678704|Erectile Dysfunction
506190|NCT00678704|Diabetes Mellitus
506191|NCT00678704|Sexual Dysfunction
506192|NCT00678691|fibromyalgia
506193|NCT00678691|fatigue
506194|NCT00678678|Physiotherapy
506195|NCT00678678|Breathing exercises
506196|NCT00678678|Bariatric Surgery
506197|NCT00678678|Laparoscopy
506198|NCT00678665|ecg
506199|NCT00678665|TSA2000
506200|NCT00678665|Heart rate variability
506201|NCT00678665|wavelets
506202|NCT00678652|Meningococcal vaccine
506203|NCT00678652|Neisseria meningitidis
506204|NCT00678639|ACS
506205|NCT00678639|Acute Coronary Syndrome
506206|NCT00678639|Chest pain
506207|NCT00678639|Cardiac MRI
506208|NCT00678639|CMR
506209|NCT00678639|Risk Stratification
506210|NCT00678639|Emergency Department
506211|NCT00678626|Key words: Docetaxel; breast cancer; breast diseases; breast neoplasms; antineoplastic agents; neoplasms;HER-2 negative; Stage IIIB or IV breast cancer.
506212|NCT00678613|probiotics
506213|NCT00678613|cirrhosis
506214|NCT00678613|prophylaxis
506215|NCT00678613|cirrhotic
506216|NCT00678613|patients
506217|NCT00678613|with
506218|NCT00678613|ascites
506219|NCT00678613|using
506220|NCT00678600|Informatics
506221|NCT00678600|Alerts
506222|NCT00678600|Toxicity
506223|NCT00678600|Virologic failure
506224|NCT00678600|Suboptimal follow up
506225|NCT00678587|elective invasive procedure.
506226|NCT00678587|platelet transfusion
506227|NCT00678587|chronic liver disease-related thrombocytopenia
506228|NCT00678587|platelets
506229|NCT00678587|thrombopoietin
506230|NCT00678574|hormones
506231|NCT00678574|menses
506232|NCT00678574|PMS
506233|NCT00678574|PMDD
506234|NCT00678561|chronic plaque psoriasis, topical treatment
506235|NCT00678535|1st line treatment for Gastric Cancer
506236|NCT00678535|Cetuximab
506237|NCT00678535|Capecitabine
506238|NCT00678535|Xeloda
506239|NCT00678535|Cisplatin
506240|NCT00678535|Progression-free survival
506241|NCT00678522|Atorvastatin
506242|NCT00678522|Renal function
506243|NCT00678522|Hemodynamics
506244|NCT00678522|Diabetes type II
506245|NCT00678522|sodium excretion
506246|NCT00678509|HLA-A*2402
506247|NCT00678509|Peptide Vaccine
506248|NCT00678509|TTK
506249|NCT00678496|CBT-software
506250|NCT00678496|Computerised Cognitive Behavioural Therapy
506251|NCT00678496|CCBT
506252|NCT00678496|Cognitive Therapy
506253|NCT00678496|Therapy, Computer-Assisted
506254|NCT00678496|Depression
506255|NCT00678496|Multiple Sclerosis
506256|NCT00678483|Cholesterol
506257|NCT00678483|HDL
506258|NCT00678483|triglycerides
506259|NCT00678483|insulin
506260|NCT00678483|blood glucose
506261|NCT00678457|alcohol dependence
506262|NCT00678457|alcohol abuse
506263|NCT00678457|drinking
506264|NCT00678457|alcohol
506265|NCT00678444|Anxiety
506266|NCT00678444|Satisfaction
506267|NCT00678444|Incomplete bladder emptying
506268|NCT00678444|Clean Intermittent Self-catheterization
506269|NCT00678444|Prolapse/incontinence surgery
506270|NCT00678431|Alzheimer's Disease
506271|NCT00678431|Dementia
506272|NCT00678431|Nutritional Supplement
506273|NCT00678431|Resveratrol
506274|NCT00678418|Addiction
506275|NCT00678418|Opiate dependence
506276|NCT00678418|Inpatient detoxification
506277|NCT00678418|opioid dependence
506278|NCT00678418|heroin dependence
506279|NCT00678405|Breathlessness
506280|NCT00678405|Dyspnoea
506281|NCT00678405|Dyspnea
506282|NCT00678405|Palliative care
506283|NCT00678405|RCT
506284|NCT00678405|Randomised controlled trial
506285|NCT00678405|Lung cancer
506286|NCT00678405|COPD
506287|NCT00678405|Heart failure
506288|NCT00678405|Chronic respiratory disease
506289|NCT00678392|Axitinib in Second Line Treatment of Patients With Metastatic Renal Cell Cancer
506290|NCT00678379|Tonsillectomy
506291|NCT00678379|Postoperative Pain
506292|NCT00678379|Clonidine
506293|NCT00678379|Anesthetics, Local
506294|NCT00678366|laparoscopy
506295|NCT00678366|carbon dioxide
506296|NCT00678366|oxygen
506297|NCT00678366|pain
506298|NCT00678366|inflammation
506299|NCT00678353|Degenerative disc disease
506300|NCT00678340|Randomized Controlled Trial
506301|NCT00678340|Single-Blind Study
506302|NCT00678340|Catheter Ablation
506303|NCT00678327|stage III adult Hodgkin lymphoma
506304|NCT00678327|stage IV adult Hodgkin lymphoma
506305|NCT00678327|adult nodular sclerosis Hodgkin lymphoma
506306|NCT00678327|adult lymphocyte depletion Hodgkin lymphoma
506307|NCT00678327|adult lymphocyte predominant Hodgkin lymphoma
506308|NCT00678327|adult mixed cellularity Hodgkin lymphoma
506309|NCT00678327|stage II adult Hodgkin lymphoma
506310|NCT00678314|Anesthetics
506311|NCT00678314|Local
506312|NCT00678314|ropivacaine
506313|NCT00678314|Surgery
506314|NCT00678314|Hand
506315|NCT00678314|carpel tunnel
506316|NCT00678314|Carpal tunnel surgery
506317|NCT00678301|pneumococcal conjugate vaccine
506318|NCT00678301|Streptococcus pneumoniae
506319|NCT00678288|Renal Cell Cancer
506320|NCT00678288|Interferon
506321|NCT00678275|Hematopoietic Stem Cell Transplantation
506322|NCT00678262|pain
506323|NCT00678262|ECG
506324|NCT00678262|Heart rate variability
506325|NCT00678262|wavelets
506326|NCT00678249|Hemodialysis
506327|NCT00678249|Vascular Prosthesis
506328|NCT00678249|stenoses
506329|NCT00678249|grafts
506330|NCT00678236|RSA
506331|NCT00678236|Gonarthritis
506332|NCT00678236|Bone Cement
506460|NCT00677716|brain cancer
506461|NCT00677716|Cotara
506333|NCT00678210|dose response; PASI 75 response endpoint; subjects with moderate to severe chronic plaque psoriasis
506334|NCT00678197|Quality of care
506335|NCT00678197|Access to care
506336|NCT00678197|Health Outcomes
506337|NCT00678184|Atorvastatin
506338|NCT00678184|healthy
506339|NCT00678184|sodium excretion
506340|NCT00678184|hemodynamics
506341|NCT00678184|tubular function
506342|NCT00678171|Degenerative Disc Disease
506343|NCT00678158|High Does Single Fraction IGRT
506344|NCT00678158|Bone
506345|NCT00678158|Lymph Nodes
506346|NCT00678158|Soft Tissue
506347|NCT00678145|Diabetes
506348|NCT00678145|Hypoglycemia
506349|NCT00678145|HAAF
506350|NCT00678145|Counterregulation
506351|NCT00678132|PARP Inhibitor
506352|NCT00678132|Combination Study
506353|NCT00678132|Chemotherapy
506354|NCT00678132|Advanced Cancer
506355|NCT00678132|Neoplasms
506356|NCT00678132|Cancer
506357|NCT00678132|Solid Tumor
506358|NCT00678119|Kidney cancer
506359|NCT00678119|Renal cancer
506360|NCT00678119|Renal Cell Carcinoma
506361|NCT00678106|dalbavancin adolescent subjects
506362|NCT00678093|Low back pain
506363|NCT00678093|Manual therapy
506364|NCT00678093|Mulligan snag
506365|NCT00678080|Type 2 diabetes mellitus
506366|NCT00678080|Pregnancy
506367|NCT00678080|Metformin
506368|NCT00678080|Insulin
506369|NCT00678080|Pregnant women
506370|NCT00678067|Hypercholesterolemic children
506371|NCT00678067|Docosahexaenoic acid
506372|NCT00678067|Eicosapentaenoic acid
506373|NCT00678067|Blood lipid profile
506374|NCT00678041|urinary catheterization
506375|NCT00678041|urinary tract infection
506376|NCT00678041|urinary incontinence
506377|NCT00678041|pelvic floor prolapse
506378|NCT00678041|antibiotics
506379|NCT00678028|MBL, UTI
506380|NCT00678015|NDGA
506381|NCT00678015|Prostate Cancer
506382|NCT00678002|solid organ transplant
506383|NCT00677989|perforated appendicitis
506384|NCT00677989|laparoscopic appendectomy
506385|NCT00677989|open appendectomy
506386|NCT00677989|cytokines
506387|NCT00677989|free radicals
506388|NCT00677989|oxidized proteins
506389|NCT00677976|fMRI
506390|NCT00677976|IBS
506391|NCT00677976|Brain Activation
506392|NCT00677963|carotid
506393|NCT00677963|atherosclerosis
506394|NCT00677963|arteriosclerosis
506395|NCT00677963|plaque
506396|NCT00677963|neovascularization
506397|NCT00677963|carotid endarterectomy
506398|NCT00677950|Degenerative Disc Disease
506399|NCT00677937|diabetes mellitus
506400|NCT00677937|prevention
506401|NCT00677937|education
506402|NCT00677937|impaired glucose tolerance
506403|NCT00677937|multi-ethnic
506404|NCT00677924|Colorectal Neoplasms
506405|NCT00677924|Colorectal Tumors
506406|NCT00677924|Colorectal Carcinoma
506407|NCT00677911|Chronic pain
506408|NCT00677911|Interleukin-6
506409|NCT00677911|pain catastrophizing
506410|NCT00677911|cytokines
506411|NCT00677911|cortisol
506412|NCT00677898|Patient-Centered Care
506413|NCT00677898|Adverse effects
506414|NCT00677898|Antipsychotics
506415|NCT00677885|Alzheimer Disease
506416|NCT00677885|Parkinson's Disease
506417|NCT00677885|Frontotemporal Dementia
506418|NCT00677885|PET Imaging
506419|NCT00677885|AD
506420|NCT00677885|Parkinson Disease
506421|NCT00677885|PD
506422|NCT00677872|Moderate to severe COPD and coincident pulmonary hypertension
506423|NCT00677859|Leukemia
506424|NCT00677859|Graft vs. Host Disease
506425|NCT00677859|Hematopoietic Stem Cell Transplant
506426|NCT00677859|Bone Marrow Transplant
506427|NCT00677859|Myelodysplasia
506428|NCT00677846|contrast agent ultrasound, vein thrombosis, vascularization
506429|NCT00677833|P. Falciparum Malaria
506430|NCT00677833|drug treatment
506431|NCT00677833|clinical trial
506432|NCT00677820|Influenza
506433|NCT00677820|FluMist
506434|NCT00677820|vaccine
506435|NCT00677820|prevention
506436|NCT00677820|trivalent
506437|NCT00677807|COPD
506438|NCT00677807|adults
506439|NCT00677807|β2-agonist
506440|NCT00677807|indacaterol
506441|NCT00677794|Video Capsule Endoscopy
506442|NCT00677794|Small Bowel
506443|NCT00677768|Biomarkers
506444|NCT00677768|Plasma
506445|NCT00677768|Cerebrospinal Fluid
506446|NCT00677768|DNA
506447|NCT00677768|Serum
506448|NCT00677755|Medical abortion
506449|NCT00677755|emergency contraception
506450|NCT00677755|mifepristone
506451|NCT00677742|oral contraception
506452|NCT00677742|hormonal contraception
506453|NCT00677742|contraceptive behavior
506454|NCT00677742|patient compliance
506455|NCT00677729|bronchiolitis
506456|NCT00677729|hypertonic saline
506457|NCT00677729|infants
506458|NCT00677716|glioblastoma multiforme
506459|NCT00677716|GBM
506462|NCT00677716|radioactive isotope
506463|NCT00677716|monoclonal antibody
506464|NCT00677716|Glioblastoma multiforme at first relapse
506465|NCT00677703|birth control pills
506466|NCT00677703|contraception
506467|NCT00677703|continuation
506468|NCT00677703|text messaging
506469|NCT00677703|contraceptive continuation
506470|NCT00677703|contraceptive knowledge
506471|NCT00677690|COPD
506472|NCT00677677|Lung transplant
506473|NCT00677677|Liver transplant
506474|NCT00677677|Kidney transplant
506475|NCT00677677|Pancreas transplant
506476|NCT00677677|HPV
506477|NCT00677677|Human Papillomavirus Quadrivalent Vaccine
506478|NCT00677664|diabetic retinopathy
506479|NCT00677664|panretinal photocoagulation
506480|NCT00677664|copaxone
506481|NCT00677664|nerve fiber layer thickness
506482|NCT00677664|retinal function
506483|NCT00677651|adipose
506484|NCT00677651|lean
506485|NCT00677651|obese
506486|NCT00677651|overweight
506487|NCT00677651|healthy
506488|NCT00677625|Liver
506489|NCT00677625|Transplant
506490|NCT00677612|HLA-A*0201
506491|NCT00677612|Peptide Vaccine
506492|NCT00677612|VEGFR1
506493|NCT00677612|VEGFR2
506494|NCT00677599|Cardiovascular disease
506495|NCT00677599|type 2 diabetes
506496|NCT00677599|flavonoids
506497|NCT00677599|cocoa
506498|NCT00677599|soy
506499|NCT00677599|epicatechin
506500|NCT00677599|postmenopausal
506501|NCT00677599|carotid intima media thickness
506502|NCT00677599|plaque volume
506503|NCT00677586|colorectal neoplasms
506504|NCT00677586|liver metastasis
506505|NCT00677586|surgery
506506|NCT00677573|ART
506507|NCT00677573|poor responder
506508|NCT00677573|GnRH antagonist
506509|NCT00677573|Gonadotropins
506510|NCT00677560|resistance
506511|NCT00677560|reactance
506512|NCT00677560|inflammation
506513|NCT00677547|Kidney
506514|NCT00677547|Influenza vaccine
506515|NCT00677547|CMI
506516|NCT00677534|Endstage renal disease
506517|NCT00677534|Vitamin D
506518|NCT00677534|Monocyte function
506519|NCT00677508|Constipation
506520|NCT00677508|Fecal incontinence
506521|NCT00677508|Quality of life
506522|NCT00677508|Health related quality of life
506523|NCT00677495|Gluten-free diet
506524|NCT00677495|Celiac Disease
506525|NCT00677495|Genetic predisposition
506526|NCT00677495|Phage display library
506527|NCT00677495|Autoimmune diseases
506528|NCT00677482|liver transplant
506529|NCT00677482|lung transplant
506530|NCT00677482|kidney transplant
506531|NCT00677482|heart transplant
506532|NCT00677482|CMV microRNA
506533|NCT00677469|Hyperthyroidism
506534|NCT00677469|Cholestyramine
506535|NCT00677456|Gastric Cancer
506536|NCT00677456|total gastrectomy
506537|NCT00677456|reconstruction
506538|NCT00677456|life quality
506539|NCT00677443|metastatic colorectal cancer
506540|NCT00677443|S-1
506541|NCT00677443|Capecitabine
506542|NCT00677443|Oxaliplatin
506543|NCT00677443|non-inferiority study
506544|NCT00677430|Breast Cancer
506545|NCT00677430|Breast Reconstruction
506546|NCT00677430|Digital Imaging
506547|NCT00677430|Questionnaire
506548|NCT00677430|Survey
506549|NCT00677404|Peripheral vascular diseases
506550|NCT00677404|chronic lower limb ischemia
506551|NCT00677391|Obesity
506552|NCT00677378|TRPV1
506553|NCT00677378|Nerve growth factor
506554|NCT00677378|Capsaicin
506555|NCT00677378|TrkA
506556|NCT00677378|Retrosternal pain
506557|NCT00677378|Epigastric pain
506558|NCT00677378|Esophagitis
506559|NCT00677378|Gastrointestinal symptoms
506560|NCT00677352|Panic Disorder
506561|NCT00677339|Tuberculosis
506562|NCT00677339|Adjunctive therapy
506563|NCT00677339|L-arginine
506564|NCT00677339|Nitric oxide
506565|NCT00677339|Vitamin D
506566|NCT00677326|HLA-A*0201
506567|NCT00677326|Peptide Vaccine
506568|NCT00677326|VEGFR1
506569|NCT00677326|VEGFR2
506570|NCT00677313|metreleptin
506571|NCT00677313|leptin
506572|NCT00677313|Amylin
506573|NCT00677313|diabetes mellitus
506574|NCT00677313|hypertriglyceridemia
506575|NCT00677313|lipodystrophy
506576|NCT00677300|HIV
506577|NCT00677300|Treatment Naive
506578|NCT00677287|HLA-A*2402
506579|NCT00677287|Peptide Vaccine
506580|NCT00677287|RNF43
506581|NCT00677287|TOMM34
506582|NCT00677287|VEGFR1
506583|NCT00677287|VEGFR2
506584|NCT00677274|Epidural analgesia
506585|NCT00677274|Patient-controlled analgesia
506586|NCT00677261|Knee
506587|NCT00677261|Arthroplasty
506588|NCT00677261|Sciatic
506589|NCT00677261|Nerve
506590|NCT00677261|Block
506591|NCT00677261|Regional
506592|NCT00677261|Anesthesia
506593|NCT00677261|Infiltration
506594|NCT00677261|Local Anesthetic
506595|NCT00677261|Analgesia
506596|NCT00677248|Eprotirome
506597|NCT00677248|KB2115
506598|NCT00677248|dyslipidemia
506599|NCT00677248|hypercholesterolemia
506600|NCT00677248|hypertriglyceridemia
506601|NCT00677235|Hemodialysis
506602|NCT00677235|Vascular Prosthesis
506603|NCT00677235|Stenosis
506604|NCT00677235|ESRD
506605|NCT00677222|Acute Myocardial Infarction, Heart Attack
506606|NCT00677209|house dust mite
506607|NCT00677209|asthma
506608|NCT00677209|autovaccine
506609|NCT00677209|allergy
506610|NCT00677196|PNL
506611|NCT00677196|Lithoclast
506612|NCT00677196|Stonebreaker
506613|NCT00677196|efficiency stone fragmentation
506614|NCT00677183|NASH
506615|NCT00677183|Biomarker
506616|NCT00677157|Fatigue
506617|NCT00677157|Fibromyalgia
506618|NCT00677157|Pain
506619|NCT00677157|Complex Regional Pain Syndrome
506620|NCT00677157|Reflex Sympathetic Dystrophy
506621|NCT00677157|CPRS
506622|NCT00677157|RSD
506623|NCT00677144|Colorectal Neoplasm
506624|NCT00677144|S-1
506625|NCT00677144|Capecitabine
506626|NCT00677144|Oxaliplatin
506627|NCT00677131|pediatrics
506628|NCT00677131|antibiotics
506629|NCT00677131|patient education
506630|NCT00677118|Nasopharyngeal carcinoma
506631|NCT00677118|Concurrent chemoradiotherapy
506632|NCT00677118|Adjuvant chemotherapy
506633|NCT00677118|Clinical trial
506634|NCT00677105|Lymphoma
506635|NCT00677105|Neoplasms
506636|NCT00677105|Solid Tumors
506637|NCT00677105|Advanced Cancer
506638|NCT00677092|Treatment
506639|NCT00677092|Chronic kidney disease
506640|NCT00677092|Fibrosing disorders
506641|NCT00677092|Imatinib mesylate
506642|NCT00677079|BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
506643|NCT00677079|BRCA-1
506644|NCT00677079|BRCA-2
506645|NCT00677066|bronchiolitis
506646|NCT00677066|oxygen
506647|NCT00677066|children
506648|NCT00677053|Unstable Angina
506649|NCT00677053|Myocardial Infarction
506650|NCT00677053|Thrombolysis
506651|NCT00677053|Anticoagulant
506652|NCT00677053|Acute Coronary Syndrome
506653|NCT00677027|Beta-glucan
506654|NCT00677027|immune system
506655|NCT00677027|Healthy subjects
506656|NCT00677014|Heart Failure
506657|NCT00677014|HF
506658|NCT00677014|Cardiac Resynchronization Therapy
506659|NCT00677014|CRT
506660|NCT00677014|Optimization
506661|NCT00677014|SmartDelay
506662|NCT00677014|Echocardiography
506663|NCT00677014|AV Delay
506664|NCT00677001|Solid tumors
506665|NCT00677001|solid malignancies
506666|NCT00677001|neoplasms
506667|NCT00677001|refractory solid tumors
506668|NCT00677001|advanced solid tumors
506669|NCT00676988|Luminal Crohn's Disease
506670|NCT00676988|Infliximab
506671|NCT00676975|Irritable Bowel disease
506672|NCT00676975|Traditional Chinese Medicine
506673|NCT00676962|Implementation
506674|NCT00676962|facilitation
506675|NCT00676962|psychotherapy
506676|NCT00676962|training
506677|NCT00676949|epitope peptide
506678|NCT00676949|cyclophosphamide
506679|NCT00676949|interleukin-2
506680|NCT00676936|Cancer
506681|NCT00676936|pain
506682|NCT00676936|corticosteroids
506683|NCT00676936|palliative
506684|NCT00676936|supportive care
506685|NCT00676936|Cancer patients with pain
506686|NCT00676910|Advanced Cancer
506687|NCT00676910|Malignancies
506688|NCT00676910|Neoplasms
506689|NCT00676910|Incurable Solid Cancers
506690|NCT00676897|statin, sepsis, septic shock, simvastatin
506691|NCT00676884|atopic eczema
506692|NCT00676884|atopic dermatitis
506693|NCT00676884|allergy
506694|NCT00676858|Embolism
506695|NCT00676858|Argon
506696|NCT00676845|Arterial stiffness
506697|NCT00676845|Vascular protection
506698|NCT00676832|colitis
506699|NCT00676832|ulcerative
506700|NCT00676832|moderate
506701|NCT00676832|severe
506702|NCT00676806|Umbilical cord blood transplantation
506703|NCT00676806|full ablation conditioning
506704|NCT00676806|reduced intensity conditioning
506705|NCT00676793|breast cancer
506706|NCT00676793|EGCG
506707|NCT00676793|Polyphenon E
506708|NCT00676793|c-Met
506709|NCT00676793|VEGF
506710|NCT00676793|HGF
506711|NCT00676780|EGCG
506712|NCT00676780|polyphenols
506713|NCT00676780|biomarkers
506714|NCT00676780|prostate specific antigen
506715|NCT00676767|Aging
506716|NCT00676767|Diabetes
506717|NCT00676767|Diet
506718|NCT00676767|Fiber
506719|NCT00676754|Multidrug-Resistant Tuberculosis, tuberculosis, Peru
506720|NCT00676728|Advanced or Refractory Leukemia
506721|NCT00676728|Myelodysplastic Syndromes
506722|NCT00676728|JNJ 26481585
506723|NCT00676728|Histone-Deacetylase Inhibitor
506724|NCT00676728|Advanced Leukemia
506725|NCT00676728|Refractory Leukemia
506726|NCT00676702|Pancrelipase
506727|NCT00676702|PANCREASE MT
506728|NCT00676702|Cross-Over Studies
506729|NCT00676702|Duodenum
506730|NCT00676702|Intestine, Small
506731|NCT00676702|Lipase
506732|NCT00676702|Amylases
506733|NCT00676702|Peptide Hydrolases
506734|NCT00676702|Intubation
506735|NCT00676702|Safety
506736|NCT00676702|Capsules
506737|NCT00676689|Pulmonic
506738|NCT00676689|Regurgitation
506739|NCT00676689|Pulmonary Valve Conduit
506740|NCT00676689|Stenosis
506741|NCT00676689|Congenital Heart Defect
506742|NCT00676676|Depression
506743|NCT00676676|Major Depressive Disorder
506744|NCT00676663|Breast Neoplasms
506745|NCT00676663|Breast Tumor
506746|NCT00676663|Mammary Neoplasms
506747|NCT00676650|Docetaxel-refractory mCRPC
506748|NCT00676650|Second-line treatment with sunitinib and prednisone
506749|NCT00676637|Adherence
506750|NCT00676637|Compliance
506751|NCT00676637|Glaucoma
506752|NCT00676637|Ocular Hypertension
506753|NCT00676624|uveitis
506754|NCT00676624|vitrectomy
506755|NCT00676624|infection
506756|NCT00676624|severe
506757|NCT00676611|Acetabular Fractures
506758|NCT00676598|therapeutic hypothermia
506759|NCT00676585|Cardiac Arrest, Shock, Steroids
506760|NCT00676572|severe asthma
506761|NCT00676572|corticosteroid insensitivity
506762|NCT00676559|Diabetic
506763|NCT00676559|Macular
506764|NCT00676559|Edema
506765|NCT00676559|DME
506766|NCT00676559|Clinically Significant Macular Edema (CSME)
506767|NCT00676533|Cipro
506768|NCT00676533|Urinary Tract Infection
506769|NCT00676520|Angioplasty
506770|NCT00676520|Coronary Restenosis
506771|NCT00676520|Coronary Artery Disease
506772|NCT00676520|Coronary Artery Restenosis
506773|NCT00676520|Coronary Artery Stenosis
506774|NCT00676520|Total Artery Occlusion
506775|NCT00676520|Stents
506776|NCT00676520|Stent Thrombosis
506777|NCT00676520|Total Coronary Occlusion
506778|NCT00676520|Vascular Disease
506779|NCT00676520|Myocardial Ischemia
506780|NCT00676507|Gene therapy
506781|NCT00676507|Flow cytometry
506782|NCT00676507|Immunoenzyme technique
506783|NCT00676507|Laboratory biomarker analysis
506784|NCT00676507|Quality-of-life-assessment
506785|NCT00676507|Tumor cell-derivative vaccine therapy
506786|NCT00676481|Patient Education
506787|NCT00676481|Emergency Medicine
506788|NCT00676481|HIV Prevention
506789|NCT00676481|HIV Seronegativity
506790|NCT00676468|Asthma
506791|NCT00676468|Inflammation
506792|NCT00676468|Airway
506793|NCT00676468|Fish Oil
506794|NCT00676468|Singulair
506795|NCT00676455|CT Software
506796|NCT00676455|MeVis™
506797|NCT00676455|Metastatic pulmonary and hepatic lesion growth
506798|NCT00676416|General anesthesia
506799|NCT00676416|Propofol
506800|NCT00676416|Immunity
506801|NCT00676416|Alveolar Macrophages
506802|NCT00676403|pregabalin, RLS, efficacy, safety
506803|NCT00676390|Heart Failure
506804|NCT00676377|Neostigmine, Post Operative, Ileus
506805|NCT00676364|pediatric patients
506806|NCT00676364|pain
506807|NCT00676364|anxiety
506808|NCT00676364|topical anesthetic
506809|NCT00676364|randomized control trial
506810|NCT00676338|Amylin
506811|NCT00676338|Lilly
506812|NCT00676338|exenatide once weekly
506813|NCT00676338|Byetta
506814|NCT00676338|Januvia
506815|NCT00676338|sitagliptin
506816|NCT00676338|thiazolidinedione
506817|NCT00676325|anterior vaginal prolapse
506818|NCT00676325|traditional treatment
506819|NCT00676325|mesh, graft
506820|NCT00676325|NAZCA TC™ POP REPAIR SYSTEM
506821|NCT00676325|colporrhaphy
506822|NCT00676312|Osteoporosis
506823|NCT00676312|parathyroid hormone
506824|NCT00676312|pharmacodynamic
506825|NCT00676312|pharmacokinetic
506826|NCT00676299|Advanced Solid Cancers
506827|NCT00676299|Refractory Solid Cancers
506828|NCT00676299|Protein Kinase Inhibitors
506829|NCT00676299|Phase 1 Study
506830|NCT00676299|Oral Chemotherapy
506831|NCT00676286|Prostate cancer active surveillance
506832|NCT00676286|3 Tesla MR biological imaging in prostate cancer
506833|NCT00676286|tumor gene re-arrangements in prostate cancer
506834|NCT00676260|Glucose Metabolism Disorder
506835|NCT00676260|Dysmetabolic Syndrome
506836|NCT00676260|Type II Diabetes
506837|NCT00676260|Diabetes Mellitus
506838|NCT00676260|Lipoatrophic
506839|NCT00676260|Dyslipidemia
506840|NCT00676260|Drug Therapy
506841|NCT00676247|Ultrasonography
506842|NCT00676247|Doppler
506843|NCT00676247|Hemodynamics
506844|NCT00676247|Neurobehavioral development
506845|NCT00676234|erythropoietin
506846|NCT00676221|Renal transplant recipient
506847|NCT00676221|Immunosuppression
506848|NCT00676221|Gastro-intestinal symptoms
506849|NCT00676221|Quality of life
506850|NCT00676221|Cellcept
506851|NCT00676221|Myfortic
506852|NCT00676221|Kidney transplant patients.
506853|NCT00676208|Shared Medical Appointments
506854|NCT00676208|Diabetes
506855|NCT00676208|Education
506856|NCT00676169|Pseudomonas aeruginosa
506857|NCT00676169|EPIC
506858|NCT00676156|multiple sclerosis
506859|NCT00676156|lipoic acid
506860|NCT00676156|LA
506861|NCT00676156|pharmacokinetics
506862|NCT00676156|immunological effects
506863|NCT00676143|antibody
506864|NCT00676143|immunotherapy
506865|NCT00676130|Cellulitis
506866|NCT00676130|Bactrim
506867|NCT00676130|Trimethoprim Sulfamethoxazole
506868|NCT00676130|MRSA
506869|NCT00676130|Methicillin-resistant Staphylococcus aureus
506870|NCT00676117|male
506871|NCT00676117|Japan
506872|NCT00676117|Japanese
506873|NCT00676117|Healthy volunteers
506874|NCT00676104|Traumatic Brain Injury
506875|NCT00676104|Trauma
506876|NCT00676104|Hypothermia
506877|NCT00676091|Pneumococcal conjugate vaccine
506878|NCT00676065|Contraception
506879|NCT00676065|Thromboembolism
506880|NCT00676065|Breast Cancer
506881|NCT00676052|COPD
506882|NCT00676052|Multicenter
506883|NCT00676052|GSK233705B
506884|NCT00676052|double-blind
506885|NCT00676052|Chronic Obstructive Pulmonary Disease (COPD)
506886|NCT00676052|randomized
506887|NCT00676039|Therapeutic Equivalency
506888|NCT00676039|Human Experimentation
506889|NCT00676039|Bioequivalence
506890|NCT00676039|Brand name
506891|NCT00676039|Generic
506892|NCT00676039|Antidepressant
506893|NCT00676039|Healthy volunteers
506894|NCT00676026|menses
506895|NCT00676026|women
506896|NCT00676026|healthy controls
506897|NCT00676026|Healthy females with regular menstrual cycles
506898|NCT00676013|Burns
506899|NCT00676013|Skin grafting
506900|NCT00676013|AlloDerm
506901|NCT00676013|Integra
506902|NCT00676013|Homograft
506903|NCT00676013|Autograft
506904|NCT00676013|Burn Scar
506905|NCT00675987|Impaired Fasting Glucose FPG >100-<126 mg/dL
506906|NCT00675974|Burn
506907|NCT00675974|Scar
506908|NCT00675974|Pressure garments
506909|NCT00675974|Wound healing
506910|NCT00675974|Burn Injury
506911|NCT00675961|Tomsk
506912|NCT00675961|TB-Alcohol
506913|NCT00675961|Alcohol and co-occurring disease
506914|NCT00675961|Brief counseling intervention
506915|NCT00675961|Naltrexone
506916|NCT00675948|Palliative Care
506917|NCT00675948|Pain
506918|NCT00675948|Cancer
506919|NCT00675935|Patient falls
506920|NCT00675935|fall risk
506921|NCT00675935|fall prevention
506922|NCT00675922|Burn
506923|NCT00675922|Wounds
506924|NCT00675922|Wound infection
506925|NCT00675922|Topical antimicrobials
506926|NCT00675922|Cerium
506927|NCT00675922|Dakins
506928|NCT00675922|Sulfamylon Soaks
506929|NCT00675922|Silver Nitrate
506930|NCT00675909|Sedation
506931|NCT00675909|Anxiety
506932|NCT00675909|Minor procedures
506933|NCT00675909|Emergency Department
506934|NCT00675896|major depression with comorbid fibromyalgia.
506935|NCT00675870|Acute Promyelocytic Leukemia
506936|NCT00675870|Cancer
506937|NCT00675870|Leukemia
506938|NCT00675870|APL
506939|NCT00675870|ATRA
506940|NCT00675870|Tretinoid
506941|NCT00675870|Vesanoid
506942|NCT00675870|Retinoic Acid Receptor Alpha
506943|NCT00675870|All Trans Retinoic Acid
506944|NCT00675870|Arsenic Trioxide
506945|NCT00675870|Trisenox
506946|NCT00675870|Retinoid
506947|NCT00675870|Relapsed or Refractory Acute Promyelocytic Leukemia
506948|NCT00675857|Type II diabetes
506949|NCT00675857|Metabolic syndrome
506950|NCT00675844|Extension study
506951|NCT00675844|HIV-1 infection
506952|NCT00675844|Treatment Naive
506953|NCT00675831|CD25+
506954|NCT00675831|Tregs
506955|NCT00675831|DLI
506956|NCT00675831|Donor lymphocyte infusion
506957|NCT00675818|acute kidney injury
506958|NCT00675818|renal replacement therapy
506959|NCT00675818|critical care unit
506960|NCT00675818|hemodialysis
506961|NCT00675818|hemofiltration
506962|NCT00675805|intravenous immunoglobulin
506963|NCT00675805|IVIG
506964|NCT00675805|adverse reactions
506965|NCT00675779|endometriosis
506966|NCT00675779|atorvastatin
506967|NCT00675779|oral
506968|NCT00675779|contraception
506969|NCT00675779|pain
506970|NCT00675779|relief
506971|NCT00675779|pelvic pain in women with endometriosis
506972|NCT00675753|Genes
506973|NCT00675753|Ethnology
506974|NCT00675753|Cytokines
506975|NCT00675753|prematurity
506976|NCT00675727|Melanoma
506977|NCT00675727|Mycobacterium w
506978|NCT00675714|anabolic agents
506979|NCT00675714|exercise
506980|NCT00675701|To determine whether lixivaptan administration at supratherapeutic or therapeutic doses results in the prolongation of the QTc interval.
506981|NCT00675688|Menopause
506982|NCT00675675|Tourette Syndrome
506983|NCT00675675|Chronic Tic Disorder
506984|NCT00675675|Tics
506985|NCT00675675|Behavior Therapy
506986|NCT00675675|Habit Reversal Training
506987|NCT00675675|Child
506988|NCT00675675|Adolescent
506989|NCT00675675|Neuroimaging
506990|NCT00675662|Obesity
506991|NCT00675662|overweight
506992|NCT00675662|BMI
506993|NCT00675662|ifestyle
506994|NCT00675662|diet
506995|NCT00675662|nutrition
506996|NCT00675662|physical activity
506997|NCT00675662|pre-school
506998|NCT00675662|toddlers
506999|NCT00675662|children
507000|NCT00675662|Prevention of overweight and obesity in pre-school children
507001|NCT00675649|Injections
507002|NCT00675649|Severe, persistent asthma
507003|NCT00675636|colon cancer
507004|NCT00675636|hereditary non-polyposis colon cancer
507005|NCT00675636|rectal cancer
507006|NCT00675636|familial adenomatous polyposis
507007|NCT00675623|Alzheimer's disease, clinical trial, memory loss, mitochondria,
507008|NCT00675623|investigational drug, neurodegenerative disease, dementia
507009|NCT00675610|communication
507010|NCT00675610|HIV/AIDS
507011|NCT00675610|Treatment Experienced
507012|NCT00675597|Bevacizumab (Avastin)
507013|NCT00675597|Taxotere (Docetaxel)
507014|NCT00675597|Vinorelbine Tartrate (Navelbine)
507015|NCT00675597|07-178
507016|NCT00675558|Obesity
507017|NCT00675558|morbid obesity
507018|NCT00675558|bariatric surgery
507019|NCT00675532|Opioids, vivitrol, naltrexone, primary care
507020|NCT00675519|problem drinkers
507021|NCT00675506|Growth Hormone Releasing Hormone
507022|NCT00675506|Growth Hormone Pulse
507023|NCT00675506|Visceral Adipose Tissue
507024|NCT00675506|Carotid Intima-Media Thickness
507025|NCT00675480|myocardial infarction, thrombectomy, salvage index
507026|NCT00675467|Pediatric Cancer
507027|NCT00675467|Focus Group
507028|NCT00675467|Pediatric cancer patients
507029|NCT00675467|Parents of Pediatric cancer patients
507030|NCT00675467|Pediatric Palliative Care Program
507031|NCT00675454|COPD
507032|NCT00675454|Lung Volume Reduction Surgery
507033|NCT00675454|Lung Transplant
507034|NCT00675454|Quality of Life
507035|NCT00675441|Chronic Graft-versus-Host Disease
507036|NCT00675441|cGVHD
507037|NCT00675441|GVHD
507038|NCT00675441|Lenalidomide
507039|NCT00675441|Revlimid
507040|NCT00675441|CC-5013
507041|NCT00675441|Stem Cell Transplant
507042|NCT00675441|Allogeneic hematopoietic stem cell transplantation
507043|NCT00675441|Allogeneic HSCT
507044|NCT00675441|HSCT
507045|NCT00675441|Post-Transplant Prophylactic Immunosuppressive Therapy
507046|NCT00675441|Steroids
507047|NCT00675441|Standard-of-care steroid treatment
507048|NCT00675441|Corticosteroids
507049|NCT00675441|Prednisone
507050|NCT00675441|Medrol
507051|NCT00675428|Relapsed or refractory Multiple Myeloma
507052|NCT00675415|Hypoxemia
507053|NCT00675415|Capnography
507054|NCT00675415|Apnea
507055|NCT00675415|Sedation
507056|NCT00675415|ERCP
507057|NCT00675415|EUS
507058|NCT00675389|HIV
507059|NCT00675389|AIDS
507060|NCT00675389|Community Health Workers
507061|NCT00675389|Mobile Phones
507062|NCT00675389|Adherence
507063|NCT00675389|Antiretroviral Therapy
507064|NCT00675376|COPD
507065|NCT00675376|Lung Transplant
507066|NCT00675376|Quality of Life
507067|NCT00675376|End Stage Lung Disease
507068|NCT00675363|ICU
507069|NCT00675363|Sedation strategies
507070|NCT00675363|Daily sedative interruption
507071|NCT00675363|Sedation protocols
507072|NCT00675363|Mechanical Ventilation
507073|NCT00675363|Sedation
507074|NCT00675350|Omacetaxine
507075|NCT00675350|Homoharringtonine
507076|NCT00675350|HHT
507077|NCT00675350|Solid and hematologic malignant tumors
507078|NCT00675337|iron stores
507079|NCT00675337|anemia
507080|NCT00675337|iron deficiency
507081|NCT00675337|infancy
507082|NCT00675337|placental transfusion
507083|NCT00675337|iron deficiency in infancy
507084|NCT00675337|anemia in infancy
507085|NCT00675337|placement of neonate
507086|NCT00675324|Colonoscopy
507087|NCT00675324|Bowel preparation
507088|NCT00675324|Salt and electrolyte balance
507089|NCT00675324|Patients undergoing colonoscopy
507090|NCT00675324|Complication with traditional bowel preparation
507091|NCT00675324|Bowel purity degree without traditional bowel preparation
507092|NCT00675311|Remote monitoring
507093|NCT00675311|Type 1 Diabetes
507094|NCT00675311|Type 2 diabetes
507095|NCT00675298|Prostatitis
507096|NCT00675298|Cystitis, Interstitial
507097|NCT00675298|Urinary Bladder, Overactive
507098|NCT00675298|Chronic pelvic pain syndrome
507099|NCT00675298|Painful bladder syndrome
507100|NCT00675298|Urgency
507101|NCT00675298|Frequency
507102|NCT00675285|airway inflammation
507103|NCT00675285|childhood asthma
507104|NCT00675285|fractional exhaled nitric oxide
507105|NCT00675285|leukotriene receptor antagonists
507106|NCT00675285|lung function
507107|NCT00675272|brain death
507108|NCT00675272|subarachnoid hemorrhage
507109|NCT00675272|traumatic brain injury
507110|NCT00675272|brain injury
507111|NCT00675272|intracerebral hemorrhage
507112|NCT00675272|organ donation
507113|NCT00675259|stage II breast cancer
507114|NCT00675259|stage IIIA breast cancer
507115|NCT00675259|stage IIIB breast cancer
507116|NCT00675259|stage IIIC breast cancer
507117|NCT00675246|corticoid therapy
507118|NCT00675246|fetal lung maturation
507119|NCT00675246|late preterm
507120|NCT00675246|respiratory distress syndrome
507121|NCT00675246|neonatal death
507122|NCT00675233|recurrent squamous cell carcinoma of the larynx
507123|NCT00675233|stage I squamous cell carcinoma of the larynx
507124|NCT00675233|stage III squamous cell carcinoma of the larynx
507125|NCT00675233|stage IV squamous cell carcinoma of the larynx
507126|NCT00675233|stage 0 laryngeal cancer
507127|NCT00675207|glaucoma
507128|NCT00675207|ocular hypertension
507129|NCT00675207|adjunctive treatment
507130|NCT00675207|prostaglandin
507131|NCT00675207|prostaglandin analog
507132|NCT00675207|brimonidine
507133|NCT00675207|dorzolamide
507134|NCT00675207|brinzolamide
507135|NCT00675207|alpha agonist
507136|NCT00675207|carbonic anhydrase inhibitor
507137|NCT00675207|intraocular pressure
507138|NCT00675194|cisplatin
507139|NCT00675194|capecitabine
507140|NCT00675194|gastric
507141|NCT00675194|irinotecan
507142|NCT00675194|metastatic
507143|NCT00675194|chemotherapy
507144|NCT00675181|melatonin
507145|NCT00675181|skin blood flow
507146|NCT00675181|choroidal blood flow
507147|NCT00675181|vasospastic subjects
507148|NCT00675181|normal subjects
507149|NCT00675168|Lung Cancer
507150|NCT00675168|PET/CT
507151|NCT00675168|Diagnosis
507152|NCT00675155|Apoplexy
507153|NCT00675155|Cerebral Stroke
507154|NCT00675155|Cerebrovascular Accident
507155|NCT00675155|Cerebrovascular Accident, Acute
507156|NCT00675155|Cerebrovascular Apoplexy
507157|NCT00675155|Cerebrovascular Stroke
507158|NCT00675142|Infertility
507159|NCT00675142|Intra-uterine insemination
507160|NCT00675142|ovarian stimulation
507161|NCT00675116|safety,
507162|NCT00675116|healthy volunteers,
507163|NCT00675116|GW823296,
507164|NCT00675116|pharmacokinetics
507165|NCT00675103|Gout
507166|NCT00675103|Gouty Arthritis
507167|NCT00675103|Anti-Gout preparations
507168|NCT00675090|Alzheimers Disease
507169|NCT00675077|Akinetic-Rigid Variant of Huntington Disease
507170|NCT00675077|Chorea, Chronic Progressive Hereditary (Huntington)
507171|NCT00675077|Chronic Progressive Hereditary Chorea (Huntington)
507172|NCT00675077|Huntington Chorea
507173|NCT00675077|Huntington Chronic Progressive Hereditary Chorea
507174|NCT00675077|Huntington Disease, Akinetic-Rigid Variant
507175|NCT00675077|Huntington Disease, Juvenile
507176|NCT00675077|Huntington Disease, Juvenile-Onset
507177|NCT00675064|pharmacokinetics,
507178|NCT00675064|safety
507179|NCT00675064|single ascending dose,
507180|NCT00675064|Healthy volunteers,
507181|NCT00675051|To determine if there is a trans-pulmonary gradient in the levels of EMPs in patients with PH
507182|NCT00675051|To determine if the EMPs measured at the pulmonary capillary wedge position correlates even more strongly with the severity of PH than the circulating levels
507183|NCT00675051|To determine if PH therapy with ET-1 receptor blocker will modify EMPs levels
507184|NCT00675012|NGR-hTNF
507185|NCT00675012|Capecitabine
507186|NCT00675012|Oxaliplatin
507187|NCT00675012|Colon cancer
507188|NCT00674999|Burn
507189|NCT00674999|Partial thickness burn
507190|NCT00674960|Brain Atrophy, Circumscribed Lobar
507191|NCT00674960|Circumscribed Lobar Atrophy of the Brain
507192|NCT00674960|Lobar Atrophy (Brain)
507193|NCT00674960|Pick Disease
507194|NCT00674960|Pick's Disease
507195|NCT00674960|Picks Disease of Brain
507196|NCT00674947|Relapsed
507197|NCT00674947|Refractory
507198|NCT00674934|MS (Multiple Sclerosis)
507199|NCT00674934|Multiple Sclerosis, Acute Fulminating
507200|NCT00674934|Sclerosis, Disseminated
507201|NCT00674921|Opportunistic Infections
507202|NCT00674921|AIDS
507203|NCT00674921|HIV
507204|NCT00674921|Treatment Experienced
507205|NCT00674908|Vaccine
507206|NCT00674908|Prevention
507207|NCT00674908|Diphtheria
507208|NCT00674908|Tetanus
507209|NCT00674908|Pertussis
507210|NCT00674908|Hepatitis B
507211|NCT00674908|Haemophilus influenzae type b
507212|NCT00674908|Vaccine interchangeability
507213|NCT00674908|Single vs mixed sequence
507214|NCT00674908|Healthy infants
507215|NCT00674895|Idiopathic Parkinson's Disease
507216|NCT00674895|Lewy Body Parkinson's Disease
507217|NCT00674895|Paralysis Agitans
507218|NCT00674895|Parkinson's Disease, Idiopathic
507219|NCT00674895|Parkinson's Disease, Lewy Body
507220|NCT00674895|Primary Parkinsonism
507221|NCT00674882|Hematopoietic stem cell transplant
507222|NCT00674882|Follow-up studies
507223|NCT00674882|Outcomes research
507224|NCT00674882|Data collection
507225|NCT00674869|sealant
507226|NCT00674869|pit
507227|NCT00674869|child
507228|NCT00674869|over
507229|NCT00674869|6 years old
507230|NCT00674869|least
507231|NCT00674843|MYOTONIC DYSTROPHY
507232|NCT00674843|MYOPATHIES
507233|NCT00674843|Distal Myopathies
507234|NCT00674843|Muscular Dystrophy, Duchenne
507235|NCT00674843|Phosphorylase Deficiency (McArdle Disease)
507236|NCT00674817|salbutamol,
507237|NCT00674817|Chronic Obstructive Pulmonary Disease (COPD)
507238|NCT00674817|GSK961081 muscarinic receptor antagonist,
507239|NCT00674817|COPD
507240|NCT00674817|ipratropium bromide,
507241|NCT00674817|Asthma
507242|NCT00674817|ß2-adrenergic agonist,
507243|NCT00674804|Communicating a Diagnosis
507244|NCT00674804|Cancer Diagnosis
507245|NCT00674804|Recurrence of Cancer
507246|NCT00674804|Initial Cancer Diagnosis
507247|NCT00674791|Immunotherapeutic vaccine
507248|NCT00674791|breast cancer
507249|NCT00674791|TxN2-3M0 breast cancer
507250|NCT00674791|metastatic breast cancer
507251|NCT00674791|immunotherapy
507252|NCT00674791|antigen
507253|NCT00674791|Histologically confirmed, TxN2-3M0 or metastatic breast cancer
507254|NCT00674778|Radial
507255|NCT00674778|Femoral
507256|NCT00674778|artery
507257|NCT00674778|Invasive cardiology safety
507258|NCT00674739|external genital warts
507259|NCT00674739|perianal warts
507260|NCT00674739|condylomata acuminata
507261|NCT00674739|venereal warts
507262|NCT00674739|HPV types 6 and 11
507263|NCT00674726|appendicitis
507264|NCT00674726|gastroenteritis
507265|NCT00674726|temperature
507266|NCT00674726|fever
507267|NCT00674726|acute abdomen
507268|NCT00674726|Axilo-rectal temperature in appendicitis
507269|NCT00674726|Axilo-rectal temperature in gastroenteritis
507270|NCT00674713|Patients undergoing laparoscopic cholecystectomy for cholelithiasis
507271|NCT00674700|House dust mites allergy
507272|NCT00674674|topotecan
507273|NCT00674674|pharmacokinetics
507274|NCT00674674|neoplastic
507275|NCT00674674|meningitis
507276|NCT00674661|ectasia
507277|NCT00674661|cross-linking
507278|NCT00674661|crosslinking
507279|NCT00674661|cornea
507280|NCT00674661|riboflavin
507281|NCT00674661|UVA
507282|NCT00674648|Multiple Diseases
507283|NCT00674648|Hematopoietic System
507284|NCT00674648|CMV-PP65 PROTEIN SPECIFIC T CELLS
507285|NCT00674635|adaptive study,
507286|NCT00674635|DAS28,
507287|NCT00674635|monoclonal antibody
507288|NCT00674635|GSK315234A;
507289|NCT00674635|rheumatoid arthritis,
507290|NCT00674622|Lateral epicondylitis
507291|NCT00674622|Tennis elbow
507292|NCT00674622|Prolotherapy
507293|NCT00674609|Palliative Care
507294|NCT00674609|Pain
507295|NCT00674609|Cancer
507296|NCT00674596|PTX3, ramipril, endothelial dysfunction
507297|NCT00674596|1- Diabetic proteinuria
507298|NCT00674596|2- The aim of this study was to find out whether the
507299|NCT00674596|beneficial effects of RAS blockage in diabetic
507300|NCT00674596|proteinuria has any relation with the alteration
507301|NCT00674596|of PTX3 levels.
507302|NCT00674583|Conjugate vaccine
507303|NCT00674583|Meningococcal disease
507304|NCT00674583|Immunogenicity
507305|NCT00674583|Meningococcal vaccine
507306|NCT00674583|Safety
507307|NCT00674570|Stress Disorders, Posttraumatic
507308|NCT00674570|Hydrocortisone
507309|NCT00674570|Cycloserine
507310|NCT00674570|Extinction, Psychological
507311|NCT00674570|PTSD
507312|NCT00674570|San Francisco
507313|NCT00674557|recurrent breast cancer
507314|NCT00674557|stage IIIA breast cancer
507315|NCT00674557|stage IIIB breast cancer
507316|NCT00674557|stage IIIC breast cancer
507317|NCT00674557|stage IV breast cancer
507318|NCT00674557|HER2-negative breast cancer
507319|NCT00674557|estrogen receptor-positive breast cancer
507320|NCT00674557|progesterone receptor-positive breast cancer
507321|NCT00674544|childhood
507322|NCT00674544|children
507323|NCT00674544|obesity
507324|NCT00674544|physical activity
507325|NCT00674544|nutrition
507326|NCT00674544|fitness
507327|NCT00674544|family
507328|NCT00674531|Arteriosclerosis
507329|NCT00674531|Arterial Occlusive Diseases
507330|NCT00674531|Enterovirus
507331|NCT00674531|Artery resection
507332|NCT00674518|Health Promotion
507333|NCT00674518|Health Behavior Change
507334|NCT00674518|Physical Activity
507335|NCT00674518|Dietary Change
507336|NCT00674518|Weight Loss
507337|NCT00674518|Obesity
507338|NCT00674479|Advanced Hematologic Malignancies
507339|NCT00674479|Cancer
507340|NCT00674479|Blood
507341|NCT00674479|Bone marrow
507342|NCT00674479|Lymph nodes
507343|NCT00674479|JAK kinase inhibitor INCB018424 phosphate
507344|NCT00674479|Acute Myeloid Leukemia
507345|NCT00674479|AML
507346|NCT00674479|Acute Lymphocytic leukemia
507347|NCT00674479|ALL
507348|NCT00674479|Myelodysplastic Syndrome
507349|NCT00674479|MDS
507350|NCT00674479|Chronic myelogenous leukemia - Blast Crisis
507351|NCT00674479|CML
507352|NCT00674479|INCB018424
507353|NCT00674466|GLP-1, incretin, type 2 diabetes
507354|NCT00674453|Osteoporosis
507355|NCT00674453|lasofoxifene
507356|NCT00674453|bone density
507357|NCT00674453|bone markers
507358|NCT00674440|Congenital Hyperinsulinism
507359|NCT00674440|Hyperinsulinism
507360|NCT00674440|Persistent Hyperinsulinemic Hypoglycemia of Infancy
507361|NCT00674440|CHI
507362|NCT00674440|PHHI
507363|NCT00674440|F-DOPA
507364|NCT00674440|L-fluoro-dihydroxyphenylalanine
507365|NCT00674427|AML
507366|NCT00674427|ALL
507367|NCT00674427|MDS
507368|NCT00674427|CLL
507369|NCT00674427|Multiple Myeloma
507370|NCT00674414|stage IA breast cancer
507371|NCT00674414|stage IB breast cancer
507372|NCT00674414|stage II breast cancer
507373|NCT00674414|stage IIIA breast cancer
507374|NCT00674414|HER2-positive breast cancer
507375|NCT00674388|Children
507376|NCT00674388|Anesthesia
507377|NCT00674388|Surgery
507378|NCT00674388|Complication
507379|NCT00674375|Chest Pain
507380|NCT00674375|Acute Myocardial Infarction
507381|NCT00674375|Patient Safety
507382|NCT00674375|Misdiagnosis
507383|NCT00674362|Rheumatoid Arthritis
507384|NCT00674362|Moderate to Low Disease activity
507385|NCT00674362|Certolizumab pegol
507386|NCT00674336|Norovirus
507387|NCT00674336|Gastroenteritis
507388|NCT00674336|Clinical Trial
507389|NCT00674336|Stomach flu
507390|NCT00674336|Oysters
507391|NCT00674336|Shellfish
507392|NCT00674336|high hydrostatic pressures
507393|NCT00674323|Polypoidal choroidal vasculopathy
507394|NCT00674323|PCV
507395|NCT00674323|Age-related macular degeneration (AMD) variant
507396|NCT00674323|vision
507397|NCT00674323|polyps
507398|NCT00674323|indocyanine green angiography
507399|NCT00674323|verteporfin
507400|NCT00674323|ranibizumab
507401|NCT00674323|photodynamic therapy
507402|NCT00674297|Persistently Antiphospholipid Antibody Positive Patients
507403|NCT00674271|Diabetes Mellitus, Type 2
507404|NCT00674271|Mannose-Binding lectin
507405|NCT00674271|Toll-Like Receptors
507406|NCT00674271|Atherosclerosis
507407|NCT00674271|Carotid Arteries
507408|NCT00674271|Diabetes Complications
507409|NCT00674271|Diabetic Angiopathies
507410|NCT00674258|HLA-A*2402
507411|NCT00674258|Peptide Vaccine
507412|NCT00674258|URLC10
507413|NCT00674258|TTK
507414|NCT00674258|KOC1
507415|NCT00674245|heartburn
507416|NCT00674245|acid reflux
507417|NCT00674245|GERD
507418|NCT00674245|spectrum analysis
507419|NCT00674245|electroencephalogram
507420|NCT00674245|esophagitis
507421|NCT00674245|peptic
507422|NCT00674232|incomplete abortion
507423|NCT00674232|spontaneous miscarriage
507424|NCT00674219|GAD
507425|NCT00674206|Metastatic breast cancer
507426|NCT00674154|Vitamin D
507427|NCT00674154|Primary hyperparathyroidism
507428|NCT00674154|hypercalcemia
507429|NCT00674141|Multiple Sclerosis, relapsing remitting, Dexamethasone
507430|NCT00674128|pacemaker
507431|NCT00674128|cardioverter-defibrillator
507432|NCT00674128|ICD
507433|NCT00674128|cardiac resynchronization device
507434|NCT00674128|cyanoacrylate
507435|NCT00674128|suture
507436|NCT00674128|Dermabond
507437|NCT00674128|Vicryl
507438|NCT00674102|Vascular disrupting agent
507439|NCT00674102|Non-small cell lung cancer
507440|NCT00674089|IMR
507441|NCT00674089|Newborn Mortality
507442|NCT00674089|Vitamin A Effectiveness
507443|NCT00674089|Premature Mortality
507444|NCT00674089|Mortality
507445|NCT00674063|Chronic Plaque Psoriasis
507446|NCT00674063|Alefacept
507447|NCT00674050|Healthy Males or Females subjects
507448|NCT00674037|recruitment
507449|NCT00674037|physicians participating in the recruitment of patients
507450|NCT00674024|Pazopanib
507451|NCT00674024|Tyrosine Kinase Inhibitor
507452|NCT00674024|Advanced Cancer
507453|NCT00674024|Pharmacokinetics
507454|NCT00674024|Cancer
507455|NCT00674024|Solid Tumor
507456|NCT00674024|Lymphoma
507457|NCT00674011|hypertension
507458|NCT00674011|bevacizumab
507459|NCT00674011|metastatic breast cancer
507460|NCT00673998|Isokinetic
507461|NCT00673998|Fatigue
507462|NCT00673998|Strength
507463|NCT00673998|Older
507464|NCT00673985|SFA, Edwards, Popliteal, LifeStent, PTA, Nitinol
507465|NCT00673972|Functional dyspepsia
507466|NCT00673972|Gastric emptying
507467|NCT00673972|Helicobacter pylori
507468|NCT00673972|Lansoprazole
507469|NCT00673972|Epigastric pain syndrome
507470|NCT00673972|Postprandial distress syndrome
507471|NCT00673959|Dry eye
507472|NCT00673959|artificial tears
507473|NCT00673946|bronchiolitis
507474|NCT00673946|hospitalization
507475|NCT00673946|oximetry
507476|NCT00673946|pediatrics
507477|NCT00673920|RA
507478|NCT00673907|Wood smoke
507479|NCT00673907|Health effects
507480|NCT00673907|Human
507481|NCT00673907|Airway inflammation
507482|NCT00673907|Cardiovascular effects
507483|NCT00673855|Dry eye
507484|NCT00673855|Artificial tear
507485|NCT00673842|Noninvasive assessment
507486|NCT00673842|Holter
507487|NCT00673829|Breast Cancer
507488|NCT00673829|T cells
507489|NCT00673829|Gene Transfer
507490|NCT00673816|Von Hippel Lindau
507491|NCT00673816|Sunitinib Malate
507492|NCT00673816|Sutent
507493|NCT00673816|Von Hippel-Lindau Syndrome
507494|NCT00673816|VHL
507495|NCT00673803|posterior capsule opacification
507496|NCT00673803|micro incision
507497|NCT00673803|sharp optic edge
507498|NCT00673790|nebivolol
507499|NCT00673790|BYSTOLIC ™
507500|NCT00673790|hydrochlorothiazide
507501|NCT00673790|lisinopril
507502|NCT00673790|Prinivil (TM)
507503|NCT00673790|Zestril (TM)
507504|NCT00673790|losartan
507505|NCT00673790|Cozaar (TM)
507506|NCT00673790|Impaired Fasting Glucose
507507|NCT00673790|Impaired Glucose Tolerance
507508|NCT00673790|hypertension
507509|NCT00673777|HLA-A*0201
507510|NCT00673777|Peptide Vaccine
507511|NCT00673777|URLC10
507512|NCT00673777|VEGFR1
507513|NCT00673777|VEGFR2
507514|NCT00673751|mesenteric blood flow
507515|NCT00673751|GLP-2
507516|NCT00673751|short bowel syndrome
507517|NCT00673751|Glucagon-Like Peptide 2
507518|NCT00673738|Lung
507519|NCT00673738|Thoracic
507520|NCT00673738|Immunotherapy
507521|NCT00673738|Radiotherapy
507522|NCT00673738|LA - NSCLC
507523|NCT00673738|Non-Small Cell Lung Cancer
507524|NCT00673725|Atopic Dermatitis
507525|NCT00673712|Coronary Artery Bypass Graft Surgery
507526|NCT00673712|Pneumonia
507527|NCT00673712|Surgical Site Infection
507528|NCT00673699|NBI
507529|NCT00673699|gastroscopy
507530|NCT00673699|biopsy
507531|NCT00673699|intestinal metaplasia
507532|NCT00673686|Oral contraceptive
507533|NCT00673686|Ovulation
507534|NCT00673686|Missing pills
507535|NCT00673686|Intake compliance
507536|NCT00673686|Cycle control
507537|NCT00673660|Statins
507538|NCT00673660|Compliance
507539|NCT00673660|Dyslipidemia
507540|NCT00673647|cannabis
507541|NCT00673647|dependence
507542|NCT00673647|marijuana
507543|NCT00673647|CBT
507544|NCT00673647|efficacy of CBT for cannabis use disorders
507545|NCT00673634|preoxygenation
507546|NCT00673634|method
507547|NCT00673634|efficiency
507548|NCT00673634|obesity
507549|NCT00673634|BiPAP
507550|NCT00673634|FeO2
507551|NCT00673621|Asthmatics and non-asthmatic male and female subjects
507552|NCT00673608|Haemoglobinopathies,
507553|NCT00673608|Myelodysplastic Syndromes,
507554|NCT00673608|Transfusional iron overload,
507555|NCT00673608|cardiac iron load
507556|NCT00673595|smoking
507557|NCT00673595|varenicline
507558|NCT00673595|flow-mediated dilation
507559|NCT00673595|blood pressure
507560|NCT00673595|baroreflex
507561|NCT00673582|Statins
507562|NCT00673582|Intima Media Thickness
507563|NCT00673582|Plaque Area
507564|NCT00673569|recurrent non-small cell lung cancer
507565|NCT00673569|stage IV non-small cell lung cancer
507566|NCT00673569|stage IIIA non-small cell lung cancer
507567|NCT00673569|stage IIIB non-small cell lung cancer
507568|NCT00673556|Chronic Plaque Psoriasis
507569|NCT00673556|Alefacept
507570|NCT00673543|Corticosteroids
507571|NCT00673543|Pregnancy
507572|NCT00673543|Glucose control
507573|NCT00673530|Hospital malnutrition
507574|NCT00673530|Nutritional Status
507575|NCT00673530|Nutrition Assessment
507576|NCT00673530|Enteral Nutrition
507577|NCT00673530|Parenteral Nutrition
507578|NCT00673530|Severity of illness index
507579|NCT00673530|cost analysis
507580|NCT00673517|Acute respiratory distress syndrome
507581|NCT00673517|Ventilator induced lung injury
507582|NCT00673517|High frequency oscillation
507583|NCT00673517|Lung protective ventilation
507584|NCT00673517|Biomarkers
507585|NCT00673517|Biotrauma
507586|NCT00673504|cancer
507587|NCT00673504|pancreatic cancer
507588|NCT00673504|gemcitabine
507589|NCT00673504|sunitinib
507590|NCT00673504|Phase 2
507591|NCT00673491|Critical Pathways
507592|NCT00673491|Stroke
507593|NCT00673491|Randomized Controlled Trial
507594|NCT00673491|Effectiveness
507595|NCT00673439|heparin-induced thrombocytopenia
507596|NCT00673439|thrombocytopenia
507597|NCT00673439|HIT
507598|NCT00673439|thrombosis
507599|NCT00673439|blood clot
507600|NCT00673439|blood thinner
507601|NCT00673439|anticoagulant
507602|NCT00673439|heparin
507603|NCT00673439|warfarin
507604|NCT00673439|fondaparinux
507605|NCT00673439|Arixtra
507606|NCT00673426|enoxaparin
507607|NCT00673426|chronic renal disease
507608|NCT00673426|Anticoagulant activity of enoxaparin sodic
507609|NCT00673413|Perception
507610|NCT00673413|Emotions
507611|NCT00673413|Adaptation
507612|NCT00673413|Estomia
507613|NCT00673400|Obstructed defecation syndrome
507614|NCT00673400|ODS
507615|NCT00673400|Rectocele
507616|NCT00673400|Intussusception
507617|NCT00673400|STARR
507618|NCT00673387|overweight
507619|NCT00673387|obesity
507620|NCT00673387|pramlintide
507621|NCT00673387|metreleptin
507622|NCT00673387|Amylin
507623|NCT00673374|emergency
507624|NCT00673374|acute
507625|NCT00673374|nontraumatic
507626|NCT00673374|abdominal pain
507627|NCT00673374|tenderness
507628|NCT00673374|CT scan
507629|NCT00673374|radiation
507630|NCT00673374|diagnosis
507631|NCT00673348|Mycoses
507632|NCT00673348|Voriconazole
507633|NCT00673335|breast cancer
507634|NCT00673335|hereditary breast/ovarian cancer (BRCA1, BRCA2)
507635|NCT00673335|BRCA1 mutation carrier
507636|NCT00673335|BRCA2 mutation carrier
507637|NCT00673322|Colorectal Cancer
507638|NCT00673322|T cells
507639|NCT00673322|Gene Transfer
507640|NCT00673309|burns
507641|NCT00673296|Bevacizumab
507642|NCT00673296|Diabetic premacular hemorrhage
507643|NCT00673296|Intravitreal gas
507644|NCT00673283|lung cancer
507645|NCT00673283|nodules
507646|NCT00673283|radiography
507647|NCT00673283|CT
507648|NCT00673283|Stereoscopy
507649|NCT00673257|unspecified childhood solid tumor, protocol specific
507650|NCT00673244|Renal Replacement Therapy
507651|NCT00673244|Dialysis
507652|NCT00673231|Dapagliflozin
507653|NCT00673231|efficacy
507654|NCT00673231|safety
507655|NCT00673231|add on to insulin
507656|NCT00673231|Oral AntiDiabetic
507657|NCT00673231|Type 2 diabetes
507658|NCT00673218|IL13
507659|NCT00673218|Cytokines
507660|NCT00673218|Basophil stimulation
507661|NCT00673205|androgen antagonists
507662|NCT00673205|prostate neoplasms
507663|NCT00673179|Doxorubicin
507664|NCT00673179|AD
507665|NCT00673179|Hydroxydaunomycin hydrochloride
507666|NCT00673179|Cisplatin
507667|NCT00673179|Paraplatin®
507668|NCT00673179|Methotrexate
507669|NCT00673179|Ifosfamide
507670|NCT00673179|Osteosarcoma
507671|NCT00673179|Sargramostim
507672|NCT00673179|Leukine™
507673|NCT00673179|Leucovorin
507674|NCT00673179|Gemcitabine
507675|NCT00673179|Gemzar
507676|NCT00673179|Gemcitabine Hydrochloride
507677|NCT00673179|GM-CSF
507678|NCT00673179|Questionnaire
507679|NCT00673179|Survey
507680|NCT00673166|Staff motivation
507681|NCT00673166|Hospital mortality
507682|NCT00673166|Perception of quality of care
507683|NCT00673140|ALS (Amyotrophic Lateral Sclerosis)
507684|NCT00673140|Amyotrophic Lateral Sclerosis With Dementia
507685|NCT00673140|Amyotrophic Lateral Sclerosis, Guam Form
507686|NCT00673140|Dementia With Amyotrophic Lateral Sclerosis
507687|NCT00673140|Gehrig's Disease
507688|NCT00673140|Guam Form of Amyotrophic Lateral Sclerosis
507689|NCT00673140|Lou Gehrig Disease
507690|NCT00673127|hormone refractory
507691|NCT00673127|KHAD
507692|NCT00673127|ketoconazole
507693|NCT00673127|dutasteride
507694|NCT00673127|hydrocortisone
507695|NCT00673114|Haplo/cord
507696|NCT00673114|hematologic malignancy
507697|NCT00673114|MDS
507698|NCT00673114|Aplastic Anemia
507699|NCT00673114|AML
507700|NCT00673114|ALL
507701|NCT00673114|CML
507702|NCT00673101|liver fibrosis, cirrhosis
507703|NCT00673101|FibroScan
507704|NCT00673101|transient elastography
507705|NCT00673101|elastometry
507706|NCT00673101|methotrexate
507707|NCT00673101|non invasive blood markers
507708|NCT00673101|FibroTest
507709|NCT00673101|treatment
507710|NCT00673075|carvedilol
507711|NCT00673075|Coreg (TM)
507712|NCT00673075|hypertension
507713|NCT00673075|blood pressure
507714|NCT00673075|coronary artery disease
507715|NCT00673075|Nebivolol
507716|NCT00673075|BYSTOLIC (TM)
507717|NCT00673049|IGR-1R
507718|NCT00673049|Non small cell lung cancer
507719|NCT00673049|CP-751
507720|NCT00673049|871
507721|NCT00673049|Figitumumab
507722|NCT00673036|Coronary syndrome
507723|NCT00673036|Myocardial infarction
507724|NCT00673036|French registry
507725|NCT00673010|124-IODINE
507726|NCT00673010|I-131 METAIODOBENZ SULF (MIBG)
507727|NCT00673010|Thyroid
507728|NCT00673010|Parathyroid
507729|NCT00672997|Glaucoma
507730|NCT00672997|Hypertension
507731|NCT00672984|QT/QTc
507732|NCT00672958|Major Depressive Disorder
507733|NCT00672958|Depression
507734|NCT00672958|Drug Therapy
507735|NCT00672958|Major Depressive Episode
507736|NCT00672932|raltegravir
507737|NCT00672932|central nervous system (CNS)
507738|NCT00672932|HIV-1
507739|NCT00672932|AIDS
507740|NCT00672932|cerebrospinal fluid (CSF)
507741|NCT00672932|immunoactivation
507742|NCT00672932|antiretroviral therapy
507743|NCT00672932|suppression
507744|NCT00672919|Glucose Metabolism Disorder
507745|NCT00672919|Dysmetabolic Syndrome
507746|NCT00672919|Type II Diabetes
507747|NCT00672919|Diabetes Mellitus, Lipoatrophic
507748|NCT00672919|Dyslipidemia
507749|NCT00672919|Drug Therapy
507750|NCT00672906|anorexia nervosa
507751|NCT00672906|group parent training
507752|NCT00672906|caregiver burden
507753|NCT00672906|eating disorders
507754|NCT00672906|treatment
507755|NCT00672893|central airway stenosis, lung sounds, airway obstruction, bronchial obstruction, bronchoscopic treatment
507756|NCT00672880|Chronic low back pain accompanied by depression
507757|NCT00672854|parenteral nutrition
507758|NCT00672854|lipid emulsion
507759|NCT00672854|nosocomial infection
507760|NCT00672854|mortality
507761|NCT00672854|endothelial function
507762|NCT00672854|inflammatory markers
507763|NCT00672854|oxidative stress
507764|NCT00672854|immune function
507765|NCT00672854|autonomic nervous system
507766|NCT00672854|insulin sensitivity
507767|NCT00672854|carbohydrate metabolism
507768|NCT00672841|candidemia
507769|NCT00672841|invasive candidiasis
507770|NCT00672841|preemptive antifungal therapy
507771|NCT00672841|surveillance
507772|NCT00672841|β-D-Glucan (BDG)
507773|NCT00672828|colon cancer
507774|NCT00672828|rectal cancer
507775|NCT00672815|coordinated school health
507776|NCT00672815|school health policy evaluation
507777|NCT00672815|physical activity
507778|NCT00672802|Chronic Obstructive Pulmonary Disease
507779|NCT00672802|COPD
507780|NCT00672802|Insomnia
507781|NCT00672802|Drug Therapy
507782|NCT00672789|Sickle cell anemia
507783|NCT00672789|Children
507784|NCT00672789|Hydroxyurea
507785|NCT00672789|Treatment Adherence
507786|NCT00672776|hippocampus
507787|NCT00672776|paroxetine
507788|NCT00672776|stress
507789|NCT00672776|PTSD
507790|NCT00672763|Crohn's Disease
507791|NCT00672763|Inflammatory Bowel Disease
507792|NCT00672763|Vitamin D
507793|NCT00672763|Randomised
507794|NCT00672763|Placebo
507795|NCT00672750|laparoscopic
507796|NCT00672750|myomectomy
507797|NCT00672750|menorrhagia
507798|NCT00672750|pelvic pain
507799|NCT00672724|Insomnia
507800|NCT00672724|Sleep Disorder
507801|NCT00672724|Drug Therapy
507802|NCT00672711|Complex Regional Pain Syndrome
507803|NCT00672711|Chronic Post-surgical Pain
507804|NCT00672711|Genetic susceptibility
507805|NCT00672711|COMT
507806|NCT00672698|SURGICAL RISK
507807|NCT00672698|ELDERLY
507808|NCT00672698|MAJOR SURGERY
507809|NCT00672698|P-POSSUM
507810|NCT00672698|SAPS II
507811|NCT00672685|Cognitive decline
507812|NCT00672685|omega-3 fatty acids
507813|NCT00672685|nutrition
507814|NCT00672685|physical exercise
507815|NCT00672685|cognitive training
507816|NCT00672685|social activities
507817|NCT00672685|frailty
507818|NCT00672672|Wound healing of surgical site treated with autologous platlet gel
507819|NCT00672659|Lost of interest, Depressed Mood
507820|NCT00672646|Analgesic effect
507821|NCT00672633|Omega 3 Fatty Acids
507822|NCT00672633|Triglycerides
507823|NCT00672633|Lovaza
507824|NCT00672633|Trial
507825|NCT00672620|Major Depressive Disorder
507826|NCT00672620|Depression
507827|NCT00672620|Drug Therapy
507828|NCT00672620|Major Depressive Episode
507829|NCT00672607|premenstual syndrome, PMS, clinical trial
507830|NCT00672581|Hepatic Impairment
507831|NCT00672568|Rotator cuff, Shoulder, Arthroscopic shoulder surgery
507832|NCT00672555|pilonidal sinus
507833|NCT00672555|recurrence
507834|NCT00672555|Limberg flap
507835|NCT00672542|melanoma
507836|NCT00672542|dendritic cell
507837|NCT00672542|immunoproteasome
507838|NCT00672542|vaccine
507839|NCT00672529|Childhood Asthma
507840|NCT00672529|Inhaled Corticosteroids
507841|NCT00672529|Alternative Medicine
507842|NCT00672529|Vitamins, minerals, and fish oil as Add-on Treatment
507843|NCT00672516|hemorrhage
507844|NCT00672516|cardiopulmonary bypass
507845|NCT00672516|blood component transfusion
507846|NCT00672516|hemostasis, surgical
507847|NCT00672503|indwelling urinary catheters
507848|NCT00672503|urinary tract infections
507849|NCT00672503|foley-catheter related infections
507850|NCT00672503|hospital acquired CA-UTI
507851|NCT00672490|Acute Mania
507852|NCT00672490|Bipolar Disorder
507853|NCT00672490|Quetiapine Fumarate
507854|NCT00672490|Lithium
507855|NCT00672477|opioid-induced constipation
507856|NCT00672464|Schizophrenia
507857|NCT00672464|Schizoaffective
507858|NCT00672464|Cardiovascular
507859|NCT00672464|Olanzapine
507860|NCT00672464|Metformin
507861|NCT00672464|Simvastatin
507862|NCT00672451|diabetic kidney disease
507863|NCT00672451|albuminuria
507864|NCT00672412|Treatment Experienced
507865|NCT00672399|Amylin
507866|NCT00672399|Eli Lilly
507867|NCT00672399|exenatide
507868|NCT00672399|moxifloxacin
507869|NCT00672386|Diabetes
507870|NCT00672386|Type 2 Diabetes
507871|NCT00672386|Adult-Onset Diabetes Mellitus
507872|NCT00672386|Metabolic Syndrome
507873|NCT00672386|HbA1c
507874|NCT00672386|Body Weight
507875|NCT00672386|Metformin
507876|NCT00672373|Tardive Dyskinesia
507877|NCT00672373|Schizophrenia
507878|NCT00672373|Extract of Gingko Biloba
507879|NCT00672360|Autism Spectrum Disorder
507880|NCT00672347|caudal anesthesia, clonidine, morphine, bupivacaine
507881|NCT00672334|Cardiac surgery
507882|NCT00672334|Cardiopulmonary bypass
507883|NCT00672334|Oxidative stress
507884|NCT00672334|Acute renal dysfunction
507885|NCT00672334|Sodium bicarbonate
507886|NCT00672321|recurrent melanoma
507887|NCT00672321|stage IB melanoma
507888|NCT00672321|stage II melanoma
507889|NCT00672321|stage IIIA melanoma
507890|NCT00672308|Cholera, benefiber, ORS
507891|NCT00672295|Ovarian Cancer
507892|NCT00672295|Peritoneal Cancer
507893|NCT00672295|Tubal Cancer
507894|NCT00672295|Fallopian Tube Cancer
507895|NCT00672295|Dasatinib
507896|NCT00672295|Sprycel
507897|NCT00672295|Paclitaxel
507898|NCT00672295|Taxol
507899|NCT00672295|Carboplatin
507900|NCT00672295|Paraplatin
507901|NCT00672282|androgen antagonists
507902|NCT00672282|prostate neoplasms
507903|NCT00672269|carcinoid
507904|NCT00672269|family members
507905|NCT00672269|familial
507906|NCT00672269|tumors
507907|NCT00672269|cancer
507908|NCT00672256|Smoking
507909|NCT00672256|fMRI
507910|NCT00672243|GBM
507911|NCT00672243|Brain tumor
507912|NCT00672243|Erlotinib
507913|NCT00672243|Sirolimus
507914|NCT00672243|Glioblastoma multiforme
507915|NCT00672243|Glioblastoma
507916|NCT00672243|Gliosarcoma3
507917|NCT00672243|Tarceva
507918|NCT00672243|Rapamune
507919|NCT00672230|Lactation
507920|NCT00672230|Breast milk
507921|NCT00672230|Lutein
507922|NCT00672230|Lutein supplement
507923|NCT00672217|Breast cancer survivors, insomnia, quality of life
507924|NCT00672204|Islet transplant
507925|NCT00672204|Diabetes Mellitus
507926|NCT00672204|Hypoglycemia
507927|NCT00672191|HIV
507928|NCT00672191|Human immunodeficiency virus
507929|NCT00672191|Immunodeficiency Virus, Human
507930|NCT00672191|HIV-1
507931|NCT00672191|ART
507932|NCT00672191|antiretroviral therapy
507933|NCT00672191|HAART
507934|NCT00672191|highly active retroviral therapy
507935|NCT00672191|cluster of differentiation CD 4+ T cell counts
507936|NCT00672191|HIV-1 Subjects successfully ART treated
507937|NCT00672191|Treatment Experienced
507938|NCT00672178|RCC
507939|NCT00672178|metastatic
507940|NCT00672178|sorafenib
507941|NCT00672165|MAB HUM 195 ACTINIUM-225 LABELED
507942|NCT00672165|HEMATOPOIETIC SYSTEM
507943|NCT00672165|02-017
507944|NCT00672152|Autologous transplantation
507945|NCT00672152|Allogeneic transplantation
507946|NCT00672139|Opioid-Induced Constipation
507947|NCT00672100|Peripheral Nerve Infusion,
507948|NCT00672100|continuous brachial plexus block,
507949|NCT00672100|post-operative pain
507950|NCT00672100|diaphragmatic paresis
507951|NCT00672087|Chronic Prostatitis with Chronic Pelvic Pain Syndrome
507952|NCT00672087|Chronic Bacterial Prostatitis
507953|NCT00672087|Asymptomatic Inflammatory Prostatitis
507954|NCT00672087|Painful Bladder Syndrome
507955|NCT00672087|Cystitis, Interstitial
507956|NCT00672074|Postoperative Ileus
507957|NCT00672061|Sleep Apnea, Obstructive
507958|NCT00672061|Insomnia
507959|NCT00672061|Drug Therapy
507960|NCT00672048|glaucoma
507961|NCT00672048|optometrists
507962|NCT00672035|LT
507963|NCT00672035|Healthy Adults
507964|NCT00672035|Dose Ranging
507965|NCT00672035|Patch
507966|NCT00672035|Vaccine
507967|NCT00672009|prostate cancer
507968|NCT00672009|radical prostatectomy
507969|NCT00672009|ixabepilone
507970|NCT00671970|Glioblastoma
507971|NCT00671970|Gliosarcoma
507972|NCT00671970|Recurrent MG
507973|NCT00671970|Malignant glioma
507974|NCT00671970|Glioma
507975|NCT00671970|Glioblastoma multiforme (GBM)
507976|NCT00671970|GBM
507977|NCT00671970|Brain tumor
507978|NCT00671970|Anaplastic astrocytoma
507979|NCT00671970|Anaplastic oligodendroglioma
507980|NCT00671970|Anaplastic oligoastrocytoma
507981|NCT00671970|Bevacizumab
507982|NCT00671970|Avastin
507983|NCT00671970|Erlotinib
507984|NCT00671970|Tarceva
507985|NCT00671957|Obesity
507986|NCT00671957|Bariatric
507987|NCT00671957|Surgery
507988|NCT00671957|Activity
507989|NCT00671944|protein
507990|NCT00671944|calcium
507991|NCT00671944|parathyroid hormone
507992|NCT00671944|bone markers
507993|NCT00671944|calcium kinetics
507994|NCT00671944|absorption
507995|NCT00671931|dexmedetomidine
507996|NCT00671931|neuromonitoring
507997|NCT00671931|spine procedures
507998|NCT00671931|safe dose
507999|NCT00671931|1- safe dose of dexmedetomidine when used in total intravenous anesthesia for procedures require neuromonitoring
508000|NCT00671931|2- safe dose of propofol when uses in comination with dexmedetomidine in neuromontoring
508001|NCT00671931|3effect of dexmedetomidine on somatosensory evoked potential and motor evoked potentials
508002|NCT00671918|breast cancer
508003|NCT00671918|lymph nodes
508004|NCT00671918|melanoma
508005|NCT00671918|surgery
508006|NCT00671905|atrial fibrillation
508007|NCT00671905|PV isolation
508008|NCT00671905|ablation
508009|NCT00671905|ganglionic plexi
508010|NCT00671905|parasympathetic denervation
508011|NCT00671892|LPS endotoxin
508012|NCT00671892|asthma
508013|NCT00671866|OP
508014|NCT00671866|Pesticides
508015|NCT00671866|Long-Term Low Level Exposure
508016|NCT00671866|Occupational Health
508017|NCT00671866|Neurobehavioral Effects
508018|NCT00671853|Bipolar Disorder
508019|NCT00671853|Anxiety
508020|NCT00671853|Anxiety Disorders
508021|NCT00671853|Substance Use Disorders
508022|NCT00671827|Gynecologic Cancer
508023|NCT00671827|Cervical Cancer
508024|NCT00671827|Endometrial Cancer
508025|NCT00671827|Fallopian Tube Cancer
508026|NCT00671827|Ovarian Cancer
508027|NCT00671827|Uterine Cancer
508028|NCT00671827|Vaginal Cancer
508029|NCT00671827|Vulvar Cancer
508030|NCT00671827|Questionnaire
508031|NCT00671827|Survey
508032|NCT00671827|Robot-Assisted Surgery
508033|NCT00671814|antibiotic
508034|NCT00671801|Malignant Gliomas
508035|NCT00671801|Glioblastoma Multiforme
508036|NCT00671801|Gliosarcoma
508037|NCT00671801|Anaplastic Astrocytoma
508038|NCT00671801|Anaplastic Oligodendroglioma
508039|NCT00671801|Anaplastic Oligoastrocytoma
508040|NCT00671801|Camptosar
508041|NCT00671801|Irinotecan
508042|NCT00671801|CPT-11
508043|NCT00671801|Lenalidomide
508044|NCT00671801|Revlimid
508045|NCT00671801|CC-5013
508046|NCT00671775|Bariatric Surgery
508047|NCT00671775|Obesity
508048|NCT00671775|Cognitive Function
508049|NCT00671736|cystic fibrosis
508050|NCT00671736|Moli1901
508051|NCT00671736|Lancovutide
508052|NCT00671736|2622U90
508053|NCT00671736|duramycin
508054|NCT00671736|lung
508055|NCT00671723|Atelectasis
508056|NCT00671710|malignant glial brain tumors
508057|NCT00671697|MDS
508058|NCT00671697|hypomethylating agent
508059|NCT00671697|oxidative stress
508060|NCT00671684|Hirschsprung's disease
508061|NCT00671684|Constipation
508062|NCT00671684|Endoscopy, digestive system
508063|NCT00671684|Diagnosis
508064|NCT00671684|Colonoscopy
508065|NCT00671658|Lymphoma
508066|NCT00671658|HYPER-CVAD
508067|NCT00671658|Leukemia
508068|NCT00671658|Acute Lymphoblastic Leukemia
508069|NCT00671658|ALL
508070|NCT00671658|Remission Duration
508071|NCT00671658|Chemotherapy
508072|NCT00671658|Asparaginase
508073|NCT00671658|Cyclophosphamide
508074|NCT00671658|Cytarabine
508075|NCT00671658|Dexamethasone
508076|NCT00671658|Doxorubicin
508077|NCT00671658|Leukine
508078|NCT00671658|Methotrexate
508079|NCT00671658|Rituximab
508080|NCT00671658|Vincristine
508081|NCT00671645|pilot study
508082|NCT00671645|rectal
508083|NCT00671645|carcinoma
508084|NCT00671645|phase II
508085|NCT00671645|preoperative
508086|NCT00671645|RadioChemo
508087|NCT00671645|molecular
508088|NCT00671645|target
508089|NCT00671645|therapy
508090|NCT00671645|T3
508091|NCT00671645|ABCSG
508092|NCT00671645|TAKO
508093|NCT00671645|R04
508094|NCT00671645|08
508095|NCT00671632|Addiction
508096|NCT00671619|opthalmology
508097|NCT00671619|antibody fragment
508098|NCT00671619|TNF alpha
508099|NCT00671606|Endometrial Cancer
508100|NCT00671606|Lymphatic Mapping
508101|NCT00671606|Sentinel Node Identification
508102|NCT00671606|Lymph Node
508103|NCT00671606|Intraoperative lymphatic mapping
508104|NCT00671606|Total hysterectomy
508105|NCT00671606|Bilateral salpingooophorectomy
508106|NCT00671606|Lymph node staging
508107|NCT00671606|Laparotomy
508108|NCT00671606|Laparoscopy
508109|NCT00671593|Allergy
508110|NCT00671593|Asthma
508111|NCT00671593|healthy
508112|NCT00671593|Normal
508113|NCT00671580|Skin Infections
508114|NCT00671580|Complicated Skin and Skin Structure Infections
508115|NCT00671567|Sleep Disorder
508116|NCT00671567|Insomnia
508117|NCT00671554|Melanoma
508118|NCT00671554|Dendritic cells
508119|NCT00671554|Cell therapy
508120|NCT00671554|BCG vaccine
508121|NCT00671528|Impetiginous
508122|NCT00671515|Depressive Disorder, Major
508123|NCT00671515|Metabolic Syndrome X
508124|NCT00671515|pioglitazone
508125|NCT00671489|Patients
508126|NCT00671489|high-energy
508127|NCT00671489|admitted
508128|NCT00671489|intensive care unit
508129|NCT00671489|motor vehicle accident
508130|NCT00671489|falling from height
508131|NCT00671489|other accident
508132|NCT00671476|ductal breast carcinoma in situ
508133|NCT00671463|Pancreas surgery
508134|NCT00671463|Pancreatic adenocarcinoma
508135|NCT00671463|Pancreatic neuroendocrine tumor
508136|NCT00671463|Pancreatic duct stenting
508137|NCT00671437|squamous cell carcinoma of the head and neck
508138|NCT00671424|Interaction,
508139|NCT00671424|Diabetes,
508140|NCT00671424|healthy male subjects
508141|NCT00671424|GSK189075,
508142|NCT00671424|Diuretics,
508143|NCT00671411|Ultrasound
508144|NCT00671411|07-165
508145|NCT00671398|Insomnia
508146|NCT00671398|Sleep Disorder
508147|NCT00671398|Drug Therapy
508148|NCT00671385|screening
508149|NCT00671385|compositional analysis
508150|NCT00671385|metabolism
508151|NCT00671385|breast
508152|NCT00671385|breast cyst
508153|NCT00671385|breast infection
508154|NCT00671385|breast inflammation
508155|NCT00671385|lipoma
508156|NCT00671385|benign growth
508157|NCT00671385|Women without a diagnosis for a region of interest in the breast
508158|NCT00671372|CRC
508159|NCT00671372|Metastatic CRC
508160|NCT00671372|APO2L/TRAIL
508161|NCT00671359|Food effects
508162|NCT00671346|Cancer
508163|NCT00671346|Coronary artery disease
508164|NCT00671346|Myocardial infarction
508165|NCT00671346|Cerebrovascular stroke
508166|NCT00671346|Homocysteine
508167|NCT00671346|Vitamin B Complex
508168|NCT00671346|Folic acid
508169|NCT00671346|Vitamin B12
508170|NCT00671346|Vitamin B6
508171|NCT00671346|Pyridoxal phosphate
508172|NCT00671346|Osteoporotic fractures
508173|NCT00671346|Diabetes
508174|NCT00671333|Randomized
508175|NCT00671333|Prospective
508176|NCT00671333|Procedure / Surgery
508177|NCT00671320|acute ankle sprain, acute pain, South America
508178|NCT00671307|Gelsolin
508179|NCT00671307|Trauma
508180|NCT00671307|Pneumonia
508181|NCT00671307|Peritonitis
508182|NCT00671307|Burn
508183|NCT00671307|Infection
508184|NCT00671307|Sepsis
508185|NCT00671307|Systemic Inflammatory Response Syndrome
508186|NCT00671294|Insomnia
508187|NCT00671281|FESS
508188|NCT00671281|Tranexamic acid
508189|NCT00671281|Hemostasis
508190|NCT00671281|Visualization
508191|NCT00671268|Grass pollen allergy
508192|NCT00671268|specific immunotherapy
508193|NCT00671255|Chronic Insomnia
508194|NCT00671255|Drug Therapy
508195|NCT00671255|Elderly
508196|NCT00671242|Fluorine-18-α-methyltyrosine,
508197|NCT00671242|Positron emission tomography,
508198|NCT00671242|Fluorine-18-fluorodeoxyglucose,
508199|NCT00671242|Lung cancer,
508200|NCT00671242|Angiogenesis
508201|NCT00671242|The median VEGF rate was 45% (range, 10-78%).
508202|NCT00671242|High expression was seen in 30 patients (81%, 30/37).
508203|NCT00671242|VEGF expression was statistically associated with progressively growing microvessel count.
508204|NCT00671229|Healthy
508205|NCT00671229|Asthma
508206|NCT00671229|Nitric Oxide
508207|NCT00671216|safety
508208|NCT00671216|pharmacodynamics
508209|NCT00671216|Muscarinic Receptor Antagonist
508210|NCT00671216|tolerability
508211|NCT00671216|healthy subjects
508212|NCT00671216|GS642444
508213|NCT00671216|GSK233705
508214|NCT00671216|Anticholinergic
508215|NCT00671216|ß2 agonist
508216|NCT00671216|pharmacokinetics
508217|NCT00671203|Tissue oximetry
508218|NCT00671203|Ischemia
508219|NCT00671203|Aortic Aneurysm Repair
508220|NCT00671203|Aortic Stent
508221|NCT00671203|Vascular Stent
508222|NCT00671203|Aortic graft
508223|NCT00671203|Vascular graft
508224|NCT00671190|Sleep Disorder
508225|NCT00671190|Circadian Rhythm Sleep Disorder
508226|NCT00671190|Drug Therapy
508227|NCT00671177|colonoscopy
508228|NCT00671177|diagnostic techniques
508229|NCT00671177|digestive system
508230|NCT00671177|endoscopy
508231|NCT00671177|gastrointestinal
508232|NCT00671151|COPD exacerbation
508233|NCT00671151|histone
508234|NCT00671151|steroid resistance
508235|NCT00671151|inflammation
508236|NCT00671151|theophylline
508237|NCT00671138|Celiac disease
508238|NCT00671138|Parasitic infections
508239|NCT00671138|necator americanus
508240|NCT00671138|Immunity
508241|NCT00671125|Sleep Disorder
508242|NCT00671125|Insomnia
508243|NCT00671125|Drug Therapy
508244|NCT00671112|recurrent grade 1 follicular lymphoma
508245|NCT00671112|recurrent grade 2 follicular lymphoma
508246|NCT00671112|recurrent grade 3 follicular lymphoma
508247|NCT00671112|recurrent mantle cell lymphoma
508248|NCT00671112|recurrent marginal zone lymphoma
508249|NCT00671112|recurrent small lymphocytic lymphoma
508250|NCT00671112|Waldenstrom's macroglobulinemia
508251|NCT00671112|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
508252|NCT00671112|nodal marginal zone B-cell lymphoma
508253|NCT00671112|splenic marginal zone lymphoma
508254|NCT00671112|refractory hairy cell leukemia
508255|NCT00671112|B-cell chronic lymphocytic leukemia
508256|NCT00671112|refractory chronic lymphocytic leukemia
508257|NCT00671112|hairy cell leukemia
508258|NCT00671112|cutaneous B and T cell lymphoma
508259|NCT00671112|transformed lymphoma
508260|NCT00671112|transformed B and T cell cutaneous lymphoma
508261|NCT00671112|relapsed or refractory diffuse large B cell lymphoma
508262|NCT00671112|extranodal T cell lymphomas
508263|NCT00671112|anaplastic large cell lymphoma
508264|NCT00671112|angioimmunoblastic T cell lymphoma
508265|NCT00671112|PTCL-NOS
508266|NCT00671112|nasal or disseminated extranodal T/NK lymphoma
508267|NCT00671112|enteropathy-associated T cell lymphoma
508268|NCT00671112|hepatosplenic gamma/delta T cell lymphoma
508269|NCT00671112|subcutaneous panniculitis-like T cell lymphoma
508270|NCT00671112|T-prolymphocytic leukemia
508271|NCT00671112|adult T-cell leukemia/lymphoma
508272|NCT00671112|large granular lymphocytic leukemia
508273|NCT00671112|aggressive NK leukemia
508274|NCT00671099|Patients
508275|NCT00671099|with high-energy
508276|NCT00671099|admitted
508277|NCT00671099|intensive care unit
508278|NCT00671099|motor vehicle accident
508279|NCT00671099|falling from height
508280|NCT00671099|other accident
508281|NCT00671086|Chronic Insomnia
508282|NCT00671086|DIMS (Disorders of Initiating and Maintaining Sleep)
508283|NCT00671086|Disorders of Initiating and Maintaining Sleep
508284|NCT00671086|Insomnia Disorder Sleep Initiation Dysfunction
508285|NCT00671086|Transient Insomnia
508286|NCT00671086|Drug Therapy
508287|NCT00671086|Sleep Disorders, Intrinsic
508288|NCT00671073|Airflow Obstruction, Chronic
508289|NCT00671073|Chronic Airflow Obstruction
508290|NCT00671073|Chronic Obstructive Pulmonary Disease
508291|NCT00671073|Chronic Obstructive Airway Disease
508292|NCT00671073|Chronic Obstructive Lung Disease
508293|NCT00671073|COPD
508294|NCT00671073|COAD
508295|NCT00671060|intrauterine fetal death
508296|NCT00671060|misoprostol
508297|NCT00671047|Autoimmune Diseases
508298|NCT00671047|Lupus
508299|NCT00671021|platelet aggregation
508300|NCT00671021|aspirin
508301|NCT00670995|Tobacco use among middle and junior high school students remains a concern among health educators.
508302|NCT00670995|The use of tobacco prevention programs and their integration into school-based curricula has been lacking due to a number of factors.
508303|NCT00670982|HER2 positive
508304|NCT00670982|bevacizumab
508305|NCT00670982|vinorelbine
508306|NCT00670982|trastuzumab
508307|NCT00670969|Obesity
508308|NCT00670956|prenatal steroids
508309|NCT00670956|hydrops
508310|NCT00670956|congenital cystic adenomatoid malformation of the lung
508311|NCT00670956|prenatal intervention
508312|NCT00670956|betamethasone
508313|NCT00670956|prenatal diagnosis
508314|NCT00670943|Clopidogrel discontinuation
508315|NCT00670943|Platelet aggregation
508316|NCT00670930|Asthma, adults, anti-immunoglobulin E ( IgE), omalizumab, airway inflammation, airway remodeling, allergy
508317|NCT00670917|pain
508318|NCT00670917|unspecified adult solid tumor, protocol specific
508319|NCT00670917|accelerated phase chronic myelogenous leukemia
508320|NCT00670917|acute undifferentiated leukemia
508321|NCT00670917|adult acute lymphoblastic leukemia in remission
508322|NCT00670917|adult acute myeloid leukemia in remission
508323|NCT00670917|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
508324|NCT00670917|adult acute myeloid leukemia with inv(16)(p13;q22)
508325|NCT00670917|adult acute myeloid leukemia with t(15;17)(q22;q12)
508523|NCT00670657|invasive candidiasis
508326|NCT00670917|adult acute myeloid leukemia with t(16;16)(p13;q22)
508327|NCT00670917|adult acute myeloid leukemia with t(8;21)(q22;q22)
508328|NCT00670917|atypical chronic myeloid leukemia, BCR-ABL negative
508329|NCT00670917|blastic phase chronic myelogenous leukemia
508330|NCT00670917|chronic myelomonocytic leukemia
508331|NCT00670917|chronic phase chronic myelogenous leukemia
508332|NCT00670917|mast cell leukemia
508333|NCT00670917|meningeal chronic myelogenous leukemia
508334|NCT00670917|progressive hairy cell leukemia, initial treatment
508335|NCT00670917|prolymphocytic leukemia
508336|NCT00670917|recurrent adult acute lymphoblastic leukemia
508337|NCT00670917|recurrent adult acute myeloid leukemia
508338|NCT00670917|recurrent adult T-cell leukemia/lymphoma
508339|NCT00670917|refractory chronic lymphocytic leukemia
508340|NCT00670917|refractory hairy cell leukemia
508341|NCT00670917|relapsing chronic myelogenous leukemia
508342|NCT00670917|secondary acute myeloid leukemia
508343|NCT00670917|stage 0 chronic lymphocytic leukemia
508344|NCT00670917|stage I adult T-cell leukemia/lymphoma
508345|NCT00670917|stage I chronic lymphocytic leukemia
508346|NCT00670917|stage II adult T-cell leukemia/lymphoma
508347|NCT00670917|stage II chronic lymphocytic leukemia
508348|NCT00670917|stage III adult T-cell leukemia/lymphoma
508349|NCT00670917|stage III chronic lymphocytic leukemia
508350|NCT00670917|stage IV adult T-cell leukemia/lymphoma
508351|NCT00670917|stage IV chronic lymphocytic leukemia
508352|NCT00670917|T-cell large granular lymphocyte leukemia
508353|NCT00670917|untreated adult acute lymphoblastic leukemia
508354|NCT00670917|untreated adult acute myeloid leukemia
508355|NCT00670917|untreated hairy cell leukemia
508356|NCT00670917|recurrent adult Hodgkin lymphoma
508357|NCT00670917|stage I adult Hodgkin lymphoma
508358|NCT00670917|stage II adult Hodgkin lymphoma
508359|NCT00670917|stage III adult Hodgkin lymphoma
508360|NCT00670917|stage IV adult Hodgkin lymphoma
508361|NCT00670917|anaplastic large cell lymphoma
508362|NCT00670917|angioimmunoblastic T-cell lymphoma
508363|NCT00670917|cutaneous B-cell non-Hodgkin lymphoma
508364|NCT00670917|recurrent cutaneous T-cell non-Hodgkin lymphoma
508365|NCT00670917|stage I cutaneous T-cell non-Hodgkin lymphoma
508366|NCT00670917|stage II cutaneous T-cell non-Hodgkin lymphoma
508367|NCT00670917|stage III cutaneous T-cell non-Hodgkin lymphoma
508368|NCT00670917|stage IV cutaneous T-cell non-Hodgkin lymphoma
508369|NCT00670917|recurrent mycosis fungoides/Sezary syndrome
508370|NCT00670917|stage I mycosis fungoides/Sezary syndrome
508371|NCT00670917|stage II mycosis fungoides/Sezary syndrome
508372|NCT00670917|stage III mycosis fungoides/Sezary syndrome
508373|NCT00670917|stage IV mycosis fungoides/Sezary syndrome
508374|NCT00670917|adult grade III lymphomatoid granulomatosis
508375|NCT00670917|adult nasal type extranodal NK/T-cell lymphoma
508376|NCT00670917|Waldenstrom macroglobulinemia
508377|NCT00670917|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
508378|NCT00670917|nodal marginal zone B-cell lymphoma
508379|NCT00670917|splenic marginal zone lymphoma
508380|NCT00670917|contiguous stage II adult Burkitt lymphoma
508381|NCT00670917|contiguous stage II adult diffuse large cell lymphoma
508382|NCT00670917|contiguous stage II adult diffuse mixed cell lymphoma
508383|NCT00670917|contiguous stage II adult diffuse small cleaved cell lymphoma
508384|NCT00670917|contiguous stage II adult immunoblastic large cell lymphoma
508385|NCT00670917|contiguous stage II adult lymphoblastic lymphoma
508386|NCT00670917|contiguous stage II grade 1 follicular lymphoma
508387|NCT00670917|contiguous stage II grade 2 follicular lymphoma
508388|NCT00670917|contiguous stage II grade 3 follicular lymphoma
508389|NCT00670917|contiguous stage II mantle cell lymphoma
508390|NCT00670917|contiguous stage II marginal zone lymphoma
508391|NCT00670917|stage I adult Burkitt lymphoma
508392|NCT00670917|stage I adult diffuse large cell lymphoma
508393|NCT00670917|stage I adult diffuse mixed cell lymphoma
508394|NCT00670917|stage I adult diffuse small cleaved cell lymphoma
508395|NCT00670917|stage I adult immunoblastic large cell lymphoma
508396|NCT00670917|stage I adult lymphoblastic lymphoma
508397|NCT00670917|stage I grade 1 follicular lymphoma
508398|NCT00670917|stage I grade 2 follicular lymphoma
508399|NCT00670917|stage I grade 3 follicular lymphoma
508400|NCT00670917|stage I mantle cell lymphoma
508401|NCT00670917|stage I marginal zone lymphoma
508402|NCT00670917|stage I small lymphocytic lymphoma
508403|NCT00670917|noncontiguous stage II adult Burkitt lymphoma
508404|NCT00670917|noncontiguous stage II adult diffuse large cell lymphoma
508405|NCT00670917|noncontiguous stage II adult diffuse mixed cell lymphoma
508406|NCT00670917|noncontiguous stage II adult diffuse small cleaved cell lymphoma
508407|NCT00670917|noncontiguous stage II adult immunoblastic large cell lymphoma
508408|NCT00670917|noncontiguous stage II adult lymphoblastic lymphoma
508409|NCT00670917|noncontiguous stage II grade 1 follicular lymphoma
508410|NCT00670917|noncontiguous stage II grade 2 follicular lymphoma
508411|NCT00670917|noncontiguous stage II grade 3 follicular lymphoma
508412|NCT00670917|noncontiguous stage II mantle cell lymphoma
508413|NCT00670917|noncontiguous stage II marginal zone lymphoma
508414|NCT00670917|noncontiguous stage II small lymphocytic lymphoma
508415|NCT00670917|stage III adult Burkitt lymphoma
508524|NCT00670657|Ambisome
508416|NCT00670917|stage III adult diffuse large cell lymphoma
508417|NCT00670917|stage III adult diffuse mixed cell lymphoma
508418|NCT00670917|stage III adult diffuse small cleaved cell lymphoma
508419|NCT00670917|stage III adult immunoblastic large cell lymphoma
508420|NCT00670917|stage III adult lymphoblastic lymphoma
508421|NCT00670917|stage III grade 1 follicular lymphoma
508422|NCT00670917|stage III grade 2 follicular lymphoma
508423|NCT00670917|stage III grade 3 follicular lymphoma
508424|NCT00670917|stage III mantle cell lymphoma
508425|NCT00670917|stage III marginal zone lymphoma
508426|NCT00670917|stage III small lymphocytic lymphoma
508427|NCT00670917|stage IV adult Burkitt lymphoma
508428|NCT00670917|stage IV adult diffuse large cell lymphoma
508429|NCT00670917|stage IV adult diffuse mixed cell lymphoma
508430|NCT00670917|stage IV adult diffuse small cleaved cell lymphoma
508431|NCT00670917|stage IV adult immunoblastic large cell lymphoma
508432|NCT00670917|stage IV adult lymphoblastic lymphoma
508433|NCT00670917|stage IV grade 1 follicular lymphoma
508434|NCT00670917|stage IV grade 2 follicular lymphoma
508435|NCT00670917|stage IV grade 3 follicular lymphoma
508436|NCT00670917|stage IV mantle cell lymphoma
508437|NCT00670917|stage IV marginal zone lymphoma
508438|NCT00670917|stage IV small lymphocytic lymphoma
508439|NCT00670917|recurrent adult Burkitt lymphoma
508440|NCT00670917|recurrent adult diffuse large cell lymphoma
508441|NCT00670917|recurrent adult diffuse mixed cell lymphoma
508442|NCT00670917|recurrent adult diffuse small cleaved cell lymphoma
508443|NCT00670917|recurrent adult grade III lymphomatoid granulomatosis
508444|NCT00670917|recurrent adult immunoblastic large cell lymphoma
508445|NCT00670917|recurrent adult lymphoblastic lymphoma
508446|NCT00670917|recurrent grade 1 follicular lymphoma
508447|NCT00670917|recurrent grade 2 follicular lymphoma
508448|NCT00670917|recurrent grade 3 follicular lymphoma
508449|NCT00670917|recurrent mantle cell lymphoma
508450|NCT00670917|recurrent marginal zone lymphoma
508451|NCT00670917|recurrent small lymphocytic lymphoma
508452|NCT00670917|intraocular lymphoma
508453|NCT00670917|primary central nervous system non-Hodgkin lymphoma
508454|NCT00670917|primary central nervous system Hodgkin lymphoma
508455|NCT00670917|post-transplant lymphoproliferative disorder
508456|NCT00670917|chronic eosinophilic leukemia
508457|NCT00670917|chronic neutrophilic leukemia
508458|NCT00670917|primary myelofibrosis
508459|NCT00670917|essential thrombocythemia
508460|NCT00670917|polycythemia vera
508461|NCT00670917|extramedullary plasmacytoma
508462|NCT00670917|isolated plasmacytoma of bone
508463|NCT00670917|monoclonal gammopathy of undetermined significance
508464|NCT00670917|stage I multiple myeloma
508465|NCT00670917|stage II multiple myeloma
508466|NCT00670917|stage III multiple myeloma
508467|NCT00670917|primary systemic amyloidosis
508468|NCT00670917|refractory multiple myeloma
508469|NCT00670917|de novo myelodysplastic syndromes
508470|NCT00670917|previously treated myelodysplastic syndromes
508471|NCT00670917|secondary myelodysplastic syndromes
508472|NCT00670917|myelodysplastic/myeloproliferative neoplasm, unclassifiable
508473|NCT00670904|Smoking cessation
508474|NCT00670904|Pharmacist-delivered
508475|NCT00670865|Hospitalization
508476|NCT00670865|Continuity of care
508477|NCT00670865|Discharge summary
508478|NCT00670865|Quality improvement
508479|NCT00670865|Medical records systems
508480|NCT00670865|Hospital information systems
508481|NCT00670852|Glenoid component
508482|NCT00670852|radiolucent lines
508483|NCT00670852|Glenoid loosening
508484|NCT00670852|glenohumeral arthritis
508485|NCT00670852|autologous bone graft
508486|NCT00670839|Hepatitis B vaccination
508487|NCT00670839|GenHevac-B Pasteur
508488|NCT00670839|HIV infection
508489|NCT00670826|Patient warming
508490|NCT00670813|Depression
508491|NCT00670813|(total) sleep deprivation
508492|NCT00670813|Modafinil
508493|NCT00670813|polysomnography sleep
508494|NCT00670800|Polycystic Ovary Syndrome
508495|NCT00670800|Insulin resistance
508496|NCT00670800|Metformin
508497|NCT00670800|Brain function
508498|NCT00670787|Hypertension
508499|NCT00670787|combination pill
508500|NCT00670787|compliance
508501|NCT00670774|Kidney
508502|NCT00670774|Transplant
508503|NCT00670774|donor
508504|NCT00670761|misoprostol
508505|NCT00670761|incomplete abortion
508506|NCT00670761|sublingual
508507|NCT00670761|postabortion care
508508|NCT00670761|MVA
508509|NCT00670748|Metastatic Cancer
508510|NCT00670748|Gene Therapy
508511|NCT00670748|Immunotherapy
508512|NCT00670748|Tumor Regression
508513|NCT00670748|Metastatic Melanoma
508514|NCT00670748|Metastatic Renal Cell Cancer
508515|NCT00670735|Pediatric Hydrocephalus
508516|NCT00670709|encephalography
508517|NCT00670709|quantitative
508518|NCT00670709|biomarkers
508519|NCT00670696|Topical anesthesia
508520|NCT00670696|Rapydan
508521|NCT00670696|Topical anaesthesia for venous cannulation
508522|NCT00670657|candidemia
508525|NCT00670657|liposomal amphotericin B
508526|NCT00670644|male breast cancer
508527|NCT00670644|recurrent breast cancer
508528|NCT00670644|stage I breast cancer
508529|NCT00670644|stage II breast cancer
508530|NCT00670644|stage IIIA breast cancer
508531|NCT00670644|stage IIIB breast cancer
508532|NCT00670644|stage IIIC breast cancer
508533|NCT00670644|stage IV breast cancer
508534|NCT00670631|Multiple Myeloma
508535|NCT00670631|myeloma
508536|NCT00670605|unspecified adult solid tumor, protocol specific
508537|NCT00670605|unspecified childhood solid tumor, protocol specific
508538|NCT00670592|HCD122
508539|NCT00670592|CD40
508540|NCT00670592|NHL
508541|NCT00670592|HL
508542|NCT00670579|TIVAD
508543|NCT00670579|complications
508544|NCT00670579|nursing
508545|NCT00670579|cystic fibrosis
508546|NCT00670579|implanted
508547|NCT00670553|Prostate,
508548|NCT00670553|Head & Neck,
508549|NCT00670553|Esophageal
508550|NCT00670540|pulmonary embolism
508551|NCT00670540|duplex ultrasound examination
508552|NCT00670540|recurrence
508553|NCT00670527|Prostate cancer
508554|NCT00670527|[18F] Fluorocholine PET/CT
508555|NCT00670527|FCH
508556|NCT00670527|lymph node metastasis
508557|NCT00670527|staging
508558|NCT00670527|sensitivity
508559|NCT00670527|specificity
508560|NCT00670527|PROPET
508561|NCT00670514|RCT
508562|NCT00670514|tobacco
508563|NCT00670514|treatment intensity
508564|NCT00670514|dentistry
508565|NCT00670514|follow-up
508566|NCT00670514|Smoking cessation
508567|NCT00670514|Cost effectiveness
508568|NCT00670475|osteoarthritis
508569|NCT00670475|Knee
508570|NCT00670475|virgin olive oil
508571|NCT00670475|piroxicam
508572|NCT00670475|Topical
508573|NCT00670462|obesity, weight loss, treatment
508574|NCT00670449|FTY720
508575|NCT00670449|multiple sclerosis
508576|NCT00670449|MS
508577|NCT00670423|Tacrolimus
508578|NCT00670423|Sirolimus
508579|NCT00670423|Bortezomib
508580|NCT00670423|Acute Graft Versus Host Disease
508581|NCT00670423|Allogeneic Peripheral Blood Stem Cell Transplantation
508582|NCT00670410|Neuroblastoma
508583|NCT00670410|Autologous Transplant
508584|NCT00670410|Allogeneic Transplant
508585|NCT00670410|Immunotherapy
508586|NCT00670397|stage I squamous cell carcinoma of the lip and oral cavity
508587|NCT00670397|recurrent squamous cell carcinoma of the lip and oral cavity
508588|NCT00670397|stage 0 lip and oral cavity cancer
508589|NCT00670384|SLIT
508590|NCT00670384|Immunotherapy
508591|NCT00670384|Short ragweed
508592|NCT00670384|SAR
508593|NCT00670384|Seasonal allergic rhinitis
508594|NCT00670371|Caregiver burden
508595|NCT00670358|contiguous stage II adult diffuse large cell lymphoma
508596|NCT00670358|noncontiguous stage II adult diffuse large cell lymphoma
508597|NCT00670358|stage III adult diffuse large cell lymphoma
508598|NCT00670358|stage IV adult diffuse large cell lymphoma
508599|NCT00670358|contiguous stage II grade 3 follicular lymphoma
508600|NCT00670358|noncontiguous stage II grade 3 follicular lymphoma
508601|NCT00670358|stage III grade 3 follicular lymphoma
508602|NCT00670358|stage IV grade 3 follicular lymphoma
508603|NCT00670345|tranexamic acid
508604|NCT00670345|prostatectomy
508605|NCT00670345|surgery
508606|NCT00670332|coronary artery disease
508607|NCT00670332|echocardiography
508608|NCT00670332|cardiac imaging
508609|NCT00670332|heart disease
508610|NCT00670332|ultrasound contrast agent
508611|NCT00670332|prognosis
508612|NCT00670306|Cetrorelix
508613|NCT00670306|BPH
508614|NCT00670293|Anorexia Nervosa
508615|NCT00670293|PET Imaging
508616|NCT00670293|Dopamine
508617|NCT00670280|Neonatal Intensive Care Units
508618|NCT00670280|Infant Morbidity
508619|NCT00670280|Low Birth Weight
508620|NCT00670280|Low Income Populations
508621|NCT00670280|MCH Research
508622|NCT00670280|Respiratory Illnesses
508623|NCT00670280|Substance Exposed Infants
508624|NCT00670280|Counseling
508625|NCT00670267|Asthma
508626|NCT00670267|hyperresponsiveness
508627|NCT00670254|Sepsis
508628|NCT00670254|Septic
508629|NCT00670254|Shock
508630|NCT00670254|Glucocorticoids
508631|NCT00670254|Hydrocortisone
508632|NCT00670215|Prevention of infectious complications
508633|NCT00670215|transrectal needle biopsies of the prostate
508634|NCT00670215|TRNBP
508635|NCT00670202|Patients scheduled for elective carotid endarterectomy
508636|NCT00670163|Men Who Have Sex With Men
508637|NCT00670111|Heart failure
508638|NCT00670111|exercise capacity
508639|NCT00670111|ejection fraction
508640|NCT00670111|Heart failure normal ejection fraction
508641|NCT00670059|Single embryo transfer/ aneuploidy screening
508642|NCT00670046|recurrent prostate cancer
508643|NCT00670046|stage I prostate cancer
508644|NCT00670046|stage IIB prostate cancer
508645|NCT00670046|stage IIA prostate cancer
508646|NCT00670046|stage III prostate cancer
508647|NCT00670046|stage IV prostate cancer
508648|NCT00670033|IOP
508649|NCT00670033|Open-angle glaucoma
508650|NCT00670033|Ocular Hypertension
508651|NCT00670020|Women undergoing Cesarean section after the onset of labor
508652|NCT00670007|Alpha1-proteinase inhibitor deficiency
508653|NCT00670007|Chronic augmentation and maintenance therapy
508654|NCT00670007|Emphysema
508655|NCT00670007|Emphysema due to Alpha 1-proteinase inhibitor deficiency
508656|NCT00669994|UTI
508657|NCT00669994|Urinary Tract Infection
508658|NCT00669981|PTSD
508659|NCT00669981|Relationship Distress
508660|NCT00669981|Couple Therapy
508661|NCT00669968|PET myocardial perfusion imaging
508662|NCT00669968|Cardiac PET
508663|NCT00669968|Rubidium
508664|NCT00669968|Coronary Artery CT Angiogram
508665|NCT00669968|Coronary Flow Reserve
508666|NCT00669968|Adenosine stress test
508667|NCT00669955|H. Pylori
508668|NCT00669955|Quadruple therapy
508669|NCT00669955|Eradication rate
508670|NCT00669955|Multinational trial
508671|NCT00669955|Resistance to antibiotics
508672|NCT00669955|Subjects with confirmed Helicobacter Pylori infection
508673|NCT00669942|Rheumatoid Arthritis
508674|NCT00669929|Cost effectiveness analysis of rotavirus vaccination
508675|NCT00669916|Plaque psoriasis
508676|NCT00669890|AML
508677|NCT00669890|JMML
508678|NCT00669890|MDS
508679|NCT00669890|Allogenic Atem Cell Transplant
508680|NCT00669890|Gemtuzumab Ozogamicin
508681|NCT00669877|Burkitt's Lymphoma
508682|NCT00669877|Burkitt's Like Lymphoma
508683|NCT00669877|Leukemia
508684|NCT00669877|Hyper-CVAD
508685|NCT00669877|Rituximab
508686|NCT00669877|Methotrexate
508687|NCT00669877|Cytarabine
508688|NCT00669851|coronary artery disease
508689|NCT00669851|echocardiography
508690|NCT00669851|cardiac imaging
508691|NCT00669851|heart disease
508692|NCT00669851|ultrasound contrast agent
508693|NCT00669851|myocardial contrast enhancement
508694|NCT00669851|myocardial perfusion
508695|NCT00669838|Anesthesia, Local
508696|NCT00669838|Lidocaine
508697|NCT00669838|Dental care
508698|NCT00669838|Arrhythmias, Cardiac
508699|NCT00669838|Anxiety
508700|NCT00669825|Celiac Disease
508701|NCT00669812|small intestine lymphoma
508702|NCT00669812|stage I adult T-cell leukemia/lymphoma
508703|NCT00669812|stage II adult T-cell leukemia/lymphoma
508704|NCT00669812|stage III adult T-cell leukemia/lymphoma
508705|NCT00669812|stage IV adult T-cell leukemia/lymphoma
508706|NCT00669786|Ongoing Pregnancy Rate
508707|NCT00669760|cystic fibrosis
508708|NCT00669760|Staphylococcus aureus
508709|NCT00669760|persistent colonization-infection
508710|NCT00669760|clinical status
508711|NCT00669760|lung function
508712|NCT00669747|Ductal Carcinoma In Situ
508713|NCT00669747|DCIS
508714|NCT00669747|Breast Cancer
508715|NCT00669747|Carboplatin
508716|NCT00669747|Intraductal
508717|NCT00669721|osteoprotegerin
508718|NCT00669721|RANKL
508719|NCT00669721|heparin
508720|NCT00669721|hemodialysis
508721|NCT00669721|anticoagulation
508722|NCT00669721|vascular calcification
508723|NCT00669708|dry skin
508724|NCT00669708|cooling
508725|NCT00669708|itch
508726|NCT00669695|statins
508727|NCT00669695|cardiovascular risk
508728|NCT00669695|Obstructive sleep apnea syndrome (OSAS) patients
508729|NCT00669643|Leprosy
508730|NCT00669643|Communicable Diseases
508731|NCT00669643|Skin Diseases
508732|NCT00669643|Multidrug Therapy
508733|NCT00669643|MDT
508734|NCT00669643|Uniform Multidrug Therapy
508735|NCT00669643|U-MDT
508736|NCT00669630|Community-based Participatory Research (CBPR)
508737|NCT00669630|Vulnerable population
508738|NCT00669630|High-risk population
508739|NCT00669630|African-Americans
508740|NCT00669630|Health Disparities
508741|NCT00669630|Clinical Trial
508742|NCT00669617|chronic obstructive pulmonary disease
508743|NCT00669617|COPD
508744|NCT00669617|indacaterol
508745|NCT00669617|adults
508746|NCT00669604|Mother to child transmission of HIV
508747|NCT00669604|HIV infected children
508748|NCT00669591|breast cancer
508749|NCT00669591|docetaxel chemotherapy
508750|NCT00669591|bavituximab
508751|NCT00669591|monoclonal antibody
508752|NCT00669578|secondary myelofibrosis
508753|NCT00669578|polycythemia vera
508754|NCT00669578|essential thrombocythemia
508755|NCT00669578|primary myelofibrosis
508756|NCT00669565|Locally Advanced or Metastatic Breast Cancer
508757|NCT00669539|Amblyopia associated with strabismus
508758|NCT00669539|Refractive error
508759|NCT00669526|anxiety
508760|NCT00669526|depression
508761|NCT00669526|Major Depressive Disorder
508762|NCT00669526|child
508763|NCT00669526|adolescent
508764|NCT00669526|CBT
508765|NCT00669526|Cognitive-Behavioral Therapy
508766|NCT00669526|primary care
508767|NCT00669513|partial sleep deprivation
508768|NCT00669513|endothelial dysfunction
508769|NCT00669513|sympathetic activity
508770|NCT00669513|inflammation
508771|NCT00669500|dietary intake
508772|NCT00669500|genetic predisposition
508773|NCT00669500|body composition
508774|NCT00669487|HIV/AIDS patients
508775|NCT00669461|Constipation
508776|NCT00669461|Parkinson's Disease
508777|NCT00669448|Multiple chemical sensitivities
508778|NCT00669448|MCS
508779|NCT00669448|Mindfulness-based cognitive therapy
508780|NCT00669448|MBCT
508781|NCT00669448|Behavioural intervention
508782|NCT00669448|Stress
508783|NCT00669448|Illness perceptions
508784|NCT00669448|Pilot trial
508785|NCT00669435|Essential hypertension
508786|NCT00669435|Liver steatosis
508787|NCT00669422|Ovarian Cancer
508788|NCT00669422|Fallopian Tube Cancer
508789|NCT00669422|Peritoneal Cancer
508790|NCT00669422|Uterine Neoplasms
508791|NCT00669422|Vulvar Cancer
508792|NCT00669422|Endometrial Cancer
508793|NCT00669422|Cervical Cancer
508794|NCT00669422|Assay
508795|NCT00669422|Chemotherapy
508796|NCT00669422|Recurrent
508797|NCT00669422|Refractory
508798|NCT00669422|Persistent
508799|NCT00669422|Chemoresponse
508800|NCT00669422|Sensitivity
508801|NCT00669422|Precision Therapeutics
508802|NCT00669422|ChemoFx
508803|NCT00669409|monoclonal antibody
508804|NCT00669396|contraception
508805|NCT00669396|emergency contraception
508806|NCT00669396|pregnancy prevention after unprotected intercourse
508807|NCT00669383|premature delivery
508808|NCT00669383|respiratory distress syndrome
508809|NCT00669370|advanced gastric cancer
508810|NCT00669370|adenocarcinoma
508811|NCT00669357|End stage heart disease
508812|NCT00669344|cognition
508813|NCT00669344|stroke
508814|NCT00669344|VCI
508815|NCT00669344|VCIND
508816|NCT00669344|Cognitive Impairment, No Dementia
508817|NCT00669331|randomized clinical trial
508818|NCT00669331|mannitol
508819|NCT00669331|mucoactive
508820|NCT00669318|refractory chronic lymphocytic leukemia
508821|NCT00669318|recurrent small lymphocytic lymphoma
508822|NCT00669318|B-cell chronic lymphocytic leukemia
508823|NCT00669305|Genetics
508824|NCT00669305|Blood cells
508825|NCT00669305|Vector-mediated gene transfer
508826|NCT00669305|Bone marrow
508827|NCT00669305|CD34 cells
508828|NCT00669292|esophageal cancer
508829|NCT00669292|peptide
508830|NCT00669292|URLC10
508831|NCT00669292|TTK
508832|NCT00669292|CpG7909
508833|NCT00669214|Raptiva
508834|NCT00669214|Moderate plaque psoriasis
508835|NCT00669214|Severe plaque psoriasis
508836|NCT00669214|Scalp
508837|NCT00669201|cartilage
508838|NCT00669201|osteoarthritis
508839|NCT00669201|T2 mapping
508840|NCT00669201|MRI
508841|NCT00669201|Wrist
508842|NCT00669188|Patient Provider Interaction
508843|NCT00669188|Physician Training
508844|NCT00669188|Patient Provider Training
508845|NCT00669175|Naloxone
508846|NCT00669175|Neonate
508847|NCT00669175|Pain
508848|NCT00669149|ptca
508849|NCT00669149|antiaggregant therapy
508850|NCT00669149|anticoagulant therapy
508851|NCT00669136|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
508852|NCT00669136|AFP Immunization
508853|NCT00669123|Chondroitin sulphate
508854|NCT00669123|Knee osteoarthritis
508855|NCT00669123|Psoriasis
508856|NCT00669110|MDD
508857|NCT00669110|Depression
508858|NCT00669110|Pediatrics
508859|NCT00669110|Major Depressive Disorder
508860|NCT00669097|ADME
508861|NCT00669097|TKI258
508862|NCT00669097|RTKs inhibitor
508863|NCT00669097|PDGRF inhibitor
508864|NCT00669097|VEGFER inhibitor
508865|NCT00669084|Innate Immunity
508866|NCT00669084|Malaria
508867|NCT00669084|Plasmodium
508868|NCT00669084|Hemoglobinopathy
508869|NCT00669084|G6PD Deficiency
508870|NCT00669058|hygiene
508871|NCT00669045|TNKase
508872|NCT00669045|AMI
508873|NCT00669006|neuropathic pain
508874|NCT00669006|database
508875|NCT00669006|prospective
508876|NCT00669006|national
508877|NCT00668980|Down syndrome
508878|NCT00668980|symbolic representation
508879|NCT00668980|gestures
508880|NCT00668980|expressive language development
508881|NCT00668967|Cardiovascular Diseases
508882|NCT00668967|Hypertension
508883|NCT00668954|Diabetes
508884|NCT00668954|Pomegranate
508885|NCT00668954|Biomarkers
508886|NCT00668954|Antioxidant
508887|NCT00668941|Bone Density
508888|NCT00668941|Bone Turnover
508889|NCT00668941|Histomorphometry
508890|NCT00668902|CYP2C19
508891|NCT00668902|Pantoprazole
508892|NCT00668902|Genotype
508893|NCT00668902|Pharmacokinetics
508894|NCT00668902|Metabolism
508895|NCT00668889|Hygiene
508896|NCT00668876|immunonutrition
508897|NCT00668876|pancreaticoduodenectomy
508898|NCT00668876|Th1
508899|NCT00668876|Th2
508900|NCT00668876|Th17
508901|NCT00668837|Paliperidone
508902|NCT00668837|schizophrenia
508903|NCT00668824|Congenital Heart Disease (CHD)
508904|NCT00668811|thyroid cancer
508905|NCT00668811|metastatic thyroid cancer
508906|NCT00668811|differentiated thyroid cancer
508907|NCT00668811|papillary thyroid cancer
508908|NCT00668811|follicular thyroid cancer
508909|NCT00668811|Histologically confirmed
508910|NCT00668811|metastatic stage 2,stage 3, or stage 4 differentiated thyroid cancer
508911|NCT00668798|cytomegalovirus breast milk preterm infants transmission
508912|NCT00668798|transmission of CMV via thawed frozen breast milk
508913|NCT00668785|Ranibizumab
508914|NCT00668785|Proliferative Diabetic Retinopathy
508915|NCT00668785|Macular Edema following Panretinal Photocoagulation
508916|NCT00668785|Safety and Efficacy
508917|NCT00668785|Intravitreal Injection
508918|NCT00668759|atrial fibrillation
508919|NCT00668759|atrial fib
508920|NCT00668759|AF
508921|NCT00668746|chronic periodontitis, antibiotic resistance
508922|NCT00668733|Actinic keratoses
508923|NCT00668733|Dermatologic disease
508924|NCT00668720|tinnitus
508925|NCT00668720|transcranial magnetic stimulation
508926|NCT00668707|melatonin
508927|NCT00668707|natural health product (NHP)
508928|NCT00668707|lung cancer
508929|NCT00668707|complementary and alternative medicine (CAM)
508930|NCT00668707|randomized clinical trial
508931|NCT00668694|Psychosocial stimulation in addition to iron supplementation will improve mental and psychomotor development, language, behavior and growth of IDA infants.
508932|NCT00668694|With the addition of stimulation IDA infants will catch up to the non-anemic infants.
508933|NCT00668681|Abdominal Aortic Aneurysm
508934|NCT00668655|Rosacea, metronidazole
508935|NCT00668629|Hygiene
508936|NCT00668616|breast cancer with 1-3 afflicted axillary lymph nodes
508937|NCT00668603|Postmenopausal vasomotor symptoms
508938|NCT00668603|Hot flush
508939|NCT00668603|Vascular function
508940|NCT00668603|Cardiac function
508941|NCT00668603|Cardiovascular risk factor
508942|NCT00668590|Diabetes
508943|NCT00668577|Hygiene
508944|NCT00668564|Inborn errors of metabolism
508945|NCT00668564|Sphingolipidoses
508946|NCT00668564|Recessive Leukodystrophies- GLD, Krabbe disease, MLD
508947|NCT00668564|Peroxisomal Disorders
508948|NCT00668564|Wolman syndrome
508949|NCT00668564|Niemann-Pick B patients
508950|NCT00668564|Niemann-Pick C subtype 2
508951|NCT00668551|Parkinson disease
508952|NCT00668551|Telemedicine
508953|NCT00668538|Miconazole
508954|NCT00668538|CYP1A2
508955|NCT00668538|CYP3A4
508956|NCT00668538|Women
508957|NCT00668538|Healthy Subjects
508958|NCT00668525|Depression
508959|NCT00668525|Major Depressive Disorder
508960|NCT00668525|Escitalopram
508961|NCT00668512|metastatic cutaneous melanoma
508962|NCT00668512|alpha-gal glycolipids
508963|NCT00668486|Hygiene
508964|NCT00668473|systemic sclerosis angiogenesis
508965|NCT00668460|hygiene
508966|NCT00668447|bone density
508967|NCT00668447|bone loss
508968|NCT00668447|postmenopausal
508969|NCT00668434|Back Pain
508970|NCT00668434|Leg Pain
508971|NCT00668421|Myelofibrosis
508972|NCT00668421|Essential Thrombocythemia
508973|NCT00668421|Polycythemia Vera
508974|NCT00668421|JAK2 V617F Mutation
508975|NCT00668421|Lestaurtinib
508976|NCT00668408|OTLT
508977|NCT00668408|COPD
508978|NCT00668408|CHRONIC HYPOXEMIA
508979|NCT00668408|CHF
508980|NCT00668395|CYP2B6
508981|NCT00668395|Efavirenz
508982|NCT00668395|Pharmacokinetics
508983|NCT00668395|Pharmacogenetics
508984|NCT00668395|Drug-Interactions
508985|NCT00668382|Cancerous solid tumors
508986|NCT00668382|Alpha-Gal Glycosphingolipids
508987|NCT00668369|Liver Transplantation
508988|NCT00668369|Tolerance
508989|NCT00668369|Hepatitis C virus infection
508990|NCT00668369|Immune responses
508991|NCT00668369|Allograft tolerance
508992|NCT00668369|Immunosuppression weaning
508993|NCT00668369|Immunosuppression minimization
508994|NCT00668356|HIV disease in children
508995|NCT00668356|HIV
508996|NCT00668356|children
508997|NCT00668356|didanosine
508998|NCT00668356|bioequivalence
508999|NCT00668356|pharmacokinetics
509000|NCT00668356|treatment experienced
509001|NCT00668343|edss attack
509002|NCT00668330|Bone mineral density
509003|NCT00668330|ibandronate
509004|NCT00668330|alfacalcidol
509005|NCT00668317|Hyper-responsiveness, reflux cough
509006|NCT00668304|Sinusitis
509007|NCT00668291|Endocrinology, CARNEY Complex,
509008|NCT00668291|primary pigmented nodular adrenocortical disease (PPNAD),
509009|NCT00668291|PRKAR1A
509010|NCT00668278|Supraglottic airway
509011|NCT00668278|I-gel
509012|NCT00668278|Laryngeal mask
509013|NCT00668278|Controlled ventilation
509014|NCT00668278|Peak airway pressure
509015|NCT00668278|Seal pressure
509016|NCT00668278|Anaesthesia
509017|NCT00668278|Surgery
509018|NCT00668265|Generalized Anxiety Disorder
509019|NCT00668265|Opiate Dependence
509020|NCT00668265|Methadone-Maintenance
509021|NCT00668265|Drug Addiction Treatment
509022|NCT00668252|endothelial progenitor cells
509023|NCT00668252|estrogen
509024|NCT00668252|menopause
509025|NCT00668252|cardiovascular risk
509026|NCT00668239|diffuse macular oedema
509027|NCT00668239|type 2 diabetes mellitus
509028|NCT00668239|laser therapy
509029|NCT00668226|Hygiene
509030|NCT00668213|Macular Degeneration
509031|NCT00668200|Paget's
509032|NCT00668200|hypocalcemia
509033|NCT00668200|zoledronic acid
509034|NCT00668200|serum calcium
509035|NCT00668187|Tay-Sachs disease
509036|NCT00668187|Sandhoff disease
509037|NCT00668187|Late Onset Tay-Sachs disease
509038|NCT00668187|LOTS
509039|NCT00668187|hexosaminidase A deficiency
509040|NCT00668187|hexosaminidase A and B deficiency
509041|NCT00668187|infantile Tay-Sachs disease
509042|NCT00668187|adult-onset Tay-Sachs disease
509043|NCT00668187|prospective
509044|NCT00668187|natural history
509045|NCT00668187|GM1 gangliosidosis
509046|NCT00668187|gangliosidoses
509047|NCT00668187|β-galactosidase
509048|NCT00668187|β-galactosidase deficiency
509049|NCT00668187|hexosaminidase
509050|NCT00668187|hexosaminidase deficiency
509051|NCT00668187|Tay-Sachs
509052|NCT00668187|Sandhoff
509053|NCT00668187|juvenile Tay-Sachs
509054|NCT00668187|juvenile Tay-Sachs disease
509055|NCT00668187|late onset Tay-Sachs
509056|NCT00668187|juvenile Sandhoff
509057|NCT00668187|juvenile Sandhoff disease
509058|NCT00668187|GM2 gangliosidosis
509059|NCT00668148|Sarcoma
509060|NCT00668148|Ewing's sarcoma / peripheral neuroectodermal tumor (PNET);
509061|NCT00668148|rhabdomyosarcoma;
509062|NCT00668148|leiomyosarcoma;
509063|NCT00668148|adipocytic sarcoma
509064|NCT00668148|synovial sarcoma
509065|NCT00668135|Erectile Dysfunction
509066|NCT00668135|Vardenafil
509067|NCT00668109|Erectile Dysfunction
509068|NCT00668109|Diabetes mellitus
509069|NCT00668109|Hypertension
509070|NCT00668109|Hyperlipidemia
509071|NCT00668109|Vardenafil
509072|NCT00668096|Erectile Dysfunction
509073|NCT00668096|PDE5 inhibitors
509074|NCT00668083|second line
509075|NCT00668083|Prostate Cancer
509076|NCT00668083|bicalutamide
509077|NCT00668083|biochemical relapse/progression in patients with Prostate Cancer treated with bicalutamide 150mg
509078|NCT00668070|NASH
509079|NCT00668070|Chronic liver disease
509080|NCT00668057|Male Erectile Dysfunction
509081|NCT00668044|Ciprofloxacin regimen in compromised patients
509082|NCT00668044|Ciprofloxacin
509083|NCT00668044|Burned patients
509084|NCT00668031|Transfusion requirements
509085|NCT00668031|Hip replacement surgery
509086|NCT00668031|Prevention of blood loss
509087|NCT00668031|Bloodloss
509088|NCT00668018|Male Erectile Dysfunction
509089|NCT00668018|Vardenafil
509090|NCT00668005|Erectile Dysfunction
509091|NCT00668005|Arterial hypertension
509092|NCT00668005|Vardenafil
509093|NCT00667992|Asthma hyperreactivity
509094|NCT00667979|Erectile Dysfunction
509095|NCT00667979|Vardenafil
509096|NCT00667966|Spinal cord injury
509097|NCT00667966|Urodynamic
509098|NCT00667966|Erectile dysfunction
509099|NCT00667966|Vardenafil
509100|NCT00667953|Temzolomide
509101|NCT00667953|Gleevec
509102|NCT00667953|Melanoma
509103|NCT00667953|Advanced melanoma
509104|NCT00667953|Phase II
509105|NCT00667940|Medical education
509106|NCT00667940|faculty development
509107|NCT00667940|rater training
509108|NCT00667940|clinical competence
509109|NCT00667940|assessment
509110|NCT00667927|Autologous bone marrow transplant
509111|NCT00667927|gene marking
509112|NCT00667914|Hip-unit
509113|NCT00667914|Geriatric care
509114|NCT00667914|Mobility
509115|NCT00667914|Site of residence
509116|NCT00667901|stage III melanoma
509117|NCT00667901|stage IV melanoma
509118|NCT00667888|Prostate Cancer
509119|NCT00667888|Radiation
509120|NCT00667888|Radiotherapy
509121|NCT00667888|Intensity Modulated Radiotherapy
509122|NCT00667888|IMRT
509123|NCT00667888|Hypofractionated Intensity Modulated Radiotherapy
509124|NCT00667888|HIMRT
509125|NCT00667875|Alcohol Dependence
509126|NCT00667875|Alcoholism
509127|NCT00667875|Naltrexone
509128|NCT00667875|Aripiprazole
509129|NCT00667875|Substance Abuse
509130|NCT00667862|Prostate
509131|NCT00667862|Cancer
509132|NCT00667862|Adenocarcinoma
509133|NCT00667862|Prostate-Specific Antigen
509134|NCT00667862|metastatic
509135|NCT00667862|male
509136|NCT00667862|HRPC
509137|NCT00667862|DACi
509138|NCT00667849|Tibia
509139|NCT00667836|Neurofibromatosis Type 1
509140|NCT00667836|NF1
509141|NCT00667836|Spinal Anomalies
509142|NCT00667823|SERAPHIN
509143|NCT00667823|Pulmonary Arterial Hypertension
509144|NCT00667823|ACT-064992
509145|NCT00667810|antibody
509146|NCT00667810|immunotherapy
509147|NCT00667797|Asthma
509148|NCT00667797|COPD
509149|NCT00667797|chronic emphysema
509150|NCT00667797|chronic bronchitis
509151|NCT00667784|pediatric stem cell donor
509152|NCT00667784|emotional sequelae
509153|NCT00667784|physical sequelae
509154|NCT00667784|psychological consequences of minor donation
509155|NCT00667784|Bone Marrow Transplantation
509156|NCT00667784|Questionnaire
509157|NCT00667784|Survey
509158|NCT00667784|Sibling Donor
509159|NCT00667784|Stem Cell Transplant
509160|NCT00667784|Well-Being
509161|NCT00667771|Alcohol
509162|NCT00667771|Naltrexone
509163|NCT00667771|fMRI
509164|NCT00667771|Alcoholism
509165|NCT00667771|Alcoholics
509166|NCT00667771|Alcohol Dependence
509167|NCT00667745|Lithium
509168|NCT00667745|Symptoms
509169|NCT00667745|Medication Changes
509170|NCT00667732|diabetes
509171|NCT00667732|insulin
509172|NCT00667732|byetta
509173|NCT00667732|glucose
509174|NCT00667732|blood sugar
509175|NCT00667732|metformin
509176|NCT00667732|A1c
509177|NCT00667719|essential hypertension
509178|NCT00667719|high blood pressure
509179|NCT00667693|intubation
509180|NCT00667693|obese
509181|NCT00667680|tDCS, major depression
509182|NCT00667667|whole body vibration
509183|NCT00667667|exercise
509184|NCT00667667|postmenopausal
509185|NCT00667667|BMD
509186|NCT00667667|bone
509187|NCT00667667|elderly females
509188|NCT00667667|Caucasian race
509189|NCT00667654|Osteoarthritis, Knee
509190|NCT00667641|unspecified adult solid tumor, protocol specific
509191|NCT00667641|recurrent breast cancer
509192|NCT00667641|stage IV breast cancer
509193|NCT00667641|recurrent prostate cancer
509194|NCT00667641|stage IV prostate cancer
509195|NCT00667641|recurrent colon cancer
509196|NCT00667641|stage IV colon cancer
509197|NCT00667641|recurrent pancreatic cancer
509198|NCT00667641|stage IV pancreatic cancer
509199|NCT00667641|recurrent ovarian epithelial cancer
509200|NCT00667641|stage IV ovarian epithelial cancer
509201|NCT00667641|recurrent ovarian germ cell tumor
509202|NCT00667641|stage IV ovarian germ cell tumor
509203|NCT00667641|recurrent non-small cell lung cancer
509204|NCT00667641|stage IV non-small cell lung cancer
509205|NCT00667641|recurrent melanoma
509206|NCT00667641|stage IV melanoma
509207|NCT00667641|stage IV papillary thyroid cancer
509208|NCT00667641|recurrent thyroid cancer
509209|NCT00667615|vorinostat
509210|NCT00667615|rituximab
509211|NCT00667615|cyclophosphamide
509212|NCT00667615|etoposide
509213|NCT00667615|prednisone
509214|NCT00667615|Quality of life
509215|NCT00667615|08-045
509216|NCT00667602|Meningococcal
509217|NCT00667602|ACWY
509218|NCT00667602|Conjugate Vaccine
509219|NCT00667602|Meningitis
509220|NCT00667602|Toddlers
509221|NCT00667602|Infants
509222|NCT00667602|Concomitant Vaccination
509223|NCT00667589|sorafenib
509224|NCT00667589|rash
509225|NCT00667589|hand foot skin reaction
509226|NCT00667576|chronic kidney disease
509227|NCT00667576|secondary hyperparathyroidism
509228|NCT00667576|hemodialysis
509229|NCT00667576|paricalcitol
509230|NCT00667576|maxacalcitol
509231|NCT00667563|human papilloma virus infection
509232|NCT00667563|cervical cancer
509233|NCT00667563|cervical intraepithelial neoplasia
509234|NCT00667563|HIV infection
509235|NCT00667550|Lower urinary tract symptoms
509236|NCT00667550|Colorectal disorders
509237|NCT00667550|Urinary incontinence
509238|NCT00667550|Fecal incontinence
509239|NCT00667550|Voiding dysfunction
509240|NCT00667550|Urgency frequency
509241|NCT00667550|Sexual dysfunction
509242|NCT00667550|Colorectal malignancies
509243|NCT00667550|Inflammatory bowel disease
509244|NCT00667524|Eosinophilic Esophagitis
509245|NCT00667524|Dysphagia
509246|NCT00667524|Esophageal bougienage
509247|NCT00667524|Esophageal Dilation
509248|NCT00667511|ESRD
509249|NCT00667511|End Stage Renal Disease
509250|NCT00667511|Daily Hemodialysis
509251|NCT00667511|Nocturnal Hemodialysis
509252|NCT00667511|Hemodialysis
509253|NCT00667511|Kidney Failure
509254|NCT00667511|Kidney Disease
509255|NCT00667498|Pediatric Obesity
509256|NCT00667498|Insulin Resistance
509257|NCT00667498|Hyperinsulinemia
509258|NCT00667498|Metformin
509259|NCT00667498|Glucose Tolerance
509260|NCT00667498|Microalbuminuria
509261|NCT00667498|Adolescents
509262|NCT00667498|Visceral Fat
509263|NCT00667472|port wine stain birthmarks
509264|NCT00667459|Cervical Disc
509265|NCT00667446|GnRH analog
509266|NCT00667446|Luteinizing hormone (LH)
509267|NCT00667446|Gonadotrophin-releasing hormone agonist(GnRHa)
509268|NCT00667446|Suppression of LH
509269|NCT00667446|Gonadotrophin-releasing hormone (GnRH)
509270|NCT00667446|CPP
509271|NCT00667446|Leuprolide acetate
509272|NCT00667446|Central Precocious Puberty
509273|NCT00667446|Depot formulation
509274|NCT00667446|Lupron
509275|NCT00667446|Tanner staging
509276|NCT00667446|Pediatrics
509277|NCT00667433|HIV
509278|NCT00667433|African American
509279|NCT00667433|treatment naïve
509280|NCT00667420|gastric
509281|NCT00667420|esophageal
509282|NCT00667420|panitumumab
509283|NCT00667407|Asthma
509284|NCT00667394|Brain Tumor
509285|NCT00667394|Chemotherapy
509286|NCT00667394|Radiation
509287|NCT00667394|Anti-Angiogenesis
509288|NCT00667394|Glioblastoma
509289|NCT00667394|Glioma
509290|NCT00667381|Ultrasound guidance
509291|NCT00667381|Vascular access
509292|NCT00667381|Vascular complications
509293|NCT00667368|bacterial vaginosis, women, chlamydia, gonorrhea, mentronidazole, vaginal, children
509294|NCT00667355|Ankylosing Spondylitis
509295|NCT00667329|Waldenstrom's Macroglobulinemia
509296|NCT00667329|Lymphoma
509297|NCT00667329|2CdA
509298|NCT00667329|Cladribine
509299|NCT00667329|Leustatin
509300|NCT00667329|Cyclophosphamide
509301|NCT00667329|Cytoxan
509302|NCT00667329|Neosar
509303|NCT00667329|Rituxan
509304|NCT00667329|Rituximab
509305|NCT00667316|low back pain
509306|NCT00667316|workers
509307|NCT00667316|disability
509308|NCT00667316|sick leave
509309|NCT00667303|Hematopoietic stem cell transplant
509310|NCT00667290|functional ability
509311|NCT00667290|gait
509312|NCT00667290|musculoskeletal disorder therapy
509313|NCT00667290|peripheral blood vessel disorder
509314|NCT00667277|Myelofibrosis
509315|NCT00667277|Idiopathic
509316|NCT00667277|Bevacizumab
509317|NCT00667277|Avastin
509318|NCT00667277|bone marrow fibrosis
509319|NCT00667277|bone marrow angiogenesis
509320|NCT00667277|JAK2
509321|NCT00667264|pain
509322|NCT00667264|phantom limb
509323|NCT00667264|stump pain
509324|NCT00667264|catheter
509325|NCT00667264|nerve block
509326|NCT00667264|peripheral nerve block
509327|NCT00667264|ucsd
509328|NCT00667264|Post-amputation phantom limb or stump pain
509329|NCT00667251|recurrent breast cancer
509330|NCT00667251|HER2-positive breast cancer
509331|NCT00667251|stage IV breast cancer
509332|NCT00667212|anger
509333|NCT00667212|intermittent
509334|NCT00667212|explosive
509335|NCT00667199|Hormone Refractory Prostate Cancer
509336|NCT00667199|Bone Metastases
509337|NCT00667199|Radium-223
509338|NCT00667199|Palliation of bone pain
509339|NCT00667186|HIV
509340|NCT00667186|Prevention
509341|NCT00667186|Public Health
509342|NCT00667186|Screening
509343|NCT00667160|Mild Atopic Dermatitis
509344|NCT00667160|Protopic
509345|NCT00667160|Pediatric
509346|NCT00667134|systemic sclerosis autoantibodies
509347|NCT00667121|psychosocial effects of cancer and its treatment
509348|NCT00667121|breast cancer
509349|NCT00667121|hot flashes
509350|NCT00667121|depression
509351|NCT00667095|OAB
509352|NCT00667095|Over Active Bladder
509353|NCT00667095|overactive bladder
509354|NCT00667095|Urinary Urge Incontinence
509355|NCT00667095|Urinary Incontinence
509356|NCT00667095|Botox
509357|NCT00667095|DMSO
509358|NCT00667095|bladder instillation
509359|NCT00667095|instillation
509360|NCT00667095|detrusor hyperreflexia
509361|NCT00667095|urge incontinence
509362|NCT00667082|Non small Cell Lung Cancer
509363|NCT00667082|Pancreatic Cancer
509364|NCT00667082|Melanoma
509365|NCT00667082|Lymphoma
509366|NCT00667082|Multiple Myeloma
509367|NCT00667069|adenocarcinoma of the prostate
509368|NCT00667069|stage III prostate cancer
509369|NCT00667069|stage IV prostate cancer
509370|NCT00667056|Chronic Allergic Contact Dermatitis
509371|NCT00667056|Protopic
509372|NCT00667043|therapeutic hypothermia
509373|NCT00667043|cardiac arrest
509374|NCT00667043|sedation
509375|NCT00667043|remifentanil
509376|NCT00667043|propofol
509377|NCT00667043|fentanyl
509378|NCT00667043|midazolam
509379|NCT00667030|Inflammation
509380|NCT00667030|Aging
509381|NCT00667030|Metabolism
509382|NCT00667030|Exercise
509383|NCT00667017|recurrent mycosis fungoides/Sezary syndrome
509822|NCT00665769|chronic lung disease
509384|NCT00667017|recurrent cutaneous T-cell non-Hodgkin lymphoma
509385|NCT00666991|ovarian cancer
509386|NCT00666991|Mullerian tumors
509387|NCT00666991|peritoneal cavity carcinoma
509388|NCT00666991|gastrointestinal tract tumor
509389|NCT00666991|GI tract tumor
509390|NCT00666991|pancreatic cancer
509391|NCT00666991|colon cancer
509392|NCT00666978|bladder cancer
509393|NCT00666978|cervical cancer
509394|NCT00666978|esophageal cancer
509395|NCT00666978|gastric cancer
509396|NCT00666978|renal cell carcinoma
509397|NCT00666978|adult primary liver cancer
509398|NCT00666978|non-small cell lung cancer
509399|NCT00666978|small cell lung cancer
509400|NCT00666978|pancreatic cancer
509401|NCT00666978|hypopharyngeal cancer
509402|NCT00666978|laryngeal cancer
509403|NCT00666978|lip and oral cavity cancer
509404|NCT00666978|nasopharyngeal cancer
509405|NCT00666978|oropharyngeal cancer
509406|NCT00666978|paranasal sinus and nasal cavity cancer
509407|NCT00666978|adult acute myeloid leukemia
509408|NCT00666978|tobacco use disorder
509409|NCT00666965|SPM 962
509410|NCT00666965|rotigotine
509411|NCT00666965|Idiopathic Restless Legs Syndrome
509412|NCT00666965|RLS
509413|NCT00666926|Pancreatic Neoplasm
509414|NCT00666926|Head and Neck neoplasm
509415|NCT00666926|Prostatic neoplasms; Focal Adhesion Kinase
509416|NCT00666926|Phase 1
509417|NCT00666926|Pharmacodynamics
509418|NCT00666926|FDG-PET
509419|NCT00666913|breast cancer in situ
509420|NCT00666913|stage I breast cancer
509421|NCT00666913|stage II breast cancer
509422|NCT00666913|stage IIIA breast cancer
509423|NCT00666913|stage IIIB breast cancer
509424|NCT00666913|stage IIIC breast cancer
509425|NCT00666913|hot flashes
509426|NCT00666887|Multiple Sclerosis
509427|NCT00666887|Clinically Isolated Syndrome
509428|NCT00666887|Minocycline
509429|NCT00666887|Placebo
509430|NCT00666874|Obesity, lifestyle, vascular inflammation
509431|NCT00666848|Metabolic syndrome
509432|NCT00666848|Hypertension
509433|NCT00666848|Sitagliptin
509434|NCT00666848|Enalapril
509435|NCT00666835|Treatment of anemia in hemodialysis patients
509436|NCT00666822|stage I breast cancer
509437|NCT00666822|stage II breast cancer
509438|NCT00666822|stage IIIA breast cancer
509439|NCT00666809|Vardenafil,
509440|NCT00666809|Tinnitus
509441|NCT00666757|Severe Depressive Episode
509442|NCT00666744|exercise
509443|NCT00666744|frequency
509444|NCT00666744|duration
509445|NCT00666731|male breast cancer
509446|NCT00666731|breast cancer
509447|NCT00666731|ductal breast carcinoma in situ
509448|NCT00666731|lobular breast carcinoma in situ
509449|NCT00666731|atypical ductal breast hyperplasia
509450|NCT00666705|maraviroc
509451|NCT00666705|raltegravir
509452|NCT00666705|drug interaction study
509453|NCT00666705|healthy volunteers
509454|NCT00666692|cancer
509455|NCT00666692|carcinoma
509456|NCT00666692|monoclonal antibody therapy
509457|NCT00666692|anti-angiogenesis
509458|NCT00666666|prostate Cancer
509459|NCT00666666|adenocarcinoma of the prostate
509460|NCT00666666|stage IV prostate cancer
509461|NCT00666666|newly diagnosed stage IV prostate cancer
509462|NCT00666653|Parkinson's disease
509463|NCT00666653|Dopamine Agonist
509464|NCT00666653|Levodopa
509465|NCT00666653|Pharmacokinetics
509466|NCT00666653|Dyskinesia
509467|NCT00666640|Osteoporosis
509468|NCT00666640|Fracture
509469|NCT00666640|DXA
509470|NCT00666640|Dual energy x-ray absorptiometry
509471|NCT00666640|Computed tomography
509472|NCT00666640|3D DXA
509473|NCT00666627|Osteoporosis
509474|NCT00666627|Post-menopausal osteoporosis
509475|NCT00666627|Bisphosphonates
509476|NCT00666627|Alendronate
509477|NCT00666627|Ibandronate
509478|NCT00666627|Risedronate
509479|NCT00666614|Sleep
509480|NCT00666614|Fatigue
509481|NCT00666614|High Dose Chemotherapy
509482|NCT00666601|Microdialysis
509483|NCT00666601|Antibiotic
509484|NCT00666601|Healthy subjects
509485|NCT00666549|Myeloproliferative Disease
509486|NCT00666549|Myelofibrosis
509487|NCT00666549|Idiopathic Myelofibrosis
509488|NCT00666549|Essential Thrombocythemia
509489|NCT00666549|Polycythemia Vera
509490|NCT00666536|Hypertension
509491|NCT00666536|adults
509492|NCT00666536|Valsartan + Amlodipine
509493|NCT00666536|Angiotensin Receptor Blockers
509494|NCT00666523|osteoarthritis, knee or hip
509495|NCT00666510|nitric oxide
509496|NCT00666510|bronchospasm
509497|NCT00666510|anesthesia
509498|NCT00666510|induced sputum
509499|NCT00666510|asthma
509500|NCT00666497|Acute Myeloid Leukemia
509501|NCT00666497|Myelodysplastic Syndrome
509502|NCT00666497|Azacitidine
509503|NCT00666497|Vidaza
509504|NCT00666497|MGCD0103
509505|NCT00666497|Histone deacetylase inhibitor
509506|NCT00666497|DNA methyltransferase inhibitor
509507|NCT00666497|Epigenetic Therapy
509508|NCT00666484|neurotoxicity
509509|NCT00666484|stage I adult Hodgkin lymphoma
509510|NCT00666484|stage II adult Hodgkin lymphoma
509511|NCT00666484|stage III adult Hodgkin lymphoma
509512|NCT00666484|stage IV adult Hodgkin lymphoma
509513|NCT00666484|adult lymphocyte depletion Hodgkin lymphoma
509514|NCT00666484|adult lymphocyte predominant Hodgkin lymphoma
509515|NCT00666484|adult mixed cellularity Hodgkin lymphoma
509516|NCT00666484|adult nodular sclerosis Hodgkin lymphoma
509517|NCT00666471|epistaxis
509518|NCT00666471|Epistaxis refractory to emergency physician treatment
509519|NCT00666458|Type 2 diabetes
509520|NCT00666458|metformin
509521|NCT00666445|Alzheimer's Disease
509522|NCT00666445|Diagnosis
509523|NCT00666445|Neuronal function
509524|NCT00666445|Cognitive Impairment
509525|NCT00666445|Magnetoencephalography
509526|NCT00666432|schizophrenia
509527|NCT00666432|bipolar
509528|NCT00666432|eye movements
509529|NCT00666432|phenotype
509530|NCT00666432|biochemical
509531|NCT00666432|relatives
509532|NCT00666419|nonspecific low back pain
509533|NCT00666419|schoolchildren
509534|NCT00666419|prevalence
509535|NCT00666393|IONSYS™
509536|NCT00666393|Pain, Postoperative
509537|NCT00666393|Analgesia, Patient-Controlled
509538|NCT00666393|Opioids
509539|NCT00666393|Pediatrics
509540|NCT00666380|Malaria
509541|NCT00666380|Vaccine
509542|NCT00666380|MSP-1 (merozoite surface protein-1)
509543|NCT00666380|Phase 1
509544|NCT00666367|COPD
509545|NCT00666354|Nail Psoriasis
509546|NCT00666354|Psoriasis
509547|NCT00666354|Fingernail Psoriasis
509548|NCT00666354|Methotrexate
509549|NCT00666328|Hypertension
509550|NCT00666328|Hemorrhage
509551|NCT00666328|Intracranial Pressure
509552|NCT00666328|Antihypertensive Agent
509553|NCT00666328|Calcium Channel Blocker
509554|NCT00666315|Consecutive euthyroid patients with multinodular goiter for whom a total Thyroidectomy under general anesthesia is indicated
509555|NCT00666302|Atopic Dermatitis
509556|NCT00666302|Protopic
509557|NCT00666302|Elidel
509558|NCT00666289|polycythemia vera
509559|NCT00666289|essential thrombocythemia
509560|NCT00666289|idiopathic myelofibrosis
509561|NCT00666289|family clusters
509562|NCT00666250|blood pressure
509563|NCT00666250|dyslipidemia
509564|NCT00666250|hyperglycemia
509565|NCT00666237|Glaucoma
509566|NCT00666237|Tube shunt surgery
509567|NCT00666237|Trabeculectomy
509568|NCT00666224|Clinically Definite Multiple Sclerosis
509569|NCT00666224|Clinically Isolated Syndrome
509570|NCT00666224|Multiple Sclerosis
509571|NCT00666211|pain
509572|NCT00666211|unspecified adult solid tumor, protocol specific
509573|NCT00666211|accelerated phase chronic myelogenous leukemia
509574|NCT00666211|acute undifferentiated leukemia
509575|NCT00666211|adult acute lymphoblastic leukemia in remission
509576|NCT00666211|adult acute myeloid leukemia in remission
509577|NCT00666211|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
509578|NCT00666211|adult acute myeloid leukemia with inv(16)(p13;q22)
509579|NCT00666211|adult acute myeloid leukemia with t(15;17)(q22;q12)
509580|NCT00666211|adult acute myeloid leukemia with t(16;16)(p13;q22)
509581|NCT00666211|adult acute myeloid leukemia with t(8;21)(q22;q22)
509582|NCT00666211|atypical chronic myeloid leukemia, BCR-ABL negative
509583|NCT00666211|blastic phase chronic myelogenous leukemia
509584|NCT00666211|chronic myelomonocytic leukemia
509585|NCT00666211|chronic phase chronic myelogenous leukemia
509586|NCT00666211|mast cell leukemia
509587|NCT00666211|meningeal chronic myelogenous leukemia
509588|NCT00666211|progressive hairy cell leukemia, initial treatment
509589|NCT00666211|prolymphocytic leukemia
509590|NCT00666211|recurrent adult acute lymphoblastic leukemia
509591|NCT00666211|recurrent adult acute myeloid leukemia
509592|NCT00666211|recurrent adult T-cell leukemia/lymphoma
509593|NCT00666211|refractory chronic lymphocytic leukemia
509594|NCT00666211|refractory hairy cell leukemia
509595|NCT00666211|relapsing chronic myelogenous leukemia
509596|NCT00666211|secondary acute myeloid leukemia
509597|NCT00666211|stage I adult T-cell leukemia/lymphoma
509598|NCT00666211|stage I chronic lymphocytic leukemia
509599|NCT00666211|stage II adult T-cell leukemia/lymphoma
509600|NCT00666211|stage II chronic lymphocytic leukemia
509601|NCT00666211|stage III adult T-cell leukemia/lymphoma
509602|NCT00666211|stage III chronic lymphocytic leukemia
509603|NCT00666211|stage IV adult T-cell leukemia/lymphoma
509604|NCT00666211|stage IV chronic lymphocytic leukemia
509605|NCT00666211|T-cell large granular lymphocyte leukemia
509606|NCT00666211|stage I adult Hodgkin lymphoma
509607|NCT00666211|stage II adult Hodgkin lymphoma
509608|NCT00666211|stage III adult Hodgkin lymphoma
509609|NCT00666211|stage IV adult Hodgkin lymphoma
509610|NCT00666211|anaplastic large cell lymphoma
509611|NCT00666211|angioimmunoblastic T-cell lymphoma
509612|NCT00666211|cutaneous B-cell non-Hodgkin lymphoma
509613|NCT00666211|recurrent cutaneous T-cell non-Hodgkin lymphoma
509614|NCT00666211|stage I cutaneous T-cell non-Hodgkin lymphoma
509615|NCT00666211|stage II cutaneous T-cell non-Hodgkin lymphoma
509616|NCT00666211|stage III cutaneous T-cell non-Hodgkin lymphoma
509617|NCT00666211|stage IV cutaneous T-cell non-Hodgkin lymphoma
509618|NCT00666211|recurrent mycosis fungoides/Sezary syndrome
509619|NCT00666211|stage I mycosis fungoides/Sezary syndrome
509620|NCT00666211|stage II mycosis fungoides/Sezary syndrome
509621|NCT00666211|stage III mycosis fungoides/Sezary syndrome
509622|NCT00666211|stage IV mycosis fungoides/Sezary syndrome
509623|NCT00666211|adult grade III lymphomatoid granulomatosis
509624|NCT00666211|adult nasal type extranodal NK/T-cell lymphoma
509625|NCT00666211|Waldenstrom macroglobulinemia
509626|NCT00666211|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
509627|NCT00666211|nodal marginal zone B-cell lymphoma
509628|NCT00666211|splenic marginal zone lymphoma
509629|NCT00666211|contiguous stage II adult Burkitt lymphoma
509630|NCT00666211|contiguous stage II adult diffuse large cell lymphoma
509631|NCT00666211|contiguous stage II adult diffuse mixed cell lymphoma
509632|NCT00666211|contiguous stage II adult diffuse small cleaved cell lymphoma
509633|NCT00666211|contiguous stage II adult immunoblastic large cell lymphoma
509634|NCT00666211|contiguous stage II adult lymphoblastic lymphoma
509635|NCT00666211|contiguous stage II grade 1 follicular lymphoma
509636|NCT00666211|contiguous stage II grade 2 follicular lymphoma
509637|NCT00666211|contiguous stage II grade 3 follicular lymphoma
509638|NCT00666211|contiguous stage II mantle cell lymphoma
509639|NCT00666211|contiguous stage II marginal zone lymphoma
509640|NCT00666211|stage I adult Burkitt lymphoma
509641|NCT00666211|stage I adult diffuse large cell lymphoma
509642|NCT00666211|stage I adult diffuse mixed cell lymphoma
509643|NCT00666211|stage I adult diffuse small cleaved cell lymphoma
509644|NCT00666211|stage I adult immunoblastic large cell lymphoma
509645|NCT00666211|stage I adult lymphoblastic lymphoma
509646|NCT00666211|stage I grade 1 follicular lymphoma
509647|NCT00666211|stage I grade 2 follicular lymphoma
509648|NCT00666211|stage I grade 3 follicular lymphoma
509649|NCT00666211|stage I mantle cell lymphoma
509650|NCT00666211|stage I marginal zone lymphoma
509651|NCT00666211|stage I small lymphocytic lymphoma
509652|NCT00666211|noncontiguous stage II adult Burkitt lymphoma
509653|NCT00666211|noncontiguous stage II adult diffuse large cell lymphoma
509654|NCT00666211|noncontiguous stage II adult diffuse mixed cell lymphoma
509655|NCT00666211|noncontiguous stage II adult diffuse small cleaved cell lymphoma
509656|NCT00666211|noncontiguous stage II adult immunoblastic large cell lymphoma
509657|NCT00666211|noncontiguous stage II adult lymphoblastic lymphoma
509658|NCT00666211|noncontiguous stage II grade 1 follicular lymphoma
509659|NCT00666211|noncontiguous stage II grade 2 follicular lymphoma
509660|NCT00666211|noncontiguous stage II grade 3 follicular lymphoma
509661|NCT00666211|noncontiguous stage II mantle cell lymphoma
509662|NCT00666211|noncontiguous stage II marginal zone lymphoma
509663|NCT00666211|noncontiguous stage II small lymphocytic lymphoma
509664|NCT00666211|stage III adult Burkitt lymphoma
509665|NCT00666211|stage III adult diffuse large cell lymphoma
509666|NCT00666211|stage III adult diffuse mixed cell lymphoma
509667|NCT00666211|stage III adult diffuse small cleaved cell lymphoma
509668|NCT00666211|stage III adult immunoblastic large cell lymphoma
509669|NCT00666211|stage III adult lymphoblastic lymphoma
509670|NCT00666211|stage III grade 1 follicular lymphoma
509671|NCT00666211|stage III grade 2 follicular lymphoma
509672|NCT00666211|stage III grade 3 follicular lymphoma
509673|NCT00666211|stage III mantle cell lymphoma
509674|NCT00666211|stage III marginal zone lymphoma
509675|NCT00666211|stage III small lymphocytic lymphoma
509676|NCT00666211|stage IV adult Burkitt lymphoma
509677|NCT00666211|stage IV adult diffuse large cell lymphoma
509678|NCT00666211|stage IV adult diffuse mixed cell lymphoma
509679|NCT00666211|stage IV adult diffuse small cleaved cell lymphoma
509680|NCT00666211|stage IV adult immunoblastic large cell lymphoma
509681|NCT00666211|stage IV adult lymphoblastic lymphoma
509682|NCT00666211|stage IV grade 1 follicular lymphoma
509683|NCT00666211|stage IV grade 2 follicular lymphoma
509684|NCT00666211|stage IV grade 3 follicular lymphoma
509685|NCT00666211|stage IV mantle cell lymphoma
509686|NCT00666211|stage IV marginal zone lymphoma
509687|NCT00666211|stage IV small lymphocytic lymphoma
509688|NCT00666211|recurrent adult Burkitt lymphoma
509689|NCT00666211|recurrent adult diffuse large cell lymphoma
509690|NCT00666211|recurrent adult diffuse mixed cell lymphoma
509691|NCT00666211|recurrent adult diffuse small cleaved cell lymphoma
509692|NCT00666211|recurrent adult grade III lymphomatoid granulomatosis
509693|NCT00666211|recurrent adult immunoblastic large cell lymphoma
509694|NCT00666211|recurrent adult lymphoblastic lymphoma
509695|NCT00666211|recurrent grade 1 follicular lymphoma
509696|NCT00666211|recurrent grade 2 follicular lymphoma
509697|NCT00666211|recurrent grade 3 follicular lymphoma
509698|NCT00666211|recurrent mantle cell lymphoma
509699|NCT00666211|recurrent marginal zone lymphoma
509700|NCT00666211|recurrent small lymphocytic lymphoma
509701|NCT00666211|intraocular lymphoma
509702|NCT00666211|primary central nervous system non-Hodgkin lymphoma
509703|NCT00666211|primary central nervous system Hodgkin lymphoma
509704|NCT00666211|post-transplant lymphoproliferative disorder
509705|NCT00666211|chronic eosinophilic leukemia
509706|NCT00666211|chronic neutrophilic leukemia
509707|NCT00666211|primary myelofibrosis
509708|NCT00666211|essential thrombocythemia
509709|NCT00666211|polycythemia vera
509710|NCT00666211|extramedullary plasmacytoma
509711|NCT00666211|isolated plasmacytoma of bone
509712|NCT00666211|monoclonal gammopathy of undetermined significance
509713|NCT00666211|stage I multiple myeloma
509714|NCT00666211|stage II multiple myeloma
509715|NCT00666211|stage III multiple myeloma
509716|NCT00666211|primary systemic amyloidosis
509717|NCT00666211|refractory multiple myeloma
509718|NCT00666211|de novo myelodysplastic syndromes
509719|NCT00666211|previously treated myelodysplastic syndromes
509720|NCT00666211|secondary myelodysplastic syndromes
509721|NCT00666211|myelodysplastic/myeloproliferative neoplasm, unclassifiable
509722|NCT00666211|recurrent adult Hodgkin lymphoma
509723|NCT00666185|Micafungin
509724|NCT00666185|Esophageal Candidiasis
509725|NCT00666185|Fluconazole
509726|NCT00666172|Women's Health
509727|NCT00666172|Obesity
509728|NCT00666172|Metabolic Syndrome
509729|NCT00666172|Arterial Function
509730|NCT00666172|Lipoproteins
509731|NCT00666172|Overweight
509732|NCT00666159|Atopic Dermatitis
509733|NCT00666159|Protopic
509734|NCT00666159|Pediatric
509735|NCT00666146|Schizophrenia
509736|NCT00666146|Genetics
509737|NCT00666146|Eyetracking
509738|NCT00666133|Preeclampsia
509739|NCT00666133|Eclampsia
509740|NCT00666133|Magnesium Sulfate
509741|NCT00666107|HPV
509742|NCT00666107|HIV
509743|NCT00666107|Gardasil
509744|NCT00666107|Vaccine
509745|NCT00666094|Type 2-diabetes
509746|NCT00666094|exercise therapy
509747|NCT00666094|RCT
509748|NCT00666094|Norway
509749|NCT00666081|Pazopanib, paclitaxel, carboplatin
509750|NCT00666068|Patients with hypopituitarism
509751|NCT00666055|Sex
509752|NCT00666055|Aging
509753|NCT00666055|Antiretroviral
509754|NCT00666055|Pharmacokinetics
509755|NCT00666055|post-menopausal women with HIV infection
509756|NCT00666055|pre-menopausal women with HIV infection
509757|NCT00666029|metabolic syndrome
509758|NCT00666029|Volunteers recruited from the community
509759|NCT00666016|non alcoholic steatohepatitis nash hepatoprotective hepatoprotection ALT AST new drug candidate interventional study TRO19622 Trophos cholest-4-en-3-one oxime
509760|NCT00666003|Hemodynamics
509761|NCT00665977|Obstructive Sleep Apnea
509762|NCT00665977|Nasal Congestion
509763|NCT00665977|Sinus congestion
509764|NCT00665964|osteoarthritis
509765|NCT00665964|knee
509766|NCT00665964|total knee arthroplasty
509767|NCT00665964|gonarthrrsis
509768|NCT00665964|polyethylene
509769|NCT00665964|posterior stabilized
509770|NCT00665951|pediatric
509771|NCT00665951|pharmacokinetics
509772|NCT00665951|HIV infection
509773|NCT00665938|Physical development
509774|NCT00665899|breast cancer
509775|NCT00665899|couples
509776|NCT00665899|cognitive behavioral therapy
509777|NCT00665899|Women with early stage breast cancer and their partners.
509778|NCT00665886|Peripheral venous catheter
509779|NCT00665886|Catheter-related complication
509780|NCT00665886|Bacterial Colonization
509781|NCT00665886|Dwell time
509782|NCT00665886|Closed system
509783|NCT00665886|Costs
509784|NCT00665886|Polyurethane
509785|NCT00665886|Teflon
509786|NCT00665873|Totally Implantable Venous Access Devices
509787|NCT00665873|Infections
509788|NCT00665873|Chemotherapy
509789|NCT00665873|Valuated infections TIVAD
509790|NCT00665860|Osteoporosis
509791|NCT00665860|Soy isoflavones
509792|NCT00665860|Postmenopausal women
509793|NCT00665860|Safety
509794|NCT00665860|Efficacy
509795|NCT00665860|Effective dosage
509796|NCT00665847|HIV-1
509797|NCT00665847|TMC125-TiDP35-C213
509798|NCT00665847|TMC125-C213
509799|NCT00665821|nonspecific low back pain
509800|NCT00665821|disability
509801|NCT00665821|sick leave
509802|NCT00665821|catastrophizing
509803|NCT00665821|workers
509804|NCT00665795|Dysthyroid Optic Neuropathy
509805|NCT00665795|multidetector computed tomography
509806|NCT00665795|color doppler
509807|NCT00665795|Grave´s Orbitopathy
509808|NCT00665795|Grave´s Disease
509809|NCT00665795|morphometric analysis
509810|NCT00665782|anxiety disorder
509811|NCT00665782|depression
509812|NCT00665782|psychosocial effects of cancer and its treatment
509813|NCT00665782|ductal breast carcinoma in situ
509814|NCT00665782|breast cancer in situ
509815|NCT00665782|stage I breast cancer
509816|NCT00665782|stage II breast cancer
509817|NCT00665782|stage IIIA breast cancer
509818|NCT00665782|stage IIIB breast cancer
509819|NCT00665782|stage IIIC breast cancer
509820|NCT00665769|hypercapnia
509821|NCT00665769|normocapnia
509823|NCT00665769|periventricular leukomalacia
509824|NCT00665769|intraventricular hemorrhage
509825|NCT00665769|hypotension
509826|NCT00665769|cerebral autoregulation
509827|NCT00665769|heart rate variability
509828|NCT00665769|autonomic nervous system
509829|NCT00665769|detrended fluctuation analysis
509830|NCT00665756|Glaucoma
509831|NCT00665756|Drainage implant
509832|NCT00665756|Ahmed valve
509833|NCT00665756|Second trabeculectomy
509834|NCT00665717|interaction
509835|NCT00665717|statins
509836|NCT00665717|pharmacokinetics
509837|NCT00665704|Smoking Cessation
509838|NCT00665704|Internet
509839|NCT00665704|Intervention Studies
509840|NCT00665704|Health Services Accessibility
509841|NCT00665691|All Malignancies
509842|NCT00665652|Neuropathy
509843|NCT00665652|Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
509844|NCT00665652|MGUS
509845|NCT00665639|Micafungin
509846|NCT00665639|Esophageal Candidiasis
509847|NCT00665639|caspofungin
509848|NCT00665613|warfarin use
509849|NCT00665600|COPD
509850|NCT00665600|Chronic Bronchitis
509851|NCT00665600|Chronic Emphysema
509852|NCT00665587|Atrial fibrillation
509853|NCT00665587|Maze procedure
509854|NCT00665587|Mid-term results
509855|NCT00665587|Long-term results
509856|NCT00665587|Surgical ablation
509857|NCT00665561|Maraviroc
509858|NCT00665561|HIV-1
509859|NCT00665561|Safety
509860|NCT00665561|Non-interventional
509861|NCT00665548|Knee Osteoarthritis
509862|NCT00665548|magnetic resonance imaging
509863|NCT00665548|x rays
509864|NCT00665535|Pressure ulcers
509865|NCT00665535|Nursing facilities
509866|NCT00665535|Elderly
509867|NCT00665535|At risk for pressure ulcers
509868|NCT00665522|Pain
509869|NCT00665522|Postoperative Analgesia
509870|NCT00665522|Patient-Controlled Opioids
509871|NCT00665509|Influenza
509872|NCT00665509|Vaccine
509873|NCT00665509|CHMP criteria
509874|NCT00665496|Erectile Dysfunction
509875|NCT00665496|Vardenafil
509876|NCT00665496|Onset of action
509877|NCT00665470|Malignant Melanoma
509878|NCT00665470|HLA-A2
509879|NCT00665470|Immunotherapy
509880|NCT00665470|Clinical Response
509881|NCT00665470|Skin Cancer
509882|NCT00665457|stage II breast cancer
509883|NCT00665457|stage IIIA breast cancer
509884|NCT00665457|stage IIIB breast cancer
509885|NCT00665457|stage IIIC breast cancer
509886|NCT00665444|bipolar disorder
509887|NCT00665444|sedation
509888|NCT00665444|overweight
509889|NCT00665444|Abilify
509890|NCT00665444|medication
509891|NCT00665418|Anesthesia
509892|NCT00665418|children
509893|NCT00665418|Larynx
509894|NCT00665405|Delivery, obstetric
509895|NCT00665405|Atelectasis
509896|NCT00665392|stage III squamous cell carcinoma of the oropharynx
509897|NCT00665392|stage IV squamous cell carcinoma of the oropharynx
509898|NCT00665392|tongue cancer
509899|NCT00665379|leg lymphedema
509900|NCT00665379|volume measurement
509901|NCT00665379|compression therapy
509902|NCT00665379|interface pressure
509903|NCT00665379|static stiffness index (SSI)
509904|NCT00665379|volume change
509905|NCT00665353|HIV
509906|NCT00665353|HCV
509907|NCT00665340|Erectile Dysfunction
509908|NCT00665340|Vardenafil
509909|NCT00665327|Community Acquired Pneumonia
509910|NCT00665327|Pneumonia,
509911|NCT00665327|CAP
509912|NCT00665314|Mobilisation stem cells
509913|NCT00665314|G-CSF Mobilisation Regimen
509914|NCT00665314|Lymphoma
509915|NCT00665314|Multiple Myeloma
509916|NCT00665314|Adult patients with lymphoma (Non Hodgkin's Lymphoma, Hodgkin's Disease) or Multiple Myeloma who previously failed Stem Cell Collections or Collection attempts.
509917|NCT00665301|Non-invasive Cardiac Output
509918|NCT00665288|cardiac arrest
509919|NCT00665288|heart arrest
509920|NCT00665288|CPR
509921|NCT00665288|resuscitation
509922|NCT00665288|bystander CPR
509923|NCT00665275|complementary
509924|NCT00665275|alternative
509925|NCT00665275|medicine
509926|NCT00665262|analgesia
509927|NCT00665262|hip arthroplasty
509928|NCT00665262|knee arthroplasty
509929|NCT00665249|problem drinking
509930|NCT00665249|heavy drinking
509931|NCT00665249|Alcohol
509932|NCT00665249|moderation
509933|NCT00665249|motivational interviewing
509934|NCT00665236|Migraine
509935|NCT00665223|Huntington's Disease
509936|NCT00665210|hip arthritis
509937|NCT00665210|implant sizing
509938|NCT00665197|Esophageal cancer
509939|NCT00665197|Brachytherapy
509940|NCT00665197|Radiotherapy
509941|NCT00665197|Palliation
509942|NCT00665197|Dysphagia
509943|NCT00665184|Hypokinesia
509944|NCT00665184|Gait
509945|NCT00665184|Quality of life
509946|NCT00665184|Dopamine replacement
509947|NCT00665184|Resistance training
509948|NCT00665171|Polycystic ovary syndrome
509949|NCT00665171|Single nucleotide polymorphism
509950|NCT00665171|Whole genome analysis
509951|NCT00665171|Multigenerational family study
509952|NCT00665158|Abdominal obesity, exercise, behaviour modification
509953|NCT00665145|Diabetes Mellitus, Type 1
509954|NCT00665145|Diabetes Mellitus, Type 2
509955|NCT00665145|Diabetic Polyneuropathy
509956|NCT00665145|Stem Cells
509957|NCT00665132|wrist
509958|NCT00665132|hand
509959|NCT00665132|pain
509960|NCT00665132|failed CTR
509961|NCT00665132|carpal tunnel syndrome
509962|NCT00665132|CTS
509963|NCT00665132|CTR
509964|NCT00665132|carpel tunnel release
509965|NCT00665132|Peripheral nerve
509966|NCT00665132|Median nerve
509967|NCT00665119|Respiratory Insufficiency
509968|NCT00665119|Respiration, Artificial
509969|NCT00665119|Remifentanil
509970|NCT00665119|Respiratory Mechanics
509971|NCT00665119|Work of Breathing
509972|NCT00665106|Diabetic macular edema
509973|NCT00665106|Diabetes
509974|NCT00665106|Diabetic retinopathy
509975|NCT00665067|Myeloproliferative Disease
509976|NCT00665067|Myelofibrosis
509977|NCT00665067|Idiopathic Myelofibrosis
509978|NCT00665067|Essential Thrombocythemia
509979|NCT00665067|Polycythemia Vera
509980|NCT00665067|Biomarkers
509981|NCT00665067|Philadelphia Chromosome Negative
509982|NCT00665067|Clonal Hematopoietic malignancies
509983|NCT00665054|Vardenafil
509984|NCT00665054|Erectile dysfunction
509985|NCT00665054|SSES-E (sexual self-efficacy scale - erectile function)
509986|NCT00665028|Anesthesia
509987|NCT00665028|Postoperative myocardial ischemia
509988|NCT00665028|ST monitoring
509989|NCT00665015|pleural effusion
509990|NCT00665015|coronary artery bypass
509991|NCT00665015|heart valve replacement
509992|NCT00665002|Myeloid
509993|NCT00665002|Monocytic
509994|NCT00665002|Hematopoietic
509995|NCT00665002|Neoplasms
509996|NCT00665002|Acute Myelogenous Leukemia
509997|NCT00665002|AML
509998|NCT00665002|Myelodysplastic Syndrome
509999|NCT00665002|MDS
510000|NCT00664989|Hemiarthroplasty Stemmed Resurfacing Conventional Shoulder
510001|NCT00664976|bipolar depression
510002|NCT00664976|Electroconvulsive therapy
510003|NCT00664963|Arterial Occlusive Diseases
510004|NCT00664963|Peripheral Vascular Diseases
510005|NCT00664963|Drug eluting stent
510006|NCT00664963|Restenosis
510007|NCT00664963|Below the knee
510008|NCT00664963|Intervention
510009|NCT00664950|intertrochanteric hip fracture fixation
510010|NCT00664950|interTAN IM Nail
510011|NCT00664950|sliding hip screw
510012|NCT00664924|ICU
510013|NCT00664898|anti-CD40
510014|NCT00664898|Myeloma
510015|NCT00664885|non-psychiatric
510016|NCT00664885|clinics
510017|NCT00664872|case manager
510018|NCT00664872|suicide
510019|NCT00664872|attempt
510020|NCT00664872|effectiveness
510021|NCT00664859|LCP-AtorFen
510022|NCT00664859|Non-HDL cholesterol
510023|NCT00664859|Triglycerides
510024|NCT00664859|HDL cholesterol
510025|NCT00664859|LDL cholesterol
510026|NCT00664859|Atorvastatin
510027|NCT00664859|Fenofibrate
510028|NCT00664846|Stroke
510029|NCT00664846|Prevention Therapy
510030|NCT00664833|Erectile dysfunction
510031|NCT00664833|Phosphodiesterase Type 5 Inhibitors
510032|NCT00664833|Patient education
510033|NCT00664833|Impotence
510034|NCT00664833|Vardenafil
510035|NCT00664820|Rheumatoid Arthritics
510036|NCT00664820|probiotics
510037|NCT00664820|Lactobacillus
510038|NCT00664781|stage IIIA breast cancer
510039|NCT00664781|stage IIIB breast cancer
510040|NCT00664781|stage IIIC breast cancer
510041|NCT00664781|stage IV breast cancer
510042|NCT00664781|recurrent breast cancer
510043|NCT00664781|stage IV ovarian epithelial cancer
510044|NCT00664781|recurrent ovarian germ cell tumor
510045|NCT00664781|stage IV ovarian germ cell tumor
510046|NCT00664781|ovarian stromal cancer
510047|NCT00664781|ovarian sarcoma
510048|NCT00664781|BRCA1 mutation carrier
510049|NCT00664781|BRCA2 mutation carrier
510050|NCT00664781|stage IIIA ovarian epithelial cancer
510051|NCT00664781|stage IIIA ovarian germ cell tumor
510052|NCT00664781|stage IIIB ovarian epithelial cancer
510053|NCT00664781|stage IIIB ovarian germ cell tumor
510054|NCT00664781|stage IIIC ovarian epithelial cancer
510055|NCT00664781|stage IIIC ovarian germ cell tumor
510056|NCT00664781|ovarian papillary serous carcinoma
510057|NCT00664768|hypoallergenicity
510058|NCT00664768|Cow Milk Allergy
510059|NCT00664768|DBPCFC
510060|NCT00664768|Stool microflora
510061|NCT00664768|Stool characteristics
510062|NCT00664755|Menstrual Cycle effects
510063|NCT00664755|Cue Reactivity
510064|NCT00664755|Smoking Cessation
510065|NCT00664755|Impulsivity
510191|NCT00664157|Facial expression recognition of emotion
510066|NCT00664742|Metabolic syndrome,dyslipidemia,fluvastatin extended release
510067|NCT00664729|Abdominal
510068|NCT00664729|obesity
510069|NCT00664729|exercise
510070|NCT00664729|intensity
510071|NCT00664729|weight loss
510072|NCT00664729|women
510073|NCT00664716|Rheumatoid Arthritis
510074|NCT00664716|RA
510075|NCT00664716|DMARD inadequate response
510076|NCT00664716|Methotrexate
510077|NCT00664703|Dopamine Uptake Inhibitors
510078|NCT00664703|Dopamine
510079|NCT00664703|Methylphenidate
510080|NCT00664703|Mental Disorders Diagnosed in Childhood
510081|NCT00664703|Neurologic Manifestations
510082|NCT00664703|Attention Deficit and Disruptive Behavior Disorders
510083|NCT00664703|Hyperkinesis
510084|NCT00664703|Dyskinesias
510085|NCT00664690|shoulder surgery
510086|NCT00664690|analgesia
510087|NCT00664677|Adult
510088|NCT00664677|Leukemia
510089|NCT00664677|Terameprocol
510090|NCT00664677|Survivin
510091|NCT00664677|AML
510092|NCT00664677|ALL
510093|NCT00664677|ATL
510094|NCT00664677|CML
510095|NCT00664677|CLL
510096|NCT00664677|CMML
510097|NCT00664677|MDS
510098|NCT00664664|insomnia
510099|NCT00664664|sleep maintenance insomnia
510100|NCT00664664|sleep quality
510101|NCT00664664|non-restorative sleep
510102|NCT00664664|multiple awakenings
510103|NCT00664651|joint contracture
510104|NCT00664651|total knee arthroplasty
510105|NCT00664612|Cervical Spine
510106|NCT00664599|Ocular lesions, Visual Acuity, Retinal Vasculitis
510107|NCT00664586|Terameprocol (EM-1421)
510108|NCT00664586|Phase 1
510109|NCT00664586|Infusion
510110|NCT00664586|Refractory Solid Tumors
510111|NCT00664586|Lymphoma
510112|NCT00664586|Maximum Tolerated Dose
510113|NCT00664586|Tumor Response
510114|NCT00664586|Tumor Markers
510115|NCT00664586|Pharmacokinetics
510116|NCT00664573|Safety
510117|NCT00664573|Rheumatoid Arthritis
510118|NCT00664573|Baminercept alfa
510119|NCT00664573|Methotrexate
510120|NCT00664573|BG9924
510121|NCT00664573|Efficacy
510122|NCT00664547|obesity, exercise, diet, insulin resistance
510123|NCT00664508|Arthroplasty
510124|NCT00664508|Hip Replacement
510125|NCT00664508|motion analysis
510126|NCT00664495|Obesity, exercise, diet, insulin resistance
510127|NCT00664456|stage IIB prostate cancer
510128|NCT00664456|stage IIA prostate cancer
510129|NCT00664456|stage I prostate cancer
510130|NCT00664443|cardiac arrest
510131|NCT00664443|CPR
510132|NCT00664443|resuscitation
510133|NCT00664443|bystander CPR
510134|NCT00664443|dispatch-assisted CPR
510135|NCT00664430|Dialysis
510136|NCT00664430|Calcitriol Resistant
510137|NCT00664430|Secondary Hyperparathyroidism
510138|NCT00664417|Influenza
510139|NCT00664417|A/H5N1
510140|NCT00664417|Orthomyxoviridae Infections
510141|NCT00664417|Influenza Pandemics
510142|NCT00664404|Smoking
510143|NCT00664404|Smoking Cessation
510144|NCT00664404|Nicotine Withdrawal
510145|NCT00664404|Nicotine Dependence
510146|NCT00664404|Neuroregulatory Effects
510147|NCT00664404|Magnetic Resonance Imaging
510148|NCT00664404|MRI
510149|NCT00664378|Multiple myeloma, relapsed, refractory
510150|NCT00664365|Premature ejaculation.
510151|NCT00664365|FTIH,
510152|NCT00664365|GSK958108,
510153|NCT00664365|5HT1a antagonist,
510154|NCT00664352|Double blind
510155|NCT00664352|Placebo controlled
510156|NCT00664352|wound healing
510157|NCT00664339|Heart failure,
510158|NCT00664339|infection,
510159|NCT00664339|immune system,
510160|NCT00664339|atherosclerosis
510161|NCT00664326|Renal Cell Carcinoma
510162|NCT00664313|Linezolid
510163|NCT00664313|Zyvox
510164|NCT00664313|Peripheral Neuropathy
510165|NCT00664313|Optic Neuropathy
510166|NCT00664313|Anemia
510167|NCT00664313|Thrombocytopenia
510168|NCT00664300|Gilles de la Tourette's syndrome
510169|NCT00664300|Facial expression recognition of emotion
510170|NCT00664300|Frequency levels
510171|NCT00664300|Automatic and voluntary information treatment
510172|NCT00664300|Patient with Gilles de la Tourette's syndrome
510173|NCT00664261|tobacco use disorder
510174|NCT00664235|Pressure Ulcers
510175|NCT00664235|Tissue Injury
510176|NCT00664222|heart failure
510177|NCT00664222|insulin resistance
510178|NCT00664222|inflammatory cytokine
510179|NCT00664222|spironolactone
510180|NCT00664222|furosemide
510181|NCT00664209|Parkinson's disease
510182|NCT00664209|levodopa
510183|NCT00664209|Helicobacter pylori
510184|NCT00664196|Prostate Cancer
510185|NCT00664196|T cells
510186|NCT00664196|Gene Transfer
510187|NCT00664183|diabetic retinopathy
510188|NCT00664157|Idiopathic Parkinson's disease
510189|NCT00664157|L-Dopa
510190|NCT00664157|Deep Brain stimulation
510192|NCT00664157|Frequency levels
510193|NCT00664157|Automatic and voluntary information treatment
510194|NCT00664157|Patient with an Idiopathic Parkinson's disease
510195|NCT00664131|Acute Lymphoblastic Leukemia
510196|NCT00664131|ALL survivors
510197|NCT00664131|ALL neurologic symptoms
510198|NCT00664131|ALL neurologic disability
510199|NCT00664131|ALL late effects
510200|NCT00664118|Doula
510201|NCT00664118|Patient-controlled epidural analgesia
510202|NCT00664118|Neuraxial analgesia
510203|NCT00664118|Labor analgesia
510204|NCT00664105|stage IIIA non-small cell lung cancer
510205|NCT00664105|stage IIIB non-small cell lung cancer
510206|NCT00664092|Substance Abuse
510207|NCT00664092|Ex-Offenders
510208|NCT00664092|Substance Abuse Recovery
510209|NCT00664079|Thyroid Deficiency
510210|NCT00664079|Thyroid Stimulating Hormone
510211|NCT00664053|bone mineral density
510212|NCT00664053|bone turnover markers
510213|NCT00664053|strength
510214|NCT00664053|balance
510215|NCT00664014|hyponatremia
510216|NCT00664014|Non-acute and non hypovolemic hyponatremia
510217|NCT00663988|face transplantation
510218|NCT00663975|cystic fibrosis
510219|NCT00663975|pancreatic insufficiency
510220|NCT00663975|pancreatic enzymes
510221|NCT00663975|pediatrics
510222|NCT00663962|Thoracotomy
510223|NCT00663962|Post-surgical
510224|NCT00663962|Pregabalin
510225|NCT00663949|diabetes
510226|NCT00663949|proteinuria
510227|NCT00663949|pentoxifylline
510228|NCT00663936|Alzheimer's Disease
510229|NCT00663936|Alzheimer's
510230|NCT00663923|Excimer Laser
510231|NCT00663923|photorefractive keratectomy
510232|NCT00663923|astigmatism
510233|NCT00663910|basal cell carcinoma of the skin
510234|NCT00663910|squamous cell carcinoma of the skin
510235|NCT00663910|recurrent skin cancer
510236|NCT00663897|functional dyspepsia
510237|NCT00663897|epigastric pain syndrome
510238|NCT00663897|postprandial distress syndrome
510239|NCT00663897|proton pump inhibitor
510240|NCT00663897|5 HT-4 receptor agonist
510241|NCT00663884|diabetes mellitus, Type 2
510242|NCT00663884|mitiglinide
510243|NCT00663871|Fish Oil
510244|NCT00663871|Omega-3 fatty acids
510245|NCT00663871|Affect
510246|NCT00663871|Depression
510247|NCT00663871|Anger
510248|NCT00663871|Nutrition
510249|NCT00663871|Impulsivity
510250|NCT00663871|Aggression
510251|NCT00663871|Cognition
510252|NCT00663871|Behavior
510253|NCT00663845|Male Erectile Dysfunction
510254|NCT00663845|Dyslipidemia
510255|NCT00663845|Vardenafil
510256|NCT00663832|Male
510257|NCT00663832|Prostate
510258|NCT00663832|Cancer
510259|NCT00663832|HRPC
510260|NCT00663832|DACi
510261|NCT00663819|Low anterior colon resection
510262|NCT00663819|Proctectomy
510263|NCT00663819|Proctocolectomy
510264|NCT00663819|Anastomosis
510265|NCT00663819|Rectal Cancer
510266|NCT00663819|Ileostomy
510267|NCT00663806|UTI
510268|NCT00663793|Male Contraception
510269|NCT00663793|Hypogonadism
510270|NCT00663793|Testosterone
510271|NCT00663780|pharmacogenomics
510272|NCT00663780|polymorphisms
510273|NCT00663780|wound healing
510274|NCT00663754|Body Image
510275|NCT00663741|Unresectable / recurrent gastric cancer
510276|NCT00663741|Sorafenib
510277|NCT00663741|S-1
510278|NCT00663741|Gastric
510279|NCT00663741|Cisplatin
510280|NCT00663741|CDDP
510281|NCT00663728|Erectile Dysfunction
510282|NCT00663728|Vardenafil
510283|NCT00663715|Sciatic Nerve
510284|NCT00663715|Peripheral Nerve Block
510285|NCT00663715|Lower extremity surgery
510286|NCT00663715|Local Anesthesia
510287|NCT00663715|Ultrasound guided nerve blocks
510288|NCT00663689|erlotinib
510289|NCT00663650|Basal Cell Carcinoma
510290|NCT00663650|BCC
510291|NCT00663650|Periocular BCC
510292|NCT00663650|Frozen Section Control
510293|NCT00663650|Permanent Section Control
510294|NCT00663650|Recurrence Rates
510295|NCT00663637|endotracheal tube obstruction, occlusion
510296|NCT00663637|mechanical ventilation, complication
510297|NCT00663637|work of breathing
510298|NCT00663637|airway resistance
510299|NCT00663637|secretions
510300|NCT00663637|pneumonia, ventilator associated
510301|NCT00663637|biofilms
510302|NCT00663637|endotracheal tube
510303|NCT00663611|Immune Function
510304|NCT00663611|Metabolism
510305|NCT00663611|Pulsatile Growth Hormone
510306|NCT00663598|Erectile Dysfunction
510307|NCT00663598|Vardenafil
510308|NCT00663585|Migraine
510309|NCT00663585|Headache
510310|NCT00663585|Vipassana
510311|NCT00663585|Meditation
510312|NCT00663585|Intensive
510313|NCT00663572|Newborn
510314|NCT00663572|nutrition
510315|NCT00663572|genetic
510316|NCT00663572|feeding behaviour
510317|NCT00663572|psychomotor development
510318|NCT00663572|long-term effects
510319|NCT00663572|nutritional imprinting.
510320|NCT00663559|renal
510321|NCT00663559|Sunitinib
510322|NCT00663559|Unresectable and/or metastatic renal cell cancer
510323|NCT00663546|Malaria
510324|NCT00663546|Plasmodium
510325|NCT00663546|Hemoglobin E
510326|NCT00663546|Alpha-thalssemia
510327|NCT00663546|G6PD Deficiency
510328|NCT00663533|Vasectomy
510329|NCT00663533|Contraception
510330|NCT00663520|Cardiac disease
510331|NCT00663520|vascular dysfunction
510332|NCT00663520|women
510333|NCT00663520|chest pain
510334|NCT00663520|echocardiography
510335|NCT00663507|Sickle Cell Disease
510336|NCT00663507|Immunosuppression
510337|NCT00663507|Organ & Tissue Transplantation
510338|NCT00663507|Transplantation Immunology
510339|NCT00663494|heart failure
510340|NCT00663494|MMP
510341|NCT00663494|coronary sinus
510342|NCT00663481|CoFactor
510343|NCT00663481|ANX-510
510344|NCT00663468|determine changes in patient pain level
510345|NCT00663468|determine changes in patient functionality
510346|NCT00663468|determine changes in patient life quality
510347|NCT00663455|kidney transplant recipients
510348|NCT00663455|children and adolescents with kidney transplants
510349|NCT00663442|ADHD
510350|NCT00663442|side effects
510351|NCT00663442|sleep
510352|NCT00663442|dopamine
510353|NCT00663442|pharmacogenetics
510354|NCT00663403|daptomycin
510355|NCT00663403|pharmacokinetics
510356|NCT00663403|renal replacement therapy
510357|NCT00663403|critical illness
510358|NCT00663403|intensive care units
510359|NCT00663377|Heart Failure
510360|NCT00663377|Insulin Resistance
510361|NCT00663377|Losartan
510362|NCT00663377|ACE inhibitor
510363|NCT00663377|Inflammatory cytokine
510364|NCT00663364|dry skin
510365|NCT00663351|Arthritis
510366|NCT00663351|Osteoarthritis
510367|NCT00663351|Traumatic Arthritis
510368|NCT00663351|Degenerative Joint Disease
510369|NCT00663351|Avascular Necrosis
510370|NCT00663338|Stroke
510371|NCT00663338|Hemispatial neglect
510372|NCT00663338|Unilateral neglect
510373|NCT00663338|Spatial neglect
510374|NCT00663338|Motor
510375|NCT00663338|Weakness
510376|NCT00663312|Idiopathic Parkinson's disease
510377|NCT00663312|Deep Brain stimulation
510378|NCT00663312|Hepatic glucose production
510379|NCT00663312|Insulin
510380|NCT00663312|Weight gain
510381|NCT00663312|Patient with an Idiopathic Parkinson's disease
510382|NCT00663299|Intracranial aneurysm
510383|NCT00663247|Diverticular disease
510384|NCT00663247|Inflammation
510385|NCT00663247|Mesalazine
510386|NCT00663234|Treatment Experienced
510387|NCT00663221|Osteoporosis prevention
510388|NCT00663195|heart failure
510389|NCT00663195|fibrosis
510390|NCT00663195|MMP
510391|NCT00663195|spironolactone
510392|NCT00663195|furosemide
510393|NCT00663182|Entecavir
510394|NCT00663182|cirrhosis
510395|NCT00663182|anti-viral
510396|NCT00663182|therapy
510397|NCT00663169|Arthritis Gouty
510398|NCT00663169|ACZ885
510399|NCT00663169|IL1B protein
510400|NCT00663169|Pain
510401|NCT00663156|lipoaugmentation
510402|NCT00663156|breast augmentation
510403|NCT00663156|fat grafting
510404|NCT00663156|liposuction
510405|NCT00663156|lipoinfiltration
510406|NCT00663156|Spear
510407|NCT00663156|breast implants
510408|NCT00663156|ASERF
510409|NCT00663156|Lipivage
510410|NCT00663156|Baker
510411|NCT00663156|harvest
510412|NCT00663156|autologous
510413|NCT00663156|Georgetown
510414|NCT00663143|investigate
510415|NCT00663143|TZD exposure
510416|NCT00663143|in vitro
510417|NCT00663143|alters
510418|NCT00663143|bone
510419|NCT00663143|formation
510420|NCT00663143|differentiation
510421|NCT00663143|capacity
510422|NCT00663143|bone marrow
510423|NCT00663143|stromal cells
510424|NCT00663130|Erectile Dysfunction
510425|NCT00663130|Vardenafil
510426|NCT00663117|naltrexone
510427|NCT00663117|LDN
510428|NCT00663117|IBD
510429|NCT00663117|Inflammatory bowel disease
510430|NCT00663104|early menopause
510431|NCT00663104|exercise
510432|NCT00663104|phytoestrogen
510433|NCT00663104|bone
510434|NCT00663104|CHD-risk factors
510435|NCT00663091|WPP-201
510436|NCT00663078|Cognitive Behavioral Therapy
510437|NCT00663078|expert patient programme
510438|NCT00663078|deprived population
510439|NCT00663078|women
510440|NCT00663065|Healthy subjects over 65
510441|NCT00663065|healthy subjects
510442|NCT00663052|Enbrel
510443|NCT00663052|Psoriasis
510444|NCT00663052|Topical Psoriasis
510445|NCT00663052|Wyeth Psoriasis
510446|NCT00663052|Active Psoriasis
510447|NCT00663039|Schizophrenia
510448|NCT00663039|Eye movements
510449|NCT00663039|phenotype
510450|NCT00663039|biochemical
510451|NCT00663039|relatives
510452|NCT00663026|antibody
510453|NCT00663026|immunotherapy
510454|NCT00663013|burn
510455|NCT00663013|pain
510456|NCT00663013|anxiety
510457|NCT00663000|acromegaly
510458|NCT00663000|diabetes
510459|NCT00663000|insulin resistance
510460|NCT00663000|impaired glucose tolerance
510461|NCT00662987|tonsillectomy
510462|NCT00662987|antibiotics
510463|NCT00662961|Plastic Surgery
510464|NCT00662948|Folicular Lymphoma
510465|NCT00662948|Consolidation
510466|NCT00662948|Maintenance
510467|NCT00662935|deep brain stimulation
510468|NCT00662935|cluster headache
510469|NCT00662935|hypothalamus
510470|NCT00662922|critical illness
510471|NCT00662922|hypoglycemia
510472|NCT00662922|neurocognitive dysfunction
510473|NCT00662922|intensive insulin therapy
510474|NCT00662909|Overactive bladder (OAB)
510475|NCT00662909|Frequency
510476|NCT00662909|Micturition
510477|NCT00662909|Urgency
510478|NCT00662909|Urinary incontinence
510479|NCT00662909|Urinary urge incontinence
510480|NCT00662909|YM178
510481|NCT00662883|ketamine
510482|NCT00662883|corticosteroid
510483|NCT00662883|intranasal
510484|NCT00662883|phase I
510485|NCT00662883|Healthy volunteers
510486|NCT00662870|DAPTACEL
510487|NCT00662870|Diphtheria
510488|NCT00662870|Tetanus
510489|NCT00662870|Whooping Cough
510490|NCT00662870|Polio
510491|NCT00662870|Haemophilus influenzae type b
510492|NCT00662870|Pertussis
510493|NCT00662857|Diabetic adult male, diabetic adult female
510494|NCT00662844|Vitamin D insufficiency,vitamin D3 treatment,young women
510495|NCT00662831|Diabetic Foot Ulcers Neuroischaemic
510496|NCT00662805|pharmacovigilance
510497|NCT00662805|COPD
510498|NCT00662779|asthma
510499|NCT00662779|exercise induced bronchospasm
510500|NCT00662779|prevention
510501|NCT00662779|EIB
510502|NCT00662779|children
510503|NCT00662766|Black currant
510504|NCT00662766|Berry seed
510505|NCT00662766|Press residue
510506|NCT00662766|Tocopherol
510507|NCT00662766|Fatty acids
510508|NCT00662766|Fiber
510509|NCT00662766|Total phenols
510510|NCT00662766|TEAC
510511|NCT00662766|Comet assay
510512|NCT00662766|Dihydroxybenzoic acid
510513|NCT00662753|hypertension
510514|NCT00662753|home blood pressure monitoring
510515|NCT00662753|nurse telephone follow up
510516|NCT00662753|medically underserved populations
510517|NCT00662727|Extracorporeal Shockwave Therapy
510518|NCT00662727|Myocardial Ischemia
510519|NCT00662727|Refractory Angina
510520|NCT00662701|Atrial Fibrillation
510521|NCT00662688|thromboembolism
510522|NCT00662688|chemotherapeutic agent toxicity
510523|NCT00662688|adenocarcinoma of the pancreas
510524|NCT00662688|stage IV pancreatic cancer
510525|NCT00662688|recurrent pancreatic cancer
510526|NCT00662675|Exocrine pancreatic insufficiency
510527|NCT00662675|Steatorrhea
510528|NCT00662675|Malabsorption syndromes
510529|NCT00662675|Cystic fibrosis
510530|NCT00662675|Pediatrics
510531|NCT00662675|Adult
510532|NCT00662675|Pancrelipase
510533|NCT00662662|Oropharyngeal Cancer
510534|NCT00662662|Non-Oropharyngeal Cancer
510535|NCT00662662|Head and Neck Cancer
510536|NCT00662662|Squamous Cell Carcinoma
510537|NCT00662662|Squamous cell carcinoma of the head and neck
510538|NCT00662662|SCCHN
510539|NCT00662662|HPV-16
510540|NCT00662662|Questionnaire
510541|NCT00662662|Sexual Behavior
510542|NCT00662662|Survey
510543|NCT00662649|Multiple sclerosis.
510544|NCT00662649|Relapse-remitting
510545|NCT00662649|Fingolimod
510546|NCT00662623|Chronic Obstructive Sleep Apnea
510547|NCT00662623|Sleep Apnea
510548|NCT00662623|Sleep Apnea Treatment
510549|NCT00662597|Tumor vascular disrupting agent
510550|NCT00662597|VDA
510551|NCT00662597|ASA404
510552|NCT00662597|non-small cell lung cancer
510553|NCT00662597|NSCLC
510554|NCT00662584|repetitive magnetic transcranial stimulation (rTMS)
510555|NCT00662584|functional magnetic resonance imaging (fMRI)
510556|NCT00662571|nucleotide polymorphisms
510557|NCT00662571|disequilibrium haplotype
510558|NCT00662571|acamprosate
510559|NCT00662571|differentiate
510560|NCT00662571|pharmacogenomic
510561|NCT00662571|effective individualized treatment
510562|NCT00662571|alcohol dependent
510563|NCT00662571|N-methyl-D-aspartate receptor (NMDA)
510564|NCT00662571|metabotropic glutamate receptor
510565|NCT00662571|decreasing craving
510566|NCT00662571|abstinence maintenance
510567|NCT00662558|Chronic low back pain
510568|NCT00662545|HIV
510569|NCT00662545|Hepatitis B
510570|NCT00662545|treatment experienced
510571|NCT00662532|Peri-implantitis; antibiotic
510572|NCT00662493|knee pain
510573|NCT00662493|exercise
510574|NCT00662493|rehabilitation
510575|NCT00662480|population
510576|NCT00662480|screening
510577|NCT00662480|abdominal aortic aneurysms
510578|NCT00662480|peripheral arterial disease
510579|NCT00662480|hypertension
510580|NCT00662480|Prevention
510581|NCT00662467|Myocardial Infarction
510582|NCT00662467|Hemorrhage
510583|NCT00662467|Thromboembolism
510584|NCT00662467|Clopidogrel
510585|NCT00662467|Aspirin
510586|NCT00662467|Warfarin
510587|NCT00662454|contraceptive
510588|NCT00662454|efficacy
510589|NCT00662454|body weight
510590|NCT00662441|Erectile Dysfunction
510591|NCT00662441|Vardenafil
510592|NCT00662428|cost-benefit analysis
510593|NCT00662428|practice guideline
510594|NCT00662428|inpatients
510595|NCT00662415|phantom limb pain
510596|NCT00662415|fMRI
510597|NCT00662415|mirror therapy
510598|NCT00662402|K Grant
510599|NCT00662402|Career Advancement
510600|NCT00662402|Award
510601|NCT00662402|Consultation
510602|NCT00662402|Application
510603|NCT00662402|K
510604|NCT00662402|The NIH priority score of the reviewed proposal.
510605|NCT00662402|Percent of subjects who obtain funding for proposal.
510606|NCT00662402|Percent of subjects who submit proposals for funding.
510607|NCT00662389|skin laxity, wrinkles, rhytids
510608|NCT00662363|constipation
510609|NCT00662363|opioid
510610|NCT00662363|rehabilitation
510611|NCT00662363|post-operative
510612|NCT00662363|orthopedic
510613|NCT00662350|BPH
510614|NCT00662337|Bioequivalence, diphenhydramine hydrochloride
510615|NCT00662298|severe asthma
510616|NCT00662298|prednisolone pharmacokinetics
510617|NCT00662298|anti-inflammatory effects
510618|NCT00662285|iron status
510619|NCT00662285|blood donors
510620|NCT00662272|Flu
510621|NCT00662272|Influenza vaccine
510622|NCT00662272|Adjuvant
510623|NCT00662272|Safety of an adjuvanted vaccine
510624|NCT00662272|Immune response to an adjuvanted vaccine
510625|NCT00662259|Anxiety disorders
510626|NCT00662259|Generalized anxiety
510627|NCT00662233|alveolar childhood rhabdomyosarcoma
510628|NCT00662233|previously treated childhood rhabdomyosarcoma
510629|NCT00662233|previously untreated childhood rhabdomyosarcoma
510630|NCT00662233|recurrent childhood rhabdomyosarcoma
510631|NCT00662233|nonmetastatic childhood soft tissue sarcoma
510632|NCT00662233|recurrent childhood soft tissue sarcoma
510633|NCT00662233|childhood desmoplastic small round cell tumor
510634|NCT00662233|ovarian sarcoma
510635|NCT00662233|stage II uterine sarcoma
510636|NCT00662233|stage III uterine sarcoma
510637|NCT00662233|embryonal childhood rhabdomyosarcoma
510638|NCT00662220|chronic
510639|NCT00662220|hepatitis C
510640|NCT00662220|ribavirin
510641|NCT00662220|SVR
510642|NCT00662220|genotype one
510643|NCT00662220|genotype four
510644|NCT00662207|electric stimulation
510645|NCT00662207|urethral obstruction
510646|NCT00662207|urodynamics
510647|NCT00662207|urology
510648|NCT00662194|HIV
510649|NCT00662194|HBV
510650|NCT00662194|HCV
510651|NCT00662194|co-infection
510652|NCT00662194|innate immunity
510653|NCT00662181|growth hormone
510654|NCT00662181|quality of life
510655|NCT00662181|fat redistribution
510656|NCT00662181|sugar metabolism
510657|NCT00662181|fat metabolism
510658|NCT00662181|cytokines
510659|NCT00662168|carcinoid
510660|NCT00662168|familial
510661|NCT00662168|Collect and describe information about the medical and environmental factors associated with each cases of carcinoid carcinoma
510662|NCT00662168|Develop a genogram representing the family cancer history of cases of Carcinoid.
510663|NCT00662155|Primary Insomnia
510664|NCT00662155|Cognitive Behavioral Therapy
510665|NCT00662155|Insomnia
510666|NCT00662155|Sleep
510667|NCT00662155|Zolpidem
510668|NCT00662155|Ambien
510669|NCT00662155|CBT
510670|NCT00662155|CBT-I
510671|NCT00662142|DHA
510672|NCT00662142|fMRI
510673|NCT00662129|stage IV breast cancer
510674|NCT00662129|male breast cancer
510675|NCT00662129|recurrent breast cancer
510676|NCT00662116|diastolic heart failure
510677|NCT00662103|fatigue
510678|NCT00662103|long-term effects secondary to cancer therapy in adults
510679|NCT00662103|psychosocial effects of cancer and its treatment
510680|NCT00662103|cancer survivor
510681|NCT00662103|stage IA breast cancer
510682|NCT00662103|stage IB breast cancer
510683|NCT00662103|stage II breast cancer
510684|NCT00662103|stage IIIA breast cancer
510685|NCT00662103|stage IIIB breast cancer
510686|NCT00662103|stage IIIC breast cancer
510687|NCT00662103|breast cancer in situ
510688|NCT00662090|MDS
510689|NCT00662090|JMML
510690|NCT00662090|EWOG-MDS
510691|NCT00662090|Myelodysplastic Syndromes (MDS)
510692|NCT00662090|Juvenile Myelomonocytic Leukemia (JMML)
510693|NCT00662077|osteoporosis
510694|NCT00662077|bifosfonates
510695|NCT00662077|ibandronate
510696|NCT00662064|Lower urinary tract
510697|NCT00662064|Physiology
510698|NCT00662064|Pathology
510699|NCT00662064|Immunohistochemistry
510700|NCT00662064|Urinary bladder
510701|NCT00662051|Asthma
510702|NCT00662051|Exhaled Nitric Oxide
510703|NCT00662051|Asthma Control Test
510704|NCT00662038|idiopathic
510705|NCT00662038|pulmonary
510706|NCT00662038|fibrosis
510707|NCT00662012|Leishmaniasis
510708|NCT00662012|Sodium stibogluconate
510709|NCT00662012|Pentostam
510710|NCT00662012|sand fly
510711|NCT00661999|unspecified adult solid tumor, protocol specific
510712|NCT00661999|monoclonal gammopathy of undetermined significance
510713|NCT00661999|extramedullary plasmacytoma
510714|NCT00661999|isolated plasmacytoma of bone
510715|NCT00661999|refractory multiple myeloma
510716|NCT00661999|stage I multiple myeloma
510717|NCT00661999|stage II multiple myeloma
510718|NCT00661999|stage III multiple myeloma
510719|NCT00661999|primary systemic amyloidosis
510720|NCT00661999|Waldenstrom macroglobulinemia
510721|NCT00661999|post-transplant lymphoproliferative disorder
510722|NCT00661999|stage I adult T-cell leukemia/lymphoma
510723|NCT00661999|stage II adult T-cell leukemia/lymphoma
510724|NCT00661999|stage III adult T-cell leukemia/lymphoma
510725|NCT00661999|stage IV adult T-cell leukemia/lymphoma
510726|NCT00661999|recurrent adult T-cell leukemia/lymphoma
510727|NCT00661999|angioimmunoblastic T-cell lymphoma
510728|NCT00661999|anaplastic large cell lymphoma
510729|NCT00661999|stage I cutaneous T-cell non-Hodgkin lymphoma
510730|NCT00661999|stage II cutaneous T-cell non-Hodgkin lymphoma
510731|NCT00661999|stage III cutaneous T-cell non-Hodgkin lymphoma
510732|NCT00661999|stage IV cutaneous T-cell non-Hodgkin lymphoma
510733|NCT00661999|recurrent cutaneous T-cell non-Hodgkin lymphoma
510734|NCT00661999|stage I mycosis fungoides/Sezary syndrome
510735|NCT00661999|stage II mycosis fungoides/Sezary syndrome
510736|NCT00661999|stage III mycosis fungoides/Sezary syndrome
510737|NCT00661999|stage IV mycosis fungoides/Sezary syndrome
510738|NCT00661999|recurrent mycosis fungoides/Sezary syndrome
510739|NCT00661999|stage I adult Hodgkin lymphoma
510740|NCT00661999|stage II adult Hodgkin lymphoma
510741|NCT00661999|stage III adult Hodgkin lymphoma
510742|NCT00661999|stage IV adult Hodgkin lymphoma
510743|NCT00661999|recurrent adult Hodgkin lymphoma
510744|NCT00661999|recurrent adult grade III lymphomatoid granulomatosis
510745|NCT00661999|stage I adult Burkitt lymphoma
510746|NCT00661999|stage III adult Burkitt lymphoma
510747|NCT00661999|stage IV adult Burkitt lymphoma
510748|NCT00661999|noncontiguous stage II adult Burkitt lymphoma
510749|NCT00661999|noncontiguous stage II adult diffuse large cell lymphoma
510750|NCT00661999|noncontiguous stage II adult diffuse mixed cell lymphoma
510751|NCT00661999|noncontiguous stage II adult diffuse small cleaved cell lymphoma
510752|NCT00661999|noncontiguous stage II adult immunoblastic large cell lymphoma
510753|NCT00661999|noncontiguous stage II adult lymphoblastic lymphoma
510754|NCT00661999|noncontiguous stage II grade 1 follicular lymphoma
510755|NCT00661999|noncontiguous stage II grade 2 follicular lymphoma
510756|NCT00661999|noncontiguous stage II grade 3 follicular lymphoma
510757|NCT00661999|noncontiguous stage II mantle cell lymphoma
510758|NCT00661999|noncontiguous stage II marginal zone lymphoma
510759|NCT00661999|noncontiguous stage II small lymphocytic lymphoma
510760|NCT00661999|contiguous stage II adult Burkitt lymphoma
510761|NCT00661999|contiguous stage II adult diffuse large cell lymphoma
510762|NCT00661999|contiguous stage II adult diffuse mixed cell lymphoma
510763|NCT00661999|contiguous stage II adult diffuse small cleaved cell lymphoma
510764|NCT00661999|contiguous stage II adult immunoblastic large cell lymphoma
510765|NCT00661999|contiguous stage II adult lymphoblastic lymphoma
510766|NCT00661999|contiguous stage II grade 1 follicular lymphoma
510767|NCT00661999|contiguous stage II grade 2 follicular lymphoma
510768|NCT00661999|contiguous stage II grade 3 follicular lymphoma
510769|NCT00661999|contiguous stage II mantle cell lymphoma
510770|NCT00661999|contiguous stage II marginal zone lymphoma
510771|NCT00661999|contiguous stage II small lymphocytic lymphoma
510772|NCT00661999|stage I adult diffuse large cell lymphoma
510773|NCT00661999|stage I adult diffuse mixed cell lymphoma
510774|NCT00661999|stage I adult diffuse small cleaved cell lymphoma
510775|NCT00661999|stage III adult diffuse large cell lymphoma
510776|NCT00661999|stage III adult diffuse mixed cell lymphoma
510777|NCT00661999|stage III adult diffuse small cleaved cell lymphoma
510778|NCT00661999|stage IV adult diffuse large cell lymphoma
510779|NCT00661999|stage IV adult diffuse mixed cell lymphoma
510780|NCT00661999|stage IV adult diffuse small cleaved cell lymphoma
510781|NCT00661999|stage I adult immunoblastic large cell lymphoma
510782|NCT00661999|stage III adult immunoblastic large cell lymphoma
510783|NCT00661999|stage IV adult immunoblastic large cell lymphoma
510784|NCT00661999|stage I adult lymphoblastic lymphoma
510785|NCT00661999|stage III adult lymphoblastic lymphoma
510786|NCT00661999|stage IV adult lymphoblastic lymphoma
510787|NCT00661999|stage I grade 1 follicular lymphoma
510788|NCT00661999|stage I grade 2 follicular lymphoma
510789|NCT00661999|stage I grade 3 follicular lymphoma
510790|NCT00661999|stage III grade 1 follicular lymphoma
510791|NCT00661999|stage III grade 2 follicular lymphoma
510792|NCT00661999|stage III grade 3 follicular lymphoma
510793|NCT00661999|stage IV grade 1 follicular lymphoma
510794|NCT00661999|stage IV grade 2 follicular lymphoma
510795|NCT00661999|stage IV grade 3 follicular lymphoma
510796|NCT00661999|stage I mantle cell lymphoma
510797|NCT00661999|stage I marginal zone lymphoma
510798|NCT00661999|stage III mantle cell lymphoma
510799|NCT00661999|stage III marginal zone lymphoma
510800|NCT00661999|stage IV mantle cell lymphoma
510801|NCT00661999|stage IV marginal zone lymphoma
510802|NCT00661999|stage I small lymphocytic lymphoma
510803|NCT00661999|stage III small lymphocytic lymphoma
510804|NCT00661999|stage IV small lymphocytic lymphoma
510805|NCT00661999|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
510806|NCT00661999|nodal marginal zone B-cell lymphoma
510807|NCT00661999|splenic marginal zone lymphoma
510808|NCT00661999|recurrent adult Burkitt lymphoma
510809|NCT00661999|recurrent adult diffuse large cell lymphoma
510810|NCT00661999|recurrent adult diffuse mixed cell lymphoma
510811|NCT00661999|recurrent adult diffuse small cleaved cell lymphoma
510812|NCT00661999|recurrent adult immunoblastic large cell lymphoma
510813|NCT00661999|recurrent adult lymphoblastic lymphoma
510814|NCT00661999|recurrent grade 1 follicular lymphoma
510815|NCT00661999|recurrent grade 2 follicular lymphoma
510816|NCT00661999|recurrent grade 3 follicular lymphoma
510817|NCT00661999|recurrent mantle cell lymphoma
510818|NCT00661999|recurrent marginal zone lymphoma
510819|NCT00661999|recurrent small lymphocytic lymphoma
510820|NCT00661999|adult acute lymphoblastic leukemia in remission
510821|NCT00661999|recurrent adult acute lymphoblastic leukemia
510822|NCT00661999|untreated adult acute lymphoblastic leukemia
510823|NCT00661999|stage I chronic lymphocytic leukemia
510824|NCT00661999|stage II chronic lymphocytic leukemia
510825|NCT00661999|stage III chronic lymphocytic leukemia
510826|NCT00661999|stage IV chronic lymphocytic leukemia
510827|NCT00661999|refractory chronic lymphocytic leukemia
510828|NCT00661999|refractory hairy cell leukemia
510829|NCT00661999|progressive hairy cell leukemia, initial treatment
510830|NCT00661999|prolymphocytic leukemia
510831|NCT00661999|anemia
510832|NCT00661999|T-cell large granular lymphocyte leukemia
510833|NCT00661999|acute undifferentiated leukemia
510834|NCT00661999|mast cell leukemia
510835|NCT00661999|adult nasal type extranodal NK/T-cell lymphoma
510836|NCT00661999|untreated hairy cell leukemia
510837|NCT00661973|asthma
510838|NCT00661973|airway smooth muscle
510839|NCT00661973|inhaled corticosteroids
510840|NCT00661960|HIV Positive
510841|NCT00661960|AIDS
510842|NCT00661960|Antiretroviral Therapy
510843|NCT00661960|Gastrointestinal-Associated Lymphoid Tissue
510844|NCT00661960|Immune Reconstitution
510845|NCT00661960|treatment experienced
510846|NCT00661947|fructose
510847|NCT00661947|sucrose
510848|NCT00661947|high fructose corn syrup
510849|NCT00661947|serum uric acid
510850|NCT00661947|lactate
510851|NCT00661947|glucose
510852|NCT00661947|triglycerides
510853|NCT00661947|Bioavailability of fructose from two formulations
510854|NCT00661934|Subject undergoing Dialysis and Subject suffering from Cardiac Malfunction
510855|NCT00661921|Type 2 Diabetes Mellitus
510856|NCT00661921|AMG 108
510857|NCT00661921|HbA1C
510858|NCT00661921|glucose
510859|NCT00661921|metformin
510860|NCT00661921|sulfonylurea
510861|NCT00661921|IL-1 Inhibitor
510862|NCT00661921|biologic
510863|NCT00661921|subcutaneous injection
510864|NCT00661895|African American
510865|NCT00661882|adenocarcinoma of the pancreas
510866|NCT00661882|recurrent pancreatic cancer
510867|NCT00661882|stage I pancreatic cancer
510868|NCT00661882|stage II pancreatic cancer
510869|NCT00661882|stage III pancreatic cancer
510870|NCT00661856|Soy Isoflavones, Bone Mineral Density, Post menopausal women
510871|NCT00661843|insomnia
510872|NCT00661843|geriatric
510873|NCT00661843|yoga
510874|NCT00661843|sleep
510875|NCT00661843|electrocardiogram
510876|NCT00661830|advanced
510877|NCT00661830|metastatic
510878|NCT00661830|biliary
510879|NCT00661830|tract
510880|NCT00661817|Exercise
510881|NCT00661817|Physical Fitness
510882|NCT00661817|Patient Compliance
510883|NCT00661817|Health Behavior
510884|NCT00661791|preterm infants
510885|NCT00661791|massage
510886|NCT00661791|physical activity
510887|NCT00661791|weight gain
510888|NCT00661791|length of hospital stay
510889|NCT00661791|NICU
510890|NCT00661765|varenicline bioavailability transdermal smoking cessation
510891|NCT00661739|palliative
510892|NCT00661739|Breast cancer
510893|NCT00661739|metastatic
510894|NCT00661739|Bendamustine
510895|NCT00661739|phase I
510896|NCT00661726|Thalassemia Intermedia
510897|NCT00661713|Meningococcal disease
510898|NCT00661713|Neisseria meningitidis serogroup B
510899|NCT00661713|prevention
510900|NCT00661713|vaccination
510901|NCT00661713|adolescents
510902|NCT00661700|Erectile Dysfunction
510903|NCT00661700|Quality of Life
510904|NCT00661661|Long term open label study in Japan
510905|NCT00661661|CP-690
510906|NCT00661661|550
510907|NCT00661661|tofacitinib
510908|NCT00661648|surgery
510909|NCT00661635|Laparoscopic Cholecystectomy Surgery, Acute Pain, Perioperative Pain
510910|NCT00661609|Anti-mitotic
510911|NCT00661609|Eg5 Inhibitor
510912|NCT00661609|Kinesin Spindle Protein Inhibitor
510913|NCT00661609|Urothelial Cancer
510914|NCT00661609|Bladder Cancer
510915|NCT00661609|Renal Pelvis Cancer
510916|NCT00661609|Urethra Cancer
510917|NCT00661609|Ureter Cancer
510918|NCT00661609|Recurrent
510919|NCT00661609|Advanced
510920|NCT00661609|Stage IV
510921|NCT00661596|Erectile Dysfunction
510922|NCT00661596|Vardenafil
510923|NCT00661583|trabeculectomy
510924|NCT00661583|glaucoma
510925|NCT00661583|ranibizumab
510926|NCT00661570|laryngectomy
510927|NCT00661570|larynx cancer
510928|NCT00661557|Booster vaccination
510929|NCT00661557|Meningococcal vaccine
510930|NCT00661557|Meningococcal disease
510931|NCT00661557|Safety
510932|NCT00661557|immunogenicity
510933|NCT00661544|Multiple Myeloma
510934|NCT00661544|Ascorbic Acid
510935|NCT00661544|Vitamin C
510936|NCT00661544|Arsenic Trioxide
510937|NCT00661544|Trisenox
510938|NCT00661544|Melphalan
510939|NCT00661544|Autologous Stem Cell Transplant
510940|NCT00661544|Stem Cell Transplantation
510941|NCT00661531|Breast cancer
510942|NCT00661531|Metastatic breast cancer
510943|NCT00661531|ER positive breast cancer
510944|NCT00661531|Hormonal therapy
510945|NCT00661492|Androgen-independent prostate cancer(AIPC)
510946|NCT00661466|Gastrointestinal surgery
510947|NCT00661466|Post operative pain
510948|NCT00661453|Spinal Muscular Atrophy
510949|NCT00661453|SMA
510950|NCT00661453|Valproic Acid
510951|NCT00661427|Head and Neck cancer
510952|NCT00661427|Cetuximab
510953|NCT00661414|Cancer
510954|NCT00661414|Solid tumors
510955|NCT00661401|gammaglobulin
510956|NCT00661401|subcutaneous infusion
510957|NCT00661401|specific antibodies
510958|NCT00661401|primary antibody deficiency
510959|NCT00661375|BAY 43-9006
510960|NCT00661375|Phase II
510961|NCT00661375|Renal cell carcinoma
510962|NCT00661375|Response rate
510963|NCT00661362|DPP-4 inhibitors
510964|NCT00661362|HbA1c
510965|NCT00661362|Incretins
510966|NCT00661349|Kaletra
510967|NCT00661349|Nevirapina
510968|NCT00661349|HCV chronic infection
510969|NCT00661349|Fibroscan
510970|NCT00661349|hepatic fibrosis
510971|NCT00661349|treatment experienced
510972|NCT00661336|stage III melanoma
510973|NCT00661336|recurrent melanoma
510974|NCT00661310|re-admissions
510975|NCT00661310|medicines
510976|NCT00661310|management
510977|NCT00661310|patients
510978|NCT00661310|80 years and older
510979|NCT00661310|acute
510980|NCT00661310|admissions
510981|NCT00661310|hospital
510982|NCT00661297|Erectile Dysfunction
510983|NCT00661297|Vardenafil
510984|NCT00661271|mindfulness
510985|NCT00661271|meditation
510986|NCT00661271|urban youth
510987|NCT00661271|stress reduction
510988|NCT00661271|adolescent
510989|NCT00661271|Stress reduction for urban youth
510990|NCT00661258|HIV antiretroviral treatment adherence intervention China
510991|NCT00661258|adherence to antiretroviral treatment
510992|NCT00661258|treatment experienced
510993|NCT00661232|Myocardial Viability
510994|NCT00661232|Delayed Enhancement Magnetic Resonance Imaging
510995|NCT00661232|Functional Recovery
510996|NCT00661206|Clopidogrel
510997|NCT00661206|Drug-eluting stent
510998|NCT00661193|recurrent non-small cell lung cancer
510999|NCT00661193|stage IIIB non-small cell lung cancer
511000|NCT00661193|stage IV non-small cell lung cancer
511001|NCT00661193|adenocarcinoma of the lung
511002|NCT00661193|large cell lung cancer
511003|NCT00661193|squamous cell lung cancer
511004|NCT00661141|acetaldehyde
511005|NCT00661141|ethanol
511006|NCT00661141|ALDH2
511007|NCT00661128|Sudden Cardiac Arrest
511008|NCT00661115|Erectile dysfunction
511009|NCT00661115|Sexual Dysfunction
511010|NCT00661089|stroke
511011|NCT00661089|shoulder pain
511012|NCT00661089|spasticity
511013|NCT00661063|neuropathic pain
511014|NCT00661063|ketamine
511015|NCT00661063|clonidine
511016|NCT00661063|association
511017|NCT00661024|thyroid surgery
511018|NCT00661024|recurrent laryngeal nerves visualization
511019|NCT00661024|intraoperative neuromonitoring
511020|NCT00661024|predictive values
511021|NCT00661011|Non-small cell lung carcinoma
511022|NCT00661011|Concomitant radiochemotherapy
511023|NCT00661011|Cisplatin
511024|NCT00661011|Vinorelbine
511025|NCT00661011|Radiotherapy
511026|NCT00661011|Chemotherapy
511027|NCT00661011|Unresectable stage III non-small cell lung carcinoma
511028|NCT00661011|Surgery
511029|NCT00661011|Unresectable stage III non-small cell lung carcinoma not suitable for radical radiotherapy after objective response to induction chemotherapy
511030|NCT00660998|Erectile dysfunction
511031|NCT00660998|Diabetes mellitus type 1
511032|NCT00660998|Vardenafil
511033|NCT00660985|Acne vulgaris
511034|NCT00660985|Differin
511035|NCT00660985|Adapalene
511036|NCT00660972|HIV Integrase Inhibitors
511037|NCT00660972|HIV Nucleoside Reverse Transcriptase Inhibitors
511038|NCT00660972|Treatment Naive
511039|NCT00660972|Viral Load
511040|NCT00660959|Euvolemic
511041|NCT00660959|Hyponatremia
511042|NCT00660959|Serum Sodium
511043|NCT00660959|Fluid Overload
511044|NCT00660959|Vasopressin Antagonist
511045|NCT00660946|anticoagulation in dialysis patients
511046|NCT00660946|chronic anticoagulation
511047|NCT00660946|warfarin
511048|NCT00660946|hemodialysis
511049|NCT00660946|INR
511050|NCT00660946|Point of Care
511051|NCT00660933|postpartum anemia
511052|NCT00660933|intravenous iron
511053|NCT00660907|Dapagliflozin
511054|NCT00660907|efficacy
511055|NCT00660907|safety
511056|NCT00660907|metformin
511057|NCT00660907|Type 2 diabetes
511058|NCT00660894|adenocarcinoma of the colon
511059|NCT00660894|stage III colon cancer
511060|NCT00660881|Lupus
511061|NCT00660881|Monoclonal antibody
511062|NCT00660881|B-Cell immunotherapy
511063|NCT00660868|smell
511064|NCT00660868|olfaction
511065|NCT00660868|olfactory sensitivity
511066|NCT00660868|smell loss
511067|NCT00660868|chemoreception
511068|NCT00660855|laparoscopy
511069|NCT00660842|quality of life
511070|NCT00660842|weekly therapy
511071|NCT00660842|neurotoxicity
511072|NCT00660816|recurrent non-small cell lung cancer
511073|NCT00660816|stage IIIB non-small cell lung cancer
511074|NCT00660816|stage IV non-small cell lung cancer
511075|NCT00660803|Advanced Breast Cancer
511076|NCT00660803|Hormone Therapy
511077|NCT00660790|diabetes mellitus type II, therapy non-responders
511078|NCT00660777|oropharyngeal exercises
511079|NCT00660777|obstructive sleep apnea
511080|NCT00660777|speech therapy
511081|NCT00660764|cholesterol
511082|NCT00660764|coronary heart disease
511083|NCT00660764|rosuvastatin
511084|NCT00660764|LDL-C goal
511085|NCT00660764|hypercholesterolemia
511086|NCT00660764|secondary prevention
511087|NCT00660764|primary prevention
511088|NCT00660764|CVA
511089|NCT00660751|Physiology of Serotonergic and Adrenergic systems
511090|NCT00660738|chronic obstructive pulmonary disease
511091|NCT00660738|walking
511092|NCT00660738|exercise test
511093|NCT00660738|quality of life
511094|NCT00660738|dyspnea
511095|NCT00660738|desaturation
511096|NCT00660725|Gemcitabine
511097|NCT00660725|Oxaliplatin
511098|NCT00660725|Vandetanib
511099|NCT00660725|Phase I
511100|NCT00660712|Bipolar disorder
511101|NCT00660712|patient characteristics
511102|NCT00660712|treatment characteristics
511103|NCT00660699|Cholangiocarcinoma
511104|NCT00660699|Gallbladder
511105|NCT00660699|Pancreatic
511106|NCT00660699|Ampullary
511107|NCT00660699|Cancer
511108|NCT00660686|randomized clinical trial
511109|NCT00660686|elderly
511110|NCT00660686|cancer survivor
511111|NCT00660686|bone health
511112|NCT00660686|body composition
511113|NCT00660686|signs and symptoms
511114|NCT00660686|Androgen Deprivation Therapy
511115|NCT00660673|levodopa/carbidopa intestinal gel
511116|NCT00660673|Dyskinesia
511117|NCT00660673|Carbidopa
511118|NCT00660673|Parkinson's Disease
511119|NCT00660673|Severe Motor Fluctuations
511120|NCT00660673|Levodopa
511121|NCT00660660|GERD
511122|NCT00660660|Esophageal Reflux
511123|NCT00660660|Gastro-Esophageal Reflux
511124|NCT00660660|Regurgitation
511125|NCT00660660|Gastric
511126|NCT00660647|Rheumatoid arthritis, adalimumab, efficacy, adverse events
511127|NCT00660634|Peripheral arterial obstructive disease
511128|NCT00660634|Intermittent Claudication
511129|NCT00660634|Endovascular treatment
511130|NCT00660634|Flow-mediated dilation
511131|NCT00660621|High Grade
511132|NCT00660621|Malignant
511133|NCT00660621|GBM
511134|NCT00660608|Transfusion regulation
511135|NCT00660595|Schizophrenia
511136|NCT00660595|Schizoaffective psychosis
511137|NCT00660595|Schizophreniformic psychosis
511138|NCT00660595|Pilot study
511139|NCT00660595|Quetiapine Prolong
511140|NCT00660595|Risperidone
511141|NCT00660582|Erbitux
511142|NCT00660582|Colorectal cancer
511143|NCT00660582|Oxaliplatin
511144|NCT00660582|Flox
511145|NCT00660582|Fluorouracil + folinic acid
511146|NCT00660582|K-RAS
511147|NCT00660569|asthma treatment
511148|NCT00660569|utilization
511149|NCT00660569|real life practice
511150|NCT00659503|Seasonal Allergic Rhinitis
511151|NCT00659503|Ciclesonide
511152|NCT00659503|Hay Fever
511153|NCT00659503|SAR
511154|NCT00659490|Analgesic effect
511155|NCT00659490|Molar extraction
511156|NCT00659464|Infrared Spectroscopy
511157|NCT00659464|Syncope
511158|NCT00659464|Tilt Table Testing
511159|NCT00659451|Hypertension
511160|NCT00659451|Diabetes mellitus
511161|NCT00659451|Heart
511162|NCT00659412|Psoriatic arthritis
511163|NCT00659412|psoriasis
511164|NCT00659412|Alefacept
511165|NCT00659399|Pretreated Ovarian Carcinoma
511166|NCT00659386|Heart failure
511167|NCT00659386|Parvovirus B19
511168|NCT00659386|Intravenous immuneglobulin
511169|NCT00659373|cognitive/functional effects
511170|NCT00659373|psychosocial effects of cancer and its treatment
511171|NCT00659373|fatigue
511172|NCT00659373|sleep disorders
511173|NCT00659373|stage IA breast cancer
511174|NCT00659373|stage IB breast cancer
511175|NCT00659373|stage II breast cancer
511176|NCT00659373|stage IIIA breast cancer
511177|NCT00659334|Combidex
511178|NCT00659334|Diagnostic imaging
511179|NCT00660530|stage 5
511180|NCT00660530|chronic
511181|NCT00660530|hemodialysis
511182|NCT00660504|Extensive Disease-Small Cell Lung Cancer
511183|NCT00660491|flow mediated dilatation
511184|NCT00660491|maximal oxygen uptake
511185|NCT00660491|blood lipid
511186|NCT00660465|Regional BOLD signal dependency on arterial PaCO2.
511187|NCT00660465|Effect of breathing exercises on brain regional O2 level.
511188|NCT00660465|Healthy subjects
511189|NCT00660452|Allergy
511190|NCT00660452|SLIT
511191|NCT00660452|Asthma
511192|NCT00660452|House Dust Mites
511193|NCT00660439|PTSD
511194|NCT00660426|cancer
511195|NCT00660426|gastrointestinal
511196|NCT00660426|tumor
511197|NCT00660413|Acceleromyography
511198|NCT00660413|Mechanomyography
511199|NCT00660413|Neuromuscular block
511200|NCT00660413|Neuromuscular monitoring
511201|NCT00660413|Dose-response
511202|NCT00660413|Potency
511203|NCT00660413|Rocuronium
511204|NCT00660400|Myeloid
511205|NCT00660400|Monocytic
511206|NCT00660387|levodopa-carbidopa
511207|NCT00660387|Carbidopa
511208|NCT00660387|levodopa
511209|NCT00660387|dyskinesia
511210|NCT00660387|Duodopa
511211|NCT00660387|levodopa-carbidopa intestinal gel
511212|NCT00660387|Severe Motor Fluctuations
511213|NCT00660387|levodopa/carbidopa suspension
511214|NCT00660387|DUOPA
511215|NCT00660361|HIV
511216|NCT00660361|HBV
511217|NCT00660361|co-infection
511218|NCT00660361|drug resistance
511219|NCT00660361|tenofovir
511220|NCT00660361|HIV-HBV co-infection
511221|NCT00660348|recurrent pancreatic cancer
511222|NCT00660348|stage III pancreatic cancer
511223|NCT00660348|stage IV pancreatic cancer
511224|NCT00660348|adenocarcinoma of the pancreas
511225|NCT00660348|pain
511226|NCT00660348|stage II pancreatic cancer
511227|NCT00660335|secretin, RG1068, MRCP, pancreas
511228|NCT00660322|Asthma
511229|NCT00660322|Telemedicine
511230|NCT00660322|Randomized controlled trial
511231|NCT00660309|Type 2 diabetes mellitus
511232|NCT00660309|renal disease
511233|NCT00660309|hypertension
511234|NCT00660309|renal blood flow
511235|NCT00660309|retinal blood flow
511236|NCT00660309|aliskiren
511237|NCT00660309|irbesartan
511238|NCT00660309|captopril
511239|NCT00660296|CO2
511240|NCT00660296|pain
511241|NCT00660296|colonoscopy
511242|NCT00660296|cancer
511243|NCT00660296|screening
511244|NCT00660283|GBM
511245|NCT00660283|Newly
511246|NCT00660283|diagnosed
511247|NCT00660283|malignant
511248|NCT00660283|high grade
511249|NCT00660270|Chemotherapy
511250|NCT00660270|Radiation
511251|NCT00660244|Arimidex
511252|NCT00660244|Post menopausal
511253|NCT00660244|arthralgia
511254|NCT00660231|recurrent mycosis fungoides/Sezary syndrome
511255|NCT00660231|stage IB mycosis fungoides/Sezary syndrome
511256|NCT00660231|stage II mycosis fungoides/Sezary syndrome
511257|NCT00660231|stage III mycosis fungoides/Sezary syndrome
511258|NCT00660231|stage IV mycosis fungoides/Sezary syndrome
511259|NCT00660231|recurrent cutaneous T-cell non-Hodgkin lymphoma
511260|NCT00660231|stage IB cutaneous T-cell non-Hodgkin lymphoma
511261|NCT00660231|stage II cutaneous T-cell non-Hodgkin lymphoma
511262|NCT00660231|stage III cutaneous T-cell non-Hodgkin lymphoma
511263|NCT00660231|stage IV cutaneous T-cell non-Hodgkin lymphoma
511390|NCT00659594|Hay Fever
511264|NCT00660218|Stage III and IV head and neck cancer
511265|NCT00660205|DVT
511266|NCT00660205|PE
511267|NCT00660205|D-dimer
511268|NCT00660205|cancer
511269|NCT00660205|VTE
511270|NCT00660192|Migraine, refractory migraine, Pain, Botulinum Toxin , Botox
511271|NCT00660179|pulmonary arterial hypertension SERAPHIN
511272|NCT00660166|Natural killer cells
511273|NCT00660166|autologous stem cell transplant
511274|NCT00660166|immunotherapy
511275|NCT00660153|Advanced Colorectal Cancer and Other Gastrointestinal Cancers
511276|NCT00660153|tivozanib
511277|NCT00660153|AV-951
511278|NCT00660140|Cholangiocarcinoma
511279|NCT00660140|Gallbladder
511280|NCT00660140|Cancer
511281|NCT00660114|Cough variant asthma
511282|NCT00660114|Pulmicort® Respules®
511283|NCT00660114|Chinese patient Eligibility
511284|NCT00660101|ovarian cancer
511285|NCT00660101|vaccine
511286|NCT00660101|immunotherapy
511287|NCT00660101|autologous
511288|NCT00660075|Diabetes mellitus
511289|NCT00660075|Postprandial
511290|NCT00660075|Hyperlipidemia
511291|NCT00660075|Atherosclerosis
511292|NCT00660062|Major depression
511293|NCT00660062|relapse prevention
511294|NCT00660062|ECT
511295|NCT00660062|escitalopram
511296|NCT00660062|nortriptyline
511297|NCT00660036|Acute myeloid leukemia
511298|NCT00660036|Refractory
511299|NCT00660036|Relapsed
511300|NCT00660036|Second line
511301|NCT00660036|Gemtuzumab ozogamicin
511302|NCT00660036|Mitoxantrone
511303|NCT00660036|Etoposide
511304|NCT00660036|Phase I
511305|NCT00660036|Phase II
511306|NCT00660010|CPP
511307|NCT00660010|central precocious puberty
511308|NCT00660010|pediatrics
511309|NCT00660010|suppression of LH
511310|NCT00660010|Lupron
511311|NCT00660010|leuprolide acetate
511312|NCT00660010|depot formulation
511313|NCT00660010|GnRHa
511314|NCT00660010|GnRH agonist
511315|NCT00660010|GNRH analog
511316|NCT00660010|LH
511317|NCT00660010|Tanner staging
511318|NCT00659997|Ascariasis
511319|NCT00659997|Trichuriasis
511320|NCT00659997|Drug resistance
511321|NCT00659984|recurrent neuroblastoma
511322|NCT00659971|oral candidiasis
511323|NCT00659958|zonisamide
511324|NCT00659958|partial onset seizures
511325|NCT00659958|effectiveness
511326|NCT00659958|tolerability
511327|NCT00659945|Postoperation, nausea, vomiting, anesthesia, plastic surgery
511328|NCT00659932|diabetes
511329|NCT00659932|cognitive behavioural therapy
511330|NCT00659906|randomized clinical trial
511331|NCT00659906|cancer survivor
511332|NCT00659906|bone health
511333|NCT00659906|body composition
511334|NCT00659906|signs and symptoms
511335|NCT00659893|Peplin
511336|NCT00659893|PEP005
511337|NCT00659893|Actinic Keratosis
511338|NCT00659880|Meniscus transplant
511339|NCT00659880|Meniscal allograft
511340|NCT00659880|MAT
511341|NCT00659880|Knee
511342|NCT00659867|Ulcerative Colitis
511343|NCT00659867|Endomicroscopy
511344|NCT00659867|Chromoendoscopy
511345|NCT00659867|Confocal colonoscope
511346|NCT00659867|Surveillance colonoscopy
511347|NCT00659854|obstructive sleep apnea syndrome
511348|NCT00659854|The study examines the response of infants diagnosed with obstructive sleep apnea syndrome to diet changes
511349|NCT00659841|Seasonal Allergic Rhinitis
511350|NCT00659841|Ciclesonide
511351|NCT00659841|Hay Fever
511352|NCT00659841|SAR
511353|NCT00659828|Congenital leptin deficiency
511354|NCT00659828|Obesity
511355|NCT00659828|Metabolic Syndrome
511356|NCT00659828|Diabetes
511357|NCT00659776|ferumoxytol
511358|NCT00659763|IBS
511359|NCT00659763|Diagnosis
511360|NCT00659750|Perennial Allergic Rhinitis
511361|NCT00659750|Ciclesonide
511362|NCT00659750|PAR
511363|NCT00659737|Post-operative Nausea and Vomiting (PONV)
511364|NCT00659724|Dialyzer
511365|NCT00659698|surgical
511366|NCT00659698|site
511367|NCT00659698|infection
511368|NCT00659685|Bioequivalence
511369|NCT00659685|Ondansetron ODT
511370|NCT00659685|Fasting
511371|NCT00659685|To Determine Bioequivalence Under Fasting conditions
511372|NCT00659672|hypertension
511373|NCT00659672|prehypertension
511374|NCT00659672|high blood pressure
511375|NCT00659672|blood pressure
511376|NCT00659672|heart disease
511377|NCT00659646|Diabetes
511378|NCT00659646|ulcers
511379|NCT00659646|ulcerations
511380|NCT00659646|infection
511381|NCT00659633|lidocaine
511382|NCT00659633|allodynia
511383|NCT00659633|chronic regional pain syndrome
511384|NCT00659633|pain
511385|NCT00659620|Kidney Transplant
511386|NCT00659620|Chronic Allograft Nephropathy
511387|NCT00659620|Mesenchymal Stem Cell infusion
511388|NCT00659594|Seasonal Allergic rhinitis
511389|NCT00659594|Ciclesonide
511391|NCT00659594|SAR
511392|NCT00659568|unspecified adult solid tumor, protocol specific
511393|NCT00659568|stage III renal cell cancer
511394|NCT00659568|stage IV renal cell cancer
511395|NCT00659568|recurrent renal cell cancer
511396|NCT00659568|recurrent endometrial carcinoma
511397|NCT00659568|stage III endometrial carcinoma
511398|NCT00659568|stage IV endometrial carcinoma
511399|NCT00659568|recurrent breast cancer
511400|NCT00659568|stage IIIA breast cancer
511401|NCT00659568|stage IIIB breast cancer
511402|NCT00659568|stage IIIC breast cancer
511403|NCT00659568|stage IV breast cancer
511404|NCT00659568|recurrent small cell lung cancer
511405|NCT00659568|extensive stage small cell lung cancer
511406|NCT00659568|stage III adult Burkitt lymphoma
511407|NCT00659568|stage III adult diffuse large cell lymphoma
511408|NCT00659568|stage III adult diffuse mixed cell lymphoma
511409|NCT00659568|stage III adult diffuse small cleaved cell lymphoma
511410|NCT00659568|stage III adult Hodgkin lymphoma
511411|NCT00659568|stage III adult immunoblastic large cell lymphoma
511412|NCT00659568|stage III adult lymphoblastic lymphoma
511413|NCT00659568|stage III adult T-cell leukemia/lymphoma
511414|NCT00659568|stage III cutaneous T-cell non-Hodgkin lymphoma
511415|NCT00659568|stage III grade 1 follicular lymphoma
511416|NCT00659568|stage III grade 2 follicular lymphoma
511417|NCT00659568|stage III grade 3 follicular lymphoma
511418|NCT00659568|stage III mantle cell lymphoma
511419|NCT00659568|stage III marginal zone lymphoma
511420|NCT00659568|stage III small lymphocytic lymphoma
511421|NCT00659568|stage IV adult Burkitt lymphoma
511422|NCT00659568|stage IV adult diffuse large cell lymphoma
511423|NCT00659568|stage IV adult diffuse mixed cell lymphoma
511424|NCT00659568|stage IV adult diffuse small cleaved cell lymphoma
511425|NCT00659568|stage IV adult Hodgkin lymphoma
511426|NCT00659568|stage IV adult immunoblastic large cell lymphoma
511427|NCT00659568|stage IV adult lymphoblastic lymphoma
511428|NCT00659568|stage IV adult T-cell leukemia/lymphoma
511429|NCT00659568|stage IV cutaneous T-cell non-Hodgkin lymphoma
511430|NCT00659568|stage IV grade 1 follicular lymphoma
511431|NCT00659568|stage IV grade 2 follicular lymphoma
511432|NCT00659568|stage IV grade 3 follicular lymphoma
511433|NCT00659568|stage IV mantle cell lymphoma
511434|NCT00659568|stage IV marginal zone lymphoma
511435|NCT00659568|stage IV small lymphocytic lymphoma
511436|NCT00659568|recurrent adult Burkitt lymphoma
511437|NCT00659568|recurrent adult diffuse large cell lymphoma
511438|NCT00659568|recurrent adult diffuse mixed cell lymphoma
511439|NCT00659568|recurrent adult diffuse small cleaved cell lymphoma
511440|NCT00659568|recurrent adult grade III lymphomatoid granulomatosis
511441|NCT00659568|recurrent adult Hodgkin lymphoma
511442|NCT00659568|recurrent adult immunoblastic large cell lymphoma
511443|NCT00659568|recurrent adult lymphoblastic lymphoma
511444|NCT00659568|recurrent adult T-cell leukemia/lymphoma
511445|NCT00659568|recurrent cutaneous T-cell non-Hodgkin lymphoma
511446|NCT00659568|recurrent grade 1 follicular lymphoma
511447|NCT00659568|recurrent grade 2 follicular lymphoma
511448|NCT00659568|recurrent grade 3 follicular lymphoma
511449|NCT00659568|recurrent mantle cell lymphoma
511450|NCT00659568|recurrent marginal zone lymphoma
511451|NCT00659568|recurrent small lymphocytic lymphoma
511452|NCT00659568|anaplastic large cell lymphoma
511453|NCT00659568|angioimmunoblastic T-cell lymphoma
511454|NCT00659568|recurrent mycosis fungoides/Sezary syndrome
511455|NCT00659568|stage III mycosis fungoides/Sezary syndrome
511456|NCT00659568|stage IV mycosis fungoides/Sezary syndrome
511457|NCT00659568|adult nasal type extranodal NK/T-cell lymphoma
511458|NCT00659568|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
511459|NCT00659568|nodal marginal zone B-cell lymphoma
511460|NCT00659568|splenic marginal zone lymphoma
511461|NCT00659568|Waldenström macroglobulinemia
511462|NCT00659555|vascular endothelial growth factor,
511463|NCT00659555|drug interaction,
511464|NCT00659555|angiogenesis,
511465|NCT00659555|pharmacokinetics,
511466|NCT00659555|age-related macular degeneration,
511467|NCT00659555|pazopanib,
511468|NCT00659555|ketoconazole
511469|NCT00659542|inguinal hernia
511470|NCT00659542|inguinal hernioplasty
511471|NCT00659542|mesh fixation
511472|NCT00659542|Lichtenstein hernioplasty
511473|NCT00659529|cystic fibrosis
511474|NCT00659529|inflammation
511475|NCT00659529|pH
511476|NCT00659529|EBC
511477|NCT00659529|sputum biomarkers
511478|NCT00659529|phosphodiesterase inhibitors
511479|NCT00659308|pain
511480|NCT00659308|bullous keratopathy
511481|NCT00659308|amniotic membrane
511482|NCT00659308|anterior stromal puncture
511483|NCT00659269|Vitamin B-12
511484|NCT00659269|Vitamin B-6
511485|NCT00659269|Chemotherapy-Induced Neuropathy
511486|NCT00659269|Taxanes
511487|NCT00659269|Vinca alkaloid
511488|NCT00659269|Heavy metals
511489|NCT00659269|Neuropathy
511490|NCT00659269|Nerve pain
511491|NCT00659256|Hepatitis C Virus
511492|NCT00659256|Atherosclerosis
511493|NCT00659256|Intima-Media Thickness
511494|NCT00659256|Coronary Artery Calcium Score
511495|NCT00659256|Hepatitis C
511496|NCT00659243|Replacement therapy
511497|NCT00659243|Pasteurized breast milk
511498|NCT00659243|Preterm infants
511499|NCT00659243|BSSL
511500|NCT00659230|PTSD
511501|NCT00659230|Veterans
511502|NCT00659230|Nepicastat
511503|NCT00659230|OIF/OEF
511504|NCT00659217|Mesenchymal Stem Cells
511505|NCT00659217|lupus Nephritis
511506|NCT00659191|Healthy volunteer,
511507|NCT00659191|HIV infected subjects
511508|NCT00659178|Doxil,
511509|NCT00659178|pegylated liposomal doxorubicin,
511510|NCT00659178|ovarian cancer
511511|NCT00659178|IL-18,
511512|NCT00659178|combination study,
511513|NCT00659178|immunotherapy,
511514|NCT00659178|cytokine,
511515|NCT00659165|diabetes
511516|NCT00659165|insulin dependent diabetes
511517|NCT00659165|diabetes mellitus
511518|NCT00659165|detemir
511519|NCT00659165|levemir
511520|NCT00659165|glargine
511521|NCT00659165|lantus
511522|NCT00659165|insulin
511523|NCT00659165|appetite
511524|NCT00659165|satiety
511525|NCT00659165|centrally acting mediators of satiety
511526|NCT00659165|three factor eating questionnaire
511527|NCT00659165|PYY
511528|NCT00659165|ghrelin
511529|NCT00659165|leptin
511530|NCT00659152|ALI/ARDS
511531|NCT00659113|stage IIA esophageal cancer
511532|NCT00659113|stage IIB esophageal cancer
511533|NCT00659113|stage IIIA esophageal cancer
511534|NCT00659113|stage IIIB esophageal cancer
511535|NCT00659113|stage IIIC esophageal cancer
511536|NCT00659113|stage IV esophageal cancer
511537|NCT00659087|Total Knee
511538|NCT00659087|Range of Motion
511539|NCT00659087|Pain
511540|NCT00659074|bioequivalence
511541|NCT00659074|Ondansetron ODT
511542|NCT00659074|Fasting
511543|NCT00659074|To Determine Bioequivalence Under Fasting Conditions
511544|NCT00659061|micronutrients
511545|NCT00659048|Perennial Allergic Rhinitis
511546|NCT00659048|Ciclesonide
511547|NCT00659048|PAR
511548|NCT00659035|driving
511549|NCT00659035|opioids
511550|NCT00659035|impairment
511551|NCT00659035|ability
511552|NCT00659035|patients
511553|NCT00659035|receiving
511554|NCT00659035|oral morphine
511555|NCT00659035|severe
511556|NCT00659022|colorectal cancer
511557|NCT00659022|liver metastases
511558|NCT00659022|angiogenesis
511559|NCT00659022|metabolism
511560|NCT00659009|environmental
511561|NCT00659009|hypobaric hypoxia
511562|NCT00659009|sleep
511563|NCT00659009|respiratory-disturbance
511564|NCT00659009|neurobehavioral performance
511565|NCT00659009|Effect of altitude on sleep-related respiratory disturbance
511566|NCT00658970|Open label
511567|NCT00658970|Dose escalation
511568|NCT00658957|Diabetes
511569|NCT00658957|Foot Ulcer
511570|NCT00658944|Stress urinary incontinence
511571|NCT00658944|Mixed urinary incontinence
511572|NCT00658944|surgery
511573|NCT00658944|trans obturator tape
511574|NCT00658944|Maximum urethral closure pressure
511575|NCT00658944|Valsalva leak point pressure
511576|NCT00658944|outcome
511577|NCT00658931|Depression
511578|NCT00658931|Bereavement
511579|NCT00658931|Pilot Projects
511580|NCT00658931|Antidepressant Drugs
511581|NCT00658918|Perennial Allergic Rhinitis
511582|NCT00658918|Ciclesonide
511583|NCT00658918|Hay Fever
511584|NCT00658918|PAR
511585|NCT00658905|Preterm infants
511586|NCT00658905|Replacement therapy
511587|NCT00658905|Infant formula
511588|NCT00658905|BSSL
511589|NCT00658905|BSSL is present in fresh mother's milk but not in infant formula.
511590|NCT00658892|recurrent melanoma
511591|NCT00658892|stage IV melanoma
511592|NCT00658866|ertapenem tissue PK
511593|NCT00658853|COPD
511594|NCT00658853|training
511595|NCT00658853|VO2peak
511596|NCT00658853|performance
511597|NCT00658853|ventilation
511598|NCT00658853|high aerobic intensity treadmill walking
511599|NCT00658853|one leg training by cycling
511600|NCT00658827|Inflammatory Bowel Disease
511601|NCT00658827|Rheumatoid Arthritis
511602|NCT00658827|Psoriatic Arthritis
511603|NCT00658827|Ankylosing Spondylitis
511604|NCT00658827|Psoriasis
511605|NCT00658827|Pregnant women exposed to infliximab
511606|NCT00658775|GERD
511607|NCT00658775|erosive GERD
511608|NCT00658775|erosive esophagitis
511609|NCT00658749|AIR645
511610|NCT00658749|Altair Therapeutics
511611|NCT00658749|IL4
511612|NCT00658749|IL13
511613|NCT00658749|IL-4
511614|NCT00658749|IL-13
511615|NCT00658710|hemiplegia
511616|NCT00658710|stroke
511617|NCT00658710|TRIDENT
511618|NCT00658697|Rising PSA
511619|NCT00658697|androgen deprivation
511620|NCT00658697|bevacizumab (avastin)
511621|NCT00658697|docetaxel
511622|NCT00658697|lupron
511623|NCT00658697|zoladex
511624|NCT00658697|bicalutamide
511625|NCT00658658|Epidermal Growth Factor
511626|NCT00658658|Pediatric
511627|NCT00658658|Solid Tumors
511628|NCT00658658|Panitumumab
511629|NCT00658658|Dose Limiting Toxicity
511630|NCT00658645|Schizophrenia
511631|NCT00658645|Antipsychotic
511632|NCT00658645|Bifeprunox
511633|NCT00658632|GERD
511634|NCT00658632|erosive GERD
511635|NCT00658632|erosive esophagitis
511636|NCT00658606|plaque psoriasis
511637|NCT00658606|alefacept
511638|NCT00658606|Amevive
511639|NCT00658606|narrow band ultraviolet B
511640|NCT00658606|phototherapy
511641|NCT00658593|adenocarcinoma of the extrahepatic bile duct
511642|NCT00658593|unresectable extrahepatic bile duct cancer
511643|NCT00658593|recurrent extrahepatic bile duct cancer
511644|NCT00658593|adenocarcinoma of the gallbladder
511645|NCT00658593|adenocarcinoma with squamous metaplasia of the gallbladder
511646|NCT00658593|unresectable gallbladder cancer
511647|NCT00658593|recurrent gallbladder cancer
511648|NCT00658593|liver and intrahepatic biliary tract cancer
511649|NCT00658580|Small cell lung carcinoma
511650|NCT00658580|Chemotherapy
511651|NCT00658580|Phase III randomised study
511652|NCT00658528|GERD
511653|NCT00658528|erosive GERD
511654|NCT00658528|erosive esophagitis
511655|NCT00658476|Adolescent Depression
511656|NCT00658476|Depression
511657|NCT00658476|Teenage Depression
511658|NCT00658476|Los Angeles
511659|NCT00658463|Diabetes
511660|NCT00658463|Triglycerides
511661|NCT00658463|HDL-cholesterol
511662|NCT00658463|kinetic
511663|NCT00658463|rosuvastatin
511664|NCT00658450|Malaria, Cerebral
511665|NCT00658437|Melanoma, Stage IV, Phase II
511666|NCT00658411|AML
511667|NCT00658411|ALL
511668|NCT00658411|MDS
511669|NCT00658411|iron overload
511670|NCT00658411|deferoxamine
511671|NCT00658398|Alcohol
511672|NCT00658398|dependency
511673|NCT00658385|GCSF
511674|NCT00658372|PD 0332334 phase 3 pivotal trial
511675|NCT00658359|Immunosuppression
511676|NCT00658359|JAK3 inhibitor
511677|NCT00658359|kidney transplantation
511678|NCT00658346|HIV-1 group O
511679|NCT00658346|HIV-1 group M
511680|NCT00658346|Cameroon
511681|NCT00658346|HIV-1 infection
511682|NCT00658346|treatment naïve
511683|NCT00658333|Renal Transplantation
511684|NCT00658333|Immunosuppression
511685|NCT00658333|Renal transplant recipients
511686|NCT00658333|Gastrointestinal symptoms associated with MMF therapy
511687|NCT00658320|Renal transplantation
511688|NCT00658320|everolimus
511689|NCT00658320|mycophenolate mofetil
511690|NCT00658320|cyclosporine
511691|NCT00658320|corticosteroid
511692|NCT00658320|basiliximab
511693|NCT00658320|Banff diagnosis
511694|NCT00658320|Acute rejection
511695|NCT00658320|Therapeutic drug monitoring (TDM)
511696|NCT00658320|de novo renal transplant recipient
511697|NCT00658307|repetitive transcranial magnetic stimulation
511698|NCT00658307|double-blind
511699|NCT00658307|sham-controlled
511700|NCT00658307|randomized
511701|NCT00658281|Breast Cancer
511702|NCT00658281|On Board Imager Kilovoltage
511703|NCT00658281|Cone Beam Computed Tomography
511704|NCT00658281|Electronic Portal Imaging Device
511705|NCT00658281|Lymph Nodes
511706|NCT00658281|CBCT
511707|NCT00658281|OBI KV
511708|NCT00658268|Surgical procedures operative
511709|NCT00658268|Prosthesis implantation
511710|NCT00658268|Arthroplasty replacement
511711|NCT00658255|stable asthma
511712|NCT00658255|adults
511713|NCT00658255|formoterol
511714|NCT00658255|Symbicort
511715|NCT00658255|Oxis Turbuhaler
511716|NCT00658255|bronchodilation
511717|NCT00658242|craniofacial
511718|NCT00658242|maxillofacial
511719|NCT00658242|osteotomy
511720|NCT00658242|craniectomy
511721|NCT00658242|craniotomy
511722|NCT00658229|Exercise
511723|NCT00658229|Prostatic
511724|NCT00658229|Neoplasm
511725|NCT00658229|Androgen
511726|NCT00658229|Deprivation
511727|NCT00658216|Diagnosis and prognosis
511728|NCT00658216|Very elderly population
511729|NCT00658216|Heart failure
511730|NCT00658216|Brain natriuretic peptide
511731|NCT00658216|Observational prospective study
511732|NCT00658216|Older
511733|NCT00658216|Dyspneic patients aged 80
511734|NCT00658203|CRT-P
511735|NCT00658203|PEA
511736|NCT00658203|Severe Heart Failure (NYHA Class III or IV)
511737|NCT00658203|Cardiomyopathy of any etiology
511738|NCT00658203|Sinus rhythm
511739|NCT00658203|Reduced Left-Ventricular Ejection Fraction
511740|NCT00658203|LVEDD>30 mm/m2
511741|NCT00658203|QRS Duration: > 150 ms or > 120 ms
511742|NCT00658203|Aortic Pre-Ejection Delay > 140 ms
511743|NCT00658203|Interventricular Mechanical Delay > 40 ms
511870|NCT00657605|Metabolic syndrome
511744|NCT00658203|Delayed activation of postero-lateral Left Ventricular wall
511745|NCT00658203|Optimal and stable pharmacological treatment
511746|NCT00658190|Cervical cancer, automation, Internet, telecytology
511747|NCT00658177|Erectile dysfunction
511748|NCT00658177|Vardenafil
511749|NCT00658164|Nonalcoholic fatty liver disease associated with increased iron stores
511750|NCT00658151|focus
511751|NCT00658151|study
511752|NCT00658151|evaluate
511753|NCT00658151|sonographic
511754|NCT00658151|findings
511755|NCT00658151|colon
511756|NCT00658151|patients
511757|NCT00658151|developed
511758|NCT00658086|ALN-RSV01
511759|NCT00658086|Respiratory Syncytial Virus
511760|NCT00658073|Kidney transplant
511761|NCT00658073|Mesenchymal stem cell (MSC)
511762|NCT00658060|FMF, Exertional leg pain
511763|NCT00658047|Arthritis, Rheumatoid
511764|NCT00658047|Phase II
511765|NCT00658047|Rheumatoid Arthritis
511766|NCT00658034|Cancer
511767|NCT00658034|Fatigue
511768|NCT00658034|Acupuncture
511769|NCT00658021|diabetes
511770|NCT00658021|adolescents
511771|NCT00658021|exenatide
511772|NCT00658021|Astra Zeneca
511773|NCT00658008|PD 0332334 phase 3 pivotal trial
511774|NCT00657995|pancreatogenic
511775|NCT00657995|diabetes
511776|NCT00657995|artificial
511777|NCT00657995|pancreas
511778|NCT00657969|Polymorphism, genetic
511779|NCT00657969|Risk factors
511780|NCT00657969|Carotid Artery, Internal, Dissection
511781|NCT00657969|Vertebral Artery Dissection
511782|NCT00657969|Genetic predisposition
511783|NCT00657969|Outcome
511784|NCT00657969|Therapy
511785|NCT00657956|osteoarthritis
511786|NCT00657956|arthroplasty
511787|NCT00657956|knee joint
511788|NCT00657956|radiography
511789|NCT00657956|surgery
511790|NCT00657956|Bone Density
511791|NCT00657956|Outcome Assessment (Health Care)
511792|NCT00657943|carotid
511793|NCT00657943|intima
511794|NCT00657943|media
511795|NCT00657943|thickness
511796|NCT00657943|insulin
511797|NCT00657943|metformin
511798|NCT00657917|leishmaniasis
511799|NCT00657917|cutaneous
511800|NCT00657917|Old World
511801|NCT00657917|Leishmania major
511802|NCT00657917|Treatment
511803|NCT00657904|androgen antagonists
511804|NCT00657904|prostate neoplasms
511805|NCT00657891|Allergic Asthma
511806|NCT00657891|Anti IgE
511807|NCT00657891|Xolair
511808|NCT00657891|Basophil
511809|NCT00657891|IL-13
511810|NCT00657891|IL-4
511811|NCT00657891|Histamine
511812|NCT00657878|platinum free interval
511813|NCT00657878|chemotherapy
511814|NCT00657852|pamidronate,bone loss, liver transplantation
511815|NCT00657839|Benign Prostate Hyperplasia
511816|NCT00657839|Vardenafil
511817|NCT00657839|Genital Disease
511818|NCT00657839|Male: Signs and symptoms of Benign Prostate Hyperplasia
511819|NCT00657826|Diseased Heart Valve, Replacement
511820|NCT00657813|Alzheimer
511821|NCT00657813|SPECT
511822|NCT00657800|diabetes, inpatient, education,
511823|NCT00657787|Posttraumatic Stress Disorder
511824|NCT00657787|Veterans
511825|NCT00657787|Health Services
511826|NCT00657774|Asthma
511827|NCT00657774|Mild to Moderate
511828|NCT00657748|Leukodystrophy
511829|NCT00657748|Canavan disease,
511830|NCT00657748|Aspartoacylase,
511831|NCT00657748|Lithium,
511832|NCT00657748|Glyceryl Triacetate
511833|NCT00657735|bipolar
511834|NCT00657735|depression
511835|NCT00657735|prefrontal
511836|NCT00657735|cortex
511837|NCT00657735|antidepressant
511838|NCT00657735|response
511839|NCT00657722|Pulmonary hypertension
511840|NCT00657722|Chronic thromboembolic pulmonary hypertension
511841|NCT00657722|Operability
511842|NCT00657722|Thromboendarteriectomy
511843|NCT00657722|Operative mortality rate
511844|NCT00657722|Technical failure
511845|NCT00657722|Pulmonary angiography
511846|NCT00657722|Computed tomography
511847|NCT00657709|infant
511848|NCT00657709|Meningococcal disease
511849|NCT00657709|prevention
511850|NCT00657709|vaccination
511851|NCT00657696|primary health care
511852|NCT00657696|organizations
511853|NCT00657696|learning
511854|NCT00657696|quality of health care
511855|NCT00657683|GBS
511856|NCT00657683|GBS prevention
511857|NCT00657670|refractive error
511858|NCT00657670|spectacles
511859|NCT00657670|ready made spectacles
511860|NCT00657670|vision
511861|NCT00657670|cost effectiveness
511862|NCT00657657|Hepatitis
511863|NCT00657657|vaccine
511864|NCT00657644|Erectile Dysfunction
511865|NCT00657631|Acceptance and Commitment Therapy
511866|NCT00657631|Delusions
511867|NCT00657618|Leishmaniasis, Sodium stibogluconate, Pentostam, sand fly
511868|NCT00657605|Congenital leptin deficiency
511869|NCT00657605|Obesity
511871|NCT00657605|Diabetes
511872|NCT00657592|Depression
511873|NCT00657592|Los Angeles
511874|NCT00657592|Ziprasidone
511875|NCT00657566|intraabdominal
511876|NCT00657566|peritonitis
511877|NCT00657566|sepsis
511878|NCT00657566|duration
511879|NCT00657566|antibiotics
511880|NCT00657540|black widow spider
511881|NCT00657540|antivenom
511882|NCT00657540|latrodectism
511883|NCT00657527|Crestor
511884|NCT00657527|Rosuvastatin
511885|NCT00657527|Cholesterol
511886|NCT00657527|Coronary artery disease
511887|NCT00657527|Myocardial ischaemia.
511888|NCT00657514|hemoglobin desaturation kinetics
511889|NCT00657514|peripheral arterial disease
511890|NCT00657514|chronic angina
511891|NCT00657514|exercise tolerance
511892|NCT00657501|testosterone
511893|NCT00657501|hypoactive sexual desire disorder
511894|NCT00657501|menopause
511895|NCT00657488|Multiple Myeloma, Thalidomide, dose, dexamethasone
511896|NCT00657475|Heparin low dose
511897|NCT00657475|Inflammation
511898|NCT00657475|Blood loss
511899|NCT00657462|Medical Informatics Applications
511900|NCT00657462|Software
511901|NCT00657462|Utilization
511902|NCT00657449|sprains and strains
511903|NCT00657436|Acute Coronary Syndrome
511904|NCT00657436|Myocardial Infarction
511905|NCT00657436|Coronary Artery Disease
511906|NCT00657423|Lung Neoplasms
511907|NCT00657423|Endostatins
511908|NCT00657423|Vascular Endothelial Growth Factors
511909|NCT00657423|Fibroblast Growth Factors
511910|NCT00657423|Survival Rate
511911|NCT00657410|idiopathic thrombocytopenic purpura
511912|NCT00657397|Methadone
511913|NCT00657397|Substance Dependence
511914|NCT00657384|Specify the primary condition or disease being studied Major Hepatectomy
511915|NCT00657371|Colorectal Cancer
511916|NCT00657371|Colonoscopy
511917|NCT00657371|Third Eye Retroscope
511918|NCT00657371|Third Eye Retroscope Auxiliary Imaging System
511919|NCT00657371|Polypectomy
511920|NCT00657358|lidocaine
511921|NCT00657358|allodynia
511922|NCT00657358|chronic regional pain syndrome
511923|NCT00657358|pain
511924|NCT00657345|trastuzumab
511925|NCT00657345|breast cancer
511926|NCT00657345|her2 positive breast cancer
511927|NCT00657306|Cirrhosis
511928|NCT00657306|Ascites
511929|NCT00657306|Adrenal insufficiency
511930|NCT00657306|Hepatorenal syndrome
511931|NCT00657306|Portal hypertension
511932|NCT00657293|COPD
511933|NCT00657293|arm training
511934|NCT00657293|dyspnoea
511935|NCT00657293|quality of life
511936|NCT00657267|recurrent glioblastoma
511937|NCT00657267|temodar
511938|NCT00657267|temozolomide
511939|NCT00657254|Extension
511940|NCT00657254|Sorafenib
511941|NCT00657254|Survival
511942|NCT00657241|cardiac work
511943|NCT00657241|coreg cr
511944|NCT00657241|valsartan
511945|NCT00657241|tonometry
511946|NCT00657228|Anaphylaxis
511947|NCT00657228|Anaphylactoid reactions
511948|NCT00657202|NF1
511949|NCT00657202|neurofibroma
511950|NCT00657202|ranibizumab
511951|NCT00657202|Lucentis
511952|NCT00657189|Sifalimumab
511953|NCT00657189|MEDI-545
511954|NCT00657189|Lupus erythematosus, systemic
511955|NCT00657163|Stroke recovery
511956|NCT00657163|Pharmacological modulation
511957|NCT00657163|Selective Serotonin Reuptake Inhibitor (SSRI)
511958|NCT00657163|Fluoxetine
511959|NCT00657163|Brain plasticity
511960|NCT00657163|Ischemic Stroke and Motor impairment
511961|NCT00657163|Modulation of recovery and cerebral plasticity by Fluoxetine
511962|NCT00657137|HER2/neu positive
511963|NCT00657137|locally advanced or metastatic
511964|NCT00657124|AEN
511965|NCT00657111|influenza, elderly, United Kingdom
511966|NCT00657098|Side effects
511967|NCT00657098|Angiogenesis inhibitors
511968|NCT00657098|Epidermal growth factor receptor inhibitors
511969|NCT00657098|Tyrosinekinase inhibitors
511970|NCT00657085|Laser hair removal
511971|NCT00657072|scapholunate instability
511972|NCT00657072|neural networks
511973|NCT00657072|scaphoid
511974|NCT00657072|lunate
511975|NCT00657072|Suspected torn scapholunate interosseous ligament
511976|NCT00657072|Suspected other torn wrist ligaments
511977|NCT00657059|IgA nephropathy
511978|NCT00657059|mycophenolate mofetil
511979|NCT00657033|Erectile Dysfunction
511980|NCT00657020|nicotine
511981|NCT00657020|therapy
511982|NCT00657020|fMRI/EEG
511983|NCT00657020|replacement
511984|NCT00657007|lupus
511985|NCT00657007|SLE
511986|NCT00656994|Sleep Disorder
511987|NCT00656994|Insomnia
511988|NCT00656981|Moderate Acne Vulgaris
511989|NCT00656981|Acne
511990|NCT00656968|peptic ulcer disease
511991|NCT00656968|gastric cancer
511992|NCT00656968|therapeutics
511993|NCT00656955|Survival Study
511994|NCT00656955|Kidney Cancer
511995|NCT00656955|Renal Cell Cancer
511996|NCT00656955|Tumor Markers
511997|NCT00656955|Heterogeneity
511998|NCT00656955|Molecular Epidemiology
511999|NCT00656955|Survival
512000|NCT00656955|Occupational Exposure
512001|NCT00656955|Renal Cancer
512002|NCT00656942|Pain
512003|NCT00656929|Vitamin D
512004|NCT00656929|Viral URI
512005|NCT00656929|Influenza
512006|NCT00656929|Colds
512007|NCT00656916|Post-Transplant Constrictive Bronchiolitis
512008|NCT00656916|Bronchiolitis
512009|NCT00656916|Fluticasone Propionate
512010|NCT00656916|Inhaled Corticosteroids
512011|NCT00656916|Lung Condition
512012|NCT00656916|PTCB
512013|NCT00656903|Lucentis
512014|NCT00656903|Indocyanine Green Angiography
512015|NCT00656903|Choroidal Neovascularization
512016|NCT00656903|Macular Degeneration
512017|NCT00656903|Ranibizumab
512018|NCT00656903|Age-Related Macular Degeneration
512019|NCT00656903|AMD
512020|NCT00656890|ulcerative colitis, rectal bleeding
512021|NCT00656877|Fat Embolism Total Knee Arthroplasty
512022|NCT00656864|Diabetes
512023|NCT00656864|pioglitazone
512024|NCT00656864|GIP
512025|NCT00656851|HIV/AIDS
512026|NCT00656851|Heart disease
512027|NCT00656851|Diabetes
512028|NCT00656851|Cardiovascular disease risk
512029|NCT00656851|Dyslipidemia
512030|NCT00656851|Visceral adiposity
512031|NCT00656851|treatment experienced
512032|NCT00656838|colon
512033|NCT00656838|rectal
512034|NCT00656838|cancer
512035|NCT00656838|screening
512036|NCT00656825|P144
512037|NCT00656825|TGF-β1
512038|NCT00656825|Healthy volunteers
512039|NCT00656825|Cutaneous tolerability
512040|NCT00656825|Skin fibrosis
512041|NCT00656825|systemic scleroderma
512042|NCT00656825|systemic sclerosis
512043|NCT00656825|Safety
512044|NCT00656812|advanced MALT lymphoma
512045|NCT00656812|Rituximab
512046|NCT00656812|2CdA
512047|NCT00656812|chemotherapy
512048|NCT00656812|immunotherapy
512049|NCT00656773|morphine, sufentanil, acute pain, opioid, Prehospital Emergency Care
512050|NCT00656760|unknown primary, head and neck cancer, squamous cell carcinoma
512051|NCT00656760|Unknown primary head and neck cancer
512052|NCT00656747|Chronic Obstructive Pulmonary Disease (COPD)
512053|NCT00656747|Acute exacerbation of COPD (AECOPD)
512054|NCT00656747|chronic bronchitis
512055|NCT00656747|bronchitis
512056|NCT00656747|chest infection
512057|NCT00656747|smoking
512058|NCT00656747|lung disease
512059|NCT00656747|lung
512060|NCT00656747|lungs
512061|NCT00656734|Medarex Inc.
512062|NCT00656721|bronchiectasis
512063|NCT00656721|physiotherapy
512064|NCT00656721|flutter valve
512065|NCT00656721|impulse oscillation technique
512066|NCT00656708|Burns
512067|NCT00656708|Wounds
512068|NCT00656708|Healthcare associated infections
512069|NCT00656708|MRSA
512070|NCT00656708|VRE
512071|NCT00656695|Iminoral
512072|NCT00656695|Neoral
512073|NCT00656695|Acute renal transplant rejection
512074|NCT00656682|Prevention & Control
512075|NCT00656682|Hyperglycemia
512076|NCT00656682|Obesity
512077|NCT00656682|Diabetes Mellitus
512078|NCT00656682|Cost Benefit Analysis
512079|NCT00656669|newly diagnosed breast cancer
512080|NCT00656669|neoadjuvant therapy
512081|NCT00656656|pemphigus
512082|NCT00656656|rituximab
512083|NCT00656656|immunoadsorption
512084|NCT00656656|dexamethasone
512085|NCT00656656|treatment
512086|NCT00656656|management
512087|NCT00656617|Acute Myeloid Leukemia
512088|NCT00656617|(AML)
512089|NCT00656617|Myelodysplastic syndrome
512090|NCT00656617|(MDS)
512091|NCT00656617|Leukemia
512092|NCT00656617|Idarubicin
512093|NCT00656617|Cytarabine
512094|NCT00656617|Vorinostat
512095|NCT00656617|Ara-C
512096|NCT00656604|recurrent breast cancer
512097|NCT00656604|stage I breast cancer
512098|NCT00656604|stage II breast cancer
512099|NCT00656604|stage IIIA breast cancer
512100|NCT00656604|stage IIIB breast cancer
512101|NCT00656604|stage IIIC breast cancer
512102|NCT00656591|Child mortality, Nepal, Community, care practices
512103|NCT00656578|Foot
512104|NCT00656578|Bunion
512105|NCT00656578|Bunionectomy
512106|NCT00656578|Hallux Valgus Deformity
512107|NCT00656578|Surgery for Transpositional first metatarsal osteotomy - Bunionectomy
512108|NCT00656565|measure inspiratory spirometry with dry powder inhaler device in series with the spirometer
512109|NCT00656526|analgesia, postlaminectomy , lidocaine, dorsal root
512110|NCT00656513|hypopharyngeal cancer
512111|NCT00656513|laryngeal cancer
512112|NCT00656513|lip and oral cavity cancer
512113|NCT00656513|nasopharyngeal cancer
512114|NCT00656513|paranasal sinus and nasal cavity cancer
512115|NCT00656513|oropharyngeal cancer
512116|NCT00656513|salivary gland cancer
512368|NCT00655486|seizures
512117|NCT00656513|metastatic squamous neck cancer with occult primary
512118|NCT00656513|xerostomia
512119|NCT00656513|tongue cancer
512120|NCT00656500|surgical patients
512121|NCT00656500|cigarette smoking
512122|NCT00656500|postoperative complications
512123|NCT00656500|telephone counseling
512124|NCT00656500|quitlines
512125|NCT00656487|Cannabis Dependence
512126|NCT00656487|Marijuana Dependence
512127|NCT00656487|Cannabis Withdrawal
512128|NCT00656487|Rimonabant
512129|NCT00656487|CB1 receptor antagonist
512130|NCT00656487|Neuropsychology
512131|NCT00656487|fMRI
512132|NCT00656487|Endocannabinoids
512133|NCT00656487|Cortisol
512134|NCT00656474|burn wounds
512135|NCT00656474|wound healing
512136|NCT00656461|Advanced cancer
512137|NCT00656448|Acute Myelogenous Leukemia
512138|NCT00656448|AML
512139|NCT00656448|Myelodysplastic Syndrome
512140|NCT00656448|MDS
512141|NCT00656448|Leukemia
512142|NCT00656448|Procrit
512143|NCT00656448|Epoetin Alfa
512144|NCT00656448|Epogen
512145|NCT00656435|proliferative diabetic retinopathy
512146|NCT00656435|bevacizumab (Avastin)
512147|NCT00656435|vitreous hemorrhage
512148|NCT00656435|long acting gas
512149|NCT00656422|insulin therapy
512150|NCT00656422|hepatic fat
512151|NCT00656422|type 2 diabetes
512152|NCT00656422|body composition
512153|NCT00656422|comparison of insulin detemir and insulin glargine
512154|NCT00656422|Changes in Hepatic Fat
512155|NCT00656422|Obesity
512156|NCT00656409|Ataxia telangiectasia,
512157|NCT00656409|Conjugated pneumococcal,
512158|NCT00656409|Prevenar,
512159|NCT00656409|Immunogenicity ,
512160|NCT00656409|Vaccine
512161|NCT00656396|Blood loss
512162|NCT00656396|Point of care monitoring
512163|NCT00656396|FFP
512164|NCT00656396|Major surgery
512165|NCT00656396|Prothrombin Time
512166|NCT00656396|Blood coagulation tests
512167|NCT00656383|venous ulcer, leg ulcer, stasis ulcer
512168|NCT00656370|Hylenex
512169|NCT00656370|subcutaneous infusion
512170|NCT00656370|hyaluronidase
512171|NCT00656370|rHuPH20
512172|NCT00656370|recombinant human hyaluronidase
512173|NCT00656344|PTSD
512174|NCT00656344|Substance Abuse
512175|NCT00656344|WTC attacks
512176|NCT00656344|Iraq War
512177|NCT00656318|women
512178|NCT00656318|menses
512179|NCT00656318|oral contraceptives
512180|NCT00656318|Healthy menstruating females
512181|NCT00656305|Bone Cancer
512182|NCT00656305|Pain Palliation
512183|NCT00656305|Metastasis
512184|NCT00656305|Multiple Myeloma
512185|NCT00656305|Breast Cancer
512186|NCT00656305|Lung Cancer
512187|NCT00656305|Prostate Cancer
512188|NCT00656305|cancer related Pain
512189|NCT00656305|Tumors
512190|NCT00656292|Plasma concentrations of inflammatory markers
512191|NCT00656292|(CRP, IL-6, TNF-a), AST, ALT, and CK
512192|NCT00656279|chronic kidney disease
512193|NCT00656279|predialysis
512194|NCT00656279|hyperphosphatemia
512195|NCT00656279|dietary intervention
512196|NCT00656279|intensive dietary education
512197|NCT00656279|low phosphorus diet
512198|NCT00656266|renal insufficiency and/or renal failure after liver transplantation
512199|NCT00656214|Lichen Planus
512200|NCT00656201|Infertility
512201|NCT00656201|In vitro fertilization
512202|NCT00656201|Embryo transfer
512203|NCT00656201|Crinone
512204|NCT00656201|Intramuscular Progesterone
512205|NCT00656201|Progesterone support
512206|NCT00656188|Erectile Dysfunction
512207|NCT00656188|Vardenafil
512208|NCT00656175|lipodystrophy
512209|NCT00656175|fat
512210|NCT00656175|visceral fat
512211|NCT00656175|HIV
512212|NCT00656175|women
512213|NCT00656175|raltegravir
512214|NCT00656175|ART
512215|NCT00656175|anti HIV therapy
512216|NCT00656175|NNRTI
512217|NCT00656175|Protease inhibitor
512218|NCT00656175|integrase inhibitor
512219|NCT00656175|treatment experienced
512220|NCT00656149|telerehabilitation
512221|NCT00656149|functional electrical stimulation
512222|NCT00656149|spinal cord injury
512223|NCT00656149|hand function rehabilitation
512224|NCT00656123|adenocarcinoma of the colon
512225|NCT00656123|adenocarcinoma of the rectum
512226|NCT00656123|stage IV colon cancer
512227|NCT00656123|stage IV rectal cancer
512228|NCT00656123|liver metastases
512229|NCT00656110|Restless legs syndrome
512230|NCT00656110|Morton's neuroma
512231|NCT00656110|Randomized controlled trial
512232|NCT00656097|Rabies post-exposure prophylaxis
512233|NCT00656071|ARDS
512234|NCT00656071|Acute respiratory distress syndrome
512235|NCT00656071|Adult respiratory distress syndrome
512236|NCT00656071|respiratory distress
512237|NCT00656058|Leukotriene
512238|NCT00656058|Chronic Graft-Versus-Host Disease
512239|NCT00656058|Montelukast
512240|NCT00656058|Stem Cell Transplant
512241|NCT00656058|Bronchiolitis Obliterans
512242|NCT00656045|Obesity
512243|NCT00656045|Physical Activity
512244|NCT00656045|Weight Loss
512245|NCT00656045|Exercise
512246|NCT00656045|Dietary Intake
512247|NCT00656045|Energy
512248|NCT00656045|Behavioral
512249|NCT00656045|Healthy Eating
512250|NCT00656032|insulin resistance
512251|NCT00656032|end stage renal disease
512252|NCT00656006|Hepatitis C
512253|NCT00656006|Chronic
512254|NCT00656006|Genotype 2 or 3
512255|NCT00656006|Treatment naive
512256|NCT00655993|COPD
512257|NCT00655993|Inflammation
512258|NCT00655993|CRP levels
512259|NCT00655993|simvastatin
512260|NCT00655954|COPD
512261|NCT00655954|asthma
512262|NCT00655954|smokers
512263|NCT00655954|healthy volunteers
512264|NCT00655954|bronchiectasis
512265|NCT00655954|cystic fibrosis
512266|NCT00655941|Osteoarthritis
512267|NCT00655941|Obesity
512268|NCT00655941|Weight loss
512269|NCT00655941|Dietary instruction
512270|NCT00655941|Exercise
512271|NCT00655941|Attention
512272|NCT00655928|Acute lung injury
512273|NCT00655928|Lung resection
512274|NCT00655902|Trans fat
512275|NCT00655902|Obesity
512276|NCT00655902|Insulin sensitivity
512277|NCT00655876|stage IIA esophageal cancer
512278|NCT00655876|stage IIB esophageal cancer
512279|NCT00655876|stage IIIA esophageal cancer
512280|NCT00655876|stage IIIB esophageal cancer
512281|NCT00655876|stage IIIC esophageal cancer
512282|NCT00655876|stage IV esophageal cancer
512283|NCT00655876|squamous cell carcinoma of the esophagus
512284|NCT00655863|Glucose Metabolism Disorder
512285|NCT00655863|Dysmetabolic Syndrome
512286|NCT00655863|Type II Diabetes
512287|NCT00655863|Diabetes Mellitus
512288|NCT00655863|Lipoatrophic; Dyslipidemia
512289|NCT00655863|Drug Therapy
512290|NCT00655850|Lung Cancer
512291|NCT00655850|Non-Small Cell Lung Cancer
512292|NCT00655850|Metronomic Chemotherapy
512293|NCT00655837|Antigens, CD40
512294|NCT00655837|Antibodies, Monoclonal
512295|NCT00655837|Combined Modality Therapy
512296|NCT00655837|Lymphoma, Large B-Cell, Diffuse
512297|NCT00655837|Lymphoma, Non-Hodgkin
512298|NCT00655837|Hematologic Diseases
512299|NCT00655837|Immunoproliferative Disorders
512300|NCT00655837|Lymphatic Diseases
512301|NCT00655837|Lymphoproliferative Disorders
512302|NCT00655837|Lymphoma
512303|NCT00655811|Healthy volunteers
512304|NCT00655785|Epitope peptide
512305|NCT00655785|CTL
512306|NCT00655785|Pancreatic cancer
512307|NCT00655785|Vaccination VEGFR1
512308|NCT00655785|VEGFR2
512309|NCT00655772|chlorine
512310|NCT00655772|dioxide
512311|NCT00655772|mouthwash
512312|NCT00655772|organoleptic
512313|NCT00655772|measurements
512314|NCT00655772|volatile
512315|NCT00655772|sulfur
512316|NCT00655772|compounds
512317|NCT00655746|Healthy Subjects
512318|NCT00655720|infant formula
512319|NCT00655707|Adult stem cell therapy
512320|NCT00655694|COPD
512321|NCT00655694|smokers
512322|NCT00655694|healthy volunteers
512323|NCT00655681|pediatric osteoporosis
512324|NCT00655681|pediatric osteopenia
512325|NCT00655681|pamidronate
512326|NCT00655681|post operative osteopenia
512327|NCT00655668|NHL, Non-Hodgkin's Lymphoma, T-cell Lymphoma
512328|NCT00655629|Erectile Dysfunction
512329|NCT00655603|GLP-1
512330|NCT00655603|Glucagon secretion
512331|NCT00655603|Glucose turn-over
512332|NCT00655590|Erectile Dysfunction
512333|NCT00655590|Sildenafil
512334|NCT00655590|Vardenafil
512335|NCT00655590|Spermatogenesis
512336|NCT00655590|Sperm concentration
512337|NCT00655590|Sperm count
512338|NCT00655590|Morphology
512339|NCT00655590|Motility
512340|NCT00655590|Reproductive hormonal
512341|NCT00655577|Aging
512342|NCT00655577|Osteoporosis
512343|NCT00655577|Exercise
512344|NCT00655577|Population based
512345|NCT00655577|Randomized trial
512346|NCT00655577|Falls
512347|NCT00655577|Fractures
512348|NCT00655551|epilepsy
512349|NCT00655551|seizures
512350|NCT00655551|Lacosamide
512351|NCT00655551|Vimpat
512352|NCT00655551|intravenous
512353|NCT00655525|inflammation
512354|NCT00655525|end stage renal disease
512355|NCT00655512|pimecrolimus
512356|NCT00655512|hydrocortison
512357|NCT00655512|betamethasone
512358|NCT00655512|clobetasol-17-Propionat
512359|NCT00655512|Optical Coherence Tomography
512360|NCT00655512|skin healthy probands
512361|NCT00655499|adenocarcinoma of the colon
512362|NCT00655499|adenocarcinoma of the rectum
512363|NCT00655499|stage IV colon cancer
512364|NCT00655499|recurrent rectal cancer
512365|NCT00655499|stage IV rectal cancer
512366|NCT00655499|recurrent colon cancer
512367|NCT00655486|Epilepsy
512369|NCT00655486|antiepileptic
512370|NCT00655486|Lacosamide
512371|NCT00655486|Vimpat
512372|NCT00655486|safety
512373|NCT00655486|adjunctive
512374|NCT00655460|Glucose
512375|NCT00655460|Insulin
512376|NCT00655460|computer
512377|NCT00655460|critical care
512378|NCT00655447|oophorectomy
512379|NCT00655447|ovarian conservation
512380|NCT00655447|stroke
512381|NCT00655447|breast cancer
512382|NCT00655447|ovarian cancer
512383|NCT00655447|other cancer
512384|NCT00655447|hip fracture
512385|NCT00655434|Herpes simplex virus 2
512386|NCT00655434|HSV 2
512387|NCT00655434|Antibody status to Herpesvirus 2, Human
512388|NCT00655421|screening
512389|NCT00655421|oral precancers
512390|NCT00655421|tobacco users
512391|NCT00655421|VELScope
512392|NCT00655421|Visual Inspection
512393|NCT00655421|Toluidine Blue
512394|NCT00655408|Infants
512395|NCT00655408|Prevalence
512396|NCT00655408|Iron
512397|NCT00655408|Deficiency
512398|NCT00655408|Treatment
512399|NCT00655395|Leukemia
512400|NCT00655395|MDS
512401|NCT00655382|dynamic pelvic mri
512402|NCT00655382|dynamic mri
512403|NCT00655382|STARR procedure
512404|NCT00655382|STARR
512405|NCT00655382|ODS
512406|NCT00655382|obstructive defecation syndrome
512407|NCT00655382|outlet obstruction
512408|NCT00655382|obstructed defecation
512409|NCT00655382|stapled trans anal rectal resection
512410|NCT00655356|Treatment of moderate to severe bilateral nasolabial fold wrinkles
512411|NCT00655343|GvHD
512412|NCT00655343|aGvHD prophylaxis
512413|NCT00655343|Matched unrelated donor
512414|NCT00655343|ATG
512415|NCT00655343|SCT
512416|NCT00655343|BMT
512417|NCT00655343|polyclonal antibody
512418|NCT00655343|GvHD prophylaxis for patients with ALL, AML, CML, MDS, OMF
512419|NCT00655343|Patients with allogeneic BM or PBSC transplantation
512420|NCT00655343|Patients with a matched unrelated donor
512421|NCT00655330|Type 2 diabetes mellitus
512422|NCT00655330|Nephropathy
512423|NCT00655330|valsartan
512424|NCT00655330|probucol
512425|NCT00655330|Proteinuria
512426|NCT00655317|acupuncture
512427|NCT00655317|colon surgery
512428|NCT00655317|post operative ileus
512429|NCT00655317|post ileus
512430|NCT00655317|ileus
512431|NCT00655317|colectomy
512432|NCT00655317|colorectal pathology
512433|NCT00655291|pain
512434|NCT00655278|Movement Disorder
512435|NCT00655252|Expanded access
512436|NCT00655252|metastatic renal cell cancer
512437|NCT00655252|progression despite VEGF receptors
512438|NCT00655239|Ultra High Risk of Schizophrenia
512439|NCT00655239|Prodrome
512440|NCT00655239|Psychosis
512441|NCT00655239|Schizophrenia
512442|NCT00655239|Cognitive Remediation
512443|NCT00655226|Cognitive Behavior Therapy
512444|NCT00655226|Interferon-alpha
512445|NCT00655226|Communicable Diseases
512446|NCT00655226|Liver Diseases
512447|NCT00655226|Depression
512448|NCT00655226|Hepatitis, Chronic
512449|NCT00655226|Interferons
512450|NCT00655226|Ribavirin
512451|NCT00655226|Hepatitis, Viral, Human
512452|NCT00655226|Infection
512453|NCT00655226|Hepatitis
512454|NCT00655226|Mood Disorders
512455|NCT00655226|Peginterferon alfa-2a
512456|NCT00655226|Hepatitis C
512457|NCT00655226|Interferon Alfa-2a
512458|NCT00655226|Interferon Alfa-2b
512459|NCT00655226|Depressive Disorder, Major
512460|NCT00655226|Depressive Disorder
512461|NCT00655213|Pacing, AV conduction disorders, minimized ventricular pacing, AF
512462|NCT00655174|autism
512463|NCT00655174|fluvoxamine
512464|NCT00655174|sertraline
512465|NCT00655174|selective seratonin reuptake inhibitors
512466|NCT00655174|paediatrics
512467|NCT00655161|NSCLC
512468|NCT00655161|Cancer Immunotherapy
512469|NCT00655148|DTaP-IPV
512470|NCT00655148|Clinical Trial
512471|NCT00655148|Safety
512472|NCT00655148|Immunogenicity
512473|NCT00655109|Allergic conjunctivitis
512474|NCT00655109|Allergic rhinoconjunctivitis
512475|NCT00655096|Screening Protocol
512476|NCT00655096|Eye Diseases
512477|NCT00655083|Infantile colic
512478|NCT00655083|Abdominal Cramps
512479|NCT00655083|Colicky Pain
512480|NCT00655083|Functional gastrointestinal disorders
512481|NCT00655070|Hibernating Myocardium
512482|NCT00655070|Blood Flow
512483|NCT00655070|Ultrasound
512484|NCT00655070|PET imaging
512485|NCT00655057|Dopamine Transporter
512486|NCT00655057|Biomarker
512487|NCT00655057|SPECT Brain Imaging
512488|NCT00655057|Antidepressant Therapy
512489|NCT00655031|Punicaceae
512490|NCT00655031|Pomegranate
512491|NCT00655018|Non-Alcoholic Fatty Liver Disease (NAFLD)
512492|NCT00655018|Non-Alcoholic Steatohepatitis (NASH)
512493|NCT00655018|Liver histology
512494|NCT00655018|Insulin Resistance
512495|NCT00655018|Weight loss
512496|NCT00655018|Alpha-tocopherol
512497|NCT00655018|ascorbic acid
512498|NCT00655005|head and neck cancer
512499|NCT00654966|Urotensin II
512500|NCT00654966|Soluble epoxide hydrolase
512501|NCT00654966|Iontophoresis
512502|NCT00654966|Healthy volunteers
512503|NCT00654953|cocaine dependence
512504|NCT00654953|depressive symptoms
512505|NCT00654953|relapse
512506|NCT00654953|sertraline
512507|NCT00654953|gabapentin
512508|NCT00654927|multiple sclerosis
512509|NCT00654927|MS
512510|NCT00654927|walking
512511|NCT00654927|leg strength
512512|NCT00654927|demyelination
512513|NCT00654914|Sexual Dysfunction
512514|NCT00654901|Diphtheria
512515|NCT00654901|Tetanus
512516|NCT00654901|Pertussis
512517|NCT00654901|Hepatitis B
512518|NCT00654901|Poliomyelitis
512519|NCT00654901|Invasive Haemophilus influenzae type b.
512520|NCT00654901|Haemophilus Influenzae Type B Infection
512521|NCT00654888|cataract extraction
512522|NCT00654888|surgery
512523|NCT00654888|corneal disease
512524|NCT00654875|Essential Hypertension
512525|NCT00654849|Electrosurgery
512526|NCT00654849|Gyrus Pk
512527|NCT00654849|abdominal hysterectomy
512528|NCT00654849|Blood Loss, Surgical
512529|NCT00654849|Length of stay
512530|NCT00654849|Overall cost
512531|NCT00654836|recurrent breast cancer
512532|NCT00654836|stage III breast cancer
512533|NCT00654836|stage IV breast cancer
512534|NCT00654810|functional ability
512535|NCT00654810|gait
512536|NCT00654810|musculoskeletal disorder therapy
512537|NCT00654810|peripheral blood vessel disorder
512538|NCT00654797|Glucose
512539|NCT00654797|Insulin
512540|NCT00654797|computer
512541|NCT00654797|critical care
512542|NCT00654784|Duchenne Muscular Dystrophy
512543|NCT00654784|DMD
512544|NCT00654784|Duchenne
512545|NCT00654771|protein/creatinine ratio
512546|NCT00654771|clean catch urine
512547|NCT00654771|catheterized urine
512548|NCT00654758|cancer
512549|NCT00654758|carcinoma
512550|NCT00654758|chemotherapy
512551|NCT00654758|monoclonal antibody therapy
512552|NCT00654758|anti-angiogenesis
512553|NCT00654745|blood pressure reduction
512554|NCT00654732|Hodgkin Lymphoma
512555|NCT00654732|Lymphoma
512556|NCT00654732|Adriamycin
512557|NCT00654732|Doxorubicin Hydrochloride
512558|NCT00654732|Adriamycin PFS®
512559|NCT00654732|Adriamycin RDF™
512560|NCT00654732|Rituxan
512561|NCT00654732|Rituximab
512562|NCT00654732|Bleomycin
512563|NCT00654732|Bleomycin sulfate
512564|NCT00654732|Blenoxane®
512565|NCT00654732|BLM
512566|NCT00654732|Vinblastine
512567|NCT00654732|Velban
512568|NCT00654732|Dacarbazine
512569|NCT00654732|DTIC
512570|NCT00654732|DTIC-Dome®
512571|NCT00654732|R-ABVD
512572|NCT00654732|ABVD
512573|NCT00654719|Heart failure
512574|NCT00654719|cachexia
512575|NCT00654706|Schizophrenia
512576|NCT00654706|Cognition
512577|NCT00654706|MATRICS Consensus Cognitive Battery
512578|NCT00654693|NTX
512579|NCT00654693|Nihon Kohden
512580|NCT00654693|mobile monitoring
512581|NCT00654693|monitoring
512582|NCT00654693|nihon
512583|NCT00654693|kohden
512584|NCT00654693|monitoring device
512585|NCT00654693|remote monitoring
512586|NCT00654693|wireless
512587|NCT00654680|Erectile Dysfunction
512588|NCT00654680|Traumatic spinal cord injury
512589|NCT00654680|Vardenafil
512590|NCT00654667|Resveratrol
512591|NCT00654667|Insulin Resistance
512592|NCT00654667|Metabolic Syndrome
512593|NCT00654667|Sirtuin 1
512594|NCT00654667|IGF-1
512595|NCT00654667|Satiety
512596|NCT00654667|Leptin
512597|NCT00654667|Adiponectin
512598|NCT00654641|Surgical Wound Dehiscence
512599|NCT00654641|Wound Infection
512600|NCT00654641|Obesity
512601|NCT00654641|Cesarean Delivery
512602|NCT00654641|Wound Closure
512603|NCT00654641|Negative Pressure wound closure
512604|NCT00654615|unstable metaphyseal distal radius fractures
512605|NCT00654615|randomized controlled trial
512606|NCT00654615|surgical fixation
512607|NCT00654615|volar plate
512608|NCT00654615|intramedullary distal radius fixation system
512609|NCT00654602|cholesterol
512610|NCT00654602|low density lipoproteins
512611|NCT00654602|dyslipidaemia
512612|NCT00654602|Rosuvastatin
512613|NCT00654602|Crestor
512614|NCT00654589|Hematopoietic stem cell transplantation
512615|NCT00654589|HCT
512616|NCT00654589|iron overload
512617|NCT00654589|chelators
512618|NCT00654589|ICL670
512619|NCT00654589|deferasirox
512620|NCT00654589|serum ferritin
512621|NCT00654589|LIC
512622|NCT00654589|transfusional hemosiderosis
512623|NCT00654589|blood transfusions
512624|NCT00654589|adults
512625|NCT00654589|iron chelation
512626|NCT00654589|3-6 months
512627|NCT00654589|allogeneic hematopoietic stem cell transplantation
512628|NCT00654576|schizophrenia
512629|NCT00654576|antipsychotic
512630|NCT00654576|outcome
512631|NCT00654576|psychosocial intervention
512632|NCT00654563|Memory Disorders
512633|NCT00654563|Memory loss
512634|NCT00654563|Age Associated Memory Impairment
512635|NCT00654550|Photorefractive keratectomy
512636|NCT00654550|Re-epithelialization
512637|NCT00654550|Nexagon
512638|NCT00654550|PRK
512639|NCT00654550|Coda
512640|NCT00654537|Cholesterol
512641|NCT00654537|hypercholesterolemia
512642|NCT00654537|low density lipoproteins
512643|NCT00654524|Endometriosis
512644|NCT00654524|Recurrence
512645|NCT00654524|Pregnancy Rate
512646|NCT00654524|Laparoscopy
512647|NCT00654524|Gonadotropin-Releasing Hormone
512648|NCT00654511|Dexmedetomidine,
512649|NCT00654511|fentanyl,
512650|NCT00654511|tonsillectomy
512651|NCT00654511|and adenoidectomy,
512652|NCT00654485|Cholesterol
512653|NCT00654485|hypercholesterolemia
512654|NCT00654485|low density lipoproteins
512655|NCT00654485|metabolic syndrome
512656|NCT00654485|Rosuvastatin
512657|NCT00654472|magnetic resonance imaging, mitral valve area
512658|NCT00654446|Cholesterol
512659|NCT00654446|low density lipoproteins
512660|NCT00654446|dyslipidaemia
512661|NCT00654446|Rosuvastatin
512662|NCT00654446|Crestor
512663|NCT00654446|Simvastatin
512664|NCT00654446|Zocor
512665|NCT00654446|Renal
512666|NCT00654446|kidney
512667|NCT00654433|Hurler Syndrome
512668|NCT00654433|MPS I
512669|NCT00654433|Hurler-Scheie Syndrome
512670|NCT00654433|Hunter Syndrome
512671|NCT00654433|MPS II
512672|NCT00654433|Sanfilippo Syndrome
512673|NCT00654433|MPS III
512674|NCT00654433|Maroteaux-Lamy Syndrome
512675|NCT00654433|MPS VI
512676|NCT00654433|Krabbe Disease
512677|NCT00654433|Globoid Leukodystrophy
512678|NCT00654433|Metachromatic Leukodystrophy
512679|NCT00654433|MLD
512680|NCT00654433|Adrenoleukodystrophy
512681|NCT00654433|ALD
512682|NCT00654433|Adrenomyeloneuropathy
512683|NCT00654433|AMN
512684|NCT00654433|Sandhoff Disease
512685|NCT00654433|Tay Sachs Disease
512686|NCT00654433|Pelizaeus Merzbacher
512687|NCT00654433|PMD
512688|NCT00654433|Niemann-Pick Disease A
512689|NCT00654433|Niemann-Pick Disease B
512690|NCT00654433|Alpha-mannosidosis
512691|NCT00654433|Inherited metabolic diseases
512692|NCT00654433|Inborn errors of metabolism
512693|NCT00654433|Lysosomal storage diseases
512694|NCT00654433|Peroxisomal storage diseases
512695|NCT00654433|Hematopoietic stem cell transplantation
512696|NCT00654433|Umbilical cord blood transplantation
512697|NCT00654433|Mucopolysaccharidosis
512698|NCT00654433|Mucopolysaccharidosis I
512699|NCT00654433|Mucopolysaccharidosis II
512700|NCT00654433|Mucopolysaccharidosis III
512701|NCT00654433|Mucopolysaccharidosis VI
512702|NCT00654433|I Cell disease
512703|NCT00654433|Fucosidosis
512704|NCT00654433|GM1 Gangliosidosis
512705|NCT00654433|Canavan Disease
512706|NCT00654407|Cholesterol
512707|NCT00654407|hypercholesterolemia
512708|NCT00654407|Coronary Heart disease
512709|NCT00654407|low density lipoproteins
512710|NCT00654407|Rosuvastatin
512711|NCT00654407|Atorvastatin
512712|NCT00654407|simvastatin
512713|NCT00654394|Cholesterol
512714|NCT00654394|Carotid Artery Stenosis
512715|NCT00654394|Hypercholesterolemia
512716|NCT00654394|Rosuvastatin
512717|NCT00654394|Crestor
512718|NCT00654368|Amgen
512719|NCT00654355|atopic dermatitis
512720|NCT00654355|eczema
512721|NCT00654342|Sentinel lymph node-colon cancer
512722|NCT00654329|Dexmedetomidine, transmucosal, myringotomy,
512723|NCT00654316|TB
512724|NCT00654316|Tuberculosis
512725|NCT00654316|MVA85A
512726|NCT00654316|Vaccine
512727|NCT00654316|BCG
512728|NCT00654303|Cholesterol
512729|NCT00654303|Hypercholesterolaemia
512730|NCT00654303|Statins
512731|NCT00654290|Atrial fibrillation
512732|NCT00654290|coronary bypass
512733|NCT00654290|Amiodarone
512734|NCT00654290|Propranolol
512735|NCT00654290|Coronary Artery Bypass Graft (CABG)
512736|NCT00654277|bioequivalence
512737|NCT00654277|Ondansetron ODT
512738|NCT00654277|Fasting
512739|NCT00654277|To determine bioequivalence under fasting conditions
512740|NCT00654251|Spinocerebellar ataxia
512741|NCT00654251|Machado-Joseph disease
512742|NCT00654251|Gait monitoring
512743|NCT00654251|Functional vision assessment
512744|NCT00654238|Thyroid Cancer
512745|NCT00654238|Anaplastic
512746|NCT00654238|Medullary
512747|NCT00654238|sorafenib
512748|NCT00654225|Cholesterol
512749|NCT00654225|low density lipoproteins
512750|NCT00654225|dyslipidaemia
512751|NCT00654225|Rosuvastatin
512752|NCT00654225|Crestor
512753|NCT00654225|Atorvastatin
512754|NCT00654225|Lipitor
512755|NCT00654225|South Asian
512756|NCT00654212|stenting, laparoscopic surgery, colon cancer
512757|NCT00654199|CABG
512758|NCT00654199|Ventricular Asynchrony
512759|NCT00654199|Normal Sinus Rhythm
512760|NCT00654186|Androgen Independent Prostate Cancer (AIPC)
512761|NCT00654186|Chemo naive
512762|NCT00654173|Cholesterol
512763|NCT00654173|low density lipoproteins
512764|NCT00654173|dyslipidaemia
512765|NCT00654173|Rosuvastatin
512766|NCT00654173|Crestor
512767|NCT00654173|Atorvastatin
512768|NCT00654173|Lipitor
512769|NCT00654173|Zocor
512770|NCT00654173|simvastatin
512771|NCT00654160|stage IIIB anal cancer
512772|NCT00654160|stage IV anal cancer
512773|NCT00654160|recurrent anal cancer
512774|NCT00654160|carcinoma of the appendix
512775|NCT00654160|stage III colon cancer
512776|NCT00654160|stage IV colon cancer
512777|NCT00654160|recurrent colon cancer
512778|NCT00654160|stage III rectal cancer
512779|NCT00654160|stage IV rectal cancer
512780|NCT00654160|recurrent rectal cancer
512781|NCT00654160|stage III esophageal cancer
512782|NCT00654160|stage IV esophageal cancer
512783|NCT00654160|recurrent esophageal cancer
512784|NCT00654160|recurrent extrahepatic bile duct cancer
512785|NCT00654160|unresectable extrahepatic bile duct cancer
512786|NCT00654160|unresectable gallbladder cancer
512787|NCT00654160|recurrent gallbladder cancer
512788|NCT00654160|stage III gastric cancer
512789|NCT00654160|stage IV gastric cancer
512790|NCT00654160|recurrent gastric cancer
512791|NCT00654160|metastatic gastrointestinal carcinoid tumor
512792|NCT00654160|recurrent gastrointestinal carcinoid tumor
512793|NCT00654160|regional gastrointestinal carcinoid tumor
512794|NCT00654160|gastrointestinal stromal tumor
512795|NCT00654160|advanced adult primary liver cancer
512796|NCT00654160|localized unresectable adult primary liver cancer
512797|NCT00654160|recurrent adult primary liver cancer
512798|NCT00654160|stage II pancreatic cancer
512799|NCT00654160|stage III pancreatic cancer
512800|NCT00654160|stage IV pancreatic cancer
512801|NCT00654160|recurrent pancreatic cancer
512802|NCT00654160|recurrent small intestine cancer
512803|NCT00654160|small intestine adenocarcinoma
512804|NCT00654160|small intestine leiomyosarcoma
512805|NCT00654160|small intestine lymphoma
512806|NCT00654147|HIV
512807|NCT00654147|antiretroviral therapy naive
512808|NCT00654147|Integrase inhibitor
512809|NCT00654147|HIV/AIDS
512810|NCT00654147|treatment naïve
512811|NCT00654121|prevention
512812|NCT00654108|Escherichia coli, cholera, diarrhea, vaccine
512813|NCT00654069|Pain
512814|NCT00654056|Type 2 diabetes
512815|NCT00654056|Severe insulin resistance
512816|NCT00654043|Bioequivalence
512817|NCT00654043|Torsemide Tablets
512818|NCT00654043|fed
512819|NCT00654043|To determine bioequivalence under fed conditions.
512820|NCT00654030|Lung Cancer Vaccine
512821|NCT00654030|Early Stage Lung Cancer
512822|NCT00654030|Lung Cancer
512823|NCT00654004|trifunctional
512824|NCT00654004|protein
512825|NCT00654004|deficiency
512826|NCT00654004|TFP
512827|NCT00654004|weight
512828|NCT00654004|regulation
512829|NCT00653991|HIV/AIDS Prevention
512830|NCT00653991|Men Who Have Sex With Men (MSM)
512831|NCT00653991|Risky Sexual Behavior
512832|NCT00653991|Socially Optimized Learning in a Virtual Environment (SOLVE)
512833|NCT00653991|HIV Seronegativity
512834|NCT00653978|ERCP
512835|NCT00653978|cholangiocarcinoma
512836|NCT00653978|hilar stricture
512837|NCT00653965|Cholesterol
512838|NCT00653965|low density lipoproteins
512839|NCT00653965|dyslipidaemia
512840|NCT00653965|Rosuvastatin
512841|NCT00653965|Crestor
512842|NCT00653965|Atorvastatin
512843|NCT00653965|Lipitor
512844|NCT00653965|Hispanic
512845|NCT00653952|Paclitaxel HCl
512846|NCT00653952|CAELYX
512847|NCT00653952|DOXIL
512848|NCT00653952|Ovarian Carcinoma
512849|NCT00653952|Doxorubicin HCl
512850|NCT00653939|non-small cell lung cancer
512851|NCT00653939|non-small cell lung carcinoma
512852|NCT00653939|neoplasms, lung
512853|NCT00653939|lung cancer
512854|NCT00653939|tumors
512855|NCT00653939|NSCLC
512856|NCT00653926|Postoperative pain
512857|NCT00653926|Local infiltration analgesia
512858|NCT00653926|Knee arthroplasty
512859|NCT00653926|Postoperative pain management following unicompartmental knee arthroplasty
512860|NCT00653900|Verify now
512861|NCT00653900|platelet function
512862|NCT00653900|platelet function testing
512863|NCT00653900|bleeding risk
512864|NCT00653900|periprocedural bleeding
512865|NCT00653900|clopidogrel
512866|NCT00653900|Our initial goal is to establish if a certain degree of
512867|NCT00653900|platelet function abnormality can predict a higher bleeding
512868|NCT00653900|or higher transfusions.
512869|NCT00653887|Biofeedback
512870|NCT00653887|anal sphincter
512871|NCT00653887|cortical excitability
512872|NCT00653887|magnetic stimulation
512873|NCT00653887|incontinence
512874|NCT00653887|constipation
512875|NCT00653874|jaundice
512876|NCT00653874|neonates
512877|NCT00653874|transcutaneous bilirubinometry
512878|NCT00653874|clinical assessment of bilirubin
512879|NCT00653861|Aesthetic correction
512880|NCT00653848|Adjuvant treatment, intermediate and high risk, radical radiotherapy
512881|NCT00653822|Amevive
512882|NCT00653822|alefacept
512883|NCT00653822|pharmacokinetics
512884|NCT00653822|Japanese
512885|NCT00653783|Parkinson disease
512886|NCT00653783|Multiple System Atrophy
512887|NCT00653783|MSA
512888|NCT00653783|Progressive Supranuclear Palsy
512889|NCT00653783|PSP
512890|NCT00653783|observational
512891|NCT00653783|biomarker
512892|NCT00653757|stage I prostate cancer
512893|NCT00653757|stage II prostate cancer
512894|NCT00653757|stage III prostate cancer
512895|NCT00653757|stage IV prostate cancer
512896|NCT00653744|Cholesterol
512897|NCT00653744|low density lipoproteins
512898|NCT00653744|dyslipidaemia
512899|NCT00653744|Rosuvastatin
512900|NCT00653744|Crestor
512901|NCT00653744|Atorvastatin
512902|NCT00653744|Lipitor
512903|NCT00653744|African American
512904|NCT00653731|dementia
512905|NCT00653731|snoezelen
512906|NCT00653731|structured reminiscence therapy
512907|NCT00653731|10-minutes activation
512908|NCT00653731|apathy
512909|NCT00653718|Pain
512910|NCT00653718|Characterize musculoskeletal pain
512911|NCT00653718|Breast cancer patients treated with aromatase inhibitors
512912|NCT00653705|Probiotics
512913|NCT00653705|Children
512914|NCT00653705|Child Care Center
512915|NCT00653705|Nutrition
512916|NCT00653705|Health promotion
512917|NCT00653692|Substance abuse
512918|NCT00653692|fetal development
512919|NCT00653692|vagal tone
512920|NCT00653679|exercise
512921|NCT00653679|muscle protein signalling
512922|NCT00653679|protein synthesis
512923|NCT00653666|CPT1A
512924|NCT00653666|steatosis
512925|NCT00653666|deficiency
512926|NCT00653666|metabolic
512927|NCT00653666|response
512928|NCT00653666|fasting
512929|NCT00653653|pharmacogenetics
512930|NCT00653653|pharmacoeconomics
512931|NCT00653653|adverse events
512932|NCT00653653|drug metabolism
512933|NCT00653640|rehabilitation
512934|NCT00653640|head injury
512935|NCT00653640|3 months post injury
512936|NCT00653640|require manual assistance or walking aids to walk
512937|NCT00653640|very slow walking speed
512938|NCT00653640|able to follow two step commands
512939|NCT00653614|Oral contraception
512940|NCT00653601|GPI
512941|NCT00653601|glycoprotein IIb/IIIa inhibitor
512942|NCT00653601|Aggrastat
512943|NCT00653601|Tirofiban
512944|NCT00653601|Verify now
512945|NCT00653601|platelet function testing
512946|NCT00653601|bridge therapy
512947|NCT00653588|Cholesterol
512948|NCT00653588|low density lipoproteins
512949|NCT00653588|Hypercholesterolemia
512950|NCT00653588|Coronary Heart Disease
512951|NCT00653588|Rosuvastatin
512952|NCT00653588|Crestor
512953|NCT00653588|Atorvastatin
512954|NCT00653588|Lipitor
512955|NCT00653575|Sexual Behavior
512956|NCT00653575|HIV
512957|NCT00653575|Sexually Transmitted Diseases
512958|NCT00653562|polysomnography
512959|NCT00653562|zolpidem
512960|NCT00653562|Sleep disorders
512961|NCT00653562|adolescent
512962|NCT00653549|Bioequivalence
512963|NCT00653549|Torsemide Tablets
512964|NCT00653549|fasting
512965|NCT00653536|stroke
512966|NCT00653536|neuroflo
512967|NCT00653536|device
512968|NCT00653536|failure to recanalize
512969|NCT00653510|Type 2 diabetes
512970|NCT00653510|Dysregulation
512971|NCT00653510|Metabolism
512972|NCT00653510|Cardiac output
512973|NCT00653497|Osteoarthritis
512974|NCT00653484|colon cancer
512975|NCT00653484|rectal cancer
512976|NCT00653484|obesity
512977|NCT00653471|obesity
512978|NCT00653471|osa
512979|NCT00653471|capnography
512980|NCT00653471|general anesthesia
512981|NCT00653458|bioequivalence
512982|NCT00653458|Ondansetron ODT
512983|NCT00653458|fed
512984|NCT00653458|To determine bioequivalence under fed conditions
512985|NCT00653445|Low density lipoproteins
512986|NCT00653445|Hypercholesterolemia
512987|NCT00653445|Coronary Heart Disease
512988|NCT00653445|Rosuvastatin
512989|NCT00653445|Crestor
512990|NCT00653445|Ezetimibe
512991|NCT00653432|Treatment
512992|NCT00653432|Osteoarthritis
512993|NCT00653419|bioequivalence
512994|NCT00653419|buspirone HCl
512995|NCT00653419|fasting
512996|NCT00653406|Schizophrenia
512997|NCT00653406|Risperidone
512998|NCT00653406|Intramuscular injection
512999|NCT00653406|Pharmacokinetics
513000|NCT00653393|bioequivalence, single- dose, fasting
513001|NCT00653380|bioequivalence
513002|NCT00653380|doxycycline monohydrate
513003|NCT00653380|fasting
513004|NCT00653367|Thoracotomy
513005|NCT00653367|Nerve section
513006|NCT00653367|QST
513007|NCT00653367|Quantitative Sensory Test
513008|NCT00653367|Muscle sparing Posterolateral thoracotomy
513009|NCT00653367|Chest
513010|NCT00653367|Wall
513011|NCT00653367|Surgical
513012|NCT00653367|Incision
513013|NCT00653367|Tumors or cancer of the lung
513014|NCT00653354|hallux valgus
513015|NCT00653341|insulin naive
513016|NCT00653328|recurrent ovarian epithelial cancer
513017|NCT00653328|fallopian tube cancer
513018|NCT00653328|peritoneal cavity cancer
513019|NCT00653315|Bioequivalence, Tramadol APAP, fasting
513020|NCT00653263|methamphetamine
513021|NCT00653263|drug abuse
513022|NCT00653263|withdrawal
513023|NCT00653250|stage I non-small cell lung cancer
513024|NCT00653250|stage II non-small cell lung cancer
513025|NCT00653250|stage IIIA non-small cell lung cancer
513026|NCT00653224|levocetirizine
513027|NCT00653224|Xyzal
513028|NCT00653224|Seasonal Allergic Rhinitis
513029|NCT00653224|total symptom score
513030|NCT00653224|quality of life
513031|NCT00652145|ulcerative colitis
513032|NCT00652145|inflammatory bowel disease
513033|NCT00653198|Rotavirus severe gastroenteritis (RV SGE)
513034|NCT00653185|Glucose Metabolism Disorder
513035|NCT00653185|Dysmetabolic Syndrome
513036|NCT00653185|Type II Diabetes
513037|NCT00653185|Diabetes Mellitus, Lipoatrophic
513038|NCT00653185|Dyslipidemia
513039|NCT00653185|Hyperglycemia
513040|NCT00653172|CAP
513041|NCT00653172|community acquired pneumonia
513042|NCT00653159|Intrauterine device, contraception, unplanned pregnancy
513043|NCT00653146|cervical cancer
513044|NCT00653146|psychosocial effects of cancer and its treatment
513045|NCT00653146|human papilloma virus infection
513046|NCT00653146|atypical squamous cells of undetermined significance
513047|NCT00653146|low-grade squamous intraepithelial lesion
513048|NCT00653133|ultrasonography
513049|NCT00653133|peripheral nerve block
513050|NCT00653133|peripheral nerve stimulation
513051|NCT00653120|Bioequivalence, Propranolol ER capsules, fasting
513052|NCT00653107|Palliation
513053|NCT00653107|Cancer oesophagus
513054|NCT00653107|Stent
513055|NCT00653107|Brachytherapy
513056|NCT00653107|Randomized
513057|NCT00653094|crohn
513058|NCT00653094|fistula
513059|NCT00653094|surgery
513060|NCT00653094|fibrin glue
513061|NCT00653094|seton drainage
513062|NCT00653081|Shoulder pain
513063|NCT00653081|Supervised Exercises
513064|NCT00653081|Radial Shock Wave Therapy
513065|NCT00653055|Bioequivalence
513066|NCT00653055|Cabergoline
513067|NCT00653055|Fasting
513068|NCT00653042|Myocardial Ischemia
513069|NCT00653042|kidney failure
513070|NCT00653042|CABG
513071|NCT00653042|cardiopulmonary bypass (CPB) pump
513072|NCT00653042|Coronary Artery Bypass Surgery
513073|NCT00653042|heart surgery
513074|NCT00653042|nesiritide
513075|NCT00653042|Coronary Heart Disease
513076|NCT00653029|Post concussion syndrome
513077|NCT00653029|Mild traumatic brain injury
513078|NCT00653029|Effort
513079|NCT00653029|fmri
513080|NCT00653016|Contraception
513081|NCT00653016|norelgestromin
513082|NCT00653016|ethinyl estradiol
513083|NCT00653016|transdermal contraceptive patch
513084|NCT00653016|EVRA
513085|NCT00653016|ORTHO EVRA
513086|NCT00653003|Bioequivalence, Leflunomide, fed
513087|NCT00652977|sphincter tears
513088|NCT00652977|Ritgen maneuver
513089|NCT00652977|perineal tears
513090|NCT00652977|prevention
513091|NCT00652977|delivery
513092|NCT00652964|sleep apnea, PHOX2B, hypoventilation, polysomnography
513093|NCT00652938|Co-administration
513094|NCT00652938|HPV vaccine
513095|NCT00652938|Cervical cancer
513096|NCT00652925|arthritis
513097|NCT00652925|juvenile
513098|NCT00652912|bioequivalence, Clonazepam ODT , fasting
513099|NCT00652899|recurrent ovarian epithelial cancer
513100|NCT00652899|recurrent ovarian germ cell tumor
513101|NCT00652899|stage IV ovarian epithelial cancer
513102|NCT00652899|stage IV ovarian germ cell tumor
513103|NCT00652899|fallopian tube cancer
513104|NCT00652899|peritoneal cavity cancer
513105|NCT00652886|Bioequivalence, Oxandrolone,fasting
513106|NCT00652873|Bioequivalence
513107|NCT00652873|Cabergoline
513108|NCT00652873|Fed
513109|NCT00652860|lung metastases
513110|NCT00652860|stage III adult soft tissue sarcoma
513111|NCT00652834|Renal transplant recipients
513235|NCT00652275|vaccine
513112|NCT00652834|Gastrointestinal findings in small bowel capsule endoscopy
513113|NCT00652834|Mycophenolic acid
513114|NCT00652834|Mycophenolate Mofetil
513115|NCT00652834|Mycophenolate Sodium
513116|NCT00652821|bioequivalence, single-dose, fed
513117|NCT00652808|knee, OA patients
513118|NCT00652795|bioequivalence
513119|NCT00652795|doxycycline monohydrate
513120|NCT00652795|fasting
513121|NCT00652769|Lung
513122|NCT00652769|Cancer
513123|NCT00652769|Staging
513124|NCT00652769|Endobronchial
513125|NCT00652769|Ultrasound
513126|NCT00652769|Endoscopic
513127|NCT00652756|Respiration, Artificial
513128|NCT00652756|Transportation of Patients
513129|NCT00652756|Intubation, Intratracheal
513130|NCT00652756|Tracheostomy
513131|NCT00652743|immunogenicity
513132|NCT00652743|safety
513133|NCT00652743|GSK pandemic candidate vaccine
513134|NCT00652730|bioequivalence
513135|NCT00652730|buspirone HCl
513136|NCT00652730|fed
513137|NCT00652704|Bioequivalence
513138|NCT00652704|Doxycycline Monohydrate
513139|NCT00652704|Fed
513140|NCT00652691|peritoneal cavity cancer
513141|NCT00652691|ovarian clear cell tumor with proliferating activity
513142|NCT00652691|ovarian endometrioid adenocarcinoma
513143|NCT00652691|ovarian mixed epithelial carcinoma
513144|NCT00652691|recurrent ovarian epithelial cancer
513145|NCT00652691|ovarian mucinous cystadenocarcinoma
513146|NCT00652691|ovarian serous cystadenocarcinoma
513147|NCT00652691|ovarian undifferentiated adenocarcinoma
513148|NCT00652678|Breast cancer
513149|NCT00652678|Radiation effects
513150|NCT00652665|Bioequivalence, single-dose, fasting
513151|NCT00652652|Congestive Heart Failure (CHF)
513152|NCT00652652|Heart Failure
513153|NCT00652652|Chronic Heart Failure
513154|NCT00652652|Dyspnea
513155|NCT00652652|nesiritide
513156|NCT00652652|Natrecor
513157|NCT00652639|bioequivalence, Clonazepam tablets, fasting
513158|NCT00652626|MDS
513159|NCT00652626|AML
513160|NCT00652626|Solid Tumors
513161|NCT00652626|Azacitidine
513162|NCT00652626|PK
513163|NCT00652626|Pharmacokinetics
513164|NCT00652626|Renal Impairment
513165|NCT00652626|Multiple Myeloma
513166|NCT00652626|Non-Hodgkin's Lymphoma
513167|NCT00652626|Hodgkin's Disease
513168|NCT00652613|3DCRT
513169|NCT00652613|IMRT
513170|NCT00652613|HNSCC
513171|NCT00652613|Quality of life
513172|NCT00652613|Major salivary gland sparing
513173|NCT00652613|Pattern of local and loco-regional recurrence
513174|NCT00652613|Disease Free Survival (DFS) & Overall Survival (OAS)
513175|NCT00652613|Dose reduction to normal structures with IMRT
513176|NCT00652600|Bioequivalence, Propranolol ER capsules, fed
513177|NCT00652587|hepatocellular carcinoma
513178|NCT00652587|hepatectomy
513179|NCT00652587|chemoembolization
513180|NCT00652587|randomized controlled trial
513181|NCT00652587|prognosis
513182|NCT00652574|Malignant Pleural Mesothelioma
513183|NCT00652574|Dasatinib
513184|NCT00652574|BMS-354825
513185|NCT00652574|Sprycel
513186|NCT00652574|MPM
513187|NCT00652548|Clavicle
513188|NCT00652548|Fracture
513189|NCT00652548|Ultrasound
513190|NCT00652548|Radiation
513191|NCT00652522|AF ablation
513192|NCT00652522|Pulmonary vein isolation(PVI)
513193|NCT00652522|reduced LV ejection fraction
513194|NCT00652522|symptomatic atrial fibrillation
513195|NCT00652522|persistent AF
513196|NCT00652470|infants
513197|NCT00652470|Hydrocephalus
513198|NCT00652470|Cerebrospinal Fluid Shunt
513199|NCT00652470|Ventriculostomy
513200|NCT00652470|neurosurgery
513201|NCT00652418|Magnevist
513202|NCT00652418|Magnetic Resonance Angiography
513203|NCT00652418|Meglumine gadopentetate
513204|NCT00652418|Determination of effective dose in MRA
513205|NCT00652405|cephalic phase reflex
513206|NCT00652405|gene expression
513207|NCT00652405|inflammation
513208|NCT00652405|adiponectin
513209|NCT00652405|pancreatic polypeptide
513210|NCT00652392|asthma
513211|NCT00652392|adolescents
513212|NCT00652392|adults
513213|NCT00652392|Symbicort
513214|NCT00652392|budesonide/formoterol
513215|NCT00652392|budesonide
513216|NCT00652379|Acromegaly
513217|NCT00652379|Insulin sensitivity
513218|NCT00652379|Glucose tolerance
513219|NCT00652379|Body composition
513220|NCT00652379|Growth Hormone
513221|NCT00652353|Clinical decision rule
513222|NCT00652353|Ottawa Ankle Rule
513223|NCT00652353|Ottawa Foot Rule
513224|NCT00652353|Ankle
513225|NCT00652353|Trauma
513226|NCT00652353|Education
513227|NCT00652353|Foot Trauma
513228|NCT00652314|Hemostatic products
513229|NCT00652314|Surgical hemostasis
513230|NCT00652314|Thrombi-gel
513231|NCT00652314|Gelatin Sponge
513232|NCT00652314|Time to hemostasis
513233|NCT00652288|Type I Diabetes Mellitus
513234|NCT00652275|Malaria
513236|NCT00652275|Merozoite surface Antigene
513237|NCT00652275|Mali
513238|NCT00652275|Children
513239|NCT00652262|Vardenafil
513240|NCT00652262|PDE5 inhibitor
513241|NCT00652262|Erectile dysfunction
513242|NCT00652262|Spinal cord injury
513243|NCT00652249|Hydrocephalus
513244|NCT00652249|shunt dysfunction
513245|NCT00652249|shunt flow
513246|NCT00652236|Low back pain
513247|NCT00652236|Economics
513248|NCT00652236|Cost-effectiveness
513249|NCT00652210|Bladder cancer
513250|NCT00652210|prostate cancer
513251|NCT00652210|multiphoton microscopy
513252|NCT00652197|Hydrocephalus
513253|NCT00652197|shunt dysfunction
513254|NCT00652197|shunt flow
513255|NCT00652184|antiviral
513256|NCT00652184|herpes zoster
513257|NCT00652184|postherpetic neuralgia
513258|NCT00652184|varicella zoster virus
513259|NCT00652184|shingles
513260|NCT00652171|Treatment
513261|NCT00652171|Augmentation
513262|NCT00652171|Resistant depression
513263|NCT00652171|Lamotrigine
513264|NCT00652132|ototoxicity
513265|NCT00652132|childhood hepatoblastoma
513266|NCT00652132|stage I childhood liver cancer
513267|NCT00652132|stage II childhood liver cancer
513268|NCT00652132|stage III childhood liver cancer
513269|NCT00652119|Ovarian Cancer
513270|NCT00652119|Peritoneal Cancer
513271|NCT00652119|Fallopian Tube Cancer
513272|NCT00652119|Carcinoma of Mullerian Origin
513273|NCT00652119|Paclitaxel
513274|NCT00652119|Taxol
513275|NCT00652119|Carboplatin
513276|NCT00652119|Paraplatin®
513277|NCT00652119|Avastin
513278|NCT00652119|Bevacizumab
513279|NCT00652119|Anti-VEGF monoclonal antibody
513280|NCT00652119|rhuMAb-VEGF
513281|NCT00652067|Mycobacterium avium-intracellulare
513282|NCT00652041|Multiple Myeloma
513283|NCT00652041|Relapsed
513284|NCT00652041|Refractary
513285|NCT00652028|Pharmacokinetics
513286|NCT00652028|Pharmacodynamics
513287|NCT00652028|Escalating dose
513288|NCT00652028|Dexmedotimidine
513289|NCT00652028|Intubated
513290|NCT00652028|Mechanically ventilated
513291|NCT00652028|Pediatrics
513292|NCT00652015|in-stent-thrombosis
513293|NCT00652015|CD39
513294|NCT00652015|CD73
513295|NCT00652015|EPC
513296|NCT00652002|Asthma
513297|NCT00652002|Symbicort
513298|NCT00652002|budesonide/formoterol
513299|NCT00652002|budesonide
513300|NCT00652002|formoterol
513301|NCT00651989|optical coherence tomography
513302|NCT00651989|spectral domain
513303|NCT00651989|time domain
513304|NCT00651976|stage IA breast cancer
513305|NCT00651976|stage IB breast cancer
513306|NCT00651976|stage II breast cancer
513307|NCT00651976|stage III breast cancer
513308|NCT00651976|HER2-negative breast cancer
513309|NCT00651976|estrogen receptor-positive breast cancer
513310|NCT00651950|Hydrocephalus
513311|NCT00651950|shunt dysfunction
513312|NCT00651950|shunt flow
513313|NCT00651937|Multiple Myeloma
513314|NCT00651937|Primary Amyloidosis
513315|NCT00651937|Cytokine Modulation
513316|NCT00651937|Melphalan
513317|NCT00651937|Alkeran
513318|NCT00651937|Transplant Induced Symptoms
513319|NCT00651937|Stem Cell Infusion
513320|NCT00651937|Autologous stem cell transplant
513321|NCT00651937|ASCT
513322|NCT00651937|Granulocyte-colony stimulating factor
513323|NCT00651937|G-CSF
513324|NCT00651937|Apheresis
513325|NCT00651924|chronic pain
513326|NCT00651924|IVR
513327|NCT00651924|cognitive-behavior therapy
513328|NCT00651898|abdominal surgery
513329|NCT00651898|hypothermia
513330|NCT00651898|circulating water mattress
513331|NCT00651885|UT-15C
513332|NCT00651885|Peripheral Vascular Disease
513333|NCT00651885|Treprostinil
513334|NCT00651872|Posttraumatic Stress Disorder
513335|NCT00651872|Functional Impairment
513336|NCT00651872|Veterans
513337|NCT00651872|Military Personnel
513338|NCT00651846|Contraception
513339|NCT00651846|Hemostasis
513340|NCT00651846|Blood Coagulation
513341|NCT00651820|wound healing
513342|NCT00651820|scarring
513343|NCT00651820|collagenase
513344|NCT00651820|Santyl
513345|NCT00651794|Neonatal Resuscitation
513346|NCT00651794|Patient Care Team
513347|NCT00651794|Medical Errors
513348|NCT00651781|Acute Myeloid Leukemia
513349|NCT00651781|Relapsed
513350|NCT00651781|Refractory
513351|NCT00651768|asthma
513352|NCT00651768|adults
513353|NCT00651768|adolescents
513354|NCT00651768|safety
513355|NCT00651768|Symbicort
513356|NCT00651768|budesonide/formoterol
513357|NCT00651768|budesonide
513358|NCT00651755|Non-Hodgkin's Lymphoma
513359|NCT00651755|Lymphoma
513360|NCT00651755|Nausea
513361|NCT00651755|Cyclophosphamide
513362|NCT00651755|Cytoxan
513363|NCT00651755|Neosar
513364|NCT00651755|Doxorubicin
513365|NCT00651755|AD
513366|NCT00651755|Hydroxydaunomycin hydrochloride
513367|NCT00651755|Vincristine
513368|NCT00651755|Prednisone
513369|NCT00651755|Rituximab
513370|NCT00651755|Rituxan
513371|NCT00651755|Aprepitant
513372|NCT00651755|Emend
513373|NCT00651755|L754030
513374|NCT00651755|MK869
513375|NCT00651755|Drug Metabolism
513376|NCT00651755|CHOP
513377|NCT00651755|R-CHOP
513378|NCT00651755|NHL
513379|NCT00651716|stage III adult Burkitt lymphoma
513380|NCT00651716|stage III adult diffuse large cell lymphoma
513381|NCT00651716|stage III adult diffuse mixed cell lymphoma
513382|NCT00651716|stage III adult diffuse small cleaved cell lymphoma
513383|NCT00651716|stage III adult Hodgkin lymphoma
513384|NCT00651716|stage III adult immunoblastic large cell lymphoma
513385|NCT00651716|stage III adult lymphoblastic lymphoma
513386|NCT00651716|stage III grade 1 follicular lymphoma
513387|NCT00651716|stage III grade 2 follicular lymphoma
513388|NCT00651716|stage III grade 3 follicular lymphoma
513389|NCT00651716|stage III mantle cell lymphoma
513390|NCT00651716|stage III marginal zone lymphoma
513391|NCT00651716|stage III small lymphocytic lymphoma
513392|NCT00651716|stage IV adult Burkitt lymphoma
513393|NCT00651716|stage IV adult diffuse large cell lymphoma
513394|NCT00651716|stage IV adult diffuse mixed cell lymphoma
513395|NCT00651716|stage IV adult diffuse small cleaved cell lymphoma
513396|NCT00651716|stage IV adult Hodgkin lymphoma
513397|NCT00651716|stage IV adult immunoblastic large cell lymphoma
513398|NCT00651716|stage IV adult lymphoblastic lymphoma
513399|NCT00651716|stage IV grade 1 follicular lymphoma
513400|NCT00651716|stage IV grade 2 follicular lymphoma
513401|NCT00651716|stage IV grade 3 follicular lymphoma
513402|NCT00651716|stage IV mantle cell lymphoma
513403|NCT00651716|stage IV marginal zone lymphoma
513404|NCT00651716|stage IV small lymphocytic lymphoma
513405|NCT00651716|recurrent adult Burkitt lymphoma
513406|NCT00651716|recurrent adult diffuse large cell lymphoma
513407|NCT00651716|recurrent adult diffuse mixed cell lymphoma
513408|NCT00651716|recurrent adult diffuse small cleaved cell lymphoma
513409|NCT00651716|recurrent adult Hodgkin lymphoma
513410|NCT00651716|recurrent adult immunoblastic large cell lymphoma
513411|NCT00651716|recurrent adult lymphoblastic lymphoma
513412|NCT00651716|recurrent cutaneous T-cell non-Hodgkin lymphoma
513413|NCT00651716|recurrent grade 1 follicular lymphoma
513414|NCT00651716|recurrent grade 2 follicular lymphoma
513415|NCT00651716|recurrent grade 3 follicular lymphoma
513416|NCT00651716|recurrent mantle cell lymphoma
513417|NCT00651716|recurrent marginal zone lymphoma
513418|NCT00651716|recurrent small lymphocytic lymphoma
513419|NCT00651716|recurrent mycosis fungoides/Sezary syndrome
513420|NCT00651716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
513421|NCT00651716|nodal marginal zone B-cell lymphoma
513422|NCT00651716|splenic marginal zone lymphoma
513423|NCT00651716|noncontiguous stage II adult Burkitt lymphoma
513424|NCT00651716|noncontiguous stage II adult diffuse large cell lymphoma
513425|NCT00651716|noncontiguous stage II adult diffuse mixed cell lymphoma
513426|NCT00651716|noncontiguous stage II adult diffuse small cleaved cell lymphoma
513427|NCT00651716|noncontiguous stage II adult immunoblastic large cell lymphoma
513428|NCT00651716|noncontiguous stage II adult lymphoblastic lymphoma
513429|NCT00651716|noncontiguous stage II grade 1 follicular lymphoma
513430|NCT00651716|noncontiguous stage II grade 2 follicular lymphoma
513431|NCT00651716|noncontiguous stage II grade 3 follicular lymphoma
513432|NCT00651716|noncontiguous stage II mantle cell lymphoma
513433|NCT00651716|noncontiguous stage II marginal zone lymphoma
513434|NCT00651716|noncontiguous stage II small lymphocytic lymphoma
513435|NCT00651716|accelerated phase chronic myelogenous leukemia
513436|NCT00651716|adult acute lymphoblastic leukemia in remission
513437|NCT00651716|adult acute myeloid leukemia in remission
513438|NCT00651716|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
513439|NCT00651716|adult acute myeloid leukemia with inv(16)(p13;q22)
513440|NCT00651716|adult acute myeloid leukemia with t(15;17)(q22;q12)
513441|NCT00651716|adult acute myeloid leukemia with t(16;16)(p13;q22)
513442|NCT00651716|adult acute myeloid leukemia with t(8;21)(q22;q22)
513443|NCT00651716|atypical chronic myeloid leukemia, BCR-ABL negative
513444|NCT00651716|blastic phase chronic myelogenous leukemia
513445|NCT00651716|chronic myelomonocytic leukemia
513446|NCT00651716|chronic phase chronic myelogenous leukemia
513447|NCT00651716|recurrent adult acute lymphoblastic leukemia
513448|NCT00651716|recurrent adult acute myeloid leukemia
513449|NCT00651716|refractory chronic lymphocytic leukemia
513450|NCT00651716|refractory hairy cell leukemia
513451|NCT00651716|relapsing chronic myelogenous leukemia
513452|NCT00651716|secondary acute myeloid leukemia
513453|NCT00651716|stage III chronic lymphocytic leukemia
513454|NCT00651716|stage IV chronic lymphocytic leukemia
513455|NCT00651716|chronic eosinophilic leukemia
513456|NCT00651716|primary myelofibrosis
513457|NCT00651716|chronic neutrophilic leukemia
513458|NCT00651716|de novo myelodysplastic syndromes
513459|NCT00651716|disseminated neuroblastoma
513460|NCT00651716|myelodysplastic/myeloproliferative neoplasm, unclassifiable
513461|NCT00651716|poor prognosis metastatic gestational trophoblastic tumor
513462|NCT00651716|previously treated myelodysplastic syndromes
513463|NCT00651716|recurrent neuroblastoma
513464|NCT00651716|recurrent ovarian epithelial cancer
513465|NCT00651716|recurrent ovarian germ cell tumor
513466|NCT00651716|recurrent malignant testicular germ cell tumor
513467|NCT00651716|secondary myelodysplastic syndromes
513468|NCT00651716|stage I multiple myeloma
513469|NCT00651716|stage II multiple myeloma
513470|NCT00651716|stage III multiple myeloma
513471|NCT00651716|stage II ovarian epithelial cancer
513472|NCT00651716|stage III ovarian epithelial cancer
513473|NCT00651716|stage IV ovarian epithelial cancer
513474|NCT00651716|stage III malignant testicular germ cell tumor
513475|NCT00651716|stage IIIA breast cancer
513476|NCT00651716|stage IIIB breast cancer
513477|NCT00651716|stage IIIC breast cancer
513478|NCT00651716|stage IV breast cancer
513479|NCT00651716|refractory multiple myeloma
513480|NCT00651677|hand assisted laparoscopy
513481|NCT00651677|rectal cancer
513482|NCT00651677|short term outcomes
513483|NCT00651677|straight laparoscopy
513484|NCT00651651|Asthma
513485|NCT00651651|Symbicort
513486|NCT00651651|budesonide/formoterol
513487|NCT00651651|budesonide
513488|NCT00651651|formoterol
513489|NCT00651638|PK and safety profile of ARQ 197
513490|NCT00651625|arthrocentesis
513491|NCT00651625|injections
513492|NCT00651625|anesthesia
513493|NCT00651625|biopsy
513494|NCT00651625|aspiration
513495|NCT00651625|syringe
513496|NCT00651625|safety
513497|NCT00651625|pain
513498|NCT00651599|Vasomotor symptoms
513499|NCT00651599|Vasomotor System
513500|NCT00651573|Surgery
513501|NCT00651573|Cardiopulmonary bypass
513502|NCT00651573|Coronary artery bypass graft
513503|NCT00651573|Valve procedure
513504|NCT00651573|Hematocrit level
513505|NCT00651573|Outcomes
513506|NCT00651547|Asthma
513507|NCT00651547|Symbicort
513508|NCT00651547|budesonide/formoterol
513509|NCT00651547|budesonide
513510|NCT00651547|formoterol
513511|NCT00651547|children
513512|NCT00651534|Formulation Drug Study, healthy postmenopausal
513513|NCT00651521|Angiographic CAD
513514|NCT00651521|Chronic kidney disease
513515|NCT00651521|Left ventricular dysfunction
513516|NCT00651521|Body mass index
513517|NCT00651521|Cardiovascular mortality
513518|NCT00651521|Coronary angiography
513519|NCT00651508|Patients with Advanced or Metastatic stage IIIB/IV Non-Small Cell Lung Cancer
513520|NCT00651495|Decision aids
513521|NCT00651495|Seniors
513522|NCT00651495|Chronic disease management
513523|NCT00651495|Advance directives
513524|NCT00651469|Moderate Acne Vulgaris
513525|NCT00651469|Acne
513526|NCT00651443|galiximab
513527|NCT00651443|Untreated NHL
513528|NCT00651443|antibody
513529|NCT00651443|open-label
513530|NCT00651430|Balance
513531|NCT00651430|Voluntary stepping
513532|NCT00651430|function
513533|NCT00651430|disability
513534|NCT00651430|fear of falls
513535|NCT00651430|Total Hip Arthroplasty
513536|NCT00651417|Organic germanium
513537|NCT00651417|fatigue
513538|NCT00651417|radiation therapy
513539|NCT00651417|breast cancer
513540|NCT00651417|prostate cancer
513541|NCT00651365|Advanced solid tumors
513542|NCT00651365|Refractory solid tumor
513543|NCT00651365|Antineoplastic protocol
513544|NCT00651365|Drug therapy
513545|NCT00651365|Pharmacokinetics
513546|NCT00651365|Met inhibitor
513547|NCT00651352|NRT
513548|NCT00651352|Bioequivalence
513549|NCT00651352|Nicotine
513550|NCT00651339|Cerebral Palsy
513551|NCT00651339|Balance
513552|NCT00651339|Gait
513553|NCT00651326|adenocarcinoma of the prostate
513554|NCT00651326|stage I prostate cancer
513555|NCT00651326|stage II prostate cancer
513556|NCT00651326|stage III prostate cancer
513557|NCT00651326|stage IV prostate cancer
513558|NCT00651313|Dysmenorrhea
513559|NCT00651313|Periods
513560|NCT00651313|Menstrual
513561|NCT00651313|Primary dysmenorrhea in women with recurrent dysmenorrhea
513562|NCT00651261|adult acute basophilic leukemia
513563|NCT00651261|adult acute eosinophilic leukemia
513564|NCT00651261|adult acute lymphoblastic leukemia
513565|NCT00651261|adult acute megakaryoblastic leukemia (M7)
513566|NCT00651261|adult acute minimally differentiated myeloid leukemia (M0)
513567|NCT00651261|adult acute monoblastic leukemia (M5a)
513568|NCT00651261|adult acute monocytic leukemia (M5b)
513569|NCT00651261|adult acute myeloblastic leukemia with maturation (M2)
513570|NCT00651261|adult acute myeloblastic leukemia without maturation (M1)
513571|NCT00651261|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
513572|NCT00651261|adult acute myeloid leukemia with inv(16)(p13;q22)
513573|NCT00651261|adult acute myeloid leukemia with t(16;16)(p13;q22)
513699|NCT00650507|cardiac surgery
513574|NCT00651261|adult acute myeloid leukemia with t(8;21)(q22;q22)
513575|NCT00651261|adult acute myelomonocytic leukemia (M4)
513576|NCT00651261|adult erythroleukemia (M6a)
513577|NCT00651261|adult pure erythroid leukemia (M6b)
513578|NCT00651261|untreated adult acute myeloid leukemia
513579|NCT00651248|Saliva
513580|NCT00651248|Oral health
513581|NCT00651248|Aged
513582|NCT00651209|Hepatitis B, chronic
513583|NCT00651209|Telbivudine
513584|NCT00651209|Tenofovir
513585|NCT00651209|Roadmap Concept
513586|NCT00651196|Type 1 diabetes
513587|NCT00651196|bone
513588|NCT00651170|Median block nerve
513589|NCT00651170|Ultrasound
513590|NCT00651131|post-surgical
513591|NCT00651131|wound infection
513592|NCT00651131|superficial
513593|NCT00651131|deep
513594|NCT00651131|surgical
513595|NCT00651105|Diabetes
513596|NCT00651105|Hyperglycemia
513597|NCT00651105|Healthy
513598|NCT00651105|Vildagliptin
513599|NCT00651105|Adults
513600|NCT00651092|turbinectomy
513601|NCT00651079|GSK1247303,
513602|NCT00651079|Integrase,
513603|NCT00651079|First Time in Human
513604|NCT00651066|HIV
513605|NCT00651066|Tuberculosis
513606|NCT00651066|Rifabutin
513607|NCT00651066|Pharmacokinetics
513608|NCT00651066|Vietnam
513609|NCT00651040|Polymyositis
513610|NCT00651040|Dermatomyositis
513611|NCT00651040|Glucocorticoids
513612|NCT00651040|Methotrexate
513613|NCT00651001|fructose
513614|NCT00651001|leptin
513615|NCT00651001|metabolic syndrome
513616|NCT00651001|blood pressure
513617|NCT00651001|inflammation
513618|NCT00651001|Relationship of fructose intake to leptin levels
513619|NCT00651001|Relationship of fructose to metabolic syndrome
513620|NCT00651001|Relationship of fructose to inflammation parameters
513621|NCT00651001|Relationship of fructose to blood pressure
513622|NCT00650988|Barrett's Esophagus
513623|NCT00650988|Cryospray ablation
513624|NCT00650988|High Grade Dysplasia
513625|NCT00650988|Early Esophageal Cancers
513626|NCT00650988|Esophageal Neoplasms
513627|NCT00650988|Esophageal Intramucosal Cancer (IMCA)
513628|NCT00650988|Esophageal Cancer limited to esophageal wall
513629|NCT00650988|Barretts esophagus High Grade Dysplasia (HGD)
513630|NCT00650975|STEMI
513631|NCT00650975|Laser
513632|NCT00650975|Thrombus
513633|NCT00650975|Thrombectomy
513634|NCT00650962|CPR
513635|NCT00650962|Preshock CPR
513636|NCT00650962|OHCA
513637|NCT00650962|EMS
513638|NCT00650949|Glioblastoma multiforme
513639|NCT00650949|Glioma
513640|NCT00650949|Phase Ib/II
513641|NCT00650949|CYT997
513642|NCT00650936|Atrial
513643|NCT00650936|Septal
513644|NCT00650936|Defect
513645|NCT00650910|lapatinib
513646|NCT00650910|Metastatic ErbB2 positive breast cancer
513647|NCT00650910|digoxin
513648|NCT00650897|Efficacy
513649|NCT00650897|Antidepressant
513650|NCT00650897|Escitalopram
513651|NCT00650897|Major Depression
513652|NCT00650897|Diabetes Mellitus
513653|NCT00650897|Self Care
513654|NCT00650884|Dynamic Splinting for low-load, prolonged-duration stretch
513655|NCT00650871|GW679769,
513656|NCT00650871|sleep,
513657|NCT00650871|cognitive function,
513658|NCT00650871|primary insomnia,
513659|NCT00650871|polysomnography.
513660|NCT00650858|Intraventricular hemorrhage (IVH)
513661|NCT00650858|rt-PA
513662|NCT00650845|contrast-induced nephropathy, creatinemia
513663|NCT00650832|HIV, anti-infectives
513664|NCT00650806|Obesity
513665|NCT00650806|Overweight
513666|NCT00650806|Weight loss
513667|NCT00650806|Anti-Obesity Agents
513668|NCT00650806|Human
513669|NCT00650793|Schizophrenia
513670|NCT00650793|paliperidone
513671|NCT00650780|Viatmin D, 25-hydroxyvitamin D, Vitamin D binding protein
513672|NCT00650754|DHEA
513673|NCT00650754|Pregnancy
513674|NCT00650741|Endothelial Dysfunction
513675|NCT00650741|FMD
513676|NCT00650728|radiofrequency ablation
513677|NCT00650715|Fibromyalgia
513678|NCT00650715|Whole-Body vibration
513679|NCT00650715|Exercise
513680|NCT00650715|IGF-1
513681|NCT00650702|glaucoma, ocular hypertension, IOP
513682|NCT00650624|knee osteoarthritis; Japan
513683|NCT00650598|anterior cruciate ligament, arthroscopy, knee, post-surgical pain
513684|NCT00650585|smoking
513685|NCT00650585|alcohol
513686|NCT00650585|prevention
513687|NCT00650585|prevention & control
513688|NCT00650572|human epidermal growth factor receptor 2
513689|NCT00650572|epidermal growth factor receptor
513690|NCT00650572|EGFR
513691|NCT00650572|type I receptor tyrosine kinase
513692|NCT00650559|COPD
513693|NCT00650559|Emphysema
513694|NCT00650559|thorax enlargement
513695|NCT00650559|LVRS
513696|NCT00650546|Non-alcoholic steatohepatitis
513697|NCT00650546|NASH
513698|NCT00650507|children
513700|NCT00650507|remote ischemic preconditioning
513701|NCT00650507|SHAM
513702|NCT00650507|ischemia-reperfusion
513703|NCT00650468|Renal Transplantation
513704|NCT00650468|Prograf
513705|NCT00650455|valdecoxib, severe rheumatoid arthritis
513706|NCT00650260|intraoperative warming
513707|NCT00650260|anesthesia
513708|NCT00650260|hypothermia
513709|NCT00650260|body temperature
513710|NCT00650182|patch
513711|NCT00650182|fentanyl
513712|NCT00650182|chronic pain
513713|NCT00650143|Stem cell
513714|NCT00650143|Myocardial infarction
513715|NCT00650143|G-CSF
513716|NCT00650143|CD26-inhibition
513717|NCT00650130|driving under the influence
513718|NCT00650130|psychoactive substances
513719|NCT00650130|oral fluid
513720|NCT00650130|whole blood
513721|NCT00650130|plasma
513722|NCT00650130|Ratio of psychoactive substances in whole blood-plasma-oral fluid
513723|NCT00650130|Prevalence of psychoactive substances in road traffic
513724|NCT00650104|ropinirole IR
513725|NCT00650104|efficacy
513726|NCT00650104|safety
513727|NCT00650104|open-label
513728|NCT00650104|long term safety; REQUIP
513729|NCT00650104|ropinirole XL
513730|NCT00650104|ropinirole CR
513731|NCT00650104|Parkinson's disease
513732|NCT00650091|Idiopathic Pulmonary Fibrosis
513733|NCT00650091|Prednisone
513734|NCT00650091|Azathioprine
513735|NCT00650091|NAC
513736|NCT00650091|N-acetylcysteine
513737|NCT00650078|Signs and Symptoms
513738|NCT00650078|Autoimmune Diseases
513739|NCT00650078|Joint Diseases
513740|NCT00650078|Arthritis
513741|NCT00650078|Connective Tissue Diseases
513742|NCT00650078|Arthritis, Rheumatoid
513743|NCT00650078|Rheumatic Diseases
513744|NCT00650078|Predniso(lo)ne
513745|NCT00650039|Post surgical pain
513746|NCT00650039|Anterior Cruciate ligament reconstruction
513747|NCT00650039|Arthroscopy
513748|NCT00650039|Perioperative pain
513749|NCT00649961|Premature Birth
513750|NCT00649961|Brain injury
513751|NCT00649961|Neuroprotection
513752|NCT00649961|Melatonin
513753|NCT00649961|Pharmacokinetics
513754|NCT00649922|Vaccines with adalimumab dosing
513755|NCT00649909|Diabetes Mellitus
513756|NCT00649909|Type II
513757|NCT00649909|Aspirin
513758|NCT00649909|Resistance
513759|NCT00649883|Influenza
513760|NCT00649883|vaccine
513761|NCT00649883|children
513762|NCT00649792|multiple sclerosis
513763|NCT00649792|MS
513764|NCT00649792|walking
513765|NCT00649792|leg strength
513766|NCT00649792|demyelination
513767|NCT00649766|tailored health messages
513768|NCT00649766|glaucoma
513769|NCT00649766|diabetic retinopathy
513770|NCT00649766|dilated fundus exams
513771|NCT00649766|health behavior
513772|NCT00649753|sacroiliac joint dysfunction
513773|NCT00649753|algometer
513774|NCT00649753|Chiropractic
513775|NCT00649753|Manual Therapy
513776|NCT00649753|indicator points associated with sacroiliac joint dysfunction
513777|NCT00649701|HIV
513778|NCT00649701|Internet
513779|NCT00649701|MSM
513780|NCT00649701|Condom Use
513781|NCT00649701|Disclosure
513782|NCT00649610|acute low back pain
513783|NCT00649584|Antigens, CD30
513784|NCT00649584|Antibody-Drug Conjugate
513785|NCT00649584|Antibodies, Monoclonal
513786|NCT00649584|monomethyl auristatin E
513787|NCT00649584|Combined Modality Therapy
513788|NCT00649584|Drug Therapy
513789|NCT00649584|Immunotherapy
513790|NCT00649584|Lymphoma, Non-Hodgkin
513791|NCT00649584|Disease, Hodgkin
513792|NCT00649584|Lymphoma, Large-Cell, Anaplastic
513793|NCT00649584|Hematologic Diseases
513794|NCT00649584|Lymphoma
513795|NCT00649428|Treatment of moderate to severe bilateral nasolabial fold wrinkles
513796|NCT00649337|mammography
513797|NCT00649337|ultrasound
513798|NCT00649337|breast cancer
513799|NCT00649337|screening
513800|NCT00649298|Randomized Controlled Trial
513801|NCT00649298|Clinical Trial
513802|NCT00649298|Controlled Clinical Trial
513803|NCT00649298|Clinical Trial, Phase IV
513804|NCT00649298|Multicenter Study
513805|NCT00649298|End Stage Kidney Disease
513806|NCT00649298|Hemodialysis
513807|NCT00649298|Renal Dialysis
513808|NCT00649298|Renal Replacement Therapy
513809|NCT00649298|Nocturnal Dialysis
513810|NCT00649298|Extended dialysis
513811|NCT00649298|Quality of Life
513812|NCT00649298|Quality Adjusted Life Year
513813|NCT00649298|Hypertrophy, Left Ventricular
513814|NCT00649298|Blood Pressure
513815|NCT00649298|Hypertension
513816|NCT00649298|Anemia
513817|NCT00649298|Hematinics
513818|NCT00649298|Erythropoiesis Stimulating Agents
513819|NCT00649298|Cost-utility Analysis
513820|NCT00649298|Economic Evaluation
513821|NCT00649298|Health Care Utilisation
513822|NCT00649298|Health Care Costs
513823|NCT00649298|Health Expenditures
513824|NCT00649298|Hospitalization
513825|NCT00649298|Cost Analysis
513826|NCT00649298|Cardiovascular Diseases
513827|NCT00649298|Acute Coronary Syndrome
513828|NCT00649298|Myocardial Infarction
513829|NCT00649298|Stroke
513830|NCT00649298|Cerebrovascular Disorders
513831|NCT00649298|Mortality
513832|NCT00649298|Arteriovenous Fistula
513833|NCT00649298|Arteriovenous Shunt, Surgical
513834|NCT00649298|Thrombosis
513835|NCT00649298|Infection
513836|NCT00649246|genetics
513837|NCT00649246|type 1 diabetes
513838|NCT00649246|biomarkers
513839|NCT00649246|autoimmunity
513840|NCT00649207|WBRT
513841|NCT00649207|Brain Metastases
513842|NCT00649207|Radiation
513843|NCT00649207|ABT-888
513844|NCT00649207|PARP
513845|NCT00649142|Groin hernia
513846|NCT00649142|Chronic postsurgical pain
513847|NCT00649142|open mesh repair
513848|NCT00649142|laparoscopic mesh glue fixation
513849|NCT00649142|Sensory changes after groin hernia repair
513850|NCT00649025|Asthma
513851|NCT00649025|Asthma Moderate to Severe
513852|NCT00648999|Kaletra
513853|NCT00648986|brittle nails
513854|NCT00648986|Tazarotene
513855|NCT00648986|Tazorac
513856|NCT00648973|Seasonal Allergic Rhinitis, nasal congestion
513857|NCT00648908|multiple sclerosis
513858|NCT00648908|MS
513859|NCT00648908|walking
513860|NCT00648908|leg strength
513861|NCT00648908|demyelination
513862|NCT00648895|Hypertension
513863|NCT00648895|Blood pressure
513864|NCT00648895|Nebivolol
513865|NCT00648895|Bystolic (TM)
513866|NCT00648895|Metoprolol ER (TM)
513867|NCT00648869|pharmaceutical preparations
513868|NCT00648817|HIV-1
513869|NCT00648817|tenofovir DF
513870|NCT00648739|B-cell Chronic Lymphocytic Leukemia
513871|NCT00648739|Leukemia
513872|NCT00648739|Multiple Myeloma
513873|NCT00648739|CD200
513874|NCT00648739|Anti-CD200
513875|NCT00648687|prematurity
513876|NCT00648687|retinopathy of prematurity
513877|NCT00648687|pain
513878|NCT00648687|very low birth weight infants
513879|NCT00648635|Rectal Cancer
513880|NCT00648635|Recurrent Rectal Adenocarcinoma
513881|NCT00648635|Quality of Life
513882|NCT00648635|QOL
513883|NCT00648635|Questionnaire
513884|NCT00648635|Survey
513885|NCT00648609|Community based self management of COPD with palliative care
513886|NCT00648479|Fracture Fixation
513887|NCT00648453|Fontain II-III stage
513888|NCT00648375|Propanolol
513889|NCT00648375|Beta Blockers
513890|NCT00648375|Reconsolidation
513891|NCT00648375|Cognitive Therapy
513892|NCT00648375|PTSD
513893|NCT00648323|Benign Prostate Hyperplasia
513894|NCT00648284|Type 2 diabetes
513895|NCT00648284|CV risk
513896|NCT00648284|rosiglitazone
513897|NCT00648284|AVANDIA
513898|NCT00648258|osteoarthritis, knee
513899|NCT00648258|osteoarthritis, hip
513900|NCT00648245|chronic obstructive pulmonary disease
513901|NCT00648245|COPD
513902|NCT00648245|Chronic bronchitis
513903|NCT00648232|HIV
513904|NCT00648232|AIDS
513905|NCT00648232|Prevention
513906|NCT00648232|VCT
513907|NCT00648232|Voluntary Counseling and Testing
513908|NCT00648206|driving under the influence
513909|NCT00648206|psychoactive substances
513910|NCT00648206|blood samples
513911|NCT00648206|Prevalence of psychoactive substances in road traffic
513912|NCT00648167|ESRD
513913|NCT00648167|end-stage renal disease
513914|NCT00648167|end stage renal disease
513915|NCT00648167|hemodialysis
513916|NCT00648167|dialysis
513917|NCT00648167|kidney failure
513918|NCT00648167|renal failure
513919|NCT00648167|kidney
513920|NCT00648167|renal
513921|NCT00648167|phosphate binder
513922|NCT00648167|phosphorus
513923|NCT00648115|Veterans
513924|NCT00648115|Substance-Related Disorders
513925|NCT00648115|Mental Health
513926|NCT00648102|Breast cancer
513927|NCT00648102|Colorectal cancer
513928|NCT00648102|Pancreatic cancer
513929|NCT00648102|Bladder cancer
513930|NCT00648102|Ovarian cancer
513931|NCT00648102|Metastatic cancer
513932|NCT00648102|Locally advanced cancer
513933|NCT00648102|Cancer Vaccine
513934|NCT00648102|Vaccine
513935|NCT00648089|Acute ST Elevation Myocardial Infarction
513936|NCT00648037|RITUXIMAB
513937|NCT00648037|Lymphoma
513938|NCT00647998|Surgical complications
513939|NCT00647998|Spinal ischemia
513940|NCT00647998|Stroke
513941|NCT00647998|Neuroprotection
513942|NCT00647946|lipodystrophy
513943|NCT00647933|Females
513944|NCT00647933|Corifollitropin alfa
513945|NCT00647933|Antibodies
513946|NCT00647933|Pharmacokinetics
513947|NCT00647933|Pharmacodynamics
513948|NCT00647868|pharmacokinetics
513949|NCT00647868|testosterone
513950|NCT00647868|hypogonadism
513951|NCT00647829|pharyngitis, sore throat
513952|NCT00647790|PET imaging
513953|NCT00647790|invasive breast cancer
513954|NCT00647725|Epidural analgesia
513955|NCT00647725|Latent analgesia
513956|NCT00647725|Active analgesia
513957|NCT00647725|Labor delivery
513958|NCT00647699|keratoconus
513959|NCT00647699|cross-linking
513960|NCT00647699|riboflavin
513961|NCT00647699|UVA light
513962|NCT00647699|cornea
513963|NCT00647595|Obesity
513964|NCT00647595|Physical activity
513965|NCT00647595|Pregnancy
513966|NCT00647595|Diabetes mellitus
513967|NCT00647582|stage I breast cancer
513968|NCT00647582|stage II breast cancer
513969|NCT00647569|vertical rectus abdominis musculocutaneus flap
513970|NCT00647569|mesh repair
513971|NCT00647569|salvage surgery
513972|NCT00647530|adenocarcinoma of the colon
513973|NCT00647530|stage I colon cancer
513974|NCT00647530|stage II colon cancer
513975|NCT00647530|stage III colon cancer
513976|NCT00647504|stent thrombosis
513977|NCT00647504|stent restenosis
513978|NCT00647504|intravascular ultrasound
513979|NCT00647478|Insulin-like Growth Factor
513980|NCT00647478|Insulin-like Growth Factor binding protein 3
513981|NCT00647478|Insulin-like Growth Factor-I system component levels
513982|NCT00647478|Insulin-like Growth Factor-I polymorphism
513983|NCT00647478|Alzheimer's disease
513984|NCT00647478|Mild Cognitive Impairment
513985|NCT00647478|Normal cognitive function
513986|NCT00647478|Observational cross sectional study
513987|NCT00647465|Influenza vaccine
513988|NCT00647465|interferon
513989|NCT00647465|adjuvant
513990|NCT00647465|the elderly
513991|NCT00647452|Lipid metabolism
513992|NCT00647452|VLDL
513993|NCT00647452|Exercise
513994|NCT00647452|Lipid metabolism in exercise
513995|NCT00647439|OCULAR INFLAMMATORY DISEASE
513996|NCT00647439|Immune Mediated
513997|NCT00647439|Gene Expression Patterns
513998|NCT00647439|Diabetic Retinopathy
513999|NCT00647439|Age-Related Macular Degeneration
514000|NCT00647439|AMD
514001|NCT00647439|Uveitis
514002|NCT00647426|Stage IIIB/IV
514003|NCT00647413|smoking
514004|NCT00647413|passive smoking
514005|NCT00647413|exposure to environmental smoke
514006|NCT00647413|home smoking ban
514007|NCT00647413|urinary cotinine
514008|NCT00647400|Psoriasis
514009|NCT00647387|muscular
514010|NCT00647387|ventricular
514011|NCT00647387|septal
514012|NCT00647387|defects
514013|NCT00647387|VSD
514014|NCT00646347|stroke
514015|NCT00646347|upper limb rehabilitation
514016|NCT00646347|treatment
514017|NCT00646347|movement recovery from sever paralytic upper limb
514018|NCT00646347|neuro hand orthosis
514019|NCT00646347|self practice program
514020|NCT00646347|subacute
514021|NCT00646334|Large Pore Size Propylene Mesh
514022|NCT00646334|Incisional Hernia
514023|NCT00646334|Randomized Controlled Double-blind Study
514024|NCT00647361|respiratory insufficiency
514025|NCT00647361|respiration
514026|NCT00647361|ventilators
514027|NCT00647361|diaphragm
514028|NCT00647361|electromyography
514029|NCT00647361|mechanical ventilation
514030|NCT00647348|Secondary progressive Multiple Sclerosis
514031|NCT00647348|Simvastatin
514032|NCT00647348|MRI
514033|NCT00647322|Intractable epilepsy, Drug Reduction, Antiepileptic medication
514034|NCT00647296|ALS
514035|NCT00647296|Amyotrophic Lateral Sclerosis
514036|NCT00647296|Lou Gehrig
514037|NCT00647296|Lou Gehrig's
514038|NCT00647296|Lou Gehrig's disease
514039|NCT00647296|Motor Neuron Disease
514040|NCT00647296|Nervous System Diseases
514041|NCT00647296|KNS-760704
514042|NCT00647283|Liver Transplantation
514043|NCT00647283|Tolerance
514044|NCT00647283|Allograft tolerance
514045|NCT00647283|Immunosuppression minimization
514046|NCT00647283|Immunosuppression weaning
514047|NCT00647283|Immunological tolerance
514048|NCT00647257|Sick Sinus Syndrome; Atrial Fibrillation; Pacemaker
514049|NCT00647244|Tenofovir
514050|NCT00647244|Abacavir
514051|NCT00647244|Antiretroviral therapy
514052|NCT00647244|HIV
514053|NCT00647244|Nucleoside analogue reverse transcriptase inhibitor
514054|NCT00647231|Osteoarthritis,Knee,Ketoprofen,Pain,Patch,Analgesic
514055|NCT00647218|stage II breast cancer
514056|NCT00647218|stage IIIA breast cancer
514057|NCT00647218|stage IIIB breast cancer
514058|NCT00647218|stage IIIC breast cancer
514059|NCT00647205|Interferon, gamma
514060|NCT00647205|HIV Infections
514061|NCT00647205|Tuberculosis
514062|NCT00647192|atrial fibrillation
514063|NCT00647192|electrical cardioversion
514064|NCT00647192|prevention of atrial fibrillation recurrence
514065|NCT00647192|mineralocorticoid receptor blocker
514066|NCT00647192|eplerenone
514067|NCT00647192|Recurrence of atrial fibrillation after cardioversion
514068|NCT00647179|Acromegaly
514069|NCT00647179|Growth Hormone
514070|NCT00647179|Insulin resistance
514071|NCT00647179|Glucose tolerance
514072|NCT00647179|Body Composition
514073|NCT00647179|Substrate metabolism
514074|NCT00647166|Vasculitis
514075|NCT00647166|Polyarteritis nodosa (PAN)
514076|NCT00647166|Microscopic polyangiitis (MPA)
514077|NCT00647166|Eosinophilic granulomatosis with polyangiitis (EGPA)
514078|NCT00647166|Churg Strauss syndrome (CSS)
514079|NCT00647166|Azathioprine
514080|NCT00647153|stage I colon cancer
514081|NCT00647153|stage II colon cancer
514082|NCT00647153|stage III colon cancer
514083|NCT00647153|stage IV colon cancer
514084|NCT00647153|stage I rectal cancer
514085|NCT00647153|stage II rectal cancer
514086|NCT00647153|stage III rectal cancer
514087|NCT00647153|stage IV rectal cancer
514088|NCT00647140|Thyroid neoplasm
514089|NCT00647140|Thyroid carcinoma
514090|NCT00647140|Medullary carcinoma
514091|NCT00647140|Positron Emission Tomography (PET)
514092|NCT00647140|18F-L DOPA
514093|NCT00647140|Calcitonin
514094|NCT00647140|Carcinoembryonic Antibodies
514095|NCT00647140|Cervical ultrasonography
514096|NCT00647140|Cervical-chest-abdomen tomography
514097|NCT00647140|Cervical-chest-abdomen magnetic resonance imaging
514098|NCT00647140|Osseous radionuclide imaging
514099|NCT00647140|Post-PET surgery
514100|NCT00647140|Post-PET biopsy
514101|NCT00647140|Post-PET histology
514102|NCT00647127|Buprenorphine
514103|NCT00647127|Fentanyl
514104|NCT00647127|Analgesic effect
514105|NCT00647127|Anti-hyperalgesic effect
514106|NCT00647127|Experimental pain
514107|NCT00647114|Cancers expressing HER-2 and/or CEA
514108|NCT00647088|Aortic Valve stenosis
514109|NCT00647088|Genetic
514110|NCT00647088|Mineralisation inhibitors
514111|NCT00647075|Breast cancer
514112|NCT00647075|undergoing
514113|NCT00647075|adjuvant/neoadjuvant chemotherapy
514114|NCT00647075|symptomatic therapy
514115|NCT00647036|Parenteral nutrition, Infants, Dipeotiven, Microbial invasion
514116|NCT00646997|atrial fibrillation, left atrium, velocity vector imaging
514117|NCT00646984|Lipodystrophy
514118|NCT00646984|Treatment interruption
514119|NCT00646984|HIV
514120|NCT00646971|Isoprostane
514121|NCT00646971|Alkane
514122|NCT00646971|Exhaled condensate
514123|NCT00646971|Peripheral arterial tonometry
514124|NCT00646971|Polysomnography
514125|NCT00646971|Obstructive Sleep Apnea
514126|NCT00646971|Hypoxia
514127|NCT00646945|Patient in a oncology unit who has to undergo a painful or invasive procedure
514128|NCT00646906|acetaminophen
514129|NCT00646906|low dose aspirin
514130|NCT00646906|cyclooxygenase
514131|NCT00646906|prostaglandin
514132|NCT00646906|drug interaction
514133|NCT00646906|platelet inhibition
514134|NCT00646906|urinary prostaglandin metabolites
514135|NCT00646906|oxidant stress
514136|NCT00646906|smoking
514137|NCT00646893|aneuploidy
514138|NCT00646893|miscarriage
514139|NCT00646893|pregnancy loss
514140|NCT00646893|PGD
514141|NCT00646893|PGS
514142|NCT00646893|Preimplantation Genetic Diagnosis
514143|NCT00646893|chromosome abnormalities
514144|NCT00646893|IVF
514145|NCT00646893|ART
514146|NCT00646867|Tetrix cream, contact dermatitis, effect on burning and itching
514147|NCT00646854|Lymphoma, T-Cell
514148|NCT00646854|Lymphoma, T-Cell, Peripheral
514149|NCT00646854|MabCampath
514150|NCT00646854|Campath
514151|NCT00646854|CHOP-14
514152|NCT00646854|CD52 expression
514153|NCT00646841|Essential hypertension, doxazosin, ambulatory blood pressure monitoring
514154|NCT00646828|Pseudohypoaldosteronism type 1
514155|NCT00646828|Mineralocorticoid receptor
514156|NCT00646828|Aldosterone
514157|NCT00646828|Cardiovascular disease
514158|NCT00646815|insulin sensitivity
514159|NCT00646815|substrate metabolism
514160|NCT00646815|fatty liver
514161|NCT00646815|intramyocellular lipids
514162|NCT00646815|growth hormone deficiency
514163|NCT00646815|Growth hormone deficiency (Adult)
514164|NCT00646750|Z-BEAM
514165|NCT00646750|Autologous
514166|NCT00646750|Lymphoma
514167|NCT00646750|GELTAMO
514168|NCT00646737|Kidney transplantation
514169|NCT00646737|conversion
514170|NCT00646737|mycophenolate mofetil
514171|NCT00646737|mycophenolate sodium,
514172|NCT00646737|tacrolimus
514173|NCT00646724|Islets of Langerhans Transplantation
514174|NCT00646724|Mesenchymal Stem Cells
514175|NCT00646724|Type 1 Diabetes Mellitus
514176|NCT00646698|VLDL-TG kinetics
514177|NCT00646698|Obesity
514178|NCT00646698|Body composition
514179|NCT00646698|Tracers
514180|NCT00646698|Tissue biopsies
514181|NCT00646672|ECMO
514182|NCT00646672|Cerebral Perfusion
514183|NCT00646672|Carotid Artery
514184|NCT00646672|Aneurysm
514185|NCT00646672|Cerebral Circulation
514186|NCT00646672|Common Carotid Artery Occlusion
514187|NCT00646659|stage III squamous cell carcinoma of the hypopharynx
514188|NCT00646659|stage III squamous cell carcinoma of the larynx
514189|NCT00646659|stage III squamous cell carcinoma of the lip and oral cavity
514190|NCT00646659|stage III squamous cell carcinoma of the oropharynx
514191|NCT00646659|stage IV squamous cell carcinoma of the hypopharynx
514192|NCT00646659|stage IV squamous cell carcinoma of the larynx
514193|NCT00646659|stage IV squamous cell carcinoma of the lip and oral cavity
514194|NCT00646659|stage IV squamous cell carcinoma of the oropharynx
514195|NCT00646659|untreated metastatic squamous neck cancer with occult primary
514196|NCT00646646|Sedation
514197|NCT00646646|Eye Movements
514198|NCT00646633|Cancer
514199|NCT00646633|Acupuncture
514200|NCT00646620|asthma
514201|NCT00646620|bronchodilatation
514202|NCT00646620|Symbicort
514203|NCT00646620|budesonide/formoterol
514204|NCT00646620|Advair Diskus
514205|NCT00646620|Ventolin
514206|NCT00646607|colorectal neoplasm
514207|NCT00646607|high risk
514208|NCT00646607|stage II/III
514209|NCT00646594|Asthma
514210|NCT00646594|inhaled cortocisteroids
514211|NCT00646594|Symbicort
514212|NCT00646594|budesonide/formoterol
514213|NCT00646594|Advair
514214|NCT00646594|fluticasone/salmeterol
514215|NCT00646581|Schizophrenia
514216|NCT00646581|Memory
514217|NCT00646581|Concentration
514218|NCT00646581|Insulin
514219|NCT00646568|IVF
514220|NCT00646568|ovarian reserve
514221|NCT00646568|androgens
514222|NCT00646568|thecal cells
514223|NCT00646568|Fertility Agents, Female
514224|NCT00646555|Tissue Samples
514225|NCT00646555|VEGF Receptors
514226|NCT00646555|VEGF
514227|NCT00646555|Microvessel Density
514228|NCT00646555|Hypoxia Inducible Factor
514229|NCT00646555|Inflammatory Breast Cancer
514230|NCT00646555|IBC
514231|NCT00646542|Type 2 diabetes, vildagliptin
514232|NCT00646529|asthma
514233|NCT00646529|children
514234|NCT00646529|Symbicort
514235|NCT00646529|budesonide/formoterol
514236|NCT00646529|Pulmicort
514237|NCT00646529|budesonide
514238|NCT00646516|Asthma
514239|NCT00646516|inhaled corticosteroids
514240|NCT00646516|Symbicort
514241|NCT00646516|budesonide/formoterol
514242|NCT00646516|budesonide
514243|NCT00646503|Hepatitis B, Chronic
514244|NCT00646503|Telbivudine
514245|NCT00646503|Polymerase Chain reaction
514246|NCT00646490|serum, pleural effusion, procalcitonin, pneumonia
514247|NCT00646464|CPT
514248|NCT00646464|ADHD
514249|NCT00646451|Essential tremor
514250|NCT00646451|Activities of Daily Living (ADL's)
514251|NCT00646438|Diabetes
514252|NCT00646438|CABG
514253|NCT00646425|Non-infectious uveitis
514254|NCT00646412|randomized, controlled, single-blind study
514255|NCT00646412|Adhesion Prophylaxis
514256|NCT00646412|Abdominal Surgery
514257|NCT00646412|Laparotomy, median
514258|NCT00646399|Staphylococcal
514259|NCT00646399|Coagulase Negative Staphylococcus
514260|NCT00646399|Monoclonal antibodies
514261|NCT00646399|Very Low Birth Weight Infants
514262|NCT00646399|Prophylaxis
514263|NCT00646373|Cardiac surgery
514264|NCT00646373|Pump prime
514265|NCT00646373|Blood transfusions
514266|NCT00646360|birth size, gestational age, development, child growth,
514267|NCT00646360|prenatal nutrition, DHA
514268|NCT00646321|asthma
514269|NCT00646321|children
514270|NCT00646321|adolescents
514271|NCT00646321|Symbicort
514272|NCT00646321|budesonide/ formoterol
514273|NCT00646321|budesonide
514274|NCT00646308|growth hormone deficiency, pituitary tumors
514275|NCT00646295|TRO
514276|NCT00646269|Dementia ; Alzheimer's Disease ; Non pharmacological treatments ; cognitive training ; reminiscence therapy ; efficacy assessment
514277|NCT00646256|schizoaffective
514278|NCT00646256|schizotypal
514279|NCT00646243|Heart failure
514280|NCT00646243|echocardiography
514281|NCT00646243|cardiac resynchronization therapy
514282|NCT00646243|left ventricular dyssynchrony
514283|NCT00646230|recurrent neuroblastoma
514284|NCT00646217|SELF Care Talk
514285|NCT00646217|stroke
514286|NCT00646217|caregivers
514287|NCT00646217|Caregiving as experienced by older adults caring for a spouse/partner with a first-ever stroke
514288|NCT00646204|Parkinson's disease
514289|NCT00646204|non-motor symptoms
514290|NCT00646165|Leukemia, CLL
514291|NCT00646152|Antiviral
514292|NCT00646152|Influenza
514293|NCT00646152|Interferon
514294|NCT00646152|Prophylaxis
514295|NCT00646152|SARS
514296|NCT00646152|Healthy Volunteer
514297|NCT00646152|HV
514298|NCT00646139|unspecified adult solid tumor, protocol specific
514299|NCT00646139|recurrent adult T-cell leukemia/lymphoma
514300|NCT00646139|stage III adult T-cell leukemia/lymphoma
514301|NCT00646139|stage IV adult T-cell leukemia/lymphoma
514302|NCT00646139|adult grade III lymphomatoid granulomatosis
514303|NCT00646139|adult nasal type extranodal NK/T-cell lymphoma
514304|NCT00646139|anaplastic large cell lymphoma
514305|NCT00646139|angioimmunoblastic T-cell lymphoma
514306|NCT00646139|splenic marginal zone lymphoma
514307|NCT00646139|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
514308|NCT00646139|nodal marginal zone B-cell lymphoma
514309|NCT00646139|stage III adult Burkitt lymphoma
514310|NCT00646139|stage III adult diffuse large cell lymphoma
514311|NCT00646139|stage III adult diffuse mixed cell lymphoma
514312|NCT00646139|stage III adult diffuse small cleaved cell lymphoma
514313|NCT00646139|stage III adult Hodgkin lymphoma
514314|NCT00646139|stage III adult immunoblastic large cell lymphoma
514315|NCT00646139|stage III adult lymphoblastic lymphoma
514316|NCT00646139|stage III cutaneous T-cell non-Hodgkin lymphoma
514317|NCT00646139|stage III mycosis fungoides/Sezary syndrome
514318|NCT00646139|stage III grade 1 follicular lymphoma
514319|NCT00646139|stage III grade 2 follicular lymphoma
514320|NCT00646139|stage III grade 3 follicular lymphoma
514321|NCT00646139|stage III mantle cell lymphoma
514322|NCT00646139|stage III marginal zone lymphoma
514323|NCT00646139|stage III small lymphocytic lymphoma
514324|NCT00646139|stage IV adult Burkitt lymphoma
514325|NCT00646139|stage IV adult diffuse large cell lymphoma
514326|NCT00646139|stage IV adult diffuse mixed cell lymphoma
514327|NCT00646139|stage IV adult diffuse small cleaved cell lymphoma
514328|NCT00646139|stage IV adult Hodgkin lymphoma
514329|NCT00646139|stage IV adult immunoblastic large cell lymphoma
514330|NCT00646139|stage IV adult lymphoblastic lymphoma
514331|NCT00646139|stage IV cutaneous T-cell non-Hodgkin lymphoma
514332|NCT00646139|stage IV mycosis fungoides/Sezary syndrome
514333|NCT00646139|stage IV grade 1 follicular lymphoma
514334|NCT00646139|stage IV grade 2 follicular lymphoma
514335|NCT00646139|stage IV grade 3 follicular lymphoma
514336|NCT00646139|stage IV mantle cell lymphoma
514337|NCT00646139|stage IV marginal zone lymphoma
514338|NCT00646139|stage IV small lymphocytic lymphoma
514339|NCT00646139|recurrent adult Hodgkin lymphoma
514340|NCT00646139|recurrent adult Burkitt lymphoma
514341|NCT00646139|recurrent adult diffuse large cell lymphoma
514342|NCT00646139|recurrent adult diffuse mixed cell lymphoma
514343|NCT00646139|recurrent adult diffuse small cleaved cell lymphoma
514344|NCT00646139|recurrent adult grade III lymphomatoid granulomatosis
514345|NCT00646139|recurrent adult immunoblastic large cell lymphoma
514346|NCT00646139|recurrent adult lymphoblastic lymphoma
514347|NCT00646139|recurrent cutaneous T-cell non-Hodgkin lymphoma
514348|NCT00646139|recurrent mycosis fungoides/Sezary syndrome
514349|NCT00646139|recurrent grade 1 follicular lymphoma
514350|NCT00646139|recurrent grade 2 follicular lymphoma
514351|NCT00646139|recurrent grade 3 follicular lymphoma
514352|NCT00646139|recurrent mantle cell lymphoma
514353|NCT00646139|recurrent marginal zone lymphoma
514354|NCT00646139|recurrent small lymphocytic lymphoma
514355|NCT00646139|intraocular lymphoma
514356|NCT00646139|primary central nervous system non-Hodgkin lymphoma
514357|NCT00646139|post-transplant lymphoproliferative disorder
514358|NCT00646139|cutaneous B-cell non-Hodgkin lymphoma
514359|NCT00646139|Waldenstrom macroglobulinemia
514360|NCT00646139|small intestine lymphoma
514361|NCT00646100|hepatocellular carcinoma
514362|NCT00646100|transcatheter arterial chemoembolization
514363|NCT00646100|prospective control study
514364|NCT00646100|best support care
514365|NCT00646100|survival
514366|NCT00646074|Caregiver
514367|NCT00646074|Alzheimer's disease
514368|NCT00646074|Caregiving as experienced by older adults caring for a spouse with Alzheimer's disease or dementia
514369|NCT00646061|renal colic
514370|NCT00646048|Abdominal Aortic Aneurysm
514371|NCT00646048|AAA
514372|NCT00646048|TriVascular Stent-Graft System
514373|NCT00646048|Stent-Graft
514374|NCT00646022|Neuroendocrine
514375|NCT00646022|PET
514376|NCT00646022|Gastrointestinal
514377|NCT00646022|Serotonin
514378|NCT00646022|Carcinoid Tumor
514379|NCT00646022|Gastrointestinal Carcinoid Tumor
514380|NCT00646022|Familial Cancer Tumor
514381|NCT00646009|asthma
514382|NCT00646009|adults
514383|NCT00646009|Symbicort
514384|NCT00646009|budesonide/formoterol
514385|NCT00646009|Advair Diskus
514386|NCT00646009|Ventolin
514387|NCT00645996|Probiotics
514388|NCT00645996|vaccines
514389|NCT00645996|Measles
514390|NCT00645996|Mumps
514391|NCT00645996|Rubella
514392|NCT00645983|Chamomile
514393|NCT00645983|Anxiety
514394|NCT00645983|Complementary and Alternative Medicine
514395|NCT00645970|chronic pain
514396|NCT00645970|combat injuries
514397|NCT00645970|pain assessment
514398|NCT00645970|multiple traumas
514399|NCT00645970|rehabilitation
514400|NCT00645957|drainage
514401|NCT00645957|irrigation
514402|NCT00645931|Bone Marrow
514403|NCT00645931|Bone Marrow Transplant
514404|NCT00645931|Pediatric
514405|NCT00645931|Psychological Impact
514406|NCT00645931|Psychology
514407|NCT00645918|Platelets
514408|NCT00645918|Platelet Function Tests
514409|NCT00645918|Clopidogrel
514410|NCT00645918|Drug Eluting Stents
514411|NCT00645918|Acute Coronary Syndrome
514412|NCT00645918|Myocardial Ischemia
514413|NCT00645918|Stent Thrombosis
514414|NCT00645918|Heart Diseases
514415|NCT00645918|Coronary Disease
514416|NCT00645918|Arterial Occlusive Disease
514417|NCT00645879|Propionic Acidemia
514418|NCT00645879|hyperammonemia
514419|NCT00645879|hypotonia
514420|NCT00645879|glutamine
514421|NCT00645879|ornithine alpha ketoglutarate
514422|NCT00645879|citrate
514423|NCT00645866|stage IIIA breast cancer
514424|NCT00645866|stage IIIB breast cancer
514425|NCT00645866|stage IIIC breast cancer
514426|NCT00645840|Type 1 diabetes mellitus
514427|NCT00645840|IL1 beta
514428|NCT00645840|Anakinra
514429|NCT00645827|Insulin
514430|NCT00645827|Blood Glucose
514431|NCT00645801|Routine screening colonoscopy
514432|NCT00645801|Colonoscopy Preparation
514433|NCT00645801|Amitiza
514434|NCT00645801|GoLYTELY
514435|NCT00645801|Pegylated Electrolytes
514436|NCT00645801|Preparation Solution
514437|NCT00645801|Colonoscopy Solution
514438|NCT00645788|Ciprofloxacin
514439|NCT00645788|cystic fibrosis
514440|NCT00645788|sweat test
514441|NCT00645788|pulmonary function test
514442|NCT00645775|Weight loss
514443|NCT00645775|Antiobesity
514444|NCT00645775|Metabolic syndrome
514445|NCT00645775|Leptin
514446|NCT00645762|Chronic rhinosinusitis
514447|NCT00645762|Chronic sinusitis
514448|NCT00645762|Maxillary sinus
514449|NCT00645762|Anterior ethmoid sinus
514450|NCT00645762|Ethmoid infundibulum
514451|NCT00645762|Balloon dilation
514452|NCT00645762|Endoscopic visualization
514453|NCT00645762|Local anesthesia
514454|NCT00645762|Canine fossa
514455|NCT00645762|Less invasive
514456|NCT00645736|Chronic Hepatitis B
514457|NCT00645723|Acinetobacter baumanii
514458|NCT00645723|Ventilator-associated pneumonia
514459|NCT00645697|tuberculosis
514460|NCT00645697|Multifocal serpiginous choroiditis
514461|NCT00645697|histoplasmosis
514462|NCT00645697|Harada toxoplasmosis
514463|NCT00645684|Gastrointestinal Anastomosis
514464|NCT00645684|Multicentre
514465|NCT00645684|Randomized controlled single-blind study
514466|NCT00645684|synthetic, absorbable, braided and coated suture material
514467|NCT00645684|Laparotomy
514468|NCT00645645|Holoprosencephaly
514469|NCT00645645|Agenesis of Corpus
514470|NCT00645645|Callosum
514471|NCT00645645|Genetic Tests
514472|NCT00645632|localized osteosarcoma
514473|NCT00645619|Pneumonia,viral
514474|NCT00645619|Pneumonia,bacterial
514475|NCT00645619|TREM-1 protein,human
514476|NCT00645606|B-cell chronic lymphocytic leukemia
514477|NCT00645606|Binet B or C stage chronic lymphocytic leukemia
514478|NCT00645593|Bladder Cancer
514479|NCT00645567|Biomechanics
514480|NCT00645567|Ergonomics
514481|NCT00645567|Spinal Cord Injury
514482|NCT00645567|Pain
514483|NCT00645567|Shoulder
514484|NCT00645554|Galantamine oral solution
514485|NCT00645554|Galantamine tablet
514486|NCT00645554|Bioequivalence
514487|NCT00645541|Breast Cancer
514488|NCT00645541|Carcinoma of the Breast
514489|NCT00645541|Lymph Nodes
514490|NCT00645541|Lymphazurin
514491|NCT00645541|Axillary Reverse Mapping
514492|NCT00645528|insulin
514493|NCT00645528|teaching
514494|NCT00645502|Schizophrenia
514495|NCT00645502|Risperidone
514496|NCT00645502|Orally-disintegrating tablet
514497|NCT00645502|Bioequivalence
514498|NCT00645489|heart failure intervention
514499|NCT00645476|DSM-IV diagnostic criteria for any bipolar disorder (type I, type II, and NOS)
514500|NCT00645476|(diagnosed with the use of the Structured Clinical Interview for DSM-IV-TR Mood Module (SCID Mood Module)
514501|NCT00645450|Stress
514502|NCT00645450|Posttraumatic
514503|NCT00645450|PTSD
514504|NCT00645450|Propranolol
514505|NCT00645450|Treatment
514506|NCT00645437|renal diseases
514507|NCT00645437|levofloxacin
514508|NCT00645411|Influenza
514509|NCT00645411|Flu
514510|NCT00645411|Cell Culture-Derived
514511|NCT00645411|Egg-Derived
514512|NCT00645411|Healthy Children
514513|NCT00645411|Healthy Adolescents
514514|NCT00645411|Safety
514515|NCT00645411|Immunogenicity
514516|NCT00645411|Trivalent
514517|NCT00645411|Inactivated
514518|NCT00645411|Vaccination
514519|NCT00645385|GBM
514520|NCT00645385|AA
514521|NCT00645385|AO
514522|NCT00645385|Brain
514523|NCT00645385|Tumors
514524|NCT00645385|Malignant
514525|NCT00645385|Glioblastoma
514526|NCT00645385|Multiforme
514527|NCT00645385|Carmustine
514528|NCT00645385|implant
514529|NCT00645385|BCNU
514530|NCT00645385|Gliadel
514531|NCT00645385|Wafers
514532|NCT00645385|MRS
514533|NCT00645385|Spectroscopy
514534|NCT00645359|dMRI
514535|NCT00645359|diffusion MRI
514536|NCT00645359|Diffuse large B-cell lymphoma
514537|NCT00645359|DLBCL
514538|NCT00645346|GBS
514539|NCT00645333|breast cancer
514540|NCT00645333|Phase I clinical trial
514541|NCT00645333|cancer stem cells
514542|NCT00645333|agents with other mechanisms of action
514543|NCT00645333|Notch inhibitors
514544|NCT00645307|paliperidone
514545|NCT00645307|Schizophrenia
514546|NCT00645294|Hepatitis B
514547|NCT00645294|Adefovir dipivoxil
514548|NCT00645294|Children
514549|NCT00645294|Adolescents
514550|NCT00645294|Pharmacokinetics
514551|NCT00645190|Alzheimer Disease
514552|NCT00645190|galantamine
514553|NCT00645177|Breast Cancer
514554|NCT00645164|wound healing
514555|NCT00645164|photoallergenicity
514556|NCT00645164|Healthy subjects
514557|NCT00645138|breast carcinoma
514558|NCT00645138|breast cancer
514559|NCT00645138|paravertebral block
514560|NCT00645138|comparison of paravertebral block and general anesthesia
514561|NCT00645138|ultrasound
514562|NCT00645125|pediatric taste test
514563|NCT00645125|antibiotic taste test
514564|NCT00645125|cefdinir
514565|NCT00645125|amoxicillin
514566|NCT00645099|Paliperidone ER
514567|NCT00645099|Olanzapine
514568|NCT00645099|Schizophrenia
514569|NCT00645073|Acute Bacterial Sinusitis
514570|NCT00645060|unspecified adult solid tumor, protocol specific
514571|NCT00645047|PTSD
514572|NCT00645047|Telemedicine
514573|NCT00645047|Patient-Centered Care
514574|NCT00645047|Professional Patient Relationship
514575|NCT00645047|Psychotherapy
514576|NCT00645047|Cognitive Therapy
514577|NCT00645008|Stressors
514578|NCT00645008|Patient Satisfaction
514579|NCT00645008|Cardiothoracic-Intensive Care Unit
514580|NCT00645008|Coronary bypass patient
514581|NCT00644995|Depression
514582|NCT00644995|Smoking
514583|NCT00644995|Physical Activity
514584|NCT00644930|ARDS,
514585|NCT00644930|noninvasive ventilation,
514586|NCT00644930|intubation,
514587|NCT00644930|mortality,
514588|NCT00644930|intensive care
514589|NCT00644917|wound healing
514590|NCT00644917|phototoxicity
514591|NCT00644917|Healthy Subjects
514592|NCT00644904|Multiple Sclerosis
514593|NCT00644904|Vitamin D
514594|NCT00644904|Safety
514595|NCT00644891|Pediatric taste test
514596|NCT00644891|Antibiotic taste test
514597|NCT00644891|cefdinir
514598|NCT00644891|amoxicillin
514599|NCT00644878|leukemia
514600|NCT00644878|chronic myelogenous leukemia
514601|NCT00644878|chronic phase
514602|NCT00644878|molecular response
514603|NCT00644878|nilotinib
514604|NCT00644878|ENABL
514605|NCT00644852|Schizophrenia
514606|NCT00644852|Schizoaffective disorder
514607|NCT00644852|Risperidone long-acting injectable, Long-term evaluation
514608|NCT00644826|randomized controlled trial
514609|NCT00644826|public health
514610|NCT00644826|Preventive Health Services
514611|NCT00644787|Pain
514612|NCT00644787|Cancer
514613|NCT00644787|Fentanyl
514614|NCT00644787|JNS020QD
514615|NCT00644787|JNS005
514616|NCT00644774|pediatric taste test
514617|NCT00644774|antibiotic taste test
514618|NCT00644774|cefdinir
514619|NCT00644774|azithromycin
514620|NCT00644761|Hepatitis B
514621|NCT00644761|Post-Liver Transplantation
514622|NCT00644761|Adefovir Dipivoxil
514623|NCT00644761|Tacrolimus
514624|NCT00644761|Cyclosporine
514625|NCT00644735|Erosive Esophagitis
514626|NCT00644735|Nexium
514627|NCT00644735|Esomeprazole
514628|NCT00644735|Lansoprazole
514629|NCT00644735|Heartburn
514630|NCT00644722|Intubation
514631|NCT00644722|Out-of-hospital
514632|NCT00644722|Laryngoscope
514633|NCT00644722|Blades
514634|NCT00644722|Emergency
514635|NCT00644696|Neuroblastoma
514636|NCT00644696|Irinotecan
514637|NCT00644696|Bortezomib
514638|NCT00644683|premenopausal women with breast cancer
514639|NCT00644657|Platelets, platelet aggregation inhibitors
514640|NCT00644644|NTX
514641|NCT00644644|Nihon Kohden
514642|NCT00644644|mobile monitoring
514643|NCT00644618|pancreatic cancer
514644|NCT00644618|locally advanced
514645|NCT00644592|Healthy Volunteers
514646|NCT00644579|wart
514647|NCT00644579|cutaneous
514648|NCT00644579|transplant
514649|NCT00644579|Cutaneous warts in immune suppressed, kidney transplant patients
514650|NCT00644566|ADHD
514651|NCT00644566|Primary Care
514652|NCT00644566|Pediatrics
514653|NCT00644566|Health services
514654|NCT00644566|shared care
514655|NCT00644566|care manager
514656|NCT00644566|screening
514657|NCT00644540|Influenza
514658|NCT00644540|vaccines
514659|NCT00644540|children
514660|NCT00644527|depression
514661|NCT00644527|music
514662|NCT00644527|sound
514663|NCT00644527|randomized controlled trial
514664|NCT00644514|LPS endotoxin
514665|NCT00644514|Asthma
514666|NCT00644501|type 1 diabetes
514667|NCT00644501|beta cells
514668|NCT00644501|immunomodulation
514669|NCT00644501|immunointervention
514670|NCT00644475|Hypertension
514671|NCT00644475|Insulin sensitivity
514672|NCT00644475|Fibrinolysis
514673|NCT00644462|wheeze detection
514674|NCT00644436|tetrix cream
514675|NCT00644436|substantivity
514676|NCT00644436|resistance to a gentle wash
514677|NCT00644436|Tetrix Cream remaining on hands after gentle washing with soap and water.
514678|NCT00644423|PTSD
514679|NCT00644423|Cognition
514680|NCT00644423|Fish Oil
514681|NCT00644423|Omega-3 Fatty Acid
514682|NCT00644410|heart failure
514683|NCT00644410|stem cell
514684|NCT00644410|mesenchymal stromal cell
514685|NCT00644410|mesenchymal stem cell
514686|NCT00644397|distal femur fracture
514687|NCT00644397|locked plates
514688|NCT00644397|functional outcomes
514689|NCT00644397|cost management
514690|NCT00644397|femur head
514691|NCT00644397|femur neck
514692|NCT00644384|basal cell carcinoma of the skin
514693|NCT00644384|squamous cell carcinoma of the skin
514694|NCT00644371|Allogeneic
514695|NCT00644371|Lymphoma
514696|NCT00644371|GELTAMO
514697|NCT00644371|Z-RIC
514698|NCT00644345|Microvolt T wave alternans
514699|NCT00644345|reproducibility
514700|NCT00644319|malignant pleural effusion
514701|NCT00644306|Multiple Myeloma, very elderly patients, thalidomide
514702|NCT00644280|Glaucoma,Ahmed Valve
514703|NCT00644267|hypertension
514704|NCT00644267|cardiovascular risk
514705|NCT00644267|risk score
514706|NCT00644254|Prognosis
514707|NCT00644254|Extracapsular lymph node involvement
514708|NCT00644241|stem cell therapy
514709|NCT00644241|T2DM
514710|NCT00644241|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus
514711|NCT00644215|injected bleb
514712|NCT00644215|mitomycin drop
514713|NCT00644215|5-Fu injection
514714|NCT00644215|early bleb failure
514715|NCT00644202|weight control
514716|NCT00644189|clofarabine
514717|NCT00644189|Clolar
514718|NCT00644189|lymphoma
514719|NCT00644189|NHL
514720|NCT00644189|oral chemotherapy
514721|NCT00644163|HIV
514722|NCT00644163|STI
514723|NCT00644163|Risk Reduction
514724|NCT00644163|Couples
514725|NCT00644163|African American
514726|NCT00644163|HIV Seronegativity
514727|NCT00644150|Risk Reduction Counseling
514728|NCT00644150|Anhui, China
514729|NCT00644150|HIV
514730|NCT00644150|STI
514731|NCT00644137|smoking sensations
514732|NCT00644137|no cravings
514733|NCT00644137|desire to smoke
514734|NCT00644124|Non-Hodgkin's lymphoma
514735|NCT00644124|angiogenesis inhibitors
514736|NCT00644124|CHOP protocol
514737|NCT00644111|Minimally Invasive Decompression and Fusion
514738|NCT00644111|Postoperative analgesia
514739|NCT00644111|Epidural
514740|NCT00644111|Lumbar
514741|NCT00644085|IVF and ICSI
514742|NCT00644072|Hsp90 Inhibitor
514743|NCT00644072|Her2
514744|NCT00644072|Neoplasms
514745|NCT00644072|Advanced Cancer
514746|NCT00644072|Cancer
514747|NCT00644072|Solid Tumor
514748|NCT00644072|Lymphoma
514749|NCT00644059|Influenza
514750|NCT00644059|vaccine
514751|NCT00644059|children
514752|NCT00644046|Chronic Kidney Disease
514753|NCT00644046|Prevention
514754|NCT00644046|Cardiovascular disease
514755|NCT00644020|Hepatocellular carcinoma
514756|NCT00644020|recurrence
514757|NCT00644007|Erectile dysfunction
514758|NCT00644007|Hypertension
514759|NCT00644007|SK3530
514760|NCT00643994|Prostate Cancer
514761|NCT00643994|CyberKnife
514762|NCT00643994|Stereotactic Radiosurgery
514763|NCT00643994|Radiotherapy
514764|NCT00643994|Radiation
514765|NCT00643994|Prostate Tumor
514766|NCT00643994|Prostate Surgery
514767|NCT00643968|HIV virological control
514768|NCT00643968|Lipid profile and morphological fat distribution
514769|NCT00643968|Treatment Experienced
514770|NCT00643955|Evaluation of muscle strength and central activation
514771|NCT00643214|Tetrix Cream
514772|NCT00643214|Antigen reaction
514773|NCT00643214|effect on healing
514774|NCT00643214|To determine if application of Tetrix Cream to lesions of contact dermatitis interferes with their rate of healing
514775|NCT00643188|Atrial fibrillation
514776|NCT00643188|Ablation
514777|NCT00643188|Heart failure
514778|NCT00643188|Home Monitoring
514779|NCT00643175|The main objective is to have an endocrinologist treat osteoporosis in patients with fragility hip fractures.
514780|NCT00643162|Depression
514781|NCT00643162|Massage
514782|NCT00643162|Lexapro
514783|NCT00643162|Alternative Therapy
514784|NCT00643162|Anti-depressant
514785|NCT00643123|Bipolar Disorder
514786|NCT00643123|Mania
514787|NCT00643123|Mixed mania
514788|NCT00643123|Allopurinol
514789|NCT00643123|Treatment-Resistant mania
514790|NCT00643110|Hypoglycemia
514791|NCT00643097|adult giant cell glioblastoma
514792|NCT00643097|adult gliosarcoma
514793|NCT00643097|adult glioblastoma
514794|NCT00643084|Colorectal
514795|NCT00643084|Bowel preparation
514796|NCT00643084|Laparoscopic surgery
514797|NCT00643929|HCV
514798|NCT00643929|ITP
514799|NCT00643929|ocular safety
514800|NCT00643929|eltrombopag olamine
514801|NCT00643929|thrombopoietin receptor agonist
514802|NCT00643929|lens opacity
514803|NCT00643929|cataract
514804|NCT00643929|SB-497115-GR
514805|NCT00643929|CIT
514806|NCT00643916|Meningitis; Meningococcal Infection
514807|NCT00643903|Side Effects
514808|NCT00643903|Adherence
514809|NCT00643903|Coping
514810|NCT00643903|HIV
514811|NCT00643903|AIDS
514812|NCT00643903|Complementary Therapies
514813|NCT00643890|Keywords:
514814|NCT00643890|Parkinson's disease
514815|NCT00643890|Gene transfer
514816|NCT00643890|Gene therapy
514817|NCT00643890|Subthalamic nucleus
514818|NCT00643890|Adeno-associated virus
514819|NCT00643890|Study placed in the following topic categories:
514820|NCT00643890|Ganglion Cysts
514821|NCT00643890|Movement Disorders
514822|NCT00643890|Parkinson Disease
514823|NCT00643890|Basal Ganglia Diseases
514824|NCT00643890|Central Nervous System Diseases
514825|NCT00643890|Parkinsonian Disorders
514826|NCT00643890|Neurodegenerative Diseases
514827|NCT00643890|Brain Diseases
514828|NCT00643890|Additional relevant MeSH terms:
514829|NCT00643890|Nervous System Diseases
514830|NCT00643877|Colorectal Neoplasms
514831|NCT00643877|Regional
514832|NCT00643877|Liver
514833|NCT00643877|Neoplasm Metastasis
514834|NCT00643864|mirror training
514835|NCT00643864|stroke
514836|NCT00643864|hemiparesis
514837|NCT00643864|rehabilitation
514838|NCT00643825|Temozolomide
514839|NCT00643825|Phase II
514840|NCT00643825|Chemotherapy
514841|NCT00643825|Glioblastoma
514842|NCT00643825|Progression-free Survival
514843|NCT00643812|Firearm storage
514844|NCT00643812|Suicide
514845|NCT00643812|Unintentional injury
514846|NCT00643812|Alaska Native
514847|NCT00643812|Suicide Attempt
514848|NCT00643773|Elderly
514849|NCT00643760|Peripheral Diabetic Neuropathy (PDN)
514850|NCT00643760|Neuropathic Pain
514851|NCT00643747|retinal dystrophy
514852|NCT00643747|Leber congenital amaurosis
514853|NCT00643747|RPE65
514854|NCT00643747|gene therapy
514855|NCT00643721|Young healthy athletes
514856|NCT00643708|anovulation
514857|NCT00643708|laser
514858|NCT00643708|ovarian interstitial
514859|NCT00643708|polycystic ovary syndrome
514860|NCT00643708|ultrasound-guided
514861|NCT00643695|hepatitis C
514862|NCT00643695|depression
514863|NCT00643695|exercise
514864|NCT00643682|colonoscopy
514865|NCT00643682|bowel preparation
514866|NCT00643682|patient education
514867|NCT00643682|polyp detection
514868|NCT00643656|Liver biopsy
514869|NCT00643643|HIV
514870|NCT00643643|Treatment Naïve
514871|NCT00643630|Tetrix crea
514872|NCT00643630|skin barrier
514873|NCT00643630|antigen reaction
514874|NCT00643630|prevention
514875|NCT00643630|The efficacy of Tetrix Cream to prevent an antigen reaction on the skin.
514876|NCT00643617|Prostate Cancer
514877|NCT00643617|CyberKnife
514878|NCT00643617|Stereotactic Radiosurgery
514879|NCT00643617|Radiosurgery
514880|NCT00643617|Prostate Tumor
514881|NCT00643617|Prostate Surgery
514882|NCT00643604|Pulmonary arterial hypertension
514883|NCT00643604|treatment satisfaction
514884|NCT00643604|rapid switch
514885|NCT00643604|remodulin
514886|NCT00643604|Quality of life
514887|NCT00643591|high grade glioma
514888|NCT00643591|FDG-PET-CT
514889|NCT00643591|blood proteins
514890|NCT00643591|prognosis
514891|NCT00643578|formoterol
514892|NCT00643578|methacholine challenge
514893|NCT00643552|Muscle Strength
514894|NCT00643526|Rheumatoid arthritis
514895|NCT00643526|Psoriatic arthritis
514896|NCT00643526|Ankylosing spondylitis
514897|NCT00643526|Psoriasis
514898|NCT00643526|Autoinjector
514899|NCT00643513|QUALITY OF LIFE
514900|NCT00643513|POSTMENOPAUSAL WOMEN
514901|NCT00643513|HORMONE RECEPTOR POSITIVE DISSEMINATED BREAST CANCER
514902|NCT00643513|FASLODEX
514903|NCT00643500|Levetiracetam
514904|NCT00643500|Keppra
514905|NCT00643487|Observe the mechanical behavior of the IPP
514906|NCT00643435|self-efficacy
514907|NCT00643435|chronic illness
514908|NCT00643435|health behavior
514909|NCT00643435|education, medical, residency
514910|NCT00643422|normal eyes
514911|NCT00643396|small cell lung cancer
514912|NCT00643396|radiotherapy
514913|NCT00643370|lung cancer
514914|NCT00643370|tumor motion
514915|NCT00643357|children with burns
514916|NCT00643357|Child between 5 and 15 years of age , burned for many days and who has to undergo at least 3 procedures of care
514917|NCT00643344|obesity
514918|NCT00643344|mindfulness based stress reduction
514919|NCT00643344|diet and exercise
514920|NCT00643344|mindful eating
514921|NCT00643344|stress
514922|NCT00643331|Osteoporosis
514923|NCT00643331|Exercise
514924|NCT00643331|Low bone density
514925|NCT00643331|Falls
514926|NCT00643318|lung cancer
514927|NCT00643318|lung tumor
514928|NCT00643318|non-small cell lung cancer
514929|NCT00643318|NSCLC
514930|NCT00643318|CyberKnife
514931|NCT00643318|radiosurgery
514932|NCT00643318|lung surgery
514933|NCT00643305|HIV
514934|NCT00643305|Motivational Interviewing
514935|NCT00643305|Skills
514936|NCT00643305|Prevention
514937|NCT00643305|Mental illness
514938|NCT00643305|Risk reduction
514939|NCT00643305|HIV/AIDS
514940|NCT00643305|HIV Seronegativity
514941|NCT00643279|implantable hemodynamic monitor
514942|NCT00643279|Intracardiac pressures
514943|NCT00643266|recollection training
514944|NCT00643266|aging
514945|NCT00643266|amnestic mild cognitive impairment
514946|NCT00643266|fMRI
514947|NCT00643253|exclusive breastfeeding
514948|NCT00643253|breastfeeding promotion
514949|NCT00643253|health promotion
514950|NCT00643240|recurrent adult acute lymphoblastic leukemia
514951|NCT00643240|recurrent childhood acute lymphoblastic leukemia
514952|NCT00643240|refractory chronic lymphocytic leukemia
514953|NCT00643071|Ulcerative colitis
514954|NCT00643071|Tacrolimus
514955|NCT00643071|FK506
514956|NCT00643071|Treatment outcome
514957|NCT00643058|LPS endotoxin
514958|NCT00643045|Parkinson Disease
514959|NCT00643019|Sexually Transmitted Infections
514960|NCT00643019|Secondary Prevention
514961|NCT00643019|Cognitive Behavioral Intervention
514962|NCT00643006|Fibromyalgia
514963|NCT00643006|Physical activity
514964|NCT00643006|Function
514965|NCT00643006|Pain
514966|NCT00643006|Exercise
514967|NCT00643006|Inflammation
514968|NCT00642980|Pregnancy
514969|NCT00642980|Preterm delivery
514970|NCT00642980|Bacterial vaginosis
514971|NCT00642980|Randomized Clinical Trial
514972|NCT00642980|Clindamycin
514973|NCT00642928|Excessive Daytime Sleepiness
514974|NCT00642928|Parkinson's disease
514975|NCT00642902|Relapsing Multiple Sclerosis
514976|NCT00642902|Atacicept
514977|NCT00642889|Parkinson's disease
514978|NCT00642863|iron deficiency
514979|NCT00642863|iron deficiency anemia
514980|NCT00642863|infant
514981|NCT00642863|development
514982|NCT00642863|behavior
514983|NCT00642837|Health-Related Quality of Life
514984|NCT00642837|KEQ-5D
514985|NCT00642837|Sleep disturbance
514986|NCT00642837|Sleep quality
514987|NCT00642837|SF-1
514988|NCT00642837|Pain intensity
514989|NCT00642837|Pain relief
514990|NCT00642837|Tramadol
514991|NCT00642837|Acetaminophen
514992|NCT00642811|coronary artery disease (CAD)
514993|NCT00642811|heart attack
514994|NCT00642811|stable angina
514995|NCT00642785|herpes
514996|NCT00642785|HSV
514997|NCT00642785|zoster
514998|NCT00642785|HZV
514999|NCT00642785|shingles
515000|NCT00642772|Osteoarthritis
515001|NCT00642772|Veterans
515002|NCT00642772|Physical Therapy
515003|NCT00642772|Health Services Research
515004|NCT00642759|NSCLC
515005|NCT00642759|Abraxane
515006|NCT00642759|Carboplatin
515007|NCT00642759|Bevacizumab
515008|NCT00642759|Avastin
515009|NCT00642746|Colon
515010|NCT00642746|Cancer
515011|NCT00642746|Metastatic
515012|NCT00642746|Colorectal
515013|NCT00642707|HIV
515014|NCT00642707|Treatment Naïve
515015|NCT00642694|MDD
515016|NCT00642694|Major Depressive Disorder
515017|NCT00642694|Depression
515018|NCT00642694|Initial Insomnia
515019|NCT00642694|sleep
515020|NCT00642694|difficulty sleeping
515021|NCT00642694|down
515022|NCT00642694|sad
515023|NCT00642694|Major Depressive Disorder(MDD) and initial insomnia
515024|NCT00642655|IVIG
515025|NCT00642655|Rituximab
515026|NCT00642655|Highly Sensitized
515027|NCT00642655|Kidney Transplantation
515028|NCT00642642|Acne
515029|NCT00642590|Fertility
515030|NCT00642590|Pregnancy
515031|NCT00642590|Conception
515032|NCT00642590|Infertility
515033|NCT00642590|Behavioral
515034|NCT00642590|Lifestyle
515035|NCT00642590|Nutrition
515036|NCT00642564|Epilepsy
515037|NCT00642564|Headache
515038|NCT00642564|Migraine
515039|NCT00642551|vitamin K2
515040|NCT00642551|menaquinone-7
515041|NCT00642551|bone health
515042|NCT00642551|vascular health
515043|NCT00642538|Diabetic adult male, diabetic postmenopausal women
515044|NCT00642525|detection of anastomotic leakage
515045|NCT00642525|esophageal resection
515046|NCT00642525|diagnostic safety
515047|NCT00642512|CINV
515048|NCT00642512|chemotherapy
515049|NCT00642512|nausea
515050|NCT00642512|vomiting
515051|NCT00642512|retching
515052|NCT00642499|HIV
515053|NCT00642499|AIDS
515054|NCT00642499|nausea
515055|NCT00642499|vomiting
515056|NCT00642499|HAART
515057|NCT00642499|Treatment Experienced
515058|NCT00642499|HIV Infections
515059|NCT00642486|treatment
515060|NCT00642486|positive airway pressure
515061|NCT00642486|compliance
515062|NCT00642486|cost effectiveness
515063|NCT00642486|clinical trial
515064|NCT00642447|noninvasive ventilation
515065|NCT00642447|helium
515066|NCT00642447|oxygen
515067|NCT00642447|sulfur mustard
515068|NCT00642447|chronic bronchitis
515069|NCT00642447|bronchiolitis
515070|NCT00642434|diabetes blood pressure oxidative stress
515071|NCT00642421|Acromegaly
515072|NCT00642395|Multiple Myeloma
515073|NCT00642395|Autologous Stem Cells Transplantation
515074|NCT00642395|High Dose Melphalan
515075|NCT00642395|Bortezomib
515076|NCT00642382|Osteoarthritis
515077|NCT00642382|Hyaluronic Acid
515078|NCT00642369|Polysomnograph
515079|NCT00642356|Idiopathic Parkinson's disease
515080|NCT00642356|carbidopa/levodopa/entacapone
515081|NCT00642356|non-motor symptoms
515082|NCT00642356|motor-symptoms
515083|NCT00642343|Balance
515084|NCT00642343|Severe, Profound deafness
515085|NCT00642343|Children
515086|NCT00642343|unilateral/bilateral cochlear implants
515087|NCT00642343|unilateral cochlear implant
515088|NCT00642343|bilateral cochlear implants
515089|NCT00642330|patent
515090|NCT00642330|ductus
515091|NCT00642330|arteriosus
515092|NCT00642330|ibuprofen
515093|NCT00642330|premature
515094|NCT00642330|infant
515095|NCT00642317|Healthy Control
515096|NCT00642317|Tobacco Use
515097|NCT00642317|Tobacco Initiation
515098|NCT00642317|Smoking
515099|NCT00642317|Questionnaire
515100|NCT00642317|Survey
515101|NCT00642291|Emtricitabine
515102|NCT00642291|Pediatric
515103|NCT00642291|HIV-1
515104|NCT00642291|Treatment of HIV-1
515105|NCT00642278|Type 2 diabetes mellitus
515106|NCT00642278|Metformin
515107|NCT00642278|Hemoglobin A1c
515108|NCT00642252|remineraliation
515109|NCT00642252|pre-existing white-spot (non-cavitated) enamel lesions
515110|NCT00642239|Sodium Glycididazole, Radiochemotherapy, Esophageal Carcinoma
515111|NCT00642226|Branch Retinal Vein Occlusion
515112|NCT00642226|BRVO
515113|NCT00642226|Macular Edema
515114|NCT00642226|Triamcinolone
515115|NCT00642226|Vitrectomy
515116|NCT00642213|stroke
515117|NCT00642213|ischemic
515118|NCT00642213|TIA
515119|NCT00642213|hemorrhage
515120|NCT00642213|incidence
515121|NCT00642213|case-fatality
515122|NCT00642213|risk factors
515123|NCT00642213|genetic
515124|NCT00642187|Asthma
515125|NCT00642187|Pulmicort
515126|NCT00642187|Turbuhaler
515127|NCT00642187|Budesonide
515128|NCT00642187|Flexhaler
515129|NCT00642161|Asthma
515130|NCT00642161|Pulmicort
515131|NCT00642161|Children
515132|NCT00642161|Paediatrics
515133|NCT00642161|budesonide
515134|NCT00642161|Flexhaler
515135|NCT00642148|GW856553
515136|NCT00642148|p38 MAPK
515137|NCT00642148|Chronic Obstructive Pulmonary Disease
515138|NCT00642135|premature
515139|NCT00642135|neonates
515140|NCT00642135|infants
515141|NCT00642135|children
515142|NCT00642135|Mydriasert®
515143|NCT00642135|mydriasis
515144|NCT00642135|fundus
515145|NCT00642135|Tropicamide
515146|NCT00642135|Phenylephrine
515147|NCT00642135|clinical trial
515148|NCT00642135|Infant
515149|NCT00642135|premature newborns
515150|NCT00642135|bilateral diagnosis fundus
515151|NCT00642122|Asthma
515152|NCT00642122|Pulmicort
515153|NCT00642122|budesonide
515154|NCT00642122|respules
515155|NCT00642122|turbuhaler
515156|NCT00642096|High blood pressure
515157|NCT00642096|hypertension
515158|NCT00642096|(TOPROL-XL)
515159|NCT00642096|metoprolol succinate
515160|NCT00642096|hydrochlorothiazide
515161|NCT00642083|outflow stenosis
515162|NCT00642083|stentgraft
515163|NCT00642070|Current symptoms of urinary tract infection
515164|NCT00642057|chorea
515165|NCT00642057|dyskinesia
515166|NCT00642057|hyperkinetic
515167|NCT00642044|Keratoconus
515168|NCT00642031|Hematologic Malignancies
515169|NCT00642031|Leukemia
515170|NCT00642031|Chronic Myelomonocytic Leukemia
515171|NCT00642031|Acute Lymphocytic Leukemia
515172|NCT00642031|Chronic Lymphocytic Leukemia
515173|NCT00642031|Chronic Myelogenous Leukemia
515174|NCT00642031|Agnogenic Myeloid Metaplasia
515175|NCT00642031|Triciribine Phosphate Monohydrate
515176|NCT00642031|Triciribine
515177|NCT00642031|TCN-PM
515178|NCT00642031|VD-0002
515179|NCT00642018|Hormone Refractory Prostate Cancer
515180|NCT00642005|Humidification
515181|NCT00642005|Laparoscopy
515182|NCT00642005|Colon
515183|NCT00642005|Hemicolectomy
515184|NCT00642005|Warming
515185|NCT00641992|amebic liver abscess
515186|NCT00641992|failure
515187|NCT00641992|prognosis
515188|NCT00641979|Allergic rhinitis
515189|NCT00641979|Nasal symptoms
515190|NCT00641979|Congestion
515191|NCT00641979|Rhinorrhea
515192|NCT00641979|Sneeze
515193|NCT00641979|budesonide
515194|NCT00641979|Rhinocort AQUA
515195|NCT00641953|Foot Pain
515196|NCT00641953|Diabetic Neuropathy Pain
515197|NCT00641953|Diabetic Peripheral Neuropathy foot pain
515198|NCT00641940|Prevention
515199|NCT00641940|Girls
515200|NCT00641940|Resilience
515201|NCT00641927|bipolar disorder
515202|NCT00641927|bipolar type II disorder
515203|NCT00641927|antidepressant
515204|NCT00641927|mood stabilizer
515205|NCT00641927|venlafaxine
515206|NCT00641927|lithium carbonate
515207|NCT00641914|Asthma
515208|NCT00641914|Pulmicort
515209|NCT00641914|budesonide
515210|NCT00641901|gingivitis
515211|NCT00641901|pregnancy
515212|NCT00641901|pre-term birth
515213|NCT00641888|Cardiovascular risk
515214|NCT00641888|Inflammatory biomarkers
515215|NCT00641888|Human immunodeficiency virus
515216|NCT00641875|arterial stiffness
515217|NCT00641875|artery
515218|NCT00641875|aortic pulse wave velocity
515219|NCT00641875|pulse wave analysis
515220|NCT00641875|augmentation index
515221|NCT00641875|end stage renal disease
515222|NCT00641875|nocturnal hemodialysis
515223|NCT00641875|extended hours of hemodialysis
515224|NCT00641875|cardiovascular
515225|NCT00641875|hemodialysis
515226|NCT00641862|Pregnancy
515227|NCT00641862|Maternal Nutritional Status
515228|NCT00641862|Vitamin B12
515229|NCT00641849|BMI
515230|NCT00641849|Physical Activity
515231|NCT00641849|Food
515232|NCT00641849|Nutrition
515233|NCT00641849|Dietary behaviors
515234|NCT00641849|Diet
515235|NCT00641849|Adult
515236|NCT00641849|Adults
515237|NCT00641849|Fat
515238|NCT00641849|Fats
515239|NCT00641849|Self monitoring
515240|NCT00641849|Automated feedback
515241|NCT00640835|Opioid dependence
515242|NCT00641823|Orthopedic Surgical Procedures
515243|NCT00641810|Caffeine
515244|NCT00641810|Snoring
515245|NCT00641810|Sleep
515246|NCT00641797|Canalith Repositioning Technique
515247|NCT00641797|Vertigo
515248|NCT00641784|Composite Early neonatal Outcome
515249|NCT00641784|Late Neurological neonatal outcome
515250|NCT00641758|Coronary Artery Disease
515251|NCT00641758|endothelial dysfunction
515252|NCT00641758|Nitric oxide
515253|NCT00641745|Lurasidone
515254|NCT00641745|Schizophrenia
515255|NCT00641745|Latuda
515256|NCT00641732|venous thromboembolism
515257|NCT00641732|oral anticoagulant
515258|NCT00641732|direct factor Xa inhibitor
515259|NCT00641732|total knee replacement
515260|NCT00641732|drug therapy
515261|NCT00641693|Allergic rhinitis
515262|NCT00641693|Paediatric
515263|NCT00641693|Nasal symptoms
515264|NCT00641693|Congestion
515265|NCT00641693|Rhinorrhea
515266|NCT00641693|Sneeze
515267|NCT00641693|budesonide
515268|NCT00641693|Rhinocort AQUA
515269|NCT00641680|Seasonal allergic rhinitis
515270|NCT00641680|Nasal symptoms
515271|NCT00641680|Congestion
515272|NCT00641680|Rhinorrhea
515273|NCT00641680|Sneeze
515274|NCT00641680|budesonide
515275|NCT00641680|Rhinocort AQUA
515276|NCT00641680|Fluticasone propionate
515277|NCT00641680|Flonase
515278|NCT00641667|Pain
515279|NCT00641667|Cancer
515280|NCT00641667|Fentanyl
515281|NCT00641667|JNS020QD
515282|NCT00641654|Chronic hepatitis C
515283|NCT00641654|genotype 2 or 3
515284|NCT00641654|relapse
515285|NCT00641654|pegylated interferon
515286|NCT00641654|ribavirin
515287|NCT00641641|Viral compartments
515288|NCT00641641|integrase inhibitor therapy
515289|NCT00641641|viral species
515290|NCT00641628|Nipple sparing mastectomy
515291|NCT00641628|NAC conservation
515292|NCT00641602|Erosive Esophagitis
515293|NCT00641602|Nexium
515294|NCT00641602|Heartburn
515295|NCT00641589|Chronic Kidney Disease
515296|NCT00641589|anemia
515297|NCT00641589|epoetin alfa
515298|NCT00641576|Endosseous implants
515299|NCT00641563|dexmedetomidine
515300|NCT00641563|midazolam
515301|NCT00641563|remifentanil
515302|NCT00641563|Electroencephalography
515303|NCT00641563|Event related potentials
515304|NCT00641563|BIS
515305|NCT00641563|Bispectral Index
515306|NCT00641563|Response Entropy
515307|NCT00641563|State Entropy
515308|NCT00641550|physical exercise
515309|NCT00641550|maternal complications
515310|NCT00641550|preterm labor
515311|NCT00641550|birthweight
515312|NCT00641550|Apgar scores
515313|NCT00641524|Non-alcoholic fatty liver disease
515314|NCT00641524|liver fibrosis
515315|NCT00641524|metabolic syndrome
515316|NCT00641524|iron overload
515317|NCT00641524|phlebotomy
515318|NCT00641511|PTSD
515319|NCT00641498|suicide
515320|NCT00641498|parasuicide
515321|NCT00641498|prevention
515322|NCT00641498|individual supportive psychotherapy
515323|NCT00641472|Asthma
515324|NCT00641472|Pulmicort
515325|NCT00641472|Children
515326|NCT00641472|paediatrics
515327|NCT00641472|budesonide
515328|NCT00641459|Behavioral and Psychological Symptoms of Dementia
515329|NCT00641459|BPSD
515330|NCT00641459|NPI
515331|NCT00641459|CGI
515332|NCT00641459|MMSE
515333|NCT00641446|Children
515334|NCT00641446|Asthma
515335|NCT00641446|Varivax
515336|NCT00641446|varicella
515337|NCT00641446|Pulmicort
515338|NCT00641446|budesonide
515339|NCT00641433|chemocautery
515340|NCT00641420|Acne scarring
515341|NCT00641420|Post inflammatory hyperpigmentation
515342|NCT00641407|Bedtime insulins
515343|NCT00641407|Poorly controlled type 2 diabetes
515344|NCT00641407|Glycemic control
515345|NCT00641407|HbA1c
515346|NCT00641394|cortisol
515347|NCT00641394|hydrocortisone
515348|NCT00641394|psychotherapy
515349|NCT00641394|Emotional Freedom Techniques (EFT)
515350|NCT00641394|Cognitive Behavioral Therapy (CBT)
515351|NCT00641394|depression
515352|NCT00641394|anxiety
515353|NCT00641381|stage III adult Hodgkin lymphoma
515354|NCT00641381|stage III childhood Hodgkin lymphoma
515355|NCT00641381|stage IV adult Hodgkin lymphoma
515356|NCT00641381|stage IV childhood Hodgkin lymphoma
515357|NCT00641381|recurrent childhood lymphoblastic lymphoma
515358|NCT00641381|recurrent mantle cell lymphoma
515359|NCT00641381|recurrent adult Hodgkin lymphoma
515360|NCT00641381|recurrent/refractory childhood Hodgkin lymphoma
515361|NCT00641381|recurrent adult T-cell leukemia/lymphoma
515362|NCT00641381|recurrent cutaneous T-cell non-Hodgkin lymphoma
515363|NCT00641381|AIDS-related diffuse large cell lymphoma
515364|NCT00641381|AIDS-related diffuse mixed cell lymphoma
515365|NCT00641381|AIDS-related immunoblastic large cell lymphoma
515366|NCT00641381|AIDS-related lymphoblastic lymphoma
515367|NCT00641381|AIDS-related small noncleaved cell lymphoma
515368|NCT00641381|Burkitt lymphoma
515369|NCT00641381|stage III adult diffuse large cell lymphoma
515370|NCT00641381|stage III adult diffuse mixed cell lymphoma
515371|NCT00641381|stage IV adult diffuse large cell lymphoma
515372|NCT00641381|stage IV adult diffuse mixed cell lymphoma
515373|NCT00641381|stage III grade 3 follicular lymphoma
515374|NCT00641381|stage IV grade 3 follicular lymphoma
515375|NCT00641381|stage III adult immunoblastic large cell lymphoma
515376|NCT00641381|stage IV adult immunoblastic large cell lymphoma
515377|NCT00641381|stage III adult lymphoblastic lymphoma
515378|NCT00641381|stage III childhood lymphoblastic lymphoma
515379|NCT00641381|stage IV adult lymphoblastic lymphoma
515380|NCT00641381|stage IV childhood lymphoblastic lymphoma
515381|NCT00641381|stage III adult Burkitt lymphoma
515382|NCT00641381|stage IV adult Burkitt lymphoma
515383|NCT00641381|HIV Infections
515384|NCT00641381|Treatment Experienced
515385|NCT00641368|Adolescent
515386|NCT00641368|Child
515387|NCT00641368|Computer
515388|NCT00641368|Depression
515389|NCT00641368|Resilience
515390|NCT00641342|Parastomal hernia
515391|NCT00641342|Onlay mesh
515392|NCT00641342|Sublay mesh
515393|NCT00641342|Pain
515394|NCT00641342|Health questionnaire
515395|NCT00641329|ADHD
515396|NCT00641329|ADD
515397|NCT00641329|Attention Deficit Hyperactivity Disorder
515398|NCT00641329|Attention Deficit
515399|NCT00641329|Clonidine
515400|NCT00641329|CLONICEL
515401|NCT00641329|Addrenex
515402|NCT00641316|Freeze-dried bone allograft
515403|NCT00641316|Platelet-rich plasma
515404|NCT00641316|Platelet-derived growth factors
515405|NCT00641316|Laser-threaded dental implants
515406|NCT00641316|Resorbable blast textured dental implants
515407|NCT00641303|pain
515408|NCT00641303|fatigue
515409|NCT00641303|hot flashes
515410|NCT00641303|sleep disorders
515411|NCT00641303|depression
515412|NCT00641303|anxiety disorder
515413|NCT00641303|stage I breast cancer
515414|NCT00641303|stage II breast cancer
515415|NCT00641303|stage IIIA breast cancer
515416|NCT00641303|stage IIIB breast cancer
515417|NCT00641303|stage IIIC breast cancer
515418|NCT00641290|CABG
515419|NCT00641290|Valve surgery
515420|NCT00641277|endosseous dental implants
515421|NCT00641277|dental aesthetics
515422|NCT00641264|Laryngopharyngeal reflux (LPR)
515423|NCT00641264|Omeprazole
515424|NCT00641264|Losec
515425|NCT00641264|Quality of Life
515426|NCT00641264|Laryngitis
515427|NCT00641251|T2 Diabetes
515428|NCT00641251|Type 2 diabetes CVD event rates and mortality
515429|NCT00641238|NSCLC
515430|NCT00641238|lung cancer
515431|NCT00641225|Ascending Single Dose
515432|NCT00641225|Safety
515433|NCT00641225|Pharmacokinetics
515434|NCT00641225|Open-label
515435|NCT00641212|Allergic rhinitis
515436|NCT00641212|Perennial allergic rhinitis
515437|NCT00641212|Paediatric
515438|NCT00641212|Growth
515439|NCT00641212|budesonide
515440|NCT00641212|Rhinocort AQUA
515441|NCT00641199|Antibiotic-associated diarrhea
515442|NCT00641199|Probiotic
515443|NCT00641199|Quality of life
515444|NCT00641199|Antibiotics
515445|NCT00641186|excessive daytime somnolence
515446|NCT00641186|Parkinson disease
515447|NCT00641186|sleep disturbance
515448|NCT00641173|PTSD
515449|NCT00641173|cortisol
515450|NCT00641173|hippocampus
515451|NCT00641173|memory
515452|NCT00641160|vinorelbine
515453|NCT00641160|metronomic dosing
515454|NCT00641160|oral administration
515455|NCT00641160|nonhematologic malignancies
515456|NCT00641160|pharmacokinetics
515457|NCT00641134|Cardiac Rehabilitation
515458|NCT00641134|Old age
515459|NCT00641134|Home physical training
515460|NCT00641108|SPECT Brain Imaging
515461|NCT00641108|Cognitive Therapy
515462|NCT00641108|Serotonin Transporter Binding
515463|NCT00641108|Predictive Biomarker
515464|NCT00641095|contiguous stage II mantle cell lymphoma
515465|NCT00641095|noncontiguous stage II mantle cell lymphoma
515466|NCT00641095|stage I mantle cell lymphoma
515467|NCT00641095|stage III mantle cell lymphoma
515468|NCT00641095|stage IV mantle cell lymphoma
515469|NCT00641069|Cardiac arrest
515470|NCT00641069|Cardiopulmonary resuscitation
515471|NCT00641056|diabetes
515472|NCT00641056|exenatide
515473|NCT00641056|exenatide once weekly
515474|NCT00641056|metformin
515475|NCT00641056|sulfonylurea
515476|NCT00641056|insulin glargine
515477|NCT00641056|Amylin
515478|NCT00641056|Lilly
515479|NCT00641030|de novo myelodysplastic syndromes
515480|NCT00641030|previously treated myelodysplastic syndromes
515481|NCT00641030|secondary myelodysplastic syndromes
515482|NCT00641030|adult acute lymphoblastic leukemia in remission
515483|NCT00641030|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
515484|NCT00641030|adult acute myeloid leukemia with inv(16)(p13;q22)
515485|NCT00641030|adult acute myeloid leukemia with t(15;17)(q22;q12)
515486|NCT00641030|adult acute myeloid leukemia with t(16;16)(p13;q22)
515487|NCT00641030|adult acute myeloid leukemia with t(8;21)(q22;q22)
515488|NCT00641030|adult acute myeloid leukemia in remission
515489|NCT00641030|recurrent adult acute myeloid leukemia
515490|NCT00641030|childhood acute myeloid leukemia in remission
515491|NCT00641030|recurrent childhood acute myeloid leukemia
515492|NCT00641030|secondary acute myeloid leukemia
515493|NCT00641030|childhood myelodysplastic syndromes
515494|NCT00641030|recurrent adult acute lymphoblastic leukemia
515495|NCT00641030|recurrent childhood acute lymphoblastic leukemia
515496|NCT00641030|childhood acute lymphoblastic leukemia in remission
515497|NCT00640991|Clinical Trial
515498|NCT00640991|Insulin
515499|NCT00640978|Pancreatic Cancer
515500|NCT00640978|Advanced Pancreatic Cancer
515501|NCT00640978|Unresectable
515502|NCT00640978|Metastatic
515503|NCT00640978|RAD001
515504|NCT00640978|Everolimus
515505|NCT00640978|Erlotinib
515506|NCT00640978|OSI-774
515507|NCT00640978|Erlotinib Hydrochloride
515508|NCT00640978|Tarceva
515509|NCT00640952|Parkinson's disease
515510|NCT00640952|impulse control behaviors
515511|NCT00640952|dopa-dysregulation
515512|NCT00640939|Tendonitis
515513|NCT00640939|Bursitis
515514|NCT00640913|Defunctioning stoma
515515|NCT00640913|Low anterior resection
515516|NCT00640913|TME surgery
515517|NCT00640913|Early stoma reversal
515518|NCT00640900|overweight
515519|NCT00640900|obesity
515520|NCT00640900|weight loss
515521|NCT00640900|commercial weight loss program
515522|NCT00640887|HIV
515523|NCT00640887|Tuberculosis
515524|NCT00640887|Rifabutin
515525|NCT00640887|Pharmacokinetics
515526|NCT00640887|South Africa
515527|NCT00640874|Prophylaxis
515528|NCT00640874|pandemic influenza
515529|NCT00640874|influenza A
515530|NCT00640874|H5N1 virus
515531|NCT00640861|stage II breast cancer
515532|NCT00640861|stage IIIA breast cancer
515533|NCT00640861|stage IIIB breast cancer
515534|NCT00640861|stage IIIC breast cancer
515535|NCT00640861|stage IA breast cancer
515536|NCT00640861|stage IB breast cancer
515537|NCT00640861|triple-negative breast cancer
515538|NCT00640861|HER2-positive breast cancer
515539|NCT00640809|Bowel Disease
515540|NCT00640796|Hematologic malignancies, non-B lineage
515541|NCT00640796|NK cell expansion
515542|NCT00640796|CliniMACS device
515543|NCT00640796|Immunotherapy
515544|NCT00640783|Metabolic syndrome
515545|NCT00640783|Mediterranean diet
515546|NCT00640783|Inflammatory markers
515547|NCT00640783|Endothelial function
515548|NCT00640757|Methionine
515549|NCT00640757|Metabolic syndrome
515550|NCT00640757|Glucose Metabolism
515551|NCT00640757|Amino acid
515552|NCT00640757|Insulin clamp
515553|NCT00640744|Atherogenesis
515554|NCT00640744|Atheroma
515555|NCT00640744|Arteriosclerosis
515556|NCT00640731|DVT
515557|NCT00640731|Peripheral Vascular Disease
515558|NCT00640731|Venous Thrombosis
515559|NCT00640731|Deep Vein Thrombosis
515560|NCT00640718|heart and respiratory monitoring
515561|NCT00640692|Gastrointestinal stromal tumor
515562|NCT00640692|GIST
515563|NCT00640692|Sunitinib
515564|NCT00640692|Imatinib
515565|NCT00640679|Clopidogrel
515566|NCT00640679|Drug-eluting Stent
515567|NCT00640666|Breast cancer
515568|NCT00640666|Exercise
515569|NCT00640666|Biomarkers
515570|NCT00640653|Sexual Behavior
515571|NCT00640653|Abstinence
515572|NCT00640653|Intervention Studies
515573|NCT00640653|HIV
515574|NCT00640653|Sexually Transmitted Infection
515575|NCT00640653|Theory of Planned Behavior
515576|NCT00640653|HIV Seronegativity
515577|NCT00640640|IOP
515578|NCT00640640|OPA
515579|NCT00640640|AMD
515580|NCT00640640|bevacizumab
515581|NCT00640640|ranibizumab
515582|NCT00640640|choroidal blood flow
515583|NCT00640640|DCT
515584|NCT00640640|Ocular Pulse Amplitude change following anti VEGF
515585|NCT00640640|Ocular Pulse Amplitude
515586|NCT00640614|Dermatitis, Contact
515587|NCT00640601|Seroquel
515588|NCT00640601|schizophrenia
515589|NCT00640601|Extended Release
515590|NCT00640588|Hepatitis B, chronic
515591|NCT00640588|Viral kinetics
515592|NCT00640588|Telbivudine
515593|NCT00640588|Adefovir
515594|NCT00640588|Compliance
515595|NCT00640562|Schizophrenia
515596|NCT00640562|Depression
515597|NCT00640562|Quetiapine
515598|NCT00640549|LDL-subfractions, HDL-subfractions, non insulin dependent diabetes mellitus (NIDDM), hyperlipidemia, atorvastatin
515599|NCT00640497|acute GVHD
515600|NCT00640497|immunotoxin
515601|NCT00640497|anti-CD3
515602|NCT00640497|anti-CD7
515603|NCT00640497|Ricin A
515604|NCT00640471|recurrent colon cancer
515605|NCT00640471|stage IV colon cancer
515606|NCT00640471|recurrent rectal cancer
515607|NCT00640471|stage IV rectal cancer
515608|NCT00640445|Clinical Trial
515609|NCT00640445|Combat Disorders
515610|NCT00640445|PTSD
515611|NCT00640445|Internet-Based Intervention
515612|NCT00640445|Mental Health Services
515613|NCT00640445|Post-deployment Reintegration
515614|NCT00640393|Etanercept, UVB, Enbrel, Psoriasis.
515615|NCT00640380|cervical
515616|NCT00640380|paravertebral
515617|NCT00640380|block
515618|NCT00640367|Acute ischemic stroke
515619|NCT00640367|thrombolysis
515620|NCT00640367|intra-arterial thrombolysis
515621|NCT00640354|Automated External Defibrillator
515622|NCT00640354|Resuscitation
515623|NCT00640354|Pediatric
515624|NCT00640328|relapsing forms of multiple sclerosis
515625|NCT00640328|ofatumumab
515626|NCT00640328|multiple sclerosis
515627|NCT00640315|Chronic obstructive pulmonary disease
515628|NCT00640315|COPD
515629|NCT00640315|Pulmonary hypertension
515630|NCT00640302|Index cases
515631|NCT00640302|pandemic influenza
515632|NCT00640302|influenza A
515633|NCT00640302|H5N1 virus
515634|NCT00640289|Factor XIII Deficiency
515635|NCT00640289|Rare Bleeding Disorder
515636|NCT00640289|Hemophilia
515637|NCT00640289|Fibrogammin P
515638|NCT00640276|pitavastatin
515639|NCT00640276|metabolic syndrome
515640|NCT00640276|metabolic syndrome risk score
515641|NCT00640276|hypercholesterolemia
515642|NCT00640263|HIV-1
515643|NCT00640263|Breastfeeding
515644|NCT00640263|Prevention
515645|NCT00640263|lamivudine
515646|NCT00640263|lopinavir/ritonavir
515647|NCT00640250|Dermatitis, Contact, Bronopol, Disperse Blue 106
515648|NCT00640237|Vitamine D State
515649|NCT00640211|Prophylaxis
515650|NCT00640211|pandemic influenza
515651|NCT00640211|influenza A
515652|NCT00640211|H5N1 virus
515653|NCT00640198|Aphasia
515654|NCT00640198|Memantine
515655|NCT00640198|Constraint-induced language therapy
515656|NCT00640198|Event-related potentials
515657|NCT00640159|Parkinson's disease
515658|NCT00640159|selegiline to Zelapar switch
515659|NCT00640159|orally disintegrating formulation
515660|NCT00640133|Deep Brain Stimulation
515661|NCT00640133|Treatment Refractory
515662|NCT00640133|Ventral Internal Capsule/Ventral Striatum
515663|NCT00640133|Neurosurgery
515664|NCT00640133|Neuroimaging
515665|NCT00640120|wheeze detection
515666|NCT00640107|Magnetic Resonance Imaging
515667|NCT00640094|Melatonin
515668|NCT00640094|Acute myocardial infarction
515669|NCT00640094|Primary angioplasty
515670|NCT00640081|adenocarcinoma of the colon
515671|NCT00640081|stage IV colon cancer
515672|NCT00640081|adenocarcinoma of the rectum
515673|NCT00640081|stage IV rectal cancer
515674|NCT00640081|stage III colon cancer
515675|NCT00640081|stage III rectal cancer
515676|NCT00640081|recurrent colon cancer
515677|NCT00640081|recurrent rectal cancer
515678|NCT00640068|coronary artery disease
515679|NCT00640068|chest pain
515680|NCT00640068|coronary artery bypass graft
515681|NCT00640068|stress test
515682|NCT00640068|Coronary Angiography
515683|NCT00640055|verbal autopsy
515684|NCT00640055|stillbirth
515685|NCT00640055|neonatal death
515686|NCT00640042|pain
515687|NCT00640042|opioid
515688|NCT00640042|abuse
515689|NCT00640042|moderate-severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time
515690|NCT00640029|Arthroplasty
515691|NCT00640029|Arthrodesis
515692|NCT00640029|Prosthesis
515693|NCT00640029|Disc replacement
515694|NCT00640029|Spine
515695|NCT00640029|Lumbar
515696|NCT00640029|Cervical
515697|NCT00640029|Intervertebral disk
515698|NCT00640029|Cervical or lumbar intervertebral disk
515699|NCT00640029|Degenerative pathology
515700|NCT00640016|Asthma
515701|NCT00640016|CAT-354
515702|NCT00640016|Tralokinumab
515703|NCT00640003|AT
515704|NCT00640003|Ataxia
515705|NCT00640003|Telangiectasia
515706|NCT00639990|Intraabdominal pressure
515707|NCT00639977|Intraocular Pressure
515708|NCT00639977|Acupuncture
515709|NCT00639977|Healthy Volunteers
515710|NCT00639964|diabetes
515711|NCT00639964|pregnancy
515712|NCT00639964|macrosomia
515713|NCT00639964|lipidics markers
515714|NCT00639964|nutritional factors
515715|NCT00639964|placenta
515716|NCT00639964|umbilical blood cord
515717|NCT00639951|Snake Bite
515718|NCT00639951|Antivenin Treatment
515719|NCT00639938|Pregnancy, High-Risk
515720|NCT00639938|HIV Seronegativity
515721|NCT00639912|contrast induced nephropathy STEMI PCI
515722|NCT00639899|Varicocele
515723|NCT00639873|Uncomplicated P. falciparum malaria
515724|NCT00639860|extraction
515725|NCT00639860|implant
515726|NCT00639860|alveolar ridge preservation
515727|NCT00639847|Asthma management
515728|NCT00639847|cost
515729|NCT00639847|disease management
515730|NCT00639847|respiratory care
515731|NCT00639847|nursing
515732|NCT00639847|health care utilization
515733|NCT00639847|health related quality of life
515734|NCT00639834|rheumatoid
515735|NCT00639834|arthritis
515736|NCT00639834|RA
515737|NCT00639834|joint inflammation
515738|NCT00639834|autoimmune
515739|NCT00639834|Medarex
515740|NCT00639834|Rheumatology
515741|NCT00639821|Gene expression microarray
515742|NCT00639821|Inflammatory bowel disease
515743|NCT00639821|Infliximab
515744|NCT00639808|delayed gastric emptying
515745|NCT00639808|symptomatic gastroparesis
515746|NCT00639808|diabetes mellitus
515747|NCT00639795|Thoracic paravertebral block
515748|NCT00639795|Cytokines
515749|NCT00639795|Video assisted thorascopic surgery
515750|NCT00639795|Pain
515751|NCT00639782|thromboembolism
515752|NCT00639782|mechanical heart valves
515753|NCT00639782|randomized
515754|NCT00639769|recurrent squamous cell carcinoma of the hypopharynx
515755|NCT00639769|stage IV squamous cell carcinoma of the hypopharynx
515756|NCT00639769|stage IV squamous cell carcinoma of the larynx
515757|NCT00639769|stage IV verrucous carcinoma of the larynx
515758|NCT00639769|recurrent squamous cell carcinoma of the larynx
515759|NCT00639769|recurrent verrucous carcinoma of the larynx
515760|NCT00639769|recurrent squamous cell carcinoma of the lip and oral cavity
515761|NCT00639769|stage IV squamous cell carcinoma of the lip and oral cavity
515762|NCT00639769|recurrent verrucous carcinoma of the oral cavity
515763|NCT00639769|stage IV verrucous carcinoma of the oral cavity
515764|NCT00639769|metastatic squamous neck cancer with occult primary squamous cell carcinoma
515765|NCT00639769|recurrent metastatic squamous neck cancer with occult primary
515766|NCT00639769|untreated metastatic squamous neck cancer with occult primary
515767|NCT00639769|recurrent squamous cell carcinoma of the nasopharynx
515768|NCT00639769|stage IV squamous cell carcinoma of the nasopharynx
515769|NCT00639769|recurrent squamous cell carcinoma of the oropharynx
515770|NCT00639769|stage IV squamous cell carcinoma of the oropharynx
515771|NCT00639769|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
515772|NCT00639769|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
515773|NCT00639769|recurrent salivary gland cancer
515774|NCT00639769|salivary gland squamous cell carcinoma
515775|NCT00639769|stage IV salivary gland cancer
515776|NCT00639756|Uric acid
515777|NCT00639756|Fructose
515778|NCT00639756|Hypertension
515779|NCT00639756|Insulin
515780|NCT00639756|Glucose
515781|NCT00639756|HOMA
515782|NCT00639743|Pulmonary embolism
515783|NCT00639743|Heparin
515784|NCT00639743|Thrombolytic therapy
515785|NCT00639743|Bleeding
515786|NCT00639730|Epilepsy
515787|NCT00639717|GVHD
515788|NCT00639704|MRI
515789|NCT00639704|SPECT
515790|NCT00639704|Cardiac function
515791|NCT00639691|Asthma, Anti-immunoglobin E, omalizumab
515792|NCT00639678|healthy volunteers
515793|NCT00639665|Cocoa, diabetes, polyphenols
515794|NCT00639652|Carcinoma, Basal Cell
515795|NCT00639652|3D-histology
515796|NCT00639652|Micrographic surgery
515797|NCT00639652|Mohs surgery
515798|NCT00639652|Shave excision
515799|NCT00639652|Recurrence
515800|NCT00639652|Esthetic outcome
515801|NCT00639639|adult giant cell glioblastoma
515802|NCT00639639|adult gliosarcoma
515803|NCT00639587|Cetirizine
515804|NCT00639587|Zyrtec
515805|NCT00639574|Pain, morphine, nefopam, co analgesia, ureteral calculi, emergency
515806|NCT00639561|digestive system
515807|NCT00639561|Diet
515808|NCT00639548|Deep Sedation
515809|NCT00639548|EEG
515810|NCT00639548|Event-Related Potentials
515811|NCT00639548|Evoked potentials, auditory
515812|NCT00639548|BIS-Index
515813|NCT00639548|Entropy
515814|NCT00639548|ICU
515815|NCT00639535|Radiology
515816|NCT00639535|MRI
515817|NCT00639535|Positron emission tomography
515818|NCT00639535|Breast Abnormalities
515819|NCT00639535|Dense Breast Tissue
515820|NCT00639522|Liposomal paclitaxel
515821|NCT00639522|Maximum tolerated dose
515822|NCT00639522|Pharmacokinetics
515823|NCT00639522|Gastric carcinoma
515824|NCT00639496|Idiopathic Pulmonary Fibrosis
515825|NCT00639470|Patient Education Handout
515826|NCT00639470|Parents
515827|NCT00639470|Patient Education
515828|NCT00639457|PPAR-gamma agonist
515829|NCT00639457|glucose metabolism
515830|NCT00639457|inflammation
515831|NCT00639457|adipose tissue distribution
515832|NCT00639457|cardiac function
515833|NCT00639457|vascular function
515834|NCT00639457|mass spectrometry
515835|NCT00639457|Treatment Experienced
515836|NCT00639431|phantom limb pain
515837|NCT00639431|limb amputation
515838|NCT00639431|Amputation
515839|NCT00639431|Phantom Limb
515840|NCT00639431|Pain
515841|NCT00639405|Parathyroid
515842|NCT00639405|MRI
515843|NCT00639405|SPECT
515844|NCT00639392|Sickle cell disease
515845|NCT00639379|toric contact lenses
515846|NCT00639379|vision
515847|NCT00639379|comfort
515848|NCT00639379|toric fit characteristics
515849|NCT00639379|slit lamp findings
515850|NCT00639366|recurrent breast cancer
515851|NCT00639366|stage IIIA breast cancer
515852|NCT00639366|stage IIIB breast cancer
515853|NCT00639366|stage IIIC breast cancer
515854|NCT00639366|stage IV breast cancer
515855|NCT00639327|Stomach Neoplasms
515856|NCT00639327|Second line chemotherapy
515857|NCT00639327|Refractory to S-1
515858|NCT00639327|irinotecan
515859|NCT00639327|S-1 and Irinotecan Combination
515860|NCT00639327|Phase III study
515861|NCT00639314|pylorus-preserving pancreaticoduodenectomy
515862|NCT00639314|pylorus-resecting pancreaticoduodenectomy
515863|NCT00639314|randomized controlled trial
515864|NCT00639314|delayed gastric empty
515865|NCT00639314|quality of life
515866|NCT00639301|Survivor
515867|NCT00639301|Quality of Life
515868|NCT00639301|Eye
515869|NCT00639288|Alcohol Dependence
515870|NCT00639288|PTSD
515871|NCT00639288|CPT-C
515872|NCT00639262|Sorafenib
515873|NCT00639262|Radiation Therapy
515874|NCT00639262|Radiotherapy
515875|NCT00639262|Temozolomide
515876|NCT00639262|Brain Metastases
515877|NCT00639262|Brain Tumors
515878|NCT00639236|COPD
515879|NCT00639236|Hypertonic saline
515880|NCT00639236|Quality of life
515881|NCT00639236|Dyspnoea.
515882|NCT00639223|Statin related myalgia
515883|NCT00639223|Hyperlipidemia
515884|NCT00639223|Red yeast rice
515885|NCT00639223|Cardiovascular Diseases
515886|NCT00639223|Nutritional and Metabolic Diseases
515887|NCT00639210|breast cancer
515888|NCT00639210|exercise
515889|NCT00639210|osteoporosis
515890|NCT00639210|fracture
515891|NCT00639210|quality of life
515892|NCT00639197|Tunneling
515893|NCT00639197|Short term
515894|NCT00639197|central venous catheters
515895|NCT00639197|Ultrasound Guided
515896|NCT00639197|Internal jugular
515897|NCT00639197|Assess safety and improve technical difficulty
515898|NCT00639184|asphyxia
515899|NCT00639184|neurodevelopmental outcome
515900|NCT00639184|home counseling
515901|NCT00639171|breast
515902|NCT00639171|diagnostic radiology
515903|NCT00639171|suspicious breast tumors
515904|NCT00639171|MRI
515905|NCT00639145|HIV
515906|NCT00639145|Pregnancy
515907|NCT00639145|Antiretrovirals
515908|NCT00639145|HIV Seronegativity
515909|NCT00639145|Treatment Experienced
515910|NCT00639132|Natural History
515911|NCT00639132|Metachromatic Leukodystrophy
515912|NCT00639132|Disease Progression
515913|NCT00639106|Breast expander
515914|NCT00639106|Breast reconstruction
515915|NCT00639106|implants
515916|NCT00639106|08-024
515917|NCT00639093|cigarette smoking
515918|NCT00639093|psychoeducational and motivational program
515919|NCT00639093|virtual reality
515920|NCT00639080|Type 2 diabetes
515921|NCT00639080|Dyslipidemia
515922|NCT00639067|Cancer of Lung
515923|NCT00639067|Cancer of the Lung
515924|NCT00639067|Lung Cancer
515925|NCT00639067|Neoplasms, Lung
515926|NCT00639067|Neoplasms, Pulmonary
515927|NCT00639067|Pulmonary Cancer
515928|NCT00639067|Pulmonary Neoplasms
515929|NCT00639054|classification
515930|NCT00639054|diagnosis
515931|NCT00639054|genetics
515932|NCT00639054|mortality
515933|NCT00639054|pathology
515934|NCT00639041|n-3 LC-PUFA
515935|NCT00639041|hypertriglyceridemic
515936|NCT00639041|human
515937|NCT00639041|TAG
515938|NCT00639028|ankle
515939|NCT00639028|diagnosis
515940|NCT00639028|sprain
515941|NCT00639028|care
515942|NCT00639028|injury
515943|NCT00639028|stress radiography
515944|NCT00639028|ultrasonography
515945|NCT00639015|Sepsis
515946|NCT00639015|Septic Shock
515947|NCT00639015|phenylephrine
515948|NCT00639015|norepinephrine
515949|NCT00639015|catecholamine
515950|NCT00638976|Eptifibatide
515951|NCT00638976|IV eptifibatide
515952|NCT00638976|GP IIB/IIIA inhibitors
515953|NCT00638976|DES stent
515954|NCT00638950|n-3 LC-PUFA
515955|NCT00638950|Rheumatoid arthritis
515956|NCT00638950|disease activity
515957|NCT00638950|inflammation
515958|NCT00638950|oxidative stress
515959|NCT00638950|immune system
515960|NCT00638924|healthy sedentary women
515961|NCT00638885|PTSD
515962|NCT00638885|hippocampus
515963|NCT00638885|twins
515964|NCT00638872|diabetes
515965|NCT00638872|foot ulcer
515966|NCT00638872|polydeoxyribonucleotide
515967|NCT00638859|Community-Acquired pneumonia
515968|NCT00638859|CAP
515969|NCT00638859|children
515970|NCT00638859|Child
515971|NCT00638846|toric contact lenses
515972|NCT00638846|vision
515973|NCT00638846|comfort
515974|NCT00638846|toric fit characteristics
515975|NCT00638846|slit lamp findings
515976|NCT00638833|Multiple Sclerosis
515977|NCT00638820|osteopetrosis
515978|NCT00638794|Myocardial Infarction
515979|NCT00638794|Myocardial Ischemia
515980|NCT00638781|Acute ischemic stroke
515981|NCT00638768|physical therapy
515982|NCT00638768|rehabilitation
515983|NCT00638768|pain
515984|NCT00638768|osteoporosis
515985|NCT00638768|vertebral fracture
515986|NCT00638755|Allergic Rhinitis
515987|NCT00638755|Perennial Allergic Rhinitis
515988|NCT00638755|Allergies to perennial allergens
515989|NCT00638755|Allergies to perennial allergens (e.g. dog, cat, dust mites, etc.)
515990|NCT00638742|Latanoprost Pediatrics Pharmacokinetics Safety
515991|NCT00638729|bispectral index
515992|NCT00638729|sedation
515993|NCT00638729|stress hormones
515994|NCT00638729|cognitive function
515995|NCT00638716|Type 2 Diabetes Mellitus, incretins, GLP-1, HbA1c, metformin
515996|NCT00638703|hyperoxaluria
515997|NCT00638703|PH
515998|NCT00638703|oxalate
515999|NCT00638690|Metastatic Castration-Resistant Prostate Cancer
516000|NCT00638690|CRPC
516001|NCT00638690|Abiraterone Acetate
516002|NCT00638690|CB7630
516003|NCT00638677|Oral microbiology
516004|NCT00638664|conventional pulse sequences for MR
516005|NCT00638664|cardiac chambers and walls
516006|NCT00638664|cardio-thoracic vasculature
516007|NCT00638664|the great vessels
516008|NCT00638664|coronary vasculature
516009|NCT00638664|cardiac
516010|NCT00638664|great vessels
516011|NCT00638651|Tattoos
516012|NCT00638651|Black/blue tattoos
516013|NCT00638638|Myocardial infarction
516014|NCT00638638|Angioplasty
516015|NCT00638638|Coronary stenting
516016|NCT00638638|Abciximab
516017|NCT00638638|Myocardial reperfusion
516018|NCT00638638|Microcirculation
516019|NCT00638638|EKG
516020|NCT00638638|ST elevation myocardial infarction within 6 h of symptom onset
516021|NCT00638625|Needle biopsy
516022|NCT00638625|CT Scan
516023|NCT00638625|Lung Tumor
516024|NCT00638625|Lung Mass
516025|NCT00638612|Immunotherapy
516026|NCT00638612|Gene Therapy
516027|NCT00638612|Cytotoxicity
516028|NCT00638612|Tumor vaccine
516029|NCT00638612|Radiation
516030|NCT00638612|Surgery
516031|NCT00638612|Chemoradiation
516032|NCT00638599|Intubation, intratracheal
516033|NCT00638599|Homeostasis
516034|NCT00638599|Mastectomy, modified radical
516035|NCT00638599|Breast Neoplasms
516036|NCT00638560|PGC-1alpha
516037|NCT00638560|PPARgamma
516038|NCT00638560|oxidative stress
516039|NCT00638560|training intervention
516040|NCT00638547|Hurler Syndrome
516041|NCT00638547|mucopolysaccharidosis type I
516042|NCT00638547|Iduronidase deficiency
516043|NCT00638534|Acute Otitis Media
516044|NCT00638534|AOM
516045|NCT00638534|children
516046|NCT00638534|Child
516047|NCT00638521|lipids
516048|NCT00638521|proteins
516049|NCT00638521|membrane
516050|NCT00638521|lipid raft
516051|NCT00638482|Dent's disease
516052|NCT00638482|Nephrolithiasis
516053|NCT00638482|clinical trial
516054|NCT00638482|thiazides
516055|NCT00638469|Psoriasis
516056|NCT00638469|Biologic
516057|NCT00638469|adalimumab
516058|NCT00638469|narrowband UVB
516059|NCT00638469|phototherapy
516060|NCT00638469|half-side comparison
516061|NCT00638456|Eosinophils
516062|NCT00638456|Esophagitis
516063|NCT00638456|Microscopy
516064|NCT00638443|Neurogenic claudication, lumbar spinal stenosis, treadmill testing
516065|NCT00638430|myopia
516066|NCT00638430|Humphery Matrix 30-2 test
516067|NCT00638404|Preoperative somatic questions
516068|NCT00638404|Preoperative audio tone evaluations
516069|NCT00638404|Preoperative anxiety and previous experience with postop pain
516070|NCT00638391|Primary early MCa
516071|NCT00638391|Arimidex
516072|NCT00638378|Prostate Cancer
516073|NCT00638365|Cystic Fibrosis, Pseudomonas aeruginosa, Pulmonary CF
516074|NCT00638352|Core Biopsy
516075|NCT00638352|Needle Biopsy
516076|NCT00638352|Percutaneous Biopsy
516077|NCT00638339|Respiration, artificial
516078|NCT00638339|respiratory insufficiency
516079|NCT00638339|noninvasive ventilation
516080|NCT00638339|sleep deprivation
516081|NCT00638339|intensive care units
516082|NCT00638326|Clopidogrel, thrombosis, Percutaneous Transluminal Coronary Angioplasty, stents
516083|NCT00638313|GLP-1
516084|NCT00638300|hemodialysis
516085|NCT00638300|iron
516086|NCT00638300|inflammation
516087|NCT00638300|atomic absorption
516088|NCT00638300|dialysate
516089|NCT00638300|advanced oxidation protein products
516090|NCT00638300|large pore dialysate
516091|NCT00638300|bicarbonate
516092|NCT00638300|calcium
516093|NCT00638300|citrate
516094|NCT00638300|ligand
516095|NCT00638287|Subjects with pituitary disease undergoing testing for GH
516096|NCT00638287|deficiency
516097|NCT00638287|Subjects with suspicion for (or diagnosis of) acromegaly
516098|NCT00638287|undergoing OGTT testing
516099|NCT00638287|Normal controls without evidence of pituitary dysfunction
516100|NCT00638274|Quality of pain relief with 2 different methods of identifying epidural space
516101|NCT00638261|Psoriasis
516102|NCT00638261|Biologic
516103|NCT00638261|Adalimumab
516104|NCT00638261|Narrow-band UVB
516105|NCT00638261|phototherapy
516106|NCT00638261|half-side comparison
516107|NCT00638248|Acute ischemic stroke
516108|NCT00638235|Pelvic floor repair
516109|NCT00638235|prolapse
516110|NCT00638235|mesh
516111|NCT00638222|Carvedilol
516112|NCT00638222|Heart Disease
516113|NCT00638222|Vascular Disease
516114|NCT00638222|Kidney
516115|NCT00638196|relapsing multiple sclerosis
516116|NCT00638196|polyunsaturated fatty acids
516117|NCT00638196|omega-6 fatty acids
516118|NCT00638170|Urinary Tract Infections
516119|NCT00638170|Cranberry
516120|NCT00638170|Prevention
516121|NCT00638157|Gram-positive bacterial infections
516122|NCT00638157|Staph Aureus
516123|NCT00638157|endocarditis
516124|NCT00638157|bacteremia
516125|NCT00638157|methicillin-resistant Staphylococcus aureus (MRSA)
516126|NCT00638144|Hepatitis C
516127|NCT00638144|liver transplantation
516128|NCT00638144|antibodies mediated neutralization
516129|NCT00638144|monoclonal antibodies
516130|NCT00638092|hypothyroxinemia
516131|NCT00638092|preterm infants
516132|NCT00638092|iodine
516133|NCT00638092|neurodevelopmental outcome
516134|NCT00638092|Iodine supplementation
516135|NCT00638092|Randomised controlled trial
516136|NCT00638079|Pharmacokinetics
516137|NCT00638079|Food Effect
516138|NCT00638079|Bioavailability
516139|NCT00638079|Megace ES
516140|NCT00638066|vaginismus
516141|NCT00638066|botulinum toxin A
516142|NCT00638066|dyspareunia
516143|NCT00638066|unconsummated marriage
516144|NCT00638040|hypoxia
516145|NCT00638040|lactate
516146|NCT00638040|pH
516147|NCT00638040|tumor microenvironments
516148|NCT00638040|survival
516149|NCT00638027|multiple sclerosis
516150|NCT00638014|Sternal wound closure
516151|NCT00638014|cardiac surgery
516152|NCT00638014|sternal nonunion
516153|NCT00638001|patients with haemophilia A moderate or severe
516154|NCT00638001|patients with haemophilia B moderate or severe
516155|NCT00637988|Barrett's Esophagus
516156|NCT00637988|Nexium
516157|NCT00637975|neuropathic pain
516158|NCT00637975|oxycodone
516159|NCT00637975|pregabalin
516160|NCT00637975|Patients with cancer and presenting a neuropathic pain
516161|NCT00637962|HIV
516162|NCT00637962|AIDS
516163|NCT00637962|Vaccine
516164|NCT00637962|intravaginal
516165|NCT00637962|mucosal
516166|NCT00637962|HIV Seronegativity
516167|NCT00637949|Osteoarthritis
516168|NCT00637949|lumiracoxib
516169|NCT00637949|rofecoxib
516170|NCT00637949|Cox-2
516171|NCT00637949|Osteoarthritis (primary osteoarthritis hip, hand, knee or spine (cervical or lumbar)
516172|NCT00637936|perioperative oxygen
516173|NCT00637936|respiratory complications
516174|NCT00637923|Hepatitis C, Chronic
516175|NCT00637910|Advanced NSCLC
516176|NCT00637910|EGFR
516177|NCT00637910|EGFR copy number
516178|NCT00637910|Kras mutations
516179|NCT00637910|EGRF mutations
516180|NCT00637910|Docetaxel
516181|NCT00637910|Erlotinib
516182|NCT00637910|Polymorphisms
516183|NCT00637897|recurrent breast cancer
516184|NCT00637897|stage IV breast cancer
516185|NCT00637871|Casodex
516186|NCT00637871|bicalutamide
516187|NCT00637871|Tamoxifen
516188|NCT00637871|Gynaecomastia
516189|NCT00637871|Prostate Cancer
516190|NCT00637845|Nexium
516191|NCT00637845|Esomeprazole Magnesium
516192|NCT00637845|Gastroesophageal Reflux Disease
516193|NCT00637845|Heartburn
516194|NCT00637832|recurrent grade 1 follicular lymphoma
516195|NCT00637832|recurrent grade 2 follicular lymphoma
516196|NCT00637832|recurrent grade 3 follicular lymphoma
516197|NCT00637832|contiguous stage II grade 1 follicular lymphoma
516198|NCT00637832|contiguous stage II grade 2 follicular lymphoma
516199|NCT00637832|contiguous stage II grade 3 follicular lymphoma
516200|NCT00637832|noncontiguous stage II grade 1 follicular lymphoma
516201|NCT00637832|noncontiguous stage II grade 2 follicular lymphoma
516202|NCT00637832|noncontiguous stage II grade 3 follicular lymphoma
516203|NCT00637832|stage III grade 1 follicular lymphoma
516204|NCT00637832|stage III grade 2 follicular lymphoma
516205|NCT00637832|stage III grade 3 follicular lymphoma
516206|NCT00637832|stage IV grade 1 follicular lymphoma
516207|NCT00637832|stage IV grade 2 follicular lymphoma
516208|NCT00637832|stage IV grade 3 follicular lymphoma
516209|NCT00637806|Megestrol acetate
516210|NCT00637806|Anorexia
516211|NCT00637806|Cachexia
516212|NCT00637806|Cancer
516213|NCT00637806|Unintended weight loss
516214|NCT00637806|Body weight
516215|NCT00637806|Appetite
516216|NCT00637806|Megace ES
516217|NCT00637793|Xerostomia
516218|NCT00637793|Sjogren's Syndrome
516219|NCT00637780|Sulfasalazine delayed release tablets
516220|NCT00637780|azulfidine entabs
516221|NCT00637780|Pharmacokinetics
516222|NCT00637780|Juvenile Idiopathic Arthritis (JIA)
516223|NCT00637767|stage I multiple myeloma
516224|NCT00637767|stage II multiple myeloma
516225|NCT00637767|stage III multiple myeloma
516226|NCT00637754|ICD
516227|NCT00637754|Sports
516228|NCT00637741|Peripheral Vascular Disease
516229|NCT00637741|Intermittent claudication
516230|NCT00637741|Critical Limb Ischemia
516231|NCT00637741|TASC
516232|NCT00637728|Megestrol acetate
516233|NCT00637728|Anorexia
516234|NCT00637728|Cachexia
516235|NCT00637728|Lung cancer
516236|NCT00637728|Pancreatic cancer
516237|NCT00637728|Unintended weight loss
516238|NCT00637728|Body weight
516239|NCT00637728|Appetite
516240|NCT00637728|Megace ES
516241|NCT00637689|Chronic graft versus host disease
516242|NCT00637689|Allogeneic hematopoietic cell transplantation
516243|NCT00637689|Biomarkers
516244|NCT00637689|Response criteria
516245|NCT00637689|Surrogate endpoints
516246|NCT00637689|Natural history
516247|NCT00637676|malignant pleural effusion
516248|NCT00637676|subcutaneous tunneled drainage
516249|NCT00637676|talc pleurodesis
516250|NCT00637663|Chronic hepatitis B
516251|NCT00637663|Lamivudine
516252|NCT00637663|Entecavir
516253|NCT00637637|tumors metastatic to brain
516254|NCT00637637|stage IV adenoid cystic carcinoma of the oral cavity
516255|NCT00637637|stage IV adrenocortical carcinoma
516256|NCT00637637|stage IV adult Burkitt lymphoma
516257|NCT00637637|stage IV adult diffuse large cell lymphoma
516358|NCT00637546|Diabetes
516258|NCT00637637|stage IV adult diffuse mixed cell lymphoma
516259|NCT00637637|stage IV adult diffuse small cleaved cell lymphoma
516260|NCT00637637|stage IV adult Hodgkin lymphoma
516261|NCT00637637|stage IV adult immunoblastic large cell lymphoma
516262|NCT00637637|stage IV adult lymphoblastic lymphoma
516263|NCT00637637|stage IV adult T-cell leukemia/lymphoma
516264|NCT00637637|stage IV anal cancer
516265|NCT00637637|stage IV basal cell carcinoma of the lip
516266|NCT00637637|stage IV bladder cancer
516267|NCT00637637|stage IV borderline ovarian surface epithelial-stromal tumor
516268|NCT00637637|stage IV breast cancer
516269|NCT00637637|stage IV childhood anaplastic large cell lymphoma
516270|NCT00637637|stage IV childhood Hodgkin lymphoma
516271|NCT00637637|stage IV childhood large cell lymphoma
516272|NCT00637637|stage IV childhood liver cancer
516273|NCT00637637|stage IV childhood lymphoblastic lymphoma
516274|NCT00637637|stage IV childhood small noncleaved cell lymphoma
516275|NCT00637637|stage IV chronic lymphocytic leukemia
516276|NCT00637637|stage IV colon cancer
516277|NCT00637637|stage IV cutaneous T-cell non-Hodgkin lymphoma
516278|NCT00637637|stage IV esophageal cancer
516279|NCT00637637|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
516280|NCT00637637|stage IV follicular thyroid cancer
516281|NCT00637637|stage IV gastric cancer
516282|NCT00637637|stage IV grade 1 follicular lymphoma
516283|NCT00637637|stage IV grade 2 follicular lymphoma
516284|NCT00637637|stage IV grade 3 follicular lymphoma
516285|NCT00637637|stage IV hypopharyngeal cancer
516286|NCT00637637|stage IV inverted papilloma of the paranasal sinus and nasal cavity
516287|NCT00637637|stage IV laryngeal cancer
516288|NCT00637637|stage IV lip and oral cavity cancer
516289|NCT00637637|stage IV lymphoepithelioma of the nasopharynx
516290|NCT00637637|stage IV lymphoepithelioma of the oropharynx
516291|NCT00637637|stage IV mantle cell lymphoma
516292|NCT00637637|stage IV marginal zone lymphoma
516293|NCT00637637|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
516294|NCT00637637|stage IV mucoepidermoid carcinoma of the oral cavity
516295|NCT00637637|stage IV mycosis fungoides/Sezary syndrome
516296|NCT00637637|stage IV nasopharyngeal cancer
516297|NCT00637637|stage IV non-small cell lung cancer
516298|NCT00637637|stage IV oropharyngeal cancer
516299|NCT00637637|stage IV ovarian epithelial cancer
516300|NCT00637637|stage IV pancreatic cancer
516301|NCT00637637|stage IV papillary thyroid cancer
516302|NCT00637637|stage IV paranasal sinus and nasal cavity cancer
516303|NCT00637637|stage IV penile cancer
516304|NCT00637637|stage IV prostate cancer
516305|NCT00637637|stage IV rectal cancer
516306|NCT00637637|stage IV renal cell cancer
516307|NCT00637637|stage IV salivary gland cancer
516308|NCT00637637|stage IV small lymphocytic lymphoma
516309|NCT00637637|stage IV squamous cell carcinoma of the hypopharynx
516310|NCT00637637|stage IV squamous cell carcinoma of the larynx
516311|NCT00637637|stage IV squamous cell carcinoma of the lip and oral cavity
516312|NCT00637637|stage IV squamous cell carcinoma of the nasopharynx
516313|NCT00637637|stage IV squamous cell carcinoma of the oropharynx
516314|NCT00637637|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
516315|NCT00637637|stage IV endometrial carcinoma
516316|NCT00637637|stage IV verrucous carcinoma of the larynx
516317|NCT00637637|stage IV verrucous carcinoma of the oral cavity
516318|NCT00637637|stage IVB vulvar cancer
516319|NCT00637637|stage IV Wilms tumor
516320|NCT00637637|stage IVB cervical cancer
516321|NCT00637637|stage IVB vaginal cancer
516322|NCT00637637|metastatic adult malignant fibrous histiocytoma of bone
516323|NCT00637637|metastatic childhood malignant fibrous histiocytoma of bone
516324|NCT00637637|metastatic gastrointestinal carcinoid tumor
516325|NCT00637637|metastatic parathyroid cancer
516326|NCT00637637|metastatic pheochromocytoma
516327|NCT00637637|metastatic squamous neck cancer with occult primary squamous cell carcinoma
516328|NCT00637637|metastatic squamous neck cancer with occult primary
516329|NCT00637637|metastatic transitional cell cancer of the renal pelvis and ureter
516330|NCT00637637|disseminated neuroblastoma
516331|NCT00637637|unspecified adult solid tumor, protocol specific
516332|NCT00637637|unspecified childhood solid tumor, protocol specific
516333|NCT00637637|tongue cancer
516334|NCT00637624|Acetylcysteine
516335|NCT00637624|Cisplatin
516336|NCT00637624|Neuropathy
516337|NCT00637624|Antioxidants
516338|NCT00637598|Diagnostic Imaging
516339|NCT00637598|Mammography
516340|NCT00637598|Breast Tomosynthesis
516341|NCT00637572|Weight loss
516342|NCT00637572|Cachexia
516343|NCT00637572|Anorexia
516344|NCT00637572|Megestrol acetate oral suspension
516345|NCT00637572|Nanocrystal dispersion
516346|NCT00637572|Nanocrystal technology
516347|NCT00637572|Body weight changes
516348|NCT00637572|AIDS wasting
516349|NCT00637572|HIV wasting
516350|NCT00637572|Emaciation
516351|NCT00637572|Megace ES
516352|NCT00637572|Megace
516353|NCT00637572|Treatment Experienced
516354|NCT00637559|Nexium
516355|NCT00637559|Barrett's esophagus
516356|NCT00637546|Treatment
516357|NCT00637546|Efficacy
516359|NCT00637546|Gait
516360|NCT00637546|Balance
516361|NCT00637520|Nonalcoholic Fatty Liver Disease
516362|NCT00637520|Insulin Resistance
516363|NCT00637520|Lipid Metabolism
516364|NCT00637507|High-Frequency Ventilation
516365|NCT00637507|Tracheal Gas Insufflation
516366|NCT00637507|Respiration, Artificial
516367|NCT00637507|Respiratory Distress Syndrome
516368|NCT00637507|Adult
516369|NCT00637494|psychotic depression
516370|NCT00637494|major depression with psychotic features
516371|NCT00637494|psychosis
516372|NCT00637416|horseness
516373|NCT00637403|renal impairment
516374|NCT00637403|end stage renal disease
516375|NCT00637403|megestrol acetate
516376|NCT00637403|pharmacokinetics
516377|NCT00637403|hemodialysis
516378|NCT00637403|renal dialysis
516379|NCT00637403|kidney failure, chronic
516380|NCT00637403|renal insufficiency
516381|NCT00637403|Megace ES
516382|NCT00637377|Eye diseases
516383|NCT00637377|Vision Impairment and Blindness
516384|NCT00637377|Eyes and Vision
516385|NCT00637377|Seniors
516386|NCT00637377|Neovascular Age-Related Macular Degeneration (AMD)
516387|NCT00637377|Retinal Disease
516388|NCT00637364|pain
516389|NCT00637364|pancreas
516390|NCT00637364|pancreatic cancer
516391|NCT00637364|pancreatic adenocarcinoma
516392|NCT00637364|ductal adenocarcinoma
516393|NCT00637338|Long-acting GLP-1 Diabetes
516394|NCT00637325|trastuzumab optimization in breast cancer
516395|NCT00637299|COPD
516396|NCT00637286|Zolmitriptan
516397|NCT00637286|ZOMIG
516398|NCT00637286|migraine
516399|NCT00637286|headache response
516400|NCT00637286|headache
516401|NCT00637286|headache pain
516402|NCT00637286|MIDAS
516403|NCT00637286|HCPC
516404|NCT00637273|diabetes
516405|NCT00637273|exenatide once weekly
516406|NCT00637273|Byetta
516407|NCT00637273|sitagliptin
516408|NCT00637273|Januvia
516409|NCT00637273|thiazolidinedione
516410|NCT00637273|Amylin
516411|NCT00637273|Lilly
516412|NCT00637273|Pioglitazone
516413|NCT00637260|motorcortex stimulation
516414|NCT00637260|Parkinson's disease
516415|NCT00637260|neuromodulation
516416|NCT00637247|pancreatic cancer
516417|NCT00637247|metastatic
516418|NCT00637247|chemotherapy naive
516419|NCT00637221|Safety
516420|NCT00637221|Tolerability
516421|NCT00637208|prostate cancer
516422|NCT00637208|venography
516423|NCT00637208|male patients
516424|NCT00637208|Localized microscopic prostate cancer up to Gleason 6 (3+3)
516425|NCT00637208|PSA level <14
516426|NCT00637208|presence of varicocele
516427|NCT00637195|Human papillomavirus (HPV) vaccine
516428|NCT00637195|Hepatitis B
516429|NCT00637195|Cervical cancer
516430|NCT00637195|HPV
516431|NCT00637195|Papillomavirus
516432|NCT00637182|Gynecomastia
516433|NCT00637182|Anastrazole
516434|NCT00637182|Arimidex
516435|NCT00637182|Pubertal
516436|NCT00637182|males
516437|NCT00637182|boys
516438|NCT00637169|oxygen therapy
516439|NCT00637169|neurodevelopmental impairment
516440|NCT00637156|Symptomatic DDD at Two Adjacent Levels of cervical spine
516441|NCT00637143|Renal transplant
516442|NCT00637143|Cyclosporine
516443|NCT00637143|Tacrolimus
516444|NCT00637143|Intervention
516445|NCT00637143|Interstitial Fibrosis Tubular Atrophy
516446|NCT00637143|Chronic Renal Allograft Failure
516447|NCT00637117|Lymphoma, Dendritic, Vaccine, Radiotherapy
516448|NCT00637104|percutaneous transluminal coronary angioplasty
516449|NCT00637104|stents
516450|NCT00637104|restenosis
516451|NCT00637104|biocompatible materials
516452|NCT00637104|ceramics
516453|NCT00637078|hypertension
516454|NCT00637078|hypercholesterolemia
516455|NCT00637078|family physicians
516456|NCT00637078|fixed dose combination therapy
516457|NCT00637078|cluster randomized controlled trial
516458|NCT00637065|Pulmonary hypertension
516459|NCT00637065|Interstitial lung disease
516460|NCT00637065|Idiopathic pulmonary fibrosis
516461|NCT00637065|Nonspecific interstitial pneumonia
516462|NCT00637065|Bosentan
516463|NCT00637065|Endothelin receptor antagonists
516464|NCT00637065|Pulmonary vascular resistance
516465|NCT00637052|preleukemia
516466|NCT00637052|dysplasia of myeloid blood cells
516467|NCT00637039|Advanced cancer
516468|NCT00637039|Solid tumour
516469|NCT00637039|Solid malignancies
516470|NCT00637039|Neoplasms
516471|NCT00637026|Iressa, Gefitinib, Breast Cancer, Surgery
516472|NCT00637013|Subacromial impingement
516473|NCT00637013|Shoulder
516474|NCT00637013|RCT
516475|NCT00637013|Effectiveness
516476|NCT00637013|Cost-effectiveness
516477|NCT00637000|Opioid dependence
516478|NCT00637000|Opioid withdrawal symptoms
516479|NCT00636987|aortic valve
516480|NCT00636987|mitral valve
516481|NCT00636987|heart valve
516482|NCT00636987|tissue valve
516483|NCT00636987|bioprosthesis
516484|NCT00636987|valve disorder
516485|NCT00636987|valve disease
516486|NCT00636987|cardiac surgery
516487|NCT00636987|aortic valve regurgitation
516488|NCT00636987|aortic valve stenosis
516489|NCT00636987|mitral valve regurgitation
516490|NCT00636987|mitral valve stenosis
516491|NCT00636974|Patients who are going to have regional anaesthesia for lower limbs surgery.
516492|NCT00636974|Leg Surgery.
516493|NCT00636961|COPD, Indacaterol Maleate, Exercise testing
516494|NCT00636948|Rectal cancer surgery
516495|NCT00636948|Symptomatic anastomotic leakage
516496|NCT00636948|Defunctioning stoma
516497|NCT00636948|TME surgery
516498|NCT00636935|Pneumocystis jirovecii Pneumonia
516499|NCT00636935|Corticosteroid Therapy
516500|NCT00636935|HIV
516501|NCT00636935|Pneumonia
516502|NCT00636935|Pulmonary Function Testing
516503|NCT00636935|Antibiotics
516504|NCT00636935|Prednisone
516505|NCT00636935|Human Immunodeficiency Virus
516506|NCT00636935|CD4
516507|NCT00636935|CD8
516508|NCT00636935|Viral Load
516509|NCT00636935|Bactrim
516510|NCT00636935|Pentamidine
516511|NCT00636935|Atovaquone
516512|NCT00636935|Primaquine/Clindamycin
516513|NCT00636935|Trimethoprim/Dapsone
516514|NCT00636922|Acute Myeloid Leukemia
516515|NCT00636922|Elderly
516516|NCT00636922|Unfit
516517|NCT00636922|Everolimus
516518|NCT00636922|RAD001
516519|NCT00636909|AML
516520|NCT00636909|ALL
516521|NCT00636909|CML
516522|NCT00636909|CLL
516523|NCT00636909|MDS
516524|NCT00636909|NHL
516525|NCT00636909|HODGKIN'S LYMPHOMA
516526|NCT00636909|APLASTIC ANEMIA
516527|NCT00636909|MULTIPLE MYELOMA
516528|NCT00636909|MYELOPROLIFERATIVE DISORDER
516529|NCT00636909|ALLOGENEIC
516530|NCT00636909|STEM CELL TRANSPLANT
516531|NCT00636909|HEMATOLOGIC DISORDERS
516532|NCT00636909|CYCLOPHOSPHAMIDE
516533|NCT00636909|FLUDARABINE
516534|NCT00636909|CYCLOSPORINE
516535|NCT00636909|METHOTREXATE
516536|NCT00636909|G-CSF
516537|NCT00636909|GVHD
516538|NCT00636909|ENGRAFTMENT
516539|NCT00636909|CHIMERISM
516540|NCT00636896|weight gain
516541|NCT00636896|olanzapine
516542|NCT00636896|atypical antipsychotic
516543|NCT00636883|Pancreatic cancer
516544|NCT00636857|Water-Electrolyte Imbalance
516545|NCT00636844|chemotherapy, cardiotoxicity
516546|NCT00636831|Prophylactic
516547|NCT00636831|Antibiotic
516548|NCT00636831|Infection
516549|NCT00636831|Primary case
516550|NCT00636805|Aloxi
516551|NCT00636805|Brain Neoplasm, Primary
516552|NCT00636805|Brain Neoplasms, Malignant
516553|NCT00636766|cardiovascular events
516554|NCT00636753|Metabolic and endocrine changes in schizophrenic patients by antipsychotics treatment.
516555|NCT00636740|Prostate cancer, hormone resistant, bisphosphonate
516556|NCT00636727|arthrocentesis
516557|NCT00636727|arthroscopy
516558|NCT00636727|arthroplasty
516559|NCT00636714|intensive insulin therapy
516560|NCT00636714|glucose control
516561|NCT00636714|nurse directed
516562|NCT00636714|nomogram directed
516563|NCT00636701|Cerebrovascular Accident
516564|NCT00636701|rehabilitation
516565|NCT00636688|Obesity
516566|NCT00636688|Lifestyle changes
516567|NCT00636675|Accidental falls
516568|NCT00636649|Eating disorder
516569|NCT00636636|Postherpetic Neuralgia (PHN), shingles
516570|NCT00636623|Pilates Exercises
516571|NCT00636623|Connective Tissue Massage
516572|NCT00636610|Hedgehog
516573|NCT00636610|CRC
516574|NCT00636610|Colorectal Cancer
516575|NCT00636610|Hedgehog Pathway Inhibitor
516576|NCT00636584|sodium nitroprusside
516577|NCT00636584|thyroid hormones
516578|NCT00636584|thoracic surgery
516579|NCT00636571|Exercise
516580|NCT00636571|Non-Small Cell Lung Cancer
516581|NCT00636571|Cardiopulmonary Fitness
516582|NCT00636558|coxsackie virus
516583|NCT00636558|melanoma
516584|NCT00636558|breast cancer
516585|NCT00636558|prostate cancer
516586|NCT00636545|Genasense
516587|NCT00636545|oblimersen
516588|NCT00636545|antisense
516589|NCT00636545|Bcl-2 antisense
516590|NCT00636545|Solid Tumors
516591|NCT00636519|Botulism Antitoxin,Heptavalent,Bivalent,EDB Muscle,Paralysis
516592|NCT00636506|Erectile dysfunction
516593|NCT00636506|Impotence
516594|NCT00636493|retinal vein occlusion
516595|NCT00636493|sustained drug delivery implant
516596|NCT00636493|steroid
516597|NCT00636493|macular edema
516598|NCT00636480|Antimicrobial
516599|NCT00636480|Antisepsis
516600|NCT00636467|Breast cancer (tumors> 2 cm)
516601|NCT00636467|Detection
516602|NCT00636467|Axillary sentinel lymph node
516603|NCT00636454|OA
516604|NCT00636454|Pain
516605|NCT00636454|Cognitive Therapy
516606|NCT00636454|Behavior Therapy
516607|NCT00636454|Knee OA
516608|NCT00636454|Hip OA
516609|NCT00636441|Early-Stage Breast Cancer
516610|NCT00636441|Preoperative systemic chemotherapy (PST)
516611|NCT00636441|Genomic
516612|NCT00636441|Genomic Predictor
516613|NCT00636441|Genomic Expression Profiles
516614|NCT00636441|Randomized
516615|NCT00636441|Pathologic complete response (pCR)
516616|NCT00636441|HER2 negative
516617|NCT00636441|Doxorubicin and docetaxel
516618|NCT00636441|Doxorubicin and cyclophosphamide
516619|NCT00636428|endoscopy
516620|NCT00636428|Midazolam
516621|NCT00636428|pediatric
516622|NCT00636428|sedation
516623|NCT00636428|comfort
516624|NCT00636415|Analgesia
516625|NCT00636415|Morphine
516626|NCT00636415|Bupivacaine
516627|NCT00636415|Osteoarthritis
516628|NCT00636415|Knee
516629|NCT00636402|Vessel Sealing System
516630|NCT00636402|Cold Knife
516631|NCT00636402|Tonsillectomy
516632|NCT00636402|Pain
516633|NCT00636402|Postoperative
516634|NCT00636389|Hemodialysis
516635|NCT00636389|Dialysis, Renal
516636|NCT00636389|Dialysis, Extracorporeal
516637|NCT00636389|Extracorporeal Dialysis
516638|NCT00636376|elevated intracranial pressure
516639|NCT00636376|inadequate cerebral perfusion
516640|NCT00636376|secondary brain damage
516641|NCT00636350|pepper carotenoids
516642|NCT00636350|xanthophylls
516643|NCT00636350|healthy volunteers
516644|NCT00636337|Pediatric
516645|NCT00636337|Brain Tumor
516646|NCT00636337|Acute Lymphoblastic Leukemia
516647|NCT00636337|Inattention
516648|NCT00636337|Childhood cancer survivors
516649|NCT00636324|Respiratory distress syndrome
516650|NCT00636324|Preterm infants
516651|NCT00636324|Extubation failure
516652|NCT00636324|Pneumothorax
516653|NCT00636324|Lung injury
516654|NCT00636324|Airway pressure
516655|NCT00636311|Hodgkin disease
516656|NCT00636311|Salvage therapy
516657|NCT00636311|Bortezomib
516658|NCT00636311|Transplantation
516659|NCT00636298|esophageal carcinoma
516660|NCT00636298|cancer of the esophagus
516661|NCT00636298|locally advanced or metastatic esophageal cancer
516662|NCT00636285|A110
516663|NCT00636285|Safety
516664|NCT00636272|ICD
516665|NCT00636272|CRT-D
516666|NCT00635271|Asthma
516667|NCT00635271|Biomarker
516668|NCT00635271|Exhaled Breath Condensate
516669|NCT00635271|Cytokine
516670|NCT00635271|Healthy Volunteer
516671|NCT00635271|HV
516672|NCT00635258|GnRH antagonist
516673|NCT00635258|oocyte donation
516674|NCT00635258|pregnancy
516675|NCT00635258|implantation
516676|NCT00635245|stage IA breast cancer
516677|NCT00635245|stage IB breast cancer
516678|NCT00635245|stage II breast cancer
516679|NCT00635232|Hypertension
516680|NCT00635232|High Blood Pressure
516681|NCT00635219|Major depressive disorder
516682|NCT00635219|Placebo-controlled
516683|NCT00635219|Active reference
516684|NCT00635219|Multicenter study
516685|NCT00635219|Randomised study
516686|NCT00635219|Acute treatment
516687|NCT00635206|OSA
516688|NCT00635193|Ovarian neoplasms
516689|NCT00635193|Angiogenesis inhibitors
516690|NCT00635193|Angiogenesis
516691|NCT00635193|Volociximab
516692|NCT00635193|Ovarian cancer
516693|NCT00635193|Antibody
516694|NCT00635193|Monoclonals
516695|NCT00633529|Phase 1b
516696|NCT00633529|Non-Small Cell Lung Cancer
516697|NCT00633529|Advanced or Metastatic Disease
516698|NCT00633529|Prior chemotherapy
516699|NCT00633516|moles
516700|NCT00633516|melanoma
516701|NCT00633503|free tissue transfer
516702|NCT00633503|pedicle tissue transfer
516703|NCT00633503|complications
516704|NCT00633503|modulated imaging spectroscopy
516705|NCT00633503|observation
516706|NCT00633503|clinical observation/diagnosis
516707|NCT00633503|tissue defects requiring free tissue transfer
516708|NCT00633503|tissue defects requiring pedicle tissue transfer
516709|NCT00633490|Toxicity
516710|NCT00633490|Efficacy
516711|NCT00633477|Systemic Inflammatory Response Syndrome
516712|NCT00633477|Septic Shock
516713|NCT00633477|Septicemia
516714|NCT00633477|Drug Therapy
516715|NCT00633451|shoulder pain
516716|NCT00633451|shoulder impingement syndrome
516717|NCT00633451|manual therapy
516718|NCT00633451|rehabilitation
516719|NCT00633438|Knee Surgery Arthroscopic Surgery
516720|NCT00633412|NSAID
516721|NCT00633412|Nexium
516722|NCT00633412|esomeprazole
516723|NCT00633412|Gastric Ulcers
516724|NCT00633399|Major Depressive Disorder
516725|NCT00633399|Major Depression
516726|NCT00633399|Depression
516727|NCT00633399|Geodon
516728|NCT00633399|Ziprasidone
516729|NCT00633399|SSRI Augmentation
516730|NCT00633399|Treatment Resistant Depression
516731|NCT00633386|Knee Surgery
516732|NCT00633386|Arthroscopic Surgery
516733|NCT00633373|lung
516734|NCT00633373|transplant
516735|NCT00633373|transplant rejection
516736|NCT00633373|Cyclosporine
516737|NCT00633373|bronchiolitis obliterans
516738|NCT00633373|aerosol
516739|NCT00633360|Women
516740|NCT00633360|PMS
516741|NCT00633360|Depression
516742|NCT00636259|Prostate cancer
516743|NCT00636259|Casodex
516744|NCT00636233|anencephaly
516745|NCT00636233|acrania
516746|NCT00636220|HIV-1 Infections
516747|NCT00636155|Small Lymphocytic Lymphoma
516748|NCT00636155|Chronic Lymphocytic Leukemia
516749|NCT00636155|EL625
516750|NCT00636155|cenersen
516751|NCT00636129|relaxation
516752|NCT00636129|relaxation response
516753|NCT00636129|meditation
516754|NCT00636129|nitric oxide
516755|NCT00636129|stress management
516756|NCT00636129|stress
516757|NCT00636129|Relaxation Techniques
516758|NCT00636116|snake bite
516759|NCT00636116|antivenin treatment
516760|NCT00636103|Traditional Chinese Medicine
516761|NCT00636103|Asthma
516762|NCT00636103|Paediatric
516763|NCT00636077|Hemodialysis
516764|NCT00636077|Dialysis, Renal
516765|NCT00636051|evidence based practice beliefs
516766|NCT00636051|evidence based practice implementation
516767|NCT00636051|evidence based practice dissemination
516768|NCT00636038|beta-carotene
516769|NCT00636038|yellow maize
516770|NCT00636038|vitamin A
516771|NCT00636012|acupuncture
516772|NCT00636012|Acupuncture points
516773|NCT00635986|Analgesia
516774|NCT00635986|Fentanyl
516775|NCT00635986|Orthopedic
516776|NCT00635986|Mechanism of action
516777|NCT00635986|Surgery
516778|NCT00635973|Iressa
516779|NCT00635973|Gefitinib
516780|NCT00635973|Cancer
516781|NCT00635973|Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial
516782|NCT00635960|Amyotrophic Lateral Sclerosis
516783|NCT00635960|ALS
516784|NCT00635960|Growth Hormone
516785|NCT00635960|IGF-I
516786|NCT00635947|Amniotic fluid index
516787|NCT00635947|maternal hydration
516788|NCT00635947|isotonic solution
516789|NCT00635947|Amniotic Fluid
516790|NCT00635934|Lumbar Degenerative Disc Disease at One Level from L4-S1
516791|NCT00635921|Borderline Personality Disorder
516792|NCT00635921|ziprasidone
516793|NCT00635895|Fibromyalgia
516794|NCT00635895|Manual Lymphatic Drainage
516795|NCT00635895|Connective Tissue Massage
516796|NCT00635895|Pain
516797|NCT00635895|Health Related Quality of Life
516798|NCT00635895|Randomized Controlled Trial
516799|NCT00635882|mometasone
516800|NCT00635882|formoterol
516801|NCT00635869|evidence based practice beliefs
516802|NCT00635869|evidence based practice implementation
516803|NCT00635869|evidence based practice knowledge
516804|NCT00635869|nurse physician collaboration
516805|NCT00635856|Iressa
516806|NCT00635856|Gefitinib
516807|NCT00635856|Prostate Cancer
516808|NCT00635856|PSA
516809|NCT00635843|Lumbar degenerative disc disease at one level from L4-S1
516810|NCT00635817|CPP
516811|NCT00635817|central precocious puberty
516812|NCT00635817|pediatrics
516813|NCT00635817|suppression of luteinizing hormone
516814|NCT00635817|Lupron
516815|NCT00635817|leuprolide acetate
516816|NCT00635817|depot formulation
516817|NCT00635817|GnRHa
516818|NCT00635817|GnRH agonist
516819|NCT00635817|GnRH analog
516820|NCT00635817|luteinizing hormone
516821|NCT00635791|Malignant Solid Tumour
516822|NCT00635791|Renal cell carcinoma
516823|NCT00635791|Non small cell lung carcinoma
516824|NCT00635765|Acromegaly
516825|NCT00635752|TF-CBT
516826|NCT00635752|Effectiveness study
516827|NCT00635752|Trauma
516828|NCT00635752|Therapy
516829|NCT00635739|Whey protein
516830|NCT00635739|Resistance exercise
516831|NCT00635739|Physical activity
516832|NCT00635739|Mobility disability
516833|NCT00635739|Physical function
516834|NCT00635739|Muscle mass
516835|NCT00635739|Muscle strength
516836|NCT00635739|Older Adults
516837|NCT00635739|Mobility-Limited
516838|NCT00635726|Bladder Cancer
516839|NCT00635713|Advanced breast cancer, FASLODEX, ARIMIDEX, Fulvestrant, Anastrozole, postmenopausal
516840|NCT00635700|psychosis
516841|NCT00635700|schizophrenia
516842|NCT00635700|prodrome
516843|NCT00635700|ziprasidone
516844|NCT00635700|placebo
516845|NCT00635687|variceal bleeding
516846|NCT00635687|transient elastography
516847|NCT00635674|sleep apnea
516848|NCT00635674|risk factors
516849|NCT00635674|continuous positive airway pressure
516850|NCT00635674|insulin resistance
516851|NCT00635674|metabolic syndrome
516852|NCT00635674|compliance
516853|NCT00635661|function
516854|NCT00635661|disability
516855|NCT00635635|Stress Disorders, Post-Traumatic
516856|NCT00635635|Anxiety,
516857|NCT00635635|Depression,
516858|NCT00635635|Guided Imagery
516859|NCT00635635|Military Sexual Trauma
516860|NCT00635622|Bacterial Vaginosis
516861|NCT00635622|BV
516862|NCT00635622|UCSF
516863|NCT00635622|SFGH
516864|NCT00635596|MT110
516865|NCT00635596|solid tumors
516866|NCT00635596|phase I
516867|NCT00635596|BiTE
516868|NCT00635596|bispecific T-cell engager
516869|NCT00635583|Bone
516870|NCT00635583|Dairy Intervention
516871|NCT00635583|Girls
516872|NCT00635583|Boys
516873|NCT00635583|Calcium
516874|NCT00635583|Bone Mineralization
516875|NCT00635583|Peak Bone Mass
516876|NCT00635583|Bone and Bones
516877|NCT00635583|Female
516878|NCT00635583|Male
516879|NCT00635583|Adolescent
516880|NCT00635583|Healthy
516881|NCT00635570|Contraception, Compliance, Acceptability
516882|NCT00635557|Recurrent
516883|NCT00635557|Relapsed
516884|NCT00635557|Glioblastoma
516885|NCT00635557|Multiforme
516886|NCT00635544|Adolescence
516887|NCT00635544|Overweight
516888|NCT00635544|Dietary Fiber
516889|NCT00635544|Glycemic Index
516890|NCT00635544|Healthy lifestyle
516891|NCT00635518|Health Plan Implementation
516892|NCT00635518|Feeding and Eating Disorders of Childhood
516893|NCT00635518|Breast Feeding
516894|NCT00635518|Overweight
516895|NCT00635518|Child
516896|NCT00635518|Infant Nutrition Physiology
516897|NCT00635518|Public Health
516898|NCT00635505|Asthma
516899|NCT00635505|albuterol
516900|NCT00635505|HFA
516901|NCT00635492|diabetes
516902|NCT00635492|insulin
516903|NCT00635492|exenatide
516904|NCT00635492|Byetta
516905|NCT00635492|Amylin
516906|NCT00635492|Lilly
516907|NCT00635479|Fractures
516908|NCT00635479|Pelvic bones
516909|NCT00635479|Acetabulum
516910|NCT00635479|Hip bones
516911|NCT00635466|laparoscopic surgery, rectal carcinoma, phase II trial
516912|NCT00635453|Breast Feeding
516913|NCT00635453|Child
516914|NCT00635453|Infant Nutrition Physiology
516915|NCT00635453|Public Health
516916|NCT00635453|Morbidity
516917|NCT00635453|Health Plan Implementation
516918|NCT00635440|skeletal muscle
516919|NCT00635440|ubiquitin
516920|NCT00635440|proteasome
516921|NCT00635440|IGF-1
516922|NCT00635440|MGF
516923|NCT00635440|protein catabolism
516924|NCT00635440|neuromuscular electrical stimulation
516925|NCT00635440|Investigate effect of NMES on muscle metabolism of catabolic patients
516926|NCT00635427|VPRIV
516927|NCT00635427|Enzyme Replacement Therapy
516928|NCT00635427|Gaucher disease
516929|NCT00635427|glucocerebrosidase
516930|NCT00635427|beta-glucocerebrosidase
516931|NCT00635427|Acid beta-glucocerebrosidase
516932|NCT00635427|glucosylceramidase
516933|NCT00635427|D-glucosyl-N-acylsphingosine glucohydrolase
516934|NCT00635427|gene activation
516935|NCT00635427|human
516936|NCT00635414|Gastroesophageal Reflux Disease (GERD), esomeprazole, Nexium
516937|NCT00635362|Contraception
516938|NCT00635362|Contraceptive Devices
516939|NCT00635362|Intrauterine Devices
516940|NCT00635362|Unplanned Pregnancy
516941|NCT00635362|Postpartum Period
516942|NCT00635349|WOMAC
516943|NCT00635349|Knee osteoarthritis pain
516944|NCT00635349|Pain intensity
516945|NCT00635349|Tramadol
516946|NCT00635349|Acetaminophen
516947|NCT00635349|Meloxicam
516948|NCT00635349|Aceclofenac
516949|NCT00635336|Epitope peptide
516950|NCT00635336|CTL
516951|NCT00635336|Advanced bladder cancer
516952|NCT00635336|Vaccination
516953|NCT00635336|advanced bladder cancer which showed resistance for standard treatments
516954|NCT00635310|Chronic hepatitis C
516955|NCT00635310|Chronic hepatitis B
516956|NCT00635310|Liver biopsy
516957|NCT00635310|Hemodialysis
516958|NCT00635310|1-Deamino-8- D-Arginine Vasopressin
516959|NCT00635297|osteoporosis
516960|NCT00635297|vertebroplasty
516961|NCT00635297|prophylactic
516962|NCT00635297|vertebrae
516963|NCT00635297|fracture
516964|NCT00635180|Isometric exercise
516965|NCT00635180|intraocular pressure
516966|NCT00635180|Physiological changes in intraocular pressure during isometric exercise
516967|NCT00635167|Prostate cancer
516968|NCT00635167|prostatic vascularity
516969|NCT00635167|External Beam Radiation treatment
516970|NCT00635167|Contrast Enhanced transrectal Ultrasound
516971|NCT00635154|stage I multiple myeloma
516972|NCT00635154|stage II multiple myeloma
516973|NCT00635154|stage III multiple myeloma
516974|NCT00635141|Cystic Fibrosis
516975|NCT00635141|Lung Clearance Index
516976|NCT00635141|Hypertonic Saline
516977|NCT00635141|Pediatrics
516978|NCT00635128|Diphtheria
516979|NCT00635128|vaccine
516980|NCT00635128|DTP
516981|NCT00635128|Poliomyelitis
516982|NCT00635128|Pertussis
516983|NCT00635128|Booster
516984|NCT00635128|Tetanus
516985|NCT00635102|Alcohol Dependence, Alcoholism, Glycine, D-Cycloserine
516986|NCT00635089|Eosinophilic Esophagitis
516987|NCT00635089|Cinquil
516988|NCT00635063|Cancer Breakthrough Pain
516989|NCT00635050|Breast cancer
516990|NCT00635037|Myofascial pain syndrome
516991|NCT00635037|Acupuncture
516992|NCT00635037|Nonsteroidal anti-inflammatory agents
516993|NCT00635037|Muscle relaxants, central
516994|NCT00635037|Quality of life.
516995|NCT00635037|muscle relaxants, analgesia
516996|NCT00635024|refractory multiple myeloma
516997|NCT00635024|stage I multiple myeloma
516998|NCT00635024|stage II multiple myeloma
516999|NCT00635024|stage III multiple myeloma
517000|NCT00635011|comorbidity
517001|NCT00635011|Quality of Life
517002|NCT00635011|Body Weight Changes
517003|NCT00634998|Vitamin C
517004|NCT00634998|Ascorbic Acid
517005|NCT00634998|Diabetic Neuropathies
517006|NCT00634972|Retinopathy of Prematurity
517007|NCT00634972|Premature Infants
517008|NCT00634972|ACULAR
517009|NCT00634972|Refresh Tears
517010|NCT00634959|HIV Infections
517011|NCT00634959|Treatment Naïve
517012|NCT00634946|Chemonucleolysis
517013|NCT00634946|Lumbar Vertebrae
517014|NCT00634946|Hernia
517015|NCT00634933|active
517016|NCT00634933|rheumatoid
517017|NCT00634933|arthritis
517018|NCT00634933|anti CD20
517019|NCT00634920|De novo renal transplantation
517020|NCT00634907|Genotyping
517021|NCT00634907|Warfarin dosing
517022|NCT00634907|arthroplasty
517023|NCT00634894|Ovarian Cancer
517024|NCT00634894|Fallopian Tube Cancer
517025|NCT00634894|Peritoneal Cancer
517026|NCT00634894|Femara
517027|NCT00634894|Letrozole
517028|NCT00634894|Placebo
517029|NCT00634881|B-cell chronic lymphocytic leukemia
517030|NCT00634881|stage III chronic lymphocytic leukemia
517031|NCT00634881|stage IV chronic lymphocytic leukemia
517032|NCT00634881|stage I chronic lymphocytic leukemia
517033|NCT00634881|stage II chronic lymphocytic leukemia
517034|NCT00634868|ulcer wound diabetes
517035|NCT00634855|Endothelial progenitor cells
517036|NCT00634855|Endothelial dysfunction
517037|NCT00634777|HNSCC biopsy-proven
517038|NCT00634777|T1-T4 oral cavity oropharynx hypopharynx larynx
517039|NCT00634777|N+ scheduled for an organ preservation treatment protocol based on concomitant
517040|NCT00634777|chemoradiation
517041|NCT00634764|Maternal weight gain
517042|NCT00634764|Neonatal birth weight
517043|NCT00634764|Weight gain attitude
517044|NCT00634764|Pregnancy
517045|NCT00634764|Body fat
517046|NCT00634764|Maternal Behavior
517047|NCT00634764|Birth outcomes
517048|NCT00634751|advanced pancreatic and biliary tract carcinomas
517049|NCT00634738|ischemic compression;carpal tunnel syndrome
517050|NCT00634725|adenocarcinoma of the pancreas
517051|NCT00634725|stage III pancreatic cancer
517052|NCT00634712|Congestive Heart Failure
517053|NCT00634712|Atacand
517054|NCT00634712|Candesartan
517055|NCT00634686|Omega-3 fatty acids
517056|NCT00634686|immune response
517057|NCT00634673|Serum Fatty Acids
517058|NCT00634673|FABP2 Gene
517059|NCT00634673|Polymorphism Ala54Thr
517060|NCT00634647|Chemotherapy
517061|NCT00634647|Pharmacokinetics
517062|NCT00634647|Gene Polymorphisms
517063|NCT00634647|Prostate Cancer
517064|NCT00634634|breast cancer
517065|NCT00634634|Postmenopausal Women with Hormone Receptor-Positive Locally Advanced Breast Cancer
517066|NCT00634621|Bladder
517067|NCT00634621|Cancer
517068|NCT00634621|Cystoscopy
517069|NCT00634621|Hexaminolevulinate
517070|NCT00634621|Hexvix
517071|NCT00634595|clinical trial
517072|NCT00634595|randomized
517073|NCT00634595|Endostatin
517074|NCT00634595|gene therapy
517075|NCT00634595|head and neck cancer
517076|NCT00634595|head and neck squamous carcinoma
517077|NCT00634582|adenocarcinoma of the prostate
517078|NCT00634582|stage IV prostate cancer
517079|NCT00634582|recurrent prostate cancer
517080|NCT00634582|bone metastases
517081|NCT00634569|CVID, XLA, hyper IgM syndrome, Wiskott-Aldrich Syndrome
517082|NCT00634556|Tourette Syndrome
517083|NCT00634556|fMRI
517084|NCT00634556|levodopa
517085|NCT00634556|working memory
517086|NCT00634556|dopamine
517087|NCT00634543|Diabetic neuropathy
517088|NCT00634543|Ultracet
517089|NCT00634543|Tramadol hydrochloride
517090|NCT00634543|Acetaminophen
517091|NCT00634543|Gabapentin
517092|NCT00634530|Pregnancy
517093|NCT00634530|Prenatal Care
517094|NCT00634530|Weight
517095|NCT00634530|Nutritional Status
517096|NCT00634504|high dose methotrexate
517097|NCT00634504|Voraxaze
517098|NCT00634504|leucovorin
517099|NCT00634504|delayed elimination
517100|NCT00634504|methotrexate toxicity
517101|NCT00634504|rescue
517102|NCT00634504|renal insufficiency
517103|NCT00634478|essential tremor
517104|NCT00634478|deep brain stimulation
517105|NCT00634452|Hodgkin's
517106|NCT00634452|Cancer
517107|NCT00634452|bi-measurable disease
517108|NCT00634452|Lymphoma
517109|NCT00634439|cerebrovascular accident
517110|NCT00634439|stroke
517111|NCT00634439|transient ischemic attack
517112|NCT00634439|TIA
517113|NCT00634439|CVA
517114|NCT00634439|attention deficit hyperactivity disorder
517115|NCT00634439|ADHD
517116|NCT00634426|Spine
517117|NCT00634426|Neoplasm metastasis
517118|NCT00634426|Treatment, surgical
517119|NCT00634426|Treatment, nonoperative
517120|NCT00634426|Quality of life
517121|NCT00634413|COPD
517122|NCT00634400|Congestive Heart Failure
517123|NCT00634400|Atacand
517124|NCT00634400|Candesartan
517125|NCT00633698|lipoprotein(a)
517126|NCT00633698|niacin
517127|NCT00633698|placebo
517128|NCT00633698|intervention
517129|NCT00633685|Posttraumatic Stress Disorder
517130|NCT00633685|Fluoxetine
517131|NCT00633685|Factors predicting response
517132|NCT00633685|Resilience
517133|NCT00633685|Pharmacologic augmentation strategies
517134|NCT00633672|NSAID
517135|NCT00633672|Nexium
517136|NCT00633672|esomeprazole
517137|NCT00633672|Gastric Ulcers
517138|NCT00633659|Hemospan
517139|NCT00633659|Oxygen carriers
517140|NCT00633659|Blood substitutes
517141|NCT00633659|Ischemia
517142|NCT00633659|Tissue oxygenation
517143|NCT00633646|nitrogen balance
517144|NCT00633646|malnutrition
517145|NCT00633646|chronic kidney disease
517146|NCT00633646|diet
517147|NCT00633646|glomerular filtration rate
517148|NCT00633633|Heart Failure
517149|NCT00633633|Lifestyle Intervention
517150|NCT00633633|Exercise
517151|NCT00633633|Diet
517152|NCT00633620|colonoscopy
517153|NCT00633620|narrow band imaging
517154|NCT00633620|adenoma
517155|NCT00633620|diagnosis
517156|NCT00633620|colonoscopic adenoma detection
517157|NCT00633594|Mantle Cell Lymphoma
517158|NCT00633594|Rituximab
517159|NCT00633594|Lenalidomide
517160|NCT00633594|Bortezomib
517161|NCT00633594|Phase 1/2
517162|NCT00633581|fatigue
517163|NCT00633581|ascorbic acid
517164|NCT00633581|oxidative stress
517165|NCT00633568|Non-small cell lung carcinoma
517166|NCT00633568|Concomitant radiochemotherapy
517167|NCT00633568|Cisplatin
517168|NCT00633568|Docetaxel
517169|NCT00633568|Radiotherapy
517170|NCT00633568|Chemotherapy
517171|NCT00633568|Unresectable stage III non-small cell lung carcinoma
517172|NCT00633542|thalidomide
517173|NCT00633542|maintenance
517174|NCT00633542|interferon
517175|NCT00633542|dexamethasone
517176|NCT00633542|newly diagnosed multiple myeloma
517177|NCT00633542|relapsed refractory multiple myeloma
517178|NCT00634374|Rx medibottle
517179|NCT00634374|Oral syringe
517180|NCT00634374|Liquid medication
517181|NCT00634374|Bitter-tasting
517182|NCT00634374|Infants
517183|NCT00634322|osteosarcoma
517184|NCT00634322|high dose methotrexate
517185|NCT00634322|leucovorin
517186|NCT00634309|Congestive Heart Failure
517187|NCT00634309|Atacand
517188|NCT00634309|Candesartan
517189|NCT00634296|Heart failure
517190|NCT00634296|Systolic dysfunction
517191|NCT00634296|Inspiratory muscle weakness
517192|NCT00634270|Plexiform, Neurofibromatosis Type 1, Sirolimus, Phase II
517193|NCT00634257|Advanced Cancer
517194|NCT00634257|Solid Tumors
517195|NCT00634257|Spirituality
517196|NCT00634257|Religiosity
517197|NCT00634257|Symptom Distress
517198|NCT00634257|Quality of Life
517199|NCT00634257|Caregivers
517200|NCT00634257|Questionnaire
517201|NCT00634257|Survey
517202|NCT00634244|Acute Myelogenous Leukemia (AML), Carboplatin, Topotecan, Flavopiridol, Mitoxantrone, Cytosine Arabinoside, Sirolimus, Etoposide
517203|NCT00634231|Malignant glioma
517204|NCT00634231|Glioblastoma multiforme
517205|NCT00634231|Anaplastic astrocytoma
517206|NCT00634231|Recurrent ependymoma
517207|NCT00634231|Gene therapy
517208|NCT00634231|Immunotherapy
517209|NCT00634218|nicotine
517210|NCT00634218|smoking
517211|NCT00634218|smoking cessation
517212|NCT00634205|Mesothelioma
517213|NCT00634205|Valproate
517214|NCT00634205|Doxorubicin
517215|NCT00634205|Chemotherapy
517216|NCT00634205|Phase II
517217|NCT00634192|Chronic infection with P. aeruginosa in Cystic Fibrosis subjects
517218|NCT00634179|Lymphoma
517219|NCT00634166|thermal injuries
517220|NCT00634166|burns
517221|NCT00634166|Burn Patients (Subjects with Thermal Injuries Requiring Meshed Autografts)
517222|NCT00634140|gallbladder
517223|NCT00634140|ezetimibe for 4 to 6 weeks prior to gallbladder removal
517224|NCT00634114|Reflux Esophagitis
517225|NCT00634075|Severe sepsis
517226|NCT00634075|Proinflammatory cytokines
517227|NCT00634075|ICU
517228|NCT00634062|Affective Lability
517229|NCT00634062|Borderline Personality Disorder
517230|NCT00634062|Pharmacotherapy
517231|NCT00634049|invasive fungal infections caused by rare molds, rare yeasts
517232|NCT00634049|BAL8557
517233|NCT00634049|Isavuconazole
517234|NCT00634049|Aspergillosis
517235|NCT00634049|or by dimorphic fungi
517236|NCT00634049|ASP9766
517237|NCT00634036|Asthma
517238|NCT00634036|obesity
517239|NCT00634036|exacerbation
517240|NCT00634036|asthmatics
517241|NCT00634036|fat
517242|NCT00634036|overweight
517243|NCT00634036|adipose tissue
517244|NCT00634036|leptin
517245|NCT00634036|adiponectin
517246|NCT00634036|pioglitazone
517247|NCT00634036|Actos
517248|NCT00634036|wheezing
517249|NCT00634036|Pittsburgh
517250|NCT00634036|Pennsylvania
517251|NCT00634036|pulmonary
517252|NCT00634036|lung
517253|NCT00634010|Advanced Cancer
517254|NCT00634010|Solid Tumors
517255|NCT00634010|Cancer Pain
517256|NCT00634010|Opioid Pain Killer
517257|NCT00634010|Morphine
517258|NCT00634010|Methadone
517259|NCT00633997|Diabetes mellitus
517260|NCT00633997|type 2 diabetes
517261|NCT00633997|vildagliptin
517262|NCT00633997|pharmacokinetics
517263|NCT00633984|Social Anxiety Disorder
517264|NCT00633984|Cognitive Behavioral Group Therapy
517265|NCT00633984|D-cycloserine
517266|NCT00633971|Post thrombotic syndrome
517267|NCT00633971|Thrombosis
517268|NCT00633971|Deep vein thrombosis
517269|NCT00633971|Venous thrombosis
517270|NCT00633971|Edema
517271|NCT00633971|stasis ulcers
517272|NCT00633958|18F-FLT
517273|NCT00633958|FLT
517274|NCT00633958|PET
517275|NCT00633958|CNS tumors
517276|NCT00633958|Newly
517277|NCT00633958|diagnosed
517278|NCT00633945|Cutaneous Lupus Erythematosus
517279|NCT00633945|CLE
517280|NCT00633945|lenalidomide
517281|NCT00633945|revlimid
517282|NCT00633945|thalidomide derivative
517283|NCT00633945|drug
517284|NCT00633945|lupus
517285|NCT00633932|Reflux Esophagitis
517286|NCT00633919|House dust mites
517287|NCT00633919|Sublingual immunotherapy
517288|NCT00633919|Allergy
517289|NCT00633919|Allergic asthma
517290|NCT00633906|HIV
517291|NCT00633906|Sexually Transmitted diseases
517292|NCT00633906|Adolescents
517293|NCT00633906|Prevention
517294|NCT00633906|HIV Seronegativity
517295|NCT00633880|NOH
517296|NCT00633880|Neurogenic Orthostatic Hypotension
517297|NCT00633880|Orthostatic hypotension
517298|NCT00633880|PAF
517299|NCT00633880|Pure Autonomic Failure
517300|NCT00633880|MSA
517301|NCT00633880|Multiple System Atrophy
517302|NCT00633880|Neuropathy
517303|NCT00633880|Autonomic Failure
517304|NCT00633880|Parkinson
517305|NCT00633880|Dopamine Deficiency
517306|NCT00633880|Dopamine
517307|NCT00633880|Droxidopa
517308|NCT00633867|Tracheal intubation
517309|NCT00633867|Laryngoscopy
517310|NCT00633867|videolaryngoscope
517311|NCT00633867|McGrath
517312|NCT00633867|success
517313|NCT00633867|time
517314|NCT00633854|annular array ultrasound
517315|NCT00633854|ophthalmic ultrasound
517316|NCT00633854|posterior vitreous detachment (PVD)
517317|NCT00633841|Alzheimer
517318|NCT00633841|Morbus Alzheimer
517319|NCT00633841|Alzheimer Vaccine
517320|NCT00633841|Vaccine
517321|NCT00633841|AD
517322|NCT00633841|Aβ immunotherapy
517323|NCT00633828|Bone Density
517324|NCT00633828|Bone mass
517325|NCT00633828|Bone mineral density
517326|NCT00633828|Bone structure
517327|NCT00633828|Cardiovascular risk factors
517328|NCT00633828|Fat Mass
517329|NCT00633828|Adiposity
517330|NCT00633815|Supine
517331|NCT00633815|Upright
517332|NCT00633802|Risperidone
517333|NCT00633802|Borderlone Personality Disorder
517334|NCT00633776|Chronic Obstructive Pulmonary Disease
517335|NCT00633776|COPD
517336|NCT00633776|Chronic bronchitis
517337|NCT00633776|Emphysema
517338|NCT00633776|Perforomist
517339|NCT00633776|Foradil
517340|NCT00633776|CT
517341|NCT00633776|lung function
517342|NCT00633763|Diagnostic
517343|NCT00633763|PET/CT imaging of pancreas
517344|NCT00633763|Detecting pancreatic beta cell loss during diabetes
517345|NCT00633750|stage I breast cancer
517346|NCT00633750|stage II breast cancer
517347|NCT00633750|stage IIIA breast cancer
517348|NCT00633750|stage IIIB breast cancer
517349|NCT00633737|Psychology
517350|NCT00633737|Laparoscopy
517351|NCT00633737|Cholecystectomy
517352|NCT00633737|Psychoneuroimmunology
517353|NCT00633737|Wound healing
517354|NCT00633737|Preparation for surgery
517355|NCT00633737|Stress reduction
517356|NCT00633737|Stress
517357|NCT00633737|Relaxation
517358|NCT00633711|OSAS
517359|NCT00633711|blood pressure
517360|NCT00633711|sympathetic nervous system
517361|NCT00633711|treatment
517362|NCT00633711|CPAP
517363|NCT00633347|oocyte donation
517364|NCT00633347|endometrial preparation
517365|NCT00633334|Cancer
517366|NCT00633334|GI
517367|NCT00633334|Tumor
517368|NCT00633334|Gastrointestinal
517369|NCT00633334|high risk
517370|NCT00633321|smoking cessation
517371|NCT00633321|quit smoking
517372|NCT00633321|smoking vaccine
517373|NCT00633321|nicotine vaccine
517374|NCT00633321|TA-NIC
517375|NCT00633321|Aid for smoking cessation in smokers motivated to quit
517376|NCT00633308|hemodialysis
517377|NCT00633295|GIST
517378|NCT00633295|TKI
517379|NCT00633295|IMATINIB
517380|NCT00633295|NILOTINIB
517381|NCT00633295|AMN107
517382|NCT00633282|Nonalcoholic Fatty Liver Disease
517383|NCT00633282|Pioglitazone
517384|NCT00633282|Berberine
517385|NCT00633282|Impaired Glucose Metabolism
517386|NCT00633269|Poly(ADP ribose) polymerases
517387|NCT00633269|Metastatic Solid Tumours
517388|NCT00633230|hepatitis C virus
517389|NCT00633230|complementary and alternative medicine
517390|NCT00633230|peginterferon alfa and ribavirin
517391|NCT00633217|DISKUS
517392|NCT00633217|Salmeterol
517393|NCT00633217|Fluticasone Propionate
517394|NCT00633217|Chronic Obstructive Pulmonary Disease (COPD)
517395|NCT00633217|Hydroflouroalkane
517396|NCT00633217|COPD
517397|NCT00633217|HFA MDI
517398|NCT00633204|Epitope peptide, CTL, TUR-Bt, Bladder cancer, Vaccination
517399|NCT00633204|Bladder cancer after surgery
517400|NCT00633191|Cystic fibrosis
517401|NCT00633191|Prevention
517402|NCT00633191|Infection
517403|NCT00633191|Pseudomonas aeruginosa
517404|NCT00633191|Gargle
517405|NCT00633178|Prenatal Depression
517406|NCT00633178|Postpartum Depression
517407|NCT00633178|Fetal Development
517408|NCT00633178|Interpersonal Therapy
517409|NCT00633165|sarcoma
517410|NCT00633165|myxoid liposarcoma
517411|NCT00633152|complicated skin and skin structure infections
517412|NCT00633152|linezolid
517413|NCT00633152|ceftaroline
517414|NCT00633152|clinical response
517415|NCT00633152|microbiological response
517416|NCT00633152|Cellulitis
517417|NCT00633152|Abscess
517418|NCT00633152|Wound infection
517419|NCT00633152|Deeper soft tissue
517420|NCT00633152|Significant surgical intervention
517421|NCT00633152|Gram-positive bacterial infection
517422|NCT00633152|Gram-negative bacterial infection
517423|NCT00633152|bacterial infection
517424|NCT00633152|cephalosporin
517425|NCT00633152|broad-spectrum activity
517426|NCT00633139|Metazym
517427|NCT00633139|Late infantile
517428|NCT00633139|Metachromatic leukodystrophy
517429|NCT00633139|Long-term safety
517430|NCT00633126|PK
517431|NCT00633126|Pharmacokinetics
517432|NCT00633113|Total Knee Arthroplasty
517433|NCT00633113|Minimally Invasive Knee Replacement
517434|NCT00633113|Knee Osteoarthritis
517435|NCT00633113|Cost effectiveness minimally invasive knee surgery
517436|NCT00633074|Influenza
517437|NCT00633061|Childhood Cancer
517438|NCT00633061|Central Venous Catheter
517439|NCT00633061|Deep Vein Thrombosis
517440|NCT00633061|Catheter-related Infection
517441|NCT00633061|Catheter-related Occlusion
517442|NCT00633048|ascending single-dose study
517443|NCT00633048|healthy subjects
517444|NCT00633035|ulcer
517445|NCT00633035|esomeprazole
517446|NCT00633035|famotidine
517447|NCT00633035|Neurosurgery
517448|NCT00633022|FDG-PET/CT, atherosclerosis
517449|NCT00633009|Leishmaniasis
517450|NCT00633009|Delayed-Type Hypersensitivity (DTH)
517451|NCT00633009|Skin Test
517452|NCT00633009|Conversion
517453|NCT00633009|Prior exposure to Leishmania major
517454|NCT00632996|shoulder pain
517455|NCT00632996|shoulder impingement syndrome
517456|NCT00632996|manual therapy
517457|NCT00632996|rehabilitation
517458|NCT00632983|long-term effects secondary to cancer therapy in adults
517459|NCT00632983|anxiety disorder
517460|NCT00632983|sexual dysfunction
517461|NCT00632983|urinary complications
517462|NCT00632983|stage I prostate cancer
517463|NCT00632983|stage IIB prostate cancer
517464|NCT00632983|stage IIA prostate cancer
517465|NCT00632970|Raltegravir
517466|NCT00632970|Lopinavir
517467|NCT00632918|Image quality
517468|NCT00632918|Dual-source CT
517469|NCT00632918|Coronary angiography
517470|NCT00632918|Heart rate
517471|NCT00632905|Prostate Cancer
517472|NCT00632905|Prostatic adenoma
517473|NCT00632905|Prostatic neoplasm
517474|NCT00632892|oxidative stress markers in urine
517475|NCT00632892|urine norepinephrine
517476|NCT00632892|renal tubular enzyme markers
517477|NCT00632866|auto-immune diseases
517478|NCT00632866|hydroxychloroquine
517479|NCT00632866|primary Sjögren's syndrome
517480|NCT00632866|inflammatory arthritides
517481|NCT00632866|inflammatory rheumatic diseases
517482|NCT00632866|dryness
517483|NCT00632866|joint diseases
517484|NCT00632853|limited stage small cell lung cancer
517485|NCT00632814|Kogenate,
517486|NCT00632814|Children,
517487|NCT00632814|Factor VIII,
517488|NCT00632814|Hemophilia A,
517489|NCT00632814|Prophylactic
517490|NCT00632801|elective laparoscopic colectomy
517491|NCT00632801|chewing gum
517492|NCT00632801|ileus
517493|NCT00632801|post-operative care
517494|NCT00632801|colectomy
517495|NCT00632788|myocardial infarction
517496|NCT00632788|catheterization
517497|NCT00632788|angioplasty
517498|NCT00632788|door-to-balloon time
517499|NCT00632775|pediatrics
517500|NCT00632775|Hyponatremia
517501|NCT00632775|Sodium Chloride
517502|NCT00632775|maintenance fluids
517503|NCT00632762|Amantadine benefit
517504|NCT00632762|Dyskinesia
517505|NCT00632762|Parkinson's disease
517506|NCT00632736|ropinirole XL
517507|NCT00632736|REQUIP
517508|NCT00632736|Parkinson's disease
517509|NCT00632736|long term safety
517510|NCT00632736|efficacy
517511|NCT00632736|safety
517512|NCT00632736|ropinirole CR
517513|NCT00632736|ropinirole IR
517514|NCT00632736|open-label
517515|NCT00632723|oestrogen receptor
517516|NCT00632723|ER negative tumours
517517|NCT00632723|epidermal growth factor receptor (EGFR)
517518|NCT00632710|rheumatoid arthritis
517519|NCT00632710|hands
517520|NCT00632710|randomized controlled
517521|NCT00632710|low level laser
517522|NCT00632697|endometriosis
517523|NCT00632697|immunomodulation
517524|NCT00632697|infertility
517525|NCT00632697|laparoscopic surgery
517526|NCT00632697|pentoxifylline
517527|NCT00632684|Family Caregiving
517528|NCT00632684|Dementia
517529|NCT00632671|Obesity cohort
517530|NCT00632658|cGVHD
517531|NCT00632645|Huntington
517532|NCT00632645|Neuroleptic
517533|NCT00632645|Unified Huntington Disease Rating Scale (UHDRS)
517534|NCT00632645|Independence Scale
517535|NCT00632645|Neuroleptic Prescription required
517536|NCT00632632|World Trade Center Victims
517537|NCT00632632|Iraq War Veterans
517538|NCT00632632|PTSD
517539|NCT00632619|Subthreshold Manic States in Children
517540|NCT00632619|ADHD
517541|NCT00632606|pregnant women
517542|NCT00632593|Early Complications of both techniques
517543|NCT00632593|Fistula rate
517544|NCT00632593|Dehiscence rate
517545|NCT00632593|reoperation rate and cause
517546|NCT00632580|Pain, Postoperative
517547|NCT00632567|Anal incontinence
517548|NCT00632567|First delivery was traumatic
517549|NCT00632567|No anal incontinence
517550|NCT00632528|MEOPA
517551|NCT00632528|spasticity
517552|NCT00632528|multilevel surgery
517553|NCT00632528|cerebral palsy
517554|NCT00632528|children
517555|NCT00632515|Colorectal Cancer
517556|NCT00632515|CRC
517557|NCT00632515|Familial CRC
517558|NCT00632515|Cancer Screening
517559|NCT00632515|Questionnaire
517560|NCT00632515|First Degree Relatives
517561|NCT00632515|FDRs
517562|NCT00632515|Risk Communication
517563|NCT00632489|Refractory Malignancy
517564|NCT00632489|Breast Cancer
517565|NCT00632489|LBH589
517566|NCT00632489|Capecitabine
517567|NCT00632489|Lapatinib
517568|NCT00632476|Smoking During Pregnancy
517569|NCT00632476|Vitamin C
517570|NCT00632476|Newborn Lung Function
517571|NCT00632476|Ascorbic Acid
517572|NCT00632463|Transplant
517573|NCT00632463|Immunosuppression
517574|NCT00632437|Brain Tumor
517575|NCT00632437|Craniotomy Surgery
517576|NCT00632437|Brain Function
517577|NCT00632437|Intraoperative Optical Imaging
517578|NCT00632437|Speckle-Contrast Imaging
517579|NCT00632437|Cortical Mapping
517580|NCT00632437|Somatosensory Cortex
517581|NCT00632437|Cerebral blood flow
517582|NCT00632437|CBF
517583|NCT00632437|Laser Speckle Contrast Imaging
517584|NCT00632437|Multi-Spectral Imaging
517585|NCT00632398|massage
517586|NCT00632398|oncology massage
517587|NCT00632398|palliative care
517588|NCT00632398|supportive care
517589|NCT00632398|integrative oncology
517590|NCT00632398|informal caregiving
517591|NCT00632398|spouse caregiving
517592|NCT00632398|family caregiving
517593|NCT00632398|caregiver education
517594|NCT00632398|psychosocial oncology
517595|NCT00632398|caregiver stress
517596|NCT00632398|coping with cancer
517597|NCT00632398|quality of life
517598|NCT00632398|end of life care
517599|NCT00632359|Chronic Lymphocytic Leukemia
517600|NCT00632359|CLL
517601|NCT00632359|Lenalidomide
517602|NCT00632359|Revlimid
517603|NCT00632346|childhood abuse
517604|NCT00632346|overweight
517605|NCT00632346|obesity
517606|NCT00632346|BMI as a young adult
517607|NCT00632346|childhood physical abuse
517608|NCT00632346|childhood emotional abuse
517609|NCT00632346|childhood sexual abuse
517610|NCT00632346|childhood physical neglect
517611|NCT00632346|childhood emotional neglect
517612|NCT00632346|childhood witnessing of domestic violence
517613|NCT00632346|parental marital discord
517614|NCT00632346|household members with substance abuse
517615|NCT00632346|household members with mental illness
517616|NCT00632346|household members with criminal behavior
517617|NCT00632346|cumulative adverse childhood experiences
517618|NCT00632333|Epitope peptide
517619|NCT00632333|Vaccination
517620|NCT00632333|Chemoradiation
517621|NCT00632333|Esophageal cancer
517622|NCT00632320|Ventilator, mechanical
517623|NCT00632320|Ventilator weaning
517624|NCT00632320|Rapid shallow breathing index
517625|NCT00632320|Continuous positive airway pressure
517626|NCT00632320|Receiver operating characteristic curve
517627|NCT00632320|COPD
517628|NCT00632307|lung tumor
517629|NCT00632307|pleural tumor
517630|NCT00632307|interstitial lung disease
517631|NCT00632307|airway infection
517632|NCT00632307|COPD
517633|NCT00632307|sleep apnea
517634|NCT00632307|ion mobility spectrometry
517635|NCT00632307|breath analysis
517636|NCT00632294|Bone Cancer
517637|NCT00632294|Allograft Retrieval
517638|NCT00632294|Allograft Bone
517639|NCT00632294|Bone Mineral Density
517640|NCT00632268|mTOR inhibitor
517641|NCT00632268|RAD001
517642|NCT00632268|everolimus
517643|NCT00632268|chemotherapy
517644|NCT00632268|cisplatin
517645|NCT00632268|high-dose 5-FU
517646|NCT00632255|Chronic Myeloid Leukemia
517647|NCT00632255|Long term Imatinib therapy compliance
517648|NCT00632255|Newly diagnosed
517649|NCT00632255|Late side effects
517650|NCT00632229|Obsessive-Compulsive Disorder; Adults; Medication; Treatment
517651|NCT00632190|cervical cancer
517652|NCT00632190|cervical intraepithelial neoplasia grade 1
517653|NCT00632190|cervical intraepithelial neoplasia grade 2
517654|NCT00632190|cervical intraepithelial neoplasia grade 3
517655|NCT00632138|sexual dysfunction
517656|NCT00632138|psychosocial effects of cancer and its treatment
517657|NCT00632138|prostate cancer
517658|NCT00632138|benign prostatic hyperplasia
517659|NCT00632138|urinary incontinence
517660|NCT00632125|CKD subjects with or without dialysis treatment
517661|NCT00632112|large volume nebulizer
517662|NCT00632099|cocaine
517663|NCT00632099|treatment
517664|NCT00632099|progesterone
517665|NCT00632086|PK
517666|NCT00632073|HIV Infections
517667|NCT00632073|Acquired Immunodeficiency Syndrome
517668|NCT00632073|treatment experienced
517669|NCT00632060|Low Back Pain
517670|NCT00632060|Manual / Manipulative Therapy
517671|NCT00632047|breast cancer
517672|NCT00632047|cervical cancer
517673|NCT00632034|fracture
517674|NCT00632034|tibia
517675|NCT00632034|stem cell
517676|NCT00632021|Low Health Literacy
517677|NCT00632021|Medication Errors
517678|NCT00632021|Cardiovascular Disease
517679|NCT00632021|Pharmacist
517680|NCT00632021|Care Transition
517681|NCT00631995|Neisseria meningitidis
517682|NCT00631982|in vitro maturation oocytes
517683|NCT00631969|Erectile Dysfunction
517684|NCT00631917|Hypertension, aliskiren, ramipril, colonoscopy
517685|NCT00631904|Pacemaker
517686|NCT00631878|Staphylococcal
517687|NCT00631878|Monoclonal antibodies
517688|NCT00631878|Very Low Birth Weight Infants
517689|NCT00631878|Prophylaxis
517690|NCT00631865|melanocytes
517691|NCT00631852|Breast Cancer, Biomarkers, Ginseng Root
517692|NCT00631839|Thoracic Neoplasms
517693|NCT00631839|Platinum-based chemotherapy
517694|NCT00631839|3-D Conformal Radiotherapy
517695|NCT00631839|Chemo-radiotherapy induced lung injury
517696|NCT00631839|Chemo-radiotherapy induced esophagus injury
517697|NCT00631826|Shoulder
517698|NCT00631826|Injuries
517699|NCT00631826|Flexiblity
517700|NCT00631826|Rotational resistance
517701|NCT00631800|Staphylococcal
517702|NCT00631800|Monoclonal antibodies
517703|NCT00631800|Very Low Birth Weight Infants
517704|NCT00631800|Prophylaxis
517705|NCT00631787|Nitric Oxide
517706|NCT00631787|Hemolysis
517707|NCT00631787|Plasma Hemoglobin
517708|NCT00631787|Dimethyl Sulfoxide
517709|NCT00631787|Organ Dysfuntion
517710|NCT00631787|Healthy Volunteer
517711|NCT00631787|HV
517712|NCT00631774|type 2 diabetes
517713|NCT00631774|meal replacement
517714|NCT00631774|postprandial response
517715|NCT00631774|Glucerna SR
517716|NCT00631761|urethrocystoscopy
517717|NCT00631761|cystoscopy
517718|NCT00631761|objective structured assessment of surgical skills (OSATS)
517719|NCT00631748|cocaine
517720|NCT00631748|quetiapine fumarate
517721|NCT00631748|dependence
517722|NCT00631748|abuse
517723|NCT00631748|addiction
517724|NCT00631748|treatment
517725|NCT00631735|cancer
517726|NCT00631735|qualitative
517727|NCT00631722|PANSS
517728|NCT00631722|Acute Episode of Schizophrenia
517729|NCT00631696|Healthy males Human volunteers pregabalin or placebo sperm quality and quantity
517730|NCT00631657|placebo controlled
517731|NCT00631657|randomized
517732|NCT00631657|double blind
517733|NCT00631644|Adolescents
517734|NCT00631644|Eating Behavior
517735|NCT00631644|Eating in the Absence of Hunger
517736|NCT00631644|Disordered Eating
517737|NCT00631644|Food Intake
517738|NCT00631644|Macronutrient Composition
517739|NCT00631644|Obesity
517740|NCT00631644|Adolescent
517741|NCT00631644|Healthy Volunteer
517742|NCT00631644|HV
517743|NCT00631631|Drug Therapy
517744|NCT00631605|eating disorders
517745|NCT00631605|ghrelin
517746|NCT00631605|leptin
517747|NCT00631605|BIA
517748|NCT00631592|GSK1349572,
517749|NCT00631592|healthy volunteers,
517750|NCT00631592|repeat dose,
517751|NCT00631592|relative bioavailability
517752|NCT00631592|Healthy subjects
517753|NCT00631566|HIV
517754|NCT00631566|Methicillin-resistant Staphylococcus aureus (MRSA)
517755|NCT00631566|HIV and Staphylococcus aureus infection
517756|NCT00631540|renal artery stenosis
517757|NCT00631540|hypertension
517758|NCT00631540|renovascular
517759|NCT00631540|renal artery blockage
517760|NCT00631540|renal artery disease
517761|NCT00631540|renal arteries
517762|NCT00631540|angioplasty renal artery
517763|NCT00631540|renal artery stent
517764|NCT00631540|renal artery doppler
517765|NCT00631540|renovascular hypertension
517766|NCT00631540|kidney stenosis
517767|NCT00631540|renal artery
517768|NCT00631540|stent
517769|NCT00631540|stenting
517770|NCT00631540|kidney disease
517771|NCT00631540|renal failure
517772|NCT00631540|atherosclerosis
517773|NCT00631540|arterial hypertension
517774|NCT00631540|stenosis
517775|NCT00631527|Prostate Cancer
517776|NCT00631527|Radiation Therapy
517777|NCT00631527|RT
517778|NCT00631527|Radiotherapy
517779|NCT00631527|Hormone Ablation
517780|NCT00631527|Sunitinib Malate
517781|NCT00631527|Leuprolide
517782|NCT00631527|Lupron
517783|NCT00631527|Zoladex
517784|NCT00631527|Goserelin
517785|NCT00631527|Casodex
517786|NCT00631527|Bicalutamide
517787|NCT00631527|SU011248
517788|NCT00631527|Sutent
517789|NCT00631527|Angiogenesis inhibitor
517790|NCT00631514|antihypertensive drugs
517791|NCT00631514|non-steroidal anti-inflammatory drugs
517792|NCT00631514|interaction
517793|NCT00631514|family practice
517794|NCT00631514|arterial blood pressure
517795|NCT00631501|tendinopathy
517796|NCT00631501|tennis elbow
517797|NCT00631501|lateral epicondylitis
517798|NCT00631501|lateral epicondylalgia
517799|NCT00631501|MMP-inhibitor
517800|NCT00631475|Actelion
517801|NCT00631475|Idiopathic Pulmonary Fibrosis
517802|NCT00631475|bosentan
517803|NCT00631475|Tracleer
517804|NCT00631475|Interstitial Lung Disease
517805|NCT00631475|BUILD 3 (NCT00391443)
517806|NCT00631462|primary myelofibrosis
517807|NCT00631462|post-polycythemia vera myelofibrosis
517808|NCT00631462|post-essential thrombocythemia myelofibrosis
517809|NCT00631449|HIV
517810|NCT00631449|Treatment intensification
517811|NCT00631449|Low level viremia
517812|NCT00631449|Suboptimal CD4+ T cell response
517813|NCT00631449|treatment experienced
517814|NCT00631436|Diffusion Tensor Imaging
517815|NCT00631436|Electroencephalography
517816|NCT00631436|Blast Injury
517817|NCT00631436|Traumatic Brain Injury
517818|NCT00631410|Phase 1
517819|NCT00631410|CRC
517820|NCT00631410|SU011248
517821|NCT00631410|Sunitinib
517822|NCT00631410|FOLFOX
517823|NCT00631410|Colorectal cancer
517824|NCT00631410|metastatic carcinoma of the colon or rectum
517825|NCT00631397|weakening of the bones
517826|NCT00631384|Voluntary Counseling and Testing
517827|NCT00631384|HIV
517828|NCT00631384|HIV seronegativity
517829|NCT00631371|temsirolimus
517830|NCT00631371|renal cell carcinoma
517831|NCT00631371|kidney cancer
517832|NCT00631371|urogenital cancer
517833|NCT00631358|Ocular inflammation
517834|NCT00631345|prediabetes
517835|NCT00631345|overweight
517836|NCT00631345|obesity
517837|NCT00631345|metabolic syndrome
517838|NCT00631345|community health worker
517839|NCT00631332|women, dementia, cognition.
517840|NCT00631332|non-demented women at least age 65
517841|NCT00631319|OA
517842|NCT00631319|Chronic Pain
517843|NCT00631319|Osteoarthritis
517844|NCT00631319|OA Pain
517845|NCT00631319|Osteoarthritis Pain
517846|NCT00631319|Pain
517847|NCT00631319|Hip Pain
517848|NCT00631319|Knee Pain
517849|NCT00631319|Joint Pain
517850|NCT00631293|Healthy volunteers
517851|NCT00631280|Decision Aid
517852|NCT00631280|Informed Choice
517853|NCT00631280|Adherence
517854|NCT00631267|reduction
517855|NCT00631267|satisfaction
517856|NCT00631267|visual-analog scale
517857|NCT00631267|complications
517858|NCT00631267|functional outcome
517859|NCT00631267|radiological outcome
517860|NCT00631241|Cervical Cancer
517861|NCT00631241|Parametrial Lymph Nodes
517862|NCT00631241|Sentinel Nodes
517863|NCT00631241|Intraoperative Lymphatic Mapping
517864|NCT00631241|Single Photon Emission Computed Tomography
517865|NCT00631241|SPECT/CT
517866|NCT00631228|drug eluting stents
517867|NCT00631228|stents
517868|NCT00631228|Angioplasty
517869|NCT00631228|coronary artery disease
517870|NCT00631228|total coronary occlusion
517871|NCT00631228|coronary artery restenosis
517872|NCT00631228|stent thrombosis
517873|NCT00631228|vascular disease
517874|NCT00631228|myocardial ischemia
517875|NCT00631228|coronary artery stenosis
517876|NCT00631215|Hyperbaric
517877|NCT00631215|Oxygen
517878|NCT00631215|autism
517879|NCT00631202|FRDA
517880|NCT00631202|Erythropoietin
517881|NCT00631202|Epoetin alfa
517882|NCT00631189|dyslipidemia
517883|NCT00631176|oral intubation
517884|NCT00631176|just in time
517885|NCT00631176|simulation education
517886|NCT00631176|high fidelity training
517887|NCT00631176|intubation training
517888|NCT00631176|intubation success
517889|NCT00631163|Iron Overload,
517890|NCT00631163|Chelation,
517891|NCT00631163|MDS,
517892|NCT00631163|Chronic Anemia,
517893|NCT00631163|Deferasirox,
517894|NCT00631163|Transfusional hemosiderosis,
517895|NCT00631150|Levetiracetam
517896|NCT00631150|Keppra
517897|NCT00631137|musculoskeletal complications
517898|NCT00631137|adult anaplastic astrocytoma
517899|NCT00631137|adult anaplastic oligodendroglioma
517900|NCT00631137|adult giant cell glioblastoma
517901|NCT00631137|adult glioblastoma
517902|NCT00631137|adult gliosarcoma
517903|NCT00631124|Contraception
517904|NCT00631111|dental pain
517905|NCT00631111|analgesic
517906|NCT00631111|NSAID
517907|NCT00631111|ibuprofen
517908|NCT00631111|aspirin
517909|NCT00631098|Resuscitation
517910|NCT00631098|venous cannulation
517911|NCT00631098|external jugular vein
517912|NCT00631098|cubital vein
517913|NCT00631085|healthy nonsmoking nonasthmatic volunteers
517914|NCT00631072|iNKT
517915|NCT00631072|in vitro autologous iNKT
517916|NCT00631059|Hitachi
517917|NCT00631059|Leukemia
517918|NCT00631059|Relapse
517919|NCT00631059|Chemotherapy Resistance
517920|NCT00631046|n-3 LCPUFA
517921|NCT00631046|Fish oil
517922|NCT00631046|essential fatty acids
517923|NCT00631046|infant growth
517924|NCT00631046|obesity
517925|NCT00631046|Intestinal microbiota
517926|NCT00631033|obesity
517927|NCT00631033|hyperinsulinism
517928|NCT00631033|diazoxide
517929|NCT00631033|metformin
517930|NCT00631020|Youth
517931|NCT00631020|Smoking
517932|NCT00631020|Tobacco
517933|NCT00631020|Adolescent
517934|NCT00631020|Dependence
517935|NCT00631020|Teen smoking
517936|NCT00631020|Smoking and youth
517937|NCT00631020|Youth and tobacco
517938|NCT00631007|Type 2 diabetes
517939|NCT00631007|diabetes
517940|NCT00631007|diabetes mellitus
517941|NCT00631007|diabetes mellitus, type 2
517942|NCT00631007|non-TZD
517943|NCT00631007|thiazolidinedione
517944|NCT00631007|selective peroxisome proliferator-activated receptor gamma modulator
517945|NCT00631007|SPPARM
517946|NCT00631007|peroxisome proliferator-activated receptor gamma
517947|NCT00631007|PPAR gamma
517948|NCT00631007|insulin sensitizer
517949|NCT00631007|glucose control
517950|NCT00631007|endocrinopathy
517951|NCT00631007|hypoglycemic agent
517952|NCT00631007|sulfonylurea
517953|NCT00631007|metformin
517954|NCT00631007|pioglitazone
517955|NCT00631007|nutritional and metabolic diseases
517956|NCT00630994|primary myelofibrosis
517957|NCT00630994|secondary myelofibrosis
517958|NCT00630994|essential thrombocythemia
517959|NCT00630994|polycythemia vera
517960|NCT00630981|dissociative disorders
517961|NCT00630968|Levetiracetam
517962|NCT00630968|Keppra
517963|NCT00630955|Alcohol Drinking
517964|NCT00630955|Memantine
517965|NCT00630942|PSC
517966|NCT00630916|Aortic valve insufficiency
517967|NCT00630916|Aortic valve
517968|NCT00630916|Aortic disease
517969|NCT00630916|Aortic incompetence
517970|NCT00630890|Hilar Cholangiocarcinoma (Klatskin Tumor)
517971|NCT00630890|External Beam Radiation
517972|NCT00630890|Cyberknife
517973|NCT00630890|Capecitabine
517974|NCT00630864|Transthyretin, TTR, amyloidosis, TTR amyloidosis, polyneuropathy
517975|NCT00630838|Hirschsprung disease
517976|NCT00630838|enterocolitis
517977|NCT00630838|probiotics
517978|NCT00630812|cystic fibrosis
517979|NCT00630812|mannitol
517980|NCT00630812|mucoactive
517981|NCT00630799|prostate
517982|NCT00630799|cancer
517983|NCT00630773|CPR
517984|NCT00630773|compression sensor
517985|NCT00630773|chest compression adjuncts
517986|NCT00630747|Hunter syndrome
517987|NCT00630747|hunters syndrome
517988|NCT00630747|hunter's syndrome
517989|NCT00630747|hunter disease
517990|NCT00630747|hunters disease
517991|NCT00630747|hunter's disease
517992|NCT00630747|MPS II
517993|NCT00630747|MPSII
517994|NCT00630747|MPS2
517995|NCT00630747|MPS 2
517996|NCT00630747|mucopolysaccharides
517997|NCT00630747|lysosomal storage disease
517998|NCT00630747|lysosomal storage disorder
517999|NCT00630747|chronic ear infection
518000|NCT00630747|enlarged adenoids
518001|NCT00630747|mps symptoms
518002|NCT00630747|mps diagnosis
518003|NCT00630747|mps ii therapy
518004|NCT00630747|MPS II treatment
518005|NCT00630747|ert treatment
518006|NCT00630747|elaprase
518007|NCT00630747|idursulfase
518008|NCT00630747|iduronate sulfatase
518009|NCT00630747|iduronate 2 sulfatase
518010|NCT00630747|enzyme replacement therapy
518011|NCT00630747|hunter syndrome treatment
518012|NCT00630747|hunter's syndrome treatment
518013|NCT00630747|hunter syndrome therapy
518014|NCT00630747|hunter's disease treatment
518015|NCT00630747|mps society
518016|NCT00630734|HIV
518017|NCT00630734|Pravastatin
518018|NCT00630734|Darunavir
518019|NCT00630734|Ritonavir
518020|NCT00630734|Genetic
518021|NCT00630708|Renal insufficiency
518022|NCT00630708|Benazepril
518023|NCT00630708|Losartan
518024|NCT00630708|combination treatment
518025|NCT00630708|Safety
518026|NCT00630695|Axillary lymphocele breast cancer
518027|NCT00630682|Methamphetamine
518028|NCT00630682|Drug Abuse
518029|NCT00630682|Drug Treatment
518030|NCT00630682|Addiction
518031|NCT00630682|Meth
518032|NCT00630682|Treatment for Methamphetamine Dependence
518033|NCT00630669|Internal hemorrhoids
518034|NCT00630669|Rubber band ligation
518035|NCT00630669|Bipolar coagulation
518036|NCT00630656|sepsis
518037|NCT00630656|talactoferrin
518038|NCT00630656|lactoferrin
518039|NCT00630656|recombinant human lactoferrin
518040|NCT00630630|Levetiracetam
518041|NCT00630630|Keppra
518042|NCT00630617|Obesity
518043|NCT00630617|Prevention
518044|NCT00630617|Childhood
518045|NCT00630617|Children
518046|NCT00630617|Primary care-giver
518047|NCT00630604|ultrasonography
518048|NCT00630604|knee
518049|NCT00630604|early degeneration
518050|NCT00630604|cartilage
518051|NCT00630591|Daughters And MothErS Against Breast Cancer
518052|NCT00630591|DAMES
518053|NCT00630591|Breast Cancer
518054|NCT00630591|Weight Loss
518055|NCT00630591|Home-based weight loss
518056|NCT00630591|Quality of Life
518057|NCT00630591|Diet
518058|NCT00630591|Exercise
518059|NCT00630591|Daughter
518060|NCT00630591|Mother
518061|NCT00630591|Cancer Prevention
518062|NCT00630591|Prevention
518063|NCT00630578|PTSD
518064|NCT00630578|Posttraumatic Stress Disorder
518065|NCT00630578|Physical Assault
518066|NCT00630578|Physical Abuse
518067|NCT00630578|Sexual Assault
518068|NCT00630578|Sexual Abuse
518069|NCT00630578|Interpersonal Assault
518070|NCT00630578|Cognitive Processing Therapy
518071|NCT00630565|adult acute myeloid leukemia in remission
518072|NCT00630565|adult acute myeloid leukemia with inv(16)(p13;q22)
518073|NCT00630565|adult acute myeloid leukemia with t(15;17)(q22;q12)
518074|NCT00630565|adult acute myeloid leukemia with t(8;21)(q22;q22)
518075|NCT00630565|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
518076|NCT00630565|adult acute myeloid leukemia with t(16;16)(p13;q22)
518077|NCT00630565|childhood acute myeloid leukemia in remission
518078|NCT00630552|AMG 479
518079|NCT00630552|Gemcitabine
518080|NCT00630552|TR-2
518081|NCT00630552|IGF-1R
518082|NCT00630552|AMG 655
518083|NCT00630552|Pancreatic cancer
518084|NCT00630552|Adenocarcinoma of the Pancreas
518085|NCT00630552|Metastatic Pancreatic Cancer
518086|NCT00630539|Menopausal symptoms
518087|NCT00630539|Urogenital atrophy
518088|NCT00630539|Vulvar and vaginal atrophy in postmenopausal women
518089|NCT00630539|Vaginal atrophy
518090|NCT00630513|localized community acquired intra-abdominal infection (IAI)
518091|NCT00630513|antibiotics
518092|NCT00630513|localized peritonitis
518093|NCT00630513|ertapenem
518094|NCT00630500|Dementia associated with Parkinson's disease
518095|NCT00630500|Dementia with Lewy bodies
518096|NCT00630500|Memantine
518097|NCT00630500|Placebo-controlled
518098|NCT00630500|Parallel group
518099|NCT00630474|sleep apnea, rhinitis
518100|NCT00630461|mild asthma, mild allergies
518101|NCT00630435|Premarin®
518102|NCT00630422|Rett Syndrome
518103|NCT00630422|Selfcare
518104|NCT00630422|Mobility limitation
518105|NCT00630422|Interpersonal relations
518106|NCT00630422|This study avaliated patients with Rett Syndrome
518107|NCT00630409|Renal cell carcinoma
518108|NCT00630409|Kidney Cancer
518109|NCT00630409|Gemcitabine
518110|NCT00630409|Doxil
518111|NCT00630409|Chemotherapy
518112|NCT00630396|stroke
518113|NCT00630396|ischemic
518114|NCT00630396|neuroprotection
518115|NCT00630396|minocycline
518116|NCT00630396|tissue plasminogen activator (tPA)
518117|NCT00630396|biomarkers
518118|NCT00630396|pharmacokinetics
518119|NCT00630396|antiapoptotic
518120|NCT00630396|anti-inflammatory
518121|NCT00630396|treatment
518122|NCT00630396|matrix metalloproteinase-9 (MMP-9)
518123|NCT00630396|thrombolysis
518124|NCT00630396|Minocycline to Improve Neurologic Outcome in Stroke (MINOS)
518125|NCT00630396|cerebrovascular stroke
518126|NCT00630396|cerebrovascular accident
518127|NCT00630396|cerebral stroke
518128|NCT00630396|cerebrovascular accident (CVA)
518129|NCT00630383|Parasite
518130|NCT00630383|Necator
518131|NCT00630383|immune regulation
518132|NCT00630383|regulatory T cells
518133|NCT00630383|foxp3
518134|NCT00630383|cytokines
518135|NCT00630383|multiple sclerosis
518136|NCT00630383|hygiene hypothesis
518137|NCT00630357|Levetiracetam
518138|NCT00630357|Keppra
518139|NCT00630344|RAD001
518140|NCT00630344|bicalutamide
518141|NCT00630344|androgen independent prostate cancer
518142|NCT00630331|Influenza
518143|NCT00630331|Flu
518144|NCT00630331|Cell Culture-Derived
518145|NCT00630331|Egg-Derived
518146|NCT00630331|Healthy Adults
518147|NCT00630331|Efficacy
518148|NCT00630331|Safety
518149|NCT00630331|Immunogenicity
518150|NCT00630331|Trivalent
518151|NCT00630331|Inactivated
518152|NCT00630331|Influenza-Like Illness
518153|NCT00630331|Vaccination
518154|NCT00630318|MR scanning
518155|NCT00630305|toric
518156|NCT00630305|endothelial bleb
518157|NCT00630279|pancreatic exocrine insufficiency
518158|NCT00630279|chronic pancreatitis
518159|NCT00630266|Heart failure
518160|NCT00630266|left ventricular dilation
518161|NCT00630266|mitral valve repair
518162|NCT00630266|mitral valve replacement
518163|NCT00630253|Fanconi anemia
518164|NCT00630240|epirubicin
518165|NCT00630240|mitomycin C
518166|NCT00630240|cisplatin
518167|NCT00630240|Hepatocellular carcinoma
518168|NCT00630227|emphysema
518169|NCT00630227|chronic obstructive pulmonary disease
518170|NCT00630227|lung volume reduction
518171|NCT00630214|Total thyroidectomy
518172|NCT00630214|CND
518173|NCT00630214|hypocalcemia
518174|NCT00630214|calcium
518175|NCT00630214|vitamin D
518176|NCT00630201|opioid dependence
518177|NCT00630201|opioid addiction
518178|NCT00630201|buprenorphine
518179|NCT00630201|methadone
518180|NCT00630201|heroin
518181|NCT00630201|implant
518182|NCT00630201|opioid withdrawal
518183|NCT00630201|opioid pain medication
518184|NCT00630201|suboxone
518185|NCT00630188|prostate cancer screening
518186|NCT00630188|shared decision making
518187|NCT00630188|prostate-specific antigen
518188|NCT00630188|decision making
518189|NCT00630188|physician-patient relations
518190|NCT00630175|Insomnia
518191|NCT00630162|protozoa
518192|NCT00630162|Amoeba
518193|NCT00630149|Nasopharyngeal Neoplasms
518194|NCT00630149|Pemetrexed
518195|NCT00630110|Non Small Cell Lung
518196|NCT00630097|methamphetamine addiction, meth dependence
518197|NCT00630084|chronic hepatitis C
518198|NCT00630084|sustained virological response
518199|NCT00630084|peginterferon
518200|NCT00630084|ribavirin
518201|NCT00630084|neoplasms
518202|NCT00630071|Diagnostic Appendicitis
518203|NCT00630071|Procalcitonin
518204|NCT00630058|Chronic Hepatitis C
518205|NCT00630058|Protease Inhibitor
518206|NCT00630058|Telaprevir
518207|NCT00630032|stage II breast cancer
518208|NCT00630032|stage IIIA breast cancer
518209|NCT00630032|stage IIIB breast cancer
518210|NCT00630032|stage IIIC breast cancer
518211|NCT00630019|Aqueous humor penetration by anti-infectives
518212|NCT00629993|cervical cancer screening
518213|NCT00629993|medically underserved women
518214|NCT00629993|HPV vaccine
518215|NCT00629967|chronic hepatitis C
518216|NCT00629967|genotype 1
518217|NCT00629967|rapid virological response
518218|NCT00629967|sustained virological response
518219|NCT00629967|peginterferon
518220|NCT00629967|ribavirin
518221|NCT00629967|treatment duration
518222|NCT00629954|ABUJA HEART STUDY NIGERIA
518223|NCT00629954|CARDIOVASCULAR DISEASES
518224|NCT00629928|NSAID, Nexium, esomeprazole, Gastric Ulcers
518225|NCT00629915|Moyamoya
518226|NCT00629915|stroke
518227|NCT00629902|Heart valve prosthesis
518228|NCT00629889|seizure
518229|NCT00629889|adult anaplastic astrocytoma
518230|NCT00629889|adult diffuse astrocytoma
518231|NCT00629889|adult pineal gland astrocytoma
518232|NCT00629889|adult glioblastoma
518233|NCT00629889|adult gliosarcoma
518234|NCT00629889|adult giant cell glioblastoma
518235|NCT00629889|adult brain stem glioma
518236|NCT00629889|adult ependymoblastoma
518237|NCT00629889|adult medulloblastoma
518238|NCT00629889|adult supratentorial primitive neuroectodermal tumor (PNET)
518239|NCT00629889|adult ependymoma
518240|NCT00629889|adult anaplastic ependymoma
518241|NCT00629889|adult anaplastic meningioma
518242|NCT00629889|adult anaplastic oligodendroglioma
518243|NCT00629889|adult oligodendroglioma
518244|NCT00629889|adult pineoblastoma
518245|NCT00629889|adult pineocytoma
518246|NCT00629889|adult mixed glioma
518247|NCT00629889|adult papillary meningioma
518248|NCT00629889|recurrent adult brain tumor
518249|NCT00629889|adult grade II meningioma
518250|NCT00629876|Chemotherapy
518251|NCT00629876|Drug Therapy
518252|NCT00629863|stage I gastric cancer
518253|NCT00629863|stage II gastric cancer
518254|NCT00629863|stage III gastric cancer
518255|NCT00629863|stage I esophageal cancer
518256|NCT00629863|stage II esophageal cancer
518257|NCT00629863|stage III esophageal cancer
518258|NCT00629850|spinal cord injury
518259|NCT00629850|respiratory muscle training
518260|NCT00629850|sleep quality
518261|NCT00629837|FVIII
518262|NCT00629837|Long acting
518263|NCT00629837|pk
518264|NCT00629824|chronic hepatitis C
518265|NCT00629824|sustained virological response
518266|NCT00629824|rapid virological response
518267|NCT00629824|peginterferon
518268|NCT00629824|ribavirin
518269|NCT00629824|old age
518270|NCT00629811|Cicatrix
518271|NCT00629811|Scar
518272|NCT00629811|TGFβ3
518273|NCT00629811|Avotermin
518274|NCT00629811|Juvista
518275|NCT00629811|RN1001
518276|NCT00629798|Busulfan
518277|NCT00629798|Melphalan
518278|NCT00629798|Fludarabine
518279|NCT00629798|08-008
518280|NCT00629785|asthma
518281|NCT00629785|pulmonary function tests
518282|NCT00629785|obesity
518283|NCT00629772|Palmoplantar psoriasis
518284|NCT00629772|Infliximab
518285|NCT00629759|Jennerex
518286|NCT00629759|unresectable liver tumors
518287|NCT00629759|primary liver cancer
518288|NCT00629759|metastatic liver cancer
518289|NCT00629759|oncolytic virus
518290|NCT00629759|vaccinia virus
518291|NCT00629759|Pexa-Vec
518292|NCT00629746|Thyroid
518293|NCT00629746|RLN
518294|NCT00629746|EMG
518295|NCT00629733|pharmacokinetics
518296|NCT00629733|ultra low molecular weight heparin
518297|NCT00629720|elevated detrusor leak point pressure
518298|NCT00629707|diabetic ketoacidosis
518299|NCT00629707|DKA
518300|NCT00629707|cerebral edema
518301|NCT00629707|brain edema
518302|NCT00629694|adenoidectomy, myringotomy, tubes insertion, otitis media, adenoid hyperthophy
518303|NCT00629655|fMRI
518304|NCT00629655|spinal cord
518305|NCT00629655|human
518306|NCT00629655|health
518307|NCT00629655|cerebral infarction
518308|NCT00629655|healthy
518309|NCT00629642|Neurogenic bladder
518310|NCT00629642|Vesicare
518311|NCT00629629|Health Plan Implementation
518312|NCT00629629|Feeding and Eating Disorders of Childhood
518313|NCT00629629|Breastfeeding
518314|NCT00629629|Complementary feeding
518315|NCT00629629|Morbidity
518316|NCT00629629|Anemia
518317|NCT00629629|Public policy
518318|NCT00629616|stage II breast cancer
518319|NCT00629616|stage IIIA breast cancer
518320|NCT00629616|stage IIIB breast cancer
518321|NCT00629616|stage IIIC breast cancer
518322|NCT00629603|hepatitis C virus infection
518323|NCT00629603|chronic liver disease
518324|NCT00629603|fibrosis-related cytokine
518325|NCT00629577|cervical cancer
518326|NCT00629577|cervical intraepithelial neoplasia grade 1
518327|NCT00629577|cervical intraepithelial neoplasia grade 2
518328|NCT00629577|cervical intraepithelial neoplasia grade 3
518329|NCT00629564|Gastroesophageal Reflux Disease (GERD), esomeprazole, Nexium
518330|NCT00629551|Major Depressive Disorder
518331|NCT00629551|Depression
518332|NCT00629551|Major Depressive Episode
518333|NCT00629551|Antidepressant
518334|NCT00629538|congestive heart failure
518335|NCT00629538|thoracentesis
518336|NCT00629538|transudative pleural effusions
518337|NCT00629512|NSAID, Nexium, esomeprazole, Gastric Ulcers
518338|NCT00629499|Early Stage Breast Cancer
518339|NCT00629499|Her2-positive
518340|NCT00629499|nab paclitaxel
518341|NCT00629499|cyclophosphamide
518342|NCT00629499|trastuzumab
518343|NCT00629486|cytokine gene
518344|NCT00629486|hepatitis B
518345|NCT00629486|hepatocellular carcinoma
518346|NCT00629486|chronic liver disease
518347|NCT00629473|multiple myeloma
518348|NCT00629473|leukemias (inc. CLL)
518349|NCT00629473|lymphomas
518350|NCT00629473|cutaneous lymphoma
518351|NCT00629473|marginal zone lymphoma
518352|NCT00629473|advanced malignancies without standard treatment options
518353|NCT00629460|Pulmonary Nodules
518354|NCT00629447|Primary Brain Tumor
518355|NCT00629447|Venous Thromboembolism
518356|NCT00629447|Heparin
518357|NCT00629434|Diabetes Education
518358|NCT00629434|Telemedicine
518359|NCT00629395|pediatric
518360|NCT00629395|brain tumor
518361|NCT00629395|survivors
518362|NCT00629382|abdominal sepsis
518363|NCT00629382|abdominal surgery
518364|NCT00629382|septic shock
518365|NCT00629382|polymyxin B
518366|NCT00629382|hemoperfusion
518367|NCT00629382|Endotoxins
518368|NCT00629343|Soft Tissue Sarcoma
518369|NCT00629343|Mesothelioma
518370|NCT00629343|Azacitidine
518371|NCT00629343|Temozolomide
518372|NCT00629343|Temodar
518373|NCT00629330|prostate cancer
518374|NCT00629330|prostate cancer screening
518375|NCT00629330|prostate specific antigen
518376|NCT00629330|African American males
518377|NCT00629317|Skin Aging
518378|NCT00629317|Rejuvenation
518379|NCT00629317|Photodynamic Therapy
518380|NCT00629317|Methyl Aminolevulinate
518381|NCT00629304|type 1 diabetes
518382|NCT00629304|PDA phone (Personal Digital Assistant)
518383|NCT00629304|HbA1c
518384|NCT00629291|iron overload
518385|NCT00629291|Thalassemia
518386|NCT00629291|Anemia, Sickle Cell
518387|NCT00629291|Magnetic Resonance Imaging
518388|NCT00629278|stage IA breast cancer
518389|NCT00629278|stage IB breast cancer
518390|NCT00629278|stage II breast cancer
518391|NCT00629278|stage IIIA breast cancer
518392|NCT00629278|HER2-positive breast cancer
518393|NCT00629265|Dysphagia
518394|NCT00629265|Neuromuscular Electrical Stimulation (NMES)
518395|NCT00629265|Head & Neck Cancer
518396|NCT00629265|Radiation and ChemoTherapy
518397|NCT00629252|Schizophrenia
518398|NCT00629252|PPI
518399|NCT00629252|P50
518400|NCT00629252|CANTAB
518401|NCT00629252|sensory gating
518402|NCT00629252|Schizophrenic patients according to DSM-IV
518403|NCT00629239|COPD
518404|NCT00629239|tolerability
518405|NCT00629239|inhalation
518406|NCT00629226|stage IV squamous cell carcinoma of the hypopharynx
518407|NCT00629226|stage IV squamous cell carcinoma of the larynx
518408|NCT00629226|stage IV squamous cell carcinoma of the lip and oral cavity
518409|NCT00629226|stage IV squamous cell carcinoma of the oropharynx
518410|NCT00629226|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
518411|NCT00629226|recurrent squamous cell carcinoma of the hypopharynx
518412|NCT00629226|recurrent squamous cell carcinoma of the larynx
518413|NCT00629226|recurrent squamous cell carcinoma of the lip and oral cavity
518414|NCT00629226|recurrent squamous cell carcinoma of the nasopharynx
518415|NCT00629226|recurrent squamous cell carcinoma of the oropharynx
518416|NCT00629226|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
518417|NCT00629213|prevention,
518418|NCT00629213|type 2 diabetes,
518419|NCT00629213|metabolic syndrome,
518420|NCT00629213|acarbose treatment
518421|NCT00629200|Advanced Malignancies
518422|NCT00629200|Solid Tumors
518423|NCT00629200|Melanoma
518424|NCT00629200|Renal Cell Carcinoma
518425|NCT00629200|Phase I Studies
518426|NCT00629200|Sodium Stibogluconate
518427|NCT00629200|Interferon Alpha-2b
518428|NCT00629200|Intron A
518429|NCT00629200|SSG
518430|NCT00629187|Lung Neoplasm
518431|NCT00629187|Breast Neoplasm
518432|NCT00629187|Melanoma
518433|NCT00629187|Central Nervous System Neoplasms
518434|NCT00629187|Neoplasm Metastasis
518435|NCT00629187|Neoplasm Second Primary
518436|NCT00629187|Peripheral Blood Stem Cell Transplantation
518437|NCT00629174|Cognitive function
518438|NCT00629174|Elderly
518439|NCT00629174|Exercise
518440|NCT00629174|Mental activity
518441|NCT00629148|metastasis
518442|NCT00629148|chemotherapy
518443|NCT00629148|breast cancer
518444|NCT00629148|Vinorelbine
518445|NCT00629148|Capecitabine
518446|NCT00629148|sequential chemotherapy
518447|NCT00629148|TTF
518448|NCT00629135|abscess
518449|NCT00629135|intraabdominal abscess
518450|NCT00629135|Moxifloxacine
518451|NCT00629135|Moxifloxacin
518452|NCT00629135|Metronidazole
518453|NCT00629135|Tazobactam
518454|NCT00629135|Piperacilline
518455|NCT00629135|Piperacillin
518456|NCT00629135|Tazobac
518457|NCT00629122|Kidney Transplantation
518458|NCT00629122|Tacrolimus (Prograf)
518459|NCT00629122|Pharmacokinetics
518460|NCT00629122|Sublingual administration
518461|NCT00629122|Drug interactions (Cytochrome P450 and p-glycoprotein)
518462|NCT00629096|Dilated Cardiomyopathy
518463|NCT00629096|Marrow stem cells
518464|NCT00629096|Myocardial regeneration
518465|NCT00629096|Mesenchymal stem cells
518466|NCT00629096|Marrow-derived endothelial progenitor cells
518467|NCT00629083|SUI
518468|NCT00629083|Bulkamid
518469|NCT00629083|Urinary Incontinence
518470|NCT00629070|cerebral palsy
518471|NCT00629070|muscle strength
518472|NCT00629070|muscle architecture
518473|NCT00629070|ultrasound
518474|NCT00629070|rehabilitation
518475|NCT00629070|rectus femoris
518476|NCT00629070|quadriceps muscle
518477|NCT00629057|androgen-insensitive, non-metastatic, prostate, cancer
518478|NCT00629031|Visceral leishmaniasis
518479|NCT00629031|Paromomycin
518480|NCT00629018|Stem Cells
518481|NCT00629018|Heart Failure
518482|NCT00629018|Dilated Cardiomyopathy
518483|NCT00629005|rehabilitation
518484|NCT00629005|upper extremity
518485|NCT00629005|motor skills
518486|NCT00628992|COPD: chronic obstructive pulmonary disease and acute respiratory failure
518487|NCT00628953|Asthma
518488|NCT00628953|Acid Reflux
518489|NCT00628953|Nexium
518490|NCT00628953|Esomeprazole
518491|NCT00628914|Major Depressive Disorder
518492|NCT00628914|Insomnia
518493|NCT00628914|Escitalopram
518494|NCT00628914|Lexapro
518495|NCT00628914|Eszopiclone
518496|NCT00628914|Lunesta
518497|NCT00628914|Cordance
518498|NCT00628901|Leiomyoma
518499|NCT00628901|Uterine Fibroids
518500|NCT00628901|Uterine Fibroid Embolization (UFE)
518501|NCT00628901|Uterine Artery Embolization (UAE)
518502|NCT00628901|Uterine Neoplasms
518503|NCT00628901|Menorrhagia
518504|NCT00628888|Unipolar Depression
518505|NCT00628888|Anxiety
518506|NCT00628888|Adolescent
518507|NCT00628888|Emotion
518508|NCT00628888|Cognitive Behavioral
518509|NCT00628875|mechanical ventilation
518510|NCT00628875|thoracic impedence
518511|NCT00628875|defibrillator pads
518512|NCT00628875|ventilation detection
518513|NCT00628875|pediatric ventilation
518514|NCT00628862|Chronic Obstructive Pulmonary Disease
518515|NCT00628862|COPD
518516|NCT00628849|Mandible
518517|NCT00628849|fracture
518518|NCT00628849|Champy
518519|NCT00628849|AO technique
518520|NCT00628836|Neuromuscular stimulator
518521|NCT00628836|Shoulder subluxation
518522|NCT00628823|Celiac Disease
518523|NCT00628823|Endomysial antibodies
518524|NCT00628823|Mild enteropathy
518525|NCT00628823|Treatment
518526|NCT00628823|Gluten-free diet
518527|NCT00628810|adenocarcinoma of the colon
518528|NCT00628810|adenocarcinoma of the rectum
518529|NCT00628810|stage IV colon cancer
518530|NCT00628810|stage IV rectal cancer
518531|NCT00628810|recurrent colon cancer
518532|NCT00628810|recurrent rectal cancer
518533|NCT00628797|systemic sclerosis
518534|NCT00628797|skin fibrosis
518535|NCT00628784|Dysplasia
518536|NCT00628784|Ablation
518537|NCT00628784|Squamous dysplasia
518538|NCT00628784|Early esophageal adenocarcinoma
518539|NCT00628784|Cryotherapy
518540|NCT00628771|HIV Prevention
518541|NCT00628771|Teen Pregnancy
518542|NCT00628771|Translational Research
518543|NCT00628771|Group Care
518544|NCT00628771|Prenatal Care
518545|NCT00628771|STD Prevention
518546|NCT00628771|Gonorrhea
518547|NCT00628771|Chlamydia
518548|NCT00628771|Adolescent Health
518549|NCT00628771|Community Health Centers
518550|NCT00628771|CenteringPregnancy Plus
518551|NCT00628771|HIV seronegativity
518552|NCT00628758|Symbicort
518553|NCT00628758|Turbuhaler
518554|NCT00628758|Persistent Asthma
518555|NCT00628745|TRANSTHYRETIN
518556|NCT00628745|AMYLOIDOSIS
518557|NCT00628745|TRANSTHYRETIN AMYLOIDOSIS
518558|NCT00628732|Cyclophosphamide
518559|NCT00628732|Topotecan
518560|NCT00628732|Phase II
518561|NCT00628732|Children
518562|NCT00628732|Relapsed solid tumors
518563|NCT00628719|Visceral leishmaniasis
518564|NCT00628719|India
518565|NCT00628719|Liposomal Amphotericin B
518566|NCT00628719|Amphotericin B deoxycholate
518567|NCT00628706|tetrahydrocannabinol
518568|NCT00628706|memory
518569|NCT00628706|reward
518570|NCT00628706|magnetic resonance imaging
518571|NCT00628706|endocannabinoids
518572|NCT00628693|CPR
518573|NCT00628680|Renal Disease
518574|NCT00628680|Kidney Failure
518575|NCT00628680|End Stage Renal Disease
518576|NCT00628667|Chronic Posterior Laryngitis
518577|NCT00628667|CPL
518578|NCT00628667|Pharyngeal acid reflux
518579|NCT00628667|Esomeprazole
518580|NCT00628667|Nexium
518581|NCT00628654|ovarian germ cell tumor
518582|NCT00628654|ovarian epithelial cancer
518583|NCT00628628|Tumor Lysis Syndrome
518584|NCT00628628|TLS
518585|NCT00628628|hyperuricemia
518586|NCT00628628|Leukemia
518587|NCT00628628|Lymphoma
518588|NCT00628628|Acute myeloid leukemia
518589|NCT00628628|Chronic myelocytic leukemia
518590|NCT00628628|CML
518591|NCT00628628|lactate dehydrogenase
518592|NCT00628628|LDH
518593|NCT00628628|Myelodysplastic Syndrome
518594|NCT00628628|Rasburicase
518595|NCT00628628|Elitek™
518596|NCT00628615|Urodynamics
518597|NCT00628615|Overactive bladder syndrome
518598|NCT00628615|Lower urinary tract symptoms LUTS
518599|NCT00628602|Neuromuscular stimulator
518600|NCT00628602|Pressure ulcer prevention
518601|NCT00628589|schizophrenia, agitation, acute, treatment
518602|NCT00628576|Deep Venous Thrombosis
518603|NCT00628576|lower extremities
518604|NCT00628576|Chronic Venous Insufficiency
518605|NCT00628576|Postthrombotic Syndrome
518606|NCT00628576|Heparins
518607|NCT00628576|Low-molecular- weight heparin
518608|NCT00628576|Tinzaparin
518609|NCT00628550|cardiac arrest
518610|NCT00628550|cardiopulmonary arrest
518611|NCT00628550|vasopressin
518612|NCT00628550|epinephrine
518613|NCT00628550|pediatrics
518614|NCT00628550|in hospital cardiopulmonary resuscitation
518615|NCT00628537|Neuromuscular stimulator
518616|NCT00628537|Flexor deformities of wrist and fingers
518617|NCT00628498|VOD
518618|NCT00628485|swallowing function
518619|NCT00628485|neuromuscular stimulator
518620|NCT00628472|botulinum toxin a
518621|NCT00628472|botox
518622|NCT00628472|Decreasing botox injection pain
518623|NCT00628472|injections
518624|NCT00628459|iron
518625|NCT00628459|multiple micronutrient
518626|NCT00628459|malaria
518627|NCT00628459|anemia
518628|NCT00628459|preschool children
518629|NCT00628446|spinal cord injury
518630|NCT00628446|Coronary artery calcium
518631|NCT00628446|Dyslipidemia
518632|NCT00628433|phase I/II
518633|NCT00628433|ulcerative colitis
518634|NCT00628433|safety
518635|NCT00628433|tolerance
518636|NCT00628433|pharmacokinetics
518637|NCT00628420|Schizophrenia
518638|NCT00628420|N-desmethylclozapine
518639|NCT00628420|clozapine
518640|NCT00628420|psychosis
518641|NCT00628420|randomized
518642|NCT00628420|placebo studies
518643|NCT00628407|leaning
518644|NCT00628407|CPR
518645|NCT00628407|sternal pressure
518646|NCT00628407|incomplete release
518647|NCT00628407|chest compressions
518648|NCT00628407|pediatric
518649|NCT00628394|Cognition
518650|NCT00628394|schizophrenia
518651|NCT00628394|Atomoxetine
518652|NCT00628394|Strattera
518653|NCT00628394|cognitive remediation
518654|NCT00628381|sepsis
518655|NCT00628381|microcirculation
518656|NCT00628381|nitric oxide
518657|NCT00628381|citrulline
518658|NCT00628368|adenocarcinoma of the esophagus
518659|NCT00628368|squamous cell carcinoma of the esophagus
518660|NCT00628368|adenocarcinoma of the rectum
518661|NCT00628368|recurrent rectal cancer
518662|NCT00628368|stage I rectal cancer
518663|NCT00628368|stage II rectal cancer
518664|NCT00628368|stage III rectal cancer
518665|NCT00628368|stage IV rectal cancer
518666|NCT00628368|recurrent esophageal cancer
518667|NCT00628368|stage I esophageal cancer
518668|NCT00628368|stage II esophageal cancer
518669|NCT00628368|stage III esophageal cancer
518670|NCT00628368|stage IV esophageal cancer
518671|NCT00628355|lidocaine
518672|NCT00628355|ischemic compression
518673|NCT00628355|chronic pelvic pain
518674|NCT00628355|myofascial pain syndrome
518675|NCT00628342|Gastroesophageal Reflux Disease
518676|NCT00628342|GERD
518677|NCT00628342|Esomeprazole
518678|NCT00628342|Heartburn
518679|NCT00628342|Nexium
518680|NCT00628329|asthma, retinol, cis-retinoic acid
518681|NCT00628316|tinnitus
518682|NCT00628316|caffeine
518683|NCT00628303|Good health
518684|NCT00628277|Obesity
518685|NCT00628277|coronary heart disease
518686|NCT00628277|coronary risk factors
518687|NCT00628277|weight loss
518688|NCT00628277|exercise
518689|NCT00628264|cardiac surgery
518690|NCT00628264|coronary artery bypass grafting
518691|NCT00628264|valve surgery
518692|NCT00628264|acute kidney injury
518693|NCT00628251|Advanced ovarian cancer
518694|NCT00628251|BRCA1 protein
518695|NCT00628251|BRCA2 protein
518696|NCT00628251|Poly(ADP ribose) polymerases
518697|NCT00628238|Chronic Lymphocytic Leukemia Research Consortium
518698|NCT00628238|Chronic lymphocytic leukemia
518699|NCT00628238|CLL
518700|NCT00628238|CLL Research Consortium
518701|NCT00628238|CRC
518702|NCT00628238|Revlimid
518703|NCT00628238|lenalidomide
518704|NCT00628238|Rituximab
518705|NCT00628238|Rituxan
518706|NCT00628238|First-line
518707|NCT00628238|therapy
518708|NCT00628238|untreated
518709|NCT00628238|Frontline
518710|NCT00628225|Smoking cessation
518711|NCT00628212|insulin resistance
518712|NCT00628186|pancreaticoduodenectomy
518713|NCT00628186|stent
518714|NCT00628186|pancreaticojejunostomy
518715|NCT00628186|hospital stay
518716|NCT00628186|complication
518717|NCT00628186|pancreatic fistula
518718|NCT00628160|Septic shock
518719|NCT00628160|Cirrhosis
518720|NCT00628160|Survival
518721|NCT00628147|colonic neoplasms
518722|NCT00628147|colonoscopy
518723|NCT00628147|narrow band imaging
518724|NCT00628147|diagnostic techniques
518725|NCT00628134|cystic fibrosis
518726|NCT00628134|surfactant
518727|NCT00628134|aerosol
518728|NCT00628134|inhaled drug
518729|NCT00628134|inhaled antibiotic
518730|NCT00628121|infertility, menstrual cycle, LH surge
518731|NCT00628108|Xyzal
518732|NCT00628108|Levocetirizine
518733|NCT00628108|Allergy
518734|NCT00628108|Children
518735|NCT00628108|Seasonal Allergies
518736|NCT00628095|rheumatoid arthritis DMARD methotrexate
518737|NCT00628082|Cardiac Energetics
518738|NCT00628082|Dynamic Diastolic filling Assessment
518739|NCT00628082|Heart Failure with Preserved Ejection Fraction
518740|NCT00628082|Arterial and Ventricular Stiffening
518741|NCT00628069|Orthopedics
518742|NCT00628069|bone fixation
518743|NCT00628056|Perhexiline
518744|NCT00628056|diabetes
518745|NCT00628056|diabetic cardiomyopathy
518746|NCT00628056|high energy phosphate kinetics
518747|NCT00628056|magnetic resonance spectroscopy
518748|NCT00628043|Cancer
518749|NCT00628043|patients
518750|NCT00628043|with
518751|NCT00628043|chemotherapy
518752|NCT00628043|induced
518753|NCT00628043|anemia
518754|NCT00628030|Behavioral intervention
518755|NCT00628030|Obesity prevention
518756|NCT00628017|polyunsaturated fatty acids
518757|NCT00628017|Alzheimer's disease
518758|NCT00628017|mild cognitive impairment
518759|NCT00628017|fish oil
518760|NCT00628017|cognition
518761|NCT00627978|breast
518762|NCT00627965|Sildenafil citrate
518763|NCT00627965|Prevention
518764|NCT00627965|High Altitude Pulmonary Edema
518765|NCT00627965|Acute Mountain Sickness
518766|NCT00627965|Healthy Lowland Subjects
518767|NCT00627965|Pulmonary Artery Systolic Pressure
518768|NCT00627952|hypertension
518769|NCT00627952|intraglomerular pressure
518770|NCT00627926|Genotype 1
518771|NCT00627913|Floppy Iris Syndrome
518772|NCT00627900|drug-eluting stents
518773|NCT00627887|Depressive Disorder, Major
518774|NCT00627887|Electroconvulsive Therapy
518775|NCT00627887|Lithium Carbonate
518776|NCT00627887|venlafaxine
518777|NCT00627848|Alzheimer's disease
518778|NCT00627848|fmri
518779|NCT00627848|face recognition
518780|NCT00627848|rivastigmine
518781|NCT00627835|squamous cell carcinoma
518782|NCT00627835|head and neck
518783|NCT00627835|Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation
518784|NCT00627822|Medical students
518785|NCT00627822|Medical education
518786|NCT00627822|Private hospital
518787|NCT00627822|Patient satisfaction
518788|NCT00627822|Questionnaires
518789|NCT00627809|coronary microcirculation
518790|NCT00627809|acut myocardial infarction
518791|NCT00627809|infarct size
518792|NCT00627809|streptokinase
518793|NCT00627809|reperfusion
518794|NCT00627796|GH
518795|NCT00627796|IGF-I
518796|NCT00627796|tumor
518797|NCT00627796|lanreotide
518798|NCT00627770|Physical Therapy - Therapeutics - Edema
518799|NCT00627770|Arthroplasty replacement knee
518800|NCT00627770|Treatment outcome
518801|NCT00627757|metabolic syndrome
518802|NCT00627757|weight gain
518803|NCT00627757|antipsychotic drugs
518804|NCT00627757|Metabolic syndrome and treatment with antipsychotic drugs
518805|NCT00627744|Type 2 diabetes, IGT, Myocardial infarction, Incretins
518806|NCT00627731|Asthma Patients
518807|NCT00627718|Age-related macular degeneration
518808|NCT00627718|HRT
518809|NCT00627718|Macular edema
518810|NCT00627718|Screening for disease
518811|NCT00627692|Constipation in elderly patients
518812|NCT00627679|Pediatric asthma
518813|NCT00627666|adult acute lymphoblastic leukemia in remission
518814|NCT00627666|recurrent adult acute lymphoblastic leukemia
518815|NCT00627666|untreated adult acute lymphoblastic leukemia
518816|NCT00627666|adult acute myeloid leukemia in remission
518817|NCT00627666|recurrent adult acute myeloid leukemia
518818|NCT00627666|untreated adult acute myeloid leukemia
518819|NCT00627666|acute lymphocytic leukemia
518820|NCT00627666|secondary acute myeloid leukemia
518821|NCT00627666|acute undifferentiated leukemia
518822|NCT00627666|mast cell leukemia
518823|NCT00627666|accelerated phase chronic myelogenous leukemia
518824|NCT00627666|blastic phase chronic myelogenous leukemia
518825|NCT00627666|chronic phase chronic myelogenous leukemia
518826|NCT00627666|meningeal chronic myelogenous leukemia
518827|NCT00627666|relapsing chronic myelogenous leukemia
518828|NCT00627666|chronic myelomonocytic leukemia
518829|NCT00627666|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
518830|NCT00627666|adult acute myeloid leukemia with inv(16)(p13;q22)
518831|NCT00627666|adult acute myeloid leukemia with t(15;17)(q22;q12)
518832|NCT00627666|adult acute myeloid leukemia with t(16;16)(p13;q22)
518833|NCT00627666|adult acute myeloid leukemia with t(8;21)(q22;q22)
518834|NCT00627666|de novo myelodysplastic syndromes
518835|NCT00627666|previously treated myelodysplastic syndromes
518836|NCT00627666|secondary myelodysplastic syndromes
518837|NCT00627666|atypical chronic myeloid leukemia, BCR-ABL1 negative
518838|NCT00627666|myelodysplastic/myeloproliferative neoplasm, unclassifiable
518839|NCT00627666|refractory anemia with excess blasts in transformation
518840|NCT00627666|refractory anemia with excess blasts
518841|NCT00627653|PPAR
518842|NCT00627653|PET study
518843|NCT00627653|heart metabolism
518844|NCT00627614|stage I breast cancer
518845|NCT00627614|stage II breast cancer
518846|NCT00627614|stage IIIA breast cancer
518847|NCT00627614|stage IIIB breast cancer
518848|NCT00627614|stage IIIC breast cancer
518849|NCT00627614|stage IV breast cancer
518850|NCT00627588|ProSavin
518851|NCT00627588|Parkinson's Disease
518852|NCT00627588|Gene Therapy
518853|NCT00627575|drug interaction
518854|NCT00627575|pharmacokinetics
518855|NCT00627575|healthy volunteers
518856|NCT00627562|robotic
518857|NCT00627562|robot assisted
518858|NCT00627562|minimally invasive
518859|NCT00627562|tumors of head and neck
518860|NCT00627549|cystocele, anterior repair, mesh
518861|NCT00627536|scarring, Juvista, avotermin, transforming growth factor beta 3, TGFB3
518862|NCT00627510|Therapeutic Drug Monitoring (TDM)
518863|NCT00627510|Antidepressant
518864|NCT00627510|Antipsychotic
518865|NCT00627510|Treatment adherence
518866|NCT00627510|Compliance
518867|NCT00627510|Metabolism
518868|NCT00627510|Do patients take their psychiatric medication as prescribed?
518869|NCT00627510|Do psychiatric patients metabolize their medication faster than expected?
518870|NCT00627510|What are the exact odds that the patient of a physician prescribing antidepressants or antipsychotics has plasma levels that are BELOW those intended?
518871|NCT00627484|Insulin resistance
518872|NCT00627484|Insulin sensitivity
518873|NCT00627484|bariatric surgery
518874|NCT00627484|diabetes
518875|NCT00627484|calorie restriction
518876|NCT00627484|body composition
518877|NCT00627458|Hexavalent vaccine
518878|NCT00627458|Booster
518879|NCT00627432|stage III bladder cancer
518880|NCT00627432|stage IV bladder cancer
518881|NCT00627432|transitional cell carcinoma of the bladder
518882|NCT00627406|GnRH antagonist
518883|NCT00627406|GnRH agonist
518884|NCT00627406|hCG
518885|NCT00627406|OHSS
518886|NCT00627406|In vitro fertilization
518887|NCT00627406|ovulation induction
518888|NCT00627406|Clinical pregnancy rate
518889|NCT00627393|Granulocyte Transfusions
518890|NCT00627380|HIV
518891|NCT00627380|AIDS
518892|NCT00627380|insulin resistance
518893|NCT00627380|diabetes
518894|NCT00627380|dyslipidemia
518895|NCT00627380|visceral adiposity
518896|NCT00627380|subcutaneous adipose wasting
518897|NCT00627380|cardiovascular disease
518898|NCT00627380|hypertension
518899|NCT00627380|endothelial function
518900|NCT00627380|quality of life
518901|NCT00627380|Complementary Therapies
518902|NCT00627367|Acute Pain Emergency Department ED Hydromorphone Dilaudid Protocolized Nonprotocolized Usual Care
518903|NCT00627354|stage IV prostate cancer
518904|NCT00627354|recurrent prostate cancer
518905|NCT00627354|adenocarcinoma of the prostate
518906|NCT00627341|Exposure Therapy
518907|NCT00627341|Relapse Prevention
518908|NCT00627341|Anorexia Nervosa
518909|NCT00627328|Physiologic Pacing
518910|NCT00627328|Dual Chamber Pacing
518911|NCT00627328|Atrioventricular Block
518912|NCT00627328|Bradycardia
518913|NCT00627328|Sick Sinus Syndrome
518914|NCT00627315|Obesity
518915|NCT00627315|Insulin Resistance
518916|NCT00627315|Bariatric Surgery
518917|NCT00627315|Gastric Banding
518918|NCT00627315|Gastric Bypass
518919|NCT00627302|Quality of Vision
518920|NCT00627289|Chronic pain
518921|NCT00627289|groin hernia
518922|NCT00627289|neuropathic pain
518923|NCT00627289|chronic postoperative pain
518924|NCT00627289|Postherniotomy pain
518925|NCT00627289|Neuroplastic changes
518926|NCT00627276|ductal breast carcinoma in situ
518927|NCT00627276|atypical ductal breast hyperplasia
518928|NCT00627263|ICD
518929|NCT00627263|Cardiac Arrhythmia
518930|NCT00627263|Arrhythmia
518931|NCT00627263|Stress
518932|NCT00627263|Anger
518933|NCT00627250|Irritability
518934|NCT00627250|Aggression
518935|NCT00627250|Brain Injury
518936|NCT00627250|Amantadine
518937|NCT00627250|Irritability and Aggression Due to Traumatic Brain Injury
518938|NCT00627237|Brain Injuries
518939|NCT00627237|Cognitive Rehabilitation
518940|NCT00627237|Executive Functioning
518941|NCT00627211|quality assessment
518942|NCT00627211|pain reduction
518943|NCT00627211|gastroscopy
518944|NCT00627211|carbondioxide insufflation
518945|NCT00627211|Patient satisfaction
518946|NCT00627198|Metastatic; neuroendocrine tumor; clinical trial
518947|NCT00627185|Tobacco control
518948|NCT00627185|Tobacco cessation
518949|NCT00627185|Tobacco use
518950|NCT00627172|Coronary artery disease
518951|NCT00627172|MDCT
518952|NCT00627172|Positron emission tomography
518953|NCT00627172|Ultrasound
518954|NCT00627159|community-based
518955|NCT00627159|culturally-sensitive
518956|NCT00627159|high risk assessment
518957|NCT00627159|education classes
518958|NCT00627159|cardiovascular risk profile
518959|NCT00627159|Indo-Asian population
518960|NCT00627146|Diabetes Mellitus, type 1
518961|NCT00627146|ChAgly CD3
518962|NCT00627133|Alcohol seizure
518963|NCT00627120|healthy volunteers
518964|NCT00627107|ReWalk, Paraplegia, SCI
518965|NCT00627068|cardiovascular
518966|NCT00627068|vasodilation
518967|NCT00627068|endothelium
518968|NCT00627068|Subjects with high cardiovascular risk
518969|NCT00627055|Second line antiretroviral therapy
518970|NCT00627055|HIV genotypic resistance
518971|NCT00627055|Kaletra monotherapy
518972|NCT00627055|Thailand
518973|NCT00627055|48-week efficacy and safety between 2 NRTIs plus lopinavir/ritonavir (LPV/r) and LPV/r monotherapy in patients failing a standard NNRTI-based treatment regimen
518974|NCT00627055|treatment experienced
518975|NCT00627042|Liver disease
518976|NCT00627042|Neoplasms
518977|NCT00627042|Liver neoplasms
518978|NCT00627042|Carcinoma, Hepatocellular
518979|NCT00627029|Care coordination
518980|NCT00627029|Disease management
518981|NCT00627029|Medicare
518982|NCT00627029|Fee-for-service
518983|NCT00627029|Random assignment
518984|NCT00627029|Elderly
518985|NCT00627016|Non-Erosive Gastroesophageal Reflux Disease
518986|NCT00627016|GERD
518987|NCT00627016|heartburn
518988|NCT00627016|sleep disturbance
518989|NCT00627016|nocturnal Reflux
518990|NCT00626990|adult anaplastic oligodendroglioma
518991|NCT00626990|adult anaplastic astrocytoma
518992|NCT00626977|Analgesia
518993|NCT00626977|Obstetrical
518994|NCT00626977|Anesthesia
518995|NCT00626977|Epidural
518996|NCT00626977|Newborn
518997|NCT00626977|Anesthetics, local
518998|NCT00626977|Clonidine
518999|NCT00626977|Pregnant women
519000|NCT00626977|Infant, newborn
519001|NCT00626964|Arterial stiffness
519002|NCT00626964|PulseWave velocity
519003|NCT00626964|Body composition
519004|NCT00626964|Inbody
519005|NCT00626964|Morbidly Obese
519006|NCT00626964|APO A
519007|NCT00626964|APO B
519008|NCT00626964|Framingham risk score
519009|NCT00626964|Prevention of Coronary Heart Disease
519010|NCT00626964|Morbidly Obese Patients
519011|NCT00626964|Lifestyle Intervention
519012|NCT00626964|Bariatric Surgery
519013|NCT00626964|Low Energy Diet
519014|NCT00626951|LMA Supreme
519015|NCT00626951|LMA ProSeal
519016|NCT00626951|Laryngeal mask airway
519017|NCT00626951|Ventilation
519018|NCT00626938|sarcoidosis
519019|NCT00626938|protein profile
519020|NCT00626938|CYP-450
519021|NCT00626938|TNF-alpha polymorphisms
519022|NCT00626938|HLA
519023|NCT00626925|Randomized Trial
519024|NCT00626925|Medication for Heavy Drinking
519025|NCT00626925|Topiramate Treatment
519026|NCT00626912|large aneurysm
519027|NCT00626912|recurrence
519028|NCT00626912|hydrocoil
519029|NCT00626899|Validation of Cardiac Output measurement in hypothermic patients
519030|NCT00626886|Herniorrhaphy
519031|NCT00626886|Inguinal Hernia Repair
519032|NCT00626886|Postoperative pain
519033|NCT00626873|ovarian germ cell tumor
519034|NCT00626873|ovarian epithelial cancer
519035|NCT00626860|melanoma
519036|NCT00626847|primary open angle glaucoma
519037|NCT00626847|Nuclear Genetics
519038|NCT00626847|Mitochondrial DNA
519039|NCT00626847|POAG
519040|NCT00626834|cocaine addiction
519041|NCT00626834|vigabatrin
519042|NCT00626834|ovation pharmaceuticals
519043|NCT00626834|cocaine
519044|NCT00626834|cocaine related disorders
519045|NCT00626834|behavior addictive
519046|NCT00626834|mental disorders
519047|NCT00626834|therapeutic uses
519048|NCT00626834|physiologic effects of drugs
519049|NCT00626834|disorder of environmental origin
519050|NCT00626834|central nervous system stimulants
519051|NCT00626834|central nervous system agents
519052|NCT00626834|pharmacological actions
519053|NCT00626834|substance related disorders
519054|NCT00626821|Stoma
519055|NCT00626821|Ostomy
519056|NCT00626782|glaucoma
519057|NCT00626782|glucoma filtering surgery
519058|NCT00626782|ranibizumab
519059|NCT00626782|mitomycin C
519185|NCT00626249|Diabetic
519060|NCT00626782|patients requiring first time glaucoma filtering surgery
519061|NCT00626769|Genistein
519062|NCT00626769|Bone mineral density
519063|NCT00626769|digital mammography
519064|NCT00626769|safety
519065|NCT00626756|fluid
519066|NCT00626756|Lidco technology
519067|NCT00626756|guided therapy
519068|NCT00626756|fluid management guided by Lidco technology
519069|NCT00626730|adult grade II meningioma
519070|NCT00626730|adult grade III meningioma
519071|NCT00626717|Keratoconus
519072|NCT00626717|Cross linking
519073|NCT00626717|Riboflavin
519074|NCT00626704|Sarcoma
519075|NCT00626704|Soft Tissue Sarcoma
519076|NCT00626704|Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
519077|NCT00626704|AMG 655
519078|NCT00626704|STS
519079|NCT00626704|Doxorubicin
519080|NCT00626704|Death receptor
519081|NCT00626704|TRAIL receptor
519082|NCT00626704|Apoptosis
519083|NCT00626691|antioxidant
519084|NCT00626691|walnut
519085|NCT00626691|nutritional status
519086|NCT00626691|Antioxidant capacity
519087|NCT00626678|Pemphigus Vulgaris
519088|NCT00626678|Azathioprine
519089|NCT00626678|Prednisone
519090|NCT00626665|Raynaud disease
519091|NCT00626665|Scleroderma
519092|NCT00626639|palifermin
519093|NCT00626639|Clinical Trial
519094|NCT00626639|Oncology
519095|NCT00626639|Head & Neck
519096|NCT00626626|leukemia
519097|NCT00626626|myelodysplastic syndrome
519098|NCT00626626|chronic myelogenous leukemia
519099|NCT00626626|lymphoma
519100|NCT00626626|mantle cell lymphoma
519101|NCT00626600|Oxycodone Hydrochloride 50mg/mL
519102|NCT00626600|Observational
519103|NCT00626600|Infusion
519104|NCT00626600|Severe cancer pain
519105|NCT00626587|Endobronchial ultrasonography
519106|NCT00626587|Peripheral pulmonary lesions
519107|NCT00626587|Transbronchial needle aspiration
519108|NCT00626587|Probe location
519109|NCT00626587|Diagnostic yield
519110|NCT00626587|EBUS guided TBNA for peripheral pulmonary lesions
519111|NCT00626574|Epoetin alfa
519112|NCT00626574|aneurysm
519113|NCT00626574|subarachnoid hemorrhage
519114|NCT00626561|Cervical Cancer
519115|NCT00626561|Uterine Cancer
519116|NCT00626561|Bevacizumab
519117|NCT00626561|Avastin
519118|NCT00626561|Anti-VEGF monoclonal antibody
519119|NCT00626561|rhuMAb-VEGF
519120|NCT00626561|Paclitaxel
519121|NCT00626561|Taxol
519122|NCT00626548|Hormone Resistant Prostate Cancer
519123|NCT00626548|Endothelin A Receptor Antagonist
519124|NCT00626548|Endothelin A
519125|NCT00626548|Endothelin A antagonist
519126|NCT00626535|Symptomatic Gastroesophageal Reflux Disease (sGERD)
519127|NCT00626535|Nexium
519128|NCT00626535|Esomeprazole
519129|NCT00626522|Bronchitis
519130|NCT00626522|Chronic
519131|NCT00626522|Emphysema
519132|NCT00626522|Smokers or ex-Smokers
519133|NCT00626509|stage IV renal cell cancer
519134|NCT00626483|adult giant cell glioblastoma
519135|NCT00626483|adult gliosarcoma
519136|NCT00626470|Trochanter
519137|NCT00626470|Femur
519138|NCT00626470|Fracture
519139|NCT00626431|Lupron Depot
519140|NCT00626431|prostate cancer
519141|NCT00626431|leuprolide acetate
519142|NCT00626405|stage IV melanoma
519143|NCT00626379|Coronary Heart Disease
519144|NCT00626379|Subclinical Atherosclerosis
519145|NCT00626379|CVD-Related Markers of Inflammation
519146|NCT00626379|Mortality
519147|NCT00626366|Nasal Spray
519148|NCT00626366|Nasal Drop
519149|NCT00626366|Intranasal Medication
519150|NCT00626353|Stroke
519151|NCT00626353|rehabilitation
519152|NCT00626353|motor recovery
519153|NCT00626353|cognition
519154|NCT00626353|quality of life
519155|NCT00626340|menopause
519156|NCT00626340|women
519157|NCT00626340|major depressive disorder
519158|NCT00626340|Magnetic Resonance Spectroscopy
519159|NCT00626327|vaccine
519160|NCT00626327|toddlers
519161|NCT00626327|healthy
519162|NCT00626327|meningitis
519163|NCT00626327|meningococcal
519164|NCT00626327|measles
519165|NCT00626327|mumps
519166|NCT00626327|rubella
519167|NCT00626327|varicella
519168|NCT00626327|Prevention of Meningococcal disease types ACWY
519169|NCT00626301|efficacy
519170|NCT00626301|safety
519171|NCT00626301|pharmacokinetics
519172|NCT00626301|LPV/r monotherapy
519173|NCT00626301|Thai children
519174|NCT00626301|efficacy safety LPV/r monotherapy maintenance
519175|NCT00626301|treatment experienced
519176|NCT00626288|Mesalazine in Irritable Bowel Syndrome
519177|NCT00626275|Rheumatoid arthritis
519178|NCT00626275|arthritis
519179|NCT00626262|Gastroesophageal reflux disease
519180|NCT00626262|Nexium
519181|NCT00626262|Esomeprazole
519182|NCT00626262|Administration methods.
519183|NCT00626249|Nephropathy
519184|NCT00626249|Kidney Disease
519186|NCT00626249|Renal
519187|NCT00626249|Diabetics
519188|NCT00626236|ADHD and conduct problems
519189|NCT00626223|ESRD patients
519190|NCT00626223|C-reactive protein
519191|NCT00626223|homocysteine
519192|NCT00626223|5-MTHF
519193|NCT00626223|survival
519194|NCT00626223|Hemodialysis patients
519195|NCT00626210|Mild Cognitive Impairment (MCI)
519196|NCT00626210|Sleep
519197|NCT00626210|Fatigue
519198|NCT00626210|Memory
519199|NCT00626197|SLE
519200|NCT00626197|Lupus
519201|NCT00626197|BELONG
519202|NCT00626184|Celiac Disease
519203|NCT00626171|smoking
519204|NCT00626171|asthma
519205|NCT00626171|sputum
519206|NCT00626158|pancreatic cancer
519207|NCT00626158|biliary cancer
519208|NCT00626158|gemcitabine
519209|NCT00626158|capecitabine
519210|NCT00626145|BMMNC
519211|NCT00626145|STEMI
519212|NCT00626145|stem cell
519213|NCT00626145|intracoronary delivery
519214|NCT00626132|Blood pressure
519215|NCT00626132|Herbs
519216|NCT00626132|Food
519217|NCT00626119|breast cancer
519218|NCT00626106|postmenopausal
519219|NCT00626106|hormone receptor positive
519220|NCT00626106|locally advanced
519221|NCT00626106|metastatic
519222|NCT00626080|Insulin
519223|NCT00626080|Detemir
519224|NCT00626080|Brain
519225|NCT00626080|Glucose metabolism
519226|NCT00626067|Travatan Dosing Aid
519227|NCT00626067|compliance monitoring dispenser
519228|NCT00626054|Colonoscopy
519229|NCT00626054|PEG Solution
519230|NCT00626041|Community pharmacies
519231|NCT00626041|Primary care networks
519232|NCT00626041|Global risk assessment
519233|NCT00626041|Blood pressure screening
519234|NCT00626028|Pulmonary Vasculature
519235|NCT00626028|Nitric Oxide
519236|NCT00626028|INOmax®
519237|NCT00626028|Acute Lung Injury
519238|NCT00626028|Pulmonary Vasodilator Testing
519239|NCT00626028|Idiopathic Pulmonary Arterial Hypertension
519240|NCT00626028|Congenital Heart Disease
519241|NCT00626028|reversible pulmonary hypertension
519242|NCT00626028|vasoreactivity
519243|NCT00626015|adult glioblastoma
519244|NCT00626015|adult giant cell glioblastoma
519245|NCT00626015|adult gliosarcoma
519246|NCT00626015|adult high grade glioma
519247|NCT00626002|Open label
519248|NCT00625989|asthma
519249|NCT00625989|atopy
519250|NCT00625989|allergen challenge
519251|NCT00625989|sputum myeloid and plasmacytoid dendritic cells
519252|NCT00625976|Complex regional pain syndrome type I
519253|NCT00625976|Graded exposure in vivo
519254|NCT00625976|Physiotherapy
519255|NCT00625976|Pain-related fear
519256|NCT00625963|Pulmonary Hypertension;
519257|NCT00625963|ILD;
519258|NCT00625963|CT Imaging;
519259|NCT00625963|Echocardiogram;
519260|NCT00625963|Hemodynamic measurements of RHC.
519261|NCT00625963|Pulmonary Function Tests
519262|NCT00625950|Hyperprolactinemia
519263|NCT00625950|Endometriosis
519264|NCT00625950|laparoscopy
519265|NCT00625950|angiogenesis, VEGF
519266|NCT00625937|stage III squamous cell carcinoma of the hypopharynx
519267|NCT00625937|stage IV squamous cell carcinoma of the hypopharynx
519268|NCT00625937|stage III verrucous carcinoma of the oral cavity
519269|NCT00625937|stage IV verrucous carcinoma of the oral cavity
519270|NCT00625937|stage III squamous cell carcinoma of the lip and oral cavity
519271|NCT00625937|stage IV squamous cell carcinoma of the lip and oral cavity
519272|NCT00625937|stage III lymphoepithelioma of the nasopharynx
519273|NCT00625937|stage III squamous cell carcinoma of the nasopharynx
519274|NCT00625937|stage IV lymphoepithelioma of the nasopharynx
519275|NCT00625937|stage IV squamous cell carcinoma of the nasopharynx
519276|NCT00625937|stage III lymphoepithelioma of the oropharynx
519277|NCT00625937|stage III squamous cell carcinoma of the oropharynx
519278|NCT00625937|stage IV lymphoepithelioma of the oropharynx
519279|NCT00625937|stage IV squamous cell carcinoma of the oropharynx
519280|NCT00625937|tongue cancer
519281|NCT00625924|Plastic surgery
519282|NCT00625924|reconstruction
519283|NCT00625911|thoracotomy
519284|NCT00625911|minimally invasive direct coronary artery bypass
519285|NCT00625911|ketamine
519286|NCT00625911|pain
519287|NCT00625898|HER2 positive breast cancer
519288|NCT00625898|invasive breast cancer
519289|NCT00625898|bevacizumab
519290|NCT00625898|NSABP
519291|NCT00625898|Roche
519292|NCT00625898|CIRG
519293|NCT00625898|trastuzumab
519294|NCT00625898|cyclophosphamide
519295|NCT00625898|docetaxel
519296|NCT00625898|carboplatin
519297|NCT00625898|5-fluorouracil
519298|NCT00625898|epirubicin
519299|NCT00625885|Anterior Cruciate Ligament/injuries
519300|NCT00625885|Anterior Cruciate Ligament/surgery
519301|NCT00625885|Knee injuries/surgery
519302|NCT00625885|Outcomes research
519303|NCT00625885|Prospective Studies
519304|NCT00625859|pharmacokinetics,
519305|NCT00625859|pharmacodynamics
519306|NCT00625859|Healthy adult male volunteers,
519307|NCT00625820|Kidney Disease
519308|NCT00625820|Albuminuria
519309|NCT00625820|Glomerular filtration rate
519310|NCT00625807|Stress
519311|NCT00625807|meditation
519312|NCT00625807|stress reduction
519313|NCT00625807|fMRI
519314|NCT00625807|behavioral
519315|NCT00625781|Gestational diabetes mellitus
519316|NCT00625781|Impaired glucose Tolerance
519317|NCT00625781|Pregnancy
519318|NCT00625781|Fetal macrosomia
519319|NCT00625781|Treatment
519320|NCT00625781|Perinatal morbidity
519321|NCT00625768|Antibody
519322|NCT00625768|safety
519323|NCT00625768|tolerability
519324|NCT00625768|efficacy
519325|NCT00625768|metastatic renal cell carcinoma
519326|NCT00625768|metastatic malignant melanoma
519327|NCT00625755|renal cell carcinoma
519328|NCT00625755|AJCC Stage IV (primary or relasped) renal cell carcinoma
519329|NCT00625742|Advanced Cancer
519330|NCT00625742|Cancer Cachexia
519331|NCT00625742|Cachexia
519332|NCT00625742|Melatonin
519333|NCT00625742|Juven
519334|NCT00625742|Exercise Training
519335|NCT00625742|Weight Loss
519336|NCT00625729|recurrent adult grade III lymphomatoid granulomatosis
519337|NCT00625729|adult nasal type extranodal NK/T-cell lymphoma
519338|NCT00625729|Waldenstrom macroglobulinemia
519339|NCT00625729|recurrent adult Burkitt lymphoma
519340|NCT00625729|recurrent adult diffuse large cell lymphoma
519341|NCT00625729|recurrent adult diffuse mixed cell lymphoma
519342|NCT00625729|recurrent adult diffuse small cleaved cell lymphoma
519343|NCT00625729|recurrent adult immunoblastic large cell lymphoma
519344|NCT00625729|recurrent adult lymphoblastic lymphoma
519345|NCT00625729|recurrent grade 1 follicular lymphoma
519346|NCT00625729|recurrent grade 2 follicular lymphoma
519347|NCT00625729|recurrent grade 3 follicular lymphoma
519348|NCT00625729|recurrent mantle cell lymphoma
519349|NCT00625729|recurrent marginal zone lymphoma
519350|NCT00625729|recurrent small lymphocytic lymphoma
519351|NCT00625729|refractory chronic lymphocytic leukemia
519352|NCT00625703|Pharmacokinetic
519353|NCT00625690|lung cancer
519354|NCT00625677|meningococcal serogroup C vaccine
519355|NCT00625677|reduced dose
519356|NCT00625677|meningococcal serogroup C conjugate vaccine
519357|NCT00625677|pneumococcal conjugate vaccine
519358|NCT00625664|Cancer
519359|NCT00625664|Neoplasms
519360|NCT00625664|Bladder
519361|NCT00625664|Urothelial Tract
519362|NCT00625651|Colon Cancer
519363|NCT00625651|Colorectal Cancer
519364|NCT00625651|Rectal Cancer
519365|NCT00625651|AMG 655
519366|NCT00625651|Bevacizumab
519367|NCT00625651|Modified FOLFOX6
519368|NCT00625651|mFOLFOX6
519369|NCT00625651|FOLFOX
519370|NCT00625638|Advanced Cancer
519371|NCT00625638|Caregiver
519372|NCT00625638|Interactive Voice Response
519373|NCT00625638|Symptom Control
519374|NCT00625638|IVR System
519375|NCT00625638|Questionnaire
519376|NCT00625625|stage I colon cancer
519377|NCT00625625|stage II colon cancer
519378|NCT00625625|stage III colon cancer
519379|NCT00625625|stage I rectal cancer
519380|NCT00625625|stage II rectal cancer
519381|NCT00625625|stage III rectal cancer
519382|NCT00625586|adenocarcinoma of the pancreas
519383|NCT00625586|stage IV pancreatic cancer
519384|NCT00625586|recurrent pancreatic cancer
519385|NCT00625573|Colon Cancer
519386|NCT00625573|Abraxis Oncology
519387|NCT00625573|Abraxane
519388|NCT00625573|Phase II
519389|NCT00625573|Colorectal
519390|NCT00625573|Mt. Sinai Medical Center
519391|NCT00625573|CCOP
519392|NCT00625560|Chronic hepatitis B
519393|NCT00625560|Lamivudine
519394|NCT00625560|Entecavir
519395|NCT00625534|Hernia
519396|NCT00625534|Laparoscopy
519397|NCT00625534|Pain
519398|NCT00625534|Sexual
519399|NCT00625534|Quality
519400|NCT00625521|Discoid lupus erythematosus
519401|NCT00625495|Gastroesophageal reflux disease
519402|NCT00625495|Nexium
519403|NCT00625495|Esomeprazole
519404|NCT00625495|Administration methods.
519405|NCT00625482|BCG vaccine
519406|NCT00625482|Oral polio vaccine
519407|NCT00625482|Vitamin A supplementation
519408|NCT00625482|Low-birth-weigth
519409|NCT00625482|Sex-differential
519410|NCT00625482|Prevention
519411|NCT00625482|Immunological parameters
519412|NCT00625469|pulmonary arterial hypertension
519413|NCT00625469|idiopathic pulmonary fibrosis
519414|NCT00625469|bosentan
519415|NCT00625456|phase I
519416|NCT00625456|advanced metastatic solid tumors
519417|NCT00625456|oncolytic virus
519418|NCT00625456|vaccinia virus
519419|NCT00625456|melanoma
519420|NCT00625456|lung cancer
519421|NCT00625456|renal cell carcinoma
519422|NCT00625456|squamous cell carcinoma of the head and neck
519423|NCT00625456|Pexa-Vec
519424|NCT00625443|Idiopathic Thrombocytopenic Purpura
519425|NCT00625443|ITP
519426|NCT00625443|Chronic Idiopathic Thrombocytopenic Purpura
519427|NCT00625430|Prostate Cancer
519428|NCT00625430|Gene Therapy
519429|NCT00625430|Fludarabine
519430|NCT00625430|Adenovirus
519431|NCT00625430|phase I
519432|NCT00625417|male breast cancer
519433|NCT00625417|stage IA breast cancer
519434|NCT00625417|stage IB breast cancer
519435|NCT00625417|stage II breast cancer
519436|NCT00625417|stage IIIA breast cancer
519437|NCT00625417|stage IIIB breast cancer
519438|NCT00625417|stage IIIC breast cancer
519439|NCT00625417|stage IV breast cancer
519440|NCT00625404|Aspartate Aminotransferase (AST)
519441|NCT00625404|Alanine Aminotransferase (ALT)
519442|NCT00625404|HIV
519443|NCT00625404|HIV Prevention
519444|NCT00625404|Oral PrEP
519445|NCT00625404|Truvada
519446|NCT00625404|women
519447|NCT00625404|Tenofovir
519448|NCT00625404|TDF
519449|NCT00625404|FTC
519450|NCT00625404|emtricitabine
519451|NCT00625404|hepatitis
519452|NCT00625404|Pre-exposure Prophylaxis (PrEP)
519453|NCT00625404|HIV Seronegativity
519454|NCT00625391|postmenopausal, bone, dietary supplement, mind-body exercise
519455|NCT00625378|Cancer
519456|NCT00625378|Sorafenib
519457|NCT00625378|Extension program
519458|NCT00625365|DEFINITY
519459|NCT00625365|Safety
519460|NCT00625365|Survelliance
519461|NCT00625352|Carcinoma, Non-Small-Cell Lung
519462|NCT00625352|Aged
519463|NCT00625352|Gemcitabine
519464|NCT00625352|UFT
519465|NCT00625339|Chronic hepatitis B
519466|NCT00625339|Lamivudine
519467|NCT00625339|Entecavir
519468|NCT00625326|psoriasis
519469|NCT00625313|Cataract
519470|NCT00625313|aphakia
519471|NCT00625313|intraocular lens
519472|NCT00625313|IOL
519473|NCT00625313|Optical correction of aphakia
519474|NCT00625300|repetitive transcranial stimulation
519475|NCT00625300|Parkinson's Disease
519476|NCT00625274|Nexium
519477|NCT00625274|esomeprazole
519478|NCT00625274|lansoprazole
519479|NCT00625274|pantoprazole
519480|NCT00625274|Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
519481|NCT00625261|Language delay
519482|NCT00625261|Speech and language disorders
519483|NCT00625261|Early language intervention
519484|NCT00625261|Parent-based language intervention
519485|NCT00625235|Obesity
519486|NCT00625235|Weight loss
519487|NCT00625235|Weight maintenance
519488|NCT00625235|VLED
519489|NCT00625222|Electroencephalography
519490|NCT00625222|Seizure frequency
519491|NCT00625222|Seizure severity
519492|NCT00625209|septic shock
519493|NCT00625209|coagulation
519494|NCT00625209|immunomodulation
519495|NCT00625209|survival
519496|NCT00625196|Healthy Japanese volunteers
519497|NCT00625183|adenocarcinoma of the rectum
519498|NCT00625183|stage II rectal cancer
519499|NCT00625183|stage III rectal cancer
519500|NCT00625170|Antipsychotics
519501|NCT00625170|Olanzapine
519502|NCT00625170|Haloperidol
519503|NCT00625170|Insulin resistance
519504|NCT00625170|Dyslipidemia
519505|NCT00625131|Stress Disorders, Posttraumatic
519506|NCT00625131|Tobacco Use Disorder
519507|NCT00625118|Hib conjugate vaccine
519508|NCT00625118|reactogenicity
519509|NCT00625118|local reactions
519510|NCT00625118|systemic symptoms
519511|NCT00625092|peritoneal cavity cancer
519512|NCT00625079|pulmonary hypertension
519513|NCT00625079|pulmonary arterial hypertension
519514|NCT00625079|interstitial lung disease
519515|NCT00625079|idiopathic pulmonary fibrosis
519516|NCT00625066|precancerous condition
519517|NCT00625066|colon cancer
519518|NCT00625066|rectal cancer
519519|NCT00625053|Neuroticism
519520|NCT00625053|Hernia, ventral
519521|NCT00625053|Laparoscopy
519522|NCT00625053|Quality of life
519523|NCT00625040|Incretin effect
519524|NCT00625040|Gastric banding
519525|NCT00625040|Glucagon
519526|NCT00625040|Glucagon-Like Peptide 1
519527|NCT00625040|Gastric Inhibitory Peptide
519528|NCT00625040|Glucose Intestinal Peptide
519529|NCT00625040|Insulin
519530|NCT00625040|C-peptide
519531|NCT00625027|Emergency Department Visit
519532|NCT00625027|Telehealth Ontario
519533|NCT00625027|Triage Levels
519534|NCT00625014|Insulin resistance
519535|NCT00625014|Dyslipidemia
519536|NCT00625014|Haloperidol
519537|NCT00625001|Turner Syndrome
519538|NCT00625001|bone mineral density
519539|NCT00625001|estrogen replacement therapy
519540|NCT00625001|dual energy x-ray absorptiometry
519541|NCT00624988|Spinal cord injury
519542|NCT00624988|vibration therapy
519543|NCT00624988|bone density
519544|NCT00624962|childhood soft tissue sarcoma
519545|NCT00624962|neuroblastoma
519546|NCT00624962|childhood hepatoblastoma
519547|NCT00624962|childhood cerebellar astrocytoma
519548|NCT00624962|childhood ependymoma
519549|NCT00624962|childhood brain stem glioma
519550|NCT00624962|childhood meningioma
519551|NCT00624962|childhood myelodysplastic syndromes
519552|NCT00624962|unspecified childhood solid tumor, protocol specific
519553|NCT00624962|childhood acute myeloid leukemia/other myeloid malignancies
519554|NCT00624962|central nervous system neoplasm
519555|NCT00624962|Wilms tumor and other childhood kidney tumors
519556|NCT00624962|childhood brain tumor
519557|NCT00624962|childhood medulloblastoma
519558|NCT00624949|Turner syndrome
519559|NCT00624949|aortic dimensions
519560|NCT00624949|blood pressure
519561|NCT00624949|aortic dilatation
519562|NCT00624949|aortic rupture
519563|NCT00624936|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
519564|NCT00624936|adult acute myeloid leukemia with inv(16)(p13;q22)
519565|NCT00624936|adult acute myeloid leukemia with t(15;17)(q22;q12)
519566|NCT00624936|adult acute myeloid leukemia with t(16;16)(p13;q22)
519567|NCT00624936|adult acute myeloid leukemia with t(8;21)(q22;q22)
519568|NCT00624936|recurrent adult acute myeloid leukemia
519569|NCT00624936|myelodysplastic/myeloproliferative neoplasm, unclassifiable
519570|NCT00624936|myelodysplastic syndromes
519571|NCT00624936|secondary acute myeloid leukemia
519572|NCT00624923|Coronary Artery Disease
519573|NCT00624923|Inflammation
519574|NCT00624923|Overweight
519575|NCT00624923|Metabolic Syndrome
519576|NCT00624923|Salsalate
519577|NCT00624910|Post Operative Pain
519578|NCT00624910|Hysterectomy
519579|NCT00624884|Aortic regurgitation,velocity vector imaging
519580|NCT00624871|Interleukin 1-beta
519581|NCT00624871|Interleukin 6
519582|NCT00624871|Vitamin C
519583|NCT00624871|HIE
519584|NCT00624871|neonates
519585|NCT00624858|Depression
519586|NCT00624858|depressed
519587|NCT00624858|overweight
519588|NCT00624858|obese
519589|NCT00624845|Meniscectomy
519590|NCT00624832|Asthma
519591|NCT00624832|allergen challenge
519592|NCT00624832|bronchoprovocation
519593|NCT00624832|Methacholine challenge
519594|NCT00624832|serum Immunoglobulin E
519595|NCT00624832|Nitric Oxide
519596|NCT00624832|skin prick test
519597|NCT00624819|Streptococcus pneumoniae
519598|NCT00624819|Haemophilus influenzae
519599|NCT00624819|Pneumococcal conjugate vaccine
519600|NCT00624819|Antibody persistence
519601|NCT00624806|Pressure ulcer
519602|NCT00624806|Telemedicine
519603|NCT00624793|Nausea
519604|NCT00624793|Vomiting
519605|NCT00624793|Retching
519606|NCT00624793|HIV/AIDS
519607|NCT00624793|Symptom Management
519608|NCT00624793|Complementary Therapies
519609|NCT00624767|insulin
519610|NCT00624767|insulin aspart
519611|NCT00624767|Type 2 Diabetes
519612|NCT00624767|diabetes mellitus
519613|NCT00624754|Obstructive airway disease
519614|NCT00624754|bronchiolitis obliterans
519615|NCT00624754|allogeneic hematopoietic stem cell transplantation
519616|NCT00624754|bone marrow transplantation
519617|NCT00624754|inhaled treatment
519618|NCT00624754|Budesonide Formoterol
519619|NCT00624741|Parkinson's disease
519620|NCT00624741|Antiparkinsonian
519621|NCT00624741|Compassionate use
519622|NCT00624728|Positron-Emission Tomography
519623|NCT00624728|Alovudine [Substance Name]
519624|NCT00624728|18F-FLT
519625|NCT00624728|Magnetic Resonance Imaging
519626|NCT00624728|Astrocytoma
519627|NCT00624728|Glioblastoma
519628|NCT00624702|Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)
519629|NCT00624689|Body composition
519630|NCT00624689|Glucose tolerance
519631|NCT00624689|Intima-media thickness
519632|NCT00624689|Visual acuity
519633|NCT00624689|Neurological development
519634|NCT00624676|Acne
519635|NCT00624676|lipophilic hydroxy acid
519636|NCT00624676|benzoyl peroxide
519637|NCT00624663|Rivastigmine, Repeated administration, Healthy Volunteers, organophosphate poisoning, protection, pharmacokinetics, behavioral effects
519638|NCT00624650|Acute Lung Injury
519639|NCT00624650|Extravascular Lung Water
519640|NCT00624650|Acute Respiratory Distress Syndrome
519641|NCT00624637|aromatherapy
519642|NCT00624637|massage
519643|NCT00624637|comfort
519644|NCT00624637|postoperative
519645|NCT00624637|infants
519646|NCT00624637|craniofacial surgery
519647|NCT00624624|hypogonadotropic hypogonadism
519648|NCT00624624|bariatric surgery
519649|NCT00624624|serum androgen levels
519650|NCT00624624|bone density
519651|NCT00624611|CPB
519652|NCT00624611|red blood cell washing
519653|NCT00624585|MDS
519654|NCT00624585|MDS/MPD
519655|NCT00624585|MDS/AML
519656|NCT00624585|CMML
519657|NCT00624585|Excess Marrow Blasts
519658|NCT00624572|primary teeth
519659|NCT00624572|chlorexidine
519660|NCT00624572|root canal therapy
519661|NCT00624572|Pulpectomy
519662|NCT00624559|Salt sensitivity of Blood Pressure
519663|NCT00624546|GERD
519664|NCT00624546|gastroesophageal reflux
519665|NCT00624546|antireflux surgery
519666|NCT00624546|Barrett's
519667|NCT00624546|Esophagus
519668|NCT00624546|Esophagitis
519669|NCT00624533|Low back Pain
519670|NCT00624533|Physical Therapy Modalities
519671|NCT00624533|Exercise Movement Techniques
519672|NCT00624533|Primary Health Care
519673|NCT00624520|Stress, Psychological
519674|NCT00624520|Tachycardia, Ventricular
519675|NCT00624520|Defibrillators, Implantable
519676|NCT00624520|Death, Sudden Cardiac
519677|NCT00624520|Cognitive Therapy
519678|NCT00624520|Anger
519679|NCT00624494|venous oxygen saturation
519680|NCT00624494|transpulmonary thermodilution
519681|NCT00624481|osteoporosis
519682|NCT00624481|osteopenia
519683|NCT00624481|bone mineral density
519684|NCT00624481|teriparatide
519685|NCT00624468|atacicept
519686|NCT00624468|neuritis
519687|NCT00624455|Gabapentin
519688|NCT00624455|tonsillectomy
519689|NCT00624455|post-operative pain
519690|NCT00624455|morphine requirements
519691|NCT00624455|randomized double blind
519692|NCT00624455|adenotonsillectomy
519693|NCT00624429|Asthma
519694|NCT00624429|Children
519695|NCT00624416|Obesity therapy
519696|NCT00624416|fat
519697|NCT00624416|drug mechanism
519698|NCT00624416|adipose tissue
519699|NCT00624416|cellular pharmacology
519700|NCT00624403|Anesthesia
519701|NCT00624403|Laryngeal mask airway
519702|NCT00624351|Lupus
519703|NCT00624351|Monoclonal antibody
519704|NCT00624351|B-Cell immunotherapy
519705|NCT00624338|Atacicept 75 and 150 mg
519706|NCT00624338|Placebo
519707|NCT00624325|genotype 1 nonresponders
519708|NCT00624312|Procrit
519709|NCT00624312|Erythropoietin
519710|NCT00624312|Patients undergoing major surgical oncology operations
519711|NCT00624299|botox
519712|NCT00624299|limb reconstructions
519713|NCT00624299|limb reconstruction surgery
519714|NCT00624286|chronic obstructive pulmonary disease
519715|NCT00624286|COPD
519716|NCT00624286|indacaterol
519717|NCT00624273|digital ulcers,
519718|NCT00624273|systemic sclerosis,
519719|NCT00624273|sildenafil,
519720|NCT00624273|vasoactive therapies
519721|NCT00624260|Colorectal cancer
519722|NCT00624260|Recurrence
519723|NCT00624260|Positron Emission Tomography
519724|NCT00624260|Colorectal Cancer with high risk of recurrence stage III
519725|NCT00624260|Colorectal Cancer with high risk of recurrence stage IV
519726|NCT00624260|T4N0M0 operated in emergency( because of perforation)
519727|NCT00624247|routine HIV testing
519728|NCT00624247|jails
519729|NCT00624247|criminal justice system
519730|NCT00624247|substance abuse
519731|NCT00624247|mental illness
519732|NCT00624247|HIV
519733|NCT00624234|neurofibromatosis type 1
519734|NCT00624234|reading disabilities
519735|NCT00624234|NF-1
519736|NCT00624234|learning disabilities
519737|NCT00624234|tutoring intervention
519738|NCT00624208|Randomized
519739|NCT00624208|double-blind
519740|NCT00624208|4-group clinical interventional study
519741|NCT00624195|HIV Dementia
519742|NCT00624195|HAART
519743|NCT00624195|Cognitive Impairment
519744|NCT00624195|Antiretroviral Regimen
519745|NCT00624195|Viral Load
519746|NCT00624195|CNS Drug Penetration
519747|NCT00624169|Perforated peptic ulcer
519748|NCT00624169|Mortality
519749|NCT00624156|Breast Cancer
519750|NCT00624143|Antifungal prophylaxis, acute leukemia induction,
519751|NCT00624130|Contraception,
519752|NCT00624130|Cycle control,
519753|NCT00624130|Bleeding pattern
519754|NCT00624117|shoulder joint
519755|NCT00624117|recovery of function
519756|NCT00624117|effectiveness of rehabilitation
519757|NCT00624117|rehabilitation
519758|NCT00624104|VLDL
519759|NCT00624104|Kinetics
519760|NCT00624104|Hyperinsulinaemia
519761|NCT00624104|Obesity
519762|NCT00624091|Early-surgery, infective endocarditis, in-hospital mortality
519763|NCT00624078|faboterapics
519764|NCT00624078|treatment
519765|NCT00624078|scorpion sting
519766|NCT00624078|envenomation
519767|NCT00624065|target blood pressure
519768|NCT00624065|hypertension
519769|NCT00624065|COREG CR
519770|NCT00624065|carvedilol CR
519771|NCT00624065|Stage 1 or 2 essential hypertension
519772|NCT00624065|lisinopril
519773|NCT00624039|presbyopia
519774|NCT00624013|Diabetes
519775|NCT00624013|Depression
519776|NCT00624013|diabetes outcomes
519777|NCT00624013|quality of life
519778|NCT00624000|Ischemic Stroke
519779|NCT00623987|Residual vein thrombosis
519780|NCT00623987|Optimal duration
519781|NCT00623987|Oral anticoagulants
519782|NCT00623974|Hypocalcemia
519783|NCT00623974|Teriparatide
519784|NCT00623974|Forteo
519785|NCT00623974|Calcium
519786|NCT00623974|Calcitriol
519787|NCT00623974|Rocaltrol
519788|NCT00623961|Neuropathic Pain
519789|NCT00623948|Pressure ulcers
519790|NCT00623948|Electrical Stimulation
519791|NCT00623948|Spinal Cord Injury
519792|NCT00623935|AML
519793|NCT00623922|Patient education
519794|NCT00623922|Nurse consultation
519795|NCT00623922|Arthritis
519796|NCT00623922|Wellbeing
519797|NCT00623922|Coping
519798|NCT00623922|Health related quality of life
519799|NCT00623909|Laser Therapy
519800|NCT00623909|Post Thoracotomy Pain
519801|NCT00623909|AvicennaTM laser
519802|NCT00623896|Nehb
519803|NCT00623896|ST Elevation Myocardial Infarcton
519804|NCT00623896|STEMI
519805|NCT00623896|ECG
519806|NCT00623883|Human Colonic Aberrant Crypt Foci
519807|NCT00623857|Micronutrients
519808|NCT00623857|Zinc
519809|NCT00623857|Vitamins
519810|NCT00623857|Trace elements
519811|NCT00623857|Minerals
519812|NCT00623857|Vitamin A
519813|NCT00623857|Vitamin B1
519814|NCT00623857|Vitamin B2
519815|NCT00623857|Niacin
519816|NCT00623857|Vitamin B6
519817|NCT00623857|Folic acid
519818|NCT00623857|Vitamin B12
519819|NCT00623857|Vitamin C
519820|NCT00623857|Vitamin D
519821|NCT00623857|Vitamin E
519822|NCT00623857|Vitamin K
519823|NCT00623857|Iron
519824|NCT00623857|Iodine
519825|NCT00623857|Copper
519826|NCT00623857|Selenium
519827|NCT00623857|Magnesium
519828|NCT00623857|Calcium
519829|NCT00623857|Malaria
519830|NCT00623857|Immunity
519831|NCT00623857|Anthropometry
519832|NCT00623844|Prevention
519833|NCT00623844|Physical activity
519834|NCT00623844|Obesity
519835|NCT00623844|Motor skills
519836|NCT00623844|Kindergarten
519837|NCT00623831|MBV
519838|NCT00623831|Mixed Bacterial Vaccine
519839|NCT00623831|NY-ESO-1
519840|NCT00623818|Mirror Therapy
519841|NCT00623818|Phantom Limb Pain
519842|NCT00623818|Amputee
519843|NCT00623818|Healthy Volunteer
519844|NCT00623818|HV
519845|NCT00623792|Morbid obesity
519846|NCT00623792|Diet therapy
519847|NCT00623792|Bariatric Surgery
519848|NCT00623792|Gastric bypass
519849|NCT00623792|Behavior therapy
519850|NCT00623792|Randomized controlled trial
519851|NCT00623792|Weight loss
519852|NCT00623753|Vaccine
519853|NCT00623753|Prevention
519854|NCT00623753|HIV
519855|NCT00623753|AIDS
519856|NCT00623753|Human Immunodeficiency Virus
519857|NCT00623753|HIV Seronegativity, HIV Preventive Vaccine
519858|NCT00623740|Hydrocortisone
519859|NCT00623740|Very low birth weight
519860|NCT00623740|Bronchopulmonary dysplasia
519861|NCT00623740|Prevention Cerebral palsy
519862|NCT00623727|Hemophilia A
519863|NCT00623727|FVIII disease
519864|NCT00623727|rFVIII
519865|NCT00623701|sublingual grass pollen preparation
519866|NCT00623701|IgE-mediated Allergic Disease attributed to grass pollen
519867|NCT00623688|Metered Dose Inhalers
519868|NCT00623688|Nebulizers
519869|NCT00623688|Randomized Controlled Trial
519870|NCT00623675|zeolites
519871|NCT00623675|nutraceuticals
519872|NCT00623675|natural supplements
519873|NCT00623675|Healthy volunteers
519874|NCT00623662|Glucose infusion
519875|NCT00623662|Liver function
519876|NCT00623662|Liver resection
519877|NCT00623662|Albumin synthesis
519878|NCT00623662|Stable isotopes
519879|NCT00623636|Migraine
519880|NCT00623610|Diabetes mellitus, type 1
519881|NCT00623610|pancreatic beta cell
519882|NCT00623610|transplantation
519883|NCT00623584|penetrating keratoplasty
519884|NCT00623584|corneal transplantation
519885|NCT00623584|corneal grafting
519886|NCT00623584|corneal grafts
519887|NCT00623584|culture media
519888|NCT00623584|corneal culturing
519889|NCT00623584|in vitro culturing
519890|NCT00623571|frail elderly
519891|NCT00623571|hospital at home
519892|NCT00623571|heart failure
519893|NCT00623571|Acute exacerbation of chronic heart failure
519894|NCT00623558|head and neck neoplasm
519895|NCT00623558|cetuximab
519896|NCT00623558|docetaxel
519897|NCT00623558|cisplatin
519898|NCT00623558|radiotherapy
519899|NCT00623545|Exenatide
519900|NCT00623545|Byetta
519901|NCT00623545|weight loss
519902|NCT00623545|energy expenditure
519903|NCT00623545|normal volunteers
519904|NCT00623532|Tertiary prevention of disability
519905|NCT00623519|Adjuvant postmenopausal breast cancer women
519906|NCT00623506|TBI
519907|NCT00623506|Pregnenolone
519908|NCT00623506|Cognition
519909|NCT00623493|Screening
519910|NCT00623493|Suicide
519911|NCT00623493|Emergency Department
519912|NCT00623493|Children and Adolescents
519913|NCT00623493|Suicide Risk
519914|NCT00623480|Hemophilia A
519915|NCT00623467|Central Nervous System Imaging
519916|NCT00623467|Diagnostic Imaging
519917|NCT00623454|anxiety
519918|NCT00623454|panic disorder
519919|NCT00623454|chest pain
519920|NCT00623454|palpitations
519921|NCT00623441|Coronary Artery Disease
519922|NCT00623441|Drug-eluting stent
519923|NCT00623402|Metastatic melanoma
519924|NCT00623402|Pegylated interferon
519925|NCT00623402|Protein Kinase Inhibitors
519926|NCT00623402|Sorafenib
519927|NCT00623402|PegIntron
519928|NCT00623402|Therapeutic Uses
519929|NCT00623402|melanoma (skin)
519930|NCT00623389|Neurologic disorders
519931|NCT00623389|Rare disease
519932|NCT00623389|Spinal cord injuries
519933|NCT00623389|Stroke
519934|NCT00623389|Paraplegia
519935|NCT00623389|Tetraplegia
519936|NCT00623363|Parkinson's Disease
519937|NCT00623363|motor complications
519938|NCT00623363|dyskinesia
519939|NCT00623363|Motor complications associated with Parkinson's
519940|NCT00623350|Telemedicine
519941|NCT00623350|Stroke, Acute
519942|NCT00623350|Rural
519943|NCT00623350|Thrombolysis
519944|NCT00623350|Consultation
519945|NCT00623337|care seeking
519946|NCT00623337|pregnancy and childbirth
519947|NCT00623337|newborn care practices
519948|NCT00623337|low birth weight babies
519949|NCT00623298|Posttraumatic stress disorder
519950|NCT00623298|depression
519951|NCT00623298|Narrative Exposure Therapy
519952|NCT00623298|Interpersonal Psychotherapy
519953|NCT00623285|Pain.
519954|NCT00623285|Postoperative.
519955|NCT00623285|CABG.
519956|NCT00623272|The assessment of left ventricular ejection fraction (LVEF)
519957|NCT00623246|Obstructive Sleep Apnea
519958|NCT00623246|OSA
519959|NCT00623246|Adherence
519960|NCT00623246|CPAP
519961|NCT00623246|Cognition
519962|NCT00623233|Breast Neoplasm
519963|NCT00623220|pain, retinopathy of prematurity, infant, premature, eye exam, nitrous oxide
519964|NCT00623207|Chest Pain Low work Capacity Rate Incompetence
519965|NCT00623181|Influenza
519966|NCT00623181|Influenza virus
519967|NCT00623168|Ribavirin
519968|NCT00623168|Hemorrhagic Fever with Renal Syndrome
519969|NCT00623155|malaria
519970|NCT00623155|intermittent preventive treatment
519971|NCT00623155|season
519972|NCT00623155|children
519973|NCT00623142|Myocardial protection
519974|NCT00623142|Ischemic Reperfusion Injury
519975|NCT00623142|Hyperbaric Oxygen
519976|NCT00623142|Preconditioning
519977|NCT00623129|hypopharyngeal cancer
519978|NCT00623129|lip and oral cavity cancer
519979|NCT00623129|laryngeal cancer
519980|NCT00623129|nasopharyngeal cancer
519981|NCT00623129|oropharyngeal cancer
519982|NCT00623129|paranasal sinus and nasal cavity cancer
519983|NCT00623129|salivary gland cancer
519984|NCT00623129|xerostomia
519985|NCT00623129|radiation toxicity
519986|NCT00623116|Kallmann Syndrome
519987|NCT00623116|hypogonadotropic hypogonadism
519988|NCT00623103|Parkinson's disease dementia
519989|NCT00623103|cholinesterase inhibitor
519990|NCT00623103|rivastigmine
519991|NCT00623090|prostate cancer screening education
519992|NCT00623090|behavioral oncology
519993|NCT00623090|randomized trial
519994|NCT00623077|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
519995|NCT00623077|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
519996|NCT00623077|childhood hepatoblastoma
519997|NCT00623077|recurrent childhood liver cancer
519998|NCT00623077|stage IV childhood liver cancer
519999|NCT00623077|adult primary liver cancer
520000|NCT00623077|previously treated childhood rhabdomyosarcoma
520001|NCT00623077|recurrent childhood rhabdomyosarcoma
520002|NCT00623077|previously untreated childhood rhabdomyosarcoma
520003|NCT00623077|metastatic childhood soft tissue sarcoma
520004|NCT00623077|recurrent childhood soft tissue sarcoma
520005|NCT00623077|recurrent adult soft tissue sarcoma
520006|NCT00623077|stage IV adult soft tissue sarcoma
520007|NCT00623077|recurrent Wilms tumor and other childhood kidney tumors
520008|NCT00623077|stage IV Wilms tumor
520009|NCT00623077|stage V Wilms tumor
520010|NCT00623077|rhabdoid tumor of the kidney
520011|NCT00623077|stage IV renal cell cancer
520012|NCT00623077|childhood mixed glioma
520013|NCT00623077|recurrent childhood cerebellar astrocytoma
520014|NCT00623077|recurrent childhood cerebral astrocytoma
520015|NCT00623077|recurrent childhood ependymoma
520016|NCT00623077|recurrent childhood medulloblastoma
520017|NCT00623077|recurrent childhood pineoblastoma
520018|NCT00623077|recurrent childhood supratentorial primitive neuroectodermal tumor
520019|NCT00623077|recurrent childhood visual pathway glioma
520020|NCT00623077|untreated childhood brain stem glioma
520021|NCT00623077|untreated childhood cerebellar astrocytoma
520022|NCT00623077|childhood infratentorial ependymoma
520023|NCT00623077|childhood supratentorial ependymoma
520024|NCT00623077|childhood high-grade cerebellar astrocytoma
520025|NCT00623077|childhood high-grade cerebral astrocytoma
520026|NCT00623077|childhood low-grade cerebellar astrocytoma
520027|NCT00623077|childhood low-grade cerebral astrocytoma
520028|NCT00623077|newly diagnosed childhood ependymoma
520029|NCT00623077|childhood atypical teratoid/rhabdoid tumor
520030|NCT00623077|recurrent retinoblastoma
520031|NCT00623077|extraocular retinoblastoma
520032|NCT00623077|intraocular retinoblastoma
520033|NCT00623077|childhood renal cell carcinoma
520034|NCT00623077|clear cell renal cell carcinoma
520035|NCT00623077|recurrent renal cell cancer
520036|NCT00623077|recurrent childhood visual pathway and hypothalamic glioma
520037|NCT00623077|unspecified adult solid tumor, protocol specific
520038|NCT00623077|unspecified childhood solid tumor, protocol specific
520039|NCT00623064|transitional cell carcinoma of the bladder
520040|NCT00623064|stage IV bladder cancer
520041|NCT00623064|stage III bladder cancer
520042|NCT00623064|metastatic transitional cell cancer of the renal pelvis and ureter
520043|NCT00623064|regional transitional cell cancer of the renal pelvis and ureter
520044|NCT00623051|male circumcision
520045|NCT00623051|HIV
520046|NCT00623051|sexual behavior
520047|NCT00623051|HIV prevention
520048|NCT00623051|HIV Seronegativity
520049|NCT00623038|Apgar score
520050|NCT00623038|neonatal assessment
520051|NCT00623038|preterm infants
520052|NCT00623038|resuscitation
520053|NCT00623025|HIV
520054|NCT00623025|Steatorrhea
520055|NCT00622999|Malnutrition
520056|NCT00622999|Colon cancer
520057|NCT00622999|Colon surgery
520058|NCT00622999|Outcome
520059|NCT00622999|Complication rate
520060|NCT00622973|Prostate cancer
520061|NCT00622973|Bladder cancer
520062|NCT00622973|Pelvic lymph node metastases
520063|NCT00622973|Diffusion-weighted MRI
520064|NCT00622973|Sinerem (USPIO)-enhanced MRI
520065|NCT00622973|Imaging influence on surgery
520066|NCT00622973|Noninvasive detection of pelvic lymph node metastases
520067|NCT00622973|Influence of imaging protocol on surgical outcome
520068|NCT00622960|obesity
520069|NCT00622960|type 2 diabetes
520070|NCT00622960|weight loss
520071|NCT00622960|monounsaturated fat
520072|NCT00622960|diet
520073|NCT00622947|Depression
520074|NCT00622947|antidepressant effect
520075|NCT00622947|rTMS
520076|NCT00622947|sham
520077|NCT00622947|cognition
520078|NCT00622947|saliva cortisol
520079|NCT00622947|brain derived neurotropic factor
520080|NCT00622934|multiple trauma
520081|NCT00622921|PTSD
520082|NCT00622921|alcohol dependence
520083|NCT00622895|scleroderma
520084|NCT00622895|systemic sclerosis
520085|NCT00622882|Staphylococcus aureus
520086|NCT00622882|Bacteremia
520087|NCT00622882|Outcome
520088|NCT00622882|Mortality
520089|NCT00622882|Recurrence
520090|NCT00622882|Infectious Diseases specialists
520091|NCT00622869|Liver transplantation
520092|NCT00622869|everolimus
520093|NCT00622869|calcineurin inhibitors
520094|NCT00622869|tacrolimus
520095|NCT00622869|renal function
520096|NCT00622869|MDRD formula
520097|NCT00622869|progression of fibrosis
520098|NCT00622856|diabetes
520099|NCT00622856|adolescents
520100|NCT00622856|psychological therapy
520101|NCT00622843|pneumococcal conjugate vaccine
520102|NCT00622843|polysaccharide vaccine
520103|NCT00622843|PPV
520104|NCT00622843|PCV
520105|NCT00622843|Streptococcus pneumoniae
520106|NCT00622843|Prevnar
520107|NCT00622843|Pneumovax
520108|NCT00622843|HIV
520109|NCT00622830|darapladib,
520110|NCT00622830|SB480848,
520111|NCT00622830|Japanese healthy volunteers
520112|NCT00622817|Epinephrine
520113|NCT00622817|Nasal decongestant
520114|NCT00622817|RSV
520115|NCT00622817|xylometazoline
520116|NCT00622817|Bronchiolitis
520117|NCT00622804|Stomach cancer
520118|NCT00622804|Gastrectomy
520119|NCT00622804|Postgastrectomy syndrome
520120|NCT00622791|Cardiopulmonary bypass
520121|NCT00622791|coronary artery bypass graft
520122|NCT00622791|coronary artery disease
520123|NCT00622791|propofol
520124|NCT00622791|pharmacokinetics
520125|NCT00622791|pharmacodynamics
520126|NCT00622778|intracranial bleeding
520127|NCT00622778|computed tomography scan
520128|NCT00622765|Obesity, Overweight, Body Weight, Body Size, Nutritional and Metabolic Diseases
520129|NCT00622752|Smoking cessation
520130|NCT00622752|Craving
520131|NCT00622752|Smokers
520132|NCT00622739|Bipolar Disorder
520133|NCT00622739|Children
520134|NCT00622739|Adolescents
520135|NCT00622739|Treatment
520136|NCT00622726|Vascular Endothelial Growth Factor
520137|NCT00622726|Angiogenesis Inhibitor
520138|NCT00622726|Premature infants
520139|NCT00622726|Bevacizumab
520140|NCT00622726|Zone I or Posterior Zone II ROP
520141|NCT00622726|Aggressive Posterior ROP
520142|NCT00622726|Stage 3 ROP
520143|NCT00622726|Neonatal Intensive Care Unit
520144|NCT00622713|Alzheimer's disease
520145|NCT00622713|cholinesterase inhibitor
520146|NCT00622713|rivastigmine
520147|NCT00622700|MS
520148|NCT00622700|Clinically Isolated Syndrome
520149|NCT00622700|CIS
520150|NCT00622700|CDMS
520151|NCT00622700|relapses
520152|NCT00622687|iloprost
520153|NCT00622687|systemic sclerosis
520154|NCT00622687|digital ulcers
520155|NCT00622687|observational study
520156|NCT00622687|randomized
520157|NCT00622674|recurrent breast cancer
520158|NCT00622674|recurrent non-small cell lung cancer
520159|NCT00622674|recurrent small cell lung cancer
520160|NCT00622674|recurrent colon cancer
520161|NCT00622674|recurrent pancreatic cancer
520162|NCT00622674|recurrent head and neck cancer
520163|NCT00622674|recurrent sarcoma
520164|NCT00622674|recurrent kidney cancer
520165|NCT00622674|recurrent renal cell cancer
520166|NCT00622661|Glycemic response
520167|NCT00622661|Glycemic index
520168|NCT00622661|Obesity
520169|NCT00622661|Carbohydrates
520170|NCT00622661|Insulin
520171|NCT00622661|Blood glucose
520172|NCT00622648|Medical prevention therapy
520173|NCT00622635|chronic obstructive pulmonary disease
520174|NCT00622635|COPD
520175|NCT00622635|indacaterol
520176|NCT00622609|first time in human,
520177|NCT00622609|MAG
520178|NCT00622609|monoclonal antibody,
520179|NCT00622609|healthy subjects,
520180|NCT00622609|GSK249320,
520181|NCT00622596|opiate dependence
520182|NCT00622596|buprenorphine
520183|NCT00622583|Herniorrhaphy
520184|NCT00622570|Traumatic brain injury, barbiturate coma
520185|NCT00622544|Microalbuminuria
520186|NCT00622544|Proteinuria
520187|NCT00622531|heart failure
520188|NCT00622531|BNP
520189|NCT00622531|natriuretic peptide
520190|NCT00622518|otitis media
520191|NCT00622518|children
520192|NCT00622505|Multiple myeloma
520193|NCT00622505|zoledronic acid
520194|NCT00622505|skeletal complications
520195|NCT00622505|bone
520196|NCT00622492|VV-ECMO
520197|NCT00622492|VA-ECMO
520198|NCT00622492|PPHN
520199|NCT00622492|organ circulation
520200|NCT00622479|Sorafenib
520201|NCT00622479|Hypophosphatemia
520202|NCT00622479|Left ventricular ejection fraction (LVEF)
520203|NCT00622479|Beta-type Natriuretic Peptide (BNP)
520204|NCT00622466|stage IV breast cancer
520205|NCT00622466|male breast cancer
520206|NCT00622466|recurrent breast cancer
520207|NCT00622466|HER2-negative breast cancer
520208|NCT00622440|HSIL
520209|NCT00622440|HGAIN
520210|NCT00622440|AIN
520211|NCT00622440|neoplasia
520212|NCT00622440|dysplasia
520213|NCT00622440|TCM
520214|NCT00622440|Traditional Chinese Medicine
520215|NCT00622401|stage IV breast cancer
520216|NCT00622401|dendritic cell vaccine
520217|NCT00622401|tumor fusion vaccine
520218|NCT00622401|IL-12
520219|NCT00622375|Pharmacokinetic study
520220|NCT00622375|Healthy subjects
520221|NCT00622362|Immunotherapy
520222|NCT00622362|Allergy
520223|NCT00622362|Allergoid
520224|NCT00622362|Depigmented
520225|NCT00622362|Polymerized
520226|NCT00622362|Allergen-extract
520227|NCT00622362|mites
520228|NCT00622362|Asthma
520229|NCT00622349|Randomised phase III
520230|NCT00622349|Chemotherapy
520231|NCT00622349|Advanced non-small cell lung carcinoma
520232|NCT00622336|Multiple Myeloma
520233|NCT00622336|Revlimid
520234|NCT00622323|diabetes
520235|NCT00622323|exenatide
520236|NCT00622323|metformin
520237|NCT00622323|sulfonylurea
520238|NCT00622323|Byetta
520239|NCT00622323|Amylin
520240|NCT00622323|Lilly
520241|NCT00622271|Type 1 Diabetes Mellitus
520242|NCT00622271|Adolescents and Families
520243|NCT00622271|Group Therapy Intervention
520244|NCT00622258|everolimus
520245|NCT00622258|mTOR inhibitor
520246|NCT00622258|non-Hodgkin's lymphoma
520247|NCT00622245|Depression
520248|NCT00622245|Bipolar disorder
520249|NCT00622245|Placebo-controlled
520250|NCT00622245|Double-blind
520251|NCT00622245|Multicenter
520252|NCT00622245|Clinical study
520253|NCT00622245|Mania
520254|NCT00622232|HIV-1
520255|NCT00622232|treatment experienced, complementary therapies
520256|NCT00622219|Alcohol abuse
520257|NCT00622219|Drug abuse
520258|NCT00622206|Pharmacokinetics
520259|NCT00622206|ritonavir
520260|NCT00622206|saquinavir
520261|NCT00622206|safety and toxicity
520262|NCT00622206|treatment experienced
520263|NCT00622193|NSCLC
520264|NCT00622180|Vitiligo
520265|NCT00622180|Light treatment for vitiligo
520266|NCT00622180|Excilite
520267|NCT00622167|Plaque characteristics
520268|NCT00622167|DSCT
520269|NCT00622167|IVUS
520270|NCT00622141|bioequivalence
520271|NCT00622141|ritonavir boosted generic GPO saquinavir
520272|NCT00622141|saftey
520273|NCT00622141|pharmacokinetics
520274|NCT00622128|Behavioral Research
520275|NCT00622128|Dementia
520276|NCT00622128|Aggression
520277|NCT00622102|warfarin
520278|NCT00622102|adherence
520279|NCT00622102|Mechanical heart valves
520280|NCT00622089|diabetes
520281|NCT00622089|type 2 diabetes
520282|NCT00622089|cholesterol
520283|NCT00622076|postoperative
520284|NCT00622076|Catheterization
520285|NCT00622076|colporrhaphy
520286|NCT00622076|cystocele
520287|NCT00622076|cystitis
520288|NCT00622063|cancer, solid tumor
520289|NCT00622024|Arrhythmia
520290|NCT00622024|Depression
520291|NCT00622024|Coronary Artery Disease
520292|NCT00621998|Risperidone
520293|NCT00621998|Olanzapine
520294|NCT00621998|Tardive dyskinesia
520295|NCT00621972|acute renal failure
520296|NCT00621972|arteriovenous fistula
520297|NCT00621972|KIM-1
520298|NCT00621972|chronic kidney disease
520299|NCT00621959|levocetirizine
520300|NCT00621959|Xyzal
520301|NCT00621959|Seasonal Allergic Rhinitis
520302|NCT00621959|total symptom score
520303|NCT00621959|quality of life
520304|NCT00621946|Asthma
520305|NCT00621946|Depression
520306|NCT00621946|Escitalopram
520307|NCT00621907|randomized
520308|NCT00621907|analgesic
520309|NCT00621907|caesarean scars
520310|NCT00621907|locoregional anaesthesia
520311|NCT00621907|infiltration
520312|NCT00621907|levobupivacaïne
520313|NCT00621907|Chirocaïne
520314|NCT00621907|caesarian
520315|NCT00621907|unique administration
520316|NCT00621907|post-caesarian analgesic
520317|NCT00621894|Immune thrombocytopenic purpura
520318|NCT00621894|thrombopoietin mimetic
520319|NCT00621894|ITP
520320|NCT00621881|hepatic impairment
520321|NCT00621868|Diabetes Mellitus, Type 2
520322|NCT00621868|ASP1941
520323|NCT00621842|Geriatric Psychiatry
520324|NCT00621842|Aged
520325|NCT00621842|lamotrigine
520326|NCT00621816|nitroprusside
520327|NCT00621816|intensive care unit
520328|NCT00621816|hypertension
520329|NCT00621816|blood pressure reduction
520330|NCT00621803|Probiotic
520331|NCT00621803|Pseudomonas aeruginosa
520332|NCT00621803|Gastric colonization
520333|NCT00621803|Respiratory tract colonization
520334|NCT00621803|Ventilator aquired pneumoniae
520335|NCT00621803|determine the effect of oral administration of this probiotic on gastric and respiratory tract colonisation/infection by P. aeruginosa
520336|NCT00621790|fenoldopam
520337|NCT00621790|acute renal failure
520338|NCT00621790|renal replacement therapy
520339|NCT00621790|mortality
520340|NCT00621790|cardiac surgery
520341|NCT00621790|cardiac anesthesia
520342|NCT00621790|intensive care unit
520343|NCT00621777|schizophrenia
520344|NCT00621777|bipolar disorder
520345|NCT00621777|varenicline
520346|NCT00621777|smoking cessation
520347|NCT00621777|relapse prevention
520348|NCT00621777|cognitive behavioral therapy
520349|NCT00621764|Japanese encephalitis (JE)
520350|NCT00621764|Hepatitis A
520351|NCT00621764|Inactivated Mouse-Brain
520352|NCT00621751|Brain Injury
520353|NCT00621751|Irritability
520354|NCT00621751|Aggression
520355|NCT00621738|mental stress
520356|NCT00621738|cardiovascular risk factor
520357|NCT00621738|platelet adhesion
520358|NCT00621725|Advanced cancer
520359|NCT00621725|metastatic
520360|NCT00621725|hepatic impairment
520361|NCT00621712|Renal Dialysis
520362|NCT00621712|Dialysis, Extracorporeal
520363|NCT00621712|Dialysis, Renal
520364|NCT00621712|Extracorporeal Dialysis
520365|NCT00621699|pharmacokinetics
520366|NCT00621699|drug interactions
520367|NCT00621699|ezetimibe
520368|NCT00621699|tacrolimus
520369|NCT00621699|human experimentation
520370|NCT00621686|adult glioblastoma
520371|NCT00621686|adult giant cell glioblastoma
520372|NCT00621686|adult gliosarcoma
520373|NCT00621686|recurrent adult brain tumor
520374|NCT00621673|Hemophilia A,
520375|NCT00621673|Inhibitor formation,
520376|NCT00621673|rFVIII
520377|NCT00621660|Acupuncture therapy
520378|NCT00621660|Cancer
520379|NCT00621660|Emesis
520380|NCT00621660|Expectations
520381|NCT00621660|Placebo
520382|NCT00621647|Seroquel
520383|NCT00621647|dementia
520384|NCT00621647|agitation symptoms
520385|NCT00621647|Alzheimer's disease
520386|NCT00621647|vascular dementia
520387|NCT00621647|quetiapine fumarate
520388|NCT00621634|Tardive dyskinesia
520389|NCT00621634|Schizophrenia
520390|NCT00621634|Essential fatty acids
520391|NCT00621621|atrioventricular nodal reentrant tachycardia
520392|NCT00621621|AVNRT
520393|NCT00621608|Chronic ulcers
520394|NCT00621608|Diabetes
520395|NCT00621608|Hyperbaric Oxygen Therapy
520396|NCT00621595|School Breakfast
520397|NCT00621595|Diet
520398|NCT00621595|Nutrition
520399|NCT00621595|Brain Function
520400|NCT00621595|Cognition
520401|NCT00621595|USDA
520402|NCT00621595|Healthy Children
520403|NCT00621569|Blood Pressure
520404|NCT00621569|Dash Diet
520405|NCT00621543|Intrauterine Device
520406|NCT00621543|Induced Abortion
520407|NCT00621543|Medical Abortion
520408|NCT00621530|Total hip arthroplasty
520409|NCT00621530|Total hip replacement
520410|NCT00621530|Pain, postoperative
520411|NCT00621530|Ketorolac
520412|NCT00621530|Patients undergoing unilateral total hip arthroplasty
520413|NCT00621517|Restless Legs Syndrome
520414|NCT00621517|Bupropion
520415|NCT00621504|ceftaroline
520416|NCT00621504|Community-acquired pneumonia
520417|NCT00621504|CAP
520418|NCT00621504|IV (intravenous)
520419|NCT00621504|Streptococcus pneumoniae
520420|NCT00621504|Haemophilus influenzae
520421|NCT00621504|Mycoplasma pneumoniae
520422|NCT00621504|Chlamydophila spp
520423|NCT00621504|Legionella spp
520424|NCT00621504|Multi-drug resistant Streptococcus pneumoniae (MDRSP)
520425|NCT00621504|antimicrobial resistance
520426|NCT00621504|pneumococci
520427|NCT00621504|Ceftriaxone
520428|NCT00621504|bacteria
520429|NCT00621504|ß-lactam
520430|NCT00621504|beta-lactam
520431|NCT00621504|antibiotic
520432|NCT00621491|cardiac pacing
520433|NCT00621491|pacing complication
520434|NCT00621491|venous thrombosis
520435|NCT00621491|warfarin
520436|NCT00621491|anticoagulation
520437|NCT00621491|randomized trial
520438|NCT00621465|Psychosis
520439|NCT00621465|Homelessness
520440|NCT00621465|Case Management
520441|NCT00621465|Severe Mental Illness
520442|NCT00621439|ocular melanoma
520443|NCT00621426|T wave alternans (TWA)
520444|NCT00621426|dialysis
520445|NCT00621426|end stage renal disease
520446|NCT00621426|sudden cardiac death
520447|NCT00621426|T-wave alternans
520448|NCT00621426|Cardiac electrical instability
520449|NCT00621426|Sympathetic and electrolyte-induced alterations
520450|NCT00621426|Ventricular repolarization
520451|NCT00621413|prostate
520452|NCT00621413|cancer
520453|NCT00621413|intermediate risk
520454|NCT00621413|high risk
520455|NCT00621413|brachytherapy
520456|NCT00621413|Cesium-131
520457|NCT00621413|seed brachytherapy
520458|NCT00621413|intermediate and high risk cancer of the prostate
520459|NCT00621400|newly-diagnosed light-chain (AL)-amyloidosis
520460|NCT00621387|reactive arthritis
520461|NCT00621387|antibiotics
520462|NCT00621374|Pain Management
520463|NCT00621374|Cognitive Behavior Therapy
520464|NCT00621374|Hypnosis
520465|NCT00621361|Lung Cancer
520466|NCT00621361|AZD2171
520467|NCT00621361|cediranib
520468|NCT00621361|RECENTIN
520469|NCT00621361|etoposide
520470|NCT00621361|cisplatin
520471|NCT00621348|maintenance fluids
520472|NCT00621348|hyponatremia
520473|NCT00621348|vasopressin
520474|NCT00621348|children
520475|NCT00621335|Open angle glaucoma
520476|NCT00621335|Ocular hypertension
520477|NCT00621335|Parallel comparison
520478|NCT00621335|Combigan
520479|NCT00621335|Cosopt
520480|NCT00621322|Tuberculosis vaccine
520481|NCT00621309|drug interactions
520482|NCT00621309|cytochrome P4503A4
520483|NCT00621309|Pregnane X-receptor
520484|NCT00621309|induction
520485|NCT00621309|drug metabolism
520486|NCT00621296|Chronic Hepatitis C
520487|NCT00621296|Protease Inhibitor
520488|NCT00621270|Major Depression Neurogenesis
520489|NCT00621270|Major Depressive Disorder with Concomitant Anxiety
520490|NCT00621257|IBD
520491|NCT00621257|Inflammatory Bowel Disease
520492|NCT00621257|Crohn's Disease
520493|NCT00621257|Ulcerative Colitis
520494|NCT00621257|Vitamin D
520495|NCT00621244|HDAC inhibitor
520496|NCT00621244|Oral
520497|NCT00621244|LBH589
520498|NCT00621244|Lymphoma
520499|NCT00621244|Leukemia
520500|NCT00621244|Multiple myeloma
520501|NCT00621231|Protein Function
520502|NCT00621231|normal versus high protein intake
520503|NCT00621218|tretinoin, efficacy, safety, rosacea
520504|NCT00621205|Insulin resistance, weight reduction, adipose tissue, peripheral
520505|NCT00621205|mononuclear cells, gene expression profile, transcriptomics
520506|NCT00621192|meropenem
520507|NCT00621192|infants
520508|NCT00621192|intra-abdominal infection
520509|NCT00621192|pharmacokinetics
520510|NCT00621192|safety
520511|NCT00621179|Endometriosis,infertility,in vitro fertilization
520512|NCT00621166|Generic lopinavir/ritonavir
520513|NCT00621166|Pharmacokinetics
520514|NCT00621166|Pregnancy
520515|NCT00621166|Antiviral activity
520516|NCT00621166|Safety
520517|NCT00621153|Candesartan Cilexetil
520518|NCT00621153|hydrochlorothiazide
520519|NCT00621153|severe hypertension
520520|NCT00621114|Dialysis, Extracorporeal
520521|NCT00621114|Dialysis, Renal
520522|NCT00621114|Extracorporeal Dialysis
520523|NCT00621114|Hemodialysis
520524|NCT00621101|pharmacokinetics
520525|NCT00621101|drug interactions
520526|NCT00621101|ezetimibe
520527|NCT00621101|sirolimus
520528|NCT00621101|human experimentation
520529|NCT00621075|PAH; V/Q SCAN;RHC;Echo;CT Scans; Angiography;PFTs
520530|NCT00621062|varicose
520531|NCT00621062|vein
520532|NCT00621062|ligation
520533|NCT00621062|laser
520534|NCT00621062|foam
520535|NCT00621062|sclerotherapy
520536|NCT00621062|radiofrequency
520537|NCT00621062|duplex
520538|NCT00621062|sf36
520539|NCT00621062|Aberdeen
520540|NCT00621062|VCSS
520541|NCT00621062|quality
520542|NCT00621062|recurrence
520543|NCT00621049|Non-Small Cell Lung Cancer
520544|NCT00621049|Resected
520545|NCT00621049|Carboplatin
520546|NCT00621049|Docetaxel
520547|NCT00621049|Bevacizumab
520548|NCT00621049|Erlotinib
520549|NCT00621036|primary central nervous system non-Hodgkin lymphoma
520550|NCT00621036|primary central nervous system Hodgkin lymphoma
520551|NCT00621036|stage IV adult T-cell leukemia/lymphoma
520552|NCT00621036|adult nasal type extranodal NK/T-cell lymphoma
520553|NCT00621036|anaplastic large cell lymphoma
520554|NCT00621036|angioimmunoblastic T-cell lymphoma
520555|NCT00621036|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
520556|NCT00621036|stage IV adult Burkitt lymphoma
520557|NCT00621036|stage IV adult diffuse large cell lymphoma
520558|NCT00621036|stage IV adult diffuse mixed cell lymphoma
520559|NCT00621036|stage IV adult diffuse small cleaved cell lymphoma
520560|NCT00621036|stage IV adult Hodgkin lymphoma
520561|NCT00621036|stage IV adult immunoblastic large cell lymphoma
520562|NCT00621036|stage IV adult lymphoblastic lymphoma
520563|NCT00621036|stage IV childhood Hodgkin lymphoma
520564|NCT00621036|stage IV childhood large cell lymphoma
520565|NCT00621036|stage IV childhood lymphoblastic lymphoma
520566|NCT00621036|stage IV childhood small noncleaved cell lymphoma
520567|NCT00621036|stage IV cutaneous T-cell non-Hodgkin lymphoma
520568|NCT00621036|stage IV mycosis fungoides/Sezary syndrome
520569|NCT00621036|stage IV grade 1 follicular lymphoma
520570|NCT00621036|stage IV grade 2 follicular lymphoma
520571|NCT00621036|stage IV grade 3 follicular lymphoma
520572|NCT00621036|stage IV mantle cell lymphoma
520573|NCT00621036|stage IV marginal zone lymphoma
520574|NCT00621036|stage IV small lymphocytic lymphoma
520575|NCT00621036|intraocular lymphoma
520576|NCT00621036|post-transplant lymphoproliferative disorder
520577|NCT00621036|cutaneous B-cell non-Hodgkin lymphoma
520578|NCT00621036|Waldenstrom macroglobulinemia
520579|NCT00621036|small intestine lymphoma
520580|NCT00621036|stage IV childhood anaplastic large cell lymphoma
520581|NCT00621023|Myelodysplastic syndrome
520582|NCT00621023|MDS
520583|NCT00620997|cornea
520584|NCT00620997|analgesia
520585|NCT00620997|topical
520586|NCT00620997|anesthetic
520587|NCT00620984|Staphylococcus aureus
520588|NCT00620984|Breastfeeding
520589|NCT00620984|Lactational Mastitis
520590|NCT00620984|Polymerase Chain Reaction (PCR) amplification analysis
520591|NCT00620984|staphylococcal infections
520592|NCT00620984|staphylococcal Carrier State
520593|NCT00620971|Non Small Cell Lung Cancer
520594|NCT00620971|Cisplatin
520595|NCT00620971|VInorelbine
520596|NCT00620971|Docetaxel
520597|NCT00620971|Gemcitabine
520598|NCT00620971|Bevacizumab
520599|NCT00620958|Mediation
520600|NCT00620958|Outcome
520601|NCT00620958|CBT
520602|NCT00620958|Child Anxiety Intervention
520603|NCT00620945|Congenital heart surgery
520604|NCT00620945|Cardiopulmonary bypass
520605|NCT00620945|Phenoxybenzamine
520606|NCT00620906|manipulation
520607|NCT00620906|manual therapy
520608|NCT00620906|Sacroiliac joint
520609|NCT00620906|effects on manipulation on sacroiliac joint
520610|NCT00620893|Dry eye signs and symptoms
520611|NCT00620893|refractive regression
520612|NCT00620841|Tacrolimus
520613|NCT00620841|Renal Transplantation
520614|NCT00620841|genetic polymorphisms
520615|NCT00620841|Drug drug interactions
520616|NCT00620815|avian flu
520617|NCT00620815|seasonal influenza vaccine
520618|NCT00620815|influenza vaccine
520619|NCT00620815|prepandemic vaccine
520620|NCT00620815|virus strain with the potential to cause pandemic
520621|NCT00620815|tetravalent vaccine
520622|NCT00620815|Prophylaxis of influenza
520623|NCT00620802|Platelet function testing
520624|NCT00620802|Healthy volunteers
520625|NCT00620789|Insomnia
520626|NCT00620789|Depression
520627|NCT00620776|Generalized Anxiety Disorder
520628|NCT00620776|Cognitive Behavioral Therapy
520629|NCT00620776|Psychotherapy plus medication
520630|NCT00620776|Combined treatment
520631|NCT00620763|Meat protein
520632|NCT00620763|acid load
520633|NCT00620763|calcium retention
520634|NCT00620763|postmenopausal women
520635|NCT00620750|Alcohol dependence
520763|NCT00620178|candesartan
520636|NCT00620711|Hypoxic ischemic encephalopathy
520637|NCT00620711|HIE
520638|NCT00620711|Neonatal encephalopathy
520639|NCT00620711|Cooling
520640|NCT00620711|hypothermia
520641|NCT00620698|amyotrophic lateral sclerosis
520642|NCT00620698|motor neuron disease
520643|NCT00620698|outcome measure
520644|NCT00620698|biomarker
520645|NCT00620698|impedance
520646|NCT00620685|Arthritis, rheumatoid
520647|NCT00620672|n-3 supplementation during pregnancy
520648|NCT00620672|DHA and pregnancy, infant development
520649|NCT00620672|n-3 status and gestation
520650|NCT00620672|DHA and visual acuity and cognition during infancy
520651|NCT00620646|clopidogrel
520652|NCT00620646|platelets
520653|NCT00620646|percutaneous coronary intervention
520654|NCT00620633|Bone Marrow
520655|NCT00620620|Healthy adult volunteers
520656|NCT00620607|gastric
520657|NCT00620594|Neoplasms
520658|NCT00620594|breast neoplasms
520659|NCT00620594|breast diseases
520660|NCT00620594|solid tumors
520661|NCT00620594|BEZ235
520662|NCT00620594|breast cancer
520663|NCT00620594|PI3K Inhibitor
520664|NCT00620594|Phosphatidylinositol 3
520665|NCT00620594|kinase
520666|NCT00620594|advanced
520667|NCT00620568|Safety
520668|NCT00620568|Tolerability
520669|NCT00620568|Schizophrenia
520670|NCT00620542|Coronary artery disease
520671|NCT00620529|polycystic ovary syndrome
520672|NCT00620529|cardiovascular risk
520673|NCT00620529|metabolism
520674|NCT00620529|blood pressure
520675|NCT00620529|liver fat
520676|NCT00620529|heart rate variability
520677|NCT00620503|PK
520678|NCT00620503|Pharmacokinetics
520679|NCT00620490|Epidural analgesia
520680|NCT00620490|Contraindications
520681|NCT00620490|Paravertebral nerve block analgesia
520682|NCT00620490|ropivacaine
520683|NCT00620490|Visual analogical scale
520684|NCT00620490|Morphine
520685|NCT00620490|Side effects
520686|NCT00620490|Pain and thoracotomy
520687|NCT00620451|Treatment
520688|NCT00620451|Active
520689|NCT00620451|Celiac
520690|NCT00620451|Remission
520691|NCT00620451|Induction
520692|NCT00620438|Lumefantrine
520693|NCT00620438|Efavirenz
520694|NCT00620438|Nevirapine
520695|NCT00620438|Rifampicin
520696|NCT00620438|HIV
520697|NCT00620425|sumatriptan
520698|NCT00620425|Intraject
520699|NCT00620425|Local Site Reactions
520700|NCT00620412|influenza
520701|NCT00620412|vaccines
520702|NCT00620412|probiotics
520703|NCT00620412|LGG
520704|NCT00620399|lumbar fusion
520705|NCT00620386|Intubating conditions
520706|NCT00620386|Bonfils intubation fiberscope
520707|NCT00620386|Macintosh laryngoscope
520708|NCT00620386|neuromuscular blockade
520709|NCT00620373|Dense breast tissue
520710|NCT00620373|Breast Cancer Screening
520711|NCT00620373|Molecular Breast Imaging
520712|NCT00620373|Breast Cancer
520713|NCT00620373|Breast
520714|NCT00620360|dietary fructose
520715|NCT00620360|plasma lipids
520716|NCT00620360|healthy humans
520717|NCT00620360|gender differences
520718|NCT00620360|hepatic de novo lipogenesis
520719|NCT00620347|SCLC (small cell lung cancer)
520720|NCT00620347|ED (extensive disease)
520721|NCT00620347|RR (response rate)
520722|NCT00620334|ASTHMA
520723|NCT00620295|recurrent pancreatic cancer
520724|NCT00620295|recurrent breast cancer
520725|NCT00620295|recurrent small cell lung cancer
520726|NCT00620295|recurrent non-small cell lung cancer
520727|NCT00620295|recurrent colon cancer
520728|NCT00620295|recurrent prostate cancer
520729|NCT00620295|recurrent head and neck cancer
520730|NCT00620295|ovarian cancer
520731|NCT00620295|recurrent uterine cancer
520732|NCT00620295|recurrent kidney cancer
520733|NCT00620295|recurrent osteosarcoma
520734|NCT00620269|NSCLC
520735|NCT00620269|EGFR mutation
520736|NCT00620269|Erlotinib
520737|NCT00620269|IP chemotherapy
520738|NCT00620269|CCRT
520739|NCT00620256|Glaucoma
520740|NCT00620256|Hypertension
520741|NCT00620243|Ovarian cancer
520742|NCT00620243|PET
520743|NCT00620243|CT
520744|NCT00620243|04-064
520745|NCT00620230|Allergic rhinitis, anti-interleukin 4
520746|NCT00620217|heart ischemia
520747|NCT00620217|coronary artery disease
520748|NCT00620217|plasmid
520749|NCT00620217|VEGF
520750|NCT00620217|FGF
520751|NCT00620217|percutaneous
520752|NCT00620217|gene therapy
520753|NCT00620217|SPECT
520754|NCT00620217|nuclear magnetic resonance
520755|NCT00620204|atorvastatin
520756|NCT00620204|Angina Pectoris, Variant
520757|NCT00620204|endothelial dysfunction
520758|NCT00620191|metformin
520759|NCT00620191|mild cognitive impairment
520760|NCT00620191|alzheimer's disease
520761|NCT00620191|overweight
520762|NCT00620191|insulin
520764|NCT00620178|losartan
520765|NCT00620178|blood pressure
520766|NCT00620178|cardiovascular disease
520767|NCT00620178|health care consumption
520768|NCT00620165|tremor
520769|NCT00620165|writing
520770|NCT00620165|feeding
520771|NCT00620165|pouring
520772|NCT00620139|head and neck squamous cell carcinoma
520773|NCT00620139|chemoradiotherapy
520774|NCT00620139|molecular effects
520775|NCT00620139|05-016
520776|NCT00620126|Inflammatory bowel disease
520777|NCT00620126|Ulcerative colitis
520778|NCT00620126|Telemedicine
520779|NCT00620126|Telemanagement
520780|NCT00620126|Chronic disease
520781|NCT00620087|Atypical lobular hyperplasia
520782|NCT00620087|Atypical ductal hyperplasia
520783|NCT00620087|Lobular carcinoma in situ
520784|NCT00620087|Molecular Breast Imaging
520785|NCT00620074|invasive aspergillosis, opportunistic mold infection
520786|NCT00620048|heart
520787|NCT00620048|stem Cells
520788|NCT00620048|low EF
520789|NCT00620048|heart attack
520790|NCT00620048|cardiomyopathy
520791|NCT00620048|congestive heart failure
520792|NCT00620048|cardiovascular disease
520793|NCT00620048|Heart Failure
520794|NCT00620048|Low Ejection Fraction
520795|NCT00620022|indacaterol
520796|NCT00620022|chronic obstructive pulmonary disease
520797|NCT00620022|exercise endurance
520798|NCT00620022|moderate to severe chronic obstructive pulmonary disease
520799|NCT00620022|COPD
520800|NCT00620009|Empathy
520801|NCT00620009|Feedback
520802|NCT00620009|Psychotherapy
520803|NCT00619996|Prostate Cancer
520804|NCT00619996|Sorafenib
520805|NCT00619996|Nexavar
520806|NCT00619996|Docetaxel
520807|NCT00619996|Pisa
520808|NCT00619996|Ricci
520809|NCT00619983|Asymmetric Diabetic Proximal Motor Neuropathy
520810|NCT00619983|Diabetic Autonomic Neuropathy
520811|NCT00619983|Diabetic Neuralgia
520812|NCT00619983|Diabetic Neuropathy, Painful
520813|NCT00619983|Neuralgia, Diabetic
520814|NCT00619983|Low back pain, chronic
520815|NCT00619944|HIV
520816|NCT00619944|lumefantrine
520817|NCT00619944|lopinavir
520818|NCT00619944|Africa
520819|NCT00619944|Antimalarials
520820|NCT00619944|treatment naïve
520821|NCT00619931|Healthy adult volunteers
520822|NCT00619918|bronchiolitis
520823|NCT00619918|hypertonic saline
520824|NCT00619905|Rheumatoid Arthritis
520825|NCT00619905|Anti-interleukin-1 beta
520826|NCT00619905|ACZ885
520827|NCT00619892|SSRI Resistant
520828|NCT00619892|Seroquel SR
520829|NCT00619892|Seroquel XR
520830|NCT00619892|Panic Disorder
520831|NCT00619892|Comorbid Panic Disorder
520832|NCT00619892|Quetiapine SR
520833|NCT00619892|Quetiapine XR
520834|NCT00619879|Leukemia, Myelogenous, Chronic
520835|NCT00619879|Leukemia, Lymphoblastic, Acute
520836|NCT00619879|Leukemia, Myelogenous, Acute
520837|NCT00619879|Myeloproliferative-Myelodysplastic Diseases
520838|NCT00619879|Juvenile Myelomonocytic Leukemia
520839|NCT00619879|Dysmyelopoietic Syndromes
520840|NCT00619879|Lymphoma, Malignant
520841|NCT00619879|Stem Cell Transplantation, Hematopoietic
520842|NCT00619879|Allogeneic Transplantation
520843|NCT00619879|Human Leukocyte Antigens
520844|NCT00619879|Busulfan
520845|NCT00619879|Total Body Irradiation
520846|NCT00619879|VP-16
520847|NCT00619879|Etoposide
520848|NCT00619879|Cyclophosphamide
520849|NCT00619879|Graft-Versus-Host Disease
520850|NCT00619866|bone mineral density
520851|NCT00619866|NBI-56418
520852|NCT00619866|estradiol
520853|NCT00619866|Endometriosis
520854|NCT00619866|Pelvic Pain
520855|NCT00619853|Improving the assisting hand function in children with Hemiplegic Cerebral palsy
520856|NCT00619840|ADHD
520857|NCT00619840|Attention Deficit Hyperactivity Disorder
520858|NCT00619840|adult
520859|NCT00619840|methylphenidate hydrochloride
520860|NCT00619840|Medikinet retard
520861|NCT00619840|long-term observation
520862|NCT00619840|controlled clinical trial
520863|NCT00619840|safety
520864|NCT00619840|randomized, double-blind, placebo-controlled trial
520865|NCT00619840|treatment
520866|NCT00619840|central nervous system stimulants
520867|NCT00619840|therapeutic uses
520868|NCT00619827|Sublingual immunotherapy
520869|NCT00619827|Rhinitis
520870|NCT00619827|Conjunctivitis
520871|NCT00619827|Allergen challenge
520872|NCT00619827|Allergen exposition chamber
520873|NCT00619827|Grass pollen tablet
520874|NCT00619827|Allergic rhinoconjunctivitis
520875|NCT00619814|Colon polyps
520876|NCT00619814|Fecal occult blood test
520877|NCT00619814|Double contrast barium enema
520878|NCT00619814|Colonoscopy
520879|NCT00619801|Xyzal
520880|NCT00619801|Levocetirizine
520881|NCT00619801|Allergy
520882|NCT00619801|Children
520883|NCT00619801|Seasonal Allergies
520884|NCT00619775|Carotid Artery Disease
520885|NCT00619775|Embolic Protection
520886|NCT00619762|Breast reconstruction
520887|NCT00619736|Healthy
520888|NCT00619710|skin infections
520889|NCT00619710|MERREM
520890|NCT00619710|PRIMAXIN IV
520891|NCT00619710|complex abscess
520892|NCT00619710|perirectal abscess
520893|NCT00619710|wound infections
520894|NCT00619710|infected ischemic/diabetic ulcers
520895|NCT00619710|cellulitis
520896|NCT00619710|Meropenem
520897|NCT00619710|Imipenem-cilastatin
520898|NCT00619671|Rituxan
520899|NCT00619671|Rituximab
520900|NCT00619671|Myasthenia Gravis
520901|NCT00619671|MG
520902|NCT00619658|telephone follow-up
520903|NCT00619658|medical abortion
520904|NCT00619658|induced abortion
520905|NCT00619645|recurrent adult acute myeloid leukemia
520906|NCT00619645|adult acute lymphoblastic leukemia in remission
520907|NCT00619645|refractory anemia with excess blasts
520908|NCT00619645|refractory anemia with ringed sideroblasts
520909|NCT00619645|refractory anemia
520910|NCT00619645|refractory cytopenia with multilineage dysplasia
520911|NCT00619645|previously treated myelodysplastic syndromes
520912|NCT00619645|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
520913|NCT00619645|adult acute myeloid leukemia in remission
520914|NCT00619645|adult acute myeloid leukemia with inv(16)(p13;q22)
520915|NCT00619645|adult acute myeloid leukemia with t(15;17)(q22;q12)
520916|NCT00619645|adult acute myeloid leukemia with t(16;16)(p13;q22)
520917|NCT00619645|adult acute myeloid leukemia with t(8;21)(q22;q22)
520918|NCT00619645|chronic phase chronic myelogenous leukemia
520919|NCT00619645|relapsing chronic myelogenous leukemia
520920|NCT00619645|refractory chronic lymphocytic leukemia
520921|NCT00619645|recurrent adult Hodgkin lymphoma
520922|NCT00619645|refractory multiple myeloma
520923|NCT00619645|recurrent adult acute lymphoblastic leukemia
520924|NCT00619645|stage III chronic lymphocytic leukemia
520925|NCT00619645|stage IV chronic lymphocytic leukemia
520926|NCT00619645|stage III adult Hodgkin lymphoma
520927|NCT00619645|stage IV adult Hodgkin lymphoma
520928|NCT00619645|secondary acute myeloid leukemia
520929|NCT00619645|recurrent small lymphocytic lymphoma
520930|NCT00619645|stage III small lymphocytic lymphoma
520931|NCT00619645|stage IV small lymphocytic lymphoma
520932|NCT00619645|stage III grade 1 follicular lymphoma
520933|NCT00619645|stage III grade 2 follicular lymphoma
520934|NCT00619645|stage III grade 3 follicular lymphoma
520935|NCT00619645|stage IV grade 1 follicular lymphoma
520936|NCT00619645|stage IV grade 2 follicular lymphoma
520937|NCT00619645|stage IV grade 3 follicular lymphoma
520938|NCT00619645|recurrent grade 1 follicular lymphoma
520939|NCT00619645|recurrent grade 2 follicular lymphoma
520940|NCT00619645|recurrent grade 3 follicular lymphoma
520941|NCT00619645|stage III adult diffuse large cell lymphoma
520942|NCT00619645|stage III adult diffuse mixed cell lymphoma
520943|NCT00619645|stage III adult diffuse small cleaved cell lymphoma
520944|NCT00619645|stage IV adult diffuse large cell lymphoma
520945|NCT00619645|stage IV adult diffuse mixed cell lymphoma
520946|NCT00619645|stage IV adult diffuse small cleaved cell lymphoma
520947|NCT00619645|recurrent adult diffuse large cell lymphoma
520948|NCT00619645|recurrent adult diffuse mixed cell lymphoma
520949|NCT00619645|recurrent adult diffuse small cleaved cell lymphoma
520950|NCT00619645|stage III adult immunoblastic large cell lymphoma
520951|NCT00619645|stage IV adult immunoblastic large cell lymphoma
520952|NCT00619645|recurrent adult immunoblastic large cell lymphoma
520953|NCT00619645|stage III adult lymphoblastic lymphoma
520954|NCT00619645|stage IV adult lymphoblastic lymphoma
520955|NCT00619645|recurrent adult lymphoblastic lymphoma
520956|NCT00619645|stage III adult Burkitt lymphoma
520957|NCT00619645|stage IV adult Burkitt lymphoma
520958|NCT00619645|recurrent adult Burkitt lymphoma
520959|NCT00619645|stage I multiple myeloma
520960|NCT00619645|stage II multiple myeloma
520961|NCT00619645|stage III multiple myeloma
520962|NCT00619645|de novo myelodysplastic syndromes
520963|NCT00619645|secondary myelodysplastic syndromes
520964|NCT00619619|MDD
520965|NCT00619619|Child
520966|NCT00619619|Adolescent
520967|NCT00619619|Pharmacokinetic
520968|NCT00619619|Outpatient
520969|NCT00619619|Pediatrics
520970|NCT00619619|Depressive Disorder
520971|NCT00619619|Major
520972|NCT00619606|prevention of hypoxia
520973|NCT00619606|prevention of hypercapnia
520974|NCT00619593|Heart failure
520975|NCT00619593|Ventricular Fibrillation
520976|NCT00619593|Sudden cardiac death
520977|NCT00619593|Hospitalization due to heart failure
520978|NCT00619593|Implantable cardioverter-defibrillator
520979|NCT00619593|Risk of 1st heart failure hospitalization
520980|NCT00619580|E coli
520981|NCT00619567|Cognition
520982|NCT00619567|Rehabilitation
520983|NCT00619567|Cognitive Stimulation
520984|NCT00619567|Human Immunodeficiency Virus
520985|NCT00619567|AIDS
520986|NCT00619554|Healthy volunteers
520987|NCT00619541|HCC
520988|NCT00619541|Sorafenib
520989|NCT00619541|Pisa
520990|NCT00619541|Ricci
520991|NCT00619541|5-FU
520992|NCT00619541|5FU
520993|NCT00619541|5 FU
520994|NCT00619541|Advanced HCC
520995|NCT00619528|Transplants
520996|NCT00619528|Kidney Transplantation
520997|NCT00619528|Immunosuppression
520998|NCT00619528|HLA Antigens
520999|NCT00619528|Stem Cells
521000|NCT00619528|Bone Marrow
521001|NCT00619515|adenocarcinoma of the prostate
521002|NCT00619515|stage I prostate cancer
521003|NCT00619515|stage II prostate cancer
521004|NCT00619502|Hepatitis B
521005|NCT00619502|Polio
521006|NCT00619502|Diphtheria
521007|NCT00619502|Pertussis
521008|NCT00619502|H.influenzae type b
521009|NCT00619476|Neuropathic Pain
521010|NCT00619476|Post-herpetic neuralgia
521011|NCT00619476|PHN
521012|NCT00619463|Traumatic Brain Injury
521013|NCT00619463|Exercise
521014|NCT00619463|Cognition
521015|NCT00619463|Brain Derived Neurotrophic Factor (BDNF)
521016|NCT00619463|peripheral vascular endothelial growth factor (VEGF)
521017|NCT00619450|atrial fibrillation
521018|NCT00619450|cardiac pacing
521019|NCT00619450|CAT scanner
521020|NCT00619437|schizophrenia
521021|NCT00619437|genetics
521022|NCT00619437|family
521023|NCT00619437|multiplex
521024|NCT00619437|haplotypes
521025|NCT00619424|erlotinib
521026|NCT00619424|pharmacokinetics
521027|NCT00619424|Solid tumors
521028|NCT00619424|pemetrexed
521029|NCT00619424|anti-angiogenesis
521030|NCT00619424|pazopanib (GW786034)
521031|NCT00619424|cytokine and angiogenic factors
521032|NCT00619411|Major Depression
521033|NCT00619411|Dysthymic Disorder
521034|NCT00619411|Adjustment Disorder
521035|NCT00619411|With Depressed Mood
521036|NCT00619411|Depressive
521037|NCT00619411|Disorder Not
521038|NCT00619411|Otherwise
521039|NCT00619411|Specified
521040|NCT00619411|Adolescent
521041|NCT00619411|Psychotherapy
521042|NCT00619398|FK506
521043|NCT00619398|tacrolimus
521044|NCT00619398|prograf
521045|NCT00619398|Liver transplantation
521046|NCT00619385|Pharmacokinetics
521047|NCT00619372|OKT3
521048|NCT00619372|beta-glucosylceramide
521049|NCT00619372|oral tolerance
521050|NCT00619372|anti-CD3
521051|NCT00619372|Safety assessment and healthy volunteers
521052|NCT00619346|Safety
521053|NCT00619346|Tolerability
521054|NCT00619346|Assessment of potential adverse events and/or laboratory abnormalities
521055|NCT00619320|HIV primary prevention
521056|NCT00619320|Health promotion
521057|NCT00619320|Health behavior
521058|NCT00619320|Risk reduction behavior
521059|NCT00619320|Sexual behavior
521060|NCT00619320|Safe sex
521061|NCT00619320|Women's health
521062|NCT00619320|Minority health
521063|NCT00619320|Pregnant Women
521064|NCT00619320|HIV seronegativity
521065|NCT00619294|Coronary Vasospasm
521066|NCT00619294|Endothelium, Vascular
521067|NCT00619294|Vasodilation
521068|NCT00619294|Hyperemia
521069|NCT00619281|Cardiac surgery
521070|NCT00619281|Low cardiac output syndrome
521071|NCT00619281|Mortality
521072|NCT00619281|Morbidity
521073|NCT00619268|Temsirolimus
521074|NCT00619268|Bevacizumab
521075|NCT00619268|Metastatic renal cell carcinoma
521076|NCT00619268|Non-progression
521077|NCT00619255|Adolescents
521078|NCT00619255|Quality Assurance and Improvement
521079|NCT00619255|Substance Abuse
521080|NCT00619255|Posttraumatic Stress
521081|NCT00619255|Family Centered Care
521082|NCT00619255|Trauma Systems
521083|NCT00619242|Esophageal cancer
521084|NCT00619229|Alprostadil
521085|NCT00619229|prostaglandin E1
521086|NCT00619229|Prostavasin®
521087|NCT00619229|macular degeneration
521088|NCT00619216|Orthotopic Liver Transplant Recipients with GI disturbance
521089|NCT00619203|Bacterial meningitis
521090|NCT00619203|glycerol
521091|NCT00619203|high dose paracetamol
521092|NCT00619203|children
521093|NCT00619190|open label
521094|NCT00619190|aripiprazole
521095|NCT00619190|children
521096|NCT00619190|adolescents
521097|NCT00619190|autism spectrum disorders
521098|NCT00619164|Platelet Aggregation Inhibitors
521099|NCT00619164|Coronary Stenosis
521100|NCT00619164|Coronary Thrombosis
521101|NCT00619151|aortic valve
521102|NCT00619151|heart valve
521103|NCT00619151|valve replacement
521104|NCT00619151|Valve disease
521105|NCT00619138|Cognitive therapy
521106|NCT00619138|Stepped care
521107|NCT00619138|Self-help
521108|NCT00619138|Internet
521109|NCT00619138|Anxiety
521110|NCT00619112|adult glioblastoma
521111|NCT00619112|adult gliosarcoma
521112|NCT00619112|adult anaplastic astrocytoma
521113|NCT00619112|adult anaplastic oligodendroglioma
521114|NCT00619112|adult mixed glioma
521115|NCT00619112|recurrent adult brain tumor
521116|NCT00619099|Myelodysplastic Syndrome
521117|NCT00619099|Decitabine
521118|NCT00619099|Dacogen
521119|NCT00619099|MGI PHARMA, Inc.
521120|NCT00619086|thyroidectomy
521121|NCT00619086|dexamethasone
521122|NCT00619086|steroid
521123|NCT00619086|nausea
521124|NCT00619073|blood platelets
521125|NCT00619073|platelet aggregation inhibitors
521126|NCT00619073|antiplatelet drugs
521127|NCT00619073|clopidogrel
521128|NCT00619060|skin cancer
521129|NCT00619060|healthy, no evidence of disease
521130|NCT00619021|recurrent non-small cell lung cancer
521131|NCT00619021|stage I non-small cell lung cancer
521132|NCT00619021|stage II non-small cell lung cancer
521133|NCT00619008|obesity
521134|NCT00619008|low carbohydrate diet
521135|NCT00619008|high complex carbohydrate diet
521136|NCT00619008|weight regulation hormones
521137|NCT00619008|hunger
521138|NCT00619008|satiety
521139|NCT00619008|energy expenditure
521140|NCT00619008|body composition
521141|NCT00619008|weight loss
521142|NCT00618982|Kidney cancer,
521143|NCT00618982|Sorafenib,
521144|NCT00618982|Dose escalation,
521145|NCT00618982|No previous treatment
521146|NCT00618969|Haploidentical
521147|NCT00618969|peripheral blood stem cell transplantation
521148|NCT00618969|leukemia
521149|NCT00618969|myeloma
521150|NCT00618969|Hodgkin's disease
521151|NCT00618969|non-Hodgkin's lymphoma
521152|NCT00618956|NSRI
521153|NCT00618956|milnacipran
521154|NCT00618956|fibromyalgia
521155|NCT00618956|blood pressure
521156|NCT00618956|hypertension
521157|NCT00618917|NSCLC
521158|NCT00618917|lung cancer
521159|NCT00618917|chemotherapy
521160|NCT00618917|radiation therapy
521161|NCT00618917|radiation toxicity
521162|NCT00618904|Probiotics
521163|NCT00618904|Functional Gastrointestinal Symptoms
521164|NCT00618865|Omega-3 Fatty Acids
521165|NCT00618865|Major Depressive Disorder
521166|NCT00618865|Pregnancy
521167|NCT00618865|Women during pregnancy and after childbirth are more vulnerable to psychiatric disorders
521168|NCT00618865|Pharmacotherapy for depression during pregnancy is a clinical dilemma.
521169|NCT00618865|Omega-3 polyunsaturated fatty acids (PUFAs) might be a promising alternative of treatment for pregnant women with depression.
521170|NCT00618852|Pediatrics
521171|NCT00618852|Erythrocyte Transfusion
521172|NCT00618852|Furosemide
521173|NCT00618852|Fluid Overload
521174|NCT00618839|Complex skin defects
521175|NCT00618839|Burns
521176|NCT00618839|Wound infection
521177|NCT00618839|Skin trauma
521178|NCT00618826|Breast cancer
521179|NCT00618800|Falls
521180|NCT00618800|Elderly
521181|NCT00618800|Injury
521182|NCT00618800|Medication
521183|NCT00618800|Pharmacy
521184|NCT00618800|Pharmacist
521185|NCT00618761|glucose clamp
521186|NCT00618761|beta-cell
521187|NCT00618748|Bipolar
521188|NCT00618709|Healthy volunteers
521189|NCT00618696|recurrent adult acute lymphoblastic leukemia
521190|NCT00618696|recurrent adult acute myeloid leukemia
521191|NCT00618696|secondary acute myeloid leukemia
521192|NCT00618696|previously treated myelodysplastic syndromes
521193|NCT00618696|blastic phase chronic myelogenous leukemia
521194|NCT00618696|relapsing chronic myelogenous leukemia
521195|NCT00618696|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
521196|NCT00618696|adult acute myeloid leukemia with inv(16)(p13;q22)
521197|NCT00618696|adult acute myeloid leukemia with t(15;17)(q22;q12)
521198|NCT00618696|adult acute myeloid leukemia with t(16;16)(p13;q22)
521199|NCT00618696|adult acute myeloid leukemia with t(8;21)(q22;q22)
521200|NCT00618683|AVNRT
521201|NCT00618683|Atrioventricular
521202|NCT00618683|nodal reentrant circuit
521203|NCT00618683|nodal reentrant tachycardia
521204|NCT00618683|Paroxysmal supraventricular tachycardia
521205|NCT00618670|aging
521206|NCT00618670|gait
521207|NCT00618670|musculoskeletal disorder therapy
521208|NCT00618670|peripheral blood vessel disorder
521209|NCT00618670|muscle function
521210|NCT00618670|muscle strength
521211|NCT00618670|quality of life
521212|NCT00618657|pre-operative
521213|NCT00618657|neo-adjuvant
521214|NCT00618657|triple negative
521215|NCT00618657|HER2 positive
521216|NCT00618657|hormone receptor positive
521217|NCT00618657|breast
521218|NCT00618657|Carboplatin
521219|NCT00618657|Nab-paclitaxel
521220|NCT00618657|Trastuzumab
521221|NCT00618657|Bevacizumab
521222|NCT00618657|Inflammatory
521223|NCT00618631|Smoking
521224|NCT00618631|Nicotine
521225|NCT00618631|Endogenous Opioids
521226|NCT00618631|PET Study
521227|NCT00618631|Carfentanil
521228|NCT00618605|HIV Seronegativity
521229|NCT00618605|HIV Preventative Vaccine
521230|NCT00618592|carbohydrate supplementation
521231|NCT00618592|cardiac surgery
521232|NCT00618592|spine surgery
521233|NCT00618592|insulin resistance
521234|NCT00618592|insulin sensitivity
521235|NCT00618592|short insulin tolerance test
521236|NCT00618592|HOMA
521237|NCT00618592|outcomes
521238|NCT00618579|Interaction with LMWH or warfarin
521239|NCT00618566|Women with physical Disabilities
521240|NCT00618566|Secondary Conditions
521241|NCT00618566|Depression
521242|NCT00618566|Cognitive Behavioral Therapy
521243|NCT00618566|Consumer Control
521244|NCT00618553|Lung Cancer
521245|NCT00618553|Pulmonary Rehabilitation
521246|NCT00618553|Questionnaire
521247|NCT00618553|Survey
521248|NCT00618553|Lung Function
521249|NCT00618553|Quality of Life
521250|NCT00618540|childhood Langerhans cell histiocytosis
521251|NCT00618527|relapsing remitting multiple sclerosis
521252|NCT00618527|multiple sclerosis
521253|NCT00618514|Varicose Veins
521254|NCT00618514|Laser Ablation
521255|NCT00618514|Laser Wire Fibers
521256|NCT00618501|untreated adult acute lymphoblastic leukemia
521257|NCT00618488|Probiotics
521258|NCT00618488|BB12
521259|NCT00618488|Gastrointestinal Symptoms
521260|NCT00618475|Depression
521261|NCT00618475|End Stage Renal Disease
521262|NCT00618475|Kidney Disease
521263|NCT00618475|Mental Health
521264|NCT00618462|Cognitive Behavioral Therapy
521265|NCT00618462|Pathological Gambling
521266|NCT00618449|Trachoma
521267|NCT00618449|Chlamydia trachomatis
521268|NCT00618436|Seizures
521269|NCT00618436|Traumatic Brain Injury
521270|NCT00618436|Subarachnoid Hemorrhage
521271|NCT00618423|Neuropathic pain
521272|NCT00618423|Chronic pain
521273|NCT00618423|Acute postoperative pain
521274|NCT00618423|Ketamine
521275|NCT00618423|Back surgery
521276|NCT00618423|Anesthesia
521277|NCT00618423|Perioperative
521278|NCT00618397|ketamine
521279|NCT00618397|pharmacokinetics
521280|NCT00618397|sedation
521281|NCT00618397|critical care
521282|NCT00618397|opioid tolerance
521283|NCT00618397|NMDA Antagonist
521284|NCT00618384|TACE
521285|NCT00618384|hepatocellular carcinoma
521286|NCT00618371|Intensification
521287|NCT00618371|HIV viremia
521288|NCT00618371|Human Immunodeficiency Virus
521289|NCT00618345|refractory multiple myeloma
521290|NCT00618293|intraoperative bleeding
521291|NCT00618293|aortic-valve replacement
521292|NCT00618293|aortic stenosis
521293|NCT00618293|Von Willebrand
521294|NCT00618293|HEAMATE
521295|NCT00618254|Prevention of nausea and vomiting associated with radiation or chemotherapy
521296|NCT00618241|interactions
521297|NCT00618241|neuropathic pain
521298|NCT00618241|pharmacokinetics
521299|NCT00618215|cluster-randomised trial
521300|NCT00618215|routine oral examination
521301|NCT00618215|implementation research
521302|NCT00618215|practice based research
521303|NCT00618215|CPG
521304|NCT00618215|recall interval assignment for routine oral examination
521305|NCT00618215|prescription bitewing radiographs
521306|NCT00618215|preventive advice and feed back oral disease
521307|NCT00618176|Acquired Immunodeficiency Syndrome
521308|NCT00618176|adverse effects
521309|NCT00618176|Treatment Outcome
521310|NCT00618176|Drug Resistance, Viral
521311|NCT00618176|treatment naïve
521312|NCT00618163|Anti-inflammatory
521313|NCT00618150|GERD
521314|NCT00618150|Dyspepsia
521315|NCT00618150|Education
521316|NCT00618150|Information
521317|NCT00618137|Chronic obstructive pulmonary disease
521318|NCT00618137|Gene expression profiling
521319|NCT00618137|Inert dusts
521320|NCT00618137|Natural course
521321|NCT00618137|Prospective assessment
521322|NCT00618124|solid tumor malignancy, SU011248, sunitinib, capecitabine, Phase 1
521323|NCT00618111|Prevention of nausea and vomiting associated with radiation or chemotherapy
521324|NCT00618098|anticoagulant reversal
521325|NCT00618098|urgent surgery
521326|NCT00618098|invasive procedures
521327|NCT00618098|vitamin K
521328|NCT00618098|prothrombin complex concentrate
521329|NCT00618072|hyperinsulinemia
521330|NCT00618072|insulin resistance
521331|NCT00618072|perimenopause
521332|NCT00618072|obesity
521333|NCT00618072|overweight
521334|NCT00618072|women
521335|NCT00618033|Hemodialysis
521336|NCT00618033|ESRD
521337|NCT00618020|CTO
521338|NCT00618020|Chronic Total Occlusion
521339|NCT00618020|Revascularization
521340|NCT00617994|psoriasis
521341|NCT00617981|hepatocellular carcinoma
521342|NCT00617981|liver cancer
521343|NCT00617942|Breast Cancer
521344|NCT00617929|chronic myelogenous leukemia
521345|NCT00617929|acute lymphoblastic leukemia
521346|NCT00617929|chronic myeloid leukemia
521347|NCT00617929|lymphoblastic leukemia
521348|NCT00617929|acute myeloid leukemia
521349|NCT00617929|chronic eosinophilic leukemia
521350|NCT00617929|primary myelofibrosis
521351|NCT00617929|chronic myelomonocytic leukemia
521352|NCT00617929|chronic neutrophilic leukemia
521353|NCT00617929|de novo myelodysplastic syndromes
521354|NCT00617929|disseminated neuroblastoma
521355|NCT00617929|juvenile myelomonocytic leukemia
521356|NCT00617929|Burkitt lymphoma
521357|NCT00617929|rhabdomyosarcoma
521358|NCT00617929|myelodysplastic syndromes
521359|NCT00617929|Hodgkin lymphoma
521360|NCT00617929|lymphoblastic lymphoma
521361|NCT00617929|breast cancer
521362|NCT00617929|follicular lymphoma
521363|NCT00617929|mantle cell lymphoma
521364|NCT00617929|marginal zone lymphoma
521365|NCT00617929|recurrent neuroblastoma
521366|NCT00617929|recurrent ovarian epithelial cancer
521367|NCT00617929|recurrent ovarian germ cell tumor
521368|NCT00617929|recurrent small lymphocytic lymphoma
521369|NCT00617929|recurrent malignant testicular germ cell tumor
521370|NCT00617929|recurrent Wilms tumor and other childhood kidney tumors
521371|NCT00617929|recurrent/refractory childhood Hodgkin lymphoma
521372|NCT00617929|refractory hairy cell leukemia
521373|NCT00617929|refractory multiple myeloma
521374|NCT00617929|relapsing chronic myelogenous leukemia
521375|NCT00617929|secondary acute myeloid leukemia
521376|NCT00617929|secondary myelodysplastic syndromes
521377|NCT00617929|splenic marginal zone lymphoma
521378|NCT00617929|stage I multiple myeloma
521379|NCT00617929|stage II multiple myeloma
521380|NCT00617929|stage III multiple myeloma
521381|NCT00617929|stage II ovarian epithelial cancer
521382|NCT00617929|stage III adult Burkitt lymphoma
521383|NCT00617929|stage III adult diffuse large cell lymphoma
521384|NCT00617929|stage III adult diffuse mixed cell lymphoma
521385|NCT00617929|stage III adult diffuse small cleaved cell lymphoma
521386|NCT00617929|stage III adult Hodgkin lymphoma
521387|NCT00617929|stage III adult immunoblastic large cell lymphoma
521388|NCT00617929|stage III adult lymphoblastic lymphoma
521389|NCT00617929|stage III chronic lymphocytic leukemia
521390|NCT00617929|stage III grade 1 follicular lymphoma
521391|NCT00617929|stage III grade 2 follicular lymphoma
521392|NCT00617929|stage III grade 3 follicular lymphoma
521393|NCT00617929|stage III mantle cell lymphoma
521394|NCT00617929|stage III marginal zone lymphoma
521395|NCT00617929|stage III ovarian epithelial cancer
521396|NCT00617929|stage III small lymphocytic lymphoma
521397|NCT00617929|stage III malignant testicular germ cell tumor
521398|NCT00617929|stage IIIA breast cancer
521399|NCT00617929|stage IIIB breast cancer
521400|NCT00617929|stage IIIC breast cancer
521401|NCT00617929|stage IV adult Burkitt lymphoma
521402|NCT00617929|stage IV adult diffuse large cell lymphoma
521403|NCT00617929|stage IV adult diffuse mixed cell lymphoma
521404|NCT00617929|stage IV adult diffuse small cleaved cell lymphoma
521405|NCT00617929|stage IV adult Hodgkin lymphoma
521406|NCT00617929|stage IV adult immunoblastic large cell lymphoma
521407|NCT00617929|stage IV adult lymphoblastic lymphoma
521408|NCT00617929|stage IV breast cancer
521409|NCT00617929|stage IV chronic lymphocytic leukemia
521410|NCT00617929|stage IV grade 1 follicular lymphoma
521411|NCT00617929|stage IV grade 2 follicular lymphoma
521412|NCT00617929|stage IV grade 3 follicular lymphoma
521413|NCT00617929|stage IV mantle cell lymphoma
521414|NCT00617929|stage IV marginal zone lymphoma
521415|NCT00617929|stage IV ovarian epithelial cancer
521416|NCT00617929|stage IV small lymphocytic lymphoma
521417|NCT00617929|refractory chronic lymphocytic leukemia
521418|NCT00617916|hyperspectral imaging
521419|NCT00617916|tissue oxygenation
521420|NCT00617916|diabetic foot ulcers
521421|NCT00617916|wound healing
521422|NCT00617916|prevention
521423|NCT00617903|rosacea
521424|NCT00617903|papulopustular
521425|NCT00617903|azelaic acid
521426|NCT00617903|foam
521427|NCT00617890|anti-IGF-1R
521428|NCT00617851|Influenza
521429|NCT00617851|adults
521430|NCT00617851|different lots
521431|NCT00617851|trivalent subunit influenza virus vaccine (IVV)
521432|NCT00617851|trivalent subunit influenza vaccine
521433|NCT00617838|Celiac disease
521434|NCT00617838|genetic risk
521435|NCT00617838|gluten introduction
521436|NCT00617838|predicting antibodies
521437|NCT00617825|chronic venous disorders
521438|NCT00617825|cryotherapy
521439|NCT00617825|skin microcirculation
521440|NCT00617825|skin temperature
521441|NCT00617812|Vaccine
521442|NCT00617812|Prevention
521443|NCT00617812|Diphtheria
521444|NCT00617812|Tetanus
521445|NCT00617812|Pertussis
521446|NCT00617812|Hepatitis B
521447|NCT00617812|Haemophilus influenzae type b
521448|NCT00617812|Healthy infants
521449|NCT00617799|stage IV renal cell cancer
521450|NCT00617799|stage IV melanoma
521451|NCT00617786|urinary urgency
521452|NCT00617786|urinary frequency
521453|NCT00617786|urge incontinence
521454|NCT00617786|sacral neuromodulation therapy
521455|NCT00617786|urgency
521456|NCT00617786|frequency
521457|NCT00617773|recurrent ovarian epithelial cancer
521458|NCT00617773|recurrent fallopian tube cancer
521459|NCT00617773|recurrent primary peritoneal cancer
521460|NCT00617747|Zolmitriptan
521461|NCT00617747|ZOMIG
521462|NCT00617747|migraine
521463|NCT00617747|headache response
521464|NCT00617747|headache
521465|NCT00617747|headache pain
521466|NCT00617734|Squamous Cell Carcinoma in Head and Neck
521467|NCT00617734|Prior Platinum-based chemotherapy
521468|NCT00617734|Cetuximab
521469|NCT00617734|Erbitux
521470|NCT00617734|IMC-A12
521471|NCT00617721|Defective gene(s) in plasma membrane remodelling.
521472|NCT00617721|Scott syndrome,
521473|NCT00617721|Reduced prothrombin consumption,
521474|NCT00617721|Circulating biomakers of scott syndrome
521475|NCT00617695|Zolmitriptan
521476|NCT00617695|ZOMIG
521477|NCT00617695|migraine
521478|NCT00617695|headache response
521479|NCT00617695|headache
521480|NCT00617695|headache pain
521481|NCT00617682|Maternal immunization
521482|NCT00617682|Pneumococcal conjugate vaccine
521483|NCT00617682|Otitis media
521484|NCT00617669|Hormone Resistant Prostate Cancer
521485|NCT00617669|Endothelin A Receptor Antagonist
521486|NCT00617669|Endothelin A
521487|NCT00617669|Endothelin A antagonist
521488|NCT00617656|LUNG CANCER
521489|NCT00617643|Nevirapine
521490|NCT00617643|Rifampicin
521491|NCT00617643|Pharmacokinetics
521492|NCT00617617|isoflavones
521493|NCT00617617|soy
521494|NCT00617604|kidney transplant
521495|NCT00617604|alefacept
521496|NCT00617591|Lenalidomide
521497|NCT00617591|Revlimid
521498|NCT00617591|Pegylated Liposomal Doxorubicin
521499|NCT00617591|Doxil
521500|NCT00617591|Dexamethasone
521501|NCT00617591|Decadron
521502|NCT00617578|Antitachy pacing
521503|NCT00617578|Implantable cardioverter-defibrillator
521504|NCT00617552|postoperative ileus
521505|NCT00617552|POI
521506|NCT00617552|major open abdominal surgery
521507|NCT00617539|recurrent breast cancer
521508|NCT00617539|stage IV breast cancer
521509|NCT00617539|male breast cancer
521510|NCT00617539|tumors metastatic to brain
521511|NCT00617526|HIV
521512|NCT00617526|treatment naïve
521513|NCT00617500|climacteric
521514|NCT00617500|complementary therapy
521515|NCT00617500|hormonal replacement therapy
521516|NCT00617474|erythropoietin
521517|NCT00617474|kidney allograft survival
521518|NCT00617474|Recombinant Erythropoietin
521519|NCT00617474|erythropoietin (Epo)-induced protein 29, human
521520|NCT00617461|Post-herpetic neuralgia(PHN)
521521|NCT00617461|Neuropathic pain
521522|NCT00617448|diathermy hemorrhoids
521523|NCT00617448|Ligasure
521524|NCT00617448|randomized controlled trial
521525|NCT00617448|Postoperative pain
521526|NCT00617448|Surgical Procedure, Ambulatory
521527|NCT00617448|Local Anesthesia
521528|NCT00617448|Safety procedure long term
521529|NCT00617448|Day Surgery
521530|NCT00617435|Trans fatty acid
521531|NCT00617435|Insulin resistance
521532|NCT00617435|Skeletal muscle
521533|NCT00617435|Adipose tissue
521534|NCT00617409|SCLC
521535|NCT00617409|vaccine
521536|NCT00617409|immunize
521537|NCT00617396|Irritable Bowel Syndrome
521538|NCT00617396|Seroquel
521539|NCT00617396|Abdominal Pain
521540|NCT00617383|demyelinating disease
521541|NCT00617383|multiple sclerosis
521542|NCT00617383|female monozygotic identical twins
521543|NCT00617383|MS
521544|NCT00617383|non-concordant
521545|NCT00617383|clinically isolated syndrome - CIS
521546|NCT00617383|brain MRI
521547|NCT00617383|proteomics
521548|NCT00617370|CYCLOPHOSPHAMIDE (CYTOXAN)
521549|NCT00617370|EPIRUBICIN
521550|NCT00617370|PEGFILGRASTIM
521551|NCT00617370|TAXOL (PACLITAXEL)
521552|NCT00617357|incisional hernia
521553|NCT00617357|abdominal hernia repair
521554|NCT00617357|Ventral incisional hernia repair
521555|NCT00617344|Dengue fever
521556|NCT00617344|Dengue hemorrhagic fever
521557|NCT00617344|Dengue virus
521558|NCT00617331|vaccine, priming, influenza, flu, A/H9N2
521559|NCT00617318|Pomegranate
521560|NCT00617318|Influenza
521561|NCT00617318|Common Cold
521562|NCT00617318|Cough
521563|NCT00617318|Severity
521564|NCT00617318|Efficacy
521565|NCT00617305|ambrisentan
521566|NCT00617305|PAH
521567|NCT00617305|combination therapy
521568|NCT00617305|phosphodiesterase type-5 inhibitor (PDE-5i)
521569|NCT00617305|cardiovascular
521570|NCT00617305|endothelin receptor antagonist
521571|NCT00617305|ERA
521572|NCT00617292|21-hydroxylase deficiency
521573|NCT00617292|21OHD
521574|NCT00617292|CAH
521575|NCT00617266|tobacco, cessation, BPO, RCT, KAP
521576|NCT00617240|antipsychotic
521577|NCT00617240|metformin
521578|NCT00617240|children
521579|NCT00617240|adolescents
521580|NCT00617227|Enteral vancomycin therapy, serum vancomycin levels, renal failure
521581|NCT00617214|Schizophrenia
521582|NCT00617214|Integrated care program
521583|NCT00617214|Seroquel
521584|NCT00617201|cocaine
521585|NCT00617201|dependence
521586|NCT00617201|stimulants
521587|NCT00617188|recurrent ovarian epithelial cancer
521588|NCT00617175|Implantable Cardiac Defibrillator
521589|NCT00617175|therapies reduction
521590|NCT00617175|Shocks
521591|NCT00617175|Quality of Life
521592|NCT00617149|exercise,
521593|NCT00617149|excessive weight gain during pregnancy
521594|NCT00617136|Surgery
521595|NCT00617136|Anesthesia
521596|NCT00617136|Hypothermia
521597|NCT00617136|Temperature
521598|NCT00617136|Perioperative
521599|NCT00617136|Temperature Management
521600|NCT00617110|diesel exhaust particles
521601|NCT00617110|live attenuated influenza virus vaccine
521602|NCT00617110|flu vaccine
521603|NCT00617097|Pain associated with first trimester surgical abortion
521604|NCT00617084|Drug Eluting Stents
521605|NCT00617084|Interventional Cardiology
521606|NCT00617071|colon cancer
521607|NCT00617071|rectal cancer
521608|NCT00617058|antipsychotic
521609|NCT00617058|metformin
521610|NCT00617058|children
521611|NCT00617058|adolescents
521612|NCT00617045|Post Partum Depression
521613|NCT00617006|Anesthesia Workspace
521614|NCT00617006|Hospital Acquired Infections
521615|NCT00617006|Hand Hygiene
521616|NCT00617006|Alcohol Based Cleanser
521617|NCT00617006|Bacterial Contamination
521618|NCT00616980|PAD
521619|NCT00616980|PVD
521620|NCT00616980|CLI
521621|NCT00616980|Stem Cells
521622|NCT00616967|stage II breast cancer
521623|NCT00616967|stage IIIA breast cancer
521624|NCT00616967|stage IIIB breast cancer
521625|NCT00616967|stage IIIC breast cancer
521626|NCT00616967|ductal breast carcinoma
521627|NCT00616967|lobular breast carcinoma
521628|NCT00616954|mismatched
521629|NCT00616954|Stem cell transplatation
521630|NCT00616954|Bone marrow transplantation
521631|NCT00616954|T cell depletion
521632|NCT00616954|engraftment
521633|NCT00616954|Patients undergoing allogeneic haplo-SCT
521634|NCT00616941|NY-ESO-1 OLP4
521635|NCT00616941|Ovarian Cancer
521636|NCT00616941|Cancer Vaccine
521637|NCT00616928|vaccines
521638|NCT00616928|immunogenicity
521639|NCT00616928|human
521640|NCT00616928|safety
521641|NCT00616928|influenza
521642|NCT00616915|Wellbutrin SR
521643|NCT00616902|Zemplar, paricalcitol, PRIMO II
521644|NCT00616876|lactulose
521645|NCT00616876|prebiotic
521646|NCT00616876|premature infant
521647|NCT00616876|enteral feeding
521648|NCT00616876|stools
521649|NCT00616876|lactobacillus
521650|NCT00616876|nutrition
521651|NCT00616876|growth
521652|NCT00616850|Total Knee Arthroplasty
521653|NCT00616850|Intravenous Lidocaine Infusion
521654|NCT00616850|Femoral Block Catheter
521655|NCT00616837|Remote consultation/*methods
521656|NCT00616837|Orthopaedics methods
521657|NCT00616837|Telemedicine
521658|NCT00616837|Follow-up study
521659|NCT00616837|Ambulatory care
521660|NCT00616824|Acellular dermal matrix
521661|NCT00616824|breast reconstruction
521662|NCT00616824|tissue expander
521663|NCT00616824|postoperative pain
521664|NCT00616824|complication
521665|NCT00616824|pain
521666|NCT00616824|patient satisfaction
521667|NCT00616811|Type 2 diabetes, vildagliptin
521668|NCT00616785|stage IIIA non-small cell lung cancer
521669|NCT00616785|stage IIIB non-small cell lung cancer
521670|NCT00616759|Depression
521671|NCT00616759|Electroconvulsive therapy
521672|NCT00616746|Alcohol, nicotine
521673|NCT00616733|Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI
521674|NCT00616720|stage I multiple myeloma
521675|NCT00616720|stage II multiple myeloma
521676|NCT00616720|stage III multiple myeloma
521677|NCT00616720|refractory multiple myeloma
521678|NCT00616707|Inflammation
521679|NCT00616707|Oxidative Stress
521680|NCT00616707|Microalbuminuria
521681|NCT00616668|Transtibial amputees due to vascular diseases.
521682|NCT00616655|Anxiety
521683|NCT00616642|recurrent pituitary tumor
521684|NCT00616642|ACTH-producing pituitary tumor
521685|NCT00616642|nonfunctioning pituitary tumor
521686|NCT00616616|appendectomy
521687|NCT00616616|cholecystectomy
521688|NCT00616616|gastric banding
521689|NCT00616616|adrenalectomy
521690|NCT00616616|Gastric lap-band placement
521691|NCT00616603|Total Knee Arthroplasty.
521692|NCT00616603|Sciatic nerve Blocks.
521693|NCT00616603|Dexamethasone.
521694|NCT00616590|sleep disorders
521695|NCT00616590|psychosocial effects of cancer and its treatment
521696|NCT00616590|fatigue
521697|NCT00616590|recurrent squamous cell carcinoma of the hypopharynx
521698|NCT00616590|stage I squamous cell carcinoma of the hypopharynx
521699|NCT00616590|stage II squamous cell carcinoma of the hypopharynx
521700|NCT00616590|stage III squamous cell carcinoma of the hypopharynx
521701|NCT00616590|stage IV squamous cell carcinoma of the hypopharynx
521702|NCT00616590|recurrent squamous cell carcinoma of the larynx
521703|NCT00616590|recurrent verrucous carcinoma of the larynx
521704|NCT00616590|stage I squamous cell carcinoma of the larynx
521705|NCT00616590|stage I verrucous carcinoma of the larynx
521706|NCT00616590|stage II squamous cell carcinoma of the larynx
521707|NCT00616590|stage II verrucous carcinoma of the larynx
521708|NCT00616590|stage III squamous cell carcinoma of the larynx
521709|NCT00616590|stage III verrucous carcinoma of the larynx
521710|NCT00616590|stage IV squamous cell carcinoma of the larynx
521711|NCT00616590|stage IV verrucous carcinoma of the larynx
521712|NCT00616590|recurrent adenoid cystic carcinoma of the oral cavity
521713|NCT00616590|recurrent mucoepidermoid carcinoma of the oral cavity
521714|NCT00616590|recurrent verrucous carcinoma of the oral cavity
521715|NCT00616590|stage I adenoid cystic carcinoma of the oral cavity
521716|NCT00616590|stage I mucoepidermoid carcinoma of the oral cavity
521717|NCT00616590|stage I verrucous carcinoma of the oral cavity
521718|NCT00616590|stage II adenoid cystic carcinoma of the oral cavity
521719|NCT00616590|stage II mucoepidermoid carcinoma of the oral cavity
521720|NCT00616590|stage II verrucous carcinoma of the oral cavity
521721|NCT00616590|stage III adenoid cystic carcinoma of the oral cavity
521722|NCT00616590|stage III mucoepidermoid carcinoma of the oral cavity
521723|NCT00616590|stage III verrucous carcinoma of the oral cavity
521724|NCT00616590|stage IV adenoid cystic carcinoma of the oral cavity
521725|NCT00616590|stage IV mucoepidermoid carcinoma of the oral cavity
521726|NCT00616590|stage IV verrucous carcinoma of the oral cavity
521727|NCT00616590|stage I squamous cell carcinoma of the lip and oral cavity
521728|NCT00616590|stage II squamous cell carcinoma of the lip and oral cavity
521729|NCT00616590|stage III squamous cell carcinoma of the lip and oral cavity
521730|NCT00616590|stage IV squamous cell carcinoma of the lip and oral cavity
521731|NCT00616590|recurrent basal cell carcinoma of the lip
521732|NCT00616590|recurrent squamous cell carcinoma of the lip and oral cavity
521733|NCT00616590|stage I basal cell carcinoma of the lip
521734|NCT00616590|stage II basal cell carcinoma of the lip
521735|NCT00616590|stage III basal cell carcinoma of the lip
521736|NCT00616590|stage IV basal cell carcinoma of the lip
521737|NCT00616590|metastatic squamous neck cancer with occult primary squamous cell carcinoma
521738|NCT00616590|recurrent metastatic squamous neck cancer with occult primary
521739|NCT00616590|recurrent lymphoepithelioma of the nasopharynx
521740|NCT00616590|recurrent squamous cell carcinoma of the nasopharynx
521741|NCT00616590|stage I lymphoepithelioma of the nasopharynx
521742|NCT00616590|stage I squamous cell carcinoma of the nasopharynx
521743|NCT00616590|stage II lymphoepithelioma of the nasopharynx
521744|NCT00616590|stage II squamous cell carcinoma of the nasopharynx
521745|NCT00616590|stage III lymphoepithelioma of the nasopharynx
521746|NCT00616590|stage III squamous cell carcinoma of the nasopharynx
521747|NCT00616590|stage IV lymphoepithelioma of the nasopharynx
521748|NCT00616590|stage IV squamous cell carcinoma of the nasopharynx
521749|NCT00616590|recurrent lymphoepithelioma of the oropharynx
521750|NCT00616590|recurrent squamous cell carcinoma of the oropharynx
521751|NCT00616590|stage I lymphoepithelioma of the oropharynx
521752|NCT00616590|stage I squamous cell carcinoma of the oropharynx
521753|NCT00616590|stage II lymphoepithelioma of the oropharynx
521754|NCT00616590|stage II squamous cell carcinoma of the oropharynx
521755|NCT00616590|stage III lymphoepithelioma of the oropharynx
521756|NCT00616590|stage III squamous cell carcinoma of the oropharynx
521757|NCT00616590|stage IV lymphoepithelioma of the oropharynx
521758|NCT00616590|stage IV squamous cell carcinoma of the oropharynx
521759|NCT00616590|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
521760|NCT00616590|recurrent inverted papilloma of the paranasal sinus and nasal cavity
521761|NCT00616590|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
521762|NCT00616590|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
521763|NCT00616590|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
521764|NCT00616590|stage I inverted papilloma of the paranasal sinus and nasal cavity
521765|NCT00616590|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
521766|NCT00616590|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
521767|NCT00616590|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
521768|NCT00616590|stage II inverted papilloma of the paranasal sinus and nasal cavity
521769|NCT00616590|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
521770|NCT00616590|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
521771|NCT00616590|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
521772|NCT00616590|stage III inverted papilloma of the paranasal sinus and nasal cavity
521773|NCT00616590|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
521774|NCT00616590|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
521775|NCT00616590|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
521776|NCT00616590|stage IV inverted papilloma of the paranasal sinus and nasal cavity
521777|NCT00616590|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
521778|NCT00616590|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
521779|NCT00616590|recurrent salivary gland cancer
521780|NCT00616590|stage I salivary gland cancer
521781|NCT00616590|stage II salivary gland cancer
521782|NCT00616590|stage III salivary gland cancer
521783|NCT00616590|stage IV salivary gland cancer
521784|NCT00616577|Caudal Epidural Ropivacaine
521785|NCT00616564|GM-CSF
521786|NCT00616564|Interleukin
521787|NCT00616564|IL-2
521788|NCT00616564|Sargrostim
521789|NCT00616551|Acromegaly
521790|NCT00616538|Atopic
521791|NCT00616538|Dermatitis
521792|NCT00616538|eczema
521793|NCT00616538|skin barrier
521794|NCT00616538|ceramide
521795|NCT00616538|topical
521796|NCT00616538|inflamation
521797|NCT00616538|steroid
521798|NCT00616538|SCORAD
521799|NCT00616538|glucocorticoids
521800|NCT00616538|EpiCeram
521801|NCT00616538|Cutivate
521802|NCT00616538|fluticasone
521803|NCT00616512|Water
521804|NCT00616512|oral care
521805|NCT00616512|oral hygiene
521806|NCT00616512|dysphagia
521807|NCT00616512|thin liquid dysphagia
521808|NCT00616512|thickened liquids
521809|NCT00616499|stage IIIA non-small cell lung cancer
521810|NCT00616499|adenocarcinoma of the lung
521811|NCT00616499|bronchoalveolar cell lung cancer
521812|NCT00616499|large cell lung cancer
521813|NCT00616460|safety
521814|NCT00616460|efficacy
521815|NCT00616421|vaccine
521816|NCT00616421|children
521817|NCT00616421|healthy
521818|NCT00616421|meningitis
521819|NCT00616421|meningococcal
521820|NCT00616421|prevention of meningococcal disease serogroups ACWY
521821|NCT00616421|Menveo
521822|NCT00616408|GH
521823|NCT00616408|IGF-I
521824|NCT00616408|GH-secreting tumors
521825|NCT00616408|Octreotide
521826|NCT00616395|Infant Nutrition
521827|NCT00616395|Soy Phytochemicals
521828|NCT00616395|Infant Body Composition
521829|NCT00616395|Brain Function
521830|NCT00616395|Cognition and Development
521831|NCT00616395|Healthy Infants
521832|NCT00616382|PDA
521833|NCT00616382|indomethacin
521834|NCT00616382|pentoxifylline
521835|NCT00616382|Patent Ductus Arteriosus [PDA] resistant to therapy
521836|NCT00616369|pulmonary hypertension
521837|NCT00616369|hypertension
521838|NCT00616369|cardiomyopathy
521839|NCT00616369|arrhythmias
521840|NCT00616356|Yellow Fever
521841|NCT00616343|ET
521842|NCT00616317|Antiphospholipid Syndrome
521843|NCT00616304|severe falciparum malaria
521844|NCT00616291|recurrent prostate cancer
521845|NCT00616291|stage IV prostate cancer
521846|NCT00616278|Growth Failure AND
521847|NCT00616278|Chronic Renal Insufficiency OR
521848|NCT00616278|End Stage Renal Disease
521849|NCT00616265|Sleep apnea
521850|NCT00616265|Refractory Hypertension
521851|NCT00616265|Difficult-to-treat hypertension
521852|NCT00616265|CPAP
521853|NCT00616252|Antiretroviral
521854|NCT00616252|Pharmacokinetics
521855|NCT00616252|Pregnancy
521856|NCT00616239|Melasma
521857|NCT00616239|Dark spots on the face
521858|NCT00614263|Colonoscopy
521859|NCT00614263|Sedation levels
521860|NCT00614250|Obstructive sleep apnea
521861|NCT00614211|Cervix
521862|NCT00614211|Cervical
521863|NCT00614211|Cancer
521864|NCT00614211|Carcinoma
521865|NCT00614211|Radical hysterectomy
521866|NCT00614211|Hysterectomy
521867|NCT00614211|Laparoscopy
521868|NCT00614211|Laparoscopic
521869|NCT00614211|Robotic
521870|NCT00614211|Squamous Cell
521871|NCT00614211|Adenosquamous
521872|NCT00614211|Adenocarcinoma
521873|NCT00614211|Lymphatic Mapping
521874|NCT00614211|IOLM
521875|NCT00614211|SPECT
521876|NCT00614211|Sentinel Node
521877|NCT00614211|Uterine cervix
521878|NCT00614198|autism
521879|NCT00614198|autism spectrum disorder
521880|NCT00614198|diet
521881|NCT00614198|gluten
521882|NCT00614198|casein
521883|NCT00614198|intervention
521884|NCT00614198|peptide
521885|NCT00614198|randomised
521886|NCT00614198|controlled
521887|NCT00614198|adaptive design
521888|NCT00614198|Autism Diagnostic Observation Schedule (ADOS)
521889|NCT00614198|Gilliam Autism Rating Scale (GARS)
521890|NCT00614198|Vineland Adaptive Behaviour Scale (VABS)
521891|NCT00614198|Attention-Deficit Hyperactivity Disorder (ADHD)-IV Scale
521892|NCT00614172|Proton
521893|NCT00614172|Radiation
521894|NCT00614172|Breast cancer
521895|NCT00614159|Child age 1-10 years having a GI Endoscopy with sedation
521896|NCT00614146|liver failure, albumin dialysis, liver support
521897|NCT00614133|protein metabolism
521898|NCT00614133|surgery
521899|NCT00614133|parenteral nutrition
521900|NCT00616213|unspecified adult solid tumor, protocol specific
521901|NCT00616200|D-IBS (diarrhea predominant irritable bowel syndrome)
521902|NCT00616174|Cesarean delivery
521903|NCT00616174|Active Warming
521904|NCT00616174|Neonatal Temperature
521905|NCT00616161|Acute Heart Failure
521906|NCT00616161|Inotropes
521907|NCT00616161|Lusitropic agents
521908|NCT00616161|Istaroxime
521909|NCT00616161|PST2744
521910|NCT00616148|Epilepsy
521911|NCT00616148|Seizures
521912|NCT00616135|Breast
521913|NCT00616135|Stem Cell
521914|NCT00616135|Adipose Derived Stem Cells
521915|NCT00616135|Adipose Derived Regenerative Cells
521916|NCT00616135|ADRC
521917|NCT00616135|Reconstructive Breast Surgery
521918|NCT00616135|Breast Reconstruction
521919|NCT00616135|Cancer
521920|NCT00616135|Carcinoma
521921|NCT00616135|Autologous fat transplantation
521922|NCT00616135|Autologous fat
521923|NCT00616135|Cosmetic breast deformities
521924|NCT00616135|Functional breast deformity
521925|NCT00616135|Lumpectomy
521926|NCT00616135|Segmental mastectomy
521927|NCT00616135|Quadrantectomy
521928|NCT00616135|breast conservation therapy
521929|NCT00616122|recurrent breast cancer
521930|NCT00616122|stage IV breast cancer
521931|NCT00616122|male breast cancer
521932|NCT00616096|Serum Immunoglobulin E above 5000 kU/l
521933|NCT00616083|Breast Feeding
521934|NCT00616083|Body Composition
521935|NCT00616083|Body Fat
521936|NCT00616083|Infant
521937|NCT00616083|Diet
521938|NCT00616083|Healthy Infants
521939|NCT00616057|fructans supplementation
521940|NCT00616044|Spinal Anesthesia
521941|NCT00616044|Epidural Anesthesia
521942|NCT00616044|Orthopedic procedures
521943|NCT00616031|stage IIIB non-small cell lung cancer
521944|NCT00616031|stage IV non-small cell lung cancer
521945|NCT00616018|acetaminophen
521946|NCT00616018|protein adducts
521947|NCT00616018|hepatic function
521948|NCT00616018|drug safety
521949|NCT00616018|non drinkers
521950|NCT00616005|Glioblastoma
521951|NCT00616005|GBM
521952|NCT00616005|Brain tumor
521953|NCT00616005|Temodar
521954|NCT00616005|Temozolomide
521955|NCT00616005|Irinotecan
521956|NCT00616005|CPT-11
521957|NCT00616005|Camptosar
521958|NCT00616005|Malignant glioma
521959|NCT00616005|Anaplastic astrocytoma
521960|NCT00616005|Glioblastoma multiforme
521961|NCT00615979|trauma
521962|NCT00615979|portable ultrasound
521963|NCT00615979|telemedicine
521964|NCT00615979|Department of Defense
521965|NCT00615966|kidney transplantation
521966|NCT00615966|ischemia-reperfusion injury
521967|NCT00615966|phosphatidylserine binding
521968|NCT00615953|GH Registry
521969|NCT00615953|Norditropin National Registry
521970|NCT00615940|HER2negative
521971|NCT00615927|Glioblastoma
521972|NCT00615927|Gliosarcoma
521973|NCT00615927|glioblastoma multiforme (GBM)
521974|NCT00615927|GBM
521975|NCT00615927|Imatinib Mesylate
521976|NCT00615927|Gleevec
521977|NCT00615927|Hydroxyurea
521978|NCT00615927|Droxia
521979|NCT00615927|Hydrea
521980|NCT00615927|Hydroxycarbamide
521981|NCT00615927|Imatinib
521982|NCT00615927|Brain tumor
521983|NCT00615927|Malignant brain tumor
521984|NCT00615927|Recurrent glioblastoma multiforme
521985|NCT00615927|Progressive glioblastoma multiforme
521986|NCT00615901|cyclophosphamide
521987|NCT00615901|methotrexate
521988|NCT00615901|fluorouracil
521989|NCT00615901|PEG-filgrastim
521990|NCT00615888|elective open repair
521991|NCT00615888|complications
521992|NCT00615888|morbidity and mortality
521993|NCT00615888|fast track patient management
521994|NCT00615875|naproxen
521995|NCT00615875|acute pain
521996|NCT00615875|postoperative pain
521997|NCT00615875|thoracic surgery
521998|NCT00615875|head and neck surgery
521999|NCT00615875|opiate sparing
522000|NCT00615862|Sepsis, alcoholism, cortisol, delirium, critical care
522001|NCT00615849|pneumothorax, thoracoscopy, pleurodesis
522002|NCT00615823|Pulmonary Arterial Hypertension
522003|NCT00615810|LDL
522004|NCT00615810|HDL
522005|NCT00615810|triglycerides
522006|NCT00615810|non HDL cholesterol
522007|NCT00615810|cholesterol
522008|NCT00615810|HIV 1
522009|NCT00615810|Metabolic parameters
522010|NCT00615810|treatment experienced
522011|NCT00615784|Acute Myeloid Leukemia
522012|NCT00615784|AML
522013|NCT00615784|Bexarotene
522014|NCT00615758|Erlotinib
522015|NCT00615758|Biological therapy
522016|NCT00615758|Tyrosin Kinase Inhibitor therapy
522017|NCT00615745|Human Immunodeficiency Virus
522018|NCT00615745|treatment experienced
522019|NCT00615732|qigong
522020|NCT00615732|traditional chinese medicine
522021|NCT00615732|exercise therapy
522022|NCT00615732|neck pain
522023|NCT00615719|Chest Pain
522024|NCT00615719|Coronary Angiography
522025|NCT00615719|Acute Coronary Syndromes
522026|NCT00615719|Computed Tomography
522027|NCT00615706|asthma, inhaled corticosteroids
522028|NCT00615693|Uveitis
522029|NCT00615693|Macular Edema
522030|NCT00615667|Refractory Nephrotic syndrome
522031|NCT00615667|Tacrolimus
522032|NCT00615654|Hydrotherapy,
522033|NCT00615654|RCT,
522034|NCT00615641|Children
522035|NCT00615641|Nutrition
522036|NCT00615641|Body Fat
522037|NCT00615641|Physical Activity
522038|NCT00615641|Diet
522039|NCT00615641|Childhood Obesity
522040|NCT00615641|Healthy Children
522041|NCT00615628|Inheritance of Osteosarcoma & Paget's Disease through Chromosome 18
522042|NCT00615615|Levetiracetam
522043|NCT00615615|Keppra
522044|NCT00615602|Early breast cancer
522045|NCT00615602|Axillary node positive
522046|NCT00615602|HER2 overexpression
522047|NCT00615602|Adjuvant chemotherapy
522048|NCT00615602|Dose dense
522049|NCT00615602|Docetaxel
522050|NCT00615602|Trastuzumab
522051|NCT00615602|FEC
522052|NCT00615589|Stage II/III Multiple Myeloma(within 10 months from diagnosis)
522053|NCT00615589|high risk
522054|NCT00615589|relapse
522055|NCT00615589|persistent
522056|NCT00615576|Male,
522057|NCT00615576|Healthy Volunteer,
522058|NCT00615576|Smoker,
522059|NCT00615576|Cystic Fibrosis,
522060|NCT00615576|Chronic Obstructive Lung Disease
522061|NCT00615550|Preterm
522062|NCT00615550|Cervix
522063|NCT00615537|Thyroid Nodule
522064|NCT00615537|Thyroid Cancer
522065|NCT00615537|Laser Ablation
522066|NCT00615537|LITT
522067|NCT00615537|Nodular Goiter
522068|NCT00615537|Thyroid Mass
522069|NCT00615524|Breast cancer
522070|NCT00615524|Advanced
522071|NCT00615524|Metastatic
522072|NCT00615524|Pazopanib
522073|NCT00615524|GW786034
522074|NCT00615524|Exemestane
522075|NCT00615524|Efficacy
522076|NCT00615524|Tolerability
522077|NCT00615524|Health-Related Quality of Life
522078|NCT00615511|schizophrenia
522079|NCT00615511|schizoaffective disorder
522080|NCT00615511|negative symptoms
522081|NCT00615511|cognition
522082|NCT00615498|Asthma, obesity, bariatric
522083|NCT00615485|Examine the risk of osteoporosis in survivors of solid pediatric cancers
522084|NCT00615472|Parkinson's Disease
522085|NCT00615472|Deep brain stimulation (DBS)
522086|NCT00615472|Subthalamic Nucleus
522087|NCT00615472|Total Intravenous Anesthesia
522088|NCT00615472|Inhalational Anesthesia
522089|NCT00615459|Chronic obstructive pulmonary disease, indacaterol, tiotropium, placebo controlled
522090|NCT00615446|solid tumor malignancy, SU011248, sunitinib, neoplasms
522091|NCT00615433|Schizophrenia
522092|NCT00615433|Latuda
522093|NCT00615433|Lurasidone
522094|NCT00615420|Mucositis
522095|NCT00615420|Radiation
522096|NCT00615420|Honey
522097|NCT00615407|Asthma, alcohol
522098|NCT00615394|cardiomyopathy, stem cell, cardiac failure
522099|NCT00615381|Intracranial Aneurysm, Unruptured
522100|NCT00615381|Craniotomy
522101|NCT00615381|Insulin
522102|NCT00615381|Neuropsychology
522103|NCT00615368|Type 1 diabetes
522104|NCT00615368|Hypoglycaemia
522105|NCT00615368|Cognitive function
522106|NCT00615368|Erythropoietin
522107|NCT00615355|vitiligo
522108|NCT00615355|narrow-band UVB
522109|NCT00615355|ReCell
522110|NCT00615355|transplantation
522111|NCT00615355|laser
522112|NCT00614107|Atrial Fibrillation post open heart surgery
522113|NCT00614094|placenta, hypoglycemia
522114|NCT00614081|Glomerular filtration rate measurement
522115|NCT00614081|Contrast-enhanced dynamic MR imaging
522116|NCT00614081|Renal transplant recipients
522117|NCT00614068|Treatment
522118|NCT00614068|PTSD
522119|NCT00614042|CLL
522120|NCT00614042|NHL
522121|NCT00614042|TRU-016
522122|NCT00614042|chronic lymphocytic leukemia
522123|NCT00614042|non-Hodgkin's lymphoma
522124|NCT00614029|sumatriptan
522125|NCT00614029|Injections
522126|NCT00614029|Subcutaneous
522127|NCT00614016|healthy volunteers
522128|NCT00614003|decisional conflict;
522129|NCT00614003|decision quality;
522130|NCT00614003|place of end of life care;
522131|NCT00614003|provider education
522132|NCT00613977|fetal lung maturity
522133|NCT00613977|lamellar body count
522134|NCT00613964|Natriuretic Peptides
522135|NCT00613964|Heart Failure
522136|NCT00613964|Renal Failure
522137|NCT00615329|Create tumor specific gene profiles to improve diagnostic accuracy
522138|NCT00615329|Perform gene set validation for diagnostic predictive power
522139|NCT00615329|Define deviant gene list implicated in pathogenesis
522140|NCT00615303|Bowel preparation, colonoscopy, simethicone, air bubble
522141|NCT00615277|Young adults
522142|NCT00615277|Long-chain polyunsaturated fatty acids
522143|NCT00615277|Cognitive function
522144|NCT00615277|Mood
522145|NCT00615277|Supply with omega-3 fatty acids
522146|NCT00615251|In vitro fertilization
522147|NCT00615238|overweight, physical activity, body composition, metabolic syndrome
522148|NCT00615225|brain death
522149|NCT00615225|inflammation
522150|NCT00615225|endotoxin
522151|NCT00615225|transplantation
522152|NCT00615225|graft
522153|NCT00615225|apoptosis
522154|NCT00615225|Systemic inflammatory response
522155|NCT00615225|Apoptosis activation
522156|NCT00615225|Graft outcome
522157|NCT00615212|GSK376501,
522158|NCT00615212|Cytochrome P450 isoenzymes,
522159|NCT00615212|Healthy Subjects,
522160|NCT00615212|Repeat Dose
522161|NCT00615186|Neuradiab
522162|NCT00615186|Locoregional glioblastoma multiforme disease
522163|NCT00615186|Anti-tenascin
522164|NCT00615186|Radiolabeled antibody therapy
522165|NCT00615186|Survival
522166|NCT00615173|Tacrolimus
522167|NCT00615173|lupus nephritis
522168|NCT00615160|Metastatic melanoma
522169|NCT00615160|anti angiogenetic treatment
522170|NCT00615147|Any cancer
522171|NCT00615147|suspected pulmonary embolism
522172|NCT00615134|treatment experienced
522173|NCT00615121|Smoking
522174|NCT00615121|Hypertension
522175|NCT00615121|Diabetes
522176|NCT00615121|Cardiovascular disease
522177|NCT00615121|Renal Failure
522178|NCT00615043|Transurethral resection of bladder tumor
522179|NCT00615043|TURBT
522180|NCT00615030|COPD, bronchodilator, long acting beta agonist, LABA
522181|NCT00615017|Sepsis
522182|NCT00615017|septic shock
522183|NCT00615017|Systemic Inflammatory Response Syndrome
522184|NCT00615004|Acromegaly
522185|NCT00615004|GH
522186|NCT00615004|IGF-I
522187|NCT00615004|Octreotide-LAR
522188|NCT00615004|Lanreotide
522189|NCT00615004|Transsphenoidal surgery
522190|NCT00614991|Healthy Subjects
522191|NCT00614991|Pharmacokinetics study
522192|NCT00614991|Pharmacokinetics of medications
522193|NCT00614978|HER-2 positive; brain metastases
522194|NCT00614965|Cancer
522195|NCT00614965|NSCLC
522196|NCT00614965|second-line chemotherapy
522197|NCT00614965|irinotecan
522198|NCT00614965|pemetrexed
522199|NCT00614939|DPP-4 inhibitors
522200|NCT00614939|HbA1c
522201|NCT00614939|incretins
522202|NCT00614939|Renal Impairment
522203|NCT00614926|Fatigue
522204|NCT00614926|low energy
522205|NCT00614926|ALS
522206|NCT00614926|treatment
522207|NCT00614913|Proton
522208|NCT00614913|Radiotherapy
522209|NCT00614913|Hepatocellular carcinoma
522210|NCT00614913|Liver Cancer
522211|NCT00614900|COPD
522212|NCT00614900|pulmonary hypertension
522213|NCT00614900|NT-proBNP
522214|NCT00614900|6 minutes walk test
522215|NCT00614887|Subarachnoid hemorrhage
522216|NCT00614887|Pituitary gland
522217|NCT00614887|Adrenal gland
522218|NCT00614874|Asthma
522219|NCT00614874|Avandia
522220|NCT00614861|Non-cancer pain
522221|NCT00614861|Pain
522222|NCT00614848|restenosis
522223|NCT00614835|Gemcitabine
522224|NCT00614835|Docetaxel
522225|NCT00614835|uterine sarcoma
522226|NCT00614809|gefitinib
522227|NCT00614809|brain metastasis
522228|NCT00614796|COPD
522229|NCT00614796|Lifestyle
522230|NCT00614796|Pedometer
522231|NCT00614783|Screening
522232|NCT00614770|colonoscopy
522233|NCT00614744|NICHD Neonatal Research Network
522234|NCT00614744|Hypoxic-ischemic encephalopathy (HIE)
522235|NCT00614744|Hypothermia
522236|NCT00614744|Neonatal depression
522237|NCT00614744|Perinatal asphyxia
522238|NCT00614731|Keyhole Limpet Hemocyanin
522239|NCT00614731|KLH
522240|NCT00614731|atopic dermatitis
522241|NCT00614731|IgG antibodies
522242|NCT00614731|scarification
522243|NCT00614718|Implantable cardioverter defibrillator
522244|NCT00614718|lead failure
522245|NCT00614718|pace/sense lead
522246|NCT00614718|ICD complication
522247|NCT00614718|inappropriate therapy
522248|NCT00614718|Defibrillators
522249|NCT00614679|biofilm
522250|NCT00614679|catheter lock solution
522251|NCT00614679|catheter salvage
522252|NCT00614666|coccidioidomycosis
522253|NCT00614666|Valley Fever
522254|NCT00614666|nikkomycin Z
522255|NCT00614653|Pancreatic Cancer
522256|NCT00614653|Bevacizumab
522257|NCT00614653|Avastin™
522258|NCT00614653|Anti-VEGF monoclonal antibody
522259|NCT00614653|rhuMAb-VEGF
522260|NCT00614653|Erlotinib
522261|NCT00614653|Erlotinib Hydrochloride
522262|NCT00614653|Tarceva
522263|NCT00614653|OSI-774
522264|NCT00614653|Capecitabine
522265|NCT00614653|Xeloda
522266|NCT00614640|HAART
522267|NCT00614640|Therapeutic vaccine
522268|NCT00614614|Meningococcal disease
522269|NCT00614614|Toddlers
522270|NCT00614614|Neisseria meningitidis
522271|NCT00614614|Meningococcal vaccines
522272|NCT00614614|Immunogenicity
522273|NCT00614614|Human serum bactericidal assay
522274|NCT00614614|Safety
522275|NCT00614614|Vaccines, conjugate
522276|NCT00614614|Booster vaccination
522277|NCT00614601|pancreatic cancer
522278|NCT00614601|vaccine therapy
522279|NCT00614588|temperature
522280|NCT00614588|monitor
522281|NCT00614588|surgery
522282|NCT00614562|critical associated illness polyneuropathy or polymyopathy (CIP/M)
522283|NCT00614549|Levetiracetam
522284|NCT00614549|Keppra
522285|NCT00614549|Epilepsy
522286|NCT00614549|Efficacy
522287|NCT00614549|Safety
522288|NCT00614536|Reflux Symptom Index
522289|NCT00614536|Reflux Finding Score
522290|NCT00614536|Rabeprazole
522291|NCT00614536|LaryngoPharyngeal Reflux Disease
522292|NCT00614536|GastroEsophageal Reflux Disease
522293|NCT00614523|MDS
522294|NCT00614523|Low Risk MDS
522295|NCT00614523|Intermediate-1 Risk MDS
522296|NCT00614523|Thrombocytopenia
522297|NCT00614484|Proton
522298|NCT00614484|Radiation
522299|NCT00614458|latent HIV
522300|NCT00614458|resting CD4+ T cell
522301|NCT00614458|valproic acid (VPA)
522302|NCT00614458|Raltegravir (MK-0518) intensification
522303|NCT00614458|HIV replication
522304|NCT00614458|treatment experienced
522305|NCT00614445|Nausea
522306|NCT00614445|Vomiting
522307|NCT00614445|Pregnancy
522308|NCT00614445|Hyperemesis gravidarum
522309|NCT00614445|Pregnancy complications
522310|NCT00614432|anticoagulation
522311|NCT00614432|surgical abortion
522312|NCT00614419|Hernioplasty
522313|NCT00614419|polypropylene
522314|NCT00614419|extracellular matrix
522315|NCT00614419|xenograft
522316|NCT00614406|Celebrex
522317|NCT00614406|prostaglandin inhibitor
522318|NCT00614406|ovulation
522319|NCT00614406|menstrual cycles
522320|NCT00614367|chromosomal abnormalities in single cells
522321|NCT00614354|99mTc-glucarate imaging to detect acute coronary syndrome
522322|NCT00614341|diabetes mellitus
522323|NCT00614341|neuropathy
522324|NCT00614341|distal symmetric polyneuropathy
522325|NCT00614341|pulsed electric fild
522326|NCT00614328|Alcohol
522327|NCT00614328|Alcohol Abuse
522328|NCT00614328|Alcohol Drinking
522329|NCT00614289|Mild to Moderate Hand Dermatitis
522330|NCT00614289|Hand Eczema
522331|NCT00614276|Sexual Dysfunction
522332|NCT00614276|Cancer-related Sexual Dysfunction
522333|NCT00614276|Female Cancer Survivors
522334|NCT00614276|Tendrils
522335|NCT00614276|Website program
522336|NCT00614276|Self-help tool
522337|NCT00614276|Sexual counseling
522338|NCT00614276|Questionnaires
522339|NCT00613938|Acute pain
522340|NCT00613938|bunionectomy
522341|NCT00613938|tapentadol
522342|NCT00613925|endometrial biopsy
522343|NCT00613925|pain management
522344|NCT00613912|Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Perfusion, brain
522345|NCT00613899|home care
522346|NCT00613899|home rehabilitation
522347|NCT00613899|telemedicine
522348|NCT00613899|ALS
522349|NCT00613886|NPH
522350|NCT00613886|Normal Pressure Hydrocephalus
522351|NCT00613873|colonoscopy
522352|NCT00613860|Endoscopic lung volume reduction, heterogeneous emphysema, interventional bronchoscopy
522353|NCT00613847|PET Scan
522354|NCT00613847|Invasive Solid Tumors
522355|NCT00613834|Essure sterilization
522356|NCT00613834|pain management
522357|NCT00613834|intrauterine lidocaine infusion
522358|NCT00613821|surgical abortion
522359|NCT00613821|pain management
522360|NCT00613808|venous
522361|NCT00613808|leg
522362|NCT00613808|ulcer
522363|NCT00613795|pneumonia
522364|NCT00613795|ventilator associated pneumonia
522365|NCT00613795|probiotics
522366|NCT00613795|Lactobacillus GG
522367|NCT00613769|Surgical site infections
522368|NCT00613717|iron deficiency anemia
522369|NCT00613717|iron deficiency
522370|NCT00613717|infant
522371|NCT00613717|development
522372|NCT00613717|behavior
522373|NCT00613691|Refractory
522374|NCT00613691|Progressive
522375|NCT00613678|pain
522376|NCT00613678|activities of daily living
522377|NCT00613678|symptoms
522378|NCT00613678|self-management
522379|NCT00613652|solid tumors
522380|NCT00613652|solid malignancies
522381|NCT00613626|Extensive Stage
522382|NCT00613626|Untreated
522383|NCT00613600|Safety
522384|NCT00613600|Efficacy
522385|NCT00613600|Glucomannan
522386|NCT00613600|Dietary fiber
522387|NCT00613600|Weight loss
522388|NCT00613587|Interleukin 13
522389|NCT00613587|Interleukin 4
522390|NCT00613587|Leukotrienes
522391|NCT00613587|Basophil Histamine Release
522392|NCT00613561|Patients with the Severe Immunodeficiency diseases
522393|NCT00613561|Severe Immunodeficiency diseases
522394|NCT00613548|Moderate
522395|NCT00613548|Mitral
522396|NCT00613548|Regurgitation
522397|NCT00613548|CABG
522398|NCT00613535|Partial Meniscectomy
522399|NCT00613535|Partial Thickness Knee Tear
522400|NCT00613535|MR Imaging
522401|NCT00613535|Mechanical Debridement
522402|NCT00613535|Crepitus
522403|NCT00613535|Stability
522404|NCT00613535|Coblation
522405|NCT00613535|Bipolar Radiofrequency
522406|NCT00613535|Debridement
522407|NCT00613535|Recurrent Knee Pain
522408|NCT00613535|meniscectomy
522409|NCT00613535|meniscus
522410|NCT00613535|cartilage lesion
522411|NCT00613535|articular cartilage lesion
522412|NCT00613535|articular cartilage
522413|NCT00613535|knee
522414|NCT00613522|Sleep apnea, Berlin, Stroke
522415|NCT00613509|Melanoma, Cancer
522416|NCT00613496|Atrial Fibrillation
522417|NCT00613496|irbesartan
522418|NCT00613496|AT-II-antagonist
522419|NCT00613496|Adhesion Molecules
522420|NCT00613496|oxidative stress markers
522421|NCT00613496|hsCRP
522422|NCT00613496|ICAM
522423|NCT00613496|VCAM
522424|NCT00613496|MCP-1
522425|NCT00613496|vWF
522426|NCT00613496|TGFβ1
522427|NCT00613496|TNF-α
522428|NCT00613496|Interleukin-6
522429|NCT00613496|8isoProstaglandinF2α
522430|NCT00613470|Depression
522431|NCT00613470|Antidepressants
522432|NCT00613444|Acne
522433|NCT00613444|laser
522434|NCT00613431|pharmacodynamics
522435|NCT00613405|substance-related disorders
522436|NCT00613392|antioxidant
522437|NCT00613392|oxidant stress
522438|NCT00613392|trauma
522439|NCT00613392|free radical
522440|NCT00613379|HIV
522441|NCT00613379|treatment naïve
522442|NCT00613366|intrauterine device
522443|NCT00613366|cervical dilation
522444|NCT00613366|nulliparous women
522445|NCT00613366|pain management
522446|NCT00613353|Female
522447|NCT00613340|Cervical pain
522448|NCT00613340|Zygapophysial joint
522449|NCT00613340|Specificity
522450|NCT00613327|Overactive bladder
522451|NCT00613327|Oxybutynin chloride
522452|NCT00613327|OROS
522453|NCT00613288|acute
522454|NCT00613288|testosterone
522455|NCT00613288|experimental
522456|NCT00613288|hypogonadism
522457|NCT00613288|lipolysis
522458|NCT00613288|insulin sensitivity
522459|NCT00613288|protein
522460|NCT00613288|metabolism
522461|NCT00613288|Experimental hypogonadism
522462|NCT00613288|Testosterone substitution
522463|NCT00613275|PNRP
522464|NCT00613275|Navigation
522465|NCT00613275|Navigator
522466|NCT00613275|Activation
522467|NCT00613275|Disparities
522468|NCT00613275|Primary Care
522469|NCT00613275|Racial and Ethnic Minorities
522470|NCT00613262|Narrow Band Imaging
522471|NCT00613249|HIV-1 Infection
522472|NCT00613249|HIV Seronegativity
522473|NCT00613223|Malignant Gliomas
522474|NCT00613223|Etopophos
522475|NCT00613223|Toposar
522476|NCT00613223|VePesid
522477|NCT00613223|Etoposide
522478|NCT00613223|Vandetanib
522479|NCT00613223|Zactima
522480|NCT00613223|ZD6474
522481|NCT00613223|VP-16
522482|NCT00613223|Brain Tumor
522483|NCT00613223|Recurring Malignant Brain Tumor
522484|NCT00613223|Gliosarcoma
522485|NCT00613223|Glioblastoma
522486|NCT00613223|Glioma
522487|NCT00613223|Malignant Glioma
522488|NCT00613223|GBM
522489|NCT00613210|preterm delivery
522490|NCT00613210|shory cervix
522491|NCT00613210|amniotic fluid sludge
522492|NCT00613210|uterine artery doppler
522493|NCT00613210|singeltone
522494|NCT00613210|normal amniotic fluid index
522495|NCT00613210|without rupter of membranes
522496|NCT00613210|24-34 weeks of gestation
522497|NCT00613197|Crohn's Disease
522498|NCT00613184|Respiratory Syncytial virus
522499|NCT00613184|Bronchiolitis
522500|NCT00613184|Pediatric
522501|NCT00613171|Systemic sclerosis, scleroderma, fibrosis, STI571, imatinib
522502|NCT00613158|Subclincal Atherosclerosis
522503|NCT00613145|Refractory Malignancy
522504|NCT00613145|Phase I
522505|NCT00613145|Sorafenib
522506|NCT00613145|Capecitabine
522507|NCT00613132|Glioblastoma
522508|NCT00613132|Gliosarcoma
522509|NCT00613132|GBM
522510|NCT00613132|Brain tumor
522511|NCT00613132|RAD0001
522512|NCT00613132|Hydroxyurea
522513|NCT00613132|Gleevec
522514|NCT00613132|Imatinib
522515|NCT00613132|Droxia
522516|NCT00613132|Everolimus
522517|NCT00613132|Hydrea
522518|NCT00613132|Hydroxycarbamide
522519|NCT00613132|Recurrent GBM
522520|NCT00613132|Imatinib mesylate
522521|NCT00613132|Glioblastoma multiforme
522522|NCT00613119|Inflammation
522523|NCT00613119|Frontotemporal Dementia
522524|NCT00613119|Dementia
522525|NCT00613119|PBR28
522526|NCT00613119|PET Imaging
522527|NCT00613093|Temodar
522528|NCT00613093|Temozolomide
522529|NCT00613093|O6-BG
522530|NCT00613093|O6-Benzylguanine
522531|NCT00613093|NSC 637037
522532|NCT00613093|Temodar-Resistant Malignant Glioma
522533|NCT00613093|Brain tumor
522534|NCT00613093|CNS tumor
522535|NCT00613093|Cerebral glioblastoma
522536|NCT00613093|Anaplastic astrocytomas
522537|NCT00613093|Glioma
522538|NCT00613080|stage III rectal cancer
522539|NCT00613080|adenocarcinoma of the rectum
522540|NCT00613067|Generalized anxiety disorder
522541|NCT00613067|N100
522542|NCT00613067|Central serotonergic activity
522543|NCT00613054|GBM
522544|NCT00613054|Brain tumor
522545|NCT00613054|Zactima
522546|NCT00613054|Gleevec
522547|NCT00613054|Hydroxyurea
522548|NCT00613054|Glioblastoma
522549|NCT00613054|Gliosarcoma
522550|NCT00613054|Recurrent malignant glioma
522551|NCT00613054|ZD6474
522552|NCT00613054|Malignant glioma
522553|NCT00613054|Imatinib
522554|NCT00613054|Droxia
522555|NCT00613054|Hydrea
522556|NCT00613054|Hydroxycarbamide
522557|NCT00613054|Vandetanib
522558|NCT00613028|Glioblastoma
522559|NCT00613028|Gliosarcoma
522560|NCT00613028|GBM
522561|NCT00613028|Bevacizumab
522562|NCT00613028|Avastin
522563|NCT00613028|Etoposide
522564|NCT00613028|Brain tumor
522565|NCT00613028|Irinotecan
522566|NCT00613028|Glioblastoma multiforme
522567|NCT00613028|Temodar
522568|NCT00613028|Temozolomide
522569|NCT00613028|Etopophos
522570|NCT00613028|Toposar
522571|NCT00613028|VePesid
522572|NCT00613028|VP-16
522573|NCT00613028|Camptosar
522574|NCT00613015|Cocaine Addiction
522575|NCT00613015|Cocaine Dependence
522576|NCT00613002|hypoactive sexual desire disorder
522577|NCT00613002|testosterone
522578|NCT00613002|menopause
522579|NCT00612989|Glioblastoma
522580|NCT00612989|Gliosarcoma
522581|NCT00612989|GBM
522582|NCT00612989|Temodar
522583|NCT00612989|Temozolomide
522584|NCT00612989|O6-BG
522585|NCT00612989|O6-Benzylguanine
522586|NCT00612989|Recurrent GBM
522587|NCT00612989|Progressive GBM
522588|NCT00612989|Brain tumor
522589|NCT00612989|Malignant glioma
522590|NCT00612989|Neulasta
522591|NCT00612989|Pegfilgrastim
522592|NCT00612976|treatment of COPD
522593|NCT00612976|documentation of relevant data
522594|NCT00612976|related to the budesonide/formoterole therapy in patients with COPD.
522595|NCT00612963|Candidiasis, Oral
522596|NCT00612963|Thrush
522597|NCT00612963|Candidiasis
522598|NCT00612937|Group B Streptococci
522599|NCT00612937|Respiratory Disease
522600|NCT00612937|Beta Lactam
522601|NCT00612937|Newborn
522602|NCT00612937|Respiratory Distress
522603|NCT00612898|HIV infection
522604|NCT00612898|Drug resistance
522605|NCT00612898|Reverse transcriptase inhibitor
522606|NCT00612898|Nucleoside analogue
522607|NCT00612898|treatment experienced
522608|NCT00612859|Levetiracetam
522609|NCT00612859|Keppra
522610|NCT00612846|Common Bile Duct Calculi
522611|NCT00612846|Choledocholithiasis
522612|NCT00612846|Endoscopic sphincterotomy
522613|NCT00612846|Cholecystectomy, laparoscopic
522614|NCT00612846|Laparoscopic bile duct exploration
522615|NCT00612833|Vasectomy
522616|NCT00612833|Male contraception
522617|NCT00612833|Contraceptive effectiveness
522618|NCT00612833|Semen analysis
522619|NCT00612833|Surgical techniques
522620|NCT00612833|Fascial interposition
522621|NCT00612833|Cautery
522622|NCT00612833|The relative contraceptive effectiveness of three methods of occluding the vas, in the context of a no-scalpel vasectomy procedure.
522623|NCT00612820|Vienna Challenge Chamber
522624|NCT00612820|Seasonal Allergic Rhinitis,
522625|NCT00612807|Older Adults
522626|NCT00612794|exenatide
522627|NCT00612794|Byetta
522628|NCT00612794|diabetes
522629|NCT00612794|Amylin
522630|NCT00612794|Lilly
522631|NCT00612781|intraocular lens
522632|NCT00612781|blue-light filtering intraocular lens
522633|NCT00612781|contrast acuity
522634|NCT00612781|color vision
522635|NCT00612768|Bioequivalence
522636|NCT00612768|Thimerosal
522637|NCT00612768|Fragrance Mix
522638|NCT00612768|PVP formulation
522639|NCT00612768|Contact dermatitis
522640|NCT00612755|chronic hepatitis C
522641|NCT00612755|co-infection
522642|NCT00612755|extend treatment
522643|NCT00612755|co-infected HIV-HCV
522644|NCT00612742|Cardiovascular event
522645|NCT00612742|Breast Cancer
522646|NCT00612742|Testosterone
522647|NCT00612742|Menopause
522648|NCT00612742|Hypoactive Sexual Desire Disorder
522649|NCT00612729|intraocular lens
522650|NCT00612729|light filtering intraocular lens
522651|NCT00612729|contrast acuity
522652|NCT00612729|color vision
522653|NCT00612716|stage I multiple myeloma
522654|NCT00612716|stage II multiple myeloma
522655|NCT00612716|stage III multiple myeloma
522656|NCT00612716|refractory multiple myeloma
522657|NCT00612716|recurrent adult Hodgkin lymphoma
522658|NCT00612716|recurrent/refractory childhood Hodgkin lymphoma
522659|NCT00612716|refractory chronic lymphocytic leukemia
522660|NCT00612716|stage III chronic lymphocytic leukemia
522661|NCT00612716|stage IV chronic lymphocytic leukemia
522662|NCT00612716|recurrent adult grade III lymphomatoid granulomatosis
522772|NCT00612430|Bevacizumab
522663|NCT00612716|adult nasal type extranodal NK/T-cell lymphoma
522664|NCT00612716|Waldenstrom macroglobulinemia
522665|NCT00612716|recurrent adult Burkitt lymphoma
522666|NCT00612716|stage I adult Burkitt lymphoma
522667|NCT00612716|stage II adult Burkitt lymphoma
522668|NCT00612716|stage III adult Burkitt lymphoma
522669|NCT00612716|stage IV adult Burkitt lymphoma
522670|NCT00612716|recurrent adult diffuse large cell lymphoma
522671|NCT00612716|recurrent adult diffuse mixed cell lymphoma
522672|NCT00612716|recurrent adult diffuse small cleaved cell lymphoma
522673|NCT00612716|recurrent adult immunoblastic large cell lymphoma
522674|NCT00612716|stage I adult immunoblastic large cell lymphoma
522675|NCT00612716|stage II adult immunoblastic large cell lymphoma
522676|NCT00612716|stage III adult immunoblastic large cell lymphoma
522677|NCT00612716|stage IV adult immunoblastic large cell lymphoma
522678|NCT00612716|recurrent adult lymphoblastic lymphoma
522679|NCT00612716|stage I adult lymphoblastic lymphoma
522680|NCT00612716|stage II adult lymphoblastic lymphoma
522681|NCT00612716|stage III adult lymphoblastic lymphoma
522682|NCT00612716|stage IV adult lymphoblastic lymphoma
522683|NCT00612716|recurrent grade 1 follicular lymphoma
522684|NCT00612716|recurrent grade 2 follicular lymphoma
522685|NCT00612716|recurrent grade 3 follicular lymphoma
522686|NCT00612716|recurrent mantle cell lymphoma
522687|NCT00612716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
522688|NCT00612716|nodal marginal zone B-cell lymphoma
522689|NCT00612716|recurrent marginal zone lymphoma
522690|NCT00612716|splenic marginal zone lymphoma
522691|NCT00612716|recurrent small lymphocytic lymphoma
522692|NCT00612716|recurrent childhood anaplastic large cell lymphoma
522693|NCT00612716|recurrent childhood grade III lymphomatoid granulomatosis
522694|NCT00612716|childhood diffuse large cell lymphoma
522695|NCT00612716|childhood immunoblastic large cell lymphoma
522696|NCT00612716|recurrent childhood large cell lymphoma
522697|NCT00612716|recurrent childhood lymphoblastic lymphoma
522698|NCT00612716|childhood nasal type extranodal NK/T-cell lymphoma
522699|NCT00612716|Burkitt lymphoma
522700|NCT00612716|recurrent childhood small noncleaved cell lymphoma
522701|NCT00612716|stage I childhood small noncleaved cell lymphoma
522702|NCT00612716|stage II childhood small noncleaved cell lymphoma
522703|NCT00612716|stage III childhood small noncleaved cell lymphoma
522704|NCT00612716|stage IV childhood small noncleaved cell lymphoma
522705|NCT00612703|Cancer, oral, erlotinib, tarceva, solid tumor, advanced tumor, phase 1
522706|NCT00612703|Tumor
522707|NCT00612690|Children
522708|NCT00612690|School-Based Mental Health Services
522709|NCT00612690|Urban Poverty
522710|NCT00612677|recurrent
522711|NCT00612677|non-small cell
522712|NCT00612651|GBM
522713|NCT00612651|Malignant glioma
522714|NCT00612651|Brain tumor
522715|NCT00612651|Temodar
522716|NCT00612651|Temozolomide
522717|NCT00612651|SCH 66336
522718|NCT00612651|Farnesyl transferase inhibitor
522719|NCT00612651|Glioblastoma multiforme
522720|NCT00612651|Gliosarcoma
522721|NCT00612651|Anaplastic astrocytoma
522722|NCT00612651|Anaplastic oligodendroglioma
522723|NCT00612651|Anaplastic oligoastrocytoma
522724|NCT00612638|Temodar
522725|NCT00612638|Temozolomide
522726|NCT00612638|O6-Benzylguanine
522727|NCT00612638|O6-BG
522728|NCT00612638|NSC 637037
522729|NCT00612638|Irinotecan
522730|NCT00612638|CPT-11
522731|NCT00612638|Recurrent cerebral anaplastic glioma
522732|NCT00612638|Progressive cerebral anaplastic glioma
522733|NCT00612638|Malignant glioma
522734|NCT00612560|breast neoplasms
522735|NCT00612560|phytoestrogens
522736|NCT00612560|tumor characteristics
522737|NCT00612560|proliferation
522738|NCT00612560|apoptosis
522739|NCT00612560|estrogen receptor
522740|NCT00612560|HER2
522741|NCT00612547|Protozoan Infections
522742|NCT00612547|Communicable Diseases
522743|NCT00612547|Malaria Infection
522744|NCT00612547|Malaria, falciparum
522745|NCT00612547|Malaria, vivax
522746|NCT00612547|Artesunate Amodiaquine
522747|NCT00612521|Coronary artery disease
522748|NCT00612521|Coronary artery stenting
522749|NCT00612521|peri-procedural myonecrosis
522750|NCT00612521|Adenosine
522751|NCT00612508|contraception
522752|NCT00612508|NuvaRing
522753|NCT00612508|Desogen
522754|NCT00612508|vaginal biopsy
522755|NCT00612482|Substance abuse
522756|NCT00612469|dental caries
522757|NCT00612469|vancomycin
522758|NCT00612469|chlorhexidine
522759|NCT00612469|sodium fluoride
522760|NCT00612469|mutans streptococci
522761|NCT00612456|angiogenesis
522762|NCT00612456|pazopanib,
522763|NCT00612456|age-related macular degeneration (AMD),
522764|NCT00612456|vascular endothelial growth factor (VEGF),
522765|NCT00612456|choroidal neovascularization (CNV),
522766|NCT00612443|breast cancer
522767|NCT00612430|Glioblastoma
522768|NCT00612430|Gliosarcoma
522769|NCT00612430|GBM
522770|NCT00612430|MG
522771|NCT00612430|Brain tumor
522773|NCT00612430|Avastin
522774|NCT00612430|Etoposide
522775|NCT00612430|VP-16
522776|NCT00612430|Etopophos
522777|NCT00612430|Toposar
522778|NCT00612430|VePesid
522779|NCT00612430|Glioblastoma multiforme
522780|NCT00612430|Recurrent GBM
522781|NCT00612430|Anaplastic astrocytoma
522782|NCT00612430|Malignant glioma
522783|NCT00612417|Interaction with recombinant FVIII
522784|NCT00612404|gastrointestinal disorder
522785|NCT00612404|endoscopy
522786|NCT00612404|patient with gastrointestinal disorders for whom an endoscopy is performed and who is treated with esomeprazole afterwards.
522787|NCT00612391|humerus fracture
522788|NCT00612378|Glabellar Furrowing
522789|NCT00612365|Body Composition
522790|NCT00612365|Abdomen
522791|NCT00612365|Atherosclerosis
522792|NCT00612339|Glioma
522793|NCT00612339|Temozolomide
522794|NCT00612339|Temodar
522795|NCT00612339|Avastin
522796|NCT00612339|Bevacizumab
522797|NCT00612339|GBM
522798|NCT00612339|Gliosarcoma
522799|NCT00612339|Multifocal GBM
522800|NCT00612339|Brain tumor
522801|NCT00612339|Unresectable GBM
522802|NCT00612339|Glioblastoma multiforme
522803|NCT00612313|Major Depressive Disorder
522804|NCT00612313|MDD
522805|NCT00612313|Children
522806|NCT00612313|Adolescents
522807|NCT00612313|Antidepressant
522808|NCT00612313|CBT
522809|NCT00612300|Ambulatory stroke patients
522810|NCT00612300|Gait training
522811|NCT00612300|Lokomat
522812|NCT00612300|Physical therapy
522813|NCT00612287|Pain
522814|NCT00612287|Chronic pain
522815|NCT00612287|Buprenorphine
522816|NCT00612287|Drug addiction
522817|NCT00612274|allogeneic
522818|NCT00612261|Branch retinal vein occlusion; treatment
522819|NCT00612248|Osteoarthritis
522820|NCT00612248|Thumb
522821|NCT00612248|Splint
522822|NCT00612248|Pain
522823|NCT00612248|Function
522824|NCT00612248|Osteoarthritis of the trapeziometacarpal (TMC) joint
522825|NCT00612235|epilepsy
522826|NCT00612235|lamotrigine
522827|NCT00612235|levetiracetam
522828|NCT00612235|carbamazepine
522829|NCT00612235|phenytoin
522830|NCT00612235|lamictal
522831|NCT00612235|keppra
522832|NCT00612235|tegretol
522833|NCT00612235|carbatrol
522834|NCT00612235|dilantin
522835|NCT00612222|Immunotherapy
522836|NCT00612222|Metastatic Melanoma
522837|NCT00612222|Vaccination
522838|NCT00612222|Tumor Regression
522839|NCT00612222|Skin Cancer
522840|NCT00612209|ARQ 197, advanced solid tumors, phase 1, dose escalation, pharmacodynamics, safety
522841|NCT00612196|Safety and tolerability
522842|NCT00612183|non-Hodgkin's lymphoma
522843|NCT00612183|mantle cell lymphoma
522844|NCT00612170|Phase 3, safety and efficacy study, [S,S[-Reboxetine, Fibromyalgia
522845|NCT00612157|Obstructive Sleep Apnea
522846|NCT00612157|Continuous Positive Airway Pressure
522847|NCT00612157|CPAP Compliance
522848|NCT00612157|Non-benzodiazepine hypnotics
522849|NCT00612144|Type 2 DM
522850|NCT00612131|medical residents PGY 2 and 3
522851|NCT00612118|Allergic rhinitis,
522852|NCT00612118|Vienna Challenge Chamber
522853|NCT00612105|Postherpetic Neuralgia, PHN, Shingles,
522854|NCT00612092|Coronary CT angiography
522855|NCT00612092|Radiation dose estimates
522856|NCT00612079|Sertindole
522857|NCT00612079|sensory gating
522858|NCT00612079|PPI
522859|NCT00612079|P50 suppression
522860|NCT00612079|CANTAB
522861|NCT00612079|Effect of Sertindole on sensory gating (P50 suppression)
522862|NCT00612079|on sensorimotor gating (PPI)
522863|NCT00612079|and cognition (CANTAB)
522864|NCT00612066|ACTH-producing pituitary tumor
522865|NCT00612053|cardiovascular disease
522866|NCT00612053|coronary artery bypass grafting (CABG)
522867|NCT00612053|coronary artery disease (CAD)
522868|NCT00612053|percutaneous transluminal coronary angioplasty (PCI)
522869|NCT00612053|unprotected left main disease
522870|NCT00612027|gastrointestinal disorder
522871|NCT00612027|acid associated gastrointestinal symptoms.
522872|NCT00612027|esomeprazole therapy in patients with gastrointestinal disorders
522873|NCT00612027|patients with acid associated gastrointestinal symptoms
522874|NCT00612014|delayed gastric emptying
522875|NCT00612014|symptomatic gastroparesis
522876|NCT00612014|diabetes mellitus
522877|NCT00612001|adult anaplastic astrocytoma
522878|NCT00612001|adult glioblastoma
522879|NCT00612001|adult giant cell glioblastoma
522880|NCT00612001|adult gliosarcoma
522881|NCT00612001|adult anaplastic oligodendroglioma
522882|NCT00612001|recurrent adult brain tumor
522883|NCT00612001|adult mixed glioma
522884|NCT00611988|Walking therapy
522885|NCT00611988|Diabetes mellitus
522886|NCT00611988|Peripheral arterial disease
522887|NCT00611975|Gonadal Steroid Hormones
522888|NCT00611975|Healthy Volunteers
522889|NCT00611975|Antidepressant Side Effects
522890|NCT00611975|Fluoxetine
522891|NCT00611975|Bupropion
522892|NCT00611975|Prolactin
522893|NCT00611975|Testosterone
522894|NCT00611975|Estradiol
522895|NCT00611975|Progesterone
522896|NCT00611975|Sexual Function
522897|NCT00611975|Serotonin Reuptake Inhibitors
522898|NCT00611975|17-OH Pregnenolone
522899|NCT00611949|Geranium oil
522900|NCT00611949|Neuropathy
522901|NCT00611949|Shingles
522902|NCT00611949|Herpes zoster
522903|NCT00611936|Atomoxetine
522904|NCT00611936|Stress
522905|NCT00611936|d-amphetamine
522906|NCT00611923|Premenstrual Dysphoric Disorder
522907|NCT00611923|PMDD
522908|NCT00611923|PMS
522909|NCT00611897|NMDA
522910|NCT00611897|glutamate
522911|NCT00611897|N-acetylcysteine
522912|NCT00611897|P3
522913|NCT00611858|5-FU
522914|NCT00611858|cetuximab
522915|NCT00611858|radiation
522916|NCT00611858|adenocarcinoma of the rectum
522917|NCT00611858|neoadjuvant therapy
522918|NCT00611845|CABG surgery requiring CPB and at increased risk of bleeding and blood transfusion
522919|NCT00611832|behavior problems
522920|NCT00611832|children
522921|NCT00611832|prevention
522922|NCT00611832|television
522923|NCT00611832|media
522924|NCT00611832|parenting
522925|NCT00611819|hepatitis
522926|NCT00611819|co-infection
522927|NCT00611806|Cognition
522928|NCT00611806|Folic Acid
522929|NCT00611806|B12
522930|NCT00611793|Refractory Malignancy
522931|NCT00611793|Advanced Malignancies
522932|NCT00611793|PTK787/ZK222584
522933|NCT00611793|Bevacizumab
522934|NCT00611780|Coronary CT angiography
522935|NCT00611780|Radiation dose estimates
522936|NCT00611741|MRS, glutamate, osmolality
522937|NCT00611728|Glioblastoma
522938|NCT00611728|CPT 11
522939|NCT00611728|Sutent
522940|NCT00611728|Sunitinib
522941|NCT00611728|Sunitinib malate
522942|NCT00611728|Malignant Glioma
522943|NCT00611728|GBM
522944|NCT00611728|Irinotecan
522945|NCT00611728|Camptosar
522946|NCT00611728|Anaplastic astrocytoma
522947|NCT00611728|Anaplastic oligodendroglioma
522948|NCT00611728|Anaplastic oligoastrocytoma
522949|NCT00611728|SU011248
522950|NCT00611728|Brain tumor
522951|NCT00611728|Recurrent malignant glioma
522952|NCT00611715|recurrent breast cancer
522953|NCT00611715|stage IV breast cancer
522954|NCT00611702|ELISPOT
522955|NCT00611702|RT-PCR
522956|NCT00611702|Luminex
522957|NCT00611702|Genomics
522958|NCT00611689|Refractory Malignancy
522959|NCT00611689|Solid Tumors
522960|NCT00611689|PTK787
522961|NCT00611689|ZK222584
522962|NCT00611676|osteoarthritis pain
522963|NCT00611676|activity limitation
522964|NCT00611676|antidepressant
522965|NCT00611676|depression
522966|NCT00611676|single-blind
522967|NCT00611663|Pneumococcal vaccine
522968|NCT00611663|SLE
522969|NCT00611663|Vaccination
522970|NCT00611663|Immunosuppression
522971|NCT00611663|SLE as defined by the ACR classification
522972|NCT00611663|Stable SLE
522973|NCT00611663|SLE treated by systemic corticosteroids
522974|NCT00611650|non-small cell lung cancer
522975|NCT00611650|squamous lung dysplasia
522976|NCT00611650|tobacco use disorder
522977|NCT00611637|Immunotherapy
522978|NCT00611624|MammoSite
522979|NCT00611624|brachytherapy
522980|NCT00611572|GABA
522981|NCT00611572|glutamate
522982|NCT00611572|NMDA
522983|NCT00611572|P300
522984|NCT00611572|MMN
522985|NCT00611559|Infanrix hexa
522986|NCT00611559|combined vaccine
522987|NCT00611546|preterm
522988|NCT00611546|parenteral nutrition
522989|NCT00611546|TPN
522990|NCT00611546|lipid emulsions
522991|NCT00611546|photo-protection
522992|NCT00611546|oxidative stress
522993|NCT00611533|Menopause
522994|NCT00611533|Cognition
522995|NCT00611520|treatment of COPD
522996|NCT00611520|related to the budesonide/formoterole therapy in patients with COPD.
522997|NCT00611494|Drug tolerance
522998|NCT00611494|Quality of Life
522999|NCT00611429|Treatment
523000|NCT00611429|Adherence
523001|NCT00611429|Intervention
523002|NCT00611429|Quality of Life
523003|NCT00611416|catechins
523004|NCT00611416|caffeine
523005|NCT00611416|energy expenditure
523006|NCT00611416|fat oxidation
523007|NCT00611416|appetite
523008|NCT00611403|LASIK
523009|NCT00611390|Viral laryngitis;
523010|NCT00611390|Viral tracheitis;
523011|NCT00611390|Herbal medicine;
523012|NCT00611390|Traditional medicine;
523013|NCT00611390|Aromatic essential oils;
523014|NCT00611377|delirium
523015|NCT00611377|mechanical ventilation
523016|NCT00611377|age
523017|NCT00611377|severity score
523018|NCT00611364|Physical therapy
523019|NCT00611364|hypertension
523020|NCT00611364|aged
523021|NCT00611364|exercise
523022|NCT00611364|Physical exercise
523023|NCT00611364|Physical activity
523024|NCT00611351|graft versus host disease
523025|NCT00611351|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
523026|NCT00611351|adult acute myeloid leukemia with inv(16)(p13;q22)
523027|NCT00611351|adult acute myeloid leukemia with t(15;17)(q22;q12)
523028|NCT00611351|adult acute myeloid leukemia with t(16;16)(p13;q22)
523029|NCT00611351|adult acute myeloid leukemia with t(8;21)(q22;q22)
523030|NCT00611351|recurrent adult acute myeloid leukemia
523031|NCT00611351|untreated adult acute myeloid leukemia
523032|NCT00611351|untreated adult acute lymphoblastic leukemia
523033|NCT00611351|accelerated phase chronic myelogenous leukemia
523034|NCT00611351|blastic phase chronic myelogenous leukemia
523035|NCT00611351|chronic phase chronic myelogenous leukemia
523036|NCT00611351|relapsing chronic myelogenous leukemia
523037|NCT00611351|stage III multiple myeloma
523038|NCT00611351|refractory multiple myeloma
523039|NCT00611351|de novo myelodysplastic syndromes
523040|NCT00611351|myelodysplastic/myeloproliferative disease, unclassifiable
523041|NCT00611351|previously treated myelodysplastic syndromes
523042|NCT00611351|secondary myelodysplastic syndromes
523043|NCT00611351|secondary myelofibrosis
523044|NCT00611351|secondary acute myeloid leukemia
523045|NCT00611351|recurrent adult Burkitt lymphoma
523046|NCT00611351|recurrent adult diffuse large cell lymphoma
523047|NCT00611351|recurrent adult diffuse mixed cell lymphoma
523048|NCT00611351|recurrent adult diffuse small cleaved cell lymphoma
523049|NCT00611351|recurrent adult Hodgkin lymphoma
523050|NCT00611351|recurrent adult immunoblastic large cell lymphoma
523051|NCT00611351|recurrent adult lymphoblastic lymphoma
523052|NCT00611351|recurrent adult T-cell leukemia/lymphoma
523053|NCT00611351|recurrent cutaneous T-cell non-Hodgkin lymphoma
523054|NCT00611351|recurrent grade 1 follicular lymphoma
523055|NCT00611351|recurrent grade 2 follicular lymphoma
523056|NCT00611351|recurrent grade 3 follicular lymphoma
523057|NCT00611351|recurrent mantle cell lymphoma
523058|NCT00611351|recurrent marginal zone lymphoma
523059|NCT00611351|recurrent small lymphocytic lymphoma
523060|NCT00611351|recurrent adult acute lymphoblastic leukemia
523061|NCT00611351|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
523062|NCT00611351|nodal marginal zone B-cell lymphoma
523063|NCT00611351|splenic marginal zone lymphoma
523064|NCT00611351|adult nasal type extranodal NK/T-cell lymphoma
523065|NCT00611351|stage III adult Hodgkin lymphoma
523066|NCT00611351|stage IV adult Hodgkin lymphoma
523067|NCT00611351|stage III adult T-cell leukemia/lymphoma
523068|NCT00611351|stage IV adult T-cell leukemia/lymphoma
523069|NCT00611351|stage III adult Burkitt lymphoma
523070|NCT00611351|stage IV adult Burkitt lymphoma
523071|NCT00611351|stage III adult diffuse large cell lymphoma
523072|NCT00611351|stage IV adult diffuse large cell lymphoma
523073|NCT00611351|stage III adult diffuse mixed cell lymphoma
523074|NCT00611351|stage IV adult diffuse mixed cell lymphoma
523075|NCT00611351|stage III adult immunoblastic large cell lymphoma
523076|NCT00611351|stage IV adult immunoblastic large cell lymphoma
523077|NCT00611351|stage III adult lymphoblastic lymphoma
523078|NCT00611351|stage IV adult lymphoblastic lymphoma
523079|NCT00611351|stage III grade 1 follicular lymphoma
523080|NCT00611351|stage III grade 2 follicular lymphoma
523081|NCT00611351|stage III grade 3 follicular lymphoma
523082|NCT00611351|stage IV grade 1 follicular lymphoma
523083|NCT00611351|stage IV grade 2 follicular lymphoma
523084|NCT00611351|stage IV grade 3 follicular lymphoma
523085|NCT00611351|stage III mantle cell lymphoma
523086|NCT00611351|stage IV mantle cell lymphoma
523087|NCT00611351|stage III marginal zone lymphoma
523088|NCT00611351|stage IV marginal zone lymphoma
523089|NCT00611351|stage III small lymphocytic lymphoma
523090|NCT00611351|stage IV small lymphocytic lymphoma
523091|NCT00611351|stage III adult diffuse small cleaved cell lymphoma
523092|NCT00611351|stage IV adult diffuse small cleaved cell lymphoma
523093|NCT00611351|adult acute lymphoblastic leukemia in remission
523094|NCT00611351|adult acute myeloid leukemia in remission
523095|NCT00611351|atypical chronic myeloid leukemia
523096|NCT00611351|noncontiguous stage II adult Burkitt lymphoma
523097|NCT00611351|noncontiguous stage II adult diffuse large cell lymphoma
523098|NCT00611351|noncontiguous stage II adult diffuse mixed cell lymphoma
523099|NCT00611351|noncontiguous stage II adult diffuse small cleaved cell lymphoma
523100|NCT00611351|noncontiguous stage II adult immunoblastic large cell lymphoma
523101|NCT00611351|noncontiguous stage II adult lymphoblastic lymphoma
523102|NCT00611351|noncontiguous stage II grade 1 follicular lymphoma
523103|NCT00611351|noncontiguous stage II grade 2 follicular lymphoma
523104|NCT00611351|noncontiguous stage II grade 3 follicular lymphoma
523105|NCT00611351|noncontiguous stage II mantle cell lymphoma
523106|NCT00611351|noncontiguous stage II marginal zone lymphoma
523107|NCT00611351|noncontiguous stage II small lymphocytic lymphoma
523108|NCT00611351|refractory hairy cell leukemia
523109|NCT00611351|stage I multiple myeloma
523110|NCT00611351|stage II multiple myeloma
523111|NCT00611338|Complementary Therapies
523112|NCT00611325|Glioblastoma
523113|NCT00611325|Gliosarcoma
523114|NCT00611325|Glioblastoma multiforme
523115|NCT00611325|Recurrent malignant glioma
523116|NCT00611325|GBM
523117|NCT00611325|Recurrent GBM
523118|NCT00611325|Malignant glioma
523119|NCT00611325|Brain tumor
523120|NCT00611325|Avastin
523121|NCT00611325|Bevacizumab
523122|NCT00611325|Bortezomib
523123|NCT00611325|Velcade
523124|NCT00611312|Alzheimer's disease
523125|NCT00611312|Cognitive training
523126|NCT00611299|Probiotics
523127|NCT00611299|Immune response
523128|NCT00611299|Blood lipids
523129|NCT00611299|Intestinal microflora
523130|NCT00611299|Tolerance
523131|NCT00611286|Drug-eluting stent
523132|NCT00611286|clopidogrel
523133|NCT00611286|bare metal stent
523134|NCT00611286|landmark analysis
523135|NCT00611286|Patients with coronary artery disease
523136|NCT00611273|Glabellar Furrowing
523137|NCT00611260|Meditation
523138|NCT00611260|Congestive Heart Failure
523139|NCT00611260|ICD
523140|NCT00611260|Cardiac Resynchronization Therapy
523141|NCT00611221|massage
523142|NCT00611221|labour
523143|NCT00611195|Anesthesia
523144|NCT00611195|Children
523145|NCT00611195|Larynx
523146|NCT00611182|dyspnea
523147|NCT00611182|pulmonary fibrosis
523148|NCT00611182|interstitial lung disease
523149|NCT00611182|shortness of breath
523150|NCT00611169|Angioplasty, Transluminal, Percutaneous Coronary
523151|NCT00611169|tirofiban
523152|NCT00611169|Magnetic Resonance Imaging
523153|NCT00611169|Myocardial Infarction
523154|NCT00611156|Thermogenesis
523155|NCT00611156|Meal-induced thermogenesis
523156|NCT00611156|energy expenditure
523157|NCT00611156|fat oxidation
523158|NCT00611156|bioactive ingredients
523159|NCT00611156|spices
523160|NCT00611156|ginger
523161|NCT00611156|horseradish
523162|NCT00611156|black pepper
523163|NCT00611156|mustard
523164|NCT00611143|Off-pump coronary artery bypass graft
523165|NCT00611143|Atorvastatin
523166|NCT00611143|Postoperative atrial fibrillation
523167|NCT00611130|Cocaine
523168|NCT00611130|Addiction
523169|NCT00611130|Dependence
523170|NCT00611130|Treatment
523171|NCT00611117|adaptation to high fat diet
523172|NCT00611117|activity
523173|NCT00611117|exercise
523174|NCT00611104|breast cancer
523175|NCT00611078|Soft Tissue Sarcoma
523176|NCT00611078|environment
523177|NCT00611078|pollutants
523178|NCT00611078|04-088
523179|NCT00611052|Depressive Disorder
523180|NCT00611052|Depressive Disorder, Major
523181|NCT00611052|Mental Health
523182|NCT00611052|Prevention
523183|NCT00611039|Darunavir/ritonavir
523184|NCT00611039|virtual inhibitory quotient
523185|NCT00611039|dose reduction
523186|NCT00611026|Treatment of overactive bladder
523187|NCT00611013|Development of multi-purpose novel imaging protocols
523188|NCT00611000|colon cancer
523189|NCT00611000|rectal cancer
523190|NCT00610987|Antibiotic Prophylaxis
523191|NCT00610974|Spinal cord injury
523192|NCT00610974|walking
523193|NCT00610974|gait training
523194|NCT00610974|body-weight supported treadmill training
523195|NCT00610974|rehabilitation
523196|NCT00610961|BK Polyomavirus
523197|NCT00610961|Transplantation, Kidney
523198|NCT00610961|Transplantation, Pancreas
523199|NCT00610948|unspecified adult solid tumor, protocol specific
523200|NCT00610935|Influenza
523201|NCT00610935|Subjects with uncomplicated acute influenza
523202|NCT00610922|Performance of motor skills
523203|NCT00610909|IBS
523204|NCT00610870|Myocardial infarct size
523205|NCT00610870|Atorvastatin
523206|NCT00610870|SPECT
523207|NCT00610870|Hydroxymethylglutaryl-CoA Reductase Inhibitors
523208|NCT00610844|lung cancer
523209|NCT00610844|lung metastasis
523210|NCT00610844|radiofrequency ablation
523211|NCT00610805|SLE
523212|NCT00610805|lupus
523213|NCT00610805|cardiovascular
523214|NCT00610805|IMT
523215|NCT00610805|Systemic Lupus Erythematosus
523216|NCT00610779|Rhino-sinusitis;
523217|NCT00610779|Herbal medicine;
523218|NCT00610779|Traditional medicine;
523219|NCT00610779|Aromatic essential oils;
523220|NCT00610766|coronary CT angiography
523221|NCT00610766|radiation dose estimates
523222|NCT00610753|Anorexia nervosa
523223|NCT00610753|Adolescents
523224|NCT00610753|Family therapy
523225|NCT00610740|recurrent cervical cancer
523226|NCT00610740|cervical cancer
523227|NCT00610740|endometrial carcinoma
523228|NCT00610740|ovarian epithelial cancer
523229|NCT00610740|recurrent ovarian epithelial cancer
523230|NCT00610740|recurrent endometrial carcinoma
523231|NCT00610727|Migraine, Prochlorperazine aerosol
523232|NCT00610714|Cancer
523233|NCT00610714|Tumour
523234|NCT00610714|Ovarian Neoplasms
523235|NCT00610714|Ovarian Cancer
523236|NCT00610675|Fifty two weeks
523237|NCT00610675|Open label
523238|NCT00610675|extension
523239|NCT00610662|cervical cancer
523240|NCT00610662|cervical intraepithelial neoplasia grade 1
523241|NCT00610662|cervical intraepithelial neoplasia grade 2
523242|NCT00610662|cervical intraepithelial neoplasia grade 3
523243|NCT00610649|randomized
523244|NCT00610649|placebo controlled
523245|NCT00610649|maximum tolerated dose
523246|NCT00610636|FOLFOX-4
523247|NCT00610636|neoadjuvant chemotherapy
523248|NCT00610636|colorectal cancer
523249|NCT00610636|liver metastasis
523250|NCT00610636|resectability
523251|NCT00610623|Pseudomonas aeruginosa
523252|NCT00610623|Pneumonia
523253|NCT00610623|Ventilator-Associated
523254|NCT00610623|Quorum Sensing
523255|NCT00610610|Fibromyalgia
523256|NCT00610610|Paroxetine
523257|NCT00610597|liver
523258|NCT00610597|alcohol
523259|NCT00610597|lymphocyte
523260|NCT00610584|seasonal allergic rhinitis
523261|NCT00610584|acupuncture
523262|NCT00610584|RCT
523263|NCT00610584|CAM
523264|NCT00610571|Temodar
523265|NCT00610571|Temozolomide
523266|NCT00610571|Topotecan
523267|NCT00610571|Hycamtin
523268|NCT00610571|Malignant Gliomas
523269|NCT00610571|Brain tumor
523270|NCT00610571|Anaplastic astrocytoma
523271|NCT00610571|AA
523272|NCT00610571|GBM
523273|NCT00610571|Glioblastoma Multiform
523274|NCT00610571|Gliosarcoma
523275|NCT00610545|ATORVASTATIN
523276|NCT00610545|VASCULAR SURGERY
523277|NCT00610545|CARDIOVASCULAR OUTCOMES
523278|NCT00610532|pharmacoresistance
523279|NCT00610532|healthy volunteers
523280|NCT00610519|Viral pharyngo-tonsillitis;
523281|NCT00610519|Herbal medicine;
523282|NCT00610519|Traditional medicine;
523283|NCT00610519|Aromatic essential oils;
523284|NCT00610506|Atypical Depression
523285|NCT00610493|Advanced Cancer
523286|NCT00610493|Bevacizumab
523287|NCT00610493|Temsirolimus
523288|NCT00610493|Avastin
523289|NCT00610493|Torisel
523290|NCT00610493|CCI-779
523291|NCT00610493|Anti-VEGF monoclonal antibody
523292|NCT00610493|rhuMAb-VEGF
523293|NCT00610493|dynamic contrast-enhanced magnetic resonance imaging
523294|NCT00610493|DCE
523295|NCT00610493|magnetic resonance imaging
523296|NCT00610493|MRI
523297|NCT00610480|Dry Eyes
523298|NCT00610480|Tear Film Stability
523299|NCT00610454|Levetiracetam
523300|NCT00610454|Keppra
523301|NCT00610441|randomized
523302|NCT00610441|double blind
523303|NCT00610441|placebo controlled
523304|NCT00610428|Migraine, Staccato Prochlorperazine
523305|NCT00610428|Migraine headache with or without aura.
523306|NCT00610376|Handwashing
523307|NCT00610376|Randomized controlled trial
523308|NCT00610376|Cluster randomization
523309|NCT00610376|Community intervention trial
523310|NCT00610376|Disease prevention
523311|NCT00610376|Pediatric communicable disease
523312|NCT00610376|Preschool
523313|NCT00610376|Illness absenteeism
523314|NCT00610350|Levosimendan
523315|NCT00610350|pre-conditioning
523316|NCT00610350|cardiac surgery
523317|NCT00610350|myocardial function
523318|NCT00610350|contractility
523319|NCT00610350|heart
523320|NCT00610350|ischaemia
523321|NCT00610324|oropharyngeal cleansing
523322|NCT00610324|oral decontamination
523323|NCT00610324|oropharyngeal bacterial flora
523324|NCT00610324|oropharyngeal colonization
523325|NCT00610324|critical illness
523326|NCT00610324|mechanical ventilation
523327|NCT00610324|tracheal intubation
523328|NCT00610324|prophylaxis
523329|NCT00610311|Metastatic Melanoma
523330|NCT00610311|Immunotherapy
523331|NCT00610311|Vaccination
523332|NCT00610311|Tumor Regression
523333|NCT00610311|Skin Cancer
523334|NCT00610298|disability affecting strength, balance and coordination
523335|NCT00610272|single bone metastasis
523336|NCT00610272|multiple bone metastasis
523337|NCT00610272|pain relief
523338|NCT00610272|radiotherapy
523339|NCT00610259|Depressive disorder
523340|NCT00610259|Sleep initiation and maintenance disorder
523341|NCT00610259|Behavior therapy
523342|NCT00610246|Thorax
523343|NCT00610246|Abdomen
523344|NCT00610246|Pelvis
523345|NCT00610246|Lesion
523346|NCT00610246|Cancer
523347|NCT00610246|Radiation
523348|NCT00610246|Chemotherapy
523349|NCT00610246|Phase 1
523350|NCT00610246|Advanced Cancer
523351|NCT00610246|Sorafenib
523352|NCT00610246|Nexavar
523353|NCT00610246|BAY43-9006
523354|NCT00610233|deep brain stimulation
523355|NCT00610233|urodynamics
523356|NCT00610220|pediatrics
523357|NCT00610220|wrist fractures
523358|NCT00610220|casting
523359|NCT00610220|wrist splint
523360|NCT00610207|Anal fistula
523361|NCT00610207|fistula in ano
523362|NCT00610207|anorectal fistula
523363|NCT00610207|Crohn's Disease
523364|NCT00610181|Breast Cancer
523365|NCT00610181|Breast Carcinoma
523366|NCT00610181|Invasive Lobular Cancer
523367|NCT00610181|Mixed Invasive Ductal-lobular Carcinoma
523368|NCT00610181|Magnetic Resonance Imaging
523369|NCT00610181|MRI
523370|NCT00610168|dTpa vaccine
523371|NCT00610168|pertussis
523372|NCT00610168|Tdap
523373|NCT00610168|Boostrix
523374|NCT00610168|booster
523375|NCT00610168|tetanus
523376|NCT00610168|diphtheria
523377|NCT00610142|atopic dermatitis
523378|NCT00610142|pimecrolimus
523379|NCT00610142|hydrocortison
523380|NCT00610142|Optical Coherence Tomography
523381|NCT00610129|MK-0646
523382|NCT00610090|UNITE
523383|NCT00610090|AAA
523384|NCT00610090|Abdominal Aortic Aneurysms
523385|NCT00610090|Stent
523386|NCT00610090|Graft
523387|NCT00610077|Letrozole
523388|NCT00610077|Clomiphene citrate
523389|NCT00610077|Anovulatory infertility
523390|NCT00610077|Ovulation induction
523391|NCT00610064|Refractory lower urinary tract dysfunction
523392|NCT00610064|Sacral neuromodulation
523393|NCT00610064|Brain effects
523394|NCT00610064|Neuroimaging
523395|NCT00610064|Neuromodulation
523396|NCT00610051|severe heart failure
523397|NCT00610051|transplants
523398|NCT00610038|neonatal
523399|NCT00610038|diabetes mellitus
523400|NCT00610038|mutation
523401|NCT00610038|KIR6.2
523402|NCT00610038|SUR1
523403|NCT00610038|Neonatal diabetes mellitus with KIR6.2 or SUR1 mutations
523404|NCT00610025|NOTES
523405|NCT00610025|transgastric endoscopy
523406|NCT00610025|obesity surgery
523407|NCT00610025|Roux-en-Y surgery
523408|NCT00610012|Advanced Renal Cell Carcinoma
523409|NCT00610012|MRCC
523410|NCT00610012|Therapy-reality
523411|NCT00610012|Observation
523412|NCT00610012|Registry
523413|NCT00610012|RCC
523414|NCT00610012|ARCC
523415|NCT00610012|Germany
523416|NCT00610012|Metastatic Renal Cell Carcinoma
523417|NCT00610012|Renal Cell Carcinoma
523418|NCT00610012|Renal Cell Cancer
523419|NCT00610012|Sorafenib
523420|NCT00610012|Sunitinib
523421|NCT00610012|Interferon
523422|NCT00610012|Interleukin
523423|NCT00610012|Temsirolimus
523424|NCT00610012|Pazopanib
523425|NCT00610012|Cytokines
523426|NCT00610012|VEGF
523427|NCT00609999|Glioblastoma
523428|NCT00609999|Gliosarcoma
523429|NCT00609999|GBM
523430|NCT00609999|Recurrent MG
523431|NCT00609999|Erlotinib
523432|NCT00609999|Dasatinib
523433|NCT00609999|Brain tumor
523434|NCT00609999|Malignant glioma
523435|NCT00609999|Tarceva
523436|NCT00609999|Sprycel
523437|NCT00609986|Kidney
523438|NCT00609986|Transplantation
523439|NCT00609986|Diabetes
523440|NCT00609986|Hyperglycemia
523441|NCT00609973|Postoperative recurrence, inflammatory bowel disease
523442|NCT00609960|children anesthesia anxiety clowns
523443|NCT00609934|renal cell carcinoma
523444|NCT00609934|kidney cancer
523445|NCT00609934|bone metastases
523446|NCT00609934|RCC
523447|NCT00609934|bone pain
523448|NCT00609934|palliative radiotherapy
523449|NCT00609934|sorafenib
523450|NCT00609934|radiation
523451|NCT00609934|renal cell
523452|NCT00609882|Nasal CPAP
523453|NCT00609882|High flow nasal cannula
523454|NCT00609882|Neonate
523455|NCT00609843|Bladder cancer
523456|NCT00609843|Radiotherapy
523457|NCT00609843|Tumour delineation
523458|NCT00609843|Markers
523459|NCT00609830|Glucocorticoids
523460|NCT00609830|Osteoporosis
523461|NCT00609830|Rheumatoid Arthritis
523462|NCT00609830|Prevention
523463|NCT00609830|GIOP
523464|NCT00609830|Patient Education
523465|NCT00609817|Relapsed Multiple Myeloma
523466|NCT00609817|Refractory Multiple Myeloma
523467|NCT00609817|GCS 100
523468|NCT00609804|Non-Small Cell Lung Cancer
523469|NCT00609804|Advanced
523470|NCT00609804|Erlotinib
523471|NCT00609804|Sorafenib
523472|NCT00609804|Progressing on erlotinib
523473|NCT00609791|recurrent breast cancer
523474|NCT00609791|stage IV breast cancer
523475|NCT00609791|male breast cancer
523476|NCT00609778|CPR
523477|NCT00609778|Mechanical
523478|NCT00609778|Manual
523479|NCT00609778|Survival
523480|NCT00609778|ROSC
523481|NCT00609765|advanced
523482|NCT00609765|unresectable
523483|NCT00609765|metastatic
523484|NCT00609765|endocrine
523485|NCT00609765|tumors
523486|NCT00609752|Crohn Disease
523487|NCT00609752|Children
523488|NCT00609752|Bone Density
523489|NCT00609752|Prednisolone
523490|NCT00609752|Liquid Diet Therapy
523491|NCT00609752|Quality of Life
523492|NCT00609752|Metabolic Bone Disease
523493|NCT00609739|juvenile myelomonocytic leukemia
523616|NCT00609154|Non diabetic control
523494|NCT00609726|Endoscopic Ultrasonography
523495|NCT00609726|Pancreatitis
523496|NCT00609726|EUS
523497|NCT00609713|Child
523498|NCT00609713|Obesity
523499|NCT00609700|burn injury
523500|NCT00609700|volume replacement
523501|NCT00609700|Ringer's Lactate solution
523502|NCT00609700|Ringer's Acetate solution
523503|NCT00609700|volume replacement with crystalloids
523504|NCT00609687|sarcoidosis
523505|NCT00609687|diagnostic vitrectomy
523506|NCT00609687|vitreous biopsy
523507|NCT00609687|sarcoidosis-associated ocular inflammation
523508|NCT00609674|Perennial allergic rhinitis; fluticasone furoate nasal spray
523509|NCT00609661|Mesenchymal Stem Cells, Burn
523510|NCT00609648|Dental Anxiety
523511|NCT00609648|Dental Phobia
523512|NCT00609648|Odontophobia
523513|NCT00609635|Respiratory
523514|NCT00609635|RSV-induced respiratory illness
523515|NCT00609622|metastatic colorectal cancer sunitinib (Sutent) bevacizumab (Avastin) randomized study
523516|NCT00609609|Allogeneic stem cell grafts
523517|NCT00609609|Allogeneic bone marrow graft
523518|NCT00609609|Blood and Marrow Transplantation
523519|NCT00609609|Stem cell graft
523520|NCT00609609|Graft Versus Host Disease
523521|NCT00609609|GVHD
523522|NCT00609609|Extracorporeal Photopheresis
523523|NCT00609609|ECP
523524|NCT00609609|Photopheresis
523525|NCT00609609|Methylprednisolone
523526|NCT00609609|Medrol
523527|NCT00609609|Depo-Medrol
523528|NCT00609609|Solu-Medrol
523529|NCT00609596|dutasteride
523530|NCT00609596|tamsulosin
523531|NCT00609596|benign prostatic hyperplasia
523532|NCT00609570|hypertension
523533|NCT00609570|supplement
523534|NCT00609570|HRV
523535|NCT00609557|osteoarthritis pain
523536|NCT00609557|activity limitation
523537|NCT00609557|antidepressant
523538|NCT00609557|depression
523539|NCT00609557|single-blind
523540|NCT00609544|Non Dialysis-dependent chronic kidney disease and anemia
523541|NCT00609531|Restricted repetitive behaviors
523542|NCT00609531|restricted interests
523543|NCT00609531|Aspergers
523544|NCT00609531|Autism
523545|NCT00609505|Hereditary Breast and Ovarian Cancer syndrome
523546|NCT00609505|genetic counseling
523547|NCT00609505|breast cancer
523548|NCT00609505|ovarian cancer
523549|NCT00609505|telemedicine
523550|NCT00609505|Cancer genetic counseling
523551|NCT00609479|Distal radius fracture
523552|NCT00609479|Colle´s fracture
523553|NCT00609479|Internal fixation
523554|NCT00609479|External fixation
523555|NCT00609479|DASH
523556|NCT00609479|PRWE
523557|NCT00609466|Opioid
523558|NCT00609466|Central acting analgesic
523559|NCT00609466|CG5503 IR
523560|NCT00609466|Postoperative pain
523561|NCT00609466|Bunionectomy
523562|NCT00609466|Morphine
523563|NCT00609466|Placebo
523564|NCT00609453|Control participants
523565|NCT00609440|Morquio's disease; physiotherapy; results
523566|NCT00609427|cognitive training
523567|NCT00609427|cognitive rehabilitation
523568|NCT00609414|Burns
523569|NCT00609414|Albumin
523570|NCT00609414|Fluid Resuscitation
523571|NCT00609401|Sorafenib
523572|NCT00609401|RCC
523573|NCT00609401|Metastatic disease
523574|NCT00609375|Sepsis
523575|NCT00609375|Bacteremia
523576|NCT00609375|Intravenous infusions
523577|NCT00609375|cefepime
523578|NCT00609362|BMD
523579|NCT00609362|Rosiglitazone
523580|NCT00609362|Bone marrow fat
523581|NCT00609349|risk factors for pulmonary arterial hypertension
523582|NCT00609323|Pain
523583|NCT00609323|postherpetic neuralgia
523584|NCT00609310|clinical trial
523585|NCT00609310|flavonoid treatment
523586|NCT00609310|neoplasia recurrence
523587|NCT00609310|colorectal cancer
523588|NCT00609310|polypectomy
523589|NCT00609310|adenoma in Colon
523590|NCT00609310|Neoplasia Recurrence Rates
523591|NCT00609310|postpolypectomy patients
523592|NCT00609297|unspecified adult solid tumor, protocol specific
523593|NCT00609297|pain
523594|NCT00609284|Stage III
523595|NCT00609284|Stage IV
523596|NCT00609284|locally advanced
523597|NCT00609245|epilepsy
523598|NCT00609245|photosensitive
523599|NCT00609245|valproic acid
523600|NCT00609219|recurrent nasopharyngeal cancer
523601|NCT00609219|stage II nasopharyngeal cancer
523602|NCT00609219|stage III nasopharyngeal cancer
523603|NCT00609219|stage IV nasopharyngeal cancer
523604|NCT00609180|Acute Lung Injury
523605|NCT00609180|Acute Respiratory Distress Syndrome
523606|NCT00609180|Feeding
523607|NCT00609180|Critical Care
523608|NCT00609180|Ventilator
523609|NCT00609180|Omega-3 Fatty Acid
523610|NCT00609180|Antioxidant
523611|NCT00609167|stage II multiple myeloma
523612|NCT00609167|stage III multiple myeloma
523613|NCT00609154|Type 2 diabetes
523614|NCT00609154|Insulin
523615|NCT00609154|biosynthesis
523617|NCT00609128|tears
523618|NCT00609128|conjunctival epithelial cells
523619|NCT00609128|olopatadine
523620|NCT00609128|impression cytology
523621|NCT00609115|Sub-acute care
523622|NCT00609115|Robotics
523623|NCT00609102|Type 2 diabetes
523624|NCT00609089|Family
523625|NCT00609089|treatment
523626|NCT00609089|reinforcement
523627|NCT00609089|substance
523628|NCT00609089|trial
523629|NCT00609089|drug
523630|NCT00609089|abuse
523631|NCT00609089|HIV
523632|NCT00609089|risk
523633|NCT00609063|Statins
523634|NCT00609063|Myalgia
523635|NCT00609063|Muscle Cramp
523636|NCT00609050|cystic fibrosis
523637|NCT00609050|exercise
523638|NCT00609050|perceived exertion
523639|NCT00609050|aerobic fitness
523640|NCT00609050|lung function
523641|NCT00609050|health related quality of life
523642|NCT00609050|self-regulated exercise
523643|NCT00609037|Gastric Bypass
523644|NCT00609037|Body contouring
523645|NCT00609037|Excessive weight loss
523646|NCT00609011|Melanoma
523647|NCT00609011|Metastatic
523648|NCT00608998|Chronic renal failure
523649|NCT00608998|Vasculopathy
523650|NCT00608998|Cardiovascular risk
523651|NCT00608998|Chronic renal failure patients
523652|NCT00608985|sleeplessness
523653|NCT00608985|orexin receptor antagonist
523654|NCT00608985|almorexant
523655|NCT00608985|insomnia
523656|NCT00608972|negative for a protein called HER2/neu
523657|NCT00608972|negative for estrogen receptors (ER) and progesterone receptors (PR).
523658|NCT00608972|breast cancer
523659|NCT00608959|Skin colonization
523660|NCT00608959|Catheter colonization
523661|NCT00608959|Catheter site infection
523662|NCT00608946|efficacy of treatment with copper in patients with mild Alzheimer´s disease
523663|NCT00608946|cognitive status over time
523664|NCT00608946|CSF and volumetric data over time (1 year)
523665|NCT00608933|unspecified adult solid tumor, protocol specific
523666|NCT00608933|unspecified childhood solid tumor, protocol specific
523667|NCT00608920|SPECT
523668|NCT00608894|Autoimmune hepatitis
523669|NCT00608894|Chronic active hepatitis
523670|NCT00608881|Huntington's disease
523671|NCT00608881|Huntington disease
523672|NCT00608881|HD
523673|NCT00608881|coenzyme Q10
523674|NCT00608881|CoQ
523675|NCT00608868|Carcinoma
523676|NCT00608868|Non Small Cell Lung
523677|NCT00608868|EGFR mutation
523678|NCT00608868|Gefitinib
523679|NCT00608855|bone metastases
523680|NCT00608855|pain
523681|NCT00608855|unspecified adult solid tumor, protocol specific
523682|NCT00608816|epinephrine
523683|NCT00608790|Tuberculosis, TB, Mycobacterium tuberculosis, children, South Africa
523684|NCT00608777|Localized mild breakthrough
523685|NCT00608764|Chronic Obstructive Pulmonary Disease
523686|NCT00608764|COPD
523687|NCT00608764|Emphysema
523688|NCT00608764|Chronic Bronchitis
523689|NCT00608764|Genetics
523690|NCT00608764|Association Studies
523691|NCT00608764|Computed Tomography
523692|NCT00608751|Newly Diagnosed head and neck cancer
523693|NCT00608738|neutropenia
523694|NCT00608738|infection
523695|NCT00608738|radiation toxicity
523696|NCT00608738|chemotherapeutic agent toxicity
523697|NCT00608738|malnutrition
523698|NCT00608738|musculoskeletal complications
523699|NCT00608738|thrombocytopenia
523700|NCT00608738|unspecified adult solid tumor, protocol specific
523701|NCT00608725|heart rate
523702|NCT00608725|blood pressure
523703|NCT00608725|blood volume
523704|NCT00608725|sympathetic nervous system
523705|NCT00608725|orthostatic tachycardia
523706|NCT00608725|orthostatic intolerance
523707|NCT00608725|POTS
523708|NCT00608712|bariatric surgery
523709|NCT00608712|ulcer prevention
523710|NCT00608699|Flushing
523711|NCT00608699|GSK256073A,
523712|NCT00608699|Dose Escalation,
523713|NCT00608699|Immediate Release Niacin,
523714|NCT00608686|NIAAA
523715|NCT00608686|Alcohol
523716|NCT00608686|Neurosteroids
523717|NCT00608686|Intoxication
523718|NCT00608673|discoid lupus erythematosus
523719|NCT00608673|pimecrolimus 1% cream
523720|NCT00608673|betamethasone valerate 0.1% cream
523721|NCT00608660|Peripheral Facial Paralysis
523722|NCT00608660|Acupuncture
523723|NCT00608660|RCT
523724|NCT00608634|actinic keratosis
523725|NCT00608621|physostigmine
523726|NCT00608621|postoperative analgesia
523727|NCT00608621|pain
523728|NCT00608621|patient-controlled analgesia
523729|NCT00608621|Opioid consumption
523730|NCT00608621|Pain quality (VAS Score)
523731|NCT00608621|Hemodynamics
523732|NCT00608621|Mobilisation
523733|NCT00608621|Side effects
523734|NCT00608595|adenocarcinoma of the rectum
523735|NCT00608595|recurrent rectal cancer
523736|NCT00608595|stage I rectal cancer
523737|NCT00608595|stage II rectal cancer
523738|NCT00608595|stage III rectal cancer
523739|NCT00608582|Transcranial Magnetic Stimulation, Repetitive
523740|NCT00608582|TMS
523741|NCT00608582|Treat Naming
523742|NCT00608582|Aphasia
523743|NCT00608582|Chronic Stroke
523744|NCT00608582|Randomized, Controlled Trial
523745|NCT00608569|Drug Therapy, Combination
523746|NCT00608569|HIV Non-Nucleoside Reverse Transcriptase Inhibitors
523747|NCT00608569|HIV Protease Inhibitors
523748|NCT00608569|Viral Load
523749|NCT00608569|Virologic Failure
523750|NCT00608556|Heterotaxy
523751|NCT00608556|Primary Ciliary Dyskinesia
523752|NCT00608556|Congenital Heart Disease
523753|NCT00608556|Genetic Study
523754|NCT00608556|Situs Inversus
523755|NCT00608543|cognitive function
523756|NCT00608543|psychosocial function
523757|NCT00608543|augmentation
523758|NCT00608543|treatment refractory depression
523759|NCT00608530|pain
523760|NCT00608530|chronic pain
523761|NCT00608530|chronic back pain
523762|NCT00608530|randomized clinical trial
523763|NCT00608517|graft versus host disease
523764|NCT00608517|accelerated phase chronic myelogenous leukemia
523765|NCT00608517|adult acute lymphoblastic leukemia in remission
523766|NCT00608517|adult acute myeloid leukemia in remission
523767|NCT00608517|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
523768|NCT00608517|adult acute myeloid leukemia with inv(16)(p13;q22)
523769|NCT00608517|adult acute myeloid leukemia with t(15;17)(q22;q12)
523770|NCT00608517|adult acute myeloid leukemia with t(16;16)(p13;q22)
523771|NCT00608517|adult acute myeloid leukemia with t(8;21)(q22;q22)
523772|NCT00608517|blastic phase chronic myelogenous leukemia
523773|NCT00608517|childhood acute lymphoblastic leukemia in remission
523774|NCT00608517|childhood acute myeloid leukemia in remission
523775|NCT00608517|childhood chronic myelogenous leukemia
523776|NCT00608517|chronic phase chronic myelogenous leukemia
523777|NCT00608517|de novo myelodysplastic syndromes
523778|NCT00608517|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
523779|NCT00608517|myelodysplastic/myeloproliferative disease, unclassifiable
523780|NCT00608517|nodal marginal zone B-cell lymphoma
523781|NCT00608517|noncontiguous stage II adult Burkitt lymphoma
523782|NCT00608517|noncontiguous stage II adult diffuse large cell lymphoma
523783|NCT00608517|noncontiguous stage II adult diffuse mixed cell lymphoma
523784|NCT00608517|noncontiguous stage II adult diffuse small cleaved cell lymphoma
523785|NCT00608517|noncontiguous stage II adult immunoblastic large cell lymphoma
523786|NCT00608517|noncontiguous stage II adult lymphoblastic lymphoma
523787|NCT00608517|noncontiguous stage II adult non-Hodgkin lymphoma
523788|NCT00608517|noncontiguous stage II grade 1 follicular lymphoma
523789|NCT00608517|noncontiguous stage II grade 2 follicular lymphoma
523790|NCT00608517|noncontiguous stage II grade 3 follicular lymphoma
523791|NCT00608517|noncontiguous stage II mantle cell lymphoma
523792|NCT00608517|noncontiguous stage II marginal zone lymphoma
523793|NCT00608517|noncontiguous stage II small lymphocytic lymphoma
523794|NCT00608517|previously treated myelodysplastic syndromes
523795|NCT00608517|secondary acute myeloid leukemia
523796|NCT00608517|secondary myelodysplastic syndromes
523797|NCT00608517|splenic marginal zone lymphoma
523798|NCT00608517|stage I multiple myeloma
523799|NCT00608517|stage II multiple myeloma
523800|NCT00608517|refractory multiple myeloma
523801|NCT00608517|stage III adult Burkitt lymphoma
523802|NCT00608517|stage III adult Hodgkin lymphoma
523803|NCT00608517|stage III adult diffuse large cell lymphoma
523804|NCT00608517|stage III adult diffuse mixed cell lymphoma
523805|NCT00608517|stage III adult diffuse small cleaved cell lymphoma
523806|NCT00608517|stage III adult immunoblastic large cell lymphoma
523807|NCT00608517|stage III adult lymphoblastic lymphoma
523808|NCT00608517|stage III chronic lymphocytic leukemia
523809|NCT00608517|stage III grade 1 follicular lymphoma
523810|NCT00608517|stage III grade 2 follicular lymphoma
523811|NCT00608517|stage III grade 3 follicular lymphoma
523812|NCT00608517|stage III mantle cell lymphoma
523813|NCT00608517|stage III marginal zone lymphoma
523814|NCT00608517|stage III multiple myeloma
523815|NCT00608517|stage III small lymphocytic lymphoma
523816|NCT00608517|stage IV adult Burkitt lymphoma
523817|NCT00608517|stage IV adult Hodgkin lymphoma
523818|NCT00608517|stage IV adult diffuse large cell lymphoma
523819|NCT00608517|stage IV adult diffuse mixed cell lymphoma
523820|NCT00608517|stage IV adult diffuse small cleaved cell lymphoma
523821|NCT00608517|stage IV adult immunoblastic large cell lymphoma
523822|NCT00608517|stage IV adult lymphoblastic lymphoma
523823|NCT00608517|stage IV chronic lymphocytic leukemia
523824|NCT00608517|stage IV grade 1 follicular lymphoma
523825|NCT00608517|stage IV grade 2 follicular lymphoma
523826|NCT00608517|stage IV grade 3 follicular lymphoma
523827|NCT00608517|stage IV mantle cell lymphoma
523828|NCT00608517|stage IV marginal zone lymphoma
523829|NCT00608517|stage IV small lymphocytic lymphoma
523830|NCT00608517|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
523831|NCT00608517|Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia
523832|NCT00608517|refractory chronic lymphocytic leukemia
523833|NCT00608517|childhood myelodysplastic syndromes
523834|NCT00608517|stage III adult T-cell leukemia/lymphoma
523835|NCT00608517|stage IV adult T-cell leukemia/lymphoma
523836|NCT00608517|adult nasal type extranodal NK/T-cell lymphoma
523837|NCT00608517|childhood nasal type extranodal NK/T-cell lymphoma
523838|NCT00608517|stage III cutaneous T-cell non-Hodgkin lymphoma
523839|NCT00608517|stage IV cutaneous T-cell non-Hodgkin lymphoma
523840|NCT00608517|recurrent cutaneous T-cell non-Hodgkin lymphoma
523841|NCT00608517|recurrent adult T-cell leukemia/lymphoma
523842|NCT00608504|Behavioral Economics
523843|NCT00608504|Drug self administration
523844|NCT00608504|Opioid
523845|NCT00608491|Acute Decompensated Heart Failure
523846|NCT00608491|Acute Decompensated Heart Failure With Cardiorenal Syndrome
523847|NCT00608491|Cardiorenal Syndrome
523848|NCT00608491|Persistent Congestion
523849|NCT00608491|Ultra Filtration
523850|NCT00608465|Fibrolytic Dysfunction
523851|NCT00608465|Obesity
523852|NCT00608465|PAI-1
523853|NCT00608452|Lung
523854|NCT00608452|Ovarian
523855|NCT00608452|Breast
523856|NCT00608452|Hodgkin's
523857|NCT00608439|CAST
523858|NCT00608439|Centella asiatica
523859|NCT00608439|Diabetes
523860|NCT00608439|Diabetic neuropathy
523861|NCT00608426|African Americans
523862|NCT00608426|telephone counseling
523863|NCT00608426|community health planning
523864|NCT00608426|ethnic groups
523865|NCT00608400|CLA
523866|NCT00608400|PTH
523867|NCT00608400|nutritional supplement
523868|NCT00608374|Waldenström macroglobulinemia
523869|NCT00608374|splenic marginal zone lymphoma
523870|NCT00608374|stage I marginal zone lymphoma
523871|NCT00608374|stage III marginal zone lymphoma
523872|NCT00608374|stage IV marginal zone lymphoma
523873|NCT00608374|contiguous stage II marginal zone lymphoma
523874|NCT00608374|noncontiguous stage II marginal zone lymphoma
523875|NCT00608348|exercise
523876|NCT00608348|hypoglycemia
523877|NCT00608348|sympathetic nerve activity
523878|NCT00608335|Antifungal
523879|NCT00608335|Echinocandin
523880|NCT00608335|Candidiasis
523881|NCT00608335|Micafungin
523882|NCT00608322|Sepsis
523883|NCT00608322|Severe sepsis
523884|NCT00608322|Septic shock
523885|NCT00608283|Kidney transplant
523886|NCT00608283|Live donor transplant
523887|NCT00608244|Tacrolimus
523888|NCT00608244|Pharmacokinetics
523889|NCT00608244|Liver Transplantation
523890|NCT00608218|Asthma
523891|NCT00608218|ciclesonide
523892|NCT00608218|inhaled steroids
523893|NCT00608218|Alvesco
523894|NCT00608205|stage III squamous cell carcinoma of the hypopharynx
523895|NCT00608205|stage III squamous cell carcinoma of the lip and oral cavity
523896|NCT00608205|stage III squamous cell carcinoma of the oropharynx
523897|NCT00608205|stage III squamous cell carcinoma of the larynx
523898|NCT00608205|stage IV squamous cell carcinoma of the hypopharynx
523899|NCT00608205|stage IV squamous cell carcinoma of the lip and oral cavity
523900|NCT00608205|stage IV squamous cell carcinoma of the oropharynx
523901|NCT00608205|stage IV squamous cell carcinoma of the larynx
523902|NCT00608192|HIV
523903|NCT00608192|viral hepatitis
523904|NCT00608192|methadone maintenance
523905|NCT00608192|case management
523906|NCT00608192|costs
523907|NCT00608192|vaccination
523908|NCT00608192|risk reduction education
523909|NCT00608179|epinephrine
523910|NCT00608179|glucose clamp
523911|NCT00608153|essential hypertension
523912|NCT00608153|ARB
523913|NCT00608153|compliance
523914|NCT00608153|candesartan
523915|NCT00608140|Advanced Heart Failure
523916|NCT00608140|Non-Ischemic Heart Failure
523917|NCT00608140|Mitral Regurgitation
523918|NCT00608140|Mitral Valve Replacement
523919|NCT00608140|Congestive Heart Failure
523920|NCT00608140|Surgical Mitral Valvuloplasty
523921|NCT00608140|Dilated Cardiomyopathy
523922|NCT00608140|Annular Ring
523923|NCT00608101|hypoglycemia
523924|NCT00608101|exercise
523925|NCT00608101|corticosteroids
523926|NCT00608088|Breast feeding
523927|NCT00608088|breastfeeding
523928|NCT00608088|randomized clinical trial
523929|NCT00608088|poverty
523930|NCT00608062|endothelial function
523931|NCT00608062|women
523932|NCT00608062|female
523933|NCT00608062|estrogen deficiency
523934|NCT00608062|sex hormones
523935|NCT00608062|adiposity
523936|NCT00608062|oxidative stress
523937|NCT00608062|antioxidants
523938|NCT00608049|Blood Pressure
523939|NCT00608049|Diabetes
523940|NCT00608049|Nutrition
523941|NCT00608049|Dietary Carbohydrate
523942|NCT00608049|Lipoproteins
523943|NCT00608049|Insulin Resistance
523944|NCT00608036|Adolescents
523945|NCT00608036|Neighborhood
523946|NCT00608036|Walkability
523947|NCT00608036|Physical Activity
523948|NCT00608036|Quality of Life
523949|NCT00608036|Ecological Analysis
523950|NCT00608036|Dietary Patterns
523951|NCT00608036|Weight Status
523952|NCT00608036|Neighborhood Environment
523953|NCT00608036|Food Environment
523954|NCT00608036|Recreation Environment
523955|NCT00608023|HIV
523956|NCT00608023|Lipodystrophy
523957|NCT00608023|Abdominal fat accumulation
523958|NCT00608023|Growth hormone releasing hormone
523959|NCT00608023|HIV-associated lipodystrophy
523960|NCT00608023|Treatment experienced
523961|NCT00608010|Preservation of supernumerary embryos in an IVF program
523962|NCT00607997|Leukemia
523963|NCT00607997|Myeloid
523964|NCT00607997|Elderly
523965|NCT00607997|Hematologic
523966|NCT00607997|Blood
523967|NCT00607997|Cancer
523968|NCT00607997|Malignancy
523969|NCT00607997|SNS-595
523970|NCT00607997|Sunesis
523971|NCT00607997|Hematologic Diseases
523972|NCT00607997|Myelodysplastic Syndromes
523973|NCT00607997|Older
523974|NCT00607997|voreloxin
523975|NCT00607997|reveal-1
523976|NCT00607984|thiotepa
523977|NCT00607984|melphalan
523978|NCT00607984|brain tumor
523979|NCT00607984|tumors of central nervous system and other solid tumors
523980|NCT00607971|Constipation predominant irritable bowel syndrome
523981|NCT00607958|Tipranavir
523982|NCT00607958|ritonavir
523983|NCT00607958|dose reduction
523984|NCT00607958|inhibitory quotient
523985|NCT00607945|Type 2 diabetes mellitus
523986|NCT00607945|conjugated linoleic acid
523987|NCT00607945|weight loss
523988|NCT00607945|rosiglitazone
523989|NCT00607945|glucose control
523990|NCT00607945|insulin sensitivity
523991|NCT00607932|recurrent prostate cancer
523992|NCT00607906|safety
523993|NCT00607906|pharmacodynamics
523994|NCT00607906|diabetes
523995|NCT00607906|pharmacokinetics
523996|NCT00607893|Sleep-Disordered Breathing
523997|NCT00607880|vascular access device complications
523998|NCT00607880|unspecified adult solid tumor, protocol specific
523999|NCT00607867|Diabetes Mellitus (type 2)
524000|NCT00607867|Diet
524001|NCT00607867|Glycohemoglobin
524002|NCT00607867|Lipids
524003|NCT00607867|Kidney Function
524004|NCT00607867|Glycemic Index
524005|NCT00607867|Dietary Protein
524006|NCT00607867|Dietary Carbohydrate
524007|NCT00607854|Zevalin
524008|NCT00607854|Reduced intensity conditioning
524009|NCT00607854|Allogenic stem cell transplantation
524010|NCT00607828|adult primary hepatocellular carcinoma
524011|NCT00607828|advanced adult primary liver cancer
524012|NCT00607828|localized unresectable adult primary liver cancer
524013|NCT00607828|recurrent adult primary liver cancer
524014|NCT00607815|PTSD
524015|NCT00607815|OEF/OIF
524016|NCT00607815|Combat
524017|NCT00607815|Treatment
524018|NCT00607815|CPT
524019|NCT00607815|PCT
524020|NCT00607815|Cognitive
524021|NCT00607802|unspecified adult solid tumor, protocol specific
524022|NCT00607802|unspecified childhood solid tumor, protocol specific
524023|NCT00607776|dry, eyes
524024|NCT00607776|Amelioration of dry eye symptoms
524025|NCT00607763|Antifungal
524026|NCT00607763|Echinocandin
524027|NCT00607763|Candidiasis
524028|NCT00607763|Micafungin
524029|NCT00607750|Wet AMD, Comentis, ATG003, mecamylamine
524030|NCT00607724|unspecified adult solid tumor, protocol specific
524031|NCT00607685|Trabeculectomy
524032|NCT00607685|Wound healing
524033|NCT00607685|5 Fluorouracil
524034|NCT00607685|Hyaluronic acid
524035|NCT00607685|post-operative scarring
524036|NCT00607672|Angiotensin Converting Enzyme
524037|NCT00607672|Angiotensin Receptor Blockers
524038|NCT00607672|Cardiopulmonary Bypass
524039|NCT00607672|Fibrinolysis
524040|NCT00607672|Inflammation
524041|NCT00607659|Chlamydia
524042|NCT00607659|Chlamydia trachomatis
524043|NCT00607659|Adolescent Health
524044|NCT00607659|Female Health
524045|NCT00607659|Sexually Transmitted Infections
524046|NCT00607659|Infertility
524047|NCT00607659|Pelvic Inflammatory Disease
524048|NCT00607646|hypoglycemia
524049|NCT00607646|dehydroepiandrosterone
524050|NCT00607633|essential hypertension
524051|NCT00607633|ARB
524052|NCT00607633|left ventricular hypertrophy
524053|NCT00607633|candesartan
524054|NCT00607620|Alcohol Abuse
524055|NCT00607620|Alcohol Dependence
524056|NCT00607620|Alcohol Use Disorder
524057|NCT00607620|Screening
524058|NCT00607620|Brief Intervention
524059|NCT00607620|Motivational Interviewing
524060|NCT00607607|ovarian cancer
524061|NCT00607607|endometrial cancer
524062|NCT00607581|amyloidosis
524063|NCT00607581|lenalidomide
524064|NCT00607581|cyclophosphamide
524065|NCT00607581|dexamethasone
524066|NCT00607568|physical stress
524067|NCT00607568|psychological stress
524068|NCT00607555|Infant, premature
524069|NCT00607555|Infant, very low birth weight
524070|NCT00607555|Apnea
524071|NCT00607555|Feeding methods
524072|NCT00607555|Diaphragm
524073|NCT00607542|spasticity
524074|NCT00607542|cerebral palsy
524075|NCT00607542|baclofen
524076|NCT00607542|pharmacokinetics
524077|NCT00607542|pharmacodynamics
524078|NCT00607542|dosing
524079|NCT00607542|safety
524080|NCT00607542|efficacy
524081|NCT00607529|Multiple Diseases
524082|NCT00607516|fracture
524083|NCT00607516|arthroplasty
524084|NCT00607516|wear
524085|NCT00607516|osteoporosis
524086|NCT00607516|bone
524087|NCT00607490|Vulvodynia
524088|NCT00607490|Vulvar pain
524089|NCT00607490|Dyspareunia
524090|NCT00607490|Sexual dysfunction
524091|NCT00607490|Vestibulitis
524092|NCT00607464|Hypothermia, premature infants, Polyethylene occlusive wrap
524093|NCT00607438|Locally Advanced or Metastatic
524094|NCT00607425|non-small cell lung cancer
524095|NCT00607425|screening
524096|NCT00607425|saliva
524097|NCT00607425|gene expression
524098|NCT00607425|healthy control subject
524099|NCT00607412|PTSD
524100|NCT00607412|substance use disorders
524101|NCT00607412|psychotherapy
524102|NCT00607399|Solid tumor
524103|NCT00607399|Advanced Cancer
524104|NCT00607399|MET Inhibitor
524105|NCT00607399|Receptor Tyrosine Kinase Inhibitor (RTKI)
524106|NCT00607386|Hunter syndrome
524107|NCT00607386|hunters syndrome
524108|NCT00607386|hunter's syndrome
524109|NCT00607386|hunter disease
524110|NCT00607386|hunters disease
524111|NCT00607386|hunter's disease
524112|NCT00607386|MPS II
524113|NCT00607386|MPSII
524114|NCT00607386|MPS2
524115|NCT00607386|MPS 2
524116|NCT00607386|mucopolysaccharides
524117|NCT00607386|lysosomal storage disease
524118|NCT00607386|lysosomal storage disorder
524119|NCT00607386|chronic ear infection
524120|NCT00607386|enlarged adenoids
524121|NCT00607386|mps symptoms
524122|NCT00607386|mps diagnosis
524123|NCT00607386|mps ii therapy
524124|NCT00607386|MPS II treatment
524125|NCT00607386|ert treatment
524126|NCT00607386|elaprase
524127|NCT00607386|idursulfase
524128|NCT00607386|iduronate sulfatase
524129|NCT00607386|iduronate 2 sulfatase
524130|NCT00607386|enzyme replacement therapy
524131|NCT00607386|hunter syndrome treatment
524132|NCT00607386|hunter's syndrome treatment
524133|NCT00607386|hunter syndrome therapy
524134|NCT00607386|hunter's disease treatment
524135|NCT00607386|mps society
524136|NCT00607373|Apolipoprotein B
524137|NCT00607373|Homozygous Familial Hypercholesterolemia
524138|NCT00607373|LDL-receptor gene
524139|NCT00607360|cocaine addiction, treatment, contingency management, employment intervention
524140|NCT00607347|Keywords by National Institute of General Medical Sciences
524141|NCT00607347|Hypertension
524142|NCT00607347|Adverse metabolic effects
524143|NCT00607347|Beta blockers
524144|NCT00607347|Dyslipidemia
524145|NCT00607347|Atenolol
524146|NCT00607347|New onset diabetes
524147|NCT00607347|Pharmacokinetic study
524148|NCT00607347|Oral glucose tolerance test
524149|NCT00607334|Child Language
524150|NCT00607334|Language Therapy
524151|NCT00607334|Vocabulary
524152|NCT00607321|restenosis
524153|NCT00607321|Coronary Disease
524154|NCT00607321|Coronary Arteriosclerosis
524155|NCT00607321|Arterial Occlusive Diseases
524156|NCT00607295|chemotherapy
524157|NCT00607295|hormonal therapy
524158|NCT00607295|urogenital atrophy
524159|NCT00607269|Drug Abuse
524160|NCT00607269|Contingency management
524161|NCT00607269|Voucher-based Reinforcement Therapy
524162|NCT00607269|Homosexuality
524163|NCT00607269|Homeless Persons
524164|NCT00607243|Smallpox vaccine efficacy
524165|NCT00607230|type 1 diabetes mellitus
524166|NCT00607230|immune modulation
524167|NCT00607230|cure
524168|NCT00607230|autoimmunity
524169|NCT00607217|Coronary artery diseases
524170|NCT00607217|Myocardial infarction
524171|NCT00607217|Stable angina
524172|NCT00607217|Influenza
524173|NCT00607217|Vaccine
524174|NCT00607204|Basic Research
524175|NCT00607204|Individual Sleep Duration
524176|NCT00607204|Melatonin
524177|NCT00607204|Electroencephalogram
524178|NCT00607204|Alertness
524179|NCT00607204|Mood
524180|NCT00607191|Idiopathic talipes equinovarus (ITEV)
524181|NCT00607178|Influenza
524182|NCT00607178|Vaccine
524183|NCT00607126|impaired ambulation
524184|NCT00607113|Neuroendocrine Carcinoma
524185|NCT00607113|Avastin
524186|NCT00607113|Bevacizumab
524187|NCT00607113|RAD001
524188|NCT00607113|Everolimus
524189|NCT00607100|High-Resolution Optical Coherence Tomography
524190|NCT00607100|Retinal Nerve Fiber Layer
524191|NCT00607100|Band Atrophy
524192|NCT00607061|Glutathione
524193|NCT00607061|Cysteine
524194|NCT00607061|Synthesis rate
524195|NCT00607061|Newborns
524196|NCT00607061|Low birth weight newborn babies
524197|NCT00607022|dental implant
524198|NCT00607022|early loading
524199|NCT00607022|traditional loading
524200|NCT00607022|anterior
524201|NCT00607022|implant stability
524202|NCT00607022|Subjects presenting with one tooth missing in the anterior
524203|NCT00607022|incisor/canine) or pre-molar regions of the mandible
524204|NCT00607022|or maxilla with existing teeth that were healthy
524205|NCT00607022|or adequately restored shall be screened.
524206|NCT00606996|Drug Abuse
524207|NCT00606996|Drug Dependence
524208|NCT00606996|Alcohol Abuse
524209|NCT00606996|Alcohol Dependence
524210|NCT00606996|Major Depressive Disorder
524211|NCT00606996|Dysthymic Disorder
524212|NCT00606996|Prisoners
524213|NCT00606996|Women
524214|NCT00606970|Chemotherapy
524215|NCT00606970|Breast Cancer
524216|NCT00606970|Colon Cancer
524217|NCT00606970|Lung Cancer
524218|NCT00606957|Obesity
524219|NCT00606957|Metabolism
524220|NCT00606944|enhanced recovery program
524221|NCT00606931|biopsy
524222|NCT00606931|PET
524223|NCT00606931|image-guidance
524224|NCT00606931|breast cancer
524225|NCT00606931|FDG
524226|NCT00606931|PEM
524227|NCT00606918|Strength testing
524228|NCT00606918|Disease progression
524229|NCT00606918|ALS
524230|NCT00606918|Healthy Adults
524231|NCT00606905|Recurrent miscarriage
524232|NCT00606905|Recurrent spontaneous abortion
524233|NCT00606905|Habitual abortion
524234|NCT00606905|IVIG
524235|NCT00606905|Randomized Controlled Trial
524236|NCT00606892|therapeutic effects
524237|NCT00606879|Solid tumor
524238|NCT00606879|Advanced Cancer
524239|NCT00606879|MET inhibitor
524240|NCT00606879|Receptor Tyrosine Kinase Inhibitor (RTKI)
524241|NCT00606866|renal, metastatic, carcinoma
524242|NCT00606853|Substance abuse
524243|NCT00606853|Contingency Management
524244|NCT00606840|overweight
524245|NCT00606840|prevention of weight gain
524246|NCT00606840|young adults
524247|NCT00606840|self-regulation
524248|NCT00606840|daily weighing
524249|NCT00606840|weight gain prevention
524250|NCT00606827|Contrast-induced nephrophaty
524251|NCT00606827|Contrast media
524252|NCT00606827|Angiography
524253|NCT00606827|Coronary percutaneous intervention
524254|NCT00606814|Solid Tumors, IPI-504, docetaxel,cancer
524255|NCT00606801|cognitive enhancers
524256|NCT00606801|Nootropic Agents
524257|NCT00606788|randomized clinical trials
524258|NCT00606788|intensive care
524259|NCT00606788|mechanical ventilation
524260|NCT00606788|ventilator weaning
524261|NCT00606788|clinical protocols
524262|NCT00606788|therapy, computer-assisted
524263|NCT00606788|humans
524264|NCT00606788|various surgical diseases requiring mechanical ventilation over 24 hours
524265|NCT00606775|Adrenergic beta-Antagonists
524266|NCT00606775|Duchenne Muscular Dystrophy
524267|NCT00606775|Cardiomyopathies
524268|NCT00606775|Troponin I
524269|NCT00606762|laparoscopic cholecystectomy
524270|NCT00606762|low pressure pneumoperitoneum
524271|NCT00606736|right ventricular outflow tract arrhythmia
524272|NCT00606736|sex hormone level
524273|NCT00606736|menstrual cycle
524274|NCT00606736|Gonadal Hormones
524275|NCT00606723|relapsed or refractory AML
524276|NCT00606723|in children, adolescents and young adults
524277|NCT00606697|Primary Insomnia Adults
524278|NCT00606684|Chronic Obstructive Pulmonary Disease (COPD)
524279|NCT00606684|COPD
524280|NCT00606684|GW642444
524281|NCT00606671|polycystic ovary syndrome (PCOS)
524282|NCT00606658|Insomnia
524283|NCT00606658|Ayurveda
524284|NCT00606658|Shirodhara
524285|NCT00606658|Quality of Life
524286|NCT00606632|Renal Mass
524287|NCT00606632|Clear Cell Renal Cell Carcinoma
524288|NCT00606632|Cancer of Kidney
524289|NCT00606632|Kidney Cancer
524290|NCT00606632|Neoplasms
524291|NCT00606632|cG250
524292|NCT00606632|antibody, monoclonal
524293|NCT00606632|Iodine 124
524294|NCT00606632|Positron-Emission Tomography
524295|NCT00606632|Kidney
524296|NCT00606632|Renal Cancer
524297|NCT00606632|Renal Neoplasms
524298|NCT00606619|Gastrectomy
524299|NCT00606619|Oral feeding
524300|NCT00606619|Nutrition
524301|NCT00606619|Gastric cancer
524302|NCT00606593|insomnia
524303|NCT00606593|elderly
524304|NCT00606593|sleeplessness
524305|NCT00606580|cutaneous leishmaniasis, topical treatment, Tunisia
524306|NCT00606567|Defibrillators, Implantable
524307|NCT00606554|Respiratory Insufficiency
524308|NCT00606554|Ventilators, Mechanical
524309|NCT00606554|Ventilator Weaning
524310|NCT00606554|Therapy, Computer-Assisted
524311|NCT00606541|Social Anxiety Disorder
524312|NCT00606541|Quetiapine XR
524313|NCT00606541|Prevention
524314|NCT00606541|tolerability
524315|NCT00606528|Antiviral therapy
524316|NCT00606515|Pharmacokinetics
524317|NCT00606515|Liposomal paclitaxel
524445|NCT00605878|HG
524318|NCT00606502|Stage IIIB/IV non-small cell lung cancer
524319|NCT00606502|Non-small cell lung cancer
524320|NCT00606502|NSCLC
524321|NCT00606502|Lung Cancer
524322|NCT00606502|Pralatrexate
524323|NCT00606502|Erlotinib
524324|NCT00606502|Tarceva
524325|NCT00606502|PDX
524326|NCT00606502|Smoking
524327|NCT00606502|Smoker
524328|NCT00605371|Healthy volunteers
524329|NCT00605371|Bioequivalence
524330|NCT00605371|Food Effects
524331|NCT00605358|geriatric depression
524332|NCT00605319|BPH
524333|NCT00605319|BOO
524334|NCT00605306|Asthma
524335|NCT00605306|spirometry
524336|NCT00605306|lung function
524337|NCT00605306|serum cortisol
524338|NCT00605306|serum potassium
524339|NCT00605306|plasma glucose
524340|NCT00605280|randomized sham-controlled multicenter macular edema
524341|NCT00605267|Breast Cancer
524342|NCT00605267|Breast Neoplasms
524343|NCT00605267|Tumors or cancer of the human BREAST
524344|NCT00605267|Tumor or cancer of the human MAMMARY GLAND
524345|NCT00606450|plaque psoriasis
524346|NCT00606437|Umbilical Cord Blood Graft
524347|NCT00606437|Stem Cell Transplantation
524348|NCT00606424|head and neck cancer
524349|NCT00606411|Sleep-Related Eating Disorder
524350|NCT00606411|Topiramate
524351|NCT00606411|Parasomnia
524352|NCT00606398|colorectal metastases
524353|NCT00606385|Recurrence
524354|NCT00606385|Survival
524355|NCT00606385|Immunology
524356|NCT00606385|Laparoscopy
524357|NCT00606372|Off-pump
524358|NCT00606372|OPCAB
524359|NCT00606372|EuroSCORE
524360|NCT00606372|high-risk patients
524361|NCT00606372|Quality of life
524362|NCT00606372|Validity of EuroSCORE
524363|NCT00606359|Influenza
524364|NCT00606359|Orthomyxoviridae Infections
524365|NCT00606359|Renal Transplant
524366|NCT00606346|Crohn's Disease
524367|NCT00606346|Ulcerative Colitis
524368|NCT00606346|Indeterminate Colitis
524369|NCT00606346|Inflammatory Bowel Diseases
524370|NCT00606346|Immunomodulators
524371|NCT00606346|infliximab
524372|NCT00606346|TNF-alpha
524373|NCT00606333|Coronary artery disease
524374|NCT00606333|drug-eluting stents
524375|NCT00606333|sirolimus-eluting coronary stents
524376|NCT00606294|Head
524377|NCT00606294|Neck
524378|NCT00606294|04-070
524379|NCT00606268|Antifungal Prophylaxis
524380|NCT00606268|Hematopoietic Stem Cell Transplant
524381|NCT00606268|HSCT
524382|NCT00606268|Micafungin
524383|NCT00606255|blood pressure
524384|NCT00606255|compliance
524385|NCT00606255|treatment
524386|NCT00606216|MRI
524387|NCT00606164|Alzheimer's Disease
524388|NCT00606164|bryostatin 1
524389|NCT00606164|bryostatin
524390|NCT00606164|safety
524391|NCT00606164|efficacy
524392|NCT00606164|pharmacokinetics
524393|NCT00606164|pharmacodynamics
524394|NCT00606164|protein kinase C
524395|NCT00606151|drug eluding stents
524396|NCT00606151|perioperative bridging
524397|NCT00606151|Stents
524398|NCT00606125|Chemotherapy
524399|NCT00606125|Solid Tumors
524400|NCT00606125|Sorafenib
524401|NCT00606125|Carboplatin
524402|NCT00606125|Paclitaxel
524403|NCT00606099|Adults
524404|NCT00606099|compensated chronic hepatitis B
524405|NCT00606099|telbivudin
524406|NCT00606099|aedevofir dipivoxil
524407|NCT00606086|Hepatitis, HCV, Liver disease, HepC
524408|NCT00606060|Hemophilia,
524409|NCT00606060|Continuous Infusion
524410|NCT00606047|femoroacetabular impingement
524411|NCT00606034|Type 2 diabetes
524412|NCT00606034|Insulin Resistance
524413|NCT00606034|Continuous Subcutaneous Insulin Infusion
524414|NCT00606034|U-500 Insulin
524415|NCT00606034|Omnipod
524416|NCT00606008|Sutent
524417|NCT00605982|MRI
524418|NCT00605969|femoroacetabular, impingement
524419|NCT00605956|head lice
524420|NCT00605956|NatrOVA Creme Rinse - 1% is intended for the treatment of head lice
524421|NCT00605943|Retinal Disease
524422|NCT00605943|Bevacizumab
524423|NCT00605943|Ranibizumab
524424|NCT00605943|Retinal Eye Disease
524425|NCT00605943|Macular Degeneration
524426|NCT00605930|Progressive Supranuclear Palsy
524427|NCT00605930|PSP
524428|NCT00605930|Nutriceutical
524429|NCT00605930|Pyruvate
524430|NCT00605930|Creatine
524431|NCT00605930|Niacinamide
524432|NCT00605904|Chemical Stressor
524433|NCT00605904|Alcoholism
524434|NCT00605904|Yohimbine
524435|NCT00605904|Acamprosate
524436|NCT00605904|Craving
524437|NCT00605878|Atopic Dermatitis (Eczema)
524438|NCT00605878|Bacteria
524439|NCT00605878|Filaggrin
524440|NCT00605878|Skin
524441|NCT00605878|Microbiome
524442|NCT00605878|Atopic Dermatitis
524443|NCT00605878|Eczema
524444|NCT00605878|Health Volunteer
524446|NCT00605852|Allergic rhinitis
524447|NCT00605852|first time in human
524448|NCT00605839|mobile technology
524449|NCT00605839|cell phones
524450|NCT00605839|type 1 diabetes
524451|NCT00605800|Liver resection
524452|NCT00605774|catecholamines
524453|NCT00605774|diabetes
524454|NCT00605774|exercise
524455|NCT00605761|Cystic Fibrosis
524456|NCT00605761|Lung function
524457|NCT00605761|Anti-Inflammatory
524458|NCT00605748|catheter ablation
524459|NCT00605748|atrial fibrillation
524460|NCT00605748|pulmonary vein
524461|NCT00605696|Acute Respiratory Distress Syndrome
524462|NCT00605696|Acute Lung Injury
524463|NCT00605657|ALPS
524464|NCT00605657|Valproic Acid
524465|NCT00605657|Lymphadenopathy
524466|NCT00605657|Splenomegaly
524467|NCT00605657|Histone Deacytelase (HDAC) Inhibitor
524468|NCT00605657|Autoimmune Lymphoproliferative Syndrome
524469|NCT00605631|Pacing
524470|NCT00605605|endothelial function
524471|NCT00605605|atherosclerosis
524472|NCT00605605|smoking
524473|NCT00605605|inflammation
524474|NCT00605605|antioxidant
524475|NCT00605592|Type 1 Diabetes
524476|NCT00605592|Kidney Transplant
524477|NCT00605592|Hypoglycemic Unawareness
524478|NCT00605592|Islet Transplant
524479|NCT00605592|Pancreatic Islet Cell Transplantation
524480|NCT00605592|University of Virginia
524481|NCT00605592|Islet Transplantation
524482|NCT00605592|Kidney Transplantation
524483|NCT00605566|Neuroendocrine
524484|NCT00605566|sorafenib
524485|NCT00605566|cyclophosphamide
524486|NCT00605566|pharmacodynamic
524487|NCT00605540|COPD
524488|NCT00605540|Survival
524489|NCT00605540|Exacerbation
524490|NCT00605540|Disease markers
524491|NCT00605527|Acute Lung Injury
524492|NCT00605527|Acute Respiratory Distress Syndrome
524493|NCT00605514|Hemorrhagic Fever
524494|NCT00605514|Healthy
524495|NCT00605514|Immunity
524496|NCT00605514|T-Cells
524497|NCT00605514|Filovirus
524498|NCT00605514|Healthy Volunteer
524499|NCT00605514|HV
524500|NCT00605488|Pet Scan
524501|NCT00605475|Type 2 Diabetes Mellitus
524502|NCT00605475|Canakinumab
524503|NCT00605475|ACZ885
524504|NCT00605475|IL-1B antagonist
524505|NCT00605475|metformin
524506|NCT00605475|glycemic control
524507|NCT00605475|insulin sensitivity
524508|NCT00605449|GSK376501
524509|NCT00605449|Simvastatin
524510|NCT00605449|Healthy Subjects
524511|NCT00605449|Repeat Dose
524512|NCT00605449|Drug Interaction
524513|NCT00605449|Randomized
524514|NCT00605449|Pharmacokinetics
524515|NCT00605436|overweight
524516|NCT00605436|sedentary
524517|NCT00605436|metabolic syndrome
524518|NCT00605423|AMD
524519|NCT00605423|Almera
524520|NCT00605423|Steroid
524521|NCT00605423|Macular
524522|NCT00605423|ARMD
524523|NCT00605410|Methacholine bronchoprovocation
524524|NCT00605410|Antimuscarinic
524525|NCT00605397|Cu-64 LABELED TRASTUZUMAB
524526|NCT00605254|P-Glycoprotein
524527|NCT00605254|Positron Emission Tomography
524528|NCT00605254|Blood Brain Barrier
524529|NCT00605254|Quantitative Imaging
524530|NCT00605254|Multi-Drug Transporter
524531|NCT00605254|Healthy Volunteer
524532|NCT00605254|HV
524533|NCT00605241|pharmacodynamics,
524534|NCT00605241|pharmacokinetics,
524535|NCT00605241|tolerability,
524536|NCT00605241|Safety,
524537|NCT00605241|single dose,
524538|NCT00605241|placebo,
524539|NCT00605241|Nicotine reward
524540|NCT00605241|GSK598809
524541|NCT00605176|Actinic keratosis
524542|NCT00605176|Skin disease
524543|NCT00605163|Parkinson disease, observational, longitudinal
524544|NCT00605150|Unresectable HCC
524545|NCT00605124|osteoarthritis
524546|NCT00605124|knee
524547|NCT00605124|total knee arthroplasty
524548|NCT00605124|exercise
524549|NCT00605098|HIV
524550|NCT00605098|Pregnancy
524551|NCT00605098|Vertical disease transmission
524552|NCT00605098|Pharmacokinetics
524553|NCT00605098|HIV seronegativity
524554|NCT00605072|cognitive disorders
524555|NCT00605072|angiotensin receptor blockers
524556|NCT00605059|Alzheimer
524557|NCT00605059|SPECT
524558|NCT00605046|Alzheimer
524559|NCT00605046|SPECT
524560|NCT00605007|COPD
524561|NCT00605007|Diabetes
524562|NCT00605007|Respiratory Disorders
524563|NCT00604994|Lymphoedema
524564|NCT00604994|Gynaecology
524565|NCT00604994|Oncology
524566|NCT00604994|Malignant
524567|NCT00604994|Benign
524568|NCT00604994|Incidence
524569|NCT00604955|visceral leishmaniasis
524570|NCT00604955|kala-azar
524571|NCT00604955|Bihar, India
524572|NCT00604942|Oesophagus
524573|NCT00604942|Dysphagia
524574|NCT00604942|Impedance
524575|NCT00604942|High Resolution Manometry
524576|NCT00604942|Peristalsis
524577|NCT00604942|Contractile Pressure
524578|NCT00604942|Coordination of contraction
524579|NCT00604942|Bolus transport
524580|NCT00604929|muscle protein synthesis
524581|NCT00604929|whole-body protein breakdown
524582|NCT00604929|nutrition
524583|NCT00604916|oral hygiene
524584|NCT00604890|Double-Blind
524585|NCT00604890|Placebo
524586|NCT00604890|Topical
524587|NCT00604890|Treatment
524588|NCT00604890|Dose-Ranging
524589|NCT00604890|sBCC
524590|NCT00604877|exercise
524591|NCT00604877|glucose metabolism
524592|NCT00604877|insulin sensitivity
524593|NCT00604877|Vascular Function
524594|NCT00604864|deep endometriosis
524595|NCT00604864|pelvic pain
524596|NCT00604864|infliximab
524597|NCT00604864|anti TNFa
524598|NCT00604838|amniotic fluid leakage
524599|NCT00604838|urinary incontinence
524600|NCT00604838|pregnancy
524601|NCT00604838|home test
524602|NCT00604838|vaginal wetness
524603|NCT00604825|vasomotor symptoms
524604|NCT00604825|hormone therapy
524605|NCT00604825|hot flashes
524606|NCT00604825|menopause
524607|NCT00604786|Basophils
524608|NCT00604786|Mast Cells
524609|NCT00604786|IgE
524610|NCT00604786|IgE receptors
524611|NCT00604786|omalizumab
524612|NCT00604773|delirium
524613|NCT00604773|critical care
524614|NCT00604773|risk factors
524615|NCT00604773|prediction
524616|NCT00604747|motor learning
524617|NCT00604747|hemiplegia
524618|NCT00604747|stroke
524619|NCT00604747|practice
524620|NCT00604747|physiotherapy
524621|NCT00604695|ST-Elevation Myocardial Infarction
524622|NCT00604695|Acute Myocardial Infarction
524623|NCT00604695|No Reflow
524624|NCT00604682|psoriasis
524625|NCT00604669|Diabetes
524626|NCT00604669|Nutrition/Dietics
524627|NCT00604669|clinical outcomes
524628|NCT00604669|total parenteral nutrition
524629|NCT00604643|Abdominal Aneurysm
524630|NCT00604643|Endovascular Aortic Repair (EVAR)
524631|NCT00604643|Endovascular Stent Graft
524632|NCT00604643|Endograft
524633|NCT00604630|stroke
524634|NCT00604630|EPO
524635|NCT00604630|erythropoietin
524636|NCT00604630|ischemia
524637|NCT00604630|hypoxia
524638|NCT00604630|antiapoptosis
524639|NCT00604630|neuroprotection
524640|NCT00604630|rtPA
524641|NCT00604630|thrombolysis
524642|NCT00604630|stroke, middle cerebral artery
524643|NCT00604630|Ischemic stroke in the middle cerebral artery territory
524644|NCT00604617|Mycobacterium tuberculosis
524645|NCT00604617|Tuberculin Test
524646|NCT00604617|South Africa
524647|NCT00604591|Dementia Treatment
524648|NCT00604591|Frontotemporal Dementia
524649|NCT00604591|Dopamine
524650|NCT00604591|Frontotemporal Lobar Degeneration
524651|NCT00604578|Pioglitazone
524652|NCT00604578|Asthma
524653|NCT00604578|Peroxisome Proliferator-Advanced Receptor Gamma
524654|NCT00604578|Airflow Obstruction
524655|NCT00604578|Airway Inflammation
524656|NCT00604565|Hemodialysis
524657|NCT00604552|Abdominal Aneurysm
524658|NCT00604552|Endovascular Aortic Repair (EVAR)
524659|NCT00604552|Endovascular Stent Graft
524660|NCT00604552|Endograft
524661|NCT00604539|Chondroitin sulphate
524662|NCT00604539|Synovitis
524663|NCT00604539|Knee osteoarthritis
524664|NCT00604539|Magnetic Resonance Imaging
524665|NCT00604526|recurrent
524666|NCT00604487|induction
524667|NCT00604487|cervix
524668|NCT00604487|balloon
524669|NCT00604487|Bishop
524670|NCT00604474|Deafness
524671|NCT00604474|Hearing Loss
524672|NCT00604474|Cochlear Implants
524673|NCT00604474|Advanced Bionics
524674|NCT00604474|HiResolution Bionic Ear System
524675|NCT00604461|Carboplatin
524676|NCT00604461|Bevacizumab
524677|NCT00604461|Avastin
524678|NCT00604461|Pemetrexed
524679|NCT00604461|Alimta
524680|NCT00604448|pulses
524681|NCT00604448|beans
524682|NCT00604448|obesity
524683|NCT00604448|overweight
524684|NCT00604448|metabolic syndrome
524685|NCT00604435|breast cancer
524686|NCT00604435|neoadjuvant chemotherapy
524687|NCT00604435|docetaxel
524688|NCT00604435|epirubicin
524689|NCT00604435|recombinant human endostatin (endostar)
524690|NCT00604435|chemotherapy
524691|NCT00604435|endostatin
524692|NCT00604422|Colonic disease
524693|NCT00604422|Ulcerative colitis
524694|NCT00604422|suspected or known colonic disease
524695|NCT00604357|CNI free
524696|NCT00604357|mTOR inhibition
524697|NCT00604357|induction
524698|NCT00604357|IL2 receptor antibodies
524699|NCT00604357|renal function
524700|NCT00604357|liver transplantation
524701|NCT00604331|Pyruvic Acid
524702|NCT00604331|Shock, Cardiogenic
524703|NCT00604331|Catecholamines
524704|NCT00604331|Intra-Aortic Balloon Pumping
524705|NCT00604331|Cardiac Output
524706|NCT00604331|Cardiac Index
524707|NCT00604331|Cardiac Function
524708|NCT00604318|quality of life
524709|NCT00604292|Colonic Diseases
524710|NCT00604279|Schizophrenia
524711|NCT00604279|Paliperidone
524712|NCT00604279|Paliperidone palmitate
524713|NCT00604279|Risperidone
524714|NCT00604279|Risperidone long acting injection
524715|NCT00604279|R092670
524716|NCT00604266|Potentially resectable hilar cholangiocarcinoma as per initial imaging studies.
524717|NCT00604266|Able to undergo PET/CT and MRI with Gadolinium
524718|NCT00604240|NICU
524719|NCT00604240|caregivers
524720|NCT00604240|discharge instructions
524721|NCT00604227|high altitude pulmonary edema
524722|NCT00604227|pulmonary interstitial fluid
524723|NCT00604227|pulmonary function testing
524724|NCT00604227|hypoxia
524725|NCT00604227|pulmonary endothelial function
524726|NCT00604227|high altitude exposure without prior acclimatization
524727|NCT00604214|Sepsis
524728|NCT00604214|Septic shock
524729|NCT00604201|Myelodyplastic Syndrome (MDS)
524730|NCT00604201|Severe Aplastic Anemia (SAA)
524731|NCT00604201|Stem Cell Transplant
524732|NCT00604201|Haploidentical Stem Cells
524733|NCT00604201|Umbilical Cord Blood
524734|NCT00604201|Severe Aplastic Anemia
524735|NCT00604201|Myelodysplastic Syndrome
524736|NCT00604201|MDS
524737|NCT00604175|HIV
524738|NCT00604175|HPV 6
524739|NCT00604175|HPV 11
524740|NCT00604175|HPV 16
524741|NCT00604175|HPV 18
524742|NCT00604175|Vaccine
524743|NCT00604162|Suspected colonic disease
524744|NCT00604162|Known colonic disease
524745|NCT00604136|melanoma
524746|NCT00604136|tumor infiltrating lymphocytes
524747|NCT00604136|interleukin-2
524748|NCT00604123|JNJ-17166864
524749|NCT00604123|allergic rhinitis
524750|NCT00604123|pharmacokinetics
524751|NCT00604123|biomarkers
524752|NCT00604123|rhinitis symptoms
524753|NCT00604123|mountain cedar pollen
524754|NCT00604110|Biventricular pacing
524755|NCT00604110|resynchronisation therapy
524756|NCT00604110|cardiac surgery
524757|NCT00604110|ejection fraction of less 45%
524758|NCT00604097|youth suicide
524759|NCT00604097|family therapy
524760|NCT00604097|primary care
524761|NCT00604097|intervention
524762|NCT00604084|Scabies
524763|NCT00604084|Ivermectin
524764|NCT00604084|Lindane
524765|NCT00604084|Mass Eradication
524766|NCT00604071|HMP, CNV, PHP, HPHP, AMD
524767|NCT00604058|Poliomyelitis
524768|NCT00604058|intradermal
524769|NCT00604045|post traumatic stress disorder
524770|NCT00604045|cognitive bias
524771|NCT00604045|attention
524772|NCT00604045|combat
524773|NCT00604045|neuroimaging
524774|NCT00604032|Safety when exposed to sunlight
524775|NCT00604019|sepsis
524776|NCT00604019|septic shock
524777|NCT00604006|Prevention of heart failure in individuals at high risk
524778|NCT00603993|Rheumatoid arthritis
524779|NCT00603967|Breast Cancer
524780|NCT00603967|Postmenopausal
524781|NCT00603967|Aromatase
524782|NCT00603954|Nonmyeloablative conditioning.
524783|NCT00603954|Hematological malignancies.
524784|NCT00603954|GVHD.
524785|NCT00603941|Anaplastic Thyroid Cancer
524786|NCT00603941|Neoplasm
524787|NCT00603941|Tumor
524788|NCT00603941|Anti-neoplastic Agent
524789|NCT00603941|First-line treatment of advanced Anaplastic thyroid cancer
524790|NCT00603928|attitude
524791|NCT00603928|attitude of health personnel
524792|NCT00603928|ethics
524793|NCT00603928|bioethics
524794|NCT00603928|biomedical ethics
524795|NCT00603928|patient care
524796|NCT00603928|physicians
524797|NCT00603928|placebo effect
524798|NCT00603928|placebos
524799|NCT00603928|questionnaires
524800|NCT00603928|therapy
524801|NCT00603928|general practice
524802|NCT00603915|gemcitabine
524803|NCT00603915|carboplatin
524804|NCT00603915|cisplatin
524805|NCT00603915|erlotinib
524806|NCT00603915|tarceva
524807|NCT00603915|nasopharyngeal
524808|NCT00603902|Obesity
524809|NCT00603902|Weight loss
524810|NCT00603902|lorcaserin
524811|NCT00603902|APD356
524812|NCT00603902|BLOSSOM
524813|NCT00603902|Hypertension
524814|NCT00603902|Dyslipidemia
524815|NCT00603902|Sleep apnea
524816|NCT00603902|glucose tolerance
524817|NCT00603902|cardiovascular disease
524818|NCT00603902|Arena
524819|NCT00603889|Hookworm
524820|NCT00603889|Allergy
524821|NCT00603889|Vaccine
524822|NCT00603889|Skin test
524823|NCT00603863|pancreatic cancer
524824|NCT00603863|hPAM4
524825|NCT00603863|MUC1 antibody
524826|NCT00603863|cancer of the pancreas
524827|NCT00603850|HMP, PHP, AMD, CNV, HPHP
524828|NCT00603837|Hypothermia
524829|NCT00603837|Prevention
524830|NCT00603837|ELGANs(Extremely low gestational age neonates)
524831|NCT00603837|Polyethylene Wrap
524832|NCT00603837|Sodium Acetate Transport Mattress
524833|NCT00603824|heparin-Induced thrombocytopenia
524834|NCT00603824|fondaparinux
524835|NCT00603811|Influenza vaccines
524836|NCT00603811|M2e
524837|NCT00603798|Actinic keratosis
524838|NCT00603798|Dermatologic disease
524839|NCT00603785|Chronic sinusitis
524840|NCT00603785|Xolair
524841|NCT00603785|Nasal Discharge
524842|NCT00603785|Nasal Obstruction
524843|NCT00603785|Facial Pain
524844|NCT00603785|Hyposmia
524845|NCT00603772|Tretinoin
524846|NCT00603772|exposure to UV light
524847|NCT00603772|phototoxicity
524848|NCT00603772|Safety when exposed to sunlight
524849|NCT00603759|COX2 inhibitor
524850|NCT00603759|head and neck cancer
524851|NCT00603759|chemoradiation
524852|NCT00603746|Adolescents
524853|NCT00603746|Adults
524854|NCT00603746|Asthma
524855|NCT00603746|Pharmacokinetics
524856|NCT00603746|Pharmacogenetics
524857|NCT00603746|GW685698X
524858|NCT00603733|Ulcerative Colitis
524859|NCT00603733|5-Aminosalicylate
524860|NCT00603720|PET
524861|NCT00603720|Heart metabolism
524862|NCT00603720|Nitric oxide
524863|NCT00603720|Myocardial remodeling
524864|NCT00603707|capsule
524865|NCT00603707|constipation
524866|NCT00603707|whole gut transit
524867|NCT00603707|colonic transit
524868|NCT00603707|gastric emptying
524869|NCT00603707|small bowel transit
524870|NCT00603694|Hippocampus
524871|NCT00603694|Memory
524872|NCT00603694|Radiation
524873|NCT00603681|constipation
524874|NCT00603681|aged
524875|NCT00603681|polyethylene glycol
524876|NCT00603668|CLL
524877|NCT00603655|Diet
524878|NCT00603655|glycemic load
524879|NCT00603655|overweight
524880|NCT00603655|obesity
524881|NCT00603655|hyperlipidemia
524882|NCT00603642|AMG 531
524883|NCT00603642|Idiopathic Thrombocytopenic Purpura
524884|NCT00603642|ITP
524885|NCT00603642|Thrombocytopenia
524886|NCT00603642|Japan
524887|NCT00603642|Placebo controlled
524888|NCT00603642|Phase 3
524889|NCT00603629|Acute Asthma
524890|NCT00603616|Inflammatory Bowel Disease
524891|NCT00603616|Crohn disease
524892|NCT00603616|Crohn's disease
524893|NCT00603616|Rifaximin
524894|NCT00603603|C-section
524895|NCT00603603|Surg Wound Infect
524896|NCT00603590|Cardiovascular disease
524897|NCT00603590|primary prevention
524898|NCT00603590|Polypill
524899|NCT00603590|efficacy
524900|NCT00603590|safety
524901|NCT00603590|ADR
524902|NCT00603590|Diabetes
524903|NCT00603590|Adherence
524904|NCT00603590|Compliance
524905|NCT00603564|CPAP
524906|NCT00603564|community-acquired pneumonia
524907|NCT00603564|acute respiratory failure
524908|NCT00603564|hypoxemia
524909|NCT00603564|Continuous Positive Airway Pressure
524910|NCT00603551|Osteoporosis
524911|NCT00603551|Cancer
524912|NCT00603551|Chemotherapy
524913|NCT00603551|Bone Density
524914|NCT00603551|DXA Scan
524915|NCT00603551|Heel Scan
524916|NCT00603538|CP-751,871, Non-small cell lung cancer, Phase 1
524917|NCT00603512|Phase II MTX add-on study in Japan
524918|NCT00603499|Diabetes
524919|NCT00603499|Hypertension
524920|NCT00603499|Hypomagnesemia
524921|NCT00603486|Non-invasive Blood Pressure (NIBP)
524922|NCT00603486|GE Dinamap
524923|NCT00603486|SuperSTAT
524924|NCT00603460|Ovarian Cancer
524925|NCT00603460|Peritoneal Cancer
524926|NCT00603434|Methamphetamine
524927|NCT00603421|borderline personality disorder
524928|NCT00603421|suicide
524929|NCT00603421|suicidality
524930|NCT00603421|suicide attempt
524931|NCT00603421|suicidal behavior
524932|NCT00603421|self-injurious behavior
524933|NCT00603421|self-harm behavior
524934|NCT00603421|suicide prevention center
524935|NCT00603421|telephone intervention
524936|NCT00603408|Breast Cancer
524937|NCT00603408|Locally Advanced
524938|NCT00603408|Neoadjuvant
524939|NCT00603382|Adults
524940|NCT00603382|Pharmacokinetics
524941|NCT00603382|Pharmacogenetics
524942|NCT00603382|Asthma
524943|NCT00603382|Adolescents
524944|NCT00603382|GW685698X
524945|NCT00603369|HIV prevention
524946|NCT00603369|HIV seronegativity
524947|NCT00603356|GIST
524948|NCT00603356|Ovarian Cancer
524949|NCT00603356|Mesothelioma
524950|NCT00603356|Renal
524951|NCT00603356|Colorectal Cancer
524952|NCT00603356|Sarcoma
524953|NCT00603356|NSCLC
524954|NCT00603356|Cancer
524955|NCT00603343|antimuscarinics
524956|NCT00603343|children
524957|NCT00603343|overactive bladder
524958|NCT00603343|propiverine
524959|NCT00603343|urinary incontinence
524960|NCT00603343|urotherapy
524961|NCT00603330|Mesenchymal stem cells
524962|NCT00603330|Graft-versus-host disease
524963|NCT00603330|Poor graft function
524964|NCT00603330|Chimerism
524965|NCT00603330|Hematopoietic cell transplantation recipients
524966|NCT00603330|Low donor T-cell chimerism
524967|NCT00603317|Warfarin
524968|NCT00603317|Drug interaction
524969|NCT00603317|Pharmacogenetics
524970|NCT00603317|Amoxicillin
524971|NCT00603317|Clavulanic acid
524972|NCT00603304|Serenoa repens
524973|NCT00603304|Urological symptoms
524974|NCT00603304|hyperplasia
524975|NCT00603304|BPH
524976|NCT00603291|obesity
524977|NCT00603291|weight loss
524978|NCT00603291|lorcaserin
524979|NCT00603291|APD356
524980|NCT00603291|BLOOM-DM
524981|NCT00603291|hypertension
524982|NCT00603291|dyslipidemia
524983|NCT00603291|sleep apnea
524984|NCT00603291|glucose tolerance
524985|NCT00603291|cardiovascular disease
524986|NCT00603291|Arena
524987|NCT00603278|Adolescents
524988|NCT00603278|Adults
524989|NCT00603278|Pharmacokinetics
524990|NCT00603278|Asthma
524991|NCT00603278|GW685698X
524992|NCT00603278|Pharmacogenetics
524993|NCT00603265|Diabetic Peripheral Neuropathy
524994|NCT00603265|Neuropathic Pain
524995|NCT00603252|combined hepatitis A and B vaccine
524996|NCT00603252|risk factors
524997|NCT00603239|diabetes
524998|NCT00603239|exenatide
524999|NCT00603239|metformin
525000|NCT00603239|thiazolidinedione
525001|NCT00603239|Byetta
525002|NCT00603239|Amylin
525003|NCT00603239|Lilly
525004|NCT00603226|Coronary slow flow phenomenon
525005|NCT00603226|Coronary angiography
525006|NCT00603226|Acute coronary syndrome
525007|NCT00603226|Chest pain
525008|NCT00603226|Unstable angina
525009|NCT00603213|Congestive Heart Failure
525010|NCT00603213|Impedance
525011|NCT00603213|Optivol Thoracid Fluid Status monitoring system
525012|NCT00603200|Quality of Life
525013|NCT00603187|Male Contraception
525014|NCT00603187|Acyline
525015|NCT00603174|NAVA
525016|NCT00603174|mechanical ventilation
525017|NCT00603174|infants
525018|NCT00603174|pediatric intensive care
525019|NCT00603174|infant
525020|NCT00603148|Genetic Polymorphism
525021|NCT00603148|Integrin alpha2beta1
525022|NCT00603148|Phenotype
525023|NCT00603122|altitude illness
525024|NCT00603122|hypoxia
525025|NCT00603109|Body weight, fat mass, growth hormone, ghrelin
525026|NCT00603083|Hip Arthroplasty
525027|NCT00603083|Treatment Outcome
525028|NCT00603083|Local Anesthesia
525029|NCT00603070|Medication Errors
525030|NCT00603070|Adverse Drug Events
525031|NCT00603070|Patient Safety
525032|NCT00603070|Electronic Prescribing Systems
525033|NCT00603070|Medication Reconciliation
525034|NCT00603057|Non Small Cell Lung Cancer
525035|NCT00603018|eating disorders
525036|NCT00603018|anorexia nervosa
525037|NCT00603018|anorexia
525038|NCT00603018|PET
525039|NCT00603018|brain imaging
525040|NCT00603018|serotonin
525041|NCT00603018|fMRI
525042|NCT00603018|Prozac
525043|NCT00603018|fluoxetine
525044|NCT00603005|Glaucoma
525045|NCT00603005|Adherence
525046|NCT00602992|3T MRI
525047|NCT00602992|Gamma Knife Radiosurgery
525048|NCT00602979|endotracheal intubation
525049|NCT00602979|intubation
525050|NCT00602979|laryngoscopy
525051|NCT00602979|laryngoscope
525052|NCT00602979|surgery
525053|NCT00602966|Oocyte cryopreservation
525054|NCT00602966|slow freeze
525055|NCT00602966|vitrification
525056|NCT00602940|PCOS
525057|NCT00602940|ovulation
525058|NCT00602940|hormones
525059|NCT00602940|women
525060|NCT00602927|Varenicline, Imaging, fMRI
525061|NCT00602914|MicronJet (microneedles)
525062|NCT00602914|Intradermal
525063|NCT00602862|Angiogenesis inhibitors
525064|NCT00602836|B-cell chronic lymphocytic leukemia
525065|NCT00602836|stage I chronic lymphocytic leukemia
525066|NCT00602836|stage II chronic lymphocytic leukemia
525067|NCT00602836|stage III chronic lymphocytic leukemia
525068|NCT00602836|stage IV chronic lymphocytic leukemia
525069|NCT00602836|contiguous stage II small lymphocytic lymphoma
525070|NCT00602836|noncontiguous stage II small lymphocytic lymphoma
525071|NCT00602836|stage I small lymphocytic lymphoma
525072|NCT00602836|stage III small lymphocytic lymphoma
525073|NCT00602836|stage IV small lymphocytic lymphoma
525074|NCT00602758|AIDS
525075|NCT00602758|Adherence
525076|NCT00602758|Antiretroviral Therapy
525077|NCT00602758|HIV
525078|NCT00602745|pancreatic cancer
525079|NCT00602732|Partner Abuse
525080|NCT00602732|Preventive Intervention
525081|NCT00602732|Postpartum Depression
525082|NCT00602732|Postpartum PTSD
525083|NCT00602706|refractory multiple myeloma
525084|NCT00602706|stage I multiple myeloma
525085|NCT00602706|stage II multiple myeloma
525086|NCT00602706|stage III multiple myeloma
525087|NCT00602693|chronic myelogenous leukemia
525088|NCT00602693|recurrent mantle cell lymphoma
525089|NCT00602693|prolymphocytic leukemia
525090|NCT00602693|advanced chronic lymphocytic leukemia
525091|NCT00602693|small lymphocytic lymphoma
525092|NCT00602693|B-cell lymphoma
525093|NCT00602693|follicular lymphoma
525094|NCT00602693|diffuse large cell lymphoma
525095|NCT00602693|anaplastic large cell lymphoma
525096|NCT00602693|Hodgkin lymphoma
525097|NCT00602693|multiple myeloma
525098|NCT00602680|Alzheimer
525099|NCT00602680|cognitive
525100|NCT00602667|untreated childhood medulloblastoma
525101|NCT00602667|untreated childhood supratentorial primitive neuroectodermal tumor
525102|NCT00602667|untreated childhood pineoblastoma
525103|NCT00602667|childhood atypical teratoid/rhabdoid tumor
525104|NCT00602667|childhood choroid plexus tumor
525105|NCT00602667|childhood high grade glioma
525106|NCT00602667|newly diagnosed childhood ependymoma
525107|NCT00602628|ductal breast carcinoma in situ
525108|NCT00602628|invasive ductal breast carcinoma
525109|NCT00602628|breast cancer in situ
525110|NCT00602628|stage I breast cancer
525111|NCT00602628|stage II breast cancer
525112|NCT00602628|stage IIIA breast cancer
525113|NCT00602602|stage IV pancreatic cancer
525114|NCT00602602|recurrent pancreatic cancer
525115|NCT00602589|open-label
525116|NCT00602589|randomized
525117|NCT00602589|crossover
525118|NCT00602589|bioequivalence
525119|NCT00602576|recurrent melanoma
525120|NCT00602576|stage III melanoma
525121|NCT00602576|stage IV melanoma
525122|NCT00602563|Generalized Anxiety Disorder
525123|NCT00602563|Information Processing
525124|NCT00602550|HIV
525125|NCT00602537|Bipolar Type II Disorder
525126|NCT00602537|Hypomania
525127|NCT00602537|Antidepressant
525128|NCT00602537|Mood Stabilizer
525129|NCT00602537|Venlafaxine
525130|NCT00602537|Lithium Carbonate
525131|NCT00602537|Major Depressive Episode
525132|NCT00602537|Hypomanic Episodes
525133|NCT00602537|Prevention of Depression Relapse
525134|NCT00602511|Melfalan refractory multiple myeloma
525135|NCT00602511|Multiple myeloma
525136|NCT00602511|Relapsing
525137|NCT00602511|Refractory
525138|NCT00602511|Thalidomide
525139|NCT00602511|Bortezomib
525140|NCT00602511|Randomized clinical trial
525141|NCT00602485|adherence, cardiac rehabilitation
525142|NCT00602446|iron overload
525143|NCT00602433|advanced nonsmall cell lung cancer
525144|NCT00602420|pain
525145|NCT00602420|musculoskeletal complications
525146|NCT00602420|unspecified adult solid tumor, protocol specific
525147|NCT00602368|cervical cancer
525148|NCT00602368|cervical intraepithelial neoplasia grade 1
525149|NCT00602368|cervical intraepithelial neoplasia grade 2
525150|NCT00602368|cervical intraepithelial neoplasia grade 3
525151|NCT00602355|Postpartum
525152|NCT00602355|Depression
525153|NCT00602355|Medication Therapy
525154|NCT00602355|Zoloft
525155|NCT00602355|Sertraline
525156|NCT00602355|Interpersonal Psychotherapy
525157|NCT00602329|recurrent colon cancer
525158|NCT00602329|recurrent rectal cancer
525159|NCT00602329|stage III colon cancer
525160|NCT00602329|stage III rectal cancer
525161|NCT00602329|stage IV colon cancer
525162|NCT00602329|stage IV rectal cancer
525163|NCT00602329|adenocarcinoma of the colon
525164|NCT00602329|adenocarcinoma of the rectum
525165|NCT00602316|invasive ductal breast carcinoma
525166|NCT00602316|stage IA breast cancer
525167|NCT00602316|stage IB breast cancer
525168|NCT00602316|stage II breast cancer
525169|NCT00602316|stage IIIA breast cancer
525170|NCT00602290|Major Depression
525171|NCT00602290|Geriatric Major Unipolar Depression
525172|NCT00602290|Executive Cognitive Dysfunction
525173|NCT00602290|Elderly
525174|NCT00602290|Geriatric
525175|NCT00602290|Executive Cognitive Impairment
525176|NCT00602290|Quality of Life
525177|NCT00602290|Disability
525178|NCT00602290|Comorbidity
525179|NCT00602290|Medical Burden
525180|NCT00602290|Safety
525181|NCT00602290|Candidate Genes
525182|NCT00602264|Anorexia nervosa
525183|NCT00602264|Adipokines
525184|NCT00602264|Ghrelin
525185|NCT00602264|Fat mass
525186|NCT00602212|generalized anxiety disorder (GAD)
525187|NCT00602199|stage IV melanoma
525188|NCT00602186|female voiding dysfunction
525189|NCT00602186|Tamsolusin
525190|NCT00602186|prazosin
525191|NCT00602160|Food allergy
525192|NCT00602160|Chinese Herbs
525193|NCT00602160|Investigational new drug
525194|NCT00602160|Herbs
525195|NCT00602160|Therapeutic medicine
525196|NCT00602160|Traditional Chinese medicine
525197|NCT00602147|mucositis
525198|NCT00602147|stage I multiple myeloma
525199|NCT00602147|stage II multiple myeloma
525200|NCT00602147|stage III multiple myeloma
525201|NCT00602147|refractory multiple myeloma
525202|NCT00602108|stage I breast cancer
525203|NCT00602108|stage II breast cancer
525204|NCT00602095|Labor induction
525205|NCT00602095|cervical ripening
525206|NCT00602095|misoprostol
525207|NCT00602095|dinoprostone
525208|NCT00602095|balloon catheter
525209|NCT00602095|prostaglandin
525210|NCT00602082|pancreatic alpha cell adenoma
525211|NCT00602082|pancreatic alpha cell carcinoma
525212|NCT00602082|pancreatic beta islet cell adenoma
525213|NCT00602082|pancreatic beta islet cell carcinoma
525214|NCT00602082|pancreatic delta cell adenoma
525215|NCT00602082|pancreatic delta cell carcinoma
525216|NCT00602082|pancreatic G-cell adenoma
525217|NCT00602082|pancreatic G-cell carcinoma
525218|NCT00602082|gastrinoma
525219|NCT00602082|insulinoma
525220|NCT00602082|glucagonoma
525221|NCT00602082|pancreatic polypeptide tumor
525222|NCT00602082|somatostatinoma
525223|NCT00602082|metastatic gastrointestinal carcinoid tumor
525224|NCT00602082|recurrent gastrointestinal carcinoid tumor
525225|NCT00602082|regional gastrointestinal carcinoid tumor
525226|NCT00602082|islet cell carcinoma
525227|NCT00602082|recurrent islet cell carcinoma
525228|NCT00602069|PTSD
525229|NCT00602069|Intimate Partner Violence
525230|NCT00602069|Cognitive Behavioral Therapy
525231|NCT00602069|Empowerment
525232|NCT00602056|Immunization dropout
525233|NCT00602056|Immunization card
525234|NCT00602056|Center based education
525235|NCT00602030|lung cancer
525236|NCT00602030|NSCLC
525237|NCT00602030|lung neoplasms
525238|NCT00602030|respiratory
525239|NCT00602004|Arteriovenous fistula
525240|NCT00602004|hypertrophy
525241|NCT00602004|losartan
525242|NCT00601991|untreated adult acute myeloid leukemia
525243|NCT00601991|recurrent adult acute myeloid leukemia
525244|NCT00601978|Parkinson's disease
525245|NCT00601978|carbidopa/levodopa/entacapone
525246|NCT00601978|carbidopa/levodopa
525247|NCT00601978|non-motor symptoms
525248|NCT00601978|event-related potential
525249|NCT00601978|ERP
525250|NCT00601978|EEG
525251|NCT00601978|electroencephalogram
525252|NCT00601952|post traumatic stress disorder
525253|NCT00601952|cognitive bias
525254|NCT00601952|attention
525255|NCT00601952|combat
525256|NCT00601939|Abused
525257|NCT00601939|Female
525258|NCT00601939|African American
525259|NCT00601939|Group Empowerment Psychoeducational Intervention
525260|NCT00601939|Enhanced Treatment as Usual
525261|NCT00601926|papillary renal cell carcinoma
525262|NCT00601926|stage III renal cell cancer
525263|NCT00601926|stage IV renal cell cancer
525264|NCT00601913|stage I squamous cell carcinoma of the oropharynx
525265|NCT00601913|stage II squamous cell carcinoma of the oropharynx
525266|NCT00601913|stage I squamous cell carcinoma of the larynx
525267|NCT00601913|stage II squamous cell carcinoma of the larynx
525268|NCT00601913|stage I squamous cell carcinoma of the lip and oral cavity
525269|NCT00601913|stage II squamous cell carcinoma of the lip and oral cavity
525270|NCT00601913|stage I squamous cell carcinoma of the hypopharynx
525271|NCT00601913|stage II squamous cell carcinoma of the hypopharynx
525272|NCT00601913|stage I verrucous carcinoma of the larynx
525273|NCT00601913|stage I verrucous carcinoma of the oral cavity
525274|NCT00601913|stage II verrucous carcinoma of the oral cavity
525275|NCT00601887|Anti-inflammatory
525276|NCT00601848|stage IIIA non-small cell lung cancer
525277|NCT00601848|stage IIIB non-small cell lung cancer
525278|NCT00601848|malignant pleural effusion
525279|NCT00601835|Diphtheria
525280|NCT00601835|Tetanus
525281|NCT00601809|Gastrointestinal
525282|NCT00601809|Adhesive Small Intestine Obstruction
525283|NCT00601809|Oral water soluble contrast
525284|NCT00601809|Non-operative Conservative Management
525285|NCT00601809|Operative rate
525286|NCT00601809|Hospital stay
525287|NCT00601796|adenocarcinoma of the lung
525288|NCT00601796|stage IV non-small cell lung cancer
525289|NCT00601757|Preventive Intervention
525290|NCT00601757|Postpartum Depression
525291|NCT00601757|Women on Public Assistance
525292|NCT00601744|Orbital Exenteration
525293|NCT00601744|Eye Cancer
525294|NCT00601744|Social-Psychological Aspects
525295|NCT00601744|Quality of Life
525296|NCT00601744|Questionnaire
525297|NCT00601744|Facial Appearance
525298|NCT00601744|Survey
525299|NCT00601744|Interview
525300|NCT00601731|Prevention of Meningococcal disease
525301|NCT00601705|adenocarcinoma of the esophagus
525302|NCT00601705|adenocarcinoma of the stomach
525303|NCT00601705|stage III esophageal cancer
525304|NCT00601705|stage IV esophageal cancer
525305|NCT00601705|stage III gastric cancer
525306|NCT00601705|stage IV gastric cancer
525307|NCT00601705|stage II esophageal cancer
525308|NCT00601705|stage II gastric cancer
525309|NCT00601692|squamous cell carcinoma of the esophagus
525310|NCT00601692|adenocarcinoma of the esophagus
525311|NCT00601692|stage II esophageal cancer
525312|NCT00601692|stage III esophageal cancer
525313|NCT00601692|stage IV esophageal cancer
525314|NCT00601679|CHF treatment&prognosis,NT-proBNP testing.
525315|NCT00601653|Binge Eating Disorder
525316|NCT00601653|BED
525317|NCT00601653|Nutrition
525318|NCT00601653|Energy Density
525319|NCT00601653|Cognitive Behavioral Therapy
525320|NCT00601653|CBT
525321|NCT00601640|skin cancer
525322|NCT00601627|adenocarcinoma of the pancreas
525323|NCT00601627|stage II pancreatic cancer
525324|NCT00601627|stage III pancreatic cancer
525325|NCT00601614|unspecified adult solid tumor, protocol specific
525326|NCT00601601|stage 0 cervical cancer
525327|NCT00601601|cervical intraepithelial neoplasia grade 1
525328|NCT00601601|cervical intraepithelial neoplasia grade 2
525329|NCT00601601|cervical intraepithelial neoplasia grade 3
525330|NCT00601562|HIV
525331|NCT00601549|Rectal cancer
525332|NCT00601549|CCRT
525333|NCT00601549|Laparoscopic Surgery
525334|NCT00601549|rectal cancer can be resected by curative and elective surgery
525335|NCT00601549|rectal adenocarcinoma below peritoneal reflection
525336|NCT00601549|American Society of Anesthesiology（ASA） classⅠ to Ⅲ lesions
525337|NCT00601510|stage III gastric cancer
525338|NCT00601510|stage IV gastric cancer
525339|NCT00601484|Painful Bladder Syndrome, monoclonal antibody
525340|NCT00601471|ankle sprain
525341|NCT00601471|ankle injuries
525342|NCT00601471|sprains and strains
525343|NCT00601458|Primary, unilateral, first metatarsal bunionectomy with osteotomy
525344|NCT00601445|Changes in sleep with aging
525345|NCT00601432|open-label
525346|NCT00601432|randomized
525347|NCT00601432|crossover
525348|NCT00601432|food effect
525349|NCT00601406|male breast cancer
525350|NCT00601406|stage IA breast cancer
525351|NCT00601406|stage IB breast cancer
525352|NCT00601406|stage II breast cancer
525353|NCT00601406|stage I prostate cancer
525354|NCT00601406|stage IIB prostate cancer
525355|NCT00601406|stage IIA prostate cancer
525356|NCT00601406|stage III prostate cancer
525357|NCT00601406|stage IA cervical cancer
525358|NCT00601406|stage IB cervical cancer
525359|NCT00601406|stage IIA cervical cancer
525360|NCT00601406|stage IIB cervical cancer
525361|NCT00601406|stage III cervical cancer
525362|NCT00601406|stage IVA cervical cancer
525363|NCT00601406|stage IVB cervical cancer
525364|NCT00601406|stage I vaginal cancer
525365|NCT00601406|stage II vaginal cancer
525366|NCT00601406|stage III vaginal cancer
525367|NCT00601406|stage IVA vaginal cancer
525368|NCT00601406|stage IVB vaginal cancer
525369|NCT00601406|stage IA vulvar cancer
525370|NCT00601406|stage IB vulvar cancer
525371|NCT00601406|stage II vulvar cancer
525372|NCT00601406|stage IIIC vulvar cancer
525373|NCT00601406|stage IIIA vulvar cancer
525374|NCT00601406|stage IIIB vulvar cancer
525375|NCT00601406|stage IVB vulvar cancer
525376|NCT00601406|stage IA ovarian epithelial cancer
525377|NCT00601406|stage IB ovarian epithelial cancer
525378|NCT00601406|stage IC ovarian epithelial cancer
525379|NCT00601406|stage IA ovarian germ cell tumor
525380|NCT00601406|stage IB ovarian germ cell tumor
525381|NCT00601406|stage IC ovarian germ cell tumor
525382|NCT00601406|stage IIA ovarian epithelial cancer
525383|NCT00601406|stage IIB ovarian epithelial cancer
525384|NCT00601406|stage IIC ovarian epithelial cancer
525385|NCT00601406|stage IIA ovarian germ cell tumor
525386|NCT00601406|stage IIB ovarian germ cell tumor
525387|NCT00601406|stage IIC ovarian germ cell tumor
525388|NCT00601406|stage IIIA ovarian epithelial cancer
525389|NCT00601406|stage IIIB ovarian epithelial cancer
525390|NCT00601406|stage IIIC ovarian epithelial cancer
525391|NCT00601406|stage IIIA ovarian germ cell tumor
525392|NCT00601406|stage IIIB ovarian germ cell tumor
525393|NCT00601406|stage IIIC ovarian germ cell tumor
525394|NCT00601406|stage IV ovarian epithelial cancer
525395|NCT00601406|stage IV ovarian germ cell tumor
525396|NCT00601406|stage II endometrial carcinoma
525397|NCT00601406|ovarian stromal cancer
525398|NCT00601406|ovarian sarcoma
525399|NCT00601406|stage IA fallopian tube cancer
525400|NCT00601406|stage IB fallopian tube cancer
525401|NCT00601406|stage IC fallopian tube cancer
525402|NCT00601406|stage IIA fallopian tube cancer
525403|NCT00601406|stage IIB fallopian tube cancer
525404|NCT00601406|stage IIC fallopian tube cancer
525405|NCT00601406|stage IIIA fallopian tube cancer
525406|NCT00601406|stage IIIB fallopian tube cancer
525407|NCT00601406|stage IIIC fallopian tube cancer
525408|NCT00601406|stage IV fallopian tube cancer
525409|NCT00601406|recurrent primary peritoneal cavity cancer
525410|NCT00601406|stage IA primary peritoneal cavity cancer
525411|NCT00601406|stage IB primary peritoneal cavity cancer
525412|NCT00601406|stage IC primary peritoneal cavity cancer
525413|NCT00601406|stage IIA primary peritoneal cavity cancer
525414|NCT00601406|stage IIB primary peritoneal cavity cancer
525415|NCT00601406|stage IIC primary peritoneal cavity cancer
525416|NCT00601406|stage IIIA primary peritoneal cavity cancer
525417|NCT00601406|stage IIIB primary peritoneal cavity cancer
525418|NCT00601406|stage IIIC primary peritoneal cavity cancer
525419|NCT00601406|stage IV primary peritoneal cavity cancer
525420|NCT00601406|stage IA endometrial carcinoma
525421|NCT00601406|stage IB endometrial carcinoma
525422|NCT00601406|stage IIIA endometrial carcinoma
525423|NCT00601406|stage IIIB endometrial carcinoma
525424|NCT00601406|stage IIIC endometrial carcinoma
525425|NCT00601406|stage IVA endometrial carcinoma
525426|NCT00601406|stage IVB endometrial carcinoma
525427|NCT00601406|stage IA uterine sarcoma
525428|NCT00601406|stage IB uterine sarcoma
525429|NCT00601406|stage IC uterine sarcoma
525430|NCT00601406|stage IIA uterine sarcoma
525431|NCT00601406|stage IIB uterine sarcoma
525432|NCT00601406|stage IIIA uterine sarcoma
525433|NCT00601406|stage IIIB uterine sarcoma
525434|NCT00601406|stage IIIC uterine sarcoma
525435|NCT00601406|stage IVA uterine sarcoma
525436|NCT00601406|stage IVB uterine sarcoma
525437|NCT00601354|Binge Eating
525438|NCT00601354|Orlistat
525439|NCT00601354|Alli
525440|NCT00601354|Guided Self-Help
525441|NCT00601341|arthralgia
525442|NCT00601341|joint pain
525443|NCT00601341|knee injuries
525444|NCT00601341|knee joint
525445|NCT00601341|low back pain
525446|NCT00601289|pituitary chromophobe adenoma
525447|NCT00601289|recurrent pituitary tumor
525448|NCT00601289|ACTH-producing pituitary tumor
525449|NCT00601289|growth hormone-producing pituitary tumor
525450|NCT00601289|prolactin-producing pituitary tumor
525451|NCT00601289|pituitary basophilic adenoma
525452|NCT00601289|pituitary eosinophilic adenoma
525453|NCT00601289|prolactin secreting adenoma
525454|NCT00601289|nonfunctioning pituitary tumor
525455|NCT00601276|pedophilia
525456|NCT00601276|antiandrogens
525457|NCT00601276|gonadotropin releasing hormone agonists
525458|NCT00601263|Chinese Herbal Therapy
525459|NCT00601263|Asthma
525460|NCT00601263|Investigational new drug (IND)
525461|NCT00601263|Complementary and Alternative Medicine
525462|NCT00601237|HIV Prevention
525463|NCT00601237|Mobile Phone
525464|NCT00601237|Technology-Based Intervention
525465|NCT00601237|HIV
525466|NCT00601237|HIV Seronegativity
525467|NCT00601224|Social Cognition
525468|NCT00601224|Group Therapy
525469|NCT00601224|Psychosocial Intervention
525470|NCT00601198|Oxaliplatin-induced Neuropathy
525471|NCT00601198|Colon and rectum
525472|NCT00601185|06-009
525473|NCT00601185|Confocal reflectance microscopy
525474|NCT00601185|shave-biopsy
525475|NCT00601172|vomiting
525476|NCT00601172|colorectal cancer
525477|NCT00601172|nausea
525478|NCT00601172|oxaliplatin
525479|NCT00601159|Metastatic Breast Cancer
525480|NCT00601159|triple-negative Breast Cancer
525481|NCT00601159|cisplatin
525482|NCT00601159|chemotherapy
525483|NCT00601146|Hodgkin's disease
525484|NCT00601146|CT scan
525485|NCT00601133|Solid Tumors
525486|NCT00601133|Acute Inpatient Rehabilitation
525487|NCT00601133|Postural Instability
525488|NCT00601133|Balance
525489|NCT00601133|Function
525490|NCT00601133|Walking
525491|NCT00601133|Questionnaire
525492|NCT00601133|Survey
525493|NCT00601120|antiangiogenic therapy
525494|NCT00601120|RF ablation
525495|NCT00601107|psoriasis
525496|NCT00601107|psoriasis vulgaris
525497|NCT00601107|plaque psoriasis
525498|NCT00601107|chronic plaque psoriasis
525499|NCT00601094|stage IIIB non-small cell lung cancer
525500|NCT00601094|stage IV non-small cell lung cancer
525501|NCT00601094|recurrent non-small cell lung cancer
525502|NCT00601081|Very low birth weight infants
525503|NCT00601081|HMF
525504|NCT00601081|immune system function
525505|NCT00601068|osteonecrosis, jaws, bisphosphonate, fosamax, alendronate
525506|NCT00601055|COPD
525507|NCT00601055|Geriatric Depression
525508|NCT00601055|Problem-Solving Therapy
525509|NCT00601055|Treatment Adherence
525510|NCT00601042|smoking reduction
525511|NCT00601042|smoking cessation
525512|NCT00601042|randomized trial
525513|NCT00601042|Swedish snus
525514|NCT00601042|smokeless tobacco
525515|NCT00601029|Exertional Rhabdomyolysis
525516|NCT00601016|Infantile hemangioma
525517|NCT00601016|Hemangioma
525518|NCT00601016|Hemangioma of Infancy
525519|NCT00601016|benign tumors of infancy
525520|NCT00601016|Congenital hemangioma
525521|NCT00601016|Capillary
525522|NCT00600990|post-operative nausea and vomiting
525523|NCT00600990|PONV
525524|NCT00600977|ALL
525525|NCT00600977|Chemotherapy
525526|NCT00600977|Pharmacokinetics of doxorubicin (pegylated or not)
525527|NCT00600977|elderly ALL
525528|NCT00600964|CLL
525529|NCT00600964|obatoclax
525530|NCT00600938|iron overload
525531|NCT00600938|cardiac iron
525532|NCT00600938|haemosiderosis
525533|NCT00600938|myocardial T2*
525534|NCT00600938|left ventricular ejection fraction
525535|NCT00600938|LVEF
525536|NCT00600938|cardiac dysfunction
525537|NCT00600938|thalassaemia
525538|NCT00600938|Diamond Blackfan anemia
525539|NCT00600938|DBA
525540|NCT00600938|sideroblastic anemia
525541|NCT00600938|myelodysplastic syndromes
525542|NCT00600938|MDS (low and INT-1 risk as per the IPSS for MDS)
525543|NCT00600938|liver MRI
525544|NCT00600938|deferasirox
525545|NCT00600938|deferoxamine
525546|NCT00600938|ICL670
525547|NCT00600938|DFO
525548|NCT00600938|cardiovascular magnetic resonance imaging
525549|NCT00600925|Colorectal surgery
525550|NCT00600912|lipid emulsion
525551|NCT00600912|fish oil
525552|NCT00600912|parenteral nutrition
525553|NCT00600912|leucotriene LTB5
525554|NCT00600912|hepatic function
525555|NCT00600899|Postoperative pain treatment
525556|NCT00600886|Acromegaly,
525557|NCT00600886|adult,
525558|NCT00600886|growth hormone,
525559|NCT00600886|insulin-like growth factor I,
525560|NCT00600886|somatostatin analogue
525561|NCT00600873|neuroprotection
525562|NCT00600873|oxidative stress
525563|NCT00600860|MDS (all IPSS subtypes)
525564|NCT00600860|Newly diagnosed
525565|NCT00600847|urticaria
525566|NCT00600847|cold urticaria
525567|NCT00600847|acquired cold urticaria
525568|NCT00600808|SR-hGH, Pharmacokinetics, Pharmacodynamics
525569|NCT00600795|NPH
525570|NCT00600795|TGF-beta
525571|NCT00600782|Tuberculosis vaccine
525572|NCT00600769|MAC
525573|NCT00600769|NTM
525574|NCT00600756|schizophrenia
525575|NCT00600756|SWNK
525576|NCT00600743|Eating
525577|NCT00600743|Food Intake
525578|NCT00600743|Appetite
525579|NCT00600730|fMRi
525580|NCT00600730|hypoglycemia
525581|NCT00600717|Magnetoencephalography(MEG)
525582|NCT00600717|Sensorimotor
525583|NCT00600717|Auditory
525584|NCT00600717|Visual
525585|NCT00600717|Language
525586|NCT00600717|This study focuses on normal MEG data
525587|NCT00600704|Allogenic Blood Use
525588|NCT00600704|Total Blood Loss
525589|NCT00600704|Reinfusion of Washed Shed Blood
525590|NCT00600691|Finasteride
525591|NCT00600691|hematuria
525592|NCT00600691|hematospermia
525593|NCT00600691|prostate biopsy
525594|NCT00600678|food for special medical purposes
525595|NCT00600665|Sickle Cell Anemia
525596|NCT00600665|Sickle Cell Disease
525597|NCT00600652|glucocorticoid-receptor
525598|NCT00600652|flow cytometry
525599|NCT00600652|glucocorticoid-resistant
525600|NCT00600652|prediction
525601|NCT00600639|old patients
525602|NCT00600639|NIV
525603|NCT00600639|Intubation
525604|NCT00600639|COPD
525605|NCT00600613|Radiation Therapy
525606|NCT00600587|Carcinoma, Non-Small-Cell Lung
525607|NCT00600587|Genes, erbB-1
525608|NCT00600587|tyrosine kinase inhibitor
525609|NCT00600587|Neoadjuvant Therapy
525610|NCT00600574|fibromyalgia
525611|NCT00600574|physical therapies
525612|NCT00600574|stretching
525613|NCT00600574|Ai Chi
525614|NCT00600561|meditation
525615|NCT00600561|mindfulness
525616|NCT00600561|HIV
525617|NCT00600561|CD4
525618|NCT00600561|Complementary Therapies
525619|NCT00600548|Cutaneous leishmaniasis
525620|NCT00600548|Miltefosine
525621|NCT00600548|Meglumine antimoniate
525622|NCT00600548|L. braziliensis, L. guyanensis
525623|NCT00600535|Prostate neoplasms
525624|NCT00600535|Abiraterone acetate
525625|NCT00600535|CB7630
525626|NCT00600535|Prostate cancer
525627|NCT00600535|Pharmacokinetics
525628|NCT00600522|intraoperative ultrasonography
525629|NCT00600522|hepatectomy
525630|NCT00600522|colorectal liver metastases
525631|NCT00600522|hepatocellular carcinoma
525632|NCT00600522|contrast enhanced intraoperative ultrasonography.
525633|NCT00600509|Levetiracetam
525634|NCT00600509|Keppra
525635|NCT00600496|ARRY-142886
525636|NCT00600496|AZD6244
525637|NCT00600496|Cancer
525638|NCT00600496|Colon Cancer
525639|NCT00600496|Breast Cancer
525640|NCT00600496|Lung Cancer
525641|NCT00600496|Melanoma
525642|NCT00600496|Kidney Cancer
525643|NCT00600483|obesity
525644|NCT00600483|diabetes
525645|NCT00600470|Behavior Problems
525646|NCT00600470|Behavior Disorders
525647|NCT00600457|healing time
525648|NCT00600457|pain
525649|NCT00600457|infection
525650|NCT00600444|permanent venous access
525651|NCT00600444|chemotherapy
525652|NCT00600444|parenteral nutrition
525653|NCT00600444|Patients with a benign and/or malignant diseases which demand a safe and permanent venous access, e.g. for chemotherapy and/or parenteral nutrition
525654|NCT00600444|benign diseases
525655|NCT00600444|malignant diseases
525656|NCT00600431|nevus count
525657|NCT00600431|children
525658|NCT00600431|chemotherapy
525659|NCT00600418|PTSD
525660|NCT00600418|DYADIC TREATMENT
525661|NCT00600418|WAR AND TERROR
525662|NCT00600418|Posttraumatic symptoms among toddlers
525663|NCT00600405|Nephrolithiasis
525664|NCT00600405|Ureteral Calculi
525665|NCT00600379|stroke chronic gait deficits virtual reality training
525666|NCT00600327|Stroke
525667|NCT00600327|thrombosis
525668|NCT00600327|thromboembolic
525669|NCT00600327|Transient Ischemic Attack
525670|NCT00600327|TIA
525671|NCT00600314|Graft-Versus-Host Disease
525672|NCT00600314|Transplantation, Allogeneic
525673|NCT00600314|Transplantation, Hematopoietic Stem Cell
525674|NCT00600314|Calorimetry, Respiration
525675|NCT00600301|Macula
525676|NCT00600301|Edema
525677|NCT00600275|BGT226
525678|NCT00600275|Solid tumors
525679|NCT00600275|Breast cancer
525680|NCT00600275|Cowden Syndrome
525681|NCT00600275|Phosphatidylinositol 3'-kinase (PI3K) inhibitor
525682|NCT00600275|Advanced solid tumors (including sporadic and Cowden Syndrome) (Phase I part)
525683|NCT00600275|Advanced breast cancer (including sporadic and Cowden Syndrome) (Phase II part)
525684|NCT00600262|severe nonproliferative
525685|NCT00600262|proliferative diabetic retinopathy
525686|NCT00600262|active photocoagulated diabetic retinopathy
525687|NCT00600262|intravitreal bevacizumab
525688|NCT00600249|Breast cancer.
525689|NCT00600249|Triple negative.
525690|NCT00600249|Neoadjuvant chemotherapy.
525691|NCT00600249|Targeted therapy.
525692|NCT00600236|Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
525693|NCT00600236|Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy
525694|NCT00600184|Stroke
525695|NCT00600184|Rehabilitation
525696|NCT00600184|Robotics
525697|NCT00600171|dose ranging
525698|NCT00600171|placebo
525699|NCT00600171|asthma
525700|NCT00600171|safety
525701|NCT00600171|efficacy
525702|NCT00600171|pharmacokinetics
525703|NCT00600158|colectomy
525704|NCT00600145|Human volunteers
525705|NCT00600145|amphetamine dependence
525706|NCT00600119|NKTR, constipation, opioid, induced, bowel, dysfunction, Naloxol, Naloxone, Narcan, PEG naloxol, OIC, OBD, Nektar
525707|NCT00600093|Amantadine
525708|NCT00600067|Diabetes
525709|NCT00600067|Type 2 Diabetes
525710|NCT00600067|Diabetes Mellitus
525711|NCT00600067|Metabolic Diseases
525712|NCT00600067|Glucose Metabolism Disorders
525713|NCT00600067|Glycemic Control
525714|NCT00600054|Diffuse intrinsic pontine glioma
525715|NCT00600054|Common Terminology Criteria
525716|NCT00600054|Epidermal Growth factor receptor
525717|NCT00600054|Human antihuman antibody
525718|NCT00600054|pharmacokinetics
525719|NCT00600054|monoclonal antibody
525720|NCT00600054|Informed Consent Form
525721|NCT00600041|Proton Pump Inhibitors
525722|NCT00600041|pantoprazole
525723|NCT00600041|Cardiac Output
525724|NCT00600041|Echocardiography
525725|NCT00600041|adverse effects
525726|NCT00600028|idiopathic pulmonary fibrosis cough
525727|NCT00600015|Non-Small Cell Lung Cancer
525728|NCT00600015|Advanced
525729|NCT00600015|Sorafenib
525730|NCT00600015|Erlotinib
525731|NCT00600015|Double-blind
525732|NCT00600015|Placebo-controlled
525733|NCT00600002|GM-CSF
525734|NCT00600002|Leukine
525735|NCT00599989|long-term effects secondary to cancer therapy in adults
525736|NCT00599989|skin reactions secondary to radiation therapy
525737|NCT00599989|stage I breast cancer
525738|NCT00599989|stage II breast cancer
525739|NCT00599989|invasive lobular breast carcinoma with predominant in situ component
525740|NCT00599989|invasive lobular breast carcinoma
525741|NCT00599989|comedo ductal breast carcinoma
525742|NCT00599989|ductal breast carcinoma in situ
525743|NCT00599989|invasive ductal breast carcinoma
525744|NCT00599989|medullary ductal breast carcinoma with lymphocytic infiltrate
525745|NCT00599989|mucinous ductal breast carcinoma
525746|NCT00599989|papillary ductal breast carcinoma
525747|NCT00599989|tubular ductal breast carcinoma
525748|NCT00599989|Paget disease of the breast with intraductal carcinoma
525749|NCT00599989|Paget disease of the breast with invasive ductal carcinoma
525750|NCT00599989|breast cancer in situ
525751|NCT00599950|Mitomycin C
525752|NCT00599950|Corneal epithelium
525753|NCT00599950|Photorefractive keratectomy (PRK)
525754|NCT00599950|Confocal microscope
525755|NCT00599937|APL
525756|NCT00599924|advanced solid tumors,
525757|NCT00599924|colorectal cancer,
525758|NCT00599924|sunitinib (SUTENT),
525759|NCT00599924|FOLFOX
525760|NCT00599911|Drug therapy
525761|NCT00599911|Depressive disorder
525762|NCT00599911|Antidepressive agents
525763|NCT00599911|Depressive symptoms
525764|NCT00599911|Affective disorders
525765|NCT00599911|Randomized controlled trial
525766|NCT00599911|Placebo-controlled
525767|NCT00599911|Double-blind
525768|NCT00599911|Active reference
525769|NCT00599911|Multicenter study
525770|NCT00599898|Preterm labor
525771|NCT00599898|Atosiban
525772|NCT00599898|Nifedipine
525773|NCT00599872|Allergy
525774|NCT00599872|Sublingual Immunotherapy
525775|NCT00599872|Allergic Rhinitis
525776|NCT00599859|lactase
525777|NCT00599859|lactose
525778|NCT00599859|microflora
525779|NCT00599846|age-related macular degeneration
525780|NCT00599846|geographic atrophy
525781|NCT00599833|adenocarcinoma of the pancreas
525782|NCT00599833|stage III pancreatic cancer
525783|NCT00599820|Angioid Streaks
525784|NCT00599820|Choroidal Neovascularization
525785|NCT00599820|Bevacizumab
525786|NCT00599794|Sepsis
525787|NCT00599794|Intravascular volume
525788|NCT00599794|Ultrasound
525789|NCT00599794|Noninvasive measurement
525790|NCT00599781|adenosine deaminase
525791|NCT00599781|SCID
525792|NCT00599781|gene therapy
525793|NCT00599781|retroviral vector
525794|NCT00599742|Balance disorder
525795|NCT00599742|Vestibular disorder
525796|NCT00599742|Generalized anxiety disorder
525797|NCT00599742|Separation anxiety disorder
525798|NCT00599742|Children
525799|NCT00599742|Balance training
525800|NCT00599716|dry eye syndrome
525801|NCT00599716|dry eye disease
525802|NCT00599716|Vismed
525803|NCT00599716|dry eye
525804|NCT00599716|sodium hyaluronate
525805|NCT00599716|hyaluronic acid
525806|NCT00599690|Epi-LASIK-LASIK microkeratome
525807|NCT00599690|Corneal thickness
525808|NCT00599690|Confocal microscope
525809|NCT00599677|acupuncture
525810|NCT00599677|meridian
525811|NCT00599677|acupoint
525812|NCT00599664|Urinary Calculi
525813|NCT00599664|Urinary Stones
525814|NCT00599664|Urinary Tract Stones
525815|NCT00599664|Calculi
525816|NCT00599651|Respiratory Distress Syndrome
525817|NCT00599651|Newborn RDS
525818|NCT00599625|Crohn's Disease
525819|NCT00599612|GW856553,
525820|NCT00599612|radiolabel
525821|NCT00599612|ADME,
525822|NCT00599599|Prolonged Exposure Therapy
525823|NCT00599599|Adherence to HIV Medications
525824|NCT00599599|Complementary Therapies
525825|NCT00599586|migraine
525826|NCT00599586|acupuncture
525827|NCT00599586|efficacy
525828|NCT00599586|safety
525829|NCT00599586|meridian
525830|NCT00599586|acupoint
525831|NCT00599573|HIV
525832|NCT00599573|cocaine dependence
525833|NCT00599573|cocaine abuse
525834|NCT00599573|cocaine addiction
525835|NCT00599573|cocaine users
525836|NCT00599573|cocaine-related disorders
525837|NCT00599573|HIV Infection
525838|NCT00599560|Meniere's disease
525839|NCT00599560|stress
525840|NCT00599560|vasopressin
525841|NCT00599560|endolymphatic sac
525842|NCT00599560|V2 receptor
525843|NCT00599560|cyclic AMP
525844|NCT00599560|Plasma vasopressin level and V2R mRNA expression level in the endolymphatic sac both were significantly higher in patients with Meniere's disease.
525845|NCT00599560|In Meniere's disease, there were significant negative co-relationships between vasopressin and V2R.
525846|NCT00599560|The cyclic AMP activity was basically up-regulated in the endolymphatic sac in Meniere's disease..
525847|NCT00599560|The cyclic AMP sensitivity for vasopressin was significantly elevated in the endolymphatic sac in Meniere's disease.
525848|NCT00599547|Hematopoietic Stem Cell Transplantation
525849|NCT00599521|Acne Vulgaris
525850|NCT00599521|Adapalene
525851|NCT00599508|memory
525852|NCT00599508|aging
525853|NCT00599495|Hematopoietic Stem Cell Transplantation
525854|NCT00599495|Multiple Myeloma
525855|NCT00599482|HEMOGLOBIN SC DISEASE
525856|NCT00599482|HEMOGLOBIN C DISEASE
525857|NCT00599482|SICKLE CELL TRAIT
525858|NCT00599482|THALASSEMIA
525859|NCT00599469|Acute Confusional Senile Dementia
525860|NCT00599469|Alzheimer Type Senile Dementia
525861|NCT00599469|SENILE PLAQUES
525862|NCT00599469|NEUROFIBRILLARY TANGLES
525863|NCT00599469|NEUROPIL THREADS
525864|NCT00599456|Hot flashes
525865|NCT00599456|Menopause
525866|NCT00599456|Omega 3 fatty Acids
525867|NCT00599443|Cell-derived subunit influenza vaccine
525868|NCT00599443|Safety
525869|NCT00599443|Reactogenicity
525870|NCT00599430|Probiotic
525871|NCT00599430|Lactobacillus
525872|NCT00599430|NCFM
525873|NCT00599430|Bifidobacterium
525874|NCT00599430|Healthy children
525875|NCT00599404|Pharmacokinetics study
525876|NCT00599391|KIDNEY FAILURE, ACUTE
525877|NCT00599391|KIDNEY FAILURE, CHRONIC
525878|NCT00599391|RENAL INSUFFICIENCY
525879|NCT00599365|adherence
525880|NCT00599365|pharmacist intervention
525881|NCT00599365|persistence
525882|NCT00599365|renal clinic
525883|NCT00599365|pill count
525884|NCT00599352|Hypovitaminosis
525885|NCT00599352|Chronic liver disease
525886|NCT00599339|Rotigotine
525887|NCT00599339|Neupro
525888|NCT00599326|Exjade PCT Study
525889|NCT00599326|PCT Study
525890|NCT00599326|Porphyria Cutanea Tarda
525891|NCT00599287|ICU delirium
525892|NCT00599287|Hypoactive delirium
525893|NCT00599287|Haloperidol
525894|NCT00599287|Methylphenidate
525895|NCT00599287|Rivastigmine
525896|NCT00599287|Hypoactive ICU delirium
525897|NCT00599274|Multiple Sclerosis
525898|NCT00599274|Interferon beta 1a
525899|NCT00599274|Avonex
525900|NCT00599261|Cardiac Pacemaker, Artificial
525901|NCT00599248|osteoarthritis, knee
525902|NCT00599235|Hypertension
525903|NCT00599235|Exercise capacity
525904|NCT00599235|PDE5 inhibitors
525905|NCT00599222|AMD
525906|NCT00599222|macular degeneration
525907|NCT00599222|anti-VEGF
525908|NCT00599222|laser treatment
525909|NCT00599196|Rotigotine
525910|NCT00599196|Neupro®
525911|NCT00599183|Cervical spine herniation
525912|NCT00599183|MRI cervical spine
525913|NCT00599183|Diffusion tensor imaging cervical spine
525914|NCT00599170|This is a standard phase II trial, in which patients with newly diagnosed diffuse large B cell lymphoma will receive R-CHOP with GM-CSF
525915|NCT00599144|Cholecystectomy
525916|NCT00599131|Cancer of Larynx
525917|NCT00599118|Atrial Fibrillation
525918|NCT00599118|Genetics
525919|NCT00599092|pituitary tumor
525920|NCT00599092|recurrence
525921|NCT00599079|MAC
525922|NCT00599066|M-Entropy
525923|NCT00599053|Ureaplasma
525924|NCT00599053|Bronchopulmonary dysplasia
525925|NCT00599053|very low birthweight
525926|NCT00599014|Cardiomyopathy, heart failure, DNA,
525927|NCT00599014|echocardiography, messenger RNA, natural history
525928|NCT00599001|healthy volunteer
525929|NCT00599001|research subjects
525930|NCT00599001|Immunostimulatory sequence (ISS)
525931|NCT00599001|phase 1
525932|NCT00598988|infectious mononucleosis, mono, acupuncture
525933|NCT00598975|Phase 2a: Multiple solid tumor types
525934|NCT00598975|Phase 2b: Second-Line Colorectal Cancer (CRC)
525935|NCT00598962|MAC
525936|NCT00598949|Pituitary
525937|NCT00598949|Adenoma
525938|NCT00598949|Tumor
525939|NCT00598949|Acromegaly
525940|NCT00598949|Prolactinoma
525941|NCT00598949|Cushing's
525942|NCT00598936|Hypoxia
525943|NCT00598936|Cerebral Hypoxia
525944|NCT00598923|tbi
525945|NCT00598923|traumatic brain injury
525946|NCT00598923|epilepsy
525947|NCT00598910|HIV infection
525948|NCT00598897|MAC
525949|NCT00598884|Clinical Protocols
525950|NCT00598884|Behavioral Research
525951|NCT00598884|Prevention
525952|NCT00598871|Thymosin beta 4
525953|NCT00598871|Corneal wound healing
525954|NCT00598871|Vitrectomy
525955|NCT00598871|Diabetes
525956|NCT00598858|prostate cancer
525957|NCT00598858|Prostatectomy
525958|NCT00598845|Endometrial cancer
525959|NCT00598845|Molecular markers
525960|NCT00598845|Lymph node metastasis
525961|NCT00598845|Prospective study
525962|NCT00598845|Prognosis
525963|NCT00598845|Cancer of Endometrium
525964|NCT00598845|Tumor Markers, Biological
525965|NCT00598832|Acne Vulgaris
525966|NCT00598832|Adapalene
525967|NCT00598819|Cerebral Oxygenation
525968|NCT00598819|Oxygen Monitoring
525969|NCT00598806|Noninvasive Bladder Cancer
525970|NCT00598780|Levocetirizine
525971|NCT00598780|Xyzal
525972|NCT00598780|Rhinitis allergic persistent
525973|NCT00598780|Rhinitis nonseasonal
525974|NCT00598767|Aortic valve insufficiency
525975|NCT00598767|Aortic valve stenosis
525976|NCT00598767|3D echocardiogram
525977|NCT00598767|3D computed tomography
525978|NCT00598754|Aortic valve stenosis
525979|NCT00598754|Aortic valve insufficiency
525980|NCT00598754|Two dimensional echocardiography
525981|NCT00598754|Three dimensional echocardiography
525982|NCT00598741|Bone
525983|NCT00598741|Sarcoma
525984|NCT00598741|04-083
525985|NCT00598728|Survivors
525986|NCT00598728|Quality of Life
525987|NCT00598715|In-stent restenosis
525988|NCT00598715|In-DES-restenosis
525989|NCT00598715|paclitaxel
525990|NCT00598715|sirolimus
525991|NCT00598689|LASIK
525992|NCT00598689|Ocular Lubricants
525993|NCT00598689|Corneal Epithelium
525994|NCT00598689|Wound Healing
525995|NCT00598663|Type 1 diabetes
525996|NCT00598650|Lewy Body Disease
525997|NCT00598650|Dementia
525998|NCT00598650|Clinical Trial
525999|NCT00598650|Phase II
526000|NCT00598650|E2020
526001|NCT00598650|donepezil hydrochloride
526002|NCT00598637|drug eluting stent
526003|NCT00598637|left main disease
526004|NCT00598611|urticaria
526005|NCT00598598|Aortic valve insufficiency
526006|NCT00598598|Aortic valve stenosis
526007|NCT00598598|3D echocardiogram
526008|NCT00598572|Deferoxamine
526009|NCT00598572|Safety
526010|NCT00598572|Intracerebral hemorrhage
526011|NCT00598559|Acute pain
526012|NCT00598559|Fever
526013|NCT00598559|IV Acetaminophen
526014|NCT00598559|Analgesic
526015|NCT00598546|Stomach
526016|NCT00598546|Gastric
526017|NCT00598546|Stomach Tumor
526018|NCT00598546|Stomach Cancer
526019|NCT00598507|ZK-EPO
526020|NCT00598507|ZK219477
526021|NCT00598507|EpothiloneZK
526022|NCT00598494|effect of bedrest
526023|NCT00598494|cardiac atrophy
526024|NCT00598481|SCID
526025|NCT00598481|gene therapy
526026|NCT00598481|Adenosine deaminase
526027|NCT00598481|retroviral vector
526028|NCT00598455|angiomyolipomata
526029|NCT00598455|tuberous sclerosis complex
526030|NCT00598442|anemia
526031|NCT00598442|chronic kidney disease
526032|NCT00598442|CKD
526033|NCT00598442|chronic renal failure
526034|NCT00598442|CRF
526035|NCT00598442|erythropoietin
526036|NCT00598442|EPO
526037|NCT00598442|erythropoiesis stimulating agent
526038|NCT00598442|ESA
526039|NCT00598442|Hematide™
526040|NCT00598442|hemoglobin
526041|NCT00598442|Hb
526042|NCT00598442|Hgb
526043|NCT00598442|Omontys
526044|NCT00598442|peginesatide
526045|NCT00598442|red blood cell
526046|NCT00598442|red blood cell production
526047|NCT00598429|NICHD Neonatal Research Network
526048|NCT00598429|Hypoxemic respiratory failure (HRF)
526049|NCT00598429|Persistent pulmonary hypertension of the newborn (PPHN)
526050|NCT00598429|Prostaglandin E1 (PGE1)
526051|NCT00598429|Mechanical ventilation
526052|NCT00598429|Meconium, aspiration
526053|NCT00598416|Hepatitis C
526054|NCT00598416|Substance Abuse
526055|NCT00598416|Psychoeducation
526056|NCT00598416|Psychiatric functioning
526057|NCT00598416|Physical Functioning
526058|NCT00598416|Quality of Life
526059|NCT00598416|NIAAA
526060|NCT00598416|Alcohol
526061|NCT00598403|Cystitis
526062|NCT00598390|Cannabinoid
526063|NCT00598390|CB1 Receptor
526064|NCT00598390|Brain Imaging
526065|NCT00598390|PET Imaging
526066|NCT00598390|[11C]MePPEP
526067|NCT00598390|Healthy Volunteer
526068|NCT00598390|HV
526069|NCT00598377|Autosomal dominant polycystic kidney disease
526070|NCT00598377|Adrenal functions
526071|NCT00598377|Renal volume
526072|NCT00598377|Glomerular filtration rate
526073|NCT00598377|Adrenal Cortex Function Tests
526074|NCT00598364|thyroid
526075|NCT00598364|nodule
526076|NCT00598364|genetic
526077|NCT00598364|mutation
526078|NCT00598364|malignancy
526079|NCT00598351|Meningioma
526080|NCT00598351|Ependymoma
526081|NCT00598351|Schwannoma
526082|NCT00598351|Acoustic Neuroma
526083|NCT00598351|Vestibular Schwannoma
526084|NCT00598351|Neurofibromatosis Type 2
526085|NCT00598351|NF2
526086|NCT00598325|Nicotine
526087|NCT00598325|Vaccine
526088|NCT00598325|Immunogenicity
526089|NCT00598325|Tobacco
526090|NCT00598325|Habits
526091|NCT00598299|corneal epithelium
526092|NCT00598286|CB1 Receptor
526093|NCT00598286|PET
526094|NCT00598286|Cannabinoid
526095|NCT00598286|[18F]FMPEP-d2
526096|NCT00598286|Brain Imaging
526097|NCT00598286|Healthy Volunteer
526098|NCT00598286|HV
526099|NCT00598273|anemia
526100|NCT00598273|chronic kidney disease
526101|NCT00598273|CKD
526102|NCT00598273|chronic renal failure
526103|NCT00598273|CRF
526104|NCT00598273|erythropoietin
526105|NCT00598273|EPO
526106|NCT00598273|erythropoiesis stimulating agent
526107|NCT00598273|ESA
526108|NCT00598273|Hematide™
526109|NCT00598273|hemoglobin
526110|NCT00598273|Hb
526111|NCT00598273|Hgb
526112|NCT00598273|Omontys
526113|NCT00598273|peginesatide
526114|NCT00598273|red blood cell
526115|NCT00598273|red blood cell production
526116|NCT00598260|active management
526117|NCT00598260|induction of labor
526118|NCT00598260|cesarean delivery
526119|NCT00598260|Cesarean
526120|NCT00598247|Colon Cancer Rectal Colorectal Women
526121|NCT00598208|In-vitro fertilization
526122|NCT00598195|Ketamine
526123|NCT00598195|Phamacokinetics
526124|NCT00598195|Cardiopulmonary bypass (CPB)
526125|NCT00598195|ketamine/norketamine pharmacokinetic parameters
526126|NCT00598182|Attention Deficit Disorder with Hyperactivity
526127|NCT00598182|OROS methylphenidate
526128|NCT00598169|AIDS-related diffuse large cell lymphoma
526129|NCT00598169|AIDS-related diffuse mixed cell lymphoma
526130|NCT00598169|AIDS-related diffuse small cleaved cell lymphoma
526131|NCT00598169|AIDS-related immunoblastic large cell lymphoma
526132|NCT00598169|AIDS-related lymphoblastic lymphoma
526133|NCT00598169|AIDS-related peripheral/systemic lymphoma
526134|NCT00598169|AIDS-related primary CNS lymphoma
526135|NCT00598169|AIDS-related small noncleaved cell lymphoma
526136|NCT00598130|Patients undergoing elective open partial nephrectomy surgery
526137|NCT00598130|Excision of a kidney
526138|NCT00598117|Esophageal
526139|NCT00598117|CancerEsophagus
526140|NCT00598104|Asthma, interleukin-13
526141|NCT00598091|Solid Tumors
526142|NCT00598091|Phase I
526143|NCT00598091|Expanded Cohort
526144|NCT00598091|Pancreatic Cancer
526145|NCT00598091|Dasatinib
526146|NCT00598091|Gemcitabine
526147|NCT00598065|lung
526148|NCT00598052|Marijuana dependence withdrawal Escitalopram
526149|NCT00598026|Tele medicine
526150|NCT00598026|ICD follow-up
526151|NCT00598026|Cost / benefit study
526152|NCT00598013|Kidney Transplantation
526153|NCT00598013|Thiazolidinediones
526154|NCT00598013|Insulin Resistance
526155|NCT00598013|Atherosclerosis
526156|NCT00598000|Lung cancer
526157|NCT00598000|Quality of Life
526158|NCT00598000|VATS
526159|NCT00598000|thoracotomy
526160|NCT00598000|05-006
526161|NCT00597987|BRCA1
526162|NCT00597974|carotid artery stenosis
526163|NCT00597974|Neuropsychological tests
526164|NCT00597974|Stroke
526165|NCT00597974|Transient ischemia
526166|NCT00597974|Stenting
526167|NCT00597961|Lung
526168|NCT00597961|skin
526169|NCT00597961|melanoma
526170|NCT00597948|mental retardation
526171|NCT00597948|downs syndrome
526172|NCT00597948|autism
526173|NCT00597948|autism spectrum disorder
526174|NCT00597948|cerebral palsy
526175|NCT00597948|developmental disability
526176|NCT00597948|developmental disabilities
526177|NCT00597948|intellectual disability
526178|NCT00597948|intellectual disabilities
526179|NCT00597948|health promotion
526180|NCT00597948|disease prevention
526181|NCT00597948|physical health
526182|NCT00597948|emotional health
526183|NCT00597948|behavioral health
526184|NCT00597948|mental health
526185|NCT00597948|spiritual health
526186|NCT00597948|prevention
526187|NCT00597935|prolapse
526188|NCT00597935|urinary incontinence
526189|NCT00597935|uterosacral vaginal vault ligament suspension
526190|NCT00597935|sacrospinous ligament fixation
526191|NCT00597935|behavioral therapy
526192|NCT00597935|pelvic muscle training
526193|NCT00597922|Acute Myocardial Infarction
526194|NCT00597922|Heart Attack
526195|NCT00597922|Gender Differences
526196|NCT00597922|Risk Factors
526197|NCT00597922|Quality of Care
526198|NCT00597909|Ammonul®
526199|NCT00597909|sodium phenylacetate and sodium benzoate
526200|NCT00597909|hepatic encephalopathy
526201|NCT00597909|Grade 3 or 4 Hepatic Encephalopathy
526202|NCT00597883|carotid endarterectomy
526203|NCT00597883|Neuropsychological tests
526204|NCT00597883|Stroke
526205|NCT00597883|Transient ischemia
526206|NCT00597870|TAA
526207|NCT00597844|type I thyroplasty
526208|NCT00597844|unilateral vocal fold augmentation
526209|NCT00597831|depression
526210|NCT00597831|electroconvulsive therapy
526211|NCT00597831|Ultrasonography Doppler Transcranial
526212|NCT00597831|intracranial pressure
526213|NCT00597792|Gastroesophageal Reflux Disease (GERD)
526214|NCT00597792|Plicator
526215|NCT00597792|Full-thickness Plication
526216|NCT00597779|intertrochanteric fractures
526217|NCT00597766|CVA
526218|NCT00597766|Hemiplegia
526219|NCT00597766|Hemiplegic shoulder pain
526220|NCT00597766|Subacromial steroid injection
526221|NCT00597753|anemia
526222|NCT00597753|chronic kidney disease
526223|NCT00597753|CKD
526224|NCT00597753|chronic renal failure
526225|NCT00597753|CRF
526226|NCT00597753|dialysis
526227|NCT00597753|erythropoietin
526228|NCT00597753|EPO
526229|NCT00597753|erythropoiesis stimulating agent
526230|NCT00597753|ESA
526231|NCT00597753|Hematide™
526232|NCT00597753|hemodialysis
526233|NCT00597753|hemoglobin
526234|NCT00597753|Hb
526235|NCT00597753|Hgb
526236|NCT00597753|Omontys
526237|NCT00597753|peginesatide
526238|NCT00597753|red blood cell
526239|NCT00597753|red blood cell production
526240|NCT00597727|Peanut Allergy
526241|NCT00597727|Sublingual immunotherapy
526242|NCT00597714|Stem Cell Transplantation, Non-myeloablative
526243|NCT00597701|Alcohol withdrawal
526244|NCT00597701|Delirium tremors
526245|NCT00597675|Peanut allergy
526246|NCT00597636|smokers
526247|NCT00597623|Osteoarthritis
526248|NCT00597623|Hand
526249|NCT00597623|Tumor Necrosis Factor-alpha inhibitors
526250|NCT00597623|Biological Therapy
526251|NCT00597610|Rectum
526252|NCT00597610|Rectal
526253|NCT00597597|Metastatic breast cancer
526254|NCT00597597|ER and PR hormone receptor negative
526255|NCT00597597|HER2/neu negative
526256|NCT00597597|EGFR positive
526257|NCT00597584|anemia
526258|NCT00597584|chronic kidney disease
526259|NCT00597584|CKD
526260|NCT00597584|chronic renal failure
526261|NCT00597584|CRF
526262|NCT00597584|dialysis
526263|NCT00597584|erythropoietin
526264|NCT00597584|EPO
526265|NCT00597584|erythropoiesis stimulating agent
526266|NCT00597584|ESA
526267|NCT00597584|Hematide™
526268|NCT00597584|hemodialysis
526269|NCT00597584|hemoglobin
526270|NCT00597584|Hb
526271|NCT00597584|Hgb
526272|NCT00597584|Omontys
526273|NCT00597584|peginesatide
526274|NCT00597584|red blood cell
526275|NCT00597584|red blood cell production
526276|NCT00596505|proliferative diabetic retinopathy
526277|NCT00596505|bevacizumab (Avastin)
526278|NCT00596505|vitreous hemorrhage
526279|NCT00596505|silicone oil
526280|NCT00596479|CAD
526281|NCT00596479|G-CSF
526282|NCT00596479|Collaterals
526283|NCT00596479|CFI
526284|NCT00596479|perfusion
526285|NCT00596466|open-label
526286|NCT00596466|extension study
526287|NCT00596466|pregabalin
526288|NCT00596466|partial epilepsy
526289|NCT00596453|Prostate Specific Antigen (PSA)
526290|NCT00596453|Elevated Prostate Specific Antigen (PSA)
526291|NCT00596440|smoking
526292|NCT00596440|teachable moment
526293|NCT00596440|cancer
526294|NCT00596427|type two diabetes
526295|NCT00596427|gluconeogenesis
526296|NCT00596427|glucose
526297|NCT00596427|lipid synthesis
526298|NCT00596427|hepatic insulin sensitivity
526299|NCT00596427|colesevelam HCl
526300|NCT00597558|Egg allergy
526301|NCT00597545|Carotid Endarterectomy
526302|NCT00597545|Neuropsychological tests
526303|NCT00597545|Stroke
526304|NCT00597545|Transient ischemia
526305|NCT00597545|Hypoperfusion
526306|NCT00597545|Ischemia
526307|NCT00597532|Breast Cancer
526308|NCT00597532|Soy
526309|NCT00597532|Milk
526310|NCT00597532|Supplementation
526311|NCT00597532|02-062
526312|NCT00597519|Cancer
526313|NCT00597519|Leukemia
526314|NCT00597519|Myelodysplastic Syndrome
526315|NCT00597519|Non-Hodgkin's Lymphoma
526316|NCT00597519|Total Body Irradiation
526317|NCT00597519|Umbilical Cord Blood Grafts
526318|NCT00597519|06-014
526319|NCT00597506|colorectal
526320|NCT00597506|refractory
526321|NCT00597506|adenocarcinoma
526322|NCT00597506|bevacizumab
526323|NCT00597506|everolimus
526324|NCT00597493|Recurrent Glioblastoma Multiforme
526325|NCT00597493|GBM
526326|NCT00597493|Glioblastoma
526327|NCT00597493|Sorafenib
526328|NCT00597493|Temozolomide
526329|NCT00597493|Brain Tumor
526330|NCT00597493|Recurrent GBM
526331|NCT00597493|Temodar
526332|NCT00597493|Gliosarcoma
526333|NCT00597493|Glioma
526334|NCT00597493|Nexavar
526335|NCT00597480|Growth hormone
526336|NCT00597480|Child
526337|NCT00597480|insulin resistance
526338|NCT00597480|metabolic syndrome X
526339|NCT00597480|children born small for gestational age
526340|NCT00597467|myopia
526341|NCT00597467|hyperopia
526342|NCT00597467|extended wear
526343|NCT00597467|ametropia
526344|NCT00597454|Breast
526345|NCT00597441|unrelated
526346|NCT00597441|umbilical cord blood transplantation
526347|NCT00597441|thymus transplantation
526348|NCT00597415|Osteoarthritis
526349|NCT00597415|Knee pain
526350|NCT00597402|Avastin
526351|NCT00597402|Bevacizumab
526352|NCT00597402|Temozolomide
526353|NCT00597402|Temodar
526354|NCT00597402|Irinotecan
526355|NCT00597402|Camptosar
526356|NCT00597402|GBM
526357|NCT00597402|Glioblastoma Multiforme
526358|NCT00597402|Gliosarcoma
526359|NCT00597402|Brain tumor
526360|NCT00597402|Glioma
526361|NCT00597402|New GBM
526362|NCT00597402|Newly diagnosed GBM or gliosarcoma malignant brain tumor
526363|NCT00597389|posttraumatic stress disorder
526364|NCT00597389|propranolol
526365|NCT00597389|inderol
526366|NCT00597389|child
526367|NCT00597389|trauma
526368|NCT00597389|Posttraumatic stress disorders (PTSD)
526369|NCT00597376|memory loss
526370|NCT00597363|vascular access site
526371|NCT00597363|arterial puncture
526372|NCT00597363|femoral pseudoaneurysm
526373|NCT00597350|Fenugreek
526374|NCT00597350|Trigonella foenum-graecum
526375|NCT00597350|Diabetes mellitus
526376|NCT00597350|Blood sugar
526377|NCT00597350|Insulin
526378|NCT00597350|Glucose
526379|NCT00597337|bullying
526380|NCT00597337|victimisation
526381|NCT00597337|aggressive behavior
526382|NCT00597324|Allen's test
526383|NCT00597324|lactate
526384|NCT00597324|safety
526385|NCT00597324|radial intervention
526386|NCT00597324|Patients with coronary artery disease
526387|NCT00597311|rectal cancer
526388|NCT00597311|radiotherapy
526389|NCT00597311|radiochemotherapy
526390|NCT00597298|diaphragmatic paralysis
526391|NCT00597298|cardiac surgery
526392|NCT00597298|respiratory muscle training
526393|NCT00597285|18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
526394|NCT00597285|Magnetic Resonance
526395|NCT00597285|Epilepsy
526396|NCT00597285|HHV-6B
526397|NCT00597285|Healthy Volunteer
526398|NCT00597285|HV
526399|NCT00597272|melanoma
526400|NCT00597272|resected local
526401|NCT00597272|systemic metastasis
526402|NCT00597259|hepatitis B, entecavir, pegylated interferon alfa-2a
526403|NCT00597246|Brain
526404|NCT00597246|CNS
526405|NCT00597246|Central Nervous System
526406|NCT00597207|CPR
526407|NCT00597207|mechanical
526408|NCT00597207|manual
526409|NCT00597207|outcome
526410|NCT00597207|survival
526411|NCT00597207|quality
526412|NCT00597194|inguinal hernia
526413|NCT00597194|laparoscopic repair
526414|NCT00597194|open repair
526415|NCT00597194|randomized
526416|NCT00597181|Inflammatory response
526417|NCT00597168|Schizophrenia
526418|NCT00597168|atypical antipsychotic
526419|NCT00597168|quality of life
526420|NCT00597168|ambulatory setting
526421|NCT00597142|renal stent
526422|NCT00597142|stent
526423|NCT00597142|atherosclerosis
526424|NCT00597142|aortorenal ostium
526425|NCT00597142|renal
526426|NCT00597142|renal artery
526427|NCT00597142|PTRA
526428|NCT00597129|pancreatic cancer
526429|NCT00597129|cancer of the pancreas
526430|NCT00597129|pancreas cancer
526431|NCT00597116|Mesothelioma
526432|NCT00597116|inoperable
526433|NCT00597116|relapsed
526434|NCT00597103|Hemodialysis
526435|NCT00597103|Frequent Hemodialysis
526436|NCT00597103|Sleep Apnea
526437|NCT00597103|Restless Leg Syndrome
526438|NCT00597103|Cognitive Function
526439|NCT00597090|Infections
526440|NCT00597090|lymphoma
526441|NCT00597064|asthma
526442|NCT00597064|asthma control questionnaire
526443|NCT00597064|oral corticosteroid
526444|NCT00597064|air trapping
526445|NCT00597064|AQLQ
526446|NCT00597064|control
526447|NCT00597064|quality of life
526448|NCT00597038|Dasatinib
526449|NCT00597038|Dacarbazine
526450|NCT00597025|Malnutrition
526451|NCT00597025|Hypoalbuminemia
526452|NCT00597025|Dietary Supplements
526453|NCT00597025|Hemodialysis
526454|NCT00597025|Peritoneal Dialysis
526455|NCT00597012|Meniscal Tear
526456|NCT00597012|Osteoarthritis
526457|NCT00597012|Arthroscopic Partial Meniscectomy
526458|NCT00597012|Physical Therapy
526459|NCT00596999|Myelodysplastic Syndrome (MDS)
526460|NCT00596999|Acute myelogenous Leukemia (AML)
526461|NCT00596999|Acute Lymphocytic Leukemia (ALL)
526462|NCT00596999|Sickle Cell Disease (SCD)
526463|NCT00596999|Beta Thalassemia
526464|NCT00596999|Inborn Errors of Metabolism
526465|NCT00596999|Severe Combined Immunodeficiency Disease (SCID)
526466|NCT00596986|Depression
526467|NCT00596986|Duloxetine
526468|NCT00596986|Psychotherapy
526469|NCT00596986|Magnetic Resonance Imaging
526470|NCT00596960|Alcohol Abuse
526471|NCT00596960|Alcohol Dependence
526472|NCT00596960|Carbohydrate Deficient Transferrin
526473|NCT00596960|Drug Dependence
526474|NCT00596960|Hepatitis C
526475|NCT00596960|Motivation
526476|NCT00596947|kidney transplantation
526477|NCT00596947|tacrolimus
526478|NCT00596947|Prograf
526479|NCT00596947|mycophenolate mofetil
526480|NCT00596947|CellCept
526481|NCT00596947|corticosteroid withdrawal
526482|NCT00596947|prednisone withdrawal
526483|NCT00596947|prednisone maintenance
526484|NCT00596947|rabbit antithymocyte globulin
526485|NCT00596947|Thymoglobulin
526486|NCT00596934|Nonalcoholic fatty liver disease
526487|NCT00596934|Insulin resistance
526488|NCT00596934|Obesity
526489|NCT00596934|Leptin therapy
526490|NCT00596934|NASH
526491|NCT00596921|Ultrasonography
526492|NCT00596921|Central Venous Pressure
526493|NCT00596921|Noninvasive monitoring
526494|NCT00596921|Shock
526495|NCT00596921|Resuscitation
526496|NCT00596908|Essential Tremor
526497|NCT00596908|Parkinsonian Tremor
526498|NCT00596908|Parkinson Disease
526499|NCT00596908|Upper Extremity Tremor with duration of less than 2 years
526500|NCT00596895|Isoflavone, PSA, prostate cancer, recurrent, quality of life
526501|NCT00596882|smoking cessation
526502|NCT00596882|nicotine dependence
526503|NCT00596882|message prime
526504|NCT00596882|recruitment
526505|NCT00596856|Early childhood caries - ECC
526506|NCT00596856|Referral behavior
526507|NCT00596856|Oral health risk assessment
526508|NCT00596856|Guideline development and dissemination
526509|NCT00596830|IGF-1R inhibitor
526510|NCT00596830|Non-small-cell lung carcinoma
526511|NCT00596830|CP-751
526512|NCT00596830|871
526513|NCT00596817|Relapse prevention
526514|NCT00596817|Antidepressants
526515|NCT00596817|Placebo-controlled
526516|NCT00596817|Double-blind
526517|NCT00596817|Multicentre study
526518|NCT00596804|NHL
526519|NCT00596804|Non-Hodgkin's lymphoma
526520|NCT00596804|follicular lymphoma
526521|NCT00596804|B-cell lymphoma
526522|NCT00596804|diffuse large cell lymphoma
526523|NCT00596804|small lymphoctytic lymphoma
526524|NCT00596804|Mantle cell lymphoma
526525|NCT00596804|MALT
526526|NCT00596804|marginal zone lymphoma
526527|NCT00596804|High-Grade
526528|NCT00596804|Intermediate-Grade
526529|NCT00596804|Low-Grade
526530|NCT00596804|Mixed
526531|NCT00596778|Physical therapy specialty
526532|NCT00596778|Postoperative period. Abdominal surgery
526533|NCT00596778|Anesthesia recovery period
526534|NCT00596778|Spirometry
526535|NCT00596765|Brain Injury
526536|NCT00596765|Neuropsychology
526537|NCT00596765|Cognitive Behavioral Therapy
526538|NCT00596765|Neuropsychological Rehabilitation
526539|NCT00596752|Alprostadil
526540|NCT00596752|Prostavasin
526541|NCT00596752|PAOD
526542|NCT00596752|Fontaine Stage IV
526543|NCT00596739|Bariatric surgery, weight loss surgery, male infertility, Roux-En-Y, gastric banding
526544|NCT00596726|All patients presenting for high-risk cardiac surgery and who might post-operatively meet the study inclusion criteria are potential study candidates.
526545|NCT00596713|general population
526546|NCT00596700|Capsule endoscopy
526547|NCT00596700|Crohn's disease
526548|NCT00596700|IBD
526549|NCT00596700|Activity score
526550|NCT00596700|Small bowel
526551|NCT00596700|Crohn's disease of the small bowel in any stage
526552|NCT00596700|Recruiting
526553|NCT00596687|diabetes
526554|NCT00596687|post-op complications
526555|NCT00596687|inpatient hyperglycemia
526556|NCT00596674|Women
526557|NCT00596674|Fibromyalgia Syndrome
526558|NCT00596674|Health Behaviors
526559|NCT00596674|Quality of Life
526560|NCT00596661|coronary stent
526561|NCT00596648|Lung Cancer
526562|NCT00596648|Non-Small-Cell Lung Cancer
526563|NCT00596648|NSCLC
526564|NCT00596635|UTI
526565|NCT00596635|elderly
526566|NCT00596635|prevention
526567|NCT00596635|cranberry
526568|NCT00596635|E.Coli
526569|NCT00596622|Major Depressive or Manic Episodes
526570|NCT00596622|Bipolar
526571|NCT00596622|Mania
526572|NCT00596622|Depression
526573|NCT00596622|Lithium
526574|NCT00596622|fMRI
526575|NCT00596622|Pictures
526576|NCT00596622|Brain Scan
526577|NCT00596609|Injections, intrathecal
526578|NCT00596609|Transcranial
526579|NCT00596609|Spinal Fusion
526580|NCT00596609|Evoked Potentials, Motor
526581|NCT00596596|Constipation
526582|NCT00596596|prucalopride
526583|NCT00596570|Atrial fibrillation
526584|NCT00596570|Oral Anticoagulation
526585|NCT00596570|Percutaneous coronary intervention
526586|NCT00596557|Renal function, heart transplant, everolimus
526587|NCT00596544|sexual dysfunction
526588|NCT00596531|Tinnitus
526589|NCT00596531|acamprosate
526590|NCT00596531|clinical trial
526591|NCT00596414|liver
526592|NCT00596414|biopsy
526593|NCT00596388|HMP, AMD, CNV, PHP, HPHP
526594|NCT00596375|Lidocaine
526595|NCT00596375|Infant
526596|NCT00596375|Urinary Catheterization
526597|NCT00596375|Emergency Medicine
526598|NCT00596375|Analgesia
526599|NCT00596362|Melanoma
526600|NCT00596362|Eye
526601|NCT00596362|Avastin
526602|NCT00596349|epithelial Ovarian Cancer
526603|NCT00596349|Quality of Life
526604|NCT00596349|Survivorship
526605|NCT00596323|antenna
526606|NCT00596323|continuous glucose monitoring
526607|NCT00596323|electromagnetic
526608|NCT00596310|Lung cancer
526609|NCT00596310|screening
526610|NCT00596297|Diabetic Retinopathy
526611|NCT00596297|Vitreous Hemorrhage
526612|NCT00596297|Bevacizumab
526613|NCT00596297|pars plana vitrectomy
526614|NCT00596297|preoperative
526615|NCT00596284|Cognitive Behavior Therapy
526616|NCT00596284|Alzheimer's Disease
526617|NCT00596258|Cervical Intraepithelial Neoplasia (CIN)
526618|NCT00596258|High-grade Cervical Intraepithelial Neoplasia
526619|NCT00596258|High-grade Squamous Intraepithelial Lesions (HSIL)
526620|NCT00596258|Human Papilloma Virus (HPV)
526621|NCT00596258|High-Grade Cervical Intraepithelial Lesions (CIN 2/3)
526622|NCT00596245|non-smoking healthy volunteers aged 18 - 35
526623|NCT00596219|HEAD
526624|NCT00596219|NECK
526625|NCT00596219|SQUAMOUS
526626|NCT00596219|CARCINOMA
526627|NCT00596193|Hyperalgesia
526628|NCT00596193|nociceptors
526629|NCT00596193|Neurons
526630|NCT00596180|carbon monoxide poisoning
526631|NCT00596180|brain injury
526632|NCT00596167|Short-daily hemodialysis
526633|NCT00596167|pharmacokinetics
526634|NCT00596167|levofloxacin
526635|NCT00596167|gentamicin
526636|NCT00596167|vancomycin
526637|NCT00596141|oral periodontal gingival intraoral mucosal mucoperiosteal
526638|NCT00596141|Surgery, Oral
526639|NCT00596128|Blood glucose
526640|NCT00596128|Clinical pathways
526641|NCT00596076|Low back pain
526642|NCT00596063|pharmacokinetics
526643|NCT00596063|pharmacodynamics
526644|NCT00596063|recombinant human insulin
526645|NCT00596063|healthy volunteers
526646|NCT00596050|procedural sedation
526647|NCT00596050|fracture reduction
526648|NCT00596050|pediatric emergency medicine
526649|NCT00596050|etomidate
526650|NCT00596050|ketamine
526651|NCT00596050|analgesia
526652|NCT00596037|Growth hormone Deficiency
526653|NCT00596011|prostate cancer
526654|NCT00596011|PIN
526655|NCT00596011|polyphenon E
526656|NCT00596011|EGCG
526657|NCT00595998|AMD, HMP, PHP
526658|NCT00595985|Time to Progression
526659|NCT00595985|Toxicity
526660|NCT00595985|Overall survival
526661|NCT00595985|Response rate
526662|NCT00595985|Quality of live
526663|NCT00595985|Toxicities
526664|NCT00595972|Time to Progression
526665|NCT00595972|Overall survival
526666|NCT00595972|Response rate
526667|NCT00595972|Quality of Live
526668|NCT00595972|Toxicities
526669|NCT00595933|Head and Neck cancer
526670|NCT00595933|Radiation therapy
526671|NCT00595933|Dry mouth remedies
526672|NCT00595933|Dry Mouth
526673|NCT00595933|Xerostomia
526674|NCT00595920|Tovaxin
526675|NCT00595920|Autologous
526676|NCT00595920|T-cell vaccine (TCV)
526677|NCT00595907|tuberculosis
526678|NCT00595907|interferon gamma release assays
526679|NCT00595907|treatment
526680|NCT00595894|rheumatoid arthritis
526681|NCT00595894|African Americans
526682|NCT00595894|osteopenia
526683|NCT00595894|osteoporosis
526684|NCT00595894|bone mineral density
526685|NCT00595881|Bedside emergency ultrasound
526686|NCT00595881|Abscess
526687|NCT00595881|Cellulitis
526688|NCT00595881|Soft tissue infection
526689|NCT00595881|Methicillin resistant staphylococcus aureus (MRSA)
526690|NCT00595868|Nicotine
526691|NCT00595868|Smoking
526692|NCT00595868|Smoking Cessation
526693|NCT00595855|glaucoma
526694|NCT00595855|surgery
526695|NCT00595855|non penetrating procedures
526696|NCT00595855|cataract
526697|NCT00595842|Mineral trioxide aggregate
526698|NCT00595829|Polycythemia Vera
526699|NCT00595829|PV
526700|NCT00595816|low back pain
526701|NCT00595816|physical fitness
526702|NCT00595816|injury
526703|NCT00595816|prevention
526704|NCT00595816|conscripts
526705|NCT00595777|Institutional change
526706|NCT00595777|Improved pain management
526707|NCT00595764|Buprenorphine
526708|NCT00595764|Buprenorphine/naloxone
526709|NCT00595764|Counseling
526710|NCT00595764|Primary care
526711|NCT00595751|ADHD, Attention Deficit Hyperactivity Disorder
526712|NCT00595738|Congestive heart failure
526713|NCT00595738|Cardiac biomarkers
526714|NCT00595738|Hemodynamics
526715|NCT00595738|Tailored therapy
526716|NCT00595725|Cervix
526717|NCT00595725|Endometrium
526718|NCT00595725|Cervical Carcinoma
526719|NCT00595725|Lymphatic Mapping
526720|NCT00595712|Genovarum
526721|NCT00595712|Medial opening-wedge high tibial osteotomy
526722|NCT00595712|allograft
526723|NCT00595686|Hematologic Malignancies Hsp90 Hematologic Malignancy
526724|NCT00595673|Perfusion
526725|NCT00595673|Echocardiograpy
526726|NCT00595673|SPECT
526727|NCT00595673|angiography
526728|NCT00595673|Chest pain
526729|NCT00595660|Palpable Breast Mass
526730|NCT00595660|FNA
526731|NCT00595660|Cytology
526732|NCT00595660|Fine needle aspiration
526733|NCT00595660|Specimen Adequacy
526734|NCT00595634|Hip
526735|NCT00595634|Fracture
526736|NCT00595634|Intertrochanteric
526737|NCT00595634|intramedullary
526738|NCT00595608|aftercare
526739|NCT00595608|nasal septum
526740|NCT00595608|turbinates
526741|NCT00595595|Dental Pulp
526742|NCT00595595|Regenerative Medicine
526743|NCT00595595|Odontoblasts
526744|NCT00595595|Stem Cells
526745|NCT00595595|Growth factor differentiation of stem/progenitor cells
526746|NCT00595595|Odontoblast-specific cell phenotypes
526747|NCT00595569|flexible insulin therapy
526748|NCT00595569|diabetes education
526749|NCT00595569|diabetes
526750|NCT00595569|insulin
526751|NCT00595569|Weekly ambulatory sessions
526752|NCT00595556|Zonisamide
526753|NCT00595556|Pharmacotherapy
526754|NCT00595556|Alcohol dependence
526755|NCT00595556|anticonvulsant
526756|NCT00595530|ketamine
526757|NCT00595530|vasoocclusive pain
526758|NCT00595517|gastrointestinal
526759|NCT00595517|GI
526760|NCT00595517|NSAID
526761|NCT00595517|Japan
526762|NCT00595517|Japanese
526763|NCT00595517|Gastric ulcer
526764|NCT00595517|duodenal ulcer
526765|NCT00595504|schizophrenia
526766|NCT00595504|metabolism
526767|NCT00595504|antipsychotics
526768|NCT00595504|diabetes
526769|NCT00595504|rozerem
526770|NCT00595491|Asthma
526771|NCT00595491|Inflammation
526772|NCT00595491|Allergic
526773|NCT00595491|Airway
526774|NCT00595491|Challenge
526775|NCT00595491|Chemokines
526776|NCT00595439|Sensory Evoked Potentials (SEPs)
526777|NCT00595439|Electromyogram
526778|NCT00595439|Transcranial Magnetic Stimulation (TMS)
526779|NCT00595439|Complex Regional Pain Syndrome
526780|NCT00595439|Focal Hand Dystonia
526781|NCT00595439|Focal Dystonia
526782|NCT00595439|Chronic Regional Pain Syndrome
526783|NCT00595439|CRPS
526784|NCT00595426|Knee Arthroplasty
526785|NCT00595426|Factor Xa
526786|NCT00595426|VTE
526787|NCT00595426|Thrombosis
526788|NCT00595426|Anticoagulants
526789|NCT00595413|Rheumatoid arthritis
526790|NCT00595413|Atacicept
526791|NCT00595413|Adalimumab
526792|NCT00595413|Humira®
526793|NCT00595387|Cognitive Behavioral Therapy
526794|NCT00595361|asthma
526795|NCT00595361|exercise induced asthma
526796|NCT00595361|exercise induced bronchoconstriction
526797|NCT00595361|long acting beta agonist
526798|NCT00595361|salmeterol
526799|NCT00595361|exercise challenge
526800|NCT00595361|bronchoprotection
526801|NCT00595361|beta 2 adrenergic receptor polymorphisms
526802|NCT00595361|pharmacogenetics
526803|NCT00595335|Thyroid-associated ophthalmopathy
526804|NCT00595335|Rituximab
526805|NCT00595335|Proptosis
526806|NCT00595322|Bevacizumab
526807|NCT00595322|Radiation Treatment
526808|NCT00595322|Brain Cancer
526809|NCT00595296|BreastCancer
526810|NCT00595296|Sentinel Lymph Nodes
526811|NCT00595296|Metastasis
526812|NCT00595283|Preschool Onset Major Depressive Disorder
526813|NCT00595283|Preschool Depression
526814|NCT00595283|Emotion Development
526815|NCT00595283|Parent Child Interaction
526816|NCT00595257|PAD, CLI, Critical Limb Ischemia, bone marrow, stem cell, injection, infusion
526817|NCT00595244|Perfusion
526818|NCT00595244|Echocardiograpy
526819|NCT00595244|SPECT
526820|NCT00595244|angiography
526821|NCT00595244|Chest pain
526822|NCT00595231|GAD
526823|NCT00595218|Patient Preferences
526824|NCT00595218|Patient Satisfaction
526825|NCT00595218|Patient-Doctor Relationship
526826|NCT00595205|vaccination
526827|NCT00595205|intussusception
526828|NCT00595205|Rotavirus
526829|NCT00595205|vaccine
526830|NCT00595179|Infrared
526831|NCT00595179|Imaging Techniques
526832|NCT00595179|Kidney Reperfusion
526833|NCT00595179|Pneumoperitoneum
526834|NCT00595179|Nephrectomy
526835|NCT00595166|Women with excessive vaginal tissue that obstruct the examiner's view of the cervix during a vaginal speculum examination
526836|NCT00595140|Acromegaly,
526837|NCT00595140|growth hormone receptor antagonist,
526838|NCT00595140|somatostatin analogue,
526839|NCT00595140|combined medical treatment,
526840|NCT00595140|acute effect,
526841|NCT00595140|endogenous GH
526842|NCT00595127|Fanconi
526843|NCT00595127|Anemia
526844|NCT00595127|Stem Cell
526845|NCT00595127|Transplant
526846|NCT00595114|COPD
526847|NCT00595114|Airway
526848|NCT00595114|Inflammation
526849|NCT00595114|Infection
526850|NCT00595114|Lipid Mediators
526851|NCT00595114|Oxidative Stress
526852|NCT00595088|Bladder Cancer
526853|NCT00595088|Refractory
526854|NCT00595075|sleep
526855|NCT00595075|performance
526856|NCT00595075|night shift
526857|NCT00595075|Ramelteon
526858|NCT00595075|Healthy Individuals
526859|NCT00595062|Breast
526860|NCT00595062|Cancer
526861|NCT00595049|pulmonary
526862|NCT00595049|arterial
526863|NCT00595049|artery
526864|NCT00595049|hypertension
526865|NCT00595049|systemic
526866|NCT00595049|sclerosis
526867|NCT00595049|scleroderma
526868|NCT00595049|remodelling
526869|NCT00595049|bosentan
526870|NCT00595049|tracleer
526871|NCT00595049|intravascular
526872|NCT00595023|Sentinel lymph node
526873|NCT00595023|Metastasis
526874|NCT00595010|Child Maltreatment
526875|NCT00595010|Child Neglect
526876|NCT00595010|Child Physical Abuse
526877|NCT00595010|Evidence-Based Practice
526878|NCT00594997|Lyme disease
526879|NCT00594997|educational intervention for children
526880|NCT00594997|tick borne illness
526881|NCT00594997|prophylactic therapy in children
526882|NCT00594997|Self-efficacy
526883|NCT00594997|tick prevention
526884|NCT00594997|tick avoidance
526885|NCT00594997|health behavior modification
526886|NCT00594971|Health Services Research
526887|NCT00594971|Family practice
526888|NCT00594932|lupus, arthritis, mycophenolate, biomarkers
526889|NCT00594919|acute kidney injury
526890|NCT00594919|ngal
526891|NCT00594919|cardiac surgery
526892|NCT00594906|Fracture Healing
526893|NCT00594906|Teriparatide
526894|NCT00594906|Forteo
526895|NCT00594906|Pelvic Fractures
526896|NCT00594893|Hip
526897|NCT00594893|Arthroplasty
526898|NCT00594893|Minimally Invasive
526899|NCT00594880|HIV
526900|NCT00594880|HIV-1
526901|NCT00594880|Pegasys
526902|NCT00594880|Peg-IFN-Alpha-2A
526903|NCT00594880|Viral Suppression
526904|NCT00594880|ART cessation
526905|NCT00594880|Immune function
526906|NCT00594880|Innate Immunity
526907|NCT00594880|Toxicity
526908|NCT00594880|Immune-based therapy
526909|NCT00594880|Treatment interruption
526910|NCT00594867|Healthy
526911|NCT00594867|Volunteer
526912|NCT00594854|NSAID
526913|NCT00594854|Gastric Ulcer
526914|NCT00594854|High risk
526915|NCT00594854|Arthrotec
526916|NCT00594854|Vimovo
526917|NCT00594841|Acromioclavicular Joint
526918|NCT00594841|Shoulder dislocation
526919|NCT00594841|AC dislocation
526920|NCT00594828|Patient self-testing
526921|NCT00594828|Oral anticoagulation therapy
526922|NCT00594828|Expert Systems
526923|NCT00594828|Point-of-Care Systems
526924|NCT00594828|International Normalized Ratio
526925|NCT00594815|Lymphoma
526926|NCT00594815|Central Nervous System
526927|NCT00594802|ALLERGIC REACTION
526928|NCT00594789|Osteoporosis
526929|NCT00594789|Fractures
526930|NCT00594789|Bone densitometry
526931|NCT00594789|Dual-energy x-ray absorptiometry
526932|NCT00594776|Cone Beam CT
526933|NCT00594776|CBCT
526934|NCT00594776|Bone Tumors
526935|NCT00594776|Autographs
526936|NCT00594776|Allographs
526937|NCT00594763|Turner syndrome
526938|NCT00594763|Thromboembolic disease
526939|NCT00594737|PET
526940|NCT00594737|frontotemporal dementia
526941|NCT00594737|memantine
526942|NCT00594737|Pick's disease
526943|NCT00594724|Tongue
526944|NCT00594724|Carcinoma
526945|NCT00594724|Cancer
526946|NCT00594724|02-093
526947|NCT00594711|Psychotherapy
526948|NCT00594711|depression
526949|NCT00594698|Perfusion
526950|NCT00594698|Echocardiography
526951|NCT00594698|Cardiac angiography
526952|NCT00594698|SPECT
526953|NCT00594685|Heparin
526954|NCT00594685|Thromboembolism
526955|NCT00594685|Thrombosis
526956|NCT00594672|Age-Related Macular Degeneration (AMD)
526957|NCT00594672|Cataracts
526958|NCT00594672|Age Related Macular Degeneration
526959|NCT00594672|AMD
526960|NCT00594672|Cataract
526961|NCT00594659|Marijuana
526962|NCT00594659|Treatment
526963|NCT00594659|Behavioral
526964|NCT00594659|Computer
526965|NCT00594659|Internet
526966|NCT00594646|HIV Prevention
526967|NCT00594646|Non-occupational post-exposure prophylaxis
526968|NCT00594646|HIV seronegativity
526969|NCT00594633|Cognitive dysfunction
526970|NCT00594607|clotting
526971|NCT00594607|hemodialysis
526972|NCT00594607|anticoagulation
526973|NCT00594607|bleeding risk
526974|NCT00594594|spinal cord injury
526975|NCT00594594|urinary tract infection
526976|NCT00594594|probiotics
526977|NCT00594594|Lactobacilli
526978|NCT00594581|cicatrix, scarring, TGF-beta3, avotermin, Juvista
526979|NCT00594555|Blood disease, bone marrow
526980|NCT00594555|AML
526981|NCT00594555|CML,Blast Crisis
526982|NCT00594542|lidocaine
526983|NCT00594542|local anesthesia
526984|NCT00594542|Mohs micrographic surgery
526985|NCT00594529|Neoadjuvant chemotherapy
526986|NCT00594529|Metastatic liver lesions from colorectal cancers
526987|NCT00594516|Low Back Pain
526988|NCT00594516|Dose Equivalence
526989|NCT00594516|Tapentadol (CG5503)
526990|NCT00594516|Tapentadol-IR
526991|NCT00594516|Tapentadol-ER
526992|NCT00594503|traumatic brain injury
526993|NCT00594490|Breast, reconstruction, silicone
526994|NCT00594477|IMRT
526995|NCT00594477|breast cancer with regional nodal metastasis
526996|NCT00594464|Rotigotine
526997|NCT00594464|NEUPRO®
526998|NCT00594464|Parkinson's Disease (PD)
526999|NCT00594464|perioperative use
527000|NCT00594464|anaesthesia,
527001|NCT00594451|rheumatoid arthritis
527002|NCT00594451|cigarette smoking
527003|NCT00594451|gene-environmental interactions
527004|NCT00594451|autoimmunity
527005|NCT00594451|disease severity
527006|NCT00594438|Synthes Reamer-Irrigator-Aspirator (RIA)
527007|NCT00594438|Zimmer Sentinal Reamer
527008|NCT00594438|Transesophageal Echocardiogram (TEE)
527009|NCT00594412|1H-Magnetic Resonance Spectroscopy
527010|NCT00594412|Hepatic Steatosis
527011|NCT00594412|Liver Fat
527012|NCT00594412|Liver Biopsy
527013|NCT00594412|Liver
527014|NCT00594412|Hepatitis
527015|NCT00594412|Fatty Liver
527016|NCT00594399|Aging
527017|NCT00594399|Exercise
527018|NCT00594399|Impaired Glucose Tolerance
527019|NCT00594399|Obesity
527020|NCT00594399|Functional Status
527021|NCT00594399|Disability
527022|NCT00594399|Health Services Research
527023|NCT00594399|Randomized Controlled Trial
527024|NCT00594399|Diabetes
527025|NCT00594399|Adaptive Randomization Design
527026|NCT00594386|Rotigotine
527027|NCT00594386|Neupro
527028|NCT00594373|Microbicide
527029|NCT00594373|HIV Seronegativity
527030|NCT00594360|Exercise Prescription
527031|NCT00594360|Self-efficacy
527032|NCT00594360|Decisional Balance
527033|NCT00594360|Readiness to Change
527034|NCT00594360|Physical Activity
527035|NCT00594347|Streptococcus pneumoniae
527036|NCT00594334|osteopenia
527037|NCT00594334|periodontitis
527038|NCT00594321|spinal fractures
527039|NCT00594269|Antidepressants
527040|NCT00594269|Antipsychotics
527041|NCT00594269|Dementia
527042|NCT00594269|Discontinuation study
527043|NCT00594269|Behavioural- and Psychological Symptoms in Dementia
527044|NCT00594256|Schizophrenia
527045|NCT00594256|Sleep Architecture
527046|NCT00594256|Sodium Oxybate
527047|NCT00594256|Insomnia
527048|NCT00594256|Cognition
527049|NCT00594230|Myelodysplastic Syndromes (MDS)
527050|NCT00594230|Refractory
527051|NCT00594230|LBH589
527052|NCT00594217|PCOS
527053|NCT00594191|Statins
527054|NCT00594191|HMG-CoA reductase inhibitors
527055|NCT00594191|Cirrhosis
527056|NCT00594191|Portal hypertension
527057|NCT00594191|Variceal bleeding
527058|NCT00594178|spinal cord injury
527059|NCT00594165|Rotigotine
527060|NCT00594152|Diabetic autonomic neuropathy
527061|NCT00594139|non-neurogenic over active bladder
527062|NCT00594139|urge predominant incontinence
527063|NCT00594126|Myeloma
527064|NCT00594126|Multiple Myeloma
527065|NCT00594126|Relapsed Multiple Myeloma
527066|NCT00594126|Refractory Multiple Myeloma
527067|NCT00594126|Relapsed or Refractory Multiple Myeloma
527068|NCT00594100|carotid artery stenosis
527069|NCT00594100|embolic protection device
527070|NCT00594100|GORE Neuro Protection System
527071|NCT00594100|GORE Flow Reversal System
527072|NCT00594100|reverse flow
527073|NCT00594100|proximal occlusion device
527074|NCT00594100|GNPS
527075|NCT00594100|Parodi
527076|NCT00594100|EMPiRE
527077|NCT00594100|distal embolization
527078|NCT00594100|minimizing risks of CAS
527079|NCT00594100|PAES
527080|NCT00594048|high blood pressure
527081|NCT00594035|Spinal procedure
527082|NCT00594035|Dura incision
527083|NCT00594022|Electric Stimulation
527084|NCT00594022|Latency to Persistent Sleep (LPS)
527085|NCT00594022|Transient Insomnia
527086|NCT00594022|Insomnia
527087|NCT00593970|influenza
527088|NCT00593970|vaccine
527089|NCT00593970|pregnancy
527090|NCT00593957|Rett Syndrome
527091|NCT00593957|Dextromethorphan
527092|NCT00593944|CLL
527093|NCT00593944|Chronic Lymphocytic Leukemia
527094|NCT00593944|B cell
527095|NCT00593944|leukemia
527096|NCT00593944|lymphocyte
527097|NCT00593944|antibody
527098|NCT00593944|monoclonal
527099|NCT00593944|cancer
527100|NCT00593944|blood
527101|NCT00593931|Brain functional MRI
527102|NCT00593918|RSV, asthma, innate immunity, gene, cytokines
527103|NCT00593905|Pulmonary Arterial Hypertension
527104|NCT00593905|Pulmonary Hypertension
527105|NCT00593905|Pharmacogenomics
527106|NCT00593905|DNA Testing
527107|NCT00593905|sitaxsentan
527108|NCT00593905|bosentan
527109|NCT00593905|ambrisentan
527110|NCT00593905|elevated pulmonary artery pressures
527111|NCT00593905|Letairis
527112|NCT00593905|Tracleer
527113|NCT00593905|Thelin
527114|NCT00593905|Primary Pulmonary Hypertension
527115|NCT00593905|Pulmonary Artery
527116|NCT00593892|Cytokine Levels
527117|NCT00593892|Traumatic Injury
527118|NCT00593892|Multisystem Organ Failure
527119|NCT00593879|MDD
527120|NCT00593879|Depression
527121|NCT00593879|Mecamylamine
527122|NCT00593879|Add-on Therapy
527123|NCT00593879|Major Depressive Disorder
527124|NCT00593866|Patients who have confirmed cancer arising from the pancreas
527125|NCT00593853|LHRH-agonist related fatigue
527126|NCT00593801|extremely low birth weight infants
527127|NCT00593801|transfusion need
527128|NCT00593801|erythropoietin
527129|NCT00593801|trace elements
527130|NCT00593801|antioxidant enzymes
527131|NCT00593801|reduction of the transfusion need by EPO treatment
527132|NCT00593801|trace elements and antioxidant enzymes in blood
527133|NCT00593788|GIN test
527134|NCT00593788|gap detection
527135|NCT00593788|temporal resolution
527136|NCT00593788|auditory perception
527137|NCT00593788|psychoacoustics
527138|NCT00593775|implantation rate
527139|NCT00593762|Peripheral arterial occlusive disease
527140|NCT00593762|Aspirin
527141|NCT00593762|Clopidogrel
527142|NCT00593762|Resistance
527143|NCT00593762|Catheter interventional procedure
527144|NCT00593762|ASA and clopidogrel resistance
527145|NCT00593749|obesity prevention
527146|NCT00593749|corner stores
527147|NCT00593749|schools
527148|NCT00593736|Delayed sleep phase syndrome; drug therapy
527149|NCT00593723|IMRT
527150|NCT00593710|Randomized
527151|NCT00593710|double-blind superiority trial
527152|NCT00593697|breast cancer
527153|NCT00593697|adjuvant therapy
527154|NCT00593697|trastuzumab
527155|NCT00593697|chemotherapy
527156|NCT00593684|neonate
527157|NCT00593684|central lines
527158|NCT00593684|very low birth weight
527159|NCT00593684|silver alginate
527160|NCT00593671|aneuploidies in 7 chromosomes increased with advanced maternal age
527161|NCT00593658|hypoxemia
527162|NCT00593658|liver transplantation evaluation
527163|NCT00593658|cirrhosis
527164|NCT00593645|Conditioning regimens
527165|NCT00593645|Stem Cell Transplantation
527166|NCT00593645|Hematopoietic Stem Cell Transplantation
527167|NCT00593645|Allogeneic Stem Cell Transplantation
527168|NCT00593645|Nonmyeloablative conditioning
527169|NCT00593645|Clofarabine
527170|NCT00593645|Cytarabine
527171|NCT00593645|Anti-thymocyte globulin
527172|NCT00593632|low HDL
527173|NCT00593619|Intravenous Iron
527174|NCT00593619|Safety
527175|NCT00593619|Perioperative
527176|NCT00593619|Iron deficiency
527177|NCT00593619|Non hemodialysis population
527178|NCT00593619|Perioperative blood conservation
527179|NCT00593606|Rotigotine
527180|NCT00593606|NEUPRO
527181|NCT00593606|Switching trial from ropinirole to rotigotine,
527182|NCT00593606|safety and tolerability
527183|NCT00593606|Parkinson disease
527184|NCT00593593|benign prostate hyperplasia
527185|NCT00593593|Dutasteride
527186|NCT00593593|pharmacovigilance
527187|NCT00593580|Ovarian cancer
527188|NCT00593580|bone mineral density
527189|NCT00593580|bisphosphonates
527190|NCT00593580|chemotherapy
527191|NCT00593567|Diabetic Foot Ulcer
527192|NCT00593541|MRI
527193|NCT00593528|Cirrhosis, STIC TIPS, Portal Hypertension, Transjugular Intrahepatic Portosystemic Shunt , Stents, PTFE
527194|NCT00593528|cirrhotic HTP
527195|NCT00593502|influenza
527196|NCT00593502|children
527197|NCT00593502|acute otitis media
527198|NCT00593502|oseltamivir
527199|NCT00593489|Insulin
527200|NCT00593489|Diabetes Mellitus
527201|NCT00593489|Practice Behaviour
527202|NCT00593489|Preceptor
527203|NCT00593489|Pharmacy
527204|NCT00593476|Type 2 Diabetes
527205|NCT00593476|Glycemic Control
527206|NCT00593476|Diabetes Support and Education
527207|NCT00593476|Portion Control
527208|NCT00593476|Prepackaged meals
527209|NCT00593463|opioid dependence
527210|NCT00593463|methadone
527211|NCT00593463|opioid
527212|NCT00593450|bevacizumab
527213|NCT00593450|ranibizumab
527214|NCT00593450|choroidal neovascularization
527215|NCT00593437|bone density diagnostic equipment discrepancies
527216|NCT00593411|MD Analyze
527217|NCT00593411|Central Nervous System
527218|NCT00593411|Spine Disease
527219|NCT00593411|Peripheral Nerve
527220|NCT00593398|Malaria
527221|NCT00593398|pregnant women
527222|NCT00593398|infants
527223|NCT00593398|Cameroon
527224|NCT00593385|Symptomatic claudication or rest pain and angiographic confirmation of either de novo or restenotic lesions in the common and/or external iliac artery.
527225|NCT00593372|Alzheimer's Disease
527226|NCT00593372|Memory
527227|NCT00593372|Treatment
527228|NCT00593359|Spinal surgery
527229|NCT00593359|Prone spinal surgery
527230|NCT00593333|Femur Fracture
527231|NCT00593333|Intramedullary Nailing
527232|NCT00593333|Trochanteric Nailing
527233|NCT00593333|Piriformis Starting Portal
527234|NCT00593333|Trochanteric Insertion Portal
527235|NCT00593320|SRS
527236|NCT00593307|glycemic response
527237|NCT00593307|hunger
527238|NCT00593294|PCOS
527239|NCT00593294|oral contraceptives
527240|NCT00593294|physical exercise
527241|NCT00593294|CVR
527242|NCT00593281|Hyaluronidase
527243|NCT00593281|Hylenex
527244|NCT00593281|subcutaneous
527245|NCT00593281|morphine
527246|NCT00593281|absorption
527247|NCT00593281|bioavailability
527248|NCT00593281|PK study of morphine in patients with pain
527249|NCT00593242|hypoxic-ischemic encephalopathy
527250|NCT00593242|autologous cord blood cells
527251|NCT00593242|newborn infants
527252|NCT00593229|Thrombotic microangiopathy (TMA)
527253|NCT00593229|Hemolytic uremic syndrome (HUS)
527254|NCT00593229|Thrombotic thrombocytopenic purpura (TTP)
527255|NCT00593216|functional magnetic Resonance Imaging
527256|NCT00593216|vertigo
527257|NCT00593216|vestibular
527258|NCT00593177|Plaque psoriasis
527259|NCT00593177|Psoriasis
527260|NCT00593164|Hypothermia, Induced
527261|NCT00593164|Death, Sudden, Cardiac
527262|NCT00593164|Resuscitation
527263|NCT00593164|Coma
527264|NCT00593151|Antimetabolites
527265|NCT00593151|Virus Diseases
527266|NCT00593151|Anti-Infective Agents
527267|NCT00593151|RNA Virus Infections
527268|NCT00593151|Digestive System Diseases
527269|NCT00593151|Flaviviridae Infections
527270|NCT00593151|Antineoplastic Agents
527271|NCT00593151|Therapeutic Uses
527272|NCT00593151|Antiviral Agents
527273|NCT00593151|Molecular Mechanisms of Action
527274|NCT00593151|Pharmacologic Actions
527275|NCT00593138|Focalin XR
527276|NCT00593138|Adult
527277|NCT00593138|PET scan
527278|NCT00593125|cocaine
527279|NCT00593125|opioids
527280|NCT00593125|heroin
527281|NCT00593125|levetiracetam
527282|NCT00593112|HMRS Scanning
527283|NCT00593112|ADHD
527284|NCT00593112|Child
527285|NCT00593112|Adolescent
527286|NCT00593112|HMRS Scans
527287|NCT00593099|Bipolar Disorder
527288|NCT00593099|Nicotine Dependence
527289|NCT00593099|Smoking Cessation
527290|NCT00593099|Bupropion, sustained-release
527291|NCT00593086|wound care
527292|NCT00593060|Temsirolimus
527293|NCT00593060|cetuximab
527294|NCT00593060|metastatic disease
527295|NCT00593047|hypercholesterolemia
527296|NCT00593034|Alcohol abuse
527297|NCT00593034|Drug abuse
527298|NCT00593021|Obscure Gastrointestinal Bleeding
527299|NCT00593021|Occult Gastrointestinal Bleeding
527300|NCT00593021|Overt Gastrointestinal Bleeding
527301|NCT00593021|Capsule Endoscopy
527302|NCT00593021|CT Enterography
527303|NCT00593008|metastatic pancreatic cancer
527304|NCT00592943|Adults
527305|NCT00592943|Healthy Volunteers
527306|NCT00592943|Nuvigil
527307|NCT00592943|Armodafinil
527308|NCT00592943|DAT occupancy in healthy volunteers
527309|NCT00592930|anorexia nervosa, treatment, adolescents, olanzapine
527310|NCT00592917|osteoporosis
527311|NCT00592917|fractures
527312|NCT00592917|risk of fracture
527313|NCT00592917|vitamin-D
527314|NCT00592917|calcium
527315|NCT00592917|falls
527316|NCT00592917|bone mineral density
527317|NCT00592917|bone metabolism
527318|NCT00592904|Neuralgia
527319|NCT00592904|neuropathy
527320|NCT00592891|brain injury
527321|NCT00592891|brain disorders
527322|NCT00592852|bipolar disorder
527323|NCT00592852|obsessive compulsive disorder
527324|NCT00592852|Prozac
527325|NCT00592839|Nocturnal vasomotor symptoms in postmenopausal women
527326|NCT00592826|PHP
527327|NCT00592826|HMP
527328|NCT00592826|HPHP
527329|NCT00592826|AMD
527330|NCT00592826|CNV
527331|NCT00592813|rehabilitation
527332|NCT00592813|function
527333|NCT00592800|statistics
527334|NCT00592800|probability
527335|NCT00592774|Post-Herpetic Neuralgia
527336|NCT00592774|PHN)
527337|NCT00592761|Deglutition Disorders
527338|NCT00592761|Mendelsohn Maneuver
527339|NCT00592761|SEMG
527340|NCT00592748|charged particle radiation therapy
527341|NCT00592696|Adolescent depression
527342|NCT00592696|Adolescent smoking
527343|NCT00592683|bipolar disorder
527344|NCT00592683|fish oil
527345|NCT00592683|aripiprazole
527346|NCT00592683|children
527347|NCT00592657|retrospective chart review
527348|NCT00592657|Jimsonweed ingestion
527349|NCT00592644|ectasia
527350|NCT00592644|vascular lesions
527351|NCT00592644|vocal cords
527352|NCT00592644|voice
527353|NCT00592644|pulsed dye laser
527354|NCT00592631|asthma
527355|NCT00592631|sleep apnea
527356|NCT00592618|ESRD
527357|NCT00592618|Hemodialysis
527358|NCT00592618|Sleep Apnea
527359|NCT00592592|pediatric rhabdomyosarcoma
527360|NCT00592592|proton radiation therapy
527361|NCT00592566|Severe leptospirosis
527362|NCT00592566|Pulmonary hemorrhage
527363|NCT00592553|Duchenne muscular dystrophy
527364|NCT00592553|Becker muscular dystrophy
527365|NCT00592553|Nonsense mutation
527366|NCT00592553|Premature stop codon
527367|NCT00592553|DMD/BMD
527368|NCT00592553|PTC124
527369|NCT00592514|Patients undergoing head and neck surgery that involves the upper aerodigestive tract
527370|NCT00592501|proton radiation
527371|NCT00592501|photon radiation
527372|NCT00592501|5-FU
527373|NCT00592501|cisplatin
527374|NCT00592488|Septic shock
527375|NCT00592488|Acetyl-L-carnitine
527376|NCT00592475|conivaptan
527377|NCT00592475|Liver Cirrhosis
527378|NCT00592475|Hypertension, Portal
527379|NCT00592462|Breast Cancer
527380|NCT00592462|Whole Body MRI
527381|NCT00592462|Magnetic Resonance Imaging
527382|NCT00592462|Metastases
527383|NCT00592449|Insomnia
527384|NCT00592449|Knee pain
527385|NCT00592449|Osteoarthritis
527386|NCT00592449|Arthritis
527387|NCT00592449|Sleep
527388|NCT00592436|ADHD
527389|NCT00592436|pediatric
527390|NCT00592436|children
527391|NCT00592423|Lateral neck rotation
527392|NCT00592423|Continuous Positive Airway Pressure
527393|NCT00592397|Dietary Intervention
527394|NCT00592397|Nutrigenomics
527395|NCT00592397|Diet, Carbohydrate-Restricted
527396|NCT00592397|Gene Expression
527397|NCT00592397|Gene Expression Profiling
527398|NCT00592397|Oligonucleotide Array Sequence Analysis
527399|NCT00592397|Biological Markers
527400|NCT00592397|Food
527401|NCT00592397|Obesity
527402|NCT00592397|Blood
527403|NCT00592397|Subcutaneous Fat, Abdominal
527404|NCT00592384|spinal cord injuries
527405|NCT00592384|major depressive disorder
527406|NCT00592384|dysthymia
527407|NCT00592384|antidepressant agents
527408|NCT00592384|pain
527409|NCT00592384|quality of life
527410|NCT00592384|muscle spasticity
527411|NCT00592384|community participation
527412|NCT00592384|anxiety
527413|NCT00592358|bipolar disorder
527414|NCT00592358|children
527415|NCT00592358|adolescents
527416|NCT00592358|Invega
527417|NCT00592345|sarcoma of the thoracic/lumbar/spine/sacrum
527418|NCT00592345|paraspinal soft tissues
527419|NCT00592345|proton radiation therapy
527420|NCT00592345|photon radiation therapy
527421|NCT00592345|radiation applicator plaque
527422|NCT00592319|Papilloma
527423|NCT00592319|pulsed dye laser
527424|NCT00592319|Celebrex
527425|NCT00592319|voice
527426|NCT00592306|ATG
527427|NCT00592306|rabbit thymoglobulin
527428|NCT00592306|reperfusion lung injury
527429|NCT00592306|primary graft dysfunction
527430|NCT00592306|lung transplantation
527431|NCT00592293|proton beam radiation
527432|NCT00592280|Pancreas transplantation
527433|NCT00592280|graft pancreatitis
527434|NCT00592280|Two-layer method
527435|NCT00592280|organ preservation
527436|NCT00592267|pediatric
527437|NCT00592267|bipolar disorder
527438|NCT00592254|ADHD
527439|NCT00592254|Adults
527440|NCT00592241|Insulin Pump
527441|NCT00592228|intermediate lesion
527442|NCT00592228|drug-eluting stent
527443|NCT00592228|fractional flow reserve
527444|NCT00592215|Second trimester labor induction
527445|NCT00592202|Morbid obesity
527446|NCT00592202|Adolescents
527447|NCT00592202|Gastric restrictive procedure
527448|NCT00592202|Adjustable gastric band
527449|NCT00592202|Treatment
527450|NCT00592189|Burns
527451|NCT00592189|Wound healing
527452|NCT00592189|Amnion
527453|NCT00592163|Cancer
527454|NCT00592163|Arsenic
527455|NCT00592150|Essential Hypertension
527456|NCT00592137|calcium carbonate
527457|NCT00592137|obesity
527458|NCT00592137|dairy
527459|NCT00592137|energy expenditure
527460|NCT00592124|Microbicide
527461|NCT00592124|HIV Seronegativity
527462|NCT00592111|Pediatric
527463|NCT00592111|Hodgkin's Disease
527464|NCT00592111|96-016
527465|NCT00592098|Lower limb amputation at least 6 months prior to inclusion
527466|NCT00592098|Presenting with moderate-to-severe pain intensity
527467|NCT00592098|Outpatients, aged 18 years and above
527468|NCT00592085|Tobacco Use
527469|NCT00592085|Smoking
527470|NCT00592085|Alcohol Use
527471|NCT00592085|Smoking Cessation
527472|NCT00592072|Diabetes Mellitus, Type 1
527473|NCT00592072|Medium Chain Fatty Acid
527474|NCT00592072|Hypoglycemia
527475|NCT00592046|Phase I
527476|NCT00592046|Hematologic Cancers
527477|NCT00592046|Blood Cancers
527478|NCT00592046|Leukemia
527479|NCT00592046|multiple myeloma
527480|NCT00592046|myelodysplasia (MDS)
527481|NCT00592046|Relapsed/refractory leukemia or lymphoma
527482|NCT00592033|COPD oxygen
527483|NCT00592033|COPD rehabilitation
527484|NCT00592033|exercise
527485|NCT00592020|kidney
527486|NCT00592020|transplantation
527487|NCT00592020|minimal invasive
527488|NCT00592020|short transverse
527489|NCT00592020|hockey stick
527490|NCT00592020|incision
527491|NCT00592020|quality of life
527492|NCT00592020|planned kidney transplantation
527493|NCT00592007|Non Small Cell Lung Cancer
527494|NCT00592007|Stage IIIB
527495|NCT00592007|Stage IV
527496|NCT00592007|Stable on Erlotinib
527497|NCT00592007|Exhibit Positivity for Estrogen or Progesterone Receptor
527498|NCT00591994|tinnitus
527499|NCT00591994|piribedil
527500|NCT00591994|acoustic otoemissions
527501|NCT00591994|ECoG
527502|NCT00591981|Geriatric
527503|NCT00591981|Thoracic
527504|NCT00591981|neoplasm
527505|NCT00591981|(Patients over 70 years of age) Geriatric oncology patients with thoracic neoplasms of the lung, esophagus, pleura and thymus.
527506|NCT00591968|ultrasound
527507|NCT00591968|telediagnosis
527508|NCT00591968|teleultrasound
527509|NCT00591968|telesonography
527510|NCT00591968|teleultrasonography
527511|NCT00591968|teleradiology
527512|NCT00591968|telemedicine
527513|NCT00591968|dominican republic
527514|NCT00591968|puntacana
527515|NCT00591968|veron
527516|NCT00591968|store-and-forward
527517|NCT00591968|asynchronous
527518|NCT00591955|geriatric
527519|NCT00591955|sepsis
527520|NCT00591955|outcome assessment(healthcare)
527521|NCT00591942|dental cement
527522|NCT00591942|ceramic crowns
527523|NCT00591942|three-unit bridges
527524|NCT00591942|sensitivity
527525|NCT00591916|burn
527526|NCT00591916|donor site
527527|NCT00591916|grafting
527528|NCT00591916|scar
527529|NCT00591903|Diabetes and Cardiac Proteomics
527530|NCT00591903|Atrial Appendage and Proteomics
527531|NCT00591903|Diabetic Cardiomyopathy
527532|NCT00591903|Tissue Sample
527533|NCT00591877|GERDCAM: Complementary and alternative medicine
527534|NCT00591877|NERD: non-erosive reflux disease
527535|NCT00591877|GERD: gastroesophageal reflux disease
527536|NCT00591877|AC: acupuncture
527537|NCT00591877|SAC: sham acupuncture
527538|NCT00591877|LES: lower esophageal sphincter pressure
527539|NCT00591877|TLESR: transient lower esophageal sphincter relaxation
527540|NCT00591877|Acupuncture
527541|NCT00591877|Yoga
527542|NCT00591864|Benign breast disease
527543|NCT00591864|Breast
527544|NCT00591864|MRI
527545|NCT00591864|Mammography
527546|NCT00591864|Ultrasound
527547|NCT00591864|Molecular Breast Imaging
527548|NCT00591864|Breast Cancer
527549|NCT00591851|breast cancer
527550|NCT00591851|adenocarcinoma of the breast
527551|NCT00591851|cardiac safety
527552|NCT00591851|Breast cancer patients seen at the Memorial Sloan-Kettering Cancer Center
527553|NCT00591838|SBRT
527554|NCT00591773|Blood pressure
527555|NCT00591773|Blood pressure monitoring, ambulatory
527556|NCT00591760|Heart Failure
527557|NCT00591760|Growth Hormone
527558|NCT00591760|Anabolism
527559|NCT00591760|Anabolic Deficiency
527560|NCT00591760|Hormone replacement
527561|NCT00591747|randomized clinical trial
527562|NCT00591747|elderly
527563|NCT00591747|cancer survivor
527564|NCT00591747|bone health
527565|NCT00591747|body composition
527566|NCT00591747|signs and symptoms
527567|NCT00591734|Metastatic Melanoma
527568|NCT00591734|Everolimus
527569|NCT00591734|RAD001
527570|NCT00591734|Bevacizumab
527571|NCT00591721|energy conservation education
527572|NCT00591721|occupational therapy intervention
527573|NCT00591721|fatigue management
527574|NCT00591721|psychoeducation
527575|NCT00591708|calcium
527576|NCT00591708|bone
527577|NCT00591708|bone density
527578|NCT00591708|adolescence
527579|NCT00591695|Malignant Colorectal Obstruction
527580|NCT00591695|Stent Bridge to Surgery
527581|NCT00591669|Inflammatory bowel disease
527582|NCT00591669|Crohn's disease
527583|NCT00591643|Adrenal tumors
527584|NCT00591643|Adrenal malignancies
527585|NCT00591643|abnormal hormonal secretions
527586|NCT00591643|electrolytes abnormalities
527587|NCT00591643|Imaging
527588|NCT00591643|Scanning
527589|NCT00591643|tumor localization
527590|NCT00591630|Diffuse Large Cell Lymphoma
527591|NCT00591630|Lymphoma
527592|NCT00591630|Zevalin
527593|NCT00591630|Ibritumomab
527594|NCT00591630|IDEC-Y2B8
527595|NCT00591630|Carmustine
527596|NCT00591630|BCNU
527597|NCT00591630|BiCNU
527598|NCT00591630|Etoposide
527599|NCT00591630|VePesid
527600|NCT00591630|Cytarabine
527601|NCT00591630|Ara-C
527602|NCT00591630|Cytosar
527603|NCT00591630|DepoCyt
527604|NCT00591630|Cytosine arabinosine hydrochloride
527605|NCT00591630|Melphalan
527606|NCT00591630|Rituximab
527607|NCT00591630|Rituxan
527608|NCT00591630|BEAM
527609|NCT00591617|Opioids
527610|NCT00591617|drug dependence
527611|NCT00591617|drug abuse
527612|NCT00591617|treatment
527613|NCT00591604|burn
527614|NCT00591604|vitamin D
527615|NCT00591604|nutrition
527616|NCT00591604|burn recovery
527617|NCT00591591|Obstructive Sleep Apnea Syndrome
527618|NCT00591591|sleep disordered breathing
527619|NCT00591591|polysomnography (psg)
527620|NCT00591591|continuous positive airway pressure (cpap)
527621|NCT00591591|brain vascular autoregulation
527622|NCT00591591|brain tissue oxygenation
527623|NCT00591591|near-infrared spectroscopy
527624|NCT00591591|Obstructive Sleep Apnea
527625|NCT00591578|Blood pressure
527626|NCT00591578|blood pressure monitoring, ambulatory
527627|NCT00591565|Anxiety
527628|NCT00591565|SSRI
527629|NCT00591565|SNRI
527630|NCT00591565|Acamprosate
527631|NCT00591552|Lung cancer
527632|NCT00591552|Lymph node dissection
527633|NCT00591539|Carotid Artery Disease
527634|NCT00591539|Intima-Media Thickening
527635|NCT00591539|Carotid Ultrasound
527636|NCT00591539|Pediatric Cancer Survivors
527637|NCT00591539|Cancer Survivors
527638|NCT00591539|Head or Neck Cancer
527639|NCT00591539|Radiation Therapy
527640|NCT00591526|APL
527641|NCT00591513|burns
527642|NCT00591513|burn scars
527643|NCT00591513|congenital giant nevi
527644|NCT00591500|Melanoma
527645|NCT00591500|Skin cancer
527646|NCT00591500|Genetic Susceptibility
527647|NCT00591500|polymorphisms
527648|NCT00591487|suction
527649|NCT00591487|assisted
527650|NCT00591487|lipectomy
527651|NCT00591487|liposuction
527652|NCT00591487|contour
527653|NCT00591487|cosmetic
527654|NCT00591487|plastic
527655|NCT00591487|surgery
527656|NCT00591487|Klein
527657|NCT00591487|tumescent
527658|NCT00591487|technique
527659|NCT00591487|Healthy women wanting Suction Assisted Lipectomy
527660|NCT00591474|VRE
527661|NCT00591474|Probiotics
527662|NCT00591474|colonization
527663|NCT00591474|gut health
527664|NCT00591461|Barrett's Esophagus
527665|NCT00591461|Upper Endoscopy
527666|NCT00591461|Esophageal biopsies
527667|NCT00591461|Accuracy
527668|NCT00591461|Interobserver Agreement
527669|NCT00591448|Thermal injury
527670|NCT00591435|Anesthesia
527671|NCT00591435|Surgery
527672|NCT00591435|Education
527673|NCT00591435|Economics
527674|NCT00591422|Arsenic
527675|NCT00591422|Cancer
527676|NCT00591383|Cancer
527677|NCT00591383|Indibulin
527678|NCT00591383|Erlotinib
527679|NCT00591370|Memorial Sloan-Kettering Cancer Center patients with measurable, unresectable stage
527680|NCT00591370|III or IV melanoma
527681|NCT00591357|Antibiotic associated diarrhea
527682|NCT00591357|Clostridium difficile
527683|NCT00591357|loperamide
527684|NCT00591344|Parkinson's disease
527685|NCT00591344|exercise
527686|NCT00591331|Head Lice
527687|NCT00591318|Ceftriaxone
527688|NCT00591318|Psychosis
527689|NCT00591318|Schizophrenia
527690|NCT00591318|Schizoaffective Disorder
527691|NCT00591305|papilloma
527692|NCT00591305|PDL
527693|NCT00591305|diindolylmethane
527694|NCT00591305|recurrence
527695|NCT00591292|cancer
527696|NCT00591292|tumor
527697|NCT00591292|solid tumor
527698|NCT00591292|advanced tumor
527699|NCT00591279|large bowel cancer
527700|NCT00591279|polyps
527701|NCT00591279|colorectal cancer
527702|NCT00591266|Blood pressure
527703|NCT00591266|blood pressure monitoring ambulatory
527704|NCT00591266|Drug Therapy
527705|NCT00591253|Blood pressure
527706|NCT00591253|blood pressure monitoring ambulatory
527707|NCT00591253|Drug Therapy
527708|NCT00591240|RNA, ribosomal, 16S
527709|NCT00591240|Biosensing techniques
527710|NCT00591240|Microchip analytical procedures
527711|NCT00591214|Chronic Hepatitis C
527712|NCT00591214|Protease Inhibitor
527713|NCT00591201|Spondylarthritis
527714|NCT00591201|TNF
527715|NCT00591201|Infliximab
527716|NCT00591201|Ankylosing spondylitis
527717|NCT00591201|Juvenile SpA
527718|NCT00591201|Juvenile arthritis
527719|NCT00591188|kidney cancer, capecitabine, interferon
527720|NCT00591162|Bone, Dexa, Parathyroid, Diuretic, Tetracycline
527721|NCT00591149|cancer
527722|NCT00591149|head and neck cancer
527723|NCT00591149|squamous cell cancer
527724|NCT00591123|Unresectable
527725|NCT00591123|Metastatic
527726|NCT00591123|Esophagus
527727|NCT00591123|Gastric Cardia
527728|NCT00591097|urine
527729|NCT00591097|pediatric
527730|NCT00591097|Normal urine from healthy pediatric population
527731|NCT00591084|randomized trial
527732|NCT00591084|ischemic stroke
527733|NCT00591084|Ginsenoside-Rd
527734|NCT00591071|hyperglycemia
527735|NCT00591071|insulin treatment
527736|NCT00591071|intensive care
527737|NCT00591071|hypoglycemia
527738|NCT00591071|mechanical ventilation
527739|NCT00591071|critically ill patients
527740|NCT00591058|recurrent glioma
527741|NCT00591058|Phase I
527742|NCT00591058|Multi-Center
527743|NCT00591058|Open label
527744|NCT00591058|Brain Cancer
527745|NCT00591058|Brain tumor
527746|NCT00591058|GBM
527747|NCT00591058|Glioma
527748|NCT00591058|Glioblastoma multiforme
527749|NCT00591045|gastric adenocarcinoma
527750|NCT00591045|neoadjuvant chemotherapy
527751|NCT00591045|efficacy
527752|NCT00591045|safety
527753|NCT00591045|chemotherapy
527754|NCT00591032|Critical illness
527755|NCT00591032|Euthyroid sick syndromes
527756|NCT00591032|Intensive care
527757|NCT00591032|Non-thyroidal illness syndrome
527758|NCT00591032|Low-T3 syndrome
527759|NCT00591019|P50, Psychomotor Vigilance Test (PVT), Arousal, Reaction Time
527760|NCT00591006|Phenytoin
527761|NCT00591006|Dilantin
527762|NCT00591006|Corticosteroid
527763|NCT00591006|Neuroprotection
527764|NCT00591006|Mania
527765|NCT00591006|Cognition
527766|NCT00591006|Mood
527767|NCT00591006|Memory
527768|NCT00591006|Hydrocortisone
527769|NCT00591006|Healthy Controls
527770|NCT00591006|MRI
527771|NCT00591006|hippocampal activation
527772|NCT00590993|MRSI
527773|NCT00590993|MRI
527774|NCT00590993|Prostate Cancer
527775|NCT00590980|Stroke
527776|NCT00590980|TIA (transient ischemic attack)
527777|NCT00590980|Brain
527778|NCT00590980|Blood Flow
527779|NCT00590980|Quantitative magnetic resonance angiography (QMRA)
527780|NCT00590967|para-aortic lymph nodes
527781|NCT00590954|Malignant Gliomas
527782|NCT00590954|CNS
527783|NCT00590954|Brain Cancer
527784|NCT00590954|Cancer
527785|NCT00590954|Perifosine
527786|NCT00590941|Lymphoma
527787|NCT00590941|Rituximab
527788|NCT00590941|CHOP
527789|NCT00590915|ALL
527790|NCT00590902|non small cell lung cancer
527791|NCT00590889|artificial heart valve
527792|NCT00590889|mitral heart valve
527793|NCT00590889|aortic heart valve
527794|NCT00590889|endocarditis
527795|NCT00590889|Aortic valve disease requiring replacement
527796|NCT00590889|Mitral valve disease requiring replacement
527797|NCT00590876|Diabetes Mellitus, Type 1
527798|NCT00590876|Hypoglycemia
527799|NCT00590876|Pancreatic Islet Cell Allotransplantation
527800|NCT00590863|depression, medication, antidepressant, chronic, recurrent
527801|NCT00590837|AML
527802|NCT00590837|Chemotherapy
527803|NCT00590837|older
527804|NCT00590837|De novo AML
527805|NCT00590824|Melanoma
527806|NCT00590824|hu14.18-IL2
527807|NCT00590811|adolescents
527808|NCT00590811|young adults
527809|NCT00590811|dysmenorrhea
527810|NCT00590811|pelvic pain
527811|NCT00590798|Cardiac Catheterization
527812|NCT00590798|Walk
527813|NCT00590798|Heart Catheterization
527814|NCT00590798|Coronary Disease
527815|NCT00590798|Heart Disease
527816|NCT00590798|Coronary Artery Disease
527817|NCT00590785|High Risk
527818|NCT00590785|Breast Cancer
527819|NCT00590785|Positive Nodes
527820|NCT00590785|Cyclophosphamide
527821|NCT00590785|Doxorubicin
527822|NCT00590785|96-041
527823|NCT00590772|sleep
527824|NCT00590772|somnolence
527825|NCT00590772|allergies
527826|NCT00590772|rhinitis
527827|NCT00590772|fatigue
527828|NCT00590720|Asthma
527829|NCT00590720|Bronchitis
527830|NCT00590707|Hip fractures
527831|NCT00590707|Femoral neck fractures
527832|NCT00590707|Trochanteric fractures
527833|NCT00590707|Intertrochanteric fractures
527834|NCT00590707|Subtrochanteric fractures
527835|NCT00590707|Delirium
527836|NCT00590707|Confusion
527837|NCT00590694|ranibizumab
527838|NCT00590694|Lucentis
527839|NCT00590694|Pigment Epithelial Detachment
527840|NCT00590694|Macular Degeneration
527841|NCT00590694|PrONTO
527842|NCT00590668|atrial fibrillation
527843|NCT00590668|pulmonary vein ablation
527844|NCT00590668|pulmonary vein stenosis
527845|NCT00590655|maintenance therapy
527846|NCT00590642|obsessive compulsive disorder
527847|NCT00590642|OCD
527848|NCT00590642|treatment-resistant
527849|NCT00590642|SSRI
527850|NCT00590629|Women with and without CAD
527851|NCT00590616|Aortic atheroma
527852|NCT00590603|Multiple myeloma
527853|NCT00590577|Schizophrenia
527854|NCT00590577|Long-acting injectable antipsychotic medication
527855|NCT00590564|Hepatitis C
527856|NCT00590564|Sho-saiko-to
527857|NCT00590564|SST
527858|NCT00590564|Interferon Therapy
527859|NCT00590551|Skin Breakdown
527860|NCT00590551|Skin Damage
527861|NCT00590551|Skin Integrity
527862|NCT00590551|Pressure
527863|NCT00590551|Slings
527864|NCT00590525|hsCRP
527865|NCT00590512|dietary salt
527866|NCT00590512|sodium
527867|NCT00590512|blood vessels
527868|NCT00590512|vascular function
527869|NCT00590512|endothelial function
527870|NCT00590512|heart disease risk
527871|NCT00590512|cardiovascular disease risk
527872|NCT00590499|agitation
527873|NCT00590499|craniotomy
527874|NCT00590499|incidence
527875|NCT00590499|risk factor
527876|NCT00590499|outcome
527877|NCT00590473|Interstitial Cystitis
527878|NCT00590473|IC
527879|NCT00590473|Neuromodulation
527880|NCT00590473|Interstim Therapy
527881|NCT00590460|Allogeneic Stem Cell Transplant
527882|NCT00590460|Fanconi Anemia
527883|NCT00590460|Severe Aplastic Anemia
527884|NCT00590460|fludarabine
527885|NCT00590460|campath
527886|NCT00590460|anti-CD45
527887|NCT00590447|1st-line therapy
527888|NCT00590447|single agent rituximab
527889|NCT00590447|CHOP
527890|NCT00590447|risk stratification
527891|NCT00590434|CRC - Colorectal cancer
527892|NCT00590434|CVA - Cerebral Vascular Accident
527893|NCT00590434|MI - Myocardial Infarction
527894|NCT00590434|CAD - Coronary Artery Disease
527895|NCT00590434|DM - Diabetes Mellitus
527896|NCT00590434|PVD - Peripheral Vascular Disease
527897|NCT00590434|NSAIDS - Non-Steroidal Anti inflammatory Drugs
527898|NCT00590434|screening
527899|NCT00590434|colonoscopy
527900|NCT00590408|coenzyme Q10
527901|NCT00590408|statin
527902|NCT00590408|myalgia
527903|NCT00590395|Cholecystitis
527904|NCT00590395|FDG PET/CT
527905|NCT00590395|HIDA scan
527906|NCT00590356|Device closure
527907|NCT00590304|Asthma, Children, Rural Population, Morbidity, Endotoxin
527908|NCT00590291|Coronary Artery Disease
527909|NCT00590291|Arteriovenous Malformations
527910|NCT00590291|Myocardial Infarction
527911|NCT00590291|CAD
527912|NCT00590291|MI
527913|NCT00590291|Heart Attack
527914|NCT00590291|AVM
527915|NCT00590291|genetic
527916|NCT00590291|familial
527917|NCT00590278|Tomudex
527918|NCT00590278|inoperable rectal cancer
527919|NCT00590278|recurrent rectal cancer
527920|NCT00590265|bipolar type II disorder
527921|NCT00590265|depression
527922|NCT00590265|remission
527923|NCT00590265|light-therapy
527924|NCT00590265|efficacy
527925|NCT00590265|safety
527926|NCT00590252|Magnetic Resonance
527927|NCT00590252|Imaging
527928|NCT00590252|Spectroscopy
527929|NCT00590239|Barrett's Esophagus
527930|NCT00590239|Neoplasia
527931|NCT00590239|Endoscopic mucosal resection
527932|NCT00590239|High resolution endoscopy
527933|NCT00590239|Chromoendoscopy
527934|NCT00590226|type 2 diabetes
527935|NCT00590226|inpatient hyperglycemia
527936|NCT00590226|SQ insulin
527937|NCT00590226|Hospitalized patients with type 2 diabetes
527938|NCT00590213|Casodex
527939|NCT00590213|Prostate Cancer
527940|NCT00590200|CAD
527941|NCT00590200|Cardiovascular Disease
527942|NCT00590200|CVD
527943|NCT00590200|MI
527944|NCT00590200|Myocardial Infarction
527945|NCT00590200|Heart Attack
527946|NCT00590200|CABG
527947|NCT00590200|Revascularization
527948|NCT00590200|genetic
527949|NCT00590174|stent
527950|NCT00590174|antiplatelet therapy
527951|NCT00590161|Fatty Liver
527952|NCT00590161|Nonalcoholic fatty liver disease (NALFD)
527953|NCT00590161|NAFLD
527954|NCT00590161|Nonalcoholic steatohepatitis (NASH)
527955|NCT00590161|NASH
527956|NCT00590161|pentoxifylline
527957|NCT00590135|calcific aortic valve stenosis
527958|NCT00590135|echocardiography, transthoracic
527959|NCT00590122|Parkinson's disease
527960|NCT00590122|"time to on"
527961|NCT00590122|delayed on
527962|NCT00590109|Breast Cancer
527963|NCT00590109|Jewish
527964|NCT00590109|BRCA1
527965|NCT00590109|BRCA2
527966|NCT00590109|97-029
527967|NCT00590096|Neuroblastoma
527968|NCT00590096|Pheochromocytoma
527969|NCT00590096|MIBG
527970|NCT00590083|stem cell transplantation
527971|NCT00590083|adenovirus
527972|NCT00590083|Cytotoxic T-Lymphocytes
527973|NCT00590083|prophylaxis
527974|NCT00590070|myocardial infarction
527975|NCT00590070|no reflow
527976|NCT00590070|primary PCI
527977|NCT00590070|Coronary no-reflow phenomenon
527978|NCT00590070|primary percutaneous coronary intervention (primary PCI)
527979|NCT00590044|Diabetic ketoacidosis
527980|NCT00590044|insulin therapy
527981|NCT00590044|DKA
527982|NCT00590031|Esophageal Carcinoma
527983|NCT00590031|Cisplatin
527984|NCT00590031|Irinotecan
527985|NCT00590031|Radiation Therapy
527986|NCT00590031|02-045
527987|NCT00590018|Congenital heart disease.
527988|NCT00590018|Low cardiac output syndrome.
527989|NCT00590018|Corticosteroids.
527990|NCT00590018|Hydrocortisone.
527991|NCT00590018|Blood pressure.
527992|NCT00590018|Inotropes.
527993|NCT00590005|severe asthma
527994|NCT00590005|poorly controlled asthma
527995|NCT00589979|Osteoarthritis
527996|NCT00589979|Knee
527997|NCT00589979|Lidoderm
527998|NCT00589979|Lidocaine
527999|NCT00589979|Topical patch
528000|NCT00589979|Adjunct therapy
528001|NCT00589966|prostate cancer treatment
528002|NCT00589966|treatment side-effects
528003|NCT00589966|early diagnosis
528004|NCT00589966|African American Men
528005|NCT00589966|coping skills training
528006|NCT00589966|quality of life
528007|NCT00589966|Prostate cancer treatment side-effects
528008|NCT00589953|Extreme Prematurity
528009|NCT00589953|Erythropoietin
528010|NCT00589953|Perinatal Brain Injury
528011|NCT00589953|Intraventricular Hemorrhage
528012|NCT00589953|Periventricular Leukomalacia
528013|NCT00589953|Neurodevelopmental Outcomes
528014|NCT00589953|Randomized Clinical Trial
528015|NCT00589927|stents
528016|NCT00589927|cilostazol
528017|NCT00589914|Schizophrenia
528018|NCT00589914|long-acting injectable antipsychotic medication
528019|NCT00589901|metastatic breast cancer
528020|NCT00589901|capecitabine
528021|NCT00589901|synergistic effect
528022|NCT00589901|chemotherapy
528023|NCT00589888|hypertension
528024|NCT00589888|metabolic syndrome
528025|NCT00589888|vascular reactivity
528026|NCT00589888|Elevated blood pressure
528027|NCT00589888|lipid toxicity
528028|NCT00589875|Immunotherapy
528029|NCT00589875|Cytotoxicity
528030|NCT00589875|Tumor vaccine
528031|NCT00589862|Drug Eluting Stents
528032|NCT00589862|Clopidogrel Resistance
528033|NCT00589862|Aspirin Resistance
528034|NCT00589849|Myocardial Infarction
528035|NCT00589849|Arrhythmia
528036|NCT00589849|T-wave alternans
528037|NCT00589836|HCM
528038|NCT00589836|HOCM
528039|NCT00589836|hypertrophic cardiomyopathy
528040|NCT00589836|tissue doppler echocardiography
528041|NCT00589836|myocardial torsion
528042|NCT00589823|Pain
528043|NCT00589823|Cancer
528044|NCT00589823|Breakthrough
528045|NCT00589810|ISR
528046|NCT00589810|in-stent restenosis
528047|NCT00589810|restenosis
528048|NCT00589810|BMS
528049|NCT00589810|bare metal stent
528050|NCT00589810|revascularization
528051|NCT00589810|genetic
528052|NCT00589810|cardiac catheterization
528053|NCT00589797|Degenerative
528054|NCT00589797|Disc
528055|NCT00589784|Sunitinib
528056|NCT00589784|Brain Cancer
528057|NCT00589784|CNS Cancer
528058|NCT00589784|meningioma
528059|NCT00589784|intracranial hemangiopericytoma
528060|NCT00589784|hemangioblastoma
528061|NCT00589784|malignant meningioma
528062|NCT00589784|neurofibromatosis
528063|NCT00589784|neurofibromatosis type 1
528064|NCT00589784|neurofibromatosis type 2
528065|NCT00589784|07-135
528066|NCT00589771|IBS
528067|NCT00589771|Saccharomyces boulardii
528068|NCT00589771|probiotics
528069|NCT00589771|cytokine
528070|NCT00589771|histology
528071|NCT00589771|Efficacy
528072|NCT00589758|Right Ventricle
528073|NCT00589758|Echocardiogram
528074|NCT00589758|Evaluation of Heart Failure
528075|NCT00589745|Diagnosis
528076|NCT00589732|stents
528077|NCT00589732|angiotensin-converting enzyme
528078|NCT00589719|Asthma; minority; low-income; African American; Arkansas
528079|NCT00589706|high grade gliomas of the brain
528080|NCT00589706|anti-body treatment
528081|NCT00589706|survival
528082|NCT00589693|Ventilator-Associated Pneumonia
528083|NCT00589693|Pneumonia, hospital-acquired
528084|NCT00589693|Doripenem
528085|NCT00589693|Imipenem-cilastatin
528086|NCT00589680|Acidosis, Diabetic
528087|NCT00589680|Diabetic Acidosis
528088|NCT00589680|Diabetic Ketosis
528089|NCT00589680|Ketoacidosis, Diabetic
528090|NCT00589680|Ketosis, Diabetic
528091|NCT00589667|Head and Neck Cancer
528092|NCT00589667|GEMCITABINE
528093|NCT00589667|PEMETREXED
528094|NCT00589667|ALTIMA
528095|NCT00589667|epidermoid/squamous cell
528096|NCT00589667|carcinoma
528097|NCT00589667|pharynx
528098|NCT00589667|larynx
528099|NCT00589667|paranasal sinus
528100|NCT00589667|head/neck squamous cell carcinoma
528101|NCT00589654|amenorrhea
528102|NCT00589654|menstrual cycle
528103|NCT00589654|Breast cancer
528104|NCT00589654|questionnaire
528105|NCT00589654|97-127
528106|NCT00589641|adolescents
528107|NCT00589641|suicidal ideation and behavior
528108|NCT00589641|depression
528109|NCT00589641|substance abuse
528110|NCT00589628|Childhood
528111|NCT00589628|Uveitis
528112|NCT00589615|vitamin D
528113|NCT00589615|bone density
528114|NCT00589602|Adult luekemias
528115|NCT00589602|lymphoma
528116|NCT00589602|myelodysplastic syndromes
528117|NCT00589602|plasma cell disorders
528118|NCT00589589|burns
528119|NCT00589589|hypoglycemia
528120|NCT00589589|hyperglycemia
528121|NCT00589589|glucose monitoring
528122|NCT00589563|graft versus host disease
528123|NCT00589563|infection
528124|NCT00589563|adult favorable prognosis Hodgkin lymphoma
528125|NCT00589563|adult unfavorable prognosis Hodgkin lymphoma
528126|NCT00589563|childhood favorable prognosis Hodgkin lymphoma
528127|NCT00589563|childhood unfavorable prognosis Hodgkin lymphoma
528128|NCT00589563|cutaneous B-cell non-Hodgkin lymphoma
528129|NCT00589563|recurrent adult Hodgkin lymphoma
528130|NCT00589563|recurrent cutaneous T-cell non-Hodgkin lymphoma
528131|NCT00589563|recurrent/refractory childhood Hodgkin lymphoma
528132|NCT00589563|stage I adult Hodgkin lymphoma
528133|NCT00589563|stage I childhood Hodgkin lymphoma
528134|NCT00589563|stage I cutaneous T-cell non-Hodgkin lymphoma
528135|NCT00589563|stage II adult Hodgkin lymphoma
528136|NCT00589563|stage II childhood Hodgkin lymphoma
528137|NCT00589563|stage II cutaneous T-cell non-Hodgkin lymphoma
528138|NCT00589563|stage III adult Hodgkin lymphoma
528139|NCT00589563|stage III childhood Hodgkin lymphoma
528140|NCT00589563|stage III cutaneous T-cell non-Hodgkin lymphoma
528141|NCT00589563|stage IV adult Hodgkin lymphoma
528142|NCT00589563|stage IV childhood Hodgkin lymphoma
528143|NCT00589563|stage IV cutaneous T-cell non-Hodgkin lymphoma
528144|NCT00589563|anaplastic large cell lymphoma
528145|NCT00589563|angioimmunoblastic T-cell lymphoma
528146|NCT00589563|Burkitt lymphoma
528336|NCT00589355|c-reactive protein
528147|NCT00589563|contiguous stage II adult Burkitt lymphoma
528148|NCT00589563|contiguous stage II adult diffuse large cell lymphoma
528149|NCT00589563|contiguous stage II adult diffuse mixed cell lymphoma
528150|NCT00589563|contiguous stage II adult diffuse small cleaved cell lymphoma
528151|NCT00589563|contiguous stage II adult immunoblastic large cell lymphoma
528152|NCT00589563|contiguous stage II adult lymphoblastic lymphoma
528153|NCT00589563|contiguous stage II grade 1 follicular lymphoma
528154|NCT00589563|contiguous stage II grade 2 follicular lymphoma
528155|NCT00589563|contiguous stage II grade 3 follicular lymphoma
528156|NCT00589563|contiguous stage II mantle cell lymphoma
528157|NCT00589563|contiguous stage II marginal zone lymphoma
528158|NCT00589563|contiguous stage II small lymphocytic lymphoma
528159|NCT00589563|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
528160|NCT00589563|nodal marginal zone B-cell lymphoma
528161|NCT00589563|noncontiguous stage II adult Burkitt lymphoma
528162|NCT00589563|noncontiguous stage II adult diffuse large cell lymphoma
528163|NCT00589563|noncontiguous stage II adult diffuse mixed cell lymphoma
528164|NCT00589563|noncontiguous stage II adult diffuse small cleaved cell lymphoma
528165|NCT00589563|noncontiguous stage II adult immunoblastic large cell lymphoma
528166|NCT00589563|noncontiguous stage II adult lymphoblastic lymphoma
528167|NCT00589563|noncontiguous stage II grade 1 follicular lymphoma
528168|NCT00589563|noncontiguous stage II grade 2 follicular lymphoma
528169|NCT00589563|noncontiguous stage II grade 3 follicular lymphoma
528170|NCT00589563|noncontiguous stage II mantle cell lymphoma
528171|NCT00589563|noncontiguous stage II marginal zone lymphoma
528172|NCT00589563|noncontiguous stage II small lymphocytic lymphoma
528173|NCT00589563|recurrent adult Burkitt lymphoma
528174|NCT00589563|recurrent adult diffuse large cell lymphoma
528175|NCT00589563|recurrent adult diffuse mixed cell lymphoma
528176|NCT00589563|recurrent adult diffuse small cleaved cell lymphoma
528177|NCT00589563|recurrent adult grade III lymphomatoid granulomatosis
528178|NCT00589563|recurrent adult immunoblastic large cell lymphoma
528179|NCT00589563|recurrent adult lymphoblastic lymphoma
528180|NCT00589563|recurrent adult T-cell leukemia/lymphoma
528181|NCT00589563|recurrent childhood anaplastic large cell lymphoma
528182|NCT00589563|recurrent childhood grade III lymphomatoid granulomatosis
528183|NCT00589563|recurrent childhood lymphoblastic lymphoma
528184|NCT00589563|recurrent childhood small noncleaved cell lymphoma
528185|NCT00589563|recurrent grade 1 follicular lymphoma
528186|NCT00589563|recurrent grade 2 follicular lymphoma
528187|NCT00589563|recurrent grade 3 follicular lymphoma
528188|NCT00589563|recurrent grade I lymphomatoid granulomatosis
528189|NCT00589563|recurrent grade II lymphomatoid granulomatosis
528190|NCT00589563|recurrent mantle cell lymphoma
528191|NCT00589563|recurrent marginal zone lymphoma
528192|NCT00589563|recurrent small lymphocytic lymphoma
528193|NCT00589563|small intestine lymphoma
528194|NCT00589563|splenic marginal zone lymphoma
528195|NCT00589563|stage I adult Burkitt lymphoma
528196|NCT00589563|stage I adult diffuse large cell lymphoma
528197|NCT00589563|stage I adult diffuse mixed cell lymphoma
528198|NCT00589563|stage I adult diffuse small cleaved cell lymphoma
528199|NCT00589563|stage I adult immunoblastic large cell lymphoma
528200|NCT00589563|stage I adult lymphoblastic lymphoma
528201|NCT00589563|stage I adult T-cell leukemia/lymphoma
528202|NCT00589563|stage III adult Burkitt lymphoma
528203|NCT00589563|stage III adult diffuse large cell lymphoma
528204|NCT00589563|stage III adult diffuse mixed cell lymphoma
528205|NCT00589563|stage III adult diffuse small cleaved cell lymphoma
528206|NCT00589563|stage III adult immunoblastic large cell lymphoma
528207|NCT00589563|stage III adult lymphoblastic lymphoma
528208|NCT00589563|stage III adult T-cell leukemia/lymphoma
528209|NCT00589563|stage III childhood anaplastic large cell lymphoma
528210|NCT00589563|stage III childhood lymphoblastic lymphoma
528211|NCT00589563|stage III childhood small noncleaved cell lymphoma
528212|NCT00589563|stage III grade 1 follicular lymphoma
528213|NCT00589563|stage III grade 2 follicular lymphoma
528214|NCT00589563|stage III grade 3 follicular lymphoma
528215|NCT00589563|stage III mantle cell lymphoma
528216|NCT00589563|stage III marginal zone lymphoma
528217|NCT00589563|stage III small lymphocytic lymphoma
528218|NCT00589563|stage IV adult Burkitt lymphoma
528219|NCT00589563|stage IV adult diffuse large cell lymphoma
528220|NCT00589563|stage IV adult diffuse mixed cell lymphoma
528221|NCT00589563|stage IV adult diffuse small cleaved cell lymphoma
528222|NCT00589563|stage IV adult immunoblastic large cell lymphoma
528223|NCT00589563|stage IV adult lymphoblastic lymphoma
528224|NCT00589563|stage IV adult T-cell leukemia/lymphoma
528225|NCT00589563|stage IV childhood anaplastic large cell lymphoma
528226|NCT00589563|stage IV childhood lymphoblastic lymphoma
528227|NCT00589563|stage IV childhood small noncleaved cell lymphoma
528228|NCT00589563|stage IV grade 1 follicular lymphoma
528229|NCT00589563|stage IV grade 2 follicular lymphoma
528230|NCT00589563|stage IV grade 3 follicular lymphoma
528231|NCT00589563|stage IV mantle cell lymphoma
528232|NCT00589563|stage IV marginal zone lymphoma
528233|NCT00589563|stage IV small lymphocytic lymphoma
528234|NCT00589563|adult acute myeloid leukemia in remission
528235|NCT00589563|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
528236|NCT00589563|adult acute myeloid leukemia with inv(16)(p13;q22)
528237|NCT00589563|adult acute myeloid leukemia with t(15;17)(q22;q12)
528238|NCT00589563|adult acute myeloid leukemia with t(16;16)(p13;q22)
528239|NCT00589563|adult acute myeloid leukemia with t(8;21)(q22;q22)
528240|NCT00589563|childhood acute myeloid leukemia in remission
528241|NCT00589563|recurrent adult acute myeloid leukemia
528242|NCT00589563|recurrent childhood acute myeloid leukemia
528243|NCT00589563|secondary acute myeloid leukemia
528244|NCT00589563|adult acute lymphoblastic leukemia in remission
528245|NCT00589563|childhood acute lymphoblastic leukemia in remission
528246|NCT00589563|recurrent adult acute lymphoblastic leukemia
528247|NCT00589563|recurrent childhood acute lymphoblastic leukemia
528248|NCT00589563|accelerated phase chronic myelogenous leukemia
528249|NCT00589563|chronic phase chronic myelogenous leukemia
528250|NCT00589563|refractory chronic lymphocytic leukemia
528251|NCT00589563|relapsing chronic myelogenous leukemia
528252|NCT00589563|stage I chronic lymphocytic leukemia
528253|NCT00589563|stage II chronic lymphocytic leukemia
528254|NCT00589563|stage III chronic lymphocytic leukemia
528255|NCT00589563|stage IV chronic lymphocytic leukemia
528256|NCT00589563|stage I multiple myeloma
528257|NCT00589563|stage II multiple myeloma
528258|NCT00589563|stage III multiple myeloma
528259|NCT00589563|childhood myelodysplastic syndromes
528260|NCT00589563|de novo myelodysplastic syndromes
528261|NCT00589563|myelodysplastic/myeloproliferative neoplasm, unclassifiable
528262|NCT00589563|previously treated myelodysplastic syndromes
528263|NCT00589563|secondary myelodysplastic syndromes
528264|NCT00589563|atypical chronic myeloid leukemia, BCR-ABL negative
528265|NCT00589563|chronic myelomonocytic leukemia
528266|NCT00589563|juvenile myelomonocytic leukemia
528267|NCT00589563|primary myelofibrosis
528268|NCT00589563|secondary myelofibrosis
528269|NCT00589550|clear cell renal cell carcinoma
528270|NCT00589550|stage III renal cell cancer
528271|NCT00589550|stage IV renal cell cancer
528272|NCT00589537|testicular seminoma
528273|NCT00589537|stage I malignant testicular germ cell tumor
528274|NCT00589524|blocked arteries
528275|NCT00589524|narrowing arteries
528276|NCT00589524|IVUS
528277|NCT00589524|CT
528278|NCT00589511|Bilateral severe to profound sensorineural hearing loss
528279|NCT00589459|undiagnosed diabetes
528280|NCT00589459|undiagnosed pre-diabetes
528281|NCT00589459|acute coronary syndrome
528282|NCT00589459|undiagnosed pre-diabetes and undiagnosed diabetes
528283|NCT00589446|Embryoscopy
528284|NCT00589446|recurrent miscarriage
528285|NCT00589446|missed abortion
528286|NCT00589446|Structural anomalies in recurrent miscarriage
528287|NCT00589446|Embryoscopically directed biopsy for karyotyping
528288|NCT00589420|adenocarcinoma of the prostate
528289|NCT00589420|recurrent prostate cancer
528290|NCT00589420|stage IV prostate cancer
528291|NCT00589394|pneumococcal vaccine
528292|NCT00589394|normal response
528293|NCT00589394|immunodeficiency
528294|NCT00589394|Healthy patients
528295|NCT00589394|Healthy Volunteers
528296|NCT00589381|unspecified adult solid tumor, protocol specific
528297|NCT00589381|recurrent adult Hodgkin lymphoma
528298|NCT00589381|recurrent adult T-cell leukemia/lymphoma
528299|NCT00589381|anaplastic large cell lymphoma
528300|NCT00589381|angioimmunoblastic T-cell lymphoma
528301|NCT00589381|recurrent cutaneous T-cell non-Hodgkin lymphoma
528302|NCT00589381|recurrent mycosis fungoides/Sezary syndrome
528303|NCT00589381|recurrent adult grade III lymphomatoid granulomatosis
528304|NCT00589381|adult nasal type extranodal NK/T-cell lymphoma
528305|NCT00589381|Waldenström macroglobulinemia
528306|NCT00589381|recurrent adult Burkitt lymphoma
528307|NCT00589381|recurrent adult diffuse large cell lymphoma
528308|NCT00589381|recurrent adult diffuse mixed cell lymphoma
528309|NCT00589381|recurrent adult diffuse small cleaved cell lymphoma
528310|NCT00589381|recurrent adult immunoblastic large cell lymphoma
528311|NCT00589381|recurrent adult lymphoblastic lymphoma
528312|NCT00589381|recurrent grade 1 follicular lymphoma
528313|NCT00589381|recurrent grade 2 follicular lymphoma
528314|NCT00589381|recurrent grade 3 follicular lymphoma
528315|NCT00589381|recurrent mantle cell lymphoma
528316|NCT00589381|recurrent marginal zone lymphoma
528317|NCT00589381|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
528318|NCT00589381|nodal marginal zone B-cell lymphoma
528319|NCT00589381|splenic marginal zone lymphoma
528320|NCT00589381|recurrent small lymphocytic lymphoma
528321|NCT00589368|Brain Infarction
528322|NCT00589368|pathology
528323|NCT00589368|physiopathology
528324|NCT00589368|psychology
528325|NCT00589368|rehabilitation
528326|NCT00589368|Fingers
528327|NCT00589368|Grasp
528328|NCT00589368|Functional Laterality
528329|NCT00589368|Hand
528330|NCT00589368|Strength
528331|NCT00589368|Neuronal Plasticity
528332|NCT00589368|Psychomotor Performance
528333|NCT00589368|Biomechanis
528334|NCT00589368|Touch
528335|NCT00589368|Weight-Bearing
528337|NCT00589355|endothelial dysfunction
528338|NCT00589355|glucose intolerance
528339|NCT00589329|Preterm birth
528340|NCT00589329|antibiotics
528341|NCT00589329|preterm labor
528342|NCT00589329|respiratory distress
528343|NCT00589329|pergnancy
528344|NCT00589303|Atrial Fibrillation
528345|NCT00589303|Heart Failure
528346|NCT00589303|AV Node ablation
528347|NCT00589303|Cardiac pacemaker
528348|NCT00589303|Antiarrhythmic drug
528349|NCT00589290|Histone deacetylase (HDAC) Inhibitors
528350|NCT00589290|Mediastinal Neoplasm
528351|NCT00589290|Thymic Carcinoma
528352|NCT00589290|Thymoma
528353|NCT00589277|Smoking
528354|NCT00589277|Tobacco
528355|NCT00589277|Message Framing
528356|NCT00589264|zinc
528357|NCT00589264|iron
528358|NCT00589264|child development
528359|NCT00589264|visual attention
528360|NCT00589264|Peru
528361|NCT00589251|penicillin allergy, penicillin skin test
528362|NCT00589238|stage II breast cancer
528363|NCT00589238|stage IIIA breast cancer
528364|NCT00589238|stage IIIB breast cancer
528365|NCT00589238|stage IIIC breast cancer
528366|NCT00589225|PH
528367|NCT00589225|PH type I
528368|NCT00589225|Primary Hyperoxaluria
528369|NCT00589225|Hyperoxaluria
528370|NCT00589225|Primary Oxalosis
528371|NCT00589225|PH type II
528372|NCT00589225|PH type III
528373|NCT00589225|Genetic testing for PH
528374|NCT00589225|Genetic testing for Primary Hyperoxaluria
528375|NCT00589225|Hereditary study for PH
528376|NCT00589225|Hereditary study for Primary Hyperoxaluria
528377|NCT00589212|GliaSite
528378|NCT00589212|Brain metastases
528379|NCT00589212|1-3 METS
528380|NCT00589186|stage IV squamous cell carcinoma of the nasopharynx
528381|NCT00589186|stage IV lymphoepithelioma of the nasopharynx
528382|NCT00589186|recurrent squamous cell carcinoma of the nasopharynx
528383|NCT00589186|recurrent lymphoepithelioma of the nasopharynx
528384|NCT00589173|Preventive Care
528385|NCT00589173|Health information technology
528386|NCT00589173|Personal health record
528387|NCT00589121|radiation fibrosis
528388|NCT00589121|radiation toxicity
528389|NCT00589121|lymphedema
528390|NCT00589121|musculoskeletal complications
528391|NCT00589121|stage I adult soft tissue sarcoma
528392|NCT00589121|stage II adult soft tissue sarcoma
528393|NCT00589121|adult extraskeletal chondrosarcoma
528394|NCT00589121|stage III adult soft tissue sarcoma
528395|NCT00589108|knee arthroplasty
528396|NCT00589082|AML
528397|NCT00589082|elderly
528398|NCT00589082|DaunoXome
528399|NCT00589056|stage IIIA non-small cell lung cancer
528400|NCT00589056|stage IIIB non-small cell lung cancer
528401|NCT00589056|recurrent non-small cell lung cancer
528402|NCT00589030|adult primary hepatocellular carcinoma
528403|NCT00589030|advanced adult primary liver cancer
528404|NCT00589030|localized unresectable adult primary liver cancer
528405|NCT00589030|recurrent adult primary liver cancer
528406|NCT00588978|c-reactive protein
528407|NCT00588978|obesity
528408|NCT00588978|women's cardiovascular health
528409|NCT00588965|QT interval
528410|NCT00588965|beta-blocker
528411|NCT00588965|exercise
528412|NCT00588965|electrocardiogram
528413|NCT00588965|repolarizaton
528414|NCT00588939|reflux
528415|NCT00588939|heartburn
528416|NCT00588926|Deep Brain Stimulation
528417|NCT00588926|Movement Disorders
528418|NCT00588926|Remifentanil
528419|NCT00588926|Sedation
528420|NCT00588926|Basal Ganglia electrical activity
528421|NCT00588913|recurrent renal cell cancer
528422|NCT00588913|stage IV renal cell cancer
528423|NCT00588913|clear cell renal cell carcinoma
528424|NCT00588913|lung metastases
528425|NCT00588900|stage IV colon cancer
528426|NCT00588900|stage IV rectal cancer
528427|NCT00588900|recurrent colon cancer
528428|NCT00588900|recurrent rectal cancer
528429|NCT00588874|male osteoporosis
528430|NCT00588874|male osteopenia
528431|NCT00588874|calciotropic hormones
528432|NCT00588848|Obstructive Sleep Apnea Hypopnea Syndrome
528433|NCT00588848|OSA
528434|NCT00588848|Postoperative
528435|NCT00588848|CPAP
528436|NCT00588835|pharmacokinetics
528437|NCT00588835|nausea and vomiting post chemotherapy
528438|NCT00588822|monoclonal gammopathy of undetermined significance
528439|NCT00588796|fibrinogen
528440|NCT00588796|burns
528441|NCT00588796|trauma
528442|NCT00588796|metabolism
528443|NCT00588757|IVC filters
528444|NCT00588757|Trauma
528445|NCT00588757|Dwell time
528446|NCT00588718|Necrotizing enterocolitis
528447|NCT00588718|Progressive necrotizing enterocolitis
528448|NCT00588718|Proteomics in blood
528449|NCT00588718|Genomics in blood
528450|NCT00588718|Multi-center
528451|NCT00588705|Daughters
528452|NCT00588705|Communication
528453|NCT00588705|genetic risk
528454|NCT00588705|Genetic Counseling
528455|NCT00588692|Heart Failure
528456|NCT00588692|Afterload Reduction
528457|NCT00588692|Sphygmocor
528458|NCT00588679|Prostate Cancer
528459|NCT00588679|Cancer
528460|NCT00588679|MRI
528461|NCT00588679|Magnetic Resonance Imaging
528462|NCT00588679|06-035
528463|NCT00588666|Myeloproliferative Disorder
528464|NCT00588666|urinary bladder
528465|NCT00588666|Cancer
528466|NCT00588666|ureter
528467|NCT00588666|renal pelvis
528468|NCT00588666|chemotherapy
528469|NCT00588653|Crohn's disease
528470|NCT00588653|capsule endoscopy
528471|NCT00588653|computed tomography enterography
528472|NCT00588653|colonoscopy
528473|NCT00588653|small bowel follow-through
528474|NCT00588640|Pain
528475|NCT00588640|HEENT cancer
528476|NCT00588627|Chronic cough
528477|NCT00588627|Post nasal drip
528478|NCT00588588|Ventilator associated pneumonia
528479|NCT00588588|Intensive Care
528480|NCT00588588|Antibiotics
528481|NCT00588588|Mortality
528482|NCT00588588|Length of stay
528483|NCT00588575|Barrett's Esophagus
528484|NCT00588562|PH
528485|NCT00588562|PH1
528486|NCT00588562|PH2
528487|NCT00588562|PH3
528488|NCT00588562|PHI
528489|NCT00588562|PHII
528490|NCT00588562|PHIII
528491|NCT00588562|PH NonI-NonII
528492|NCT00588562|Primary Hyperoxaluria
528493|NCT00588562|Primary Oxalosis
528494|NCT00588562|Hyperoxaluria
528495|NCT00588562|Oxalate
528496|NCT00588562|Cystinuria
528497|NCT00588562|Cystine
528498|NCT00588562|APRT
528499|NCT00588562|Adenine phosphoribosyl transferase deficiency
528500|NCT00588562|Dent disease
528501|NCT00588562|Dent
528502|NCT00588536|Langerhans Cell Histiocytosis
528503|NCT00588536|LCH
528504|NCT00588536|6-Thioguanine
528505|NCT00588536|6-TG
528506|NCT00588536|Methotrexate
528507|NCT00588536|MTX
528508|NCT00588536|94-132
528509|NCT00588523|Brain
528510|NCT00588523|CNS
528511|NCT00588523|TEMOZOLOMIDE
528512|NCT00588523|Busulfan
528513|NCT00588523|Thiotepa
528514|NCT00588510|Sarcoma
528515|NCT00588510|Bone
528516|NCT00588497|female sterilization, micro-insert, hysteroscopy
528517|NCT00588484|Carotid artery
528518|NCT00588484|Common carotid artery
528519|NCT00588484|Measurement
528520|NCT00588484|Ultrasound
528521|NCT00588458|Primary sclerosing cholangitis
528522|NCT00588458|Computed tomographic cholangiography
528523|NCT00588458|MELD score
528524|NCT00588458|Mayo risk score for PSC
528525|NCT00588445|Lung Cancer
528526|NCT00588445|Non-small cell lung cancer
528527|NCT00588445|Gefitnib
528528|NCT00588445|Cancer
528529|NCT00588445|NSCLC
528530|NCT00588445|bronchioloalveolar cancer
528531|NCT00588445|smoker
528532|NCT00588432|Stroke
528533|NCT00588432|Immobilization
528534|NCT00588432|Myofacial Pain
528535|NCT00588432|Hyperthyroid Myopathy
528536|NCT00588419|Breast Cancer
528537|NCT00588419|Cancer
528538|NCT00588419|Breast Sensation
528539|NCT00588419|Postmastectomy Breast Reconstruction
528540|NCT00588406|acute, emergency department
528541|NCT00588380|GLP-1
528542|NCT00588380|Insulin Secretion
528543|NCT00588367|Inflammation
528544|NCT00588367|Pancreas
528545|NCT00588367|Chronic pancreatitis
528546|NCT00588367|Alcoholic pancreatitis
528547|NCT00588367|Carcinoma, pancreatic ductal
528548|NCT00588367|Pancreatic neoplasms
528549|NCT00588354|herniated disk
528550|NCT00588354|radiculopathy
528551|NCT00588354|clonidine
528552|NCT00588354|epidural
528553|NCT00588354|steroid
528554|NCT00588354|corticosteroid
528555|NCT00588354|nucleus pulposus
528556|NCT00588354|transforaminal
528557|NCT00588341|Melanoma
528558|NCT00588341|Skin Cancer
528559|NCT00588341|Cancer
528560|NCT00588341|Temozolamide
528561|NCT00588341|TMZ
528562|NCT00588302|primary biliary cirrhosis
528563|NCT00588302|ursodeoxycholic acid
528564|NCT00588289|Pediatric Cancers
528565|NCT00588289|Oncology
528566|NCT00588276|measurable disease
528567|NCT00588276|locally advanced disease
528568|NCT00588263|Ashkenazi Jewish
528569|NCT00588263|Cancer
528570|NCT00588263|00-087
528571|NCT00588237|ovary
528572|NCT00588237|BEVACIZUMAB
528573|NCT00588237|CISPLATIN
528574|NCT00588237|TAXOL
528575|NCT00588224|stomach
528576|NCT00588224|accommodation
528577|NCT00588224|volume
528578|NCT00588224|SPECT
528579|NCT00588224|3 dimensional ultrasonography
528580|NCT00588224|healthy volunteers
528581|NCT00588211|Cancer related-Risks
528582|NCT00588211|Risk Perception
528583|NCT00588211|Survey
528584|NCT00588211|Focus Group
528585|NCT00588211|Smoking cessation
528586|NCT00588211|tobacco
528587|NCT00588198|histologically confirmed melanoma of any site
528588|NCT00588185|Progressive Prostate Cancer
528589|NCT00588185|[18F]-Fluoro-2-Deoxy-D-Glucose
528590|NCT00588185|[18F] Dihydro-Testosterone
528591|NCT00588185|Pet Imaging
528592|NCT00588185|Pet scan
528593|NCT00588185|00-095
528594|NCT00588172|Metformin
528595|NCT00588172|Type 2 diabetes
528596|NCT00588172|Oct1
528597|NCT00588159|Preoperative gabapentin
528598|NCT00588159|Acute pain
528599|NCT00588159|Post-thoracotomy pain
528600|NCT00588159|Epidural analgesia
528601|NCT00588146|anemia
528602|NCT00588146|HHT
528603|NCT00588146|Liver disease
528604|NCT00588146|Hypoxemia
528605|NCT00588146|Iron deficiency anemia
528606|NCT00588146|Liver disease with high cardiac output
528607|NCT00588146|Diffuse pulmonary AVMs with hypoxemia
528608|NCT00588133|antifibrinolytic, bleeding, heart
528609|NCT00588120|Hyperoxaluria
528610|NCT00588120|Unknown Hyperoxaluria
528611|NCT00588120|Enteric Hyperoxaluria
528612|NCT00588120|Oxaluric
528613|NCT00588120|High Oxalate
528614|NCT00588120|Oxalate
528615|NCT00588120|C13
528616|NCT00588120|Oxalate Diet
528617|NCT00588107|Cancer
528618|NCT00588107|Smoker
528619|NCT00588107|Web based intervention
528620|NCT00588107|Partnership for Health
528621|NCT00588107|Cancer Survivors
528622|NCT00588094|Lymphoma
528623|NCT00588094|ASCT
528624|NCT00588094|B-cell non-Hodgkin's lymphoma
528625|NCT00588094|Cancer
528626|NCT00588094|Second line therapy
528627|NCT00588094|ICE
528628|NCT00588094|Stem cell transplant
528629|NCT00588081|Vaginal Reconstruction
528630|NCT00588068|Adrenal Gland
528631|NCT00588068|No stage requirement
528632|NCT00588042|Angioplasty, Transluminal, Percutaneous Coronary
528633|NCT00588042|Coronary Artery Disease
528634|NCT00588042|Coronary Occlusion
528635|NCT00588029|Family members
528636|NCT00588016|Itraconazole
528637|NCT00588003|Breast
528638|NCT00588003|ANASTROZOLE
528639|NCT00587990|Chronic Ischemic Left Ventricular Dysfunction
528640|NCT00587977|Abdominal aortic aneurysm
528641|NCT00587964|Cancer
528642|NCT00587964|Brain Metastasis
528643|NCT00587964|Radiosurgery
528644|NCT00587964|Bladder cancer
528645|NCT00587964|Breast cancer
528646|NCT00587964|Cervical cancer
528647|NCT00587964|Colon cancer
528648|NCT00587964|HEENT cancer
528649|NCT00587964|Lung cancer
528650|NCT00587964|Melanoma
528651|NCT00587964|Pancreatic cancer
528652|NCT00587964|Prostate cancer
528653|NCT00587964|Rectal cancer
528654|NCT00587964|Sarcoma
528655|NCT00587964|Testicular cancer
528656|NCT00587964|Radiation
528657|NCT00587951|Clinical decision-making
528658|NCT00587951|Ictal SPECT
528659|NCT00587951|Epilepsy surgery
528660|NCT00587938|congestive heart failure
528661|NCT00587938|Brain naturietic peptide
528662|NCT00587938|hospital utilization cost
528663|NCT00587925|osteoporosis
528664|NCT00587912|Kaposi's Sarcoma AIDS Related
528665|NCT00587912|Kaposi's Sarcoma Classical
528666|NCT00587912|Non-Hodgkin's Lymphoma
528667|NCT00587912|HEMATOPOIETIC SYSTEM
528668|NCT00587912|Cancer
528669|NCT00587912|AIDS
528670|NCT00587899|Atrial Fibrillation
528671|NCT00587899|AF
528672|NCT00587899|A fib
528673|NCT00587899|cardiac ablation
528674|NCT00587899|modified maze procedure
528675|NCT00587886|Cancer
528676|NCT00587886|Endometrial cancer
528677|NCT00587886|Ovarian cancer
528678|NCT00587886|Corpus Uteri
528679|NCT00587886|Endometrium
528680|NCT00587873|Relapsed
528681|NCT00587873|Hodgkin's Disease
528682|NCT00587873|Methotrexate
528683|NCT00587873|6-Thioguanine
528684|NCT00587873|94-030
528685|NCT00587847|leukemia
528686|NCT00587821|Breast Cancer
528687|NCT00587821|Breast biopsy
528688|NCT00587808|Heart Failure
528689|NCT00587808|Heart Failure, Diastolic
528690|NCT00587808|Stroke Volume
528691|NCT00587769|Smoking
528692|NCT00587769|Smoking cessation
528693|NCT00587769|Bupropion
528694|NCT00587769|Varenicline
528695|NCT00587769|Tobacco use disorder
528696|NCT00587756|intraoperative ultrasonography
528697|NCT00587756|colorectal liver metastases
528698|NCT00587756|hepatectomy
528699|NCT00587756|portal vein embolization
528700|NCT00587756|Liver
528701|NCT00587730|heart disease
528702|NCT00587730|cardiac disease
528703|NCT00587730|chest pain
528704|NCT00587730|myocardial infarction
528705|NCT00587730|heart attack
528706|NCT00587691|Tovaxin
528707|NCT00587691|TCV
528708|NCT00587691|Autologous
528709|NCT00587678|PAD
528710|NCT00587665|Pain
528711|NCT00587652|Barrett Esophagus
528712|NCT00587652|Methylene blue
528713|NCT00587652|Chromoendoscopy
528714|NCT00587639|Adolescent
528715|NCT00587639|Depression
528716|NCT00587639|rTMS
528717|NCT00587626|neck pain
528718|NCT00587626|shoulder pain
528719|NCT00587626|cervical pain
528720|NCT00587626|chronic
528721|NCT00587626|recurrent
528722|NCT00586781|ankle replacement
528723|NCT00586781|end-stage arthritis of the ankle
528724|NCT00586781|degenerative ankle disease
528725|NCT00586755|Intensive Induction
528726|NCT00586755|High Dose Chemotherapy
528727|NCT00586755|Bone Marrow Transplantation
528728|NCT00586755|Mantle Cell Lymphoma
528729|NCT00586742|SLAP lesions
528730|NCT00586742|labral repair
528731|NCT00586742|bicepstenodesis
528732|NCT00586742|conservative treatment
528733|NCT00586729|Burn
528734|NCT00586729|Burn wound management
528735|NCT00586729|Burn graft
528736|NCT00587600|Barrett's Esophagus
528737|NCT00587600|High Grade Dysplasia
528738|NCT00587600|Photodynamic Therapy
528739|NCT00587574|chronic graft-versus-host disease
528740|NCT00587561|schizophrenia
528741|NCT00587561|social cognition
528742|NCT00587561|cognition
528743|NCT00587561|treatment
528744|NCT00587561|outcome
528745|NCT00587548|locate the ureters during abdominal surgery
528746|NCT00587535|hemochromatosis
528747|NCT00587535|liver cirrhosis
528748|NCT00587535|liver diseases
528749|NCT00587522|Gastroesophageal Reflux Disease (GERD)
528750|NCT00587522|NDO Full-thickness Plicator
528751|NCT00587522|Plicator
528752|NCT00587522|Endoluminal GERD Therapy
528753|NCT00587496|HSV DNA
528754|NCT00587496|volunteers
528755|NCT00587483|cardiopulmonary bypass
528756|NCT00587483|reperfusion ventricular fibrillation
528757|NCT00587483|ventricular fibrillation
528758|NCT00587483|amiodarone
528759|NCT00587483|lidocaine
528760|NCT00587483|cardiac surgery
528761|NCT00587470|valve, mitral, regurgitation
528762|NCT00587444|heparin management
528763|NCT00587431|Prostate
528764|NCT00587431|Cancer
528765|NCT00587431|Docetaxel
528766|NCT00587431|03-076
528767|NCT00587405|Watermelon Stomach
528768|NCT00587405|Cryotherapy
528769|NCT00587405|Argon Plasma Coagulation
528770|NCT00587392|Gastroesophageal Reflux Disease (GERD)
528771|NCT00587392|Long-term follow-up (LTFU)
528772|NCT00587392|Endoscopic Full-thickness Plication
528773|NCT00587392|Plicator
528774|NCT00587379|testing for Endothelial Dysfunction and coronary angiography
528775|NCT00587353|tobacco use cessation
528776|NCT00587353|radiation oncology
528777|NCT00587353|smoking
528778|NCT00587314|Photodynamic Therapy
528779|NCT00587314|Barrett's Esophagus
528780|NCT00587314|Early Esophageal Adenocarcinoma
528781|NCT00587301|Child Obesity
528782|NCT00587288|Cinquil™
528783|NCT00587288|Reslizumab
528784|NCT00587275|Gastroesophageal Reflux Disease
528785|NCT00587275|GERD
528786|NCT00587262|Cochlear
528787|NCT00587262|Hearing
528788|NCT00587262|High frequency hearing loss
528789|NCT00587249|Malaria, Plasmodium falciparium, Hepatitis B Core Antigen, Circumsporozoite Epitopes
528790|NCT00587236|Autofluorescence
528791|NCT00587236|Narrow Band
528792|NCT00587236|High definition white light
528793|NCT00587210|Crohn Disease
528794|NCT00587210|Inflammatory Bowel Disease
528795|NCT00587197|esophageal varices
528796|NCT00587197|portal hypertension
528797|NCT00587197|gastric varices
528798|NCT00587197|cost effectiveness
528799|NCT00587184|Barrett's Esophagus
528800|NCT00587184|Confocal Microscopy
528801|NCT00587171|Amblyopia
528802|NCT00587171|Vision Therapy
528803|NCT00587171|Patching
528804|NCT00587158|Paricalcitol
528805|NCT00587158|Parathyroid Hormone
528806|NCT00587158|Bone Alkaline Phosphatase
528807|NCT00587158|Chronic Kidney Disease
528808|NCT00587158|Glomerular Filtration Rate
528809|NCT00587158|Vitamin D Receptor
528810|NCT00587158|Interstitial Fibrosis and Tubular Atrophy
528811|NCT00587158|Zemplar®
528812|NCT00587145|Stomach Neoplasms
528813|NCT00587145|Secondary
528814|NCT00587145|Combination chemotherapy
528815|NCT00587145|S-1
528816|NCT00587145|Docetaxel
528817|NCT00587145|oxaliplatin
528818|NCT00587132|Diabetes mellitus
528819|NCT00587132|Peutz-Jeghers syndrome
528820|NCT00587119|Urso
528821|NCT00587119|Budesonide
528822|NCT00587119|PBC
528823|NCT00587119|overlap AIH
528824|NCT00587119|PBC with overlap features of autoimmune hepatitis
528825|NCT00587093|Newly diagnosed
528826|NCT00587093|CA 125
528827|NCT00587093|CT scan
528828|NCT00587093|01-048
528829|NCT00587067|FUDR
528830|NCT00587067|FLOXORUIDINE
528831|NCT00587067|DEXAMETHASONE
528832|NCT00587067|Hepatic
528833|NCT00587067|Cancer
528834|NCT00587067|02-120
528835|NCT00587054|leukemia
528836|NCT00587054|non-Hodgkins
528837|NCT00587054|lymphoblastic lymphoma
528838|NCT00587054|myelodysplastic syndrome
528839|NCT00587054|paroxysmal nocturnal hemoglobinuria (PNH)
528840|NCT00587054|cytoreductive regimen
528841|NCT00587054|allogeneic stem cell transplant
528842|NCT00587041|Synbiotic
528843|NCT00587041|Urine Oxalate
528844|NCT00587041|Probiotic
528845|NCT00587041|Kidney Stone
528846|NCT00587041|Gastric Bypass
528847|NCT00587041|Crohn's
528848|NCT00587041|Stone
528849|NCT00587041|Hyperoxaluria
528850|NCT00587041|Enteric Hyperoxaluria
528851|NCT00587028|Colonography
528852|NCT00587028|Colonoscopy
528853|NCT00587028|Virtual
528854|NCT00587028|Computed Tomographic Colonography
528855|NCT00587028|Large intestine
528856|NCT00587028|colon
528857|NCT00587002|Acute Coronary Syndrome
528858|NCT00587002|Women
528859|NCT00586989|Barrett's Esophagus
528860|NCT00586989|Esophageal Cancer
528861|NCT00586989|High Grade Dysplasia
528862|NCT00586976|pain, ropivacaine, infusion, sternotomy
528863|NCT00586963|Erosive Esophagitis
528864|NCT00586963|Reflux Esophagitis
528865|NCT00586963|GERD
528866|NCT00586950|Myocardial Free Fatty Acid metabolism
528867|NCT00586950|High risk patients
528868|NCT00586950|End-stage renal failure
528869|NCT00586950|Cardiovascular events
528870|NCT00586950|prognosis
528871|NCT00586937|Lung Cancer Survivors
528872|NCT00586911|Nonalcoholic Steatohepatitis
528873|NCT00586911|NASH
528874|NCT00586911|Betaine
528875|NCT00586898|Prostate
528876|NCT00586898|Cancer
528877|NCT00586898|Hormones
528878|NCT00586898|01-085
528879|NCT00586898|ANTIFUNGAL ANTIBIOTICS
528880|NCT00586898|ESTROGENS
528881|NCT00586898|LUPRON
528882|NCT00586898|TESTOSTERONE
528883|NCT00586898|ZOLADEX
528884|NCT00586885|Nonalcoholic Steatohepatitis
528885|NCT00586885|NASH
528886|NCT00586885|L-Alanine
528887|NCT00586872|Barrett's Esophagus
528888|NCT00586872|Early Esophageal Adenocarcinoma
528889|NCT00586872|Endoscopic Mucosal Resection
528890|NCT00586859|Gastroesophageal Reflux Disease (GERD)
528891|NCT00586859|NDO Full-thickness Plicator
528892|NCT00586859|Plicator
528893|NCT00586859|Endoluminal GERD Therapy
528894|NCT00586846|Cisplatin
528895|NCT00586846|Doxorubicin
528896|NCT00586846|Methotrexate
528897|NCT00586846|Osteosarcoma
528898|NCT00586846|03-074
528899|NCT00586833|Heart Failure
528900|NCT00586833|Heart Failure, Diastolic
528901|NCT00586833|Dyspnea, Paroxysmal
528902|NCT00586833|Edema, Cardiac
528903|NCT00586820|Coronary Atherosclerosis
528904|NCT00586820|Microvascular Dysfunction
528905|NCT00586820|Non-ST Elevation Myocardial Infarction
528906|NCT00586807|Ulcerative colitis
528907|NCT00586807|pediatrics
528908|NCT00586807|UC
528909|NCT00586807|protein metabolism
528910|NCT00586807|energy expenditure
528911|NCT00586794|Hypertension
528912|NCT00586794|Eisenmenger
528913|NCT00586703|Stem cell transplant
528914|NCT00586703|mismatched donor
528915|NCT00586703|NK infusion
528916|NCT00586690|Stem cell transplant
528917|NCT00586690|matched donor
528918|NCT00586690|NK infusion
528919|NCT00586677|child abuse
528920|NCT00586677|child neglect
528921|NCT00586677|PCIT
528922|NCT00586677|Lutzker
528923|NCT00586677|attachment
528924|NCT00586677|parenting
528925|NCT00586638|cognition
528926|NCT00586638|cognition disorders
528927|NCT00586638|executive function
528928|NCT00586638|cognitive control
528929|NCT00586638|attentional control
528930|NCT00586638|biomedical enhancement
528931|NCT00586638|cognitive enhancement
528932|NCT00586638|computerized
528933|NCT00586638|computer-based
528934|NCT00586638|video game
528935|NCT00586612|Conjugate vaccine
528936|NCT00586612|Persistence
528937|NCT00586612|Hib vaccine
528938|NCT00586612|Combination vaccine
528939|NCT00586612|Meningococcal vaccine
528940|NCT00586612|Safety
528941|NCT00586612|Preterm/full-term infants
528942|NCT00586612|Immunogenicity
528943|NCT00586599|IBD
528944|NCT00586599|CD
528945|NCT00586599|UC
528946|NCT00586599|Crohn's Disease
528947|NCT00586599|Ulcerative Colitis
528948|NCT00586599|Pediatric
528949|NCT00586599|inflammatory markers
528950|NCT00586573|ADHD
528951|NCT00586573|Namenda
528952|NCT00586560|solid tumors
528953|NCT00586547|Haploidentical
528954|NCT00586547|Stem Cell Transplant
528955|NCT00586547|Graft-Versus-Host disease
528956|NCT00586534|crack, cocaine, addiction treatment, virtual reality
528957|NCT00586521|Coagulation Disorders
528958|NCT00586495|Sorafenib
528959|NCT00586495|Nexavar
528960|NCT00586495|Metastatic RCC
528961|NCT00586495|Renal Cell Carcinoma
528962|NCT00586495|Unresectable RCC
528963|NCT00586482|cigarettes, surgery
528964|NCT00586482|Smokers scheduled for elective surgery
528965|NCT00586469|Influenza
528966|NCT00586443|solid tumors
528967|NCT00586443|avastin
528968|NCT00586443|Phase I
528969|NCT00586443|Phase 1
528970|NCT00586443|combination therapy
528971|NCT00586443|bevacizumab
528972|NCT00586443|RAD001
528973|NCT00586443|everolimus
528974|NCT00586443|pantitumumab
528975|NCT00586430|apolipoprotein E e4
528976|NCT00586430|Alzheimer's disease
528977|NCT00586430|somnolence
528978|NCT00586430|Early detection
528979|NCT00586417|angiogenesis
528980|NCT00586417|tumor angiogenesis
528981|NCT00586417|biomarkers
528982|NCT00586417|healthy volunteers
528983|NCT00586404|Barrett's Esophagus
528984|NCT00586404|Esophageal neoplasms
528985|NCT00586404|gastroesophageal reflux
528986|NCT00586404|gastrointestinal neoplasms
528987|NCT00586391|B cell Lymphoma
528988|NCT00586391|Cancer
528989|NCT00586391|Chronic Lymphocytic Leukemia
528990|NCT00586391|CD19 CHIMERIC RECEPTOR EXPRESSING T LYMPHOCYTES
528991|NCT00586391|Acute Lymphocytic Leukemia
528992|NCT00586365|complex elbow trauma
528993|NCT00586365|prevention
528994|NCT00586365|complication
528995|NCT00586365|naproxen
528996|NCT00586365|NSAIDS
528997|NCT00586352|Pediatric
528998|NCT00586352|Crohn's disease
528999|NCT00586352|Ulcerative colitis
529000|NCT00586339|HPV
529001|NCT00586339|Human papillomavirus (HPV) vaccine
529002|NCT00586339|Human Immunodeficiency Virus (HIV)
529003|NCT00586339|Cervical cancer
529004|NCT00586339|Papillomavirus
529005|NCT00586326|MammoSite
529006|NCT00586326|DCIS
529007|NCT00586313|EUS Biopsy for Non-alcoholic Fatty Liver Disease
529008|NCT00586300|Knee pain
529009|NCT00586287|Phenprocoumon
529010|NCT00586287|Dosing algorithm
529011|NCT00586287|loading dose
529012|NCT00586274|Stem Cell Transplant
529013|NCT00586274|Anemia
529014|NCT00586274|Fanconi
529015|NCT00586261|Kidney Failure, Chronic
529016|NCT00586261|Renal Insufficiency, Chronic
529017|NCT00586261|Proteinuria
529018|NCT00586261|Albuminuria
529019|NCT00586248|Peripheral nerve stimulator, cardiac pacemaker
529020|NCT00586235|Fusion
529021|NCT00586235|Ultrasound
529022|NCT00586235|Computed tomography
529023|NCT00586222|Omega-3 Fatty Acids
529024|NCT00586222|Pediatric Bipolar Disorder
529025|NCT00586222|Adolescent Bipolar Disorder
529026|NCT00586222|MRS
529027|NCT00586209|sickle cell disease
529028|NCT00586209|sickle cell anemia
529029|NCT00586209|L-glutamine
529030|NCT00586209|Sickle Cell Anemia (homozygous and heterozygous)
529031|NCT00586209|Sickle ß0-Thalassemia
529032|NCT00586196|Delirium
529033|NCT00586196|Postoperative confusion
529034|NCT00586196|Hip fracture
529035|NCT00586196|Long bone fracture
529036|NCT00586183|Ventricular Remodeling
529037|NCT00586170|nonunion
529038|NCT00586170|fracture
529039|NCT00586157|ADHD
529040|NCT00586157|Attention Deficit Hyperactivity Disorder
529041|NCT00586157|Daytrana
529042|NCT00586157|MTS Patch
529043|NCT00586157|Methylphenidate Transdermal System
529044|NCT00586131|end-stage renal disease
529045|NCT00586131|automated peritoneal dialysis
529046|NCT00586131|metabolic acidosis
529047|NCT00586131|nitrogen balances
529048|NCT00586118|Sedation
529049|NCT00586118|Volatile anaesthetic
529050|NCT00586118|Sevoflurane
529051|NCT00586118|Propofol
529052|NCT00586118|Recovery
529053|NCT00586105|Sorafenib
529054|NCT00586105|Nexavar
529055|NCT00586105|Metastatic RCC
529056|NCT00586105|Renal Cell Carcinoma
529057|NCT00586105|Unresectable RCC
529058|NCT00586092|Phase I
529059|NCT00586092|Phase 1
529060|NCT00586092|avastin
529061|NCT00586092|bevacizumab
529062|NCT00586092|ABT-510
529063|NCT00586092|solid tumors
529064|NCT00586092|angiogenesis
529065|NCT00586066|Bipolar disorder
529066|NCT00586066|Cognitive dysfunction
529067|NCT00586066|Memantine
529068|NCT00586066|NMDA antagonist
529069|NCT00586053|Colonic Polyps
529070|NCT00586053|Colon
529071|NCT00586053|Large Intestine
529072|NCT00586053|Cecum
529073|NCT00586053|Sigmoid
529074|NCT00586053|Rectum
529075|NCT00586053|Colonoscopy
529076|NCT00586053|Virtual Colonoscopy
529077|NCT00586053|CT Colonography
529078|NCT00586053|Computed Tomographic Colonography
529079|NCT00586053|Colonography
529080|NCT00586040|skin cancer
529081|NCT00586040|skin excision
529082|NCT00586040|laser
529083|NCT00586040|superficial sutures
529084|NCT00586040|wound healing
529085|NCT00586027|cardiac surgery
529086|NCT00586027|low cardiac output
529087|NCT00586027|natriuretic peptide B
529088|NCT00586027|mortality
529089|NCT00586027|morbidity
529090|NCT00586014|Multiple myeloma
529091|NCT00586014|Autologous Stem Cell Transplant
529092|NCT00586001|Anxiety
529093|NCT00586001|Emotional Disorders
529094|NCT00586001|Unified
529095|NCT00586001|Depression
529096|NCT00585962|proton beam radiation
529097|NCT00585910|ADHD
529098|NCT00585910|Attention Deficit Hyperactivity Disorder
529099|NCT00585910|Strattera
529100|NCT00585910|Concerta
529101|NCT00585910|Atomoxetine
529102|NCT00585910|OROS Methylphenidate
529103|NCT00585897|Diabetes
529104|NCT00585897|Obesity
529105|NCT00585884|Reconstruction, Silicone prostheses
529106|NCT00585871|ICD patients with 5 VTs per 3 month period
529107|NCT00585845|Cancer
529108|NCT00585845|Ovarian cancer
529109|NCT00585845|Pancreatic cancer
529110|NCT00585845|Non-small cell lung cancer
529111|NCT00585845|Mesothelioma
529112|NCT00585845|Mesothelin
529113|NCT00585845|Immunotherapy
529114|NCT00585832|hypertension
529115|NCT00585832|pre-hypertension
529116|NCT00585832|adolescents
529117|NCT00585832|diet
529118|NCT00585832|vascular function
529119|NCT00585806|Heart Failure with preserved ejection fraction
529120|NCT00585793|HIV/AIDS
529121|NCT00585767|Hydronephrosis
529122|NCT00585715|Cellulite
529123|NCT00585715|Nd:YAG Laser
529124|NCT00585702|Bipolar Disorder
529125|NCT00585702|Pregnancy
529126|NCT00585702|Infant Development
529127|NCT00585689|Locally advanced urothelial carcinoma of the bladder
529128|NCT00585650|palmoplantar psoriasis
529129|NCT00585650|etanercept
529130|NCT00585650|Enbrel
529131|NCT00585637|Vitamin D
529132|NCT00585637|Blacks
529133|NCT00585637|cancer
529134|NCT00585637|hypertension
529135|NCT00585624|Esophagectomy
529136|NCT00585624|Pancreaticoduodenectomy
529137|NCT00585624|Whipple
529138|NCT00585611|Heart Failure, Congestive
529139|NCT00585572|Normal Tissues/Brains
529140|NCT00585572|Alzheimer
529141|NCT00585572|Motor Neuron Disease
529142|NCT00585572|Dementia
529143|NCT00585572|Healthy Control Volunteers
529144|NCT00585572|Populations At Risk
529145|NCT00585572|MCI
529146|NCT00585559|Lipid
529147|NCT00585559|Peroxidation
529148|NCT00585559|N-Acetylcysteine
529149|NCT00585559|Acetaminophen
529150|NCT00585559|Vasospasm
529151|NCT00585546|heart failure
529152|NCT00585546|dilated cardiomyopathy
529153|NCT00585546|heart assist device
529154|NCT00585546|clenbuterol
529155|NCT00585546|adrenergic beta agonists
529156|NCT00585546|heart transplantation
529157|NCT00585507|hormone receptor positive breast cancer
529158|NCT00585507|Fulvestrant
529159|NCT00585481|Epidemiological Study
529160|NCT00585481|Incidence of severe Respiratory Syncytial Virus
529161|NCT00585481|Preterm Brazilian children
529162|NCT00585455|vascular endothelium
529163|NCT00585455|nitric oxide
529164|NCT00585455|depression
529165|NCT00585455|heart failure
529166|NCT00585455|vascular biology
529167|NCT00585416|Prostate Cancer
529168|NCT00585416|Hormone Refractory
529169|NCT00585416|Metastatic
529170|NCT00585364|Allergic Bronchopulmonary Aspergillosis
529171|NCT00585364|Aspergillus fumigatus
529172|NCT00585364|cytokine expression
529173|NCT00585338|facial telangiectasia,
529174|NCT00585338|leg vein telangiectasia
529175|NCT00585338|Port Wine Stain birthmarks
529176|NCT00585312|FAP
529177|NCT00585299|steatosis
529178|NCT00585299|fatty liver
529179|NCT00585299|insulin sensitivity
529180|NCT00585299|fatty liver (steatosis)
529181|NCT00585286|acne vulgaris
529182|NCT00585286|scarring
529183|NCT00585286|laser
529184|NCT00585260|asthma
529185|NCT00585260|bronchoprovocation challenge test
529186|NCT00585260|mannitol
529187|NCT00585260|methacholine
529188|NCT00585247|birthmarks
529189|NCT00585221|Gastrointestinal stromal tumors
529190|NCT00585221|Imatinib
529191|NCT00585221|Peginterferon α-2b
529192|NCT00585221|Immunotherapy
529193|NCT00585221|Targeted therapy
529194|NCT00585208|insomnia
529195|NCT00585208|sleep disturbance
529196|NCT00585208|bipolar disorder
529197|NCT00585195|Crizotinib
529198|NCT00585195|dose-finding
529199|NCT00585195|drug-drug interaction
529200|NCT00585195|ALK rearrangements
529201|NCT00585195|c-Met mutations or amplifications
529202|NCT00585195|c-Met dependent tumors
529203|NCT00585195|ROS1 rearrangements
529204|NCT00585195|c-Met exon 14 deletion
529205|NCT00585195|c-Met exon 14 skipping
529206|NCT00585195|c-Met exon 14 alterations
529207|NCT00585182|Obesity
529208|NCT00585182|venous thrombosis
529209|NCT00585182|Anticoagulants
529210|NCT00585169|Pathological Gambling
529211|NCT00585169|Compulsive Gambling
529212|NCT00585169|Gambling Addiction
529213|NCT00585169|Gambling
529214|NCT00585169|Treatment
529215|NCT00585169|Memantine
529216|NCT00585169|Pharmacology
529217|NCT00585156|Celebrex, Bone Ingrowth, Pain relief
529218|NCT00585143|Dyslipidemia
529219|NCT00585078|capecitabine
529220|NCT00585078|oxaliplatin
529221|NCT00585052|Ovarian Cancer
529222|NCT00585052|Epithelial Ovarian Cancer
529223|NCT00585052|Lovastatin
529224|NCT00585052|Paclitaxel
529225|NCT00585039|child
529226|NCT00585039|emergency department
529227|NCT00585026|Refractive error
529228|NCT00585026|Asthenopia
529229|NCT00585026|Presbyopia
529230|NCT00585026|Eyeglasses
529231|NCT00585026|Productivity
529232|NCT00585026|Visual comfort
529233|NCT00585026|Ergonomics
529234|NCT00585013|Inhaled Nitric Oxide (NO)
529235|NCT00585013|Anti-inflammatory
529236|NCT00585013|Anti-reperfusion agent
529237|NCT00584974|Depression
529238|NCT00584974|Mental Disorders
529239|NCT00584974|Mood Disorders
529240|NCT00584974|Depressive Disorder, Major
529241|NCT00584974|Dysthymic Disorder
529242|NCT00584961|Metabolic Syndrome, Bipolar Disorder and Cardiovascular Risk Factors
529243|NCT00584948|FXTAS, Fragile X Premutation
529244|NCT00584935|Pemphigoid
529245|NCT00584935|Blistering Diseases
529246|NCT00584935|Blindness
529247|NCT00584935|Autoimmune
529248|NCT00584935|Rituximab
529249|NCT00584922|Esophageal injury
529250|NCT00584922|Catheter Ablation
529251|NCT00584922|Atrial Fibrillation
529252|NCT00584896|heart disease
529253|NCT00584896|coronary artery disease
529254|NCT00584896|echocardiogram
529255|NCT00584896|ultrasound
529256|NCT00584896|angiogram
529257|NCT00584896|SPECT
529258|NCT00584896|chest pain
529259|NCT00584896|perfusion
529260|NCT00584883|Patients who have newly diagnosed brain tumors
529261|NCT00584844|Live Vaccine Strain (LVS), Bacterial Infections, Ulceroglandular, Oculoglandular
529262|NCT00584831|astigmatism
529263|NCT00584831|visual acuity
529264|NCT00584831|orientation
529265|NCT00584831|contact lenses
529266|NCT00584818|coronary artery disease
529267|NCT00584818|chest pain
529268|NCT00584818|healthy volunteers
529269|NCT00584818|SPECT
529270|NCT00584818|angiogram
529271|NCT00584818|ultrasound
529272|NCT00584818|echocardiogram
529273|NCT00584818|perfusion
529274|NCT00584805|EEE
529275|NCT00584792|Prostate Cancer
529276|NCT00584779|Gabapentin Pharmacokinetics, renal impairment
529277|NCT00584753|Breast cancer
529278|NCT00584740|Crohn's disease, moderate, severe, active, AIN457
529279|NCT00584727|astigmatism
529280|NCT00584727|visual acuity
529281|NCT00584727|fit
529282|NCT00584727|comfort
529283|NCT00584727|satisfaction
529284|NCT00584727|contact lens
529285|NCT00584714|ultrasound
529286|NCT00584714|perfusion
529287|NCT00584714|SPECT
529288|NCT00584714|coronary artery disease
529289|NCT00584714|chest pain
529290|NCT00584714|low probability
529291|NCT00584714|angiography
529292|NCT00584714|clinical outcomes
529293|NCT00584688|anorexia
529294|NCT00584688|nervosa
529295|NCT00584688|eating
529296|NCT00584688|disorder
529297|NCT00584688|study
529298|NCT00584688|research
529299|NCT00584688|clinical
529300|NCT00584688|trial
529301|NCT00584688|psychiatry
529302|NCT00584688|psychiatric
529303|NCT00584675|GERD
529304|NCT00584675|laryngopharyngeal reflux disease
529305|NCT00584662|Rhinitis
529306|NCT00584649|Inappropriate Sinus Tachycardia
529307|NCT00584649|Inappropiate Tachycardia
529308|NCT00584649|Sinus Tachycardia
529309|NCT00584649|Palpitations
529310|NCT00584649|Fast Heart rate
529311|NCT00584636|child
529312|NCT00584636|emergency department
529313|NCT00584623|dysphagia
529314|NCT00584623|videofluoroscopy
529315|NCT00584623|flexible endoscopic evaluation
529316|NCT00584610|Women's health
529317|NCT00584597|Radiation-Induced Mucositis
529318|NCT00584597|Head and neck cancer
529319|NCT00584597|TRAUMEEL
529320|NCT00584597|Mucositis
529321|NCT00584597|Radiation
529322|NCT00584597|Oral cancer
529323|NCT00584597|Inflammation of the mouth
529324|NCT00584597|Homeopathic Medication
529325|NCT00584584|Allergic rhinitis, adults, monoclonal antibody, interleukin-13.
529326|NCT00584558|Arrhythmia
529327|NCT00584558|Catheter Ablation
529328|NCT00584545|pharyngeal manometry
529329|NCT00584545|videofluoroscopy
529330|NCT00584532|Localized
529331|NCT00584532|Prostate
529332|NCT00584532|Cancer
529333|NCT00584519|Schizophrenia, Overweight, Cardiovascular Risk, Obesity
529334|NCT00584506|orbital fractures
529335|NCT00584467|GEM
529336|NCT00584467|Arteriosclerosis
529337|NCT00584467|biomarkers
529338|NCT00584467|Atherosclerosis
529339|NCT00584454|Coxiella burnetti, Bacterial Infections, Rickettsia, Hepatits, Endocarditis
529340|NCT00584428|Breast Cancer
529341|NCT00584428|Cancer Treatment
529342|NCT00584428|Breast Cancer Treatment
529343|NCT00584415|Catheter Ablation
529344|NCT00584415|Atrial Fibrillation
529345|NCT00584402|liver cancer
529346|NCT00584389|Obesity
529347|NCT00584389|Energy expenditure
529348|NCT00584389|Fatty acid
529349|NCT00584389|Triglyceride
529350|NCT00584376|Essential tremor
529351|NCT00584376|tremor
529352|NCT00584376|pregabalin
529353|NCT00584376|lyrica
529354|NCT00584350|coronary angiogram
529355|NCT00584350|percutaneous coronary intervention
529356|NCT00584337|tomography
529357|NCT00584337|coronary artery disease
529358|NCT00584337|Stress Test
529359|NCT00584337|Coronary CT Angiography
529360|NCT00584337|Diagnostic Accuracy
529361|NCT00584337|Non invasive testing
529362|NCT00584324|elective surgery
529363|NCT00584324|general anesthesia
529364|NCT00584324|implicit memory
529365|NCT00584298|Barostat
529366|NCT00584298|distention
529367|NCT00584298|IBS
529368|NCT00584298|irritable
529369|NCT00584298|bowel
529370|NCT00584298|syndrome
529371|NCT00584298|colorectal
529372|NCT00584298|sensation
529373|NCT00584298|modulation
529374|NCT00584298|reproducibility
529375|NCT00584272|cleft palate
529376|NCT00584272|suture materials
529377|NCT00584259|GERD
529378|NCT00584259|Gastro-Esophageal Disease
529379|NCT00584246|Restless legs syndrome
529380|NCT00584246|RLS
529381|NCT00584246|Pregabalin
529382|NCT00584246|Lyrica
529383|NCT00584233|breast cancer
529384|NCT00584220|Astigmatism
529385|NCT00584220|vision
529386|NCT00584220|comfort
529387|NCT00584220|satisfaction
529388|NCT00584220|contact lenses
529389|NCT00584207|uterine fibroids
529390|NCT00584194|Hemorrhagic Fever, Viral Infections, Neurologic diseases, Arbovirus Infections, RVF
529391|NCT00584168|UPPP
529392|NCT00584168|Dexamethasone
529393|NCT00584168|Uvulopalatopharyngoplasty
529394|NCT00584168|Pain Management
529395|NCT00584168|Increasing pain management in patients that have undergone UPPP surgery
529396|NCT00584155|Cisplatin Ototoxicity
529397|NCT00584155|Lactated Ringer's
529398|NCT00584155|Ear Cancer
529399|NCT00584155|Hearing loss
529400|NCT00584155|Hearing loss due to Cisplatin Ototoxicity
529401|NCT00584142|breast cancer
529402|NCT00584142|survivors
529403|NCT00584129|Cancer
529404|NCT00584129|Dysphagia
529405|NCT00584129|Radiation
529406|NCT00584129|Patients with H&N cancer who will be receiving chemoradiation
529407|NCT00584116|Aortic Valve Replacement
529408|NCT00584116|AVR
529409|NCT00584103|transradial amputation
529410|NCT00584103|prosthesis
529411|NCT00584103|prefabricated prosthesis
529412|NCT00584103|inexpensive
529413|NCT00584103|custom prosthesis
529414|NCT00584103|adult individuals who have undergone a transradial amputation
529415|NCT00584090|urinary incontinence
529416|NCT00584090|parkinson's disease
529417|NCT00584090|vesicare
529418|NCT00584090|solifenacin succinate
529419|NCT00584064|patent
529420|NCT00584064|foramen
529421|NCT00584064|ovale
529422|NCT00584064|PFO
529423|NCT00584051|Control group
529424|NCT00584038|contraceptive compliance
529425|NCT00584038|educational intervention
529426|NCT00584038|oral contraception
529427|NCT00584025|Parkinson's disease
529428|NCT00584025|dyskinesia
529429|NCT00584025|levetiracetam
529430|NCT00584025|keppra
529431|NCT00584012|Any cancer
529432|NCT00584012|Breast cancer
529433|NCT00584012|Lovastatin
529434|NCT00584012|Docetaxel
529435|NCT00583999|leptin, leptin receptors, adiponectin
529436|NCT00583986|top mounted
529437|NCT00583986|actuation indicator
529438|NCT00583986|Asthma
529439|NCT00583986|COPD
529440|NCT00583986|Chronic Obstructive Pulmonary Disease
529441|NCT00583960|swallowing problems
529442|NCT00583960|tracheal stenosis
529443|NCT00583947|Asthma
529444|NCT00583947|Respiratory Tract Diseases
529445|NCT00583934|esophageal cancer, head and neck cancer, dysplasia
529446|NCT00583921|Atrial Fibrillation
529447|NCT00583921|ICD
529448|NCT00583921|BiV ICD
529449|NCT00583921|CHF
529450|NCT00583921|Congestive Heart Failure
529451|NCT00583921|AF
529452|NCT00583908|astigmatism
529453|NCT00583908|orientation
529454|NCT00583908|visual acuity
529455|NCT00583908|contact lenses
529456|NCT00583895|dermatitis
529457|NCT00583895|atopic
529458|NCT00583895|ImCOOH
529459|NCT00583895|safety
529460|NCT00583895|tolerability
529461|NCT00583895|efficacy
529462|NCT00583895|pharmacokinetics
529463|NCT00583882|Central Venous Catheter
529464|NCT00583882|Guidewire
529465|NCT00583882|Burn
529466|NCT00583869|Post-operative Pain
529467|NCT00583869|Fracture Patients
529468|NCT00583869|Pregabalin
529469|NCT00583869|LYRICA
529470|NCT00583856|computer aided design
529471|NCT00583856|maxillofacial fracture
529472|NCT00583856|orbital design
529473|NCT00583843|Lumpectomy
529474|NCT00583843|Ultrasonography
529475|NCT00583843|Radiotherapy
529476|NCT00583830|Lung Cancer
529477|NCT00583804|Spinal Cord Injury
529478|NCT00583804|Tetraplegia
529479|NCT00583804|Functional Electrical Stimulation
529480|NCT00583804|Neuroprosthesis
529481|NCT00583791|muscular
529482|NCT00583791|ventricular
529483|NCT00583791|septal
529484|NCT00583791|defects
529485|NCT00583791|VSD
529486|NCT00583778|Asthma
529487|NCT00583778|Bronchodilators
529488|NCT00583778|Levalbuterol
529489|NCT00583778|Ipratropium
529490|NCT00583765|Kidney Failure, Acute
529491|NCT00583765|Hemodialysis
529492|NCT00583765|Hemofiltration
529493|NCT00583765|Anticoagulation
529494|NCT00583765|Citrate
529495|NCT00583752|prostate cancer
529496|NCT00583752|vaccine
529497|NCT00583752|immunotherapy
529498|NCT00583739|Fatigue
529499|NCT00583739|Yoga
529500|NCT00583739|Anxiety
529501|NCT00583739|Quality of Life
529502|NCT00583726|chemotherapy
529503|NCT00583726|exercise
529504|NCT00583726|diet
529505|NCT00583726|fruit
529506|NCT00583726|vegetables
529507|NCT00583726|low-fat
529508|NCT00583700|Breast Neoplasms
529509|NCT00583700|Radiotherapy
529510|NCT00583687|Arterial pulse contour cardiac output
529511|NCT00583687|Changing vascular tone
529512|NCT00583687|Tissue Oxymetry
529513|NCT00583687|Prediction of Fluid Responsiveness
529514|NCT00583674|Gastric Cancer
529515|NCT00583674|Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
529516|NCT00583674|AMG 386
529517|NCT00583674|Cisplatin
529518|NCT00583674|Capecitabine
529519|NCT00583661|Ventricular Assist Device
529520|NCT00583661|Pediatric Ventricular Assist Device
529521|NCT00583648|urinary tract infections
529522|NCT00583648|urine
529523|NCT00583648|urinalysis
529524|NCT00583648|urine protocols
529525|NCT00583648|urinalysis protocols
529526|NCT00583648|nursing protocols
529527|NCT00583648|Emergency Department
529528|NCT00583635|Preeclampsia
529529|NCT00583635|Prevention
529530|NCT00583635|Food Supplement
529531|NCT00583622|Ovarian Cancer
529532|NCT00583622|Epithelial Ovarian Cancer
529533|NCT00583622|Bevacizumab
529534|NCT00583622|Carboplatin
529535|NCT00583622|Gemcitabine
529536|NCT00583622|Docetaxel
529537|NCT00583622|Melphalan
529538|NCT00583596|patent ductus arteriosus (PDA)
529539|NCT00583557|Rheumatoid Arthritis
529540|NCT00583557|RA
529541|NCT00583544|Healthy
529542|NCT00583544|Healthy Volunteers
529543|NCT00583531|Antibiotic-refractory Pouchitis
529544|NCT00583531|Pouchitis
529545|NCT00583531|Ulcerative Colitis
529546|NCT00583505|membranous
529547|NCT00583505|ventricular
529548|NCT00583505|septal
529549|NCT00583505|defects
529550|NCT00583505|VSD
529551|NCT00583492|Prostatic Neoplasms
529552|NCT00583492|Prostate Cancer
529553|NCT00583492|Adenocarinomas
529554|NCT00583492|Tumors of the Prostate
529555|NCT00583492|Gene Therapy
529556|NCT00583492|IMRT
529557|NCT00583466|submucosal cushion
529558|NCT00583466|polypectomy
529559|NCT00583466|endoscopic mucosal resection
529560|NCT00583453|Tonsillectomy
529561|NCT00583453|Analgesia
529562|NCT00583453|Pain measurement
529563|NCT00583453|Celecoxib
529564|NCT00583440|12-step
529565|NCT00583440|mutual help
529566|NCT00583440|dual diagnosis
529567|NCT00583440|serious mental illness
529568|NCT00583401|PFO
529569|NCT00583401|stroke
529570|NCT00583388|cardiology
529571|NCT00583388|preventive medicine
529572|NCT00583388|cardiovascular physiology
529573|NCT00583388|healthy subjects
529574|NCT00583375|arthritis
529575|NCT00583375|ankle pain
529576|NCT00583375|foot pain
529577|NCT00583375|hindfoot fracture
529578|NCT00583375|ankle fracture
529579|NCT00583362|SLE
529580|NCT00583362|Lupus
529581|NCT00583349|Bladder Cancer
529582|NCT00583349|Chemotherapy
529583|NCT00583349|Bladder Neoplasms
529584|NCT00583310|Prehypertension
529585|NCT00583297|Arrhythmia
529586|NCT00583297|Heart Failure
529587|NCT00583297|T wave Alternans (TWA)
529588|NCT00583297|Implanted Cardioverter Defibrillator(ICD)
529589|NCT00583297|Biological Markers
529590|NCT00583297|Molecular Genetics
529591|NCT00583284|delayed enhancement computed tomography
529592|NCT00583284|ventricular tachycardia ablation
529593|NCT00583284|ventricular tachycardia
529594|NCT00583245|Osteoarthritis
529595|NCT00583245|Gait training
529596|NCT00583245|Knee pain
529597|NCT00583245|Rehabilitation
529598|NCT00583245|Physical Therapy
529599|NCT00583232|Pediatric
529600|NCT00583232|Crohn's disease
529601|NCT00583232|protein metabolism
529602|NCT00583232|energy metabolism
529603|NCT00583206|sepsis
529604|NCT00583206|atrophy
529605|NCT00583206|muscle
529606|NCT00583206|weakness
529607|NCT00583193|Post Traumatic Stress Disorder
529608|NCT00583193|Duloxetine
529609|NCT00583193|Antidepressants
529610|NCT00583180|Primary and/or secondary hyperalgesia
529611|NCT00583180|hypoesthesia
529612|NCT00583167|HIV
529613|NCT00583167|AIDS
529614|NCT00583167|CNS
529615|NCT00583167|brain
529616|NCT00583167|affects
529617|NCT00583154|constipation
529618|NCT00583154|laxative
529619|NCT00583128|IBS
529620|NCT00583128|Irritable Bowel Syndrome
529621|NCT00583102|Acute Myeloid Leukemia
529622|NCT00583102|AML
529623|NCT00583102|Lovastatin
529624|NCT00583102|Cytarabine
529625|NCT00583076|Pouchitis
529626|NCT00583076|Active Pouchitis
529627|NCT00583076|Safety and Efficacy of AST120
529628|NCT00583037|Neurally Adjusted Ventilatory Assist
529629|NCT00583037|Sleep quality
529630|NCT00583037|Adult
529631|NCT00583037|Critical Care
529632|NCT00583024|prostate cancer
529633|NCT00583024|vaccine
529634|NCT00583024|immunotherapy
529635|NCT00583011|Amniocentesis
529636|NCT00583011|Genetic amniocentesis
529637|NCT00583011|Fetal lung maturity
529638|NCT00583011|Pain control
529639|NCT00583011|Pregnancy
529640|NCT00583011|High risk pregnancy
529641|NCT00582998|Vacuum Assisted Closure (VAC)
529642|NCT00582998|Calcaneus Fracture
529643|NCT00582998|Pilon Fracture
529644|NCT00582998|Tibial Plateau Fracture
529645|NCT00582998|Open Reduction and Internal Fixation
529646|NCT00582985|Tracon
529647|NCT00582985|CD105
529648|NCT00582985|Anti CD105
529649|NCT00582985|TRC105
529650|NCT00582985|Phase 1
529651|NCT00582985|Cancer
529652|NCT00582985|Monoclonal antibody
529653|NCT00582985|Solid Tumor
529654|NCT00582972|Calcium Absorption
529655|NCT00582972|Fractional Calcium Absorption
529656|NCT00582972|Omeprazole
529657|NCT00582972|Stable Calcium Isotopes
529658|NCT00582972|Proton Pump Inhibitor
529659|NCT00582972|Intestinal Absorption of Calcium
529660|NCT00582959|radiology imaging
529661|NCT00582959|malignancy
529662|NCT00582959|undergoing radiation therapy
529663|NCT00582946|Hearing Loss, Eardrum, Transducer, Hearing in Noise
529664|NCT00582933|Cancer
529665|NCT00582933|Donors
529666|NCT00582933|Leukemia
529667|NCT00582933|Myelodysplastic Syndrome
529668|NCT00582933|Non-Hodgkin's Lymphoma
529669|NCT00582933|Lymphoma
529670|NCT00582933|AML
529671|NCT00582933|ALL
529672|NCT00582933|CML
529673|NCT00582933|Allogeneic marrow transplant
529674|NCT00582933|Bone marrow transplant
529675|NCT00582920|osseous lesions
529676|NCT00582920|breast cancer
529677|NCT00582920|metastatic breast cancer
529678|NCT00582907|FMF
529679|NCT00582907|IL1 Trap (Rilonacept)
529680|NCT00582907|Periodic fever syndromes
529681|NCT00582907|Autoinflammatory syndromes
529682|NCT00582907|Familial Mediterranean Fever
529683|NCT00582907|colchicine
529684|NCT00582894|Allogenic stem cell transplant
529685|NCT00582894|Hematologic diseases
529686|NCT00582881|Anti-RNP/Sm Autoantibody-Positive
529687|NCT00582881|MCTD
529688|NCT00582881|SLE
529689|NCT00582868|Subarachnoid hemorrhage
529690|NCT00582868|Cerebral Vasospasm
529691|NCT00582868|Cleaved-tau protein
529692|NCT00582868|Brain oxygen tension level
529693|NCT00582855|AQW051
529694|NCT00582855|Mild Alzheimer's disease
529695|NCT00582855|Amnestic Mild Cognitive Impairment
529696|NCT00582842|Early Stage
529697|NCT00582842|Localized
529698|NCT00582829|Colorectal
529699|NCT00582829|Cancer
529700|NCT00582829|Screening
529701|NCT00582829|Intervention
529702|NCT00582829|Family
529703|NCT00582816|Recurrent or Refractory Leukemia or Solid Tumors in Pediatrics
529704|NCT00582803|breast cancer
529705|NCT00582803|germline mutation
529706|NCT00582803|BRCA1
529707|NCT00582803|BRCA2
529708|NCT00582803|family history
529709|NCT00582803|genetic testing
529710|NCT00582803|unaffected women over age 25 who are at elevated risk for
529711|NCT00582803|breast cancer by virtue by a hereditary predisposition
529712|NCT00582790|Renal Cell Cancer
529713|NCT00582790|Metastatic
529714|NCT00582777|nocturnal blood pressure
529715|NCT00582777|chronic renal disease
529716|NCT00582777|hypertensive renal disease
529717|NCT00582777|African Americans
529718|NCT00582777|ABPM
529719|NCT00582764|Breast Lesion
529720|NCT00582764|Lesion
529721|NCT00582764|Breast
529722|NCT00582764|Cancer
529723|NCT00582764|05-091
529724|NCT00582751|Volumetric Analysis
529725|NCT00582751|Multiple Diseases
529726|NCT00582738|Fibrosis progression
529727|NCT00582738|recurrent hepatitis C
529728|NCT00582738|viral infection
529729|NCT00582738|liver transplant recipients
529730|NCT00582738|everolimus
529731|NCT00582738|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
529732|NCT00582725|DLBCL, Elderly
529733|NCT00582725|previously untreated DLBCL in the elderly
529734|NCT00582712|medullary thyroid cancer
529735|NCT00582712|lithium
529736|NCT00582699|Pancreatic Cancer
529737|NCT00582699|Pancreatic
529738|NCT00582686|Calcaneus Fractures
529739|NCT00582686|Iliac Crest Bone Grafting
529740|NCT00582686|Open Reduction & Internal Fixation
529741|NCT00582673|Parkinson's, L-dopa, dyskinesia
529742|NCT00582634|non small cell lung cancer
529743|NCT00582634|adjuvant
529744|NCT00582634|cisplatin
529745|NCT00582634|docetaxel
529746|NCT00582621|Genetic Studies
529747|NCT00582621|00-069
529748|NCT00582621|blood
529749|NCT00582621|saliva
529750|NCT00582621|buccal cell
529751|NCT00582582|Metastatic
529752|NCT00582582|Hormone Refractory
529753|NCT00582582|Prostate Cancer
529754|NCT00582569|Breast lesion
529755|NCT00582569|Spectroscopy
529756|NCT00582569|MRI
529757|NCT00582556|bone mineral density
529758|NCT00582543|Prostate Cancer
529759|NCT00582543|Prostate
529760|NCT00582530|Prostate Cancer
529761|NCT00582530|Early Prostate Cancer
529762|NCT00582530|Radical Prostatectomy
529763|NCT00582517|Orthopaedic Trauma
529764|NCT00582517|Knee Dislocation
529765|NCT00582517|Compass Hinge External Fixator
529766|NCT00582517|External Brace
529767|NCT00582504|Encephalitis,VEE
529768|NCT00582491|Modafinil
529769|NCT00582491|Sleep
529770|NCT00582491|Cognition
529771|NCT00582491|Cocaine Dependence
529772|NCT00582478|Breast cancer
529773|NCT00582478|Quality of Life
529774|NCT00582452|HNPCC
529775|NCT00582452|prophylactic colectomy
529776|NCT00582439|Orthopaedic Trauma Fractures
529777|NCT00582439|Orthopaedic Trauma Non-unions
529778|NCT00582439|Reamer-Irrigator-Aspirator (RIA)
529779|NCT00582439|Bone Graft
529780|NCT00582426|Colorectal cancer
529781|NCT00582426|diarrhea
529782|NCT00582426|drug therapy
529783|NCT00582426|octreotide
529784|NCT00582426|fluorouracil
529785|NCT00582426|irinotecan
529786|NCT00582426|capecitabine
529787|NCT00582426|prevention
529788|NCT00582413|Head and Neck Cancer
529789|NCT00582400|livers, hepatocellular carcinoma (HCC)
529790|NCT00582374|Periodontal Disease
529791|NCT00582374|Preterm Birth
529792|NCT00582374|Low Birth Weight
529793|NCT00582374|Pregnancy
529794|NCT00582361|Open Fractures
529795|NCT00582361|Vacuum Assisted Closure (VAC) device
529796|NCT00582361|Irrigation and Debridement
529797|NCT00582348|Lung Cancer
529798|NCT00582348|Survivor
529799|NCT00582348|Lung
529800|NCT00582335|Colorectal cancer
529801|NCT00582335|Genetic testing
529802|NCT00582335|Genetic mutations
529803|NCT00582322|Breast Cancer
529804|NCT00582322|Ovarian Cancer
529805|NCT00582322|Family History
529806|NCT00582322|Genetic Studies
529807|NCT00582309|Glycemic Control
529808|NCT00582309|Intravenous Infusion
529809|NCT00582309|Standard Insulin infusion algorithm
529810|NCT00582309|Infusion
529811|NCT00582309|Critically Ill
529812|NCT00582296|Lynch syndrome
529813|NCT00582296|04-144
529814|NCT00582270|non-hodkin's lymphoma
529815|NCT00582270|follicular
529816|NCT00582270|non-follicular
529817|NCT00582270|infectious disease
529818|NCT00582257|Gastric Cancer
529819|NCT00582257|Stomach Cancer
529820|NCT00582257|05-118
529821|NCT00582244|Menopausal symptoms
529822|NCT00582244|Quality of Life
529823|NCT00582244|Breast cancer
529824|NCT00582244|Multicenter trial
529825|NCT00582231|Penile injection therapy
529826|NCT00582231|Erectile dysfunction
529827|NCT00582231|Radical pelvic surgery
529828|NCT00582231|Penile Injection Anxiety
529829|NCT00582218|HIV/AIDS
529830|NCT00582218|Access to care
529831|NCT00582205|Ovarian Cancer
529832|NCT00582205|Fallopian Tube Cancer
529833|NCT00582205|Primary Peritoneal Carcinoma
529834|NCT00582205|Uterine Cancer
529835|NCT00582205|Intraperitoneal Chemotherapy
529836|NCT00582205|IP Chemotherapy
529837|NCT00582205|Gynecologic Cancer
529838|NCT00582205|Women's Cancer
529839|NCT00582205|Cisplatin
529840|NCT00582205|Paclitaxel
529841|NCT00582205|Recurrent Platinum Sensitive Ovarian Cancer
529842|NCT00582192|Phase I trial
529843|NCT00582192|Oncologists' Communication Styles
529844|NCT00582179|Draining Hematoma
529845|NCT00582179|Vacuum Assisted Closure (VAC)
529846|NCT00582179|Negative Pressure Wound Therapy (NPWT)
529847|NCT00582179|Draining Hematoma following orthopaedic surgery
529848|NCT00582166|Zevalin, High Tumor Burden Indolent Non-Hodgkin's Lymphoma
529849|NCT00582140|Prostate
529850|NCT00582140|Cancer
529851|NCT00582140|Stage D0
529852|NCT00582140|Non-Metastatic
529853|NCT00582140|Rising PSA
529854|NCT00582127|senile
529855|NCT00582127|dementia
529856|NCT00582114|Hemodialysis
529857|NCT00582114|Hypertension
529858|NCT00582114|Left ventricular hypertrophy
529859|NCT00582101|HIV
529860|NCT00582101|prevention
529861|NCT00582101|families
529862|NCT00582101|Latinos
529863|NCT00582101|communication
529864|NCT00582101|sexuality
529865|NCT00582101|monitoring
529866|NCT00582101|health promotion
529867|NCT00582101|HIV Prevention
529868|NCT00582101|HIV Seronegativity
529869|NCT00582088|Encephalitis, Viral Infections, Neurologic diseases, Alphavirus Infections, VEE
529870|NCT00582075|Cancer
529871|NCT00582075|Brain metastases
529872|NCT00582075|Gamma Knife Radiosurgery
529873|NCT00582075|Temodar
529874|NCT00582075|Temozolomide
529875|NCT00582062|Gastric Cancer
529876|NCT00582062|Pancreatic cancer
529877|NCT00582049|Retinoblastoma
529878|NCT00582049|Sporadic heritable retinoblastoma
529879|NCT00582049|Paternal exposures
529880|NCT00582036|Hyperglycemia
529881|NCT00582036|Hematopoietic stem cell transplantation
529882|NCT00582036|Bone marrow transplant
529883|NCT00582036|High blood sugar
529884|NCT00582023|HIV
529885|NCT00582023|coping
529886|NCT00582023|emotion
529887|NCT00582023|affect
529888|NCT00582023|HIV infection
529889|NCT00582023|Complimentary therapies
529890|NCT00582010|ischemia-reperfusion
529891|NCT00582010|nitric oxide
529892|NCT00582010|inflammation
529893|NCT00582010|cell-death
529894|NCT00582010|Liver-function post transplantation
529895|NCT00581997|Pulmonary fibrosis, systemic sclerosis
529896|NCT00581984|breast cancer
529897|NCT00581984|breast reconstruction
529898|NCT00581984|silicone implants
529899|NCT00581971|Radiosensitization
529900|NCT00581971|COX-2 inhibitor
529901|NCT00581971|Celecoxib
529902|NCT00581971|Head and Neck Cancer
529903|NCT00581971|Chemoradiation
529904|NCT00581958|total body irradiation
529905|NCT00581958|Cancer
529906|NCT00581958|Hematopoietic System
529907|NCT00581932|clozapine, schizophrenia
529908|NCT00581919|previously treated multiple myeloma
529909|NCT00581906|Head and Neck Cancer
529910|NCT00581906|Head Cancer
529911|NCT00581906|Neck Cancer
529912|NCT00581906|Dynamic Contrast Enhanced MRI
529913|NCT00581906|Magnetic Resonance Spectroscopy (MRS)
529914|NCT00581906|Diffusion Weighted MRI (DW-MRI)
529915|NCT00581906|06-007
529916|NCT00581893|epilepsy
529917|NCT00581893|cognitive impairment
529918|NCT00581893|driving simulation
529919|NCT00581893|cross-over study
529920|NCT00581880|end stage
529921|NCT00581880|Terminally Ill
529922|NCT00581854|untreated mantle cell lymphoma
529923|NCT00581841|Healthy adult normals
529924|NCT00581828|Calcium Absorption
529925|NCT00581828|Intestinal Absorption of Calcium
529926|NCT00581828|Fractional Calcium Absorption
529927|NCT00581828|Stable Calcium Isotopes
529928|NCT00581828|Hypovitaminosis D
529929|NCT00581828|Vitamin D
529930|NCT00581828|Bone Mineral Density
529931|NCT00581828|Physical Function
529932|NCT00581802|CD4-Positive T-Lymphocytes
529933|NCT00581802|Treatment Naive
529934|NCT00581802|Latent HIV Infections
529935|NCT00581789|non small cell lung cancer
529936|NCT00581789|sunitinib
529937|NCT00581789|erlotinib
529938|NCT00581789|phase 1
529939|NCT00581776|Untreated Mantle Cell Lymphoma
529940|NCT00581750|Biopsy
529941|NCT00581750|Breast
529942|NCT00581750|01-135
529943|NCT00581724|breast cancer
529944|NCT00581724|Colorectal cancer
529945|NCT00581724|Prostate cancer
529946|NCT00581724|Head and Neck cancer
529947|NCT00581724|Lung cancer
529948|NCT00581724|cancer survivors
529949|NCT00581724|07-068
529950|NCT00581724|quality of life
529951|NCT00581724|Pain in cancer survivors
529952|NCT00581711|Electronic Health Record
529953|NCT00581711|Clinical Decision Support
529954|NCT00581711|Otitis Media
529955|NCT00581698|Melanoma
529956|NCT00581698|Negative regional lymph nodes
529957|NCT00581698|Primary melanomas Clark III and Breslow thickness > 1 mm, or Clark
529958|NCT00581698|IV-V and any Breslow thickness, and clinically negative regional nodes
529959|NCT00581685|Chronic pain
529960|NCT00581685|Preemptive analgesia
529961|NCT00581685|Pregabalin
529962|NCT00581685|Celecoxib
529963|NCT00581685|Hip Arthroplasty
529964|NCT00581685|Osteoarthritis
529965|NCT00581672|Anxiety
529966|NCT00581672|Black men
529967|NCT00581672|Prostate Cancer
529968|NCT00581672|07-125
529969|NCT00581633|saline
529970|NCT00581633|sodium
529971|NCT00581633|kidney
529972|NCT00581633|tachycardia
529973|NCT00581620|pneumococcus conjugated vaccine
529974|NCT00581607|Sarcoidosis
529975|NCT00581594|Pelvic organ prolapse
529976|NCT00581594|Posterior wall defects
529977|NCT00581594|Graft-augmented repair
529978|NCT00581594|Posterior colporrhaphy
529979|NCT00581581|neonatal encephalopathy
529980|NCT00581581|therapeutic hypothermia
529981|NCT00581581|head cooling
529982|NCT00581581|neonatal asphyxia
529983|NCT00581568|Skin cooling during laser treatment
529984|NCT00581555|Psoriasis
529985|NCT00581529|breast
529986|NCT00581516|Prostate Cancer
529987|NCT00581516|PCA3
529988|NCT00581503|early detection of lung and pleural cancer
529989|NCT00581503|early detection of prostate cancer
529990|NCT00581490|Premature pubarche
529991|NCT00581490|Adrenal hyperandrogenism
529992|NCT00581490|Metabolic syndrome
529993|NCT00581477|autonomic nervous system diseases
529994|NCT00581477|blood pressure
529995|NCT00581477|congenital
529996|NCT00581477|orthostasis
529997|NCT00581477|catecholamines
529998|NCT00581464|Smoking cessation
529999|NCT00581464|Tobacco dependence
530000|NCT00581464|Mindfulness
530001|NCT00581464|fMRI
530002|NCT00581464|Craving
530003|NCT00581438|Approach Haemophilia A and B
530004|NCT00581425|BCC
530005|NCT00581425|Basal Cell Carcinoma
530006|NCT00581425|Intron-A
530007|NCT00581425|Aldara
530008|NCT00581425|Basal Cell Carcinoma excluding scalp and face
530009|NCT00581412|Pelvic organ prolapse
530010|NCT00581412|Composite biologic/synthetic graft
530011|NCT00581412|Abdominal sacrocolpopexy
530012|NCT00581399|Open heart surgery
530013|NCT00581399|Cardiopulmonary Bypass
530014|NCT00581399|Coronary Artery Bypass Grafting
530015|NCT00581399|Chest Tube
530016|NCT00581399|Valve Replacement
530017|NCT00581399|Valve Repair
530018|NCT00581386|Endotracheal Intubation
530019|NCT00581386|Supraglottic Airway
530020|NCT00581373|water
530021|NCT00581373|orthostatic hypotension
530022|NCT00581373|blood pressure
530023|NCT00581360|Adenoid cystic carcinoma
530024|NCT00581360|bortezomib
530025|NCT00581360|doxorubicin
530026|NCT00581334|Pelvic organ prolapse
530027|NCT00581334|Robotic-assisted laparoscopic sacrocolpopexy
530028|NCT00581334|Post hysterectomy prolapse
530029|NCT00581334|Symptomatic post hysterectomy prolapse of stage II or greater
530030|NCT00581321|water
530031|NCT00581321|blood pressure
530032|NCT00581321|vascular resistance
530033|NCT00581321|cardiac transplantation
530034|NCT00581308|atrial septal defect, septal occluder, HELEX
530035|NCT00581295|internal bleeding
530036|NCT00581295|changes in tissue perfusion
530037|NCT00581282|Cocaine abstinence
530038|NCT00581282|PET scan
530039|NCT00581256|left sided
530040|NCT00581243|Safety,Tolerability, Schizophrenia
530041|NCT00581230|Endotracheal Intubation
530042|NCT00581230|Rapid Airway Management Positioner
530043|NCT00581217|Burn injury
530044|NCT00581217|Skin graft
530045|NCT00581217|Donor site dressing
530046|NCT00581217|Outcomes
530047|NCT00581217|Infection rate
530048|NCT00581217|Healing time
530049|NCT00581217|Cosmetic Result
530050|NCT00581217|Pain
530051|NCT00581217|Burn injured patients requiring skin grafting
530052|NCT00581204|trauma situations
530053|NCT00581204|Lower Body Negative Pressure (LBNP)
530054|NCT00581191|SAD
530055|NCT00581191|Healthy
530056|NCT00581178|Ureteral Stent
530057|NCT00581178|Kidney Stones
530058|NCT00581152|TBX3
530059|NCT00581126|BENEFIX
530060|NCT00581126|Hemophilia B
530061|NCT00581113|whole brain radiotherapy
530062|NCT00581113|neural stem cell
530063|NCT00581113|brain metastases
530064|NCT00581113|radiosurgery
530065|NCT00581100|Nail Psoriasis
530066|NCT00581100|Plaque Psoriasis
530067|NCT00581087|Hypertension, pulmonary
530068|NCT00581087|DHEA
530069|NCT00581087|six-minute walk test
530070|NCT00581087|pulmonary arterial pressure
530071|NCT00581074|obesity
530072|NCT00581074|diet
530073|NCT00581074|weight loss
530074|NCT00581074|metabolic syndrome
530075|NCT00581061|Incontinence
530076|NCT00581061|Robotic Prostatectomy
530077|NCT00581048|Asthma
530078|NCT00581048|Allergy
530079|NCT00581048|Atopy
530080|NCT00581048|Vitamin E
530081|NCT00581048|GSTP1
530082|NCT00581048|Oxidative stress
530083|NCT00581035|Meningococcal disease
530084|NCT00581035|pneumococcal disease
530085|NCT00581035|meningitis
530086|NCT00581022|postural tachycardia syndrome
530087|NCT00581022|sleep
530088|NCT00581022|insomnia
530089|NCT00581009|Sleep deprivation
530090|NCT00581009|antidepressant
530091|NCT00581009|depression
530092|NCT00581009|chronobiological
530093|NCT00580996|water
530094|NCT00580996|orthostatic hypotension
530095|NCT00580996|blood pressure
530096|NCT00580983|Head and Neck cancer
530097|NCT00580970|prostate cancer
530098|NCT00580970|radiation therapy
530099|NCT00580970|lovastatin
530100|NCT00580970|rectal injury
530101|NCT00580957|Obesity
530102|NCT00580957|Hypertension
530228|NCT00580333|ER negative
530103|NCT00580957|Autonomic Nervous System
530104|NCT00580944|Port wine stain
530105|NCT00580944|progressive malformation of human skin
530106|NCT00580931|nutraceutical, dementia, cognition, HDAC inhibitor
530107|NCT00580918|Mild Traumatic Brain Injury
530108|NCT00580918|fMRI
530109|NCT00580905|Adenosine
530110|NCT00580905|Cytokines
530111|NCT00580905|Inflammation
530112|NCT00580905|VEGF
530113|NCT00580879|Anorectal sphincter laceration
530114|NCT00580879|Pelvic floor dysfunction
530115|NCT00580879|Sphincter tear
530116|NCT00580866|Elbow
530117|NCT00580866|Upper Extremity Fractures
530118|NCT00580866|Distal Humerus
530119|NCT00580866|Elbow Injuries
530120|NCT00580866|Dislocations
530121|NCT00580866|Peri-articular Elbow Injuries
530122|NCT00580853|smoking lapse behavior
530123|NCT00580853|smoking cessation
530124|NCT00580853|varenicline
530125|NCT00580853|bupropion
530126|NCT00580853|medication effect on smoking lapse behavior
530127|NCT00580840|Rheumatoid Arthritis
530128|NCT00580840|Joint Disease
530129|NCT00580840|Arthritis
530130|NCT00580840|Certolizumab pegol
530131|NCT00580840|Cimzia
530132|NCT00580814|Brookhaven
530133|NCT00580814|ADHD
530134|NCT00580814|Dopamine
530135|NCT00580814|methylphenidate
530136|NCT00580814|PET
530137|NCT00580801|Hepatitis C
530138|NCT00580801|Telaprevir
530139|NCT00580801|Pegylated-interferon-alfa-2a
530140|NCT00580801|Pegasys
530141|NCT00580801|Ribavirin
530142|NCT00580801|Copegus
530143|NCT00580788|Endocrine System Diseases
530144|NCT00580788|MusculoSkeletal System Diseases
530145|NCT00580788|Hormones
530146|NCT00580788|Malignancy
530147|NCT00580788|Postmenopausal Women
530148|NCT00580788|Bone metabolism
530149|NCT00580775|Menopause
530150|NCT00580775|Hormone Replacement Therapy
530151|NCT00580775|Sudden Cardiac Death
530152|NCT00580749|Pancreatitis
530153|NCT00580749|enteral feeding
530154|NCT00580749|distal jejunal feeding
530155|NCT00580749|naso gastric feeding
530156|NCT00580749|pancreatic rest
530157|NCT00580736|sebaceous hyperplasia
530158|NCT00580723|acne
530159|NCT00580723|rosacea
530160|NCT00580723|acne rosacea
530161|NCT00580723|papulopustular rosacea
530162|NCT00580723|erythema
530163|NCT00580723|telangiectasia
530164|NCT00580723|flushing
530165|NCT00580710|type 1 diabetes
530166|NCT00580710|hypoglycemia
530167|NCT00580710|magnetic resonance imaging
530168|NCT00580697|Lower urinary tract symptoms
530169|NCT00580697|Gynecologic malignancy
530170|NCT00580697|Urinary incontinence
530171|NCT00580697|Fecal incontinence
530172|NCT00580697|Frequency
530173|NCT00580697|Voiding dysfunction
530174|NCT00580697|Sexual dysfunction
530175|NCT00580684|pneumococcus conjugated vaccine 7 valent
530176|NCT00580671|Adolescent Marijuana Abuse
530177|NCT00580658|Dystonia
530178|NCT00580645|alcohol
530179|NCT00580645|smoking cessation
530180|NCT00580645|varenicline
530181|NCT00580645|bupropion
530182|NCT00580645|smoking cessation medications
530183|NCT00580619|Chronic fatigue syndrome
530184|NCT00580619|Postural tachycardia syndrome
530185|NCT00580619|Autonomic nervous system
530186|NCT00580606|Food Allergy
530187|NCT00580606|Peanut Allergy
530188|NCT00580606|Sublingual Immunotherapy
530189|NCT00580593|amyotrophic lateral sclerosis
530190|NCT00580593|ALS
530191|NCT00580593|nocturnal noninvasive positive pressure ventilation
530192|NCT00580593|NIPPV
530193|NCT00580593|forced vital capacity
530194|NCT00580593|FVC
530195|NCT00580567|Impulsivity
530196|NCT00580567|Gambling
530197|NCT00580567|Pathological Gamblers
530198|NCT00580567|Problem Gamblers
530199|NCT00580567|Non-Pathological Gamblers
530200|NCT00580567|Risk-taking
530201|NCT00580567|Inhibition
530202|NCT00580567|Gambling Severity
530203|NCT00580515|Cancer
530204|NCT00580515|Randomized Controlled Trial
530205|NCT00580515|Family Therapy intervention
530206|NCT00580502|Obesity, 50 lbs overweight
530207|NCT00580489|helicopter
530208|NCT00580489|aeromedical
530209|NCT00580489|pain relief
530210|NCT00580489|analgesia
530211|NCT00580489|fentanyl
530212|NCT00580489|morphine
530213|NCT00580489|adverse events
530214|NCT00580476|Breast Cancer
530215|NCT00580476|Prostate Cancer
530216|NCT00580463|central nervous system (CNS) tumor
530217|NCT00580463|tissue collection
530218|NCT00580385|BONE
530219|NCT00580359|Stomach Neoplasms
530220|NCT00580359|Secondary
530221|NCT00580359|Combination chemotherapy
530222|NCT00580359|S-1
530223|NCT00580359|Capecitabine
530224|NCT00580346|Aspiration pneumonia
530225|NCT00580346|Implanted laryngeal stimulator
530226|NCT00580346|Vocal cord closure
530227|NCT00580346|Modified barium swallow
530229|NCT00580333|PR negative
530230|NCT00580333|HER-2 negative
530231|NCT00580320|melanoma
530232|NCT00580320|soft tissue sarcoma
530233|NCT00580320|APUD tumor
530234|NCT00580320|dacarbazine
530235|NCT00580320|bortezomib
530236|NCT00580320|velcade
530237|NCT00580307|Headache
530238|NCT00580307|Rhinogenic
530239|NCT00580307|Nose
530240|NCT00580307|Nasal septum
530241|NCT00580307|Deviated septum
530242|NCT00580307|Surgery
530243|NCT00580307|Septoplasty
530244|NCT00580307|Turbinoplasty
530245|NCT00580307|Contact point
530246|NCT00580307|HIT-6
530247|NCT00580294|Sciatica
530248|NCT00580294|Diabetic Neuropathies
530249|NCT00580294|Complex Regional Pain Syndromes
530250|NCT00580294|Low Back Pain
530251|NCT00580294|Neck Pain
530252|NCT00580294|Headache
530253|NCT00580294|Back Pain
530254|NCT00580294|Arthritis
530255|NCT00580294|Brachial Plexus Injury (stinger/burner)
530256|NCT00580294|Chronic Pain
530257|NCT00580294|Contractures
530258|NCT00580294|Diabetes
530259|NCT00580294|Fibromyalgia
530260|NCT00580294|Foot Pain
530261|NCT00580294|Fracture
530262|NCT00580294|Hip
530263|NCT00580294|Herpes Zoster (shingles)
530264|NCT00580294|Migraine
530265|NCT00580294|Neuropathic Pain
530266|NCT00580294|Osteoarthritis
530267|NCT00580294|Osteoporosis
530268|NCT00580294|Rheumatoid Arthritis
530269|NCT00580294|Scoliosis
530270|NCT00580294|Nerve pain
530271|NCT00580294|Opana
530272|NCT00580294|Opioid
530273|NCT00580294|Opioid Rotation
530274|NCT00580294|Oxymorphone
530275|NCT00580294|Morphine
530276|NCT00580294|neuropathic
530277|NCT00580294|oxycodone
530278|NCT00580281|Gastric cancer
530279|NCT00580281|Leukemia
530280|NCT00580281|Chronic Myelogenous Leukemia
530281|NCT00580281|Imatinib
530282|NCT00580281|Gleevec
530283|NCT00580255|CHF
530284|NCT00580255|CRT
530285|NCT00580255|Atrial Arrhythmias
530286|NCT00580255|Ventricular Arrhythmias
530287|NCT00580255|BioZ
530288|NCT00580255|Optivol
530289|NCT00580242|Myelodysplasia
530290|NCT00580229|Rituxan
530291|NCT00580229|Rituximab
530292|NCT00580216|stroke
530293|NCT00580216|systemic thromboembolic events
530294|NCT00580203|HEENT cancers
530295|NCT00580203|larynx
530296|NCT00580203|thyroid
530297|NCT00580203|sarcoma
530298|NCT00580203|specimen analysis
530299|NCT00580177|Inguinal hernia
530300|NCT00580177|Randomized controlled trial
530301|NCT00580177|Surgery
530302|NCT00580177|Complications
530303|NCT00580177|Surgical mesh
530304|NCT00580151|Pain not controled by morphine
530305|NCT00580151|Anxiety not controled by lorazepam
530306|NCT00580138|Deglutition Disorders
530307|NCT00580138|Evaluation
530308|NCT00580138|Real-time internet
530309|NCT00580112|Breast Neoplasms
530310|NCT00580112|Trabectedin
530311|NCT00580112|Yondelis
530312|NCT00580099|premature infant, body composition, total energy expenditure
530313|NCT00580099|inflammatory growth mediators
530314|NCT00580086|Breast cancer
530315|NCT00580086|MR spectroscopy
530316|NCT00580086|Neoadjuvant chemotherapy
530317|NCT00580060|AJCC
530318|NCT00580060|stage
530319|NCT00580060|IIB
530320|NCT00580060|IIC
530321|NCT00580060|III
530322|NCT00580060|IV
530323|NCT00580060|Melanoma
530324|NCT00580060|HLA-A2+
530325|NCT00580060|Vaccine
530326|NCT00580047|bone density
530327|NCT00580047|osteopenia
530328|NCT00580047|transplant
530329|NCT00580047|zoledronic acid
530330|NCT00580047|alendronate
530331|NCT00580034|Allogeneic Stem Cell Transplantation, Campath, HLA-Matched
530332|NCT00580021|Ashkenazi ancestry
530333|NCT00580021|mutations in BRCA1 or BRCA2
530334|NCT00580021|Breast Cancer
530335|NCT00580021|Pancreatic Cancer
530336|NCT00580008|tomography
530337|NCT00580008|coronary artery disease
530338|NCT00580008|coronary artery bypass grafting
530339|NCT00580008|vein graft
530340|NCT00579982|Mood disorder
530341|NCT00579943|very low birth weight infant
530342|NCT00579943|cerebral autoregulation
530343|NCT00579943|intraventricular hemorrhage
530344|NCT00579943|carbon dioxide
530345|NCT00579943|cerebral blood flow velocity
530346|NCT00579943|ultrasonography, Doppler, transcranial
530347|NCT00579943|cerebrovascular circulation
530348|NCT00579930|Bone
530349|NCT00579930|Soft Tissue
530350|NCT00579917|Survivor
530351|NCT00579917|Behavioral Intervention
530352|NCT00579917|Bone Marrow
530353|NCT00579917|Stem Cell Transplantation
530354|NCT00579904|PCOS
530355|NCT00579904|polycystic ovary syndrome
530356|NCT00579904|insulin resistance
530357|NCT00579904|fish oil
530358|NCT00579904|walnut-oil
530359|NCT00579904|walnuts
530360|NCT00579904|almonds
530361|NCT00579904|monounsaturated fats
530362|NCT00579904|polyunsaturated fats
530363|NCT00579904|MUFA
530364|NCT00579904|PUFA
530365|NCT00579891|colorectal cancer
530366|NCT00579891|tissue collection
530367|NCT00579865|Quality of Life
530368|NCT00579852|Lung
530369|NCT00579839|PreTerm Birth
530370|NCT00579839|PreTerm Neonate
530371|NCT00579839|High risk pregnancy
530372|NCT00579839|Preterm Baby
530373|NCT00579839|Premature Baby
530374|NCT00579839|Cord Clamping
530375|NCT00579839|Milking the cord
530376|NCT00579813|obesity
530377|NCT00579813|inflammation
530378|NCT00579813|diabetes
530379|NCT00579800|Vibrant-DE
530380|NCT00579800|IDEAL
530381|NCT00579800|MRI
530382|NCT00579800|Breast
530383|NCT00579800|07-091
530384|NCT00579787|cervical cancer
530385|NCT00579787|quality of life assessment
530386|NCT00579787|behavioral
530387|NCT00579774|Aging
530388|NCT00579774|oxidative stress
530389|NCT00579774|glycoxidative stress
530390|NCT00579774|glycation
530391|NCT00579774|inflammation
530392|NCT00579774|nutrition
530393|NCT00579774|low AGE intake
530394|NCT00579774|dietary AGEs
530395|NCT00579761|Endocarditis
530396|NCT00579761|neurological deficit
530397|NCT00579748|OCT imaging
530398|NCT00579748|Barrett's esophagus
530399|NCT00579735|Breast cancer
530400|NCT00579709|Thymus Transplantation
530401|NCT00579709|DiGeorge Anomaly
530402|NCT00579709|DiGeorge Syndrome
530403|NCT00579709|Athymia
530404|NCT00579709|Low T cell numbers
530405|NCT00579709|Immunoreconstitution
530406|NCT00579709|Immunodeficiency
530407|NCT00579709|Complete DiGeorge
530408|NCT00579709|Typical DiGeorge
530409|NCT00579709|Atypical DiGeorge
530410|NCT00579709|Complete DiGeorge Anomaly
530411|NCT00579696|Multiple Diseases
530412|NCT00579696|Queens
530413|NCT00579683|non-small cell lung cancer
530414|NCT00579683|NSCLC
530415|NCT00579683|metastatic disease
530416|NCT00579683|resistent disease
530417|NCT00579683|RNA analysis
530418|NCT00579683|04-103
530419|NCT00579670|Ziprasidone in patients with schizophrenia
530420|NCT00579657|parameters of metabolic syndrome
530421|NCT00579631|survivors
530422|NCT00579631|adolescent
530423|NCT00579631|pediatric
530424|NCT00579618|non-cancer affected volunteers
530425|NCT00579618|aged 60 years or older
530426|NCT00579605|Breastfeeding
530427|NCT00579605|Self-efficacy
530428|NCT00579605|Motivational Interviewing
530429|NCT00579579|Bowel function
530430|NCT00579579|Bladder function
530431|NCT00579579|Sexual function
530432|NCT00579579|Quality of life
530433|NCT00579566|Biochemical Determinants
530434|NCT00579566|Molecular Determinants
530435|NCT00579553|Pre Term
530436|NCT00579553|Pre Term Birth
530437|NCT00579553|Premature Birth
530438|NCT00579553|Premature baby
530439|NCT00579553|High risk pregnancy
530440|NCT00579553|Progesterone
530441|NCT00579553|IM Progesterone
530442|NCT00579553|Vaginal Progesterone
530443|NCT00579527|DiGeorge Anomaly
530444|NCT00579527|Thymus Transplantation
530445|NCT00579527|DiGeorge Syndrome
530446|NCT00579527|Athymia
530447|NCT00579527|Parathyroid Transplantation
530448|NCT00579527|Hypocalcemia
530449|NCT00579527|Hypoparathyroidism
530450|NCT00579527|Low T cell numbers
530451|NCT00579527|Immunoreconstitution
530452|NCT00579527|Immunodeficiency
530453|NCT00579527|Complete DiGeorge Anomaly
530454|NCT00579527|Complete Atypical DiGeorge Anomaly
530455|NCT00579527|Complete DiGeorge Syndrome
530456|NCT00579527|Complete Atypical DiGeorge Syndrome
530457|NCT00579501|Myxoid
530458|NCT00579501|Liposarcoma
530459|NCT00579501|Trabectedin
530460|NCT00579501|Dexamethasone
530461|NCT00579475|mifepristone
530462|NCT00579475|leiomyomas
530463|NCT00579475|breast epithelial cell proliferation
530464|NCT00579462|Stage III or IV Lung Cancer
530465|NCT00579449|child abuse
530466|NCT00579449|child neglect
530467|NCT00579436|inflammation
530468|NCT00579436|obesity
530469|NCT00579436|diabetes
530470|NCT00579423|prostate
530471|NCT00579423|cancer
530472|NCT00579423|vaccine
530473|NCT00579410|gastric acid
530474|NCT00579410|esophageal reflux
530475|NCT00579410|peptic ulcer
530476|NCT00579410|heartburn
530477|NCT00579397|Markers of Inflammation
530478|NCT00579397|acute graft versus host disease
530479|NCT00579397|predicting aGVHD
530480|NCT00579384|Photosensitive epilepsy
530481|NCT00579384|Reflex epilepsy
530482|NCT00579384|Epilepsy
530483|NCT00579384|JNJ-26489112
530484|NCT00579371|islet transplantation
530485|NCT00579371|type 1 diabetes mellitus
530486|NCT00579371|steroid-free immunosuppression
530487|NCT00579371|rabbit anti-thymocyte globulin
530488|NCT00579358|Congenital heart defects
530489|NCT00579332|PSA
530490|NCT00579332|biochemical failure
530491|NCT00579319|breast cancer
530492|NCT00579306|hypertension
530493|NCT00579306|stroke
530494|NCT00579306|cerebrovascular accident
530495|NCT00579293|adult survivor of childhood cancer
530496|NCT00579293|computer assisted screening of survivors (CASS)
530497|NCT00579280|Randomized
530498|NCT00579280|Double-Blind
530499|NCT00579280|Placebo-Controlled
530500|NCT00579280|Quetiapine
530501|NCT00579280|DivalproexSodiumER
530502|NCT00579280|Bipolar
530503|NCT00579280|Anxiety
530504|NCT00579280|Panic
530505|NCT00579280|GAD
530506|NCT00579267|MINI-KID
530507|NCT00579267|structured diagnostic interview
530508|NCT00579267|reliability and validity
530509|NCT00579267|K-SADS
530510|NCT00579267|Sheehan Disability Scale
530511|NCT00579254|Efficacy,safety & tolerability of Caduet In Patients With Cardiovascular Risk Factors
530512|NCT00579228|Diabetes
530513|NCT00579228|Vascular risk
530514|NCT00579228|Inflammation
530515|NCT00579215|Cancer
530516|NCT00579215|Enhanced Care
530517|NCT00579215|Decision-Making
530518|NCT00579215|Advance Lung Cancer
530519|NCT00579215|Questionaires
530520|NCT00579215|Stage III Lung Cancer
530521|NCT00579215|Stage IV Lung Cancer
530522|NCT00579202|Dialyzer
530523|NCT00579189|ear tubes
530524|NCT00579189|ear drainage
530525|NCT00579189|ear infection
530526|NCT00579189|ear drops
530527|NCT00579163|Blood
530528|NCT00579163|Salvia
530529|NCT00579163|Tissue
530530|NCT00579150|Birth Defects
530531|NCT00579150|High Risk Pregnancy
530532|NCT00579150|Type 2 Diabetes
530533|NCT00579137|Severe Combined Immunodeficiency Disease
530534|NCT00579137|Severe Primary Immunodeficiency Disorder
530535|NCT00579137|Undefined T cell Deficiency Disorder
530536|NCT00579137|Wiskott-Aldrick Syndrome
530537|NCT00579137|Allogeneic stem cell transplant
530538|NCT00579137|Fludarabine
530539|NCT00579137|monoclonal antibodies
530540|NCT00579124|Blood and Marrow Transplant
530541|NCT00579124|T cell Depletion
530542|NCT00579124|Unrelated
530543|NCT00579124|Related
530544|NCT00579124|Donor
530545|NCT00579111|Myelodysplastic and Myeloproliferative Disorders
530546|NCT00579111|Acute Myelogenous Leukemia
530547|NCT00579111|Acute Lymphoblastic Leukemia
530548|NCT00579111|Chronic Myelogenous Leukemia
530549|NCT00579111|Multiple Myeloma
530550|NCT00579111|Plasma Cell dyscrasia
530551|NCT00579111|Lymphoproliferative disorders
530552|NCT00579111|Hematologic Diseases
530553|NCT00579111|Fludarabine
530554|NCT00579111|Busulfan
530555|NCT00579111|Campath
530556|NCT00579111|Alemtuzumab
530557|NCT00579111|allogeneic stem cell transplant
530558|NCT00579098|Atrial Fibrillation
530559|NCT00579098|Arrhythmia
530560|NCT00579098|Pulmonary Vein Isolation
530561|NCT00579098|Left atrial catheter ablation
530562|NCT00579098|Inflammation
530563|NCT00579098|Endothelial dysfunction
530564|NCT00579072|Prostate
530565|NCT00579072|cognitive effects
530566|NCT00579072|06-084
530567|NCT00579046|Anemia
530568|NCT00579046|Chronic obstructive Pulmonary Disease
530569|NCT00579046|Erythropoietin
530570|NCT00579046|6-minute walk test
530571|NCT00579033|somatosensory
530572|NCT00579033|cortex
530573|NCT00579033|neuroimaging
530574|NCT00579033|tactile
530575|NCT00579033|cortical plasticity
530576|NCT00579033|dystonia
530577|NCT00579020|cornea
530578|NCT00579020|inflammation
530579|NCT00579020|blepharitis
530580|NCT00579020|lid infection
530581|NCT00579007|Prophylactic Mastectomy
530582|NCT00579007|Prophylactic Oophorectomy
530583|NCT00578994|Unicompartmental Knee
530584|NCT00578994|Partial Knee
530585|NCT00578994|Knee arthroplasty
530586|NCT00578981|Osteoporosis, age-related
530587|NCT00578981|Osteoporosis, Postmenopausal
530588|NCT00578981|Bone Loss
530589|NCT00578981|Low Bone Density
530590|NCT00578968|COPD
530591|NCT00578968|Tiotropium
530592|NCT00578968|Spiriva
530593|NCT00578955|Blepharoconjunctivitis, Ophthalmology
530594|NCT00578942|Allogeneic Stem Cell Transplantation, Campath, HLA-Matched
530595|NCT00578929|allergic rhinitis
530596|NCT00578929|allergies
530597|NCT00578929|seasonal allergies
530598|NCT00578903|Severe Aplastic Anemia
530599|NCT00578903|Severe
530600|NCT00578890|diabetic foot
530601|NCT00578890|osteomyelitis
530602|NCT00578877|Contraception
530603|NCT00578877|SILCS Diaphragm
530604|NCT00578877|Contraceptive Gel
530605|NCT00578864|Neuroblastoma
530606|NCT00578864|Etoposide
530607|NCT00578864|Cisplatin
530608|NCT00578864|Adriamycin
530609|NCT00578864|Cyclophosphamide
530610|NCT00578864|Cytoxan
530611|NCT00578851|Hip Arthroplasty
530612|NCT00578851|Hip Arthritis
530613|NCT00578825|Severe acute respiratory syndrome
530614|NCT00578799|ulcerative colitis
530615|NCT00578773|ear tubes
530616|NCT00578773|ear infection
530617|NCT00578773|ear drops
530618|NCT00578773|ear tube surgery
530619|NCT00578773|acute otitis media
530620|NCT00578760|hearing loss
530621|NCT00578760|ototoxicity
530622|NCT00578760|cisplatin
530623|NCT00578747|Breast Cancer
530624|NCT00578747|Breast Neoplasms
530625|NCT00578747|Targeted Radiotherapy
530626|NCT00578747|Mastectomy
530627|NCT00578747|Seroma
530628|NCT00578721|Colorectal cancer
530629|NCT00578721|aspirin
530630|NCT00578708|membranous
530631|NCT00578708|ventricular
530632|NCT00578708|septal
530633|NCT00578708|defect
530634|NCT00578708|VSD
530635|NCT00578695|Hyponatremia
530636|NCT00578695|Serum Sodium
530637|NCT00578695|Fluid Overload
530638|NCT00578695|Heart Failure
530639|NCT00578695|Acute Heart Failure
530640|NCT00578695|Vasopressin Antagonist
530641|NCT00578669|Smoking Cessation
530642|NCT00578669|Tobacco Use Cessation
530643|NCT00578669|Antidepressants
530644|NCT00578656|Food Allergy
530645|NCT00578656|Milk Allergy
530646|NCT00578643|Stem Cell Transplant
530647|NCT00578643|Chronic Granulomatous Disease
530648|NCT00578643|Fludarabine
530649|NCT00578643|Busulfan
530650|NCT00578643|Cyclophosphamide
530651|NCT00578630|pediatric tumors
530652|NCT00578630|genetic test development
530653|NCT00578630|All Pediatric patients with a histologically proven tumor.
530654|NCT00578617|Atrial fibrillation
530655|NCT00578617|Left Atrial Ablation
530656|NCT00578617|Pulmonary Vein Isolation
530657|NCT00578617|Catheter Ablation
530658|NCT00578617|Antiarrhythmic Drug Therapy
530659|NCT00578591|Graft Versus Host Disease
530660|NCT00578591|GVHD
530661|NCT00578591|allogeneic hematopoietic transplant
530662|NCT00578591|AHT
530663|NCT00578591|posttransplant
530664|NCT00578591|Rituximab
530665|NCT00578578|Omega3 fatty acids
530666|NCT00578578|hsCRP
530667|NCT00578578|CAD
530668|NCT00578565|Rheumatoid Arthritis
530669|NCT00578565|Interstitial Pneumonia
530670|NCT00578565|Rheumatology
530671|NCT00578565|Rituximab
530672|NCT00578552|tobacco
530673|NCT00578552|smoking
530674|NCT00578552|gabapentin
530675|NCT00578552|abstinence
530676|NCT00578539|Stem Cell Transplantation
530677|NCT00578526|urothelial cancer
530678|NCT00578526|targeted therapy
530679|NCT00578526|antiangiogenesis therapy
530680|NCT00578526|SU011248
530681|NCT00578526|clinical trial
530682|NCT00578500|chemotherapy, female, fertility preservation, gonadotoxicity
530683|NCT00578500|oophorectomy, in vitro maturation, ovarian cryopreservation,
530684|NCT00578500|oocyte cryopreservation, ovarian transplantation
530685|NCT00578474|Acute otitis media
530686|NCT00578474|Tympanostomy tubes
530687|NCT00578461|Stem Cell Transplant
530688|NCT00578461|myeloproliferative disease
530689|NCT00578461|myelodsyplastic disease
530690|NCT00578461|Leukemia
530691|NCT00578461|Cancer
530692|NCT00578461|Lymphoma
530693|NCT00578461|Lymphoma, Hodgkin
530694|NCT00578461|Lymphoma, non-Hodgkin
530695|NCT00578435|ERYTHROPOIESIS
530696|NCT00578435|Genetic Disorders
530697|NCT00578435|Sickle Cell Anemia
530698|NCT00578435|Thalassemia
530699|NCT00578435|Diamond Blackfan Anemia
530700|NCT00578422|PAD
530701|NCT00578422|Peripheral Artery Disease
530702|NCT00578422|IVUS
530703|NCT00578422|Plaque
530704|NCT00578409|castration resistant prostate cancer
530705|NCT00578409|progressive castrate metastatic prostate cancer
530706|NCT00578396|Grapes and colon cancer prevention
530707|NCT00578383|Depression
530708|NCT00578383|Major depression
530709|NCT00578383|Bipolar Disorder
530710|NCT00578383|Bipolar depression
530711|NCT00578383|LFMS
530712|NCT00578383|low field magnetic stimulation
530713|NCT00578383|mood disorders
530714|NCT00578383|affective disorders
530715|NCT00578370|Ciclosporin
530716|NCT00578370|Plaque type psoriasis
530717|NCT00578370|Psoriasis plaque test
530718|NCT00578370|Sonography
530719|NCT00578370|Cyclosporin
530720|NCT00578370|Psoriasis
530721|NCT00578357|problem gambling
530722|NCT00578357|personalized feedback
530723|NCT00578357|gambling addiction
530724|NCT00578344|Sickle Cell Disease
530725|NCT00578344|SCD
530726|NCT00578344|Hemoglobin SS
530727|NCT00578344|Hemoglobin SC
530728|NCT00578344|Hemoglobin Sb0/+
530729|NCT00578344|HLA genotype
530730|NCT00578344|Severe anemia
530731|NCT00578344|Transfusion therapy
530732|NCT00578331|rhinitis
530733|NCT00578331|perennial allergic rhinitis
530734|NCT00578331|allergic rhinitis
530735|NCT00578292|transfusion-dependent
530736|NCT00578292|homozygous b0/+-thalassemia
530737|NCT00578292|severe variants of b0/+-thalassemia
530738|NCT00578292|chronic transfusion therapy
530739|NCT00578292|iron chelating agents
530740|NCT00578292|severe
530741|NCT00578292|transfusion-dependent homozygous b0/+-thalassemia or severe variants of b0/+-thalassemia
530742|NCT00578266|Severe Aplastic Anemia (SAA)
530743|NCT00578266|Transplant for Severe Aplastic Anemia (SAA)
530744|NCT00578240|benign
530745|NCT00578240|Rising PSA
530746|NCT00578240|Clinical Metastases
530747|NCT00578240|90-040
530748|NCT00578227|Human papillomavirus infection,
530749|NCT00578227|cervical cancer
530750|NCT00578227|HPV vaccine,
530751|NCT00578214|mohs micrographic surgery
530752|NCT00578214|skin cancer
530753|NCT00578214|anxiety
530754|NCT00578214|basal cell carcinoma
530755|NCT00578214|squamous cell carcinoma
530756|NCT00578214|midazolam
530757|NCT00578214|versed
530758|NCT00578201|Esophageal neoplasms
530759|NCT00578201|Cetuximab
530760|NCT00578201|Oxaliplatin
530761|NCT00578201|Fluorouracil
530762|NCT00578201|radiotherapy
530763|NCT00578188|Adolescent Health
530764|NCT00578188|Sexually transmitted infection
530765|NCT00578188|Women's Health
530766|NCT00578175|Vaccines
530767|NCT00578175|Rubella
530768|NCT00578175|Varicella Vaccine
530769|NCT00578175|Children
530770|NCT00578175|Humans
530771|NCT00578175|Mumps
530772|NCT00578175|Immunogenicity
530773|NCT00578175|Safety
530774|NCT00578175|Measles
530775|NCT00578175|Combined Vaccine
530776|NCT00578162|Cancer
530777|NCT00578162|Survivors
530778|NCT00578149|chemoradiotherapy
530779|NCT00578149|Lung cancer
530780|NCT00578136|Rectus Sheath
530781|NCT00578136|Local infiltration
530782|NCT00578136|Pain Control
530783|NCT00578123|Prostate
530784|NCT00578123|Cancer
530785|NCT00578123|Quality of Life
530786|NCT00578123|Questionaires
530787|NCT00578123|04-094
530788|NCT00578110|glaucoma VEP detection device diagnosis vision
530789|NCT00578071|esophageal cancer
530790|NCT00578032|head
530791|NCT00578032|neck
530792|NCT00578032|cancer
530793|NCT00578032|reconstruction
530794|NCT00578032|quality of life
530795|NCT00578032|07-150
530796|NCT00578019|Comparative
530797|NCT00578019|Supracondylar Femur Fracture
530798|NCT00578019|Intramedullary nailing
530799|NCT00578019|Less Invasive Stabilization System (LISS) Plating
530800|NCT00578006|toxicity related symptoms
530801|NCT00578006|04-020
530802|NCT00577993|Lymphoma
530803|NCT00577993|Follicular Lymphoma
530804|NCT00577993|Indolent Lymphoma
530805|NCT00577993|Fludarabine
530806|NCT00577993|Novantrone
530807|NCT00577993|Mitoxantrone
530808|NCT00577993|Decadron
530809|NCT00577993|Dexamethasone
530810|NCT00577993|Rituximab
530811|NCT00577993|Anti-CD20
530812|NCT00577993|IDEC-C2B8
530813|NCT00577993|Chimeric Anti-CD20 Antibody
530814|NCT00577993|Interferon
530815|NCT00577993|Interferon Alpha-2b
530816|NCT00577993|IFN
530817|NCT00577993|Doxorubicin
530818|NCT00577993|Vincristine
530819|NCT00577993|Bleomycin
530820|NCT00577993|Cyclophosphamide
530821|NCT00577993|Etoposide
530822|NCT00577993|Cisplatin
530823|NCT00577993|Ara-C
530824|NCT00577993|Methyl-Prednisolone
530825|NCT00577993|Procarbazine
530826|NCT00577993|Prednisone
530827|NCT00577993|FND
530828|NCT00577980|Prostate Cancer
530829|NCT00577980|Castration-Resistant Prostate Cancer
530830|NCT00577980|Testosterone Replacement Therapy
530831|NCT00577980|Testosterone
530832|NCT00577980|CRPC
530833|NCT00577980|TRT
530834|NCT00577967|Uremic pruritis
530835|NCT00577954|Coma
530836|NCT00577954|TBI
530837|NCT00577954|Stroke
530838|NCT00577954|SAH
530839|NCT00577954|Cerebral Anoxia
530840|NCT00577954|Multimodal MRI
530841|NCT00577915|Breast cancer
530842|NCT00577915|MRI spectroscopy
530843|NCT00577915|Diagnostic radiology
530844|NCT00577902|head and neck cancer
530845|NCT00577824|diabetes
530846|NCT00577824|exenatide
530847|NCT00577824|LY2148568
530848|NCT00577824|Byetta
530849|NCT00577824|Lilly
530850|NCT00577824|Amylin
530851|NCT00577811|Special Need Plans
530852|NCT00577811|Fee for Services
530853|NCT00577811|Access to Care
530854|NCT00577811|Medicaid
530855|NCT00577798|chemotherapeutic agent toxicity
530856|NCT00577798|cardiac toxicity
530857|NCT00577798|stage I adult Hodgkin lymphoma
530858|NCT00577798|stage II adult Hodgkin lymphoma
530859|NCT00577798|stage III adult Hodgkin lymphoma
530860|NCT00577798|stage IV adult Hodgkin lymphoma
530861|NCT00577798|stage I adult T-cell leukemia/lymphoma
530862|NCT00577798|stage II adult T-cell leukemia/lymphoma
530863|NCT00577798|stage III adult T-cell leukemia/lymphoma
530864|NCT00577798|stage IV adult T-cell leukemia/lymphoma
530865|NCT00577798|anaplastic large cell lymphoma
530866|NCT00577798|angioimmunoblastic T-cell lymphoma
530867|NCT00577798|cutaneous B-cell non-Hodgkin lymphoma
530868|NCT00577798|stage I mycosis fungoides/Sezary syndrome
530869|NCT00577798|stage II mycosis fungoides/Sezary syndrome
530870|NCT00577798|stage III mycosis fungoides/Sezary syndrome
530871|NCT00577798|stage IV mycosis fungoides/Sezary syndrome
530872|NCT00577798|stage I cutaneous T-cell non-Hodgkin lymphoma
530873|NCT00577798|stage II cutaneous T-cell non-Hodgkin lymphoma
530874|NCT00577798|stage III cutaneous T-cell non-Hodgkin lymphoma
530875|NCT00577798|stage IV cutaneous T-cell non-Hodgkin lymphoma
530876|NCT00577798|adult grade III lymphomatoid granulomatosis
530877|NCT00577798|adult nasal type extranodal NK/T-cell lymphoma
530878|NCT00577798|Waldenstrom macroglobulinemia
530879|NCT00577798|contiguous stage II adult Burkitt lymphoma
530880|NCT00577798|noncontiguous stage II adult Burkitt lymphoma
530881|NCT00577798|stage I adult Burkitt lymphoma
530882|NCT00577798|stage III adult Burkitt lymphoma
530883|NCT00577798|stage IV adult Burkitt lymphoma
530884|NCT00577798|contiguous stage II adult diffuse large cell lymphoma
530885|NCT00577798|noncontiguous stage II adult diffuse large cell lymphoma
530886|NCT00577798|stage I adult diffuse large cell lymphoma
530887|NCT00577798|stage III adult diffuse large cell lymphoma
530888|NCT00577798|stage IV adult diffuse large cell lymphoma
530889|NCT00577798|contiguous stage II adult diffuse mixed cell lymphoma
530890|NCT00577798|noncontiguous stage II adult diffuse mixed cell lymphoma
530891|NCT00577798|stage I adult diffuse mixed cell lymphoma
530892|NCT00577798|stage III adult diffuse mixed cell lymphoma
530893|NCT00577798|stage IV adult diffuse mixed cell lymphoma
530894|NCT00577798|contiguous stage II adult diffuse small cleaved cell lymphoma
530895|NCT00577798|noncontiguous stage II adult diffuse small cleaved cell lymphoma
530896|NCT00577798|stage I adult diffuse small cleaved cell lymphoma
530897|NCT00577798|stage III adult diffuse small cleaved cell lymphoma
530898|NCT00577798|stage IV adult diffuse small cleaved cell lymphoma
530899|NCT00577798|contiguous stage II adult immunoblastic large cell lymphoma
530900|NCT00577798|noncontiguous stage II adult immunoblastic large cell lymphoma
530901|NCT00577798|stage I adult immunoblastic large cell lymphoma
530902|NCT00577798|stage III adult immunoblastic large cell lymphoma
530903|NCT00577798|stage IV adult immunoblastic large cell lymphoma
530904|NCT00577798|contiguous stage II adult lymphoblastic lymphoma
530905|NCT00577798|noncontiguous stage II adult lymphoblastic lymphoma
530906|NCT00577798|stage I adult lymphoblastic lymphoma
530907|NCT00577798|stage III adult lymphoblastic lymphoma
530908|NCT00577798|stage IV adult lymphoblastic lymphoma
530909|NCT00577798|contiguous stage II grade 1 follicular lymphoma
530910|NCT00577798|noncontiguous stage II grade 1 follicular lymphoma
530911|NCT00577798|stage I grade 1 follicular lymphoma
530912|NCT00577798|stage III grade 1 follicular lymphoma
530913|NCT00577798|stage IV grade 1 follicular lymphoma
530914|NCT00577798|contiguous stage II grade 2 follicular lymphoma
530915|NCT00577798|noncontiguous stage II grade 2 follicular lymphoma
530916|NCT00577798|stage I grade 2 follicular lymphoma
530917|NCT00577798|stage III grade 2 follicular lymphoma
530918|NCT00577798|stage IV grade 2 follicular lymphoma
530919|NCT00577798|contiguous stage II grade 3 follicular lymphoma
530920|NCT00577798|noncontiguous stage II grade 3 follicular lymphoma
530921|NCT00577798|stage I grade 3 follicular lymphoma
530922|NCT00577798|stage III grade 3 follicular lymphoma
530923|NCT00577798|stage IV grade 3 follicular lymphoma
530924|NCT00577798|contiguous stage II mantle cell lymphoma
530925|NCT00577798|noncontiguous stage II mantle cell lymphoma
530926|NCT00577798|stage I mantle cell lymphoma
530927|NCT00577798|stage III mantle cell lymphoma
530928|NCT00577798|stage IV mantle cell lymphoma
530929|NCT00577798|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
530930|NCT00577798|nodal marginal zone B-cell lymphoma
530931|NCT00577798|splenic marginal zone lymphoma
530932|NCT00577798|contiguous stage II marginal zone lymphoma
530933|NCT00577798|noncontiguous stage II marginal zone lymphoma
530934|NCT00577798|stage I marginal zone lymphoma
530935|NCT00577798|stage III marginal zone lymphoma
530936|NCT00577798|stage IV marginal zone lymphoma
530937|NCT00577798|contiguous stage II small lymphocytic lymphoma
530938|NCT00577798|noncontiguous stage II small lymphocytic lymphoma
530939|NCT00577798|stage I small lymphocytic lymphoma
530940|NCT00577798|stage III small lymphocytic lymphoma
530941|NCT00577798|stage IV small lymphocytic lymphoma
530942|NCT00577785|cystectomy
530943|NCT00577772|SmartPill Capsule
530944|NCT00577772|Digestive System Diseases
530945|NCT00577772|Small Bowel Bacterial Overgrowth
530946|NCT00577772|Gastrointestinal Device
530947|NCT00577772|Oro-cecal
530948|NCT00577759|Quality assurance, health care
530949|NCT00577759|primary health care
530950|NCT00577759|community health services
530951|NCT00577759|referral and consultation
530952|NCT00577759|exercise
530953|NCT00577759|diet
530954|NCT00577759|tobacco
530955|NCT00577746|Non Small Cell Lung
530956|NCT00577733|Pulmonary function test
530957|NCT00577733|Methacholine challenge
530958|NCT00577733|Breathing variability
530959|NCT00577733|Polygraphy
530960|NCT00577707|Lung Cancer
530961|NCT00577707|Erlotinib
530962|NCT00577707|clinical stage IB-IIIA
530963|NCT00577694|recurrent adult acute myeloid leukemia
530964|NCT00577681|HIV
530965|NCT00577681|Lipoproteins
530966|NCT00577681|Inflammatory Markers
530967|NCT00577681|Coagulation Markers
530968|NCT00577681|Treatment Experienced
530969|NCT00577655|Pediatric, asthma, albuterol-HFA and Placebo
530970|NCT00577642|aminobisphosphonates
530971|NCT00577629|high risk non-hodgkins lymphoma
530972|NCT00577629|NHL
530973|NCT00577629|Bexxar
530974|NCT00577629|high dose chemotherapy
530975|NCT00577616|Endovascular repair
530976|NCT00577616|Ruptured aorta-iliac aneurysms
530977|NCT00577616|Mortality at 30 days
530978|NCT00577603|stoma, hernia, mesh
530979|NCT00577590|Type II Diabetes Mellitus
530980|NCT00577590|Diabetes
530981|NCT00577590|PET
530982|NCT00577590|Heart Metabolism
530983|NCT00577590|Lovaza
530984|NCT00577525|LATENT VIRAL INFECTION
530985|NCT00577525|GENOME HYBRIDIZATION
530986|NCT00577525|HERPES VIRUS
530987|NCT00577525|ADENOVIRUS
530988|NCT00577499|cystic fibrosis
530989|NCT00577499|constipation
530990|NCT00577499|lubiprostone
530991|NCT00577499|nutrition
530992|NCT00577499|pulmonary function
530993|NCT00577447|autism
530994|NCT00577447|omega-3 fatty acids
530995|NCT00577447|docosahexaenoic acid
530996|NCT00577434|Procedural sedation
530997|NCT00577434|Sedation for diagnostic imaging
530998|NCT00577408|Opiate Dependence
530999|NCT00577408|Heroin Dependence
531000|NCT00577408|Naltrexone
531001|NCT00577382|Sutent
531002|NCT00577382|malignant melanoma
531003|NCT00577369|arterial line
531004|NCT00577369|end-expiratory desflurane
531005|NCT00577304|Raynaud's
531006|NCT00577304|Nitroglycerin
531007|NCT00577304|Scleroderma
531008|NCT00577278|graft versus host disease
531009|NCT00577278|contiguous stage II grade 1 follicular lymphoma
531010|NCT00577278|contiguous stage II grade 2 follicular lymphoma
531011|NCT00577278|contiguous stage II grade 3 follicular lymphoma
531012|NCT00577278|noncontiguous stage II grade 1 follicular lymphoma
531013|NCT00577278|noncontiguous stage II grade 2 follicular lymphoma
531014|NCT00577278|noncontiguous stage II grade 3 follicular lymphoma
531015|NCT00577278|recurrent grade 1 follicular lymphoma
531016|NCT00577278|recurrent grade 2 follicular lymphoma
531017|NCT00577278|recurrent grade 3 follicular lymphoma
531018|NCT00577278|stage I grade 1 follicular lymphoma
531019|NCT00577278|stage I grade 2 follicular lymphoma
531020|NCT00577278|stage I grade 3 follicular lymphoma
531021|NCT00577278|stage III grade 1 follicular lymphoma
531022|NCT00577278|stage III grade 2 follicular lymphoma
531023|NCT00577278|stage III grade 3 follicular lymphoma
531024|NCT00577278|stage IV grade 1 follicular lymphoma
531025|NCT00577278|stage IV grade 2 follicular lymphoma
531026|NCT00577278|stage IV grade 3 follicular lymphoma
531027|NCT00577278|contiguous stage II adult diffuse large cell lymphoma
531028|NCT00577278|noncontiguous stage II adult diffuse large cell lymphoma
531029|NCT00577278|recurrent adult diffuse large cell lymphoma
531030|NCT00577278|stage I adult diffuse large cell lymphoma
531031|NCT00577278|stage III adult diffuse large cell lymphoma
531032|NCT00577278|stage IV adult diffuse large cell lymphoma
531033|NCT00577278|Waldenstrom macroglobulinemia
531034|NCT00577278|contiguous stage II marginal zone lymphoma
531035|NCT00577278|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
531036|NCT00577278|nodal marginal zone B-cell lymphoma
531037|NCT00577278|noncontiguous stage II marginal zone lymphoma
531038|NCT00577278|recurrent marginal zone lymphoma
531039|NCT00577278|stage I marginal zone lymphoma
531040|NCT00577278|stage III marginal zone lymphoma
531041|NCT00577278|stage IV marginal zone lymphoma
531042|NCT00577278|B-cell chronic lymphocytic leukemia
531043|NCT00577278|refractory chronic lymphocytic leukemia
531044|NCT00577278|stage I chronic lymphocytic leukemia
531045|NCT00577278|stage II chronic lymphocytic leukemia
531046|NCT00577278|stage III chronic lymphocytic leukemia
531047|NCT00577278|stage IV chronic lymphocytic leukemia
531048|NCT00577278|contiguous stage II mantle cell lymphoma
531049|NCT00577278|noncontiguous stage II mantle cell lymphoma
531050|NCT00577278|recurrent mantle cell lymphoma
531051|NCT00577278|stage I mantle cell lymphoma
531052|NCT00577278|stage III mantle cell lymphoma
531053|NCT00577278|stage IV mantle cell lymphoma
531054|NCT00577278|contiguous stage II adult diffuse mixed cell lymphoma
531055|NCT00577278|noncontiguous stage II adult diffuse mixed cell lymphoma
531056|NCT00577278|recurrent adult diffuse mixed cell lymphoma
531057|NCT00577278|stage I adult diffuse mixed cell lymphoma
531058|NCT00577278|stage III adult diffuse mixed cell lymphoma
531059|NCT00577278|stage IV adult diffuse mixed cell lymphoma
531060|NCT00577278|contiguous stage II small lymphocytic lymphoma
531061|NCT00577278|noncontiguous stage II small lymphocytic lymphoma
531062|NCT00577278|recurrent small lymphocytic lymphoma
531063|NCT00577278|stage I small lymphocytic lymphoma
531064|NCT00577278|stage III small lymphocytic lymphoma
531065|NCT00577278|stage IV small lymphocytic lymphoma
531066|NCT00577265|Asthma Control
531067|NCT00577252|Cystic fibrosis
531068|NCT00577252|Adolescents
531069|NCT00577252|Coping Compliance
531070|NCT00577252|Adjustment
531071|NCT00577226|scoliosis, immature spine
531072|NCT00577213|Diagnosis
531073|NCT00577213|Hemangiomas
531074|NCT00577213|Vascular Malformations
531075|NCT00577213|Venular Malformations
531076|NCT00577213|Venous Malformations
531077|NCT00577213|Lymphatic Malformations
531078|NCT00577213|Arteriovenous Malformations
531079|NCT00577174|Children
531080|NCT00577174|Obesity
531081|NCT00577174|Insulin resistance
531082|NCT00577174|Diabetes
531083|NCT00577174|Mitochondrial Function
531084|NCT00577161|pixantrone
531085|NCT00577161|NHL
531086|NCT00577161|rituximab
531087|NCT00577161|fludarabine
531088|NCT00577148|NASH
531089|NCT00577148|chronic liver disease
531090|NCT00577135|Loop Diuretics
531091|NCT00577135|Furosemide
531092|NCT00577135|Fluid Overload
531093|NCT00577135|Cardio Renal Failure
531094|NCT00577122|Medroxyprogesterone progesterone acetate (MPA)
531095|NCT00577122|Cyclophosphamide plus Methotrexate
531096|NCT00577096|multiple myeloma
531097|NCT00577096|polysomnography
531098|NCT00577096|quality of life
531099|NCT00577096|exercise
531100|NCT00577083|miss rates
531101|NCT00577057|Nasopharyngeal Carcinoma
531102|NCT00577057|Stage III - IVB
531103|NCT00577044|NAFLD
531104|NCT00577005|GABAergic
531105|NCT00577005|levetiracetam
531106|NCT00576992|Barrett's Esophagus
531107|NCT00576992|Demographics
531108|NCT00576992|Questionnaire
531109|NCT00576992|Heartburn
531110|NCT00576979|recurrent adult acute lymphoblastic leukemia
531111|NCT00576979|recurrent childhood acute lymphoblastic leukemia
531112|NCT00576940|enteral nutrition, immunomodulating nutrition
531113|NCT00576927|Sleep hygiene
531114|NCT00576927|Sleep latency
531115|NCT00576927|Elderly sleep
531116|NCT00576927|Nursing Home sleep
531117|NCT00576914|adjuvant therapy
531118|NCT00576914|non-small cell lung cancer
531119|NCT00576914|vinorelbine
531120|NCT00576914|cisplatin
531121|NCT00576914|recombinant human endostatin(endostar)
531122|NCT00576888|Multifocal lymphangioendoltheliomatosis with thrombocytopenia
531123|NCT00576888|Cutaneovisceral angiomatosis with thrombocytopenia
531124|NCT00576888|Thrombocytopenia
531125|NCT00576888|Hemangiomas
531126|NCT00576888|Hemangiomatosis
531127|NCT00576888|Lymphatic malformation
531128|NCT00576888|Kasabach-Merritt
531129|NCT00576888|Blue-rubber bleb nevus
531130|NCT00576888|Angiomatosis
531131|NCT00576875|Depression
531132|NCT00576875|Elderly
531133|NCT00576875|Neuroimaging
531134|NCT00576875|Postmortem
531135|NCT00576875|Knockout mouse
531136|NCT00576836|Thymus Transplantation
531137|NCT00576836|DiGeorge Syndrome
531138|NCT00576836|DiGeorge Anomaly
531139|NCT00576836|Athymia
531140|NCT00576836|Parathyroid Transplantation
531141|NCT00576836|Hypocalcemia
531142|NCT00576836|Hypoparathyroidism
531143|NCT00576836|Low T cell numbers
531144|NCT00576836|Immunoreconstitution
531145|NCT00576836|Immunodeficiency
531146|NCT00576836|Complete DiGeorge
531147|NCT00576836|Complete DiGeorge Anomaly
531148|NCT00576836|Typical DiGeorge
531149|NCT00576823|child
531150|NCT00576823|bladder
531151|NCT00576823|neuropathic
531152|NCT00576823|alpha blockers
531153|NCT00576797|vaginal
531154|NCT00576797|bacteria
531155|NCT00576797|microflora
531156|NCT00576797|bacterial DNA
531157|NCT00576797|To determine the normal bacteria in the vagina
531158|NCT00576784|type 2 diabetes
531159|NCT00576784|insulin treatment
531160|NCT00576784|ß-cell function
531161|NCT00576745|Sutures
531162|NCT00576732|Irritability
531163|NCT00576732|Risperidone
531164|NCT00576732|Antipsychotic agent
531165|NCT00576732|Autism
531166|NCT00576732|Adolescents
531167|NCT00576732|Children
531168|NCT00576706|Patients with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis or any other arthritis-like disease requiring continuous NSAIDs therapy
531169|NCT00576693|ischemic stroke
531170|NCT00576693|intracranial stenting
531171|NCT00576693|vascular risk factor management
531172|NCT00576680|RAD001
531173|NCT00576680|temozolomide
531174|NCT00576667|NASH
531175|NCT00576667|chronic liver disease
531176|NCT00576615|healthy volunteers
531177|NCT00576615|amnesic effects
531178|NCT00576589|Safety in patients with Asymptomatic cholelithiasis/gallstones.
531179|NCT00576576|Atherosclerosis, vulnerable plaque, IVUS, shear stress
531180|NCT00576563|rectal cancer
531181|NCT00576563|blood proteins
531182|NCT00576563|irradiation
531183|NCT00576563|FDG-PET-CT
531184|NCT00576550|Hand eczema
531185|NCT00576550|Prevention
531186|NCT00576537|New/Recurrent Glioblastoma
531187|NCT00576524|Hypotension during dialysis
531188|NCT00576524|End Stage Renal Disease
531189|NCT00576524|Decrease complications during dialysis
531190|NCT00576524|Low Blood Pressure
531191|NCT00576511|Constipation
531192|NCT00576511|Prucalopride
531193|NCT00576511|Colonic Transit Time
531194|NCT00576498|GERD
531195|NCT00576498|NBI
531196|NCT00576498|AFI
531197|NCT00576498|IM
531198|NCT00576498|SSBE
531199|NCT00576498|LSBE
531200|NCT00576498|LGD
531201|NCT00576498|HGD
531202|NCT00576485|Cataract
531203|NCT00576485|Intraocular lens
531204|NCT00576485|Spherical aberration
531205|NCT00576485|Contrast sensitivity
531206|NCT00576472|Brain Tumor, Acute Lymphoblastic Leukemia, Methylphenidate, Cognitive Late Effects
531207|NCT00576407|Thymus Transplantation
531208|NCT00576407|DiGeorge Syndrome
531209|NCT00576407|Athymia
531210|NCT00576407|Low T cell numbers
531211|NCT00576407|Immunoreconstitution
531212|NCT00576407|Primary immunodeficiency
531213|NCT00576407|DiGeorge Anomaly
531214|NCT00576407|Complete DiGeorge
531215|NCT00576407|Typical DiGeorge
531216|NCT00576394|Glucose, Insulin
531217|NCT00576381|Precedex
531218|NCT00576381|Open Heart Surgery
531219|NCT00576381|Dexmedetomidine
531220|NCT00576381|Sedation
531221|NCT00576355|Adolescent
531222|NCT00576355|Psychopathology
531223|NCT00576355|Interpersonal Therapy
531224|NCT00576355|Interpersonal and Social Rhythm Therapy
531225|NCT00576329|vitreoretinal surgery, ketorolac, Acular, mydriasis
531226|NCT00576316|Asthma
531227|NCT00576264|open abdominal surgery
531228|NCT00576264|abdominal laparoscopic surgery
531229|NCT00576264|peritoneal stem cells
531230|NCT00576264|patients scheduled for any type of elective intra-abdominal surgery at Cedars-Sinai Medical Center with designated surgeons
531231|NCT00576251|Ocular inflammation
531232|NCT00576251|blepharaconjunctivitis
531233|NCT00576238|Atopic eczema
531234|NCT00576238|Topical corticosteroid
531235|NCT00576225|NSCLC
531236|NCT00576225|women
531237|NCT00576225|CT-2103
531238|NCT00576225|paclitaxel
531239|NCT00576225|carboplatin
531240|NCT00576212|termination fetal anomaly
531241|NCT00576212|psychological sequelae pregnancy termination for anomalies
531242|NCT00576212|supportive follow-up pregnancy termination anomalies
531243|NCT00576173|Cancer pain
531244|NCT00576173|Breakthrough pain
531245|NCT00576173|acetaminophen
531246|NCT00576173|tramadol hydrochloride
531247|NCT00576173|Ultracet
531248|NCT00576160|medication adherence
531249|NCT00576147|TBI
531250|NCT00576147|NIRS
531251|NCT00576147|Hematoma
531252|NCT00576134|Larynx, tracheotomy, titanium beads
531253|NCT00576082|Lyme borreliosis
531254|NCT00576082|Erythema migrans
531255|NCT00576082|Borrelial lymphocytoma
531256|NCT00576082|Acrodermatitis chronica atrophicans
531257|NCT00576082|Borrelia burgdorferi
531258|NCT00576082|Borrelia afzelii
531259|NCT00576082|Borrelia garinii
531260|NCT00576069|asthma
531261|NCT00576069|lung function
531262|NCT00576069|inflammation
531263|NCT00576056|Hepatocellular
531264|NCT00576056|Carcinoma
531265|NCT00576056|TACE
531266|NCT00576056|Sorafenib
531267|NCT00576056|Transcatheter Arterial Chemoembolization
531268|NCT00576056|Nexavar
531269|NCT00576056|Unresectable
531270|NCT00576043|training
531271|NCT00576043|Patient satisfaction
531272|NCT00576043|endoscopy
531273|NCT00576043|simulator
531274|NCT00576043|Safety
531275|NCT00576017|Cancer pain treatment
531276|NCT00576017|Fentanyl TTS
531277|NCT00576017|Dihydrocodeine
531278|NCT00576017|Tramadol
531279|NCT00576017|Cancer pain
531280|NCT00576017|Durogesic
531281|NCT00576017|Ultram
531282|NCT00576004|Pelvic organ prolapse, Urinary incontinence, Burch colposuspension, surgery
531283|NCT00575991|conjugated linoleic acid, body fat, children, overweight
531284|NCT00575978|breast cancer
531285|NCT00575965|simvastatin
531286|NCT00575939|HIV
531287|NCT00575939|IMT
531288|NCT00575939|coronary
531289|NCT00575939|Treatment Naive
531290|NCT00575926|Randomized controlled trial
531291|NCT00575926|Lingzhi
531292|NCT00575926|Immune functions
531293|NCT00575926|Quality of life
531294|NCT00575926|Survival
531295|NCT00575900|Adolescent obesity,
531296|NCT00575900|low carbohydrate diets
531297|NCT00575900|metabolic risk factors
531298|NCT00575900|BMI
531299|NCT00575887|Temozolomide
531300|NCT00575887|Brain Tumor, Recurrent
531301|NCT00575887|Chemotherapy
531302|NCT00575874|rivoglitazone HCl
531303|NCT00575874|pioglitazone HCl
531304|NCT00575874|thiazolidinedione
531547|NCT00574639|Type 1 Diabetes
531305|NCT00575874|peroxisome proliferator-activated receptor gamma (PPAR gamma)
531306|NCT00575874|type 2 diabetes mellitus
531307|NCT00575861|asthma
531308|NCT00575861|nitric oxide gas exchange
531309|NCT00575861|lung function
531310|NCT00575848|Schizophrenia
531311|NCT00575848|Glycine
531312|NCT00575848|Magnetic Resonance Spectroscopy (MRS)
531313|NCT00575835|vitamin D
531314|NCT00575835|seasonal variation
531315|NCT00575835|PTH
531316|NCT00575835|bone markers
531317|NCT00575822|GERD
531318|NCT00575822|Sham
531319|NCT00575822|Randomized Controlled Study
531320|NCT00575822|Endoscopic Full-thickness Plication
531321|NCT00575822|Plicator
531322|NCT00575809|Mucositis, hematopoietic stem cell transplantation, chemotherapy
531323|NCT00575796|pediatrics
531324|NCT00575796|Low Grade Glioma
531325|NCT00575796|Vinblastine
531326|NCT00575783|type 1 diabetes
531327|NCT00575783|hypoglycemia
531328|NCT00575783|magnetic resonance imaging
531329|NCT00575757|Steatosis
531330|NCT00575757|NASH
531331|NCT00575744|Sentinel Lymph Node Biopsy
531332|NCT00575744|Axillary Node Dissection
531333|NCT00575744|Intraoperative Injection
531334|NCT00575744|Lumpectomy
531335|NCT00575744|Mastectomy
531336|NCT00575718|Quitting tobacco
531337|NCT00575718|tobacco use
531338|NCT00575705|cystic kidney disease
531339|NCT00575705|polycystic kidney disease
531340|NCT00575705|congenital hepatic fibrosis
531341|NCT00575705|genetic disease
531342|NCT00575679|Automobile driving
531343|NCT00575679|Driving under the influence
531344|NCT00575679|Interview, psychological
531345|NCT00575679|Brief intervention
531346|NCT00575679|Brief motivational interview
531347|NCT00575666|cognition, psychopathology
531348|NCT00575653|Guillain-Barre Syndrome
531349|NCT00575653|Meningococcal vaccines
531350|NCT00575653|Tetravalent Meningococcal Vaccine
531351|NCT00575653|Vaccination
531352|NCT00575653|Vaccines
531353|NCT00575653|Vaccines, Conjugate
531354|NCT00575627|Hepatitis C
531355|NCT00575627|persistently normal ALT
531356|NCT00575627|pNNALT
531357|NCT00575627|Theraphy for Hepatitis C
531358|NCT00575627|Pegylated Interferon
531359|NCT00575627|Combined therapy
531360|NCT00575614|Constipation
531361|NCT00575614|Prucalopride
531362|NCT00575614|Ano-rectal physiology
531363|NCT00575614|Oro-caecal transit time
531364|NCT00575614|QOL
531365|NCT00575601|pco
531366|NCT00575601|simvastatin
531367|NCT00575601|ivf
531368|NCT00575601|embryo transfer
531369|NCT00575588|DPP-4 Inhibitors
531370|NCT00575588|HbA1c
531371|NCT00575588|incretins
531372|NCT00575575|Suicidal ideation
531373|NCT00575575|cognitive behavior therapy
531374|NCT00575536|spasticity
531375|NCT00575536|rhizotomy
531376|NCT00575536|surgery
531377|NCT00575523|atropine
531378|NCT00575523|percutaneous ethanol instillation
531379|NCT00575523|hepatoma
531380|NCT00575523|bradycardia
531381|NCT00575523|arrhythmia
531382|NCT00575510|unified theory of behavior
531383|NCT00575510|Pap test
531384|NCT00575510|cervical dysplasia
531385|NCT00575510|women's health
531386|NCT00575497|Hemodialysis
531387|NCT00575497|Adequacy
531388|NCT00575497|Frequency
531389|NCT00575484|Congestive Heart Failure
531390|NCT00575484|Renal Insufficiency
531391|NCT00575484|Hypertonic Saline Solution
531392|NCT00575484|Diuretic Resistance
531393|NCT00575484|Cardiorenal Syndrome
531394|NCT00575471|rivoglitazone HCl
531395|NCT00575471|thiazolidinedione
531396|NCT00575471|peroxisome proliferator-activated receptor gamma (PPARgamma)
531397|NCT00575471|diabetes mellitus, type 2
531398|NCT00575432|magnetic resonance imaging
531399|NCT00575432|renal function
531400|NCT00575432|renal transplant
531401|NCT00575432|urinary calculi
531402|NCT00575432|healthy controls
531403|NCT00575432|kidney
531404|NCT00575419|Contrast Induced Nephropathy
531405|NCT00575393|stage IIIB non-small cell lung cancer
531406|NCT00575393|stage IV non-small cell lung cancer
531407|NCT00575393|recurrent non-small cell lung cancer
531408|NCT00575354|Sevoflurane
531409|NCT00575354|Isoflurane
531410|NCT00575354|Breast tumor
531411|NCT00575354|Anesthesia
531412|NCT00575341|Central Adrenal Insufficiency
531413|NCT00575341|DHEA
531414|NCT00575341|Pubes
531415|NCT00575328|Sexual Dysfunction
531416|NCT00575328|Bipolar Disorder
531417|NCT00575315|HIV-HCV Coinfection
531418|NCT00575315|HIV
531419|NCT00575315|Histology
531420|NCT00575302|IVF
531421|NCT00575302|poor responder
531422|NCT00575302|recFSH
531423|NCT00575302|Fertilization in Vitro
531424|NCT00575302|Poor responders
531425|NCT00575276|Pain, Cholecystectomy, Cytokines, Sex Differences
531426|NCT00575263|Pain, Sodium Channel, Dental pulp
531427|NCT00575250|Osteoporosis/prevention & control
531428|NCT00575250|Osteoporosis Prevention and Self-Management Course
531429|NCT00575250|Patient Education/*trends//Questionnaires
531430|NCT00575250|Adult//Aged//Middle Aged
531431|NCT00575250|Life Style//
531432|NCT00575237|Laparoscopic Surgery
531433|NCT00575237|Shoulder pain
531434|NCT00575237|PDNV
531435|NCT00575237|Anesthesia
531436|NCT00575237|Residual CO2
531437|NCT00575237|Postoperative Pain
531438|NCT00575237|Female ASA 1 and 2 outpatients who were scheduled for elective gynecologic laparoscopic surgery
531439|NCT00575224|Hepatitis C
531440|NCT00575224|Genotype 6
531441|NCT00575224|Novel genoytpe
531442|NCT00575224|HCV
531443|NCT00575224|Treatment
531444|NCT00575211|New onset cardiomyopathy
531445|NCT00575211|Onset of symptoms less than 6 months
531446|NCT00575211|LVEF < 40%
531447|NCT00575198|Chest tubes
531448|NCT00575198|Trauma
531449|NCT00575185|Mono
531450|NCT00575185|Mononucleosis
531451|NCT00575185|Epstein-Barr virus
531452|NCT00575172|type2 diabetes mellitus
531453|NCT00575172|cardiovascular disease
531454|NCT00575172|macrovascular event
531455|NCT00575159|Adult male and females,
531456|NCT00575159|type 1 Diabetes mellitus, pharmacokinetics,
531457|NCT00575159|pharmacodynamics
531458|NCT00575146|glioblastoma
531459|NCT00575146|ketogenic diet
531460|NCT00575120|Endothelial Function, MRI, Vascular Biology
531461|NCT00575081|Physiological Brain Atlas, Brain registry, Brain database
531462|NCT00575042|PBC
531463|NCT00575042|Primary Biliary Cirrhosis
531464|NCT00575042|Fenofibrate
531465|NCT00575042|Triglide
531466|NCT00575029|megestrol acetate
531467|NCT00575029|adrenal insufficiency
531468|NCT00575029|adrenal suppression
531469|NCT00574990|Interdisciplinary Communication
531470|NCT00574990|Safety Management
531471|NCT00574990|Management, Medication Therapy
531472|NCT00574990|Cooperative Behavior
531473|NCT00574990|Drug Therapy Management
531474|NCT00574990|Physician Nurse Relationships
531475|NCT00574990|Side Effects
531476|NCT00574990|Hospital Information Systems
531477|NCT00574990|Documentation
531478|NCT00574990|Quality Assurance, Health Care
531479|NCT00574977|vaccinia
531480|NCT00574977|virus
531481|NCT00574977|tumor
531482|NCT00574977|melanoma
531483|NCT00574977|breast cancer
531484|NCT00574977|squamous cell cancer
531485|NCT00574977|colorectal
531486|NCT00574977|liver
531487|NCT00574977|pancreatic
531488|NCT00574977|adenocarcinoma
531489|NCT00574951|fallopian tube cancer
531490|NCT00574951|recurrent ovarian epithelial cancer
531491|NCT00574951|primary peritoneal cavity cancer
531492|NCT00574925|H. pylori
531493|NCT00574912|Type 2 diabetes
531494|NCT00574912|Insulin Glargine
531495|NCT00574912|Endogenous Glucose Production
531496|NCT00574899|Prostate
531497|NCT00574873|Bosutinib
531498|NCT00574873|imatinib
531499|NCT00574873|CML
531500|NCT00574860|Oral Mucositis
531501|NCT00574860|Chemoradiation therapy
531502|NCT00574860|Head and neck cancer
531503|NCT00574847|ischemic heart disease
531504|NCT00574847|mental stress-induced myocardial ischemia
531505|NCT00574847|escitalopram
531506|NCT00574821|Hypertrophic Cardiomyopathy(HCM)
531507|NCT00574821|Magnetocardiography (MCG)
531508|NCT00574808|Primary care
531509|NCT00574808|Prevention of Cardiovascular Disease
531510|NCT00574808|Chronic Disease Management
531511|NCT00574808|Chronic Disease Prevention
531512|NCT00574808|Chronic Care Model
531513|NCT00574808|Outreach Facilitation
531514|NCT00574782|cholesterol, coronary heart disease
531515|NCT00574782|rosuvastatin
531516|NCT00574782|LDL-C goal
531517|NCT00574782|hypercholesterolemia
531518|NCT00574769|RAD001
531519|NCT00574769|mTOR inhibition
531520|NCT00574769|docetaxel
531521|NCT00574769|bevacizumab
531522|NCT00574769|adenocarcinoma of the prostate
531523|NCT00574769|recurrent prostate cancer
531524|NCT00574769|stage IV prostate cancer
531525|NCT00574769|prostate cancer
531526|NCT00574769|Metastatic, androgen independent prostate cancer
531527|NCT00574743|ERL080A, Heart Transplantation, Mycophenolate, EC-MPS
531528|NCT00574717|hyperopia
531529|NCT00574717|ocular refraction
531530|NCT00574717|infant
531531|NCT00574717|vision
531532|NCT00574691|Closure Device
531533|NCT00574691|Angiography
531534|NCT00574691|Angioplasty
531535|NCT00574691|Hemostasis
531536|NCT00574691|Heart Catheterization
531537|NCT00574691|Coronary Angiography
531538|NCT00574678|Screening tool for cancer
531539|NCT00574665|Type 2 Diabetes
531540|NCT00574665|Endothelial Function
531541|NCT00574665|Fibrinolytic Balance
531542|NCT00574652|HCV+
531543|NCT00574652|cryoglobulinemia
531544|NCT00574652|Vasculitis
531545|NCT00574652|IL-2 treatment
531546|NCT00574652|safety and efficacy
531548|NCT00574639|Alprazolam
531549|NCT00574639|Exercise
531550|NCT00574626|NHL
531551|NCT00574626|Non Hodgkins Lymphoma
531552|NCT00574626|BMT
531553|NCT00574626|Bone Marrow Transplant
531554|NCT00574626|PBSCT
531555|NCT00574626|Peripheral Blood Stem Cell Transplant
531556|NCT00574626|PSCT
531557|NCT00574613|Skin fibrosis
531558|NCT00574613|systemic scleroderma
531559|NCT00574613|systemic sclerosis
531560|NCT00574613|P144
531561|NCT00574613|orphan drug
531562|NCT00574613|soluble collagen
531563|NCT00574613|durometer
531564|NCT00574613|skin fibrosis in systemic sclerosis
531565|NCT00574600|HIV Seronegativity
531566|NCT00574600|HIV Preventive Vaccine
531567|NCT00574587|Vorinostat
531568|NCT00574587|Neoadjuvant Chemotherapy
531569|NCT00574574|cardiovascular disease
531570|NCT00574574|CVD
531571|NCT00574574|skin health
531572|NCT00574574|postmenopausal women
531573|NCT00574574|anthocyanin
531574|NCT00574574|inflammation
531575|NCT00574561|CT angiography (CTA)
531576|NCT00574561|Magnetocardiography (MCG)
531577|NCT00574561|heart disease
531578|NCT00574548|Vaccines, Pneumococcal Conjugate Vaccine
531579|NCT00574535|Reproductive Hormones
531580|NCT00574522|HIV
531581|NCT00574522|AIDS
531582|NCT00574522|Radiation
531583|NCT00574522|Far infrared
531584|NCT00574522|Treatment
531585|NCT00574522|Acquired Immunodeficiency Syndrome
531586|NCT00574522|Complimentary therapies
531587|NCT00574509|NHL
531588|NCT00574509|Non Hodgkins Lymphoma
531589|NCT00574509|131Iodine-Anti-B1 Radioimmunotherapy
531590|NCT00574509|Autologous Hematopoietic Stem Cell Transplant
531591|NCT00574509|AHSCT
531592|NCT00574496|recurrent adult Hodgkin lymphoma
531593|NCT00574496|recurrent/refractory childhood Hodgkin lymphoma
531594|NCT00574496|adult lymphocyte depletion Hodgkin lymphoma
531595|NCT00574496|adult nodular sclerosis Hodgkin lymphoma
531596|NCT00574496|adult mixed cellularity Hodgkin lymphoma
531597|NCT00574496|childhood lymphocyte depletion Hodgkin lymphoma
531598|NCT00574496|childhood mixed cellularity Hodgkin lymphoma
531599|NCT00574496|childhood nodular sclerosis Hodgkin lymphoma
531600|NCT00574496|stage III adult Hodgkin lymphoma
531601|NCT00574496|stage IV adult Hodgkin lymphoma
531602|NCT00574496|stage III childhood Hodgkin lymphoma
531603|NCT00574496|stage IV childhood Hodgkin lymphoma
531604|NCT00574483|Renal cell carcinoma
531605|NCT00574457|Atherosclerosis
531606|NCT00574457|Cardiovascular Risk Prevention
531607|NCT00574457|Carotid Ultrasound
531608|NCT00574457|Handheld ultrasound
531609|NCT00574457|Office Practice
531610|NCT00574457|Carotid Intima Media Thickness
531611|NCT00574457|Carotid Plaque
531612|NCT00574444|transvaginal peritoneoscopy
531613|NCT00574431|Critical care
531614|NCT00574431|Intensive care unit
531615|NCT00574431|Early enteral nutrition
531616|NCT00574431|Nutritional management protocol
531617|NCT00574418|Fibroid Tumor
531618|NCT00574418|Fibroid Uterus
531619|NCT00574418|Fibroids, Uterine
531620|NCT00574418|Fibromyoma
531621|NCT00574418|Uterine Neoplasms
531622|NCT00574405|Insulin pump
531623|NCT00574405|Beta cell
531624|NCT00574392|skin disorders
531625|NCT00574379|Allergic Rhinitis
531626|NCT00574379|Mountain Cedar Pollen
531627|NCT00574379|Pollen Allergy
531628|NCT00574379|Rhinoconjunctivitis
531629|NCT00574366|recurrent breast cancer
531630|NCT00574366|stage IV breast cancer
531631|NCT00574366|male breast cancer
531632|NCT00574353|colorectal cancer
531633|NCT00574353|07-151
531634|NCT00574340|Type 2 Diabetes
531635|NCT00574340|Endothelial Function
531636|NCT00574340|Fibrinolytic Balance
531637|NCT00574340|Hypoglycemia
531638|NCT00574327|Role
531639|NCT00574327|Registry
531640|NCT00574327|Barrett's Esophagus
531641|NCT00574314|women
531642|NCT00574314|Registry
531643|NCT00574301|Image Guided Vacuum Assisted Biopsy
531644|NCT00574301|Radiofrequency Ablation
531645|NCT00574301|Breast Conservation Therapy
531646|NCT00574301|Mastectomy
531647|NCT00574301|MRI
531648|NCT00574288|Multiple Myeloma
531649|NCT00574288|Daratumumab
531650|NCT00574288|Safety
531651|NCT00574288|HuMax-CD38
531652|NCT00574288|Dose-escalation
531653|NCT00574275|metastatic pancreatic cancer
531654|NCT00574275|angiogenesis inhibitor
531655|NCT00574275|gemcitabine
531656|NCT00574262|acute ischemic stroke
531657|NCT00574262|clinical pathway
531658|NCT00574262|quality of care
531659|NCT00574262|secondary prevention
531660|NCT00574249|Psoriasis
531661|NCT00574249|Moderate Psoriasis
531662|NCT00574249|Severe Psoriasis
531663|NCT00574249|Chronic Plaque Psoriasis
531664|NCT00574249|Severe Chronic Plaque Psoriasis
531665|NCT00574210|Seasonal Allergic Rhinitis (SAR)
531786|NCT00573703|Stress incontinence
531666|NCT00574210|Environmental Exposure Chamber (EEC)
531667|NCT00574210|Therapeutic Uses
531668|NCT00574210|Antihistamine Drug
531669|NCT00574210|Ragweed Pollen
531670|NCT00574197|Heart Transplant
531671|NCT00574197|gastrointestinal
531672|NCT00574197|Cellcept
531673|NCT00574197|Myfortic
531674|NCT00574197|GI
531675|NCT00574197|GI symptoms with Mycophenolate Mofetil after heart transplant
531676|NCT00574184|ED
531677|NCT00574184|Erectile Dysfunction
531678|NCT00574158|ozone
531679|NCT00574158|inflammatory airway disease
531680|NCT00574158|polymorphisms
531681|NCT00574145|fatigue
531682|NCT00574145|depression
531683|NCT00574145|psychosocial effects of cancer and its treatment
531684|NCT00574145|stage I breast cancer
531685|NCT00574145|stage II breast cancer
531686|NCT00574145|stage IIIA breast cancer
531687|NCT00574145|stage IIIB breast cancer
531688|NCT00574145|stage IIIC breast cancer
531689|NCT00574145|recurrent breast cancer
531690|NCT00574119|heart failure
531691|NCT00574119|positron emission tomography
531692|NCT00574119|magnetic resonance imaging
531693|NCT00574119|myocardial energetics
531694|NCT00574119|myocardial perfusion
531695|NCT00574106|Cancer
531696|NCT00574106|Tumors
531697|NCT00574093|combination therapy
531698|NCT00574093|Lucentis
531699|NCT00574093|Visudyne
531700|NCT00574054|Familial Dementia
531701|NCT00574054|Semantic Dementia
531702|NCT00574054|Senile Paranoid Dementia
531703|NCT00574041|Multiple Sclerosis
531704|NCT00574041|Avonex
531705|NCT00574041|side effects
531706|NCT00574041|flu like symptoms
531707|NCT00574028|IBD Study
531708|NCT00574015|toothache
531709|NCT00574015|regional anesthesia
531710|NCT00574015|emergency department
531711|NCT00573989|recurrent squamous cell carcinoma of the hypopharynx
531712|NCT00573989|recurrent squamous cell carcinoma of the larynx
531713|NCT00573989|recurrent verrucous carcinoma of the larynx
531714|NCT00573989|recurrent squamous cell carcinoma of the lip and oral cavity
531715|NCT00573989|recurrent verrucous carcinoma of the oral cavity
531716|NCT00573989|metastatic squamous neck cancer with occult primary squamous cell carcinoma
531717|NCT00573989|recurrent metastatic squamous neck cancer with occult primary
531718|NCT00573989|recurrent squamous cell carcinoma of the oropharynx
531719|NCT00573976|SCIM
531720|NCT00573976|SCIM III
531721|NCT00573976|Multi-Center
531722|NCT00573976|United States
531723|NCT00573963|Cesarean section
531724|NCT00573950|cilostazol
531725|NCT00573950|Type 2 Diabetes mellitus
531726|NCT00573950|Metabolic Syndrome
531727|NCT00573950|adipocytokines
531728|NCT00573950|arterial stiffness
531729|NCT00573950|Pulse wave velocity
531730|NCT00573937|Neoplasms
531731|NCT00573937|Pain
531732|NCT00573937|Methadone
531733|NCT00573937|Morphine
531734|NCT00573911|Barrett's esophagus
531735|NCT00573911|GERD
531736|NCT00573898|daptomycin
531737|NCT00573885|non-small cell lung cancer
531738|NCT00573885|small cell lung cancer
531739|NCT00573885|tobacco use disorder
531740|NCT00573872|Radiosurgery
531741|NCT00573872|Phase II
531742|NCT00573872|Cancer
531743|NCT00573872|Spinal
531744|NCT00573872|AVM
531745|NCT00573859|Smoking
531746|NCT00573859|ADHD
531747|NCT00573859|Stimulant medication
531748|NCT00573846|IBD
531749|NCT00573833|adenocarcinoma of the prostate
531750|NCT00573833|stage IIB prostate cancer
531751|NCT00573833|stage IIA prostate cancer
531752|NCT00573820|Tumors or cancer of the prostate
531753|NCT00573820|Cancer of Prostate
531754|NCT00573820|Cancer of the Prostate
531755|NCT00573820|Neoplasms, Prostate
531756|NCT00573820|Neoplasms, Prostatic
531757|NCT00573820|Prostate Cancer
531758|NCT00573820|Prostate Neoplasms
531759|NCT00573820|Prostatic Cancer
531760|NCT00573807|Neuralgia, Sciatic
531761|NCT00573807|Sciatic Neuralgia
531762|NCT00573807|Sciatica, Bilateral
531763|NCT00573807|Lower back pain
531764|NCT00573794|Ulcerative Colitis
531765|NCT00573781|Systems biology
531766|NCT00573781|Nutrigenomics
531767|NCT00573781|Metabolomics
531768|NCT00573781|Gene expression
531769|NCT00573781|Fat tissue
531770|NCT00573781|Peripheral mononuclear cells
531771|NCT00573781|Gene clusters
531772|NCT00573781|Gene expression profiles
531773|NCT00573781|Personal diets
531774|NCT00573781|Metabolic syndrome
531775|NCT00573781|Type 2 Diabetes
531776|NCT00573781|Atherosclerosis
531777|NCT00573768|Ankle, sprain, diclofenac diethylamine
531778|NCT00573755|stage IV breast cancer
531779|NCT00573755|recurrent breast cancer
531780|NCT00573742|hypertension
531781|NCT00573729|vascular malformation
531782|NCT00573716|bone mineral content
531783|NCT00573716|aripiprazole monotherapy
531784|NCT00573716|risperidone monotherapy
531785|NCT00573703|Laparoscopic Burch colposuspension
531787|NCT00573703|Surgery
531788|NCT00573703|TOT
531789|NCT00573703|Treatment
531790|NCT00573703|Predominant or genuine stress urinary incontinence
531791|NCT00573690|unspecified adult solid tumor, protocol specific
531792|NCT00573664|Cesarean section
531793|NCT00573664|Gabapentin
531794|NCT00573651|JIA
531795|NCT00573651|SEA syndrome
531796|NCT00573651|AS
531797|NCT00573651|psoriatic arthritis
531798|NCT00573651|HPV vaccine
531799|NCT00573638|glaucoma
531800|NCT00573638|compliance
531801|NCT00573638|eye drops
531802|NCT00573638|deliver aid
531803|NCT00573638|Patients could range anywhere from 40 to 80 years old
531804|NCT00573638|Patients must have diagnosis requiring treatment with Xalatan.
531805|NCT00573638|Patients will be male or female and from any racial/ethnic background.
531806|NCT00573612|Fibromyalgia
531807|NCT00573612|Fibromyalgia patients
531808|NCT00573599|Migraine
531809|NCT00573599|Emergency
531810|NCT00573599|imitrex
531811|NCT00573599|prochlorperazine
531812|NCT00573599|Acute Migraine Headache in the Emergency Department
531813|NCT00573573|PRIMARY HYPERPARATHYROIDISM
531814|NCT00573573|PARATHYROID NEOPLASMS
531815|NCT00573573|SECONDARY HYPERPARATHYROIDISM
531816|NCT00573573|HYPOCALCEMIA
531817|NCT00573560|Heart failure
531818|NCT00573560|percutaneous
531819|NCT00573560|interventional cardiology
531820|NCT00573560|apical remodeling
531821|NCT00573560|LV dilatation
531822|NCT00573560|akinesis
531823|NCT00573560|dyskinesis
531824|NCT00573547|depression
531825|NCT00573547|chronic renal failures
531826|NCT00573547|end stage renal disease
531827|NCT00573534|Attention Deficit Hyperactivity Disorder
531828|NCT00573534|ADHD
531829|NCT00573534|ADD
531830|NCT00573534|Prevention
531831|NCT00573534|Substance use
531832|NCT00573534|Adolescent
531833|NCT00573521|ESBL positive cultures
531834|NCT00573508|Overactive Bladder
531835|NCT00573495|Advanced breast cancer
531836|NCT00573482|weight gain prevention
531837|NCT00573482|obesity
531838|NCT00573482|overweight
531839|NCT00573482|food environment
531840|NCT00573482|The intervention group received the education in REDE techniques
531841|NCT00573482|The control group received no intervention at all.
531842|NCT00573482|Both groups were exposed to the food labels and the new lower ED foods.
531843|NCT00573482|Only the intervention group received the education sessions and only they were eligible for the price reductions.
531844|NCT00573469|gastrointestinal
531845|NCT00573469|GI
531846|NCT00573469|Crohn's disease
531847|NCT00573469|Japan
531848|NCT00573469|Japanese
531849|NCT00573456|Thye 1 Diabetes
531850|NCT00573456|Type 2 Diabetes
531851|NCT00573443|Amyotrophic Lateral Sclerosis (Lou Gehrig's disease, ALS)
531852|NCT00573443|Multiple Sclerosis (MS)
531853|NCT00573430|Candesartan Cilexetil
531854|NCT00573430|Non-diabetic Nephropathy
531855|NCT00573430|hypertension
531856|NCT00573430|urine protein creatinine ratio
531857|NCT00573417|Schizophrenia
531858|NCT00573417|Clozapine
531859|NCT00573417|Cognition
531860|NCT00573417|Metabolic Syndrome
531861|NCT00573417|Negative Symptoms
531862|NCT00573417|Wakefulness
531863|NCT00573417|Fatigue
531864|NCT00573404|gastrointestinal stromal tumor
531865|NCT00573378|CML
531866|NCT00573365|dermatitis
531867|NCT00573365|skin
531868|NCT00573365|radiation
531869|NCT00573365|light
531870|NCT00573365|LED photomodulation
531871|NCT00573365|Gentlewaves
531872|NCT00573352|Arthritis, Degenerative
531873|NCT00573352|Osteoarthrosis
531874|NCT00573352|Osteoarthrosis Deformans
531875|NCT00573339|Cardiac
531876|NCT00573339|MRI
531877|NCT00573339|normal controls
531878|NCT00573313|Alcoholic Liver Disease (ALD)
531879|NCT00573313|S-adenosylmethionine
531880|NCT00573313|SAMe
531881|NCT00573300|Schizophrenia
531882|NCT00573300|Immune System
531883|NCT00573300|Kynurenate
531884|NCT00573300|tryptophan metabolism
531885|NCT00573300|NMDA receptor
531886|NCT00573300|indolamine 2,3-deoxygenase (IDO)
531887|NCT00573287|Clozapine, risperidone, first episode,
531888|NCT00573274|Cesarean section
531889|NCT00573274|Cardiac Output
531890|NCT00573274|Physioflow
531891|NCT00573274|Cardiography, Impedance
531892|NCT00573261|Diabetic neuropathy
531893|NCT00573261|Pregabalin
531894|NCT00573261|Lyrica
531895|NCT00573248|Nicotine
531896|NCT00573248|ADHD
531897|NCT00573248|Gender
531898|NCT00573235|isolates
531899|NCT00573235|infection
531900|NCT00573235|E coli isolates
531901|NCT00573222|Asthma
531902|NCT00573209|Impotence
531903|NCT00573209|Male Impotence
531904|NCT00573209|Male Sexual Impotence
531905|NCT00573196|Affective Psychosis, Bipolar
531906|NCT00573196|Depression, Bipolar
531907|NCT00573196|Mania
531908|NCT00573196|Manic Disorder
531909|NCT00573196|Manic State
531910|NCT00573196|Manic-Depressive Psychosis
531911|NCT00573196|Psychoses, Manic-Depressive
531912|NCT00573196|Psychosis, Manic-Depressive
531913|NCT00573183|Cocaine, methamphetamine, amphetamine, other stimulant drugs
531914|NCT00573170|Migraine, acute
531915|NCT00573170|Migraine
531916|NCT00573170|Butalbital-containing Combination Medication (BCM)
531917|NCT00573170|Naproxen sodium
531918|NCT00573170|Sumatriptan succinate
531919|NCT00573170|TREXIMET®
531920|NCT00573157|nephritis
531921|NCT00573157|atacicept
531922|NCT00573131|Esophageal cancer
531923|NCT00573131|Localized esophageal cancer
531924|NCT00573131|Operable esophageal cancer
531925|NCT00573131|Loco-regional esophageal cancer
531926|NCT00573131|Esophagectomy
531927|NCT00573131|Phase 2
531928|NCT00573131|Paclitaxel
531929|NCT00573131|Tumor
531930|NCT00573131|Local
531931|NCT00573131|Chemotherapy
531932|NCT00573131|radiation therapy
531933|NCT00573131|surgery
531934|NCT00573131|OncoGel
531935|NCT00573131|Squamous cell carcinoma of the esophagus
531936|NCT00573118|Pregnancy complications: preeclampsia , severe IUGR , IUFD or placental abruption (n = 5).
531937|NCT00573092|Cardiovascular Epidemiology
531938|NCT00573092|Genomics
531939|NCT00573092|Genome-Wide Association Study
531940|NCT00573079|Kidney
531941|NCT00573079|Infants
531942|NCT00573066|Postoperative from cardiac surgery
531943|NCT00573066|Dexmedetomidine
531944|NCT00573053|hypercapneic response
531945|NCT00573053|hyperoxic response
531946|NCT00573053|breathing pattern
531947|NCT00573053|periodic breathing
531948|NCT00573053|sighs
531949|NCT00573040|Radiotherapy
531950|NCT00573040|NSCLC
531951|NCT00573040|Stage III non-small cell lung cancer
531952|NCT00573027|microvascular dysfunction
531953|NCT00573027|Microvascular
531954|NCT00573014|Obtunded blunt trauma patients
531955|NCT00573001|naive
531956|NCT00573001|HIV-1
531957|NCT00573001|simplified treatment
531958|NCT00573001|Treatment Experienced
531959|NCT00572988|symptom management
531960|NCT00572988|function status
531961|NCT00572988|physical activity
531962|NCT00572988|health care utilization
531963|NCT00572975|New diagnostic test for Cystic Fibrosis.
531964|NCT00572949|heart disease
531965|NCT00572949|chest pain
531966|NCT00572949|coronary artery disease
531967|NCT00572949|atherosclerosis
531968|NCT00572936|Glaucoma
531969|NCT00572936|Ocular Hypertension
531970|NCT00572936|Timolol®, Latanoprost® and Dorzolamide®
531971|NCT00572923|radiotherapy
531972|NCT00572923|LD-SCLC
531973|NCT00572923|stage I-III small cell lung cancer
531974|NCT00572897|Myelofibrosis
531975|NCT00572897|Myeloproliferative disease
531976|NCT00572897|Stem Cell Transplant
531977|NCT00572897|Allogeneic Transplant
531978|NCT00572897|Conditioning Regimen
531979|NCT00572897|Reduced Intensity Regimen
531980|NCT00572897|Fludarabine
531981|NCT00572897|Melphalan
531982|NCT00572897|ATG
531983|NCT00572884|permethrin
531984|NCT00572884|pyrethroid
531985|NCT00572884|pharmacokinetics
531986|NCT00572884|metabolism
531987|NCT00572884|accelerator mass spectrometry
531988|NCT00572884|human exposure
531989|NCT00572858|Hypo E
531990|NCT00572845|Basal Energy Expenditure
531991|NCT00572845|Spasticity
531992|NCT00572845|Modified Ashworth Scale
531993|NCT00572845|Penn Spasm Frequency Score
531994|NCT00572832|Human Papillomavirus Vaccine
531995|NCT00572819|Hysteroscopy
531996|NCT00572819|Misoprostol
531997|NCT00572819|Postmenopausal women
531998|NCT00572819|Cervical ripening
531999|NCT00572819|Dilatation
532000|NCT00572819|Sequential trial
532001|NCT00572819|Estradiol
532002|NCT00572780|Crohn's Disease
532003|NCT00572780|CT Enteroclysis
532004|NCT00572767|randomised-controlled trial
532005|NCT00572767|ischemic stroke
532006|NCT00572767|motor recovery
532007|NCT00572767|amphetamine
532008|NCT00572767|motor recovery of patients after a first-ever ischemic stroke
532009|NCT00572741|Autism
532010|NCT00572741|vitamin B 12
532011|NCT00572741|glutathione
532012|NCT00572715|kidney
532013|NCT00572715|neonates
532014|NCT00572702|Biocompatible Materials
532015|NCT00572702|Female
532016|NCT00572702|Humans
532017|NCT00572702|Pelvic Floor
532018|NCT00572702|Polypropylenes
532019|NCT00572702|Prostheses and Implants
532020|NCT00572702|Surgical Mesh
532021|NCT00572702|Uterine Prolapse/*therapy
532022|NCT00572689|Exenatide
532023|NCT00572689|TCF7L2 polymorphism
532024|NCT00572689|Pharmacodynamics
532025|NCT00572689|Pharmacokinetics
532026|NCT00572663|Proteinuria
532027|NCT00572663|Antioxidant
532028|NCT00572663|N-acetylcysteine
532029|NCT00572650|Type-2 diabetes, DPP-4 inhibitor, vildagliptin
532030|NCT00572624|Abdominal Obesity
532031|NCT00572624|Heart Metabolism
532032|NCT00572624|Type II Diabetes Mellitus
532033|NCT00572624|PET
532034|NCT00572624|Fatty Acid
532035|NCT00572611|Mass Balance
532036|NCT00572611|Metabolism
532037|NCT00572611|Absorption
532038|NCT00572611|Excretion
532039|NCT00572611|Pharmacokinetics
532040|NCT00572598|PET
532041|NCT00572598|multidrug resistance
532042|NCT00572598|fluoropaclitaxel
532043|NCT00572598|paclitaxel
532044|NCT00572598|breast cancer
532045|NCT00572598|dosimetry
532046|NCT00572598|imaging feasibility
532047|NCT00572585|Ulcerative colitis
532048|NCT00572585|immunosuppressive therapy
532049|NCT00572585|AEB071
532050|NCT00572585|Modified Baron score
532051|NCT00572585|Partial Mayo score
532052|NCT00572533|End-Stage Renal Disease
532053|NCT00572533|Chronic Hemodialysis
532054|NCT00572520|Depressive Disorder
532055|NCT00572520|Weight Loss
532056|NCT00572520|Behavioral Treatment
532057|NCT00572520|Behavior Therapy
532058|NCT00572520|Randomized Clinical Trial
532059|NCT00572507|Absorbable Monofilament Suture Material
532060|NCT00572507|Safety and Efficacy
532061|NCT00572507|Abdominal Wall/ Fascia
532062|NCT00572507|Laparotomy
532063|NCT00572494|Tibial arteries
532064|NCT00572494|Absorbable implants
532065|NCT00572494|Stents
532066|NCT00572494|Limb salvage
532067|NCT00572481|Sentinel Lymph Node Biopsy
532068|NCT00572481|Axillary Node Dissection
532069|NCT00572481|Prevention of lymphedema
532070|NCT00572481|Prevention of neuroma
532071|NCT00572481|Prevention of seroma
532072|NCT00572468|cancer
532073|NCT00572468|pre-operative surgery
532074|NCT00572468|prostate
532075|NCT00572468|prostatectomy
532076|NCT00572468|radiation
532077|NCT00572455|Open-Angle Glaucoma
532078|NCT00572455|Ocular Hypertension
532079|NCT00572442|Non-invasive heart scan
532080|NCT00572442|MCG
532081|NCT00572442|Cardiac Risk Factors
532082|NCT00572442|healthy volunteers
532083|NCT00572429|HIV/AIDS
532084|NCT00572429|HAART
532085|NCT00572429|high cholesterol
532086|NCT00572429|exercise
532087|NCT00572429|L-carnitine
532088|NCT00572429|Complimentary therapies
532089|NCT00572416|fatigue
532090|NCT00572416|activity-rest
532091|NCT00572416|sleep-wake
532092|NCT00572416|psychological distress
532093|NCT00572416|symptom management
532094|NCT00572403|microalbuminuria
532095|NCT00572403|risk factors
532096|NCT00572377|Sexual
532097|NCT00572377|Arousal
532098|NCT00572377|Female
532099|NCT00572364|Cancer
532100|NCT00572364|Advanced solid malignancies
532101|NCT00572351|Wine
532102|NCT00572325|radiotherapy
532103|NCT00572325|NSCLC
532104|NCT00572325|stage III non-small cell lung cancer
532105|NCT00572312|Proteinuria,
532106|NCT00572312|atorvastatin
532107|NCT00572299|glucocorticoids, prednisone, alendronate,osteoclasts
532108|NCT00572286|heart transplant
532109|NCT00572286|advanced heart failure
532110|NCT00572286|orthotropic heart transplantation
532111|NCT00572286|(MCG) magnetocardiograph
532112|NCT00572286|echocardiogram
532113|NCT00572260|MRSA
532114|NCT00572260|Increased risk for infection
532115|NCT00572234|Methamphetamine
532116|NCT00572234|Bupropion SR
532117|NCT00572221|CQI
532118|NCT00572221|QA
532119|NCT00572221|Best Practice
532120|NCT00572221|Quality Improvement
532121|NCT00572221|Nursing Facilities
532122|NCT00572221|Nursing Homes
532123|NCT00572221|Care
532124|NCT00572195|Epilepsy
532125|NCT00572195|Responsive neurostimulation
532126|NCT00572195|RNS System
532127|NCT00572195|NeuroPace
532128|NCT00572195|Brain stimulation
532129|NCT00572195|Seizures
532130|NCT00572182|recurrent childhood brain stem glioma
532131|NCT00572182|childhood central nervous system germ cell tumor
532132|NCT00572182|recurrent childhood cerebellar astrocytoma
532133|NCT00572182|recurrent childhood cerebral astrocytoma
532134|NCT00572182|childhood high-grade cerebral astrocytoma
532135|NCT00572182|childhood choroid plexus tumor
532136|NCT00572182|childhood craniopharyngioma
532137|NCT00572182|recurrent childhood ependymoma
532138|NCT00572182|recurrent childhood medulloblastoma
532139|NCT00572182|childhood oligodendroglioma
532140|NCT00572182|recurrent childhood pineoblastoma
532141|NCT00572182|recurrent childhood supratentorial primitive neuroectodermal tumor
532142|NCT00572182|childhood atypical teratoid/rhabdoid tumor
532143|NCT00572182|childhood spinal cord neoplasm
532144|NCT00572182|childhood infratentorial ependymoma
532145|NCT00572182|childhood supratentorial ependymoma
532146|NCT00572182|recurrent childhood visual pathway and hypothalamic glioma
532147|NCT00572182|childhood grade III meningioma
532148|NCT00572156|IGF-1 Deficiency
532149|NCT00572156|growth
532150|NCT00572156|ISS
532151|NCT00572156|Constitutional growth delay
532152|NCT00572156|Primary IGFD
532153|NCT00572156|Primary IGF Deficiency
532154|NCT00572143|Colonic Neoplasms/surgery*
532155|NCT00572143|Continuity of Patient Care*
532156|NCT00572143|Follow-Up Studies
532157|NCT00572143|Quality of Life
532158|NCT00572143|Patient Satisfaction
532159|NCT00572130|Tumor-targeted gene medicine
532160|NCT00572130|Cyclin G1 gene
532161|NCT00572130|Osteosarcoma
532162|NCT00572117|Bipolar Disorder
532163|NCT00572117|Manic Disorder
532164|NCT00572117|Alcoholism
532165|NCT00572117|Alcohol Abuse
532166|NCT00572117|Alcohol Dependence
532167|NCT00572117|Clinical Trial
532168|NCT00572117|Evaluation Trial
532169|NCT00572117|Intervention Trial
532170|NCT00572117|Validation Studies
532171|NCT00572091|Heart Failure
532172|NCT00572091|Mitral Regurgitation
532173|NCT00572078|solid tumor
532174|NCT00572039|Age-Related Macular Degeneration
532175|NCT00572039|AMD
532176|NCT00572039|Vision Function
532177|NCT00572039|Problem Solving Treatment
532178|NCT00572039|PST
532179|NCT00572026|Attention deficit
532180|NCT00572026|Hyperactivity
532181|NCT00572026|Attention deficit hyperactivity disorder
532182|NCT00571987|Breast cancer
532183|NCT00571987|Lumpectomy
532184|NCT00571987|Radiofrequency Ablation
532185|NCT00571987|Negative margins
532186|NCT00571987|Breast Conserving Surgery
532187|NCT00571961|HIV
532188|NCT00571961|Pharmacokinetics
532189|NCT00571961|Buprenorphine
532190|NCT00571961|Kaletra
532191|NCT00571961|HIV Seronegativity
532192|NCT00571948|infant, complementary food, iron, meat, LC-PUFA, omega-3,
532193|NCT00571948|rapeseed oil, diet
532194|NCT00571922|methamphetamine, crystal, treatment
532195|NCT00571909|Polycystic Kidney Disease
532196|NCT00571909|Chronic Kidney Pain
532197|NCT00571909|Autosomal Dominant Polycystic Kidney
532198|NCT00571909|Kidney Cyst
532199|NCT00571909|VSPL
532200|NCT00571909|video thoracoscopic splanchnicectomy
532201|NCT00571896|constipation
532202|NCT00571896|SennaS
532203|NCT00571883|stage I squamous cell carcinoma of the lip and oral cavity
532204|NCT00571883|stage II squamous cell carcinoma of the lip and oral cavity
532205|NCT00571883|tongue cancer
532206|NCT00571844|High Blood Pressure
532207|NCT00571844|Exercise
532208|NCT00571844|Diet
532209|NCT00571844|Biomarkers
532210|NCT00571831|macula edema
532211|NCT00571831|intraocular lens
532212|NCT00571831|prospective randomized parallel clinical design
532213|NCT00571818|euglycemic
532214|NCT00571818|transplant
532215|NCT00571818|pancreas
532216|NCT00571818|hyperglycemic
532217|NCT00571818|kidney
532218|NCT00571805|cigarette
532219|NCT00571805|craving
532220|NCT00571805|reward
532221|NCT00571792|COPD
532222|NCT00571792|The cohort will be comprised of normal non-smoking individuals, those individuals
532223|NCT00571792|who smoke who do not exhibit symptoms of COPD and individuals who smoke who do demonstrate
532224|NCT00571792|symptoms of COPD
532225|NCT00571766|chronic hypertension in pregnancy
532226|NCT00571766|chronic Hypertension
532227|NCT00571753|pulmonary tuberculosis
532228|NCT00571753|NAT2 genotyping
532229|NCT00571753|hepatotoxicity of isoniazid
532230|NCT00571740|stage IV colon cancer
532231|NCT00571740|stage IV rectal cancer
532232|NCT00571740|recurrent colon cancer
532233|NCT00571740|recurrent rectal cancer
532234|NCT00571727|growth
532235|NCT00571727|insulin like growth factor
532236|NCT00571727|Larons syndrome
532237|NCT00571714|Chronic hepatitis C
532238|NCT00571714|Pilot Comparison
532239|NCT00571714|Peginterferon alph-2a
532240|NCT00571714|Ribavirin
532241|NCT00571714|Betaine
532242|NCT00571714|Genotype 1
532243|NCT00571714|Treatment naive
532244|NCT00571701|HPV
532245|NCT00571701|RRP
532246|NCT00571688|Bipolar Disorder
532247|NCT00571688|Depression, Bipolar
532248|NCT00571688|Mania
532249|NCT00571675|Prostate Cancer
532250|NCT00571675|Hormone Refractory Prostate Cancer
532251|NCT00571675|HRPC
532252|NCT00571675|Docetaxel
532253|NCT00571675|Taxotere
532254|NCT00571675|Prednisone
532255|NCT00571675|Metastatic (Stage IV) Disease
532256|NCT00571675|Chemotherapy-naïve metastatic Hormone Refractory Prostate Cancer (HRPC)
532257|NCT00571649|Acute medical illnesses with increased risk for VTE.
532258|NCT00571649|Deep vein thrombosis (DVT)
532259|NCT00571649|Pulmonary embolism (PE),
532260|NCT00571649|Venous Thromboembolic disease (VTE),
532261|NCT00571649|Medical illness
532262|NCT00571636|Opioids infusion
532263|NCT00571636|mechanical ventilation
532264|NCT00571623|Brain Injury
532265|NCT00571623|Intracranial hypertension
532266|NCT00571623|Human subjects
532267|NCT00571623|Nursing care
532268|NCT00571610|Heart Failure
532269|NCT00571610|Mitral Regurgitation
532270|NCT00571597|surgery
532271|NCT00571597|ablation
532272|NCT00571597|radiofrequency
532273|NCT00571597|minimaze
532274|NCT00571597|transtelephonic monitoring
532275|NCT00571571|Identity difussion
532276|NCT00571571|Adolescent psychotherapy
532277|NCT00571571|Transference Focused Psychotherapy for Adolescents
532278|NCT00571571|Identity
532279|NCT00571571|Identity crisis
532280|NCT00571571|Identity pathology
532281|NCT00571545|Traumatic brain injury
532282|NCT00571545|Depression
532283|NCT00571545|Exercise
532284|NCT00571506|Diabetes Mellitus, Type 2
532285|NCT00571506|Vascular Diseases
532286|NCT00571506|Thiazolidinediones
532287|NCT00571506|Platelet Aggregation
532288|NCT00571493|non-hodgkin's lymphoma
532289|NCT00571493|mantle cell lymphoma
532290|NCT00571493|BEAM
532291|NCT00571493|Velcade
532292|NCT00571480|auricular acupuncture
532293|NCT00571480|pregnancy related low back pain
532294|NCT00571480|acupuncture
532295|NCT00571467|Autoimmune Diseases
532296|NCT00571467|Bleeding Disorders
532297|NCT00571467|Blood and Blood Disorders
532298|NCT00571454|depression
532299|NCT00571454|primary care
532300|NCT00571454|Latino
532301|NCT00571454|telephone
532302|NCT00571454|care management
532303|NCT00571441|stroke
532304|NCT00571441|Brain injury
532305|NCT00571441|nursing
532306|NCT00571441|Critical care
532307|NCT00571428|COPD
532308|NCT00571428|Chronic Bronchitis
532309|NCT00571428|Emphysema
532310|NCT00571415|Image guided adaptive radiotherapy
532311|NCT00571402|Family Treatment
532312|NCT00571402|Pharmacotherapy
532313|NCT00571389|Stage IV
532314|NCT00571389|Advanced Stage III
532315|NCT00571376|Quality of health care
532316|NCT00571376|Health care costs
532317|NCT00571350|Cystocele
532318|NCT00571350|tension free vaginal tapes
532319|NCT00571350|urinary incontinence
532320|NCT00571337|Stop infliximab.
532321|NCT00571324|hyperinsulinism
532322|NCT00571324|hypoglycemia
532323|NCT00571324|KATP channel
532324|NCT00571324|Kir6.2
532325|NCT00571311|Assent
532326|NCT00571311|Adolescent
532327|NCT00571311|Informed Consent
532328|NCT00571298|Extrapleural pneumonectomy
532329|NCT00571298|Pleurectomy Decortication
532330|NCT00571298|Mesothelioma
532331|NCT00571298|cisplatin
532332|NCT00571298|gemcitabine
532333|NCT00571298|amifostine
532334|NCT00571298|sodium thiosulfate
532335|NCT00571285|Parkinson's disease
532336|NCT00571285|Nutrition
532337|NCT00571285|Vitamin supplement
532338|NCT00571285|Motor function
532339|NCT00571285|Non-motor function
532340|NCT00571272|Cholestatic Liver Disease
532341|NCT00571272|Cholestasis
532342|NCT00571272|Childhood Diseases
532343|NCT00571272|Genetic Diseases
532344|NCT00571272|Bile Acid Synthesis and Metabolism Defects
532345|NCT00571272|Progressive Familial Intrahepatic Cholestasis
532346|NCT00571259|Sodium citrate
532347|NCT00571259|Gentamicin
532348|NCT00571259|Prophylaxis
532349|NCT00571259|Hemodialysis
532350|NCT00571259|Central venous catheter
532351|NCT00571246|treatment
532352|NCT00571246|Lamotrigine
532353|NCT00571246|Topiramate
532354|NCT00571246|alcohol dependence
532355|NCT00571246|post traumatic stress disorder
532356|NCT00571233|Single Ventricle
532357|NCT00571233|Congenital Heart Disease
532358|NCT00571233|Children
532359|NCT00571233|Fontan
532360|NCT00571233|Tricuspid Atresia
532361|NCT00571233|Hypoplastic Left Heart Syndrome
532362|NCT00571233|Heart Failure
532363|NCT00571233|Biomarkers
532364|NCT00571233|Single ventricle physiology such as:
532365|NCT00571233|unbalanced AV canal
532366|NCT00571233|Interested in patients both before and after Fontan Surgery
532367|NCT00571220|gastric bypass
532368|NCT00571220|diabetes
532369|NCT00571220|obesity
532370|NCT00571220|diet-induced weight loss
532371|NCT00571220|incretin levels (GLP-1,GIP)
532372|NCT00571220|incretin effect
532373|NCT00571207|driving under the influence of drugs
532374|NCT00571207|on-site oral fluid screening devices
532375|NCT00571207|checklist
532376|NCT00571194|pravastatin, peritoneal dialysis, pediatric patients
532377|NCT00571181|Algorithms
532378|NCT00571181|Anesthesia, General/*methods
532379|NCT00571181|Anesthetics, Intravenous/*administration & dosage
532380|NCT00571181|Drug Delivery Systems/*methods/statistics & numerical data
532381|NCT00571181|Electroencephalography/drug effects/*methods/
532382|NCT00571181|Feasibility Studies
532383|NCT00571181|Propofol/*administration & dosage
532384|NCT00571181|Remifentanil/*administration & dosage
532385|NCT00571181|Bronchoscopy/*methods
532386|NCT00571181|Prospective Studies
532387|NCT00571181|Software
532388|NCT00571168|chemotherapy induced nausea and vomiting
532389|NCT00571168|autologous peripheral blood stemcell transplantation
532390|NCT00571168|high dose chemotherapy
532391|NCT00571142|edema
532392|NCT00571142|retinal thickness
532393|NCT00571142|diabetic retinopathy
532394|NCT00571129|Primary,silicone tube,revision,mitomycin C,endoscopic DCR
532395|NCT00571116|Metastatic Melanoma
532396|NCT00571116|Disulfiram
532397|NCT00571116|Arsenic Trioxide
532398|NCT00571116|Metastatic Melanoma and at Least One Prior Systemic Therapy
532399|NCT00571090|Thyroid nodule
532400|NCT00571090|Biopsy, Fine-Needle
532401|NCT00571077|Thyroid neoplasms
532402|NCT00571077|thyroid nodules
532403|NCT00571077|electrical impedance scanning
532404|NCT00571051|MEG, mindfulness, tactile perception
532405|NCT00571038|Hypertension
532406|NCT00571038|Self-help groups
532407|NCT00571038|Community health networks
532408|NCT00571038|Health knowledge, attitudes, practice
532409|NCT00571038|Patient participation
532410|NCT00571038|Randomized clinical trial
532411|NCT00571025|Mild Cognitive Impairment
532412|NCT00571025|disease/disorder proneness/risk
532413|NCT00571025|family genetics
532414|NCT00571025|genetic counseling
532415|NCT00571025|genetic marker
532416|NCT00571025|genetic polymorphism
532417|NCT00571025|genetic susceptibility
532418|NCT00571012|glaucoma
532419|NCT00571012|outflow facility
532420|NCT00571012|Healthy eye function
532421|NCT00570999|Peripheral blood stem cell transplantation
532422|NCT00570999|Palifermin
532423|NCT00570999|Kepivance
532424|NCT00570999|Prevenar
532425|NCT00570999|Placebo
532426|NCT00570986|Plaque Psoriasis
532427|NCT00570973|Variceal Bleeding
532428|NCT00570973|Cirrhosis
532429|NCT00570973|Encephalopathy
532430|NCT00570973|Endoscopic band ligation
532431|NCT00570973|TIPS
532432|NCT00570960|Peritonitis
532433|NCT00570947|CPR Anytime
532434|NCT00570921|Breast cancer
532435|NCT00570921|Fulvestrant
532436|NCT00570921|Everolimus
532437|NCT00570908|brain metastasis
532438|NCT00570908|breast cancer
532439|NCT00570908|metastatic breast cancer
532440|NCT00570895|Iron
532441|NCT00570895|Absorption
532442|NCT00570895|Ascorbic Acid
532443|NCT00570895|Ferrous Fumarate
532444|NCT00570882|Renal cell carcinoma
532445|NCT00570882|Sunitinib
532446|NCT00570882|phase II study
532447|NCT00570882|Randomized study
532448|NCT00570869|Infant CPR
532449|NCT00570856|Folic Acid
532450|NCT00570856|Homocysteine
532451|NCT00570856|intima-media thickness
532452|NCT00570817|Methotrexate
532453|NCT00570817|Nephrotoxicity
532454|NCT00570817|Hydration
532455|NCT00570817|Acute lymphoblastic leukemia
532456|NCT00570817|Non-Hodgkin's lymphoma
532457|NCT00570817|Medulloblastoma
532458|NCT00570817|Ependymoma
532459|NCT00570817|Prolonged elimination time of methotrexate
532460|NCT00570804|Smoking Cessation
532461|NCT00570804|Puerto Rico Quitline
532462|NCT00570804|Motivational Relapse Prevention
532463|NCT00570804|Oral Cancer
532464|NCT00570804|Risk Reduction
532465|NCT00570804|Tobacco Use
532466|NCT00570804|Alcohol Use
532467|NCT00570804|MAPS
532468|NCT00570804|Motivation and Problem-Solving
532469|NCT00570804|Telephone Interview
532470|NCT00570804|Counseling
532471|NCT00570791|Cornea
532472|NCT00570791|Tonometers
532473|NCT00570791|Goldmann applanation
532474|NCT00570791|Tonopen
532475|NCT00570791|Shiotz
532476|NCT00570791|Pneumatonometer
532477|NCT00570778|QVA, Indacaterol, Glycopyrrolate, Concept1, COPD, cross over study, safety and efficacy, trough FEV1
532478|NCT00570739|Colesevelam
532479|NCT00570739|Type 2 Diabetes Mellitus
532480|NCT00570739|Pre-diabetes
532481|NCT00570739|Metformin
532482|NCT00570700|prostate
532483|NCT00570687|Inhaled Insulin
532484|NCT00570674|SSCHN
532485|NCT00570674|Abraxane
532486|NCT00570674|IMRT
532487|NCT00570648|Corneal transplantation
532488|NCT00570635|GIST
532489|NCT00570635|Gastrointestinal Cancer
532490|NCT00570622|Cirrhosis
532491|NCT00570622|oxidative stress
532492|NCT00570622|pioglitazone
532493|NCT00570609|CPR
532494|NCT00570583|Depression
532495|NCT00570583|Cognitive impairment
532496|NCT00570583|Dementia
532497|NCT00570583|Neuroimaging
532498|NCT00570583|Genetics
532499|NCT00570570|stroke
532500|NCT00570570|hemiplegia
532501|NCT00570570|gait
532502|NCT00570570|Strengthening
532503|NCT00570570|Physiotherapy
532504|NCT00570557|Skill Maintenance
532505|NCT00570557|Skill Decay
532506|NCT00570557|Screening
532507|NCT00570544|copd
532508|NCT00570544|emphysema
532509|NCT00570544|tiotropium
532510|NCT00570544|lung function
532511|NCT00570544|dynamic hyperinflation
532512|NCT00570518|driving under the influence
532513|NCT00570518|psychoactive substances
532514|NCT00570518|roadside surveys
532515|NCT00570518|hospital surveys
532759|NCT00569465|hypertension
532516|NCT00570518|accident involvement risk estimation
532517|NCT00570492|allergic rhinitis
532518|NCT00570492|fluticasone furoate nasal spray
532519|NCT00570492|growth
532520|NCT00570479|Retisert
532521|NCT00570479|Uveitis
532522|NCT00570479|glaucoma
532523|NCT00570466|Type 2 Diabetes
532524|NCT00570466|Prevention
532525|NCT00570466|Children
532526|NCT00570466|Diet
532527|NCT00570466|Physical Activity
532528|NCT00570440|AE adverse event
532529|NCT00570440|AIDS acquired immunodeficiency syndrome
532530|NCT00570440|ALT (SGPT) alanine aminotransferase
532531|NCT00570440|ART antiretroviral therapy
532532|NCT00570440|AST (SGOT) aspartate aminotransferase
532533|NCT00570440|DCF data collection forms
532534|NCT00570440|DMC Data Monitoring Committee
532535|NCT00570440|FDA (U.S.) Food and Drug Administration
532536|NCT00570440|GCP Good Clinical Practice guidelines
532537|NCT00570440|HB sAg Hepatitis B surface antigen
532538|NCT00570440|ICH International Conference of Harmonisation
532539|NCT00570440|IND Investigational New Drug Application
532540|NCT00570440|IRB Institutional Review Board
532541|NCT00570440|IU international units
532542|NCT00570440|mg milligram(s)
532543|NCT00570440|mm3 cubic millimeter(s)
532544|NCT00570440|PCR polymerase chain reaction
532545|NCT00570440|SAE serious adverse event
532546|NCT00570440|µg microgram
532547|NCT00570440|ULN upper limit of the normal range
532548|NCT00570440|WB Western Blot
532549|NCT00570427|psychotherapy
532550|NCT00570427|behavior therapy
532551|NCT00570427|counseling
532552|NCT00570427|aging
532553|NCT00570427|medically underserved population
532554|NCT00570401|adenocarcinoma of the lung
532555|NCT00570401|stage IIIA non-small cell lung cancer
532556|NCT00570401|stage IIIB non-small cell lung cancer
532557|NCT00570401|stage IV non-small cell lung cancer
532558|NCT00570401|recurrent non-small cell lung cancer
532559|NCT00570388|Neurocognitive
532560|NCT00570388|Alcohol Dependence
532561|NCT00570388|Prometa
532562|NCT00570388|Prometa Protocol
532563|NCT00570388|Starosta
532564|NCT00570375|Blood disease, bone marrow
532565|NCT00570362|Normal tension glaucoma
532566|NCT00570362|Glutathione
532567|NCT00570362|Antioxidant
532568|NCT00570349|Inhaled Nitric oxide
532569|NCT00570349|Cystic Fibrosis
532570|NCT00570336|HCV
532571|NCT00570336|HCV treatment failure
532572|NCT00570336|Elevated aminotransferases
532573|NCT00570323|Breast Cancer
532574|NCT00570323|HORMONE RECEPTOR POSITIVE BREAST CANCER
532575|NCT00570297|Pediatric
532576|NCT00570297|Polymorphism, Genetic
532577|NCT00570297|Adrenergic beta-Agonists
532578|NCT00570284|Cancer
532579|NCT00570284|solid tumor
532580|NCT00570284|food effect
532581|NCT00570284|HDAC inhibitor
532582|NCT00570284|oral
532583|NCT00570284|LBH589
532584|NCT00570271|placebo effect
532585|NCT00570271|blood pressure
532586|NCT00570271|autonomic nervous system
532587|NCT00570271|prestige
532588|NCT00570271|basic research on physiological placebo effects
532589|NCT00570245|Lung transplantation
532590|NCT00570232|Resectable, recurrent head and neck cancer
532591|NCT00570206|Probation
532592|NCT00570206|Motivational
532593|NCT00570180|newly diagnosed
532594|NCT00570167|Osteoarthritis
532595|NCT00570167|Hip
532596|NCT00570167|Artroplasty
532597|NCT00570167|Resurfacing
532598|NCT00570154|Mitochondrial Function in Monocytes
532599|NCT00570154|Macrophages and Diabetes or Insulin Resistance
532600|NCT00570154|Peripheral Blood Mononuclear Cells
532601|NCT00570154|Diabetes
532602|NCT00570154|Monocyte
532603|NCT00570154|Macrophages
532604|NCT00570154|Proteome
532605|NCT00570154|Type 2 Diabetes
532606|NCT00570154|Insulin Resistance
532607|NCT00570154|Insulin Sensitivity
532608|NCT00570154|Pre-Diabetes
532609|NCT00570154|Healthy Volunteer
532610|NCT00570154|HV
532611|NCT00570128|Down Syndrome
532612|NCT00570128|trisomy 21
532613|NCT00570115|Sleep Apnea Syndromes diastolic disfunction left atrium
532614|NCT00570102|dietary manipulation
532615|NCT00570102|infants
532616|NCT00570102|feasibility
532617|NCT00570102|Type 1 Diabetes Mellitus, Beta-cell Autoimmunity
532618|NCT00570089|Ranolazine
532619|NCT00570089|Myocardial ischemia
532620|NCT00570089|Double blinded
532621|NCT00570089|Placebo controlled
532622|NCT00570063|Schizophrenia, acute exacerbation, and PF-02545920
532623|NCT00570050|Major Depressive Disorder, Memory, Executive function
532624|NCT00570037|Influenza
532625|NCT00570037|Vaccine
532626|NCT00570037|Children
532627|NCT00570024|Acupuncture
532628|NCT00570024|Coronary Artery Disease
532629|NCT00569985|AIDS-related diffuse large cell lymphoma
532630|NCT00569985|AIDS-related diffuse mixed cell lymphoma
532631|NCT00569985|AIDS-related diffuse small cleaved cell lymphoma
532632|NCT00569985|AIDS-related immunoblastic large cell lymphoma
532633|NCT00569985|AIDS-related small noncleaved cell lymphoma
532634|NCT00569985|HIV-associated Hodgkin lymphoma
532635|NCT00569985|Treatment Experienced
532636|NCT00569959|fasting lipid measures
532637|NCT00569959|non-fasting lipid measures
532638|NCT00569959|clinical decision-making
532639|NCT00569959|LDL-Cholesterol
532640|NCT00569946|AG-013736
532641|NCT00569946|RCC
532642|NCT00569946|Phase 2
532643|NCT00569933|Hip Surgery
532644|NCT00569933|Perioperative
532645|NCT00569933|suggestions/imagery
532646|NCT00569907|type 2 diabetes
532647|NCT00569907|continuous glucose monitoring
532648|NCT00569907|exenatide
532649|NCT00569907|exenatide use
532650|NCT00569881|Epithelium
532651|NCT00569881|Wound Healing
532652|NCT00569881|PRK
532653|NCT00569868|PLASMACYTOMA
532654|NCT00569829|cognitive behavioral therapy
532655|NCT00569829|anxiety disorders
532656|NCT00569829|school-based intervention
532657|NCT00569829|randomized, controlled trial
532658|NCT00569816|myocardial protection
532659|NCT00569816|pharmacological preconditioning
532660|NCT00569816|volatile anesthetics
532661|NCT00569816|myocardial injury following CABG surgery
532662|NCT00569790|S-1
532663|NCT00569790|Irinotecan
532664|NCT00569790|Bevacizumab
532665|NCT00569764|schizophrenia
532666|NCT00569764|metabolic syndrome
532667|NCT00569764|aripiprazole
532668|NCT00569751|de novo
532669|NCT00569751|coronary
532670|NCT00569751|coronary artery disease
532671|NCT00569751|coronary disease
532672|NCT00569738|neuroendocrine tumor
532673|NCT00569738|somatostatin analog
532674|NCT00569738|Gallium 68
532675|NCT00569738|PET
532676|NCT00569712|non-small cell lung cancer
532677|NCT00569712|precancerous condition
532678|NCT00569699|S-1
532679|NCT00569699|Bevacizumab
532680|NCT00569686|PAD
532681|NCT00569686|peripheral artery disease
532682|NCT00569673|recurrent ovarian epithelial cancer
532683|NCT00569673|fallopian tube cancer
532684|NCT00569673|primary peritoneal cavity cancer
532685|NCT00569660|Myelofibrosis
532686|NCT00569660|MF
532687|NCT00569660|Leukemia
532688|NCT00569660|Azacitidine
532689|NCT00569660|Vidaza
532690|NCT00569647|preoperative anxiety
532691|NCT00569647|burn reconstruction
532692|NCT00569634|Venous blood gas
532693|NCT00569634|Arterial blood gas
532694|NCT00569634|pH
532695|NCT00569634|pCO2
532696|NCT00569634|Bicarbonate
532697|NCT00569608|Parental stress
532698|NCT00569608|Early discharge
532699|NCT00569608|Anxiety
532700|NCT00569608|Depression
532701|NCT00569608|Neonatal Intensive Care Unit
532702|NCT00569595|Prevention of Diabetes and other chronic diseases
532703|NCT00569582|Cushing's Disease
532704|NCT00569582|Cushing's Syndrome
532705|NCT00569582|Cushings
532706|NCT00569582|Pituitary
532707|NCT00569582|ACTH
532708|NCT00569582|Adrenocorticotropic hormone
532709|NCT00569582|Ectopic
532710|NCT00569582|Adrenal adenoma
532711|NCT00569582|Adrenal carcinoma
532712|NCT00569582|Adrenal autonomy
532713|NCT00569582|Cortisol
532714|NCT00569582|Hypercortisolemia
532715|NCT00569582|Cushingoid
532716|NCT00569582|Moon facies
532717|NCT00569582|Dorsocervical fat
532718|NCT00569582|Plethora
532719|NCT00569582|Hirsutism
532720|NCT00569582|Violaceous striae
532721|NCT00569582|Hormone
532722|NCT00569582|Contraceptive
532723|NCT00569582|Endocrine
532724|NCT00569582|Cushing Syndrome
532725|NCT00569582|Ectopic ACTH Secretion
532726|NCT00569556|Diabetes Mellitus
532727|NCT00569556|Chronic Care Model
532728|NCT00569556|Case Management
532729|NCT00569543|breast cancer in situ
532730|NCT00569543|ductal breast carcinoma in situ
532731|NCT00569543|stage I breast cancer
532732|NCT00569543|stage II breast cancer
532733|NCT00569543|stage IIIA breast cancer
532734|NCT00569543|stage IIIB breast cancer
532735|NCT00569543|stage IIIC breast cancer
532736|NCT00569543|stage IV breast cancer
532737|NCT00569530|nitric oxide
532738|NCT00569530|surfactant
532739|NCT00569530|bronchopulmonary dysplasia
532740|NCT00569530|prematurity
532741|NCT00569530|neonates
532742|NCT00569530|iNO
532743|NCT00569530|Infasurf
532744|NCT00569530|lung function
532745|NCT00569530|ventilated infants
532746|NCT00569517|obesity
532747|NCT00569517|CBT
532748|NCT00569517|Atypical antipsychotics
532749|NCT00569517|metabolic syndrome
532750|NCT00569504|schizophrenia
532751|NCT00569504|antipsychotics
532752|NCT00569504|metabolic syndrome
532753|NCT00569504|prevalence
532754|NCT00569478|ICD
532755|NCT00569478|Rehabilitation
532756|NCT00569465|nitric oxide
532757|NCT00569465|oxidative stress
532758|NCT00569465|diabetes
532760|NCT00569465|endothelial dysfunction
532761|NCT00569439|Labor
532762|NCT00569439|Carbohydrate
532763|NCT00569439|Dystocia
532764|NCT00569413|Sex
532765|NCT00569413|brain imaging
532766|NCT00569413|dopamine
532767|NCT00569413|sexual disorder
532768|NCT00569387|pancreatic cancer
532769|NCT00569387|vaccine
532770|NCT00569361|allergic rhinitis to dust mite
532771|NCT00569361|allergic rhinitis associated with bronchial hyperreactivity
532772|NCT00569361|allergic rhinitis associated with asthma
532773|NCT00569335|S-1, Bevacizumab, Irinotecan
532774|NCT00569322|ICU
532775|NCT00569322|Admission
532776|NCT00569322|BG
532777|NCT00569309|contiguous stage II mantle cell lymphoma
532778|NCT00569309|noncontiguous stage II mantle cell lymphoma
532779|NCT00569309|recurrent mantle cell lymphoma
532780|NCT00569309|stage I mantle cell lymphoma
532781|NCT00569309|stage III mantle cell lymphoma
532782|NCT00569309|stage IV mantle cell lymphoma
532783|NCT00569309|recurrent adult diffuse large cell lymphoma
532784|NCT00569309|stage III adult diffuse large cell lymphoma
532785|NCT00569309|stage IV adult diffuse large cell lymphoma
532786|NCT00569309|contiguous stage II grade 1 follicular lymphoma
532787|NCT00569309|contiguous stage II grade 2 follicular lymphoma
532788|NCT00569309|contiguous stage II grade 3 follicular lymphoma
532789|NCT00569309|noncontiguous stage II grade 1 follicular lymphoma
532790|NCT00569309|noncontiguous stage II grade 2 follicular lymphoma
532791|NCT00569309|noncontiguous stage II grade 3 follicular lymphoma
532792|NCT00569309|recurrent grade 1 follicular lymphoma
532793|NCT00569309|recurrent grade 2 follicular lymphoma
532794|NCT00569309|recurrent grade 3 follicular lymphoma
532795|NCT00569309|stage I grade 1 follicular lymphoma
532796|NCT00569309|stage I grade 2 follicular lymphoma
532797|NCT00569309|stage I grade 3 follicular lymphoma
532798|NCT00569309|stage III grade 1 follicular lymphoma
532799|NCT00569309|stage III grade 2 follicular lymphoma
532800|NCT00569309|stage III grade 3 follicular lymphoma
532801|NCT00569309|stage IV grade 1 follicular lymphoma
532802|NCT00569309|stage IV grade 2 follicular lymphoma
532803|NCT00569309|stage IV grade 3 follicular lymphoma
532804|NCT00569309|recurrent adult Hodgkin lymphoma
532805|NCT00569309|stage I multiple myeloma
532806|NCT00569309|stage II multiple myeloma
532807|NCT00569309|stage III multiple myeloma
532808|NCT00569309|refractory multiple myeloma
532809|NCT00569309|contiguous stage II adult diffuse large cell lymphoma
532810|NCT00569309|noncontiguous stage II adult diffuse large cell lymphoma
532811|NCT00569309|stage I adult diffuse large cell lymphoma
532812|NCT00569309|adult nasal type extranodal NK/T-cell lymphoma
532813|NCT00569309|angioimmunoblastic T-cell lymphoma
532814|NCT00569309|anaplastic large cell lymphoma
532815|NCT00569309|small intestine lymphoma
532816|NCT00569296|recurrent non-small cell lung cancer
532817|NCT00569296|stage IV non-small cell lung cancer
532818|NCT00569283|adult acute lymphoblastic leukemia in remission
532819|NCT00569283|adult acute myeloid leukemia in remission
532820|NCT00569283|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
532821|NCT00569283|adult acute myeloid leukemia with inv(16)(p13;q22)
532822|NCT00569283|adult acute myeloid leukemia with t(15;17)(q22;q12)
532823|NCT00569283|adult acute myeloid leukemia with t(16;16)(p13;q22)
532824|NCT00569283|adult acute myeloid leukemia with t(8;21)(q22;q22)
532825|NCT00569283|accelerated phase chronic myelogenous leukemia
532826|NCT00569283|atypical chronic myeloid leukemia, BCR-ABL1 negative
532827|NCT00569283|blastic phase chronic myelogenous leukemia
532828|NCT00569283|childhood acute lymphoblastic leukemia in remission
532829|NCT00569283|childhood acute myeloid leukemia in remission
532830|NCT00569283|chronic eosinophilic leukemia
532831|NCT00569283|primary myelofibrosis
532832|NCT00569283|chronic myelomonocytic leukemia
532833|NCT00569283|chronic neutrophilic leukemia
532834|NCT00569283|chronic phase chronic myelogenous leukemia
532835|NCT00569283|de novo myelodysplastic syndromes
532836|NCT00569283|disseminated neuroblastoma
532837|NCT00569283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
532838|NCT00569283|juvenile myelomonocytic leukemia
532839|NCT00569283|myelodysplastic/myeloproliferative neoplasm, unclassifiable
532840|NCT00569283|nodal marginal zone B-cell lymphoma
532841|NCT00569283|noncontiguous stage II adult Burkitt lymphoma
532842|NCT00569283|noncontiguous stage II adult diffuse large cell lymphoma
532843|NCT00569283|noncontiguous stage II adult diffuse mixed cell lymphoma
532844|NCT00569283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
532845|NCT00569283|noncontiguous stage II adult immunoblastic large cell lymphoma
532846|NCT00569283|noncontiguous stage II adult lymphoblastic lymphoma
532847|NCT00569283|noncontiguous stage II grade 1 follicular lymphoma
532848|NCT00569283|noncontiguous stage II grade 2 follicular lymphoma
532849|NCT00569283|noncontiguous stage II grade 3 follicular lymphoma
532850|NCT00569283|noncontiguous stage II mantle cell lymphoma
532851|NCT00569283|noncontiguous stage II marginal zone lymphoma
532852|NCT00569283|noncontiguous stage II small lymphocytic lymphoma
532853|NCT00569283|high risk metastatic gestational trophoblastic tumor
532854|NCT00569283|previously treated childhood rhabdomyosarcoma
532855|NCT00569283|previously treated myelodysplastic syndromes
532856|NCT00569283|recurrent adult acute lymphoblastic leukemia
532857|NCT00569283|recurrent adult acute myeloid leukemia
532858|NCT00569283|recurrent adult Burkitt lymphoma
532859|NCT00569283|recurrent adult diffuse large cell lymphoma
532860|NCT00569283|recurrent adult diffuse mixed cell lymphoma
532861|NCT00569283|recurrent adult diffuse small cleaved cell lymphoma
532862|NCT00569283|recurrent adult Hodgkin lymphoma
532863|NCT00569283|recurrent adult immunoblastic large cell lymphoma
532864|NCT00569283|recurrent adult lymphoblastic lymphoma
532865|NCT00569283|recurrent/refractory childhood Hodgkin lymphoma
532866|NCT00569283|recurrent childhood acute lymphoblastic leukemia
532867|NCT00569283|recurrent childhood acute myeloid leukemia
532868|NCT00569283|recurrent childhood large cell lymphoma
532869|NCT00569283|recurrent childhood lymphoblastic lymphoma
532870|NCT00569283|recurrent childhood rhabdomyosarcoma
532871|NCT00569283|recurrent childhood small noncleaved cell lymphoma
532872|NCT00569283|recurrent cutaneous T-cell non-Hodgkin lymphoma
532873|NCT00569283|recurrent mycosis fungoides/Sezary syndrome
532874|NCT00569283|recurrent grade 1 follicular lymphoma
532875|NCT00569283|recurrent grade 2 follicular lymphoma
532876|NCT00569283|recurrent grade 3 follicular lymphoma
532877|NCT00569283|stage III grade 1 follicular lymphoma
532878|NCT00569283|stage III grade 2 follicular lymphoma
532879|NCT00569283|stage III grade 3 follicular lymphoma
532880|NCT00569283|stage IV grade 1 follicular lymphoma
532881|NCT00569283|stage IV grade 2 follicular lymphoma
532882|NCT00569283|stage IV grade 3 follicular lymphoma
532883|NCT00569283|recurrent mantle cell lymphoma
532884|NCT00569283|stage III mantle cell lymphoma
532885|NCT00569283|stage IV mantle cell lymphoma
532886|NCT00569283|recurrent marginal zone lymphoma
532887|NCT00569283|splenic marginal zone lymphoma
532888|NCT00569283|stage III marginal zone lymphoma
532889|NCT00569283|stage IV marginal zone lymphoma
532890|NCT00569283|recurrent neuroblastoma
532891|NCT00569283|recurrent ovarian epithelial cancer
532892|NCT00569283|recurrent ovarian germ cell tumor
532893|NCT00569283|recurrent small lymphocytic lymphoma
532894|NCT00569283|stage III small lymphocytic lymphoma
532895|NCT00569283|stage IV small lymphocytic lymphoma
532896|NCT00569283|recurrent malignant testicular germ cell tumor
532897|NCT00569283|stage III malignant testicular germ cell tumor
532898|NCT00569283|childhood malignant ovarian germ cell tumor
532899|NCT00569283|childhood malignant testicular germ cell tumor
532900|NCT00569283|recurrent Wilms tumor and other childhood kidney tumors
532901|NCT00569283|refractory chronic lymphocytic leukemia
532902|NCT00569283|refractory hairy cell leukemia
532903|NCT00569283|refractory multiple myeloma
532904|NCT00569283|relapsing chronic myelogenous leukemia
532905|NCT00569283|secondary acute myeloid leukemia
532906|NCT00569283|secondary myelodysplastic syndromes
532907|NCT00569283|stage I multiple myeloma
532908|NCT00569283|stage II multiple myeloma
532909|NCT00569283|stage II ovarian epithelial cancer
532910|NCT00569283|stage III adult Burkitt lymphoma
532911|NCT00569283|stage III adult diffuse large cell lymphoma
532912|NCT00569283|stage III adult diffuse mixed cell lymphoma
532913|NCT00569283|stage III adult diffuse small cleaved cell lymphoma
532914|NCT00569283|stage III adult immunoblastic large cell lymphoma
532915|NCT00569283|stage III adult lymphoblastic lymphoma
532916|NCT00569283|stage III chronic lymphocytic leukemia
532917|NCT00569283|stage IV chronic lymphocytic leukemia
532918|NCT00569283|stage III ovarian epithelial cancer
532919|NCT00569283|stage III multiple myeloma
532920|NCT00569283|stage IIIA breast cancer
532921|NCT00569283|stage IIIB breast cancer
532922|NCT00569283|stage IIIC breast cancer
532923|NCT00569283|stage IV breast cancer
532924|NCT00569283|stage III adult Hodgkin lymphoma
532925|NCT00569283|stage IV adult Burkitt lymphoma
532926|NCT00569283|stage IV adult diffuse large cell lymphoma
532927|NCT00569283|stage IV adult diffuse mixed cell lymphoma
532928|NCT00569283|stage IV adult diffuse small cleaved cell lymphoma
532929|NCT00569283|stage IV adult Hodgkin lymphoma
532930|NCT00569283|stage IV adult immunoblastic large cell lymphoma
532931|NCT00569283|stage IV adult lymphoblastic lymphoma
532932|NCT00569283|stage IV ovarian epithelial cancer
532933|NCT00569257|LHRH receptor
532934|NCT00569257|receptor positive tumors
532935|NCT00569257|platinum resistant ovarian cancer
532936|NCT00569244|Primary Dysmenorrhea
532937|NCT00569244|Menstrual Pain
532938|NCT00569244|Oral Contraception
532939|NCT00569231|Warts
532940|NCT00569231|Candida
532941|NCT00569231|HPV
532942|NCT00569231|Injections, Intralesional
532943|NCT00569231|Immune System
532944|NCT00569192|asthmatic children
532945|NCT00569179|Myeloid Malignancies
532946|NCT00569179|Bone Marrow Transplant
532947|NCT00569179|AML
532948|NCT00569179|ALL
532949|NCT00569179|MDS
532950|NCT00569179|CML
532951|NCT00569166|fatigue
532952|NCT00569166|sleep disorders
532953|NCT00569166|ductal breast carcinoma in situ
532954|NCT00569166|lobular breast carcinoma in situ
532955|NCT00569166|breast cancer
532956|NCT00569166|hot flashes
533700|NCT00565708|stage II colon cancer
532957|NCT00569153|Androgen-independent prostate cancer, metastatic
532958|NCT00569088|hemorrhagic stroke
532959|NCT00569088|Chinese Medicine
532960|NCT00569088|pathogenesis
532961|NCT00569088|YURE
532962|NCT00569075|Apoptic biomarkers
532963|NCT00569075|Early detection periodontitis
532964|NCT00569075|Gingival crevicular fluid
532965|NCT00569075|Healthy subjects
532966|NCT00569062|Psychomotor retardation,
532967|NCT00569062|Major Depressive Disorder (MDD),
532968|NCT00569062|GW856553,
532969|NCT00569062|cytokines
532970|NCT00569036|Advanced or Metastatic Solid Tumors or Neoplasms
532971|NCT00569023|Beta Carotene
532972|NCT00569023|visual functions
532973|NCT00569023|Fundus albipunctatus
532974|NCT00569023|Night Blindness
532975|NCT00569010|Acute Myelogenous Leukemia
532976|NCT00569010|AML
532977|NCT00569010|Myelodysplastic Syndrome
532978|NCT00569010|MDS
532979|NCT00569010|Leukemia
532980|NCT00568997|Atopic dermatitis, eczema, children, pediatric patients, pimecrolimus, malignancy, registry
532981|NCT00568971|DCF
532982|NCT00568971|Advanced gastric cancer
532983|NCT00568971|Phase II study
532984|NCT00568971|Efficacy
532985|NCT00568971|Toxicity
532986|NCT00568958|heavy episodic drinking
532987|NCT00568958|young adults
532988|NCT00568958|naltrexone
532989|NCT00568958|BASICS counseling
532990|NCT00568958|alcohol-related consequences
532991|NCT00568958|double-blind trial
532992|NCT00568958|randomized clinical trial
532993|NCT00568945|Atrial Fibrillation
532994|NCT00568945|Capadenoson
532995|NCT00568880|stage I multiple myeloma
532996|NCT00568880|stage II multiple myeloma
532997|NCT00568880|stage III multiple myeloma
532998|NCT00568880|refractory multiple myeloma
532999|NCT00568841|advanced Non-Small-Cell Lung Cancer
533000|NCT00568841|erlotinib
533001|NCT00568841|FDG-PET
533002|NCT00568841|FLT-PET
533003|NCT00568828|Macular Teleangiectasia
533004|NCT00568828|Macular Pigment
533005|NCT00568815|DLBCL
533006|NCT00568815|Rituximab
533007|NCT00568815|ESHAP
533008|NCT00568815|Efficacy
533009|NCT00568815|Toxicity
533010|NCT00568789|Insomnia
533011|NCT00568789|Aged
533012|NCT00568789|Postural Balance
533013|NCT00568789|Drug Therapy
533014|NCT00568763|stage IV melanoma
533015|NCT00568763|recurrent melanoma
533016|NCT00568750|gastrointestinal stromal tumor
533017|NCT00568737|Severe Sepsis
533018|NCT00568724|Hydronephrosis
533019|NCT00568724|Ureteral obstruction
533020|NCT00568711|Doxycycline,
533021|NCT00568711|Rifampin
533022|NCT00568711|Scrub typhus.
533023|NCT00568672|Major Depression
533024|NCT00568672|Olanzapine
533025|NCT00568672|add-on therapy
533026|NCT00568672|antidepressant
533027|NCT00568672|atypical antipsychotic
533028|NCT00568659|Gas exchange
533029|NCT00568659|Respiratory mechanics
533030|NCT00568659|Ventilator Induced Lung Injury
533031|NCT00568607|NK/T cell lymphoma
533032|NCT00568607|Response Rate
533033|NCT00568607|TTP
533034|NCT00568607|OS
533035|NCT00568607|Toxicities
533036|NCT00568594|Apolipoprotein A-I,
533037|NCT00568594|Atherosclerosis,
533038|NCT00568594|HDL,
533039|NCT00568594|Inflammation,
533040|NCT00568568|Growth Hormone
533041|NCT00568568|GH signaling
533042|NCT00568568|Insulin resistance
533043|NCT00568568|Insulin Signaling
533044|NCT00568542|cardiomyopathy
533045|NCT00568542|ischemia
533046|NCT00568542|percutaneous coronary intervention
533047|NCT00568542|remodeling
533048|NCT00568529|Advanced gastric cancer
533049|NCT00568529|Response rate
533050|NCT00568529|Side effects
533051|NCT00568529|time to progression
533052|NCT00568529|overall survival
533053|NCT00568516|ASP3550
533054|NCT00568516|Degarelix
533055|NCT00568516|Prostate cancer
533056|NCT00568516|Prostatic neoplasms
533057|NCT00568503|COPD/TIOTROPIUM/QAX028
533058|NCT00568477|Rituximab, Heemannn
533059|NCT00568464|ESFT (Ewing's sarcoma family of tumors)
533060|NCT00568464|Response rate
533061|NCT00568464|TTP
533062|NCT00568464|OS
533063|NCT00568464|Toxicity
533064|NCT00568451|stage IV melanoma
533065|NCT00568451|recurrent melanoma
533066|NCT00568412|atopic dermatitis
533067|NCT00568399|Coronary
533068|NCT00568399|Calcification
533069|NCT00568399|Dialysis
533070|NCT00568399|Thiosulfate
533071|NCT00568399|Cardiovascular
533072|NCT00568386|Dry eye
533073|NCT00568373|Gastroparesis
533074|NCT00568373|Gastric electrical stimulator
533075|NCT00568347|chronic airflow obstruction
533076|NCT00568334|chickenpox
533077|NCT00568334|varicella
533078|NCT00568334|two-dose schedule
533079|NCT00568334|second year of life
533080|NCT00568321|monoclonal antibody
533701|NCT00565708|stage III colon cancer
533081|NCT00568308|Hepatocellular Carcinoma
533082|NCT00568308|PI-88
533083|NCT00568308|Phase III
533084|NCT00568308|Adjuvant Therapy
533085|NCT00568308|Hepatoma
533086|NCT00568308|Liver Cancer
533087|NCT00568269|Recurrence rate after inguinal hernia repair on primary inguinal herina.
533088|NCT00568256|Ulcerative Colitis
533089|NCT00568256|IBD Flare-Up
533090|NCT00568256|Stress
533091|NCT00568243|Visuomotor Integration
533092|NCT00568243|Visual Attention
533093|NCT00568243|Healthy Volunteer
533094|NCT00568243|HV
533095|NCT00568230|heart failure
533096|NCT00568230|mitral regurgitation
533097|NCT00568204|pruritus, itching, mexyn-a, clearitch, magicool-plus
533098|NCT00568191|Age-related macular degeneration
533099|NCT00568191|choroidal neovascularization
533100|NCT00568191|Stratus OCT
533101|NCT00568191|Cirrus OCT
533102|NCT00568165|Heart failure, congestive
533103|NCT00568165|Echocardiography
533104|NCT00568165|Patient care team
533105|NCT00568152|Apples
533106|NCT00568152|Dietary intervention
533107|NCT00568152|Procyanidins
533108|NCT00568139|adrenal cancer
533109|NCT00568139|mitotane (Lysodren)
533110|NCT00568139|adverse events
533111|NCT00568126|Antidepressant Induced Sexual Dysfunction
533112|NCT00568126|Depression
533113|NCT00568126|Sexual Dysfunction
533114|NCT00568113|preterm labour
533115|NCT00568113|n acetyl cysteine
533116|NCT00568113|bacterial vaginosis
533117|NCT00568100|gas exchange
533118|NCT00568100|pressure support ventilation
533119|NCT00568100|respiratory mechanics
533120|NCT00568100|COPD
533121|NCT00568100|NAVA
533122|NCT00568087|N-acetylcysteine
533123|NCT00568087|Alcoholism
533124|NCT00568087|Treatment
533125|NCT00568061|INOT44
533126|NCT00568061|NOMI
533127|NCT00568048|stage IV melanoma
533128|NCT00568048|recurrent melanoma
533129|NCT00568035|diabetic
533130|NCT00568035|peripheral
533131|NCT00568035|neuropathy
533132|NCT00568009|Congestive Heart Failure
533133|NCT00568009|Impaired Renal Function
533134|NCT00567996|Chronic obstructive pulmonary disease, indacaterol, salmeterol, placebo controlled
533135|NCT00567970|liver metastases
533136|NCT00567957|pre-eclampsia
533137|NCT00567957|remifentanil
533138|NCT00567957|anesthesia, general
533139|NCT00567957|analgesics, opioid
533140|NCT00567957|anesthetics, intravenous
533141|NCT00567957|Cesarean section
533142|NCT00567957|newborn
533143|NCT00567957|maternal haemodynamic
533144|NCT00567944|Physical Therapy Modalities
533145|NCT00567944|Electric Stimulation
533146|NCT00567944|Postural Balance
533147|NCT00567918|Keratoconjunctivitis
533148|NCT00567918|Vernal keratoconjunctivitis
533149|NCT00567918|FK506
533150|NCT00567918|Tacrolimus
533151|NCT00567905|Type 2 Diabetes
533152|NCT00567905|Green tea extract
533153|NCT00567905|overweight
533154|NCT00567892|tinnitus
533155|NCT00567892|subjective tinnitus
533156|NCT00567892|therapy
533157|NCT00567892|repetitive transcranial magnetic stimulation
533158|NCT00567892|clinical trial
533159|NCT00567879|Breast Cancer
533160|NCT00567879|HER2 positive
533161|NCT00567879|adult-female
533162|NCT00567879|LBH589
533163|NCT00567879|HDAC inhibitor
533164|NCT00567879|panobinostat
533165|NCT00567853|mitral valve regurgitation
533166|NCT00567853|mitral valve disease
533167|NCT00567853|mitral valve repair
533168|NCT00567853|mitral valve dysfunction
533169|NCT00567853|heart valve
533170|NCT00567853|valve disease
533171|NCT00567853|cardiac surgery
533172|NCT00567840|Early Bactericidal Activity
533173|NCT00567840|EBA
533174|NCT00567840|pulmonary tuberculosis
533175|NCT00567840|PA-824
533176|NCT00567840|Pretomanid
533177|NCT00567840|CL-007
533178|NCT00567827|Pneumonia
533179|NCT00567814|Cocaine
533180|NCT00567814|Dependence
533181|NCT00567814|Addiction
533182|NCT00567814|Cortisol
533183|NCT00567814|GABA
533184|NCT00567801|Lower Extremity
533185|NCT00567801|Ischemia
533186|NCT00567788|Glaucoma, angle-closure
533187|NCT00567762|Keratoconjunctivitis
533188|NCT00567762|vernal keratoconjunctivitis
533189|NCT00567762|FK506
533190|NCT00567762|Tacrolimus
533191|NCT00567749|HIV-1 Infections
533192|NCT00567736|low back pain
533193|NCT00567736|complementary therapies
533194|NCT00567697|ranibizumab
533195|NCT00567697|CRVO
533196|NCT00567697|macular edema
533197|NCT00567697|sham
533198|NCT00567684|Transitional Cell Carcinoma
533199|NCT00567684|Urothelial Cancer
533200|NCT00567684|Bladder Cancer
533201|NCT00567684|Computed Tomography Urography
533202|NCT00567684|CTU
533203|NCT00567684|Intravenous Urography
533204|NCT00567684|IVU
533205|NCT00567684|TCC
533333|NCT00567086|Migraine
533206|NCT00567684|transitional cell carcinomas
533207|NCT00567671|keratoconus
533208|NCT00567671|ectasia
533209|NCT00567671|cross-linking
533210|NCT00567671|riboflavin
533211|NCT00567671|UVA light
533212|NCT00567671|cornea
533213|NCT00567632|Pneumococci
533214|NCT00567632|Antibody
533215|NCT00567632|Standard laboratory values
533216|NCT00567619|GERD
533217|NCT00567619|NIS
533218|NCT00567580|stage IIB prostate cancer
533219|NCT00567580|stage IIA prostate cancer
533220|NCT00567580|stage III prostate cancer
533221|NCT00567580|adenocarcinoma of the prostate
533222|NCT00567554|breast cancer
533223|NCT00567554|primary systemic therapy
533224|NCT00567554|pCR Rates
533225|NCT00567554|Bevacizumab
533226|NCT00567554|Trastuzumab
533227|NCT00567554|Lapatinib
533228|NCT00567554|Everolimus
533229|NCT00567541|shoulder
533230|NCT00567541|pain
533231|NCT00567541|stroke
533232|NCT00567541|subluxation
533233|NCT00567528|Soft tissue injuries
533234|NCT00567528|Topical ibuprofen
533235|NCT00567528|Adolescent athletes
533236|NCT00567489|ESRD
533237|NCT00567489|Diabetes
533238|NCT00567489|CAPD
533239|NCT00567489|APD
533240|NCT00567476|Asthma, anti-immunoglobulin E, omalizumab
533241|NCT00567463|Asthma
533242|NCT00567463|Bronchial hyperresponsiveness
533243|NCT00567463|Methacholine
533244|NCT00567463|Induced sputum
533245|NCT00567463|bronchial biopsies
533246|NCT00567450|sciatic block
533247|NCT00567450|ropivacaine
533248|NCT00567450|mepivacaine
533249|NCT00567450|locoregional anesthesia
533250|NCT00567437|aortic stenosis
533251|NCT00567437|prognosis
533252|NCT00567437|brain natriuretic peptide
533253|NCT00567424|epilepsy
533254|NCT00567424|refractory
533255|NCT00567424|seizure
533256|NCT00567424|drug interactions
533257|NCT00567424|pharmacokinetics
533258|NCT00567411|Glaucoma
533259|NCT00567411|Laser
533260|NCT00567411|laser trabeculoplasty
533261|NCT00567411|selective laser trabeculoplasty
533262|NCT00567411|intraocular pressure
533263|NCT00567398|ESRD
533264|NCT00567398|Diabetes
533265|NCT00567398|CAPD
533266|NCT00567398|APD
533267|NCT00567372|Diffuse diabetic macular edema
533268|NCT00567372|sub-tenon
533269|NCT00567372|Bevacizumab
533270|NCT00567359|NSCLC
533271|NCT00567359|erlotinib
533272|NCT00567359|epidermal growth factor receptor
533273|NCT00567359|EGFR
533274|NCT00567346|randomised
533275|NCT00567346|double-blind
533276|NCT00567346|placebo-controlled
533277|NCT00567346|efficacy and safety
533278|NCT00567346|Oralgen® Grass Pollen
533279|NCT00567346|allergic rhinoconjunctivitis
533280|NCT00567346|Allergy
533281|NCT00567346|Rhinoconjunctivitis
533282|NCT00567346|Immunotherapy
533283|NCT00567346|Grass pollen extract
533284|NCT00567320|varenicline
533285|NCT00567294|Osteoporosis
533286|NCT00567294|Medication adherence
533287|NCT00567294|Telephonic education
533288|NCT00567294|Motivational interviewing
533289|NCT00567281|Schizoaffective disorder
533290|NCT00567281|Auditory Hallucinations
533291|NCT00567281|Voices
533292|NCT00567281|Repetitive Transcranial Magnetic Stimulation
533293|NCT00567281|rTMS
533294|NCT00567281|Wernicke's Area
533295|NCT00567281|Middle Temporal Cortex
533296|NCT00567281|Persistent Auditory Hallucinations
533297|NCT00567281|"Previously Participated in Parent rTMS Protocol"
533298|NCT00567268|Post-Marketing surveillance
533299|NCT00567255|Obesity
533300|NCT00567242|aphasia
533301|NCT00567242|therapies, investigational
533302|NCT00567242|rehabilitation of speech and language disorders
533303|NCT00567242|magnetic resonance imaging, functional
533304|NCT00567242|language
533305|NCT00567229|refractory multiple myeloma
533306|NCT00567190|Herceptin
533307|NCT00567190|Breast cancer
533308|NCT00567190|MBC
533309|NCT00567190|Taxotere
533310|NCT00567190|HER2
533311|NCT00567190|HER2 positive breast cancer
533312|NCT00567190|HER2 + breast cancer
533313|NCT00567190|HER2-positive
533314|NCT00567190|HER2-positive metastatic breast cancer
533315|NCT00567164|Oral Contraception
533316|NCT00567164|Birth Control pill
533317|NCT00567164|Healthy women requesting oral contraception
533318|NCT00567164|Contraceptive efficacy
533319|NCT00567125|low-pressure pneumoperitoneum
533320|NCT00567125|laparoscopy
533321|NCT00567125|cytokines
533322|NCT00567125|VEGF-A
533323|NCT00567125|endostatin
533324|NCT00567099|Psychiatry
533325|NCT00567099|Antipsychotic
533326|NCT00567099|Psychopharmacology
533327|NCT00567099|Clinical Trial
533328|NCT00567099|Open Label
533329|NCT00567099|Schizophrenia
533330|NCT00567099|Sensory Gating
533331|NCT00567099|Attention
533332|NCT00567099|Memory
533334|NCT00567073|Glycogen Storage Disease Type II (GSD-II)
533335|NCT00567073|GSD-II
533336|NCT00567073|Pompe Disease
533337|NCT00567073|Pompe Disease (Late-Onset)
533338|NCT00567073|Acid Maltase Deficiency Disease
533339|NCT00567073|Glycogenosis II
533340|NCT00567060|Piracetam
533341|NCT00567060|Nootropil
533342|NCT00567034|Zyprexa
533343|NCT00567034|naltrexone
533344|NCT00567034|schizophrenia
533345|NCT00567034|Metabolic Syndrome
533346|NCT00567034|pain
533347|NCT00567021|reflux
533348|NCT00567021|NSAR treatment
533349|NCT00567021|Patients with reflux symptoms or gastrointestinal symptoms after NSAR Treatment
533350|NCT00567008|cocaine
533351|NCT00567008|crack cocaine
533352|NCT00567008|cocaine-related disorders
533353|NCT00567008|substance-related disorders
533354|NCT00567008|alpha4beta2 nicotinic acetylcholine receptor
533355|NCT00566995|Kidney Tumors
533356|NCT00566995|Clear Cell Renal Cancer
533357|NCT00566995|VEGFR Inhibitor
533358|NCT00566995|EGFR Inhibitor
533359|NCT00566995|VHL
533360|NCT00566995|Von Hippel Lindau
533361|NCT00566995|Kidney Tumor
533362|NCT00566982|Urogenital atrophy
533363|NCT00566982|Menopausal symptoms
533364|NCT00566982|Vulvar and vaginal atrophy in postmenopausal women
533365|NCT00566982|Vaginal atrophy
533366|NCT00566969|cocaine, opiate, methadone, carvedilol
533367|NCT00566956|Hydrosalpinx/IVF/Reproductive outcome.
533368|NCT00566956|Hydrosalpinx
533369|NCT00566943|Staple Line Reinforcement, Buttress
533370|NCT00566917|Vagina
533371|NCT00566917|Prolapse
533372|NCT00566917|Anterior vaginal wall prolapse
533373|NCT00566904|Post-herpetic Neuralgia
533374|NCT00566904|Pain after Shingles
533375|NCT00566904|Shingles
533376|NCT00566904|PHN
533377|NCT00566891|percutaneous coronary angioplasty
533378|NCT00566891|pci
533379|NCT00566891|tirofiban
533380|NCT00566891|side effects
533381|NCT00566878|Glycogen Storage Disease
533382|NCT00566878|GSD-II
533383|NCT00566878|Pompe Disease
533384|NCT00566878|Pompe Disease (Late-Onset)
533385|NCT00566878|Acid Maltase Deficiency Disease
533386|NCT00566878|Glycogenosis II
533387|NCT00566852|cognitive/functional effects
533388|NCT00566852|neurotoxicity
533389|NCT00566852|tumors metastatic to brain
533390|NCT00566852|unspecified adult solid tumor, protocol specific
533391|NCT00566839|COPD
533392|NCT00566839|LVRS
533393|NCT00566839|Awake surgery
533394|NCT00566839|Thoracic epidural anesthesia
533395|NCT00566839|One-lung ventilation
533396|NCT00566839|Emphysema
533397|NCT00566839|VATS
533398|NCT00566839|Lung surgery
533399|NCT00566826|Physical Function
533400|NCT00566826|Total Knee Replacement
533401|NCT00566826|Physical Activity
533402|NCT00566826|Behavioral Support
533403|NCT00566826|Arthroplasty
533404|NCT00566826|Function
533405|NCT00566826|Self-Care
533406|NCT00566813|Diabetes Mellitus, Type 1
533407|NCT00566813|Islets of Langerhans Transplantation
533408|NCT00566813|Exenatide
533409|NCT00566813|Soluble tumor necrosis factor receptor
533410|NCT00566800|esophageal cancer
533411|NCT00566800|Barrett esophagus
533412|NCT00566787|AF
533413|NCT00566787|Atrial Fibrillation
533414|NCT00566787|afib
533415|NCT00566787|racing heart
533416|NCT00566787|cabg
533417|NCT00566787|valve
533418|NCT00566787|ablation
533419|NCT00566787|bipolar
533420|NCT00566787|radiofrequency
533421|NCT00566787|rf
533422|NCT00566774|myocardial infarction
533423|NCT00566774|secondary prevention
533424|NCT00566774|health insurance
533425|NCT00566774|cost-sharing
533426|NCT00566761|Macular edema
533427|NCT00566761|central retinal vein occlusion
533428|NCT00566761|bevacizumab
533429|NCT00566761|triamcinolone
533430|NCT00566709|transfusion
533431|NCT00566709|NIRS
533432|NCT00566709|cerebral oxygenation
533433|NCT00566709|red blood cell
533434|NCT00566709|near infrared spectroscopy
533435|NCT00566696|Haploidentical stem cell transplant
533436|NCT00566696|Allogeneic stem cell transplant
533437|NCT00566696|Mismatched family member stem cell donor transplant
533438|NCT00566696|Bone marrow transplant
533439|NCT00566696|High risk hematologic malignancies
533440|NCT00566696|T cell depletion methodology
533441|NCT00566696|Miltenyi Biotec CliniMACS stem cell selection device
533442|NCT00566696|Campath-1H intravenous
533443|NCT00566683|Propofol
533444|NCT00566683|colonoscopy
533445|NCT00566683|sedation
533446|NCT00566683|pain
533447|NCT00566683|compare NAPS versus diazemuls in outpatient colonoscopy
533448|NCT00566670|Hemodialysis
533449|NCT00566657|Critical Limb Ischemia
533450|NCT00566657|Peripheral Artery Disease
533451|NCT00566657|Plasmid based gene therapy
533452|NCT00566644|endometrial cancer
533453|NCT00566644|hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2)
533454|NCT00566631|Schizophrenia
533455|NCT00566631|Paliperidone Extended Release (ER)
533456|NCT00566631|Invega
533457|NCT00566618|Breast Cancer
533458|NCT00566618|Bone Metastases
533459|NCT00566618|Breast Cancer with Bone Metastases
533460|NCT00566618|Breast Cancer with Metastases to Bone
533461|NCT00566618|Dasatinib
533462|NCT00566618|Zometa
533463|NCT00566618|Zoledronic Acid
533464|NCT00566618|Zoledronate
533465|NCT00566618|BMS-345825
533466|NCT00566618|Sprycel®
533467|NCT00566579|Human papillomavirus
533468|NCT00566579|Clearance
533469|NCT00566579|Cryotherapy
533470|NCT00566566|adipocytokines
533471|NCT00566566|inflammatory markers
533472|NCT00566566|cardiovascular disease
533473|NCT00566566|diabetes mellitus
533474|NCT00566566|Leptin
533475|NCT00566553|Grape Seed Extract
533476|NCT00566553|Breast Cancer
533477|NCT00566553|Estrogen Levels
533478|NCT00566553|Aromatase Inhibitor
533479|NCT00566540|stage III squamous cell carcinoma of the hypopharynx
533480|NCT00566540|stage IV squamous cell carcinoma of the hypopharynx
533481|NCT00566540|stage III squamous cell carcinoma of the lip and oral cavity
533482|NCT00566540|stage IV squamous cell carcinoma of the lip and oral cavity
533483|NCT00566540|stage III squamous cell carcinoma of the oropharynx
533484|NCT00566540|stage IV squamous cell carcinoma of the oropharynx
533485|NCT00566540|stage II squamous cell carcinoma of the hypopharynx
533486|NCT00566514|fibromyalgia
533487|NCT00566514|ribose
533488|NCT00566514|d-ribose
533489|NCT00566514|dextrose
533490|NCT00566501|Moderate-to-severe
533491|NCT00566501|Alzheimer's
533492|NCT00566501|Disease
533493|NCT00566488|Thymus Transplantation
533494|NCT00566488|Parathyroid Transplantation
533495|NCT00566488|DiGeorge Syndrome
533496|NCT00566488|Hypoparathyroidism
533497|NCT00566488|Athymia
533498|NCT00566449|Attention Deficit Hyperactivity Disorder
533499|NCT00566449|ADHD
533500|NCT00566449|JNJ-31001074
533501|NCT00566436|Peripheral Arterial Occlusive Disease
533502|NCT00566436|Superficial Femoral Artery
533503|NCT00566436|Remote Endarterectomy
533504|NCT00566436|Suprageniculate Bypass Surgery
533505|NCT00566436|Blood Vessel Prosthesis Implantation
533506|NCT00566436|Vascular Patency
533507|NCT00566423|PAH
533508|NCT00566423|Biomarkers
533509|NCT00566423|MIF
533510|NCT00566423|BNP
533511|NCT00566423|6 Minute Walk (6MW)
533512|NCT00566410|DCA
533513|NCT00566410|Phase I
533514|NCT00566410|Dose Escalation
533515|NCT00566410|Solid Tumours
533516|NCT00566410|Dichloroacetate
533517|NCT00566410|Pharmacokinetic
533518|NCT00566397|RI RI Study Rage Inhibitors
533519|NCT00566384|Loss of libido
533520|NCT00566384|Acquired, oral contraceptive -associated female sexual dysfunction
533521|NCT00566371|attention deficit hyperactivity disorder
533522|NCT00566371|insomnia
533523|NCT00566371|atomoxetine
533524|NCT00566358|diabetes mellitus, type 2
533525|NCT00566358|duodenal exclusion
533526|NCT00566358|bariatric surgery
533527|NCT00566358|Glucagon-Like Peptide 1
533528|NCT00566358|Gastric Inhibitory Polypeptide
533529|NCT00566358|insulin
533530|NCT00566358|glucagon
533531|NCT00566358|ghrelin
533532|NCT00566332|Waldenström Macroglobulinemia
533533|NCT00566332|Lymphoplasmacytic lymphoma
533534|NCT00566332|Splenic Marginal Zone Lymphoma
533535|NCT00566332|Fludarabine
533536|NCT00566332|Chlorambucil
533537|NCT00566319|Exercise
533538|NCT00566306|Clostridium difficile
533539|NCT00566306|disinfectant
533540|NCT00566280|MBI
533541|NCT00566280|Mammogram
533542|NCT00566280|Breast Cancer
533543|NCT00566280|Breast Ultrasound
533544|NCT00566280|Bloody Nipple Discharge
533545|NCT00566280|Molecular Breast Imaging
533546|NCT00566254|Epilepsy
533547|NCT00566254|paediatric
533548|NCT00566254|partial onset seizures
533549|NCT00566241|Body weight
533550|NCT00566241|Body composition
533551|NCT00566241|Pulmonary function
533552|NCT00566241|Carbohydrate tolerance
533553|NCT00566228|noncontiguous stage II adult diffuse large cell lymphoma
533554|NCT00566228|stage III adult diffuse large cell lymphoma
533555|NCT00566228|stage IV adult diffuse large cell lymphoma
533556|NCT00566228|recurrent adult diffuse large cell lymphoma
533557|NCT00566215|diabetes mellitus, type 2
533558|NCT00566215|Insulin resistance
533559|NCT00566215|Intra-Abdominal Fat
533560|NCT00566215|Omentum
533561|NCT00566215|duodenal exclusion
533562|NCT00566215|bariatric surgery
533563|NCT00566215|Glucagon-Like Peptide 1
533564|NCT00566215|Gastric Inhibitory Polypeptide
533565|NCT00566215|insulin
533566|NCT00566215|glucagon
533567|NCT00566215|ghrelin
533568|NCT00566215|adiponectin
533569|NCT00566215|Cytokines
533570|NCT00566202|Major Depressive Disorder
533571|NCT00566202|Depression
533572|NCT00566202|JNJ-18038683
533573|NCT00566202|Escitalopram
533574|NCT00566189|diabetes mellitus, type 2
533575|NCT00566189|Insulin resistance
533576|NCT00566189|Intra-Abdominal Fat
533577|NCT00566189|Omentum
533578|NCT00566189|duodenal exclusion
533579|NCT00566189|bariatric surgery
533580|NCT00566189|Glucagon-Like Peptide 1
533581|NCT00566189|Gastric Inhibitory Polypeptide
533582|NCT00566189|insulin
533583|NCT00566189|glucagon
533584|NCT00566189|ghrelin
533585|NCT00566189|adiponectin
533586|NCT00566189|Cytokines
533587|NCT00566176|Atrial Fibrillation
533588|NCT00566176|AF
533589|NCT00566176|AFIB
533590|NCT00566176|racing heart
533591|NCT00566176|pulmonary vein isolation
533592|NCT00566176|pvi
533593|NCT00566176|mini maze
533594|NCT00566176|maze
533595|NCT00566150|Keppra
533596|NCT00566150|Levetiracetam
533597|NCT00566150|Anticonvulsant
533598|NCT00566150|Depression
533599|NCT00566150|Bipolar Disorder
533600|NCT00566150|Affective Disorders
533601|NCT00566150|Mood Disorders
533602|NCT00566150|Double Blind
533603|NCT00566150|Acute Antidepressant Effects
533604|NCT00566137|Scleroderma
533605|NCT00566137|Pulmonary Hypertension
533606|NCT00566124|Levemir, Lantus, Insulatard, Pharmacodynamics, Healthy humans
533607|NCT00566111|Ceftriaxone
533608|NCT00566111|Acute Antidepressant Effects
533609|NCT00566111|Glutamatergic System
533610|NCT00566111|Double-Blind
533611|NCT00566111|Mood Disorders
533612|NCT00566111|Bipolar Disorder
533613|NCT00566111|Depression
533614|NCT00566111|Affective Disorders
533615|NCT00566098|stage II multiple myeloma
533616|NCT00566098|stage III multiple myeloma
533617|NCT00566085|MBI
533618|NCT00566085|Breast Cancer
533619|NCT00566085|Neoadjuvant Therapy
533620|NCT00566085|Molecular Breast Imaging
533621|NCT00566072|the effect of information on compliance of medication
533622|NCT00566059|therapeutic advice
533623|NCT00566033|AUDIT
533624|NCT00566033|Chronic kidney disease
533625|NCT00566033|Clinical trial
533626|NCT00566033|Creatinine
533627|NCT00566033|Multiple intervents
533628|NCT00566033|Nephrology guidelines.
533629|NCT00566020|Open-label extension
533630|NCT00566020|Tolerability
533631|NCT00566020|Safety
533632|NCT00566020|Lamotrigine
533633|NCT00566020|Bipolar I disorder
533634|NCT00566007|disc herniation
533635|NCT00566007|lumbar
533636|NCT00566007|ozone therapy
533637|NCT00565994|hemodialysis
533638|NCT00565994|Vascular access
533639|NCT00565994|arteriovenous fistula
533640|NCT00565994|indwelling percutaneous catheters
533641|NCT00565994|arteriovenous grafts
533642|NCT00565981|B-CLL
533643|NCT00565981|refractory
533644|NCT00565981|molecular profiling
533645|NCT00565981|alemtuzumab
533646|NCT00565981|fludarabinephosphate
533647|NCT00565968|stage IIIB melanoma
533648|NCT00565968|stage IIIC melanoma
533649|NCT00565968|recurrent melanoma
533650|NCT00565955|Montelukast
533651|NCT00565955|Acute Asthma
533652|NCT00565942|Integrative medicine
533653|NCT00565942|Primary care
533654|NCT00565942|Swedish massage therapy
533655|NCT00565942|Manual therapy
533656|NCT00565942|Naprapathy
533657|NCT00565942|Shiatsu
533658|NCT00565942|Acupuncture/TCM
533659|NCT00565942|Qigong
533660|NCT00565942|Pragmatic RCT
533661|NCT00565942|Health services research
533662|NCT00565929|Variola major, smallpox, vaccine, hematopoietic stem cell transplant
533663|NCT00565916|Post-Menopausal
533664|NCT00565916|PET
533665|NCT00565916|Estrogen
533666|NCT00565916|Progesterone
533667|NCT00565916|Heart Metabolism
533668|NCT00565916|Cardiovascular Disease
533669|NCT00565903|pleuropulmonary blastoma
533670|NCT00565903|PPB
533671|NCT00565903|cystic nephroma
533672|NCT00565903|DICER1
533673|NCT00565903|miRNA
533674|NCT00565890|very low birth weight infant
533675|NCT00565890|hypothyroxinemia
533676|NCT00565890|outcomes
533677|NCT00565877|Catheter
533678|NCT00565877|Peripherally inserted central catheter
533679|NCT00565877|ultrasound
533680|NCT00565877|malposition
533681|NCT00565864|Hypothyroidism
533682|NCT00565864|Cognition
533683|NCT00565864|Metabolism
533684|NCT00565838|Randomized study
533685|NCT00565838|surgical treatment
533686|NCT00565838|autologous fascial sling
533687|NCT00565838|TVT
533688|NCT00565838|stress urinary incontinence.
533689|NCT00565812|knee Osteoarthritis Disease Modifying Osteoarthritis Drug
533690|NCT00565799|DM
533691|NCT00565760|Acute
533692|NCT00565760|Pain
533693|NCT00565747|GM-CSF
533694|NCT00565747|infertility
533695|NCT00565721|Static PET imaging
533696|NCT00565721|Dynamic PET imaging
533697|NCT00565721|Angiogenesis
533698|NCT00565721|αvβ3 integrins
533699|NCT00565721|oncology imaging
533702|NCT00565708|stage II rectal cancer
533703|NCT00565708|stage III rectal cancer
533704|NCT00565695|Visual Outcomes
533705|NCT00565695|Patient Satisfaction
533706|NCT00565695|Cataract Extraction
533707|NCT00565669|Treatment
533708|NCT00565669|Dry Eye
533709|NCT00565656|Myelodysplastic syndromes (int-1, int-2 and high risk according to IPSS) with excess of marrow blasts including CMML with leucocytes<10 000/mm3
533710|NCT00565643|Adhesion
533711|NCT00565643|Seprafilm
533712|NCT00565643|Cesarean section
533713|NCT00565617|depression
533714|NCT00565617|epidural
533715|NCT00565617|cortical stimulation
533716|NCT00565617|brain stimulation
533717|NCT00565617|treatment-resistant
533718|NCT00565617|deep brain stimulation
533719|NCT00565617|TMS
533720|NCT00565617|DBS
533721|NCT00565617|ECS
533722|NCT00565604|Perforator Veins
533723|NCT00565604|Incompetent Veins
533724|NCT00565604|Varicose Veins
533725|NCT00565591|asthma
533726|NCT00565591|inhaler device
533727|NCT00565591|albuterol sulfate
533728|NCT00565565|Biventriular chronic heart failure, Pulmonary hypertension
533729|NCT00565552|silicone gel
533730|NCT00565552|cicatrix
533731|NCT00565552|wound healing
533732|NCT00565552|scar
533733|NCT00565552|keloid
533734|NCT00565539|PEGylated recombinant interleukin 29
533735|NCT00565539|interferon lambda
533736|NCT00565539|interleukin 29
533737|NCT00565539|hepatitis C
533738|NCT00565539|virus
533739|NCT00565539|infection
533740|NCT00565539|liver
533741|NCT00565526|Autonomic Nervous System
533742|NCT00565526|Sjogren's Syndrome
533743|NCT00565526|Pathogenesis
533744|NCT00565526|Cholinergic
533745|NCT00565526|Parasympathetic
533746|NCT00565526|Sjogren Syndrome
533747|NCT00565487|Radiotherapy
533748|NCT00565487|Non-operable pancreatic cancer
533749|NCT00565487|locally advanced pancreatic cancer
533750|NCT00565474|Renal transplantation
533751|NCT00565474|fluvastatin
533752|NCT00565448|Nasopharyngeal carcinoma
533753|NCT00565435|Chiari I Malformation
533754|NCT00565422|Internet addiction
533755|NCT00565422|Problematic internet use
533756|NCT00565422|Escitalopram
533757|NCT00565422|Lexapro
533758|NCT00565409|Active Rheumatoid Arthritis
533759|NCT00565383|Pregnancy
533760|NCT00565383|37 Weeks Gestation
533761|NCT00565383|Breech Presentation
533762|NCT00565383|Version Procedure
533763|NCT00565383|Pain Control
533764|NCT00565383|Neuraxial analgesia
533765|NCT00565370|Gastric cancer
533766|NCT00565370|capecitabine
533767|NCT00565370|cisplatin
533768|NCT00565370|sorafenib
533769|NCT00565370|phase I
533770|NCT00565370|phase II
533771|NCT00565357|Postnatal Growth
533772|NCT00565357|Postnatal Development
533773|NCT00565357|Noise
533774|NCT00565357|Neonatal Intensive Care Unit
533775|NCT00565344|Medicaid
533776|NCT00565344|Disenrollment
533777|NCT00565318|Benfotiamine
533778|NCT00565318|Diabetes
533779|NCT00565318|Nephropathy
533780|NCT00565305|Healing Touch
533781|NCT00565305|NK cytotoxicity
533782|NCT00565305|cytokines
533783|NCT00565305|fatigue
533784|NCT00565279|Seborrhoeic dermatitis
533785|NCT00565253|pulmonary embolism
533786|NCT00565253|inhaled nitric oxide
533787|NCT00565240|ovarian synchronization
533788|NCT00565240|folliculogenesis
533789|NCT00565214|vitamin supplements
533790|NCT00565214|healthy smokers
533791|NCT00565214|epithelial lung tissue
533792|NCT00565214|bronchoscopy
533793|NCT00565214|antioxidant levels
533794|NCT00565201|Stroke, Cerebrovascular accident, Spasticity, Arm, Hand
533795|NCT00565175|Treatment resistant
533796|NCT00565175|Chronic
533797|NCT00565136|Device study
533798|NCT00565136|Pelvic floor weakness
533799|NCT00565136|Fecal incontinence
533800|NCT00565123|bacterial conjunctivitis levofloxacin fluoroquinolone
533801|NCT00565097|Polycystic Liver Disease
533802|NCT00565097|Autosomal Dominant Polycystic Kidney Disease
533803|NCT00565097|Liver cyst
533804|NCT00565097|Lanreotide
533805|NCT00565071|Cost-effectiveness
533806|NCT00565071|Diagnosis
533807|NCT00565071|Treatment
533808|NCT00565071|Malaria
533809|NCT00565045|hand
533810|NCT00565045|stroke
533811|NCT00565045|hemiplegia
533812|NCT00565045|electrical stimulation
533813|NCT00565045|recovery
533814|NCT00565032|postpartum depression
533815|NCT00565032|thyroxine
533816|NCT00565032|thyroid antibodies
533817|NCT00565032|thyroid stimulating hormone
533818|NCT00565032|Edinburgh Postnatal Depression Scale (EPDS)
533819|NCT00564980|Randomized
533820|NCT00564980|Prospective
533821|NCT00564980|Procedure / Surgery
533822|NCT00564954|ADHD
533823|NCT00564954|children
533824|NCT00564954|laboratory classroom
533825|NCT00564954|Attention Deficit Hyperactivity Disorder
533826|NCT00564941|Myelodysplastic Syndromes
533827|NCT00564941|beta-Thalassemia
533828|NCT00564941|Iron Overload
533829|NCT00564941|Iron Chelating Agents
533830|NCT00564941|deferasirox
533831|NCT00564928|Hormone resistant prostate cancer
533832|NCT00564928|castrate resistant prostate cancer
533833|NCT00564928|HRPC
533834|NCT00564928|CRPC
533835|NCT00564915|Epilepsy
533836|NCT00564902|Macular Pigment Optical Density
533837|NCT00564902|Skin Carotenoids
533838|NCT00564902|Lipofuscin
533839|NCT00564902|Photostress (Glare Recovery)
533840|NCT00564902|Visual Field Progression
533841|NCT00564902|Contrast Sensitivity
533842|NCT00564902|Color Vision
533843|NCT00564902|Cognitive Function
533844|NCT00564889|primary systemic amyloidosis
533845|NCT00564876|Non Small Cell Lung Cancer (NSCLC)
533846|NCT00564876|carcinoma
533847|NCT00564876|dasatinib
533848|NCT00564876|neoadjuvant
533849|NCT00564876|adjuvant
533850|NCT00564876|resection
533851|NCT00564876|genomic signature
533852|NCT00564876|predictor
533853|NCT00564876|microarray
533854|NCT00564863|Diarrhea
533855|NCT00564863|ETEC
533856|NCT00564837|Anterior cruciate ligament
533857|NCT00564837|Reconstruction
533858|NCT00564837|Rehabilitation
533859|NCT00564837|Home-based
533860|NCT00564824|coronary disease
533861|NCT00564824|atherosclerosis
533862|NCT00564824|endothelial function
533863|NCT00564824|caffeine
533864|NCT00564824|cerebrovascular disease
533865|NCT00564824|prevention
533866|NCT00564811|Agaricus blazei (Murrill) ss. Heinemann,
533867|NCT00564811|Hepatitis C
533868|NCT00564811|Nutritional status
533869|NCT00564811|Liver Function Tests
533870|NCT00564811|Antiviral Agents
533871|NCT00564798|protocoladolescents
533872|NCT00564798|children
533873|NCT00564798|health behaviours/attitudes
533874|NCT00564798|weight loss/management
533875|NCT00564798|program evaluation
533876|NCT00564772|raltegravir
533877|NCT00564772|lopinavir
533878|NCT00564772|ritonavir
533879|NCT00564772|pharmacokinetics
533880|NCT00564759|CGD
533881|NCT00564746|radiolabel
533882|NCT00564746|SB-681323,
533883|NCT00564746|ADME,
533884|NCT00564694|adenocarcinoma of the colon
533885|NCT00564694|recurrent colon cancer
533886|NCT00564694|stage I colon cancer
533887|NCT00564694|stage II colon cancer
533888|NCT00564694|stage III colon cancer
533889|NCT00564694|stage IV colon cancer
533890|NCT00564694|adenocarcinoma of the rectum
533891|NCT00564694|recurrent rectal cancer
533892|NCT00564694|stage I rectal cancer
533893|NCT00564694|stage II rectal cancer
533894|NCT00564694|stage III rectal cancer
533895|NCT00564694|stage IV rectal cancer
533896|NCT00564655|pediatrics
533897|NCT00564655|Gastric Tube Insertion
533898|NCT00564655|Anesthesia
533899|NCT00564655|Regional Anesthetic
533900|NCT00564655|Transversus Abdominal Plane
533901|NCT00564616|cardiac arrest
533902|NCT00564616|video cell phone
533903|NCT00564616|dispatcher-assisted CPR
533904|NCT00564603|Glucocorticoid
533905|NCT00564603|Opioids
533906|NCT00564603|Balanced analgesia
533907|NCT00564577|Diarrhea ETEC
533908|NCT00564564|obsessive compulsive disorder
533909|NCT00564564|pharmacological treatment
533910|NCT00564564|quetiapine
533911|NCT00564564|clomipramine
533912|NCT00564564|SSRI
533913|NCT00564551|Prediabetes
533914|NCT00564551|Type 2 diabetes
533915|NCT00564551|Metabolic syndrome
533916|NCT00564551|Insulin resistance syndrome
533917|NCT00564551|Weight loss
533918|NCT00564551|Milk products
533919|NCT00564551|Calcium
533920|NCT00564538|liver transplant
533921|NCT00564525|children
533922|NCT00564525|abdominal pain
533923|NCT00564525|amitriptyline
533924|NCT00564512|B-cell chronic lymphocytic leukemia
533925|NCT00564512|stage I chronic lymphocytic leukemia
533926|NCT00564512|stage II chronic lymphocytic leukemia
533927|NCT00564512|stage III chronic lymphocytic leukemia
533928|NCT00564512|stage IV chronic lymphocytic leukemia
533929|NCT00564499|COPD
533930|NCT00564499|Symbicort
533931|NCT00564499|General Practitioners
533932|NCT00564486|Abdominal Laparoscopic Surgery
533933|NCT00564473|internal medicine
533934|NCT00564473|herbal medicine
533935|NCT00564473|prevalence
533936|NCT00564473|attitudes
533937|NCT00564473|herb-drug interaction
533938|NCT00564434|delirium
533939|NCT00564434|pathophysiology
533940|NCT00564434|risk factors
533941|NCT00564434|pain
533942|NCT00564434|dementia
533943|NCT00564382|Acute coronary syndrome
533944|NCT00564382|Cardiac Magnetic Resonance Imaging
533945|NCT00564382|Contrast agents
533946|NCT00564382|Gadolinium
533947|NCT00564369|HIV testing
533948|NCT00564369|HIV Seronegativity
534071|NCT00563784|Squamous Cell Carcinoma
533949|NCT00564356|cataract, phacoemulsification, coumadin, antiaggregants
533950|NCT00564343|Balance
533951|NCT00564343|Water based training
533952|NCT00564343|Physical functioning
533953|NCT00564343|stepping behavior
533954|NCT00564330|dental erosion
533955|NCT00564330|OCT
533956|NCT00564330|proton pump inhibitor
533957|NCT00564317|PTSD
533958|NCT00564317|Depression
533959|NCT00564317|Suicidality
533960|NCT00564317|trauma-focussed treatment
533961|NCT00564317|KIDNET
533962|NCT00564317|Narrative Exposure Therapy for Children
533963|NCT00564317|Meditation
533964|NCT00564317|Relaxation
533965|NCT00564317|War
533966|NCT00564304|Nasal Potential Difference
533967|NCT00564291|OCT
533968|NCT00564278|Hispanic Americans
533969|NCT00564278|Major Depressive Disorder
533970|NCT00564278|Antidepressant Therapy
533971|NCT00564278|Motivational Interviewing
533972|NCT00564278|Treatment Retention
533973|NCT00564278|Treatment Adherence
533974|NCT00564265|GIST
533975|NCT00564226|urge urinary incontinence
533976|NCT00564213|Myopia
533977|NCT00564213|Mitomycin
533978|NCT00564200|Multiple Myeloma, transplant
533979|NCT00564174|recurrent pregnancy loss
533980|NCT00564174|lupus anticoagulant
533981|NCT00564174|anti cardiolipin antibodies
533982|NCT00564174|thrombophilia
533983|NCT00564174|low molecular weight heparin
533984|NCT00564174|aspirin
533985|NCT00564174|randomized clinical trial
533986|NCT00564148|antiVEGF therapy
533987|NCT00564135|hysterectomy
533988|NCT00564135|laparoscopy
533989|NCT00564135|urinary retention
533990|NCT00564135|urinary tract infection
533991|NCT00564135|catheterization
533992|NCT00564122|Murmur
533993|NCT00564122|Artificial-Intelligence
533994|NCT00564122|Stethoscope
533995|NCT00564122|Congenital Heart Disease
533996|NCT00564122|Structural Heart Disease
533997|NCT00564083|Compare the relative differences between the organic and sythentic materials for sacryl colpopexy.
533998|NCT00564070|Depression
533999|NCT00564070|Diabetes
534000|NCT00564070|Adherence
534001|NCT00564057|HIV
534002|NCT00564057|blood pressure
534003|NCT00564057|left ventricle
534004|NCT00564057|metabolic profile
534005|NCT00564057|treatment experienced
534006|NCT00564044|biofilm-infection-related immune hyperreactivity
534007|NCT00564044|mesh extrusion
534008|NCT00564044|mid-urethral sling
534009|NCT00564044|determine the immune reactivity of biofilms in mesh erosion
534010|NCT00564031|hormone replacement therapy; endothelial function;
534011|NCT00564018|type 1 diabetes, basal-bolus, honeymoon, C-peptide
534012|NCT00564005|stroke rehabilitation
534013|NCT00564005|cortical reorganization
534014|NCT00564005|kinematic analysis
534015|NCT00563979|age related macular degeneration
534016|NCT00563979|supplementation
534017|NCT00563979|macular pigment
534018|NCT00563966|smoking pregnancy behaviour polymorphisms
534019|NCT00563953|Breast
534020|NCT00563953|Cancer
534021|NCT00563953|Anthracyclines
534022|NCT00563953|Cardiopathy
534023|NCT00563940|diabetic macular edema
534024|NCT00563940|OCT
534025|NCT00563927|Nasopharyngeal Carcinoma
534026|NCT00563927|T1-4N2-3M0
534027|NCT00563914|Malaria
534028|NCT00563901|CHD
534029|NCT00563901|Combined CHD
534030|NCT00563901|Stroke
534031|NCT00563901|Combined Cardiovascular Disease (CVD)
534032|NCT00563901|Pharmacogenetics
534033|NCT00563901|End-Stage Renal Disease
534034|NCT00563901|Heart Failure
534035|NCT00563901|Hospitalized/Fatal Heart Failure
534036|NCT00563901|Angina
534037|NCT00563901|Coronary Revascularizations
534038|NCT00563901|CHD Mortality
534039|NCT00563901|Lisinopril
534040|NCT00563901|Chlorthalidone
534041|NCT00563901|Amlodipine
534042|NCT00563901|Doxazosin
534043|NCT00563888|PTSD
534044|NCT00563888|torture survivors
534045|NCT00563888|Narrative Exposure Therapy
534046|NCT00563888|trauma-related memory processes
534047|NCT00563888|steady state visual evoked fields
534048|NCT00563875|Platelets
534049|NCT00563875|Platelet aggregation
534050|NCT00563875|Drug resistance
534051|NCT00563875|Aspirin
534052|NCT00563875|Diabetes mellitus
534053|NCT00563862|Nasopharyngeal Carcinoma
534054|NCT00563862|T3-4N0-1M0
534055|NCT00563836|ovarian cancer
534056|NCT00563836|catumaxomab
534057|NCT00563836|phase II
534058|NCT00563836|intraoperative
534059|NCT00563836|adjuvant
534060|NCT00563836|trifunctional antibody
534061|NCT00563823|stage IV melanoma
534062|NCT00563823|recurrent melanoma
534063|NCT00563810|Adult
534064|NCT00563810|Aged
534065|NCT00563797|treatment
534066|NCT00563797|alcohol dependence
534067|NCT00563797|depression
534068|NCT00563797|mecamylamine
534069|NCT00563784|Non-Small Cell Lung Cancer
534070|NCT00563784|Lung Cancer
534072|NCT00563784|Adenocarcinoma
534073|NCT00563784|Bronchoalveolar Cell Carcinoma
534074|NCT00563784|Large Cell Anaplastic Carcinoma
534075|NCT00563784|Giant Cell Carcinoma
534076|NCT00563784|Clear Cell Carcinoma
534077|NCT00563784|Erlotinib
534078|NCT00563784|Erlotinib Hydrocholoride
534079|NCT00563784|OSI-774
534080|NCT00563784|Tarceva
534081|NCT00563784|Carboplatin
534082|NCT00563784|Paraplatin
534083|NCT00563784|Paclitaxel
534084|NCT00563784|Taxol
534085|NCT00563784|NSCLC
534086|NCT00563758|Chronic constipation
534087|NCT00563745|COPD
534088|NCT00563745|ALS
534089|NCT00563745|Telemedicine
534090|NCT00563745|mechanical ventilation
534091|NCT00563745|Integrated care
534092|NCT00563745|strict follow up
534093|NCT00563745|impact and costs on health care resources
534094|NCT00563745|telemedicine programme
534095|NCT00563745|home mechanical ventilation (HMV)
534096|NCT00563745|frail patients
534097|NCT00563745|chronic respiratory failure (CRF)
534098|NCT00563693|heart failure
534099|NCT00563693|cheyne stokes respiration
534100|NCT00563693|adaptive servo ventilator
534101|NCT00563680|AMG 479
534102|NCT00563680|IGF-1R
534103|NCT00563680|Insulin-like growth factor
534104|NCT00563680|Insulin-like growth factor receptor
534105|NCT00563680|Ewing's
534106|NCT00563680|Sarcoma
534107|NCT00563667|Pterygium
534108|NCT00563667|Cataract
534109|NCT00563667|Astigmatism
534110|NCT00563654|Benign Prostatic Hyperplasia (BPH)
534111|NCT00563654|Acute Retention of Urine (AUR)
534112|NCT00563641|NCPAP
534113|NCT00563641|Very early surfactant
534114|NCT00563628|Pattern Scan Laser.
534115|NCT00563628|Photocoagulation.
534116|NCT00563628|Diabetic retinopathy treatment.
534117|NCT00563628|Laser treatment
534118|NCT00563615|Constipation (idiopathic)
534119|NCT00563602|Portal hypertension
534120|NCT00563602|Prevention of rebleeding
534121|NCT00563602|Complications of cirrhosis
534122|NCT00563602|Portal hemodynamic
534123|NCT00563602|Prazosine
534124|NCT00563602|Nadolol
534125|NCT00563602|isosorbide mononitrate
534126|NCT00563589|Acute graft-versus-host disease post high risk allogeneic stem cell transplantation
534127|NCT00563576|Depo-Provera
534128|NCT00563576|Medroxyprogesterone Acetate
534129|NCT00563576|Metrorrhagia
534130|NCT00563576|Irregular Bleeding
534131|NCT00563563|Nicotine-dependence in overweight and obese subjects
534132|NCT00563537|neurology
534133|NCT00563537|sclerosis
534134|NCT00563537|imaging
534135|NCT00563537|tomography
534136|NCT00563511|smoking cessation
534137|NCT00563498|Veno-occlusive disease
534138|NCT00563498|Mucositis
534139|NCT00563485|Benign Prostatic Hyperplasia (BPH)
534140|NCT00563485|Acute Retention of Urine (AUR)
534141|NCT00563472|Healthy female volunteers will participate in this study
534142|NCT00563459|Epilepsy, seizures
534143|NCT00563459|partial onset seizures
534144|NCT00563459|anti-epileptic drugs (AED)
534145|NCT00563459|carisbamate
534146|NCT00563459|topiramate
534147|NCT00563459|levetiracetam
534148|NCT00563446|Anemia
534149|NCT00563446|End-stage renal failure
534150|NCT00563446|Continuous ambulatory peritoneal dialysis
534151|NCT00563433|diabetic
534152|NCT00563433|diabetes mellitus
534153|NCT00563433|foot
534154|NCT00563433|ulcers
534155|NCT00563433|Floxin
534156|NCT00563433|oral antibiotic
534157|NCT00563433|topical cream
534158|NCT00563420|Lung cancer
534159|NCT00563407|skin toxicity prediction
534160|NCT00563407|cardiac toxicity prediction
534161|NCT00563394|diabetic
534162|NCT00563394|diabetes mellitus
534163|NCT00563394|foot
534164|NCT00563394|ulcers
534165|NCT00563394|Floxin
534166|NCT00563394|oral antibiotic
534167|NCT00563394|topical cream
534168|NCT00563355|chronic kidney disease
534169|NCT00563355|cardiovascular disease
534170|NCT00563342|Ethanol, lock solution, infection
534171|NCT00563329|Smokers who are not willing to quit in the near future but intend to reduce smoking
534172|NCT00563316|colorectal cancer
534173|NCT00563316|chemotherapy
534174|NCT00563316|cancer
534175|NCT00563316|metastatic
534176|NCT00563316|irinotecan
534177|NCT00563316|EGFr
534178|NCT00563316|epidermal growth factor
534179|NCT00563277|Pterygium
534180|NCT00563277|Cataract
534181|NCT00563277|Intraocular lens power calculation accuracy
534182|NCT00563264|obesity
534183|NCT00563264|parenting
534184|NCT00563264|postpartum period
534185|NCT00563264|family research
534186|NCT00563251|Bronchiolitis obliterans in bone marrow transplant recipients
534187|NCT00563238|Extubation
534188|NCT00563212|Lung Diseases, Interstitial
534189|NCT00563212|Fibrosis
534190|NCT00563212|Interferons
534191|NCT00563212|Pulmonary Fibrosis
534192|NCT00563212|Pathologic Processes
534193|NCT00563212|Lung Diseases
534194|NCT00563212|Fibrosing alveolitis
534195|NCT00563212|Interferon-gamma, Recombinant
534196|NCT00563212|Aerosols
534197|NCT00563199|smoking cessation
534198|NCT00563199|smoking behaviors
534199|NCT00563186|infection control
534200|NCT00563186|nosocomial infection
534201|NCT00563186|hospital design
534202|NCT00563186|physical plant design
534203|NCT00563186|antibiotic resistant organisms
534204|NCT00563160|lung cancer
534205|NCT00563147|tivozanib
534206|NCT00563147|AV-951
534207|NCT00563134|Suspected or confirmed severe Gram-negative sepsis
534208|NCT00563121|Retinopathy of Prematurity
534209|NCT00563121|ROP
534210|NCT00563121|Vascular Endothelial Growth Factor
534211|NCT00563121|VEGF
534212|NCT00563121|Vitreous
534213|NCT00563121|Subretinal Fluid
534214|NCT00563121|ELISA
534215|NCT00563121|VEGF levels in Aqueous, Vitreous and subretinal Fluid
534216|NCT00563108|Acute graft-versus-host disease post allogeneic stem cell transplantation
534217|NCT00563095|Hepatocellular carcinoma
534218|NCT00563082|SLE
534219|NCT00563082|Genetics
534220|NCT00563069|diagnostic and therapeutic rigid cystoscopy
534221|NCT00563056|Formoterol
534222|NCT00563056|Fluticasone
534223|NCT00563056|Asthma
534224|NCT00563043|Pattern Scan Laser.
534225|NCT00563043|Photocoagulation.
534226|NCT00563043|Diabetic retinopathy treatment.
534227|NCT00563043|Laser treatment.
534228|NCT00563043|Electroretinogram.
534229|NCT00563043|a wave.
534230|NCT00563043|b wave.
534231|NCT00563043|Implicit time.
534232|NCT00563030|Cardiopulmonary bypass
534233|NCT00563030|Neutrophils
534234|NCT00563030|Coronary artery bypass graft surgery
534235|NCT00563017|Catatonic Schizophrenia
534236|NCT00563017|Disorganized Schizophrenia
534237|NCT00563017|Paranoid Schizophrenia
534238|NCT00563017|Undifferentiated Schizophrenia
534239|NCT00563017|Schizo-affective disorders
534240|NCT00563004|Diabetes mellitus
534241|NCT00563004|Herbal treatment
534242|NCT00563004|Food supplement
534243|NCT00562991|exhaled NO
534244|NCT00562991|asthma
534245|NCT00562991|child
534246|NCT00562978|recurrent grade 1 follicular lymphoma
534247|NCT00562978|recurrent grade 2 follicular lymphoma
534248|NCT00562978|recurrent grade 3 follicular lymphoma
534249|NCT00562978|recurrent adult diffuse large cell lymphoma
534250|NCT00562978|recurrent adult diffuse mixed cell lymphoma
534251|NCT00562978|recurrent adult diffuse small cleaved cell lymphoma
534252|NCT00562978|recurrent adult immunoblastic large cell lymphoma
534253|NCT00562978|recurrent mantle cell lymphoma
534254|NCT00562978|stage III grade 1 follicular lymphoma
534255|NCT00562978|stage III grade 2 follicular lymphoma
534256|NCT00562978|stage III grade 3 follicular lymphoma
534257|NCT00562978|stage IV grade 1 follicular lymphoma
534258|NCT00562978|stage IV grade 2 follicular lymphoma
534259|NCT00562978|stage IV grade 3 follicular lymphoma
534260|NCT00562978|stage III adult diffuse large cell lymphoma
534261|NCT00562978|stage III adult diffuse mixed cell lymphoma
534262|NCT00562978|stage III adult diffuse small cleaved cell lymphoma
534263|NCT00562978|stage IV adult diffuse large cell lymphoma
534264|NCT00562978|stage IV adult diffuse mixed cell lymphoma
534265|NCT00562978|stage IV adult diffuse small cleaved cell lymphoma
534266|NCT00562978|stage III mantle cell lymphoma
534267|NCT00562978|stage IV mantle cell lymphoma
534268|NCT00562978|stage III adult immunoblastic large cell lymphoma
534269|NCT00562978|stage IV adult immunoblastic large cell lymphoma
534270|NCT00562952|Natriuretic peptide
534271|NCT00562952|Prognosis
534272|NCT00562952|Diabetes
534273|NCT00562952|Heart failure
534274|NCT00562952|Heart disease
534275|NCT00562939|Antibody Formation
534276|NCT00562939|Antibody Affinity
534277|NCT00562939|Immunity
534278|NCT00562939|Pneumococcal Vaccines
534279|NCT00562939|Oligodeoxyribonucleotides
534280|NCT00562926|Schizophrenia
534281|NCT00562926|Schizophrenia spectrum disorder
534282|NCT00562913|Cancer
534283|NCT00562913|Sorafenib
534284|NCT00562913|Cyclophosphamide
534285|NCT00562913|Doxorubicin
534286|NCT00562887|Crohn's Disease
534287|NCT00562874|HIV
534288|NCT00562874|AIDS
534289|NCT00562874|WOMEN
534290|NCT00562874|KENYA
534291|NCT00562874|NUTRITION
534292|NCT00562874|HIV/AIDS
534293|NCT00562874|treatment naive
534294|NCT00562861|Bipolar Disorder
534295|NCT00562861|Bipolar Depression
534296|NCT00562861|Clinical Trials, Phase II
534297|NCT00562861|Clinical Pharmacology
534298|NCT00562848|gastric emptying
534299|NCT00562848|pharmacokinetic
534300|NCT00562848|tolerability
534301|NCT00562848|safety
534302|NCT00562848|GSK962040
534303|NCT00562848|gut motility
534304|NCT00562848|First Time in Human
534305|NCT00562835|ARDS
534306|NCT00562835|Adult
534307|NCT00562835|Methylprednisolone
534308|NCT00562796|Growth Hormone Deficiency
534309|NCT00562796|Cardiovascular Disease
534310|NCT00562796|Intra-abdominal Fat
534311|NCT00562796|Insulin Resistance
534312|NCT00562783|HBV
534313|NCT00562783|HCV
534314|NCT00562783|Liver cirrhosis
534315|NCT00562770|Chronic Lymphocytic Leukemia
534316|NCT00562770|CLL
534317|NCT00562770|Leukemia
534318|NCT00562757|Wedensky modulation
534319|NCT00562757|Risk stratification
534320|NCT00562757|Electrophysiology
534321|NCT00562757|Noninvasive
534322|NCT00562757|Ischemic heart disease
534323|NCT00562757|ICD guidelines
534324|NCT00562757|Myocardial infarction
534325|NCT00562718|stage II breast cancer
534326|NCT00562718|stage IIIA breast cancer
534327|NCT00562718|stage IIIB breast cancer
534328|NCT00562718|male breast cancer
534329|NCT00562718|recurrent breast cancer
534330|NCT00562705|growth hormone
534331|NCT00562705|eating regulation
534332|NCT00562705|nutritional intervention
534333|NCT00562705|short stature
534334|NCT00562705|ISS
534335|NCT00562705|SGA
534336|NCT00562705|IGHD
534337|NCT00562705|MPHD
534338|NCT00562692|Heart failure
534339|NCT00562692|OAD
534340|NCT00562692|BNP
534341|NCT00562692|Heart Failure patients who present to the emergency department
534342|NCT00562679|Patients with coronary artery disease
534343|NCT00562666|cell therapy
534344|NCT00562666|T lymphocytes
534345|NCT00562666|hepatic intra-arterial injection
534346|NCT00562653|profile autoantibodies
534347|NCT00562653|clinical symptoms
534348|NCT00562640|recurrent ovarian epithelial cancer
534349|NCT00562640|stage IV ovarian epithelial cancer
534350|NCT00562640|recurrent primary peritoneal cavity cancer
534351|NCT00562640|stage IIIA primary peritoneal cavity cancer
534352|NCT00562640|stage IIIB primary peritoneal cavity cancer
534353|NCT00562640|stage IIIC primary peritoneal cavity cancer
534354|NCT00562640|stage IV primary peritoneal cavity cancer
534355|NCT00562640|recurrent fallopian tube cancer
534356|NCT00562640|stage IIIA fallopian tube cancer
534357|NCT00562640|stage IIIB fallopian tube cancer
534358|NCT00562640|stage IIIC fallopian tube cancer
534359|NCT00562640|stage IV fallopian tube cancer
534360|NCT00562640|stage IIIA ovarian epithelial cancer
534361|NCT00562640|stage IIIB ovarian epithelial cancer
534362|NCT00562640|stage IIIC ovarian epithelial cancer
534363|NCT00562640|06-155
534364|NCT00562627|osteoarthritis
534365|NCT00562627|knee arthroplasty
534366|NCT00562627|local infiltration analgesia
534367|NCT00562627|TKA
534368|NCT00562627|epidural analgesia
534369|NCT00562627|operation
534370|NCT00562627|surgery
534371|NCT00562601|Leukapheresis
534372|NCT00562601|Plasmapheresis
534373|NCT00562601|Lymphocytes
534374|NCT00562601|Neutrophils
534375|NCT00562536|Umbilical cord clamping
534376|NCT00562536|Preterm infants
534377|NCT00562536|Randomized controlled trial
534378|NCT00562536|For women giving birth to singleton infants 32 weeks gestational age or less
534379|NCT00562523|Cancer
534380|NCT00562523|Docetaxel
534381|NCT00562523|Sorafenib
534382|NCT00562510|HIV-1 infection
534383|NCT00562510|raltegravir
534384|NCT00562510|immune discordance
534385|NCT00562510|treatment experienced
534386|NCT00562497|Acute GVHD
534387|NCT00562497|Acute Graft Versus Host Disease
534388|NCT00562471|adhesions
534389|NCT00562471|gynecologic surgery
534390|NCT00562471|laparoscopy
534391|NCT00562471|laparotomy
534392|NCT00562471|polyethylene glycol
534393|NCT00562471|hydrogel
534394|NCT00562471|Adhesions following gynecologic surgery to remove myomas
534395|NCT00562458|Advanced breast cancer
534396|NCT00562458|Advanced breast cancer in postmenopausal women
534397|NCT00562445|Adrenal insufficiency
534398|NCT00562445|GI bleeding
534399|NCT00562445|Portal hypertension
534400|NCT00562445|Acute pancreatitis
534401|NCT00562445|Critical emergencies in digestive diseases
534402|NCT00562445|Severe acute pancreatitis
534403|NCT00562432|atrial fibrillation
534404|NCT00562432|CABG
534405|NCT00562432|ganglionated plexi
534406|NCT00562406|Macular edema secondary to branch retinal vein occlusion
534407|NCT00562380|cutaneous B-cell non-Hodgkin lymphoma
534408|NCT00562380|angioimmunoblastic T-cell lymphoma
534409|NCT00562380|stage IV cutaneous T-cell non-Hodgkin lymphoma
534410|NCT00562380|adult nasal type extranodal NK/T-cell lymphoma
534411|NCT00562380|anaplastic large cell lymphoma
534412|NCT00562380|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
534413|NCT00562380|nodal marginal zone B-cell lymphoma
534414|NCT00562380|recurrent adult Burkitt lymphoma
534415|NCT00562380|recurrent adult diffuse large cell lymphoma
534416|NCT00562380|recurrent adult diffuse mixed cell lymphoma
534417|NCT00562380|recurrent adult diffuse small cleaved cell lymphoma
534418|NCT00562380|recurrent adult grade III lymphomatoid granulomatosis
534419|NCT00562380|recurrent adult immunoblastic large cell lymphoma
534534|NCT00561886|COPD
534420|NCT00562380|recurrent adult lymphoblastic lymphoma
534536|NCT00561886|dysnpea
534421|NCT00562380|recurrent cutaneous T-cell non-Hodgkin lymphoma
534422|NCT00562380|recurrent grade 1 follicular lymphoma
534423|NCT00562380|recurrent grade 2 follicular lymphoma
534424|NCT00562380|recurrent grade 3 follicular lymphoma
534425|NCT00562380|recurrent mantle cell lymphoma
534426|NCT00562380|recurrent marginal zone lymphoma
534427|NCT00562380|recurrent small lymphocytic lymphoma
534428|NCT00562380|small intestine lymphoma
534429|NCT00562380|splenic marginal zone lymphoma
534430|NCT00562380|unspecified adult solid tumor, protocol specific
534431|NCT00562380|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
534432|NCT00562380|adult desmoplastic small round cell tumor
534433|NCT00562380|recurrent adult soft tissue sarcoma
534434|NCT00562380|recurrent prostate cancer
534435|NCT00562354|Vaccines, Pneumococcal Conjugate Vaccine
534436|NCT00562341|obesity
534437|NCT00562341|psa
534438|NCT00562341|prostate cancer
534439|NCT00562328|stage 0 chronic lymphocytic leukemia
534440|NCT00562328|stage I chronic lymphocytic leukemia
534441|NCT00562328|stage II chronic lymphocytic leukemia
534442|NCT00562302|lung biopsy
534443|NCT00562289|Stroke
534444|NCT00562289|Patent Foramen Ovale
534445|NCT00562289|Atrial septal aneurysm
534446|NCT00562289|Antiplatelet therapy
534447|NCT00562289|Oral anticoagulants
534448|NCT00562289|Transcatheter closure
534449|NCT00562289|Migraine
534450|NCT00562276|IUD
534451|NCT00562276|insertion timing
534452|NCT00562263|overweight
534453|NCT00562263|obesity
534454|NCT00562263|adolescent
534455|NCT00562263|insulin resistance
534456|NCT00562263|treatment
534457|NCT00562237|immunogenicity
534458|NCT00562237|safety
534459|NCT00562237|adjuvanted pandemic vaccine
534460|NCT00562224|PCI-24781
534461|NCT00562224|Neoplasms by site
534462|NCT00562224|Lymphoma, non-hodgkin
534463|NCT00562224|Hodgkin disease
534464|NCT00562224|Multiple myeloma
534465|NCT00562224|Leukemia, lymphocytic, chronic
534466|NCT00562211|children
534467|NCT00562185|recurrent ovarian epithelial cancer
534468|NCT00562185|ovarian sarcoma
534469|NCT00562185|recurrent ovarian germ cell tumor
534470|NCT00562185|ovarian stromal cancer
534471|NCT00562159|rhinoconjunctivitis
534472|NCT00562159|rhinitis
534473|NCT00562159|conjunctivitis
534474|NCT00562159|allergy
534475|NCT00562159|allergen
534476|NCT00562159|immunotherapy
534477|NCT00562146|nutrition
534478|NCT00562146|enteral access
534479|NCT00562107|Minimized ventricular pacing, clinical outcome, SafeR, AAIsafeR, dual chamber pacemaker therapy, % of ventricular pacing, hospitalizations, symptomatic AF
534480|NCT00562094|Pantoprazole
534481|NCT00562094|eGERD (Erosive Gastroesophageal Reflux Disease)
534482|NCT00562094|NERD (Non-Erosive Reflux Disease)
534483|NCT00562094|sleep disorders
534484|NCT00562081|asthma
534485|NCT00562081|Virtual Asthma Clinic
534486|NCT00562081|metabolites
534487|NCT00562081|asthma education
534488|NCT00562068|recurrent adult T-cell leukemia/lymphoma
534489|NCT00562068|stage I adult T-cell leukemia/lymphoma
534490|NCT00562068|stage II adult T-cell leukemia/lymphoma
534491|NCT00562068|stage III adult T-cell leukemia/lymphoma
534492|NCT00562068|stage IV adult T-cell leukemia/lymphoma
534493|NCT00562068|anaplastic large cell lymphoma
534494|NCT00562068|angioimmunoblastic T-cell lymphoma
534495|NCT00562068|small intestine lymphoma
534496|NCT00562068|peripheral T-cell lymphoma
534497|NCT00562042|pulmonary embolism
534498|NCT00562042|risk stratification
534499|NCT00562042|prognosis
534500|NCT00562042|troponin
534501|NCT00562042|Brain natriuretic peptide
534502|NCT00562042|echocardiogram
534503|NCT00562029|Diabetes Mellitus
534504|NCT00562029|Surgery
534505|NCT00562029|Duodenal Bypass
534506|NCT00562029|Resolution
534507|NCT00562029|Surgical Procedures
534508|NCT00562016|Patient undergoing scheduled PCI
534509|NCT00562003|Ovarian cancer study
534510|NCT00561990|pancreatic cancer
534511|NCT00561977|Nutrition
534512|NCT00561977|Dietary Quality
534513|NCT00561977|Weight loss
534514|NCT00561938|Confocal laser endomicroscopy
534515|NCT00561938|cancerous and non-cancerous conditions
534516|NCT00561938|tolerance
534517|NCT00561938|intravenous fluorescein
534518|NCT00561938|Digestive symptoms or disease requiring an endoscopy procedure (upper GI endoscopy or colonoscopy) performed under general anaesthesia
534519|NCT00561912|Renal Cell Carcinoma
534520|NCT00561912|Renal Cell Cancer
534521|NCT00561912|Clear Cell
534522|NCT00561912|Kidney
534523|NCT00561912|Decitabine
534524|NCT00561912|Dacogen
534525|NCT00561912|5-Aza-Deoxycytidine
534526|NCT00561912|Interferon Alfa-2b
534527|NCT00561912|Intron A®
534528|NCT00561912|RCC
534529|NCT00561899|safety
534530|NCT00561899|tolerability
534531|NCT00561899|efficacy
534532|NCT00561899|intermittent prevetive treatment
534533|NCT00561899|children
534535|NCT00561886|lung function
534537|NCT00561873|astrocytoma, glioblastoma, intrinsic pontine glioma
534538|NCT00561860|Obstructive sleep apnea-hypopnea
534539|NCT00561860|Telemedicine
534540|NCT00561834|non-arteritic ischemic optic neuropathy
534541|NCT00561834|ranibizumab
534542|NCT00561834|naion
534543|NCT00561821|elderly
534544|NCT00561821|randomized
534545|NCT00561821|placebo controlled
534546|NCT00561808|PCO/PCOD
534547|NCT00561808|IVM
534548|NCT00561808|Immature Oocytes
534549|NCT00561795|AGO
534550|NCT00561795|Advanced,
534551|NCT00561795|Gynaecologic cancer(s),
534552|NCT00561795|Genetics
534553|NCT00561795|GW786034,
534554|NCT00561795|Pazopanib,
534555|NCT00561782|Spinal Cord Injury Pain
534556|NCT00561782|Chronic Neuropathic Pain
534557|NCT00561782|SCI Pain
534558|NCT00561782|Pain, Chronic Neuropathic
534559|NCT00561782|Spectroscopy, Magnetic Resonance
534560|NCT00561782|MRS
534561|NCT00561782|Traumatic Brain Injury Pain
534562|NCT00561769|poor responder
534563|NCT00561769|growth hormone
534564|NCT00561769|luteal
534565|NCT00561756|cutaneous B-cell non-Hodgkin lymphoma
534566|NCT00561756|recurrent grade 1 follicular lymphoma
534567|NCT00561756|recurrent grade 2 follicular lymphoma
534568|NCT00561756|recurrent grade 3 follicular lymphoma
534569|NCT00561756|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
534570|NCT00561756|recurrent marginal zone lymphoma
534571|NCT00561756|recurrent mantle cell lymphoma
534572|NCT00561756|recurrent adult diffuse large cell lymphoma
534573|NCT00561756|recurrent adult diffuse mixed cell lymphoma
534574|NCT00561743|Multiple myeloma
534575|NCT00561743|response rate
534576|NCT00561743|peripheral stem cell transplant
534577|NCT00561743|safety
534578|NCT00561743|tolerability
534579|NCT00561730|PPI (Proton Pump Inhibitor) therapy
534580|NCT00561730|Pantoprazole
534581|NCT00561730|eGERD (Erosive Gastroesophageal Reflux Disease)
534582|NCT00561730|NERD (Non-Erosive Reflux Disease)
534583|NCT00561717|Seasonal Allergic Rhinitis
534584|NCT00561717|Ragweed
534585|NCT00561717|Pollen
534586|NCT00561717|Allergy
534587|NCT00561704|obese female
534588|NCT00561704|Type 2 Diabetes
534589|NCT00561704|Diabetic Nephropathy
534590|NCT00561704|Glucose Metabolism
534591|NCT00561704|Angiotensin II Type 1 Receptor Blockers
534592|NCT00561704|Adiponectin
534593|NCT00561691|diffuse instrinsic ponitine glioma, brainstem
534594|NCT00561678|Postoperative Confusion
534595|NCT00561678|Postoperative Delirium
534596|NCT00561678|PD
534597|NCT00561678|Postoperative Cognitive Dysfunction
534598|NCT00561678|POCD
534599|NCT00561652|Low back pain
534600|NCT00561652|Chiropractic
534601|NCT00561652|Exercise
534602|NCT00561652|Veterans
534603|NCT00561639|sepsis
534604|NCT00561639|immunosuppressed
534605|NCT00561639|multiplex PCR
534606|NCT00561639|diagnosis
534607|NCT00561639|therapeutic
534608|NCT00561613|Diaphragm
534609|NCT00561613|postcoital test
534610|NCT00561613|SILCS
534611|NCT00561613|nonoxynol-9
534612|NCT00561600|Hip arthroplasty
534613|NCT00561600|Acetabular cup replacement
534614|NCT00561600|Acetabulum arthroplasty
534615|NCT00561587|novel antipsychotic
534616|NCT00561587|quetiapine
534617|NCT00561587|depression
534618|NCT00561587|psychopathology
534619|NCT00561574|elderly
534620|NCT00561574|randomized
534621|NCT00561574|double blind
534622|NCT00561561|Schizophrenia
534623|NCT00561561|Prepulse Inhibition
534624|NCT00561561|Acoustic Startle
534625|NCT00561535|IBS
534626|NCT00561535|Diarrhea
534627|NCT00561535|Rome III
534628|NCT00561522|Recurrence
534629|NCT00561522|Metastasis
534630|NCT00561522|Hepatocellular Carcinoma
534631|NCT00561522|Radical Hepatic Resection
534632|NCT00561522|Drug Prevention
534633|NCT00561522|Capecitabine
534634|NCT00561522|Surgery
534635|NCT00561496|HIV prevention
534636|NCT00561496|Microbicides
534637|NCT00561496|Pharmacokinetics
534638|NCT00561496|vaginal biopsies
534639|NCT00561483|Acute heart failure
534640|NCT00561483|cystatin C
534641|NCT00561483|renal failure
534642|NCT00561483|biomarker
534643|NCT00561470|colorectal cancer
534644|NCT00561470|metastatic
534645|NCT00561470|anti-angiogenic
534646|NCT00561470|irinotecan
534647|NCT00561470|5-FU
534648|NCT00561470|FOLFIRI
534649|NCT00561457|Iliac
534650|NCT00561457|Artery
534651|NCT00561457|Occlusive
534652|NCT00561457|Stenosis
534653|NCT00561444|Prostate Cancer
534654|NCT00561444|Radical retropubic prostatectomy
534655|NCT00561444|Robotic prostatectomy
534656|NCT00561444|Photon external beam radiation
534657|NCT00561444|Photon external beam radiation with hormone therapy
534658|NCT00561444|Proton radiation
534659|NCT00561444|Radioisotopic implant
534660|NCT00561444|Cryotherapy
534661|NCT00561444|Quality of Life
534662|NCT00561444|Questionnaire
534663|NCT00561444|Survey
534664|NCT00561444|QOL
534665|NCT00561431|CVVHDF Dose Study
534666|NCT00561418|recurrent adult diffuse large cell lymphoma
534667|NCT00561418|stage III adult diffuse large cell lymphoma
534668|NCT00561418|stage IV adult diffuse large cell lymphoma
534669|NCT00561418|recurrent grade 3 follicular lymphoma
534670|NCT00561418|recurrent adult Hodgkin lymphoma
534671|NCT00561418|recurrent mantle cell lymphoma
534672|NCT00561418|adult nasal type extranodal NK/T-cell lymphoma
534673|NCT00561418|angioimmunoblastic T-cell lymphoma
534674|NCT00561418|recurrent adult T-cell leukemia/lymphoma
534675|NCT00561418|stage III adult T-cell leukemia/lymphoma
534676|NCT00561418|stage IV adult T-cell leukemia/lymphoma
534677|NCT00561418|small intestine lymphoma
534678|NCT00561418|anaplastic large cell lymphoma
534679|NCT00561405|Stroke
534680|NCT00561405|Walking
534681|NCT00561405|Motor learning
534682|NCT00561405|Skill acquisition
534683|NCT00561392|Alzheimer's Disease
534684|NCT00561392|Rivastigmine
534685|NCT00561392|Patch
534686|NCT00561379|Diffuse Large B Cell Lymphoma
534687|NCT00561379|not previously treated
534688|NCT00561366|ALS
534689|NCT00561366|Lou Gehrig's disease
534690|NCT00561353|Hepatitis C, Chronic
534691|NCT00561353|Tibotec
534692|NCT00561353|TMC435350-TiDP16-C201
534693|NCT00561353|TMC435350-C201
534694|NCT00561353|TMC435
534695|NCT00561353|PEGASYS (peginterferon alpha-2a, PegIFNα-2a)
534696|NCT00561353|COPEGUS (ribavirin)
534697|NCT00561340|ADHD
534698|NCT00561340|Growth
534699|NCT00561340|Atomoxetine
534700|NCT00561340|Pediasure
534701|NCT00561327|hypertension
534702|NCT00561327|angiotensin receptor blockers
534703|NCT00561327|peroxisome proliferator activated receptor gamma
534704|NCT00561314|sexual dysfunction
534705|NCT00561314|urinary incontinence
534706|NCT00561314|adenocarcinoma of the prostate
534707|NCT00561314|stage I prostate cancer
534708|NCT00561314|stage IIB prostate cancer
534709|NCT00561314|stage IIA prostate cancer
534710|NCT00561288|Acetaminophen
534711|NCT00561288|Social Psychology
534712|NCT00561288|Affect
534713|NCT00561288|Interpersonal Rejection
534714|NCT00561262|adenocarcinoma of the prostate
534715|NCT00561262|stage I prostate cancer
534716|NCT00561262|stage IIB prostate cancer
534717|NCT00561262|stage IIA prostate cancer
534718|NCT00561262|stage III prostate cancer
534719|NCT00561223|chronic obstructive pulmonary disease
534720|NCT00561223|pulmonary hypertension
534721|NCT00561210|infections
534722|NCT00561184|H5N1 Pandemic
534723|NCT00561145|Anorexia of ageing
534724|NCT00561145|Anorexia of aging
534725|NCT00561145|Energy balance
534726|NCT00561145|Elderly
534727|NCT00561132|vanadium
534728|NCT00561132|insulin sensitivity
534729|NCT00561132|impaired glucose tolerance
534730|NCT00561132|triglycerides
534731|NCT00561119|maintenance chemotherapy
534732|NCT00561119|metastatic or recurrent breast cancer
534733|NCT00561119|gemcitabine
534734|NCT00561119|paclitaxel(GP)
534735|NCT00561106|Bell´s palsy
534736|NCT00561106|prednisone
534737|NCT00561106|valacyclovir
534738|NCT00561093|Hypoalbuminemia
534739|NCT00561093|Protein-energy malnutrition
534740|NCT00561093|Inflammation
534741|NCT00561093|Oxidative stress
534742|NCT00561093|Chronic Kidney disease (CKD) stage 5
534743|NCT00561093|maintenance hemodialysis
534744|NCT00561067|Spinal cord injury
534745|NCT00561067|spinal shock
534746|NCT00561067|erythropoietin
534747|NCT00561054|Coimbra
534748|NCT00561054|NSCLC
534749|NCT00561054|CETUXIMAB
534750|NCT00561041|alcohol
534751|NCT00561041|alcohol use disorder
534752|NCT00561041|cognitive-behavioral therapy
534753|NCT00561041|brief phone aftercare intervention
534754|NCT00561041|individual aftercare therapy
534755|NCT00561028|Atherosclerosis
534756|NCT00561028|Coronary artery disease
534757|NCT00561028|Chlamydia pneumoniae
534758|NCT00561028|Mycoplasma pneumoniae
534759|NCT00561015|Hepatitis C, Chronic
534760|NCT00561015|Genotype 2
534761|NCT00561015|Genotype 3
534762|NCT00561015|Telaprevir
534763|NCT00561002|Influenza Vaccine
534764|NCT00561002|Influenza Virus
534765|NCT00561002|Orthomyxoviridae Infections
534766|NCT00561002|Fluzone®
534767|NCT00560989|Chronic Beryllium Disease
534768|NCT00560989|CBD
534769|NCT00560989|Beryllium
534770|NCT00560989|Genetic
534771|NCT00560989|Environmental
534772|NCT00560976|neutrophil gelatinase associated lipocalin
534773|NCT00560976|hemodialysis
534774|NCT00560976|iron
534775|NCT00560976|inflammation
534776|NCT00560976|Oxidative Stress
534777|NCT00560963|Advanced or metastatic pancreas carcinoma
534778|NCT00560963|gemcitabine
534779|NCT00560963|everolimus
534780|NCT00560937|Schizophrenia
534781|NCT00560937|Pregnenolone
534782|NCT00560937|Cognition
534783|NCT00560937|Negative Symptoms
534784|NCT00560911|oral anticoagulation
534785|NCT00560911|self-management
534786|NCT00560911|elderly patients
534787|NCT00560911|randomised controlled trial
534788|NCT00560898|staining
534789|NCT00560898|epithelial barrier function
534790|NCT00560885|atrial fibrillation
534791|NCT00560885|af
534792|NCT00560885|ablation
534793|NCT00560885|arrhythmia
534794|NCT00560885|racing heart
534795|NCT00560885|afib
534796|NCT00560885|surgical ablation
534797|NCT00560872|atrial flutter
534798|NCT00560872|ablation
534799|NCT00560872|navigation
534800|NCT00560859|Sleep disordered breathing
534801|NCT00560859|Sleep apnea
534802|NCT00560859|Tonsillectomy
534803|NCT00560859|Adenoidectomy
534804|NCT00560859|Snoring
534805|NCT00560859|Neurobehavioral Manifestations
534806|NCT00560859|Obstructive Sleep Apnea Syndrome
534807|NCT00560846|Gastric cancer
534808|NCT00560846|Esophageal cancer
534809|NCT00560846|Surgical complications
534810|NCT00560846|Immunonutrition
534811|NCT00560820|β-thalassemia
534812|NCT00560820|transfusional iron overload
534813|NCT00560820|renal function
534814|NCT00560820|renal biomarkers
534815|NCT00560820|deferasirox
534816|NCT00560807|WAD II
534817|NCT00560807|WAD III
534818|NCT00560807|mobilization
534819|NCT00560807|dosage
534820|NCT00560807|acute whiplash associated disorders (WAD) II and III (113) with a symptom duration of less than 30 days
534821|NCT00560807|neck pain
534822|NCT00560794|Minimal Residual Disease
534823|NCT00560794|adult ALL
534824|NCT00560794|immunotherapeutic treatment
534825|NCT00560794|anti-CD19 bispecific antibody derivative
534826|NCT00560794|Blinatumomab
534827|NCT00560794|MT103
534828|NCT00560781|PTSD
534829|NCT00560781|Pregnenolone
534830|NCT00560781|Cognition
534831|NCT00560768|Risk stratification method, negative predictive value, fast ventricular arrhythmias, ICD
534832|NCT00560768|The negative predictive value of the T amplitude variance as a method for risk stratification for patients with an increased risk for SCD.
534833|NCT00560755|Prevention of: measles, mumps, rubella and varicella
534834|NCT00560729|elderly people
534835|NCT00560690|Hepatitis C
534836|NCT00560690|metformin
534837|NCT00560690|Insulin Resistance
534838|NCT00560677|Schizophrenia
534839|NCT00560677|PTSD
534840|NCT00560677|Cognition
534841|NCT00560664|knee
534842|NCT00560664|chondral defect
534843|NCT00560664|osteochondral defect
534844|NCT00560651|keratoconus
534845|NCT00560651|cornea
534846|NCT00560651|cross linking
534847|NCT00560651|UV-light
534848|NCT00560651|riboflavin
534849|NCT00560612|PTSD
534850|NCT00560612|Paroxetine
534851|NCT00560612|Subthreshold
534852|NCT00560599|MRSA
534853|NCT00560599|Methicillin Resistant Staphylococcus aureus
534854|NCT00560599|Staphylococcus aureus
534855|NCT00560599|Skin Infections
534856|NCT00560599|Body Decolonization
534857|NCT00560599|Environmental Decolonization
534858|NCT00560586|sleep fragmentation
534859|NCT00560586|apnea
534860|NCT00560586|hypoxia
534861|NCT00560560|Refractory Colorectal
534862|NCT00560560|Single arm
534863|NCT00560560|Phase 2
534864|NCT00560534|Magnetic resonance
534865|NCT00560534|whole body
534866|NCT00560534|angiography
534867|NCT00560534|venous compression
534868|NCT00560534|MRI
534869|NCT00560521|CPAP
534870|NCT00560521|Tuberculosis
534871|NCT00560521|Pleural effusion
534872|NCT00560521|Physiotherapy
534873|NCT00560495|stage I non-small cell lung cancer
534874|NCT00560495|stage II non-small cell lung cancer
534875|NCT00560495|stage IIIA non-small cell lung cancer
534876|NCT00560495|stage IIIB non-small cell lung cancer
534877|NCT00560495|adenocarcinoma of the lung
534878|NCT00560495|adenosquamous cell lung cancer
534879|NCT00560495|large cell lung cancer
534880|NCT00560495|squamous cell lung cancer
534881|NCT00560482|prostate
534882|NCT00560482|cancer
534883|NCT00560482|prostatic cancer
534884|NCT00560482|castrate-resistant prostate cancer (CRPC)
534885|NCT00560469|Adipokines
534886|NCT00560469|Inflammation
534887|NCT00560469|Metabolic syndrome
534888|NCT00560456|Age, Snoring, Driving simulator, Sleep deprivation, chronic sleep restriction, objective and subjective sleepiness
534889|NCT00560443|bone fracture
534890|NCT00560443|ketorolac
534891|NCT00560443|tramadol
534892|NCT00560378|Tacrolimus
534893|NCT00560378|Administration, topical
534894|NCT00560378|Drug safety
534895|NCT00560378|Adults
534896|NCT00560378|Children
534897|NCT00560365|stage I colon cancer
534898|NCT00560365|stage II colon cancer
534899|NCT00560365|stage III colon cancer
534900|NCT00560365|stage I rectal cancer
534901|NCT00560365|stage II rectal cancer
534902|NCT00560365|stage III rectal cancer
534903|NCT00560339|Congestive Heart Failure
534904|NCT00560339|Implantable Defibrillators
534905|NCT00560339|Intrathoracic Impedance
534906|NCT00560326|Paediatric patients
534907|NCT00560326|Tacrolimus
534908|NCT00560326|Dermatitis, Atopic
534909|NCT00560313|Meningococcal disease
534910|NCT00560313|prevention
534911|NCT00560313|vaccination
534912|NCT00560287|Amyotrophic Lateral Sclerosis
534913|NCT00560287|Non-invasive ventilation
534914|NCT00560287|Chronic Respiratory Failure
534915|NCT00560261|Sickle cell disease;
534916|NCT00560261|Lung capillary blood volume;
534917|NCT00560261|Children
534918|NCT00560248|Chest Pain
534919|NCT00560248|STEMI
534920|NCT00560248|UA/NSTEMI
534921|NCT00560248|ACS
534922|NCT00560248|Emergency Department
534923|NCT00560222|randomized controlled trial
534924|NCT00560222|lactoferrin
534925|NCT00560222|children
534926|NCT00560222|diarrhea
534927|NCT00560222|malnutrition
534928|NCT00560222|growth
534929|NCT00560209|ONO-1101
534930|NCT00560209|Coronary Artery Disease
534931|NCT00560209|Multi-slice CT
534932|NCT00560196|Neuropathic pain
534933|NCT00560196|Chronic pain
534934|NCT00560196|Depression
534935|NCT00560196|Anxiety
534936|NCT00560183|Acute
534937|NCT00560183|Bunionectomy
534938|NCT00560170|HMG-CoA Reductase Inhibitors
534939|NCT00560170|endothelial function
534940|NCT00560170|HMG-CoA Reductase Inhibitors on vascular protection
534941|NCT00560157|ICU patients
534942|NCT00560118|recurrent melanoma
534943|NCT00560118|stage IV melanoma
534944|NCT00560105|COPD
534945|NCT00560092|Magnesium
534946|NCT00560092|Pain
534947|NCT00560092|Morphine
534948|NCT00560092|Intrathecal
534949|NCT00560092|NMDA
534950|NCT00560092|Elective total hip replacement under intrathecal anesthesia
534951|NCT00560066|influenza
534952|NCT00560066|vaccine
534953|NCT00560053|Multiple Myeloma
534954|NCT00560053|Alternating chemotherapy
534955|NCT00560053|Transplantation
534956|NCT00560040|Troponin
534957|NCT00560040|Natriuretic Peptide, Brain
534958|NCT00560040|Exercise
534959|NCT00560040|Echocardiography
534960|NCT00560027|postpartum depression
534961|NCT00560027|intimate partner violence
534962|NCT00560001|frail elderly
534963|NCT00560001|medication errors
534964|NCT00560001|patient compliance & attitudes
534965|NCT00560001|guideline adherence
534966|NCT00559988|Implanted Cardioverter Defibrillator
534967|NCT00559988|Cardiac Resynchronization Therapy Defibrillator
534968|NCT00559988|Home Monitoring
534969|NCT00559988|Oral Anticoagulation
534970|NCT00559975|Adjuvanted Influenza Vaccine
534971|NCT00559962|LDL
534972|NCT00559962|hepatic fat
534973|NCT00559897|bone metastases
534974|NCT00559897|stage IIIB non-small cell lung cancer
534975|NCT00559897|stage IV non-small cell lung cancer
534976|NCT00559897|recurrent non-small cell lung cancer
534977|NCT00559884|pharmacokinetics,
534978|NCT00559884|healthy male and females,
534979|NCT00559884|pharmacodynamics
534980|NCT00559871|dyskinesia
534981|NCT00559871|movement disorders
534982|NCT00559871|basal ganglia diseases
534983|NCT00559871|JP-1730
534984|NCT00559871|Parkinson
534985|NCT00559871|end-of-dose wearing off
534986|NCT00559871|fluctuations
534987|NCT00559858|palmar-plantar erythrodysesthesia
534988|NCT00559858|breast cancer
534989|NCT00559858|male breast cancer
534990|NCT00559858|colon cancer
534991|NCT00559858|rectal cancer
534992|NCT00559832|acute mountain sickness
534993|NCT00559832|intermittent hypoxia
534994|NCT00559832|acclimatization
534995|NCT00559819|Alcohol
534996|NCT00559819|Driving
534997|NCT00559819|Impairment
534998|NCT00559806|immobilisation
534999|NCT00559806|aging
535000|NCT00559806|resistance training
535001|NCT00559806|atrophy
535002|NCT00559806|The effect of immobilisation in elderly compared to young individuals
535003|NCT00559780|Resistance training
535004|NCT00559780|Aging
535005|NCT00559780|hip-surgery
535006|NCT00559767|Kidney Function
535007|NCT00559767|Genes
535008|NCT00559767|Association Analysis
535009|NCT00559767|Polymorphisms
535010|NCT00559767|Diabetes
535011|NCT00559741|stage IV colon cancer
535012|NCT00559741|recurrent colon cancer
535013|NCT00559741|stage IV rectal cancer
535014|NCT00559741|recurrent rectal cancer
535015|NCT00559715|bevacizumab
535016|NCT00559715|ranibizumab
535017|NCT00559715|macular degeneration
535018|NCT00559715|age-related
535019|NCT00559715|neovascular
535020|NCT00559715|intravitreal injection
535021|NCT00559715|vision loss
535022|NCT00559715|outpatient setting
535023|NCT00559702|natalizumab
535024|NCT00559702|multiple sclerosis
535025|NCT00559702|Tysabri ®
535026|NCT00559689|asthma patients
535027|NCT00559689|well-controlled
535028|NCT00559676|recurrent colon cancer
535029|NCT00559676|stage IV colon cancer
535030|NCT00559676|recurrent rectal cancer
535031|NCT00559676|stage IV rectal cancer
535032|NCT00559663|Flavonoid
535033|NCT00559663|hsCRP
535034|NCT00559663|HDL
535035|NCT00559663|LDL
535036|NCT00559663|platelet reactivity
535037|NCT00559650|Acute decompensated heart failure
535038|NCT00559650|Double blind study,
535039|NCT00559650|BAY58-2667
535040|NCT00559650|Soluble guanylate cyclase activator
535041|NCT00559624|safety
535042|NCT00559624|tolerability
535043|NCT00559624|dose-escalation
535044|NCT00559611|Non-Small Lung Cancer
535045|NCT00559611|Lung Cancer
535046|NCT00559611|Endobronchial Ultrasound
535047|NCT00559611|Fine Needle Aspiration
535048|NCT00559611|Mediastinoscopy
535049|NCT00559611|EBUS-FNA
535050|NCT00559611|EBUS
535051|NCT00559611|Needle Biopsy
535052|NCT00559611|NSCLC
535053|NCT00559598|pancreatic cancer
535054|NCT00559598|extrahepatic bile duct cancer
535055|NCT00559572|Exercise
535056|NCT00559572|Group Counseling
535057|NCT00559572|Obesity
535058|NCT00559559|Primary and secondary prevention for ventricular tachycardia
535059|NCT00559520|Patients
535060|NCT00559520|Suffering
535061|NCT00559520|Undernutrition
535062|NCT00559520|Requiring
535063|NCT00559520|Vascular
535064|NCT00559520|Surgery
535065|NCT00559494|complete spinal cord injury
535066|NCT00559494|incomplete spinal cord injury
535067|NCT00559494|central cord spinal cord injury
535068|NCT00559494|traumatic
535069|NCT00559481|recurrent prostate cancer
535070|NCT00559442|high altitude pulmonary edema
535071|NCT00559442|hypoxic pulmonary vasoconstriction
535072|NCT00559442|right ventricular function
535073|NCT00559442|hypoxia
535074|NCT00559429|Prostate Cancer
535075|NCT00559416|HIV/AIDS
535076|NCT00559416|HLA-B*57
535077|NCT00559416|Cell Transfer
535078|NCT00559416|HIV
535079|NCT00559416|treatment experienced
535080|NCT00559403|Human immunodeficiency virus
535081|NCT00559403|South Africa
535082|NCT00559403|Intervention Studies
535083|NCT00559403|Sexual Behavior
535084|NCT00559403|Adolescents
535085|NCT00559403|STD
535086|NCT00559403|HIV Seronegativity
535087|NCT00559390|Polycystic Ovary Syndrome
535088|NCT00559390|Metabolic Syndrome
535089|NCT00559390|PCOS
535090|NCT00559390|children
535091|NCT00559390|girls
535092|NCT00559390|daughters
535093|NCT00559390|sisters
535094|NCT00559390|irregular periods
535095|NCT00559351|esophagectomy
535096|NCT00559351|chemotherapy
535097|NCT00559351|chemoradiotherapy
535098|NCT00559351|combined modality therapy
535099|NCT00559338|CHF
535100|NCT00559338|Heart Failure
535101|NCT00559338|Dyspnea
535102|NCT00559338|Cardiomyopathy
535103|NCT00559312|mild COPD
535104|NCT00559312|dyspnea
535105|NCT00559312|exercise
535106|NCT00559312|combination therapy
535107|NCT00559299|163090
535108|NCT00559299|placebo-controlled
535109|NCT00559299|MDD
535110|NCT00559299|Depression
535111|NCT00559299|Tolerability
535112|NCT00559299|MDE
535113|NCT00559286|perfusion
535114|NCT00559286|microcirculation
535115|NCT00559286|RBC function
535116|NCT00559286|NO metabolism
535117|NCT00559286|AT receptor blocker
535118|NCT00559234|Optic Nerve
535119|NCT00559234|Retina
535120|NCT00559234|Cornea
535121|NCT00559234|Lens
535122|NCT00559234|Ocular Genetic Diseases
535123|NCT00559234|Inherited Eye Disease
535124|NCT00559234|Genetic Eye Disease
535125|NCT00559221|AML
535126|NCT00559208|Children and Youth
535127|NCT00559208|Families
535128|NCT00559208|Differential Response
535129|NCT00559195|unspecified adult solid tumor, protocol specific
535130|NCT00559195|anemia
535131|NCT00559195|fatigue
535132|NCT00559169|epilepsy
535133|NCT00559169|seizures
535134|NCT00559169|menstrual cycle
535135|NCT00559156|recurrent squamous cell carcinoma of the hypopharynx
535136|NCT00559156|stage III squamous cell carcinoma of the hypopharynx
535137|NCT00559156|stage IV squamous cell carcinoma of the hypopharynx
535138|NCT00559156|stage III squamous cell carcinoma of the larynx
535139|NCT00559156|stage IV squamous cell carcinoma of the larynx
535140|NCT00559156|recurrent squamous cell carcinoma of the larynx
535141|NCT00559156|recurrent squamous cell carcinoma of the lip and oral cavity
535142|NCT00559156|stage III squamous cell carcinoma of the lip and oral cavity
535143|NCT00559156|stage IV squamous cell carcinoma of the lip and oral cavity
535144|NCT00559156|metastatic squamous neck cancer with occult primary squamous cell carcinoma
535261|NCT00558740|Lipid oxidation
535145|NCT00559156|recurrent metastatic squamous neck cancer with occult primary
535146|NCT00559156|recurrent squamous cell carcinoma of the nasopharynx
535147|NCT00559156|stage III squamous cell carcinoma of the nasopharynx
535148|NCT00559156|stage IV squamous cell carcinoma of the nasopharynx
535149|NCT00559156|recurrent squamous cell carcinoma of the oropharynx
535150|NCT00559156|stage III squamous cell carcinoma of the oropharynx
535151|NCT00559156|stage IV squamous cell carcinoma of the oropharynx
535152|NCT00559156|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
535153|NCT00559156|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
535154|NCT00559156|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
535155|NCT00559156|recurrent salivary gland cancer
535156|NCT00559156|salivary gland squamous cell carcinoma
535157|NCT00559156|stage III salivary gland cancer
535158|NCT00559156|stage IV salivary gland cancer
535159|NCT00559143|AV conduction disturbances
535160|NCT00559143|LV function
535161|NCT00559143|Biventricular Pacing
535162|NCT00559143|Conductance Catheters
535163|NCT00559130|Acute Respiratory Distress Syndrome
535164|NCT00559130|Acute Lung Injury
535165|NCT00559130|Sepsis
535166|NCT00559130|Hemoperfusion
535167|NCT00559104|stage III adult diffuse mixed cell lymphoma
535168|NCT00559104|stage IV adult diffuse mixed cell lymphoma
535169|NCT00559104|stage III adult immunoblastic large cell lymphoma
535170|NCT00559104|stage IV adult immunoblastic large cell lymphoma
535171|NCT00559104|stage IV mantle cell lymphoma
535172|NCT00559104|stage III mantle cell lymphoma
535173|NCT00559104|stage III adult diffuse large cell lymphoma
535174|NCT00559104|stage IV adult diffuse large cell lymphoma
535175|NCT00559104|stage III adult Burkitt lymphoma
535176|NCT00559104|stage IV adult Burkitt lymphoma
535177|NCT00559091|AML
535178|NCT00559091|Acute myelocytic leukemia
535179|NCT00559091|leukemia
535180|NCT00559091|relapsed
535181|NCT00559091|refractory
535182|NCT00559091|M4
535183|NCT00559091|M5
535184|NCT00559078|Adrenal Hyperplasia, Congenital
535185|NCT00559078|Psychosexual Development
535186|NCT00559078|Sexual Development
535187|NCT00559078|Intersex
535188|NCT00559078|Qualitative
535189|NCT00559078|CAH
535190|NCT00559078|Interview
535191|NCT00559078|Disorder of Sex Development
535192|NCT00559078|Telephone
535193|NCT00559078|Quality of Life
535194|NCT00559078|Mental Health
535195|NCT00559078|Counseling
535196|NCT00559065|Case-Cohort Study
535197|NCT00559065|Leukemia
535198|NCT00559065|Lymphoma
535199|NCT00559065|Benzene
535200|NCT00559065|Blood Disorders
535201|NCT00559065|Solvent Exposure
535202|NCT00559065|Cancer Risk
535203|NCT00559052|Enzymes
535204|NCT00559052|VIOKASE
535205|NCT00559052|Bioavailability
535206|NCT00559039|breast cancer
535207|NCT00559039|unspecified adult solid tumor, protocol specific
535208|NCT00559013|Staple line reinforcement
535209|NCT00559013|Staple line buttress
535210|NCT00559013|Anastomotic reinforcement
535211|NCT00559000|PTSD
535212|NCT00559000|Children
535213|NCT00559000|trauma-focused Treatment
535214|NCT00559000|KIDNET
535215|NCT00559000|Narrative Exposure Therapy for Children
535216|NCT00558987|Discipline
535217|NCT00558987|Parenting
535218|NCT00558987|Primary Care
535219|NCT00558987|Videos
535220|NCT00558961|CLL
535221|NCT00558961|chronic lymphocytic leukemia
535222|NCT00558961|leukemia
535223|NCT00558961|gleevec
535224|NCT00558961|chlorambucil
535225|NCT00558948|Bone Marrow Transplant
535226|NCT00558948|Bone Mineral Density
535227|NCT00558948|Survivors
535228|NCT00558948|Muscle Strength
535229|NCT00558922|Lung
535230|NCT00558922|Non small cell
535231|NCT00558922|antisense
535232|NCT00558922|oligonucleotide
535233|NCT00558922|paclitaxel
535234|NCT00558922|carboplatin
535235|NCT00558896|stage II multiple myeloma
535236|NCT00558896|stage III multiple myeloma
535237|NCT00558896|refractory multiple myeloma
535238|NCT00558870|Solid Tumors
535239|NCT00558870|Morphine
535240|NCT00558870|Methadone
535241|NCT00558870|Co-Opioid Analgesic
535242|NCT00558870|Pain
535243|NCT00558844|Cystic Fibrosis
535244|NCT00558844|Respiratory Infections
535245|NCT00558844|Pulmonary Cystic Fibrosis
535246|NCT00558844|CFTR
535247|NCT00558831|Acne
535248|NCT00558779|Coronary artery bypass
535249|NCT00558779|off pump coronary artery bypass grafting (OPCAB)
535250|NCT00558766|Disruptive Behavior Disorders
535251|NCT00558766|Behavior
535252|NCT00558766|Gambling
535253|NCT00558766|Dopaminergic Mechanisms
535254|NCT00558766|Dopamine
535255|NCT00558766|Parkinson Disease
535256|NCT00558766|PD
535257|NCT00558740|Dietary protein
535258|NCT00558740|Fructose
535259|NCT00558740|VLDL-triglycerides
535260|NCT00558740|Hepatic de novo lipogenesis
535262|NCT00558727|Advanced Solid Tumors
535263|NCT00558727|Solid Tumors
535264|NCT00558727|Tumor
535265|NCT00558727|Non-Hodgkin's Lymphoma
535266|NCT00558727|Chemotherapy
535267|NCT00558727|Benzoquinone
535268|NCT00558701|burns
535269|NCT00558701|donor site
535270|NCT00558701|healing
535271|NCT00558701|microcurrent
535272|NCT00558675|Non-Hodgkins Lymphoma
535273|NCT00558675|Hodgkins Lymphoma
535274|NCT00558675|Acute Lymphoblastic Leukemia
535275|NCT00558675|Chronic Myeloid Leukemia
535276|NCT00558675|Chronic Lymphocytic Leukemia
535277|NCT00558675|Multiple Myeloma
535278|NCT00558675|Immunotherapy
535279|NCT00558675|Allogeneic Cell Therapy
535280|NCT00558662|compression therapy
535281|NCT00558662|venous leg ulcer
535282|NCT00558662|sub bandage pressure
535283|NCT00558636|NSCLC
535284|NCT00558623|lead, blood
535285|NCT00558623|pregnancy
535286|NCT00558623|calcium
535287|NCT00558623|randomized trial
535288|NCT00558623|dietary supplementation
535289|NCT00558623|bone resorption
535290|NCT00558597|Proteomics
535291|NCT00558597|Lung Transplantation
535292|NCT00558584|dilated cardiomyopathy
535293|NCT00558584|immunoadsorption
535294|NCT00558584|immunoglobulin G
535295|NCT00558558|Solid Tumors
535296|NCT00558558|Cancer-Associated Anorexia
535297|NCT00558558|Weight Loss
535298|NCT00558558|Haelan
535299|NCT00558558|Fermented Soy Product
535300|NCT00558558|Nutrition
535301|NCT00558558|Cachexia
535302|NCT00558545|Breast
535303|NCT00558545|paclitaxel
535304|NCT00558545|antisense
535305|NCT00558545|oligonucleotide
535306|NCT00558532|Morbid obesity
535307|NCT00558532|Omega-3 fatty acid levels
535308|NCT00558519|B-cell adult acute lymphoblastic leukemia
535309|NCT00558519|T-cell adult acute lymphoblastic leukemia
535310|NCT00558519|untreated adult acute lymphoblastic leukemia
535311|NCT00558506|Ankylosing spondylitis
535312|NCT00558506|activity
535313|NCT00558506|treatment
535314|NCT00558506|clinical trial
535315|NCT00558454|Iron supplements
535316|NCT00558454|Infant
535317|NCT00558454|Low birth weight
535318|NCT00558454|Prevention of iron deficiency and its physiological consequences
535319|NCT00558454|Safety
535320|NCT00558376|Colonoscopy
535321|NCT00558363|Prostate Cancer
535322|NCT00558363|AVODART
535323|NCT00558363|PSA
535324|NCT00558363|dutasteride
535325|NCT00558363|PSADT
535326|NCT00558363|Prostate specific antigen
535327|NCT00558363|radical therapy
535328|NCT00558363|doubling time
535329|NCT00558350|lobectomy
535330|NCT00558350|inflammatory reaction
535331|NCT00558350|intrapulmonary
535332|NCT00558350|intrapleural
535333|NCT00558337|Treatment of Parkinson's Disease
535334|NCT00558324|LASIK
535335|NCT00558324|Confocal microscopy
535336|NCT00558324|Flap
535337|NCT00558311|Aneurysmal
535338|NCT00558311|Subarachnoid
535339|NCT00558311|Hemorrhage
535340|NCT00558311|vasospasm
535341|NCT00558311|clazosentan
535342|NCT00558311|PIVLAZ
535343|NCT00558311|Actelion
535344|NCT00558311|surgical clipping
535345|NCT00558298|schizophrenia
535346|NCT00558298|schizoaffective disorder
535347|NCT00558298|risperidone
535348|NCT00558298|intramuscular injection
535349|NCT00558298|long-acting injectable
535350|NCT00558285|COPD
535351|NCT00558285|Chronic Obstructive Pulmonary Disease
535352|NCT00558285|Indacaterol
535353|NCT00558285|QVA149
535354|NCT00558272|breast cancer
535355|NCT00558272|prostate cancer
535356|NCT00558272|metastatic bone disease
535357|NCT00558272|Subjects with breast cancer or prostate cancer with metastatic bone disease
535358|NCT00558246|Breast Lift
535359|NCT00558246|Breast Reduction
535360|NCT00558246|Breast Reconstruction
535361|NCT00558246|Plastic Surgery
535362|NCT00558246|Skin Closure
535363|NCT00558246|Wound Healing
535364|NCT00558246|Dermabond
535365|NCT00558233|Colorectal cancer
535366|NCT00558233|Screening
535367|NCT00558233|Health literacy
535368|NCT00558233|Patient education
535369|NCT00558233|Computer assisted instruction
535370|NCT00558220|Lymphoma, B-cell
535371|NCT00558220|Immunotherapy, passive
535372|NCT00558220|Remission induction
535373|NCT00558220|Autologous transplantation
535374|NCT00558207|Pancreatic cancer
535375|NCT00558207|pancreas cancer
535376|NCT00558207|Locally advanced or metastatic pancreatic adenocarcioma
535377|NCT00558194|Weight loss
535378|NCT00558181|B CLL
535379|NCT00558181|Chronic B Lymphocytic Leukemia
535380|NCT00558181|Methylprednisolone
535381|NCT00558181|Rituximab
535382|NCT00558168|Anastrazole
535383|NCT00558168|safety
535384|NCT00558168|early breast cancer
535385|NCT00558155|immunonutrition
535386|NCT00558155|enteral nutrition
535387|NCT00558155|parenteral nutrition
535388|NCT00558155|surgery
535389|NCT00558142|contrast nephropathy
535390|NCT00558142|radiocontrast-induced nephropathy
535391|NCT00558142|chronic kidney disease
535392|NCT00558142|acetylcysteine
535393|NCT00558142|clinical study
535394|NCT00558129|Lumbar Spinal Stenosis
535395|NCT00558129|X-STOP® IPD
535396|NCT00558129|Interspinous process decompression
535397|NCT00558129|Neurogenic Intermittent Claudication
535398|NCT00558116|Carpal Tunnel Syndrome
535399|NCT00558116|Dynamic Splinting
535400|NCT00558116|Nerve Conduction Studies
535401|NCT00558116|Splinting
535402|NCT00558116|Levine Katz Survey
535403|NCT00558103|GW572016
535404|NCT00558103|Breast Cancer
535405|NCT00558103|RECIST
535406|NCT00558103|Inflammatory Breast Cancer
535407|NCT00558103|Pazopanib
535408|NCT00558103|ErbB2
535409|NCT00558103|Cutaneous Disease
535410|NCT00558103|Tykerb
535411|NCT00558103|Inflammatory
535412|NCT00558103|Skin
535413|NCT00558103|Her2
535414|NCT00558103|Lapatinib
535415|NCT00558103|GW786034
535416|NCT00558090|pain
535417|NCT00558090|Intensive Care Unit
535418|NCT00558090|morphine
535419|NCT00558090|pKpD
535420|NCT00558090|numerical rating scale
535421|NCT00558090|critically ill patients
535422|NCT00558077|Anovulation
535423|NCT00558077|Clomiphene citrate
535424|NCT00558077|Fertility
535425|NCT00558077|Metformin
535426|NCT00558077|Ovulation induction
535427|NCT00558077|PCOS
535428|NCT00558077|Sterility
535429|NCT00558077|Treatment
535430|NCT00558077|Clomiphene citrate-resistance
535431|NCT00558051|Colorectal Cancer
535432|NCT00558051|Colorectal Carcinoma
535433|NCT00558051|Colorectal Tumors
535434|NCT00558051|Neoplasms, Colorectal
535435|NCT00558038|Hepatic
535436|NCT00558038|Encephalopathy
535437|NCT00558038|Liver
535438|NCT00558038|Liver Disease
535439|NCT00558038|Liver Failure
535440|NCT00558038|Lactulose
535441|NCT00558038|AST-120
535442|NCT00558012|Osteoporosis
535443|NCT00558012|Bone loss
535444|NCT00558012|Frail Geriatric Women
535445|NCT00558012|Nursing Home Patients
535446|NCT00558012|Fragility Fractures
535447|NCT00557999|Cardiology
535448|NCT00557999|Mechanical ventilation
535449|NCT00557999|Intensive care
535450|NCT00557986|1-Metastatic breast cancer
535451|NCT00557986|2-Surgery
535452|NCT00557986|3-Survival
535453|NCT00557947|Abdominoplasty
535454|NCT00557947|Body Lift
535455|NCT00557947|Plastic Surgery
535456|NCT00557947|Skin Closure
535457|NCT00557947|Wound Healing
535458|NCT00557947|Dermabond
535459|NCT00557934|tetralogy of Fallot
535460|NCT00557934|right ventricular dysfunction
535461|NCT00557934|pulmonary insufficiency
535462|NCT00557934|pulmonary valve replacement
535463|NCT00557934|pressure-volume loops
535464|NCT00557934|long-term follow-up in tetralogy of Fallot
535465|NCT00557921|ACS
535466|NCT00557921|CAD
535467|NCT00557921|MI
535468|NCT00557921|PCI
535469|NCT00557921|PTCA
535470|NCT00557921|NSTEMI
535471|NCT00557921|STEMI
535472|NCT00557921|acute coronary syndrome
535473|NCT00557921|cerebrovascular disorders
535474|NCT00557921|coronary artery stent placement
535475|NCT00557921|coronary thrombosis
535476|NCT00557921|myocardial infarction
535477|NCT00557921|myocardial ischemia
535478|NCT00557921|percutaneous coronary intervention
535479|NCT00557921|percutaneous transluminal coronary angioplasty
535480|NCT00557921|peripheral vascular diseases
535481|NCT00557921|duodenal obstruction
535482|NCT00557921|duodenal ulcer
535483|NCT00557921|dyspepsia
535484|NCT00557921|esophagitis, peptic
535485|NCT00557921|gastric outlet obstruction
535486|NCT00557921|gastroduodenal ulcer
535487|NCT00557921|gastroesophageal reflux disease
535488|NCT00557921|gastrointestinal hemorrhage
535489|NCT00557921|peptic ulcer
535490|NCT00557921|peptic ulcer perforation
535491|NCT00557908|Von Willebrand Disease
535492|NCT00557908|VWD
535493|NCT00557908|prophylaxis
535494|NCT00557895|Asthma
535495|NCT00557895|Hypersensitivity
535496|NCT00557895|Peanut Allergy
535497|NCT00557895|Eosinophilic Esophagitis
535498|NCT00557895|Eosinophilic Gastroenteritis
535499|NCT00557882|prolapse
535500|NCT00557882|uterus
535501|NCT00557882|mesh
535502|NCT00557882|bladder
535503|NCT00557856|Solid Tumors Transforming Growth Factor Beta Activin Receptor-like Kinase 1
535504|NCT00557843|Bupivacaine
535505|NCT00557843|Colon
535506|NCT00557843|Surgery
535507|NCT00557843|Oxygenation
535508|NCT00557830|Renal Cell Carcinoma
535509|NCT00557830|Kidney Cancer
535510|NCT00557817|HCT
535511|NCT00557817|autologous
535512|NCT00557817|erythropoiesis
535513|NCT00557817|iron saccharate
535514|NCT00557817|erythropoietin
535515|NCT00557817|darbepoetin alpha
535516|NCT00557804|Congestive Heart Failure
535517|NCT00557791|AMD
535518|NCT00557791|ARMD
535519|NCT00557791|Exudative Macular Degeneration
535520|NCT00557791|Bevasiranib
535521|NCT00557791|siRNA
535522|NCT00557778|prevention
535523|NCT00557778|dyslipidemia
535524|NCT00557765|Tuberculosis
535525|NCT00557765|Latent tuberculosis infection
535526|NCT00557765|Interferon gamma release assay
535527|NCT00557765|Contact tracing
535528|NCT00557739|CRx-191
535529|NCT00557739|Plaque
535530|NCT00557739|Psoriasis
535531|NCT00557739|nortriptyline hydrochloride
535532|NCT00557739|mometasone furoate
535533|NCT00557739|psoriatic infiltrate
535534|NCT00557726|Inflammation
535535|NCT00557726|Infection
535536|NCT00557726|Fever
535537|NCT00557700|Mild to moderate asthma
535538|NCT00557687|IVF
535539|NCT00557687|ovarian reserve
535540|NCT00557687|poor response
535541|NCT00557661|Heart failure
535542|NCT00557661|CD-NP
535543|NCT00557648|Anxiety
535544|NCT00557648|Children
535545|NCT00557648|Cognitive-Behavioral Therapy
535546|NCT00557648|School-Based Interventions
535547|NCT00557635|pseudo-arthrosis, osseous matrix, cell therapy
535548|NCT00557622|PTSD (Posttraumatic Stress Disorder)
535549|NCT00557622|CAPS
535550|NCT00557622|fMRI
535551|NCT00557622|Paroxetine
535552|NCT00557609|Microphthalmia transcription (MiT) factor associated tumors
535553|NCT00557609|Alveolar soft part sarcoma (ASPS)
535554|NCT00557609|Clear cell sarcoma (CCS)
535555|NCT00557609|Renal cell carcinoma (RCC)
535556|NCT00557596|Pancreatic
535557|NCT00557596|antisense
535558|NCT00557596|oligonucleotide
535559|NCT00557596|gemcitabine
535560|NCT00557583|VBY-376 Hepatitis C pharmacokinetics safety
535561|NCT00557570|Antiretroviral
535562|NCT00557570|Opportunistic Infection
535563|NCT00557570|treatment experienced
535564|NCT00557570|treatment naive
535565|NCT00557557|Colorectal
535566|NCT00557557|liver
535567|NCT00557557|cancer
535568|NCT00557557|metastases
535569|NCT00557544|migraine
535570|NCT00557544|metoclopramide
535571|NCT00557544|ketoprofen
535572|NCT00557544|child
535573|NCT00557492|pancreas
535574|NCT00557492|pancreatic
535575|NCT00557492|cancer
535576|NCT00557492|resectable
535577|NCT00557466|QMF
535578|NCT00557466|indacaterol
535579|NCT00557466|TWISTHALER® device
535580|NCT00557440|Asthma
535581|NCT00557440|QMF
535582|NCT00557440|Indacaterol
535583|NCT00557440|Mometasone
535584|NCT00557427|mild to moderate depression according to the DSM-IV scale
535585|NCT00557414|acute respiratory distress syndrome
535586|NCT00557414|soluble triggering receptor expressed on myeloid cells-1
535587|NCT00557414|prognosis
535588|NCT00557388|muscle loss
535589|NCT00557388|aging
535590|NCT00557388|protein
535591|NCT00557388|amino acids
535592|NCT00557388|exercise
535593|NCT00557388|protein synthesis
535594|NCT00557375|Brain Tumors
535595|NCT00557375|Survey
535596|NCT00557362|Keratitis
535597|NCT00557362|Eye Infection, Fungal
535598|NCT00557362|Fungal Eye Infection
535599|NCT00557362|Ocular Infection, Fungal
535600|NCT00557362|Fungal Keratitis
535601|NCT00557362|Mycotic Infections, Ocular
535602|NCT00557362|Voriconazole
535603|NCT00557362|Natamycin
535604|NCT00557349|gastric bypass surgery
535605|NCT00557349|anastomosis, Roux-en-Y
535606|NCT00557349|Complication, Postoperative
535607|NCT00557310|osteoporosis, teriparatide, postmenopausal, MRI, finite element analysis
535608|NCT00557297|asthma
535609|NCT00557297|SMART
535610|NCT00557297|inhaled
535611|NCT00557297|glucocorticosteroid
535612|NCT00557297|reliever
535613|NCT00557297|maintenance
535614|NCT00557297|single inhaler
535615|NCT00557284|Atopic Dermatitis (Eczema) associated with food allergies
535616|NCT00557245|HIV infection
535617|NCT00557245|HIV uninfected partners
535618|NCT00557245|Double Blind
535619|NCT00557245|Placebo
535620|NCT00557245|Seroconversion
535621|NCT00557245|TDF
535622|NCT00557245|FTC TDF
535623|NCT00557245|Safety
535624|NCT00557245|HIV Seronegativity
535625|NCT00557232|bevacizumab
535626|NCT00557232|rubeosis iridis
535627|NCT00557232|glaucoma
535628|NCT00557219|cardiac surgery
535629|NCT00557219|fenoldopam
535630|NCT00557219|ketanserin
535631|NCT00557219|renal replacement therapy
535632|NCT00557206|Recurrent Disease
535633|NCT00557206|Metastatic Disease
535634|NCT00557206|Squamous Cell Carcinoma
535635|NCT00557206|Multicenter
535636|NCT00557206|Phase II
535637|NCT00557180|Steroid Resistance
535638|NCT00557180|Inflammation
535639|NCT00557154|Pediatrics
535640|NCT00557154|Venous access
535641|NCT00557154|Emergency
535642|NCT00557141|Single arm observational retrospective and prospective study
535643|NCT00557128|COREG CR,
535644|NCT00557128|lisinopril,
535645|NCT00557128|hypertension,
535646|NCT00557128|dose proportionality,
535647|NCT00557128|fixed dose combination (FDC)
535648|NCT00557115|Quality of life
535649|NCT00557115|Quadriceps
535650|NCT00557115|Muscle
535651|NCT00557115|Exacerbation
535652|NCT00557102|liver metastases
535653|NCT00557102|lung metastases
535654|NCT00557102|recurrent rectal cancer
535655|NCT00557102|stage IV rectal cancer
535656|NCT00557102|adenocarcinoma of the rectum
535657|NCT00557102|adenocarcinoma of the colon
535658|NCT00557102|recurrent colon cancer
535659|NCT00557102|stage IV colon cancer
535660|NCT00557089|Pediatrics
535661|NCT00557089|Cystic Fibrosis
535662|NCT00557089|Lung Clearance Index
535663|NCT00557089|rhDNAse
535664|NCT00557076|Randomized Clinical Trial
535665|NCT00557076|Auditory Stimulation
535666|NCT00557050|Hamstring
535667|NCT00557050|Muscle
535668|NCT00557050|Injury
535669|NCT00557050|Prevention
535670|NCT00557050|Muscles
535671|NCT00557037|Castrate and Non-Castrate Prostate Cancer
535672|NCT00557024|hepatocellular carcinoma
535673|NCT00557024|liver cancer
535674|NCT00557024|radiofrequency ablation
535675|NCT00557024|radiotherapy
535676|NCT00557024|adjuvant therapy
535677|NCT00556998|pharmacokinetics and safety data of voriconazole in immunocompromised adolescents
535678|NCT00556959|ADHD
535679|NCT00556959|Clonidine
535680|NCT00556959|Attention Deficit
535681|NCT00556959|Hyperactivity
535682|NCT00556959|CLONICEL
535683|NCT00556959|Addrenex
535684|NCT00556946|Vascular Malformation
535685|NCT00556933|Induction
535686|NCT00556933|rATG
535687|NCT00556933|Calcineurin-inhibitor withdrawal
535688|NCT00556920|Coreg CR
535689|NCT00556907|DCIS
535690|NCT00556907|To evaluate Preoperative mammagraphy and MRI to select candiates with DCIS for IORT
535691|NCT00556868|High school students
535692|NCT00556868|Boarding school
535693|NCT00556868|Breakfast
535694|NCT00556868|Fasting
535695|NCT00556868|Memory
535696|NCT00556868|Attention
535697|NCT00556868|Mood
535698|NCT00556855|chronic hand dermatitis
535699|NCT00556855|research study
535700|NCT00556855|E-do
535701|NCT00556855|HK-03
535702|NCT00556842|Hemi-Arthroplasty
535703|NCT00556842|Total Hip Arthroplasty
535704|NCT00556816|COPD
535705|NCT00556816|outpatient on demand clinic
535706|NCT00556803|hepatocellular carcinoma
535707|NCT00556803|liver cancer
535708|NCT00556803|radiofrequency ablation
535709|NCT00556803|transcatheter arterial chemoembolization
535710|NCT00556803|adjuvant therapy
535711|NCT00556777|stage I breast cancer
535712|NCT00556764|ANAM
535713|NCT00556764|Parkinson's
535714|NCT00556751|Electrocardiogram
535715|NCT00556751|Electrocardiography
535716|NCT00556751|Cardiovascular Risk Factors
535717|NCT00556751|Cholesterol
535718|NCT00556751|Blood Pressure
535719|NCT00556751|Diabetes
535720|NCT00556738|HFPV
535721|NCT00556738|neonatal respiratory distress
535722|NCT00556699|NHL
535723|NCT00556699|Rituxan
535724|NCT00556699|anti-CD40
535725|NCT00556673|Asthma, QMF149, fixed combination of indacaterol and mometasone furoate
535726|NCT00556660|Alzheimer
535727|NCT00556660|SPECT
535728|NCT00556647|fast-track diagnosis
535729|NCT00556647|PET-CT
535730|NCT00556647|endoscopic techniques
535731|NCT00556647|lung cancer
535732|NCT00556634|HIV
535733|NCT00556634|efavirenz
535734|NCT00556634|central nervous system
535735|NCT00556634|adverse effects
535736|NCT00556621|stage II bladder cancer
535737|NCT00556621|stage III bladder cancer
535738|NCT00556621|transitional cell carcinoma of the bladder
535739|NCT00556595|atrial fibrillation
535740|NCT00556595|paroxysmal
535741|NCT00556595|symptomatic
535742|NCT00556595|drug-refractory
535743|NCT00556569|Physical activity
535744|NCT00556569|Obesity
535745|NCT00556543|Rib Fracture
535746|NCT00556543|Rib Fracture Repair
535747|NCT00556543|Rib Fracture ORIF
535748|NCT00556543|Flail Chest
535749|NCT00556543|Implant
535750|NCT00556543|Prosthesis
535751|NCT00556543|Rib fracture non-union
535752|NCT00556543|Chest wall deformity
535753|NCT00556530|Congenital Heart Defects
535754|NCT00556530|Single Nucleotide Polymorphisms
535755|NCT00556530|Copy Number Variations
535756|NCT00556530|Whole Genome Association Study
535757|NCT00556517|Hamstring
535758|NCT00556517|Strain
535759|NCT00556517|Rehabilitation
535760|NCT00556517|muscles
535761|NCT00556504|add-on treatment
535762|NCT00556504|botanical drug
535763|NCT00556504|HCV genotype 1
535764|NCT00556504|TCM-700C
535765|NCT00556504|genotype I
535766|NCT00556491|renal
535767|NCT00556491|kidney
535768|NCT00556491|injury
535769|NCT00556491|acute
535770|NCT00556491|bypass
535771|NCT00556491|cardiac
535772|NCT00556491|minocycline
535773|NCT00556491|prevention
535774|NCT00556491|Acute Kidney Failure
535775|NCT00556478|Premature Ejaculation
535776|NCT00556478|Lidocaine
535777|NCT00556478|Prilocaine
535778|NCT00556478|EMLA® cream
535779|NCT00556478|topical anesthetics
535780|NCT00556465|diabetic nephropathy
535781|NCT00556465|proteinuria
535782|NCT00556465|antioxidant
535783|NCT00556439|Vasculitis
535784|NCT00556439|Arteritis
535785|NCT00556439|Takayasu's
535786|NCT00556439|Temporal Arteritis
535787|NCT00556439|Abatacept
535788|NCT00556426|Venous Thromboembolic Disease
535789|NCT00556426|IVC Filter
535790|NCT00556426|Pulmonary Embolism
535791|NCT00556413|stage IV colon cancer
535792|NCT00556413|stage IV rectal cancer
535793|NCT00556413|recurrent colon cancer
535794|NCT00556413|recurrent rectal cancer
535795|NCT00556400|Uterine Bleeding
535796|NCT00556400|Thrombocytopenia
535797|NCT00556400|Aplastic Anemia
535798|NCT00556400|Oral Contraceptive Pills
535799|NCT00556400|Menorrhagia
535800|NCT00556387|traumatic brain injury
535801|NCT00556374|confirmed adenocarcinoma
535802|NCT00556374|non-metastatic breast cancer
535803|NCT00556374|estrogen receptor positive
535804|NCT00556374|progesterone receptor positive
535805|NCT00556374|non-steroidal aromatase
535806|NCT00556374|aromatase inhibitor therapy
535807|NCT00556374|postmenopausal woman
535808|NCT00556374|adjuvant chemotherapy
535809|NCT00556374|neoadjuvant chemotherapy
535810|NCT00556348|bevacizumab
535811|NCT00556348|AMD
535812|NCT00556348|Complications
535813|NCT00556348|Visual acuity
535814|NCT00556348|OCt
535815|NCT00556348|Age Macular Degeneration
535816|NCT00556335|manual aspiration
535817|NCT00556335|conventional
535818|NCT00556335|length of stay
535819|NCT00556283|outlet obstruction
535820|NCT00556283|rectocele
535821|NCT00556270|pain
535822|NCT00556270|fentanyl
535823|NCT00556270|transdermal patch
535824|NCT00556257|Immunosuppression, JAK3 inhibitor, kidney transplantation
535825|NCT00556231|NIRS
535826|NCT00556231|cardiac output
535827|NCT00556231|anaerobic threshold
535828|NCT00556231|exercise stress
535829|NCT00556231|congenital heart defect
535830|NCT00556218|Breast Cancer
535831|NCT00556218|Tibetan Meditation
535832|NCT00556218|Quality of Life
535833|NCT00556218|Cognitive Function
535834|NCT00556218|QOL
535835|NCT00556205|mRCC
535836|NCT00556205|sunitinib
535837|NCT00556205|bevacizumab
535838|NCT00556192|SLE
535839|NCT00556192|Rituximab
535840|NCT00556192|Methylprednisolone
535841|NCT00556192|Cyclophosphamide
535842|NCT00556166|Enterra therapy
535843|NCT00556166|Gastric Simulation System
535844|NCT00556153|brain tumors, children
535845|NCT00556127|Large B-cell Lymphoma
535846|NCT00556127|Rituximab
535847|NCT00556127|ASCT
535848|NCT00556114|eye exam
535849|NCT00556114|Retina
535850|NCT00556101|Magnetic resonance
535851|NCT00556101|whole body
535852|NCT00556101|angiography
535853|NCT00556101|questionnaire
535854|NCT00556088|LBH589
535855|NCT00556088|Phase I
535856|NCT00556088|Solid Tumors
535857|NCT00556088|Paclitaxel
535858|NCT00556088|Carboplatin
535859|NCT00556088|Bevacizumab
535860|NCT00556088|Dose escalation
535861|NCT00556075|Endometriosis
535862|NCT00556075|Pelvic pain
535863|NCT00556075|Oral progesterone blocker
535864|NCT00556049|mRCC
535865|NCT00556049|sunitinib
535866|NCT00556049|gemcitabine
535867|NCT00556036|healthy
535868|NCT00556036|overweight
535869|NCT00556036|obese
535870|NCT00556036|anorexia nervosa
535871|NCT00556036|weight
535872|NCT00556036|cortisol
535873|NCT00556036|hormone
535874|NCT00556036|bone density
535875|NCT00556036|bone
535876|NCT00556036|osteopenia
535877|NCT00556036|osteoporosis
535878|NCT00556036|amenorrhea
535879|NCT00556036|menses
535880|NCT00556036|irregular
535881|NCT00556036|stress
535882|NCT00556036|depression
535883|NCT00556036|exercise
535884|NCT00556036|diet
535885|NCT00556023|interventional
535886|NCT00556023|dose-finding
535887|NCT00555997|Major Depressive Disorder
535888|NCT00555997|Major Depression
535889|NCT00555997|Depression
535890|NCT00555997|Geodon
535891|NCT00555997|Ziprasidone
535892|NCT00555984|Intracranial tumors
535893|NCT00555984|Inflammatory markers
535894|NCT00555984|Craniotomy
535895|NCT00555984|Postoperative complications
535896|NCT00555958|Obesity
535897|NCT00555958|Bariatric surgery
535898|NCT00555958|Excess weight loss
535899|NCT00555958|Vagus nerve
535900|NCT00555958|Vagal blocking
535901|NCT00555958|VBLOC(TM) therapy
535902|NCT00555945|Intertrochanteric fracture
535903|NCT00555945|Gamma3 intramedullary nail
535904|NCT00555945|Sliding hip screw
535905|NCT00555932|Intracranial Thrombosis
535906|NCT00555932|Cerebral Sinovenous Thrombosis
535907|NCT00555932|Pediatrics
535908|NCT00555932|Cranial Ultrasound
535909|NCT00555919|Metastatic breast cancer stage IV
535910|NCT00555919|Metastatic breast cancer
535911|NCT00555919|mBC
535912|NCT00555919|Stage IV breast cancer
535913|NCT00555919|Hormone receptor positive breast cancer
535914|NCT00555893|randomized
535915|NCT00555893|blinded
535916|NCT00555893|controlled
535917|NCT00555893|efficacy
535918|NCT00555867|hormone-receptor positive primary breast cancer
535919|NCT00555867|compliance
535920|NCT00555867|Postmenopausal women
535921|NCT00555854|Motivational interviewing,
535922|NCT00555854|Multidisciplinary
535923|NCT00555854|Life style changes
535924|NCT00555854|Prevention
535925|NCT00555854|Compliance
535926|NCT00555854|Self Care
535927|NCT00555854|Behaviour
535928|NCT00555841|breast cancer
535929|NCT00555828|Myocardial Infarction
535930|NCT00555828|Myocardial infarct
535931|NCT00555828|Infarction
535932|NCT00555802|Low Back Pain
535933|NCT00555802|Motor Control Exercise
535934|NCT00555802|General exercise
535935|NCT00555802|Ultrasonography, Multifidus
535936|NCT00555802|Transversus abdominis
535937|NCT00555802|Randomized Controlled trial.
535938|NCT00555789|kidney transplantation
535939|NCT00555789|rejection
535940|NCT00555789|AEB071
535941|NCT00555789|tacrolimus
535942|NCT00555789|mycophenolic acid
535943|NCT00555789|immunosuppression
535944|NCT00555776|tinnitus
535945|NCT00555776|gabapentin
535946|NCT00555763|Intraocular pressure
535947|NCT00555763|Goldmann tonometry
535948|NCT00555763|applanation tonometry
535949|NCT00555763|Tonometry, Ocular
535950|NCT00555750|sleep
535951|NCT00555750|metabolism
535952|NCT00555750|insulin
535953|NCT00555750|glucose
535954|NCT00555750|actigraphy
535955|NCT00555750|diary
535956|NCT00555750|volumetry
535957|NCT00555750|GABA
535958|NCT00555737|Celiac Disease
535959|NCT00555737|Capsule Endoscopy
535960|NCT00555737|small Bowel Disease
535961|NCT00555724|Relapsed
535962|NCT00555724|refractory
535963|NCT00555724|solid tumor
535964|NCT00555711|Brain tumor
535965|NCT00555698|DBS
535966|NCT00555698|Depression
535967|NCT00555685|Heart Failure
535968|NCT00555685|Renal failure
535969|NCT00555685|Hyponatremia
535970|NCT00555659|Degeneration
535971|NCT00555659|Spondylosis
535972|NCT00555659|Spondylolisthesis
535973|NCT00555659|Stenosis
535974|NCT00555633|Photoprotection
535975|NCT00555633|Sunscreen
535976|NCT00555633|After-sun-lotion
535977|NCT00555633|DNA repair enzymes
535978|NCT00555633|liposomes
535979|NCT00555633|skin cancer
535980|NCT00555633|Xeroderma pigmentosum
535981|NCT00555633|Basal cell nevus syndrome
535982|NCT00555607|asthma
535983|NCT00555607|COPD
535984|NCT00555607|severe
535985|NCT00555607|controlled
535986|NCT00555607|mild
535987|NCT00555607|biomarker
535988|NCT00555607|exacerbation
535989|NCT00555594|corneal neovascularization
535990|NCT00555594|Bevacizumab (Avastin)
535991|NCT00555594|Immunologic rejection
535992|NCT00555594|vascular endothelial growth factor
535993|NCT00555581|Systemic Sclerosis
535994|NCT00555568|mental health
535995|NCT00555568|group processes
535996|NCT00555555|Factor VIII deficiency
535997|NCT00555555|Von Willebrand disease
535998|NCT00555555|FVIII/VWF concentrate
535999|NCT00555555|Bleeding disorders
536000|NCT00555555|Blood disorders
536001|NCT00555542|B-cell
536002|NCT00555542|rituximab
536003|NCT00555542|Rheumatoid Arthritis
536004|NCT00555529|COPD
536005|NCT00555529|exhaled breath condensate
536006|NCT00555529|applanation tonometry
536007|NCT00555529|induced sputum
536008|NCT00555529|smokers
536009|NCT00555529|healthy control
536010|NCT00555516|Breast Cancer、 Chemotherapy、 Neutropenia、WBC
536011|NCT00555503|prospective study
536012|NCT00555503|registry
536013|NCT00555503|quality of life
536014|NCT00555503|mastectomy
536015|NCT00555503|reconstructive surgical procedures
536016|NCT00555503|BrCa1
536017|NCT00555503|BrCa2
536018|NCT00555503|breast cancer prevention
536019|NCT00555490|Soy
536020|NCT00555490|Diabetes
536021|NCT00555490|Nephropathy
536022|NCT00555477|premenopausal breast cancer with chemotherapy-induced ovarian failure
536023|NCT00555464|hemangioma, steroid, prednisolone, vincristine
536024|NCT00555451|phase I
536025|NCT00555451|safety
536026|NCT00555451|tolerance
536027|NCT00555451|insulin resistance
536028|NCT00555451|obese
536029|NCT00555451|pharmacokinetics
536030|NCT00555438|major orthopaedic surgery
536031|NCT00555438|venous thromboembolic events prevention
536032|NCT00555438|renal impairment
536033|NCT00555438|Arixtra
536034|NCT00555438|anti-Xa activity
536035|NCT00555425|Buprenorphine
536036|NCT00555425|Buprenorphine/naloxone
536037|NCT00555425|Counseling
536038|NCT00555425|Primary care
536039|NCT00555412|pharmacokinetic
536040|NCT00555412|multidose
536041|NCT00555412|Staccato Loxapine
536042|NCT00555399|Glioblastoma Multiforme
536043|NCT00555399|Anaplastic Glioma
536044|NCT00555399|Vorinostat
536045|NCT00555399|Suberoylanilide Hydroxamic Acid
536046|NCT00555399|SAHA
536047|NCT00555399|MSK-390
536048|NCT00555399|Zolinza
536049|NCT00555399|Isotretinoin
536050|NCT00555399|Accutane
536051|NCT00555399|13-cis-Retinoic Acid
536052|NCT00555399|Carboplatin
536053|NCT00555399|Paraplatin
536054|NCT00555399|CBT
536055|NCT00555399|Temozolomide
536056|NCT00555399|Temodar
536057|NCT00555386|Selenium
536058|NCT00555386|Soy
536059|NCT00555386|Breast Cancer Risk
536060|NCT00555373|Pediatric
536061|NCT00555373|Renal
536062|NCT00555373|Transplant
536063|NCT00555360|Health Information Technology
536064|NCT00555360|Patient Care Management
536065|NCT00555360|Self Care
536066|NCT00555360|Quality of Life
536067|NCT00555360|Family or non-Family Informal Caregivers
536068|NCT00555347|Sarcoidosis
536069|NCT00555347|Fatigue
536070|NCT00555334|hepatocellular carcinoma
536071|NCT00555334|liver cancer
536072|NCT00555334|radiofrequency ablation
536073|NCT00555334|lamivudine
536074|NCT00555308|urolithiasis
536075|NCT00555308|ultrasound
536076|NCT00555308|hydronephrosis
536077|NCT00555282|central venous catheter
536078|NCT00555282|cvc
536079|NCT00555282|coated catheter
536080|NCT00555282|bacteriaemia
536081|NCT00555282|bloodstream infection
536082|NCT00555269|Macular pucker
536083|NCT00555269|Macular hole
536084|NCT00555269|Membrane Blue
536085|NCT00555269|Infracyanine Green
536086|NCT00555269|Peripheral Visual Field
536087|NCT00555256|NSCLC
536088|NCT00555243|Laparoscopic Surgical Simulation
536089|NCT00555230|HMG-CoA reductase inhibitors
536090|NCT00555230|Crestor
536091|NCT00555230|Rosuvastatin
536092|NCT00555217|kidney disease
536093|NCT00555217|nephropathy
536094|NCT00555217|type 2 diabetes
536095|NCT00555217|hyperkalemia
536096|NCT00555217|acute kidney injury
536097|NCT00555204|mild to moderate Alzheimer's disease, memory, cognition, dementia
536098|NCT00555191|fructose
536099|NCT00555191|Irritable bowel syndrome
536100|NCT00555191|malabsorption
536101|NCT00555191|Glut5 transporter gene
536102|NCT00555178|Polymorphic light eruption
536103|NCT00555178|Regulatory T cells (Tregs)
536104|NCT00555178|Seasonal fluctuation
536105|NCT00555178|UV radiation
536106|NCT00555178|Phototherapy
536107|NCT00555165|Macular Degeneration
536108|NCT00555165|Visual Impairment
536109|NCT00555165|Quality of Life
536110|NCT00555165|Implantable Telescope
536111|NCT00555139|CRF-1 antagonists,
536112|NCT00555139|depression,
536113|NCT00555139|anxiety,
536114|NCT00555139|fMRI
536115|NCT00555126|Polytrauma
536116|NCT00555126|Hypothermia
536117|NCT00555126|Wound Infection
536118|NCT00555126|Blood Loss
536119|NCT00555126|Combined perioperative morbidity
536120|NCT00555113|pseudoxanthoma elasticum
536121|NCT00555113|Visual acuity
536122|NCT00555113|Choroidal neovascularization
536123|NCT00555113|angioid streaks
536124|NCT00555087|Erectile dysfunction
536125|NCT00555087|Hypogonadotrophic males
536126|NCT00555061|SID
536127|NCT00555061|impetigo
536128|NCT00555061|pharmacokinetics
536129|NCT00555061|Retapamulin ointment, 1%
536130|NCT00555061|Skin abnormalities
536131|NCT00555061|Dermatoses
536132|NCT00555061|pediatric
536133|NCT00555061|infection
536134|NCT00555061|SITL
536135|NCT00555048|graft versus host disease
536136|NCT00555048|adult acute megakaryoblastic leukemia (M7)
536137|NCT00555048|adult acute monoblastic leukemia (M5a)
536138|NCT00555048|adult acute monocytic leukemia (M5b)
536139|NCT00555048|adult acute myeloblastic leukemia with maturation (M2)
536140|NCT00555048|adult acute myeloblastic leukemia without maturation (M1)
536141|NCT00555048|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
536142|NCT00555048|adult acute myelomonocytic leukemia (M4)
536143|NCT00555048|adult acute promyelocytic leukemia (M3)
536144|NCT00555048|adult erythroleukemia (M6a)
536145|NCT00555048|adult pure erythroid leukemia (M6b)
536146|NCT00555048|childhood acute megakaryocytic leukemia (M7)
536260|NCT00554671|guideline adherence
536147|NCT00555048|childhood acute monoblastic leukemia (M5a)
536148|NCT00555048|childhood acute monocytic leukemia (M5b)
536149|NCT00555048|childhood acute myeloblastic leukemia with maturation (M2)
536150|NCT00555048|childhood acute myeloblastic leukemia without maturation (M1)
536151|NCT00555048|childhood acute myelomonocytic leukemia (M4)
536152|NCT00555048|childhood acute promyelocytic leukemia (M3)
536153|NCT00555048|accelerated phase chronic myelogenous leukemia
536154|NCT00555048|adult acute lymphoblastic leukemia in remission
536155|NCT00555048|adult acute myeloid leukemia in remission
536156|NCT00555048|adult acute myeloid leukemia with inv(16)(p13;q22)
536157|NCT00555048|adult acute myeloid leukemia with t(15;17)(q22;q12)
536158|NCT00555048|adult acute myeloid leukemia with t(16;16)(p13;q22)
536159|NCT00555048|adult acute myeloid leukemia with t(8;21)(q22;q22)
536160|NCT00555048|blastic phase chronic myelogenous leukemia
536161|NCT00555048|childhood acute lymphoblastic leukemia in remission
536162|NCT00555048|childhood acute myeloid leukemia in remission
536163|NCT00555048|childhood chronic myelogenous leukemia
536164|NCT00555048|chronic phase chronic myelogenous leukemia
536165|NCT00555048|recurrent adult acute lymphoblastic leukemia
536166|NCT00555048|recurrent adult acute myeloid leukemia
536167|NCT00555048|recurrent childhood acute lymphoblastic leukemia
536168|NCT00555048|recurrent childhood acute myeloid leukemia
536169|NCT00555048|relapsing chronic myelogenous leukemia
536170|NCT00555048|secondary acute myeloid leukemia
536171|NCT00555048|childhood myelodysplastic syndromes
536172|NCT00555048|de novo myelodysplastic syndromes
536173|NCT00555048|myelodysplastic/myeloproliferative diseases
536174|NCT00555048|secondary myelodysplastic syndromes
536175|NCT00555035|GSK1349572,
536176|NCT00555035|healthy volunteers
536177|NCT00555022|Muscarinic Receptor Antagonist,
536178|NCT00555022|Anticholinergic,
536179|NCT00555022|COPD,
536180|NCT00555022|FTIH,
536181|NCT00555022|Plethysmography
536182|NCT00555009|traumatic brain Injury, cognitive function
536183|NCT00554996|urinary tract infection
536184|NCT00554996|urinary catheter
536185|NCT00554996|Escherichia coli
536186|NCT00554996|biofilm
536187|NCT00554983|Recombinant birch pollen allergy
536188|NCT00554983|IgE-mediated allergic disease attributed to birch pollen
536189|NCT00554970|Adult Asthmatics
536190|NCT00554944|Fluid Management
536191|NCT00554944|surgery
536192|NCT00554944|Obesity
536193|NCT00554918|adenocarcinoma of the prostate
536194|NCT00554918|recurrent prostate cancer
536195|NCT00554918|stage IV prostate cancer
536196|NCT00554918|bone metastases
536197|NCT00554905|ablation
536198|NCT00554905|catheter
536199|NCT00554905|Carcinoma, Hepatocellular
536200|NCT00554905|therapy
536201|NCT00554905|Chemoembolization, Therapeutic
536202|NCT00554905|Humans
536203|NCT00554905|Liver Neoplasms
536204|NCT00554892|Rectal cancer
536205|NCT00554892|Sphincter preservation
536206|NCT00554892|Mechanical bowel preparation
536207|NCT00554892|Post operative morbidity
536208|NCT00554892|Anastomotic leakage
536209|NCT00554827|Relapsed or Refractory Cutaneous T-cell Lymphoma
536210|NCT00554827|Lymphoma
536211|NCT00554827|Cutaneous T-cell Lymphoma
536212|NCT00554827|T-cell Lymphoma
536213|NCT00554827|Mycosis fungoides
536214|NCT00554827|Sézary syndrome
536215|NCT00554827|Primary cutaneous anaplastic large cell
536216|NCT00554814|Iron deficiency
536217|NCT00554814|Ferritin
536218|NCT00554814|Encapsulated iron
536219|NCT00554814|Infant formula
536220|NCT00554801|Central Auditory Processing
536221|NCT00554801|Traumatic Brain Injury
536222|NCT00554801|Hearing Loss
536223|NCT00554775|tumors metastatic to brain
536224|NCT00554775|stage IV non-small cell lung cancer
536225|NCT00554775|recurrent non-small cell lung cancer
536226|NCT00554762|mechanical pain,
536227|NCT00554762|heat pain,
536228|NCT00554762|dose,
536229|NCT00554762|efficacy
536230|NCT00554762|dose response,
536231|NCT00554762|GW842166,
536232|NCT00554762|Single,
536233|NCT00554762|pharmacodynamics,
536234|NCT00554762|repeat dose,
536235|NCT00554749|Selective mutism
536236|NCT00554749|Children
536237|NCT00554749|Treatment
536238|NCT00554736|Pollen Allergy
536239|NCT00554736|Allergy
536240|NCT00554723|Stroke
536241|NCT00554723|Cerebral infarct
536242|NCT00554723|Recovery
536243|NCT00554723|Double blind
536244|NCT00554723|Randomized
536245|NCT00554723|Placebo
536246|NCT00554723|Traditional Chinese Medicine
536247|NCT00554723|Neuroaid
536248|NCT00554710|Crohn's disease
536249|NCT00554710|immunomodulators
536250|NCT00554710|biologicals
536251|NCT00554697|tissue oxygenation
536252|NCT00554697|perioperative
536253|NCT00554697|outcome
536254|NCT00554684|Outcome
536255|NCT00554684|Elderly
536256|NCT00554684|ICU
536257|NCT00554684|Quality of Life
536258|NCT00554671|Diabetes Mellitus
536259|NCT00554671|Clinical pharmacists
536261|NCT00554671|group medical visits
536262|NCT00554671|behavioral modification
536263|NCT00554671|pharmacotherapy
536264|NCT00554645|obesity
536265|NCT00554645|children
536266|NCT00554645|psychological intervention
536267|NCT00554632|Contraceptive
536268|NCT00554632|Venous thrombosis
536269|NCT00554632|Coagulation parameter
536270|NCT00554619|Pulmonary Arterial Hypertension
536271|NCT00554619|Ambrisentan
536272|NCT00554606|Rheumatoid Arthritis
536273|NCT00554606|Anit-interleukin-1 beta
536274|NCT00554606|ACZ885
536275|NCT00554580|continuous positive airway pressure
536276|NCT00554580|outcome measure
536277|NCT00554580|clinical trial
536278|NCT00554567|HIV/AIDS
536279|NCT00554567|Voluntary Counseling and Testing
536280|NCT00554567|Rural India
536281|NCT00554567|HIV Care
536282|NCT00554567|Health Services Research
536283|NCT00554528|Cervical
536284|NCT00554528|disc
536285|NCT00554528|prosthesis
536286|NCT00554528|adjacent
536287|NCT00554528|disease
536288|NCT00554528|randomized
536289|NCT00554528|prospective
536290|NCT00554528|study
536291|NCT00554515|Kidney
536292|NCT00554515|Renal Cell
536293|NCT00554515|Metastatic
536294|NCT00554515|interleukin-2
536295|NCT00554515|select
536296|NCT00554489|recurrent adult acute myeloid leukemia
536297|NCT00554489|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
536298|NCT00554489|adult acute myeloid leukemia with inv(16)(p13;q22)
536299|NCT00554489|adult acute myeloid leukemia with t(15;17)(q22;q12)
536300|NCT00554489|adult acute myeloid leukemia with t(16;16)(p13;q22)
536301|NCT00554489|adult acute myeloid leukemia with t(8;21)(q22;q22)
536302|NCT00554476|Lateral Epicondylitis
536303|NCT00554476|Treatment
536304|NCT00554476|Corticosteroid
536305|NCT00554476|Elbow Cast
536306|NCT00554476|Icing
536307|NCT00554476|NSAIDs
536308|NCT00554463|limited stage small cell lung cancer
536309|NCT00554437|Accidental Falls
536310|NCT00554437|RCT
536311|NCT00554437|Age 65 and older
536312|NCT00554437|noninstitualized populations
536313|NCT00554424|oocyte retrieval
536314|NCT00554424|pain relief
536315|NCT00554424|Local anaesthetic
536316|NCT00554411|Travatan Z
536317|NCT00554411|glaucoma
536318|NCT00554411|tear film break up time
536319|NCT00554398|Raltegravir
536320|NCT00554398|MK-0518
536321|NCT00554398|Treatment intensification
536322|NCT00554398|HIV-1 latency
536323|NCT00554398|HIV eradication
536324|NCT00554398|treatment experienced
536325|NCT00554372|Jennerex
536326|NCT00554372|HCC
536327|NCT00554372|unresectable primary hepatocellular carcinoma
536328|NCT00554372|hepatocellular carcinoma
536329|NCT00554372|liver cancer
536330|NCT00554372|Phase 2
536331|NCT00554372|oncolytic virus
536332|NCT00554372|Pexa-Vec
536333|NCT00554359|Acute Kidney Injury
536334|NCT00554359|Acute Renal Failure
536335|NCT00554346|COX-2; post-operative ; sports injury; surgical pain
536336|NCT00554320|vulvodynia
536337|NCT00554320|painful bladder syndrome
536338|NCT00554320|myofascial pain syndrome
536339|NCT00554320|pelvic floor tension myalgia
536340|NCT00554307|patent ductus arteriosus
536341|NCT00554307|indomethacin
536342|NCT00554307|neoprofen
536343|NCT00554307|blood flow
536344|NCT00554294|children
536345|NCT00554294|primary prevention
536346|NCT00554294|environmental change
536347|NCT00554294|behavioural change
536348|NCT00554294|school setting
536349|NCT00554294|changing of drinking habits
536350|NCT00554294|promotion of drinking tap water
536351|NCT00554281|Type 1 diabetes
536352|NCT00554281|Hypoglycemia
536353|NCT00554281|Glucose sensor
536354|NCT00554268|Advanced Cancers
536355|NCT00554268|Solid Tumors
536356|NCT00554268|PBI-05204
536357|NCT00554255|Pharmacodynamics
536358|NCT00554255|Japanese
536359|NCT00554255|safety
536360|NCT00554255|Pharmacokinetics
536361|NCT00554242|endothelium
536362|NCT00554242|antioxidants
536363|NCT00554242|flavonoids
536364|NCT00554229|Hormone Resistant Prostate Cancer
536365|NCT00554229|Endothelin A Receptor Antagonist
536366|NCT00554229|Endothelin A
536367|NCT00554229|Endothelin A antagonist
536368|NCT00554216|Obesity, morbid obesity
536369|NCT00554190|rhinosinusitis, ethmoid
536370|NCT00554177|sexual
536371|NCT00554177|combat
536372|NCT00554177|PTSD
536373|NCT00554177|Clinical trial
536374|NCT00554177|Trauma
536375|NCT00554177|PTSD treatment
536376|NCT00554177|PTSD medication
536377|NCT00554177|Post traumatic stress disorder
536378|NCT00554164|Aggressive non-Hodgkin's lymphoma
536379|NCT00554164|Positron emission tomography
536380|NCT00554164|Chemotherapy
536381|NCT00554138|rosuvastatin
536382|NCT00554138|dipyridamole
536383|NCT00554138|caffeine
536875|NCT00552045|genotype
536384|NCT00554125|Sirolimus; Orthotopic liver transplantation; HCC
536385|NCT00554112|Exercise Training
536386|NCT00554112|Glucose Intolerance
536387|NCT00554112|Human Aging
536388|NCT00554112|Insulin Secretion
536389|NCT00554073|Magnetic resonance
536390|NCT00554073|whole body
536391|NCT00554073|angiography
536392|NCT00554073|vasovist
536393|NCT00554073|gadofosveset
536394|NCT00554073|blood pool agent
536395|NCT00554073|3T
536396|NCT00554073|1.5T
536397|NCT00554073|Field strength
536398|NCT00554047|Dementia
536399|NCT00554047|Caregivers
536400|NCT00554047|Costs and cost analysis
536401|NCT00554047|Multicenter study
536402|NCT00554047|Randomized controlled trial
536403|NCT00554047|Quality Adjusted Life Years
536404|NCT00554047|Quality of life
536405|NCT00554047|Technology assessment, biomedical; Methods
536406|NCT00554034|gingivitis, localized treatment
536407|NCT00554021|Central venous catheter
536408|NCT00554021|nosocomial infection
536409|NCT00554008|Appendicitis
536410|NCT00554008|laparoscopy
536411|NCT00554008|randomized trial
536412|NCT00554008|children
536413|NCT00554008|pediatric
536414|NCT00553982|Replacement
536415|NCT00553982|Knee
536416|NCT00553982|Patella
536417|NCT00553982|Arthroplasty
536418|NCT00553969|cardiovascular disease prevention
536419|NCT00553943|lymphoma
536420|NCT00553943|cerebral lymphoma
536421|NCT00553943|central nervous system
536422|NCT00553943|cytarabine
536423|NCT00553943|rituximab
536424|NCT00553943|Diffuse large B-cell lymphomas, with cerebral or neuromeningeal involvement
536425|NCT00553930|HCV/HIV-coinfected patients
536426|NCT00553930|Peginterferon alfa-2a
536427|NCT00553917|Pregnancy
536428|NCT00553917|Depression
536429|NCT00553917|Antidepressants
536430|NCT00553852|Very Severe Obesity
536431|NCT00553852|Body Composition
536432|NCT00553852|GH deficiency
536433|NCT00553852|IGF-I
536434|NCT00553852|LASGB
536435|NCT00553852|GH therapy
536436|NCT00553839|anesthesia
536437|NCT00553839|children
536438|NCT00553839|ketamine
536439|NCT00553839|pharmacokinetics
536440|NCT00553813|Unresectable
536441|NCT00553813|Gemcitabine
536442|NCT00553813|Taxane
536443|NCT00553813|TPI 287
536444|NCT00553787|Obesity, Type 2 diabetes
536445|NCT00553774|CAD Patients on Optimal Treatment
536446|NCT00553761|Band atrophy
536447|NCT00553761|Pattern electroretinogram
536448|NCT00553761|Chiasmal compression
536449|NCT00553761|Neural loss
536450|NCT00553761|Electrophysiological tests
536451|NCT00553722|hypertension
536452|NCT00553722|dialysis
536453|NCT00553722|hyperaldosteronism
536454|NCT00553709|nausea
536455|NCT00553709|vomiting
536456|NCT00553709|retching
536457|NCT00553709|emesis
536458|NCT00553709|surgery
536459|NCT00553709|anesthesia
536460|NCT00553696|chemotherapy
536461|NCT00553696|combination
536462|NCT00553683|stage IV pancreatic cancer
536463|NCT00553683|adult primary hepatocellular carcinoma
536464|NCT00553683|advanced adult primary liver cancer
536465|NCT00553683|recurrent adult primary liver cancer
536466|NCT00553683|localized unresectable adult primary liver cancer
536467|NCT00553683|recurrent pancreatic cancer
536468|NCT00553683|recurrent colon cancer
536469|NCT00553683|recurrent breast cancer
536470|NCT00553683|recurrent gastric cancer
536471|NCT00553683|recurrent ovarian epithelial cancer
536472|NCT00553683|recurrent melanoma
536473|NCT00553683|stage IV breast cancer
536474|NCT00553683|stage IV gastric cancer
536475|NCT00553683|stage IV colon cancer
536476|NCT00553683|stage IV ovarian epithelial cancer
536477|NCT00553683|stage IV melanoma
536478|NCT00553683|liver metastases
536479|NCT00553670|coronary artery
536480|NCT00553670|bifurcation
536481|NCT00553670|stent
536482|NCT00553670|intravascular ultrasound
536483|NCT00553670|fractional flow reserve
536484|NCT00553657|Experimental Medicine
536485|NCT00553631|Enzyme Replacement Therapy
536486|NCT00553631|Gaucher disease
536487|NCT00553631|glucocerebrosidase
536488|NCT00553631|beta-glucocerebrosidase
536489|NCT00553631|Acid beta-glucocerebrosidase
536490|NCT00553631|glucosylceramidase
536491|NCT00553631|D-glucosyl-N-acylsphingosine glucohydrolase
536492|NCT00553631|gene activation
536493|NCT00553631|human
536494|NCT00553618|Interleukin 2
536495|NCT00553618|Proleukin
536496|NCT00553618|DTIC
536497|NCT00553618|Dacarbazine
536498|NCT00553618|metastatic melanoma
536499|NCT00553618|adjuvant
536500|NCT00553605|Renal Colic Pain Urinary Tract Colic
536501|NCT00553579|contrast sensitivity, retention time
536502|NCT00553566|stage 0 bladder cancer
536503|NCT00553566|stage I bladder cancer
536504|NCT00553566|transitional cell carcinoma of the bladder
536623|NCT00553085|children
536505|NCT00553553|Intrathecal morphine ITM intravenous morphine remifentanil hepatic resection
536506|NCT00553553|Adult
536507|NCT00553553|ASA I-III (stable)
536508|NCT00553553|Liver dysfunction requiring primary parenchymal resection
536509|NCT00553540|backache
536510|NCT00553540|low backpain
536511|NCT00553540|sciatica
536512|NCT00553514|Infertility
536513|NCT00553514|Oligo-anovulation
536514|NCT00553514|GONAL-f®
536515|NCT00553514|AS900672-Enriched
536516|NCT00553514|hyperglycosylated recombinant human follicle stimulating hormone (r-hFSH)
536517|NCT00553501|stage II grade 1 follicular lymphoma
536518|NCT00553501|stage II grade 2 follicular lymphoma
536519|NCT00553501|stage II grade 3 follicular lymphoma
536520|NCT00553501|stage III grade 1 follicular lymphoma
536521|NCT00553501|stage III grade 2 follicular lymphoma
536522|NCT00553501|stage III grade 3 follicular lymphoma
536523|NCT00553501|stage IV grade 1 follicular lymphoma
536524|NCT00553501|stage IV grade 2 follicular lymphoma
536525|NCT00553501|stage IV grade 3 follicular lymphoma
536526|NCT00553488|diabetes
536527|NCT00553488|insulin
536528|NCT00553488|subcutaneous
536529|NCT00553488|intra-dermal
536530|NCT00553488|blood glucose
536531|NCT00553462|stage IIIA non-small cell lung cancer
536532|NCT00553462|stage IIIB non-small cell lung cancer
536533|NCT00553462|adenocarcinoma of the lung
536534|NCT00553462|bronchoalveolar cell lung cancer
536535|NCT00553462|large cell lung cancer
536536|NCT00553462|squamous cell lung cancer
536537|NCT00553449|nocturnal heartburn
536538|NCT00553449|day-time heartburn
536539|NCT00553449|rabeprazole
536540|NCT00553449|GERD
536541|NCT00553436|colon
536542|NCT00553436|rectum
536543|NCT00553436|polyp
536544|NCT00553436|EMR
536545|NCT00553436|Established indication for a procedure greater than colonoscopy and colonic polypectomy
536546|NCT00553410|stage IA breast cancer
536547|NCT00553410|stage IB breast cancer
536548|NCT00553410|stage II breast cancer
536549|NCT00553410|stage IIIA breast cancer
536550|NCT00553397|Living donor lung transplant
536551|NCT00553397|End stage lung disease
536552|NCT00553384|smell
536553|NCT00553384|olfaction
536554|NCT00553384|androstadienone
536555|NCT00553384|women
536556|NCT00553384|pheromones
536557|NCT00553384|Healthy Volunteers
536558|NCT00553384|Physiological Effects of Androstadienone Exposure
536559|NCT00553371|stage II malignant testicular germ cell tumor
536560|NCT00553371|stage III malignant testicular germ cell tumor
536561|NCT00553358|Lapatinib
536562|NCT00553358|ErbB2+
536563|NCT00553358|Early Breast Cancer
536564|NCT00553358|Neoadjuvant
536565|NCT00553345|transitional cell carcinoma of the bladder
536566|NCT00553345|stage 0 bladder cancer
536567|NCT00553345|stage I bladder cancer
536568|NCT00553319|ADHD
536569|NCT00553319|Cocaine
536570|NCT00553319|Treatment
536571|NCT00553293|infertility
536572|NCT00553293|in vitro fertilization
536573|NCT00553293|LH supplementation
536574|NCT00553293|Benefits
536575|NCT00553241|TIA
536576|NCT00553241|prognosis
536577|NCT00553241|evaluation
536578|NCT00553241|management
536579|NCT00553228|maternal immunization
536580|NCT00553228|whooping cough
536581|NCT00553228|pertussis
536582|NCT00553215|transitional cell carcinoma of the bladder
536583|NCT00553215|stage 0 bladder cancer
536584|NCT00553215|stage I bladder cancer
536585|NCT00553215|stage II bladder cancer
536586|NCT00553202|recurrent childhood acute myeloid leukemia
536587|NCT00553202|childhood myelodysplastic syndromes
536588|NCT00553189|PARP Inhibitor
536589|NCT00553189|Advanced Cancer
536590|NCT00553189|Combination Therapy
536591|NCT00553189|Early Trial
536592|NCT00553189|DNA Damage Repair
536593|NCT00553189|Topotecan
536594|NCT00553189|Cancer
536595|NCT00553189|Solid Tumor
536596|NCT00553189|Lymphoma
536597|NCT00553176|Infliximab
536598|NCT00553176|Immune disorder
536599|NCT00553176|Remicade
536600|NCT00553176|Registry
536601|NCT00553176|Crohn's Disease
536602|NCT00553163|Hypnotherapy
536603|NCT00553163|Prevention of relapse
536604|NCT00553163|ulcerative colitis
536605|NCT00553150|adult gliosarcoma
536606|NCT00553150|adult giant cell glioblastoma
536607|NCT00553150|adult glioblastoma
536608|NCT00553150|adult anaplastic astrocytoma
536609|NCT00553150|adult diffuse astrocytoma
536610|NCT00553150|adult pilocytic astrocytoma
536611|NCT00553150|adult subependymal giant cell astrocytoma
536612|NCT00553137|oropharyngeal candidiasis
536613|NCT00553124|stage 0 bladder cancer
536614|NCT00553124|stage I bladder cancer
536615|NCT00553124|stage II bladder cancer
536616|NCT00553124|transitional cell carcinoma of the bladder
536617|NCT00553111|syphilis
536618|NCT00553111|video education
536619|NCT00553111|knowledge
536620|NCT00553111|black
536621|NCT00553111|hispanic
536622|NCT00553085|anxiety disorders
536624|NCT00553085|neurodevelopmental disorder
536625|NCT00553085|neurodevelopmental delay
536626|NCT00553085|temperament
536627|NCT00553072|Asphyxia
536628|NCT00553072|perinatal
536629|NCT00553072|magnesium sulphate
536630|NCT00553059|nausea and vomiting
536631|NCT00553059|unspecified adult solid tumor
536632|NCT00553059|Palonosetron
536633|NCT00553059|Dexamethasone
536634|NCT00553046|ethics
536635|NCT00553046|COPD
536636|NCT00553046|end of life
536637|NCT00553046|mechanical ventilation
536638|NCT00553046|CRF home ventilated patients
536639|NCT00553033|Patients must be candidable to liver resection
536640|NCT00553007|Periodontal disease
536641|NCT00553007|Metabolic Syndrome
536642|NCT00552994|Drug eluting stent
536643|NCT00552994|Diabetics
536644|NCT00552994|Intravascular ultrasound
536645|NCT00552994|Pathophysiologic (neointimal hyperplasia and peri-stent remodeling)
536646|NCT00552981|common cold
536647|NCT00552981|Finnish sauna
536648|NCT00552981|rct
536649|NCT00552968|trauma
536650|NCT00552968|pain
536651|NCT00552955|Lymphangioleiomyomatosis
536652|NCT00552955|Abdominal Lymphangioleiomyomas
536653|NCT00552955|Chyle
536654|NCT00552955|Ascites
536655|NCT00552955|Tuberous Sclerosis Complex
536656|NCT00552955|LAM
536657|NCT00552942|obesity
536658|NCT00552942|diabetes
536659|NCT00552942|cytokines
536660|NCT00552890|obesity
536661|NCT00552890|atkins
536662|NCT00552890|weight reduction
536663|NCT00552890|kidney function
536664|NCT00552877|PCI
536665|NCT00552877|Drug-eluting stent
536666|NCT00552851|acromegaly
536667|NCT00552851|heart failure
536668|NCT00552851|hypertrophy
536669|NCT00552851|cardiomegaly
536670|NCT00552838|Antimicrobial prescribing
536671|NCT00552838|Antimicrobial utilization
536672|NCT00552825|acute lymphoblastic leukemia
536673|NCT00552825|long-term lung function
536674|NCT00552812|Aortic Coarctation
536675|NCT00552812|Heart Defects, Congenital
536676|NCT00552812|Stents
536677|NCT00552812|Heart Catheterization
536678|NCT00552799|cellulitis
536679|NCT00552799|lymphoedema
536680|NCT00552799|penicillin
536681|NCT00552799|clinical trial
536682|NCT00552786|noise
536683|NCT00552786|hearing loss
536684|NCT00552786|temporary threshold shift
536685|NCT00552773|SINUSITIS
536686|NCT00552773|CYCLAMEN
536687|NCT00552747|fenofibrate
536688|NCT00552747|coronary heart disease
536689|NCT00552747|mixed hyperlipidemia
536690|NCT00552734|Type 1 diabetes
536691|NCT00552734|Improved glycemic control
536692|NCT00552734|Glucose excursions
536693|NCT00552734|Target range glucose levels
536694|NCT00552734|Insulin guidance software
536695|NCT00552734|Advisor
536696|NCT00552721|Motor control
536697|NCT00552721|Spasticity
536698|NCT00552708|COREG CR
536699|NCT00552695|intravenous catheter
536700|NCT00552695|emergency department
536701|NCT00552695|pain
536702|NCT00552682|HIV
536703|NCT00552682|fibromialgy
536704|NCT00552682|chronic fatigue syndrome
536705|NCT00552682|duloxetine
536706|NCT00552682|pain
536707|NCT00552682|treatment experienced
536708|NCT00552682|Fibromialgy in patients with HIV-1 infection
536709|NCT00552669|Drug Eluting Stents
536710|NCT00552669|Stents Bare Metal
536711|NCT00552669|Stent Thrombosis
536712|NCT00552669|Coronary revascularization
536713|NCT00552669|Survival
536714|NCT00552656|Angioplasty, Transluminal, Percutaneous Coronary
536715|NCT00552656|Drug-eluting stents
536716|NCT00552656|Treatment Outcome
536717|NCT00552643|Recalcitrant ulcers
536718|NCT00552643|Chronic wounds
536719|NCT00552643|Venous insufficiency wounds
536720|NCT00552643|Ulcers
536721|NCT00552643|Exposed bones
536722|NCT00552643|Exposed Tendons
536723|NCT00552643|Granulation tissue
536724|NCT00552643|Polyheal 1
536725|NCT00552643|Wound care
536726|NCT00552643|Wound healing
536727|NCT00552643|Diabetic wounds healing
536728|NCT00552643|Post trauma
536729|NCT00552643|Post surgery complication
536730|NCT00552643|Recalcitrant wounds including venous, post-operative and post-traumatic chronic wounds with different etiologies including wounds with exposed bone and tendon.
536731|NCT00552630|lead poisoning
536732|NCT00552630|chelation
536733|NCT00552604|multiple sclerosis
536734|NCT00552604|muscle stiffness
536735|NCT00552604|spasticity
536736|NCT00552604|pain
536737|NCT00552604|treatment
536738|NCT00552604|cannabinoids
536739|NCT00552591|family risk
536740|NCT00552591|behavior modification
536741|NCT00552591|lifestyle change
536742|NCT00552591|prevention of CHD
536743|NCT00552591|health care costs
536744|NCT00552578|drug dependence
536745|NCT00552578|substance abuse
536746|NCT00552578|substance use disorders
536747|NCT00552578|myofascial pain syndrome
536748|NCT00552578|neuralgia
536749|NCT00552578|back pain
536750|NCT00552565|IBS, IBS-D, R-verapamil, Arverpamil, Rezular
536751|NCT00552552|cancer-related fatigue
536752|NCT00552552|self-management
536753|NCT00552552|patient education
536754|NCT00552552|cancer survivors
536755|NCT00552552|chronic disease
536756|NCT00552539|syphilis
536757|NCT00552539|educational video
536758|NCT00552539|knowledge
536759|NCT00552539|black
536760|NCT00552539|Hispanic
536761|NCT00552526|Epilepsy
536762|NCT00552526|Children
536763|NCT00552526|Mental retardation
536764|NCT00552526|Ketogenic diet
536765|NCT00552526|Diet
536766|NCT00552513|timing
536767|NCT00552513|intervention
536768|NCT00552513|early
536769|NCT00552513|delayed
536770|NCT00552513|acute coronary syndromes
536771|NCT00552513|PCI
536772|NCT00552513|angiography
536773|NCT00552513|Non ST-segment elevation myocardial infarction
536774|NCT00552513|unstable angina
536775|NCT00552487|isolated ACTH deficiency
536776|NCT00552487|Hashimoto disease
536777|NCT00552487|Hashimoto thyroiditis
536778|NCT00552487|autoimmune thyroiditis
536779|NCT00552474|Parkinson disease
536780|NCT00552474|Movement disorders
536781|NCT00552474|Deep Brain Stimulation
536782|NCT00552474|Libra
536783|NCT00552474|l-dopa
536784|NCT00552474|levodopa
536785|NCT00552474|neuromodulation
536786|NCT00552474|neurostimulation
536787|NCT00552474|Electrical stimulation of the brain
536788|NCT00552474|STN
536789|NCT00552474|Subthalamic nucleus
536790|NCT00552461|Pulmonary alveolar proteinosis
536791|NCT00552461|Primary Pulmonary alveolar proteinosis
536792|NCT00552461|Rituximab
536793|NCT00552461|Idiopathic
536794|NCT00552461|Symptomatic
536795|NCT00552461|GM-CSF Antibody
536796|NCT00552448|Pediatric, asthma, pediatric ICU
536797|NCT00552422|gastroparesis
536798|NCT00552422|gastroesophageal reflux
536799|NCT00552409|Diabetes mellitus
536800|NCT00552409|Type 2 diabetes
536801|NCT00552409|Chronic kidney disease
536802|NCT00552409|Diabetic kidney disease
536803|NCT00552409|Microalbuminuria
536804|NCT00552409|Albuminuria
536805|NCT00552409|Vitamin D
536806|NCT00552409|Cholecalciferol
536807|NCT00552409|Kidney
536808|NCT00552409|Renal
536809|NCT00552409|Cardiovascular
536810|NCT00552409|Clinical trial
536811|NCT00552409|Placebo
536812|NCT00552396|multiple myeloma
536813|NCT00552396|Anti-KIR (1-7F9)
536814|NCT00552383|Preterm Infant
536815|NCT00552383|Behaviour
536816|NCT00552383|Developmental Care
536817|NCT00552383|NIDCAP
536818|NCT00552383|Family Centred Care
536819|NCT00552383|Neurodevelopmental Outcome, preterm infant
536820|NCT00552344|CDP 870
536821|NCT00552344|Certolizumab Pegol
536822|NCT00552344|CIMZIA
536823|NCT00552344|Crohn's Disease
536824|NCT00552344|Crohn Disease
536825|NCT00552344|CD Induction
536826|NCT00552344|Induction
536827|NCT00552344|Clinical response
536828|NCT00552344|Clinical remission
536829|NCT00552292|metabolic syndrome
536830|NCT00552292|hypertension
536831|NCT00552292|obesity
536832|NCT00552292|dyslipidemia
536833|NCT00552292|hyperglycemia
536834|NCT00552292|cardiovascular complications
536835|NCT00552279|HPV
536836|NCT00552279|cervical cancer
536837|NCT00552279|papillomavirus
536838|NCT00552279|Human papillomavirus (HPV) vaccine
536839|NCT00552266|Methylphenidate
536840|NCT00552266|Trichotillomania
536841|NCT00552266|Attention deficit
536842|NCT00552214|Nucleic acid test
536843|NCT00552214|HIV-1
536844|NCT00552214|hepatitis
536845|NCT00552214|HBV
536846|NCT00552214|HCV
536847|NCT00552214|TMA
536848|NCT00552214|HIV Seronegativity
536849|NCT00552201|kidney transplantation
536850|NCT00552201|Tacrolimus
536851|NCT00552201|P450 3A5 cytochrome
536852|NCT00552201|genotype
536853|NCT00552188|Atherosclerosis
536854|NCT00552084|Fish Oil
536855|NCT00552071|Acromegaly
536856|NCT00552071|Octreotide LAR
536857|NCT00552071|Ultrasound guidance
536858|NCT00552058|CDP 870
536859|NCT00552058|Certolizumab Pegol
536860|NCT00552058|CIMZIA ®
536861|NCT00552058|Crohn's disease
536862|NCT00552058|Induction
536863|NCT00552058|Clinical remission
536864|NCT00552058|Clinical response
536865|NCT00552045|epilepsy
536866|NCT00552045|localization-related epilepsy
536867|NCT00552045|idiopathic generalized epilepsy
536868|NCT00552045|infantile spasms
536869|NCT00552045|Lennox-Gastaut syndrome
536870|NCT00552045|polymicrogyria
536871|NCT00552045|periventricular heterotopias
536872|NCT00552045|malformations of cortical development
536873|NCT00552045|phenome
536874|NCT00552045|genome
536876|NCT00552045|phenotype
536877|NCT00552006|PTSD
536878|NCT00552006|Treatment
536879|NCT00552006|Randomized Controlled Clinical Trial
536880|NCT00552006|Combat
536881|NCT00552006|Child Soldiers
536882|NCT00552006|Dissemination
536883|NCT00552006|Narrative Exposure Therapy
536884|NCT00552006|Africa
536885|NCT00551993|laparoscopy
536886|NCT00551993|robot
536887|NCT00551993|vaginal prolapse
536888|NCT00551993|sacrocolpopexy
536889|NCT00551993|sacral colpopexy
536890|NCT00551980|Headache
536891|NCT00551980|Cervical Pain
536892|NCT00551980|Cognitive treatment
536893|NCT00551980|Relaxation
536894|NCT00551980|Exercise
536895|NCT00551967|clinical outcomes
536896|NCT00551967|radiographic outcomes
536897|NCT00551967|total hip arthroplasty
536898|NCT00551967|survivorship
536899|NCT00551928|Multiple Myeloma
536900|NCT00551928|Lenalidomide
536901|NCT00551928|High dose Melphalan
536902|NCT00551928|Mobilization
536903|NCT00551928|CD34
536904|NCT00551902|Glaucoma
536905|NCT00551902|trabeculectomy
536906|NCT00551902|anterior chamber maintainer
536907|NCT00551902|anterior chamber infusion
536908|NCT00551889|unspecified adult solid tumor, protocol specific
536909|NCT00551863|alcohol, drugs, aggression, substance use disorder treatment
536910|NCT00551850|epidermal growth factor inhibitor
536911|NCT00551850|solid tumors
536912|NCT00551850|advanced cancer
536913|NCT00551837|Lung Transplantation
536914|NCT00551837|Kidney Transplnatation
536915|NCT00551837|Chroinic Kidney Disease
536916|NCT00551837|Influenza
536917|NCT00551824|esophageal stricture
536918|NCT00551811|SB-656933-AAA,
536919|NCT00551811|single dose,
536920|NCT00551811|ozone challenge
536921|NCT00551798|Hodgkin's Disease
536922|NCT00551798|Malignant lymphomas high grade
536923|NCT00551798|Chemoresistance
536924|NCT00551798|MIBI
536925|NCT00551798|PGP
536926|NCT00551798|MRP1
536927|NCT00551798|Tumor response
536928|NCT00551785|Hypoactive Sexual Desire Disorder
536929|NCT00551785|Menopause
536930|NCT00551785|Androgen
536931|NCT00551772|Bio-availability, healthy elderly volunteers
536932|NCT00551759|adenocarcinoma of the esophagus
536933|NCT00551759|chemoradiotherapy
536934|NCT00551759|oxaliplatin
536935|NCT00551759|cetuximab
536936|NCT00551759|docetaxel
536937|NCT00551746|purple grape juice
536938|NCT00551746|antioxidants
536939|NCT00551746|platelet aggregation
536940|NCT00551746|anti-thrombotic
536941|NCT00551733|recurrent non-small cell lung cancer
536942|NCT00551733|stage IIIB non-small cell lung cancer
536943|NCT00551733|stage IV non-small cell lung cancer
536944|NCT00551720|HIV
536945|NCT00551720|HIV positive
536946|NCT00551720|AIDS
536947|NCT00551720|smoking cessation
536948|NCT00551720|smoking
536949|NCT00551720|smoking counseling
536950|NCT00551707|CombinatoRx
536951|NCT00551707|CRx-102
536952|NCT00551707|Rheumatoid Arthritis
536953|NCT00551707|Prednisolone
536954|NCT00551707|Dipyridamole
536955|NCT00551707|ACR20
536956|NCT00551694|GSK256073A
536957|NCT00551681|cardiac resynchronisation therapy
536958|NCT00551681|epicardial lead
536959|NCT00551681|coronary sinus
536960|NCT00551655|Human Immunodeficiency Viruses
536961|NCT00551655|Glomerular Filtration Rate
536962|NCT00551655|Tenofovir
536963|NCT00551655|Treatment Experienced
536964|NCT00551642|Preemie, Inhaled Nitric Oxide
536965|NCT00551603|epoetinum beta once-weekly
536966|NCT00551603|darbepoetinum once-fortnightly
536967|NCT00551603|anemia correction
536968|NCT00551603|hemoglobin stability
536969|NCT00551590|diabetes mellitus
536970|NCT00551590|DPP-4 inhibitor
536971|NCT00551590|sitagliptin
536972|NCT00551590|exendin(9-39)
536973|NCT00551590|GLP-1
536974|NCT00551577|Ovarian neoplasms,
536975|NCT00551577|Neoadjuvant Therapy,
536976|NCT00551577|Docetaxel,
536977|NCT00551577|Neoplasm, Residual
536978|NCT00551564|total body water
536979|NCT00551564|T2DM,
536980|NCT00551564|Healthy Obese,
536981|NCT00551564|Insulin Resistance,
536982|NCT00551564|Rosiglitazone maleate,
536983|NCT00551564|Glucose Disposal,
536984|NCT00551564|hyperinsulinemic-euglycemic clamp,
536985|NCT00551551|Pelvic floor
536986|NCT00551551|Kegel exercises
536987|NCT00551551|Quality of Life
536988|NCT00551551|Pelvic Pain
536989|NCT00551538|Diabetes
536990|NCT00551538|Diabetic
536991|NCT00551538|Insulin
536992|NCT00551538|Glargine
536993|NCT00551538|Lispro
536994|NCT00551525|stage IIB prostate cancer
536995|NCT00551525|stage IIA prostate cancer
536996|NCT00551525|stage III prostate cancer
536997|NCT00551525|stage IV prostate cancer
536998|NCT00551512|cancer
536999|NCT00551512|solid tumors
537000|NCT00551499|Sleep Apnea, CRT
537001|NCT00551486|Pyrosequencing
537002|NCT00551486|BRAFV600E mutation
537003|NCT00551486|Thyroid incidentaloma
537004|NCT00551486|Ultrasound-guided fine-needle aspiration biopsy
537005|NCT00551473|pharmacodynamics,
537006|NCT00551473|tolerance
537007|NCT00551473|H2 antagonist,
537008|NCT00551473|AH23844,
537009|NCT00551473|lavoltidine,
537010|NCT00551473|gastroesophageal reflux disease (GERD), pharmacokinetics,
537011|NCT00551460|adult acute promyelocytic leukemia (M3)
537012|NCT00551460|adult acute myeloid leukemia with t(15;17)(q22;q12)
537013|NCT00551460|adult acute myeloid leukemia with inv(16)(p13;q22)
537014|NCT00551460|adult acute myeloid leukemia with t(16;16)(p13;q22)
537015|NCT00551460|untreated adult acute myeloid leukemia
537016|NCT00551395|glaucoma
537017|NCT00551395|laser
537018|NCT00551395|trabeculoplasty
537019|NCT00551382|Montelukast
537020|NCT00551382|Upper respiratory tract infection
537021|NCT00551382|leukotriene
537022|NCT00551382|Children
537023|NCT00551369|stage I non-small cell lung cancer
537024|NCT00551369|stage II non-small cell lung cancer
537025|NCT00551369|adenocarcinoma of the lung
537026|NCT00551369|large cell lung cancer
537027|NCT00551369|squamous cell lung cancer
537028|NCT00551369|adenosquamous cell lung cancer
537029|NCT00551356|Diabetes
537030|NCT00551356|Diabetic
537031|NCT00551356|Insulin
537032|NCT00551356|Humalog
537033|NCT00551356|Lantus
537034|NCT00551356|Glargine
537035|NCT00551356|Lispro
537036|NCT00551330|Treatment Experienced
537037|NCT00551317|SB480848,
537038|NCT00551317|Japanese healthy volunteers
537039|NCT00551317|darapladib,
537040|NCT00551278|sentinel lymph node
537041|NCT00551278|metastasis
537042|NCT00551278|molecular pathology
537043|NCT00551239|stage I grade 1 follicular lymphoma
537044|NCT00551239|stage I grade 2 follicular lymphoma
537045|NCT00551239|stage III grade 1 follicular lymphoma
537046|NCT00551239|stage III grade 2 follicular lymphoma
537047|NCT00551239|stage IV grade 1 follicular lymphoma
537048|NCT00551239|stage IV grade 2 follicular lymphoma
537049|NCT00551239|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
537050|NCT00551239|nodal marginal zone B-cell lymphoma
537051|NCT00551239|splenic marginal zone lymphoma
537052|NCT00551239|contiguous stage II grade 1 follicular lymphoma
537053|NCT00551239|contiguous stage II grade 2 follicular lymphoma
537054|NCT00551239|noncontiguous stage II grade 1 follicular lymphoma
537055|NCT00551239|noncontiguous stage II grade 2 follicular lymphoma
537056|NCT00551239|recurrent grade 1 follicular lymphoma
537057|NCT00551239|recurrent grade 2 follicular lymphoma
537058|NCT00551239|contiguous stage II marginal zone lymphoma
537059|NCT00551239|noncontiguous stage II marginal zone lymphoma
537060|NCT00551239|recurrent marginal zone lymphoma
537061|NCT00551239|stage I marginal zone lymphoma
537062|NCT00551239|stage III marginal zone lymphoma
537063|NCT00551239|stage IV marginal zone lymphoma
537064|NCT00551239|contiguous stage II small lymphocytic lymphoma
537065|NCT00551239|noncontiguous stage II small lymphocytic lymphoma
537066|NCT00551239|recurrent small lymphocytic lymphoma
537067|NCT00551239|stage I small lymphocytic lymphoma
537068|NCT00551239|stage III small lymphocytic lymphoma
537069|NCT00551239|stage IV small lymphocytic lymphoma
537070|NCT00551239|refractory chronic lymphocytic leukemia
537071|NCT00551239|stage I chronic lymphocytic leukemia
537072|NCT00551239|stage II chronic lymphocytic leukemia
537073|NCT00551239|stage III chronic lymphocytic leukemia
537074|NCT00551239|stage IV chronic lymphocytic leukemia
537075|NCT00551226|TB
537076|NCT00551226|Patients with tuberculosis
537077|NCT00551213|anti-IGF-1R
537078|NCT00551200|Buphenyl
537079|NCT00551200|Sodium Phenylbutyrate
537080|NCT00551200|Urea Cycle Disorder
537081|NCT00551200|UCD
537082|NCT00551161|Alzheimer disease
537083|NCT00551161|memantine
537084|NCT00551161|cholinesterase inhibitors
537085|NCT00551161|magnetic resonance spectroscopy
537086|NCT00551161|N-acetylaspartate
537087|NCT00551161|inositol
537088|NCT00551161|cerebrospinal fluid
537089|NCT00551161|tau proteins
537090|NCT00551161|amyloid beta-protein
537091|NCT00551135|postoperative pain chronic pain
537092|NCT00551122|recurrent malignant testicular germ cell tumor
537093|NCT00551122|testicular seminoma
537094|NCT00551122|recurrent ovarian germ cell tumor
537095|NCT00551122|stage IV ovarian germ cell tumor
537096|NCT00551122|stage III malignant testicular germ cell tumor
537097|NCT00551122|testicular choriocarcinoma and seminoma
537098|NCT00551122|testicular embryonal carcinoma and seminoma
537099|NCT00551122|testicular embryonal carcinoma and teratoma with seminoma
537100|NCT00551122|testicular embryonal carcinoma and yolk sac tumor with seminoma
537101|NCT00551122|testicular yolk sac tumor and teratoma with seminoma
537102|NCT00551122|recurrent extragonadal non-seminomatous germ cell tumor
537103|NCT00551122|recurrent extragonadal seminoma
537104|NCT00551122|stage IV extragonadal non-seminomatous germ cell tumor
537105|NCT00551122|stage IV extragonadal seminoma
537220|NCT00550550|allergen
537106|NCT00551122|recurrent extragonadal germ cell tumor
537107|NCT00551122|ovarian mixed germ cell tumor
537108|NCT00551122|adult central nervous system germ cell tumor
537109|NCT00551096|Advanced Solid Tumors
537110|NCT00551096|Biliary or Pancreatic Malignancies
537111|NCT00551044|prostatic neoplasms
537112|NCT00551044|bicalutamide
537113|NCT00551044|quality of life
537114|NCT00551044|osteoporosis
537115|NCT00551031|Influenza
537116|NCT00551031|Orthomyxoviruses
537117|NCT00551031|Myxovirus Infection
537118|NCT00551031|Inactivated Split-virion influenza vaccine
537119|NCT00551031|Elderly
537120|NCT00551018|Treatment Naive
537121|NCT00551005|unspecified adult solid tumor, protocol specific
537122|NCT00550992|untreated childhood acute lymphoblastic leukemia
537123|NCT00550992|T-cell childhood acute lymphoblastic leukemia
537124|NCT00550992|acute undifferentiated leukemia
537125|NCT00550979|gestational diabetes mellitus
537126|NCT00550979|cardiovascular disease risk
537127|NCT00550979|heart disease risk
537128|NCT00550966|Fibromyalgia
537129|NCT00550966|Quality of life
537130|NCT00550966|Primary Care
537131|NCT00550966|Non-pharmacological treatment
537132|NCT00550966|Cost / Cost-efficacy
537133|NCT00550940|epilepsy
537134|NCT00550940|attention
537135|NCT00550940|emotion
537136|NCT00550940|behavior problems
537137|NCT00550940|child
537138|NCT00550940|adolescent
537139|NCT00550927|unspecified adult solid tumor, protocol specific
537140|NCT00550914|Papilloma, Papillomatosis, Laser, Laser Surgery
537141|NCT00550901|unspecified adult solid tumor, protocol specific
537142|NCT00550888|uterus
537143|NCT00550888|abdominal delivery
537144|NCT00550888|suture techniques
537145|NCT00550875|Allergic rhinoconjunctivitis,
537146|NCT00550875|Immunotherapy
537147|NCT00550862|PBC, Primary Biliary Cirrhosis, Liver,
537148|NCT00550836|adenocarcinoma of the pancreas
537149|NCT00550836|duct cell adenocarcinoma of the pancreas
537150|NCT00550836|stage IV pancreatic cancer
537151|NCT00550810|Sutent
537152|NCT00550797|Steroid-naive, non-smokers
537153|NCT00550797|Mild to moderate allergic asthmatic adults
537154|NCT00550784|recurrent ovarian epithelial cancer
537155|NCT00550784|stage III ovarian epithelial cancer
537156|NCT00550784|stage IV ovarian epithelial cancer
537157|NCT00550784|fallopian tube cancer
537158|NCT00550784|peritoneal cavity cancer
537159|NCT00550758|Methacholine challenge; Spirometry, Early childhood
537160|NCT00550732|Triazoles
537161|NCT00550706|Prescription point prevalence
537162|NCT00550706|Drug utilization
537163|NCT00550706|Define Daily Dose
537164|NCT00550693|bloodstream infections
537165|NCT00550693|hemodialysis catheter
537166|NCT00550667|Attention-deficit hyperactivity disorder
537167|NCT00550667|adult
537168|NCT00550667|diagnostic validity
537169|NCT00550667|neuropsychological functions
537170|NCT00550667|social functioning
537171|NCT00550654|unspecified adult solid tumor, protocol specific
537172|NCT00550654|recurrent adult soft tissue sarcoma
537173|NCT00550654|recurrent melanoma
537174|NCT00550654|recurrent osteosarcoma
537175|NCT00550654|recurrent renal cell cancer
537176|NCT00550654|recurrent uterine sarcoma
537177|NCT00550654|stage IV adult soft tissue sarcoma
537178|NCT00550654|stage IV melanoma
537179|NCT00550654|stage IV uterine sarcoma
537180|NCT00550654|ovarian sarcoma
537181|NCT00550654|chondrosarcoma
537182|NCT00550654|metastatic osteosarcoma
537183|NCT00550654|stage IV renal cell cancer
537184|NCT00550654|lung metastases
537185|NCT00550654|liver metastases
537186|NCT00550654|bone metastases
537187|NCT00550641|fibromyalgia
537188|NCT00550641|pool-based exercise
537189|NCT00550628|neoplasm of uncertain malignant potential
537190|NCT00550628|colon cancer
537191|NCT00550615|Non-Hodgkins Lymphoma
537192|NCT00550615|Relapsed Non Hodgkins Lymphoma
537193|NCT00550615|Refractory Non Hodgkins Lymphoma
537194|NCT00550615|Dasatinib
537195|NCT00550602|Tracheomalacia
537196|NCT00550602|Tracheobronchomalacia
537197|NCT00550602|Airway Stabilization
537198|NCT00550602|Bronchoscopy
537199|NCT00550602|Stent Placement
537200|NCT00550602|Tracheobronchoplasty
537201|NCT00550602|COPD
537202|NCT00550589|high-grade squamous intraepithelial lesion
537203|NCT00550589|stage 0 anal cancer
537204|NCT00550576|Digoxin Antibodies
537205|NCT00550576|Bipolar Disorder
537206|NCT00550563|recurrent colon cancer
537207|NCT00550563|stage I colon cancer
537208|NCT00550563|stage II colon cancer
537209|NCT00550563|stage III colon cancer
537210|NCT00550563|stage IV colon cancer
537211|NCT00550563|recurrent rectal cancer
537212|NCT00550563|stage I rectal cancer
537213|NCT00550563|stage II rectal cancer
537214|NCT00550563|stage III rectal cancer
537215|NCT00550563|stage IV rectal cancer
537216|NCT00550550|rhinoconjunctivitis
537217|NCT00550550|rhinitis
537218|NCT00550550|conjunctivitis
537219|NCT00550550|allergy
537221|NCT00550550|immunotherapy
537222|NCT00550537|stage IIIB non-small cell lung cancer
537223|NCT00550537|stage IV non-small cell lung cancer
537224|NCT00550537|recurrent non-small cell lung cancer
537225|NCT00550537|squamous cell lung cancer
537226|NCT00550537|adenosquamous cell lung cancer
537227|NCT00550537|bronchoalveolar cell lung cancer
537228|NCT00550537|large cell lung cancer
537229|NCT00550537|adenocarcinoma of the lung
537230|NCT00550524|Knee osteoarthritis
537231|NCT00550511|Abdominal pain
537232|NCT00550511|ultrasound
537233|NCT00550511|surgery
537234|NCT00550511|emergency department
537235|NCT00550511|diagnostic accuracy
537236|NCT00550498|Retinal Vasculitis
537237|NCT00550498|Retinal Edema
537238|NCT00550498|Behcet's Disease
537239|NCT00550472|probiotics
537240|NCT00550472|atopic dermatitis
537241|NCT00550472|immune system
537242|NCT00550472|human
537243|NCT00550472|Lactobacillus
537244|NCT00550472|Bifidobacterium
537245|NCT00550472|healthy subjects
537246|NCT00550459|Hyponatremia
537247|NCT00550459|Cognitive
537248|NCT00550459|Neurological Function
537249|NCT00550459|Elderly
537250|NCT00550446|Janus Kinase 3 Clinical Trial
537251|NCT00550420|open-label extension
537252|NCT00550420|tolerability
537253|NCT00550420|Alzheimer's disease
537254|NCT00550420|Rosiglitazone extended-release (XR)
537255|NCT00550420|safety
537256|NCT00550420|cognition
537257|NCT00550420|BRL-049653
537258|NCT00550407|Lamotrigine
537259|NCT00550407|Prevention of relapse or recurrence of a mood episode
537260|NCT00550407|Bipolar I disorder
537261|NCT00550394|Adolescents
537262|NCT00550381|healthy subjects
537263|NCT00550342|Focal segmental glomerulosclerosis
537264|NCT00550342|FSGS
537265|NCT00550342|Proteinuria
537266|NCT00550342|rituximab
537267|NCT00550342|B cell
537268|NCT00550342|autoimmune
537269|NCT00550342|CD20
537270|NCT00550342|treatment
537271|NCT00550342|children
537272|NCT00550290|vulvectomy
537273|NCT00550290|wound infection
537274|NCT00550290|wound complication
537275|NCT00550290|prophylactic antibiotic
537276|NCT00550290|Post-operative wound complications following vulvectomy
537277|NCT00550277|Renal Cell Carcinoma
537278|NCT00550277|Refractory
537279|NCT00550277|LBH589
537280|NCT00550264|Hospital Readmission
537281|NCT00550264|Continuity of Care
537282|NCT00550264|Quality of Health Care
537283|NCT00550251|Nausea
537284|NCT00550251|Vomiting
537285|NCT00550251|Emesis
537286|NCT00550251|Palliative
537287|NCT00550251|Terminal
537288|NCT00550251|Cancer
537289|NCT00550238|Parkinson's Disease Psychosis
537290|NCT00550225|succinate
537291|NCT00550225|anti-muscarinic
537292|NCT00550225|b-agonist
537293|NCT00547820|radiation dose
537294|NCT00547820|VCUG
537295|NCT00547820|pediatric patients
537296|NCT00547807|Pain, neonate, nursing care
537297|NCT00547729|Heart Failure
537298|NCT00547729|Left Atrial Pressure Monitoring
537299|NCT00547716|Hepatitis C
537300|NCT00547716|Omega 3 fatty acids
537301|NCT00547716|Omacor
537302|NCT00547716|Interferon
537303|NCT00547703|Nonulcer dyspepsia
537304|NCT00547703|Functional dyspepsia
537305|NCT00547703|Antidepressant use in dyspepsia
537306|NCT00547703|Nortriptyline
537307|NCT00547703|Tricyclic antidepressants
537308|NCT00547677|liver metastases
537309|NCT00547677|unspecified adult solid tumor, protocol specific
537310|NCT00547664|Hylenex, time tagged pain pain reduction, hospice population
537311|NCT00547651|Small Cell Lung Cancer
537312|NCT00547651|Lung Cancer
537313|NCT00547651|Limited Disease Sensitive Small Cell Lung Cancer
537314|NCT00547651|Extensive Disease Sensitive Small Cell Lung Cancer
537315|NCT00547651|Limited Disease Refractory Small Cell Lung Cancer
537316|NCT00547651|Extensive Disease Refractory Small Cell Lung Cancer
537317|NCT00547651|Refractory Small Cell Lung Cancer
537318|NCT00547651|Sensitive Small Cell Lung Cancer
537319|NCT00547638|laceration/wound closure
537320|NCT00547638|topical skin adhesive
537321|NCT00547612|adenocarcinoma of the pancreas
537322|NCT00547612|stage I pancreatic cancer
537323|NCT00547612|stage II pancreatic cancer
537324|NCT00547612|stage III pancreatic cancer
537325|NCT00547612|stage IV pancreatic cancer
537326|NCT00547612|recurrent pancreatic cancer
537327|NCT00547560|Alzheimer Disease
537328|NCT00547547|unspecified adult solid tumor, protocol specific
537329|NCT00550212|healthy subjects
537330|NCT00550199|Solid Tumors
537331|NCT00550199|Phase I
537332|NCT00550199|LBH589
537333|NCT00550199|Gemcitabine
537334|NCT00550186|spinal anesthesia
537335|NCT00550186|preload
537336|NCT00550186|diuresis
537337|NCT00550186|bladder retention
537338|NCT00550147|ADHD-Combined TypeDisruptive behavior Disorder
537339|NCT00550134|Breast Cancer
537340|NCT00550134|Quality of life
537341|NCT00550108|pancreatic cyst
537342|NCT00550108|ethanol injection
537343|NCT00550095|Microalbuminuria/proteinuria
537344|NCT00550095|hypertensive patients with type 2 diabetes
537345|NCT00550095|Valsartan
537346|NCT00550095|microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes
537347|NCT00550082|Anticoagulation
537348|NCT00550082|High-Risk
537349|NCT00550082|Deep Vein Thrombosis
537350|NCT00550082|Pulmonary Embolism
537351|NCT00550082|Surgery
537352|NCT00550069|late preterm infants
537353|NCT00550069|near term infants
537354|NCT00550069|outcome
537355|NCT00550056|PTSD, Posttraumatic Stress Disorder, refugees, war
537356|NCT00550043|Rheumatoid arthritis
537357|NCT00550030|Psoriasis
537358|NCT00550030|UVB radiation
537359|NCT00550030|Biologics
537360|NCT00550030|Etanercept
537361|NCT00550030|PASI
537362|NCT00550004|Unresectable
537363|NCT00550004|locally advanced
537364|NCT00550004|metastatic pancreatic adenocarcinoma
537365|NCT00550004|Stage III
537366|NCT00550004|Stage IV
537367|NCT00549991|High Blood Pressure
537368|NCT00549978|Safety and Pharmacokinetics in healthy subjects
537369|NCT00549939|child
537370|NCT00549939|bladder
537371|NCT00549939|neuropathic
537372|NCT00549939|alpha blockers
537373|NCT00549913|adjacent vertebral levels between L1 and S1
537374|NCT00549900|HPV vaccine,
537375|NCT00549900|Cervical cancer
537376|NCT00549900|Human papillomavirus infection,
537377|NCT00549874|insulin resistance
537378|NCT00549874|type 2 diabetes
537379|NCT00549874|myocardial perfusion
537380|NCT00549874|nitrosative stress
537381|NCT00549874|thiazolidinediones
537382|NCT00549861|Cardiac Magnetic Resonance Imaging
537383|NCT00549861|Contrast agents
537384|NCT00549861|Gadobutrol
537385|NCT00549861|Fibrosis
537386|NCT00549861|Prognosis
537387|NCT00549861|Magnetic Resonance
537388|NCT00549861|Gadolinium
537389|NCT00549848|Leukemia
537390|NCT00549835|mucositis pain
537391|NCT00549835|cancer
537392|NCT00549835|pain
537393|NCT00549835|acupuncture
537394|NCT00549835|mucositis
537395|NCT00549835|cancer pain
537396|NCT00549822|aromatase inhibitor
537397|NCT00549822|CA 15-3
537398|NCT00549822|Hormone receptor positive
537399|NCT00549809|mechanical ventilation; respiratory failure
537400|NCT00549796|coronary artery disease
537401|NCT00549796|angioplasty
537402|NCT00549796|stent
537403|NCT00549796|percutaneous coronary intervention
537404|NCT00549796|on-site cardiac surgery
537405|NCT00549796|randomized trial
537406|NCT00549770|Hypertension, valsartan, LCZ696
537407|NCT00549757|Type 2 diabetes mellitus
537408|NCT00549757|renal morbidity and mortality
537409|NCT00549757|cardiovascular disease
537410|NCT00549757|micro-albuminuria
537411|NCT00549757|macro-albuminuria
537412|NCT00549757|RAAS
537413|NCT00549757|renin inhibitor
537414|NCT00549757|Reduced estimated glomerular filtration rate
537415|NCT00549744|ASTHMA
537416|NCT00549744|CLINICAL ENDPOINT,
537417|NCT00549731|autism
537418|NCT00549731|autistic
537419|NCT00549731|language
537420|NCT00549731|development
537421|NCT00549731|developmental
537422|NCT00549731|assessment
537423|NCT00549718|Schizophrenia
537424|NCT00549718|SM-13496
537425|NCT00549718|Latuda
537426|NCT00549718|Lurasidone
537427|NCT00549705|Anticoagulation
537428|NCT00549705|Thrombosis
537429|NCT00549705|Bleeding
537430|NCT00549705|Clotting
537431|NCT00549705|Pulmonary Embolism
537432|NCT00549705|Deep Vein Thrombosis
537433|NCT00549679|Chronic Obstructive Pulmonary Disease (COPD)
537434|NCT00549679|COPD
537435|NCT00549679|Repeat Dose
537436|NCT00549679|GSK256066
537437|NCT00549666|OC DDI
537438|NCT00549666|lurasidone
537439|NCT00549666|Latuda
537440|NCT00549666|schizophenia
537441|NCT00549653|GW856553,
537442|NCT00549653|drug-drug interactions,
537443|NCT00549653|rosuvastatin
537444|NCT00549640|nicotine dependence
537445|NCT00549640|tobacco dependence
537446|NCT00549614|heart failure
537447|NCT00549601|Alzheimer's
537448|NCT00549601|rivastigmine
537449|NCT00549601|transdermal
537450|NCT00549601|safety
537451|NCT00549601|randomized
537452|NCT00549601|switch
537453|NCT00549601|patch
537454|NCT00549588|Polymorphic light eruption
537455|NCT00549588|UV radiation
537456|NCT00549588|photoprotection
537457|NCT00549588|sunscreen
537458|NCT00549588|DNA repair enzymes
537459|NCT00549588|after-sun-lotion
537460|NCT00549575|Severe Intra uterine growth retardation below the third centile with abnormal uterine doppler
537461|NCT00549575|Severe growth retardation with pathologic uterine Doppler
537462|NCT00549575|L-Arginine
537463|NCT00549575|Nitric Oxide Donor
537464|NCT00549562|Autistic Disorder
537465|NCT00549536|calcium supplementation
537466|NCT00549536|intracellular ions
537467|NCT00549536|sodium/hydrogen exchange activity
537468|NCT00549523|HIV
537469|NCT00549523|Alternative Medicine
537470|NCT00549523|Complementary Medicine
537471|NCT00549510|COREG CR,
537472|NCT00549510|lisinopril,
537473|NCT00549510|hypertension,
537474|NCT00549510|dose proportionality,
537475|NCT00549510|fixed dose combination (FDC)
537476|NCT00549497|GW870086X, inhaled, asthma, cortisol, pharmacokinetics, osteocalcin
537477|NCT00549484|Thrombocytopenia
537478|NCT00549484|Thrombopoietin
537479|NCT00549484|Platelet Transfusion
537480|NCT00549484|Platelet Factor 4
537481|NCT00549471|children with cerebral palsy ages eight to eleven.
537482|NCT00549458|Week pelvic floor muscle in females
537483|NCT00549445|Chronic Obstructive Pulmonary Disease
537484|NCT00549445|COPD
537485|NCT00549445|Exacerbation
537486|NCT00549445|Macrolide
537487|NCT00549406|Vision
537488|NCT00549406|Visual attention
537489|NCT00549406|Postural balance
537490|NCT00549406|Geriatrics
537491|NCT00549393|intensive care unit
537492|NCT00549393|Healthcare associated infections (HAI)
537493|NCT00549393|pediatric
537494|NCT00549380|Aneurysmal Disease in Thorax, Abdominal or Extremity
537495|NCT00549367|Nutritional status
537496|NCT00549367|Nutrition counselling
537497|NCT00549367|Nutrition assessment
537498|NCT00549367|HIV
537499|NCT00549367|Alternative Medicine
537500|NCT00549367|Complementary Medicine
537501|NCT00549354|Abdominal Infrarenal Aortic
537502|NCT00549354|Aorto-Iliac Aneurysms
537503|NCT00549341|Torticollis
537504|NCT00549341|Cervical Dystonia
537505|NCT00549328|anti-angiogenesis
537506|NCT00549328|Non-small cell lung cancer,
537507|NCT00549328|pazopanib (GW786034)
537508|NCT00547534|Bortezomib
537509|NCT00547534|Bendamustine
537510|NCT00547534|Rituximab
537511|NCT00547534|Relapsed
537512|NCT00547534|Refractory
537513|NCT00547534|Mantle Cell
537514|NCT00547534|Indolent
537515|NCT00549263|Safety
537516|NCT00549263|Pharmacokinetics
537517|NCT00549263|Bioequivalence
537518|NCT00549250|Human papillomavirus 6/11
537519|NCT00549250|Neonates
537520|NCT00549250|Human papillomavirus 6 or 11 infection
537521|NCT00549237|RYGBP
537522|NCT00549237|Early nutrition
537523|NCT00549237|Lean body mass
537524|NCT00549237|Length of stay
537525|NCT00549237|Body Composition
537526|NCT00549211|Healthy Subjects,
537527|NCT00549211|Safety,
537528|NCT00549211|Tolerability,
537529|NCT00549211|Pharmacokinetics
537530|NCT00549198|tenofovir
537531|NCT00549198|HIV
537532|NCT00549198|efavirenz
537533|NCT00549198|naive
537534|NCT00549198|lamivudine
537535|NCT00549198|abacavir
537536|NCT00549198|emtricitabine
537537|NCT00549198|renal
537538|NCT00549172|Osteoarthritis, Knee
537539|NCT00549172|Arthroscopic Surgery
537540|NCT00549172|Menisci, Medial
537541|NCT00549172|Placebo Effect
537542|NCT00549172|Treatment Efficacy
537543|NCT00549159|menorrhagia
537544|NCT00549159|dysfunctional uterine bleeding
537545|NCT00549159|endometrial ablation
537546|NCT00549146|reversibility
537547|NCT00549146|COPD
537548|NCT00549146|lung function
537549|NCT00549133|Microalbuminaria in hypertensive patients with type II diabetes mellitus
537550|NCT00549120|Healthy Subjects
537551|NCT00549120|muscarinic receptor antagonist
537552|NCT00549120|propranolol
537553|NCT00549120|beta-blocker
537554|NCT00549120|beta-agonist
537555|NCT00549107|low cardiac output syndrome
537556|NCT00549107|open heart surgery
537557|NCT00549107|infants
537558|NCT00549107|Low cardiac output syndrome in infants undergoing corrective open heart surgery
537559|NCT00549081|DHEA
537560|NCT00549081|IVF
537561|NCT00549081|low ovarian response
537562|NCT00549055|Macugen Age-related macular degeneration (AMD) Observational study
537563|NCT00549042|Back Pain
537564|NCT00549042|Chronic Low Back Pain
537565|NCT00549042|Chronic Back Pain
537566|NCT00549042|Pain
537567|NCT00549042|Chronic Pain
537568|NCT00549029|muscle disorder
537569|NCT00549029|statins
537570|NCT00549029|creatine kinase
537571|NCT00549016|Aneurysm Exclusion
537572|NCT00548977|spermatogenesis defect
537573|NCT00548977|male infertility
537574|NCT00548977|azoospermia
537575|NCT00548977|oligozoospermia
537576|NCT00548977|Y chromosome markers
537577|NCT00548977|estrogen gene
537578|NCT00548964|Ketamine
537579|NCT00548964|glutamate
537580|NCT00548964|N-methyl-D-aspartate
537581|NCT00548964|treatment resistant
537582|NCT00548964|major depressive disorder
537583|NCT00548964|lithium
537584|NCT00548951|Dementia
537585|NCT00548938|Brain Tumor
537586|NCT00548938|GBM
537587|NCT00548938|Glioblastoma Multiforme
537588|NCT00548938|Giladel
537589|NCT00548938|Temozolomide
537590|NCT00548912|Kidney Failure, Chronic
537591|NCT00548912|Hemodialysis
537592|NCT00548912|Spironolactone
537593|NCT00548899|Neoadjuvant chemotherapy
537594|NCT00548899|Targeted therapy
537595|NCT00548886|QT Prolongation
537596|NCT00548886|QT Interval
537597|NCT00548886|Epinephrine
537598|NCT00548886|Stress test
537599|NCT00548847|Leukemia
537600|NCT00548834|CDP870
537601|NCT00548834|Certolizumab Pegol
537602|NCT00548795|Acute Respiratory Distress Syndrome
537603|NCT00548795|ARDS
537604|NCT00548795|Neutrophil
537605|NCT00548769|SB-683699,
537606|NCT00548769|firategrast,
537607|NCT00548769|PK,
537608|NCT00548769|surface area,
537609|NCT00548769|multiple sclerosis
537610|NCT00548756|Brain Cancer
537611|NCT00548756|Whole Brain Radiation Therapy
537612|NCT00548756|Quality of Life
537613|NCT00548756|QOL
537614|NCT00548756|Questionnaire
537615|NCT00548756|Survey
537616|NCT00548756|WBRT
537617|NCT00548743|Depression
537618|NCT00548743|Postpartum
537619|NCT00548743|Dyad satisfaction
537620|NCT00548743|Parenting comfort
537621|NCT00548743|Screening
537622|NCT00548743|Management
537623|NCT00548743|Follow up
537624|NCT00548743|Primary care
537625|NCT00548743|Practice based research
537626|NCT00548730|Bronchoscopy
537627|NCT00548730|Endoscopy
537628|NCT00548730|Image Enhancement
537629|NCT00548730|Autofluorescence
537630|NCT00548730|Narrow Band Image
537631|NCT00548717|GVHD
537632|NCT00548717|Stem cell transplantation
537633|NCT00548717|Sirolimus
537634|NCT00548704|Extravasation
537635|NCT00548704|Anthracyclines
537636|NCT00548678|diclofenac, platelet aggregation, ketorolac, aspirin
537637|NCT00548665|Atherosclerosis
537638|NCT00548665|Smoking cessation
537639|NCT00548665|Diagnostic techniques, cardiovascular
537640|NCT00548665|Ultrasonography
537641|NCT00548665|Health behavior
537642|NCT00548652|apathy
537643|NCT00548652|obesity
537644|NCT00548652|methylphenidate
537645|NCT00548652|MOVE
537646|NCT00548652|medical crisis counselling
537647|NCT00548626|Pancreatic Cancer
537648|NCT00548626|Endoscopic Ultrasonography
537649|NCT00548626|Fine-Needle Aspiration
537650|NCT00548626|Cytopathology
537651|NCT00548613|Myocardial Infarction
537652|NCT00548613|Heart Attack
537653|NCT00548613|Coronary Artery Bypass Grafting
537654|NCT00548600|Prostate Cancer
537655|NCT00548600|Iridium
537656|NCT00548600|Implant
537657|NCT00548600|Radiotherapy
537658|NCT00548587|Acute Coronary Syndrome
537659|NCT00548561|extravasation
537660|NCT00548561|anthracyclines
537661|NCT00548548|Avastin
537662|NCT00548548|Metastatic Adenocarcinoma
537663|NCT00548548|AVAGAST
537664|NCT00547482|Type 2 Diabetes
537665|NCT00547482|Overweight
537666|NCT00547482|Obese
537667|NCT00547469|Irritable Bowel Syndrome
537668|NCT00547469|IBS-c
537669|NCT00547469|IBS constipation
537670|NCT00547469|women with IBS
537671|NCT00547469|women with constipation
537672|NCT00547443|stage IIIA non-small cell lung cancer
537673|NCT00547443|stage IIIB non-small cell lung cancer
537674|NCT00547443|recurrent non-small cell lung cancer
537675|NCT00547443|adenocarcinoma of the lung
537676|NCT00547443|squamous cell lung cancer
537677|NCT00547443|large cell lung cancer
537678|NCT00547443|bronchoalveolar cell lung cancer
537679|NCT00547443|adenosquamous cell lung cancer
537680|NCT00547391|adults
537681|NCT00547391|children
537682|NCT00547391|tonsillectomy
537683|NCT00547378|overactive bladder, urinary incontinence, incontinence,Urgency-frequency
537684|NCT00547365|primary systemic amyloidosis
537685|NCT00547339|adenocarcinoma of the prostate
537686|NCT00547339|stage I prostate cancer
537687|NCT00547339|stage IIB prostate cancer
537688|NCT00547339|stage IIA prostate cancer
537689|NCT00547300|Hypertension
537690|NCT00547300|Nebivolol
537691|NCT00547300|Beta blocker
537692|NCT00547300|Tolerability
537693|NCT00547261|solid tumor
537694|NCT00547261|antimitotic
537695|NCT00547261|tubulin binder
537696|NCT00547248|Booster vaccination.
537697|NCT00547248|Immunogenicity
537698|NCT00547248|Pneumococcal vaccine
537699|NCT00547248|Safety
537700|NCT00547248|Pneumococcal disease
537701|NCT00547235|infection
537702|NCT00547235|precancerous/nonmalignant condition
537703|NCT00547196|refractory chronic lymphocytic leukemia
537704|NCT00547196|adult acute myeloid leukemia in remission
537705|NCT00547196|recurrent adult acute myeloid leukemia
537706|NCT00547196|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
537707|NCT00547196|adult acute myeloid leukemia with inv(16)(p13;q22)
537708|NCT00547196|adult acute myeloid leukemia with t(15;17)(q22;q12)
537817|NCT00548158|diabetes
537709|NCT00547196|adult acute myeloid leukemia with t(16;16)(p13;q22)
537710|NCT00547196|adult acute myeloid leukemia with t(8;21)(q22;q22)
537711|NCT00547196|adult acute lymphoblastic leukemia in remission
537712|NCT00547196|accelerated phase chronic myelogenous leukemia
537713|NCT00547196|blastic phase chronic myelogenous leukemia
537714|NCT00547196|chronic phase chronic myelogenous leukemia
537715|NCT00547196|de novo myelodysplastic syndromes
537716|NCT00547196|previously treated myelodysplastic syndromes
537717|NCT00547196|secondary myelodysplastic syndromes
537718|NCT00547196|recurrent adult Burkitt lymphoma
537719|NCT00547196|recurrent adult diffuse large cell lymphoma
537720|NCT00547196|recurrent adult diffuse mixed cell lymphoma
537721|NCT00547196|recurrent adult diffuse small cleaved cell lymphoma
537722|NCT00547196|recurrent adult grade III lymphomatoid granulomatosis
537723|NCT00547196|recurrent adult immunoblastic large cell lymphoma
537724|NCT00547196|recurrent adult lymphoblastic lymphoma
537725|NCT00547196|recurrent grade 1 follicular lymphoma
537726|NCT00547196|recurrent grade 2 follicular lymphoma
537727|NCT00547196|recurrent grade 3 follicular lymphoma
537728|NCT00547196|recurrent mantle cell lymphoma
537729|NCT00547196|recurrent marginal zone lymphoma
537730|NCT00547196|recurrent small lymphocytic lymphoma
537731|NCT00547196|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
537732|NCT00547196|nodal marginal zone B-cell lymphoma
537733|NCT00547196|splenic marginal zone lymphoma
537734|NCT00547196|relapsing chronic myelogenous leukemia
537735|NCT00547196|recurrent cutaneous T-cell non-Hodgkin lymphoma
537736|NCT00547196|secondary acute myeloid leukemia
537737|NCT00548522|Type 1 Diabetes
537738|NCT00548522|Pregnancy
537739|NCT00548522|Islet Mass
537740|NCT00548522|C-peptide
537741|NCT00548496|fractured wrist
537742|NCT00548496|Distal radial fracture,
537743|NCT00548483|Endotracheal intubation
537744|NCT00548483|Laryngeal edema
537745|NCT00548483|Cuff-leak test
537746|NCT00548483|Corticosteroids
537747|NCT00548483|This study was to ascertain whether administration of dexamethasone to critically intubated patients prevent postextubation airway obstruction.
537748|NCT00548483|This study was to compare high dose and low dose dexamethasone in preventing noninvasive ventilation or reintubation among critically ill intubated patients
537749|NCT00548470|schizophrenia
537750|NCT00548470|varenicline
537751|NCT00548470|cognition
537752|NCT00548470|cigarette smoking
537753|NCT00548457|the function of the endothelium of the arteries in patients suffering from ectatic coronary arteries
537754|NCT00548444|Tuberculosis
537755|NCT00548444|Lymphocyte kinetics
537756|NCT00548444|MVA85A
537757|NCT00548444|Deuterium
537758|NCT00548431|Leukemia, Lymphocytic, Acute [C04.557.337.428.511]
537759|NCT00548431|6-mercaptopurine
537760|NCT00548431|methotrexate
537761|NCT00548431|asparaginase
537762|NCT00548405|Multiple Sclerosis
537763|NCT00548392|breast
537764|NCT00548392|cancer
537765|NCT00548392|ultrasound
537766|NCT00548392|high risk
537767|NCT00548392|marker clip
537768|NCT00548379|vitamin D
537769|NCT00548379|pneumonia
537770|NCT00548366|cirrhosis
537771|NCT00548366|portal hypertension
537772|NCT00548366|ascites
537773|NCT00548366|sodium restriction
537774|NCT00548327|Genes
537775|NCT00548327|Dorsolateral Prefrontal Cortex
537776|NCT00548327|Dopamine
537777|NCT00548327|Functional Magnetic Resonance Imaging
537778|NCT00548327|Neuropsychological Testing
537779|NCT00548327|Schizophrenia
537780|NCT00548327|Atomoxetine
537781|NCT00548327|Cognitive Study
537782|NCT00548327|Pharmacogenetics
537783|NCT00548327|Normal Volunteers
537784|NCT00548327|Catechol-O-Methyltransferase
537785|NCT00548327|Healthy Volunteer
537786|NCT00548314|Matriderm
537787|NCT00548314|Dermal matrix
537788|NCT00548314|VAC therapy
537789|NCT00548314|Split skin graft
537790|NCT00548314|Burns
537791|NCT00548314|Scar quality
537792|NCT00548275|Buprenorphine
537793|NCT00548275|Drug counseling
537794|NCT00548275|HIV risk reduction counseling
537795|NCT00548275|HIV Seronegativity
537796|NCT00548275|HIV risk behaviors
537797|NCT00548262|Open-label
537798|NCT00548262|non-comparative study to evaluate short course of IV anidulafungin
537799|NCT00548262|followed by oral voriconazole
537800|NCT00548262|for tx of candidemia/invasive candidiasis.
537801|NCT00548249|Subjects with ESRD receiving chronic Hemodialysis
537802|NCT00548236|exercise intervention
537803|NCT00548236|AACT
537804|NCT00548223|recurrence of stroke
537805|NCT00548223|Dengzhan Shengmai Capsule
537806|NCT00548223|Traditional Chinese Medicine
537807|NCT00548210|Hypertrophy
537808|NCT00548210|scarring
537809|NCT00548210|scar treatment
537810|NCT00548210|silicone
537811|NCT00548197|Intravitreal Bevacizumab injection
537812|NCT00548197|Pars plana vitrectomy
537813|NCT00548197|tractional retinal detachment
537814|NCT00548197|Diabetic retinopathy
537815|NCT00548184|primary breast cancers
537816|NCT00548184|Locally advanced breast cancers
537818|NCT00548145|Pitavastatin
537819|NCT00548145|Statins
537820|NCT00548145|Donepezil
537821|NCT00548145|Alzheimer's Disease
537822|NCT00548145|Hypercholesterolemia
537823|NCT00548145|ADAS-Jcog
537824|NCT00548145|Alzheimer Disease (MMSE 15-23 and CDR1 or 2)
537825|NCT00548106|infant formula, milk allergy, hydrolized whey
537826|NCT00548093|non-small cell lung cancer
537827|NCT00548093|advanced
537828|NCT00548093|previously treated
537829|NCT00548067|High blood pressure, hypertension, drug interaction, steady state, valsartan, hydrochlorothiazide, amlodipine
537830|NCT00548054|cholera
537831|NCT00548054|vaccine
537832|NCT00548054|Kolkata
537833|NCT00548054|West Bengal
537834|NCT00548054|India
537835|NCT00548054|immunogenicity
537836|NCT00548054|safety
537837|NCT00548054|infants
537838|NCT00548054|expanded programme on immunization
537839|NCT00548041|HIV
537840|NCT00548041|Emergency Department
537841|NCT00548041|HIV Seronegativity
537842|NCT00548002|Staphylococcus aureus
537843|NCT00548002|bacteremia
537844|NCT00548002|endocarditis
537845|NCT00548002|sepsis
537846|NCT00548002|fluoroquinolone
537847|NCT00548002|rifampin
537848|NCT00548002|levofloxacin
537849|NCT00548002|trovafloxacin
537850|NCT00547989|ASA class I and II
537851|NCT00547976|Inflammation
537852|NCT00547976|Unstable Plaque
537853|NCT00547976|Macrophage
537854|NCT00547976|Thrombosis
537855|NCT00547976|Autoradiography
537856|NCT00547976|Atherosclerosis
537857|NCT00547976|Vasculitis
537858|NCT00547963|Alcohol Drinking
537859|NCT00547963|Marijuana Smoking
537860|NCT00547963|Substance Use
537861|NCT00547963|Emergency Department (ED)
537862|NCT00547937|Sleep Apnea
537863|NCT00547937|Oxidative Stress
537864|NCT00547937|Nitric oxide
537865|NCT00547937|Cardiovascular disease
537866|NCT00547911|Entacapone
537867|NCT00547911|Carbidopa
537868|NCT00547911|Locus Ceruleus/Norepinephrine-Autonomic System
537869|NCT00547911|Norepinephrine
537870|NCT00547911|Adrenergic Nervous System
537871|NCT00547898|HIV
537872|NCT00547898|AIDS
537873|NCT00547898|Diarrhea
537874|NCT00547898|HIV Associated Diarrhea
537875|NCT00547885|dihydrocodeine
537876|NCT00547885|opioids, long acting
537877|NCT00547885|opioids, short acting
537878|NCT00547885|Chronic pain
537879|NCT00547885|non-malignant pain
537880|NCT00547859|microcirculation
537881|NCT00547859|cardiac surgery
537882|NCT00547859|metabolism
537883|NCT00547859|capnometry
537884|NCT00547846|Cough
537885|NCT00547846|Antitussive
537886|NCT00547846|PDC-748
537887|NCT00547846|PhytoHealth
537888|NCT00547833|language disorders
537889|NCT00547833|language learning disabilities
537890|NCT00547833|vocabulary
537891|NCT00547833|reading
537892|NCT00547170|pelvic infection
537893|NCT00547170|abortion
537894|NCT00547170|doxycycline
537895|NCT00547157|head and neck
537896|NCT00547157|squamous cell carcinoma
537897|NCT00547157|radiotherapy
537898|NCT00547157|chemoradiotherapy
537899|NCT00547157|panitumumab
537900|NCT00547157|locally advanced head & neck cancer
537901|NCT00547157|EGFr
537902|NCT00547157|epidermal growth factor receptor
537903|NCT00547157|SCCHN
537904|NCT00547157|locally advanced SCCHN
537905|NCT00547157|HNC
537906|NCT00547157|epidermal growth factor
537907|NCT00547131|tumors metastatic to brain
537908|NCT00547131|recurrent adult brain tumor
537909|NCT00547118|Metabolic abnormalities
537910|NCT00547118|Safety
537911|NCT00547118|Satiety
537912|NCT00547105|recurrent non-small cell lung cancer
537913|NCT00547105|stage IIIB non-small cell lung cancer
537914|NCT00547105|stage IV non-small cell lung cancer
537915|NCT00547105|stage IIIA non-small cell lung cancer
537916|NCT00547066|ITP
537917|NCT00547066|hA20
537918|NCT00547066|Treatment
537919|NCT00547040|calcification
537920|NCT00547040|bone lesions
537921|NCT00547027|diabetes
537922|NCT00547027|physical activity
537923|NCT00547027|print-based intervention
537924|NCT00547027|tailored intervention
537925|NCT00547014|treatment, parallel assignment, double blind, randomized, placebo control, safety study,SLE (Systemic Lupus Erythematosus)
537926|NCT00547001|Menopause
537927|NCT00547001|Hot flashes
537928|NCT00547001|vasomotor symptoms
537929|NCT00547001|tapering regimen
537930|NCT00547001|hormonal therapy
537931|NCT00547001|Other menopausal symptoms including mood changes
537932|NCT00546988|primary treatment
537933|NCT00546988|allogeneic stem-cell transplantation
537934|NCT00546988|high-dose therapy
537935|NCT00546988|cytogenetics
537936|NCT00546975|gastrointestinal surgery
537937|NCT00546975|nutritional intervention
537938|NCT00546975|functional status
537939|NCT00546975|quality of life
537940|NCT00546949|Decompression, Surgical
537941|NCT00546949|x-stop
537942|NCT00546949|lumbar decompression
537943|NCT00546949|spinal stenosis
537944|NCT00546949|radiculopathy
537945|NCT00546936|Histoplasmosis
537946|NCT00546884|End of Life
537947|NCT00546884|Advance Directives
537948|NCT00546884|Randomized controlled trial
537949|NCT00546884|End of life care
537950|NCT00546884|End of life advance care planning
537951|NCT00546858|Pelvic pain
537952|NCT00546858|Vulvar pain
537953|NCT00546806|Rehabilitation,
537954|NCT00546806|Treatment outcome,
537955|NCT00546806|Whiplash injuries,
537956|NCT00546806|Randomized Clinical Trials
537957|NCT00546793|humanized anti-CD20 veltuzumab (IMMU-106) administered subcutaneously
537958|NCT00546780|Multiple Myeloma
537959|NCT00546780|Heat Shock Protein 90
537960|NCT00546780|Hsp90
537961|NCT00546780|KOS-953
537962|NCT00546780|17-AAG
537963|NCT00546780|bortezomib
537964|NCT00546780|first relapse
537965|NCT00546780|tanespimycin
537966|NCT00546780|TIME-1
537967|NCT00546741|Diabetes,NOS
537968|NCT00546689|HIV
537969|NCT00546689|aids
537970|NCT00546689|intestinal parasites
537971|NCT00546689|eosinophils
537972|NCT00546689|immunoglobulins
537973|NCT00546689|HIV/aids
537974|NCT00546689|Treatment Experienced
537975|NCT00546663|Cystic Fibrosis, hypertonic saline
537976|NCT00546650|Focus of study is to compare pharmacokinetics
537977|NCT00546611|PEP005
537978|NCT00546611|Common Wart(s)
537979|NCT00546611|Common warts (verruca[e] vulgaris)
537980|NCT00546598|Total hip replacement, Total hip arthroplasty
537981|NCT00546585|influenza, inactivated influenza A/H7N7 vaccine, parent protocol
537982|NCT00546559|Lipophilic statins
537983|NCT00546559|Insulin resistance
537984|NCT00546559|simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
537985|NCT00546546|Crohn
537986|NCT00546546|immunosuppressants
537987|NCT00546546|natural history
537988|NCT00546546|steroids
537989|NCT00546520|Asthma
537990|NCT00546520|Ciclesonide
537991|NCT00546520|Airway hyperresponsiveness
537992|NCT00546520|Sputum
537993|NCT00546520|Nitric oxide
537994|NCT00546468|stomach cancer
537995|NCT00546468|laparoscopy
537996|NCT00546468|gastrectomy
537997|NCT00546468|QOL
537998|NCT00546468|survival
537999|NCT00546468|clinical study
538000|NCT00546455|Obesity
538001|NCT00546455|insulin resistance
538002|NCT00546442|insulin resistance
538003|NCT00546442|chronic hepatitis C
538004|NCT00546442|genotype 1
538005|NCT00546429|Proximal femoral fracture
538006|NCT00546429|Trochanteric fracture
538007|NCT00546429|Intramedullary nailing
538008|NCT00546403|Excessive Daytime Sleepiness
538009|NCT00546377|B-cell chronic lymphocytic leukemia
538010|NCT00546377|Waldenstrom macroglobulinemia
538011|NCT00546377|recurrent mantle cell lymphoma
538012|NCT00546377|recurrent small lymphocytic lymphoma
538013|NCT00546377|refractory chronic lymphocytic leukemia
538014|NCT00546377|recurrent marginal zone lymphoma
538015|NCT00546377|recurrent grade 1 follicular lymphoma
538016|NCT00546377|recurrent grade 2 follicular lymphoma
538017|NCT00546377|recurrent grade 3 follicular lymphoma
538018|NCT00546351|Lacosamide
538019|NCT00546299|Ambulatory oxygen therapy
538020|NCT00546299|COPD
538021|NCT00546299|exertional hypoxemia
538022|NCT00546273|LTBI (Latent tuberculosis infection)
538023|NCT00546273|TB(Tuberculosis)
538024|NCT00546273|Vaccine
538025|NCT00546260|STEMI
538026|NCT00546260|ACS
538027|NCT00546234|asthma
538028|NCT00546234|tiotropium
538029|NCT00546234|smoking
538030|NCT00546234|eNO
538031|NCT00546234|metabolites
538032|NCT00546234|Virtual Asthma Clinic
538033|NCT00546221|Depression
538034|NCT00546221|Mental health
538035|NCT00546221|Exercise
538036|NCT00546221|Prescribed exercise
538037|NCT00546221|Physical health
538038|NCT00546221|Social wellbeing
538039|NCT00546208|bladder function
538040|NCT00546208|cutaneous ureterostomy
538041|NCT00546208|hydronephrosis
538042|NCT00546195|Cord Blood
538043|NCT00546195|Neutrophils
538044|NCT00546195|Polysaccharide
538045|NCT00546195|Gene Expression
538046|NCT00546182|Lipophilic statins
538047|NCT00546182|Insulin resistance
538048|NCT00546182|hypercholesterolemic patients
538049|NCT00546169|Patients undergoing elective or acute cholecystectomy
538050|NCT00546156|ER positive
538051|NCT00546156|PR positive
538052|NCT00546143|Asthma, anti-immunoglobulin E, omalizumab
538053|NCT00546130|ED-SCLC
538054|NCT00546130|small cell lung cancer
538055|NCT00546130|CPT-11
538056|NCT00546130|irinotecan hydrochloride
538057|NCT00546130|CDDP
538058|NCT00546130|cisplatin
538059|NCT00546130|PSK
538060|NCT00546130|Krestin
538061|NCT00546117|otitis media with effusion
538062|NCT00546117|gastroesophageal reflux
538063|NCT00546117|ear infection
538064|NCT00546117|proton pump inhibitor
538065|NCT00546104|Advanced Breast Cancer
538066|NCT00546104|Breast cancer
538067|NCT00546104|Dasatinib
538068|NCT00546104|Inoperable Stage III Breast Cancer
538069|NCT00546104|Metastatic Breast Cancer
538070|NCT00546104|Stage IV Breast Cancer
538071|NCT00546091|Imaging
538072|NCT00546091|Multi-Spectral Imaging
538073|NCT00546091|Thermography
538074|NCT00546091|Laser Doppler Imaging
538075|NCT00546091|Vasculature
538076|NCT00546091|Healthy Volunteer
538077|NCT00546091|HV
538078|NCT00546078|HPV vaccine
538079|NCT00546078|Cervical cancer
538080|NCT00546078|Human papillomavirus infection
538081|NCT00546065|Barrett's esophagus
538082|NCT00546065|ablation
538083|NCT00546065|esomeprazole
538084|NCT00546065|Barrett's cancer
538085|NCT00546065|Ablation of Barrett's esophagus
538086|NCT00546065|Surveillance of Barrett's esophagus after endoscopic resection of Barrett's cancer
538087|NCT00546065|Recurrence of Barrett's cancer
538088|NCT00546039|Prostate cancer
538089|NCT00546039|Localized prostatectomy
538090|NCT00546039|Laparoscopic prostatectomy
538091|NCT00546039|Chemoprevention
538092|NCT00546039|Genistein
538093|NCT00546039|BONISTEIN™
538094|NCT00546026|placental function
538095|NCT00546026|high-risk pregnancies
538096|NCT00546026|psychological distress
538097|NCT00546013|abdominal aortic aneurysms
538098|NCT00546013|pseudoexfoliation syndrome
538099|NCT00546013|glaucoma
538100|NCT00545987|HIV vaccine
538101|NCT00545987|HIV
538102|NCT00545987|AIDS
538103|NCT00545987|prevention
538104|NCT00545987|HIV/AIDS
538105|NCT00545987|HIV Preventative Vaccine
538106|NCT00545987|HIV Seronegativity
538107|NCT00545974|Randomized
538108|NCT00545974|Double-Blind
538109|NCT00545974|Placebo-Controlled
538110|NCT00545974|memantine
538111|NCT00545974|Namenda
538112|NCT00545974|Frontotemporal Dementia
538113|NCT00545974|Semantic Dementia
538114|NCT00545974|FTD
538115|NCT00545974|SD
538116|NCT00545974|dementia
538117|NCT00545974|behavioral decline
538118|NCT00545974|cognitive decline
538119|NCT00545961|respiratory infection
538120|NCT00545961|sinusitis
538121|NCT00545961|rhinosinusitis
538122|NCT00545961|children
538123|NCT00545961|middle meatal specimens
538124|NCT00545961|respiratory track bacteria
538125|NCT00545961|amoxicillin-clavulanate
538126|NCT00545961|pneumococci
538127|NCT00545961|haemophilus
538128|NCT00545961|moraxella
538129|NCT00545948|Non-Small-Cell Lung Cancer
538130|NCT00545948|NSCLC
538131|NCT00545948|Non-Squamous
538132|NCT00545948|Genomics
538133|NCT00545948|Guided Therapy
538134|NCT00545948|Directed Therapy
538135|NCT00545948|Genomic Expression Profiles
538136|NCT00545948|Chemotherapy Sensitivity
538137|NCT00545922|chronic obstructive pulmonary disease
538138|NCT00545922|anxiety
538139|NCT00545922|depression
538140|NCT00545922|cognitive behavioral therapy
538141|NCT00545883|GERD
538142|NCT00545883|esophagitis
538143|NCT00545883|PPI
538144|NCT00545857|Type 1 diabetes
538145|NCT00545857|Insulin dependent diabetes
538146|NCT00545857|Juvenile onset diabetes
538147|NCT00545857|pioglitazone
538148|NCT00545831|Home Parenteral Nutrition
538149|NCT00545831|Sepsis Prevention
538150|NCT00545831|Central Venous Catheters
538151|NCT00545831|Taurolidine
538152|NCT00545805|Insulin resistance
538153|NCT00545805|Metabolic syndrome X
538154|NCT00545805|Obesity
538155|NCT00545805|Intra-Abdominal Fat
538156|NCT00545805|Omentum
538157|NCT00545805|Bariatric surgery
538158|NCT00545805|Glucose Clamp Technique
538159|NCT00545805|Intravenous Glucose Tolerance Test
538160|NCT00545805|Adiponectin
538161|NCT00545805|Cytokines
538162|NCT00545792|Recurrent Endometrial cancer
538163|NCT00545792|Recurrent Cervical cancer
538164|NCT00545792|Recurrent Ovarian cancer
538165|NCT00545792|Recurrent Vaginal cancer
538166|NCT00545792|Recurrent Vulvar cancer
538167|NCT00545792|Vaginal recurrence
538168|NCT00545792|Brachytherapy
538169|NCT00545792|Radiation Treatment
538170|NCT00545792|External Beam Radiation
538171|NCT00545792|Avastin
538172|NCT00545792|Bevacizumab
538173|NCT00545766|Prostate Cancer
538174|NCT00545766|Hormone Refractory
538175|NCT00545766|Vinflunine
538176|NCT00545766|Salvage Chemotherapy
538177|NCT00545753|Human Head lice
538178|NCT00545727|Diabetes
538179|NCT00545727|Children
538180|NCT00545727|Adolescents
538181|NCT00545727|Diet
538182|NCT00545727|Glycemic index
538183|NCT00545701|Influenza
538184|NCT00545701|A/H5N1 strain
538185|NCT00545701|Orthomyxoviridae Infections
538186|NCT00545701|Influenza Pandemics
538187|NCT00545662|traumatic brain injury
538188|NCT00545662|cognition
538189|NCT00545662|behavioral outcome
538190|NCT00545662|functional outcome
538191|NCT00545662|treatment
538192|NCT00545662|early intervention
538193|NCT00545662|citicoline
538194|NCT00545649|Fibromyalgia
538195|NCT00545649|chronic pain
538196|NCT00545649|physical
538197|NCT00545649|exercise
538198|NCT00545649|activity
538199|NCT00545649|education
538200|NCT00545623|HIV/AIDS
538201|NCT00545623|Alternative Medicine
538202|NCT00545623|Complementary Medicine
538203|NCT00545597|adrenoleukodystrophy
538204|NCT00545597|adrenomyeloneuropathy
538205|NCT00545558|Antiretroviral Therapy, Highly Active
538206|NCT00545558|Coinfection
538207|NCT00545558|Treatment Naive
538208|NCT00545545|Colorectal
538209|NCT00545545|Carcinoma
538210|NCT00545545|Recurrent
538211|NCT00545545|Progressive
538212|NCT00545545|Cetuximab
538213|NCT00545545|Irinotecan
538214|NCT00545545|5-Fluorouracil
538215|NCT00545519|Multiple Myeloma
538216|NCT00545519|Thymoglobulin
538217|NCT00545506|wound infection
538218|NCT00545506|tissue oxygen tension
538219|NCT00545506|local warming
538220|NCT00545493|Rasmussen encephalitis
538221|NCT00545493|Chronic encephalitis
538222|NCT00545493|Cerebral hemiatrophy
538223|NCT00545493|Hemiparesis
538224|NCT00545493|Epilepsy
538225|NCT00545467|Aripiprazole
538226|NCT00545467|schizophrenia
538227|NCT00545467|antipsychotics
538228|NCT00545467|pharmacogenomics
538229|NCT00545467|cytochrome P450 enzyme
538230|NCT00545454|Inflammation
538231|NCT00545454|anti-cytokine
538232|NCT00545454|anti-chemokine
538233|NCT00545441|Anal fistula
538234|NCT00545441|fistula in ano
538235|NCT00545441|anorectal fistula
538236|NCT00545428|Nasal acquired diseases
538237|NCT00545428|Nasal congenital diseases
538238|NCT00545428|Rhinoplasty
538239|NCT00545428|Grafts
538240|NCT00545415|fruit
538241|NCT00545415|antioxidant
538242|NCT00545415|Healthy subjects
538243|NCT00545350|Prevention
538244|NCT00545350|Falls, accidental falls
538245|NCT00545350|Fractures
538246|NCT00545350|Physical injuries
538247|NCT00545350|Women
538248|NCT00545350|Elderly
538249|NCT00545350|Physical exercise
538250|NCT00545350|Balance exercise
538251|NCT00545311|multiple inhaled, NVA237, COPD
538252|NCT00545298|Nitric Oxide
538253|NCT00545298|Venous Leg Ulcers
538254|NCT00545285|clinical outcomes
538255|NCT00545285|radiographic outcomes
538256|NCT00545285|total hip arthroplasty
538257|NCT00545285|survivorship
538258|NCT00545272|QMF
538259|NCT00545272|indacaterol
538260|NCT00545272|Twisthaler®
538261|NCT00545259|Organ transplant, liver, pharmacokinetics, AEB071, immunosuppression
538262|NCT00545246|VEGF Trap
538263|NCT00545194|Prostaglandin E2
538264|NCT00545194|Intravaginal gel
538265|NCT00545194|Bishop score
538266|NCT00545194|Induction of labor
538267|NCT00545194|randomized trial
538268|NCT00545194|Vaginal insert
538269|NCT00545181|bacterial vaginosis
538270|NCT00545181|vaginal acidifying gel
538271|NCT00545181|recurrence
538272|NCT00545168|head lice
538273|NCT00545025|Influenza
538274|NCT00545025|Influenza vaccine
538275|NCT00545012|Levetiracetam
538276|NCT00545012|Keppra
538277|NCT00544999|recurrent adult acute myeloid leukemia
538278|NCT00544999|secondary acute myeloid leukemia
538279|NCT00544999|adult acute minimally differentiated myeloid leukemia (M0)
538280|NCT00544999|adult acute myeloblastic leukemia without maturation (M1)
538281|NCT00544999|adult acute myeloblastic leukemia with maturation (M2)
538282|NCT00544999|adult acute myelomonocytic leukemia (M4)
538283|NCT00544999|adult acute monoblastic leukemia (M5a)
538284|NCT00544999|adult acute monocytic leukemia (M5b)
538285|NCT00544999|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
538286|NCT00544999|adult acute myeloid leukemia with inv(16)(p13;q22)
538287|NCT00544999|adult acute myeloid leukemia with t(16;16)(p13;q22)
538288|NCT00544999|adult acute myeloid leukemia with t(8;21)(q22;q22)
538289|NCT00544986|breast cancer
538290|NCT00544986|post menopausal women
538291|NCT00544986|Post menopausal women with hormone sensitive advanced breast cancer
538292|NCT00544960|AT101
538293|NCT00544960|AT-101
538294|NCT00544960|cancer
538295|NCT00544960|lung
538296|NCT00544960|non-small cell
538297|NCT00544960|docetaxel
538298|NCT00544960|bcl
538299|NCT00544947|Respiratory Depression
538300|NCT00544947|Caesarean Section
538301|NCT00544947|Diamorphine
538302|NCT00544947|Fentanyl
538303|NCT00544908|stage IV pancreatic cancer
538304|NCT00544869|Vasopressin antagonist , Cardiac Edema ,Diuretics
538305|NCT00544856|mild Alzheimer's disease
538306|NCT00544856|mild cognitive impairment
538307|NCT00544830|stage IV prostate cancer
538943|NCT00542906|healthy volunteers
538308|NCT00544830|adenocarcinoma of the prostate
538309|NCT00544830|recurrent prostate cancer
538310|NCT00544817|Concurrent Radiation Therapy
538311|NCT00544817|Temozolomide
538312|NCT00544817|Sorafenib
538313|NCT00544817|First-line
538314|NCT00544817|Glioblastoma Multiforme
538315|NCT00544817|Phase II
538316|NCT00544804|recurrent breast cancer
538317|NCT00544804|stage IIIA breast cancer
538318|NCT00544804|stage IIIB breast cancer
538319|NCT00544804|stage IIIC breast cancer
538320|NCT00544804|stage IV breast cancer
538321|NCT00544804|bone metastases
538322|NCT00544791|Mild Cognitive Impairment
538323|NCT00544791|Melatonin
538324|NCT00544791|Antioxidant
538325|NCT00544791|Memory
538326|NCT00544791|Alzheimer
538327|NCT00544778|recurrent adult soft tissue sarcoma
538328|NCT00544778|stage III adult soft tissue sarcoma
538329|NCT00544778|stage IV adult soft tissue sarcoma
538330|NCT00544778|metastatic osteosarcoma
538331|NCT00544778|recurrent osteosarcoma
538332|NCT00544778|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
538333|NCT00544778|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
538334|NCT00544778|Ewing sarcoma of bone
538335|NCT00544765|Breast cancer
538336|NCT00544765|neoadjuvant therapy
538337|NCT00544765|pCR rates
538338|NCT00544752|sleep apnea syndromes, ambient indoor temperature
538339|NCT00544739|Coronary Artery Disease
538340|NCT00544739|Premature
538341|NCT00544739|Female
538342|NCT00544726|Rehabilitation
538343|NCT00544700|stage IV colon cancer
538344|NCT00544700|stage IV rectal cancer
538345|NCT00544687|Skin
538346|NCT00544687|Atrophy
538347|NCT00544687|CRX-191
538348|NCT00544687|mometasone furoate
538349|NCT00544687|nortriptyline hydrochloride
538350|NCT00544687|Skin Thickness in Normal Healthy Volunteers
538351|NCT00544674|extensive stage small cell lung cancer
538352|NCT00544674|limited stage small cell lung cancer
538353|NCT00544674|recurrent small cell lung cancer
538354|NCT00544648|stage IV non-small cell lung cancer
538355|NCT00544648|stage IIIB non-small cell lung cancer
538356|NCT00544622|Stroke treatment
538357|NCT00544622|Rehabilitation
538358|NCT00544622|Stroke chain
538359|NCT00544622|Stroke unit
538360|NCT00544609|Bladder
538361|NCT00544609|Sorafenib
538362|NCT00544609|Radiotherapy
538363|NCT00544583|Abdominal wall
538364|NCT00544570|recurrent adult Hodgkin lymphoma
538365|NCT00544570|recurrent/refractory childhood Hodgkin lymphoma
538366|NCT00544544|Bipolar
538367|NCT00544544|depression
538368|NCT00544531|MI oocytes, FISH,chromosomal aberrations
538369|NCT00544518|type 2 diabetes
538370|NCT00544518|Benfluorex
538371|NCT00544518|Metformin
538372|NCT00544518|insulin secretion
538373|NCT00544518|glucose control
538374|NCT00544492|arteriovenous fistula
538375|NCT00544492|dialysis access
538376|NCT00544492|pain
538377|NCT00544492|anxiety
538378|NCT00544492|fistula related complications
538379|NCT00544492|aneurysm
538380|NCT00544466|acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
538381|NCT00544466|adult acute lymphoblastic leukemia in remission
538382|NCT00544466|adult acute myeloid leukemia in remission
538383|NCT00544466|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
538384|NCT00544466|adult acute myeloid leukemia with del(5q)
538385|NCT00544466|adult acute myeloid leukemia with inv(16)(p13;q22)
538386|NCT00544466|adult acute myeloid leukemia with t(15;17)(q22;q12)
538387|NCT00544466|adult acute myeloid leukemia with t(16;16)(p13;q22)
538388|NCT00544466|adult acute myeloid leukemia with t(8;21)(q22;q22)
538389|NCT00544466|untreated adult acute myeloid leukemia
538390|NCT00544466|recurrent adult acute myeloid leukemia
538391|NCT00544466|childhood acute myeloid leukemia in remission
538392|NCT00544466|recurrent childhood acute myeloid leukemia
538393|NCT00544466|untreated childhood acute myeloid leukemia and other myeloid malignancies
538394|NCT00544466|de novo myelodysplastic syndromes
538395|NCT00544466|previously treated myelodysplastic syndromes
538396|NCT00544466|secondary myelodysplastic syndromes
538397|NCT00544466|secondary acute myeloid leukemia
538398|NCT00544466|childhood acute lymphoblastic leukemia in remission
538399|NCT00544466|recurrent adult acute lymphoblastic leukemia
538400|NCT00544466|recurrent childhood acute lymphoblastic leukemia
538401|NCT00544466|untreated adult acute lymphoblastic leukemia
538402|NCT00544466|untreated childhood acute lymphoblastic leukemia
538403|NCT00544466|childhood myelodysplastic syndromes
538404|NCT00544453|SPECT
538405|NCT00544453|Alzheimer disease
538406|NCT00544440|Prostate neoplasms
538407|NCT00544440|Prostate cancer
538408|NCT00544440|Castration-resistant prostate cancer
538409|NCT00544440|Abiraterone acetate
538410|NCT00544440|CB7630
538411|NCT00544440|Prednisone
538412|NCT00544440|Testosterone
538413|NCT00544440|Bone marrow
538414|NCT00544427|Upper Areo-Digestive tract
538415|NCT00544414|stage III squamous cell carcinoma of the larynx
538416|NCT00544414|stage IV squamous cell carcinoma of the larynx
539195|NCT00541879|Prevention
538417|NCT00544414|stage III squamous cell carcinoma of the hypopharynx
538418|NCT00544414|stage III squamous cell carcinoma of the oropharynx
538419|NCT00544414|stage IV squamous cell carcinoma of the hypopharynx
538420|NCT00544414|stage IV squamous cell carcinoma of the oropharynx
538421|NCT00544414|stage III squamous cell carcinoma of the lip and oral cavity
538422|NCT00544414|stage IV squamous cell carcinoma of the lip and oral cavity
538423|NCT00544414|stage II squamous cell carcinoma of the larynx
538424|NCT00544414|stage II squamous cell carcinoma of the hypopharynx
538425|NCT00544414|stage II squamous cell carcinoma of the oropharynx
538426|NCT00544401|infertility
538427|NCT00544401|in vitro fertilization
538428|NCT00544401|intracytoplasmic sperm implantation
538429|NCT00544401|acupuncture
538430|NCT00544401|hypnosis
538431|NCT00544401|hypnopuncture
538432|NCT00544388|Levocetirizine dihydrochloride
538433|NCT00544388|Xyzal tablet
538434|NCT00544362|adenocarcinoma of the esophagus
538435|NCT00544362|squamous cell carcinoma of the esophagus
538436|NCT00544362|stage IIIA esophageal cancer
538437|NCT00544362|stage IIIB esophageal cancer
538438|NCT00544362|stage IIIC esophageal cancer
538439|NCT00544362|stage IV esophageal cancer
538440|NCT00544349|stage IV colon cancer
538441|NCT00544349|recurrent colon cancer
538442|NCT00544349|stage IV rectal cancer
538443|NCT00544349|recurrent rectal cancer
538444|NCT00544349|liver metastases
538445|NCT00544336|unspecified adult solid tumor, protocol specific
538446|NCT00544336|recurrent breast cancer
538447|NCT00544336|stage I breast cancer
538448|NCT00544336|stage II breast cancer
538449|NCT00544336|stage IIIA breast cancer
538450|NCT00544336|stage IIIB breast cancer
538451|NCT00544336|stage IIIC breast cancer
538452|NCT00544336|stage IV breast cancer
538453|NCT00544336|recurrent prostate cancer
538454|NCT00544336|stage I prostate cancer
538455|NCT00544336|stage II prostate cancer
538456|NCT00544336|stage III prostate cancer
538457|NCT00544336|stage IV prostate cancer
538458|NCT00544336|extensive stage small cell lung cancer
538459|NCT00544336|limited stage small cell lung cancer
538460|NCT00544336|recurrent non-small cell lung cancer
538461|NCT00544336|recurrent small cell lung cancer
538462|NCT00544336|stage I non-small cell lung cancer
538463|NCT00544336|stage II non-small cell lung cancer
538464|NCT00544336|stage IIIA non-small cell lung cancer
538465|NCT00544336|stage IIIB non-small cell lung cancer
538466|NCT00544336|stage IV non-small cell lung cancer
538467|NCT00544336|recurrent colon cancer
538468|NCT00544336|stage I colon cancer
538469|NCT00544336|stage II colon cancer
538470|NCT00544336|stage III colon cancer
538471|NCT00544336|stage IV colon cancer
538472|NCT00544336|recurrent squamous cell carcinoma of the hypopharynx
538473|NCT00544336|stage I squamous cell carcinoma of the hypopharynx
538474|NCT00544336|stage II squamous cell carcinoma of the hypopharynx
538475|NCT00544336|stage III squamous cell carcinoma of the hypopharynx
538476|NCT00544336|stage IV squamous cell carcinoma of the hypopharynx
538477|NCT00544336|recurrent squamous cell carcinoma of the larynx
538478|NCT00544336|recurrent verrucous carcinoma of the larynx
538479|NCT00544336|stage I squamous cell carcinoma of the larynx
538480|NCT00544336|stage I verrucous carcinoma of the larynx
538481|NCT00544336|stage II squamous cell carcinoma of the larynx
538482|NCT00544336|stage II verrucous carcinoma of the larynx
538483|NCT00544336|stage III squamous cell carcinoma of the larynx
538484|NCT00544336|stage III verrucous carcinoma of the larynx
538485|NCT00544336|stage IV squamous cell carcinoma of the larynx
538486|NCT00544336|stage IV verrucous carcinoma of the larynx
538487|NCT00544336|recurrent adenoid cystic carcinoma of the oral cavity
538488|NCT00544336|recurrent mucoepidermoid carcinoma of the oral cavity
538489|NCT00544336|recurrent verrucous carcinoma of the oral cavity
538490|NCT00544336|stage I adenoid cystic carcinoma of the oral cavity
538491|NCT00544336|stage I mucoepidermoid carcinoma of the oral cavity
538492|NCT00544336|stage I verrucous carcinoma of the oral cavity
538493|NCT00544336|stage II adenoid cystic carcinoma of the oral cavity
538494|NCT00544336|stage II mucoepidermoid carcinoma of the oral cavity
538495|NCT00544336|stage II verrucous carcinoma of the oral cavity
538496|NCT00544336|stage III adenoid cystic carcinoma of the oral cavity
538497|NCT00544336|stage III mucoepidermoid carcinoma of the oral cavity
538498|NCT00544336|stage III verrucous carcinoma of the oral cavity
538499|NCT00544336|stage IV adenoid cystic carcinoma of the oral cavity
538500|NCT00544336|stage IV mucoepidermoid carcinoma of the oral cavity
538501|NCT00544336|stage IV verrucous carcinoma of the oral cavity
538502|NCT00544336|stage I squamous cell carcinoma of the lip and oral cavity
538503|NCT00544336|stage II squamous cell carcinoma of the lip and oral cavity
538504|NCT00544336|stage III squamous cell carcinoma of the lip and oral cavity
538505|NCT00544336|stage IV squamous cell carcinoma of the lip and oral cavity
538506|NCT00544336|recurrent basal cell carcinoma of the lip
538507|NCT00544336|recurrent squamous cell carcinoma of the lip and oral cavity
538508|NCT00544336|stage I basal cell carcinoma of the lip
538509|NCT00544336|stage II basal cell carcinoma of the lip
538510|NCT00544336|stage III basal cell carcinoma of the lip
538511|NCT00544336|stage IV basal cell carcinoma of the lip
538512|NCT00544336|metastatic squamous neck cancer with occult primary squamous cell carcinoma
538513|NCT00544336|recurrent metastatic squamous neck cancer with occult primary
538514|NCT00544336|untreated metastatic squamous neck cancer with occult primary
538515|NCT00544336|recurrent lymphoepithelioma of the nasopharynx
538516|NCT00544336|recurrent squamous cell carcinoma of the nasopharynx
538517|NCT00544336|stage I lymphoepithelioma of the nasopharynx
538518|NCT00544336|stage I squamous cell carcinoma of the nasopharynx
538519|NCT00544336|stage II lymphoepithelioma of the nasopharynx
538520|NCT00544336|stage II squamous cell carcinoma of the nasopharynx
538521|NCT00544336|stage III lymphoepithelioma of the nasopharynx
538522|NCT00544336|stage III squamous cell carcinoma of the nasopharynx
538523|NCT00544336|stage IV lymphoepithelioma of the nasopharynx
538524|NCT00544336|stage IV squamous cell carcinoma of the nasopharynx
538525|NCT00544336|recurrent lymphoepithelioma of the oropharynx
538526|NCT00544336|recurrent squamous cell carcinoma of the oropharynx
538527|NCT00544336|stage I lymphoepithelioma of the oropharynx
538528|NCT00544336|stage I squamous cell carcinoma of the oropharynx
538529|NCT00544336|stage II lymphoepithelioma of the oropharynx
538530|NCT00544336|stage II squamous cell carcinoma of the oropharynx
538531|NCT00544336|stage III lymphoepithelioma of the oropharynx
538532|NCT00544336|stage III squamous cell carcinoma of the oropharynx
538533|NCT00544336|stage IV lymphoepithelioma of the oropharynx
538534|NCT00544336|stage IV squamous cell carcinoma of the oropharynx
538535|NCT00544336|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
538536|NCT00544336|recurrent inverted papilloma of the paranasal sinus and nasal cavity
538537|NCT00544336|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
538538|NCT00544336|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
538539|NCT00544336|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
538540|NCT00544336|stage I inverted papilloma of the paranasal sinus and nasal cavity
538541|NCT00544336|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
538542|NCT00544336|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
538543|NCT00544336|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
538544|NCT00544336|stage II inverted papilloma of the paranasal sinus and nasal cavity
538545|NCT00544336|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
538546|NCT00544336|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
538547|NCT00544336|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
538548|NCT00544336|stage III inverted papilloma of the paranasal sinus and nasal cavity
538549|NCT00544336|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
538550|NCT00544336|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
538551|NCT00544336|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
538552|NCT00544336|stage IV inverted papilloma of the paranasal sinus and nasal cavity
538553|NCT00544336|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
538554|NCT00544336|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
538555|NCT00544336|high-grade salivary gland mucoepidermoid carcinoma
538556|NCT00544336|low-grade salivary gland mucoepidermoid carcinoma
538557|NCT00544336|recurrent salivary gland cancer
538558|NCT00544336|salivary gland acinic cell tumor
538559|NCT00544336|salivary gland adenocarcinoma
538560|NCT00544336|salivary gland adenoid cystic carcinoma
538561|NCT00544336|salivary gland anaplastic carcinoma
538562|NCT00544336|salivary gland malignant mixed cell type tumor
538563|NCT00544336|salivary gland poorly differentiated carcinoma
538564|NCT00544336|salivary gland squamous cell carcinoma
538565|NCT00544336|stage I salivary gland cancer
538566|NCT00544336|stage II salivary gland cancer
538567|NCT00544336|stage III salivary gland cancer
538568|NCT00544336|stage IV salivary gland cancer
538569|NCT00544323|alveolar bone
538570|NCT00544323|radiographic alveolar bone changes around oral implants of various designs 12 m post loading
538571|NCT00544297|Actinic Keratosis
538572|NCT00544297|Topical
538573|NCT00544297|Dermatology
538574|NCT00544297|Hand
538575|NCT00544284|adult glioblastoma
538576|NCT00544284|adult anaplastic astrocytoma
538577|NCT00544284|adult giant cell glioblastoma
538578|NCT00544284|recurrent adult brain tumor
538579|NCT00544284|adult gliosarcoma
538580|NCT00544284|adult mixed glioma
538581|NCT00544284|adult anaplastic oligodendroglioma
538582|NCT00544284|primary central nervous system lymphoma
538583|NCT00544284|adult diffuse astrocytoma
538584|NCT00544284|adult brain stem glioma
538585|NCT00544284|adult central nervous system germ cell tumor
538586|NCT00544284|adult choroid plexus tumor
538587|NCT00544284|adult craniopharyngioma
538588|NCT00544284|adult ependymoblastoma
538589|NCT00544284|adult medulloblastoma
538590|NCT00544284|adult supratentorial primitive neuroectodermal tumor (PNET)
538591|NCT00544284|adult anaplastic ependymoma
538592|NCT00544284|adult ependymoma
538593|NCT00544284|adult myxopapillary ependymoma
538594|NCT00544284|adult subependymoma
538595|NCT00544284|adult anaplastic meningioma
538596|NCT00544284|adult melanocytic lesion
538597|NCT00544284|adult meningeal hemangiopericytoma
538944|NCT00542906|Somatosensory stimuli
538598|NCT00544284|adult grade I meningioma
538599|NCT00544284|adult grade II meningioma
538600|NCT00544284|adult grade III meningioma
538601|NCT00544284|adult papillary meningioma
538602|NCT00544284|adult oligodendroglioma
538603|NCT00544284|adult pineoblastoma
538604|NCT00544284|adult pineocytoma
538605|NCT00544284|tumors metastatic to brain
538606|NCT00544284|unspecified adult solid tumor, protocol specific
538607|NCT00544284|adult pilocytic astrocytoma
538608|NCT00544284|adult subependymal giant cell astrocytoma
538609|NCT00544271|BOOSTRIX
538610|NCT00544271|INFANRIX
538611|NCT00544258|Pharmacokinetic study
538612|NCT00544258|Actinic Keratosis
538613|NCT00544258|Topical
538614|NCT00544258|Dermatology
538615|NCT00544245|overweight
538616|NCT00544245|obesity
538617|NCT00544245|accelerometer
538618|NCT00544245|pedometer
538619|NCT00544245|energy balance
538620|NCT00544245|weight loss
538621|NCT00544245|weight maintenance
538622|NCT00544232|Breast Cancer
538623|NCT00544232|neoadjuvant therapy
538624|NCT00544232|pCR rates
538625|NCT00544219|contiguous stage II adult diffuse large cell lymphoma
538626|NCT00544219|noncontiguous stage II adult diffuse large cell lymphoma
538627|NCT00544219|stage I adult diffuse large cell lymphoma
538628|NCT00544219|stage III adult diffuse large cell lymphoma
538629|NCT00544219|stage IV adult diffuse large cell lymphoma
538630|NCT00544193|adenocarcinoma of the extrahepatic bile duct
538631|NCT00544193|adenocarcinoma of the gallbladder
538632|NCT00544193|adenocarcinoma of the pancreas
538633|NCT00544193|adenocarcinoma of the stomach
538634|NCT00544193|stage I pancreatic cancer
538635|NCT00544193|stage II pancreatic cancer
538636|NCT00544193|stage III pancreatic cancer
538637|NCT00544193|localized extrahepatic bile duct cancer
538638|NCT00544193|recurrent extrahepatic bile duct cancer
538639|NCT00544193|unresectable extrahepatic bile duct cancer
538640|NCT00544193|localized gallbladder cancer
538641|NCT00544193|recurrent gallbladder cancer
538642|NCT00544193|unresectable gallbladder cancer
538643|NCT00544193|recurrent gastric cancer
538644|NCT00544193|stage II gastric cancer
538645|NCT00544193|stage III gastric cancer
538646|NCT00544193|stage IV gastric cancer
538647|NCT00544193|stage I gastric cancer
538648|NCT00544193|recurrent pancreatic cancer
538649|NCT00544193|small intestine adenocarcinoma
538650|NCT00544193|stage IV pancreatic cancer
538651|NCT00544167|Breast Cancer
538652|NCT00544167|Early Stage
538653|NCT00544167|High Risk
538654|NCT00544167|Node Positive
538655|NCT00544167|Doxorubicin
538656|NCT00544167|Cyclophosphamide
538657|NCT00544167|Paclitaxel
538658|NCT00544167|Sorafenib
538659|NCT00544154|CDP870
538660|NCT00544154|Certolizumab pegol
538661|NCT00544141|Temperature measurement
538662|NCT00544128|HIV
538663|NCT00544128|initial therapy
538664|NCT00544128|once daily
538665|NCT00544128|randomized trial
538666|NCT00544128|non inferiority
538667|NCT00544128|Treatment Naive
538668|NCT00544115|graft versus host disease
538669|NCT00544115|recurrent adult acute lymphoblastic leukemia
538670|NCT00544115|recurrent childhood acute lymphoblastic leukemia
538671|NCT00544115|untreated adult acute lymphoblastic leukemia
538672|NCT00544115|untreated childhood acute lymphoblastic leukemia
538673|NCT00544115|de novo myelodysplastic syndromes
538674|NCT00544115|previously treated myelodysplastic syndromes
538675|NCT00544115|secondary myelodysplastic syndromes
538676|NCT00544115|refractory anemia with excess blasts in transformation
538677|NCT00544115|refractory anemia with excess blasts
538678|NCT00544115|atypical chronic myeloid leukemia
538679|NCT00544115|chronic myelomonocytic leukemia
538680|NCT00544115|juvenile myelomonocytic leukemia
538681|NCT00544115|myelodysplastic/myeloproliferative disease, unclassifiable
538682|NCT00544115|recurrent adult acute myeloid leukemia
538683|NCT00544115|recurrent childhood acute myeloid leukemia
538684|NCT00544115|adult acute myeloid leukemia in remission
538685|NCT00544115|childhood acute myeloid leukemia in remission
538686|NCT00544115|secondary acute myeloid leukemia
538687|NCT00544115|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
538688|NCT00544115|adult acute myeloid leukemia with inv(16)(p13;q22)
538689|NCT00544115|adult acute myeloid leukemia with t(15;17)(q22;q12)
538690|NCT00544115|adult acute myeloid leukemia with t(16;16)(p13;q22)
538691|NCT00544115|adult acute myeloid leukemia with t(8;21)(q22;q22)
538692|NCT00544115|accelerated phase chronic myelogenous leukemia
538693|NCT00544115|blastic phase chronic myelogenous leukemia
538694|NCT00544115|childhood chronic myelogenous leukemia
538695|NCT00544115|chronic phase chronic myelogenous leukemia
538696|NCT00544115|relapsing chronic myelogenous leukemia
538697|NCT00544115|chronic eosinophilic leukemia
538698|NCT00544115|chronic idiopathic myelofibrosis
538699|NCT00544115|chronic neutrophilic leukemia
538700|NCT00544115|essential thrombocythemia
538701|NCT00544115|polycythemia vera
538702|NCT00544115|Waldenstrom macroglobulinemia
538945|NCT00542906|fMRI
538703|NCT00544115|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
538704|NCT00544115|nodal marginal zone B-cell lymphoma
538705|NCT00544115|recurrent adult Burkitt lymphoma
538706|NCT00544115|recurrent adult diffuse large cell lymphoma
538707|NCT00544115|recurrent adult diffuse mixed cell lymphoma
538708|NCT00544115|recurrent adult diffuse small cleaved cell lymphoma
538709|NCT00544115|recurrent adult immunoblastic large cell lymphoma
538710|NCT00544115|recurrent adult lymphoblastic lymphoma
538711|NCT00544115|recurrent grade 1 follicular lymphoma
538712|NCT00544115|recurrent grade 2 follicular lymphoma
538713|NCT00544115|recurrent grade 3 follicular lymphoma
538714|NCT00544115|recurrent mantle cell lymphoma
538715|NCT00544115|recurrent marginal zone lymphoma
538716|NCT00544115|recurrent small lymphocytic lymphoma
538717|NCT00544115|splenic marginal zone lymphoma
538718|NCT00544115|recurrent childhood grade III lymphomatoid granulomatosis
538719|NCT00544115|childhood nasal type extranodal NK/T-cell lymphoma
538720|NCT00544115|recurrent childhood large cell lymphoma
538721|NCT00544115|childhood diffuse large cell lymphoma
538722|NCT00544115|childhood immunoblastic large cell lymphoma
538723|NCT00544115|recurrent childhood lymphoblastic lymphoma
538724|NCT00544115|Burkitt lymphoma
538725|NCT00544115|recurrent childhood small noncleaved cell lymphoma
538726|NCT00544115|anaplastic large cell lymphoma
538727|NCT00544115|angioimmunoblastic T-cell lymphoma
538728|NCT00544115|recurrent adult T-cell leukemia/lymphoma
538729|NCT00544115|recurrent adult grade III lymphomatoid granulomatosis
538730|NCT00544115|adult nasal type extranodal NK/T-cell lymphoma
538731|NCT00544115|recurrent adult Hodgkin lymphoma
538732|NCT00544115|recurrent/refractory childhood Hodgkin lymphoma
538733|NCT00544115|refractory chronic lymphocytic leukemia
538734|NCT00544115|refractory multiple myeloma
538735|NCT00544115|stage III multiple myeloma
538736|NCT00544115|aplastic anemia
538737|NCT00544115|paroxysmal nocturnal hemoglobinuria
538738|NCT00544115|adult acute lymphoblastic leukemia in remission
538739|NCT00544115|childhood acute lymphoblastic leukemia in remission
538740|NCT00544115|recurrent cutaneous T-cell non-Hodgkin lymphoma
538741|NCT00544115|recurrent mycosis fungoides/Sezary syndrome
538742|NCT00544115|stage II multiple myeloma
538743|NCT00544102|Insulin Resistance
538744|NCT00544102|Systemic Lupus Erythematosus
538745|NCT00544102|Atherosclerosis
538746|NCT00544102|Lupus
538747|NCT00544102|SLE
538748|NCT00544089|azoospermia FISH IL-18 TESTICULAR BIOPSY
538749|NCT00544063|unspecified adult solid tumor, protocol specific
538750|NCT00544050|Levetiracetam
538751|NCT00544050|Keppra
538752|NCT00544024|Mefloquine
538753|NCT00544011|stage IV colon cancer
538754|NCT00544011|stage IV rectal cancer
538755|NCT00544011|adenocarcinoma of the colon
538756|NCT00544011|adenocarcinoma of the rectum
538757|NCT00543998|Sinusitis
538758|NCT00543985|metabolic syndrome
538759|NCT00543985|obesity
538760|NCT00543985|exercise
538761|NCT00543907|breast reconstruction
538762|NCT00543907|DIEP flap
538763|NCT00543894|Antibiotic, ICU, hospital acquired infection.
538764|NCT00543881|telemedicine
538765|NCT00543881|remote patient monitoring
538766|NCT00543881|chronic heart failure
538767|NCT00543881|mortality
538768|NCT00543881|health economics
538769|NCT00543855|Lewy Body Disease
538770|NCT00543855|Dementia
538771|NCT00543855|Clinical Trial
538772|NCT00543855|Phase II
538773|NCT00543855|E2020
538774|NCT00543855|donepezil hydrochloride
538775|NCT00543842|Rectal Cancer
538776|NCT00543842|Bevacizumab
538777|NCT00543842|Erlotinib
538778|NCT00543842|Capecitabine
538779|NCT00543829|breast cancer
538780|NCT00543829|doxorubicin
538781|NCT00543829|docetaxel
538782|NCT00543829|tamoxifen
538783|NCT00543777|Liver Cancer
538784|NCT00543777|Magnetic Resonance Elastography
538785|NCT00543777|2-Point Dixon Magnetic Resonance Imaging
538786|NCT00543777|Liver Disease
538787|NCT00543777|Fatty Liver
538788|NCT00543777|Liver Fibrosis
538789|NCT00543777|Liver Cirrhosis
538790|NCT00543777|MRE
538791|NCT00543777|2PD MRI
538792|NCT00543777|phase correction algorithm
538793|NCT00543764|Intraoperative Pathway
538794|NCT00543764|Breast Reconstruction
538795|NCT00543764|DIEP flap
538796|NCT00543725|Antiretroviral
538797|NCT00543725|HIV-1
538798|NCT00543725|AIDS
538799|NCT00543725|TMC278-C215
538800|NCT00543725|TMC278-TiDP6-C215
538801|NCT00543725|Treatment Naive
538802|NCT00543712|Sarcoma
538803|NCT00543712|synovial sarcoma
538804|NCT00543712|APM4171g
538805|NCT00543686|Pre-School Asthma
538806|NCT00543686|Responder Profiles
538807|NCT00543686|Fluticasone
538808|NCT00543686|Montelukast
538809|NCT00543686|Leukotriene
538810|NCT00543686|Children with Pre-School Asthma
538811|NCT00543673|Healthy term infants
538812|NCT00543660|Corneal transplantation, Descemet membrane, endothelium
538813|NCT00543647|Fenofibrate
538814|NCT00543647|Glomerular filtration rate
538815|NCT00543647|inulin clearance
538816|NCT00543647|creatinine
538817|NCT00543647|healthy volunteers
538818|NCT00543647|cross-over
538819|NCT00543608|pneumonia
538820|NCT00543608|nosocomial pneumonia
538821|NCT00543569|kidney transplant
538822|NCT00543569|alefacept
538823|NCT00543530|HIV
538824|NCT00543530|Treatment Experienced
538825|NCT00543504|Advanced Cancer
538826|NCT00543504|Bevacizumab
538827|NCT00543504|Avastin
538828|NCT00543504|Sorafenib
538829|NCT00543504|BAY 43-9006
538830|NCT00543504|Erlotinib
538831|NCT00543504|OSI-774
538832|NCT00543504|Tarceva
538833|NCT00543504|Trastuzumab
538834|NCT00543504|Herceptin
538835|NCT00543504|Sunitinib
538836|NCT00543504|SU011248
538837|NCT00543504|Sutent
538838|NCT00543504|Cetuximab
538839|NCT00543504|Lapatinib
538840|NCT00543504|Tykerb
538841|NCT00543504|Anti-VEGF monoclonal antibody
538842|NCT00543504|rhuMAb-VEGF
538843|NCT00543504|Erlotinib hydrochloride
538844|NCT00543504|GW572016
538845|NCT00543504|Sunitinib Malate
538846|NCT00543478|Irritable bowel syndrome
538847|NCT00543478|Diarrhea
538848|NCT00543478|Probiotics
538849|NCT00543426|Fuzheng Huayu Tablets
538850|NCT00543426|Multicenter clinical study
538851|NCT00543348|BALLOON ANGIOPLASTY
538852|NCT00543348|AUTOGENOUS FISTULA
538853|NCT00543335|Non-Small Cell Lung Cancer
538854|NCT00543335|Lung Cancer
538855|NCT00543335|NSCLC
538856|NCT00543335|Radiation Therapy
538857|NCT00543335|Sorafenib
538858|NCT00543335|BAY 43-9006
538859|NCT00543335|Thoracic Radiation
538860|NCT00543309|Fontan Operation
538861|NCT00543309|Cardiopulmonary Bypass
538862|NCT00543309|Heart Defects, Congenital
538863|NCT00543309|Milrinone
538864|NCT00543309|Natriuretic peptide, brain
538865|NCT00543296|uveitis
538866|NCT00543296|Cystoid Macular Edema (CME)
538867|NCT00543296|fluocinolone acetonide
538868|NCT00543296|non-infectious uveitis affecting the posterior segment
538869|NCT00543270|EVAR
538870|NCT00543270|AAA
538871|NCT00543270|Aneurysm
538872|NCT00543270|Powerlink
538873|NCT00543244|Chronic hepatitis C
538874|NCT00543244|Pegylated interferon
538875|NCT00543244|Ribavirin
538876|NCT00543244|Virokinetics
538877|NCT00543231|ECOG
538878|NCT00543231|MRT
538879|NCT00543231|NCI CTC
538880|NCT00543231|SAE
538881|NCT00543231|Short Intravenous Infusion to Patients with Solid Tumors
538882|NCT00543192|Endometrial Cancer
538883|NCT00543192|Sexual Function
538884|NCT00543166|Sjögren's syndrome
538885|NCT00543166|fatigue
538886|NCT00543166|salivary gland
538887|NCT00543166|dehydroepiandrosterone
538888|NCT00543153|Advanced Cancer
538889|NCT00543153|Exceptional Patient
538890|NCT00543153|Cancer Care
538891|NCT00543153|Interview
538892|NCT00543140|Obesity
538893|NCT00543140|Morbid Obesity
538894|NCT00543114|CLL
538895|NCT00543114|SLL
538896|NCT00543114|Revlimid
538897|NCT00543114|lenalidomide
538898|NCT00543101|HIV/AIDS
538899|NCT00543101|darunavir
538900|NCT00543101|Protease inhibitors
538901|NCT00543101|Dual boosted
538902|NCT00543101|Treatment experienced
538903|NCT00543088|Schizophrenia
538904|NCT00543088|Bipolar Disorder
538905|NCT00543088|manic episode
538906|NCT00543088|atypical antipsychotic
538907|NCT00543088|Schizophrenia or Bipolar Disorder (currently in a manic episode)
538908|NCT00543075|Renal Function
538909|NCT00543075|Adult
538910|NCT00543075|Genasense
538911|NCT00543075|oblimersen
538912|NCT00543075|G3139
538913|NCT00543075|Genta
538914|NCT00543075|Pharmacokinetics
538915|NCT00543049|platinum refractory
538916|NCT00543049|epithelial ovarian cancer
538917|NCT00543049|primary cancer of the peritoneum
538918|NCT00543049|cancer of the fallopian tube
538919|NCT00543036|Cannabis
538920|NCT00543036|Addiction
538921|NCT00543036|Craving
538922|NCT00543036|TMS
538923|NCT00542997|Subcutaneous immune globulin
538924|NCT00542997|SCIG
538925|NCT00542971|Leukemia
538926|NCT00542971|AML
538927|NCT00542971|High-Risk MDS
538928|NCT00542971|Acute Myeloid Leukemia
538929|NCT00542971|High-Risk Myelodysplastic Disorder
538930|NCT00542971|Idarubicin
538931|NCT00542971|Ara-C
538932|NCT00542971|Cytarabine
538933|NCT00542971|Sorafenib
538934|NCT00542971|BAY43-9006
538935|NCT00542958|Cancer
538936|NCT00542958|Refractory solid tumor
538937|NCT00542945|Heart Failure
538938|NCT00542945|ICD
538939|NCT00542945|Dilated cardiomyopathy
538940|NCT00542932|COPD
538941|NCT00542932|Exercise
538942|NCT00542932|Home
538946|NCT00542906|second somatosensory area
538947|NCT00542906|insular cortex
538948|NCT00542906|functional anatomy
538949|NCT00542893|bcl-2
538950|NCT00542893|CFR
538951|NCT00542893|DTIC
538952|NCT00542893|ECOG
538953|NCT00542893|EMEA
538954|NCT00542893|MedDRA
538955|NCT00542893|NCI CTC
538956|NCT00542893|SAE
538957|NCT00542880|COPD
538958|NCT00542880|Symbicort
538959|NCT00542880|Seretide
538960|NCT00542867|Hypercholesterolemia
538961|NCT00542867|Third Joint European Task Force guidelines
538962|NCT00542867|Survey
538963|NCT00542854|arrhythmia
538964|NCT00542854|pacemaker
538965|NCT00542854|defibrillator
538966|NCT00542854|electromagnetic interference
538967|NCT00542841|Adrenal Hyperplasia, Congenital
538968|NCT00542841|Steroid Biosynthesis Disorders
538969|NCT00542815|Chronic Kidney Disease
538970|NCT00542815|Dialysis
538971|NCT00542815|Hyperphosphatemia
538972|NCT00542802|post stroke epileptic late onset seizures
538973|NCT00542789|gastrointestinal
538974|NCT00542789|GI
538975|NCT00542789|NSAID
538976|NCT00542789|Japan
538977|NCT00542789|Japanese
538978|NCT00542789|Gastric ulcer
538979|NCT00542789|duodenal ulcer
538980|NCT00542776|inflammatory bowel disease (IBD)
538981|NCT00542776|immunosuppressed or non-immunosuppressed
538982|NCT00542776|influenza vaccine
538983|NCT00542776|antibody titers
538984|NCT00542776|seroprotective titers
538985|NCT00542776|vaccine-associated adverse events
538986|NCT00542763|Sjogren's syndrome
538987|NCT00542763|Mycophenolate sodium
538988|NCT00542750|Cannabis
538989|NCT00542750|Marijuana
538990|NCT00542750|Pharmacotherapy
538991|NCT00542750|Adolescent
538992|NCT00542737|Acute Lung Injury
538993|NCT00542737|Acute Respiratory Distress Syndrome
538994|NCT00542737|Acute Respiratory Failure
538995|NCT00542737|Web-Based Intervention
538996|NCT00542737|Lung Preventive Ventilation
538997|NCT00542724|Insulin
538998|NCT00542724|Diabetes Mellitus type I
538999|NCT00542724|Juvenile diabetes
539000|NCT00542711|Curcumin
539001|NCT00542711|Bioavilability
539002|NCT00542711|Healthy subjects
539003|NCT00542698|Type 2 Diabetes Mellitus
539004|NCT00542698|Glucose Monitor graphs
539005|NCT00542698|Physical Activity
539006|NCT00542672|Mexican American
539007|NCT00542672|Dietary Intake
539008|NCT00542672|Child-Feeding Practices
539009|NCT00542672|Weight
539010|NCT00542672|Cultural Values
539011|NCT00542659|Atrial fibrillation
539012|NCT00542659|Maze procedure
539013|NCT00542633|Diabetes mellitus type 2
539014|NCT00542633|Diabetes
539015|NCT00542633|Insulin
539016|NCT00542633|NIDDM
539017|NCT00542633|Rapid acting
539018|NCT00542607|Levocetirizine dihydrochloride
539019|NCT00542607|Xyzal tablets
539020|NCT00542594|breast cancer
539021|NCT00542594|anastrozole
539022|NCT00542581|Visual Outcomes
539023|NCT00542581|Patient Satisfaction
539024|NCT00542581|Ophthalmology
539025|NCT00542581|Cataractous Lens
539026|NCT00542542|Breast Cancer
539027|NCT00542542|Reconstructive Surgery
539028|NCT00542542|Paravertebral Block
539029|NCT00542542|Anesthesia
539030|NCT00542542|Propofol
539031|NCT00542542|Fentanyl
539032|NCT00542542|Ropivacaine
539033|NCT00542542|Midazolam
539034|NCT00542529|Healthy Subjects
539035|NCT00542516|Hip Replacement Arthroplasty
539036|NCT00542516|Hydroxyethyl Starch
539037|NCT00542516|Hemodilution
539038|NCT00542516|Hetastarch
539039|NCT00542516|Colloids
539040|NCT00542503|Cardiac Outcomes
539041|NCT00542503|MRI
539042|NCT00542503|Cardiac Stress Testing
539043|NCT00542490|Endometrial cancer
539044|NCT00542490|Gynecologic Cancer
539045|NCT00542490|Vaginal Cuff Brachytherapy
539046|NCT00542490|Vaginal radiation
539047|NCT00542464|Safety in Healthy Adult Subjects
539048|NCT00542451|node-negative breast cancer
539049|NCT00542451|HER-2 positive
539050|NCT00542438|Cardiovascular Disease
539051|NCT00542438|Cancer Prevention
539052|NCT00542438|Physical Activity
539053|NCT00542438|Body Composition
539054|NCT00542438|Environment
539055|NCT00542438|Exercise
539056|NCT00542425|osteoporosis
539057|NCT00542425|postmenopausal
539058|NCT00542425|bone loss
539059|NCT00542399|levemir
539060|NCT00542399|type 1 diabetes
539061|NCT00542386|Chronic Kidney Disease
539062|NCT00542386|Dialysis
539063|NCT00542386|Hyperphosphatemia
539064|NCT00542386|Dyslipidemia
539065|NCT00542386|Phosphate binder
539066|NCT00542373|Oral Cancer
539067|NCT00542373|Oral Cavity Mucosa
539068|NCT00542373|Leukoplakia
539069|NCT00542373|Erythroplakia
539070|NCT00542373|Fluorescence Imaging
539071|NCT00542373|Reflectance Imaging
539072|NCT00542373|Multispectral Digital Microscope
539073|NCT00542373|Portable Spectroscopy System
539074|NCT00542373|Fast Excitation-Emission Matrix
539075|NCT00542373|PS2
539076|NCT00542373|MDM
539077|NCT00542373|Fast EEM4
539078|NCT00542360|Accidental Falls
539079|NCT00542360|Aged
539080|NCT00542360|Social Marketing
539081|NCT00542360|Exercise
539082|NCT00542360|Accident Prevention
539083|NCT00542360|Religion
539084|NCT00542360|Randomized Controlled Trial
539085|NCT00542347|gastric acid
539086|NCT00542347|proton pump inhibitors
539087|NCT00542347|omeprazole
539088|NCT00542347|esomeprazole
539089|NCT00542334|Nocturnal Hypoglycemia
539090|NCT00542334|Type 1 diabetes
539091|NCT00542334|Children
539092|NCT00542334|Adolescents
539093|NCT00542334|CGMS
539094|NCT00542321|lateral rotation
539095|NCT00542321|kinetic therapy
539096|NCT00542321|mechanical ventilation
539097|NCT00542321|pulmonary complications
539098|NCT00542282|lung sounds,
539099|NCT00542282|airway obstruction,
539100|NCT00542282|asthma,
539101|NCT00542282|auscultation
539102|NCT00542269|Hypertension
539103|NCT00542269|Metabolic Syndrome
539104|NCT00542269|Dual combination therapy
539105|NCT00542269|Triple combination therapy
539106|NCT00542269|Aliskiren
539107|NCT00542269|Direct Renin inhibitor
539108|NCT00542256|Apoplexy
539109|NCT00542256|Cerebral Stroke
539110|NCT00542256|Cerebrovascular Accident, Acute
539111|NCT00542256|Cerebrovascular Apoplexy
539112|NCT00542256|Cerebrovascular Stroke
539113|NCT00542256|CVA (Cerebrovascular Accident)
539114|NCT00542256|Stroke
539115|NCT00542256|Stroke, Acute
539116|NCT00542256|Vascular Accident, Brain
539117|NCT00542243|enlarged prostate
539118|NCT00542243|finasteride
539119|NCT00542230|Erythrocytes
539120|NCT00542230|Drug Screen
539121|NCT00542230|Sickle Cell Trait
539122|NCT00542230|Sickle Cell Disease
539123|NCT00542217|Healthy Volunteers
539124|NCT00542204|Diabetes
539125|NCT00542204|Blood Glucose Self-Monitoring
539126|NCT00542204|Home Blood Glucose Monitoring
539127|NCT00542204|Internet
539128|NCT00542204|Personal Health Record (PHR)
539129|NCT00542204|Health Information Technology (HIT)
539130|NCT00542204|Care management
539131|NCT00542204|Disease Management
539132|NCT00542204|Diabetes self-management
539133|NCT00542204|Consumer Health Information
539134|NCT00542204|Medical Records Systems, Computerized
539135|NCT00542204|Computerized Medical Records System
539136|NCT00542204|Automated Medical Records System
539137|NCT00542204|Electronic Health Record (EHR)
539138|NCT00542204|Remote patient monitoring
539139|NCT00542191|Triple negative (ER/PR negative; HER2 negative)
539140|NCT00542178|Type 2 Diabetes Mellitus
539141|NCT00542178|Cardiovascular Diseases
539142|NCT00542152|IBD
539143|NCT00542152|Ulcerative colitis
539144|NCT00542152|refractory to steroids
539145|NCT00542139|Osteoarthritis
539146|NCT00542139|Knee arthroplasty
539147|NCT00542139|Steroid injection
539148|NCT00542139|Rehabilitation
539149|NCT00542126|GnRH analog, IVF, infertility, frozen-thawed embryos
539150|NCT00542113|Parental
539151|NCT00542113|Parents
539152|NCT00542113|Prevention
539153|NCT00542113|Energy balance
539154|NCT00542113|Glucose regulation
539155|NCT00542113|Healthy lifestyles
539156|NCT00542113|Healthy families
539157|NCT00542113|Active living
539158|NCT00542074|Bacterial vaginosis
539159|NCT00542074|recurrence
539160|NCT00542074|male factor
539161|NCT00542061|COPD
539162|NCT00542061|Asthma
539163|NCT00542061|Lung function
539164|NCT00542061|Monitoring
539165|NCT00542061|Primary Care
539166|NCT00542048|Hepatic metastases
539167|NCT00542048|Angiogenesis
539168|NCT00542048|EndoTAG-1
539169|NCT00542048|Pharmacokinetics
539170|NCT00542048|Pharmacodynamics
539171|NCT00542048|Metastases of the liver
539172|NCT00542035|Analgesia
539173|NCT00542009|Phase 2A, safety and efficacy trial with CE-326,597 in patients with T2DM.
539174|NCT00541983|Diabetes
539175|NCT00541983|Type 2
539176|NCT00541983|Mellitus
539177|NCT00541970|viral infections
539178|NCT00541970|Human Papillomavirus (HPV) vaccine
539179|NCT00541970|safety
539180|NCT00541970|vaccine
539181|NCT00541970|immunogenicity
539182|NCT00541970|cervical cancer
539183|NCT00541957|Major depression
539184|NCT00541957|Primary care
539185|NCT00541944|hyponatremia
539186|NCT00541944|diagnosis and treatment of hyponatremia
539187|NCT00541944|classification of hyponatremia
539188|NCT00541918|sevoflurane,
539189|NCT00541918|propofol,
539190|NCT00541918|heart surgery,
539191|NCT00541918|cardiopulmonary bypass,
539192|NCT00541918|memory disorders,
539193|NCT00541892|Cell Culture Techniques
539194|NCT00541879|Childhood
539196|NCT00541879|Energy balance
539197|NCT00541879|Glucose regulation
539198|NCT00541879|Healthy lifestyle
539199|NCT00541879|Healthy eating
539200|NCT00541879|Active living
539201|NCT00541866|Leukemia
539202|NCT00541866|Acute Myeloid
539203|NCT00541866|Relapsed
539204|NCT00541866|Refractory
539205|NCT00541866|Cancer
539206|NCT00541866|AML
539207|NCT00541866|Cytarabine
539208|NCT00541866|SNS-595
539209|NCT00541866|Phase 1
539210|NCT00541866|Voreloxin
539211|NCT00541853|Autosomal Dominant Polycystic Kidney Disease
539212|NCT00541853|Hypertension
539213|NCT00541853|Angiotensin-2 Receptor Blocker
539214|NCT00541853|Calcium Channel Blocker
539215|NCT00541853|Kidney Volume
539216|NCT00541840|Sarcoma
539217|NCT00541840|Sorafenib
539218|NCT00541840|GEIS
539219|NCT00541827|Sepsis. Shock, septic. Mitochondria.
539220|NCT00541814|Renal Transplantation
539221|NCT00541814|Calcineurin Inhibitor
539222|NCT00541814|Cyclosporine
539223|NCT00541814|Withdrawal
539224|NCT00541814|Minimisation
539225|NCT00541762|Neurotensin
539226|NCT00541762|Human
539227|NCT00541762|Physiology of neurotensin
539228|NCT00541762|fat perfusion
539229|NCT00541762|healthy subjects
539230|NCT00541749|SLE
539231|NCT00541736|Familial Hemiplegic Migraine
539232|NCT00541710|menopause
539233|NCT00541710|genistein
539234|NCT00541710|pre-diabetes
539235|NCT00541671|Narcotics
539236|NCT00541671|Nausea
539237|NCT00541619|hypertension
539238|NCT00541619|sympathetic activity
539239|NCT00541619|early renal damage
539240|NCT00541606|Diabetes Mellitus, Type 2
539241|NCT00541606|Pharmaceutical Care
539242|NCT00541606|Collaborative Practice
539243|NCT00541593|Pancreatic pseudocyst
539244|NCT00541593|NOTES
539245|NCT00541567|Wheight management in T2D
539246|NCT00541515|Type 1 diabetes
539247|NCT00541515|Artificial pancreas
539248|NCT00541515|Insulin Pump
539249|NCT00541502|evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan
539250|NCT00541489|Osteoarthritis
539251|NCT00541489|Osteoarthritis, Hip
539252|NCT00541463|HIV
539253|NCT00541463|Treatment Experienced
539254|NCT00541437|Change from baseline of HbA1c after 16 weeks of treatment
539255|NCT00541437|Change from baseline of FPG after 16 weeks of treatment
539256|NCT00541437|Change from baseline of diabetes self-care scale by patient on drug administration after 16 weeks of treatment
539257|NCT00541424|Mantle Cell Lymphoma
539258|NCT00541424|Lymphoma
539259|NCT00541424|CT Colonography
539260|NCT00541424|PET Scan
539261|NCT00541424|PET/CT Scan
539262|NCT00541424|Gas Insufflation
539263|NCT00541398|Antipsychotic polypharmacy
539264|NCT00541398|Schizophrenia
539265|NCT00541398|Implementation of clinical guidelines
539266|NCT00541385|malaria
539267|NCT00541385|pediatric
539268|NCT00541385|Africa
539269|NCT00541385|Phillipines
539270|NCT00541385|Coartem
539271|NCT00541385|Artesunate
539272|NCT00541385|lumefantrine
539273|NCT00541385|Arthemeter
539274|NCT00541385|pyronaridine
539275|NCT00541385|Pyramax
539276|NCT00541346|Autism
539277|NCT00541346|Autism Spectrum Disorders
539278|NCT00541346|ADHD
539279|NCT00541333|Dry Age Related Macular Degeneration
539280|NCT00541333|Dry AMD
539281|NCT00541320|Anti-thrombolytic direct Factor Xa inhibitor
539282|NCT00541307|Peripheral Arterial Disease
539283|NCT00541307|Peripheral Vascular Disease
539284|NCT00541294|Tuberculosis
539285|NCT00541294|HIV
539286|NCT00541294|Diagnostics
539287|NCT00541294|Pediatrics
539288|NCT00541281|prostate cancer
539289|NCT00541281|hormone resistant
539290|NCT00541281|metastatic
539291|NCT00541281|estramustine combine to docetaxel
539292|NCT00541281|randomized study
539293|NCT00541268|Heart Failure
539294|NCT00541268|ICD
539295|NCT00541268|Dilated cardiomyopathy
539296|NCT00541255|Bronchial Asthma
539297|NCT00541255|Food Allergy
539298|NCT00541255|Bronchial Hyperresponsiveness
539299|NCT00541216|congenital myasthenia
539300|NCT00541216|ephedrine
539301|NCT00541203|tomography
539302|NCT00541203|coronary artery disease
539303|NCT00541203|Stress Test
539304|NCT00541203|Coronary Angiography
539305|NCT00541190|cystic fibrosis
539306|NCT00541190|mucociliary clearance
539307|NCT00541190|outcome measures
539308|NCT00541177|prevention myopia
539309|NCT00541164|CMT
539310|NCT00541164|Charcot-Marie Tooth
539311|NCT00541164|CoQ10
539312|NCT00541164|Coenzyme Q10
539313|NCT00541151|Stress urinary incontinence in Women
539314|NCT00541138|tumors metastatic to brain
539315|NCT00541138|recurrent adult brain tumor
539316|NCT00541138|adult anaplastic astrocytoma
539317|NCT00541138|adult diffuse astrocytoma
539547|NCT00540345|peginterferon
539318|NCT00541138|adult giant cell glioblastoma
539319|NCT00541138|adult gliosarcoma
539320|NCT00541138|adult pilocytic astrocytoma
539321|NCT00541138|adult pineal gland astrocytoma
539322|NCT00541138|adult subependymal giant cell astrocytoma
539323|NCT00541138|adult brain stem glioma
539324|NCT00541138|adult anaplastic ependymoma
539325|NCT00541138|adult ependymoma
539326|NCT00541138|adult myxopapillary ependymoma
539327|NCT00541138|adult subependymoma
539328|NCT00541138|adult anaplastic oligodendroglioma
539329|NCT00541138|adult oligodendroglioma
539330|NCT00541138|unspecified adult solid tumor, protocol specific
539331|NCT00541138|adult mixed glioma
539332|NCT00541125|recurrent colon cancer
539333|NCT00541125|stage IV colon cancer
539334|NCT00541125|recurrent rectal cancer
539335|NCT00541125|stage IV rectal cancer
539336|NCT00541125|adenocarcinoma of the colon
539337|NCT00541125|adenocarcinoma of the rectum
539338|NCT00541112|stage III rectal cancer
539339|NCT00541112|stage IV rectal cancer
539340|NCT00541112|adenocarcinoma of the rectum
539341|NCT00541099|stage IIIA non-small cell lung cancer
539342|NCT00541099|stage IIIB non-small cell lung cancer
539343|NCT00541099|stage IV non-small cell lung cancer
539344|NCT00541086|stage IA breast cancer
539345|NCT00541086|stage IB breast cancer
539346|NCT00541086|stage II breast cancer
539347|NCT00541086|stage IIIA breast cancer
539348|NCT00541086|stage IIIB breast cancer
539349|NCT00541086|stage IIIC breast cancer
539350|NCT00541086|estrogen receptor-positive breast cancer
539351|NCT00541086|progesterone receptor-positive breast cancer
539352|NCT00541073|advanced malignant mesothelioma
539353|NCT00541073|recurrent malignant mesothelioma
539354|NCT00541060|caries susceptibility,enamel matrix,candidate genes,mutation
539355|NCT00541047|sexual dysfunction
539356|NCT00541047|urinary complications
539357|NCT00541047|gastrointestinal complications
539358|NCT00541047|adenocarcinoma of the prostate
539359|NCT00541047|stage I prostate cancer
539360|NCT00541047|stage IIB prostate cancer
539361|NCT00541047|stage IIA prostate cancer
539362|NCT00541047|stage III prostate cancer
539363|NCT00541034|B-cell chronic lymphocytic leukemia
539364|NCT00541034|stage I small lymphocytic lymphoma
539365|NCT00541034|stage II small lymphocytic lymphoma
539366|NCT00541034|stage III small lymphocytic lymphoma
539367|NCT00541034|stage IV small lymphocytic lymphoma
539368|NCT00541034|stage I chronic lymphocytic leukemia
539369|NCT00541034|stage II chronic lymphocytic leukemia
539370|NCT00541034|stage III chronic lymphocytic leukemia
539371|NCT00541034|stage IV chronic lymphocytic leukemia
539372|NCT00541021|stage III pancreatic cancer
539373|NCT00541021|stage IV pancreatic cancer
539374|NCT00541021|adenocarcinoma of the pancreas
539375|NCT00541021|recurrent pancreatic cancer
539376|NCT00541008|type 1 papillary renal cell carcinoma
539377|NCT00541008|type 2 papillary renal cell carcinoma
539378|NCT00541008|stage IV renal cell cancer
539379|NCT00541008|stage III renal cell cancer
539380|NCT00540982|unspecified adult solid tumor, protocol specific
539381|NCT00540982|recurrent non-small cell lung cancer
539382|NCT00540982|stage IIIA non-small cell lung cancer
539383|NCT00540982|stage IIIB non-small cell lung cancer
539384|NCT00540982|stage IV non-small cell lung cancer
539385|NCT00540969|bone metastases
539386|NCT00540969|pain
539387|NCT00540969|unspecified adult solid tumor, protocol specific
539388|NCT00540969|stage IV melanoma
539389|NCT00540969|stage IV renal cell cancer
539390|NCT00540956|untreated adult acute myeloid leukemia
539391|NCT00540956|adult acute megakaryoblastic leukemia (M7)
539392|NCT00540956|adult acute minimally differentiated myeloid leukemia (M0)
539393|NCT00540956|adult acute monoblastic leukemia (M5a)
539394|NCT00540956|adult acute monocytic leukemia (M5b)
539395|NCT00540956|adult acute myeloblastic leukemia with maturation (M2)
539396|NCT00540956|adult acute myeloblastic leukemia without maturation (M1)
539397|NCT00540956|adult acute myelomonocytic leukemia (M4)
539398|NCT00540956|adult erythroleukemia (M6a)
539399|NCT00540956|adult pure erythroid leukemia (M6b)
539400|NCT00540956|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
539401|NCT00540956|adult acute myeloid leukemia with inv(16)(p13;q22)
539402|NCT00540956|adult acute myeloid leukemia with t(16;16)(p13;q22)
539403|NCT00540956|adult acute myeloid leukemia with t(8;21)(q22;q22)
539404|NCT00540943|cetuximab
539405|NCT00540943|irinotecan,
539406|NCT00540943|pazopanib,
539407|NCT00540943|Colorectal cancer,
539408|NCT00540904|contrast
539409|NCT00540904|nephropathy
539410|NCT00540904|bicarbonate
539411|NCT00540904|prevention
539412|NCT00540878|Formulation Drug Study
539413|NCT00540865|Homebound Persons
539414|NCT00540865|Case Management
539415|NCT00540865|Problem Solving Therapy
539416|NCT00540852|Breast cancer receiving chemotherapy
539417|NCT00540813|bifurcation stenosis
539418|NCT00540813|Patients with documented ischemia due to a de-novo bifurcation stenosis
539419|NCT00540800|anthracycline pre-treated
539420|NCT00540800|chemotherapy
539421|NCT00540800|first-line
539422|NCT00540800|metastatic breast cancer
539423|NCT00540800|locally advanced breast cancer
539424|NCT00540774|oral cancer
539425|NCT00540774|oral mucositis
539426|NCT00540774|oral stomatitis
539427|NCT00540774|Dry mouth
539428|NCT00540774|Gingivitis
539429|NCT00540761|Coronary Artery Disease
539430|NCT00540761|Atherosclerosis
539431|NCT00540748|first trimester abortion
539432|NCT00540748|oxytocin
539433|NCT00540696|Anemia
539434|NCT00540696|Non-Myeloid Malignancies
539435|NCT00540696|darbepoetin alfa
539436|NCT00540696|chemotherapy
539437|NCT00540670|Coronary artery disease
539438|NCT00540644|Multiple Myeloma
539439|NCT00540644|Revlimid
539440|NCT00540631|House Dust Mite Allergen
539441|NCT00540631|Aluminium hydroxide-adsorbed
539442|NCT00540605|Microbicide
539443|NCT00540605|Pregnancy
539444|NCT00540605|HIV Seronegativity
539445|NCT00540592|Influenza vaccine GSK576389A
539446|NCT00540592|Influenza infection
539447|NCT00540592|Fluarix
539448|NCT00540579|Pancreas
539449|NCT00540579|Untreated
539450|NCT00540579|Advanced
539451|NCT00540579|Gemcitabine
539452|NCT00540579|CC-4047
539453|NCT00540553|SARM,
539454|NCT00540553|FTIH,
539455|NCT00540553|pharmacokinetics
539456|NCT00540527|acute ischemic stroke;thrombolysis;intraarterial thrombolysis
539457|NCT00540514|Advanced Non-Small Cell Lung Cancer
539458|NCT00540501|zanamivir,
539459|NCT00540501|influenza virus,
539460|NCT00540501|healthy volunteer,
539461|NCT00540501|PK, drug interaction,
539462|NCT00540501|IV, and oseltamivir.
539463|NCT00540475|Idiopathic Pulmonary Fibrosis
539464|NCT00540475|Interstitial Lung Disease
539465|NCT00540462|Type II Diabetes Mellitus
539466|NCT00540462|Gastric bypass
539467|NCT00540462|Obese-related diabetes mellitus
539468|NCT00540462|Sugar control
539469|NCT00540462|treatment of obesity related diabetes mellitus
539470|NCT00540449|TMC278-C209
539471|NCT00540449|Antiretroviral
539472|NCT00540449|Non-nucleoside reverse transcriptase inhibitor
539473|NCT00540449|HIV-1
539474|NCT00540449|AIDS
539475|NCT00540449|TMC278-TiDP6-C209
539476|NCT00540449|Treatment Naive
539477|NCT00540436|Ambrisentan
539478|NCT00540436|Pulmonary Arterial Hypertension
539479|NCT00540436|6MWD
539480|NCT00540423|thrombopoietin,
539481|NCT00540423|immunosuppressive therapy,
539482|NCT00540423|eltrombopag,
539483|NCT00540423|idiopathic thrombocytopenic purpura,
539484|NCT00540423|blood platelet,
539485|NCT00540423|splenectomy
539486|NCT00538759|Aortic valve stenosis
539487|NCT00538759|Balloon aortic valvuloplasty
539488|NCT00538759|Aortic valve restenosis
539489|NCT00538733|myeloma
539490|NCT00538733|newly diagnosed multiple myeloma
539491|NCT00538720|Primary Hyperparathyroidism
539492|NCT00538720|PHPT
539493|NCT00538720|Parathyroid glands
539494|NCT00538720|Vitamin D deficiency
539495|NCT00538720|Vitamin D
539496|NCT00538720|Ergocalciferol
539497|NCT00538707|mental stress
539498|NCT00538707|platelet adhesion
539499|NCT00538707|platelet function
539500|NCT00538707|catecholamines
539501|NCT00538694|Moderate to severe community-acquired acute bacterial pneumonia due to S. Pneumoniae
539502|NCT00538668|Prostate
539503|NCT00538668|Prostate Cancer
539504|NCT00538668|Prostate Ca
539505|NCT00538655|amphetamine
539506|NCT00538655|methamphetamine
539507|NCT00538655|addition
539508|NCT00538655|treatment study
539509|NCT00538655|drug use
539510|NCT00538655|modafinil
539511|NCT00538642|schizophrenia
539512|NCT00538642|antipsychotics
539513|NCT00538642|diabetes
539514|NCT00538642|bipolar disorder
539515|NCT00538616|Brain Injury
539516|NCT00538590|ologen
539517|NCT00538590|collagen matrix
539518|NCT00538590|glaucoma
539519|NCT00538590|trabeculectomy
539520|NCT00538590|Mitomycin-C
539521|NCT00538577|Necrotizing fasciitis
539522|NCT00538564|prolonged, painful erection
539523|NCT00538564|priapism
539524|NCT00538564|sickle cell anemia
539525|NCT00538551|HD
539526|NCT00538551|NHL
539527|NCT00538538|Macular Degeneration
539528|NCT00538538|AMD
539529|NCT00538538|Hemorrhage
539530|NCT00538538|Wet AMD
539531|NCT00535353|recurrent colon cancer
539532|NCT00535353|stage IV colon cancer
539533|NCT00535353|recurrent rectal cancer
539534|NCT00535353|stage IV rectal cancer
539535|NCT00535353|stage III rectal cancer
539536|NCT00535353|stage III colon cancer
539537|NCT00540384|Anemia
539538|NCT00540384|Solid tumors
539539|NCT00540384|Multicycle chemotherapy
539540|NCT00540384|NESP
539541|NCT00540371|Port Wine Stain
539542|NCT00540358|Triple negative breast cancer
539543|NCT00540345|chronic hepatitis C
539544|NCT00540345|genotype 2
539545|NCT00540345|rapid virological response
539546|NCT00540345|sustained virological response
539548|NCT00540345|ribavirin
539549|NCT00540345|treatment duration
539550|NCT00540332|Oncology
539551|NCT00540332|KGF
539552|NCT00540332|HNC
539553|NCT00540332|head and neck
539554|NCT00540332|oral mucositis
539555|NCT00540332|OM
539556|NCT00540332|proteinurea
539557|NCT00540332|palifermin
539558|NCT00540332|clinical trial
539559|NCT00540319|Risky behaviors
539560|NCT00540319|Prenatal care
539561|NCT00540319|Substance use
539562|NCT00540319|Domestic violence
539563|NCT00540306|breast tissue
539564|NCT00540280|NSCLC
539565|NCT00540267|Schizophrenia
539566|NCT00540267|Alcohol Abuse
539567|NCT00540267|Bone Density
539568|NCT00540254|Chronic Fatigue
539569|NCT00540254|Insomnia
539570|NCT00540254|Cognitive Behavioral Therapy
539571|NCT00540228|Influenza
539572|NCT00540228|Influenza Vaccine
539573|NCT00540202|Effectiveness
539574|NCT00540202|Oral quinine
539575|NCT00540202|Coartem
539576|NCT00540202|Uncomplicated malaria
539577|NCT00540202|Children
539578|NCT00540189|appendicitis, perforated, children
539579|NCT00540176|Dichloroacetate
539580|NCT00540176|Glioblastoma Multiforme
539581|NCT00540176|Glioma
539582|NCT00540150|Immunotherapy
539583|NCT00540150|Mite
539584|NCT00540150|Asthma
539585|NCT00540150|bronchial provocation
539586|NCT00540150|SIT
539587|NCT00540150|specific immunotherapy
539588|NCT00540137|Antiretroviral therapy
539589|NCT00540137|Neurocognitive function
539590|NCT00540137|Magnetic resonance spectroscopy
539591|NCT00540137|HIV disease
539592|NCT00540137|Treatment Naive
539593|NCT00540111|Soluble fiber
539594|NCT00540111|HIV/aids
539595|NCT00540111|Hypertriglyceridemia
539596|NCT00540111|Cytokines
539597|NCT00540111|Alternative Medicine
539598|NCT00540111|Complementary Medicine
539599|NCT00540098|panic disorder
539600|NCT00540098|pharmacotherapy
539601|NCT00540098|non-pharmacological treatment
539602|NCT00540098|SSRI
539603|NCT00540098|paroxetine
539604|NCT00540098|exercise
539605|NCT00540072|Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
539606|NCT00540059|Prostate carcinoma
539607|NCT00540059|LHRH
539608|NCT00540059|Zoladex
539609|NCT00540046|IUD
539610|NCT00540046|Second trimester termination
539611|NCT00540046|Contraception
539612|NCT00540033|probiotics
539613|NCT00540033|necrotizing enterocolitis
539614|NCT00540033|preterm very low birth weight infants (VLBW)
539615|NCT00540020|Brain Injuries
539616|NCT00540020|Cognition
539617|NCT00540020|Randomized Trials
539618|NCT00540020|Rehabilitation
539619|NCT00540020|Treatment Outcome
539620|NCT00540007|Hodgkin Lymphoma
539621|NCT00540007|Lenalidomide
539622|NCT00540007|Anti-neoplastic agents
539623|NCT00540007|Thalidomide
539624|NCT00539994|Altabax
539625|NCT00539994|SB-275833
539626|NCT00539994|retapamulin
539627|NCT00539994|nasal colonization
539628|NCT00539994|PK
539629|NCT00539994|tolerability
539630|NCT00539994|safety
539631|NCT00539994|efficacy
539632|NCT00539981|Influenza
539633|NCT00539955|intimate partner violence
539634|NCT00539955|alcohol use
539635|NCT00539955|substance use
539636|NCT00539942|Randomized Clinical Trials
539637|NCT00539942|Randomized Controlled Trial
539638|NCT00539942|Venous thrombosis
539639|NCT00539942|Anticoagulant Drugs
539640|NCT00539942|Doppler Ultrasound
539641|NCT00539942|Postoperative complications
539642|NCT00539903|Activity Level
539643|NCT00539877|Gstric cancer
539644|NCT00539877|Pritoneal seeding
539645|NCT00539877|Intraperitoneal chemotherapy
539646|NCT00539877|Irinotecan
539647|NCT00539864|Influenza
539648|NCT00539851|Allogenic Stem Cell Transplantation
539649|NCT00539851|Diabetes Mellitus
539650|NCT00539838|SLE
539651|NCT00539825|Anticholinergic,
539652|NCT00539825|Plethysmography
539653|NCT00539825|Muscarinic Receptor Antagonist,
539654|NCT00539825|COPD,
539655|NCT00539825|FTIH,
539656|NCT00539812|Intimate partner violence
539657|NCT00539812|alcohol use
539658|NCT00539812|substance use
539659|NCT00539799|systemic lupus erythematosus
539660|NCT00539799|lupus nephritis
539661|NCT00539786|Patients with extraesophageal manifestation of gastroesophageal reflux disease
539662|NCT00536926|telemedicine
539663|NCT00536926|lung transplantation
539664|NCT00536926|home spirometry
539665|NCT00536913|Symbicort pMDI
539666|NCT00536913|spacer
539667|NCT00536913|children
539668|NCT00536900|Substance abuse
539669|NCT00536900|Behavior therapy
539670|NCT00536900|representative payee
539671|NCT00536900|cocaine abuse
539672|NCT00536900|alcohol abuse
539673|NCT00536900|case management
539674|NCT00536900|dual diagnosis
539796|NCT00539331|NSCLC
539675|NCT00536874|adenocarcinoma of the pancreas
539676|NCT00536874|stage IA pancreatic cancer
539677|NCT00536874|stage IB pancreatic cancer
539678|NCT00536874|stage IIA pancreatic cancer
539679|NCT00536874|stage IIB pancreatic cancer
539680|NCT00536874|stage III pancreatic cancer
539681|NCT00536861|erlotinib
539682|NCT00536861|cranial radiotherapy
539683|NCT00536848|Probiotics
539684|NCT00536848|HIV
539685|NCT00536848|AIDS
539686|NCT00536848|Diarrhea
539687|NCT00536848|Lactobacillus rhamnosus GR-1
539688|NCT00536848|Lactobacillus reuteri RC-14
539689|NCT00536848|Immune system
539690|NCT00536848|Infectious Diseases
539691|NCT00536848|Complementary Therapies
539692|NCT00536848|Treatment Naive
539693|NCT00539760|domain antibody
539694|NCT00539760|Rheumatoid Arthritis,
539695|NCT00539747|Presymptomatic
539696|NCT00539747|Huntington Disease
539697|NCT00539747|Meaning Making
539698|NCT00539747|Genetic Testing
539699|NCT00539747|HD
539700|NCT00539734|age-related macular degeneration (AMD)
539701|NCT00539734|choroidal neovascularization membrane(CNVM)
539702|NCT00539734|ranibizumab
539703|NCT00539734|anti-vascular endothelial growth factor
539704|NCT00539734|electrophysiology
539705|NCT00539734|electroretinography
539706|NCT00539721|Nausea
539707|NCT00539721|Vomiting
539708|NCT00539708|Non-invasive ventilation
539709|NCT00539708|Hypercapnic respiratory failure
539710|NCT00539708|Mechanical ventilation
539711|NCT00539708|Respiratory failure after extubation
539712|NCT00539695|Stem Cell transplant
539713|NCT00539695|Graft verus host disease
539714|NCT00539695|IL-2
539715|NCT00539695|acute lymphoblastic leukemia
539716|NCT00539695|ALL
539717|NCT00539695|acute myelogenous leukemia
539718|NCT00539695|AML
539719|NCT00539695|chronic myelogenous leukemia
539720|NCT00539695|myelodysplastic syndrome
539721|NCT00539695|myeloproliferative disorder
539722|NCT00539695|Hodgkin lymphoma
539723|NCT00539695|non-Hodgkin lymphoma
539724|NCT00539695|non-malignant diseases requiring allogeneic HSCT
539725|NCT00539656|Cord blood stem cell transplantation
539726|NCT00539656|Ex vivo expansion
539727|NCT00539656|Alternative donor
539728|NCT00539643|Liver Cancer
539729|NCT00539643|Hepatoma
539730|NCT00539643|07-099
539731|NCT00539617|metastatic esophageal cancer
539732|NCT00539617|erlotinib
539733|NCT00539617|folfox
539734|NCT00539617|advanced esophageal cancer
539735|NCT00539617|unresectable esophageal cancer
539736|NCT00539604|Comparison study between MDCT and coronary angiography
539737|NCT00539591|Cutaneous Melanoma
539738|NCT00539565|biliary atresia
539739|NCT00539565|Kasai portoenterostomy
539740|NCT00539565|corticosteroids
539741|NCT00539513|obsessive-compulsive disorder
539742|NCT00539513|OCD
539743|NCT00539513|glutamate
539744|NCT00539513|N-Acetylcysteine
539745|NCT00539513|augmentation
539746|NCT00539500|Neuroblastoma
539747|NCT00539500|ClinicMACS
539748|NCT00539500|CliniMACS
539749|NCT00539500|Stem Cell Transplantation
539750|NCT00539500|Blood And Marrow Transplantation
539751|NCT00539500|Pediatric
539752|NCT00539500|Solid Tumors
539753|NCT00539500|Carboplatin
539754|NCT00539500|Paraplatin
539755|NCT00539500|Etoposide
539756|NCT00539500|VePesid
539757|NCT00539500|Melphalan
539758|NCT00539500|Alkeran
539759|NCT00539500|CD133+ Cells
539760|NCT00539474|ROLL trial
539761|NCT00539474|Minimally invasive surgery
539762|NCT00539474|Non palpable breast cancer
539763|NCT00539435|Diabetes Mellitus
539764|NCT00539435|Pulsatile Intravenous Insulin Therapy
539765|NCT00539435|Diabetic Cardiac Quality of Life
539766|NCT00539435|Cardiac Disease
539767|NCT00539422|breast cancer
539768|NCT00539422|cytochrome 450
539769|NCT00539422|CYP2D6*4
539770|NCT00539422|Ferritin
539771|NCT00539422|oxidative stress
539772|NCT00539422|cancer
539773|NCT00539422|cancer breast
539774|NCT00539409|Diabetes Mellitus
539775|NCT00539409|Pulsatile Intravenous Insulin Therapy
539776|NCT00539409|Diabetic Quality of Life
539777|NCT00539409|Orthostatic Hypotension
539778|NCT00539409|Brittle or Labile diabetes
539779|NCT00539383|Lung cancer
539780|NCT00539383|Breast cancer
539781|NCT00539383|Melanoma
539782|NCT00539383|Hepatocellular carcinoma
539783|NCT00539383|Brain metastases
539784|NCT00539370|Scleritis
539785|NCT00539370|Intermediate Uveitis
539786|NCT00539370|Posterior Uveitis
539787|NCT00539370|Intraocular Inflammatory Disease
539788|NCT00539370|Data Analysis
539789|NCT00539370|Data Collection
539790|NCT00539370|Sample Analysis
539791|NCT00539357|Cranial Electrostimulation Therapy
539792|NCT00539344|Glioblastoma multiforme
539793|NCT00539344|Anaplastic astrocytoma
539794|NCT00539344|Anaplastic oligodendroglioma
539795|NCT00539331|Non-small Cell Lung Cancer
539797|NCT00539331|AZD2171
539798|NCT00539331|Paclitaxel/Carboplatin
539799|NCT00539331|Non-small Cell Lung Cancer (NSCLC)
539800|NCT00539305|selective androgen receptor modulators (SARMs)
539801|NCT00539305|hormone replacement therapy
539802|NCT00539305|age-associated cognitive decline
539803|NCT00539305|testosterone supplementation
539804|NCT00539292|pediatrics
539805|NCT00539292|gastroschisis
539806|NCT00539292|silastic spring-loaded silo
539807|NCT00539279|Cognitive- Behavior Therapy
539808|NCT00539279|Combat Disorders
539809|NCT00539279|Elderly
539810|NCT00539279|Geriatrics
539811|NCT00539279|Implosive therapy
539812|NCT00539279|Neuropsychological Test
539813|NCT00539279|Post-traumatic Stress Disorder
539814|NCT00539279|Psychotherapy
539815|NCT00539279|Randomized Controlled Trial
539816|NCT00539279|Relaxation techniques
539817|NCT00539266|Claudication
539818|NCT00539266|Critical limb ischemia
539819|NCT00539266|Cell therapy
539820|NCT00539266|Bone marrow
539821|NCT00539253|liver cancer
539822|NCT00539253|transarterial chemoembolization
539823|NCT00539240|acid reflux
539824|NCT00539240|acid regurgitation
539825|NCT00539240|esophagitis
539826|NCT00539240|GERD
539827|NCT00539240|heartburn
539828|NCT00539240|pain
539829|NCT00539240|peptic
539830|NCT00539227|Breast Cancer
539831|NCT00539227|Nipple-Areolar Complex
539832|NCT00539227|Mastectomy
539833|NCT00539227|Prophylactic mastectomy
539834|NCT00539227|Immediate reconstruction
539835|NCT00539227|Reconstructive surgery
539836|NCT00539227|Questionnaire
539837|NCT00539227|Survey
539838|NCT00539227|NAC
539839|NCT00539201|GSK706769,
539840|NCT00539201|CCR5 inhibitor,
539841|NCT00539201|HIV
539842|NCT00539188|Borderline Personality Disorder(BPD)
539843|NCT00539188|Dialectical Behavioral Therapy (DBT)
539844|NCT00539188|glutamate
539845|NCT00539188|N-Acetylcysteine
539846|NCT00539188|Borderline Personality Disorder with Self-Injurious Behavior
539847|NCT00539175|diabetes mellitus
539848|NCT00539175|neuropathy
539849|NCT00539175|diabetic neuropathy
539850|NCT00539162|Ovarian Cancer
539851|NCT00539162|CA 125 Algorithm
539852|NCT00539162|Cancer Detection
539853|NCT00539162|Questionnaire
539854|NCT00539162|Survey
539855|NCT00539149|Acute otitis media
539856|NCT00539149|Otitis media with effusion
539857|NCT00539149|Tympanic membrane perforation
539858|NCT00539136|GSK561679,
539859|NCT00539136|Pharmacokinetic,
539860|NCT00539136|healthy volunteers,
539861|NCT00539136|Gamma Scintigraphy,
539862|NCT00539136|PillCam™,
539863|NCT00539136|acoustic vest
539864|NCT00539123|buprenorphine
539865|NCT00539123|drug counseling
539866|NCT00539123|HIV risk reduction counseling
539867|NCT00539097|pediatrics
539868|NCT00539084|microneedles
539869|NCT00539084|microneedle
539870|NCT00539084|intradermal
539871|NCT00539071|schizophrenia
539872|NCT00539071|schizoaffective disorder
539873|NCT00539071|long acting injectable
539874|NCT00539071|treatment resistant
539875|NCT00539045|myocardial infarction, thrombus
539876|NCT00539032|N. meningitidis
539877|NCT00539032|Meningitis
539878|NCT00539032|Meningococcemia
539879|NCT00539019|nutrition assessment
539880|NCT00539019|pediatric
539881|NCT00539006|fluticasone propionate
539882|NCT00539006|seasonal allergic rhinitis
539883|NCT00539006|fluticasone furoate
539884|NCT00539006|experience
539885|NCT00539006|GW685698X
539886|NCT00539006|preference
539887|NCT00538980|Polycythemia Vera
539888|NCT00538980|PV
539889|NCT00538980|P Vera
539890|NCT00538967|Collagenases
539891|NCT00538967|MMP
539892|NCT00538967|Cathepsins
539893|NCT00538967|Doxycycline
539894|NCT00538967|Aneurysm
539895|NCT00538954|Perioperative
539896|NCT00538954|recovery
539897|NCT00538954|nutrition
539898|NCT00538954|enhanced
539899|NCT00538954|laxative
539900|NCT00538941|chocolate,
539901|NCT00538941|heart failure,
539902|NCT00538941|endothelial function,
539903|NCT00538941|platelet adhesion,
539904|NCT00538941|oxidative stress,
539905|NCT00538941|baroreceptor function,
539906|NCT00538928|acute respiratory distress syndrome
539907|NCT00538928|extracorporeal lung support
539908|NCT00538928|hypoxia
539909|NCT00538928|hypercapnia
539910|NCT00538928|acute respiratory distress syndrome (ARDS)
539911|NCT00538915|immunodeficiency
539912|NCT00538915|humoral immunity
539913|NCT00538915|antibody deficiency
539914|NCT00538915|PID
539915|NCT00538915|PIDD
539916|NCT00538902|Humira, methotrexate
539917|NCT00538889|Adult
539918|NCT00538850|unspecified adult solid tumor, protocol specific
539919|NCT00538850|pain
540185|NCT00538850|adult medulloblastoma
540398|NCT00538850|stage IA melanoma
539920|NCT00538850|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
539921|NCT00538850|adult acute myeloid leukemia with inv(16)(p13;q22)
539922|NCT00538850|adult acute myeloid leukemia with t(15;17)(q22;q12)
539923|NCT00538850|adult acute myeloid leukemia with t(16;16)(p13;q22)
539924|NCT00538850|adult acute myeloid leukemia with t(8;21)(q22;q22)
539925|NCT00538850|stage IV chronic lymphocytic leukemia
539926|NCT00538850|accelerated phase chronic myelogenous leukemia
539927|NCT00538850|blastic phase chronic myelogenous leukemia
539928|NCT00538850|chronic myelomonocytic leukemia
539929|NCT00538850|chronic phase chronic myelogenous leukemia
539930|NCT00538850|noncontiguous stage II adult Burkitt lymphoma
539931|NCT00538850|noncontiguous stage II adult diffuse large cell lymphoma
539932|NCT00538850|noncontiguous stage II adult diffuse mixed cell lymphoma
539933|NCT00538850|noncontiguous stage II adult diffuse small cleaved cell lymphoma
539934|NCT00538850|noncontiguous stage II adult immunoblastic large cell lymphoma
539935|NCT00538850|noncontiguous stage II adult lymphoblastic lymphoma
539936|NCT00538850|noncontiguous stage II small lymphocytic lymphoma
539937|NCT00538850|noncontiguous stage II marginal zone lymphoma
539938|NCT00538850|noncontiguous stage II grade 1 follicular lymphoma
539939|NCT00538850|noncontiguous stage II grade 2 follicular lymphoma
539940|NCT00538850|noncontiguous stage II grade 3 follicular lymphoma
539941|NCT00538850|noncontiguous stage II mantle cell lymphoma
539942|NCT00538850|stage III adult Burkitt lymphoma
539943|NCT00538850|stage III adult diffuse large cell lymphoma
539944|NCT00538850|stage III adult diffuse mixed cell lymphoma
539945|NCT00538850|stage III adult diffuse small cleaved cell lymphoma
539946|NCT00538850|stage III adult immunoblastic large cell lymphoma
539947|NCT00538850|stage III adult lymphoblastic lymphoma
539948|NCT00538850|stage III small lymphocytic lymphoma
539949|NCT00538850|stage III marginal zone lymphoma
539950|NCT00538850|stage III grade 1 follicular lymphoma
539951|NCT00538850|stage III grade 2 follicular lymphoma
539952|NCT00538850|stage III grade 3 follicular lymphoma
539953|NCT00538850|stage III mantle cell lymphoma
539954|NCT00538850|stage IV adult Burkitt lymphoma
539955|NCT00538850|stage IV adult diffuse large cell lymphoma
539956|NCT00538850|stage IV adult diffuse mixed cell lymphoma
539957|NCT00538850|stage IV adult diffuse small cleaved cell lymphoma
539958|NCT00538850|stage IV adult immunoblastic large cell lymphoma
539959|NCT00538850|stage IV adult lymphoblastic lymphoma
539960|NCT00538850|stage IV small lymphocytic lymphoma
539961|NCT00538850|stage IV marginal zone lymphoma
539962|NCT00538850|stage IV grade 1 follicular lymphoma
539963|NCT00538850|stage IV grade 2 follicular lymphoma
539964|NCT00538850|stage IV grade 3 follicular lymphoma
539965|NCT00538850|stage IV mantle cell lymphoma
539966|NCT00538850|recurrent adult Burkitt lymphoma
539967|NCT00538850|recurrent adult diffuse large cell lymphoma
539968|NCT00538850|recurrent adult diffuse mixed cell lymphoma
539969|NCT00538850|recurrent adult diffuse small cleaved cell lymphoma
539970|NCT00538850|recurrent adult Hodgkin lymphoma
539971|NCT00538850|recurrent adult immunoblastic large cell lymphoma
539972|NCT00538850|recurrent adult lymphoblastic lymphoma
539973|NCT00538850|recurrent cutaneous T-cell non-Hodgkin lymphoma
539974|NCT00538850|recurrent small lymphocytic lymphoma
539975|NCT00538850|recurrent marginal zone lymphoma
539976|NCT00538850|recurrent grade 1 follicular lymphoma
539977|NCT00538850|recurrent grade 2 follicular lymphoma
539978|NCT00538850|recurrent grade 3 follicular lymphoma
539979|NCT00538850|recurrent mantle cell lymphoma
539980|NCT00538850|recurrent mycosis fungoides/Sezary syndrome
539981|NCT00538850|stage I multiple myeloma
539982|NCT00538850|stage II multiple myeloma
539983|NCT00538850|stage III multiple myeloma
539984|NCT00538850|de novo myelodysplastic syndromes
539985|NCT00538850|myelodysplastic/myeloproliferative neoplasm, unclassifiable
539986|NCT00538850|previously treated myelodysplastic syndromes
539987|NCT00538850|secondary myelodysplastic syndromes
539988|NCT00538850|atypical chronic myeloid leukemia, BCR-ABL1 negative
539989|NCT00538850|stage II adult Hodgkin lymphoma
539990|NCT00538850|stage III adult Hodgkin lymphoma
539991|NCT00538850|stage IV adult Hodgkin lymphoma
539992|NCT00538850|contiguous stage II adult Burkitt lymphoma
539993|NCT00538850|stage I adult Burkitt lymphoma
539994|NCT00538850|contiguous stage II adult diffuse large cell lymphoma
539995|NCT00538850|contiguous stage II adult diffuse mixed cell lymphoma
539996|NCT00538850|contiguous stage II adult diffuse small cleaved cell lymphoma
539997|NCT00538850|contiguous stage II small lymphocytic lymphoma
539998|NCT00538850|contiguous stage II marginal zone lymphoma
539999|NCT00538850|stage I adult diffuse large cell lymphoma
540000|NCT00538850|stage I adult diffuse mixed cell lymphoma
540001|NCT00538850|stage I adult diffuse small cleaved cell lymphoma
540002|NCT00538850|stage I small lymphocytic lymphoma
540003|NCT00538850|stage I marginal zone lymphoma
540004|NCT00538850|contiguous stage II grade 1 follicular lymphoma
540005|NCT00538850|contiguous stage II grade 2 follicular lymphoma
540006|NCT00538850|contiguous stage II grade 3 follicular lymphoma
540007|NCT00538850|stage I grade 1 follicular lymphoma
540008|NCT00538850|stage I grade 2 follicular lymphoma
540009|NCT00538850|stage I grade 3 follicular lymphoma
540010|NCT00538850|contiguous stage II mantle cell lymphoma
540011|NCT00538850|stage I mantle cell lymphoma
540012|NCT00538850|contiguous stage II adult immunoblastic large cell lymphoma
540013|NCT00538850|stage I adult immunoblastic large cell lymphoma
540014|NCT00538850|contiguous stage II adult lymphoblastic lymphoma
540015|NCT00538850|stage I adult lymphoblastic lymphoma
540016|NCT00538850|refractory multiple myeloma
540017|NCT00538850|anaplastic large cell lymphoma
540018|NCT00538850|angioimmunoblastic T-cell lymphoma
540019|NCT00538850|recurrent adult T-cell leukemia/lymphoma
540020|NCT00538850|stage I adult T-cell leukemia/lymphoma
540021|NCT00538850|stage II adult T-cell leukemia/lymphoma
540022|NCT00538850|stage III adult T-cell leukemia/lymphoma
540023|NCT00538850|stage IV adult T-cell leukemia/lymphoma
540024|NCT00538850|stage I cutaneous T-cell non-Hodgkin lymphoma
540025|NCT00538850|stage II cutaneous T-cell non-Hodgkin lymphoma
540026|NCT00538850|stage III cutaneous T-cell non-Hodgkin lymphoma
540027|NCT00538850|stage IV cutaneous T-cell non-Hodgkin lymphoma
540028|NCT00538850|stage I mycosis fungoides/Sezary syndrome
540029|NCT00538850|stage II mycosis fungoides/Sezary syndrome
540030|NCT00538850|stage III mycosis fungoides/Sezary syndrome
540031|NCT00538850|stage IV mycosis fungoides/Sezary syndrome
540032|NCT00538850|chronic eosinophilic leukemia
540033|NCT00538850|primary myelofibrosis
540034|NCT00538850|chronic neutrophilic leukemia
540035|NCT00538850|essential thrombocythemia
540036|NCT00538850|polycythemia vera
540037|NCT00538850|relapsing chronic myelogenous leukemia
540038|NCT00538850|T-cell large granular lymphocyte leukemia
540039|NCT00538850|recurrent adult acute lymphoblastic leukemia
540040|NCT00538850|recurrent adult acute myeloid leukemia
540041|NCT00538850|untreated adult acute lymphoblastic leukemia
540042|NCT00538850|untreated adult acute myeloid leukemia
540043|NCT00538850|secondary acute myeloid leukemia
540044|NCT00538850|acute undifferentiated leukemia
540045|NCT00538850|refractory chronic lymphocytic leukemia
540046|NCT00538850|stage 0 chronic lymphocytic leukemia
540047|NCT00538850|stage I chronic lymphocytic leukemia
540048|NCT00538850|stage II chronic lymphocytic leukemia
540049|NCT00538850|stage III chronic lymphocytic leukemia
540050|NCT00538850|refractory hairy cell leukemia
540051|NCT00538850|progressive hairy cell leukemia, initial treatment
540052|NCT00538850|prolymphocytic leukemia
540053|NCT00538850|recurrent adult grade III lymphomatoid granulomatosis
540054|NCT00538850|Waldenström macroglobulinemia
540055|NCT00538850|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
540056|NCT00538850|nodal marginal zone B-cell lymphoma
540057|NCT00538850|splenic marginal zone lymphoma
540058|NCT00538850|post-transplant lymphoproliferative disorder
540059|NCT00538850|extramedullary plasmacytoma
540060|NCT00538850|isolated plasmacytoma of bone
540061|NCT00538850|monoclonal gammopathy of undetermined significance
540062|NCT00538850|primary systemic amyloidosis
540063|NCT00538850|adult acute lymphoblastic leukemia in remission
540064|NCT00538850|adult acute myeloid leukemia in remission
540065|NCT00538850|adult grade III lymphomatoid granulomatosis
540066|NCT00538850|AIDS-related peripheral/systemic lymphoma
540067|NCT00538850|AIDS-related primary CNS lymphoma
540068|NCT00538850|intraocular lymphoma
540069|NCT00538850|meningeal chronic myelogenous leukemia
540070|NCT00538850|primary central nervous system non-Hodgkin lymphoma
540071|NCT00538850|primary central nervous system Hodgkin lymphoma
540072|NCT00538850|stage I adult Hodgkin lymphoma
540073|NCT00538850|recurrent squamous cell carcinoma of the hypopharynx
540074|NCT00538850|stage I squamous cell carcinoma of the hypopharynx
540075|NCT00538850|stage II squamous cell carcinoma of the hypopharynx
540076|NCT00538850|stage III squamous cell carcinoma of the hypopharynx
540077|NCT00538850|stage IV squamous cell carcinoma of the hypopharynx
540078|NCT00538850|recurrent squamous cell carcinoma of the larynx
540079|NCT00538850|recurrent verrucous carcinoma of the larynx
540080|NCT00538850|stage I squamous cell carcinoma of the larynx
540081|NCT00538850|stage I verrucous carcinoma of the larynx
540082|NCT00538850|stage II squamous cell carcinoma of the larynx
540083|NCT00538850|stage II verrucous carcinoma of the larynx
540084|NCT00538850|stage III squamous cell carcinoma of the larynx
540085|NCT00538850|stage III verrucous carcinoma of the larynx
540086|NCT00538850|stage IV squamous cell carcinoma of the larynx
540087|NCT00538850|stage IV verrucous carcinoma of the larynx
540088|NCT00538850|recurrent adenoid cystic carcinoma of the oral cavity
540089|NCT00538850|recurrent mucoepidermoid carcinoma of the oral cavity
540090|NCT00538850|recurrent verrucous carcinoma of the oral cavity
540091|NCT00538850|stage I adenoid cystic carcinoma of the oral cavity
540092|NCT00538850|stage I mucoepidermoid carcinoma of the oral cavity
540093|NCT00538850|stage I verrucous carcinoma of the oral cavity
540094|NCT00538850|stage II adenoid cystic carcinoma of the oral cavity
540095|NCT00538850|stage II mucoepidermoid carcinoma of the oral cavity
540096|NCT00538850|stage II verrucous carcinoma of the oral cavity
540097|NCT00538850|stage III adenoid cystic carcinoma of the oral cavity
540098|NCT00538850|stage III mucoepidermoid carcinoma of the oral cavity
540099|NCT00538850|stage III verrucous carcinoma of the oral cavity
540100|NCT00538850|stage IV adenoid cystic carcinoma of the oral cavity
540101|NCT00538850|stage IV mucoepidermoid carcinoma of the oral cavity
540102|NCT00538850|stage IV verrucous carcinoma of the oral cavity
540103|NCT00538850|stage I squamous cell carcinoma of the lip and oral cavity
540104|NCT00538850|stage II squamous cell carcinoma of the lip and oral cavity
540105|NCT00538850|stage III squamous cell carcinoma of the lip and oral cavity
540106|NCT00538850|stage IV squamous cell carcinoma of the lip and oral cavity
540107|NCT00538850|recurrent basal cell carcinoma of the lip
540108|NCT00538850|recurrent squamous cell carcinoma of the lip and oral cavity
540109|NCT00538850|stage I basal cell carcinoma of the lip
540110|NCT00538850|stage II basal cell carcinoma of the lip
540111|NCT00538850|stage III basal cell carcinoma of the lip
540112|NCT00538850|stage IV basal cell carcinoma of the lip
540113|NCT00538850|metastatic squamous neck cancer with occult primary squamous cell carcinoma
540114|NCT00538850|recurrent metastatic squamous neck cancer with occult primary
540115|NCT00538850|untreated metastatic squamous neck cancer with occult primary
540116|NCT00538850|recurrent lymphoepithelioma of the nasopharynx
540117|NCT00538850|recurrent squamous cell carcinoma of the nasopharynx
540118|NCT00538850|stage I lymphoepithelioma of the nasopharynx
540119|NCT00538850|stage I squamous cell carcinoma of the nasopharynx
540120|NCT00538850|stage II lymphoepithelioma of the nasopharynx
540121|NCT00538850|stage II squamous cell carcinoma of the nasopharynx
540122|NCT00538850|stage III lymphoepithelioma of the nasopharynx
540123|NCT00538850|stage III squamous cell carcinoma of the nasopharynx
540124|NCT00538850|stage IV lymphoepithelioma of the nasopharynx
540125|NCT00538850|stage IV squamous cell carcinoma of the nasopharynx
540126|NCT00538850|recurrent lymphoepithelioma of the oropharynx
540127|NCT00538850|recurrent squamous cell carcinoma of the oropharynx
540128|NCT00538850|stage I lymphoepithelioma of the oropharynx
540129|NCT00538850|stage I squamous cell carcinoma of the oropharynx
540130|NCT00538850|stage II lymphoepithelioma of the oropharynx
540131|NCT00538850|stage II squamous cell carcinoma of the oropharynx
540132|NCT00538850|stage III lymphoepithelioma of the oropharynx
540133|NCT00538850|stage III squamous cell carcinoma of the oropharynx
540134|NCT00538850|stage IV lymphoepithelioma of the oropharynx
540135|NCT00538850|stage IV squamous cell carcinoma of the oropharynx
540136|NCT00538850|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
540137|NCT00538850|recurrent inverted papilloma of the paranasal sinus and nasal cavity
540138|NCT00538850|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
540139|NCT00538850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
540140|NCT00538850|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
540141|NCT00538850|stage I inverted papilloma of the paranasal sinus and nasal cavity
540142|NCT00538850|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
540143|NCT00538850|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
540144|NCT00538850|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
540145|NCT00538850|stage II inverted papilloma of the paranasal sinus and nasal cavity
540146|NCT00538850|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
540147|NCT00538850|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
540148|NCT00538850|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
540149|NCT00538850|stage III inverted papilloma of the paranasal sinus and nasal cavity
540150|NCT00538850|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
540151|NCT00538850|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
540152|NCT00538850|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
540153|NCT00538850|stage IV inverted papilloma of the paranasal sinus and nasal cavity
540154|NCT00538850|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
540155|NCT00538850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
540156|NCT00538850|high-grade salivary gland mucoepidermoid carcinoma
540157|NCT00538850|low-grade salivary gland mucoepidermoid carcinoma
540158|NCT00538850|recurrent salivary gland cancer
540159|NCT00538850|salivary gland acinic cell tumor
540160|NCT00538850|salivary gland adenocarcinoma
540161|NCT00538850|salivary gland adenoid cystic carcinoma
540162|NCT00538850|salivary gland anaplastic carcinoma
540163|NCT00538850|salivary gland malignant mixed cell type tumor
540164|NCT00538850|salivary gland poorly differentiated carcinoma
540165|NCT00538850|salivary gland squamous cell carcinoma
540166|NCT00538850|stage I salivary gland cancer
540167|NCT00538850|stage II salivary gland cancer
540168|NCT00538850|stage III salivary gland cancer
540169|NCT00538850|stage IV salivary gland cancer
540170|NCT00538850|adult grade I meningioma
540171|NCT00538850|adult choroid plexus tumor
540172|NCT00538850|adult craniopharyngioma
540173|NCT00538850|adult myxopapillary ependymoma
540174|NCT00538850|adult diffuse astrocytoma
540175|NCT00538850|adult pilocytic astrocytoma
540176|NCT00538850|adult pineocytoma
540177|NCT00538850|adult ependymoma
540178|NCT00538850|adult subependymoma
540179|NCT00538850|adult oligodendroglioma
540180|NCT00538850|adult subependymal giant cell astrocytoma
540181|NCT00538850|meningeal melanocytoma
540182|NCT00538850|adult meningeal hemangiopericytoma
540183|NCT00538850|adult pineal gland astrocytoma
540184|NCT00538850|adult central nervous system germ cell tumor
540186|NCT00538850|adult supratentorial primitive neuroectodermal tumor (PNET)
540187|NCT00538850|adult ependymoblastoma
540188|NCT00538850|adult anaplastic astrocytoma
540189|NCT00538850|adult anaplastic ependymoma
540190|NCT00538850|adult glioblastoma
540191|NCT00538850|adult gliosarcoma
540192|NCT00538850|adult giant cell glioblastoma
540193|NCT00538850|adult grade III meningioma
540194|NCT00538850|adult anaplastic oligodendroglioma
540195|NCT00538850|adult pineoblastoma
540196|NCT00538850|adult mixed glioma
540197|NCT00538850|recurrent adult brain tumor
540198|NCT00538850|adult anaplastic meningioma
540199|NCT00538850|adult papillary meningioma
540200|NCT00538850|adult brain stem glioma
540201|NCT00538850|stage IA cervical cancer
540202|NCT00538850|stage IB cervical cancer
540203|NCT00538850|stage IIA cervical cancer
540204|NCT00538850|stage IIB cervical cancer
540205|NCT00538850|stage III cervical cancer
540206|NCT00538850|stage IVA cervical cancer
540207|NCT00538850|stage IVB cervical cancer
540208|NCT00538850|recurrent cervical cancer
540209|NCT00538850|recurrent endometrial carcinoma
540210|NCT00538850|stage I endometrial carcinoma
540211|NCT00538850|stage II endometrial carcinoma
540212|NCT00538850|stage III endometrial carcinoma
540213|NCT00538850|stage IV endometrial carcinoma
540214|NCT00538850|fallopian tube cancer
540215|NCT00538850|recurrent ovarian epithelial cancer
540216|NCT00538850|recurrent ovarian germ cell tumor
540217|NCT00538850|stage I ovarian epithelial cancer
540218|NCT00538850|stage I ovarian germ cell tumor
540219|NCT00538850|stage II ovarian epithelial cancer
540220|NCT00538850|stage II ovarian germ cell tumor
540221|NCT00538850|stage III ovarian epithelial cancer
540222|NCT00538850|stage III ovarian germ cell tumor
540223|NCT00538850|stage IV ovarian epithelial cancer
540224|NCT00538850|stage IV ovarian germ cell tumor
540225|NCT00538850|ovarian sarcoma
540226|NCT00538850|ovarian stromal cancer
540227|NCT00538850|recurrent uterine sarcoma
540228|NCT00538850|stage I uterine sarcoma
540229|NCT00538850|stage II uterine sarcoma
540230|NCT00538850|stage III uterine sarcoma
540231|NCT00538850|stage IV uterine sarcoma
540232|NCT00538850|recurrent colon cancer
540233|NCT00538850|stage I colon cancer
540234|NCT00538850|stage II colon cancer
540235|NCT00538850|stage III colon cancer
540236|NCT00538850|stage IV colon cancer
540237|NCT00538850|recurrent bladder cancer
540238|NCT00538850|recurrent gallbladder cancer
540239|NCT00538850|stage I bladder cancer
540240|NCT00538850|stage II bladder cancer
540241|NCT00538850|stage III bladder cancer
540242|NCT00538850|stage IV bladder cancer
540243|NCT00538850|recurrent gastric cancer
540244|NCT00538850|stage I gastric cancer
540245|NCT00538850|stage II gastric cancer
540246|NCT00538850|stage III gastric cancer
540247|NCT00538850|stage IV gastric cancer
540248|NCT00538850|advanced adult primary liver cancer
540249|NCT00538850|recurrent small intestine cancer
540250|NCT00538850|localized transitional cell cancer of the renal pelvis and ureter
540251|NCT00538850|metastatic transitional cell cancer of the renal pelvis and ureter
540252|NCT00538850|recurrent renal cell cancer
540253|NCT00538850|recurrent transitional cell cancer of the renal pelvis and ureter
540254|NCT00538850|regional transitional cell cancer of the renal pelvis and ureter
540255|NCT00538850|stage I renal cell cancer
540256|NCT00538850|stage II renal cell cancer
540257|NCT00538850|stage III renal cell cancer
540258|NCT00538850|stage IV renal cell cancer
540259|NCT00538850|distal urethral cancer
540260|NCT00538850|proximal urethral cancer
540261|NCT00538850|recurrent urethral cancer
540262|NCT00538850|urethral cancer associated with invasive bladder cancer
540263|NCT00538850|stage I adrenocortical carcinoma
540264|NCT00538850|stage II adrenocortical carcinoma
540265|NCT00538850|stage III adrenocortical carcinoma
540266|NCT00538850|stage IV adrenocortical carcinoma
540267|NCT00538850|recurrent adrenocortical carcinoma
540268|NCT00538850|extragonadal germ cell tumor
540269|NCT00538850|localized gastrointestinal carcinoid tumor
540270|NCT00538850|metastatic gastrointestinal carcinoid tumor
540271|NCT00538850|recurrent gastrointestinal carcinoid tumor
540272|NCT00538850|regional gastrointestinal carcinoid tumor
540273|NCT00538850|gastrinoma
540274|NCT00538850|insulinoma
540275|NCT00538850|WDHA syndrome
540276|NCT00538850|glucagonoma
540277|NCT00538850|pancreatic polypeptide tumor
540278|NCT00538850|somatostatinoma
540279|NCT00538850|recurrent islet cell carcinoma
540280|NCT00538850|carcinoma of the appendix
540281|NCT00538850|localized extrahepatic bile duct cancer
540282|NCT00538850|recurrent extrahepatic bile duct cancer
540283|NCT00538850|unresectable extrahepatic bile duct cancer
540284|NCT00538850|localized gallbladder cancer
540285|NCT00538850|unresectable gallbladder cancer
540286|NCT00538850|gastrointestinal stromal tumor
540287|NCT00538850|localized resectable adult primary liver cancer
540288|NCT00538850|localized unresectable adult primary liver cancer
540289|NCT00538850|recurrent adult primary liver cancer
540290|NCT00538850|stage I pancreatic cancer
540291|NCT00538850|stage II pancreatic cancer
540292|NCT00538850|stage III pancreatic cancer
540293|NCT00538850|stage IV pancreatic cancer
540294|NCT00538850|recurrent pancreatic cancer
540295|NCT00538850|small intestine adenocarcinoma
540296|NCT00538850|small intestine leiomyosarcoma
540297|NCT00538850|small intestine lymphoma
540298|NCT00538850|stage I non-small cell lung cancer
540299|NCT00538850|stage II non-small cell lung cancer
540300|NCT00538850|stage IIIA non-small cell lung cancer
540301|NCT00538850|stage IIIB non-small cell lung cancer
540302|NCT00538850|stage IV non-small cell lung cancer
540303|NCT00538850|recurrent non-small cell lung cancer
540304|NCT00538850|pulmonary carcinoid tumor
540305|NCT00538850|extensive stage small cell lung cancer
540306|NCT00538850|limited stage small cell lung cancer
540307|NCT00538850|recurrent small cell lung cancer
540308|NCT00538850|liver metastases
540309|NCT00538850|lung metastases
540310|NCT00538850|primary peritoneal cavity cancer
540311|NCT00538850|lung papilloma
540312|NCT00538850|peripheral primitive neuroectodermal tumor of the kidney
540313|NCT00538850|clear cell sarcoma of the kidney
540314|NCT00538850|rhabdoid tumor of the kidney
540315|NCT00538850|congenital mesoblastic nephroma
540316|NCT00538850|stage II breast cancer
540317|NCT00538850|stage IIIA breast cancer
540318|NCT00538850|stage IIIB breast cancer
540319|NCT00538850|stage IIIC breast cancer
540320|NCT00538850|stage IV breast cancer
540321|NCT00538850|recurrent breast cancer
540322|NCT00538850|male breast cancer
540323|NCT00538850|breast cancer in situ
540324|NCT00538850|localized osteosarcoma
540325|NCT00538850|metastatic osteosarcoma
540326|NCT00538850|recurrent osteosarcoma
540327|NCT00538850|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
540328|NCT00538850|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
540329|NCT00538850|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
540330|NCT00538850|chondrosarcoma
540331|NCT00538850|malignant giant cell tumor of bone
540332|NCT00538850|desmoid tumor
540333|NCT00538850|stage I adult soft tissue sarcoma
540334|NCT00538850|stage II adult soft tissue sarcoma
540335|NCT00538850|stage III adult soft tissue sarcoma
540336|NCT00538850|stage IV adult soft tissue sarcoma
540337|NCT00538850|recurrent adult soft tissue sarcoma
540338|NCT00538850|recurrent thymoma and thymic carcinoma
540339|NCT00538850|advanced malignant mesothelioma
540340|NCT00538850|localized malignant mesothelioma
540341|NCT00538850|recurrent malignant mesothelioma
540342|NCT00538850|phosphaturic mesenchymal tumor
540343|NCT00538850|stage I malignant testicular germ cell tumor
540344|NCT00538850|stage II malignant testicular germ cell tumor
540345|NCT00538850|stage III malignant testicular germ cell tumor
540346|NCT00538850|recurrent malignant testicular germ cell tumor
540347|NCT00538850|stage 0 penile cancer
540348|NCT00538850|stage I penile cancer
540349|NCT00538850|stage II penile cancer
540350|NCT00538850|stage III penile cancer
540351|NCT00538850|stage IV penile cancer
540352|NCT00538850|recurrent penile cancer
540353|NCT00538850|stage I prostate cancer
540354|NCT00538850|stage IIB prostate cancer
540355|NCT00538850|stage IIA prostate cancer
540356|NCT00538850|stage III prostate cancer
540357|NCT00538850|stage IV prostate cancer
540358|NCT00538850|recurrent prostate cancer
540359|NCT00538850|stage 0 vaginal cancer
540360|NCT00538850|stage I vaginal cancer
540361|NCT00538850|stage II vaginal cancer
540362|NCT00538850|stage III vaginal cancer
540363|NCT00538850|stage IVA vaginal cancer
540364|NCT00538850|stage IVB vaginal cancer
540365|NCT00538850|recurrent vaginal cancer
540366|NCT00538850|stage 0 vulvar cancer
540367|NCT00538850|stage I vulvar cancer
540368|NCT00538850|stage II vulvar cancer
540369|NCT00538850|stage III vulvar cancer
540370|NCT00538850|stage IVB vulvar cancer
540371|NCT00538850|recurrent vulvar cancer
540372|NCT00538850|stage 0 anal cancer
540373|NCT00538850|stage I anal cancer
540374|NCT00538850|stage II anal cancer
540375|NCT00538850|stage IIIA anal cancer
540376|NCT00538850|stage IIIB anal cancer
540377|NCT00538850|stage IV anal cancer
540378|NCT00538850|recurrent anal cancer
540379|NCT00538850|stage 0 rectal cancer
540380|NCT00538850|stage I rectal cancer
540381|NCT00538850|stage II rectal cancer
540382|NCT00538850|stage III rectal cancer
540383|NCT00538850|stage IV rectal cancer
540384|NCT00538850|recurrent rectal cancer
540385|NCT00538850|stage 0 esophageal cancer
540386|NCT00538850|stage I esophageal cancer
540387|NCT00538850|stage II esophageal cancer
540388|NCT00538850|stage III esophageal cancer
540389|NCT00538850|stage IV esophageal cancer
540390|NCT00538850|recurrent esophageal cancer
540391|NCT00538850|stage I thymoma
540392|NCT00538850|stage II thymoma
540393|NCT00538850|stage III thymoma
540394|NCT00538850|stage IVA thymoma
540395|NCT00538850|stage IVB thymoma
540396|NCT00538850|recurrent melanoma
540397|NCT00538850|stage 0 melanoma
540399|NCT00538850|stage IB melanoma
540400|NCT00538850|stage IIA melanoma
540401|NCT00538850|stage IIB melanoma
540402|NCT00538850|stage IIC melanoma
540403|NCT00538850|stage IIIA melanoma
540404|NCT00538850|stage IIIB melanoma
540405|NCT00538850|stage IIIC melanoma
540406|NCT00538850|stage IV melanoma
540407|NCT00538824|myeloma
540408|NCT00538824|relapsed or refractory multiple myeloma
540409|NCT00538798|Pharmacokinetics
540410|NCT00538798|Binding Potential
540411|NCT00538798|Glutamate
540412|NCT00538798|Positron Emission Tomography
540413|NCT00538798|Metabolic Glutamate Receptors
540414|NCT00538798|Healthy Volunteer
540415|NCT00538798|HV
540416|NCT00538785|Synagis, motavizumab, palivizumab, children, MEDI-524, RSV, congenital hear disease
540417|NCT00538772|Metastatic Renal Cell Carcinoma
540418|NCT00538772|Biomarkers
540419|NCT00538772|Biomarkers in patients with Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
540420|NCT00538512|Influenza
540421|NCT00538512|Live attenuated influenza vaccine
540422|NCT00538512|Inactivated influenza vaccine
540423|NCT00538512|Vaccine Efficacy
540424|NCT00538499|pain
540425|NCT00538499|perioperative/postoperative complications
540426|NCT00538486|Hypertension
540427|NCT00538486|Abdominal obesity
540428|NCT00538486|Treatment
540429|NCT00538473|GSK Bio's influenza vaccine GSK576389A
540430|NCT00538473|Influenza Infection
540431|NCT00538473|Fluarix
540432|NCT00538460|tomography
540433|NCT00538460|coronary artery disease
540434|NCT00538460|magnetic resonance imaging
540435|NCT00538447|CML
540436|NCT00538434|Eosinophilic Esophagitis
540437|NCT00538434|GERD
540438|NCT00538434|EE
540439|NCT00538434|Reslizumab
540440|NCT00538434|IL-5
540441|NCT00538434|Interleukin-5
540442|NCT00538434|Cinquil
540443|NCT00538421|propofol
540444|NCT00538421|Anaesthesia
540445|NCT00538421|Sevoflurane
540446|NCT00538421|Abdominal
540447|NCT00538421|Aortic
540448|NCT00538421|Aneurysm
540449|NCT00538408|Magnetic resonance
540450|NCT00538408|whole body
540451|NCT00538408|angiography
540452|NCT00538408|vasovist
540453|NCT00538408|gadofosveset
540454|NCT00538408|dotarem
540455|NCT00538408|blood pool agent
540456|NCT00538382|Malaria
540457|NCT00538382|Pregnancy
540458|NCT00538382|Artesunate
540459|NCT00538382|Pharmacokinetics
540460|NCT00538382|Pharmacodynamics
540461|NCT00538382|Democratic Republic of Congo
540462|NCT00538369|Nursing
540463|NCT00538369|critical care
540464|NCT00538369|sedation assessment
540465|NCT00538369|Bispectral index
540466|NCT00538356|Heart failure
540467|NCT00538356|Rehospitalization:
540468|NCT00538356|Packer composite score
540469|NCT00538356|Home Monitoring
540470|NCT00538356|Cardiac resynchronization therapy
540471|NCT00538356|Implantable cardioverter-defibrillator
540472|NCT00538343|brain metastases
540473|NCT00538343|breast cancer
540474|NCT00536835|Non-Hodgkins Lymphoma
540475|NCT00536835|Cancer
540476|NCT00536835|First time in human
540477|NCT00536835|PLK1 inhibitor
540478|NCT00536835|Advanced Solid Tumor
540479|NCT00536835|GSK461364
540480|NCT00536822|rehabilitation
540481|NCT00536822|pediatrics
540482|NCT00536809|fluoropyrimidines cancers
540483|NCT00536809|Metastatic Colorectal Cancer
540484|NCT00536809|Advanced Colorectal Cancer
540485|NCT00536809|oxaliplatin
540486|NCT00536809|lapatinib
540487|NCT00536809|capecitabine
540488|NCT00536796|Hyperlipidemia
540489|NCT00536796|Need-to-treat
540490|NCT00536796|NIS
540491|NCT00536796|Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes
540492|NCT00536783|Psychiatry
540493|NCT00536783|Antipsychotic
540494|NCT00536783|Psychopharmacology
540495|NCT00536783|Clinical Trial
540496|NCT00536783|Open Label
540497|NCT00536783|Schizophrenia
540498|NCT00536783|Sensory Gating
540499|NCT00536783|Attention
540500|NCT00536783|Memory
540501|NCT00536731|Asthma
540502|NCT00536731|Symbicort
540503|NCT00536718|invasive lobular breast carcinoma with predominant in situ component
540504|NCT00536718|invasive lobular breast carcinoma
540505|NCT00536718|lobular breast carcinoma in situ
540506|NCT00536705|asthma
540507|NCT00536705|child
540508|NCT00536705|transforming growth factor beta(TGF-β)
540509|NCT00536705|Leukotriene Antagonists(Montelukast)
540510|NCT00536692|macular edema
540511|NCT00536692|DME
540512|NCT00536692|diabetic
540513|NCT00536692|mecamylamine
540514|NCT00536692|Comentis
540515|NCT00536679|GSK163090
540516|NCT00536679|Relative Bioavailability
540517|NCT00536679|Food Effect
540518|NCT00536679|Randomised
540519|NCT00536666|Chronic kidney disease
540520|NCT00536666|Aneamia
540521|NCT00536666|Iron oligosaccharide
540522|NCT00536666|Chronic kidney disease patients
540523|NCT00536653|prostate cancer
540524|NCT00536653|bone density
540525|NCT00536653|osteoporosis
540526|NCT00536653|androgen antagonists
540527|NCT00536640|Non Small Cell Lung Carcinoma (NSCLC Stage III an IV)
540528|NCT00536627|DNA vaccine
540529|NCT00538317|Acute myocardial infarction,
540530|NCT00538317|GPIIbIIIa inhibitors,
540531|NCT00538317|primary angioplasty,
540532|NCT00538317|tirofiban
540533|NCT00538291|recurrent colon cancer
540534|NCT00538291|stage IV colon cancer
540535|NCT00538291|recurrent rectal cancer
540536|NCT00538291|stage IV rectal cancer
540537|NCT00538278|AML
540538|NCT00538265|liver transplantation, hepatitis C virus, immunoprophylaxis
540539|NCT00538252|drug use, antisocial behavior, early intervention, prevention
540540|NCT00538213|Influenza vaccine GSK576389A
540541|NCT00538213|Fluarix
540542|NCT00538213|Influenza infection
540543|NCT00538200|Nutrition
540544|NCT00538200|COPD
540545|NCT00538161|Acute lung injury
540546|NCT00538161|cardiac surgery
540547|NCT00538161|The incidence of ARDS after elective cardiac surgery is 1-3%
540548|NCT00538161|The impairment of lung function and oxygenation may occur in 20-80% of patients undergoing surgery.
540549|NCT00538161|The purpose of this study is to assess the efficacy of low tidal volume ventilation.
540550|NCT00538161|Reducing interleukin and cytokine production may prevent or reduce the incidence of acute lung injury.
540551|NCT00538135|randomised controlled trial
540552|NCT00538135|borderline personality disorder
540553|NCT00538135|cognitive behavioural therapy
540554|NCT00538135|treatment as usual
540555|NCT00538122|schizophrenia
540556|NCT00538122|schizoaffective disorder
540557|NCT00538122|bipolar disorder
540558|NCT00538122|antipsychotic drug treatment
540559|NCT00538122|safety
540560|NCT00538122|arrythmias
540561|NCT00538109|CML in Blast Crisis
540562|NCT00538109|Accelerated Phase oe Chronic Phase
540563|NCT00538096|B-cell Non-Hodgkin's Lymphoma
540564|NCT00538083|Cocoa
540565|NCT00538083|Overweight adults
540566|NCT00538083|Endothelial function
540567|NCT00538083|Blood pressure
540568|NCT00538083|Cardiovascular disease risk
540569|NCT00538083|Dark chocolate
540570|NCT00538083|Sugar
540571|NCT00538070|Sarcosine
540572|NCT00538070|Glycine
540573|NCT00538070|Magnetic Resonance Spectroscopy
540574|NCT00538070|Schizophrenia
540575|NCT00538057|Healthy volunteers
540576|NCT00538044|pulmonary hypertension
540577|NCT00538044|simvastatin
540578|NCT00538044|advanced pulmonary hypertension secondary to congenital heart disease
540579|NCT00538044|advanced pulmonary hypertension secondary to chronic pulmonary embolism
540580|NCT00538005|recurrent melanoma
540581|NCT00538005|stage IV melanoma
540582|NCT00537992|combined surgery,
540583|NCT00537992|cataract surgery,
540584|NCT00537992|vitrectomy,
540585|NCT00537992|blue light-filter iols
540586|NCT00537979|Dialysis
540587|NCT00537979|Hyperparathyroidism
540588|NCT00537979|Zemplar
540589|NCT00537966|Primary HIV Infection
540590|NCT00537953|Leishmaniasis
540591|NCT00537953|Cutaneous leishmaniasis
540592|NCT00537953|Miltefosine
540593|NCT00537953|Glucantime
540594|NCT00537953|Antimony
540595|NCT00537953|Pentavalent antimonials
540596|NCT00537953|Combination therapy
540597|NCT00537927|laparoscopic correction
540598|NCT00537927|ventral and incisional hernia
540599|NCT00537927|mesh fixation
540600|NCT00537927|postoperative pain
540601|NCT00537914|Small for Gestational Age, Omnitrope®/Somatropin, rhGH,SGA
540602|NCT00536614|pancreatic cancer
540603|NCT00536614|metastatic
540604|NCT00536614|EGFR
540605|NCT00536614|locally advanced pancreatic cancer
540606|NCT00536575|Multiple Myeloma
540607|NCT00536575|Relapsed
540608|NCT00536575|Refractory
540609|NCT00536575|Sorafenib
540610|NCT00536575|Bortezomib
540611|NCT00536562|Comprehensive Cardiac Rehabilitation
540612|NCT00536562|Randomized Controlled Trial
540613|NCT00536562|TIA (Transient Ischemic Attack)
540614|NCT00536562|Mild Non-Disabling Stroke
540615|NCT00536562|Vascular Protection
540616|NCT00536549|Glucose monitoring system
540617|NCT00536549|life style intervention
540618|NCT00536536|Childhood
540619|NCT00536536|Obesity
540620|NCT00536536|Primary Care
540621|NCT00536523|constipation, impaction, and bowel obstruction
540622|NCT00536523|ovarian epithelial cancer
540623|NCT00536523|peritoneal cavity cancer
540624|NCT00536523|fallopian tube cancer
540625|NCT00536510|High Cholesterol
540626|NCT00536510|Excess lipids
540627|NCT00536497|GW842166,
540628|NCT00536497|Healthy volunteers,
540629|NCT00536497|Inflammatory Pain.
540630|NCT00536484|Overactive Bladder
540631|NCT00536458|localized low grade lymphoma
540632|NCT00536458|Chemotherapy
540633|NCT00536458|Radiotherapy
540634|NCT00536458|Molecular analyses
540635|NCT00536458|primary
540636|NCT00536445|NAVA
540637|NCT00536445|Preterm
540638|NCT00536445|Case study
540639|NCT00536406|Geriatric
540640|NCT00536406|Nursing Homes
540641|NCT00536393|diffuse larg cells lymphoma
540642|NCT00536393|chemotherapy
540643|NCT00536393|toxicity
540644|NCT00536393|diffuse high grade lymphoma
540645|NCT00536367|Heart Failure, Congestive
540646|NCT00536367|Mortality Prediction Model
540647|NCT00535340|Anxiety
540648|NCT00535340|Anti-Anxiety Agents
540649|NCT00537901|Colon and Rectum Cancer
540650|NCT00537862|Kidney Transplant Patients
540651|NCT00537862|Immunosuppresion
540652|NCT00537862|Enteric-coated mycophenolate sodium
540653|NCT00537836|Hot flushes
540654|NCT00537836|Therapy of hot flushes
540655|NCT00537836|17ß-estradiol (E2)
540656|NCT00537836|Hormone replacement therapy
540657|NCT00537823|Colorectal Cancer
540658|NCT00537823|Metastasis
540659|NCT00537823|Neoadjuvant Therapy
540660|NCT00537810|Obesity
540661|NCT00537810|Binge eating
540662|NCT00537810|Sibutramine
540663|NCT00537810|Self-help
540664|NCT00537810|Primary care
540665|NCT00537797|Thyroid Neoplasms
540666|NCT00537797|Positron Emission Tomography
540667|NCT00537797|18FDG
540668|NCT00537784|platelets tendon ligament
540669|NCT00537771|Early Breast cancer
540670|NCT00537771|adjuvant therapy
540671|NCT00537771|hormone receptor
540672|NCT00537771|hormonal therapy
540673|NCT00537771|anastrozole
540674|NCT00537771|tamoxifen
540675|NCT00537758|binge eating disorder
540676|NCT00537758|cognitive behavior therapy
540677|NCT00537758|combination therapy
540678|NCT00537758|obesity
540679|NCT00537758|weight loss
540680|NCT00537758|body weight
540681|NCT00537758|clinical trial
540682|NCT00537758|dietary restriction
540683|NCT00537758|overeating
540684|NCT00537758|weight control
540685|NCT00537732|gastro-oesophageal reflux disease
540686|NCT00537719|healthy
540687|NCT00537719|pharmacodynamics
540688|NCT00537719|glucagon-like peptide 1
540689|NCT00537719|pharmacokinetics
540690|NCT00537719|scintigraphy
540691|NCT00537719|radiation
540692|NCT00537719|albiglutide
540693|NCT00537706|Socioeconomic Determinants
540694|NCT00537706|Health Status
540695|NCT00537706|Low-income
540696|NCT00537706|Priority-setting
540697|NCT00537706|Group Discussion
540698|NCT00537693|Continuous Renal Replacement Therapy (CRRT)
540699|NCT00537693|Sepsis
540700|NCT00537693|Convection
540701|NCT00537693|Diffusion
540702|NCT00537680|Friedreich's Ataxia
540703|NCT00537680|Idebenone
540704|NCT00537680|ICARS
540705|NCT00537667|IL-1ra
540706|NCT00537667|PEG sTNF-RI
540707|NCT00537667|Synovial biopsy
540708|NCT00537667|Inflammation
540709|NCT00537667|Bone and Cartilage Destruction
540710|NCT00537667|Rheumatoid Arthritis
540711|NCT00537654|benign prostatic hyperplasia,
540712|NCT00537654|AVODART,
540713|NCT00537654|FLOMAX
540714|NCT00537641|noninvasive ventilation
540715|NCT00537602|cystic fibrosis
540716|NCT00537602|miglustat
540717|NCT00537602|Zavesca
540718|NCT00537602|Actelion
540719|NCT00537602|nasal potential difference
540720|NCT00537602|transmembrane conductance regulator (CFTR)
540721|NCT00537589|arthrocentesis
540722|NCT00537589|ultrasound
540723|NCT00537589|emergency
540724|NCT00537550|ALL
540725|NCT00537550|Adult
540726|NCT00537537|Hepatitis B, Chronic, Hepatitis B e Antigen positive, Adults, Telbivudine, Adefovir
540727|NCT00537524|Bird flu
540728|NCT00537524|seasonal influenza vaccine
540729|NCT00537524|influenza vaccine
540730|NCT00537524|prepandemic vaccine
540731|NCT00537524|virus strain with the potential to cause pandemic
540732|NCT00537524|toddlers
540733|NCT00537524|children
540734|NCT00537524|adolescents
540735|NCT00537498|urokinase, diabetes, wound healing, major amputation
540736|NCT00537485|SPM 962
540737|NCT00537485|rotigotine
540738|NCT00537485|Parkinson's disease
540739|NCT00537485|monotherapy
540740|NCT00537472|Bupivacaine
540741|NCT00537472|spinal anesthesia
540742|NCT00537472|total knee arthroplasty
540743|NCT00537459|Premature ejaculation (PE) ejaculatory latency time (ELT)
540744|NCT00537446|noninvasive ventilation
540745|NCT00537433|Medication errors
540746|NCT00537433|Patient nonadherence
540747|NCT00537433|Literacy
540748|NCT00537433|Communication
540749|NCT00537420|weight loss
540750|NCT00537420|dieting
540751|NCT00537407|Hepatitis
540752|NCT00537407|Hepatitis C
540753|NCT00537394|Treatment Experienced
540754|NCT00537381|Prostatic neoplasms
540755|NCT00537381|CNTO 95
540756|NCT00537381|Intetumumab
540757|NCT00537381|Docetaxel
540758|NCT00537381|Prednisone
540759|NCT00537368|infusion
540760|NCT00537368|CNTO 888
540761|NCT00537368|Phase 1
540762|NCT00537368|solid tumor
540763|NCT00537368|cancer
540764|NCT00537355|ragweed
540765|NCT00537355|ragweed allergy
540766|NCT00537355|allergy
540767|NCT00537355|allergies
540768|NCT00537355|allergic
540769|NCT00537355|seasonal allergic rhinitis
540770|NCT00537355|allergic rhinitis
540771|NCT00537342|Immunotherapy
540772|NCT00537342|Allergoid
540773|NCT00537342|Depigmented
540774|NCT00537342|Polymerized
540775|NCT00537342|Allergen-extract
540776|NCT00537342|Rhinoconjunctivitis
540777|NCT00537290|antiphospholipid syndrome
540778|NCT00537264|health-related quality of life
540779|NCT00537264|primary care
540780|NCT00537264|computer-assisted instruction
540781|NCT00537238|Epilepsies partial
540782|NCT00537238|Partial Seizure Disorder
540783|NCT00537238|Complex Partial Seizure Disorder
540784|NCT00537238|Epilepsy
540785|NCT00537225|peripheral arterial disease
540786|NCT00537225|walking time
540787|NCT00537225|lifestyle modification
540788|NCT00537225|cardiovascular risk reduction
540789|NCT00537225|exercise
540790|NCT00537225|diet
540791|NCT00537225|claudication
540792|NCT00537212|Psoriasis
540793|NCT00537212|Weight loss
540794|NCT00537212|diet
540795|NCT00537199|Head And Neck
540796|NCT00537199|Oropharynx
540797|NCT00537199|Oral Cancer
540798|NCT00537199|OraTest
540799|NCT00537199|OraTest Dye
540800|NCT00537199|Rinse Staining Procedure
540801|NCT00537199|Visual Examination
540802|NCT00537186|Congestive heart failure
540803|NCT00537186|Anaemia
540804|NCT00537186|Iron oligosaccharide
540805|NCT00537160|Pediatrics
540806|NCT00537147|Chimeric West Nile Virus
540807|NCT00537147|West Nile Virus
540808|NCT00537147|Dengue Virus
540809|NCT00537134|Aneurysm
540810|NCT00537134|Brain
540811|NCT00537134|Unruptured
540812|NCT00537134|observation
540813|NCT00537134|treatment
540814|NCT00537134|Endovascular
540815|NCT00537121|recurrent gastric cancer
540816|NCT00537121|stage IV gastric cancer
540817|NCT00537121|recurrent esophageal cancer
540818|NCT00537121|stage IV esophageal cancer
540819|NCT00537121|adenocarcinoma of the esophagus
540820|NCT00537121|adenocarcinoma of the stomach
540821|NCT00537121|squamous cell carcinoma of the esophagus
540822|NCT00537121|adult primary hepatocellular carcinoma
540823|NCT00537121|stage III gastric cancer
540824|NCT00537121|stage III esophageal cancer
540825|NCT00537121|advanced adult primary liver cancer
540826|NCT00537121|localized unresectable adult primary liver cancer
540827|NCT00537121|recurrent adult primary liver cancer
540828|NCT00537108|Pregnancy in adolescence
540829|NCT00537095|follicular
540830|NCT00537095|papillary
540831|NCT00537082|FTY720,
540832|NCT00537082|MS
540833|NCT00537043|hypertension,
540834|NCT00537043|carvedilol,
540835|NCT00537043|repeat-dosing
540836|NCT00537004|primary progressive aphasia
540837|NCT00537004|frontotemporal dementia
540838|NCT00537004|semantic dementia
540839|NCT00537004|progressive nonfluent aphasia
540840|NCT00537004|progressive aphasia
540841|NCT00537004|frontotemporal lobar degeneration
540842|NCT00536978|Lymphoma
540843|NCT00536978|Leukemia
540844|NCT00536978|B-Cell Lymphoid Malignancies
540845|NCT00536978|CLL
540846|NCT00536978|Cll/Small Lymphocytic Lymphoma
540847|NCT00536978|Follicular Lymphoma
540848|NCT00536978|Mantle Cell Lymphoma
540849|NCT00536978|Diffuse Large Cell Lymphoma
540850|NCT00536978|Splenic Lymphoma
540851|NCT00536978|MALT
540852|NCT00536978|Lymphoplasmacytic Lymphoma
540853|NCT00536978|Burkitt's Lymphoma
540854|NCT00536978|ARA-C
540855|NCT00536978|BCNU
540856|NCT00536978|Campath-1H
540857|NCT00536978|Cytoxan
540858|NCT00536978|Etoposide
540859|NCT00536978|Fludarabine
540860|NCT00536978|Melphalan
540861|NCT00536978|Rituximab
540862|NCT00536978|Allogeneic Stem Cell Transplant
540863|NCT00536978|T-Cell Cell Adback
540864|NCT00536978|Natural Killer (NK) Cell Adback
540865|NCT00536965|Hyperlipidemia
540866|NCT00536965|Need-to-treat
540867|NCT00536965|NIS
540868|NCT00536965|Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes
540869|NCT00536952|recurrent squamous cell carcinoma of the hypopharynx
540870|NCT00536952|stage III squamous cell carcinoma of the hypopharynx
540871|NCT00536952|stage IV squamous cell carcinoma of the hypopharynx
540872|NCT00536952|stage III squamous cell carcinoma of the larynx
540873|NCT00536952|stage IV squamous cell carcinoma of the larynx
540874|NCT00536952|recurrent squamous cell carcinoma of the larynx
540875|NCT00536952|recurrent squamous cell carcinoma of the lip and oral cavity
540876|NCT00536952|stage III squamous cell carcinoma of the lip and oral cavity
540877|NCT00536952|stage IV squamous cell carcinoma of the lip and oral cavity
540878|NCT00536952|recurrent squamous cell carcinoma of the nasopharynx
540879|NCT00536952|stage III squamous cell carcinoma of the nasopharynx
540880|NCT00536952|stage IV squamous cell carcinoma of the nasopharynx
540881|NCT00536952|recurrent squamous cell carcinoma of the oropharynx
540882|NCT00536952|stage III squamous cell carcinoma of the oropharynx
540883|NCT00536952|stage IV squamous cell carcinoma of the oropharynx
540884|NCT00536341|Chronic Lymphocytic Leukemia
540885|NCT00536341|untreated
540886|NCT00536341|minimally treated
540887|NCT00536341|fludarabine
540888|NCT00536341|rituximab
540889|NCT00536341|lenalidomide
540890|NCT00536328|Reflux Impact Scale (RIS)
540891|NCT00536328|predictive value
540892|NCT00536328|treatment success
540893|NCT00536328|patient satisfaction
540894|NCT00536328|proton pump inhibitor
540895|NCT00536328|gastro-esophageal reflux disease
540896|NCT00536328|PPU
540897|NCT00536315|COPD
540898|NCT00536302|OA
540899|NCT00536302|Knee arthritis
540900|NCT00536302|Osteoarthritis
540901|NCT00536302|Nutritional supplement
540902|NCT00536302|CAM
540903|NCT00536302|MRI
540904|NCT00536289|Blunt needles
540905|NCT00536289|obstetric lacerations
540906|NCT00536289|Needlestick injuries
540907|NCT00536289|Needlestick injuries to physicians
540908|NCT00536276|vitamin D
540909|NCT00536250|Pre-Diabetes
540910|NCT00536250|Childhood Obesity
540911|NCT00536250|Metabolic Syndrome
540912|NCT00536250|insulin resistance
540913|NCT00536250|Impaired Glucose Tolerance
540914|NCT00536250|Non Alcoholic Fatty Liver Disease
540915|NCT00536250|High Molecular Weight Adiponectin
540916|NCT00536250|Hypoadiponectinemia
540917|NCT00536224|Health promotion
540918|NCT00536224|Emergency Medical Services
540919|NCT00536224|Randomized controlled trial
540920|NCT00536211|Exercise
540921|NCT00536211|Physical Activity
540922|NCT00536211|Metformin
540923|NCT00536211|Hyperinsulinemic-Euglycemic Clamp
540924|NCT00536211|Muscle Biopsy
540925|NCT00536211|Fatty Acid Oxidation
540926|NCT00536211|Peroxisome proliferator-activated receptor gamma
540927|NCT00536211|Detraining
540928|NCT00536211|Inactivity
540929|NCT00536211|Skeletal muscle
540930|NCT00536198|Premenstrual Syndrome
540931|NCT00536185|ALOX5
540932|NCT00536185|5-lipoxygenase
540933|NCT00536185|Heart Disease
540934|NCT00536185|Blacks
540935|NCT00536172|Antidepressant
540936|NCT00536172|Major depression
540937|NCT00536172|Prevention
540938|NCT00536172|Head and neck cancer
540939|NCT00536159|nurse-community health worker team
540940|NCT00536159|perinatal depression
540941|NCT00536159|stress
540942|NCT00536159|Medicaid enhanced prenatal programs
540943|NCT00536146|Glucocorticoid
540944|NCT00536146|Steroids
540945|NCT00536146|Dose-Responsive Curve
540946|NCT00536146|EC50
540947|NCT00536146|Stress Response
540948|NCT00536146|Alcoholism
540949|NCT00536133|zinc
540950|NCT00536133|aute lower respiratory infections
540951|NCT00536120|MS
540952|NCT00536120|Multiple sclerosis
540953|NCT00536120|Relapsing forms of Multiple Sclerosis
540954|NCT00536107|Non-Small Cell Lung Cancer
540955|NCT00536107|Locally Advanced or Metastatic NSCL Cancer
540956|NCT00536094|Cognitive behavioral therapy
540957|NCT00536094|Youth
540958|NCT00536094|School
540959|NCT00536094|African American
540960|NCT00536081|Breast cancer
540961|NCT00536081|Adjuvant
540962|NCT00536081|Advanced
540963|NCT00536081|Chemotherapy
540964|NCT00536081|G-CSF
540965|NCT00536081|Pegfilgrastim
540966|NCT00536081|Prevention
540967|NCT00536081|Febrile neutropenia
540968|NCT00536068|platelet
540969|NCT00536068|aggregation
540970|NCT00536068|aspirin
540971|NCT00536055|breast cancer
540972|NCT00536055|prostate cancer
540973|NCT00536055|dyadic coping
540974|NCT00536042|minocycline
540975|NCT00536042|asthma
540976|NCT00536042|oral steroids
540977|NCT00536042|IgE
540978|NCT00536029|Melanoma
540979|NCT00536029|SIAscope
540980|NCT00536029|pigmented skin lesions
540981|NCT00536016|AMD
540982|NCT00536016|Neovascular Age-Related Macular Degeneration
540983|NCT00536003|preterm delivery
540984|NCT00536003|preterm labor
540985|NCT00536003|perinatal morbidity
540986|NCT00536003|perinatal mortality
540987|NCT00535990|Cholecystectomy
540988|NCT00535990|Appendectomy
540989|NCT00535990|Esophageal
540990|NCT00535990|Surgical
540991|NCT00535990|Procedures
540992|NCT00535990|Surgery
540993|NCT00535990|Gastric
540994|NCT00535990|bypass
540995|NCT00535977|Gene expression
540996|NCT00535977|Prostate
540997|NCT00535977|Broccoli
540998|NCT00535977|Cancer
540999|NCT00535977|Men diagnosed with high-grade Prostatic Intraepithelia Neoplasia
541000|NCT00535964|Cigarette Smoking
541001|NCT00535964|Tobacco Use
541002|NCT00535964|Adolescents
541003|NCT00535964|Anxiety Sensitivity (AS)
541004|NCT00535951|Non-small cell lung cancer
541005|NCT00535951|NSCLC
541006|NCT00535951|lung cancer
541007|NCT00535951|pleural mesothelioma
541008|NCT00535951|malignant
541009|NCT00535951|advanced stage
541010|NCT00535951|mesothelioma
541011|NCT00535951|phase I
541012|NCT00535951|LBH589
541013|NCT00535951|dextromethorphan
541014|NCT00535951|CYP2D6
541015|NCT00535951|oral
541016|NCT00535925|type 2 diabetes
541017|NCT00535925|nephropathy
541018|NCT00535925|CV events
541019|NCT00535912|CLL
541020|NCT00535899|Aortic stenosis
541021|NCT00535899|Speckle tracking imaging
541022|NCT00535899|Low ejection fraction
541023|NCT00535899|Aortic valve replacement
541024|NCT00535899|Strain
541025|NCT00535886|Trans Fatty Acids
541026|NCT00535886|conjugated linoleic acid
541027|NCT00535886|vaccenic acid
541028|NCT00535886|High Density Lipoprotein Cholesterol
541029|NCT00535886|Low Density Lipoprotein Cholesterol
541030|NCT00535886|Beef
541031|NCT00535873|Leukemia
541032|NCT00535873|CLL
541033|NCT00535873|chronic lymphocytic leukemia
541034|NCT00535873|SLL
541035|NCT00535873|small lymphocytic lymphoma
541036|NCT00535873|Untreated CLL
541037|NCT00535873|Lenalidomide
541038|NCT00535873|CC-5013
541039|NCT00535873|Revlimid
541040|NCT00535873|Oral
541041|NCT00535860|Osteoporosis
541042|NCT00535860|Transdermal
541043|NCT00535860|hPTH(1-34)
541044|NCT00535847|Genotype 1
541045|NCT00535834|stage I prostate cancer
541046|NCT00535834|stage II prostate cancer
541047|NCT00535834|stage III prostate cancer
541048|NCT00535834|adenocarcinoma of the prostate
541049|NCT00535821|Emergency Department
541050|NCT00535821|Hemodynamic Optimization
541051|NCT00535821|Esophageal Doppler monitoring
541052|NCT00535821|Early Goal-Directed Therapy
541053|NCT00535769|topical
541054|NCT00535769|medication adherence
541055|NCT00535769|adherence
541056|NCT00535769|compliance
541057|NCT00535769|medication compliance
541058|NCT00535769|sunscreen
541059|NCT00535769|reminder
541060|NCT00535756|Pancreatic Exocrine Insufficiency After Pancreatic Surgery
541061|NCT00535717|Urethral stricture
541062|NCT00535717|Ayurvedic treatment
541063|NCT00535717|mutra marg sankoch
541064|NCT00535717|uttarbasti
541065|NCT00535717|Sesame oil
541066|NCT00535717|Honey
541067|NCT00535717|Rock salt
541068|NCT00535678|Mammography
541069|NCT00535678|mammogram
541070|NCT00535678|breast
541071|NCT00535678|Abnormal and normal breast tissue
541072|NCT00535639|Tolerability of ALK Tree Tablet in patients with birch pollen induced allergy
541073|NCT00535600|Bariatric Surgery
541074|NCT00535600|Insulin Action
541075|NCT00535600|Insulin Secretion
541076|NCT00535600|Insulin Resistance
541077|NCT00535600|Gut Hormones
541078|NCT00535600|Obesity
541079|NCT00535587|Fibromyalgia
541080|NCT00535587|Exercise
541081|NCT00535587|Mestinon
541082|NCT00535574|retinoids
541083|NCT00535574|bexarotene
541084|NCT00535574|schizophrenia
541085|NCT00535574|PANSS
541086|NCT00535574|Positive and negative symptoms of schizophrenia
541087|NCT00535561|iron deficiency anemia
541088|NCT00535561|anemia
541089|NCT00535561|hypothyroidism
541090|NCT00535561|subclinical hypothyroidism
541091|NCT00535548|Chronic wounds
541092|NCT00535548|Pressure sores
541093|NCT00535548|Hematopoietic stem cells
541094|NCT00535548|Wound healing
541095|NCT00535535|Elevated triglycerides
541096|NCT00535535|Diabetes
541097|NCT00535535|Cardiovascular disease
541098|NCT00535522|Pharmacokinetics
541099|NCT00535522|pharmacodynamics
541100|NCT00535522|maximal tolerated dose
541101|NCT00535483|blood microdialysis
541102|NCT00535483|glucose monitoring
541103|NCT00535483|glucose control
541104|NCT00535483|automated blood sampling
541105|NCT00535483|online-sensor
541106|NCT00535483|algorithm
541107|NCT00535483|type 1 diabetes
541108|NCT00535457|anxiety
541109|NCT00535457|maladaptive behavior
541110|NCT00535457|anesthesia
541111|NCT00535457|Anxiety before anesthesia and maladaptive behavior after anesthesia.
541112|NCT00535444|Hypertension
541113|NCT00535444|parish nurse
541114|NCT00535431|Asthma
541115|NCT00535431|allergy
541116|NCT00535431|interleukin-4
541117|NCT00535431|interleukin-13
541118|NCT00535431|IL-4
541119|NCT00535431|IL-13
541120|NCT00535418|Breast cancer
541121|NCT00535418|neoadjuvant treatment
541122|NCT00535418|treatment duration
541123|NCT00535418|Primary hormone receptor positive
541124|NCT00535418|breast cancer in postmenopausal women
541125|NCT00535405|High Cholesterol
541126|NCT00535392|Epilepsy
541127|NCT00535392|Child
541128|NCT00535392|Levetiracetam
541129|NCT00535392|Keppra®
541130|NCT00535392|Infusion
541131|NCT00535392|Intravenous
541132|NCT00535379|glioblastoma multiforme
541133|NCT00535379|sunitinib
541134|NCT00535379|recurrent
541135|NCT00535379|progressive
541136|NCT00535327|Mammography
541137|NCT00535327|mammogram
541138|NCT00535327|breast
541139|NCT00535327|Abnormal and normal breast tissue
541140|NCT00535314|Melanoma
541141|NCT00535301|cystocele
541142|NCT00535301|uterine prolapse
541143|NCT00535301|urinary incontinence
541144|NCT00535275|NSCLC relapse after adjuvant chemotherapy
541145|NCT00535262|Bipolar
541146|NCT00535262|depression
541147|NCT00535236|Prevention of herpes zoster and HZ-related complications
541148|NCT00535223|Cognitive Behavior Therapy
541149|NCT00535223|Group therapy
541150|NCT00535223|Posttraumatic Stress Disorder
541151|NCT00535223|Randomized Controlled Trial
541152|NCT00535223|Treatment outcome
541153|NCT00535223|Veterans
541154|NCT00535223|War
541155|NCT00535210|spinal cord injury
541156|NCT00535210|exercise rehabilitation
541157|NCT00535210|inpatient
541158|NCT00535210|RCT
541159|NCT00535210|physical function
541160|NCT00535184|Mammography
541161|NCT00535184|mammogram
541162|NCT00535184|breast
541163|NCT00535184|Abnormal and normal breast tissue
541164|NCT00535158|Chronic Kidney disease
541165|NCT00535158|Dialysis
541166|NCT00535158|Vitamin D
541167|NCT00535158|Chronic kidney disease is associated with impaired muscle strength, pain and fractures.
541168|NCT00535145|antipsychotic
541169|NCT00535145|paliperidone ER
541170|NCT00535145|liver disease
541171|NCT00535145|Schizophrenia
541172|NCT00535145|Schizoaffective Disorder
541173|NCT00535145|Invega
541174|NCT00535132|schizophrenia
541175|NCT00535132|medication satisfaction, Invega
541176|NCT00535106|Ventricular fibrillation
541177|NCT00535106|Cardiac arrest
541178|NCT00535106|Automated external defibrillator
541179|NCT00535106|AED
541180|NCT00535106|Waveform based algorithms
541181|NCT00535106|VF waveform analysis
541182|NCT00535093|Pharyngitis
541183|NCT00535093|Community infections
541184|NCT00535093|Rapid Testing
541185|NCT00535093|Group A Streptococcus
541186|NCT00535080|actinic
541187|NCT00535080|keratoses
541188|NCT00535080|superficial
541189|NCT00535080|basal
541190|NCT00535080|carcinomas
541191|NCT00535080|Bowen's
541192|NCT00535080|large or multiple superficial Basal Carcinomas
541193|NCT00535067|Breast Cancer
541194|NCT00535067|Questionnaire
541195|NCT00535067|Survey
541196|NCT00535067|Neuropathic Pain
541197|NCT00535067|Cancer Survivors
541198|NCT00535067|Quality of Life
541199|NCT00535067|QOL
541200|NCT00535054|Dry Eye Syndrome
541201|NCT00535041|Pilot trial of pre-operative chemo/RT using Xeloda and external beam RT followed by definite surgery in patients with localized rectal CA
541202|NCT00535028|asthma
541203|NCT00535028|allergy
541204|NCT00535028|interleukin-4
541205|NCT00535028|interleukin-13
541206|NCT00535028|IL-4
541207|NCT00535028|IL-13
541208|NCT00535028|atopic
541209|NCT00535028|late asthmatic response
541210|NCT00535028|inflammation
541211|NCT00535002|Cocaine Addiction
541212|NCT00535002|Cocaine Dependence
541213|NCT00534989|NHL and HD
541214|NCT00534963|sonohysterography, catheter placement
541215|NCT00534950|Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck
541216|NCT00534937|Venous stasis ulcer
541217|NCT00534937|Compression pump
541218|NCT00534937|Randomized trial
541219|NCT00534937|Flexitouch compression
541220|NCT00534924|IR injury
541221|NCT00534924|MRI
541222|NCT00534924|Vitamin C
541223|NCT00534924|Postconditioning
541224|NCT00534911|Depression
541225|NCT00534911|Physical Illness
541226|NCT00534911|Inflammatory Bowel Disease
541227|NCT00534911|Cognitive Behavioral Therapy
541228|NCT00534885|inactivated hepatitis A vaccine
541229|NCT00534885|Healive
541230|NCT00534885|safety
541231|NCT00534885|immunogenicity
541232|NCT00534885|immune persistence
541233|NCT00534872|4 Parallel cohorts
541234|NCT00534872|Healthy Female
541235|NCT00534872|Healthy Elderly
541236|NCT00534872|Pharmacokinetic
541237|NCT00534872|Safety and Tolerability
541238|NCT00534846|premenstrual syndrome
541239|NCT00534846|mastalgia
541240|NCT00534846|toremifene
541241|NCT00534846|selective estrogen receptor modulators
541242|NCT00534833|Diphtheria
541243|NCT00534833|Tetanus
541244|NCT00534833|Pertussis
541245|NCT00534833|Hepatitis B Hansenula (HB)
541246|NCT00534833|Haemophilus influenzae type b
541247|NCT00534820|Cytogenetic Analysis of Bone Marrow Specimen in Non-Hodgkin's Lymphoma or Hodgkin's Disease
541248|NCT00534781|Achilles
541249|NCT00534781|Tendinosis
541250|NCT00534781|Tendinitis
541251|NCT00534781|Achilles Tendinosis
541252|NCT00534781|Achilles Tendinitis
541253|NCT00534781|Coblation
541254|NCT00534781|Bipolar Radiofrequency
541255|NCT00534781|Surgical Debridement
541256|NCT00534781|Debridement
541257|NCT00534781|Heel Pain
541258|NCT00534781|Achilles Pain
541259|NCT00533767|Hantavirus cardiopulmonary syndrome, Andes virus, Chile
541260|NCT00533754|age-related macular degeneration, genetics
541261|NCT00533741|Severe Acute Respiratory Syndrome, Coronavirus, vaccine
541262|NCT00533715|Inspiratory Spirometry; Preschool Children; Computer games
541263|NCT00533715|Health
541264|NCT00533702|Phase II
541265|NCT00533702|Melanoma
541266|NCT00533702|IMC-1121B
541267|NCT00533702|ImClone
541268|NCT00534742|Siblings
541269|NCT00534729|Organ Preservation
541270|NCT00534729|Carboplatin
541271|NCT00534729|Taxol
541272|NCT00534729|RT
541273|NCT00534729|laryngeal & Hypopharyngeal CA
541274|NCT00534729|Locally advanced laryngeal & Hypopharyngeal CA
541275|NCT00534716|Cannabis
541276|NCT00534716|doping
541277|NCT00534716|THC
541278|NCT00534716|GC/MS
541279|NCT00534716|Pharmacokinetics
541280|NCT00534716|Volunteers
541281|NCT00534690|Pulmonary disease
541282|NCT00534690|Intubation, Intratracheal
541283|NCT00534690|Positive-pressure ventilation
541284|NCT00534677|Variceal bleed
541285|NCT00534677|Cirrhosis
541286|NCT00534677|Vasoactive agents
541287|NCT00534677|Terlipressin
541288|NCT00534677|Octreotide
541289|NCT00534677|Safety & Efficacy
541290|NCT00534638|HPV vaccine
541291|NCT00534638|Healthy adolescents
541292|NCT00534638|Cervical cancer
541293|NCT00534638|Safety
541294|NCT00534638|Immunogenicity
541295|NCT00534638|Cervarix
541296|NCT00534625|Asthma, exacerbation, pulmonary function
541297|NCT00534612|Parotid gland neoplasms
541298|NCT00534599|Generalized anxiety disorders
541299|NCT00534599|anxiety
541300|NCT00534599|adjunct treatment in anxiety
541301|NCT00534599|anxiety disorder
541302|NCT00534599|partial or non-responder in anxiety
541303|NCT00534586|Pain
541304|NCT00534586|SSEP
541305|NCT00534586|CHEPS
541306|NCT00534586|Propofol
541307|NCT00534586|Sevoflurane
541308|NCT00534586|S-Ketamine
541309|NCT00534586|Remifentanil
541310|NCT00534586|Healthy volunteers
541311|NCT00534534|Pancreatitis
541312|NCT00534534|acute
541313|NCT00534534|alcoholic
541314|NCT00534534|recurrence
541315|NCT00534534|alcoholism
541316|NCT00534534|treatment
541317|NCT00534534|Acute alcoholic pancreatitis
541318|NCT00534521|overactive bladder
541319|NCT00534521|posterior tibial nerve stimulation
541320|NCT00534508|Skin
541321|NCT00534508|Pharmacokinetics
541322|NCT00534508|Tacrolimus
541323|NCT00534508|dermatitis, atopic
541324|NCT00534495|Systemic Juvenile Idiopathic Arthritis
541325|NCT00534495|Juvenile Rheumatoid Arthritis
541326|NCT00534495|Systemic Juvenile Rheumatoid Arthritis
541327|NCT00534482|fitness
541328|NCT00534469|adult acute myeloid leukemia in remission
541329|NCT00534469|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
541330|NCT00534469|adult acute myeloid leukemia with inv(16)(p13;q22)
541331|NCT00534469|adult acute myeloid leukemia with t(16;16)(p13;q22)
541332|NCT00534469|adult acute myeloid leukemia with t(8;21)(q22;q22)
541333|NCT00534469|adult acute basophilic leukemia
541334|NCT00534469|adult acute eosinophilic leukemia
541335|NCT00534469|adult erythroleukemia (M6a)
541336|NCT00534469|adult pure erythroid leukemia (M6b)
541337|NCT00534469|adult acute megakaryoblastic leukemia (M7)
541338|NCT00534469|adult acute minimally differentiated myeloid leukemia (M0)
541339|NCT00534469|adult acute monoblastic leukemia (M5a)
541340|NCT00534469|adult acute monocytic leukemia (M5b)
541341|NCT00534469|adult acute myeloblastic leukemia with maturation (M2)
541342|NCT00534469|adult acute myeloblastic leukemia without maturation (M1)
541343|NCT00534469|adult acute myelomonocytic leukemia (M4)
541344|NCT00534456|exploratory study
541345|NCT00534456|anemia
541346|NCT00534456|pharmacogenetics testing
541347|NCT00534456|biomarkers
541348|NCT00534456|echocardiography
541349|NCT00534443|peptic ulcer
541350|NCT00534443|gastritis
541351|NCT00534443|sTREM-1
541352|NCT00534443|cytokines
541353|NCT00534443|Changes of inflammatory status in gastric mucosa
541354|NCT00534443|sTREM-1 as a disease marker
541355|NCT00534430|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
541356|NCT00534430|adult acute myeloid leukemia with inv(16)(p13;q22)
541357|NCT00534430|adult acute myeloid leukemia with t(15;17)(q22;q12)
541358|NCT00534430|adult acute myeloid leukemia with t(16;16)(p13;q22)
541359|NCT00534430|adult acute myeloid leukemia with t(8;21)(q22;q22)
541360|NCT00534430|recurrent adult acute myeloid leukemia
541361|NCT00534430|adult acute myeloid leukemia in remission
541579|NCT00533819|Female school children
541362|NCT00534430|recurrent childhood acute myeloid leukemia
541363|NCT00534430|recurrent adult acute lymphoblastic leukemia
541364|NCT00534430|recurrent childhood acute lymphoblastic leukemia
541365|NCT00534430|blastic phase chronic myelogenous leukemia
541366|NCT00534430|refractory anemia with excess blasts in transformation
541367|NCT00534430|refractory anemia with excess blasts
541368|NCT00534430|previously treated myelodysplastic syndromes
541369|NCT00534430|secondary myelodysplastic syndromes
541370|NCT00534417|Hormone
541371|NCT00534417|Receptor
541372|NCT00534417|Positive
541373|NCT00534417|Metastatic
541374|NCT00534417|Breast
541375|NCT00534417|Cancer
541376|NCT00534404|Internet-Assisted Tobacco Treatments
541377|NCT00534404|Online Smoking Cessation Programs
541378|NCT00534404|Nicotine Patches
541379|NCT00534404|Telephone Counseling
541380|NCT00534404|Smoking Abstinence
541381|NCT00534391|Antibiotics
541382|NCT00534391|hordeolum
541383|NCT00534378|Nerve agent
541384|NCT00534378|Midazolam
541385|NCT00534378|Seizures
541386|NCT00534378|Severe recurrent convulsive seizures induced by nerve agent exposure
541387|NCT00534365|stress urinary incontinence
541388|NCT00534365|sling procedures
541389|NCT00534365|tension-free vaginal tape
541390|NCT00534352|HIV
541391|NCT00534352|AIDS
541392|NCT00534352|Immunodeficiency Virus, Human
541393|NCT00534352|PREZISTA
541394|NCT00534352|darunavir
541395|NCT00534352|TMC114
541396|NCT00534352|TMC125
541397|NCT00534352|Protease Inhibitor
541398|NCT00534352|Non-Nucleoside Reverse Transcriptase Inhibitor
541399|NCT00534352|Truvada
541400|NCT00534352|Treatment Naive
541401|NCT00534300|ICD-pacemaker
541402|NCT00534287|sepsis
541403|NCT00534287|antibiotics
541404|NCT00534287|carbapenems
541405|NCT00534287|fluoroquinolones
541406|NCT00534287|Severe sepsis and septic shock
541407|NCT00534274|stage II breast cancer
541408|NCT00534274|stage IIIA breast cancer
541409|NCT00534261|Multiple Sclerosis
541410|NCT00534261|Avonex
541411|NCT00534261|Interferon beta-1a
541412|NCT00534222|Patients with a manic episode
541413|NCT00534222|Patients diagnosed w/schizophrenia, who start a treatment with an atypical antipsychotic & who are at least scored as moderately ill on the CGI at baseline
541414|NCT00534209|stage IIIB non-small cell lung cancer
541415|NCT00534209|stage IV non-small cell lung cancer
541416|NCT00534196|recurrent prostate cancer
541417|NCT00534196|stage I prostate cancer
541418|NCT00534196|stage IIB prostate cancer
541419|NCT00534196|stage IIA prostate cancer
541420|NCT00534196|stage III prostate cancer
541421|NCT00534183|Metabolic syndrome
541422|NCT00534183|Obesity
541423|NCT00534183|Diabetes
541424|NCT00534170|Probiotic
541425|NCT00534170|Prevention of diarrhoea
541426|NCT00534170|Nutritional status
541427|NCT00534157|intracranial pressure
541428|NCT00534157|intraocular pressure
541429|NCT00534157|tonometry
541430|NCT00534118|accelerated phase chronic myelogenous leukemia
541431|NCT00534118|chronic phase chronic myelogenous leukemia
541432|NCT00534118|relapsing chronic myelogenous leukemia
541433|NCT00534118|childhood chronic myelogenous leukemia
541434|NCT00534118|previously treated myelodysplastic syndromes
541435|NCT00534118|recurrent adult acute lymphoblastic leukemia
541436|NCT00534118|recurrent childhood acute lymphoblastic leukemia
541437|NCT00534118|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
541438|NCT00534118|adult acute myeloid leukemia with inv(16)(p13;q22)
541439|NCT00534118|adult acute myeloid leukemia with t(15;17)(q22;q12)
541440|NCT00534118|adult acute myeloid leukemia with t(16;16)(p13;q22)
541441|NCT00534118|adult acute myeloid leukemia with t(8;21)(q22;q22)
541442|NCT00534118|recurrent adult acute myeloid leukemia
541443|NCT00534118|recurrent childhood acute myeloid leukemia
541444|NCT00534118|stage I multiple myeloma
541445|NCT00534118|stage II multiple myeloma
541446|NCT00534118|stage III multiple myeloma
541447|NCT00534118|refractory multiple myeloma
541448|NCT00534118|recurrent adult Hodgkin lymphoma
541449|NCT00534118|recurrent/refractory childhood Hodgkin lymphoma
541450|NCT00534118|recurrent adult Burkitt lymphoma
541451|NCT00534118|recurrent adult diffuse large cell lymphoma
541452|NCT00534118|recurrent adult diffuse mixed cell lymphoma
541453|NCT00534118|recurrent adult diffuse small cleaved cell lymphoma
541454|NCT00534118|recurrent adult immunoblastic large cell lymphoma
541455|NCT00534118|recurrent adult lymphoblastic lymphoma
541456|NCT00534118|recurrent grade 1 follicular lymphoma
541457|NCT00534118|recurrent grade 2 follicular lymphoma
541458|NCT00534118|recurrent grade 3 follicular lymphoma
541459|NCT00534118|recurrent mantle cell lymphoma
541460|NCT00534118|recurrent marginal zone lymphoma
541461|NCT00534118|recurrent small lymphocytic lymphoma
541462|NCT00534118|recurrent adult grade III lymphomatoid granulomatosis
541463|NCT00534118|Waldenstrom macroglobulinemia
541464|NCT00534118|recurrent childhood grade III lymphomatoid granulomatosis
541465|NCT00534118|recurrent childhood large cell lymphoma
541466|NCT00534118|recurrent childhood lymphoblastic lymphoma
541467|NCT00534118|childhood diffuse large cell lymphoma
541468|NCT00534118|childhood immunoblastic large cell lymphoma
541469|NCT00534118|recurrent childhood small noncleaved cell lymphoma
541470|NCT00534118|de novo myelodysplastic syndromes
541471|NCT00534118|secondary acute myeloid leukemia
541472|NCT00534118|secondary myelodysplastic syndromes
541473|NCT00534118|splenic marginal zone lymphoma
541474|NCT00534118|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
541475|NCT00534118|nodal marginal zone B-cell lymphoma
541476|NCT00534118|recurrent cutaneous T-cell non-Hodgkin lymphoma
541477|NCT00534118|recurrent mycosis fungoides/Sezary syndrome
541478|NCT00534118|cutaneous B-cell non-Hodgkin lymphoma
541479|NCT00534105|Pregnancy
541480|NCT00534105|Gestational diabetes
541481|NCT00534105|Hyperlipidemia
541482|NCT00534092|Lumbar Spinal Stenosis
541483|NCT00534092|X STOP
541484|NCT00534079|Cystic Fibrosis and chronic rhinosinusitis
541485|NCT00534066|Natriuretic Peptide, Brain
541486|NCT00534053|colon cancer screening
541487|NCT00534053|mail reminders
541488|NCT00534053|fecal occult blood test
541489|NCT00534053|compliance
541490|NCT00534027|NSCLC
541491|NCT00534027|Non-Small Cell Lung Cancer
541492|NCT00534027|Paclitaxel
541493|NCT00534027|Carboplatin
541494|NCT00534027|AMG 655
541495|NCT00534001|bladder cancer
541496|NCT00534001|cervical cancer
541497|NCT00534001|esophageal cancer
541498|NCT00534001|gastric cancer
541499|NCT00534001|renal cell carcinoma
541500|NCT00534001|adult primary liver cancer
541501|NCT00534001|non-small cell lung cancer
541502|NCT00534001|small cell lung cancer
541503|NCT00534001|pancreatic cancer
541504|NCT00534001|hypopharyngeal cancer
541505|NCT00534001|laryngeal cancer
541506|NCT00534001|lip and oral cavity cancer
541507|NCT00534001|nasopharyngeal cancer
541508|NCT00534001|oropharyngeal cancer
541509|NCT00534001|paranasal sinus and nasal cavity cancer
541510|NCT00534001|adult acute myeloid leukemia
541511|NCT00534001|tobacco use disorder
541512|NCT00533988|Central venous catheters
541513|NCT00533988|Antimicrobial impregnated catheters
541514|NCT00533988|Duration of catheter use
541515|NCT00533988|Catheter-related infection
541516|NCT00533988|Insertion site
541517|NCT00533988|Parenteral nutrition
541518|NCT00533988|Critically ill patients (multidisciplinary)
541519|NCT00533975|Colon Cancer screening
541520|NCT00533975|immunofecal occult blood test
541521|NCT00533975|colonoscopy
541522|NCT00533975|diagnostic validity
541523|NCT00533962|Glaucoma
541524|NCT00533962|Anecortave Acetate
541525|NCT00533962|Intraocular pressure
541526|NCT00533962|Advanced glaucoma cases with uncontrolled IOP
541527|NCT00533949|radiation toxicity
541528|NCT00533949|stage IIIA non-small cell lung cancer
541529|NCT00533949|stage IIIB non-small cell lung cancer
541530|NCT00533936|stage II breast cancer
541531|NCT00533936|stage IIIA breast cancer
541532|NCT00533936|stage IIIB breast cancer
541533|NCT00533936|stage IIIC breast cancer
541534|NCT00533923|Nonmyeloablative Allogeneic Stem Cell Transplantation
541535|NCT00533923|mini-transplant
541536|NCT00533923|AML
541537|NCT00533923|ALL
541538|NCT00533923|CML
541539|NCT00533923|CLL
541540|NCT00533923|Myelodysplastic syndrome
541541|NCT00533923|Relapsed non-Hodgkin's or Hodgkin's lymphoma
541542|NCT00533923|Relapsed multiple myeloma
541543|NCT00533923|Aplastic anemia
541544|NCT00533923|Myeloproliferative disorder
541545|NCT00533923|GM-CSF
541546|NCT00533923|Cyclosporin
541547|NCT00533923|Fludarabine (FLUDARA)
541548|NCT00533923|Cyclophosphamide
541549|NCT00533923|CAMPATH-1H
541550|NCT00533923|GVHD
541551|NCT00533923|CMV
541552|NCT00533923|AML in first remission, first relapse or subsequent remission
541553|NCT00533923|ALL in first relapse, second or subsequent remission
541554|NCT00533923|ALL in first remission, in a high-risk category
541555|NCT00533923|Aplastic anemia characterized by ANC< 1000 and/or platelets < 30 without transfusional support
541556|NCT00533923|Myeloproliferative disorder (P Vera, CMML, ET)
541557|NCT00533910|Minimal hepatic encephalopathy
541558|NCT00533897|Rheumatoid Arthritis (RA)
541559|NCT00533884|delirium
541560|NCT00533884|cognitive/functional effects
541561|NCT00533884|hypopharyngeal cancer
541562|NCT00533884|laryngeal cancer
541563|NCT00533884|lip and oral cavity cancer
541564|NCT00533884|metastatic squamous neck cancer with occult primary
541565|NCT00533884|nasopharyngeal cancer
541566|NCT00533884|oropharyngeal cancer
541567|NCT00533884|paranasal sinus and nasal cavity cancer
541568|NCT00533884|salivary gland cancer
541569|NCT00533884|esophageal cancer
541570|NCT00533884|non-small cell lung cancer
541571|NCT00533884|small cell lung cancer
541572|NCT00533871|Natriuretic Peptide Brain
541573|NCT00533858|Systolic hypertension
541574|NCT00533832|depression
541575|NCT00533832|vagus nerve stimulation
541576|NCT00533819|Exercise intervention
541577|NCT00533819|Maths Scores
541578|NCT00533819|Blood pressure
541580|NCT00533819|Body mass index
541581|NCT00533806|Cognitive Behavior Therapy
541582|NCT00533806|Active Control
541583|NCT00533806|Relaxation Therapy
541584|NCT00533806|Young Children
541585|NCT00533793|bone, tibial shaft fracture
541586|NCT00533637|Allergic rhinitis
541587|NCT00533637|Nasal spray
541588|NCT00533637|Anti-histamine
541589|NCT00533637|Tolerability
541590|NCT00533624|Gastrointestinal toxicity
541591|NCT00533585|Non-Small Cell Lung Cancer
541592|NCT00533585|Lung Cancer
541593|NCT00533585|NSCLC
541594|NCT00533585|malignant pleural effusions
541595|NCT00533585|Sorafenib
541596|NCT00533585|Paclitaxel
541597|NCT00533585|Taxol
541598|NCT00533585|Carboplatin
541599|NCT00533585|Paraplatin
541600|NCT00533585|Bevacizumab
541601|NCT00533585|Avastin
541602|NCT00533585|BAY 43-9006
541603|NCT00533585|Anti-VEGF monoclonal antibody
541604|NCT00533585|rhuMAb-VEGF
541605|NCT00533559|type 2 diabetes
541606|NCT00533559|free fatty acids
541607|NCT00533559|insulin resistance
541608|NCT00533559|beta cell lipotoxic effect
541609|NCT00533546|Acute Ischemic Stroke
541610|NCT00533533|Docetaxel,Oxaliplatin
541611|NCT00533533|Phase I/II study
541612|NCT00533533|Advanced gastric cancer
541613|NCT00533533|First line treatment
541614|NCT00533533|Advanced gastric cancer with measurable disease
541615|NCT00533507|Pneumococcal vaccine.
541616|NCT00533507|Pneumococcal disease
541617|NCT00533507|Safety
541618|NCT00533507|Immunogenicity
541619|NCT00533507|Primary vaccination
541620|NCT00533468|pain
541621|NCT00533468|lumbar puncture
541622|NCT00533468|neonates
541623|NCT00533468|infants
541624|NCT00533468|emergency department
541625|NCT00533468|topical anesthesia
541626|NCT00533468|LMX4
541627|NCT00533455|Antipsychotics, tremor
541628|NCT00533442|Rapamycin
541629|NCT00533442|Mycophenolate mofetil
541630|NCT00533442|kidney-pancreas transplant
541631|NCT00533416|Myelodyplastic Syndrome (MDS)
541632|NCT00533416|Selective Mitotic Inhibitor
541633|NCT00533416|Targeted Therapy
541634|NCT00533416|Myelodysplastic Syndrome
541635|NCT00533416|MDS
541636|NCT00532701|Chronic hepatitis C
541637|NCT00532701|Genotype
541638|NCT00532701|Interferon
541639|NCT00532701|Ribavirin
541640|NCT00532701|Genotype 2
541641|NCT00532701|Peginterferon
541642|NCT00532688|acetylcysteine
541643|NCT00532688|N-acetylcysteine
541644|NCT00532688|heart failure
541645|NCT00532688|renal failure
541646|NCT00532675|Myeloma
541647|NCT00532675|Multiple Myeloma
541648|NCT00532675|Lenalidomide
541649|NCT00532675|Revlimid
541650|NCT00532675|Dexamethasone
541651|NCT00532675|LBH589
541652|NCT00532675|Combination
541653|NCT00532662|Epidural
541654|NCT00532662|Intravenous
541655|NCT00532662|Ketamine
541656|NCT00532662|Analgesia
541657|NCT00532662|Caudal
541658|NCT00532662|Pediatric
541659|NCT00532662|Regional
541660|NCT00532662|Local Anesthetics
541661|NCT00532636|Airway
541662|NCT00532636|Airway obstruction
541663|NCT00532636|Mouth-to-mask resuscitation
541664|NCT00532636|Respiration artificial
541665|NCT00532636|Ventilation
541666|NCT00532636|Ventilation of an unprotected airway
541667|NCT00532636|Safety and efficiency of mask ventilation
541668|NCT00532636|Avoidance of stomach inflation
541669|NCT00532610|Diabetes,
541670|NCT00532610|ECG,
541671|NCT00532610|Healthy Volunteers
541672|NCT00532610|GSK189075,
541673|NCT00532597|Vascular Endothelium-Dependent Relaxation
541674|NCT00532597|Hemodialysis
541675|NCT00532597|Hemodiafiltration
541676|NCT00533390|efavirenz
541677|NCT00533390|tuberculosis
541678|NCT00533390|AIDS
541679|NCT00533390|rifampicin
541680|NCT00533390|efficacy
541681|NCT00533390|safety
541682|NCT00533390|Treatment Naive
541683|NCT00533338|Breast Cancer
541684|NCT00533338|Cancer Survivors
541685|NCT00533338|Weight Gain Prevention
541686|NCT00533338|Diet
541687|NCT00533338|Exercise
541688|NCT00533338|Questionnaire
541689|NCT00533338|Survey
541690|NCT00533299|Epigenetics, hydralazine, valproate, ovarian cancer
541691|NCT00533286|physiotherapy
541692|NCT00533286|Tuebingen concept
541693|NCT00533286|benzodiazepines
541694|NCT00533286|muscle relaxants
541695|NCT00533286|disc herniation
541696|NCT00533260|Patients with a manic episode or patients diagnosed with schizophrenia , patients who are being treated with quetiapine and are on a stable dosing regime
541697|NCT00533247|Cox-2 Inhibitor
541698|NCT00533247|Pre-emptive Pain
541699|NCT00533247|Preoperative Pain
541700|NCT00533247|Pain Prophylaxis
541701|NCT00533247|Celebrex
541702|NCT00533247|Celecoxib
541703|NCT00533234|Elbow fracture
541704|NCT00533234|Elbow dislocation
541705|NCT00533234|Radial head fracture
541706|NCT00533234|Radial neck fracture
541707|NCT00533221|growth hormone
541708|NCT00533221|strength
541709|NCT00533221|Spinal muscular atrophy type II and III
541710|NCT00533195|UVA1
541711|NCT00533195|PUVA
541712|NCT00533195|atopic dermatitis
541713|NCT00533182|Influenza Infection
541714|NCT00533182|Immunocompromised Host
541715|NCT00533182|Resistance Mutations
541716|NCT00533182|Prolonged Infection
541717|NCT00533169|Neuroblastoma
541718|NCT00533169|ZD6474
541719|NCT00533169|Zactima
541720|NCT00533169|Isotretinoin
541721|NCT00533169|13-Cis Retinoic Acid
541722|NCT00533169|Accutane
541723|NCT00533169|Pediatric Neuroblastoma
541724|NCT00533156|Closure Device
541725|NCT00533156|Angiography
541726|NCT00533156|Angioplasty
541727|NCT00533156|Hemostasis
541728|NCT00533156|Heart Catheterization
541729|NCT00533156|Vascular Closure
541730|NCT00533156|Peripheral Closure
541731|NCT00533156|Coronary Angiography
541732|NCT00533143|Solid cancer patient
541733|NCT00533143|Non-invasive ventilation
541734|NCT00533143|Acute Respiratory Failure
541735|NCT00533130|AO
541736|NCT00533130|Pediatric
541737|NCT00533130|Classification
541738|NCT00533130|Long Bones
541739|NCT00533130|fractures
541740|NCT00533130|bones
541741|NCT00533117|suicide
541742|NCT00533117|self-mutilation
541743|NCT00533117|fluoxetine
541744|NCT00533117|placebo
541745|NCT00533117|dialectical behavior therapy
541746|NCT00533117|supportive therapy
541747|NCT00533104|Limb ischemia
541748|NCT00533104|Cell Therapy
541749|NCT00533078|omega3 fatty acid
541750|NCT00533078|parenteral nutrition
541751|NCT00533078|chemotherapy
541752|NCT00533078|infection
541753|NCT00533078|neutropenia
541754|NCT00533065|Aging
541755|NCT00533052|Behavioral weight loss
541756|NCT00532974|HIV
541757|NCT00532974|Human Immunodeficiency Virus
541758|NCT00532974|Vaccines
541759|NCT00532974|HIV Vaccines
541760|NCT00532974|Peptide
541761|NCT00532974|Peptide Vaccines
541762|NCT00532974|HIV 1
541763|NCT00532883|Sickle Cell Disease
541764|NCT00532883|Vaso-occlusive Event
541765|NCT00532883|Painful Crises
541766|NCT00532883|Acute Chest Syndrome
541767|NCT00532870|laparoscopy
541768|NCT00532870|ventral hernia
541769|NCT00532870|mesh
541770|NCT00532870|Ventral hernias are the second most common type of abdominal hernias after inguinal hernias.
541771|NCT00532870|The majority of ventral hernias are incisional hernias that develop in 11% to 20% of patients who undergo Laparotomy .
541772|NCT00532870|Surgeons have struggled to reduce the morbidity from incarceration (6% to 15% of cases) and strangulation (2%) of these hernias.
541773|NCT00532857|Patients with HER2 + stage II/III breast cancer
541774|NCT00532844|6R-BH4
541775|NCT00532844|BH4
541776|NCT00532844|BH4 deficiency
541777|NCT00532844|sapropterin dihydrochloride
541778|NCT00532844|endothelial dysfunction
541779|NCT00532844|NO
541780|NCT00532844|Hypertension
541781|NCT00532844|Nitric Oxide
541782|NCT00532844|Vitamin C
541783|NCT00532818|Epigenetic therapy
541784|NCT00532818|Hydralazine
541785|NCT00532818|Valproate
541786|NCT00532818|Cervical cancer
541787|NCT00532818|Randomized
541788|NCT00532818|Phase III
541789|NCT00532805|Alpha 1-Antitrypsin Deficiency
541790|NCT00532792|Avian
541791|NCT00532792|Pandemic
541792|NCT00532792|Influenza
541793|NCT00532792|A/H5N1
541794|NCT00532779|Obesity
541795|NCT00532779|Antiobesity agents
541796|NCT00532779|Antiobesity drugs
541797|NCT00532779|Overweight drug therapy
541798|NCT00532779|Obese drug therapy
541799|NCT00532779|Weight loss drug effects
541800|NCT00532779|Bupropion administration and dosage
541801|NCT00532779|Naltrexone administration and dosage
541802|NCT00532779|Double blind method
541803|NCT00532779|Combination drug therapy
541804|NCT00532779|Delayed action preparations
541805|NCT00532766|Healthy subjects
541806|NCT00532753|empowerment
541807|NCT00532753|health
541808|NCT00532753|education
541809|NCT00532740|liver metastases
541810|NCT00532740|advanced adult primary liver cancer
541811|NCT00532727|Breast Cancer
541812|NCT00532727|Triple Negative
541813|NCT00532584|COPD
541814|NCT00532584|inhaled steroids
541815|NCT00532584|bronchodilator
541816|NCT00532584|gene expression
541817|NCT00532584|smoker's lungs
541818|NCT00532571|CoQ10
541819|NCT00532571|PSP
541820|NCT00532571|CBD
541821|NCT00532558|Hyperlipidemia
541822|NCT00532558|Drug Therapy
541823|NCT00532532|Multiple sclerosis
541824|NCT00532493|Combat Trauma
541825|NCT00532493|Post traumatic stress disorder
541826|NCT00532493|PTSD
541827|NCT00532493|Sleep Disturbance
541828|NCT00532493|Trauma-Related Nightmares
541829|NCT00532480|Depression
541830|NCT00532480|Duloxetine
541831|NCT00532480|fMRI
541832|NCT00532480|pictures
541833|NCT00532467|healthy volunteers
541834|NCT00532415|Vitrectomy
541835|NCT00532415|Visualization
541836|NCT00532402|Monitoring
541837|NCT00532402|Breathing Gas
541838|NCT00532402|Propofol
541839|NCT00532389|Myeloma
541840|NCT00532389|Multiple Myeloma
541841|NCT00532389|Bortezomib
541842|NCT00532389|LBH589
541843|NCT00532389|Combination
541844|NCT00532376|epilepsy
541845|NCT00532376|depression
541846|NCT00532376|fMRI
541847|NCT00532376|emotion
541848|NCT00532350|COPD
541849|NCT00532350|pharmacokinetics
541850|NCT00532350|plethysmography
541851|NCT00532350|cycle ergometry
541852|NCT00532350|exercise testing
541853|NCT00532350|spirometry
541854|NCT00532337|ONO-5334
541855|NCT00532337|osteoporosis
541856|NCT00532337|osteopenia
541857|NCT00532324|Methicillin resistant Staphylococcus aureus
541858|NCT00532324|Staphylococcus aureus
541859|NCT00532324|Healthy term and near term neonates
541860|NCT00532324|Prevention
541861|NCT00532324|Nasal and Vaginal Colonization rates
541862|NCT00532324|Pregnant women
541863|NCT00532311|Hyperlipidemia
541864|NCT00532311|Drug Therapy
541865|NCT00532298|Fluarix
541866|NCT00532298|Influenza Infection
541867|NCT00532298|GSK Biologicals' influenza vaccine GSK576389A
541868|NCT00532259|Lymphoma, Large B-Cell, Diffuse
541869|NCT00532259|Transformed Follicular Lymphoma
541870|NCT00532259|Stem cell transplantation
541871|NCT00532259|Relapsed
541872|NCT00532259|Refractory
541873|NCT00532233|Idiopathic Pulmonary Fibrosis
541874|NCT00532220|osteonecrosis
541875|NCT00532220|bone marrow edema
541876|NCT00532220|ibandronate
541877|NCT00532220|bisphosphonate
541878|NCT00532220|knee
541879|NCT00532194|ovarian cancer
541880|NCT00532194|fallopian tube cancer
541881|NCT00532194|primary serous peritoneal cancer
541882|NCT00532194|gynaecological carcinoma
541883|NCT00532194|randomised controlled trial
541884|NCT00532194|Cediranib
541885|NCT00532194|AZD2171
541886|NCT00532194|efficacy
541887|NCT00532181|Health insurance
541888|NCT00532181|Health utilization rates
541889|NCT00532181|Saving Behavior
541890|NCT00532181|Risk aversion
541891|NCT00532168|advanced HIV-infected patients
541892|NCT00532168|late presenters
541893|NCT00532168|antiretroviral therapy
541894|NCT00532168|immune reconstitution
541895|NCT00532168|Treatment Naive
541896|NCT00532155|lung cancer
541897|NCT00532155|angiogenesis inhibitor
541898|NCT00532155|chemotherapy
541899|NCT00532116|Healthy
541900|NCT00532116|Elderly
541901|NCT00532116|Non Elderly
541902|NCT00532116|Healthy Volunteers
541903|NCT00532103|Suicidal Ideation
541904|NCT00532103|Major Depressive Disorder
541905|NCT00532103|Suicide Risk
541906|NCT00532103|Antidepressant Medication
541907|NCT00532077|renal,
541908|NCT00532077|pharmacology,
541909|NCT00532077|Osteoporosis
541910|NCT00532064|Advanced Cancers
541911|NCT00532064|Cardiotoxicity Detection
541912|NCT00532064|Heart Damage
541913|NCT00532064|Troponin 1 Blood Test
541914|NCT00532064|B-type Natriuretic Peptide Blood Test
541915|NCT00532064|Questionnaire
541916|NCT00532064|Survey
541917|NCT00532064|BNP
541918|NCT00532051|cataract, lasik, laser refractive surgery
541919|NCT00532038|Osteoarthritis
541920|NCT00532038|Pain
541921|NCT00532025|Sorafenib
541922|NCT00532025|NSCLC
541923|NCT00532025|Adjuvant Treatment
541924|NCT00532025|resected Non-Small Cell Lung Carcinoma
541925|NCT00532012|Rheumatoid Arthritis
541926|NCT00532012|RhuDex®
541927|NCT00532012|Meglumine
541928|NCT00532012|Oral Bioavailability
541929|NCT00531999|Raltegravir
541930|NCT00531999|Euglycaemic clamp
541931|NCT00531999|healthy volunteer
541932|NCT00531986|Monotherapy
541933|NCT00531986|Neuropsychological tests
541934|NCT00531986|HIV viral load in ZNS
541935|NCT00531986|HIV viral load in genital
541936|NCT00531986|Lumbar puncture and HIV viral load in ZNS
541937|NCT00531986|Monotherapy and compartment failure (ZNS and genital)
541938|NCT00531986|ZNS viral load under monotherapy
541939|NCT00531986|Genital viral load under monotherapy
541940|NCT00531986|Neuropsychological tests (HIV Dementia)
541941|NCT00531986|Treatment Experienced
541942|NCT00531973|breast cancer
541943|NCT00531973|echocardiography
541944|NCT00531973|neoplasia
541945|NCT00531947|Mental Health
541946|NCT00531947|Adolescents
541947|NCT00531947|Major Depressive Disorder
541948|NCT00531947|Depression
541949|NCT00531947|Adolescent Depression
541950|NCT00531947|Pediatric Depression
541951|NCT00531921|Heart Diseases
541952|NCT00531921|Kidney Diseases
541953|NCT00531921|Liver Diseases
541954|NCT00531921|Liver Failure
541955|NCT00531921|Lung Diseases
541956|NCT00531921|Transplant
541957|NCT00531921|Transplantation, Homologous
541958|NCT00531921|Rejection
541959|NCT00531921|Kidney Failure
541960|NCT00531908|Growth Hormone
541961|NCT00531908|Epithelial sodium channel
541962|NCT00531908|Hypertension
541963|NCT00531908|A Furosemide
541964|NCT00531908|Nasal Mucosa
541965|NCT00531895|major depression
541966|NCT00531895|chronic headache
541967|NCT00531895|antidepressant
541968|NCT00531895|duloxetine
541969|NCT00531882|healthy volunteers
541970|NCT00531882|neutrophil migration
541971|NCT00531882|anti inflammatory non-steroidal agent
541972|NCT00531882|simvastatin
541973|NCT00531882|pioglitazone
541974|NCT00531869|safewater
541975|NCT00531869|randomized
541976|NCT00531856|Kidney Transplant, Carbon Monoxide
541977|NCT00531843|deep vein thrombosis
541978|NCT00531843|venous thromboembolism
541979|NCT00531843|pulmonary embolism
541980|NCT00531830|children with PDD
541981|NCT00531791|COPD
541982|NCT00531791|exacerbation
541983|NCT00531791|fluticasone
541984|NCT00531791|salmeterol
541985|NCT00531791|steroid
541986|NCT00531778|Women with increased risk for developing ovarian cancer
541987|NCT00531778|early detection
541988|NCT00531778|biomarker for ovarian cancer
541989|NCT00531765|contrast-induced-nephropathy,
541990|NCT00531765|cardiac cath
541991|NCT00531765|creatinine
541992|NCT00531765|contrast
541993|NCT00531765|nephropathy
541994|NCT00531739|Surgery
541995|NCT00531739|Colectomy
541996|NCT00531739|Proctocolectomy
541997|NCT00531739|Adhesions
541998|NCT00531713|hypothyroidism, quality og life, depression
541999|NCT00531700|influenza
542000|NCT00531700|risk behaviors
542001|NCT00531700|immunization
542002|NCT00531700|knowledge attitudes behaviors
542003|NCT00531700|personally controlled health record
542004|NCT00531700|Indivo
542005|NCT00531687|relapse
542006|NCT00531674|Efficacy of public health intervention (nutrition)
542007|NCT00531648|Toddlers that having feeding disorders and SPD
542008|NCT00531635|Mixed hemopoietic chimerism, Fludarabine, TBI, PBSC, immunosuppression, Mycophenolate Mofetil
542009|NCT00531622|Depression
542010|NCT00531622|Major Depressive Episode
542011|NCT00531622|Antidepressant
542012|NCT00531596|Elderly
542013|NCT00531596|Non Elderly
542014|NCT00531596|Healthy Volunteers
542015|NCT00531583|AML in 1st & 2nd complete remission w/no HLA matched related donor
542016|NCT00531570|Women with ultrasound defined complex pelvic masses
542017|NCT00531557|Darunavir
542018|NCT00531557|Euglycaemic clamp
542019|NCT00531557|HIV
542020|NCT00531557|Treatment Experienced
542021|NCT00531531|pulmonary infection
542022|NCT00531531|transmission
542023|NCT00531531|P.Aeruginosa
542024|NCT00531531|surfaces
542025|NCT00531518|Schizophrenia
542026|NCT00531518|Bipolar disorder
542027|NCT00531518|Psychosis
542028|NCT00531518|Prodromal psychosis
542029|NCT00531518|Family psychoeducation
542030|NCT00531518|Supported education
542031|NCT00531518|Supported employment
542032|NCT00531518|Ulra-high-risk for psychosis
542033|NCT00531518|Major depression
542034|NCT00531518|Bipolar disorder, with psychotic features
542035|NCT00531518|Major depression, with psychotic features
542036|NCT00531518|Attenuated, prodromal psychotic symptoms
542037|NCT00531505|Obesity
542038|NCT00531492|Maternal and child health
542039|NCT00531492|Developing country
542040|NCT00531492|Skin to skin care
542041|NCT00531492|Newly born low birth weight infants and their mothers
542042|NCT00531492|(Delivery at University Hospital Center, Mahajanga, Madagascar)
542043|NCT00531466|Spinal cord injury
542044|NCT00531440|Renal transplantation, everolimus, Immunosuppressants
542045|NCT00531427|Chronic pain,
542046|NCT00531427|OA of the knee,
542047|NCT00531427|opioid,
542048|NCT00531427|transdermal
542049|NCT00531414|Asthmatic
542050|NCT00531414|healthy
542051|NCT00531401|Non-Small-Cell Lung
542052|NCT00531362|Atherosclerosis
542053|NCT00531362|Aspirin
542054|NCT00531362|Resistance,
542055|NCT00531362|Acute coronary syndromes
542056|NCT00531349|Endometrial Cancer
542057|NCT00531349|Anesthesia; regional
542058|NCT00531349|cancer recurrence
542059|NCT00531349|Analgesia; opioid
542060|NCT00531336|age-related Macular degeneration
542061|NCT00531336|Macugen
542062|NCT00531336|Avastin
542063|NCT00531323|Pharmacokinetic
542064|NCT00531323|TMC125
542065|NCT00531323|Healthy volunteers
542066|NCT00531323|Efavarinz
542067|NCT00531310|CML
542068|NCT00531310|allogeneic SCT
542069|NCT00531310|matched family donor
542070|NCT00531310|unrelated donor
542071|NCT00531310|cord blood donor
542072|NCT00531310|persistent disease
542073|NCT00531284|Non-small cell lung carcinoma
542074|NCT00531284|Small-cell lung carcinoma
542075|NCT00531284|Ovarian Cancer
542076|NCT00531284|Renal Cancer
542077|NCT00531284|Other solid tumors
542078|NCT00531284|multiple myeloma
542079|NCT00531284|lymphoma
542080|NCT00531258|Depression
542081|NCT00531258|TBI
542082|NCT00531258|TMS
542083|NCT00531258|Major Depression resulting from a mild to moderate closed head injury
542084|NCT00531245|TS-1 and oxaliplatin
542085|NCT00531245|Phase I/II study
542086|NCT00531245|Colorectal cancer
542087|NCT00531245|First line treatment
542088|NCT00531232|Previously treated Myelodysplastic Syndromes (MDS)
542089|NCT00531232|oral clofarabine
542090|NCT00531232|Intermediate-1, Intermediate-2 and High Risk Myelodysplastic Syndromes (MDS)
542091|NCT00531232|secondary AML (with history of MDS)
542092|NCT00531219|appendicitis
542093|NCT00531219|cholelithiasis
542094|NCT00531219|gallstones
542095|NCT00531193|Healthy male volunteers
542096|NCT00531180|Esophageal Cancer
542097|NCT00531180|Lung Cancer
542098|NCT00531180|Thoracic Malignancies
542099|NCT00531180|4D CT scans
542100|NCT00531180|Lung Function
542101|NCT00531167|lamivudine resistant mutations
542102|NCT00531167|rescue therapy
542103|NCT00531141|age-related macular degeneration
542104|NCT00531141|optical coherence tomography
542105|NCT00531141|retinal thickness
542106|NCT00531141|exudative age-related macular degeneration
542107|NCT00531128|Sitosterol
542108|NCT00531128|Nutrigenomics
542109|NCT00531128|Gene Expression
542110|NCT00531128|Insulin Resistance
542111|NCT00531128|Sitosterolemia
542112|NCT00531115|metastatic colorectal cancer
542113|NCT00531115|elderly patients
542114|NCT00531115|cetuximab, oxaliplatin, capecitabine
542115|NCT00531102|oxygen
542116|NCT00531102|continuous positive airway pressure
542117|NCT00531102|infant, newborn
542118|NCT00531102|resuscitation
542119|NCT00531089|TTP
542120|NCT00531089|thrombotic thrombocytopenic purpura
542121|NCT00531089|HUS
542122|NCT00531089|hemolytic uremic syndrome
542123|NCT00531089|plasma exchange
542124|NCT00531076|bevacizumab
542125|NCT00531076|thoracic radiotherapy
542126|NCT00531076|locally-advanced non-small cell lung cancer
542127|NCT00531063|Renal transplantation, everolimus, Immunosuppressants
542128|NCT00531050|COPD
542129|NCT00531050|cycle ergometry
542130|NCT00531050|exercise testing
542131|NCT00531050|spirometry
542132|NCT00531050|cardiovascular
542133|NCT00531050|salbutamol
542134|NCT00531050|indacaterol
542135|NCT00531050|chronic obstructive pulmonary disease
542136|NCT00531037|AV block, SND, BTS, AAIsafeR, SafeR, PM implanted
542137|NCT00531024|Exudative Neovascular
542138|NCT00531024|AMD
542139|NCT00531024|Avastin
542140|NCT00531024|Systemic
542141|NCT00531024|Exudative Age-Related Macular Degeneration
542142|NCT00531011|Stents
542143|NCT00531011|Drug-eluting Stent
542144|NCT00531011|Angioplasty
542145|NCT00531011|Coronary Artery stenosis
542146|NCT00531011|Coronary Artery Stent Restenosis
542147|NCT00531011|Stent Thrombosis
542148|NCT00530998|appendicitis
542149|NCT00530998|cholelithiasis
542150|NCT00530998|Gallstones
542151|NCT00530985|disability
542152|NCT00530985|substance abuse
542153|NCT00530985|vocational rehabilitation
542154|NCT00530985|case management
542155|NCT00530972|co-infected HCV/HIV
542156|NCT00530972|relapsers
542157|NCT00530907|Advanced Cancer
542158|NCT00530907|Valproic Acid
542159|NCT00530907|Depakene
542160|NCT00530907|Bevacizumab
542161|NCT00530907|Avastin
542162|NCT00530907|Anti-VEGF monoclonal antibody
542163|NCT00530907|rhuMAb-VEGF
542164|NCT00530894|Valvular Heart Disease
542165|NCT00530894|Critical/Severe Aortic Stenosis
542166|NCT00530894|High risk symptomatic patients
542167|NCT00530868|Hormonal and antibody therapy for breast cancer
542168|NCT00530868|Hormonal therapy for breast cancer
542169|NCT00530868|Antibody therapy for breast cancer
542170|NCT00530855|Epilepsy
542171|NCT00530855|Partial-onset Seizures
542172|NCT00530855|Lacosamide
542173|NCT00530855|Monotherapy
542174|NCT00530855|Vimpat
542175|NCT00530829|diarrhea
542176|NCT00530829|zinc
542177|NCT00530829|oral rehydration therapy
542178|NCT00530803|pain
542179|NCT00530803|venipuncture
542180|NCT00530803|children
542181|NCT00530790|Restless Legs Syndrome
542182|NCT00530777|Disease Transmission, Vertical
542183|NCT00530777|valacyclovir
542184|NCT00530777|Randomized Controlled Trials
542185|NCT00530777|HIV
542186|NCT00530777|herpes
542187|NCT00530777|Herpesvirus 2, Human
542188|NCT00530777|HIV Seronegativity
542189|NCT00530764|Pain
542190|NCT00530764|Cancer
542191|NCT00530764|Palliative
542192|NCT00530751|breast cancer
542193|NCT00530738|HPN
542194|NCT00530738|lipid emulsion
542195|NCT00530738|long term
542196|NCT00530738|insufficient enteral resorption capacity
542197|NCT00530725|occult pneumothorax
542198|NCT00530725|mechanical ventilation
542199|NCT00530725|critical care
542200|NCT00530725|pneumothorax
542201|NCT00530725|thoracostomy
542202|NCT00530712|SFA
542203|NCT00530712|Popliteal
542204|NCT00530712|Stent
542205|NCT00530712|EverFlex
542206|NCT00530699|Acute Myeloid Leukaemia
542207|NCT00530699|Phase 1
542208|NCT00530699|AZD1152
542209|NCT00530686|Diabetes Mellitus
542210|NCT00530686|Hypoglycemia
542211|NCT00530686|Hyperglycemia
542212|NCT00530686|Type 1 Diabetes
542213|NCT00530686|Islet cell transplantation
542214|NCT00530660|Pandemic influenza
542215|NCT00530647|Brain motor network, Plasticity, functional MRI, Stroke
542216|NCT00530634|stage II non-small cell lung cancer
542217|NCT00530634|stage IIIA non-small cell lung cancer
542218|NCT00530634|stage IIIB non-small cell lung cancer
542219|NCT00530595|hemodialysis
542220|NCT00530582|progesterone, postmenopause, sleep-EEG
542221|NCT00530569|Breast Cancer
542222|NCT00530569|Herceptin Therapy
542223|NCT00530543|Robot
542224|NCT00530543|Gait
542225|NCT00530543|Stroke
542226|NCT00530530|ASP8825
542227|NCT00530530|Restless legs Syndrome
542228|NCT00530530|XP13512
542229|NCT00530517|migraine
542230|NCT00530517|sumatripatan
542231|NCT00530504|Carotid Artery Disease
542232|NCT00530504|Embolic Protection
542233|NCT00530491|lung resection
542234|NCT00530491|reduced pulmonary function
542235|NCT00530478|Donepezil
542236|NCT00530478|Stroke
542237|NCT00530478|Cognitive function
542238|NCT00530478|Cognitive neural network
542239|NCT00530452|COX-2
542240|NCT00530452|carbonic anhydrase
542241|NCT00530452|osteoarthritis
542242|NCT00530452|anti-inflammatory
542243|NCT00530452|Cyclooxygenase Inhibitors
542244|NCT00530426|Heart Failure, Congestive
542245|NCT00530426|Registry
542246|NCT00530426|Acute Decompensated Heart Failure
542247|NCT00530426|Dyspnea
542248|NCT00530400|Antibiotic prophylaxis
542249|NCT00530400|Bacterial Infections / prevention & control
542250|NCT00530400|Surgical wound infection / prevention & control
542251|NCT00530400|Neurosurgery
542252|NCT00530400|Postoperative Complications / prevention & control
542253|NCT00530400|Clinical trial [publication type]
542254|NCT00530387|Photocontact
542255|NCT00530387|Dermatitis
542256|NCT00530387|NSAID
542257|NCT00530387|Sunscreen
542258|NCT00530387|Photopatch
542259|NCT00530374|Pediatrics
542260|NCT00530374|Malnutrition
542261|NCT00530374|Iron Deficiency
542262|NCT00530374|Sprinkles
542263|NCT00530374|Oral Iron Supplementation
542264|NCT00530361|Myocardial Ischemia
542265|NCT00530361|Kidney failure
542266|NCT00530361|CABG
542267|NCT00530361|Cardiopulmonary bypass (CPB) pump
542268|NCT00530361|Coronary Artery Bypass Surgery
542269|NCT00530361|Heart surgery
542270|NCT00530361|Nesiritide
542271|NCT00530361|Coronary Heart Disease
542272|NCT00530348|Multiple Sclerosis
542273|NCT00530322|Adhesions
542274|NCT00530322|Laparoscopy
542275|NCT00530322|Colorectal surgery
542276|NCT00530322|Colorectal disease
542277|NCT00530309|GLP-1
542278|NCT00530309|type 2 diabeted mellitus
542279|NCT00530309|safety
542280|NCT00530309|GSK716155
542281|NCT00530309|GLP-1 receptor agonist
542282|NCT00530309|tolerability
542283|NCT00530309|pharmacokinetics
542284|NCT00530309|pharmacodynamics
542285|NCT00530296|Depression
542286|NCT00530296|End stage renal disease
542287|NCT00530296|Quality of Life
542288|NCT00530296|Cognitive Behavioral Therapy
542289|NCT00530283|Squamous
542290|NCT00530283|Unknown Primary
542291|NCT00530283|Patients with Squamous cell cancer neck nodes
542292|NCT00530270|Sickle Cell Disease
542293|NCT00530270|ACS
542294|NCT00530270|Acute Chest Syndrome
542295|NCT00530270|Hgb SS
542296|NCT00530270|Hgb Sβ0
542297|NCT00530270|Dexamethasone
542298|NCT00530257|Attention Deficit Hyperactivity Disorder
542299|NCT00530257|Methylphenidate
542300|NCT00530257|Attention
542301|NCT00530257|Working Memory
542302|NCT00530244|cystic fibrosis
542303|NCT00530244|fatty acids
542304|NCT00530244|docosahexaenoic acid
542305|NCT00530244|infant formula
542306|NCT00530244|growth
542307|NCT00530244|pancreatic function
542308|NCT00530231|Capsule endoscopy
542309|NCT00530231|Missing rate
542310|NCT00530218|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
542311|NCT00530218|adult acute myeloid leukemia with inv(16)(p13;q22)
542312|NCT00530218|adult acute myeloid leukemia with t(15;17)(q22;q12)
542313|NCT00530218|adult acute myeloid leukemia with t(16;16)(p13;q22)
542314|NCT00530218|adult acute myeloid leukemia with t(8;21)(q22;q22)
542315|NCT00530218|accelerated phase chronic myelogenous leukemia
542316|NCT00530218|adult acute lymphoblastic leukemia in remission
542317|NCT00530218|adult acute myeloid leukemia in remission
542318|NCT00530218|atypical chronic myeloid leukemia
542319|NCT00530218|blastic phase chronic myelogenous leukemia
542320|NCT00530218|chronic eosinophilic leukemia
542321|NCT00530218|chronic idiopathic myelofibrosis
542322|NCT00530218|chronic myelomonocytic leukemia
542323|NCT00530218|chronic neutrophilic leukemia
542324|NCT00530218|chronic phase chronic myelogenous leukemia
542325|NCT00530218|de novo myelodysplastic syndromes
542326|NCT00530218|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
542327|NCT00530218|myelodysplastic/myeloproliferative disease, unclassifiable
542328|NCT00530218|nodal marginal zone B-cell lymphoma
542329|NCT00530218|noncontiguous stage II adult Burkitt lymphoma
542330|NCT00530218|noncontiguous stage II adult diffuse large cell lymphoma
542331|NCT00530218|noncontiguous stage II adult diffuse mixed cell lymphoma
542332|NCT00530218|noncontiguous stage II adult diffuse small cleaved cell lymphoma
542333|NCT00530218|noncontiguous stage II adult immunoblastic large cell lymphoma
542334|NCT00530218|noncontiguous stage II adult lymphoblastic lymphoma
542335|NCT00530218|noncontiguous stage II grade 1 follicular lymphoma
542336|NCT00530218|noncontiguous stage II grade 2 follicular lymphoma
542337|NCT00530218|noncontiguous stage II grade 3 follicular lymphoma
542338|NCT00530218|noncontiguous stage II mantle cell lymphoma
542339|NCT00530218|noncontiguous stage II marginal zone lymphoma
542340|NCT00530218|noncontiguous stage II small lymphocytic lymphoma
542341|NCT00530218|previously treated myelodysplastic syndromes
542342|NCT00530218|recurrent adult acute lymphoblastic leukemia
542343|NCT00530218|recurrent adult acute myeloid leukemia
542344|NCT00530218|recurrent adult Burkitt lymphoma
542345|NCT00530218|recurrent adult Hodgkin lymphoma
542346|NCT00530218|recurrent adult diffuse large cell lymphoma
542347|NCT00530218|recurrent adult diffuse mixed cell lymphoma
542348|NCT00530218|recurrent adult diffuse small cleaved cell lymphoma
542349|NCT00530218|recurrent adult immunoblastic large cell lymphoma
542350|NCT00530218|recurrent adult lymphoblastic lymphoma
542351|NCT00530218|recurrent cutaneous T-cell non-Hodgkin lymphoma
542352|NCT00530218|recurrent grade 1 follicular lymphoma
542353|NCT00530218|recurrent grade 2 follicular lymphoma
542354|NCT00530218|recurrent grade 3 follicular lymphoma
542355|NCT00530218|recurrent mantle cell lymphoma
542356|NCT00530218|recurrent marginal zone lymphoma
542357|NCT00530218|recurrent mycosis fungoides/Sezary syndrome
542358|NCT00530218|recurrent small lymphocytic lymphoma
542359|NCT00530218|refractory chronic lymphocytic leukemia
542360|NCT00530218|refractory hairy cell leukemia
542361|NCT00530218|refractory multiple myeloma
542362|NCT00530218|relapsing chronic myelogenous leukemia
542363|NCT00530218|secondary acute myeloid leukemia
542364|NCT00530218|secondary myelodysplastic syndromes
542365|NCT00530218|splenic marginal zone lymphoma
542366|NCT00530218|stage I multiple myeloma
542367|NCT00530218|stage II multiple myeloma
542368|NCT00530218|stage III adult Burkitt lymphoma
542369|NCT00530218|stage III adult Hodgkin lymphoma
542370|NCT00530218|stage III adult diffuse large cell lymphoma
542371|NCT00530218|stage III adult diffuse mixed cell lymphoma
542372|NCT00530218|stage III adult diffuse small cleaved cell lymphoma
542373|NCT00530218|stage III adult immunoblastic large cell lymphoma
542374|NCT00530218|stage III adult lymphoblastic lymphoma
542375|NCT00530218|stage III chronic lymphocytic leukemia
542376|NCT00530218|stage III grade 1 follicular lymphoma
542377|NCT00530218|stage III grade 2 follicular lymphoma
542378|NCT00530218|stage III grade 3 follicular lymphoma
542379|NCT00530218|stage III mantle cell lymphoma
542380|NCT00530218|stage III marginal zone lymphoma
542381|NCT00530218|stage III multiple myeloma
542382|NCT00530218|stage III small lymphocytic lymphoma
542383|NCT00530218|stage IV adult Burkitt lymphoma
542384|NCT00530218|stage IV adult Hodgkin lymphoma
542385|NCT00530218|stage IV adult diffuse large cell lymphoma
542386|NCT00530218|stage IV adult diffuse mixed cell lymphoma
542387|NCT00530218|stage IV adult diffuse small cleaved cell lymphoma
542388|NCT00530218|stage IV adult immunoblastic large cell lymphoma
542389|NCT00530218|stage IV adult lymphoblastic lymphoma
542390|NCT00530218|stage IV chronic lymphocytic leukemia
542391|NCT00530218|stage IV grade 1 follicular lymphoma
542392|NCT00530218|stage IV grade 2 follicular lymphoma
542393|NCT00530218|stage IV grade 3 follicular lymphoma
542394|NCT00530218|stage IV mantle cell lymphoma
542395|NCT00530218|stage IV marginal zone lymphoma
542396|NCT00530218|stage IV small lymphocytic lymphoma
542397|NCT00530205|weight changes
542398|NCT00530205|malnutrition
542399|NCT00530205|stage III non-small cell lung cancer
542400|NCT00530192|Refractory Cancer
542401|NCT00530192|Molecular Profile
542402|NCT00530179|Diffuse Large B-Cell Lymphoma
542403|NCT00530179|Positron Emission Tomography
542404|NCT00530179|CHOP Chemotherapy protocol
542405|NCT00530179|Stem Cell Transplantation
542406|NCT00530179|Fluorodeoxyglucose F18
542407|NCT00530166|Asthma
542408|NCT00530166|persistant asthma
542409|NCT00530166|controller medications
542410|NCT00530166|FEV1
542411|NCT00530153|Eating
542412|NCT00530153|Food Habits
542413|NCT00530153|Adolescent
542414|NCT00530153|Dental Research
542415|NCT00530140|Follicular Lymphoma
542416|NCT00530140|Idiotype vaccine
542417|NCT00530127|Friedreich's ataxia
542418|NCT00530088|recurrent squamous cell carcinoma of the larynx
542419|NCT00530088|recurrent squamous cell carcinoma of the lip and oral cavity
542420|NCT00530088|stage I squamous cell carcinoma of the larynx
542421|NCT00530088|stage I squamous cell carcinoma of the lip and oral cavity
542422|NCT00530088|stage 0 laryngeal cancer
542423|NCT00530088|stage 0 lip and oral cavity cancer
542424|NCT00530075|Wegener Granulomatosis
542425|NCT00530075|Vasculitis
542426|NCT00530075|Gusperimus
542427|NCT00530075|Immunosuppression
542428|NCT00530062|Asthma and Poor Coordinators of Asthma Inhalers
542429|NCT00530049|psychosocial effects of cancer and its treatment
542430|NCT00530049|hypopharyngeal cancer
542431|NCT00530049|laryngeal cancer
542432|NCT00530049|lip and oral cavity cancer
542433|NCT00530049|metastatic squamous neck cancer with occult primary
542434|NCT00530049|nasopharyngeal cancer
542435|NCT00530049|oropharyngeal cancer
542436|NCT00530049|paranasal sinus and nasal cavity cancer
542437|NCT00530049|salivary gland cancer
542438|NCT00530049|tongue cancer
542439|NCT00530049|07-098
542440|NCT00530036|Mortality
542441|NCT00530036|Patient readmission
542442|NCT00530036|Institutionalization
542443|NCT00530010|adult primary hepatocellular carcinoma
542444|NCT00530010|localized unresectable adult primary liver cancer
542445|NCT00530010|advanced adult primary liver cancer
542446|NCT00529997|Lumbar Spine
542447|NCT00529997|Lumbar Spinal Stenosis
542448|NCT00529997|Spondylolisthesis
542449|NCT00529997|Dynamic Stabilization
542450|NCT00529997|Motion Preserving
542451|NCT00529997|Arthroplasty
542452|NCT00529997|Randomized
542453|NCT00529997|Investigational
542454|NCT00529997|Back Pain
542455|NCT00529997|Leg Pain
542456|NCT00529984|CEA
542457|NCT00529984|CEA-expressing malignancies
542458|NCT00529984|Metastatic malignancies
542459|NCT00529984|VRP Vaccine
542460|NCT00529984|Alphavirus replicons
542461|NCT00529984|Molecular therapeutics
542462|NCT00529984|Stage III colon cancer
542463|NCT00529971|Mindfulness
542464|NCT00529971|HIV
542465|NCT00529971|Male
542466|NCT00529971|Living with HIV
542467|NCT00529971|18-70 years of age
542468|NCT00529971|live within one hour of hospital
542469|NCT00529971|fluent in English
542470|NCT00529971|Complementary Therapies
542471|NCT00529971|HIV Therapeutic Vaccine
542472|NCT00529958|Anterior Cruciate Ligament (ACL) Reconstruction
542473|NCT00529958|Patellar Tendon
542474|NCT00529958|Hamstring Tendon
542475|NCT00529958|Double-Bundle
542476|NCT00529958|Autograft
542477|NCT00529945|PFO
542478|NCT00529945|Stroke
542479|NCT00529945|Transient Ischemic Attack
542480|NCT00529945|Migraine
542481|NCT00529945|Decompression Illness
542482|NCT00529932|Acute Myocardial Infarction
542483|NCT00529932|Celltherapy
542484|NCT00529932|Bone Marrow
542485|NCT00529919|Overweight
542486|NCT00529919|Obesity
542487|NCT00529919|Weight loss
542488|NCT00529919|Medium chain triglycerides
542489|NCT00529919|Cardiovascular disease risk
542490|NCT00529906|attention deficit hyperactivity disorder
542491|NCT00529906|neuropsychological deficits
542492|NCT00529906|endophenotype
542493|NCT00529906|molecular genetics
542494|NCT00529906|candidate gene
542495|NCT00529906|family-based association study
542496|NCT00529893|Attention-deficit/Hyperactivity Disorder
542497|NCT00529893|neuropsychological functioning
542498|NCT00529893|Atomoxetine
542499|NCT00529880|AML
542500|NCT00529867|Artemether/Lumefantrine suspension
542501|NCT00529867|P. falciparum malaria
542502|NCT00529867|children
542503|NCT00529867|uncomplicated Plasmodium falciparum malaria
542504|NCT00529854|Intensive care unit
542505|NCT00529854|medical documentation
542506|NCT00529854|medical billing
542507|NCT00529841|Salt Wasting Congenital Adrenal Hyperplasia
542508|NCT00529841|Subcutaneous Hydrocortisone
542509|NCT00529828|CLA
542510|NCT00529828|Industrial trans fatty acids
542511|NCT00529828|Oleic acid
542512|NCT00529828|Controlled dietary trial
542513|NCT00529815|Continuous
542514|NCT00529815|blood
542515|NCT00529815|glucose
542516|NCT00529815|monitoring
542517|NCT00529815|diabetes
542518|NCT00529815|type2
542519|NCT00529802|metastatic
542520|NCT00529802|renal
542521|NCT00529802|cell
542522|NCT00529802|carcinoma
542523|NCT00529802|cancer
542524|NCT00529776|Prevention of ventilator associated pneumonia
542525|NCT00529763|Chronic Phase, Advanced Phase chronic myeloid leukemia
542526|NCT00529763|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
542527|NCT00529737|Breast Cancer
542528|NCT00529737|Marker Clip Migration
542529|NCT00529737|Vacuum-Assisted Biopsy
542530|NCT00529737|Postprocedure Mammogram
542531|NCT00529737|Breast Biopsy
542532|NCT00529724|Energy metabolism, metabolic syndrome, by chronic bilateral subthalamic stimulation, Parkinson's disease
542533|NCT00529724|Patients with Parkinson's disease and will be treated by chronic bilateral subthalamic stimulation.
542534|NCT00529711|coronary
542535|NCT00529711|artery
542536|NCT00529711|bypass
542537|NCT00529711|grafting
542538|NCT00529711|IV
542539|NCT00529711|cardiac output
542540|NCT00529698|HIV
542541|NCT00529698|Tat protein
542542|NCT00529698|Preventative vaccine
542543|NCT00529698|Healthy volunteers
542544|NCT00529698|HIV-1/2 uninfected
542545|NCT00529698|HIV Preventive Vaccine
542546|NCT00529672|endovenous laser therapy
542547|NCT00529672|sclerotherapy
542548|NCT00529672|crossectomy and stripping
542549|NCT00529672|surgery
542550|NCT00529672|treatment
542551|NCT00529672|varicose veins
542552|NCT00529659|Sarcopenia (loss of muscle mass)
542553|NCT00529646|Healthy adult volunteers
542554|NCT00529633|Inflammation
542555|NCT00529633|albumin
542556|NCT00529620|Malaria
542557|NCT00529620|IPT
542558|NCT00529620|preventive treatment
542559|NCT00529607|myocardial infarction, reperfusion injury, echocardiography, magnetic resonance imaging, inflammation, nitric oxide
542560|NCT00529594|Laser Photocoagulation
542561|NCT00529594|Pain relief
542562|NCT00529581|multiple sclerosis
542563|NCT00529581|cognitive impairment
542564|NCT00529581|cognitive dysfunction
542565|NCT00529581|Cognitive Dysfunction associated with Multiple Sclerosis
542566|NCT00529568|hepatitis C
542567|NCT00529568|ribavirin
542568|NCT00529568|Hepatitis C-related thrombocytopenia
542569|NCT00529568|thrombopoietin
542570|NCT00529568|peginterferon alfa-2b
542571|NCT00529568|platelets
542572|NCT00529542|Polycystic Ovary Syndrome
542573|NCT00529529|asthma
542574|NCT00529529|QAB149
542575|NCT00529529|indacaterol
542576|NCT00529516|Fluarix
542577|NCT00529516|GSK Bio's influenza vaccine GSK576389A
542578|NCT00529516|Influenza infection
542579|NCT00529503|Lymphoproliferative Disorders
542580|NCT00529503|Lymphoma
542581|NCT00529503|Antigens, CD40
542582|NCT00529503|Antibody, Monoclonal
542583|NCT00529503|Combined Modality Therapy
542584|NCT00529503|Lymphoma, Large B-Cell, Diffuse
542585|NCT00529503|Lymphoma, Non-Hodgkin
542586|NCT00529503|Hematologic Diseases
542587|NCT00529503|Immunoproliferative Disorders
542588|NCT00529503|Lymphatic Diseases
542589|NCT00529490|coronary
542590|NCT00529490|artery
542591|NCT00529490|bypass
542592|NCT00529490|grafting
542593|NCT00529490|I.V.
542594|NCT00529490|cardiac output
542595|NCT00529464|Cervical Intraepithelial Neoplasia
542596|NCT00529464|Cervical Dysplasia
542597|NCT00529464|Cervical Cancer
542598|NCT00529464|Fluorescence Spectroscopy
542599|NCT00529464|Colposcopy
542600|NCT00529464|Loop Electrical Excision Procedure
542601|NCT00529464|LEEP
542602|NCT00529451|Hypertension, Aliskiren, Ramipril
542603|NCT00529425|Femoral neck fracture
542604|NCT00529425|Hip fracture
542605|NCT00529399|immune tolerance
542606|NCT00529399|immunotherapy
542607|NCT00529399|antigen-specific tolerance
542608|NCT00529399|vaccine induced tolerance
542609|NCT00529399|Beta-cell function
542610|NCT00529399|T-cells
542611|NCT00529399|DPT-1
542612|NCT00529399|treatment of type 1 diabetes
542613|NCT00529399|new onset type 1 diabetes
542614|NCT00529399|juvenile diabetes
542615|NCT00529399|T1D
542616|NCT00529399|diabetes mellitus
542617|NCT00529399|Type 1 diabetes TrialNet
542618|NCT00529399|TrialNet
542619|NCT00529386|prostatitis
542620|NCT00529386|Botox
542621|NCT00529360|Acute Leukemia
542622|NCT00529360|Allogeneic Stem Cell Transplant
542623|NCT00529360|Clofarabine
542624|NCT00529360|Acute Lymphoblastic Leukemia
542625|NCT00529360|Acute Myelogenous Leukemia
542626|NCT00529334|Breast Cancer
542627|NCT00529334|Partial breast irradiation
542628|NCT00529334|Radiosurgery
542629|NCT00529334|CyberKnife
542630|NCT00529334|Radiotherapy
542631|NCT00529334|PBI
542632|NCT00529308|Tourette
542633|NCT00529308|Tourette's
542634|NCT00529295|misoprostol
542635|NCT00529295|labor induction
542636|NCT00529282|Low numbers of neutrophils in the blood
542637|NCT00529282|increased body temperature
542638|NCT00529282|cancer chemotherapy
542639|NCT00529282|ceftobiprole
542640|NCT00529282|pseudomonas infections
542641|NCT00529269|Renal Transplant Patients, GI symptom, Enteric-coated mycophenolate sodium
542642|NCT00529256|Adult smokers
542643|NCT00529243|Treatment Experience
542644|NCT00529243|On enfuvirtide
542645|NCT00529230|Advanced Cancer
542646|NCT00529230|Chronic Opioid Therapy
542647|NCT00529230|Secondary Hypogonadism
542648|NCT00529230|Cancer-Related Pain Syndromes
542649|NCT00529230|Questionnaire
542650|NCT00529217|Dissociative
542651|NCT00529217|Dissociation
542652|NCT00529217|Depersonalization
542653|NCT00529217|Depersonalization Disorder
542654|NCT00529217|Transcranial Magnetic Stimulation
542655|NCT00529217|TMS
542656|NCT00529217|Depersonalization Disorder (DPD)
542657|NCT00529217|rTMS
542658|NCT00529204|Fatty Liver
542659|NCT00529204|Nonalcoholic fatty liver disease
542660|NCT00529204|NAFDL
542661|NCT00529204|Diabetes
542662|NCT00529204|ALT
542663|NCT00529204|exenatide
542664|NCT00529191|Type I Diabetes (T1DM)
542665|NCT00529191|Atorvastatin (Lipitor)
542666|NCT00529191|Insulin
542667|NCT00529191|Pancreas
542668|NCT00529191|Beta Cells
542669|NCT00529165|injection to meal time
542670|NCT00529165|human insulin
542671|NCT00529152|Iron Overload
542672|NCT00529139|Extended dialysis
542673|NCT00529139|Acute kidney injury
542674|NCT00529139|Intensive care unit
542675|NCT00529139|Renal replacement therapy
542676|NCT00529139|Survival
542677|NCT00529139|Dialysis
542678|NCT00529126|hemorrhoidectomy
542679|NCT00529126|pain
542680|NCT00529126|Postoperative
542681|NCT00529126|analgesia
542682|NCT00529113|pancreatic cancer
542683|NCT00529113|gemcitabine
542684|NCT00529087|Opioid-Induced Constipation
542685|NCT00529074|Epidural Analgesia
542686|NCT00529061|Sickle Cell Disease
542687|NCT00529061|Sickle Cell Anemia
542688|NCT00529048|Type 2 diabetes mellitus
542689|NCT00529048|Incretin effect
542690|NCT00529048|Glucagon-Like Peptide 1
542691|NCT00529048|Gastric Inhibitory Polypeptide
542692|NCT00529035|Chronic GVHD
542693|NCT00529035|Steroid refractory GVHD
542694|NCT00529035|allogeneic stem cell transplantation
542695|NCT00529022|Advanced Cancer
542696|NCT00529022|Solid Tumors
542697|NCT00529022|Ovarian Cancer
542698|NCT00529022|Fallopian Tube Cancer
542699|NCT00529022|Peritoneal Cancer
542700|NCT00529022|Azacitidine
542701|NCT00529022|5-Azacitidine
542702|NCT00529022|5-Aza
542703|NCT00529022|Vidaza™
542704|NCT00529022|5-AZC
542705|NCT00529022|AZA-CR
542706|NCT00529022|Ladakamycin
542707|NCT00529022|NSC-102816
542708|NCT00529022|Vidaza
542709|NCT00529022|Valproic Acid
542710|NCT00529022|Depakene
542711|NCT00529022|Carboplatin
542712|NCT00529022|Paraplatin
542713|NCT00527241|partner violence, spouse abuse
542714|NCT00527228|Muscular dystrophy
542715|NCT00527228|therapy
542716|NCT00527228|steroids
542717|NCT00527228|deflazacort
542718|NCT00527228|dysferlinopathy
542719|NCT00527228|LGMD
542720|NCT00527228|MM
542721|NCT00527189|Arthritis
542722|NCT00527189|Exercise
542723|NCT00527189|Balance - Postural Control
542724|NCT00527176|Systemic Lupus Erythematosus
542725|NCT00527176|Corticosteroid
542726|NCT00527176|Pulse therapy
542727|NCT00527176|Diffusion weighted imaging
542728|NCT00527176|q Space Imaging
542729|NCT00527163|Echocardiogram
542730|NCT00527163|Endothelial Dysfunction
542731|NCT00527163|Malaria
542732|NCT00527163|Mali
542733|NCT00527163|Screening
542734|NCT00529009|PK analysis
542735|NCT00528983|Myelodysplastic Syndromes MDS
542736|NCT00528983|Acute Myelogenous Leukemia AML
542737|NCT00528983|Chronic Myelomonocytic Leukemia CMML
542738|NCT00528970|POI
542739|NCT00528970|Hernia
542740|NCT00528970|Ventral Wall Hernia Repair
542741|NCT00528970|Post Operative Ileus
542742|NCT00528957|Phase 3
542743|NCT00528957|Randomized, Open-Label
542744|NCT00528957|Treatment-Experienced
542745|NCT00528957|Highly Active Antiretroviral Therapy
542746|NCT00528957|HIV
542747|NCT00528957|Tenofovir DF
542748|NCT00528957|Pediatrics
542749|NCT00528944|alveolar volume
542750|NCT00528944|pulmonary function testing
542751|NCT00528944|emphysema
542752|NCT00528931|Assessment of AUX I and/or AUX II in human plasma
542753|NCT00528918|diabetes
542754|NCT00528918|hyperglycemia
542755|NCT00528918|insulin
542756|NCT00528918|Apidra
542757|NCT00528918|Glargine
542758|NCT00528905|Schizophrenia
542759|NCT00528905|Cognitive Deficits
542760|NCT00528892|Treatment Experienced
542761|NCT00528879|Diabetes Mellitus, Type 2
542762|NCT00528879|Diabetes Mellitus
542763|NCT00528879|Endocrine System Diseases
542764|NCT00528879|Glucose Metabolism Disorders
542765|NCT00528879|Metabolic Diseases
542766|NCT00528879|Metformin
542767|NCT00528879|Hypoglycemic Agents
542768|NCT00528879|Pharmacologic Actions
542769|NCT00528879|Physiological Effects of Drugs
542770|NCT00528866|adenocarcinoma of the prostate
542771|NCT00528866|stage IIB prostate cancer
542772|NCT00528866|stage IIA prostate cancer
542773|NCT00528866|stage III prostate cancer
542774|NCT00528866|stage IV prostate cancer
542775|NCT00528853|Bronchiolitis Obliterans Syndrome
542776|NCT00528827|Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children
542777|NCT00528814|Hand Sanitizer
542778|NCT00528814|Respiratory Infection
542779|NCT00528801|Sickle Cell Disease
542780|NCT00528801|Sickle Cell Anemia
542781|NCT00528801|Hemoglobin SS
542782|NCT00528801|Hemoglobin SB0
542783|NCT00528775|adenocarcinoma of the lung
542784|NCT00528775|large cell lung cancer
542785|NCT00528775|squamous cell lung cancer
542786|NCT00528775|recurrent non-small cell lung cancer
542787|NCT00528775|stage IIIA non-small cell lung cancer
542788|NCT00528775|stage IIIB non-small cell lung cancer
542789|NCT00528775|stage IV non-small cell lung cancer
542790|NCT00528762|Epidemiology
542791|NCT00528762|Puberty
542792|NCT00528762|Body Weight
542793|NCT00528762|Body Image
542794|NCT00528762|Focus Group
542795|NCT00528749|Respiratory effort
542796|NCT00528749|Upper Airway Resistance Syndrome
542797|NCT00528736|preterm infants < 28 weeks
542798|NCT00528736|B-type natriuretic peptide
542799|NCT00528736|prediction
542800|NCT00528736|ductus intervention
542801|NCT00528723|beclomethasone
542802|NCT00528723|as needed
542803|NCT00528723|salbutamol
542804|NCT00528723|wheezing
542805|NCT00528710|S-Adenosylmethionine
542806|NCT00528684|Oncolytics Biotech
542807|NCT00528684|cancer alternative therapies
542808|NCT00528684|malignant glioma
542809|NCT00528684|glioblastoma multiforme
542810|NCT00528684|oncolytic virus
542811|NCT00528684|reovirus
542812|NCT00528684|REOLYSIN
542813|NCT00528671|phenprocoumon
542814|NCT00528671|INR self-management
542815|NCT00528671|mechanical heart valve replacement
542816|NCT00528671|bleeding
542817|NCT00528671|thromboembolism
542818|NCT00528658|Soft Tissue Injuries
542819|NCT00528632|Gallstones
542820|NCT00528632|Gallbladder
542821|NCT00528632|Cholesterolosis
542822|NCT00528632|Serum cholesterol
542823|NCT00528632|triglycerides
542824|NCT00528632|Body Mass Index
542825|NCT00528619|Solid tumor malignancy
542826|NCT00528619|non-small cell lung cancer
542827|NCT00528619|sunitinib
542828|NCT00528619|pemetrexed
542829|NCT00528619|Phase 1
542830|NCT00528619|Mesothelioma
542831|NCT00528593|HIV
542832|NCT00528593|AIDS
542833|NCT00528593|neuropathy
542834|NCT00528593|Procrit
542835|NCT00528593|epoetin alfa
542836|NCT00528593|erythropoetin
542837|NCT00528593|Treatment Experienced
542838|NCT00528580|Sepsis
542839|NCT00528580|Statin
542840|NCT00528580|Infection
542841|NCT00528580|Immunomodulatory
542842|NCT00528554|CINV
542843|NCT00528554|chemotherapy induced nausea and vomiting (CINV)
542844|NCT00528528|Chronic Hepatitis C
542845|NCT00528528|Genotype 1
542846|NCT00528528|Telaprevir
542847|NCT00528528|Treatment-naïve
542848|NCT00528528|VX-950-C208
542849|NCT00528528|VX-950-TiDP24-C208
542850|NCT00528515|anesthesia intravenous
542851|NCT00528515|propofol
542852|NCT00528515|anesthesia inhalation
542853|NCT00528515|desflurane
542854|NCT00528515|heart surgery
542855|NCT00528515|coronary artery by-pass off-pump
542856|NCT00528515|hemodynamic processes
542857|NCT00528515|anesthesia
542858|NCT00528502|Parathyroid Disease
542859|NCT00528502|Minimal Invasive Parathyroid Surgery
542860|NCT00528502|MIPS
542861|NCT00528502|Laryngeal Reflexes
542862|NCT00528502|Lidocaine
542863|NCT00528502|Saline
542864|NCT00528489|HIV Seronegativity
542865|NCT00528489|DNA Plasmid Vaccine
542866|NCT00528489|HIV Preventive Vaccine
542867|NCT00528476|pyelonephritis
542868|NCT00528476|cystitis
542869|NCT00528476|risk factor
542870|NCT00528476|children
542871|NCT00528476|urodynamics
542872|NCT00528463|Pre-emptive analgesia
542873|NCT00528463|Peripheral nerve block (sciatic)
542874|NCT00528463|phantom lomb pain
542875|NCT00528450|adult acute promyelocytic leukemia (M3)
542876|NCT00528450|adult acute myeloid leukemia with t(15;17)(q22;q12)
542877|NCT00528450|untreated adult acute myeloid leukemia
542878|NCT00528437|Recurrent or refractory medulloblastoma/PNET
542879|NCT00528437|CNS germ cell tumors
542880|NCT00528437|Ependymomas
542881|NCT00528437|AT/RT
542882|NCT00528437|High grade glioma
542883|NCT00528437|Other malignant brain tumors
542884|NCT00528411|Coronary artery disease
542885|NCT00528411|CAD
542886|NCT00528411|heart attack
542887|NCT00528411|stable angina
542888|NCT00528411|Stable coronary artery disease
542889|NCT00528398|adult acute megakaryoblastic leukemia (M7)
542890|NCT00528398|adult acute minimally differentiated myeloid leukemia (M0)
542891|NCT00528398|adult acute monoblastic leukemia (M5a)
542892|NCT00528398|adult acute monocytic leukemia (M5b)
542893|NCT00528398|adult acute myeloblastic leukemia with maturation (M2)
542894|NCT00528398|adult acute myeloblastic leukemia without maturation (M1)
543019|NCT00528112|IUS
542895|NCT00528398|adult acute myelomonocytic leukemia (M4)
542896|NCT00528398|adult erythroleukemia (M6a)
542897|NCT00528398|adult pure erythroid leukemia (M6b)
542898|NCT00528398|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
542899|NCT00528398|adult acute myeloid leukemia with inv(16)(p13;q22)
542900|NCT00528398|adult acute myeloid leukemia with t(16;16)(p13;q22)
542901|NCT00528398|adult acute myeloid leukemia with t(8;21)(q22;q22)
542902|NCT00528398|secondary acute myeloid leukemia
542903|NCT00528398|untreated adult acute myeloid leukemia
542904|NCT00528385|Proteinuria
542905|NCT00528385|Renin-Angiotensin-Aldosterone System
542906|NCT00528385|Aldosterone Antagonists
542907|NCT00528359|antipsychotic drugs
542908|NCT00528359|schizophrenia
542909|NCT00528359|β-cell function
542910|NCT00528359|insulin resistance
542911|NCT00528346|chronic pain
542912|NCT00528346|functional magnetic resonance imaging
542913|NCT00528346|fMRI
542914|NCT00528346|cognitive training
542915|NCT00528333|Lintuzumab
542916|NCT00528333|Antigens, CD33
542917|NCT00528333|Antibodies, Monoclonal
542918|NCT00528333|Leukemia, Myeloid, Acute
542919|NCT00528333|Hematologic Diseases
542920|NCT00528333|Leukemia
542921|NCT00528320|Congestive Heart Failure
542922|NCT00528320|Heart Failure
542923|NCT00528320|Cardiac Resynchronization Therapy
542924|NCT00528320|ICD
542925|NCT00528320|Implantable Cardioverter-Defibrillator
542926|NCT00528320|Defibrillator
542927|NCT00528307|myocardial perfusion
542928|NCT00528307|His ablation
542929|NCT00528307|biventricular pacing
542930|NCT00528307|His bundle ablation for atrial fibrillation
542931|NCT00528294|Recurrent head and neck tumors
542932|NCT00528281|Non Small Cell Lung Cancer (NSCLC)
542933|NCT00528281|Pemetrexed,
542934|NCT00528281|Lapatinib (GW572016),
542935|NCT00528268|Spinal Muscular Atrophy
542936|NCT00528268|SMA
542937|NCT00528268|Sodium Phenylbutyrate
542938|NCT00528255|cervical ripening
542939|NCT00528255|induction of labor
542940|NCT00527098|Trauma Resuscitation
542941|NCT00527072|plaque psoriasis
542942|NCT00527072|psoriasis
542943|NCT00527072|infliximab
542944|NCT00527072|remicade
542945|NCT00527072|etanercept
542946|NCT00527072|enbrel
542947|NCT00527072|psunrise
542948|NCT00527072|C0168Z04
542949|NCT00527059|Cardiorenal syndrome
542950|NCT00527033|YM178
542951|NCT00527033|Urinary Bladder, Overactive
542952|NCT00527020|qEEG
542953|NCT00527020|GlyT-1 inhibitor
542954|NCT00527020|healthy volunteers
542955|NCT00527020|ERP
542956|NCT00527020|FTIH
542957|NCT00527020|MMN
542958|NCT00527020|GSK1018921
542959|NCT00527020|schizophrenia
542960|NCT00527020|single-dose
542961|NCT00527007|Vasopressor
542962|NCT00527007|Epinephrine
542963|NCT00527007|Norepinephrine
542964|NCT00527007|Cooling
542965|NCT00527007|Fever
542966|NCT00527007|ICU
542967|NCT00526994|intimate partner violence
542968|NCT00526994|domestic violence
542969|NCT00526994|spouse abuse
542970|NCT00526994|screening
542971|NCT00525928|craving
542972|NCT00525928|smoking
542973|NCT00525928|depression
542974|NCT00525915|Esophageal Cancer
542975|NCT00525915|Gastroesophageal Cancer
542976|NCT00525915|Gastroesophageal Junction
542977|NCT00525915|Radiation Therapy
542978|NCT00525915|5-Fluorouracil
542979|NCT00525915|5-FU
542980|NCT00525915|Adrucil
542981|NCT00525915|Efudex
542982|NCT00525915|Oxaliplatin
542983|NCT00528216|Analgesics
542984|NCT00528216|Capsaicin
542985|NCT00528203|Sickle Cell Disease
542986|NCT00528203|Sickle Cell Anemia
542987|NCT00528203|DNA
542988|NCT00528190|Cystic Fibrosis
542989|NCT00528190|Aspergillus Fumigatus
542990|NCT00528190|randomized controlled clinical trials
542991|NCT00528177|kappa-opioid receptor
542992|NCT00528177|my-opioid receptor
542993|NCT00528177|oxycodone
542994|NCT00528177|morphine
542995|NCT00528177|postoperative pain
542996|NCT00528164|children
542997|NCT00528164|overweight
542998|NCT00528164|obesity
542999|NCT00528164|family
543000|NCT00528164|intervention
543001|NCT00528164|control
543002|NCT00528164|randomized
543003|NCT00528164|physical activity
543004|NCT00528164|diet
543005|NCT00528164|nutrition
543006|NCT00528164|behavior
543007|NCT00528164|body mass index
543008|NCT00528151|Curcumin, LHON, antioxidant, visual outcome
543009|NCT00528138|Appendicitis
543010|NCT00528138|Hyperbilirubinemia
543011|NCT00528138|CRP
543012|NCT00528138|Values of bilirubin
543013|NCT00528138|Values of liver function test
543014|NCT00528138|Values of white blood cells
543015|NCT00528138|Values of CRP
543016|NCT00528112|Contraception
543017|NCT00528112|Intrauterine
543018|NCT00528112|IUD
543020|NCT00528086|Group visits
543021|NCT00528073|Rifaximin-EIR
543022|NCT00528073|Crohn's disease
543023|NCT00528073|remission
543024|NCT00528060|HIV infections
543025|NCT00528060|atazanavir
543026|NCT00528060|Pharmacokinetics
543027|NCT00528060|Treatment Naive
543028|NCT00528047|Cancer
543029|NCT00528047|Solid Tumor
543030|NCT00528047|Metastatic
543031|NCT00528047|Neoplasm, Malignant
543032|NCT00528034|Vaginal Cancer
543033|NCT00528034|Lymphoscintigraphy
543034|NCT00528034|Lymphatic Mapping
543035|NCT00528034|Sentinel Lymph Node
543036|NCT00528034|Isosulfan Blue
543037|NCT00528034|Lymph
543038|NCT00528021|Head Lice
543039|NCT00528021|Lice Infestation
543040|NCT00528021|Pediculosis
543041|NCT00528021|Pediculosis Capitis
543042|NCT00528008|infection
543043|NCT00528008|sepsis
543044|NCT00528008|povidone-iodine
543045|NCT00528008|chlorhexidine gluconate
543046|NCT00528008|fever
543047|NCT00528008|erythema
543048|NCT00528008|leukocytosis
543049|NCT00528008|drainage
543050|NCT00528008|vaginal discharge
543051|NCT00528008|elective cesarean section
543052|NCT00527982|Head and Neck Cancer
543053|NCT00527982|Lung Cancer
543054|NCT00527982|Non-Small Cell Lung Cancer
543055|NCT00527982|Celecoxib
543056|NCT00527982|Celebrex
543057|NCT00527969|American ginseng extract
543058|NCT00527969|Panax quinquefolius
543059|NCT00527969|Memory enhancement
543060|NCT00527969|Cognitive function
543061|NCT00527969|Working memory
543062|NCT00527969|Declarative memory
543063|NCT00527969|Psychomotor speed
543064|NCT00527969|Executive skills
543065|NCT00527969|Psychosocial adaptation
543066|NCT00527956|Breastfeeding premature infants
543067|NCT00527930|Breast Neoplasms
543068|NCT00527930|Oxaliplatin
543069|NCT00527930|S1
543070|NCT00527917|IC/PBS
543071|NCT00527917|Interstitial Cystitis/Painful Bladder Syndrome
543072|NCT00527904|osteoarthritis
543073|NCT00527904|rheumatoid arthritis
543074|NCT00527904|ankylosing spondylisit
543075|NCT00527904|NSAIDS
543076|NCT00527891|Liver Cancer
543077|NCT00527891|Magnetic Resonance Imaging
543078|NCT00527891|Signa Excite 3.0T MRI Scan
543079|NCT00527878|Hyper-IgE Recurrent Infection Syndrome
543080|NCT00527878|Ranitidine Therapy
543081|NCT00527878|Job's Syndrome
543082|NCT00527878|Cross-Over Study
543083|NCT00527878|Double-Blind Placebo Controlled
543084|NCT00527878|Hyper-IgE Syndrome
543085|NCT00527878|Job Syndrome
543086|NCT00527878|Immune Deficiency
543087|NCT00527865|Influenza, Flu, DAS181, Fludase
543088|NCT00527852|Flocked swab
543089|NCT00527852|Group A streptococcus
543090|NCT00527826|Severe and very severe COPD (GOLD stage III / IV) exacerbations
543091|NCT00527826|health care utilisation
543092|NCT00527826|Chronic Obstructive Pulmonary Disease (COPD)
543093|NCT00527826|quality of life
543094|NCT00527826|compliance
543095|NCT00527826|salmeterol/fluticasone combination
543096|NCT00527813|acute respiratory distress syndrome
543097|NCT00527813|prone position
543098|NCT00527813|Acute respiratory distress syndrome (ARDS)
543099|NCT00527800|Malaria
543100|NCT00527800|HIV
543101|NCT00527800|Trimethoprim-sulfamethoxazole
543102|NCT00527800|Artemether-lumefantrine
543103|NCT00527800|Dihydroartemisinin-piperaquine
543104|NCT00527800|Acute Infection
543105|NCT00527787|NSAID
543106|NCT00527787|gastric ulcers
543107|NCT00527787|Vimovo
543108|NCT00527787|Naproxen
543109|NCT00527787|Esomeprazole
543110|NCT00527774|Hepatitis C
543111|NCT00527774|malnutrition-inflammation complex syndrome (MICS)
543112|NCT00527774|dialysis
543113|NCT00527774|mortality
543114|NCT00527774|hospitalization
543115|NCT00527774|health-related quality of life (HRQOL)
543116|NCT00527774|peripheral arterial occlusive disease (PAOD)
543117|NCT00527761|Metastatic Melanoma
543118|NCT00527761|Temozolomide
543119|NCT00527761|Temodar
543120|NCT00527761|Taxotere
543121|NCT00527761|Cisplatin
543122|NCT00527761|TTC
543123|NCT00527748|Range of Motion
543124|NCT00527748|Ankle Fractures
543125|NCT00527748|Elderly patients
543126|NCT00527735|Non Small Cell Lung Cancer (NSCLC)
543127|NCT00527735|Small Cell Lung Cancer (SCLC)
543128|NCT00527722|Lung Cancer
543129|NCT00527722|Bio-Seal Track Plug
543130|NCT00527722|Lung Biopsy
543131|NCT00527722|Lung Plug
543132|NCT00527722|Air Leaks
543133|NCT00527683|vigabatrin
543134|NCT00527683|GVG
543135|NCT00527683|addiction
543136|NCT00527683|treatment
543137|NCT00527683|cocaine dependence
543138|NCT00527670|Genomics
543139|NCT00527657|Brain Neoplasms
543140|NCT00527657|Melanoma
543141|NCT00527657|Metastatic Melanoma
543142|NCT00527657|Brain Metastasis
543143|NCT00527657|Temozolomide
543144|NCT00527657|Temodar
543145|NCT00527657|Thalidomide
543146|NCT00527657|Thalomid
543147|NCT00527657|Lomustine
543148|NCT00527657|CCNU
543149|NCT00527657|CeeNU
543150|NCT00527644|biliary leaks after laparoscopic cholecystectomy
543151|NCT00527631|advanced ovarian cancer
543152|NCT00527631|whole abdominal irradiation
543153|NCT00527631|intensity modulated radiotherapy
543154|NCT00527631|ovarian cancer stage FIGO III
543155|NCT00527618|Herpes Simplex Virus Type 2
543156|NCT00527618|Human Immunodeficiency Virus
543157|NCT00527618|Treatment Naive
543158|NCT00527605|placebo control
543159|NCT00527605|Chinese
543160|NCT00527605|Dutasteride
543161|NCT00527605|Randomized
543162|NCT00527605|Benign Prostatic Hyperplasia
543163|NCT00527605|Double blind
543164|NCT00527592|Comfort
543165|NCT00527579|Epilepsy
543166|NCT00527579|Taenia Solium
543167|NCT00527579|Microglia
543168|NCT00527579|Neuroinflammation
543169|NCT00527579|Compartment Model
543170|NCT00527579|Neurocysticercosis
543171|NCT00527579|Healthy Volunteer
543172|NCT00527579|HV
543173|NCT00527566|Churg Strauss Syndrome
543174|NCT00527553|Macular pigment
543175|NCT00527553|AMD
543176|NCT00527553|ARM
543177|NCT00527514|Hypertension
543178|NCT00527514|Angiotensin Receptor Blocker
543179|NCT00527514|Calcium Channel Blocker
543180|NCT00527514|Stage I and II Hypertension
543181|NCT00527501|Open-angle glaucoma
543182|NCT00527501|ocular hypertension
543183|NCT00527488|Benign Prostate Hyperplasia
543184|NCT00527488|BPH
543185|NCT00527488|PK/PD
543186|NCT00527488|GnRH antagonist
543187|NCT00527475|Anti-VEGF therapy
543188|NCT00527475|photodynamic therapy
543189|NCT00527475|neovascularization
543190|NCT00527462|Asthma GINA 1
543191|NCT00527423|VEGF Trap-Eye
543192|NCT00527423|Macular Degeneration
543193|NCT00527423|AMD
543194|NCT00527423|Neovascular Age-Related Macular Degeneration
543195|NCT00527397|Diabetes Mellitus
543196|NCT00527384|Stress
543197|NCT00527371|Benign hyperplasia of the prostate
543198|NCT00527358|violence
543199|NCT00527345|Asthma
543200|NCT00527345|Diesel exhaust
543201|NCT00527332|Hospitalization
543202|NCT00527332|Postoperative care
543203|NCT00527332|Quality of Life
543204|NCT00527332|Health economy
543205|NCT00527332|Anesthesia. Spinal
543206|NCT00527332|Anesthesia, General
543207|NCT00527319|NSCLC
543208|NCT00527319|anorexia
543209|NCT00527319|cachexia
543210|NCT00527319|grip strength
543211|NCT00527319|lean body mass
543212|NCT00527306|aphthous stomatitis
543213|NCT00527306|canker sores
543214|NCT00527306|multivitamins
543215|NCT00527306|vitamin deficiency
543216|NCT00527293|stage I breast cancer
543217|NCT00527293|stage II breast cancer
543218|NCT00527293|invasive ductal breast carcinoma
543219|NCT00527293|medullary ductal breast carcinoma with lymphocytic infiltrate
543220|NCT00527293|mucinous ductal breast carcinoma
543221|NCT00527293|tubular ductal breast carcinoma
543222|NCT00527293|papillary ductal breast carcinoma
543223|NCT00527280|Allotransplantation:composite tissue
543224|NCT00527280|Face transplantation
543225|NCT00526955|Manual muscle testing
543226|NCT00526942|ACRD
543227|NCT00526942|Visual Memory
543228|NCT00526942|Visual Perception
543229|NCT00526942|Speed
543230|NCT00526942|Computerized
543231|NCT00526942|SAAGE
543232|NCT00526942|Cognitive Decline
543233|NCT00526916|Epilepsy
543234|NCT00526916|Taenia Solium
543235|NCT00526916|Microglia
543236|NCT00526916|Neuroinflammation
543237|NCT00526916|Compartment Model
543238|NCT00526916|Neurocysticercosis
543239|NCT00526916|Healthy Volunteer
543240|NCT00526916|HV
543241|NCT00526903|IBS
543242|NCT00526903|abdominal pain
543243|NCT00526903|recurrent abdominal pain
543244|NCT00526903|irritable bowel syndrome
543245|NCT00526903|diarrhea
543246|NCT00526903|constipation
543247|NCT00526903|bloating
543248|NCT00526890|squamous cell lung cancer
543249|NCT00526890|adenocarcinoma of the lung
543250|NCT00526890|bronchoalveolar cell lung cancer
543251|NCT00526890|large cell lung cancer
543252|NCT00526890|stage IIIA non-small cell lung cancer
543253|NCT00526890|stage IIIB non-small cell lung cancer
543254|NCT00526890|adenosquamous cell lung cancer
543255|NCT00526877|Schizophrenia
543256|NCT00526877|Schizoaffective disorders
543257|NCT00526877|Risperidone
543258|NCT00526877|Risperdal Consta
543259|NCT00526864|Burden of Illness for Herpes zoster in Thailand.
543260|NCT00526851|lip and oral cavity cancer
543261|NCT00526851|oropharyngeal cancer
543262|NCT00526838|Solid Tumor
543263|NCT00526838|Multiple Myeloma
543264|NCT00526786|Low Grade Dysplasia
543265|NCT00526786|High Grade Dysplasia
543266|NCT00526786|Barrett's Esophagus
543267|NCT00526786|Cryospray ablation
543268|NCT00526786|ICE
543269|NCT00526786|Cryotherapy
543270|NCT00526786|Cryo
543271|NCT00526786|CryoSpray
543272|NCT00526773|motivational therapy
543273|NCT00526760|Dexmedetomidine, Sedation, Long-term, Phase 3
543274|NCT00526734|stage I multiple myeloma
543275|NCT00526734|stage II multiple myeloma
543276|NCT00526734|stage III multiple myeloma
543277|NCT00526721|Hypercholesterolemia
543278|NCT00526721|Crestor
543279|NCT00526721|LDL target goal
543280|NCT00526721|high risk patients
543281|NCT00526721|Naturalistic
543282|NCT00526721|Observational
543283|NCT00526708|dyslipidemia
543284|NCT00526708|hypertension
543285|NCT00526708|rosuvastatin
543286|NCT00526708|efficacy
543287|NCT00526708|Naturalistic
543288|NCT00526708|Observational
543289|NCT00526695|Ischemia/Reperfusion
543290|NCT00526695|Organ Protection
543291|NCT00526695|Anesthetics
543292|NCT00526682|Antiobesity
543293|NCT00526682|Weight loss
543294|NCT00526669|tumor biopsy
543295|NCT00526669|capecitabine
543296|NCT00526669|first line
543297|NCT00526669|Gastro Esophageal (GE) Junction Cancer
543298|NCT00526669|Gastric cancer
543299|NCT00526669|newly diagnosed
543300|NCT00526669|GE junction
543301|NCT00526669|lapatinib
543302|NCT00526669|metastatic or unresectable
543303|NCT00526656|transitional cell carcinoma of the bladder
543304|NCT00526656|stage II bladder cancer
543305|NCT00526656|stage III bladder cancer
543306|NCT00526656|stage IV bladder cancer
543307|NCT00526643|stage IIIB
543308|NCT00526643|Stage IV
543309|NCT00526643|chemotherapy
543310|NCT00526643|monotherapy
543311|NCT00526643|combination chemotherapy
543312|NCT00526643|poor performance status
543313|NCT00526630|freezing
543314|NCT00526630|gait
543315|NCT00526630|festination
543316|NCT00526630|shuffling
543317|NCT00526630|balance
543318|NCT00526617|Solid Tumor
543319|NCT00526617|Melanoma
543320|NCT00526617|Breast cancer
543321|NCT00526617|Ovarian cancer
543322|NCT00526617|Primary peritoneal cancer
543323|NCT00526617|Fallopian tube cancer
543324|NCT00526617|Hepatocellular carcinoma
543325|NCT00526617|HCC
543326|NCT00526617|BRCA deficient
543327|NCT00526617|BRCA mutation
543328|NCT00526617|Temozolomide
543329|NCT00526617|Temodar
543330|NCT00526617|TMZ
543331|NCT00526617|ABT-888
543332|NCT00526617|PARP inhibitor
543333|NCT00526604|return to work
543334|NCT00526604|low back pain
543335|NCT00526604|work related rehabilitation
543336|NCT00526591|adenocarcinoma of the prostate
543337|NCT00526591|stage I prostate cancer
543338|NCT00526591|stage II prostate cancer
543339|NCT00526591|stage III prostate cancer
543340|NCT00526578|Pancreatic Cancer
543341|NCT00526578|Pancreatic Cancer Genetic Epidemiology
543342|NCT00526578|PACGENE
543343|NCT00526578|Healthy Control
543344|NCT00526578|Familial Pancreatic Cancer
543345|NCT00526578|FPC
543346|NCT00526578|Questionnaire
543347|NCT00526552|dyslipidemia
543348|NCT00526552|rosuvastatin
543349|NCT00526552|diabetes
543350|NCT00526552|cholesterol
543351|NCT00526552|Naturalistic
543352|NCT00526552|Observational
543353|NCT00526539|THR
543354|NCT00526539|reversed hybrid
543355|NCT00526539|wear
543356|NCT00526500|Severe Traumatic Brain Injury
543357|NCT00526500|Subarachnoid Hemorrhage
543358|NCT00526500|Anoxic Brain Injury
543359|NCT00526500|Passive Gait Training
543360|NCT00526500|Tilt Table With Integrated Stepping System
543361|NCT00526500|Electroencephalogram
543362|NCT00526500|Event Related Potentials
543363|NCT00526487|Thoracic Dissection
543364|NCT00526487|Dissection
543365|NCT00526487|Endovascular
543366|NCT00526461|stage 0 non-small cell lung cancer
543367|NCT00526461|adenocarcinoma of the lung
543368|NCT00526461|squamous cell lung cancer
543369|NCT00526461|large cell lung cancer
543370|NCT00526448|high dose of ribavirin
543371|NCT00526448|extend treatment duration
543372|NCT00526448|tailoring treatment
543373|NCT00526435|Arthritis
543374|NCT00526435|osteoarthritis
543375|NCT00526435|rheumatoid arthritis
543376|NCT00526435|fibromyalgia
543377|NCT00526435|lupus
543378|NCT00526422|Questionnaire, dental caries, diagnosis,treatment
543379|NCT00526409|Acute Lymphoblastic Leukemia
543380|NCT00526396|chemotherapy
543381|NCT00526396|toxicity adjusted dose
543382|NCT00526383|Major depressive disorder
543383|NCT00526383|Antidepressants
543384|NCT00526383|Weight gain
543385|NCT00526383|Metabolic syndromes
543386|NCT00526370|self test
543387|NCT00526370|PAP smear
543388|NCT00526370|tampon test
543389|NCT00526370|E6/E7
543390|NCT00526370|mRNA
543391|NCT00526370|HPV
543392|NCT00526357|omega-3 fatty acids
543393|NCT00526357|asthma
543394|NCT00526357|airway hyperresponsiveness
543395|NCT00526357|inflammation
543396|NCT00526344|remission of asthma
543397|NCT00526331|Perioperative Therapy
543398|NCT00526331|Perioperative Hydration
543399|NCT00526331|Arterial Pressure Based Cardiac Output
543400|NCT00526331|Vigileo Monitor
543401|NCT00526331|FloTrac Sensor
543402|NCT00526331|Fluid Volume
543403|NCT00526331|APCO
543404|NCT00526318|localized resectable neuroblastoma
543405|NCT00526318|localized unresectable neuroblastoma
543406|NCT00526318|regional neuroblastoma
543407|NCT00526318|stage 4S neuroblastoma
543408|NCT00526318|disseminated neuroblastoma
543409|NCT00526305|Acute Lymphoblastic Leukemia
543410|NCT00526305|Chromosome Philadelphia positive
543411|NCT00526292|recurrent adult acute lymphoblastic leukemia
543412|NCT00526292|recurrent adult acute myeloid leukemia
543413|NCT00526292|blastic phase chronic myelogenous leukemia
543414|NCT00526292|previously treated myelodysplastic syndromes
543415|NCT00526292|childhood myelodysplastic syndromes
543416|NCT00526292|recurrent childhood acute lymphoblastic leukemia
543417|NCT00526292|recurrent childhood acute myeloid leukemia
543418|NCT00526292|childhood chronic myelogenous leukemia
543419|NCT00526292|relapsing chronic myelogenous leukemia
543420|NCT00526292|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
543421|NCT00526292|adult acute myeloid leukemia with inv(16)(p13;q22)
543422|NCT00526292|adult acute myeloid leukemia with t(15;17)(q22;q12)
543423|NCT00526292|adult acute myeloid leukemia with t(16;16)(p13;q22)
543424|NCT00526292|adult acute myeloid leukemia with t(8;21)(q22;q22)
543425|NCT00526279|Hypertension
543426|NCT00526279|Atacand/Atacand plus
543427|NCT00526279|COMBAT
543428|NCT00526279|Compliance
543429|NCT00526279|Naturalistic
543430|NCT00526279|Observational
543431|NCT00526253|Congestive Heart Failure
543432|NCT00526253|CHF
543433|NCT00526253|Heart Disease
543434|NCT00526253|Heart Attack
543435|NCT00526253|Stem Cell
543436|NCT00526253|Myoblast
543437|NCT00526253|Bioheart
543438|NCT00526214|Spontaneous intracerebral hemorrhage
543439|NCT00526214|Acute Spontaneous, Supratentorial intracerebral hemorrhage
543440|NCT00526201|Arthritis
543441|NCT00526201|Osteoarthritis
543442|NCT00526201|Rheumatoid Arthritis
543443|NCT00526201|Fibromyalgia
543444|NCT00526201|Lupus
543445|NCT00526188|Primovist
543446|NCT00526188|Chinese patients
543447|NCT00526188|Liver MRI
543448|NCT00526175|Acute Lymphoblastic Leukemia
543449|NCT00526175|Minimal Residual Disease
543450|NCT00526149|recurrent squamous cell carcinoma of the hypopharynx
543451|NCT00526149|recurrent squamous cell carcinoma of the larynx
543452|NCT00526149|recurrent squamous cell carcinoma of the lip and oral cavity
543453|NCT00526149|recurrent squamous cell carcinoma of the oropharynx
543454|NCT00526149|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
543455|NCT00526149|metastatic squamous neck cancer with occult primary squamous cell carcinoma
543456|NCT00526149|recurrent metastatic squamous neck cancer with occult primary
543457|NCT00526149|recurrent breast cancer
543458|NCT00526149|stage IV breast cancer
543459|NCT00526149|recurrent ovarian epithelial cancer
543460|NCT00526149|stage IV ovarian epithelial cancer
543461|NCT00526149|stage III ovarian epithelial cancer
543462|NCT00526149|recurrent adult soft tissue sarcoma
543463|NCT00526149|stage III adult soft tissue sarcoma
543464|NCT00526149|stage IV adult soft tissue sarcoma
543465|NCT00526149|adult leiomyosarcoma
543466|NCT00526149|uterine leiomyosarcoma
543467|NCT00526149|adult alveolar soft-part sarcoma
543468|NCT00526149|adult angiosarcoma
543469|NCT00526149|adult desmoplastic small round cell tumor
543470|NCT00526149|adult epithelioid sarcoma
543471|NCT00526149|adult fibrosarcoma
543472|NCT00526149|adult liposarcoma
543473|NCT00526149|adult malignant fibrous histiocytoma
543474|NCT00526149|adult malignant mesenchymoma
543475|NCT00526149|adult neurofibrosarcoma
543476|NCT00526149|adult rhabdomyosarcoma
543477|NCT00526149|adult synovial sarcoma
543478|NCT00526149|endometrial stromal sarcoma
543479|NCT00526149|ovarian carcinosarcoma
543480|NCT00526149|ovarian sarcoma
543481|NCT00526149|recurrent uterine sarcoma
543482|NCT00526149|stage IV uterine sarcoma
543483|NCT00526149|recurrent melanoma
543484|NCT00526149|stage IV melanoma
543485|NCT00526136|Atrial Fibrillation
543486|NCT00526123|Dialysis
543487|NCT00526123|Dialysis Catheter
543488|NCT00526123|Kidney Disease
543489|NCT00526123|Dialysis Clinic
543490|NCT00526123|Chronic Catheter
543491|NCT00526123|Catheter
543492|NCT00526123|Kidney
543493|NCT00526110|Gastrointestinal Diseases
543494|NCT00526110|Adenocarcinoma of the Stomach
543495|NCT00526110|Gastroesophageal Junction Cancer
543496|NCT00526110|Cancer of the Stomach
543497|NCT00526110|5-Fluorouracil
543498|NCT00526110|5-FU
543499|NCT00526110|Adrucil
543500|NCT00526110|Efudex
543501|NCT00526110|Docetaxel
543502|NCT00526110|Oxaliplatin
543503|NCT00526110|Eloxatin
543504|NCT00526110|Taxotere
543505|NCT00526110|Esophagus
543506|NCT00526084|ALL
543507|NCT00526084|Healthy subjects
543508|NCT00526071|Fabry Disease
543509|NCT00526071|Lysosomal Storage Disorder
543510|NCT00526058|Heparin
543511|NCT00526058|Extracorporeal
543512|NCT00526058|Low Density Lipo-Protein (LDL) Cholesterol
543513|NCT00526058|Apheresis
543514|NCT00526058|Device
543515|NCT00526045|AUY922
543516|NCT00526045|Solid tumors
543517|NCT00526045|Breast Cancer
543518|NCT00526045|Phase I/II
543519|NCT00526045|Advanced Solid malignancies (Phase I)
543520|NCT00526045|Breast Cancer ( Phase II )
543521|NCT00526045|HER2+
543522|NCT00526045|ER+
543523|NCT00526045|HSP90
543524|NCT00526032|Skin Cancer
543525|NCT00526032|Cancerous skin lesions
543526|NCT00526032|Melanoma Detection
543527|NCT00526032|Spectroscopic Oblique-Incidence Reflectometry
543528|NCT00526032|OIR Imaging Probe
543529|NCT00526019|remission of asthma
543530|NCT00526006|Clinical significance of the acid rebound phenomenon after withdrawal of treatment with a PPI
543531|NCT00525993|sports
543532|NCT00525993|ankle
543533|NCT00525993|sprain
543534|NCT00525993|etoricoxib
543535|NCT00525993|antiinflammatory
543536|NCT00525993|treatment outcome
543537|NCT00525980|Breast Cancer
543538|NCT00525980|Cancer Risk
543539|NCT00525980|CD-ROM
543540|NCT00525980|Focus Group
543541|NCT00525980|Cancer Genetics
543542|NCT00525967|Cancer Pain
543543|NCT00525967|Methadone
543544|NCT00525967|Morphine
543545|NCT00525967|Acetaminophen
543546|NCT00525967|Palliative Care
543547|NCT00525954|Coronary
543548|NCT00525954|Artery
543549|NCT00525954|Artheroschlerosis
543550|NCT00525954|Phospholipase
543551|NCT00525954|CAD
543552|NCT00525954|Coronary Artery Disease (CAD)
543553|NCT00525889|diabetes
543554|NCT00525889|juvenile diabetes
543555|NCT00525889|type 1 diabetes
543556|NCT00525889|diabetes mellitus
543557|NCT00525889|recent onset
543558|NCT00525889|new onset
543559|NCT00525876|Mantle Cell Lymphoma
543560|NCT00525876|Lymphoma
543561|NCT00525876|Allogeneic Stem Cell Transplant
543562|NCT00525876|Rituximab
543563|NCT00525876|Cyclophosphamide
543564|NCT00525876|Neosar
543565|NCT00525876|Cytoxan
543566|NCT00525876|Fludarabine
543567|NCT00525876|Fludara
543568|NCT00525876|Fludarabine phosphate
543569|NCT00525876|Rituxan
543570|NCT00525876|Alemtuzumab
543571|NCT00525876|CAMPATH-1H
543572|NCT00525876|Campath
543573|NCT00525876|Total Body Irradiation
543574|NCT00525876|TBI
543575|NCT00525863|schizophrenia
543576|NCT00525863|oxygen therapy
543577|NCT00525850|cardiovascular disease
543578|NCT00525850|weight loss
543579|NCT00525837|varenicline
543580|NCT00525837|depression
543581|NCT00525837|anhedonia
543582|NCT00525837|smoking
543583|NCT00525824|Hypercholesterolaemia
543584|NCT00525824|Coronary Heart Disease (CHD)
543585|NCT00525824|Atherosclerosis
543586|NCT00525798|Osteoporosis, oral salmon calcitonin, treatment, efficacy, tolerability
543587|NCT00525785|Stomach Cancer
543588|NCT00525785|Gastric Cancer
543589|NCT00525785|Adenocarcinoma of the Stomach
543590|NCT00525785|Gastroesophageal Junction
543591|NCT00525785|Esophageal
543592|NCT00525785|Gastric
543593|NCT00525785|5-Fluorouracil
543594|NCT00525785|5-FU
543595|NCT00525785|Adrucil
543596|NCT00525785|Efudex
543597|NCT00525785|Folinic Acid
543598|NCT00525785|Oxaliplatin
543599|NCT00525785|Eloxatin
543600|NCT00525785|Chemoradiotherapy
543601|NCT00525785|Radiation
543602|NCT00525785|Radiotherapy
543603|NCT00525785|XRT
543604|NCT00525772|asthma
543605|NCT00525772|exercise induced bronchoconstriction
543606|NCT00525772|sputum eosinophils
543607|NCT00525759|Breast cancer
543608|NCT00525759|Zoledronic acid
543609|NCT00525759|Neoadjuvant chemotherapy
543610|NCT00525759|Synergy
543611|NCT00525759|Apoptosis
543612|NCT00525746|Acute Myeloid Leukemia
543613|NCT00525746|Myelodysplastic Syndrome
543614|NCT00525746|Leukemia
543615|NCT00525746|MDS
543616|NCT00525746|AML
543617|NCT00525746|Malignancy
543618|NCT00525746|Molecular Epidemiology
543619|NCT00525746|Epidemiologic markers
543620|NCT00525746|Clinical markers
543621|NCT00525746|Constitutional genetic markers
543622|NCT00525746|Case-comparison study
543623|NCT00525733|HIV-1
543624|NCT00525733|Acute Infection
543625|NCT00525733|Treatment Naive
543626|NCT00525720|Prostate Cancer
543627|NCT00525720|Prostatic Carcinoma
543628|NCT00525720|Intermediate prostate cancer
543629|NCT00525720|Transperineal Interstitial Permanent Brachytherapy
543630|NCT00525720|Brachytherapy
543631|NCT00525720|Prostate brachytherapy
543632|NCT00525720|Prostate implant
543633|NCT00525720|Prostate
543634|NCT00525720|Questionnaire
543635|NCT00525720|Survey
543636|NCT00525707|acute heart failure
543637|NCT00525707|Actelion
543638|NCT00525707|tezosentan
543639|NCT00525707|acute decompensation of chronic heart failure
543640|NCT00525707|New onset of heart failure
543641|NCT00525681|Obese
543642|NCT00525681|Calcineurine inhibitor
543643|NCT00525681|Pharmacokinetics
543644|NCT00525681|Interaction
543645|NCT00525668|multiple sclerosis
543646|NCT00525668|inflammation
543647|NCT00525668|neurodegeneration
543648|NCT00525668|neuroprotection
543649|NCT00525655|Familial Adenomatous Polyposis
543650|NCT00525655|Colorectal Cancer
543651|NCT00525655|Multimedia Intervention
543652|NCT00525655|Questionnaire
543653|NCT00525655|Survey
543654|NCT00525655|FAP
543655|NCT00525642|Breast-adjuvant
543656|NCT00525642|Breast-chemotherapy
543657|NCT00525642|Combination chemotherapy regimens
543658|NCT00525616|bullous pemphigoid
543659|NCT00525616|mabthera
543660|NCT00525603|Chronic Lymphocytic Leukemia
543661|NCT00525603|CML
543662|NCT00525603|Leukemia
543663|NCT00525603|Cyclophosphamide
543664|NCT00525603|Fludarabine
543665|NCT00525603|Alemtuzumab
543666|NCT00525603|Rituximab
543667|NCT00525603|CFAR
543668|NCT00525590|Gliadel
543669|NCT00525577|Type 2 diabetes, glycemic control
543670|NCT00525564|Chronic Obstructive Pulmonary Disease (COPD)
543671|NCT00525564|Exercise
543672|NCT00525564|Endurance shuttle walking test
543673|NCT00525564|Bronchodilation
543674|NCT00525564|Salmeterol
543675|NCT00525525|Glioblastoma
543676|NCT00525525|Gliosarcoma
543677|NCT00525525|Bevacizumab
543678|NCT00525525|Avastin
543679|NCT00525525|Erlotinib
543680|NCT00525525|Tarceva
543681|NCT00525525|Temozolomide
543682|NCT00525525|Temodar
543683|NCT00525499|acne
543684|NCT00525486|Nifedipine
543685|NCT00525486|Tocolysis
543686|NCT00525486|Maintenance
543687|NCT00525486|Preterm delivery
543688|NCT00525486|extended release nifedipine
543689|NCT00525486|PTL
543690|NCT00525460|fertility
543691|NCT00525460|stage I ovarian cancer
543692|NCT00525460|stage II ovarian cancer
543693|NCT00525460|fertility sparing
543694|NCT00525447|Antigens, CD40
543695|NCT00525447|Antibodies, Monoclonal
543696|NCT00525447|Combined Modality Therapy
543697|NCT00525447|Multiple Myeloma
543698|NCT00525447|Blood Coagulation Disorders
543699|NCT00525447|Hematologic Diseases
543700|NCT00525447|Hemorrhagic Disorders
543701|NCT00525447|Hemostatic Disorders
543702|NCT00525447|Immunoproliferative Disorders
543703|NCT00525447|Lymphoproliferative Disorders
543704|NCT00525447|Paraproteinemias
543705|NCT00525447|Vascular Diseases
543706|NCT00525447|Antibody-Dependent Cell Cytotoxicity
543707|NCT00525434|Laser bonding soft tissue albumin
543708|NCT00525421|curcuminoids
543709|NCT00525421|oral lichen planus
543710|NCT00525421|c reactive protein
543711|NCT00525421|interleukin 6
543712|NCT00525408|HRPC
543713|NCT00525408|Metastatic Hormone Refractory Prostate Cancer
543714|NCT00525408|Docetaxel
543715|NCT00525408|Mycobacterium w
543716|NCT00525395|Phototherapy
543717|NCT00525395|Vitiligo scoring system
543718|NCT00525382|Levocetirizine dihydrochloride
543719|NCT00525382|Xyzal tablets
543720|NCT00525356|Aorta
543721|NCT00525356|Dissection
543722|NCT00525356|Thoracic
543723|NCT00525343|Avonex pivotal trial
543724|NCT00525343|Avonex
543725|NCT00525343|Avonex long term follow-up
543726|NCT00525343|Avonex outcomes
543727|NCT00525317|Pregnancy
543728|NCT00525317|Magnesium
543729|NCT00525317|Leg Pain
543730|NCT00525304|medical co-morbidity
543731|NCT00525304|diabetes
543732|NCT00525304|heart disease
543733|NCT00525304|respiratory illness
543734|NCT00525291|Exercise Therapy
543735|NCT00525291|Biofeedback (Psychology)
543736|NCT00525291|Adult
543737|NCT00525291|Fecal Incontinence/*therapy
543738|NCT00525291|EMG - Biofeedback
543739|NCT00525291|EMG - Triggered Stimulation
543740|NCT00525291|Augmented biofeedback
543741|NCT00525278|Levocetirizine dihydrochloride
543742|NCT00525278|Xyzal tablets
543743|NCT00525265|Vasopressin antagonist
543744|NCT00525265|Cardiac Edema
543745|NCT00525265|Diuretics
543746|NCT00525252|Liver cirrhosis
543747|NCT00525252|Alcoholism
543748|NCT00525252|Craving
543749|NCT00525239|Lipids
543750|NCT00525239|lipoproteins
543751|NCT00525239|VLDL
543752|NCT00525239|triglycerides
543753|NCT00525239|apo B100
543754|NCT00525239|HDL
543755|NCT00525239|apo A1
543756|NCT00525239|endothelial dysfunction
543757|NCT00525239|insulin secretion
543758|NCT00525239|hyperglycemic clamp
543759|NCT00525239|HIV-seronegative Volunteers
543760|NCT00525239|HIV-infected subjects starting an efavirenz-based regimen
543761|NCT00525239|Treatment Experienced
543762|NCT00525226|Psychiatry
543763|NCT00525226|Psychology
543764|NCT00525226|Pregnancy
543765|NCT00525226|Stress
543766|NCT00525226|Anxiety
543767|NCT00525213|Rheumatoid Arthritis
543768|NCT00525200|predictive marker
543769|NCT00525200|personalized therapy
543770|NCT00525200|response assessment
543771|NCT00525200|p53 genotype
543772|NCT00525187|onychomycosis
543773|NCT00525187|diabetic neuropathic patients
543774|NCT00525187|reliability of the diagnostic of onychomycosis
543775|NCT00525174|Amblyopia
543776|NCT00525174|Patching
543777|NCT00525174|Bangerter filters
543778|NCT00525161|breast cancer
543779|NCT00525161|Sorafenib
543780|NCT00525161|Nexavar
543781|NCT00525161|Endocrine Therapy
543782|NCT00525122|hyperthyroidism
543783|NCT00525122|radioactive iodine
543784|NCT00525122|antithyroid drugs
543785|NCT00525122|Hyperthyroidism, treatment with radioactive iodine without antithyroid drugs
543786|NCT00525109|Cholesterol
543787|NCT00525109|Hyperlipidemia
543788|NCT00525109|Gene array
543789|NCT00525083|hyperlipidemia
543790|NCT00525083|HDL-C
543791|NCT00525083|low density lipoprotein
543792|NCT00525057|Bone Cancer
543793|NCT00525057|Orthopaedic Oncology
543794|NCT00525057|Orthopaedics
543795|NCT00525057|Myeloma
543796|NCT00525057|Lymphoma
543797|NCT00525057|Deep Venous Thrombosis
543798|NCT00525057|DVT Prophylaxis
543799|NCT00525057|Thromboembolic disease
543800|NCT00525057|Blood clots
543801|NCT00525057|Dalteparin
543802|NCT00525057|Fragmin
543803|NCT00525057|Surgery
543804|NCT00525057|Bone Tumor
543805|NCT00525057|Tumor of soft tissue
543806|NCT00525057|Lower extremity
543807|NCT00525057|Leg
543808|NCT00525057|TED hose
543809|NCT00525057|Mechanical compression stocking
543810|NCT00525031|Melanoma
543811|NCT00525031|Temozolomide
543812|NCT00525031|Temodar
543813|NCT00525031|Pegylated Interferon Alpha-2b
543814|NCT00525031|PEG-Intron
543815|NCT00525031|PGI
543816|NCT00525031|Resectable metastatic melanoma
543817|NCT00525031|Surgery
543818|NCT00525018|Pain
543819|NCT00525018|Functional neuroimaging
543820|NCT00525018|Neuropathy
543821|NCT00525018|Thermal sensation
543822|NCT00525005|Stomach Neoplasm
543823|NCT00525005|Docetaxel
543824|NCT00525005|Oxaliplatin
543825|NCT00525005|S-1
543826|NCT00524992|Focal Segmental Glomerulosclerosis
543827|NCT00524992|Collapsing Glomerulopathy
543828|NCT00524992|Anti-Retroviral Toxicity
543829|NCT00524992|Lipodystrophy
543830|NCT00524992|Metabolic Syndrome
543831|NCT00524992|Tubular Injury
543832|NCT00524992|Renal Biopsy
543833|NCT00524992|Proteinuria
543834|NCT00524992|Tenofovir Toxicity
543835|NCT00524992|HAART Toxicity
543836|NCT00524992|HIV Positive
543837|NCT00524992|HIV-Associated Focal Segmental Glomerulosclerosis
543838|NCT00524953|allogeneic bone marrow transplantation
543839|NCT00524953|non-T-cell depleted
543840|NCT00524953|UV-c
543841|NCT00524953|GVHD
543842|NCT00524940|Influenza
543843|NCT00524940|Orthomyxoviruses
543844|NCT00524940|Inactivated Split-virion influenza vaccine
543845|NCT00524927|Incident Pain
543846|NCT00524927|Bone Marrow Biopsy
543847|NCT00524914|Parkinson's disease
543848|NCT00524914|Pain
543849|NCT00524914|Nociceptive threshold
543850|NCT00524914|Functional imaging
543851|NCT00524914|Cerebral activity
543852|NCT00524914|Dopamine agonist.
543853|NCT00524901|Apoptosis
543854|NCT00524901|CABG
543855|NCT00524901|Coronary Artery Disease
543856|NCT00524901|Three Vessel Disease
543857|NCT00524901|Erythropoietin
543858|NCT00524901|EPO-receptor signaling
543859|NCT00524888|Hand
543860|NCT00524888|Laceration
543861|NCT00524888|bioadhesive
543862|NCT00524888|ER
543863|NCT00524888|Hand laceration distal to the volar wrist crease
543864|NCT00524875|Proliferative diabetic retinopathy
543865|NCT00524875|Bevacizumab
543866|NCT00524875|Early post-vitrectomy vitreous hemorrhage
543867|NCT00524862|Implantable Cardioverter Defibrillator
543868|NCT00524862|Ejection Fraction
543869|NCT00524862|QRS duration
543870|NCT00524849|Breast cancer
543871|NCT00524849|Bone metastasis
543872|NCT00524849|Circulating VEGF
543873|NCT00524849|Zoledronic acid
543874|NCT00524849|Angiogenesis
543875|NCT00524836|levocetirizine dihydrochloride
543876|NCT00524836|Xyzal tablets
543877|NCT00524823|Prostate Cancer
543878|NCT00524823|Hyperplasia - BPH
543879|NCT00524823|FACS
543880|NCT00524823|Prostate Cancer, Hyperplasia - BPH, Malignancy
543881|NCT00524797|Myelosuppression,
543882|NCT00524797|chemotherapeutic agents,
543883|NCT00524797|leucopenia,
543884|NCT00524797|thrombocytopenia,
543885|NCT00524797|Profonycia
543886|NCT00524784|GVHD
543887|NCT00524784|HSCT
543888|NCT00524784|BMT
543889|NCT00524784|APOPTOTIC CELLS
543890|NCT00524771|Contraception
543891|NCT00524771|Contraceptive Vaginal Ring
543892|NCT00524758|ologen
543893|NCT00524758|oculusgen
543894|NCT00524758|collagen matrix
543895|NCT00524758|trabeculectomy
543896|NCT00524758|filtering surgery
543897|NCT00524758|mitomycin-C
543898|NCT00524758|MMC
543899|NCT00524758|Aeon Astron
543900|NCT00524745|Gardasil
543901|NCT00524745|Human Papillomavirus
543902|NCT00524745|HPV vaccine
543903|NCT00524745|Cervical cancer
543904|NCT00524732|Pertussis
543905|NCT00524732|Tetanus
543906|NCT00524732|Diphtheria
543907|NCT00524706|S-1
543908|NCT00524706|oral fluoropyrimidine
543909|NCT00524706|tegafur
543910|NCT00524706|Gimeracil
543911|NCT00524706|Oteracil Potassium
543912|NCT00524706|Leucovorin
543913|NCT00524706|Calcium Folinate
543914|NCT00524706|Oxaliplatin
543915|NCT00524706|L-OHP
543916|NCT00524706|colorectal cancer
543917|NCT00524693|Bronchiolitis
543918|NCT00524693|controlled clinical trial
543919|NCT00524693|pediatrics
543920|NCT00524693|Infants
543921|NCT00524693|montelukast
543922|NCT00524693|Respiratory syncytial virus
543923|NCT00524680|adenocarcinoma of the prostate
543924|NCT00524680|recurrent prostate cancer
543925|NCT00524680|stage I prostate cancer
543926|NCT00524680|stage II prostate cancer
543927|NCT00524680|stage III prostate cancer
543928|NCT00524680|stage IV prostate cancer
543929|NCT00524667|Active CLL
543930|NCT00524654|To determine the effects of cervical spine manipulation on postural control.
543931|NCT00524641|Asthma
543932|NCT00524641|Symbicort
543933|NCT00524641|NIS
543934|NCT00524615|resistant hypertension treatment
543935|NCT00524615|spironolactone
543936|NCT00524615|aldosterone antagonists
543937|NCT00524615|resistant arterial hypertension
543938|NCT00524615|refractory arterial hypertension
543939|NCT00524602|Stereotaxis
543940|NCT00524602|Arrythmia
543941|NCT00524602|Catheter ablation
543942|NCT00524602|Heart
543943|NCT00524589|recurrent prostate cancer
543944|NCT00524576|Hepatitis B
543945|NCT00524576|Persistence
543946|NCT00524576|Challenge dose
543947|NCT00524563|Acinetobacter
543948|NCT00524563|bloodstream infection
543949|NCT00524563|Isolate
543950|NCT00524550|Moderate alcohol consumption
543951|NCT00524550|insulin secretion
543952|NCT00524550|insulin sensitivity
543953|NCT00524550|Beta-cell function
543954|NCT00524550|Adiponectin
543955|NCT00524550|Appetite
543956|NCT00524550|Satiety
543957|NCT00524550|Alcohol-induced gene expression
543958|NCT00524550|Endocannabinoids
543959|NCT00524550|Glucose metabolism
543960|NCT00524550|Lipid metabolism
543961|NCT00524550|Ratio HMW/total adiponectin
543962|NCT00524550|Appetite regulation
543963|NCT00524550|Alcohol-induced adiponectin increase
543964|NCT00524537|Crohn's Disease
543965|NCT00524524|solid tumors
543966|NCT00524524|biopsy
543967|NCT00524511|cesarean
543968|NCT00524511|wound
543969|NCT00524511|Dermabond
543970|NCT00524511|superglue
543971|NCT00524511|staples
543972|NCT00524511|wound complications
543973|NCT00524498|OPC-18
543974|NCT00524498|Interferon-alpha
543975|NCT00524498|Fluorouracil
543976|NCT00524485|actinic keratosis
543977|NCT00524472|Hyperinsulinemic glucose control
543978|NCT00524472|cardiac surgery
543979|NCT00524472|Outcome
543980|NCT00524459|stage IIIA breast cancer
543981|NCT00524459|stage IIIB breast cancer
543982|NCT00524446|Infant
543983|NCT00524446|Sub-Saharan Africa
543984|NCT00524446|Complementary feeding
543985|NCT00524446|Fortified spread
543986|NCT00524446|Lipid-based nutrient supplement
543987|NCT00524446|Malnutrition
543988|NCT00524446|Stunting
543989|NCT00524446|Growth
543990|NCT00524446|Morbidity
543991|NCT00524446|Development
543992|NCT00524446|Haemoglobin
543993|NCT00524433|acute heart failure
543994|NCT00524433|acute decompensation of chronic heart failure
543995|NCT00524433|new onset of heart failure
543996|NCT00524433|tezosentan
543997|NCT00524433|Actelion
543998|NCT00524420|Pain
543999|NCT00524420|Fatigue
544000|NCT00524420|Chronic Fatigue Syndrome
544001|NCT00524420|Chronic Fatigue-Fibromyalgia Syndrome
544002|NCT00524420|Depression
544003|NCT00524420|Major Depressive Disorder
544004|NCT00524407|Anemia
544005|NCT00524407|hemoglobin
544006|NCT00524407|chemotherapy
544007|NCT00524407|hematologic response
544008|NCT00524407|subcutaneous injection
544009|NCT00524407|Epoetin alfa
544010|NCT00524407|FACT-An
544011|NCT00524407|LASA
544012|NCT00524407|PROCRIT
544013|NCT00524394|VLBW
544014|NCT00524394|sepsis
544015|NCT00524394|diagnosis
544016|NCT00524394|suspected sepsis
544017|NCT00524368|Human immunodeficiency virus - type 1
544018|NCT00524368|HIV-1 Infection
544019|NCT00524368|TMC-114
544020|NCT00524368|Darunavir
544021|NCT00524368|Ritonavir
544022|NCT00524355|GERD
544023|NCT00524355|GIS
544024|NCT00524355|heartburn
544025|NCT00524355|NIS
544026|NCT00524355|PPI
544027|NCT00524342|IL-11
544028|NCT00524342|von Willebrand disease
544029|NCT00524342|von Willebrand factor
544030|NCT00524342|VWFmRNA
544031|NCT00524342|menorrhagia
544032|NCT00524329|upper GI-symptoms
544033|NCT00524329|heartburn
544034|NCT00524329|NSAID
544035|NCT00524329|risk
544036|NCT00524329|PPI
544037|NCT00524329|Bloating
544038|NCT00524329|Regurgitation
544039|NCT00524316|adult primary hepatocellular carcinoma
544040|NCT00524316|advanced adult primary liver cancer
544041|NCT00524316|localized unresectable adult primary liver cancer
544042|NCT00524316|recurrent adult primary liver cancer
544043|NCT00524303|ErbB2 Overexpressing
544044|NCT00524303|ErbB2 Positive
544045|NCT00524303|Lapatinib
544046|NCT00524303|Invasive Breast Cancer
544047|NCT00524290|Acinetobacter
544048|NCT00524290|infection
544049|NCT00524290|isolate
544050|NCT00524277|stage I breast cancer
544051|NCT00524277|stage II breast cancer
544052|NCT00524277|stage IIIA breast cancer
544053|NCT00524277|stage IIIB breast cancer
544054|NCT00524277|stage IIIC breast cancer
544055|NCT00524277|male breast cancer
544056|NCT00524251|Patients with reflux complaints
544057|NCT00524251|GERD
544058|NCT00524251|quality of life
544059|NCT00524251|lifestyle adjustments
544060|NCT00524238|hypothyroidism
544061|NCT00524238|glucose turnover
544062|NCT00524238|clamp
544063|NCT00524238|insulin resistance
544064|NCT00524238|lipid turnover
544065|NCT00524238|amino acid turnover
544066|NCT00524225|IL-11
544067|NCT00524225|von Willebrand disease
544068|NCT00524225|von Willebrand factor
544069|NCT00524225|VWFmRNA
544070|NCT00524225|surgery
544071|NCT00524199|homocysteine
544072|NCT00524199|hemodialysis
544073|NCT00524199|mesna
544074|NCT00524186|stage III gastric cancer
544075|NCT00524186|stage IV gastric cancer
544076|NCT00524186|adenocarcinoma of the esophagus
544077|NCT00524186|stage IV esophageal cancer
544078|NCT00524186|recurrent gastric cancer
544079|NCT00524186|recurrent esophageal cancer
544080|NCT00524186|adenocarcinoma of the stomach
544081|NCT00524173|Emtricitabine
544082|NCT00524173|Tenofovir
544083|NCT00524173|Antiviral Therapy
544084|NCT00524173|Hepatitis B
544085|NCT00524173|HBV
544086|NCT00524160|Fentanyl
544087|NCT00524160|opioid analgesics
544088|NCT00524160|arthritis
544089|NCT00524160|osteoarthritis
544090|NCT00524160|rheumatoid arthritis
544091|NCT00524160|transdermal administration
544092|NCT00524147|loculated pleural effusion
544093|NCT00524147|pigtail drainage
544094|NCT00524147|pleural effusion
544095|NCT00524147|pleural thickening
544096|NCT00524147|tuberculosis
544097|NCT00524134|Epilepsy
544098|NCT00524134|Seizure
544099|NCT00524134|p-glycoprotein
544100|NCT00524121|adenocarcinoma of the esophagus
544101|NCT00524121|squamous cell carcinoma of the esophagus
544102|NCT00524121|stage I esophageal cancer
544103|NCT00524121|stage II esophageal cancer
544104|NCT00524121|stage III esophageal cancer
544105|NCT00524121|stage IV esophageal cancer
544106|NCT00524108|shunt
544107|NCT00524108|internal ventriculoperitoneal
544108|NCT00524095|prophylaxis
544109|NCT00524095|Antibiotic
544110|NCT00524095|inhaled steroids
544111|NCT00524095|bronchiectasis
544112|NCT00524095|prevalence
544113|NCT00524095|chronic bronchitis
544114|NCT00524069|stage I pancreatic cancer
544115|NCT00524069|stage II pancreatic cancer
544116|NCT00524069|adenocarcinoma of the pancreas
544117|NCT00524056|Essential Tremor
544118|NCT00524056|Tremor
544119|NCT00524056|Anti-epileptic drug (AED)
544120|NCT00524043|Schizophrenia
544121|NCT00524030|Epilepsy
544122|NCT00524030|partial seizures
544123|NCT00524030|pregabalin monotherapy
544124|NCT00524030|double-blind and randomized trial
544125|NCT00524017|hypopharyngeal cancer
544126|NCT00524017|laryngeal cancer
544127|NCT00524017|lip and oral cavity cancer
544128|NCT00524017|nasopharyngeal cancer
544129|NCT00524017|oropharyngeal cancer
544130|NCT00524017|paranasal sinus and nasal cavity cancer
544131|NCT00524017|salivary gland cancer
544132|NCT00524017|precancerous condition
544133|NCT00524004|Passive immunization, Bovine Milk Immunoglobuin
544134|NCT00523978|Atrial Fibrillation
544135|NCT00523965|Kala-azar
544136|NCT00523965|miltefosine
544137|NCT00523965|liposomal amphotericin B
544138|NCT00523952|dermatitis, atopic
544139|NCT00523952|tacrolimus
544140|NCT00523952|adult
544141|NCT00523939|Lymphoma
544142|NCT00523939|Leukemia
544143|NCT00523939|Leukemic Meningitis
544144|NCT00523939|Lymphomatous Meningitis
544145|NCT00523926|Tuberculosis
544146|NCT00523913|type 2 diabetes mellitus;
544147|NCT00523913|diabetes;
544148|NCT00523913|rosiglitazone
544149|NCT00523913|Avandia;
544150|NCT00523900|malnutrition
544151|NCT00523900|underweight
544152|NCT00523900|low body weight
544153|NCT00523900|BMI under 19
544154|NCT00523900|under nourished
544155|NCT00523900|malnourished
544156|NCT00523887|Radiation pain
544157|NCT00523887|Duragesic
544158|NCT00523887|Fentanyl
544159|NCT00523887|Pain
544160|NCT00523861|Glucose
544161|NCT00523861|Insulin sensitivity
544162|NCT00523861|Glucose metabolism
544163|NCT00523861|Appetite
544164|NCT00523861|Satiety
544165|NCT00523848|stage I multiple myeloma
544166|NCT00523848|stage II multiple myeloma
544167|NCT00523848|stage III multiple myeloma
544168|NCT00523822|This study seeks to determine if the correction of a sacroiliac lesion can produce a functional change in cervical spine.
544169|NCT00523809|Breast Cancer
544170|NCT00523809|Ovarian Cancer
544171|NCT00523809|Stem Cell Transplantation
544172|NCT00523809|Bevacizumab
544173|NCT00523809|Fludarabine
544174|NCT00523809|Melphalan
544175|NCT00523809|Avastin
544176|NCT00523809|Thymoglobulin
544177|NCT00523809|ATG
544178|NCT00523809|Antithymocyte Globulin
544179|NCT00523809|Allogeneic Hematopoietic Stem Cell Transplantation
544180|NCT00523809|AHSCT
544181|NCT00523796|dyslipidemia
544182|NCT00523796|in practice survey
544183|NCT00523796|Vietnam
544184|NCT00523783|Schizophrenia
544185|NCT00523783|Schizoaffective
544186|NCT00523783|quetiapine
544187|NCT00523783|long-term efficacy
544188|NCT00523783|Naturalistic
544189|NCT00523783|Observational
544190|NCT00523770|Invasive Pneumococcal Diseases
544191|NCT00523770|Pneumonia
544192|NCT00523757|heart failure
544193|NCT00523757|collagen
544194|NCT00523757|diastolic function
544195|NCT00523744|hypertension, valsartan, amlodipine
544196|NCT00523731|Stem cells
544197|NCT00523731|Rest pain
544198|NCT00523731|claudication
544199|NCT00523731|chronic ischemic or non-healing ulcers
544200|NCT00523731|Angiogenesis
544201|NCT00523731|no-option cases
544202|NCT00523718|obsessive-compulsive disorder
544203|NCT00523718|OCD
544204|NCT00523718|glutamate
544205|NCT00523718|riluzole
544206|NCT00523718|augmentation
544207|NCT00523718|treatment
544208|NCT00523705|premenstrual syndrome
544209|NCT00523705|PMS
544210|NCT00523705|PMDD
544211|NCT00523705|treatment
544212|NCT00523705|SSRI
544213|NCT00523692|Early arthritis
544214|NCT00523692|Rheumatoid arthritis
544215|NCT00523692|Rheumatoid factor
544216|NCT00523692|Anti CCP antibody
544217|NCT00523692|Remission
544218|NCT00523692|Anti-TNF therapy
544219|NCT00523692|methotrexate
544220|NCT00523679|Asthma
544221|NCT00523679|Symbicort
544222|NCT00523679|SMART
544223|NCT00523679|inhaler
544224|NCT00523679|compliance
544225|NCT00523679|Naturalistic
544226|NCT00523679|Observational
544227|NCT00523666|Alzheimer's disease
544228|NCT00523666|diffusion tensor imaging
544229|NCT00523640|metastatic
544230|NCT00523640|renal cell
544231|NCT00523640|kidney
544232|NCT00523640|neoplasm
544233|NCT00523627|Energy Expenditure
544234|NCT00523627|Adaptive Thermogenesis
544235|NCT00523627|Low-protein Overfeeding
544236|NCT00523627|Fasting
544237|NCT00523627|Weight Gain
544238|NCT00523614|venous thromboembolism
544239|NCT00523601|Bipolar depression
544240|NCT00523601|quetiapine
544241|NCT00523601|observational
544242|NCT00523601|Naturalistic
544243|NCT00523588|Cutaneous lupus erythematosus
544244|NCT00523588|Pulsed dye laser
544245|NCT00523575|Elderly
544246|NCT00523575|Osteoporosis
544247|NCT00523575|hip fracture
544248|NCT00523575|malnutrition
544249|NCT00523575|nutritional support
544250|NCT00523562|fructose
544251|NCT00523562|dietary lipids
544252|NCT00523562|dietary proteins
544253|NCT00523562|hepatic steatosis
544254|NCT00523562|insulin resistance
544255|NCT00523562|Healthy humans
544256|NCT00523562|overweight humans
544257|NCT00523562|obese humans
544258|NCT00523549|Hypertension
544259|NCT00523549|systolic blood pressure
544260|NCT00523549|diastolic dysfunction
544261|NCT00523549|valsartan
544262|NCT00523549|amlodipine
544263|NCT00523536|High Blood Pressure
544264|NCT00523536|Cardiovascular
544265|NCT00523523|Rehabilitation
544266|NCT00523523|hemiplegia
544267|NCT00523523|stroke
544268|NCT00523523|upper extremity
544269|NCT00523523|motor skills
544270|NCT00523523|therapy
544271|NCT00523510|breastmilk
544272|NCT00523510|perinatal HIV
544273|NCT00523510|infant feeding
544274|NCT00523510|flash heat
544275|NCT00523510|pasteurization
544276|NCT00523510|pmtct
544277|NCT00523510|HIV
544278|NCT00523510|HIV Seronegativity
544279|NCT00523510|Treatment Naive
544280|NCT00523497|Severe community-acquired pneumonia
544281|NCT00523497|Noninvasive mechanical ventilation
544282|NCT00523497|Acute hypoxemic respiratory failure.
544283|NCT00523484|Beck Anxiety Inventory
544284|NCT00523484|Prostate Cancer
544285|NCT00523484|Prostate Specific Antigen
544286|NCT00523484|Naturalistic
544287|NCT00523484|Observational
544288|NCT00523471|prostate cancer
544289|NCT00523471|gamma H2AX
544290|NCT00523471|radiosensitivity
544291|NCT00523458|Co-infection
544292|NCT00523458|Tuberculosis
544293|NCT00523458|HIV
544294|NCT00523458|Drug interactions
544295|NCT00523458|Non nucleoside reverse transcriptase inhibitors
544296|NCT00523458|Therapy
544297|NCT00523458|Treatment Naive
544298|NCT00523445|Schizophrenia
544299|NCT00523445|Cognition
544300|NCT00523445|Varenicline
544301|NCT00523432|ovarian cancer
544302|NCT00523432|cervical cancer
544303|NCT00523432|uterine cancer
544304|NCT00523432|fallopian tube cancer
544305|NCT00523432|endometrial cancer
544306|NCT00523432|vaginal cancer
544307|NCT00523432|peritoneal cancer
544308|NCT00523432|reproductive cancer
544309|NCT00523406|choroidal neovascularisation,
544310|NCT00523406|vision,
544311|NCT00523406|macula,
544312|NCT00523406|macular degeneration
544313|NCT00523406|optical coherence tomography
544314|NCT00523406|neovascular age related macular degeneration
544315|NCT00523367|Gastro Esophageal Reflux Disease (GERD)
544316|NCT00523367|Chronic Obstructive Pulmonary Disease (COPD)
544317|NCT00523354|Eosinophilic Esophagitis
544318|NCT00523354|TNF-alpha
544319|NCT00523354|TNF-alpha Blockade
544320|NCT00523354|Infliximab
544321|NCT00523341|postmenopausal osteoporosis
544322|NCT00523341|low bone density
544323|NCT00523341|fractures
544324|NCT00523341|low bone mass
544325|NCT00523328|Rheumatoid Arthritis
544326|NCT00523328|Arthritis
544327|NCT00523328|BG9924
544328|NCT00523328|methotrexate
544329|NCT00523315|Aromatase Inhibitor
544330|NCT00523315|Breast Cancer
544331|NCT00523315|compliance
544332|NCT00523315|Naturalistic
544333|NCT00523315|Observational
544334|NCT00523302|Major Depression
544335|NCT00523302|Fibromyalgia
544336|NCT00523302|TMS
544337|NCT00523289|Ropivacaine
544338|NCT00523289|Bupivacaine
544339|NCT00523289|Upper Extremity
544340|NCT00523289|Local anesthetic
544341|NCT00523276|Severe acute respiratory syndrome, SARS, China
544342|NCT00523250|Glaucoma
544343|NCT00523224|Stem cells
544344|NCT00523224|Coronary Artery Bypass grafting
544345|NCT00523224|Congestive Heart Failure
544346|NCT00523224|Coronary Artery Disease
544347|NCT00523224|Angiogenesis
544348|NCT00523211|Acquired Immunodeficiency Syndrome
544349|NCT00523211|Treatment Experienced
544350|NCT00523198|Cortisol
544351|NCT00523185|alcohol withdrawal
544352|NCT00523185|lorazepam
544353|NCT00523185|diazepam
544354|NCT00523172|Chiropractic Manipulation
544355|NCT00523159|clear cell renal cell carcinoma
544356|NCT00523146|primary dysmenorrhea
544357|NCT00523146|Herbal remedy
544358|NCT00523133|alcoholism
544359|NCT00523133|naltrexone
544360|NCT00523133|motivational enhancement therapy
544361|NCT00523107|Fatigue
544362|NCT00523107|Standard Palliative Care
544363|NCT00523107|PG2
544364|NCT00523107|QLQ-C30
544365|NCT00523107|Compassionate
544366|NCT00523081|adolescent depression treatment, cognitive behavioral therapy,
544367|NCT00523081|collaborative care
544368|NCT00523068|overactive bladder
544369|NCT00523068|stress urinary incontinence
544370|NCT00523068|detrusor overactivity
544371|NCT00523068|urodynamics
544372|NCT00523055|Pain
544373|NCT00523055|Brachial Plexus Anesthesia
544374|NCT00523055|Plasma Lidocaine Levels
544375|NCT00523055|Ultrasound
544376|NCT00523029|Self-management programs
544377|NCT00523029|Chronic medical illness
544378|NCT00523016|acupuncture
544379|NCT00523016|electroacupuncture
544380|NCT00523016|sham acupuncture
544381|NCT00523016|spinal cord injury
544382|NCT00523016|neuropathic pain
544383|NCT00523016|burning pain
544384|NCT00523003|weight loss
544385|NCT00523003|obesity
544386|NCT00523003|high protein
544387|NCT00523003|meal replacement
544388|NCT00522977|Myocardial strain
544389|NCT00522977|Myocardial function
544390|NCT00522977|Pregnancy
544391|NCT00522977|Postpartum
544392|NCT00522977|Echocardiography
544393|NCT00522977|Myocardial adaptation to pregnancy
544394|NCT00522977|Systolic function
544395|NCT00522977|Diastolic function
544396|NCT00522964|Chinese-American
544397|NCT00522964|Children
544398|NCT00522964|Obesity
544399|NCT00522964|health behaviors
544400|NCT00522964|Behavioral intervention
544401|NCT00522964|normal
544402|NCT00522951|MRI
544403|NCT00522951|Brain Metastasis
544404|NCT00522951|Gadolinium
544405|NCT00522951|Imaging
544406|NCT00522951|Diagnostic Agent
544407|NCT00522938|Lung
544408|NCT00522938|Cancer
544409|NCT00522938|Non-small
544410|NCT00522938|Lung Cancer
544411|NCT00522938|NSCLC
544412|NCT00522938|erlotinib
544413|NCT00522938|oral
544414|NCT00522938|Locally Advanced Non-small Cell Lung Cancer
544415|NCT00522938|Metastatic Non-small Cell Lung Cancer
544416|NCT00522925|hypertension
544417|NCT00522925|high blood pressure
544418|NCT00522912|Trachoma
544419|NCT00522912|Trichiasis
544420|NCT00522912|Surgery
544421|NCT00522912|Epilation
544422|NCT00522912|Ethiopia
544423|NCT00522899|aged
544424|NCT00522899|exercise
544425|NCT00522899|cognitive therapy
544426|NCT00522899|dementia
544427|NCT00522899|prevention
544428|NCT00522886|cetuximab
544429|NCT00522886|concurrent
544430|NCT00522886|iso-toxic
544431|NCT00522886|NSCLC
544432|NCT00522873|Postmenopausal Symptoms e.g.
544433|NCT00522873|Hot flushes
544434|NCT00522873|Sweating episodes
544435|NCT00522873|Vaginal dryness
544436|NCT00522860|Trichiasis
544437|NCT00522860|Trachoma
544438|NCT00522860|Surgery
544439|NCT00522860|Suture
544440|NCT00522860|Ethiopia
544441|NCT00522847|Postmenopausal
544442|NCT00522847|non dry eye
544443|NCT00522834|melanoma
544444|NCT00522834|oncology
544445|NCT00522834|Stage IV Metastatic Melanoma
544446|NCT00522821|IgG subclass deficiency
544447|NCT00522821|Anti-polysaccharide deficiency
544448|NCT00522821|therapy
544449|NCT00522821|Immunoglobulins, Intravenous
544450|NCT00522821|co-trimoxazole
544451|NCT00522808|HCV
544452|NCT00522808|antiviral
544453|NCT00522808|PK
544454|NCT00522808|Safety
544455|NCT00522795|Esophageal Cancer
544456|NCT00522769|binge eating
544457|NCT00522769|adolescent girls
544458|NCT00522769|cognitive behavioral therapy
544459|NCT00522756|Kidney Failure, Acute
544460|NCT00522756|Cardiac Surgical Procedures
544461|NCT00522756|Sodium Bicarbonate
544462|NCT00522756|Sodium Chloride
544463|NCT00522756|Prevention and control
544464|NCT00522743|SGA
544465|NCT00522743|GH
544466|NCT00522743|GnRHa
544467|NCT00522743|IGF-1
544468|NCT00522730|Liver failure
544469|NCT00522730|Liver cirrhosis
544470|NCT00522730|Parenteral nutrition
544471|NCT00522730|Enteral nutrition
544472|NCT00522730|Lipids
544473|NCT00522730|Safety
544474|NCT00522730|Drug tolerance
544475|NCT00522704|Arteriovenous fistula
544476|NCT00522704|Access blood flow
544477|NCT00522704|Extracorporeal blood flow
544478|NCT00522704|Dynamic arterial line pressure
544479|NCT00522704|Hemodialysis treatment
544480|NCT00522691|Fecal incontinence
544481|NCT00522691|sacral nerve stimulation
544482|NCT00522678|Healthy Volunteers
544483|NCT00522652|cancer
544484|NCT00522652|advanced cancer
544485|NCT00522652|lymphoma
544486|NCT00522639|lung cancer
544487|NCT00522639|FDG-PET-CT
544488|NCT00522639|blood proteins
544489|NCT00522639|prognose
544490|NCT00522626|Fetus
544491|NCT00522626|Drug abuse
544492|NCT00522626|Fetal development
544493|NCT00522626|Substance abuse
544494|NCT00522626|Opioids
544495|NCT00522626|Methadone
544496|NCT00522613|recovery
544497|NCT00522613|serious mental illness
544498|NCT00522613|bipolar disorder
544499|NCT00522613|schizophrenia
544500|NCT00522613|schizoaffective disorder
544501|NCT00522600|eyedrops
544502|NCT00522600|compliance
544503|NCT00522600|glaucoma medications
544504|NCT00522600|adherence
544505|NCT00522574|Myeloproliferative Disorders
544506|NCT00522561|Healthy volunteers
544507|NCT00522561|running
544508|NCT00522561|energetic cost
544509|NCT00522561|limb mechanical characteristics
544510|NCT00522561|contractile components
544511|NCT00522561|elastic components
544512|NCT00522561|healthy men doing regularly physical activities
544513|NCT00522548|African American
544514|NCT00522548|Kidney Transplant
544515|NCT00522535|AAA
544516|NCT00522535|Abdominal Aortic Aneurysms
544517|NCT00522535|Endovascular
544518|NCT00522535|EVAR
544519|NCT00522535|Aorta
544520|NCT00522535|Stent Graft
544521|NCT00522535|Stent
544522|NCT00522535|Tortuous
544523|NCT00522535|High Angle
544524|NCT00522535|Angled Necks
544525|NCT00522522|Naturalistic, retrospective, utilization of care services, diagnosis, epilepsy
544526|NCT00522496|Craniocerebral trauma
544527|NCT00522496|matrix metalloproteinase
544528|NCT00522496|microdialysis
544529|NCT00522457|Breast Cancer
544530|NCT00522457|investigational drug
544531|NCT00522457|drug therapy
544532|NCT00522457|Antineoplastic Protocols
544533|NCT00522457|Immunotherapy
544534|NCT00522457|Metastatic breast cancer
544535|NCT00522457|Advanced breast cancer
544536|NCT00522457|Stage IV breast cancer
544537|NCT00522457|Her-2/neu expressing breast cancer
544538|NCT00522457|Her-2/neu
544539|NCT00522457|Trastuzumab refractory
544540|NCT00522431|Hypogonadism
544541|NCT00522418|Epilepsy
544542|NCT00522418|VNS Therapy
544543|NCT00522405|Transarterial chemoembolisation
544544|NCT00522405|Thalidomide
544545|NCT00522405|Capecitabine
544546|NCT00522405|Treatment
544547|NCT00522392|Consolidation therapy
544548|NCT00522392|First-line therapy
544549|NCT00522392|Proteasome inhibitor
544550|NCT00522392|Thalidomide analogue
544551|NCT00522392|Quality of life
544552|NCT00522379|Parkinson's disease
544553|NCT00522379|rotigotine
544554|NCT00522379|patch
544555|NCT00522379|transdermal
544556|NCT00522379|dopamine agonist
544557|NCT00522379|off time
544558|NCT00522379|Neupro
544559|NCT00522353|obesity
544560|NCT00522353|weight loss
544561|NCT00522353|satiety hormones
544562|NCT00522353|body composition
544563|NCT00522353|appetite ratings
544564|NCT00522340|Implantable Cardioverter Defibrillators
544565|NCT00522340|ICD
544566|NCT00522340|Exercise
544567|NCT00522340|Cardiac
544568|NCT00522340|Inflammation
544569|NCT00522327|Immigrant
544570|NCT00522327|Interpreting
544571|NCT00522314|Non-invasive ventilation
544572|NCT00522314|Airway clearance
544573|NCT00522314|Bronchiectasis
544574|NCT00522301|recurrent ovarian epithelial cancer
544575|NCT00522301|fallopian tube cancer
544576|NCT00522301|primary peritoneal cavity cancer
544577|NCT00522301|stage I ovarian epithelial cancer
544578|NCT00522301|stage II ovarian epithelial cancer
544579|NCT00522301|stage III ovarian epithelial cancer
544580|NCT00522301|stage IV ovarian epithelial cancer
544581|NCT00522288|Myopia
544582|NCT00522288|Self-Perception
544583|NCT00522288|Contact Lenses
544584|NCT00522288|Glasses
544585|NCT00522288|Randomized
544586|NCT00522288|Children
544587|NCT00522288|Self-esteem
544588|NCT00522275|Adjunctive treatment in epilepsy
544589|NCT00522275|add-on treatment for epilepsy
544590|NCT00522275|partial seizures
544591|NCT00522275|AEDs
544592|NCT00522275|antiepileptic drugs
544593|NCT00522275|seizures
544594|NCT00522262|Breast Neoplasms
544595|NCT00522262|Exercise
544596|NCT00522262|Physical activity
544597|NCT00522262|Estrone
544598|NCT00522262|Estradiol
544599|NCT00522262|Adiposity
544600|NCT00522262|Breast density
544601|NCT00522262|Mammographic density
544602|NCT00522262|Insulin-Like Growth Factor I
544603|NCT00522262|Insulin Resistance
544604|NCT00522262|Women
544605|NCT00522262|Postmenopause
544606|NCT00522249|Metastatic Renal Cell Carcinoma
544607|NCT00522249|RCC
544608|NCT00522249|M3thodist
544609|NCT00522249|Pegylated Alfa Interferon
544610|NCT00522249|Sunitinib
544611|NCT00522249|Tarceva
544612|NCT00522249|Peg IFN
544613|NCT00522236|Adjuvanted Influenza Vaccine
544614|NCT00522223|Cervical Cancer
544615|NCT00522223|Cancer Survivors
544616|NCT00522223|Cervix Cancer
544617|NCT00522223|Sexual Functioning
544618|NCT00522223|Quality Of Life
544619|NCT00522223|Questionnaire
544620|NCT00522223|Radiation Therapy
544621|NCT00522223|Radical Hysterectomy
544622|NCT00522210|type 1 diabetes
544623|NCT00522210|children
544624|NCT00522210|long acting insulin analogue
544625|NCT00522210|hemoglobin A1c
544626|NCT00522197|non-small cell lung cancer
544627|NCT00522197|small cell lung cancer
544628|NCT00522197|squamous lung dysplasia
544629|NCT00522184|intra-articular injection
544630|NCT00522184|acute synovitis
544631|NCT00522184|etanercept
544632|NCT00522171|Harmonic
544633|NCT00522171|Massive Weight Loss
544634|NCT00522171|Electro Surgery
544635|NCT00522171|Skin and Fat Redundancy after massive weight loss
544636|NCT00522171|Obesity
544637|NCT00522145|Non-Small-Cell Lung Cancer
544638|NCT00522132|intravenous artesunate
544639|NCT00522132|severe malaria
544640|NCT00522132|Plasmodium falciparum
544641|NCT00522132|Africa
544642|NCT00522132|Severe Plasmodium falciparum Malaria
544643|NCT00522119|Essential Hypertension
544644|NCT00522119|High Blood Pressure
544645|NCT00522106|Behavioral graded activity
544646|NCT00522106|Hip
544647|NCT00522106|Knee
544648|NCT00522106|Physical therapy
544649|NCT00522106|Exercise therapy
544650|NCT00522093|constipation
544651|NCT00522067|influenza
544652|NCT00522067|influenza vaccine
544653|NCT00522067|adjuvanted influenza vaccine
544654|NCT00522067|subunit influenza vaccine
544655|NCT00522067|surface antigen
544656|NCT00522054|Exercise
544657|NCT00522054|Physical function
544658|NCT00522054|Rheumatoid arthritis
544659|NCT00522054|Tai Chi
544660|NCT00522041|Pain associated with chronic anal fissure
544661|NCT00522028|QoL
544662|NCT00522028|Osteodensitometry
544663|NCT00522028|Arterial pressure
544664|NCT00522028|PTH
544665|NCT00522015|PSP
544666|NCT00522015|dementia
544667|NCT00522015|neuropsychology
544668|NCT00522015|treatment
544669|NCT00522002|Connective tissue diseases
544670|NCT00522002|Blood coagulation disorders
544671|NCT00522002|Leg ulcers
544672|NCT00522002|Rheumatoid Arthritis
544673|NCT00522002|Systemic Lupus Erythematosus
544674|NCT00522002|Systemic Scleroderma
544675|NCT00522002|Mixed Connective Tissue Disease
544676|NCT00521989|Osteoarthritis
544677|NCT00521989|Knee
544678|NCT00521989|CRx-102
544679|NCT00521989|prednisolone
544680|NCT00521989|dipyridamole
544681|NCT00521989|CombinatoRx
544682|NCT00521989|WOMAC
544683|NCT00521976|Risk assessment
544684|NCT00521976|Chest pain
544685|NCT00521976|Coronary Artery Disease
544686|NCT00521976|Acute coronary syndromes
544687|NCT00521976|Factor XIIa
544688|NCT00521976|B-type natriuretic peptide (BNP)
544689|NCT00521976|high-sensitive C-reactive protein (hsCRP)
544690|NCT00521976|Omega-3
544691|NCT00521963|Intraarticular injection
544692|NCT00521963|Infliximab
544693|NCT00521950|Pharmacogenetics
544694|NCT00521950|Cost Effectiveness
544695|NCT00521950|Inflammatory Bowel Diseases
544696|NCT00521950|Crohn Disease
544697|NCT00521950|Ulcerative Colitis
544698|NCT00521950|Randomized Controlled Trials
544699|NCT00521911|Intervention Studies
544700|NCT00521911|Randomized Controlled Trials
544701|NCT00521911|Cognitive Therapy
544702|NCT00521911|Hospitals, General
544703|NCT00521911|Prevalence
544704|NCT00521898|Corneal transplantation, Descemet membrane
544705|NCT00521885|Bleeding rates
544706|NCT00521885|Prophylaxis for deep vein thrombosis
544707|NCT00521872|surgery (STARR operation)
544708|NCT00521859|Hematologic Malignancies
544709|NCT00521859|Leukemia
544710|NCT00521859|Lymphoma
544711|NCT00521859|Myeloma
544712|NCT00521859|Hodgkin's Disease
544713|NCT00521859|Hematopoietic Cell Transplantation
544714|NCT00521859|Cloretazine
544715|NCT00521859|VNP40101M
544716|NCT00521859|Fludarabine
544717|NCT00521859|Fludarabine Phosphate
544718|NCT00521859|Fludara
544719|NCT00521859|ATG
544720|NCT00521859|Antithymocyte
544721|NCT00521859|Thymoglobulin
544722|NCT00521833|Kataract
544723|NCT00521833|Astigmatism
544724|NCT00521833|phacoemulsification
544725|NCT00521820|Glucose Metabolism Disorder
544726|NCT00521820|Dysmetabolic Syndrome
544727|NCT00521820|Type II Diabetes
544728|NCT00521820|Diabetes Mellitus, Lipoatrophic
544729|NCT00521820|Dyslipidemia
544730|NCT00521820|Drug Therapy
544731|NCT00521807|Hypnosis,
544732|NCT00521807|Chronic widespread pain,
544733|NCT00521807|CWP,
544734|NCT00521807|General Practice
544735|NCT00521794|Arrhythmia
544736|NCT00521794|Muscle Weakness
544737|NCT00521794|Periodic Paralysis
544738|NCT00521794|Channelopathy
544739|NCT00521781|Unresectable or Metastatic Adenocarcinoma Prostate Cancer
544740|NCT00521781|Hormonal Therapy
544741|NCT00521781|Abraxane
544742|NCT00521781|M3thodist
544743|NCT00521768|Post traumatic stress disorder
544744|NCT00521768|Anxiety disorder
544745|NCT00521768|Comunity base intervention
544746|NCT00521768|Education
544747|NCT00521768|Behavioural treatment
544748|NCT00521755|Laser bonding soft tissue albumin
544749|NCT00521742|Glucose Metabolism Disorder
544750|NCT00521742|Dysmetabolic Syndrome
544751|NCT00521742|Type II Diabetes
544752|NCT00521742|Diabetes Mellitus, Lipoatrophic
544753|NCT00521742|Dyslipidemia
544754|NCT00521742|Drug Therapy
544755|NCT00521729|Thyroid
544756|NCT00521729|Thermoregulation
544757|NCT00521729|Catecholamines
544758|NCT00521729|Energy Expenditure
544759|NCT00521729|Obesity
544760|NCT00521729|Healthy Volunteer
544761|NCT00521729|HV
544762|NCT00521716|Hip Prosthesis Implantation
544763|NCT00521703|endoscopy, gastrointestinal
544764|NCT00521703|lidocaine
544765|NCT00521703|propofol
544766|NCT00521703|child
544767|NCT00521703|adolescent
544768|NCT00521677|VAP
544769|NCT00521677|Oral care
544770|NCT00521677|Acquired pneumonia
544771|NCT00521677|Mortality
544772|NCT00521677|LOS in ICU
544773|NCT00521677|LOS in hospital
544774|NCT00521677|All patients on ventilator in the ICU
544775|NCT00521664|proof of safety and cost effectiveness of the new therapeutic platelet transfusion strategy
544776|NCT00521651|Physical Fitness
544777|NCT00521651|Energy Expenditure
544778|NCT00521651|Nutrition Transition
544779|NCT00521651|Biomarker
544780|NCT00521651|Activity Monitors
544781|NCT00521651|Cancer Risk
544782|NCT00521612|sevoflurane
544783|NCT00521612|isoflurane
544784|NCT00521612|anaesthesia
544785|NCT00521586|Pneumococcal Conjugate Vaccine
544786|NCT00521560|High-Dose Radio-Immuno- and Chemotherapy
544787|NCT00521560|stem cell transplantation
544788|NCT00521560|90Y-Ibritumomab-Tiuxetan
544789|NCT00521547|Acupuncture
544790|NCT00521547|Analgesia
544791|NCT00521547|Functional magnetic resonance imaging (fMRI)
544792|NCT00521547|Neuronal Mechanisms
544793|NCT00521547|Quantitative Peripheral Sensory Testings
544794|NCT00521547|Normal Volunteers
544795|NCT00521534|Sleep related Breathing Disorder
544796|NCT00521534|Congestive Heart Failure
544797|NCT00521534|Atrial Overdrive Pacing
544798|NCT00521534|Cardiac Resynchronization Therapy
544799|NCT00521508|IgA
544800|NCT00521508|kidney
544801|NCT00521508|Berger'disease
544802|NCT00521508|regulatory T cells
544803|NCT00521508|pathogenesis of Berger's disease
544804|NCT00521495|static magnetic field
544805|NCT00521495|permanent magnet
544806|NCT00521495|carpal tunnel syndrome
544807|NCT00521495|median nerve
544808|NCT00521482|recurrent
544809|NCT00521482|after standard therapy
544810|NCT00521469|Disequilibrium
544811|NCT00521469|Spinal Manipulation
544812|NCT00521469|Postural control
544813|NCT00521430|recurrent childhood grade III lymphomatoid granulomatosis
544814|NCT00521430|childhood diffuse large cell lymphoma
544815|NCT00521430|recurrent childhood large cell lymphoma
544816|NCT00521430|childhood immunoblastic large cell lymphoma
544817|NCT00521430|recurrent childhood lymphoblastic lymphoma
544818|NCT00521430|childhood nasal type extranodal NK/T-cell lymphoma
544819|NCT00521430|recurrent childhood small noncleaved cell lymphoma
544820|NCT00521430|adult acute myeloid leukemia in remission
544821|NCT00521430|adult acute lymphoblastic leukemia in remission
544822|NCT00521430|aplastic anemia
544823|NCT00521430|recurrent childhood acute lymphoblastic leukemia
544824|NCT00521430|childhood acute lymphoblastic leukemia in remission
544825|NCT00521430|childhood acute myeloid leukemia in remission
544826|NCT00521430|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
544827|NCT00521430|adult acute myeloid leukemia with inv(16)(p13;q22)
544828|NCT00521430|adult acute myeloid leukemia with t(15;17)(q22;q12)
544829|NCT00521430|adult acute myeloid leukemia with t(16;16)(p13;q22)
544830|NCT00521430|adult acute myeloid leukemia with t(8;21)(q22;q22)
544831|NCT00521430|refractory anemia with excess blasts in transformation
544832|NCT00521430|refractory anemia with excess blasts
544833|NCT00521430|refractory anemia with ringed sideroblasts
544834|NCT00521430|refractory anemia
544835|NCT00521430|refractory multiple myeloma
544836|NCT00521430|chronic myelomonocytic leukemia
544837|NCT00521430|accelerated phase chronic myelogenous leukemia
544838|NCT00521430|blastic phase chronic myelogenous leukemia
544839|NCT00521430|chronic phase chronic myelogenous leukemia
544840|NCT00521430|relapsing chronic myelogenous leukemia
544841|NCT00521430|recurrent adult Hodgkin lymphoma
544842|NCT00521430|recurrent adult T-cell leukemia/lymphoma
544843|NCT00521430|anaplastic large cell lymphoma
544844|NCT00521430|angioimmunoblastic T-cell lymphoma
544845|NCT00521430|recurrent cutaneous T-cell non-Hodgkin lymphoma
544846|NCT00521430|recurrent mycosis fungoides/Sezary syndrome
544847|NCT00521430|adult nasal type extranodal NK/T-cell lymphoma
544848|NCT00521430|Waldenström macroglobulinemia
544849|NCT00521430|recurrent adult Burkitt lymphoma
544850|NCT00521430|recurrent adult diffuse large cell lymphoma
544851|NCT00521430|recurrent adult diffuse mixed cell lymphoma
544852|NCT00521430|recurrent adult diffuse small cleaved cell lymphoma
544853|NCT00521430|recurrent adult grade III lymphomatoid granulomatosis
544854|NCT00521430|recurrent adult immunoblastic large cell lymphoma
544855|NCT00521430|recurrent adult lymphoblastic lymphoma
544856|NCT00521430|recurrent grade 1 follicular lymphoma
544857|NCT00521430|recurrent grade 2 follicular lymphoma
544858|NCT00521430|recurrent grade 3 follicular lymphoma
544859|NCT00521430|recurrent mantle cell lymphoma
544860|NCT00521430|recurrent marginal zone lymphoma
544861|NCT00521430|recurrent small lymphocytic lymphoma
544862|NCT00521430|stage I multiple myeloma
544863|NCT00521430|stage II multiple myeloma
544864|NCT00521430|stage III multiple myeloma
544865|NCT00521430|cutaneous B-cell non-Hodgkin lymphoma
544866|NCT00521430|unspecified adult solid tumor, protocol specific
544867|NCT00521430|childhood chronic myelogenous leukemia
544868|NCT00521430|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
544869|NCT00521430|nodal marginal zone B-cell lymphoma
544870|NCT00521430|splenic marginal zone lymphoma
544871|NCT00521430|recurrent adult acute lymphoblastic leukemia
544872|NCT00521430|recurrent adult acute myeloid leukemia
544873|NCT00521430|recurrent childhood acute myeloid leukemia
544874|NCT00521430|recurrent/refractory childhood Hodgkin lymphoma
544875|NCT00521430|secondary myelodysplastic syndromes
544876|NCT00521430|de novo myelodysplastic syndromes
544877|NCT00521430|previously treated myelodysplastic syndromes
544878|NCT00521417|RCT
544879|NCT00521404|Pancreatic cancer
544880|NCT00521404|chemotherapy naive
544881|NCT00521404|unresectable or metastatic pancreatic cancer
544882|NCT00521404|CS1008
544883|NCT00521404|Gemcitabine
544884|NCT00521404|Gemzar
544885|NCT00521391|smoking cessation
544886|NCT00521391|nicotine
544887|NCT00521391|physical activity
544888|NCT00521378|Diabetes
544889|NCT00521378|Type 1 and Type 2 Diabetes
544890|NCT00521365|Bipolar Disorder
544891|NCT00521365|Bipolar Affective Psychosis
544892|NCT00521365|Mania
544893|NCT00521365|Manic Disorder
544894|NCT00521365|Manic State
544895|NCT00521352|TMS
544896|NCT00521352|Dorsolateral Prefrontal Cortex
544897|NCT00521339|Apremilast,
544898|NCT00521339|Psoriasis,
544899|NCT00521339|PASI-75,
544900|NCT00521339|sPGA
544901|NCT00521326|doppler
544902|NCT00521326|coronary stenosis
544903|NCT00521326|non-invasive testing
544904|NCT00521326|A prospective study of a new diagnostic method.
544905|NCT00521326|Study consists of a transthoracic doppler of LAD.
544906|NCT00521326|Doppler to be performed prior to coronary angiography.
544907|NCT00521326|F/U doppler examination for those who undergo PCI.
544908|NCT00521326|Doppler results will be compared with coronary angiography.
544909|NCT00521300|Acromegaly
544910|NCT00521287|Immunologic Surveillance
544911|NCT00521287|Vaccination
544912|NCT00521287|Immunotherapy
544913|NCT00521287|Dendritic Cells
544914|NCT00521274|Progressive Hormone Refractory Prostate Cancer
544915|NCT00521274|HRPC
544916|NCT00521274|MVA 5T4
544917|NCT00521274|Trovax®
544918|NCT00521274|Docetaxel
544919|NCT00521274|M3thodist
544920|NCT00521261|recurrent adult Burkitt lymphoma
544921|NCT00521261|recurrent adult diffuse large cell lymphoma
544922|NCT00521261|recurrent adult diffuse mixed cell lymphoma
544923|NCT00521261|recurrent adult diffuse small cleaved cell lymphoma
544924|NCT00521261|recurrent adult immunoblastic large cell lymphoma
544925|NCT00521261|recurrent adult lymphoblastic lymphoma
544926|NCT00521261|recurrent adult T-cell leukemia/lymphoma
544927|NCT00521261|recurrent cutaneous T-cell non-Hodgkin lymphoma
544928|NCT00521261|recurrent grade 1 follicular lymphoma
544929|NCT00521261|recurrent grade 2 follicular lymphoma
544930|NCT00521261|recurrent grade 3 follicular lymphoma
544931|NCT00521261|recurrent mantle cell lymphoma
544932|NCT00521261|recurrent marginal zone lymphoma
544933|NCT00521261|recurrent small lymphocytic lymphoma
544934|NCT00521261|Waldenstrom macroglobulinemia
544935|NCT00521261|adult nasal type extranodal NK/T-cell lymphoma
544936|NCT00521261|recurrent adult grade III lymphomatoid granulomatosis
544937|NCT00521261|cutaneous B-cell non-Hodgkin lymphoma
544938|NCT00521248|Neonatal Abstinence Syndrome
544939|NCT00521248|buprenorphine
544940|NCT00521248|neonatal
544941|NCT00521248|opioid withdrawal
544942|NCT00521235|risk factors
544943|NCT00521235|metabolic syndrome
544944|NCT00521235|dentists
544945|NCT00521235|trainers
544946|NCT00521235|Healthy subjects
544947|NCT00521235|students
544948|NCT00521235|seniors
544949|NCT00521222|asthma
544950|NCT00521222|beta agonist
544951|NCT00521222|bronchodilator
544952|NCT00521222|pulmonary
544953|NCT00521222|genotype
544954|NCT00521222|pharmacogenomics
544955|NCT00521222|corticosteroid
544956|NCT00521222|allergy
544957|NCT00521222|immunology
544958|NCT00521209|Impoverished Population
544959|NCT00521196|migraine
544960|NCT00521196|headache
544961|NCT00521196|chronic
544962|NCT00521196|pain
544963|NCT00521196|brain
544964|NCT00521196|neurology
544965|NCT00521196|stimulation
544966|NCT00521196|noninvasive
544967|NCT00521196|transcranial
544968|NCT00521196|direct
544969|NCT00521196|current
544970|NCT00521196|tDCS
544971|NCT00521196|tms
544972|NCT00521196|rTMS
544973|NCT00521196|BIDMC
544974|NCT00521183|adult tumors metastatic to brain
544975|NCT00521170|Levocetirizine
544976|NCT00521170|Wheal and flare
544977|NCT00521170|Allergic
544978|NCT00521157|Substance abuse
544979|NCT00521157|Opiate dependency
544980|NCT00521157|Treatment
544981|NCT00521157|Relapse prevention
544982|NCT00521131|Levocetirizine dihydrochloride
544983|NCT00521131|Xyzal tablets
544984|NCT00521118|nonmetastatic gestational trophoblastic tumor
544985|NCT00521118|hydatidiform mole
544986|NCT00521105|Type 1 Diabetes
544987|NCT00521105|Telemedicine
544988|NCT00521105|Children
544989|NCT00521092|Treatment Experienced
544990|NCT00521079|Obesity
544991|NCT00521079|Bariatric surgery
544992|NCT00521079|Excess weight loss
544993|NCT00521079|Vagus nerve
544994|NCT00521079|Vagal blocking
544995|NCT00521079|VBLOC(TM) therapy
544996|NCT00521053|immune
544997|NCT00521053|vaccine
544998|NCT00521053|systemic
544999|NCT00521053|Metastatic Melanoma (AJCC Stage III or IV)
545000|NCT00521040|Levocetirizine dihydrochloride
545001|NCT00521040|Xyzal tablets
545002|NCT00521027|Debridement
545003|NCT00521027|hydrosurgery
545004|NCT00521027|Versajet
545005|NCT00521027|leg ulcer
545006|NCT00521014|recurrent grade 1 follicular lymphoma
545007|NCT00521014|recurrent grade 2 follicular lymphoma
545008|NCT00521014|recurrent grade 3 follicular lymphoma
545009|NCT00521001|stage IV melanoma
545010|NCT00520988|hypertension
545011|NCT00520988|intervention
545012|NCT00520988|disease management
545013|NCT00520988|telephone-based
545014|NCT00520988|Hypertension: diagnosed but uncontrolled
545015|NCT00520975|Trastuzumab
545016|NCT00520975|Bevacizumab
545017|NCT00520975|Metastatic Breast Cancer
545018|NCT00520975|HER2/NEU
545019|NCT00520962|cardiovascular disease
545020|NCT00520962|glucose intolerance
545021|NCT00520962|type 2 diabetes
545022|NCT00520962|endothelial dysfunction
545023|NCT00520962|inflammation
545024|NCT00520962|Age> 30 years, male and female
545025|NCT00520962|Fasting glucose below 126 mg/dl
545026|NCT00520949|H.pylori
545027|NCT00520949|Triple therapy failure
545028|NCT00520949|Quadruple therapy
545029|NCT00520910|Polypodium leucotomos, Ultraviolet Rays, Heliocare, calaguala, anapsos
545030|NCT00520910|Skin Aging and Damage
545031|NCT00520897|chronic HIV infection
545032|NCT00520897|Human Immunodeficiency Virus
545033|NCT00520897|Treatment Experienced
545034|NCT00520884|frailty
545035|NCT00520884|ghrelin
545036|NCT00520884|appetite
545037|NCT00520884|weight loss
545038|NCT00520871|Cardiovascular disease
545039|NCT00520871|Blueberruy
545040|NCT00520871|Antioxidants
545041|NCT00520871|Oxidative stress
545042|NCT00520871|Inflammation
545043|NCT00520845|recurrent non-small cell lung cancer
545044|NCT00520845|stage IV non-small cell lung cancer
545045|NCT00520845|stage IIIB non-small cell lung cancer
545046|NCT00520845|stage IIIA non-small cell lung cancer
545047|NCT00520832|Primary Insomnia
545048|NCT00520832|Microcurrent Therapy
545049|NCT00520832|Sleep Surveys
545050|NCT00520819|Antioxidants
545051|NCT00520819|Phytochemicals
545052|NCT00520819|Oxidative stress
545053|NCT00520819|Inflammation
545054|NCT00520819|Endothelial function
545055|NCT00520806|Heart failure
545056|NCT00520806|Renal dysfunction
545057|NCT00520806|Relaxin
545058|NCT00520806|Vasodilator
545059|NCT00520780|Chronic Heart Failure
545060|NCT00520780|Iron deficiency
545061|NCT00520780|Iron deficiency anaemia
545062|NCT00520780|Anaemia
545063|NCT00520780|Heart disease
545064|NCT00520767|primary systemic amyloidosis
545065|NCT00520767|light chain deposition disease
545066|NCT00520754|levocetirizine dihydrochloride Xyzal tablets
545067|NCT00520741|Epilepsy
545068|NCT00520741|Partial Onset Seizures
545069|NCT00520741|Lacosamide
545070|NCT00520741|Monotherapy
545071|NCT00520741|Vimpat
545072|NCT00520728|Schizophrenia
545073|NCT00520728|Psychosis
545074|NCT00520728|Occupational Disengagement
545075|NCT00520728|Occupational Imbalance
545076|NCT00520715|fluoroquinolone resistance
545077|NCT00520715|commensal flora
545078|NCT00520715|carriage
545079|NCT00520702|Non-Small Cell Lung Cancer
545080|NCT00520702|Lung Cancer
545081|NCT00520702|3-Dimensional Conformal Radiation Therapy
545082|NCT00520702|Intensity Modulated Radiation Therapy
545083|NCT00520702|3D CRT
545084|NCT00520702|IMRT
545085|NCT00520702|NSCLC
545086|NCT00520702|TRP
545087|NCT00520702|Treatment related pneumonitis
545088|NCT00520663|Distribution,
545089|NCT00520663|SB-649868,
545090|NCT00520663|Healthy,
545091|NCT00520663|Excretion,
545092|NCT00520663|Sleep disturbances
545093|NCT00520663|Volunteer,
545094|NCT00520663|Metabolism,
545095|NCT00520663|Absorption,
545096|NCT00520624|EIL
545097|NCT00520611|Obesity
545098|NCT00520611|Weight Loss
545099|NCT00520611|Financial Incentives
545100|NCT00520611|Lottery
545101|NCT00520611|Deposit
545102|NCT00520585|atorvastatin
545103|NCT00520585|repolarisation
545104|NCT00520585|cardiomyocytes
545105|NCT00520572|Rheumatoid Arthritis
545106|NCT00520546|PET
545107|NCT00520546|MRI
545108|NCT00520546|Choline
545109|NCT00520546|FEC
545110|NCT00520546|prostate cancer
545111|NCT00520533|Clinical trials
545112|NCT00520533|cG250 mAb
545113|NCT00520533|monoclonal antibody G250
545114|NCT00520533|sunitinib
545115|NCT00520533|angiogenesis inhibitors
545116|NCT00520533|Positron-Emission Tomography
545117|NCT00520533|Pharmacokinetics
545118|NCT00520533|Pharmacodynamics
545119|NCT00519831|stage IIIB non-small cell lung cancer
545120|NCT00519831|stage IV non-small cell lung cancer
545121|NCT00519831|recurrent non-small cell lung cancer
545122|NCT00519818|Congenital Adrenal Hyperplasia
545123|NCT00519818|Hydrocortisone
545124|NCT00519818|Pharmacokinetic
545125|NCT00519818|Pharmacodynamic
545126|NCT00519805|thromboembolism
545127|NCT00519805|extensive stage small cell lung cancer
545128|NCT00519805|limited stage small cell lung cancer
545129|NCT00519805|stage IV non-small cell lung cancer
545130|NCT00519805|stage II non-small cell lung cancer
545131|NCT00519805|stage IIIA non-small cell lung cancer
545132|NCT00519805|stage IIIB non-small cell lung cancer
545133|NCT00519805|stage I non-small cell lung cancer
545134|NCT00519792|Relapse
545135|NCT00519792|HCV
545136|NCT00519792|Hepatitis C
545137|NCT00519792|Interferon
545138|NCT00519792|Ribavirin
545139|NCT00519779|affect
545140|NCT00519779|inflammation
545141|NCT00519766|Ratio of 3-Hydroxycotinine to Cotinine
545142|NCT00519766|Nicotine Metabolism
545143|NCT00519766|Pregnancy
545144|NCT00519753|Glaucoma
545145|NCT00519740|grass-pollen
545146|NCT00519740|allergy
545147|NCT00519740|bronchial hyperreactivity
545148|NCT00519740|asthma
545149|NCT00519727|diabetes
545150|NCT00519701|sickle cell anemia
545151|NCT00519701|hydroxyurea
545152|NCT00519688|tegafur
545153|NCT00519688|thalidomide
545154|NCT00519688|advanced hepatocellular carcinoma
545155|NCT00519675|Chronic hand eczema
545156|NCT00519675|Chronic hand dermatitis
545157|NCT00519675|Patients with chronic hand eczema, who are refractory to topical corticosteroids
545158|NCT00519662|Solid
545159|NCT00519662|Tumors
545160|NCT00519662|Advanced
545161|NCT00519649|Hepatitis B vaccine
545162|NCT00519649|Challenge dose
545163|NCT00520520|post resuscitation
545164|NCT00520520|post ventricular fibrillation
545165|NCT00520520|patients receiving mild therapeutic hypothermia
545166|NCT00520507|Depression
545167|NCT00520507|Bipolar Disorder
545168|NCT00520507|Major
545169|NCT00520494|Previously Untreated Patient (PUP)
545170|NCT00520494|Primary Immunodeficiency (PID)
545171|NCT00520494|CVID
545172|NCT00520494|XLA
545173|NCT00520494|Subcutaneous immunoglobulin (SCIG)
545174|NCT00520494|IgG trough level
545175|NCT00520494|Quality of life
545176|NCT00520494|Common variable immunodeficiency (CVID)
545177|NCT00520494|X-linked agammaglobulinemia (XLA)
545178|NCT00520468|Myelodysplastic Syndrome
545179|NCT00520468|MDS
545180|NCT00520468|Erythropoietin
545181|NCT00520468|Darbepoetin alfa
545182|NCT00520468|Aranesp
545183|NCT00520468|Erythropoiesis stimulating protein
545184|NCT00520468|G-CSF
545185|NCT00520468|Filgrastim
545186|NCT00520468|Neupogen
545187|NCT00520468|Prednisone
545188|NCT00520468|Cyclosporin A
545189|NCT00520468|Sandimmune
545190|NCT00520468|CYA
545191|NCT00520468|Cyclosporine
545192|NCT00520442|fracture
545193|NCT00520429|Depression
545194|NCT00520429|Anxiety
545195|NCT00520429|Pulmonary Disease, Chronic Obstructive
545196|NCT00520429|Heart Failure, Congestive
545197|NCT00520377|Sinus Lift Surgery
545198|NCT00520377|Sinus Floor Augmentation
545199|NCT00520377|Insufficient Bone Height
545200|NCT00520338|celecoxib
545201|NCT00520338|postoperative pain
545202|NCT00520338|thyroidectomy
545203|NCT00520325|MBL deficient oncologic hematologic pediatric fever neutropenia
545204|NCT00520312|Peripheral Arterial Disease
545205|NCT00520312|PAD
545206|NCT00520312|Functional Impairment
545207|NCT00520312|Magnetic Resonance Imaging
545208|NCT00520299|metastatic melanoma
545209|NCT00520299|ADI
545210|NCT00520299|ADI PEG 20
545211|NCT00520299|ADI SS PEG 20,000mw
545212|NCT00520299|arginine
545213|NCT00520299|enzyme therapy
545214|NCT00520286|Methamphetamine Dependence
545215|NCT00520247|enalapril
545216|NCT00520247|folic acid
545217|NCT00520247|hyperglycemia
545218|NCT00520247|hypertension
545219|NCT00520247|fasting plasma glucose
545220|NCT00520234|Candida
545221|NCT00520234|Prophylaxis
545222|NCT00520234|High risk adults
545223|NCT00520234|Intensive care unit (ICU)
545224|NCT00520221|minocycline
545225|NCT00520221|pleurodesis
545226|NCT00520221|aspiration
545227|NCT00520221|pneumothorax
545351|NCT00519363|Lupus
545228|NCT00520221|Primary spontaneous pneumothorax
545229|NCT00520221|First attack
545230|NCT00520221|Successful aspiration
545231|NCT00520208|ATRA
545232|NCT00520208|Trisenox
545233|NCT00520208|Arsenic
545234|NCT00520208|Arsenic Trioxide
545235|NCT00520208|APL
545236|NCT00520169|bioavailability
545237|NCT00520143|GSD-II, Pompe Disease, Glycogen Storage Disease II
545238|NCT00520130|Unrelated Donors
545239|NCT00520130|Reduced Intensity Stem Cell Transplant
545240|NCT00520130|Leukemia
545241|NCT00520130|Lymphoma
545242|NCT00520130|Allogeneic Stem Cell Transplant
545243|NCT00520130|Myelodysplastic Syndrome
545244|NCT00520130|Multiple Myeloma
545245|NCT00520091|adenocarcinoma of the esophagus
545246|NCT00520091|squamous cell carcinoma of the esophagus
545247|NCT00520091|stage II esophageal cancer
545248|NCT00520091|stage III esophageal cancer
545249|NCT00520091|stage IV esophageal cancer
545250|NCT00520052|bisphosphonates, prostate cancer, bone density, osteoporosis
545251|NCT00520039|Otitis Media
545252|NCT00520039|Effusion
545253|NCT00520039|OMM
545254|NCT00520039|OMT
545255|NCT00520039|Resolution
545256|NCT00520026|suicide
545257|NCT00520026|prevention
545258|NCT00520026|lithium
545259|NCT00520026|suicidality
545260|NCT00520000|unspecified adult solid tumor, protocol specific
545261|NCT00519987|pharmacokinetics
545262|NCT00519974|psychosocial effects of cancer and its treatment
545263|NCT00519974|stage I breast cancer
545264|NCT00519974|stage II breast cancer
545265|NCT00519974|stage IIIA breast cancer
545266|NCT00519974|stage IIIB breast cancer
545267|NCT00519974|stage IIIC breast cancer
545268|NCT00519974|stage IV breast cancer
545269|NCT00519974|recurrent breast cancer
545270|NCT00519935|Insulin Dependent Diabetes Mellitus
545271|NCT00519935|family therapy
545272|NCT00519935|adolescents
545273|NCT00519909|dairy products, calcium, fat excretion, energy excretion
545274|NCT00519883|Anastrozole
545275|NCT00519883|Exercise
545276|NCT00519870|Pulmonary hypertension
545277|NCT00519870|Angiotensin receptor blocker
545278|NCT00519870|Calcium channel blocker
545279|NCT00519636|experience
545280|NCT00519636|GW685698X
545281|NCT00519636|fluticasone furoate
545282|NCT00519636|preference
545283|NCT00519636|seasonal allergic rhinitis
545284|NCT00519636|fluticasone propionate
545285|NCT00519623|diabetes
545286|NCT00519623|insulin
545287|NCT00519623|blood sugar
545288|NCT00519623|type 1 diabetes
545289|NCT00519623|insulin dependent diabetes
545290|NCT00519623|transdermal
545291|NCT00519610|portal hypertension, H-graft shunt
545292|NCT00519597|Coronary Artery Disease
545293|NCT00519597|Sleep Apnea
545294|NCT00519597|CPAP
545295|NCT00519597|Revascularization
545296|NCT00519597|Mortality
545297|NCT00519584|Interscalene nerve block
545298|NCT00519584|Dexamethasone
545299|NCT00519584|Ropivacaine
545300|NCT00519571|Dental Implantation, Endosseous
545301|NCT00519545|breast
545302|NCT00519545|cancer
545303|NCT00519545|stage
545304|NCT00519545|one
545305|NCT00519545|four
545306|NCT00519532|Neupro®
545307|NCT00519532|Rotigotine
545308|NCT00519532|Parkinson's Disease
545309|NCT00519519|Rebleeding after endoscopic therapy
545310|NCT00519506|Pulmonary Embolism
545311|NCT00519506|PE
545312|NCT00519493|Clozex
545313|NCT00519493|Sutures
545314|NCT00519480|Tolerability
545315|NCT00519480|GSK189075,
545316|NCT00519480|Metformin,
545317|NCT00519480|Safety,
545318|NCT00519480|Diabetes,
545319|NCT00519467|dose-ranging study
545320|NCT00519467|SB-714703
545321|NCT00519467|artesunate,
545322|NCT00519467|malaria
545323|NCT00519467|CDA,
545324|NCT00519467|chlorproguanil,
545325|NCT00519467|dapsone,
545326|NCT00519454|Systemic Lupus Erythematosus
545327|NCT00519454|Estrogen receptors
545328|NCT00519454|T cells
545329|NCT00519454|Hormones
545330|NCT00519454|Female adult SLE
545331|NCT00519441|laparoscopic Heller myotomy, achalasia, reflux
545332|NCT00519428|depression
545333|NCT00519428|MDD
545334|NCT00519428|Major Depressive Disorder
545335|NCT00519415|Tongue plate
545336|NCT00519415|Facemask
545337|NCT00519415|class III maxillary deficiency
545338|NCT00519415|orthodontic angle class three
545339|NCT00519402|partial tonsillectomy
545340|NCT00519402|complete tonsillectomy
545341|NCT00519402|tonsillectomy
545342|NCT00519402|obstruction sleep disordered breathing OSDB
545343|NCT00519402|apnea
545344|NCT00519376|pharmacodynamics,
545345|NCT00519376|Chronic Obstructive Pulmonary Disease (COPD)
545346|NCT00519376|safety,
545347|NCT00519376|COPD patients
545348|NCT00519376|pharmacokinetics,
545349|NCT00519376|tolerability,
545350|NCT00519376|GW642444,
545352|NCT00519363|TLR's
545353|NCT00519363|Hyperlipidemia
545354|NCT00519363|age eighteen to sixty
545355|NCT00519363|female with SLE
545356|NCT00519363|SLEDAI, greater than four
545357|NCT00519363|LDL cholesterol elevated
545358|NCT00519350|SIRS, sepsis and related syndromes
545359|NCT00519337|Atrial Fibrillation
545360|NCT00519337|cardiac surgery
545361|NCT00519337|ascorbic acid
545362|NCT00519337|vitamin-c
545363|NCT00519337|inflammation
545364|NCT00519324|Gastric Cancer
545365|NCT00519324|RAD001
545366|NCT00519324|mTOR
545367|NCT00519311|Intellectual disability
545368|NCT00519311|Health promotion
545369|NCT00519311|RCT
545370|NCT00519298|Alzheimer Disease
545371|NCT00519285|metastatic
545372|NCT00519285|prostate
545373|NCT00519285|cancer
545374|NCT00519272|Cervical Cancer
545375|NCT00519272|Cervix
545376|NCT00519272|Precancerous Lesions
545377|NCT00519272|Cervical carcinoma in situ
545378|NCT00519272|CIS
545379|NCT00519272|Early cervical cancer detection and treatment
545380|NCT00519272|Barriers to Care
545381|NCT00519272|Harris County
545382|NCT00519272|Questionnaire
545383|NCT00519246|Breast Neoplasms
545384|NCT00519246|Non-Steroidal Anti-Inflammatory Agents
545385|NCT00519246|Analgesia
545386|NCT00519233|HRPC
545387|NCT00519233|Advanced hormone refractory prostate cancer
545388|NCT00519220|achalasia, Heller myotomy
545389|NCT00519207|pediatrics
545390|NCT00519207|pain
545391|NCT00519207|infants
545392|NCT00519207|newborn screening
545393|NCT00519207|venipuncture
545394|NCT00519207|lidocaine
545395|NCT00519207|sucrose
545396|NCT00519194|Arrhythmia
545397|NCT00519194|Atrial Fibrillation
545398|NCT00519181|HTLV
545399|NCT00519181|HAM/TSP
545400|NCT00519181|VALPROIC ACID
545401|NCT00519181|PROVIRAL LOAD
545402|NCT00519129|Pain
545403|NCT00519129|Patient satisfaction
545404|NCT00519103|microarray
545405|NCT00519103|Inflammtion
545406|NCT00519103|fibrosis
545407|NCT00519090|leukemia
545408|NCT00519090|bone marrow
545409|NCT00519090|leukemia symptoms
545410|NCT00519090|cml
545411|NCT00519090|complete blood count
545412|NCT00519090|lymphocyte
545413|NCT00519090|blood cancer
545414|NCT00519090|leukocytes
545415|NCT00519090|chronic leukemia
545416|NCT00519090|bone marrow biopsy
545417|NCT00519090|leukemia research
545418|NCT00519090|leukemia cells
545419|NCT00519090|bone marrow disease
545420|NCT00519090|chronic myeloid leukemia
545421|NCT00519090|blood cancer symptoms
545422|NCT00519090|white blood cell diseases
545423|NCT00519090|chronic myelogenous leukemia
545424|NCT00519090|leukemia treatment
545425|NCT00519090|leukemia facts
545426|NCT00519090|leucemia
545427|NCT00519090|facts about leukemia
545428|NCT00519090|myelogenous leukemia
545429|NCT00519090|newly diagnosed CML
545430|NCT00519090|suboptimal response
545431|NCT00519090|Philadelphia chromosome positive (Ph+)
545432|NCT00519090|chronic myelogenous leukemia in chronic phase (CML-CP)
545433|NCT00519077|cancer
545434|NCT00519077|squamous cell
545435|NCT00519077|carcinoma
545436|NCT00519077|head
545437|NCT00519077|neck
545438|NCT00519064|influenza
545439|NCT00519064|influenza vaccine
545440|NCT00519064|adjuvanted influenza vaccine
545441|NCT00519064|H5N1 influenza antigen
545442|NCT00519051|depression
545443|NCT00519051|primary care
545444|NCT00519051|pharmacotherapy
545445|NCT00519038|Critical Pathways
545446|NCT00519038|Congestive Heart Failure
545447|NCT00519038|Randomized Controlled Trial
545448|NCT00519038|Effectiveness
545449|NCT00519025|Linezolid
545450|NCT00519025|Staphylococcus Aureus
545451|NCT00519025|Infections
545452|NCT00519012|early nonresponse
545453|NCT00518999|cognition, attention, memory, executive functions, illness-awareness, insight.
545454|NCT00518986|Obstructive Sleep Apnea/Hypopnea Syndrome
545455|NCT00518986|Excessive Sleepiness
545456|NCT00518960|ProAlgaZyme
545457|NCT00518960|Algae
545458|NCT00518960|High density lipoprotein; HDL
545459|NCT00518960|C-Reactive Protein; CRP
545460|NCT00518960|Hyperlipidemia
545461|NCT00518960|Metabolic Syndrome
545462|NCT00518947|Bipolar Disorder
545463|NCT00518947|Mania
545464|NCT00518947|Antimanic
545465|NCT00518947|Verapamil
545466|NCT00518947|Lithium
545467|NCT00518934|Safety and efficiency of angiogenesis for patients with limb
545468|NCT00518934|ischemia by transplantation of human cord blood mononuclear
545469|NCT00518934|cells
545470|NCT00518921|adenosin agonist
545471|NCT00518921|chronic stable angina
545472|NCT00518908|Ischemia reperfusion injury
545473|NCT00518908|Organ protection
545474|NCT00518895|Melanoma
545475|NCT00518895|Advanced Melanoma
545476|NCT00518895|Malignant Melanoma
545477|NCT00518895|Metastatic Melanoma
545478|NCT00518895|Skin Cancer
545479|NCT00518895|Genasense
545480|NCT00518895|oblimersen
545481|NCT00518895|antisense
545482|NCT00518895|Bcl-2 antisense
545483|NCT00518895|G3139
545484|NCT00518895|dacarbazine
545485|NCT00518869|Non-Small Cell Lung Cancer (NSCLC)
545486|NCT00518869|Complementary and Alternative Medicine (CAM)
545487|NCT00518869|Chemotherapy
545488|NCT00518869|Myelosuppression
545489|NCT00518869|Quality of Life
545490|NCT00518869|Fatigue
545491|NCT00518869|EORTC QLQ-C30 and LC13
545492|NCT00518856|birth asphyxia
545493|NCT00518856|neonatal sepsis
545494|NCT00518856|maternal to child transmission of HIV
545495|NCT00518843|binge eating
545496|NCT00518843|purging
545497|NCT00518830|postnatal depression
545498|NCT00518830|primary care
545499|NCT00518830|depressed women
545500|NCT00518817|Dystrophy
545501|NCT00518817|Cardiomyopathy
545502|NCT00518791|Integrated health care system
545503|NCT00518791|Treatment effectiveness
545504|NCT00518791|Cost effectiveness
545505|NCT00518791|Program evaluation
545506|NCT00518778|fusariosis
545507|NCT00518778|solid organ transplants
545508|NCT00518765|aliskiren, renal hemodynamics, hormonal response, renin pathway, RAAS biomarkers
545509|NCT00518752|Ventilator Acquired Pneumonia
545510|NCT00518752|Oral Hygiene
545511|NCT00518752|Oral Care
545512|NCT00518752|Xerostomia
545513|NCT00518726|Adjuvanted Influenza Vaccine
545514|NCT00518713|Epilepsy
545515|NCT00518713|Lennox-Gastaut Syndrome
545516|NCT00518713|Drop seizures
545517|NCT00518713|Clobazam
545518|NCT00518674|pain
545519|NCT00518674|local infiltration analgesia
545520|NCT00518661|quinolone resistance
545521|NCT00518661|ESBL
545522|NCT00518661|Klebsiella species
545523|NCT00518661|Infection
545524|NCT00518648|Accidental falls
545525|NCT00518648|Prevention
545526|NCT00518648|Treatment effectiveness
545527|NCT00518635|Growth hormone
545528|NCT00518635|Insulin sensitivity
545529|NCT00518635|Polycystic ovary
545530|NCT00518609|Neonatal
545531|NCT00518609|Sepsis
545532|NCT00518609|Global Network
545533|NCT00518609|Antibiotics
545534|NCT00518609|India
545535|NCT00518609|International
545536|NCT00518609|Maternal and child health
545537|NCT00518596|Neonatal
545538|NCT00518596|Sepsis
545539|NCT00518596|Global Network
545540|NCT00518596|Probiotics
545541|NCT00518596|India
545542|NCT00518596|International
545543|NCT00518596|Maternal and child health
545544|NCT00518583|Breast cancer
545545|NCT00518583|Over-expressing Her2-neu
545546|NCT00518570|PMDD
545547|NCT00518570|PMS
545548|NCT00518570|Levetiracetam
545549|NCT00518557|liver cancer
545550|NCT00518557|interventional radiology
545551|NCT00518557|Chemoembolization
545552|NCT00518557|Safety
545553|NCT00518557|Effectiveness
545554|NCT00518544|hydroxyethyl starch, blood type, coagulation
545555|NCT00518531|osteoporosis
545556|NCT00518531|low bone mineral density
545557|NCT00518531|alendronate
545558|NCT00518531|denosumab
545559|NCT00518531|adherence
545560|NCT00518531|preference
545561|NCT00518531|satisfaction
545562|NCT00518531|postmenopausal
545563|NCT00518531|women
545564|NCT00518518|Asthma
545565|NCT00518518|Sublingual immunotherapy
545566|NCT00518518|Children
545567|NCT00518505|GERD, laparoscopic surgery
545568|NCT00518479|Hypertension
545569|NCT00518479|Left Ventricular Hypertrophy
545570|NCT00518466|Obesity
545571|NCT00518453|Influenza vaccine
545572|NCT00518440|Liver disease
545573|NCT00518440|Liver injury
545574|NCT00518414|infant, formula, LC PUFA
545575|NCT00518401|A hypoperfusion of the blood through a leg
545576|NCT00518401|Stem cells
545577|NCT00518401|Stem cell transplantation
545578|NCT00518401|Stem cell autologous transplantation
545579|NCT00518388|Epidemiology
545580|NCT00518388|Cervical Cancer
545581|NCT00518388|Human Papillomavirus
545582|NCT00518388|Focus Group
545583|NCT00518388|Questionnaire
545584|NCT00518388|Survey
545585|NCT00518388|HPV
545586|NCT00518362|TW
545587|NCT00518362|Valsartan
545588|NCT00518362|treatment
545589|NCT00518362|diabetic nephropathy
545590|NCT00518362|Proteinuria
545591|NCT00518323|Schizophrenia
545592|NCT00518323|Antipsychotic
545593|NCT00518310|Interstitial lung disease
545594|NCT00518310|Idiopathic pulmonary fibrosis
545595|NCT00518310|Usual interstitial pneumonia
545596|NCT00518310|Cryptogenic fibrosing alveolitis
545597|NCT00518310|Therapy
545598|NCT00518310|Azathioprine
545599|NCT00518310|Steroids
545600|NCT00518310|Glucocorticoids
545601|NCT00518310|Corticosteroids
545602|NCT00518310|Prednisone
545603|NCT00518297|Antivirals / HIV
545604|NCT00518284|Restenosis
545605|NCT00518284|Superficial Femoral Artery
545606|NCT00518284|Prevention of restenosis
545607|NCT00518284|Revascularization of the superficial Femoral Artery
545608|NCT00518258|Parkinson's Disease
545609|NCT00518258|Magnetic Resonance Imaging (MRI)
545610|NCT00518258|neuropsychological assessment
545611|NCT00518245|unstable angina
545612|NCT00518245|drug therapy
545613|NCT00518245|myocardial ischemia
545614|NCT00518245|myocardial infarction
545615|NCT00518245|hemorrhage
545616|NCT00518232|Methylphenidate
545617|NCT00518232|Attention Deficit Hyperactivity Disorder
545618|NCT00518219|TW
545619|NCT00518219|Valsartan
545620|NCT00518219|treatment
545621|NCT00518219|membranous nephropathy
545622|NCT00518219|proteinuria
545623|NCT00518206|Clinical Trial
545624|NCT00518206|Phase II
545625|NCT00518206|Cancer Vaccine
545626|NCT00518206|NY-ESO-1 protein, human
545627|NCT00518206|ISCOMATRIX, immunological adjuvant
545628|NCT00518206|Cyclophosphamide
545629|NCT00518206|T-Cells, Regulatory
545630|NCT00518180|Meningococcal
545631|NCT00518180|meningitis
545632|NCT00518180|vaccine
545633|NCT00518180|adolescents
545634|NCT00518167|Type 2 diabetes
545635|NCT00518167|primary prevention
545636|NCT00518167|diet
545637|NCT00518167|physical activity
545638|NCT00518167|intervention
545639|NCT00518167|impaired glucose tolerance
545640|NCT00518167|lifestyle
545641|NCT00518167|randomized controlled study
545642|NCT00518154|AIDS
545643|NCT00518154|Immunological non-responders
545644|NCT00518154|Neuroimmune modulation
545645|NCT00518154|Pyridostigmine
545646|NCT00518154|Treatment Experienced
545647|NCT00518128|Obstructive Sleep Apnea
545648|NCT00518128|Leptin
545649|NCT00518128|Homocysteine
545650|NCT00518128|C-reactive protein
545651|NCT00518115|GLP-1,
545652|NCT00518115|Type 2 Diabetes,
545653|NCT00518115|pharmacokinetics,
545654|NCT00518115|pharmacodynamics,
545655|NCT00518115|GSK716155,
545656|NCT00518115|metformin,
545657|NCT00518115|exenatide
545658|NCT00518115|Type 2 Diabetes Mellitus
545659|NCT00518102|REGRANEX (becaplermin)
545660|NCT00518102|Platelet-derived growth factor BB
545661|NCT00518102|Cancer
545662|NCT00518102|Cancer incidence
545663|NCT00518102|Cancer mortality
545664|NCT00518076|Staphylococcus aureus carriers students nursing
545665|NCT00518050|Health Behaviors
545666|NCT00518050|Surveillance
545667|NCT00518050|06-128
545668|NCT00518024|tinnitus
545669|NCT00518024|transcranial magnetic stimulation
545670|NCT00518024|treatment
545671|NCT00518024|cortex
545672|NCT00517998|Lung volume reduction
545673|NCT00517998|Bronchoscopy
545674|NCT00517998|Emphysema
545675|NCT00517998|COPD
545676|NCT00517998|NETT
545677|NCT00517998|Lung disease
545678|NCT00517998|COLD
545679|NCT00517998|BLVR
545680|NCT00517985|perimenopausal depression
545681|NCT00517985|duloxetine
545682|NCT00517985|cymbalta
545683|NCT00517985|major depressive disorder
545684|NCT00517985|women
545685|NCT00517972|perimenopausal depression
545686|NCT00517972|omacor
545687|NCT00517972|major depressive disorder
545688|NCT00517972|women
545689|NCT00517959|Stereotactic radiotherapy
545690|NCT00517959|conformal radiotherapy
545691|NCT00517959|late sequelae
545692|NCT00517959|cognition
545693|NCT00517959|endocrine dysfunction
545694|NCT00517946|anti-allergy.
545695|NCT00517946|seasonal allergic rhinitis (SAR),
545696|NCT00517946|intranasal allergen challenge,
545697|NCT00517946|MRI,
545698|NCT00517933|Idiopathic Pulmonary Fibrosis
545699|NCT00517933|Pulmonary Hypertension
545700|NCT00517894|lymphoma
545701|NCT00517894|aggressive
545702|NCT00517894|chemotherapy
545703|NCT00517894|dose-dense
545704|NCT00517868|bladder
545705|NCT00517868|pain
545706|NCT00517868|urgency
545707|NCT00517868|frequency
545708|NCT00517842|Parkinson's disease
545709|NCT00517829|metastatic gastric or adenocarcinoma of the GE junction
545710|NCT00517803|micronutrients
545711|NCT00517803|immunodeficiency
545712|NCT00517803|probiotics
545713|NCT00517803|yogurt
545714|NCT00517803|Healthy
545715|NCT00517803|Acquired Immunodeficiency Syndrome
545716|NCT00517803|Complementary Therapies
545717|NCT00517790|Refractory
545718|NCT00517790|Metastatic
545719|NCT00517777|sleep apnea syndrome
545720|NCT00517777|metabolic syndrome
545721|NCT00517777|cardiac remodelling
545722|NCT00517777|continuous positive airway pressure ventilation
545723|NCT00517764|major depressive disorder
545724|NCT00517764|MDD
545725|NCT00517764|escitalopram
545726|NCT00517764|open-label
545727|NCT00517764|major depression
545728|NCT00517764|serotonin transporter
545729|NCT00517764|brain-derived neurotrophic factor
545730|NCT00517751|Lumbar Spinal Stenosis
545731|NCT00517751|X-STOP Spacer
545732|NCT00517751|Interspinous process decompression
545733|NCT00517751|Neurogenic Intermittent Claudication
545734|NCT00517725|exercise
545735|NCT00517725|lung diffusion
545736|NCT00517725|hypoxia
545737|NCT00517725|chemoreceptor
545738|NCT00517725|beta-blockers
545739|NCT00517725|heart failure
545740|NCT00517712|Acute promyelocytic leukemia
545741|NCT00517712|Arsenic trioxide
545742|NCT00517712|Molecular remission
545743|NCT00517712|Toxicity profile
545744|NCT00517712|Maintenance therapy
545745|NCT00517686|Poor risk factor control
545746|NCT00517686|Treatment intensification
545747|NCT00517686|Medication adherence
545748|NCT00517686|Cardiovascular disease (CVD)
545749|NCT00517673|Healthy Volunteer
545750|NCT00517660|Healthy subjects
545751|NCT00517660|Lower Respiratory Tract Infections
545752|NCT00517660|Upper Respiratory Tract Infections
545753|NCT00517647|ADHD
545754|NCT00517647|atomoxetine
545755|NCT00517647|preschool children
545756|NCT00517647|efficacy
545757|NCT00517647|safety
545758|NCT00517634|asthma
545759|NCT00517634|allergen challenge
545760|NCT00517634|IL-5
545761|NCT00517634|eosinophils
545762|NCT00517621|Peritoneal cancer
545763|NCT00517621|Relapse or progression
545764|NCT00516607|recurrent adult brain tumor
545765|NCT00516607|adult mixed glioma
545766|NCT00516607|adult anaplastic astrocytoma
545767|NCT00516607|adult anaplastic oligodendroglioma
545768|NCT00516607|adult glioblastoma
545769|NCT00516607|adult anaplastic ependymoma
545770|NCT00516607|adult giant cell glioblastoma
545771|NCT00516607|adult gliosarcoma
545772|NCT00516607|adult pineal gland astrocytoma
545773|NCT00516581|Pneumocystis Pneumonia
545774|NCT00516581|Acquired Immune Deficiency Syndrome
545775|NCT00516581|Highly Active Antiretroviral Therapy
545776|NCT00516581|Treatment Experienced
545777|NCT00516581|Treatment Naive
545778|NCT00516555|Breech Presentation
545779|NCT00516555|External Cephalic version
545780|NCT00516555|Thyroid Function Tests
545781|NCT00516542|stage IV breast cancer
545782|NCT00516542|recurrent breast cancer
545783|NCT00516542|male breast cancer
545784|NCT00516516|muscle cramp
545785|NCT00516516|pregnancy
545786|NCT00516516|carnitine
545787|NCT00516516|randomized controlled clinical trials
545788|NCT00516490|GnRH agonist
545789|NCT00516490|IVF/ICSI outcome
545790|NCT00516490|luteal phase
545791|NCT00516477|Adeno-Associated Virus (AAV)
545792|NCT00516477|Leber Congenital Amaurosis
545793|NCT00516477|Gene transfer
545794|NCT00516464|Proliferative Diabetic Retinopathy
545795|NCT00516464|Vitrectomy
545796|NCT00516464|Ranibizumab
545797|NCT00516438|malignant solid tumours
545798|NCT00516438|Poly(ADP ribose)
545799|NCT00516438|polymerases
545800|NCT00516425|stage IA breast cancer
545801|NCT00516425|stage IB breast cancer
545802|NCT00516425|stage II breast cancer
545803|NCT00516425|stage IIIA breast cancer
545804|NCT00516412|contiguous stage II mantle cell lymphoma
545805|NCT00516412|noncontiguous stage II mantle cell lymphoma
545806|NCT00516412|recurrent mantle cell lymphoma
545807|NCT00516412|stage I mantle cell lymphoma
545808|NCT00516412|stage III mantle cell lymphoma
545809|NCT00516412|stage IV mantle cell lymphoma
545810|NCT00516399|Fungal keratitis
545811|NCT00516399|povidone iodine
545812|NCT00516399|childhood blindness
545813|NCT00516399|povidone-iodine
545814|NCT00516386|Adolescents
545815|NCT00516386|Anorexia nervosa (AN)
545816|NCT00516386|Bone formation markers
545817|NCT00516386|Insulin like growth factor-1 (IGF-I)
545818|NCT00516373|advanced ovarian cancer
545819|NCT00516373|BRCA 1 protein
545820|NCT00516373|BRCA 2 protein
545821|NCT00516373|Poly(ADP ribose)polymerases
545822|NCT00517595|Non-Small Cell Lung Cancer
545823|NCT00517582|ACE Inhibitor
545824|NCT00517582|Angioedema
545825|NCT00517582|Bradykinin
545826|NCT00517582|Swelling
545827|NCT00517569|Gene Therapy
545828|NCT00517569|GX-12
545829|NCT00517569|HIV-1
545830|NCT00517569|Interleukin
545831|NCT00517569|AIDS
545832|NCT00517569|HIV-1 type B infection
545833|NCT00517569|Treatment Naive
545834|NCT00517556|Dysmenorrhea
545835|NCT00517556|continuous OCP
545836|NCT00517543|inflammation
545837|NCT00517517|Pandemic influenza
545838|NCT00517504|methylphenidate
545839|NCT00517504|ritalin
545840|NCT00517504|attention deficit hyperactivity disorder
545841|NCT00517504|developmental disorder
545842|NCT00517504|preschool children
545843|NCT00517426|heart failure,
545844|NCT00517426|exercise
545845|NCT00517426|periodic breathing,
545846|NCT00517426|acetazolamide
545847|NCT00517400|PTSD
545848|NCT00517387|Depression
545849|NCT00517387|SSRI
545850|NCT00517387|Atypical Antipsychotic
545851|NCT00517387|Cognition
545852|NCT00517387|Mood
545853|NCT00517387|Quality of Life
545854|NCT00517348|Adult
545855|NCT00517335|anorexia nervosa
545856|NCT00517335|bulimia nervosa
545857|NCT00517322|left atrial volume
545858|NCT00517322|hypertension
545859|NCT00517322|ramipril
545860|NCT00517322|irbesartan
545861|NCT00517322|diastolic function
545862|NCT00517283|diabetes
545863|NCT00517283|gastric emptying
545864|NCT00517283|exenatide
545865|NCT00517283|Byetta
545866|NCT00517283|Amylin
545867|NCT00517283|Lilly
545868|NCT00517270|Non-cardiac chest pain
545869|NCT00517257|Retinal vein occlusion
545870|NCT00517257|Retinal vein thrombosis
545871|NCT00517257|Central retinal vein occlusion
545872|NCT00517257|Branch retinal vein occlusion
545873|NCT00517257|Visual loss
545874|NCT00517257|Atorvastatin
545875|NCT00517257|Statin
545876|NCT00517257|Neovascularization
545877|NCT00517257|Thrombosis
545878|NCT00517244|Children
545879|NCT00517244|Healthy Controls
545880|NCT00517244|Assessment
545881|NCT00517231|Pulmonary tuberculosis
545882|NCT00517231|Mycobacterium tuberculosis
545883|NCT00517231|Cytokines
545884|NCT00517231|Acute Phase Response
545885|NCT00517231|Treatment
545886|NCT00517218|Evaluate the Effect of Genasense on the Efficacy/Safety of Rituximab/Fludarabine Treatment in Untreated Subjects With Chronic Lymphocyctic Leukemia
545887|NCT00517205|upper ureteric stone
545888|NCT00517179|Benign Prostatic Hyperplasia (BPH)
545889|NCT00517179|Erectile Dysfunction (ED)
545890|NCT00517166|tourniquet
545891|NCT00517166|extremity injury
545892|NCT00517166|hemostatic device
545893|NCT00517153|Zavesca
545894|NCT00517153|miglustat
545895|NCT00517153|Niemann-Pick Type C
545896|NCT00517153|Actelion
545897|NCT00517140|Pregnancy women with a scarred uterus due to previous caesarean section
545898|NCT00517127|Intraoperative care
545899|NCT00517127|Ringer's lactate
545900|NCT00517127|Voluven
545901|NCT00517127|Cardiovascular diagnostic technique
545902|NCT00517127|Doppler effect
545903|NCT00517114|Reflux laryngitis
545904|NCT00517101|spondyloarthropathy
545905|NCT00517101|inflammatory bowel disease
545906|NCT00517101|antibodies
545907|NCT00517088|Physical Activity
545908|NCT00517088|Breast Cancer
545909|NCT00517075|Transcranial Magnetic Stimulation
545910|NCT00517075|Repetitive Transcranial Magnetic Stimulation
545911|NCT00517075|Schizophrenia
545912|NCT00517075|Schizoaffective Disorder
545913|NCT00517075|Treatment
545914|NCT00517075|Negative Symptoms
545915|NCT00517075|Social Dysfunction
545916|NCT00517075|TMS
545917|NCT00517075|rTMS
545918|NCT00517062|Growth hormone
545919|NCT00517062|insulin sensitivity
545920|NCT00517062|cortisol
545921|NCT00517049|NHL
545922|NCT00517049|Rituxan
545923|NCT00517049|Lymphoma
545924|NCT00517049|CD20-positive
545925|NCT00517049|B-Cell
545926|NCT00517049|APM4083g
545927|NCT00517036|Major Depression
545928|NCT00517036|Omega-3
545929|NCT00517036|Major Depressive Disorder
545930|NCT00517023|Implantable Loop Recorder
545931|NCT00517023|Home monitoring
545932|NCT00517023|Syncope/ Falls Clinic
545933|NCT00517010|Age-related macular degeneration
545934|NCT00517010|Exudative age-related macular degeneration
545935|NCT00517010|Wet macular degeneration
545936|NCT00517010|Intravitreal injection
545937|NCT00517010|Proton beam irradiation
545938|NCT00517010|Lucentis
545939|NCT00517010|Ranibizumab
545940|NCT00516997|triglycerides
545941|NCT00516997|insulin
545942|NCT00516997|very low birthweight infants
545943|NCT00516997|necrotizing enterocolitis
545944|NCT00516997|retinopathy of prematurity
545945|NCT00516997|Hypertriglyceridemia (200 mg/dl or greater)
545946|NCT00516997|Hyperglycemia (200 mg/dl or greater)
545947|NCT00516984|Relationship between Osteopathic Manipulative Therapy (OMT) and the autonomic nervous system
545948|NCT00516984|LF/HF ratio
545949|NCT00516971|Non-erosive reflux disease
545950|NCT00516958|diabetic
545951|NCT00516958|ulcer
545952|NCT00516958|infection
545953|NCT00516958|topical
545954|NCT00516958|wound
545955|NCT00516945|hepatitis B during cancer chemotherapy
545956|NCT00516932|Suicidal Event
545957|NCT00516932|Behavioral Activation
545958|NCT00516919|Obesity
545959|NCT00516919|Binge Eating
545960|NCT00516919|Monolingual Hispanic Persons
545961|NCT00516919|Orlistat
545962|NCT00516919|Behavioral Weight Loss Treatment
545963|NCT00516893|natalizumab
545964|NCT00516893|Tysabri
545965|NCT00516893|Multiple Sclerosis
545966|NCT00516893|Relapsing Forms of Multiple Sclerosis
545967|NCT00516880|chronic kidney disease
545968|NCT00516880|cardiovascular disease
545969|NCT00516854|Non-cardiac chest pain
545970|NCT00516841|epithelial ovarian cancer
545971|NCT00516841|peritoneal cancer
545972|NCT00516841|platinum-resistant ovarian cancer
545973|NCT00516841|Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
545974|NCT00516828|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
545975|NCT00516828|adult acute myeloid leukemia with inv(16)(p13;q22)
545976|NCT00516828|adult acute myeloid leukemia with t(15;17)(q22;q12)
545977|NCT00516828|adult acute myeloid leukemia with t(16;16)(p13;q22)
545978|NCT00516828|adult acute myeloid leukemia with t(8;21)(q22;q22)
545979|NCT00516828|untreated adult acute myeloid leukemia
545980|NCT00516828|secondary acute myeloid leukemia
545981|NCT00516828|de novo myelodysplastic syndromes
545982|NCT00516828|secondary myelodysplastic syndromes
545983|NCT00516802|Poly(ADP ribose) polymerases
545984|NCT00516802|dacarbazine
545985|NCT00516750|recurrent bladder cancer
545986|NCT00516750|stage II bladder cancer
545987|NCT00516750|stage III bladder cancer
545988|NCT00516750|stage IV bladder cancer
545989|NCT00516724|malignant solid tumours
545990|NCT00516724|Poly(ADP ribose) polymerases
545991|NCT00516711|Surgery with Pringle maneuver needed for liver resection
545992|NCT00516698|stage I breast cancer
545993|NCT00516698|stage II breast cancer
545994|NCT00516698|stage IIIA breast cancer
545995|NCT00516698|stage IIIC breast cancer
545996|NCT00516685|LUNG CANCER
545997|NCT00516685|NSCLC
545998|NCT00516685|EGF
545999|NCT00516685|CANCER VACCINE
546000|NCT00516685|IMMUNOTHERAPY
546001|NCT00516672|lapatinib,
546002|NCT00516672|cancer
546003|NCT00516672|pharmacokinetics,
546004|NCT00516672|safety,
546005|NCT00516672|pazopanib,
546006|NCT00516672|Japanese patients,
546007|NCT00516659|ETEC
546008|NCT00516659|Traveler's diarrhea
546009|NCT00516659|TCI
546010|NCT00516659|patch vaccine
546011|NCT00516659|diarrhea prevention
546012|NCT00516659|epidemiology ETEC
546013|NCT00516659|Escherichia coli
546014|NCT00516646|Advanced Glycation End-products (AGEs)
546015|NCT00516646|Alegebrium
546016|NCT00516633|Asthma
546017|NCT00516633|Adherence
546018|NCT00516633|Burden of asthma
546019|NCT00516633|Quality of life
546020|NCT00516633|Questionnaires
546021|NCT00516620|Body Weight
546022|NCT00516360|Catheter related bloodstream infections
546023|NCT00516360|Infant, Newborn
546024|NCT00516360|Intensive Care Units, Neonatal
546025|NCT00516360|Neonatal Central Line Infections
546026|NCT00516347|adenocarcinoma of the esophagus
546027|NCT00516347|esophageal cancer
546028|NCT00516347|Barrett esophagus
546029|NCT00516334|brain
546030|NCT00516334|electroencephalography
546031|NCT00516334|premature infant
546032|NCT00516334|neurodevelopment
546033|NCT00516321|thrombopoietin
546034|NCT00516321|hepatitis C
546035|NCT00516321|ribavirin
546036|NCT00516321|platelets
546037|NCT00516321|Hepatitis C-related thrombocytopenia
546038|NCT00516321|peginterferon alfa-2a
546039|NCT00516308|CLI
546040|NCT00516308|Critical Limb Ischemia
546041|NCT00516308|PAD
546042|NCT00516308|Paripheral Arterial Disease
546043|NCT00516308|Artherosclerosis
546044|NCT00516308|Leg pain
546045|NCT00516308|Cardiovascular
546046|NCT00516308|Atherectomy
546047|NCT00516308|NightHawk
546048|NCT00516282|adult glioblastoma
546049|NCT00516282|adult giant cell glioblastoma
546050|NCT00516282|adult gliosarcoma
546051|NCT00516282|adult anaplastic astrocytoma
546052|NCT00516282|adult anaplastic oligodendroglioma
546053|NCT00516282|adult mixed glioma
546054|NCT00516269|Breast Cancer
546055|NCT00516269|Gastrointestinal Cancer
546056|NCT00516269|GI Cancer
546057|NCT00516269|Fatigue
546058|NCT00516269|OROS Methylphenidate HCl
546059|NCT00516269|Methylphenidate
546060|NCT00516269|Methylphenidate Hydrochloride
546061|NCT00516269|Concerta
546062|NCT00516269|Ritalin
546063|NCT00516269|Placebo
546064|NCT00516256|Prostate Cancer
546065|NCT00516256|Quality of Life
546066|NCT00516256|Cancer Information Mentor
546067|NCT00516256|CHESS
546068|NCT00516256|the Comprehensive Health Enhancement Support System
546069|NCT00516256|Social support
546070|NCT00516256|Skill-building tools
546071|NCT00516230|Colonic Neoplasms
546072|NCT00516230|Lynch syndrome
546073|NCT00516217|recurrent adult Hodgkin lymphoma
546074|NCT00516217|adult lymphocyte predominant Hodgkin lymphoma
546075|NCT00516204|Hyperlipidemia
546076|NCT00516204|Diabetics
546077|NCT00516204|NIS
546078|NCT00516204|Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)
546079|NCT00516191|Multiple Myeloma
546080|NCT00516191|Velcade
546081|NCT00516191|Doxil
546082|NCT00516191|Melphalan
546083|NCT00516178|Fish oil supplement
546084|NCT00516178|n-3 PUFA
546085|NCT00516178|Cardiac function
546086|NCT00516178|Membrane incorporation
546087|NCT00516178|Inflammation
546088|NCT00516178|Clinical outcome
546089|NCT00516165|liver cancer
546090|NCT00516165|RAD001
546091|NCT00516152|Matched Unrelated Donor
546092|NCT00516152|Stem Cell Transplantation
546093|NCT00516152|Busulfan
546094|NCT00516152|fludarabine
546095|NCT00516152|Hematopoietic Disorder
546096|NCT00516139|Epilepsy elderly seizure
546097|NCT00516126|hemostasis monitoring
546098|NCT00516126|perioperative blood loss
546099|NCT00516113|paroxetine
546100|NCT00516113|onset of action
546101|NCT00516113|serotonin reuptake inhibitors
546102|NCT00516100|NSCLC
546103|NCT00516087|Nasopharyngeal Carcinoma
546104|NCT00516074|exenatide
546105|NCT00516074|Byetta
546106|NCT00516074|type 2 diabetes
546107|NCT00516074|heart rate
546108|NCT00516074|Amylin
546109|NCT00516074|Lilly
546110|NCT00516048|exenatide
546111|NCT00516048|Byetta
546112|NCT00516048|antibodies
546113|NCT00516048|Amylin
546114|NCT00516048|Lilly
546115|NCT00516035|Bird Flu
546116|NCT00516009|RADICULAR PAIN
546117|NCT00516009|DISC HERNIATION
546118|NCT00516009|DEXAMETHASONE
546119|NCT00516009|VAS
546120|NCT00515996|panic disorder
546121|NCT00515996|paroxetine
546122|NCT00515996|genetic polymorphism
546123|NCT00515996|serotonin
546124|NCT00515983|melanoma
546125|NCT00515983|dendritic cells
546126|NCT00515983|apoptotic/necrotic cells
546127|NCT00515983|therapeutic vaccine
546128|NCT00515970|Carcinoma, Basal Cell
546129|NCT00515970|Curettage
546130|NCT00515970|Excision
546131|NCT00515970|Recurrence
546132|NCT00515970|Complication
546133|NCT00515970|Esthetic outcome
546134|NCT00515944|No condition
546135|NCT00515944|healthy volunteers
546136|NCT00515931|Gastrointestinal stromal tumor
546137|NCT00515931|GIST
546138|NCT00515931|Sarcoma
546139|NCT00515931|Radiation therapy
546140|NCT00515931|Radiotherapy
546141|NCT00515918|Iron deficiency
546142|NCT00515918|brain
546143|NCT00515918|cognition
546144|NCT00515918|behavior
546145|NCT00515879|Generalized subtype
546146|NCT00515866|Advanced pancreatic cancer
546147|NCT00515866|Poly (ADP ribose) polymerases
546148|NCT00515866|Advanced Solid Tumours
546149|NCT00515853|Rectal neoplasms
546150|NCT00515853|Biofeedback (Psychology)
546151|NCT00515853|Fecal Incontinence
546152|NCT00515853|Aged
546153|NCT00515853|Anterior resection
546154|NCT00515827|Treatment Experienced
546155|NCT00515814|Legal blindness
546156|NCT00515814|Retinopathy pigmentosa
546157|NCT00515814|Hereditary condition
546158|NCT00515814|Photo-receptor degeneration
546159|NCT00515814|Retina implant
546160|NCT00515814|Subretinal implant
546161|NCT00515801|diabetes mellitus type 1
546162|NCT00515801|hypoglycemia
546163|NCT00515801|sulfonylurea
546164|NCT00515801|glucagon
546165|NCT00515788|Neoplastic Meningitis
546166|NCT00515788|Leptomeningeal Disease
546167|NCT00515788|Temozolomide
546168|NCT00515788|Temodar
546169|NCT00515788|DepoCyt
546170|NCT00515788|Liposomal Cytarabine
546171|NCT00515788|Liposomal ara-C
546172|NCT00515762|persistent alopecia
546173|NCT00515762|docetaxel
546174|NCT00515762|breast cancer
546175|NCT00515736|selenium
546176|NCT00515736|oxidative stress
546177|NCT00515736|glutathione peroxidase
546178|NCT00515736|critically ill
546179|NCT00515736|outcome
546180|NCT00515736|supplementation
546181|NCT00515723|control
546182|NCT00515723|risperidone
546183|NCT00515723|olanzapine
546184|NCT00515723|quetiapine
546185|NCT00515723|ziprasidone
546186|NCT00515710|Hemophilia B
546187|NCT00515710|Gene Transfer
546188|NCT00515710|Adeno-Associated Virus (AAV)
546189|NCT00515710|Coagulation Factor IX
546190|NCT00515710|Long-term Follow-up
546191|NCT00515710|Delayed Adverse Events
546192|NCT00515671|self-management
546193|NCT00515671|recovery
546194|NCT00515671|severe mental illness
546195|NCT00515658|Major depression
546196|NCT00515658|Theta-burst rTMS
546197|NCT00515658|Cortical excitability
546198|NCT00515658|Hamilton depression rating scale
546199|NCT00515645|Autonomic nervous system
546200|NCT00515645|Immersion
546201|NCT00515645|Heart rate variability
546202|NCT00515645|Head-down tilt
546203|NCT00515645|Healthy volunteers
546204|NCT00515632|Type 2 diabetes mellitus on Stable insulin therapy
546205|NCT00515632|Balaglitazone
546206|NCT00515632|Pioglitazone (Actos®)
546207|NCT00515632|HbA1c
546208|NCT00515632|Weight gain
546209|NCT00515632|Oedema
546210|NCT00515632|Fasting blood glucose
546211|NCT00515593|osteoporosis
546212|NCT00515593|postmenopausal women
546213|NCT00515593|Severe postmenopausal osteoporosis
546214|NCT00515580|obstructive sleep apnea
546215|NCT00515580|upper airway resistance syndrome
546216|NCT00515580|tongue suture
546217|NCT00515580|retrolingual tongue collapse
546218|NCT00515580|minimally invasive
546219|NCT00515567|explanted lungs
546220|NCT00515567|pulmonary fibrosis
546221|NCT00515554|Hodgkin lymphoma
546222|NCT00515554|PET
546223|NCT00515554|advances stages
546224|NCT00515554|Rituximab
546225|NCT00515541|Platelet
546226|NCT00515541|Cardiovascular
546227|NCT00515541|Lipid
546228|NCT00515541|Fish Oil
546229|NCT00515541|Omega 3
546230|NCT00515541|DHA
546231|NCT00515541|EPA
546232|NCT00515541|Bleeding
546233|NCT00515541|Clotting
546234|NCT00515541|platelet function
546235|NCT00515541|Lipid profile
546236|NCT00515541|Weight and Bleeding risk
546237|NCT00515528|metastatic melanoma
546238|NCT00515502|chronic obstructive pulmonary disease,
546239|NCT00515502|GSK573719,
546240|NCT00515502|muscarinic receptor antagonist
546241|NCT00515489|Schizophrenia
546242|NCT00515489|Schizoaffective Disorder
546243|NCT00515489|Schizophreniform Disorders
546244|NCT00515476|metabolic syndrome
546245|NCT00515476|HDL-Cholesterol
546246|NCT00515476|EPC
546247|NCT00515476|endothelial function
546248|NCT00515476|reduced blood HDL-Cholesterol level
546249|NCT00515463|Osteopenia
546250|NCT00515463|Osteoporosis
546251|NCT00515463|AMG 162
546252|NCT00515463|Postmenopausal
546253|NCT00515463|Pre-filled syringe
546254|NCT00515450|Myasthenia Gravis
546255|NCT00515437|Sialorrhea
546256|NCT00515424|Glaucoma
546257|NCT00515424|Ocular Hypertension
546258|NCT00515424|RKI983
546259|NCT00515424|Primary Open Angle Glaucoma and Ocular Hypertension
546260|NCT00515411|gastroesophageal junction
546261|NCT00515411|gastric cancer
546262|NCT00515411|adenocarcinoma
546263|NCT00515411|unresectable gastric cancer
546264|NCT00515411|metastatic gastric
546265|NCT00515385|Randomized
546266|NCT00515385|Double-Blind
546267|NCT00515385|Dose-Escalation
546268|NCT00515385|Cohort Study
546269|NCT00515372|Ovarian Cancer
546270|NCT00515372|Peritoneal Cancer
546271|NCT00515372|Fallopian Tube Cancer
546272|NCT00515372|Depression
546273|NCT00515372|Telephone Counseling
546274|NCT00515372|Quality of Life
546275|NCT00515359|Sedation
546276|NCT00515359|MRI
546277|NCT00515359|pediatric
546278|NCT00515359|propofol
546279|NCT00515359|brain
546280|NCT00515359|spine
546281|NCT00515359|quality of MRI
546282|NCT00515359|Continuous propofol dosing
546283|NCT00515359|continuous propofol administration
546284|NCT00515359|Intermittent propofol dosing
546285|NCT00515359|intermittent propofol administration
546286|NCT00515359|Sedative agent
546287|NCT00515359|propofol continuous infusions
546288|NCT00515359|Recovery time
546289|NCT00515359|Complications of sedation
546290|NCT00515359|bolus dosing
546291|NCT00515346|CLI
546292|NCT00515346|Critical Limb Ischemia
546293|NCT00515333|Alzheimer
546294|NCT00515333|Dementia
546295|NCT00515320|Autism
546296|NCT00515320|children
546297|NCT00515320|adolescent
546298|NCT00515320|Fluoxetine
546299|NCT00515320|Autistic Disorder
546300|NCT00515320|Repetitive behavior
546301|NCT00515320|SSRI
546302|NCT00515320|Selective Serotonin Reuptake Inhibitor
546303|NCT00515307|Hypercholesterolemia, Familial
546304|NCT00515307|Bone marrow
546305|NCT00515307|Mesenchymal stem cell
546306|NCT00515307|Hepatocyte
546307|NCT00515294|Caffeine
546308|NCT00515294|Alcohol
546309|NCT00515294|Alcohol Consumption
546310|NCT00515294|Residual Effects
546311|NCT00515294|Family History
546312|NCT00515294|Psychomotor Vigilance Test
546313|NCT00515294|Driving Simulation
546314|NCT00515294|Reaction Time
546315|NCT00515281|prematurity
546316|NCT00515281|nitric oxide
546317|NCT00515281|bronchopulmonary dysplasia
546318|NCT00515281|intraventricular hemorrhage
546319|NCT00515281|periventricular leukomalacia
546320|NCT00515281|neurodevelopment
546321|NCT00515268|LPS challenge,
546322|NCT00515268|Healthy volunteers
546323|NCT00515255|Obsessive Compulsive Disorder
546324|NCT00515255|Neuropharm
546325|NCT00515255|NPL-2003
546326|NCT00515242|massage therapy
546327|NCT00515242|relaxation treatments
546328|NCT00515229|cystic fibrosis
546329|NCT00515229|ceramide
546330|NCT00515229|amitriptyline
546331|NCT00515229|Pseudomonas aeruginosa
546332|NCT00515229|lung function
546333|NCT00515216|Phase II
546334|NCT00515216|Gastric cancer
546335|NCT00515216|Gastroesophageal cancer
546336|NCT00515216|Metastatic
546337|NCT00515216|FOLFOX
546338|NCT00515216|Thymidylate synthase
546339|NCT00515216|Pharmacogenomic
546340|NCT00515203|Immune (Idiopathic) Thrombocytopenic Purpura
546341|NCT00515203|Pediatric Idiopathic Thrombocytopenic Purpura
546342|NCT00515190|Stomach Neoplasms
546343|NCT00515190|Secondary
546344|NCT00515190|Combination chemotherapy
546345|NCT00515190|S-1
546346|NCT00515190|oxaliplatin
546347|NCT00515177|mindfulness
546348|NCT00515177|meditation
546349|NCT00515177|MBSR
546350|NCT00515177|mindfulness meditation
546351|NCT00515177|sleep
546352|NCT00515177|insomnia
546353|NCT00515177|chronic insomnia
546354|NCT00515177|primary insomnia
546355|NCT00515177|Minnesota
546356|NCT00515164|lung volume reduction
546357|NCT00515164|emphysema
546358|NCT00515164|chronic obstructive pulmonary disease
546359|NCT00515151|Bloodstream Infection
546360|NCT00515151|Bacteremia
546361|NCT00515151|Central Venous Catheter
546362|NCT00515151|Alcohol
546363|NCT00515151|Disinfection
546364|NCT00515151|Octenidine Dihydrochloride
546365|NCT00515138|B-Cell NHL
546366|NCT00515138|Autologous Stem Cell Transplant
546367|NCT00515138|RICE
546368|NCT00515125|Quality of life
546369|NCT00515125|Supplement
546370|NCT00515125|Care home
546371|NCT00515125|Elderly
546372|NCT00515125|Malnutrition
546373|NCT00515112|prostate
546374|NCT00515112|cancer
546375|NCT00515112|testosterone replacement
546376|NCT00515112|AndroGel
546377|NCT00515112|prostatic cancer
546378|NCT00515112|prostatic neoplasms
546379|NCT00515099|New-onset Type 1 Diabetes Mellitus
546380|NCT00515099|New-onset T1DM
546381|NCT00515099|New-onset Type 1 Diabetes
546382|NCT00515099|New-onset T1D
546383|NCT00515099|Newly Diagnosed Type 1 Diabetes Mellitus
546384|NCT00515099|Autoimmune diabetes
546385|NCT00515099|Thymoglobulin
546386|NCT00515099|ATG
546387|NCT00515099|Rabbit antithymocyte globulin
546388|NCT00515086|Glioblastoma Multiforme, GBM, RAD001, RAD
546389|NCT00515073|Endometrial Cancer
546390|NCT00515073|Papillary Serous Carcinoma
546391|NCT00515073|Pelvic Radiation Therapy
546392|NCT00515073|Paclitaxel
546393|NCT00515073|Taxol
546394|NCT00515060|Advanced Cancer
546395|NCT00515060|Therapy-Induced Pain
546396|NCT00515060|Pain Threshold
546397|NCT00515060|Sensory Tests
546398|NCT00515060|Stimuli
546399|NCT00515060|Pain
546400|NCT00515047|Atopic Dermatitis
546401|NCT00515047|Eczema
546402|NCT00515047|Eczema Herpeticum
546403|NCT00515047|Molluscum Contagiousum
546404|NCT00515047|Herpes Simplex
546405|NCT00515047|Vaccinia
546406|NCT00515034|Doripenem
546407|NCT00515034|Imipenem
546408|NCT00515034|Cilastatin
546409|NCT00515034|Vancomycin
546410|NCT00515034|DORIBAX, DORIPREX, FINIBAX, DURAPTA, PRIMAXIN, Anti Bacterial Agents
546411|NCT00515034|Ileus
546412|NCT00515034|Hospitalized
546413|NCT00515034|Fever
546414|NCT00515021|Metabolic syndrome
546415|NCT00515021|Aldosterone inhibitor
546416|NCT00515021|Diurnal drug regimen
546417|NCT00515021|PAI-1 levels
546418|NCT00514982|Hermansky-Pudlak Syndrome
546419|NCT00514982|Colitis
546420|NCT00514982|Medical Therapy
546421|NCT00514982|Immunopathogenesis
546422|NCT00514982|Cytokine
546423|NCT00514982|Hermansky-Pudlak Syndrome Associated Colitis
546424|NCT00514982|HPS
546425|NCT00514969|accelerated and blastic phase
546426|NCT00514969|STI571
546427|NCT00514956|Post-Traumatic Stress Syndrome (PTSD)
546428|NCT00514930|radiofrequency ablation
546429|NCT00514930|liver cancer
546430|NCT00514930|complications
546431|NCT00514930|liver tumors
546432|NCT00514904|safety
546433|NCT00514904|meningococcal vaccine
546434|NCT00514904|immunogenicity
546435|NCT00514878|nausea
546436|NCT00514878|postoperative nausea and vomiting
546437|NCT00514878|postoperative pain
546438|NCT00514865|ONO-2333Ms
546439|NCT00514865|Major Depressive Disorder
546440|NCT00514839|Prescription drug use disorder
546441|NCT00514839|Brief intervention
546442|NCT00514839|General hospital
546443|NCT00514839|Motivational Interviewing
546444|NCT00514800|Home monitoring
546445|NCT00514800|Primary care
546446|NCT00514800|Hypertension
546447|NCT00514800|TIA
546448|NCT00514787|Asthma
546449|NCT00514787|NIS
546450|NCT00514774|Huntington chorea
546451|NCT00514774|chorea
546452|NCT00514774|hereditary
546453|NCT00514774|tauroursodeoxycholic acid
546454|NCT00514774|ursodeoxycholic acid
546455|NCT00514774|TUDCA
546456|NCT00514774|UDCA
546457|NCT00514761|colorectal cancer
546458|NCT00514761|AZD6244
546459|NCT00514748|breast reconstruction
546460|NCT00514748|DIEP
546461|NCT00514748|vessel pedicle
546462|NCT00514735|atrial fibrillation
546463|NCT00514722|Hematopoietic malignancies
546464|NCT00514722|Umbilical cord blood transplantation
546465|NCT00514722|Lymphoma: diffuse large cell, mantle cell, peripheral T-cell, T-NK cell, or Hodgkin's
546466|NCT00514709|Diphtheria
546467|NCT00514709|Tetanus
546468|NCT00514709|Pertussis
546469|NCT00514709|Hepatitis B Hansenula (HB)
546470|NCT00514709|Haemophilus influenzae type b
546471|NCT00514696|Cancer
546472|NCT00514696|Leukemia
546473|NCT00514696|GCS-100
546474|NCT00514696|CLL
546475|NCT00514670|Prevention of gastrointestinal and respiratory illness
546476|NCT00514644|Panorama
546477|NCT00514644|Carotid stenoses
546478|NCT00514618|Term Pregnancy
546479|NCT00514618|Diabetes
546480|NCT00514618|Cervical Ripening
546481|NCT00514618|Induction
546482|NCT00514618|misoprostol
546483|NCT00514618|Term Gestational Diabetics
546484|NCT00514605|HIV 1
546485|NCT00514605|AIDS
546486|NCT00514605|Assay
546487|NCT00514605|Rapid Test
546488|NCT00514605|HIV-1
546489|NCT00514605|HIV Seronegativity
546490|NCT00514592|Carotid stenosis
546491|NCT00514592|Carotid endarterectomy
546492|NCT00514579|Cord Blood Stem Cell Transplantation
546493|NCT00514579|Hematologic Malignancies
546494|NCT00514579|Leukemia
546495|NCT00514579|Myelodysplastic Syndrome
546496|NCT00514566|Polyamide
546497|NCT00514566|Polydioxanone
546498|NCT00514566|Midline
546499|NCT00514566|Abdominal
546500|NCT00514566|Closure
546501|NCT00514553|Prenatal Testing
546502|NCT00514553|Test Decision-Making
546503|NCT00514553|Decision-Making Intervention
546504|NCT00514553|Theory of Unconscious Thought
546505|NCT00514553|Informed Choice
546506|NCT00514553|Decision Making
546507|NCT00514553|Counseling
546508|NCT00514540|Prostate Cancer
546509|NCT00514540|Anaplastic Prostate Cancer
546510|NCT00514540|Carboplatin
546511|NCT00514540|Docetaxel
546512|NCT00514540|Taxotere
546513|NCT00514540|Paraplatin
546514|NCT00514514|Everolimus
546515|NCT00514514|mycophenolate
546516|NCT00514514|CNI-free
546517|NCT00514514|kidney transplantation
546518|NCT00514488|chronic myeloid leukemia
546519|NCT00514488|STI 571
546520|NCT00514488|CML022
546521|NCT00514475|Mantle cell lymphoma
546522|NCT00514475|Zevalin
546523|NCT00514475|90Y-ibritumomab tiuxetan
546524|NCT00514475|Radioimmunotherapy
546525|NCT00514475|High-dose therapy
546526|NCT00514475|First line
546527|NCT00514436|Asthma
546528|NCT00514436|children
546529|NCT00514436|low-income, underserved
546530|NCT00514436|Reduction in hospitalization
546531|NCT00514410|Depression
546532|NCT00514410|Folate
546533|NCT00514410|Folic acid
546534|NCT00514410|Antidepressants
546535|NCT00514397|untreated childhood brain stem glioma
546536|NCT00514371|Multiple Myeloma
546537|NCT00514371|Heat Shock Protein 90
546538|NCT00514371|Hsp90
546539|NCT00514371|KOS-953
546540|NCT00514371|17-AAG
546541|NCT00514371|bortezomib
546542|NCT00514371|relapsed-refractory
546543|NCT00514371|tanespimycin
546544|NCT00514358|Fungal
546545|NCT00514358|Infection
546546|NCT00514358|sepsis
546547|NCT00514358|pharmacokinetics
546548|NCT00514345|chemotherapeutic agent toxicity
546549|NCT00514345|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
546550|NCT00514345|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
546551|NCT00514345|nonmetastatic childhood soft tissue sarcoma
546552|NCT00514345|unspecified childhood solid tumor, protocol specific
546553|NCT00514345|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
546554|NCT00514345|metastatic childhood soft tissue sarcoma
546555|NCT00514345|recurrent childhood soft tissue sarcoma
546556|NCT00514345|previously treated childhood rhabdomyosarcoma
546557|NCT00514345|recurrent childhood rhabdomyosarcoma
546558|NCT00514332|colorectal stents
546559|NCT00514332|colonic obstruction
546560|NCT00514332|colonic adenocarcinoma
546561|NCT00514332|colorectal surgery
546562|NCT00514306|Advanced Cancer
546563|NCT00514306|Breast cancer
546564|NCT00514306|Renal cancer
546565|NCT00514306|Ovarian Cancer
546566|NCT00514306|Metastatic Cancer
546567|NCT00514306|Non-small cell lung cancer
546568|NCT00514306|Colorectal cancer
546569|NCT00514293|recurrent non-small cell lung cancer
546570|NCT00514293|stage IIIB non-small cell lung cancer
546571|NCT00514293|stage IV non-small cell lung cancer
546572|NCT00514280|Lead and Smoke Study in D.C.
546573|NCT00514280|Birth Weight
546574|NCT00514280|Gestational Age
546575|NCT00514280|Lead
546576|NCT00514280|Tobacco Smoke
546577|NCT00514267|Prostate Cancer
546578|NCT00514267|HRPC
546579|NCT00514267|Hormone Refractory Prostate Cancer
546580|NCT00514267|YM155
546581|NCT00514267|Treatment Outcome
546582|NCT00514267|Solid Tumors
546583|NCT00514254|endometrial cancer
546584|NCT00514254|risk factors
546585|NCT00514254|questionnaire
546586|NCT00514254|07-093
546587|NCT00514228|adult primary hepatocellular carcinoma
546588|NCT00514228|localized unresectable adult primary liver cancer
546589|NCT00514228|advanced adult primary liver cancer
546590|NCT00514228|recurrent adult primary liver cancer
546591|NCT00514215|lung metastases
546592|NCT00514215|stage I non-small cell lung cancer
546593|NCT00514215|stage II non-small cell lung cancer
546594|NCT00514215|stage IIIA non-small cell lung cancer
546595|NCT00514215|stage IIIB non-small cell lung cancer
546596|NCT00514215|stage IV non-small cell lung cancer
546597|NCT00514215|recurrent non-small cell lung cancer
546598|NCT00514215|recurrent renal cell cancer
546599|NCT00514215|stage IV renal cell cancer
546600|NCT00514215|unspecified adult solid tumor, protocol specific
546601|NCT00514202|cocaine
546602|NCT00514202|ADHD
546603|NCT00514202|attention
546604|NCT00514202|hyperactivity
546605|NCT00514202|drug
546606|NCT00514202|dependence
546607|NCT00514189|Acute Myelogenous Leukemia
546608|NCT00514189|Leukemia
546609|NCT00514189|Autologous Dendritic Cells
546610|NCT00514189|Vaccine
546611|NCT00514189|AML
546612|NCT00514189|mRNA
546613|NCT00514163|pancreatic carcinoma
546614|NCT00514163|gemcitabine
546615|NCT00514163|S-1
546616|NCT00514163|phaseⅡstudy
546617|NCT00514150|angiography
546618|NCT00514150|complications
546619|NCT00514150|contrast media
546620|NCT00514150|kidney
546621|NCT00514150|prevention
546622|NCT00514098|Microbicide
546623|NCT00514098|Seroconversion
546624|NCT00514098|Treatment Experienced
546625|NCT00514098|Treatment Naive
546626|NCT00514085|recurrent melanoma
546627|NCT00514085|stage IV melanoma
546628|NCT00514072|stage IV prostate cancer
546629|NCT00514072|recurrent prostate cancer
546630|NCT00514059|Diphteria-tetanus-pertussis-polio vaccine
546631|NCT00514059|Booster immunization
546632|NCT00514059|Vaccine effect (Diphtheria-tetanus-acellular pertussis-polio)
546633|NCT00514059|Immunity
546634|NCT00514059|Safety
546635|NCT00514046|Multiple Endocrine Neoplasia (MEN)
546636|NCT00514046|Medullary Thyroid Carcinoma
546637|NCT00514046|Molecularly-Targeted Therapy
546638|NCT00514046|Pediatric
546639|NCT00514046|Pharmacokinetics
546640|NCT00514046|MTC
546641|NCT00514046|Multiple Endocrine Neoplasia
546642|NCT00514046|MEN
546643|NCT00514020|adenocarcinoma of the stomach
546644|NCT00514020|stage IV gastric cancer
546645|NCT00514020|recurrent gastric cancer
546646|NCT00514007|Non-small cell lung cancer
546647|NCT00514007|Ovarian cancer
546648|NCT00514007|Renal cancer
546649|NCT00514007|Advanced Cancer
546650|NCT00514007|Metastatic cancer
546651|NCT00514007|Breast cancer
546652|NCT00514007|Colorectal cancer
546653|NCT00513994|Pharmacokinetics
546654|NCT00513994|Nitroglycerin
546655|NCT00513994|pharmacokinetics study of nitroglycerin containing treatments
546656|NCT00513981|unspecified childhood solid tumor, protocol specific
546657|NCT00513981|recurrent osteosarcoma
546658|NCT00513981|recurrent childhood soft tissue sarcoma
546659|NCT00513981|recurrent childhood ependymoma
546660|NCT00513981|untreated childhood brain stem glioma
546661|NCT00513981|recurrent childhood brain stem glioma
546662|NCT00513955|recurrent mantle cell lymphoma
546663|NCT00513942|Fetal Movement
546664|NCT00513942|Maternal-Fetal-Attachment
546665|NCT00513942|Fetus
546666|NCT00513929|Severe Pneumonia
546667|NCT00513929|Zinc
546668|NCT00513929|Associated pathogens
546669|NCT00513929|Severe Pneumonia by type of associated pathogens
546670|NCT00513929|Severe Pneumonia by basal plasma zinc status
546671|NCT00513916|breast cancer
546672|NCT00513916|healthy, no evidence of disease
546673|NCT00513903|Pulmonary Diseases
546674|NCT00513903|Continuity of Pharmacy Care
546675|NCT00513890|Bronchiolitis
546676|NCT00513890|Esophageal pressure mesurement
546677|NCT00513890|Clinical score
546678|NCT00513890|Citical care
546679|NCT00513890|Infant
546680|NCT00513877|recurrent malignant mesothelioma
546681|NCT00513877|stage IA malignant mesothelioma
546682|NCT00513877|stage IB malignant mesothelioma
546683|NCT00513877|stage II malignant mesothelioma
546684|NCT00513877|stage III malignant mesothelioma
546685|NCT00513877|stage IV malignant mesothelioma
546686|NCT00513864|Opioid Analgesics
546687|NCT00513864|Morphine
546688|NCT00513864|Codeine
546689|NCT00513864|Sickle Cell Disease
546690|NCT00513851|Advanced Cancer
546691|NCT00513851|Non-small cell lung cancer
546692|NCT00513851|Small cell lung cancer
546693|NCT00513851|Uterine cancer
546694|NCT00513851|Ovarian cancer
546695|NCT00513851|Renal cancer
546696|NCT00513851|Head and neck cancer
546697|NCT00513851|Cervical cancer
546698|NCT00513851|Metastatic cancer
546699|NCT00513851|Colorectal cancer
546700|NCT00513851|Gastrointestinal stromal tumors
546701|NCT00513825|Contrast Nephropathy
546702|NCT00513825|Sodium Bicarbonate
546703|NCT00513825|Prevention
546704|NCT00513786|Endometrial Cancer
546705|NCT00513786|Advanced Stage Endometrial Cancer
546706|NCT00513786|Stage 3 or 4 endometrial cancer
546707|NCT00513786|Cancer treatment
546708|NCT00513786|gyn cancer
546709|NCT00513773|Abdominal Aortic Aneurysm,
546710|NCT00513773|Inflammation and Risk Prediction
546711|NCT00513773|Diagnostic Tool Efficacy
546712|NCT00513760|Pharmacogenetics
546713|NCT00513760|Singulair
546714|NCT00513760|montelukast
546715|NCT00513760|Leukotriene Antagonists
546716|NCT00513760|Anti-Asthmatic Agents
546717|NCT00513760|Intestinal Absorption
546718|NCT00513760|pharmacokinetics
546719|NCT00513760|absorption
546720|NCT00513760|biochemical transport
546721|NCT00513760|Membrane Transport Proteins
546722|NCT00513760|Drug Interactions
546723|NCT00513747|B-cell chronic lymphocytic leukemia
546724|NCT00513747|stage 0 chronic lymphocytic leukemia
546725|NCT00513747|stage I chronic lymphocytic leukemia
546726|NCT00513734|keratopathy
546727|NCT00513734|exposure
546728|NCT00513734|intensive care
546729|NCT00513734|eye
546730|NCT00513734|ulcer
546731|NCT00513734|Corneal
546732|NCT00513721|prostate
546733|NCT00513721|prostate cancer
546734|NCT00513721|surgical margins
546735|NCT00513721|gleason score
546736|NCT00513721|positive lateral biopsies
546737|NCT00513708|Detoxification
546738|NCT00513708|Treatment
546739|NCT00513682|Cystic Fibrosis
546740|NCT00513682|Pancreatic insufficiency
546741|NCT00513682|Steatorrhea
546742|NCT00513682|Children 7 to 11 years
546743|NCT00513682|pancreatic enzyme
546744|NCT00513669|Malaria
546745|NCT00513669|Vaccine
546746|NCT00513669|Falciparum
546747|NCT00513669|Trial
546748|NCT00513669|Phase I
546749|NCT00513669|Safety
546750|NCT00513669|Immunogenicity
546751|NCT00513656|Efficacy
546752|NCT00513656|chronic
546753|NCT00513656|cancer
546754|NCT00513656|pain
546755|NCT00513656|constipation
546756|NCT00513656|oxycodone
546757|NCT00513656|naloxone
546758|NCT00513656|Moderate to severe chronic cancer pain
546759|NCT00513643|euglycaemic glucose clamp
546760|NCT00513643|duration of action
546761|NCT00513643|late metabolic activity
546762|NCT00513643|hypoglycaemia
546763|NCT00513617|Sickle Cell Disease
546764|NCT00513617|Anemia
546765|NCT00513617|Nitric Oxide
546766|NCT00513617|Vaso Occlusive Events
546767|NCT00513617|Arginine Supplementation
546768|NCT00513604|Clinical Response
546769|NCT00513604|Immunotherapy
546770|NCT00513604|Cancer
546771|NCT00513604|Cytokines
546772|NCT00513604|Adoptive Cell Therapy
546773|NCT00513604|Melanoma
546774|NCT00513604|Skin Cancer
546775|NCT00513604|Malignant Melanoma
546776|NCT00513591|Pregnancy
546777|NCT00513591|Lupus (systemic lupus erythematosus or cutaneous lupus)
546778|NCT00513591|Rheumatoid Arthritis
546779|NCT00513591|Sjogren's Syndrome
546780|NCT00513591|Scleroderma
546781|NCT00513578|refractory anemia with excess blasts
546782|NCT00513578|refractory anemia with ringed sideroblasts
546783|NCT00513578|refractory anemia
546784|NCT00513578|refractory cytopenia with multilineage dysplasia
546785|NCT00513578|de novo myelodysplastic syndromes
546786|NCT00513578|secondary myelodysplastic syndromes
546787|NCT00513565|GSK561679,
546788|NCT00513565|single,
546789|NCT00513565|dose,
546790|NCT00513565|lorazepam,
546791|NCT00513565|fMRI,
546792|NCT00513565|BOLD,
546793|NCT00513565|healthy volunteers
546794|NCT00513539|unresectable gallbladder cancer
546795|NCT00513539|recurrent gallbladder cancer
546796|NCT00513539|metastatic gallbladder cancer
546797|NCT00513539|cholangiocarcinoma of the gallbladder
546798|NCT00513539|unresectable extrahepatic bile duct cancer
546799|NCT00513539|recurrent extrahepatic bile duct cancer
546800|NCT00513539|metastatic extrahepatic bile duct cancer
546801|NCT00513539|cholangiocarcinoma of the extrahepatic bile duct
546802|NCT00513526|infection
546803|NCT00513526|low-grade squamous intraepithelial lesion
546804|NCT00513526|atypical squamous cells of undetermined significance
546805|NCT00513513|HIV
546806|NCT00513513|AIDS
546807|NCT00513513|TMC114
546808|NCT00513513|Protease inhibitor
546809|NCT00513513|Darunavir
546810|NCT00513513|Antiretroviral agents
546811|NCT00513513|Treatment Naive
546812|NCT00513500|community health care
546813|NCT00513500|community health worker
546814|NCT00513500|malaria
546815|NCT00513500|pneumonia
546816|NCT00513500|rapid diagnostic test
546817|NCT00513487|Allergic Rhinitis
546818|NCT00513487|dust mites
546819|NCT00513487|IgE
546820|NCT00513487|IL-13
546821|NCT00513487|nasal
546822|NCT00513487|inflammation
546823|NCT00513474|graft versus host disease
546824|NCT00513474|anaplastic large cell lymphoma
546825|NCT00513474|angioimmunoblastic T-cell lymphoma
546935|NCT00513240|electroencephalogram
546826|NCT00513474|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
546827|NCT00513474|nodal marginal zone B-cell lymphoma
546828|NCT00513474|recurrent adult Burkitt lymphoma
546829|NCT00513474|recurrent adult diffuse large cell lymphoma
546830|NCT00513474|recurrent adult diffuse mixed cell lymphoma
546831|NCT00513474|recurrent adult diffuse small cleaved cell lymphoma
546832|NCT00513474|recurrent adult Hodgkin lymphoma
546833|NCT00513474|recurrent adult immunoblastic large cell lymphoma
546834|NCT00513474|recurrent adult lymphoblastic lymphoma
546835|NCT00513474|recurrent adult T-cell leukemia/lymphoma
546836|NCT00513474|recurrent cutaneous T-cell non-Hodgkin lymphoma
546837|NCT00513474|recurrent grade 1 follicular lymphoma
546838|NCT00513474|recurrent grade 2 follicular lymphoma
546839|NCT00513474|recurrent grade 3 follicular lymphoma
546840|NCT00513474|recurrent mantle cell lymphoma
546841|NCT00513474|recurrent marginal zone lymphoma
546842|NCT00513474|recurrent mycosis fungoides/Sezary syndrome
546843|NCT00513474|recurrent small lymphocytic lymphoma
546844|NCT00513474|splenic marginal zone lymphoma
546845|NCT00513474|Waldenström macroglobulinemia
546846|NCT00513474|recurrent adult acute lymphoblastic leukemia
546847|NCT00513474|refractory chronic lymphocytic leukemia
546848|NCT00513474|recurrent adult acute myeloid leukemia
546849|NCT00513474|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
546850|NCT00513474|adult acute myeloid leukemia with inv(16)(p13;q22)
546851|NCT00513474|adult acute myeloid leukemia with t(15;17)(q22;q12)
546852|NCT00513474|adult acute myeloid leukemia with t(16;16)(p13;q22)
546853|NCT00513474|adult acute myeloid leukemia with t(8;21)(q22;q22)
546854|NCT00513474|accelerated phase chronic myelogenous leukemia
546855|NCT00513474|blastic phase chronic myelogenous leukemia
546856|NCT00513474|chronic phase chronic myelogenous leukemia
546857|NCT00513474|relapsing chronic myelogenous leukemia
546858|NCT00513474|previously treated myelodysplastic syndromes
546859|NCT00513474|primary myelofibrosis
546860|NCT00513474|atypical chronic myeloid leukemia, BCR-ABL1 negative
546861|NCT00513474|chronic eosinophilic leukemia
546862|NCT00513474|chronic myelomonocytic leukemia
546863|NCT00513474|de novo myelodysplastic syndromes
546864|NCT00513474|myelodysplastic/myeloproliferative neoplasm, unclassifiable
546865|NCT00513474|refractory hairy cell leukemia
546866|NCT00513474|refractory multiple myeloma
546867|NCT00513474|secondary acute myeloid leukemia
546868|NCT00513474|secondary myelodysplastic syndromes
546869|NCT00513448|Chronic Disabling Condition
546870|NCT00513448|Comparative Evaluation
546871|NCT00513448|Physical Activity
546872|NCT00513448|Physical Therapy
546873|NCT00513448|Rehabilitation
546874|NCT00513422|Osteoarthritis, knee
546875|NCT00513422|Glucosamine
546876|NCT00513422|Chondroitin
546877|NCT00513422|Disease progression
546878|NCT00513422|NSAIDs
546879|NCT00513409|Immunogenicity
546880|NCT00513409|Pneumococcal disease
546881|NCT00513409|Safety
546882|NCT00513409|Booster vaccination
546883|NCT00513409|Pneumococcal vaccine
546884|NCT00513396|Randomized control trial
546885|NCT00513396|multidrug resistant tuberculosis
546886|NCT00513396|isoniazid
546887|NCT00513396|standardized regimen
546888|NCT00513396|adjuvant therapy
546889|NCT00513383|basaloid squamous cell carcinoma
546890|NCT00513383|undifferentiated carcinoma
546891|NCT00513383|adenosquamous cell carcinoma
546892|NCT00513370|Psoriasis
546893|NCT00513370|adalimumab
546894|NCT00513357|Gastrointestinal Cancer
546895|NCT00513357|Lung Cancer
546896|NCT00513357|Cachexia
546897|NCT00513357|Melatonin
546898|NCT00513357|Placebo
546899|NCT00513357|Anorexia
546900|NCT00513357|Weight Loss
546901|NCT00513344|Endothelial function
546902|NCT00513344|Arterial stiffness
546903|NCT00513344|Dark chocolate
546904|NCT00513344|Milk chocolate
546905|NCT00513344|Polyphenols
546906|NCT00513331|Barrett's Esophagus
546907|NCT00513331|GERD
546908|NCT00513331|Carcinoma
546909|NCT00513318|Umbilical cord blood transplantation
546910|NCT00513318|hematopoietic malignancies
546911|NCT00513305|acute myeloid leukemia, cytarabine, arsenic trioxide.
546912|NCT00513279|Safety,
546913|NCT00513279|tolerability,
546914|NCT00513279|pharmacokinetics,
546915|NCT00513279|pharmacodynamics,
546916|NCT00513279|repeat dose,
546917|NCT00513279|placebo,
546918|NCT00513279|GSK618334
546919|NCT00513266|recurrent rectal cancer
546920|NCT00513266|stage IV rectal cancer
546921|NCT00513266|recurrent colon cancer
546922|NCT00513266|stage IV colon cancer
546923|NCT00513266|adenocarcinoma of the colon
546924|NCT00513266|adenocarcinoma of the rectum
546925|NCT00513266|liver metastases
546926|NCT00513266|lung metastases
546927|NCT00513253|lapatinib
546928|NCT00513253|Healthy Adult Volunteer
546929|NCT00513240|erythropoetin
546930|NCT00513240|neuroprotection
546931|NCT00513240|neonate
546932|NCT00513240|cardiac
546933|NCT00513240|magnetic resonance imaging
546934|NCT00513240|brain magnetic resonance imaging
546936|NCT00513214|Diabetes
546937|NCT00513214|Type 2
546938|NCT00513214|Mellitus
546939|NCT00513201|lyspro
546940|NCT00513201|regular insulin
546941|NCT00513201|cirrhotic patients
546942|NCT00513188|angioimmunoblastic T-cell lymphoma
546943|NCT00513188|anaplastic large cell lymphoma
546944|NCT00513188|adult nasal type extranodal NK/T-cell lymphoma
546945|NCT00513188|stage IV mycosis fungoides/Sezary syndrome
546946|NCT00513188|stage IV cutaneous T-cell non-Hodgkin lymphoma
546947|NCT00513175|Allogeneic SCT
546948|NCT00513175|Matched unrelated donors
546949|NCT00513175|hematologic malignancies
546950|NCT00513175|renal cell carcinoma
546951|NCT00513175|aplastic anemia
546952|NCT00513162|Advanced Cancers
546953|NCT00513162|Brain
546954|NCT00513162|CNS
546955|NCT00513162|Neural
546956|NCT00513162|Pediatrics
546957|NCT00513162|Spinal
546958|NCT00513162|Neuroectodermal Tumor
546959|NCT00513162|Brain Metastases
546960|NCT00513162|Valproate
546961|NCT00513162|Valproic Acid
546962|NCT00513162|Depakene
546963|NCT00513162|Etoposide
546964|NCT00513162|VePesid
546965|NCT00513149|angioplasty
546966|NCT00513149|clopidogrel
546967|NCT00513149|coronary artery disease
546968|NCT00513149|PFA
546969|NCT00513136|Fatigue
546970|NCT00513136|Breast Cancer
546971|NCT00513136|Behavioral Research
546972|NCT00513136|Quality of Life
546973|NCT00513123|Digital Colposcopy for Fluorescence
546974|NCT00513123|DCF
546975|NCT00513123|Fluorescence Spectroscopy
546976|NCT00513123|Digital Colposcopy
546977|NCT00513123|DC
546978|NCT00513123|Cervical Intraepithelial Neoplasia
546979|NCT00513123|Cervical Cancer
546980|NCT00513123|Cervix
546981|NCT00513123|Vagina
546982|NCT00513123|Lesions of the cervix
546983|NCT00513123|Precancerous lesions
546984|NCT00513110|Endotoxin
546985|NCT00513110|Adenosine
546986|NCT00513110|Caffeine
546987|NCT00513110|AMPD1 polymorphism
546988|NCT00513097|Epidemiology
546989|NCT00513097|Cancer Prevention
546990|NCT00513097|Smoking Cessation
546991|NCT00513097|Smoking Prevention
546992|NCT00513097|Focus Groups
546993|NCT00513084|Behavioral,
546994|NCT00513084|Self-Determination Theory,
546995|NCT00513084|Motivational Interviewing,
546996|NCT00513084|Exercise, Physical Activity,
546997|NCT00513084|Motivation,
546998|NCT00513084|Moderators,
546999|NCT00513084|Mediators,
547000|NCT00513084|Predictors,
547001|NCT00513084|Weight
547002|NCT00513058|metastatic breast cancer
547003|NCT00513058|advanced breast cancer
547004|NCT00513045|Nightmares
547005|NCT00513045|treatment
547006|NCT00513045|self-help
547007|NCT00513032|propofol
547008|NCT00513032|anaesthesia induction
547009|NCT00513032|parathyroidectomy
547010|NCT00513032|methylene blue
547011|NCT00513032|General anesthesia
547012|NCT00513019|Neurotic Excoriation
547013|NCT00513019|Pathologic Skin Picking
547014|NCT00513019|Psychogenic Excoriation
547015|NCT00512993|Postoperative treatment with zoledronic acid
547016|NCT00512993|Preoperative anthracycline/taxane containing chemotherapy
547017|NCT00512980|intermediate stages
547018|NCT00512967|oxidative stress
547019|NCT00512967|antioxidants
547020|NCT00512967|inflammation
547021|NCT00512967|quercetin
547022|NCT00512954|airway inflammation
547023|NCT00512954|susceptibility to infections
547024|NCT00512954|inflammatory response in blood and urine
547025|NCT00512954|infective exacerbations
547026|NCT00512954|asthma
547027|NCT00512954|COPD
547028|NCT00512928|vitamin K2
547029|NCT00512928|oral anticoagulation
547030|NCT00512928|interference
547031|NCT00512928|level of anticoagulation
547032|NCT00512928|carboxylation level of osteocalcin and matrix-gla protein
547033|NCT00512915|Farfield Sensing
547034|NCT00512915|Pacing lead
547035|NCT00512915|Postventricular atrial blanking
547036|NCT00512915|Bradycardia
547037|NCT00512902|active alveolitis in systemic sclerosis
547038|NCT00512889|CTL
547039|NCT00512889|MART-1
547040|NCT00512889|Melan-A
547041|NCT00512889|artificial APC
547042|NCT00512889|melanoma
547043|NCT00512889|metastatic melanoma
547044|NCT00512889|adoptive immunotherapy
547045|NCT00512889|adoptive cell transfer
547046|NCT00512889|immunotherapy
547047|NCT00512850|Folic acid
547048|NCT00512850|Adenoma of Large Intestine
547049|NCT00512837|Telemedicine
547050|NCT00512837|clinical management
547051|NCT00512837|empowerment
547052|NCT00512837|engagement
547053|NCT00512837|education
547054|NCT00512824|calcium
547055|NCT00512824|probiotics
547056|NCT00512824|diarrhea
547057|NCT00512824|children
547058|NCT00512824|Indonesia
547059|NCT00512824|Healthy children
547060|NCT00512824|acute diarrhea
547061|NCT00512811|furosemide
547062|NCT00512811|inhalation
547063|NCT00512811|dyspnea
547064|NCT00512811|spirometry
547065|NCT00512811|mustard gas
547066|NCT00512811|bronchiolitis
547067|NCT00512811|sulfur mustard
547068|NCT00512798|stage III melanoma
547069|NCT00512798|stage IV melanoma
547070|NCT00512798|recurrent melanoma
547071|NCT00512798|unspecified adult solid tumor, protocol specific
547072|NCT00512798|recurrent adult brain tumor
547073|NCT00512798|melanoma (skin)
547074|NCT00512785|Imidafenacin
547075|NCT00512785|KRP-197/ONO-8025
547076|NCT00512785|overactive bladder
547077|NCT00512785|antimuscarinic
547078|NCT00512772|Time series
547079|NCT00512772|Implementation
547080|NCT00512746|small cell lung cancer
547081|NCT00512746|non-small cell lung cancer
547082|NCT00512746|precancerous condition
547083|NCT00512733|Healthy volunteers
547084|NCT00512720|PAD
547085|NCT00512720|Peripheral Artery Disease
547086|NCT00512720|PVD
547087|NCT00512720|Peripheral Vascular Disease
547088|NCT00512720|Leg Blockage
547089|NCT00512720|Angioplasty
547090|NCT00512720|Stent
547091|NCT00512720|Claudication
547092|NCT00512707|testosterone
547093|NCT00512707|erectile dysfunction
547094|NCT00512707|sildenafil
547095|NCT00512694|Lupus
547096|NCT00512694|Systemic Lupus Erythematosus
547097|NCT00512694|Cutaneous Lupus
547098|NCT00512681|Stomach Neoplasms
547099|NCT00512681|Secondary
547100|NCT00512681|Combination chemotherapy
547101|NCT00512681|S-1
547102|NCT00512681|irinotecan
547103|NCT00512681|oxaliplatin
547104|NCT00512655|Fear of falling
547105|NCT00512655|Intraindividual variability
547106|NCT00512655|Cognition
547107|NCT00512655|Fall prevention
547108|NCT00512655|Fear
547109|NCT00512655|Frail elderly
547110|NCT00512655|Intervention
547111|NCT00512642|Non-Small Cell Lung Cancer
547112|NCT00512642|p53
547113|NCT00512642|Smoking
547114|NCT00512642|Carcinogenesis
547115|NCT00512642|Loss of Heterozygosity
547116|NCT00512629|PN
547117|NCT00512629|cholestasis
547118|NCT00512629|gastrointestinal disease in infants
547119|NCT00512629|short bowel syndrome
547120|NCT00512616|Ceftriaxone
547121|NCT00512616|Acute Antidepressant Effects
547122|NCT00512616|Glutamatergic System
547123|NCT00512616|Double-Blind
547124|NCT00512616|Mood Disorders
547125|NCT00512616|Bipolar Disorder
547126|NCT00512616|Depression
547127|NCT00512603|cerebro vascular event
547128|NCT00512590|fibromyalgia
547129|NCT00512590|relaxation
547130|NCT00512590|imagery
547131|NCT00512590|pain
547132|NCT00512590|functional status
547133|NCT00512590|self efficacy
547134|NCT00512590|minority health
547135|NCT00512577|sickle cell disease
547136|NCT00512577|pre-operative transfusion
547137|NCT00512577|blood transfusion
547138|NCT00512564|Sickle Cell Anemia
547139|NCT00512564|Sickle Cell Thalassemia
547140|NCT00512564|Iron overload
547141|NCT00512564|Non transferrin binding iron
547142|NCT00512564|Hepcidin
547143|NCT00512551|Cervical Cancer
547144|NCT00512551|DNA Array Analysis
547145|NCT00512551|Gene Expression
547146|NCT00512551|DNA
547147|NCT00512538|Diabetic foot
547148|NCT00512512|transoral
547149|NCT00512512|transluminal
547150|NCT00512512|endoscopic
547151|NCT00512512|laparoscopic
547152|NCT00512512|liver
547153|NCT00512512|biopsy
547154|NCT00512499|Osteoporosis
547155|NCT00512499|Fragility fractures
547156|NCT00512499|Fracture clinics
547157|NCT00512499|Orthopedic surgeons
547158|NCT00512473|GH, GH receptor blockade, GH signaling, insulin resistance
547159|NCT00512460|Neoplastic Meningitis
547160|NCT00512460|Leptomeningeal Disease
547161|NCT00512460|Solid Tumor
547162|NCT00512460|Lymphoma
547163|NCT00512460|Leukemia
547164|NCT00512460|Brain Tumor
547165|NCT00512460|RTA 744
547166|NCT00512447|Aging
547167|NCT00512434|tibial
547168|NCT00512434|shaft
547169|NCT00512434|fracture
547170|NCT00512434|open
547171|NCT00512434|bone-marrow
547172|NCT00512434|graft
547173|NCT00512434|injection
547174|NCT00512434|mesenchymal stem cell
547175|NCT00512408|To assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly CHF patients
547176|NCT00512395|laparoscopic colorectal surgery
547177|NCT00512395|epidural analgesia
547178|NCT00512395|pain score
547179|NCT00512395|postoperative ileus
547180|NCT00512382|GER Gastrointestinal reflux
547181|NCT00512382|Aspiration
547182|NCT00512382|ASHTMA
547183|NCT00512382|COUGH
547184|NCT00512382|WHEEZE
547185|NCT00512382|PH-IMPEDANCE
547186|NCT00512382|WEEM Wheezy Monitor
547187|NCT00512369|Metabolic pathways
547188|NCT00512369|Atherosclerosis
547189|NCT00512369|Monocyte Function
547190|NCT00512343|Synovial Fluid
547191|NCT00512343|Arthritis
547192|NCT00512343|Paired serum/synovial fluid samples
547193|NCT00512330|childhood
547194|NCT00512330|tuberculosis
547195|NCT00512330|diagnostic
547196|NCT00512330|lipoarabinomannan
547197|NCT00512330|ELISA
547198|NCT00512330|Tuberculosis in Childhood
547199|NCT00512317|partial onset epilepsy
547200|NCT00512317|adult epilepsy
547201|NCT00512317|partial seizures
547202|NCT00512317|anticonvulsant
547203|NCT00512317|catamenial epilepsy
547204|NCT00512317|adult partial onset epilepsy
547205|NCT00512291|Advanced Cancer
547206|NCT00512291|Hyperactive Delirium
547207|NCT00512291|Mixed Delirium
547208|NCT00512291|Olanzapine
547209|NCT00512278|Hepatitis
547210|NCT00512278|HCV
547211|NCT00512278|Hepatitis C
547212|NCT00512265|n-acetylcysteine
547213|NCT00512265|esophagectomy
547214|NCT00512265|inflammatory reaction
547215|NCT00512265|pulmonary morbidity
547216|NCT00512252|Plerixafor
547217|NCT00512252|CXCR4
547218|NCT00512252|Chemosensitization
547219|NCT00512239|Early Rheumatoid Arthritis
547220|NCT00512239|Early inflammatory arthritis
547221|NCT00512239|Biomarkers
547222|NCT00512239|Autoantibodies
547223|NCT00512239|Anti-Sa antibodies
547224|NCT00512239|Anti-CCP antibodies
547225|NCT00512226|Sickle Cell Anemia
547226|NCT00512226|Sickle Cell Thalassemia
547227|NCT00512226|Iron Overload
547228|NCT00512226|MRI
547229|NCT00512213|preoperative Immunonutrition
547230|NCT00512213|major abdominal surgery
547231|NCT00512213|complication
547232|NCT00512174|Portable Ultrasound Scanner
547233|NCT00512174|Non Invasive Bladder Volume Measurement
547234|NCT00512174|Radical Cystectomy
547235|NCT00512174|Bladder Reconstruction
547236|NCT00512161|Any patient undergoing elective cardiac surgery
547237|NCT00512122|early parenteral nutrition
547238|NCT00512122|critical illness
547239|NCT00512122|respiratory failure
547240|NCT00512122|kidney failure
547241|NCT00512122|hepatic failure
547242|NCT00512122|muscle strength
547243|NCT00512122|rehabilitation
547244|NCT00512122|overfeeding
547245|NCT00512122|Reduced Oral Intake
547246|NCT00512109|vascular risk
547247|NCT00512109|perioperative
547248|NCT00512109|vascular events
547249|NCT00512109|cohort study
547250|NCT00512109|surgery
547251|NCT00512096|Genitourinary
547252|NCT00512096|Penile Cancer
547253|NCT00512096|Neoadjuvant Chemotherapy
547254|NCT00512096|Extirpative Surgery
547255|NCT00512096|TanyN2-3M0 Squamous Cell Carcinoma of the Penis
547256|NCT00512096|Cisplatin
547257|NCT00512096|Platinol-AQ
547258|NCT00512096|Platinol
547259|NCT00512096|CDDP
547260|NCT00512096|Ifosfamide
547261|NCT00512096|Ifex
547262|NCT00512096|Paclitaxel
547263|NCT00512096|Taxol
547264|NCT00512083|Leukemia, Myeloid + Acute Disease
547265|NCT00512070|schizophrenia
547266|NCT00512070|schizoaffective disorder
547267|NCT00512070|bipolar disorder
547268|NCT00512070|olanzapine
547269|NCT00512070|melatonin
547270|NCT00512070|obesity
547271|NCT00512070|metabolic syndrome
547272|NCT00512057|cardiac syndrome X
547273|NCT00512057|endothelial function
547274|NCT00512044|anesthesia, Longo, mucosectomy, hemorrhoids
547275|NCT00512031|atherosclerosis
547276|NCT00512031|metabolic pathways
547277|NCT00512031|monocyte adhesion,
547278|NCT00512018|Electric Stimulation
547279|NCT00512018|Quadriceps Muscle
547280|NCT00512018|Muscle Strength
547281|NCT00512018|Neuromuscular Properties
547282|NCT00512018|Tension-Length Relationship
547283|NCT00512018|Healthy young adults
547284|NCT00512005|Functional Mitral Regurgitation (FMR)
547285|NCT00512005|Ischemic Mitral Regurgitation
547286|NCT00512005|Less invasive repair
547287|NCT00512005|Percutaneous MV repair
547288|NCT00512005|Mitral Valve Repair
547289|NCT00512005|Heart Failure
547290|NCT00512005|Left Ventricular Dysfunction
547291|NCT00511992|Ovarian Cancer
547292|NCT00511992|Gynecologic Cancer
547293|NCT00511992|Ovarian Carcinoma
547294|NCT00511992|Peritoneal Carcinoma
547295|NCT00511992|IP chemotherapy
547296|NCT00511992|Intraperitoneal
547297|NCT00511992|Avastin
547298|NCT00511992|Bevacizumab
547299|NCT00511979|Healthy Patients
547300|NCT00511966|Gastroesophageal Reflux
547301|NCT00511966|Rabeprazole
547302|NCT00511953|Hot flashes
547303|NCT00511953|Hot flushes
547304|NCT00511953|Postmenopausal symptoms
547305|NCT00511927|heart
547306|NCT00511927|failure
547307|NCT00511927|growth
547308|NCT00511927|hormone
547309|NCT00511927|igf
547310|NCT00511927|dilative
547311|NCT00511927|cardiomyopathy
547312|NCT00511914|Influenza vaccine
547313|NCT00511901|anemia
547314|NCT00511901|function
547315|NCT00511901|rehabilitation
547316|NCT00511888|chronic heart failure
547317|NCT00511888|hypertension
547318|NCT00511888|beta blockers
547319|NCT00511875|diabetic retinopathy
547320|NCT00511875|diabetes
547321|NCT00511875|diabetic eye studies
547322|NCT00511875|neovascularization
547323|NCT00511862|TheraSphere
547324|NCT00511862|radioactive microspheres
547325|NCT00511862|Yttrium-90
547326|NCT00511862|Yttrium glass microspheres
547327|NCT00511836|alcoholism
547328|NCT00511836|addiction
547329|NCT00511836|alcohol detoxification
547330|NCT00511823|drug-drug interaction,
547331|NCT00511823|rosiglitazone,
547332|NCT00511823|safety
547333|NCT00511823|CYP2C8,
547334|NCT00511823|pharmacokinetics,
547335|NCT00511823|CYP3A4,
547336|NCT00511823|granisetron,
547337|NCT00511823|dolasetron,
547338|NCT00511823|CYP2D6,
547339|NCT00511823|casopitant,
547340|NCT00511810|Sadness
547341|NCT00511810|Insomnia
547342|NCT00511810|Loss of appetite
547343|NCT00511810|Fatigue
547344|NCT00511810|Trouble thinking
547345|NCT00511797|Dysmenorrhea
547346|NCT00511797|Dysmenorrheal score
547347|NCT00511797|Drospirenone
547348|NCT00511797|DRSP
547349|NCT00511797|Ethinylestradiol
547350|NCT00511784|Contraception
547351|NCT00511784|Hormonal contraception
547352|NCT00511784|Oral contraception
547353|NCT00511784|Ethinyl estradiol, Levonorgestrel, Contraception
547354|NCT00511784|Transdermal
547355|NCT00511784|Venous thromboembolism
547356|NCT00511784|Norelgestromin
547357|NCT00511771|Tegaserod, treatment IND, irritable bowel syndrome with constipation, IBS-C, chronic idiopathic constipation, CIC, chronic constipation, CC
547358|NCT00511758|Cervical Dysplasia
547359|NCT00511758|Digital Imaging
547360|NCT00511758|Colposcopy
547361|NCT00511758|Cervix
547362|NCT00511745|Interactions
547363|NCT00511745|Adjusted doses
547364|NCT00511745|Duodenal Ulcer
547365|NCT00511745|Gastric Ulcer
547366|NCT00511745|Erosive or ulcerate Gastroesophageal Reflux
547367|NCT00511745|Rabeprazole
547368|NCT00511745|Gastroesophageal reflux
547369|NCT00511693|fragility fracture
547370|NCT00511693|management of osteoporosis
547371|NCT00511693|osteoporosis coordinator
547372|NCT00511693|small volume hospitals
547373|NCT00511654|NK1 receptor antagonists,
547374|NCT00511654|depression
547375|NCT00511641|Ovarian Cancer
547376|NCT00511641|Cancer Screening
547377|NCT00511641|Quality of Life
547378|NCT00511641|Questionnaire
547379|NCT00511641|Screening
547380|NCT00511641|Survey
547381|NCT00511628|Schizophrenia
547382|NCT00511628|Risperidone
547383|NCT00511628|Schizoaffective disorder
547384|NCT00511628|Schizophreniform disorder
547385|NCT00511628|Weight gain
547386|NCT00511615|Cervical Intraepithelial Neoplasia
547387|NCT00511615|Loop Electrosurgical Excision Procedure
547388|NCT00511615|Cervical Cancer
547389|NCT00511615|Colposcopy
547390|NCT00511615|Molecular Imaging
547391|NCT00511615|LEEP
547392|NCT00511576|Advanced or Metastatic Breast Cancer
547393|NCT00511576|Breast Cancer
547394|NCT00511576|Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
547395|NCT00511576|Hormone Refractory Prostate Cancer
547396|NCT00511576|Prostate Cancer
547397|NCT00511576|Gastric Cancer
547398|NCT00511576|Advanced Gastric Adenocarcinoma
547399|NCT00511576|HDAC Inhibitor
547400|NCT00511576|Taxotere
547401|NCT00511576|Docetaxel
547402|NCT00511563|Cortisol,
547403|NCT00511563|stress,
547404|NCT00511563|response,
547405|NCT00511563|Irritable Bowel Syndrome,
547406|NCT00511563|cytokine.
547407|NCT00511550|peripheral blood stem cells
547408|NCT00511550|filgrastim-mobilized
547409|NCT00511550|allogeneic transplantation
547410|NCT00511550|Unrelated Donors for allogeneic transplantation
547411|NCT00511537|AML
547412|NCT00511537|ALL
547413|NCT00511537|CML
547414|NCT00511537|Lymphoma
547415|NCT00511537|Myelodysplasia
547416|NCT00511537|Unrelated stem cell transplantation
547417|NCT00511537|Hematopoietic disorders
547418|NCT00511524|CB2,
547419|NCT00511524|PET
547420|NCT00511524|brain,
547421|NCT00511524|inflammation,
547422|NCT00511524|analgesia,
547423|NCT00511511|hypertension
547424|NCT00511511|angiogenesis inhibitors
547425|NCT00511511|tyrosine kinase inhibitor
547426|NCT00511511|Sunitinib
547427|NCT00511498|Laparoscopic Radical Prostatectomy
547428|NCT00511498|Nightly sildenafil
547429|NCT00511485|Cancer
547430|NCT00511485|Adenocarcinoma
547431|NCT00511485|Phase II
547432|NCT00511485|Lung
547433|NCT00511485|Non-small cell lung cancer
547434|NCT00511485|NSCLC
547435|NCT00511485|EC145
547436|NCT00511485|EC20
547437|NCT00511459|Randomized
547438|NCT00511459|4-Arm
547439|NCT00511459|Placebo controlled
547440|NCT00511459|Phase 2 Trial
547441|NCT00511459|AMG 386
547442|NCT00511459|Paclitaxel
547443|NCT00511459|Bevacizumab
547444|NCT00511459|First-line Therapy
547445|NCT00511459|Her-2 Negative
547446|NCT00511459|Metastatic or Locally Recurrent Breast Cancer
547447|NCT00511446|Stomach neoplasms
547448|NCT00511446|docetaxel
547449|NCT00511446|oxaliplatin
547450|NCT00511446|capecitabine
547451|NCT00511420|cocoa
547452|NCT00511420|cardiovascular disease
547453|NCT00511420|blood pressure
547454|NCT00511407|Acute renal failure
547455|NCT00511407|Bioartificial kidney
547456|NCT00511407|Cell therapy
547457|NCT00511407|Hemofiltration
547458|NCT00511407|Septic shock
547459|NCT00511394|Decompensated Cirrhosis with Ascites
547460|NCT00511381|Hearing Loss
547461|NCT00511381|Late-Onset Hearing Loss
547462|NCT00511381|Deafness
547463|NCT00511368|HIV
547464|NCT00511368|treatment experienced
547465|NCT00511368|AIDS
547466|NCT00511329|growth hormone
547467|NCT00511329|short stature
547468|NCT00511329|growth failure
547469|NCT00511329|chronic illness
547470|NCT00511303|Philadelphia chromosome
547471|NCT00511303|protein-tyrosine kinases
547472|NCT00511290|Primary disease or condition being studied: Asthma -COPD-Interstitial Lung Diseases-Occupational Lung Diseases
547473|NCT00511277|quetiapine
547474|NCT00511277|schizophrenia
547475|NCT00511277|first-episode psychosis
547476|NCT00511277|depression
547477|NCT00511277|psychopathology
547478|NCT00511264|Laparoscopy
547479|NCT00511264|Ultrasound
547480|NCT00511264|Cancer
547481|NCT00511264|Biopsy
547482|NCT00511251|IS-SEM
547483|NCT00511238|Onyx
547484|NCT00511238|PR171
547485|NCT00511238|carfilzomib
547486|NCT00511238|multiple myeloma
547487|NCT00511238|relapsed
547488|NCT00511238|refractory
547489|NCT00511225|dialysis
547490|NCT00511225|Vitamin D
547491|NCT00511212|severe peritonitis
547492|NCT00511212|SSI
547493|NCT00511212|lower digestive tract surgery
547494|NCT00511212|Severe peritonitis after lower digestive tract surgery
547495|NCT00511186|Sepsis
547496|NCT00511186|Alkaline Phosphatase
547497|NCT00511186|inflammation
547498|NCT00511186|infection
547499|NCT00511186|renal failure
547500|NCT00511173|mechanical valve
547501|NCT00511160|myocarditis
547502|NCT00511160|parvovirus B19 (PVB19)
547503|NCT00511160|human herpes virus 6 (HHV6)
547504|NCT00511160|cardiac magnetic resonance tomography (CMR)
547505|NCT00511147|IVIG
547506|NCT00511147|ITP
547507|NCT00511134|insomnia
547508|NCT00511134|nicotine dependence
547509|NCT00511134|smoking
547510|NCT00511134|smoking cessation
547511|NCT00511134|zyban
547512|NCT00511121|chronic myeloid leukemia
547513|NCT00511121|tyrosine kinase
547514|NCT00511108|Type 2 Diabetes Mellitus (T2DM)
547515|NCT00511095|Hepatitis B vaccine
547516|NCT00511095|HBV vaccine
547517|NCT00511095|Hepatitis B
547518|NCT00511095|Hepatitis
547519|NCT00511095|HBV
547520|NCT00511069|Bortezomib
547521|NCT00511069|CML033
547522|NCT00511056|HIV
547523|NCT00511056|Adherence
547524|NCT00511056|Compliance
547525|NCT00511056|Highly Active Antiretroviral Therapy (HAART)
547526|NCT00511056|ARV
547527|NCT00511056|ART
547528|NCT00511056|Sexual Risk Behavior
547529|NCT00511056|Unsafe
547530|NCT00511056|Transmission
547531|NCT00511043|PTK787
547532|NCT00511043|DLCL
547533|NCT00511043|Diffuse large cell lymphoma
547534|NCT00511030|Diabetes
547535|NCT00511017|Solid Tumors
547536|NCT00511017|Doxercalciferol
547537|NCT00511017|Pediatric Cancer
547538|NCT00511017|Recurrent Pediatric Solid Tumors
547539|NCT00511017|Calcium
547540|NCT00511017|Vitamin D
547541|NCT00511004|Brugia Malayi
547542|NCT00511004|Lymphatic Filariasis
547543|NCT00511004|Albendazole
547544|NCT00511004|Diethylcarbamazine
547545|NCT00510991|ASTHMA
547546|NCT00510978|Inflammatory Bowel Disease IBD
547547|NCT00510978|Ulcerative Colitis
547548|NCT00510978|Crohn's disease
547549|NCT00510978|Probiotics
547550|NCT00510978|Gastrointestinal
547551|NCT00510965|choroidal neovascularization
547552|NCT00510965|angioid streaks
547553|NCT00510965|pseudoxanthoma elasticum
547554|NCT00510965|Groenblad-Strandberg-Syndrome
547555|NCT00510965|therapy
547556|NCT00510965|ranibizumab
547557|NCT00510965|lucentis
547558|NCT00510965|Choroidal neovascularization in patients with PXE
547559|NCT00510952|diabetes
547560|NCT00510952|type 2
547561|NCT00510939|Acute myeloid leukemia
547562|NCT00510939|NFkB activity and leukemia
547563|NCT00510939|expression of NFkB
547564|NCT00510913|Treatment efficacy
547565|NCT00510913|Transplantation rejection
547566|NCT00510913|Kidney transplantation
547567|NCT00510913|Cyclosporine
547568|NCT00510913|tacrolimus
547569|NCT00510887|follicular lymphoma
547570|NCT00510887|Velcade
547571|NCT00510887|VR-FND
547572|NCT00510874|Influenza
547573|NCT00510874|GSK 1557484A vaccine
547574|NCT00510861|male age, assisted reproduction, sperm, pregnancy outcome
547575|NCT00510835|septic shock
547576|NCT00510835|resuscitation
547577|NCT00510835|sepsis
547578|NCT00510835|cost-effectiveness
547579|NCT00510835|sepsis-induced organ dysfunction
547580|NCT00510835|early goal directed therapy
547581|NCT00510835|emergency medicine
547582|NCT00510835|critical care medicine
547583|NCT00510822|Cimicoxib
547584|NCT00510822|Cox-2 inhibitor
547585|NCT00510822|Sertraline
547586|NCT00510796|Hereditary Non-Polyposis Colon Cancer
547587|NCT00510796|Colon Cancer
547588|NCT00510796|Endometrial Cancer
547589|NCT00510796|Cancer Screening
547590|NCT00510796|Interview
547591|NCT00510796|HNPCC
547592|NCT00510783|tonic-clonic seizure
547593|NCT00510783|emergency department
547594|NCT00510783|IV levetiracetam
547595|NCT00510783|Keppra
547596|NCT00510783|seizures
547597|NCT00510783|phenytoin
547598|NCT00510783|Dilantin
547599|NCT00510783|Grand Mal seizure
547600|NCT00510770|CPAP
547601|NCT00510770|Post-opreative
547602|NCT00510770|ARF
547603|NCT00510770|liver transplant
547604|NCT00510770|Post-operative hypoxemia in liver transplant
547605|NCT00510744|obesity, bariatric surgery, pancreatic secretion
547606|NCT00510731|Ventricular Tachycardia
547607|NCT00510731|Cardiac Sudden Death
547608|NCT00510731|Ventricular Fibrillation
547609|NCT00510731|Heart Rate Variability
547610|NCT00510718|Prostate
547611|NCT00510718|Cancer
547612|NCT00510718|Hormone
547613|NCT00510718|Refractory
547614|NCT00510718|Castration
547615|NCT00510705|adiposity
547616|NCT00510692|Eicosapentaenoic Acid
547617|NCT00510692|EPA
547618|NCT00510692|EPA 99%
547619|NCT00510692|Fatty acid
547620|NCT00510692|omega-3
547621|NCT00510692|apoptosis
547622|NCT00510692|cell proliferation
547623|NCT00510692|colonic mucosa
547624|NCT00510692|polyp
547625|NCT00510692|Familial Adenomatous Polyposis Coli
547626|NCT00510692|FAP
547627|NCT00510692|resolvin
547628|NCT00510692|Ileo-rectal anastomosis
547629|NCT00510692|IRA
547630|NCT00510692|PUFA
547631|NCT00510692|Endoscopy
547632|NCT00510679|Benin
547633|NCT00510679|child health
547634|NCT00510679|developing country
547635|NCT00510679|health services research
547636|NCT00510679|health worker performance
547637|NCT00510679|Integrated Management of Childhood Illness
547638|NCT00510666|Pain, Postoperative
547639|NCT00510666|Analgesics, Opioid
547640|NCT00510666|Analgesia, Patient-Controlled
547641|NCT00510666|Pain Measurement
547642|NCT00510653|Ovarian Cancer
547643|NCT00510653|Primary Peritoneal Cancer
547644|NCT00510653|Fallopian Tube Cancer
547645|NCT00510653|Recurrent Platinum-Resistant
547646|NCT00510653|Taxane-Resistant
547647|NCT00510653|Epithelial Ovarian Cancer
547648|NCT00510653|Imatinib Mesylate
547649|NCT00510653|Gleevec
547650|NCT00510653|STI571
547651|NCT00510653|Protein tyrosine kinase inhibitor
547652|NCT00510640|thyroid carcinoma
547653|NCT00510640|Sunitinib
547654|NCT00510640|RECIST guidelines
547655|NCT00510627|Metastatic Liver Cancer
547656|NCT00510627|Colorectal Cancer
547657|NCT00510627|Radiofrequency Ablation
547658|NCT00510627|Chemotherapy
547659|NCT00510614|Bacterial Vaginosis
547660|NCT00510614|Recurrent Bacterial Vaginosis
547661|NCT00510588|adiposity
547662|NCT00510575|Juvenile Scoliosis
547663|NCT00510575|Adolescent Scoliosis
547664|NCT00510575|Scoliosis Management
547665|NCT00510575|Spinal Fusion
547666|NCT00510575|Scoliosis instrumentation
547667|NCT00510575|Juvenile or Adolescent Idiopathic Scoliosis
547668|NCT00510562|Cranial manipulation
547669|NCT00510562|Visual function
547670|NCT00510536|Psoriasis, arthritis, arthralgia
547671|NCT00510523|MS
547672|NCT00510523|Balance
547673|NCT00510523|Multiple Sclerosis
547674|NCT00510510|COPD
547675|NCT00510510|glycopyrronium bromide
547676|NCT00510510|antimuscarinic
547677|NCT00510497|dendritic cell
547678|NCT00510497|therapeutic vaccine
547679|NCT00510497|HIV-1
547680|NCT00510497|apoptotic cells
547681|NCT00510497|Phase I/II
547682|NCT00510484|Pancreatic exocrine insufficiency
547683|NCT00510484|Cystic Fibrosis
547684|NCT00510445|Non Small Cell Lung Cancer
547685|NCT00510445|Advanced Non Small Cell Lung Cancer
547686|NCT00510445|Metastatic Non Small Cell Lung Cancer
547687|NCT00510432|heparin
547688|NCT00510432|heparin-induced thrombocytopenia
547689|NCT00510432|HIT
547690|NCT00510432|allergy
547691|NCT00510432|skin
547692|NCT00510432|dermatology
547693|NCT00510432|DTH
547694|NCT00510432|delayed-type hypersensitivity
547695|NCT00510432|histology
547696|NCT00510432|Patients receiving sc heparin therapy
547697|NCT00510432|Age over 18 years
547698|NCT00510432|Recruitment will stop when 20 patients with skin lesions are included
547699|NCT00510419|Migraine
547700|NCT00510406|Lower Urinary Tract Symptoms
547701|NCT00510406|Treatment
547702|NCT00510406|Solifenacin succinate
547703|NCT00510406|Tamsulosin hydrochloride
547704|NCT00510406|Prostatic Hyperplasia
547705|NCT00510393|Critical Limb Ischemia
547706|NCT00510393|CLI
547707|NCT00510393|Drug Eluting Stent
547708|NCT00510393|DES
547709|NCT00510393|Bare Metal Stent
547710|NCT00510393|BMS
547711|NCT00510367|Breast Cancer
547712|NCT00510367|FAC
547713|NCT00510367|Doxorubicin
547714|NCT00510367|Adriamycin
547715|NCT00510367|Rubex
547716|NCT00510367|5-Fluorouracil
547717|NCT00510367|5-FU
547718|NCT00510367|Adrucil
547719|NCT00510367|Efudex
547720|NCT00510367|Cyclophosphamide
547721|NCT00510367|Cytoxan
547722|NCT00510367|Neosar
547723|NCT00510367|Pregnancy
547724|NCT00510354|Progressive GIST
547725|NCT00510354|Resistance to Imatinib mesylate
547726|NCT00510341|Behavior Change Counseling
547727|NCT00510341|Motivational Interviewing
547728|NCT00510341|Chronic Care Model
547729|NCT00510341|Communication
547730|NCT00510341|Residency Training
547731|NCT00510341|Skill Assessment
547732|NCT00510328|whole body vibration
547733|NCT00510328|muscle physiology
547734|NCT00510315|leukemia
547735|NCT00510315|survivors
547736|NCT00510315|women
547737|NCT00510315|leukemia survivors
547738|NCT00510315|cancer or a related illness
547739|NCT00510315|Hodgkin's Lymphoma
547740|NCT00510315|Non-Hodgkin's Lymphoma
547741|NCT00510315|myelodysplastic syndrome
547742|NCT00510315|aplastic anemia
547743|NCT00510315|treated with total body irradiation
547744|NCT00510315|followed by an allogeneic or autologous stem cell transplant
547745|NCT00510302|Ultraviolet Radiation
547746|NCT00510302|Melanoma
547747|NCT00510302|Questionnaire
547748|NCT00510302|Survey
547749|NCT00510302|First Degree Relative
547750|NCT00510302|Interview
547751|NCT00510289|Sorafenib
547752|NCT00510289|Myelodysplastic Syndromes
547753|NCT00510289|MDS
547754|NCT00510263|Prednisolone
547755|NCT00510263|Valacyclovir
547756|NCT00510250|Cervix Cancer
547757|NCT00510250|Cervical Cancer
547758|NCT00510250|Sorafenib
547759|NCT00510250|Cisplatin
547760|NCT00510250|Radiation
547761|NCT00510250|Radiotherapy
547762|NCT00510250|Phase I
547763|NCT00510250|Phase II
547764|NCT00510250|Carcinoma
547765|NCT00510250|Cancer
547766|NCT00510250|Cervix
547767|NCT00510237|HIV
547768|NCT00510237|Adolescents newly diagnosed with HIV
547769|NCT00510198|Heart Disease
547770|NCT00510198|Congestive Heart Failure
547771|NCT00510198|Thoracic Fluid Monitoring
547772|NCT00510185|coronary artery disease
547773|NCT00510185|coronary angioplasty
547774|NCT00510185|coronary artery bypass surgery
547775|NCT00510185|elderly
547776|NCT00510172|Headache
547777|NCT00510172|Migraine
547778|NCT00510172|Vasodilatation
547779|NCT00510159|Schistosoma haematobium
547780|NCT00510159|Praziquantel
547781|NCT00510159|Artesunate + Sulfamethoxypyrazine/pyrimethamine
547782|NCT00510159|Randomized double blind placebo controlled clinical trial
547783|NCT00510120|Attention Deficit and Disruptive Behavior Disorders
547784|NCT00510120|Conduct Disorder
547785|NCT00510120|Behavior Problems in Youth
547786|NCT00510120|Argumentativeness
547787|NCT00510120|Children
547788|NCT00510120|Therapy
547789|NCT00510120|Attention Deficit Disorder
547790|NCT00510094|Social Skills
547791|NCT00510094|Anger Management
547792|NCT00510094|Relational Aggression
547793|NCT00510068|Phase III
547794|NCT00510068|Advanced Neuroendocrine Tumor in adults
547795|NCT00510068|RAD001
547796|NCT00510068|NET
547797|NCT00510068|everolimus
547798|NCT00510068|mTOr
547799|NCT00510068|islet cell
547800|NCT00510068|neuroendocrine
547801|NCT00510042|von Willebrand disease
547802|NCT00510042|von Willebrand factor
547803|NCT00510042|national study
547804|NCT00510042|bleeding disorder
547805|NCT00510042|quality of life
547806|NCT00510016|infants
547807|NCT00510016|opioid withdrawal
547808|NCT00510016|abstinence syndrome
547809|NCT00510016|methadone
547810|NCT00510016|heroin
547811|NCT00510003|Atopic dermatitis, children, pimecrolimus, eczema
547812|NCT00509990|Atopic dermatitis, pimecrolimus, children
547813|NCT00509951|Neuroses
547814|NCT00509951|Evidence-Based Treatment
547815|NCT00509951|Clinical Investigation
547816|NCT00509951|Young Patients
547817|NCT00509951|Phobic Disorders
547818|NCT00509951|Fear
547819|NCT00509951|Phobias
547820|NCT00509938|immunocompromized
547821|NCT00509938|hLF1-11
547822|NCT00509938|antimicrobial
547823|NCT00509938|peptide
547824|NCT00509938|lactoferrin
547825|NCT00509860|Advanced Sarcomas
547826|NCT00509860|Irinotecan
547827|NCT00509860|Camptosar
547828|NCT00509860|CPT-11
547829|NCT00509847|S. epidermidis
547830|NCT00509847|Staphylococcus
547831|NCT00509847|Lactoferrin
547832|NCT00509847|hLF1-11
547833|NCT00509847|Bacteraemia
547834|NCT00509834|hLF1-11
547835|NCT00509834|Candida
547836|NCT00509834|candidaemia
547837|NCT00509834|lactoferrin
547838|NCT00509782|Solid Tumors
547839|NCT00509782|Anti-Tumor Effects
547840|NCT00509782|ZIO-101
547841|NCT00509769|Trastuzumab emtansine
547842|NCT00509769|MBC
547843|NCT00509769|Breast cancer
547844|NCT00509769|HER2-positive breast cancer
547845|NCT00509769|HER2
547846|NCT00509756|healthy subjects
547847|NCT00509743|Adult volunteers
547848|NCT00509730|stress urinary incontinence
547849|NCT00509730|urodynamics
547850|NCT00509730|randomized clinical trial
547851|NCT00509730|surgery
547852|NCT00509717|quality of health care
547853|NCT00509717|prescriptions, drug
547854|NCT00509717|anticholesteremic agents
547855|NCT00509717|community pharmacy services
547856|NCT00509704|Sutent
547857|NCT00509704|tumor necrosis
547858|NCT00509704|DCE-MRI (Dynamic enhanced magnetic resonance imaging)
547859|NCT00509691|infection
547860|NCT00509691|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
547861|NCT00509691|adult acute myeloid leukemia with inv(16)(p13;q22)
547862|NCT00509691|adult acute myeloid leukemia with t(15;17)(q22;q12)
547863|NCT00509691|adult acute myeloid leukemia with t(16;16)(p13;q22)
547864|NCT00509691|adult acute myeloid leukemia with t(8;21)(q22;q22)
547865|NCT00509691|accelerated phase chronic myelogenous leukemia
547866|NCT00509691|adult acute lymphoblastic leukemia in remission
547867|NCT00509691|adult acute myeloid leukemia in remission
547868|NCT00509691|atypical chronic myeloid leukemia, BCR-ABL1 negative
547869|NCT00509691|blastic phase chronic myelogenous leukemia
547870|NCT00509691|childhood acute lymphoblastic leukemia in remission
547871|NCT00509691|childhood acute myeloid leukemia in remission
547872|NCT00509691|childhood chronic myelogenous leukemia
547873|NCT00509691|chronic eosinophilic leukemia
547874|NCT00509691|primary myelofibrosis
547875|NCT00509691|chronic myelomonocytic leukemia
547876|NCT00509691|chronic neutrophilic leukemia
547877|NCT00509691|chronic phase chronic myelogenous leukemia
547878|NCT00509691|de novo myelodysplastic syndromes
547879|NCT00509691|disseminated neuroblastoma
547880|NCT00509691|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
547881|NCT00509691|juvenile myelomonocytic leukemia
547882|NCT00509691|myelodysplastic/myeloproliferative neoplasm, unclassifiable
547883|NCT00509691|nodal marginal zone B-cell lymphoma
547884|NCT00509691|noncontiguous stage II adult Burkitt lymphoma
547885|NCT00509691|noncontiguous stage II adult diffuse large cell lymphoma
547886|NCT00509691|noncontiguous stage II adult diffuse mixed cell lymphoma
547887|NCT00509691|noncontiguous stage II adult diffuse small cleaved cell lymphoma
547888|NCT00509691|noncontiguous stage II adult immunoblastic large cell lymphoma
547889|NCT00509691|noncontiguous stage II adult lymphoblastic lymphoma
547890|NCT00509691|noncontiguous stage II grade 1 follicular lymphoma
547891|NCT00509691|noncontiguous stage II grade 2 follicular lymphoma
547892|NCT00509691|noncontiguous stage II grade 3 follicular lymphoma
547893|NCT00509691|noncontiguous stage II mantle cell lymphoma
547894|NCT00509691|noncontiguous stage II marginal zone lymphoma
547895|NCT00509691|noncontiguous stage II small lymphocytic lymphoma
547896|NCT00509691|high risk metastatic gestational trophoblastic tumor
547897|NCT00509691|previously treated childhood rhabdomyosarcoma
547898|NCT00509691|previously treated myelodysplastic syndromes
547899|NCT00509691|recurrent adult acute lymphoblastic leukemia
547900|NCT00509691|recurrent adult acute myeloid leukemia
547901|NCT00509691|recurrent adult Burkitt lymphoma
547902|NCT00509691|recurrent adult Hodgkin lymphoma
547903|NCT00509691|recurrent adult diffuse large cell lymphoma
547904|NCT00509691|recurrent adult diffuse mixed cell lymphoma
547905|NCT00509691|recurrent adult diffuse small cleaved cell lymphoma
547906|NCT00509691|recurrent adult immunoblastic large cell lymphoma
547907|NCT00509691|recurrent adult lymphoblastic lymphoma
547908|NCT00509691|recurrent breast cancer
547909|NCT00509691|recurrent/refractory childhood Hodgkin lymphoma
547910|NCT00509691|recurrent childhood acute lymphoblastic leukemia
547911|NCT00509691|recurrent childhood acute myeloid leukemia
547912|NCT00509691|recurrent childhood large cell lymphoma
547913|NCT00509691|recurrent childhood lymphoblastic lymphoma
547914|NCT00509691|recurrent childhood rhabdomyosarcoma
547915|NCT00509691|recurrent childhood small noncleaved cell lymphoma
547916|NCT00509691|recurrent cutaneous T-cell non-Hodgkin lymphoma
547917|NCT00509691|recurrent grade 1 follicular lymphoma
547918|NCT00509691|recurrent grade 2 follicular lymphoma
547919|NCT00509691|recurrent grade 3 follicular lymphoma
547920|NCT00509691|recurrent mantle cell lymphoma
547921|NCT00509691|recurrent marginal zone lymphoma
547922|NCT00509691|recurrent mycosis fungoides/Sezary syndrome
547923|NCT00509691|recurrent neuroblastoma
547924|NCT00509691|recurrent ovarian epithelial cancer
547925|NCT00509691|recurrent ovarian germ cell tumor
547926|NCT00509691|recurrent small lymphocytic lymphoma
547927|NCT00509691|recurrent malignant testicular germ cell tumor
547928|NCT00509691|recurrent Wilms tumor and other childhood kidney tumors
547929|NCT00509691|refractory chronic lymphocytic leukemia
547930|NCT00509691|refractory hairy cell leukemia
547931|NCT00509691|refractory multiple myeloma
547932|NCT00509691|relapsing chronic myelogenous leukemia
547933|NCT00509691|secondary acute myeloid leukemia
547934|NCT00509691|secondary myelodysplastic syndromes
547935|NCT00509691|splenic marginal zone lymphoma
547936|NCT00509691|stage I multiple myeloma
547937|NCT00509691|stage II multiple myeloma
547938|NCT00509691|stage III adult Burkitt lymphoma
547939|NCT00509691|stage III adult Hodgkin lymphoma
547940|NCT00509691|stage III adult diffuse large cell lymphoma
547941|NCT00509691|stage III adult diffuse mixed cell lymphoma
547942|NCT00509691|stage III adult diffuse small cleaved cell lymphoma
547943|NCT00509691|stage III adult immunoblastic large cell lymphoma
547944|NCT00509691|stage III adult lymphoblastic lymphoma
547945|NCT00509691|stage III chronic lymphocytic leukemia
547946|NCT00509691|stage III grade 1 follicular lymphoma
547947|NCT00509691|stage III grade 2 follicular lymphoma
547948|NCT00509691|stage III grade 3 follicular lymphoma
547949|NCT00509691|stage III mantle cell lymphoma
547950|NCT00509691|stage III marginal zone lymphoma
547951|NCT00509691|stage III multiple myeloma
547952|NCT00509691|stage III small lymphocytic lymphoma
547953|NCT00509691|stage III malignant testicular germ cell tumor
547954|NCT00509691|stage IIIA breast cancer
547955|NCT00509691|stage IIIB breast cancer
547956|NCT00509691|stage IIIC breast cancer
547957|NCT00509691|stage IV adult Burkitt lymphoma
547958|NCT00509691|stage IV adult Hodgkin lymphoma
547959|NCT00509691|stage IV adult diffuse large cell lymphoma
547960|NCT00509691|stage IV adult diffuse mixed cell lymphoma
547961|NCT00509691|stage IV adult diffuse small cleaved cell lymphoma
547962|NCT00509691|stage IV adult immunoblastic large cell lymphoma
547963|NCT00509691|stage IV adult lymphoblastic lymphoma
547964|NCT00509691|stage IV breast cancer
547965|NCT00509691|stage IV chronic lymphocytic leukemia
547966|NCT00509691|stage IV grade 1 follicular lymphoma
547967|NCT00509691|stage IV grade 2 follicular lymphoma
547968|NCT00509691|stage IV grade 3 follicular lymphoma
547969|NCT00509691|stage IV mantle cell lymphoma
547970|NCT00509691|stage IV marginal zone lymphoma
547971|NCT00509691|stage IV ovarian epithelial cancer
547972|NCT00509691|stage IV small lymphocytic lymphoma
547973|NCT00509691|stage IIA ovarian epithelial cancer
547974|NCT00509691|stage IIA ovarian germ cell tumor
547975|NCT00509691|stage IIB ovarian epithelial cancer
547976|NCT00509691|stage IIB ovarian germ cell tumor
547977|NCT00509691|stage IIC ovarian epithelial cancer
547978|NCT00509691|stage IIC ovarian germ cell tumor
547979|NCT00509691|stage IIIA ovarian epithelial cancer
547980|NCT00509691|stage IIIA ovarian germ cell tumor
547981|NCT00509691|stage IIIB ovarian epithelial cancer
547982|NCT00509691|stage IIIB ovarian germ cell tumor
547983|NCT00509691|stage IIIC ovarian epithelial cancer
547984|NCT00509691|stage IIIC ovarian germ cell tumor
547985|NCT00509691|stage IV ovarian germ cell tumor
547986|NCT00509678|Rituximab
547987|NCT00509678|Rituxan
547988|NCT00509678|Psoriatic Arthritis
547989|NCT00509678|Arthritis
547990|NCT00509665|recurrent squamous cell carcinoma of the hypopharynx
547991|NCT00509665|recurrent squamous cell carcinoma of the larynx
547992|NCT00509665|recurrent verrucous carcinoma of the larynx
547993|NCT00509665|recurrent adenoid cystic carcinoma of the oral cavity
547994|NCT00509665|recurrent basal cell carcinoma of the lip
547995|NCT00509665|recurrent mucoepidermoid carcinoma of the oral cavity
547996|NCT00509665|recurrent squamous cell carcinoma of the lip and oral cavity
547997|NCT00509665|recurrent verrucous carcinoma of the oral cavity
547998|NCT00509665|recurrent metastatic squamous neck cancer with occult primary
547999|NCT00509665|recurrent lymphoepithelioma of the nasopharynx
548000|NCT00509665|recurrent squamous cell carcinoma of the nasopharynx
548001|NCT00509665|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
548002|NCT00509665|recurrent inverted papilloma of the paranasal sinus and nasal cavity
548003|NCT00509665|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
548004|NCT00509665|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
548005|NCT00509665|recurrent salivary gland cancer
548006|NCT00509665|recurrent lymphoepithelioma of the oropharynx
548007|NCT00509665|recurrent squamous cell carcinoma of the oropharynx
548008|NCT00509652|Hemochromatosis
548009|NCT00509652|Primary hemochromatosis
548010|NCT00509652|Hereditary hemochromatosis
548011|NCT00509652|Therapy
548012|NCT00509652|Erythrocyte apheresis
548013|NCT00509652|Phlebotomy
548014|NCT00509652|Apheresis
548015|NCT00509652|Efficacy
548016|NCT00509626|fatigue
548017|NCT00509626|psychosocial effects of cancer and its treatment
548018|NCT00509626|weight changes
548019|NCT00509626|depression
548020|NCT00509626|stage I breast cancer
548021|NCT00509626|stage II breast cancer
548022|NCT00509600|Juvenile Myelomonocytic Leukemia
548023|NCT00509600|JMML
548024|NCT00509600|Leukemia
548025|NCT00509600|Etanercept
548026|NCT00509600|Enbrel
548027|NCT00509574|Single Nucleotide Polymorphism
548028|NCT00509574|statins
548029|NCT00509574|hyperlipidemia
548030|NCT00509561|adenocarcinoma of the esophagus
548031|NCT00509561|squamous cell carcinoma of the esophagus
548032|NCT00509561|stage IA esophageal cancer
548033|NCT00509561|stage IB esophageal cancer
548034|NCT00509561|stage IIA esophageal cancer
548035|NCT00509561|stage IIB esophageal cancer
548036|NCT00509561|stage IIIA esophageal cancer
548037|NCT00509561|stage IIIB esophageal cancer
548038|NCT00509561|stage IIIC esophageal cancer
548039|NCT00509535|Vitreoscilla filiformis extract
548040|NCT00509535|SCORAD
548041|NCT00509535|pruritus
548042|NCT00509535|microflora
548043|NCT00509535|TEWL
548044|NCT00509509|Hereditary Breast Cancer (BRCA1, BRCA2)
548045|NCT00509496|Refractory
548046|NCT00509496|Gene Therapy
548047|NCT00509496|HLA-A2 Positive
548048|NCT00509496|Stage IV Melanoma
548049|NCT00509496|Melanoma
548050|NCT00509496|Skin Cancer
548051|NCT00509496|Malignant Melanoma
548052|NCT00509483|multinodular
548053|NCT00509483|goitre
548054|NCT00509483|recombinant human TSH
548055|NCT00509457|NSCLC, vaccination
548056|NCT00509457|Inoperable NSCLC stage IIIA/B in good performance status
548057|NCT00509431|adult giant cell glioblastoma
548058|NCT00509431|adult gliosarcoma
548059|NCT00509431|adult anaplastic astrocytoma
548060|NCT00509431|adult anaplastic oligodendroglioma
548061|NCT00509431|adult mixed glioma
548062|NCT00509431|recurrent adult brain tumor
548063|NCT00509431|adult glioblastoma
548064|NCT00509431|adult pilocytic astrocytoma
548065|NCT00509431|adult diffuse astrocytoma
548066|NCT00509431|adult subependymal giant cell astrocytoma
548067|NCT00509431|adult oligodendroglioma
548068|NCT00509418|Nonalcoholic steatohepatitis
548069|NCT00509418|Nonalcoholic Fatty Liver
548070|NCT00509418|Nutritional supplement
548071|NCT00509418|Diet
548072|NCT00509418|Exercise
548073|NCT00509405|Endogenous acid production
548074|NCT00509405|metabolic acidosis
548075|NCT00509405|potassium citrate
548076|NCT00509405|osteoporosis
548077|NCT00509405|sarcopenia
548078|NCT00509405|hypertension
548079|NCT00509405|Effect of potassium citrate on bone mineral density and bone mass
548080|NCT00509392|Varicose veins, venous reflux, GSV disease
548081|NCT00509379|Relapsed/refractory indolent lymphoma
548082|NCT00509379|Non-follicular Lymphoma
548083|NCT00509379|Mantle cell non-Hodgkin Lymphoma
548084|NCT00509379|Patients naïve or sensitive to rituximab
548085|NCT00509379|Patients not eligible for high dose chemotherapy with ASCT
548086|NCT00509366|genomics
548087|NCT00509366|genomics predictor
548088|NCT00509366|genomics analysis
548089|NCT00509366|squamous
548090|NCT00509366|non-squamous
548091|NCT00509353|recurrent neuroblastoma
548092|NCT00509340|antiretroviral
548093|NCT00509340|adherence
548094|NCT00509340|poor antiretroviral adherence
548095|NCT00509327|postoperative ileus
548096|NCT00509327|colorectal surgery
548097|NCT00509327|bisacodyl
548098|NCT00509327|laxatives
548099|NCT00509301|brain cancer
548100|NCT00509301|Cotara
548101|NCT00509301|radioactive isotope
548102|NCT00509301|monoclonal antibody
548103|NCT00509301|radiation distribution
548104|NCT00509288|Refractory
548105|NCT00509288|Gene Therapy
548106|NCT00509288|HLA-A2 Positive
548107|NCT00509288|Stage IV Melanoma
548108|NCT00509288|Melanoma
548109|NCT00509288|Skin Cancer
548110|NCT00509288|Malignant Melanoma
548111|NCT00509223|Type 2 diabetes
548112|NCT00509223|Obstructive sleep apnea
548113|NCT00509223|Glycemic control
548114|NCT00509223|Insulin resistance
548115|NCT00509223|Sleep disordered breathing
548116|NCT00509210|Liver Disease
548117|NCT00509197|Asthma
548118|NCT00509197|Non-eosinophilic Asthma
548119|NCT00509197|sputum eosinophils
548120|NCT00509197|Inhaled Corticosteroids
548121|NCT00509184|untreated
548122|NCT00509171|embolism
548123|NCT00509171|femur fracture
548124|NCT00509171|lavage
548125|NCT00509171|TEE
548126|NCT00509171|reamer
548127|NCT00509171|IM nail
548128|NCT00509158|safety
548129|NCT00509158|immunogenicity
548130|NCT00509158|efficacy
548131|NCT00509145|Relapsing
548132|NCT00509145|Remitting
548133|NCT00509119|apoplexia
548134|NCT00509119|Intracranial and intraarterial pressure curves in acute apoplectic patients
548135|NCT00509106|ceftaroline
548136|NCT00509106|Community-acquired pneumonia
548137|NCT00509106|CAP
548138|NCT00509106|Streptococcus pneumoniae
548139|NCT00509106|Haemophilus influenzae
548140|NCT00509106|Mycoplasma pneumoniae
548141|NCT00509106|chlamydophila spp
548142|NCT00509106|Legionella ssp
548143|NCT00509106|multi-drug resistant Streptococcus pneumoniae (MDRSP)
548144|NCT00509106|antimicrobial resistance
548145|NCT00509106|pneumococci
548146|NCT00509106|beta-lactam
548147|NCT00509106|ceftaroline fosamil
548148|NCT00509106|ceftriaxone
548149|NCT00509106|antibiotic
548150|NCT00509093|adult acute minimally differentiated myeloid leukemia (M0)
548151|NCT00509093|adult acute myeloblastic leukemia with maturation (M2)
548152|NCT00509093|adult acute myeloblastic leukemia without maturation (M1)
548153|NCT00509093|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
548154|NCT00509093|adult acute myeloid leukemia with inv(16)(p13;q22)
548155|NCT00509093|adult acute myeloid leukemia with t(16;16)(p13;q22)
548156|NCT00509093|adult acute myeloid leukemia with t(8;21)(q22;q22)
548157|NCT00509093|adult acute myelomonocytic leukemia (M4)
548158|NCT00509093|adult acute megakaryoblastic leukemia (M7)
548159|NCT00509093|adult acute monoblastic leukemia (M5a)
548160|NCT00509093|adult acute monocytic leukemia (M5b)
548161|NCT00509093|adult erythroleukemia (M6a)
548162|NCT00509093|adult pure erythroid leukemia (M6b)
548163|NCT00509093|adult acute basophilic leukemia
548164|NCT00509093|adult acute eosinophilic leukemia
548165|NCT00509093|adult acute myeloid leukemia in remission
548166|NCT00509080|mitral regurgitation
548167|NCT00509080|BNP
548168|NCT00509080|NT-proBNP
548169|NCT00509080|natriuretic peptides
548170|NCT00509080|valvular heart disease
548171|NCT00509067|Schizoaffective Disorder
548172|NCT00509067|Acetylcholine
548173|NCT00509067|Nicotinic Receptors
548174|NCT00509067|Nicotine
548175|NCT00509067|Galantamine
548176|NCT00509067|negative symptoms
548177|NCT00509054|Parastomal hernia, wound infection, stoma care.
548178|NCT00509041|advanced malignant mesothelioma
548179|NCT00509041|epithelial mesothelioma
548180|NCT00509041|recurrent malignant mesothelioma
548181|NCT00509041|sarcomatous mesothelioma
548182|NCT00509028|Asthma
548183|NCT00509028|Bronchial
548184|NCT00509015|antimalarials
548185|NCT00509015|malaria transmission
548186|NCT00509015|mass drug administration
548187|NCT00509015|artemisinin-based combination therapy
548188|NCT00509015|primaquine
548189|NCT00509015|gametocytes
548190|NCT00509015|QT-NASBA
548191|NCT00509002|Salivary Gland Cancer
548192|NCT00509002|Iressa
548193|NCT00509002|ZD1839
548194|NCT00508989|Acetylcholine
548195|NCT00508989|Forearm Blood Flow
548196|NCT00508989|HDL
548197|NCT00508989|L-NMMA
548198|NCT00508989|Sickle Cell Anemia
548199|NCT00508989|Sickle Cell Disease
548200|NCT00508976|bupivacaine
548201|NCT00508976|marcaine
548202|NCT00508976|lidocaine
548203|NCT00508976|normal saline
548204|NCT00508976|narcotics
548205|NCT00508976|analog pain scale
548206|NCT00508976|postoperative pain
548207|NCT00508976|preemptive
548208|NCT00508976|aerosolization
548209|NCT00508976|streamed
548210|NCT00508963|New World Cutaneous or Mucocutaneous Leishmaniasis
548211|NCT00508950|Vaccines
548212|NCT00508950|Pneumococcal Conjugate Vaccine
548213|NCT00508950|Adult
548214|NCT00508937|Diet
548215|NCT00508937|Protein
548216|NCT00508937|Glucose
548217|NCT00508937|Insulin
548218|NCT00508937|Cholesterol
548219|NCT00508937|Triglycerides
548220|NCT00508937|LDL subclasses
548221|NCT00508924|Argatroban
548222|NCT00508924|Direct thrombin inhibitor
548223|NCT00508924|Percutaneous coronary intervention
548224|NCT00508924|Activated clotting time
548225|NCT00508924|PCI
548226|NCT00508924|ACT
548227|NCT00508911|open-label,
548228|NCT00508911|repeat-dose,
548229|NCT00508911|single-sequence,
548230|NCT00508911|GW876008,
548231|NCT00508911|pharmacokinetics,
548232|NCT00508911|oral contraceptive,
548233|NCT00508911|Combine Oral Contraceptives,
548234|NCT00508911|female,
548235|NCT00508911|volunteers
548236|NCT00508898|lupus nephritis
548237|NCT00508898|proteinuria
548238|NCT00508898|chronic kidney diseases
548239|NCT00508898|SLE
548240|NCT00508885|hyperphosphatemia
548241|NCT00508885|niacinamide
548242|NCT00508885|ESRD
548243|NCT00508885|peritoneal dialysis
548244|NCT00508885|renal osteodystrophy
548245|NCT00508872|Colorectal Liver Metastases
548246|NCT00508872|Oxaliplatin
548247|NCT00508872|Eloxatin
548248|NCT00508872|Fluorouracil
548249|NCT00508872|Leucovorin
548250|NCT00508872|Bevacizumab
548377|NCT00508482|Functional constipation
548251|NCT00508872|Anti-VEGF monoclonal antibody
548252|NCT00508872|rhuMAb-VEGF
548253|NCT00508872|Folfox-B
548254|NCT00508872|5-FU
548255|NCT00508872|Avastin
548256|NCT00508859|depression
548257|NCT00508859|adolescents
548258|NCT00508859|maintenance treatment
548259|NCT00508859|antidepressant
548260|NCT00508846|Hereditary Non-Polyposis Colon Cancer
548261|NCT00508846|Gynecologic Cancers
548262|NCT00508846|Genetic Counseling
548263|NCT00508846|Questionnaire
548264|NCT00508846|Survey
548265|NCT00508846|HNPCC
548266|NCT00508833|Adjuvants
548267|NCT00508833|HBsAg
548268|NCT00508820|Platelet
548269|NCT00508820|AMG 531
548270|NCT00508820|Thrombopoietin
548271|NCT00508820|blood disorder
548272|NCT00508820|bleeding disorder
548273|NCT00508820|immune thrombocytopenic purpura
548274|NCT00508820|idiopathic thrombocytopenic purpura
548275|NCT00508820|immune (idiopathic) thrombocytopenic purpura
548276|NCT00508820|TPO
548277|NCT00508820|thrombopoietic protein
548278|NCT00508807|Lymphoid Malignancies
548279|NCT00508807|Solid Tumors
548280|NCT00508807|RTA 402
548281|NCT00508794|Breast Cancer
548282|NCT00508794|Tibetan Yoga
548283|NCT00508794|Stretching Program
548284|NCT00508794|Yoga
548285|NCT00508794|Quality of Life
548286|NCT00508794|Questionnaire
548287|NCT00508794|Survey
548288|NCT00508768|Rheumatoid Arthritis
548289|NCT00508768|Methotrexate
548290|NCT00508755|cerebrovascular accident
548291|NCT00508755|electrical stimulation
548292|NCT00508755|gait training
548293|NCT00508755|motor learning
548294|NCT00508742|Nasopharyngeal Colonization
548295|NCT00508742|Streptococcus pneumoniae
548296|NCT00508742|Healthy Infants
548297|NCT00508742|Vaccines
548298|NCT00508742|Pneumococcal Conjugate Vaccine
548299|NCT00508716|Congestive Heart Failure
548300|NCT00508716|Health Literacy
548301|NCT00508716|Health Education
548302|NCT00508716|Congestive Heart Failure (inpatients)
548303|NCT00508703|Uterine Cancer
548304|NCT00508703|Cervical Cancer
548305|NCT00508703|Endometrial Cancer
548306|NCT00508703|Intensity Modulated Radiotherapy
548307|NCT00508703|IMRT
548308|NCT00508703|Computed Tomography
548309|NCT00508703|CT
548310|NCT00508703|CT Scan
548311|NCT00508690|Antibiotic Prophylaxis
548312|NCT00508690|Colorectal Surgery
548313|NCT00508690|Laparoscopy
548314|NCT00508677|Attention Deficit Hyperactivity Disorder
548315|NCT00508677|Mazindol
548316|NCT00508664|by laryngectomy operable carcinoma of the larynx and the hypopharynx
548317|NCT00508651|parainfluenza virus, children, vaccine
548318|NCT00508638|Heart Failure
548319|NCT00508612|Blood Pressure
548320|NCT00508612|Systolic Blood Pressure
548321|NCT00508612|Diastolic Blood Pressure
548322|NCT00508612|Ambulatory Blood Pressure Monitoring
548323|NCT00508612|Relaxation
548324|NCT00508612|Meditation
548325|NCT00508612|Coping Skills
548326|NCT00508612|Adolescents
548327|NCT00508599|type 2 diabetes
548328|NCT00508599|bed rest
548329|NCT00508599|insulin resistance
548330|NCT00508599|insulin
548331|NCT00508599|glucose
548332|NCT00508599|orthostatic response
548333|NCT00508586|Breast cancer
548334|NCT00508586|PTC299
548335|NCT00508586|VEGF
548336|NCT00508586|Angiogenesis
548337|NCT00508586|Post-transcriptional control
548338|NCT00508586|Aromatase inhibitors
548339|NCT00508573|Hereditary Nonpolyposis Colorectal Cancer
548340|NCT00508573|Lynch Syndrome
548341|NCT00508573|HNPCC
548342|NCT00508573|Syndrome Registry
548343|NCT00508573|Questionnaire
548344|NCT00508573|Endometrial cancer
548345|NCT00508573|Ovarian cancer
548346|NCT00508560|Contingency management
548347|NCT00508560|Smoking cessation
548348|NCT00508560|Psychotic disorders
548349|NCT00508560|Veterans
548350|NCT00508547|Methotrexate
548351|NCT00508547|Acitretin
548352|NCT00508547|Cyclosporine
548353|NCT00508547|Systemic PUVA
548354|NCT00508547|Infliximab
548355|NCT00508547|Adalimumab
548356|NCT00508547|Alefacept
548357|NCT00508547|Efalizumab
548358|NCT00508547|Etanercept
548359|NCT00508547|Psoriasis
548360|NCT00508547|Psoriatic arthritis
548361|NCT00508547|Skin disease
548362|NCT00508547|Cosentyx
548363|NCT00508534|pharmacokinetic study,
548364|NCT00508534|gastric pH
548365|NCT00508521|cerebrovascular accident
548366|NCT00508521|electrical stimulation
548367|NCT00508521|motor learning
548368|NCT00508521|upper extremity rehabilitation
548369|NCT00508508|Heart Failure
548370|NCT00508508|Peer Support
548371|NCT00508508|Self Management
548372|NCT00508495|pain, postoperative
548373|NCT00508495|replacement, total hip
548374|NCT00508495|total hip replacement
548375|NCT00508495|arthroplasty, replacement, hip
548376|NCT00508482|Acupuncture
548378|NCT00508469|Intraocular pressure
548379|NCT00508469|Open-angle glaucoma
548380|NCT00508469|Ocular hypertension
548381|NCT00508469|Adherence
548382|NCT00508469|Compliance
548383|NCT00508456|Glioblastoma Multiforme
548384|NCT00508456|Methionine Restriction
548385|NCT00508456|Hominex-2
548386|NCT00508456|Methionine Restriction Diet
548387|NCT00508456|Hominex-2 Amino Acid-Modified Medical Food
548388|NCT00508456|Temozolomide
548389|NCT00508456|Temodar
548390|NCT00508443|Stereotactic Spine Radiotherapy System
548391|NCT00508443|SSRS
548392|NCT00508443|CT-on-Rails
548393|NCT00508443|Metastatic Spine Disease
548394|NCT00508443|Spinal Neoplasms
548395|NCT00508443|Radiation Therapy
548396|NCT00508443|Trilogy
548397|NCT00508443|Cancer
548398|NCT00508443|Breast Cancer
548399|NCT00508443|Gastrointestinal Cancer
548400|NCT00508443|Genitourinary Disease
548401|NCT00508443|Lung Cancer
548402|NCT00508443|Lymphoma
548403|NCT00508443|Melanoma
548404|NCT00508443|Sarcoma
548405|NCT00508443|Spinal Cancer
548406|NCT00508430|ASP8825
548407|NCT00508430|Diabetic Neuropathies
548408|NCT00508430|Pain
548409|NCT00508417|Malaria Incidence
548410|NCT00508417|Anemia
548411|NCT00508417|Clinical Malaria
548412|NCT00508378|Ovarian Cancer
548413|NCT00508378|Quality of Life
548414|NCT00508378|Chemotherapy Side-Effects
548415|NCT00508378|Interview
548416|NCT00508378|Questionnaire
548417|NCT00508378|Caregivers
548418|NCT00508365|lisinopril
548419|NCT00508365|carvedilol
548420|NCT00508365|hypertension
548421|NCT00508352|breast
548422|NCT00508352|cancer
548423|NCT00508352|locoregional
548424|NCT00508352|IMRT
548425|NCT00508352|tomotherapy
548426|NCT00508339|Soft Tissue Sarcoma
548427|NCT00508339|Limb Sparing Surgery
548428|NCT00508339|Toronto Extremity Salvage Score
548429|NCT00508339|Radiotherapy
548430|NCT00508339|Quality of Life
548431|NCT00508339|Questionnaire
548432|NCT00508339|Survey
548433|NCT00508339|TESS
548434|NCT00508326|Advanced Cancer
548435|NCT00508326|Solid Tumor
548436|NCT00508326|Liver Metastasis
548437|NCT00508326|Hepatic Artery Infusion
548438|NCT00508326|Liver
548439|NCT00508326|Paclitaxel
548440|NCT00508326|Taxol
548441|NCT00508313|Lung Cancer
548442|NCT00508313|Healthy Control
548443|NCT00508313|Thermal Imaging
548444|NCT00508313|Thermal Signatures
548445|NCT00508313|Radiation Therapy
548446|NCT00508313|Chemoradiation Therapy
548447|NCT00508300|laparoscopic
548448|NCT00508300|colectomy
548449|NCT00508300|Fast Track
548450|NCT00508300|epidural
548451|NCT00508274|Advanced Metastatic Breast Cancer
548452|NCT00508274|breast cancer
548453|NCT00508274|lapatinib
548454|NCT00508274|HER2+ positive
548455|NCT00508274|TYVERB
548456|NCT00508274|TYKERB
548457|NCT00508261|Meningococcal vaccine
548458|NCT00508261|Immunogenicity
548459|NCT00508261|Routine infancy vaccination
548460|NCT00508261|Safety
548461|NCT00508248|omega 3fatty acids
548462|NCT00508235|Neurofibromatosis
548463|NCT00508235|Quality of Friendships
548464|NCT00508235|Disease Severity
548465|NCT00508235|Questionnaire
548466|NCT00508235|NF-1
548467|NCT00508222|HIV
548468|NCT00508222|HCV
548469|NCT00508222|HIV/HCV Co-infection
548470|NCT00508222|Kaletra Monotherapy
548471|NCT00508222|Treatment Experienced
548472|NCT00508209|high-dose melphalan
548473|NCT00508209|bortezomib
548474|NCT00508209|response
548475|NCT00508209|toxicity
548476|NCT00508209|relapse
548477|NCT00508196|right ventricular pacing
548478|NCT00508196|endothelial function
548479|NCT00508196|cardiac output
548480|NCT00508183|full thickness rotator cuff tear
548481|NCT00508170|Head and Neck Cancer
548482|NCT00508170|Human Papillomavirus Infection
548483|NCT00508170|Oropharyngeal Patients
548484|NCT00508170|Sexual Behavior
548485|NCT00508170|Questionnaire
548486|NCT00508144|Non-Small Cell Lung Cancer
548487|NCT00508144|Lung Cancer
548488|NCT00508144|NSCLC
548489|NCT00508144|Malignant pleural effusion
548490|NCT00508144|Pericardial effusion
548491|NCT00508144|Pemetrexed
548492|NCT00508144|Alimta
548493|NCT00508144|LY231514
548494|NCT00508144|Poor Performance Status
548495|NCT00508144|Asymptomatic Brain Metastases
548496|NCT00508131|Milk fortification
548497|NCT00508131|Effectivness evaluation
548498|NCT00508131|Iron deficiency anemia
548499|NCT00508131|Stunting
548500|NCT00508131|Zinc deficiency
548501|NCT00508118|Aortic Arch Reconstruction Surgery
548502|NCT00508105|Osteoarthritis
548503|NCT00508105|Shoulder
548504|NCT00508105|tenotomy
548505|NCT00508105|ostotomy
548506|NCT00508092|appendicectomy
548507|NCT00508092|pain
548508|NCT00508092|local anaesthetic
548509|NCT00508092|nerve block
548510|NCT00508092|Post operative pain following appendicectomy
548511|NCT00508079|Venous Disease
548512|NCT00508079|Varicose Veins
548513|NCT00508079|Chronic Venous Insufficiency
548514|NCT00508079|PAD
548515|NCT00508066|Congenital Scoliosis
548516|NCT00508066|Idiopathic Scoliosis
548517|NCT00508066|Spinal Fusion
548518|NCT00508066|Post-Operative Pain Management
548519|NCT00508066|Infusion Catheter
548520|NCT00508053|wound infection
548521|NCT00508053|incisional hernia
548522|NCT00508053|wound dehiscence
548523|NCT00508053|wound healing
548524|NCT00508053|postoperative complications
548525|NCT00508053|surgical techniques
548526|NCT00508040|Birdshot Retine choroidopathy
548527|NCT00508040|Macular edema
548528|NCT00508040|Prednisone
548529|NCT00508040|Interferon alpha 2a
548530|NCT00508040|Associated with Cystoid macular edema
548531|NCT00508040|With Visual acuity loss
548532|NCT00508027|sickle cell disease
548533|NCT00508027|simvastatin
548534|NCT00508027|statin drugs
548535|NCT00508027|nitric oxide donors
548536|NCT00508027|vascular injury
548537|NCT00508014|Cardiovascular disease
548538|NCT00508014|Diabetes
548539|NCT00508014|Quality improvement
548540|NCT00508014|Peer review
548541|NCT00508001|Hepatocellular carcinoma
548542|NCT00508001|Advanced solid, malignant tumour
548543|NCT00507988|Cognitive Training
548544|NCT00507988|Complex Problem Solving
548545|NCT00507988|Goal Management
548546|NCT00507988|Planning
548547|NCT00507975|Smoking
548548|NCT00507975|pregnancy
548549|NCT00507975|newborn
548550|NCT00507975|birth weight
548551|NCT00507975|nicotine patch
548552|NCT00507975|birth
548553|NCT00507962|Advanced Cancer
548554|NCT00507962|Dominant Liver Involvement
548555|NCT00507962|Hepatic Intraarterial Cisplatin
548556|NCT00507962|Cisplatin
548557|NCT00507962|Liposomal Doxorubicin
548558|NCT00507962|Platinol-AQ
548559|NCT00507962|Platinol
548560|NCT00507962|CDDP
548561|NCT00507962|Doxil
548562|NCT00507962|Liposomal
548563|NCT00507962|Doxorubicin Hydrochloride
548564|NCT00507949|COPD
548565|NCT00507949|body weight
548566|NCT00507949|megestrol acetate
548567|NCT00507949|cytokines
548568|NCT00507936|Diabetic Neuropathy
548569|NCT00507936|Painful
548570|NCT00507936|Diabetic Polyneuropathy
548571|NCT00507936|Neuralgia
548572|NCT00507936|Diabetic
548573|NCT00507936|Diabetic Neuropathies
548574|NCT00507936|Diabetic Neuralgia
548575|NCT00507923|Breast Cancer
548576|NCT00507923|Tibetan Yoga
548577|NCT00507923|Stretching
548578|NCT00507923|Yoga
548579|NCT00507923|Fatigue
548580|NCT00507923|Sleep
548581|NCT00507923|Questionnaire
548582|NCT00507923|Survey
548583|NCT00507910|ankle fracture
548584|NCT00507910|pes planus
548585|NCT00507897|thyroid nodules, blood pressure, thyroid hormones
548586|NCT00507884|Kidney Neoplasms
548587|NCT00507884|Renal Tumors
548588|NCT00507884|Magnetic Resonance Imaging
548589|NCT00507884|3 Tesla MRI
548590|NCT00507884|MRI
548591|NCT00507871|cryptosporidiosis, Cryptosporidium, Uganda, diarrhea
548592|NCT00507858|Head and Neck Cancer
548593|NCT00507858|Squamous Cell Cancer
548594|NCT00507858|Alimta
548595|NCT00507858|Pemetrexed
548596|NCT00507858|Dexamethasone
548597|NCT00507858|HNSCC
548598|NCT00507858|Decadron
548599|NCT00507832|Prurigo nodularis
548600|NCT00507819|Other Single Ventricle Anatomy
548601|NCT00507819|Hypoplastic Left Heart Syndrome
548602|NCT00507819|Tricuspid Atresia
548603|NCT00507806|Acute Ischemic Stroke
548604|NCT00507806|Microbubbles
548605|NCT00507806|Transcranial Doppler ultrasound
548606|NCT00507806|TIBI
548607|NCT00507806|Symptomatic Intracranial Hemorrhage
548608|NCT00507806|modified Rankin Scale
548609|NCT00507806|Recanalization
548610|NCT00507806|Perflutren
548611|NCT00507780|GnRH Antagonist
548612|NCT00507780|Premature Ovarian Failure
548613|NCT00507780|Fertility
548614|NCT00507780|Chemotherapy
548615|NCT00507780|POF
548616|NCT00507754|Advanced Cancer
548617|NCT00507754|Solid Tumors
548618|NCT00507754|Latent Mycobacterium Tuberculosis
548619|NCT00507754|Tuberculin Skin Test
548620|NCT00507754|Tuberculosis
548621|NCT00507754|T-SPOT TB test
548622|NCT00507754|TB
548623|NCT00507741|Cancer
548624|NCT00507741|Ovarian
548625|NCT00507741|Endometrial
548626|NCT00507741|Phase II
548627|NCT00507741|EC145
548628|NCT00507741|EC20
548629|NCT00507728|Pharmacogenetics
548630|NCT00507728|Emotional Reactivity
548631|NCT00507728|Smoking Cessation Counseling
548632|NCT00507728|Smoking
548633|NCT00507728|Bupropion
548634|NCT00507728|Wellbutrin
548635|NCT00507728|Wellbutrin SR
548636|NCT00507728|Zyban
548637|NCT00507728|Varenicline
548638|NCT00507728|Chantix
548639|NCT00507728|Placebo
548640|NCT00507715|Parkinson's Disease, Idiopathic
548641|NCT00507715|l-dopa levels
548642|NCT00507715|plantago ovata husk
548643|NCT00507689|Truvada
548644|NCT00507689|HBIg
548645|NCT00507689|Chronic Hepatitis B Recurrence
548646|NCT00507689|Post Orthotopic Liver Transplant
548647|NCT00507676|Asthma
548648|NCT00507676|Wheezing
548649|NCT00507676|Infant
548650|NCT00507663|beta blocker
548651|NCT00507663|functional recovery
548652|NCT00507650|Pressure ulcers
548653|NCT00507650|Geriatrics
548654|NCT00507650|Nursing home
548655|NCT00507650|Fluid balance
548656|NCT00507650|Collagen deposition
548657|NCT00507611|breast
548658|NCT00507611|sentinel lymph node
548659|NCT00507611|node mapping
548660|NCT00507598|colorectal cancer
548661|NCT00507598|metabolomics
548662|NCT00507585|Liver Cancer
548663|NCT00507585|Liver metastases
548664|NCT00507585|Metastatic advanced solid tumors
548665|NCT00507585|Advanced solid tumors metastatic to the liver
548666|NCT00507585|Hepatic Arterial Infusion
548667|NCT00507585|Intra-arterial hepatic oxaliplatin
548668|NCT00507585|Fluorouracil
548669|NCT00507585|5-FU
548670|NCT00507585|Adrucil
548671|NCT00507585|Efudex
548672|NCT00507585|5-fluorouracil
548673|NCT00507585|Avastin
548674|NCT00507585|Leucovorin
548675|NCT00507585|Oxaliplatin
548676|NCT00507585|Bevacizumab
548677|NCT00507572|Solid Tumors
548678|NCT00507572|Pregnancy
548679|NCT00507572|Data Collection
548680|NCT00507546|sleep
548681|NCT00507546|melatonin
548682|NCT00507546|spinal cord injury
548683|NCT00507546|insomnia
548684|NCT00507546|tetraplegia
548685|NCT00507533|CPAP
548686|NCT00507533|Hematologic
548687|NCT00507533|Neutropenic
548688|NCT00507533|ARF
548689|NCT00507520|RCT
548690|NCT00507520|Almonds
548691|NCT00507520|Hyperlipidemia
548692|NCT00507520|Blood Lipids
548693|NCT00507507|tenofovir
548694|NCT00507507|monotherapy
548695|NCT00507507|emtricitabine
548696|NCT00507507|combination
548697|NCT00507507|hepatitis B
548698|NCT00507494|posttransplant diabetes mellitus
548699|NCT00507494|kidney transplantation
548700|NCT00507494|filtration fraction
548701|NCT00507494|proteinuria
548702|NCT00507481|Sleep
548703|NCT00507481|ICU
548704|NCT00507481|Delirium
548705|NCT00507481|Post surgical ventilated patients
548706|NCT00507481|ICU patients
548707|NCT00507468|bone marrow
548708|NCT00507468|autologous
548709|NCT00507468|ejection fraction
548710|NCT00507468|left ventricle
548711|NCT00507468|heart attack
548712|NCT00507468|myocardial infarction
548713|NCT00507468|left ventricular dysfunction post myocardial infarction
548714|NCT00507455|Lower Urinary Tract Symptoms
548715|NCT00507455|Bladder Outlet Obstruction
548716|NCT00507455|Treatment
548717|NCT00507455|Solifenacin Succinate
548718|NCT00507455|Tamsulosin hydrochloride
548719|NCT00507442|Treatment for patients with multiple myeloma
548720|NCT00507442|who have received no prior treatment
548721|NCT00507429|thyroid neoplasms
548722|NCT00507429|thyroid cancer
548723|NCT00507429|thyroid carcinoma
548724|NCT00507390|fish oils
548725|NCT00507377|Esophageal Benign Disease
548726|NCT00507377|Gastroesophageal Reflux Disease
548727|NCT00507377|Hiatal Hernia
548728|NCT00507377|Antireflux Surgery
548729|NCT00507377|Short Esophagus
548730|NCT00507351|Breast Cancer
548731|NCT00507351|Colorectal Cancer
548732|NCT00507351|Lung Cancer
548733|NCT00507351|Prostate Cancer
548734|NCT00507351|Pain Management
548735|NCT00507351|Questionnaire
548736|NCT00507351|Survey
548737|NCT00507338|percutaneous coronary intervention
548738|NCT00507325|Malignant Melanoma
548739|NCT00507325|Blood Sample
548740|NCT00507325|Tumor Sample
548741|NCT00507325|Long-term storage
548742|NCT00507325|Sample Collection
548743|NCT00507312|To assess two new diagnostic devices for detecting early Heart Failure.
548744|NCT00507299|Child maltreatment
548745|NCT00507299|Physician education
548746|NCT00507299|Prevention
548747|NCT00507273|Gastrointestinal Stromal Tumors
548748|NCT00507273|Gastrointestinal Cancer
548749|NCT00507273|GISTs
548750|NCT00507273|GIST Registry
548751|NCT00507273|Registry
548752|NCT00507260|Leukemia
548753|NCT00507260|Lymphoma
548754|NCT00507260|Post-Allogeneic Blood and Marrow Transplantation
548755|NCT00507260|Blood and Marrow Transplantation
548756|NCT00507260|BMT
548757|NCT00507260|Cancer-Related Fatigue
548758|NCT00507260|Fatigue
548759|NCT00507260|Nutritional Assessment
548760|NCT00507260|Nutritional Intervention
548761|NCT00507260|Malnutrition
548762|NCT00507247|Catheter-Related Infection
548763|NCT00507247|Bloodstream Infections
548764|NCT00507247|Staphylococcus Aureus
548765|NCT00507247|Daptomycin
548766|NCT00507234|COPD
548767|NCT00507221|HIV
548768|NCT00507221|Helminthiasis
548769|NCT00507221|Co-infection
548770|NCT00507221|Treatment Naive
548771|NCT00507208|trismus
548772|NCT00507208|head and neck cancer
548773|NCT00507195|Postanethesia cognitive recovery
548774|NCT00507195|Postoperative delirium
548775|NCT00507195|hypnotics
548776|NCT00507195|propofol
548777|NCT00507195|sevoflurane
548778|NCT00507195|desflurane
548779|NCT00507195|postoperative cognitive recovery
548780|NCT00507182|Oral Mucosa Lesions
548781|NCT00507182|Oral Cancer
548782|NCT00507182|Neoplasia and Dysplasia in oral cavity mucosa
548783|NCT00507182|Fluorescence Spectroscopy
548784|NCT00507182|Reflectance Spectroscopy
548785|NCT00507182|Pre-cancerous lesions
548786|NCT00507182|Cancerous lesions
548787|NCT00507182|Mouth
548788|NCT00505154|Heart failure
548789|NCT00505154|inflammation
548790|NCT00505154|cytokines
548791|NCT00505141|Childhood Brain Cancer
548792|NCT00505141|Childhood Acute Lymphoblastic Leukemia
548793|NCT00505128|Biliary pancreatitis
548794|NCT00505128|Bile duct stones
548795|NCT00505128|EUS Endoscopic UltraSonography
548796|NCT00505128|Endoscopic sphincterotomy
548797|NCT00505128|ERCP
548798|NCT00504023|Paget disease of the vulva
548799|NCT00504023|recurrent vulvar cancer
548800|NCT00504023|stage 0 vulvar cancer
548801|NCT00504023|stage I vulvar cancer
548802|NCT00504023|stage II vulvar cancer
548803|NCT00504023|stage III vulvar cancer
548804|NCT00504023|imiquimod
548805|NCT00504023|07-029
548806|NCT00504010|arnica
548807|NCT00504010|muscle soreness
548808|NCT00504010|exercise
548809|NCT00504010|eccentric
548810|NCT00503997|stage III squamous cell carcinoma of the hypopharynx
548811|NCT00503997|stage III squamous cell carcinoma of the larynx
548812|NCT00503997|stage III squamous cell carcinoma of the lip and oral cavity
548813|NCT00503997|stage III squamous cell carcinoma of the oropharynx
548814|NCT00503997|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
548815|NCT00503997|stage IV squamous cell carcinoma of the hypopharynx
548816|NCT00503997|stage IV squamous cell carcinoma of the larynx
548817|NCT00503997|stage IV squamous cell carcinoma of the lip and oral cavity
548818|NCT00503997|stage IV squamous cell carcinoma of the oropharynx
548819|NCT00503997|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
548820|NCT00503997|untreated metastatic squamous neck cancer with occult primary
548821|NCT00503984|Adenocarcinoma of the prostate
548822|NCT00503984|Recurrent prostate cancer
548823|NCT00503984|Stage IV prostate cancer
548824|NCT00503984|Pain
548825|NCT00503971|Vorinostat
548826|NCT00503971|NSCLC
548827|NCT00503971|EGFR
548828|NCT00503971|Erlotinib
548829|NCT00503958|non-small cell lung cancer
548830|NCT00503958|small cell lung cancer
548831|NCT00503958|health status unknown
548832|NCT00503945|sleep apnea
548833|NCT00503945|continuous positive airway pressure
548834|NCT00503945|echocardiography
548835|NCT00503945|Natriuretic peptide
548836|NCT00503932|Rectal Cancer
548837|NCT00503932|Capecitabine
548838|NCT00503932|Proton Therapy
548839|NCT00503932|Adenocarcinoma of the rectum
548840|NCT00503932|Gastrointestinal
548841|NCT00503932|Proton Radiotherapy
548842|NCT00503919|Cervix
548843|NCT00503919|Cervical dysplasia
548844|NCT00503919|Cervical neoplasia
548845|NCT00503919|Cervical intraepithelial neoplasia
548846|NCT00503919|Multi-spectral Digital Colposcopy
548847|NCT00503919|MDC
548848|NCT00503919|Acetic acid
548849|NCT00503919|Colposcopy
548850|NCT00503919|Spectroscopy
548851|NCT00503919|Fluorescence Spectroscopy
548852|NCT00503919|Abnormal Pap Smear
548853|NCT00503906|stage IV breast cancer
548854|NCT00503906|recurrent breast cancer
548855|NCT00503893|Wilms' Tumor
548856|NCT00503893|Genitourinary Anomalies
548857|NCT00503893|Beckwith-Wiedemann Hemihypertrophy
548858|NCT00503893|Aniridia
548859|NCT00503893|Questionnaire
548860|NCT00503880|de novo myelodysplastic syndromes
548861|NCT00503880|previously treated myelodysplastic syndromes
548862|NCT00503880|secondary myelodysplastic syndromes
548863|NCT00507143|Colorectal neoplasms
548864|NCT00507143|Secondary
548865|NCT00507143|irinotecan
548866|NCT00507143|Pharmacokinetics
548867|NCT00507143|Pharmacodynamics
548868|NCT00507143|SLCO1B1
548869|NCT00507143|PXR
548870|NCT00507117|Obstructive Sleep Apnea
548871|NCT00507117|Polysomnography
548872|NCT00507117|Non-benzodiazepine hypnotics
548873|NCT00507104|traumatic brain injury
548874|NCT00507104|Subarachnoid Hemorrhage
548875|NCT00507104|Hypopituitarism
548876|NCT00507091|ZD6474
548877|NCT00507091|Irinotecan
548878|NCT00507091|5-Fluorouracil
548879|NCT00507091|Leucovorin
548880|NCT00507091|colorectal
548881|NCT00507078|Obstructive Sleep Apnea
548882|NCT00507078|Leptin
548883|NCT00507078|Homocysteine
548884|NCT00507078|C-reactive Protein
548885|NCT00507052|Hemodialysis
548886|NCT00507052|Residual Renal Function
548887|NCT00507039|PD20 FEV1
548888|NCT00507039|grass pollen
548889|NCT00507039|one-step
548890|NCT00507013|vascular closure device
548891|NCT00506974|sleep
548892|NCT00506974|normal sleepers
548893|NCT00506948|Hematological Malignancies
548894|NCT00506948|Myelodysplastic Syndrome
548895|NCT00506948|Graft Versus Host Disease
548896|NCT00506948|GVHD
548897|NCT00506948|Allogeneic Hematopoietic Stem Cell Transplantation
548898|NCT00506948|AHSCT
548899|NCT00506948|Leukemia
548900|NCT00506948|Lymphoma
548901|NCT00506948|T-Cells
548902|NCT00506948|Thymoglobulin
548903|NCT00506948|ATG
548904|NCT00506948|rATG
548905|NCT00506948|Rabbit Antithymocyte Globulin
548906|NCT00506948|Rapamune
548907|NCT00506948|Sirolimus
548908|NCT00506948|Mycophenolate Mofetil
548909|NCT00506948|Cellcept
548910|NCT00506948|MMF
548911|NCT00506935|methamphetamine
548912|NCT00506935|GVG
548913|NCT00506935|vigabatrin
548914|NCT00506935|stimulant
548915|NCT00506922|Graft-Versus-Host Disease
548916|NCT00506922|GVHD Prevention
548917|NCT00506922|Hodgkin's Disease
548918|NCT00506922|Leukemia
548919|NCT00506922|Lymphoma
548920|NCT00506922|Methotrexate
548921|NCT00506922|Tacrolimus
548922|NCT00506922|Pentostatin
548923|NCT00506909|oxytocin
548924|NCT00506896|Rheumatoid Arthritis
548925|NCT00506896|glucocorticoid
548926|NCT00506896|intraarticular injection
548927|NCT00506896|arthritis
548928|NCT00506870|Heart Valve Prosthesis Implantation
548929|NCT00506870|INR self monitoring
548930|NCT00506870|cost benefit evaluation
548931|NCT00506857|Hematologic Malignancies
548932|NCT00506857|Blood And Marrow Transplantation
548933|NCT00506857|Leukemia
548934|NCT00506857|MDS
548935|NCT00506857|Lymphoma
548936|NCT00506857|Myeloma
548937|NCT00506857|Fludarabine
548938|NCT00506857|Fludara
548939|NCT00506857|Fludarabine Phosphate
548940|NCT00506857|Busulfan
548941|NCT00506857|Busulfex
548942|NCT00506857|Myleran
548943|NCT00506857|Progenitor Cell Transplantation
548944|NCT00506857|Granulocyte colony stimulating factor
548945|NCT00506857|G-CSF
548946|NCT00506857|Apheresis
548947|NCT00506857|Blood cell infusion
548948|NCT00506844|Rectal neoplasms
548949|NCT00506844|Neoadjuvant treatment
548950|NCT00506844|Cetuximab
548951|NCT00506844|Irinotecan
548952|NCT00506844|Capecitabine
548953|NCT00506844|Radiotherapy
548954|NCT00506844|Combination chemotherapy
548955|NCT00506818|emotional symptoms
548956|NCT00506818|vascular risk-factors
548957|NCT00506805|solid tumor malignancy; Hsp90
548958|NCT00506792|Cystic fibrosis, QAU145, nasal potential difference
548959|NCT00506779|Uterine Papillary Serous Carcinoma
548960|NCT00506779|Uterine Cancer
548961|NCT00506779|UPSC
548962|NCT00506779|Taxol
548963|NCT00506779|Paclitaxel
548964|NCT00506779|Gleevec
548965|NCT00506779|Imatinib Mesylate
548966|NCT00506779|STI571
548967|NCT00506766|Urinary Incontinence
548968|NCT00506766|Self efficacy
548969|NCT00506766|Pelvic floor muscle training
548970|NCT00506766|Bladder training
548971|NCT00506714|Osteoarthritis
548972|NCT00506714|Walking Sticks
548973|NCT00506714|Canes
548974|NCT00506675|Amblyopia
548975|NCT00506675|Atropine
548976|NCT00506675|Patching
548977|NCT00506649|protocol
548978|NCT00506649|analgesia
548979|NCT00506649|sedation
548980|NCT00506649|delirium
548981|NCT00506649|coma
548982|NCT00506623|Rectal neoplasm
548983|NCT00506623|Neoadjuvant therapy
548984|NCT00506623|Radiotherapy
548985|NCT00506623|Combination chemotherapy
548986|NCT00506623|Irinotecan
548987|NCT00506623|Capecitabine
548988|NCT00506610|Pain
548989|NCT00506610|Postherpetic Neuralgia
548990|NCT00506610|Neuralgia, Postherpetic
548991|NCT00506610|Shingles
548992|NCT00506610|Herpes Zoster
548993|NCT00506610|Neuropathic Pain
548994|NCT00506597|Acute Lymphoblastic Leukemia
548995|NCT00506597|Leukemia
548996|NCT00506597|Erwinia L-Asparaginase
548997|NCT00506597|Erwinase
548998|NCT00506584|Human milk nutritional intervention
548999|NCT00506584|Pre-term, very low birth weight
549000|NCT00506584|Fortification of human breast milk
549001|NCT00506571|colorectal neoplasms
549002|NCT00506571|secondary
549003|NCT00506571|Combination chemotherapy
549004|NCT00506571|S-1
549005|NCT00506571|irinotecan
549006|NCT00506571|oxaliplatin
549007|NCT00506558|cervical spondylotic myelopathy
549008|NCT00506558|degenerative cervical spondylosis
549009|NCT00506558|spinal fusion
549010|NCT00506532|Pulmonary Surfactants
549011|NCT00506532|Lung transplantation
549012|NCT00506532|Primary Graft Dysfunction
549013|NCT00506519|DIC associated with severe sepsis
549014|NCT00506506|N-acetylcysteine
549015|NCT00506506|Chronic kidney disease
549016|NCT00506506|eGFR
549017|NCT00506506|Cystatin C
549018|NCT00506506|proteinuria
549019|NCT00506506|Stage 3 chronic kidney disease
549020|NCT00506493|Persistent Atrial Fibrillation Surgical RF Ablation
549021|NCT00506493|Perisistent Atrial Fibrillation
549022|NCT00506493|Surgical Ablation
549023|NCT00506480|Embryo Implantation
549024|NCT00506480|Endometrium
549025|NCT00506480|endometrial implantation
549026|NCT00506480|Oocyte Donation
549027|NCT00506480|in vitro fertilization
549028|NCT00506480|endometrial sampling
549029|NCT00506467|Intrathoracic Malignancy
549030|NCT00506467|Lung Cancer
549031|NCT00506467|Vibration Response Imaging
549032|NCT00506467|VRI
549033|NCT00506454|Fatigue
549034|NCT00506454|Hemodialysis
549035|NCT00506454|Endotoxemia
549036|NCT00506454|Phospholipid
549037|NCT00506454|Emulsion
549038|NCT00506441|Chronic Kidney Disease
549039|NCT00506441|Dialysis
549040|NCT00506441|Hyperphosphatemia
549041|NCT00506441|Phosphate binder
549042|NCT00506428|aging
549043|NCT00506428|sleep
549044|NCT00506428|sleep deprivation
549045|NCT00506428|performance
549046|NCT00506428|memory
549047|NCT00506428|metabolism
549048|NCT00506415|Alzheimer's
549049|NCT00506415|Patch
549050|NCT00506415|Cognitive
549051|NCT00506415|Decline
549052|NCT00506402|Adult patients with refractory leukemias, MDS or AMM
549053|NCT00506389|Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic Dyssomnias, Sleep Disorders, Nervous System Diseases, Mental Disorders
549054|NCT00506376|Cervical Cancer
549055|NCT00506376|Hysterectomy
549056|NCT00506376|Interview
549057|NCT00506363|scar
549058|NCT00506363|surgery
549059|NCT00506363|lasers
549060|NCT00506324|Intensity Modulated Radiotherapy
549061|NCT00506324|Chemotherapy
549062|NCT00506324|Head and Neck Neoplasms
549063|NCT00506324|Dysphagia
549064|NCT00506311|Superficial Groin Dissection
549065|NCT00506311|Melanoma
549066|NCT00506311|Fibrin Tissue Adhesive
549067|NCT00506311|Fibrin Sealant
549068|NCT00506311|Tisseel
549069|NCT00506311|Seroma
549070|NCT00506298|Diabetes
549071|NCT00506298|CRx-401
549072|NCT00506298|Bezafibrate
549073|NCT00506298|Diflunisal
549074|NCT00506298|Metformin
549075|NCT00506298|plasma glucose
549076|NCT00506285|Attention Deficit Hyperactivity Disorder
549077|NCT00506285|ADHD
549078|NCT00506285|Adult
549079|NCT00506285|Methylphenidate Transdermal System
549080|NCT00506285|Daytrana
549081|NCT00506272|diabetes mellitus
549082|NCT00506272|hyperglycemia
549083|NCT00506272|hypoglycemia
549084|NCT00506272|self care
549085|NCT00506259|Deletion 17p11.2
549086|NCT00506259|Melatonin
549087|NCT00506259|Phototherapy
549088|NCT00506259|Behavioral Phenotype
549089|NCT00506259|Developmental Delay/MR
549090|NCT00506259|Smith-Magenis Syndrome
549091|NCT00506259|Sleep Disturbance
549092|NCT00506259|SMS
549093|NCT00506259|Sleep Disorder
549094|NCT00506246|anaesthesia
549095|NCT00506233|Graft-Versus-Host Disease
549096|NCT00506233|GVHD
549097|NCT00506233|Questionnaire
549098|NCT00504062|asthma
549099|NCT00504062|bronchial
549100|NCT00504049|Cerebral Palsy
549101|NCT00504049|Electromyography
549102|NCT00504049|Wavelet Analysis
549103|NCT00504036|Obesity
549104|NCT00504036|Morbid obesity
549105|NCT00504036|Gastric balloon
549106|NCT00504036|Gastric by-pass
549107|NCT00504036|Morbid obesity with BMI > 45 kg/m²
549108|NCT00506207|Gastrointestinal neoplasms
549109|NCT00506207|Combination chemotherapy
549110|NCT00506207|S-1
549111|NCT00506207|Irinotecan
549112|NCT00506207|Oxaliplatin
549113|NCT00506194|type 2 diabetes
549114|NCT00506194|oral glucose tolerance test
549115|NCT00506194|insulin
549116|NCT00506194|oral anti-diabetic drug
549117|NCT00506194|ß-cell function
549118|NCT00506168|Colorectal neoplasms
549119|NCT00506168|Secondary
549120|NCT00506168|Drug therapy, combination
549121|NCT00506168|Irinotecan
549122|NCT00506168|Capecitabine
549123|NCT00506155|Bladder Cancer
549124|NCT00506155|Urothelial Cancer
549125|NCT00506155|Avastin
549126|NCT00506155|Bevacizumab
549127|NCT00506155|Cisplatin
549128|NCT00506155|Doxorubicin
549129|NCT00506155|Methotrexate
549130|NCT00506155|Vinblastine
549131|NCT00506155|M-VAC
549132|NCT00506129|Cutaneous T-Cell Lymphoma
549133|NCT00506129|CTCL
549134|NCT00506129|Allogeneic Transplantation
549135|NCT00506129|Lymphoma
549136|NCT00506129|Allogeneic peripheral blood progenitor cell
549137|NCT00506129|PBPC
549138|NCT00506129|Bone Marrow transplantation
549139|NCT00506129|Stem Cell Transplant
549140|NCT00506129|SCT
549141|NCT00506129|Fludarabine
549142|NCT00506129|Fludarabine Phosphate
549143|NCT00506129|Fludara
549144|NCT00506129|Melphalan
549145|NCT00506116|Pelvic floor muscle training
549146|NCT00506116|Self-directed pushing
549147|NCT00506116|Antenatal perineal massage
549148|NCT00506103|Thyroidectomy
549149|NCT00506103|Central neck dissection
549150|NCT00506103|Harmonic scalpel
549151|NCT00506103|Perioperative complications
549152|NCT00506090|scar
549153|NCT00506090|surgery
549154|NCT00506090|lasers
549155|NCT00506077|Undifferentiated schizophrenia
549156|NCT00506077|residual schizophrenia
549157|NCT00506064|Breast Cancer
549158|NCT00506064|Sleep
549159|NCT00506064|Melatonin
549160|NCT00506064|Placebo
549161|NCT00506064|Survey
549162|NCT00506064|Postoperative Srejic Sleep SAT Survey
549163|NCT00506051|Non-small cell lung cancer
549164|NCT00506051|lung cancer
549165|NCT00506051|alimta
549166|NCT00506051|vandetanib
549167|NCT00506051|phase 1
549168|NCT00506038|Calcific Tendinitis
549169|NCT00506025|Pregnancy
549170|NCT00506025|Cranberry
549171|NCT00506025|Asymptomatic Bacteruria
549172|NCT00506012|Myoclonus Dystonia
549173|NCT00506012|Essential Myoclonus
549174|NCT00506012|Inherited Myoclonus
549175|NCT00506012|Dyskinesia
549176|NCT00506012|Movement Disorder
549177|NCT00505999|Multiple Myeloma
549178|NCT00505999|Etiology
549179|NCT00505999|Risk Factors
549180|NCT00505999|Healthy Controls
549181|NCT00505999|Questionnaire
549182|NCT00505999|Survey
549183|NCT00505947|macular edema
549184|NCT00505947|diabetes mellitus
549185|NCT00505947|visual loss
549186|NCT00505947|diabetic retinopathy
549187|NCT00505947|macula
549188|NCT00505947|maculopathy
549189|NCT00505947|infliximab
549190|NCT00505934|Epilepsy
549191|NCT00505934|Child
549192|NCT00505934|Levetiracetam
549193|NCT00505934|Keppra®
549194|NCT00505934|Infusion
549195|NCT00505934|Intravenous
549196|NCT00505921|T-Cell Lymphoma
549197|NCT00505921|Lymphoma
549198|NCT00505921|Campath-1H
549199|NCT00505921|Allogenic Transplantation
549200|NCT00505921|Stem Cell Transplant
549201|NCT00505921|Alemtuzumab
549202|NCT00505895|Multiple Myeloma
549203|NCT00505895|Fludarabine
549204|NCT00505895|Fludara
549205|NCT00505895|Fludarabine Phosphate
549206|NCT00505895|Melphalan
549207|NCT00505895|Alkeran
549208|NCT00505895|Stem Cell Infusion
549209|NCT00505895|Stem Cell Transfusion
549210|NCT00505895|SCT
549211|NCT00505895|Allogeneic Peripheral Blood Stem Cell Transfusion
549212|NCT00505895|APBSCT
549213|NCT00505895|Bone Marrow Transplantation
549214|NCT00505895|BMT
549215|NCT00505895|Rituxan
549216|NCT00505895|Rituximab
549217|NCT00505895|FM140
549218|NCT00505895|FM100
549219|NCT00505882|Type 1 diabetes
549220|NCT00505882|Pramlintide
549221|NCT00505882|Weight gain
549222|NCT00505882|Intensive insulin therapy
549223|NCT00505882|Beta cell
549224|NCT00505869|Pregnant Smokers
549225|NCT00505869|Mood Management Intervention
549226|NCT00505869|Health & Wellness Intervention
549227|NCT00505869|Smoking Cessation
549228|NCT00505869|Questionnaire
549229|NCT00505869|Survey
549230|NCT00505830|Asperger Syndrom
549231|NCT00505830|Autism Quotient
549232|NCT00505830|French version
549233|NCT00505830|screening
549234|NCT00505830|diagnostic test
549235|NCT00505830|accuracy
549236|NCT00505804|dexmedetomidine
549237|NCT00505804|haloperidol
549238|NCT00505791|Acute decompensated heart failure
549239|NCT00505791|Normal left ventricular ejection fraction
549240|NCT00505791|Vasodilator therapy
549241|NCT00505765|Cognition
549242|NCT00505765|Schizophrenia
549243|NCT00505752|Assisted reproductive technology, follicle stimulating hormone
549244|NCT00505739|Endometrial Cancer
549245|NCT00505739|Low Grade Endometrial Stromal Sarcoma
549246|NCT00505739|RU-486
549247|NCT00505739|Mifepristone
549248|NCT00505739|LGESS
549249|NCT00505726|Cervical Intraepithelial Neoplasia
549250|NCT00505726|Cervical Cancer
549251|NCT00505726|Reflectance Confocal Imaging
549252|NCT00505726|Colposcopy
549253|NCT00505713|Sarcoma
549254|NCT00505713|Rexin-G
549255|NCT00505713|Gene Therapy
549256|NCT00505700|acute myeloid leukemia
549257|NCT00505687|Rotigotine
549258|NCT00505687|Neupro®
549259|NCT00505661|Ovarian Cancer
549260|NCT00505661|Fallopian Tube Cancer
549261|NCT00505661|Peritoneal Cancer
549262|NCT00505661|Letrozole
549263|NCT00505661|Femara
549264|NCT00505648|Hypersensitivity
549265|NCT00505648|Syndrome
549266|NCT00505648|Tegeline
549267|NCT00505635|advanced stage IV melanoma
549268|NCT00505635|unresectable stage III melanoma
549269|NCT00505635|Melanoma
549270|NCT00505635|Temozolomide
549271|NCT00505635|Velban
549272|NCT00505635|Vinblastine
549273|NCT00505635|Cisplatin
549274|NCT00505635|Interleukin-2
549275|NCT00505635|Intron-A
549276|NCT00505635|Interferon Alpha-2b
549277|NCT00505635|Thalidomide
549278|NCT00505635|Thalomid
549279|NCT00505635|Temodar
549280|NCT00505635|Proleukin
549281|NCT00505609|fertility awareness-based method
549282|NCT00505609|family planning
549283|NCT00505609|Standard Days Method
549284|NCT00505609|Institute for Reproductive Health
549285|NCT00505609|Efficacy
549286|NCT00505609|CycleBeads
549287|NCT00505596|Prenatal testing
549288|NCT00505596|Decisionmaking
549289|NCT00505596|Decision aid
549290|NCT00505596|Informed choice
549291|NCT00505570|Migraine
549292|NCT00505570|Migraine with aura
549293|NCT00505570|Patent foramen ovale
549294|NCT00505570|PFO
549295|NCT00505557|augmentation mammoplasty
549296|NCT00505557|Dual plane
549297|NCT00505557|Endoscope
549298|NCT00505557|Transaxillary incision
549299|NCT00505544|Advanced Cancer
549300|NCT00505544|Questionnaire
549301|NCT00505544|Survey
549302|NCT00505544|Sleep Disturbance
549303|NCT00505544|Sleep Quality
549304|NCT00505531|Pain
549305|NCT00505518|Major Depressive Disorder
549306|NCT00505518|Telepsychiatry
549307|NCT00505518|Chinese American
549308|NCT00505518|Nursing Home
549309|NCT00505505|Neurointensive care
549310|NCT00505505|Intensive insulin infusion
549311|NCT00505505|Hypoglycemia
549312|NCT00505505|Postoperative Mortality
549313|NCT00505505|Postoperative Morbidity
549314|NCT00505505|Neurologic outcome
549315|NCT00505492|Malignant Mixed Mesodermal Tumor
549316|NCT00505492|MMMT
549317|NCT00505492|Uterine Neoplasms
549318|NCT00505492|Radiation Therapy
549319|NCT00505492|Paclitaxel
549320|NCT00505492|Carboplatin
549321|NCT00505492|Cisplatin
549322|NCT00505492|Taxol
549323|NCT00505479|Congenital Hypothyroidism
549324|NCT00505479|pregnancy
549325|NCT00505479|iodine
549326|NCT00505479|deficiency
549327|NCT00505466|Human Genetics
549328|NCT00505466|Genetic Counseling
549329|NCT00505466|Genetic Testing
549330|NCT00505466|p53 Mutation
549331|NCT00505466|Genetics
549332|NCT00505453|Influenza
549333|NCT00505427|PCOS
549334|NCT00505427|polycystic ovary syndrome
549335|NCT00505427|polycystic ovarian syndrome
549336|NCT00505427|alpha lipoic acid
549337|NCT00505427|insulin resistance
549338|NCT00505427|oxidative stress
549339|NCT00505414|Chronic Tumor Related Pain
549340|NCT00505414|Analgesic
549341|NCT00505414|Tapentadol Extended Release
549342|NCT00505414|Morphine Sulfate Controlled Release
549343|NCT00505414|Pain assessment
549344|NCT00505414|Placebo
549345|NCT00505401|HIV
549346|NCT00505401|Tat protein
549347|NCT00505401|HIV Therapeutic Vaccine
549348|NCT00505388|asthma
549349|NCT00505388|bronchial
549350|NCT00505388|Symbicort
549351|NCT00505375|CTLA4-Ig
549352|NCT00505375|Abatacept
549353|NCT00505375|Beta-cell function
549354|NCT00505375|T-cells
549355|NCT00505375|DPT-1
549356|NCT00505375|treatment
549357|NCT00505375|treatment of type 1 diabetes
549358|NCT00505375|new onset type 1 diabetes
549359|NCT00505375|juvenile diabetes
549360|NCT00505375|T1D
549361|NCT00505375|diabetes mellitus
549362|NCT00505375|Type 1 diabetes TrialNet
549363|NCT00505375|TrialNet
549364|NCT00505349|neurotrophic factors
549365|NCT00505349|cognitive status
549366|NCT00505349|young adults
549367|NCT00505349|mature adults
549368|NCT00505349|cognitive training
549369|NCT00505336|Diastolic heart failure
549370|NCT00505336|Markers of collagen turnover
549371|NCT00505336|Statins
549372|NCT00505336|Aldosterone receptor blockers
549373|NCT00505323|Cortex stimulation
549374|NCT00505323|Focal secondary Dystonia
549375|NCT00505323|Effectiveness
549376|NCT00505323|Quality of life improvement
549377|NCT00505323|Focal dystonias secondary to central grey nuclei lesions
549378|NCT00505310|Kidney Cancer
549379|NCT00505310|Renal Cell Carcinoma
549380|NCT00505310|Emotional Expression
549381|NCT00505310|Writing
549382|NCT00505310|Questionnaire
549383|NCT00505310|Survey
549384|NCT00505297|Osteoarthritis (OA)
549385|NCT00505297|Magnetic Resonance Imaging (MRI)
549386|NCT00505297|delayed Gadolinium Enhanced MRI of cartilage (dGEMRIC)
549387|NCT00505297|disease modifying osteoarthritis drug (DMOAD)
549388|NCT00505297|Potentially rapidly progressing osteoarthritis
549389|NCT00505297|MRI measurement of cartilage
549390|NCT00505284|Diabetic neuropathy
549391|NCT00505271|Breast Cancer
549392|NCT00505271|Rexin-G
549393|NCT00505271|Gene Therapy
549394|NCT00505258|Bacteremia
549395|NCT00505258|Bloodstream infection
549396|NCT00505258|Staphylococcus aureus
549397|NCT00505258|Staphylococcal Infections
549398|NCT00505258|MRSA
549399|NCT00505258|MSSA
549400|NCT00505245|Advanced Cancer
549401|NCT00505245|Symptom Distress
549402|NCT00505245|MDASI
549403|NCT00505245|M.D. Anderson Symptom Inventory
549404|NCT00505245|Quality of Life
549405|NCT00505245|Questionnaire
549406|NCT00505245|Interactive voice response telephone system
549407|NCT00505245|IVR
549408|NCT00505232|Y-90 Ibritumomab tiuxetan
549409|NCT00505232|Rituximab
549410|NCT00505232|Hyper-CVAD
549411|NCT00505232|Mantle Cell Lymphoma Patients
549412|NCT00505232|Zevalin(R)
549413|NCT00505219|Osteonecrosis
549414|NCT00505180|Hemodialysis
549415|NCT00505180|Mortality
549416|NCT00505167|Alzheimer's disease
549417|NCT00505167|Memantine
549418|NCT00505167|Donepezil
549419|NCT00505167|Magnetic resonance Spectroscopy
549420|NCT00505167|randomized trial
549421|NCT00505102|Kidney Diseases
549422|NCT00505102|Heart Transplantation
549423|NCT00505102|Everolimus
549424|NCT00505102|Cyclosporine Toxicity
549425|NCT00505089|pharmacokinetic, pharmacodynamic, subcutaneous, intravenous, ACZ885, patients, rheumatoid, arthritis.
549426|NCT00505076|Cognition
549427|NCT00505076|Schizophrenia
549428|NCT00505063|vaccine
549429|NCT00505063|childhood
549430|NCT00505063|cancer
549431|NCT00505050|heart failure, disease program management, treatment, education
549432|NCT00505037|ASP1585
549433|NCT00505037|Renal Dialysis
549434|NCT00505037|Chronic Kidney Disease
549435|NCT00505037|Hyperphosphatemia
549436|NCT00505024|Non-Small Cell Lung Cancer
549437|NCT00505024|Esophageal Cancer
549438|NCT00505024|Lung Cancer
549439|NCT00505024|Interactive Voice Response System
549440|NCT00505024|IVRS
549441|NCT00505011|susceptibility
549442|NCT00505011|genes
549443|NCT00505011|environment
549444|NCT00505011|ophthalmopathy
549445|NCT00505011|outcome
549446|NCT00504998|Pancreatic cancer
549447|NCT00504998|Rexin-G
549448|NCT00504998|Treatment
549449|NCT00504985|Advanced Cancer
549450|NCT00504985|Hematologic Malignancy
549451|NCT00504985|Fatigue
549452|NCT00504985|Emergency Center
549453|NCT00504985|Survey
549454|NCT00504959|Age-related macular degeneration (AMD),
549455|NCT00504959|choroidal neovascularization (CNV),
549456|NCT00504959|vascular endothelial growth factor (VEGF)
549457|NCT00504946|allergen immunotherapy premedication
549458|NCT00504933|Rhinitis
549459|NCT00504933|Allergic
549460|NCT00504933|Seasonal
549461|NCT00504933|Hay Fever
549462|NCT00504933|Pollen Allergy
549463|NCT00504933|Pollinosis
549464|NCT00504933|Rhinoconjunctivitis
549465|NCT00504920|Leukemia
549466|NCT00504920|Myelodysplastic Syndrome
549467|NCT00504920|Acute Myeloblastic Leukemia
549468|NCT00504920|Symptom-Related Cytokines
549469|NCT00504920|Blood or Marrow Transplantation
549470|NCT00504920|Questionnaire
549471|NCT00504907|RSV
549472|NCT00504894|N/A healthy volunteers
549473|NCT00504881|Epilepsy
549474|NCT00504881|Brivaracetam
549475|NCT00504881|Partial Onset Seizures
549476|NCT00504855|Pressure ulcer
549477|NCT00504855|Waterproof
549478|NCT00504855|Gortex
549479|NCT00504855|Cast padding
549480|NCT00504855|Pediatric
549481|NCT00504855|Heel
549482|NCT00504842|Acute Ischemic Stroke
549483|NCT00504842|Microbubbles
549484|NCT00504842|Transcranial Doppler ultrasound
549485|NCT00504842|TIBI
549486|NCT00504842|Symptomatic Intracranial Hemorrhage
549487|NCT00504842|modified Rankin Scale
549488|NCT00504842|Recanalization
549489|NCT00504842|Perflutren
549490|NCT00504829|LCP-AtorFen
549491|NCT00504829|Non-HDL cholesterol
549492|NCT00504829|Triglycerides
549493|NCT00504829|HDL cholesterol
549494|NCT00504829|LDL cholesterol
549495|NCT00504829|Atorvastatin
549496|NCT00504829|Fenofibrate
549497|NCT00504816|healthy female,
549498|NCT00504816|pharmacokinetics,
549499|NCT00504816|pharmacodynamics
549500|NCT00504816|drug interaction,
549501|NCT00504803|HCT, nonmyeloablative, mesenchymal stem cells, GVHD
549502|NCT00504790|CENPE,
549503|NCT00504790|Phase I,
549504|NCT00504790|GSK923295,
549505|NCT00504790|maximally tolerated dose, pharmacokinetics,
549506|NCT00504790|First Time in Human,
549507|NCT00504790|pharmacodynamics
549508|NCT00504790|Refractory Cancer
549509|NCT00504790|cancer,
549510|NCT00504764|Relapsed Acute Promyelocytic Leukemia
549511|NCT00504764|Arsenic Trioxide
549512|NCT00504751|diffuse large b cell
549513|NCT00504738|lung disease
549514|NCT00504738|chronic obstructive pulmonary disease (COPD)
549515|NCT00504738|asthma
549516|NCT00504738|smokers
549517|NCT00504738|non-smokers
549518|NCT00504725|Lobectomy
549519|NCT00504725|VATS
549520|NCT00504712|Testosterone
549521|NCT00504712|Hypogonadism
549522|NCT00504712|Diabetes
549523|NCT00504712|PVD
549524|NCT00504712|RCT
549525|NCT00504699|breast cancer
549526|NCT00504699|ovarian stimulation
549527|NCT00504699|aromatase inhibitors
549528|NCT00504699|letrozole
549529|NCT00504699|fertility preservation
549530|NCT00504699|recurrence
549531|NCT00504660|Anaplastic Glioma
549532|NCT00504660|Glioblastoma Multiforme
549533|NCT00504660|Brain Cancer
549534|NCT00504660|6-Thioguanine
549535|NCT00504660|Capecitabine
549536|NCT00504660|Celecoxib
549537|NCT00504660|Temozolomide
549538|NCT00504660|Xeloda
549539|NCT00504660|Temodar
549540|NCT00504660|TMZ
549541|NCT00504660|CCNU
549542|NCT00504660|6-TG
549543|NCT00504647|Hypertrophic
549544|NCT00504647|Cardiomyopathy
549545|NCT00504647|Diastolic
549546|NCT00504647|Ventricular
549547|NCT00504647|Interaction
549548|NCT00504647|Biventricular
549549|NCT00504647|Pacemaker
549550|NCT00504634|Multiple Myeloma
549551|NCT00504634|Post Allogeneic Transplantation
549552|NCT00504634|Bortezomib
549553|NCT00504634|Velcade
549554|NCT00504634|PS-341
549555|NCT00504621|personality
549556|NCT00504621|fatigue
549557|NCT00504621|quality of life
549558|NCT00504621|health care consumption
549559|NCT00504595|Rheumatoid Arthritis
549560|NCT00504582|Axillary Node Dissection
549561|NCT00504582|Fibrin Sealant
549562|NCT00504582|Tisseel
549563|NCT00504582|Melanoma
549564|NCT00504582|Seroma
549565|NCT00504556|Anti-coagulant
549566|NCT00504556|Non-valvular
549567|NCT00504556|Venous Thromboembolism
549568|NCT00504556|Prevention of Blood Clots
549569|NCT00504556|Atrial Fibrillation
549570|NCT00504556|Non-valvular atrial fibrillation
549571|NCT00504543|Kidney transplant, AEB071
549572|NCT00504517|Outpatient continuity training
549573|NCT00504517|Relevant, Patient-centered curriculum
549574|NCT00504517|Evaluation
549575|NCT00504517|New graduation requirements
549576|NCT00504504|Hodgkin's Disease
549577|NCT00504504|Lymphoma
549578|NCT00504504|Rituximab
549579|NCT00504504|Rituxan
549580|NCT00504504|Adriamycin
549581|NCT00504504|Doxorubicin
549582|NCT00504504|Rubex
549583|NCT00504504|Bleomycin
549584|NCT00504504|Bleomycin sulfate
549585|NCT00504504|Blenoxane
549586|NCT00504504|BLM
549587|NCT00504504|Dacarbazine
549588|NCT00504504|DTIC
549589|NCT00504504|DTIC-Dome
549590|NCT00504504|Vincristine
549591|NCT00504504|Vinblastine
549592|NCT00504504|Vinblastine Sulfate
549593|NCT00504504|ABVD
549594|NCT00504504|ABVD Chemotherapy Treatment
549595|NCT00504491|Rituximab-CHOP
549596|NCT00504491|Alemtuzumab
549597|NCT00504491|Chronic lymphocytic leukaemia
549598|NCT00504478|Inflammation
549599|NCT00504478|carbohydrates
549600|NCT00504478|omega-3
549601|NCT00504478|overweight
549602|NCT00504478|diet
549603|NCT00504465|Labor
549604|NCT00504465|Labor induction
549605|NCT00504465|Cervical ripening
549606|NCT00504465|Dinoprostone
549607|NCT00504465|Fetal safety
549608|NCT00504465|Oxytocin
549609|NCT00504465|Cesarean delivery
549610|NCT00504452|HIV
549611|NCT00504452|viral
549612|NCT00504452|Viral decay acceleration
549613|NCT00504452|ART
549614|NCT00504452|HAART
549615|NCT00504452|Treatment Experienced
549616|NCT00504439|SB-656933,
549617|NCT00504439|COPD,
549618|NCT00504439|CXCR2,
549619|NCT00504439|CD11b,
549620|NCT00504439|repeat dose,
549621|NCT00504439|safety,
549622|NCT00504439|tolerability.
549623|NCT00504413|Metabolic Networks and Pathways
549624|NCT00504413|Methadone
549625|NCT00504413|Polymorphism, genetic
549626|NCT00504413|Cytochrome P-450 Enzyme System
549627|NCT00504400|macular telangiectasia
549628|NCT00504400|parafoveal telangiectasis
549629|NCT00504400|nonproliferative
549630|NCT00504400|therapy
549631|NCT00504400|intravitreal injection
549632|NCT00504400|ranibizumab
549633|NCT00504400|lucentis
549634|NCT00504387|Burning mouth disorder
549635|NCT00504387|Taste disorder
549636|NCT00504387|Quantitative sensory testing
549637|NCT00504387|Gustatory testing
549638|NCT00504387|Neuropathic orofacial pain
549639|NCT00504387|Oral burning
549640|NCT00504374|Lung Cancer
549641|NCT00504374|Epidemiology
549642|NCT00504374|Symptoms
549643|NCT00504374|Gene Polymorphisms
549644|NCT00504374|Questionnaire
549645|NCT00504374|Survey
549646|NCT00504361|Asthma
549647|NCT00504361|COPD
549648|NCT00504361|Interstitial Lung Disease
549649|NCT00504361|Cystic Fibrosis
549650|NCT00504361|Lung Cancer
549651|NCT00504361|smokers
549652|NCT00504361|non-smokers
549653|NCT00504348|Interstitial pneumonitis
549654|NCT00504348|Polymyositis
549655|NCT00504348|Dermatomyositis
549656|NCT00504348|Tacrolimus
549657|NCT00504348|Corticosteroids
549658|NCT00504348|Interstitial pneumonitis associated with polymyositis or dermatomyositis
549659|NCT00504335|Acute Radiation Syndrome
549660|NCT00504335|Hematopoietic Syndrome
549661|NCT00504335|Radiation Injury
549662|NCT00504335|BIO 300
549663|NCT00504322|Esophageal Neoplasms
549664|NCT00504309|triglycerides
549665|NCT00504309|hypertriglyceridemia
549666|NCT00504309|omega-3
549667|NCT00504309|n-3
549668|NCT00504309|eicosapentaenoic acid
549669|NCT00504309|EPA
549670|NCT00504309|docosahexaenoic acid
549671|NCT00504309|DHA
549672|NCT00504309|flow mediated dilation
549673|NCT00504309|fish
549674|NCT00504309|Moderate hypertriglyceridemia
549675|NCT00504296|unspecified adult solid tumor, protocol specific
549676|NCT00504283|Renal colic, pain, protocol, emergency department
549677|NCT00504257|recurrent ovarian epithelial cancer
549678|NCT00504257|recurrent primary peritoneal cavity cancer
549679|NCT00504257|recurrent fallopian tube cancer
549680|NCT00504244|SLE
549681|NCT00504244|SLEDAI
549682|NCT00504244|Azathioprine
549683|NCT00504244|Myfortic
549684|NCT00504231|influenza
549685|NCT00504231|prevention
549686|NCT00504231|intradermal
549687|NCT00504231|vaccine
549688|NCT00504231|delivery
549689|NCT00504231|elderly
549690|NCT00504218|Growth Factor
549691|NCT00504218|Hypothalamic-Pituitary Dysfunction
549692|NCT00504218|Primary Disorders of the Thyroid
549693|NCT00504218|Decreased Bone Mineral Density
549694|NCT00504218|Endocrine Side Effects Related to Cancer Therapy
549695|NCT00504218|Primary Gonadal Dysfunction
549696|NCT00504218|Obesity
549697|NCT00504218|Impaired Glucose Tolerance
549698|NCT00504218|Thyroid Disorder
549699|NCT00504218|Cancer Therapy Endocrine Side Effects
549700|NCT00504218|Pituitary Dysfunction
549701|NCT00504218|Childhood Cancer Survivors
549702|NCT00504205|unspecified adult solid tumor, protocol specific
549703|NCT00504205|anaplastic large cell lymphoma
549704|NCT00504205|angioimmunoblastic T-cell lymphoma
549705|NCT00504205|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
549706|NCT00504205|intraocular lymphoma
549707|NCT00504205|nodal marginal zone B-cell lymphoma
549708|NCT00504205|recurrent adult Burkitt lymphoma
549709|NCT00504205|recurrent adult diffuse large cell lymphoma
549710|NCT00504205|recurrent adult diffuse mixed cell lymphoma
549711|NCT00504205|recurrent adult diffuse small cleaved cell lymphoma
549712|NCT00504205|recurrent adult Hodgkin lymphoma
549713|NCT00504205|recurrent adult immunoblastic large cell lymphoma
549714|NCT00504205|recurrent adult lymphoblastic lymphoma
549715|NCT00504205|recurrent cutaneous T-cell non-Hodgkin lymphoma
549716|NCT00504205|recurrent grade 1 follicular lymphoma
549717|NCT00504205|recurrent grade 2 follicular lymphoma
549718|NCT00504205|recurrent grade 3 follicular lymphoma
549719|NCT00504205|recurrent mantle cell lymphoma
549720|NCT00504205|recurrent marginal zone lymphoma
549721|NCT00504205|recurrent mycosis fungoides/Sezary syndrome
549722|NCT00504205|recurrent small lymphocytic lymphoma
549723|NCT00504205|splenic marginal zone lymphoma
549724|NCT00504205|stage III adult Burkitt lymphoma
549725|NCT00504205|stage III adult diffuse large cell lymphoma
549726|NCT00504205|stage III adult diffuse mixed cell lymphoma
549727|NCT00504205|stage III adult diffuse small cleaved cell lymphoma
549728|NCT00504205|stage III adult Hodgkin lymphoma
549729|NCT00504205|stage III adult immunoblastic large cell lymphoma
549730|NCT00504205|stage III adult lymphoblastic lymphoma
549731|NCT00504205|stage III adult T-cell leukemia/lymphoma
549732|NCT00504205|stage III cutaneous T-cell non-Hodgkin lymphoma
549733|NCT00504205|stage III grade 1 follicular lymphoma
549734|NCT00504205|stage III grade 2 follicular lymphoma
549735|NCT00504205|stage III grade 3 follicular lymphoma
549736|NCT00504205|stage III mantle cell lymphoma
549737|NCT00504205|stage III marginal zone lymphoma
549738|NCT00504205|stage III mycosis fungoides/Sezary syndrome
549739|NCT00504205|stage III small lymphocytic lymphoma
549740|NCT00504205|stage IV adult Burkitt lymphoma
549741|NCT00504205|stage IV adult diffuse large cell lymphoma
549742|NCT00504205|stage IV adult diffuse mixed cell lymphoma
549743|NCT00504205|stage IV adult diffuse small cleaved cell lymphoma
549744|NCT00504205|stage IV adult Hodgkin lymphoma
549745|NCT00504205|stage IV adult immunoblastic large cell lymphoma
549746|NCT00504205|stage IV adult lymphoblastic lymphoma
549857|NCT00503763|Paraprotein
549747|NCT00504205|stage IV adult T-cell leukemia/lymphoma
549748|NCT00504205|stage IV cutaneous T-cell non-Hodgkin lymphoma
549749|NCT00504205|stage IV grade 1 follicular lymphoma
549750|NCT00504205|stage IV grade 2 follicular lymphoma
549751|NCT00504205|stage IV grade 3 follicular lymphoma
549752|NCT00504205|stage IV mantle cell lymphoma
549753|NCT00504205|stage IV marginal zone lymphoma
549754|NCT00504205|stage IV mycosis fungoides/Sezary syndrome
549755|NCT00504205|stage IV small lymphocytic lymphoma
549756|NCT00504205|Waldenstrom macroglobulinemia
549757|NCT00504205|primary central nervous system non-Hodgkin lymphoma
549758|NCT00504179|coronary artery bypass graft
549759|NCT00504179|osteopathic manipulative treatment
549760|NCT00504179|cardiovascular disease
549761|NCT00504140|Osteosarcoma
549762|NCT00504140|Interferon Alpha
549763|NCT00504140|IFN-
549764|NCT00504140|Roferon
549765|NCT00504140|Recombinant Interferon Alpha
549766|NCT00504140|Etoposide
549767|NCT00504140|VP-16
549768|NCT00504127|Arthritis
549769|NCT00504127|Degenerative
549770|NCT00504114|Osteoarthritis, knee
549771|NCT00504114|anterior cruciate ligament
549772|NCT00504114|Magnetic Resonance Imaging
549773|NCT00504101|stage I multiple myeloma
549774|NCT00504101|stage II multiple myeloma
549775|NCT00504101|stage III multiple myeloma
549776|NCT00504088|CLI
549777|NCT00504088|Critical Limb Ischemia
549778|NCT00504088|PAD
549779|NCT00504088|Peripheral Arterial Disease
549780|NCT00504088|Artherosclerosis
549781|NCT00504088|Leg Pain
549782|NCT00504088|Cardiovascular
549783|NCT00504088|Artherectomy
549784|NCT00504088|Bypass
549785|NCT00504088|Peripheral Bypass
549786|NCT00504088|PROOF
549787|NCT00504075|Idiopathic Thrombocytopenic Purpura
549788|NCT00504075|Bleeding disorders
549789|NCT00504075|Immune System and Disorders
549790|NCT00503867|unresectable hepatocellular carcinoma
549791|NCT00503867|HCC
549792|NCT00503867|SIR-Spheres
549793|NCT00503867|Y-90 Microspheres
549794|NCT00503867|brachytherapy
549795|NCT00503867|SIRT
549796|NCT00503867|liver cancer
549797|NCT00503854|Solid Tumors
549798|NCT00503854|Febrile Neutropenia
549799|NCT00503854|Fatigue
549800|NCT00503854|Symptom Burden
549801|NCT00503854|Questionnaire
549802|NCT00503854|Survey
549803|NCT00503841|stage I breast cancer
549804|NCT00503841|recurrent breast cancer
549805|NCT00503841|stage II breast cancer
549806|NCT00503841|stage IIIA breast cancer
549807|NCT00503841|stage IIIB breast cancer
549808|NCT00503841|stage IIIC breast cancer
549809|NCT00503828|Derris Scandens Benth extract
549810|NCT00503828|Osteoarthritis
549811|NCT00503828|WOMAC
549812|NCT00503828|6-minute walk
549813|NCT00503815|colonoscopy
549814|NCT00503815|bowel preparation
549815|NCT00503815|prep
549816|NCT00503802|Sleep Apnea
549817|NCT00503802|Sleep disordered breathing
549818|NCT00503802|Nasal Obstruction
549819|NCT00503802|Turbinate
549820|NCT00503802|Radiofrequency
549821|NCT00503802|Continuous positive airway pressure
549822|NCT00503802|CPAP
549823|NCT00503802|Sleep surgery
549824|NCT00503789|Healthy infants
549825|NCT00503776|xerostomia
549826|NCT00503776|mucositis
549827|NCT00503776|dysphagia
549828|NCT00503776|radiation toxicity
549829|NCT00503776|chemotherapeutic agent toxicity
549830|NCT00503776|stage III squamous cell carcinoma of the hypopharynx
549831|NCT00503776|stage IV squamous cell carcinoma of the hypopharynx
549832|NCT00503776|recurrent squamous cell carcinoma of the hypopharynx
549833|NCT00503776|stage III squamous cell carcinoma of the larynx
549834|NCT00503776|stage III verrucous carcinoma of the larynx
549835|NCT00503776|stage IV squamous cell carcinoma of the larynx
549836|NCT00503776|stage IV verrucous carcinoma of the larynx
549837|NCT00503776|recurrent squamous cell carcinoma of the larynx
549838|NCT00503776|recurrent verrucous carcinoma of the larynx
549839|NCT00503776|stage III squamous cell carcinoma of the lip and oral cavity
549840|NCT00503776|stage III verrucous carcinoma of the oral cavity
549841|NCT00503776|stage IV squamous cell carcinoma of the lip and oral cavity
549842|NCT00503776|stage IV verrucous carcinoma of the oral cavity
549843|NCT00503776|recurrent squamous cell carcinoma of the lip and oral cavity
549844|NCT00503776|recurrent verrucous carcinoma of the oral cavity
549845|NCT00503776|stage III squamous cell carcinoma of the nasopharynx
549846|NCT00503776|stage IV squamous cell carcinoma of the nasopharynx
549847|NCT00503776|recurrent squamous cell carcinoma of the nasopharynx
549848|NCT00503776|stage III squamous cell carcinoma of the oropharynx
549849|NCT00503776|stage IV squamous cell carcinoma of the oropharynx
549850|NCT00503776|recurrent squamous cell carcinoma of the oropharynx
549851|NCT00503776|salivary gland squamous cell carcinoma
549852|NCT00503776|stage III salivary gland cancer
549853|NCT00503776|stage IV salivary gland cancer
549854|NCT00503776|recurrent salivary gland cancer
549855|NCT00503763|Smoldering multiple myeloma
549856|NCT00503763|Simvastatin
549858|NCT00503750|Breast Cancer
549859|NCT00503737|colorectal cancer screening
549860|NCT00503737|National Colorectal Cancer Roundtable Toolbox
549861|NCT00503724|recurrent childhood brain stem glioma
549862|NCT00503724|childhood central nervous system germ cell tumor
549863|NCT00503724|recurrent childhood cerebellar astrocytoma
549864|NCT00503724|recurrent childhood cerebral astrocytoma
549865|NCT00503724|childhood choroid plexus tumor
549866|NCT00503724|childhood craniopharyngioma
549867|NCT00503724|childhood infratentorial ependymoma
549868|NCT00503724|childhood supratentorial ependymoma
549869|NCT00503724|recurrent childhood ependymoma
549870|NCT00503724|recurrent childhood medulloblastoma
549871|NCT00503724|childhood oligodendroglioma
549872|NCT00503724|recurrent childhood supratentorial primitive neuroectodermal tumor
549873|NCT00503724|recurrent childhood visual pathway and hypothalamic glioma
549874|NCT00503724|recurrent childhood visual pathway glioma
549875|NCT00503724|childhood grade I meningioma
549876|NCT00503724|childhood grade II meningioma
549877|NCT00503724|childhood grade III meningioma
549878|NCT00503724|recurrent childhood subependymal giant cell astrocytoma
549879|NCT00503724|recurrent childhood pineoblastoma
549880|NCT00503724|recurrent childhood brain tumor
549881|NCT00503724|disseminated neuroblastoma
549882|NCT00503724|recurrent neuroblastoma
549883|NCT00503711|ZD6474 PK
549884|NCT00503685|Metastatic Colorectal Cancer with Disease Progression
549885|NCT00503685|Failed prior to Anti-EGFr Therapy
549886|NCT00503672|Motor Activity
549887|NCT00503672|Pregnancy
549888|NCT00503672|Accelerometer
549889|NCT00503659|PC20 FEV1
549890|NCT00503659|PD20FEV1
549891|NCT00503659|bronchial hyperreactivity
549892|NCT00503659|bronchial asthma
549893|NCT00503646|psychosocial effects of cancer and its treatment
549894|NCT00503646|sexual dysfunction and infertility
549895|NCT00503646|sexuality and reproductive issues
549896|NCT00503646|stage IIB prostate cancer
549897|NCT00503646|stage IIA prostate cancer
549898|NCT00503646|stage I prostate cancer
549899|NCT00503633|sleep disorders
549900|NCT00503633|genetics
549901|NCT00503620|Cerebral Palsy
549902|NCT00503620|Botulinum Toxin
549903|NCT00503620|Neuromuscular Function
549904|NCT00503607|colonoscopy
549905|NCT00503607|bowel preparation
549906|NCT00503607|prep
549907|NCT00503594|Primary central nervous system lymphoma
549908|NCT00503594|Brain lymphoma
549909|NCT00503594|Elderly
549910|NCT00503594|Chemotherapy
549911|NCT00503594|Methotrexate
549912|NCT00503594|Temozolomide
549913|NCT00503594|Procarbazine
549914|NCT00503594|Vincristine
549915|NCT00503594|Cytarabine
549916|NCT00503568|stage IIIB non-small cell lung cancer
549917|NCT00503568|stage IV non-small cell lung cancer
549918|NCT00503568|recurrent non-small cell lung cancer
549919|NCT00503555|Primary Health Care
549920|NCT00503555|Hispanic Americans
549921|NCT00503542|Vaginitis
549922|NCT00503542|Bacterial Vaginosis
549923|NCT00503542|Vaginal trichomoniasis
549924|NCT00503542|Vulvovaginal candidiasis
549925|NCT00503516|weight loss, appetite, dementia, megestrol acetate
549926|NCT00503477|Japan
549927|NCT00503477|Phase I
549928|NCT00503477|solid tumor
549929|NCT00503477|AZD2171
549930|NCT00503464|guideline
549931|NCT00503464|adherence
549932|NCT00503451|Advanced cancer
549933|NCT00503451|solid tumors
549934|NCT00503451|lymphoma
549935|NCT00503451|HDAC
549936|NCT00503451|LBH589
549937|NCT00503451|adults
549938|NCT00503451|non-Hodgkin's lymphoma
549939|NCT00503438|Arthritis
549940|NCT00503438|Osteoarthritis
549941|NCT00503438|Arthroplasty
549942|NCT00503412|phase I
549943|NCT00503412|AZD2171
549944|NCT00503412|solid tumor
549945|NCT00503412|metastatic tumor
549946|NCT00503399|Glucocorticoid Induced
549947|NCT00503386|chemotherapy-induced nausea and vomiting
549948|NCT00503386|acute
549949|NCT00503386|delayed
549950|NCT00503386|emesis
549951|NCT00503386|antiemetics
549952|NCT00503386|5-HT3 receptor antagonist
549953|NCT00503386|granisetron
549954|NCT00503386|palonosetron
549955|NCT00503360|Ocular Hypertension
549956|NCT00503360|SAD448
549957|NCT00503347|coinfection with chronic hepatitis C virus and HIV
549958|NCT00503347|Treatment Naive
549959|NCT00503321|gastric cancer, TS-1, PSK
549960|NCT00503308|HIV Seronegativity
549961|NCT00503295|reovirus
549962|NCT00503295|oncolytic virus
549963|NCT00503295|sarcoma
549964|NCT00503295|REOLYSIN
549965|NCT00503295|Oncolytics Biotech
549966|NCT00503269|Haemorrhoidectomy
549967|NCT00503269|Local anaesthesia
549968|NCT00503256|Chronic Lymphocytic Leukemia
549969|NCT00503256|Leukemia
549970|NCT00503256|Lymphoma
549971|NCT00503256|Questionnaire
549972|NCT00503256|Survey
549973|NCT00503256|CLL
549974|NCT00503230|tobacco
549975|NCT00503230|smoking
549976|NCT00503230|HIV
549977|NCT00503230|Latino
549978|NCT00503217|intrauterine insemination
549979|NCT00503217|GnRH agonist
549980|NCT00503217|implantation
549981|NCT00503204|cancer
549982|NCT00503204|tumor
549983|NCT00503204|advance solid tumour
549984|NCT00503204|glioblastoma
549985|NCT00503204|malignant brain tumour
549986|NCT00503191|Autism
549987|NCT00503191|Neurodevelopmental disorder
549988|NCT00503165|Menitorix
549989|NCT00503165|vaccine
549990|NCT00503126|pediatrics
549991|NCT00503126|bivalirudin
549992|NCT00503100|Pain
549993|NCT00503100|Preterm-Born Adolescents
549994|NCT00503087|Injections
549995|NCT00503087|Vacuum
549996|NCT00503087|Pain
549997|NCT00503087|Pneumatic Skin Flattening
549998|NCT00503087|PSF
549999|NCT00503074|Diet, reducing
550000|NCT00503074|Television
550001|NCT00503074|Child Behavior
550002|NCT00503061|pharmaceopidemiological
550003|NCT00503061|Symbicort SMART
550004|NCT00503061|GPRD
550005|NCT00503048|atopy
550006|NCT00503048|atopic diseases
550007|NCT00503048|children
550008|NCT00503048|orphanages
550009|NCT00503035|Familial Adenomatous Polyposis
550010|NCT00503035|Colorectal Tumors
550011|NCT00503035|Molecular Targeting
550012|NCT00503035|Celecoxib
550013|NCT00503035|Celebrex
550014|NCT00503035|SC-58635
550015|NCT00503035|Apoptosis Induction
550016|NCT00503035|Colon
550017|NCT00503035|Rectum
550018|NCT00503035|colonoscopy
550019|NCT00503035|Biopsy
550020|NCT00503022|Wet age-related macular degeneration
550021|NCT00503022|ACZ885
550022|NCT00503009|Rhinovirus
550023|NCT00503009|Asthma
550024|NCT00502983|Acute Myelogenous Leukemia
550025|NCT00502983|Epidemiology
550026|NCT00502983|Leukemia
550027|NCT00502983|Healthy Control
550028|NCT00502983|Lifestyle Factors
550029|NCT00502983|Genetic Susceptibility
550030|NCT00502983|Interview
550031|NCT00502983|AML
550032|NCT00502970|Chronic HCV
550033|NCT00502970|Treatment
550034|NCT00502957|biofeedback
550035|NCT00502957|constipation
550036|NCT00502944|HIV
550037|NCT00502944|Testing
550038|NCT00502944|HIV Seronegativity
550039|NCT00502905|Acute Myeloid Leukemia
550040|NCT00502905|Myelodysplastic Syndromes
550041|NCT00502905|Busulfan
550042|NCT00502905|Busulfex
550043|NCT00502905|Myleran
550044|NCT00502905|Fludarabine
550045|NCT00502905|Fludarabine Phosphate
550046|NCT00502905|Fludara
550047|NCT00502892|Solid Tumors
550048|NCT00502892|Topotecan
550049|NCT00502892|Hycamtin
550050|NCT00502892|Ifosfamide
550051|NCT00502892|Ifex
550052|NCT00502892|Carboplatin
550053|NCT00502892|Paraplatin
550054|NCT00502892|Pediatric
550055|NCT00502892|Children
550056|NCT00502892|Young Adults
550057|NCT00502866|breastfeeding
550058|NCT00502866|vitamin D supplementation
550059|NCT00502866|rickets
550060|NCT00502827|Human Immunodeficiency Virus
550061|NCT00502827|HIV positive
550062|NCT00502827|HIV Positive Smokers
550063|NCT00502827|AIDS
550064|NCT00502827|Cell Phone Intervention
550065|NCT00502827|CPI
550066|NCT00502827|Smoking Cessation
550067|NCT00502827|Interview
550068|NCT00502814|Breast Cancer
550069|NCT00502814|3-D Optical Surface Scan
550070|NCT00502814|Soft Tissue Biomechanics
550071|NCT00502814|Mechanical Testing
550072|NCT00502814|Skin Ultrasound
550073|NCT00502814|Magnetic Resonance Imaging
550074|NCT00502814|CT Scan
550075|NCT00502801|Pneumonia
550076|NCT00502801|Lung Infection
550077|NCT00502801|Bacterial Infection
550078|NCT00502801|Hospital-Acquired Infection
550079|NCT00502801|Ventilator Infection
550080|NCT00502801|Antibiotic Therapy
550081|NCT00502775|ragweed
550082|NCT00502775|once daily
550083|NCT00502775|fexofenadine
550084|NCT00502775|fluticasone furoate
550085|NCT00502775|allergic rhinitis
550086|NCT00502762|small-cell lung cancer
550087|NCT00502762|refractory
550088|NCT00502762|topotecan
550089|NCT00502749|Leukemia
550090|NCT00502749|Lymphoma
550091|NCT00502749|Exercise
550092|NCT00502749|Quality of Life
550093|NCT00502749|Questionnaire
550094|NCT00502749|Survey
550095|NCT00502723|Retropubic Prostatectomy
550096|NCT00502723|Surgical Procedures
550097|NCT00502723|Laparoscopic
550098|NCT00502697|preterm
550099|NCT00502697|prematurity
550100|NCT00502697|home visitation
550101|NCT00502697|system of care
550102|NCT00502684|breast cancer
550103|NCT00502684|surgery
550104|NCT00502684|immune suppression
550105|NCT00502684|beta blockers
550106|NCT00502684|COX2 inhibitors
550107|NCT00502658|Overweight
550108|NCT00502658|Obese
550109|NCT00502658|Dietary Supplements
550110|NCT00502658|Shakes
550111|NCT00502658|Nutrition
550112|NCT00502658|Overweight and Obese Adults (BMI 25-35)
550113|NCT00502645|algorithm
550114|NCT00502645|cs-1 decision support system
550115|NCT00502645|insulin
550116|NCT00502645|hyperglycemia
550117|NCT00502645|tight glycemic control
550118|NCT00502645|intensive care
550119|NCT00502645|adults
550120|NCT00502632|Pleural empyema
550121|NCT00502632|Pleural effusion
550122|NCT00502632|Dornase alfa
550123|NCT00502632|Urokinase
550124|NCT00502632|Children
550125|NCT00502619|Low back pain
550126|NCT00502619|acupuncture
550127|NCT00502619|treadmill exercise
550128|NCT00502606|provisional restoration
550129|NCT00502606|antibacterial nanoparticles
550130|NCT00502606|cement
550131|NCT00502606|biofilm
550132|NCT00502606|bacteria
550133|NCT00502606|flora
550134|NCT00502606|plaque
550135|NCT00502606|dental
550136|NCT00502606|prosthesis
550137|NCT00502593|Influenza
550138|NCT00502593|Pandemic Influenza Vaccine (GSK1562902A)
550139|NCT00502580|Oral Cancer
550140|NCT00502580|Multispectral Digital Microscope
550141|NCT00502580|Multispectral Digital Imaging
550142|NCT00502580|Interview
550143|NCT00502580|MDM
550144|NCT00502567|advanced solid tumors
550145|NCT00502567|AZD2171
550146|NCT00502567|Phase I
550147|NCT00502554|lung function
550148|NCT00502554|FEV1
550149|NCT00502528|Infarction
550150|NCT00502528|Endothelin
550151|NCT00502528|Perfusion
550152|NCT00502515|Diabetes
550153|NCT00502515|Neuropathy
550154|NCT00502502|Anal Cancer
550155|NCT00502502|Colorectal Cancer
550156|NCT00502502|Esophageal Cancer
550157|NCT00502502|Gastric Cancer
550158|NCT00502502|Lung Cancer
550159|NCT00502502|Questionnaire
550160|NCT00502502|Survey
550161|NCT00502502|Chemoradiation Therapy
550162|NCT00502502|Symptoms
550163|NCT00502502|Cytokines
550164|NCT00502489|prolonged mechanical ventilation; weaning;rehabilitation
550165|NCT00502476|MRSA
550166|NCT00502476|VRE
550167|NCT00502476|BSI
550168|NCT00502463|head and neck cancer, stage III/IV
550169|NCT00502463|no prior radiotherapy of head and neck region
550170|NCT00502450|Acute mastoiditis
550171|NCT00502450|Hearing loss
550172|NCT00502450|Mastoidectomy
550173|NCT00502450|Audiogram
550174|NCT00502424|Rheumatoid Arthritis
550175|NCT00502424|Hand
550176|NCT00502424|Splint
550177|NCT00502424|Occupational Therapy
550178|NCT00502411|Soft Tissue Sarcoma
550179|NCT00502411|External Beam Radiotherapy
550180|NCT00502411|Radiation Therapy
550181|NCT00502411|Extremity and Trunk
550182|NCT00502411|EBRT
550183|NCT00502411|Sarcoma
550184|NCT00502411|Doxorubicin
550185|NCT00502411|AD
550186|NCT00502411|Hydroxydaunomycin hydrochloride
550187|NCT00502411|XRT
550188|NCT00502411|RT
550189|NCT00502411|Radiotherapy
550190|NCT00502385|Phase I
550191|NCT00502385|AML
550192|NCT00502385|de novo or secondary AML
550193|NCT00502385|AZD2171
550194|NCT00502359|Gestational diabetes, screening, glucose monitoring
550195|NCT00502346|Pharmacodynamics
550196|NCT00502333|back pain
550197|NCT00502333|neck pain
550198|NCT00502333|prognosis
550199|NCT00502333|catastrophizing
550200|NCT00502333|coping strategies
550201|NCT00502333|disability
550202|NCT00502333|Prognosis for back and neck pain
550203|NCT00502320|Seasonal Affective Disorder
550204|NCT00502320|Ramelteon
550205|NCT00502320|Psychiatry
550206|NCT00502320|Randomized Controlled Trial
550207|NCT00502320|Hamilton Depression Rating Scale- SAD Version
550208|NCT00502320|Circadian Rhythm
550209|NCT00502307|Renal Cell Carcinoma
550210|NCT00502307|AV-951
550211|NCT00502307|tivozanib
550212|NCT00502294|Ulcerative Colitis, UC, Intravenous Steroid-Refractory Ulcerative Colitis, IVSR-UC
550213|NCT00502281|Gonadotropins
550214|NCT00502281|Infertility
550215|NCT00502281|Intrauterine insemination
550216|NCT00502281|PCOS
550217|NCT00502281|Timed intercourse
550218|NCT00502281|Treatment
550219|NCT00502268|Coronary Calcification
550220|NCT00502268|Endstage Renal Disease
550221|NCT00502268|Parathyroid hormone
550222|NCT00502255|Telemonitoring
550223|NCT00502255|Cost-effectiveness
550224|NCT00502255|Heart failure
550225|NCT00502255|Case management
550226|NCT00502229|Clomiphene citrate
550227|NCT00502229|Controlled overian stimulation
550228|NCT00502229|Infertility
550229|NCT00502229|Metformin
550230|NCT00502229|Polycystic ovary syndrome
550231|NCT00502229|Treatment
550232|NCT00502216|Tobacco
550233|NCT00502216|Smoking
550234|NCT00502216|Weight
550235|NCT00502216|Naltrexone
550236|NCT00502216|Varenicline
550237|NCT00502203|Uterine Neoplasms
550238|NCT00502203|Endometrial Cancer
550239|NCT00502203|Paclitaxel
550240|NCT00502203|Taxol
550241|NCT00502203|Carboplatin
550242|NCT00502203|Paraplatin
550243|NCT00502203|Malignant Mixed Mullerian Tumors
550244|NCT00502203|MMMT
550245|NCT00502203|Immunohistochemical markers
550246|NCT00502190|pessary
550247|NCT00502190|extending pregnancy
550248|NCT00502177|Continuous Hyperthermic Peritoneal Perfusion
550249|NCT00502177|Peritoneal Neoplasms
550250|NCT00502177|Quality of Life
550251|NCT00502177|Questionnaire
550252|NCT00502177|Survey
550253|NCT00502177|CHPP
550254|NCT00502164|Advanced Prostate Cancer
550255|NCT00502138|diabetes
550256|NCT00502138|insulin
550257|NCT00502138|pramlintide
550258|NCT00502138|IDDM
550259|NCT00502125|Reflectance Confocal Imaging
550260|NCT00502125|Oral Mucosal Lesions
550261|NCT00502125|Oral Mucosa Disease
550262|NCT00502125|Neoplasia Detection
550263|NCT00502112|Lintuzumab
550264|NCT00502112|Antigens, CD33
550265|NCT00502112|Antibodies, Monoclonal
550266|NCT00502112|Combined Modality Therapy
550267|NCT00502112|Myelodysplastic Syndromes
550268|NCT00502112|Hematologic Diseases
550269|NCT00502112|Preleukemia
550270|NCT00502099|Chronic hepatitis C
550271|NCT00502099|pegylated interferon alfa-2a
550272|NCT00502099|ribavirin, rapid virologic response
550273|NCT00502099|early virologic response
550274|NCT00502099|sustained virologic response
550275|NCT00502086|Chronic hepatitis C
550276|NCT00502086|Cirrhosis of the liver
550277|NCT00502086|Mortality
550278|NCT00502086|Complications
550279|NCT00502086|Health-related quality of live
550280|NCT00502086|Hepatocellular carcinoma
550281|NCT00502086|Nutritional supplement
550282|NCT00501384|cirrhotic ascites
550283|NCT00501371|Benign Prostatic Hyperplasia
550284|NCT00501371|MCS
550285|NCT00501371|Lower Urinary Tract Symptoms
550286|NCT00501371|International prostate symptom score
550287|NCT00501371|Voiding
550288|NCT00501371|Alpha-blockers
550289|NCT00501358|SLEEP APNEA
550290|NCT00501358|venous thromboembolism
550291|NCT00501358|COAGULABILITY
550292|NCT00501358|COAGULATION FACTORS
550293|NCT00501358|HYPOXIA
550294|NCT00501345|Thrombocytopenia
550295|NCT00501345|Platelet Function
550296|NCT00501345|Acute Coronary Syndrome
550297|NCT00501345|Myocardial Infarction
550298|NCT00501345|Heart Attack
550299|NCT00501345|Aspirin
550300|NCT00501332|neutropenia
550301|NCT00501332|breast
550302|NCT00501332|cancer
550303|NCT00501332|chemotherapy
550304|NCT00501319|Interactive Voice Response Telephone System
550305|NCT00501319|Non-Small Cell Lung Cancer
550306|NCT00501319|Lung Cancer
550307|NCT00501319|Questionnaire
550308|NCT00501319|Survey
550309|NCT00501319|NSCLC
550310|NCT00501319|IVR
550311|NCT00501306|Condyloma Accuminata
550312|NCT00501306|Low Grade Squamous Intraepithelial Lesion
550313|NCT00501306|High Grade Squamous Intraepithelial Lesion
550314|NCT00501306|Anal Cancer Screening
550315|NCT00501280|Epidemiology
550316|NCT00501280|Genetic Susceptibility
550317|NCT00501280|Migrant Farmworker Children
550318|NCT00501280|Migrant Education Program
550319|NCT00501280|Interview
550320|NCT00501280|Questionnaire
550321|NCT00501267|solabegron,
550322|NCT00501267|oxybutynin,
550323|NCT00501267|healthy adults,
550324|NCT00501267|drug interaction
550325|NCT00501254|Slow release ASA
550326|NCT00501254|Platelet functionalism
550327|NCT00501254|Secondary cardiovascular prevention
550328|NCT00501228|Graft-Versus-Host Disease
550329|NCT00501228|Stem Cell Transplantation
550330|NCT00501228|Tissue Repair
550331|NCT00501228|Organ-Specific Tissue Damage
550332|NCT00501228|Filgrastim
550333|NCT00501228|RhG-CSF
550334|NCT00502060|Phase I
550335|NCT00502060|AZD2171
550336|NCT00502060|ZD1839
550337|NCT00502060|solid tumor
550338|NCT00502047|plantago ovata husk
550339|NCT00502047|soluble fibre
550340|NCT00502047|hypercholesterolemia
550341|NCT00502047|cardiovascular risk factor
550342|NCT00502034|Carcinoma, Renal Cell
550343|NCT00502034|Low-dose Interleukin
550344|NCT00502034|Adjuvant Immunotherapy
550345|NCT00502021|obesity
550346|NCT00502021|alpha linolenic acid
550347|NCT00502021|flaxseed
550348|NCT00502021|C-reactive protein
550349|NCT00502021|inflammation
550350|NCT00502008|Diabetes
550351|NCT00502008|India
550352|NCT00502008|Coccinia Cordifolia
550353|NCT00502008|Coccinia indica
550354|NCT00502008|Blood glucose levels
550355|NCT00501995|High Dose Cyclophosphamide
550356|NCT00501995|Systemic Sclerosis
550357|NCT00501995|Scleroderma
550358|NCT00501995|immunoablation
550359|NCT00501982|surfactant
550360|NCT00501982|RDS
550361|NCT00501982|nCPAP
550362|NCT00501982|Mechanical Ventilation
550363|NCT00501982|Premature Infants
550364|NCT00501982|Neonatal Respiratory Distress Syndrome (nRDS)
550365|NCT00501969|Rotigotine
550366|NCT00501969|Neupro®
550367|NCT00501956|chronic renal replacement therapy
550368|NCT00501956|malnutrition anorexia
550369|NCT00501956|parenteral nutrition
550370|NCT00501930|Dose Escalation;
550371|NCT00501930|Supratherapeutic;
550372|NCT00501930|GSK189075;
550373|NCT00501930|Diabetes
550374|NCT00501917|acute myocardial infarction
550375|NCT00501904|Anovulation
550376|NCT00501904|Infertility
550377|NCT00501904|Metformin
550378|NCT00501904|PCOS
550379|NCT00501904|Treatment
550380|NCT00501891|Glioblastoma Multiforme
550381|NCT00501891|Brain and Central Nervous System Tumors
550382|NCT00501891|Recurrent Malignant Glioma
550383|NCT00501891|Recurrent Glioblastoma Multiforme
550384|NCT00501891|Avastin
550385|NCT00501891|Bevacizumab
550386|NCT00501891|Temodar
550387|NCT00501891|Temozolomide
550388|NCT00501878|phenylephrine
550389|NCT00501878|mydriasis
550390|NCT00501878|diabetes mellitus
550391|NCT00501865|healthy volunteers
550392|NCT00501865|food effect,
550393|NCT00501865|quantitative pharmacokinetic analysis,
550394|NCT00501865|GW273225,
550395|NCT00501852|COPD, Age≥40 yrs, Glycopyrronium Bromide
550396|NCT00501839|Anovulation
550397|NCT00501839|Clomiphene citrate
550398|NCT00501839|Infertility
550399|NCT00501839|PCOS
550400|NCT00501839|Treatment
550401|NCT00501826|Leukemia
550402|NCT00501826|ALL
550403|NCT00501826|T-cell ALL
550404|NCT00501826|Lymphoblastic Lymphoma
550405|NCT00501826|Hyper-CVAD
550406|NCT00501826|Doxorubicin
550407|NCT00501826|Cyclophosphamide
550408|NCT00501826|Cytarabine
550409|NCT00501826|Dexamethasone
550410|NCT00501826|Methotrexate
550411|NCT00501826|Vincristine
550412|NCT00501826|Nelarabine
550413|NCT00501813|Hepatocellular carcinoma
550414|NCT00501813|Intrahepatic vessels invasion
550415|NCT00501813|Hepatectomy
550416|NCT00501813|Transcatheter arterial chemoembolization
550417|NCT00501813|Local regional treatment
550418|NCT00501800|Reproductive Health
550419|NCT00501800|Fertility
550420|NCT00501800|Infertility
550421|NCT00501800|Genetics
550422|NCT00501800|Continental Population Groups
550423|NCT00501800|Epidemiology
550424|NCT00501800|Aging
550425|NCT00501800|Health
550426|NCT00501787|Anovulation
550427|NCT00501787|metformin
550428|NCT00501787|PCOS
550429|NCT00501787|treatment
550430|NCT00501774|Localized vulvodynia
550431|NCT00501774|Helicobacter pylori
550432|NCT00501774|peptic disease
550433|NCT00501774|omeprazole
550434|NCT00501761|Endometrial Cancer
550435|NCT00501761|Healthy Controls
550436|NCT00501761|Social Cognitive Theory
550437|NCT00501761|Behavioral Intervention
550438|NCT00501761|Physical Activity
550439|NCT00501761|Exercise Program
550440|NCT00501761|Questionnaire
550441|NCT00501748|Neuromyelitis Optica
550442|NCT00501748|acute transverse myelitis
550443|NCT00501735|T-Cell
550444|NCT00501735|Lymphoma
550445|NCT00501735|Forodesine
550446|NCT00501735|Mycosis Fungoides
550447|NCT00501722|cirrhotic ascites
550448|NCT00501722|hyponatraemia
550449|NCT00501683|metabolite profiling
550450|NCT00501683|excretion,
550451|NCT00501683|radioactivity,
550452|NCT00501683|pharmacokinetic,
550453|NCT00501683|mass balance,
550454|NCT00501670|Herpes zoster
550455|NCT00501670|PCR
550456|NCT00501670|Varicella zoster Virus (VZV)
550457|NCT00501670|Shingles
550458|NCT00501670|GSK Biologicals
550459|NCT00501657|gastric emptying
550460|NCT00501657|glycemia
550461|NCT00501657|appetite
550462|NCT00501657|incretin hormones
550463|NCT00501644|Müllerian Carcinomas
550464|NCT00501644|Ovarian Cancer
550465|NCT00501644|Fallopian Tube Cancer
550466|NCT00501644|Peritoneal Cancer
550467|NCT00501644|Epithelial Ovarian
550468|NCT00501644|Peritoneal
550469|NCT00501644|Fallopian Tube
550470|NCT00501644|Chemoimmunotherapy
550471|NCT00501644|Platinum Sensitive Müllerian
550472|NCT00501644|Carboplatin
550473|NCT00501644|Paraplatin
550474|NCT00501644|GM-CSF
550475|NCT00501644|Sargramostim
550476|NCT00501644|Interferon Gamma
550477|NCT00501644|Quality of Life
550478|NCT00501644|QOL
550479|NCT00501631|Addiction
550480|NCT00501631|Alcoholism
550481|NCT00501631|Inpatient detoxification
550482|NCT00501618|Schizophrenia
550483|NCT00501618|Schizoaffective Disorder
550484|NCT00501618|Orally dissolving clozapine
550485|NCT00501618|orally disintegrating clozapine
550486|NCT00501618|bio-equivalence
550487|NCT00501618|desmethylclozapine
550488|NCT00501618|clozapine plasma level
550489|NCT00501618|equivalence
550490|NCT00501618|fazaclo
550491|NCT00501618|generic clozapine
550492|NCT00501605|Phase I
550493|NCT00501605|AZD2171
550494|NCT00501605|advanced solid tumors
550495|NCT00501592|Farnesoid X receptor agonist
550496|NCT00501592|Metabolic Disorder
550497|NCT00501592|Diabetes
550498|NCT00501592|NAFLD
550499|NCT00501566|cirrhotic ascites
550500|NCT00501553|Heart Failure,
550501|NCT00501553|Vitamin D status,
550502|NCT00501553|NT-proBNP
550503|NCT00501540|low-grade neuroendocrine tumors
550504|NCT00501540|lithium
550505|NCT00501527|Allergoid
550506|NCT00501527|Depigmented
550507|NCT00501527|Polymerized
550508|NCT00501527|Allergen-extract
550509|NCT00501527|Rhinoconjunctivitis
550510|NCT00501527|Asthma
550511|NCT00501514|chronic heart failure
550512|NCT00501514|cardiopulmonary exercise
550513|NCT00501514|oxygen consumption
550514|NCT00501514|growth hormone
550515|NCT00501501|Rehospitalization
550516|NCT00501501|Cesarean
550517|NCT00501501|Vaginal delivery
550518|NCT00501488|pharmacodynamics
550519|NCT00501488|insulin resistance
550520|NCT00501488|therapy
550521|NCT00501488|volunteer
550522|NCT00501475|N-acetylcysteine
550523|NCT00501475|nephropathy
550524|NCT00501475|bicarbonate
550525|NCT00501462|Type 2 Diabetes Mellitus
550526|NCT00501462|renal insufficiency
550527|NCT00501449|Multiple Endocrine Neoplasia
550528|NCT00501449|Questionnaire
550529|NCT00501449|Psychosocial
550530|NCT00501449|Surveillance Behaviors
550531|NCT00501449|MEN Syndromes
550532|NCT00501423|antiplatelet drug
550533|NCT00501423|resistance
550534|NCT00501423|atherothrombosis
550535|NCT00501410|Colorectal Cancer
550536|NCT00501410|Dual Inhibition of EGFR
550537|NCT00501410|FOLFOX Chemotherapy
550538|NCT00501410|5-FU
550539|NCT00501410|Cetuximab
550540|NCT00501410|Dasatinib
550541|NCT00501410|Leucovorin
550542|NCT00501410|Oxaliplatin
550543|NCT00501410|5-Fluorouracil
550544|NCT00501410|BMS-354825
550545|NCT00501410|Eloxatin
550546|NCT00501410|Sprycel
550547|NCT00501410|C225
550548|NCT00501410|Erbitux
550549|NCT00501410|IMC-C225
550550|NCT00501410|Adrucil
550551|NCT00501410|Efudex
550552|NCT00501410|Folinic Acid
550553|NCT00501397|ketoconazole,
550554|NCT00501397|drug interaction,
550555|NCT00501397|pharmacokinetics
550556|NCT00501397|T2DM,
550557|NCT00501215|Primary Hyperparathyroidism
550558|NCT00501215|PHPT
550559|NCT00501215|Parathyroidectomy
550560|NCT00501215|Polysomnogram
550561|NCT00501215|PSG
550562|NCT00501215|Sleep Quality
550563|NCT00501215|Interview
550564|NCT00501202|diabetes mellitus
550565|NCT00501202|diabetic microvascular injury
550566|NCT00501202|painful polyneuropathy.
550567|NCT00501189|Gardasil
550568|NCT00501189|Human Papilloma Virus
550569|NCT00501189|Papanicolaou Smear
550570|NCT00501189|ASCUS
550571|NCT00501189|LGSIL
550572|NCT00501189|Human Papilloma Virus Vaccine
550573|NCT00501189|Human Papillomavirus Infection
550574|NCT00501176|Pancreas
550575|NCT00501176|cancer
550576|NCT00501176|SEMS
550577|NCT00501176|Plastic
550578|NCT00501176|stent
550579|NCT00501176|Whipple
550580|NCT00501176|Jaundicie
550581|NCT00501163|Schizophrenia
550582|NCT00501163|Cardiovascular
550583|NCT00501163|Risk
550584|NCT00501150|linezolid
550585|NCT00501150|vancomycin
550586|NCT00501150|glycopeptides
550587|NCT00501150|methicillin resistant staphylococcus aureus
550588|NCT00501150|resistant gram positive infections
550589|NCT00501137|HPV
550590|NCT00501137|HPV vaccine
550591|NCT00501137|Gardasil
550592|NCT00501137|Human Papillomavirus
550593|NCT00501137|vaccine
550594|NCT00501137|2 dose versus 3
550595|NCT00501111|Dementia
550596|NCT00501111|Alzheimer Type
550597|NCT00501111|Alzheimer Disease
550598|NCT00501098|Leukemia
550599|NCT00501098|Prophylaxis
550600|NCT00501098|Fungal Infections
550601|NCT00501098|Caspofungin
550602|NCT00501072|hyperglycemia
550603|NCT00501072|hypoglycemia
550604|NCT00501072|glucose variability
550605|NCT00501072|insulin infusion system; implantable insulin pump
550606|NCT00501072|continuous glucose monitoring
550607|NCT00501059|Primary prevention of coronary heart disease
550608|NCT00501059|Stroke and cardiovascular death
550609|NCT00501059|Aspirin
550610|NCT00501046|Kidney Diseases
550611|NCT00501033|Induction of labor
550612|NCT00501033|Cesarean
550613|NCT00501033|Endometritis
550614|NCT00501033|Foley
550615|NCT00501033|Infections
550616|NCT00501020|Type 2 Diabetes
550617|NCT00501020|metformin
550618|NCT00501020|rosiglitazone
550619|NCT00500994|Conversion Disorder
550620|NCT00500994|Psychogenic Movement Disorders
550621|NCT00500994|Non-Epileptic Seizure
550622|NCT00500994|Functional Magnetic Resonance Imaging (fMRI)
550623|NCT00500994|Genetic Polymorphisms
550624|NCT00500994|Psychogenic Movement Disorder
550625|NCT00500994|PMD
550626|NCT00500994|NES
550627|NCT00500994|Healthy Volunteer
550628|NCT00500994|HV
550629|NCT00500981|Fluid responsiveness
550630|NCT00500968|Pancreas
550631|NCT00500968|Leakage
550632|NCT00500968|Fistula
550633|NCT00500968|tail
550634|NCT00500955|microalbuminuria,
550635|NCT00500955|Type 2 Diabetes
550636|NCT00500955|rosiglitazone,
550637|NCT00500942|Interventional Radiology
550638|NCT00500942|Pain Quantification
550639|NCT00500942|Pain Management
550640|NCT00500942|Patient Satisfaction
550641|NCT00500942|Questionnaire
550642|NCT00500942|Survey
550643|NCT00500929|OHSP
550644|NCT00500929|High risk
550645|NCT00500929|Geriatrics
550646|NCT00500903|Advanced malignancies
550647|NCT00500890|Choroid Plexus Tumors
550648|NCT00500890|Carboplatin
550649|NCT00500890|Cyclophosphamide
550650|NCT00500890|Etoposide
550651|NCT00500890|Vincristine
550652|NCT00500890|Paraplatin
550653|NCT00500890|Cytoxan
550654|NCT00500890|Neosar
550655|NCT00500877|Smoking cessation
550656|NCT00500877|Phone Counseling
550657|NCT00500864|COPD
550658|NCT00500864|Magnesium
550659|NCT00500864|Pulmonary function
550660|NCT00500864|Exercise Physiology
550661|NCT00500851|critical illness
550662|NCT00500851|enteral nutrition
550663|NCT00500851|gastrointestinal intubation
550664|NCT00500838|Cardiac Resynchronization Therapy
550665|NCT00500838|Transthoracic Impedance
550666|NCT00500825|Cardiopulmonary resuscitation
550667|NCT00500825|Therapeutic hypothermia
550668|NCT00500825|resting energy expenditure
550669|NCT00500812|biologic drug
550670|NCT00500812|transport sequence
550671|NCT00500812|rho
550672|NCT00500812|spinal cord injury
550673|NCT00500812|paralysis
550674|NCT00500812|paraplegia
550675|NCT00500812|tetraplegia
550676|NCT00500812|quadraplegia
550677|NCT00500812|trauma
550678|NCT00500812|nervous system
550679|NCT00500812|fibrin sealant
550680|NCT00500812|neurosurgery
550681|NCT00500799|Transcranial Magnetic Stimulation (TMS)
550682|NCT00500799|Blink Reflex
550683|NCT00500799|Blepharospasm
550684|NCT00500799|Healthy Volunteer
550685|NCT00500799|HV
550686|NCT00500773|cardiovascular risc factors
550687|NCT00500773|inflammation
550688|NCT00500773|aerobic and exertional exercise
550689|NCT00500760|Head and Neck Cancer
550690|NCT00500760|panitumumab
550691|NCT00500747|hepatitis C, HCV, vaccine, recombinant vaccine, adjuvant
550692|NCT00500734|Cardiomyopathy
550693|NCT00500734|Tissue Bank
550694|NCT00500734|Heart Disease
550695|NCT00500734|Heart Failure
550696|NCT00500734|Congestive Heart Failure
550697|NCT00500721|healthy subjects
550698|NCT00500708|Heart failure
550699|NCT00500708|Implanted Cardioverter Defibrillator
550700|NCT00500708|Biological Markers
550701|NCT00500708|Molecular Genetics
550702|NCT00500682|Kidney Diseases
550703|NCT00500669|Varicose veins
550704|NCT00500669|wound infection
550705|NCT00500669|recurrence
550706|NCT00500617|Atherosclerosis
550707|NCT00500617|Biological Markers
550708|NCT00500617|Molecular Genetics
550709|NCT00500591|Endometrial Abnormalities
550710|NCT00500591|Endometrial Cancer
550711|NCT00500591|Obesity
550712|NCT00500591|Survey
550713|NCT00500591|Questionnaire
550714|NCT00500578|Hematological Malignancies
550715|NCT00500578|Respiratory Infection
550716|NCT00500578|Respiratory Syncytial Virus
550717|NCT00500578|RSV
550718|NCT00500578|Ribavirin
550719|NCT00500578|Virazole
550720|NCT00500565|Breast Cancer
550721|NCT00500565|On-Q Pain Relief System
550722|NCT00500565|Transverse Rectus Abdominous Myocutaneous
550723|NCT00500565|Breast Reconstruction
550724|NCT00500565|TRAM flap
550725|NCT00500565|Bupivicaine
550726|NCT00500565|Pain Management
550727|NCT00500552|Perhexiline
550728|NCT00500552|Hypertrophic Cardiomyopathy
550729|NCT00500539|Asthma
550730|NCT00500539|omalizumab
550731|NCT00500539|safety
550732|NCT00500539|allergic asthma
550733|NCT00500539|adolescents
550734|NCT00500526|COPD
550735|NCT00500526|Pulmonary function
550736|NCT00500526|Respiratory muscle
550737|NCT00500526|Dyspnea
550738|NCT00500526|Quality of life
550739|NCT00500513|Lung Cancer
550740|NCT00500513|Respiratory-Induced Tumor Motion
550741|NCT00500513|Tumor Motion
550742|NCT00500513|Pulmonary Function
550743|NCT00500513|Fiducial Marker
550744|NCT00500487|HIV prevention
550745|NCT00500487|HIV seronegativity
550746|NCT00500474|Meniere's disease
550747|NCT00500474|inner ear
550748|NCT00500474|endolymphatic sac drainage
550749|NCT00500474|steroids
550750|NCT00500474|declined surgery
550751|NCT00500474|natural course
550752|NCT00500474|Efficacy of steroids via endolymphatic sac
550753|NCT00500474|for intractable Meniere's disease
550754|NCT00500461|Muscarinic Receptor Antagonist,
550755|NCT00500461|intravenous infusion,
550756|NCT00500461|pharmacokinetics
550757|NCT00500461|healthy subjects,
550758|NCT00500461|safety,
550759|NCT00500461|tolerability,
550760|NCT00500461|Anticholinergic,
550761|NCT00500461|oral dosing,
550762|NCT00500448|Arthritis, Knee, Quadriceps, Electrical Stimulation, Women
550763|NCT00500435|Cervical Cancer
550764|NCT00500435|Laparoscopy
550765|NCT00500435|Lymph Node Dissection
550766|NCT00500435|Extraperitoneal Laparoscopic Lymphadenectomy
550767|NCT00500422|Solid Tumors
550768|NCT00500422|Doxil
550769|NCT00500422|Adriamycin
550770|NCT00500422|Pegylated Liposomal Doxorubicin
550771|NCT00500422|Liposomal Doxorubicin
550772|NCT00500422|Doxorubicin Hydrochloride
550773|NCT00500422|Gemcitabine
550774|NCT00500422|Gemzar
550775|NCT00500422|Bortezomib
550776|NCT00500422|Velcade
550777|NCT00500422|PS341
550778|NCT00500422|PS-341
550779|NCT00500422|LDP-341
550780|NCT00500422|MLN341
550781|NCT00500409|rhPTH(1-34)
550782|NCT00500409|Osteoporosis
550783|NCT00500396|Retinopathy of Prematurity.
550784|NCT00500396|ROP.
550785|NCT00500396|Vascular Endothelial Growth Factor.
550786|NCT00500396|VEGF.
550787|NCT00500396|Vitreous.
550788|NCT00500396|Subretinal Fluid.
550789|NCT00500396|ELISA.
550790|NCT00500383|Breast Cancer Risk
550791|NCT00500383|BRCA1
550792|NCT00500383|BRCA2
550793|NCT00500383|Breast Cancer Susceptibility gene
550794|NCT00500383|Optical Transillumination Spectroscopy
550795|NCT00500383|Transillumination Breast Spectroscopy
550796|NCT00500370|exenatide
550797|NCT00500370|obesity
550798|NCT00500370|diabetes
550799|NCT00500370|Amylin
550800|NCT00500370|Lilly
550801|NCT00500344|Age-related Macular Degeneration
550802|NCT00500344|Choroidal Neovascularization
550803|NCT00500344|Electroretinography
550804|NCT00500344|Retinal Function
550805|NCT00500331|Pioglitazone
550806|NCT00500331|HbA1c
550807|NCT00500331|Diabetes mellitus
550808|NCT00500318|Bronchitis, Chronic; Emphysema
550809|NCT00500305|indomethacin therapy
550810|NCT00500305|patent ductus arteriosus
550811|NCT00500292|colorectal
550812|NCT00500292|cancer
550813|NCT00500292|zactima
550814|NCT00500279|Drug-eluting stent
550815|NCT00500279|Restenosis
550816|NCT00500279|Celecoxib
550817|NCT00500266|pneumococcal conjugate vaccine
550818|NCT00500266|vaccine
550819|NCT00500253|exhaled nitric oxide
550820|NCT00500253|asthma
550821|NCT00500253|children
550822|NCT00500253|inhaled glucocorticosteroids
550823|NCT00500240|Acute Lymphocytic Leukemia
550824|NCT00500240|Leukemia
550825|NCT00500240|Lymphoma
550826|NCT00500240|Burkitts Lymphoma
550827|NCT00500240|Lymphoblastic Leukemia
550828|NCT00500240|Blood Sugar
550829|NCT00500240|Hyperglycemia
550830|NCT00500240|Insulin Aspart
550831|NCT00500240|Insulin Glargine
550832|NCT00500240|Hyper-CVAD
550833|NCT00500214|inguinal hernia
550834|NCT00500214|herniorrhaphy
550835|NCT00500214|mesh repair
550836|NCT00500214|ilioinguinal neurectomy
550837|NCT00500214|postoperative pain in cases and controls during one year.
550838|NCT00500214|postoperative hyposthesia in cases and controls during one year.
550839|NCT00500201|Healthy Volunteer
550840|NCT00500188|Gastrointestinal Stromal Tumors
550841|NCT00500188|GIST
550842|NCT00500188|Kit expression
550843|NCT00500188|Resectable
550844|NCT00500188|Imatinib Mesylate
550845|NCT00500188|Gleevec
550846|NCT00500188|STI-571
550847|NCT00500188|Imatinib
550848|NCT00500188|NSC-716051
550849|NCT00500175|diabetes
550850|NCT00500175|ulceration
550851|NCT00500175|amputation
550852|NCT00500175|pressure sores
550853|NCT00500175|shear friction
550854|NCT00500136|bias
550855|NCT00500123|alpha-1
550856|NCT00500123|antitrypsin
550857|NCT00500123|AAT
550858|NCT00500123|genetic testing
550859|NCT00500123|alpha-1 antitrypsin deficiency
550860|NCT00500123|AATD
550861|NCT00500110|Prostate Cancer
550862|NCT00500110|Hormonal Ablation
550863|NCT00500110|Docetaxel
550864|NCT00500110|Imatinib Mesylate
550865|NCT00500110|STI571
550866|NCT00500110|Gleevec
550867|NCT00500110|Taxotere
550868|NCT00500110|Goserelin Acetate
550869|NCT00500110|Zoladex
550870|NCT00500110|Leuprolide
550871|NCT00500110|Lupron
550872|NCT00500084|Chronic Pancreatitis
550873|NCT00500084|Pancreatectomy
550874|NCT00500058|Rituximab,
550875|NCT00500058|oncology
550876|NCT00500058|IL-18,
550877|NCT00500058|combination study,
550878|NCT00500058|cytokine,
550879|NCT00500045|CRVO
550880|NCT00500045|HRVO
550881|NCT00500045|BRVO
550882|NCT00500032|Adult
550883|NCT00499980|Breast cancer
550884|NCT00499980|Spectroscopy, Near-Infrared
550885|NCT00499980|Oximetry
550886|NCT00499967|genital warts
550887|NCT00499967|venereal warts
550888|NCT00499967|human papilloma virus
550889|NCT00499954|microdialysis
550890|NCT00499954|subcutaneous adipose tissue
550891|NCT00499954|glucose sensor
550892|NCT00499954|glucose monitoring
550893|NCT00499954|type 1 diabetes
550894|NCT00499954|Guardian RT
550895|NCT00499954|Glucoday S
550896|NCT00499941|Alpha 1-Antitrypsin Deficiency
550897|NCT00499928|SB-751689
550898|NCT00499928|osteoporosis
550899|NCT00499928|metabolism
550900|NCT00499928|excretion
550901|NCT00499902|AIS
550902|NCT00499902|acute ischemic stroke
550903|NCT00499902|stroke
550904|NCT00499902|alfimeprase
550905|NCT00499902|blood clot
550906|NCT00499902|brain
550907|NCT00499902|thrombus
550908|NCT00499902|thrombolytic
550909|NCT00499902|thrombosis
550910|NCT00499902|plasminogen activator
550911|NCT00499902|arterial flow
550912|NCT00499902|neurology
550913|NCT00499902|intra-arterial
550914|NCT00499902|intra-thrombus
550915|NCT00499902|catheter-directed
550916|NCT00499902|symptomatic ICH
550917|NCT00499902|ICH
550918|NCT00499902|AOL
550919|NCT00499902|arterial occlusive lesion
550920|NCT00499902|recanalization
550921|NCT00499889|Chronic Myelogenous Leukemia
550922|NCT00499889|Allogeneic Stem Cell Transplantation
550923|NCT00499889|Leukemia
550924|NCT00499889|Imatinib Mesylate
550925|NCT00499889|Gleevec
550926|NCT00499889|Busulfan
550927|NCT00499889|Busulfex
550928|NCT00499889|Myleran
550929|NCT00499889|Fludarabine
550930|NCT00499889|ATG
550931|NCT00499889|STI571
550932|NCT00499889|Antithymocyte Globulin
550933|NCT00499889|Thymoglobulin
550934|NCT00499876|Human immune deficiency virus
550935|NCT00499876|Acquired immune deficiency syndrome
550936|NCT00499876|malaria
550937|NCT00499876|mefloquine
550938|NCT00499876|prophylaxis
550939|NCT00499876|HIV/AIDS
550940|NCT00499876|Treatment Naive
550941|NCT00499850|ZD6474
550942|NCT00499850|FOLFOX
550943|NCT00499850|colorectal
550944|NCT00499850|adenocarcinoma
550945|NCT00499824|Diabetes
550946|NCT00499824|Management guidelines
550947|NCT00499824|Efficacy
550948|NCT00499798|infertility
550949|NCT00499798|chemotherapeutic agent toxicity
550950|NCT00499798|adult anaplastic astrocytoma
550951|NCT00499798|adult diffuse astrocytoma
550952|NCT00499798|adult giant cell glioblastoma
550953|NCT00499798|adult gliosarcoma
550954|NCT00499798|adult pilocytic astrocytoma
550955|NCT00499798|adult brain stem glioma
550956|NCT00499798|adult central nervous system germ cell tumor
550957|NCT00499798|adult choroid plexus tumor
550958|NCT00499798|adult craniopharyngioma
550959|NCT00499798|adult ependymoblastoma
550960|NCT00499798|adult medulloblastoma
550961|NCT00499798|adult supratentorial primitive neuroectodermal tumor (PNET)
550962|NCT00499798|adult anaplastic ependymoma
550963|NCT00499798|adult ependymoma
550964|NCT00499798|adult myxopapillary ependymoma
550965|NCT00499798|adult subependymoma
550966|NCT00499798|adult anaplastic meningioma
550967|NCT00499798|meningeal melanocytoma
550968|NCT00499798|adult meningeal hemangiopericytoma
550969|NCT00499798|adult papillary meningioma
550970|NCT00499798|adult grade I meningioma
550971|NCT00499798|adult grade II meningioma
550972|NCT00499798|adult grade III meningioma
550973|NCT00499798|adult anaplastic oligodendroglioma
550974|NCT00499798|adult oligodendroglioma
550975|NCT00499798|adult pineoblastoma
550976|NCT00499798|adult pineocytoma
550977|NCT00499798|adult mixed glioma
550978|NCT00499798|recurrent adult brain tumor
550979|NCT00499798|adult subependymal giant cell astrocytoma
550980|NCT00499785|depression
550981|NCT00499785|cognitive/functional effects
550982|NCT00499785|untreated adult acute myeloid leukemia
550983|NCT00499785|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
550984|NCT00499785|adult acute myeloid leukemia with inv(16)(p13;q22)
550985|NCT00499785|adult acute myeloid leukemia with t(15;17)(q22;q12)
550986|NCT00499785|adult acute myeloid leukemia with t(16;16)(p13;q22)
550987|NCT00499785|adult acute myeloid leukemia with t(8;21)(q22;q22)
550988|NCT00499759|fatigue
550989|NCT00499759|depression
550990|NCT00499759|psychosocial effects of cancer and its treatment
550991|NCT00499759|musculoskeletal complications
550992|NCT00499759|acute undifferentiated leukemia
550993|NCT00499759|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
550994|NCT00499759|adult acute myeloid leukemia with inv(16)(p13;q22)
550995|NCT00499759|adult acute myeloid leukemia with t(15;17)(q22;q12)
550996|NCT00499759|adult acute myeloid leukemia with t(16;16)(p13;q22)
550997|NCT00499759|adult acute myeloid leukemia with t(8;21)(q22;q22)
550998|NCT00499759|untreated adult acute lymphoblastic leukemia
550999|NCT00499759|untreated adult acute myeloid leukemia
551000|NCT00499759|recurrent adult acute myeloid leukemia
551001|NCT00499759|secondary acute myeloid leukemia
551002|NCT00499759|recurrent adult acute lymphoblastic leukemia
551003|NCT00499746|drug discrimination
551004|NCT00499746|opioid pharmacology
551005|NCT00499746|behavioral pharmacology
551006|NCT00499746|human research
551007|NCT00499733|carcinoma of unknown primary
551008|NCT00499733|recurrent carcinoma of unknown primary
551009|NCT00499733|stage IIIA non-small cell lung cancer
551010|NCT00499733|stage IIIB non-small cell lung cancer
551011|NCT00499733|stage IV non-small cell lung cancer
551012|NCT00499733|recurrent non-small cell lung cancer
551013|NCT00499733|extensive stage small cell lung cancer
551014|NCT00499733|recurrent small cell lung cancer
551015|NCT00499733|stage III renal cell cancer
551016|NCT00499733|stage IV renal cell cancer
551017|NCT00499733|recurrent renal cell cancer
551018|NCT00499733|stage III prostate cancer
551019|NCT00499733|stage IV prostate cancer
551020|NCT00499733|recurrent prostate cancer
551021|NCT00499733|male breast cancer
551022|NCT00499733|recurrent breast cancer
551023|NCT00499733|stage IIIA breast cancer
551024|NCT00499733|stage IIIB breast cancer
551025|NCT00499733|stage IIIC breast cancer
551026|NCT00499733|stage IV breast cancer
551027|NCT00499733|chondrosarcoma
551028|NCT00499733|metastatic osteosarcoma
551029|NCT00499733|recurrent osteosarcoma
551030|NCT00499733|stage III adult soft tissue sarcoma
551031|NCT00499733|stage IV adult soft tissue sarcoma
551032|NCT00499733|recurrent adult soft tissue sarcoma
551033|NCT00499733|previously treated childhood rhabdomyosarcoma
551034|NCT00499733|recurrent childhood rhabdomyosarcoma
551035|NCT00499733|metastatic childhood soft tissue sarcoma
551036|NCT00499733|recurrent childhood soft tissue sarcoma
551037|NCT00499733|ovarian sarcoma
551038|NCT00499733|stage III uterine sarcoma
551039|NCT00499733|stage IV uterine sarcoma
551040|NCT00499733|recurrent Kaposi sarcoma
551041|NCT00499733|classic Kaposi sarcoma
551042|NCT00499733|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
551043|NCT00499733|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
551044|NCT00499733|stage III colon cancer
551045|NCT00499733|stage IV colon cancer
551046|NCT00499733|recurrent colon cancer
551047|NCT00499733|localized unresectable adult primary liver cancer
551048|NCT00499733|recurrent adult primary liver cancer
551049|NCT00499733|recurrent childhood liver cancer
551050|NCT00499733|stage III childhood liver cancer
551051|NCT00499733|stage IV childhood liver cancer
551052|NCT00499733|stage III pancreatic cancer
551053|NCT00499733|localized osteosarcoma
551054|NCT00499733|malignant giant cell tumor of bone
551055|NCT00499733|stage IV melanoma
551056|NCT00499733|recurrent melanoma
551057|NCT00499733|stage III squamous cell carcinoma of the hypopharynx
551058|NCT00499733|stage IV squamous cell carcinoma of the hypopharynx
551059|NCT00499733|recurrent squamous cell carcinoma of the hypopharynx
551060|NCT00499733|stage III squamous cell carcinoma of the larynx
551061|NCT00499733|stage III verrucous carcinoma of the larynx
551062|NCT00499733|stage IV squamous cell carcinoma of the larynx
551063|NCT00499733|stage IV verrucous carcinoma of the larynx
551064|NCT00499733|recurrent squamous cell carcinoma of the larynx
551065|NCT00499733|recurrent verrucous carcinoma of the larynx
551066|NCT00499733|stage III basal cell carcinoma of the lip
551067|NCT00499733|stage III squamous cell carcinoma of the lip and oral cavity
551068|NCT00499733|stage III verrucous carcinoma of the oral cavity
551069|NCT00499733|stage IV adenoid cystic carcinoma of the oral cavity
551070|NCT00499733|stage IV squamous cell carcinoma of the lip and oral cavity
551071|NCT00499733|recurrent adenoid cystic carcinoma of the oral cavity
551072|NCT00499733|recurrent mucoepidermoid carcinoma of the oral cavity
551073|NCT00499733|recurrent squamous cell carcinoma of the lip and oral cavity
551074|NCT00499733|recurrent verrucous carcinoma of the oral cavity
551075|NCT00499733|metastatic squamous neck cancer with occult primary squamous cell carcinoma
551076|NCT00499733|recurrent metastatic squamous neck cancer with occult primary
551077|NCT00499733|untreated metastatic squamous neck cancer with occult primary
551078|NCT00499733|stage III squamous cell carcinoma of the nasopharynx
551079|NCT00499733|stage IV squamous cell carcinoma of the nasopharynx
551080|NCT00499733|recurrent squamous cell carcinoma of the nasopharynx
551081|NCT00499733|stage III squamous cell carcinoma of the oropharynx
551082|NCT00499733|stage IV squamous cell carcinoma of the oropharynx
551083|NCT00499733|recurrent squamous cell carcinoma of the oropharynx
551084|NCT00499733|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
551085|NCT00499733|stage III inverted papilloma of the paranasal sinus and nasal cavity
551419|NCT00499109|Customized Chemotherapy
551086|NCT00499733|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
551087|NCT00499733|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
551088|NCT00499733|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
551089|NCT00499733|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
551090|NCT00499733|high-grade salivary gland mucoepidermoid carcinoma
551091|NCT00499733|salivary gland adenocarcinoma
551092|NCT00499733|salivary gland adenoid cystic carcinoma
551093|NCT00499733|salivary gland anaplastic carcinoma
551094|NCT00499733|salivary gland malignant mixed cell type tumor
551095|NCT00499733|salivary gland poorly differentiated carcinoma
551096|NCT00499733|salivary gland squamous cell carcinoma
551097|NCT00499733|low-grade salivary gland mucoepidermoid carcinoma
551098|NCT00499733|salivary gland acinic cell tumor
551099|NCT00499733|stage III salivary gland cancer
551100|NCT00499733|stage IV salivary gland cancer
551101|NCT00499733|recurrent salivary gland cancer
551102|NCT00499733|intraocular lymphoma
551103|NCT00499733|recurrent childhood lymphoblastic lymphoma
551104|NCT00499733|recurrent pancreatic cancer
551105|NCT00499733|recurrent uterine sarcoma
551106|NCT00499733|newly diagnosed carcinoma of unknown primary
551107|NCT00499733|advanced adult primary liver cancer
551108|NCT00499733|ciliary body and choroid melanoma, medium/large size
551109|NCT00499733|conjunctival melanoma
551110|NCT00499733|stage IV pancreatic cancer
551111|NCT00499733|stage IIIA melanoma
551112|NCT00499733|stage IIIB melanoma
551113|NCT00499733|stage IIIC melanoma
551114|NCT00499733|tongue cancer
551115|NCT00499720|Cystic Fibrosis
551116|NCT00499720|Pseudomonas aeruginosa
551117|NCT00499720|airway infection
551118|NCT00499720|Aztreonam Lysine for Inhalation
551119|NCT00499707|HbA1c
551120|NCT00499707|Drug-naive
551121|NCT00499707|type 2 diabetes
551122|NCT00499694|stage IV prostate cancer
551123|NCT00499694|recurrent prostate cancer
551124|NCT00499694|adenocarcinoma of the prostate
551125|NCT00499681|stage I breast cancer
551126|NCT00499681|stage II breast cancer
551127|NCT00499681|stage IIIA breast cancer
551128|NCT00499681|stage IIIB breast cancer
551129|NCT00499668|unspecified adult solid tumor, protocol specific
551130|NCT00499668|nausea and vomiting
551131|NCT00499668|chronic myelogenous leukemia
551132|NCT00499668|chronic eosinophilic leukemia
551133|NCT00499668|chronic idiopathic myelofibrosis
551134|NCT00499668|chronic neutrophilic leukemia
551135|NCT00499668|essential thrombocythemia
551136|NCT00499668|polycythemia vera
551137|NCT00499668|adult acute lymphoblastic leukemia
551138|NCT00499668|adult acute myeloid leukemia
551139|NCT00499668|acute undifferentiated leukemia
551140|NCT00499668|mast cell leukemia
551141|NCT00499668|adult T-cell leukemia/lymphoma
551142|NCT00499668|T-cell large granular lymphocyte leukemia
551143|NCT00499668|chronic lymphocytic leukemia
551144|NCT00499668|hairy cell leukemia
551145|NCT00499668|prolymphocytic leukemia
551146|NCT00499668|AIDS-related lymphoma
551147|NCT00499668|adult Hodgkin lymphoma
551148|NCT00499668|anaplastic large cell lymphoma
551149|NCT00499668|angioimmunoblastic T-cell lymphoma
551150|NCT00499668|cutaneous B-cell non-Hodgkin lymphoma
551151|NCT00499668|cutaneous T-cell non-Hodgkin lymphoma
551152|NCT00499668|mycosis fungoides/Sezary syndrome
551153|NCT00499668|adult grade III lymphomatoid granulomatosis
551154|NCT00499668|adult nasal type extranodal NK/T-cell lymphoma
551155|NCT00499668|Waldenstrom macroglobulinemia
551156|NCT00499668|adult Burkitt lymphoma
551157|NCT00499668|adult diffuse large cell lymphoma
551158|NCT00499668|adult diffuse mixed cell lymphoma
551159|NCT00499668|adult diffuse small cleaved cell lymphoma
551160|NCT00499668|adult immunoblastic large cell lymphoma
551161|NCT00499668|adult lymphoblastic lymphoma
551162|NCT00499668|grade 1 follicular lymphoma
551163|NCT00499668|grade 2 follicular lymphoma
551164|NCT00499668|grade 3 follicular lymphoma
551165|NCT00499668|mantle cell lymphoma
551166|NCT00499668|marginal zone lymphoma
551167|NCT00499668|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
551168|NCT00499668|nodal marginal zone B-cell lymphoma
551169|NCT00499668|splenic marginal zone lymphoma
551170|NCT00499668|small lymphocytic lymphoma
551171|NCT00499668|intraocular lymphoma
551172|NCT00499668|primary central nervous system lymphoma
551173|NCT00499668|post-transplant lymphoproliferative disorder
551174|NCT00499668|multiple myeloma and other plasma cell neoplasms
551175|NCT00499668|myelodysplastic syndromes
551176|NCT00499668|atypical chronic myeloid leukemia
551177|NCT00499668|chronic myelomonocytic leukemia
551178|NCT00499668|myelodysplastic/myeloproliferative disease, unclassifiable
551179|NCT00499668|chronic myeloproliferative disorders
551180|NCT00499668|myelodysplastic/myeloproliferative diseases
551181|NCT00499642|Healthy Subjects
551182|NCT00499629|healthy subjects
551183|NCT00499616|regional neuroblastoma
551184|NCT00499616|disseminated neuroblastoma
551185|NCT00499616|stage 4S neuroblastoma
551186|NCT00499616|localized unresectable neuroblastoma
551420|NCT00499096|Chronic Illness
551187|NCT00499616|localized resectable neuroblastoma
551188|NCT00499603|Breast Cancer
551189|NCT00499603|ER negative
551190|NCT00499603|PR negative
551191|NCT00499603|HER2neu negative
551192|NCT00499603|Tumor Triple Negative Receptors
551193|NCT00499603|Paclitaxel
551194|NCT00499603|Taxol
551195|NCT00499603|RAD001
551196|NCT00499603|FEC
551197|NCT00499603|5-Fluorouracil
551198|NCT00499603|5-FU
551199|NCT00499603|Adrucil
551200|NCT00499603|Efudex
551201|NCT00499603|Epirubicin
551202|NCT00499603|Cyclophosphamide
551203|NCT00499590|AMD
551204|NCT00499590|Macular Degeneration
551205|NCT00499590|bevasiranib
551206|NCT00499590|COBALT study
551207|NCT00499590|age related macular degeneration
551208|NCT00499590|wet AMD
551209|NCT00499590|wet age related macular degeneration
551210|NCT00499577|stage I multiple myeloma
551211|NCT00499577|stage II multiple myeloma
551212|NCT00499577|stage III multiple myeloma
551213|NCT00499577|refractory multiple myeloma
551214|NCT00499551|Anterior Uveitis
551215|NCT00499551|Posterior Uveitis
551216|NCT00499551|Intermediate Uveitis
551217|NCT00499551|Panuveitis
551218|NCT00499551|Iontophoresis
551219|NCT00499551|Dexamethasone
551220|NCT00499538|healthy subjects
551221|NCT00499525|male breast cancer
551222|NCT00499525|recurrent breast cancer
551223|NCT00499525|stage IIIB breast cancer
551224|NCT00499525|stage IIIC breast cancer
551225|NCT00499525|stage IV breast cancer
551226|NCT00499525|stage IIIA breast cancer
551227|NCT00499512|Ovarian Cancer
551228|NCT00499512|Peritoneal Cancer
551229|NCT00499512|Fallopian Tube Cancer
551230|NCT00499512|Spirituality
551231|NCT00499512|Religion
551232|NCT00499512|Quality of Life
551233|NCT00499512|Questionnaire
551234|NCT00499512|Survey
551235|NCT00499499|Cancer
551236|NCT00499499|solid tumors
551237|NCT00499486|recurrent pancreatic cancer
551238|NCT00499486|stage III pancreatic cancer
551239|NCT00499486|stage IV pancreatic cancer
551240|NCT00499486|adenocarcinoma of the pancreas
551241|NCT00499460|healthy, no evidence of disease
551242|NCT00499447|stage I non-small cell lung cancer
551243|NCT00499447|adenocarcinoma of the lung
551244|NCT00499447|adenosquamous cell lung cancer
551245|NCT00499447|large cell lung cancer
551246|NCT00499447|squamous cell lung cancer
551247|NCT00499434|aids
551248|NCT00499421|Prostate Cancer
551249|NCT00499421|External Beam Radiation Therapy
551250|NCT00499421|Fiducial Markers
551251|NCT00499421|Acculoc System
551252|NCT00499421|Center Of Mass
551253|NCT00499421|EBRT
551254|NCT00499408|adenocarcinoma of the prostate
551255|NCT00499408|stage I prostate cancer
551256|NCT00499408|stage II prostate cancer
551257|NCT00499408|stage III prostate cancer
551258|NCT00499395|stage IV colon cancer
551259|NCT00499395|stage IV rectal cancer
551260|NCT00499395|recurrent colon cancer
551261|NCT00499395|recurrent rectal cancer
551262|NCT00499395|liver metastases
551263|NCT00499382|Advanced Cancers
551264|NCT00499382|Cardiac Function
551265|NCT00499382|Nuclear Medicine Cardiac Scan
551266|NCT00499382|Positron Emission Tomography
551267|NCT00499382|Radionuclide Ventriculography
551268|NCT00499382|Ventricular Ejection Fraction
551269|NCT00499382|PET/CT
551270|NCT00499382|RNV
551271|NCT00499356|friction
551272|NCT00499356|pressure
551273|NCT00499356|insole
551274|NCT00499356|ulcer
551275|NCT00499356|prevention
551276|NCT00499343|Non-Hodgkin's Lymphoma
551277|NCT00499343|Lymphoma
551278|NCT00499343|Etoposide
551279|NCT00499343|G-CSF
551280|NCT00499343|GM-CSF
551281|NCT00499343|Isophosphamide
551282|NCT00499343|Rituximab
551283|NCT00499343|Ifosfamide
551284|NCT00499343|Sargramostim
551285|NCT00499343|Leukine
551286|NCT00499343|Filgrastim
551287|NCT00499343|Neupogen
551288|NCT00499343|Apheresis
551289|NCT00499343|Stem Cell Collection
551290|NCT00499330|stage IA non-small cell lung cancer
551291|NCT00499330|adenocarcinoma of the lung
551292|NCT00499330|squamous cell lung cancer
551293|NCT00499330|large cell lung cancer
551294|NCT00499330|adenosquamous cell lung cancer
551295|NCT00499330|bronchoalveolar cell lung cancer
551296|NCT00499317|Urgency
551297|NCT00499317|Frequency
551298|NCT00499317|Pelvic pain
551299|NCT00499317|Sexual dysfunction
551300|NCT00499317|Erectile dysfunction
551301|NCT00499317|Painful intercourse
551302|NCT00499304|Forced oscillation Technique (FOT)
551303|NCT00499304|Expiratory flow limitation (EFL)
551304|NCT00499304|Breathing artifacts
551305|NCT00499304|COPD
551306|NCT00499291|unspecified adult solid tumor, protocol specific
551307|NCT00499291|recurrent breast cancer
551308|NCT00499291|stage IIIA breast cancer
551309|NCT00499291|stage IIIB breast cancer
551310|NCT00499291|stage IIIC breast cancer
551311|NCT00499291|recurrent prostate cancer
551312|NCT00499291|stage III prostate cancer
551313|NCT00499291|stage IV prostate cancer
551314|NCT00499291|recurrent non-small cell lung cancer
551315|NCT00499291|stage IIIA non-small cell lung cancer
551316|NCT00499291|stage IIIB non-small cell lung cancer
551317|NCT00499291|stage IV non-small cell lung cancer
551318|NCT00499291|extensive stage small cell lung cancer
551319|NCT00499291|recurrent small cell lung cancer
551320|NCT00499291|recurrent bladder cancer
551321|NCT00499291|stage III bladder cancer
551322|NCT00499291|stage IV bladder cancer
551323|NCT00499291|recurrent renal cell cancer
551324|NCT00499291|stage III renal cell cancer
551325|NCT00499291|stage IV renal cell cancer
551326|NCT00499291|clear cell sarcoma of the kidney
551327|NCT00499291|rhabdoid tumor of the kidney
551328|NCT00499291|recurrent malignant testicular germ cell tumor
551329|NCT00499291|stage III malignant testicular germ cell tumor
551330|NCT00499291|recurrent cervical cancer
551331|NCT00499291|stage III cervical cancer
551332|NCT00499291|stage IVA cervical cancer
551333|NCT00499291|stage IVB cervical cancer
551334|NCT00499291|recurrent endometrial carcinoma
551335|NCT00499291|stage III endometrial carcinoma
551336|NCT00499291|stage IV endometrial carcinoma
551337|NCT00499291|fallopian tube cancer
551338|NCT00499291|recurrent ovarian epithelial cancer
551339|NCT00499291|stage III ovarian epithelial cancer
551340|NCT00499291|stage IV ovarian epithelial cancer
551341|NCT00499291|recurrent ovarian germ cell tumor
551342|NCT00499291|stage III ovarian germ cell tumor
551343|NCT00499291|stage IV ovarian germ cell tumor
551344|NCT00499291|ovarian sarcoma
551345|NCT00499291|ovarian stromal cancer
551346|NCT00499291|recurrent uterine sarcoma
551347|NCT00499291|stage III uterine sarcoma
551348|NCT00499291|stage IV uterine sarcoma
551349|NCT00499291|recurrent hypopharyngeal cancer
551350|NCT00499291|stage III hypopharyngeal cancer
551351|NCT00499291|stage IV hypopharyngeal cancer
551352|NCT00499291|recurrent laryngeal cancer
551353|NCT00499291|stage III laryngeal cancer
551354|NCT00499291|stage IV laryngeal cancer
551355|NCT00499291|recurrent lip and oral cavity cancer
551356|NCT00499291|stage III lip and oral cavity cancer
551357|NCT00499291|stage IV lip and oral cavity cancer
551358|NCT00499291|recurrent metastatic squamous neck cancer with occult primary
551359|NCT00499291|untreated metastatic squamous neck cancer with occult primary
551360|NCT00499291|recurrent nasopharyngeal cancer
551361|NCT00499291|stage III nasopharyngeal cancer
551362|NCT00499291|stage IV nasopharyngeal cancer
551363|NCT00499291|recurrent oropharyngeal cancer
551364|NCT00499291|stage III oropharyngeal cancer
551365|NCT00499291|stage IV oropharyngeal cancer
551366|NCT00499291|recurrent paranasal sinus and nasal cavity cancer
551367|NCT00499291|stage III paranasal sinus and nasal cavity cancer
551368|NCT00499291|stage IV paranasal sinus and nasal cavity cancer
551369|NCT00499291|recurrent salivary gland cancer
551370|NCT00499291|stage III salivary gland cancer
551371|NCT00499291|stage IV salivary gland cancer
551372|NCT00499291|recurrent esophageal cancer
551373|NCT00499291|stage III esophageal cancer
551374|NCT00499291|stage IV esophageal cancer
551375|NCT00499291|recurrent gastric cancer
551376|NCT00499291|stage III gastric cancer
551377|NCT00499291|stage IV gastric cancer
551378|NCT00499291|adult central nervous system germ cell tumor
551379|NCT00499291|adult teratoma
551380|NCT00499291|ovarian teratoma
551381|NCT00499291|testicular teratoma
551382|NCT00499291|recurrent adult soft tissue sarcoma
551383|NCT00499291|stage III adult soft tissue sarcoma
551384|NCT00499291|stage IV adult soft tissue sarcoma
551385|NCT00499291|recurrent carcinoma of unknown primary
551386|NCT00499278|Osteoarthritis
551387|NCT00499278|joint
551388|NCT00499278|knee
551389|NCT00499278|hip
551390|NCT00499278|surgery
551391|NCT00499265|recurrent pancreatic cancer
551392|NCT00499265|stage III pancreatic cancer
551393|NCT00499265|adenocarcinoma of the pancreas
551394|NCT00499239|Hematologic Malignancies
551395|NCT00499239|CLL
551396|NCT00499239|NHL
551397|NCT00499239|Chronic Lymphocytic Leukemia
551398|NCT00499239|Non-Hodgkin's Lymphoma
551399|NCT00499239|CLL and NHL
551400|NCT00499239|Multiple Myeloma
551401|NCT00499239|MM
551402|NCT00499187|Fanconi
551403|NCT00499187|Kidney
551404|NCT00499187|Renal
551405|NCT00499187|HIV
551406|NCT00499187|HIV-1
551407|NCT00499187|Treatment Experienced
551408|NCT00499174|stage II prostate cancer
551409|NCT00499174|adenocarcinoma of the prostate
551410|NCT00499161|Individualized care
551411|NCT00499161|Relationship based care
551412|NCT00499161|Negotiated care
551413|NCT00499161|Patient focused care
551414|NCT00499122|stage II breast cancer
551415|NCT00499122|stage IIIC breast cancer
551416|NCT00499122|inflammatory breast cancer
551417|NCT00499109|RRM1
551418|NCT00499109|ERCC1
551421|NCT00499096|Disease management
551422|NCT00499096|Health Behaviors
551423|NCT00499096|Mood Disorders-Bipolar
551424|NCT00499083|stage II breast cancer
551425|NCT00499083|stage IIIA breast cancer
551426|NCT00499083|stage IIIB breast cancer
551427|NCT00499083|stage IIIC breast cancer
551428|NCT00499070|refractory cytopenia with multilineage dysplasia
551429|NCT00499070|aplastic anemia
551430|NCT00499070|Fanconi anemia
551431|NCT00499070|dyskeratosis congenita
551432|NCT00499070|Shwachman-Diamond syndrome
551433|NCT00499070|Pearson marrow-pancreas syndrome
551434|NCT00499057|early stage breast cancer
551435|NCT00499044|cognition
551436|NCT00499044|attention
551437|NCT00499044|memory
551438|NCT00499044|concentration
551439|NCT00499044|schizophrenia
551440|NCT00499018|Large B-Cell Lymphoma
551441|NCT00499018|Rituximab
551442|NCT00499018|Autologous Stem Cell Transplantation
551443|NCT00498992|dermatologic complications
551444|NCT00498992|unspecified adult solid tumor, protocol specific
551445|NCT00498979|stage IV melanoma
551446|NCT00498979|adult anaplastic astrocytoma
551447|NCT00498979|adult diffuse astrocytoma
551448|NCT00498979|adult glioblastoma
551449|NCT00498979|adult giant cell glioblastoma
551450|NCT00498979|adult pilocytic astrocytoma
551451|NCT00498979|adult brain stem glioma
551452|NCT00498979|adult anaplastic ependymoma
551453|NCT00498979|adult ependymoma
551454|NCT00498979|adult myxopapillary ependymoma
551455|NCT00498979|adult subependymoma
551456|NCT00498979|adult anaplastic oligodendroglioma
551457|NCT00498979|adult oligodendroglioma
551458|NCT00498979|mixed gliomas
551459|NCT00498979|recurrent adult brain tumor
551460|NCT00498979|recurrent melanoma
551461|NCT00498979|adult gliosarcoma
551462|NCT00498979|adult subependymal giant cell astrocytoma
551463|NCT00498979|adult pineal gland astrocytoma
551464|NCT00498966|Kidney
551465|NCT00498966|perifosine
551466|NCT00498966|Progression on treatment with sunitinib or sorafenib
551467|NCT00498953|stage II squamous cell carcinoma of the hypopharynx
551468|NCT00498953|stage III squamous cell carcinoma of the hypopharynx
551469|NCT00498953|stage IV squamous cell carcinoma of the hypopharynx
551470|NCT00498953|stage III squamous cell carcinoma of the larynx
551471|NCT00498953|stage IV squamous cell carcinoma of the larynx
551472|NCT00498940|LV function, Compliance, wall motion, echocardiography
551473|NCT00498927|recurrent adult brain tumor
551474|NCT00498927|adult giant cell glioblastoma
551475|NCT00498927|adult glioblastoma
551476|NCT00498927|adult gliosarcoma
551477|NCT00498927|adult anaplastic astrocytoma
551478|NCT00498927|adult diffuse astrocytoma
551479|NCT00498927|adult pilocytic astrocytoma
551480|NCT00498927|adult subependymal giant cell astrocytoma
551481|NCT00498927|adult anaplastic ependymoma
551482|NCT00498927|adult ependymoma
551483|NCT00498927|adult myxopapillary ependymoma
551484|NCT00498927|adult subependymoma
551485|NCT00498927|adult anaplastic oligodendroglioma
551486|NCT00498927|adult oligodendroglioma
551487|NCT00498927|adult brain stem glioma
551488|NCT00498927|adult mixed glioma
551489|NCT00498927|adult pineal gland astrocytoma
551490|NCT00498914|Lymphoma, Large-Cell, Diffuse
551491|NCT00498914|Lymphoma, B-Cell
551492|NCT00498914|YM155
551493|NCT00498914|Treatment outcomes
551494|NCT00498914|Refractory
551495|NCT00498901|stage IV breast cancer
551496|NCT00498901|recurrent breast cancer
551497|NCT00498888|urge urinary incontinence
551498|NCT00498888|rehabilitation
551499|NCT00498888|anticholinergic
551500|NCT00498875|Oropharyngeal Cancer
551501|NCT00498875|Head and Neck Cancer
551502|NCT00498875|Depression
551503|NCT00498875|Questionnaire
551504|NCT00498875|Survey
551505|NCT00498875|Interview
551506|NCT00498849|Sleep apnea
551507|NCT00498849|Continuous positive airway pressure
551508|NCT00498849|Microarray
551509|NCT00498849|Polysomnography
551510|NCT00498836|CP-4055
551511|NCT00498836|Elacyt
551512|NCT00498836|Cancer
551513|NCT00498836|Metastatic
551514|NCT00498836|Malignant melanoma
551515|NCT00498836|Combination treatment
551516|NCT00498836|Sorafenib
551517|NCT00498836|Nexavar
551518|NCT00498797|prostate cancer
551519|NCT00498797|zactima
551520|NCT00498797|vandetanib
551521|NCT00498797|metastatic
551522|NCT00498784|Intra-uterine contraception
551523|NCT00498784|Intrauterine Devices
551524|NCT00498771|Lymphedema
551525|NCT00498771|Aquatic Exercise
551526|NCT00498771|Breast Cancer
551527|NCT00498758|Parkinson's disease
551528|NCT00498758|Gait Disturbances
551529|NCT00498758|Mobility
551530|NCT00498758|Quality of life
551531|NCT00498732|Obstructive sleep apnea syndrome; CPAP, microarray
551532|NCT00498719|Leukemia
551533|NCT00498719|Lymphoma
551534|NCT00498719|Brain Tumor
551535|NCT00498719|Attention Deficit
551536|NCT00498719|Cognitive Training Program
551537|NCT00498719|Central Nervous System
551538|NCT00498719|CNS
551539|NCT00498719|CTP
551540|NCT00498706|Depressive Disorder, Major
551541|NCT00498706|Cognitive Behavioral Therapy
551542|NCT00498706|Psychotherapy
551543|NCT00498706|Telemedicine
551544|NCT00498706|Primary Care
551545|NCT00498680|Erectile Dysfunction
551546|NCT00498680|Treatment
551547|NCT00498680|PDE5i
551548|NCT00498667|PET/CT
551549|NCT00498667|Aggressive non-Hodgkin Lymphoma
551550|NCT00498654|Prevention of Typhoid Fever in Adult Travelers
551551|NCT00498641|perceptual learning
551552|NCT00498641|occlusion therapy
551553|NCT00498628|Alcoholism
551554|NCT00498628|Alcohol dependence
551555|NCT00498628|Quetiapine
551556|NCT00498615|scleroderma
551557|NCT00498615|Raynaud's phenomenon
551558|NCT00498615|Rho-kinase inhibitor
551559|NCT00498576|hypertension
551560|NCT00498576|kidney transplant
551561|NCT00498576|melatonin
551562|NCT00498576|adiponectin
551563|NCT00498563|high altitude
551564|NCT00498563|sleep
551565|NCT00498563|altitude illness
551566|NCT00498563|neurobehavioral manifestations
551567|NCT00498563|psychomotor performance
551568|NCT00498563|mood states
551569|NCT00498550|Clozapine
551570|NCT00498550|Schizophrenia
551571|NCT00498550|Dual Diagnosis
551572|NCT00498550|Substance Abuse
551573|NCT00498550|Cannabis Abuse
551574|NCT00498537|spironolactone
551575|NCT00498537|aldosterone
551576|NCT00498537|diabetic nephropathy
551577|NCT00498537|proteinuria
551578|NCT00498537|hyperkalemia
551579|NCT00498537|albuminuria
551580|NCT00498537|renal failure
551581|NCT00498524|implantable cardioverter-defibrillator
551582|NCT00498524|ischemic cardiomyopathy
551583|NCT00498524|ventricular arrhythmias
551584|NCT00498524|sibling concordance
551585|NCT00498511|Anemia, Iron-Deficiency
551586|NCT00498511|Endoscopy, Gastrointestinal
551587|NCT00498511|Male, aged 18 to 40
551588|NCT00498498|severe head injury
551589|NCT00498498|Endothelin
551590|NCT00498498|CSF
551591|NCT00498498|Plasma
551592|NCT00498498|Cellular Apoptosis
551593|NCT00498485|chronic
551594|NCT00498485|fatigue
551595|NCT00498485|pain
551596|NCT00498485|sleep
551597|NCT00498485|xyrem
551598|NCT00498485|must have chronic fatigue syndrome
551599|NCT00498485|no hypertension
551600|NCT00498485|no sleep apnea
551601|NCT00498472|BNP
551602|NCT00498472|heart failure
551603|NCT00498459|Physical activity
551604|NCT00498459|Randomised trial
551605|NCT00498459|Prevention
551606|NCT00498459|Adolescents
551607|NCT00498459|Obesity
551608|NCT00498459|Cardiovascular risk factors
551609|NCT00498433|Aliskiren
551610|NCT00498433|Renin-Angiotensin System (RAS)
551611|NCT00498433|Hypertension
551612|NCT00498433|Abdominal obesity
551613|NCT00498420|HUE-MAN
551614|NCT00498420|Rare disorder
551615|NCT00498420|Hepatosplenomegaly
551616|NCT00498420|Dysostosis
551617|NCT00498407|CP-4055
551618|NCT00498407|ELACYT(TM)
551619|NCT00498407|Cancer
551620|NCT00498407|Colorectal cancer
551621|NCT00498407|CRC
551622|NCT00498407|Second line therapy
551623|NCT00498394|Obesity
551624|NCT00498394|Weight loss
551625|NCT00498394|Diet fads
551626|NCT00498368|Estimated glomerular filtration rate (GFR)
551627|NCT00498368|Proteinuria
551628|NCT00498368|Renal Fibrosis
551629|NCT00498355|uveitis
551630|NCT00498355|cytoid macular edema
551631|NCT00498355|steroid
551632|NCT00498355|Lucentis
551633|NCT00498329|fMRI
551634|NCT00498329|Electroencephalogram (EEG)
551635|NCT00498329|Attention
551636|NCT00498329|Sensorimotor Integration
551637|NCT00498329|Human Brain
551638|NCT00498329|Healthy Volunteer
551639|NCT00498329|HV
551640|NCT00498316|Myelodysplastic Syndrome
551641|NCT00498316|Leukemia
551642|NCT00498316|Cord Blood Expansion
551643|NCT00498316|Umbilical Cord Blood
551644|NCT00498316|Mesenchymal Stem Cells
551645|NCT00498316|Acute Myelogenous Leukemia
551646|NCT00498316|Acute Lymphoblastic Leukemia
551647|NCT00498316|ALL
551648|NCT00498316|AML
551649|NCT00498316|MDS
551650|NCT00498303|influenza vaccine
551651|NCT00498290|Enhanced Recovery After Surgery Protocol(ERAS)
551652|NCT00498290|Colorectal Surgery
551653|NCT00498277|Osteoporosis
551654|NCT00498277|Magnetic Resonance Imaging
551655|NCT00498277|Vertebral Fractures
551656|NCT00498277|Quantitative Diffusion
551657|NCT00498277|Fat Imaging
551658|NCT00498277|Spine
551659|NCT00498264|Exercise
551660|NCT00498264|Rehabilitation
551661|NCT00498264|Strength exercise
551662|NCT00498264|Aerobic exercise
551663|NCT00498264|Pain
551664|NCT00498251|lung injury, acute
551916|NCT00497224|Pancreatic Carcinoma
551665|NCT00498251|thoracic surgical procedures
551666|NCT00498251|lung cancer
551667|NCT00498251|salbutamol
551668|NCT00498238|Arterial stiffness, Augmentation index, Subclinical Hypothyroidism
551669|NCT00498225|Pancreatic Cancer
551670|NCT00498212|Heplisav
551671|NCT00498212|Hepatitis B
551672|NCT00498212|Hepatitis
551673|NCT00498212|HBV
551674|NCT00498212|Hepatitis B vaccine
551675|NCT00498212|kidney disease
551676|NCT00498212|renal disease
551677|NCT00498212|kidney failure
551678|NCT00498212|renal failure
551679|NCT00498199|Multiples sclerosis
551680|NCT00498199|oscillopsia
551681|NCT00498199|eye movements
551682|NCT00498199|motion detection
551683|NCT00498199|retinal slip
551684|NCT00498199|nystagmus
551685|NCT00498186|Rotigotine
551686|NCT00498186|Neupro®
551687|NCT00498173|Autistic Disorder
551688|NCT00498173|Autism Spectrum Disorder
551689|NCT00498160|Kidney transplant
551690|NCT00498160|Tolerance
551691|NCT00498160|Marrow/stem cell transplant
551692|NCT00498147|amputation
551693|NCT00498147|angina
551694|NCT00498147|angiography
551695|NCT00498147|angioplasty
551696|NCT00498147|arterial disease
551697|NCT00498147|artery disease
551698|NCT00498147|bypass
551699|NCT00498147|CABG
551700|NCT00498147|cad
551701|NCT00498147|carotid
551702|NCT00498147|cerebral accident
551703|NCT00498147|CHF
551704|NCT00498147|CRF
551705|NCT00498147|CVA
551706|NCT00498147|endarterectomy
551707|NCT00498147|heart attack
551708|NCT00498147|heart failure
551709|NCT00498147|infarct
551710|NCT00498147|kidney disease
551711|NCT00498147|kidney failure
551712|NCT00498147|laser
551713|NCT00498147|nephropathy
551714|NCT00498147|neuropathy
551715|NCT00498147|pad
551716|NCT00498147|PCI
551717|NCT00498147|percutaneous coronary
551718|NCT00498147|percutaneous transluminal
551719|NCT00498147|pvd
551720|NCT00498147|renal failure
551721|NCT00498147|retinopathy
551722|NCT00498147|revascularization
551723|NCT00498147|schemia
551724|NCT00498147|stenosis
551725|NCT00498147|stent
551726|NCT00498147|stroke
551727|NCT00498147|transient
551728|NCT00498147|ulcer
551729|NCT00498147|vascular disease
551730|NCT00498134|Gastric cancer
551731|NCT00498121|Ventilator associated pneumonia.
551732|NCT00498121|Procalcitonin.
551733|NCT00498108|Rotigotine
551734|NCT00498108|Restless Legs Syndrome
551735|NCT00498095|Delayed renal graft function
551736|NCT00498095|Acute renal allograft dysfunction
551737|NCT00498069|Critical limb ischemia due to peripheral arterial occlusive disease
551738|NCT00498069|Autologous bone marrow concentrate
551739|NCT00498056|HIV Seronegativity
551740|NCT00498056|HIV Preventive Vaccine
551741|NCT00498043|Lymphoma
551742|NCT00498043|PET
551743|NCT00498043|Chemotherapy
551744|NCT00498043|Rituximab
551745|NCT00498030|Insulin Resistance
551746|NCT00498030|Stress, Psychological
551747|NCT00498017|Infections
551748|NCT00498004|Quality of Life
551749|NCT00498004|Schizophrenia
551750|NCT00498004|Quetiapine
551751|NCT00498004|Risperidone
551752|NCT00497991|AML
551753|NCT00497991|phase I/II
551754|NCT00497991|AZD1152
551755|NCT00497991|Acute Myeloid Leukaemia
551756|NCT00497965|Balance
551757|NCT00497965|Chiropractic
551758|NCT00497965|Older Adults
551759|NCT00497952|Relapsing-remitting multiple sclerosis
551760|NCT00497952|Marrow/Stem cell transplant
551761|NCT00497939|Benign Prostatic Hyperplasia (BPH)
551762|NCT00497939|Currently on alpha blocker
551763|NCT00497926|Kidney transplant
551764|NCT00497926|Tolerance
551765|NCT00497926|Marrow/Enriched Hematopoetic Stem Cell Transplant
551766|NCT00497913|Tennis Elbow
551767|NCT00497913|Botulinum Toxin
551768|NCT00497874|depression
551769|NCT00497874|stage of change
551770|NCT00497874|intervention
551771|NCT00497874|randomized clinical trial
551772|NCT00497874|population-based
551773|NCT00497874|expert system
551774|NCT00497861|Low back pain
551775|NCT00497861|Chiropractic
551776|NCT00497861|Spinal manipulation
551777|NCT00497861|Activator Methods Chiropractic Technique
551778|NCT00497835|motor seizures
551779|NCT00497835|accelerometer
551780|NCT00497835|algorithm
551781|NCT00497835|detection
551782|NCT00497835|alert
551783|NCT00497822|Dementia
551784|NCT00497809|Breast Cancer
551785|NCT00497809|Neutropenia
551786|NCT00497809|Chemotherapy
551787|NCT00497809|High risk
551788|NCT00497796|cytomegalovirus
551789|NCT00497796|CMV
551790|NCT00497796|prophylaxis
551791|NCT00497796|liver
551792|NCT00497796|liver transplant
551917|NCT00497224|Pancreas
551793|NCT00497757|Marrow/hematopoietic stem cell transplant
551794|NCT00497744|CAPD peritonitis
551795|NCT00497744|Peritoneal Dialysis, Continuous Ambulatory
551796|NCT00497731|Advanced solid tumors
551797|NCT00497705|Ebsteins Anomaly
551798|NCT00497705|Heart Septal Defects, Ventricle
551799|NCT00497705|Heart Defects, Congenital
551800|NCT00497705|Double Outlet Right Ventricle
551801|NCT00497705|Truncus Arteriosus Persistant
551802|NCT00497705|Ebstein's Anomaly
551803|NCT00497705|Congenital Heart Disease
551804|NCT00497705|Heart Defects
551805|NCT00497679|advanced solid tumours
551806|NCT00497666|Diabetes
551807|NCT00497666|Diabetic nephropathy
551808|NCT00497666|renal protection
551809|NCT00497640|sleep apnea, titration, CPAP, neural network
551810|NCT00497614|Rheumatoid arthritis
551811|NCT00497614|Positron emission tomodensitometry
551812|NCT00497614|Tumor necrosis factor alpha inhibitor
551813|NCT00497601|Visceral Leishmaniasis
551814|NCT00497601|Amphotericin B
551815|NCT00497601|Fat emulsion
551816|NCT00497588|laryngeal cancer
551817|NCT00497588|RADIOTHERAPY
551818|NCT00497588|Voice Quality
551819|NCT00497575|Congenital Hypothyroidism
551820|NCT00497575|diagnosis
551821|NCT00497575|L-thyroxine
551822|NCT00497575|newborn screening
551823|NCT00497562|Fibromyalgia
551824|NCT00497562|growth hormone
551825|NCT00497562|IGF-1
551826|NCT00497562|FIQ
551827|NCT00497549|Esophagectomy
551828|NCT00497549|hand sewn anastomosis
551829|NCT00497549|side-to-side stapled
551830|NCT00497536|Type 1 Diabetes Mellitus
551831|NCT00497536|Continuous Subcutaneous Insulin Infusion (CSII)
551832|NCT00497523|Asthma
551833|NCT00497523|Young Children
551834|NCT00497523|Corticosteroids
551835|NCT00497523|Beclomethasone
551836|NCT00497523|Salbutamol
551837|NCT00497523|Beclomethasone/Salbutamol fixed combination
551838|NCT00497523|Suspension for nebulisation
551839|NCT00497510|Balance
551840|NCT00497510|Chiropractic
551841|NCT00497510|Older Adults
551842|NCT00497497|CRC
551843|NCT00497497|Colon cancer
551844|NCT00497497|Avastin
551845|NCT00497497|APM4187g
551846|NCT00497471|Plasmodium Falciparum
551847|NCT00497471|Antimlarial chemoprophylaxis
551848|NCT00497471|Iron supplementation
551849|NCT00497471|Tanzania
551850|NCT00497458|breast
551851|NCT00497458|neoplasms
551852|NCT00497458|anastrazole
551853|NCT00497458|testosterone
551854|NCT00497445|Peripheral arterial disease
551855|NCT00497445|Exercise therapy
551856|NCT00497445|Angioplasty
551857|NCT00497445|Bypass surgery
551858|NCT00497432|Hyperbaric Oxygen
551859|NCT00497419|STEMI
551860|NCT00497419|ST elevation myocardial infarction
551861|NCT00497406|submandibular salivary gland transfer
551862|NCT00497406|intensity-modulated radiation therapy
551863|NCT00497406|helical tomotherapy
551864|NCT00497406|reduction of xerostomia
551865|NCT00497393|Emergency department, administration, overcrowding
551866|NCT00497367|safety
551867|NCT00497367|feasibility
551868|NCT00497367|bifurcation
551869|NCT00497367|lesion
551870|NCT00497367|de novo
551871|NCT00497367|intervention
551872|NCT00497354|Ultrasound, Complications, Regional Anesthesia
551873|NCT00497341|infection after total knee arthroplasty
551874|NCT00497328|contrast induced nephropathy
551875|NCT00497315|Non-Small Cell Lung Cancer
551876|NCT00497315|NSCLC
551877|NCT00497315|Chemoradiation
551878|NCT00497315|locally advanced NSCLC
551879|NCT00497315|pemetrexed
551880|NCT00497315|lung cancer
551881|NCT00497302|cocaine
551882|NCT00497302|opiate
551883|NCT00497302|pregnancy
551884|NCT00497302|post-partum
551885|NCT00497302|neonatal abstinence syndrome
551886|NCT00497302|contingency management
551887|NCT00497302|Reinforcement Based Treatment
551888|NCT00497302|women
551889|NCT00497289|n-3 PUFA
551890|NCT00497289|parenteral nutrition
551891|NCT00497289|preterm infant
551892|NCT00497276|Adults
551893|NCT00497276|Anesthesia recovery period
551894|NCT00497276|Comparative study
551895|NCT00497276|Electric stimulation
551896|NCT00497276|Humans
551897|NCT00497276|Nerve blocks/methods/indications
551898|NCT00497276|Patient satisfaction
551899|NCT00497276|Peripheral nerves
551900|NCT00497276|Sciatic nerve/ultrasonography
551901|NCT00497276|Ultrasonography
551902|NCT00497276|Treatment outcome
551903|NCT00497276|Nerve blocks/economics
551904|NCT00497250|Phase 1 Clinical Trials
551905|NCT00497250|Iressa
551906|NCT00497250|radiation therapy
551907|NCT00497250|Chinese
551908|NCT00497250|NSCLC
551909|NCT00497250|chemotherapy
551910|NCT00497237|Asthma
551911|NCT00497237|Stepdown
551912|NCT00497237|Beclomethasone
551913|NCT00497237|Formoterol
551914|NCT00497237|Corticosteroids
551915|NCT00497224|Pancreatic Cancer
551918|NCT00497224|Adenocarcinoma
551919|NCT00497224|Erlotinib
551920|NCT00497224|Tarceva
551921|NCT00497224|OSI-774
551922|NCT00497224|Phase II
551923|NCT00497211|First large acute myocardial infarction
551924|NCT00497198|Type 2 Diabetes
551925|NCT00497198|anion-exchange resin
551926|NCT00497185|Mindfulness-Based Cognitive Therapy
551927|NCT00497185|Somatization Disorder
551928|NCT00497185|Medically Unexplained Symptoms
551929|NCT00497185|Functional Somatic Symptoms
551930|NCT00497185|SF-36
551931|NCT00497159|Trial of Dimebon to treat patients with mild-to-moderate Huntington's disease.
551932|NCT00497146|paricalcitol
551933|NCT00497146|Zemplar
551934|NCT00497146|PRIMO
551935|NCT00497146|Chronic Kidney Disease Stage 3B/4
551936|NCT00497133|glucoseintolerance
551937|NCT00497120|sleep apnea
551938|NCT00497120|snoring
551939|NCT00497120|acetazolamide
551940|NCT00497120|uvulopalatopharyngoplasty
551941|NCT00497120|daytime sleepiness
551942|NCT00497120|upper airway
551943|NCT00497107|UFT/LV
551944|NCT00497107|PSK
551945|NCT00497107|Colorectal cancer
551946|NCT00497107|Adjuvant therapy
551947|NCT00497094|carotid artery stenting
551948|NCT00497094|atherosclerosis
551949|NCT00497094|cerebrovascular
551950|NCT00497094|stroke
551951|NCT00497081|Methamphetamine
551952|NCT00497081|HIV
551953|NCT00497081|MSM
551954|NCT00497081|HIV Seronegativity
551955|NCT00497068|smoking
551956|NCT00497068|pregnancy
551957|NCT00497068|neonatal abstinence syndrome
551958|NCT00497055|Methamphetamine
551959|NCT00497055|HIV
551960|NCT00497055|MSM
551961|NCT00497055|HIV Seronegativity
551962|NCT00497029|dental caries
551963|NCT00497029|early childhood caries
551964|NCT00497029|caries prevention
551965|NCT00497029|infants
551966|NCT00497016|hypertension
551967|NCT00497016|statin
551968|NCT00497016|sympathetic
551969|NCT00497003|Endothelial function
551970|NCT00497003|Beta blocker
551971|NCT00497003|Type 2 diabetes
551972|NCT00497003|Chronic heart failure
551973|NCT00496990|male
551974|NCT00496990|female
551975|NCT00496990|couple
551976|NCT00496990|cocaine
551977|NCT00496990|opiate
551978|NCT00496990|methadone
551979|NCT00496990|detoxification
551980|NCT00496990|pregnancy
551981|NCT00496977|lung cancer
551982|NCT00496977|CT scan
551983|NCT00496977|screening
551984|NCT00496964|Botulinum toxin type A
551985|NCT00496964|Patellofemoral pain syndrome
551986|NCT00496964|Knee Injuries
551987|NCT00496964|Exercise Therapy
551988|NCT00496951|Neonatal abstinence syndrome
551989|NCT00496951|Methadone
551990|NCT00496951|Vagal tone
551991|NCT00496938|Stents
551992|NCT00496938|Angioplasty
551993|NCT00496938|Total coronary occlusions
551994|NCT00496938|Coronary restenosis
551995|NCT00496938|Stent thrombosis
551996|NCT00496938|Everolimus
551997|NCT00496899|Labor
551998|NCT00496899|Obstetric
551999|NCT00496899|cervical dilatation
552000|NCT00496886|Pain
552001|NCT00496886|Nociception
552002|NCT00496873|Non-Hodgkin's Lymphoma
552003|NCT00496873|NHL
552004|NCT00496873|Lymphoma
552005|NCT00496873|B-cell chronic lymphocytic leukemia
552006|NCT00496873|SLL
552007|NCT00496873|Small Lymphocytic Lymphoma
552008|NCT00496873|Lymphoplasmacytic lymphoma/immunocytoma
552009|NCT00496873|Follicular lymphoma
552010|NCT00496873|Extranodal marginal zone B-cell lymphoma of MALT type
552011|NCT00496873|Nodal marginal zone B-cell lymphoma
552012|NCT00496873|Chronic Lymphocytic Leukemia
552013|NCT00496873|CLL
552014|NCT00496873|Bulky Lymphoma
552015|NCT00496873|Nipent
552016|NCT00496873|Cytoxan
552017|NCT00496873|Rituxan
552018|NCT00496873|Cyclophosphamide
552019|NCT00496873|Rituximab
552020|NCT00496873|Pentostatin
552021|NCT00496860|cancer
552022|NCT00496860|p53
552023|NCT00496860|immunotherapy
552024|NCT00496860|targeted
552025|NCT00496860|metastatic
552026|NCT00496860|malignancy
552027|NCT00496860|malignancies
552028|NCT00496860|interleukin-2
552029|NCT00496860|IL-2
552030|NCT00496860|fusion protein
552031|NCT00496860|antitumor
552032|NCT00496860|melanoma
552033|NCT00496860|renal cancer
552034|NCT00496860|lung cancer
552035|NCT00496860|kidney cancer
552036|NCT00496860|breast cancer
552037|NCT00496860|colorectal cancer
552038|NCT00496860|colon cancer
552039|NCT00496860|renal cell carcinoma
552040|NCT00496860|advanced cancer
552041|NCT00496860|head and neck cancer
552042|NCT00496860|breast tumors
552043|NCT00496860|cancer of head and neck
552044|NCT00496860|esophagus cancer
552045|NCT00496860|lymphoma
552046|NCT00496860|ovarian cancer
552047|NCT00496860|ovary cancer
552048|NCT00496860|bladder cancer
552049|NCT00496860|stomach cancer
552050|NCT00496860|TCR
552051|NCT00496860|T-cell receptor
552052|NCT00496860|P53 gene
552053|NCT00496860|p53 tumor suppressor protein
552054|NCT00496847|rhPDGF,
552055|NCT00496847|periodontal disease
552056|NCT00496821|Respiratory Syncytial Virus
552057|NCT00496808|Ductal Carcinoma In Situ
552058|NCT00496808|Breast Cancer
552059|NCT00496808|Herceptin
552060|NCT00496808|Trastuzumab
552061|NCT00496808|DCIS
552062|NCT00496795|Breast cancer, chemoresistance, predictive markers.
552063|NCT00496782|Treatment Experienced
552064|NCT00496756|clear cell renal cell carcinoma
552065|NCT00496756|stage III renal cell cancer
552066|NCT00496756|stage IV renal cell cancer
552067|NCT00496756|recurrent renal cell cancer
552068|NCT00496730|Metabolic Disorder
552069|NCT00496717|Calcium scoring/aorta/ cardiovascular risk factor/scann
552070|NCT00496717|Patients with at least one cardiovascular risk factor
552071|NCT00496704|adenocarcinoma of the colon
552072|NCT00496704|recurrent colon cancer
552073|NCT00496704|stage III colon cancer
552074|NCT00496704|stage IV colon cancer
552075|NCT00496704|adenocarcinoma of the rectum
552076|NCT00496704|recurrent rectal cancer
552077|NCT00496704|stage III rectal cancer
552078|NCT00496704|stage IV rectal cancer
552079|NCT00496691|HIV prevention
552080|NCT00496691|HIV Seronegativity
552081|NCT00496678|PNRP
552082|NCT00496678|navigation
552083|NCT00496678|navigator
552084|NCT00496678|activation
552085|NCT00496678|disparities
552086|NCT00496678|randomized control trial
552087|NCT00496678|primary care
552088|NCT00496678|racial and ethnic minorities
552089|NCT00496665|Stage IV breast cancer
552090|NCT00496665|metronomic chemotherapy
552091|NCT00496652|Squamous Cell Carcinomas of the Head and Neck
552092|NCT00496652|Epidermal Growth Factor receptor
552093|NCT00496652|Antibody
552094|NCT00496652|Radiotherapy
552095|NCT00496639|hemodialysis
552096|NCT00496639|arterio-venous grafts
552097|NCT00496639|angioplasty
552098|NCT00496639|stents
552099|NCT00496639|mechanical thrombectomy
552100|NCT00496626|HPV infections
552101|NCT00496613|Breast cancer
552102|NCT00496613|survivor
552103|NCT00496587|Genitourinary
552104|NCT00496587|Kidney Cancer
552105|NCT00496587|Sarcomatoid Renal Cell Carcinoma
552106|NCT00496587|Renal Cell Carcinoma
552107|NCT00496587|RCC
552108|NCT00496587|Sarcomatoid Carcinoma of the Kidney
552109|NCT00496587|Unresectable renal cell carcinoma
552110|NCT00496587|Capecitabine
552111|NCT00496587|Xeloda
552112|NCT00496587|Gemcitabine
552113|NCT00496587|Gemzar
552114|NCT00496587|Bevacizumab
552115|NCT00496587|Anti-VEGF monoclonal antibody
552116|NCT00496587|rhuMAb-VEGF
552117|NCT00496587|Avastin
552118|NCT00496587|Vascular Endothelial Growth Factor
552119|NCT00496587|VEGF
552120|NCT00496574|asthma
552121|NCT00496574|immunotherapy
552122|NCT00496574|efficacy
552123|NCT00496574|children
552124|NCT00496574|symptoms score
552125|NCT00496574|quality of life
552126|NCT00496574|spirometry
552127|NCT00496574|PC20M
552128|NCT00496561|asthma
552129|NCT00496561|immunotherapy
552130|NCT00496561|children
552131|NCT00496561|regulatory T cells
552132|NCT00496561|ECP
552133|NCT00496561|PC20M
552134|NCT00496561|Quality of Life
552135|NCT00496561|Symptoms score
552136|NCT00496561|Spirometry
552137|NCT00496548|Crohn's Disease
552138|NCT00496535|head
552139|NCT00496535|neck
552140|NCT00496535|cancer
552141|NCT00496535|neoplasm
552142|NCT00496522|Skull Base Chondrosarcoma
552143|NCT00496522|Proton Beam Therapy
552144|NCT00496522|Chondrosarcoma
552145|NCT00496522|CNS
552146|NCT00496509|ZD6474
552147|NCT00496509|Colorectal Cancer
552148|NCT00496509|Liver Metastases
552149|NCT00496509|Biomarkers
552150|NCT00496483|Tacrolimus
552151|NCT00496483|Pharmacokinetics
552152|NCT00496483|Kidney Transplantation
552153|NCT00496470|Chronic Obstructive Pulmonary Disease, COPD
552154|NCT00496457|Diabetic Neuropathy
552155|NCT00496457|Painful Peripheral Diabetic Neuropathy
552156|NCT00496457|TRO19622
552157|NCT00496457|Trophos
552158|NCT00496444|Advanced Cancers
552159|NCT00496444|Azacytidine
552160|NCT00496444|5-Azacitidine
552161|NCT00496444|5-aza
552162|NCT00496444|Vidaza
552163|NCT00496444|5-AZC
552164|NCT00496444|AZA-CR
552165|NCT00496444|Ladakamycin
552166|NCT00496444|NSC-102816
552167|NCT00496444|Valproic Acid
552168|NCT00496444|Depakene
552169|NCT00496418|colostomy
552170|NCT00496418|parastomal
552171|NCT00496418|peristomal
552172|NCT00496418|hernia
552173|NCT00496418|mesh
552174|NCT00496418|surgery
552175|NCT00496418|Indication for permanent end colostomy
552176|NCT00496405|Vascular endothelial growth factor.
552177|NCT00496405|Retinal Thickness
552178|NCT00496405|Diabetic Macular Edema
552179|NCT00496405|Optical Coherent Tomography
552180|NCT00496392|breakthrough pain in patients with cancer
552181|NCT00496379|metastatic breast cancer
552182|NCT00496379|invasive breast cancer
552183|NCT00496379|brain metastases
552184|NCT00496379|ZK-EPO
552185|NCT00496353|Neoplasm Malignant
552186|NCT00496340|Pentostatin
552187|NCT00496340|Busulfan
552188|NCT00496340|Rituxan
552189|NCT00496340|Allogeneic Hematopoietic Stem Cell Transplantation
552190|NCT00496301|renal
552191|NCT00496301|sorafenib
552192|NCT00496301|Unresectable and/or metastatic renal cell cancer
552193|NCT00496288|BRCA mutation
552194|NCT00496288|Breast cancer
552195|NCT00496288|Prophylactic breast irradiation
552196|NCT00496288|Prevention of contralateral breast cancer
552197|NCT00496275|NSCLC
552198|NCT00496275|ZACTIMA
552199|NCT00496262|Congenital fibrinogen deficiency
552200|NCT00496262|Fibrinogen concentrate
552201|NCT00496262|Pharmacokinetics
552202|NCT00496262|Thrombelastography
552203|NCT00496249|Prostate
552204|NCT00496249|cancer
552205|NCT00496249|brachytherapy
552206|NCT00496249|radiation
552207|NCT00496249|semen
552208|NCT00496249|fertility
552209|NCT00496236|head
552210|NCT00496236|neck
552211|NCT00496236|cancer
552212|NCT00496236|neoplasm
552213|NCT00496223|Sunitinib
552214|NCT00496223|Dacarbazine
552215|NCT00496223|Melanoma
552216|NCT00496210|Adaptation
552217|NCT00496210|Pervasive Developmental Disorder
552218|NCT00496210|Autism Spectrum Disorders
552219|NCT00496210|Pervasive Developmental Disorders
552220|NCT00496210|Caregiver Adaptation
552221|NCT00496197|candidemia
552222|NCT00496197|invasive candidiasis
552223|NCT00496197|fungal bloodstream infection
552224|NCT00496184|Nifedipine treatment
552225|NCT00496184|Vestibulitis
552226|NCT00496184|Placebo
552227|NCT00496158|Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus
552228|NCT00496158|hepatitis b virus
552229|NCT00496145|diabetes
552230|NCT00496145|self management
552231|NCT00496145|patient education
552232|NCT00496145|telephone reinforcement
552233|NCT00496145|Spanish Diabetes
552234|NCT00496145|Tomando Control de su Diabetes
552235|NCT00496132|CLL
552236|NCT00496132|Leukemia
552237|NCT00496132|Lymph
552238|NCT00496119|Proton Beam Therapy
552239|NCT00496119|Skull Base Chordoma
552240|NCT00496119|Chordoma of the Skull Base
552241|NCT00496119|Chordoma
552242|NCT00496080|Menorrhagia associated with Uterine Fibroids
552243|NCT00496067|Fibroids
552244|NCT00496067|Menorrhagia
552245|NCT00496067|Menorrhagia associated with uterine fibroids
552246|NCT00496041|Stenosis (> 75%) or occlusion of the superficial femoral artery
552247|NCT00496028|Solid tumors
552248|NCT00496028|locally advanced or Metastatic Cancer suitable for treatment with carboplatin and/or paclitaxel
552249|NCT00496015|Streptococcus Pneumoniae Vaccines
552250|NCT00496015|Meningococcal disease
552251|NCT00496015|Carriage
552252|NCT00496015|Prophylactic antipyretic
552253|NCT00496015|Safety
552254|NCT00496015|Pneumococcal vaccine
552255|NCT00496015|Fever
552256|NCT00496015|Pneumococcal disease
552257|NCT00496015|Immunogenicity
552258|NCT00496015|Meningococcal vaccine
552259|NCT00496015|Booster vaccination
552260|NCT00496002|Hepatitis B virus
552261|NCT00496002|Nucleoside Treatment-Naïve Patients with HBeAg Positive
552262|NCT00495989|Handicapped individuals
552263|NCT00495976|common cold
552264|NCT00495976|flu
552265|NCT00495976|influenza
552266|NCT00495963|Mechanical ventilation, Ventilator- associated pneumonia, Bronchoalveolar lavage, Pediatric intensive care unit, Flexible bronchoscopy, Critical care
552267|NCT00495950|Melanoma
552268|NCT00495950|Lymphedema
552269|NCT00495950|Limb Swelling
552270|NCT00495950|Questionnaire
552271|NCT00495950|Quality of Life
552272|NCT00495950|Physical Function
552273|NCT00495950|Survey
552274|NCT00495885|Sleep problems
552275|NCT00495885|insomnia
552276|NCT00495885|sleeplessness
552277|NCT00495885|primary insomnia
552278|NCT00495885|insomnia disorder
552279|NCT00495872|Solid Tumors
552280|NCT00495872|Advanced Cancer
552281|NCT00495872|Dasatinib
552282|NCT00495872|Erlotinib
552283|NCT00495872|Lapatinib
552284|NCT00495872|Lenalidomide
552285|NCT00495872|Sorafenib
552286|NCT00495872|Erlotinib Hydrochloride
552287|NCT00495872|Sunitinib Malate
552288|NCT00495872|Sunitinib
552289|NCT00495872|Valproic Acid
552290|NCT00495872|SU011248
552291|NCT00495859|Immunonutrition
552292|NCT00495859|immune enhancing diets
552293|NCT00495859|arginine
552294|NCT00495859|ω-3 fatty acids
552295|NCT00495859|nucleotides
552296|NCT00495859|liver transplantation
552297|NCT00495859|clinical trial
552298|NCT00495846|Hepatocellular carcinoma
552299|NCT00495846|Somatostatin analogues
552300|NCT00495846|Somatostatin receptors
552301|NCT00495846|Octreotide
552302|NCT00495846|Lanreotide
552303|NCT00495846|IGF-I
552304|NCT00495846|IGF-II
552305|NCT00495833|Hypertension
552306|NCT00495820|Alzheimer's Disease
552307|NCT00495820|Apathy
552308|NCT00495820|Dementia
552309|NCT00495820|Methylphenidate
552310|NCT00495807|Psychological Tests
552311|NCT00495807|Pain, Postoperative
552312|NCT00495807|Nurses
552313|NCT00495794|diabetes
552314|NCT00495794|hypertension
552315|NCT00495794|adherence
552316|NCT00495794|implementation
552317|NCT00495794|medications
552318|NCT00495794|organization of care
552319|NCT00495781|functional iron deficiency
552320|NCT00495781|renal anemia
552321|NCT00495781|dialysis
552322|NCT00495781|erythropoietin
552323|NCT00495781|darbepoetin
552324|NCT00495768|Hepatitis C
552325|NCT00495768|HCV
552326|NCT00495768|Depression
552327|NCT00495768|Interferons
552328|NCT00495768|Ribavirin
552329|NCT00495755|Chronic Graft-vs-Host Disease
552330|NCT00495729|SB-649868,
552331|NCT00495729|Simvastatin
552332|NCT00495729|Repeated dose,
552333|NCT00495703|Cancer survivors
552334|NCT00495703|Chemotherapy
552335|NCT00495703|Cognitive function
552336|NCT00495703|Exercise
552337|NCT00495703|Physical Activity
552338|NCT00495690|Zinc recipients
552339|NCT00495690|Placebo recipients
552340|NCT00495677|Treatment Experienced
552341|NCT00495677|Treatment Naive
552342|NCT00495664|titanium
552343|NCT00495664|paclitaxel
552344|NCT00495664|stent
552345|NCT00495664|myocardial infarction
552346|NCT00495664|angioplasty
552347|NCT00495664|PCI
552348|NCT00495651|HIV
552349|NCT00495651|HAART
552350|NCT00495651|Early Intervention
552351|NCT00495651|Naive patients
552352|NCT00495638|6-Minute Walk
552353|NCT00495638|Chuvash Polycythemia
552354|NCT00495638|Echocardiogram
552355|NCT00495638|Sickle Cell Anemia
552356|NCT00495638|Pulmonary Function Tests
552357|NCT00495638|Sickle Cell Disease
552358|NCT00495638|SCD
552359|NCT00495638|Pulmonary Hypertension
552360|NCT00495625|Hepatocellular cancer (HCC)
552361|NCT00495625|Sunitinib malate
552362|NCT00495625|Vascular endothelial growth factor (VEGF)
552363|NCT00495625|Platelet-derived growth factor (PDGF)
552364|NCT00495625|Tyrosine kinases
552365|NCT00495625|Liver
552366|NCT00495612|Xolair
552367|NCT00495612|Allergic asthma
552368|NCT00495612|Cat allergy
552369|NCT00495599|Obese
552370|NCT00495599|Adipose Tissue
552371|NCT00495599|Visfatin
552372|NCT00495599|Gastric Bypass Surgery
552373|NCT00495586|COPD
552374|NCT00495586|Antibiotics
552375|NCT00495560|induction
552376|NCT00495560|abortion
552377|NCT00495560|injection, intra-amniotic
552378|NCT00495560|misoprostol
552379|NCT00495547|Myelodysplastic Syndrome
552380|NCT00495547|Red Cell transfusion dependent
552381|NCT00495521|Crohn's
552382|NCT00495521|Crohn's Disease
552383|NCT00495521|Acute Flare
552384|NCT00495521|Mild to Moderate Crohn's Disease
552385|NCT00495521|Children
552386|NCT00495521|Pediatrics
552387|NCT00495521|Ileo-cecal
552388|NCT00495521|Pediatric Crohn's Disease
552389|NCT00495521|New Onset Crohn's Disease
552390|NCT00495521|Recently diagnosed Crohn's Disease
552391|NCT00495508|Quinine
552392|NCT00495508|Artemether
552393|NCT00495508|Lumefantrine
552394|NCT00495508|malaria
552395|NCT00495508|Uganda
552396|NCT00495508|Artemisinin- based combination therapy
552397|NCT00495508|pregnancy
552398|NCT00495508|Malaria In Pregnancy
552399|NCT00495482|Euthanasia
552400|NCT00495482|Assisted Suicide
552401|NCT00495482|Assisted Dying
552402|NCT00495482|Palliative Care Medicine
552403|NCT00495469|Diabetes mellitus HbA1c
552404|NCT00495456|cardiovascular
552405|NCT00495456|risk
552406|NCT00495456|longitudinal
552407|NCT00495456|prospective
552408|NCT00495430|Healthy
552409|NCT00495430|Lung sounds
552410|NCT00495430|Breath sounds
552411|NCT00495417|Alzheimer
552412|NCT00495417|Morbus Alzheimer
552413|NCT00495417|Alzheimer Vaccine
552414|NCT00495417|Vaccine
552415|NCT00495417|AD
552416|NCT00495417|Aβ immunotherapy
552417|NCT00495404|chronic non-malignant pain
552418|NCT00495404|opiates
552419|NCT00495404|prescriptions
552420|NCT00495404|addiction
552421|NCT00495391|Hepatitis C, Chronic
552422|NCT00495378|PROCRIT
552423|NCT00495378|Epoetin alfa
552424|NCT00495378|chemotherapy related anemia
552425|NCT00495365|Anemia
552426|NCT00495365|low blood count
552427|NCT00495365|chronic kidney disease
552428|NCT00495365|chronic kidney failure
552429|NCT00495365|darbepoetin alfa
552430|NCT00495365|epoetin alfa
552431|NCT00495365|recombinant human erythropoietin
552432|NCT00495352|Schizophrenia
552433|NCT00495352|NRT
552434|NCT00495352|Bupropion
552435|NCT00495352|Stages of change
552436|NCT00495326|drug interactions
552437|NCT00495326|Treatment Naive
552438|NCT00495313|Rosacea
552439|NCT00495300|HSC/MUD Transplant
552440|NCT00495300|NMDP
552441|NCT00495300|NMDP Data Collection
552442|NCT00495300|NMDP Samples
552443|NCT00495300|BMT
552444|NCT00495300|Samples
552445|NCT00495287|Acute myelogenous leukemia
552446|NCT00495287|Adult patients
552447|NCT00495287|Cytogenetic risk class
552448|NCT00495287|Clinico-cytogenetic risk model
552449|NCT00495287|Risk-oriented therapy
552450|NCT00495274|Bioequivalent
552451|NCT00495274|pharmacodynamic
552452|NCT00495274|Reference formulation
552453|NCT00495274|5 new formulation
552454|NCT00495274|Food effect
552455|NCT00495274|Pharmacokinetics
552456|NCT00495261|Gambling
552457|NCT00495261|Mindfulness
552458|NCT00495261|Cognitive Behavioural Therapy
552459|NCT00495248|group intervention
552460|NCT00495248|stroke
552461|NCT00495248|senior centres
552462|NCT00495248|health promotion
552463|NCT00495235|Endometrial Cancer
552464|NCT00495235|Polycystic Ovarian Syndrome
552465|NCT00495235|Insulin Resistance
552466|NCT00495235|Pre-diabetes
552467|NCT00495235|Harris County
552468|NCT00495235|PCOS
552469|NCT00495235|Uterus
552470|NCT00495235|Questionnaire
552471|NCT00495235|Body mass index
552472|NCT00495235|BMI
552473|NCT00495222|gastrojejunostomy
552474|NCT00495222|stoma
552475|NCT00495209|Complementary and Alternative Medicine
552476|NCT00495209|Breast Cancer
552477|NCT00495209|Qigong
552478|NCT00495209|Medical Qigong
552479|NCT00495209|External Qi Therapy
552480|NCT00495209|EQT
552481|NCT00495183|cocaine dependence
552482|NCT00495183|cocaine use
552483|NCT00495183|CNS stimulants
552484|NCT00495183|caffeine
552485|NCT00495183|biperiden
552486|NCT00495183|placebo
552487|NCT00495170|Non-Small Cell Lung Cancer
552488|NCT00495170|Lung Cancer
552489|NCT00495170|Proton Radiotherapy
552490|NCT00495170|Proton Beam
552491|NCT00495170|Paclitaxel
552492|NCT00495170|Taxol
552493|NCT00495170|Carboplatin
552494|NCT00495170|Paraplatin
552495|NCT00495170|NSCLC
552496|NCT00495144|Phase I
552497|NCT00495144|Advanced Solid Tumors
552498|NCT00495144|Hypoxia
552499|NCT00495144|Prodrug
552500|NCT00495144|Multi-Center
552501|NCT00495144|Open-Label
552502|NCT00495144|Dose-Escalation
552503|NCT00495131|Chronic hepatitis C
552504|NCT00495131|Genotype 1
552505|NCT00495131|Interferon
552506|NCT00495131|Ribavirin
552507|NCT00495118|schizophrenia
552508|NCT00495118|schizoaffective disorder
552509|NCT00495118|risperidone
552510|NCT00495118|intramuscular injection
552511|NCT00495118|long-acting injectable
552512|NCT00495092|cocaine dependence
552513|NCT00495092|cocaine use
552514|NCT00495092|cocaine craving
552515|NCT00495079|acute
552516|NCT00495079|lymphoblastic
552517|NCT00495079|lymphocytic
552518|NCT00495079|leukemia
552519|NCT00495079|leukaemia
552520|NCT00495079|lukemia
552521|NCT00495079|leukimia
552522|NCT00495079|ALL
552523|NCT00495079|Marqibo
552524|NCT00495079|Hana Biosciences
552525|NCT00495079|vincristine
552526|NCT00495079|liposomal
552527|NCT00495079|liposome
552528|NCT00495079|optisome
552529|NCT00495079|hematology
552530|NCT00495079|malignancy
552531|NCT00495079|hematological
552532|NCT00495079|relapsed
552533|NCT00495079|anti-leukemia
552534|NCT00495079|adult
552535|NCT00495079|chemotherapy
552536|NCT00495053|overactive bladder, urinary urgency
552537|NCT00495040|Non-Small Cell Lung Cancer
552538|NCT00495040|Lung Cancer
552539|NCT00495040|Proton Radiotherapy
552540|NCT00495040|Proton Beam
552541|NCT00495040|NSCLC
552542|NCT00495027|PTSD
552543|NCT00495027|prevention
552544|NCT00495027|World Wide Web
552545|NCT00495027|Behavior Therapy
552546|NCT00495014|GSK376501,
552547|NCT00495014|Single Dose,
552548|NCT00495014|Dose Escalation,
552549|NCT00495014|Healthy Overweight/Obese Volunteer
552550|NCT00494949|Anesthesia, spinal
552551|NCT00494949|Blood substitutes
552552|NCT00494949|Oxygen therapeutics
552553|NCT00494949|Orthopedic surgery
552554|NCT00494949|Plasma expanders
552555|NCT00494949|Vasoconstriction
552556|NCT00494949|Hemospan
552557|NCT00494936|HIV
552558|NCT00494936|HCV
552559|NCT00494936|Treatment Naive
552560|NCT00494936|Treatment Experienced
552561|NCT00494936|HIV and HCV Coinfection
552562|NCT00494910|Palliative Care
552563|NCT00494910|Terminally Ill
552564|NCT00494910|Group Therapy
552565|NCT00494910|07-094
552566|NCT00494884|Type 2 diabetes
552567|NCT00494884|vildagliptin
552568|NCT00494884|metformin combination
552569|NCT00494871|BAY59-7939
552570|NCT00494871|Rivaroxaban
552571|NCT00494871|Non-Valvular Atrial Fibrillation
552572|NCT00494871|Japanese Patients
552573|NCT00494871|Phase III
552574|NCT00494871|12620
552575|NCT00494858|Bulimia nervosa
552576|NCT00494858|Cognitive Behavioral Therapy
552577|NCT00494858|Personality Disorders
552578|NCT00494845|Mindfulness
552579|NCT00494845|Elderly
552580|NCT00494845|Chronic Illness
552581|NCT00494845|Back Pain
552582|NCT00494845|Chronic Low Back Pain
552583|NCT00494845|Older adults over the age of sixty-five
552584|NCT00494845|MMSE score of over 23
552585|NCT00494845|Speaks English
552586|NCT00494832|Dexmedetomidine
552587|NCT00494832|Evoked potentials
552588|NCT00494832|Spine surgery
552589|NCT00494819|ADHD, subtype, methylphenidate, neuropsychological measures
552590|NCT00494806|Postoperative Ileus (POI)
552591|NCT00494806|Rocking Chair
552592|NCT00494806|Abdominal Cancer
552593|NCT00494793|Open abdomen
552594|NCT00494793|Fascial closure
552595|NCT00494793|Vacuum assisted wound closure
552596|NCT00494793|Mesh
552597|NCT00494793|Abdominal compartment syndrome
552598|NCT00494793|Intraabdominal pressure
552599|NCT00494793|Incisional hernia
552600|NCT00494780|CHOP (cyclophosphamide,doxorubicin,vincristine,prednisolone)
552601|NCT00494780|ofatumumab
552602|NCT00494767|body composition
552603|NCT00494767|hunger
552604|NCT00494767|weight loss
552605|NCT00494767|4C model
552606|NCT00494767|obesity
552607|NCT00494754|autism spectrum disorder
552608|NCT00494754|family genetic study
552609|NCT00494754|gene
552610|NCT00494754|phenotype
552611|NCT00494754|endophenotype
552612|NCT00494728|Smoking
552613|NCT00494728|Depression
552614|NCT00494728|Major Depressive Disorder
552615|NCT00494728|Cognitive Behavioral Analysis System of Psychotherapy
552616|NCT00494728|Smoking Cessation Treatment
552617|NCT00494728|Nicotine Replacement Therapy
552618|NCT00494728|Nicotine Patch
552619|NCT00494728|CBASP
552620|NCT00494728|MDD
552621|NCT00494702|Asphyxia
552622|NCT00494702|Resuscitation
552623|NCT00494702|Oxidative stress
552624|NCT00494702|Prematurity
552625|NCT00494702|Follow up
552626|NCT00494689|transcranial sonolysis or monitoring
552627|NCT00494689|rapid magnetic stimulation
552628|NCT00494689|cerebral ischemia
552629|NCT00494689|hydrocephalus
552630|NCT00494689|Barthel's index
552631|NCT00494676|Hemianopia
552632|NCT00494676|Mobility
552633|NCT00494676|Rehabilitation
552634|NCT00494676|Low vision
552635|NCT00494663|diabetes
552636|NCT00494663|type 2 diabetes
552637|NCT00494663|cholesterol
552638|NCT00494650|PTSD
552639|NCT00494650|Schizophrenia
552640|NCT00494650|Schizoaffective Disorder
552641|NCT00494650|Bipolar Disorder
552642|NCT00494650|Major Depression
552643|NCT00494624|Wheezing
552644|NCT00494624|virus
552645|NCT00494624|child
552646|NCT00494598|opioids, cerebral perfusion, arterial pharmacokinetics
552647|NCT00494585|CEP-701
552648|NCT00494585|Leukemia
552649|NCT00494585|Myelofibrosis
552650|NCT00494585|MF
552651|NCT00494585|JAK2
552652|NCT00494585|Tyrosine Kinase Inhibitor
552653|NCT00494585|Lestaurtinib
552654|NCT00494585|Chronic Idiopathic Myelofibrosis
552655|NCT00494585|CIMF
552656|NCT00494572|Montelukast
552657|NCT00494572|Albuterol
552658|NCT00494572|Status Asthmaticus
552659|NCT00494572|Asthma
552660|NCT00494559|Type 2 Diabetes
552661|NCT00494559|Pioglitazone
552662|NCT00494559|restenosis
552663|NCT00494546|prostate
552664|NCT00494546|brachytherapy
552665|NCT00494533|pulmonary arterial hypertension
552666|NCT00494533|prostacyclin analogue
552667|NCT00494533|intravenous
552668|NCT00494520|Anomia
552669|NCT00494520|Aphasia
552670|NCT00494520|Traumatic Brain Injury
552671|NCT00494520|Cerebrovascular Accident
552672|NCT00494507|periodic paralysis
552673|NCT00494507|dichlorphenamide
552674|NCT00494494|cystoid macular edema
552675|NCT00494494|cataract
552676|NCT00494494|nonsteroidal antiinflammatory drugs
552677|NCT00494494|optical coherence tomography
552678|NCT00494481|Zactima
552679|NCT00494468|Insomnia
552680|NCT00494468|Sleep Disorder
552681|NCT00494468|Sleep Deprivation
552682|NCT00494455|critical illness
552683|NCT00494455|hyperglycemia
552684|NCT00494455|intensive insulin therapy
552685|NCT00494455|glucose monitoring
552686|NCT00494455|shock
552687|NCT00494442|Advanced ovarian cancer
552688|NCT00494442|Poly(ADP ribose) polymerases
552689|NCT00494442|KU-0059436
552690|NCT00494442|AZD2281
552691|NCT00494442|BRCA1 protein
552692|NCT00494442|BRCA2 protein
552693|NCT00494429|Preterm Neonates
552694|NCT00494429|Morphine
552695|NCT00494429|Critically ill
552696|NCT00494403|sprain proprioception
552697|NCT00494390|Biometry
552698|NCT00494390|corneal opacity
552699|NCT00494390|astigmatism
552700|NCT00494390|refraction
552701|NCT00494364|ear disease
552702|NCT00494364|otitis
552703|NCT00494364|Eustachian tube
552704|NCT00494364|mastoid air cells
552705|NCT00494364|Normal healthy volunteers
552706|NCT00494351|Hidradenitis Suppurativa
552707|NCT00494351|Nd:YAG laser
552708|NCT00494338|Metastatic Androgen Independent Prostate Cancer (MAIPC)
552709|NCT00494325|age related maculopathy, macular pigment
552710|NCT00494312|Glucose Metabolism Disorder
552711|NCT00494312|Dysmetabolic Syndrome
552712|NCT00494312|Type II Diabetes
552713|NCT00494312|Diabetes Mellitus
552714|NCT00494312|Lipoatrophic
552715|NCT00494312|Dyslipidemia
552716|NCT00494312|Liver
552717|NCT00494312|Drug Therapy
552718|NCT00494299|HCC
552719|NCT00494299|Cancer
552720|NCT00494299|Liver Cancer
552721|NCT00494299|TACE
552722|NCT00494286|Abuse Focused Cognitive Behavioral Therapy
552723|NCT00494286|Treatment Effectiveness Research
552724|NCT00494286|Treatment Dissemination
552725|NCT00494273|Haitian American Adolescents
552726|NCT00494273|HIV Prevention
552727|NCT00494273|Cognitive Behavioral Intervention
552728|NCT00494260|recurrent abdominal pain
552729|NCT00494260|illness behavior
552730|NCT00494260|social learning
552731|NCT00494260|cognitive behavioral therapy
552732|NCT00494247|acute coronary syndromes
552733|NCT00494247|endothelial progenitor cells
552734|NCT00494247|coronary stent
552735|NCT00494234|Advanced breast cancer
552736|NCT00494234|Poly(ADP ribose) polymerases
552737|NCT00494234|AZD2281,KU-0059436 (olaparib)
552738|NCT00494234|BRCA1 protein
552739|NCT00494234|BRCA2 protein
552740|NCT00494221|Colorectal cancer
552741|NCT00494221|Recentin
552742|NCT00494221|Metastatic Cancer
552743|NCT00494221|FOLFOX
552744|NCT00494208|androgens
552745|NCT00494208|testosterone
552746|NCT00494208|testosterone deficiency
552747|NCT00494208|women
552748|NCT00494208|menopause
552749|NCT00494208|surgical Menopause
552750|NCT00494208|hysterectomy
552751|NCT00494208|oophorectomy
552752|NCT00494208|ovariectomy
552753|NCT00494208|sexual dysfunction
552754|NCT00494208|sexual function
552755|NCT00494208|muscle function
552756|NCT00494208|insulin sensitivity
552757|NCT00494208|body composition
552758|NCT00494195|limb girdle muscular dystrophy type 2D
552759|NCT00494195|alpha-sarcoglycanopathy
552760|NCT00494195|LGMD
552761|NCT00494195|LGMD2D
552762|NCT00494195|gene therapy
552763|NCT00494195|gene transfer
552764|NCT00494195|muscular dystrophy
552765|NCT00494195|SGCA
552766|NCT00494195|sarcoglycan
552767|NCT00494195|limb girdle
552768|NCT00494195|adeno-associated virus
552769|NCT00494195|AAV
552770|NCT00494195|AAV1
552771|NCT00494182|Head and Neck Cancer
552772|NCT00494182|Squamous Cell Carcinoma
552773|NCT00494182|Sorafenib
552774|NCT00494182|BAY 43-9006
552775|NCT00494182|Carboplatin
552776|NCT00494182|Paclitaxel
552777|NCT00494182|SCCHN
552778|NCT00494169|Idiopathic Hypogonadotropic Hypogonadism
552779|NCT00494169|Kallmann Syndrome
552780|NCT00494169|Puberty
552781|NCT00494169|Pituitary Abnormalities
552782|NCT00494169|Hypothalamus
552783|NCT00494169|anosmia
552784|NCT00494169|GnRH deficiency
552785|NCT00494143|Amputee
552786|NCT00494143|Economy
552787|NCT00494143|Efficiency
552788|NCT00494143|Foot
552789|NCT00494143|Gait
552790|NCT00494143|Kinematics
552791|NCT00494143|Kinetics
552792|NCT00494143|Prosthesis
552793|NCT00494104|vitamin D deficiency
552794|NCT00494104|breastfed infant
552795|NCT00494104|northern latitude
552796|NCT00494104|infant
552797|NCT00494104|breastfed
552798|NCT00494104|winter
552799|NCT00494104|vitamin D status
552800|NCT00494078|critical illness
552801|NCT00494078|hyperglycemia
552802|NCT00494078|intensive insulin therapy
552803|NCT00494078|glucose monitoring
552804|NCT00494052|Coronary Heart Disease
552805|NCT00494052|Choice Behavior
552806|NCT00494052|Risk Factors
552807|NCT00494052|Risk Assessment
552808|NCT00494052|Primary Prevention
552809|NCT00494052|Decision Making
552810|NCT00494052|Decision Aids
552811|NCT00494052|Patient Compliance
552812|NCT00494039|prostate
552813|NCT00494039|cancer
552814|NCT00494039|radiation
552815|NCT00494039|brachytherapy
552816|NCT00494013|diabetes
552817|NCT00494013|type 2
552818|NCT00493987|Testosterone
552819|NCT00493987|Androgens
552820|NCT00493987|Dihydrotestosterone
552821|NCT00493987|5-alpha reductase
552822|NCT00493987|Body Composition
552823|NCT00493987|Muscle
552824|NCT00493987|Sexual function
552825|NCT00493987|Men
552826|NCT00493987|Healthy Men
552827|NCT00493974|Chronic Obstructive Pulmonary Disease
552828|NCT00493974|COPD
552829|NCT00493974|Exacerbation
552830|NCT00493974|Anti-leukotriene
552831|NCT00493974|Length of Stay
552832|NCT00493974|LOS
552833|NCT00493961|Kallmann Syndrome
552834|NCT00493961|Idiopathic Hypogonadotropic Hypogonadism
552835|NCT00493961|GnRH deficiency
552836|NCT00493935|bedtime snack
552837|NCT00493935|hypoglycemia
552838|NCT00493935|Diabetes Mellitus, Type I
552839|NCT00493935|glucose monitoring
552840|NCT00493922|Malaria
552841|NCT00493922|Diagnosis
552842|NCT00493922|Rapid diagnostic tests
552843|NCT00493922|Microscopy
552844|NCT00493922|Clinical diagnosis
552845|NCT00493922|Africa
552846|NCT00493909|thoracotomy
552847|NCT00493909|pain therapy
552848|NCT00493909|thoracic paravertebral blockade
552849|NCT00493909|intrathecal opioids
552850|NCT00493909|thoracic epidural analgesia
552851|NCT00493909|Analgesia after thoracotomy
552852|NCT00493896|Venous Thromboembolism Prophylaxis
552853|NCT00493896|VTE prophylaxis
552854|NCT00493883|Therasphere
552855|NCT00493883|Yttrium
552856|NCT00493883|liver
552857|NCT00493883|cancer
552858|NCT00493883|radiation
552859|NCT00493857|Colorectal cancer
552860|NCT00493857|Monoclonal antibody
552861|NCT00493857|Anti-EGFR
552862|NCT00493844|Chest pain
552863|NCT00493844|Unstable angina
552864|NCT00493844|NT-proBNP
552865|NCT00493844|Exercise test.
552866|NCT00493831|smoking reduction
552867|NCT00493831|inflammation
552868|NCT00493831|harm reduction
552869|NCT00493831|lipid biomarkers
552870|NCT00493818|GSK690693,
552871|NCT00493818|Solid Tumors,
552872|NCT00493818|Lymphoma,
552873|NCT00493818|AKT
552874|NCT00493805|homeostasis model assessment of insulin resistance
552875|NCT00493766|LBH589
552876|NCT00493766|Prostate Cancer
552877|NCT00493766|HRPC
552878|NCT00493766|Hormone Refractory Prostate Cancer
552879|NCT00493740|Cephalic phase, oncology patients
552880|NCT00493727|Oxidative stress
552881|NCT00493727|N-acetylcysteine
552882|NCT00493727|NAC
552883|NCT00493727|Isoprostane
552884|NCT00493727|Proteinuria
552885|NCT00493727|Diabetes
552886|NCT00493727|Mucomyst
552887|NCT00493727|albuminuria
552888|NCT00493714|Advanced Cancer
552889|NCT00493714|Delirium
552890|NCT00493714|Restlessness
552891|NCT00493714|Confusion
552892|NCT00493714|Caregivers
552893|NCT00493714|Questionnaire
552894|NCT00493688|Abdominal Cancer
552895|NCT00493688|Pelvic Cancer
552896|NCT00493688|Perioperative Energy Dynamics
552897|NCT00493688|Cardiopulmonary Exercise Testing
552898|NCT00493688|CPET
552899|NCT00493675|Cystic duct leakage
552900|NCT00493636|Breast Cancer
552901|NCT00493610|Oxidant stress
552902|NCT00493610|N-acetylcysteine
552903|NCT00493610|Hepatitis C
552904|NCT00493610|Liver disease
552905|NCT00493610|Mucomyst
552906|NCT00493610|Isoprostane
552907|NCT00493597|Atherosclerosis
552908|NCT00493597|Restenosis
552909|NCT00493597|EPC
552910|NCT00493597|DC
552911|NCT00493584|Myocardial Infarction
552912|NCT00493584|Myocardial Ischemia
552913|NCT00493584|Myocardial Revascularization
552914|NCT00493584|Telemedicine
552915|NCT00493584|Percutaneous Transluminal Coronary Angioplasty
552916|NCT00493571|Myelodysplastic Syndromes
552917|NCT00493571|MDS
552918|NCT00493571|Gimatecan
552919|NCT00493571|Leukemia
552920|NCT00493558|Roentgen Stereophotogrammetric Analysis
552921|NCT00493558|Trabecular Metal Posterior Lumbar Interbody Cage
552922|NCT00493558|Posterior Lumbar Interbody Fusion Cage
552923|NCT00493558|Posterior Lumbar spine fusion surgery
552924|NCT00493545|Multicenter
552925|NCT00493545|Open-Label
552926|NCT00493545|Nonrandomized
552927|NCT00493545|Safety
552928|NCT00493519|Cephalic phase
552929|NCT00493519|Anorexia nervosa
552930|NCT00493519|Bulimia nervosa
552931|NCT00493519|obese binge eaters
552932|NCT00493519|VAS
552933|NCT00493519|EDI
552934|NCT00493519|shame-feed procedure
552935|NCT00493506|ProAlgaZyme
552936|NCT00493506|HIV
552937|NCT00493506|HAART
552938|NCT00493506|hsCRP
552939|NCT00493506|Oxidative stress
552940|NCT00493506|CD4+ lymphocytes
552941|NCT00493506|Algae
552942|NCT00493506|HAART adverse effects
552943|NCT00493506|HBV
552944|NCT00493493|Cymetra
552945|NCT00493467|Non-Hodgkin's Lymphoma
552946|NCT00493467|Lymphoma
552947|NCT00493467|Indolent Lymphomas
552948|NCT00493467|Ibritumomab Tiuxetan
552949|NCT00493467|Zevalin
552950|NCT00493454|Indolent Lymphoma
552951|NCT00493454|Extranodal Marginal
552952|NCT00493454|Nodal Marginal Zone
552953|NCT00493454|Splenic Marginal
552954|NCT00493454|MALT Type
552955|NCT00493454|Zevalin
552956|NCT00493454|Ibritumomab Tiuxetan
552957|NCT00493454|Rituximab
552958|NCT00493428|Hepatocellular Carcinoma
552959|NCT00493428|GABAergic Activity
552960|NCT00493428|Baclofen
552961|NCT00493415|microcirculation
552962|NCT00493415|sepsis
552963|NCT00493415|nitroglycerine
552964|NCT00493415|SDF imaging
552965|NCT00493402|Antineoplastic Agents
552966|NCT00493402|administration & dosage
552967|NCT00493402|Carcinoma, Hepatocellular
552968|NCT00493402|Chemoembolization, Therapeutic
552969|NCT00493402|Humans
552970|NCT00493402|Liver Neoplasms
552971|NCT00493402|therapy
552972|NCT00493389|ACTH stimulation test
552973|NCT00493389|cortisol
552974|NCT00493389|stress
552975|NCT00493376|tirapazamine
552976|NCT00493376|DNA damage
552977|NCT00493376|comet assay
552978|NCT00493363|falciparum malaria
552979|NCT00493363|artemisinins
552980|NCT00493363|artesunate
552981|NCT00493363|resistance
552982|NCT00493350|Breast Cancer
552983|NCT00493350|Circulating Tumor Cells
552984|NCT00493350|Gene Profiling
552985|NCT00493350|International Stage Stratification Study
552986|NCT00493350|Blood Sample
552987|NCT00493350|ISSS
552988|NCT00493337|Adherence
552989|NCT00493337|Compliance
552990|NCT00493337|Statins
552991|NCT00493337|Intervention
552992|NCT00493337|Hypercholesterolemia
552993|NCT00493324|psoriasis
552994|NCT00493324|alefacept
552995|NCT00493324|polyvalent pneumococcal vaccine
552996|NCT00493324|Immunization
552997|NCT00493298|disease progression
552998|NCT00493298|Multiple Sclerosis
552999|NCT00493298|disease activity
553000|NCT00493298|Tysabri
553001|NCT00493298|natalizumab
553002|NCT00493298|long-term safety
553003|NCT00493285|Lower Respiratory Tract Illness
553004|NCT00493285|RSV and PIV3 infection
553005|NCT00493272|Blood coagulation disorder, acquired
553006|NCT00493272|Hemodilution
553007|NCT00493272|Fibrinogen
553008|NCT00493272|Hemostasis
553009|NCT00493272|HES
553010|NCT00493259|Health-Related Quality of Life
553011|NCT00493233|schizophrenia
553012|NCT00493233|antipsychotics
553013|NCT00493233|polypharmacy
553014|NCT00493233|double-blind
553015|NCT00493233|randomized
553016|NCT00493220|ceftriaxone
553017|NCT00493220|cephalosporins
553018|NCT00493220|pharmacokinetics
553019|NCT00493220|subcutaneous
553020|NCT00493220|hyaluronoglucosaminidase
553021|NCT00493220|hyaluronidase
553022|NCT00493220|hyaluronan
553023|NCT00493220|rHuPH20
553024|NCT00493194|Cyclosporine toxicity
553025|NCT00493194|Interstitial Fibrosis
553026|NCT00493194|Chronic allograft nephropathy
553027|NCT00493194|Sirolimus
553028|NCT00493181|oprelvekin
553029|NCT00493181|tyrosine kinase inhibitor
553030|NCT00493181|Chronic Myelogenous Leukemia
553031|NCT00493181|Leukemia
553032|NCT00493181|CML
553033|NCT00493181|Thrombocytopenia
553034|NCT00493181|Imatinib
553035|NCT00493181|IL-11
553036|NCT00493181|Interleukin 11
553037|NCT00493181|Neumega
553038|NCT00493129|Systemic Mastocytosis
553039|NCT00493129|SM
553040|NCT00493129|Mast Cell Leukemia
553041|NCT00493129|Leukemia
553042|NCT00493129|Denileukin Diftitox
553043|NCT00493129|Ontak
553044|NCT00493116|recovery of efficacy
553045|NCT00493116|MxA protein
553046|NCT00493116|neutralizing antibodies
553047|NCT00493116|Multiple sclerosis
553048|NCT00493103|thyroglobulin gene
553049|NCT00493103|congenital hypothyroidism
553050|NCT00493103|gene mutations
553051|NCT00493103|fetal goiter
553052|NCT00493103|iodine nutrition
553053|NCT00493090|Professional
553054|NCT00493090|patient partnership
553055|NCT00493090|patient satisfaction
553056|NCT00493090|professional training
553057|NCT00493077|Multiple Sclerosis
553058|NCT00493077|Neutralizing antibodies
553059|NCT00493077|Safety
553060|NCT00493077|Low immunogenicity
553061|NCT00493077|interferon
553062|NCT00493077|interferon-beta-1a
553063|NCT00493051|diabetes
553064|NCT00493051|nonhealing
553065|NCT00493051|ulcers
553066|NCT00493051|neuropathic
553067|NCT00493038|Treatment of acute bacterial rhinosinusitis
553068|NCT00493025|adenocarcinoma of the esophagus
553069|NCT00493025|stage II esophageal cancer
553070|NCT00493025|stage III esophageal cancer
553071|NCT00493025|stage IV esophageal cancer
553072|NCT00493012|body weight
553073|NCT00493012|body compostion
553074|NCT00493012|vitamin D
553075|NCT00493012|blood pressure
553076|NCT00492999|recurrent colon cancer
553077|NCT00492999|stage IV colon cancer
553078|NCT00492999|recurrent rectal cancer
553079|NCT00492999|stage IV rectal cancer
553080|NCT00492999|adenocarcinoma of the colon
553081|NCT00492999|adenocarcinoma of the rectum
553082|NCT00492999|liver metastases
553083|NCT00492986|Renal Cell Cancer (RCC)
553084|NCT00492986|Cancer
553085|NCT00492973|arthroplasty
553086|NCT00492973|replacement
553087|NCT00492973|knee
553088|NCT00492960|Celiac Disease
553089|NCT00492947|Phase I
553090|NCT00492947|dendritic cell
553091|NCT00492947|vaccine
553092|NCT00492947|intra tumoral
553093|NCT00492947|squamous cell carcinoma
553094|NCT00492934|subfertility
553095|NCT00492934|endometrium thickness
553096|NCT00492934|implantation rate
553097|NCT00492934|embryo cryopreservation
553098|NCT00492934|embryo transfer
553099|NCT00492921|graft versus host disease
553100|NCT00492908|Coronary Revascularization
553101|NCT00492908|Titanium-Nitride-Oxide Coated Stent
553102|NCT00492908|Zotarolimus-Eluting Stent
553103|NCT00492882|Polycystic Ovary Syndrome
553104|NCT00492882|Follicular Arrest
553105|NCT00492882|Anti-Mullerian Hormone
553106|NCT00492882|FSH
553107|NCT00492869|kidney transplantation
553108|NCT00492869|rejection
553109|NCT00492869|AEB071
553110|NCT00492869|tacrolimus
553111|NCT00492869|mycophenolic
553112|NCT00492869|basiliximab
553113|NCT00492869|immunosuppression
553114|NCT00492856|adult acute myeloid leukemia with t(15;17)(q22;q12)
553115|NCT00492856|adult acute promyelocytic leukemia (M3)
553116|NCT00492856|untreated adult acute myeloid leukemia
553117|NCT00492843|Ibandronate, Lung cancer, bone metastasis
553118|NCT00492830|Phase 1
553119|NCT00492830|TRC093
553120|NCT00492830|denatured collagen
553121|NCT00492830|solid tumor
553122|NCT00492830|antibody
553123|NCT00492830|TRACON
553124|NCT00492830|Locally advanced solid tumors
553125|NCT00492830|Metastatic solid tumors
553126|NCT00492817|Spinal Neoplasms
553127|NCT00492817|Paraspinal Metastases
553128|NCT00492817|Stereotactic Body Radiotherapy
553129|NCT00492817|CT-on-Rails
553130|NCT00492817|Spinal Cord
553131|NCT00492817|SBRT
553132|NCT00492804|inguinal hernia
553133|NCT00492804|chronic pain
553134|NCT00492804|neurectomy
553135|NCT00492804|hypesthesia
553136|NCT00492791|crohn's disease
553137|NCT00492791|capsule endoscopes
553138|NCT00492765|Combination therapy
553139|NCT00492765|Simvastatin
553140|NCT00492765|Multiple Sclerosis
553141|NCT00492765|Interferon-beta-1a
553142|NCT00492739|Orthotopic liver transplantation
553143|NCT00492739|Pediatric
553144|NCT00492739|Immunosuppression
553145|NCT00492739|Varicella vaccine
553146|NCT00492739|B cell response
553147|NCT00492739|T cell response
553148|NCT00492739|Antibodies
553149|NCT00492739|Varicella
553150|NCT00492739|Chickenpox
553151|NCT00492739|transplantation
553152|NCT00492726|Complicated Intra-Abdominal Infections
553153|NCT00492713|Bioavailability
553154|NCT00492713|Dark Chocolate
553155|NCT00492713|Milk Chocolate
553156|NCT00492713|Polyphenols
553157|NCT00492700|steatosis,
553158|NCT00492700|fibrosis,
553159|NCT00492700|diabetes,
553160|NCT00492700|obesity
553161|NCT00492687|adult anaplastic astrocytoma
553162|NCT00492687|adult giant cell glioblastoma
553163|NCT00492687|adult gliosarcoma
553164|NCT00492687|adult glioblastoma
553165|NCT00492674|TKA
553166|NCT00492674|Arthroplasty
553167|NCT00492674|Knee
553168|NCT00492674|Osteoarthritis
553169|NCT00492674|Rehabilitation
553170|NCT00492661|Tacrolimus
553171|NCT00492661|Prograf
553172|NCT00492661|PRIDE
553173|NCT00492648|GSK Biologicals
553174|NCT00492648|Varicella Zoster Virus (VZV)
553175|NCT00492648|Intracellular cytokine staining (ICS)
553176|NCT00492648|Vaccine
553177|NCT00492648|Cell mediated immunity (CMI)
553178|NCT00492648|Herpes Zoster (HZ)
553179|NCT00492648|Shingles
553180|NCT00492622|Gastroparesis
553181|NCT00492622|Gastroesophageal reflux disease
553182|NCT00492622|heartburn
553183|NCT00492609|Surgery
553184|NCT00492609|Navigation
553185|NCT00492609|ACL
553186|NCT00492609|IKDC
553187|NCT00492609|comparative study
553188|NCT00492583|probiotic
553189|NCT00492583|health
553190|NCT00492583|bifidobacterium lactis
553191|NCT00492583|BB-12
553192|NCT00492570|Multiple Sclerosis
553193|NCT00492570|Cognitive Dysfunction in Multiple sclerosis
553194|NCT00492570|early treatment
553195|NCT00492570|Avonex
553196|NCT00492570|interferon beta 1a
553197|NCT00492570|Cognitive Dysfunction
553198|NCT00492557|Pneumococcal Disease
553199|NCT00492557|Pneumococcal Conjugate Vaccine
553200|NCT00492544|Human Papillomavirus (HPV) vaccine
553201|NCT00492544|safety
553202|NCT00492544|cervical cancer
553203|NCT00492544|immunogenicity
553204|NCT00492544|vaccine
553205|NCT00492544|viral infections
553206|NCT00492544|pre-adolescent and adolescent females
553207|NCT00492531|Interventional Study
553208|NCT00492531|6-Minute Walk
553209|NCT00492531|Sickle Cell Anemia
553210|NCT00492531|Sildenafil/Viagra
553211|NCT00492531|Tricuspid Regurgitant Velocity
553212|NCT00492531|Sickle Cell Disease
553213|NCT00492531|Pulmonary Hypertension
553214|NCT00492518|Contrast Induced Nephropathy
553215|NCT00492518|Prophylaxis
553216|NCT00492518|Theophylline
553217|NCT00492518|Acetylcysteine
553218|NCT00492518|Coronary angiography
553219|NCT00492505|stage IIIA melanoma
553220|NCT00492505|stage IIIB melanoma
553221|NCT00492505|stage IIIC melanoma
553222|NCT00492492|radius,
553223|NCT00492492|pinning,
553224|NCT00492492|fixed-angle plate,
553225|NCT00492492|quick-DASH,
553226|NCT00492492|HERZBERG-score.
553227|NCT00492466|Multiple Sclerosis
553228|NCT00492466|antibody
553229|NCT00492466|Neutralizing antibody
553230|NCT00492466|Binding antibody
553231|NCT00492466|MxA protein
553232|NCT00492440|recurrent renal cell cancer
553233|NCT00492440|stage IV renal cell cancer
553234|NCT00492440|stage III renal cell cancer
553235|NCT00492440|recurrent melanoma
553236|NCT00492440|stage IV melanoma
553237|NCT00492414|Panic disorder (PD)
553238|NCT00492388|breakthrough
553239|NCT00492388|pain
553240|NCT00492388|cancer
553241|NCT00492362|hemodialysis
553242|NCT00492362|exercise
553243|NCT00492362|physical fitness
553244|NCT00492362|dialysis adequacy
553245|NCT00492349|Varenicline
553246|NCT00492349|Neurobiology
553247|NCT00492349|clinical trial
553248|NCT00492349|cognitive deficits
553249|NCT00492349|Schizophreniform Disorder
553250|NCT00492336|Cognitive impairments
553251|NCT00492336|Negative symptoms
553252|NCT00492323|pain following the healing of rashes and blisters
553253|NCT00492323|herpes virus
553254|NCT00492323|rash
553255|NCT00492323|varicella-zoster virus
553256|NCT00492323|shingles.
553257|NCT00492310|Smoking
553258|NCT00492310|tobacco
553259|NCT00492310|women
553260|NCT00492310|yoga
553261|NCT00492284|Macular Degeneration
553262|NCT00492284|AMD
553263|NCT00492284|CNV
553264|NCT00492284|Choroidal neovascularization
553265|NCT00492284|Photodynamic therapy
553266|NCT00492284|CNV Secondary to Age Related Macular Degeneration
553267|NCT00492271|Friulimicin B
553268|NCT00492271|Lipopeptide Antibiotic
553269|NCT00492271|First in Man
553270|NCT00492258|stage II renal cell cancer
553271|NCT00492258|stage III renal cell cancer
553272|NCT00492258|stage IV renal cell cancer
553273|NCT00492258|stage I renal cell cancer
553274|NCT00492258|clear cell renal cell carcinoma
553275|NCT00492258|papillary renal cell carcinoma
553276|NCT00492245|PTK
553277|NCT00492245|corneal opacity
553278|NCT00492245|mitomycin
553279|NCT00492232|Chronic Insomnia
553280|NCT00492232|Sleep Initiation and Maintenance Disorder
553281|NCT00492232|Drug Therapy
553282|NCT00492219|arthroplasty
553283|NCT00492219|replacement
553284|NCT00492219|knee
553285|NCT00492219|prosthesis
553286|NCT00492206|Non Small Cell Lung Cancer
553287|NCT00492206|NSCLC
553288|NCT00492206|EGFR Inhibitor
553289|NCT00492206|Radiation Therapy
553290|NCT00492193|Hand assist laparoscopic partial large bowel resection
553291|NCT00492193|Laparoscopic partial large bowel resection
553292|NCT00492167|recurrent neuroblastoma
553293|NCT00492167|regional neuroblastoma
553294|NCT00492167|stage 4S neuroblastoma
553295|NCT00492167|disseminated neuroblastoma
553296|NCT00492154|FRACTURE OF DISTAL RADIUS
553297|NCT00492141|Ewing's Sarcoma
553298|NCT00492141|Lung Involvement
553299|NCT00492141|Temozolomide
553300|NCT00492141|Temodar
553301|NCT00492141|Aerosol Liposomal 9-Nitro-20(S)-Camptothecin
553302|NCT00492141|Aerosol L9-NC
553303|NCT00492141|L9-NC
553304|NCT00492128|hypertension
553305|NCT00492128|angiotensin receptor blocker
553306|NCT00492128|diuretic
553307|NCT00492128|combination therapy
553308|NCT00492115|sleep
553309|NCT00492115|dementia
553310|NCT00492115|apnea
553311|NCT00492115|memory
553312|NCT00492115|Parkinson's disease
553313|NCT00492102|pharmacokinetics
553314|NCT00492102|Montelukast
553315|NCT00492102|bronchopulmonary dysplasia
553316|NCT00492102|Pharmacokinetics of Montelukast
553317|NCT00492076|Specific immunotherapy
553318|NCT00492076|Mite
553319|NCT00492076|Asthma
553320|NCT00492063|safety
553321|NCT00492063|immunogenicity
553322|NCT00492063|non-inferiority
553323|NCT00492063|MDCK
553324|NCT00492063|cell culture-derived
553325|NCT00492063|subunit influenza vaccine
553326|NCT00492063|influenza prevention
553327|NCT00492050|Waldenstrom's Macroglobulinemia
553328|NCT00492050|Macroglobulinemic Lymphoma
553329|NCT00492050|Stem Cell Collection
553330|NCT00492050|Bortezomib
553331|NCT00492050|LDP-341
553332|NCT00492050|MLN341
553333|NCT00492050|PS-341
553334|NCT00492050|Velcade
553335|NCT00492050|Rituximab
553336|NCT00492050|Rituxan
553337|NCT00492037|hyponatremia
553338|NCT00492037|hypervolemic
553339|NCT00492037|euvolemic
553340|NCT00492037|conivaptan
553341|NCT00492024|Respiratory Tract Infection
553342|NCT00492024|Bacterial Sinusitis
553343|NCT00492011|Circadian Rhythm Disorders
553344|NCT00492011|Biological Clock Disturbances
553345|NCT00492011|Jet Lag Syndrome
553346|NCT00492011|Time Zone Change Syndrome
553347|NCT00492011|Drug Therapy
553348|NCT00491985|Influenza A/H5N1 Virus
553349|NCT00491985|Influenza Pandemic
553350|NCT00491985|Orthomyxoviridae Infections
553351|NCT00491959|oral mucosa
553352|NCT00491959|limbal insufficiency
553353|NCT00491959|transplantation
553354|NCT00491959|cornea
553355|NCT00491959|ocular surface
553356|NCT00491946|Cancer
553357|NCT00491946|Actinomycin
553358|NCT00491946|Vincristine
553359|NCT00491920|osteoporosis
553360|NCT00491920|bone mineral density
553361|NCT00491920|vitamin D
553362|NCT00491907|folic acid
553363|NCT00491907|endothelial function
553364|NCT00491907|baroreceptor function
553365|NCT00491907|heart failure
553366|NCT00491894|Mental Retardation
553367|NCT00491894|Neurological Impairment
553368|NCT00491894|Cerebral Palsy
553369|NCT00491894|Drooling
553370|NCT00491894|Neurological Conditions
553371|NCT00491881|blood pressure
553372|NCT00491881|No added salt diet
553373|NCT00491881|urinary sodium
553374|NCT00491855|Advanced Peritoneal Carcinomatosis
553375|NCT00491855|Peritoneal Cancer
553376|NCT00491855|Bevacizumab
553377|NCT00491855|Avastin
553378|NCT00491855|vascular endothelial growth factor
553379|NCT00491855|Anti-VEGF monoclonal antibody
553380|NCT00491855|rhuMAb-VEGF
553381|NCT00491855|Oxaliplatin
553382|NCT00491855|Eloxatin
553383|NCT00491855|Paclitaxel
553384|NCT00491855|Taxol
553385|NCT00491842|Huntington's Disease
553386|NCT00491842|Disclosure
553387|NCT00491842|Adaptation
553388|NCT00491842|Communication About Huntington's Disease
553389|NCT00491842|Huntington Disease
553390|NCT00491842|HD
553391|NCT00491842|Phone Interview
553392|NCT00491816|breast
553393|NCT00491816|cancer
553394|NCT00491816|breast cancer
553395|NCT00491803|COPD
553396|NCT00491790|montelukast
553397|NCT00491790|Albuterol
553398|NCT00491790|Status Asthmaticus
553399|NCT00491790|Asthma
553400|NCT00491777|Noninvasive
553401|NCT00491777|Hemodynamic
553402|NCT00491777|Monitoring
553403|NCT00491777|Critical Care
553404|NCT00491777|Swan-Ganz
553405|NCT00491751|endothelium
553406|NCT00491751|nitric oxide
553407|NCT00491751|statins
553408|NCT00491751|ascorbic acid
553409|NCT00491738|RCC
553410|NCT00491738|Renal cell cancer
553411|NCT00491738|Avastin
553412|NCT00491738|Sutent
553413|NCT00491712|Glaucoma
553414|NCT00491712|Neovascular Glaucoma
553415|NCT00491712|Drainage implant devices
553416|NCT00491712|Silicone Ahmed Tube
553417|NCT00491712|Triamcinolone
553418|NCT00491699|NSCLC
553419|NCT00491686|Long-term depression
553420|NCT00491673|Fracture
553421|NCT00491673|Femoral neck
553422|NCT00491673|Arthroplasty
553423|NCT00491660|Gravity
553424|NCT00491660|Mechanical ventilation
553425|NCT00491660|Infants
553426|NCT00491660|Ventilator-associated pneumonia
553427|NCT00491660|Types of bacterial colonies in subjects at 2-5 days of mechanical ventilation
553428|NCT00491660|Colony count of an organism was cultured
553429|NCT00491647|ADHD, time perception, treatments
553430|NCT00491634|acute myeloid leukemia
553431|NCT00491634|myelodysplastic syndrome
553432|NCT00491634|allogeneic stem cell transplantation
553433|NCT00491634|reduced-intensity conditioning
553434|NCT00491634|treosulfan
553435|NCT00491621|kidney
553436|NCT00491621|tumor
553437|NCT00491621|Molecular Markers
553438|NCT00491621|Cytology
553439|NCT00491621|Histology
553440|NCT00491621|Cystic kidney tumor
553441|NCT00491608|Phase 3b
553442|NCT00491608|rThrombin
553443|NCT00491608|spine surgery
553444|NCT00491608|vascular surgery
553445|NCT00491608|hemostasis
553446|NCT00491608|immunogenicity
553447|NCT00491608|safety
553448|NCT00491595|Soy isoflavones
553449|NCT00491595|Genotoxicity
553450|NCT00491595|Apoptosis
553451|NCT00491595|Estrogenic effects
553452|NCT00491569|Schizophrenia
553453|NCT00491569|sarcosine
553454|NCT00491569|D-serine
553455|NCT00491569|NMDA
553456|NCT00491556|Atazanavir/Ritonavir (ATV/r)
553457|NCT00491556|highly-active antiretroviral therapy (HAART)
553458|NCT00491556|Treatment Naive
553459|NCT00491491|non-Hodgkin's lymphoma
553460|NCT00491491|autologous stem cell transplantation
553461|NCT00491491|radioimmunotherapy
553462|NCT00491491|zevalin
553463|NCT00491478|Repetitive behavior disorder
553464|NCT00491478|Stereotypy
553465|NCT00491478|Sertraline
553466|NCT00491465|Type 1 Diabetes, physical activity, pediatric, metabolic control
553467|NCT00491452|Ischemic MR
553468|NCT00491452|Annuloplasty
553469|NCT00491439|in vivo confocal microscopy
553470|NCT00491439|vitrectomy
553471|NCT00491439|corneal transplantation
553472|NCT00491439|Epi-LASIK
553473|NCT00491439|wound healing
553474|NCT00491426|Infection
553475|NCT00491426|Anti-Infective Agents
553476|NCT00491426|Antifungal Agents
553477|NCT00491426|Proteomics
553478|NCT00491413|neurodevelopmental outcomes
553479|NCT00491400|endothelium
553480|NCT00491400|obesity
553481|NCT00491400|diabetes mellitus
553482|NCT00491400|dyslipidemia
553483|NCT00491387|hypertension
553484|NCT00491387|sympathetic nervous system
553485|NCT00491361|ADHD, SNAP-IV, SDQ, ASRS, reliability, validity
553486|NCT00491348|Generalized anxiety disorder
553487|NCT00491348|fMRI
553488|NCT00491348|Worry
553489|NCT00491335|AIDS
553490|NCT00491335|Lung Cancer
553491|NCT00491335|Emphysema
553492|NCT00491335|Nicotine
553493|NCT00491335|HIV Infection
553494|NCT00491335|Smoking
553495|NCT00491322|Vitamin D
553496|NCT00491322|Vitamin D deficiency
553497|NCT00491322|Insulin resistance
553498|NCT00491322|Diabetes
553499|NCT00491322|Diabetes mellitus
553500|NCT00491322|FGF-23
553501|NCT00491322|FGF23
553502|NCT00491322|Phosphate
553503|NCT00491296|S/P Transuretral resection of bladder tumor
553504|NCT00491296|Recurrent tumor after BCG Treatment
553505|NCT00491270|Vaginosis, Bacterial
553506|NCT00491270|Abortion, Spontaneous
553507|NCT00491270|Premature Birth
553508|NCT00491257|Influenza
553509|NCT00491257|Orthomyxoviridae Infections
553510|NCT00491257|Orthomyxoviruses
553511|NCT00491257|Split-virion influenza vaccine
553512|NCT00491244|Chronic hepatitis C
553513|NCT00491244|Hemodialysis
553514|NCT00491244|Interferon
553515|NCT00491244|Ribavirin
553516|NCT00491231|orthostatic hypotension
553517|NCT00491231|ambulatory blood pressure monitoring
553518|NCT00491218|impact of cardiac computed tomography on outpatient angina evaluation
553519|NCT00491218|downstream resource utilization
553520|NCT00491192|Fever
553521|NCT00491192|Acute cerebral damage
553522|NCT00491192|Normothermia
553523|NCT00491192|Diclofenac
553524|NCT00491192|ICU
553525|NCT00491192|Outcome
553526|NCT00491192|Intracranial pressure
553527|NCT00491192|Cerebral perfusion pressure
553528|NCT00491192|Traumatic brain injury
553529|NCT00491192|Subarachnoid hemorrhage
553530|NCT00491179|Chronic hepatitis C
553531|NCT00491179|hemodialysis
553532|NCT00491179|interferon
553533|NCT00491179|ribavirin
553534|NCT00491166|diabetic macular edema
553535|NCT00491166|bromfenac ophthalmic solution
553536|NCT00491153|asthma
553537|NCT00491153|airway hyperresponsiveness
553538|NCT00491153|dry powder mannitol inhalation
553539|NCT00491153|methacholine
553540|NCT00491140|EGFR
553541|NCT00491140|KRAS
553542|NCT00491140|BRAF
553543|NCT00491140|MET
553544|NCT00491140|IGFR1
553545|NCT00491101|Asthma Control
553546|NCT00491101|Quality of Life
553547|NCT00491101|Children
553548|NCT00491101|Polish Version of PAQLQ(S) by Juniper
553549|NCT00491075|Renal Cell Carcinoma
553550|NCT00491075|Non-Clear Cell
553551|NCT00491075|Pemetrexed
553552|NCT00491075|Gemcitabine
553553|NCT00491075|LY231514
553554|NCT00491075|Alimta
553555|NCT00491075|MTA
553556|NCT00491075|Multitargeted Antifolate
553557|NCT00491075|NSC-698037
553558|NCT00491075|Gemcitabine Hydrochloride
553559|NCT00491075|Gemzar
553560|NCT00491075|RCC
553561|NCT00491062|Parkinson's disease
553562|NCT00491062|enteric nervous system
553563|NCT00491049|prophylaxis
553564|NCT00491049|intraocular surgery
553565|NCT00491049|endophthalmitis
553566|NCT00491049|antibiotic
553567|NCT00491036|Acute myocardial infarction
553568|NCT00491036|cardiogenic shock
553569|NCT00491036|percutaneous coronary intervention
553570|NCT00491036|intraaortic balloon counterpulsation
553571|NCT00491036|Acute myocardial infarction - cardiogenic shock
553572|NCT00491010|atrial flutter
553573|NCT00491010|ablation
553574|NCT00491010|voltage targeted
553575|NCT00490997|ketamine
553576|NCT00490997|propofol
553577|NCT00490997|sedation
553578|NCT00490997|pediatric
553579|NCT00490997|emergency department
553580|NCT00490997|fracture
553581|NCT00490984|obstructive sleep apena
553582|NCT00490984|tongue
553583|NCT00490984|surgery
553584|NCT00490971|Bipolar Disorder
553585|NCT00490971|Mania
553586|NCT00490971|Depression
553587|NCT00490971|Manic-Depressive Disorder
553588|NCT00490958|heart Failure
553589|NCT00490958|haemodialysis
553590|NCT00490958|telmisartan
553591|NCT00490958|angiotensin converting enzyme inhibitor
553592|NCT00490932|Watery diarrhea
553593|NCT00490932|Bloody diarrhea
553594|NCT00490919|Chronic pain
553595|NCT00490919|opioid
553596|NCT00490919|transdermal
553597|NCT00490919|Moderate to severe chronic low back pain
553598|NCT00490906|MS (Multiple Sclerosis)
553599|NCT00490893|counterregulation
553600|NCT00490893|hypoglycemia unawareness
553601|NCT00490893|insulin therapy
553602|NCT00490828|Cardiac surgery
553603|NCT00490828|systemic inflammatory response syndrome
553604|NCT00490828|health-related quality of life
553605|NCT00490802|Autism
553606|NCT00490802|Treatment
553607|NCT00490802|Oxytocin
553608|NCT00490802|Adults
553609|NCT00490802|Autism Spectrum Disorder
553610|NCT00490789|tuberous sclerosis
553611|NCT00490789|lymphangioleiomyomatosis
553612|NCT00490789|sirolimus
553613|NCT00490789|angiomyolioma
553614|NCT00490789|rapamycin
553615|NCT00490789|mTOR
553616|NCT00490776|Cutaneous T-Cell Lymphoma
553617|NCT00490776|adults
553618|NCT00490776|Mycosis Fungoides
553619|NCT00490776|Sézary Syndrome
553620|NCT00490776|CTCL
553621|NCT00490763|Prostate Cancer
553622|NCT00490763|Active Surveillance
553623|NCT00490763|Prostate Specific Antigen
553624|NCT00490763|Questionnaire
553625|NCT00490763|Survey
553626|NCT00490750|Heller Dor
553627|NCT00490750|Heller Toupet
553628|NCT00490750|Myotomy
553629|NCT00490737|ESRD
553630|NCT00490737|dialysis
553631|NCT00490737|hemodialysis
553632|NCT00490737|continuous ambulatory peritoneal dialysis
553633|NCT00490724|Heart failure, congestive
553634|NCT00490724|Nesiritide and
553635|NCT00490724|JNS004
553636|NCT00490698|Kidney Cancer
553637|NCT00490698|Renal Cell Carcinoma
553638|NCT00490698|Bone-Targeted Therapy
553639|NCT00490698|Zoledronate
553640|NCT00490698|Zometa
553641|NCT00490698|Atorvastatin
553642|NCT00490698|Lipitor
553643|NCT00490698|RCC
553644|NCT00490672|Hypertension
553645|NCT00490672|Diabetes Mellitus
553646|NCT00490672|Hyperlipidaemia
553647|NCT00490672|Primary Care
553648|NCT00490672|Community Care
553649|NCT00490672|Multiple Risk Factors Interventional Strategies
553650|NCT00490646|Locally advanced and/or metastatic breast cancer
553651|NCT00490633|Influenza
553652|NCT00490633|Non Pharmaceutical Intervention
553653|NCT00490633|Face Mask
553654|NCT00490633|Hand Hygiene
553655|NCT00490620|primary biliary cirrhosis C06.552.630.400
553656|NCT00490620|retroviral infection C02.782.815
553657|NCT00490607|Hemagiomas of infancy
553658|NCT00490594|ACL
553659|NCT00490594|ligament
553660|NCT00490594|ACL injury
553661|NCT00490581|Early housing after hospitalization
553662|NCT00490568|cognition
553663|NCT00490568|Alzheimer's disease
553664|NCT00490568|Rosiglitazone extended-release (XR)
553665|NCT00490568|safety
553666|NCT00490568|adjunctive therapy
553667|NCT00490568|BRL-049653
553668|NCT00490568|tolerability
553669|NCT00490568|open-label extension
553670|NCT00490555|Male Contraception
553671|NCT00490555|Testosterone
553672|NCT00490555|Testis
553673|NCT00490555|Contraception
553674|NCT00490555|Prostate
553675|NCT00490542|Bipolar Disorder
553676|NCT00490542|Major Depression
553677|NCT00490542|Clinical pharmacology
553678|NCT00490542|Clinical Trial
553679|NCT00490516|Schizophrenia, psychotic disorders
553680|NCT00490503|Breast Cancer
553681|NCT00490503|Magnetic Resonance Imaging
553682|NCT00490503|Magnetic Resonance Spectroscopy
553683|NCT00490503|DCE-MRI
553684|NCT00490503|DW-MRI
553685|NCT00490503|MRS
553686|NCT00490503|MRI
553687|NCT00490477|acute renal failure
553688|NCT00490477|lipopolysaccharide
553689|NCT00490477|tubular apoptosis
553690|NCT00490477|Polymyxin-B fiber
553691|NCT00490477|Severe sepsis from gram negative infection
553692|NCT00490464|Patients with SAH or ICH
553693|NCT00490438|perineometry
553694|NCT00490438|Modified Oxford Score
553695|NCT00490438|pelvic muscles evaluation
553696|NCT00490438|urinary incontinence
553697|NCT00490438|vaginal palpation
553698|NCT00490425|probiotics
553699|NCT00490425|LGG
553700|NCT00490425|praevention
553701|NCT00490425|allergic asthma
553702|NCT00490425|children
553703|NCT00490412|Vitamin D
553704|NCT00490412|Treatment Experienced
553705|NCT00490386|Retrospective
553706|NCT00490386|Length of Stay
553707|NCT00490386|Helicobacter pylori
553708|NCT00490347|VentrAssistTM
553709|NCT00490347|LVAD
553710|NCT00490347|End-stage heart failure
553711|NCT00490347|Cardiomyopathy
553712|NCT00490334|Carcinomas
553713|NCT00490334|Squamous Cel
553714|NCT00490334|Adenocarcinoma
553715|NCT00490334|Acute Lymphocytic Leukemia
553716|NCT00490321|VentrAssistTM
553717|NCT00490321|LVAD
553718|NCT00490321|End-stage heart failure
553719|NCT00490321|Cardiomyopathy
553720|NCT00490308|luteal
553721|NCT00490308|phase
553722|NCT00490308|estradiol
553723|NCT00490308|pregnancy
553724|NCT00490308|rate
553725|NCT00490295|biomarkers
553726|NCT00490295|brain ischemia
553727|NCT00490295|neonates
553728|NCT00490295|cardiac surgery
553729|NCT00490295|congenital heart disease
553730|NCT00490282|Head and Neck Cancer
553731|NCT00490282|Oropharyngeal Cancer
553732|NCT00490282|Adaptive Radiotherapy
553733|NCT00490282|Intensity Modulated Radiation Therapy
553734|NCT00490282|IMRT
553735|NCT00490282|ART
553736|NCT00490269|Marijuana dependence
553737|NCT00490256|Selective Cerebral Perfusion
553738|NCT00490256|Renal Complications
553739|NCT00490256|Gastrointestinal Complications
553740|NCT00490256|Aortic Arch Reconstruction
553741|NCT00490256|Modified Perfusion
553742|NCT00490256|Cardiopulmonary Bypass
553743|NCT00490256|Pediatrics
553744|NCT00490256|Cardiac Defects
553745|NCT00490256|intestinal ischemia
553746|NCT00490256|necrotizing entercolitis
553747|NCT00490256|Near Infra-red spectroscopy
553748|NCT00490256|Creatinine
553749|NCT00490256|C-reactive protein levels
553750|NCT00490243|Asthma
553751|NCT00490243|Children
553752|NCT00490243|Exercise
553753|NCT00490243|Pulmonary Function
553754|NCT00490243|Budesonide
553755|NCT00490243|Montelukast
553756|NCT00490243|Formoterol
553757|NCT00490230|Paromomycin
553758|NCT00490230|Gentamicin
553759|NCT00490217|Spontaneous bacterial peritonitis
553760|NCT00490217|incidence
553761|NCT00490217|Finland
553762|NCT00490217|etiology
553763|NCT00490217|liver cirrhosis
553764|NCT00490204|Cetirizine
553765|NCT00490204|Perennial Allergic Rhinitis
553766|NCT00490204|Placebo control
553767|NCT00490204|anti-histamine
553768|NCT00490178|Type II diabetes
553769|NCT00490178|dyslipidemia
553770|NCT00490178|metformin
553771|NCT00490178|fenofibrate
553772|NCT00490178|synordia
553773|NCT00490152|HIV
553774|NCT00490152|Microbicide Gel
553775|NCT00490152|HIV Seronegativity
553776|NCT00490139|Adjuvant
553777|NCT00490139|ErbB2-overexpressing
553778|NCT00490139|Early stage breast cancer
553779|NCT00490139|HER2/neu gene amplified
553780|NCT00490126|Laparoscopic Surgery
553781|NCT00490126|Laparoscopy
553782|NCT00490126|Gynecology
553783|NCT00490126|Demographics
553784|NCT00490126|Perioperative Care
553785|NCT00490100|X-Linked Severe Combined Immune Deficiency (XSCID)
553786|NCT00490100|Growth Hormone
553787|NCT00490100|Insulin-Like Growth Factor 1 (IGF)-1
553788|NCT00490100|Bone Age
553789|NCT00490100|Growth Failure
553790|NCT00490100|XSCID
553791|NCT00490100|X-Linked Severe Combined Immunodeficiency
553792|NCT00490087|Atypical endometrial polyps
553793|NCT00490087|Atypical Endometrial Hyperplasia
553794|NCT00490087|Hysteroscopic resection
553795|NCT00490087|Conservative treatment
553796|NCT00490087|Fertile women
553797|NCT00490074|AIDS Vaccines
553798|NCT00490074|Vaccines, DNA
553799|NCT00490074|HIV Preventive Vaccine
553800|NCT00490074|HIV Seronegativity
553801|NCT00490048|Ulcerative colits
553802|NCT00490048|lung
553803|NCT00490048|Induced sputum
553804|NCT00490048|Our aim to evaluate lung involvement in Ulcerative colitis patients by induced sputum
553805|NCT00490035|Epilepsy
553806|NCT00490035|Brivaracetam
553807|NCT00490035|Partial Onset Seizures
553808|NCT00490022|Dihydrotestosterone
553809|NCT00490022|Androgen
553810|NCT00490022|Prostate
553811|NCT00489970|Persistence
553812|NCT00489970|immunogenicity
553813|NCT00489957|congenital cardiac disorders
553814|NCT00489957|echocardiography
553815|NCT00489944|ciliary body and choroid melanoma, medium/large size
553816|NCT00489944|extraocular extension melanoma
553817|NCT00489944|iris melanoma
553818|NCT00489944|epithelioid cell intraocular melanoma
553819|NCT00489944|stage IIB intraocular melanoma
553820|NCT00489944|stage IIIA intraocular melanoma
553821|NCT00489944|stage IIIB intraocular melanoma
553822|NCT00489944|stage IIIC intraocular melanoma
553823|NCT00489944|stage IV intraocular melanoma
553824|NCT00489931|Avian Influenza
553825|NCT00489931|Healthy
553826|NCT00489931|Immunity
553827|NCT00489931|Preventive
553828|NCT00489931|Bird Flu
553829|NCT00489931|Healthy Volunteer
553830|NCT00489931|HV
553831|NCT00489905|prostate cancer
553832|NCT00489905|bone mineral density
553833|NCT00489892|traumatic brain injury
553834|NCT00489892|TBI
553835|NCT00489892|working memory
553836|NCT00489892|modafinil
553837|NCT00489892|fMRI
553838|NCT00489892|MRI
553839|NCT00489879|Mobile Health Units
553840|NCT00489879|Chronic Disease
553841|NCT00489866|PTSD
553842|NCT00489866|Antidepressant
553843|NCT00489866|Aripiprazole
553844|NCT00489866|OEF
553845|NCT00489866|OIF
553846|NCT00489853|COPD
553847|NCT00489840|Chronic Central Serous Chorioretinopathy
553848|NCT00489827|Coronary Artery Bypass
553849|NCT00489827|Myocardial Protection
553850|NCT00489827|Angina, Unstable
553851|NCT00489827|Myocardial Ischemia
553852|NCT00489827|Myocardial Infarction
553853|NCT00489827|Unstable Coronary Artery Disease
553854|NCT00489827|Glutamate
553855|NCT00489814|Prostate Cancer
553856|NCT00489814|Prostate Proton Therapy
553857|NCT00489814|Proton Radiation Therapy
553858|NCT00489814|Proton Radiotherapy
553859|NCT00489814|Quality of Life
553860|NCT00489814|QOL
553861|NCT00489814|Questionnaire
553862|NCT00489801|Cardiac Rehabilitation
553863|NCT00489801|Exercise
553864|NCT00489801|Heart failure
553865|NCT00489801|Coronary heart disease
553866|NCT00489788|MRI
553867|NCT00489788|Ventricular Strain
553868|NCT00489788|Pulmonary Valve Replacement
553869|NCT00489788|Post Tetralogy of Fallot
553870|NCT00489762|Childhood
553871|NCT00489762|Asthma
553872|NCT00489762|Heating
553873|NCT00489762|Insulation
553874|NCT00489762|Respiratory symptoms
553875|NCT00489749|Achilles tendon rupture
553876|NCT00489749|Open surgical repair
553877|NCT00489749|Early functional mobilization
553878|NCT00489749|Weightbearing
553879|NCT00489749|Rehabilitation
553880|NCT00489736|Atrial Fibrillation
553881|NCT00489736|sinus rhythm
553882|NCT00489736|amiodarone
553883|NCT00489723|size of stone 1-2 cm
553884|NCT00489723|Pt. with no use of alfa bloker prior ESWL
553885|NCT00489723|Pt. without internal stent
553886|NCT00489710|stage IV renal cell cancer
553887|NCT00489710|recurrent renal cell cancer
553888|NCT00489697|colorectal cancer
553889|NCT00489697|hepatic metastases
553890|NCT00489697|bevacizumab
553891|NCT00489697|anti-angiogenic agent
553892|NCT00489697|chemotherapy regimens
553893|NCT00489697|tumor vascularity
553894|NCT00489697|Contrast-enhanced ultrasound
553895|NCT00489671|pancreatic cancer
553896|NCT00489671|precancerous condition
553897|NCT00489658|Human African trypanosomiasis
553898|NCT00489658|sleeping sickness
553899|NCT00489658|Trypanosoma brucei gambiense
553900|NCT00489658|combination
553901|NCT00489658|eflornithine
553902|NCT00489658|nifurtimox
553903|NCT00489658|Human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense in the late stage (stage 2 or meningo-encephalitic)
553904|NCT00489645|pramlintide
553905|NCT00489645|gastric emptying
553906|NCT00489645|T1DM
553907|NCT00489645|postprandial
553908|NCT00489632|Leukemia
553909|NCT00489632|Pediatrics
553910|NCT00489632|Cancer
553911|NCT00489632|Coping
553912|NCT00489632|Caregiver
553913|NCT00489632|Questionnaire
553914|NCT00489632|Children
553915|NCT00489632|Resiliency
553916|NCT00489632|Adjustment
553917|NCT00489632|Illness-related factors
553918|NCT00489619|Infectious diseases
553919|NCT00489619|Democratic Republic of Congo
553920|NCT00489619|Malaria
553921|NCT00489619|International
553922|NCT00489619|Maternal and child health
553923|NCT00489619|Women's Health
553924|NCT00489619|Global Network
553925|NCT00489619|Sexually transmitted infections (STIs)
553926|NCT00489606|SK3530
553927|NCT00489606|tamsulosin
553928|NCT00489606|hemodynamic interaction
553929|NCT00489606|safety
553930|NCT00489593|Advanced Cancer
553931|NCT00489593|Weight Loss
553932|NCT00489593|Cachexia
553933|NCT00489593|Olanzapine
553934|NCT00489593|Zyprexa
553935|NCT00489593|Fluoxetine
553936|NCT00489593|Symbyax
553937|NCT00489580|stroke
553938|NCT00489580|weakness
553939|NCT00489580|motor recovery
553940|NCT00489567|Rotavirus gastroenteritis
553941|NCT00489554|Primary vaccination
553942|NCT00489554|Safety
553943|NCT00489554|Pneumococcal vaccine.
553944|NCT00489554|Pneumococcal disease
553945|NCT00489554|Immunogenicity
553946|NCT00489541|paclitaxel-eluting stent
553947|NCT00489541|PES
553948|NCT00489528|serostim
553949|NCT00489528|Dose-Response Relationship, Drug
553950|NCT00489528|Body Composition
553951|NCT00489515|adenocarcinoma of the gallbladder
553952|NCT00489515|stage I pancreatic cancer
553953|NCT00489515|stage II pancreatic cancer
553954|NCT00489515|stage III pancreatic cancer
553955|NCT00489515|stage IV pancreatic cancer
553956|NCT00489515|stage I colon cancer
553957|NCT00489515|stage II colon cancer
553958|NCT00489515|stage III colon cancer
553959|NCT00489515|stage IV colon cancer
553960|NCT00489515|stage I gastric cancer
553961|NCT00489515|stage II gastric cancer
553962|NCT00489515|stage III gastric cancer
553963|NCT00489515|stage IV gastric cancer
553964|NCT00489515|localized gallbladder cancer
553965|NCT00489515|small intestine adenocarcinoma
553966|NCT00489515|adenocarcinoma of the colon
553967|NCT00489515|adenocarcinoma of the pancreas
553968|NCT00489515|adenocarcinoma of the stomach
553969|NCT00489489|MS
553970|NCT00489489|interferon-beta
553971|NCT00489489|adjunctive therapy
553972|NCT00489489|relapses
553973|NCT00489476|Staccato® Loxapine, Migraine
553974|NCT00489463|LNG-IUS
553975|NCT00489463|TCu 380A
553976|NCT00489463|Ultrasonography
553977|NCT00489463|Doppler color
553978|NCT00489463|power Doppler
553979|NCT00489463|female
553980|NCT00489463|Volunteers
553981|NCT00489450|SK3530
553982|NCT00489450|alcohol
553983|NCT00489450|pharmacokinetics
553984|NCT00489450|safety
553985|NCT00489437|diagnosis
553986|NCT00489424|zoledronic acid
553987|NCT00489424|post dose symptoms
553988|NCT00489424|transient
553989|NCT00489424|acetaminophen
553990|NCT00489424|fluvastatin
553991|NCT00489411|unspecified adult solid tumor, protocol specific
553992|NCT00489411|neurotoxicity
553993|NCT00489411|pain
553994|NCT00489411|peripheral neuropathy
553995|NCT00489385|Fibrosis
553996|NCT00489385|Viral Kinetics
553997|NCT00489385|Hepatotoxicity
553998|NCT00489385|Immunity
553999|NCT00489385|HIV Infection
554000|NCT00489385|Hepatitis C
554001|NCT00489385|HCV
554002|NCT00489385|Treatment Experienced
554003|NCT00489385|Treatment Naive
554004|NCT00489333|ProAlgaZyme
554005|NCT00489333|Metabolic syndrome
554006|NCT00489333|Inflammation
554007|NCT00489333|Cardiovascular
554008|NCT00489333|hsCRP
554009|NCT00489333|Lipids
554010|NCT00489333|Algae
554011|NCT00489320|Coronary disease
554012|NCT00489320|Arteries
554013|NCT00489320|Atherosclerosis
554014|NCT00489320|Arteriosclerosis
554015|NCT00489307|Advanced Cancer
554016|NCT00489307|Solid Tumors
554017|NCT00489307|Fatigue
554018|NCT00489307|Pain
554019|NCT00489307|Nausea
554020|NCT00489307|Anorexia
554021|NCT00489307|Dexamethasone
554022|NCT00489307|Decadron
554023|NCT00489307|Placebo
554024|NCT00489294|Human growth hormone
554025|NCT00489294|idiopathic short stature
554026|NCT00489294|short stature
554027|NCT00489281|sickle cell disease
554028|NCT00489268|Barrett's Esophagus
554029|NCT00489268|Intestinal Metaplasia
554030|NCT00489268|Radiofrequency Ablation
554031|NCT00489255|Parkinson's disease
554032|NCT00489255|Anti-emetic
554033|NCT00489255|Nausea
554034|NCT00489255|Vomiting
554035|NCT00489229|Rosiglitazone
554036|NCT00489229|Ramipril
554037|NCT00489229|Impaired glucose tolerance
554038|NCT00489229|Arterial stiffness
554039|NCT00489229|Diabetic vasculopathy
554040|NCT00489216|Graft Versus Host Disease
554041|NCT00489216|GVHD
554042|NCT00489216|Efalizumab
554043|NCT00489216|Raptiva
554044|NCT00489216|Steroid
554045|NCT00489216|Refractory
554046|NCT00489216|Skin
554047|NCT00489216|Liver
554048|NCT00489216|Lineberger
554049|NCT00489216|University of North Carolina
554050|NCT00489177|cardiac resynchronization therapy
554051|NCT00489177|response
554052|NCT00489177|Defibrillators
554053|NCT00489164|DIABETIC PATIENTS WITH NATIVE CORONARY ARTERY LESIONS
554054|NCT00489151|HBV
554055|NCT00489125|long-term effects secondary to cancer therapy in adults
554056|NCT00489125|recurrent breast cancer
554057|NCT00489125|stage I breast cancer
554058|NCT00489125|stage II breast cancer
554059|NCT00489125|stage IIIA breast cancer
554060|NCT00489125|stage IIIB breast cancer
554061|NCT00489125|stage IIIC breast cancer
554062|NCT00489125|stage IV breast cancer
554063|NCT00489086|nevoid basal cell carcinoma syndrome
554064|NCT00489086|basal cell carcinoma of the skin
554065|NCT00489060|Cryoablation
554066|NCT00489060|Radiation
554067|NCT00489060|Prostate Cancer
554068|NCT00489034|HIV
554069|NCT00489034|adolescent females
554070|NCT00489034|adherence
554071|NCT00489034|clinical care
554072|NCT00489034|risk behaviors
554073|NCT00489021|Subacute care
554074|NCT00489021|Activities of Daily Living
554075|NCT00489021|Cognition assessment
554076|NCT00489021|Mood assessment
554077|NCT00489021|Incontinence control
554078|NCT00489008|Lung Cancer
554079|NCT00489008|Non-Small Cell
554080|NCT00489008|Stereotactic Body Radiation Therapy
554081|NCT00489008|SBRT
554082|NCT00489008|NSCLC
554083|NCT00488995|HIV Therapeutic Vaccine
554084|NCT00488982|Metastatic Hormone Refractory Prostate Cancer
554085|NCT00488969|Morphine
554086|NCT00488969|Chronic Pain
554087|NCT00488969|Spinal Cord Injury
554088|NCT00488969|Neuropathic Pain
554089|NCT00488956|foot
554090|NCT00488956|ankle
554091|NCT00488956|edema
554092|NCT00488943|Stent-Graft
554093|NCT00488943|AAA
554094|NCT00488943|Abdominal Aortic Anuerysm
554095|NCT00488943|Zenith
554096|NCT00488943|Endovascular
554097|NCT00488943|Treatment with Zenith Aortic Stent-Graft for repair Abdominal Aortic Aneurysm
554098|NCT00488930|Obesity
554099|NCT00488930|Hyperglycemia
554100|NCT00488930|Diabetes Mellitus Type I
554101|NCT00488930|Diabetes Mellitus Type II
554102|NCT00488917|Liver cirrhosis
554103|NCT00488917|acute liver failure
554104|NCT00488917|liver transplantation
554105|NCT00488917|sepsis, infection
554106|NCT00488917|endothelium
554107|NCT00488917|lipids
554108|NCT00488917|diagnosis
554109|NCT00488917|prognosis
554110|NCT00488904|infection
554111|NCT00488904|colorectalcancer
554112|NCT00488904|omega-3 fedtsyre
554113|NCT00488904|complications
554114|NCT00488891|Schizophrenia
554115|NCT00488891|Paliperdone ER
554116|NCT00488891|Invega
554117|NCT00488891|Observational
554118|NCT00488891|Antipsychotic agents
554119|NCT00488878|Ovarian Cancer
554120|NCT00488878|Ovarian Carcinoma
554121|NCT00488878|Low-Grade Serous Carcinoma
554122|NCT00488878|Low Malignant Potential
554123|NCT00488878|Peritoneum Tumors
554124|NCT00488878|Psammocarcinoma
554125|NCT00488878|Data Collection
554126|NCT00488878|Research Database
554127|NCT00488865|increased risk for PE require caval interruption
554128|NCT00488839|Spasticity
554129|NCT00488839|Multiple Sclerosis
554130|NCT00488826|Vaccines, Pneumococcal Conjugate Vaccine
554131|NCT00488813|Tzh-Chi ESBL study
554132|NCT00488800|Pneumococcal Infections/PC (Prevention & Control)
554133|NCT00488787|dental
554134|NCT00488787|surgery
554135|NCT00488787|analgesia
554136|NCT00488787|2-4 impacted third molars
554137|NCT00488774|Colitis, ulcerative
554138|NCT00488774|Golimumab
554139|NCT00488774|CNTO 148
554140|NCT00488761|Tigecycline
554141|NCT00488761|cSSSI
554142|NCT00488761|complicated skin and skin structure infections
554143|NCT00488748|MST
554144|NCT00488748|Magnetic Seizure Therapy
554145|NCT00488748|ECT
554146|NCT00488748|Electroconvulsive Therapy
554147|NCT00488748|Depression
554148|NCT00488748|Magnetic
554149|NCT00488735|Randomized controlled trial
554150|NCT00488735|Back pain
554151|NCT00488735|Neck pain
554152|NCT00488735|Rehabilitation
554153|NCT00488735|Cognitive-behavioral
554154|NCT00488735|Primary care
554155|NCT00488735|Sick-listing
554156|NCT00488735|Health-care utilization.
554157|NCT00488722|To observe the biological changes under concurrent Zoladex and CEF as neoadjuvant regimen with respect to the ER,PR,cerbB-2 status before and after therapy
554158|NCT00488709|Acute Myeloid Leukemia
554159|NCT00488709|Multi Drug Resistance
554160|NCT00488696|Aneurysm
554161|NCT00488696|Aortic Arch
554162|NCT00488696|Endovascular
554163|NCT00488696|Stent-Graft
554164|NCT00488683|Meningococcal disease
554165|NCT00488683|Prevention
554166|NCT00488683|Vaccination
554167|NCT00488670|Alzheimer's disease
554168|NCT00488670|elderly
554169|NCT00488670|open-label
554170|NCT00488670|escitalopram
554171|NCT00488657|speech
554172|NCT00488657|Parkinson's disease
554173|NCT00488657|treatment
554174|NCT00488657|speech intelligibility
554175|NCT00488657|speaking rate
554176|NCT00488644|Hypothyroidism
554177|NCT00488644|Brain Tumor
554178|NCT00488644|Levothyroxine
554179|NCT00488644|Liothyronine
554180|NCT00488644|Synthroid
554181|NCT00488644|Cytomel
554182|NCT00488631|Colitis, Ulcerative
554183|NCT00488631|Golimumab
554184|NCT00488631|CNTO 148
554185|NCT00488618|Mania
554186|NCT00488618|Bipolar I Disorder
554187|NCT00488618|Acute Mania Associated with Bipolar I Disorder
554188|NCT00488592|Myelodysplastic Syndrome (MDS)
554189|NCT00488592|Acute Myeloid Leukemia (AML)
554190|NCT00488592|Chronic Myeloid Leukemia (CML)
554191|NCT00488592|Wilm's Tumor-1
554192|NCT00488592|Proteinase-3
554193|NCT00488592|Myelodysplastic Syndrome
554194|NCT00488592|MDS
554195|NCT00488592|Acute Myeloid Leukemia
554196|NCT00488592|AML
554197|NCT00488592|Chronic Myeloid Leukemia
554198|NCT00488592|CML
554199|NCT00488579|iron prophylaxis
554200|NCT00488579|pregnancy
554201|NCT00488579|birth weight
554202|NCT00488579|prematurity
554203|NCT00488579|perinatal mortality
554204|NCT00488566|bipolar disorder,
554205|NCT00488566|single doses,
554206|NCT00488566|resting motor threshold
554207|NCT00488566|TMS,
554208|NCT00488553|Lymphoma
554209|NCT00488553|Epidemiology
554210|NCT00488553|Lifestyle Factors
554211|NCT00488553|Questionnaire
554212|NCT00488553|Survey
554213|NCT00488540|newborn
554214|NCT00488540|infant
554215|NCT00488540|pain
554216|NCT00488540|acetaminophen
554217|NCT00488540|paracetamol
554218|NCT00488540|mode of delivery
554219|NCT00488540|vacuum extraction
554220|NCT00488540|forceps extraction
554221|NCT00488540|cesarean section
554222|NCT00488540|EDIN scale
554223|NCT00488540|Bernese Pain Scale for Neonates
554224|NCT00488540|pain after different modes of delivery in newborn infants
554225|NCT00488540|efficacy of acetaminophen as analgesia for newborn infants
554226|NCT00488514|Long-term Safety
554227|NCT00488514|Migraine
554228|NCT00488514|Adolescent Migraine Headache
554229|NCT00488514|sumatriptan succinate
554230|NCT00488514|naproxen sodium
554231|NCT00488501|intrathoracic impedance
554232|NCT00488501|cardiac resynchronization therapy
554233|NCT00488501|heart failure
554234|NCT00488462|obstetric hemorrhage
554235|NCT00488462|hypovolemic shock
554236|NCT00488462|non-pneumatic anti-shock garment
554237|NCT00488462|safe motherhood
554238|NCT00488462|maternal mortality
554239|NCT00488462|maternal morbidity
554240|NCT00488449|Dose Escalation
554241|NCT00488449|GSK256073A,
554242|NCT00488436|Myelodysplastic Syndrome
554243|NCT00488436|Antithymocyte Globulin
554244|NCT00488436|Cyclosporine
554245|NCT00488423|diabetes
554246|NCT00488423|MIDAS
554247|NCT00488423|gut hormones
554248|NCT00488423|gastric bypass
554249|NCT00488423|lap band
554250|NCT00488410|Chronic heart failure
554251|NCT00488410|real time three-dimensional echocardiography
554252|NCT00488410|cardiac resynchronization therapy
554253|NCT00488410|ventricular asynchrony
554254|NCT00488410|systolic dysynchrony index
554255|NCT00488397|Tygacil
554256|NCT00488397|microdilution method
554257|NCT00488397|Tigecycline
554258|NCT00488397|In-Vitro
554259|NCT00488384|Squamous cell carcinoma of the skin under hemodialysis
554260|NCT00488371|Streptococcus pneumoniae nasopharyngeal carriage
554261|NCT00488358|abdominal
554262|NCT00488358|aortic
554263|NCT00488358|aneurysm
554264|NCT00488358|Zenith
554265|NCT00488358|blood pressure
554266|NCT00488345|cIAI
554267|NCT00488345|cSSSI
554268|NCT00488345|CAP
554269|NCT00488345|Child
554270|NCT00488332|Head and Neck Cancer
554271|NCT00488332|Oral Mucositis
554272|NCT00488332|Optical Coherence Tomography
554273|NCT00488332|Fluorescence Spectroscopy
554274|NCT00488332|Optical Assessment
554275|NCT00488319|Schizophrenia
554276|NCT00488319|Adolescent
554277|NCT00488319|Paliperidone
554278|NCT00488319|Antipsychotic agents
554279|NCT00488319|Antipsychotic drugs
554280|NCT00488319|Psychosis.
554281|NCT00488306|Tigecycline
554282|NCT00488306|Complicated intra-abdominal infections
554283|NCT00488306|cIAI
554284|NCT00488293|Telemedicine
554285|NCT00488293|Skin diseases
554286|NCT00488293|Dermatology
554287|NCT00488293|Quality of life
554288|NCT00488293|Economics
554289|NCT00488280|walking
554290|NCT00488280|walking recovery
554291|NCT00488280|physical therapy
554292|NCT00488280|locomotor training
554293|NCT00488280|body weight support
554294|NCT00488280|neuroplasticity
554295|NCT00488280|step
554296|NCT00488280|treadmill
554297|NCT00488280|treadmill training
554298|NCT00488280|locomotion
554299|NCT00488267|Osteoarthritis
554300|NCT00488267|Pain
554301|NCT00488254|Long QT Syndrome
554302|NCT00488254|Romano Ward
554303|NCT00488254|Jervell-Lange Nielson Syndrome
554304|NCT00488241|Eczema
554305|NCT00488241|Medical device
554306|NCT00488215|constipation
554307|NCT00488215|prucalopride
554308|NCT00488215|MTD
554309|NCT00488215|cardiovascular safety
554310|NCT00488202|Advanced Ovarian Cancer
554311|NCT00488202|Sexual Function
554312|NCT00488176|seasonal allergic rhinitis
554313|NCT00488176|children
554314|NCT00488176|montelukast
554315|NCT00488176|cetirizine
554316|NCT00488163|schizophrenia
554317|NCT00488163|cognition
554318|NCT00488163|atomoxetine
554319|NCT00488163|norepinephrine
554320|NCT00488163|dopamine
554321|NCT00488137|constipation
554322|NCT00488137|prucalopride
554323|NCT00488137|QOL
554324|NCT00488137|SCBM
554325|NCT00488137|PAC-SYM
554326|NCT00488124|short stature
554327|NCT00488111|Regional anesthesia
554328|NCT00488111|Fluid Therapy
554329|NCT00488111|Hemostasis, Surgical
554330|NCT00488098|Healthy Bioequivalence
554331|NCT00488085|Crohn’s disease, obesity, REE, body composition, fat absorption
554332|NCT00488072|Advanced Cancer
554333|NCT00488072|Anorexia
554334|NCT00488072|Weight Loss
554335|NCT00488072|Insomnia
554336|NCT00488072|Appetite
554337|NCT00488072|Mirtazapine
554338|NCT00488072|Placebo
554339|NCT00488059|Treatment Experienced
554340|NCT00488046|Bird Flu
554341|NCT00488033|Coronary Artery Disease
554342|NCT00488033|Diabetes
554343|NCT00488033|CT Angiography
554344|NCT00488020|rest pain
554345|NCT00488020|ischemic ulcers
554346|NCT00488007|Alzheimer disease
554347|NCT00488007|Cognitive impairment
554348|NCT00488007|Sensorineural hearing loss
554349|NCT00488007|Hearing aids
554350|NCT00487994|Hypercholesterolemia
554351|NCT00487994|Hyperlipidemia
554352|NCT00487994|Drug Therapy
554353|NCT00487981|Pain
554354|NCT00487981|Implantable stimulation device
554355|NCT00487981|Neuropathy
554356|NCT00487968|healthy adult volunteers
554357|NCT00487968|eltrombopag
554358|NCT00487955|gastritis
554359|NCT00487955|helicobacter pylori
554360|NCT00487955|REE
554361|NCT00487955|patients with gastritis that refers to helicobacter pylori treatment
554362|NCT00487929|sleep apnea
554363|NCT00487929|morbidity
554364|NCT00487929|cardiovascular
554365|NCT00487929|cpap
554366|NCT00487929|oxidative stress
554367|NCT00487916|Blood Stage
554368|NCT00487916|Investigational
554369|NCT00487916|Vaccine
554370|NCT00487916|Malaria
554371|NCT00487916|Healthy Volunteer
554372|NCT00487916|HV
554373|NCT00487903|Coronary Artery Disease
554374|NCT00487903|Echocardiogram
554375|NCT00487903|Contrast
554376|NCT00487903|Perfusion
554377|NCT00487903|Ultrasound
554378|NCT00487903|Normal volunteers
554379|NCT00487890|Geriatric
554380|NCT00487890|Abdominal
554381|NCT00487890|Surgery
554382|NCT00487890|gastrointestinal surgery
554383|NCT00487890|intrabdominal surgery
554384|NCT00487877|metabolism, temperature changing, skin, heart rate
554385|NCT00487851|Pancreatic
554386|NCT00487851|cancer
554387|NCT00487851|Periampullay
554388|NCT00487851|Neoplasms
554389|NCT00487851|Biliary
554390|NCT00487851|Duodenal
554391|NCT00487851|Jaundice
554392|NCT00487851|obstruction
554393|NCT00487851|pancreas cancer
554394|NCT00487851|Pancreatic cancer
554395|NCT00487838|Autofluorescence Imaging
554396|NCT00487838|Early Age-Related Maculopathy
554397|NCT00487838|Photochemical Changes
554398|NCT00487838|Colored Sunglasses
554399|NCT00487838|Pseudophakes
554400|NCT00487838|Fundus Camera
554401|NCT00487838|Confocal Scanning Laser Ophthalmoscope
554402|NCT00487838|Molecular Imaging within Retina
554403|NCT00487838|Spectral Balance among Photochemical Processes
554404|NCT00487838|Noninvasive Autofluorescence Imaging
554405|NCT00487838|Age-Related Maculopathy (AMD)
554406|NCT00487838|Age-Related Macular Degeneration
554407|NCT00487838|AMD
554408|NCT00487838|Age-Related Macular Changes
554409|NCT00487838|Early Age-Related Macular Changes
554410|NCT00487825|ACR20, ACR50, ACZ885 (anti-interleukin-1beta monoclonal antibody), rheumatoid arthritis, methotrexate
554411|NCT00487812|Acute myocardial infarction
554412|NCT00487812|left ventricular remodelling
554413|NCT00487812|SPECT imaging
554414|NCT00487799|Acute Decompensated Heart Failure
554415|NCT00487799|ADHF
554416|NCT00487799|Heart Failure
554417|NCT00487786|Antisense
554418|NCT00487786|Heat Shock Protein
554419|NCT00487773|asthma
554420|NCT00487773|children
554421|NCT00487773|inhaled glucocorticosteroids
554422|NCT00487773|bone metabolism
554423|NCT00487760|Lung Cancer
554424|NCT00487760|African-American Families
554425|NCT00487760|Genetic Risk Communication
554426|NCT00487760|Interest in Genetic Testing and Genetics Research
554427|NCT00487760|Health Disparities
554428|NCT00487760|Smoking Cessation
554429|NCT00487734|Metabolic Syndrome
554430|NCT00487734|Hypogonadism
554431|NCT00487734|Insulin Resistance
554432|NCT00487721|Prostate cancer
554433|NCT00487708|ACZ885
554434|NCT00487708|NALP3 mutations
554435|NCT00487708|Interleukin-1beta
554436|NCT00487708|Muckle-Wells Syndrome
554437|NCT00487695|Barrett's esophagus
554438|NCT00487695|Esophageal adenocarcinoma
554439|NCT00487695|Endoscopy
554440|NCT00487695|Confocal laser endomicroscopy
554441|NCT00487682|herpes zoster
554442|NCT00487682|ASP2151
554443|NCT00487682|Valacyclovir hydrochloride
554444|NCT00487669|paclitaxel poliglumex
554445|NCT00487669|xyotax
554446|NCT00487669|alimta
554447|NCT00487669|advanced non-small cell lung cancer
554448|NCT00487643|Lacritin
554449|NCT00487630|Heterozygous females
554450|NCT00487630|Cardiomyopathy
554451|NCT00487617|Arteriopathy
554452|NCT00487617|endothelial function
554453|NCT00487617|fruit juice
554454|NCT00487604|Coronary Artery Disease
554455|NCT00487604|Drug Eluting Stent
554456|NCT00487604|Bare Metal Stent
554457|NCT00487604|Subacute thrombosis
554458|NCT00487604|Bleeding
554459|NCT00487604|Economic
554460|NCT00487591|cholesterol
554461|NCT00487591|dyslipidemia
554462|NCT00487591|omega 3
554463|NCT00487578|Post traumatic headache
554464|NCT00487578|Head trauma
554465|NCT00487578|Head injury
554466|NCT00487578|Headache
554467|NCT00487578|Naratriptan
554468|NCT00487565|Total knee replacement
554469|NCT00487565|Total knee arthroplasty
554470|NCT00487565|Osteoarthritis
554471|NCT00487565|Rheumatoid or other inflammatory arthritis
554472|NCT00487565|Post-traumatic or juvenile arthritis
554473|NCT00487552|endoscopy
554474|NCT00487552|esophagogastroduodenoscopy
554475|NCT00487552|gastric outlet obstruction
554476|NCT00487552|gastro-jejunostomy
554477|NCT00487552|gastric malignancy
554478|NCT00487552|duodenal stent
554479|NCT00487552|Malignant Gastric Outlet Obstruction
554480|NCT00487539|Colitis, Ulcerative
554481|NCT00487539|Golimumab
554482|NCT00487539|CNTO 148
554483|NCT00487526|Bypass
554484|NCT00487526|Duodenal jejunal
554485|NCT00487526|type 2 diabetes
554486|NCT00487526|non-obese adults
554487|NCT00487513|Follicular B Cell lymphoma
554488|NCT00487513|vaccination
554489|NCT00487500|Major Depressive Disorder
554490|NCT00487500|Electroconvulsive Therapy
554491|NCT00487487|Candidates for this study are survivors of paralytic poliomyelitis
554492|NCT00487461|SAH
554493|NCT00487461|Vasospasm
554494|NCT00487448|Myelodysplastic Syndrome
554495|NCT00487448|Chemotherapy
554496|NCT00487448|Peripheral blood stem cells transplantation
554497|NCT00487448|Bone marrow transplantation
554498|NCT00487448|Secondary Acute Myeloblastic Leukemia
554499|NCT00487435|CG5503
554500|NCT00487435|Tapentadol
554501|NCT00487435|chronic non-malignant pain
554502|NCT00487435|osteoarthritis
554503|NCT00487435|lower back pain
554504|NCT00487435|analgesic
554505|NCT00487435|opioid
554506|NCT00487422|constipation
554507|NCT00487422|prucalopride
554508|NCT00487422|QOL
554509|NCT00487422|SCBM
554510|NCT00487422|PAC-SYM
554511|NCT00487409|Ulcerative colitis
554512|NCT00487409|Crohn's disease
554513|NCT00487409|Colorectal polyps
554514|NCT00487409|Colorectal malignancy
554515|NCT00487409|Endometriosis
554516|NCT00487409|Diverticulitis
554517|NCT00487409|Colonic inertia
554518|NCT00487396|capsule endoscopy
554519|NCT00487396|Crohn's disease
554520|NCT00487396|small bowel disease
554521|NCT00487396|inflammatory bowel disease
554522|NCT00487396|Patients with suspected small bowel Crohn's disease
554523|NCT00487383|Cerebellum
554524|NCT00487383|Transcranial Magnetic Stimulation (TMS)
554525|NCT00487383|Blepharospasm
554526|NCT00487383|DYT-1 Generalized Dystonia
554527|NCT00487383|Focal Dystonia
554528|NCT00487383|Dystonia
554529|NCT00487383|Healthy Volunteer
554530|NCT00487383|HV
554531|NCT00487370|Acupuncture
554532|NCT00487370|Gold implantation
554533|NCT00487370|Osteoarthritis
554534|NCT00487370|Knee osteoarthritis
554535|NCT00487370|Double-blind, randomized controlled trial
554536|NCT00487370|Intervention
554537|NCT00487370|Family practice
554538|NCT00487357|Epidemiology
554539|NCT00487357|Cancer Prevention
554540|NCT00487357|Questionnaire
554541|NCT00487357|MATCh
554542|NCT00487357|Survey
554543|NCT00487344|medicaid
554544|NCT00487344|insurance
554545|NCT00487344|education
554546|NCT00487344|clinical
554547|NCT00487344|trial
554548|NCT00487344|healthcare
554549|NCT00487344|reimburse
554550|NCT00487344|pay
554551|NCT00487344|free
554552|NCT00487344|assist
554553|NCT00487344|study
554554|NCT00487344|oklahoma
554555|NCT00487344|edmond
554556|NCT00487344|Oklahoma City
554557|NCT00487344|diet
554558|NCT00487344|nutrition
554559|NCT00487344|weight loss
554560|NCT00487344|body
554561|NCT00487344|fat
554562|NCT00487344|obese
554563|NCT00487344|overweight
554564|NCT00487344|health
554565|NCT00487344|medical
554566|NCT00487344|therapy
554567|NCT00487344|meal plan
554568|NCT00487344|jenny craig
554569|NCT00487344|weight watcher
554570|NCT00487344|LA Weightloss
554571|NCT00487344|Bryan Attebery
554572|NCT00487344|Results
554573|NCT00487344|YMCA
554574|NCT00487344|UCO
554575|NCT00487344|OSU
554576|NCT00487344|OU
554577|NCT00487344|clinics
554578|NCT00487344|physicians
554579|NCT00487344|surgery
554580|NCT00487344|pills
554581|NCT00487344|financial
554582|NCT00487344|money
554583|NCT00487331|Solid Tumors
554584|NCT00487331|Acupuncture
554585|NCT00487331|Uncontrolled Pain
554586|NCT00487331|Pain
554587|NCT00487318|fluvastatin
554588|NCT00487318|hepatitis C
554589|NCT00487318|chronic hepatitis C
554590|NCT00487318|not previously treated with pegylated interferon and ribavirin
554591|NCT00487305|GM-CSF
554592|NCT00487305|vaccine
554593|NCT00487305|K562
554594|NCT00487292|accidents
554595|NCT00487292|shift work
554596|NCT00487292|sleepiness
554597|NCT00487292|naps
554598|NCT00487292|bright light pulses
554599|NCT00487292|sleep
554600|NCT00487279|Coronary
554601|NCT00487279|Artery
554602|NCT00487279|Disease
554603|NCT00487279|Sudden
554604|NCT00487279|Cardiac
554605|NCT00487279|Death
554606|NCT00487279|ICD
554607|NCT00487266|Acupuncture
554608|NCT00487266|Torque
554609|NCT00487266|Force Decay
554610|NCT00487253|Cutaneous Leishmaniasis
554611|NCT00487253|Leishmania Viannia
554612|NCT00487253|Pediatric
554613|NCT00487253|Miltefosine
554614|NCT00487253|Randomized
554615|NCT00487253|Colombia
554616|NCT00487240|diabetes
554617|NCT00487240|type 1
554618|NCT00487227|caffeine
554619|NCT00487227|coffee
554620|NCT00487227|decaffeinated
554621|NCT00487227|cognition
554622|NCT00487227|mood
554623|NCT00487227|autonomic
554624|NCT00487201|liver transplantation
554625|NCT00487201|biliary strictures
554626|NCT00487201|ERCP
554627|NCT00487175|Pain
554628|NCT00487175|sensitization
554629|NCT00487175|analgesia
554630|NCT00487175|Healthy volunteers and pain
554631|NCT00487162|glycemic control, diabetes, obesity, comorbidities
554632|NCT00487149|Repeatability
554633|NCT00487149|Respiratory Muscle Strength
554634|NCT00487136|Drug Interaction
554635|NCT00487136|Pharmacokinetics
554636|NCT00487136|Pharmacodynamics
554637|NCT00487123|Hypertension, compliance, Valsartan, hydrochlorothiazide (HCTZ)
554638|NCT00487110|Pain
554639|NCT00487110|serotonin
554640|NCT00487110|interaction
554641|NCT00487110|Patients with postsurgical pain, after ear surgery
554642|NCT00487097|intensive care
554643|NCT00487097|critically ill
554644|NCT00487097|fish oil
554645|NCT00487097|pressure sores
554646|NCT00487084|analgesia
554647|NCT00487084|tubal ligation
554648|NCT00487084|chloroprocaine
554649|NCT00487071|Anal fistula
554650|NCT00487071|High-type
554651|NCT00487071|Anal fistula plug
554652|NCT00487071|Efficacy
554653|NCT00487071|Recurrence
554654|NCT00487058|Gimatecan
554655|NCT00487058|topoisomerase I inhibitor
554656|NCT00487058|advanced solid tumors
554657|NCT00487045|Hemorrhoids
554658|NCT00487045|Thrombosed External Hemorrhoids (TEH)
554659|NCT00487045|Reduction
554660|NCT00487045|Prevention
554661|NCT00487045|Stabilizer Device
554662|NCT00487045|Pregnant
554663|NCT00487045|Vaginal Birth
554664|NCT00487045|Single Birth
554665|NCT00487045|Asymptomatic Hemorrhoids
554666|NCT00487032|allergic rhinitis
554667|NCT00487032|rhinitis medicamentosa
554668|NCT00487032|imidazolines
554669|NCT00487032|corticosteroid
554670|NCT00487019|ampicillin
554671|NCT00487019|penicillin G
554672|NCT00487019|gentamicin
554673|NCT00487019|neonatal sepsis
554674|NCT00487019|empiric therapy
554675|NCT00486993|Diet
554676|NCT00486993|Exercise
554677|NCT00486993|Smoking
554678|NCT00486993|Stress
554679|NCT00486993|Polyphenols
554680|NCT00486980|influenza
554681|NCT00486967|Insulin resistance, heart failure, congestive heart failure,
554682|NCT00486967|Peak VO2, Endothelial Function, Leptin, TNF.
554683|NCT00486954|lapatinib
554684|NCT00486954|paclitaxel
554685|NCT00486954|ErbB2
554686|NCT00486954|Gastric cancer
554687|NCT00486954|Advanced gastric cancer
554688|NCT00486941|Primary Prevention
554689|NCT00486941|Health Promotion
554690|NCT00486941|Diet
554691|NCT00486941|Exercise
554692|NCT00486941|Risk Factors
554693|NCT00486941|Randomized Controlled Trial
554694|NCT00486928|Valves, heart disease, prosthesis.
554695|NCT00486915|Atrial Fibrillation
554696|NCT00486915|Left Atrial Appendage
554697|NCT00486915|Surgical Ligation
554698|NCT00486915|Thromboembolism
554699|NCT00486915|Cerebrovascular Accident
554700|NCT00486902|Ketamine
554701|NCT00486902|Spinal Anesthesia
554702|NCT00486902|C-section
554703|NCT00486889|Glycogenesis 2
554704|NCT00486876|Irritable bowel syndrome
554705|NCT00486876|Diarrhea predominant Irritable Bowel Syndrome
554706|NCT00486876|Alternating Irritable Bowel Syndrome
554707|NCT00486863|Philippines, Schistosoma japonicum, Schistosomiasis, pregnant women, fetuses, 08-0049
554708|NCT00486850|RDS
554709|NCT00486850|Preterm
554710|NCT00486850|SIMV
554711|NCT00486850|NIPPV
554712|NCT00486811|Osteoarthritis
554713|NCT00486811|Knee
554714|NCT00486811|Pain Assessment
554715|NCT00486811|CG5503 PR
554716|NCT00486811|Centrally acting analgesic
554717|NCT00486811|Placebo
554718|NCT00486811|Oxycodone
554719|NCT00486811|Chronic Pain due to knee Osteoarthritis
554720|NCT00486811|Tapentadol
554721|NCT00486798|acute schizophrenia
554722|NCT00486798|schizoaffective disorder
554723|NCT00486798|psychosis Not Otherwise Specified (NOS)
554724|NCT00486798|bipolar mania with psychotic symptoms
554725|NCT00486772|This study was designed to investigate whether the suggested beneficial effects of sevelamer on VC were related to fetuin-A levels in patients with CKD.
554726|NCT00486746|sleep apnea
554727|NCT00486746|lifestyle intervention
554728|NCT00486746|cardiovascular
554729|NCT00486733|extracorporeal shock wave therapy
554730|NCT00486733|soft tissue wounds
554731|NCT00486707|Ovarian Cancer
554732|NCT00486707|Questionnaire
554733|NCT00486707|Genetic Testing
554734|NCT00486707|Survey
554735|NCT00486694|Malaria, vivax
554736|NCT00486694|Afghanistan
554737|NCT00486694|Sulfadoxine-pyrimethamine
554738|NCT00486694|drug resistance
554739|NCT00486681|Glucose monitoring
554740|NCT00486681|Diabetes management
554741|NCT00486681|Information system
554742|NCT00486681|In-patient glycemic control
554743|NCT00486668|HER2 positive breast cancer
554744|NCT00486668|invasive breast cancer
554745|NCT00486668|lapatinib
554746|NCT00486668|neoadjuvant
554747|NCT00486668|NSABP
554748|NCT00486668|paclitaxel
554749|NCT00486668|trastuzumab
554750|NCT00486668|doxorubicin
554751|NCT00486668|cyclophosphamide
554752|NCT00486655|Cholecystectomy
554753|NCT00486655|NOTES
554754|NCT00486655|Transgastric
554755|NCT00486629|Exercise
554756|NCT00486629|Diet
554757|NCT00486629|Pregnancy
554758|NCT00486629|Obesity
554759|NCT00486629|Macrosomia
554760|NCT00485641|Stroke
554761|NCT00485641|SaeboFlex
554762|NCT00485641|Hand function
554763|NCT00485615|eicosapentaenoic acid
554764|NCT00485615|fish oil
554765|NCT00485615|Omega 3
554766|NCT00485615|Social Anxiety Disorder
554767|NCT00485602|malocclusion
554768|NCT00485602|aligner
554769|NCT00485602|crowding
554770|NCT00485602|expansion
554771|NCT00485602|orthodontic treatment
554772|NCT00486603|adult glioblastoma
554773|NCT00486603|adult gliosarcoma
554774|NCT00486603|adult giant cell glioblastoma
554775|NCT00486590|Human milk fortification
554776|NCT00486590|Premature neonate
554777|NCT00486590|Very low birth weight
554778|NCT00486577|Hearing Disorders, Hearing Loss, Hyperacusis, Tinnitus, chronic cortical stimulation, functional magnetic resonance imaging
554779|NCT00486564|Treatment
554780|NCT00486564|Refractory or Relapsed
554781|NCT00486551|Anger control training
554782|NCT00486551|Cognitive behavioral therapy
554783|NCT00486551|Behavior therapy
554784|NCT00486551|Tourette Syndrome
554785|NCT00486551|Randomized trial
554786|NCT00486551|Anger
554787|NCT00486551|Aggression
554788|NCT00486525|fatigue
554789|NCT00486525|depression
554790|NCT00486525|pain
554791|NCT00486525|cancer survivor
554792|NCT00486525|stage IA breast cancer
554793|NCT00486525|stage IB breast cancer
554794|NCT00486525|stage II breast cancer
554795|NCT00486525|stage IIIA breast cancer
554796|NCT00486525|breast cancer in situ
554797|NCT00486512|colorectal, adenomas, prevention
554798|NCT00486499|radiation
554799|NCT00486499|brachytherapy
554800|NCT00486499|prostate
554801|NCT00486499|cancer
554802|NCT00486486|24-hour IOP control
554803|NCT00486460|Locally advanced or metastatic adenocarcinoma of the
554804|NCT00486460|pancreas
554805|NCT00486460|confirmed by histology or cytology
554806|NCT00486460|Inoperatable
554807|NCT00486434|Osteoarthritis, oral salmon calcitonin, treatment, efficacy, tolerability
554808|NCT00486421|idiopathic thrombocytopenic purpura
554809|NCT00486408|HIV Seronegativity
554810|NCT00486408|HIV Preventive Vaccine
554811|NCT00486408|Adenovirus
554812|NCT00486395|prematurity
554813|NCT00486395|randomized trial
554814|NCT00486395|RDS
554815|NCT00486395|surfactant
554816|NCT00486395|CPAP
554817|NCT00486395|ventilation
554818|NCT00486382|visceral leishmaniasis
554819|NCT00486382|vaccine
554820|NCT00486369|Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers
554948|NCT00485836|CRVO
554821|NCT00486356|unspecified adult solid tumor, protocol specific
554822|NCT00486356|recurrent gastric cancer
554823|NCT00486356|stage IV gastric cancer
554824|NCT00486356|advanced adult primary liver cancer
554825|NCT00486356|localized unresectable adult primary liver cancer
554826|NCT00486356|recurrent adult primary liver cancer
554827|NCT00486356|recurrent extrahepatic bile duct cancer
554828|NCT00486356|unresectable extrahepatic bile duct cancer
554829|NCT00486356|recurrent gallbladder cancer
554830|NCT00486356|unresectable gallbladder cancer
554831|NCT00486343|Asthma
554832|NCT00486343|ICS
554833|NCT00486343|5-LO Inhibition
554834|NCT00486343|Leukotrienes
554835|NCT00486343|Asthma control
554836|NCT00486343|Asthma exacerbations
554837|NCT00486330|HIV
554838|NCT00486330|Pharmacokinetics
554839|NCT00486330|Buprenorphine
554840|NCT00486330|Tipranavir
554841|NCT00486330|HIV Seronegativity
554842|NCT00486317|Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers
554843|NCT00486304|cachexia
554844|NCT00486304|weight changes
554845|NCT00486304|recurrent oropharyngeal cancer
554846|NCT00486304|stage I oropharyngeal cancer
554847|NCT00486304|stage II oropharyngeal cancer
554848|NCT00486304|stage III oropharyngeal cancer
554849|NCT00486304|stage IV oropharyngeal cancer
554850|NCT00486291|Diabetes, Obese diabetics
554851|NCT00486265|Phase I
554852|NCT00486265|Phase II
554853|NCT00486265|acute myelogenous leukemia
554854|NCT00486265|AML
554855|NCT00486265|cancer
554856|NCT00486239|Epilepsy
554857|NCT00486239|memory
554858|NCT00486239|emotion
554859|NCT00486213|dermatologic complications
554860|NCT00486213|chemotherapeutic agent toxicity
554861|NCT00486213|palmar-plantar erythrodysesthesia
554862|NCT00486213|unspecified adult solid tumor, protocol specific
554863|NCT00486200|Herpes Genitalis
554864|NCT00486200|Herpes Simplex Virus Genital Infection
554865|NCT00486200|Genital Herpes
554866|NCT00486200|ASP2151
554867|NCT00486200|Treatment Outcome
554868|NCT00486200|Sexually Transmitted Disease
554869|NCT00486187|Type 2 Diabetes Mellitus
554870|NCT00486187|Thiazolidinediones
554871|NCT00486187|Rosiglitazone
554872|NCT00486187|Adipokine
554873|NCT00486187|Inflammation
554874|NCT00486187|Cardiometabolic risk
554875|NCT00486187|Angiotensin receptor blocker
554876|NCT00486174|Sepsis
554877|NCT00486174|Methylene Blue
554878|NCT00486174|Norepinephrine
554879|NCT00486161|Obesity
554880|NCT00486161|Ghrelin
554881|NCT00486161|Non-esterified fatty acids
554882|NCT00486161|Growth hormone
554883|NCT00486161|Insulin
554884|NCT00486161|Cycloergometer exercise
554885|NCT00486148|Formula
554886|NCT00486148|Feeding
554887|NCT00486148|Healthy
554888|NCT00486148|Full
554889|NCT00486148|Term
554890|NCT00486148|Infants
554891|NCT00486135|Cancer
554892|NCT00486135|Solid tumors
554893|NCT00486135|Lymphoma
554894|NCT00486109|Diabetes
554895|NCT00486096|cannulation
554896|NCT00486096|infant
554897|NCT00486096|femoral arterial
554898|NCT00486070|cardiac anomaly
554899|NCT00486070|pulmonary veins
554900|NCT00486070|cyanosis
554901|NCT00486070|flow reversal
554902|NCT00486070|TAPAVC
554903|NCT00486057|Daclizumab
554904|NCT00486057|Immuno-suppression protocol
554905|NCT00486057|Heart Transplant
554906|NCT00486057|Rejection
554907|NCT00486044|amyloid protein
554908|NCT00486044|apolipoprotein
554909|NCT00486044|cerebrospinal fluid
554910|NCT00486044|cerebrovascular circulation
554911|NCT00486044|inflammation
554912|NCT00486044|magnetic resonance imaging
554913|NCT00486044|prevention & control
554914|NCT00486031|IBD
554915|NCT00486031|UC
554916|NCT00486031|Ulcerative Colitis
554917|NCT00486031|Inflammatory Bowel Disease
554918|NCT00486018|Lucentis
554919|NCT00486018|RVO
554920|NCT00486018|BRVO
554921|NCT00486018|Edema
554922|NCT00485992|blood stream infection
554923|NCT00485992|CICU
554924|NCT00485992|pediatric
554925|NCT00485992|chlorhexidine swabs
554926|NCT00485979|Breast Cancer
554927|NCT00485979|Neoadjuvant therapy
554928|NCT00485966|Adult Leukemia
554929|NCT00485966|CLL
554930|NCT00485966|B-CLL
554931|NCT00485966|Chronic Lymphocytic Leukemia
554932|NCT00485966|B-cell CLL
554933|NCT00485953|Osteoporosis
554934|NCT00485953|breast cancer
554935|NCT00485953|aromatase inhibitors
554936|NCT00485953|bone loss
554937|NCT00485953|bone mineral density
554938|NCT00485940|constipation
554939|NCT00485940|prucalopride
554940|NCT00485940|QOL
554941|NCT00485940|SCBM
554942|NCT00485940|PAC-SYM
554943|NCT00485927|Trauma
554944|NCT00485927|Stress
554945|NCT00485927|Simulation
554946|NCT00485914|employment
554947|NCT00485914|work
554949|NCT00485836|RVO
554950|NCT00485836|Lucentis
554951|NCT00485836|Edema
554952|NCT00485797|attention deficit hyperactivity disorder (ADHD)
554953|NCT00485797|Dual tasking
554954|NCT00485797|Postural Control
554955|NCT00485797|Methylphenidate (Ritalin)
554956|NCT00485797|The focus of the study is To explore the effects of Ritalin on postural control in ADHD Children, during single and dual task conditions.
554957|NCT00485784|Identify in a population of patients with a PE, an IUGR and a FD a modification of circulating endothelial biomarkers compared with normal pregnancy.
554958|NCT00485745|surgery
554959|NCT00485745|repeat sternotomy
554960|NCT00485745|pediatrics
554961|NCT00485732|Cervical neoplasia
554962|NCT00485732|AS04
554963|NCT00485732|Randomized
554964|NCT00485732|Cervical cancer
554965|NCT00485732|HPV-16/18 L1 VLP AS04
554966|NCT00485732|Phase IIIb
554967|NCT00485732|Korea
554968|NCT00485732|HPV
554969|NCT00485732|Double-blind
554970|NCT00485732|Controlled
554971|NCT00485719|Cancer
554972|NCT00485719|Solid Tumors
554973|NCT00485706|dialysis
554974|NCT00485706|vascular calcification
554975|NCT00485706|bone mineralism
554976|NCT00485706|arterial stiffness
554977|NCT00485706|bone metabolism
554978|NCT00485706|chronic kidney disease
554979|NCT00485693|pain
554980|NCT00485693|postoperative
554981|NCT00485693|total knee arthroplasty
554982|NCT00485693|analgesia
554983|NCT00485667|pain
554984|NCT00485667|postoperative
554985|NCT00485654|Heterotaxy Syndrome
554986|NCT00485654|Intestinal Malrotation
554987|NCT00485654|Functional Asplenia
554988|NCT00485654|Complex Cyanotic heart disease
554989|NCT00485589|FILM
554990|NCT00485589|RA
554991|NCT00485589|anti-CD20
554992|NCT00485589|CD20
554993|NCT00485563|Cancer
554994|NCT00485563|Vaccine
554995|NCT00485563|Phase 2
554996|NCT00485563|folate-hapten conjugate
554997|NCT00485563|Progressive
554998|NCT00485563|Metastatic
554999|NCT00485563|Experimental
555000|NCT00485537|GnRH antagonist
555001|NCT00485537|GnRH agonist
555002|NCT00485537|ICSI
555003|NCT00485537|miscarriage rate
555004|NCT00485537|pregnancy outcome
555005|NCT00485524|Near Infrared Spectroscopy
555006|NCT00485524|Serum Lactate Levels
555007|NCT00485524|post operative outcomes
555008|NCT00485485|Head and Neck Cancer
555009|NCT00485485|Squamous Cell Cancer
555010|NCT00485485|Imatinib Mesylate
555011|NCT00485485|Gleevec
555012|NCT00485485|Imatinib
555013|NCT00485485|STI571
555014|NCT00485485|Docetaxel
555015|NCT00485485|Taxotere
555016|NCT00485472|Osteoarthritis
555017|NCT00485472|lacosamide
555018|NCT00485472|VIMPAT
555019|NCT00485433|hernia
555020|NCT00485433|unilateral
555021|NCT00485433|postoperative
555022|NCT00485433|analgesia
555023|NCT00485420|Internet based disease management program
555024|NCT00485394|AMD
555025|NCT00485394|age-related macular degeneration
555026|NCT00485394|geographic atrophy
555027|NCT00485394|GA
555028|NCT00485368|marfan syndrome
555029|NCT00485368|aortic root diameter
555030|NCT00485355|hysterectomy
555031|NCT00485355|Laparoscopy
555032|NCT00485355|robotics
555033|NCT00485342|Chronic hepatitis C,Genotype1,Naïf,bitherapy,Ribavirin adaptation,ribavirin AUC
555034|NCT00485329|Chronic Wounds, Venous Ulcers, Papain, Debridement, Continuous streaming
555035|NCT00485329|DermaStream-EnzyStream
555036|NCT00485316|Colorectal carcinoma
555037|NCT00485316|Rectal carcinoma
555038|NCT00485316|Laparoscopy
555039|NCT00485316|Laparoscopic surgery
555040|NCT00485316|Open surgery
555041|NCT00485316|Randomized trial
555042|NCT00485303|Prostatic Neoplasms
555043|NCT00485303|Prostate cancer
555044|NCT00485303|Abiraterone acetate
555045|NCT00485303|CB7630
555046|NCT00485303|Prednisone
555047|NCT00485290|cirrhosis, Portal Hypertension, Esophageal Varices, Meal
555048|NCT00485277|Breast cancer
555049|NCT00485277|Vaccine
555050|NCT00485277|Metastatic
555051|NCT00485277|HER-2-positive
555052|NCT00485277|Phase I
555053|NCT00485277|HER-2 Positive Metastatic Breast Cancer
555054|NCT00485251|operation time in minutes
555055|NCT00485251|pain score from 1-10
555056|NCT00485251|recurrence
555057|NCT00485251|survival
555058|NCT00485238|glaucoma
555059|NCT00485212|postoperative pain
555060|NCT00485199|Pneumatic Retinopexy
555061|NCT00485199|vitrectomy
555062|NCT00485199|retinal detachment
555063|NCT00485199|macular hole
555064|NCT00485199|treatment
555065|NCT00485199|multi-center
555066|NCT00485199|Retinal Detachment due to Myopic Macular hole
555067|NCT00485160|Patent Ductus Arteriosus
555068|NCT00485160|Indomethacin
555069|NCT00485160|Ibuprofen
555070|NCT00485160|Renal effects
555071|NCT00485147|Claudication
555072|NCT00485147|peripheral arterial disease
555073|NCT00485147|Diagnosis
555074|NCT00485147|Exercise
555075|NCT00485147|Walking impairment
555076|NCT00485147|Disability
555077|NCT00485121|Ezetimibe
555078|NCT00485121|Statin
555079|NCT00485121|Low- density lipoprotein cholesterol
555080|NCT00485121|Adipokine
555081|NCT00485121|Adiponectin
555082|NCT00485121|C-reactive protein
555083|NCT00485121|Coronary artery disease
555084|NCT00485121|Metabolic Syndrome
555085|NCT00485121|Obesity
555086|NCT00485108|primary open angle glaucoma
555087|NCT00485108|pseudoexfoliation glaucoma
555088|NCT00485108|selective laser trabeculoplasty
555089|NCT00485108|intra ocular pressure
555090|NCT00485108|anti-inflammatory therapy
555091|NCT00485108|prednisolone acetate 1%
555092|NCT00485108|ketorolac tromethamine 0.5%
555093|NCT00485082|Cystic Fibrosis
555094|NCT00485082|Disclosure
555095|NCT00485082|Dating Partner
555096|NCT00485082|Phone Interview
555097|NCT00485069|Ropinirole hydrochloride
555098|NCT00485069|L-dopa
555099|NCT00485069|Parkinson's Disease
555100|NCT00485069|Dopamine agonist
555101|NCT00485056|Diabetes
555102|NCT00485056|Tissue doppler imaging
555103|NCT00485056|Wave intensity analysis.
555104|NCT00485043|T'ai Chi
555105|NCT00485043|Osteoarthritis
555106|NCT00485043|Exercise
555107|NCT00485043|Older adults
555108|NCT00485030|coronary artery disease
555109|NCT00485030|stent
555110|NCT00485030|angioplasty
555111|NCT00485017|Obesity
555112|NCT00485017|Weight Loss
555113|NCT00485004|Coronary artery disease
555114|NCT00485004|Stent
555115|NCT00485004|Angioplasty
555116|NCT00484991|Phenylketonuria
555117|NCT00484991|PKU
555118|NCT00484991|Phenylketonurias
555119|NCT00484991|Hyperphenylalaninaemia
555120|NCT00484991|Hydroxylase Deficiency
555121|NCT00484978|Stereotactic Radiosurgery
555122|NCT00484978|Surgery
555123|NCT00484978|Metastatic tumor to brain
555124|NCT00484978|radiation
555125|NCT00484978|Brain Metastases of all pathologies
555126|NCT00484965|Coronary stent
555127|NCT00484965|Inflammation
555128|NCT00484965|Atherosclerosis
555129|NCT00484965|Immunosuppressive
555130|NCT00484952|rotavirus
555131|NCT00484952|diarrheal diseases
555132|NCT00484952|hospitalizations
555133|NCT00484952|multicenter
555134|NCT00484952|children
555135|NCT00484952|under five year old
555136|NCT00484952|Hospitalization due to diarhheal diseases
555137|NCT00484952|Hospitalization due to rotavirus gastroenteritis
555138|NCT00484952|Nosocomial rotavirus infections
555139|NCT00484926|coronary disease
555140|NCT00484926|stents
555141|NCT00484926|antiplatelet drugs
555142|NCT00484926|drug-eluting stents
555143|NCT00484913|healthy subjects
555144|NCT00484900|Open randomized multi-centre clinical trial in Africa
555145|NCT00484900|Uncomplicated P. falciparum malaria
555146|NCT00484900|Artemisinin-based Combination Therapy
555147|NCT00484900|Artesunate + sulfalene + pyrimethamine
555148|NCT00484900|24 hour treatment
555149|NCT00484900|Artemether + lumefantrine
555150|NCT00484887|Hernia mesh
555151|NCT00484887|Implanted mesh material
555152|NCT00484887|Explanted mesh material
555153|NCT00484874|Hodgkin's lymphoma
555154|NCT00484874|Radioimmunotherapy
555155|NCT00484874|Bexxar
555156|NCT00484874|I-131 Tositumomab
555157|NCT00484874|Safety
555158|NCT00484874|Efficacy
555159|NCT00484874|Nuclear Medicine
555160|NCT00484874|Monoclonal antibody
555161|NCT00484874|Radiolabeled
555162|NCT00484861|Women
555163|NCT00484861|Healthy Volunteers
555164|NCT00484861|Triglyceride
555165|NCT00484861|Healthy Volunteer
555166|NCT00484861|HV
555167|NCT00484848|oncology, medical
555168|NCT00484848|implantable catheter
555169|NCT00484848|vascular access ports
555170|NCT00484848|persistent withdrawal occlusion
555171|NCT00484848|Vortex®
555172|NCT00484848|Celsite®
555173|NCT00484848|Vacutainer®
555174|NCT00484848|venous cut-down
555175|NCT00484835|Abdominal
555176|NCT00484835|Hysterectomy
555177|NCT00484835|Electrocoagulation forceps
555178|NCT00484835|Electrosurgery
555179|NCT00484835|Gyrus plasma open seal forceps
555180|NCT00484835|Patients undergoing abdominal hysterectomy for various reasons
555181|NCT00484809|rheumatoid arthritis
555182|NCT00484809|juvenile rheumatoid arthritis
555183|NCT00484796|Carotid Surgery
555184|NCT00484796|Cerebral Ischemia
555185|NCT00484796|Cognitive Deficits
555186|NCT00484796|Somatosensory-evoked Potentials
555187|NCT00484796|Neuromonitoring
555188|NCT00484783|Laparoscopic Surgical Procedures
555189|NCT00484783|Endoscopic Surgical Procedures
555190|NCT00484783|Laparoscopic & endoscopic procedures with a gastrotomy
555191|NCT00484783|or opening in bladder or urethra
555192|NCT00484770|heart failure, brain natriuretic peptide
555193|NCT00484757|Narcolepsy
555194|NCT00484757|Orexines
555195|NCT00484757|sleep
555196|NCT00484757|cognition
555197|NCT00484757|cytokines
555198|NCT00484744|pain
555199|NCT00484744|orthodontic
555200|NCT00484744|acetaminophen
555201|NCT00484744|ibuprofen
555202|NCT00484744|separator
555203|NCT00484705|Androgens
555204|NCT00484705|Menstrual pattern
555205|NCT00484705|Insulin resistance
555206|NCT00484705|Adipocytes
555207|NCT00484705|Obesity
555208|NCT00484705|Stress
555209|NCT00484705|Muscle sympathetic nerve activity
555210|NCT00484705|Psychological distress and quality of life
555211|NCT00484692|randomized controlled trial
555212|NCT00484692|smoking cessation
555213|NCT00484692|nicotine dependence
555214|NCT00484692|sustained-release bupropion
555215|NCT00484692|psychotherapy
555216|NCT00484692|psychodynamic model training
555217|NCT00484666|recurrent
555218|NCT00484666|platinum
555219|NCT00484666|resistant
555220|NCT00484666|ovarian
555221|NCT00484666|primary
555222|NCT00484666|peritoneal
555223|NCT00484666|cancer
555224|NCT00484653|To achieve a quality and quantitative molecular biology assay for vaginal flora abnormalities
555225|NCT00484627|Exercise
555226|NCT00484627|HIV
555227|NCT00484627|Creatine
555228|NCT00484627|Muscle
555229|NCT00484614|Breast Cancer, breast conserving surgery
555230|NCT00484588|VAP
555231|NCT00484575|Sevoflurane
555232|NCT00484575|CABG
555233|NCT00484575|cardioprotection
555234|NCT00484575|AnaConDa
555235|NCT00484562|oxygen
555236|NCT00484562|COPD
555237|NCT00484562|exercise
555238|NCT00484549|Fabry disease, Screening, Ischemic stroke
555239|NCT00484536|CDP323
555240|NCT00484536|Relapsing Multiple Sclerosis
555241|NCT00484536|Magnetic Resonance Imaging
555242|NCT00484536|Oral Compound
555243|NCT00484536|MS
555244|NCT00484523|To constitute a standardized database of multimode neural imaging.
555245|NCT00484510|Ascorbic Acid
555246|NCT00484510|Vitamin C
555247|NCT00484510|Charcot Marie Tooth
555248|NCT00484510|CMT
555249|NCT00484510|CMT1a
555250|NCT00484497|Sleep quality
555251|NCT00484497|food supplement
555252|NCT00484497|randomized controlled trial
555253|NCT00484497|actigraphy
555254|NCT00484497|Leeds
555255|NCT00484497|Volunteers presenting moderate primary insomnia
555256|NCT00484484|Cancer
555257|NCT00484484|Refractory pain
555258|NCT00484484|Uncontrolled pain
555259|NCT00484484|Ketamine
555260|NCT00484484|Uncontrolled cancer pain
555261|NCT00484458|Degenerative Disc Disease
555262|NCT00484458|Total Disc Replacement
555263|NCT00484445|Chronic critical illness
555264|NCT00484445|Functional status
555265|NCT00484445|Outcomes
555266|NCT00484445|Post-ICU
555267|NCT00484432|NGR-hTNF
555268|NCT00484432|Ovarian cancer
555269|NCT00484432|Doxorubicin
555270|NCT00484419|Colesevelam HCl,
555271|NCT00484419|rosiglitazone
555272|NCT00484419|sitagliptin
555273|NCT00484419|Type 2 diabetes
555274|NCT00484419|metformin
555275|NCT00484406|Matrix Metalloproteinases
555276|NCT00484406|Atherosclerosis
555277|NCT00484406|Genetic polymorphism
555278|NCT00484406|Acute coronary syndromes
555279|NCT00484380|Valvular surgery
555280|NCT00484380|Diagnostic accuracy of coronary angiography
555281|NCT00484380|Coronary stenosis
555282|NCT00484380|Coronary revascularisation
555283|NCT00484367|Alcohol abuse
555284|NCT00484367|Substance abuse
555285|NCT00484367|Cannabis abuse
555286|NCT00484367|Adolescents
555287|NCT00484367|Group therapy
555288|NCT00484367|Family therapy
555289|NCT00484354|Acute Renal Failure
555290|NCT00484354|Cardiac Surgery
555291|NCT00484354|Sodium Bicarbonate
555292|NCT00484354|Length of Stay
555293|NCT00484354|Mortality
555294|NCT00484341|NGR-hTNF
555295|NCT00484341|Doxorubicin
555296|NCT00484341|Soft Tissue Sarcoma
555297|NCT00484328|hepatitis C
555298|NCT00484328|Ribavirin
555299|NCT00484328|Dosage
555300|NCT00484328|Pharmacokinetics
555301|NCT00484315|drug-eluting stent
555302|NCT00484315|paclitaxel-eluting stent
555303|NCT00484315|DES
555304|NCT00484302|Marijuana Abuse
555305|NCT00484302|Psychotic Disorders
555306|NCT00484302|Schizophrenia
555307|NCT00484276|NGR-hTNF
555308|NCT00484276|malignant pleural mesothelioma
555309|NCT00484250|Oral Lichen Planus
555310|NCT00484250|Metronidazole
555311|NCT00484250|Doxycycline
555312|NCT00484237|Rheumatoid Arthritis
555313|NCT00484211|NGR-hTNF, Hepatocellular Carcinoma (HCC)
555314|NCT00484185|Hemophilia B
555315|NCT00484185|BeneFIX
555316|NCT00484185|Safety
555317|NCT00484185|Efficacy
555318|NCT00484172|Obesity
555319|NCT00484159|Low back pain of suspected lumbar zygapophysial etiology
555320|NCT00484146|Sepsis
555321|NCT00484146|Early Stage
555322|NCT00484146|Immune System
555323|NCT00484146|Receptors
555324|NCT00484146|Cytokines
555325|NCT00484133|sepsis
555326|NCT00484133|severe sepsis
555327|NCT00484133|microcirculation
555328|NCT00484133|Orthogonal polarisation spectral
555329|NCT00484120|Osteoarthritis
555330|NCT00484120|Diclofenac
555331|NCT00484120|Nano-emulsion
555332|NCT00484094|Rapamune
555333|NCT00484094|Safety
555334|NCT00484094|Efficacy
555335|NCT00484094|Kidney Transplantation
555336|NCT00484081|TESE
555337|NCT00484081|NON-OBSTRUCTIVE
555338|NCT00484081|MICRODISSECTION
555339|NCT00484081|AZOOSPERMIA
555340|NCT00484081|ICSI
555341|NCT00484068|type 2 diabetes
555342|NCT00484068|microalbuminuria
555343|NCT00484068|chicken-based diet
555344|NCT00484068|ACE inhibitor
555345|NCT00484055|Antibiotic Prophylaxis
555346|NCT00484042|pancreatitis
555347|NCT00484042|polyamine
555348|NCT00484042|cytokine
555349|NCT00484029|Temporomandibular Disorders
555350|NCT00484029|TMD
555351|NCT00484029|TMJ/TMD
555352|NCT00484029|Pain Management
555353|NCT00484029|Pain
555354|NCT00484029|Headaches
555355|NCT00484016|adjuvant
555356|NCT00484016|chemotherapy
555357|NCT00484016|observation
555358|NCT00484016|resected
555359|NCT00484016|cancers
555360|NCT00484003|Atopic eczema
555361|NCT00484003|Pimecrolimus
555362|NCT00484003|Children
555363|NCT00484003|Quality of life
555364|NCT00484003|Safety
555365|NCT00484003|Atopic dermatitis
555366|NCT00483990|Phase I Study in healthy subjects
555367|NCT00483964|Schizophrenia
555368|NCT00483964|Herbal extracts
555369|NCT00483964|Randomized
555370|NCT00483964|Controlled
555371|NCT00483964|Clinical Trial
555372|NCT00483951|Myocardial Infarction
555373|NCT00483951|Myocardial Ischemia
555374|NCT00483951|Atherosclerosis
555375|NCT00483951|Congenital Heart Disease
555376|NCT00483951|Valvular Heart Disease
555377|NCT00483951|Heart Disease
555378|NCT00483951|Cardiovascular Disease
555379|NCT00483951|Heart Valve Disease
555380|NCT00483925|Langerhans cell histiocytosis
555381|NCT00483925|flow mediated dilatation
555382|NCT00483925|intima media thickness
555383|NCT00483925|insulin resistance
555384|NCT00483925|hypopituitarism
555385|NCT00483925|glucose and lipid metabolism,
555386|NCT00483925|structural arterial and functional endothelial properties in patients with multisystem LCH
555387|NCT00483912|pancreatitis, MARS
555388|NCT00483912|severe acute pancreatitis with early multiple organ failure
555389|NCT00483899|GW870086X Asthma Crossover repeat dose inhaled
555390|NCT00483886|constipation
555391|NCT00483886|prucalopride
555392|NCT00483886|QOL
555393|NCT00483886|SCBM
555394|NCT00483886|PAC-SYM
555395|NCT00483873|Cardiac Arrest, Neurological Recovery, EEG, Quantitative EEG
555396|NCT00483860|Cancer
555397|NCT00483860|Solid tumor,
555398|NCT00483860|normal renal function
555399|NCT00483860|renal impairment,
555400|NCT00483860|prior platinum-based chemotherapy,
555401|NCT00483847|TYGRIS - Rest of World (ROW)
555402|NCT00483847|TYSABRI
555403|NCT00483847|natalizumab
555404|NCT00483847|Multiple Sclerosis
555405|NCT00483834|Bevacizumab
555406|NCT00483834|Avastin
555407|NCT00483834|CPT-11
555408|NCT00483834|Irinotecan
555409|NCT00483834|Camptothecin-11
555410|NCT00483834|Capecitabine
555411|NCT00483834|Xeloda
555412|NCT00483834|Metastatic
555413|NCT00483834|Colorectal
555414|NCT00483834|Colon
555415|NCT00483834|Rectal
555416|NCT00483821|stage I squamous cell carcinoma of the hypopharynx
555417|NCT00483821|stage II squamous cell carcinoma of the hypopharynx
555418|NCT00483821|stage III squamous cell carcinoma of the hypopharynx
555419|NCT00483821|stage IV squamous cell carcinoma of the hypopharynx
555420|NCT00483821|stage I squamous cell carcinoma of the larynx
555421|NCT00483821|stage II squamous cell carcinoma of the larynx
555422|NCT00483821|stage III squamous cell carcinoma of the larynx
555423|NCT00483821|stage IV squamous cell carcinoma of the larynx
555424|NCT00483821|stage I squamous cell carcinoma of the lip and oral cavity
555425|NCT00483821|stage II squamous cell carcinoma of the lip and oral cavity
555426|NCT00483821|stage III squamous cell carcinoma of the lip and oral cavity
555427|NCT00483821|stage IV squamous cell carcinoma of the lip and oral cavity
555428|NCT00483821|stage I squamous cell carcinoma of the oropharynx
555429|NCT00483821|stage II squamous cell carcinoma of the oropharynx
555430|NCT00483821|stage III squamous cell carcinoma of the oropharynx
555431|NCT00483821|stage IV squamous cell carcinoma of the oropharynx
555432|NCT00483821|stage I verrucous carcinoma of the larynx
555433|NCT00483821|stage II verrucous carcinoma of the larynx
555434|NCT00483821|stage III verrucous carcinoma of the larynx
555654|NCT00483275|Patient Education
555435|NCT00483821|stage IV verrucous carcinoma of the larynx
555436|NCT00483821|stage I verrucous carcinoma of the oral cavity
555437|NCT00483821|stage II verrucous carcinoma of the oral cavity
555438|NCT00483821|stage III verrucous carcinoma of the oral cavity
555439|NCT00483821|stage IV verrucous carcinoma of the oral cavity
555440|NCT00482820|anxiety
555441|NCT00482820|attention-biases
555442|NCT00482820|children
555443|NCT00482807|stage I prostate cancer
555444|NCT00482807|stage II prostate cancer
555445|NCT00482807|stage III prostate cancer
555446|NCT00482807|stage IV prostate cancer
555447|NCT00482807|adenocarcinoma of the prostate
555448|NCT00482807|recurrent prostate cancer
555449|NCT00482794|Antiphospholipid Antibody Syndrome
555450|NCT00482781|Apnea
555451|NCT00482781|Bradycardia
555452|NCT00482781|Preterm Infant
555453|NCT00482781|Immunization
555454|NCT00482781|DTaP
555455|NCT00482768|Diabetes, type II; Primary Health Care; Outpatient Care
555456|NCT00482755|male breast cancer
555457|NCT00482755|stage II breast cancer
555458|NCT00482755|stage IIIA breast cancer
555459|NCT00482742|Chronic Total Occlusion
555460|NCT00482716|unspecified adult solid tumor, protocol specific
555461|NCT00482716|refractory multiple myeloma
555462|NCT00482716|stage I multiple myeloma
555463|NCT00482716|stage II multiple myeloma
555464|NCT00482716|stage III multiple myeloma
555465|NCT00482716|noncontiguous stage II adult diffuse small cleaved cell lymphoma
555466|NCT00482716|noncontiguous stage II grade 1 follicular lymphoma
555467|NCT00482716|noncontiguous stage II grade 2 follicular lymphoma
555468|NCT00482716|noncontiguous stage II marginal zone lymphoma
555469|NCT00482716|noncontiguous stage II small lymphocytic lymphoma
555470|NCT00482716|contiguous stage II adult diffuse small cleaved cell lymphoma
555471|NCT00482716|contiguous stage II grade 1 follicular lymphoma
555472|NCT00482716|contiguous stage II grade 2 follicular lymphoma
555473|NCT00482716|contiguous stage II marginal zone lymphoma
555474|NCT00482716|contiguous stage II small lymphocytic lymphoma
555475|NCT00482716|stage I adult diffuse small cleaved cell lymphoma
555476|NCT00482716|stage III adult diffuse small cleaved cell lymphoma
555477|NCT00482716|stage IV adult diffuse small cleaved cell lymphoma
555478|NCT00482716|stage I grade 1 follicular lymphoma
555479|NCT00482716|stage I grade 2 follicular lymphoma
555480|NCT00482716|stage III grade 1 follicular lymphoma
555481|NCT00482716|stage III grade 2 follicular lymphoma
555482|NCT00482716|stage IV grade 1 follicular lymphoma
555483|NCT00482716|stage IV grade 2 follicular lymphoma
555484|NCT00482716|stage I marginal zone lymphoma
555485|NCT00482716|stage III marginal zone lymphoma
555486|NCT00482716|stage IV marginal zone lymphoma
555487|NCT00482716|stage I small lymphocytic lymphoma
555488|NCT00482716|stage III small lymphocytic lymphoma
555489|NCT00482716|stage IV small lymphocytic lymphoma
555490|NCT00482716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
555491|NCT00482716|nodal marginal zone B-cell lymphoma
555492|NCT00482716|splenic marginal zone lymphoma
555493|NCT00482716|recurrent adult diffuse small cleaved cell lymphoma
555494|NCT00482716|recurrent grade 1 follicular lymphoma
555495|NCT00482716|recurrent grade 2 follicular lymphoma
555496|NCT00482716|recurrent marginal zone lymphoma
555497|NCT00482716|recurrent small lymphocytic lymphoma
555498|NCT00482716|stage I chronic lymphocytic leukemia
555499|NCT00482716|stage II chronic lymphocytic leukemia
555500|NCT00482716|stage III chronic lymphocytic leukemia
555501|NCT00482716|stage IV chronic lymphocytic leukemia
555502|NCT00482716|refractory chronic lymphocytic leukemia
555503|NCT00482716|anemia
555504|NCT00482703|Imatinib resistant or intolerant chronic phase CML
555505|NCT00482690|Smoking cessation
555506|NCT00482690|Biomarkers
555507|NCT00482690|Aldehydes
555508|NCT00482690|Exhaled breath
555509|NCT00482690|Harm Reduction
555510|NCT00482690|Cigarette smoking
555511|NCT00482690|cessation
555512|NCT00482690|reduction
555513|NCT00482677|adult glioblastoma
555514|NCT00482677|adult giant cell glioblastoma
555515|NCT00482677|adult gliosarcoma
555516|NCT00483782|stage IV ovarian epithelial cancer
555517|NCT00483782|Brenner tumor
555518|NCT00483782|ovarian carcinosarcoma
555519|NCT00483782|ovarian clear cell cystadenocarcinoma
555520|NCT00483782|ovarian endometrioid adenocarcinoma
555521|NCT00483782|ovarian mixed epithelial carcinoma
555522|NCT00483782|ovarian mucinous cystadenocarcinoma
555523|NCT00483782|ovarian serous cystadenocarcinoma
555524|NCT00483782|ovarian undifferentiated adenocarcinoma
555525|NCT00483782|stage IA ovarian epithelial cancer
555526|NCT00483782|stage IB ovarian epithelial cancer
555527|NCT00483782|stage IC ovarian epithelial cancer
555528|NCT00483782|stage IIA ovarian epithelial cancer
555529|NCT00483782|stage IIB ovarian epithelial cancer
555530|NCT00483782|stage IIC ovarian epithelial cancer
555531|NCT00483782|stage IIIA ovarian epithelial cancer
555532|NCT00483782|stage IIIB ovarian epithelial cancer
555533|NCT00483782|stage IIIC ovarian epithelial cancer
555534|NCT00483782|stage IA fallopian tube cancer
555535|NCT00483782|stage IB fallopian tube cancer
555536|NCT00483782|stage IC fallopian tube cancer
555537|NCT00483782|stage IIA fallopian tube cancer
555538|NCT00483782|stage IIB fallopian tube cancer
555539|NCT00483782|stage IIC fallopian tube cancer
555540|NCT00483782|stage IIIA fallopian tube cancer
555541|NCT00483782|stage IIIB fallopian tube cancer
555542|NCT00483782|stage IIIC fallopian tube cancer
555543|NCT00483782|stage IV fallopian tube cancer
555544|NCT00483782|stage IA primary peritoneal cavity cancer
555545|NCT00483782|stage IB primary peritoneal cavity cancer
555546|NCT00483782|stage IC primary peritoneal cavity cancer
555547|NCT00483782|stage IIA primary peritoneal cavity cancer
555548|NCT00483782|stage IIB primary peritoneal cavity cancer
555549|NCT00483782|stage IIC primary peritoneal cavity cancer
555550|NCT00483782|stage IIIA primary peritoneal cavity cancer
555551|NCT00483782|stage IIIB primary peritoneal cavity cancer
555552|NCT00483782|stage IIIC primary peritoneal cavity cancer
555553|NCT00483782|stage IV primary peritoneal cavity cancer
555554|NCT00483769|Cystis Fibrosis
555555|NCT00483769|Glucose intolerance
555556|NCT00483769|Glargine
555557|NCT00483769|FEV1%
555558|NCT00483756|Immunosuppression
555559|NCT00483756|JAK3 inhibitor
555560|NCT00483756|kidney transplantation.
555561|NCT00483717|Migraine
555562|NCT00483717|Ketorolac
555563|NCT00483704|multiple attacks of moderate to severe migraine headaches
555564|NCT00483691|Intervention
555565|NCT00483691|Home Visit
555566|NCT00483691|Growth
555567|NCT00483691|Child Development
555568|NCT00483678|psychosocial effects of cancer and its treatment
555569|NCT00483678|sexual dysfunction
555570|NCT00483678|sexuality and reproductive issues
555571|NCT00483678|recurrent prostate cancer
555572|NCT00483678|stage III prostate cancer
555573|NCT00483678|stage IV prostate cancer
555574|NCT00483665|endoleak
555575|NCT00483652|multiple sclerosis
555576|NCT00483652|MS
555577|NCT00483652|walking
555578|NCT00483652|leg strength
555579|NCT00483652|demyelination
555580|NCT00483639|anxiety disorder
555581|NCT00483639|long-term effects secondary to cancer therapy in adults
555582|NCT00483639|head and neck cancer
555583|NCT00483639|non-small cell lung cancer
555584|NCT00483639|small cell lung cancer
555585|NCT00483626|hemodynamic
555586|NCT00483626|pulmonary hypertension
555587|NCT00483626|sildenafil
555588|NCT00483613|Daily stress
555589|NCT00483613|Cognitive-behavioral therapy
555590|NCT00483613|Quality of life
555591|NCT00483613|SLEDAI
555592|NCT00483600|Fondaparinux
555593|NCT00483600|Pharmacokinetic
555594|NCT00483587|NSTEMI
555595|NCT00483587|Acute coronary syndrome
555596|NCT00483587|Heme arginate
555597|NCT00483587|HO-1
555598|NCT00483587|Heme oxygenase-1
555599|NCT00483574|Menactra® vaccine
555600|NCT00483574|Meningococcal meningitis
555601|NCT00483574|Measles
555602|NCT00483574|Mumps
555603|NCT00483574|Rubella
555604|NCT00483574|Varicella virus
555605|NCT00483574|Haemophilus influenzae type b
555606|NCT00483574|Pneumococcal conjugate vaccine
555607|NCT00483561|adenocarcinoma of the prostate
555608|NCT00483561|recurrent prostate cancer
555609|NCT00483561|stage III prostate cancer
555610|NCT00483561|stage IV prostate cancer
555611|NCT00483535|Gw273225, Oral Contraceptive Interaction
555612|NCT00483522|Rehabilitation
555613|NCT00483522|Directive counseling
555614|NCT00483522|Brain injuries
555615|NCT00483509|NGR-hTNF
555616|NCT00483509|SCLC
555617|NCT00483483|HIV
555618|NCT00483483|Unsafe sex
555619|NCT00483483|High-risk sex
555620|NCT00483483|Needle sharing
555621|NCT00483483|STDs
555622|NCT00483470|Hepatitis A
555623|NCT00483457|unspecified adult solid tumor, protocol specific
555624|NCT00483444|Rehabilitation
555625|NCT00483444|Brain injuries
555626|NCT00483444|Directive counseling
555627|NCT00483431|vitamin K2
555628|NCT00483431|dosis-response
555629|NCT00483431|osteocalcin
555630|NCT00483431|matrix-gla protein
555631|NCT00483418|male
555632|NCT00483418|cancer
555633|NCT00483405|advanced adult primary liver cancer
555634|NCT00483405|localized unresectable adult primary liver cancer
555635|NCT00483405|recurrent adult primary liver cancer
555636|NCT00483405|adult primary hepatocellular carcinoma
555637|NCT00483392|insulin
555638|NCT00483392|rosiglitazone
555639|NCT00483392|metformin
555640|NCT00483392|hiv
555641|NCT00483392|protease inhibitors
555642|NCT00483366|unspecified adult solid tumor, protocol specific
555643|NCT00483327|Well
555644|NCT00483327|Moderately
555645|NCT00483327|Differentiated
555646|NCT00483301|Melanoma
555647|NCT00483301|Abraxane
555648|NCT00483301|Sorafenib
555649|NCT00483301|BAY 43-9006
555650|NCT00483301|Abraxis
555651|NCT00483288|cervical cancer
555652|NCT00483275|Accidental Falls
555653|NCT00483275|Accident Prevention
555655|NCT00483275|Exercise Training
555656|NCT00483275|Alfacalcidol
555657|NCT00483262|Temsirolimus
555658|NCT00483262|Bortezomib
555659|NCT00483249|Thoracoabdominal
555660|NCT00483249|Paravisceral
555661|NCT00483249|Aneurysm
555662|NCT00483249|Endovascular
555663|NCT00483249|Stent-Graft
555664|NCT00483249|Aorta
555665|NCT00483236|Non-Ischaemic Cardiomyopathy
555666|NCT00483223|ER negative
555667|NCT00483223|PgR negative
555668|NCT00483223|HER2 negative
555669|NCT00483223|cisplatin
555670|NCT00483223|carboplatinum
555671|NCT00483223|platinum
555672|NCT00483223|p63
555673|NCT00483223|p73
555674|NCT00483197|VentrAssistTM
555675|NCT00483197|LVAD
555676|NCT00483197|End-stage heart failure
555677|NCT00483197|Cardiomyopathy
555678|NCT00483158|Helicobacter pylori
555679|NCT00483158|Fluoroquinolones
555680|NCT00483158|First in Man
555681|NCT00483119|pemphigus vulgaris
555682|NCT00483119|IVIg
555683|NCT00483119|cyclophosphamide
555684|NCT00483119|treatment
555685|NCT00483119|pemphigus antibodies
555686|NCT00483106|Attention Deficit Hyperactivity Disorder
555687|NCT00483106|Genetics
555688|NCT00483106|Pharmacogenetics
555689|NCT00483093|NGR-hTNF
555690|NCT00483093|cisplatin
555691|NCT00483093|solid tumors
555692|NCT00483080|NGR-hTNF
555693|NCT00483080|CRC
555694|NCT00483067|Idiopathic Hypereosinophilic Syndrome
555695|NCT00483067|Leukemia
555696|NCT00483067|2-Chlorodeoxyadenosine
555697|NCT00483067|Cladribine
555698|NCT00483067|Cytarabine
555699|NCT00483067|Ara-C
555700|NCT00483067|2-CdA
555701|NCT00483067|G-CSF
555702|NCT00483067|HES
555703|NCT00483054|HIV
555704|NCT00483054|tuberculosis
555705|NCT00483054|efavirenz
555706|NCT00483054|nevirapine
555707|NCT00483054|rifampicin
555708|NCT00483054|co-infected HIV and tuberculosis patients
555709|NCT00483015|presentation
555710|NCT00483015|outcome
555711|NCT00483015|response
555712|NCT00483015|never- smokers
555713|NCT00483002|A prospective and observational program to monitor use in real practice including efficacy of Varenicline in Korea.
555714|NCT00482963|HIV
555715|NCT00482963|Contraception
555716|NCT00482963|Antiretroviral agents
555717|NCT00482963|Pharmacokinetics
555718|NCT00482937|Safety
555719|NCT00482937|Heart Failure
555720|NCT00482924|obesity
555721|NCT00482924|cardiovascular risk profiles
555722|NCT00482924|adipokines
555723|NCT00482924|preatherosclerosis
555724|NCT00482924|low grade inflammation
555725|NCT00482924|dyslipidemia
555726|NCT00482924|insulin resistance
555727|NCT00482924|brown adipose tissue
555728|NCT00482924|white adipose tissue
555729|NCT00482911|recurrent intraocular melanoma
555730|NCT00482911|metastatic intraocular melanoma
555731|NCT00482911|ciliary body and choroid melanoma, medium/large size
555732|NCT00482911|extraocular extension melanoma
555733|NCT00482911|iris melanoma
555734|NCT00482911|conjunctival melanoma
555735|NCT00482885|Esophagus
555736|NCT00482885|Peristalsis
555737|NCT00482885|Contractile Pressure
555738|NCT00482885|Coordination of contraction
555739|NCT00482885|Bolus transport
555740|NCT00482885|Esophageal function
555741|NCT00482872|stage I squamous cell carcinoma of the hypopharynx
555742|NCT00482872|stage II squamous cell carcinoma of the hypopharynx
555743|NCT00482872|stage III squamous cell carcinoma of the hypopharynx
555744|NCT00482872|stage IV squamous cell carcinoma of the hypopharynx
555745|NCT00482872|recurrent squamous cell carcinoma of the hypopharynx
555746|NCT00482872|stage I squamous cell carcinoma of the larynx
555747|NCT00482872|stage II squamous cell carcinoma of the larynx
555748|NCT00482872|stage III squamous cell carcinoma of the larynx
555749|NCT00482872|stage IV squamous cell carcinoma of the larynx
555750|NCT00482872|recurrent squamous cell carcinoma of the larynx
555751|NCT00482872|stage I squamous cell carcinoma of the lip and oral cavity
555752|NCT00482872|stage II squamous cell carcinoma of the lip and oral cavity
555753|NCT00482872|stage III squamous cell carcinoma of the lip and oral cavity
555754|NCT00482872|stage IV squamous cell carcinoma of the lip and oral cavity
555755|NCT00482872|recurrent squamous cell carcinoma of the lip and oral cavity
555756|NCT00482872|metastatic squamous neck cancer with occult primary squamous cell carcinoma
555757|NCT00482872|recurrent metastatic squamous neck cancer with occult primary
555758|NCT00482872|untreated metastatic squamous neck cancer with occult primary
555759|NCT00482872|stage I squamous cell carcinoma of the nasopharynx
555760|NCT00482872|stage II squamous cell carcinoma of the nasopharynx
555761|NCT00482872|stage III squamous cell carcinoma of the nasopharynx
555762|NCT00482872|stage IV squamous cell carcinoma of the nasopharynx
555763|NCT00482872|recurrent squamous cell carcinoma of the nasopharynx
555764|NCT00482872|stage I squamous cell carcinoma of the oropharynx
555765|NCT00482872|stage II squamous cell carcinoma of the oropharynx
555766|NCT00482872|stage III squamous cell carcinoma of the oropharynx
555767|NCT00482872|stage IV squamous cell carcinoma of the oropharynx
555768|NCT00482872|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
555769|NCT00482872|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
555770|NCT00482872|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
555771|NCT00482872|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
555772|NCT00482872|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
555773|NCT00482872|salivary gland squamous cell carcinoma
555774|NCT00482872|recurrent verrucous carcinoma of the larynx
555775|NCT00482872|recurrent verrucous carcinoma of the oral cavity
555776|NCT00482872|stage I verrucous carcinoma of the larynx
555777|NCT00482872|stage I verrucous carcinoma of the oral cavity
555778|NCT00482872|stage II verrucous carcinoma of the larynx
555779|NCT00482872|stage II verrucous carcinoma of the oral cavity
555780|NCT00482872|stage III verrucous carcinoma of the larynx
555781|NCT00482872|stage III verrucous carcinoma of the oral cavity
555782|NCT00482872|stage IV verrucous carcinoma of the larynx
555783|NCT00482872|stage IV verrucous carcinoma of the oral cavity
555784|NCT00482872|recurrent squamous cell carcinoma of the oropharynx
555785|NCT00482859|Fibromyalgia Syndrome
555786|NCT00482846|mucositis
555787|NCT00482846|drug/agent toxicity by tissue/organ
555788|NCT00482846|stage II multiple myeloma
555789|NCT00482846|stage III multiple myeloma
555790|NCT00482846|refractory multiple myeloma
555791|NCT00482833|adult acute promyelocytic leukemia (M3)
555792|NCT00482833|adult acute myeloid leukemia with t(15;17)(q22;q12)
555793|NCT00482833|untreated adult acute myeloid leukemia
555794|NCT00482586|adult primary liver cancer
555795|NCT00482586|liver metastases
555796|NCT00482573|Electrocardiography, ambulatory/methods
555797|NCT00482573|Blood Pressure monitoring, ambulatory/methods
555798|NCT00482573|Cardiotocography/methods
555799|NCT00482573|Dental restoration, permanent
555800|NCT00482573|Anesthesia, local /methods
555801|NCT00482573|Lidocaine
555802|NCT00482573|Vasoconstrictor Agents
555803|NCT00482573|Epinephrine
555804|NCT00482573|Pregnancy
555805|NCT00482573|Rheumatic Heart Disease
555806|NCT00482560|Sucrose
555807|NCT00482560|Breastfeeding
555808|NCT00482560|Heel lance
555809|NCT00482547|urinary tract infection
555810|NCT00482547|urinary catheter
555811|NCT00482521|unspecified adult solid tumor, protocol specific
555812|NCT00482508|Asthma
555813|NCT00482508|anti immunoglobulin E
555814|NCT00482508|omalizumab
555815|NCT00482495|refractory multiple myeloma
555816|NCT00482495|stage I multiple myeloma
555817|NCT00482495|stage II multiple myeloma
555818|NCT00482495|stage III multiple myeloma
555819|NCT00482482|Yoga
555820|NCT00482482|Bipolar disorder
555821|NCT00482482|Major depression
555822|NCT00482482|Dysthymia
555823|NCT00482482|Randomized
555824|NCT00482469|ischemia-reperfusion
555825|NCT00482469|ischemia
555826|NCT00482469|reperfusion
555827|NCT00482469|DIEP-flap
555828|NCT00482469|flap
555829|NCT00482456|Nitrous oxide
555830|NCT00482456|Homocysteine
555831|NCT00482456|folate
555832|NCT00482456|vitamin B12
555833|NCT00482430|Undifferentiated schizophrenia
555834|NCT00482430|Residual schizophrenia
555835|NCT00482391|recurrent breast cancer
555836|NCT00482391|stage I breast cancer
555837|NCT00482391|stage II breast cancer
555838|NCT00482391|stage IIIA breast cancer
555839|NCT00482391|stage IIIB breast cancer
555840|NCT00482391|stage IIIC breast cancer
555841|NCT00482391|male breast cancer
555842|NCT00482378|stage I multiple myeloma
555843|NCT00482378|stage II multiple myeloma
555844|NCT00482378|stage III multiple myeloma
555845|NCT00482378|refractory multiple myeloma
555846|NCT00482378|pain
555847|NCT00482365|adult primary hepatocellular carcinoma
555848|NCT00482365|advanced adult primary liver cancer
555849|NCT00482365|localized resectable adult primary liver cancer
555850|NCT00482365|localized unresectable adult primary liver cancer
555851|NCT00482365|recurrent adult primary liver cancer
555852|NCT00482339|bacterial contamination
555853|NCT00482339|platelet concentrates
555854|NCT00482339|blood donation
555855|NCT00482339|looxster
555856|NCT00482339|pureprove
555857|NCT00482339|bacterial genomic DNA
555858|NCT00482339|bacterial contamination of platelet concentrates
555859|NCT00482339|"Preparation of bacterial DNA in blood"
555860|NCT00482339|comparison of blood culture versus NAT
555861|NCT00482313|Attention Deficit Hyperactivity Disorder
555862|NCT00482313|ADHD
555863|NCT00482313|Prison
555864|NCT00482313|Treatment
555865|NCT00482313|Randomized
555866|NCT00482313|Double-Blind
555867|NCT00482313|Placebo Control
555868|NCT00482313|Parallel Assignment
555869|NCT00482313|Efficacy Study
555870|NCT00482300|Histologically proved endometrial carcinoma preoperatively supposed stage I-II
555871|NCT00482274|adenocarcinoma of the prostate
555872|NCT00482274|recurrent prostate cancer
555873|NCT00482274|stage I prostate cancer
555874|NCT00482274|stage II prostate cancer
555875|NCT00482274|stage III prostate cancer
555876|NCT00482274|stage IV prostate cancer
555877|NCT00482261|myeloma
555878|NCT00482261|relapse
555879|NCT00482261|refractory
555880|NCT00482261|elderly
555881|NCT00482261|lenalidomide
555882|NCT00482248|Asthma
555883|NCT00482248|anti-immunoglobulin E
555884|NCT00482248|omalizumab
555885|NCT00482248|allergic asthma
555886|NCT00482222|adenocarcinoma of the colon
555887|NCT00482222|stage IV colon cancer
555888|NCT00482222|adenocarcinoma of the rectum
555889|NCT00482222|stage IV rectal cancer
555890|NCT00482222|liver metastases
555891|NCT00482222|recurrent colon cancer
555892|NCT00482222|recurrent rectal cancer
555893|NCT00482209|mifepristone, misoprostol, medical abortion
555894|NCT00482183|Bare metal stent
555895|NCT00482183|Major adverse cardiac events
555896|NCT00482183|Pioglitazone
555897|NCT00482183|Restenosis
555898|NCT00482183|Sirolimus eluting stent
555899|NCT00482144|Pulsed-Dye Laser
555900|NCT00482118|Air Pollution
555901|NCT00482118|Tumor Markers
555902|NCT00482118|Genetic Polymorphisms
555903|NCT00482118|Molecular Epidemiology
555904|NCT00482118|Environmental Epidemiology
555905|NCT00482118|Lung Cancer
555906|NCT00482105|melanoma
555907|NCT00482092|Crohn's disease
555908|NCT00482092|adult stem cell therapy
555909|NCT00482066|Wegener's granulomatosis
555910|NCT00482066|Microscopic polyangiitis
555911|NCT00482066|Churg Strauss Syndrome
555912|NCT00482066|ANCA
555913|NCT00482040|CPAP
555914|NCT00482040|Preterm
555915|NCT00482040|Prematurity
555916|NCT00482040|Apnea of prematurity
555917|NCT00482027|HIV vaccine
555918|NCT00482027|Adeno-associated virus vactored vaccine
555919|NCT00482027|HIV-1 subtype C
555920|NCT00482027|Safety
555921|NCT00482027|Immunogenicity
555922|NCT00482027|Biodistribution
555923|NCT00482027|HIV prevention
555924|NCT00482001|Donepezil
555925|NCT00482001|Driving
555926|NCT00482001|Cholinesterase Inhibitors
555927|NCT00482001|Geriatric Psychiatry
555928|NCT00482001|Psychopharmacology
555929|NCT00482001|Aricept
555930|NCT00481988|depression
555931|NCT00481988|transcranial direct current stimulation
555932|NCT00481988|direct current stimulation
555933|NCT00481988|tdcs
555934|NCT00481975|binge eating
555935|NCT00481975|eating disorders
555936|NCT00481975|obesity
555937|NCT00481949|Gastro-oesophageal reflux disease
555938|NCT00481949|pH measurement
555939|NCT00481949|symptom association
555940|NCT00481949|wireless pH monitoring system
555941|NCT00481949|Functional Heartburn
555942|NCT00481949|Gastro-esophageal reflux disease
555943|NCT00481936|Neoplasms
555944|NCT00481936|Neoplasm, Epithelial
555945|NCT00481936|Neoplasm, Glandular
555946|NCT00481923|hypocaloric diet
555947|NCT00481923|energy intake
555948|NCT00481897|overweight
555949|NCT00481897|obesity
555950|NCT00481897|type 2 diabetes
555951|NCT00481897|diabetes
555952|NCT00481897|worksite cost
555953|NCT00481897|nutrition
555954|NCT00481884|Breast Cancer
555955|NCT00481884|Radiation Dermatitis
555956|NCT00481884|RadiaPlexRx Gel
555957|NCT00481884|Aquaphor
555958|NCT00481871|Lymphoproliferative malignancies
555959|NCT00481871|Lymphoma
555960|NCT00481871|Hodgkin's lymphoma (HL)
555961|NCT00481871|Non-Hodgkin's lymphoma (NHL)
555962|NCT00481871|PTCL
555963|NCT00481871|T/NK-cell leukemia/lymphoma
555964|NCT00481871|T-cell lymphoma/leukemia (HTLV 1+)
555965|NCT00481871|Angioimmunoblastic T-cell lymphoma
555966|NCT00481871|Blastic NK lymphoma
555967|NCT00481871|Anaplastic large cell lymphoma
555968|NCT00481871|T/NK-cell lymphoma
555969|NCT00481871|Enteropathy-type intestinal lymphoma
555970|NCT00481871|Hepatosplenic T-cell lymphoma
555971|NCT00481871|Extranodal peripheral T/NK-cell lymphoma
555972|NCT00481871|Subcutaneous panniculitis T-cell lymphoma
555973|NCT00481871|Transformed mycosis fungoides
555974|NCT00481871|PDX
555975|NCT00481871|Pralatrexate
555976|NCT00481871|Gemcitabine
555977|NCT00481871|Gemzar
555978|NCT00481871|Vitamin B12
555979|NCT00481871|Folic acid
555980|NCT00481858|chronic lymphocytic leukemia
555981|NCT00481858|biomarker
555982|NCT00481858|prognosis
555983|NCT00481858|apoptosis
555984|NCT00481858|neoplasm/cancer diagnosis
555985|NCT00481858|stable isotope
555986|NCT00481858|diagnosis evaluation
555987|NCT00481858|outcomes
555988|NCT00481858|CD19
555989|NCT00481858|CD5
555990|NCT00481819|Kidney Transplantation
555991|NCT00481819|Tacrolimus
555992|NCT00481819|Methylprednisolone
555993|NCT00481819|Prednisolone
555994|NCT00481819|Mycophenolate Mofetil
555995|NCT00481806|Virchow's Triad
555996|NCT00481806|Thrombin
555997|NCT00481806|Graft Failure
555998|NCT00481793|Plutonium
555999|NCT00481793|Ionizing Radiation
556000|NCT00481793|Polymorphism
556001|NCT00481793|Biological Marker
556002|NCT00481793|Russia
556003|NCT00481767|Cervical cancer;
556004|NCT00481767|Human papillomavirus (HPV) vaccine
556005|NCT00481767|HPV;
556006|NCT00481767|Papillomavirus;
556007|NCT00481754|Endometrium
556008|NCT00481754|PTEN
556009|NCT00481754|Hormones
556010|NCT00481754|Carcinogenesis
556011|NCT00481754|Etiology
556012|NCT00481754|Tissue Evaluation
556013|NCT00481754|Questionnaire
556014|NCT00481741|Angioplasty, Percutaneous TransluminalCoronary
556015|NCT00481715|Web-Based Weight Loss Program
556016|NCT00481715|Cash Incentive Weight Loss Program
556017|NCT00481715|North Carolina
556018|NCT00481689|Cipro
556019|NCT00481689|Complicated UTI
556020|NCT00481689|Pseudomonas aeruginosa
556021|NCT00481676|Chronic urticaria, omalizumab, thyroperoxidase, IgE
556022|NCT00480649|SERETIDE
556023|NCT00480649|asthma
556024|NCT00480649|Korean
556025|NCT00480649|ACT
556026|NCT00480623|Prostate Cancer
556027|NCT00480623|Biochemical Failure
556028|NCT00480623|Radical Prostatectomy
556029|NCT00480610|Dermatitis, atopic
556030|NCT00480610|Tacrolimus
556031|NCT00480610|Adult
556032|NCT00480610|treatment outcomes
556033|NCT00481637|paraneoplastic; autoimmunity;
556034|NCT00481624|advanced lung cancer
556035|NCT00481624|Procrit
556036|NCT00481624|Epoetin Alfa
556037|NCT00481624|Ferric Gluconate
556038|NCT00481624|iron supplementation
556039|NCT00481611|Industry Hygiene
556040|NCT00481611|Molecular Epidemiology
556041|NCT00481611|Cancer Susceptibility
556042|NCT00481611|Genotoxicity
556043|NCT00481611|Immune Function
556044|NCT00481611|Cancer Susceptability
556045|NCT00481585|claudin
556046|NCT00481585|electrophysiology
556047|NCT00481585|breast
556048|NCT00481585|screening
556049|NCT00481572|Sepsis
556050|NCT00481572|Septic Shock
556051|NCT00481572|vasopressin
556052|NCT00481572|terlipressin
556053|NCT00481559|Voraxaze
556054|NCT00481559|glucarpidase
556055|NCT00481559|carboxypeptidase
556056|NCT00481559|cancer
556057|NCT00481559|lymphoma
556058|NCT00481559|leukemia
556059|NCT00481559|osteosarcoma
556060|NCT00481559|methotrexate
556061|NCT00481559|delayed elimination
556062|NCT00481559|renal insufficiency
556063|NCT00481559|toxicity
556064|NCT00481546|Leber congenital amaurosis
556065|NCT00481546|LCA
556066|NCT00481546|RPE65
556067|NCT00481546|Retinal disease due to RPE65 mutations
556068|NCT00481546|RPE65-associated Leber congenital amaurosis
556069|NCT00481533|Cesarean Delivery
556070|NCT00481533|Uterine Contractility
556071|NCT00481507|Probiotic
556072|NCT00481507|Cultured dairy drink
556073|NCT00481507|Health
556074|NCT00481507|10 day antibiotic
556075|NCT00481507|Otherwise healthy
556076|NCT00481494|Glaucoma
556077|NCT00481494|Drug compliance
556078|NCT00481494|Personality
556079|NCT00481481|Tacrolimus, Kidney Transplantation
556080|NCT00481468|Coronary artery disease
556081|NCT00481468|chest pain
556082|NCT00481455|Glioblastoma Multiforme
556083|NCT00481455|temozolomide
556084|NCT00481442|Septic shock
556085|NCT00481442|Sepsis
556086|NCT00481442|Norepinephrine
556087|NCT00481442|Phenylephrine
556088|NCT00481429|Biomarker
556089|NCT00481429|Glitazone
556090|NCT00481429|Diabetes
556091|NCT00481416|Esophageal Varices
556092|NCT00481416|PillCam Eso
556093|NCT00481416|Capsule Endoscopy
556094|NCT00481416|Given Imaging
556095|NCT00481416|Inscope
556096|NCT00481403|Sperm, male fertility, microarrays
556097|NCT00481390|HIV
556098|NCT00481390|HLA-B*5701
556099|NCT00481390|prevalence
556100|NCT00481390|Treatment Experienced
556101|NCT00481390|Treatment Naive
556102|NCT00481377|Ablation
556103|NCT00481377|Ventricular tachycardia
556104|NCT00481377|coronary artery disease
556105|NCT00481377|Implantable cardioverter defibrillator interventions
556106|NCT00481364|hemodialysis
556107|NCT00481364|endothelial function
556108|NCT00481364|coronary artery calcification
556109|NCT00481364|atherosclerosis
556110|NCT00481364|statin
556111|NCT00481351|artificial chilomicrons kinetics
556112|NCT00481351|ezetimibe plus statin
556113|NCT00481351|lipid lowering therapy
556114|NCT00481338|Cohort
556115|NCT00481338|Quality of life
556116|NCT00481338|Health resource use
556117|NCT00481338|Disability
556118|NCT00481338|Prognosis
556119|NCT00481312|Initial Sedation
556120|NCT00481312|Mechanical ventilation
556121|NCT00481299|Insulin
556122|NCT00481299|glucose
556123|NCT00481299|lipids
556124|NCT00481299|prolactinoma
556125|NCT00481299|hyperprolactinemia
556126|NCT00481286|Group clinics
556127|NCT00481286|Goal setting
556128|NCT00481286|Diabetes
556129|NCT00481286|Hypertension
556130|NCT00481286|Age 50+
556131|NCT00481273|MDS
556132|NCT00481260|Hgb C
556133|NCT00481260|Screening
556134|NCT00481247|Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
556135|NCT00481234|Anesthesia, General
556136|NCT00481234|Abnormalities, Cardiovascular
556137|NCT00481234|Heart Rate
556138|NCT00481234|Forecasting
556139|NCT00481221|Thalassemia
556140|NCT00481221|Iron Deficiency
556141|NCT00481221|Carrier screening
556142|NCT00481208|open-angle glaucoma
556143|NCT00481208|diurnal fluctuation
556144|NCT00481208|intraocular pressure
556145|NCT00481208|peripapillary retinal blood flow
556146|NCT00481208|latent asymmetric intraocular pressure
556147|NCT00481182|PK
556148|NCT00481182|PD
556149|NCT00481182|FPV
556150|NCT00481182|RTV
556151|NCT00481182|APV
556152|NCT00481182|ritonavir
556153|NCT00481182|fosamprenavir
556154|NCT00481182|amprenavir
556155|NCT00481182|methadone
556156|NCT00481182|pharmacokinetics
556157|NCT00481182|pharmacodynamics
556158|NCT00481169|Postmenopausal Osteoporosis
556159|NCT00481143|Myelodysplastic Syndrome
556160|NCT00481143|MDS
556161|NCT00481143|iron overload
556162|NCT00481143|chelation
556163|NCT00481143|chelators
556164|NCT00481143|ICL670
556165|NCT00481143|Deferasirox
556166|NCT00481143|serum ferritin
556167|NCT00481143|LIC
556168|NCT00481143|transfusional hemosiderosis
556169|NCT00481143|Refractory Anemia
556170|NCT00481143|RA
556171|NCT00481143|Refractory Anemia with Ringed Sideroblasts
556172|NCT00481143|RARS
556173|NCT00481143|blood transfusions
556174|NCT00481143|Mydelodysplastic Syndrome(s)
556175|NCT00481130|Alport Syndrome
556176|NCT00481130|x linked
556177|NCT00481130|autosomal dominant Alport syndrome
556178|NCT00481130|glomerular basement membrane
556179|NCT00481130|hereditary nephritis
556180|NCT00481130|familial benign haematuria
556181|NCT00481130|type IV collagen
556182|NCT00481130|hereditary nephritis with neurosensory deafness
556183|NCT00481130|vison loss
556184|NCT00481104|Obesity
556185|NCT00481065|Bird flu
556186|NCT00481065|influenza vaccine
556187|NCT00481065|Seasonal influenza vaccine
556188|NCT00481065|Prepandemic vaccine
556189|NCT00481052|Adult
556190|NCT00481052|CML
556191|NCT00481052|Philadelphia positive
556192|NCT00481052|Nilotinib
556193|NCT00481052|early chronic phase
556194|NCT00481052|untreated or treated only with Hydroxyurea or Anagrelide
556195|NCT00481052|Chronic Myeloid Leukemia
556196|NCT00481039|Sickle cell disease
556197|NCT00481039|Sickle cell thalassemia
556198|NCT00481039|Population screening
556199|NCT00481013|Spinal Muscular Atrophy
556200|NCT00481013|Adult
556201|NCT00481000|Dialectical Cognitive Therapy
556202|NCT00481000|Clinical Psychology
556203|NCT00480987|High-Risk Myelodysplastic Syndromes
556204|NCT00480987|Acute Myeloid Leukemia
556205|NCT00480987|Leukemia
556206|NCT00480987|Oxaliplatin
556207|NCT00480987|Fludarabine
556208|NCT00480987|Cytarabine
556209|NCT00480987|AML
556210|NCT00480987|MDS
556211|NCT00480974|Sickle cell anemia
556212|NCT00480974|Sickle cell thalassemia
556213|NCT00480974|Hydroxyurea
556214|NCT00480948|infant
556215|NCT00480948|infant formula
556216|NCT00480948|fatty acids
556217|NCT00480948|palmitic acid
556218|NCT00480948|stool
556219|NCT00480948|calcium
556220|NCT00480935|Localized
556221|NCT00480935|Renal Cell Carcinoma
556222|NCT00480935|Neoadjuvant
556223|NCT00480935|Sunitinib Malate (Sutent)
556224|NCT00480922|non-alcoholic fatty liver disease
556225|NCT00480922|steatohepatitis
556226|NCT00480922|overweight
556227|NCT00480922|insulin resistance
556228|NCT00480896|Dermatitis, atopic
556229|NCT00480896|Tacrolimus
556230|NCT00480896|Child
556231|NCT00480896|treatment outcomes
556232|NCT00480883|cutaneous leishmaniasis of the old world
556233|NCT00480870|Alzheimer
556234|NCT00480870|polysomnography
556235|NCT00480870|REM sleep
556236|NCT00480870|donepezil
556237|NCT00480870|sleep apnea
556238|NCT00480870|oxygen saturation
556239|NCT00480857|Prostate
556240|NCT00480857|Radiation
556241|NCT00480844|schizophrenia
556242|NCT00480844|Sertindole
556243|NCT00480844|Risperidone
556244|NCT00480844|cognitive impairment
556245|NCT00480831|NSCLC
556246|NCT00480831|Cancer
556247|NCT00480831|Avastin
556248|NCT00480831|APM4074g
556249|NCT00480792|Hepatitis B vaccination
556250|NCT00480792|GenHevac-B Pasteur
556251|NCT00480792|HIV Infections
556252|NCT00480779|Prediabetes
556253|NCT00480779|Metabolic syndrome
556254|NCT00480779|Prevention
556255|NCT00480779|Lifestyle intervention
556256|NCT00480766|Glucocorticoid
556257|NCT00480753|Raynaud's phenomenon
556258|NCT00480753|Raynaud's Disease
556259|NCT00480753|Raynaud's disease secondary to scleroderma
556260|NCT00480753|Raynaud's phenomenon secondary to autoimmune disease
556261|NCT00480740|Dexmedetomidine
556262|NCT00480740|Congenital heart disease
556263|NCT00480740|pharmacokinetics
556264|NCT00480740|pharmacodynamics
556265|NCT00480740|pediatric
556266|NCT00480740|Bidirectional cavopulmonary anastomosis
556267|NCT00480740|Fontan physiology
556268|NCT00480740|Cardiac transplant
556269|NCT00480727|Halo Thoracic Orthosis
556270|NCT00480727|Re-tension
556271|NCT00480727|Pin loosening
556272|NCT00480714|TB
556273|NCT00480714|Vaccine
556274|NCT00480714|BCG
556275|NCT00480701|Alzheimer
556276|NCT00480701|Parkinson
556277|NCT00480701|dementia
556278|NCT00480701|neurologic
556279|NCT00480688|TB
556280|NCT00480688|BCG
556281|NCT00480675|bursitis
556282|NCT00480675|injection
556283|NCT00480675|fluoroscopy
556284|NCT00480662|Paget's bone disease
556285|NCT00480597|gemcitabine
556286|NCT00480597|vinorelbine
556287|NCT00480597|cisplatin
556288|NCT00480597|capecitabine
556289|NCT00480597|pretreated metastatic breast cancer
556290|NCT00480584|pancreatic
556291|NCT00480584|gemcitabine
556292|NCT00480584|erlotinib (HER1/epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor)
556293|NCT00480584|capecitabine
556294|NCT00480571|chronic schizophrenia or schizo-affective disorder
556295|NCT00480558|HIV
556296|NCT00480558|MVA85A
556297|NCT00480558|TB
556298|NCT00480558|Tuberculosis
556299|NCT00480558|Human Immunodeficiency Virus
556300|NCT00480558|Safety
556301|NCT00480558|Immunogenicity
556302|NCT00480558|Efficacy
556303|NCT00480558|Treatment Naive
556304|NCT00480545|Women with bleeding disorders
556305|NCT00480545|Menstrual cycle
556306|NCT00480545|Women
556307|NCT00480545|Healthy volunteers
556308|NCT00480532|birth control
556309|NCT00480532|continuous contraception
556310|NCT00480532|break-through bleeding
556311|NCT00480519|meatotomy
556312|NCT00480519|meatal stenosis
556313|NCT00480519|local anaesthesia
556314|NCT00480519|feasibility
556315|NCT00480519|pain control
556316|NCT00480506|chimerism
556317|NCT00480506|allogenic hematopoietic transplantation
556318|NCT00480506|assay
556319|NCT00480480|Trauma
556320|NCT00480480|Grief
556321|NCT00480480|Depression
556322|NCT00480480|Adolescent
556323|NCT00480480|War
556324|NCT00480480|Group
556325|NCT00480480|Therapy
556326|NCT00480480|Treatment
556327|NCT00480480|Intervention
556328|NCT00480480|School
556329|NCT00480480|Development
556330|NCT00480454|TB
556331|NCT00480454|Tuberculosis
556332|NCT00480454|Infants
556333|NCT00480454|EPI
556334|NCT00480441|Marijuana
556335|NCT00480441|Addiction
556336|NCT00480441|Substance Withdrawal Syndrome
556337|NCT00480441|Clinical Trial
556338|NCT00480441|Dronabinol
556339|NCT00480441|Behavioral Therapy
556340|NCT00480441|Adults
556341|NCT00480441|Neuroimaging
556342|NCT00480441|Neuropsychological Testing
556343|NCT00480441|Neurocognitive Testing
556344|NCT00480441|Behavioral Probes
556345|NCT00480428|Radioactive Fallout
556346|NCT00480428|Childhood Exposures
556347|NCT00480428|External Radiation Dose
556348|NCT00480428|Internal Radiation Dose to Thyroid Gland
556349|NCT00480428|Pasture-Dairy Animal- Milk- Thyroid Pathway
556350|NCT00480402|preterm birth
556351|NCT00480402|progesterone
556352|NCT00480402|twins
556353|NCT00480402|Preterm birth in twin gestations
556354|NCT00480389|Clear cell Renal cell carcinoma
556355|NCT00480389|Metastatic
556356|NCT00480389|Sorafenib tosylate
556357|NCT00480389|Preoperative treatment
556358|NCT00480376|transrectal biopsy
556359|NCT00480376|prostate
556360|NCT00480376|prophylaxis antibiotic
556361|NCT00480363|Smoldering Multiple Myeloma
556362|NCT00480363|PETHEMA
556363|NCT00480363|Smoldering
556364|NCT00480350|HIV
556365|NCT00480350|virological response
556366|NCT00480350|CD4
556367|NCT00480350|food supplement
556368|NCT00480350|Human Immunodeficiency Virus
556369|NCT00480350|Complementary Therapies
556370|NCT00480337|PCOS
556371|NCT00480337|Fertility Preservation
556372|NCT00480337|Repeated IVF Failure
556373|NCT00480337|S/P Hyperstimulation
556374|NCT00480311|symptomatic
556375|NCT00480311|lumbar spinal stenosis
556376|NCT00480311|disability
556377|NCT00480311|fear avoidance beliefs
556378|NCT00480311|quality of life
556379|NCT00480285|Gastroesophageal reflux disease
556380|NCT00480285|Laparoscopic Nissen Fundoplication
556381|NCT00480285|Laparoscopic anterior partial fundoplication
556382|NCT00480272|rheumatoid arthritis
556383|NCT00480272|clinical remission
556384|NCT00480259|blood urea nitrogen
556385|NCT00480259|nitrogen balance
556386|NCT00480259|nutrition
556387|NCT00480259|intensive care
556388|NCT00480246|receptor oocupancy
556389|NCT00480233|depression
556390|NCT00480233|screening
556391|NCT00480233|primary care
556392|NCT00480233|validity
556393|NCT00480233|Hebrew
556394|NCT00480233|Primary care and general medical patients
556395|NCT00480220|specific care
556396|NCT00480220|assistance plan
556397|NCT00480220|Alzheimer's disease
556398|NCT00480181|Neuropathic pain
556399|NCT00480181|Multiple Sclerosis
556400|NCT00480181|Nabilone
556401|NCT00480181|Gabapentin
556402|NCT00480168|child
556403|NCT00480168|adolescent
556404|NCT00480168|weight gain
556405|NCT00480168|endocrine disruptors
556406|NCT00480129|grass allergies,
556407|NCT00480129|ragweed allergies,
556408|NCT00480129|probiotics, lactobacillus,
556409|NCT00480129|bifidobacterium,
556410|NCT00480129|functional foods,
556411|NCT00480129|yogurt,
556412|NCT00480129|inflammatory cytokines
556413|NCT00480116|Consistency
556414|NCT00480116|Immunogenicity
556415|NCT00480103|Embryo morphological and chromosomal features
556416|NCT00480103|Implantation and pregnancy rate
556417|NCT00480090|Prostate
556418|NCT00480090|Androgen independent
556419|NCT00480090|Phase II
556420|NCT00480090|Second line
556421|NCT00480090|Androgen-independent prostate cancer
556422|NCT00480077|Heart Failure, randomized, OptiVol® Fluid status monitoring
556423|NCT00480064|AML
556424|NCT00480064|older patients
556425|NCT00480064|lomustine
556426|NCT00480051|Cardiac Failure
556427|NCT00480051|Pacemaker
556428|NCT00480051|Dyssynchrony
556429|NCT00480051|Cardiac Magnetic Resonance
556430|NCT00480051|Narrow QRS
556431|NCT00480038|symptomatic
556432|NCT00480038|lumbar disc herniation
556433|NCT00480038|disability
556434|NCT00480038|fear avoidance beliefs
556435|NCT00480038|quality of life
556436|NCT00480025|ASCI
556437|NCT00480025|Immunotherapeutic
556438|NCT00480025|MAGRIT
556439|NCT00480025|Tumor antigen
556440|NCT00480025|Non-small-cell lung cancer
556441|NCT00480025|Adjuvant cancer therapy
556442|NCT00480012|healthy subjects
556443|NCT00479999|HIV-Negative
556444|NCT00479999|Healthy
556445|NCT00479999|Immunity
556446|NCT00479999|Preventive
556447|NCT00479999|Virus
556448|NCT00479999|Healthy Volunteer
556449|NCT00479999|HV
556450|NCT00479999|HIV Preventive Vaccine
556451|NCT00479986|diabetes mellitus
556452|NCT00479986|monocyte activation
556453|NCT00479986|cardiovascular risk
556454|NCT00479973|diabetes
556455|NCT00479973|non-insulin dependant diabetes
556456|NCT00479973|type 2 diabetes
556457|NCT00479973|cinnamon
556458|NCT00479973|natural health product
556459|NCT00479973|hypercholesterolemia
556460|NCT00479973|dyslipidemia
556461|NCT00479973|elevated cholesterol
556462|NCT00479960|Asthenozoospermia
556463|NCT00479960|Azoospermia
556464|NCT00479960|Oligospermia
556465|NCT00479960|Omega-3
556466|NCT00479960|Fatty Acids
556467|NCT00479947|Yeast vaginitis
556468|NCT00479947|Probiotics
556469|NCT00479947|Lactobacilli
556470|NCT00479947|Fluconazole
556471|NCT00479934|scleroderma
556472|NCT00479934|imatinib
556473|NCT00479934|PDGFR
556474|NCT00479934|Rodnan
556475|NCT00479921|Influenza
556476|NCT00479921|Vaccine
556477|NCT00479921|CHMP criteria
556478|NCT00479908|Blood pressure
556479|NCT00479908|Angina
556480|NCT00479908|Sildenafil
556481|NCT00479908|Phosphodiesterase type 5
556482|NCT00479908|Organic nitrate
556483|NCT00479908|Glyceryl trinitrate
556484|NCT00479908|Drug interaction
556485|NCT00479895|Percutaneous Coronary Intervention
556486|NCT00479895|Myocardial Ischemia
556487|NCT00479895|Balloon Occlusion
556488|NCT00479895|Catheter Lab
556489|NCT00479856|ErbB1
556490|NCT00479856|ErbB2
556491|NCT00479856|GW572016
556492|NCT00479856|lapatinib
556493|NCT00479856|Relapsed breast cancer
556494|NCT00479856|dual tyrosine kinase inhibitor
556495|NCT00479856|MBC
556496|NCT00479856|EGFR
556497|NCT00479856|Her-2/neu
556498|NCT00479856|FISH amplification
556499|NCT00479843|Alzheimer Disease
556500|NCT00479843|Dementia
556501|NCT00479843|Elderly
556502|NCT00479843|Nutrition
556503|NCT00479843|Malnutrition
556504|NCT00479843|Weight Loss
556505|NCT00479830|Epidemiology
556506|NCT00479830|Health Risks
556507|NCT00479830|Questionnaire
556508|NCT00479830|Interview
556509|NCT00479830|South Asian
556510|NCT00479830|Asian Indian
556511|NCT00479830|Bangladeshi
556512|NCT00479830|Pakistani
556513|NCT00479830|Sri Lankan
556514|NCT00479817|Advanced Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
556515|NCT00479804|indication for CMR
556516|NCT00479791|Type 2 diabetes mellitus
556517|NCT00479791|Fatty acids
556518|NCT00479791|Postprandial response
556519|NCT00479791|Insulin
556520|NCT00479791|Glucose
556521|NCT00479791|Triglycerides
556522|NCT00479778|Postmenopause
556523|NCT00479765|glioblastoma multiforme
556524|NCT00479765|recurrent
556525|NCT00479765|Phase 1
556526|NCT00479765|Phase 2
556527|NCT00479765|Phase I
556528|NCT00479765|Phase II
556529|NCT00479765|brain
556530|NCT00479765|cancer
556531|NCT00479765|paclitaxel
556532|NCT00479765|intracranial
556533|NCT00479765|tumor
556534|NCT00479765|local
556535|NCT00479765|chemotherapy
556536|NCT00479765|brain tumor
556537|NCT00479765|brain cancer
556538|NCT00479765|glioma
556539|NCT00479765|OncoGel
556540|NCT00479739|formoterol/budesonide
556541|NCT00479739|exacerbations
556542|NCT00479739|Salmeterol/fluticasone propionate
556543|NCT00479739|adjustable maintenance dosing
556544|NCT00479739|asthma control
556545|NCT00479713|High Cholesterol
556546|NCT00479687|Osteoarthritis
556547|NCT00479687|Shoulder
556548|NCT00479687|HA
556549|NCT00479674|Metastatic Breast Cancer
556550|NCT00479674|Advanced Breast Cancer
556551|NCT00479674|Hormone Receptor AND Her2/neu Negative
556552|NCT00479674|Triple Negative
556553|NCT00479674|Triple Negative Breast Cancer
556554|NCT00479674|Stage IV or Inoperable Stage III Breast Cancer
556555|NCT00479661|initial sedation
556556|NCT00479661|mechanical ventilation
556557|NCT00479635|HRPC
556558|NCT00479635|TPI 287
556559|NCT00479635|Taxane
556560|NCT00479635|MDR
556561|NCT00479635|Hormone Refractory Prostate Cancer
556562|NCT00479622|Membranous Nephropathy
556563|NCT00479622|Systemic Lupus Erythematosus
556564|NCT00479609|Insulin resistance
556565|NCT00479609|Glucose tolerance
556566|NCT00479609|Type 2 diabetes
556567|NCT00479609|Androgen sensitivity
556568|NCT00479596|Overactive Bladder
556569|NCT00479596|OAB
556570|NCT00479596|Refractory OAB
556571|NCT00479596|Botox
556572|NCT00479596|Bladder
556573|NCT00479583|Cancer (solid tumors)
556574|NCT00479557|Alzheimer's Disease
556575|NCT00479557|active immunization
556576|NCT00479531|Restless Legs Syndrome
556577|NCT00479531|Sequential Compression Device
556578|NCT00479531|Sleep Quality
556579|NCT00479531|Quality of Life
556580|NCT00479518|stroke
556581|NCT00479518|transient ischemic attack
556582|NCT00479518|albuminuria
556583|NCT00479518|BNP
556584|NCT00479518|Cystatin C
556585|NCT00479492|Obesity, weight loss
556586|NCT00479479|cobalamin
556587|NCT00479479|methylmalonic acid
556588|NCT00479479|homocysteine
556589|NCT00479479|folate
556590|NCT00479479|newborns
556591|NCT00479479|infants
556592|NCT00479479|Deficiency Disease
556593|NCT00479479|Breastfeeding
556594|NCT00479479|Infant
556595|NCT00479427|osteoarthritis pain assessments
556596|NCT00479375|screening
556597|NCT00479375|human papillomavirus
556598|NCT00479362|Pacemaker
556599|NCT00479362|Cardioverter-defibrillator
556600|NCT00479362|Hemorrhage
556601|NCT00479362|Hematoma
556602|NCT00479362|Thrombosis
556603|NCT00479362|Embolism
556604|NCT00479336|OPC-41061
556605|NCT00479336|Tolvaptan
556606|NCT00479336|ascites
556607|NCT00479336|Cirrhosis
556608|NCT00479323|pneumococcal vaccine, Pneumovax, reference sera, serum 89SF
556609|NCT00479284|Non-invasive ventilation
556610|NCT00479284|Polysomnography
556611|NCT00479284|Average volume assured pressure support
556612|NCT00479271|RCT
556613|NCT00479271|Dementia
556614|NCT00479271|community trial
556615|NCT00479271|Homebased care
556616|NCT00479271|caregiver burden
556617|NCT00479271|Behavioural problems
556618|NCT00479271|Dementia in subjects
556619|NCT00479271|behavioral problems in subjects
556620|NCT00479271|Mental health of carers
556621|NCT00479245|nonspecific low back pain
556622|NCT00479245|disability
556623|NCT00479245|fear avoidance beliefs
556624|NCT00479245|quality of life
556625|NCT00479232|Leukemia
556626|NCT00479232|Myelocytic
556627|NCT00479232|Acute Myelodysplastic Syndromes
556628|NCT00479206|artesuante
556629|NCT00479206|falciparum malaria
556630|NCT00479206|Cambodia
556631|NCT00479206|Artemisinin resistance
556632|NCT00479193|Burns
556633|NCT00479193|Dressing change
556634|NCT00479180|Hemodialysis access
556635|NCT00479180|Arteriovenous graft
556636|NCT00479180|Arteriovenous fistula
556637|NCT00479180|End stage renal disease
556638|NCT00479167|Non-Hodgkin's Lymphoma
556639|NCT00479167|Follicular Non-Hodgkin's Lymphoma
556640|NCT00479167|Lymphoma
556641|NCT00479154|Restless Leg Syndrome
556642|NCT00479154|Botulinum Toxin
556643|NCT00479154|RLS
556644|NCT00479141|Treatment Naive
556645|NCT00479141|Treatment Experienced
556646|NCT00479141|Complementary Therapies
556647|NCT00479128|Solid Tumor
556648|NCT00479128|Bladder Cancer
556649|NCT00479128|Ureteral Cancer
556650|NCT00479128|Urothelial Cancer
556651|NCT00479128|Urethral Cancer
556652|NCT00479128|Renal Pelvis Tumor
556653|NCT00479128|Bortezomib
556654|NCT00479128|Gemcitabine
556655|NCT00479128|Doxorubicin
556656|NCT00479128|Gemzar
556657|NCT00479128|Adriamycin
556658|NCT00479128|Velcade
556659|NCT00479128|LDP-341
556660|NCT00479128|MLN341
556661|NCT00479128|PS-341
556662|NCT00479128|Gemcitabine Hydrochloride
556663|NCT00479128|AD
556664|NCT00479128|Hydroxydaunomycin hydrochloride
556665|NCT00479102|Iron supplementation
556666|NCT00479102|Babies
556667|NCT00479102|Prevention
556668|NCT00479089|Transitional Cell Carcinoma
556669|NCT00479089|Urothelium
556670|NCT00479089|Urothelial Cancer
556671|NCT00479089|Bladder Cancer
556672|NCT00479089|Docetaxel
556673|NCT00479089|Taxotere
556674|NCT00479089|ZD1839
556675|NCT00479089|Gefitinib
556676|NCT00479089|Iressa
556677|NCT00479089|Consolidation Therapy
556678|NCT00479076|antineoplastic agents
556679|NCT00479076|VEGF Trap
556680|NCT00479063|MODIC changes
556681|NCT00479063|chronic low back pain
556682|NCT00479063|magnetic resonance imaging (MRI)
556683|NCT00479063|vertebrae
556684|NCT00479063|intervertebral disc
556685|NCT00479050|Hepatocellular carcinoma,treatment
556686|NCT00479037|postmenopausal women with primary osteoporosis
556687|NCT00479011|fluid management
556688|NCT00479011|arterial pulse pressure variation
556689|NCT00479011|high-risk surgery
556690|NCT00478998|expulsion therapy
556691|NCT00478998|tamsulosin
556692|NCT00478998|ureterolithiasis
556693|NCT00478998|stents
556694|NCT00478985|Leukemia
556695|NCT00478985|Adult Chronic
556696|NCT00478985|Myeloid
556697|NCT00478972|obese
556698|NCT00478972|diabetes
556699|NCT00478972|cannabinoid-1 receptor
556700|NCT00478959|Lenalidomide
556701|NCT00478959|Revlimid
556702|NCT00478959|Hodgkin's
556703|NCT00478959|Hodgkin
556704|NCT00478959|Hodgkin's Lymphoma
556705|NCT00478959|Hodgkin's Disease
556706|NCT00478959|Lymphoma
556707|NCT00478946|colorectal cancer
556708|NCT00478946|picoplatin
556709|NCT00478946|FOLFOX
556710|NCT00478946|FOLPI
556711|NCT00478946|chemotherapy
556712|NCT00478933|Arrhythmia
556713|NCT00478933|Ventricular
556714|NCT00478933|Atrial
556715|NCT00478933|Tachycardia
556716|NCT00478933|Fibrillation
556717|NCT00478933|Flutter
556718|NCT00478933|GNB3
556719|NCT00478933|GNAS
556720|NCT00478933|GNAQ
556721|NCT00478907|oculocardiac reflex; strabismus surgery;
556722|NCT00478894|Anterior cruciate ligament / injuries
556723|NCT00478894|Anterior cruciate ligament / surgery
556724|NCT00478894|knee injuries / surgery
556725|NCT00478894|outcomes research
556726|NCT00478894|prospective studies
556727|NCT00478894|osteoarthritis
556728|NCT00478868|MODIC changes
556729|NCT00478868|chronic low back pain
556730|NCT00478868|magnetic resonance imaging (MRI)
556731|NCT00478868|vertebrae
556732|NCT00478868|intervertebral disc
556733|NCT00478842|Gilles de la Tourette syndrome
556734|NCT00478842|Deep brain stimulation
556735|NCT00478842|Globus PALLIDUS
556736|NCT00478816|Bird flu
556737|NCT00478816|influenza vaccine
556738|NCT00478816|prepandemic vaccine
556739|NCT00478803|Standardized surgical procedure
556740|NCT00478803|Aortic root aneurysm
556741|NCT00478803|Dystrophic aortic insufficiency
556742|NCT00478803|Conservative aortic valve surgery
556743|NCT00478803|Aortic annuloplasty
556744|NCT00478803|Mechanical aortic valve replacement
556745|NCT00478803|Sinus of Valsalva
556746|NCT00478803|Cardiac Surgical Procedures
556747|NCT00478790|Glaucoma
556748|NCT00478790|Pterygium
556749|NCT00478790|collagen matrix
556750|NCT00478790|OculusGen
556751|NCT00478790|trabeculectomy
556752|NCT00478790|Anti scarring
556753|NCT00478790|pterygium recurrence
556754|NCT00478790|tissue engineering
556755|NCT00478790|ologen
556756|NCT00478790|Aeon Astron
556757|NCT00478777|CC-5013
556758|NCT00478777|Revlimid
556759|NCT00478777|Lenalidomide
556760|NCT00478777|Celgene
556761|NCT00478777|Multiple Myeloma
556762|NCT00478764|intraocular
556763|NCT00478764|triamcinolone
556764|NCT00478764|gatifloxicin
556765|NCT00478764|inflammation
556766|NCT00478764|visual acuity
556767|NCT00478751|Visible light, Long UVA,Pigmentation
556768|NCT00478751|Normal healthy volunteers with dark skin type.
556769|NCT00478738|b-agonist,
556770|NCT00478738|COPD.
556771|NCT00478738|pharmacodynamic,
556772|NCT00478738|pharmacokinetic,
556773|NCT00478738|anti muscarinic,
556774|NCT00478725|Metastatic Cancer
556775|NCT00478725|Advanced Cancer
556776|NCT00478712|Hirschsprung
556777|NCT00478699|SCAT
556778|NCT00478699|BRCA1
556779|NCT00478699|BRCA1 mRNA Levels
556780|NCT00478699|ADJUVANT
556781|NCT00478699|LUNG
556782|NCT00478699|GECP-SCAT
556783|NCT00478686|Breast Cancer
556784|NCT00478686|Dihydropyrimidine Dehydrogenase
556785|NCT00478686|DPYD
556786|NCT00478686|DPYD Variants
556787|NCT00478686|Toxicity
556788|NCT00478686|Capecitabine
556789|NCT00478686|Xeloda
556790|NCT00478673|NexStent
556791|NCT00478673|FilterWire EZ
556792|NCT00478673|Boston Scientific
556793|NCT00478673|Carotid Artery
556794|NCT00478673|Carotid Endarterectomy
556795|NCT00478673|Carotid Revascularization
556796|NCT00478647|Enzyme Replacement Therapy
556797|NCT00478647|Gaucher disease
556798|NCT00478647|glucocerebrosidase
556799|NCT00478647|beta-glucocerebrosidase
556800|NCT00478647|Acid beta-glucocerebrosidase
556801|NCT00478647|glucosylceramidase
556802|NCT00478647|D-glucosyl-N-acylsphingosine glucohydrolase
556803|NCT00478647|gene activation
556804|NCT00478647|human
556805|NCT00478634|Colorectal Cancer
556806|NCT00478634|Colorectal Carcinoma
556807|NCT00478634|Colorectal Tumors
556808|NCT00478634|Neoplasms, Colorectal
556809|NCT00478621|HPV
556810|NCT00478595|obese
556811|NCT00478595|diabetes
556812|NCT00478595|cannabinoid-1 receptor
556813|NCT00478582|Anemia
556814|NCT00478582|Visual scale
556815|NCT00478582|nephrological patients
556816|NCT00478582|Anemia in nephrological patients
556817|NCT00478556|CT scan
556818|NCT00478556|oral contrast
556819|NCT00478543|Loop diuretics
556820|NCT00478543|Chronic Kidney Disease
556821|NCT00478543|Hypertension
556822|NCT00478543|Blood pressure control
556823|NCT00478543|Left ventricular mass
556824|NCT00478517|Spinal trauma
556825|NCT00478517|erythropoietin
556826|NCT00478517|dose escalation study
556827|NCT00478504|anovulation
556828|NCT00478504|ovulation induction,
556829|NCT00478504|polycystic ovarian syndrome
556830|NCT00478504|clomifene citrate
556831|NCT00478504|letrozole
556832|NCT00478478|Stroke
556833|NCT00478478|Ischemic
556834|NCT00478478|Thrombus
556835|NCT00478478|Embolectomy
556836|NCT00478478|Thrombectomy
556837|NCT00478478|Merci
556838|NCT00478478|Concentric
556839|NCT00478478|Embolus
556840|NCT00478478|Embolism
556841|NCT00478478|Mechanical
556842|NCT00478465|chronic fatigue syndrome
556843|NCT00478465|fatigue
556844|NCT00478465|valganciclovir
556845|NCT00478465|valcyte
556846|NCT00478465|Epstein-Barr virus
556847|NCT00478465|EBV
556848|NCT00478465|Human herpes virus 6
556849|NCT00478465|HHV 6
556850|NCT00478465|herpes viruses
556851|NCT00478465|herpes
556852|NCT00478439|aging
556853|NCT00478439|age-related macular degeneration
556854|NCT00478439|macular pigment
556855|NCT00478439|dark adaptation
556856|NCT00478400|Recovery
556857|NCT00478400|Magnetic resonance imaging
556858|NCT00478400|Awareness
556859|NCT00478400|Neurologic deficits
556860|NCT00478387|Advanced Ovarian and Primary Peritoneal Cancer in Remission
556861|NCT00478348|Postoperative Complications
556862|NCT00478348|Drainage
556863|NCT00478348|Infection
556864|NCT00478348|Seroma
556865|NCT00478348|Hematoma
556866|NCT00478348|Recurrence
556867|NCT00478348|Abdominal Wall
556868|NCT00478348|Hernia
556869|NCT00478348|Surgical Mesh
556870|NCT00478335|congenital nephrogenic diabetes insipidus
556871|NCT00478335|polyuria
556872|NCT00478335|urine osmolality
556873|NCT00478335|aquaporin-2
556874|NCT00478335|vasopressin V2 receptor
556875|NCT00478322|Diabetes;
556876|NCT00478322|Type II diabetes;
556877|NCT00478322|Non-insulin dependent diabetes;
556878|NCT00478322|Obesity
556879|NCT00478309|colon cancer
556880|NCT00478309|rectal cancer
556881|NCT00478309|healthy, no evidence of disease
556882|NCT00478296|Pulmonary hypertension
556883|NCT00478296|Sildenafil
556884|NCT00478296|Bosentan
556885|NCT00478296|Trisomy 21
556886|NCT00478296|Atrial septal defect
556887|NCT00478283|breast cancer
556888|NCT00478257|fatigue
556889|NCT00478257|sleep
556890|NCT00478257|quality of life
556891|NCT00478257|light
556892|NCT00478257|cancer
556893|NCT00478244|epidermolysis bullosa
556894|NCT00478244|dystrophic epidermolysis bullosa
556895|NCT00478231|Multicenter
556896|NCT00478231|Open Label
556897|NCT00478231|Non-Comparative Safety Study Of Maraviroc
556898|NCT00478231|Treatment Experienced
556899|NCT00478218|stage I multiple myeloma
556900|NCT00478218|stage II multiple myeloma
556901|NCT00478218|stage III multiple myeloma
556902|NCT00478205|Moderate to Severe Alzheimer's Disease
556903|NCT00478192|hyponatremia
556904|NCT00478192|hypervolemic
556905|NCT00478192|euvolemic
556906|NCT00478192|edematous
556907|NCT00478192|conivaptan
556908|NCT00478179|herpes zoster
556909|NCT00478179|shingles
556910|NCT00478179|PHN
556911|NCT00478179|post herpetic neuralgia
556912|NCT00478179|neuropathic pain
556913|NCT00477334|Recurrent genital herpes
556914|NCT00477334|Black population
556915|NCT00477321|Interleukin 7
556916|NCT00477321|Immune Reconstitution
556917|NCT00477321|T Cell Turnover
556918|NCT00477321|CD4 Lymphenia
556919|NCT00477321|Immune-Based Therapies
556920|NCT00477321|HIV Infection
556921|NCT00477308|HIV children
556922|NCT00477308|genotypic resistance
556923|NCT00477308|dual NRTIs
556924|NCT00477308|Salvage therapy
556925|NCT00477308|treatment outcome
556926|NCT00477308|Salvage therapy based on genotyping results
556927|NCT00477308|Treatment Failure
556928|NCT00477295|Epilepsy
556929|NCT00477282|Ovarian
556930|NCT00477282|Cancer
556931|NCT00477282|Advanced Ovarian Cancer
556932|NCT00477269|Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571
556933|NCT00477256|Pediatric Cancer
556934|NCT00477256|Child Adjustment
556935|NCT00477256|School Reintegration
556936|NCT00477256|Caregiver
556937|NCT00477256|Questionnaire
556938|NCT00477256|Quality of Life
556939|NCT00477256|Survey
556940|NCT00477243|Advanced Cancer
556941|NCT00477243|Palliative Care Patients
556942|NCT00477243|Spirituality
556943|NCT00477243|Locus of Control
556944|NCT00477243|Questionnaire
556945|NCT00477230|AF
556946|NCT00477230|PAF
556947|NCT00477230|paroxysmal atrial fibrillation
556948|NCT00477230|ablation
556949|NCT00477230|failed drugs
556950|NCT00477217|Osteonecrosis
556951|NCT00477217|zoledronic acid
556952|NCT00477217|knee
556953|NCT00478114|Renal Cell Carcinoma
556954|NCT00478114|Sorafenib
556955|NCT00478101|Pain
556956|NCT00478088|Single Level
556957|NCT00478088|Cervical Disc Disease
556958|NCT00478075|stage I multiple myeloma
556959|NCT00478075|stage II multiple myeloma
556960|NCT00478075|stage III multiple myeloma
556961|NCT00478075|refractory multiple myeloma
556962|NCT00478062|stage I adult Hodgkin lymphoma
556963|NCT00478062|stage II adult Hodgkin lymphoma
556964|NCT00478062|stage III adult Hodgkin lymphoma
556965|NCT00478062|stage IV adult Hodgkin lymphoma
556966|NCT00478049|Non-Small Cell Lung Cancer
556967|NCT00478036|glaucoma
556968|NCT00478036|selective laser trabeculoplasty
556969|NCT00478036|anterior chamber flare
556970|NCT00478023|Opioid
556971|NCT00478023|Central acting analgesic
556972|NCT00478023|Pain postoperative
556973|NCT00478023|Abdomen acute
556974|NCT00478023|CG5503 IR
556975|NCT00478023|Morphine
556976|NCT00478023|Placebo
556977|NCT00478010|psychosocial effects of cancer and its treatment
556978|NCT00478010|stage III colon cancer
556979|NCT00478010|stage IV colon cancer
556980|NCT00478010|stage III rectal cancer
556981|NCT00478010|stage IV rectal cancer
556982|NCT00478010|stage II pancreatic cancer
556983|NCT00478010|stage III pancreatic cancer
556984|NCT00478010|stage IV pancreatic cancer
556985|NCT00477997|Growth Hormone
556986|NCT00477997|Insulin Signaling
556987|NCT00477997|GH signaling
556988|NCT00477984|Alcohol
556989|NCT00477984|Driving
556990|NCT00477984|Multitasking
556991|NCT00477984|ERP
556992|NCT00477984|social drinkers
556993|NCT00477971|primary systemic amyloidosis
556994|NCT00477958|cognitive/functional effects
556995|NCT00477958|psychosocial effects of cancer and its treatment
556996|NCT00477958|unspecified adult solid tumor, protocol specific
556997|NCT00477945|Non Hodgkin's Lymphoma
556998|NCT00477945|High Risk or Refractory Non Hodgkin's Lymphoma
556999|NCT00477945|APBSCT
557000|NCT00477945|clofarabine
557001|NCT00477932|Pentalogy of Cantrell
557002|NCT00477932|mutations
557003|NCT00477932|DNA
557004|NCT00477932|RNA
557005|NCT00477919|stage IV melanoma
557006|NCT00477919|stage IV renal cell cancer
557007|NCT00477919|unresectable extrahepatic bile duct cancer
557008|NCT00477919|advanced malignant mesothelioma
557009|NCT00477919|stage IV prostate cancer
557010|NCT00477919|adult giant cell glioblastoma
557011|NCT00477919|adult gliosarcoma
557012|NCT00477919|extensive stage small cell lung cancer
557131|NCT00477555|aortic valve
557013|NCT00477919|stage IV non-small cell lung cancer
557014|NCT00477919|stage IV colon cancer
557015|NCT00477919|stage IV gastric cancer
557016|NCT00477919|stage IV esophageal cancer
557017|NCT00477919|stage IV bladder cancer
557018|NCT00477919|male breast cancer
557019|NCT00477919|stage IV breast cancer
557020|NCT00477919|stage IV ovarian epithelial cancer
557021|NCT00477919|stage IV ovarian germ cell tumor
557022|NCT00477919|ovarian sarcoma
557023|NCT00477919|ovarian stromal cancer
557024|NCT00477919|fatigue
557025|NCT00477919|anorexia
557026|NCT00477919|cachexia
557027|NCT00477919|pain
557028|NCT00477919|weight changes
557029|NCT00477919|depression
557030|NCT00477919|poor performance status
557031|NCT00477919|recurrent adult brain tumor
557032|NCT00477919|clear cell sarcoma of the kidney
557033|NCT00477919|advanced adult primary liver cancer
557034|NCT00477919|recurrent adult primary liver cancer
557035|NCT00477919|recurrent small cell lung cancer
557036|NCT00477919|recurrent bladder cancer
557037|NCT00477919|recurrent breast cancer
557038|NCT00477919|recurrent colon cancer
557039|NCT00477919|recurrent esophageal cancer
557040|NCT00477919|recurrent gastric cancer
557041|NCT00477919|recurrent melanoma
557042|NCT00477919|recurrent non-small cell lung cancer
557043|NCT00477919|recurrent ovarian epithelial cancer
557044|NCT00477919|recurrent ovarian germ cell tumor
557045|NCT00477919|stage IV pancreatic cancer
557046|NCT00477919|recurrent prostate cancer
557047|NCT00477919|recurrent renal cell cancer
557048|NCT00477919|recurrent pancreatic cancer
557049|NCT00477919|stage IV rectal cancer
557050|NCT00477919|recurrent rectal cancer
557051|NCT00477919|recurrent malignant mesothelioma
557052|NCT00477919|recurrent carcinoma of unknown primary
557053|NCT00477919|stage IV adult soft tissue sarcoma
557054|NCT00477919|recurrent adult soft tissue sarcoma
557055|NCT00477919|stage IV uterine sarcoma
557056|NCT00477919|recurrent uterine sarcoma
557057|NCT00477919|recurrent extrahepatic bile duct cancer
557058|NCT00477919|unresectable gallbladder cancer
557059|NCT00477919|recurrent gallbladder cancer
557060|NCT00477919|adult glioblastoma
557061|NCT00477906|melanoma
557062|NCT00477906|vaccine
557063|NCT00477906|metastatic
557064|NCT00477906|autologous
557065|NCT00477880|gastric cancer
557066|NCT00477880|giant hypertrophic gastritis
557067|NCT00477867|stage III ovarian epithelial cancer
557068|NCT00477841|esophageal Cancer
557069|NCT00477841|Dysphagia
557070|NCT00477841|Stent
557071|NCT00477841|interstitial brachytherapy
557072|NCT00477828|sleep apnea
557073|NCT00477828|dementia
557074|NCT00477828|excessive sleepiness
557075|NCT00477828|cognition
557076|NCT00477815|stage I multiple myeloma
557077|NCT00477815|refractory multiple myeloma
557078|NCT00477815|stage II multiple myeloma
557079|NCT00477815|stage III multiple myeloma
557080|NCT00477802|Parkinson's disease
557081|NCT00477802|levodopa-induced cervical dyskinesias
557082|NCT00477789|chronic heart failure
557083|NCT00477789|diastolic dysfunction
557084|NCT00477789|uric acid
557085|NCT00477776|Beginning of breastfeeding
557086|NCT00477750|stage I multiple myeloma
557087|NCT00477750|stage II multiple myeloma
557088|NCT00477750|stage III multiple myeloma
557089|NCT00477737|cardioprotection
557090|NCT00477737|sevoflurane
557091|NCT00477737|esophageal Doppler
557092|NCT00477737|thermodilution
557093|NCT00477737|coronary artery bypass
557094|NCT00477724|latent
557095|NCT00477711|Cetuximab
557096|NCT00477711|cisplatin
557097|NCT00477711|capecitabine
557098|NCT00477711|first line treatment
557099|NCT00477685|Glaucoma
557100|NCT00477685|Collagen matrix
557101|NCT00477685|OculusGen
557102|NCT00477685|Phacotrabeculectomy
557103|NCT00477685|anti scarring
557104|NCT00477685|tissue engineering
557105|NCT00477685|ologen
557106|NCT00477685|Aeon Astron
557107|NCT00477672|Parkinson's disease, psychotic disorders
557108|NCT00477659|fMRI study; open-label donepezil
557109|NCT00477646|colon cancer
557110|NCT00477646|rectal cancer
557111|NCT00477646|breast cancer
557112|NCT00477646|cervical cancer
557113|NCT00477633|Contraception
557114|NCT00477620|Myopia
557115|NCT00477620|Prevention
557116|NCT00477594|Familial Hypercholesterolemia
557117|NCT00477594|Heterozygous Familial Hypercholesterolemia
557118|NCT00477594|Homozygous Familial Hypercholesterolemia
557119|NCT00477594|ISIS 301012
557120|NCT00477594|mipomersen
557121|NCT00477594|Open Label Extension
557122|NCT00477581|diabetes
557123|NCT00477581|exenatide
557124|NCT00477581|sitagliptin
557125|NCT00477581|Amylin
557126|NCT00477581|Lilly
557127|NCT00477568|Wheelchair users
557128|NCT00477568|Back pain
557129|NCT00477568|Prevalence
557130|NCT00477568|Risk factors
557132|NCT00477555|concomitant procedures
557133|NCT00477555|porcine bioprosthesis
557134|NCT00477555|stented valve
557135|NCT00477542|Clofarabine
557136|NCT00477542|allogeneic HSCT
557137|NCT00477542|refractory malignancies
557138|NCT00477503|Central Nervous System Tumors
557139|NCT00477503|Brain Tumors
557140|NCT00477503|Leptomeningeal Metastasis
557141|NCT00477503|Cerebral Spinal Fluid
557142|NCT00477503|Human CSF Flow
557143|NCT00477503|Nuclear Imaging
557144|NCT00477503|Gallium-67 Citrate
557145|NCT00477503|In-111 DTPA
557146|NCT00477477|overweight
557147|NCT00477477|metabolic syndrome
557148|NCT00477477|adolescent
557149|NCT00477477|cardiovascular
557150|NCT00477477|risk factors
557151|NCT00477477|hypertension
557152|NCT00477477|dyslipidemia
557153|NCT00477477|inflammation
557154|NCT00477477|coagulopathy
557155|NCT00477464|dual kinase inhibitor,
557156|NCT00477464|EGFR/ErbB1,
557157|NCT00477464|ErbB2-overexpressing,
557158|NCT00477464|GW572016,
557159|NCT00477464|advanced/metastatic breast cancer, Lapatinib,
557160|NCT00477464|HER-2/new,
557161|NCT00477464|pharmacokinetics
557162|NCT00477451|Staccato™ Alprazolam, Panic Attack
557163|NCT00477425|Avastin
557164|NCT00477412|Mantle Cell Lymphoma
557165|NCT00477412|Lymphoma
557166|NCT00477412|Bortezomib
557167|NCT00477412|LDP-341
557168|NCT00477412|MLN341
557169|NCT00477412|Velcade
557170|NCT00477412|Cyclophosphamide
557171|NCT00477412|Neosar
557172|NCT00477412|Cytoxan
557173|NCT00477412|Doxorubicin
557174|NCT00477412|Adriamycin
557175|NCT00477412|Rubex
557176|NCT00477412|Rituximab
557177|NCT00477412|Vincristine
557178|NCT00477412|Methotrexate
557179|NCT00477412|Cytarabine
557180|NCT00477412|Cytosar
557181|NCT00477412|DepoCyt
557182|NCT00477412|Cytosine arabinosine hydrochloride
557183|NCT00477412|Mesna
557184|NCT00477412|Dexamethasone
557185|NCT00477399|Obesity
557186|NCT00477399|Weight loss maintenance
557187|NCT00477399|QOL
557188|NCT00477399|Life Style
557189|NCT00477399|Follow Up
557190|NCT00477386|recurrent ovarian cancer
557191|NCT00477386|platinum resistant
557192|NCT00477386|decitabine
557193|NCT00477347|Liver Transplantation
557194|NCT00477347|Anesthesia, general
557195|NCT00477347|Closed-loop
557196|NCT00477204|Type 1 Diabetes Mellitus
557197|NCT00477204|dyslipidemia
557198|NCT00477204|adolescents
557199|NCT00477191|psoriasis
557200|NCT00477191|metabolic syndrome
557201|NCT00477191|Syndrome X
557202|NCT00477191|diabetes
557203|NCT00477191|insulin resistance
557204|NCT00477191|obesity
557205|NCT00477191|hypertension
557206|NCT00477191|hyperlipidemia
557207|NCT00477191|hypercholesterolemia
557208|NCT00477178|possible problems using codeine when driving
557209|NCT00477165|Irritable bowel syndrome
557210|NCT00477165|Antidepressant
557211|NCT00477165|IBS
557212|NCT00477165|Serotonin-reuptake inhibitor
557213|NCT00477165|SSRI
557214|NCT00477165|Visceral sensitivity
557215|NCT00477165|Barostat
557216|NCT00477165|Quality of life
557217|NCT00477165|Depression
557218|NCT00477152|dehydration
557219|NCT00477152|fluid therapy
557220|NCT00477152|pediatrics
557221|NCT00477152|emergency medicine
557222|NCT00477152|hyaluronoglucosaminidase
557223|NCT00477152|hyaluronidase
557224|NCT00477152|hypodermoclysis
557225|NCT00477152|clysis
557226|NCT00477152|subcutaneous hydration
557227|NCT00477152|subcutaneous rehydration
557228|NCT00477152|hyaluronan
557229|NCT00477152|rHuPH20
557230|NCT00477126|ritonavir generic capsule
557231|NCT00477126|Norvir®
557232|NCT00477126|Thailand
557233|NCT00477126|Determine bioequivalence between Norvir and GPO ritonavir
557234|NCT00477113|natalizumab
557235|NCT00477113|MS
557236|NCT00477113|Tysabri
557237|NCT00477113|Multiple Sclerosis
557238|NCT00477113|TYGRIS
557239|NCT00477100|Inflammatory Breast Cancer
557240|NCT00477100|Cancer Registry
557241|NCT00477100|Core Biopsy
557242|NCT00477100|Skin Biopsy
557243|NCT00477100|IBC
557244|NCT00477074|chronic obstructive pulmonary disease
557245|NCT00477074|emphysema
557246|NCT00477074|inflammation
557247|NCT00477074|repair
557248|NCT00477061|MORPHINE
557249|NCT00477061|ANALGESIA
557250|NCT00477061|ACUTE APPENDICITS
557251|NCT00477048|IDV nephrotoxicity
557252|NCT00477022|Diabetic Foot Ulcer
557253|NCT00477022|Vacuum compression therapy
557254|NCT00477022|Stereology
557255|NCT00477022|Ulcer Area
557256|NCT00477022|Vasotrain
557257|NCT00477022|Random Controlled Trial.
557258|NCT00477009|Sleep apnea syndromes
557259|NCT00477009|Snoring
557260|NCT00477009|Mandibular advancement
557261|NCT00477009|Activator appliances
557262|NCT00477009|Disorders of excessive somnolence
557263|NCT00477009|Blood pressure
557264|NCT00477009|Inflammation
557265|NCT00477009|Oxidative stress
557266|NCT00477009|Hormones
557267|NCT00477009|Markers of Metabolic Syndrome X
557268|NCT00476996|RA
557269|NCT00476996|SCRIPT
557270|NCT00476996|anti-CD20
557271|NCT00476996|CD20
557272|NCT00476983|saquinavir/ritonavir 1500/100 mg once daily
557273|NCT00476970|Colorectal Cancer
557274|NCT00476970|Cancer Screening
557275|NCT00476970|Patient Navigation
557276|NCT00476970|Low English Proficiency
557277|NCT00476957|Drug Eluting Stents
557278|NCT00476957|Interventional Cardiology
557279|NCT00476944|CAD
557280|NCT00476944|Coronary Artery Disease
557281|NCT00476944|Angiomax
557282|NCT00476944|Bivalirudin
557283|NCT00476944|PCI
557284|NCT00476944|MAVE
557285|NCT00476944|Heparin
557286|NCT00476931|Diabetic neuropathy
557287|NCT00476931|Diabetes Type 1 or 2
557288|NCT00476931|Moderate to severe sensorimotor diabetic polyneuropathy
557289|NCT00476931|Unmeasurable nerve conduction velocity
557290|NCT00476918|diabetic macular edema
557291|NCT00476918|triamcinolone acetonide
557292|NCT00476918|intravitreal
557293|NCT00476918|steroid
557294|NCT00476905|Basal Cell Carcinoma
557295|NCT00476905|Squamous Cell Carcinoma
557296|NCT00476905|Pre-Cancer Lesions
557297|NCT00476905|Pigmented Lesions
557298|NCT00476905|Benign Lesions
557299|NCT00476905|Skin Cancer
557300|NCT00476905|Spectral Diagnosis
557301|NCT00476905|Optical Spectroscopy
557302|NCT00476892|Pelvic organ prolapse
557303|NCT00476892|Pelvic floor muscle training
557304|NCT00476892|Prolapse symptoms
557305|NCT00476892|Urinary symptoms
557306|NCT00476892|Sexual function
557307|NCT00476892|randomised controlled trial
557308|NCT00476879|Growth hormone
557309|NCT00476879|Fasting
557310|NCT00476879|Signaltransduction
557311|NCT00476879|fatty liver
557312|NCT00476879|insulin sensitivity
557313|NCT00476879|forearm model
557314|NCT00476879|protein metabolism
557315|NCT00476879|respiratory quotient
557316|NCT00476866|Paraplegia
557317|NCT00476866|tetraplegia
557318|NCT00476866|lung compliance
557319|NCT00476866|work of breathing
557320|NCT00476866|hyperinflation
557321|NCT00476866|rehabilitation
557322|NCT00476853|HIV-TB
557323|NCT00476853|nevirapine based HAART with rifampin treated TB
557324|NCT00476853|Compare PK profile, efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus 600 mg/day in HIV/TB co-infected patients
557325|NCT00476853|Treatment Naive
557326|NCT00476827|Breast Cancer
557327|NCT00476827|Metastatic
557328|NCT00476827|Brain
557329|NCT00476827|Anti-angiogenesis
557330|NCT00476814|cystic fibrosis,
557331|NCT00476814|nasal potential difference,
557332|NCT00476814|primary sclerosing cholangitis
557333|NCT00476801|UVA1
557334|NCT00476801|scleroderma
557335|NCT00476801|keloids
557336|NCT00476801|light therapy
557337|NCT00476801|morphea
557338|NCT00476788|pediatrics
557339|NCT00476788|CSII
557340|NCT00476788|diabetes
557341|NCT00476788|C-peptide
557342|NCT00476788|adverse events
557343|NCT00476775|obesity
557344|NCT00476775|prevention
557345|NCT00476775|girls
557346|NCT00476775|Latina/Hispanic
557347|NCT00476775|Dance
557348|NCT00476775|television
557349|NCT00476775|screen time
557350|NCT00476736|COPD
557351|NCT00476736|Pulmonary function
557352|NCT00476736|Air trapping
557353|NCT00476736|Acetyl cystein
557354|NCT00476723|HIV infection
557355|NCT00476723|Hepatitis coinfection
557356|NCT00476710|Type 2 diabetes mellitus
557357|NCT00476710|Bile acid
557358|NCT00476710|Stable isotope
557359|NCT00476710|Colesevelam HCl
557360|NCT00476710|Impaired Glucose Tolerance
557361|NCT00476697|UVA1
557362|NCT00476697|scleroderma
557363|NCT00476697|keloids
557364|NCT00476697|morphea
557365|NCT00476697|light therapy
557366|NCT00476684|radiofrequency
557367|NCT00476671|neuropsychiatric
557368|NCT00476671|neurocognitive
557369|NCT00476671|psychiatric
557370|NCT00476671|HIV related dementia
557371|NCT00476671|MCMD
557372|NCT00476671|HIV-1
557373|NCT00476671|Prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in HIV-1 infected patients with undetectable viral load in the HAART era.
557374|NCT00476671|Treatment Experienced
557375|NCT00476658|Obesity
557376|NCT00476658|macrophage infiltration
557377|NCT00476658|insulinoresistance
557378|NCT00476658|inflammation
557379|NCT00476632|Epidemiology
557380|NCT00476632|Questionnaire
557381|NCT00476632|Controls
557382|NCT00476619|Contrast
557383|NCT00476619|Nephropathy
557384|NCT00476619|acute renal failure
557385|NCT00476619|Erythropoietin
557386|NCT00476619|CT scan
557387|NCT00476606|HIV children
557388|NCT00476606|HAART
557389|NCT00476606|ARV
557390|NCT00476606|Second line HAART
557391|NCT00476606|Viral Load
557392|NCT00476606|Combination drug
557393|NCT00476606|Treatment Experienced
557394|NCT00476606|Treatment Naive
557395|NCT00476593|Uveitis
557396|NCT00476593|Iritis
557397|NCT00476593|Macular Thickness
557398|NCT00476593|HLA-B27 related
557399|NCT00476593|Macular edema
557400|NCT00476593|Macular thickening
557401|NCT00476593|OCT
557402|NCT00476593|mfERG
557403|NCT00476593|Eye drops
557404|NCT00476593|Dexamethosone
557405|NCT00476593|Diclofenac
557406|NCT00476593|Retinal aging
557407|NCT00476580|Sri Lankan Sinhalese
557408|NCT00476580|Epidemiology
557409|NCT00476580|Cancer Risk
557410|NCT00476580|US Migrant
557411|NCT00476580|Questionnaire
557412|NCT00476580|Survey
557413|NCT00476580|Acculturation
557414|NCT00476580|Health and Cancer Risks
557415|NCT00476580|Health Habits
557416|NCT00476567|exercise
557417|NCT00476567|pregnancy
557418|NCT00476567|prevention
557419|NCT00476567|pregnancy-related diseases
557420|NCT00476567|labor
557421|NCT00476567|complications
557422|NCT00476567|physiotherapy
557423|NCT00476554|CTCL
557424|NCT00476541|AML
557425|NCT00476541|Children
557426|NCT00476541|Gemtuzumab ozogamicin
557427|NCT00476541|Stem cell transplantation
557428|NCT00476528|Posttraumatic amnesia
557429|NCT00476528|Early intervention
557430|NCT00476528|A systematic nursing programme in the ICU
557431|NCT00476528|Early identification of patients with posttraumatic amnesia
557432|NCT00476515|Kidney transplantation
557433|NCT00476515|Donor specific antibodies
557434|NCT00476515|Positive cross match
557435|NCT00476502|genetic polymorphism
557436|NCT00476502|CYP 3A
557437|NCT00476502|MDR-1
557438|NCT00476502|Thai
557439|NCT00476502|HIV
557440|NCT00476502|Treatment Experienced
557441|NCT00476489|secondary adrenal insuffiency
557442|NCT00476489|hypothalamus-pituitary-adrenal axis impairement
557443|NCT00476489|topical steroids
557444|NCT00476476|Tarceva
557445|NCT00476476|erlotinib
557446|NCT00476476|squamous cell carcinoma of the vulvar
557447|NCT00476463|TDF+FTC
557448|NCT00476463|FTC
557449|NCT00476463|HIV/HBV
557450|NCT00476463|TDF compared to TDF+FTC in HIV/HBV
557451|NCT00476463|Treatment Naive
557452|NCT00476450|Oral Microbial Flora
557453|NCT00476450|Hematopoietic Stem Cell Transplant
557454|NCT00476450|Allogeneic Stem Cell Transplant
557455|NCT00476424|once daily Efavirenz 400 mg
557456|NCT00476424|PK once daily Efavirenz 400 mg versus 600 mg
557457|NCT00476424|Treatment Experienced
557458|NCT00476411|isolated HBc
557459|NCT00476411|HBV vaccine response
557460|NCT00476411|occult HBV in isolated antiHBC compared HIV to non HIV
557461|NCT00476398|Capsule endoscopy
557462|NCT00476398|Wireless imaging
557463|NCT00476398|esophagus
557464|NCT00476398|stomach
557465|NCT00476372|neuropsychology
557466|NCT00476372|cognitive impairment
557467|NCT00476372|motor disorder
557468|NCT00476372|parkinson's disease
557469|NCT00476359|Lopinavir/r
557470|NCT00476359|Saquinavir
557471|NCT00476359|Dual boosted PIs
557472|NCT00476359|Pharmacokinetics
557473|NCT00476359|HIV children
557474|NCT00476359|C min
557475|NCT00476359|Second line HAART
557476|NCT00476359|ARV
557477|NCT00476359|VL failure
557478|NCT00476359|Dosage
557479|NCT00476359|To evaluate treatment response
557480|NCT00476359|Treatment Experienced
557481|NCT00476346|physical training
557482|NCT00476346|military training
557483|NCT00476346|bone
557484|NCT00476346|fracture prevention
557485|NCT00476346|young adult
557486|NCT00476333|EMG
557487|NCT00476333|Kinetics
557488|NCT00476333|Kinematics
557489|NCT00476333|Perturbation
557490|NCT00476333|Footwear
557491|NCT00476320|echocardiography
557492|NCT00476320|myocardial infarction
557493|NCT00476320|magnetic resonance imaging
557494|NCT00476320|revascularization
557495|NCT00476320|viability
557496|NCT00476307|Flu vaccine
557497|NCT00476294|Multiple Myeloma
557498|NCT00476294|Disease-Free Survival
557499|NCT00476294|AMD3100
557500|NCT00476294|G-CSF
557501|NCT00476294|Autologous Transplantation
557502|NCT00476255|child safety restraint
557503|NCT00476255|injury prevention
557504|NCT00476255|automotive
557505|NCT00476242|heroin abuse
557506|NCT00476242|opiate abuse
557507|NCT00476242|opioid dependence
557508|NCT00476242|naltrexone
557509|NCT00476242|memantine
557510|NCT00476229|Non-Hodgkin's Lymphoma
557511|NCT00476229|Chronic Lymphocytic Leukemia
557512|NCT00476229|Hodgkin's Lymphoma
557513|NCT00476229|Lymphoma
557514|NCT00476229|Leukemia
557515|NCT00476229|Mycophenolate Mofetil
557516|NCT00476229|Tacrolimus
557517|NCT00476229|Thymoglobulin
557518|NCT00476229|Total Lymphoid Irradiation
557519|NCT00476216|Non-Small Cell Lung Cancer
557520|NCT00476216|Venous Thromboembolism
557521|NCT00476216|VTE
557522|NCT00476216|Arixtra
557523|NCT00476203|Breast Cancer
557524|NCT00476203|Yoga
557525|NCT00476203|Quality of Life
557526|NCT00476203|Obesity
557527|NCT00476203|Fatigue
557528|NCT00476203|Weight
557529|NCT00476190|ALL
557530|NCT00476177|DC
557531|NCT00476177|DLI
557532|NCT00476177|graft vs. host disease
557533|NCT00476177|GVHD
557534|NCT00476164|chronic allograft nephropathy
557535|NCT00476164|C4d
557536|NCT00476164|Anti-CD20
557537|NCT00476164|B cells
557538|NCT00476164|Antibody
557539|NCT00476151|DPN
557540|NCT00476151|Diabetic
557541|NCT00476151|Nerve Pain
557542|NCT00476138|Epigallocatechin-Gallate
557543|NCT00476138|Glaucoma
557544|NCT00476138|Optic Nerve
557545|NCT00476138|Pattern Electroretinogram
557546|NCT00476138|Retinal Ganglion Cells
557547|NCT00476112|Atrial flutter
557548|NCT00476112|RSD1235
557549|NCT00476086|oxaliplatin
557550|NCT00476086|gemcitabine
557551|NCT00476086|MMMT
557552|NCT00476060|Cirrhosis
557553|NCT00476060|Bone marrow
557554|NCT00476060|Mesenchymal stem cell
557555|NCT00476060|MELD score
557556|NCT00476060|Quality of life
557557|NCT00476034|Osteoarthritis
557558|NCT00476034|lumiracoxib
557559|NCT00476034|celecoxib
557560|NCT00476034|Cox-2
557561|NCT00476034|knee
557562|NCT00476021|postpartum
557563|NCT00476021|contraception
557564|NCT00476021|postplacental IUD
557565|NCT00476021|intrauterine devices
557566|NCT00476008|Alzheimer's Disease
557567|NCT00476008|Mild Alzheimer's Disease
557568|NCT00476008|Driving
557569|NCT00476008|Driving Impairment
557570|NCT00475982|Diet
557571|NCT00475982|Insulin-like Growth Factor
557572|NCT00475982|Weight Loss
557573|NCT00475956|Cancer
557574|NCT00475956|Tumour
557575|NCT00475956|Advanced Solid Tumour
557576|NCT00475956|Lung Cancer
557577|NCT00475956|Breast Cancer
557578|NCT00475956|Cholangiocarcinoma
557579|NCT00475956|Colon Cancer
557580|NCT00475956|Gastric Cancer
557581|NCT00475956|Choriocarcinoma
557582|NCT00475956|Liver Cancer
557583|NCT00475956|Myeloma
557584|NCT00475956|Ovarian Cancer
557585|NCT00475956|Pancreatic Cancer
557586|NCT00475956|Peritoneal Cancer
557587|NCT00475943|Swallowing Disorders
557588|NCT00475943|Swallowing
557589|NCT00475943|Videofluoroscopy
557590|NCT00475943|Dysphagia
557591|NCT00475943|Epiglottis
557592|NCT00475943|Healthy Volunteer
557593|NCT00475943|HV
557594|NCT00475930|MRSA
557595|NCT00475930|Staphylococcus aureus
557596|NCT00475917|Advanced malignancies
557597|NCT00475917|Solid tumor
557598|NCT00475904|Post Herpetic Neuralgia
557599|NCT00475904|PHN
557600|NCT00475904|Neuropathy
557601|NCT00475904|Nerve Pain
557602|NCT00475904|Topical
557603|NCT00475891|isolate
557604|NCT00475891|infection
557605|NCT00475891|linezolid
557606|NCT00475878|opiate use
557607|NCT00475878|depression
557608|NCT00475878|buprenorphine
557609|NCT00475878|escitalopram
557610|NCT00475865|MS
557611|NCT00475865|glatiramer acetate
557612|NCT00475865|adjunctive therapy
557613|NCT00475865|relapses
557614|NCT00475852|Heart Decompensation
557615|NCT00475852|Dyspnea
557616|NCT00475852|Heart failure
557617|NCT00475852|Nesiritide
557618|NCT00475852|Decompensated
557619|NCT00475852|ADHF
557620|NCT00475839|stress urinary incontinence
557621|NCT00475839|sling procedures
557622|NCT00475839|tension-free vaginal tape
557623|NCT00475839|transobturator
557624|NCT00475826|Heterozigous Familial Hypercholesterolemia
557625|NCT00475826|Sub-clinical atherosclerosis
557626|NCT00475826|Chylomicrons metabolism
557627|NCT00475826|Statin plus ezetimibe
557628|NCT00475826|Coronary artery calcification
557629|NCT00475813|Paediatric subjects with asthma
557630|NCT00475800|Osteoarthritis
557631|NCT00475800|lumiracoxib
557632|NCT00475800|celecoxib
557633|NCT00475800|Cox-2
557634|NCT00475800|knee
557635|NCT00475787|Older Adults
557636|NCT00475787|Patient Education
557637|NCT00475787|Randomized Controlled Trial
557638|NCT00475787|Sham procedure
557639|NCT00475787|Spinal Manipulation
557640|NCT00475787|Veterans
557641|NCT00475761|Breast biopsy
557642|NCT00475761|Breast imaging
557643|NCT00475761|Breast Cancer
557644|NCT00475761|Mammographic Density
557645|NCT00475761|Breast
557646|NCT00475748|cervical spine
557647|NCT00475748|spinal cord
557648|NCT00475748|trauma
557649|NCT00475748|spinal cord injury
557650|NCT00475748|central cord syndrome
557651|NCT00475722|cancer
557652|NCT00475722|colon
557653|NCT00475722|prevention
557654|NCT00475722|healthy eating
557655|NCT00475722|Mediterranean diet
557656|NCT00475722|PGE2
557657|NCT00475722|cyclooxygenase
557658|NCT00475722|lipoxygenase
557659|NCT00475722|Healthy People 2010 diet
557660|NCT00475722|dietary prevention of colon cancer
557661|NCT00475709|aortic valve
557662|NCT00475709|heart valve
557663|NCT00475709|tissue valve
557664|NCT00475709|bioprosthesis
557665|NCT00475709|valve disorder
557666|NCT00475709|valve disease
557667|NCT00475709|cardiac surgery
557668|NCT00475709|aortic valve stenosis
557669|NCT00475709|aortic valve regurgitation
557670|NCT00475683|Doxorubicin
557671|NCT00475683|Mucositis
557672|NCT00475683|Prevention
557673|NCT00475683|Curcumin
557674|NCT00475631|Clubfoot
557675|NCT00475631|Chart review
557676|NCT00475618|Early chilhood caries
557677|NCT00475618|Prevention
557678|NCT00475618|Fluoride varnish
557679|NCT00475618|fluoride toothpaste
557680|NCT00475618|non fluoride tooth paste
557681|NCT00475618|Professional cleaning
557682|NCT00475605|atopic dermatitis
557683|NCT00475605|child
557684|NCT00475605|tacrolimus ointment
557685|NCT00475605|Protopic Ointment
557686|NCT00475592|Esophageal Varices
557687|NCT00475592|Gastric Varices
557688|NCT00475592|Capsule Endoscopy
557689|NCT00475592|Portal Hypertension
557690|NCT00475592|Cirrhosis
557691|NCT00475592|Gastrointestinal Hemorrhage
557692|NCT00475579|ventilator-associated pneumonia
557693|NCT00475579|endotracheal tube
557694|NCT00475579|polyurethane cuff
557695|NCT00475579|polyvinyl cuff
557696|NCT00475579|subglottic secretion drainage
557697|NCT00475553|spotting
557698|NCT00475553|PMS
557699|NCT00475553|nuvaring
557700|NCT00475553|birth control
557701|NCT00475553|pelvic pain
557702|NCT00475553|headache
557703|NCT00475553|mood swings
557704|NCT00475553|continuous use
557705|NCT00475540|prolapse
557706|NCT00475540|uterus
557707|NCT00475540|pelvic organ
557708|NCT00475540|vaginal prolpase
557709|NCT00475514|Menstrually-related Migraine Headache
557710|NCT00475514|'Difficult to Treat' as specified in protocol
557711|NCT00475501|anabolic effects
557712|NCT00475501|finasteride
557713|NCT00475501|male hypogonadism
557714|NCT00475501|sarcopenia
557715|NCT00475501|testosterone
557716|NCT00475488|radial artery
557717|NCT00475488|right internal thoracic artery
557718|NCT00475488|saphenous vein
557719|NCT00475488|grafts
557720|NCT00475488|coronary bypass surgery
557721|NCT00475475|Overweight
557722|NCT00475475|Obesity
557723|NCT00475475|Appetite
557724|NCT00475475|Dietary sugars
557725|NCT00475475|Fructose
557726|NCT00475475|Glucose
557727|NCT00475475|Leptin
557728|NCT00475475|Insulin
557729|NCT00475475|Ghrelin
557730|NCT00475462|Metoprolol and Syncope
557731|NCT00475449|percutaneous coronary intervention
557732|NCT00475449|Stent
557733|NCT00475449|coronary artery bypass grafting
557734|NCT00475436|muscarinic receptor antagonist
557735|NCT00475436|GSK573719,
557736|NCT00475436|chronic obstructive pulmonary disease,
557737|NCT00475410|Autologous adipose-derived stem cells
557738|NCT00475410|Complex perianal fistula
557739|NCT00475410|Inflammatory Bowel Disease
557740|NCT00475410|Advanced cell therapy
557741|NCT00475410|Fibrin glue
557742|NCT00475384|Acute Myelogenous Leukemia
557743|NCT00475384|Acute Lymphocytic Leukemia
557744|NCT00475384|Myelodysplastic Syndrome
557745|NCT00475384|Stem Cell Transplant
557746|NCT00475384|Haploidentical Donor
557747|NCT00475384|Leukemia
557748|NCT00475384|Fludarabine
557749|NCT00475384|Total Body Irradiation
557750|NCT00475384|Thiotepa
557751|NCT00475371|Healthy
557752|NCT00475371|Diabetes Mellitus: Type II
557753|NCT00475345|Nocturnal hypoglycemia
557754|NCT00475345|Bedtime snacks
557755|NCT00475345|Continuous glucose monitoring
557756|NCT00475345|Continuous subcutaneous insulin infusion
557757|NCT00475345|CSII
557758|NCT00475345|Intensive therapy
557759|NCT00475319|Dry Eye Syndromes
557760|NCT00475319|OPC-12759
557761|NCT00475306|Metoclopramide
557762|NCT00475306|Nausea
557763|NCT00475306|Akathisia
557764|NCT00475306|Emergency department
557765|NCT00475293|metastatic colorectal cancer
557766|NCT00475293|2nd-line Therapy
557767|NCT00475293|panitumumab
557768|NCT00475293|irinotecan
557769|NCT00475280|geriatric assessment adapted therapy
557770|NCT00475280|Leukemia, Lymphoblastic, Acute
557771|NCT00475280|Older patients
557772|NCT00475280|> 60 years old
557773|NCT00475280|Ph negative
557774|NCT00475267|aortic valve
557775|NCT00475267|heart valve
557776|NCT00475267|tissue valve
557777|NCT00475267|bioprosthesis
557778|NCT00475267|valve disorder
557779|NCT00475267|valve disease
557780|NCT00475267|cardiac surgery
557781|NCT00475267|aortic valve stenosis
557782|NCT00475267|aortic valve regurgitation
557783|NCT00475254|Retinitis Pigmentosa
557784|NCT00475254|stress
557785|NCT00475254|sleepiness
557786|NCT00475254|low vision
557787|NCT00475254|mind-body
557788|NCT00475241|Combat Disorders
557789|NCT00475241|Cortisol
557790|NCT00475241|Posttraumatic Stress Disorder (PTSD)
557791|NCT00475241|Psychophysiology
557792|NCT00475241|Therapy
557793|NCT00475241|Treatment
557794|NCT00475241|Veterans
557795|NCT00475228|levonorgestrel IUD
557796|NCT00475228|IUD
557797|NCT00475228|dilation and evacuation
557798|NCT00475228|second trimester
557799|NCT00475228|contraception
557800|NCT00475189|birth control
557801|NCT00475189|PMS
557802|NCT00475189|headaches
557803|NCT00475189|mood swings
557804|NCT00475189|pelvic pain
557805|NCT00475176|Hepatitis C Virus Genotype 1
557806|NCT00475176|Non-Responders
557807|NCT00475176|SAMe
557808|NCT00475176|Natural Killer Cells
557809|NCT00475176|Interferon Signaling
557810|NCT00475176|Ribavirin
557811|NCT00475176|Peginterferon
557812|NCT00475176|Hemolysis
557813|NCT00475176|STAT
557814|NCT00475176|Hepatitis C
557815|NCT00475163|Obesity
557816|NCT00475163|Mentoring
557817|NCT00475163|Fitness
557818|NCT00475163|Self-esteem
557819|NCT00475137|Bipolar II Disorder
557820|NCT00475137|depression
557821|NCT00475137|Lamotrigine
557822|NCT00475137|Add On antidepressant
557823|NCT00475137|randomized
557824|NCT00475137|single blind
557825|NCT00475137|parallel group
557826|NCT00475124|Pacemaker follow-up
557827|NCT00475124|Telecardiology
557828|NCT00475124|Home Monitoring
557829|NCT00475111|Cognitive Behavioral Intervention
557830|NCT00475111|Emotion Regulation
557831|NCT00475111|Pain Management
557832|NCT00475111|Psychological Adaptation
557833|NCT00475111|Coping Efficacy
557834|NCT00475111|Markers of Disease Activity
557835|NCT00475098|Low molecular weight heparin
557836|NCT00475098|Lung cancer
557837|NCT00475098|Non small cell lung cancer
557838|NCT00475098|Adjuvant therapy
557839|NCT00475098|Anticoagulants
557840|NCT00475098|Heparin
557841|NCT00475085|nausea and vomiting
557842|NCT00475085|recurrent breast cancer
557843|NCT00475085|stage I breast cancer
557844|NCT00475085|stage II breast cancer
557845|NCT00475085|stage IIIA breast cancer
557846|NCT00475085|stage IIIB breast cancer
557847|NCT00475085|stage IIIC breast cancer
557848|NCT00475085|stage IV breast cancer
557849|NCT00475085|inflammatory breast cancer
557850|NCT00475085|male breast cancer
557851|NCT00475059|kidney transplantation
557852|NCT00475059|Glomerular filtration rate
557853|NCT00475059|inulin clearance
557854|NCT00475059|MDRD equation
557855|NCT00475059|cystatin C
557856|NCT00475059|cimetidine
557857|NCT00475046|smoking
557858|NCT00475046|post partum
557859|NCT00475046|relapse prevention
557860|NCT00475046|motivational interviewing
557861|NCT00475046|TTM
557862|NCT00475046|implement motivational enhancement interventions in pediatric practices
557863|NCT00475046|examine the effectiveness of the intervention
557864|NCT00475046|develop measurements appropriate to tailor interventions
557865|NCT00475046|analyze further unfavorable and favorable factors outlined by previous research
557866|NCT00475020|Idiopathic Myelofibrosis
557867|NCT00475020|Myelofibrosis
557868|NCT00475020|Essential Thrombocythemia
557869|NCT00475020|Polycythemia Vera
557870|NCT00475020|Busulfan
557871|NCT00475020|Antithymocyte Globulin
557872|NCT00475020|ATG
557873|NCT00475020|Fludarabine
557874|NCT00475020|Thymoglobulin
557875|NCT00475007|Emphysema
557876|NCT00475007|IBV® Valve
557877|NCT00475007|COPD
557878|NCT00475007|Shortness of Breath
557879|NCT00475007|Spiration
557880|NCT00474994|chondrosarcoma
557881|NCT00474994|recurrent osteosarcoma
557882|NCT00474994|localized adult malignant fibrous histiocytoma of bone
557883|NCT00474994|metastatic adult malignant fibrous histiocytoma of bone
557884|NCT00474994|recurrent adult malignant fibrous histiocytoma of bone
557885|NCT00474994|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
557886|NCT00474994|recurrent Kaposi sarcoma
557887|NCT00474994|recurrent uterine sarcoma
557888|NCT00474994|adult leiomyosarcoma
557889|NCT00474994|adult malignant fibrous histiocytoma
557890|NCT00474994|adult rhabdomyosarcoma
557891|NCT00474994|dermatofibrosarcoma protuberans
557892|NCT00474994|stage III adult soft tissue sarcoma
557893|NCT00474994|stage IV adult soft tissue sarcoma
557894|NCT00474994|ovarian sarcoma
557895|NCT00474994|uterine leiomyosarcoma
557896|NCT00474994|stage III uterine sarcoma
557897|NCT00474994|stage IV uterine sarcoma
557898|NCT00474994|desmoid tumor
557899|NCT00474994|adult angiosarcoma
557900|NCT00474994|recurrent adult soft tissue sarcoma
557901|NCT00474994|uterine carcinosarcoma
557902|NCT00474994|endometrial stromal sarcoma
557903|NCT00474994|fibrosarcomatous osteosarcoma
557904|NCT00474994|chondrosarcomatous osteosarcoma
557905|NCT00474994|adult alveolar soft-part sarcoma
557906|NCT00474994|adult epithelioid sarcoma
557907|NCT00474994|adult extraskeletal chondrosarcoma
557908|NCT00474994|adult extraskeletal osteosarcoma
557909|NCT00474994|adult fibrosarcoma
557910|NCT00474994|adult malignant hemangiopericytoma
557911|NCT00474994|adult malignant mesenchymoma
557912|NCT00474994|adult neurofibrosarcoma
557913|NCT00474994|adult synovial sarcoma
557914|NCT00474994|adult desmoplastic small round cell tumor
557915|NCT00474994|adult liposarcoma
557916|NCT00474994|anaplastic osteosarcoma
557917|NCT00474994|mixed osteosarcoma
557918|NCT00474994|small intestine leiomyosarcoma
557919|NCT00474994|osteoblastic osteosarcoma
557920|NCT00474994|telangiectatic osteosarcoma
557921|NCT00474994|classic Kaposi sarcoma
557922|NCT00474994|immunosuppressive treatment related Kaposi sarcoma
557923|NCT00474994|AIDS-related Kaposi sarcoma
557924|NCT00474981|neonatal mortality
557925|NCT00474981|infant mortality
557926|NCT00474981|newborn caring practices
557927|NCT00474942|Hypertension
557928|NCT00474942|Metabolic Alkalosis
557929|NCT00474942|Hypokalemia
557930|NCT00474929|recurrent adult Hodgkin lymphoma
557931|NCT00474929|recurrent cutaneous T-cell non-Hodgkin lymphoma
557932|NCT00474929|stage III multiple myeloma
557933|NCT00474929|refractory multiple myeloma
557934|NCT00474929|Waldenström macroglobulinemia
557935|NCT00474929|recurrent adult Burkitt lymphoma
557936|NCT00474929|recurrent adult diffuse large cell lymphoma
557937|NCT00474929|recurrent adult diffuse mixed cell lymphoma
557938|NCT00474929|recurrent adult diffuse small cleaved cell lymphoma
557939|NCT00474929|recurrent adult immunoblastic large cell lymphoma
557940|NCT00474929|recurrent adult lymphoblastic lymphoma
557941|NCT00474929|recurrent grade 1 follicular lymphoma
557942|NCT00474929|recurrent grade 2 follicular lymphoma
557943|NCT00474929|recurrent grade 3 follicular lymphoma
557944|NCT00474929|recurrent mantle cell lymphoma
557945|NCT00474929|recurrent marginal zone lymphoma
557946|NCT00474929|recurrent small lymphocytic lymphoma
557947|NCT00474929|cutaneous B-cell non-Hodgkin lymphoma
557948|NCT00474929|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
557949|NCT00474929|nodal marginal zone B-cell lymphoma
557950|NCT00474929|splenic marginal zone lymphoma
557951|NCT00474929|recurrent mycosis fungoides/Sezary syndrome
557952|NCT00474929|recurrent adult grade III lymphomatoid granulomatosis
557953|NCT00474916|Neuropathic pain
557954|NCT00474916|Cancer
557955|NCT00474890|Seasonal allergic rhinitis
557956|NCT00474877|Clinical
557957|NCT00474877|Splints
557958|NCT00474877|Rheumatoid
557959|NCT00474864|Endothelial Function,
557960|NCT00474864|vascular compliance,
557961|NCT00474864|atherosclerosis
557962|NCT00474851|Endometriosis
557963|NCT00474851|Adolescents
557964|NCT00474851|Bone density
557965|NCT00474851|GnRH Agonist
557966|NCT00474851|Add-back therapy
557967|NCT00474838|type 2 diabetes mellitus
557968|NCT00474838|intensive insulin therapy
557969|NCT00474786|Metastatic or Advanced Renal Cell Carcinoma
557970|NCT00474747|Severe Aplastic Anemia
557971|NCT00474747|Total Body Irradiation
557972|NCT00474747|Antithymocyte Globulin
557973|NCT00474747|Cyclophosphamide
557974|NCT00474747|Cytoxan
557975|NCT00474747|Neosar
557976|NCT00474747|Fludarabine
557977|NCT00474747|Fludara
557978|NCT00474747|Fludarabine Phosphate
557979|NCT00474747|Thymoglobulin
557980|NCT00474747|ATG
557981|NCT00474747|TBI
557982|NCT00474747|Cyclosporine
557983|NCT00474747|Tacrolimus
557984|NCT00474734|hepatocellular carcinoma
557985|NCT00474734|liver transplantation
557986|NCT00474734|staging
557987|NCT00474734|intravascular ultrasound
557988|NCT00474721|child
557989|NCT00474721|pain
557990|NCT00474721|analgesics
557991|NCT00474695|Exudative age-related macular degeneration
557992|NCT00474682|ferric pyrophosphate, iron bioavailability, fortification,
557993|NCT00474669|Ovarian Carcinoma
557994|NCT00474656|high frequency oscillation
557995|NCT00474656|lung-protective ventilation
557996|NCT00474656|ARDS
557997|NCT00474656|ventilator-induced lung injury
557998|NCT00474630|Obesity
557999|NCT00474630|Overweight
558000|NCT00474630|Diabetes Mellitus, Type 2
558001|NCT00474604|breast cancer
558128|NCT00474123|simvastatin
558129|NCT00474123|ezetimibe
558002|NCT00474591|Coronary artery bypass surgery, fondaparinux, graft patency, graft occlusion, graft failure, anticoagulation
558003|NCT00474565|Catheter,
558004|NCT00474565|Aortic root injection,
558005|NCT00474565|low dose contrast injection,
558006|NCT00474565|coronary artery angiogarm and
558007|NCT00474565|coronary artery bypass graft imaging.
558008|NCT00474539|Vaccine
558009|NCT00474526|Meningococcal
558010|NCT00474526|meningitis
558011|NCT00474526|vaccine
558012|NCT00474526|infants
558013|NCT00474526|Meningococcal meningitis
558014|NCT00474526|Meningococcal disease
558015|NCT00474513|AD, H3, Brain, Cognitive Impairment
558016|NCT00474500|Iron absorption
558017|NCT00474500|Coca-Cola
558018|NCT00474487|Meningococcal
558019|NCT00474487|meningitis
558020|NCT00474487|vaccine
558021|NCT00474487|adolescents
558022|NCT00474487|adults
558023|NCT00474474|virtual patient
558024|NCT00474474|therapeutic decision making
558025|NCT00474461|coronary artery disease
558026|NCT00474461|Heart Attack
558027|NCT00474461|Heart failure
558028|NCT00474461|Cardiac Stem Cells
558029|NCT00474461|Coronary Artery Bypass
558030|NCT00474448|Hereditary Multiple Exostoses
558031|NCT00474448|Survey
558032|NCT00474448|Quality of Life
558033|NCT00474448|Hereditary Multiple Exostoses,
558034|NCT00474448|also known as Multiple Hereditary Exostoses,
558035|NCT00474448|also known as Hereditary Multiple Osteochondromas
558036|NCT00474435|Tuberculosis
558037|NCT00474435|HIV
558038|NCT00474435|Coinfection
558039|NCT00474435|Pharmacokinetics
558040|NCT00474435|Emtricitabine
558041|NCT00474435|Tenofovir
558042|NCT00474435|Rifampin
558043|NCT00474435|Efavirenz
558044|NCT00474435|Treatment Naive
558045|NCT00474422|breastfeeding
558046|NCT00474422|support
558047|NCT00474409|Vertigo
558048|NCT00474409|Posterior circulation infarction
558049|NCT00474396|Uric acid
558050|NCT00474396|Dairy
558051|NCT00474396|Diet
558052|NCT00474383|Prostate neoplasms
558053|NCT00474383|CB7630
558054|NCT00474383|Abiraterone acetate
558055|NCT00474383|Glucocorticoid
558056|NCT00474383|Prednisone
558057|NCT00474383|Prednisolone
558058|NCT00474370|Acquired Immunodeficiency Syndrome
558059|NCT00474357|Bipolar affective disorder
558060|NCT00474357|myths
558061|NCT00474357|preconceived notions
558062|NCT00474357|stigma
558063|NCT00474357|hope
558064|NCT00474344|Genetics
558065|NCT00474344|Clubfoot
558066|NCT00474344|DNA
558067|NCT00474344|Idiopathic Talipes Equinovarus also known as Clubfoot
558068|NCT00474331|DNA sequencing
558069|NCT00474331|EXT genes
558070|NCT00474331|Hereditary Multiple Exostoses,
558071|NCT00474331|also known as Multiple Hereditary Exostoses,
558072|NCT00474331|also known as Hereditary Multiple Osteochondromas
558073|NCT00474318|Adolescents
558074|NCT00474318|Obesity
558075|NCT00474318|Bariatrics
558076|NCT00474318|Surgery for Weight Loss
558077|NCT00474318|Teen-LABS
558078|NCT00474305|PTSD
558079|NCT00474305|Prolonged Exposure
558080|NCT00474305|Virtual Reality
558081|NCT00474292|Stroke
558082|NCT00474292|Rehabilitation
558083|NCT00474292|Plasticity
558084|NCT00474292|fMRI
558085|NCT00474292|Reorganization
558086|NCT00474279|Growth hormone secretagogue
558087|NCT00474279|Body composition
558088|NCT00474279|Functional ability
558089|NCT00474279|Aging
558090|NCT00474279|Sarcopenia
558091|NCT00474266|MMRV vaccine
558092|NCT00474266|co-administration
558093|NCT00474266|immunogenicity
558094|NCT00474266|meningococcal vaccine
558095|NCT00474266|conjugate vaccine
558096|NCT00474240|cholesterol
558097|NCT00474227|obesity
558098|NCT00474227|weight gain
558099|NCT00474227|schizophrenia
558100|NCT00474227|schizoaffective disorder
558101|NCT00474227|antipsychotic induced weight gain
558102|NCT00474214|STEMI
558103|NCT00474214|Primary PCI
558104|NCT00474214|Length of Stay
558105|NCT00474214|Early Discharge
558106|NCT00474201|Pharmacokinetic
558107|NCT00474201|HIV
558108|NCT00474201|Drug-Drug Interaction
558109|NCT00474201|Lopinavir/Ritonavir
558110|NCT00474201|Gemfibrozil
558111|NCT00474201|Healthy Volunteer
558112|NCT00474201|HV
558113|NCT00474188|Celgene
558114|NCT00474188|Revlimid
558115|NCT00474188|Lenalidomide
558116|NCT00474188|Diffuse Large B-cell lymphoma
558117|NCT00474188|Non-Hodgkins lymphoma
558118|NCT00474188|CC-5013
558119|NCT00474188|Response Rate
558120|NCT00474188|Tumor Control Rate
558121|NCT00474188|Duration of Response
558122|NCT00474188|Time to Progression
558123|NCT00474188|Progression-free survival and safety
558124|NCT00474162|Cesarean section
558125|NCT00474162|coagulation changes
558126|NCT00474123|angina
558127|NCT00474123|atherosclerosis
558130|NCT00474123|inflammation
558131|NCT00474110|Ketamine
558132|NCT00474110|hydromorphone
558133|NCT00474110|pediatric mucositis
558134|NCT00474097|Colorectal Neoplasms
558135|NCT00474097|Colitis, Ulcerative
558136|NCT00474097|Diverticulitis
558137|NCT00474097|Colonic Polyps
558138|NCT00474097|Crohn Disease
558139|NCT00474084|Stent
558140|NCT00474084|Hydroxyapatite
558141|NCT00474084|Coronary Artery Stenosis
558142|NCT00474084|Angioplasty
558143|NCT00474071|Remifentanil
558144|NCT00474071|endotracheal intubation
558145|NCT00474071|pediatrics
558146|NCT00474058|rotigotine
558147|NCT00474058|Neupro®
558148|NCT00474058|Parkinson's Disease
558149|NCT00474032|Idiopathic clubfoot
558150|NCT00474032|Botox injection
558151|NCT00474032|Idiopathic Talipes Equinovarus, also known as Idiopathic clubfoot
558152|NCT00474019|pediatrics
558153|NCT00474019|neonates
558154|NCT00473993|Hepatitis C
558155|NCT00473993|Opioid Maintenance Treatment
558156|NCT00473993|Methadone
558157|NCT00473993|Buprenorphine
558158|NCT00473993|Heroin
558159|NCT00473993|Interferon, pegylated
558160|NCT00473980|MHC
558161|NCT00473980|CTLs
558162|NCT00473980|Colon carcinoma
558163|NCT00473980|NSAID
558164|NCT00473980|Survival
558165|NCT00473967|Vaccine
558166|NCT00473967|Hookworm
558167|NCT00473967|Phase 1
558168|NCT00473967|Na-ASP-2
558169|NCT00473941|colorectal cancer
558170|NCT00473941|colon cancer
558171|NCT00473941|rectal cancer
558172|NCT00473928|Macular
558173|NCT00473928|degeration
558174|NCT00473928|Complement
558175|NCT00473876|Chronic Heart Failure
558176|NCT00473876|Insulin Resistance
558177|NCT00473876|Metformin
558178|NCT00473876|Peak VO2
558179|NCT00473863|Acute coronary syndrome
558180|NCT00473863|Acute myocardial infarction
558181|NCT00473863|Unstable angina
558182|NCT00473863|Coronary computed tomographic angiography
558183|NCT00473863|Coronary Angiography
558184|NCT00473863|Tomography, X-Ray Computed
558185|NCT00473863|Tomography, Spiral Computed
558186|NCT00473850|DNA sequencing
558187|NCT00473850|EXT genes
558188|NCT00473850|Hereditary Multiple Exostoses,
558189|NCT00473850|also known as Multiple Hereditary Exostoses,
558190|NCT00473850|also known as Hereditary Multiple Osteochondromas
558191|NCT00473837|malaria
558192|NCT00473837|anaemia
558193|NCT00473837|chloroquine
558194|NCT00473837|iron delocalisation
558195|NCT00473837|macrophages
558196|NCT00473824|hepatitis C
558197|NCT00473824|liver transplantation
558198|NCT00473824|immune globulin
558199|NCT00473811|Glycemic index
558200|NCT00473811|carbohydrates
558201|NCT00473811|diabetes mellitus, type 2
558202|NCT00473811|randomized clinical trial
558203|NCT00473798|Patient Satisfaction
558204|NCT00473798|Quality of Life
558205|NCT00473798|Psychological Distress
558206|NCT00473798|Cervical Cancer
558207|NCT00473798|Cervical Cancer Screening
558208|NCT00473798|Questionnaire
558209|NCT00473785|Cardiovascular disease
558210|NCT00473785|Prevention
558211|NCT00473785|Lifestyle
558212|NCT00473772|cobalt chromium stent
558213|NCT00473772|paclitaxel coated balloon catheter
558214|NCT00473772|DEBlue
558215|NCT00473772|drug eluting balloon
558216|NCT00473746|Prostate neoplasms
558217|NCT00473746|Hormone refractory prostate cancer
558218|NCT00473746|Abiraterone acetate
558219|NCT00473746|CB7630
558220|NCT00473733|PATIENTS WITH DIABETES MELLITUS TYPE 2
558221|NCT00473733|UNDERGO UPPER ENDOSCOPY
558222|NCT00473733|BIOPSIES FOR GLP RECEPTORS EXPRESSION
558223|NCT00473733|PCR ANALYSIS
558224|NCT00473707|Third stage of labor
558225|NCT00473668|Hepatitis B
558226|NCT00473668|Tetanus
558227|NCT00473668|Diphtheria
558228|NCT00473668|Pertussis
558229|NCT00473668|Haemophilus influenzae type b Vaccines
558230|NCT00473655|Triglycerides
558231|NCT00473655|hypertriglyceridemia
558232|NCT00473655|statins
558233|NCT00473655|rosuvastatin
558234|NCT00473655|hyperlipoproteinemia
558235|NCT00473655|Fredrickson Type IIb or IV
558236|NCT00473642|Ranibizumab
558237|NCT00473642|Lucentis
558238|NCT00473642|Verteporfin
558239|NCT00473642|Visudyne
558240|NCT00473642|Photodynamic therapy
558241|NCT00473616|Phase I
558242|NCT00473616|solid tumors
558243|NCT00473616|solid malignancies
558244|NCT00473616|cancer Eligibility
558245|NCT00473603|androgens
558246|NCT00473603|fatty acids
558247|NCT00473590|Avastin
558248|NCT00473590|AMBER
558249|NCT00473590|Myeloma
558250|NCT00473590|Velcade
558251|NCT00473564|Lesions
558252|NCT00473564|Biopsy
558253|NCT00473564|Surgery
558254|NCT00473551|Chronic Lymphocytic Leukemia
558255|NCT00473551|Lymphoma
558256|NCT00473551|Myeloma
558257|NCT00473551|Leukemia
558258|NCT00473551|Anti-Third Party Cytolytic Lymphocytes
558259|NCT00473551|Indolent Lymphoid Malignancies
558260|NCT00473551|Fludarabine
558261|NCT00473551|Fludara
558262|NCT00473551|Rituximab
558263|NCT00473551|Rituxan
558264|NCT00473551|Cyclophosphamide
558265|NCT00473551|Cytoxan®
558266|NCT00473551|Neosar®
558267|NCT00473551|Stem Cell Transplantation
558268|NCT00473551|T-lymphocytes
558269|NCT00473551|Miltenyi CliniMACS System
558270|NCT00473551|Graft vs. Host Disease
558271|NCT00473551|GVHD
558272|NCT00473551|Allogenic Transplant
558273|NCT00473551|Sirolimus
558274|NCT00473551|Rapamycin
558275|NCT00473538|Structured exercise training program
558276|NCT00473538|Infertility
558277|NCT00473538|Menstrual cycle
558278|NCT00473538|PCOS
558279|NCT00473538|Treatment
558280|NCT00473512|Abiraterone acetate
558281|NCT00473512|CB7630
558282|NCT00473512|Prostatic neoplasms
558283|NCT00473512|Hormone refractory prostate cancer
558284|NCT00473512|Castration resistant prostate cancer
558285|NCT00473512|Castration refractory prostate cancer
558286|NCT00473499|drug eluting balloon
558287|NCT00473499|drug eluting stent
558288|NCT00473499|stem cells
558289|NCT00473473|homeopathy
558290|NCT00473473|Traumeel
558291|NCT00473473|mechanical ventilation
558292|NCT00473473|secretions
558293|NCT00473460|Chronic bronchitis
558294|NCT00473460|Chronic obstructive pulmonary disease
558295|NCT00473460|Acute exacerbation of chronic bronchitis
558296|NCT00473460|Prevention therapy
558297|NCT00473460|Antibiotics
558298|NCT00473460|Fluoroquinolone
558299|NCT00473460|Moxifloxacin
558300|NCT00473460|AECB
558301|NCT00473447|Rehabilitation
558302|NCT00473447|Children
558303|NCT00473447|Cerebral Palsy
558304|NCT00473447|Arm
558305|NCT00473447|Paresis
558306|NCT00473434|Schizophrenia
558307|NCT00473434|Drug Therapy
558308|NCT00473434|Treatment Outcome
558309|NCT00473408|Glioma
558310|NCT00473408|DCE-MRI
558311|NCT00473408|Angiogenesis
558312|NCT00473408|Cancer stem cells
558313|NCT00473408|Tumor vasculature
558314|NCT00473382|Lucentis
558315|NCT00473382|DME
558316|NCT00473382|Diabetes
558317|NCT00473382|Vision loss
558318|NCT00472667|Bacterial infections
558319|NCT00472667|Procalcitonin
558320|NCT00472667|Intensive care unit
558321|NCT00472667|Antibiotic therapy
558322|NCT00472667|Suspicion of bacterial infection or proven
558323|NCT00472654|bone mass
558324|NCT00472654|calcium absorption
558325|NCT00472654|bone quality
558326|NCT00472654|fracture risk
558327|NCT00472615|Bipolar Disorder
558328|NCT00472615|Menstrual Cycle
558329|NCT00472615|Depression
558330|NCT00472615|Mania or Hypomania
558331|NCT00472615|Predictor
558332|NCT00473369|atypical adenoma
558333|NCT00473369|Ki-67
558334|NCT00473369|p53
558335|NCT00473369|pituitary
558336|NCT00473369|prognosis
558337|NCT00473356|Morbid obesity
558338|NCT00473356|Lean body mass
558339|NCT00473356|amino acid supplement
558340|NCT00473356|laparoscopic gastric bypass
558341|NCT00473343|Photodynamic therapy (PDT)
558342|NCT00473343|PDT with Metvix cream
558343|NCT00473343|"High risk BCC"
558344|NCT00473343|Basal Cell carcinoma
558345|NCT00473343|Histologically confirmed complete response
558346|NCT00473330|Lucentis
558347|NCT00473330|DME
558348|NCT00473330|Diabetes
558349|NCT00473330|Vision loss
558350|NCT00473317|sunlight
558351|NCT00473317|UVB
558352|NCT00473317|Vitamin D
558353|NCT00473304|Safety
558354|NCT00473304|Efficacy
558355|NCT00473304|Adaptation
558356|NCT00473304|myopia and contact lens wear in children
558357|NCT00473291|pleural effusion
558358|NCT00473291|lung sounds
558359|NCT00473291|acoustic monitoring
558360|NCT00473278|tear protein
558361|NCT00473252|aspergillus infections
558362|NCT00473252|immunosuppression
558363|NCT00473252|kidney transplantation
558364|NCT00473252|hemodialysis
558365|NCT00473252|galactomannan test
558366|NCT00473252|fine dust
558367|NCT00473252|construction activity
558368|NCT00473252|airborne aspergillus spores
558369|NCT00473239|vitamin D
558370|NCT00473239|cholecalciferol
558371|NCT00473239|25-hydroxyvitamin D
558372|NCT00473213|Multiple Sclerosis
558373|NCT00473213|Interferon
558374|NCT00473213|Magnetic Resonance
558375|NCT00473200|hyperhomocysteinemia
558376|NCT00473200|homocysteine
558377|NCT00473200|S-adenosylmethionine
558378|NCT00473200|SAMe
558379|NCT00473200|Asymmetric dimethylagrinine (ADMA)
558380|NCT00473187|X-linked dominant hypophosphatemic rickets
558381|NCT00473187|growth disorders
558382|NCT00473187|anthropometry
558383|NCT00473187|human growth hormone
558384|NCT00473174|Ramipril
558385|NCT00473174|Ambulatory blood pressure monitoring
558386|NCT00473174|Chronotherapy
558387|NCT00473174|Circadian
558388|NCT00473174|Non-dipper
558389|NCT00473161|movement disorders
558390|NCT00473161|childhood
558391|NCT00473148|Duration of weaning from invasive ventilation
558392|NCT00473148|Mechanical ventilation
558393|NCT00473148|Weaning
558394|NCT00473148|B-type natriuretic peptide
558395|NCT00473148|Fluid balance
558396|NCT00473148|Diuretics
558397|NCT00473148|Intubated patient receiving mechanical ventilation
558398|NCT00473148|for at least 24 hours
558399|NCT00473148|Respiratory insufficiency
558400|NCT00473135|Dengue Fever
558401|NCT00473135|Dengue Vaccine
558402|NCT00473135|Dengue Virus
558403|NCT00473135|Dengue Hemorrhagic Fever
558404|NCT00473135|Dengue Shock Syndrome
558405|NCT00473122|Breast Cancer
558406|NCT00473122|Breast Reconstruction
558407|NCT00473122|Delayed-Immediate Reconstruction
558408|NCT00473122|Postmastectomy Radiation Therapy
558409|NCT00473122|Mastectomy
558410|NCT00473122|XRT
558411|NCT00473109|Hemodialysis
558412|NCT00473109|Heparin
558413|NCT00473109|Clotting
558414|NCT00473096|Decision making
558415|NCT00473096|Patient Education
558416|NCT00473096|Indigency
558417|NCT00473096|Minority group
558418|NCT00473083|Rash
558419|NCT00473083|Erlotinib
558420|NCT00473083|Lung Cancer
558421|NCT00473057|acute stroke
558422|NCT00473057|middle cerebral artery
558423|NCT00473057|autologous transplantation
558424|NCT00473057|bone marrow cells
558425|NCT00473057|stem cells
558426|NCT00473057|cell therapy
558427|NCT00473031|bone mass
558428|NCT00473031|calcium absorption
558429|NCT00473031|bone quality
558430|NCT00473031|fracture risk
558431|NCT00473018|postexposure prophylaxis
558432|NCT00473018|HIV Seronegativity
558433|NCT00472992|Pregnancy
558434|NCT00472992|TYSABRI
558435|NCT00472940|Cancer
558436|NCT00472940|Hypogonadism
558437|NCT00472940|testosterone
558438|NCT00472940|cachexia
558439|NCT00472914|Hypertonia
558440|NCT00472914|Childhood
558441|NCT00472901|Polymorphic Light Eruption (PLE)
558442|NCT00472901|Afamelanotide
558443|NCT00472901|CUV1647
558444|NCT00472901|photoprotection
558445|NCT00472901|sun poisoning
558446|NCT00472888|Alpha-adrenergic blockers
558447|NCT00472888|cataract surgery
558448|NCT00472888|pseudoexfoliation syndrome
558449|NCT00472888|diabetes mellitus
558450|NCT00472888|hypertension
558451|NCT00472888|pupil
558452|NCT00472875|hypoglycaemia
558453|NCT00472875|type 1 diabetes mellitus
558454|NCT00472849|OFAR 2
558455|NCT00472849|Oxaliplatin
558456|NCT00472849|Fludarabine
558457|NCT00472849|Cytarabine
558458|NCT00472849|Ara-C
558459|NCT00472849|Rituximab
558460|NCT00472849|Richter's Transformation
558461|NCT00472849|Prolymphocytic Leukemia
558462|NCT00472849|B-Cell Chronic Lymphocytic Leukemia
558463|NCT00472849|Leukemia
558464|NCT00472849|CLL
558465|NCT00472823|cholecalciferol
558466|NCT00472823|vitamin D deficiency
558467|NCT00472823|bone density
558468|NCT00472823|dietary calcium
558469|NCT00472823|hypercalcemia
558470|NCT00472823|hypercalciuria
558471|NCT00472810|Glaucoma
558472|NCT00472810|Collagen matrix
558473|NCT00472810|ologen
558474|NCT00472810|OculusGen
558475|NCT00472810|Antifibrotic
558476|NCT00472810|Trabeculectomy
558477|NCT00472810|anti scarring
558478|NCT00472810|tissue engineering
558479|NCT00472810|high risk patient for trabeculectomy
558480|NCT00472810|Aeon Astron
558481|NCT00472771|Recurrent extensive small cell lung cancer
558482|NCT00472745|bone mass
558483|NCT00472745|calcium absorption
558484|NCT00472745|bone quality
558485|NCT00472745|fracture risk
558486|NCT00472745|arthritis
558487|NCT00472745|osteoporosis
558488|NCT00472732|UCD
558489|NCT00472732|OTCD
558490|NCT00472732|Ammonia
558491|NCT00472732|Urea Metabolism
558492|NCT00472732|Inborn Errors
558493|NCT00472719|HIV Seronegativity
558494|NCT00472719|HIV Preventive Vaccine
558495|NCT00472719|Adenovirus
558496|NCT00472706|Treatment
558497|NCT00472706|Excision
558498|NCT00472706|Photodynamic therapy
558499|NCT00472706|Recurrence rate
558500|NCT00472706|Cosmetic outcome
558501|NCT00472693|Breast cancer
558502|NCT00472693|Metastatic breast cancer
558503|NCT00472693|Second-Line Therapy
558504|NCT00472693|Triple Negative
558505|NCT00472693|Her-2 negative
558506|NCT00472693|Hormone receptor negative
558507|NCT00472693|Abraxane
558508|NCT00472693|Bevacizumab
558509|NCT00472680|bone mass
558510|NCT00472680|calcium absorption
558511|NCT00472680|bone quality
558512|NCT00472680|fracture risk
558513|NCT00472602|Opisthorchis viverrini, liver fluke, Thailand, cancer
558514|NCT00472576|NMDA Receptor
558515|NCT00472576|Depression Treatment
558516|NCT00472576|Unipolar Depression
558517|NCT00472576|Treatment Resistant
558518|NCT00472576|Glutamatergic
558519|NCT00472576|Depression
558520|NCT00472576|Major Depression
558521|NCT00472563|bicarbonate
558522|NCT00472563|nephropathy
558523|NCT00472563|contrast
558524|NCT00472550|esomeprazole, gastric emptying, reflux
558525|NCT00472537|Ventral hernia
558526|NCT00472537|Incisional hernia
558527|NCT00472498|Cardiac Arrest
558528|NCT00472498|Biphasic Defibrillator
558529|NCT00472472|restenosis
558530|NCT00472472|peripheral arterial disease
558531|NCT00472472|paccocath
558532|NCT00472472|drug-coated balloon
558533|NCT00472459|Non-melanoma skin cancer
558534|NCT00472459|Organ transplant recipients
558535|NCT00472459|Photodynamic therapy
558536|NCT00472459|Actinic keratosis
558537|NCT00472446|Surgery
558538|NCT00472446|Thyroid gland
558539|NCT00472446|cervical block
558540|NCT00472446|Pain, Postoperative
558541|NCT00472433|Alemtuzumab in autoimmune cytopenias
558542|NCT00470418|Alzheimer Disease
558543|NCT00470418|Alzheimer Type Senile Dementia
558544|NCT00470418|Alzheimer's Disease
558545|NCT00470418|clinical trial
558546|NCT00470418|dementia
558547|NCT00470418|diabetes
558548|NCT00470418|dietary supplements
558549|NCT00470418|Senile Dementia, Alzheimer Type
558550|NCT00470418|Therapeutics
558551|NCT00470405|adult solid tumor
558552|NCT00470405|unspecified adult solid tumor, protocol specific
558553|NCT00470405|stage IV adult Hodgkin lymphoma
558554|NCT00470405|anaplastic large cell lymphoma
558555|NCT00470405|angioimmunoblastic T-cell lymphoma
558556|NCT00470405|cutaneous B-cell non-Hodgkin lymphoma
558557|NCT00470405|stage IV cutaneous T-cell non-Hodgkin lymphoma
558558|NCT00470405|adult nasal type extranodal NK/T-cell lymphoma
558559|NCT00470405|adult grade III lymphomatoid granulomatosis
558560|NCT00470405|Waldenstrom macroglobulinemia
558561|NCT00470405|stage IV adult Burkitt lymphoma
558562|NCT00470405|stage IV adult diffuse large cell lymphoma
558563|NCT00470405|stage IV adult diffuse mixed cell lymphoma
558564|NCT00470405|stage IV adult diffuse small cleaved cell lymphoma
558565|NCT00470405|stage IV adult immunoblastic large cell lymphoma
558566|NCT00470405|stage IV adult lymphoblastic lymphoma
558567|NCT00470405|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
558568|NCT00470405|stage IV grade 1 follicular lymphoma
558569|NCT00470405|stage IV grade 2 follicular lymphoma
558570|NCT00470405|stage IV grade 3 follicular lymphoma
558571|NCT00470405|stage IV mantle cell lymphoma
558572|NCT00470405|nodal marginal zone B-cell lymphoma
558573|NCT00470405|stage IV marginal zone lymphoma
558574|NCT00470405|stage IV small lymphocytic lymphoma
558575|NCT00470405|recurrent adult grade III lymphomatoid granulomatosis
558576|NCT00470405|recurrent adult Burkitt lymphoma
558577|NCT00470405|recurrent adult diffuse large cell lymphoma
558578|NCT00470405|recurrent adult diffuse mixed cell lymphoma
558579|NCT00470405|recurrent adult diffuse small cleaved cell lymphoma
558580|NCT00470405|recurrent adult Hodgkin lymphoma
558581|NCT00470405|recurrent adult immunoblastic large cell lymphoma
558582|NCT00470405|recurrent adult lymphoblastic lymphoma
558583|NCT00470405|recurrent cutaneous T-cell non-Hodgkin lymphoma
558584|NCT00470405|recurrent grade 1 follicular lymphoma
558585|NCT00470405|recurrent grade 2 follicular lymphoma
558586|NCT00470405|recurrent grade 3 follicular lymphoma
558587|NCT00470405|recurrent mantle cell lymphoma
558588|NCT00470405|splenic marginal zone lymphoma
558589|NCT00470405|recurrent marginal zone lymphoma
558590|NCT00470405|recurrent small lymphocytic lymphoma
558591|NCT00470405|recurrent mycosis fungoides/Sezary syndrome
558592|NCT00470405|stage IV mycosis fungoides/Sezary syndrome
558593|NCT00470392|Erythema
558594|NCT00470392|optimization
558595|NCT00470392|Papule
558596|NCT00470392|Plaque
558597|NCT00470392|pretreatment
558598|NCT00470392|T cells
558599|NCT00470392|UVB laser light
558600|NCT00470392|psoriasis
558601|NCT00470392|topical administration
558602|NCT00470379|stage II melanoma
558603|NCT00470379|stage III melanoma
558604|NCT00470379|stage IV melanoma
558605|NCT00470366|stage II malignant testicular germ cell tumor
558606|NCT00470366|stage III malignant testicular germ cell tumor
558607|NCT00470366|testicular choriocarcinoma and embryonal carcinoma
558608|NCT00470366|testicular choriocarcinoma and seminoma
558609|NCT00470366|testicular choriocarcinoma and teratoma
558610|NCT00470366|testicular choriocarcinoma and yolk sac tumor
558611|NCT00470366|testicular choriocarcinoma
558612|NCT00470366|testicular embryonal carcinoma and seminoma
558613|NCT00470366|testicular embryonal carcinoma and teratoma with seminoma
558614|NCT00470366|testicular embryonal carcinoma and teratoma
558615|NCT00470366|testicular embryonal carcinoma and yolk sac tumor with seminoma
558727|NCT00472355|Parkinson's disease
558616|NCT00470366|testicular embryonal carcinoma and yolk sac tumor
558617|NCT00470366|testicular embryonal carcinoma
558618|NCT00470366|testicular seminoma
558619|NCT00470366|testicular yolk sac tumor and teratoma with seminoma
558620|NCT00470366|testicular yolk sac tumor and teratoma
558621|NCT00470366|testicular yolk sac tumor
558622|NCT00470366|stage I malignant testicular germ cell tumor
558623|NCT00470366|adult central nervous system germ cell tumor
558624|NCT00470366|ovarian choriocarcinoma
558625|NCT00470366|ovarian dysgerminoma
558626|NCT00470366|ovarian embryonal carcinoma
558627|NCT00470366|ovarian yolk sac tumor
558628|NCT00470366|ovarian immature teratoma
558629|NCT00470366|ovarian mature teratoma
558630|NCT00470366|ovarian monodermal and highly specialized teratoma
558631|NCT00470366|ovarian polyembryoma
558632|NCT00470366|ovarian mixed germ cell tumor
558633|NCT00470366|stage IV ovarian germ cell tumor
558634|NCT00470366|stage IV extragonadal seminoma
558635|NCT00470366|stage I extragonadal non-seminomatous germ cell tumor
558636|NCT00470366|stage II extragonadal non-seminomatous germ cell tumor
558637|NCT00470366|stage III extragonadal non-seminomatous germ cell tumor
558638|NCT00470366|stage IV extragonadal non-seminomatous germ cell tumor
558639|NCT00470366|adult teratoma
558640|NCT00470366|testicular immature teratoma
558641|NCT00470366|testicular mature teratoma
558642|NCT00470366|stage IA ovarian germ cell tumor
558643|NCT00470366|stage IB ovarian germ cell tumor
558644|NCT00470366|stage IC ovarian germ cell tumor
558645|NCT00470366|stage IIA ovarian germ cell tumor
558646|NCT00470366|stage IIB ovarian germ cell tumor
558647|NCT00470366|stage IIC ovarian germ cell tumor
558648|NCT00470366|stage IIIA ovarian germ cell tumor
558649|NCT00470366|stage IIIB ovarian germ cell tumor
558650|NCT00470366|stage IIIC ovarian germ cell tumor
558651|NCT00470353|recurrent colon cancer
558652|NCT00470353|stage I colon cancer
558653|NCT00470353|stage II colon cancer
558654|NCT00470353|stage III colon cancer
558655|NCT00470340|Recurrence
558656|NCT00470340|Neoplasm Recurrence, Local
558657|NCT00470340|Liver
558658|NCT00470340|Liver Neoplasms
558659|NCT00470340|Liver Cirrhosis
558660|NCT00470340|Carcinoma, Hepatocellular
558661|NCT00470340|Iodized Oil
558662|NCT00470340|gemcitabine [Substance Name]
558663|NCT00470340|oxaliplatin [Substance Name]
558664|NCT00470340|gemcitabine-oxaliplatin regimen [Substance Name]
558665|NCT00470340|Randomized Controlled Trials
558666|NCT00470340|Multicenter Studies
558667|NCT00470340|Cisplatin
558668|NCT00470340|Injections, Intra-Arterial
558669|NCT00470340|Injections, Intravenous
558670|NCT00470340|Chemotherapy, Adjuvant
558671|NCT00470327|Interstitial lung diseases
558672|NCT00470327|idiopathic pulmonary fibrosis
558673|NCT00470327|Sarcoidosis
558674|NCT00470327|mRNA and cytokine expression
558675|NCT00470314|Acute liver failure
558676|NCT00470314|Ornithine Aspartate
558677|NCT00470314|Ammonia
558678|NCT00470314|Encephalopathy
558679|NCT00470288|cesarean delivery
558680|NCT00470288|bladder flaps
558681|NCT00470275|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
558682|NCT00470262|fatty acid oxidation complex
558683|NCT00470262|fenofibrate
558684|NCT00470262|Inflammation
558685|NCT00470262|Peroxisome Proliferator-Activated Receptors
558686|NCT00470262|pioglitazone
558687|NCT00470262|Prediabetic State
558688|NCT00470262|insulin resistance
558689|NCT00470249|stage IIIB breast cancer
558690|NCT00470249|stage IIIC breast cancer
558691|NCT00470249|stage IV breast cancer
558692|NCT00470249|recurrent breast cancer
558693|NCT00470249|male breast cancer
558694|NCT00470249|stage IIIA breast cancer
558695|NCT00470236|Ductal carcinoma in-situ
558696|NCT00470236|Breast conserving therapy
558697|NCT00470236|Whole breast radiation therapy
558698|NCT00470236|Tumour bed boost
558699|NCT00470236|Fractionation schedules
558700|NCT00470236|Completely excised non-low risk DCIS
558701|NCT00470223|localized osteosarcoma
558702|NCT00470223|metastatic osteosarcoma
558703|NCT00470210|Ribavirin
558704|NCT00470210|non-responders
558705|NCT00470210|HCV co-infected patients
558706|NCT00470210|sustained virological response
558707|NCT00470210|Treatment Experienced
558708|NCT00470184|adenocarcinoma of the esophagus
558709|NCT00470184|squamous cell carcinoma of the esophagus
558710|NCT00470184|stage II esophageal cancer
558711|NCT00470184|stage III esophageal cancer
558712|NCT00470184|stage IV esophageal cancer
558713|NCT00472407|Normal
558714|NCT00472394|Medical abortion
558715|NCT00472394|Preferences
558716|NCT00472394|Willingness to Pay
558717|NCT00472381|Acute Ischemic Stroke
558718|NCT00472381|Post-Stroke Hyperglycaemia
558719|NCT00472381|Insulin treatment
558720|NCT00472381|Insulin
558721|NCT00472381|DWI
558722|NCT00472381|MRI
558723|NCT00472368|Advanced cancer
558724|NCT00472368|lymphoma
558725|NCT00472368|chronic hematological malignancies
558726|NCT00472368|adult
558728|NCT00472355|PD
558729|NCT00472355|apomorphine
558730|NCT00472342|impaired glucose tolerance
558731|NCT00472342|impaired fasting glucose
558732|NCT00472342|diabetes
558733|NCT00472342|adipokine
558734|NCT00472342|adiponectin
558735|NCT00472342|RBP-4
558736|NCT00472342|adrenomedullin
558737|NCT00472303|Opioid
558738|NCT00472303|Central acting analgesic
558739|NCT00472303|CG5503 PR
558740|NCT00472303|Tumor related pain
558741|NCT00472303|Cancer related pain
558742|NCT00472303|Morphine
558743|NCT00472303|Pain assessment
558744|NCT00472303|Placebo
558745|NCT00472290|Hematology
558746|NCT00472290|MDS
558747|NCT00472290|Myelodysplastic Syndromes
558748|NCT00472290|Thrombocytopenia
558749|NCT00472264|methodology study, PET Imaging, COPD patients
558750|NCT00472251|dutasteride
558751|NCT00472251|body mass index
558752|NCT00472251|testosterone
558753|NCT00472225|Chronic graft-versus-host disease
558754|NCT00472225|rituximab
558755|NCT00472186|Tonsillectomy
558756|NCT00472186|Pain
558757|NCT00472173|Apexification
558758|NCT00472173|Pulp necrosis
558759|NCT00472173|Calcium hydroxide
558760|NCT00472173|MTA
558761|NCT00472173|pulp necrosis of an anterior immature tooth
558762|NCT00472160|Preoxygenation
558763|NCT00472160|Non Invasive Ventilation
558764|NCT00472160|Continuous Positive Airway Pressure,
558765|NCT00472160|Intubation,
558766|NCT00472160|Organ failure
558767|NCT00472134|Hernia
558768|NCT00472134|Ventral
558769|NCT00472134|Laparoscopic Hernia Repair
558770|NCT00472108|Nodular Basal Cell Carcinoma
558771|NCT00472108|Basal Cell Carcinoma
558772|NCT00472108|PDT with Metvix 160 mg/g cream
558773|NCT00472108|PDT with placebo cream
558774|NCT00472108|Histological verification
558775|NCT00472095|diabetes
558776|NCT00472095|fotonovela
558777|NCT00472095|Latino
558778|NCT00472082|Immunosuppression
558779|NCT00472082|Renal Transplantation
558780|NCT00472069|Stress Urinary Incontinence
558781|NCT00472069|striated urethral sphincter insufficiency
558782|NCT00472069|myofibers
558783|NCT00472069|satellite cells
558784|NCT00472069|myotubes
558785|NCT00472069|urethral
558786|NCT00472069|Muscle fibres
558787|NCT00472056|Non-Hodgkin's Lymphoma
558788|NCT00472056|Lymphoid Malignancies
558789|NCT00472056|Lymphoma
558790|NCT00472056|BEAM Chemotherapy
558791|NCT00472056|Carmustine
558792|NCT00472056|BCNU
558793|NCT00472056|BiCNU
558794|NCT00472056|Etoposide
558795|NCT00472056|VePesid
558796|NCT00472056|Cytarabine
558797|NCT00472056|Cytosar
558798|NCT00472056|DepoCyt
558799|NCT00472056|Cytosine arabinosine hydrochloride
558800|NCT00472056|Ara-C
558801|NCT00472056|Melphalan
558802|NCT00472056|Rituximab
558803|NCT00472056|Rituxan
558804|NCT00472043|Nodular Basal Cell Carcinoma
558805|NCT00472043|Basal Cell Carcinoma
558806|NCT00472043|Photodynamic therapy (PDT)
558807|NCT00472043|Metvix
558808|NCT00472043|Histological verification
558809|NCT00472043|PDT with Metvix cream
558810|NCT00472043|PDT with Placebo cream
558811|NCT00472030|bullous pemphigoid
558812|NCT00472030|omalizumab
558813|NCT00472030|xolair
558814|NCT00472030|IgE
558815|NCT00472030|autoimmunity
558816|NCT00472030|skin disease
558817|NCT00472017|untreated childhood brain stem glioma
558818|NCT00471991|Oral contraceptive
558819|NCT00471991|ovulation inhibitory effect
558820|NCT00471978|non-small cell lung cancer
558821|NCT00471978|small cell lung cancer
558822|NCT00471978|pulmonary carcinoid tumor
558823|NCT00471952|Migraine
558824|NCT00471939|Burn, Meshed skin graft, PDGF
558825|NCT00471939|deep partial thickness or full thickness burns
558826|NCT00471926|Diabetes Care
558827|NCT00471913|Femur
558828|NCT00471913|Fracture
558829|NCT00471913|Antegrade
558830|NCT00471913|Nailing
558831|NCT00471913|Shaft
558832|NCT00471913|Abductor
558833|NCT00471887|stage III melanoma
558834|NCT00471887|stage IV melanoma
558835|NCT00471887|recurrent melanoma
558836|NCT00471861|Inflammatory Markers
558837|NCT00471861|Migraine
558838|NCT00471848|Thymoglobuline
558839|NCT00471848|Rabbit ATG
558840|NCT00471848|Ciclosporin
558841|NCT00471848|Aplastic Anemia
558842|NCT00471835|stage II non-small cell lung cancer
558843|NCT00471835|stage I non-small cell lung cancer
558844|NCT00471835|adenocarcinoma of the lung
558845|NCT00471835|adenosquamous cell lung cancer
558846|NCT00471835|large cell lung cancer
558847|NCT00471835|squamous cell lung cancer
558848|NCT00471822|Streptococcus pneumoniae nasopharyngeal carriage
558849|NCT00471796|Patients with functional chest pain and functional heartburns
558850|NCT00471783|gingivitis
558851|NCT00471783|chlorhexidine
558852|NCT00471783|dental floss
558853|NCT00471783|RCT
558854|NCT00471783|bleeding on probing
558855|NCT00471783|gingival and plaque indices
558856|NCT00471757|pnuemonia
558857|NCT00471757|influenca
558858|NCT00471744|benign epilepsy
558859|NCT00471744|pediatrics
558860|NCT00471744|children
558861|NCT00471744|rolandic epilepsy
558862|NCT00471744|levetiracetam
558863|NCT00471744|sulthiame
558864|NCT00471731|Ocular Surface Disease
558865|NCT00471731|Imprinting
558866|NCT00471731|Eye Abnormalities
558867|NCT00471731|Ovarian Insufficiency
558868|NCT00471731|Women's Eye Health and Disease
558869|NCT00471731|Turner Syndrome
558870|NCT00471731|TS
558871|NCT00471731|Premature Ovarian Failure
558872|NCT00471731|POF
558873|NCT00471731|Healthy Volunteer
558874|NCT00471731|HV
558875|NCT00471718|adenocarcinoma of the prostate
558876|NCT00471718|stage IV prostate cancer
558877|NCT00471718|recurrent prostate cancer
558878|NCT00471705|Miltefosine
558879|NCT00471705|Leishmaniasis
558880|NCT00471705|Glucantime
558881|NCT00471705|Thermotherapy
558882|NCT00471705|Colombia
558883|NCT00471679|disseminated neuroblastoma
558884|NCT00471679|localized unresectable neuroblastoma
558885|NCT00471679|recurrent neuroblastoma
558886|NCT00471679|regional neuroblastoma
558887|NCT00471679|stage 4S neuroblastoma
558888|NCT00471666|Malaria
558889|NCT00471666|Filariasis
558890|NCT00471666|Coinfection
558891|NCT00471666|Co-Infection
558892|NCT00471653|thrombocytopenia
558893|NCT00471653|adult anaplastic oligodendroglioma
558894|NCT00471653|adult brain stem glioma
558895|NCT00471653|adult mixed glioma
558896|NCT00471653|adult giant cell glioblastoma
558897|NCT00471653|adult gliosarcoma
558898|NCT00471653|adult glioblastoma
558899|NCT00471653|adult anaplastic astrocytoma
558900|NCT00471653|adult anaplastic ependymoma
558901|NCT00471653|adult pineal gland astrocytoma
558902|NCT00471640|pneumonia
558903|NCT00471640|dexamethasone
558904|NCT00471640|community-acquired pneumonia
558905|NCT00471614|HIV
558906|NCT00471614|AIDS
558907|NCT00471614|uridine
558908|NCT00471614|mitochondria
558909|NCT00471614|insulin resistance
558910|NCT00471614|Treatment Experienced
558911|NCT00471601|recurrent breast cancer
558912|NCT00471601|stage IA breast cancer
558913|NCT00471601|stage IB breast cancer
558914|NCT00471601|stage II breast cancer
558915|NCT00471601|stage IIIA breast cancer
558916|NCT00471601|stage IIIB breast cancer
558917|NCT00471601|stage IIIC breast cancer
558918|NCT00471601|stage IV breast cancer
558919|NCT00471588|Dopamine
558920|NCT00471588|OCD
558921|NCT00471588|MRI
558922|NCT00471588|stimulant users
558923|NCT00471575|fatty liver
558924|NCT00471575|pregnancy
558925|NCT00471575|ultra sound
558926|NCT00471575|Pregnant women at the end of pregnancy or immediately after birth.
558927|NCT00471575|controls-women with normal liver
558928|NCT00471575|correlation between ultrasonography and nutritional, obsthetric and laboratory data.
558929|NCT00471562|unspecified adult solid tumor, protocol specific
558930|NCT00471549|Diabetes
558931|NCT00471549|Dyslipidaemia
558932|NCT00471549|Atherosclerosis
558933|NCT00471549|Osteoprotegerin
558934|NCT00471549|Adhesion molecules
558935|NCT00471549|Simvastatin
558936|NCT00471523|Anovulation
558937|NCT00471523|Clomiphene citrate
558938|NCT00471523|Infertility
558939|NCT00471523|Metformin
558940|NCT00471523|PCOS
558941|NCT00471523|Treatment
558942|NCT00471510|androgenetic alopecia
558943|NCT00471510|male pattern hair loss
558944|NCT00471510|male pattern baldness
558945|NCT00471510|androgenetic alopecia or male pattern hair loss
558946|NCT00471497|leukemia
558947|NCT00471497|bone marrow
558948|NCT00471497|leukemia symptoms
558949|NCT00471497|lukemia
558950|NCT00471497|cml
558951|NCT00471497|complete blood count
558952|NCT00471497|lymphocyte
558953|NCT00471497|blood cancer
558954|NCT00471497|leukocytes
558955|NCT00471497|chronic leukemia
558956|NCT00471497|bone marrow biopsy
558957|NCT00471497|leukemia research
558958|NCT00471497|leukemia cells
558959|NCT00471497|bone marrow disease
558960|NCT00471497|chronic myeloid leukemia
558961|NCT00471497|blood cancer symptoms
558962|NCT00471497|white blood cell diseases
558963|NCT00471497|chronic myelogenous leukemia
558964|NCT00471497|leukemia treatment
558965|NCT00471497|leukemia facts
558966|NCT00471497|leucemia
558967|NCT00471497|facts about leukemia
558968|NCT00471497|myelogenous leukemia
558969|NCT00471497|newly diagnosed CML
558970|NCT00471497|newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
558971|NCT00471484|adult primary hepatocellular carcinoma
559093|NCT00471055|knee
558972|NCT00471484|localized unresectable adult primary liver cancer
558973|NCT00471484|advanced adult primary liver cancer
558974|NCT00471484|childhood hepatocellular carcinoma
558975|NCT00471484|stage III childhood liver cancer
558976|NCT00471484|stage IV childhood liver cancer
558977|NCT00471471|recurrent melanoma
558978|NCT00471471|stage IV melanoma
558979|NCT00471471|ciliary body and choroid melanoma, medium/large size
558980|NCT00471471|extraocular extension melanoma
558981|NCT00471471|iris melanoma
558982|NCT00471471|recurrent intraocular melanoma
558983|NCT00471471|metastatic intraocular melanoma
558984|NCT00471471|conjunctival melanoma
558985|NCT00471471|stage IIIA melanoma
558986|NCT00471471|stage IIIB melanoma
558987|NCT00471471|stage IIIC melanoma
558988|NCT00471458|Radioiodine
558989|NCT00471458|Hyperthyroidism
558990|NCT00471458|Morbidity
558991|NCT00471458|Cardiovascular diseases
558992|NCT00471445|unspecified adult solid tumor, protocol specific
558993|NCT00471445|pain
558994|NCT00471445|neurotoxicity
558995|NCT00471445|peripheral neuropathy
558996|NCT00471432|recurrent prostate cancer
558997|NCT00471432|stage IV prostate cancer
558998|NCT00471432|recurrent renal cell cancer
558999|NCT00471432|stage IV renal cell cancer
559000|NCT00471432|recurrent non-small cell lung cancer
559001|NCT00471432|stage IV non-small cell lung cancer
559002|NCT00471432|recurrent bladder cancer
559003|NCT00471432|stage IV bladder cancer
559004|NCT00471432|recurrent breast cancer
559005|NCT00471432|stage IV breast cancer
559006|NCT00471432|recurrent ovarian epithelial cancer
559007|NCT00471432|stage IV ovarian epithelial cancer
559008|NCT00471432|unspecified adult solid tumor, protocol specific
559009|NCT00471432|male breast cancer
559010|NCT00471393|TMJ
559011|NCT00471393|Osteoarthritis
559012|NCT00471393|Degenerative Joint disease
559013|NCT00471367|Phase I
559014|NCT00471367|AZD4877
559015|NCT00471367|Lymphoma
559016|NCT00471367|B-cell non-Hodgkin lymphoma
559017|NCT00471341|arteriosclerosis
559018|NCT00471341|coronary disease
559019|NCT00471341|inflammation
559020|NCT00471341|COX-2 inhibition
559021|NCT00471341|hypertension
559022|NCT00471328|GIST
559023|NCT00471328|adults
559024|NCT00471328|imatinib resistant
559025|NCT00471328|sunitinib resistant
559026|NCT00471328|AMN107
559027|NCT00471328|nilotinib
559028|NCT00471328|treatment
559029|NCT00471328|Gastrointestinal stromal tumor (GIST)
559030|NCT00471315|SOD
559031|NCT00471315|Common Bile Duct Diseases
559032|NCT00471315|Sphincterotomy
559033|NCT00471315|Cholangiopancreatography, Endoscopic Retrograde
559034|NCT00471302|Healthy Volunteers
559035|NCT00471302|Immunological Parameters
559036|NCT00471302|Mali
559037|NCT00471302|B Lymphocyte
559038|NCT00471302|Malaria
559039|NCT00471302|Healthy Volunteer
559040|NCT00471289|Critical Limb Ischemia
559041|NCT00471289|Stents
559042|NCT00471289|Drug Eluting Stents
559043|NCT00471289|Peripheral arterial disease
559044|NCT00471289|PAD
559045|NCT00471289|Paclitaxel
559046|NCT00471289|TAXUS
559047|NCT00471289|Infrapopliteal
559048|NCT00471289|Infragenicular
559049|NCT00471289|Interventional Radiology
559050|NCT00471289|CLI
559051|NCT00471289|DES
559052|NCT00471276|Metastatic Breast Cancer
559053|NCT00471250|Bronchoscopy
559054|NCT00471250|Bronchoalveolar Lavage
559055|NCT00471250|Nasal Mucosal Biopsy
559056|NCT00471250|Research Procedures
559057|NCT00471250|Infection Susceptibility
559058|NCT00471250|Lung Infection Susceptibility
559059|NCT00471250|Healthy Volunteer
559060|NCT00471250|HV
559061|NCT00471237|bone mineral density,
559062|NCT00471237|Ronacaleret
559063|NCT00471237|teriparatide
559064|NCT00471237|alendronate,
559065|NCT00471237|Post-menopausal women,
559066|NCT00471237|osteoporosis,
559067|NCT00471237|SB-751689
559068|NCT00471185|Male Contraception
559069|NCT00471185|Acyline
559070|NCT00471146|Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer.
559071|NCT00471133|melanoma
559072|NCT00471133|DNA vaccine
559073|NCT00471133|tyrosinase
559074|NCT00471133|electroporation
559075|NCT00471107|Frontal Lobe
559076|NCT00471107|Language
559077|NCT00471107|Dementia
559078|NCT00471107|Healthy Volunteer
559079|NCT00471107|HV
559080|NCT00471094|heartburn
559081|NCT00471094|erosive esophagitis
559082|NCT00471094|healing
559083|NCT00471094|population pharmacokinetics
559084|NCT00471094|Quality of Life (QoL)
559085|NCT00471081|Neisseria meningitidis;
559086|NCT00471081|Humans;
559087|NCT00471081|Meningococcal vaccines;
559088|NCT00471081|Safety
559089|NCT00471081|Vaccines, conjugate;
559090|NCT00471081|Toddlers;
559091|NCT00471081|Immunogenicity;
559092|NCT00471055|osteoarthritis
559094|NCT00471055|capsaicin gel
559095|NCT00471055|capsicum
559096|NCT00471042|Heroin Dependence
559097|NCT00471042|Opioid Dependence
559098|NCT00471042|Primary Care
559099|NCT00471042|Buprenorphine
559100|NCT00471029|pH study, peptic ulcer, proton pump inhibitor
559101|NCT00471003|Hypertension
559102|NCT00470990|IHH
559103|NCT00470990|Kallmann syndrome
559104|NCT00470990|hypogonadism
559105|NCT00470964|laser trabeculoplasty, glaucoma, argon, titanium-sapphire
559106|NCT00470964|IOP lowering effect
559107|NCT00470964|Adverse effects
559108|NCT00470964|IOP spikes
559109|NCT00470951|rectal cancer
559110|NCT00470951|laparoscopic assisted resection
559111|NCT00470951|open resection
559112|NCT00470951|preoperative chemoradiation
559113|NCT00470951|randomized trial
559114|NCT00470925|Neurological
559115|NCT00470925|Dopamine
559116|NCT00470912|cutaneous lupus erythemaosus
559117|NCT00470912|photoprotection
559118|NCT00470912|photoprovocation
559119|NCT00470912|Sunscreen RV 2547C
559120|NCT00470899|Feto-maternal transfusion
559121|NCT00470899|Kleihauer-Betke
559122|NCT00470847|Herceptin
559123|NCT00470847|breast cancer
559124|NCT00470847|radiation therapy
559125|NCT00470847|stereotactic radiosurgery
559126|NCT00470847|SRS
559127|NCT00470847|whole brain radiation
559128|NCT00470847|WBRT
559129|NCT00470834|prostate cancer
559130|NCT00470834|androgen deprivation therapy
559131|NCT00470821|melatonin
559132|NCT00470821|actigraphy
559133|NCT00470821|sedation
559134|NCT00470821|critical patients
559135|NCT00470821|ICU
559136|NCT00470808|Minors
559137|NCT00470808|Enrollment in another study
559138|NCT00470808|Males
559139|NCT00470808|HBA1C greater than 7
559140|NCT00470808|Drug therapy for DM
559141|NCT00470795|diabetes
559142|NCT00470795|gastroparesis
559143|NCT00470795|acupuncture
559144|NCT00470795|symptoms
559145|NCT00470795|gastric emptying
559146|NCT00470782|colonic neoplasms
559147|NCT00470782|exercise
559148|NCT00470782|body composition
559149|NCT00470782|anthropometry
559150|NCT00470769|Color-Doppler Ultrasonography
559151|NCT00470769|Renal scintigraphy
559152|NCT00470769|Kidney failure
559153|NCT00470769|GFR
559154|NCT00470743|Ibuprofen
559155|NCT00470743|Indomethacin
559156|NCT00470743|Infant, very low birth weight
559157|NCT00470743|Prematurity
559158|NCT00470743|Ductus Arteriosus, patent
559159|NCT00470717|late preterm infant
559160|NCT00470717|breastfeeding
559161|NCT00470717|formula feeding
559162|NCT00470717|rehospitalization
559163|NCT00470717|telephone
559164|NCT00470704|HER2-positive breast cancer
559165|NCT00470704|Herceptin
559166|NCT00470704|trastuzumab
559167|NCT00470678|Age-related
559168|NCT00470678|macular
559169|NCT00470678|degeneration
559170|NCT00470678|AMD
559171|NCT00470678|Ranibizumab
559172|NCT00470678|Anti-VEGF
559173|NCT00470678|choroidal
559174|NCT00470678|neovascularization
559175|NCT00470678|CNV
559176|NCT00470678|Asian patients
559177|NCT00470678|Korea
559178|NCT00470678|Taiwan
559179|NCT00470678|associated
559180|NCT00470652|pain
559181|NCT00470652|Pain Measurement
559182|NCT00470652|Decision Making, Computer-Assisted
559183|NCT00470652|Informatics
559184|NCT00470639|TMS
559185|NCT00470639|Treatment
559186|NCT00470639|Bipolar
559187|NCT00470639|Efficacy
559188|NCT00470626|Pulmonary Embolism
559189|NCT00470626|Venous Thromboembolism
559190|NCT00470626|Inferior Vena Cava Filter
559191|NCT00470626|IVC
559192|NCT00470626|PE
559193|NCT00470613|Neoplasm
559194|NCT00470587|chest pain
559195|NCT00470587|myocardial infarction
559196|NCT00470587|unstable angina
559197|NCT00470574|recurrent breast cancer
559198|NCT00470574|stage IV breast cancer
559199|NCT00470574|male breast cancer
559200|NCT00470561|mammographic breast density aspirin
559201|NCT00470548|male breast cancer
559202|NCT00470548|recurrent breast cancer
559203|NCT00470548|stage IIIA breast cancer
559204|NCT00470548|stage IIIB breast cancer
559205|NCT00470548|stage IIIC breast cancer
559206|NCT00470548|stage IV breast cancer
559207|NCT00470548|stage IIIA non-small cell lung cancer
559208|NCT00470548|stage IIIB non-small cell lung cancer
559209|NCT00470548|stage IV non-small cell lung cancer
559210|NCT00470548|recurrent non-small cell lung cancer
559211|NCT00470548|unspecified adult solid tumor, protocol specific
559212|NCT00470535|adenocarcinoma of the pancreas
559213|NCT00470535|recurrent pancreatic cancer
559214|NCT00470535|stage III pancreatic cancer
559215|NCT00470535|stage IV pancreatic cancer
559216|NCT00470522|methotrexate
559217|NCT00470522|folic acid
559218|NCT00470522|systemic lupus erythematosus
559219|NCT00470522|steroid
559220|NCT00470483|PET
559221|NCT00470483|fRMI
559222|NCT00470483|Social Anxiety Disorder
559223|NCT00470444|Cardiac Surgery
559224|NCT00470444|Transfusion Medicine
559225|NCT00470444|Cardiac Anesthesia Risk Evaluation (CARE) Score of 3 or 4
559226|NCT00470444|(Dupuis J-Y et al, Anesthesiology 2001;94: 194-204)
559227|NCT00470158|zinc
559228|NCT00470158|iron
559229|NCT00470158|interaction
559230|NCT00470158|diarrhea
559231|NCT00470158|delivery
559232|NCT00470145|unmilled formulation,
559233|NCT00470145|micronised formulation
559234|NCT00470145|relative bioavailability,
559235|NCT00470132|ventricular shunt
559236|NCT00470119|breast cancer
559237|NCT00470119|obesity
559238|NCT00470119|weight changes
559239|NCT00470106|Cognition
559240|NCT00470106|Remediation
559241|NCT00470106|Schizophrenia
559242|NCT00470106|Social Cognition
559243|NCT00470093|refractory multiple myeloma
559244|NCT00470093|stage I multiple myeloma
559245|NCT00470093|stage II multiple myeloma
559246|NCT00470093|stage III multiple myeloma
559247|NCT00470080|Venepuncture
559248|NCT00470080|Pain
559249|NCT00470080|Emla cream
559250|NCT00470080|Oral sucrose solution
559251|NCT00470080|Premature infant
559252|NCT00470080|Premature infant admitted to the care baby unit were
559253|NCT00470080|included in the study.
559254|NCT00470080|Programed venepuncture is performed with analgesia.
559255|NCT00470067|recurrent endometrial carcinoma
559256|NCT00470067|stage III endometrial carcinoma
559257|NCT00470067|stage IV endometrial carcinoma
559258|NCT00470041|Healthy volunteers
559259|NCT00470028|TMS
559260|NCT00470028|Treatment
559261|NCT00470028|Adolescents
559262|NCT00470028|Safety
559263|NCT00470028|Efficacy
559264|NCT00470015|stage II melanoma
559265|NCT00470015|stage III melanoma
559266|NCT00470015|stage IV melanoma
559267|NCT00470015|recurrent melanoma
559268|NCT00470002|growth hormone
559269|NCT00470002|nitric oxide
559270|NCT00470002|nitrate
559271|NCT00470002|cyclic guanosine monophosphate
559272|NCT00470002|insulin-like growth factor-1
559273|NCT00470002|asymmetric dimethylarginine
559274|NCT00470002|blood pressure
559275|NCT00470002|endothelial progenitor cells
559276|NCT00469989|immune system
559277|NCT00469989|allergy
559278|NCT00469989|hookworm infection
559279|NCT00469989|parasite infection
559280|NCT00469989|asthma
559281|NCT00469976|stage IIIB non-small cell lung cancer
559282|NCT00469976|stage IV non-small cell lung cancer
559283|NCT00469976|recurrent non-small cell lung cancer
559284|NCT00469963|adult primary hepatocellular carcinoma
559285|NCT00469963|localized unresectable adult primary liver cancer
559286|NCT00469963|recurrent adult primary liver cancer
559287|NCT00469963|advanced adult primary liver cancer
559288|NCT00469950|PCI
559289|NCT00469950|stent
559290|NCT00469950|training
559291|NCT00469950|endothelial function
559292|NCT00469950|restenosis
559293|NCT00469950|late luminal loss
559294|NCT00469950|heart rate variability
559295|NCT00469950|oxygen uptake capacity
559296|NCT00469950|inflammatory markers
559297|NCT00469937|radiation toxicity
559298|NCT00469937|neurotoxicity
559299|NCT00469937|cognitive/functional effects
559300|NCT00469937|unspecified adult solid tumor, protocol specific
559301|NCT00469937|adult tumors metastatic to brain
559302|NCT00469924|Informatics
559303|NCT00469924|Clinical Laboratory Information Systems
559304|NCT00469924|Hospital Communication Systems
559305|NCT00469924|Laboratory Techniques and Procedures
559306|NCT00469924|Point-of-Care Systems
559307|NCT00469924|Therapy, Computer-Assisted
559308|NCT00469911|Heart
559309|NCT00469911|Transplant
559310|NCT00469911|MRS
559311|NCT00469911|MRI
559312|NCT00469911|Spectroscopy
559313|NCT00469898|extensive stage small cell lung cancer
559314|NCT00469885|Smoking cessation
559315|NCT00469885|cardiovascular disease
559316|NCT00469885|smoking reduction
559317|NCT00469885|nicotine replacement
559318|NCT00469859|recurrent childhood acute myeloid leukemia
559319|NCT00469859|adult acute myeloid leukemia with t(16;16)(p13;q22)
559320|NCT00469859|adult acute myeloid leukemia with t(8;21)(q22;q22)
559321|NCT00469859|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
559322|NCT00469859|adult acute myeloid leukemia with inv(16)(p13;q22)
559323|NCT00469859|adult acute myeloid leukemia with t(15;17)(q22;q12)
559324|NCT00469859|recurrent adult acute myeloid leukemia
559325|NCT00469859|secondary acute myeloid leukemia
559326|NCT00469846|Pre-Eclampsia
559327|NCT00469846|Hypertension,pregnancy-induced
559328|NCT00469846|Preterm labor
559329|NCT00469833|Diabetes
559330|NCT00469833|Glucose Tolerance
559331|NCT00469833|Incretin
559332|NCT00469833|Insulin
559333|NCT00469820|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
559334|NCT00469820|adult acute myeloid leukemia with inv(16)(p13;q22)
559335|NCT00469820|adult acute myeloid leukemia with t(15;17)(q22;q12)
559336|NCT00469820|adult acute myeloid leukemia with t(16;16)(p13;q22)
559337|NCT00469820|adult acute myeloid leukemia with t(8;21)(q22;q22)
559338|NCT00469820|recurrent adult acute lymphoblastic leukemia
559339|NCT00469820|recurrent adult acute myeloid leukemia
559340|NCT00469820|secondary acute myeloid leukemia
559341|NCT00469820|stage III multiple myeloma
559342|NCT00469820|untreated adult acute lymphoblastic leukemia
559343|NCT00469820|untreated adult acute myeloid leukemia
559344|NCT00469820|stage I multiple myeloma
559345|NCT00469820|stage II multiple myeloma
559346|NCT00469820|refractory multiple myeloma
559347|NCT00469807|Ghrelin
559348|NCT00469807|Pregnancy outcome
559349|NCT00469794|arrhythmias
559350|NCT00469794|Athletes
559351|NCT00469794|exercise
559352|NCT00469768|HIV-1 infection
559353|NCT00469768|HIV Seronegativity
559354|NCT00469742|Cardiology
559355|NCT00469742|Pediatrics
559356|NCT00469742|Cardiac Defects
559357|NCT00469742|Cardiopulmonary Bypass Surgery
559358|NCT00469742|Aprotinin
559359|NCT00469742|thrombosis
559360|NCT00469742|renal dysfunction
559361|NCT00469729|Tetraethylenepentamine
559362|NCT00469729|Umbilical Cord Blood Stem Cell Transplantation
559363|NCT00469729|Hematological Malignancies
559364|NCT00469729|Acute Lymphoid Leukemia
559365|NCT00469729|Subjects with high-risk hematologic malignancies who are candidates for allogeneic stem cell transplantation
559366|NCT00469716|Fluid balance
559367|NCT00469716|respiratory function
559368|NCT00469716|cardiac function
559369|NCT00469716|inflammation
559370|NCT00469716|Cardiopulmonary bypass
559371|NCT00469703|Pancreatitis
559372|NCT00469664|Schizophrenia
559373|NCT00469664|Schizoaffective
559374|NCT00469664|Cognitive Impairment
559375|NCT00469664|Cognition
559376|NCT00469664|Memory
559377|NCT00469664|Attention
559378|NCT00469664|Concentration
559379|NCT00469651|Malaria
559380|NCT00469651|vaccine
559381|NCT00469651|MSP3LSP
559382|NCT00469651|Safety
559383|NCT00469651|children
559384|NCT00469651|Tanzania
559385|NCT00469638|atrial fibrillation
559386|NCT00469638|paroxysmal
559387|NCT00469638|persistent
559388|NCT00469638|symptomatic
559389|NCT00469638|ablation
559390|NCT00469638|catheter
559391|NCT00469638|introducer
559392|NCT00469638|Agilis NxT
559393|NCT00469638|sinus rhythm
559394|NCT00469638|paroxysmal atrial fibrillation
559395|NCT00469638|persistent atrial fibrillation
559396|NCT00469638|symptomatic atrial fibrillation
559397|NCT00469612|Myopia
559398|NCT00469612|NeuroVision
559399|NCT00469612|Visual acuity
559400|NCT00469612|Contrast sensitivity
559401|NCT00469599|Hyperparathyroidism, Secondary
559402|NCT00469599|Kidney Failure, Chronic
559403|NCT00469599|Renal Insufficiency, Chronic
559404|NCT00469599|Vitamin D Deficiency
559405|NCT00469599|Renal Osteodystrophy
559406|NCT00469599|Hemodialysis
559407|NCT00469560|MDS
559408|NCT00469560|Chronic transfusional hemosiderosis
559409|NCT00469560|Deferasirox
559410|NCT00469547|ethanol, microbicide, sexually transmitted, Kenya, males
559411|NCT00469547|HIV Seronegativity
559412|NCT00469534|minimized time to beam
559413|NCT00469534|hypofractionated 3D CRT plus IMRT
559414|NCT00469534|PET-scan
559415|NCT00469508|Methamphetamine
559416|NCT00469508|Modafinil
559417|NCT00469508|Medication
559418|NCT00469508|Contingency Management
559419|NCT00469508|Crystal meth
559420|NCT00469508|Los Angeles
559421|NCT00469508|Addiction
559422|NCT00469508|Meth
559423|NCT00469482|Delirium
559424|NCT00469482|Cognitive Impairment
559425|NCT00469482|Sleep
559426|NCT00469482|Polysomnography
559427|NCT00469482|Sedation
559428|NCT00469482|Mechanical Ventilation
559429|NCT00469482|Critical Illness
559430|NCT00469469|Adrenal Cortex
559431|NCT00469469|ACC
559432|NCT00469456|memantine
559433|NCT00469456|Alzheimer's Disease
559434|NCT00469456|communication
559435|NCT00469443|Metastatic colorectal cancer
559436|NCT00469443|Irinotecan
559437|NCT00469443|Capecitabine
559438|NCT00469443|Bevacizumab
559439|NCT00469430|appendicitis
559440|NCT00469430|treatment
559441|NCT00469430|antibiotics
559442|NCT00469417|Methyl aminolevulinate
559443|NCT00469417|Photodynamic therapy
559444|NCT00469417|Primary Superficial Basal Cell Carcinoma
559445|NCT00469404|Transdermal patch
559446|NCT00469404|Centrally acting analgesic
559447|NCT00469404|Plasma level
559448|NCT00469404|Healthy volunteers
559449|NCT00469391|Weight Reduction
559450|NCT00469378|firategrast
559451|NCT00469378|lymphocytes
559452|NCT00469378|leukocytes
559453|NCT00469378|SB-683699
559454|NCT00469378|cerebrospinal fluid
559455|NCT00469378|relapsing forms of multiple sclerosis
559456|NCT00469365|clinical trial, medication adherence, pharmacy intervention
559457|NCT00469365|Patients with specific chronic diseases
559458|NCT00469352|Pharmacogenetics
559459|NCT00469352|Genetics
559460|NCT00469352|Treatment response
559461|NCT00469352|AMD
559462|NCT00469352|Wet AMD
559463|NCT00469352|Age-related macular degeneration
559464|NCT00469339|Diabetes
559465|NCT00469339|Colon Cancer
559466|NCT00469339|Cardiovascular Disease
559467|NCT00469326|coronary artery disease
559468|NCT00469326|percutaneous coronary intervention
559469|NCT00469326|atorvastatin
559470|NCT00468338|general anesthesia
559471|NCT00468338|dental rehabilitation
559472|NCT00468338|mental retardation
559473|NCT00468325|coronary artery disease
559474|NCT00468325|chest pain
559475|NCT00468325|emergency room
559476|NCT00468299|early
559477|NCT00468299|pregnancy
559478|NCT00468299|failure
559479|NCT00468299|mifepristone
559480|NCT00468299|misoprostol
559481|NCT00468299|buccal
559482|NCT00468299|miscarriage
559483|NCT00468299|fetal
559484|NCT00468299|demise
559485|NCT00468299|anembryonic
559486|NCT00468299|progesterone
559487|NCT00468286|Prostate Cancer
559488|NCT00468273|Deficiency Syndromes, Antibody
559489|NCT00468273|Antibody Deficiency Syndrome
559490|NCT00468273|Bruton's agammaglobulinemia
559491|NCT00468273|Common Variable Immune Deficiency
559492|NCT00468273|Hyper IgM syndromes
559493|NCT00468260|Cancer
559494|NCT00468260|EPO906
559495|NCT00468260|Patupilone
559496|NCT00468247|mean systemic pressure
559497|NCT00468247|fluid therapy
559498|NCT00468247|closed loop control
559499|NCT00468247|circulation modelling
559500|NCT00468234|smoking cessation
559501|NCT00468234|harm reduction
559502|NCT00468234|biomarker
559503|NCT00468234|exhaled breath condensate
559504|NCT00468221|Ozone
559505|NCT00468221|Healthy Adults
559506|NCT00468208|Vasculitis
559507|NCT00468208|Relapse
559508|NCT00468208|Wegener's
559509|NCT00468208|Treatment
559510|NCT00468195|tomography
559511|NCT00468195|coronary artery disease
559512|NCT00468195|obesity
559513|NCT00469313|copd
559514|NCT00469313|inspiratory muscle training
559515|NCT00469313|IF
559516|NCT00469300|herpes labialis
559517|NCT00469300|cold sore
559518|NCT00469300|acyclovir
559519|NCT00469300|iontophoresis
559520|NCT00469300|topical
559521|NCT00469287|diabetes mellitus
559522|NCT00469287|blood sugar
559523|NCT00469287|overweight
559524|NCT00469287|obesity
559525|NCT00469287|Traditional Chinese medicine
559526|NCT00469274|Pertussis
559527|NCT00469274|Healthcare worker
559528|NCT00469274|Post-exposure prophylaxis
559529|NCT00469274|Vaccination
559530|NCT00469274|Pertussis in healthcare workers following occupational
559531|NCT00469274|exposure to pertussis
559532|NCT00469261|Myocardial infarction
559533|NCT00469261|Ventricular remodeling
559534|NCT00469261|Matrix metalloproteinases
559535|NCT00469261|Doxycycline
559536|NCT00469248|Myocardial infarction
559537|NCT00469248|Cardiogenic shock
559538|NCT00469248|Systemic inflammatory response syndrome
559539|NCT00469248|Percutaneous coronary intervention
559540|NCT00469248|aortic balloon counterpulsation
559541|NCT00469222|small cell lung cancer
559542|NCT00469222|radiotherapy dose escalation
559543|NCT00469209|Multiple Myeloma
559544|NCT00469209|Melphalan
559545|NCT00469209|Trisenox
559546|NCT00469209|Arsenic Trioxide
559547|NCT00469209|Ascorbic Acid
559548|NCT00469209|Vitamin C
559549|NCT00469209|Velcade
559550|NCT00469209|Bortezomib
559551|NCT00469196|mesothelioma
559552|NCT00469196|tomotherapy
559553|NCT00469170|HIV-1
559554|NCT00469170|HIV seronegativity
559555|NCT00469157|compatibility of Optive after PRK or LASIK
559556|NCT00469144|Stem Cell Transplantation
559557|NCT00469144|Leukemia
559558|NCT00469144|Busulfan
559559|NCT00469144|Fludarabine
559560|NCT00469144|MDS
559561|NCT00469144|AML
559562|NCT00469131|liver transplantation,
559563|NCT00469131|HCV recurrence,
559564|NCT00469131|immunosuppression
559565|NCT00469105|Type 2 Diabetes
559566|NCT00469105|Diabetes Education
559567|NCT00469105|Health Literacy
559568|NCT00469079|Biomarkers
559569|NCT00469079|Smoking
559570|NCT00469079|Tobacco
559571|NCT00469079|Cessation
559572|NCT00469066|small cell lung cancer
559573|NCT00469066|bladder cancer
559574|NCT00469066|conformal radiotherapy
559575|NCT00469053|Transdermal patch
559576|NCT00469053|multidose
559577|NCT00469053|Centrally acting analgesic
559578|NCT00469053|Plasma level
559579|NCT00469053|Healthy volunteers
559580|NCT00469040|GW642444,
559581|NCT00469040|healthy subjects
559582|NCT00469040|magnesium stearate,
559583|NCT00469027|Pulmonary Arterial Hypertension (PAH)
559584|NCT00469014|Acute Myeloid Leukemia
559585|NCT00469014|AML
559586|NCT00469014|Myelodysplastic Syndrome
559587|NCT00469014|MDS
559588|NCT00469014|Chronic Myeloid Leukemia
559589|NCT00469014|CML
559590|NCT00469014|Busulfan
559591|NCT00469014|Busulfex
559592|NCT00469014|Myleran
559593|NCT00469014|Fludarabine
559594|NCT00469014|Fludara
559595|NCT00469014|Fludarabine Phosphate
559596|NCT00469014|Clofarabine
559597|NCT00469014|Clofarex
559598|NCT00469014|Clolar
559599|NCT00469014|Allogeneic stem cell transplantation
559600|NCT00469014|ASCT
559601|NCT00469014|Stem Cell
559602|NCT00469014|Gleevec
559603|NCT00469014|Imatinib Mesylate
559604|NCT00469001|Hospitalization and death from exacerbation CHF.
559605|NCT00468949|Health-Related Quality of Life
559606|NCT00468949|Dupuytren's Disease
559607|NCT00468949|Health Utilities Index
559608|NCT00468949|Short Form-36;
559609|NCT00468949|Michigan Hand Outcomes Questionnaire
559610|NCT00468936|anti-rejection
559611|NCT00468936|GI side effects
559612|NCT00468936|heart transplant patients
559613|NCT00468923|Primary prevention
559614|NCT00468923|Cholesterol lowering
559615|NCT00468923|Blood pressure lowering
559616|NCT00468923|Cardiovascular disease prevention
559617|NCT00468897|Alzheimers Disease
559618|NCT00468897|bioequivalence
559619|NCT00468897|healthy volunteers
559620|NCT00468884|Kinetics of GLP-1 and PYY3-36; increasing oral doses
559621|NCT00468858|Dengue
559622|NCT00468858|Virus
559623|NCT00468858|Live-attenuated
559624|NCT00468858|Vaccine
559625|NCT00468858|Dengue viral infection
559626|NCT00468858|Dengue Vaccine
559627|NCT00468845|pain after hysterectomy
559628|NCT00468845|amount of opioids used
559629|NCT00468819|Contrast-enhanced MRI
559630|NCT00468819|MR angiography (MRA) Children 2-17 years
559631|NCT00468806|PET scan
559632|NCT00468806|Health Males
559633|NCT00468793|central venous saturation
559634|NCT00468793|bowel surgery
559635|NCT00468793|morbidity
559636|NCT00468793|intravenous infusions
559637|NCT00468780|Canadian Triage Acuity Scale
559638|NCT00468780|paramedics
559639|NCT00468780|triage nurse
559640|NCT00468780|triage levels
559641|NCT00468780|inter-rater reliability
559642|NCT00468780|health services outcomes
559643|NCT00468767|Atrial fibrillation
559644|NCT00468767|RSD1235
559645|NCT00468767|Atrial fibrillation of 3 hours to 7 days duration.
559646|NCT00468767|Atrial fibrillation of 3 hours to 45 days duration.
559647|NCT00468741|Breast Cancer
559648|NCT00468741|Internet
559649|NCT00468741|Computer
559650|NCT00468741|Support
559651|NCT00468741|Information
559652|NCT00468741|Education
559653|NCT00468741|Control Group: Usual care and Internet access
559654|NCT00468741|CHESS Information Services only
559655|NCT00468741|CHESS Social Support & Information Services
559656|NCT00468741|CHESS Information, Social Support & Skills Services
559657|NCT00468728|CDAD, Clostridium difficile, diarrhea
559658|NCT00468728|Clostridium difficile-Associated Diarrhea
559659|NCT00468715|stage IV breast cancer
559660|NCT00468715|recurrent breast cancer
559661|NCT00468715|male breast cancer
559662|NCT00468689|SB-751689,
559663|NCT00468689|Calcium-sensing receptor antagonist (CaR),
559664|NCT00468689|Osteoporosis,
559665|NCT00468689|Parathyroid hormone (PTH),
559666|NCT00468689|Oral dose
559667|NCT00468676|major Depressive Disorder
559668|NCT00468676|Diabetes
559669|NCT00468676|Heart Disease
559670|NCT00468663|preeclampsia
559671|NCT00468663|preterm delivery
559672|NCT00468663|lipid peroxidation
559673|NCT00468663|inflammation
559674|NCT00468637|heart failure
559675|NCT00468637|cardiovascular high risk
559676|NCT00468637|erectile dysfunction
559677|NCT00468637|cardiovascular disease
559678|NCT00468624|Growth hormone
559679|NCT00468624|insulin-like growth factor 1
559680|NCT00468624|pegvisomant
559681|NCT00468611|Secondary Progressive Multiple Sclerosis
559682|NCT00468611|Multiple Sclerosis
559683|NCT00468598|troponin
559684|NCT00468598|long-term outcome
559685|NCT00468598|on-pump cardiac surgery
559686|NCT00468585|Breast cancer
559687|NCT00468585|Metastatic breast cancer
559688|NCT00468585|Breast
559689|NCT00468585|Metastatic
559690|NCT00468572|Emotion
559691|NCT00468572|Oxytocin
559692|NCT00468572|Cortisol
559693|NCT00468559|pediatrics
559694|NCT00468559|neonates
559695|NCT00468533|Arupiprazole, prolacin, PANSS, CGI, AIMS
559696|NCT00468520|induction of labor
559697|NCT00468520|cervical ripening
559698|NCT00468520|Foley catheter
559699|NCT00468520|oxytocin
559700|NCT00468507|CCK release
559701|NCT00468494|non diabetic
559702|NCT00468494|catabolic energy state
559703|NCT00468481|Healthy women requesting contraception
559704|NCT00468481|Folic Acid
559705|NCT00468468|breast cancer
559706|NCT00468468|Internet
559707|NCT00468468|computer
559708|NCT00468468|support
559709|NCT00468468|information
559710|NCT00468468|education
559711|NCT00468455|Colorectal Surgery
559712|NCT00468455|Abdominal Surgery
559713|NCT00468455|Diverticulitis
559714|NCT00468455|Colon Cancer
559715|NCT00468455|Rectal Cancer
559716|NCT00468455|Colon Polyp
559717|NCT00468455|Rectal Polyp
559718|NCT00468455|Crohn's Disease
559719|NCT00468442|Insulin dependence
559720|NCT00468442|Hypoglycemia
559721|NCT00468442|Hypoglycemia unawareness
559722|NCT00468429|Glaucoma
559723|NCT00468429|Bevacizumab
559724|NCT00468429|Glaucoma Filtration Surgery
559725|NCT00468429|Mitomycin C
559726|NCT00468429|Intraocular Pressure
559727|NCT00468403|Insulin dependence
559728|NCT00468403|Hypoglycemia
559729|NCT00468403|Hypoglycemia unawareness
559730|NCT00468364|Hypoglycemia, bedtime insulin, long-acting insulin
559731|NCT00468351|bevacizumab
559732|NCT00468351|diabetes
559733|NCT00468351|intravitreal
559734|NCT00468351|macular edema
559735|NCT00468351|triamcinolone
559736|NCT00468351|VEGF
559737|NCT00468182|Multiple sclerosis
559738|NCT00468182|Interferon beta
559739|NCT00468182|plasmacytoid dendritic cells
559740|NCT00468169|Cetuximab
559741|NCT00468169|Erbitux
559742|NCT00468169|locally
559743|NCT00468169|advanced
559744|NCT00468169|head
559745|NCT00468169|neck
559746|NCT00468169|cancer
559747|NCT00468169|neoplasms
559748|NCT00468169|squamous
559749|NCT00468169|carcinoma
559750|NCT00468169|lymphoepithelioma
559751|NCT00468156|fruit
559752|NCT00468156|vegetables
559753|NCT00468156|prevention
559754|NCT00468156|cancer
559755|NCT00468156|counseling
559756|NCT00468156|cancer risk
559757|NCT00468130|Aggression
559758|NCT00468130|Irritability
559759|NCT00468130|Global autism severity
559760|NCT00468117|Hypoglycemia
559761|NCT00468117|Kidney Transplant
559762|NCT00468117|Insulin independence
559763|NCT00468117|Islet Transplantation
559764|NCT00468117|Intensive Insulin Therapy
559765|NCT00468104|parapneumonic pleural effusion
559766|NCT00468104|empyema
559767|NCT00468104|TPA (Activase, Alteplase)
559768|NCT00468091|GLP-1
559769|NCT00468091|exendin(9-39)
559770|NCT00468091|atropine
559771|NCT00468091|human
559772|NCT00468091|motility
559773|NCT00468078|Parkinson's disease
559774|NCT00468078|Essential tremor
559775|NCT00468078|F-18 FPCIT
559776|NCT00468078|PET
559777|NCT00468065|intravenous
559778|NCT00468065|catheter
559779|NCT00468065|IV
559780|NCT00468052|obstructive sleep apnea
559781|NCT00468052|tonsillectomy
559782|NCT00468052|adenoidectomy
559783|NCT00468039|metformin
559784|NCT00468039|vildagliptin
559785|NCT00468039|initial combination
559786|NCT00468026|BPH
559787|NCT00468026|Prostate
559788|NCT00468026|Stent
559789|NCT00468026|Benign prostatic hyperplasia (BPH)
559790|NCT00468013|Fibromyalgia
559791|NCT00468013|Irritable Bowel
559792|NCT00468013|Chronic Fatigue
559793|NCT00468013|Medically Unexplained Symptoms
559794|NCT00468013|Resilience Building Exercises
559795|NCT00468013|Depression
559796|NCT00468013|Well-Being
559797|NCT00468000|Peripheral Arterial Disease
559798|NCT00468000|Critical Limb Ischemia
559799|NCT00468000|Ischemia
559800|NCT00468000|Peripheral Vascular Disease
559801|NCT00468000|ixmyelocel-T
559802|NCT00467961|CML (Chronic Myelogenous Leukemia)
559803|NCT00467961|CLL (Chronic Lymphocytic Leukemia)
559804|NCT00467961|AML (Acute Myelogenous Leukemia)
559805|NCT00467961|Leukemia
559806|NCT00467961|Chronic Lymphocytic Leukemia
559807|NCT00467961|CLL
559808|NCT00467961|Chronic Myelogenous Leukemia
559809|NCT00467961|CML
559810|NCT00467961|Acute Myelogenous Leukemia
559811|NCT00467961|AML
559812|NCT00467961|Acute B-Lymphoblastic Leukemia
559813|NCT00467961|ALL
559814|NCT00467961|Myelodysplastic Syndrome
559815|NCT00467961|MDS
559816|NCT00467948|clean contaminated, laryngectomy, wound infection
559817|NCT00467935|amd
559818|NCT00467935|disciform
559819|NCT00467935|fibrosis
559820|NCT00467935|Lucentis
559821|NCT00467935|scotoma
559822|NCT00467922|Hand-assisted colorectal surgery
559823|NCT00467922|colorectal disease
559824|NCT00467922|Crohn's
559825|NCT00467922|diverticulitis
559826|NCT00467922|Colorectal resections
559827|NCT00467909|micronutrients
559828|NCT00467909|cognition
559829|NCT00467909|DHA
559830|NCT00467909|healthy children
559831|NCT00467896|PAH
559832|NCT00467896|iloprost
559833|NCT00467896|Ventavis
559834|NCT00467896|Pulmonary Arterial Hypertension
559835|NCT00467896|Actelion Pharmaceuticals
559836|NCT00467896|Cotherix
559837|NCT00467883|Zygomycosis
559838|NCT00467883|High dose liposomal amphotericin B
559839|NCT00467870|investigational
559840|NCT00467870|testosterone
559841|NCT00467870|testosterone undecanoate
559842|NCT00467870|TU
559843|NCT00467870|Hypogonadism
559844|NCT00467870|primary hypogonadism
559845|NCT00467870|secondary hypogonadism
559846|NCT00467857|cyanoacrylates
559847|NCT00467857|microbial sealants
559848|NCT00467857|skin flora contamination
559849|NCT00467857|surgery
559850|NCT00467844|Cachexia
559851|NCT00467844|Muscle Wasting
559852|NCT00467844|Non-Small Cell Lung Cancer
559853|NCT00467844|Colorectal Cancer
559854|NCT00467844|Non-Hodgkin's Lymphoma
559855|NCT00467844|Stage 3 or 4 Breast Cancer
559856|NCT00467844|Chronis Lymphocytic Leukemia
559857|NCT00467831|Restrictive Lung Disease
559858|NCT00467831|Pulmonary Fibrosis
559859|NCT00467831|Albinism
559860|NCT00467831|Platelet Storage Pool Deficiency
559861|NCT00467831|Metabolic Disease
559862|NCT00467831|Hermansky-Pudlak Syndrome
559863|NCT00467831|HPS
559864|NCT00467831|Lung Disease
559865|NCT00467818|Aggression
559866|NCT00467818|Irritability
559867|NCT00467818|Global severity
559868|NCT00467805|Light exposure
559869|NCT00467805|light spectrum
559870|NCT00467805|reproductive hormones
559871|NCT00467805|women
559872|NCT00467792|urticaria pigmentosa
559873|NCT00467792|mastocytosis
559874|NCT00467792|mastocytomas
559875|NCT00467766|dementia
559876|NCT00467766|Counseling
559877|NCT00467753|Irritability
559878|NCT00467753|Functional Ability
559879|NCT00467753|Aggression
559880|NCT00467753|Mood Instability
559881|NCT00467727|Diagnostic Mammography
559882|NCT00467727|Breast Imaging
559883|NCT00467727|Phase Contrast Mammography
559884|NCT00467727|X-Ray Mammography
559885|NCT00467714|RHINOPLASTY ,ESTHETIC SURGERY
559886|NCT00467701|pneumonia
559887|NCT00467701|Legionnaires disease
559888|NCT00467701|risk factors
559889|NCT00467688|type 1 diabetes
559890|NCT00467688|glucose excursion
559891|NCT00467688|hypoglycemia awareness
559892|NCT00467688|continuous glucose monitoring
559893|NCT00467675|NonDiabetes
559894|NCT00467675|CGM
559895|NCT00467649|Symlin
559896|NCT00467649|Amylin
559897|NCT00467649|insulin
559898|NCT00467649|Humalog
559899|NCT00467649|Novolog
559900|NCT00467649|Apidra
559901|NCT00467636|Chronic Obstructive Pulmonary Disease
559902|NCT00467636|Corticosteroid induced hyperglycaemia
559903|NCT00467636|Insulin
559904|NCT00467623|Pregnancy
559905|NCT00467623|holotranscobalamin
559906|NCT00467623|cobalamin
559907|NCT00467623|vitamin B12 analogues
559908|NCT00467623|reference interval
559909|NCT00467610|myelodysplastic
559910|NCT00467610|MDS
559911|NCT00467610|Panhematin
559912|NCT00467610|Hemin
559913|NCT00467597|Dyskinesia
559914|NCT00467597|Levodopa
559915|NCT00467597|Movement Disorders
559916|NCT00467597|Parkinson Disease
559917|NCT00467571|chronic idiopathic thrombocytopenic purpura
559918|NCT00467571|Helicobacter pylori infection
559919|NCT00467571|platelet
559920|NCT00467558|Impulse Control Disorder
559921|NCT00467558|Compulsive Sexual Behavior
559922|NCT00467545|HBeAg-positive
559923|NCT00467545|chronic hepatitis B
559924|NCT00467545|telbivudine
559925|NCT00467519|Tetanus; Diphtheria; Pertussis; ADACEL; DAPTACEL
559926|NCT00467506|Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery
559927|NCT00467454|Pyromania
559928|NCT00467454|Fire Setting
559929|NCT00467454|Compulsive Fire Setting
559930|NCT00467428|ADHD
559931|NCT00467415|Walking
559932|NCT00467415|Treadmill
559933|NCT00467415|Partial Weightbearing
559934|NCT00467402|agomelatine, Major Depressive Disorder, MDD, depression
559935|NCT00467389|Acetylcholine
559936|NCT00467389|Acetylcholinesterase
559937|NCT00467389|Butyrylcholinesterase
559938|NCT00467389|Cholinesterase Inhibitor
559939|NCT00467350|constipation
559940|NCT00467350|treatment
559941|NCT00467350|fecal impaction
559942|NCT00467350|pediatric
559943|NCT00467337|insole
559944|NCT00467337|osteoarthritis
559945|NCT00467337|pain
559946|NCT00467337|valgus knee
559947|NCT00467324|obstructive sleep apnea
559948|NCT00467324|surgery
559949|NCT00467324|tongue
559950|NCT00467311|Contrast-induced nephropathy
559951|NCT00467311|Cystatin C
559952|NCT00467311|Contrast media
559953|NCT00467311|Creatinine
559954|NCT00467311|Cardiac Catheterization
559955|NCT00467298|Exercise
559956|NCT00467298|heart failure
559957|NCT00467298|chronic obstructive pulmonary disease
559958|NCT00467298|patient education
559959|NCT00467298|costs
559960|NCT00467298|quality of life
559961|NCT00467285|Bone Density
559962|NCT00467285|C-telopeptide
559963|NCT00467285|Dual-Energy X-Ray Absorptiometry
559964|NCT00467285|N-telopeptide
559965|NCT00467285|Osteocalcin
559966|NCT00467285|Osteoporosis
559967|NCT00467285|Thiazolidinediones
559968|NCT00467285|Type 2 Diabetes Mellitus
559969|NCT00467272|Catheter-Related Bloodstream Infections
559970|NCT00467272|Bloodstream Infection
559971|NCT00467272|Daptomycin
559972|NCT00467272|Cubicin
559973|NCT00467272|CRBSI
559974|NCT00467259|Natural Menopause
559975|NCT00467246|Diabetes emergencies
559976|NCT00467220|Calorie restriction
559977|NCT00467220|alternate day fasting
559978|NCT00467220|calorie intake
559979|NCT00467194|adult primary hepatocellular carcinoma
559980|NCT00467194|localized unresectable adult primary liver cancer
559981|NCT00467194|recurrent adult primary liver cancer
559982|NCT00467194|advanced adult primary liver cancer
559983|NCT00467181|cardiac surgery
559984|NCT00467181|renal dysfunction
559985|NCT00467168|dietary fatty acid composition
559986|NCT00467168|postprandial
559987|NCT00467168|triglyceride-rich lipoprotein
559988|NCT00467168|type 2 diabetes
559989|NCT00467155|Helicobacter pylori, children, infants, Gambia
559990|NCT00467142|stage IV colon cancer
559991|NCT00467142|stage IV rectal cancer
559992|NCT00467142|adenocarcinoma of the colon
559993|NCT00467142|adenocarcinoma of the rectum
559994|NCT00467142|recurrent colon cancer
559995|NCT00467142|recurrent rectal cancer
559996|NCT00467129|stage IV colon cancer
559997|NCT00467129|stage IV rectal cancer
559998|NCT00467116|stage III pancreatic cancer
559999|NCT00467116|adenocarcinoma of the pancreas
560000|NCT00467116|stage II pancreatic cancer
560001|NCT00467116|recurrent pancreatic cancer
560002|NCT00467103|Adult Aphasia
560003|NCT00467103|Diffusion Tensor Imaging
560004|NCT00467103|functional Magnetic Resonance Imaging
560005|NCT00467103|Language Recovery
560006|NCT00467103|Left Middle Cerebral Artery Stroke
560007|NCT00467103|Nonfluent Aphasia
560008|NCT00467090|Parkinson's Disease
560009|NCT00467090|Gene
560010|NCT00467090|Genetic
560011|NCT00467090|Family Studies
560012|NCT00467090|LRRK-2
560013|NCT00467090|Parkinson Disease
560014|NCT00467090|PD
560015|NCT00467077|recurrent renal cell cancer
560016|NCT00467077|stage IV renal cell cancer
560017|NCT00467077|stage III renal cell cancer
560018|NCT00467064|Disease self-management
560019|NCT00467064|Community programs
560020|NCT00467038|affect
560021|NCT00467038|aggression
560022|NCT00467038|anger
560023|NCT00467038|behavior therapy
560024|NCT00467038|borderline personality disorder
560025|NCT00467038|MRI, functional
560026|NCT00467025|Metastatic clear cell carcinoma of the kidney
560027|NCT00467025|RCC
560028|NCT00467012|Inoperable metastatic breast cancer
560029|NCT00466999|misoprostol
560030|NCT00466999|incomplete abortion
560031|NCT00466999|PAC
560032|NCT00466986|recurrent
560033|NCT00466986|ovarian
560034|NCT00466986|cancer
560035|NCT00466986|platinum sensitive
560036|NCT00466973|Atrial fibrillation
560037|NCT00466973|ablation device comparison
560038|NCT00466973|ablation in right atria
560039|NCT00466947|Otitis media
560040|NCT00466947|Pneumonia
560041|NCT00466947|Community acquired pneumonia (CAP)
560042|NCT00466947|Pneumococcal disease
560043|NCT00466947|Booster vaccination
560044|NCT00466947|Immunogenicity
560045|NCT00466947|Pneumococcal vaccine
560046|NCT00466947|Safety
560047|NCT00466947|Efficacy
560048|NCT00466947|Carriage
560049|NCT00466934|Cerebral Blood Flow
560050|NCT00466934|Cerebral Cortex
560051|NCT00466934|Cognition
560052|NCT00466934|Optical Imaging
560053|NCT00466934|Healthy Volunteer
560054|NCT00466934|HV
560055|NCT00466921|recurrent mycosis fungoides/Sezary syndrome
560056|NCT00466921|stage I mycosis fungoides/Sezary syndrome
560057|NCT00466921|stage II mycosis fungoides/Sezary syndrome
560058|NCT00466921|stage III mycosis fungoides/Sezary syndrome
560059|NCT00466921|stage IV mycosis fungoides/Sezary syndrome
560060|NCT00466895|Leukemia
560061|NCT00466895|Lenalidomide
560062|NCT00466882|obese
560063|NCT00466882|renal failure
560064|NCT00466882|renal transplant candidate
560065|NCT00466882|Hemodialysis BMI between 36 and 42
560066|NCT00466856|neoplastic syndrome
560067|NCT00466856|metastatic gastrointestinal carcinoid tumor
560068|NCT00466856|recurrent gastrointestinal carcinoid tumor
560069|NCT00466856|thyroid gland medullary carcinoma
560070|NCT00466856|metastatic pheochromocytoma
560071|NCT00466856|recurrent islet cell carcinoma
560072|NCT00466856|liver metastases
560073|NCT00466856|recurrent pheochromocytoma
560074|NCT00466856|gastrinoma
560075|NCT00466856|insulinoma
560076|NCT00466856|WDHA syndrome
560077|NCT00466856|glucagonoma
560078|NCT00466856|pancreatic polypeptide tumor
560079|NCT00466856|somatostatinoma
560080|NCT00466843|Abnormal hematopoiesis
560081|NCT00466843|Leukemia
560082|NCT00466843|Autoimmune Disease
560083|NCT00466830|pain
560084|NCT00466830|psychosocial effects of cancer and its treatment
560085|NCT00466830|stage IIIA breast cancer
560086|NCT00466830|stage IIIB breast cancer
560087|NCT00466830|stage I breast cancer
560088|NCT00466830|stage II breast cancer
560089|NCT00466830|stage IIIC breast cancer
560090|NCT00466817|Cytomegalovirus, congenital, infants
560091|NCT00466804|heart transplant recipients
560092|NCT00466804|organ transplantation
560093|NCT00466804|immune biomarkers
560094|NCT00466804|transplant rejection
560095|NCT00466765|Fat Grafting
560096|NCT00466765|Breast Augmentation
560097|NCT00466765|Liposuctioned Fat Transfer
560098|NCT00466765|Lumpectomy
560099|NCT00466765|Mastectomy
560100|NCT00466765|Micromastia
560101|NCT00466765|Asymmetry
560102|NCT00466765|Post Lumpectomy Filling Defects
560103|NCT00466765|Post implant removal filling defect
560104|NCT00466765|Post Mastectomy
560105|NCT00466765|Autologous Fat Transfer
560106|NCT00466765|Tubular breasts
560107|NCT00466765|Tuberous breasts
560108|NCT00466765|Constricted breasts
560109|NCT00466726|chronic myelogenous leukemia, BCR-ABL1 positive
560110|NCT00466726|accelerated phase chronic myelogenous leukemia
560111|NCT00466726|blastic phase chronic myelogenous leukemia
560112|NCT00466726|chronic phase chronic myelogenous leukemia
560113|NCT00466726|relapsing chronic myelogenous leukemia
560114|NCT00466713|Nonischemic dilated cardiomyopathy
560115|NCT00466700|Helicobacter pylori, Gambia, endoscopy, Africa
560116|NCT00466687|stage IV melanoma
560117|NCT00466687|recurrent melanoma
560118|NCT00466674|Myeloma
560119|NCT00466674|RICT
560120|NCT00466674|conditioning
560121|NCT00466674|allograft
560122|NCT00466661|Acamprosate
560123|NCT00466661|Alcoholism
560124|NCT00466661|Bipolar disorder
560125|NCT00466661|Comorbidity
560126|NCT00466661|Craving
560127|NCT00466661|Depression
560128|NCT00466661|GABA
560129|NCT00466661|Glutamate
560130|NCT00466661|Mania
560131|NCT00466661|Pharmacotherapy
560132|NCT00466661|Withdrawal
560133|NCT00466648|laparoscopy, port site, closure, Dermabond
560134|NCT00466635|Clostridium difficile Disease
560135|NCT00466635|Infectious diarrhea
560136|NCT00466635|C. difficile
560137|NCT00466635|CDAD
560138|NCT00466635|Clostridium difficile-associated diarrhea
560139|NCT00466635|Clostridium difficile diarrhea
560140|NCT00466635|Antibiotic-Associated Colitis
560141|NCT00466635|Clostridium Enterocolitis
560142|NCT00466635|Antibiotic-Associated Diarrhea
560143|NCT00466635|Pseudomembranous Colitis
560144|NCT00466635|Clostridium difficile
560145|NCT00466622|PCOS
560146|NCT00466622|pregnancy
560147|NCT00466622|metformin
560148|NCT00466622|blood flow
560149|NCT00466622|Pulsatility index
560150|NCT00466609|clomipramine
560151|NCT00466609|quetiapine
560152|NCT00466609|fluoxetine
560153|NCT00466609|placebo
560154|NCT00466609|augmentation
560155|NCT00466609|obsessive compulsive disorder
560156|NCT00466596|allergic rhinitis
560157|NCT00466596|mild asthma
560158|NCT00466596|dust mite allergy
560159|NCT00466596|gamma tocopherol
560160|NCT00466583|Carcinoma, Lymphoma
560161|NCT00466557|Malaria, Plasmodium falciparum, mosquito, Africa, Anopheles
560162|NCT00466544|Chronic tonsillitis
560163|NCT00466544|Recurrent tonsillitis
560164|NCT00466531|refractory chronic lymphocytic leukemia
560165|NCT00466531|06-138
560166|NCT00466518|Kidney transplant
560167|NCT00466518|type 2 diabetes
560168|NCT00466518|sitagliptin
560169|NCT00466505|recurrent colon cancer
560170|NCT00466505|stage IV colon cancer
560171|NCT00466505|recurrent rectal cancer
560172|NCT00466505|stage IV rectal cancer
560173|NCT00466492|Drug Administration Schedule
560174|NCT00466492|Intensive Care Units
560175|NCT00466492|Length of Stay
560176|NCT00466492|Respiration, Artificial
560177|NCT00466492|Stress Disorders, Post-Traumatic/etiology/*psychology
560178|NCT00466492|Critical Illness/*psychology
560179|NCT00466492|Pneumonia/prevention & control
560180|NCT00466492|Hypnotics and Sedatives/*administration & dosage
560181|NCT00466479|neuroprotection
560182|NCT00466479|alpha one agonists
560183|NCT00466479|glaucoma
560184|NCT00466479|visual field
560185|NCT00466466|Small-Cell Lung Cancer
560186|NCT00466466|SCLC
560187|NCT00466466|Advanced Lung Cancer
560188|NCT00466466|RAD
560189|NCT00466466|RAD001
560190|NCT00466466|Chemotherapy
560191|NCT00466466|Cisplatin
560192|NCT00466466|Etoposide
560193|NCT00466388|dry mouth
560194|NCT00466375|hemangioma
560195|NCT00466375|vascular anomaly
560196|NCT00466375|infantile hemangioma
560197|NCT00466362|Obesity
560198|NCT00466362|Diabetes
560199|NCT00466362|Weight
560200|NCT00466362|Lifestyle
560201|NCT00466362|Follow up
560202|NCT00466349|SMA Type I
560203|NCT00466349|SMA Type II
560204|NCT00466349|SMA Type III
560205|NCT00466349|SMN
560206|NCT00466349|Werdnig-Hoffman Disease
560207|NCT00466349|Spinal Muscular Atrophy
560208|NCT00466349|Registry
560209|NCT00466349|SMA Type IV
560210|NCT00466336|Chronic hepatitis C
560211|NCT00466336|Non-invasive diagnosis
560212|NCT00466336|Duplex Doppler ultrasonography
560213|NCT00466336|Biochemical indices
560214|NCT00466336|Hepatic fibrosis
560215|NCT00466336|Cirrhosis
560216|NCT00466323|Mental Illness
560217|NCT00466323|Schizophrenia
560218|NCT00466323|Education
560219|NCT00466323|Family member treatment
560220|NCT00466323|Active psychoses
560221|NCT00466310|Schizophrenia
560222|NCT00466310|Metabolomics
560223|NCT00466297|Interprofessional
560224|NCT00466297|Collaboration
560225|NCT00466297|Teamwork
560226|NCT00466297|General internal medicine
560227|NCT00466297|Cluster randomized
560228|NCT00466271|Chronic hepatitis C
560229|NCT00466271|Persistently normal alanine aminotransferase levels
560230|NCT00466271|Hepatic fibrosis
560231|NCT00466271|Non-invasive diagnosis
560232|NCT00466271|Splenic arterial pulsatility index
560233|NCT00466258|Diffuse large B cell lymphoma
560234|NCT00466258|HIV
560235|NCT00466258|R-CHOP
560236|NCT00466258|Highly active antiretroviral therapy
560237|NCT00466258|Treatment Experienced
560238|NCT00466245|MVA Vaccine
560239|NCT00466232|Small Cell
560240|NCT00466232|Lung Cancer
560241|NCT00466232|Treatment
560242|NCT00466219|Presence of HCV RNA in serum
560243|NCT00466219|Absence of graft rejection
560244|NCT00466219|Recurrent hepatitis C after liver transplantation
560245|NCT00466206|pectus excavatum
560246|NCT00466206|magnetic alteration
560247|NCT00466206|chest wall deformity
560248|NCT00466193|Insomnia
560249|NCT00466180|Once-a-day
560250|NCT00466180|Adherence
560251|NCT00466180|Nevirapine
560252|NCT00466180|Patient noncompliance
560253|NCT00466180|Administration and dosage
560254|NCT00466180|Treatment Experienced
560255|NCT00466154|Aspirin resistance
560256|NCT00466154|Platelet activation
560257|NCT00466154|Hypercholesterolemia
560258|NCT00466128|fetal membranes, preterm rupture
560259|NCT00466128|preterm rupture
560260|NCT00466128|PPROM
560261|NCT00466115|MDS
560262|NCT00466115|AML
560263|NCT00466102|Breast Cancer
560264|NCT00466102|Bone metastases as only metastatic site
560265|NCT00466102|Breast cancer, HER2 negative
560266|NCT00466102|Bone metastasis as only metastatic site
560267|NCT00466102|Pretreated with endocrine therapy
560268|NCT00466102|Up to one previous chemotherapy
560269|NCT00466102|Previous treatment with bisphosphonates allowed
560270|NCT00466089|NSCLC, lung cancer
560271|NCT00466089|Patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment.
560272|NCT00466076|Drusen
560273|NCT00466076|AMD
560274|NCT00466076|Dry form of Age related Macular Degeneration
560275|NCT00466063|Iron overload
560276|NCT00466063|children
560277|NCT00466063|deferasirox
560278|NCT00466063|Transfusion-dependent anemia
560279|NCT00466050|plaque rupture,
560280|NCT00466050|acute coronary thrombose,
560281|NCT00466050|coronary angiography,
560282|NCT00466050|IVUS
560283|NCT00466037|Rheumatoid
560284|NCT00466037|rituximab
560285|NCT00466037|influenza
560286|NCT00466024|Asthma
560287|NCT00466024|persistent
560288|NCT00466024|children
560289|NCT00466024|particulates
560290|NCT00466024|ETS
560291|NCT00465998|Ultrasound
560292|NCT00465998|Induced labor
560293|NCT00465998|Cervical length
560294|NCT00465998|Engagement of fetal head
560295|NCT00465998|Occiput posterior
560296|NCT00465998|Outcome of labor
560297|NCT00465985|Muckle-Wells Syndrome
560298|NCT00465985|children
560299|NCT00465985|systemic autoinflammatory disease
560300|NCT00465985|CIAS-1 gene
560301|NCT00465985|NALP-3
560302|NCT00465985|ACZ885
560303|NCT00465985|human monoclonal anti-human interleukin-1beta (IL-1beta)
560304|NCT00465985|antibody
560305|NCT00465985|autosomal dominant
560306|NCT00465985|familial autoinflammatory syndrome
560307|NCT00465972|HIV
560308|NCT00465972|Insomnia
560309|NCT00465972|Cytokines
560310|NCT00465972|Adherence
560311|NCT00465959|COPD
560312|NCT00465946|Salt supplementation
560313|NCT00465946|Vasovagal syncope
560314|NCT00465946|Orthostatic tolerance
560315|NCT00465946|Healthy volunteers
560316|NCT00465933|Acute Promyelocytic Leukemia
560317|NCT00465933|AIDA
560318|NCT00465920|schizophrenia
560319|NCT00465920|cognitive behavioural therapy
560320|NCT00465920|early onset psychosis
560321|NCT00465920|Psychotic disorders (schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder according to DSM IV) in adolescents
560322|NCT00465907|lung cancer with malignant pleural effusion
560323|NCT00465894|overactive bladder
560324|NCT00465894|urge leakage
560325|NCT00465894|nightime urination
560326|NCT00465894|incontinence
560327|NCT00465894|urinary frequency
560328|NCT00465881|Diabetes
560329|NCT00465881|CGM
560330|NCT00465868|Acute Myocardial Infarction
560331|NCT00465868|Coronary Revascularization
560332|NCT00465868|Microvascular Obstruction
560333|NCT00465868|Cardiac MR
560334|NCT00465868|Collagen Turnover
560335|NCT00465868|Heart failure, post-mi
560336|NCT00465855|Carbon monoxide poisoning
560337|NCT00465855|Hyperbaric oxygen therapy
560338|NCT00465855|Randomized controlled trial
560339|NCT00465855|Clinical investigation
560340|NCT00465842|Hepatitis
560341|NCT00465842|Liver Cirrhosis
560342|NCT00465842|HCC
560343|NCT00465829|Obesity
560344|NCT00465816|non-inferiority
560345|NCT00465816|adolescents
560346|NCT00465816|meningococcal vaccine
560347|NCT00465803|Open-angle glaucoma or ocular hypertension
560348|NCT00465790|biomarkers
560349|NCT00465790|neuroimaging
560350|NCT00465790|genetics
560351|NCT00465790|PET
560352|NCT00465790|Genetic and Idiopathic Parkinson
560353|NCT00465790|Multiple Systemic Atrophy
560354|NCT00465790|Huntington
560355|NCT00465790|Dopa Responsive Dystonia
560356|NCT00465777|malaria
560357|NCT00465777|mortality
560358|NCT00465777|hospital
560359|NCT00465777|incentive
560360|NCT00465777|personnel
560361|NCT00465777|paediatric
560362|NCT00465764|healthy infants
560363|NCT00465725|Picoplatin
560364|NCT00465725|tumor
560365|NCT00465725|cancer
560366|NCT00465725|sarcoma
560367|NCT00465725|neoplasm
560368|NCT00465725|advanced
560369|NCT00465725|platinum
560370|NCT00465725|chemotherapy
560371|NCT00465725|Solid Tumor
560372|NCT00465712|transabdominal amnioinfusion
560373|NCT00465712|external cephalic version
560374|NCT00465712|breech presentation
560375|NCT00465699|Eczema
560376|NCT00465699|Pediatric
560377|NCT00465699|Vitamin B12
560378|NCT00465686|handwriting
560379|NCT00465686|child
560380|NCT00465686|primary school
560381|NCT00465686|posture
560382|NCT00465686|assistive device
560383|NCT00465673|breast cancer
560384|NCT00465673|brain metastatsis
560385|NCT00465673|Lipo-Dox
560386|NCT00465660|Osteoarthritis
560387|NCT00465660|Cartilage
560388|NCT00465660|Exercise
560389|NCT00465660|Progressive Resistance Training
560390|NCT00465647|Postoperative pain
560391|NCT00465647|Hydromorphone oral solution
560392|NCT00465647|opioid
560393|NCT00465647|pharmacokinetics
560394|NCT00465647|pharmacodynamics
560395|NCT00465634|Screening
560396|NCT00465634|uterine artery Doppler
560397|NCT00465634|HELLP syndrome
560398|NCT00465634|abruption
560399|NCT00465621|Open-angle glaucoma
560400|NCT00465621|ocular hypertension
560401|NCT00465608|adults
560402|NCT00465608|PTSD
560403|NCT00465608|trauma
560404|NCT00465608|AZF
560405|NCT00465608|propranolol
560406|NCT00465608|reconsolidation
560407|NCT00465608|Post traumatic stress disorder
560408|NCT00465608|chronic form
560409|NCT00465608|PTSD (Post-Traumatic Stress Disorder)
560410|NCT00465582|carriage
560411|NCT00465582|Neisseria meningitidis
560412|NCT00465582|risk factors
560413|NCT00465569|Food Allergy
560414|NCT00465569|Oral Immunotherapy
560415|NCT00465569|Immunoglobulin E
560416|NCT00465543|Nasal polyposis
560417|NCT00465543|Mint tea
560418|NCT00465543|Double-blind
560419|NCT00465543|Placebo-controlled
560420|NCT00465543|Crossover
560421|NCT00465517|Partial onset seizures
560422|NCT00465517|Complex-partial seizures
560423|NCT00465517|Anticonvulsant
560424|NCT00465517|Partial seizures
560425|NCT00465517|Catamenial epilepsy
560426|NCT00465504|local analgesia
560427|NCT00465504|intra-articular corticosteroid injection
560428|NCT00465504|iontophoresis
560429|NCT00465504|Local analgesia for intra-articular corticosteroid injection
560430|NCT00465491|refractory
560431|NCT00465491|chemotherapy
560432|NCT00465491|progressed
560433|NCT00465491|second-line treatment
560434|NCT00465491|small cell lung cancer
560435|NCT00465491|best supportive care
560436|NCT00465491|picoplatin
560437|NCT00465478|Diabetes Mellitus
560438|NCT00465478|Bone Marros Mononuclear Cells
560439|NCT00465478|Transplantation
560440|NCT00465465|Tuberculosis
560441|NCT00465465|TB
560442|NCT00465465|MVA 85A
560443|NCT00465465|BCG
560444|NCT00465439|femoral artery sheath
560445|NCT00465439|vasovagal reaction
560446|NCT00465439|pain
560447|NCT00465439|perception
560448|NCT00465426|HIV Infection
560449|NCT00465426|Cardiovascular Disease
560450|NCT00465426|Antiretroviral Therapy
560451|NCT00465426|Inflammatory Markers
560452|NCT00465426|Treatment Experienced
560453|NCT00465413|metered-dose inhalers (MDI)
560454|NCT00465413|forced expiratory volume in 1 second (FEV1)
560455|NCT00465413|forced expiratory flow rate (FEF25-75%)
560456|NCT00465400|exudative age-related macular degeneration (AMD)
560457|NCT00465400|non-exudative age-related macular degeneration (AMD)
560458|NCT00465400|oxidative stress
560459|NCT00465400|photodynamic therapy
560460|NCT00465374|ARDS
560461|NCT00465374|Pressure/time curve
560462|NCT00465374|Stress Index
560463|NCT00465361|Growth and Development
560464|NCT00465361|Child Development
560465|NCT00465361|Developmental Surveillance
560466|NCT00465361|Medical Education
560467|NCT00465361|Internship and Residency
560468|NCT00465348|normal tension glaucoma
560469|NCT00465348|vascular dysregulation
560470|NCT00465335|computed tomography
560471|NCT00465335|stress test
560472|NCT00465335|equivocal
560473|NCT00465335|catheterization
560474|NCT00465309|Respiratory Insufficiency
560475|NCT00465309|CO2 removal
560476|NCT00465309|protective ventilation
560477|NCT00465309|ARDS
560478|NCT00465283|Donepezil, ECT, Memory Disfunction
560479|NCT00465270|Cryptogenic
560480|NCT00465270|Stroke
560481|NCT00465270|PFO
560482|NCT00465244|Prehospital and ED seizures
560483|NCT00465231|Induction of labour
560484|NCT00465231|Bupivacaine consumption
560485|NCT00465231|Prevention
560486|NCT00465218|Bioprosthesis
560487|NCT00465218|Thrombosis
560488|NCT00465218|Cerebral emboli
560489|NCT00465218|Transcranial Doppler
560490|NCT00465218|Platelet function tests
560491|NCT00465205|HIV infection
560492|NCT00465205|HIV Shedding
560493|NCT00465205|HSV suppression
560494|NCT00465205|Co-infected
560495|NCT00465205|Women
560496|NCT00465205|Reactivation
560497|NCT00465205|Valacyclovir
560498|NCT00465205|Treatment Naive
560499|NCT00465179|Non-Clear Cell Renal Carcinoma
560500|NCT00465179|Non-clear cell renal cell cancer
560501|NCT00465179|Renal Cell Cancer
560502|NCT00465179|Kidney Cancer
560503|NCT00465179|Papillary
560504|NCT00465179|Chromophobe
560505|NCT00465179|Collecting duct carcinoma
560506|NCT00465179|CDC
560507|NCT00465179|Renal medullary carcinoma
560508|NCT00465179|RMC
560509|NCT00465179|Sunitinib Malate
560510|NCT00465179|Sutent
560511|NCT00465179|SU011248
560512|NCT00465166|Accidental dural puncture
560513|NCT00465166|Labour epidural
560514|NCT00465166|Ultrasound
560515|NCT00465166|Ligamentum flavum
560516|NCT00465153|Inflammation
560517|NCT00465153|cytokines
560518|NCT00465153|sarcopenia
560519|NCT00465153|strength
560520|NCT00465153|muscle
560521|NCT00465153|aging
560522|NCT00465153|exercise
560523|NCT00465114|Preeclampsia
560524|NCT00465114|Hemodynamic monitoring
560525|NCT00465101|Benign Prostatic Hyperplasia
560526|NCT00465101|Transurethral resection of the prostate
560527|NCT00465101|Lower urinary tract symptoms
560528|NCT00465101|GreenLight
560529|NCT00465101|Laserscope
560530|NCT00465101|Photoselective vaporization of the prostate
560531|NCT00465101|enlarged prostate
560532|NCT00465062|Lysosomal Disease
560533|NCT00465062|Lipids
560534|NCT00465062|B Lymphocytes
560535|NCT00465062|Brain Damage
560536|NCT00465062|Gaucher Disease
560537|NCT00465062|GD
560538|NCT00465049|abscess, primary closure, secondary closure
560539|NCT00465036|fat absorption
560540|NCT00465036|fibres
560541|NCT00465023|proton beam irradiation
560542|NCT00465023|liver cancer
560543|NCT00465010|Adolescence
560544|NCT00465010|Sexual health
560545|NCT00465010|Communication
560546|NCT00465010|Parenting
560547|NCT00464997|methotrexate aspirin pharmacokinetics
560548|NCT00464984|Weight loss
560549|NCT00464984|Physical fitness
560550|NCT00464984|Quality of life
560551|NCT00464958|Fatigue
560552|NCT00464958|Spasticity
560553|NCT00464958|Sublingual Tizanidine
560554|NCT00464958|Epworth Sleepiness Scale
560555|NCT00464958|Fatigue Severity Scale
560556|NCT00464932|COPD
560557|NCT00464932|Vasoactive Intestinal Peptide
560558|NCT00464932|Lung Function
560559|NCT00464919|Advance, hepatocellular carcinoma
560560|NCT00464893|gastric cancer
560561|NCT00464893|catumaxomab
560562|NCT00464893|neoadjuvant chemotherapy
560563|NCT00464893|phase II
560564|NCT00464893|interoperative
560565|NCT00464893|trifunctional antibody
560566|NCT00464880|Placebo-controlled study
560567|NCT00464880|assess the renoprotective effect of renin inhibition
560568|NCT00464880|Aliskiren as an alternative to irbesartan
560569|NCT00464880|Type 2 diabetes patients
560570|NCT00464880|incipient/overt diabetic nephropathy
560571|NCT00464867|Bifidobacterium breve
560572|NCT00464867|oral whole cell cholera vaccine
560573|NCT00464867|immunogenicity
560574|NCT00464867|Supplementation with probiotic improves vibriocidal antibody response in 2-5 year old childern given the killed oral cholera vaccine
560575|NCT00464867|Supplementation with probiotics results in improving the ASC responses to CT and LPS of V. cholerae O1
560576|NCT00464854|Glucose control
560577|NCT00464854|Subcutaneous insulin treatment
560578|NCT00464854|Multiple daily injections
560579|NCT00464841|Tsui Test
560580|NCT00464841|Combined Spinal Epidural
560581|NCT00464841|Labour
560582|NCT00464828|Central venous cannulation
560583|NCT00464828|Internal jugular vein
560584|NCT00464828|Ultrasound
560585|NCT00464828|Obstetrics
560586|NCT00464815|immunogenicity
560587|NCT00464815|safety
560588|NCT00464815|meningococcal vaccine
560589|NCT00464802|healthy
560590|NCT00464802|safety
560591|NCT00464789|Postmenopausal
560592|NCT00464776|Randomized
560593|NCT00464776|double-blind
560594|NCT00464776|cross-over
560595|NCT00464776|4-period
560596|NCT00464776|4 treatment
560597|NCT00464776|within-subject placebo-controlled study
560598|NCT00464776|assess optimal renoprotective dose of Aliskiren
560599|NCT00464776|hypertensive type 2 diabetes patients
560600|NCT00464776|incipient or overt nephropathy
560601|NCT00464763|Mental Health
560602|NCT00464763|Neurological Disease
560603|NCT00464763|Heart Valve Repair Surgery
560604|NCT00464750|Cardiac output
560605|NCT00464750|Thermodilution
560606|NCT00464737|Fibromyalgia Syndrome
560607|NCT00464737|Rotigotine
560608|NCT00464737|Neupro
560609|NCT00464724|Prostate Cancer
560610|NCT00464724|Magnetic Resonance Spectroscopic Imaging
560611|NCT00464724|Perfluorocarbon Compound
560612|NCT00464724|AIR-MRSI
560613|NCT00464724|PFC-MRSI
560614|NCT00464724|3 Tesla
560615|NCT00464724|MRSI
560616|NCT00464724|PFC
560617|NCT00464711|depression
560618|NCT00464711|biology
560619|NCT00464698|OCD
560620|NCT00464698|Obsessive Compulsive Disorder
560621|NCT00464698|Obsessions
560622|NCT00464698|Compulsions
560623|NCT00464698|Duloxetine
560624|NCT00464698|Cymbalta
560625|NCT00464672|Influenza, Egg-Derived, Healthy Children, Healthy Adolescents, Healthy Adults, Safety, Immunogenicity, Trivalent, Inactivated, Vaccination
560626|NCT00464659|Sleep apnea obstructive syndrome (SAOS)
560627|NCT00464659|memory deficit
560628|NCT00464659|Continuous Positive Airway Pression (CPAP)
560629|NCT00464659|Sham CPAP
560630|NCT00464646|NSABP
560631|NCT00464646|Epirubicin
560632|NCT00464646|Cyclophosphamide
560633|NCT00464646|Docetaxel
560634|NCT00464646|Trastuzumab
560635|NCT00464646|Bevacizumab
560636|NCT00464646|Neoadjuvant Therapy
560637|NCT00464646|HER2
560638|NCT00464646|Locally Advanced Breast Cancer
560639|NCT00464646|Adjuvant Therapy
560640|NCT00464646|Pathologic Stage III Breast Cancer
560641|NCT00464646|Inflammatory Breast Cancer
560642|NCT00464633|CLL
560643|NCT00464633|PLL
560644|NCT00464633|flavopiridol
560645|NCT00464620|Dasatinib
560646|NCT00464620|Rhabdomyosarcoma
560647|NCT00464620|Malignant peripheral nerve sheath tumor
560648|NCT00464620|Chondrosarcoma
560649|NCT00464620|Ewing's
560650|NCT00464620|Alveolar soft part sarcoma (ASPS)
560651|NCT00464620|Chordoma
560652|NCT00464620|Epithelioid sarcoma
560653|NCT00464620|Giant cell tumor of bone
560654|NCT00464620|Hemangiopericytoma/solitary fibrous tumor
560655|NCT00464620|Gastrointestinal Stromal Tumor (GIST)
560656|NCT00464594|Japan Early Diabetes Intervention Study
560657|NCT00464581|non-ischemic retinopathy
560658|NCT00464568|Seasonal allergic rhinitis,
560659|NCT00464568|hayfever
560660|NCT00464555|Allogeneic Islets
560661|NCT00464555|Allogeneic Islet Transplantation
560662|NCT00464555|Type 1 diabetes mellitus
560663|NCT00464555|Type 1 diabetes
560664|NCT00464555|T1D
560665|NCT00464555|T1DM
560666|NCT00464555|Insulin dependence
560667|NCT00464555|Hypoglycemia unawareness in T1D
560668|NCT00464555|Islet transplant
560669|NCT00464555|Islet transplantation
560670|NCT00464555|Islet graft
560671|NCT00464542|herpes simplex virus
560672|NCT00464529|blood glucose
560673|NCT00464529|hyperglycemia
560674|NCT00464529|hypoglycemia
560675|NCT00464529|Perioperative care
560676|NCT00464529|inpatient
560677|NCT00464516|Breast cancer (Estrogen Receptor positive)
560678|NCT00464503|statins
560679|NCT00464503|proteinuria
560680|NCT00464503|proteomic analysis
560681|NCT00464503|healthy volunteers
560682|NCT00464490|Weaning
560683|NCT00464490|Extuvation
560684|NCT00464490|Dexmedetomidine
560685|NCT00464477|Autism
560686|NCT00464477|Autistic disorder
560687|NCT00464477|Pervasive developmental disorder
560688|NCT00464477|Asperger syndrome
560689|NCT00464477|Childhood disintegrative disorder
560690|NCT00464477|Rett syndrome
560691|NCT00464464|Parkinson's disease
560692|NCT00464464|PD
560693|NCT00464464|depression
560694|NCT00464464|cognitive-behavioral therapy
560695|NCT00464464|social support
560696|NCT00464425|Electroacupuncture
560697|NCT00464425|Postoperative ileus
560698|NCT00464425|Colorectal surgery
560699|NCT00464425|Laparoscopic surgery
560700|NCT00464425|Randomised trial
560701|NCT00464412|Osteoporosis
560702|NCT00464412|Knowledge
560703|NCT00464412|Beliefs
560704|NCT00464412|Education
560705|NCT00464412|Women
560706|NCT00464399|De novo renal transplantation
560707|NCT00464399|CNI-free protocol
560708|NCT00464399|adults
560709|NCT00464399|everolimus
560710|NCT00464399|rejections
560711|NCT00464386|Severe burns
560712|NCT00464386|Severe Trauma
560713|NCT00464386|Closed loop insulin
560714|NCT00464386|continuous glucose monitoring
560715|NCT00464373|Prostatitis
560716|NCT00464373|Chronic Prostatitis with Chronic Pelvic Pain Syndrome
560717|NCT00464373|Botulinum Toxin Type A
560718|NCT00464373|Drug therapy
560719|NCT00464373|Injections, intramuscular
560720|NCT00464347|AMD
560721|NCT00464347|wet AMD
560722|NCT00464347|verteporfin PDT
560723|NCT00464347|Avastin
560724|NCT00464347|TAC-PF
560725|NCT00464308|Gastroesophageal Reflux
560726|NCT00464308|Heartburn
560727|NCT00464308|Proton pump inhibitor
560728|NCT00464308|GORD
560729|NCT00464295|Hepatocellular Carcinoma
560730|NCT00464295|Phase 2 Trial
560731|NCT00464295|Capecitabine
560732|NCT00464295|Treatment Efficacy
560733|NCT00464282|Fluorine–18-α–methyltyrosine,
560734|NCT00464282|Positron emission tomography,
560735|NCT00464282|Fluorodeoxyglucose
560736|NCT00464282|Lung cancer,
560737|NCT00464282|Amino acid transportor 1,
560738|NCT00464282|Ki-67
560739|NCT00464282|Proven or suspected non-small cell lung cancer were enrolled in the study
560740|NCT00464269|Epilepsy
560741|NCT00464269|Brivaracetam
560742|NCT00464269|Partial Onset Seizures, Adolescents & Adults
560743|NCT00464256|abstinence
560744|NCT00464243|Sleep problems
560745|NCT00464243|Insomnia
560746|NCT00464243|Sleeplessness
560747|NCT00464243|Polysomnographic
560748|NCT00464230|Displaced Femoral Neck Fractures
560749|NCT00464230|Treatment
560750|NCT00464230|Function
560751|NCT00464230|Pain
560752|NCT00464230|Quality of life
560753|NCT00464230|Complications
560754|NCT00464230|Reoperations
560755|NCT00464230|Internal Fixation
560756|NCT00464230|Hemiarthroplasty
560757|NCT00464230|Activities of Daily Living
560758|NCT00464217|Acute Myeloblastic Leukaemia
560759|NCT00464191|bipolar depression
560760|NCT00464191|SSRI
560761|NCT00464191|escitalopram
560762|NCT00464191|bipolar disorder
560763|NCT00464191|antidepressant
560764|NCT00464191|treatment trial
560765|NCT00464191|RCT
560766|NCT00464178|multiple myeloma
560767|NCT00464178|myeloma
560768|NCT00464178|relapsed myeloma
560769|NCT00464178|refractory myeloma
560770|NCT00464178|relapsed, refractory myeloma
560771|NCT00464178|relapsed, refractory multiple myeloma
560772|NCT00464178|refractory multiple myeloma
560773|NCT00464178|relapsed multiple myeloma
560774|NCT00464178|B lymphoid malignancies
560775|NCT00464178|Myeloma, Plasma-Cell
560776|NCT00464178|Myeloma Proteins
560777|NCT00464178|hnRNP A1
560778|NCT00464178|myeloma helix-destabilizing protein, mouse
560779|NCT00464178|IgC3kappa Jir protein, human
560780|NCT00464178|gamma 3 myeloma protein Jir, human
560781|NCT00464178|M-proteins (Myeloma)
560782|NCT00464178|M315 myeloma protein, mouse
560783|NCT00464178|myeloma protein M 315, mouse
560784|NCT00464178|McPC603 antibody
560785|NCT00464178|myeloma protein McPC603 antibody
560786|NCT00464178|multiple myeloma M-proteins
560787|NCT00464178|M protein, multiple myeloma
560788|NCT00464178|myeloma cell activator
560789|NCT00464178|myeloma immunoglobulins
560790|NCT00464178|myeloma immunoglobulin M603
560791|NCT00464178|myeloma immunoglobulin S15
560792|NCT00464178|myeloma protein A48, mouse
560793|NCT00464178|A48 myeloma protein, mouse
560794|NCT00464178|ABPC48 myeloma protein, mouse
560795|NCT00464178|myeloma protein A 48, mouse
560796|NCT00464178|myeloma protein Dob
560797|NCT00464178|myeloma protein M 467
560798|NCT00464178|myeloma protein M467
560799|NCT00464178|myeloma protein MOPC 141, mouse
560800|NCT00464178|MOPC141 myeloma protein, mouse
560801|NCT00464178|myeloma protein MOPC 173
560802|NCT00464178|myeloma protein Rou
560803|NCT00464178|IgA2 myeloma protein Rou
560804|NCT00464178|myeloma protein TEPC15
560805|NCT00464178|myeloma protein T15
560806|NCT00464178|myeloma protein TEPC 15
560807|NCT00464178|myeloma protein W3129
560808|NCT00464178|myeloma protein WIE
560809|NCT00464178|myeloma-associated membrane antigen KMA
560810|NCT00464178|myeloma antigen KMA
560811|NCT00464178|MYEOV protein, human
560812|NCT00464178|protein 460
560813|NCT00464178|myeloma protein MOPC 460
560814|NCT00464178|TRAPPC1 protein, human
560815|NCT00464178|multiple myeloma protein 2, human
560816|NCT00464178|Wis heavy-chain disease protein, human
560817|NCT00464178|myeloma protein Wis, human
560818|NCT00464165|abstinence
560819|NCT00464139|endometriosis
560820|NCT00464139|prevalence
560821|NCT00464139|fertility
560822|NCT00464139|pain
560823|NCT00464139|ultrasound
560824|NCT00464126|crystalloid
560825|NCT00464126|colloid
560826|NCT00464126|pediatric
560827|NCT00464126|cardiac
560828|NCT00464126|resuscitation
560829|NCT00464126|Postoperative
560830|NCT00464113|Myeloid Leukemia
560831|NCT00464113|Lymphocytic Leukemia
560832|NCT00464113|Ph+ ALL
560833|NCT00464100|Neurodevelopmental outcomes
560834|NCT00464100|congenital heart disease
560835|NCT00464100|NIRS monitoring
560836|NCT00464100|hypoxia
560837|NCT00464074|fatigue
560838|NCT00464074|Tysabri
560839|NCT00464074|cognition
560840|NCT00464061|Sleep problems
560841|NCT00464061|Insomnia
560842|NCT00464061|Sleeplessness
560843|NCT00464061|Primary insomnia
560844|NCT00464061|Insomnia disorder
560845|NCT00464035|Obesity
560846|NCT00464035|Calcium
560847|NCT00464035|Fat absorption
560848|NCT00464035|Postprandial lipid profile
560849|NCT00464035|appetite
560850|NCT00464022|pain, endoscopy
560851|NCT00464022|Pain, endoscopy, randomised trial
560852|NCT00464009|Early childhood caries - ECC
560853|NCT00464009|Prevention
560854|NCT00464009|Continuing medical education
560855|NCT00464009|Randomized controlled trial
560856|NCT00463996|Ovarian cancer
560857|NCT00463996|MRI
560858|NCT00463996|Contrast agent
560859|NCT00463970|Chronic low back pain
560860|NCT00463970|Brief cognitive intervention
560861|NCT00463970|Cognitive behavior therapy
560862|NCT00463970|Seal oil
560863|NCT00463957|sildenafil
560864|NCT00463957|tadalafil
560865|NCT00463957|phosphodiesterase
560866|NCT00463957|visual persistence
560867|NCT00463957|reaction time
560868|NCT00463944|Electronic voting system
560869|NCT00463931|Schistosomiasis
560870|NCT00463931|Soiltransmitted helminthiasis
560871|NCT00463931|Community-based volunteer
560872|NCT00463931|School based treatment approach
560873|NCT00463905|osteoporosis
560874|NCT00463905|vertebral fractures
560875|NCT00463905|randomised controlled trial
560876|NCT00463905|screening
560877|NCT00463892|melanoma
560878|NCT00463892|lymph nodes
560879|NCT00463892|magnetic resonance imaging
560880|NCT00463892|screening
560881|NCT00463892|detection
560882|NCT00463879|Schizophrenia
560883|NCT00463879|Cognition
560884|NCT00463879|Smoking
560885|NCT00463879|Galantamine
560886|NCT00463879|Nicotine
560887|NCT00463879|Cognitive Deficits
560888|NCT00463866|Asthma
560889|NCT00463853|Bone Marrow Cells
560890|NCT00463853|Cardiovascular Surgery
560891|NCT00463853|Coronary Artery Bypass Graft
560892|NCT00463853|Phase I Study
560893|NCT00463853|Stem Cells
560894|NCT00463840|Locally advanced pancreatic cancer
560895|NCT00463840|oxaliplatin
560896|NCT00463840|chemoradiation
560897|NCT00463840|5FU
560898|NCT00463827|asthma
560899|NCT00463827|smokers
560900|NCT00463827|statin
560901|NCT00463827|atorvastatin
560902|NCT00463827|randomised
560903|NCT00463827|placebo
560904|NCT00463827|cigarette
560905|NCT00463827|blind
560906|NCT00463827|COPD
560907|NCT00463814|Advanced Malignancy
560908|NCT00463814|Cancer Eligibility
560909|NCT00463814|Malignancy
560910|NCT00463801|Complicated Skin and Skin-Structure Infections, Daptomycin, MRSA, Diabetic Foot, Abscess, Cellulitis
560911|NCT00463801|Complicated skin and skin-structure infections
560912|NCT00463788|cancer
560913|NCT00463788|breast
560914|NCT00463788|metastatic
560915|NCT00463788|triple negative
560916|NCT00463775|Treatment
560917|NCT00463775|Topiramate
560918|NCT00463775|Alcohol Dependence
560919|NCT00463775|Borderline Personality Disorder
560920|NCT00463749|primary PCI
560921|NCT00463749|nephropathy
560922|NCT00463749|infarct size
560923|NCT00463749|infarction
560924|NCT00463749|ST-elevation myocardial infarction
560925|NCT00463736|short term tocolysis
560926|NCT00463736|preterm premature rupture of membranes
560927|NCT00463723|penetrating keratoplasty
560928|NCT00463723|graft rejection
560929|NCT00463723|immunosuppression
560930|NCT00463710|MTI, DWI, Avonex, MRI
560931|NCT00463697|GW642444,
560932|NCT00463697|magnesium stearate,
560933|NCT00463697|asthmatic patients
560934|NCT00463658|Falls
560935|NCT00463658|Home Care
560936|NCT00463658|Aging Population
560937|NCT00463658|Clinical Effectiveness
560938|NCT00463658|Health Economics
560939|NCT00463632|schistosomiasis
560940|NCT00463632|anaemia
560941|NCT00463632|pregnancy
560942|NCT00463593|schistosomiasis
560943|NCT00463593|helminthes
560944|NCT00463593|anaemia
560945|NCT00463580|depression
560946|NCT00463580|TNF-alpha antagonist
560947|NCT00463580|infliximab
560948|NCT00463580|treatment resistant depression
560949|NCT00463580|major depressive disorder (MDD)
560950|NCT00463580|bipolar I disorder
560951|NCT00463580|bipolar II disorder
560952|NCT00463567|indacaterol
560953|NCT00463567|long acting beta-2 agonist
560954|NCT00463554|Incontinence
560955|NCT00463554|Stress Urinary
560956|NCT00463541|Urinary Bladder, Overactive
560957|NCT00463541|Urgency
560958|NCT00463541|VESIcare®
560959|NCT00463541|Solifenacin succinate
560960|NCT00463528|schistosomiasis
560961|NCT00463528|gender perspectives
560962|NCT00463515|Non-Small Cell Lung Cancer
560963|NCT00463515|NSCLC
560964|NCT00463515|Chemoradiation
560965|NCT00463515|lung cancer
560966|NCT00463515|induction chemotherapy
560967|NCT00463515|chemo-radiotherapy
560968|NCT00463502|The purpose of study was investigated the effect of
560969|NCT00463502|metformin on thyroid hormone metabolism in euthyroid patients
560970|NCT00463502|with type 2 DM. The results revealed significant decreases
560971|NCT00463502|in TSH and fT4
560972|NCT00463489|lifestyle intervention
560973|NCT00463489|breast
560974|NCT00463489|cancer
560975|NCT00463489|adjuvant
560976|NCT00463489|letrozole
560977|NCT00463489|weight loss
560978|NCT00463489|BMI
560979|NCT00463489|post-menopausal
560980|NCT00463489|estrogen receptor positive
560981|NCT00463489|progesterone receptor positive
560982|NCT00463450|Hormone Replacement Therapy
560983|NCT00463450|Impaired well-being, mood and sexuality
560984|NCT00463437|Fever.
560985|NCT00463437|Meningococcal disease.
560986|NCT00463437|Pneumococcal disease.
560987|NCT00463437|Meningococcal vaccine.
560988|NCT00463437|Pneumococcal vaccine.
560989|NCT00463437|Immunogenicity.
560990|NCT00463437|Booster vaccination.
560991|NCT00463437|Safety.
560992|NCT00463424|Metacarpophalangeal Joint
560993|NCT00463424|Arthroplasty, Replacement
560994|NCT00463424|Range of Motion, Articular
560995|NCT00463424|Randomized Controlled Trials
560996|NCT00463424|Swanson
560997|NCT00463424|NeuFlex
560998|NCT00463411|osteoporosis
560999|NCT00463411|male
561000|NCT00463411|fracture risk
561001|NCT00463411|genetical epidemiology
561002|NCT00463398|Endometriosis
561003|NCT00463398|Fertility Surgery
561004|NCT00463398|Quality of Life
561005|NCT00463398|Pain
561006|NCT00463398|Sexual Function
561007|NCT00463398|Health economics
561008|NCT00463398|Recurrence
561009|NCT00463398|Pregnancy
561010|NCT00463385|Celgene
561011|NCT00463385|CC-4047
561012|NCT00463385|Myelofibrosis
561013|NCT00463385|myelofibrosis with myeloid metaplasia
561014|NCT00463385|myeloid metaplasia
561015|NCT00463385|JAK2
561016|NCT00463385|CC-4047-MMM-001
561017|NCT00463385|Prednisone
561018|NCT00463385|Phase II
561019|NCT00463385|pomalidomide
561020|NCT00463385|bone marrow histology
561021|NCT00463385|imids
561022|NCT00463385|MMM
561023|NCT00463385|Ashkenazi Jewish Population
561024|NCT00463385|exposure to Thorotrast
561025|NCT00463385|exposure to solvents (benzene and toluene)
561026|NCT00463385|acute megakaryocytic leukemia
561027|NCT00463385|history of polycythemia vera
561028|NCT00463359|basal cell carcinoma
561029|NCT00463359|curettage
561030|NCT00463359|Imiquimod
561031|NCT00463359|treatment
561032|NCT00463346|Treatment
561033|NCT00463346|Alcohol Dependence
561034|NCT00463346|Schizophrenia
561035|NCT00463333|postoperative delirium
561036|NCT00463333|psychometric testing
561037|NCT00463333|EEG
561038|NCT00463333|serum markers
561039|NCT00463320|Age-related macular degeneration (AMD),
561040|NCT00463320|vascular endothelial growth factor (VEGF)receptor (VEGFR)
561041|NCT00463320|choroidal neovascularization,
561042|NCT00463307|schistosomiasis
561043|NCT00463307|Schistosoma mansoni
561044|NCT00463307|Circulating cathodic antigen urine dipstick
561045|NCT00463294|CABG
561046|NCT00463294|On-pump
561047|NCT00463294|Off-pump
561048|NCT00463281|stroke, ischemic
561049|NCT00463281|computed tomography
561050|NCT00463281|thrombolysis
561051|NCT00463268|osteopenia
561052|NCT00463268|osteoporosis prevention
561053|NCT00463268|alendronate
561054|NCT00463255|Diet
561055|NCT00463255|elderly
561056|NCT00463255|age-related diseases
561057|NCT00463255|prevention
561058|NCT00463255|cognitive decline
561059|NCT00463255|Clinical study
561060|NCT00463242|agomelatine, Major Depressive Disorder, MDD, depression
561061|NCT00463229|stroke
561062|NCT00463229|rehabilitation
561063|NCT00463229|home care services
561064|NCT00463229|effectiveness
561065|NCT00463229|quantitative research
561066|NCT00463229|interdisciplinary
561067|NCT00463229|cost
561068|NCT00463229|health services research, integrated
561069|NCT00463216|back, neck, pain, sick leave
561070|NCT00463203|primary malignant brain tumor
561071|NCT00463203|grade II glioma
561072|NCT00463203|meningeoma
561073|NCT00463203|ependymoma
561074|NCT00463203|Recurrence or progression after standard treatment
561075|NCT00463190|Probiotics
561076|NCT00463190|Diarrhea
561077|NCT00463190|Enterocolitis
561078|NCT00463177|Pain
561079|NCT00463177|Chronic pain
561080|NCT00463177|Pain disorder
561081|NCT00463177|Functional MRI
561082|NCT00463177|Sensitization
561083|NCT00463164|functional MRI
561084|NCT00463151|Rebamipide
561085|NCT00463151|Enema
561086|NCT00463151|Ulcerative Colitis
561087|NCT00463138|perceived increase or decrease in symptoms post treatment
561088|NCT00463138|Satisfaction with the treatment
561089|NCT00463125|Scleroderma, systemic
561090|NCT00463125|therapeutic
561091|NCT00463125|platelet gel
561092|NCT00463112|Obesity
561093|NCT00463112|Polycystic Ovary Syndrome
561094|NCT00463112|weight loss
561095|NCT00463112|Hyperadrogonemia
561096|NCT00463112|Sibutramine
561097|NCT00463099|Anterior Cruciate Ligament/injuries
561098|NCT00463099|Anterior Cruciate Ligament/surgery
561099|NCT00463099|Knee injuries/surgery
561100|NCT00463099|Outcomes research
561101|NCT00463099|Prospective Studies
561102|NCT00463086|Tuberculosis
561103|NCT00463086|TB
561104|NCT00463086|Mycobacteria
561105|NCT00463086|HIV
561106|NCT00463086|Human immunodeficiency virus
561107|NCT00463086|Latent tuberculosis infection
561108|NCT00463086|HAART
561109|NCT00463086|Highly active anti-retroviral therapy
561110|NCT00463086|Isoniazid preventive therapy
561111|NCT00463086|INH
561112|NCT00463086|Opportunistic infections
561113|NCT00463086|HIV-1
561114|NCT00463086|Treatment Experienced
561115|NCT00463086|AIDS
561116|NCT00463086|Mycobacterium Tuberculosis
561117|NCT00463073|Progressive primary Glioblastoma multiforme
561118|NCT00463047|Breakthrough pain
561119|NCT00463047|Opioid-tolerant
561120|NCT00463047|Chronic pain
561121|NCT00463034|stage IV breast cancer
561122|NCT00463034|stage I breast cancer
561123|NCT00463034|stage II breast cancer
561124|NCT00463034|stage IIIA breast cancer
561125|NCT00463034|stage IIIB breast cancer
561126|NCT00463034|stage IIIC breast cancer
561127|NCT00463021|Hectorol (doxercalciferol capsules)
561128|NCT00463021|Zemplar (paricalcitol injection)
561129|NCT00463008|adult anaplastic astrocytoma
561130|NCT00463008|adult anaplastic oligodendroglioma
561131|NCT00463008|adult glioblastoma
561132|NCT00463008|recurrent adult brain tumor
561133|NCT00463008|adult gliosarcoma
561134|NCT00463008|adult giant cell glioblastoma
561135|NCT00462995|Non Small Cell Lung Cancer
561136|NCT00462995|Lung Cancer
561137|NCT00462995|Erlotinib
561138|NCT00462995|Neoadjuvant Treatment
561139|NCT00462982|stage IV melanoma
561140|NCT00462982|tumors metastatic to brain
561141|NCT00462982|stage IV renal cell cancer
561142|NCT00462982|recurrent melanoma
561143|NCT00462982|recurrent renal cell cancer
561144|NCT00462969|Endometrial cancer
561145|NCT00462969|Sonohysterography
561146|NCT00462956|lapatinib
561147|NCT00462956|metastatic breast cancer
561148|NCT00462956|trastuzumab (Herceptin)
561149|NCT00462956|Stage IV breast cancer
561150|NCT00462956|ErbB2
561151|NCT00462956|ErbB1
561152|NCT00462943|CML
561153|NCT00462943|HHT
561154|NCT00462943|Homoharringtonine
561155|NCT00462943|Omacetaxine
561156|NCT00462917|disease /disorder proneness /risk
561157|NCT00462917|family genetics
561158|NCT00462917|genetic counseling
561159|NCT00462917|genetic marker
561160|NCT00462917|genetic polymorphism
561161|NCT00462917|genetic screening
561162|NCT00462917|genetic susceptibility
561163|NCT00462891|breast cancer
561164|NCT00462878|Febrile neutropenia
561165|NCT00462865|breast cancer
561166|NCT00462865|neoadjuvant chemotherapy
561167|NCT00462865|adjuvant treatment
561168|NCT00462865|consolidation therapy
561169|NCT00462865|anti-angiogenesis therapy
561170|NCT00462852|thromboembolism
561290|NCT00462540|Formoterol
561171|NCT00462852|stage III pancreatic cancer
561172|NCT00462852|stage IV pancreatic cancer
561173|NCT00462852|adenocarcinoma of the pancreas
561174|NCT00462852|recurrent pancreatic cancer
561175|NCT00462852|stage II pancreatic cancer
561176|NCT00462839|Estimated Blood Loss
561177|NCT00462839|Obstetrics
561178|NCT00462839|postpartum hemorrhage
561179|NCT00462813|cervical cancer
561180|NCT00462813|cervical intraepithelial neoplasia grade 2
561181|NCT00462813|cervical intraepithelial neoplasia grade 3
561182|NCT00462813|cervical intraepithelial neoplasia grade 1
561183|NCT00462787|acute undifferentiated leukemia
561184|NCT00462787|recurrent childhood acute lymphoblastic leukemia
561185|NCT00462787|recurrent childhood acute myeloid leukemia
561186|NCT00462787|recurrent adult acute lymphoblastic leukemia
561187|NCT00462787|recurrent adult acute myeloid leukemia
561188|NCT00462774|Myocardial infarction
561189|NCT00462774|Heart failure
561190|NCT00462774|Cell therapy
561191|NCT00462774|Bone marrow
561192|NCT00462774|CD133
561193|NCT00462774|Bypass surgery
561194|NCT00462774|Stem cells
561195|NCT00462761|RTK
561196|NCT00462761|kinase
561197|NCT00462761|inhibitor
561198|NCT00462761|tyrosine
561199|NCT00462761|acute
561200|NCT00462761|FLT3
561201|NCT00462761|AC220
561202|NCT00462761|pharmacokinetic
561203|NCT00462761|pharmacokinetics
561204|NCT00462761|PK
561205|NCT00462761|pharmacodynamic
561206|NCT00462761|pharmacodynamics
561207|NCT00462761|mutations
561208|NCT00462761|PD
561209|NCT00462761|receptor
561210|NCT00462761|class III
561211|NCT00462761|relapsed
561212|NCT00462761|refractory
561213|NCT00462761|t(8;21)
561214|NCT00462761|q22;q22
561215|NCT00462761|AML1/ETO
561216|NCT00462761|t(16;16
561217|NCT00462761|p13;q22
561218|NCT00462761|CBFbeta/MYH11
561219|NCT00462761|inv(16)
561220|NCT00462761|p13q22
561221|NCT00462761|11q23
561222|NCT00462761|dysplasia
561223|NCT00462761|myeloid
561224|NCT00462761|myelomonocytic
561225|NCT00462761|monoblastic
561226|NCT00462761|monocytic
561227|NCT00462761|erythroid
561228|NCT00462761|erythroleukemia
561229|NCT00462761|megakaryoblastic
561230|NCT00462761|basophilic
561231|NCT00462761|panmyelosis
561232|NCT00462761|myelofibrosis
561233|NCT00462735|Cancer of the Nasal Cavity
561234|NCT00462722|body composition
561235|NCT00462722|bone density
561236|NCT00462722|cyclooxygenase inhibitor
561237|NCT00462722|bone metabolism
561238|NCT00462722|muscle function
561239|NCT00462722|muscle strength
561240|NCT00462709|Hereditary angioedema
561241|NCT00462709|C1 esterase inhibitor (human)
561242|NCT00462696|stage II breast cancer
561243|NCT00462696|stage IIIA breast cancer
561244|NCT00462696|stage IIIB breast cancer
561245|NCT00462696|stage IIIC breast cancer
561246|NCT00462683|Stroke
561247|NCT00462683|Anoxia
561248|NCT00462683|Brain Injury
561249|NCT00462683|Rehabilitation
561250|NCT00462683|Osteoporosis
561251|NCT00462683|Osteopenia
561252|NCT00462670|Cardiac edema
561253|NCT00462670|OPC-41061
561254|NCT00462670|Vasopressin antagonist
561255|NCT00462657|infection
561256|NCT00462657|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
561257|NCT00462657|adult acute myeloid leukemia with inv(16)(p13;q22)
561258|NCT00462657|adult acute myeloid leukemia with t(15;17)(q22;q12)
561259|NCT00462657|adult acute myeloid leukemia with t(16;16)(p13;q22)
561260|NCT00462657|adult acute myeloid leukemia with t(8;21)(q22;q22)
561261|NCT00462657|adult acute lymphoblastic leukemia in remission
561262|NCT00462657|adult acute myeloid leukemia in remission
561263|NCT00462657|de novo myelodysplastic syndromes
561264|NCT00462657|myelodysplastic/myeloproliferative neoplasm, unclassifiable
561265|NCT00462657|previously treated myelodysplastic syndromes
561266|NCT00462657|recurrent adult acute lymphoblastic leukemia
561267|NCT00462657|recurrent adult acute myeloid leukemia
561268|NCT00462657|secondary acute myeloid leukemia
561269|NCT00462657|secondary myelodysplastic syndromes
561270|NCT00462657|graft versus host disease
561271|NCT00462644|adrenal insufficiency
561272|NCT00462644|etomidate
561273|NCT00462644|rapid sequence induction
561274|NCT00462631|coronary artery
561275|NCT00462631|Diabetes
561276|NCT00462618|Insomnia
561277|NCT00462618|Elderly
561278|NCT00462618|Affective disorders
561279|NCT00462592|exercise-induced bronchoconstriction (EIB)
561280|NCT00462592|airway inflammation
561281|NCT00462579|carbapenem-resistant acinetobacter baumannii
561282|NCT00462579|positive culture
561283|NCT00462579|positive culture for carbapenem-resistant acinetobacter
561284|NCT00462566|Motor cortex stimulation
561285|NCT00462566|neuropathic
561286|NCT00462566|pain
561287|NCT00462566|complex regional pain syndrome
561288|NCT00462566|deafferentation facial pain
561289|NCT00462540|COPD
561291|NCT00462540|Ipratropium
561292|NCT00462540|Crossover
561293|NCT00462527|Cystatin C
561294|NCT00462527|Acute renal failure
561295|NCT00462527|Gastroenteritis
561296|NCT00462527|Dehydration
561297|NCT00462501|stage II rectal cancer
561298|NCT00462501|stage III rectal cancer
561299|NCT00462501|adenocarcinoma of the rectum
561300|NCT00462475|GH
561301|NCT00462475|IGF-I
561302|NCT00462475|GH deficiency
561303|NCT00462475|Atherosclerosis
561304|NCT00462475|Insulin resistance syndrome
561305|NCT00462449|Botulinum Toxin
561306|NCT00462449|Ness H200
561307|NCT00462449|Functional Electrical Stimulation
561308|NCT00462449|Repetitive Task Practice
561309|NCT00462436|functional foods
561310|NCT00462436|soy
561311|NCT00462436|nuts
561312|NCT00462436|LDL cholesterol
561313|NCT00462436|fibre
561314|NCT00462436|secondary prevention
561315|NCT00462436|risk reduction
561316|NCT00462436|endothelial function
561317|NCT00462436|endothelial progenitor cells
561318|NCT00462436|inflammation
561319|NCT00462436|glycemic control
561320|NCT00462436|HOMA
561321|NCT00462423|Metastatic malignant melanoma
561322|NCT00462423|First-line therapy
561323|NCT00462410|recurrent breast cancer
561324|NCT00462410|stage I breast cancer
561325|NCT00462410|stage II breast cancer
561326|NCT00462410|stage IIIA breast cancer
561327|NCT00462410|stage IIIB breast cancer
561328|NCT00462410|stage IIIC breast cancer
561329|NCT00462410|stage IV breast cancer
561330|NCT00462397|cervical adenocarcinoma
561331|NCT00462397|cervical adenosquamous cell carcinoma
561332|NCT00462397|cervical squamous cell carcinoma
561333|NCT00462397|stage IB cervical cancer
561334|NCT00462397|stage IIA cervical cancer
561335|NCT00462397|stage IIB cervical cancer
561336|NCT00462397|stage III cervical cancer
561337|NCT00462397|stage IVA cervical cancer
561338|NCT00462397|recurrent cervical cancer
561339|NCT00462371|quality of life
561340|NCT00462371|child diabetes mellitus type 1
561341|NCT00462371|Continuous subcutaneous insulin infusion(CSII)
561342|NCT00462371|metabolic control
561343|NCT00462332|stage III chronic lymphocytic leukemia
561344|NCT00462332|stage IV chronic lymphocytic leukemia
561345|NCT00462306|Obstructive Sleep Apnea
561346|NCT00462306|Pregnancy
561347|NCT00462306|Berlin Questionnaire
561348|NCT00462267|Nutrition
561349|NCT00462267|Exercise
561350|NCT00462267|Body mass index
561351|NCT00462267|Lifestyle change
561352|NCT00462267|Obesity
561353|NCT00462267|Overweight
561354|NCT00462267|Adolescents
561355|NCT00462267|Teens
561356|NCT00462254|Ramelteon
561357|NCT00462254|Parkinson's disease
561358|NCT00462254|Sleep disturbances
561359|NCT00462241|Chest pain
561360|NCT00462241|Chest wall
561361|NCT00462241|Atypical chest pain
561362|NCT00462241|Non-cardiac chest pain
561363|NCT00462241|Undiagnosed chest pain
561364|NCT00462241|Physical examination
561365|NCT00462241|Randomized controlled trial
561366|NCT00462241|Treatment study
561367|NCT00462241|Chiropractor
561368|NCT00462228|traumatic brain injury
561369|NCT00462228|memory
561370|NCT00462228|attention
561371|NCT00462202|Diabetes
561372|NCT00462202|Microalbuminuria
561373|NCT00462202|Proteinuria
561374|NCT00462202|Albuminuria
561375|NCT00462202|KRX-101
561376|NCT00462202|Sulodexide
561377|NCT00462202|Nephropathy
561378|NCT00462202|Keryx
561379|NCT00462202|Collaborative Study Group
561380|NCT00462202|Diabetic nephropathy with persistent microalbuminuria
561381|NCT00462189|CAT-8015
561382|NCT00462189|HA22
561383|NCT00462189|HCL
561384|NCT00462189|Relapse
561385|NCT00462189|Refractory
561386|NCT00462189|immunotherapy
561387|NCT00462189|immunotoxin
561388|NCT00462176|colorectal endometriosis
561389|NCT00462176|deep infiltrating endometriosis
561390|NCT00462176|dysmenorroe
561391|NCT00462176|dyspareunia
561392|NCT00462176|quality of life
561393|NCT00462150|arthritis, rheumatoid
561394|NCT00462150|expressed emotion
561395|NCT00462150|randomized controlled trial
561396|NCT00462150|affect
561397|NCT00462150|blood sedimentation
561398|NCT00462150|psychophysiology
561399|NCT00462150|feasibility studies
561400|NCT00462150|intervention studies
561401|NCT00462150|time management
561402|NCT00462137|GERD
561403|NCT00462137|Gastroesphageal Reflux Disease (GERD)
561404|NCT00462124|Prostate
561405|NCT00462124|cancer
561406|NCT00462124|radiation
561407|NCT00462124|biodegradable implantable balloon
561408|NCT00462124|intrarectal balloon
561409|NCT00462111|indometacin
561410|NCT00462111|reaction time
561411|NCT00462111|postural balance
561412|NCT00462111|obstacle avoidance
561413|NCT00462111|accidental falls
561414|NCT00462098|Osteonecrosis of the jaw
561415|NCT00462098|hyperbaric oxygen
561416|NCT00462098|bisphosphonates
561417|NCT00462085|cerebral palsy
561418|NCT00462085|ankle foot orthosis
561419|NCT00462085|emg
561420|NCT00462085|surface electromyography
561421|NCT00462085|gait analysis
561422|NCT00462059|Transition of care
561423|NCT00462059|Continuity of care
561424|NCT00462046|Berberine
561425|NCT00462046|Type 2 diabetes
561426|NCT00462046|Dyslipidemia
561427|NCT00462020|appendicitis, perforation, abscess, treatment
561428|NCT00461994|OBESITY
561429|NCT00461994|CHILDREN
561430|NCT00461994|METABOLIC PARAMETERS
561431|NCT00461994|DIET
561432|NCT00461994|EXERCISE
561433|NCT00461981|Live, attenuated influenza virus vaccine (LAIV)
561434|NCT00461981|Trivalent inactivated influenza virus vaccine (TIV)
561435|NCT00461981|FluMist
561436|NCT00461968|Cholesterol
561437|NCT00461968|LDL
561438|NCT00461968|Ezetimibe
561439|NCT00461968|Statin
561440|NCT00461968|Zetia
561441|NCT00461968|Zocor
561442|NCT00461968|Simvastin
561443|NCT00461955|Symptomatic Multiple Myeloma
561444|NCT00461955|first line treatment
561445|NCT00461955|first autologous Stem Cell Transplantation
561446|NCT00461955|ex vivo amplified autologous peripheral blood stem cells
561447|NCT00461942|Health Food;
561448|NCT00461942|Green Tea;
561449|NCT00461942|Neuroprotection
561450|NCT00461929|chronic myeloid leukemia
561451|NCT00461929|gastrointestinal stromal cell tumors
561452|NCT00461929|chromosome abnormality
561453|NCT00461929|imatinib
561454|NCT00461929|bone marrow aspiration
561455|NCT00461916|half-dose depot triptorelin
561456|NCT00461916|reduced-dose daily buserelin
561457|NCT00461916|controlled ovarian stimulation
561458|NCT00461916|long protocol
561459|NCT00461916|ICSI
561460|NCT00461903|essential hypertension
561461|NCT00461903|symptomatic paroxysmal or persistent atrial fibrillation
561462|NCT00461890|Alcohol
561463|NCT00461890|Veterans
561464|NCT00461890|Primary Care
561465|NCT00461890|Naltrexone
561466|NCT00461864|fracture
561467|NCT00461864|occult
561468|NCT00461864|hip
561469|NCT00461851|Advanced/Metastatic Bladder Carcinoma
561470|NCT00461838|colorectal endometriosis
561471|NCT00461838|deep infiltrating endometriosis
561472|NCT00461838|dysmenorroe
561473|NCT00461838|dyspareunia
561474|NCT00461838|quality of life
561475|NCT00461825|Immunosuppression
561476|NCT00461825|Kidney transplantation
561477|NCT00461825|multicenter study
561478|NCT00461799|Crigler-Najjar disease.
561479|NCT00461799|Bilirubin.
561480|NCT00461799|Phototherapy.
561481|NCT00461799|Orlistat.
561482|NCT00461799|Unconjugated hyperbilirubinemia.
561483|NCT00461773|Neoadjuvant treatment
561484|NCT00461760|HPV Screening/Testing for cervical cancer screening
561485|NCT00461747|Untreated
561486|NCT00461747|Transplant
561487|NCT00461747|Younger
561488|NCT00461734|Right Ventricular High Septal Pacing
561489|NCT00461734|Right Ventricular Apical Pacing
561490|NCT00461734|Left Ventricular Dysfunction
561491|NCT00461734|Heart Block
561492|NCT00461734|Pacemaker
561493|NCT00461734|Atrial Fibrillation
561494|NCT00461734|Ejection Fraction
561495|NCT00460993|Aging
561496|NCT00460993|Sleep
561497|NCT00460993|Nursing Home
561498|NCT00460993|Sleep in nursing homes
561499|NCT00460980|resident training
561500|NCT00460980|laparoscopic skills
561501|NCT00460980|surgical skills assessment
561502|NCT00460967|non-Exudative (Dry) Age-Related Macular Degeneration
561503|NCT00460928|congenital heart block
561504|NCT00460928|neonatal lupus
561505|NCT00460928|systemic lupus erythematosus
561506|NCT00460928|Sjogren syndrome
561507|NCT00460928|autoantibodies
561508|NCT00460928|SSA/Ro
561509|NCT00460928|SSB/La
561510|NCT00460928|autoimmunity
561511|NCT00460928|pregnancy
561512|NCT00460928|intravenous immune globulin
561513|NCT00460928|IVIG
561514|NCT00460928|immunoglobulin
561515|NCT00460915|Lacidipine
561516|NCT00460915|Amlodipine
561517|NCT00460902|TMS
561518|NCT00460902|drug resistant depression
561519|NCT00461695|Cytomegalovirus (CMV)
561520|NCT00461695|Tick-borne encephalitis virus (TBEV)
561521|NCT00461695|Ageing
561522|NCT00461695|Vaccine
561523|NCT00461695|Immunity
561524|NCT00461682|TRPV1 antagonist
561525|NCT00461682|Fecal Urgency
561526|NCT00461682|rectal pain
561527|NCT00461682|IBS
561528|NCT00461669|hip
561529|NCT00461669|fracture
561530|NCT00461669|ultrasound
561531|NCT00461656|Antiseptic
561532|NCT00461656|Povidone-Iodine
561533|NCT00461643|Anovulation
561534|NCT00461643|Clomiphene citrate
561535|NCT00461643|Infertility
561536|NCT00461643|Metformin
561537|NCT00461643|PCOS
561538|NCT00461643|RCT
561539|NCT00461643|Treatment
561540|NCT00461630|coronary heart disease
561541|NCT00461630|cardiovascular disease
561542|NCT00461630|stroke
561543|NCT00461630|peripheral arterial disease
561544|NCT00461630|diabetes mellitus
561545|NCT00461630|cholesterol
561546|NCT00461630|HDL cholesterol
561547|NCT00461630|simvastatin
561548|NCT00461630|ezetimibe
561549|NCT00461630|ER niacin
561550|NCT00461630|laropiprant
561551|NCT00461617|diabetes
561552|NCT00461617|rapid and short acting insulin secretagogue
561553|NCT00461617|α-glucosidase inhibitor
561554|NCT00461617|HbA1C
561555|NCT00461617|insulin
561556|NCT00461604|gastroesophageal reflux disease
561557|NCT00461604|baclofen
561558|NCT00461604|impedance
561559|NCT00461591|Noninvasive Bladder Cancer
561560|NCT00461578|P.falciparum
561561|NCT00461578|malaria
561562|NCT00461578|lapdap+artesunate
561563|NCT00461578|safety
561564|NCT00461578|efficay
561565|NCT00461565|Retina
561566|NCT00461565|PDE-5
561567|NCT00461565|Levitra
561568|NCT00461565|Viagra
561569|NCT00461565|Normal healthy volunteers for evaluation of retinal function
561570|NCT00461552|Lipodystrophy
561571|NCT00461552|HIV
561572|NCT00461552|HAART
561573|NCT00461552|HIV Lipodystrophy Syndrome
561574|NCT00461552|Lipodystrophy syndrome
561575|NCT00461552|HIV-Associated Lipodystrophy
561576|NCT00461552|HIV-Associated Lipodystrophy Syndrome
561577|NCT00461552|Treatment Experienced
561578|NCT00461539|Tobacco Use
561579|NCT00461539|Alcohol and Drug Use
561580|NCT00461539|Obesity
561581|NCT00461539|Risky Sexual Behavior
561582|NCT00461526|IBS
561583|NCT00461526|d-IBS
561584|NCT00461526|Irritable Bowel Syndrome
561585|NCT00461513|Heart Failure, Congestive
561586|NCT00461513|Disease Management
561587|NCT00461513|Health Status
561588|NCT00461513|Quality of Life
561589|NCT00461513|Telemedicine
561590|NCT00461513|Depression
561591|NCT00461500|persistent
561592|NCT00461500|moderate
561593|NCT00461500|asthma
561594|NCT00461500|adults
561595|NCT00461500|Initial
561596|NCT00461500|Maintenance
561597|NCT00461500|Therapy
561598|NCT00461487|Adolescent Behavior
561599|NCT00461487|Communication
561600|NCT00461487|Health Behavior
561601|NCT00461487|Risk-Taking
561602|NCT00461487|Sexual Behavior
561603|NCT00461474|Shoulder pain
561604|NCT00461474|Chronic Spinal Cord Injury
561605|NCT00461474|Exercise
561606|NCT00461474|Physical therapy techniques
561607|NCT00461474|Motor performance
561608|NCT00461448|Potassium supplement
561609|NCT00461448|Rheumatoid Arthritis
561610|NCT00461448|Pain
561611|NCT00461448|Disease Activity
561612|NCT00461422|IVF
561613|NCT00461422|GnRH antagonist
561614|NCT00461409|Neonatal Seizures
561615|NCT00461409|Treatment
561616|NCT00461409|Anticonvulsant
561617|NCT00461409|Levetiracetam
561618|NCT00461396|Relapsing-Remitting Multiple Sclerosis
561619|NCT00461396|First demyelinating event
561620|NCT00461396|MRI features consistent with MS
561621|NCT00461370|safety
561622|NCT00461370|Phase 1
561623|NCT00461370|pharmacokinetics
561624|NCT00461370|SRX251
561625|NCT00461370|Azevan
561626|NCT00461370|safety in healthy volunteers
561627|NCT00461357|Old for Old
561628|NCT00461357|Eurotransplant Senior Program
561629|NCT00461357|Glomerular Filtration Rate
561630|NCT00461344|Breast
561631|NCT00461331|Type 1 diabetes mellitus
561632|NCT00461331|Glycemic control
561633|NCT00461331|Continuous subcutaneous insulin infusion
561634|NCT00461331|Continuous glucose monitoring system
561635|NCT00461318|vocational rehabilitation
561636|NCT00461318|psychosis
561637|NCT00461318|cross country comparison
561638|NCT00461305|Dysmenorrhea
561639|NCT00461305|Intracyclic bleeding
561640|NCT00461305|Drospirenone (DRSP)
561641|NCT00461305|Ethinylestradiol
561642|NCT00461279|attachment
561643|NCT00461279|depression
561644|NCT00461279|IPT
561645|NCT00461279|CBT
561646|NCT00461279|pharmacotherapy
561647|NCT00461266|Treatment Experienced
561648|NCT00461253|breast cancer
561649|NCT00461240|heart
561650|NCT00461240|MRS
561651|NCT00461240|acromegaly
561652|NCT00461240|growth hormone
561653|NCT00461227|Puerto Rican
561654|NCT00461227|Allergies
561655|NCT00461214|laparoscopy
561656|NCT00461214|surgery
561657|NCT00461214|technical skills
561658|NCT00461214|outcomes
561659|NCT00461214|resident training
561660|NCT00461201|Health Services Research
561661|NCT00461201|Nurse Practitioners
561662|NCT00461201|Outcome and Process Assessment (Health Care)
561663|NCT00461201|Patient Acceptance of Health Care
561664|NCT00461201|Patient Satisfaction
561665|NCT00461201|Primary Health Care
561666|NCT00461201|Professional Autonomy
561667|NCT00461188|acromegaly
561668|NCT00461188|gigantism
561669|NCT00461188|familial pituitary adenoma
561670|NCT00461188|Familial acromegaly
561671|NCT00461188|Familial Isolated Pituitary Adenoma
561672|NCT00461188|FIPA
561673|NCT00461188|Pituitary adenoma predisposition
561674|NCT00461188|PAP
561675|NCT00461175|Uterine Perforation
561676|NCT00461149|Acromegaly
561677|NCT00461149|GH
561678|NCT00461149|IGF-I
561679|NCT00461149|Pituitary tumors
561680|NCT00461149|Octreotide
561681|NCT00461136|Time course
561682|NCT00461136|antiproteinuric
561683|NCT00461136|blood pressure
561684|NCT00461136|lowering effect
561685|NCT00461136|initiation of renin inhibition
561686|NCT00461136|Aliskiren in Type 2 diabetes
561687|NCT00461136|incipient and/or established nephropathy
561688|NCT00461097|Egg Allergy
561689|NCT00461097|Egg Oral Immunotherapy (OIT)
561690|NCT00461097|Food Allergy
561691|NCT00461084|Lymphoma
561692|NCT00461084|Advanced Stage
561693|NCT00461084|Untreated
561694|NCT00461084|Advanced Stage Lymphoma
561695|NCT00461084|Untreated Lymphoma
561696|NCT00461084|07-038
561697|NCT00461071|Bulimia nervosa
561698|NCT00461071|Guided Self-help
561699|NCT00461071|Psycho-education
561700|NCT00461045|multiple myeloma
561701|NCT00461045|proteasome inhibitor
561702|NCT00461045|relapsed
561703|NCT00461045|refractory
561704|NCT00460889|hand assist
561705|NCT00460889|laparoscopy
561706|NCT00460889|renal donor
561707|NCT00460889|outcomes
561708|NCT00460876|topotecan
561709|NCT00460876|periocular
561710|NCT00460876|chemotherapy
561711|NCT00460863|sleep
561712|NCT00460863|hemodialysis
561713|NCT00460863|daytime sleepiness
561714|NCT00460863|temperature
561715|NCT00460837|colorectal cancer
561716|NCT00460837|bowel preparation regimen
561717|NCT00460837|patients with symptoms attributable to colorectal cancer
561718|NCT00460824|transplant
561719|NCT00460824|HLA antibodies matching
561720|NCT00460824|immunologic mismatching
561721|NCT00460811|Irritable Bowel Syndrome with Constipation
561722|NCT00460811|IBS
561723|NCT00460811|Irritable Bowel Syndrome
561724|NCT00460811|linaclotide acetate
561725|NCT00460811|linaclotide
561726|NCT00460811|MD-1100
561727|NCT00460798|Sunitinib
561728|NCT00460798|kidney diseases
561729|NCT00460798|urogenital neoplasms
561730|NCT00460798|kidney cancer
561731|NCT00460759|Mycobacterium tuberculosis, rifapentine, moxifloxacin
561732|NCT00460746|HIV
561733|NCT00460746|AIDS
561734|NCT00460746|Immunodeficiency Virus, Human
561735|NCT00460746|PREZISTA
561736|NCT00460746|darunavir
561737|NCT00460746|TMC114
561738|NCT00460746|TMC125
561739|NCT00460746|Protease Inhibitor
561740|NCT00460746|Non-Nucleoside Reverse Transcriptase Inhibitor
561741|NCT00460746|enfuvirtide
561742|NCT00460746|Treatment Experienced
561743|NCT00460720|Attention Deficit Hyperactivity Disorder
561744|NCT00460720|ADHD
561745|NCT00460720|Methylphenidate
561746|NCT00460720|MPH
561747|NCT00460720|Extended-Release Methylphenidate
561748|NCT00460707|GW679769
561749|NCT00460707|healthy adult subjects
561750|NCT00460707|casopitant
561751|NCT00460707|ketoconazole
561752|NCT00460694|allogeneic transplant
561753|NCT00460694|haematological malignancies
561754|NCT00460694|allogeneic CIK cells
561755|NCT00460681|Hepatocellular Carcinoma
561756|NCT00460681|Thymopentin
561757|NCT00460681|Recurrence
561758|NCT00460681|Resection
561759|NCT00460668|elective thoracotomy
561760|NCT00460668|pulmonary rehabilitation
561761|NCT00460668|quality of life
561762|NCT00460655|Post-Stroke
561763|NCT00460655|Lower Limb
561764|NCT00460655|botulinum toxin type A
561765|NCT00460655|Spasticity
561766|NCT00460642|Frozen embryo transfers (FET).
561767|NCT00460642|Egg donation (ED).
561768|NCT00460642|IVF.
561769|NCT00460642|ART.
561770|NCT00460642|Implantation.
561771|NCT00460642|GnRH antagonist.
561772|NCT00460642|Cetrotide.
561773|NCT00460642|Endometrial response.
561774|NCT00460642|Infertility treatments:
561775|NCT00460642|Transfer of embryos from egg donation (ED) to recipients.
561776|NCT00460629|Adoptive immunotherapy
561777|NCT00460629|BCR-ABL reactive T cells
561778|NCT00460629|Allogeneic Transplantation
561779|NCT00460616|Prolactin
561780|NCT00460616|Prolactinomas
561781|NCT00460616|Dopamine-Agonists
561782|NCT00460616|Cabergoline
561783|NCT00460616|Cardiac valve disease
561784|NCT00460603|GI neoplasms (phase 1)
561785|NCT00460590|Tuberculosis
561786|NCT00460590|TB
561787|NCT00460590|MVA 85A
561788|NCT00460577|Asthma, Formoterol, Bronchial Obstruction, Children
561789|NCT00460564|Spasticity
561790|NCT00460564|Post-Stroke
561791|NCT00460564|botulinum toxin type A
561792|NCT00460564|Upper Limb
561793|NCT00460538|Seasonal allergic rhinitis
561794|NCT00460538|lectranal
561795|NCT00460538|allergy
561796|NCT00460525|malaria, Mali, children, Plasmodium falciparum, vaccine
561797|NCT00460512|Schizophrenia
561798|NCT00460512|Flexible dosing
561799|NCT00460512|Non-acute patients
561800|NCT00460512|Antipsychotic
561801|NCT00460512|Atypical
561802|NCT00460512|INVEGA
561803|NCT00460499|Diabetes
561804|NCT00460473|Mental Health
561805|NCT00460473|Neurological Disease
561806|NCT00460473|Hip Injuries and Disorders
561807|NCT00460460|Phase I
561808|NCT00460460|cancer
561809|NCT00460460|lymphoma
561810|NCT00460460|leukemia
561811|NCT00460460|myeloma
561812|NCT00460460|AML
561813|NCT00460460|ALL
561814|NCT00460460|NHL
561815|NCT00460460|MM
561816|NCT00460447|anti-CD33
561817|NCT00460447|Immunotoxin
561818|NCT00460447|Acute myeloid leukemia
561819|NCT00460434|Prolapse
561820|NCT00460434|Urinary incontinence
561821|NCT00460434|TVT
561822|NCT00460421|Oral Mucositis
561823|NCT00460421|Acute Lymphoblastic Leukemia
561824|NCT00460421|Acute Myeloid Leukemia
561825|NCT00460421|Palifermin
561826|NCT00460421|Kepivance
561827|NCT00460408|Macular degeneration
561828|NCT00460408|Safety
561829|NCT00460408|Non-interventional
561830|NCT00460408|Non-randomized
561831|NCT00460395|Brain Metastasis
561832|NCT00460395|Cerebral Metastases
561833|NCT00460395|Brain Cancer
561834|NCT00460395|Stereotactic Radiosurgery
561835|NCT00460395|Craniotomy
561836|NCT00460382|HIV infections
561837|NCT00460382|HIV integrase inhibitor
561838|NCT00460382|etravirine
561839|NCT00460382|darunavir
561840|NCT00460382|MK 0518
561841|NCT00460382|raltegravir
561842|NCT00460382|Treatment Experienced
561843|NCT00460382|Antiviral drug resistance
561844|NCT00460369|uncomplicated malaria
561845|NCT00460369|children
561846|NCT00460369|treatment
561847|NCT00460369|effectiveness
561848|NCT00460343|patient non-adherence
561849|NCT00460343|antihypertensive agents
561850|NCT00460343|community pharmacy services
561851|NCT00460343|professional roles
561852|NCT00460330|diagnosis
561853|NCT00460330|galactomannan
561854|NCT00460330|glucan
561855|NCT00460330|real-time PCR
561856|NCT00460330|invasive fungal infection
561857|NCT00460330|aspergillosis
561858|NCT00460330|Chinese patients
561859|NCT00460317|lung
561860|NCT00460317|cancer
561861|NCT00460317|chemotherapy
561862|NCT00460317|paclitaxel
561863|NCT00460317|carboplatin
561864|NCT00460317|placebo
561865|NCT00460317|angiogenesis
561866|NCT00460317|VEGF
561867|NCT00460317|multi kinase inhibitor
561868|NCT00460304|Type I diabetes
561869|NCT00460304|Insulin pump
561870|NCT00460304|Continuous glucose monitoring
561871|NCT00460304|Insulin to carbohydrate ratio
561872|NCT00460304|Correction factor
561873|NCT00460304|Pramlintide
561874|NCT00460291|PAD
561875|NCT00460291|vein bypass
561876|NCT00460291|supported varicose veins
561877|NCT00460278|Cancer
561878|NCT00460278|Solid Tumors
561879|NCT00460265|Squamous Cell Carcinoma
561880|NCT00460265|Epidermal Growth Factor
561881|NCT00460265|Epidermal Growth Factor Receptor
561882|NCT00460265|SCCHN
561883|NCT00460265|Metastatic Head and Neck Cancer
561884|NCT00460265|EGFr
561885|NCT00460265|Head and Neck Cancer
561886|NCT00460265|Recurrent Head and Neck Cancer
561887|NCT00460252|algorithm
561888|NCT00460252|insulin
561889|NCT00460252|hyperglycemia
561890|NCT00460252|tight glycemic control
561891|NCT00460252|intensive care
561892|NCT00460252|adults
561893|NCT00460239|Opioid addiction
561894|NCT00460239|Opioid dependence
561895|NCT00460239|Buprenorphine
561896|NCT00460226|Korean
561897|NCT00460226|Bipolar I disorder
561898|NCT00460226|Non-serious rash
561899|NCT00460226|Lamotrigine
561900|NCT00460213|home blood pressure
561901|NCT00460200|depression
561902|NCT00460200|fatigue
561903|NCT00460200|sleep disorders
561904|NCT00460200|psychosocial effects of cancer and its treatment
561905|NCT00460200|ovarian epithelial cancer
561906|NCT00460187|carotid artery, distal protection device, carotid stenting
561907|NCT00460174|stage I pancreatic cancer
561908|NCT00460174|stage II pancreatic cancer
561909|NCT00460174|stage III pancreatic cancer
561910|NCT00460161|acupuncture
561911|NCT00460161|amputation
561912|NCT00460161|phantom limb pain
561913|NCT00460148|ropinirole PR/CR,
561914|NCT00460148|pharmacokinetic,
561915|NCT00460148|formulation,
561916|NCT00460148|food effect,
561917|NCT00460148|SK&F101468,
561918|NCT00460148|PD
561919|NCT00460135|Resistance
561920|NCT00460135|Training
561921|NCT00460135|Obesity
561922|NCT00460135|Children
561923|NCT00460122|Human Leukocyte Antigens (HLA)
561924|NCT00460122|Transfusion Reactions
561925|NCT00460122|Platelet Donors
561926|NCT00460109|stage III grade 1 follicular lymphoma
561927|NCT00460109|stage III grade 2 follicular lymphoma
561928|NCT00460109|stage IV grade 1 follicular lymphoma
561929|NCT00460109|stage IV grade 2 follicular lymphoma
561930|NCT00460096|Pulmonary Emphysema
561931|NCT00460083|Atopic Dermatitis
561932|NCT00460083|eczema
561933|NCT00460083|dermatitis
561934|NCT00460083|skin barrier
561935|NCT00460083|barrier repair
561936|NCT00460083|ceramide
561937|NCT00460083|physiologic lipid
561938|NCT00460083|pruritus
561939|NCT00460083|Elidel
561940|NCT00460083|Epiceram
561941|NCT00460083|topical steroid
561942|NCT00460057|osteoporosis
561943|NCT00460057|alendronate
561944|NCT00460057|bone marker
561945|NCT00460044|ADMA
561946|NCT00460044|Preterms
561947|NCT00460044|infants
561948|NCT00460044|mechanical ventilation
561949|NCT00460044|Preterm infants
561950|NCT00460031|adenocarcinoma of the prostate
561951|NCT00460031|stage III prostate cancer
561952|NCT00460031|stage IV prostate cancer
561953|NCT00460031|recurrent prostate cancer
561954|NCT00460018|Gestational Diabetes Mellitus
561955|NCT00460018|Weight Loss
561956|NCT00460018|Physical Activity
561957|NCT00460018|Breastfeeding
561958|NCT00460018|Pregnancy
561959|NCT00460018|Postpartum
561960|NCT00460018|Intervention
561961|NCT00460018|Prevention
561962|NCT00460005|Migraine
561963|NCT00460005|headache
561964|NCT00460005|observational
561965|NCT00459992|Obesity
561966|NCT00459992|Weight Gain
561967|NCT00459992|Adult
561968|NCT00459992|Histamine
561969|NCT00459992|Metabolism
561970|NCT00459992|Overweight
561971|NCT00459979|clear cell renal cell carcinoma
561972|NCT00459979|stage III renal cell cancer
561973|NCT00459979|stage IV renal cell cancer
561974|NCT00459979|papillary renal cell carcinoma
561975|NCT00459940|Growth hormone
561976|NCT00459940|Lipolysis
561977|NCT00459940|Insulin resistance
561978|NCT00459940|Pioglitazone
561979|NCT00459940|Growth hormone replaced growth hormone deficient adults
561980|NCT00459927|Adenotonsillectomy
561981|NCT00459927|Coblation tonsillectomy
561982|NCT00459927|Floseal
561983|NCT00459914|sleep apnea
561984|NCT00459914|refractory hypertension
561985|NCT00459914|continuous positive airway pressure
561986|NCT00459901|Metastatic Colorectal Cancer
561987|NCT00459888|CLI
561988|NCT00459888|Critical Limb Ischemia
561989|NCT00459888|Infrapopliteal
561990|NCT00459888|Cryoplasty
561991|NCT00459875|recurrent renal cell cancer
561992|NCT00459875|stage IV renal cell cancer
561993|NCT00459849|Melanoma
561994|NCT00459849|Brachytherapy
561995|NCT00459849|Ultrasonography
561996|NCT00459836|unspecified adult solid tumor, protocol specific
561997|NCT00459823|Cancer
561998|NCT00459823|solid tumors
561999|NCT00459810|adenocarcinoma of the prostate
562000|NCT00459810|recurrent prostate cancer
562001|NCT00459810|stage IV prostate cancer
562002|NCT00459797|GlideScope
562003|NCT00459797|cobalt
562004|NCT00459797|single-use
562005|NCT00459797|intubation
562006|NCT00459797|airway
562007|NCT00459797|Elective surgical patients requiring orotracheal intubation
562008|NCT00459784|Improvement
562009|NCT00459784|Dementia early diagnosis
562010|NCT00459784|Dementia management
562011|NCT00459784|Primary care
562012|NCT00459771|angiotensin II-receptor (AT1) blocker
562013|NCT00459771|prevention
562014|NCT00459771|trastuzumab
562015|NCT00459771|cardiotoxicity
562016|NCT00459758|hypertension
562017|NCT00459758|Hans
562018|NCT00459758|Electrical stimulation
562019|NCT00459745|Cardiovascular Disease
562020|NCT00459745|Fenofibrate
562021|NCT00459745|LDL cholesterol
562022|NCT00459745|HDL cholesterol
562023|NCT00459745|Hyperlipidemia
562024|NCT00459745|Pravastatin
562025|NCT00459745|Triglycerides
562026|NCT00459732|zinc, thalassemia, bone mineral density
562027|NCT00459719|Liver Transplantation
562028|NCT00459719|Tacrolimus
562029|NCT00459719|Methylprednisolone
562030|NCT00459719|Prednisolone
562031|NCT00459706|Rheumatoid Arthritis
562032|NCT00459693|HIV-Dementia
562033|NCT00459693|Brain
562034|NCT00459693|PET
562035|NCT00459693|PBR28
562036|NCT00459693|MCMD
562037|NCT00459693|HIV Positive
562038|NCT00459693|HIV Dementia
562039|NCT00459693|AIDS Related Dementia
562040|NCT00459693|Minor Cognitive Motor Disorder
562041|NCT00459693|Healthy Volunteer
562042|NCT00459693|HV
562043|NCT00459680|hypertension
562044|NCT00459680|acupuncture
562045|NCT00459680|laser
562046|NCT00459667|Relapsing multiple sclerosis
562047|NCT00459667|interferon beta 1b
562048|NCT00459667|Betaferon
562049|NCT00459667|Betaseron
562050|NCT00459654|HRPC
562051|NCT00459654|Recurrent Prostate Cancer
562052|NCT00459654|Metastatic Cancer
562053|NCT00459641|Osteogenic Gel
562054|NCT00459641|Solitary Bone Cysts
562055|NCT00459628|early breast cancer
562056|NCT00459628|post-operative radiation treatment
562057|NCT00459602|laparoscopic surgery
562058|NCT00459589|Cancer
562059|NCT00459589|elderly
562060|NCT00459589|malnutrition
562061|NCT00459589|chemotherapy
562062|NCT00459589|survival
562063|NCT00459589|comprehensive geriatric assessment
562064|NCT00459589|morbidity
562065|NCT00459576|Asthma
562066|NCT00459576|Eczema
562067|NCT00459576|Dermatitis, Atopic
562068|NCT00459576|Infant
562069|NCT00459563|vitamin D
562070|NCT00459563|blood pressure
562071|NCT00459563|hypertension
562072|NCT00459563|Vitamin D insufficient
562073|NCT00459563|Systolic blood pressure between 130 and 150 mmHg
562074|NCT00459550|Alzheimer's Disease
562075|NCT00459550|First Time in Human (FTIH) Study
562076|NCT00459537|Toenail fungus
562077|NCT00459537|Onychomycosis
562078|NCT00459537|Nail fungus
562079|NCT00459537|Toenail fungal infection
562080|NCT00459537|Tinea unguium
562081|NCT00459537|Dermatophytes
562082|NCT00459537|Foot dermatoses
562083|NCT00459524|Acute Myelogenous Leukemia
562084|NCT00459524|Myelodysplastic Syndrome
562085|NCT00459524|Leukemia
562086|NCT00459524|Quality of Life
562087|NCT00459524|Questionnaire
562088|NCT00459524|Survey
562089|NCT00459524|Neurocognitive Function
562090|NCT00459524|AML
562091|NCT00459524|MDS
562092|NCT00459524|QOL
562093|NCT00459511|Adrenomedullin
562094|NCT00459511|Glucose
562095|NCT00459511|Insulin
562096|NCT00459511|Systemic Inflammatory response Syndrome
562097|NCT00459511|Pediatric
562098|NCT00459511|Cortisol
562099|NCT00459511|ACTH
562100|NCT00459498|NIS
562101|NCT00459498|thyroid adenoma
562102|NCT00459498|thyroid cancer
562103|NCT00459498|Iodine uptake
562104|NCT00459498|expression
562105|NCT00459485|Plasm zinc concentration
562106|NCT00459485|Zinc supplementation
562107|NCT00459485|Assessment of zinc status
562108|NCT00459485|Plasma zinc concentration
562109|NCT00459472|resident training
562110|NCT00459472|laparoscopy
562111|NCT00459472|virtual reality
562112|NCT00459472|surgical education
562113|NCT00459446|Magnetic Resonance Imaging
562114|NCT00459446|Gadolinium Contrast
562115|NCT00459446|Gadofosveset
562116|NCT00459446|Atherosclerosis
562117|NCT00459446|Chronic Total Arterial Occlusions
562118|NCT00459446|Cardiovascular Disease
562119|NCT00459446|Blocked Arteries
562120|NCT00459446|Peripheral Artery Disease
562121|NCT00459446|PAD
562122|NCT00459446|Intermittent Claudication
562123|NCT00459446|Chronic Total Arterial Occlusion
562124|NCT00459433|Low back pain
562125|NCT00459433|Return to work
562126|NCT00459433|Biopsychosocial
562127|NCT00459433|Screening
562128|NCT00459433|SMS
562129|NCT00459433|Non specific low back pain
562130|NCT00459420|Parkinson's disease
562131|NCT00459420|Excessive Daytime Somnolence
562132|NCT00459420|Caffeine
562133|NCT00459420|Disease-Modifying
562134|NCT00459368|asthma
562135|NCT00459368|patient compliance
562136|NCT00459368|metered dose inhalers
562137|NCT00459368|corticosteroids
562138|NCT00459368|health behaviour
562139|NCT00459368|prevention & control
562140|NCT00459355|Alzheimer's disease
562141|NCT00459355|Dementia
562142|NCT00459355|Safety
562143|NCT00459355|Home Care Services
562144|NCT00459329|Depression
562145|NCT00459329|Epilepsy
562146|NCT00459329|Problem-Solving Therapy
562147|NCT00459329|Mental Health
562148|NCT00459329|Neurology
562149|NCT00459329|Home-based health care
562150|NCT00459329|Community-based program
562151|NCT00459329|Collaborative care
562152|NCT00459303|cataract
562153|NCT00459303|aspherical intraocular lenses
562154|NCT00459303|functional vision
562155|NCT00459290|recurrent ovarian epithelial cancer
562156|NCT00459290|primary peritoneal cavity cancer
562157|NCT00459290|fallopian tube cancer
562158|NCT00459277|Pain
562159|NCT00459277|Cancer
562160|NCT00459264|Folic Acid
562161|NCT00459264|Prevention
562162|NCT00459264|Depression
562163|NCT00459264|Bipolar Disorder
562164|NCT00459264|Teenagers
562165|NCT00459251|N-acetyltransferase
562166|NCT00459251|Pharmacogenetics
562167|NCT00459238|unspecified childhood solid tumor, protocol specific
562168|NCT00459225|Pediatrics
562169|NCT00459225|Cardiac Defect
562170|NCT00459225|Cardiac Surgery
562171|NCT00459225|Single Ventricle
562172|NCT00459225|Anemia
562173|NCT00459225|blood transfusions
562174|NCT00459225|red cell volume
562175|NCT00459225|red cell distribution
562176|NCT00459225|oral iron
562177|NCT00459225|ferrous sulfate
562178|NCT00459225|Congenital Cardiac Defects
562179|NCT00459225|Hemoglobin
562180|NCT00459225|Iron Deficiency
562181|NCT00459186|prostate cancer
562182|NCT00459186|RAD001
562183|NCT00459186|mTOR inhibition
562184|NCT00459186|docetaxel
562185|NCT00459173|abstinence
562186|NCT00459173|maintenance
562187|NCT00459160|Hypotensive Resuscitation
562188|NCT00459160|Hypotensive Anesthesia
562189|NCT00459160|Hemorrhagic Shock
562190|NCT00459160|Penetrating Trauma
562191|NCT00459134|sexual dysfunction
562192|NCT00459134|sexuality and reproductive issues
562193|NCT00459134|unspecified adult solid tumor, protocol specific
562194|NCT00459121|stage I non-small cell lung cancer
562195|NCT00459121|stage II non-small cell lung cancer
562196|NCT00459121|stage IIIA non-small cell lung cancer
562197|NCT00459082|Dexmedetomine
562198|NCT00459082|Post-operative cardiac surgery
562199|NCT00459069|tumor vaccine
562200|NCT00459069|GM-CSF
562201|NCT00459043|SCCHN
562202|NCT00459030|colon cancer
562203|NCT00459030|rectal cancer
562204|NCT00459017|24 hour ambulatory blood pressure measurement
562205|NCT00459017|Mean blood pressure
562206|NCT00459017|Wrist manometer
562207|NCT00459017|Frequent measurement
562208|NCT00459004|weight loss
562209|NCT00458991|Recombinant Human Growth Hormone
562210|NCT00458991|growth hormone deficiency
562211|NCT00458991|short stature
562212|NCT00458991|phenotyping
562213|NCT00458952|MIBG
562214|NCT00458952|iobenguane
562215|NCT00458952|iodine
562216|NCT00458952|I 131
562217|NCT00458952|radiotherapy
562218|NCT00458952|radiopharmaceutical
562219|NCT00458952|dosimetry
562220|NCT00458952|neuroendocrine tumor
562221|NCT00458952|Ultratrace
562222|NCT00458952|no carrier added
562223|NCT00458952|metaiodobenzyl-guanidine
562224|NCT00458926|ventilation, mechanical
562225|NCT00458926|intubation, endotracheal
562226|NCT00458926|respiratory insufficiency
562227|NCT00458913|localized malignant mesothelioma
562228|NCT00458913|recurrent malignant mesothelioma
562229|NCT00458913|advanced malignant mesothelioma
562230|NCT00458887|ototoxicity
562231|NCT00458887|unspecified childhood solid tumor, protocol specific
562232|NCT00458874|CV risk factors
562233|NCT00458874|subclinical atherosclerosis
562234|NCT00458874|lifestyle intervention
562235|NCT00458874|motivation
562236|NCT00458861|Active Rheumatoid Arthritis (RA)
562237|NCT00458848|B-cell adult acute lymphoblastic leukemia
562238|NCT00458848|T-cell adult acute lymphoblastic leukemia
562239|NCT00458848|untreated adult acute lymphoblastic leukemia
562240|NCT00458848|L1 adult acute lymphoblastic leukemia
562241|NCT00458848|L2 adult acute lymphoblastic leukemia
562242|NCT00458848|TdT positive adult acute lymphoblastic leukemia
562243|NCT00458835|Allergic rhinitis
562244|NCT00458822|primary systemic amyloidosis
562245|NCT00458809|recurrent colon cancer
562246|NCT00458809|stage IV colon cancer
562247|NCT00458809|carcinoma of the appendix
562248|NCT00458809|recurrent rectal cancer
562249|NCT00458809|stage IV rectal cancer
562250|NCT00458809|primary peritoneal cavity cancer
562251|NCT00458796|hypercalcemia of malignancy
562252|NCT00458796|musculoskeletal complications
562253|NCT00458796|pain
562254|NCT00458796|stage IV breast cancer
562255|NCT00458796|male breast cancer
562256|NCT00458796|recurrent breast cancer
562257|NCT00458796|bone metastases
562258|NCT00458783|Transfusion
562259|NCT00458783|Cardiac
562260|NCT00458783|Blood storage duration
562261|NCT00458770|Comparison of a spontaneous acute cluster headache attack and rest (no pain) in ten patients with cluster headache defined with IHS criteria
562262|NCT00458757|Amputees
562263|NCT00458757|Affordance
562264|NCT00458757|Peripersonal space
562265|NCT00458757|Pseudo neglect
562266|NCT00458757|Reaching
562267|NCT00458757|Spatial
562268|NCT00458757|visual
562269|NCT00458744|juvenile myelomonocytic leukemia
562270|NCT00458744|relapsing chronic myelogenous leukemia
562271|NCT00458744|unspecified childhood solid tumor, protocol specific
562272|NCT00458744|childhood chronic myelogenous leukemia
562273|NCT00458744|childhood acute promyelocytic leukemia (M3)
562274|NCT00458744|recurrent childhood acute lymphoblastic leukemia
562275|NCT00458744|recurrent childhood acute myeloid leukemia
562276|NCT00458744|childhood central nervous system germ cell tumor
562277|NCT00458744|childhood choroid plexus tumor
562278|NCT00458744|childhood craniopharyngioma
562279|NCT00458744|childhood infratentorial ependymoma
562280|NCT00458744|childhood grade I meningioma
562281|NCT00458744|childhood grade II meningioma
562282|NCT00458744|childhood grade III meningioma
562283|NCT00458744|childhood supratentorial ependymoma
562284|NCT00458744|recurrent childhood brain stem glioma
562285|NCT00458744|recurrent childhood cerebellar astrocytoma
562286|NCT00458744|recurrent childhood cerebral astrocytoma
562287|NCT00458744|recurrent childhood ependymoma
562288|NCT00458744|recurrent childhood medulloblastoma
562289|NCT00458744|recurrent childhood supratentorial primitive neuroectodermal tumors
562290|NCT00458744|recurrent childhood visual pathway and hypothalamic glioma
562291|NCT00458744|recurrent childhood visual pathway glioma
562292|NCT00458744|high-grade childhood cerebral astrocytoma
562293|NCT00458744|low-grade childhood cerebral astrocytoma
562294|NCT00458744|recurrent childhood brain tumor
562295|NCT00458744|childhood spinal cord tumor
562296|NCT00458744|recurrent/refractory childhood Hodgkin lymphoma
562297|NCT00458744|stage IV childhood Hodgkin lymphoma
562298|NCT00458744|recurrent childhood large cell lymphoma
562299|NCT00458744|stage IV childhood large cell lymphoma
562300|NCT00458744|recurrent childhood lymphoblastic lymphoma
562301|NCT00458744|stage IV childhood lymphoblastic lymphoma
562302|NCT00458744|recurrent childhood small noncleaved cell lymphoma
562303|NCT00458744|stage IV childhood small noncleaved cell lymphoma
562304|NCT00458744|childhood grade III lymphomatoid granulomatosis
562305|NCT00458744|childhood nasal type extranodal NK/T-cell lymphoma
562306|NCT00458744|recurrent childhood grade III lymphomatoid granulomatosis
562307|NCT00458744|recurrent childhood pineoblastoma
562308|NCT00458718|abstinence
562309|NCT00458718|nicotine patch
562310|NCT00458705|stage I multiple myeloma
562311|NCT00458705|stage II multiple myeloma
562312|NCT00458705|stage III multiple myeloma
562313|NCT00458705|refractory multiple myeloma
562314|NCT00458679|CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
562315|NCT00458679|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS
562316|NCT00458666|Amniotic fluid
562317|NCT00458666|D-dimer
562318|NCT00458666|coagulation
562319|NCT00458666|factor X activation
562320|NCT00458653|DC/tumor cell fusions
562321|NCT00458653|GM-CSF
562322|NCT00458653|high dose chemotherapy
562323|NCT00458627|Plethysmograpy
562324|NCT00458627|preschool
562325|NCT00458627|methacholine challenge
562326|NCT00458627|spirometry
562327|NCT00458627|asthma
562328|NCT00458614|Cystic Fibrosis
562329|NCT00458601|EGFRvIII vaccinetemozolomidecancer vaccineimmunotherapy
562330|NCT00458588|breast cancer
562331|NCT00458575|Retinitis Pigmentosa
562332|NCT00458575|Advanced retinitis pigmentosa (RP)
562333|NCT00458575|CNTO 2476
562334|NCT00458575|Subretinal
562335|NCT00458575|Human umbilical tissue-derived cells (hUTC)
562336|NCT00458575|Light perception (LP)
562337|NCT00458575|Hand motion (HM)
562338|NCT00458562|cervical cancer
562339|NCT00458562|atypical squamous cells of undetermined significance
562340|NCT00458562|stage 0 cervical cancer
562341|NCT00458562|cervical intraepithelial neoplasia grade 1
562342|NCT00458562|cervical intraepithelial neoplasia grade 2
562343|NCT00458562|cervical intraepithelial neoplasia grade 3
562344|NCT00458549|stage I prostate cancer
562345|NCT00458549|stage II prostate cancer
562346|NCT00458549|stage III prostate cancer
562347|NCT00458549|stage IV prostate cancer
562348|NCT00458536|GM-CSF
562349|NCT00458536|vaccine
562350|NCT00458536|debulking nephrectomy
562351|NCT00458536|dendritic cells
562352|NCT00458523|B-cell chronic lymphocytic leukemia
562353|NCT00458523|stage I chronic lymphocytic leukemia
562354|NCT00458523|stage II chronic lymphocytic leukemia
562355|NCT00458523|stage III chronic lymphocytic leukemia
562356|NCT00458523|stage 0 chronic lymphocytic leukemia
562357|NCT00458523|stage IV chronic lymphocytic leukemia
562358|NCT00458510|Pain
562359|NCT00458510|Cancer
562360|NCT00458510|Breakthrough
562361|NCT00458497|Holofiber
562362|NCT00458497|chronic foot pain
562363|NCT00458497|sleep quality
562364|NCT00458484|stage I renal cell cancer
562365|NCT00458484|stage II renal cell cancer
562366|NCT00458484|stage III renal cell cancer
562367|NCT00458484|stage IV renal cell cancer
562368|NCT00458471|Urinary Catheter
562369|NCT00458471|Spinal Cord Injury
562370|NCT00458471|Escherichia Coli
562371|NCT00458471|Urinary Tract Infection
562372|NCT00458458|Endometriosis
562373|NCT00458458|Dysmenorrhea
562374|NCT00458458|Pelvic Pain
562375|NCT00458458|Period Pain
562376|NCT00458458|Menstrual Cramps
562377|NCT00458458|Dyspareunia
562378|NCT00458458|Norethindrone Acetate
562379|NCT00458458|Lupron Depot
562380|NCT00458458|Bone Density
562381|NCT00458458|Lipid Profile
562382|NCT00458445|Attention-Deficit Hyperactivity Disorder (ADHD)
562383|NCT00458432|fMRI
562384|NCT00458432|Pavlovian Conditioning
562385|NCT00458432|Functional Activity
562386|NCT00458432|Brain
562387|NCT00458432|Fear
562388|NCT00458432|Healthy Volunteer
562389|NCT00458432|HV
562390|NCT00458419|dyspnea; leg discomfort; exercise duration
562391|NCT00458406|obstructive sleep apnea
562392|NCT00458406|child
562393|NCT00458406|CPAP
562394|NCT00458393|HIV
562395|NCT00458393|Chemoprophylaxis
562396|NCT00458393|Hepatitis
562397|NCT00458393|Viral human hepatitis
562398|NCT00458393|HIV Seronegativity
562399|NCT00458380|Doppler ultrasonography
562400|NCT00458380|Embryos
562401|NCT00458380|Infertility
562402|NCT00458380|IVF
562403|NCT00458380|Oocytes
562404|NCT00458380|Tubal factor
562405|NCT00458380|unexplained infertility
562406|NCT00458367|PASS
562407|NCT00458367|Safety Assessment
562408|NCT00458367|Efficacy Assessment
562409|NCT00458367|long-acting injectable risperidone
562410|NCT00458354|Spinal Sealant
562411|NCT00458354|Spinal Sealant System
562412|NCT00458354|Dural Repair
562413|NCT00458354|Spinal Surgery
562414|NCT00458341|Cystic fibrosis
562415|NCT00458341|Nonsense mutation
562416|NCT00458341|Premature stop codon
562417|NCT00458302|HIV
562418|NCT00458302|Monotherapy
562419|NCT00458302|Darunavir
562420|NCT00458302|Protease inhibitor
562421|NCT00458302|Early pre-treated
562422|NCT00458302|Undetectable
562423|NCT00458302|Treatment Experienced
562424|NCT00458276|Left sided heart disease
562425|NCT00458276|Elevated pulmonary arterial pressure
562426|NCT00458276|Right ventricular failure
562427|NCT00458276|Cardiac surgery
562428|NCT00458276|heart-lung machine
562429|NCT00458276|cardiopulmonary bypass
562430|NCT00458276|tezosentan
562431|NCT00458276|Actelion
562432|NCT00458263|Growth Hormone treatment
562433|NCT00458263|ISS
562434|NCT00458263|Biochemical markers
562435|NCT00458263|Growth response
562436|NCT00458250|Hematopoietic Stem Cell Transplantation
562437|NCT00458250|Haploidentical
562438|NCT00458250|Hematologic Neoplasms
562439|NCT00458250|human, Bone Marrow
562440|NCT00458250|Granulocyte Colony-stimulating Factor
562441|NCT00458250|CAMPATH
562442|NCT00458250|Alemtuzumab
562443|NCT00458250|AML
562444|NCT00458250|ALL
562445|NCT00458250|10. Eligibility
562446|NCT00458237|HER2 positive
562447|NCT00458237|metastatic breast cancer
562448|NCT00458237|RAD001
562449|NCT00458237|Herceptin
562450|NCT00458224|overweight
562451|NCT00458224|obesity
562452|NCT00458224|child
562453|NCT00458211|Schizophrenia
562454|NCT00458211|Ziprasidone
562455|NCT00458198|Selective Mutism
562456|NCT00458172|lay theories
562457|NCT00458172|health concepts
562458|NCT00458172|survey
562459|NCT00458172|internet research
562460|NCT00458172|Ideas about health
562461|NCT00458159|CC-11006
562462|NCT00458159|RA
562463|NCT00458159|MDS
562464|NCT00458159|Celgene
562465|NCT00458159|RCMD-RS
562466|NCT00458159|RARS
562467|NCT00458159|RAEB-1
562468|NCT00458159|Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
562469|NCT00458133|aerobic exercise
562470|NCT00458133|resistance exercise
562471|NCT00458133|type 2 diabetes
562472|NCT00458133|hemoglobin A1C
562473|NCT00458133|exercise
562474|NCT00458120|Dengue Fever
562475|NCT00458120|Dengue Hemorrhagic Fever
562476|NCT00458120|Dengue Vaccination
562477|NCT00458107|Pharmacokinetics
562478|NCT00458107|Pharmacodynamics
562479|NCT00458094|Exercise
562480|NCT00458094|Mental Illness
562481|NCT00458094|Community Psychiatry
562482|NCT00458094|Peer Support
562483|NCT00458094|Mental Disorders
562484|NCT00458068|preterm infant
562485|NCT00458068|iron supplementation
562486|NCT00458068|iron deficiency
562487|NCT00458068|blood transfusion
562488|NCT00458055|Lipid lowering agents
562489|NCT00458055|Drug treatment
562490|NCT00458055|Statin
562491|NCT00458055|Fibrate
562492|NCT00458055|Niacin
562493|NCT00458055|Cellular cholesterol efflux
562494|NCT00458042|Ventavis
562495|NCT00458042|iloporst
562496|NCT00458042|Remodulin
562497|NCT00458042|treprostinil
562498|NCT00458042|PAH
562499|NCT00458042|prostacyclin
562500|NCT00458029|type 2 diabetes risk factors
562501|NCT00458029|obesity
562502|NCT00458029|prevention
562503|NCT00458029|adolescence
562504|NCT00458029|school based
562505|NCT00458003|Preeclampsia
562506|NCT00458003|Spinal Anesthesia
562507|NCT00458003|Hypotension
562508|NCT00458003|Cesarean Delivery
562509|NCT00458003|Phenylephrine
562510|NCT00458003|Ephedrine
562511|NCT00457990|Neurocognitive outcome
562512|NCT00457990|preterm infant
562513|NCT00457990|very low birth weight
562514|NCT00457990|iron deficiency
562515|NCT00457990|iron supplementation
562516|NCT00457977|Chronic Obstructive Pulmonary Disease
562517|NCT00457977|COPD
562518|NCT00457977|Pneumococcal
562519|NCT00457977|Vaccine
562520|NCT00457977|Opsonization
562521|NCT00457977|Antibodies
562522|NCT00457964|Tuberous Sclerosis Complex (TSC)
562523|NCT00457964|Lymyphangioleiomyomatosis
562524|NCT00457964|Mammalian Target of Rapamycin (mTOR)
562525|NCT00457964|RAD001
562526|NCT00457964|Angiomyolipmas
562527|NCT00457951|Chronic Obstructive Pulmonary Disease
562528|NCT00457951|COPD
562529|NCT00457951|Heparin
562530|NCT00457951|ODSH
562531|NCT00457951|Exacerbations of COPD
562532|NCT00457938|lipodystrophy
562533|NCT00457925|absorption,
562534|NCT00457925|metabolism,
562535|NCT00457925|excretion
562536|NCT00457925|distribution,
562537|NCT00457899|schizophrenia
562538|NCT00457899|schizoaffective disorder
562539|NCT00457899|quetiapine
562540|NCT00457899|seroquel
562541|NCT00457899|titration
562542|NCT00457873|surgery
562543|NCT00457860|CLL
562544|NCT00457860|PLL
562545|NCT00457860|SLL
562546|NCT00457860|Relapse
562547|NCT00457860|Refractory
562548|NCT00457860|immunotoxin
562549|NCT00457860|HA22
562550|NCT00457860|CAT-8015
562551|NCT00457860|immunotherapy
562552|NCT00457847|PGD
562553|NCT00457834|Heart failure
562554|NCT00457834|Dyssynchrony
562555|NCT00457834|Cardiac resynchronization therapy
562556|NCT00457834|Atrial fibrillation
562557|NCT00457834|RVOT
562558|NCT00457834|RVapex
562559|NCT00457821|G551D mutation
562560|NCT00457821|Fibrosis
562561|NCT00457821|Pancreatic Diseases
562562|NCT00457821|Digestive System Diseases
562563|NCT00457821|Lung Diseases
562564|NCT00457821|Respiratory Tract Diseases
562565|NCT00457821|Genetic Diseases, Inborn
562566|NCT00457821|Infant, Newborn, Diseases
562567|NCT00457821|Pathologic Processes
562568|NCT00457808|TSC and LAM
562569|NCT00457808|Tuberous Sclerosis Complex and sporadic LAM
562570|NCT00457782|Cancer
562571|NCT00457782|Blood disorders
562572|NCT00457782|Leukaemia, Adult Chronic
562573|NCT00457782|Lymphoma
562574|NCT00457782|Multiple Myeloma
562575|NCT00457769|Aricept
562576|NCT00457769|Donepezil
562577|NCT00457769|Memory
562578|NCT00457769|vascular dementia
562579|NCT00457769|stroke
562580|NCT00457769|functional tasks
562581|NCT00457769|self-generation
562582|NCT00457756|LDL cholesterol
562583|NCT00457756|HDL cholesterol
562584|NCT00457756|natural supplement
562585|NCT00457756|guar gum
562586|NCT00457756|phytosterols
562587|NCT00457756|policosanol
562588|NCT00457756|chrysanthemum
562589|NCT00457743|Evaluate of RTD for Japanese GIST patients
562590|NCT00457730|Multiple Sclerosis
562591|NCT00457730|Duloxetine
562592|NCT00457730|Pain
562593|NCT00457717|myopia, auricular acupoint, atropine, RCT
562594|NCT00457704|MRSA
562595|NCT00457704|Home Care
562596|NCT00457704|Risk factors
562597|NCT00457704|transmissions
562598|NCT00457704|observational study
562599|NCT00457691|colorectal neoplasms
562600|NCT00457678|Vision loss
562601|NCT00457678|Retina
562602|NCT00457678|VEG-F
562603|NCT00457678|Fovea
562604|NCT00457678|AMD
562605|NCT00457665|HIV
562606|NCT00457665|Lipodystrophy
562607|NCT00457665|Treatment Experienced
562608|NCT00457652|Rosuvastatin
562609|NCT00457652|Caffeine
562610|NCT00457652|Ischemia
562611|NCT00457652|Reperfusion
562612|NCT00457639|lipodystrophy
562613|NCT00457626|Children
562614|NCT00457626|pediatrics
562615|NCT00457626|High Blood Pressure
562616|NCT00457626|Hypertension
562617|NCT00457626|Valsartan
562618|NCT00457613|alkaline phosphatase
562619|NCT00457613|sepsis
562620|NCT00457613|kidney function
562621|NCT00457600|information technology
562622|NCT00457600|emergency department
562623|NCT00457600|medication error
562624|NCT00457600|quality of care
562625|NCT00457600|patient-centered care
562626|NCT00456586|Parkinson's disease
562627|NCT00456586|Levodopa therapy
562628|NCT00456586|End of dose wearing off
562629|NCT00456586|Off time
562630|NCT00456573|Pediatric Obstructive sleep apnea syndrome
562631|NCT00456547|Cesarean hysterectomy
562632|NCT00456547|Postpartum hemorrhage
562633|NCT00456547|Coagulation
562634|NCT00456534|Smoking
562635|NCT00456521|Obesity
562636|NCT00456521|Behavior Modification
562637|NCT00456469|TB
562638|NCT00456469|latent
562639|NCT00456469|infection
562640|NCT00456469|Ethiopia
562641|NCT00456443|Thalassemia
562642|NCT00456443|Sickle cell anemia
562643|NCT00456443|Splenectomy
562644|NCT00456443|Infections
562645|NCT00456443|Streptococcal Pneumonia
562646|NCT00456417|Neurological
562647|NCT00456417|Alzheimers
562648|NCT00456404|peppermint water
562649|NCT00456404|nipple crack
562650|NCT00456404|lactating women
562651|NCT00456391|Brain CT scan
562652|NCT00456391|Pediatric emergency room
562653|NCT00456365|Autosomal dominant polycystic kidney disease
562654|NCT00456365|Cystic kidney disease
562655|NCT00456365|High blood pressure
562656|NCT00456365|Statin
562657|NCT00456339|Obstructive sleep apnea syndrome (OSAS) in children
562658|NCT00456326|Heparin
562659|NCT00456326|Unfractionated Heparin
562660|NCT00456326|Low Molecular Weight Heparin
562661|NCT00456326|Anticoagulation
562662|NCT00456326|Thrombocytopenia
562663|NCT00456326|Thrombosis
562664|NCT00456326|Venous Thrombosis
562665|NCT00456326|Pulmonary Embolism
562666|NCT00456313|asthma
562667|NCT00456313|fluticasone propionate
562668|NCT00456313|salmeterol/fluticasone propionate
562669|NCT00456313|combination product
562670|NCT00456313|innate immune response
562671|NCT00456313|neutrophil priming
562672|NCT00457561|The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level
562673|NCT00457548|Alcohol use
562674|NCT00457548|Brief Interventions
562675|NCT00457548|Injuries
562676|NCT00457548|Emergency Department Patients
562677|NCT00457548|Harmful and hazardous alcohol use among ED injured patients
562678|NCT00457535|recombinant human erythropoietin
562679|NCT00457535|adiponectin
562680|NCT00457535|mortality
562681|NCT00457522|intimate partner violence
562682|NCT00457522|depression
562683|NCT00457522|PTSD
562684|NCT00457522|fatigue
562685|NCT00457509|Pandemic influenza
562686|NCT00457509|Avian influenza
562687|NCT00457509|Orthomyxoviridae Infections
562688|NCT00457509|A/H5N1
562689|NCT00457496|Behavior Therapy
562690|NCT00457496|Relaxation Techniques
562691|NCT00457496|Cognitive Therapy
562692|NCT00457496|Exercise Movement Techniques
562693|NCT00457483|hypertension
562694|NCT00457483|diuretic
562695|NCT00457483|angiotensin receptor blockers
562696|NCT00457483|prediction
562697|NCT00457457|With or without erectile dysfunction
562698|NCT00457431|in-hospital cardiac arrest
562699|NCT00457431|resuscitation
562700|NCT00457431|mild therapeutic hypothermia
562701|NCT00457405|ischemia-reperfusion injury
562702|NCT00457405|atherosclerosis
562703|NCT00457405|dipyridamole
562704|NCT00457405|annexin A5 targeting
562705|NCT00457392|Non-small cell lung cancer
562706|NCT00457392|sunitinib
562707|NCT00457392|erlotinib
562708|NCT00457392|Phase 3
562709|NCT00457379|Coronary artery disease
562710|NCT00457379|HDL-Cholesterol
562711|NCT00457379|Endothelial Function
562712|NCT00457379|Endothelial Progenitor Cells
562713|NCT00457379|normal blood HDL-Cholesterol level
562714|NCT00457340|Tachycardia, Ventricular
562715|NCT00457340|Ventricular Fibrillation
562716|NCT00457327|protective ileostomy
562717|NCT00457327|rectal cancer
562718|NCT00457327|low anterior resection
562719|NCT00457314|single-large scale deletions
562720|NCT00457314|point mutations in mtDNA
562721|NCT00457301|Lung transplantation, health-related quality of life.
562722|NCT00457288|Cutaneous Mastocytosis
562723|NCT00457288|Topical treatment
562724|NCT00457262|paraoxonase1 activity
562725|NCT00457262|LDL
562726|NCT00457262|HDL
562727|NCT00457262|postmenopausal women
562728|NCT00457262|postmenopausal women and hyperlipidemia
562729|NCT00457249|Pertussis
562730|NCT00457249|Tetanus
562731|NCT00457249|Diphtheria
562732|NCT00457249|Tdap
562733|NCT00457236|Clopidogrel
562734|NCT00457236|Coronary Artery Disease
562735|NCT00457236|Dose-Response Relationship, Drug
562736|NCT00457236|Drug Resistance
562737|NCT00457236|PCI
562738|NCT00457223|pterygium
562739|NCT00457223|pterygia
562740|NCT00457223|excision
562741|NCT00457223|amniotic membrane transplantation
562742|NCT00457223|fibrin glue
562743|NCT00457223|suture
562744|NCT00457210|Psychology
562745|NCT00457197|bipolar disorder
562746|NCT00457197|alcohol dependence
562747|NCT00457197|mania
562748|NCT00457197|manic disorder
562749|NCT00457197|depression
562750|NCT00457184|Migraine
562751|NCT00457184|Thrombosis
562752|NCT00457184|Thrombophilia
562753|NCT00457171|GI-270384 colitis patients ECAM oral
562754|NCT00457158|pulmonary embolism
562755|NCT00457158|inferior vena cava filters
562756|NCT00457158|venous thrombosis
562757|NCT00457158|randomized controlled trial
562758|NCT00457145|Hyperfluorescence on Fluorescein
562759|NCT00457145|Idiopathic Juxtafoveal Telangiectasia
562760|NCT00457145|Retinal Edema/Thinning
562761|NCT00457145|Vascular Endothelial Growth Factor
562762|NCT00457145|Macular Telangiectasia
562763|NCT00457132|Knee
562764|NCT00457132|Osteoarthritis
562765|NCT00457132|WOMAC
562766|NCT00457132|ALF
562767|NCT00457132|Wedging
562768|NCT00457119|Non Small Cell Lung Cancer
562769|NCT00457119|NSCLC
562770|NCT00457119|Advanced Lung Cancer
562771|NCT00457119|RAD
562772|NCT00457119|RAD001
562773|NCT00457119|chemotherapy
562774|NCT00457119|carboplatin
562775|NCT00457119|paclitaxel
562776|NCT00457119|bevacizumab
562777|NCT00457106|panic
562778|NCT00457093|Type 2 Diabetes
562779|NCT00457093|continuous glucose monitoring
562780|NCT00457093|basal insulin
562781|NCT00457080|capnography
562782|NCT00457080|safety
562783|NCT00457080|opioids
562784|NCT00457080|respiratory depression
562785|NCT00457080|postoperative
562786|NCT00457080|orthopedic
562787|NCT00457080|OSA
562788|NCT00457080|apnea
562789|NCT00457067|Hyperfluorescence on Fluorescein
562790|NCT00457067|Idiopathic Juxtafoveal Telangiectasia
562791|NCT00457067|Retinal Edema/Thinning
562792|NCT00457067|Vascular Endothelial Growth Factor
562793|NCT00457067|Macular Telangiectasia
562794|NCT00457054|Mood Regulating Circuit
562795|NCT00457054|Lithium
562796|NCT00457054|fMRI
562797|NCT00457041|Trust
562798|NCT00457041|Decision Making
562799|NCT00457041|Vulnerability
562800|NCT00457041|Survey
562801|NCT00457028|Obsessive Compulsive Disorder
562802|NCT00457028|Anxiety
562803|NCT00457028|Treatment efficacy
562804|NCT00457002|Prevention of deep vein thrombosis and pulmonary embolism with acutely ill hospitalized patients
562805|NCT00456989|Androgen Independent
562806|NCT00456989|Prostate Cancer
562807|NCT00456989|Taxotere
562808|NCT00456989|Doxil
562809|NCT00456989|AIPC
562810|NCT00456989|Advanced Androgen-Independent Prostate Cancer
562811|NCT00456976|Seligiline
562812|NCT00456976|Negative symptoms
562813|NCT00456976|Schizopherenia
562814|NCT00456963|angiotensin converting enzyme inhibitors
562815|NCT00456963|angiotensin receptor blockers
562816|NCT00456963|diabetes
562817|NCT00456963|hypertension
562818|NCT00456963|therapeutic strategies
562819|NCT00456950|coronary atherosclerosis
562820|NCT00456950|magnetic resonance imaging
562821|NCT00456950|vulnerable plaque
562822|NCT00456924|progesterone receptor modulator
562823|NCT00456911|obesity
562824|NCT00456911|prevention
562825|NCT00456911|children
562826|NCT00456911|adults
562827|NCT00456911|family
562828|NCT00456911|dietary
562829|NCT00456911|coaching
562830|NCT00456911|body mass index
562831|NCT00456911|fat mass
562832|NCT00456885|obesity
562833|NCT00456885|double blind
562834|NCT00456885|placebo controlled
562835|NCT00456885|weight loss
562836|NCT00456885|appetite
562837|NCT00456885|energy expenditure
562838|NCT00456872|Pain during injection of the pre-procedure anesthetic
562839|NCT00456859|chronic kidney disease
562840|NCT00456859|oral carbonaceous adsorbent
562841|NCT00456859|randomized clinical trial
562842|NCT00456859|composite endpoint
562843|NCT00456846|Metastatic Breast Cancer, ABI-007, Abraxane
562844|NCT00456833|Non Small Cell Lung Cancer
562845|NCT00456833|NSCLC
562846|NCT00456833|Advanced lung cancer
562847|NCT00456833|RAD
562848|NCT00456833|RAD001
562849|NCT00456833|erlotinib
562850|NCT00456820|Mood Regulating Circuit
562851|NCT00456820|SSRI
562852|NCT00456820|fMRI
562853|NCT00456807|Human Papillomavirus
562854|NCT00456794|Parkinson's disease
562855|NCT00456794|Levodopa
562856|NCT00456794|End of dose wearing off
562857|NCT00456794|OFF time
562858|NCT00456781|rotator cuff
562859|NCT00456781|randomized clinical trial
562860|NCT00456768|Panic Disorder
562861|NCT00456768|Anxiety
562862|NCT00456768|Treatment efficacy
562863|NCT00456755|Perennial Allergic rhinitis
562864|NCT00456755|Traditional Chinese Medicine
562865|NCT00456742|Generalized Anxiety Disorder
562866|NCT00456742|Anxiety
562867|NCT00456742|Treatment efficacy
562868|NCT00456729|Iron deficiency
562869|NCT00456729|Malabsorption
562870|NCT00456729|Giardiasis
562871|NCT00456716|BAC lung cancer
562872|NCT00456716|adenocarcinoma of the lung
562873|NCT00456703|fluids,
562874|NCT00456703|restriction,
562875|NCT00456703|infection,
562876|NCT00456703|bowel surgery,
562877|NCT00456703|open abdominal
562878|NCT00456690|Thalassemia
562879|NCT00456690|Nutrition
562880|NCT00456690|Endocrine
562881|NCT00456690|BMI
562882|NCT00456677|minocycline
562883|NCT00456677|asthma
562884|NCT00456677|oral corticosteroids
562885|NCT00456664|CMV
562886|NCT00456664|IRIS
562887|NCT00456651|Sleep Apnea
562888|NCT00456651|Obesity
562889|NCT00456651|Neuropeptides
562890|NCT00456651|Hormones
562891|NCT00456638|OP-CABG
562892|NCT00456638|Depodur traditional drug
562893|NCT00456625|Hepatitis B vaccine
562894|NCT00456625|Challenge dose
562895|NCT00456300|Type 1 Diabetes
562896|NCT00456300|Hyperglycemia
562897|NCT00456300|Hypoglycemia
562898|NCT00456287|Sleep Apnea
562899|NCT00456287|Clotting- fibrinolysis patterns
562900|NCT00456287|Platelet function markers
562901|NCT00456287|Endothelial dysfunction
562902|NCT00456274|Hypothalamic Amenorrhea
562903|NCT00456274|Idiopathic hypogonadotropic hypogonadism
562904|NCT00456274|Acquired hypogonadotropic hypogonadism
562905|NCT00456274|Kallmann's Syndrome
562906|NCT00456274|Amenorrhea
562907|NCT00456274|Gonadotropin Releasing Hormone
562908|NCT00456261|Non Small Cell Lung Cancer
562909|NCT00456248|Chronic Hepatitis C
562910|NCT00456248|Liver
562911|NCT00456248|Pegylated
562912|NCT00456248|Interferon
562913|NCT00456248|Ribavirin
562914|NCT00456248|Combination
562915|NCT00456248|Nonresponder
562916|NCT00456248|Relapser
562917|NCT00456248|HCV
562918|NCT00456248|Infergen
562919|NCT00456248|SVR
562920|NCT00456222|Sleep
562921|NCT00456222|Circadian rhythms
562922|NCT00456222|Menstrual cycle
562923|NCT00456209|Lived Experiences
562924|NCT00456209|Adolescents
562925|NCT00456209|Cancer Treatment
562926|NCT00456209|Occupations
562927|NCT00456196|COPD
562928|NCT00456196|Thrombosis
562929|NCT00456196|Cancer
562930|NCT00456196|Renal
562931|NCT00456196|Elderly
562932|NCT00456196|Surgery
562933|NCT00456196|Orthopedic Surgery
562934|NCT00456196|Medically Ill
562935|NCT00456196|Deep Vein Thrombosis
562936|NCT00456196|Pulmonary Embolism
562937|NCT00456196|Anticoagulation
562938|NCT00456183|Tuberculosis
562939|NCT00456183|Latent
562940|NCT00456183|TB
562941|NCT00456183|Vaccine
562942|NCT00456183|MVA 85A
562943|NCT00456170|Vaginal
562944|NCT00456170|Hysterectomy
562945|NCT00456170|Harmonic
562946|NCT00456170|Ligasure
562947|NCT00456170|Sutures
562948|NCT00456170|Modern
562949|NCT00456170|Patients undergoing vaginal hysterectomy for various reasons
562950|NCT00456157|Osteoarthritis
562951|NCT00456157|Osteophytes
562952|NCT00456157|Knee
562953|NCT00456157|Intra-articular
562954|NCT00456157|OP-1
562955|NCT00456144|GnRH
562956|NCT00456144|Insulin sensitivity
562957|NCT00456118|recurrent pregnancy losses
562958|NCT00456118|preeclampsia
562959|NCT00456118|intervillositis
562960|NCT00456118|maternofetal alloimmunization
562961|NCT00456105|Type 2 diabetes
562962|NCT00456105|Post-op dysglycemia
562963|NCT00456105|Peripheral vascular disease
562964|NCT00456105|Infrainguinal bypass surgery
562965|NCT00456092|psoriatic arthritis
562966|NCT00456092|ACR
562967|NCT00456092|PASI
562968|NCT00456092|DAS
562969|NCT00456092|pharmacokinetic
562970|NCT00456092|biopsy
562971|NCT00456066|Acute myocardial infarction
562972|NCT00456066|Thromboaspiration
562973|NCT00456066|Infarct size
562974|NCT00456066|Left ventricular remodelling
562975|NCT00456053|Renal Anemia
562976|NCT00456053|Renal Failure
562977|NCT00456053|Kidney Disease
562978|NCT00456053|Human EPO
562979|NCT00456040|amyloidosis
562980|NCT00456040|heart failure
562981|NCT00456040|heart transplant
562982|NCT00456040|stem cell transplant
562983|NCT00456027|Type 2 Diabetes
562984|NCT00456027|LADA
562985|NCT00456027|Latent Autoimmune Diabetes in Adult
562986|NCT00456027|Autoimmunity
562987|NCT00456027|HbA1c
562988|NCT00456027|C-peptide
562989|NCT00456014|Major Depression
562990|NCT00456014|Antidepressants
562991|NCT00456001|heparin
562992|NCT00456001|low molecular weight heparin
562993|NCT00456001|enoxaparin
562994|NCT00456001|anticoagulation
562995|NCT00456001|thrombosis
562996|NCT00456001|venous thrombosis
562997|NCT00456001|thromboembolism
562998|NCT00456001|pulmonary embolism
562999|NCT00456001|medication
563000|NCT00455988|questionnaire developement
563001|NCT00455988|regularity
563002|NCT00455988|lifestyle
563003|NCT00455988|type 2 diabetes
563004|NCT00455975|Kidney Cancer
563005|NCT00455975|Renal Cancer
563006|NCT00455975|Clear Cell Carcinoma
563007|NCT00455962|estrogen
563008|NCT00455962|progesterone
563009|NCT00455962|African-American
563010|NCT00455962|Caucasian
563011|NCT00455962|infusion
563012|NCT00455962|gonadotropins
563013|NCT00455962|healthy
563014|NCT00455936|Adenocarcinoma
563015|NCT00455936|NSCLC
563016|NCT00455936|gemcitabine
563017|NCT00455936|Cisplatin
563018|NCT00455936|Gefitinib
563019|NCT00455936|Never smoker
563020|NCT00455923|asthma
563021|NCT00455923|exacerbation
563022|NCT00455923|persistent
563023|NCT00455923|bronchial hyperresponsiveness
563024|NCT00455923|mild
563025|NCT00455923|GINAII
563026|NCT00455910|Low risk myelodysplastic syndromes
563027|NCT00455910|MDS
563028|NCT00455910|Bone marrow diseases
563029|NCT00455910|Thalidomide
563030|NCT00455910|Cytopenias
563031|NCT00455910|Anemia
563032|NCT00455897|GM-CSF
563033|NCT00455897|CHOP-R
563034|NCT00455897|Leukine
563035|NCT00455897|Sargramostim
563036|NCT00455897|DLBLCL
563037|NCT00455897|NHL
563038|NCT00455897|DLBCL
563039|NCT00455871|macular degeneration
563040|NCT00455845|Endometriosis
563041|NCT00455845|Lng IUD
563042|NCT00455832|sperm chromatin structure integrity
563043|NCT00455832|sperm concentration
563044|NCT00455832|sperm motility
563045|NCT00455832|sperm morphology
563046|NCT00455832|peginterferon
563047|NCT00455832|ribavirin
563048|NCT00455832|hepatitis C
563049|NCT00455819|pulmonary embolism
563050|NCT00455819|pro-BNP
563051|NCT00455819|home treatment
563052|NCT00455806|Helicobacter pylori
563053|NCT00455806|rescue therapy
563054|NCT00455806|eradication therapy
563055|NCT00455806|esomeprazole
563056|NCT00455806|moxifloxacin
563057|NCT00455806|resistance
563058|NCT00455793|HIV
563059|NCT00455793|atherosclerosis
563060|NCT00455780|Eating
563061|NCT00455780|Dieting
563062|NCT00455780|Meal replacements
563063|NCT00455780|Energy Density
563064|NCT00455780|Weight Loss Maintenance
563065|NCT00455767|persistent ARDS
563066|NCT00455767|alveolar inflammation
563067|NCT00455767|early pulmonary fibrosis
563068|NCT00455767|mechanichal ventilation
563069|NCT00455767|P/V curve
563070|NCT00455767|Static compliance
563071|NCT00455767|elastase activity
563072|NCT00455767|inhibitor of Human Neutrophil Elastase
563073|NCT00455741|menopause
563074|NCT00455741|estrogen
563075|NCT00455741|progesterone
563076|NCT00455741|hormone replacement
563077|NCT00455741|aging
563078|NCT00455741|PET
563079|NCT00455715|Schizophrenia
563080|NCT00455715|Cognition
563081|NCT00455715|Sildenafil
563082|NCT00455715|PDE5 Inhibitor
563083|NCT00455702|schizophrenia
563084|NCT00455702|cognition
563085|NCT00455702|d-cycloserine
563086|NCT00455702|memory
563087|NCT00455689|Lupron
563088|NCT00455689|Premenopausal
563089|NCT00455689|Hot flashes
563090|NCT00455689|PET
563091|NCT00455689|MRI
563092|NCT00455676|Scarf Osteotomy
563093|NCT00455676|Chevron Osteotomy
563094|NCT00455676|Comparison
563095|NCT00455663|Schizoaffective Disorder
563096|NCT00455663|Medication Adherence
563097|NCT00455650|schizophrenia
563098|NCT00455650|cognition
563099|NCT00455650|nicotinic receptors
563100|NCT00455650|mecamylamine
563101|NCT00455650|varenicline
563102|NCT00455624|androgen deprivation therapy
563103|NCT00455624|insulin resistance
563104|NCT00455611|Heart Failure, Congestive
563105|NCT00455611|Continuous Positive Airway Pressure
563106|NCT00455611|Baroreflex
563107|NCT00455611|Echocardiography
563108|NCT00455598|Diabetes
563109|NCT00455585|Pharmacokinetics
563110|NCT00455585|Antiretrovirals
563111|NCT00455585|Uganda
563112|NCT00455585|HIV
563113|NCT00455585|Treatment Experienced
563114|NCT00455572|Immunotherapeutic
563115|NCT00455572|Adjuvant cancer therapy
563116|NCT00455572|Non-small-cell lung cancer
563117|NCT00455572|ASCI
563118|NCT00455559|Resistant Gastrointestinal Stromal Tumor
563119|NCT00455559|GIST
563120|NCT00455559|Perifosine
563121|NCT00455559|Gleevec
563122|NCT00455546|Coronary
563123|NCT00455546|Artery
563124|NCT00455546|Atherosclerosis
563125|NCT00455546|Phospholipase
563126|NCT00455546|CAD
563127|NCT00455533|Early Breast Cancer
563128|NCT00455520|Diabetic neuropathy
563129|NCT00455520|Painful Diabetic Polyneuropathy
563130|NCT00455520|Polyneuropathy
563131|NCT00455520|Peripheral neuropathy
563132|NCT00455507|Parkinson's disease
563133|NCT00455507|levodopa
563134|NCT00455507|end of dose wearing off
563135|NCT00455507|OFF time
563136|NCT00455494|Drug-resistant malaria
563137|NCT00455494|Bioavailability
563138|NCT00455494|Food-effect study
563139|NCT00455468|Severe pneumonia
563140|NCT00455468|children
563141|NCT00455468|day care management
563142|NCT00455468|hospitalized management
563143|NCT00455468|Randomized controlled trial
563144|NCT00455468|Under five children
563145|NCT00455429|Atopic Dermatitis
563146|NCT00455429|JNJ-26113100
563147|NCT00455416|Low grade lymphoma
563148|NCT00455416|Diet
563149|NCT00455416|Antioxidants
563150|NCT00455416|Non Hodgkin Lymphoma - Follicular Lymphoma grade 1&2 stage III/IV
563151|NCT00455403|Metabolic Syndrome
563152|NCT00455403|Atherosclerosis
563153|NCT00455390|Post immediate Psychotherapeutic Intervention
563154|NCT00455390|Psychotraumatic disorders
563155|NCT00455390|PTSD post traumatic syndrome disorder
563156|NCT00455390|CUMP Cellules d’Urgence Médico Psychologique
563157|NCT00455377|Cement dust exposure
563158|NCT00455377|Induced sputum
563159|NCT00455377|Airway inflammation
563160|NCT00455377|Peripheral blood inflammation markers
563161|NCT00455364|Fungal infection prophylaxis
563162|NCT00455364|Lung transplant
563163|NCT00455364|Fungal infection post lung transplant
563164|NCT00455351|Palliative treatment
563165|NCT00455351|Max. tolerable dose
563166|NCT00455338|meal
563167|NCT00455338|composition
563168|NCT00455338|postprandial
563169|NCT00455338|PCOS
563170|NCT00455338|androgen
563171|NCT00455325|Insulin Resistance
563172|NCT00455325|Atherosclerosis
563173|NCT00455325|Metabolic Syndrome
563174|NCT00455312|Dyskeratosis Congenita
563175|NCT00455312|Hematopoietic Stem Cell Transplantation
563176|NCT00455312|Severe Aplastic Anemia
563177|NCT00455299|Laparoscopy, ventral, hernia, repair, surgery
563178|NCT00455286|CNS Lymphoma
563179|NCT00455273|Breast Cancer
563180|NCT00455273|DCE MRI
563181|NCT00455234|Aggression
563182|NCT00455234|Violent behaviour in people with psychotic illness
563183|NCT00455221|CML
563184|NCT00455221|Imatinib
563185|NCT00455221|vaccine
563186|NCT00455221|peptide
563187|NCT00455221|gene
563188|NCT00455221|MRD
563189|NCT00455221|DNA
563190|NCT00455182|Acupuncture
563191|NCT00455182|Hip Arthroplasty
563192|NCT00455182|Knee Arthroplasty
563193|NCT00455182|Pain Management
563194|NCT00455169|Influenza
563195|NCT00455169|Infant, Premature
563196|NCT00455169|Immunization
563197|NCT00455169|Vaccination
563198|NCT00455156|Contraception
563199|NCT00455156|Vaginal Ring
563200|NCT00455143|Postoperative delirium
563201|NCT00455143|PD
563202|NCT00455143|Postoperative cognitive dysfunction
563203|NCT00455143|POCD
563204|NCT00455130|mannitol
563205|NCT00455130|cystic fibrosis
563206|NCT00455130|mucolytic
563207|NCT00455130|mucoactive
563208|NCT00455117|analgesia
563209|NCT00455117|pain
563210|NCT00455117|neurosurgery
563211|NCT00455117|NSAIDS
563212|NCT00455117|parecoxib
563213|NCT00455117|morphine consumption
563214|NCT00455104|Fabry Disease
563215|NCT00455104|Enzyme Replacement Therapy (ERT)
563216|NCT00455091|Post-operative Hepatocellular Carcinoma.
563217|NCT00455078|Gastric reflux
563218|NCT00455078|Lung transplant
563219|NCT00455078|chronic rejection
563220|NCT00455078|Gastric reflux in lung transplant as it relates to chronic rejection
563221|NCT00455065|whole grain
563222|NCT00455065|metabolic syndrome
563223|NCT00455065|weight loss
563224|NCT00455052|XMT-1001
563225|NCT00455052|cancer
563226|NCT00455052|tumor
563227|NCT00455052|camptothecin
563228|NCT00455052|Fleximer
563229|NCT00455052|polymer
563230|NCT00455052|Phase 1
563231|NCT00455052|safety
563232|NCT00455052|pharmacokinetics
563233|NCT00455052|maximum tolerated dose
563234|NCT00455052|NSCLC
563235|NCT00455052|non-small cell lung cancer
563236|NCT00455052|SCLC
563237|NCT00455052|small cell lung cancer
563238|NCT00455039|neoadjuvant, HER2, Breast,GSK,lapatinib
563239|NCT00455013|Kidney transplant
563240|NCT00454987|antibody persistence
563241|NCT00454987|Meningococcal serogroup C vaccine
563242|NCT00454987|conjugate vaccine
563243|NCT00454987|Haemophilus influenzae type b vaccine
563244|NCT00454974|end stage renal failure
563245|NCT00454974|dialysis
563246|NCT00454974|wearable artificial kidney
563247|NCT00454961|Malaria
563248|NCT00454961|Plasmodium falciparum
563249|NCT00454961|artemether-lumefantrine
563250|NCT00454961|effectiveness
563251|NCT00454948|Obesity prevention
563252|NCT00454948|Dietary intake
563253|NCT00454948|Physical activity
563254|NCT00454948|Mexican American
563255|NCT00454948|Family Characteristics
563256|NCT00454935|epilepsy
563257|NCT00454935|glioma
563258|NCT00454922|glaucoma
563259|NCT00454922|patient educator
563260|NCT00454909|Meningococcal Serogroups A, C, W-135 and/or Y Disease
563261|NCT00454896|Urinary Bladder, Overactive
563262|NCT00454896|Urgency
563263|NCT00454896|VESIcare®
563264|NCT00454896|Solifenacin succinate
563265|NCT00454883|Safety of ziprasidone, efficacy of ziprasidone, manic episodes in bipolar disorder, mixed episodes in bipolar disorder, schizoaffective disorder.
563266|NCT00454870|Alzheimer's Disease
563267|NCT00454870|Cognition
563268|NCT00454870|Cognitive impairment
563269|NCT00454857|Thrombocytopenia
563270|NCT00454857|Chart Review
563271|NCT00454857|Platelet
563272|NCT00454857|Retrospective
563273|NCT00454857|Prospective
563274|NCT00454857|Non-interventional
563275|NCT00454857|Health Resource Utilization (HRU)
563276|NCT00454857|Quality of Life (QOL)
563277|NCT00454857|Immune Thrombocytopenic Purpura (ITP)
563278|NCT00454857|Idiopathic Thrombocytopenic Purpura (ITP)
563279|NCT00454857|Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
563280|NCT00454857|Observational
563281|NCT00454831|Hypercholesterolemia
563282|NCT00454831|LDL-cholesterol
563283|NCT00454831|chitosan
563284|NCT00454831|HEP-40
563285|NCT00454805|Advanced Breast Cancer
563286|NCT00454792|Low back pain
563287|NCT00454792|Modic changes
563288|NCT00454779|SCCHNC
563289|NCT00454779|Metastatic
563290|NCT00454779|Recurrent
563291|NCT00454766|Patient Education
563292|NCT00454766|Cervical Dysplasia
563293|NCT00454766|Questionnaire
563294|NCT00454753|Myeloid, Chronic
563295|NCT00454753|Lymphocytic, Acute
563296|NCT00454740|Urinary Bladder, Overactive
563297|NCT00454740|Urgency
563298|NCT00454740|VESIcare®
563299|NCT00454740|Solifenacin succinate
563300|NCT00454701|Psoriasis
563301|NCT00454701|Alefacept
563302|NCT00454701|Amevive®
563303|NCT00454701|Drug exposure
563304|NCT00454688|Irritable Bowel Syndrome
563305|NCT00454688|Asimadoline
563306|NCT00454675|Smokers
563307|NCT00454675|Chronic Bronchitis
563308|NCT00454675|Pulmonary Function Test Abnormalities
563309|NCT00454675|COPD
563310|NCT00454662|Elderly
563311|NCT00454662|Hypertension
563312|NCT00454662|Cardiovascular Diseases
563313|NCT00454662|Angiotensin II Type 1 Receptor Blockers
563314|NCT00454662|Calcium Channel Blockers
563315|NCT00454662|Diuretics
563316|NCT00454662|Combination Drug Therapy
563317|NCT00454662|Diabetes
563318|NCT00454649|axitinib
563319|NCT00454649|chemotherapy
563320|NCT00454649|anti-angiogenesis
563321|NCT00454649|VEGF inhibition
563322|NCT00454623|Adiponectin
563323|NCT00454623|diabetes
563324|NCT00454623|metabolism
563325|NCT00454623|Adiponectin levels
563326|NCT00454610|Pediatric
563327|NCT00454610|Overweight
563328|NCT00454610|Obesity
563329|NCT00454610|Intervention
563330|NCT00454610|Prevention
563331|NCT00454610|Mexican American
563332|NCT00454584|Psoriasis
563333|NCT00454584|CNTO 1275
563334|NCT00454584|Etanercept
563335|NCT00454584|Immune diorder
563336|NCT00454584|Skin disorder
563337|NCT00454558|Pulmonary Arterial Hypertension (PAH)
563338|NCT00454558|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
563339|NCT00454532|Breast Cancer
563340|NCT00454532|Bionovo
563341|NCT00454532|BZL101
563342|NCT00454532|Chinese Herbs
563343|NCT00454519|peritoneal carcinomatosis
563344|NCT00454519|cisplatin
563345|NCT00454519|mitomycin
563346|NCT00454519|gastric cancer
563347|NCT00454519|colorectal cancer
563348|NCT00454493|omacor
563349|NCT00454493|fish oil
563350|NCT00454493|omega 3
563351|NCT00454493|fatty acids
563352|NCT00454493|coronary artery disease
563353|NCT00454493|endothelial function
563354|NCT00454493|heart rate variability
563355|NCT00454493|carotid intimal media thickness
563356|NCT00454493|QT dispersion
563357|NCT00454480|untreated adult acute myeloid leukemia
563358|NCT00454480|de novo myelodysplastic syndromes
563359|NCT00454480|secondary acute myeloid leukemia
563360|NCT00454480|secondary myelodysplastic syndromes
563361|NCT00454480|previously treated myelodysplastic syndromes
563362|NCT00454480|refractory anemia with excess blasts
563363|NCT00454480|adult acute basophilic leukemia
563364|NCT00454480|adult acute eosinophilic leukemia
563365|NCT00454480|adult acute megakaryoblastic leukemia (M7)
563366|NCT00454480|adult acute minimally differentiated myeloid leukemia (M0)
563367|NCT00454480|adult acute monoblastic leukemia (M5a)
563368|NCT00454480|adult acute monocytic leukemia (M5b)
563369|NCT00454480|adult acute myeloblastic leukemia with maturation (M2)
563370|NCT00454480|adult acute myeloblastic leukemia without maturation (M1)
563371|NCT00454480|adult erythroleukemia (M6a)
563372|NCT00454480|adult pure erythroid leukemia (M6b)
563373|NCT00454480|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
563374|NCT00454480|adult acute myeloid leukemia with inv(16)(p13;q22)
563375|NCT00454480|adult acute myeloid leukemia with t(16;16)(p13;q22)
563376|NCT00454480|adult acute myeloid leukemia with t(8;21)(q22;q22)
563377|NCT00454480|adult acute myelomonocytic leukemia (M4)
563378|NCT00454480|childhood myelodysplastic syndromes
563379|NCT00454454|memory
563380|NCT00454454|display enhanced testing
563381|NCT00454441|Sleep Quality
563382|NCT00454441|Menopausal Symptoms
563383|NCT00454441|Actigraph
563384|NCT00454441|Bionovo
563385|NCT00454441|MF101
563386|NCT00454428|Bypass Surgery
563387|NCT00454428|Coronary Artery
563388|NCT00454415|Diet
563389|NCT00454415|Body Mass Index
563390|NCT00454415|BMI
563391|NCT00454389|Macular
563392|NCT00454389|Degeneration
563393|NCT00454389|AMD
563394|NCT00454389|Wet Age-Related macular degeneration
563395|NCT00454376|metastatic gastrointestinal carcinoid tumor
563396|NCT00454376|recurrent gastrointestinal carcinoid tumor
563397|NCT00454376|pulmonary carcinoid tumor
563398|NCT00454376|gastrinoma
563399|NCT00454376|insulinoma
563400|NCT00454376|WDHA syndrome
563401|NCT00454376|pancreatic polypeptide tumor
563402|NCT00454376|somatostatinoma
563403|NCT00454376|glucagonoma
563404|NCT00454376|liver metastases
563405|NCT00454350|Hectorol (doxercalciferol injection)
563406|NCT00454350|Zemplar (paricalcitol injection)
563407|NCT00454337|HIV-1 infection
563408|NCT00454337|enfuvirtide
563409|NCT00454337|raltegravir
563410|NCT00454337|treatment experienced
563411|NCT00454324|Lung cancer
563412|NCT00454324|Small cell lung cancer
563413|NCT00454324|Abraxane
563414|NCT00454324|Paclitaxel
563415|NCT00454324|Carboplatin
563416|NCT00454324|Phase II
563417|NCT00454324|Randomized
563418|NCT00454324|Lineberger
563419|NCT00454324|LCCC
563420|NCT00454311|Pregnancy and implantation rates
563421|NCT00454311|Efficiency and accuracy of the genetic testing
563422|NCT00454298|Severe Osteoarthritis
563423|NCT00454298|Arthritis
563424|NCT00454285|bacteremia,cultures, infective endocarditis, prophylaxis
563425|NCT00454272|febrile
563426|NCT00454272|neutropenia
563427|NCT00454272|cancer
563428|NCT00454272|Gram positive infection
563429|NCT00454259|Postoperative Hyperalgesia
563430|NCT00454259|Human volunteer
563431|NCT00454259|Fentanyl
563432|NCT00454259|Randomized Controlled Trial
563433|NCT00454259|Pain chronicisation
563434|NCT00454259|Predictive test
563435|NCT00454233|Diabetes Mellitus Type 2
563436|NCT00454233|YM543
563437|NCT00454233|Treatment
563438|NCT00454233|Safety
563439|NCT00454233|efficacy
563440|NCT00454207|Pulmonary Arterial Hypertension, PAH
563441|NCT00454194|recurrent non-small cell lung cancer
563442|NCT00454194|stage IIIB non-small cell lung cancer
563443|NCT00454194|stage IV non-small cell lung cancer
563444|NCT00454194|adenosquamous cell lung cancer
563445|NCT00454194|adenocarcinoma of the lung
563446|NCT00454181|human immunodeficiency virus
563447|NCT00454181|human papilloma virus
563448|NCT00454181|warts, oral
563449|NCT00454181|papillomatosis
563450|NCT00454181|treatment experienced
563451|NCT00454168|adult acute minimally differentiated myeloid leukemia (M0)
563452|NCT00454168|adult acute myeloblastic leukemia with maturation (M2)
563453|NCT00454168|adult acute myeloblastic leukemia without maturation (M1)
563454|NCT00454168|adult acute myeloid leukemia in remission
563455|NCT00454168|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
563456|NCT00454168|adult acute myeloid leukemia with inv(16)(p13;q22)
563457|NCT00454168|adult acute myeloid leukemia with t(15;17)(q22;q12)
563458|NCT00454168|adult acute myeloid leukemia with t(16;16)(p13;q22)
563459|NCT00454168|adult acute myeloid leukemia with t(8;21)(q22;q22)
563460|NCT00454168|adult acute myelomonocytic leukemia (M4)
563461|NCT00454168|adult acute promyelocytic leukemia (M3)
563462|NCT00454168|secondary acute myeloid leukemia
563463|NCT00454168|adult acute monoblastic leukemia (M5a)
563464|NCT00454168|adult acute monocytic leukemia (M5b)
563465|NCT00454168|adult erythroleukemia (M6a)
563466|NCT00454168|adult pure erythroid leukemia (M6b)
563467|NCT00454168|adult acute megakaryoblastic leukemia (M7)
563468|NCT00454155|HSCT
563469|NCT00454155|AGVHD
563470|NCT00454155|Myeloablative
563471|NCT00454155|Allogeneic
563472|NCT00454155|Hematopoietic
563473|NCT00454155|Stem
563474|NCT00454155|Cell
563475|NCT00454155|Transplantation
563476|NCT00453401|cold sore
563477|NCT00453375|Diabetic
563478|NCT00453375|Diabetes
563479|NCT00453375|Type 1 Diabetes
563480|NCT00453375|Type 1 Diabetes Mellitus
563481|NCT00453375|autoimmune disease
563482|NCT00453362|NSCLC
563483|NCT00453362|Tarceva
563484|NCT00453362|Positron emission technology
563485|NCT00453362|PET
563486|NCT00453362|Computerized tomography
563487|NCT00453362|CT
563488|NCT00453349|Uncomplicated pelvic inflammatory disease
563489|NCT00453336|recurrent squamous cell carcinoma of the lip and oral cavity
563490|NCT00453336|stage II squamous cell carcinoma of the lip and oral cavity
563491|NCT00453336|stage III squamous cell carcinoma of the lip and oral cavity
563492|NCT00453336|stage IV squamous cell carcinoma of the lip and oral cavity
563493|NCT00453336|recurrent squamous cell carcinoma of the oropharynx
563494|NCT00453336|stage II squamous cell carcinoma of the oropharynx
563495|NCT00453336|stage III squamous cell carcinoma of the oropharynx
563496|NCT00453336|stage IV squamous cell carcinoma of the oropharynx
563497|NCT00453336|recurrent squamous cell carcinoma of the larynx
563498|NCT00453336|stage II squamous cell carcinoma of the larynx
563499|NCT00453336|stage III squamous cell carcinoma of the larynx
563500|NCT00453336|stage IV squamous cell carcinoma of the larynx
563501|NCT00453336|stage I squamous cell carcinoma of the larynx
563502|NCT00453336|stage I squamous cell carcinoma of the lip and oral cavity
563503|NCT00453336|stage I squamous cell carcinoma of the oropharynx
563504|NCT00453336|oral leukoplakia
563505|NCT00453323|Esophageal Cancer
563506|NCT00453323|Phase II
563507|NCT00453323|Metastatic esophageal cancer
563508|NCT00453323|Recurrent esophageal cancer
563509|NCT00453310|recurrent ovarian germ cell tumor
563510|NCT00453310|stage IV ovarian germ cell tumor
563511|NCT00453310|ovarian choriocarcinoma
563512|NCT00453310|ovarian immature teratoma
563513|NCT00453310|ovarian mature teratoma
563514|NCT00453310|recurrent malignant testicular germ cell tumor
563515|NCT00453310|testicular choriocarcinoma
563516|NCT00453310|testicular seminoma
563517|NCT00453310|testicular yolk sac tumor
563518|NCT00453310|ovarian dysgerminoma
563519|NCT00453310|ovarian embryonal carcinoma
563520|NCT00453310|ovarian yolk sac tumor
563521|NCT00453310|ovarian monodermal and highly specialized teratoma
563522|NCT00453310|ovarian polyembryoma
563523|NCT00453310|stage III malignant testicular germ cell tumor
563524|NCT00453310|ovarian mixed germ cell tumor
563525|NCT00453310|testicular choriocarcinoma and embryonal carcinoma
563526|NCT00453310|testicular choriocarcinoma and seminoma
563527|NCT00453310|testicular choriocarcinoma and teratoma
563528|NCT00453310|testicular choriocarcinoma and yolk sac tumor
563529|NCT00453310|testicular embryonal carcinoma and seminoma
563530|NCT00453310|testicular embryonal carcinoma and teratoma with seminoma
563531|NCT00453310|testicular embryonal carcinoma and teratoma
563532|NCT00453310|testicular embryonal carcinoma and yolk sac tumor with seminoma
563533|NCT00453310|testicular embryonal carcinoma and yolk sac tumor
563534|NCT00453310|testicular yolk sac tumor and teratoma with seminoma
563535|NCT00453310|testicular yolk sac tumor and teratoma
563536|NCT00453310|testicular embryonal carcinoma
563537|NCT00453310|recurrent extragonadal non-seminomatous germ cell tumor
563538|NCT00453310|recurrent extragonadal seminoma
563539|NCT00453310|stage IV extragonadal non-seminomatous germ cell tumor
563540|NCT00453310|stage IV extragonadal seminoma
563541|NCT00453310|recurrent extragonadal germ cell tumor
563542|NCT00453310|testicular immature teratoma
563543|NCT00453310|testicular mature teratoma
563544|NCT00453310|adult teratoma
563545|NCT00453297|Bionovo
563546|NCT00453297|MF101
563547|NCT00453297|Herbs
563548|NCT00453297|The primary goal of this study is to identify the highest safe oral dose of MF101 that is well tolerated in humans.
563549|NCT00453271|chronic persistent infection of the nail bed or plate
563550|NCT00454129|Feasibilty of cholangiography via double-balloon enteroscopy
563551|NCT00454116|Colon Cancer
563552|NCT00454116|Rectal Cancer
563553|NCT00454103|adrenocortical carcinoma (ACC)
563554|NCT00454103|adrenal tumor
563555|NCT00454103|metastastic adrenocortical carcinoma
563556|NCT00454090|Advanced Malignancies
563557|NCT00454077|thyroid cancer; rhTSH; thyroid ablation
563558|NCT00454064|cognitive-behavioral therapy
563559|NCT00454064|back pain
563560|NCT00454064|low back pain
563561|NCT00454064|biofeedback
563562|NCT00454064|randomized controlled study
563563|NCT00454064|EMG biofeedback
563564|NCT00454051|Asthma, anti-immunoglobulin E, omalizumab, IgE receptors
563565|NCT00454038|cystectomy
563566|NCT00454038|augmentation
563567|NCT00454038|sinus
563568|NCT00454038|amputation
563569|NCT00454038|implant
563570|NCT00454025|glaucoma
563571|NCT00454025|intraocular pressure
563572|NCT00454025|postural changes
563573|NCT00454012|non reassuring fetal heart rate tracing
563574|NCT00454012|biophysical profile
563575|NCT00454012|assessing fetal wellbeing
563576|NCT00453999|influenza
563577|NCT00453999|flu
563578|NCT00453986|immunogenicity
563579|NCT00453986|Meningococcal serogroups A, C, W-135 and/or Y disease
563580|NCT00453986|co-administration
563581|NCT00453986|meningococcal vaccine
563582|NCT00453986|lot-to-lot consistency
563583|NCT00453986|conjugate vaccine
563584|NCT00453973|anemia
563585|NCT00453973|chronic kidney disease
563586|NCT00453973|CKD
563587|NCT00453973|chronic renal failure
563588|NCT00453973|CRF
563589|NCT00453973|dialysis
563590|NCT00453973|erythropoietin
563591|NCT00453973|EPO
563592|NCT00453973|erythropoiesis stimulating agent
563593|NCT00453973|ESA
563594|NCT00453973|Hematide™
563595|NCT00453973|hemodialysis
563596|NCT00453973|hemoglobin
563597|NCT00453973|Hb
563598|NCT00453973|Hgb
563599|NCT00453973|Omontys
563600|NCT00453973|peginesatide
563601|NCT00453973|red blood cell
563602|NCT00453973|red blood cell production
563603|NCT00453960|Endometrial hyperplasia
563604|NCT00453960|Genistein
563605|NCT00453960|Isoflavones
563606|NCT00453960|dysfunctional uterine bleeding
563607|NCT00453934|Diabetes
563608|NCT00453934|Type 1 Diabetes
563609|NCT00453934|Type 2 Diabetes
563610|NCT00453934|Physiologic Insulin
563611|NCT00453934|Basal Insulin
563612|NCT00453934|Bolus Insulin
563613|NCT00453934|Mealtime insulin
563614|NCT00453934|Insulin patch
563615|NCT00453934|Multiple daily injections
563616|NCT00453921|TBI
563617|NCT00453921|Memory
563618|NCT00453921|Methylphenidate
563619|NCT00453921|Ritalin
563620|NCT00453921|Memory and Attention Training
563621|NCT00453895|Adrenal cancer refractory to cytotoxic therapy
563622|NCT00453895|Sunitinib
563623|NCT00453895|Multitargeted tyrosine-kinase inhibitor
563624|NCT00453869|Liver fibrosis
563625|NCT00453869|Hepatitis B virus and C virus
563626|NCT00453869|FibroMeter
563627|NCT00453869|FibroScan®
563628|NCT00453856|Malaria
563629|NCT00453856|Sulfadoxine
563630|NCT00453856|Pyrimethamine
563631|NCT00453856|Resistance
563632|NCT00453856|Gabon
563633|NCT00453843|Stroke
563634|NCT00453843|movement therapy
563635|NCT00453843|robotics
563636|NCT00453843|rehabilitation robotics
563637|NCT00453843|shoulder, elbow, wrist
563638|NCT00453830|Diverticulitis; laparoscopy; short term outcome
563639|NCT00453817|islet transplantation
563640|NCT00453817|imaging
563641|NCT00453817|graft monitoring
563642|NCT00453817|magnetic resonance imaging
563643|NCT00453804|Alcohol dependence
563644|NCT00453804|Major Mental Illness
563645|NCT00453804|Injectable naltrexone
563646|NCT00453791|GW805858
563647|NCT00453791|MDI
563648|NCT00453791|asthma
563649|NCT00453791|surfactant
563650|NCT00453778|mild asthma
563651|NCT00453778|FLIXOTIDE
563652|NCT00453778|methacholine
563653|NCT00453778|bronchial challenge
563654|NCT00453778|leukotriene D4
563655|NCT00453765|cough
563656|NCT00453765|hyperreactivity
563657|NCT00453765|montelukast
563658|NCT00453752|systemic sclerosis
563659|NCT00453752|pulmonary hypertension
563660|NCT00453752|echocardiography
563661|NCT00453752|N-Terminal proBNP
563662|NCT00453726|Natriuretic peptide brain
563663|NCT00453726|Continuous positive airway pressure
563664|NCT00453726|Intermittent positive pressure breathing
563665|NCT00453726|Respiratory insufficiency
563666|NCT00453713|Idiopathic pulmonary fibrosis
563667|NCT00453713|Interstitial lung disease
563668|NCT00453713|Diffuse parenchymal lung disease
563669|NCT00453713|Health disparities
563670|NCT00453700|chagas
563671|NCT00453700|trypanosoma cruzi
563672|NCT00453687|COPD
563673|NCT00453687|GSK233705,
563674|NCT00453687|Magnesium Stearate,
563675|NCT00453674|Adrenal cancer
563676|NCT00453674|Treatment
563677|NCT00453674|Surgery
563678|NCT00453674|Mitotane
563679|NCT00453661|Breast Cancer
563680|NCT00453661|Cervical Cancer
563681|NCT00453661|Prostate Cancer
563682|NCT00453661|Colorectal Cancer
563683|NCT00453661|Lung Cancer
563684|NCT00453661|Cancer Prevention
563685|NCT00453661|Treatment Demonstration for Ethnic and Racial Minorities
563686|NCT00453661|Centers for Medicare and Medicaid Services
563687|NCT00453661|CMS
563688|NCT00453661|Hispanic American
563689|NCT00453661|Cancer Screening Assessment
563690|NCT00453661|Annual Questionnaire
563691|NCT00453661|Patient Navigator
563692|NCT00453661|Educational Materials
563693|NCT00453648|stable isotopes
563694|NCT00453648|vitamin A
563695|NCT00453648|beta-carotene
563696|NCT00453648|orange-fleshed sweet potatoes
563697|NCT00453648|iron
563698|NCT00453648|zinc
563699|NCT00453648|absorption
563700|NCT00453648|bioavailability
563701|NCT00453648|vitamin A equivalency
563702|NCT00453648|Bangladesh
563703|NCT00453648|women
563704|NCT00453635|Cancer
563705|NCT00453635|Breast cancer
563706|NCT00453635|First line treatment
563707|NCT00453635|Docetaxel
563708|NCT00453635|Carboplatin
563709|NCT00453635|Herceptin
563710|NCT00453635|Vinorelbine
563711|NCT00453622|Heart Failure
563712|NCT00453622|Cardiac Resynchronization Therapy
563713|NCT00453622|Risk stratification
563714|NCT00453622|Prediction
563715|NCT00453622|Proteomics
563716|NCT00453622|Chemokine
563717|NCT00453622|cardiac enzymes
563718|NCT00453622|Brain Natriuretic Peptide
563719|NCT00453609|Bipolar Disorders
563720|NCT00453609|Schizophrenia
563721|NCT00453609|Schizoaffective Disorders
563722|NCT00453609|Alcohol Dependence
563723|NCT00453609|Long-lasting injectable naltrexone
563724|NCT00453596|infertile women
563725|NCT00453596|thin endometrial thickness
563726|NCT00453596|implantation failure
563727|NCT00453583|Pediatric
563728|NCT00453583|Allergies
563729|NCT00453583|Antihistamines
563730|NCT00453583|Non-interventional
563731|NCT00453570|Diphteria
563732|NCT00453570|Tetanus
563733|NCT00453570|Haemophilus influenzae type b
563734|NCT00453570|Poliomyelitis
563735|NCT00453570|Pertussis
563736|NCT00453557|growth hormone, obesity, visceral adiposity
563737|NCT00453544|computer assisted instruction
563738|NCT00453544|decision making
563739|NCT00453544|educational resource design /development
563740|NCT00453544|executive function
563741|NCT00453531|Forearm Ischemia
563742|NCT00453531|Endothelial Function
563743|NCT00453531|Acetyicholine Vasodilation
563744|NCT00453531|Venous Plethysmography
563745|NCT00453531|Healthy Volunteer
563746|NCT00453531|HV
563747|NCT00453518|SVG
563748|NCT00453518|Saphenous Vein Graft
563749|NCT00453518|Embolic Protection
563750|NCT00453518|Distal Protection
563751|NCT00453518|EPD
563752|NCT00453518|FiberNet
563753|NCT00453518|Saphenous Vein Graft intervention
563754|NCT00453505|Transcranial Direct Current Stimulation (TDCS)
563755|NCT00453505|Transcranial Magnetic Stimulation (TMS)
563756|NCT00453505|Peripheral Nerve Stimulation
563757|NCT00453505|Primary Motor Cortex
563758|NCT00453505|Corticomotor Excitability
563759|NCT00453505|Healthy Volunteer
563760|NCT00453505|HV
563761|NCT00453479|Chronic obstructive pulmonary disease,
563762|NCT00453479|muscarinic receptor,
563763|NCT00453479|bronchodilators
563764|NCT00453466|women experiencing domestic violence
563765|NCT00453453|Congestive heart failure
563766|NCT00453453|observation unit
563767|NCT00453453|nesiritide
563768|NCT00453440|HIV
563769|NCT00453440|HLA-B*5701
563770|NCT00453440|Abacavir hypersensitivity reaction
563771|NCT00453427|PTL NOS
563772|NCT00453427|AILD
563773|NCT00453427|NHL
563774|NCT00453427|CHOP
563775|NCT00453414|PAH
563776|NCT00453414|Pediatric
563777|NCT00453414|Pulmonary Arterial Hypertension
563778|NCT00453258|ocular proteomics
563779|NCT00453258|eye disease
563780|NCT00453258|proteomics
563781|NCT00453232|stage III malignant testicular germ cell tumor
563782|NCT00453232|testicular choriocarcinoma and seminoma
563783|NCT00453232|testicular embryonal carcinoma and seminoma
563784|NCT00453232|testicular choriocarcinoma and embryonal carcinoma
563785|NCT00453232|testicular choriocarcinoma and teratoma
563786|NCT00453232|testicular choriocarcinoma
563787|NCT00453232|testicular choriocarcinoma and yolk sac tumor
563788|NCT00453232|testicular embryonal carcinoma and teratoma with seminoma
563789|NCT00453232|testicular embryonal carcinoma and teratoma
563790|NCT00453232|testicular embryonal carcinoma and yolk sac tumor with seminoma
563791|NCT00453232|testicular embryonal carcinoma and yolk sac tumor
563792|NCT00453232|testicular embryonal carcinoma
563793|NCT00453232|testicular seminoma
563794|NCT00453232|testicular yolk sac tumor
563795|NCT00453232|testicular yolk sac tumor and teratoma with seminoma
563796|NCT00453232|testicular yolk sac tumor and teratoma
563797|NCT00453232|recurrent malignant testicular germ cell tumor
563798|NCT00453232|recurrent extragonadal non-seminomatous germ cell tumor
563799|NCT00453232|recurrent extragonadal seminoma
563800|NCT00453232|stage IV extragonadal non-seminomatous germ cell tumor
563801|NCT00453232|stage IV extragonadal seminoma
563802|NCT00453232|adult teratoma
563803|NCT00453232|testicular immature teratoma
563804|NCT00453232|testicular mature teratoma
563805|NCT00453232|recurrent extragonadal germ cell tumor
563806|NCT00453206|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
563807|NCT00453206|adult acute myeloid leukemia with inv(16)(p13;q22)
563808|NCT00453206|adult acute myeloid leukemia with t(15;17)(q22;q12)
563809|NCT00453206|adult acute myeloid leukemia with t(16;16)(p13;q22)
563810|NCT00453206|adult acute myeloid leukemia with t(8;21)(q22;q22)
563811|NCT00453206|accelerated phase chronic myelogenous leukemia
563812|NCT00453206|adult acute myeloid leukemia in remission
563813|NCT00453206|blastic phase chronic myelogenous leukemia
563814|NCT00453206|primary myelofibrosis
563815|NCT00453206|chronic phase chronic myelogenous leukemia
563816|NCT00453206|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
563817|NCT00453206|de novo myelodysplastic syndromes
563818|NCT00453206|nodal marginal zone B-cell lymphoma
563819|NCT00453206|noncontiguous stage II adult Burkitt lymphoma
563820|NCT00453206|noncontiguous stage II adult diffuse large cell lymphoma
563821|NCT00453206|noncontiguous stage II adult diffuse mixed cell lymphoma
563822|NCT00453206|noncontiguous stage II adult diffuse small cleaved cell lymphoma
563823|NCT00453206|noncontiguous stage II adult immunoblastic large cell lymphoma
563824|NCT00453206|noncontiguous stage II adult lymphoblastic lymphoma
563825|NCT00453206|noncontiguous stage II grade 1 follicular lymphoma
563826|NCT00453206|noncontiguous stage II grade 2 follicular lymphoma
563827|NCT00453206|noncontiguous stage II grade 3 follicular lymphoma
563828|NCT00453206|noncontiguous stage II mantle cell lymphoma
563829|NCT00453206|noncontiguous stage II marginal zone lymphoma
563830|NCT00453206|noncontiguous stage II small lymphocytic lymphoma
563831|NCT00453206|previously treated myelodysplastic syndromes
563832|NCT00453206|prolymphocytic leukemia
563833|NCT00453206|recurrent adult acute myeloid leukemia
563834|NCT00453206|recurrent adult Burkitt lymphoma
563835|NCT00453206|recurrent adult Hodgkin lymphoma
563836|NCT00453206|recurrent adult diffuse large cell lymphoma
563837|NCT00453206|recurrent adult diffuse mixed cell lymphoma
563838|NCT00453206|recurrent adult diffuse small cleaved cell lymphoma
563839|NCT00453206|recurrent adult immunoblastic large cell lymphoma
563840|NCT00453206|recurrent adult lymphoblastic lymphoma
563841|NCT00453206|recurrent grade 1 follicular lymphoma
563842|NCT00453206|recurrent grade 2 follicular lymphoma
563843|NCT00453206|recurrent grade 3 follicular lymphoma
563844|NCT00453206|recurrent mantle cell lymphoma
563845|NCT00453206|recurrent marginal zone lymphoma
563846|NCT00453206|recurrent small lymphocytic lymphoma
563847|NCT00453206|refractory chronic lymphocytic leukemia
563848|NCT00453206|refractory multiple myeloma
563849|NCT00453206|relapsing chronic myelogenous leukemia
563850|NCT00453206|secondary acute myeloid leukemia
563851|NCT00453206|secondary myelodysplastic syndromes
563852|NCT00453206|splenic marginal zone lymphoma
563853|NCT00453206|stage I multiple myeloma
563854|NCT00453206|stage II multiple myeloma
563855|NCT00453206|stage III adult Burkitt lymphoma
563856|NCT00453206|stage III adult Hodgkin lymphoma
563857|NCT00453206|stage III adult diffuse large cell lymphoma
563858|NCT00453206|stage III adult diffuse mixed cell lymphoma
563859|NCT00453206|stage III adult diffuse small cleaved cell lymphoma
563860|NCT00453206|stage III adult immunoblastic large cell lymphoma
563861|NCT00453206|stage III adult lymphoblastic lymphoma
563862|NCT00453206|stage III grade 1 follicular lymphoma
563863|NCT00453206|stage III grade 2 follicular lymphoma
563864|NCT00453206|stage III grade 3 follicular lymphoma
563865|NCT00453206|stage III mantle cell lymphoma
563866|NCT00453206|stage III marginal zone lymphoma
563867|NCT00453206|stage III multiple myeloma
563868|NCT00453206|stage III small lymphocytic lymphoma
563869|NCT00453206|stage IV adult Burkitt lymphoma
563870|NCT00453206|stage IV adult Hodgkin lymphoma
563871|NCT00453206|stage IV adult diffuse large cell lymphoma
563872|NCT00453206|stage IV adult diffuse mixed cell lymphoma
563873|NCT00453206|stage IV adult diffuse small cleaved cell lymphoma
563874|NCT00453206|stage IV adult immunoblastic large cell lymphoma
563875|NCT00453206|stage IV adult lymphoblastic lymphoma
563876|NCT00453206|stage IV chronic lymphocytic leukemia
563877|NCT00453206|stage IV grade 1 follicular lymphoma
563878|NCT00453206|stage IV grade 2 follicular lymphoma
563879|NCT00453206|stage IV grade 3 follicular lymphoma
563880|NCT00453206|stage IV mantle cell lymphoma
563881|NCT00453206|stage IV marginal zone lymphoma
563882|NCT00453206|stage IV small lymphocytic lymphoma
563883|NCT00453206|polycythemia vera
563884|NCT00453206|stage III chronic lymphocytic leukemia
563885|NCT00453206|recurrent/refractory childhood Hodgkin lymphoma
563886|NCT00453206|stage I childhood Hodgkin lymphoma
563887|NCT00453206|stage II childhood Hodgkin lymphoma
563888|NCT00453206|stage III childhood Hodgkin lymphoma
563889|NCT00453206|stage IV childhood Hodgkin lymphoma
563890|NCT00453206|recurrent childhood anaplastic large cell lymphoma
563891|NCT00453206|stage I childhood anaplastic large cell lymphoma
563892|NCT00453206|stage II childhood anaplastic large cell lymphoma
563893|NCT00453206|stage III childhood anaplastic large cell lymphoma
563894|NCT00453206|stage IV childhood anaplastic large cell lymphoma
563895|NCT00453206|recurrent childhood grade III lymphomatoid granulomatosis
563896|NCT00453206|recurrent childhood large cell lymphoma
563897|NCT00453206|stage I childhood large cell lymphoma
563898|NCT00453206|stage II childhood large cell lymphoma
563899|NCT00453206|stage III childhood large cell lymphoma
563900|NCT00453206|stage IV childhood large cell lymphoma
563901|NCT00453206|recurrent childhood lymphoblastic lymphoma
563902|NCT00453206|stage I childhood lymphoblastic lymphoma
563903|NCT00453206|stage II childhood lymphoblastic lymphoma
563904|NCT00453206|stage III childhood lymphoblastic lymphoma
563905|NCT00453206|stage IV childhood lymphoblastic lymphoma
563906|NCT00453206|childhood nasal type extranodal NK/T-cell lymphoma
563907|NCT00453206|recurrent childhood small noncleaved cell lymphoma
563908|NCT00453206|stage I childhood small noncleaved cell lymphoma
563909|NCT00453206|stage II childhood small noncleaved cell lymphoma
563910|NCT00453206|stage III childhood small noncleaved cell lymphoma
563911|NCT00453206|stage IV childhood small noncleaved cell lymphoma
563912|NCT00453193|T-Cell Neoplasms
563913|NCT00453193|Alemtuzumab
563914|NCT00453193|Pentostatin
563915|NCT00453193|Campath-1H
563916|NCT00453193|Deoxycoformycin
563917|NCT00453193|Lymphoma
563918|NCT00453193|Leukemia
563919|NCT00453180|Autistic Disorder
563920|NCT00453180|Asperger's
563921|NCT00453180|PDD NOS
563922|NCT00453180|Pervasive Developmental Disorder
563923|NCT00453180|Autism
563924|NCT00453180|N-acetylcysteine
563925|NCT00453180|acetylcysteine
563926|NCT00453180|NAC
563927|NCT00453180|antioxidant
563928|NCT00453180|treatment
563929|NCT00453180|core symptoms
563930|NCT00453180|Autism Spectrum Disorders
563931|NCT00453180|Asperger's Disorder
563932|NCT00453180|Pervasive Developmental Disorder Not Otherwise Specified
563933|NCT00453180|Pervasive Developmental Disorders
563934|NCT00453167|Small cell lung cancer
563935|NCT00453167|second-line therapy
563936|NCT00453141|Betamethasone for preterm labor
563937|NCT00453141|Preterm delivery
563938|NCT00453141|Infant Respiratory Distress Syndrome
563939|NCT00453128|Calcium Pyrophosphate
563940|NCT00453128|associated conditions
563941|NCT00453115|Non small cell lung cancer
563942|NCT00453115|advanced stage IIIB
563943|NCT00453115|Stage IV
563944|NCT00453102|Marginal Zone Lymphoma
564181|NCT00452127|Indolent
563945|NCT00453102|Non-gastric extranodal Marginal Zone Lymphoma
563946|NCT00453102|Splenic Marginal Zone Lymphoma
563947|NCT00453102|Nodal Marginal Zone Lymphoma
563948|NCT00453102|Gastric Marginal Zone Lymphoma
563949|NCT00453102|MZL
563950|NCT00453102|Non-gastric extranodal MZL
563951|NCT00453102|Splenic MZL
563952|NCT00453102|Nodal MZL
563953|NCT00453102|Gastric MZL
563954|NCT00453089|Chinese Herbs
563955|NCT00453089|Postmenopausal
563956|NCT00453089|Vaginal Atrophy
563957|NCT00453089|Vulvar Atrophy
563958|NCT00453089|Symptoms
563959|NCT00453089|Bionovo
563960|NCT00453089|VG101
563961|NCT00453076|Biliary Obstruction
563962|NCT00453050|stage III melanoma
563963|NCT00453050|stage IV melanoma
563964|NCT00453050|skin metastases
563965|NCT00453037|hypertension
563966|NCT00453037|self measurement of blood pressure
563967|NCT00453037|education program
563968|NCT00453037|life style
563969|NCT00453024|Advanced glaucoma
563970|NCT00453024|Ahmed glaucoma implant
563971|NCT00453024|Anterior segment optical coherence tomography
563972|NCT00453024|Pericardial patch graft
563973|NCT00453024|Tissue glue
563974|NCT00453024|Scleral flap
563975|NCT00453024|Sutures
563976|NCT00453011|vitreous loss
563977|NCT00453011|intraocular lenses
563978|NCT00453011|Patients undergoing extracapsular cataract surgery
563979|NCT00453011|Vitreous loss with sufficient capsular support for an unsutured posterior chamber lens
563980|NCT00453011|5% random sample of patients with no vitreous loss
563981|NCT00452998|Sequential Laser Iridotomy
563982|NCT00452998|Q-Switched 532 nm Laser
563983|NCT00452998|Frequency Doubled Neodymium Yag Laser
563984|NCT00452972|Cesarean delivery
563985|NCT00452972|Spinal anesthesia
563986|NCT00452972|Nausea
563987|NCT00452972|Vomiting
563988|NCT00452972|Pain
563989|NCT00452920|cervical squamous cell carcinoma
563990|NCT00452920|stage IIB cervical cancer
563991|NCT00452920|stage III cervical cancer
563992|NCT00452920|stage IVA cervical cancer
563993|NCT00452881|Non-small cell lung cancer
563994|NCT00452881|adjuvant chemotherapy
563995|NCT00452868|cognitive/functional effects
563996|NCT00452868|neurotoxicity
563997|NCT00452868|long-term effects secondary to cancer therapy in children
563998|NCT00452868|psychosocial effects of cancer and its treatment
563999|NCT00452868|radiation toxicity
564000|NCT00452868|childhood central nervous system germ cell tumor
564001|NCT00452868|childhood choroid plexus tumor
564002|NCT00452868|childhood craniopharyngioma
564003|NCT00452868|childhood grade I meningioma
564004|NCT00452868|childhood grade II meningioma
564005|NCT00452868|childhood grade III meningioma
564006|NCT00452868|childhood spinal cord neoplasm
564007|NCT00452868|childhood brain stem glioma
564008|NCT00452868|childhood cerebellar astrocytoma
564009|NCT00452868|childhood medulloblastoma
564010|NCT00452868|childhood supratentorial primitive neuroectodermal tumor
564011|NCT00452868|childhood visual pathway and hypothalamic glioma
564012|NCT00452868|childhood subependymal giant cell astrocytoma
564013|NCT00452868|childhood ependymoma
564014|NCT00452868|childhood cerebral astrocytoma/malignant glioma
564015|NCT00452855|Nausea
564016|NCT00452855|Vomiting
564017|NCT00452855|Post operative
564018|NCT00452855|Propofol remifentanil anaesthesia
564019|NCT00452855|Sevoflurane remifentanil anaesthesia
564020|NCT00452816|Chronic Disease
564021|NCT00452816|Employer Health Costs
564022|NCT00452816|Health Promotion
564023|NCT00452816|Insurance Benefits
564024|NCT00452816|Marketing of Health Services
564025|NCT00452816|Mass Screening
564026|NCT00452816|Prevention & Control
564027|NCT00452816|Tobacco Use Cessation
564028|NCT00452816|Workplace
564029|NCT00452803|Non small cell lung cancer
564030|NCT00452790|Vaccines, Pneumococcal
564031|NCT00452777|Diabetic neuropathy, painful
564032|NCT00452777|Adenosine A2A receptor
564033|NCT00452764|COPD
564034|NCT00452764|Healthy
564035|NCT00452764|Regulatory T cell
564036|NCT00452764|Heme oxygenase-1
564037|NCT00452764|peripheral blood
564038|NCT00452751|gastric cancer
564039|NCT00452751|laparoscopic surgery
564040|NCT00452751|survival
564041|NCT00452751|preoperative staging
564042|NCT00452751|morbidity
564043|NCT00452751|quality of life
564044|NCT00452751|acute inflammatory reaction
564045|NCT00452751|cost
564046|NCT00452738|animal-assisted intervention
564047|NCT00452738|pre surgery anxiety
564048|NCT00452738|post surgery pain medication consumption
564049|NCT00452712|orthostatism
564050|NCT00452712|fever
564051|NCT00452699|fluticasone propionate
564052|NCT00452699|long-term study
564053|NCT00452699|Salmeterol
564054|NCT00452699|FLOVENT 250
564055|NCT00452699|Asthma
564056|NCT00452699|ADVAIR 250
564057|NCT00452686|Chinese DT vaccin
564058|NCT00452660|IRON
564059|NCT00452660|oxidative stress
564060|NCT00452660|MDS
564061|NCT00452647|Condition: No specific disease is being studied, few procedures are excluded.
564062|NCT00452647|Focus: To obtain blood pressure data and detect any trends to a statistically significant degree.
564063|NCT00452634|Irinotecan
564064|NCT00452634|cisplatin
564065|NCT00452634|Simvastatin
564066|NCT00452634|Extensive disease
564067|NCT00452634|SCLC
564068|NCT00452621|blood draw five years after booster-immunization with TBE vaccine to investigate immunogenicity in children
564069|NCT00452621|TBE
564070|NCT00452582|ischemic stroke
564071|NCT00452582|recovery
564072|NCT00452582|sildenafil
564073|NCT00452569|Relapsed Refractory Multiple Myeloma
564074|NCT00452556|Prostatic Neoplasms
564075|NCT00452556|Radiotherapy
564076|NCT00452556|Docetaxel
564077|NCT00452556|Leuprolide Acetate
564078|NCT00452543|Major depressive disorder
564079|NCT00452543|Alcoholism
564080|NCT00452543|Alcohol abuse
564081|NCT00452543|Alcohol dependence
564082|NCT00452530|Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery
564083|NCT00452517|bare metal stents
564084|NCT00452517|sirolimus-eluting stents
564085|NCT00452517|coronary polytetrafluoroethylene stent graft
564086|NCT00452517|acute coronary syndrome
564087|NCT00452517|quantitative coronary angiography analysis
564088|NCT00452517|major adverse cardiac events
564089|NCT00452517|in-stent restenosis
564090|NCT00452517|target lesion revascularisation
564091|NCT00452478|Hyperphosphataemia
564092|NCT00452465|Elderly
564093|NCT00452465|Nursing care plan
564094|NCT00452465|Quality of Life
564095|NCT00452452|Pneumococcal Vaccines
564096|NCT00452439|Leukemia
564097|NCT00452439|Lymphoma
564098|NCT00452439|Acute Lymphocytic Leukemia
564099|NCT00452439|Lymphoblastic Lymphoma
564100|NCT00452439|Actonel
564101|NCT00452439|Risedronate
564102|NCT00452439|Bone Loss
564103|NCT00452439|Osteoporosis
564104|NCT00452426|Propofol
564105|NCT00452426|Diprivan
564106|NCT00452426|Colonoscopy
564107|NCT00452426|Endoscopy, Digestive System
564108|NCT00452426|Conscious Sedation
564109|NCT00452387|Prostate Cancer
564110|NCT00452374|B-cell chronic lymphocytic leukemia
564111|NCT00452374|Chronic Lymphocytic Leukemia
564112|NCT00452374|CLL
564113|NCT00452374|Prolymphocytic Leukemia
564114|NCT00452374|PLL
564115|NCT00452374|Richter's Transformation
564116|NCT00452374|High-grade non-Hodgkin's lymphoma
564117|NCT00452374|Hodgkin's disease
564118|NCT00452374|Acute leukemia
564119|NCT00452374|Small lymphocytic lymphoma
564120|NCT00452374|Oxaliplatin
564121|NCT00452374|Eloxatin
564122|NCT00452374|Fludarabine
564123|NCT00452374|Cytarabine
564124|NCT00452374|Ara-C
564125|NCT00452374|Cytosar
564126|NCT00452374|DepoCyt
564127|NCT00452374|Cytosine arabinosine hydrochloride
564128|NCT00452374|Rituximab
564129|NCT00452374|Rituxan
564130|NCT00452348|FLOVENT
564131|NCT00452348|fluticasone
564132|NCT00452348|12 month
564133|NCT00452348|salmeterol
564134|NCT00452348|asthma
564135|NCT00452348|ADVAIR
564136|NCT00452322|Testosterone
564137|NCT00452322|Hypogonadism
564138|NCT00452322|Safety
564139|NCT00452309|peripheral arterial disease
564140|NCT00452309|pad
564141|NCT00452309|ankle brachial index
564142|NCT00452309|abi
564143|NCT00452296|inpatients with COPD
564144|NCT00452296|glucose control
564145|NCT00452270|Common cold, xylometazoline
564146|NCT00452244|Gefitinib
564147|NCT00452244|Simvastatin
564148|NCT00452244|NSCLC
564149|NCT00452244|Advanced NSCLC
564150|NCT00452231|Post-traumatic Stress Disorder
564151|NCT00452231|Cognitive-Behavioral Therapy
564152|NCT00452218|Pulmonary Arterial Hypertension
564153|NCT00452218|PAH
564154|NCT00452205|bone marrow-derived stem cell
564155|NCT00452205|bone marrow transplantation
564156|NCT00452205|graft versus host disease
564157|NCT00452205|gastrointestinal cancer
564158|NCT00452205|after receiving bone marrow transplantation
564159|NCT00452192|Metabolic syndrome
564160|NCT00452179|Sleep maintenance
564161|NCT00452179|Insomnia
564162|NCT00452179|Sleep Consolidation
564163|NCT00452179|Sleep
564164|NCT00452179|Insomnia, primarily sleep maintenance
564165|NCT00452153|legionellosis
564166|NCT00452153|diagnosis of legionellosis
564167|NCT00452153|PCR
564168|NCT00452140|Breast Cancer
564169|NCT00452140|investigational drug
564170|NCT00452140|drug therapy
564171|NCT00452140|Antineoplastic Protocols
564172|NCT00452140|Immunotherapy
564173|NCT00452140|Metastatic breast cancer
564174|NCT00452140|Advanced breast cancer
564175|NCT00452140|Stage III to IV breast cancer
564176|NCT00452140|Hormonal therapy refractory
564177|NCT00452140|Failure of hormonal therapy
564178|NCT00452140|Her-2/neu expressing breast cancer
564179|NCT00452140|Her-2/neu
564180|NCT00452127|NHL
564182|NCT00452127|Follicular
564183|NCT00452114|Bronchiectasis
564184|NCT00452101|Osteoarthritis
564185|NCT00452101|Clinical trial
564186|NCT00452101|Aquamin F
564187|NCT00452101|Glucosamine
564188|NCT00452088|Malaria vaccine
564189|NCT00452088|Safety of MSP 3 LSP
564190|NCT00452088|Immunogenicity of MSP 3 LSP
564191|NCT00452088|Burkina Faso children
564192|NCT00452075|EGFR expression
564193|NCT00452075|erlotinib
564194|NCT00452062|cuff-leak test
564195|NCT00452062|intubation
564196|NCT00452062|corticosteroids
564197|NCT00452062|dexamethasone to reduce the occurrence of post-extubation airway obstruction
564198|NCT00452049|parathyroidectomy
564199|NCT00452049|arterial stiffness
564200|NCT00452049|renal function
564201|NCT00452036|risk factors
564202|NCT00452036|plain x ray
564203|NCT00452036|cranial computed tomography
564204|NCT00452036|minor head injury
564205|NCT00452023|Myeloproliferative Disorders
564206|NCT00452023|Essential Thrombocythemia
564207|NCT00452023|Polycythemia Vera
564208|NCT00452023|Pegasys
564209|NCT00452023|IFN-alpha2a
564210|NCT00452023|Pegylated-Interferon Alpha-2A
564211|NCT00452023|PEG-IFNa-2a
564212|NCT00452010|TENS
564213|NCT00452010|chronic low back pain
564214|NCT00452010|chronic lumbo-radiculalgia
564215|NCT00452010|placebo
564216|NCT00452010|Roland scale
564217|NCT00451997|AML
564218|NCT00451997|MDS
564219|NCT00451997|Gleevec
564220|NCT00451997|Ara-C
564221|NCT00451997|C-Kit Positive Acute Myeloid Leukemia
564222|NCT00451997|High-Risk Myelodysplastic Syndromes
564223|NCT00451984|interleukin-2
564224|NCT00451984|vaccination
564225|NCT00451984|treatment experienced
564226|NCT00451958|Degarelix
564227|NCT00451958|prostate cancer
564228|NCT00451932|Malononitrilamide
564229|NCT00451932|Immunosuppression
564230|NCT00451932|treatment efficacy
564231|NCT00451932|treatment effectiveness
564232|NCT00451919|MRI
564233|NCT00451919|Neuropsychology
564234|NCT00451893|Inguinal hernia
564235|NCT00451893|polypropylene mesh
564236|NCT00451893|heavy-weight mesh
564237|NCT00451893|light-weight mesh
564238|NCT00451880|Cancer
564239|NCT00451880|Solid Tumors
564240|NCT00451880|NSCLC
564241|NCT00451867|interstitial cystitis research
564242|NCT00451867|painful bladder syndrome research
564243|NCT00451867|pelvic pain research
564244|NCT00451867|interstitial cystitis and autoimmune
564245|NCT00451867|interstitial cystitis and cellcept
564246|NCT00451867|interstitial cystitis and mycophenolate mofetil
564247|NCT00451867|interstitial cystitis and MMF
564248|NCT00451867|interstitial cystitis and inflammation
564249|NCT00451867|inflammatory diseases and immunosupression
564250|NCT00451854|Drug testing
564251|NCT00451854|Adolescence
564252|NCT00451854|Student athlete
564253|NCT00451854|Substance abuse
564254|NCT00451854|Alcohol use
564255|NCT00451854|Drug use
564256|NCT00451841|Cough
564257|NCT00451841|Gastroesophageal reflux
564258|NCT00451841|Exhaled breath condensate
564259|NCT00451828|Statins
564260|NCT00451828|Cholesterol
564261|NCT00451828|Pharmacogenetics
564262|NCT00451802|Biotechnology
564263|NCT00451802|Specimen
564264|NCT00451802|Health Management Center
564265|NCT00451789|Minor head injury
564266|NCT00451789|iintracranial bleeding
564267|NCT00451789|traumatic brain injury
564268|NCT00451789|Cranial computed tomography
564269|NCT00451789|anticoagulatory drugs
564270|NCT00451776|cardiac surgery
564271|NCT00451776|adrenal insufficiency
564272|NCT00451776|etomidate
564273|NCT00451776|propofol
564274|NCT00451763|Fovea centralis/pathology
564275|NCT00451763|Fundus oculi
564276|NCT00451763|Retinal neovascularization
564277|NCT00451763|Telangiectasis/diagnosis
564278|NCT00451763|Tomography, optical coherence
564279|NCT00451763|Vitreous Body/drug effects
564280|NCT00451750|phobia
564281|NCT00451750|cortisol
564282|NCT00451750|memory
564283|NCT00451750|treatment
564284|NCT00451737|Six-minute walk test
564285|NCT00451737|Neuromuscular system
564286|NCT00451737|Influence factors
564287|NCT00451724|Prospective
564288|NCT00451724|Randomized
564289|NCT00451724|Double blinded
564290|NCT00451724|Sedation
564291|NCT00451724|Ketamine
564292|NCT00451724|Intranasal
564293|NCT00451711|Prophylaxis
564294|NCT00451711|Liposomal Amphotericin B
564295|NCT00451711|Acute myeloid leukaemia
564296|NCT00451711|Invasive Fungal Infections
564297|NCT00451698|Erythropoietin
564298|NCT00451698|Congenital heart surgery
564299|NCT00451672|aldosteronism, bromocriptin, hypertension
564300|NCT00451659|PTSD
564301|NCT00451659|Veterans
564302|NCT00451659|Deployed
564303|NCT00451620|Type 2 diabetes
564304|NCT00451620|Hypoglycemia
564305|NCT00451620|Oral hypoglycemic agents
564306|NCT00451620|Insulin levels
564307|NCT00451607|premature
564308|NCT00451607|newborn
564309|NCT00451607|heart rate variability
564310|NCT00451607|individualized sensorimotor care
564311|NCT00451607|noise
564312|NCT00451594|ITP
564313|NCT00451581|Endoscopic papillary balloon dilatation
564314|NCT00451581|Endoscopic sphincterotomy
564315|NCT00451581|Choledocholithiasis
564316|NCT00451581|Efficacy
564317|NCT00451581|Complication
564318|NCT00451568|Polycystic ovary syndrome
564319|NCT00451542|Bipolar Disorder
564320|NCT00451542|Relapse
564321|NCT00451542|Retrospective
564322|NCT00451516|Plant, medicine
564323|NCT00451516|Psychiatry
564324|NCT00451516|Major depressive disorder
564325|NCT00451516|Anxiety
564326|NCT00451516|Major Depressive Disorder with comorbid anxiety
564327|NCT00451503|Hearing
564328|NCT00451503|Auditory rehabilitation
564329|NCT00451503|Middle ear implant
564330|NCT00451503|Surgery
564331|NCT00451490|agomelatin
564332|NCT00451490|prozac
564333|NCT00451490|heart rate variability
564334|NCT00451490|major depression
564335|NCT00451490|sleep
564336|NCT00451490|depressive symptoms
564337|NCT00451464|Apolipoprotein, Gene polymorphism, Hyperlipidemia
564338|NCT00451451|relapsing
564339|NCT00451451|multiple sclerosis
564340|NCT00451451|oral
564341|NCT00451451|remitting
564342|NCT00451438|patellofemoral pain syndrome
564343|NCT00451438|electromyography
564344|NCT00451438|gluteus medius
564345|NCT00451438|tensor fascia lata
564346|NCT00451425|pregnancy
564347|NCT00451425|weight gain
564348|NCT00451425|obesity
564349|NCT00451425|macrosomia
564350|NCT00451412|Venous thromboembolism
564351|NCT00451412|Medical patients
564352|NCT00451412|Heparin
564353|NCT00451412|Low molecular weight heparin
564354|NCT00451412|Deep vein thrombosis
564355|NCT00451412|Certoparin
564356|NCT00451412|Embolism and Thrombosis
564357|NCT00451399|Weight gain
564358|NCT00451399|antipsychotic
564359|NCT00451399|lifestyle interventions
564360|NCT00451399|metformin
564361|NCT00451399|antipsychotic-induced weight gain.
564362|NCT00451373|ARF, dialysis, cytokine, free radical, major operations
564363|NCT00451360|Diacerein
564364|NCT00451360|Hip osteoarthritis
564365|NCT00451360|Structure-modifying effect / Chondromodulating effect
564366|NCT00451360|Double blind study
564367|NCT00451321|type 1 diabetes mellitus
564368|NCT00451321|diabetes mellitus type 1
564369|NCT00451321|type 1 diabetes
564370|NCT00451321|diabetes mellitus
564371|NCT00451321|diabetes
564372|NCT00451308|Induction of labor
564373|NCT00451308|vaginal delivery
564374|NCT00451308|cesarean section
564375|NCT00451308|foley balloon cathether
564376|NCT00451308|method of labor induction
564377|NCT00451308|perinatal outcomes
564378|NCT00451295|Chronic Kidney Disease
564379|NCT00451295|Dialysis
564380|NCT00451295|Hyperphosphatemia
564381|NCT00451269|Malaria
564382|NCT00451269|Diagnosis
564383|NCT00451269|RDT
564384|NCT00451269|pLDH
564385|NCT00451269|HRP2
564386|NCT00451269|Patients with fever and history of travel in a malaria
564387|NCT00451269|country
564388|NCT00451256|coronary artery bypass
564389|NCT00451256|cardiovascular disease
564390|NCT00451243|psoriatic arthritis
564391|NCT00451230|craving, insulin, leptin
564392|NCT00451204|Multiple sclerosis
564393|NCT00451204|estrogen
564394|NCT00451204|estriol
564395|NCT00451204|progesterone
564396|NCT00451191|benign prostatic hyperplasia
564397|NCT00451191|BPH
564398|NCT00451191|botulinum toxin
564399|NCT00451191|BoNT/A
564400|NCT00451165|Laparoscopic
564401|NCT00451165|Colon
564402|NCT00451165|Rectal
564403|NCT00451165|Surgery
564404|NCT00451165|Urinary function
564405|NCT00451165|Sexual function
564406|NCT00451165|Bowel function
564407|NCT00451165|Male
564408|NCT00451152|glaucoma
564409|NCT00451126|emotion
564410|NCT00451126|personality
564411|NCT00451126|social stress
564412|NCT00451126|appraisal
564413|NCT00451113|Type 2 diabetes
564414|NCT00451113|Older adults
564415|NCT00451113|Incretins
564416|NCT00451113|Hyperglycemia
564417|NCT00451113|Insulin resistance
564418|NCT00451087|mechanical properties
564419|NCT00451087|electromechanical delay
564420|NCT00451087|viscoelasticity
564421|NCT00451087|VMO
564422|NCT00451087|patellofemoral pain syndrome
564423|NCT00451074|Stop codon mutations
564424|NCT00451061|distal ureterolithiasis
564425|NCT00451061|α adrenoreceptors antagonist
564426|NCT00451035|Refractory Chronic Myeloid Leukemia in Chronic Phase
564427|NCT00451035|adults
564428|NCT00451035|oral LBH589
564429|NCT00451022|Fowlpox
564430|NCT00451022|Vaccinia
564431|NCT00451022|PSA
564432|NCT00451022|CEA
564433|NCT00451022|MUC-1
564434|NCT00451022|Gene Therapy
564435|NCT00451022|Long Term Survivor
564436|NCT00451022|Research Specimen
564437|NCT00451009|IVF
564438|NCT00451009|Male factor infertility
564439|NCT00451009|Cryopreservation
564440|NCT00451009|Cryoprotective agents
564441|NCT00451009|Egg Freezing
564442|NCT00450983|graft versus host disease
564443|NCT00450983|adult acute lymphoblastic leukemia in remission
564444|NCT00450983|recurrent adult acute lymphoblastic leukemia
564445|NCT00450983|childhood acute lymphoblastic leukemia in remission
564446|NCT00450983|recurrent childhood acute lymphoblastic leukemia
564447|NCT00450983|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
564448|NCT00450983|adult acute myeloid leukemia in remission
564449|NCT00450983|recurrent adult acute myeloid leukemia
564450|NCT00450983|childhood acute myeloid leukemia in remission
564451|NCT00450983|recurrent childhood acute myeloid leukemia
564452|NCT00450983|secondary acute myeloid leukemia
564453|NCT00450983|de novo myelodysplastic syndromes
564454|NCT00450983|previously treated myelodysplastic syndromes
564455|NCT00450983|secondary myelodysplastic syndromes
564456|NCT00450983|accelerated phase chronic myelogenous leukemia
564457|NCT00450983|blastic phase chronic myelogenous leukemia
564458|NCT00450983|childhood chronic myelogenous leukemia
564459|NCT00450983|relapsing chronic myelogenous leukemia
564460|NCT00450983|adult acute myeloid leukemia with inv(16)(p13;q22)
564461|NCT00450983|adult acute myeloid leukemia with t(15;17)(q22;q12)
564462|NCT00450983|adult acute myeloid leukemia with t(16;16)(p13;q22)
564463|NCT00450983|adult acute myeloid leukemia with t(8;21)(q22;q22)
564464|NCT00450983|childhood myelodysplastic syndromes
564465|NCT00450970|Hormone Refractory Prostate Cancer (HRPC)
564466|NCT00450970|Hormone Refractory Prostate Cancer
564467|NCT00450970|Unlimited Prior Cytotoxic Chemotherapy Regimens
564468|NCT00450944|B-cell adult acute lymphoblastic leukemia
564469|NCT00450944|recurrent adult acute lymphoblastic leukemia
564470|NCT00450931|health status unknown
564471|NCT00450918|Kartagener Syndrome
564472|NCT00450905|Chronic musculoskeletal pain secondary to Fibromyalgia
564473|NCT00450892|inflammatory breast cancer
564474|NCT00450892|stage II breast cancer
564475|NCT00450892|stage IIIA breast cancer
564476|NCT00450892|stage IIIB breast cancer
564477|NCT00450892|stage IIIC breast cancer
564478|NCT00450866|recurrent breast cancer
564479|NCT00450866|stage IV breast cancer
564480|NCT00450866|tumors metastatic to brain
564481|NCT00450866|leptomeningeal metastases
564482|NCT00450866|male breast cancer
564483|NCT00450853|emesis
564484|NCT00450853|granisetron
564485|NCT00450853|pharmacokinetics
564486|NCT00450853|subcutaneous.
564487|NCT00450840|septic shock
564488|NCT00450840|simvastatin
564489|NCT00450827|recurrent neuroblastoma
564490|NCT00450801|contiguous stage II mantle cell lymphoma
564491|NCT00450801|noncontiguous stage II mantle cell lymphoma
564492|NCT00450801|stage I mantle cell lymphoma
564493|NCT00450801|stage III mantle cell lymphoma
564494|NCT00450801|stage IV mantle cell lymphoma
564495|NCT00450788|Etiology
564496|NCT00450788|Carcinogens
564497|NCT00450788|Esophageal Cancer
564498|NCT00450762|pretreated
564499|NCT00450762|metastatic
564500|NCT00450736|chondrosarcoma
564501|NCT00450736|adult angiosarcoma
564502|NCT00450736|adult fibrosarcoma
564503|NCT00450736|adult leiomyosarcoma
564504|NCT00450736|adult liposarcoma
564505|NCT00450736|adult neurofibrosarcoma
564506|NCT00450736|adult synovial sarcoma
564507|NCT00450736|childhood angiosarcoma
564508|NCT00450736|childhood fibrosarcoma
564509|NCT00450736|childhood leiomyosarcoma
564510|NCT00450736|childhood liposarcoma
564511|NCT00450736|childhood neurofibrosarcoma
564512|NCT00450736|childhood synovial sarcoma
564513|NCT00450736|nonmetastatic childhood soft tissue sarcoma
564514|NCT00450736|stage II adult soft tissue sarcoma
564515|NCT00450736|stage III adult soft tissue sarcoma
564516|NCT00450736|adult malignant fibrous histiocytoma
564517|NCT00450736|adult malignant hemangiopericytoma
564518|NCT00450736|childhood malignant hemangiopericytoma
564519|NCT00450736|localized childhood malignant fibrous histiocytoma of bone
564520|NCT00450723|stage I breast cancer
564521|NCT00450723|stage II breast cancer
564522|NCT00450723|male breast cancer
564523|NCT00450697|Feeding intolerance in premature infants
564524|NCT00450697|Bolus feeding every 4 hours versus every 3 hours
564525|NCT00450697|Feeding method in premature infants
564526|NCT00450671|Fistula-in-ano
564527|NCT00450671|Anal fistula
564528|NCT00450671|Perirectal fistula
564529|NCT00450671|Collagen plug
564530|NCT00450671|Surgisis
564531|NCT00450671|Seton
564532|NCT00450658|ibuprofen
564533|NCT00450658|famotidine
564534|NCT00450658|ulcers
564535|NCT00450658|NSAIDS
564536|NCT00450658|pain
564537|NCT00450658|arthritis
564538|NCT00450658|chronic regional pain syndrome
564539|NCT00450658|chronic soft tissue pain
564540|NCT00450658|osteoarthritis
564541|NCT00450658|rheumatoid arthritis
564542|NCT00450658|chronic low back pain
564543|NCT00450645|Cancer
564544|NCT00450645|Residual vein thrombosis
564545|NCT00450645|Low Molecular Weight Heparin
564546|NCT00450645|Optimal duration
564547|NCT00450632|meningococcal infections
564548|NCT00450632|biotheque
564549|NCT00450632|genetic markers
564550|NCT00450619|Radionuclide
564551|NCT00450619|Immunotherapy
564552|NCT00450619|Radiation
564553|NCT00450619|PSA
564554|NCT00450619|Hormone Refractory Prostate Cancer
564555|NCT00450619|Prostate Cancer
564556|NCT00450593|melanoma
564557|NCT00450593|hereditary multiple melanoma
564558|NCT00450593|recurrent melanoma
564559|NCT00450593|stage 0 melanoma
564560|NCT00450593|stage IV melanoma
564561|NCT00450593|stage IA melanoma
564562|NCT00450593|stage IB melanoma
564563|NCT00450593|stage IIA melanoma
564564|NCT00450593|stage IIB melanoma
564565|NCT00450593|stage IIC melanoma
564566|NCT00450593|stage IIIA melanoma
564567|NCT00450593|stage IIIB melanoma
564568|NCT00450593|stage IIIC melanoma
564569|NCT00450580|protease inhibitor,
564570|NCT00450580|HIV-1,
564571|NCT00450580|Fosamprenavir,
564572|NCT00450580|non-HDL cholesterol
564573|NCT00450580|ritonavir,
564574|NCT00450580|naive,
564575|NCT00450567|recurrent non-small cell lung cancer
564576|NCT00450567|stage I non-small cell lung cancer
564577|NCT00450567|stage II non-small cell lung cancer
564578|NCT00450567|stage IIIA non-small cell lung cancer
564579|NCT00450567|stage IIIB non-small cell lung cancer
564580|NCT00450567|stage IV non-small cell lung cancer
564581|NCT00450554|Neisseria meningitidis B:14, P1-7, 16
564582|NCT00450554|Serum bactericidal activity
564583|NCT00450554|Menbvac
564584|NCT00450541|Advanced Cancer
564585|NCT00450541|Fatigue
564586|NCT00450541|Interview
564587|NCT00450541|Questionnaire
564588|NCT00450541|Survey
564589|NCT00450528|D-dimers
564590|NCT00450528|surgery
564591|NCT00450528|kinetics
564592|NCT00450515|recurrent breast cancer
564593|NCT00450515|stage IV breast cancer
564594|NCT00450515|male breast cancer
564595|NCT00450502|Cytotoxic
564596|NCT00450502|Pharmacokinetics
564597|NCT00450502|Toxicity
564598|NCT00450502|Neoplasms
564599|NCT00450502|Pharmacogenomics
564600|NCT00450502|Solid Tumor
564601|NCT00450502|Lymphoma
564602|NCT00450489|Type 1 Diabetes Mellitus
564603|NCT00450489|Quality of Life
564604|NCT00450489|Satisfaction of medical care delivery
564605|NCT00450476|ventilator associated pneumonia
564606|NCT00450476|prevention
564607|NCT00450476|endotracheal intubation
564608|NCT00450476|mechanical ventilation
564609|NCT00450463|Immunotherapy
564610|NCT00450463|Hormonal Therapy
564611|NCT00450463|Combination Therapy
564612|NCT00450463|Prostate Specific Antigen
564613|NCT00450463|Immunoassay
564614|NCT00450463|Prostate Cancer
564615|NCT00450437|Meningococcal
564616|NCT00450437|meningitis
564617|NCT00450437|vaccine
564618|NCT00450437|adolescents
564619|NCT00450437|adults
564620|NCT00450424|colon cancer
564621|NCT00450424|rectal cancer
564622|NCT00450424|hereditary non-polyposis colon cancer
564623|NCT00450424|recurrent colon cancer
564624|NCT00450424|stage I colon cancer
564625|NCT00450424|stage IIA colon cancer
564626|NCT00450424|stage IIB colon cancer
564627|NCT00450424|stage IIIA colon cancer
564628|NCT00450424|stage IIIB colon cancer
564629|NCT00450424|stage IIIC colon cancer
564630|NCT00450424|stage IVA colon cancer
564631|NCT00450424|stage IVB colon cancer
564632|NCT00450424|recurrent rectal cancer
564633|NCT00450424|stage I rectal cancer
564634|NCT00450424|stage IIA rectal cancer
564635|NCT00450424|stage IIB rectal cancer
564636|NCT00450424|stage IIC rectal cancer
564637|NCT00450424|stage IIIA rectal cancer
564638|NCT00450424|stage IIIB rectal cancer
564639|NCT00450424|stage IIIC rectal cancer
564640|NCT00450424|stage IVA rectal cancer
564641|NCT00450424|stage IVB rectal cancer
564642|NCT00450411|adenocarcinoma of the prostate
564643|NCT00450411|recurrent prostate cancer
564644|NCT00450411|stage I prostate cancer
564645|NCT00450411|stage IIB prostate cancer
564646|NCT00450411|stage IIA prostate cancer
564647|NCT00450398|Delayed graft function
564648|NCT00450385|recurrent adult diffuse large cell lymphoma
564649|NCT00450385|stage III adult diffuse large cell lymphoma
564650|NCT00450385|stage IV adult diffuse large cell lymphoma
564651|NCT00450385|contiguous stage II adult diffuse large cell lymphoma
564652|NCT00450385|noncontiguous stage II adult diffuse large cell lymphoma
564653|NCT00450385|stage I adult diffuse large cell lymphoma
564654|NCT00450372|recurrent melanoma
564655|NCT00450372|stage IV melanoma
564656|NCT00450359|breast cancer
564657|NCT00450333|Chronic
564658|NCT00450320|AIDS-related Kaposi sarcoma
564659|NCT00450320|recurrent Kaposi sarcoma
564660|NCT00450307|recurrent neuroblastoma
564661|NCT00450307|stage 4S neuroblastoma
564662|NCT00450307|disseminated neuroblastoma
564663|NCT00450307|localized unresectable neuroblastoma
564664|NCT00450307|regional neuroblastoma
564665|NCT00450281|stage IIIB non-small cell lung cancer
564666|NCT00450281|stage IIIA non-small cell lung cancer
564667|NCT00450281|stage IA non-small cell lung cancer
564668|NCT00450281|stage IB non-small cell lung cancer
564669|NCT00450281|stage IIA non-small cell lung cancer
564670|NCT00450281|stage IIB non-small cell lung cancer
564671|NCT00450268|Graft versus host disease
564672|NCT00450268|Allogeneic hematpoietic stem cell transplantation
564673|NCT00450242|vulvar vestibulitis
564674|NCT00450242|vestibulitis
564675|NCT00450216|ibuprofen
564676|NCT00450216|famotidine
564677|NCT00450216|ulcers
564678|NCT00450216|NSAIDS
564679|NCT00450216|pain
564680|NCT00450216|arthritis
564681|NCT00450216|chronic regional pain syndrome
564682|NCT00450216|chronic soft tissue pain
564683|NCT00450216|osteoarthritis
564684|NCT00450216|rheumatoid arthritis
564685|NCT00450216|chronic low back pain
564686|NCT00450203|adenocarcinoma of the stomach
564687|NCT00450203|adenocarcinoma of the gastro oesophageal junction
564688|NCT00450203|adenocarcinoma of the lower oesophagus
564689|NCT00450190|Growth disorders/drug therapy
564690|NCT00450177|iron
564691|NCT00450177|critical illness
564692|NCT00450177|anemia
564693|NCT00450177|infection
564694|NCT00450164|Variceal bleeding
564695|NCT00450164|Secondary profilaxis
564696|NCT00450164|Hemodynamic
564697|NCT00450164|Portal hypertension
564698|NCT00450151|Pediatric
564699|NCT00450151|Cardiopulmonary bypass Surgery
564700|NCT00450151|Cardiac Surgery
564701|NCT00450151|Platelet
564702|NCT00450151|Platelet Activation Markers
564703|NCT00450151|Platelet Factor4
564704|NCT00450151|Transforming Growth Factor Beta
564705|NCT00450138|Squamous Cell Carcinoma
564706|NCT00450125|Lung Cancer
564707|NCT00450125|Lung Resection
564708|NCT00450125|Exercise Stress Test
564709|NCT00450125|Six-Minute Walk Test
564710|NCT00450099|Epidural
564711|NCT00450099|Labor Analgesia
564712|NCT00450099|Bupivacaine
564713|NCT00450099|Dose-response
564714|NCT00450099|Minimum effective volume
564715|NCT00450060|postlumbar puncture headache
564716|NCT00450060|atraumatic needle
564717|NCT00450060|Sprotte
564718|NCT00450060|Quincke
564719|NCT00450060|lumbar puncture
564720|NCT00450060|headache
564721|NCT00450060|backache
564722|NCT00450047|cognitive impairment, ergometer, speed-feedback therapy
564723|NCT00450034|Frail Elderly
564724|NCT00450034|Patient Education
564725|NCT00450034|Drug optimization
564726|NCT00450034|Underuse
564727|NCT00450034|Vulnerable
564728|NCT00450034|Drug related hospitalization
564729|NCT00450034|Medical intervention
564730|NCT00450021|PET
564731|NCT00450021|CB1 Receptor
564732|NCT00450021|Cannabinoid
564733|NCT00450021|[11C] MePPEP
564734|NCT00450021|Brain Imaging
564735|NCT00450021|Healthy Volunteer
564736|NCT00450021|HV
564737|NCT00450008|Prostate Cancer
564738|NCT00450008|Hormone-Naïve Prostate Cancer
564739|NCT00450008|adenocarcinoma of the prostate
564740|NCT00449982|Genital warts
564741|NCT00449982|Condylomata acuminata
564742|NCT00449982|Human Papillomavirus
564743|NCT00449982|Polyphenon E
564744|NCT00449982|Green tea extract
564745|NCT00449982|Vulva
564746|NCT00449982|Penis
564747|NCT00449982|Anus
564748|NCT00449969|AED (automated external defibrillation)
564749|NCT00449969|feedback
564750|NCT00449969|out of hospital resuscitation
564751|NCT00449943|Cardiac Invasive Catheterization Angiography
564752|NCT00449943|Single Photon Emission Computed Tomography
564753|NCT00449943|Computed Tomography Angiography
564754|NCT00449917|visual caracteristics
564755|NCT00449917|macular pigment optical density
564756|NCT00449917|visual acuity
564757|NCT00449917|contrast sensibility
564758|NCT00449917|lutein
564759|NCT00449917|docosahexaenoic acid (DHA)
564760|NCT00449904|Cystic fibrosis-related exocrine pancreatic insufficiency
564761|NCT00449891|Type 1 diabetes mellitus
564762|NCT00449878|cystic fibrosis-related pancreatic insufficiency
564763|NCT00449865|Parkinson's disease
564764|NCT00449865|creatine
564765|NCT00449865|NET-PD
564766|NCT00449865|neuroprotection
564767|NCT00449865|PD
564768|NCT00449852|Randomized Control Trial
564769|NCT00449852|Smoking Cessation
564770|NCT00449852|Secondary Prevention
564771|NCT00449852|Rehabilitation
564772|NCT00449852|Counseling
564773|NCT00449839|Insulin pump treatment CSII
564774|NCT00449839|Absorption
564775|NCT00449839|Insulin Aspart
564776|NCT00449826|ACS
564777|NCT00449826|Unstable Angina
564778|NCT00449826|NSTEMI
564779|NCT00449813|Gastroesophageal reflux disease (GERD)
564780|NCT00449813|Non erosive reflux disease (NERD)
564781|NCT00449800|Sepsis
564782|NCT00449800|Ceftriaxone
564783|NCT00449800|Pharmacokinetic
564784|NCT00449800|Intensive care unit
564785|NCT00449787|Emergency department
564786|NCT00449787|headache
564787|NCT00449787|migraine
564788|NCT00449774|Food effect
564789|NCT00449774|Safety
564790|NCT00449774|Tolerability
564791|NCT00449774|Water effect
564792|NCT00449774|Bioequivalence
564793|NCT00449761|Refractory
564794|NCT00449761|Chronic Myeloid
564795|NCT00449761|Leukemia
564796|NCT00449761|accelerated phase
564797|NCT00449761|blast phase (blast crisis)
564798|NCT00449761|adults
564799|NCT00449761|oral LBH589
564800|NCT00449748|Systemic Mastocytosis
564801|NCT00449748|RAD001
564802|NCT00449735|positive isolates
564803|NCT00449735|ecoli
564804|NCT00449735|blood cultures
564805|NCT00449735|positive cultures for ecoli
564806|NCT00449735|blood stream infections
564807|NCT00449709|Pre-term labor,
564808|NCT00449709|modified release formulation
564809|NCT00449709|pharmacokinetics,
564810|NCT00449683|Depressive Disorders
564811|NCT00449683|Excessive Sweating
564812|NCT00449683|Sweating caused by antidepressants for those a depressive disorder
564813|NCT00449670|Influenza
564814|NCT00449670|Influenza Vaccine
564815|NCT00449644|Tuberculosis
564816|NCT00449644|MDR TB
564817|NCT00449631|Glaucoma
564818|NCT00449631|Drug Resistance, Multiple
564819|NCT00449631|Trabeculectomy
564820|NCT00449618|Aspirin
564821|NCT00449618|Ambulatory blood pressure monitoring
564822|NCT00449618|Chronotherapy
564823|NCT00449618|Circadian
564824|NCT00449605|Diabetes
564825|NCT00449605|Metformin
564826|NCT00449592|Stem cell transplantation
564827|NCT00449592|Mucositis
564828|NCT00449592|Zinc
564829|NCT00449579|Ischemia
564830|NCT00449579|Myocardial
564831|NCT00449579|HF-ECG
564832|NCT00449566|Magnetic Resonance Imaging
564833|NCT00449566|Diffusion Tensor Imaging
564834|NCT00449553|Glucose Metabolism Disorder
564835|NCT00449553|Dysmetabolic Syndrome
564836|NCT00449553|Type II Diabetes
564837|NCT00449553|Diabetes Mellitus, Lipoatrophic
564838|NCT00449553|Dyslipidemia
564839|NCT00449553|Drug Therapy
564840|NCT00449540|Migraine with aura
564841|NCT00449540|aura
564842|NCT00449540|TMS
564843|NCT00449527|Mild asthma
564844|NCT00449527|Moderate asthma
564845|NCT00449514|infertility
564846|NCT00449514|ovulation dysfunction
564847|NCT00449514|endometrium
564848|NCT00449514|tamoxifen
564849|NCT00449514|clomiphene citrate
564850|NCT00449501|Mild Asthma
564851|NCT00449501|Moderate Asthma
564852|NCT00449488|erythropoietin
564853|NCT00449488|myocardial infarction
564854|NCT00449488|PCI
564855|NCT00449488|left ventricular function
564856|NCT00449462|CLA
564857|NCT00449462|liver
564858|NCT00449462|kidney
564859|NCT00449449|Pertubation, tubal flushing, intrauterine insemination.
564860|NCT00449436|HIV
564861|NCT00449436|treatment experienced
564862|NCT00449423|Acute heart failure
564863|NCT00449423|Metabolic modulation
564864|NCT00449410|Atrial Fibrillation
564865|NCT00449410|elderly
564866|NCT00449410|cholesterol lowering
564867|NCT00449410|neurocognitive function
564868|NCT00449410|cerebrovascular lesion
564869|NCT00449397|First Episode Psychosis
564870|NCT00449384|Severe Impairment Battery
564871|NCT00449384|Clinical Dementia Rating
564872|NCT00449358|bcc
564873|NCT00449345|Latent tuberculosis infection
564874|NCT00449345|Health care workers
564875|NCT00449345|Tuberculin skin test
564876|NCT00449345|Mantoux skin test
564877|NCT00449345|Interferon gamma
564878|NCT00449345|Quantiferon
564879|NCT00449345|Cost effectiveness
564880|NCT00449332|Chronic rejection, lung transplant, cytokines, bos
564881|NCT00449319|AML
564882|NCT00449319|adult
564883|NCT00449319|Hydroxyurea
564884|NCT00449319|Transplant
564885|NCT00449319|Toevaluate biological characteristics at diagnosis.
564886|NCT00449319|To identify genetic alterations with prognostic relevance.
564887|NCT00449319|To follow up cases monitoring minimal disease during remission.
564888|NCT00449319|To evaluate pretreatment therapy in terms of response rate and toxicity.
564889|NCT00449319|Disease free survival.
564890|NCT00449319|Overal survival.
564891|NCT00449306|Atherosclerosis
564892|NCT00449306|Carotid plaque
564893|NCT00449306|Abdominal aortic aneurysm
564894|NCT00449306|Vulnerable plaque
564895|NCT00449306|Angiogenesis
564896|NCT00449306|Intraplaque hemorrhage
564897|NCT00449306|Carotid artery atherosclerosis
564898|NCT00449293|Smoking cessation
564899|NCT00449293|Tobacco dependence
564900|NCT00449293|Mindfulness
564901|NCT00449293|fMRI
564902|NCT00449293|Craving
564903|NCT00449280|metastatic
564904|NCT00449280|advanced disease
564905|NCT00449280|phase I
564906|NCT00449267|Lenses, Intraocular
564907|NCT00449267|Prospective Studies
564908|NCT00449267|Visual acuity
564909|NCT00449267|Clinical Trial
564910|NCT00449241|Acupuncture, Endoscopy
564911|NCT00449228|Osteoarthritis,
564912|NCT00449228|hip replacement,
564913|NCT00449228|education,
564914|NCT00449228|randomized controlled trial,
564915|NCT00449228|mini-invasive surgery
564916|NCT00449215|Peak Bone Mass; Male; Genetic Polymorphisms
564917|NCT00449189|PTSD
564918|NCT00449189|Operation Iraqi Freedom veterans
564919|NCT00449189|Mirtazapine
564920|NCT00449176|Low Back Pain
564921|NCT00449176|Chronic Pain
564922|NCT00449176|Pain Assessment
564923|NCT00449176|Tapentadol
564924|NCT00449163|stage IV colon cancer
564925|NCT00449163|stage IV rectal cancer
564926|NCT00449163|adenocarcinoma of the colon
564927|NCT00449163|adenocarcinoma of the rectum
564928|NCT00449150|Cetrorelix
564929|NCT00449137|recurrent colon cancer
564930|NCT00449137|stage IV colon cancer
564931|NCT00449137|recurrent rectal cancer
564932|NCT00449137|stage IV rectal cancer
564933|NCT00449124|hepatitis C, vaccine, TG4040
564934|NCT00449098|Glaucoma
564935|NCT00449098|Collagen matrix
564936|NCT00449098|ologen
564937|NCT00449098|OculusGen
564938|NCT00449098|Trabeculectomy
564939|NCT00449098|anti scarring
564940|NCT00449098|tissue engineering
564941|NCT00449098|high risk patient for trabeculectomy
564942|NCT00449098|Aeon Astron
564943|NCT00449059|heart transplantation
564944|NCT00449059|cyclosporine
564945|NCT00449059|hypertension
564946|NCT00449059|nitroglycerin
564947|NCT00449046|salmeterol/fluticasone propionate combination
564948|NCT00449046|pediatric bronchial asthma
564949|NCT00449033|Non-Small Cell Lung Cancer (NSCLC)
564950|NCT00449033|Cancer
564951|NCT00449020|stage IIIA non-small cell lung cancer
564952|NCT00449020|stage IIIB non-small cell lung cancer
564953|NCT00449007|Major depressive disorder
564954|NCT00449007|Alcohol abuse
564955|NCT00449007|Alcohol dependence
564956|NCT00449007|Suicide
564957|NCT00448994|adenovirus, fungal, diagnostics, children
564958|NCT00448981|Preventing upper respiratory tract infections
564959|NCT00448981|Preventing influenza
564960|NCT00448981|Preventing the common cold
564961|NCT00448981|Hand hygiene and upper respiratory infections
564962|NCT00448981|Mask use in preventing upper respiratory infections
564963|NCT00448968|Sepsis
564964|NCT00448968|Ischemia Modified Albumin
564965|NCT00448968|Systemic Inflammatory Response Syndrome
564966|NCT00448942|Staphylococcus aureus [B03.510.400.790.750.100]
564967|NCT00448942|Enterococcus faecalis [B03.510.400.800.280.280]
564968|NCT00448942|Enterococcus faecium [B03.510.400.800.280.300]
564969|NCT00448942|Bacteremia [C01.252.100]
564970|NCT00448942|Fungemia [C01.703.360]
564971|NCT00448942|Infection Control [G03.850.780.200.450]
564972|NCT00448942|Antisepsis [G03.850.780.200.450.150]
564973|NCT00448929|Glaucoma
564974|NCT00448929|Collagen matrix
564975|NCT00448929|ologen
564976|NCT00448929|OculusGen
564977|NCT00448929|Trabeculectomy
564978|NCT00448916|Partial-onset seizures; epilepsy; pediatric; pregabalin; 1 year extension study; safety; tolerability
564979|NCT00448903|diabetic
564980|NCT00448903|foot
564981|NCT00448903|ulcer
564982|NCT00448903|bemiparin
564983|NCT00448903|neuropathy
564984|NCT00448903|neuroishemic
564985|NCT00448903|diabetes
564986|NCT00448890|AMPA positive modulator, healthy volunteers
564987|NCT00448877|No specific disease is being studied, few procedures are excluded.
564988|NCT00448877|The focus of the study is to rule out the efficacy of the device, so the aim is to include as wide a variety of procedures as possible.
564989|NCT00448851|asthma
564990|NCT00448851|allergy
564991|NCT00448838|recurrent pancreatic cancer
564992|NCT00448838|stage III pancreatic cancer
564993|NCT00448838|stage IV pancreatic cancer
564994|NCT00448838|stage II pancreatic cancer
564995|NCT00448825|alcohol dependence
564996|NCT00448825|alcoholism
564997|NCT00448825|cocaine addiction
564998|NCT00448825|cocaine dependence
564999|NCT00447798|HIV positive
565000|NCT00447798|crack cocaine user
565001|NCT00447798|inpatient hospital setting
565002|NCT00447798|HIV knowledge
565003|NCT00447798|motivation
565004|NCT00447798|perceived self-efficacy
565005|NCT00447798|risky sexual behavior
565006|NCT00447798|HIV seronegativity
565007|NCT00447785|alcoholism
565008|NCT00447785|nutrition
565009|NCT00447785|craving
565010|NCT00447785|energy supplies
565011|NCT00447785|water supplies
565012|NCT00447772|Dysport, Cervical Dystonia
565013|NCT00447759|Celecoxib
565014|NCT00447759|Celebrex
565015|NCT00447759|Ibuprofen
565016|NCT00447759|Diclofenac
565017|NCT00447759|NSAID
565018|NCT00447759|Osteoarthritis
565019|NCT00447759|Rheumatoid Arthritis
565020|NCT00447759|Arthritis
565021|NCT00447759|Safety study
565022|NCT00447759|Cardiovascular safety
565023|NCT00447759|Clinical trial
565024|NCT00447759|PROBE design
565025|NCT00447759|University of Dundee
565026|NCT00447759|Medicines Monitoring Unit
565027|NCT00447759|MEMO
565028|NCT00447759|Professor Tom MacDonald
565029|NCT00447746|Comparison between D1 and D2 lymphadenectomy for gastric cancer
565030|NCT00447733|mental health
565031|NCT00447733|substance use
565032|NCT00447733|treatment
565033|NCT00447720|HIV prevention skills
565034|NCT00447720|Seriously Mentally Ill (SMI)
565035|NCT00447720|Substance abuse
565036|NCT00447720|Philadelphia
565037|NCT00447720|HIV seronegativity
565038|NCT00447707|Substance use
565039|NCT00447707|Unprotected sex
565040|NCT00447707|Behavioral intervention
565041|NCT00447707|HIV care
565042|NCT00447707|Prevention with Positives
565043|NCT00447707|HIV seronegativity
565044|NCT00447694|Iron Chelation
565045|NCT00447694|Deferasirox
565046|NCT00447694|Chelator
565047|NCT00447694|Desferal
565048|NCT00447694|beta-thalassemia
565049|NCT00447694|Iron overload
565050|NCT00448799|neurological
565051|NCT00448799|alzheimers
565052|NCT00448786|gallbladder
565053|NCT00448786|AMG 706
565054|NCT00448786|solid tumors
565055|NCT00448786|Phase 1b
565056|NCT00448786|Amgen
565057|NCT00448760|stage II esophageal cancer
565058|NCT00448760|stage III esophageal cancer
565059|NCT00448760|adenocarcinoma of the esophagus
565060|NCT00448747|Ghrelin mimetic, growth hormone secretagogue
565061|NCT00448734|metastatic
565062|NCT00448734|hormone-refractory
565063|NCT00448734|prostate cancer
565064|NCT00448734|picoplatin
565065|NCT00448734|platinum drug
565066|NCT00448734|chemotherapy
565067|NCT00448734|docetaxel
565068|NCT00448721|renal cell carcinoma
565069|NCT00448721|tyrosine kinase inhibitor failure
565070|NCT00448708|Hemodialysis Access
565071|NCT00448695|MRI
565072|NCT00448695|Laser Thermal Therapy
565073|NCT00448695|Focal Ablation
565074|NCT00448695|Prostate Cancer
565075|NCT00448682|recurrent gastric cancer
565076|NCT00448682|stage IV gastric cancer
565077|NCT00448682|adenocarcinoma of the stomach
565078|NCT00448669|HIV incidence
565079|NCT00448669|HIV prevention
565080|NCT00448669|Tenofovir
565081|NCT00448669|Emtricitabine
565082|NCT00448669|Botswana
565083|NCT00448669|HIV seronegativity
565084|NCT00448656|atrial fibrillation
565085|NCT00448656|epicardial ablation pulmonary veins
565086|NCT00448656|video assisted thoracic surgery
565087|NCT00448643|endometrial adenocarcinoma
565088|NCT00448643|endometrial clear cell carcinoma
565089|NCT00448643|endometrial papillary carcinoma
565090|NCT00448643|stage III endometrial carcinoma
565091|NCT00448643|stage IV endometrial carcinoma
565092|NCT00448630|Atypical antipsychotics, Metabolic syndrome, Safety
565093|NCT00448617|live attenuated influenza virus
565094|NCT00448617|inflammation
565095|NCT00448617|flu vaccine
565096|NCT00448617|FluMist
565097|NCT00448617|smokers
565098|NCT00448604|procalcitonin
565099|NCT00448604|acute exacerbation
565100|NCT00448604|RT-PCR
565101|NCT00448604|Biological Markers
565102|NCT00448578|Acute Mania
565103|NCT00448565|extubation
565104|NCT00448565|prediction
565105|NCT00448552|recurrent squamous cell carcinoma of the hypopharynx
565106|NCT00448552|stage IV squamous cell carcinoma of the hypopharynx
565107|NCT00448552|recurrent squamous cell carcinoma of the larynx
565108|NCT00448552|recurrent verrucous carcinoma of the larynx
565109|NCT00448552|stage IV squamous cell carcinoma of the larynx
565110|NCT00448552|stage IV verrucous carcinoma of the larynx
565111|NCT00448552|recurrent squamous cell carcinoma of the lip and oral cavity
565112|NCT00448552|stage IV squamous cell carcinoma of the lip and oral cavity
565113|NCT00448552|recurrent basal cell carcinoma of the lip
565114|NCT00448552|stage IV basal cell carcinoma of the lip
565115|NCT00448552|recurrent adenoid cystic carcinoma of the oral cavity
565116|NCT00448552|recurrent mucoepidermoid carcinoma of the oral cavity
565117|NCT00448552|recurrent verrucous carcinoma of the oral cavity
565118|NCT00448552|stage IV adenoid cystic carcinoma of the oral cavity
565119|NCT00448552|stage IV mucoepidermoid carcinoma of the oral cavity
565120|NCT00448552|stage IV verrucous carcinoma of the oral cavity
565121|NCT00448552|recurrent metastatic squamous neck cancer with occult primary
565122|NCT00448552|recurrent lymphoepithelioma of the nasopharynx
565123|NCT00448552|recurrent squamous cell carcinoma of the nasopharynx
565124|NCT00448552|stage IV lymphoepithelioma of the nasopharynx
565125|NCT00448552|stage IV squamous cell carcinoma of the nasopharynx
565126|NCT00448552|recurrent lymphoepithelioma of the oropharynx
565127|NCT00448552|recurrent squamous cell carcinoma of the oropharynx
565128|NCT00448552|stage IV lymphoepithelioma of the oropharynx
565129|NCT00448552|stage IV squamous cell carcinoma of the oropharynx
565130|NCT00448552|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
565431|NCT00448006|common
565131|NCT00448552|recurrent inverted papilloma of the paranasal sinus and nasal cavity
565132|NCT00448552|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
565133|NCT00448552|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
565134|NCT00448552|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
565135|NCT00448552|stage IV inverted papilloma of the paranasal sinus and nasal cavity
565136|NCT00448552|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
565137|NCT00448552|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
565138|NCT00448552|recurrent salivary gland cancer
565139|NCT00448552|stage IV salivary gland cancer
565140|NCT00448552|untreated metastatic squamous neck cancer with occult primary
565141|NCT00448552|metastatic squamous neck cancer with occult primary squamous cell carcinoma
565142|NCT00448539|Refractory Partial Onset Seizures, epilepsy
565143|NCT00448526|Low protein diet, type 2 Diabetic nephropathy
565144|NCT00448526|Comparing the effect of Low protein Diet on diabetic nephropathy to that of normal protein diet
565145|NCT00448513|catechin
565146|NCT00448513|oxidative stress
565147|NCT00448513|chromosome damage
565148|NCT00448513|aged
565149|NCT00448500|COPD
565150|NCT00448500|exhaled breath condenate
565151|NCT00448500|Exhaled breath condenate, acute exacerbation of COPD
565152|NCT00448487|Diabetes
565153|NCT00448487|Cardiovascular Disease
565154|NCT00448487|Haptoglobin
565155|NCT00448474|Disease self-management
565156|NCT00448474|Community program
565157|NCT00448461|coronary artery disease
565158|NCT00448461|percutaneous coronary interventions
565159|NCT00448448|adolescent idiopathic scoliosis
565160|NCT00448448|orthotics
565161|NCT00448448|bracing
565162|NCT00448448|partially randomized preference design
565163|NCT00448435|Salmeterol
565164|NCT00448435|Fluticasone propionate
565165|NCT00448435|Salmeterol/Fluticasone propionate combination
565166|NCT00448435|Pediatric bronchial asthma
565167|NCT00448422|Traveler's
565168|NCT00448422|Diarrhea
565169|NCT00448409|Prostate cancer
565170|NCT00448409|hormone refractory prostate cancer
565171|NCT00448409|androgen resistant prostate cancer
565172|NCT00448396|Cancer
565173|NCT00448396|EPO
565174|NCT00448396|Patupilone
565175|NCT00448396|Solid tumors
565176|NCT00448396|Advanced malignancies
565177|NCT00448370|Anemia, sickle cell
565178|NCT00448357|refractory multiple myeloma
565179|NCT00448357|relapsing chronic myelogenous leukemia
565180|NCT00448357|secondary acute myeloid leukemia
565181|NCT00448357|stage II multiple myeloma
565182|NCT00448357|stage III multiple myeloma
565183|NCT00448357|stage IV adult Burkitt lymphoma
565184|NCT00448357|stage IV adult diffuse large cell lymphoma
565185|NCT00448357|stage IV adult diffuse mixed cell lymphoma
565186|NCT00448357|stage IV adult diffuse small cleaved cell lymphoma
565187|NCT00448357|stage IV adult immunoblastic large cell lymphoma
565188|NCT00448357|stage IV adult lymphoblastic lymphoma
565189|NCT00448357|stage IV adult Hodgkin lymphoma
565190|NCT00448357|stage IV grade 1 follicular lymphoma
565191|NCT00448357|stage IV grade 2 follicular lymphoma
565192|NCT00448357|stage IV grade 3 follicular lymphoma
565193|NCT00448357|stage IV mantle cell lymphoma
565194|NCT00448357|stage IV marginal zone lymphoma
565195|NCT00448357|stage IV small lymphocytic lymphoma
565196|NCT00448357|Waldenstrom macroglobulinemia
565197|NCT00448357|accelerated phase chronic myelogenous leukemia
565198|NCT00448357|adult acute myeloid leukemia in remission
565199|NCT00448357|blastic phase chronic myelogenous leukemia
565200|NCT00448357|chronic eosinophilic leukemia
565201|NCT00448357|chronic neutrophilic leukemia
565202|NCT00448357|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
565203|NCT00448357|nodal marginal zone B-cell lymphoma
565204|NCT00448357|recurrent adult Burkitt lymphoma
565205|NCT00448357|recurrent adult diffuse large cell lymphoma
565206|NCT00448357|recurrent adult diffuse mixed cell lymphoma
565207|NCT00448357|recurrent adult diffuse small cleaved cell lymphoma
565208|NCT00448357|recurrent adult Hodgkin lymphoma
565209|NCT00448357|recurrent adult immunoblastic large cell lymphoma
565210|NCT00448357|recurrent adult lymphoblastic lymphoma
565211|NCT00448357|recurrent grade 1 follicular lymphoma
565212|NCT00448357|recurrent grade 2 follicular lymphoma
565213|NCT00448357|recurrent grade 3 follicular lymphoma
565214|NCT00448357|recurrent mantle cell lymphoma
565215|NCT00448357|recurrent marginal zone lymphoma
565216|NCT00448357|recurrent small lymphocytic lymphoma
565217|NCT00448357|stage III adult Burkitt lymphoma
565218|NCT00448357|stage III adult diffuse large cell lymphoma
565219|NCT00448357|stage III adult diffuse mixed cell lymphoma
565220|NCT00448357|stage III adult diffuse small cleaved cell lymphoma
565221|NCT00448357|stage III adult Hodgkin lymphoma
565222|NCT00448357|stage III adult immunoblastic large cell lymphoma
565223|NCT00448357|stage III adult lymphoblastic lymphoma
565224|NCT00448357|stage III grade 1 follicular lymphoma
565225|NCT00448357|stage III grade 2 follicular lymphoma
565226|NCT00448357|stage III grade 3 follicular lymphoma
565227|NCT00448357|stage III mantle cell lymphoma
565432|NCT00448006|bile
565228|NCT00448357|stage III marginal zone lymphoma
565229|NCT00448357|stage III small lymphocytic lymphoma
565230|NCT00448357|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
565231|NCT00448357|adult acute myeloid leukemia with inv(16)(p13;q22)
565232|NCT00448357|adult acute myeloid leukemia with t(15;17)(q22;q12)
565233|NCT00448357|adult acute myeloid leukemia with t(16;16)(p13;q22)
565234|NCT00448357|adult acute myeloid leukemia with t(8;21)(q22;q22)
565235|NCT00448357|primary myelofibrosis
565236|NCT00448357|chronic phase chronic myelogenous leukemia
565237|NCT00448357|de novo myelodysplastic syndromes
565238|NCT00448357|previously treated myelodysplastic syndromes
565239|NCT00448357|prolymphocytic leukemia
565240|NCT00448357|recurrent adult acute lymphoblastic leukemia
565241|NCT00448357|recurrent adult acute myeloid leukemia
565242|NCT00448357|refractory chronic lymphocytic leukemia
565243|NCT00448357|secondary myelodysplastic syndromes
565244|NCT00448357|stage III chronic lymphocytic leukemia
565245|NCT00448357|stage IV chronic lymphocytic leukemia
565246|NCT00448357|adult acute lymphoblastic leukemia in remission
565247|NCT00448357|polycythemia vera
565248|NCT00448357|essential thrombocythemia
565249|NCT00448357|splenic marginal zone lymphoma
565250|NCT00448357|recurrent mycosis fungoides/Sezary syndrome
565251|NCT00448357|recurrent cutaneous T-cell non-Hodgkin lymphoma
565252|NCT00448357|stage I multiple myeloma
565253|NCT00448357|recurrent adult grade III lymphomatoid granulomatosis
565254|NCT00448357|adult nasal type extranodal NK/T-cell lymphoma
565255|NCT00448344|veterans
565256|NCT00448344|smoking cessation
565257|NCT00448331|Mental Disorders
565258|NCT00448331|Mentally Ill Persons
565259|NCT00448331|Emergency Medicine
565260|NCT00448331|Emergency Department
565261|NCT00448331|Screening
565262|NCT00448318|Controlled clinical trial
565263|NCT00448305|breast cancer
565264|NCT00448305|metastatic
565265|NCT00448305|relapsed
565266|NCT00448305|triple-receptor negative
565267|NCT00448305|EndoTAG-1
565268|NCT00448305|metastatic or relapsed breast neoplasm
565269|NCT00448292|Depression
565270|NCT00448292|Major Depressive Disorder
565271|NCT00448292|Major Depression
565272|NCT00448292|MDD
565273|NCT00448266|Breast cancer
565274|NCT00448266|high-dose chemotherapy
565275|NCT00448266|Homologous Recombination Deficiency
565276|NCT00448266|Alkylator therapy
565277|NCT00448266|Peripheral Blood Progenitor Cell Support
565278|NCT00448253|Inhalational Anthrax
565279|NCT00448253|Human Immune globulin
565280|NCT00448227|Infants, Herpes simplex infection
565281|NCT00448214|Factor Xa inhibitor
565282|NCT00448214|Atrial fibrillation
565283|NCT00448214|Stroke
565284|NCT00448214|Ischemic attack
565285|NCT00448214|thromboembolism
565286|NCT00448214|Prevention and control
565287|NCT00448201|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
565288|NCT00448201|adult acute myeloid leukemia with inv(16)(p13;q22)
565289|NCT00448201|adult acute myeloid leukemia with t(15;17)(q22;q12)
565290|NCT00448201|adult acute myeloid leukemia with t(16;16)(p13;q22)
565291|NCT00448201|adult acute myeloid leukemia with t(8;21)(q22;q22)
565292|NCT00448201|prolymphocytic leukemia
565293|NCT00448201|accelerated phase chronic myelogenous leukemia
565294|NCT00448201|adult acute lymphoblastic leukemia in remission
565295|NCT00448201|adult acute myeloid leukemia in remission
565296|NCT00448201|blastic phase chronic myelogenous leukemia
565297|NCT00448201|childhood acute lymphoblastic leukemia in remission
565298|NCT00448201|childhood acute myeloid leukemia in remission
565299|NCT00448201|childhood chronic myelogenous leukemia
565300|NCT00448201|chronic phase chronic myelogenous leukemia
565301|NCT00448201|de novo myelodysplastic syndromes
565302|NCT00448201|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
565303|NCT00448201|nodal marginal zone B-cell lymphoma
565304|NCT00448201|noncontiguous stage II adult Burkitt lymphoma
565305|NCT00448201|noncontiguous stage II adult diffuse large cell lymphoma
565306|NCT00448201|noncontiguous stage II adult diffuse mixed cell lymphoma
565307|NCT00448201|noncontiguous stage II adult diffuse small cleaved cell lymphoma
565308|NCT00448201|noncontiguous stage II adult immunoblastic large cell lymphoma
565309|NCT00448201|noncontiguous stage II adult lymphoblastic lymphoma
565310|NCT00448201|noncontiguous stage II grade 1 follicular lymphoma
565311|NCT00448201|noncontiguous stage II grade 2 follicular lymphoma
565312|NCT00448201|noncontiguous stage II grade 3 follicular lymphoma
565313|NCT00448201|noncontiguous stage II mantle cell lymphoma
565314|NCT00448201|noncontiguous stage II marginal zone lymphoma
565315|NCT00448201|noncontiguous stage II small lymphocytic lymphoma
565316|NCT00448201|previously treated myelodysplastic syndromes
565317|NCT00448201|recurrent adult acute lymphoblastic leukemia
565318|NCT00448201|recurrent adult Burkitt lymphoma
565319|NCT00448201|recurrent adult Hodgkin lymphoma
565320|NCT00448201|recurrent adult diffuse large cell lymphoma
565321|NCT00448201|recurrent adult diffuse mixed cell lymphoma
565322|NCT00448201|recurrent adult diffuse small cleaved cell lymphoma
565323|NCT00448201|recurrent adult immunoblastic large cell lymphoma
565324|NCT00448201|recurrent adult lymphoblastic lymphoma
565325|NCT00448201|recurrent adult acute myeloid leukemia
565326|NCT00448201|recurrent childhood acute myeloid leukemia
565327|NCT00448201|recurrent/refractory childhood Hodgkin lymphoma
565328|NCT00448201|recurrent childhood acute lymphoblastic leukemia
565329|NCT00448201|recurrent childhood large cell lymphoma
565330|NCT00448201|recurrent childhood lymphoblastic lymphoma
565331|NCT00448201|recurrent childhood small noncleaved cell lymphoma
565332|NCT00448201|recurrent cutaneous T-cell non-Hodgkin lymphoma
565333|NCT00448201|recurrent grade 1 follicular lymphoma
565334|NCT00448201|recurrent grade 2 follicular lymphoma
565335|NCT00448201|recurrent grade 3 follicular lymphoma
565336|NCT00448201|recurrent mantle cell lymphoma
565337|NCT00448201|recurrent marginal zone lymphoma
565338|NCT00448201|recurrent mycosis fungoides/Sezary syndrome
565339|NCT00448201|recurrent small lymphocytic lymphoma
565340|NCT00448201|refractory chronic lymphocytic leukemia
565341|NCT00448201|refractory multiple myeloma
565342|NCT00448201|relapsing chronic myelogenous leukemia
565343|NCT00448201|secondary acute myeloid leukemia
565344|NCT00448201|secondary myelodysplastic syndromes
565345|NCT00448201|splenic marginal zone lymphoma
565346|NCT00448201|stage I multiple myeloma
565347|NCT00448201|stage II multiple myeloma
565348|NCT00448201|stage III adult Burkitt lymphoma
565349|NCT00448201|stage III adult Hodgkin lymphoma
565350|NCT00448201|stage III adult diffuse large cell lymphoma
565351|NCT00448201|stage III adult diffuse mixed cell lymphoma
565352|NCT00448201|stage III adult diffuse small cleaved cell lymphoma
565353|NCT00448201|stage III adult immunoblastic large cell lymphoma
565354|NCT00448201|stage III adult lymphoblastic lymphoma
565355|NCT00448201|stage III chronic lymphocytic leukemia
565356|NCT00448201|stage III grade 1 follicular lymphoma
565357|NCT00448201|stage III grade 2 follicular lymphoma
565358|NCT00448201|stage III grade 3 follicular lymphoma
565359|NCT00448201|stage III mantle cell lymphoma
565360|NCT00448201|stage III marginal zone lymphoma
565361|NCT00448201|stage III multiple myeloma
565362|NCT00448201|stage III small lymphocytic lymphoma
565363|NCT00448201|stage IV adult Burkitt lymphoma
565364|NCT00448201|stage IV adult Hodgkin lymphoma
565365|NCT00448201|stage IV adult diffuse large cell lymphoma
565366|NCT00448201|stage IV adult diffuse mixed cell lymphoma
565367|NCT00448201|stage IV adult diffuse small cleaved cell lymphoma
565368|NCT00448201|stage IV adult immunoblastic large cell lymphoma
565369|NCT00448201|stage IV adult lymphoblastic lymphoma
565370|NCT00448201|stage IV chronic lymphocytic leukemia
565371|NCT00448201|stage IV grade 1 follicular lymphoma
565372|NCT00448201|stage IV grade 2 follicular lymphoma
565373|NCT00448201|stage IV grade 3 follicular lymphoma
565374|NCT00448201|stage IV mantle cell lymphoma
565375|NCT00448201|stage IV marginal zone lymphoma
565376|NCT00448201|stage IV small lymphocytic lymphoma
565377|NCT00448201|primary myelofibrosis
565378|NCT00448201|Waldenstrom macroglobulinemia
565379|NCT00448201|adult nasal type extranodal NK/T-cell lymphoma
565380|NCT00448201|recurrent adult grade III lymphomatoid granulomatosis
565381|NCT00448201|childhood myelodysplastic syndromes
565382|NCT00448188|central venous catheter
565383|NCT00448188|international normalized ratio
565384|NCT00448188|thrombocytes
565385|NCT00448188|bleeding risk
565386|NCT00448188|all patients in need of central venous line
565387|NCT00448188|comparison of patients with normal hemostasis to such with disorders in hemostasis
565388|NCT00448175|OAB symptoms of urgency, frequency, and urge incontinence
565389|NCT00448162|hypertension, ENaC, Liddle's syndrome, variation
565390|NCT00448149|Kidney cancer
565391|NCT00448149|Renal cell carcinoma
565392|NCT00448149|Metastatic RCC
565393|NCT00448123|Kidney Stones
565394|NCT00448123|Ureteral Stones
565395|NCT00448123|Flomax
565396|NCT00448123|Emergency Medicine
565397|NCT00448123|Urology
565398|NCT00448097|Adenocarcinoma of the Prostate
565399|NCT00448097|Prostate cancer
565400|NCT00448097|Pre-Prostatectomy
565401|NCT00448097|Neoadjuvant
565402|NCT00448084|Psychogenic Movement Disorders
565403|NCT00448084|Volition
565404|NCT00448084|fMRI
565405|NCT00448084|Functional MRI
565406|NCT00448084|Functional Movement Disorder
565407|NCT00448084|Healthy Volunteer
565408|NCT00448084|HV
565409|NCT00448071|Hypotension
565410|NCT00448071|End Stage Renal Disease
565411|NCT00448071|Intra Dialytic Hypotension
565412|NCT00448071|ESRD
565413|NCT00448071|Blood Pressure
565414|NCT00448071|Dialysis
565415|NCT00448058|Flexible-dose
565416|NCT00448058|GSK372475
565417|NCT00448058|MDD
565418|NCT00448058|Venlafaxine XR
565419|NCT00448058|Major Depressive Disorder
565420|NCT00448045|Spinal cord injuries
565421|NCT00448045|Cough
565422|NCT00448045|Peak cough flow
565423|NCT00448045|Respiratory therapy
565424|NCT00448045|Rehabilitation
565425|NCT00448019|Chronic Lymphocytic Leukemia
565426|NCT00448019|Fludarabine
565427|NCT00448019|Cyclophosphamide
565428|NCT00448019|Rituximab
565429|NCT00448019|Bevacizumab
565430|NCT00448019|CLL
565433|NCT00448006|duct
565434|NCT00448006|biliary
565435|NCT00448006|malignant
565436|NCT00448006|obstruction
565437|NCT00448006|stent
565438|NCT00447993|Retinitis Pigmentosa
565439|NCT00447993|eye disease
565440|NCT00447993|retinal disorder
565441|NCT00447993|CNTF
565442|NCT00447980|Retinitis Pigmentosa
565443|NCT00447980|eye disease
565444|NCT00447980|retinal disorder
565445|NCT00447980|CNTF
565446|NCT00447967|Metastatic Gastric Cancer
565447|NCT00447967|Oxaliplatin
565448|NCT00447967|Irinotecan
565449|NCT00447954|eye disease
565450|NCT00447954|retinal disorder
565451|NCT00447954|CNTF
565452|NCT00447928|tendonitis
565453|NCT00447928|nitroglycerin
565454|NCT00447928|nitric oxide
565455|NCT00447928|lateral epicondylitis
565456|NCT00447902|treatment experienced
565457|NCT00447837|Chronic Sinusitis
565458|NCT00447824|Pain
565459|NCT00447824|Neonates
565460|NCT00447824|NIDCAP
565461|NCT00447824|Venous
565462|NCT00447824|Capillary
565463|NCT00447811|Methadone
565464|NCT00447668|Chronic Low Back Pain
565465|NCT00447668|Yoga
565466|NCT00447655|Amputation
565467|NCT00447655|Self-management
565468|NCT00447655|Rehabilitation
565469|NCT00447655|Peer support
565470|NCT00447642|immunology
565471|NCT00447642|cornea
565472|NCT00447642|allograft
565473|NCT00447642|corneal allograft rejection
565474|NCT00447642|graft failure
565475|NCT00447616|Prostate Cancer
565476|NCT00447616|Prostatectomy
565477|NCT00447564|opioid dependence
565478|NCT00447564|opioid addiction
565479|NCT00447564|buprenorphine
565480|NCT00447564|methadone
565481|NCT00447564|heroin
565482|NCT00447564|implant
565483|NCT00447564|opioid withdrawal
565484|NCT00447564|opioid pain medication
565485|NCT00447564|suboxone
565486|NCT00447551|Aesthetic facial volume enhancement
565487|NCT00447525|Prevention of : Diphtheria, Tetanus and Poliomyelitis
565488|NCT00447499|Acromegaly
565489|NCT00447499|Somatostatin Analogs
565490|NCT00447499|Somatuline® Autogel®
565491|NCT00447499|lanreotide
565492|NCT00447499|growth hormone
565493|NCT00447499|IGF-1
565494|NCT00447499|Inappropriate Growth Hormone Secretion Syndrome
565495|NCT00447499|Somatotropin Hypersecretion Syndrome
565496|NCT00447499|Inappropriate GH Secretion Syndrome
565497|NCT00447486|Osteoarthritis,
565498|NCT00447486|knee,
565499|NCT00447486|GW842166,
565500|NCT00447486|pain,
565501|NCT00447486|efficacy,
565502|NCT00447486|safety
565503|NCT00447473|Prostate Cancer
565504|NCT00447473|progressive hormone refractory prostate cancer
565505|NCT00447460|Graft-vs-host disease (GVHD)
565506|NCT00447460|Mesenchymal stem cell (MSC)
565507|NCT00447460|Allogeneic hematopoietic stem cell transplant
565508|NCT00447460|Allotransplant
565509|NCT00447460|Allogenic
565510|NCT00447460|Refractory
565511|NCT00447460|CSM/EICH2005
565512|NCT00447434|Nattokinase
565513|NCT00447434|fibrinolytic factors
565514|NCT00447434|blood lipids
565515|NCT00447434|nutrimental supplement
565516|NCT00447408|hemodialysis
565517|NCT00447408|dietary adherence
565518|NCT00447408|sodium
565519|NCT00447369|pregabalin
565520|NCT00447369|Valproic acid
565521|NCT00447369|migraine
565522|NCT00447369|prophylaxis
565523|NCT00447369|prevention
565524|NCT00447369|treatment
565525|NCT00447343|Functional MRI
565526|NCT00447343|Cervical myelopathy
565527|NCT00447343|Cervical radiculopathy
565528|NCT00447343|Brain plasticity and regeneration
565529|NCT00447330|metastatic esophagogastric adenocarcinomas
565530|NCT00447330|ESOPHAGEAL CANCER
565531|NCT00447330|GASTRIC CANCER
565532|NCT00447330|ADENOCARCINOMA
565533|NCT00447330|TARGTED THERAPY
565534|NCT00447330|BEVACIZUMAB
565535|NCT00447330|CAPECITBAINE
565536|NCT00447330|OXALIPLATIN
565537|NCT00447330|METASTATIC
565538|NCT00447317|peritoneal dialysis
565539|NCT00447317|diet
565540|NCT00447317|sodium
565541|NCT00447304|acute cholecystitis
565542|NCT00447304|cholecystectomy
565543|NCT00447304|antibiotic treatment
565544|NCT00447304|moxifloxacin
565545|NCT00447304|intraabdominal infection
565546|NCT00447304|morbidity and mortality of patients with acute cholecystitis, early surgery versus conservative therapy
565547|NCT00447291|Overweight
565548|NCT00447291|Obesity
565549|NCT00447291|Fish Oil
565550|NCT00447252|bereavement
565551|NCT00447252|grief
565552|NCT00447239|mechanical ventilated
565553|NCT00447239|surgical patients
565554|NCT00447239|pneumonia
565555|NCT00447239|blood glucose
565556|NCT00447239|insulin infusion
565557|NCT00447239|hospital stay
565558|NCT00447226|Ovarian Cancer
565559|NCT00447226|Bladder Cancer
565560|NCT00447226|ErbB2 positive
565561|NCT00447226|Lapatinib
565562|NCT00447226|Gastric/Esophageal Cancer
565563|NCT00447226|Uterine Serous Papillary Cancer
565564|NCT00447200|Stroke volume
565565|NCT00447200|SV variation
565566|NCT00447200|Esophagus Doppler
565567|NCT00447200|Goal Directed Therapy
565568|NCT00447187|corneal graft failure
565569|NCT00447187|corneal graft rejection
565570|NCT00447187|corneal transplant rejection
565571|NCT00447174|Grief
565572|NCT00447174|parental bereavement
565573|NCT00447135|Elderly
565574|NCT00447135|Trauma
565575|NCT00447135|Polymorphonuclear Leukocyte
565576|NCT00447135|Immunity
565577|NCT00447122|Pancreatic Cancer
565578|NCT00447096|Bipolar Type II
565579|NCT00447096|Depression
565580|NCT00447096|rTMS
565581|NCT00447083|Tanning
565582|NCT00447083|Musculoskeletal
565583|NCT00447083|Fibromyalgia Syndrome
565584|NCT00447070|HIV-infection
565585|NCT00447070|Dyslipidemia
565586|NCT00447070|Endothelial Dysfunction
565587|NCT00447070|Atherosclerosis
565588|NCT00447070|Protease inhibitor
565589|NCT00447070|treatment experienced
565590|NCT00447057|nonsquamous
565591|NCT00447044|Muscle loss and Maintenance of Muscle function
565592|NCT00447031|age related macular degeneration
565593|NCT00447031|intravitreal bevacizumab
565594|NCT00447031|intravitreal triamcinolone acetonide
565595|NCT00447031|neovascular age related macular degeneration
565596|NCT00447018|intracranial pressure
565597|NCT00447018|mannitol
565598|NCT00447018|hypertonic saline solution
565599|NCT00447018|brain injury
565600|NCT00447018|traumatic brain injury
565601|NCT00447018|Adult patients
565602|NCT00447018|With elevation of intracranial pressure (ICP > 20 mmHg)
565603|NCT00447005|Safety
565604|NCT00447005|PK
565605|NCT00447005|Biomarker
565606|NCT00446992|Schizophrenia
565607|NCT00446992|Schizoaffective
565608|NCT00446992|psychosis
565609|NCT00446992|olanzapine
565610|NCT00446979|Microbicides
565611|NCT00446979|HIV seronegativity
565612|NCT00446966|atrial fibrillation
565613|NCT00446966|coronary artery disease bypass graft surgery
565614|NCT00446953|Caesarean section
565615|NCT00446953|Corticosteroids
565616|NCT00446953|Betamethasone
565617|NCT00446953|Neonatal distress
565618|NCT00446927|Pediatrics
565619|NCT00446927|Cardiology
565620|NCT00446927|Cardiopulmonary Bypass
565621|NCT00446927|Heart Surgery
565622|NCT00446927|Cardiac Catheterization
565623|NCT00446927|Echocardiography
565624|NCT00446927|Imaging
565625|NCT00446927|ICG green dye
565626|NCT00446914|Hypertension
565627|NCT00446914|Blood Pressure
565628|NCT00446901|Prostate Cancer
565629|NCT00446901|Selenium
565630|NCT00446901|Chemoprevention
565631|NCT00446901|Gene expression
565632|NCT00446888|cancer
565633|NCT00446888|metastasis
565634|NCT00446875|Pain
565635|NCT00446875|Procedural pain
565636|NCT00446875|Sucrose
565637|NCT00446875|Infant
565638|NCT00446862|Definition: Fabry disease
565639|NCT00446862|Definition: Progression
565640|NCT00446862|Definition: MDRD GFR
565641|NCT00446862|Definition: Chronic Kidney Disease
565642|NCT00446862|Definition: Proteinuria
565643|NCT00446862|Definition: Enzyme Replacement Therapy
565644|NCT00446862|Definition: Anti-proteinuric therapy
565645|NCT00446849|ulcerative colitis
565646|NCT00446849|compliance
565647|NCT00446849|mesalamine
565648|NCT00446849|clinical study
565649|NCT00446849|clinical trial
565650|NCT00446849|clinical research
565651|NCT00446849|maintenance
565652|NCT00446849|long term
565653|NCT00446849|uc study
565654|NCT00446849|uc trial
565655|NCT00446849|uc research
565656|NCT00446849|open label
565657|NCT00446849|once a day
565658|NCT00446849|once
565659|NCT00446849|daily
565660|NCT00446849|daily dosing
565661|NCT00446849|simple
565662|NCT00446849|oral
565663|NCT00446836|Adenocarcinoma of the prostate
565664|NCT00446836|Recurrent prostate cancer
565665|NCT00446836|Hormone refractory prostate cancer
565666|NCT00446823|Wound healing
565667|NCT00446823|Venous stasis ulcer
565668|NCT00446823|Cellulose dressing
565669|NCT00446823|Gauze dressing
565670|NCT00446823|Chronic wound
565671|NCT00446810|diabetes
565672|NCT00446810|endothelial dysfunction
565673|NCT00446810|benfotiamine
565674|NCT00446810|postprandial
565675|NCT00446810|autonomic neuropathy
565676|NCT00446810|advanced glycation end products
565677|NCT00446797|Ankle sprain, acute pain, NSAID, celecoxib,
565678|NCT00446758|Zinc
565679|NCT00446758|HIV
565680|NCT00446758|Infants
565681|NCT00446758|Children
565682|NCT00446758|Morbidity
565683|NCT00446758|Child health outcomes
565684|NCT00446758|treatment naive
565685|NCT00446758|treatment experienced
565686|NCT00446745|Nutritional and Metabolic Diseases
565687|NCT00446745|Insulin resistance
565688|NCT00446745|Energy Metabolisms
565689|NCT00446745|Skeletal muscle
565690|NCT00446745|Visceral Adipose Tissue
565691|NCT00446719|major depression
565692|NCT00446719|antidepressant
565693|NCT00446719|quality of life
565694|NCT00446719|anxiety
565695|NCT00446706|Intrinsic PEEP
565696|NCT00446680|Mannitol
565697|NCT00446680|Cystic Fibrosis
565698|NCT00446680|Mucolytic
565699|NCT00446680|Exacerbation
565700|NCT00446680|FEV1
565701|NCT00446680|Quality of Life
565702|NCT00446641|Infarction, Cerebral
565703|NCT00446641|Cilostazol
565704|NCT00446641|Aspirin Resistance
565705|NCT00446628|Non-pharmaceutical
565706|NCT00446628|influenza
565707|NCT00446628|pandemic
565708|NCT00446615|computer decision support
565709|NCT00446615|primary care
565710|NCT00446615|kidney disease, chronic
565711|NCT00446615|prescribing
565712|NCT00446602|PROCRIT
565713|NCT00446602|Epoetin alfa
565714|NCT00446602|Myelodysplastic Syndromes
565715|NCT00446602|MDS
565716|NCT00446576|Anemia
565717|NCT00446576|early renal insufficiency
565718|NCT00446563|Left ventricular hypertrophy, hypertension, valsartan, amlodipine
565719|NCT00446537|Skill Acquisition and the Evolution of Long Term Procedural Memory in participants with ADHD: The Effect of Methylphenidate
565720|NCT00446524|Hypertension, Valsartan, Amlodipine, high blood pressure
565721|NCT00446511|children
565722|NCT00446511|pediatrics
565723|NCT00446511|high blood pressure
565724|NCT00446511|hypertension
565725|NCT00446511|valsartan
565726|NCT00446511|enalapril
565727|NCT00446485|ginkgo biloba
565728|NCT00446485|cerebrovascular insufficiency
565729|NCT00446485|mild cognitive impairment
565730|NCT00446485|concentration impairment
565731|NCT00446472|diabetes mellitus
565732|NCT00446472|diabetic neuropathies
565733|NCT00446472|peripheral vascular diseases
565734|NCT00446459|CellCept
565735|NCT00446459|Dialysis
565736|NCT00446459|Kidney
565737|NCT00446459|Renal
565738|NCT00446459|Nephropathy
565739|NCT00446459|Glomerulonephropathy
565740|NCT00446459|Immunosuppression
565741|NCT00446459|Allograft
565742|NCT00446459|Compatibility
565743|NCT00446459|HLA
565744|NCT00446459|PRA
565745|NCT00446459|Transplant
565746|NCT00446459|Sensitization
565747|NCT00446459|Antibodies
565748|NCT00446459|Diabetes
565749|NCT00446459|Hypertension
565750|NCT00446459|Transplantation, Kidney
565751|NCT00446407|Depression
565752|NCT00446407|Primary Care
565753|NCT00446407|Developing Countries
565754|NCT00446407|Common mental disorders (depressive and anxiety disorders)
565755|NCT00446394|cognition disorder
565756|NCT00446394|functional ability
565757|NCT00446394|psychomotor function
565758|NCT00446394|psychopathology
565759|NCT00446394|quality of life
565760|NCT00446381|Proliferative Diabetic Retinopathy
565761|NCT00446381|Clinically Significant Diabetic Macular Edema
565762|NCT00446381|VEGF
565763|NCT00446381|Macugen (pegaptanib)
565764|NCT00446368|metastatic kidney cancer
565765|NCT00446368|metastatic renal cell cancer
565766|NCT00446355|C diff
565767|NCT00446355|antibiotics
565768|NCT00446342|leukemia
565769|NCT00446342|lymphoma
565770|NCT00446342|myeloma
565771|NCT00446342|non-Hodgkin's
565772|NCT00446342|CLL
565773|NCT00446342|MCL
565774|NCT00446342|MM
565775|NCT00446342|Phase 1
565776|NCT00446342|hematological malignancy
565777|NCT00446316|Pharmacokinetics
565778|NCT00446316|Healthy volunteers
565779|NCT00446316|No condition
565780|NCT00446316|Pharmacokinetics study
565781|NCT00446303|MDS
565782|NCT00446303|Myelodysplastic Syndromes
565783|NCT00446303|AML
565784|NCT00446303|Intensive chemotherapy
565785|NCT00446303|azacitidine
565786|NCT00446290|To determine maximal tolerated dose of DXO regimen
565787|NCT00446277|cataract surgery, endothelial cell, cell loss, diabetes
565788|NCT00446277|mellitus type II
565789|NCT00446264|diabetes
565790|NCT00446264|hypoglycemia
565791|NCT00446251|Dialysis
565792|NCT00446251|Kidney
565793|NCT00446251|Renal
565794|NCT00446251|Nephropathy
565795|NCT00446251|Glomerulonephropathy
565796|NCT00446251|Immunosuppression
565797|NCT00446251|Graft
565798|NCT00446251|Compatibility
565799|NCT00446251|Transplant
565800|NCT00446251|Diabetes
565801|NCT00446251|Hypertension
565802|NCT00446251|Transplantation, Kidney
565803|NCT00446238|Depression
565804|NCT00446238|Physical Illness
565805|NCT00446238|Inflammatory Bowel Disease
565806|NCT00446238|Cognitive Behavioral Therapy
565807|NCT00446225|Lung
565808|NCT00446225|cancer
565809|NCT00446225|EGFR
565810|NCT00446225|Epidermal Growth Factor Receptor
565811|NCT00446225|tyrosine kinase
565812|NCT00446225|Tarceva®
565813|NCT00446225|Erlotinib
565814|NCT00446212|anaesthesia
565815|NCT00446212|propofol
565816|NCT00446212|desflurane
565817|NCT00446212|dreaming
565818|NCT00446212|electroencephalography
565819|NCT00446199|Vasomotor symptom relief
565820|NCT00446199|Postmenopausal women
565821|NCT00446199|Severe to Moderate Vasomotor symptoms
565822|NCT00446173|Chronic Myelogenous Leukemia
565823|NCT00446173|Leukemia
565824|NCT00446173|Philadelphia (Ph) chromosome positive CML
565825|NCT00446173|Busulfan
565826|NCT00446173|Busulfex
565827|NCT00446173|Myleran
565828|NCT00446173|Cyclophosphamide
565829|NCT00446173|Cytoxan
565830|NCT00446173|Neosar
565831|NCT00446173|G-CSF
565832|NCT00446173|Filgrastim
565833|NCT00446173|Neupogen
565834|NCT00446173|GM-CSF
565835|NCT00446173|Sargramostim
565836|NCT00446173|Leukine
565837|NCT00446160|Congenital Heart Disease
565838|NCT00446160|Surgery
565839|NCT00446160|Adult
565840|NCT00446147|hand-foot syndrome
565841|NCT00446147|capecitabine
565842|NCT00446147|pyridoxine
565843|NCT00446147|prevention
565844|NCT00446134|Phase 2b Dose-Ranging Study
565845|NCT00446121|COPD
565846|NCT00446108|Pulmonary Stenosis
565847|NCT00446108|Right Ventricular Dilation
565848|NCT00446108|Right Heart Failure
565849|NCT00446108|Imaging
565850|NCT00446108|Tetralogy of Fallot
565851|NCT00446095|DLCL
565852|NCT00446095|Nodular lymphoma
565853|NCT00446095|Mantle cell lymphoma
565854|NCT00446095|Syk kinase
565855|NCT00446082|Refractory/ resistant carcinoid disease
565856|NCT00446082|acromegaly
565857|NCT00446082|adults
565858|NCT00446082|pasireotide LAR
565859|NCT00446082|somatostatin analogue
565860|NCT00446082|SOM230
565861|NCT00446082|pharmacokinetics
565862|NCT00446082|Refractory or resistant carcinoid disease and acromegaly
565863|NCT00446043|Acne Vulgaris
565864|NCT00446043|Adapalene
565865|NCT00446043|Benzoyl Peroxide
565866|NCT00446017|coronary artery bypass grafting
565867|NCT00446017|inotropes
565868|NCT00446017|metabolism
565869|NCT00446017|renal failure
565870|NCT00446004|Pharmacokinetics
565871|NCT00446004|Healthy volunteers
565872|NCT00446004|No condition
565873|NCT00446004|Pharmacokinetics study
565874|NCT00445978|Sickle Cell Disease
565875|NCT00445978|SCD
565876|NCT00445978|6R-BH4
565877|NCT00445978|BH4
565878|NCT00445978|sapropterin dihydrochloride
565879|NCT00445978|endothelial dysfunction
565880|NCT00445978|Nitric Oxide
565881|NCT00445978|NO
565882|NCT00445965|recurrent childhood medulloblastoma
565883|NCT00445965|untreated childhood medulloblastoma
565884|NCT00445965|adult supratentorial primitive neuroectodermal tumor (PNET)
565885|NCT00445965|recurrent childhood supratentorial primitive neuroectodermal tumor
565886|NCT00445965|untreated childhood supratentorial primitive neuroectodermal tumor
565887|NCT00445965|adult anaplastic astrocytoma
565888|NCT00445965|adult diffuse astrocytoma
565889|NCT00445965|adult pilocytic astrocytoma
565890|NCT00445965|adult subependymal giant cell astrocytoma
565891|NCT00445965|recurrent childhood subependymal giant cell astrocytoma
565892|NCT00445965|untreated childhood subependymal giant cell astrocytoma
565893|NCT00445965|recurrent childhood cerebellar astrocytoma
565894|NCT00445965|recurrent childhood cerebral astrocytoma
565895|NCT00445965|untreated childhood cerebellar astrocytoma
565896|NCT00445965|adult brain stem glioma
565897|NCT00445965|adult mixed glioma
565898|NCT00445965|childhood mixed glioma
565899|NCT00445965|recurrent childhood brain stem glioma
565900|NCT00445965|recurrent childhood visual pathway and hypothalamic glioma
565901|NCT00445965|recurrent childhood visual pathway glioma
565902|NCT00445965|untreated childhood brain stem glioma
565903|NCT00445965|untreated childhood visual pathway and hypothalamic glioma
565904|NCT00445965|untreated childhood visual pathway glioma
565905|NCT00445965|regional neuroblastoma
565906|NCT00445965|disseminated neuroblastoma
565907|NCT00445965|recurrent neuroblastoma
565908|NCT00445965|extraocular retinoblastoma
565909|NCT00445965|recurrent retinoblastoma
565910|NCT00445965|adult anaplastic ependymoma
565911|NCT00445965|adult ependymoblastoma
565912|NCT00445965|adult ependymoma
565913|NCT00445965|adult myxopapillary ependymoma
565914|NCT00445965|adult subependymoma
565915|NCT00445965|childhood infratentorial ependymoma
565916|NCT00445965|childhood supratentorial ependymoma
565917|NCT00445965|recurrent childhood ependymoma
565918|NCT00445965|childhood atypical teratoid/rhabdoid tumor
565919|NCT00445965|recurrent melanoma
565920|NCT00445965|stage IV melanoma
565921|NCT00445965|adult medulloblastoma
565922|NCT00445965|chondrosarcoma
565923|NCT00445965|metastatic osteosarcoma
565924|NCT00445965|recurrent osteosarcoma
565925|NCT00445965|metastatic childhood soft tissue sarcoma
565926|NCT00445965|ovarian sarcoma
565927|NCT00445965|recurrent childhood soft tissue sarcoma
565928|NCT00445965|stage III adult soft tissue sarcoma
565929|NCT00445965|stage IV adult soft tissue sarcoma
565930|NCT00445965|stage III uterine sarcoma
565931|NCT00445965|stage IV uterine sarcoma
565932|NCT00445965|previously treated childhood rhabdomyosarcoma
565933|NCT00445965|recurrent childhood rhabdomyosarcoma
565934|NCT00445965|adult anaplastic oligodendroglioma
565935|NCT00445965|adult desmoplastic small round cell tumor
565936|NCT00445965|adult oligodendroglioma
565937|NCT00445965|adult giant cell glioblastoma
565938|NCT00445965|adult gliosarcoma
565939|NCT00445965|tumors metastatic to brain
565940|NCT00445965|adult rhabdomyosarcoma
565941|NCT00445965|childhood oligodendroglioma
565942|NCT00445965|childhood desmoplastic small round cell tumor
565943|NCT00445965|extensive stage small cell lung cancer
565944|NCT00445965|intraocular retinoblastoma
565945|NCT00445965|recurrent adult brain tumor
565946|NCT00445965|recurrent adult soft tissue sarcoma
565947|NCT00445965|recurrent uterine sarcoma
565948|NCT00445965|small intestine leiomyosarcoma
565949|NCT00445965|recurrent small intestine cancer
565950|NCT00445965|recurrent small cell lung cancer
565951|NCT00445965|extraocular extension melanoma
565952|NCT00445965|recurrent intraocular melanoma
565953|NCT00445965|metastatic intraocular melanoma
565954|NCT00445965|iris melanoma
565955|NCT00445965|ciliary body and choroid melanoma, medium/large size
565956|NCT00445965|newly diagnosed childhood ependymoma
565957|NCT00445965|adult glioblastoma
565958|NCT00445965|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
565959|NCT00445965|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
565960|NCT00445965|recurrent childhood pineoblastoma
565961|NCT00445965|untreated childhood pineoblastoma
565962|NCT00445965|adult pineal gland astrocytoma
565963|NCT00445965|stage IIIA melanoma
565964|NCT00445965|stage IIIB melanoma
565965|NCT00445965|stage IIIC melanoma
565966|NCT00445965|recurrent childhood anaplastic astrocytoma
565967|NCT00445965|untreated childhood anaplastic astrocytoma
565968|NCT00445965|recurrent childhood anaplastic oligoastrocytoma
565969|NCT00445965|recurrent childhood anaplastic oligodendroglioma
565970|NCT00445965|untreated childhood anaplastic oligoastrocytoma
565971|NCT00445965|untreated childhood anaplastic oligodendroglioma
565972|NCT00445965|recurrent childhood giant cell glioblastoma
565973|NCT00445965|recurrent childhood glioblastoma
565974|NCT00445965|untreated childhood giant cell glioblastoma
565975|NCT00445965|untreated childhood glioblastoma
565976|NCT00445965|recurrent childhood gliosarcoma
565977|NCT00445965|untreated childhood gliosarcoma
565978|NCT00445965|recurrent childhood gliomatosis cerebri
565979|NCT00445965|untreated childhood gliomatosis cerebri
565980|NCT00445965|childhood high-grade cerebellar astrocytoma
565981|NCT00445965|childhood high-grade cerebral astrocytoma
565982|NCT00445952|breast cancer in situ
565983|NCT00445952|stage I breast cancer
565984|NCT00445952|stage II breast cancer
565985|NCT00445952|stage IIIA breast cancer
565986|NCT00445952|stage IIIB breast cancer
565987|NCT00445952|stage IIIC breast cancer
565988|NCT00445952|stage IV breast cancer
565989|NCT00445952|recurrent breast cancer
565990|NCT00445952|male breast cancer
565991|NCT00445952|recurrent non-small cell lung cancer
565992|NCT00445952|stage I non-small cell lung cancer
565993|NCT00445952|stage II non-small cell lung cancer
565994|NCT00445952|stage IIIA non-small cell lung cancer
565995|NCT00445952|stage IIIB non-small cell lung cancer
565996|NCT00445952|stage IV non-small cell lung cancer
565997|NCT00445952|extensive stage small cell lung cancer
565998|NCT00445952|recurrent colon cancer
565999|NCT00445952|stage I colon cancer
566000|NCT00445952|stage II colon cancer
566001|NCT00445952|stage III colon cancer
566002|NCT00445952|stage IV colon cancer
566003|NCT00445952|unspecified adult solid tumor, protocol specific
566004|NCT00445952|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
566005|NCT00445952|adult acute myeloid leukemia with inv(16)(p13;q22)
566006|NCT00445952|adult acute myeloid leukemia with t(15;17)(q22;q12)
566007|NCT00445952|adult acute myeloid leukemia with t(16;16)(p13;q22)
566008|NCT00445952|adult acute myeloid leukemia with t(8;21)(q22;q22)
566009|NCT00445952|stage IV chronic lymphocytic leukemia
566010|NCT00445952|accelerated phase chronic myelogenous leukemia
566011|NCT00445952|blastic phase chronic myelogenous leukemia
566012|NCT00445952|chronic myelomonocytic leukemia
566013|NCT00445952|chronic phase chronic myelogenous leukemia
566014|NCT00445952|noncontiguous stage II adult Burkitt lymphoma
566015|NCT00445952|noncontiguous stage II adult diffuse large cell lymphoma
566016|NCT00445952|noncontiguous stage II adult diffuse mixed cell lymphoma
566017|NCT00445952|noncontiguous stage II adult diffuse small cleaved cell lymphoma
566018|NCT00445952|noncontiguous stage II adult immunoblastic large cell lymphoma
566019|NCT00445952|noncontiguous stage II adult lymphoblastic lymphoma
566020|NCT00445952|noncontiguous stage II small lymphocytic lymphoma
566021|NCT00445952|noncontiguous stage II marginal zone lymphoma
566022|NCT00445952|noncontiguous stage II grade 1 follicular lymphoma
566520|NCT00445471|Autistic Disorder
566023|NCT00445952|noncontiguous stage II grade 2 follicular lymphoma
566024|NCT00445952|noncontiguous stage II grade 3 follicular lymphoma
566025|NCT00445952|noncontiguous stage II mantle cell lymphoma
566026|NCT00445952|stage III adult Burkitt lymphoma
566027|NCT00445952|stage III adult diffuse large cell lymphoma
566028|NCT00445952|stage III adult diffuse mixed cell lymphoma
566029|NCT00445952|stage III adult diffuse small cleaved cell lymphoma
566030|NCT00445952|stage III adult immunoblastic large cell lymphoma
566031|NCT00445952|stage III adult lymphoblastic lymphoma
566032|NCT00445952|stage III small lymphocytic lymphoma
566033|NCT00445952|stage III marginal zone lymphoma
566034|NCT00445952|stage III grade 1 follicular lymphoma
566035|NCT00445952|stage III grade 2 follicular lymphoma
566036|NCT00445952|stage III grade 3 follicular lymphoma
566037|NCT00445952|stage III mantle cell lymphoma
566038|NCT00445952|stage IV adult Burkitt lymphoma
566039|NCT00445952|stage IV adult diffuse large cell lymphoma
566040|NCT00445952|stage IV adult diffuse mixed cell lymphoma
566041|NCT00445952|stage IV adult diffuse small cleaved cell lymphoma
566042|NCT00445952|stage IV adult immunoblastic large cell lymphoma
566043|NCT00445952|stage IV adult lymphoblastic lymphoma
566044|NCT00445952|stage IV small lymphocytic lymphoma
566045|NCT00445952|stage IV marginal zone lymphoma
566046|NCT00445952|stage IV grade 1 follicular lymphoma
566047|NCT00445952|stage IV grade 2 follicular lymphoma
566048|NCT00445952|stage IV grade 3 follicular lymphoma
566049|NCT00445952|stage IV mantle cell lymphoma
566050|NCT00445952|recurrent adult Burkitt lymphoma
566051|NCT00445952|recurrent adult diffuse large cell lymphoma
566052|NCT00445952|recurrent adult diffuse mixed cell lymphoma
566053|NCT00445952|recurrent adult diffuse small cleaved cell lymphoma
566054|NCT00445952|recurrent adult Hodgkin lymphoma
566055|NCT00445952|recurrent adult immunoblastic large cell lymphoma
566056|NCT00445952|recurrent adult lymphoblastic lymphoma
566057|NCT00445952|recurrent cutaneous T-cell non-Hodgkin lymphoma
566058|NCT00445952|recurrent small lymphocytic lymphoma
566059|NCT00445952|recurrent marginal zone lymphoma
566060|NCT00445952|recurrent grade 1 follicular lymphoma
566061|NCT00445952|recurrent grade 2 follicular lymphoma
566062|NCT00445952|recurrent grade 3 follicular lymphoma
566063|NCT00445952|recurrent mantle cell lymphoma
566064|NCT00445952|recurrent mycosis fungoides/Sezary syndrome
566065|NCT00445952|stage I multiple myeloma
566066|NCT00445952|stage II multiple myeloma
566067|NCT00445952|stage III multiple myeloma
566068|NCT00445952|de novo myelodysplastic syndromes
566069|NCT00445952|myelodysplastic/myeloproliferative neoplasm, unclassifiable
566070|NCT00445952|previously treated myelodysplastic syndromes
566071|NCT00445952|secondary myelodysplastic syndromes
566072|NCT00445952|atypical chronic myeloid leukemia, BCR-ABL1 negative
566073|NCT00445952|stage II adult Hodgkin lymphoma
566074|NCT00445952|stage III adult Hodgkin lymphoma
566075|NCT00445952|stage IV adult Hodgkin lymphoma
566076|NCT00445952|contiguous stage II adult Burkitt lymphoma
566077|NCT00445952|stage I adult Burkitt lymphoma
566078|NCT00445952|contiguous stage II adult diffuse large cell lymphoma
566079|NCT00445952|contiguous stage II adult diffuse mixed cell lymphoma
566080|NCT00445952|contiguous stage II adult diffuse small cleaved cell lymphoma
566081|NCT00445952|contiguous stage II small lymphocytic lymphoma
566082|NCT00445952|contiguous stage II marginal zone lymphoma
566083|NCT00445952|stage I adult diffuse large cell lymphoma
566084|NCT00445952|stage I adult diffuse mixed cell lymphoma
566085|NCT00445952|stage I adult diffuse small cleaved cell lymphoma
566086|NCT00445952|stage I small lymphocytic lymphoma
566087|NCT00445952|stage I marginal zone lymphoma
566088|NCT00445952|contiguous stage II grade 1 follicular lymphoma
566089|NCT00445952|contiguous stage II grade 2 follicular lymphoma
566090|NCT00445952|contiguous stage II grade 3 follicular lymphoma
566091|NCT00445952|stage I grade 1 follicular lymphoma
566092|NCT00445952|stage I grade 2 follicular lymphoma
566093|NCT00445952|stage I grade 3 follicular lymphoma
566094|NCT00445952|contiguous stage II mantle cell lymphoma
566095|NCT00445952|stage I mantle cell lymphoma
566096|NCT00445952|contiguous stage II adult immunoblastic large cell lymphoma
566097|NCT00445952|stage I adult immunoblastic large cell lymphoma
566098|NCT00445952|contiguous stage II adult lymphoblastic lymphoma
566099|NCT00445952|stage I adult lymphoblastic lymphoma
566100|NCT00445952|refractory multiple myeloma
566101|NCT00445952|anaplastic large cell lymphoma
566102|NCT00445952|angioimmunoblastic T-cell lymphoma
566103|NCT00445952|recurrent adult T-cell leukemia/lymphoma
566104|NCT00445952|stage I adult T-cell leukemia/lymphoma
566105|NCT00445952|stage II adult T-cell leukemia/lymphoma
566106|NCT00445952|stage III adult T-cell leukemia/lymphoma
566107|NCT00445952|stage IV adult T-cell leukemia/lymphoma
566108|NCT00445952|stage I cutaneous T-cell non-Hodgkin lymphoma
566109|NCT00445952|stage II cutaneous T-cell non-Hodgkin lymphoma
566110|NCT00445952|stage III cutaneous T-cell non-Hodgkin lymphoma
566111|NCT00445952|stage IV cutaneous T-cell non-Hodgkin lymphoma
566112|NCT00445952|stage I mycosis fungoides/Sezary syndrome
566113|NCT00445952|stage II mycosis fungoides/Sezary syndrome
566114|NCT00445952|stage III mycosis fungoides/Sezary syndrome
566115|NCT00445952|stage IV mycosis fungoides/Sezary syndrome
566116|NCT00445952|chronic eosinophilic leukemia
566117|NCT00445952|primary myelofibrosis
566118|NCT00445952|chronic neutrophilic leukemia
566119|NCT00445952|essential thrombocythemia
566120|NCT00445952|polycythemia vera
566121|NCT00445952|relapsing chronic myelogenous leukemia
566122|NCT00445952|recurrent adult acute lymphoblastic leukemia
566123|NCT00445952|recurrent adult acute myeloid leukemia
566124|NCT00445952|untreated adult acute lymphoblastic leukemia
566125|NCT00445952|untreated adult acute myeloid leukemia
566126|NCT00445952|secondary acute myeloid leukemia
566127|NCT00445952|acute undifferentiated leukemia
566128|NCT00445952|refractory chronic lymphocytic leukemia
566129|NCT00445952|stage I chronic lymphocytic leukemia
566130|NCT00445952|stage II chronic lymphocytic leukemia
566131|NCT00445952|stage III chronic lymphocytic leukemia
566132|NCT00445952|refractory hairy cell leukemia
566133|NCT00445952|progressive hairy cell leukemia, initial treatment
566134|NCT00445952|prolymphocytic leukemia
566135|NCT00445952|recurrent adult grade III lymphomatoid granulomatosis
566136|NCT00445952|Waldenstrom macroglobulinemia
566137|NCT00445952|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
566138|NCT00445952|nodal marginal zone B-cell lymphoma
566139|NCT00445952|splenic marginal zone lymphoma
566140|NCT00445952|post-transplant lymphoproliferative disorder
566141|NCT00445952|extramedullary plasmacytoma
566142|NCT00445952|monoclonal gammopathy of undetermined significance
566143|NCT00445952|primary systemic amyloidosis
566144|NCT00445952|adult acute lymphoblastic leukemia in remission
566145|NCT00445952|adult acute myeloid leukemia in remission
566146|NCT00445952|adult grade III lymphomatoid granulomatosis
566147|NCT00445952|AIDS-related peripheral/systemic lymphoma
566148|NCT00445952|AIDS-related primary CNS lymphoma
566149|NCT00445952|intraocular lymphoma
566150|NCT00445952|meningeal chronic myelogenous leukemia
566151|NCT00445952|primary central nervous system non-Hodgkin lymphoma
566152|NCT00445952|stage I adult Hodgkin lymphoma
566153|NCT00445952|adult nasal type extranodal NK/T-cell lymphoma
566154|NCT00445952|infection
566155|NCT00445952|limited stage small cell lung cancer
566156|NCT00445952|T-cell large granular lymphocyte leukemia
566157|NCT00443950|Arthritis
566158|NCT00443950|Chinese
566159|NCT00443937|Kidney Transplantation
566160|NCT00443937|Renal Transplantation
566161|NCT00443937|Mycophenolate
566162|NCT00443937|Cyclosporine
566163|NCT00443937|Everolimus
566164|NCT00443924|Bilateral ocular hypertension or early primary open angle glaucoma
566165|NCT00443911|age-related macular degeneration, rheopheresis, lutein
566166|NCT00443898|Toenail fungus
566167|NCT00443898|Onychomycosis
566168|NCT00443898|Nail fungus
566169|NCT00443898|Toenail fungal infection
566170|NCT00443898|Tinea unguium
566171|NCT00443898|Dermatophytes
566172|NCT00443898|Foot dermatoses
566173|NCT00443885|meropenem
566174|NCT00443885|imipenem
566175|NCT00443885|gram negative organism
566176|NCT00443872|Parkinson's disease
566177|NCT00443872|Dopamine agonist adverse effects
566178|NCT00443872|MAO-B inhibitor
566179|NCT00443872|orally disintegrating selegiline
566180|NCT00443872|Zelapar
566181|NCT00443859|Persistent Pulmonary Hypertension
566182|NCT00443859|N-terminal pro brain natriuretic peptide
566183|NCT00443846|Prevention of Gastroenteritis due to rotavirus infection. And prevention of Invasive disease caused by Neisseria meningitidis serogroup C.
566184|NCT00443833|Thyrotoxicosis
566185|NCT00443833|genetic association study
566186|NCT00443833|periodic paralysis
566187|NCT00443833|whole genome scan
566188|NCT00443820|Toenail fungus
566189|NCT00443820|Onychomycosis
566190|NCT00443820|Nail fungus
566191|NCT00443820|Toenail fungal infection
566192|NCT00443820|Tinea unguium
566193|NCT00443820|Dermatophytes
566194|NCT00443820|Foot dermatoses
566195|NCT00443794|POLYCAP, Primary Prevention,CVD
566196|NCT00443781|low back pain, degenerative disc disease
566197|NCT00443768|Medication
566198|NCT00443768|Diagnosis
566199|NCT00443768|Community
566200|NCT00443755|Inflammatory cytokine
566201|NCT00443755|Cardiovascular Disease
566202|NCT00443755|Thrombotic factors
566203|NCT00443755|Dyslipidemia
566204|NCT00442754|dendritic cell
566205|NCT00442754|tumor vaccine
566206|NCT00442754|NSCLC
566207|NCT00442741|Cancer
566208|NCT00442741|EPO906
566209|NCT00442741|Patupilone
566210|NCT00442728|Functional electrical stimulation
566211|NCT00442728|muscular atrophy
566212|NCT00442728|intensive care
566213|NCT00445913|type 1 diabetes
566214|NCT00445913|dendritic cells
566215|NCT00445913|cell vaccine
566216|NCT00445913|safety
566217|NCT00445913|reversal
566218|NCT00445900|primary myelofibrosis
566219|NCT00445900|essential thrombocythemia
566220|NCT00445900|polycythemia vera
566221|NCT00445900|secondary myelofibrosis
566222|NCT00445887|ovarian epithelial cancer
566223|NCT00445874|allergic conjunctivitis, ophthalmology, multicenter, controlled
566224|NCT00445861|adenocarcinoma of the esophagus
566225|NCT00445861|squamous cell carcinoma of the esophagus
566226|NCT00445861|stage II esophageal cancer
566227|NCT00445861|stage III esophageal cancer
566228|NCT00445848|stage IIIB non-small cell lung cancer
566229|NCT00445848|stage IV non-small cell lung cancer
566230|NCT00445848|adenocarcinoma of the lung
566231|NCT00445835|coronary artery disease
566232|NCT00445835|myocardial infarction
566233|NCT00445835|atherothrombosis
566234|NCT00445835|atherosclerosis
566235|NCT00445822|CML
566236|NCT00445822|Children
566237|NCT00445822|Imatinib
566238|NCT00445822|bcr-abl
566239|NCT00445822|Response
566240|NCT00445822|Imatinib mesylate
566241|NCT00445809|Kidney
566242|NCT00445809|Renal
566243|NCT00445809|Cardiac Surgery with bypass
566244|NCT00445809|Cardiovascular surgery with cardiopulmonary bypass
566245|NCT00445783|lentigo maligna malignant melanoma
566246|NCT00445783|stage IV melanoma
566247|NCT00445783|acral lentiginous malignant melanoma
566248|NCT00445783|nodular malignant melanoma
566249|NCT00445783|stage IA melanoma
566250|NCT00445783|stage IB melanoma
566251|NCT00445783|stage IIA melanoma
566252|NCT00445783|stage IIB melanoma
566253|NCT00445783|stage IIC melanoma
566254|NCT00445783|stage IIIA melanoma
566255|NCT00445783|stage IIIB melanoma
566256|NCT00445783|stage IIIC melanoma
566257|NCT00445770|Rheumatoid Arthritis
566258|NCT00445770|Arthritis
566259|NCT00445757|stage I renal cell cancer
566260|NCT00445757|stage II renal cell cancer
566261|NCT00445731|poor performance status
566262|NCT00445731|unspecified adult solid tumor, protocol specific
566263|NCT00445731|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
566264|NCT00445731|adult acute myeloid leukemia with inv(16)(p13;q22)
566265|NCT00445731|adult acute myeloid leukemia with t(15;17)(q22;q12)
566266|NCT00445731|adult acute myeloid leukemia with t(16;16)(p13;q22)
566267|NCT00445731|adult acute myeloid leukemia with t(8;21)(q22;q22)
566268|NCT00445731|accelerated phase chronic myelogenous leukemia
566269|NCT00445731|adult acute lymphoblastic leukemia in remission
566270|NCT00445731|adult acute myeloid leukemia in remission
566271|NCT00445731|atypical chronic myeloid leukemia
566272|NCT00445731|blastic phase chronic myelogenous leukemia
566273|NCT00445731|chronic eosinophilic leukemia
566274|NCT00445731|chronic idiopathic myelofibrosis
566275|NCT00445731|chronic myelomonocytic leukemia
566276|NCT00445731|chronic neutrophilic leukemia
566277|NCT00445731|chronic phase chronic myelogenous leukemia
566278|NCT00445731|de novo myelodysplastic syndromes
566279|NCT00445731|disseminated neuroblastoma
566280|NCT00445731|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
566281|NCT00445731|myelodysplastic/myeloproliferative disease, unclassifiable
566282|NCT00445731|nodal marginal zone B-cell lymphoma
566283|NCT00445731|noncontiguous stage II adult Burkitt lymphoma
566284|NCT00445731|noncontiguous stage II adult diffuse large cell lymphoma
566285|NCT00445731|noncontiguous stage II adult diffuse mixed cell lymphoma
566286|NCT00445731|noncontiguous stage II adult diffuse small cleaved cell lymphoma
566287|NCT00445731|noncontiguous stage II adult immunoblastic large cell lymphoma
566288|NCT00445731|noncontiguous stage II adult lymphoblastic lymphoma
566289|NCT00445731|noncontiguous stage II grade 1 follicular lymphoma
566290|NCT00445731|noncontiguous stage II grade 2 follicular lymphoma
566291|NCT00445731|noncontiguous stage II grade 3 follicular lymphoma
566292|NCT00445731|noncontiguous stage II mantle cell lymphoma
566293|NCT00445731|noncontiguous stage II marginal zone lymphoma
566294|NCT00445731|noncontiguous stage II small lymphocytic lymphoma
566295|NCT00445731|poor prognosis metastatic gestational trophoblastic tumor
566296|NCT00445731|previously treated myelodysplastic syndromes
566297|NCT00445731|recurrent adult acute lymphoblastic leukemia
566298|NCT00445731|recurrent adult acute myeloid leukemia
566299|NCT00445731|recurrent adult Burkitt lymphoma
566300|NCT00445731|recurrent adult Hodgkin lymphoma
566301|NCT00445731|recurrent adult diffuse large cell lymphoma
566302|NCT00445731|recurrent adult diffuse mixed cell lymphoma
566303|NCT00445731|recurrent adult diffuse small cleaved cell lymphoma
566304|NCT00445731|recurrent adult immunoblastic large cell lymphoma
566305|NCT00445731|recurrent adult lymphoblastic lymphoma
566306|NCT00445731|recurrent breast cancer
566307|NCT00445731|recurrent cutaneous T-cell non-Hodgkin lymphoma
566308|NCT00445731|recurrent grade 1 follicular lymphoma
566309|NCT00445731|recurrent grade 2 follicular lymphoma
566310|NCT00445731|recurrent grade 3 follicular lymphoma
566311|NCT00445731|recurrent mantle cell lymphoma
566312|NCT00445731|recurrent marginal zone lymphoma
566313|NCT00445731|recurrent mycosis fungoides/Sezary syndrome
566314|NCT00445731|recurrent neuroblastoma
566315|NCT00445731|recurrent ovarian epithelial cancer
566316|NCT00445731|recurrent ovarian germ cell tumor
566317|NCT00445731|recurrent small lymphocytic lymphoma
566318|NCT00445731|recurrent malignant testicular germ cell tumor
566319|NCT00445731|refractory chronic lymphocytic leukemia
566320|NCT00445731|refractory hairy cell leukemia
566321|NCT00445731|refractory multiple myeloma
566322|NCT00445731|relapsing chronic myelogenous leukemia
566323|NCT00445731|secondary acute myeloid leukemia
566324|NCT00445731|secondary myelodysplastic syndromes
566325|NCT00445731|splenic marginal zone lymphoma
566326|NCT00445731|stage I multiple myeloma
566327|NCT00445731|stage II multiple myeloma
566328|NCT00445731|stage II ovarian epithelial cancer
566329|NCT00445731|stage III adult Burkitt lymphoma
566330|NCT00445731|stage III adult Hodgkin lymphoma
566331|NCT00445731|stage III adult diffuse large cell lymphoma
566332|NCT00445731|stage III adult diffuse mixed cell lymphoma
566333|NCT00445731|stage III adult diffuse small cleaved cell lymphoma
566334|NCT00445731|stage III adult immunoblastic large cell lymphoma
566335|NCT00445731|stage III adult lymphoblastic lymphoma
566336|NCT00445731|stage III chronic lymphocytic leukemia
566337|NCT00445731|stage III grade 1 follicular lymphoma
566338|NCT00445731|stage III grade 2 follicular lymphoma
566339|NCT00445731|stage III grade 3 follicular lymphoma
566340|NCT00445731|stage III mantle cell lymphoma
566341|NCT00445731|stage III marginal zone lymphoma
566342|NCT00445731|stage III multiple myeloma
566343|NCT00445731|stage III ovarian epithelial cancer
566344|NCT00445731|stage III small lymphocytic lymphoma
566345|NCT00445731|stage III malignant testicular germ cell tumor
566346|NCT00445731|stage IIIA breast cancer
566347|NCT00445731|stage IIIB breast cancer
566348|NCT00445731|stage IIIC breast cancer
566349|NCT00445731|stage IV adult Burkitt lymphoma
566350|NCT00445731|stage IV adult Hodgkin lymphoma
566351|NCT00445731|stage IV adult diffuse large cell lymphoma
566352|NCT00445731|stage IV adult diffuse mixed cell lymphoma
566353|NCT00445731|stage IV adult diffuse small cleaved cell lymphoma
566354|NCT00445731|stage IV adult immunoblastic large cell lymphoma
566355|NCT00445731|stage IV adult lymphoblastic lymphoma
566356|NCT00445731|stage IV breast cancer
566357|NCT00445731|stage IV chronic lymphocytic leukemia
566358|NCT00445731|stage IV grade 1 follicular lymphoma
566359|NCT00445731|stage IV grade 2 follicular lymphoma
566360|NCT00445731|stage IV grade 3 follicular lymphoma
566361|NCT00445731|stage IV mantle cell lymphoma
566362|NCT00445731|stage IV marginal zone lymphoma
566363|NCT00445731|stage IV ovarian epithelial cancer
566364|NCT00445731|stage IV small lymphocytic lymphoma
566365|NCT00445679|major depressive disorder
566366|NCT00445679|MDD
566367|NCT00445679|depression
566368|NCT00445653|Barrett esophagus
566369|NCT00445627|Type 2 Diabetes
566370|NCT00445627|Obesity
566371|NCT00445627|Overweight
566372|NCT00445614|nutrition
566373|NCT00445614|cardiovascular risk
566374|NCT00445614|inflammation
566375|NCT00445614|vascular function
566376|NCT00445601|transitional cell carcinoma of the bladder
566377|NCT00445601|stage 0 bladder cancer
566378|NCT00445601|stage I bladder cancer
566379|NCT00445601|recurrent bladder cancer
566380|NCT00445575|fibrous dysplasia of bone
566381|NCT00445575|Mac Cune Albright syndrome
566382|NCT00445575|bisphosphonates
566383|NCT00445575|risedronate
566384|NCT00445562|male breast cancer
566385|NCT00445562|recurrent breast cancer
566386|NCT00445562|stage IA breast cancer
566387|NCT00445562|stage IB breast cancer
566388|NCT00445562|stage II breast cancer
566389|NCT00445562|stage IIIA breast cancer
566390|NCT00445562|stage IIIB breast cancer
566391|NCT00445562|stage IIIC breast cancer
566392|NCT00445562|stage IV breast cancer
566393|NCT00445549|Ovarian
566394|NCT00445549|VEGFR2
566395|NCT00445549|EGFR
566396|NCT00445549|Angiogenesis
566397|NCT00445549|Tyrosine Kinase
566398|NCT00445549|Protein Phosphorylation
566399|NCT00445549|Vandetanib
566400|NCT00445549|Ovarian Cancer
566401|NCT00445549|Fallopian Tube Cancer
566402|NCT00445549|Peritoneal Cancer
566403|NCT00445523|Advanced renal cancer
566404|NCT00445523|metastatic renal cancer
566405|NCT00445523|RCC
566406|NCT00445523|kidney cancer
566407|NCT00445523|M3thodist
566408|NCT00445510|GSK256066,
566409|NCT00445510|allergen,
566410|NCT00445510|challenge,
566411|NCT00445510|repeat dose,
566412|NCT00445510|AMP,
566413|NCT00445510|mild asthmatics
566414|NCT00445497|psychosocial effects of cancer and its treatment
566415|NCT00445497|anaplastic large cell lymphoma
566416|NCT00445497|angioimmunoblastic T-cell lymphoma
566417|NCT00445497|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
566418|NCT00445497|intraocular lymphoma
566419|NCT00445497|nodal marginal zone B-cell lymphoma
566420|NCT00445497|primary central nervous system non-Hodgkin lymphoma
566421|NCT00445497|primary central nervous system Hodgkin lymphoma
566422|NCT00445497|recurrent adult Burkitt lymphoma
566423|NCT00445497|recurrent adult diffuse large cell lymphoma
566424|NCT00445497|recurrent adult diffuse mixed cell lymphoma
566425|NCT00445497|recurrent adult diffuse small cleaved cell lymphoma
566426|NCT00445497|recurrent adult Hodgkin lymphoma
566427|NCT00445497|recurrent adult immunoblastic large cell lymphoma
566428|NCT00445497|recurrent adult lymphoblastic lymphoma
566429|NCT00445497|recurrent cutaneous T-cell non-Hodgkin lymphoma
566430|NCT00445497|recurrent grade 1 follicular lymphoma
566431|NCT00445497|recurrent grade 2 follicular lymphoma
566432|NCT00445497|recurrent grade 3 follicular lymphoma
566433|NCT00445497|recurrent mantle cell lymphoma
566434|NCT00445497|recurrent marginal zone lymphoma
566435|NCT00445497|recurrent mycosis fungoides/Sezary syndrome
566436|NCT00445497|recurrent small lymphocytic lymphoma
566437|NCT00445497|small intestine lymphoma
566438|NCT00445497|splenic marginal zone lymphoma
566439|NCT00445497|stage III adult Burkitt lymphoma
566440|NCT00445497|stage III adult diffuse large cell lymphoma
566441|NCT00445497|stage III adult diffuse mixed cell lymphoma
566442|NCT00445497|stage III adult diffuse small cleaved cell lymphoma
566443|NCT00445497|stage III adult Hodgkin lymphoma
566444|NCT00445497|stage III adult immunoblastic large cell lymphoma
566445|NCT00445497|stage III adult lymphoblastic lymphoma
566446|NCT00445497|stage III adult T-cell leukemia/lymphoma
566447|NCT00445497|stage III cutaneous T-cell non-Hodgkin lymphoma
566448|NCT00445497|stage III grade 1 follicular lymphoma
566449|NCT00445497|stage III grade 2 follicular lymphoma
566450|NCT00445497|stage III grade 3 follicular lymphoma
566451|NCT00445497|stage III mantle cell lymphoma
566452|NCT00445497|stage III marginal zone lymphoma
566453|NCT00445497|stage III mycosis fungoides/Sezary syndrome
566454|NCT00445497|stage III small lymphocytic lymphoma
566455|NCT00445497|stage IV adult Burkitt lymphoma
566456|NCT00445497|stage IV adult diffuse large cell lymphoma
566457|NCT00445497|stage IV adult diffuse mixed cell lymphoma
566458|NCT00445497|stage IV adult diffuse small cleaved cell lymphoma
566459|NCT00445497|stage IV adult Hodgkin lymphoma
566460|NCT00445497|stage IV adult immunoblastic large cell lymphoma
566461|NCT00445497|stage IV adult lymphoblastic lymphoma
566462|NCT00445497|stage IV adult T-cell leukemia/lymphoma
566463|NCT00445497|stage IV cutaneous T-cell non-Hodgkin lymphoma
566464|NCT00445497|stage IV grade 1 follicular lymphoma
566465|NCT00445497|stage IV grade 2 follicular lymphoma
566466|NCT00445497|stage IV grade 3 follicular lymphoma
566467|NCT00445497|stage IV mantle cell lymphoma
566468|NCT00445497|stage IV marginal zone lymphoma
566469|NCT00445497|stage IV mycosis fungoides/Sezary syndrome
566470|NCT00445497|stage IV small lymphocytic lymphoma
566471|NCT00445497|Waldenström macroglobulinemia
566472|NCT00445497|unspecified adult solid tumor, protocol specific
566473|NCT00445497|neutropenia
566474|NCT00445497|stage I adult Burkitt lymphoma
566475|NCT00445497|stage I adult diffuse large cell lymphoma
566476|NCT00445497|stage I adult diffuse mixed cell lymphoma
566477|NCT00445497|stage I adult diffuse small cleaved cell lymphoma
566478|NCT00445497|stage I adult Hodgkin lymphoma
566479|NCT00445497|stage I adult immunoblastic large cell lymphoma
566480|NCT00445497|stage I adult lymphoblastic lymphoma
566481|NCT00445497|stage II adult Hodgkin lymphoma
566482|NCT00445497|stage I mycosis fungoides/Sezary syndrome
566483|NCT00445497|stage II mycosis fungoides/Sezary syndrome
566484|NCT00445497|stage I cutaneous T-cell non-Hodgkin lymphoma
566485|NCT00445497|stage II cutaneous T-cell non-Hodgkin lymphoma
566486|NCT00445497|contiguous stage II adult Burkitt lymphoma
566487|NCT00445497|contiguous stage II adult diffuse large cell lymphoma
566488|NCT00445497|contiguous stage II adult diffuse mixed cell lymphoma
566489|NCT00445497|contiguous stage II adult diffuse small cleaved cell lymphoma
566490|NCT00445497|contiguous stage II adult immunoblastic large cell lymphoma
566491|NCT00445497|contiguous stage II adult lymphoblastic lymphoma
566492|NCT00445497|contiguous stage II grade 1 follicular lymphoma
566493|NCT00445497|contiguous stage II grade 2 follicular lymphoma
566494|NCT00445497|contiguous stage II grade 3 follicular lymphoma
566495|NCT00445497|contiguous stage II mantle cell lymphoma
566496|NCT00445497|contiguous stage II marginal zone lymphoma
566497|NCT00445497|contiguous stage II small lymphocytic lymphoma
566498|NCT00445497|noncontiguous stage II adult Burkitt lymphoma
566499|NCT00445497|noncontiguous stage II adult diffuse large cell lymphoma
566500|NCT00445497|noncontiguous stage II adult diffuse mixed cell lymphoma
566501|NCT00445497|noncontiguous stage II adult diffuse small cleaved cell lymphoma
566502|NCT00445497|noncontiguous stage II adult immunoblastic large cell lymphoma
566503|NCT00445497|noncontiguous stage II adult lymphoblastic lymphoma
566504|NCT00445497|noncontiguous stage II grade 1 follicular lymphoma
566505|NCT00445497|noncontiguous stage II grade 2 follicular lymphoma
566506|NCT00445497|noncontiguous stage II grade 3 follicular lymphoma
566507|NCT00445497|noncontiguous stage II mantle cell lymphoma
566508|NCT00445497|noncontiguous stage II marginal zone lymphoma
566509|NCT00445497|noncontiguous stage II small lymphocytic lymphoma
566510|NCT00445497|recurrent adult T-cell leukemia/lymphoma
566511|NCT00445497|stage I adult T-cell leukemia/lymphoma
566512|NCT00445497|stage II adult T-cell leukemia/lymphoma
566513|NCT00445497|adult grade III lymphomatoid granulomatosis
566514|NCT00445497|recurrent adult grade III lymphomatoid granulomatosis
566515|NCT00445497|adult nasal type extranodal NK/T-cell lymphoma
566516|NCT00445484|stage II multiple myeloma
566517|NCT00445484|stage III multiple myeloma
566518|NCT00445484|refractory multiple myeloma
566519|NCT00445471|Autism Spectrum Disorder
566521|NCT00445471|Pervasive Developmental Disorder
566522|NCT00445458|cancer
566523|NCT00445458|HKI-272
566524|NCT00445458|neratinib
566525|NCT00445458|paclitaxel
566526|NCT00445458|Taxol
566527|NCT00445458|breast cancer
566528|NCT00445445|stage I breast cancer
566529|NCT00445445|stage II breast cancer
566530|NCT00445445|stage IIIA breast cancer
566531|NCT00445445|stage IIIB breast cancer
566532|NCT00445445|stage IIIC breast cancer
566533|NCT00445445|stage IV breast cancer
566534|NCT00445445|recurrent breast cancer
566535|NCT00445445|breast cancer in situ
566536|NCT00445419|Hepatitis C
566537|NCT00445419|Liver disease
566538|NCT00445419|Viral infection
566539|NCT00445419|Virosome
566540|NCT00445419|Vaccine
566541|NCT00445419|therapeutic vaccine
566542|NCT00445419|Chronic hepatitis C virus infection
566543|NCT00445406|recurrent breast cancer
566544|NCT00445406|stage IV breast cancer
566545|NCT00445393|Observation
566546|NCT00445393|Mental health
566547|NCT00445393|Scoliosis
566548|NCT00445393|Screening
566549|NCT00445393|Adolescent idiopathic scoliosis
566550|NCT00445367|Multiple Sclerosis
566551|NCT00445367|Clinically Isolated Syndrome
566552|NCT00445367|Transverse Myelitis
566553|NCT00445367|Neuromyelitis Optica
566554|NCT00445367|Acute Disseminated Encephalomyelitis
566555|NCT00445367|Optic Neuritis
566556|NCT00445367|Repository
566557|NCT00445367|Biobank
566558|NCT00445354|cinnamon
566559|NCT00445354|diabetes
566560|NCT00445354|hemoglobin a1c
566561|NCT00445341|Microarray
566562|NCT00445341|Proteomics
566563|NCT00445341|Hybrid Schedule
566564|NCT00445341|Tumor Lysis Syndrome
566565|NCT00445341|Cyclin D1
566566|NCT00445341|Lymphoma
566567|NCT00445341|Mantle Cell Lymphoma
566568|NCT00445341|MCL
566569|NCT00445341|Diffuse Large B-Cell Lymphoma
566570|NCT00445341|DLBCL
566571|NCT00445328|hospitalised acutely medically ill patients; Venous Thromboembolism, Infection, Inflammatory Bowel Diseases, Heart Failure, Congestive, Sciatica
566572|NCT00445302|AMD3100
566573|NCT00445289|mechanical ventilation
566574|NCT00445289|ventilator weaning
566575|NCT00445289|closed-loop
566576|NCT00445289|ventilation time
566577|NCT00445276|Osteoarthritis
566578|NCT00445276|Knee
566579|NCT00445276|Diacerein
566580|NCT00445276|Painful osteoarthritis
566581|NCT00445276|Clinical trial
566582|NCT00445263|CORONARY DISEASE
566583|NCT00445250|Calcipotriol
566584|NCT00445250|Breast
566585|NCT00445250|Cancer
566586|NCT00445250|Radiotherapy
566587|NCT00445250|Radiodermatitis in Breast Cancer
566588|NCT00445237|major depression
566589|NCT00445237|TMS
566590|NCT00445224|Knee pain
566591|NCT00445224|Rehabilitation
566592|NCT00445211|Intraaortic balloon pumping
566593|NCT00445211|Heparin
566594|NCT00445211|Limb ischemia
566595|NCT00445211|Bleeding
566596|NCT00445198|SCLC
566597|NCT00445185|Dialysis
566598|NCT00445185|Pre-dialysis
566599|NCT00445185|Hepatitis B vaccine
566600|NCT00445185|vaccine
566601|NCT00445172|Amyotrophic Lateral Sclerosis
566602|NCT00445172|Motor Neurons
566603|NCT00445172|Muscular Atrophy
566604|NCT00445159|UT-15C SR, Peripheral Vascular Disease, treprostinil
566605|NCT00445146|Phase 2
566606|NCT00445146|Open-label
566607|NCT00445146|Rollover
566608|NCT00445146|Integrase Inhibitor
566609|NCT00445146|Antiretroviral Agents
566610|NCT00445146|Highly Active Antiretroviral Activity
566611|NCT00445146|HAART
566612|NCT00445146|HIV, HIV-1, AIDS virus, Human Immunodeficiency Virus
566613|NCT00445146|Acquired Immune Deficiency Syndrome Virus
566614|NCT00445146|treatment experienced
566615|NCT00445133|Neck Pain/Lumbar pain/Magnets/sleep deficiency/ insomnia/
566616|NCT00445120|Vernal keratoconjunctivitis
566617|NCT00445120|probiotic
566618|NCT00445120|Lactobacillus Rhamnosus GG
566619|NCT00445120|Children
566620|NCT00445120|Clinical trial
566621|NCT00445081|atopic dermatitis
566622|NCT00445081|prednisolone
566623|NCT00445081|ciclosporine
566624|NCT00445081|SCORAD
566625|NCT00445081|DLQI
566626|NCT00445081|QALY
566627|NCT00445081|WLQ
566628|NCT00445068|Multiple myeloma
566629|NCT00445068|adults
566630|NCT00445068|LBH589
566631|NCT00445068|refractory
566632|NCT00445055|Thyroidectomy
566633|NCT00445055|Nausea
566634|NCT00445055|Vomiting
566635|NCT00445055|Droperidol
566636|NCT00445042|Metastatic Renal Cell Carcinoma
566637|NCT00445042|Metastatic RCC
566638|NCT00445042|Kidney Cancer
566639|NCT00445042|M3thodist
566640|NCT00445029|Allergic contact dermatitis
566641|NCT00445029|para-phenylenediamine
566642|NCT00445029|effector cells
566643|NCT00445029|regulatory cells
566644|NCT00445029|pathophysiology
566645|NCT00445016|peripheral regional anesthesia
566646|NCT00445016|nerve damage
566647|NCT00445016|adverse effects
566648|NCT00445016|neurologic complication
566649|NCT00445016|neuropathy
566650|NCT00445003|Diabetic Retinopathy
566651|NCT00445003|Diabetic Macular Edema
566652|NCT00445003|Lucentis
566653|NCT00445003|Ranibizumab
566654|NCT00445003|Triamcinolone
566655|NCT00445003|Panretinal Photocoagulation
566656|NCT00445003|Combination Therapy
566657|NCT00445003|pdr
566658|NCT00444990|Lumbar pain
566659|NCT00444990|magnets
566660|NCT00444990|Reduce low back pain
566661|NCT00444977|HIV positive persons
566662|NCT00444977|Not received oral health care in the preceding 12 months.
566663|NCT00444977|treatment naive
566664|NCT00444977|treatment experienced
566665|NCT00444951|N meningitidis
566666|NCT00442780|early Parkinson's Disease
566667|NCT00442780|MOBILE
566668|NCT00442780|BIIB014
566669|NCT00442767|pediatric
566670|NCT00442767|juvenile
566671|NCT00442767|diabetes mellitus
566672|NCT00442767|Pediatric type 1 diabetes mellitus
566673|NCT00444912|AMD3100
566674|NCT00444912|stem cell mobilization
566675|NCT00444912|autologous transplant
566676|NCT00444912|Non-Hodgkin Lymphoma
566677|NCT00444912|Hodgkin Disease
566678|NCT00444899|Intensive treatment
566679|NCT00444899|dietician
566680|NCT00444886|Thoracic Outlet Syndrome (TOS)
566681|NCT00444886|Botulinum Toxin
566682|NCT00444886|Botox
566683|NCT00444886|Pain
566684|NCT00444873|Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)
566685|NCT00444847|AIDS
566686|NCT00444847|HIV
566687|NCT00444847|Hyperbaric Chamber
566688|NCT00444847|treatment experienced
566689|NCT00444821|AAA
566690|NCT00444821|Aneurysm
566691|NCT00444821|AneuRx
566692|NCT00444821|Talent
566693|NCT00444808|Rib fracture
566694|NCT00444808|Pain
566695|NCT00444808|intranasal calcitonin
566696|NCT00444795|SUTENE
566697|NCT00444795|post-marketing surveillance
566698|NCT00444795|GIST
566699|NCT00444795|RCC
566700|NCT00444795|Korea
566701|NCT00444782|Advanced Carcinoma, Hepatocellular
566702|NCT00444769|analgesia
566703|NCT00444769|post-operative pain
566704|NCT00444769|GW842166
566705|NCT00444769|non-cannabinoid agonist
566706|NCT00444769|third molar tooth extraction
566707|NCT00444756|local anesthesia
566708|NCT00444756|analgesia
566709|NCT00444756|peripheral IV
566710|NCT00444756|Local anesthesia prior to peripheral IV insertion
566711|NCT00444730|Prostate Cancer
566712|NCT00444730|Prostatectomy
566713|NCT00444730|Pelvic pain
566714|NCT00444730|urgency
566715|NCT00444730|incontinence
566716|NCT00444730|frequency
566717|NCT00444717|statin
566718|NCT00444717|metabolic syndrome
566719|NCT00444717|oxidative stress
566720|NCT00444717|inflammation
566721|NCT00444691|synovitis score
566722|NCT00444691|sensitivity to change
566723|NCT00444691|clinical examination
566724|NCT00444691|ultra-sonography
566725|NCT00444678|Previously untreated metastatic colorectal cancer
566726|NCT00444678|Metastatic Colorectal Cancer
566727|NCT00444678|combined therapy
566728|NCT00444678|biologics therapy
566729|NCT00444678|antibody
566730|NCT00444678|chemotherapy
566731|NCT00444678|EGFR
566732|NCT00444665|Glaucoma
566733|NCT00444652|Thromboprophylaxis
566734|NCT00444652|Bariatric surgery
566735|NCT00444652|prevention of venous thromboembolism in bariatric surgery
566736|NCT00444626|nasolabial folds
566737|NCT00444626|facial wrinkles
566738|NCT00444613|Amyotrophic Lateral Sclerosis (ALS)
566739|NCT00444613|motor neurons
566740|NCT00444613|muscular atrophy
566741|NCT00444613|Lou Gehrig's Disease
566742|NCT00444600|Diabetic Retinopathy
566743|NCT00444600|Diabetic Macular Edema
566744|NCT00444600|Lucentis
566745|NCT00444600|Ranibizumab
566746|NCT00444600|Triamcinolone
566747|NCT00444600|Laser photocoagulation
566748|NCT00444600|Combination Therapy
566749|NCT00444574|Attention Deficit Hyperactivity Disorder (ADHD)
566750|NCT00444561|pramlintide
566751|NCT00444561|Symlin
566752|NCT00444561|Amylin
566753|NCT00444548|Equipment
566754|NCT00444548|Supplies
566755|NCT00444535|VEGF
566756|NCT00444535|Tyrosine kinase
566757|NCT00444535|ErbB2
566758|NCT00444535|Her2-neu
566759|NCT00444535|metastatic breast cancer
566760|NCT00444535|EGFR
566761|NCT00444535|ErbB1
566762|NCT00444535|bevacizumab
566763|NCT00444535|lapatinib
566764|NCT00444522|Panic attacks, Staccato® Alprazolam
566765|NCT00444509|Asthmatic Patients
566766|NCT00444470|tranexamic acid
566767|NCT00444470|safety
566768|NCT00444470|efficacy
566769|NCT00444470|spine surgery
566770|NCT00444470|spinal fusion and decompression
566771|NCT00444470|adult
566772|NCT00444470|perioperative
566773|NCT00444470|blood loss
566774|NCT00444470|bleeding
566775|NCT00444470|blood transfusion
566776|NCT00444457|Vaccine
566777|NCT00444457|Infants
566778|NCT00444457|Pneumococcal Conjugate Vaccines
566779|NCT00444457|Vaccines, Pneumococcal
566780|NCT00444444|Autoimmune pancreatitis, HLA, relapse, Sequence-based typing
566781|NCT00444418|Drinking
566782|NCT00444418|Alcohol problems
566783|NCT00444418|Alcoholism
566784|NCT00444418|Gay men
566785|NCT00444418|Bisexual men
566786|NCT00444418|Moderation-oriented treatment
566787|NCT00444418|Controlled drinking
566788|NCT00444418|Non-abstinence based treatment
566789|NCT00444405|lumbar
566790|NCT00444405|disc
566791|NCT00444405|herniation
566792|NCT00444405|discectomy
566793|NCT00444405|fusion
566794|NCT00444405|spine
566795|NCT00444392|Obese
566796|NCT00444392|type 2 Diabetes Mellitus
566797|NCT00444392|Gastric Bypass Surgery
566798|NCT00444392|Risk of CVD
566799|NCT00444379|Kaposi's sarcoma
566800|NCT00444379|KSHV
566801|NCT00444379|AIDS
566802|NCT00444379|HHV-8
566803|NCT00444379|treatment naive
566804|NCT00444327|single nucleotide polymorphism
566805|NCT00444301|Heart failure
566806|NCT00444301|Pain
566807|NCT00444301|Symptoms
566808|NCT00444301|Advanced heart failure
566809|NCT00444301|Pain frequency, severity, location, treatments
566810|NCT00444301|Shortness of breath, anxiety, depression, cognitive function
566811|NCT00444301|Social support, other conditions and illnesses
566812|NCT00444288|Cystic Ovaries
566813|NCT00444288|Hyperandrogenism
566814|NCT00444288|Anovulation
566815|NCT00444288|Concordance Rates
566816|NCT00444288|Baseline Heritability
566817|NCT00444288|Polycystic Ovary Syndrome
566818|NCT00444288|POS
566819|NCT00444275|Gastroesophageal Reflux Disease
566820|NCT00444275|Acid Reflux
566821|NCT00444262|Hemodynamic optimisation
566822|NCT00444262|Esophageal Doppler
566823|NCT00444262|Hydroxy ethyl starch
566824|NCT00444262|Hip fracture
566825|NCT00444262|Outcome
566826|NCT00444262|Elderly subjects (≥ 70 year old)
566827|NCT00444262|General anesthesia
566828|NCT00444249|age-related macular degeneration
566829|NCT00444249|melatonin
566830|NCT00444249|blue-light filter
566831|NCT00444236|asthma
566832|NCT00444236|GERD
566833|NCT00444236|reflux
566834|NCT00444236|exercise
566835|NCT00444223|stage IIIA non-small cell lung cancer
566836|NCT00444223|stage IIIB non-small cell lung cancer
566837|NCT00444223|stage IV non-small cell lung cancer
566838|NCT00444184|travoprost/timolol fixed combination
566839|NCT00444171|critically ill
566840|NCT00444171|insulin resistance
566841|NCT00444171|intensive insulin therapy
566842|NCT00444171|computer algorithm
566843|NCT00444158|opioids
566844|NCT00444158|chronic pain
566845|NCT00444132|clopidogrel
566846|NCT00444132|platelets
566847|NCT00444132|acute coronary syndrome
566848|NCT00444132|percutaneous coronary intervention
566849|NCT00444119|adrenal insufficiency
566850|NCT00444119|subjective health status
566851|NCT00444119|quality of life
566852|NCT00444119|adrenal crisis
566853|NCT00444119|hormone replacement
566854|NCT00444119|DHEA
566855|NCT00444106|Malaria
566856|NCT00444106|hearing
566857|NCT00444106|co-artemether
566858|NCT00444106|auditory
566859|NCT00444106|Plasmodium falciparum
566860|NCT00444106|marsh fever
566861|NCT00444106|Plasmodium infections
566862|NCT00444106|remittent fever
566863|NCT00444106|paludism
566864|NCT00444106|artemether
566865|NCT00444106|artemisinins
566866|NCT00444106|benflumetol
566867|NCT00444106|lumefantrine
566868|NCT00444093|radiation therapy
566869|NCT00444093|diarrhea
566870|NCT00444093|enteritis
566871|NCT00444093|supportive therapy
566872|NCT00444093|therapy associated diarrhea
566873|NCT00444093|therapy associated enteritis
566874|NCT00444093|radiation therapy of the small pelvis
566875|NCT00444080|Ex-PRESS
566876|NCT00444080|TRABECULECTOMY
566877|NCT00444067|Prevention of CSF leak
566878|NCT00444054|Diet
566879|NCT00444054|Cancer
566880|NCT00444054|Alternative
566881|NCT00444054|Breast
566882|NCT00444054|Colon
566883|NCT00444054|Cervix
566884|NCT00444054|Uterus
566885|NCT00444054|Ovary
566886|NCT00444054|Metastatic
566887|NCT00444054|Nutrition
566888|NCT00444054|Carbohydrate
566889|NCT00444041|metastatic colorectal cancer
566890|NCT00444041|surgery
566891|NCT00444041|chemotherapy
566892|NCT00444028|Schizophrenia, Staccato Loxapine
566893|NCT00444015|Erlotinib
566894|NCT00444015|Dasatinib
566895|NCT00444015|Epidermal growth factor receptor (EGFR)
566896|NCT00444015|Tyrosine kinase
566897|NCT00444015|NSCLC
566898|NCT00444015|Pharmacokinetics (PK)
566899|NCT00444015|Lung
566900|NCT00444002|Hepatitis C
566901|NCT00444002|Steatosis
566902|NCT00444002|Oxidative Stress
566903|NCT00444002|Antioxidants
566904|NCT00444002|Inflammation
566905|NCT00444002|Fatty acids
566906|NCT00443989|Perioperative Myocardial Infarction
566907|NCT00443989|Stroke
566908|NCT00443989|Cardiac Death
566909|NCT00443989|Cardiac Arrest
566910|NCT00443989|Troponin-T
566911|NCT00443989|Non-Cardiac surgery
566912|NCT00443989|Death
566913|NCT00443976|unspecified adult solid tumor, protocol specific
566914|NCT00443976|recurrent adult Burkitt lymphoma
566915|NCT00443976|stage III adult Burkitt lymphoma
566916|NCT00443976|stage IV adult Burkitt lymphoma
566917|NCT00443976|recurrent grade 2 follicular lymphoma
566918|NCT00443976|stage III grade 2 follicular lymphoma
566919|NCT00443976|stage IV grade 2 follicular lymphoma
566920|NCT00443976|recurrent grade 3 follicular lymphoma
566921|NCT00443976|stage III grade 3 follicular lymphoma
566922|NCT00443976|stage IV grade 3 follicular lymphoma
566923|NCT00443976|recurrent mantle cell lymphoma
566924|NCT00443976|stage III mantle cell lymphoma
566925|NCT00443976|stage IV mantle cell lymphoma
566926|NCT00443976|recurrent adult diffuse large cell lymphoma
566927|NCT00443976|stage III adult diffuse large cell lymphoma
566928|NCT00443976|stage IV adult diffuse large cell lymphoma
566929|NCT00443976|recurrent adult diffuse mixed cell lymphoma
566930|NCT00443976|stage III adult diffuse mixed cell lymphoma
566931|NCT00443976|stage IV adult diffuse mixed cell lymphoma
566932|NCT00443976|recurrent adult diffuse small cleaved cell lymphoma
566933|NCT00443976|stage III adult diffuse small cleaved cell lymphoma
566934|NCT00443976|stage IV adult diffuse small cleaved cell lymphoma
566935|NCT00443976|recurrent adult immunoblastic large cell lymphoma
566936|NCT00443976|stage III adult immunoblastic large cell lymphoma
566937|NCT00443976|stage IV adult immunoblastic large cell lymphoma
566938|NCT00443976|recurrent adult lymphoblastic lymphoma
566939|NCT00443976|stage III adult lymphoblastic lymphoma
566940|NCT00443976|stage IV adult lymphoblastic lymphoma
566941|NCT00443976|recurrent grade 1 follicular lymphoma
566942|NCT00443976|stage III grade 1 follicular lymphoma
566943|NCT00443976|stage IV grade 1 follicular lymphoma
566944|NCT00443976|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
566945|NCT00443976|nodal marginal zone B-cell lymphoma
566946|NCT00443976|splenic marginal zone lymphoma
566947|NCT00443976|recurrent marginal zone lymphoma
566948|NCT00443976|stage III marginal zone lymphoma
566949|NCT00443976|stage IV marginal zone lymphoma
566950|NCT00443976|recurrent small lymphocytic lymphoma
566951|NCT00443976|stage III small lymphocytic lymphoma
566952|NCT00443976|stage IV small lymphocytic lymphoma
566953|NCT00443976|recurrent adult grade III lymphomatoid granulomatosis
566954|NCT00443976|adult grade III lymphomatoid granulomatosis
566955|NCT00443976|Waldenstrom macroglobulinemia
566956|NCT00443963|Dyspepsia in patients taking NSAIDs
566957|NCT00443742|Depression
566958|NCT00443742|Validation
566959|NCT00443742|Adolescent
566960|NCT00443742|Validation of three key questions and questionnaire
566961|NCT00443729|treatment experienced
566962|NCT00443703|treatment experienced
566963|NCT00443690|heart failure
566964|NCT00443690|diuretic
566965|NCT00443690|renal impairment
566966|NCT00443690|renal function
566967|NCT00443664|Primary Open Angle Glaucoma
566968|NCT00443651|Rituxan
566969|NCT00443651|RA
566970|NCT00443651|DMARD
566971|NCT00443651|Active Rheumatoid Arthritis
566972|NCT00443625|SK3530
566973|NCT00443625|Food effect
566974|NCT00443625|Pharmacokinetics
566975|NCT00443599|Congenital Heart Defects
566976|NCT00443599|Insulin
566977|NCT00443599|Euglycemia
566978|NCT00443599|Normoglycemia
566979|NCT00443586|Nurse
566980|NCT00443586|Home Visitation
566981|NCT00443586|Welfare
566982|NCT00443586|Social Behavior
566983|NCT00443573|metastatic colorectal carcinoma (mCRC)
566984|NCT00443573|colorectal carcinoma (CRC)
566985|NCT00443573|tissue factor
566986|NCT00443573|factor VIIa
566987|NCT00443573|rNAPc2
566988|NCT00443573|adenocarcinoma
566989|NCT00443573|targeted therapy
566990|NCT00443573|coagulation-dependent
566991|NCT00443573|RECIST
566992|NCT00443573|5-FU-based chemotherapy
566993|NCT00443573|FOLFOX
566994|NCT00443573|FOLFIRI
566995|NCT00443573|leucovorin
566996|NCT00443573|XELOX
566997|NCT00443560|Labor
566998|NCT00443560|Epidural Analgesia
566999|NCT00443560|delivery
567000|NCT00443560|vacuum extraction
567001|NCT00443560|obstetrical Forceps
567002|NCT00443547|Prospective
567003|NCT00443547|Degenerative Disc Disease
567004|NCT00443547|Cervical
567005|NCT00443547|Translational Plate
567006|NCT00443521|Diabetes Mellitus/ complications
567007|NCT00443521|Diabetic Retinopathy
567008|NCT00443521|Triamcinolone
567009|NCT00443521|Laser coagulation
567010|NCT00443521|Tomography, optical coherence
567011|NCT00443508|everolimus
567012|NCT00443508|renal transplant
567013|NCT00443508|tacrolimus
567014|NCT00443508|Certican
567015|NCT00443508|CHRONIC ALLOGRAFT NEPHROPATHY
567016|NCT00443508|Renal transplant patients
567017|NCT00443482|Asthma
567018|NCT00443482|adults
567019|NCT00443482|B2 agonist
567020|NCT00443482|formoterol
567021|NCT00443469|magnetic stimulation
567022|NCT00443469|neuropathic pain
567023|NCT00443469|spinal
567024|NCT00443469|lower limb
567025|NCT00443469|clinical trial
567026|NCT00443443|Rituximab
567027|NCT00443443|RA
567028|NCT00443443|Sunstone
567029|NCT00443443|anti-TNF
567030|NCT00443443|Rituxan
567031|NCT00443430|Childhood Arthritis
567032|NCT00443430|Juvenile Arthritis
567033|NCT00443430|Juvenile Arthritis Treatment
567034|NCT00443430|Childhood Arthritis Drug Treatment
567035|NCT00443430|Juvenile Arthritis Remission
567036|NCT00443430|Inactive Disease in Juvenile Arthritis
567037|NCT00443430|Childhood Polyarthritis
567038|NCT00443430|Extended Oligoarthritis
567039|NCT00443404|phantom
567040|NCT00443404|amputation
567041|NCT00443404|analgesia
567042|NCT00443404|pain
567043|NCT00443404|preemptive
567044|NCT00443404|perioperative
567045|NCT00443404|lower limb amputation
567046|NCT00443404|intensity of phantom limb pain
567047|NCT00443404|preemptive analgesia reduces phantom pain
567048|NCT00443404|perioperative analgesia reduces phantom pain
567049|NCT00443404|Severe Phantom Limb Pain (VAS>70 mm)
567050|NCT00443404|resistant to medical treatment one week before amputation
567051|NCT00443391|ADHD
567052|NCT00443378|computer counseling
567053|NCT00443378|HIV
567054|NCT00443378|antiretroviral adherence
567055|NCT00443378|sexual behavior
567056|NCT00443378|prevention with positives
567057|NCT00443378|HIV seronegativity
567058|NCT00443339|Myelodysplastic syndromes with IPSS Low or Int-1
567059|NCT00443339|Anemia
567060|NCT00443326|Psoriasis
567061|NCT00443326|PASI
567062|NCT00443326|Skin Biopsy
567063|NCT00443326|Human Monoclonal Antibody
567064|NCT00443313|Cervical neoplasia
567065|NCT00443313|Screening
567066|NCT00443313|HPV
567067|NCT00443313|Cervical Cancer Screening
567068|NCT00443300|AML
567069|NCT00443300|MDS
567070|NCT00443300|Protected Environment
567071|NCT00443287|Peripheral
567072|NCT00443287|Artery
567073|NCT00443287|Disease
567074|NCT00443261|Head and Neck Cancer
567075|NCT00443235|Older patients
567076|NCT00443235|untreated patients
567077|NCT00443222|infliximab
567078|NCT00443222|polymyositis
567079|NCT00443222|dermatomyositis
567080|NCT00443222|inclusion body myositis
567081|NCT00443196|Chemosensitivity
567082|NCT00443196|Ovarian Cancer
567083|NCT00443196|Chemotherapy
567084|NCT00443196|Fallopian Adenocarcinoma
567085|NCT00443196|Peritoneal Adenocarcinoma
567086|NCT00443196|Patients with pathological diagnoses of ovarian, fallopian and primary peritoneal adenocarcinomas.
567087|NCT00443196|Patients with de novo malignancies and no previous chemotherapy
567088|NCT00443196|Patients with advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols.
567089|NCT00443170|repeat dose,
567090|NCT00443170|GSK626616AC,
567091|NCT00443170|pharmacokinetic,
567092|NCT00443170|single dose,
567093|NCT00443170|cytochrome P450,
567094|NCT00443170|First time in human,
567095|NCT00443170|healthy volunteers
567096|NCT00443157|meningococcal B vaccine
567097|NCT00443144|growth hormone receptor polymorphism
567098|NCT00443144|pharmacogenomics
567099|NCT00443144|growth promoting therapy
567100|NCT00443131|Adjuvant
567101|NCT00443131|Malaria
567102|NCT00443131|Safety
567103|NCT00443131|Immunogenicity
567104|NCT00443118|Bag and mask
567105|NCT00443118|Neopuff
567106|NCT00443118|Resuscitation
567107|NCT00443118|Newborn
567108|NCT00443118|Intubation
567109|NCT00443118|devices
567110|NCT00443118|PEEP
567111|NCT00443092|osteoarthritis
567112|NCT00443092|gout
567113|NCT00443092|pain
567114|NCT00443092|uric acid
567115|NCT00443092|tart cherry
567116|NCT00443092|alternative medicine
567117|NCT00443092|knees
567118|NCT00443079|Clinical Trials
567119|NCT00443079|Pilot Projects
567120|NCT00443079|Milk Thistle
567121|NCT00443079|Liver Function Tests
567122|NCT00443066|pediatric
567123|NCT00443066|neuromuscular disease
567124|NCT00443053|superficial vein thrombosis
567125|NCT00443053|superficial thrombophlebitis
567126|NCT00443053|fondaparinux
567127|NCT00443053|deep vein thrombosis
567128|NCT00443053|venous thromboembolism treatment
567129|NCT00443053|thrombosis
567130|NCT00443014|Stimulation therapy
567131|NCT00443014|Acetylcholinesterase inhibitors
567132|NCT00443014|Synergetic
567133|NCT00443001|Non-Invasive Blood Pressure
567134|NCT00443001|Sinus Rhythm
567135|NCT00443001|Oscillometric
567136|NCT00443001|Invasive Blood Pressure
567137|NCT00443001|AAMI/ANSI SP10 Standard
567138|NCT00443001|Compliance with ANSI/AAMI SP10 2002 standard
567139|NCT00442988|NODAT
567140|NCT00442988|OGTT
567141|NCT00442988|FPG
567142|NCT00442988|Renal Transplanation
567143|NCT00442988|Risk Factors
567144|NCT00442988|Predictive value
567145|NCT00442975|Influenza Vaccine
567146|NCT00442975|CMV
567147|NCT00442949|Acute coronary syndrome
567148|NCT00442949|Angioplasty
567149|NCT00442949|Abciximab
567150|NCT00442949|Troponin release
567151|NCT00442923|Methamphetamine
567152|NCT00442923|Coreg
567153|NCT00442923|Withdrawal
567154|NCT00442923|anxiety
567155|NCT00442923|Substance Addiction
567156|NCT00442910|Safety and Acceptability
567157|NCT00442897|Hypercholesterolaemia
567158|NCT00442884|glucose control in acute stress
567159|NCT00442871|Renal Impairment,
567160|NCT00442871|chronic immune thrombocytopenia purpura,
567161|NCT00442871|thrombocytopenia,
567162|NCT00442871|chemotherapy induced thrombocytopenia
567163|NCT00442858|cardiac disease
567164|NCT00442858|cerebrovascular disease
567165|NCT00442858|GH deficiency
567166|NCT00442858|diabetes mellitus
567167|NCT00442858|hypertension
567168|NCT00442858|GH therapy
567169|NCT00442858|GH deficiency and hypopituitarims
567170|NCT00442832|cSSSI
567171|NCT00442832|Staph
567172|NCT00442832|MRSA
567173|NCT00442819|Uremic Pruritus
567174|NCT00442819|Cytokines
567175|NCT00442819|Polymethylmethacrylate Artificial Kidney
567176|NCT00442819|Hemodialysis
567177|NCT00442806|ADRC
567178|NCT00442806|Stem Cells
567179|NCT00442806|Myocardial Infarction
567180|NCT00442806|STEMI
567181|NCT00442806|Heart Disease
567182|NCT00442806|Coronary Artery Disease
567183|NCT00442806|Coronary Disease
567184|NCT00442806|ST-Elevation
567185|NCT00442806|AMI
567186|NCT00442806|Interventional Cardiology
567187|NCT00442806|Heart Attack
567188|NCT00442715|Exercise-induced asthma,
567189|NCT00442715|early childhood;
567190|NCT00442715|spirometry,
567191|NCT00442715|exercise challenge
567192|NCT00442715|Data from preschool children who were referred to the Pediatric
567193|NCT00442715|Pulmonary Clinic over a 1-year period were recruited
567194|NCT00442689|Polycystic Ovary Syndrome
567195|NCT00442689|Metabolic Syndrome
567196|NCT00442689|PCOS
567197|NCT00442689|overweight
567198|NCT00442689|infertility
567199|NCT00442689|Insulin Resistance
567200|NCT00442689|menstrual cycle
567201|NCT00442663|Labor Induction
567202|NCT00442663|Cervical Ripening
567203|NCT00442663|Foley Catheter
567204|NCT00442637|CAIRO3
567205|NCT00442637|DCCG
567206|NCT00442637|colorectal cancer
567207|NCT00442637|induction
567208|NCT00442637|metronomic chemotherapy
567209|NCT00442637|observation
567210|NCT00442637|capecitabine
567211|NCT00442637|bevacizumab
567212|NCT00442637|oxaliplatin
567213|NCT00442624|insomnia
567214|NCT00442624|glucose metabolism
567215|NCT00442624|insulin resistance
567216|NCT00442598|Ovarian
567217|NCT00442598|Cancer
567218|NCT00442598|CA-125
567219|NCT00442598|Third-line
567220|NCT00442598|Glufosfamide
567221|NCT00442546|opioid
567222|NCT00442533|Carcinoid
567223|NCT00442533|Islet Cell Cancer
567224|NCT00442533|Paraganglioma
567225|NCT00442533|Pheochromocytoma
567226|NCT00442507|Esophagus
567227|NCT00442507|Esophagogastric Junction
567228|NCT00442507|Avastin
567229|NCT00442507|Bevacizumab
567230|NCT00442507|Erlotinib
567231|NCT00442494|Atrial fibrillation after cardiac surgery
567232|NCT00442481|MDD
567233|NCT00442481|Escitalopram
567234|NCT00442481|Cipralex
567235|NCT00442481|Sleep
567236|NCT00442481|REM
567237|NCT00442481|SWS
567238|NCT00442481|Polysomnography
567239|NCT00442468|Chronic Obstructive Pulmonary Disease (COPD)
567240|NCT00442468|Chronic Bronchitis
567241|NCT00442468|Spirometry
567242|NCT00442455|Head Neck Carcinoma Erlotinib
567243|NCT00442442|Malaria
567244|NCT00442442|mosquito control
567245|NCT00442442|mosquito coils
567246|NCT00442442|LLIN
567247|NCT00442429|depression; dialysis; kidney failure, chronic
567248|NCT00442403|Malaria
567249|NCT00442403|Plasmodium falciparum
567250|NCT00442403|Chemotherapy
567251|NCT00442403|Chloroquine
567252|NCT00442403|Dehydroepiandrosterone sulphate
567253|NCT00442390|Cortisol
567254|NCT00442390|adrenal insufficiency
567255|NCT00442390|glucose metabolism
567256|NCT00442390|protein metabolism
567257|NCT00442390|lipid metabolism
567258|NCT00442390|insulin sensitivity.
567259|NCT00442377|Falciparum
567260|NCT00442377|Plasmodium
567261|NCT00442377|Malaria
567262|NCT00442364|PFO
567263|NCT00442364|Patent Foramen Ovale
567264|NCT00442364|Right-to-Left Shunt
567265|NCT00442364|Sclerotherapy
567266|NCT00442312|Combigan
567267|NCT00442299|hemodialysis, urmeic retention solute, biocompatibility
567268|NCT00442286|Hypertension
567269|NCT00442286|High Blood Pressure
567270|NCT00442286|Blood Pressure
567271|NCT00442286|Cardiovascular Disease
567272|NCT00442286|Resistant Hypertension
567273|NCT00442286|Stage 2 Hypertension
567274|NCT00442286|Hypertension that is resistant to treatment
567275|NCT00442260|breast cancer
567276|NCT00442260|advanced breast cancer
567277|NCT00442247|anterior vaginal wall prolapse, Pelvicol, biomesh
567278|NCT00442247|Anterior vaginal wall prolapse
567279|NCT00442234|Acute
567280|NCT00442234|pulmonary
567281|NCT00442234|embolism
567282|NCT00442234|accompanying
567283|NCT00442234|hemodynamic
567284|NCT00442234|instability
567285|NCT00442221|Migrane headaches
567286|NCT00442208|Healthy adults
567287|NCT00442208|Phase I
567288|NCT00442195|Tissue Procurement
567289|NCT00442195|Sample Collection
567290|NCT00442195|Biologic Samples
567291|NCT00442195|Laboratory Research
567292|NCT00442195|Healthy Volunteer
567293|NCT00442195|HV
567294|NCT00442182|autoinflammatory syndromes
567295|NCT00442169|West Nile Disease
567296|NCT00442169|Antibody response
567297|NCT00442169|Viremia
567298|NCT00442169|Safety
567299|NCT00442169|Tolerability
567300|NCT00442169|Prevention
567301|NCT00442156|Laser photocoagulation
567302|NCT00442143|CLI
567303|NCT00442143|PAOD
567304|NCT00442143|Severe lower limb ischemia
567305|NCT00442130|GM-CSF
567306|NCT00442130|GM-K562
567307|NCT00442130|vaccine
567308|NCT00442104|infantile spasms
567309|NCT00442104|anticonvulsant
567310|NCT00442104|pediatric epilepsy
567311|NCT00442104|West Syndrome
567312|NCT00442104|epileptic spasms
567313|NCT00442091|Dandelion
567314|NCT00442091|herbal remedy
567315|NCT00442091|hand eczema
567316|NCT00442091|Compositae
567317|NCT00442078|Incontinence
567318|NCT00442078|Urinary
567319|NCT00442078|Male
567320|NCT00442078|Tape
567321|NCT00442078|Transobturator
567322|NCT00442065|Abdominal aortic aneurysm study
567323|NCT00442052|Gastroprotective effects
567324|NCT00442052|Aspirin
567325|NCT00442039|Mania, Lithium, Bipolar, BPCA, pediatrics
567326|NCT00442026|Cancer
567327|NCT00442026|NSCLC
567328|NCT00442026|Elderly
567329|NCT00442026|Chemotherapy
567330|NCT00442026|Docetaxel
567331|NCT00442026|Gemcitabine
567332|NCT00442000|Prostate Cancer
567333|NCT00442000|Prostatectomy
567334|NCT00441987|Japanese
567335|NCT00441987|Healthy
567336|NCT00441987|Alzheimers Disease
567337|NCT00441974|adefovir dipivoxil
567338|NCT00441974|compensated
567339|NCT00441974|chronic hepatitis B
567340|NCT00441974|Chinese
567341|NCT00441961|Eosinophilic fasciitis, Shulman's syndrome, methotrexate
567342|NCT00441948|Hirsutism
567343|NCT00441948|Hypertrichosis
567344|NCT00441935|Urinary Retention
567345|NCT00441935|Urinary Incontinence
567346|NCT00441935|Pelvic Pain
567347|NCT00441922|Cancer
567348|NCT00441922|Elderly
567349|NCT00441922|Chemotherapy
567350|NCT00441922|Docetaxel
567351|NCT00441922|Vinorelbine
567352|NCT00441909|Anti-Infective Agents, Local
567353|NCT00441909|Healthy Women
567354|NCT00441909|Microbicides
567355|NCT00441909|UC-781
567356|NCT00441909|Vaginal Gel
567357|NCT00441909|HIV Seronegativity
567358|NCT00441896|infantile spasms
567359|NCT00441896|anticonvulsant
567360|NCT00441896|pediatric epilepsy
567361|NCT00441896|West Syndrome
567362|NCT00441896|epileptic spasms
567363|NCT00441870|Cancer
567364|NCT00441870|Phase 1
567365|NCT00441870|EC0225
567366|NCT00441870|EC20
567367|NCT00441870|Refractory
567368|NCT00441870|Metastatic
567369|NCT00441870|Experimental
567370|NCT00441857|plant sterols
567371|NCT00441857|plant stanols
567372|NCT00441857|cholesterol absorption
567373|NCT00441844|diabetes, statin, monocyte, crp, inflammation
567374|NCT00441831|Helicobacter pylori infection
567375|NCT00441831|peptic ulcer disease
567376|NCT00441831|distal partial gastrectomy
567377|NCT00441831|bile reflux
567378|NCT00441831|gastritis
567379|NCT00441831|gastrectomy
567380|NCT00441805|Acne
567381|NCT00441805|RadioFrequency
567382|NCT00441792|Sepsis
567383|NCT00441792|Etomidate
567384|NCT00441792|midazolam
567385|NCT00441792|ketamine
567386|NCT00441779|Microchimerism
567387|NCT00441779|Injuries
567388|NCT00441779|Burns
567389|NCT00441779|Orthopedic Surgery
567390|NCT00441779|Leukocytes
567391|NCT00441740|NSCLC
567392|NCT00441740|1st line treatment
567393|NCT00441740|Gemcitabine
567394|NCT00441740|Vinorelbine
567395|NCT00441740|Docetaxel
567396|NCT00441727|Peptic ulcer
567397|NCT00441727|low-dose ASA
567398|NCT00441714|cardiovascular disease
567399|NCT00441714|ischemia-reperfusion injury
567400|NCT00441714|postconditioning
567401|NCT00441714|annexin targeting
567402|NCT00441688|HLAgenetics polymorphism
567403|NCT00441688|Human Immunodeficiency virus
567404|NCT00441675|Adolescents
567405|NCT00441675|Asthma
567406|NCT00441675|long-term follow-up
567407|NCT00441675|symptoms
567408|NCT00441675|bronchial hyperresponsiveness
567409|NCT00441662|Melanoma
567410|NCT00441662|Uvea
567411|NCT00441662|Macula
567412|NCT00441662|Edema
567413|NCT00441662|Plaque radiotherapy
567414|NCT00441662|Brachytherapy
567415|NCT00441662|Triamcinolone
567416|NCT00441649|ADHD
567417|NCT00441636|depression
567418|NCT00441636|CPAP
567419|NCT00441636|obstructive sleep apnea
567420|NCT00441623|chronic kidney disease
567421|NCT00441623|cardiovascular disease
567422|NCT00441623|risk stratification
567423|NCT00441610|Gimatecan
567424|NCT00441610|topoisomerase I inhibitor
567425|NCT00441610|advanced solid tumors
567426|NCT00441597|ischemia reperfusion injury
567427|NCT00441597|atorvastatine
567428|NCT00441597|preconditioning
567429|NCT00441597|cardiovascular disease
567430|NCT00441571|prostate cancer
567431|NCT00441571|radiolabeled antibody
567432|NCT00441532|prostate
567433|NCT00441519|Gastroprotective effects
567434|NCT00441519|Aspirin
567435|NCT00441506|interruption
567436|NCT00441506|critically ill
567437|NCT00441506|sedation
567438|NCT00441506|pediatrics
567439|NCT00441506|critically ill, ventilated children
567440|NCT00441493|Hepatitis C
567441|NCT00441493|fluvastatin
567442|NCT00441480|Hypercholesterolemia
567443|NCT00441480|Hypertriglyceridemia
567444|NCT00441480|Plant sterol
567445|NCT00441480|Cholesterol
567446|NCT00441480|Fish oil
567447|NCT00441454|stress urinary incontinence
567448|NCT00441454|surgery
567449|NCT00441454|tension-free vaginal tape
567450|NCT00441454|retropubic
567451|NCT00441454|transobturator
567452|NCT00441454|quality-of-life
567453|NCT00441441|asthma
567454|NCT00441441|fluticasone propionate
567455|NCT00441441|children
567456|NCT00441441|fluticasone propionate/salmeterol
567457|NCT00441389|Bacteria
567458|NCT00441389|Viruses
567459|NCT00441389|COPD
567460|NCT00441389|infectious etiology for acute exacerbation of COPD
567461|NCT00441376|Radiofrequency ablation
567462|NCT00441376|RFA
567463|NCT00441376|Doxorubicin
567464|NCT00441376|Liposome
567465|NCT00441376|HCC
567466|NCT00441376|MLC
567467|NCT00441376|hepatocellular carcinoma
567468|NCT00441376|liver tumor
567469|NCT00441376|tumor
567470|NCT00441376|ablation
567471|NCT00441376|heat therapy
567472|NCT00441376|anti-tumor
567473|NCT00441376|liver cancer
567474|NCT00441376|metastatic liver cancer (MLC)
567475|NCT00441363|diabetes
567476|NCT00441363|diabetes mellitus
567477|NCT00441337|malignancies
567478|NCT00441337|cancer
567479|NCT00441337|non small cell lung cancer
567480|NCT00441337|lung cancer
567481|NCT00441337|colorectal cancer
567482|NCT00441337|adenocarcinoma
567483|NCT00441337|melanoma
567484|NCT00441337|malignant melanoma
567485|NCT00441337|renal cancer
567486|NCT00441337|renal carcinoma
567487|NCT00441337|carcinoma
567488|NCT00441337|prostate cancer
567489|NCT00441337|prostate adenocarcinoma
567490|NCT00441337|Recurrent or treatment refractory malignancies
567491|NCT00441324|Ovarian follicle
567492|NCT00441324|Thecal cells
567493|NCT00441324|Androgens
567494|NCT00441324|FSH sensitivity
567495|NCT00441311|colorectal cancer screening
567496|NCT00441311|primary care physicians
567497|NCT00441311|health disparities
567498|NCT00441311|stratified randomized clinical trial
567499|NCT00441298|microbicides
567500|NCT00441298|safety
567501|NCT00441298|effectiveness
567502|NCT00441298|Tenofovir gel
567503|NCT00441298|HIV
567504|NCT00441298|young women
567505|NCT00441298|HIV Seronegativity
567506|NCT00441285|neurocysticercosis
567507|NCT00441285|NCC
567508|NCT00441285|praziquantel
567509|NCT00441285|PZQ
567510|NCT00441285|albendazole
567511|NCT00441285|ABZ
567512|NCT00441285|parasite
567513|NCT00441285|pig tapeworm
567514|NCT00441285|Taenia solium
567515|NCT00441285|epilepsy
567516|NCT00441285|late-onset epilepsy
567517|NCT00441285|acquired epilepsy
567518|NCT00441272|Pioglitazone
567519|NCT00441272|Hepatic Steatosis
567520|NCT00441272|Liver Toxicity
567521|NCT00441272|Liver Biopsy
567522|NCT00441272|HIV
567523|NCT00441272|Treatment Experienced
567524|NCT00441272|Treatment Naive
567525|NCT00441259|Japanese Encephalitis
567526|NCT00441246|Acute Respiratory Infection
567527|NCT00441246|Bronchitis
567528|NCT00441246|Rhinosinusitis
567529|NCT00441220|Genetic polymorphisms
567530|NCT00441220|Cyclophosphamide
567531|NCT00441220|Cytochrome p450 CYP2C19 (Human)
567532|NCT00441220|Systemic Lupus Erythematosus
567533|NCT00441207|IV Ascorbic Acid
567534|NCT00441207|IV Vitamin C
567535|NCT00441207|Cancer
567536|NCT00441207|Advanced Solid Tumors
567537|NCT00441194|Perimetry
567538|NCT00441194|Visual Field
567539|NCT00441194|Octopus
567540|NCT00441181|Neovascular glaucoma
567541|NCT00441181|Travoprost
567542|NCT00441168|Multiple Myeloma
567543|NCT00441168|bortezomib
567544|NCT00441168|Cancer
567545|NCT00441168|Hematology
567546|NCT00441168|bone marrow
567547|NCT00441168|immunoglobulin
567548|NCT00441168|relapse
567549|NCT00441168|refractory
567550|NCT00441168|plasma cell
567551|NCT00441168|Velcade
567552|NCT00441168|adriamycin
567553|NCT00441168|dexamethasone
567554|NCT00441168|vincristine
567555|NCT00441155|Oncology
567556|NCT00441155|Cancer
567557|NCT00441155|Imatinib-Resistant Gastrointestinal Stromal Tumors
567558|NCT00441155|GIST
567559|NCT00441155|Nilotinib
567560|NCT00441155|Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)
567561|NCT00441142|Newly diagnosed malignant brain tumors.
567562|NCT00441129|Improvement of the blood glucose control
567563|NCT00441116|dutasteride
567564|NCT00441116|Androgenic alopecia
567565|NCT00441116|phase 3
567566|NCT00441103|Subjects with relapsing remitting multiple sclerosis
567567|NCT00441090|Chronic Idiopathic Thrombocytopenic Purpura
567568|NCT00441090|Idiopathic Thrombocytopenic Purpura
567569|NCT00441090|ITP
567570|NCT00441077|Genetics
567571|NCT00441077|Family History
567572|NCT00441077|Latino
567573|NCT00441077|Information Seeking
567574|NCT00441077|Lay Health Advisors
567575|NCT00441077|Cancer
567576|NCT00441077|Heart Disease
567577|NCT00441077|Diabetes
567578|NCT00441077|Information
567579|NCT00441064|High blood pressure, hypertension, aliskiren, low sodium diet
567580|NCT00441051|Sunburn, diclofenac, topical NSAID
567581|NCT00441038|Low back pain
567582|NCT00441038|disability
567583|NCT00441038|health education
567584|NCT00441025|MabCampath + CHOP in PTCL
567585|NCT00441012|Haemophilus Influenza, type b and Hepatitis B
567586|NCT00440999|P vivax
567587|NCT00440999|malaria
567588|NCT00440999|ACT
567589|NCT00440986|Clinical Management
567590|NCT00440986|Phlebotomy
567591|NCT00440986|Eritrocytoapheresis
567592|NCT00440973|kidney cancer
567593|NCT00440973|M3thodist
567594|NCT00440960|alfentanil
567595|NCT00440960|anesthesia
567596|NCT00440960|bronchoscopy
567597|NCT00440960|lidocaine
567598|NCT00440960|midazolam
567599|NCT00440960|propofol.
567600|NCT00440947|NORVIR
567601|NCT00440947|ARIES
567602|NCT00440947|EPZICOM
567603|NCT00440947|REYATAZ
567604|NCT00440947|HIV
567605|NCT00440947|simplification
567606|NCT00440947|Antiretroviral-naive
567607|NCT00440934|carcinoma, hepatocellular
567608|NCT00440934|electromagnetic fields
567609|NCT00440921|fibrin sealnat
567610|NCT00440921|knee replacement
567611|NCT00440921|hip replacement
567612|NCT00440921|woud healing
567613|NCT00440921|blood loss
567614|NCT00440921|clinical trial
567615|NCT00440921|randomized
567616|NCT00440908|Dialyzer reuse
567617|NCT00440908|Inflammatory markers
567618|NCT00440908|Nutritional status
567619|NCT00440895|Coronary artery stenting
567620|NCT00440895|Trans-radial
567621|NCT00440895|Intracoronary
567622|NCT00440895|Rescue-PCI
567623|NCT00440869|N-acetylcysteine
567624|NCT00440869|oxidative stress
567625|NCT00440869|muscle fatigue
567626|NCT00440869|end-stage renal disease
567627|NCT00440869|hemodialysis
567628|NCT00440856|Intervertebral disc
567629|NCT00440856|Lumbar discectomy
567630|NCT00440856|Outcome
567631|NCT00440856|Radiculopathy due to prolapsed intervertebral disc.
567632|NCT00440843|schizophrenia
567633|NCT00440843|attention
567634|NCT00440843|task engagement
567635|NCT00440843|antipsychotics
567636|NCT00440843|cognition
567637|NCT00440843|cognitive rehabilitation
567638|NCT00440830|acute pain
567639|NCT00440830|nicotine
567640|NCT00440830|nausea
567641|NCT00440830|sedation
567642|NCT00440817|Lymphoma
567643|NCT00440817|Rheumatoid arthritis
567644|NCT00440817|Crohn's disease
567645|NCT00440817|Remicade
567646|NCT00440817|Infliximab
567647|NCT00440804|patent ductus arterious
567648|NCT00440791|Colon
567649|NCT00440791|colonic disease
567650|NCT00440791|capsule endoscopy
567651|NCT00440791|Suspected or known colonic disease
567652|NCT00440778|Coronary artery stenting
567653|NCT00440778|Trans-radial
567654|NCT00440778|Intracoronary
567655|NCT00440765|Multiple Myeloma
567656|NCT00440765|hematological Neoplasms
567657|NCT00440765|chemotherapy
567658|NCT00440765|efficacy
567659|NCT00440765|safety
567660|NCT00440765|bortezomib
567661|NCT00440765|proteasome inhibitor
567662|NCT00440752|Artemether-lumefantrine
567663|NCT00440752|Plasmodium falciparum
567664|NCT00440752|drug resistance genes
567665|NCT00440739|postoperative pain, etoticoxib, etoricoxib
567666|NCT00440739|Pain relief after transurethral resection of prostate.
567667|NCT00440726|Acute Lymphoblastic Leukemia
567668|NCT00440726|Pediatrics
567669|NCT00440726|Relapsed
567670|NCT00440726|Recurrence
567671|NCT00440726|Bortezomib
567672|NCT00440726|Velcade
567673|NCT00440726|Therapeutic Advances in Childhood Leukemia
567674|NCT00440726|Investigational
567675|NCT00440726|Childhood
567676|NCT00440726|ALL
567677|NCT00440726|Relapsed ALL
567678|NCT00440726|Refractory ALL
567679|NCT00440726|Relapsed pediatric ALL
567680|NCT00440726|Refractory pediatric ALL
567681|NCT00440726|TACL
567682|NCT00440726|Recurrent Pediatric ALL
567683|NCT00440713|Posttraumatic Stress Disorder
567684|NCT00440713|Depression
567685|NCT00440713|Anxiety
567686|NCT00440713|Efficacy
567687|NCT00440700|Ventilator
567688|NCT00440700|chronic obstructive pulmonary disease
567689|NCT00440700|Anxiety
567690|NCT00440687|chronic obstructive pulmonary disease
567691|NCT00440687|primary care
567692|NCT00440687|randomised trials
567693|NCT00440687|therapeutic interventions
567694|NCT00440674|Direct Stenting
567695|NCT00440674|Angioplasty
567696|NCT00440674|Pre-dilatation
567697|NCT00440674|Drug-eluting stent
567698|NCT00440661|Osteoarthritis, IL-1
567699|NCT00440635|Multiple myeloma
567700|NCT00440635|bortezomib, Hematology
567701|NCT00440622|Cancer
567702|NCT00440622|Metastatic Breast cancer
567703|NCT00440622|Her-2 expression
567704|NCT00440622|Gemcitabine
567705|NCT00440622|Capecitabine
567706|NCT00440622|Herceptin
567707|NCT00440583|CHOP-Z
567708|NCT00440570|cancer
567709|NCT00440570|electromagnetic fields
567710|NCT00440570|treatment
567711|NCT00440557|Anemia
567712|NCT00440557|Chronic Kidney disease
567713|NCT00440557|Kidney disease
567714|NCT00440557|Epoetin alfa
567715|NCT00440557|Procrit
567716|NCT00440544|Tuberculosis
567717|NCT00440544|vaccine
567718|NCT00440544|nasal immunization
567719|NCT00440518|Lacosamide
567720|NCT00440518|migraine prophylaxis
567721|NCT00440518|Vimpat
567722|NCT00440505|chronic pain
567723|NCT00440505|pelvic pain
567724|NCT00440505|nicotine patch
567725|NCT00440479|Multiple Myeloma
567726|NCT00440479|hematological neoplasms
567727|NCT00440479|chemotherapy
567728|NCT00440479|efficacy
567729|NCT00440479|safety
567730|NCT00440479|bortezomib
567731|NCT00440479|proteasome inhibitor
567732|NCT00440466|Anemia
567733|NCT00440466|Reduction in the number of erythrocytes
567734|NCT00440466|Hemoglobin low level
567735|NCT00440466|Red blood cell deficiency
567736|NCT00440466|Procrit
567737|NCT00440466|Epoetin alfa
567738|NCT00440466|Chronic kidney disease
567739|NCT00440453|Internal medicine patients
567740|NCT00440440|hypogonadism
567741|NCT00440440|diabetes
567742|NCT00440440|visceral fat
567743|NCT00440440|hepatic fat
567744|NCT00440440|lean mass
567745|NCT00440427|Major Depressive Disorder
567746|NCT00440427|MDD
567747|NCT00440414|Cancer
567748|NCT00440414|Non-small-cell lung cancer
567749|NCT00440414|Chemotherapy
567750|NCT00440414|Pemetrexed
567751|NCT00440414|Erlotinib
567752|NCT00440401|Surgical treatment of haemorrhage
567753|NCT00440388|cancer
567754|NCT00440388|lymphoma
567755|NCT00440388|Non-Hodgkin's
567756|NCT00440388|Non-Hodgkins
567757|NCT00440388|AT-101
567758|NCT00440388|AT101
567759|NCT00440388|Rituxan
567760|NCT00440388|Rituximab
567761|NCT00440362|Influenza
567762|NCT00440362|Flu
567763|NCT00440362|A/Wyoming/03/2003
567764|NCT00440362|Alphavirus
567765|NCT00440349|Retroperitoneal fibrosis
567766|NCT00440349|Tamoxifen
567767|NCT00440349|Corticosteroids
567768|NCT00440349|Obstructive uropathy
567769|NCT00440349|Periaortic fibrosis
567770|NCT00440349|Chronic periaortitis
567771|NCT00440336|IOP
567772|NCT00440336|SLT
567773|NCT00440336|Laser
567774|NCT00440336|Cosopt
567904|NCT00439881|SB-681323,
567775|NCT00440323|Noise induced Situational insomnia,
567776|NCT00440323|healthy volunteers
567777|NCT00440323|SB-649868,
567778|NCT00440323|Zolpidem,
567779|NCT00440310|Liver neoplasms
567780|NCT00440310|Liver metastases
567781|NCT00440310|MCRC
567782|NCT00440310|Litx™
567783|NCT00440310|LS11
567784|NCT00440310|Colorectal cancer with recurrent liver metastases
567785|NCT00440297|hepatitis B virus
567786|NCT00440284|conventional insulin therapy
567787|NCT00440284|intensive insulin therapy
567788|NCT00440284|self-management
567789|NCT00440284|patient education
567790|NCT00440284|RCT
567791|NCT00440284|glycosylated hemoglobin
567792|NCT00440284|hypoglycemia
567793|NCT00440284|patient preference
567794|NCT00440258|Ovarian hyperstimulation syndrome, dopamine agonists, cabergoline, hemoconcentration, ascites, ovarian perfusion, dopamine receptor 2
567795|NCT00440219|Nasal polyps
567796|NCT00440219|Steroids
567797|NCT00440219|Prednisone
567798|NCT00440219|Nasal polypectomy
567799|NCT00440219|Blood loss, surgical
567800|NCT00440206|HIV
567801|NCT00440206|Immune Markers
567802|NCT00440180|Obesity
567803|NCT00440180|Low sperm count
567804|NCT00440180|Male infertility
567805|NCT00440167|capecitabine
567806|NCT00440167|gemcitabine
567807|NCT00440167|Erlotinib
567808|NCT00440167|pancreatic cancer
567809|NCT00440167|advanced
567810|NCT00440128|Casopitant,
567811|NCT00440128|Neurokinin-1 Receptor Antagonist,
567812|NCT00440128|Drug-Interaction,
567813|NCT00440128|CYP3A
567814|NCT00440128|NK-1 Receptor Antagonist,
567815|NCT00440128|GW679769,
567816|NCT00440128|Docetaxel,
567817|NCT00440102|ETOMIDATE
567818|NCT00440102|KETAMINE
567819|NCT00440102|RAPID SEQUENCE INTUBATION
567820|NCT00440102|PREHOSPITAL
567821|NCT00440102|During rapid sequence intubation
567822|NCT00440089|Cancer
567823|NCT00440089|Fatigue
567824|NCT00440089|Breast Cancer
567825|NCT00440089|Healing
567826|NCT00440089|Energy Healing
567827|NCT00440089|Complementary
567828|NCT00440089|Alternative
567829|NCT00440089|Immune
567830|NCT00440089|Cytokine
567831|NCT00440089|Hormone
567832|NCT00440089|Cortisol
567833|NCT00440089|Placebo
567834|NCT00440089|Mock Healing
567835|NCT00440076|MDS
567836|NCT00440076|Velcade
567837|NCT00440050|fish oil
567838|NCT00440050|omega-3 fatty acids
567839|NCT00440050|EPA
567840|NCT00440037|AMG 531
567841|NCT00440037|ITP
567842|NCT00440037|Long term treatment
567843|NCT00440037|Japanese
567844|NCT00440037|Romiplostim
567845|NCT00440024|Sun-Damaged Skin
567846|NCT00440024|Retinoid Intolerance
567847|NCT00440024|Tazarotene Cream
567848|NCT00440024|Dove facial cleanser
567849|NCT00440024|Dove moisturizer
567850|NCT00439998|Ultrasound
567851|NCT00439998|Obesity
567852|NCT00439998|Needle Depth
567853|NCT00439985|Type 1 Diabetes Mellitus (T1DM)
567854|NCT00439985|Metabolic Control
567855|NCT00439985|Adherence
567856|NCT00439985|Optimism
567857|NCT00439985|Parent-Child Collaboration
567858|NCT00439985|Prevention
567859|NCT00439972|Lipoproteins
567860|NCT00439972|Apolipoproteins
567861|NCT00439972|Insulin sensitivity
567862|NCT00439972|Inflammation
567863|NCT00439972|Clotting
567864|NCT00439972|Antioxidant status
567865|NCT00439972|Vascular reactivity
567866|NCT00439972|Metabolism
567867|NCT00439959|GSK625433,
567868|NCT00439959|Hepatitis C,
567869|NCT00439959|metabolic probe,
567870|NCT00439959|food-effect,
567871|NCT00439959|HCV,
567872|NCT00439959|FTIH
567873|NCT00439959|polymerase,
567874|NCT00439946|pulmonary hypertension
567875|NCT00439946|PAH
567876|NCT00439946|Remodulin
567877|NCT00439946|treprostinil
567878|NCT00439946|Quality of Life
567879|NCT00439946|rapid switch
567880|NCT00439933|Obesity
567881|NCT00439933|Children
567882|NCT00439933|Weight loss
567883|NCT00439933|Endothelial dysfunction
567884|NCT00439933|Intervention
567885|NCT00439920|ALL
567886|NCT00439907|Anal sphincter Delivery
567887|NCT00439907|Primary repair
567888|NCT00439907|End-to-end repair
567889|NCT00439907|Over-lap repair
567890|NCT00439907|Anal manometry
567891|NCT00439907|Anal sonography
567892|NCT00439907|Weksner Score
567893|NCT00439907|Rupture of the external anal sphincter during delivery
567894|NCT00439907|Anal sphincter
567895|NCT00439907|Anal sphincter rupture
567896|NCT00439894|Rheumatoid Arthritis
567897|NCT00439894|etanercept
567898|NCT00439894|Enbrel
567899|NCT00439894|Amgen
567900|NCT00439881|inflammation,
567901|NCT00439881|intravenous,
567902|NCT00439881|Chronic Obstructive Pulmonary Disease,
567903|NCT00439881|P38 inhibitor
567905|NCT00439881|rheumatoid arthritis,
567906|NCT00439868|WELLBUTRIN XL, intraocular pressure, healthy volunteers
567907|NCT00439855|Enoxaparin, heparin, hemorrhages
567908|NCT00439829|follicle
567909|NCT00439829|ovary
567910|NCT00439829|poor responder
567911|NCT00439829|stimulation
567912|NCT00439829|follicle wave emergence
567913|NCT00439816|Hypertension Outcomes
567914|NCT00439816|Health Outcomes
567915|NCT00439816|Outpatient
567916|NCT00439816|Racial Preference
567917|NCT00439816|Blood Pressure Control
567918|NCT00439816|Clinical Trial
567919|NCT00439816|Intervention
567920|NCT00439816|Lifestyle modifications
567921|NCT00439816|Ethnic Differences
567922|NCT00439816|Randomized
567923|NCT00439803|CMV
567924|NCT00439803|cytomegalovirus
567925|NCT00439803|Alphavirus
567926|NCT00439790|implantable cardioverter defibrillator
567927|NCT00439790|Heart failure
567928|NCT00439790|Sudden Cardiac Arrest
567929|NCT00439790|appropriate shock
567930|NCT00439790|Defibrillators, Implantable
567931|NCT00439764|Low back pain, health education, physical therapy
567932|NCT00439751|Prostate Cancer
567933|NCT00439751|Androgen Deprivation Therapy
567934|NCT00439751|Recurrence
567935|NCT00439751|Biochemical Failure
567936|NCT00439751|Goserelin
567937|NCT00439738|Obesity, hypertension, valsartan/hydrochlorothiazide
567938|NCT00439699|Essential Tremor
567939|NCT00439699|Memantine
567940|NCT00439699|Clinical Trial
567941|NCT00439673|MDS
567942|NCT00439673|5-Azacytidine
567943|NCT00439673|valproic acid
567944|NCT00439673|atra
567945|NCT00439673|intermediate or high risk
567946|NCT00439673|Age ≥18 yearsAge
567947|NCT00439660|Rotavirus, diarrhea, vaccine
567948|NCT00439647|Osteoporosis
567949|NCT00439647|males
567950|NCT00439647|vertebral fractures
567951|NCT00439647|clinical fractures
567952|NCT00439647|bone mineral density
567953|NCT00439647|bone biomarkers
567954|NCT00439647|zoledronic acid
567955|NCT00439634|psychometrics
567956|NCT00439634|schizophrenia
567957|NCT00439621|immunotherapy
567958|NCT00439621|allergy
567959|NCT00439608|esophageal cancer
567960|NCT00439608|gastroesophageal cancer
567961|NCT00439608|gastric cancer
567962|NCT00439595|Anaemia
567963|NCT00439595|Diagnosis
567964|NCT00439595|Primary
567965|NCT00439595|Care
567966|NCT00439595|Treatment
567967|NCT00439582|Lipoproteins
567968|NCT00439582|Milk fat
567969|NCT00439582|Public health nutrition
567970|NCT00439582|trans fatty acid
567971|NCT00439569|spinal muscular atrophy type II/III
567972|NCT00439569|SMA type II/III
567973|NCT00439569|spinal muscular atrophy
567974|NCT00439569|SMA
567975|NCT00439569|sodium phenylbutyrate
567976|NCT00439569|motor neuron disease
567977|NCT00439569|neuromuscular
567978|NCT00439569|survival motor neuron
567979|NCT00439569|SMN
567980|NCT00439569|dose escalation
567981|NCT00439556|Lymphoma
567982|NCT00439556|Bortezomib
567983|NCT00439556|Velcade
567984|NCT00439556|LDP-341
567985|NCT00439556|MLN341
567986|NCT00439556|PS-341
567987|NCT00439556|Carmustine
567988|NCT00439556|Cytarabine
567989|NCT00439556|Etoposide
567990|NCT00439556|Melphalan
567991|NCT00439556|Rituximab
567992|NCT00439556|BEAM
567993|NCT00439556|BCNU
567994|NCT00439556|BiCNU®
567995|NCT00439556|ARA-C
567996|NCT00439556|Cytosar
567997|NCT00439556|DepoCyt®
567998|NCT00439556|Cytosine arabinosine hydrochloride
567999|NCT00439556|VePesid®
568000|NCT00439556|Rituxan
568001|NCT00439543|Pulmonary fibrosis
568002|NCT00439543|pulmonary hypertension
568003|NCT00439543|Iloprost
568004|NCT00439543|Efficacy
568005|NCT00439530|oseltamivir
568006|NCT00439530|pharmacokinetics
568007|NCT00439530|probenecid
568008|NCT00439530|avian influenza
568009|NCT00439517|Cancer
568010|NCT00439517|Colorectal
568011|NCT00439517|Metastatic
568012|NCT00439517|Untreated
568013|NCT00439491|Obesity
568014|NCT00439491|Insulin resistance
568015|NCT00439491|Hypocaloric diet
568016|NCT00439491|Adipose tissue
568017|NCT00439491|adipocytokine
568018|NCT00439478|Radioiodine, Thyroid Cancer, Sialadenitis, Xerostomia
568019|NCT00439387|Serotonin
568020|NCT00439387|Epilepsy
568021|NCT00439387|Healthy Volunteer
568022|NCT00439387|HV
568023|NCT00439374|nulliparous
568024|NCT00439374|pregnancy
568025|NCT00439374|short cervix
568026|NCT00439374|progesterone
568027|NCT00439361|Hodgkin Lymphoma
568028|NCT00439361|HL
568029|NCT00439361|Relapsed Classical Hodgkin Lymphoma
568030|NCT00439361|Refractory
568031|NCT00439361|Lymphoma
568032|NCT00439361|Nodular sclerosis
568033|NCT00439361|Mixed cellularity
568034|NCT00439361|Lymphocyte-rich classical HL
568035|NCT00439361|Bortezomib
568036|NCT00439361|Velcade
568037|NCT00439361|LDP-341
568038|NCT00439361|MLN341
568039|NCT00439361|PS-341
568040|NCT00439361|Carboplatin
568041|NCT00439361|Paraplatin
568042|NCT00439361|Etoposide
568043|NCT00439361|VePesid®
568044|NCT00439361|Ifosfamide
568045|NCT00439361|Mesna
568046|NCT00439361|Mesnex
568047|NCT00439361|ICE
568048|NCT00439348|Calcium
568049|NCT00439348|Compliance
568050|NCT00439348|Medication compliance
568051|NCT00439348|electronic prescription
568052|NCT00439348|over-the-counter medications
568053|NCT00439348|OTC medications
568054|NCT00439335|Influenza, vaccine, A/H5N1
568055|NCT00439322|PTSD
568056|NCT00439296|Acute Lymphoblastic Leukemia
568057|NCT00439296|Pediatrics
568058|NCT00439296|Relapsed
568059|NCT00439296|Recurrence
568060|NCT00439296|ABT-751
568061|NCT00439296|Therapeutic Advances in Childhood Leukemia
568062|NCT00439296|Investigational
568063|NCT00439296|Childhood
568064|NCT00439296|ALL
568065|NCT00439296|Relapsed ALL
568066|NCT00439296|Refractory ALL
568067|NCT00439296|Relapsed pediatric ALL
568068|NCT00439296|Refractory pediatric ALL
568069|NCT00439296|TACL
568070|NCT00439283|Ankylosing spondylitis
568071|NCT00439283|infliximab
568072|NCT00439283|Systematic regimen
568073|NCT00439283|On-demand regimen
568074|NCT00439270|Metastatic hormone refractory prostate cancer
568075|NCT00439244|Bone Mineral Density (BMD)
568076|NCT00439244|C-Telopeptides (CTx)
568077|NCT00439244|dual x-ray absorptiometry (DXA)
568078|NCT00439244|pro-collagen type 1 N-propeptide (P1NP)
568079|NCT00439244|teriparatide
568080|NCT00439244|zoledronic acid
568081|NCT00439244|Osteoporosis
568082|NCT00439244|postmenopausal women
568083|NCT00439231|Monoclonal Antibody Therapy
568084|NCT00439231|Biologic Response Modifier Therapy
568085|NCT00439231|CLL
568086|NCT00439231|SLL
568087|NCT00439231|chemo-care (CC) 5013- Revlimid
568088|NCT00439231|Chronic Lymphocytic Leukemia
568089|NCT00439231|Small Lymphocytic Leukemia
568090|NCT00439218|spinal muscular atrophy type I
568091|NCT00439218|SMA type I
568092|NCT00439218|spinal muscular atrophy
568093|NCT00439218|SMA
568094|NCT00439218|sodium phenylbutyrate
568095|NCT00439218|motor neuron disease
568096|NCT00439218|neuromuscular
568097|NCT00439218|survival motor neuron
568098|NCT00439218|SMN
568099|NCT00439218|dose escalation
568100|NCT00439205|Oral Tumors
568101|NCT00439205|Oral Margin Spectroscopy
568102|NCT00439205|Oral Spectroscopy
568103|NCT00439205|Optical Spectroscopy
568104|NCT00439205|Oral neoplastic lesions
568105|NCT00439205|FastEEM4 System
568106|NCT00439205|Multispectral Digital Microscope
568107|NCT00439205|MDM
568108|NCT00439205|Nonstandard imaging technology
568109|NCT00439192|OAB, proof of concept
568110|NCT00439192|Overactive Bladder (OAB)
568111|NCT00439192|with incontinence
568112|NCT00439179|Pancreatic Cancer
568113|NCT00439166|doxycycline
568114|NCT00439166|rifampicin
568115|NCT00439166|cerebrospinal fluid
568116|NCT00439166|biomarkers
568117|NCT00439166|beta amyloid
568118|NCT00439166|tau
568119|NCT00439127|thyroglobulin
568120|NCT00439127|thyroid carcinoma
568121|NCT00439127|tumour marker
568122|NCT00439127|radioiodine
568123|NCT00439127|recombinant human TSH
568124|NCT00439114|Corneal topography, corneal opacity, keratitis, trachoma
568125|NCT00439101|weight loss
568126|NCT00439101|malignancy
568127|NCT00439101|corticosteroids
568128|NCT00439101|supplemental feeding
568129|NCT00439101|adrenal insufficiency
568130|NCT00439101|diabetes
568131|NCT00439088|Ambulation
568132|NCT00439088|Ambulatory Monitoring
568133|NCT00439088|Activities of Daily Living
568134|NCT00439088|Pedometer
568135|NCT00439088|Validation Studies [PT]
568136|NCT00439075|pulmonary disease
568137|NCT00439075|CPO
568138|NCT00439075|CPAP
568139|NCT00439075|oxygenation
568140|NCT00439075|out-of-hospital intervention
568141|NCT00439062|Roxithromycin,Rheumatoid arthritis,Macrolides
568142|NCT00439049|Substance Abuse
568143|NCT00439049|Treatment
568144|NCT00439049|Eligibility
568145|NCT00439036|Opiate
568146|NCT00439036|Behavior Therapy
568147|NCT00439036|Methadone
568148|NCT00439036|Acceptance and Commitment Therapy (ACT)
568149|NCT00439023|Chronic renal failure, dialysis, hemodialysis,
568150|NCT00439010|neurological
568151|NCT00439010|alzheimer
568152|NCT00438971|Panic Disorder
568153|NCT00438971|Anxiety Disorder
568154|NCT00438971|Duloxetine
568155|NCT00438958|graft versus host disease
568156|NCT00438958|adult acute myeloid leukemia in remission
568157|NCT00438958|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
568158|NCT00438958|adult acute myeloid leukemia with inv(16)(p13;q22)
568159|NCT00438958|adult acute myeloid leukemia with t(15;17)(q22;q12)
568160|NCT00438958|adult acute myeloid leukemia with t(16;16)(p13;q22)
568161|NCT00438958|adult acute myeloid leukemia with t(8;21)(q22;q22)
568162|NCT00438958|accelerated phase chronic myelogenous leukemia
568163|NCT00438958|chronic phase chronic myelogenous leukemia
568164|NCT00438958|refractory anemia with excess blasts in transformation
568165|NCT00438958|refractory anemia with excess blasts
568166|NCT00438958|refractory anemia with ringed sideroblasts
568167|NCT00438958|refractory anemia
568168|NCT00438958|chronic myelomonocytic leukemia
568169|NCT00438958|de novo myelodysplastic syndromes
568170|NCT00438958|previously treated myelodysplastic syndromes
568171|NCT00438958|secondary myelodysplastic syndromes
568172|NCT00438958|refractory chronic lymphocytic leukemia
568173|NCT00438958|stage III chronic lymphocytic leukemia
568174|NCT00438958|stage IV chronic lymphocytic leukemia
568175|NCT00438958|primary myelofibrosis
568176|NCT00438958|secondary myelofibrosis
568177|NCT00438958|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
568178|NCT00438958|nodal marginal zone B-cell lymphoma
568179|NCT00438958|recurrent adult Burkitt lymphoma
568180|NCT00438958|recurrent adult diffuse large cell lymphoma
568181|NCT00438958|recurrent adult diffuse mixed cell lymphoma
568182|NCT00438958|recurrent adult diffuse small cleaved cell lymphoma
568183|NCT00438958|recurrent adult Hodgkin lymphoma
568184|NCT00438958|recurrent adult immunoblastic large cell lymphoma
568185|NCT00438958|recurrent adult lymphoblastic lymphoma
568186|NCT00438958|recurrent cutaneous T-cell non-Hodgkin lymphoma
568187|NCT00438958|recurrent grade 1 follicular lymphoma
568188|NCT00438958|recurrent grade 2 follicular lymphoma
568189|NCT00438958|recurrent grade 3 follicular lymphoma
568190|NCT00438958|recurrent mantle cell lymphoma
568191|NCT00438958|recurrent marginal zone lymphoma
568192|NCT00438958|recurrent mycosis fungoides/Sezary syndrome
568193|NCT00438958|recurrent small lymphocytic lymphoma
568194|NCT00438958|splenic marginal zone lymphoma
568195|NCT00438958|stage III adult Burkitt lymphoma
568196|NCT00438958|stage III adult diffuse large cell lymphoma
568197|NCT00438958|stage III adult diffuse mixed cell lymphoma
568198|NCT00438958|stage III adult diffuse small cleaved cell lymphoma
568199|NCT00438958|stage III adult Hodgkin lymphoma
568200|NCT00438958|stage III adult immunoblastic large cell lymphoma
568201|NCT00438958|stage III adult lymphoblastic lymphoma
568202|NCT00438958|stage III grade 1 follicular lymphoma
568203|NCT00438958|stage III grade 2 follicular lymphoma
568204|NCT00438958|stage III grade 3 follicular lymphoma
568205|NCT00438958|stage III mantle cell lymphoma
568206|NCT00438958|stage III marginal zone lymphoma
568207|NCT00438958|stage III small lymphocytic lymphoma
568208|NCT00438958|stage IV adult Burkitt lymphoma
568209|NCT00438958|stage IV adult diffuse large cell lymphoma
568210|NCT00438958|stage IV adult diffuse mixed cell lymphoma
568211|NCT00438958|stage IV adult diffuse small cleaved cell lymphoma
568212|NCT00438958|stage IV adult Hodgkin lymphoma
568213|NCT00438958|stage IV adult immunoblastic large cell lymphoma
568214|NCT00438958|stage IV adult lymphoblastic lymphoma
568215|NCT00438958|stage IV grade 1 follicular lymphoma
568216|NCT00438958|stage IV grade 2 follicular lymphoma
568217|NCT00438958|stage IV grade 3 follicular lymphoma
568218|NCT00438958|stage IV mantle cell lymphoma
568219|NCT00438958|stage IV marginal zone lymphoma
568220|NCT00438958|stage IV small lymphocytic lymphoma
568221|NCT00438958|Waldenström macroglobulinemia
568222|NCT00438958|secondary acute myeloid leukemia
568223|NCT00438958|childhood myelodysplastic syndromes
568224|NCT00438932|phosphate, phosphorus, FGF-23, PTH, 1,25D
568225|NCT00438906|pancreatic lesions
568226|NCT00438906|pancreatic cancer
568227|NCT00438906|peutz-jeghers syndrome
568228|NCT00438906|BRCA 2 gene mutation
568229|NCT00438906|FAMMM/p16
568230|NCT00438906|Genes, BRCA2
568231|NCT00438893|Viscous dietary fiber
568232|NCT00438893|Soy protein
568233|NCT00438893|Nuts
568234|NCT00438893|Plant sterols
568235|NCT00438893|Dietary Portfolio
568236|NCT00438893|Compliance
568237|NCT00438893|Blood lipids
568238|NCT00438893|Blood pressure
568239|NCT00438867|angina
568240|NCT00438867|FGF-4
568241|NCT00438867|angiogenesis
568242|NCT00438867|growth factor
568243|NCT00438867|myocardia ischemia
568244|NCT00438867|revascularization
568245|NCT00438854|dasatinib
568246|NCT00438854|BMS-354825
568247|NCT00438854|CLL
568248|NCT00438854|SLL
568249|NCT00438854|LYN kinase
568250|NCT00438841|stage I multiple myeloma
568251|NCT00438841|stage II multiple myeloma
568252|NCT00438841|stage III multiple myeloma
568253|NCT00438828|radiation therapy
568254|NCT00438828|palliative
568255|NCT00438828|pain
568256|NCT00438815|Hereditary angioedema
568257|NCT00438815|C1 esterase inhibitor (human)
568258|NCT00438802|recurrent cutaneous T-cell non-Hodgkin lymphoma
568259|NCT00438802|angioimmunoblastic T-cell lymphoma
568260|NCT00438802|anaplastic large cell lymphoma
568261|NCT00438802|adult nasal type extranodal NK/T-cell lymphoma
568262|NCT00438802|recurrent mycosis fungoides/Sezary syndrome
568263|NCT00438763|CMC arthritis
568264|NCT00438763|splint treatment
568265|NCT00438763|patient satisfaction
568266|NCT00438763|DASH questionnaire
568267|NCT00438750|distal radius fracture
568268|NCT00438750|rehabilitation
568269|NCT00438750|volar plate fixation
568270|NCT00438750|DASH questionnaire
568271|NCT00438737|liver metastases
568272|NCT00438737|stage IV colon cancer
568273|NCT00438737|stage IV rectal cancer
568274|NCT00438737|recurrent colon cancer
568275|NCT00438737|recurrent rectal cancer
568276|NCT00438724|Caregivers
568277|NCT00438724|Caregiving
568278|NCT00438724|Spousal relationships
568279|NCT00438724|cognition disorders
568280|NCT00438724|therapy
568281|NCT00438724|mental health
568282|NCT00438724|psychosocial
568283|NCT00438698|Nutrition
568284|NCT00438698|Type 2 Diabetes
568285|NCT00438685|Substance-Related Disorders
568286|NCT00438685|Depressive Disorder
568287|NCT00438685|Anxiety Disorder
568288|NCT00438685|Adolescent
568289|NCT00438685|Behavior Therapy
568290|NCT00438685|Cognitive Therapy
568291|NCT00438685|Outpatients
568292|NCT00438685|Family Relations
568293|NCT00438685|Systems Theory
568294|NCT00438672|lateral elbow pain
568295|NCT00438672|tennis elbow
568296|NCT00438672|pain
568297|NCT00438672|psychology
568298|NCT00438659|dermatologic complications
568299|NCT00438659|skin reactions secondary to radiation therapy
568300|NCT00438659|radiation toxicity
568301|NCT00438659|breast cancer in situ
568302|NCT00438659|recurrent breast cancer
568303|NCT00438659|stage I breast cancer
568304|NCT00438659|stage II breast cancer
568305|NCT00438659|stage IIIA breast cancer
568306|NCT00438659|stage IIIB breast cancer
568307|NCT00438659|stage IIIC breast cancer
568308|NCT00438659|male breast cancer
568309|NCT00438659|ductal breast carcinoma in situ
568310|NCT00438659|stage IV breast cancer
568311|NCT00438646|Allergy
568312|NCT00438646|Asthma
568313|NCT00438646|Eczema
568314|NCT00438646|Hay Fever
568315|NCT00438646|Epidemiology
568316|NCT00438633|proximal humerus fracture
568317|NCT00438633|rehabilitation
568318|NCT00438633|non-operative treatment
568319|NCT00438633|DASH and Constant instruments
568320|NCT00438607|Moderate to late stage Parkinson's Disease
568321|NCT00438594|nurse
568322|NCT00438594|paraprofessional
568323|NCT00438594|home visits
568324|NCT00438594|pregnancy
568325|NCT00438594|welfare
568326|NCT00438594|child development
568327|NCT00438581|Zevalin
568328|NCT00438581|Autologous one Marrow Transplant
568329|NCT00438581|Non-Hodgkin's Lymphoma
568330|NCT00438568|amyloid protein
568331|NCT00438568|brain metabolism
568332|NCT00438568|glucose metabolism
568333|NCT00438568|insulin sensitivity /resistance
568334|NCT00438568|cognition disorders
568335|NCT00438555|obesity,prevention,pediatric
568336|NCT00436761|unspecified childhood solid tumor, protocol specific
568337|NCT00436748|Chronic Kidney Disease
568338|NCT00436748|Dialysis
568339|NCT00436748|Anemia
568340|NCT00436748|Nephrology
568341|NCT00436748|Pediatric
568342|NCT00436748|Hemodialysis
568343|NCT00436748|Peritoneal Dialysis
568344|NCT00436748|Chronic Renal Insufficiency
568345|NCT00436722|Liver
568346|NCT00436722|Transplantation
568347|NCT00436722|Tolerance
568348|NCT00436722|Induction
568349|NCT00436722|Tacrolimus
568350|NCT00436722|Liver transplantation
568351|NCT00436722|Adult
568352|NCT00436709|male breast cancer
568353|NCT00436709|stage I breast cancer
568354|NCT00436709|stage II breast cancer
568355|NCT00436709|stage IIIA breast cancer
568356|NCT00438542|Adiponectin, cord blood, pre-eclampsia
568357|NCT00438516|home visits
568358|NCT00438516|pregnancy
568359|NCT00438516|welfare
568360|NCT00438516|child development
568361|NCT00438516|mortality
568362|NCT00438503|Hemodialysis, diabetes mellitus,
568363|NCT00438503|Chronic renal failure, dialysis ,
568364|NCT00438490|galactorrhea
568365|NCT00438490|prolactin
568366|NCT00438490|bone turnover
568367|NCT00438490|menstrual cycle
568368|NCT00438490|Control Groups
568369|NCT00438490|Women
568370|NCT00438477|recurrent breast cancer
568371|NCT00438477|stage IIIA breast cancer
568372|NCT00438477|stage IIIB breast cancer
568373|NCT00438477|stage IIIC breast cancer
568374|NCT00438477|stage II breast cancer
568375|NCT00438451|elderly
568376|NCT00438451|focal epilepsy
568377|NCT00438451|anticonvulsive
568378|NCT00438451|treatment
568379|NCT00438451|levetiracetam
568380|NCT00438451|lamotrigine
568381|NCT00438451|carbamazepine
568382|NCT00438438|forced desynchrony
568383|NCT00438438|circadian rhythms
568384|NCT00438438|sleep restriction
568385|NCT00438438|sleep homeostasis
568386|NCT00438438|neurobehavioral performance
568387|NCT00438425|Hyperlipidemia
568388|NCT00438425|Hypercholesterolemia
568389|NCT00438425|Dietary modification
568390|NCT00438425|Portfolio
568391|NCT00438412|Noradrenalin
568392|NCT00438412|Endothelin-1
568393|NCT00438412|Angiotensin II
568394|NCT00438412|Arginine vasopressin
568395|NCT00438412|Aldosterone
568396|NCT00438412|Renin
568397|NCT00438412|Atrial natriuretic peptide
568398|NCT00438412|Brain natriuretic peptide
568399|NCT00438412|Blood pressure
568400|NCT00438412|Apnea
568401|NCT00438399|1 Galderma,
568402|NCT00438399|2 Scalp Psoriasis
568403|NCT00438399|3 Subject preference
568404|NCT00438399|4 Clobetasol propionate
568405|NCT00438399|5 Shampoo
568406|NCT00438386|Generalized Anxiety Disorder
568407|NCT00438386|Panic Disorder
568408|NCT00438386|Anxiety Disorder
568409|NCT00438386|Aripiprazole
568410|NCT00438373|Subfertility, Luteinizing hormone, receptor
568411|NCT00438360|Cyclosporine, chronic plaque psoriasis, intermittent therapy
568412|NCT00438347|Mild Cognitive Impairment
568413|NCT00438347|cognition disorders
568414|NCT00438347|brain health
568415|NCT00438347|psychological aspect of aging
568416|NCT00438347|exercise
568417|NCT00438347|physical fitness
568418|NCT00438334|Benefit
568419|NCT00438334|Directional microphones
568420|NCT00438334|Hearing
568421|NCT00438334|Hearing aids
568422|NCT00438334|Hearing loss
568423|NCT00438334|Noise
568424|NCT00438334|Objective benefit
568425|NCT00438334|Signal-to-noise ratio
568426|NCT00438334|Speech understanding
568427|NCT00438334|Subjective benefit
568428|NCT00438321|Overweight
568429|NCT00438321|obesity
568430|NCT00438321|testosterone
568431|NCT00438321|diabetes
568432|NCT00438321|metabolic syndrome
568433|NCT00438321|aging
568434|NCT00438308|distal radius fracture
568435|NCT00438308|rehabilitation
568436|NCT00438308|volar plate fixation
568437|NCT00438308|DASH questionnaire
568438|NCT00438295|glucose in dialysis water, dialysis treatment, temperature
568439|NCT00438282|nurse
568440|NCT00438282|home visits
568441|NCT00438282|pregnancy
568442|NCT00438282|welfare
568443|NCT00438282|child development
568444|NCT00438269|Infection
568445|NCT00438269|Empiric
568446|NCT00438269|Antibiotics
568447|NCT00438269|Nosocomial
568448|NCT00438269|Pyrexia
568449|NCT00438269|Leukocytosis
568450|NCT00438269|Resistance
568451|NCT00438256|accelerated short course
568452|NCT00438256|proton beam radiation
568453|NCT00438243|Pseudophakic macular edema
568454|NCT00438230|Residual vein thrombosis
568455|NCT00438230|Optimal duration
568456|NCT00438230|Oral anticoagulants
568457|NCT00438217|precocious puberty, genetics, environmental factors
568458|NCT00438204|stage IIIB non-small cell lung cancer
568459|NCT00438204|stage IV non-small cell lung cancer
568460|NCT00438204|adenocarcinoma of the lung
568461|NCT00438204|bronchoalveolar cell lung cancer
568462|NCT00438204|large cell lung cancer
568463|NCT00438204|recurrent non-small cell lung cancer
568464|NCT00438191|DeQuervain's tenosynovitis
568465|NCT00438191|splinting
568466|NCT00438191|grip strength
568467|NCT00438191|satisfaction
568468|NCT00438191|DASH questionnaire
568469|NCT00438165|nurse
568470|NCT00438165|home visits
568471|NCT00438165|pregnancy
568472|NCT00438165|welfare
568473|NCT00438165|child development
568474|NCT00438152|Lopinavir
568475|NCT00438152|Saquinavir
568476|NCT00438152|Lipids
568477|NCT00438152|HIV-1
568478|NCT00438152|Treatment Experienced
568479|NCT00438139|marijuana dependence
568480|NCT00438126|diabetes
568481|NCT00438126|Prevention
568482|NCT00438126|American Indian
568483|NCT00438113|blood pressure
568484|NCT00438113|atrial fibrillation
568485|NCT00438113|catheter ablation
568486|NCT00438100|Breast Neoplasms
568487|NCT00438100|Drug Therapy
568488|NCT00438087|Facial palsy
568489|NCT00438087|Vestibular schwannoma
568490|NCT00438087|Anti-inflammatory drugs
568491|NCT00438087|Post surgery of vestibular schwannoma
568492|NCT00438087|or of cranial base tumors
568493|NCT00438074|Breast Cancer
568494|NCT00438074|Diffuse Optical Spectroscopy
568495|NCT00438061|Lipoprotein metabolism
568496|NCT00438061|Cardiovascular disease
568497|NCT00438061|Obesity
568498|NCT00438048|Pilocarpine
568499|NCT00438048|Artificial saliva
568500|NCT00438048|Xerostomia
568501|NCT00438048|Xerostomy
568502|NCT00438048|Primary Sjogren
568503|NCT00438048|Secondary Sjogren
568504|NCT00438035|Postoperative pain
568505|NCT00438035|Heart rate variability, sympathetic, parasympathetic
568506|NCT00438035|Visual analog pain scale
568507|NCT00438035|Spectral analysis of ECG
568508|NCT00438022|Atopic Dermatitis
568509|NCT00438022|Eczema Herpeticum
568510|NCT00438009|coxsackievirus type a21
568511|NCT00438009|oncolytic virus
568512|NCT00438009|melanoma
568513|NCT00437996|Labor analgesia - clonidine - epidural
568514|NCT00437957|histone deacetylase
568515|NCT00437957|unresectable brain metastases
568516|NCT00437931|hypothyroidism
568517|NCT00437931|hyperthyroidism
568518|NCT00437931|thyroid dysfunction
568519|NCT00437931|ultrasound
568520|NCT00437931|doppler
568521|NCT00437905|peripheral vascular disease
568522|NCT00437905|percutaneous transluminal angioplasty
568523|NCT00437905|cutting balloon
568524|NCT00437905|balloon angioplasty
568525|NCT00437905|randomized controlled trial
568526|NCT00437905|restenosis
568527|NCT00437905|inflammation
568528|NCT00437892|Statins
568529|NCT00437892|secondary prevention
568530|NCT00437892|venous thromboembolism
568531|NCT00437892|d-dimer
568532|NCT00437879|Breast Cancer
568533|NCT00437879|Ultrasound
568534|NCT00437840|smoking,
568535|NCT00437840|healthy volunteers,
568536|NCT00437840|safety,
568537|NCT00437840|tolerability,
568538|NCT00437840|pharmacokinetics,
568539|NCT00437840|pharmacodynamics
568540|NCT00437827|Depression
568541|NCT00437814|Ketamine
568542|NCT00437814|Traumatic Brain Injury
568543|NCT00437814|Intracranial Hypertension
568544|NCT00436696|disseminated neuroblastoma
568545|NCT00436696|localized resectable neuroblastoma
568546|NCT00436696|localized unresectable neuroblastoma
568547|NCT00436696|recurrent neuroblastoma
568548|NCT00436696|regional neuroblastoma
568549|NCT00436683|Hyperphosphataemia
568550|NCT00436683|Phosphate binder
568551|NCT00437788|imaging
568552|NCT00437775|Diabetes Mellitus type 2
568553|NCT00437775|ACE Inhibitors
568554|NCT00437775|ARBs
568555|NCT00437775|Adverse drug effect
568556|NCT00437762|Lateral epicondylitis, tennis elbow, treatment
568557|NCT00437749|Non small cell lung cancer
568558|NCT00437749|Advanced
568559|NCT00437749|Inoperable
568560|NCT00437749|taxanes
568561|NCT00437749|carboplatin
568562|NCT00437749|multi-drug resistance
568563|NCT00437736|solid tumor
568564|NCT00437736|phase I study
568565|NCT00437736|dose-escalation
568566|NCT00437710|bone marrow, cell transplantation, stem cells, PTCA
568567|NCT00437697|dalteparin, critically ill, thromboprophylaxis
568568|NCT00437684|HIV/HCV
568569|NCT00437684|HIV and HCV coinfected patients
568570|NCT00437684|Treatment Experienced
568571|NCT00437671|trismus
568572|NCT00437671|lockjaw
568573|NCT00437645|Essential hypertension
568574|NCT00437645|blood pressure
568575|NCT00437645|edema
568576|NCT00437645|valsartan
568577|NCT00437645|amlodipine
568578|NCT00437645|combination treatment
568579|NCT00437632|repeat dose,
568580|NCT00437632|GSK598809
568581|NCT00437632|pharmacokinetics,
568582|NCT00437632|tolerability,
568583|NCT00437632|placebo,
568584|NCT00437632|Safety,
568585|NCT00437632|pharmacodynamics,
568586|NCT00437593|preretinal membrane
568587|NCT00437593|vitrectomy
568588|NCT00437593|uhr-oct
568589|NCT00437593|hd-oct
568590|NCT00437580|Vancomycin Resistant Enterococcus, probiotic
568591|NCT00437567|galacto-oligosaccharides
568592|NCT00437567|prebiotics
568593|NCT00437567|NEC
568594|NCT00437541|Insulation
568595|NCT00437541|Warmth
568596|NCT00437541|Humidity
568597|NCT00437541|Damp
568598|NCT00437541|Cold
568599|NCT00437541|Respiratory
568600|NCT00437541|Mould
568601|NCT00437528|Heat flow
568602|NCT00437528|Sensor
568603|NCT00437528|Overactive bladder
568604|NCT00437528|Urinary incontinence
568605|NCT00437502|Immunotherapeutic vaccine
568606|NCT00437502|Ovarian cancer
568607|NCT00437502|epithelial ovarian cancer
568608|NCT00437502|tubal cancer
568609|NCT00437502|peritoneal cancer
568610|NCT00437502|immunotherapy
568611|NCT00437476|HIV/HCV
568612|NCT00437476|HIV and HCV coinfected patients
568613|NCT00437476|Treatment Naive
568614|NCT00437450|Anemia
568615|NCT00437450|myelodysplastic syndromes
568616|NCT00437450|Low risk
568617|NCT00437450|Bone Marrow diseases
568618|NCT00437437|Advanced or metastatic solid tumors
568619|NCT00437424|Hepatocellular cancer
568620|NCT00437424|Other advanced solid malignancies
568621|NCT00437411|Fibromyalgia
568622|NCT00437411|Affect
568623|NCT00437411|Pain
568624|NCT00437411|Fatigue
568625|NCT00437411|Sleep
568626|NCT00437411|Stress
568627|NCT00437411|Quality of Life
568628|NCT00437411|Stress, Psychological
568629|NCT00437411|Psychophysiology
568630|NCT00437411|Randomized Controlled Trials
568631|NCT00437398|hypoglycemic unawareness
568632|NCT00437385|therapy resistant depression, severe depression
568633|NCT00437372|solid tumor
568634|NCT00437372|central nervous system
568635|NCT00437372|head and neck
568636|NCT00437372|thorax
568637|NCT00437372|pelvic area
568638|NCT00437359|Breast Neoplasms
568639|NCT00437359|Drug Therapy
568640|NCT00437346|dyspepsia
568641|NCT00437346|functional dyspepsia
568642|NCT00437346|treatment
568643|NCT00437346|drug therapy
568644|NCT00437346|information
568645|NCT00437333|Insulin sensitivity
568646|NCT00437333|Insulin-sensitizing drug
568647|NCT00437333|Metformin
568648|NCT00437333|PCOS
568649|NCT00437333|Treatment
568650|NCT00437320|PDT
568651|NCT00437320|Photoaging
568652|NCT00437320|Galderma
568653|NCT00437281|Partial-onset seizures; epilepsy; pediatric; pregabalin; safety; tolerability; pharmacokinetics
568654|NCT00437242|interval,
568655|NCT00437242|atrial fibrillation
568656|NCT00437242|QT,
568657|NCT00437242|odiparcil,
568658|NCT00437229|GW679769,
568659|NCT00437229|Casopitant,
568660|NCT00437229|Dexamethasone,
568661|NCT00437229|Healthy Human Volunteer
568662|NCT00437229|Ondansetron,
568663|NCT00437203|Advanced cancer
568664|NCT00437190|Cervical Disc Replacement
568665|NCT00437190|Spondylotic radiculopathy
568666|NCT00437190|Spondylotic myelopathy
568667|NCT00437190|Myelopathy
568668|NCT00437190|Radiculopathy
568669|NCT00437177|alcoholism
568670|NCT00437177|apomorphine
568671|NCT00437177|iodobenzamide
568672|NCT00437177|imaging
568673|NCT00437177|spect
568674|NCT00437177|relapse
568675|NCT00437164|NaBr
568676|NCT00437164|Sodium Bromide
568677|NCT00437164|DEXA Deuterium
568678|NCT00437164|Total Body Water
568679|NCT00437164|Insulin
568680|NCT00437164|D2O
568681|NCT00437164|GW677954
568682|NCT00437164|Randomized Withdrawal
568683|NCT00437164|T2DM
568684|NCT00437138|Air pollution
568685|NCT00437138|Myocardial ischemia
568686|NCT00437138|Endothelium
568687|NCT00437138|Fibrinolysis
568688|NCT00437138|Pathophysiology
568689|NCT00437138|Diesel exhaust
568690|NCT00437086|chronic myelomonocytic leukemia
568691|NCT00437086|primary myelofibrosis
568692|NCT00437073|brain metastases
568693|NCT00437073|ErbB2
568694|NCT00437073|lapatinib
568695|NCT00437073|Breast Cancer
568696|NCT00437073|HYCAMTIN
568697|NCT00437073|topotecan
568698|NCT00437073|capecitabine
568699|NCT00437073|metastatic breast cancer
568700|NCT00437073|TYKERB
568701|NCT00437073|XELODA
568702|NCT00437021|smallpox, vaccine, IMVAMUNE®
568703|NCT00437008|endothelial dysfunction
568704|NCT00437008|flow-mediated dilatation
568705|NCT00437008|advanced glycation end products
568706|NCT00437008|postprandial
568707|NCT00436995|Dialysis
568708|NCT00436995|Anaemia
568709|NCT00436969|Orthovisc
568710|NCT00436969|Osteoarthritis
568711|NCT00436969|Shoulder
568712|NCT00436969|Randomized
568713|NCT00436956|VEGF
568714|NCT00436956|Angiogenesis
568715|NCT00436956|Hormone-Refractory
568716|NCT00436956|Bone Metastases
568717|NCT00436956|Docetaxel-Resistant
568718|NCT00436956|Prostate Cancer
568719|NCT00436943|smoking cessation
568720|NCT00436943|nicotine replacement therapy
568721|NCT00436943|bupropion
568722|NCT00436943|smoking
568723|NCT00436930|recurrent melanoma
568724|NCT00436930|stage IV melanoma
568725|NCT00436917|stage I breast cancer
568726|NCT00436917|stage II breast cancer
568727|NCT00436917|stage IIIA breast cancer
568728|NCT00436917|osteoporosis
568729|NCT00436904|stage 0 chronic lymphocytic leukemia
568730|NCT00436904|stage I chronic lymphocytic leukemia
568731|NCT00436904|stage II chronic lymphocytic leukemia
568732|NCT00436904|B-cell chronic lymphocytic leukemia
568733|NCT00436891|Group A Streptococcus, scabies, pyoderma, Fiji
568734|NCT00436878|Eating Behavior
568735|NCT00436878|Children
568736|NCT00436878|Portion size
568737|NCT00436878|Experimental
568738|NCT00436826|Multiple Sclerosis
568739|NCT00436826|Relapsing forms
568740|NCT00436826|Interferon-beta therapy
568741|NCT00436787|Anticoagulation Prophylaxis
568742|NCT00436787|Venous Thrombosis
568743|NCT00436787|Deep Vein Thrombosis
568744|NCT00436787|Pulmonary Embolism
568745|NCT00436787|Fondaparinux Sodium
568746|NCT00436787|Arixtra
568747|NCT00436787|Pharmakinetics
568748|NCT00436774|long-term effects secondary to cancer therapy in children
568749|NCT00436774|neurotoxicity
568750|NCT00436774|gastrointestinal complications
568751|NCT00436774|pulmonary complications
568752|NCT00436774|sexual dysfunction
568753|NCT00436774|infertility
568754|NCT00436774|urinary complications
568755|NCT00436774|childhood extragonadal germ cell tumor
568756|NCT00436774|childhood malignant ovarian germ cell tumor
568757|NCT00436774|childhood malignant testicular germ cell tumor
568758|NCT00436774|childhood teratoma
568759|NCT00436670|Asthma
568760|NCT00436670|Allergy
568761|NCT00436670|IL-13
568762|NCT00436670|IL-4
568763|NCT00436670|IL-4R
568764|NCT00436657|Children
568765|NCT00436657|Pediatric
568766|NCT00436657|Peritoneal Tumor
568767|NCT00436657|Retroperitoneal Tumor
568768|NCT00436657|Gastrointestinal Adenocarcinoma
568769|NCT00436657|Desmoplastic Round Cell Tumor
568770|NCT00436657|Neuroblastoma
568771|NCT00436657|Ovarian Germ Cell
568772|NCT00436657|Sarcoma
568773|NCT00436657|Adrenocorticocarcinoma
568774|NCT00436657|Wilms' Tumor
568775|NCT00436657|Rhabdomyosarcoma
568776|NCT00436657|Desmoplastic Small Round Cell Tumor
568777|NCT00436657|Recurrent Tumors
568778|NCT00436657|Cisplatin
568779|NCT00436657|Platinol®-AQ
568780|NCT00436657|Platinol®
568781|NCT00436657|CDDP
568782|NCT00436657|Abdominal Wash
568783|NCT00436657|Hyperthermic Perfusion
568784|NCT00436657|Continuous Hyperthermic Peritoneal Perfusion
568785|NCT00436657|CHPP
568786|NCT00436644|recurrent ovarian epithelial cancer
568787|NCT00436644|peritoneal cavity cancer
568788|NCT00436631|epilepsy
568789|NCT00436631|seizures
568790|NCT00436631|intractable
568791|NCT00436631|ketosis
568792|NCT00436631|ketogenic
568793|NCT00436631|diet
568794|NCT00436618|recurrent adult Burkitt lymphoma
568795|NCT00436618|recurrent adult Hodgkin lymphoma
568796|NCT00436618|anaplastic large cell lymphoma
568797|NCT00436618|angioimmunoblastic T-cell lymphoma
568798|NCT00436618|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
568799|NCT00436618|nodal marginal zone B-cell lymphoma
568800|NCT00436618|splenic marginal zone lymphoma
568801|NCT00436618|small intestine lymphoma
568802|NCT00436618|recurrent adult diffuse mixed cell lymphoma
568803|NCT00436618|recurrent adult T-cell leukemia/lymphoma
568804|NCT00436618|recurrent grade 3 follicular lymphoma
568805|NCT00436618|recurrent marginal zone lymphoma
568806|NCT00436618|refractory chronic lymphocytic leukemia
568807|NCT00436618|recurrent small lymphocytic lymphoma
568808|NCT00436618|recurrent mycosis fungoides/Sezary syndrome
568809|NCT00436618|adult nasal type extranodal NK/T-cell lymphoma
568810|NCT00436618|Waldenstrom macroglobulinemia
568811|NCT00436618|recurrent adult diffuse large cell lymphoma
568812|NCT00436618|recurrent adult lymphoblastic lymphoma
568813|NCT00436618|recurrent mantle cell lymphoma
568814|NCT00436618|recurrent grade 1 follicular lymphoma
568815|NCT00436618|recurrent grade 2 follicular lymphoma
568816|NCT00436618|primary central nervous system non-Hodgkin lymphoma
568817|NCT00436618|primary central nervous system Hodgkin lymphoma
568818|NCT00436618|post-transplant lymphoproliferative disorder
568819|NCT00436618|recurrent adult diffuse small cleaved cell lymphoma
568820|NCT00436592|acute
568821|NCT00436592|ischemic
568822|NCT00436592|stroke
568823|NCT00436592|device
568824|NCT00436592|treatment
568825|NCT00436566|cardiac toxicity
568826|NCT00436566|male breast cancer
568827|NCT00436566|stage I breast cancer
568828|NCT00436566|stage II breast cancer
568829|NCT00436566|stage IIIA breast cancer
568830|NCT00436553|Age-related macular degeneration; AMD
568831|NCT00436553|choroidal neovascularization
568832|NCT00436553|verteporfin
568833|NCT00436553|ranibizumab
568834|NCT00436514|patients
568835|NCT00436514|medium risk
568836|NCT00436514|asymptomatic
568837|NCT00436514|between 50 and 74 years old
568838|NCT00436514|high risk
568839|NCT00436514|case
568840|NCT00436514|history of neoplastic colic
568841|NCT00436514|cancers
568842|NCT00436514|polyps
568843|NCT00436501|primary peritoneal cavity cancer
568844|NCT00436501|Ovarian Epithelial Cancer
568845|NCT00436501|Peritoneal Cancer
568846|NCT00436501|Fallopian Tube Cancer
568847|NCT00436501|VEGF Trap
568848|NCT00436501|aflibercept
568849|NCT00436501|vascular endothelial growth factor trap
568850|NCT00436501|Zaltrap
568851|NCT00436501|docetaxel
568852|NCT00436501|RP 56976
568853|NCT00436501|Taxotere
568854|NCT00436501|TXT
568855|NCT00436488|ICAM-1
568856|NCT00436488|Obesity
568857|NCT00436488|Gene variants
568858|NCT00436475|Glucose intolerance
568859|NCT00436475|Type 2 diabetes mellitus
568860|NCT00436475|Metabolic syndrome
568861|NCT00436462|Steroid receptors
568862|NCT00436462|Endometrium
568863|NCT00436462|IVF
568864|NCT00436462|Follicular phase
568865|NCT00436436|adult giant cell glioblastoma
568866|NCT00436436|adult gliosarcoma
568867|NCT00436436|recurrent adult brain tumor
568868|NCT00436436|adult glioblastoma
568869|NCT00436423|pancreatic neoplasm
568870|NCT00436423|drug therapy
568871|NCT00436423|gemcitabine
568872|NCT00436423|TS-1
568873|NCT00436410|stage IV colon cancer
568874|NCT00436410|stage IV rectal cancer
568875|NCT00436410|adult primary hepatocellular carcinoma
568876|NCT00436410|stage IV pancreatic cancer
568877|NCT00436410|male breast cancer
568878|NCT00436410|stage IV breast cancer
568879|NCT00436410|stage IV melanoma
568880|NCT00436410|stage I breast cancer
568881|NCT00436410|stage II breast cancer
568882|NCT00436410|stage IIIA breast cancer
568883|NCT00436410|stage IIIB breast cancer
568884|NCT00436410|stage IIIC breast cancer
568885|NCT00436410|recurrent breast cancer
568886|NCT00436410|recurrent adrenocortical carcinoma
568887|NCT00436410|stage I adrenocortical carcinoma
568888|NCT00436410|stage II adrenocortical carcinoma
568889|NCT00436410|stage III adrenocortical carcinoma
568890|NCT00436410|stage IV adrenocortical carcinoma
568891|NCT00436410|recurrent colon cancer
568892|NCT00436410|stage I colon cancer
568893|NCT00436410|stage II colon cancer
568894|NCT00436410|stage III colon cancer
568895|NCT00436410|recurrent rectal cancer
568896|NCT00436410|stage I rectal cancer
568897|NCT00436410|stage II rectal cancer
568898|NCT00436410|stage III rectal cancer
568899|NCT00436410|advanced adult primary liver cancer
568900|NCT00436410|localized resectable adult primary liver cancer
568901|NCT00436410|recurrent adult primary liver cancer
568902|NCT00436410|recurrent pancreatic cancer
568903|NCT00436410|stage I pancreatic cancer
568904|NCT00436410|stage II pancreatic cancer
568905|NCT00436410|stage III pancreatic cancer
568906|NCT00436410|recurrent melanoma
568907|NCT00436410|stage I melanoma
568908|NCT00436410|stage II melanoma
568909|NCT00436410|stage III melanoma
568910|NCT00436410|stage I renal cell cancer
568911|NCT00436410|stage II renal cell cancer
568912|NCT00436410|stage III renal cell cancer
568913|NCT00436410|stage IV renal cell cancer
568914|NCT00436410|recurrent renal cell cancer
568915|NCT00436410|recurrent ovarian epithelial cancer
568916|NCT00436410|stage I ovarian epithelial cancer
568917|NCT00436410|stage II ovarian epithelial cancer
568918|NCT00436410|stage III ovarian epithelial cancer
568919|NCT00436410|stage IV ovarian epithelial cancer
568920|NCT00436410|gastrointestinal cancer
568921|NCT00436410|adult fibrosarcoma
568922|NCT00436410|recurrent adult soft tissue sarcoma
568923|NCT00436410|stage I adult soft tissue sarcoma
568924|NCT00436410|stage II adult soft tissue sarcoma
568925|NCT00436410|stage III adult soft tissue sarcoma
568926|NCT00436410|stage IV adult soft tissue sarcoma
568927|NCT00436397|unspecified adult solid tumor, protocol specific
568928|NCT00436384|liver transplant
568929|NCT00436384|lung transplant
568930|NCT00436384|kidney transplant
568931|NCT00436384|heart transplant
568932|NCT00436384|CMV CMI
568933|NCT00436358|Mexico
568934|NCT00436358|Intussusception
568935|NCT00436358|Epidemiology
568936|NCT00436345|analgesia
568937|NCT00436345|Mechanical ventilation
568938|NCT00436345|pharmaco-economic
568939|NCT00436345|ICU
568940|NCT00436332|recurrent non-small cell lung cancer
568941|NCT00436332|stage IIIB non-small cell lung cancer
568942|NCT00436332|stage IV non-small cell lung cancer
568943|NCT00436332|bronchoalveolar cell lung cancer
568944|NCT00436332|adenocarcinoma of the lung
568945|NCT00436319|Infertility, downregulation, stimulation, agonists, long
568946|NCT00436306|prevention
568947|NCT00436306|behavior
568948|NCT00436306|risk reduction behavior
568949|NCT00436267|recurrent pancreatic cancer
568950|NCT00436267|stage IV pancreatic cancer
568951|NCT00436267|liver metastases
568952|NCT00436228|healthy volunteer,
568953|NCT00436228|Bioavailability,
568954|NCT00436228|safety
568955|NCT00436228|Phase I,
568956|NCT00436215|Sorafenib
568957|NCT00436215|Ovarian Cancer
568958|NCT00436215|Fallopian Cancer
568959|NCT00436215|Bevacizumab
568960|NCT00436215|Peritoneal Cancer
568961|NCT00436215|Fallopian Tube Cancer
568962|NCT00436202|Anemia
568963|NCT00436202|Iron
568964|NCT00436202|Supplement
568965|NCT00436189|Ovarian
568966|NCT00436189|Cancer
568967|NCT00436189|Pelvic
568968|NCT00436189|Mass
568969|NCT00436189|Tumor
568970|NCT00436189|Adnexal
568971|NCT00436189|Proteomics
568972|NCT00436176|Diabetes mellitus
568973|NCT00436176|Quality of Health Care
568974|NCT00436176|Cultural Competency
568975|NCT00436176|Performance Feedback
568976|NCT00436176|Health navigator
568977|NCT00436176|Health disparities
568978|NCT00436176|Racial disparities
568979|NCT00436150|Adolescents
568980|NCT00436150|Depression, postpartum
568981|NCT00436137|Colorectal cancer
568982|NCT00436137|Fecal occult blood test
568983|NCT00436137|Abnormal test result
568984|NCT00436137|Missed diagnosis
568985|NCT00436137|Delayed diagnosis
568986|NCT00436111|hyperprolactinemia
568987|NCT00436111|autoantibody
568988|NCT00436098|congenital heart disease
568989|NCT00436098|exercise training
568990|NCT00436098|motorpedagogical exercise
568991|NCT00436098|children
568992|NCT00436098|CHD: hemodynamically not significant defects
568993|NCT00436098|CHD: acyanotic defects after repair
568994|NCT00436098|CHD: cyanotic defects after repair
568995|NCT00436072|ZD6474
568996|NCT00436072|cetuximab
568997|NCT00436072|irinotecan
568998|NCT00436046|interferon, vaccine, influenza
568999|NCT00436020|clinical trial
569000|NCT00436020|TMS
569001|NCT00436020|depression
569002|NCT00436020|bipolar disorder
569003|NCT00436007|Africa
569004|NCT00436007|Plasmodium falciparum
569005|NCT00436007|Malaria
569006|NCT00435994|Infant
569007|NCT00435994|Respiratory Syncytial Virus
569008|NCT00435994|Bronchiolitis
569009|NCT00435981|Type 1 diabetes
569010|NCT00435981|GAD65
569011|NCT00435981|Autoimmunity
569012|NCT00435981|C-peptide
569013|NCT00435981|Children
569014|NCT00435968|NK Cells
569015|NCT00435968|Cytokines
569016|NCT00435968|Lymphocytes
569017|NCT00435968|Immunoglobulins
569018|NCT00435968|Th1 response
569019|NCT00435955|Follicular lymphoma
569020|NCT00435955|age adjusted IPI >1
569021|NCT00435955|IIL score > 2
569022|NCT00435955|Molecular remission
569023|NCT00435955|High dose chemotherapy and autologous transplantation
569024|NCT00435955|Rituximab
569025|NCT00435929|Treatment Naive
569026|NCT00435916|Antigens, CD40
569027|NCT00435916|Antibody, Monoclonal
569028|NCT00435916|Lymphoma, Large B-Cell, Diffuse
569029|NCT00435916|Lymphoma, Non-Hodgkin
569030|NCT00435916|Hematologic Diseases
569031|NCT00435916|Immunoproliferative Disorders
569032|NCT00435916|Lymphatic Diseases
569033|NCT00435916|Lymphoproliferative Disorders
569034|NCT00435916|Lymphoma
569035|NCT00435903|smoking
569036|NCT00435903|self-monitoring
569037|NCT00435903|major mental illness
569038|NCT00435903|palm pilots
569039|NCT00435903|subjects with DSM-IV Axis I diagnosis
569040|NCT00435890|ED Overcrowding
569041|NCT00435890|Length of stay
569042|NCT00435890|Emergency triage
569043|NCT00435890|triage
569044|NCT00435877|Connective Tissue
569045|NCT00435877|Stromal Cells
569046|NCT00435877|Surgical Waste
569047|NCT00435877|In Vivo Studies
569048|NCT00435877|Tissue Analysis
569049|NCT00435864|recipient of a HSC graft in Acute Myeloblastic Leukemia therapy
569050|NCT00435864|recipient of a HSC graft in others pathologies treated in hematology of Nantes university hospital or Angers university hospital
569051|NCT00435864|donors are healthy subjects
569052|NCT00435838|HLa-B*5701 Abacavir
569053|NCT00435812|HBV vaccine
569054|NCT00435812|Hepatitis B vaccine
569055|NCT00435812|Hepatitis B
569056|NCT00435812|Hepatitis
569057|NCT00435812|HBV
569058|NCT00435812|Immunostimulatory sequence (ISS)
569059|NCT00435799|keratoconus
569060|NCT00435799|corneal cross-linking
569061|NCT00435799|riboflavine
569062|NCT00435799|ultraviolet type A rays (UVA)
569063|NCT00435773|Osteoarthritis
569064|NCT00435773|Leeching
569065|NCT00435773|Randomized Controlled Trial
569066|NCT00435773|Arthralgia
569067|NCT00435760|COPD
569068|NCT00435721|schizophrenia
569069|NCT00435721|family psychoeducation
569070|NCT00435708|COPD
569071|NCT00435708|Fruit
569072|NCT00435708|Vegetables
569073|NCT00435708|Oxidative stress
569074|NCT00435708|Inflammation
569075|NCT00435695|PET scan
569076|NCT00435695|healthy males
569077|NCT00435682|The trial is performed on healthy normal males.
569078|NCT00435669|Advanced or metastatic solid tumors
569079|NCT00435656|Human immunodeficiency virus
569080|NCT00435643|Sleep apnea,
569081|NCT00435643|adiponectin ,
569082|NCT00435643|HPA axis
569083|NCT00435630|Education
569084|NCT00435630|Virtual Reality
569085|NCT00435630|Laparoscopic Surgery
569086|NCT00435630|Learning Curve
569087|NCT00435617|stroke rehabilitation
569088|NCT00435617|stroke therapy
569089|NCT00435617|hand therapy
569090|NCT00435617|stroke
569091|NCT00435617|cerebrovascular stroke
569092|NCT00435617|cerebral stroke
569093|NCT00435604|hyaluronidase
569094|NCT00435604|subcutaneous drug delivery
569095|NCT00435604|Volunteer Subjects
569096|NCT00435591|Hyponatremia
569097|NCT00435591|Euvolemia
569098|NCT00435591|Hypervolemia
569099|NCT00435591|Conivaptan
569100|NCT00435591|Vaprisol®
569101|NCT00435591|YM087
569102|NCT00435578|Recurrent Sensitive Small-Cell Lung Cancer
569103|NCT00435539|Vitreomacular Traction
569104|NCT00435539|Maculopathy
569105|NCT00435539|VMT
569106|NCT00435539|PVD
569107|NCT00435526|traveler's diarrhea
569108|NCT00435526|ETEC diarrhea
569109|NCT00435526|passive immunization
569110|NCT00435526|bovine milk prophylaxis
569111|NCT00435500|Dental caries, topical fluorides
569112|NCT00435487|Non-ST Elevation Acute Coronary Syndromes coronary interventions
569113|NCT00435474|Cancer
569114|NCT00435474|Malignant wounds
569115|NCT00435474|Quality of life
569116|NCT00435474|Body-Image
569117|NCT00435474|Cancer patients
569118|NCT00435461|once daily
569119|NCT00435461|mountain cedar
569120|NCT00435461|fexofenadine
569121|NCT00435461|allergic rhinitis
569122|NCT00435461|fluticasone furoate
569123|NCT00435448|Benign Prostatic Hyperplasia
569124|NCT00435448|BPH
569125|NCT00435448|Enlarged Prostate
569126|NCT00435435|Alcoholism
569127|NCT00435435|Dependence
569128|NCT00435435|Randomization
569129|NCT00435435|Effect
569130|NCT00435435|Disulfiram
569131|NCT00435435|Naltrexone
569132|NCT00435435|Acamprosate
569133|NCT00435383|Caudal Block
569134|NCT00435383|Oxygen Saturation
569135|NCT00435383|Uni or Bilateral Orchidopexy
569136|NCT00435357|Mobile-bearing
569137|NCT00435357|arthroplasty
569138|NCT00435357|fixed-bearing
569139|NCT00435357|knee
569140|NCT00435357|patella
569141|NCT00435357|posterior stabilized TKA
569142|NCT00435344|Pediatric practice
569143|NCT00435344|Smoking cessation
569144|NCT00435344|Smoking prevention
569145|NCT00435344|Adolescents
569146|NCT00435331|Pulmonary Arterial Hypertension
569147|NCT00435331|PPH
569148|NCT00435305|continuous infusion
569149|NCT00435305|epithelial lining fluid
569150|NCT00435305|antibiotics
569151|NCT00435305|pneumonia
569152|NCT00435305|critical illness
569153|NCT00435279|Insomnia
569154|NCT00435279|Depression
569155|NCT00435279|Major Depressive Disorder
569156|NCT00435266|myocardial infarction
569157|NCT00435266|remote
569158|NCT00435266|preconditioning
569159|NCT00435266|perconditioning
569160|NCT00435266|cardioprotection
569161|NCT00435253|emphysema
569162|NCT00435253|COPD
569163|NCT00435253|lung volume reduction
569164|NCT00435253|NETT
569165|NCT00435253|BLVR
569166|NCT00435253|biologic lung volume reduction
569167|NCT00435253|bronchoscopic lung volume reduction
569168|NCT00435227|Respiratory Syncytial Viruses
569169|NCT00435214|Cytology
569170|NCT00435214|papilloma virus
569171|NCT00435214|CIN
569172|NCT00435214|Screening
569173|NCT00435214|Cervix
569174|NCT00435214|Cervical Cancer
569175|NCT00435188|Aging
569176|NCT00435188|Cost analysis
569177|NCT00435188|Counseling
569178|NCT00435188|Disabled Persons
569179|NCT00435188|Health Promotion
569180|NCT00435188|Mobility Limitation
569181|NCT00435188|Physical Activity
569182|NCT00435188|Primary Care
569183|NCT00435188|Randomized Clinical Trial
569184|NCT00435188|Veterans
569185|NCT00435175|Estradiol
569186|NCT00435175|Lipolysis
569187|NCT00435175|Estrogen receptor
569188|NCT00435175|Adrenergic receptors
569189|NCT00435175|UCP2
569190|NCT00435175|Postmenopausal women
569191|NCT00435162|Children
569192|NCT00435162|pediatrics
569193|NCT00435162|High Blood Pressure
569194|NCT00435162|Hypertension
569195|NCT00435162|Valsartan
569196|NCT00435123|Malnutrition
569197|NCT00435123|ESRD
569198|NCT00435123|Hemodialysis
569199|NCT00435110|ARDS
569200|NCT00435110|ALI
569201|NCT00435110|Mechanical Ventilation
569202|NCT00435110|Outcome
569203|NCT00435097|colon cancer
569204|NCT00435097|metastatic colorectal cancer
569205|NCT00435097|MRI
569206|NCT00435097|Magnetic resonance imaging
569207|NCT00435097|Early cancer detection
569208|NCT00435097|medical image processing
569209|NCT00435097|machine learning
569210|NCT00435097|disease modeling
569211|NCT00435097|Colon Cancer Stage III
569212|NCT00435084|Refractory B-CLL
569213|NCT00435084|phase I/II
569214|NCT00435084|CD38
569215|NCT00435058|intraocular pressure
569216|NCT00435058|contrast sensitivity
569217|NCT00435058|visual function
569218|NCT00435045|Lovaza
569219|NCT00435045|Hyperlipidemias
569220|NCT00435045|Triglycerides
569221|NCT00435045|Lipids
569222|NCT00435045|omega-3 fatty acids
569223|NCT00435045|Hypercholesterolemia
569224|NCT00435045|Hypertriglyceridemia
569225|NCT00435045|omega-3-acid ethyl esters
569226|NCT00435045|Omacor
569227|NCT00435045|Dyslipidemias
569228|NCT00435032|ruptured appendicitis
569229|NCT00435032|children
569230|NCT00435032|surgery
569231|NCT00435032|randomized trial
569232|NCT00434993|Acute Lung Injury
569233|NCT00434993|Acute Respiratory Distress Syndrome
569234|NCT00434993|Albuterol
569235|NCT00434993|Aerosolized
569236|NCT00434993|Critical Care
569237|NCT00434993|Ventilator
569238|NCT00434980|Cognitive adaption
569239|NCT00434980|Schizophrenia
569240|NCT00434980|Cognitive rehabilitation
569241|NCT00434980|Family treatment
569242|NCT00434980|Cognitive deficits
569243|NCT00434980|Serious mental illness
569244|NCT00434967|Blood pressure reduction
569245|NCT00434967|combination therapy
569246|NCT00434967|candesartan cilexetil
569247|NCT00434967|hydrochlorothiazide
569248|NCT00434954|diabetes
569249|NCT00434954|exenatide
569250|NCT00434954|Byetta
569251|NCT00434954|Amylin
569252|NCT00434954|Lilly
569253|NCT00434941|Administration of capecitabine concomitant to radiotherapy
569254|NCT00434941|Her2: negative
569255|NCT00434928|observational
569256|NCT00434928|dietary intake
569257|NCT00434928|nutrient status
569258|NCT00434928|serum assessors
569259|NCT00434928|Attention-Deficit/Hyperactivity Disorder (ADHD)
569260|NCT00434902|Doppler Echocardiography
569261|NCT00434902|Pulmonary hypertension
569262|NCT00434902|Sickle cell disease
569263|NCT00434889|dementia
569264|NCT00434889|falls
569265|NCT00434889|risk factors
569266|NCT00434876|Alcoholism
569267|NCT00434876|Insomnia
569268|NCT00434876|Quetiapine
569269|NCT00434876|Seroquel
569270|NCT00434863|botulinum toxin type A
569271|NCT00434863|Dysport®
569272|NCT00434863|Botox®
569273|NCT00434863|hyperfunctional forehead lines
569274|NCT00434863|randomized controlled trial
569275|NCT00434863|double-blinded trial
569276|NCT00434863|electromyogram (EMG)
569277|NCT00434850|Insulin dependence
569278|NCT00434850|Hypoglycemia
569279|NCT00434850|Hyperglycemia unawareness
569280|NCT00434837|Knee
569281|NCT00434837|Ligament
569282|NCT00434837|ACL
569283|NCT00434837|Reconstruction
569284|NCT00434837|Cartilage
569285|NCT00434837|Osteoarthritis
569286|NCT00434811|Insulin dependence
569287|NCT00434811|Hypoglycemia
569288|NCT00434811|Hypoglycemia unawareness
569289|NCT00434798|Campylobacter infections
569290|NCT00434772|hypoglycemia
569291|NCT00434772|glucagon
569292|NCT00434772|neonatal
569293|NCT00434772|gestational diabetes
569294|NCT00434772|insulin
569295|NCT00434772|glyburide
569296|NCT00434759|randomized controlled trial
569297|NCT00434759|stepped-care program
569298|NCT00434759|cognitive therapy of social phobia according to D.M. Clark
569299|NCT00434733|Influenza H5N1, pandemic
569300|NCT00434720|GlideScope
569301|NCT00434720|Stylet
569302|NCT00434707|glaucoma
569303|NCT00434707|catarat
569304|NCT00434707|small pupils
569305|NCT00434694|Atrial Fibrillation
569306|NCT00434694|Catheter ablation
569307|NCT00434694|Pulmonary Vein
569308|NCT00434668|Non-Small Cell Lung Cancer
569309|NCT00434668|NSCLC
569310|NCT00434668|Adjuvant chemotherapy for completely resected NSCLC
569311|NCT00434655|Morbid obesity
569312|NCT00434655|Bariatric surgery
569313|NCT00434655|Obesity surgery
569314|NCT00434655|Gastric banding
569315|NCT00434655|Sleeve gastrectomy
569316|NCT00434642|Avastin
569317|NCT00434642|Ovarian carcinoma
569318|NCT00434642|Peritoneal carcinoma
569319|NCT00434642|Peritoneal cancer
569320|NCT00434642|Fallopian tube cancer
569321|NCT00434642|Fallopian tube carcinoma
569322|NCT00434642|OCEANS
569323|NCT00434629|lymphoma
569324|NCT00434629|Non-Hodgkin's lymphoma
569325|NCT00434629|B-cell lymphoma
569326|NCT00434629|Radioimmunotherapy
569327|NCT00434629|Bexxar
569328|NCT00434629|tositumomab
569329|NCT00434629|autologous hematopoietic stem cell transplantation
569330|NCT00434616|angiogenesis
569331|NCT00434616|Arterial Occlusive Diseases
569332|NCT00434616|Leg Ulcer
569333|NCT00434616|Gangrene
569334|NCT00434616|Ischemia
569335|NCT00434616|PAOD
569336|NCT00434616|Amputation
569337|NCT00434616|bone marrow
569338|NCT00434590|Kidney Transplantation
569339|NCT00434590|Mycophenolic Acid
569340|NCT00434590|Immunosuppression
569341|NCT00434590|Cyclosporine
569342|NCT00434577|GSK Biologicals
569343|NCT00434577|Herpes Zoster (HZ)
569344|NCT00434577|Vaccine
569345|NCT00434577|Varicella Zoster Virus (VZV)
569346|NCT00434577|Shingles
569347|NCT00434564|Stress nuclear scan
569348|NCT00434564|Acute chest pain
569349|NCT00434551|small bowel Crohn's disease
569350|NCT00434551|capsule endoscopy
569351|NCT00434551|PillCam SB
569352|NCT00434551|Patients with suspected small bowel Crohn's disease
569353|NCT00434538|Diabetic
569354|NCT00434538|Foot
569355|NCT00434538|Ulcer
569356|NCT00434538|Neuropathic
569357|NCT00434538|Chitosan
569358|NCT00434525|Morbid obesity
569359|NCT00434525|Bariatric Surgery
569360|NCT00434525|Obesity Surgery
569361|NCT00434525|Omentectomy
569362|NCT00434525|Sleeve gastrectomy
569363|NCT00434512|Gag
569364|NCT00434512|vaccine
569365|NCT00434512|adjuvant
569366|NCT00434512|HIV
569367|NCT00434512|Pol
569368|NCT00434512|Nef
569369|NCT00434499|Green Tea
569370|NCT00434499|Insulin Resistance
569371|NCT00434499|Endothelial Dysfunction
569372|NCT00434499|Nitric Oxide
569373|NCT00434499|Inflammation
569374|NCT00434499|Obesity
569375|NCT00434499|Overweight
569376|NCT00434499|Diabetes Type 2
569377|NCT00434499|High Blood Pressure
569378|NCT00434499|Healthy Volunteer
569379|NCT00434499|HV
569380|NCT00434460|Ventilator Associated Pneumonia
569381|NCT00434460|Knowledge Translation
569382|NCT00434460|Clinical Practice Guidelines
569383|NCT00434460|Education
569384|NCT00434460|Behaviour Change
569385|NCT00434447|Prostate Cancer
569386|NCT00434447|Breast Cancer
569387|NCT00434447|Multiple Myeloma
569388|NCT00434447|Zoledronic acid
569389|NCT00434447|Bone metastases
569390|NCT00434447|Skeletal Related Events (SREs)
569391|NCT00434447|Renal Impairment
569392|NCT00434447|Osteonecrosis of the Jaw (ONJ)
569393|NCT00434447|Bone involvement
569394|NCT00434447|Multiple Myeloma (MM)
569395|NCT00434434|AQUA
569396|NCT00434434|anti-CD11
569397|NCT00434434|CD11a
569398|NCT00434434|Asthma
569399|NCT00434434|Allergy
569400|NCT00434421|Perennial Allergic Rhinitis
569401|NCT00434421|Asthma
569402|NCT00434421|Sublingual Immunotherapy (SLIT)
569403|NCT00434408|omphalitis
569404|NCT00434408|neonates
569405|NCT00434408|umbilical cord
569406|NCT00434408|infection
569407|NCT00434408|infant mortality
569408|NCT00434408|neonate morbidity
569409|NCT00434408|chlorhexidine
569410|NCT00434382|auditory evoked potentials
569411|NCT00434382|sensory processing
569412|NCT00434382|monitoring
569413|NCT00434382|general anesthesia
569414|NCT00434356|Avastin
569415|NCT00434356|MBC
569416|NCT00434356|Breast Cancer
569417|NCT00434356|Sutent
569418|NCT00434343|Interstitial Cystitis
569419|NCT00434343|Painful Bladder Syndrome
569420|NCT00434343|Chronic Prostatitis
569421|NCT00434343|Chronic Pelvic Pain Syndrome
569422|NCT00434330|anemia
569423|NCT00434330|chronic kidney disease
569424|NCT00434330|CKD
569425|NCT00434330|chronic renal failure
569426|NCT00434330|CRF
569427|NCT00434330|dialysis
569428|NCT00434330|erythropoietin
569429|NCT00434330|EPO
569430|NCT00434330|erythropoiesis stimulating agent
569431|NCT00434330|ESA
569432|NCT00434330|Hematide™
569433|NCT00434330|hemodialysis
569434|NCT00434330|hemoglobin
569435|NCT00434330|Hb
569436|NCT00434330|Hgb
569437|NCT00434330|Omontys
569438|NCT00434330|peginesatide
569439|NCT00434330|red blood cell
569440|NCT00434330|red blood cell production
569441|NCT00434317|Metastasis
569442|NCT00434317|Neoplasm
569443|NCT00434317|pain
569444|NCT00434317|breast cancer
569445|NCT00434317|prostate cancer
569446|NCT00434317|bone metastasis
569447|NCT00434304|Parkinson's Disease
569448|NCT00434304|PD
569449|NCT00434291|Community-acquired Pneumonia
569450|NCT00434291|fluoroquinolone
569451|NCT00434291|TG-873870
569452|NCT00434291|Nemonoxacin
569453|NCT00434278|Lung disease
569454|NCT00434278|CF
569455|NCT00434278|Pulmozyme
569456|NCT00434265|Obesity
569457|NCT00434265|Exercise
569458|NCT00434265|Fat oxidation
569459|NCT00434265|Overweigh (IMC>25 and IMC<30)
569460|NCT00434252|Avastin
569461|NCT00434252|BEAM
569462|NCT00434252|Metastatic melanoma
569463|NCT00434239|Myelodysplasia
569464|NCT00434239|Lenalidomide
569465|NCT00434239|Ancestim
569466|NCT00434239|Pilot trial
569467|NCT00434239|Biomarkers
569468|NCT00434226|SABER-L
569469|NCT00434226|NSCLC
569470|NCT00434226|Avastin
569471|NCT00434226|Sutent
569472|NCT00434200|rheumatoid arthritis
569473|NCT00434200|exercise
569474|NCT00434200|damage
569475|NCT00434187|healthy
569476|NCT00434174|Lung cancer
569477|NCT00434174|Non small cell lung cancer
569478|NCT00434174|NSCLC
569479|NCT00434174|RAD001
569480|NCT00434174|Everolimus
569481|NCT00434174|Afinitor
569482|NCT00434174|Pemetrexed
569483|NCT00434161|Palifermin
569484|NCT00434161|KGF
569485|NCT00434161|Clinical Trial
569486|NCT00434161|Oncology
569487|NCT00434161|Oral Mucositis
569488|NCT00434161|Multiple Myeloma
569489|NCT00434161|Cataract
569490|NCT00434148|Cushing's Disease
569491|NCT00434148|pasireotide
569492|NCT00434148|SOM230
569493|NCT00434135|gemcitabine
569494|NCT00434135|pemetrexed
569495|NCT00434135|non-small cell lung cancer
569496|NCT00434122|Assisted Reproductive Technology (ART)
569497|NCT00434122|oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies
569498|NCT00434109|Carcinoid
569499|NCT00434109|Pancreatic
569500|NCT00434109|Metastatic
569501|NCT00434109|Neuroendocrine
569502|NCT00434109|Tumors
569503|NCT00434109|Hepatic
569504|NCT00434109|Artery
569505|NCT00434109|Embolization
569506|NCT00434109|Angiogenesis
569507|NCT00434109|Sunitinib
569508|NCT00434109|Malate
569509|NCT00434109|Sutent
569510|NCT00434109|Tyrosine
569511|NCT00434109|Kinase
569512|NCT00434109|Inhibitor
569513|NCT00434096|Obesity disease
569514|NCT00434096|cannabinoid-1 receptor
569515|NCT00434083|TREXIMA
569516|NCT00434083|MIGRAINE HEADACHES
569517|NCT00434083|Subjects may be enrolled if they are 18-65 years of age, have a demonstrated history of migraine headaches
569518|NCT00434070|HIV
569519|NCT00434070|Antiretrovial Therapy
569520|NCT00434070|Resistance
569521|NCT00434070|Monitoring
569522|NCT00434070|TAMS
569523|NCT00434070|Treatment Experienced
569524|NCT00434057|Pigmented Skin Lesions
569525|NCT00434057|Dermatology
569526|NCT00434057|Skin Cancer
569527|NCT00434057|Melanoma
569528|NCT00434057|MelaFind
569529|NCT00434031|locally advanced
569530|NCT00434031|stage II
569531|NCT00434031|stage IIIa
569532|NCT00434031|stage IIIb
569533|NCT00434031|HER-2 positive
569534|NCT00434031|primary
569535|NCT00434018|Wheelchairs
569536|NCT00434018|Safety
569537|NCT00434005|Air pollution
569538|NCT00434005|diesel
569539|NCT00434005|antioxidant
569540|NCT00434005|oxidative stress
569541|NCT00434005|endothelial
569542|NCT00434005|HRV
569543|NCT00434005|BAR
569544|NCT00433992|Mitochondria
569545|NCT00433992|Fat apoptosis
569546|NCT00433992|Lipoatrophy
569547|NCT00433992|Lipodystrophy
569548|NCT00433992|Thymidine
569549|NCT00433992|Treatment experienced
569550|NCT00433979|Anti-HIV agents
569551|NCT00433979|Physiological Effects of Drugs
569552|NCT00433979|ARV-associated Adverse Events
569553|NCT00433979|HAART
569554|NCT00433979|Pharmacokinetics
569555|NCT00433979|Protease Inhibitors
569556|NCT00433979|Non-nucleoside Reverse Transcriptase Inhibitors
569557|NCT00433979|Women
569558|NCT00433966|Myocardial Infarction
569559|NCT00433966|Angioplasty
569560|NCT00433966|Myocardial Ischemia
569561|NCT00433966|Myocardial Reperfusion
569562|NCT00433966|Stents
569563|NCT00433966|Heart Disease
569564|NCT00433953|Pediatric Kidney Transplant
569565|NCT00433953|Kidney Transplant
569566|NCT00433953|CellCept
569567|NCT00433953|Mycophenolate Mofetil
569568|NCT00433953|Mycophenolic Acid
569569|NCT00433940|Hemangioma
569570|NCT00433940|Corticosteroid
569571|NCT00433940|Prednisone
569572|NCT00433927|metastatic
569573|NCT00433914|Meningococcal disease, prevention, vaccination
569574|NCT00433901|obesity in children
569575|NCT00433901|childhood disorders
569576|NCT00433901|overweight children
569577|NCT00433901|physical activity
569578|NCT00433901|home environment
569579|NCT00433862|Polycythemia Vera
569580|NCT00433862|Essential Thrombocytosis
569581|NCT00433862|Idiopathic Myelofibrosis
569582|NCT00433862|Janus Kinase 2
569583|NCT00433862|CD177
569584|NCT00433862|Chronic Myeloproliferative Disorders
569585|NCT00433862|PV
569586|NCT00433862|Essential Thrombocythemia
569587|NCT00433862|ET
569588|NCT00433862|IM
569589|NCT00433836|Children
569590|NCT00433836|pediatrics
569591|NCT00433836|High Blood Pressure
569592|NCT00433836|Hypertension
569593|NCT00433836|Valsartan
569594|NCT00433836|enalapril
569595|NCT00433823|Very low level of LDL
569596|NCT00433823|Steroid hormones
569597|NCT00433823|Atorvastatin
569598|NCT00433823|Ezetimibe
569599|NCT00433823|Lipoprotein-a
569600|NCT00433810|obesity
569601|NCT00433810|bariatric surgery
569602|NCT00433810|30-day mortality
569603|NCT00433797|Prostate cancer
569604|NCT00433797|PSA
569605|NCT00433797|antioxidant
569606|NCT00433797|phytochemical
569607|NCT00433797|tomatoes
569608|NCT00433797|PUFA
569609|NCT00433797|selenium
569610|NCT00433797|soy
569611|NCT00433797|pomegranate
569612|NCT00433797|grapes
569613|NCT00433784|clopidogrel
569614|NCT00433784|platelet aggregation
569615|NCT00433784|CYP3A
569616|NCT00433784|H2 haplotype
569617|NCT00433784|polymorphisms
569618|NCT00433771|Malignant
569619|NCT00433771|Cholestasis, Extrahepatic
569620|NCT00433771|Biliary obstruction
569621|NCT00433758|Diabetes
569622|NCT00433758|Blood glucose monitoring
569623|NCT00433758|Non invasive Blood glucose monitoring
569624|NCT00433745|Myelodysplastic Syndrome (MDS)
569625|NCT00433745|Acute Myelogenous Leukemia (AML)
569626|NCT00433745|Chronic Myelogenous Leukemia (CML)
569627|NCT00433745|Acute Lymphoblastic Leukemia (ALL)
569628|NCT00433745|Wilm's Tumor-1 Peptide
569629|NCT00433745|Leukemia
569630|NCT00433745|Myelodysplastic Syndrome
569631|NCT00433745|MDS
569632|NCT00433745|Acute Myelogenous Leukemia
569633|NCT00433745|AML
569634|NCT00433745|Chronic Myelogenous Leukemia
569635|NCT00433745|CML
569636|NCT00433745|Acute Lymphoblastic Leukemia
569637|NCT00433745|ALL
569638|NCT00433732|TREXIMA
569639|NCT00433732|MIGRAINE HEADACHES
569640|NCT00433732|Subjects may be enrolled if they are 18-65 years of age, have a demonstrated history of migraine headaches
569641|NCT00433719|Human immunodeficiency virus
569642|NCT00433719|Tuberculous meningitis
569643|NCT00433719|Treatment Naive
569644|NCT00433706|Prostate adenocarcinoma treated by radiotherapy
569645|NCT00433680|adolescent
569646|NCT00433680|female
569647|NCT00433680|obesity
569648|NCT00433680|body dissatisfaction
569649|NCT00433667|RWJ-333369
569650|NCT00433667|anticonvulsants
569651|NCT00433667|antiepileptic drugs
569652|NCT00433654|Bradycardia
569653|NCT00433654|Slow heart beat
569654|NCT00433654|Magnetic resonance imaging (MRI)
569655|NCT00433641|obesity
569656|NCT00433641|pharmacogenetics
569657|NCT00433641|sibutramine
569658|NCT00433641|adrenergic
569659|NCT00433641|serotonergic
569660|NCT00433641|body composition
569661|NCT00433641|gastric emptying
569662|NCT00433628|Hemoglobin A1C
569663|NCT00433628|HIV
569664|NCT00433628|Diabetes
569665|NCT00433628|Diabetes Type 2
569666|NCT00433628|Hyperglycemia
569667|NCT00433602|thromboembolism
569668|NCT00433602|recurrent breast cancer
569669|NCT00433602|stage IV breast cancer
569670|NCT00433602|recurrent colon cancer
569671|NCT00433602|stage I colon cancer
569672|NCT00433602|stage II colon cancer
569673|NCT00433602|stage III colon cancer
569674|NCT00433602|stage IV colon cancer
569675|NCT00433602|recurrent rectal cancer
569676|NCT00433602|stage I rectal cancer
569677|NCT00433602|stage II rectal cancer
569678|NCT00433602|stage III rectal cancer
569679|NCT00433602|stage IV rectal cancer
569680|NCT00433602|recurrent gastric cancer
569681|NCT00433602|stage I gastric cancer
569682|NCT00433602|stage II gastric cancer
569683|NCT00433602|stage III gastric cancer
569684|NCT00433602|stage IV gastric cancer
569685|NCT00433602|recurrent non-small cell lung cancer
569686|NCT00433602|stage I non-small cell lung cancer
569687|NCT00433602|stage II non-small cell lung cancer
569688|NCT00433602|stage IIIA non-small cell lung cancer
569689|NCT00433602|stage IIIB non-small cell lung cancer
569690|NCT00433602|stage IV non-small cell lung cancer
569691|NCT00433602|recurrent small cell lung cancer
569692|NCT00433602|recurrent ovarian epithelial cancer
569693|NCT00433602|stage I ovarian epithelial cancer
569694|NCT00433602|stage II ovarian epithelial cancer
569695|NCT00433602|stage III ovarian epithelial cancer
569696|NCT00433602|stage IV ovarian epithelial cancer
569697|NCT00433602|recurrent ovarian germ cell tumor
569698|NCT00433602|stage I ovarian germ cell tumor
569699|NCT00433602|stage II ovarian germ cell tumor
569700|NCT00433602|stage III ovarian germ cell tumor
569701|NCT00433602|stage IV ovarian germ cell tumor
569702|NCT00433602|ovarian sarcoma
569703|NCT00433602|ovarian stromal cancer
569704|NCT00433602|recurrent pancreatic cancer
569705|NCT00433602|stage I pancreatic cancer
569706|NCT00433602|stage II pancreatic cancer
569707|NCT00433602|stage III pancreatic cancer
569708|NCT00433602|stage IV pancreatic cancer
569709|NCT00433602|recurrent prostate cancer
569710|NCT00433602|stage III prostate cancer
569711|NCT00433602|stage IV prostate cancer
569712|NCT00433602|extensive stage small cell lung cancer
569713|NCT00433602|limited stage small cell lung cancer
569714|NCT00433602|stage IIB prostate cancer
569715|NCT00433602|stage IIA prostate cancer
569716|NCT00433602|male breast cancer
569717|NCT00433589|invasive ductal breast carcinoma
569718|NCT00433589|invasive lobular breast carcinoma
569719|NCT00433589|stage IA breast cancer
569720|NCT00433589|stage IB breast cancer
569721|NCT00433589|stage II breast cancer
569722|NCT00433589|estrogen receptor-positive breast cancer
569723|NCT00433589|progesterone receptor-positive breast cancer
569724|NCT00433563|limited stage small cell lung cancer
569725|NCT00433524|unspecified adult solid tumor, protocol specific
569726|NCT00433498|extensive stage small cell lung cancer
569727|NCT00433498|limited stage small cell lung cancer
569728|NCT00433485|basal cell carcinoma of the skin
569729|NCT00433485|nevoid basal cell carcinoma syndrome
569730|NCT00433472|adult anaplastic oligodendroglioma
569731|NCT00433472|adult giant cell glioblastoma
569732|NCT00433472|adult anaplastic astrocytoma
569733|NCT00433472|recurrent adult brain tumor
569734|NCT00433472|adult glioblastoma
569735|NCT00433472|adult gliosarcoma
569736|NCT00433459|childhood lymphocyte depletion Hodgkin lymphoma
569737|NCT00433459|childhood mixed cellularity Hodgkin lymphoma
569738|NCT00433459|childhood nodular sclerosis Hodgkin lymphoma
569739|NCT00433459|stage I childhood Hodgkin lymphoma
569854|NCT00431080|Docetaxel
569740|NCT00433459|stage II childhood Hodgkin lymphoma
569741|NCT00433459|stage III childhood Hodgkin lymphoma
569742|NCT00433459|stage IV childhood Hodgkin lymphoma
569743|NCT00433446|adenocarcinoma of the prostate
569744|NCT00433446|stage IV prostate cancer
569745|NCT00433446|recurrent prostate cancer
569746|NCT00433433|adult mixed cellularity Hodgkin lymphoma
569747|NCT00433433|adult nodular sclerosis Hodgkin lymphoma
569748|NCT00433433|stage I adult Hodgkin lymphoma
569749|NCT00433433|stage II adult Hodgkin lymphoma
569750|NCT00433433|adult lymphocyte depletion Hodgkin lymphoma
569751|NCT00433420|stage II breast cancer
569752|NCT00433420|stage IIIA breast cancer
569753|NCT00433420|stage IIIB breast cancer
569754|NCT00433420|stage IIIC breast cancer
569755|NCT00433407|unspecified adult solid tumor, protocol specific
569756|NCT00433407|stage I breast cancer
569757|NCT00433407|stage II breast cancer
569758|NCT00433407|stage IIIA breast cancer
569759|NCT00433407|stage IIIB breast cancer
569760|NCT00433407|stage IIIC breast cancer
569761|NCT00433407|stage IV breast cancer
569762|NCT00433407|male breast cancer
569763|NCT00433407|recurrent breast cancer
569764|NCT00433407|stage I ovarian epithelial cancer
569765|NCT00433407|stage II ovarian epithelial cancer
569766|NCT00433407|stage III ovarian epithelial cancer
569767|NCT00433407|stage IV ovarian epithelial cancer
569768|NCT00433407|recurrent ovarian epithelial cancer
569769|NCT00433407|stage I non-small cell lung cancer
569770|NCT00433407|stage II non-small cell lung cancer
569771|NCT00433407|stage IIIA non-small cell lung cancer
569772|NCT00433407|stage IIIB non-small cell lung cancer
569773|NCT00433407|stage IV non-small cell lung cancer
569774|NCT00433407|recurrent non-small cell lung cancer
569775|NCT00433407|extensive stage small cell lung cancer
569776|NCT00433407|limited stage small cell lung cancer
569777|NCT00433407|recurrent small cell lung cancer
569778|NCT00433407|stage I prostate cancer
569779|NCT00433407|stage IIB prostate cancer
569780|NCT00433407|stage IIA prostate cancer
569781|NCT00433407|stage III prostate cancer
569782|NCT00433407|stage IV prostate cancer
569783|NCT00433407|recurrent prostate cancer
569784|NCT00433407|stage I uterine sarcoma
569785|NCT00433407|stage II uterine sarcoma
569786|NCT00433407|stage III uterine sarcoma
569787|NCT00433407|stage IV uterine sarcoma
569788|NCT00433407|recurrent uterine sarcoma
569789|NCT00433394|unspecified childhood solid tumor, protocol specific
569790|NCT00433368|L-ornithine-L-aspartate,
569791|NCT00433368|porto-systemic encephalopathy,
569792|NCT00433368|hepatic encephalopathy,
569793|NCT00433368|liver cirrhosis,
569794|NCT00433368|mental state
569795|NCT00433355|Chronic Fatigue Syndrome
569796|NCT00433355|Epstein-Barr Virus
569797|NCT00433342|Antibiotic
569798|NCT00433342|p-cresol
569799|NCT00433342|peritoneal dialysis
569800|NCT00433329|pulmonary arterial hypertension
569801|NCT00433329|bosentan
569802|NCT00433329|sildenafil
569803|NCT00433329|combination therapy
569804|NCT00433329|Compass 3
569805|NCT00433316|ropivacaine
569806|NCT00433316|laparoscopy
569807|NCT00433316|intraperitoneal
569808|NCT00433316|nebulization
569809|NCT00433316|pain
569810|NCT00433316|local analgesic
569811|NCT00433316|gynecology
569812|NCT00432250|Preterm labor
569813|NCT00432250|Cervical ultrasonography
569814|NCT00432250|Hospital stay
569815|NCT00431223|fMRI
569816|NCT00431223|working memory
569817|NCT00431223|schizophrenia
569818|NCT00431223|treatment refractory
569819|NCT00431223|cognitive skills training
569820|NCT00431223|dorsolateral prefrontal cortex
569821|NCT00431223|cognitive remediation
569822|NCT00431223|treatment refractory schizophrenia of > 5 years duration
569823|NCT00431210|NPC
569824|NCT00431210|EPV
569825|NCT00431184|bipolar disorder
569826|NCT00431184|bipolar mania
569827|NCT00431184|schizoaffective disorder
569828|NCT00431184|schizoaffective mania
569829|NCT00431184|mania
569830|NCT00431184|kappa opiates
569831|NCT00431184|opiates
569832|NCT00431171|spinal cord injuries
569833|NCT00431171|lithium
569834|NCT00431158|Acute Respiratory Distress Syndrome
569835|NCT00431158|ARDS
569836|NCT00431158|Respiratory failure
569837|NCT00431158|Mechanical Ventilation
569838|NCT00431158|Positive end expiratory pressure
569839|NCT00431158|Lung recruitment maneuver
569840|NCT00431119|bullous autoimmune disease
569841|NCT00431119|bullous pemphigoid
569842|NCT00431119|immunosuppressants
569843|NCT00431119|corticosteroids
569844|NCT00431119|mycophenolate mofetil
569845|NCT00431106|Breast cancer
569846|NCT00431106|Chemotherapy
569847|NCT00431106|Vinorelbine
569848|NCT00431106|Gemcitabine
569849|NCT00431106|Capecitabine
569850|NCT00431080|Early breast cancer
569851|NCT00431080|Axillary node positive
569852|NCT00431080|Adjuvant chemotherapy
569853|NCT00431080|Dose dense
569855|NCT00431080|Paclitaxel
569856|NCT00431080|FEC
569857|NCT00431054|Ovarian Cancer
569858|NCT00431054|Fallopian Tube Cancer
569859|NCT00431054|Peritoneal Cancer
569860|NCT00431054|Perifosine
569861|NCT00431054|Docetaxel
569862|NCT00431054|Taxotere
569863|NCT00431041|Solifenacin succinate
569864|NCT00431041|Oxybutynin immediate release
569865|NCT00431041|Xerostomia
569866|NCT00431041|Overactive bladder
569867|NCT00431028|Cataract
569868|NCT00431028|Endophthalmitis
569869|NCT00431028|Antibiotics
569870|NCT00431028|Anti-Inflammatory Agents
569871|NCT00431028|Drug Delivery Systems
569872|NCT00431015|Lung Cancer
569873|NCT00431015|Cancer of the lung
569874|NCT00431015|Non-small cell lung cancer
569875|NCT00431002|Exercise
569876|NCT00431002|Resistance training
569877|NCT00430989|Anaesthesia
569878|NCT00430989|Major Surgery
569879|NCT00430989|Coronary artery disease
569880|NCT00430989|Nitrous oxide
569881|NCT00430989|Effects of Nitrous Oxide following Anaesthesia
569882|NCT00430989|Anaesthesia and coronary artery disease
569883|NCT00433264|peritoneal dialysis
569884|NCT00433264|endothelium
569885|NCT00433264|endothelial dysfunction
569886|NCT00433238|elderly
569887|NCT00433238|Chinese
569888|NCT00433238|community living
569889|NCT00433238|measurement
569890|NCT00433238|depression
569891|NCT00433238|dementia
569892|NCT00433238|Geriatric Depression Scale
569893|NCT00433238|MiniCog
569894|NCT00433212|prematurity
569895|NCT00433212|respiratory insufficiency
569896|NCT00433212|non-invasive ventilation
569897|NCT00433212|bronchopulmonary dysplasia
569898|NCT00433212|hyaline membrane disease
569899|NCT00433199|Hypogonadism
569900|NCT00433199|Testosterone Deficiency
569901|NCT00433186|Scleroderma
569902|NCT00433173|testosterone
569903|NCT00433173|insulin sensitivity
569904|NCT00433173|insulin resistance
569905|NCT00433173|metabolic disorders
569906|NCT00433134|renal transplant recipient
569907|NCT00433134|adherence
569908|NCT00433134|compliance
569909|NCT00433134|immunosuppression
569910|NCT00433121|Antidepressive Agents
569911|NCT00433121|Neuroleptica
569912|NCT00433121|Dementia
569913|NCT00433121|Discontinuation study
569914|NCT00433121|Behavioural- and Psychological Symptoms in Dementia
569915|NCT00433108|Hepatitis C
569916|NCT00433108|antioxidant
569917|NCT00433108|liver enzymes
569918|NCT00433108|ALT
569919|NCT00433095|Navelbine
569920|NCT00433095|Herceptin
569921|NCT00433095|oral
569922|NCT00433095|breast cancer
569923|NCT00433082|Metabolic syndrome,Ramadan,Fasting,Inflammatory markers,
569924|NCT00433082|Iran
569925|NCT00433069|Chronic hepatitis C
569926|NCT00433069|Insulin resistance
569927|NCT00433069|Pioglitazone
569928|NCT00433069|Non-responders
569929|NCT00433056|STI
569930|NCT00433056|HIV
569931|NCT00433056|CD4
569932|NCT00433056|HIV-RNA
569933|NCT00433056|HAART
569934|NCT00433043|Heart Failure
569935|NCT00433043|Beta blockers
569936|NCT00433043|Resynchronization
569937|NCT00433043|Congestive Heart Failure, NYHA III-IV
569938|NCT00433043|Candidate for BIVPM
569939|NCT00433043|Not on Target Dose (Coreg 25 Bid or Toprol XL 200 qd)
569940|NCT00433030|Highly Active Antiretroviral Therapy
569941|NCT00433030|HIV Viral load
569942|NCT00433030|HIV drug Resistance
569943|NCT00433030|Thailand
569944|NCT00433017|Age-related macular degeneration
569945|NCT00433017|AMD
569946|NCT00433017|Choroidal neovascularization
569947|NCT00433017|Verteporfin
569948|NCT00433017|Ranibizumab
569949|NCT00433004|Teen
569950|NCT00433004|Plan B
569951|NCT00433004|Post Partum
569952|NCT00433004|Emergency Contraception
569953|NCT00432991|Nausea
569954|NCT00432991|Vomiting
569955|NCT00432991|Cesarean Section
569956|NCT00432978|hypoxia
569957|NCT00432978|endothelin
569958|NCT00432978|exercise
569959|NCT00432965|Wound closure
569960|NCT00432965|Accelerated healing
569961|NCT00432952|Cardiovascular Heart Disease
569962|NCT00432939|Primary Hyperparathyroidism
569963|NCT00432926|HIV
569964|NCT00432926|STDs
569965|NCT00432926|Methamphetamine abuse
569966|NCT00432926|MSM
569967|NCT00432926|HIV Seronegativity
569968|NCT00432913|Eicosapentaenoic acid
569969|NCT00432913|EPA
569970|NCT00432913|EPA 99%
569971|NCT00432913|Fatty acid
569972|NCT00432913|omega-3
569973|NCT00432913|apoptosis
569974|NCT00432913|cell proliferation
569975|NCT00432913|colonic mucosa
569976|NCT00432913|polyps
569977|NCT00432913|adenomatous polyps
569978|NCT00432913|endoscopy
569979|NCT00432913|PUFA
569980|NCT00432900|Inflammation
569981|NCT00432900|Neuroimmunology
569982|NCT00432900|Multiple Sclerosis
569983|NCT00432900|MS
569984|NCT00432900|Healthy Volunteer
569985|NCT00432900|HV
569986|NCT00432887|caffeine
569987|NCT00432887|coffee
569988|NCT00432887|glucose
569989|NCT00432887|insulin
569990|NCT00432861|cystic fibrosis
569991|NCT00432861|pancreatic insufficiency
569992|NCT00432861|PANCRECARB® MS-16 (pancrelipase)
569993|NCT00432861|steatorrhea
569994|NCT00432835|Nausea
569995|NCT00432835|Vomiting
569996|NCT00432835|Delayed gastric emptying
569997|NCT00432835|Diabetes Mellitus
569998|NCT00432835|Post-Surgical
569999|NCT00432835|Idiopathic
570000|NCT00432822|phenylketonuria
570001|NCT00432822|phenylalanine hydroxylase deficiency
570002|NCT00432822|BH4
570003|NCT00432822|responsive
570004|NCT00432822|tetrahydrobiopterin
570005|NCT00432822|newborns
570006|NCT00432822|infants
570007|NCT00432822|children
570008|NCT00432822|adolescents
570009|NCT00432809|Diabetes Mellitus, Type 2
570010|NCT00432809|Obesity
570011|NCT00432796|Anticoagulation
570012|NCT00432796|Prosthetic heart valves
570013|NCT00432796|Atrial fibrillation
570014|NCT00432796|Bridging Therapy
570015|NCT00432796|Thromboembolism
570016|NCT00432796|Warfarin
570017|NCT00432796|Low Molecular Weight Heparin
570018|NCT00432783|HIV, antiretroviral therapy, adherence, ritonavir
570019|NCT00432757|allergic conjunctivitis, ophthalmology, multicenter, controlled
570020|NCT00432744|mitochondrial diseases
570021|NCT00432744|respiratory chain complex I deficiencies
570022|NCT00432744|respiratory chain complex II deficiencies
570023|NCT00432744|respiratory chain complex III deficiencies
570024|NCT00432744|respiratory chain complex IV deficiencies
570025|NCT00432744|mutations of a gene coding for a respiratory chain component
570026|NCT00432731|Prevention of : Varicella
570027|NCT00432731|Measles
570028|NCT00432731|Mumps
570029|NCT00432731|Rubella
570030|NCT00432718|Pneumonia
570031|NCT00432718|Ventilator Associated Pneumonia
570032|NCT00432718|Prevention
570033|NCT00432705|ankle
570034|NCT00432705|sensorimotor
570035|NCT00432705|reflex
570036|NCT00432705|training
570037|NCT00432692|osteoporosis
570038|NCT00432692|falls
570039|NCT00432692|prevention
570040|NCT00432692|elderly
570041|NCT00432692|exercise
570042|NCT00432692|incidence
570043|NCT00432692|obstacle avoidance
570044|NCT00432679|rosiglitazone
570045|NCT00432679|Avandia
570046|NCT00432679|type 2 diabetes mellitus
570047|NCT00432679|diabetes
570048|NCT00432653|ankylosing spondylitis
570049|NCT00432653|rituximab
570050|NCT00432653|therapy
570051|NCT00432653|magnetic resonance imaging
570052|NCT00432640|(suspected) Non Small Cell Lung Cancer
570053|NCT00432627|Hepatic impairment
570054|NCT00432627|adults
570055|NCT00432627|deferasirox
570056|NCT00432614|Mental Disorder
570057|NCT00432614|Mood Disorder
570058|NCT00432614|Depressive Disorder
570059|NCT00432601|decision aid
570060|NCT00432601|prostate cancer
570061|NCT00432601|patient-physician communication
570062|NCT00432601|decision making
570063|NCT00432601|literacy
570064|NCT00432588|IUFD
570065|NCT00432588|POSTTERM
570066|NCT00432588|ROM
570067|NCT00432575|tobacco use cessation
570068|NCT00432575|cigarette smokers
570069|NCT00432549|Medication overuse
570070|NCT00432536|Neuro-monitoring
570071|NCT00432536|Quality Improvement
570072|NCT00432536|Cerebral emboli
570073|NCT00432536|Cerebral desaturation
570074|NCT00432536|Hypotension
570075|NCT00432523|Prevention of : Measles, Mumps, Rubella and Varicella diseases
570076|NCT00432510|Hereditary angioedema
570077|NCT00432510|C1 esterase inhibitor (human)
570078|NCT00432484|Lingzhi
570079|NCT00432484|Sen Miao San
570080|NCT00432484|Rheumatoid Arthritis
570081|NCT00432471|Skin Cancer
570082|NCT00432471|Non-Melanoma Skin Cancer
570083|NCT00432471|Optical Imaging
570084|NCT00432471|Multispectral Digital Microscope System
570085|NCT00432471|MDM
570086|NCT00432458|stage I multiple myeloma
570087|NCT00432445|Children with retinoblastoma
570088|NCT00432445|Retinoblastoma
570089|NCT00432445|Pediatrics
570090|NCT00432445|Proton Beam Radiation Therapy
570091|NCT00432445|Radiation Therapy
570092|NCT00432445|Tumor of the Eye
570093|NCT00432445|Ophthalmic EUA
570094|NCT00432445|Examination under anesthesia
570095|NCT00432445|Bilateral retinoblastoma
570096|NCT00432445|Unilateral retinoblastoma
570097|NCT00432445|Extraocular disease
570098|NCT00432445|Intraocular procedure
570099|NCT00432432|Ankylosing Spondylitis
570100|NCT00432432|MTX
570101|NCT00432432|Infliximab
570102|NCT00432419|HIV
570103|NCT00432419|Non-Hodgkin's lymphoma
570104|NCT00432419|Peripheral blood stem cells transplantation
570105|NCT00432406|Psoriatic Arthritis
570106|NCT00432406|TNF-α
570107|NCT00432406|Cardiovascular risk
570108|NCT00432406|Immunomodulatory activities
570109|NCT00432380|Placebo
570110|NCT00432380|Double blind
570111|NCT00432380|Gastroenteritis
570112|NCT00432380|Randomized
570113|NCT00432380|Oral live attenuated human rotavirus liquid vaccine
570114|NCT00432367|Malaria in pregnancy
570115|NCT00432367|Case management
570116|NCT00432367|Screening
570117|NCT00432367|RDT
570118|NCT00432367|IPTp
570119|NCT00432367|Amodiaquine
570120|NCT00432367|Artesunate
570121|NCT00432354|statin
570122|NCT00432354|systemic lupus erythematosus
570123|NCT00432354|microcirculation
570124|NCT00432302|Cancer
570125|NCT00432302|Tumor
570126|NCT00432302|Malignancy
570127|NCT00432302|Mass Balance
570128|NCT00432302|Chemotherapy
570129|NCT00432302|Drug
570130|NCT00432302|Cancer Treatment
570131|NCT00432302|Intravenous Infusion
570132|NCT00432302|Epothilone
570133|NCT00432302|Solid Tumor
570134|NCT00432289|neurological function
570135|NCT00432276|Glucose Metabolism Disorder
570136|NCT00432276|Dysmetabolic Syndrome
570137|NCT00432276|Type II Diabetes
570138|NCT00432276|Diabetes Mellitus, Lipoatrophic
570139|NCT00432276|Dyslipidemia
570140|NCT00432276|Hyperglycemia
570141|NCT00432276|Drug Therapy
570142|NCT00432198|Insomnia
570143|NCT00432198|Zolpidem
570144|NCT00432198|Adolescent
570145|NCT00432185|sBCC
570146|NCT00432185|Topical
570147|NCT00432185|Dermatology
570148|NCT00432172|Her2neu negative breast cancer.
570149|NCT00432172|Neoadjuvant treatment.
570150|NCT00432159|cervical
570151|NCT00432159|spinal
570152|NCT00432159|arthroplasty
570153|NCT00432159|disc
570154|NCT00432159|surgical
570155|NCT00432159|ACDF
570156|NCT00432159|DDD
570157|NCT00432146|Graves' disease, Lugol's solution
570158|NCT00432133|Physical Activity
570159|NCT00432133|Behavior Change
570160|NCT00432133|Mechanism
570161|NCT00432133|Environmental
570162|NCT00432133|Ecological Model of Physical Activity
570163|NCT00432107|Advanced cutaneous melanoma
570164|NCT00432107|Phase II study
570165|NCT00432094|childhood extragonadal germ cell tumor
570166|NCT00432094|childhood malignant ovarian germ cell tumor
570167|NCT00432094|childhood malignant testicular germ cell tumor
570168|NCT00432094|stage III malignant testicular germ cell tumor
570169|NCT00432094|testicular choriocarcinoma and seminoma
570170|NCT00432094|testicular embryonal carcinoma and seminoma
570171|NCT00432094|testicular embryonal carcinoma and teratoma with seminoma
570172|NCT00432094|testicular embryonal carcinoma and yolk sac tumor with seminoma
570173|NCT00432094|testicular yolk sac tumor and teratoma with seminoma
570174|NCT00432094|testicular choriocarcinoma and embryonal carcinoma
570175|NCT00432094|testicular choriocarcinoma and teratoma
570176|NCT00432094|testicular choriocarcinoma and yolk sac tumor
570177|NCT00432094|testicular choriocarcinoma
570178|NCT00432094|testicular embryonal carcinoma and teratoma
570179|NCT00432094|testicular embryonal carcinoma and yolk sac tumor
570180|NCT00432094|testicular embryonal carcinoma
570181|NCT00432094|testicular yolk sac tumor and teratoma
570182|NCT00432094|testicular yolk sac tumor
570183|NCT00432094|testicular seminoma
570184|NCT00432094|stage IV extragonadal non-seminomatous germ cell tumor
570185|NCT00432094|stage IV extragonadal seminoma
570186|NCT00432094|stage I extragonadal non-seminomatous germ cell tumor
570187|NCT00432094|stage I extragonadal seminoma
570188|NCT00432094|stage II extragonadal non-seminomatous germ cell tumor
570189|NCT00432094|stage II extragonadal seminoma
570190|NCT00432094|stage III extragonadal non-seminomatous germ cell tumor
570191|NCT00432094|stage III extragonadal seminoma
570192|NCT00432094|stage II ovarian germ cell tumor
570193|NCT00432094|stage I malignant testicular germ cell tumor
570194|NCT00432094|stage II malignant testicular germ cell tumor
570195|NCT00432094|adult teratoma
570196|NCT00432094|childhood teratoma
570197|NCT00432094|testicular immature teratoma
570198|NCT00432094|testicular mature teratoma
570199|NCT00432094|adult central nervous system germ cell tumor
570200|NCT00432094|childhood central nervous system germ cell tumor
570201|NCT00432081|Dementia
570202|NCT00432081|Inflammation
570203|NCT00432081|Anti-Inflammatory Agents
570204|NCT00432081|Anti-Inflammatory Agents, Non-Steroidal
570205|NCT00432081|Drug Therapy
570206|NCT00432068|Healthy volunteers
570207|NCT00432068|octreotide pamoate
570208|NCT00432068|pharmacokinetics
570209|NCT00432055|Adult
570210|NCT00432055|Cerebral Palsy
570211|NCT00432055|Spastic contractures
570212|NCT00432055|Botulinum toxin type A
570213|NCT00432042|Mumps and Rubella
570214|NCT00432042|Haemophilus influenzae type b (Infanrix® hexa)
570215|NCT00432029|Flicker induced vasodilatation
570216|NCT00432029|Flow mediated vasodilatation
570217|NCT00432029|Forearm blood flow
570218|NCT00432029|Retinal vessel diameter
570219|NCT00432029|Endothelial dysfunction
570220|NCT00432016|HIV
570221|NCT00432016|pharmacokinetics
570222|NCT00432016|zidovudine
570223|NCT00432016|amdoxovir
570224|NCT00432016|DAPD
570225|NCT00432016|AMDX
570226|NCT00432016|Treatment Naive
570227|NCT00432003|Treatment Experienced
570228|NCT00432003|HIV
570229|NCT00432003|Antiretroviral Therapy, Highly Active
570230|NCT00431977|Coronary Atherosclerosis
570231|NCT00431977|Diabetes Mellitus
570232|NCT00431964|azithromycin, Zithromax
570233|NCT00431951|Healthy Volunteers
570234|NCT00431925|head and neck cancer
570235|NCT00431925|radiation therapy
570236|NCT00431925|chemotherapy
570237|NCT00431925|mucositis
570238|NCT00431925|cytokines
570239|NCT00431925|gastrostomy
570240|NCT00431925|radiotherapy
570241|NCT00431912|cutaneous T-cell lymphoma
570242|NCT00431912|mycosis fungoides
570243|NCT00431912|Sézary syndrome
570244|NCT00431912|APO866
570245|NCT00431912|phase II study
570246|NCT00431899|nutrition
570247|NCT00431899|omega 3 fatty acids
570248|NCT00431899|insulin resistance
570249|NCT00431886|Chest pains
570250|NCT00431886|Computed tomography
570251|NCT00431886|Emergency
570252|NCT00431873|Lymphocytic Leukemia, Chronic (Refractory)
570253|NCT00431873|Phase II
570254|NCT00431860|Coronary atherosclerosis, Spiral Computed Tomography
570255|NCT00431847|Anesthesia, Regional
570256|NCT00431847|Causalgia
570257|NCT00431847|Trauma
570258|NCT00431847|Complex Regional Pain Syndrome Type II
570259|NCT00431847|Neuropathic Pain
570260|NCT00431847|PTSD
570261|NCT00431847|Combat Stress Disorders
570262|NCT00431847|Afghan War, 2001-
570263|NCT00431847|Iraq War, 2003-
570264|NCT00431834|Permanent Atrial Fibrillation Surgical RF Ablation
570265|NCT00431834|Permanent Atrial Fibrillation
570266|NCT00431821|Exercise
570267|NCT00431821|Rehabilitation
570268|NCT00431821|Stroke
570269|NCT00431808|Malaria
570270|NCT00431808|vaccine
570271|NCT00431808|Apical Membrane Antigene
570272|NCT00431808|Mali
570273|NCT00431808|Adults
570274|NCT00431795|Advanced breast cancer
570275|NCT00431795|Pegylated liposomal doxorubicin
570276|NCT00431795|Epirubicin
570277|NCT00431782|Atrial fibrillation
570278|NCT00431782|Anticoagulation
570279|NCT00431769|Multiple myeloma
570280|NCT00431769|Bortezomib
570281|NCT00431769|Dexamethasone
570282|NCT00431769|VELCADE
570283|NCT00431756|Barrett's esophagus
570284|NCT00431756|gastroesophageal reflux disease (GERD)
570285|NCT00431756|esophageal cancer
570286|NCT00431756|DNA methylation
570287|NCT00431743|Fluid Therapy
570288|NCT00431743|Crystalloid
570289|NCT00431743|Colloid
570290|NCT00431743|Perioperative
570291|NCT00431743|Optimization
570292|NCT00431743|Goal-directed Therapy
570293|NCT00431717|Coronary Atherosclerosis
570294|NCT00431717|Diabetes Mellitus
570295|NCT00431704|advanced
570296|NCT00431704|her-2 positive
570297|NCT00431678|Community-acquired Pneumonia
570298|NCT00431665|Renal Plasma Flow
570299|NCT00431665|Glomerular Filtration Rate
570300|NCT00431665|Free fatty acids
570301|NCT00431639|Animal-Assisted Therapy
570302|NCT00431639|Pain
570303|NCT00431639|Oncology
570304|NCT00431639|Cancer Pain
570305|NCT00431626|Benign
570306|NCT00431626|Prostatic
570307|NCT00431626|Hyperplasia
570308|NCT00431626|Lower
570309|NCT00431626|Urinary
570310|NCT00431626|Track
570311|NCT00431626|Symptoms
570312|NCT00431626|Laser
570313|NCT00431626|Transurethral
570314|NCT00431626|Prostate
570315|NCT00431613|NSCLC
570316|NCT00431613|Induction chemotherapy
570317|NCT00431613|Concurrent chemoradiotherapy
570318|NCT00431613|Consolidation therapy
570319|NCT00431613|Docetaxel
570320|NCT00431613|Gemcitabine
570321|NCT00431613|Carboplatin
570322|NCT00431600|Regional Blood Flow
570323|NCT00431600|Color Doppler Optical Coherence Tomography
570324|NCT00431600|CDOCT
570325|NCT00431600|Retinal Blood Flow
570326|NCT00431600|Hyperoxia
570327|NCT00431600|Vasoconstriction
570328|NCT00431600|Laser Doppler Velocimetry
570329|NCT00431600|Retinal Vessel Analyzer
570330|NCT00431587|morbid obesity
570331|NCT00431587|metabolic syndrome
570332|NCT00431587|visceral fat
570333|NCT00431587|peripheral fat
570334|NCT00431574|schizophrenia
570335|NCT00431574|schizoaffective
570336|NCT00431574|antipsychotic
570337|NCT00431574|randomized control trial
570338|NCT00431561|Glioblastoma
570339|NCT00431561|Anaplastic astrocytoma
570340|NCT00431561|Antisense
570341|NCT00431561|Cancer
570342|NCT00431561|Transforming growth factor beta2 (TGF-beta2)
570343|NCT00431561|Targeted therapy
570344|NCT00431561|Immunotherapy
570345|NCT00431561|Brain tumor
570346|NCT00431561|Central nervous system (CNS)
570347|NCT00431561|Convection-enhanced delivery (CED) / microperfusion
570348|NCT00431561|Locoregional application
570349|NCT00431535|Fluid
570350|NCT00431535|SvO2
570351|NCT00431535|Mobilisation
570352|NCT00431535|Orthostatic function
570353|NCT00431509|Osteoarthritis
570354|NCT00431509|Arthroplasty
570355|NCT00431509|Replacement
570356|NCT00431509|Knee
570357|NCT00431509|Instrumentation
570358|NCT00431496|Anemia
570359|NCT00431496|Intact Parathyroid Hormone (iPTH)
570360|NCT00431496|Secondary Hyperparathyroidism (SHPT)
570361|NCT00431483|antibacterial agents
570362|NCT00431483|surgery
570363|NCT00431483|pharmacist
570364|NCT00431483|economics, pharmaceutical
570365|NCT00431470|Classroom violence, character, bullying, self esteem
570366|NCT00431444|Osteoporosis
570367|NCT00431444|Post-menopausal
570368|NCT00431444|Bone mineral density
570369|NCT00431405|rheumatoid arthritis
570370|NCT00431405|cardiovascular disease
570371|NCT00431405|coronary disease
570372|NCT00431392|Choroidal blood flow
570373|NCT00431392|NO-synthase
570374|NCT00431392|light/dark transition
570375|NCT00431366|Fatigue
570376|NCT00431366|Repetitive TMS (rTMS)
570377|NCT00431366|Parkinson's Disease
570378|NCT00431366|Peg Board Test
570379|NCT00431366|Levodopa
570380|NCT00431366|Parkinson Disease
570381|NCT00431366|PD
570382|NCT00431340|Multiple myeloma
570383|NCT00431340|myeloma
570384|NCT00431340|plasma cell myeloma
570385|NCT00431340|bone marrow cancer
570386|NCT00431340|myelomatosis
570387|NCT00431340|Kahler's disease
570388|NCT00431340|PXD101
570389|NCT00431340|belinostat
570390|NCT00431340|bortezomib
570391|NCT00431327|patient navigator
570392|NCT00431327|peer support
570393|NCT00431327|colonoscopy
570394|NCT00431327|adherence
570395|NCT00431327|None: have to be scheduled for screening or diagnostic colonoscopy
570396|NCT00431314|End Stage Renal Disease
570397|NCT00431314|Hemodialysis
570398|NCT00431314|Critical Limb Ischemia
570399|NCT00431314|Autofluorescence
570400|NCT00431301|Progressive Supranuclear Palsy
570401|NCT00431301|Epidemiology
570402|NCT00431301|Case-Control
570403|NCT00431301|Genetic
570404|NCT00431301|Environmental
570405|NCT00431301|Neurodegenerative Disease
570406|NCT00431301|Movement Disorders
570407|NCT00431301|Atypical Parkinsonism
570408|NCT00431301|Parkinson Plus
570409|NCT00431301|Steele-Richardson-Olszewski
570410|NCT00431301|PSP
570411|NCT00431288|nutrition
570412|NCT00431288|adolescent nutrition
570413|NCT00431288|blood pressure
570414|NCT00431288|hypertension
570415|NCT00431288|diet therapy
570416|NCT00431288|patient education
570417|NCT00431262|alcoholism
570418|NCT00431262|antabuse
570419|NCT00431262|disulfiram
570420|NCT00431262|abstinence
570421|NCT00431262|cognitive behavioural therapy
570422|NCT00431236|highly emetogenic
570423|NCT00431236|cisplatin
570424|NCT00431236|CINV
570425|NCT00430976|psychomotor function
570426|NCT00430976|neuromuscular system
570427|NCT00430976|memory
570428|NCT00430976|brain electrical activity
570429|NCT00430976|Mental Processes
570430|NCT00430950|Moderate-to-Severe Hypertension
570431|NCT00430950|Essential Hypertension
570432|NCT00430950|Combination Therapy
570433|NCT00430950|Fixed-Combination Dose
570434|NCT00430937|Complicated Skin and Soft Tissue Infections. Daptomycin, Vancomycin, Teicoplanin
570435|NCT00430937|Complicated skin and soft tissue infections
570436|NCT00430924|Kidney Failure, Chronic
570437|NCT00430924|Proteinuria
570438|NCT00430924|Aldosterone
570439|NCT00430924|Renin-Angiotensin System
570440|NCT00430911|malignant gliomas
570441|NCT00430898|ulcerative colitis basiliximab
570442|NCT00430885|Heart failure
570443|NCT00430885|Myocardial infarction
570444|NCT00430885|Patients with acute myocardial infarction
570445|NCT00430872|Spinal Cord Tumor
570446|NCT00430872|Intramedullary Spinal Cord Tumor
570447|NCT00430872|Extramedullary Spinal Cord Tumor
570448|NCT00430872|Symptoms
570449|NCT00430872|Survey
570450|NCT00430859|Sepsis
570451|NCT00430859|Alkaline
570452|NCT00430859|Phosphatase
570453|NCT00430859|Lipopolysaccharide
570454|NCT00430846|Antigens,CD30
570455|NCT00430846|Antibody-Drug Conjugate
570456|NCT00430846|Antibodies, Monoclonal
570457|NCT00430846|Lymphoma, Non-Hodgkin
570458|NCT00430846|Disease, Hodgkin
570459|NCT00430846|Lymphoma, Large-Cell, Anaplastic
570460|NCT00430846|Hematologic Diseases
570461|NCT00430846|Lymphoma
570462|NCT00430820|Biomarkers
570463|NCT00430820|Proteomics
570464|NCT00430820|Mass spectrometry
570465|NCT00430820|Atherosclerosis
570466|NCT00430820|Acute coronary syndromes
570467|NCT00430820|Myocardial infarction
570468|NCT00430820|Coronary artery disease
570469|NCT00430807|giant cell arteritis,
570470|NCT00430807|hydroxychloroquine,
570471|NCT00430807|corticosteroid sparing,
570472|NCT00430807|corticodependence
570473|NCT00430794|resistant hypertension
570474|NCT00430794|Spironolactone
570475|NCT00430794|double-blind
570476|NCT00430794|randomised controlled trial
570477|NCT00430794|ambulatory blood pressure monitoring
570478|NCT00430781|pazopanib
570479|NCT00430781|ErB1/ErB2
570480|NCT00430781|lapatinib
570481|NCT00430781|persistent
570482|NCT00430781|VEGF
570483|NCT00430781|recurrent
570484|NCT00430781|metastatic cervical cancer
570485|NCT00430781|advanced
570486|NCT00430781|FIGO Stage IVB
570487|NCT00430768|Gene Transfer Techniques
570488|NCT00430768|Gene Therapy
570489|NCT00430768|AAV
570490|NCT00430768|AAT
570491|NCT00430768|Phase I
570492|NCT00430768|Intramuscular transfer
570493|NCT00430729|Roflumilast
570494|NCT00430703|severe traumatic brain injury
570495|NCT00430703|body weight support treadmill training
570496|NCT00430703|Electroencephalogram
570497|NCT00430703|Event Related Potentials
570498|NCT00430664|pleurodesis
570499|NCT00430664|talc
570500|NCT00430664|iodopovidone
570501|NCT00430651|Non Small Cell Lung Cancer
570502|NCT00430651|2nd line chemotherapy
570503|NCT00430651|Docetaxel
570504|NCT00430638|Hypertension
570505|NCT00430638|Angiotensin Receptor Blocker
570506|NCT00430638|Calcium Channel Blocker
570507|NCT00430638|Angiotensin Converting Enzyme Inhibitor
570508|NCT00430638|Hydrochlorothiazide
570509|NCT00430638|Stage I and II Hypertension
570510|NCT00430625|VPRIV®
570511|NCT00430625|Enzyme Replacement Therapy
570512|NCT00430625|Gaucher disease
570513|NCT00430625|glucocerebrosidase
570514|NCT00430625|beta-glucocerebrosidase
570515|NCT00430625|Acid beta-glucocerebrosidase
570516|NCT00430625|glucosylceramidase
570517|NCT00430625|D-glucosyl-N-acylsphingosine glucohydrolase
570518|NCT00430625|gene activation
570519|NCT00430625|human
570520|NCT00430612|Myocardial Infarction
570521|NCT00430612|Heart Attack
570522|NCT00430612|Beta Blockers
570523|NCT00430612|Survival
570524|NCT00430573|cognitive-behavior therapy
570525|NCT00430573|d-cycloserine
570526|NCT00430573|cognitive enhancer
570527|NCT00430573|drug dependence
570528|NCT00430573|opiate dependence
570529|NCT00430573|exposure
570530|NCT00430573|isolated doses of d-cycloserine
570531|NCT00430573|isolated doses of matching pill placebo
570532|NCT00430573|DCS
570533|NCT00430560|work therapy
570534|NCT00430560|cognitive rehabilitation
570535|NCT00430560|schizophrenia
570536|NCT00430560|schizoaffective disorder
570537|NCT00430560|treatment outcome
570538|NCT00430534|Epstein Barr Virus
570539|NCT00430534|Belgium
570540|NCT00430534|Infectious mononucleosis
570541|NCT00430521|Pandemic Flu
570542|NCT00430521|Pandemic influenza vaccine (GSK1119711A)
570543|NCT00430508|Moderate-to-Severe Hypertension
570544|NCT00430508|Essential Hypertension
570545|NCT00430508|Combination Therapy
570546|NCT00430508|Fixed-Combination Dose
570547|NCT00430495|atacicept
570548|NCT00430495|arthritis
570549|NCT00430482|Substance Dependence
570550|NCT00430482|Cognitive-Behavior Therapy
570551|NCT00430482|Opiate Dependence
570552|NCT00430482|Treatment Moderators
570553|NCT00430469|Lactoferrin
570554|NCT00430469|hLF
570555|NCT00430469|Neutropenia
570556|NCT00430469|Myeloablative
570557|NCT00430469|Treatment
570558|NCT00430469|Fungal
570559|NCT00430469|Bacterial
570560|NCT00430469|Infections
570561|NCT00430469|Bone marrow transplant
570562|NCT00430456|Aerobic exercise
570563|NCT00430456|Balance, postural
570564|NCT00430456|Cardiovascular deconditioning
570565|NCT00430456|Gait
570566|NCT00430456|MRI, functional
570567|NCT00430456|Physical therapy techniques
570568|NCT00430456|Self Efficacy
570569|NCT00430456|Treadmill test
570570|NCT00430443|Acute Lymphocytic Leukemia
570571|NCT00430443|Acute Myelogenous Leukemia
570572|NCT00430443|Annamycin
570573|NCT00430443|Liposomal Annamycin
570574|NCT00430417|Pregnancy
570575|NCT00430417|Lactation
570576|NCT00430417|Endocrine System Diseases
570577|NCT00430417|MusculoSkeletal System Disease
570578|NCT00430417|Hormone
570579|NCT00430417|Physiologic Properties
570580|NCT00430391|DVD
570581|NCT00430391|Multi-media
570582|NCT00430391|Schizophrenia
570583|NCT00430391|Normal Comparison
570584|NCT00430391|Consent procedures
570585|NCT00430378|Xerostomia
570586|NCT00430378|Dry Mouth
570587|NCT00430378|Mouth Dryness
570588|NCT00430378|Nasopharyngeal Cancer
570589|NCT00430378|Acupuncture
570590|NCT00430365|Myeloma
570591|NCT00430365|Revlimid
570592|NCT00430365|Maintenance therapy
570593|NCT00430365|Autologous Stem Cell Transplantation
570594|NCT00430313|Nausea
570595|NCT00430313|Vomiting
570596|NCT00430313|Electro-Stimulation
570597|NCT00430313|ES
570598|NCT00430313|K1 Acupuncture Point
570599|NCT00430313|Yongquan Acupuncture Point
570600|NCT00430313|TAI
570601|NCT00430313|transarterial infusion
570602|NCT00430313|liver metastasis
570603|NCT00430313|chemotherapy induced nausea and vomiting
570604|NCT00430313|CINV
570605|NCT00430313|Cisplatin
570606|NCT00430313|Oxaliplatin
570607|NCT00430300|Dry Powder for Inhalation
570608|NCT00430300|Chronic Obstructive Pulmonary Disease
570609|NCT00430300|Lung Function testing
570610|NCT00430287|primary open angle glaucoma
570611|NCT00430287|low tension glaucoma
570612|NCT00430287|pigmentary glaucoma
570613|NCT00430287|exfoliative glaucoma
570614|NCT00430274|glaucoma
570615|NCT00430274|retinal gliosis-like alterations
570616|NCT00430274|optical coherence tomography
570617|NCT00430274|automated microperimetry
570618|NCT00430261|bronchoalveolar carcinoma
570619|NCT00430261|BAC
570620|NCT00430261|adenocarcinoma
570621|NCT00430261|lung cancer
570622|NCT00430261|oral
570623|NCT00430261|Stage IIIB and IV lung cancer
570624|NCT00430261|Any bronchoalveolar carcinoma (BAC)
570625|NCT00430261|Any adenocarcinoma in a never-smoker
570626|NCT00430248|tophi
570627|NCT00430248|hyperuricemia
570628|NCT00430248|uric acid
570629|NCT00430248|Drug Therapy
570630|NCT00430235|prostate
570631|NCT00430235|cancer
570632|NCT00430235|BAY 43-9006
570633|NCT00430183|stage I prostate cancer
570634|NCT00430183|stage IIB prostate cancer
570635|NCT00430183|stage IIA prostate cancer
570636|NCT00430183|stage III prostate cancer
570637|NCT00430183|adenocarcinoma of the prostate
570638|NCT00430170|ischemia-reperfusion injury
570639|NCT00430170|adenosine
570640|NCT00430170|dipyridamole
570641|NCT00430170|caffeine
570642|NCT00430157|Vienna Challenge Chamber
570643|NCT00430157|Seasonal Allergic Rhinitis
570644|NCT00430157|Inflammation
570645|NCT00430118|T-cell childhood acute lymphoblastic leukemia
570646|NCT00430118|recurrent childhood acute lymphoblastic leukemia
570647|NCT00430118|untreated childhood acute lymphoblastic leukemia
570648|NCT00430118|B-cell childhood acute lymphoblastic leukemia
570649|NCT00430105|Vasculitis
570650|NCT00430105|ANCA
570651|NCT00430105|Wegener's granulomatosis
570652|NCT00430105|Renal vasculitis
570653|NCT00430105|Cyclophosphamide
570654|NCT00430053|stage I cutaneous T-cell non-Hodgkin lymphoma
570655|NCT00430053|stage II cutaneous T-cell non-Hodgkin lymphoma
570656|NCT00430053|stage III cutaneous T-cell non-Hodgkin lymphoma
570657|NCT00430053|stage IV cutaneous T-cell non-Hodgkin lymphoma
570658|NCT00430053|stage I mycosis fungoides/Sezary syndrome
570659|NCT00430053|stage II mycosis fungoides/Sezary syndrome
570660|NCT00430053|stage III mycosis fungoides/Sezary syndrome
570661|NCT00430053|stage IV mycosis fungoides/Sezary syndrome
570662|NCT00430040|Type 2 Diabetes Mellitus
570663|NCT00430040|Hypertension
570664|NCT00430040|Carvedilol CR
570665|NCT00430040|Beta-blocker
570666|NCT00430040|Oxidative stress
570667|NCT00430040|Inflammation
570668|NCT00430040|Vascular benefits
570669|NCT00430027|Esophageal
570670|NCT00430027|Esophagus
570671|NCT00430014|Advanced Cancer
570672|NCT00430014|Relapsed
570673|NCT00430014|Atiprimod
570674|NCT00430014|Guanylyl cyclase receptor antagonist
570675|NCT00430001|Metastatic breast neoplasm
570676|NCT00429988|breast cancer
570677|NCT00429975|fluorquinolones,
570678|NCT00429975|b-lactams,
570679|NCT00429975|immunomodulation.
570680|NCT00429962|subfoveal choroidal neovascularization (CNV)
570681|NCT00429962|age-related macular degeneration
570682|NCT00429962|ranibizumab monotherapy
570683|NCT00429962|combined verteporfin-therapy
570684|NCT00429962|Lucentis® (ranibizumab)
570685|NCT00429962|Visudyne®
570686|NCT00429962|photodynamic therapy
570687|NCT00429949|Dasatinib
570688|NCT00429949|Plateau phase
570689|NCT00429936|Dry Age Related Macular Degeneration
570690|NCT00429936|Geographic Atrophy
570691|NCT00429910|accelerated phase chronic myelogenous leukemia
570692|NCT00429910|blastic phase chronic myelogenous leukemia
570693|NCT00429910|chronic phase chronic myelogenous leukemia
570694|NCT00429910|meningeal chronic myelogenous leukemia
570695|NCT00429897|Hypertension
570696|NCT00429897|Low Renin
570697|NCT00428870|Shoulder
570698|NCT00428870|impingement
570699|NCT00428870|conservative
570700|NCT00428870|acromioplasty
570701|NCT00428870|arthroscopy
570702|NCT00428844|Osteomyelitis
570703|NCT00428844|Prosthetic Hip
570704|NCT00428844|Prosthetic Knee
570705|NCT00428844|MRSA
570706|NCT00428844|Osteomyelitis Associated with an Infected Prosthetic Hip or Knee Joint
570707|NCT00428844|Staphylococci
570831|NCT00429507|Radiation Therapy
570708|NCT00428831|influenza, genomic data, nasopharyngeal aspirate
570709|NCT00428818|MRSA
570710|NCT00428805|body composition
570711|NCT00428805|physical activity
570712|NCT00428805|dietary intake
570713|NCT00428805|children
570714|NCT00428792|ADHD
570715|NCT00428792|methylphenidate
570716|NCT00428792|children
570717|NCT00428792|food effect
570718|NCT00428792|Attention-Deficit Hyperactivity Disorder (ADHD) in children
570719|NCT00428779|Running during 24 hours
570720|NCT00428779|Voluntary evoked force on the muscles
570721|NCT00428779|Electrically evoked force on the muscles
570722|NCT00428779|EMG activity
570723|NCT00428779|Muscle biopsy
570724|NCT00428779|subjects will be recruited among experienced ultra-runners
570725|NCT00428753|avian influenza, China, H5N1
570726|NCT00428727|Diabetic foot
570727|NCT00428727|Ulcer
570728|NCT00428727|nitric oxide
570729|NCT00428727|treatment
570730|NCT00428727|donor
570731|NCT00428727|controlled trial
570732|NCT00428701|stress ulcer
570733|NCT00428701|critically ill
570734|NCT00428701|gastric acid
570735|NCT00428701|gastric aspirates
570736|NCT00428701|esomeprazole
570737|NCT00428688|Hodgkin's lymphoma
570738|NCT00428688|cardiovascular disease
570739|NCT00428688|radiation therapy
570740|NCT00428688|Brachial artery flow-mediated dilation (FMD)
570741|NCT00429884|Atrial fibrillation
570742|NCT00429871|Metastatic breast cancer;
570743|NCT00429871|First line chemotherapy;
570744|NCT00429871|Docetaxel;
570745|NCT00429871|Epirubicin;
570746|NCT00429871|Capecitabine
570747|NCT00429858|recurrent pancreatic cancer
570748|NCT00429858|stage III pancreatic cancer
570749|NCT00429858|adenocarcinoma of the pancreas
570750|NCT00429858|stage IV pancreatic cancer
570751|NCT00429845|HIV
570752|NCT00429845|HAART
570753|NCT00429845|Nutrition
570754|NCT00429845|Dyslipidemia
570755|NCT00429832|Nausea, vomiting, antiemetic
570756|NCT00429806|Vaginal atrophy
570757|NCT00429806|DHEA
570758|NCT00429806|Prasterone
570759|NCT00429806|Menopause
570760|NCT00429780|Leishmaniasis vaccine
570761|NCT00429780|Alum-ALM
570762|NCT00429780|First generation vaccine
570763|NCT00429780|Leishmanin positive
570764|NCT00429780|Healthy Volunteers
570765|NCT00429780|Response to Leishmanin (Leishmanin Skin Test>0)
570766|NCT00429780|No History of Cutaneous Leishmaniasis
570767|NCT00429767|Opioid
570768|NCT00429767|Cocaine
570769|NCT00429767|Drug Self Administration
570770|NCT00429754|Nausea and vomiting after using cytostatic drugs
570771|NCT00429728|Pharmacokinetics,
570772|NCT00429728|tolerability,
570773|NCT00429728|healthy,
570774|NCT00429728|subjects,
570775|NCT00429728|smokers,
570776|NCT00429728|non-smokers
570777|NCT00429715|Leishmaniasis vaccine
570778|NCT00429715|Alum-ALM
570779|NCT00429715|First generation vaccine
570780|NCT00429715|Healthy volunteers
570781|NCT00429715|No response to leishmanin
570782|NCT00429715|No history of cutaneous leishmaniasis
570783|NCT00429702|nausea
570784|NCT00429702|vomiting
570785|NCT00429702|emetic chemotherapy
570786|NCT00429702|unspecified childhood solid tumor, protocol specific
570787|NCT00429689|Male, MDD, Testosterone, DHEA-S,Cortisol
570788|NCT00429689|Male
570789|NCT00429689|18-65
570790|NCT00429689|Major Depression
570791|NCT00429676|Randomized
570792|NCT00429676|Controlled
570793|NCT00429676|Trial
570794|NCT00429676|Delirium
570795|NCT00429676|Haloperidol
570796|NCT00429663|distal femur
570797|NCT00429663|femur fracture
570798|NCT00429650|Weight maintenance
570799|NCT00429650|Weight loss
570800|NCT00429637|EBC pH
570801|NCT00429637|Airway acidification
570802|NCT00429637|Condensimetry
570803|NCT00429637|ARDS
570804|NCT00429637|RSV
570805|NCT00429637|ALI
570806|NCT00429637|Airway reconstruction
570807|NCT00429624|Neck Pain
570808|NCT00429624|Chiropractic manipulation
570809|NCT00429624|Randomized controlled trial
570810|NCT00429611|biphasic defibrillation
570811|NCT00429611|inhospital
570812|NCT00429611|post-resuscitation myocardial function
570813|NCT00429611|defibrillation efficacy
570814|NCT00429611|high energy versus low energy
570815|NCT00429611|cardiac arrest patients
570816|NCT00429585|tibia fracture
570817|NCT00429585|proximal tibia
570818|NCT00429572|Breast Cancer
570819|NCT00429572|PBPC Transplantation
570820|NCT00429572|Stem Cell Infusion
570821|NCT00429572|Fludarabine
570822|NCT00429572|Melphalan
570823|NCT00429559|Cancer;
570824|NCT00429559|Ovarian cancer;
570825|NCT00429559|Recurrent ovarian cancer platinum-resistant
570826|NCT00429546|Disclosure
570827|NCT00429546|Serostatus
570828|NCT00429507|Breast Cancer
570829|NCT00429507|Blood Stem Cell
570830|NCT00429507|Bone Metastases
570832|NCT00429507|Gamma Camera
570833|NCT00429507|Sm-EDTMP
570834|NCT00429507|Samarium 153-EDTMP
570835|NCT00429507|Stem Cell Transplant
570836|NCT00429507|Autologous Peripheral Blood Stem Cell Transplantation
570837|NCT00429507|PBSCT
570838|NCT00429507|Questionnaire
570839|NCT00429494|Hematopoietic Stem Cell Transplantation
570840|NCT00429494|GnRH Analogue
570841|NCT00429494|Gonadotropin-releasing hormone analogue
570842|NCT00429494|GnRH-a
570843|NCT00429494|Ovarian Function
570844|NCT00429494|Fertility
570845|NCT00429494|Leuprolide Acetate
570846|NCT00429494|Lupron Depot
570847|NCT00429494|premature ovarian failure
570848|NCT00429494|POF
570849|NCT00429494|Abnormal suppression of menstruation
570850|NCT00429494|absence of menstruation
570851|NCT00429481|Oral live attenuated human rotavirus vaccine
570852|NCT00429481|Gastroenteritis
570853|NCT00429481|Vomiting
570854|NCT00429455|Fertility
570855|NCT00429455|Menopause
570856|NCT00429455|Hematopoietic Stem Cell Transplantation
570857|NCT00429455|Questionnaire
570858|NCT00429455|Survey
570859|NCT00429442|Simvastatin
570860|NCT00429442|CNS Inflammation
570861|NCT00429442|Copaxone
570862|NCT00429429|Peanut allergy
570863|NCT00429416|Hematologic Malignancies
570864|NCT00429416|GVHD
570865|NCT00429416|Graft-Versus-Host-Disease
570866|NCT00429416|LLME
570867|NCT00429416|CD34+ stem cell infusions
570868|NCT00429416|CD34- fraction
570869|NCT00429416|Cyclosporine
570870|NCT00429416|Mycophenolate Mofetil
570871|NCT00429416|HSCT
570872|NCT00429416|Hematopoietic stem cell transplantation
570873|NCT00429403|Breast Cancer
570874|NCT00429403|Chemotherapy
570875|NCT00429403|Ovarian Function
570876|NCT00429403|Goserelin
570877|NCT00429403|Zoladex
570878|NCT00429403|Ovary function
570879|NCT00429403|Fertility
570880|NCT00429403|Early Menopause
570881|NCT00429390|Metabolic syndrome
570882|NCT00429390|Ramadan Fasting
570883|NCT00429390|Insulin sensitivity
570884|NCT00429390|Iran
570885|NCT00429377|tacrolimus
570886|NCT00429377|FK506
570887|NCT00429377|lupus nephritis
570888|NCT00429364|Aortic Root Dissection
570889|NCT00429364|Aortic Root Dilation
570890|NCT00429364|Pediatric Heart Network
570891|NCT00429338|Genitourinary
570892|NCT00429338|Prostate Cancer
570893|NCT00429338|Magnetic Resonance Imaging
570894|NCT00429338|MRI
570895|NCT00429338|Magnetic Resonance Spectroscopic Imaging
570896|NCT00429338|MRSI
570897|NCT00429338|Endorectal MRSI
570898|NCT00429338|Endorectal magnetic resonance spectroscopy imaging
570899|NCT00429338|3 Tesla
570900|NCT00429338|3T Scan
570901|NCT00429338|Endorectal coil
570902|NCT00429338|Perfluorocarbon compound
570903|NCT00429338|PFC
570904|NCT00429338|PFC-filled endorectal coil
570905|NCT00429338|PFC-MRSI
570906|NCT00429338|AIR-MRSI
570907|NCT00429325|acute infectious diarrhea,
570908|NCT00429325|fecal calprotectin,
570909|NCT00429325|stool culture,
570910|NCT00429325|hemoccult test,
570911|NCT00429325|Guaiac fecal occult blood test (FOBT)
570912|NCT00429325|fecal lactoferrin
570913|NCT00429312|Melanoma
570914|NCT00429312|Oncolytic virus
570915|NCT00429312|Pexa-Vec
570916|NCT00429299|neo-adjuvant trastuzumab early breast cancer lapatinib
570917|NCT00429286|Health Services Research
570918|NCT00429273|ADHD
570919|NCT00429273|Guanfacine
570920|NCT00429273|Methylphenidate
570921|NCT00429273|Focalin XR
570922|NCT00429273|Pediatric
570923|NCT00429273|Cognitive function
570924|NCT00429273|Combination therapy
570925|NCT00429260|depression
570926|NCT00429260|antidepressive agents
570927|NCT00429247|Occult tumor cells
570928|NCT00429247|Micrometastatic cells
570929|NCT00429247|Cytokeratin-19
570930|NCT00429247|Trastuzumab
570931|NCT00429247|Completion of Adjuvant Treatment
570932|NCT00429234|Advanced Cancer
570933|NCT00429234|Solid Tumors
570934|NCT00429234|Dasatinib
570935|NCT00429234|BMS-354825
570936|NCT00429234|Sprycel
570937|NCT00429234|Gemcitabine
570938|NCT00429234|Gemcitabine Hydrochloride
570939|NCT00429234|Gemzar
570940|NCT00429221|ADHD
570941|NCT00429208|Nicotine Dependence
570942|NCT00429208|Smoking
570943|NCT00429208|Tobacco Use Disorder
570944|NCT00429208|Nicotine Use Disorder
570945|NCT00429195|LIPGENE
570946|NCT00429195|Fatty acid
570947|NCT00429195|Dietary intervention
570948|NCT00429195|Metabolic syndrome
570949|NCT00429195|Insulin resistance
570950|NCT00429182|Breast Cancer
570951|NCT00429182|breast carcinoma
570952|NCT00429182|Carboplatin
570953|NCT00429182|Paraplatin
570954|NCT00429182|Cyclophosphamide
570955|NCT00429182|Neosar
570956|NCT00429182|Cytoxan
570957|NCT00429182|Thiotepa
570958|NCT00429182|Purged Autologous Stem Cells
570959|NCT00429182|Circulating Tumor Cells
570960|NCT00429182|CTCs
570961|NCT00429169|Major Depressive Disorder
570962|NCT00429169|MDD
570963|NCT00429156|Non-invasive ventilation
570964|NCT00429156|Non-invasive positive pressure ventilation
570965|NCT00429156|Home ventilation
570966|NCT00429156|Domiciliary ventilation
570967|NCT00429156|Chronic obstructive pulmonary disease
570968|NCT00429156|COPD
570969|NCT00429156|Respiratory failure
570970|NCT00429156|Acute hypercapnic respiratory failure
570971|NCT00429156|NIV
570972|NCT00429156|NIPPV
570973|NCT00429156|Type II respiratory failure
570974|NCT00429143|Hematologic Malignancies
570975|NCT00429143|Two Step Approach
570976|NCT00429143|Haploidentical Transplant
570977|NCT00429117|Spirituality
570978|NCT00429117|Work Related Stress
570979|NCT00429117|Religious Beliefs
570980|NCT00429117|Survey
570981|NCT00429104|Breast Cancer
570982|NCT00429104|Carcinoma of the Breast
570983|NCT00429104|HER-2/neu Overexpression
570984|NCT00429104|Herceptin
570985|NCT00429104|Trastuzumab
570986|NCT00429104|GM-CSF
570987|NCT00429104|Sargramostim
570988|NCT00429104|Leukine
570989|NCT00429078|Gastric Cancer
570990|NCT00429078|T Cells
570991|NCT00429078|Gene Transfer
570992|NCT00429065|Non-Hodgkin lymphoma
570993|NCT00429065|rituximab
570994|NCT00429065|immunotherapy
570995|NCT00429052|Coronary Disease
570996|NCT00429052|Coronary Stenosis
570997|NCT00429052|Percutaneous Transluminal Coronary Angioplasty
570998|NCT00429052|Stents
570999|NCT00429052|Sirolimus
571000|NCT00429026|Kidney Cancer
571001|NCT00429026|Renal Cell Cancer
571002|NCT00429026|Stem Cell Transplant
571003|NCT00429026|Cyclophosphamide
571004|NCT00429026|Fludarabine
571005|NCT00429026|Melphalan
571006|NCT00429026|NST
571007|NCT00429013|Pressure ulcer
571008|NCT00429013|Lingual electric stimulation
571009|NCT00429013|Paraplegic patient
571010|NCT00429013|Pressure Ulcer/Prevention & control
571011|NCT00429000|Hypothermia
571012|NCT00429000|Infant mortality
571013|NCT00429000|Infant morbidity
571014|NCT00429000|Intervention
571015|NCT00429000|Randomisation
571016|NCT00429000|Longitudinal research.
571017|NCT00429000|Low-income country
571018|NCT00428987|Energy Expenditure
571019|NCT00428987|Neurocognitive Function
571020|NCT00428987|Obesity
571021|NCT00428987|Metabolism
571022|NCT00428987|Phenotype
571023|NCT00428987|Body Composition
571024|NCT00428987|Morbid Obesity
571025|NCT00428987|Overweight
571026|NCT00428987|Healthy Volunteer
571027|NCT00428974|Psoriasis
571028|NCT00428961|diabetes mellitus
571029|NCT00428961|insulin resistance
571030|NCT00428961|atherosclerosis
571031|NCT00428948|ADPKD
571032|NCT00428948|Polycystic
571033|NCT00428948|kidney
571034|NCT00428948|ADPKD (Autosomal Dominant Polycystic Kidney Disease)
571035|NCT00428935|Duchenne
571036|NCT00428935|Muscle
571037|NCT00428935|Muscular Dystrophy
571038|NCT00428935|Gene Therapy
571039|NCT00428935|Dystrophin
571040|NCT00428935|Adeno-Associated Virus
571041|NCT00428935|AAV
571042|NCT00428922|Metastatic
571043|NCT00428922|Breast Cancer
571044|NCT00428922|MBC
571045|NCT00428909|Pharmacokinetic
571046|NCT00428909|STI571
571047|NCT00428909|imatinib
571048|NCT00428909|CML
571049|NCT00428909|Chronic Myeloid Leukemia
571050|NCT00428909|Philadelphia Chromosome
571051|NCT00428909|acetaminophen
571052|NCT00428896|Breast cancer
571053|NCT00428896|iressa circulating tumor cells
571054|NCT00428883|Scleroderma, Systemic
571055|NCT00428883|Scleroderma, Diffuse
571056|NCT00428675|screening
571057|NCT00428675|fatigue
571058|NCT00428662|coronary stenting
571059|NCT00428662|drug eluting stents
571060|NCT00428662|paclitaxel
571061|NCT00428662|nanoporous
571062|NCT00428649|Selenium supplements
571063|NCT00428649|Selenoprotein P
571064|NCT00428649|Optimization
571065|NCT00428636|ileostomy
571066|NCT00428636|rectal resection
571067|NCT00428636|proctectomy
571068|NCT00428636|stoma closure
571069|NCT00428623|Patient comfort
571070|NCT00428623|Wound dressings
571071|NCT00428623|infection
571072|NCT00428623|vascular surgery
571073|NCT00428571|Type 2 Diabetes
571074|NCT00428571|Bariatric surgery
571075|NCT00428571|Obesity
571076|NCT00428571|Laparoscopic gastric bypass
571077|NCT00428571|Laparoscopic adjustable gastric banding
571078|NCT00428558|acute myeloid leukemia
571079|NCT00428558|Core Binding Factor
571080|NCT00428558|t(8;21)
571081|NCT00428558|inv(16)
571082|NCT00428558|timed-sequential induction
571083|NCT00428545|Advanced Malignancy
571084|NCT00428545|Lymphoma
571085|NCT00428545|Myeloma
571086|NCT00428545|Solid Tumors
571087|NCT00428545|Bevacizumab
571088|NCT00428545|Avastin
571089|NCT00428545|Anti-VEGF monoclonal antibody
571090|NCT00428545|rhuMAb-VEGF
571091|NCT00428545|Bortezomib
571092|NCT00428545|Velcade
571093|NCT00428545|PS-341
571094|NCT00428545|LDP-341
571095|NCT00428545|MLN341
571096|NCT00428519|HIV infection
571097|NCT00428519|Neurokinin-1 receptor antagonist
571098|NCT00428519|CCR5 expression
571099|NCT00428519|Treatment Naive
571100|NCT00428506|ascites
571101|NCT00428506|cirrhosis
571102|NCT00428506|post-paracentesis circulatory dysfunction
571103|NCT00428506|albumin
571104|NCT00428506|portal-hypertension
571105|NCT00428493|human influenza A, H5N1, bird flu, avian influenza, China
571106|NCT00428467|Heart Failure
571107|NCT00428467|LV Geometry
571108|NCT00428467|Heart MRT
571109|NCT00428454|drug-eluting stent
571110|NCT00428454|chronic total occlusion
571111|NCT00428454|sirolimus-eluting stent
571112|NCT00428454|zotarolimus-eluting stent
571113|NCT00428454|QCA
571114|NCT00428441|D-dimer
571115|NCT00428441|Recurrence
571116|NCT00428441|Venous thromboembolism
571117|NCT00428428|kidney stone
571118|NCT00428428|ureteroscopy
571119|NCT00428402|Education
571120|NCT00428402|4th-8th Grade Student
571121|NCT00428402|MIDAS Project
571122|NCT00428402|Focus Group Discussion
571123|NCT00428402|Bastrop
571124|NCT00428389|Dementia, Alzheimer's, Rivastigmine, donepezil
571125|NCT00428363|posterior capsule opacification
571126|NCT00428363|PCO
571127|NCT00428363|after cataract
571128|NCT00428363|intraocular lens
571129|NCT00428363|optic edge design
571130|NCT00428363|sharp optic edge
571131|NCT00428337|HIV Seronegativity
571132|NCT00428337|EP1233
571133|NCT00428337|MVA-mBN32
571134|NCT00428337|HIV Preventive Vaccine
571135|NCT00428311|Polycystic ovary syndrome
571136|NCT00428311|Hyperandrogenism
571137|NCT00428311|Hirsutism
571138|NCT00428311|Cardiovascular risk
571139|NCT00428311|Chronic inflammation
571140|NCT00428311|Metformin
571141|NCT00428311|Cyproterone acetate
571142|NCT00428311|Oral contraceptives
571143|NCT00428298|Bipolar
571144|NCT00428298|Cognitive
571145|NCT00428298|Attention
571146|NCT00428298|Memory
571147|NCT00428298|Manic Depression
571148|NCT00428298|Bi-polar
571149|NCT00428285|Human Papilloma Virus
571150|NCT00428285|HIV infected MSM
571151|NCT00428285|Treatment Experienced
571152|NCT00428285|Treatment Naive
571153|NCT00428285|Anal Intraepithelial Neoplasia
571154|NCT00428272|Monoclonal Antibody Lexatumumab
571155|NCT00428272|Interferon Gamma
571156|NCT00428272|Solid Tumor
571157|NCT00428272|Phase I
571158|NCT00428272|Malignant Tumor
571159|NCT00428272|Metastatic Tumor
571160|NCT00428272|Pediatric Solid Tumor
571161|NCT00428272|Ewing Sarcoma
571162|NCT00428272|Osteosarcoma
571163|NCT00428272|Neuroblastoma
571164|NCT00428272|Rhabdomyosarcoma
571165|NCT00428246|Chronic Kidney Disease
571166|NCT00428246|Endothelial dysfunction
571167|NCT00428246|Inflammation
571168|NCT00428246|Hypertension
571169|NCT00428246|paricalcitol
571170|NCT00428246|Blood pressure
571171|NCT00428246|Vitamin D
571172|NCT00428246|Glomerular filtration rate
571173|NCT00428233|CLL
571174|NCT00428233|vaccine
571175|NCT00428220|Potentially other tumor types in the future
571176|NCT00428207|type 1 diabetes, insulin pump therapy, glycemic stability
571177|NCT00428194|stage IIA cervical cancer
571178|NCT00428194|stage IB cervical cancer
571179|NCT00428194|stage IIB cervical cancer
571180|NCT00428194|stage III cervical cancer
571181|NCT00428194|stage IVA cervical cancer
571182|NCT00428194|cervical squamous cell carcinoma
571183|NCT00428181|Brief alcohol intervention
571184|NCT00428181|Booster session
571185|NCT00428181|Personalized feedback
571186|NCT00428181|Motivational interview
571187|NCT00428181|Injury recidivism
571188|NCT00428181|Psychological Interview
571189|NCT00428181|Risk Reduction Behaviors
571190|NCT00428168|Betahistine
571191|NCT00428168|Weight Gain Control
571192|NCT00428168|Weight Gain due to Olanzapine Treatment
571193|NCT00428168|Obesity
571194|NCT00428168|Schizophrenic disorder
571195|NCT00428155|hemostasis
571196|NCT00428155|angioplasty
571197|NCT00428155|stenting
571198|NCT00428155|closure device
571199|NCT00428155|angioseal
571200|NCT00428155|starclose
571201|NCT00428142|stage III grade 1 follicular lymphoma
571202|NCT00428142|stage III grade 2 follicular lymphoma
571203|NCT00428142|stage III grade 3 follicular lymphoma
571204|NCT00428142|stage IV grade 1 follicular lymphoma
571205|NCT00428142|stage IV grade 2 follicular lymphoma
571206|NCT00428142|stage IV grade 3 follicular lymphoma
571207|NCT00428129|Acute Iliofemoral Deep Vein Thrombosis
571208|NCT00428116|HIV-1
571209|NCT00428116|Pediatric
571210|NCT00428116|HAART
571211|NCT00428116|Treatment Naive
571212|NCT00428103|Mitral valve regurgitation
571213|NCT00428090|apolipoprotein E
571214|NCT00428090|monotherapy
571215|NCT00428090|cognition
571216|NCT00428090|mild
571217|NCT00428090|rosiglitazone
571218|NCT00428090|Alzheimer's disease
571219|NCT00428090|moderate
571220|NCT00428077|Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia
571221|NCT00428077|chronic phase chronic myelogenous leukemia
571222|NCT00428064|Renal allograft
571223|NCT00428064|Renal
571224|NCT00428064|Kidney
571225|NCT00428064|Transplant
571226|NCT00428051|Epidemiology
571227|NCT00428051|Surveillance
571228|NCT00428051|Streptococcal Pneumonia
571229|NCT00428038|Infant, Premature
571230|NCT00428038|Bronchopulmonary Dysplasia
571231|NCT00428038|Asthma
571232|NCT00428025|pancreatitis
571233|NCT00428012|quality of life, kidney transplantation
571234|NCT00427999|Hormone-refractory
571235|NCT00427999|prostate cancer
571236|NCT00427999|multitargeted
571237|NCT00427999|tyrosinkinase
571238|NCT00427986|Diabetes
571239|NCT00427986|Macular oedema
571240|NCT00427986|Osmosis
571241|NCT00427986|Galactose
571242|NCT00427986|Intravenous
571243|NCT00427986|Retinal thickness
571244|NCT00427986|Starling
571245|NCT00427960|cholesterol
571246|NCT00427960|statin
571247|NCT00427960|Asian
571248|NCT00427960|LDL-cholesterol
571249|NCT00427947|phantom limb pain
571250|NCT00427947|amputation
571251|NCT00427947|anesthetics, local
571252|NCT00427947|postoperative analgesia
571253|NCT00427947|ropivacaine
571254|NCT00427947|analgesia
571255|NCT00427908|Meningococcal serogroups A, C, W-135 and/or Y diseases
571256|NCT00427908|Conjugate vaccine
571257|NCT00427908|Immunogenicity
571258|NCT00427908|Meningococcal vaccine
571259|NCT00427908|Persistence
571260|NCT00427908|Non-inferiority
571261|NCT00427895|Vaccine
571262|NCT00427895|Pneumococcal Infections Prevention and Control
571263|NCT00427843|osteoarthritis
571264|NCT00427843|knee
571265|NCT00427843|gait
571266|NCT00427843|muscle strength
571267|NCT00427843|hip
571268|NCT00427843|exercise
571269|NCT00427830|Mycobacterium tuberculosis
571270|NCT00427830|85A antigen
571271|NCT00427830|Recombinant Modified Vaccinia Ankara
571272|NCT00427830|Phase I study
571273|NCT00427830|Immunogenicity
571274|NCT00427830|BCG
571275|NCT00427817|Adenoma, Prostatic
571276|NCT00427817|Prostate
571277|NCT00427817|Proteomics
571278|NCT00427817|Urology
571279|NCT00427804|Calcium absorption
571280|NCT00427804|Vitamin D
571281|NCT00427791|Acute Lymphoblastic Leukemia
571282|NCT00427791|Leukemia
571283|NCT00427791|Total Body Irradiation
571284|NCT00427791|Etoposide
571285|NCT00427791|Rituximab
571286|NCT00427791|Rituxan
571287|NCT00427791|TBI
571288|NCT00427791|ALL
571289|NCT00427778|incontinence ring
571290|NCT00427778|pessary
571291|NCT00427778|urinary incontinence
571292|NCT00427778|urodynamic study
571293|NCT00427778|quality of life
571294|NCT00427778|crossover trial
571295|NCT00427778|randomised trial
571296|NCT00427765|Multiple Myeloma
571297|NCT00427765|Hodgkin's Disease
571298|NCT00427765|Non-Hodgkin's Lymphoma
571299|NCT00427765|Leukemia
571300|NCT00427765|Lymphoma
571301|NCT00427765|Busulfan
571302|NCT00427765|Melphalan
571303|NCT00427765|Autologous bone marrow
571304|NCT00427765|BMT
571305|NCT00427765|Peripheral blood stem cell transplant
571306|NCT00427765|PBSCT
571307|NCT00427752|Transgastric
571308|NCT00427752|Endoluminal
571309|NCT00427752|Peritoneoscopy
571310|NCT00427752|Diagnostic
571311|NCT00427752|Feasibility
571312|NCT00427739|Axial Flow Ventricular Assist Device
571313|NCT00427739|Cardiac CT
571314|NCT00427739|Stage IV heart failure
571315|NCT00427726|Gene Transfer
571316|NCT00427726|Hematopoietic Stem Cells
571317|NCT00427726|Follow-Up
571318|NCT00427713|adenocarcinoma of the rectum
571319|NCT00427713|stage III rectal cancer
571320|NCT00427713|stage II rectal cancer
571321|NCT00427700|Polycystic Ovary Syndrome
571322|NCT00427700|clomiphene citrate
571323|NCT00427700|Raloxifene
571324|NCT00427674|Parkinson
571325|NCT00427674|Imaging
571326|NCT00427661|Sickle Cell Disease
571327|NCT00427661|Thalassemia
571328|NCT00427661|Hemoglobinopathies
571329|NCT00427648|Administration, Intravesical
571330|NCT00427648|Anesthetics, Local
571331|NCT00427635|neonates
571332|NCT00427635|infants
571333|NCT00427635|GERD
571334|NCT00427635|reflux
571335|NCT00427622|hot flashes
571336|NCT00427609|Treatment
571337|NCT00427609|Psoriasis
571338|NCT00427609|efficacy
571339|NCT00427609|Bicillin
571340|NCT00427596|GW427353 oral tablets,
571341|NCT00427596|healthy adult subjects,
571342|NCT00427596|food effect
571343|NCT00427583|Malignant,
571344|NCT00427583|peripheral,
571345|NCT00427583|nerve sheath tumors,
571346|NCT00427583|MPNST,
571347|NCT00427583|neurofibromatosis,
571348|NCT00427583|NF1,
571349|NCT00427583|Imatinib mesylate
571350|NCT00427570|stage II colon cancer
571351|NCT00427570|stage III colon cancer
571352|NCT00427557|Multiple Myeloma
571353|NCT00427557|Acute Myeloid Leukemia
571354|NCT00427557|Myelodysplastic Syndrome
571355|NCT00427557|Acute Lymphoblastic Leukemia
571356|NCT00427557|Non-Hodgkin's Lymphoma
571357|NCT00427557|Hodgkin's Lymphoma
571358|NCT00427557|Chronic Lymphocytic Leukemia
571359|NCT00427557|Cellular Therapy
571360|NCT00427557|Umbilical Cord Blood Cells
571361|NCT00427557|Cord Blood Transplantation
571362|NCT00427557|Stem Cells
571363|NCT00427557|Stem Cell Transplantation
571364|NCT00427557|Allogeneic
571365|NCT00427557|Hematopoietic Stem Cell Transplantation
571366|NCT00427557|Graft vs. Host Disease
571367|NCT00427557|GVD
571368|NCT00427557|Fludarabine
571369|NCT00427557|Fludarabine Phosphate
571370|NCT00427557|Fludara
571371|NCT00427557|Melphalan
571372|NCT00427557|Rituximab
571373|NCT00427557|Rituxan
571374|NCT00427557|Leukemia
571375|NCT00427557|Lymphoma
571376|NCT00427544|Uterine leiomyomata (Fibroids)
571377|NCT00427531|hot flashes
571378|NCT00427505|Interaction
571379|NCT00427505|healthy volunteers
571380|NCT00427505|deferasirox
571381|NCT00427505|midazolam
571382|NCT00427479|Allergy
571383|NCT00427479|Food
571384|NCT00427479|Hay fever
571385|NCT00427479|Screening
571386|NCT00427453|Mycobacterium tuberculosis
571387|NCT00427453|85A antigen
571388|NCT00427453|Recombinant Modified Vaccinia Virus Ankara
571389|NCT00427453|Phase I study
571390|NCT00427453|Immunogenicity
571391|NCT00427453|BCG
571392|NCT00427440|Glioma
571393|NCT00427440|Brain Tumor
571394|NCT00427427|non-metastatic breast cancer
571395|NCT00427427|HER-2 positive breast cancer
571396|NCT00427427|Herceptin (trastuzumab)
571397|NCT00427427|delayed adjuvant therapy
571398|NCT00427427|acceptability rate
571399|NCT00427427|non-metastatic, HER-2 positive breast cancer
571400|NCT00427414|AIDS-related Kaposi sarcoma
571401|NCT00427414|recurrent Kaposi sarcoma
571402|NCT00427388|Cardiac Surgical Procedures
571403|NCT00427388|Cardiopulmonary Bypass
571404|NCT00427388|Systemic inflammatory Response Syndrome
571405|NCT00427388|Steroid
571406|NCT00427388|Myocardial Infarction
571407|NCT00427388|Randomized Clinical Trial
571408|NCT00427375|Rectal cancer surgery
571409|NCT00427375|Neoadjuvant radiochemotherapy
571410|NCT00427375|Randomized clinical trial
571411|NCT00427375|Multicenter study
571412|NCT00427349|localized gastrointestinal carcinoid tumor
571413|NCT00427349|recurrent gastrointestinal carcinoid tumor
571414|NCT00427349|metastatic gastrointestinal carcinoid tumor
571415|NCT00427349|regional gastrointestinal carcinoid tumor
571416|NCT00427349|gastrinoma
571417|NCT00427349|insulinoma
571418|NCT00427349|WDHA syndrome
571419|NCT00427349|glucagonoma
571420|NCT00427349|pancreatic polypeptide tumor
571421|NCT00427349|somatostatinoma
571422|NCT00427349|recurrent islet cell carcinoma
571423|NCT00427349|neuroendocrine tumor
571424|NCT00427336|Severe Aplastic Anemia
571425|NCT00427336|Bone Marrow Failure
571426|NCT00427336|Stem Cell Transplantation
571427|NCT00427336|Fludarabine
571428|NCT00427336|Cyclophosphamide
571429|NCT00427336|Antithymocyte Globulin
571430|NCT00427336|SAA
571431|NCT00427336|ATG
571432|NCT00427336|Cytoxan
571433|NCT00427336|Neosar
571434|NCT00427336|Fludarabine Phosphate
571435|NCT00427336|Thymoglobulin
571436|NCT00427323|sleep
571437|NCT00427323|aging
571438|NCT00427323|biological rhythm
571439|NCT00427323|melatonin
571440|NCT00427323|alertness
571441|NCT00427323|early morning awakening
571442|NCT00427323|daytime sleepiness
571443|NCT00427323|difficulty maintaining sleep
571444|NCT00427323|sleep maintenance insomnia
571445|NCT00427310|stage I colon cancer
571446|NCT00427310|stage II colon cancer
571447|NCT00427310|stage III colon cancer
571448|NCT00427310|adenocarcinoma of the colon
571449|NCT00427297|HIV-1
571450|NCT00427297|Pediatric
571451|NCT00427297|nevirapine
571452|NCT00427297|HAART
571453|NCT00427297|Resistance
571454|NCT00427297|Treatment Naive
571455|NCT00427284|Eplerenone auf die Endothelfunktion bei Patienten mit stabiler koronarer Herzkrankheit
571456|NCT00427271|aspirin
571457|NCT00427271|enalapril
571458|NCT00427271|microalbuminuria
571459|NCT00427271|glomerular filtration rate
571460|NCT00427258|healthy subjects
571461|NCT00427245|menopausal symptoms
571462|NCT00427245|infertility
571463|NCT00427245|stage IA breast cancer
571464|NCT00427245|stage IB breast cancer
571465|NCT00427245|stage II breast cancer
571466|NCT00427245|stage IIIA breast cancer
571467|NCT00427245|stage IIIB breast cancer
571468|NCT00427245|estrogen receptor-negative breast cancer
571469|NCT00427245|estrogen receptor-positive breast cancer
571470|NCT00427245|progesterone receptor-negative breast cancer
571471|NCT00427232|coronary heart disease
571472|NCT00427232|endothelins
571473|NCT00427232|coronary angiography
571474|NCT00427232|blood flow velocity
571475|NCT00427232|fractional flow reserve, myocardial
571476|NCT00427219|Benign Prostatic Hyperplasia
571477|NCT00427219|Prostatic Adenoma, Benign
571478|NCT00427219|Prostatic Hypertrophy, Benign
571479|NCT00427219|Enlarged Prostate
571480|NCT00427219|Prostatism
571481|NCT00427219|Adenoma, Prostatic
571482|NCT00427206|acetaminophen
571483|NCT00427206|alcohol
571484|NCT00427206|liver injury
571485|NCT00427193|dietary restriction
571486|NCT00427193|disease /disorder prevention /control
571487|NCT00427193|nutrition of aging
571488|NCT00427193|bioenergetics
571489|NCT00427193|cardiovascular function
571490|NCT00427193|disease /disorder proneness /risk
571491|NCT00427193|insulin sensitivity / resistance
571492|NCT00427180|Visual Perception
571493|NCT00427180|Retina
571494|NCT00427180|Light
571495|NCT00427180|Retinitis Pigmentosa
571496|NCT00427180|Visual acuity
571497|NCT00427180|Retinal Implant
571498|NCT00427180|Electrical stimulation
571499|NCT00427167|Blood Stage
571500|NCT00427167|Investigational
571501|NCT00427167|Vaccine
571502|NCT00427167|Malaria
571503|NCT00427167|Healthy Volunteer
571504|NCT00427167|HV
571505|NCT00427141|tolerability,
571506|NCT00427141|pharmacokinetics,
571507|NCT00427141|first time in human,
571508|NCT00427141|food effect
571509|NCT00427141|safety,
571510|NCT00427128|Major Depression
571511|NCT00427128|"true drug response"
571512|NCT00427128|"placebo response pattern"
571513|NCT00427128|continuation treatment outcomes
571514|NCT00427115|Patients undergoing allogeneic stem cell transplantations
571515|NCT00427102|Oral MRX-1024
571516|NCT00427102|High-Dose Cisplatin Chemotherapy
571517|NCT00427102|Standard Radiation Therapy
571518|NCT00427089|Colon cleansing
571519|NCT00427089|Polyethylene Glycol
571520|NCT00427089|Sodium Phosphate
571521|NCT00427076|vancomycin
571522|NCT00427076|cotrimoxazole
571523|NCT00427076|trimethoprim/ sulfamethoxazole
571524|NCT00427076|methicillin-resistant Staphylococcus aureus
571525|NCT00427076|Health care association infections
571526|NCT00427076|MRSA bacteremia or other microbiologically documented MRSA infections (defined clinically by CDC criteria)
571527|NCT00427076|Suspected neurosurgical meningitis
571528|NCT00427076|Sepsis during hemodialysis, catheter-associated and catheter-related infections
571529|NCT00427076|Ventilator-associated pneumonia
571530|NCT00427076|Surgical site infection in the presence of a foreign body
571531|NCT00427063|retinal vessels
571532|NCT00427063|tortuosity
571533|NCT00427050|Actinic Keratoses (AK)
571534|NCT00427050|PEP005
571535|NCT00427050|Topical
571536|NCT00427050|Dermatology
571537|NCT00427037|Vitamin D deficiency
571538|NCT00427037|Chronic Kidney Disease
571539|NCT00427024|renal transplantation
571540|NCT00427024|acute rejection
571541|NCT00427024|transport
571542|NCT00427024|transporter
571543|NCT00427024|acute rejection after renal transplantation
571544|NCT00426998|Choroidal neovascularization due to age-related macular degeneration
571545|NCT00426985|Tendonitis
571546|NCT00426985|Bursitis
571547|NCT00426985|Pain
571548|NCT00426985|Shoulder Pain
571549|NCT00426985|Elbow Pain
571550|NCT00426985|Knee Pain
571551|NCT00426985|Tendon Injury
571552|NCT00426985|Muscle, Bone and Cartilage Disorders
571553|NCT00426959|Adenocarcinoma of the prostate
571554|NCT00426959|PSA of less than 10 ng/mL
571555|NCT00426959|Combined Gleason score 6 or less
571556|NCT00426959|International Prostate Symptom Score (IPSS) must <or= to 18
571557|NCT00426946|Depression Children Reboxetine
571558|NCT00426946|A diagnosis of major depressive disorder or a dysthimic disorder according to DSM-IV-TR.
571559|NCT00426946|Drug naïve or without chronic medication for at least one month.
571560|NCT00426946|Only children who agree to participate and whose parents will sign and informed consent form will be included.
571561|NCT00426933|cSSSI
571562|NCT00426933|MRSA
571563|NCT00426920|pharmacokinetics
571564|NCT00426920|pharmacodynamics
571565|NCT00426920|inhaled
571566|NCT00426920|recombinant human insulin
571567|NCT00426907|Osteoarthritis, Knee
571568|NCT00426907|Osteotomy
571569|NCT00426907|Healing
571570|NCT00426907|Rehabilitation
571571|NCT00426907|Roentgen Stereometric Analysis
571572|NCT00426894|surveillance cultures
571573|NCT00426894|children
571574|NCT00426894|cardiac surgery
571575|NCT00426894|perioperative prophylaxis
571576|NCT00426881|Exercise
571577|NCT00426881|Resistance training
571578|NCT00426868|ADRC
571579|NCT00426868|Stem Cells
571580|NCT00426868|chronic ischemia
571581|NCT00426868|heart disease
571582|NCT00426868|coronary artery disease
571583|NCT00426868|inducible reversible ischemia
571584|NCT00426855|Lymphoma, Non-Hodgkin, Low-Grade
571585|NCT00426842|Blood pressure
571586|NCT00426842|Orthostatic hypotension
571587|NCT00426842|Spinal Cord Injury
571588|NCT00426842|Sympathetic vascular control
571589|NCT00426842|Midodrine
571590|NCT00426829|Liver Cancer
571591|NCT00426829|Biliary Tract
571592|NCT00426829|Hepatocellular Carcinoma
571593|NCT00426829|Cholangiocarcinoma
571594|NCT00426829|Bevacizumab
571595|NCT00426829|Proton Therapy
571596|NCT00426829|Radiation Therapy
571597|NCT00426829|PT
571598|NCT00426829|RT
571599|NCT00426829|Proton RT
571600|NCT00426829|Avastin
571601|NCT00426829|Anti-VEGF monoclonal antibody
571602|NCT00426829|rhuMAb-VEGF
571603|NCT00426816|primary insomnia
571604|NCT00426816|PSG sleep recordings
571605|NCT00426816|daytime cognitive function
571606|NCT00426816|Insomnia
571607|NCT00426816|SB-649868
571608|NCT00426777|prostate cancer
571609|NCT00426777|prostatic adenoma
571610|NCT00426777|prostatic neoplasm
571611|NCT00426764|peripheral T-cell lymphoma
571612|NCT00426764|T-cell lymphoma
571613|NCT00426764|romidepsin
571614|NCT00426751|Eptifibatide
571615|NCT00426751|ST-elevation Myocardial Infarction
571616|NCT00426751|STEMI
571617|NCT00426751|Abciximab
571618|NCT00426725|labor
571619|NCT00426725|pain
571620|NCT00426725|relief
571621|NCT00426725|labour
571622|NCT00426725|device
571623|NCT00426712|Chronic kidney failure
571624|NCT00426712|Chronic kidney disease
571625|NCT00426712|Hemodialysis
571626|NCT00426712|HBV vaccine
571627|NCT00426712|Hepatitis B vaccine
571628|NCT00426712|Hepatitis B
571629|NCT00426712|Hepatitis
571630|NCT00426712|HBV
571631|NCT00426712|Prevention & Control
571632|NCT00426699|enterovirus
571633|NCT00426699|meningitis
571634|NCT00426699|sepsis
571635|NCT00426699|myocarditis
571636|NCT00426699|kidney
571637|NCT00426699|urine
571638|NCT00426699|glomerulonephritis
571639|NCT00426686|thrombotic thrombocytopenic purpura
571640|NCT00426686|prognostic factors
571641|NCT00426686|ADAMTS13
571642|NCT00426673|partial onset seizures, phenytoin, dilatin, brivaracetam, interaction
571643|NCT00426660|HIV Infections
571644|NCT00426647|Osteoarthritis
571645|NCT00426647|Pain
571646|NCT00426647|Norspan
571647|NCT00426647|Buprenorphine
571648|NCT00426647|Tramadol
571649|NCT00426634|Asthma
571650|NCT00426634|Allergens
571651|NCT00426634|Mold
571652|NCT00426634|Asthma Counselor
571653|NCT00426634|Environmental Remediation
571654|NCT00426621|Knee osteoarthritis, degenerative joint disease, knee pain, joint pain, topical NSAID,
571655|NCT00426621|diclofenac sodium
571656|NCT00426608|cortisol,
571657|NCT00426608|Healthy volunteers
571658|NCT00426608|GSK561679,
571659|NCT00426608|HPA axis,
571660|NCT00426608|hormones,
571661|NCT00426582|Cancer
571662|NCT00426582|maximum tolerated dose
571663|NCT00426582|dose-limiting toxicity
571664|NCT00426582|patupilone
571665|NCT00426582|carboplatin
571666|NCT00426582|pharmacokinetics
571667|NCT00426556|Breast cancer
571668|NCT00426556|Cancer of the breast
571669|NCT00426556|Human mammary carcinoma
571670|NCT00426556|HER-2
571671|NCT00426556|Metastatic
571672|NCT00426556|everolimus
571673|NCT00426556|trastuzumab
571674|NCT00426556|paclitaxel
571675|NCT00426543|Clinical trial
571676|NCT00426543|Intervention study
571677|NCT00426543|Double-blind randomised controlled study
571678|NCT00426530|HER2-overexpressing metastatic breast cancer
571679|NCT00426530|Breast cancer
571680|NCT00426530|Cancer of the breast
571681|NCT00426530|Human mammary carcinoma
571682|NCT00426530|HER-2
571683|NCT00426530|metastatic
571684|NCT00426530|everolimus
571685|NCT00426530|trastuzumab
571686|NCT00426530|vinorelbine
571687|NCT00426517|MUD Transplant
571688|NCT00426517|Transplant
571689|NCT00426517|AlloPBSC
571690|NCT00426517|HLA Matched Transplant
571691|NCT00426517|BMT
571692|NCT00426517|Congenital Immunodeficiency
571693|NCT00426517|Bone Marrow Transplant
571694|NCT00426504|Head,
571695|NCT00426504|Neck,
571696|NCT00426504|Cancer,
571697|NCT00426504|Tomotherapy,
571698|NCT00426504|IMRT,
571820|NCT00425321|Auto immune
571699|NCT00426478|AMPM, SBP, DBP, Valsartan plus Hydrochlorothiazide, Amlodipine, high blood pressure
571700|NCT00426465|Motor Practice
571701|NCT00426465|Magnetic Stimulation
571702|NCT00426465|Stroke
571703|NCT00426465|Spacing Effect
571704|NCT00426465|Massed Practice
571705|NCT00426465|Healthy Volunteer
571706|NCT00426465|HV
571707|NCT00426452|Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor
571708|NCT00426452|Vatalinib
571709|NCT00426452|Proton-pump inhibitors
571710|NCT00426452|Omeprazole
571711|NCT00426452|Healthy Postmenopausal Female Volunteers
571712|NCT00426439|malaria
571713|NCT00426439|Plasmodium falciparum
571714|NCT00426439|children
571715|NCT00426439|Guinea-Bissau
571716|NCT00426439|artemether
571717|NCT00426439|lumefantrine
571718|NCT00426439|chloroquine
571719|NCT00426439|Coartem
571720|NCT00426413|ketosis-prone diabetes
571721|NCT00426413|diabetic ketoacidosis
571722|NCT00426413|obesity
571723|NCT00426413|insulin dependence
571724|NCT00426413|mechanisms
571725|NCT00426374|HIV
571726|NCT00426374|AIDS
571727|NCT00426374|Troponin
571728|NCT00426374|natriuretic peptide
571729|NCT00426374|heart failure
571730|NCT00426374|heart disease children
571731|NCT00426374|HIV pediatric
571732|NCT00426374|AIDS pediatric
571733|NCT00426361|Human Papillomavirus
571734|NCT00426348|IgA nephropathy
571735|NCT00426348|probucol
571736|NCT00426348|valsartan
571737|NCT00426348|treatment
571738|NCT00426348|antioxidant
571739|NCT00426348|IGA nephropathy：a kind of glomerulonephritis,which IgA is the dominant immunodeposit in mesangial areas
571740|NCT00426335|breast
571741|NCT00426335|cancer
571742|NCT00426335|cognitive behaviour therapy
571743|NCT00426335|psychological
571744|NCT00426322|maxillary sinus augmentation
571745|NCT00426322|bone graft
571746|NCT00426322|bovine bone mineral
571747|NCT00426322|dental implants
571748|NCT00426296|HIV
571749|NCT00426296|Reyataz
571750|NCT00426296|atazanavir
571751|NCT00426296|Norvir
571752|NCT00426296|ritonavir
571753|NCT00426296|Boosted
571754|NCT00426296|Lipodystrophy
571755|NCT00426296|Treatment Experienced
571756|NCT00426283|Eosinophilic Esophagitis
571757|NCT00426257|Ovarian Cancer
571758|NCT00426257|stage III
571759|NCT00426257|hyperthermic intraperitoneal chemotherapy
571760|NCT00426257|debulking surgery
571761|NCT00426257|HIPEC
571762|NCT00426244|Osteopathic Manipulative Medicine
571763|NCT00426244|Osteopathic Manipulative Treatment
571764|NCT00426244|Pregnancy
571765|NCT00426244|Physiologic
571766|NCT00426244|Gait
571767|NCT00426244|Low back pain
571768|NCT00426244|Heart rate variability
571769|NCT00426231|Randomized Controlled Trials
571770|NCT00426231|Health Education
571771|NCT00426231|Hydroxymethylglutaryl-CoA Reductase Inhibitors
571772|NCT00426231|Patient Nonadherence
571773|NCT00426218|Systemic Juvenile Idiopathic Arthritis
571774|NCT00426218|Immunogenicity
571775|NCT00426218|Pharmacokinetics
571776|NCT00426218|Anti-IL-1ß Monoclonal Antibody
571777|NCT00426218|ACZ885
571778|NCT00426218|SJIA
571779|NCT00426218|Pediatrics
571780|NCT00426205|GM-CSF
571781|NCT00426205|GVAX
571782|NCT00426205|Cancer vaccine
571783|NCT00426205|blood stem cell transplantation
571784|NCT00426205|MDS
571785|NCT00426205|AML
571786|NCT00426205|CML
571787|NCT00426192|Immunedefense Suppression
571788|NCT00426192|Cardiopulmonary Bypass
571789|NCT00426192|Mannitol
571790|NCT00426192|Hemofiltration
571791|NCT00426192|Cytokines
571792|NCT00426192|Receptors, Surface CD14
571793|NCT00426179|Imatinib, allergic inflammation, out of allergy season, repeated nasal allergen, seasonal allergic rhinitis, sensitive, Timothy grass pollen, c-kit inhibition
571794|NCT00426140|EPO
571795|NCT00426140|Patupilone
571796|NCT00426140|Solid Tumors
571797|NCT00426127|Pancreatic
571798|NCT00426127|Docetaxel
571799|NCT00426127|Doxorubicin
571800|NCT00426127|Enoxaparin
571801|NCT00425399|Schizophrenia
571802|NCT00425399|Shiatsu
571803|NCT00425386|stage III renal cell cancer
571804|NCT00425386|stage IV renal cell cancer
571805|NCT00425386|clear cell renal cell carcinoma
571806|NCT00425386|recurrent renal cell cancer
571807|NCT00425373|Hypertension, Valsartan, Amlodipine, high blood pressure
571808|NCT00425360|stage III pancreatic cancer
571809|NCT00425360|stage IV pancreatic cancer
571810|NCT00425360|duct cell adenocarcinoma of the pancreas
571811|NCT00425360|recurrent pancreatic cancer
571812|NCT00425347|Multiple myeloma, MM, plasma cell myeloma, cancer
571813|NCT00425334|Blood loss
571814|NCT00425334|Ischemia
571815|NCT00425334|Hemoglobin
571816|NCT00425334|Blood Substitutes
571817|NCT00425334|Plasma Expanders
571818|NCT00425321|Arthritis
571819|NCT00425321|Joints
571821|NCT00425308|Everolimus, calcineurine inhibitor, renal transplantation in maintenance, chronic allograft nephropathy
571822|NCT00425282|RWJ-333369
571823|NCT00425282|anticonvulsants
571824|NCT00425282|antiepileptic drugs
571825|NCT00426101|Hemophagocytic lymphohistiocytosis
571826|NCT00426075|Deep vein thrombosis of the lower extremities
571827|NCT00426062|Squamous Cell Carcinoma of Tongue and mouth floor
571828|NCT00426049|Coronary artery disease
571829|NCT00426049|Stents
571830|NCT00426049|Immunosuppressive Agents
571831|NCT00426049|Coronary restenosis
571832|NCT00426049|Safety
571833|NCT00426036|Open-label study, healthy subjects, stable impaired renal function, licarbazepine, pharmacokinetics, metabolism, safety.
571834|NCT00426023|Vernal keratoconjunctivitis
571835|NCT00426023|Cyclosporine
571836|NCT00426023|Children
571837|NCT00426023|Clinical trial
571838|NCT00426010|Placebo effect
571839|NCT00426010|Caffeine
571840|NCT00426010|Systolic BP
571841|NCT00426010|VAS
571842|NCT00425997|Hypertension, valsartan/HCTZ, amlodipine and HCTZ
571843|NCT00425984|HIV
571844|NCT00425984|Male circumcision
571845|NCT00425984|Sexually transmitted infections
571846|NCT00425984|Sexual risk behaviors
571847|NCT00425984|Adult males
571848|NCT00425984|Haemophilus ducreyi
571849|NCT00425984|Human papillomavirus
571850|NCT00425984|Rakai
571851|NCT00425984|Uganda
571852|NCT00425984|HIV seronegativity
571853|NCT00425984|HPV
571854|NCT00425984|STI
571855|NCT00425958|year and more after TBI
571856|NCT00425958|good vision
571857|NCT00425958|at least one functinal hand
571858|NCT00425958|cap[able od doing shopping during everyday life
571859|NCT00425932|Magnetic Resonance Imaging
571860|NCT00425932|Rituximab
571861|NCT00425932|Low Field MRI
571862|NCT00425932|Biomarkers
571863|NCT00425919|Type 2 Diabetes
571864|NCT00425919|Diabetes
571865|NCT00425906|psychosocial effects of cancer and its treatment
571866|NCT00425906|unspecified adult solid tumor, protocol specific
571867|NCT00425906|constipation, impaction, and bowel obstruction
571868|NCT00425906|anorexia
571869|NCT00425906|pain
571870|NCT00425893|influenza
571871|NCT00425893|masks
571872|NCT00425893|transmission
571873|NCT00425893|hand hygiene
571874|NCT00425893|non-pharmacologic interventions
571875|NCT00425880|Pregnancy
571876|NCT00425880|Asthma
571877|NCT00425880|Tobacco Abuse
571878|NCT00425880|Exhaled Nitric Oxide
571879|NCT00425867|PAR1 gene
571880|NCT00425867|polymorphisms
571881|NCT00425867|abortions
571882|NCT00425867|reccurent abortions
571883|NCT00425867|premature delivery
571884|NCT00425841|adenocarcinoma of the pancreas
571885|NCT00425841|stage III pancreatic cancer
571886|NCT00425841|stage II pancreatic cancer
571887|NCT00425815|Cognition
571888|NCT00425815|Ampakines
571889|NCT00425815|Schizophrenia
571890|NCT00425802|noncontiguous stage II adult diffuse large cell lymphoma
571891|NCT00425802|recurrent adult diffuse large cell lymphoma
571892|NCT00425802|stage III adult diffuse large cell lymphoma
571893|NCT00425802|stage IV adult diffuse large cell lymphoma
571894|NCT00425802|B-cell chronic lymphocytic leukemia
571895|NCT00425802|refractory chronic lymphocytic leukemia
571896|NCT00425802|stage III chronic lymphocytic leukemia
571897|NCT00425802|stage IV chronic lymphocytic leukemia
571898|NCT00425802|noncontiguous stage II mantle cell lymphoma
571899|NCT00425802|recurrent mantle cell lymphoma
571900|NCT00425802|stage III mantle cell lymphoma
571901|NCT00425802|stage IV mantle cell lymphoma
571902|NCT00425802|noncontiguous stage II grade 1 follicular lymphoma
571903|NCT00425802|noncontiguous stage II grade 2 follicular lymphoma
571904|NCT00425802|recurrent grade 1 follicular lymphoma
571905|NCT00425802|recurrent grade 2 follicular lymphoma
571906|NCT00425802|stage III grade 1 follicular lymphoma
571907|NCT00425802|stage III grade 2 follicular lymphoma
571908|NCT00425802|stage IV grade 1 follicular lymphoma
571909|NCT00425802|stage IV grade 2 follicular lymphoma
571910|NCT00425802|noncontiguous stage II small lymphocytic lymphoma
571911|NCT00425802|recurrent small lymphocytic lymphoma
571912|NCT00425802|stage III small lymphocytic lymphoma
571913|NCT00425802|stage IV small lymphocytic lymphoma
571914|NCT00425802|noncontiguous stage II marginal zone lymphoma
571915|NCT00425802|recurrent marginal zone lymphoma
571916|NCT00425802|splenic marginal zone lymphoma
571917|NCT00425802|stage III marginal zone lymphoma
571918|NCT00425802|stage IV marginal zone lymphoma
571919|NCT00425802|noncontiguous stage II adult immunoblastic large cell lymphoma
571920|NCT00425802|stage III adult immunoblastic large cell lymphoma
571921|NCT00425802|stage IV adult immunoblastic large cell lymphoma
571922|NCT00425802|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
571923|NCT00425802|nodal marginal zone B-cell lymphoma
571924|NCT00425802|recurrent adult immunoblastic large cell lymphoma
571925|NCT00425789|Deep Chemical Peeling
571926|NCT00425789|Hyperbaric Therapy
571927|NCT00425789|post-deep peel
571928|NCT00425776|Breast cancer
571929|NCT00425776|Acupuncture
571930|NCT00425776|Post-menopausal hot flushes
571931|NCT00425776|Se-estradiol
571932|NCT00425776|Se-endorphine
571933|NCT00425763|malaria
571934|NCT00425763|efficacy
571935|NCT00425763|intermittent preventive therapy in infants
571936|NCT00425763|drug resistance
571937|NCT00425750|stage IV squamous cell carcinoma of the lip and oral cavity
571938|NCT00425750|recurrent squamous cell carcinoma of the lip and oral cavity
571939|NCT00425750|stage IV squamous cell carcinoma of the oropharynx
571940|NCT00425750|recurrent squamous cell carcinoma of the oropharynx
571941|NCT00425750|stage IV squamous cell carcinoma of the hypopharynx
571942|NCT00425750|recurrent squamous cell carcinoma of the hypopharynx
571943|NCT00425750|stage IV squamous cell carcinoma of the larynx
571944|NCT00425750|recurrent squamous cell carcinoma of the larynx
571945|NCT00425737|Oral live attenuated human rotavirus vaccine
571946|NCT00425737|Gastroenteritis
571947|NCT00425724|proteinuria
571948|NCT00425724|nephritis
571949|NCT00425724|nephrotic syndrome
571950|NCT00425724|glomerulonephritis
571951|NCT00425711|Acamprosate
571952|NCT00425711|Alcohol Dependence
571953|NCT00425711|Driving Under the Influence
571954|NCT00425711|Drug Court
571955|NCT00425711|DUI Court
571956|NCT00425685|cardiopulmonary resuscitation, ECMO, shock, survival, heart failure, transplantation, heart assist device.
571957|NCT00425659|Health utility
571958|NCT00425659|Home sleep study
571959|NCT00425646|stage IIIB non-small cell lung cancer
571960|NCT00425646|stage IV non-small cell lung cancer
571961|NCT00425646|adenocarcinoma of the lung
571962|NCT00425646|bronchoalveolar cell lung cancer
571963|NCT00425646|large cell lung cancer
571964|NCT00425646|recurrent non-small cell lung cancer
571965|NCT00425633|Homeopathic
571966|NCT00425633|Potassium
571967|NCT00425633|Dichromate
571968|NCT00425633|Kalium
571969|NCT00425633|Bichromicum
571970|NCT00425633|Mechanical
571971|NCT00425633|Ventilation
571972|NCT00425633|Secretions
571973|NCT00425620|Chronic Sinusitis
571974|NCT00425620|Chronic Rhinosinusitis
571975|NCT00425607|Hutchinson-Gilford Progeria Syndrome
571976|NCT00425607|HGPS
571977|NCT00425607|Progeria
571978|NCT00425607|FTI
571979|NCT00425607|Farnesyltransferase Inhibitor
571980|NCT00425607|Lonafarnib
571981|NCT00425594|colonoscopy
571982|NCT00425594|bowel preparation
571983|NCT00425594|prep
571984|NCT00425581|N-terminal pro-BNP,
571985|NCT00425581|Cardiac Troponin-T,
571986|NCT00425581|Very low birth weight infants
571987|NCT00425581|hemodynamic instability
571988|NCT00425581|myocardial dysfunction
571989|NCT00425568|hypogonadism
571990|NCT00425568|low testosterone level
571991|NCT00425568|gonadal deficiency
571992|NCT00425555|Cutaneous T-Cell Lymphoma, adults
571993|NCT00425555|Mycosis Fungoides
571994|NCT00425555|Sézary Syndrome
571995|NCT00425555|CTCL
571996|NCT00425542|Pulmonary embolism
571997|NCT00425542|Outpatient care
571998|NCT00425542|Prognosis
571999|NCT00425516|neoadjuvant chemotherapy
572000|NCT00425516|breast cancer
572001|NCT00425516|sequential treatment
572002|NCT00425503|Prostate Cancer
572003|NCT00425503|Bortezomib
572004|NCT00425503|Radical Prostatectomy
572005|NCT00425503|Phase 2 Clinical Trial
572006|NCT00425477|refractory anemia with excess blasts
572007|NCT00425477|recurrent adult acute myeloid leukemia
572008|NCT00425477|untreated adult acute myeloid leukemia
572009|NCT00425477|secondary acute myeloid leukemia
572010|NCT00425477|de novo myelodysplastic syndromes
572011|NCT00425477|previously treated myelodysplastic syndromes
572012|NCT00425477|secondary myelodysplastic syndromes
572013|NCT00425477|myelodysplastic/myeloproliferative disease, unclassifiable
572014|NCT00425477|refractory anemia with ringed sideroblasts
572015|NCT00425477|refractory cytopenia with multilineage dysplasia
572016|NCT00425477|chronic myelomonocytic leukemia
572017|NCT00425477|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
572018|NCT00425477|adult acute minimally differentiated myeloid leukemia (M0)
572019|NCT00425477|adult acute myeloblastic leukemia without maturation (M1)
572020|NCT00425477|adult acute myeloblastic leukemia with maturation (M2)
572021|NCT00425477|adult acute myelomonocytic leukemia (M4)
572022|NCT00425477|adult acute monoblastic leukemia (M5a)
572023|NCT00425477|adult acute monocytic leukemia (M5b)
572024|NCT00425477|adult pure erythroid leukemia (M6b)
572025|NCT00425477|adult erythroleukemia (M6a)
572026|NCT00425477|adult acute megakaryoblastic leukemia (M7)
572027|NCT00425477|adult acute myeloid leukemia with t(16;16)(p13;q22)
572028|NCT00425477|adult acute myeloid leukemia with t(8;21)(q22;q22)
572029|NCT00425477|adult acute myeloid leukemia with inv(16)(p13;q22)
572030|NCT00425451|Periodontitis
572031|NCT00425451|Dental Care
572032|NCT00425451|Efficacy
572033|NCT00425451|Safety
572034|NCT00425425|squamous cell carcinoma of the esophagus
572035|NCT00425425|stage IIA esophageal cancer
572036|NCT00425425|stage IIB esophageal cancer
572037|NCT00425425|stage IIIA esophageal cancer
572038|NCT00425425|stage IIIB esophageal cancer
572039|NCT00425425|stage IIIC esophageal cancer
572040|NCT00425269|lifestyle intervention
572041|NCT00425269|Type 2 Diabetes
572042|NCT00425269|Metabolic syndrome
572043|NCT00425269|Pakistani women
572044|NCT00425269|dietary change
572045|NCT00425269|Physical activity
572046|NCT00425269|Norway
572047|NCT00425243|primary insomnia
572048|NCT00425243|chronic insomnia
572049|NCT00425178|Chronic wounds
572050|NCT00425178|Diabetes
572051|NCT00425178|Ulcers
572052|NCT00425178|Arterial bypass
572053|NCT00425178|Angioplasty
572054|NCT00425178|Diabetic ulcers
572055|NCT00425152|stage II colon cancer
572056|NCT00425152|stage III colon cancer
572057|NCT00425139|Cancer
572058|NCT00425139|Video game
572059|NCT00425139|Adolescent
572060|NCT00425139|Young adult
572061|NCT00425126|Delayed Graft Function
572062|NCT00425126|Kidney Transplantation
572063|NCT00425113|Mycobacterium Tuberculosis
572064|NCT00425113|Anaerobic
572065|NCT00425113|FDG-PET-HRCT
572066|NCT00425113|HRCT
572067|NCT00425113|Lesion Matrix
572068|NCT00425113|Tuberculosis
572069|NCT00425113|TB
572070|NCT00425074|slow release ASA
572071|NCT00425074|platelet functionalism
572072|NCT00425074|secondary cardiovascular prevention
572073|NCT00425035|Renal Cancer
572074|NCT00425022|lung cancer
572075|NCT00425022|video-assisted thoracic surgery
572076|NCT00425009|Berberine
572077|NCT00425009|Type 2 diabetes
572078|NCT00425009|Treatment
572079|NCT00424983|Multiple myeloma
572080|NCT00424983|breast cancer
572081|NCT00424983|zoledronic acid
572082|NCT00424983|pharmacokinetics
572083|NCT00424970|high altitude
572084|NCT00424970|hypoxia
572085|NCT00424970|pulmonary hypertension
572086|NCT00424970|polycythemia
572087|NCT00424970|hypoventilation
572088|NCT00424957|Ammonia
572089|NCT00424957|Astrocytes
572090|NCT00424957|Citric acid cycle
572091|NCT00424957|Alpha ketoglutarate dehydrogenase
572092|NCT00424944|Malaria
572093|NCT00424944|Vaccine
572094|NCT00424944|GMZ2
572095|NCT00424944|Safety
572096|NCT00424944|African
572097|NCT00424944|immunogenicity
572098|NCT00424931|narcolepsy
572099|NCT00424931|sleepiness
572100|NCT00424918|Dance
572101|NCT00424918|Peers
572102|NCT00424918|middle school-based
572103|NCT00424918|feasibility
572104|NCT00424866|Peripheral Arterial Disease
572105|NCT00424866|Ischemia
572106|NCT00424866|Intermittent Claudication
572107|NCT00424840|lung cancer, Carboplatin, bortezomib, Bevacizumab
572108|NCT00424827|pancreatic cancer, gemcitabine, 5-FU, cetuximab, radiation
572109|NCT00424814|HIV mother to child prevention
572110|NCT00424814|HIV Infections
572111|NCT00424814|Kaletra
572112|NCT00424814|Combivir
572113|NCT00424814|HIV Seronegativity
572114|NCT00424788|multiple sclerosis (MS)
572115|NCT00424775|Non-Small Cell Lung Cancer (NSCLC)
572116|NCT00424762|Diabetes Mellitus, Type 2
572117|NCT00424762|Congestive Heart Failure
572118|NCT00424762|Cardiopulmonary exercise testing
572119|NCT00424762|intracellular cardiomyocyte triglycerides
572120|NCT00424762|thiazolidinedione
572121|NCT00424762|rosiglitazone
572122|NCT00424762|nuclear magnetic resonance
572123|NCT00424749|Antineutrophil cytoplasmic antibody associated vasculitis
572124|NCT00424749|Glomerulonephritis
572125|NCT00424749|Rituximab
572126|NCT00424736|blunt trauma, pediatric patient, imaging, computer tomography
572127|NCT00424723|pemetrexed
572128|NCT00424723|neuroendocrine tumors
572129|NCT00424723|metastatic neuroendocrine tumors
572130|NCT00424710|choroidal neovascularization
572131|NCT00424697|Brain imaging,
572132|NCT00424697|fMRI,
572133|NCT00424697|stimulation,
572134|NCT00424697|pharmacodynamics,
572135|NCT00424697|tolerability,
572136|NCT00424697|healthy subjects
572137|NCT00424684|TB
572138|NCT00424684|Chronic Liver Disease
572139|NCT00424658|breathing disorders
572140|NCT00424645|Hematologic Malignancy
572141|NCT00424645|Solid Tumor
572142|NCT00424645|Glucarpidase
572143|NCT00424645|Voraxaze
572144|NCT00424645|Delayed Methotrexate Clearance
572145|NCT00424645|Placebo
572146|NCT00424619|Vitamin D
572147|NCT00424619|Hip fracture
572148|NCT00424619|Optimal level
572149|NCT00424619|Deficiency
572150|NCT00424619|Functional muscle strength
572151|NCT00424606|High risk node negative
572152|NCT00424567|Fracture
572153|NCT00424567|non union fracture
572154|NCT00424567|ununited fracture
572155|NCT00424567|pseudarthrosis
572156|NCT00424541|Pharmacokinetics, pharmacodynamics, safety, RAS profile, SPP100, aliskiren, Japanese, essential hypertension
572157|NCT00424541|Mild to moderate essential hypertension
572158|NCT00424528|COPD including chronic bronchitis and emphysema
572159|NCT00424515|Imatinib
572160|NCT00424515|Gleevec
572161|NCT00424489|Refractory Myasthenia Gravis
572162|NCT00424489|Autologous Stem Cell Transplantation
572163|NCT00424489|Cyclophosphamide and ATG
572164|NCT00424476|Autoimmune Diseases
572165|NCT00424476|Lupus
572166|NCT00424476|SLE
572167|NCT00424476|Systemic Lupus Erythematosus
572168|NCT00424476|Belimumab
572169|NCT00424476|Antibodies
572170|NCT00424463|Amyotrophic lateral sclerosis (ALS)
572171|NCT00424450|contrast ultrasound
572172|NCT00424450|muscle perfusion
572173|NCT00424424|Postoperative Dental Pain
572174|NCT00424385|AIPC, Prostate cancer
572175|NCT00424385|prostate
572176|NCT00424359|Mulitple Sclerosis
572177|NCT00424359|Ambulation
572178|NCT00424346|Active Rheumatoid Arthritis
572179|NCT00424346|anti-interleukin-1beta monoclonal antibody
572180|NCT00424346|methotrexate
572181|NCT00424320|Acute kidney failure
572182|NCT00424320|Contrast-induced nephropathy
572183|NCT00424320|Non-ionic contrast media
572184|NCT00424320|Ionic contrast media
572185|NCT00424320|Iopamidol
572186|NCT00424320|Percutaneous coronary intervention
572187|NCT00424320|Coronariography
572188|NCT00424281|Arixtra, fondaparinux, vasopressor, venous thrombolism
572189|NCT00424268|COPD
572190|NCT00424268|Roflumilast
572191|NCT00424255|Cancer of the Head and Neck
572192|NCT00424255|Neck cancer
572193|NCT00424255|Adjuvant
572194|NCT00424255|Head and neck cancer
572195|NCT00424255|High-risk head and neck cancer
572196|NCT00424255|Post-surgery
572197|NCT00424255|Head cancer
572198|NCT00424242|unspecified adult solid tumor, protocol specific
572199|NCT00424242|tumors metastatic to brain
572200|NCT00424242|leptomeningeal metastases
572201|NCT00424242|primary central nervous system non-Hodgkin lymphoma
572202|NCT00424242|primary central nervous system Hodgkin lymphoma
572203|NCT00424242|meningeal chronic myelogenous leukemia
572204|NCT00424242|relapsing chronic myelogenous leukemia
572205|NCT00424242|chronic eosinophilic leukemia
572206|NCT00424242|primary myelofibrosis
572207|NCT00424242|chronic neutrophilic leukemia
572208|NCT00424242|essential thrombocythemia
572209|NCT00424242|polycythemia vera
572210|NCT00424242|recurrent adult acute lymphoblastic leukemia
572211|NCT00424242|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
572212|NCT00424242|adult acute myeloid leukemia with inv(16)(p13;q22)
572213|NCT00424242|adult acute myeloid leukemia with t(15;17)(q22;q12)
572214|NCT00424242|adult acute myeloid leukemia with t(16;16)(p13;q22)
572215|NCT00424242|adult acute myeloid leukemia with t(8;21)(q22;q22)
572216|NCT00424242|recurrent adult acute myeloid leukemia
572217|NCT00424242|previously treated myelodysplastic syndromes
572218|NCT00424242|secondary acute myeloid leukemia
572219|NCT00424242|acute undifferentiated leukemia
572220|NCT00424242|mast cell leukemia
572221|NCT00424242|recurrent adult T-cell leukemia/lymphoma
572222|NCT00424242|stage IV adult T-cell leukemia/lymphoma
572223|NCT00424242|T-cell large granular lymphocyte leukemia
572224|NCT00424242|atypical chronic myeloid leukemia, BCR-ABL negative
572225|NCT00424242|stage IV chronic lymphocytic leukemia
572226|NCT00424242|refractory chronic lymphocytic leukemia
572227|NCT00424242|chronic myelomonocytic leukemia
572228|NCT00424242|refractory hairy cell leukemia
572229|NCT00424242|prolymphocytic leukemia
572230|NCT00424242|stage IV mycosis fungoides/Sezary syndrome
572231|NCT00424242|recurrent mycosis fungoides/Sezary syndrome
572232|NCT00424242|stage IV cutaneous T-cell non-Hodgkin lymphoma
572233|NCT00424242|recurrent cutaneous T-cell non-Hodgkin lymphoma
572234|NCT00424242|adult grade III lymphomatoid granulomatosis
572235|NCT00424242|intraocular lymphoma
572236|NCT00424242|post-transplant lymphoproliferative disorder
572237|NCT00424242|refractory multiple myeloma
572238|NCT00424242|stage IV adult Hodgkin lymphoma
572239|NCT00424242|recurrent adult Hodgkin lymphoma
572240|NCT00424242|anaplastic large cell lymphoma
572241|NCT00424242|angioimmunoblastic T-cell lymphoma
572242|NCT00424242|Waldenstrom macroglobulinemia
572243|NCT00424242|stage IV adult Burkitt lymphoma
572244|NCT00424242|recurrent adult Burkitt lymphoma
572245|NCT00424242|stage IV adult diffuse large cell lymphoma
572246|NCT00424242|stage IV adult diffuse mixed cell lymphoma
572247|NCT00424242|stage IV adult diffuse small cleaved cell lymphoma
572248|NCT00424242|stage IV adult immunoblastic large cell lymphoma
572249|NCT00424242|stage IV adult lymphoblastic lymphoma
572250|NCT00424242|stage IV grade 1 follicular lymphoma
572251|NCT00424242|stage IV grade 2 follicular lymphoma
572252|NCT00424242|stage IV grade 3 follicular lymphoma
572253|NCT00424242|stage IV mantle cell lymphoma
572254|NCT00424242|stage IV marginal zone lymphoma
572255|NCT00424242|recurrent adult diffuse large cell lymphoma
572256|NCT00424242|recurrent adult diffuse mixed cell lymphoma
572257|NCT00424242|recurrent adult diffuse small cleaved cell lymphoma
572258|NCT00424242|recurrent adult immunoblastic large cell lymphoma
572259|NCT00424242|recurrent adult lymphoblastic lymphoma
572260|NCT00424242|recurrent grade 1 follicular lymphoma
572261|NCT00424242|recurrent grade 2 follicular lymphoma
572262|NCT00424242|recurrent grade 3 follicular lymphoma
572263|NCT00424242|recurrent mantle cell lymphoma
572264|NCT00424242|recurrent marginal zone lymphoma
572265|NCT00424242|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
572266|NCT00424242|nodal marginal zone B-cell lymphoma
572267|NCT00424242|splenic marginal zone lymphoma
572268|NCT00424242|stage IV small lymphocytic lymphoma
572269|NCT00424242|recurrent small lymphocytic lymphoma
572270|NCT00424242|adult nasal type extranodal NK/T-cell lymphoma
572271|NCT00424242|accelerated phase chronic myelogenous leukemia
572272|NCT00424242|blastic phase chronic myelogenous leukemia
572273|NCT00424242|chronic phase chronic myelogenous leukemia
572274|NCT00424242|de novo myelodysplastic syndromes
572275|NCT00424242|secondary myelodysplastic syndromes
572276|NCT00424242|secondary myelofibrosis
572277|NCT00424242|AIDS-related peripheral/systemic lymphoma
572278|NCT00424242|AIDS-related primary CNS lymphoma
572279|NCT00424242|recurrent adult grade III lymphomatoid granulomatosis
572280|NCT00424242|stage III multiple myeloma
572281|NCT00424242|primary systemic amyloidosis
572282|NCT00424242|extramedullary plasmacytoma
572283|NCT00424242|monoclonal gammopathy of undetermined significance
572284|NCT00424242|isolated plasmacytoma of bone
572285|NCT00424229|MDS INT-2MDS HIGH RISKDELETION 5q[31]Lenalidomide
572286|NCT00424216|Mood
572287|NCT00424216|Emotion
572288|NCT00424216|Judgment
572289|NCT00424216|Cortex
572290|NCT00424216|Brain Stimulation
572291|NCT00424216|Healthy Volunteer
572292|NCT00424216|HV
572293|NCT00424203|cognitive/functional effects
572294|NCT00424203|depression
572295|NCT00424203|malnutrition
572296|NCT00424203|psychosocial effects of cancer and its treatment
572297|NCT00424203|stage IA breast cancer
572298|NCT00424203|stage IB breast cancer
572299|NCT00424203|stage II breast cancer
572300|NCT00424203|stage IIIA breast cancer
572301|NCT00424203|stage IIIB breast cancer
572302|NCT00424203|stage IIIC breast cancer
572303|NCT00424203|estrogen receptor-negative breast cancer
572304|NCT00424203|progesterone receptor-negative breast cancer
572305|NCT00424190|Abscess
572306|NCT00424190|Antibacterial
572307|NCT00424190|Antibiotic
572308|NCT00424190|Antimicrobial
572309|NCT00424190|Bacterial infection, skin
572310|NCT00424190|Ceftaroline
572311|NCT00424190|Ceftaroline acetate
572312|NCT00424190|Cellulitis
572313|NCT00424190|Cephalosporin
572314|NCT00424190|Complicated skin and skin structure infection
572315|NCT00424190|cSSSI
572316|NCT00424190|Intravenous
572317|NCT00424190|MRSA
572318|NCT00424190|PPI-0903
572319|NCT00424190|Prodrug
572320|NCT00424190|Skin disease, bacterial
572321|NCT00424190|Skin infection
572322|NCT00424190|Staphylococcal skin infection
572323|NCT00424190|Staphylococcus aureus
572324|NCT00424190|Streptococcal skin infection
572325|NCT00424190|Surgical site infection
572326|NCT00424190|TAK-599
572327|NCT00424177|idiopathic thrombocytopenic purpura
572328|NCT00424177|ITP
572329|NCT00424177|thrombocytopenia
572330|NCT00424177|platelets
572331|NCT00424164|male breast cancer
572332|NCT00424164|stage IIIB breast cancer
572333|NCT00424164|stage IIIC breast cancer
572334|NCT00424164|stage IV breast cancer
572335|NCT00424164|recurrent breast cancer
572336|NCT00424151|Graves' Disease
572337|NCT00424151|Dysthyroid Ophthalmopathy
572338|NCT00424151|Thyroid related orbitopathy
572339|NCT00424138|stage IIIB non-small cell lung cancer
572340|NCT00424138|stage IV non-small cell lung cancer
572341|NCT00424138|recurrent non-small cell lung cancer
572342|NCT00424138|stage IIIA non-small cell lung cancer
572343|NCT00424125|Asthma
572344|NCT00424125|Compliance
572345|NCT00424125|Randomized clinical trial
572346|NCT00424112|motivation to change
572347|NCT00424112|treatment motivation
572348|NCT00424112|alcohol use disorders
572349|NCT00424099|Advanced Cancer
572350|NCT00424099|Fatigue
572351|NCT00424099|Nursing Telephone Intervention
572352|NCT00424099|NTI
572353|NCT00424099|Methylphenidate
572354|NCT00424099|Placebo
572355|NCT00424099|Ritalin
572356|NCT00424060|adult glioblastoma
572357|NCT00424060|recurrent adult brain tumor
572358|NCT00424060|adult giant cell glioblastoma
572359|NCT00424060|adult gliosarcoma
572360|NCT00424047|Multiple Myeloma
572361|NCT00424047|Celgene
572362|NCT00424047|Revlimid
572363|NCT00424047|CC-5013
572364|NCT00424034|safety
572365|NCT00424034|Pharmacokinetics
572366|NCT00424034|effect of food on pharmacokinetics
572367|NCT00424008|Glucocorticosteroids
572368|NCT00424008|Dry Powder Inhaler
572369|NCT00424008|Bronchodilator
572370|NCT00424008|Metered-Dose Inhaler
572371|NCT00423969|Depression
572372|NCT00423969|Cognitive Impairment
572373|NCT00423956|Teeth root resorption, ultrasound, therapy
572374|NCT00423943|cognition
572375|NCT00423943|memory
572582|NCT00423605|FMS
572376|NCT00423930|stage II squamous cell carcinoma of the hypopharynx
572377|NCT00423930|stage III squamous cell carcinoma of the hypopharynx
572378|NCT00423930|stage IV squamous cell carcinoma of the hypopharynx
572379|NCT00423930|stage III squamous cell carcinoma of the larynx
572380|NCT00423930|stage IV squamous cell carcinoma of the larynx
572381|NCT00423930|stage III squamous cell carcinoma of the lip and oral cavity
572382|NCT00423930|stage IV squamous cell carcinoma of the lip and oral cavity
572383|NCT00423930|stage III squamous cell carcinoma of the oropharynx
572384|NCT00423930|stage IV squamous cell carcinoma of the oropharynx
572385|NCT00423930|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
572386|NCT00423930|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
572387|NCT00423930|tongue cancer
572388|NCT00423917|stage IV breast cancer
572389|NCT00423917|male breast cancer
572390|NCT00423917|recurrent breast cancer
572391|NCT00423904|Early intervention
572392|NCT00423904|Brief intervention
572393|NCT00423904|alcohol
572394|NCT00423904|general hospital
572395|NCT00423865|unspecified adult solid tumor, protocol specific
572396|NCT00423865|CISPLATIN
572397|NCT00423865|RAD001 (EVEROLIMUS)
572398|NCT00423865|06-129
572399|NCT00423852|recurrent ovarian germ cell tumor
572400|NCT00423852|stage III ovarian germ cell tumor
572401|NCT00423852|stage IV ovarian germ cell tumor
572402|NCT00423852|recurrent malignant testicular germ cell tumor
572403|NCT00423852|adult central nervous system germ cell tumor
572404|NCT00423852|stage III malignant testicular germ cell tumor
572405|NCT00423852|stage II malignant testicular germ cell tumor
572406|NCT00423852|recurrent extragonadal non-seminomatous germ cell tumor
572407|NCT00423852|recurrent extragonadal seminoma
572408|NCT00423852|stage III extragonadal non-seminomatous germ cell tumor
572409|NCT00423852|stage III extragonadal seminoma
572410|NCT00423852|stage IV extragonadal non-seminomatous germ cell tumor
572411|NCT00423852|stage IV extragonadal seminoma
572412|NCT00423852|recurrent extragonadal germ cell tumor
572413|NCT00423852|adult teratoma
572414|NCT00423852|testicular immature teratoma
572415|NCT00423852|testicular mature teratoma
572416|NCT00423839|Mycobacterium tuberculosis
572417|NCT00423839|Antigen 85A
572418|NCT00423839|Modified Vaccinia Virus Ankara (MVA).
572419|NCT00423826|accelerated phase chronic myelogenous leukemia
572420|NCT00423826|blastic phase chronic myelogenous leukemia
572421|NCT00423826|childhood chronic myelogenous leukemia
572422|NCT00423826|relapsing chronic myelogenous leukemia
572423|NCT00423826|adult acute lymphoblastic leukemia in remission
572424|NCT00423826|recurrent adult acute lymphoblastic leukemia
572425|NCT00423826|childhood acute lymphoblastic leukemia in remission
572426|NCT00423826|recurrent childhood acute lymphoblastic leukemia
572427|NCT00423826|adult acute myeloid leukemia in remission
572428|NCT00423826|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
572429|NCT00423826|adult acute myeloid leukemia with inv(16)(p13;q22)
572430|NCT00423826|adult acute myeloid leukemia with t(15;17)(q22;q12)
572431|NCT00423826|adult acute myeloid leukemia with t(16;16)(p13;q22)
572432|NCT00423826|adult acute myeloid leukemia with t(8;21)(q22;q22)
572433|NCT00423826|recurrent adult acute myeloid leukemia
572434|NCT00423826|adult acute minimally differentiated myeloid leukemia (M0)
572435|NCT00423826|adult acute myeloblastic leukemia without maturation (M1)
572436|NCT00423826|adult acute myeloblastic leukemia with maturation (M2)
572437|NCT00423826|adult acute promyelocytic leukemia (M3)
572438|NCT00423826|adult acute myelomonocytic leukemia (M4)
572439|NCT00423826|adult acute monoblastic leukemia (M5a)
572440|NCT00423826|adult acute monocytic leukemia (M5b)
572441|NCT00423826|adult erythroleukemia (M6a)
572442|NCT00423826|adult pure erythroid leukemia (M6b)
572443|NCT00423826|adult acute megakaryoblastic leukemia (M7)
572444|NCT00423826|childhood acute myeloblastic leukemia without maturation (M1)
572445|NCT00423826|childhood acute myeloblastic leukemia with maturation (M2)
572446|NCT00423826|childhood acute promyelocytic leukemia (M3)
572447|NCT00423826|childhood acute myelomonocytic leukemia (M4)
572448|NCT00423826|childhood acute monoblastic leukemia (M5a)
572449|NCT00423826|childhood acute monocytic leukemia (M5b)
572450|NCT00423826|childhood acute erythroleukemia (M6)
572451|NCT00423826|childhood acute megakaryocytic leukemia (M7)
572452|NCT00423826|childhood acute myeloid leukemia in remission
572453|NCT00423826|secondary myelodysplastic syndromes
572454|NCT00423826|recurrent childhood acute myeloid leukemia
572455|NCT00423826|refractory chronic lymphocytic leukemia
572456|NCT00423826|recurrent adult Hodgkin lymphoma
572457|NCT00423826|recurrent/refractory childhood Hodgkin lymphoma
572458|NCT00423826|adult grade III lymphomatoid granulomatosis
572459|NCT00423826|adult nasal type extranodal NK/T-cell lymphoma
572460|NCT00423826|Waldenstrom macroglobulinemia
572461|NCT00423826|recurrent adult Burkitt lymphoma
572462|NCT00423826|recurrent adult diffuse large cell lymphoma
572463|NCT00423826|recurrent adult diffuse mixed cell lymphoma
572464|NCT00423826|recurrent adult diffuse small cleaved cell lymphoma
572465|NCT00423826|recurrent adult immunoblastic large cell lymphoma
572466|NCT00423826|recurrent grade 1 follicular lymphoma
572467|NCT00423826|recurrent grade 2 follicular lymphoma
572468|NCT00423826|recurrent grade 3 follicular lymphoma
572469|NCT00423826|recurrent mantle cell lymphoma
572470|NCT00423826|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
572471|NCT00423826|nodal marginal zone B-cell lymphoma
572472|NCT00423826|recurrent marginal zone lymphoma
572473|NCT00423826|secondary acute myeloid leukemia
572474|NCT00423826|stage I multiple myeloma
572475|NCT00423826|stage II multiple myeloma
572476|NCT00423826|stage III multiple myeloma
572477|NCT00423826|extramedullary plasmacytoma
572478|NCT00423826|isolated plasmacytoma of bone
572479|NCT00423826|monoclonal gammopathy of undetermined significance
572480|NCT00423826|primary systemic amyloidosis
572481|NCT00423826|refractory multiple myeloma
572482|NCT00423826|de novo myelodysplastic syndromes
572483|NCT00423826|childhood acute minimally differentiated myeloid leukemia (M0)
572484|NCT00423826|childhood grade III lymphomatoid granulomatosis
572485|NCT00423826|childhood nasal type extranodal NK/T-cell lymphoma
572486|NCT00423826|recurrent adult grade III lymphomatoid granulomatosis
572487|NCT00423826|recurrent childhood large cell lymphoma
572488|NCT00423826|recurrent childhood lymphoblastic lymphoma
572489|NCT00423826|childhood diffuse large cell lymphoma
572490|NCT00423826|childhood immunoblastic large cell lymphoma
572491|NCT00423826|Burkitt lymphoma
572492|NCT00423826|recurrent childhood small noncleaved cell lymphoma
572493|NCT00423826|previously treated myelodysplastic syndromes
572494|NCT00423826|splenic marginal zone lymphoma
572495|NCT00423826|recurrent childhood grade III lymphomatoid granulomatosis
572496|NCT00423826|recurrent adult lymphoblastic lymphoma
572497|NCT00423826|recurrent small lymphocytic lymphoma
572498|NCT00423826|secondary myelofibrosis
572499|NCT00423813|FMS
572500|NCT00423813|Fibro
572501|NCT00423813|pain
572502|NCT00423813|Body pain
572503|NCT00423813|tenderness
572504|NCT00423813|stiffness
572505|NCT00423813|muscular pain
572506|NCT00423813|joint pain
572507|NCT00423787|Allergy
572508|NCT00423787|Allergoid
572509|NCT00423787|Specific Immunotherapy
572510|NCT00423774|Allogeneic Hematopoietic Stem Cell Transplant
572511|NCT00423774|Psychological Distress
572512|NCT00423774|Coping
572513|NCT00423774|Cognitive Behavior Therapy
572514|NCT00423774|Bone Marrow Transplant
572515|NCT00423774|Coping Skills
572516|NCT00423761|Pharmacokinetics,
572517|NCT00423761|tolerability,
572518|NCT00423761|healthy,
572519|NCT00423761|subjects
572520|NCT00423722|Advanced Cancer
572521|NCT00423722|Hospice Care
572522|NCT00423722|Caregiver
572523|NCT00423722|Saline
572524|NCT00423722|Hydration
572525|NCT00423722|Dehydration
572526|NCT00423709|Hodgkin's Disease
572527|NCT00423709|Allogeneic Blood Stem Cell Transplantation
572528|NCT00423709|Bone Marrow Transplantation
572529|NCT00423709|Fludarabine
572530|NCT00423709|Melphalan
572531|NCT00423696|stage IV colon cancer
572532|NCT00423696|stage IV rectal cancer
572533|NCT00423696|recurrent colon cancer
572534|NCT00423696|recurrent rectal cancer
572535|NCT00423683|Cancer
572536|NCT00423683|thromboembolism
572537|NCT00423657|Abscess
572538|NCT00423657|Antibacterial
572539|NCT00423657|Antibiotic
572540|NCT00423657|Antimicrobial
572541|NCT00423657|Bacterial infection, skin
572542|NCT00423657|Ceftaroline
572543|NCT00423657|Ceftaroline acetate
572544|NCT00423657|Cellulitis
572545|NCT00423657|Cephalosporin
572546|NCT00423657|Complicated skin and skin structure infection
572547|NCT00423657|cSSSI
572548|NCT00423657|Intravenous
572549|NCT00423657|MRSA
572550|NCT00423657|PPI-0903
572551|NCT00423657|Prodrug
572552|NCT00423657|Skin disease, bacterial
572553|NCT00423657|Skin infection
572554|NCT00423657|Staphylococcal skin infection
572555|NCT00423657|Staphylococcus aureus
572556|NCT00423657|Streptococcal skin infection
572557|NCT00423657|Surgical site infection
572558|NCT00423657|TAK-599
572559|NCT00423644|Multiple Myeloma
572560|NCT00423644|arsenic
572561|NCT00423644|cancer study
572562|NCT00423644|failed treatment
572563|NCT00423631|Pain
572564|NCT00423631|Fibromyalgia
572565|NCT00423631|Internet
572566|NCT00423618|recurrent adult soft tissue sarcoma
572567|NCT00423618|stage I adult soft tissue sarcoma
572568|NCT00423618|stage II adult soft tissue sarcoma
572569|NCT00423618|stage III adult soft tissue sarcoma
572570|NCT00423618|adult synovial sarcoma
572571|NCT00423618|adult angiosarcoma
572572|NCT00423618|adult epithelioid sarcoma
572573|NCT00423618|adult extraskeletal chondrosarcoma
572574|NCT00423618|adult leiomyosarcoma
572575|NCT00423618|adult liposarcoma
572576|NCT00423618|adult malignant fibrous histiocytoma
572577|NCT00423618|adult malignant hemangiopericytoma
572578|NCT00423618|adult malignant mesenchymoma
572579|NCT00423618|adult fibrosarcoma
572580|NCT00423618|adult neurofibrosarcoma
572581|NCT00423618|adult alveolar soft-part sarcoma
572583|NCT00423605|Fibro
572584|NCT00423605|Pain
572585|NCT00423605|Body Pain
572586|NCT00423605|Tenderness
572587|NCT00423605|Joint pain
572588|NCT00423605|Stiffness
572589|NCT00423605|Muscular Pain
572590|NCT00423566|Mycobacterium tuberculosis
572591|NCT00423566|85A antigen
572592|NCT00423566|Recombinant Modified Vaccinia virus Ankara
572593|NCT00423566|Phase I study
572594|NCT00423566|Immunogenicity
572595|NCT00423553|Nitrite and Cytoprotection
572596|NCT00423553|Ischemic Preconditioning
572597|NCT00423553|Atrial Trabeculae Contractile Function
572598|NCT00423553|Ischemia
572599|NCT00423540|magnesium infusion
572600|NCT00423540|magnesium sulfate
572601|NCT00423540|rest cramps
572602|NCT00423540|nocturnal leg cramps
572603|NCT00423540|muscle cramps
572604|NCT00423540|fractional urinary excretion
572605|NCT00423540|urinary excretion
572606|NCT00423540|24 hour urine
572607|NCT00423540|serum magnesium
572608|NCT00423540|magnesium deficiency
572609|NCT00423540|family practice
572610|NCT00423540|general practice
572611|NCT00423540|richmond
572612|NCT00423540|cramp frequency
572613|NCT00423540|magnesium status
572614|NCT00423540|urinary magnesium
572615|NCT00423540|cramp diary
572616|NCT00423540|sf 36
572617|NCT00423527|multiple sclerosis
572618|NCT00423527|central pain
572619|NCT00423527|levetiracetam
572620|NCT00423514|graft versus host disease
572621|NCT00423514|adult acute lymphoblastic leukemia in remission
572622|NCT00423514|adult acute myeloid leukemia in remission
572623|NCT00423514|childhood acute lymphoblastic leukemia in remission
572624|NCT00423514|childhood chronic myelogenous leukemia
572625|NCT00423514|recurrent childhood acute myeloid leukemia
572626|NCT00423514|accelerated phase chronic myelogenous leukemia
572627|NCT00423514|acute undifferentiated leukemia
572628|NCT00423514|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
572629|NCT00423514|blastic phase chronic myelogenous leukemia
572630|NCT00423514|juvenile myelomonocytic leukemia
572631|NCT00423514|previously treated myelodysplastic syndromes
572632|NCT00423514|recurrent adult acute lymphoblastic leukemia
572633|NCT00423514|recurrent adult acute myeloid leukemia
572634|NCT00423514|relapsing chronic myelogenous leukemia
572635|NCT00423514|secondary acute myeloid leukemia
572636|NCT00423514|secondary myelodysplastic syndromes
572637|NCT00423514|childhood acute myeloid leukemia in remission
572638|NCT00423514|de novo myelodysplastic syndromes
572639|NCT00423514|recurrent childhood acute lymphoblastic leukemia
572640|NCT00423514|chronic phase chronic myelogenous leukemia
572641|NCT00423514|adult acute myeloid leukemia with inv(16)(p13;q22)
572642|NCT00423514|adult acute myeloid leukemia with t(15;17)(q22;q12)
572643|NCT00423514|adult acute myeloid leukemia with t(16;16)(p13;q22)
572644|NCT00423514|adult acute myeloid leukemia with t(8;21)(q22;q22)
572645|NCT00423514|childhood myelodysplastic syndromes
572646|NCT00423475|adenocarcinoma of the prostate
572647|NCT00423475|stage IIB prostate cancer
572648|NCT00423475|stage IIA prostate cancer
572649|NCT00423475|stage III prostate cancer
572650|NCT00423475|recurrent prostate cancer
572651|NCT00423475|stage IV prostate cancer
572652|NCT00423462|Psychotherapy
572653|NCT00423462|Long-term effects
572654|NCT00423449|Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
572655|NCT00423436|Non-Small Cell Lung Cancer
572656|NCT00423436|Small Cell Lung Cancer
572657|NCT00423436|Voice Response System
572658|NCT00423436|Questionnaire
572659|NCT00423436|Survey
572660|NCT00423436|NSCLC
572661|NCT00423410|Cancer
572662|NCT00423410|Tumor
572663|NCT00423410|Lymphoma
572664|NCT00423397|squamous cell carcinoma of the skin
572665|NCT00423397|recurrent skin cancer
572666|NCT00423384|Ibandronate
572667|NCT00423384|Placebo
572668|NCT00423384|Doubleblind
572669|NCT00423384|Bone
572670|NCT00423384|loss
572671|NCT00423384|Kidney
572672|NCT00423384|transplant
572673|NCT00423371|first Carpometacarpal (CMC) Joint
572674|NCT00423358|rheumatoid arthritis
572675|NCT00423358|hypovitaminosis D
572676|NCT00423358|bone turnover
572677|NCT00423358|ergocalciferol
572678|NCT00423332|cancer
572679|NCT00423332|tumour
572680|NCT00423332|advanced cancer
572681|NCT00423332|Metastatic renal cell carcinoma
572682|NCT00423332|kidney cancer
572683|NCT00423332|RECENTIN
572684|NCT00423319|Prevention of deep vein thrombosis and
572685|NCT00423319|pulmonary embolism after total hip replacement surgery
572686|NCT00423293|stage II anal cancer
572687|NCT00423293|stage IIIA anal cancer
572688|NCT00423293|stage IIIB anal cancer
572689|NCT00423293|basaloid carcinoma of the anus
572690|NCT00423293|cloacogenic carcinoma of the anus
572691|NCT00423293|squamous cell carcinoma of the anus
572692|NCT00423280|Endothelium
572693|NCT00423280|Nitric Oxide
572694|NCT00423280|Magnetic Resonance Imaging
572695|NCT00423280|Tetrahydrobiopterin
572696|NCT00423254|Cancer Vaccine
572697|NCT00423228|Alzheimer's disease
572698|NCT00423228|cognitive impairment
572699|NCT00423228|cholinesterase inhibitors
572700|NCT00423228|sustained-release implants
572701|NCT00423228|long acting treatment
572702|NCT00423189|LUV
572703|NCT00423189|Lucentis
572704|NCT00423189|Visudyne
572705|NCT00423189|PDT
572706|NCT00423189|AMD
572707|NCT00423189|ARMD
572708|NCT00423189|Age
572709|NCT00423189|Related
572710|NCT00423189|Macular
572711|NCT00423189|Degeneration
572712|NCT00423163|Aspergillosis/blood
572713|NCT00423163|micafungin
572714|NCT00423163|voriconazole
572715|NCT00423163|Aspergillus
572716|NCT00423124|Hematological malignancies
572717|NCT00423124|HSV-TK
572718|NCT00423124|Haploidentical HCT
572719|NCT00423124|GvHD
572720|NCT00423124|GvL
572721|NCT00423111|Multiple sclerosis
572722|NCT00423111|Memory
572723|NCT00423111|Cognitive deficits
572724|NCT00423111|MRI
572725|NCT00423111|Hippocampus
572726|NCT00423111|Prefrontal cortex
572727|NCT00423098|Lupus Nephritis
572728|NCT00423098|enteric-coated mycophenolate sodium
572729|NCT00423098|EC-MPS
572730|NCT00423098|Myfortic
572731|NCT00423085|rivastigmine，Alzheimer's Disease, transdermal patch
572732|NCT00423072|cleft palate
572733|NCT00423072|palatoplasty
572734|NCT00423072|otitis
572735|NCT00423072|middle ear
572736|NCT00423072|Eustachian tube
572737|NCT00423059|intravitreal bevacizumab
572738|NCT00423059|proliferative diabetic retinopathy
572739|NCT00423059|VEGF
572740|NCT00423059|PEDF
572741|NCT00423046|Vaccines
572742|NCT00423046|Cervical cancer
572743|NCT00423046|Immunogenicity
572744|NCT00423046|Humans
572745|NCT00423046|Safety
572746|NCT00423046|Viral infections
572747|NCT00423046|Human papillomavirus (HPV)
572748|NCT00423046|Comparative study
572749|NCT00423046|Human papillomavirus vaccine
572750|NCT00423046|Adults
572751|NCT00423020|Acute myocardial infarction
572752|NCT00423020|Restenosis
572753|NCT00423020|erythropoietin
572754|NCT00423020|EPOC-AMI
572755|NCT00422994|end stage renal impairment
572756|NCT00422994|tolerability
572757|NCT00422994|ropinirole
572758|NCT00422994|pharmacokinetics
572759|NCT00422994|hemodialysis
572760|NCT00422981|Dementia
572761|NCT00422981|Memory
572762|NCT00422981|Alzheimers
572763|NCT00422981|Cognition
572764|NCT00422981|Mind
572765|NCT00422981|Aging
572766|NCT00422968|Coronary artery disease
572767|NCT00422968|Stent
572768|NCT00422968|Bypass surgery, coronary artery
572769|NCT00422955|fluid retention
572770|NCT00422955|Autonomic Neuropathy
572771|NCT00422929|otitis media
572772|NCT00422929|ear
572773|NCT00422929|acute otitis
572774|NCT00422929|middle ear
572775|NCT00422929|Eustachian tube
572776|NCT00422929|recurrent acute otitis media
572777|NCT00422929|chronic otitis media with effusion
572778|NCT00422929|no significant history of otitis media
572779|NCT00422903|neo-adjuvant
572780|NCT00422903|letrozole
572781|NCT00422903|lapatinib
572782|NCT00422903|primary breast cancer
572783|NCT00422890|Acute myeloid leukaemia or Myelodysplastic syndrome
572784|NCT00422877|Liver Cancer
572785|NCT00422851|otitis
572786|NCT00422851|gas diffusion
572787|NCT00422851|Eustachian tube
572788|NCT00422851|tympanic membrane
572789|NCT00422838|Hepatitis C
572790|NCT00422838|Liver
572791|NCT00422838|immunology
572792|NCT00422838|regulation
572793|NCT00422838|Genotype 1,2,3
572794|NCT00422838|Treatment
572795|NCT00422838|Chronic
572796|NCT00422838|Pegylated interferon
572797|NCT00422838|Ribavirin
572798|NCT00422825|Food effect
572799|NCT00422825|bioavailability
572800|NCT00422825|pharmacokinetic
572801|NCT00422825|imatinib
572802|NCT00422825|STI571
572803|NCT00422825|modified release formulation of STI571
572804|NCT00422825|CML
572805|NCT00422825|Chronic Myeloid Leukemia
572806|NCT00422825|Philadelphia Chromosome
572807|NCT00422812|Migraine, Staccato Prochlorperazine
572808|NCT00422812|Migraine headache with or without aura.
572809|NCT00422799|relapsed Waldenstrom's macroglobulinemia
572810|NCT00422799|refractory Waldenstrom's macroglobulinemia
572811|NCT00422799|Velcade
572812|NCT00422799|WM
572813|NCT00422786|Refractory Clear Cell Renal Cell Carcinoma
572814|NCT00422786|Phase II
572815|NCT00422786|Thallion
572816|NCT00422786|TLN-232
572817|NCT00422786|CAP-232
572818|NCT00422786|M2PK
572819|NCT00422773|phase I/II
572820|NCT00422773|cetuximab
572821|NCT00422773|oxaliplatin
572822|NCT00422773|irinotecan
572823|NCT00422773|5-FU
572824|NCT00422773|chemotherapy
572825|NCT00422773|dose escalation
572826|NCT00422773|safety
572827|NCT00422760|esophageal perforation
572828|NCT00422760|COPD
572829|NCT00422747|asthma
572830|NCT00422747|transient wheezing
572831|NCT00422747|early diagnosis
572832|NCT00422747|exhaled air
572833|NCT00422747|nitrogen monoxide
572834|NCT00422747|airway resistance
572835|NCT00422721|early severe retinal dystrophy
572836|NCT00422721|amaurosis of leber
572837|NCT00422695|HIV
572838|NCT00422695|Quantitative Sensory Testing
572839|NCT00422695|Neuropathy
572840|NCT00422695|Treatment Experienced
572841|NCT00422695|Treatment Naive
572842|NCT00422682|Solid tumors
572843|NCT00422669|Pacemaker
572844|NCT00422669|Implantable Pulse Generator (IPG)
572845|NCT00422669|AV Conduction Disturbance
572846|NCT00422669|Select Site Pacing
572847|NCT00422656|relapsed Waldenstrom's Macroglobulinemia
572848|NCT00422656|refractory Waldenstrom's Macroglobulinemia
572849|NCT00422656|WM
572850|NCT00422656|perifosine
572851|NCT00422643|OA,HA,Intra-articular
572852|NCT00422630|Weight loss
572853|NCT00422630|Obesity
572854|NCT00422630|Metabolic Syndrome
572855|NCT00422630|Diet
572856|NCT00422630|Hypertension
572857|NCT00422630|Diabetes
572858|NCT00422630|Cholesterol
572859|NCT00422617|psoriasis
572860|NCT00422617|alefacept
572861|NCT00422604|COPD
572862|NCT00422604|plethysmography.
572863|NCT00422604|muscarinic receptor antagonist
572864|NCT00422604|anticholinergic
572865|NCT00422591|Cytarabine, Idarubicin
572866|NCT00422591|Leukemia
572867|NCT00422591|Acute Myeloid Leukemia
572868|NCT00422591|AML
572869|NCT00422591|Cytarabine
572870|NCT00422591|Idarubicin
572871|NCT00422578|erectile dysfunction
572872|NCT00422578|tadalafil
572873|NCT00422565|Coronary Artery Disease
572874|NCT00422565|Stent
572875|NCT00422565|Myocardial Infarction
572876|NCT00422552|inspiratory capacity, FEV1, COPD
572877|NCT00422539|trichloroacetic acid
572878|NCT00422539|varicella scar
572879|NCT00422526|Preterm delivery, short cervix, progesterone
572880|NCT00422500|Lung Cancer
572881|NCT00422500|Advanced Lung Cancer
572882|NCT00422500|Chemotherapy Symptoms
572883|NCT00422500|Disease-Related Symptoms
572884|NCT00422500|Treatment-Related Symptoms
572885|NCT00422500|Symptom Management
572886|NCT00422500|Questionnaire
572887|NCT00422500|Telephone Interactive System
572888|NCT00422500|IVR Telephone System
572889|NCT00422500|DNA Repair Capacity
572890|NCT00422500|DRC
572891|NCT00422500|Cognitive Symptoms
572892|NCT00422487|Type 2 Diabetes Mellitus
572893|NCT00422474|Ischemic stroke
572894|NCT00422474|Baroreflex sensitivity
572895|NCT00422474|Prognosis
572896|NCT00422474|Cardiovascular autonomic regulation
572897|NCT00422461|Clinical Trial, Randomized Controlled Trial, Humans, Cyclic Nucleotide Phosphodiesterases Type 5
572898|NCT00422448|Dermoscopy
572899|NCT00422448|Histopathology
572900|NCT00422448|Genetics
572901|NCT00422448|Nevi
572902|NCT00422448|Nevogenesis
572903|NCT00422435|Percutaneous coronary intervention (PCI)
572904|NCT00422435|Drug eluting stent (DES)
572905|NCT00422422|Brivaracetam
572906|NCT00422422|Epilepsy
572907|NCT00422422|Child
572908|NCT00422422|Pharmacokinetics
572909|NCT00422422|Adolescents
572910|NCT00422409|SEMS
572911|NCT00422396|Hypertrigliceridemia
572912|NCT00422396|Metabolic syndrome
572913|NCT00422396|Obesity
572914|NCT00422396|Fenofibrate
572915|NCT00422396|Lipoproteins
572916|NCT00422396|Cytokines
572917|NCT00422357|Type 2 Diabetes Mellitus
572918|NCT00422357|Urtica Dioica (or stinging nettle)
572919|NCT00422357|Hypoglycemic agents
572920|NCT00422344|RAD001
572921|NCT00422344|Sunitinib
572922|NCT00422344|renal
572923|NCT00422344|kidney
572924|NCT00422331|Bipolar I Disorder
572925|NCT00422331|Bipolar Disorder
572926|NCT00422331|Lithium
572927|NCT00422318|Heart Failure
572928|NCT00422318|Insulin
572929|NCT00422318|Metabolism
572930|NCT00422318|Pharmacology
572931|NCT00422318|Uric Acid
572932|NCT00422305|Infant, Premature
572933|NCT00422305|Bronchopulmonary dysplasia
572934|NCT00422305|asthma
572935|NCT00422292|Menactra vaccine
572936|NCT00422292|Meningococcal meningitis
572937|NCT00422292|Measles
572938|NCT00422292|Mumps
572939|NCT00422292|Rubella
572940|NCT00422292|Varicella vaccines
572941|NCT00422292|Haemophilus influenzae type b
572942|NCT00422292|Pneumococcal conjugate vaccine
572943|NCT00422279|Bone Inductive Implant
572944|NCT00422266|Dyslipidemia
572945|NCT00422253|insulin resistance
572946|NCT00422253|insulin secretion
572947|NCT00422253|advanced glycation end-products
572948|NCT00422240|Acne vulgaris
572949|NCT00422240|Adapalene
572950|NCT00422240|Benzoyl Peroxide
572951|NCT00422214|Bipolar Disorder
572952|NCT00422214|Bipolar Depression,
572953|NCT00422214|Manic Depression
572954|NCT00422214|Seroquel
572955|NCT00422214|Seroquel SR
572956|NCT00422214|quetiapine fumarate
572957|NCT00422201|Cortisol
572958|NCT00422201|Cushing's Syndrome
572959|NCT00422201|Ectopic ACTH Secretion
572960|NCT00422201|Cushing Syndrome
572961|NCT00422175|Safety, tolerability, pharmacokinetics, pharmacodynamics, oral, BAF312, healthy volunteers
572962|NCT00422149|Sublingual immunotherapy
572963|NCT00422149|Rhinoconjunctivitis
572964|NCT00422136|middle ear
572965|NCT00422136|otitis
572966|NCT00422136|genetics
572967|NCT00422123|Bipolar Disorder
572968|NCT00422123|Bipolar Mania
572969|NCT00422123|Manic Depression
572970|NCT00422123|Seroquel
572971|NCT00422123|Seroquel SR
572972|NCT00422123|quetiapine fumarate
572973|NCT00422110|Seletracetam
572974|NCT00422110|Epilepsies
572975|NCT00422110|Partial
572976|NCT00422110|Epilepsy
572977|NCT00422110|Focal
572978|NCT00422084|Malaria
572979|NCT00422084|ACT
572980|NCT00422084|P falciparum
572981|NCT00422071|Transcranial Magnetic Stimulation (TMS)
572982|NCT00422071|Dopamine
572983|NCT00422071|Gambling
572984|NCT00422071|Healthy Volunteer
572985|NCT00422071|HV
572986|NCT00422032|Myelodysplastic Syndrome
572987|NCT00422032|Leukemia
572988|NCT00422032|Clofarabine
572989|NCT00422032|MDS
572990|NCT00422019|Renal Cancer
572991|NCT00422019|Kidney Cancer
572992|NCT00422006|bariatric surgery planned
572993|NCT00421993|Acne vulgaris
572994|NCT00421993|Adapalene
572995|NCT00421993|Benzoyl Peroxide
572996|NCT00421967|Postoperative pain
572997|NCT00421954|psychosis NOS
572998|NCT00421954|MDD w/ psychotic features
572999|NCT00421954|bipolar disorder w. psychotic features
573000|NCT00421941|enteral feeding
573001|NCT00421941|critical care
573002|NCT00421941|fish oil
573003|NCT00421941|surgical
573004|NCT00421928|Chronic Pain
573005|NCT00421928|Osteoarthritis, Knee
573006|NCT00421928|tapentadol
573007|NCT00421928|Pain Assessment
573008|NCT00421902|Hot flashes, prostate cancer, acupuncture
573009|NCT00421902|Prostate cancer patients with hot flashes due to their hormonal treatment
573010|NCT00421889|Ovarian cancer
573011|NCT00421889|Ovarian Neoplasms
573012|NCT00421889|Primary peritoneal
573013|NCT00421889|Epithelial ovarian
573014|NCT00421889|Fallopian tube
573015|NCT00421889|Bladder cancer
573016|NCT00421889|belinostat
573017|NCT00421889|PXD101
573018|NCT00421889|mixed mullerian cancer of ovarian origin
573019|NCT00421876|cardiac rehabilitation
573020|NCT00421876|lifestyle management
573021|NCT00421876|risk factor management
573022|NCT00421876|myocardial infarction
573023|NCT00421876|randomized trials
573024|NCT00421863|hypertension
573025|NCT00421863|systolic blood pressure
573026|NCT00421837|influenza, flu, genotypic analysis, sub-study
573027|NCT00421811|cancer
573028|NCT00421811|tumors
573029|NCT00421811|melanoma
573030|NCT00421811|anticarcinogenic agents
573031|NCT00421811|antineoplastic agents
573032|NCT00421811|cadherins
573033|NCT00421811|solid tumors
573034|NCT00421798|tuberculosis, paucibacillary, mycobacteria, Mexico, Colombia
573035|NCT00421785|N-acetylcysteine
573036|NCT00421785|Peritoneal Dialysis
573037|NCT00421785|ADMA
573038|NCT00421772|cerebral ventriculomegaly
573039|NCT00421772|prenatal diagnostic
573040|NCT00421772|neuropsychological outcome
573041|NCT00421759|Sensory loss
573042|NCT00421759|psychomotor function
573043|NCT00421759|balance
573044|NCT00421759|gait
573045|NCT00421733|Type 2 Diabetic Nephropathy
573046|NCT00421720|remifentanil
573047|NCT00421720|sufentanil
573048|NCT00421720|propofol
573049|NCT00421720|analgesia
573050|NCT00421720|sedation
573051|NCT00421720|mechanically ventilated
573052|NCT00421720|intensive care
573053|NCT00421720|pharmacoeconomic
573054|NCT00421720|weaning
573055|NCT00421720|delirium
573056|NCT00421720|randomized
573057|NCT00421720|Germany
573058|NCT00421707|Irritable Bowel Syndrome safety
573059|NCT00421681|Aging
573060|NCT00421681|exercise
573061|NCT00421681|health behavior
573062|NCT00421668|HIV
573063|NCT00421668|Tanzania
573064|NCT00421668|Micronutrients
573065|NCT00421668|Infants/children
573066|NCT00421668|Infectious Disease
573067|NCT00421668|Growth faltering
573068|NCT00421629|health insurance
573069|NCT00421629|hospitalization insurance
573070|NCT00421629|community based health insurance
573071|NCT00421629|health care access
573072|NCT00421629|developing countries
573073|NCT00421629|randomized controlled trials
573074|NCT00421616|Calorimetry
573075|NCT00421616|Overweight
573076|NCT00421616|Weight loss
573077|NCT00421616|Appetite
573078|NCT00421603|Cocaine
573079|NCT00421603|Adderall
573080|NCT00421603|Topiramate
573081|NCT00421603|ADHD
573082|NCT00421590|Randomized, partially blind, placebo controlled, crossover, drug interaction with concomitant antacid, pharmacokinetics, pharmacodynamics, SMC021
573083|NCT00421577|Caries Diagnosis
573084|NCT00421577|Replica technique
573085|NCT00421564|Menopausal
573086|NCT00421564|Traditional Chinese Medicine
573087|NCT00421551|HIV Infections
573088|NCT00421551|darunavir
573089|NCT00421551|Ritonavir
573090|NCT00421551|HIV Protease Inhibitors
573091|NCT00421551|treatment experienced
573092|NCT00421538|Deep vein Thrombosis
573093|NCT00421538|Calf vein thrombosis
573094|NCT00421538|Low-molecular weight heparin
573095|NCT00421538|Placebo
573096|NCT00421538|Elastic contention
573097|NCT00421538|Compression Ultrasonography
573098|NCT00421525|multiple myeloma
573099|NCT00421525|Myeloma, Plasma-Cell
573100|NCT00421525|PLASMACYTOMA
573101|NCT00421512|Renal cell carcinoma
573102|NCT00421512|Metastatic
573103|NCT00421512|Kidney Cancer
573104|NCT00421512|Bevacizumab
573105|NCT00421512|Sunitinib
573106|NCT00421486|Oral human papillomavirus infection
573107|NCT00421486|HIV-infection
573108|NCT00421486|High-risk HPV viral load
573109|NCT00421486|Oral human papillomavirus infection in HIV-positive men
573110|NCT00421486|Treatment Experienced
573111|NCT00421486|Treatment Naive
573112|NCT00421473|HIV
573113|NCT00421473|Malaria prophylaxis
573114|NCT00421473|Treatment Experienced
573115|NCT00421460|Nebido in hypogonadism with erectile dysfunction
573116|NCT00421447|Breast Cancer
573117|NCT00421447|pQCT
573118|NCT00421447|Anastrozole
573119|NCT00421447|bone geometry
573120|NCT00421434|Hepatitis C
573121|NCT00421421|Acute Urinary Retention
573122|NCT00421421|Benign Prostatic Hyperplasia
573123|NCT00421421|Trial Without Catheter
573124|NCT00421408|Dietary protein
573125|NCT00421408|Calcium
573126|NCT00421408|Parathyroid hormone
573127|NCT00421408|Bone markers
573128|NCT00421408|Bone mineral density
573129|NCT00421408|IGF-1
573130|NCT00421408|Urine Calcium
573131|NCT00421395|NHL
573132|NCT00421395|B-cell NHL
573133|NCT00421395|Non-Hodgkins lymphoma
573134|NCT00421369|Major depressive disorder
573135|NCT00421369|Antidepressants
573136|NCT00421369|Triiodothyronine (T3)
573137|NCT00421369|Thyroid Function
573138|NCT00421369|Augmentation
573139|NCT00421369|Thyroid pathway genes
573140|NCT00421356|amputation, transfemoral, lower extremity, prosthetic knee
573141|NCT00421343|disease/disorder proneness/risk
573142|NCT00421343|osteoporotic fractures
573143|NCT00421343|accidental falls
573144|NCT00421343|aging
573145|NCT00421330|Abdominal aortic aneurysm
573146|NCT00421330|AAA
573147|NCT00421330|randomised controlled trial
573148|NCT00421330|Endovascular repair
573149|NCT00421330|conventional open repair
573150|NCT00421317|Ocular, Metastatic melanoma
573151|NCT00421265|prostate cancer
573152|NCT00421265|active surveillance
573153|NCT00421265|indolent features
573154|NCT00421252|clopidogrel
573155|NCT00421252|hemorrhagic complication
573156|NCT00421252|vascular complication
573157|NCT00421252|antiplatelet agent
573158|NCT00421252|stenting
573159|NCT00421252|percutaneous coronary intervention
573160|NCT00421252|risk
573161|NCT00421252|ischemia
573162|NCT00421252|troponin
573163|NCT00421252|sheath size
573164|NCT00421239|hypertensive urgency
573165|NCT00421239|arterial hypertension
573166|NCT00421226|Safety, tolerability, pharmacokinetics, pharmacodynamics, ACZ885, Japanese,
573167|NCT00421213|APL
573168|NCT00421213|Lymphoma
573169|NCT00421213|T-cell Lymphoma
573170|NCT00421213|Peripheral T-cell Lymphoma
573171|NCT00421200|Hip arthroplasty
573172|NCT00421200|Anesthesia, spinal
573173|NCT00421200|Hypotension
573174|NCT00421200|Ischemia
573175|NCT00421200|Blood substitutes
573176|NCT00421200|Plasma expanders
573177|NCT00421187|Antibiotic resistant neutropenic fever
573178|NCT00421187|ARNF
573179|NCT00421187|Ambisome
573180|NCT00421187|Liposomal amphotericin B
573181|NCT00421174|Etanercept
573182|NCT00421174|IPS
573183|NCT00421161|olive oil
573184|NCT00421161|stasis dermatitis
573185|NCT00421161|Patients with stasis dermatitis for at least six months.
573186|NCT00421122|Chinese patients
573187|NCT00421122|COPD
573188|NCT00421109|Urticaria
573189|NCT00421109|Hives
573190|NCT00421109|Wheals
573191|NCT00421109|Flare
573192|NCT00421109|Chronic
573193|NCT00421109|Idiopathic
573194|NCT00421109|Erythema
573195|NCT00421109|Skin diseases, vascular
573196|NCT00421109|Hypersensitivity, Immediate
573197|NCT00421109|Allergic
573198|NCT00421109|Cutaneous
573199|NCT00421096|uterine cervical cancer
573200|NCT00421083|Erectile dysfunction as a result of traumatic spinal cord injury
573201|NCT00421070|Aggression
573202|NCT00421070|Massage
573203|NCT00421070|Stress
573204|NCT00421070|Psychiatric inpatient
573205|NCT00421057|Breast Cancer
573206|NCT00421057|Cancer-Related Fatigue
573207|NCT00421057|Fatigue
573208|NCT00421057|Exercise
573209|NCT00421057|Strength Training
573210|NCT00421057|Endurance Exercise
573211|NCT00421057|Questionnaire
573212|NCT00421057|Survey
573213|NCT00421044|EPO
573214|NCT00421044|Patupilone
573215|NCT00421044|Solid Tumors
573216|NCT00421018|Asthma
573217|NCT00421018|Allergy
573218|NCT00421018|Cytokines
573219|NCT00421018|Glucocorticoids
573220|NCT00421018|Inflammation
573221|NCT00421018|Nitric Oxide (NO)
573222|NCT00421018|Quality of Life
573223|NCT00421018|Self-Rated Health
573224|NCT00421018|Stress
573225|NCT00420992|hip
573226|NCT00420992|knee
573227|NCT00420992|pain
573228|NCT00420992|osteoarthritis
573229|NCT00420992|OA
573230|NCT00420992|Kadian
573231|NCT00420992|Alpharma
573232|NCT00420992|naltrexone
573233|NCT00420992|Opioid
573234|NCT00420992|morphine
573235|NCT00420992|Embeda
573236|NCT00420992|ALO-01
573237|NCT00420966|lower respiratory tract infection
573238|NCT00420966|respiratory syncytial virus infections
573239|NCT00420966|palivizumab
573240|NCT00420966|outcomes
573241|NCT00420966|utilization
573242|NCT00420966|compliance
573243|NCT00420940|vibration
573244|NCT00420940|mechanical loading
573245|NCT00420940|bone mineral density
573246|NCT00420940|women's health
573247|NCT00420940|osteoporosis
573248|NCT00420927|Early Rheumatoid Arthritis
573249|NCT00420927|Tumor Necrosis Factor Optimization
573250|NCT00420914|Thrombocytopenia
573251|NCT00420914|Platelets
573252|NCT00420914|Dose
573253|NCT00420914|Bleeding
573254|NCT00418808|motor
573255|NCT00418808|development
573256|NCT00418808|multiple pregnancies
573257|NCT00418808|general movement
573258|NCT00418808|video recording
573259|NCT00418795|Acute Intermittent Porphyria
573260|NCT00418795|treatment
573261|NCT00418795|Acute attack
573262|NCT00418769|nilotinib
573263|NCT00418769|bioavailability
573264|NCT00418769|tablet
573265|NCT00418769|capsule
573266|NCT00418769|PK
573267|NCT00418769|healthy, subject(s),
573268|NCT00418756|nilotinib
573269|NCT00418756|Rifampin
573270|NCT00418756|PK
573271|NCT00418756|healthy subjects
573272|NCT00418743|cancer
573273|NCT00418743|Lung cancer
573274|NCT00418743|small-cell lung cancer
573275|NCT00418730|androgenetic alopecia
573276|NCT00418730|male pattern hair loss
573277|NCT00418730|male pattern baldness
573278|NCT00418730|androgenetic alopecia or male pattern hair loss
573279|NCT00418704|cancer
573280|NCT00418704|Lung cancer
573281|NCT00418704|None small-cell lung cancer
573282|NCT00418691|Brain Tumor
573283|NCT00418691|Methylphenidate
573284|NCT00418691|Ritalin
573285|NCT00418691|Modafinil
573286|NCT00418691|Provigil
573287|NCT00418691|Fatigue
573288|NCT00418691|Concentration
573289|NCT00420901|function
573290|NCT00420901|inhibition
573291|NCT00420875|plantar fasciitis
573292|NCT00420875|plantar fasciosis
573293|NCT00420875|Achilles tendinosis
573294|NCT00420875|Achilles tendinitis
573295|NCT00420875|heel pain
573296|NCT00420875|fasciosis
573297|NCT00420875|fasciitis
573298|NCT00420875|tendinosis
573299|NCT00420875|tendinitis
573300|NCT00420875|conservative treatment
573301|NCT00420862|Lung neoplasms
573302|NCT00420862|Early diagnosis
573303|NCT00420862|Screening
573304|NCT00420862|Spiral Computed Tomography
573305|NCT00420862|Randomized Controlled Trial
573306|NCT00420836|Cystic fibrosis, tobramycin, PARI eFlow, PARI LC Plus, nebulizer, pharmacokinetic
573307|NCT00420823|First Episode Psychosis
573308|NCT00420797|Faecal seepage
573309|NCT00420797|ileal pouch anal anastomosis (IPAA)
573310|NCT00420797|quality of life
573311|NCT00420797|faecal incontinence
573312|NCT00420797|ileo-anal pouch construction
573313|NCT00420797|phenylephrine hydrochloride gel
573314|NCT00420797|IPAA-related faecal incontinence
573315|NCT00420797|placebo
573316|NCT00420784|Genotype 1
573317|NCT00420771|Benzodiazepine
573318|NCT00420771|Gabapentin
573319|NCT00420771|Methadone
573320|NCT00420758|Infant
573321|NCT00420758|Malnutrition
573322|NCT00420758|Sub-Saharan Africa
573323|NCT00420758|Treatment
573324|NCT00420758|Growth
573325|NCT00420758|Haemoglobin
573326|NCT00420758|Fortified spread
573327|NCT00420758|Food supplement
573328|NCT00420719|ALS
573329|NCT00420719|Amyotrophic Lateral Sclerosis
573330|NCT00420719|Lou Gehrig's disease
573331|NCT00420719|Diaphragm for Ventilatory Assist
573332|NCT00420719|Diaphragm Pacing
573333|NCT00420667|unfractionated heparin
573334|NCT00420667|enoxaparin
573335|NCT00420667|low molecular weight heparin
573336|NCT00420667|bypass surgery
573337|NCT00420667|bleeding
573338|NCT00420654|Turner syndrome
573339|NCT00420654|growth hormone treatment
573340|NCT00420654|positron emission tomography
573341|NCT00420654|heart
573342|NCT00420641|GSK372475
573343|NCT00420641|MDD
573344|NCT00420641|paroxetine
573345|NCT00420641|flexible-dose
573346|NCT00420641|Major Depressive Disorder
573347|NCT00420615|Cancer
573348|NCT00420615|EPO906
573349|NCT00420615|Patupilone
573350|NCT00420589|Weight loss
573351|NCT00420589|Weight regain
573352|NCT00420589|Weight maintenance
573353|NCT00420576|Post-menopausal
573354|NCT00420576|Traditional Chinese Medicine
573355|NCT00420576|Randomized
573356|NCT00420563|Cancer, palliative treatment
573357|NCT00420550|Interstitial Cystitis
573358|NCT00420550|Pelvic pain
573359|NCT00420550|Guided Imagery
573360|NCT00420537|Kidney
573361|NCT00420537|Heart Transplantation
573362|NCT00420537|Creatinine
573363|NCT00420537|Glomerular Filtration Rate
573364|NCT00420524|EPO
573365|NCT00420524|Patupilone
573366|NCT00420524|Solid Tumors
573367|NCT00420511|Type 2 diabetes
573368|NCT00420511|beta-cell function
573369|NCT00420511|sitagliptin
573370|NCT00420511|intensive insulin therapy
573371|NCT00420498|Schizophrenia
573372|NCT00420498|Prefrontal Cortical Function
573373|NCT00420498|Smoking
573374|NCT00420498|Cognition
573375|NCT00420498|Positive and Negative Symptoms
573376|NCT00420498|Tobacco
573377|NCT00420498|Cigarette Smoking
573378|NCT00420498|Dopamine
573379|NCT00420485|Maximum Tolerated Dose
573380|NCT00420485|Solid Tumors
573381|NCT00420485|Dose Limiting Toxicity
573382|NCT00420485|Topoisomerase-1 Inhibitor
573383|NCT00418665|Revlimid
573384|NCT00418665|Lenalidomide
573385|NCT00418665|Low Platelet Count
573386|NCT00418665|Low Risk Myelodysplastic Syndrome
573387|NCT00418665|Intermediate 1 Myelodysplastic Syndrome
573388|NCT00418665|MDS
573389|NCT00418665|Myelodysplastic Syndrome
573390|NCT00418652|Normal Controls
573391|NCT00418639|Chronic Hepatitis C
573392|NCT00418626|nilotinib
573393|NCT00418626|hepatic impairment
573394|NCT00418626|Child-Pugh scale
573395|NCT00418626|PK
573396|NCT00418626|healthy, subject(s)
573397|NCT00418626|Subjects with impaired hepatic function and healthy subjects
573398|NCT00418600|Secondary Hyperparathyroidism
573399|NCT00418600|Hectorol® (doxercalciferol capsules)
573400|NCT00418600|Hectorol® (doxercalciferol injection)
573401|NCT00418587|Vitamin D
573402|NCT00418587|Lupus
573403|NCT00418574|Ovarian cancer
573404|NCT00418574|Abagovomab
573405|NCT00418561|rhASA
573406|NCT00418561|MLD
573407|NCT00418561|Metazym
573408|NCT00418535|Lymphoma, NK/T-Cell
573409|NCT00418522|Insulin Glargine Diabetes HbA1c
573410|NCT00418509|Dose proportionality
573411|NCT00418509|pharmacokinetics
573412|NCT00418509|mometasone
573413|NCT00418509|formoterol
573414|NCT00418509|Healthy volunteers study
573415|NCT00418496|Unresectable
573416|NCT00418496|Metastatic
573417|NCT00418483|thrombolytic
573418|NCT00418483|thrombolysis
573419|NCT00418483|acute peripheral arterial occlusion
573420|NCT00418483|peripheral vascular disease
573421|NCT00418483|thrombosis
573422|NCT00418483|endovascular
573423|NCT00420433|Breast Cancer
573424|NCT00420433|Bone Metastases
573425|NCT00420433|Radiography
573426|NCT00420433|X-Ray
573427|NCT00420433|Computed Tomography
573428|NCT00420433|CT Scan
573429|NCT00420433|Skeletal Scintigraphy
573430|NCT00420394|Neoadjuvant chemotherapy
573431|NCT00420394|Adjuvant chemoradiotherapy
573432|NCT00420394|Adenocarcinoma of stomach and gastroesophageal junction
573433|NCT00420381|Recurrent Cancer
573434|NCT00420368|Infant
573435|NCT00420368|Malnutrition
573436|NCT00420368|Sub-Saharan Africa
573437|NCT00420368|Treatment
573438|NCT00420368|Growth
573439|NCT00420368|Haemoglobin
573440|NCT00420368|Fortified spread
573441|NCT00420368|Food supplement
573442|NCT00420355|antiretroviral therapy
573443|NCT00420355|protease inhibitors
573444|NCT00420355|drug interactions
573445|NCT00420355|HIV infection
573446|NCT00420355|acquired immunodeficiency syndrome
573447|NCT00420355|Treatment Experienced
573448|NCT00420342|Pre-Hypertension in Postmenopausal Women
573449|NCT00420316|Intussusception
573450|NCT00420316|Gastroenteritis
573451|NCT00420316|Finland
573452|NCT00420303|Refractory Heel Enthesitis in Spondylarthropathy
573453|NCT00420303|Spondylarthropathy
573454|NCT00420303|Refractory Heel Enthesitis
573455|NCT00420290|inflammation
573456|NCT00420290|end stage renal disease
573457|NCT00420277|Hip arthroplasty
573458|NCT00420277|Anesthesia, spinal
573459|NCT00420277|Hypotension
573460|NCT00420277|Ischemia
573461|NCT00420277|Blood substitutes
573462|NCT00420277|Plasma expanders
573463|NCT00420238|Axial Ankylosing Spondylitis
573464|NCT00420238|Adult
573465|NCT00420225|Cystocele
573466|NCT00420225|surgery
573467|NCT00420225|mesh
573468|NCT00420225|genital prolapse
573469|NCT00420212|relapsing
573470|NCT00420212|oral
573471|NCT00420212|remitting
573472|NCT00420212|multiple sclerosis
573473|NCT00420173|cutaneous lupus erythematosus
573474|NCT00420173|standardized evaluation
573475|NCT00420173|core set questionnaire
573476|NCT00420173|epidemiological data
573477|NCT00420173|laboratory features
573478|NCT00420160|Smoking cessation
573479|NCT00420160|Exercise
573480|NCT00420160|Nicotine Patch
573481|NCT00420160|Disease Prevention
573482|NCT00420147|knee osteoarthritis
573483|NCT00420147|orthosis
573484|NCT00420147|wedge
573485|NCT00420147|gait
573486|NCT00420134|mesenchymal stem cell
573487|NCT00420134|end stage liver disease
573488|NCT00420134|Cirrhosis
573489|NCT00420134|stem cell therapy
573490|NCT00420121|standardized evaluation
573491|NCT00420121|core set questionnaire
573492|NCT00420121|epidemiological data
573493|NCT00420121|laboratory analysis
573494|NCT00420108|Heart Failure, Congestive
573495|NCT00420108|Cardiac Pacemaker, Artificial
573496|NCT00420108|Ventricular Pressure
573497|NCT00420095|diabetes
573498|NCT00420095|type 1
573499|NCT00420095|type 2
573500|NCT00420082|Rhinitis
573501|NCT00420082|Seasonal
573502|NCT00420082|Allergic
573503|NCT00420082|Pollen allergy
573504|NCT00420082|Environmental Exposure Chamber
573505|NCT00420082|Challenge Chamber
573506|NCT00420043|Food effect
573507|NCT00420043|bioavailability
573508|NCT00420043|pharmacokinetic
573509|NCT00420043|STI571
573510|NCT00420043|modified release formulation of STI571
573511|NCT00420043|CML
573512|NCT00420043|Chronic Myeloid Leukemia
573513|NCT00420043|Philadelphia Chromosome
573514|NCT00420043|imatinib
573515|NCT00420030|upfront abciximab
573516|NCT00420030|PCI
573517|NCT00420030|cardiogenic shock
573518|NCT00420017|Amiodarone
573519|NCT00420017|Atrial fibrillation
573520|NCT00420017|Surgical procedures, thoracic
573521|NCT00419991|Tigecycline
573522|NCT00419991|Staphylococcal Infections
573523|NCT00419991|Catheter
573524|NCT00419952|Moderate Asthma
573525|NCT00419952|Severe Asthma
573526|NCT00419939|Severe traumatic brain injury
573527|NCT00419939|Intensive neurorehabilitation
573528|NCT00419939|"Patient Participation[Professional-Patient Relations"
573529|NCT00419939|Re-learning
573530|NCT00419939|Daily life activities
573531|NCT00419939|Rehabilitation
573532|NCT00419926|Renal, Kidney, Intensified, Enteric-coated mycophenolate sodium, Transplant
573533|NCT00419913|Ovulation Induction
573534|NCT00419913|In vitro Fertilization
573535|NCT00419913|Pregnancy
573536|NCT00419900|breast cancer
573537|NCT00419900|diagnosis
573538|NCT00419900|x-ray diffraction
573539|NCT00419900|synchrotron
573540|NCT00419900|hair
573541|NCT00419887|Safety, tolerability, pharmacokinetics, pharmacodynamics, LAF237, vildagliptin, Chinese, healthy volunteers
573542|NCT00419874|Blood-brain barrier
573543|NCT00419874|Post traumatic epilepsy
573544|NCT00419874|Seizures
573545|NCT00419861|Influenza, surveillance, flu, parent protocol
573546|NCT00419848|Acne
573547|NCT00419848|Azithromycin
573548|NCT00419848|Doxycycline
573549|NCT00419835|diabetic nephropathy
573550|NCT00419835|proteinuria
573551|NCT00419835|CKD progression
573552|NCT00419835|dialysis
573553|NCT00419822|Acupuncture
573554|NCT00419822|Range of Motion
573555|NCT00419822|Quality of Life
573556|NCT00419809|methotrexate,
573557|NCT00419809|SB-681323,
573558|NCT00419809|p38 MAP Kinase Inhibitor,
573559|NCT00419809|liver function
573560|NCT00419809|Rheumatoid Arthritis,
573561|NCT00419796|Osteoarthritis, controlled hypertension, lumiracoxib, ibuprofen, high blood pressure
573562|NCT00419783|Allergic rhinitis
573563|NCT00419783|Urticaria
573564|NCT00419770|zygomycosis
573565|NCT00419770|Rhizopus
573566|NCT00419770|iron
573567|NCT00419770|iron-chelation
573568|NCT00419770|adjunctive therapy
573569|NCT00419757|Moderate asthma
573570|NCT00419757|Severe asthma
573571|NCT00419744|COPD
573572|NCT00419731|nicotine
573573|NCT00419731|smoking
573574|NCT00419731|addiction
573575|NCT00419705|acute stroke
573576|NCT00419705|infrared laser therapy
573577|NCT00419705|clinical trial
573578|NCT00419705|safety
573579|NCT00419705|effectiveness
573580|NCT00419692|formulation,
573581|NCT00419692|controlled release for RLS,
573582|NCT00419692|pharmacokinetic,
573583|NCT00419692|RLS
573584|NCT00419692|food effect,
573585|NCT00419692|SK&F101468,
573586|NCT00419679|breast cancer
573587|NCT00419679|hair
573588|NCT00419679|fibre
573589|NCT00419679|synchrotron
573590|NCT00419679|x-ray diffraction
573591|NCT00419666|Calcitriol
573592|NCT00419666|Psoriasis
573593|NCT00419666|PK
573594|NCT00419666|Adolescents
573595|NCT00419653|schizophrenia fMRI drug therapy amisulpride
573596|NCT00419640|Sinus node disease
573597|NCT00419640|AV node disease
573598|NCT00419627|proteomics of solid tumors
573599|NCT00418470|Cystic fibrosis
573600|NCT00418470|Catheterization, peripheral
573601|NCT00418470|Phlebitis
573602|NCT00418470|Anti-Bacterial Agents
573603|NCT00418470|Osmolar Concentration
573604|NCT00418457|Breast Cancer
573605|NCT00418457|Anesthesia; regional
573606|NCT00418457|cancer recurrence
573607|NCT00418457|Anesthesia; inhalational
573608|NCT00418457|Analgesia; opioid
573609|NCT00418444|Breast cancer,group psychotherapy,RCT,women's mental health
573610|NCT00418418|Cell transplantation
573611|NCT00418418|Heart failure
573612|NCT00418418|Clinical trials
573613|NCT00418405|Arthritis, Rheumatoid
573614|NCT00418405|Cohort Studies
573615|NCT00418392|pneumothorax, aspiration, minocycline, pleurodesis
573616|NCT00418379|Sublingual immunotherapy
573617|NCT00418379|Grass pollen tablet
573618|NCT00418379|Allergic rhinoconjunctivitis
573619|NCT00418366|Mild, moderate, severe renal insufficiency
573620|NCT00418366|End stage renal disease
573621|NCT00418353|Antenatal corticosteroids
573622|NCT00418353|Betamethasone
573623|NCT00418353|Dexamethasone
573624|NCT00418353|Premature
573625|NCT00418340|Irritable Bowel Syndrome,
573626|NCT00418340|Visceral hypersensitivity,
573627|NCT00418340|probiotic therapy,
573628|NCT00418340|immune response
573629|NCT00419601|ventilated newborns (≥ 36 SSW)and infants (≤60 days)
573630|NCT00419601|of any medical condition
573631|NCT00419588|infant, premature
573632|NCT00419588|Bronchopulmonary dysplasia
573633|NCT00419588|asthma
573634|NCT00419575|renal
573635|NCT00419575|transplantation
573636|NCT00419575|immunosuppression
573637|NCT00419575|monitoring
573638|NCT00419562|oral insulin
573639|NCT00419562|autoantigen
573640|NCT00419562|self tolerance
573641|NCT00419562|oral tolerance
573642|NCT00419562|DPT-1
573643|NCT00419562|prevention
573644|NCT00419562|"at risk for developing type 1 diabetes"
573645|NCT00419562|juvenile diabetes
573646|NCT00419562|T1D
573647|NCT00419562|diabetes mellitus
573648|NCT00419562|Type 1 diabetes TrialNet
573649|NCT00419562|TrialNet
573650|NCT00419549|ERCP
573651|NCT00419549|Pancreatitis
573652|NCT00419549|Nitroglycerine
573653|NCT00419549|Valdecoxib
573654|NCT00419536|LBH
573655|NCT00419536|LBH589
573656|NCT00419536|Prostate Cancer
573657|NCT00419536|HRPC
573658|NCT00419510|Genetic counseling
573659|NCT00419510|BRCA1 and BRCA2
573660|NCT00419510|African American
573661|NCT00419497|Paleolithic diet
573662|NCT00419497|Mediterranean-style diet
573663|NCT00419497|Glucose tolerance
573664|NCT00419497|Diabetes type 2
573665|NCT00419497|Weight loss
573666|NCT00419497|Waist
573667|NCT00419471|Depression
573668|NCT00419471|Myocardial infarction
573669|NCT00419471|Angina, unstable
573670|NCT00419458|ventilator weaning
573671|NCT00419458|weaning
573672|NCT00419458|respiratory failure
573673|NCT00419458|inspiratory muscle strength training
573674|NCT00419445|Attention Deficit Hyperactivity Disorder in adults
573675|NCT00419432|Pediatrics
573676|NCT00419432|Cerebral Palsy
573677|NCT00419432|Gait Analysis
573678|NCT00419432|Orthopedic Surgery
573679|NCT00419419|Raynaud's
573680|NCT00419406|UVA1
573681|NCT00419406|N-B UVB
573682|NCT00419406|phototherapy
573683|NCT00419406|atopic dermatitis
573684|NCT00419406|SCORAD index
573685|NCT00419393|Keppra XR
573686|NCT00419393|Levetiracetam XR
573687|NCT00419393|long term
573688|NCT00419393|partial seizures
573689|NCT00419380|clogged ear tubes
573690|NCT00419354|Pacemaker
573691|NCT00419354|Tricuspid regurgitation
573692|NCT00419341|Immune globulin subcutaneous
573693|NCT00419341|SCIG
573694|NCT00419341|Primary immunodeficiency
573695|NCT00419341|PID
573696|NCT00419328|solid tumors NGR-hTNF
573697|NCT00419315|alcoholism
573698|NCT00419315|primary care
573699|NCT00419315|treatment
573700|NCT00419289|COPD, rehabilitation, quality of life
573701|NCT00419276|Total knee arthroplasty, postoperative analgesia
573702|NCT00419276|Primary, unilateral, total knee arthroplasty
573703|NCT00419263|influenza
573704|NCT00419263|flu
573705|NCT00419250|relapsed
573706|NCT00419250|refractory
573707|NCT00419250|fludarabine
573708|NCT00419250|Revlimid
573709|NCT00419250|lenalidomide
573710|NCT00419250|CLL
573711|NCT00419250|B-cell CLL
573712|NCT00419250|CC-5013
573713|NCT00419250|Chronic Lymphocytic Leukemia
573714|NCT00419237|hepatic impairment pharmacokinetics
573715|NCT00419224|Peripheral blood stem cell transplantation
573716|NCT00419224|Non-myeloabalative
573717|NCT00419224|Influenza vaccination
573718|NCT00419224|Humoral immune response
573719|NCT00419224|Immunogenicity
573720|NCT00419211|Pregnancy, Exercise, Depression
573721|NCT00419198|Ischemia
573722|NCT00419198|Reperfusion
573723|NCT00419198|Myocardial infarction
573724|NCT00419198|Postconditioning
573725|NCT00419185|macular hole surgery
573726|NCT00419185|indocyanine green
573727|NCT00419185|trypan blue
573728|NCT00419185|internal limiting membrane
573729|NCT00419172|Pharmacokinetics
573730|NCT00419172|Deferasirox
573731|NCT00419172|Exjade
573732|NCT00419172|ICL670
573733|NCT00419172|Rifampicin
573734|NCT00419172|Healthy, Volunteers
573735|NCT00419159|Colorectal cancer
573736|NCT00419159|metastatic colorectal adenocarcinoma
573737|NCT00419159|anti-EGFR antibody
573738|NCT00419146|Schizophrenia
573739|NCT00419146|Schizophreniform disorders
573740|NCT00419146|Schizoaffective disorder
573741|NCT00419146|Psychotic disorders
573742|NCT00419146|Randomized Controlled Trials
573743|NCT00419146|Longitudinal Studies
573744|NCT00419146|Fatty Acids, Omega-3
573745|NCT00419146|Eicosapentaenoic Acid
573746|NCT00419146|Vitamins
573747|NCT00419146|Antioxidants
573748|NCT00419146|Ascorbic Acid
573749|NCT00419146|Alpha-Tocopherol
573750|NCT00419146|Placebos
573751|NCT00419146|Antipsychotic Agents
573752|NCT00419146|Oxidative Stress
573753|NCT00419146|Fatty Acids, Unsaturated
573754|NCT00419146|Phospholipases
573755|NCT00419146|Niacin
573756|NCT00419146|Adverse effects
573757|NCT00419146|Delusions
573758|NCT00419146|Hallucinations
573759|NCT00419146|Neuropsychological Tests
573760|NCT00419146|Attention
573761|NCT00419146|Memory
573762|NCT00419146|Hypertriglyceridemia
573763|NCT00419146|Models, Statistical
573764|NCT00419133|Cholera
573765|NCT00419133|Vaccine
573766|NCT00419133|Kolkata
573767|NCT00419133|West Bengal
573768|NCT00419133|India
573769|NCT00419133|Immunogenicity
573770|NCT00419133|Safety
573771|NCT00419094|Keppra XR
573772|NCT00419094|conversion to monotherapy
573773|NCT00419094|partial seizures
573774|NCT00419081|leukemia
573775|NCT00419081|lymphoma
573776|NCT00419055|percutaneous coronary intervention
573777|NCT00419042|cancer
573778|NCT00419042|Lung cancer
573779|NCT00419042|None small-cell lung cancer
573780|NCT00419029|combat
573781|NCT00419029|depression
573782|NCT00419029|PTSD
573783|NCT00419029|substance abuse
573784|NCT00418990|Multivitamin
573785|NCT00418990|Academic performance
573786|NCT00418977|Anorexia Nervosa
573787|NCT00418964|Anterior cruciate ligament rupture
573788|NCT00418964|Anterior cruciate ligament(A02.513.514.100)
573789|NCT00418951|Voriconazole
573790|NCT00418951|Vfend
573791|NCT00418951|Liposomal amphotericin B
573792|NCT00418951|Ambisome
573793|NCT00418951|Acute Myelogenous Leukemia
573794|NCT00418951|Myelodysplastic Syndrome
573795|NCT00418951|AML
573796|NCT00418951|MDS
573797|NCT00418938|EGFR
573798|NCT00418938|FOLFIRI
573799|NCT00418938|2nd Line Therapy
573800|NCT00418938|2nd Line mCRC Therapy
573801|NCT00418938|mCRC
573802|NCT00418938|Irinotecan
573803|NCT00418938|panitumumab
573804|NCT00418938|bevacizumab
573805|NCT00418899|Brain Tumor
573806|NCT00418899|Glioma
573807|NCT00418899|Linkage Study
573808|NCT00418899|Survey
573809|NCT00418899|Gliogene
573810|NCT00418899|High-risk familial brain tumor pedigrees
573811|NCT00418886|NSCLC
573812|NCT00418886|Non Small Cell Lung Cancer
573813|NCT00418873|schizophrenia
573814|NCT00418873|zotepine
573815|NCT00418873|risperidone
573816|NCT00418873|second generation antipsychotic
573817|NCT00418860|Angioplasty, Transluminal, Percutaneous Coronary
573818|NCT00418860|Stent thrombosis
573819|NCT00418860|Zotarolimus-eluting stent
573820|NCT00418847|pediatrics
573821|NCT00418847|lysosomal storage diseases
573822|NCT00418847|Gangliosidoses GM2
573823|NCT00418847|Tay-Sachs disease
573824|NCT00418847|Sandhoff disease
573825|NCT00418847|Infantile GM2-activator deficiency
573826|NCT00418847|Miglustat
573827|NCT00418327|Tarceva
573828|NCT00418327|refractory and relapsed malignant brain tumors
573829|NCT00418327|newly diagnosed brain stem glioma
573830|NCT00418301|Pain
573831|NCT00418301|Neurostimulation
573832|NCT00418288|GLP-1
573833|NCT00418288|glucose metabolism
573834|NCT00418288|Type 2 diabetes
573835|NCT00418288|brain
573836|NCT00418288|PET
573837|NCT00418275|Cerebrovascular Stroke
573838|NCT00418262|fetal alcohol syndrome
573839|NCT00418262|attention deficit disorder
573840|NCT00418262|attention deficit disorder with hyperactivity
573841|NCT00418262|ADD
573842|NCT00418262|FAS
573843|NCT00418262|FASD
573844|NCT00418262|ADHD
573845|NCT00418249|Androgenetic Alopecia
573846|NCT00418249|Telogen effluvium
573847|NCT00418249|Chronic telogen effluvium
573848|NCT00418249|Menopause
573849|NCT00418249|Female Androgenetic Alopecia (FAGA)
573850|NCT00418223|Urinary retention
573851|NCT00418223|Child birth
573852|NCT00418223|Catheterization
573853|NCT00418223|Ultrasound
573854|NCT00418210|Accelerated Partial Breast Irradiation
573855|NCT00418210|Conformal Radiation Therapy
573856|NCT00418210|Feasibility
573857|NCT00418210|Early breast cancer
573858|NCT00418197|spinal stenosis
573859|NCT00418197|low back pain
573860|NCT00418197|spondylolisthesis
573861|NCT00418197|lumbar spinal stenosis
573862|NCT00418197|leg pain
573863|NCT00418197|spinal diseases
573864|NCT00418184|ADHD
573865|NCT00418184|inattentive
573866|NCT00418184|impulsive
573867|NCT00418184|hyperactive
573868|NCT00418184|poor academic performance
573869|NCT00418184|poor self-discipline
573870|NCT00418184|low self-esteem
573871|NCT00418158|Pulmonary complications
573872|NCT00418145|Relapsing Forms of Multiple Sclerosis
573873|NCT00418132|SSc
573874|NCT00418132|Systemic Sclerosis
573875|NCT00418132|Progressive Systemic Sclerosis
573876|NCT00418106|Premature birth
573877|NCT00418106|Pumping breast milk
573878|NCT00418106|Kangaroo holding
573879|NCT00418093|mullerian carcinoma
573880|NCT00418067|Coronary Artery Disease
573881|NCT00418067|Stent
573882|NCT00418028|capecitabine
573883|NCT00418028|schedule
573884|NCT00418028|breast cancer
573885|NCT00418015|µ-opioid receptor
573886|NCT00418015|neuraxial labor analgesia
573887|NCT00418015|pharmacogenetics
573888|NCT00418002|Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.
573889|NCT00418002|Healthy elderly male and female subjects
573890|NCT00417989|Glycemic control
573891|NCT00417989|Sensor
573892|NCT00417976|Advanced Pancreatic Cancer
573893|NCT00417963|Carotid
573894|NCT00417963|Artery
573895|NCT00417963|Stenosis
573896|NCT00417950|diabetes
573897|NCT00417950|acarbose
573898|NCT00417950|alcohol
573899|NCT00417950|inflammation
573900|NCT00417950|oxidative stress
573901|NCT00417950|Mild diabetes mellitus
573902|NCT00417924|Patient education
573903|NCT00417924|Patient satisfaction
573904|NCT00417924|Eye health
573905|NCT00417911|multiple myeloma
573906|NCT00417911|autologous stem cell transplantation
573907|NCT00417911|high-dose melphalan
573908|NCT00417911|bortezomib
573909|NCT00417911|consolidation
573910|NCT00417911|event free survival
573911|NCT00417911|phase III
573912|NCT00417898|Stroke
573913|NCT00417898|Cerebral Ischemia
573914|NCT00417898|Tissue Plasminogen Activator
573915|NCT00417898|Aspirin
573916|NCT00417898|Human
573917|NCT00417898|Cerebral Reperfusion
573918|NCT00417872|Clostridium difficile
573919|NCT00417846|Age-Related Macular Degeneration
573920|NCT00417846|Optical Coherence Tomography, OCT
573921|NCT00417846|Preferential Hyperacuity Perimeter, PHP
573922|NCT00417846|Amsler Grid
573923|NCT00417820|Safety, tolerability, pharmacodynamics, single administration, BCT194, healthy volunteers, psoriasis
573924|NCT00417807|refractory desmoplastic small round cell tumors
573925|NCT00417807|PDGF-R
573926|NCT00417794|attention deficit hyperactivity disorder
573927|NCT00417794|ADHD
573928|NCT00417794|fetal alcohol syndrome
573929|NCT00417794|FAS
573930|NCT00417794|FASD
573931|NCT00417794|atomoxetine hcl
573932|NCT00417781|ADHD, adolescence, family study, endophenotype, outcome
573933|NCT00417768|tissue plasminogen activator
573934|NCT00417768|intraabdominal
573935|NCT00417768|abscess
573936|NCT00417768|percutaneous drainage
573937|NCT00417755|Nutritional intake
573938|NCT00417755|Mechanical ventilation
573939|NCT00417755|Enteral feeding
573940|NCT00417742|headache
573941|NCT00417742|migraine headache
573942|NCT00417742|tension headache
573943|NCT00417729|Diabetes
573944|NCT00417729|Acarobse
573945|NCT00417729|Metformin
573946|NCT00417729|oxidative stress
573947|NCT00417729|Mean amplitude Glycemic Excursion
573948|NCT00417729|Meal test
573949|NCT00417716|Diffuse Diabetic Macular Edema
573950|NCT00417716|Intravitreal Bevacizumab
573951|NCT00417716|Anti-VEGF drugs
573952|NCT00417703|Intraocular Pressure
573953|NCT00417703|Intravitreous Injection
573954|NCT00417703|Ranibizumab
573955|NCT00417690|Crohn's Disease
573956|NCT00417690|Acute Flare
573957|NCT00417690|Mild to moderate Crohn's Disease
573958|NCT00417690|Ileocecal distribution
573959|NCT00417677|Advanced Renal Carcinoma
573960|NCT00417664|cardiac surgery
573961|NCT00417664|valvular surgery
573962|NCT00417664|delirium
573963|NCT00417664|postoperative delirium
573964|NCT00417664|cognitive dysfunction
573965|NCT00417664|altered mental status
573966|NCT00417651|Bacterial
573967|NCT00417651|contamination
573968|NCT00417651|gastrotomy
573969|NCT00417651|Complications
573970|NCT00417638|myocardial infarction
573971|NCT00417638|acute intervention
573972|NCT00417638|percutaneous intervention
573973|NCT00417638|endovascular cooling
573974|NCT00417638|endovascular rewarming
573975|NCT00417625|Coronary Artery Perfusion
573976|NCT00417625|MRI
573977|NCT00417625|Fractional Flow Reserve
573978|NCT00417625|Coronary Flow Reserve
573979|NCT00417625|Collateral Artery Perfusion
573980|NCT00417625|Cardiovascular Disease
573981|NCT00417625|Coronary Artery Disease
573982|NCT00417625|CAD
573983|NCT00417612|Rickets, Hypophosphatemia
573984|NCT00417612|Rickets, Vitamin D-Resistant
573985|NCT00417612|Rickets, X-linked hypophosphatemic
573986|NCT00417599|Prevention of overweight
573987|NCT00417599|Prevention of obesity
573988|NCT00417599|Treatment of overweight
573989|NCT00417599|Treatment of obesity
573990|NCT00417586|Stroke
573991|NCT00417573|Immunodeficiency
573992|NCT00417573|Gammaglobulin
573993|NCT00417573|IgG subclass deficiency with recurrent infections
573994|NCT00417560|Influenza A/H5N1
573995|NCT00417560|vaccine
573996|NCT00417560|avian influenza H5N1
573997|NCT00417560|H5N1
573998|NCT00417547|Self Concept
573999|NCT00417547|Eating Disorder
574000|NCT00417547|Body Mass Index
574001|NCT00417547|Dressing
574002|NCT00417547|Islamic Veil
574003|NCT00417534|Coronary Disease
574004|NCT00417534|Inflammation
574005|NCT00417534|Genetics
574006|NCT00417534|HLA Antigens
574007|NCT00417534|Aortic Valve
574008|NCT00417521|Adolescents
574009|NCT00417521|Anorexia
574010|NCT00417521|Eating disorder
574011|NCT00417521|Family therapy
574012|NCT00417508|function
574013|NCT00417508|elderly
574014|NCT00417508|ADL
574015|NCT00417508|nutritional supplementation
574016|NCT00417508|Quality of life
574017|NCT00417508|handgrip strength
574018|NCT00417508|Body Composition
574019|NCT00417495|adenocarcinoma, breast, multifocal lesions, surgery
574020|NCT00417482|Risperidone treatment, psychosis, agitation, aggression,
574021|NCT00417482|discontinuation, placebo
574022|NCT00417456|Acne
574023|NCT00417456|Telemedicine
574024|NCT00417456|Dermatology
574025|NCT00417443|epidural
574026|NCT00417443|clonidine
574027|NCT00417443|hyperalgesia
574028|NCT00417443|laparotomy
574029|NCT00417417|Endothelium
574030|NCT00417417|Inflammation
574031|NCT00417417|Nitric Oxide
574032|NCT00417417|Rilonacept
574033|NCT00417417|Cytokines
574034|NCT00417417|Coronary Artery Disease
574035|NCT00417417|CAD
574036|NCT00417417|Atherosclerosis
574037|NCT00417404|preterm
574038|NCT00417404|nutrition
574039|NCT00417404|vitamin A
574040|NCT00417404|electroretinogram
574041|NCT00417404|conjunctiva
574042|NCT00417404|vitamin A status
574043|NCT00417404|conjunctival health
574044|NCT00417378|ACS
574045|NCT00417365|odor
574046|NCT00417365|douching
574047|NCT00417365|BV
574048|NCT00417365|vaginitis
574049|NCT00417365|vaginal
574050|NCT00417365|yeast
574051|NCT00417365|ecosystem
574052|NCT00417365|Lactobacilli
574053|NCT00417365|Nugent
574054|NCT00417365|Amsel
574055|NCT00417352|no intervention
574056|NCT00417352|bracing restricted forearm and wrist movement
574057|NCT00417352|bracing with added mass near elbow
574058|NCT00417352|bracing with added mass near wrist
574059|NCT00417339|hemodialysis
574060|NCT00417339|dialysis adequacy
574061|NCT00417339|uremic retention solute
574062|NCT00417326|ONO-5046Na
574063|NCT00417326|acute respiratory failure
574064|NCT00417326|community-acquired pneumonia
574065|NCT00417313|knee pain
574066|NCT00417313|acupuncture /acupressure
574067|NCT00417313|alternative medicine
574068|NCT00417313|analgesia
574069|NCT00417313|arthritis therapy
574070|NCT00417313|chronic pain
574071|NCT00417313|functional ability
574072|NCT00417300|PTSD
574073|NCT00417300|Cognitive Behavioral Treatment
574074|NCT00417300|Child Sexual Abuse
574075|NCT00417287|Pancreas
574076|NCT00417287|Cancer
574077|NCT00417287|Carcinoma
574078|NCT00417274|Cancer of Prostate
574079|NCT00417274|Prostate Cancer
574080|NCT00417274|Cancer of the Prostate
574081|NCT00417274|Neoplasms, Prostate
574082|NCT00417274|Neoplasms, Prostatic
574083|NCT00417274|Prostate Neoplasms
574084|NCT00417274|Prostatic Cancer
574085|NCT00417274|Androgen-Independent Prostate Cancer
574086|NCT00417261|ATF936, AXT914, healthy subjects, pharmacokinetics, parathyroid hormone, osteoporosis
574087|NCT00417261|Healthy male and female subjects
574088|NCT00417235|catheter related infection
574089|NCT00417235|catheter dressing
574090|NCT00417235|prevention
574091|NCT00417235|Chlorhexidine impregnated dressings
574092|NCT00417235|Infection
574093|NCT00417235|catheterization
574094|NCT00417209|advanced pancreatic cancer
574095|NCT00417196|pharmacodynamic effects, safety, healthy subjects,
574096|NCT00417196|Healthy male and female subjects
574097|NCT00417183|GnRH antagonist
574098|NCT00417183|GnRH agonist
574099|NCT00417183|Long protocol
574100|NCT00417183|Flexible
574101|NCT00417170|High Blood pressure
574102|NCT00417170|Hypertension
574103|NCT00417170|metabolic syndrome
574104|NCT00417170|insulin resistance
574105|NCT00417170|endothelial dysfunction
574106|NCT00417170|pre-diabetic
574107|NCT00417170|amlodipine,
574108|NCT00417170|aliskiren,
574109|NCT00417170|IGT,
574110|NCT00417170|IFG,
574111|NCT00417170|MBF
574112|NCT00417157|GnRH antagonist
574113|NCT00417157|Poor responders
574114|NCT00417157|Oocyte donation
574115|NCT00417157|Modified natural cycle
574116|NCT00417144|OHSS
574117|NCT00417144|PCOS
574118|NCT00417144|GnRH antagonist
574119|NCT00417144|GnRH agonist
574120|NCT00417131|Islet transplantation,
574121|NCT00417131|coagulation,
574122|NCT00417131|graft destruction,
574123|NCT00417131|islet imaging
574124|NCT00417118|Anxiety
574125|NCT00417118|clinical trials
574126|NCT00417105|hemodialysis
574127|NCT00417105|dialysis adequacy
574128|NCT00417105|chronic kidney disease
574129|NCT00417092|coronary artery bypass grafting
574130|NCT00417092|reduced left ventricular function
574131|NCT00417092|postoperative pacing
574132|NCT00417092|cardiac resynchronization
574133|NCT00417079|Cancer
574134|NCT00417079|Prostate
574135|NCT00417066|poor responders
574136|NCT00417066|GnRH antagonist
574137|NCT00417066|GnRH agonist
574138|NCT00417066|flare up
574139|NCT00417066|short protocol
574140|NCT00417053|disseminated neuroblastoma
574141|NCT00417053|localized resectable neuroblastoma
574142|NCT00417053|localized unresectable neuroblastoma
574143|NCT00417053|regional neuroblastoma
574144|NCT00417053|stage 4S neuroblastoma
574145|NCT00417040|adenocarcinoma of the prostate
574146|NCT00417040|recurrent prostate cancer
574147|NCT00417040|stage IV prostate cancer
574148|NCT00417027|Patient controlled epidural analgesia
574149|NCT00417027|Labor analgesia
574150|NCT00417027|Epidural analgesia
574151|NCT00417014|stage I childhood Hodgkin lymphoma
574152|NCT00417014|stage II childhood Hodgkin lymphoma
574153|NCT00417014|stage III childhood Hodgkin lymphoma
574154|NCT00417014|stage IV childhood Hodgkin lymphoma
574155|NCT00417014|recurrent/refractory childhood Hodgkin lymphoma
574156|NCT00417001|sedation
574157|NCT00417001|colonoscopy
574158|NCT00417001|Aroma therapy
574159|NCT00416988|melanoma
574160|NCT00416988|weight changes
574161|NCT00416975|breast cancer
574162|NCT00416962|Oseltamivir, amantidine, Symmetrel, Tamiflu
574163|NCT00416949|anaplastic thyroid cancer
574164|NCT00416949|insular thyroid cancer
574165|NCT00416949|thyroid gland medullary carcinoma
574166|NCT00416949|recurrent thyroid cancer
574167|NCT00416949|stage I follicular thyroid cancer
574168|NCT00416949|stage I papillary thyroid cancer
574169|NCT00416949|stage II follicular thyroid cancer
574170|NCT00416949|stage II papillary thyroid cancer
574171|NCT00416949|stage III follicular thyroid cancer
574172|NCT00416949|stage III papillary thyroid cancer
574173|NCT00416949|stage IVA follicular thyroid cancer
574174|NCT00416949|stage IVB follicular thyroid cancer
574175|NCT00416949|stage IVC follicular thyroid cancer
574176|NCT00416949|stage IVA papillary thyroid cancer
574177|NCT00416949|stage IVB papillary thyroid cancer
574178|NCT00416949|stage IVC papillary thyroid cancer
574179|NCT00416923|recurrent adult Burkitt lymphoma
574180|NCT00416923|recurrent adult diffuse large cell lymphoma
574181|NCT00416923|recurrent adult diffuse mixed cell lymphoma
574182|NCT00416923|recurrent adult immunoblastic large cell lymphoma
574183|NCT00416923|recurrent adult lymphoblastic lymphoma
574184|NCT00416923|recurrent grade 1 follicular lymphoma
574185|NCT00416923|recurrent grade 2 follicular lymphoma
574287|NCT00416663|Progenitor cells
574186|NCT00416923|recurrent grade 3 follicular lymphoma
574187|NCT00416923|recurrent adult diffuse small cleaved cell lymphoma
574188|NCT00416923|recurrent mantle cell lymphoma
574189|NCT00416923|recurrent marginal zone lymphoma
574190|NCT00416923|recurrent small lymphocytic lymphoma
574191|NCT00416923|stage IV adult Burkitt lymphoma
574192|NCT00416923|stage IV adult diffuse large cell lymphoma
574193|NCT00416923|stage IV adult diffuse mixed cell lymphoma
574194|NCT00416923|stage IV adult diffuse small cleaved cell lymphoma
574195|NCT00416923|stage IV adult immunoblastic large cell lymphoma
574196|NCT00416923|stage IV adult lymphoblastic lymphoma
574197|NCT00416923|stage IV grade 1 follicular lymphoma
574198|NCT00416923|stage IV grade 2 follicular lymphoma
574199|NCT00416923|stage IV grade 3 follicular lymphoma
574200|NCT00416923|stage IV mantle cell lymphoma
574201|NCT00416923|stage IV marginal zone lymphoma
574202|NCT00416923|stage IV small lymphocytic lymphoma
574203|NCT00416923|primary central nervous system non-Hodgkin lymphoma
574204|NCT00416923|leptomeningeal metastases
574205|NCT00416923|intraocular lymphoma
574206|NCT00416923|AIDS-related primary CNS lymphoma
574207|NCT00416923|Waldenström macroglobulinemia
574208|NCT00416923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
574209|NCT00416923|nodal marginal zone B-cell lymphoma
574210|NCT00416923|splenic marginal zone lymphoma
574211|NCT00416910|refractory chronic lymphocytic leukemia
574212|NCT00416910|stage III chronic lymphocytic leukemia
574213|NCT00416910|stage IV chronic lymphocytic leukemia
574214|NCT00416910|stage I chronic lymphocytic leukemia
574215|NCT00416910|stage II chronic lymphocytic leukemia
574216|NCT00416897|stage I multiple myeloma
574217|NCT00416897|stage II multiple myeloma
574218|NCT00416897|stage III multiple myeloma
574219|NCT00416897|renal failure
574220|NCT00416884|chronic phase chronic myelogenous leukemia
574221|NCT00416884|childhood chronic myelogenous leukemia
574222|NCT00416884|relapsing chronic myelogenous leukemia
574223|NCT00416871|stage IV renal cell cancer
574224|NCT00416871|recurrent renal cell cancer
574225|NCT00416858|stage III esophageal cancer
574226|NCT00416845|pharmacodynamic effects, cardiac effects, healthy subjects, synthetic sphingosine 1 phosphate (S1P) receptor modulator
574227|NCT00416845|Healthy male and female subjects
574228|NCT00416832|stage II childhood Hodgkin lymphoma
574229|NCT00416832|stage III childhood Hodgkin lymphoma
574230|NCT00416832|stage IV childhood Hodgkin lymphoma
574231|NCT00416832|stage I childhood Hodgkin lymphoma
574232|NCT00416819|primary central nervous system non-Hodgkin lymphoma
574233|NCT00416819|primary central nervous system Hodgkin lymphoma
574234|NCT00416780|psychosocial effects of cancer and its treatment
574235|NCT00416780|recurrent breast cancer
574236|NCT00416780|stage I breast cancer
574237|NCT00416780|stage II breast cancer
574238|NCT00416780|stage IV breast cancer
574239|NCT00416767|metastatic gastrointestinal carcinoid tumor
574240|NCT00416767|recurrent gastrointestinal carcinoid tumor
574241|NCT00416767|regional gastrointestinal carcinoid tumor
574242|NCT00416767|gastrinoma
574243|NCT00416767|insulinoma
574244|NCT00416767|WDHA syndrome
574245|NCT00416767|glucagonoma
574246|NCT00416767|pancreatic polypeptide tumor
574247|NCT00416767|somatostatinoma
574248|NCT00416767|recurrent islet cell carcinoma
574249|NCT00416754|breast cancer
574250|NCT00416754|stage I breast cancer
574251|NCT00416754|stage II breast cancer
574252|NCT00416754|stage IIIA breast cancer
574253|NCT00416754|stage IIIB breast cancer
574254|NCT00416754|stage IIIC breast cancer
574255|NCT00416754|stage IV breast cancer
574256|NCT00416741|Metabolic Syndrome
574257|NCT00416741|Obesity
574258|NCT00416741|Hyperlipidemia
574259|NCT00416741|High blood pressure
574260|NCT00416741|Diabetes
574261|NCT00416728|Aliskiren , Valsartan , bioavailability, hypertension
574262|NCT00416728|Healthy male and female subjects
574263|NCT00416702|safety study, pharmacokinetic effects, healthy subjects, hepatic impairment, liver
574264|NCT00416702|Subjects with mild and moderate hepatic impairment and healthy subjects
574265|NCT00416689|nausea and vomiting
574266|NCT00416689|pulmonary carcinoid tumor
574267|NCT00416689|recurrent breast cancer
574268|NCT00416689|stage I breast cancer
574269|NCT00416689|stage II breast cancer
574270|NCT00416689|stage IIIA breast cancer
574271|NCT00416689|stage IIIB breast cancer
574272|NCT00416689|stage IIIC breast cancer
574273|NCT00416689|stage IV breast cancer
574274|NCT00416689|recurrent non-small cell lung cancer
574275|NCT00416689|stage I non-small cell lung cancer
574276|NCT00416689|stage II non-small cell lung cancer
574277|NCT00416689|stage IIIA non-small cell lung cancer
574278|NCT00416689|stage IIIB non-small cell lung cancer
574279|NCT00416689|stage IV non-small cell lung cancer
574280|NCT00416689|extensive stage small cell lung cancer
574281|NCT00416689|limited stage small cell lung cancer
574282|NCT00416689|recurrent small cell lung cancer
574283|NCT00416676|localized resectable neuroblastoma
574284|NCT00416676|localized unresectable neuroblastoma
574285|NCT00416676|regional neuroblastoma
574286|NCT00416663|Stem cells
574288|NCT00416663|Angina Pectoris
574289|NCT00416663|Heart Failure
574290|NCT00416663|Angiogenesis
574291|NCT00416650|stage IIIB non-small cell lung cancer
574292|NCT00416650|stage IV non-small cell lung cancer
574293|NCT00416650|bronchoalveolar cell lung cancer
574294|NCT00416650|recurrent non-small cell lung cancer
574295|NCT00416637|unspecified adult solid tumor, protocol specific
574296|NCT00416624|unspecified adult solid tumor, protocol specific
574297|NCT00416624|extramedullary plasmacytoma
574298|NCT00416624|isolated plasmacytoma of bone
574299|NCT00416624|refractory multiple myeloma
574300|NCT00416624|stage I multiple myeloma
574301|NCT00416624|stage II multiple myeloma
574302|NCT00416624|stage III multiple myeloma
574303|NCT00416624|Waldenstrom macroglobulinemia
574304|NCT00416624|post-transplant lymphoproliferative disorder
574305|NCT00416624|stage I adult T-cell leukemia/lymphoma
574306|NCT00416624|stage II adult T-cell leukemia/lymphoma
574307|NCT00416624|stage III adult T-cell leukemia/lymphoma
574308|NCT00416624|stage IV adult T-cell leukemia/lymphoma
574309|NCT00416624|recurrent adult T-cell leukemia/lymphoma
574310|NCT00416624|AIDS-related peripheral/systemic lymphoma
574311|NCT00416624|AIDS-related primary CNS lymphoma
574312|NCT00416624|angioimmunoblastic T-cell lymphoma
574313|NCT00416624|anaplastic large cell lymphoma
574314|NCT00416624|stage I cutaneous T-cell non-Hodgkin lymphoma
574315|NCT00416624|stage II cutaneous T-cell non-Hodgkin lymphoma
574316|NCT00416624|stage III cutaneous T-cell non-Hodgkin lymphoma
574317|NCT00416624|stage IV cutaneous T-cell non-Hodgkin lymphoma
574318|NCT00416624|recurrent cutaneous T-cell non-Hodgkin lymphoma
574319|NCT00416624|stage I mycosis fungoides/Sezary syndrome
574320|NCT00416624|stage II mycosis fungoides/Sezary syndrome
574321|NCT00416624|stage III mycosis fungoides/Sezary syndrome
574322|NCT00416624|stage IV mycosis fungoides/Sezary syndrome
574323|NCT00416624|recurrent mycosis fungoides/Sezary syndrome
574324|NCT00416624|stage I adult Hodgkin lymphoma
574325|NCT00416624|stage II adult Hodgkin lymphoma
574326|NCT00416624|stage III adult Hodgkin lymphoma
574327|NCT00416624|stage IV adult Hodgkin lymphoma
574328|NCT00416624|recurrent adult Hodgkin lymphoma
574329|NCT00416624|adult grade III lymphomatoid granulomatosis
574330|NCT00416624|stage I adult Burkitt lymphoma
574331|NCT00416624|stage III adult Burkitt lymphoma
574332|NCT00416624|stage IV adult Burkitt lymphoma
574333|NCT00416624|noncontiguous stage II adult Burkitt lymphoma
574334|NCT00416624|noncontiguous stage II adult diffuse large cell lymphoma
574335|NCT00416624|noncontiguous stage II adult diffuse mixed cell lymphoma
574336|NCT00416624|noncontiguous stage II adult diffuse small cleaved cell lymphoma
574337|NCT00416624|noncontiguous stage II adult immunoblastic large cell lymphoma
574338|NCT00416624|noncontiguous stage II adult lymphoblastic lymphoma
574339|NCT00416624|noncontiguous stage II grade 1 follicular lymphoma
574340|NCT00416624|noncontiguous stage II grade 2 follicular lymphoma
574341|NCT00416624|noncontiguous stage II grade 3 follicular lymphoma
574342|NCT00416624|noncontiguous stage II mantle cell lymphoma
574343|NCT00416624|noncontiguous stage II marginal zone lymphoma
574344|NCT00416624|noncontiguous stage II small lymphocytic lymphoma
574345|NCT00416624|contiguous stage II adult Burkitt lymphoma
574346|NCT00416624|contiguous stage II adult diffuse large cell lymphoma
574347|NCT00416624|contiguous stage II adult diffuse mixed cell lymphoma
574348|NCT00416624|contiguous stage II adult diffuse small cleaved cell lymphoma
574349|NCT00416624|contiguous stage II adult immunoblastic large cell lymphoma
574350|NCT00416624|contiguous stage II adult lymphoblastic lymphoma
574351|NCT00416624|contiguous stage II grade 1 follicular lymphoma
574352|NCT00416624|contiguous stage II grade 2 follicular lymphoma
574353|NCT00416624|contiguous stage II grade 3 follicular lymphoma
574354|NCT00416624|contiguous stage II mantle cell lymphoma
574355|NCT00416624|contiguous stage II marginal zone lymphoma
574356|NCT00416624|contiguous stage II small lymphocytic lymphoma
574357|NCT00416624|stage I adult diffuse large cell lymphoma
574358|NCT00416624|stage I adult diffuse mixed cell lymphoma
574359|NCT00416624|stage I adult diffuse small cleaved cell lymphoma
574360|NCT00416624|stage III adult diffuse large cell lymphoma
574361|NCT00416624|stage III adult diffuse mixed cell lymphoma
574362|NCT00416624|stage III adult diffuse small cleaved cell lymphoma
574363|NCT00416624|stage IV adult diffuse large cell lymphoma
574364|NCT00416624|stage IV adult diffuse mixed cell lymphoma
574365|NCT00416624|stage IV adult diffuse small cleaved cell lymphoma
574366|NCT00416624|stage I adult immunoblastic large cell lymphoma
574367|NCT00416624|stage III adult immunoblastic large cell lymphoma
574368|NCT00416624|stage IV adult immunoblastic large cell lymphoma
574369|NCT00416624|stage I adult lymphoblastic lymphoma
574370|NCT00416624|stage III adult lymphoblastic lymphoma
574371|NCT00416624|stage IV adult lymphoblastic lymphoma
574372|NCT00416624|stage I grade 1 follicular lymphoma
574373|NCT00416624|stage I grade 2 follicular lymphoma
574374|NCT00416624|stage I grade 3 follicular lymphoma
574375|NCT00416624|stage III grade 1 follicular lymphoma
574376|NCT00416624|stage III grade 2 follicular lymphoma
574377|NCT00416624|stage III grade 3 follicular lymphoma
574378|NCT00416624|stage IV grade 1 follicular lymphoma
574379|NCT00416624|stage IV grade 2 follicular lymphoma
574380|NCT00416624|stage IV grade 3 follicular lymphoma
574381|NCT00416624|stage I mantle cell lymphoma
574382|NCT00416624|stage I marginal zone lymphoma
574383|NCT00416624|stage III mantle cell lymphoma
574384|NCT00416624|stage III marginal zone lymphoma
574385|NCT00416624|stage IV mantle cell lymphoma
574386|NCT00416624|stage IV marginal zone lymphoma
574387|NCT00416624|stage I small lymphocytic lymphoma
574388|NCT00416624|stage III small lymphocytic lymphoma
574389|NCT00416624|stage IV small lymphocytic lymphoma
574390|NCT00416624|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
574391|NCT00416624|nodal marginal zone B-cell lymphoma
574392|NCT00416624|splenic marginal zone lymphoma
574393|NCT00416624|recurrent adult Burkitt lymphoma
574394|NCT00416624|recurrent adult diffuse large cell lymphoma
574395|NCT00416624|recurrent adult diffuse mixed cell lymphoma
574396|NCT00416624|recurrent adult diffuse small cleaved cell lymphoma
574397|NCT00416624|recurrent adult grade III lymphomatoid granulomatosis
574398|NCT00416624|recurrent adult immunoblastic large cell lymphoma
574399|NCT00416624|recurrent adult lymphoblastic lymphoma
574400|NCT00416624|recurrent grade 1 follicular lymphoma
574401|NCT00416624|recurrent grade 2 follicular lymphoma
574402|NCT00416624|recurrent grade 3 follicular lymphoma
574403|NCT00416624|recurrent mantle cell lymphoma
574404|NCT00416624|recurrent marginal zone lymphoma
574405|NCT00416624|recurrent small lymphocytic lymphoma
574406|NCT00416624|adult acute lymphoblastic leukemia in remission
574407|NCT00416624|recurrent adult acute lymphoblastic leukemia
574408|NCT00416624|untreated adult acute lymphoblastic leukemia
574409|NCT00416624|stage I chronic lymphocytic leukemia
574410|NCT00416624|stage II chronic lymphocytic leukemia
574411|NCT00416624|stage III chronic lymphocytic leukemia
574412|NCT00416624|stage IV chronic lymphocytic leukemia
574413|NCT00416624|refractory chronic lymphocytic leukemia
574414|NCT00416624|refractory hairy cell leukemia
574415|NCT00416624|progressive hairy cell leukemia, initial treatment
574416|NCT00416624|prolymphocytic leukemia
574417|NCT00416624|anemia
574418|NCT00416624|monoclonal gammopathy of undetermined significance
574419|NCT00416624|primary systemic amyloidosis
574420|NCT00416624|T-cell large granular lymphocyte leukemia
574421|NCT00416624|acute undifferentiated leukemia
574422|NCT00416624|mast cell leukemia
574423|NCT00416624|adult nasal type extranodal NK/T-cell lymphoma
574424|NCT00416624|untreated hairy cell leukemia
574425|NCT00416611|High blood pressure
574426|NCT00416611|Awareness
574427|NCT00416611|Treatment
574428|NCT00416611|Effective Control
574429|NCT00416611|Coronary heart disease risk reduction
574430|NCT00416611|Hypertension
574431|NCT00416585|acne
574432|NCT00416585|isotretinoin
574433|NCT00416585|calcium. vitamin D
574434|NCT00416572|psychosocial effects of cancer and its treatment
574435|NCT00416572|stage I breast cancer
574436|NCT00416572|stage II breast cancer
574437|NCT00416559|long-term effects secondary to cancer therapy in children
574438|NCT00416559|localized resectable neuroblastoma
574439|NCT00416559|localized unresectable neuroblastoma
574440|NCT00416559|regional neuroblastoma
574441|NCT00416546|Healthy Caucasians
574442|NCT00416546|Healthy Japanese subjects
574443|NCT00416546|Immunosuppressant
574444|NCT00416546|early T-cell activation blockers
574445|NCT00416546|inhibition of protein kinase C
574446|NCT00416533|recurrent prostate cancer
574447|NCT00416533|stage III prostate cancer
574448|NCT00416533|stage IV prostate cancer
574449|NCT00416533|adenocarcinoma of the prostate
574450|NCT00416520|Chronic Kidney Disease
574451|NCT00416520|Dialysis
574452|NCT00416520|Hyperphosphatemia
574453|NCT00416520|Phosphate binder
574454|NCT00416507|adenocarcinoma of the pancreas
574455|NCT00416507|stage III pancreatic cancer
574456|NCT00416507|stage II pancreatic cancer
574457|NCT00416494|adenocarcinoma of the colon
574458|NCT00416494|recurrent colon cancer
574459|NCT00416494|stage IV colon cancer
574460|NCT00416494|adenocarcinoma of the rectum
574461|NCT00416494|recurrent rectal cancer
574462|NCT00416494|stage IV rectal cancer
574463|NCT00416481|unspecified adult solid tumor, protocol specific
574464|NCT00416468|Aliskiren , Valsartan, bioavailability, hypertension
574465|NCT00416468|Healthy male and female subjects
574466|NCT00416442|healthy subjects, safety, tolerability, dose escalation, pharmacokinetics, benzodiazepine
574467|NCT00416442|Healthy male and female subjects
574468|NCT00416429|recurrent renal cell cancer
574469|NCT00416429|stage IV renal cell cancer
574470|NCT00416403|breast cancer in situ
574471|NCT00416403|ductal breast carcinoma in situ
574472|NCT00416403|stage IA breast cancer
574473|NCT00416403|stage IB breast cancer
574474|NCT00416390|benign prostatic hyperplasia
574475|NCT00416390|stage I prostate cancer
574476|NCT00416390|stage IIB prostate cancer
574477|NCT00416390|stage IIA prostate cancer
574478|NCT00416390|stage III prostate cancer
574479|NCT00416390|stage IV prostate cancer
574480|NCT00416377|stage I childhood Hodgkin lymphoma
574481|NCT00416377|stage II childhood Hodgkin lymphoma
574482|NCT00416377|stage III childhood Hodgkin lymphoma
574483|NCT00416377|stage IV childhood Hodgkin lymphoma
574484|NCT00416377|recurrent/refractory childhood Hodgkin lymphoma
574485|NCT00416364|hernia
574486|NCT00416364|inguinal
574487|NCT00416364|quality of life
574488|NCT00416351|anaplastic large cell lymphoma
574489|NCT00416351|angioimmunoblastic T-cell lymphoma
574490|NCT00416351|recurrent adult lymphoblastic lymphoma
574491|NCT00416351|recurrent adult T-cell leukemia/lymphoma
574492|NCT00416351|recurrent mycosis fungoides/Sezary syndrome
574493|NCT00416351|adult nasal type extranodal NK/T-cell lymphoma
574494|NCT00416351|prolymphocytic leukemia
574495|NCT00416351|childhood nasal type extranodal NK/T-cell lymphoma
574496|NCT00416351|recurrent childhood lymphoblastic lymphoma
574497|NCT00416351|recurrent cutaneous T-cell non-Hodgkin lymphoma
574498|NCT00416351|small intestine lymphoma
574499|NCT00416338|renal failure
574500|NCT00416338|infection
574501|NCT00416338|peritonitis
574502|NCT00416325|prostate cancer
574503|NCT00416312|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
574504|NCT00416312|nodal marginal zone B-cell lymphoma
574505|NCT00416312|recurrent adult Burkitt lymphoma
574506|NCT00416312|recurrent adult diffuse large cell lymphoma
574507|NCT00416312|recurrent adult diffuse small cleaved cell lymphoma
574508|NCT00416312|recurrent adult diffuse mixed cell lymphoma
574509|NCT00416312|recurrent adult immunoblastic large cell lymphoma
574510|NCT00416312|recurrent adult lymphoblastic lymphoma
574511|NCT00416312|recurrent grade 1 follicular lymphoma
574512|NCT00416312|recurrent grade 2 follicular lymphoma
574513|NCT00416312|recurrent grade 3 follicular lymphoma
574514|NCT00416312|recurrent mantle cell lymphoma
574515|NCT00416312|recurrent marginal zone lymphoma
574516|NCT00416312|recurrent small lymphocytic lymphoma
574517|NCT00416312|splenic marginal zone lymphoma
574518|NCT00416312|stage III adult Burkitt lymphoma
574519|NCT00416312|stage III adult diffuse large cell lymphoma
574520|NCT00416312|stage III adult diffuse mixed cell lymphoma
574521|NCT00416312|stage III adult diffuse small cleaved cell lymphoma
574522|NCT00416312|stage III adult immunoblastic large cell lymphoma
574523|NCT00416312|stage III adult lymphoblastic lymphoma
574524|NCT00416312|stage III grade 1 follicular lymphoma
574525|NCT00416312|stage III grade 2 follicular lymphoma
574526|NCT00416312|stage III grade 3 follicular lymphoma
574527|NCT00416312|stage III mantle cell lymphoma
574528|NCT00416312|stage III marginal zone lymphoma
574529|NCT00416312|stage III small lymphocytic lymphoma
574530|NCT00416312|stage IV adult Burkitt lymphoma
574531|NCT00416312|stage IV adult diffuse large cell lymphoma
574532|NCT00416312|stage IV adult diffuse small cleaved cell lymphoma
574533|NCT00416312|stage IV adult diffuse mixed cell lymphoma
574534|NCT00416312|stage IV adult immunoblastic large cell lymphoma
574535|NCT00416312|stage IV adult lymphoblastic lymphoma
574536|NCT00416312|stage IV grade 1 follicular lymphoma
574537|NCT00416312|stage IV grade 2 follicular lymphoma
574538|NCT00416312|stage IV grade 3 follicular lymphoma
574539|NCT00416312|stage IV mantle cell lymphoma
574540|NCT00416312|stage IV marginal zone lymphoma
574541|NCT00416312|stage IV small lymphocytic lymphoma
574542|NCT00416312|Waldenström macroglobulinemia
574543|NCT00416312|contiguous stage II adult Burkitt lymphoma
574544|NCT00416312|contiguous stage II adult diffuse large cell lymphoma
574545|NCT00416312|contiguous stage II adult diffuse mixed cell lymphoma
574546|NCT00416312|contiguous stage II adult diffuse small cleaved cell lymphoma
574547|NCT00416312|contiguous stage II adult immunoblastic large cell lymphoma
574548|NCT00416312|contiguous stage II adult lymphoblastic lymphoma
574549|NCT00416312|contiguous stage II grade 1 follicular lymphoma
574550|NCT00416312|contiguous stage II grade 2 follicular lymphoma
574551|NCT00416312|contiguous stage II grade 3 follicular lymphoma
574552|NCT00416312|contiguous stage II mantle cell lymphoma
574553|NCT00416312|contiguous stage II marginal zone lymphoma
574554|NCT00416312|contiguous stage II small lymphocytic lymphoma
574555|NCT00416312|noncontiguous stage II adult Burkitt lymphoma
574556|NCT00416312|noncontiguous stage II adult diffuse large cell lymphoma
574557|NCT00416312|noncontiguous stage II adult diffuse mixed cell lymphoma
574558|NCT00416312|noncontiguous stage II adult diffuse small cleaved cell lymphoma
574559|NCT00416312|noncontiguous stage II adult immunoblastic large cell lymphoma
574560|NCT00416312|noncontiguous stage II adult lymphoblastic lymphoma
574561|NCT00416312|noncontiguous stage II grade 1 follicular lymphoma
574562|NCT00416312|noncontiguous stage II grade 2 follicular lymphoma
574563|NCT00416312|noncontiguous stage II grade 3 follicular lymphoma
574564|NCT00416312|noncontiguous stage II mantle cell lymphoma
574565|NCT00416312|noncontiguous stage II marginal zone lymphoma
574566|NCT00416312|noncontiguous stage II small lymphocytic lymphoma
574567|NCT00416312|stage I adult Burkitt lymphoma
574568|NCT00416312|stage I adult diffuse large cell lymphoma
574569|NCT00416312|stage I adult diffuse mixed cell lymphoma
574570|NCT00416312|stage I adult diffuse small cleaved cell lymphoma
574571|NCT00416312|stage I adult immunoblastic large cell lymphoma
574572|NCT00416312|stage I adult lymphoblastic lymphoma
574573|NCT00416312|stage I grade 1 follicular lymphoma
574574|NCT00416312|stage I grade 2 follicular lymphoma
574575|NCT00416312|stage I grade 3 follicular lymphoma
574576|NCT00416312|stage I mantle cell lymphoma
574577|NCT00416312|stage I marginal zone lymphoma
574578|NCT00416312|stage I small lymphocytic lymphoma
574579|NCT00416312|adult grade III lymphomatoid granulomatosis
574580|NCT00416312|recurrent adult grade III lymphomatoid granulomatosis
574581|NCT00416312|primary central nervous system non-Hodgkin lymphoma
574582|NCT00416312|adult nasal type extranodal NK/T-cell lymphoma
574583|NCT00416299|Cardiac biomarker
574584|NCT00416299|cardiac surgery
574585|NCT00416299|elderly
574586|NCT00416299|postoperative complications
574587|NCT00416299|Patients aged 75 years or older undergoing cardiac surgery
574588|NCT00415584|hypercalcemia
574589|NCT00415584|transplant
574590|NCT00415571|Hypogonadism
574591|NCT00415571|Erectile Dysfunction
574592|NCT00415558|Atrial Fibrillation
574593|NCT00415545|Heart Failure
574594|NCT00415545|Patient Education
574595|NCT00415532|splenectomy
574596|NCT00415532|platelet
574597|NCT00415532|AMG 531
574598|NCT00415532|thrombopoietin
574599|NCT00415532|blood disorder
574600|NCT00415532|bleeding disorder
574601|NCT00415532|immune thrombocytopenic purpura
574602|NCT00415532|idiopathic thrombocytopenic purpura
574603|NCT00415532|immune (idiopathic) thrombocytopenic purpura
574604|NCT00415532|TPO
574605|NCT00415532|thrombopoietic protein
574606|NCT00415519|Amyotrophic lateral sclerosis
574607|NCT00415519|free radical scavenger
574608|NCT00415493|rhinitis
574609|NCT00415493|non-allergic rhinitis
574610|NCT00415493|rhinomanometry
574611|NCT00415493|cold air
574612|NCT00415493|triggers: cold, dry air inhalation
574613|NCT00415493|warm, most air inhalation
574614|NCT00415493|Nonallergic rhinitis; normal controls
574615|NCT00415467|Brain Tumor
574616|NCT00415467|Radiation Therapy System
574617|NCT00415467|GliaSite RTS
574618|NCT00415454|Pancreatic Cancer
574619|NCT00415441|physiotherapy
574620|NCT00415441|exercise
574621|NCT00415441|manual therapy
574622|NCT00415441|shoulder pain
574623|NCT00415441|rotator cuff
574624|NCT00415415|Racial Disparities
574625|NCT00415415|Psychosocial Risk Factors
574626|NCT00415415|Neighborhood Socioeconomic Status
574627|NCT00415415|CVD
574628|NCT00415415|CHD
574629|NCT00415402|Vitamin D3
574630|NCT00415402|morbidity
574631|NCT00415402|mortality
574632|NCT00415402|low birth weight
574633|NCT00415402|supplementation
574634|NCT00415402|TH1
574635|NCT00415402|TH2
574636|NCT00415402|CRP
574637|NCT00415402|Neopterin
574638|NCT00415402|immune response
574639|NCT00415389|Stroke
574640|NCT00415389|interactive educational program
574641|NCT00415389|acute ischemic stroke
574642|NCT00415376|seizure
574643|NCT00415376|adult tumors metastatic to brain
574644|NCT00415376|unspecified adult solid tumor, protocol specific
574645|NCT00415350|Bronchiectasis
574646|NCT00415350|Macrolide
574647|NCT00415350|Azithromycin
574648|NCT00415350|Antibiotic prophylaxis
574649|NCT00415350|Immunomodulation
574650|NCT00415350|Inflammation
574651|NCT00415350|Lung function
574652|NCT00415350|Sputum
574653|NCT00415350|Bacterial colonization
574654|NCT00416286|Cetylpyridinium chlorid
574655|NCT00416286|Sustained release
574656|NCT00416286|orthodontic patients
574657|NCT00416286|streptococcus mutans
574658|NCT00416286|Lactobacillus
574659|NCT00416286|Rate of bacterial load in saliva of orthodontic patients
574660|NCT00416273|Multiple Myeloma
574661|NCT00416273|Bortezomib
574662|NCT00416273|PS341
574663|NCT00416273|Proteasome inhibitor
574664|NCT00416273|Consolidation therapy
574665|NCT00416260|Respiratory Distress Syndrome, Adult
574666|NCT00416260|High-Frequency Ventilation
574667|NCT00416260|Respiration, Artificial
574668|NCT00416247|Hypnosis
574669|NCT00416247|TMS
574670|NCT00416247|Cortical excitability
574671|NCT00416221|Depression
574672|NCT00416221|Lexapro
574673|NCT00416208|Multiple Myeloma
574674|NCT00416208|Clinical trial
574675|NCT00416208|Bortezomib
574676|NCT00416208|PS341
574677|NCT00416208|Proteasome inhibitor
574678|NCT00416208|Consolidation therapy
574679|NCT00416182|Cystic fibrosis
574680|NCT00416182|chronic sinusitis
574681|NCT00416182|mucolytic
574682|NCT00416169|Frontotemporal Dementia
574683|NCT00416169|Pick Complex
574684|NCT00416169|galantamine hydrobromide
574685|NCT00416156|Obesity
574686|NCT00416156|Inflammation
574687|NCT00416143|Bed rest for idiopathic sudden sensorineural hearing loss
574688|NCT00416130|Phase I/II Clinical Trial
574689|NCT00416130|Vorinostat
574690|NCT00416130|SAHA
574691|NCT00416130|Recurrent Breast Cancer
574692|NCT00416130|Metastatic Breast Cancer
574693|NCT00416117|Neck pain
574694|NCT00416117|Cervical pain
574695|NCT00416117|Radicular pain
574696|NCT00416117|Manual therapy
574697|NCT00416117|Mobilization
574698|NCT00416117|Manipulation
574699|NCT00416104|analgesia
574700|NCT00416091|Tourette disorder, ADHD, comorbidity, neuropsychological
574701|NCT00416078|technology development and assessment
574702|NCT00416078|internet
574703|NCT00416078|randomized control trial
574704|NCT00416052|calcium
574705|NCT00416052|calciuria
574706|NCT00416052|PTH
574707|NCT00416052|1,25-vitamin D
574708|NCT00416052|Calcitriol
574709|NCT00416052|bone mineral density
574710|NCT00416052|osteodensitometry
574711|NCT00416039|midazolam
574712|NCT00416039|sublingual
574713|NCT00416039|oral morphine
574714|NCT00416039|children
574715|NCT00416039|bone fracture
574716|NCT00416039|bone fracture with a deformed member
574717|NCT00416026|Quality improvement
574718|NCT00416026|Patient-centered care
574719|NCT00416026|Acute coronary syndrome
574720|NCT00416026|Telephone counseling
574721|NCT00416013|Beta Natriuretic Peptide
574722|NCT00416013|Troponin
574723|NCT00416013|Hemodialysis
574724|NCT00416000|Open/Elective EVAR patients
574725|NCT00415987|Multiple Myeloma
574726|NCT00415974|Weight Loss
574727|NCT00415974|Obesity
574728|NCT00415974|Overweight
574729|NCT00415974|Physical Activity
574730|NCT00415974|Nutrition
574731|NCT00415974|Primary Care Physicians
574732|NCT00415974|Primary Care
574733|NCT00415974|Counseling
574734|NCT00415974|Adolescent
574735|NCT00415961|Percutaneous Coronary Intervention (PCI)
574736|NCT00415961|Drug-eluting stent (DES)
574737|NCT00415948|Heart
574738|NCT00415948|Cardiac
574739|NCT00415948|Acute Coronary Syndrome
574740|NCT00415948|Sample Procurement
574741|NCT00415922|Bioequivalence
574742|NCT00415922|bioavailability
574743|NCT00415922|carbidopa
574744|NCT00415922|levodopa
574745|NCT00415922|entacapone
574746|NCT00415922|fasting condition
574747|NCT00415922|Healthy volunteers study
574748|NCT00415909|Leukemia
574749|NCT00415909|Chronic Myelogenous Leukemia
574750|NCT00415909|CML
574751|NCT00415909|Imatinib
574752|NCT00415909|Gleevec
574753|NCT00415909|TALL-104
574754|NCT00415896|weaning
574755|NCT00415896|work of breathing
574756|NCT00415896|spontaneous breathing trial
574757|NCT00415896|rapid shallow breathing
574758|NCT00415883|Relative bioavailability, formulation, Japanese, valsartan, healthy subjects
574759|NCT00415870|Overweight
574760|NCT00415870|Cell Phone
574761|NCT00415870|Technology
574762|NCT00415857|Chronic Myelogenous Leukemia
574763|NCT00415857|Leukemia
574764|NCT00415857|Peptide Vaccine
574765|NCT00415857|PR1 Peptide
574766|NCT00415857|Imatinib
574767|NCT00415857|Gleevec
574768|NCT00415857|GM-CSF
574769|NCT00415857|Sargramostim
574770|NCT00415857|Leukine
574771|NCT00415857|Peginterferon alfa-2b
574772|NCT00415857|Peg-Intron
574773|NCT00415844|Bioequivalence
574774|NCT00415844|bioavailability
574775|NCT00415844|carbidopa
574776|NCT00415844|levodopa
574777|NCT00415844|entacapone
574778|NCT00415844|fasting condition
574779|NCT00415844|Healthy volunteers study
574780|NCT00415831|Bioequivalence
574781|NCT00415831|bioavailability
574782|NCT00415831|carbidopa
574783|NCT00415831|levodopa
574784|NCT00415831|entacapone
574785|NCT00415831|fed condition
574786|NCT00415831|Healthy volunteers study
574787|NCT00415818|Lung Cancer
574788|NCT00415818|NSCLC
574789|NCT00415818|Cancer Vaccine
574790|NCT00415818|Stage IV Non-Small Cell Lung Cancer
574791|NCT00415818|Stage IIIb Non-Small Cell Lung Cancer with effusion
574792|NCT00415792|Ovulation induction
574793|NCT00415792|hCG
574794|NCT00415792|GnRH agonist
574795|NCT00415792|hyper-responders
574796|NCT00415779|hormone refractory
574797|NCT00415779|bone metastasis
574798|NCT00415779|chemotherapy
574799|NCT00415779|biphosphonates
574800|NCT00415766|recombinant hCG
574801|NCT00415766|urinary hCG
574802|NCT00415740|Bioequivalence
574803|NCT00415740|bioavailability
574804|NCT00415740|carbidopa
574805|NCT00415740|levodopa
574806|NCT00415740|entacapone
574807|NCT00415740|fasting
574808|NCT00415740|Healthy volunteers study
574809|NCT00415714|Primary Insomnia
574810|NCT00415714|Chronic Insomnia
574811|NCT00415714|Biofeedback
574812|NCT00415714|Sleeplessness
574813|NCT00415701|Etomidate
574814|NCT00415701|Propofol
574815|NCT00415701|Adrenocortical Insufficiency
574816|NCT00415701|Hemodynamic Process
574817|NCT00415701|Vasoactive Agonists
574818|NCT00415701|Coronary Artery Bypass
574819|NCT00415701|Ischemic Coronary Heart Disease
574820|NCT00415701|Mitral valve reconstruction/replacement
574821|NCT00415701|Mitral valve regurgitation
574822|NCT00415701|Heart Valve Prosthesis
574823|NCT00415701|Cardiopulmonary Bypass
574824|NCT00415688|lifestyle modification
574825|NCT00415688|weight loss
574826|NCT00415688|hyperglycemia
574827|NCT00415688|hypoglycemic agents
574828|NCT00415675|Lung Cancer
574829|NCT00415675|Abdominal Cancer
574830|NCT00415675|Tissue Motion
574831|NCT00415675|Breathing
574832|NCT00415675|Motion CT Scans
574833|NCT00415649|HIV Preventive Vaccine
574834|NCT00415649|HIV Seronegativity
574835|NCT00415610|cerebral hemorrhage
574836|NCT00415610|intracerebral hemorrhage
574837|NCT00415610|stroke
574838|NCT00415610|hypertension
574839|NCT00415610|blood pressure
574840|NCT00415610|nicardipine
574841|NCT00415610|antihypertensive agent
574842|NCT00415610|hematoma expansion
574843|NCT00415597|chronic pain
574844|NCT00415597|joint pain
574845|NCT00415597|back pain
574846|NCT00415597|diabetic peripheral neuropathy
574847|NCT00415597|post herpetic neuralgia
574848|NCT00415597|ALO-01
574849|NCT00415597|Embeda
574850|NCT00415597|Chronic Non-Malignant Pain
574851|NCT00415337|lung
574852|NCT00415337|neoplasm
574853|NCT00415337|bronchoscopy
574854|NCT00415337|ultrasonography
574855|NCT00415337|histology
574856|NCT00415311|Liver Transplantation
574857|NCT00415311|rhMBL
574858|NCT00415298|recurrent squamous cell carcinoma of the hypopharynx
574859|NCT00415298|recurrent squamous cell carcinoma of the larynx
574860|NCT00415298|recurrent squamous cell carcinoma of the lip and oral cavity
574861|NCT00415298|recurrent squamous cell carcinoma of the nasopharynx
574862|NCT00415298|recurrent squamous cell carcinoma of the oropharynx
574863|NCT00415298|stage III squamous cell carcinoma of the hypopharynx
574864|NCT00415298|stage III squamous cell carcinoma of the larynx
574865|NCT00415298|stage III squamous cell carcinoma of the lip and oral cavity
574866|NCT00415298|stage III squamous cell carcinoma of the nasopharynx
574867|NCT00415298|stage III squamous cell carcinoma of the oropharynx
574868|NCT00415298|stage IV squamous cell carcinoma of the hypopharynx
574869|NCT00415298|stage IV squamous cell carcinoma of the larynx
574870|NCT00415298|stage IV squamous cell carcinoma of the lip and oral cavity
574871|NCT00415298|stage IV squamous cell carcinoma of the nasopharynx
574872|NCT00415298|stage IV squamous cell carcinoma of the oropharynx
574873|NCT00415285|Breast
574874|NCT00415285|Cancer
574875|NCT00415285|Early-Stage
574876|NCT00415285|Chemotherapy
574877|NCT00415233|stage I follicular thyroid cancer
574878|NCT00415233|stage I papillary thyroid cancer
574879|NCT00415233|stage II follicular thyroid cancer
574880|NCT00415233|stage II papillary thyroid cancer
574881|NCT00415233|stage III follicular thyroid cancer
574882|NCT00415233|stage III papillary thyroid cancer
574883|NCT00415233|stage IV follicular thyroid cancer
574884|NCT00415233|stage IV papillary thyroid cancer
574885|NCT00415220|Chiropractic
574886|NCT00415220|Manipulation
574887|NCT00415220|Back surgery
574888|NCT00415220|Herniated lumbar disc
574889|NCT00415220|Sciatica
574890|NCT00415220|Lumbar microdiscectomy
574891|NCT00415220|Cost-effectiveness
574892|NCT00415207|CYP2C8
574893|NCT00415207|MDR1
574894|NCT00415207|Pharmacogenetics
574895|NCT00415207|Paclitaxel
574896|NCT00415181|CYP2C8
574897|NCT00415181|MDR1
574898|NCT00415181|Pharmacogenetics
574899|NCT00415181|Paclitaxel
574900|NCT00415142|Depression
574901|NCT00415142|Major depressive disorders
574902|NCT00415142|Controlled clinical trial
574903|NCT00415129|Influenza
574904|NCT00415129|Orthomyxoviridae Infections
574905|NCT00415129|Influenza Pandemics
574906|NCT00415129|A/H5N1 strain
574907|NCT00415116|unspecified adult solid tumor, protocol specific
574908|NCT00415103|Emesis
574909|NCT00415103|Nausea
574910|NCT00415103|leukemia
574911|NCT00415103|lymphoma
574912|NCT00415090|Nevirapine
574913|NCT00415090|Antiretroviral treatment
574914|NCT00415090|Triple nucleoside therapy
574915|NCT00415090|HIV
574916|NCT00415090|Treatment Experienced
574917|NCT00415064|Multiple Myeloma
574918|NCT00415064|Perifosine
574919|NCT00415064|Lenalidomide
574920|NCT00415064|Dexamethasone
574921|NCT00415051|Rift Valley Fever, vaccine
574922|NCT00415038|hypertension
574923|NCT00415038|pharmacogenomic
574924|NCT00415038|adducin
574925|NCT00415038|ouabain
574926|NCT00415038|rostafuroxin
574927|NCT00415025|long-term effects secondary to cancer therapy in adults
574928|NCT00415025|oral complications of radiation therapy
574929|NCT00415025|radiation toxicity
574930|NCT00415025|stage III squamous cell carcinoma of the hypopharynx
574931|NCT00415025|stage IV squamous cell carcinoma of the hypopharynx
574932|NCT00415025|stage III squamous cell carcinoma of the larynx
574933|NCT00415025|stage III verrucous carcinoma of the larynx
574934|NCT00415025|stage IV squamous cell carcinoma of the larynx
574935|NCT00415025|stage IV verrucous carcinoma of the larynx
574936|NCT00415025|stage III lymphoepithelioma of the oropharynx
574937|NCT00415025|stage III squamous cell carcinoma of the oropharynx
574938|NCT00415025|stage IV lymphoepithelioma of the oropharynx
574939|NCT00415025|stage IV squamous cell carcinoma of the oropharynx
574940|NCT00415025|stage III basal cell carcinoma of the lip
574941|NCT00415025|stage III squamous cell carcinoma of the lip and oral cavity
574942|NCT00415025|stage IV basal cell carcinoma of the lip
574943|NCT00415025|stage IV squamous cell carcinoma of the lip and oral cavity
574944|NCT00415025|stage III adenoid cystic carcinoma of the oral cavity
574945|NCT00415025|stage III mucoepidermoid carcinoma of the oral cavity
574946|NCT00415025|stage III verrucous carcinoma of the oral cavity
574947|NCT00415025|stage IV adenoid cystic carcinoma of the oral cavity
574948|NCT00415025|stage IV mucoepidermoid carcinoma of the oral cavity
574949|NCT00415025|stage IV verrucous carcinoma of the oral cavity
574950|NCT00415025|metastatic squamous neck cancer with occult primary
574951|NCT00415025|stage III lymphoepithelioma of the nasopharynx
574952|NCT00415025|stage III squamous cell carcinoma of the nasopharynx
574953|NCT00415025|stage IV lymphoepithelioma of the nasopharynx
574954|NCT00415025|stage IV squamous cell carcinoma of the nasopharynx
574955|NCT00415025|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
574956|NCT00415025|stage III inverted papilloma of the paranasal sinus and nasal cavity
574957|NCT00415025|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
574958|NCT00415025|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
574959|NCT00415025|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
574960|NCT00415025|stage IV inverted papilloma of the paranasal sinus and nasal cavity
574961|NCT00415025|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
574962|NCT00415025|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
574963|NCT00415025|stage III salivary gland cancer
574964|NCT00415025|stage IV salivary gland cancer
574965|NCT00415025|recurrent salivary gland cancer
574966|NCT00415025|recurrent lymphoepithelioma of the nasopharynx
574967|NCT00415025|recurrent lymphoepithelioma of the oropharynx
574968|NCT00415025|recurrent squamous cell carcinoma of the hypopharynx
574969|NCT00415025|recurrent squamous cell carcinoma of the larynx
574970|NCT00415025|recurrent squamous cell carcinoma of the nasopharynx
574971|NCT00415025|recurrent squamous cell carcinoma of the oropharynx
574972|NCT00415025|recurrent verrucous carcinoma of the larynx
574973|NCT00415025|recurrent adenoid cystic carcinoma of the oral cavity
574974|NCT00415025|recurrent mucoepidermoid carcinoma of the oral cavity
574975|NCT00415025|recurrent verrucous carcinoma of the oral cavity
574976|NCT00415025|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
574977|NCT00415025|recurrent inverted papilloma of the paranasal sinus and nasal cavity
574978|NCT00415025|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
574979|NCT00415025|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
574980|NCT00415025|recurrent basal cell carcinoma of the lip
574981|NCT00415025|recurrent squamous cell carcinoma of the lip and oral cavity
574982|NCT00415025|recurrent metastatic squamous neck cancer with occult primary
574983|NCT00415025|untreated metastatic squamous neck cancer with occult primary
574984|NCT00414999|Macular degeneration
574985|NCT00414999|Vascular diseases
574986|NCT00414999|Retinal disorders
574987|NCT00414999|Macular edema
574988|NCT00414960|Healthy
574989|NCT00414960|Prevention
574990|NCT00414947|Bioequivalence
574991|NCT00414947|safety
574992|NCT00414947|LAF237
574993|NCT00414947|vildagliptin
574994|NCT00414947|Chinese
574995|NCT00414947|healthy subjects
574996|NCT00414934|cancer
574997|NCT00414934|bone scan
574998|NCT00414934|NaF bone PET
574999|NCT00414921|Attention deficit hyperactivity disorder
575000|NCT00414921|ADHD
575001|NCT00414921|clonidine
575002|NCT00414921|methylphenidate
575003|NCT00414921|MPH
575004|NCT00414908|Chronic Pancreatitis
575005|NCT00414908|Pancreatectomy
575006|NCT00414908|Pancreatic Exocrine Insufficiency
575007|NCT00414882|TB, tuberculosis, Mycobacterium tuberculosis, Brazil
575008|NCT00414869|Liver
575009|NCT00414869|Portal pressure
575010|NCT00414869|Fibrosis
575011|NCT00414869|Nitric oxide
575012|NCT00414856|GERD
575013|NCT00414856|gastroesophageal reflux disease
575014|NCT00414856|meal-induced gastroesophageal reflux events
575015|NCT00414843|Storage
575016|NCT00414843|Bile
575017|NCT00414843|Biomarkers
575018|NCT00414843|biliary malignancies
575019|NCT00414830|prevention
575020|NCT00414830|health technology assessment
575021|NCT00414830|population based
575022|NCT00414830|fracture
575023|NCT00414817|Inhaled Corticosteroids
575024|NCT00414817|ICS
575025|NCT00414817|Adherence
575026|NCT00414804|Pain
575027|NCT00414804|Neurostimulation
575028|NCT00414778|Safety, pharmacokinetics, oral, single dose, multiple dose, LHT344, Chinese, healthy subjects
575029|NCT00414765|Metastatic Renal Cell Carcinoma
575030|NCT00414765|Metastatic Melanoma
575031|NCT00414765|Aldesleukin
575032|NCT00414765|IL-2
575033|NCT00414752|Smoking, abstinence, craving, smoker, AFQ056, nicotine, placebo
575034|NCT00414739|growth of dendritic cells
575035|NCT00414739|prevention
575036|NCT00414726|ischemic stroke
575037|NCT00414726|normobaric oxygen therapy
575038|NCT00414713|Upper GI bleeding
575039|NCT00414713|Cirrhosis
575040|NCT00414713|Portal hypertension
575041|NCT00414713|Non-variceal bleeding
575042|NCT00414713|Transfusion
575043|NCT00414700|Cartilage
575044|NCT00414700|Articular
575045|NCT00414700|Femoral
575046|NCT00414700|Knee
575047|NCT00414687|Primary or secondary Pulmonary hypertension
575048|NCT00414687|Iloprost
575049|NCT00414687|Inhaled
575050|NCT00414687|Long-term treatment
575051|NCT00414661|Observational non-interventional long-term safety
575052|NCT00414648|Lymphangiomyomatosis
575053|NCT00414648|Lung Disease
575054|NCT00414635|HIV/AIDS
575055|NCT00414635|efavirenz
575056|NCT00414635|tenofovir
575057|NCT00414635|emtricitabine
575058|NCT00414635|FOTO
575059|NCT00414635|treatment interruption
575060|NCT00414635|Atripla
575061|NCT00414635|Truvada
575062|NCT00414635|Treatment Experienced
575063|NCT00414622|Alzheimer
575064|NCT00414622|Probable Alzheimer disease
575065|NCT00414609|myocardial infarction, aliskiren, heart failure
575066|NCT00414609|Post acute myocardial infarction with systolic dysfunction
575067|NCT00414583|Cerebrovascular Accident
575068|NCT00414583|Cerebrovascular Accident, Acute
575069|NCT00414583|CVA (Cerebrovascular Accident)
575070|NCT00414583|Cerebral Stroke
575071|NCT00414583|Stroke, Acute
575072|NCT00414583|Cerebrovascular Stroke
575073|NCT00414583|Fabry Disease
575074|NCT00414583|Anderson-Fabry Disease
575075|NCT00414583|Fabry's Disease
575076|NCT00414570|Positron Emission Tomography (PET)
575077|NCT00414570|3'-deoxy-3'(18F)fluorothymidine ([18F]FLT)
575078|NCT00414557|Musculoskeletal diseases
575079|NCT00414557|Joint diseases
575080|NCT00414544|Nasolabial folds
575081|NCT00414544|Dermal filler
575082|NCT00414544|Injectable dermal filler
575083|NCT00414544|Soft tissue augmentation
575084|NCT00414518|Acute Infection
575085|NCT00414518|Early HIV Infection
575086|NCT00414518|Short-Term Antiretroviral Therapy
575087|NCT00414518|Treatment Interruption
575088|NCT00414518|Antiretroviral Drug (ARV)
575089|NCT00414518|ART
575090|NCT00414492|metastatic colorectal cancer
575091|NCT00414492|liver metastasis
575092|NCT00414492|tumor margins
575093|NCT00414492|neoadjuvant therapy
575094|NCT00414479|schistosomiasis
575095|NCT00414479|anaemia
575096|NCT00414479|malaria
575097|NCT00414479|iron deficiency
575098|NCT00414453|Neuropathic pain
575099|NCT00414453|Chronic pain
575100|NCT00414453|Multiple sclerosis
575101|NCT00414453|Central neuropathic pain
575102|NCT00414453|Peripheral neuropathic pain
575103|NCT00414453|Opioid analgesic
575104|NCT00414453|Lidocaine
575105|NCT00414440|end-stage renal disease, ESRD, autosomal dominant polycystic kidney disease, ADPKD, everolimus
575106|NCT00414427|Knee Osteoarthritis
575107|NCT00414427|Ultrasonography
575108|NCT00414427|Corticosteroids
575109|NCT00414414|TB
575110|NCT00414414|Tuberculosis
575111|NCT00414414|HIV
575112|NCT00414414|Co-infection
575113|NCT00414414|Steroid
575114|NCT00414414|Prednisone
575115|NCT00414414|oral corticosteroids
575116|NCT00414414|TB Treatment
575117|NCT00414414|South Africa
575118|NCT00414388|AIPC
575119|NCT00414375|Perforated Appendicitis
575120|NCT00414375|Abscess
575121|NCT00414375|Appendectomy
575122|NCT00414362|Bacteremia
575123|NCT00414362|Urinary Tract Infections
575124|NCT00414362|Fluoroquinolone
575125|NCT00414349|Topical analgesic
575126|NCT00414349|Multiple dose
575127|NCT00414336|Blood Stage
575128|NCT00414336|Investigational
575129|NCT00414336|Endemic
575130|NCT00414336|Malaria
575131|NCT00414310|Decitabine
575132|NCT00414310|Dacogen
575133|NCT00414310|5-AZA
575134|NCT00414310|Valproic Acid
575135|NCT00414310|Myelodysplastic Syndrome
575136|NCT00414310|Acute Myelogenous Leukemia
575137|NCT00414310|MDS
575138|NCT00414310|AML
575139|NCT00414297|CAD
575140|NCT00414297|ECP
575141|NCT00414297|CFI
575142|NCT00414297|CPI
575143|NCT00414297|MPR
575144|NCT00414284|HIV/AIDS
575145|NCT00414284|viremia
575146|NCT00414284|Kaletra
575147|NCT00414284|pharmacokinetics
575148|NCT00414284|viral load
575149|NCT00414284|LPV/r
575150|NCT00414284|Treatment Experienced
575151|NCT00414271|gastric cancer, neo-adjuvant chemotherapy
575152|NCT00414258|Pain Response
575153|NCT00414232|Rectal Cancer
575154|NCT00414232|Chemoradiation
575155|NCT00414232|Rectal Cancer receiving chemoradiation.
575156|NCT00414206|AMD
575157|NCT00414206|Wet AMD
575158|NCT00414193|AmpC beta-lactamase
575159|NCT00414193|Bacteremia
575160|NCT00414193|Piperacillin
575161|NCT00414193|Tazobactam
575162|NCT00414167|Binge eating
575163|NCT00414167|Obesity
575164|NCT00414167|Medication
575165|NCT00414167|Craving
575166|NCT00414167|Emotional eating
575167|NCT00414154|Group based patient education,
575168|NCT00414154|multidisciplinary,
575169|NCT00414154|physical activity,
575170|NCT00414154|adherence to treatment,
575171|NCT00414154|quality of life
575172|NCT00414141|Allergy
575173|NCT00414141|Allergoid
575174|NCT00414141|Specific Immunotherapy
575175|NCT00414128|vasculitis
575176|NCT00414128|ANCA
575177|NCT00414128|mycophenolate mofetil
575178|NCT00414128|cyclophosphamide
575179|NCT00414128|Anti neutrophil cytoplasm antibody associated vasculitis
575180|NCT00414115|Observational controlled study
575181|NCT00414115|Genomic biomarkers
575182|NCT00414115|Adverse drug reaction
575183|NCT00414115|In children OR adults
575184|NCT00414102|Chronic Insomnia
575185|NCT00414102|Sleep Initiation and Maintenance Disorder
575186|NCT00414102|Drug Therapy
575187|NCT00414076|Uterine Leiomyosarcoma
575188|NCT00414076|Uterine Neoplasm
575189|NCT00414076|Uterine Sarcomas
575190|NCT00414076|Uterine Cancer
575191|NCT00414076|Uterus
575192|NCT00414076|LMS
575193|NCT00414076|ER Positivity
575194|NCT00414076|Femara
575195|NCT00414076|Letrozole
575196|NCT00414063|Fecal Energy
575197|NCT00414063|Urine Energy
575198|NCT00414063|Bomb Calorimetry
575199|NCT00414063|Gut Maintenance Flora
575200|NCT00414063|Obesity
575201|NCT00414063|Energy Metabolism
575202|NCT00414037|insomnia
575203|NCT00414037|lunesta
575204|NCT00414037|eszopiclone
575205|NCT00414037|pain
575206|NCT00414037|fMRI
575207|NCT00414024|Opioid, constipation, tegaserod
575208|NCT00414011|Removal of corneal epithelium followed by excimer laser treatment during prk
575209|NCT00413998|Functional ischaemic mitral regurgitation
575210|NCT00413985|Low Birth Weight
575211|NCT00413985|Fortified Human Milk
575212|NCT00413985|breastfeeding
575213|NCT00413985|infants
575214|NCT00413985|growth
575215|NCT00413959|NHL
575216|NCT00413946|Premature infant
575217|NCT00413946|developmental outcome
575218|NCT00413933|falls
575219|NCT00413933|prevention
575220|NCT00413933|elderly
575221|NCT00413933|multidisciplinary intervention
575222|NCT00413933|health care utilization
575223|NCT00413920|Steroids avoidance,
575224|NCT00413920|enteric-coated mycophenolate sodium (EC-MPS),
575225|NCT00413920|de novo renal transplantation
575226|NCT00413881|Residual refractive error left over from initial LASIK correction.
575227|NCT00413881|Higher Order aberrations measured using a wavefront analyzer.
575228|NCT00413868|Myopia with our without astigmatism
575229|NCT00413855|Abdominal pain
575230|NCT00413855|Appendectomy
575231|NCT00413855|Laparoscopy
575232|NCT00413855|Chronic appendicitis
575233|NCT00413855|Appendicopathy
575234|NCT00413842|Transcranial Direct Current Stimulation (tDCS)
575235|NCT00413842|Plasticity
575236|NCT00413842|Primary Motor Cortex
575237|NCT00413842|Cerebellum
575238|NCT00413842|Transcranial Magnetic Stimulation (TMS)
575239|NCT00413842|Healthy Volunteer
575240|NCT00413842|HV
575241|NCT00413829|age related macular degeneration
575242|NCT00413829|anti-VEGF therapy
575243|NCT00413816|Anemia
575244|NCT00413816|Critically ill
575245|NCT00413803|Hemodialysis
575246|NCT00413803|Nocturnal dialysis
575247|NCT00413803|Cardiovascular disease
575248|NCT00413803|Quality of Life
575249|NCT00413803|left ventricular hypertrophy
575250|NCT00413790|Heart rate, overactive bladder
575251|NCT00413751|Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia
575252|NCT00413738|Central venous catheter
575253|NCT00413738|Catheter related bloodstream infection
575254|NCT00413738|Heparin
575255|NCT00413738|Chlorhexidine
575256|NCT00413738|Sulfadiazine
575257|NCT00413725|HIV Seronegativity
575258|NCT00413725|HIV Preventive Vaccine
575259|NCT00413725|Adenovirus
575260|NCT00413712|Supraventricular Tachycardia
575261|NCT00413712|Calcium Channel Blockers
575262|NCT00413712|Verapamil
575263|NCT00413712|Diltiazem
575264|NCT00413712|Adenosine
575265|NCT00413699|long-term
575266|NCT00413699|open-label
575267|NCT00413699|safety
575268|NCT00413686|Mixed solid tumors
575269|NCT00413673|Naturally occurring low to moderate myopia, with or without low levels of astigmatism in U.S. Army personnel
575270|NCT00413660|DMARD therapy
575271|NCT00413647|CardioPET
575272|NCT00413647|Coronary Artery Disease
575273|NCT00413647|Electrocardiogram
575274|NCT00413647|Radiation Dosimetry
575275|NCT00413621|MRI
575276|NCT00413621|Alzheimer Disease
575277|NCT00413621|Amyloid
575278|NCT00413621|AD
575279|NCT00413621|Healthy Volunteer
575280|NCT00413621|HV
575281|NCT00413608|Human
575282|NCT00413608|Adults
575283|NCT00413608|Male
575284|NCT00413608|Alleles
575285|NCT00413608|Genotype
575286|NCT00413608|Platelet Aggregation/drug effects
575287|NCT00413608|Platelet Aggregation Inhibitors/*pharmacology
575288|NCT00413608|Platelet Function Tests
575289|NCT00413608|Pharmacogenetics
575290|NCT00413608|*Polymorphism, Genetic
575291|NCT00413608|Ticlopidine/*analogs & derivatives/pharmacology
575292|NCT00413608|Healthy subjects
575293|NCT00413595|Cerebrovascular Accident
575294|NCT00413595|Cerebrovascular Accident, Acute
575295|NCT00413595|Fabry Disease
575296|NCT00413595|Fabry's Disease
575297|NCT00413595|Anderson-Fabry Disease
575298|NCT00413595|CVA (Cerebrovascular Accident)
575299|NCT00413595|Stroke, acute
575300|NCT00413595|Cerebral Stroke
575301|NCT00413582|Pectus Excavatum
575302|NCT00413582|Bar Repair
575303|NCT00413582|Pain Control
575304|NCT00413582|Pectus Excavatum Repair
575305|NCT00413556|Rhinitis
575306|NCT00413556|Oral tablets
575307|NCT00413556|Ig G4
575308|NCT00413556|grass pollen
575309|NCT00413556|inmunotherapy
575310|NCT00413543|COPD
575311|NCT00413543|exacerbation
575312|NCT00413543|pulmonary rehabilitation
575313|NCT00413543|exercise tolerance
575314|NCT00413543|exacerbations
575315|NCT00413543|quality of life
575316|NCT00413543|readmissions
575317|NCT00413517|Naturally occurring myopia with or without astigmatism
575318|NCT00413504|Fondaparinux
575319|NCT00413504|Monotherapy
575320|NCT00413504|Deep Vein thrombosis
575321|NCT00413504|Pulmonary Embolism
575322|NCT00413504|Anticoagulation
575323|NCT00413491|Breast Cancer
575324|NCT00413491|BRCA1 gene
575325|NCT00413491|BRCA2 gene
575326|NCT00413491|Magnetic Resonance Imaging
575327|NCT00413491|Mammography
575328|NCT00413491|Ultrasonography
575329|NCT00413478|5-Aza
575330|NCT00413478|Azacytidine
575331|NCT00413478|Vidaza
575332|NCT00413478|CLL
575333|NCT00413478|Chronic Lymphocytic Leukemia
575334|NCT00413478|Richter's transformation
575335|NCT00413478|Leukemia
575336|NCT00413465|Renal Plasma Flow
575337|NCT00413465|Endotoxemia
575338|NCT00413465|Type 2 diabetes
575339|NCT00413452|Rheumatoid Arthritis
575340|NCT00413452|Etanercept
575341|NCT00413452|Enbrel
575342|NCT00413452|Amgen
575343|NCT00413439|Isavuconazole
575344|NCT00413439|BAL8557
575345|NCT00413439|ASP9766
575346|NCT00413439|chemotherapy
575347|NCT00413439|prophylaxis
575348|NCT00413439|systemic fungal infection
575349|NCT00413426|Pharmacokinetics
575350|NCT00413426|oral
575351|NCT00413426|single dose
575352|NCT00413426|table
575353|NCT00413426|suspension
575354|NCT00413426|release
575355|NCT00413426|darifenacin
575356|NCT00413426|healthy subjects
575357|NCT00413426|Healthy volunteers study
575358|NCT00413413|Hypertension, valsartan, amlodipine, high blood pressure
575359|NCT00413400|Inflammation
575360|NCT00413400|Visceral adiposity
575361|NCT00413400|TNF
575362|NCT00413400|Adiponectin
575363|NCT00413400|glucose tolerance
575364|NCT00413400|endothelial function
575365|NCT00413400|metabolic syndrome
575366|NCT00413387|Asthma
575367|NCT00413387|Combinations
575368|NCT00413387|Inhaled therapy
575369|NCT00413387|Corticosteroids
575370|NCT00413387|Long acting bronchodilators
575371|NCT00413387|Beclomethasone
575372|NCT00413387|Formoterol
575373|NCT00413387|Budesonide
575374|NCT00413374|Lovenox
575375|NCT00413374|Enoxaparin
575376|NCT00413374|Prophylaxis
575377|NCT00413374|Pulmonary Embolism
575378|NCT00413374|Acute Deep Vein Thrombosis
575379|NCT00413374|Venous Thrombosis
575380|NCT00413374|Thrombosis
575381|NCT00413374|Anticoagulation
575382|NCT00413361|Systemic Lupus Erythematosus
575383|NCT00413361|Hydroxychloroquine
575384|NCT00413348|Type 2 diabetes
575385|NCT00413348|Probiotics
575386|NCT00413348|Insulin-resistance
575387|NCT00413348|Inflammation
575388|NCT00413348|Hyperinsulinemic euglycemic clamp
575389|NCT00413348|Endotoxin
575390|NCT00413335|Childhood and Adolescent Obesity
575391|NCT00413335|Metabolic phenotype
575392|NCT00413335|Impaired Glucose Tolerance
575393|NCT00413335|Type 2 Diabetes Mellitus
575394|NCT00413335|Insulin Sensitivity
575395|NCT00413335|Insulin Resistance
575396|NCT00413335|Abdominal fat partitioning
575397|NCT00413335|Impaired Glucose Tolerance (IGT)
575398|NCT00413335|Type 2 Diabetes Mellitus (T2DM)
575399|NCT00413322|Advanced Solid tumor
575400|NCT00413322|Adenosarcoma
575401|NCT00413322|Androgen-independent prostate cancer
575402|NCT00413322|belinostat
575403|NCT00413322|bladder cancer
575404|NCT00413322|bladder neoplasms
575405|NCT00413322|Breast cancer
575406|NCT00413322|Carcinoma, Bronchogenic
575407|NCT00413322|Carcinoma, Non-Small-Cell Lung
575408|NCT00413322|Carcinoma, Small Cell
575409|NCT00413322|Carcinosarcoma
575410|NCT00413322|Chondrosarcoma
575411|NCT00413322|Coin Lesion, Pulmonary
575412|NCT00413322|colorectal cancer
575413|NCT00413322|Esophageal Neoplasms
575414|NCT00413322|Facial Neoplasms
575415|NCT00413322|Fibrosarcoma
575416|NCT00413322|head and neck cancer
575417|NCT00413322|Hemangiosarcoma
575418|NCT00413322|Histiocytoma, Malignant Fibrous
575419|NCT00413322|kidney cancer
575420|NCT00413322|Leiomyosarcoma
575421|NCT00413322|Liposarcoma
575422|NCT00413322|lung cancer
575423|NCT00413322|lung neoplasms
575424|NCT00413322|Lymphangiosarcoma
575425|NCT00413322|mesothelioma
575426|NCT00413322|mesothelioma, cystic
575427|NCT00413322|Mixed Tumor, Mesodermal
575428|NCT00413322|Mouth Neoplasms
575429|NCT00413322|Myosarcoma
575430|NCT00413322|Myxosarcoma
575431|NCT00413322|Osteosarcoma
575432|NCT00413322|Otorhinolaryngologic Neoplasms
575433|NCT00413322|Ovarian cancer
575434|NCT00413322|Pancoast's Syndrome
575435|NCT00413322|Parathyroid Neoplasms
575436|NCT00413322|Phyllodes Tumor
575437|NCT00413322|Pulmonary Sclerosing Hemangioma
575438|NCT00413322|sarcoma
575439|NCT00413322|thyroid cancer
575440|NCT00413322|Thyroid Neoplasms
575441|NCT00413322|Tracheal Neoplasms
575442|NCT00413322|PXD101
575443|NCT00413309|Acute Coronary Syndrome
575444|NCT00413309|Percutaneous Coronary Intervention
575445|NCT00413309|Antiplatelet Therapy
575446|NCT00413309|PillCam
575447|NCT00413309|Endoscopy
575448|NCT00413296|PTSD
575449|NCT00413296|Anxiety
575450|NCT00413296|Pharmacotherapy
575451|NCT00413296|Levetiracetam
575452|NCT00413296|Relapse prevention
575453|NCT00413283|Advanced Non-Small Cell Lung Cancer
575454|NCT00413283|Chemotherapy Induced Thrombocytopenia
575455|NCT00413283|CIT
575456|NCT00413283|NSCLC
575457|NCT00413283|Stage IIIB NSCLC
575458|NCT00413283|Stage IV NSCLC
575459|NCT00413283|Gemcitabine
575460|NCT00413283|Carboplatin
575461|NCT00413283|Cisplatin
575462|NCT00413270|Imatinib resistant,
575463|NCT00413270|Imatinib intolerant,
575464|NCT00413270|CML- blast crisis,
575465|NCT00413270|CML- Accelerated phase,
575466|NCT00413270|CML- chronic phase,
575467|NCT00413270|nilotinib,
575468|NCT00413270|Chronic myelogenous leukemia,
575469|NCT00413270|blast crisis,
575470|NCT00413270|accelerated phase,
575471|NCT00413270|chronic phase
575472|NCT00413257|Postoperative Hyperalgesia
575473|NCT00413257|cardiac Surgical Procedures
575474|NCT00413257|Nefopam
575475|NCT00413257|Randomized Controlled Trials
575476|NCT00413257|Pain and chronic disease
575477|NCT00413244|Hypogonadal
575478|NCT00413244|coronary artery disease
575479|NCT00413244|percutaneous coronary intervention (PCI)
575480|NCT00413231|Thoracic Aneurysm
575481|NCT00413231|Endovascular Aortic Repair (EVAR)
575482|NCT00413231|Endovascular Stent Graft
575483|NCT00413231|Endograft
575484|NCT00413231|Thoracic Aortic Aneurysm
575485|NCT00413231|Endovascular procedure
575486|NCT00413231|Descending Thoracic Aneurysm
575487|NCT00413231|Valiant Stent Graft System
575488|NCT00413218|Phase III study
575489|NCT00413218|Isavuconazole
575490|NCT00413218|Candidemia
575491|NCT00413218|Invasive Candida infections
575492|NCT00413218|Candidemia and other invasive candida infections
575493|NCT00413218|ASP9766
575494|NCT00413218|BAL8557
575495|NCT00413179|Polycystic Ovarian Syndrome
575496|NCT00413179|Chronic Anovulation
575497|NCT00413179|Chronic Oligoovulation
575498|NCT00413179|Infertility
575499|NCT00413179|Hyperandrogenism
575500|NCT00413179|Metformin
575501|NCT00413179|Ovulation induction
575502|NCT00413166|Acute Promyelocytic Leukemia
575503|NCT00413166|APL
575504|NCT00413166|ATRA
575505|NCT00413166|All-Trans Retinoic Acid
575506|NCT00413166|Arsenic Trioxide
575507|NCT00413166|Theophylline
575508|NCT00413166|Gemtuzumab
575509|NCT00413153|HIV
575510|NCT00413153|Kaletra
575511|NCT00413153|Reyataz
575512|NCT00413153|Insulin sensitivity
575513|NCT00413153|Lipids
575514|NCT00413153|Body Composition
575515|NCT00413153|Receiving Kaletra
575516|NCT00413153|Treatment Experienced
575517|NCT00413140|childhood disease
575518|NCT00413140|cystic fibrosis
575519|NCT00413140|exhaled breath condensate
575520|NCT00413140|exhaled nitric oxide
575521|NCT00413140|airway inflammation
575522|NCT00413140|non-invasive inflammatory markers
575523|NCT00413140|controls
575524|NCT00413140|children
575525|NCT00413127|Systemic lidocaine
575526|NCT00413127|peridural lidocaine
575527|NCT00413127|perioperative analgesia
575528|NCT00413127|inflammation
575529|NCT00413127|Anesthesia
575530|NCT00413088|renal insufficency
575531|NCT00413088|low molecular weight heparin
575532|NCT00413088|pharmacokinetics
575533|NCT00413088|elderly
575534|NCT00413075|Solid tumors
575535|NCT00413075|Adenosarcoma
575536|NCT00413075|B-cell lymphoma
575537|NCT00413075|belinostat
575538|NCT00413075|bladder cancer
575539|NCT00413075|Breast cancer
575540|NCT00413075|Carcinoma, Non-Small-Cell Lung
575541|NCT00413075|Carcinoma, Small Cell
575542|NCT00413075|Chondrosarcoma
575543|NCT00413075|colorectal cancer
575544|NCT00413075|Esophageal Neoplasms
575545|NCT00413075|Fibrosarcoma
575546|NCT00413075|head and neck cancer
575547|NCT00413075|Hemangiosarcoma
575548|NCT00413075|Hodgkins Disease
575549|NCT00413075|kidney cancer
575550|NCT00413075|Leiomyosarcoma
575551|NCT00413075|Liposarcoma
575552|NCT00413075|lung cancer
575553|NCT00413075|lymphoma
575554|NCT00413075|mesothelioma
575555|NCT00413075|mesothelioma, cystic
575556|NCT00413075|Mixed Tumor, Mesodermal
575557|NCT00413075|Osteosarcoma
575558|NCT00413075|Otorhinolaryngologic Neoplasms
575559|NCT00413075|Ovarian cancer
575560|NCT00413075|Parathyroid Neoplasms
575561|NCT00413075|Prostate cancer
575562|NCT00413075|sarcoma
575563|NCT00413075|T-cell lymphoma
575564|NCT00413075|thyroid cancer
575565|NCT00413075|PXD101
575566|NCT00413049|Hypertension, valsartan, amlodipine, high blood pressure
575567|NCT00413036|Celgene
575568|NCT00413036|Revlimid
575569|NCT00413036|CC-5013
575570|NCT00413036|Non-hodgkin's lymphoma
575571|NCT00413036|Lenalidomide
575572|NCT00413036|CC5013
575573|NCT00413036|NHL
575574|NCT00413023|depression
575575|NCT00413023|major depressive disorder
575576|NCT00413023|MDD
575577|NCT00412997|advanced solid tumor
575578|NCT00412997|Cutaneous T-cell lymphoma
575579|NCT00412997|Phase I
575580|NCT00412997|HDAC inhibitor
575581|NCT00412997|Adult patients
575582|NCT00412971|Recurrence of bladder cancer
575583|NCT00412971|Fluorescence cystoscopy
575584|NCT00412932|Hypertension
575585|NCT00412932|Angiotensin Receptor Blocker
575586|NCT00412932|Calcium Channel Blocker
575587|NCT00412932|Angiotensin Converting Enzyme Inhibitor
575588|NCT00412932|Hydrochlorothiazide
575589|NCT00412932|Stage I and II Hypertension
575590|NCT00412919|Myeloma
575591|NCT00412919|Relapsed
575592|NCT00412919|Refractory
575593|NCT00412906|Low-grade inflammation
575594|NCT00412906|insulin resistance
575595|NCT00412906|Metabolism
575596|NCT00412906|Type 2 diabetes
575597|NCT00412906|Endotoxemia
575598|NCT00412906|Fat tissue
575599|NCT00412906|Muscle tissue
575600|NCT00412906|RT-PCR
575601|NCT00412893|Phase III
575602|NCT00412893|Invasive fungal disease
575603|NCT00412893|Aspergillus species
575604|NCT00412893|Filamentous fungi
575605|NCT00412893|ASP9766
575606|NCT00412893|BAL8557
575607|NCT00412893|Isavuconazole
575608|NCT00412867|Cerebral Infarction
575609|NCT00412867|acute ischemic stroke
575610|NCT00412867|Brain ischemia
575611|NCT00412841|Avascular Necrosis
575612|NCT00412841|Lipitor
575613|NCT00412841|SLE
575614|NCT00412828|Melanoma
575615|NCT00412828|CR011-vcMMAE
575616|NCT00412815|insulin sensitivity
575617|NCT00412815|coronary artery disease
575618|NCT00412815|exercise training
575619|NCT00412802|enoxaparine
575620|NCT00412802|acute coronary syndrome
575621|NCT00412802|renal failure
575622|NCT00412802|dose adaptation
575623|NCT00412789|Advanced solid tumor
575624|NCT00412789|Patupilone
575625|NCT00412763|Acute hepatitis
575626|NCT00412763|Acute viral hepatitis
575627|NCT00412763|Acute nonviral hepatitis
575628|NCT00412763|Silymarin
575629|NCT00412763|Milk Thistle
575630|NCT00412750|hepatitis B
575631|NCT00412750|hepatitis B Virus (HBV)
575632|NCT00412750|chronic hepatitis B
575633|NCT00412750|telbivudine
575634|NCT00412750|peginterferon
575635|NCT00412724|diet
575636|NCT00412724|acceptability
575637|NCT00412724|palatability
575638|NCT00412724|food
575639|NCT00412724|questionnaire
575640|NCT00412724|Food habits
575641|NCT00412672|Myocardial infarction
575642|NCT00412672|contrast echocardiography
575643|NCT00412672|collateral circulation
575644|NCT00412659|Sinus, Pilonidal
575645|NCT00412659|Pilonidal sinus
575646|NCT00412659|Pilonidal cysts
575647|NCT00412659|Pilonidal disease
575648|NCT00412659|midline excision
575649|NCT00412659|Karydakis operation
575650|NCT00412659|expertise based study
575651|NCT00412659|surgery
575652|NCT00412659|therapy
575653|NCT00412646|HIV
575654|NCT00412646|AIDS
575655|NCT00412646|Dose finding study
575656|NCT00412646|TMC125-C203
575657|NCT00412646|Treatment Experienced
575658|NCT00412633|Obesity
575659|NCT00412633|Men
575660|NCT00412633|Overweight
575661|NCT00412607|Ventricular Tachycardia
575662|NCT00412607|Heart Diseases
575663|NCT00412607|Arrhythmia
575664|NCT00412594|Hairy Cell Leukemia
575665|NCT00412594|Leukemia
575666|NCT00412594|2CDA
575667|NCT00412594|2-chlorodeoxyadenosine
575668|NCT00412594|Rituximab
575669|NCT00412594|Rituxan
575670|NCT00412594|HCL
575671|NCT00412581|Melanoma
575672|NCT00412581|Lenalidomide
575673|NCT00412581|Dacarbazine
575674|NCT00412581|CC-5013
575675|NCT00412581|Revlimid
575676|NCT00412581|DTIC
575677|NCT00412568|Naturally occuring myopia with or without astigmatism.
575678|NCT00412542|Glioblastoma Multiforme
575679|NCT00412542|Glioma
575680|NCT00412542|Thalidomide
575681|NCT00412542|Thalomid
575682|NCT00412542|CPT-11
575683|NCT00412542|Irinotecan
575684|NCT00412542|malignant glioma
575685|NCT00412529|HBeAg-positive, chronic hepatitis B
575686|NCT00412529|telbivudine
575687|NCT00412529|entecavir
575688|NCT00412529|viral kinetics
575689|NCT00412516|Japanese Encephalitis
575690|NCT00412516|Japanese B Encephalitis
575691|NCT00412516|Japanese B Viral Encephalitis
575692|NCT00412516|Viral Encephalitis, Japanese B
575693|NCT00412490|Oral Cavity Cancer
575694|NCT00412490|Body Image
575695|NCT00412490|Smoking
575696|NCT00412490|Appearance
575697|NCT00412490|Questionnaire
575698|NCT00412490|Interview
575699|NCT00412477|HIV
575700|NCT00412477|Lfn-p24
575701|NCT00412477|Anthrax
575702|NCT00412477|IM
575703|NCT00412477|HIV-1
575704|NCT00412477|HIV Preventive Vaccine
575705|NCT00412464|fondaparinux
575706|NCT00412464|thrombosis
575707|NCT00412464|heparin-induced thrombocytopenia
575708|NCT00412464|pediatrics
575709|NCT00412451|Diabetic Macular Edema
575710|NCT00412451|PVD
575711|NCT00412451|DME
575712|NCT00412451|Diabetic Retinopathy
575713|NCT00412438|Atrial Fibrillation
575714|NCT00412425|Melanoma
575715|NCT00412425|Nausea
575716|NCT00412425|Vomiting
575717|NCT00412425|Palonosetron
575718|NCT00412425|Cisplatin
575719|NCT00412425|Vinblastine
575720|NCT00412425|Loss of Appetite
575721|NCT00412425|Weight loss
575722|NCT00412412|Cancer of Breast
575723|NCT00412412|Cancer of the Breast
575724|NCT00412399|Employment
575725|NCT00412399|Negative workplace events
575726|NCT00412399|Healthy controls
575727|NCT00412399|Fatigue
575728|NCT00412399|Physical activity
575729|NCT00412386|Pediatric
575730|NCT00412386|Congenital Heart Disease
575731|NCT00412386|Imaging
575732|NCT00412373|Schizoaffective Disorder
575733|NCT00412373|antipsychotic
575734|NCT00412373|paliperidone
575735|NCT00412373|placebo
575736|NCT00412360|Double cord blood
575737|NCT00412347|hyperglycemia
575738|NCT00412347|diabetes
575739|NCT00412347|insulin drip
575740|NCT00412347|hypoglycemia
575741|NCT00412347|general wards
575742|NCT00412321|Lymphoma, Non-Hodgkin
575743|NCT00412321|Multiple Myeloma
575744|NCT00412321|Castleman's disease
575745|NCT00412321|intravenous
575746|NCT00412321|IL-6
575747|NCT00412308|spinal cord injury
575748|NCT00412308|ventilator dependency
575749|NCT00412308|ventilator weaning
575750|NCT00412308|tidal volume
575751|NCT00412295|Naturally occuring myopia with or without astigmatism.
575752|NCT00412295|Wavefront errors
575753|NCT00412269|Insulin Sensitivity
575754|NCT00412269|Total abdominal fat
575755|NCT00412269|Visceral abdominal fat
575756|NCT00412269|Reproductive Hormones
575757|NCT00412269|Menopause
575758|NCT00412269|Diabetes
575759|NCT00412269|Fat Distribution
575760|NCT00412269|Sex Hormones
575761|NCT00412256|Treatment
575762|NCT00412256|Disease activity
575763|NCT00412256|Clinical trial
575764|NCT00412243|Burkitt's Lymphoma
575765|NCT00412243|Lymphoblastic Lymphoma
575766|NCT00412243|Acute Lymphoblastic Leukemia
575767|NCT00412243|Clofarabine
575768|NCT00412243|Clofarex
575769|NCT00412243|Clolar
575770|NCT00412243|Cyclophosphamide
575771|NCT00412243|Neosar
575772|NCT00412243|Cytoxan
575773|NCT00412230|Pre-eclampsia
575774|NCT00412230|Gestational diabetes
575775|NCT00412230|Insulin resistance
575776|NCT00412230|hypertension in pregnancy
575777|NCT00412204|double-blind
575778|NCT00412204|placebo-controlled
575779|NCT00412204|crossover
575780|NCT00412204|effects of tiotropium bromide
575781|NCT00412204|gas exchange
575782|NCT00412204|Chronic Obstructive Pulmonary Disease
575783|NCT00412204|exercise.
575784|NCT00412191|healthy volunteers
575785|NCT00412191|bioequivalence
575786|NCT00412191|food effects
575787|NCT00412178|Internet
575788|NCT00412178|mobile communication
575789|NCT00412178|glucose monitoring
575790|NCT00412165|Prevention of Type 2 Diabetes
575791|NCT00412165|Adolescents
575792|NCT00412165|Obesity
575793|NCT00412165|Overweight
575794|NCT00412165|Internet Technology
575795|NCT00412165|Cell Phone
575796|NCT00412152|A randomised
575797|NCT00412152|double blind
575798|NCT00412152|parallel group
575799|NCT00412152|multicentre study to demonstrate improvement in symptoms of constipation in subjects with non malignant pain
575800|NCT00412152|Moderate to severe chronic non-malignant pain
575801|NCT00412139|vascular calcifications
575802|NCT00412139|uremic toxins
575803|NCT00412139|renal osteodystrophy
575804|NCT00412139|Dialysis
575805|NCT00412126|Diabetes Mellitus
575806|NCT00412126|Coronary Restenosis
575807|NCT00412126|Insulin
575808|NCT00412126|Angioplasty
575809|NCT00412100|A randomised
575810|NCT00412100|double-blind
575811|NCT00412100|double-dummy
575812|NCT00412100|parallel-group multicentre study to demonstrate improvement in symptoms of constipation
575813|NCT00412100|Moderate to severe, chronic non-malignant pain
575814|NCT00412087|vitamin D
575815|NCT00412087|cholecalciferol
575816|NCT00412087|pregnant women
575817|NCT00412074|Breastfeeding
575818|NCT00412074|Vitamin D
575819|NCT00412074|Vitamin D deficiency
575820|NCT00412061|Cancer
575821|NCT00412061|Carcinoid
575822|NCT00412061|Tumor
575823|NCT00412061|Neuroendocrine
575824|NCT00412061|Carcinoma
575825|NCT00412061|Everolimus
575826|NCT00412061|Octreotide
575827|NCT00412022|early breast cancer
575828|NCT00412022|adjuvant therapy
575829|NCT00412022|premenopause
575830|NCT00412022|premenopausal
575831|NCT00412022|menopausal status
575832|NCT00412022|postmenopause
575833|NCT00412022|bone mineral density
575834|NCT00412022|hormone sensitive
575835|NCT00412022|aromatase inhibitors
575836|NCT00412022|letrozole
575837|NCT00412022|disease-free survival
575838|NCT00412009|tuberculosis
575839|NCT00412009|control
575840|NCT00412009|treatment
575841|NCT00412009|adherence
575842|NCT00411996|indinavir/ritonavir
575843|NCT00411996|HIV/TB
575844|NCT00411996|rifampicin
575845|NCT00411996|PK and efficacy of IDV/RTV 600/100 mg BID with rifampicin
575846|NCT00411996|Treatment Naive
575847|NCT00411983|chronic HIV infection
575848|NCT00411983|long term cohort of HIV infection
575849|NCT00411970|23 gauge pars plana vitrectomy
575850|NCT00411970|conjunctival erythema and injection
575851|NCT00411970|20 gauge pars plana vitrectomy
575852|NCT00411970|vitreous and retinal surgery
575853|NCT00411957|atazanavir/ritonavir
575854|NCT00411957|pharmacokinetic of ATV/r200/100 OD+2NRTIs
575855|NCT00411944|tacrolimus pharmacokinetics
575856|NCT00411944|CYP3A4 - CYP3A5
575857|NCT00411944|P-glycoprotein
575858|NCT00411944|single nucleotide polymorphisms
575859|NCT00411944|renal transplantation
575860|NCT00411944|calcineurin-inhibitor-associated nephrotoxicity
575861|NCT00411905|Myelodysplastic syndromes
575862|NCT00411905|IPSS Int-2 and High risk
575863|NCT00411905|Bortezomib
575864|NCT00411905|Low dose Cytarabine
575865|NCT00411905|Bone Marrow diseases
575866|NCT00411879|Heart Arrest
575867|NCT00411879|Cardiopulmonary Resuscitation
575868|NCT00411879|Epinephrine
575869|NCT00411879|Vasopressin
575870|NCT00411879|Adrenal Cortex Hormones
575871|NCT00411866|safety
575872|NCT00411866|pharmacokinetics,
575873|NCT00411853|Prostate, Hormone Refractory, Cancer
575874|NCT00411840|stem cell therapy
575875|NCT00411840|peripheral arterial disease
575876|NCT00411840|limb ischemia
575877|NCT00411827|Cytology
575878|NCT00411827|Keratomileusis, Laser In Situ
575879|NCT00411827|Keratectomy, Photorefractive, Excimer Laser
575880|NCT00411814|melbourne,
575881|NCT00411814|healthy
575882|NCT00411814|antibody,
575883|NCT00411814|male,
575884|NCT00411814|Safety and pharmacokinetic study,
575885|NCT00411814|mild asthmatic patients,
575886|NCT00411814|australia
575887|NCT00411814|monoclonal
575888|NCT00411814|female,
575889|NCT00411814|volunteers,
575890|NCT00411801|bleeding disorder
575891|NCT00411801|universal plasma
575892|NCT00411801|plasma
575893|NCT00411801|plasma exchange
575894|NCT00411788|HER-2 positive
575895|NCT00411788|breast cancer
575896|NCT00411788|HER-2 positive breast cancer
575897|NCT00411762|Pancreatic
575898|NCT00411736|Cystic Fibrosis
575899|NCT00411736|Pseudomonas aeruginosa
575900|NCT00411736|Azithromycin
575901|NCT00411736|Intermittent pulmonary infection
575902|NCT00411723|multiple sclerosis, chronic-progressive, relapsing-remitting
575903|NCT00411671|Lung Cancer
575904|NCT00411671|Non-Small Cell Lung Cancer
575905|NCT00411671|NSCLC
575906|NCT00411671|Sorafenib
575907|NCT00411671|BAY 43-9006
575908|NCT00411671|Battle Program
575909|NCT00411645|prevention
575910|NCT00411645|prophylaxis
575911|NCT00411645|Cytomegalovirus
575912|NCT00411645|CMV
575913|NCT00411645|allogeneic stem cell transplant
575914|NCT00411645|SCT
575915|NCT00411632|Lung Cancer
575916|NCT00411632|Non-Small Cell Lung Cancer
575917|NCT00411632|NSCLC
575918|NCT00411632|Erlotinib
575919|NCT00411632|Tarceva
575920|NCT00411632|Bexarotene
575921|NCT00411632|Targretin
575922|NCT00411632|OSI-774
575923|NCT00411632|Battle Program
575924|NCT00411619|Tuberous Sclerosis Complex (TSC)
575925|NCT00411619|Subendymal Giant Cell Astrocytomas (SEGA'S)
575926|NCT00411619|Mammalian Target of Rapamycin (mTOR)
575927|NCT00411619|Everolimus (RAD001)
575928|NCT00411619|Tuberous Sclerosis with Subependymal Giant Cell Astrocytomas
575929|NCT00411606|Healthy
575930|NCT00411606|Allergy
575931|NCT00411606|Allergic Rhinoconjunctivitis
575932|NCT00411593|Non-Small Cell Lung Cancer
575933|NCT00411593|Lung Cancer
575934|NCT00411593|NSCLC
575935|NCT00411593|Bortezomib
575936|NCT00411593|Bevacizumab
575937|NCT00411580|Mild, moderate Alzheimer's Disease (AD), Aß-specific antibody, CAD106
575938|NCT00411567|markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma
575939|NCT00411541|acute lymphoblastic leukemia, maintenance, BFM protocol
575940|NCT00411541|intermediate risk childhood acute lymphoblastic leukemia
575941|NCT00411528|Prostate Cancer
575942|NCT00411528|Hormone Refractory
575943|NCT00411528|patupilone
575944|NCT00411528|docetaxel
575945|NCT00411463|Interpersonal Therapy
575946|NCT00411463|Social Rhythm Therapy
575947|NCT00411463|Bipolar Disorder
575948|NCT00411463|Depression
575949|NCT00411463|Seroquel
575950|NCT00411450|k-ras
575951|NCT00411450|biomarker
575952|NCT00411450|colorectal
575953|NCT00411450|colon
575954|NCT00411450|rectal
575955|NCT00411450|FOLFOX
575956|NCT00411450|FOLFIRI
575957|NCT00411424|Rheumatoid Arthritis
575958|NCT00411424|Randomized Control Trial
575959|NCT00411424|Treatment outcomes
575960|NCT00411424|Monoclonal antibody
575961|NCT00411411|GLP-1
575962|NCT00411411|GIP
575963|NCT00411411|Incretin hormones
575964|NCT00411411|DPP-IV inhibitor
575965|NCT00411411|Hyperglycaemic clamp
575966|NCT00411411|Meal test
575967|NCT00411398|Anxiety, SNRI, SSRI,GAD,SAD
575968|NCT00411385|Chronic Hepatitis C
575969|NCT00411385|Hepatitis C
575970|NCT00411385|CHC
575971|NCT00411385|HepC
575972|NCT00411385|Genotype 1
575973|NCT00411385|Hepatitis
575974|NCT00411385|HCV
575975|NCT00411372|Questionnaire
575976|NCT00411372|COPD
575977|NCT00411372|Shortness of Breath
575978|NCT00411359|Refractory angina
575979|NCT00411359|Cardiac rehabilitation
575980|NCT00411359|Symptomology
575981|NCT00411359|Physical ability
575982|NCT00411359|Exercise
575983|NCT00411359|Psychology
575984|NCT00411359|Quality of life
575985|NCT00411359|Risk factors
575986|NCT00411346|Asthma
575987|NCT00411346|Self-Monitoring
575988|NCT00411346|Cost-effectiveness
575989|NCT00411333|diabetic retinopathy
575990|NCT00411333|fluorescein angiography
575991|NCT00411333|steroid
575992|NCT00411333|anti-angiogenesis
575993|NCT00411320|Asthma
575994|NCT00411320|Smoking
575995|NCT00411320|Steroid Resistance
575996|NCT00411320|Corticosteroid insensitivity
575997|NCT00411307|Analgesia
575998|NCT00411307|Postoperative pain
575999|NCT00411294|ergocalciferol
576000|NCT00411294|chronic kidney disease
576001|NCT00411294|secondary hyperparathyroidism
576002|NCT00411294|vitamin D deficiency
576003|NCT00411281|acute myeloid leukemia/transient myeloproliferative disorder
576004|NCT00411268|Chronic low back pain
576005|NCT00411268|OROS hydromorphone slow release tablet
576006|NCT00411268|Quality of Life
576007|NCT00411255|Blink Reflex
576008|NCT00411255|Transcranial Magnetic Stimulation (TMS)
576009|NCT00411255|Dystonia
576010|NCT00411255|Blepharospasm
576011|NCT00411255|BSP
576012|NCT00411255|Focal Dystonia
576013|NCT00411242|agomelatine, major depressive disorder, MDD, depression
576014|NCT00411216|vestibular rehabilitation
576015|NCT00411216|vestibular hypofunction
576016|NCT00411203|Protein kinase C, tamoxifen, acute mania, clinical trial
576017|NCT00411190|Osteoporosis
576018|NCT00411190|Osteoarthritis
576019|NCT00411190|Postmenopausal
576020|NCT00411177|end-stage renal disease
576021|NCT00411177|hemodialysis
576022|NCT00411177|cardiovascular morbidity and mortality
576023|NCT00411177|high flux dialyser
576024|NCT00411177|on-line hemodiafiltration
576025|NCT00411177|arterial stiffness
576026|NCT00411177|inflammation
576027|NCT00411177|life quality
576028|NCT00411177|left ventricular hypertrophy
576029|NCT00411164|knee pain
576030|NCT00411164|hip pain
576031|NCT00411164|opioid
576032|NCT00411151|Adenocarcinoma of esophagogastric junction
576033|NCT00411151|Adenocarcinoma of lower esophagus (Barrett carcinoma)
576034|NCT00411138|endometrial clear cell carcinoma
576035|NCT00411138|stage II endometrial carcinoma
576036|NCT00411138|stage IA grade 3 endometrial carcinoma
576037|NCT00411138|stage IB endometrial carcinoma
576038|NCT00411138|stage IIIA endometrial carcinoma
576039|NCT00411138|stage IIIB endometrial carcinoma
576040|NCT00411138|stage IIIC endometrial carcinoma
576041|NCT00411125|Postmenopausal
576042|NCT00411125|osteoporosis
576043|NCT00411125|Pharmacokinetics/dynamics
576044|NCT00411125|Calcitonin
576045|NCT00411112|Sentinel node
576046|NCT00411112|Isosulphan blue
576047|NCT00411112|Isotopic detection
576048|NCT00411112|Survival
576049|NCT00411099|agomelatine, major depressive disorder, MDD, depression
576050|NCT00411086|contiguous stage II grade 1 follicular lymphoma
576051|NCT00411086|contiguous stage II grade 2 follicular lymphoma
576052|NCT00411086|contiguous stage II grade 3 follicular lymphoma
576053|NCT00411086|noncontiguous stage II grade 1 follicular lymphoma
576054|NCT00411086|noncontiguous stage II grade 2 follicular lymphoma
576055|NCT00411086|noncontiguous stage II grade 3 follicular lymphoma
576056|NCT00411086|stage I grade 1 follicular lymphoma
576057|NCT00411086|stage I grade 2 follicular lymphoma
576058|NCT00411086|stage I grade 3 follicular lymphoma
576059|NCT00411086|stage III grade 1 follicular lymphoma
576060|NCT00411086|stage III grade 2 follicular lymphoma
576061|NCT00411086|stage III grade 3 follicular lymphoma
576062|NCT00411086|stage IV grade 1 follicular lymphoma
576063|NCT00411086|stage IV grade 2 follicular lymphoma
576064|NCT00411086|stage IV grade 3 follicular lymphoma
576065|NCT00411086|Granulocyte-Macrophage Colony Stimulating Factor
576066|NCT00411086|GM-CSF
576067|NCT00411086|Rituximab
576068|NCT00411086|Rituxan
576069|NCT00411073|darapladib
576070|NCT00411073|moxifloxacin
576071|NCT00411073|QT study
576072|NCT00411060|Rotator Cuff Tear
576073|NCT00411047|stage IIIB non-small cell lung cancer
576074|NCT00411047|stage IV non-small cell lung cancer
576075|NCT00411047|adenocarcinoma of the lung
576076|NCT00411047|bronchoalveolar cell lung cancer
576077|NCT00411047|large cell lung cancer
576078|NCT00411034|Opioids
576079|NCT00411034|Chronic Cancer Pain
576080|NCT00411034|analgesic
576081|NCT00410995|Physically fit volunteers
576082|NCT00410982|Lymphoid Malignancies
576083|NCT00410982|Hodgkin's Disease
576084|NCT00410982|Non-Hodgkin's Lymphoma
576085|NCT00410982|Acute Lymphoblastic Leukemia
576086|NCT00410982|Chronic Lymphocytic Leukemia
576087|NCT00410982|Hematopoietic Cell Transplantation
576088|NCT00410982|Myeloma
576089|NCT00410982|Leukemia
576090|NCT00410982|Lymphoma
576091|NCT00410982|Busulfan
576092|NCT00410982|Busulfex
576093|NCT00410982|Myleran
576094|NCT00410982|Gemcitabine
576095|NCT00410982|Gemcitabine Hydrochloride
576096|NCT00410982|Gemzar
576097|NCT00410982|Melphalan
576098|NCT00410982|Alkeran
576099|NCT00410969|resuscitation
576100|NCT00410969|hypothermia
576101|NCT00410956|adult primary hepatocellular carcinoma
576102|NCT00410956|localized unresectable adult primary liver cancer
576103|NCT00410956|advanced adult primary liver cancer
576104|NCT00410956|recurrent adult primary liver cancer
576105|NCT00410956|adult primary cholangiocellular carcinoma
576106|NCT00410943|Cancer pain
576107|NCT00410943|Oral analgesic
576108|NCT00410943|OROS hydromorphone HCI
576109|NCT00410930|Immunotherapy, major allergen, birch
576110|NCT00410878|Opioids
576111|NCT00410878|Chronic cancer pain
576112|NCT00410878|Analgesic
576113|NCT00410865|Oral Premalignancies
576114|NCT00410865|Mouth Cancer
576115|NCT00410865|Dysplasia/Carcinoma in Situ (CIS) of the Oral Cavity
576116|NCT00410865|Dysplasia/Carcinoma in situ (CIS) of the Oral Pharynx
576117|NCT00410865|Advexin
576118|NCT00410865|Gene Therapy
576119|NCT00410865|INGN 201
576120|NCT00410865|Wild Type p53 Gene Induction
576121|NCT00410852|Insulin
576122|NCT00410852|Hyperglycemia
576123|NCT00410852|Hypoglycemia
576124|NCT00410852|Intensive care
576125|NCT00410852|Critical care
576126|NCT00410813|stage IV breast cancer
576127|NCT00410813|male breast cancer
576128|NCT00410813|recurrent breast cancer
576129|NCT00410813|bone metastases
576130|NCT00410800|Insulin Resistance
576131|NCT00410800|Body Composition
576132|NCT00410800|Kinetic Modeling
576133|NCT00410787|Chronic cancer pain
576134|NCT00410787|OROS hydromorphone HCI (slow release)
576135|NCT00410787|long-term repeated dosing
576136|NCT00410774|stage III pancreatic cancer
576137|NCT00410774|stage I pancreatic cancer
576138|NCT00410774|adenocarcinoma of the pancreas
576139|NCT00410774|stage II pancreatic cancer
576140|NCT00410761|ZD6474
576141|NCT00410761|MTC
576142|NCT00410761|Hereditary Medullary Thyroid Cancer
576143|NCT00410761|Sporadic Medullary Thyroid Cancer
576144|NCT00410761|Medullary Thyroid Cancer
576145|NCT00410748|Chronic cancer pain
576146|NCT00410748|chronic pain
576147|NCT00410735|ONO-1078
576148|NCT00410735|chronic sinusitis
576149|NCT00410722|Nutrition
576150|NCT00410722|Type 2 Diabetes
576151|NCT00410709|Pediculosis Capitis
576152|NCT00410709|Head Lice
576153|NCT00410709|Crawlers
576154|NCT00410709|Ova
576155|NCT00410709|Nits
576156|NCT00410696|High-dose chemotherapy
576157|NCT00410696|Growth factor
576158|NCT00410696|Pegfilgrastim
576159|NCT00410683|stage IIIA non-small cell lung cancer
576160|NCT00410683|stage IIIB non-small cell lung cancer
576161|NCT00410670|Gene
576162|NCT00410670|Genetics
576163|NCT00410670|Family History
576164|NCT00410670|Radiation Therapy
576165|NCT00410670|Children
576166|NCT00410657|graft versus host disease
576167|NCT00410657|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
576168|NCT00410657|adult acute myeloid leukemia with inv(16)(p13;q22)
576169|NCT00410657|adult acute myeloid leukemia with t(15;17)(q22;q12)
576170|NCT00410657|adult acute myeloid leukemia with t(16;16)(p13;q22)
576171|NCT00410657|adult acute myeloid leukemia with t(8;21)(q22;q22)
576172|NCT00410657|accelerated phase chronic myelogenous leukemia
576173|NCT00410657|adult acute lymphoblastic leukemia in remission
576174|NCT00410657|adult acute myeloid leukemia in remission
576175|NCT00410657|atypical chronic myeloid leukemia
576176|NCT00410657|blastic phase chronic myelogenous leukemia
576177|NCT00410657|childhood chronic myelogenous leukemia
576178|NCT00410657|chronic phase chronic myelogenous leukemia
576179|NCT00410657|chronic eosinophilic leukemia
576180|NCT00410657|chronic idiopathic myelofibrosis
576181|NCT00410657|chronic myelomonocytic leukemia
576182|NCT00410657|chronic neutrophilic leukemia
576183|NCT00410657|de novo myelodysplastic syndromes
576184|NCT00410657|disseminated neuroblastoma
576185|NCT00410657|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
576186|NCT00410657|juvenile myelomonocytic leukemia
576187|NCT00410657|myelodysplastic/myeloproliferative disease, unclassifiable
576188|NCT00410657|nodal marginal zone B-cell lymphoma
576189|NCT00410657|noncontiguous stage II adult Burkitt lymphoma
576190|NCT00410657|stage III adult Burkitt lymphoma
576191|NCT00410657|stage IV adult Burkitt lymphoma
576192|NCT00410657|noncontiguous stage II adult diffuse large cell lymphoma
576193|NCT00410657|stage III adult diffuse large cell lymphoma
576194|NCT00410657|stage IV adult diffuse large cell lymphoma
576195|NCT00410657|noncontiguous stage II adult diffuse mixed cell lymphoma
576196|NCT00410657|stage III adult diffuse mixed cell lymphoma
576197|NCT00410657|stage IV adult diffuse mixed cell lymphoma
576198|NCT00410657|noncontiguous stage II adult diffuse small cleaved cell lymphoma
576199|NCT00410657|stage III adult diffuse small cleaved cell lymphoma
576200|NCT00410657|stage IV adult diffuse small cleaved cell lymphoma
576201|NCT00410657|noncontiguous stage II adult immunoblastic large cell lymphoma
576202|NCT00410657|stage III adult immunoblastic large cell lymphoma
576203|NCT00410657|stage IV adult immunoblastic large cell lymphoma
576204|NCT00410657|noncontiguous stage II adult lymphoblastic lymphoma
576205|NCT00410657|stage III adult lymphoblastic lymphoma
576206|NCT00410657|stage IV adult lymphoblastic lymphoma
576207|NCT00410657|noncontiguous stage II grade 1 follicular lymphoma
576208|NCT00410657|stage III grade 1 follicular lymphoma
576209|NCT00410657|stage IV grade 1 follicular lymphoma
576210|NCT00410657|noncontiguous stage II grade 2 follicular lymphoma
576211|NCT00410657|stage III grade 2 follicular lymphoma
576212|NCT00410657|stage IV grade 2 follicular lymphoma
576213|NCT00410657|noncontiguous stage II grade 3 follicular lymphoma
576214|NCT00410657|stage III grade 3 follicular lymphoma
576215|NCT00410657|stage IV grade 3 follicular lymphoma
576216|NCT00410657|noncontiguous stage II mantle cell lymphoma
576217|NCT00410657|stage III mantle cell lymphoma
576218|NCT00410657|stage IV mantle cell lymphoma
576219|NCT00410657|noncontiguous stage II marginal zone lymphoma
576220|NCT00410657|splenic marginal zone lymphoma
576221|NCT00410657|stage III marginal zone lymphoma
576222|NCT00410657|stage IV marginal zone lymphoma
576223|NCT00410657|noncontiguous stage II small lymphocytic lymphoma
576224|NCT00410657|stage III small lymphocytic lymphoma
576225|NCT00410657|stage IV small lymphocytic lymphoma
576226|NCT00410657|poor prognosis metastatic gestational trophoblastic tumor
576227|NCT00410657|stage I multiple myeloma
576228|NCT00410657|stage II multiple myeloma
576229|NCT00410657|stage III multiple myeloma
576230|NCT00410657|stage II ovarian epithelial cancer
576231|NCT00410657|stage III ovarian epithelial cancer
576232|NCT00410657|stage IV ovarian epithelial cancer
576233|NCT00410657|aggressive, noncontiguous stage II adult non-Hodgkin lymphoma
576234|NCT00410657|stage III adult Hodgkin lymphoma
576235|NCT00410657|stage IV adult Hodgkin lymphoma
576236|NCT00410657|stage III chronic lymphocytic leukemia
576237|NCT00410657|stage IV chronic lymphocytic leukemia
576238|NCT00410657|stage III malignant testicular germ cell tumor
576239|NCT00410657|stage IIIA breast cancer
576240|NCT00410657|stage IIIB breast cancer
576241|NCT00410657|stage IIIC breast cancer
576242|NCT00410657|stage IV breast cancer
576243|NCT00410657|childhood acute lymphoblastic leukemia in remission
576244|NCT00410657|childhood acute myeloid leukemia in remission
576245|NCT00410657|childhood myelodysplastic syndromes
576246|NCT00410644|Non-malignant chronic pain
576247|NCT00410644|pain
576248|NCT00410644|analgesics
576249|NCT00410644|opioid
576250|NCT00410631|localized resectable neuroblastoma
576251|NCT00410631|localized unresectable neuroblastoma
576252|NCT00410631|regional neuroblastoma
576253|NCT00410631|stage 4S neuroblastoma
576254|NCT00410631|disseminated neuroblastoma
576255|NCT00410631|recurrent neuroblastoma
576256|NCT00410618|cognitive/functional effects
576257|NCT00410618|long-term effects secondary to cancer therapy in adults
576258|NCT00410618|recurrent colon cancer
576259|NCT00410618|stage I colon cancer
576260|NCT00410618|stage II colon cancer
576261|NCT00410618|stage III colon cancer
576262|NCT00410618|stage IV colon cancer
576263|NCT00410592|GERD
576264|NCT00410592|acid reflux
576265|NCT00410592|heartburn
576266|NCT00410592|PPI
576267|NCT00410592|Hispanic
576268|NCT00410579|pain
576269|NCT00410579|fatigue
576270|NCT00410579|long-term effects secondary to cancer therapy in adults
576271|NCT00410579|psychosocial effects of cancer and its treatment
576272|NCT00410579|stage II rectal cancer
576273|NCT00410579|stage III rectal cancer
576274|NCT00410579|stage II colon cancer
576275|NCT00410579|stage III colon cancer
576276|NCT00410579|adenocarcinoma of the colon
576277|NCT00410566|Acid sphingomyelinase deficiency
576278|NCT00410566|Niemann-Pick disease
576279|NCT00410566|Lysosomal storage disorder
576280|NCT00410566|Enzyme replacement therapy
576281|NCT00410566|Treatment
576282|NCT00410540|Cancer pain
576283|NCT00410540|Oral analgesic
576284|NCT00410540|OROS hydromorphone HCL
576285|NCT00410540|Morphine sulfate
576286|NCT00410527|Antibacterials
576287|NCT00410527|Colonization
576288|NCT00410527|Infection
576289|NCT00410527|Pneumonia
576290|NCT00410527|Resistance
576291|NCT00410514|Beta-3 Receptor Agonist
576292|NCT00410514|YM178
576293|NCT00410514|Men
576294|NCT00410514|Lower Urinary Tract Symptoms
576295|NCT00410514|Bladder Outlet Obstruction
576296|NCT00410501|Pharmacokinetics, interaction, QAB149, indacaterol, ketoconazole, healthy subjects
576297|NCT00410488|Sarcoma
576298|NCT00410488|Palonosetron
576299|NCT00410488|Aloxi
576300|NCT00410488|Nausea
576301|NCT00410488|Vomiting
576302|NCT00410475|Ionizing Radiation
576303|NCT00410475|Cohort Study
576304|NCT00410475|Radiation-Induced Neoplasms
576305|NCT00410475|Radiologic Technologists
576306|NCT00410475|Ultraviolet Radiation
576307|NCT00410462|recurrent adult soft tissue sarcoma
576308|NCT00410462|stage IV adult soft tissue sarcoma
576309|NCT00410462|adult liposarcoma
576310|NCT00410462|adult fibrosarcoma
576311|NCT00410462|adult malignant fibrous histiocytoma
576312|NCT00410462|adult leiomyosarcoma
576313|NCT00410462|adult rhabdomyosarcoma
576314|NCT00410462|adult alveolar soft-part sarcoma
576315|NCT00410462|adult malignant mesenchymoma
576316|NCT00410462|adult angiosarcoma
576317|NCT00410462|adult epithelioid sarcoma
576318|NCT00410462|adult neurofibrosarcoma
576319|NCT00410462|adult synovial sarcoma
576320|NCT00410462|recurrent uterine sarcoma
576321|NCT00410462|stage IV uterine sarcoma
576322|NCT00410462|ovarian sarcoma
576323|NCT00410462|small intestine leiomyosarcoma
576324|NCT00410462|recurrent small intestine cancer
576325|NCT00410449|End stage renal disease treated by hemodialysis
576326|NCT00410449|Hemodialysis vascular access patency
576327|NCT00410449|Vitamin E
576328|NCT00410449|oxidative markers
576329|NCT00410449|pentosidine
576330|NCT00410449|hydroxynonenal
576331|NCT00410449|levuglandin
576332|NCT00410436|Type 1 Diabetes
576333|NCT00410436|Resistance Exercise
576334|NCT00410436|Aerobic Exercise
576335|NCT00410423|Leukemia
576336|NCT00410423|Acute Myeloid Leukemia
576337|NCT00410423|Acute Lymphoid / Lymphoblastic Leukemia
576338|NCT00410397|Low back pain
576339|NCT00410397|Hip pain
576340|NCT00410384|Antibodies
576341|NCT00410384|Autoimmune Diseases
576342|NCT00410384|Systemic Lupus Erythematosus
576343|NCT00410384|SLE
576344|NCT00410384|Belimumab
576345|NCT00410384|Lupus
576346|NCT00410371|tolerability
576347|NCT00410371|safety
576348|NCT00410371|Pharmacokinetic characteristics
576349|NCT00410358|Gimatecan
576350|NCT00410358|topoisomerase I inhibitor
576351|NCT00410358|advanced solid tumors
576352|NCT00410332|tonsillectomy
576353|NCT00410332|pain
576354|NCT00410332|homeopathy
576355|NCT00410332|Traumeel
576356|NCT00410306|Hypogonadism
576357|NCT00410306|Nebido
576358|NCT00410306|Testosterone
576359|NCT00410306|Observational Study
576360|NCT00410293|Heart failure
576361|NCT00410293|Diagnostic
576362|NCT00410293|Natriuretic peptide
576363|NCT00410293|NT-pro B-type natriuretic peptide
576364|NCT00410293|Length of stay
576365|NCT00410293|Costs
576366|NCT00410267|glaucoma
576367|NCT00410267|Post operative from selective laser trabeculoplasty
576368|NCT00410241|Genome
576369|NCT00410241|Cardiovascular Disease
576370|NCT00410241|Volunteers
576371|NCT00410241|Genes
576372|NCT00410241|Atherosclerosis
576373|NCT00410241|Coronary Artery Calcification
576374|NCT00410241|Cardiovascular
576375|NCT00410228|safety, tolerability, pharmacokinetics, pharmacodynamics, AHT956
576376|NCT00410189|Non-Small Cell Lung Cancer
576377|NCT00410189|NSCLC
576378|NCT00410189|Lung Cancer
576379|NCT00410189|ZD6474
576380|NCT00410189|Zactima
576381|NCT00410189|Vandetanib
576382|NCT00410189|BATTLE Program
576383|NCT00410163|B-cell
576384|NCT00410163|cyclophosphamide
576385|NCT00410163|fludarabine
576386|NCT00410163|Chronic Lymphocytic Leukemia
576387|NCT00410163|Ofatumumab
576388|NCT00410150|Status asthmaticus
576389|NCT00410150|Asthma
576390|NCT00410150|Helium
576391|NCT00410150|Children
576392|NCT00410124|advanced kidney cancer
576393|NCT00410124|everolimus
576394|NCT00410124|kidney cancer
576395|NCT00410124|oral therapy
576396|NCT00410111|sepsis
576397|NCT00410111|encephalopathy
576398|NCT00410111|cerebral perfusion
576399|NCT00410111|electroencephalogram
576400|NCT00410098|asthma
576401|NCT00410098|yoga
576402|NCT00410098|heat
576403|NCT00410098|humidity
576404|NCT00410098|bikram
576405|NCT00410059|Non-Small Cell Lung Cancer
576406|NCT00410059|Lung Cancer
576407|NCT00410059|NSCLC
576408|NCT00410059|Erlotinib
576409|NCT00410059|Tarceva
576410|NCT00410059|OSI-774
576411|NCT00410059|Battle Program
576412|NCT00410020|alpha linolenic acid
576413|NCT00410020|atrial fibrillation
576414|NCT00410020|omega 3 fatty acids
576415|NCT00410020|diet
576416|NCT00410020|rapeseed oil
576417|NCT00410020|canola oil
576418|NCT00410020|cardiovascular diseases
576419|NCT00410007|ADPKD
576420|NCT00410007|Urinary Aquaporin-2
576421|NCT00410007|ENaC
576422|NCT00410007|Fractional sodium excretion
576423|NCT00410007|High/low sodium diet
576424|NCT00409994|Colorectal cancer
576425|NCT00409994|M-tor inhibitor
576426|NCT00409994|Rapamycin
576427|NCT00409981|in stent restenosis
576428|NCT00409981|paclitaxel coated balloon catheter
576429|NCT00409981|paccocath
576430|NCT00409981|drug eluting balloon
576431|NCT00409968|Lung Cancer
576432|NCT00409968|Non Small Cell Lung Cancer
576433|NCT00409968|BATTLE Program
576434|NCT00409968|Umbrella Trial
576435|NCT00409968|Tumor Biopsy
576436|NCT00409968|NSCLC
576437|NCT00409955|Lamellar transplant
576438|NCT00409955|Lyophilization
576439|NCT00409955|Corneas storage
576440|NCT00409955|Keratoconus patients
576441|NCT00409955|Best corrected visual acuity < 20/60
576442|NCT00409955|Signed the consent inform
576443|NCT00409942|Chronic heart failure
576444|NCT00409942|Torasemide prolonged release
576445|NCT00409942|Myocardial fibrosis
576446|NCT00409942|Loop diuretics
576447|NCT00409942|Peptide of procollagen type 1
576448|NCT00409929|Safety, tolerability, pharmacokinetics, pharmacodynamics, AEB071, healthy subjects, transplantation
576449|NCT00409916|chronic heart failure
576450|NCT00409916|heart failure
576451|NCT00409916|congestive heart failure
576452|NCT00409916|impedance cardiography
576453|NCT00409916|ICG
576454|NCT00409916|transthoracic electrical bioimpedance
576455|NCT00409916|non-invasive
576456|NCT00409916|TEB
576457|NCT00409890|Buscopan
576458|NCT00409890|Hyoscine
576459|NCT00409890|Shortens
576460|NCT00409890|Labor
576461|NCT00409890|Stage
576462|NCT00409864|Gallbaldder Cancer
576463|NCT00409864|Endoscopic stenting
576464|NCT00409864|Percutaneous biliary drainage
576465|NCT00409851|HYPERTENSION, VALSARTAN, AMLODIPINE,SAFETY
576466|NCT00409838|Rheumatoid Arthritis, with inadequate response to methotrexate
576467|NCT00409799|Bone graft substitute
576468|NCT00409799|Promotion of bone healing
576469|NCT00409786|Obesity
576470|NCT00409786|Diabetes
576471|NCT00409786|Internet
576472|NCT00409786|Obesity with high cardiovascular risk
576473|NCT00409760|HYEPRTENSION, VALSARTAN, AMLODIPINE, high blood pressure
576474|NCT00409747|Immunology
576475|NCT00409747|Microglia
576476|NCT00409747|NF-Kappa-B
576477|NCT00409747|Antibiotic
576478|NCT00409747|Autism
576479|NCT00409747|Minocycline
576480|NCT00409747|Regressive Autism
576481|NCT00409734|pyloric
576482|NCT00409734|stenosis
576483|NCT00409721|Amyotrophic Lateral Sclerosis
576484|NCT00409721|ALS
576485|NCT00409721|Motor Neuron Disease
576486|NCT00409721|MND
576487|NCT00409721|Memantine
576488|NCT00409708|Attention Deficit Hyperactivity Disorder,
576489|NCT00409708|ADHD
576490|NCT00409708|Cytogenetic abnormalities,
576491|NCT00409708|extended-release methylphenidate,
576492|NCT00409695|Acute Graft versus Host Disease
576493|NCT00409695|aGVHD
576494|NCT00409695|Blood And Marrow Transplantation
576495|NCT00409695|Thymoglobulin
576496|NCT00409695|ATG
576497|NCT00409682|Crohn's Disease
576498|NCT00409669|Barraquer tonometer
576499|NCT00409669|Intraocular pressure
576500|NCT00409669|Tonometry
576501|NCT00409643|HYPERTENSION, VALSARTAN, AMLODIPINE, high blood pressure
576502|NCT00409630|Asthma
576503|NCT00409591|Thailand
576504|NCT00409591|Developing Countries
576505|NCT00409591|Prophylaxis
576506|NCT00409591|Mother-to-child transmission
576507|NCT00409591|HIV-1
576508|NCT00409591|HIV-1 infection
576509|NCT00409591|HIV Seronegativity
576510|NCT00409578|Post acute coronary syndrome
576511|NCT00409578|Acute
576512|NCT00409578|coronary syndrome
576513|NCT00409578|B-type natriuretic peptide
576514|NCT00409578|N-terminal
576515|NCT00409578|pro-B-type natriuretic peptide
576516|NCT00409578|myocardial infarctions
576517|NCT00409565|head and neck cancer
576518|NCT00409565|cetuximab
576519|NCT00409565|bevacizumab
576520|NCT00409565|squamous cell carcinoma
576521|NCT00409565|SCCHN
576522|NCT00409565|Squamous Cell Carcinoma of the Head and Neck
576523|NCT00409526|Iloprost
576524|NCT00409526|PPHN
576525|NCT00409526|Newborn
576526|NCT00409526|Pulmonary Hypertension
576527|NCT00409526|Term
576528|NCT00409526|Persistent Pulmonary Hypertension of the Newborn
576529|NCT00409500|Safety, tolerability, pharmacokinetics, AQW051, food, Japanese, healthy male subjects
576530|NCT00409500|Healthy volunteers study
576531|NCT00409487|obstructive sleep apnea
576532|NCT00409487|hypertension
576533|NCT00409487|ambulatory bloop pressure monitoring
576534|NCT00409448|TBI
576535|NCT00409448|intracranial edema
576536|NCT00409448|brain edema
576537|NCT00409448|craniocerebral trauma
576538|NCT00409448|head injury
576539|NCT00409448|brain hemorrhage, traumatic
576540|NCT00409448|subdural hematoma
576541|NCT00409448|brain concussion
576542|NCT00409448|head injuries, closed
576543|NCT00409448|epidural hematoma
576544|NCT00409448|extra-axial hemorrhage
576545|NCT00409448|cortical contusion
576546|NCT00409435|Postural tachycardia syndrome (POTS)
576547|NCT00409422|pediatric obesity
576548|NCT00409422|overweight
576549|NCT00409422|insulin resistance
576550|NCT00409422|hyperinsulinemia
576551|NCT00409422|weight management program
576552|NCT00409422|family-based
576553|NCT00409409|Sublingual immunotherapy
576554|NCT00409409|Grass pollen tablet
576555|NCT00409409|Allergic rhinoconjunctivitis
576556|NCT00409396|Ulcerative
576557|NCT00409396|Colitis
576558|NCT00409396|PGE-M
576559|NCT00409396|fecal calprotectin
576560|NCT00409396|disease biomarkers
576561|NCT00409383|Advanced Melanoma
576562|NCT00409383|Normal baseline LDH
576563|NCT00409383|Chemotherapy naive
576564|NCT00409357|urinary tract
576565|NCT00409344|Thoracoabdominal Aortic Aneurysm
576566|NCT00409344|Dexmedetomidine
576567|NCT00409344|Mechanical ventilation
576568|NCT00409331|Head and Neck Cancer
576569|NCT00409331|HNSCC
576570|NCT00409331|Submandibular and Sublingual Salivary Sparing
576571|NCT00409331|Amifostine
576572|NCT00409331|Ethyol
576573|NCT00409331|Radiation Therapy
576574|NCT00409318|Inflammation
576575|NCT00409318|Visceral adiposity
576576|NCT00409318|TNF
576577|NCT00409318|CRP
576578|NCT00409318|Adiponectin
576579|NCT00409318|Insulin resistance
576580|NCT00409318|metabolic syndrome
576581|NCT00409292|RAD001
576582|NCT00409292|metastatic pancreatic cancer
576583|NCT00409279|Aging
576584|NCT00409279|Parent / Adult-child interaction
576585|NCT00409279|Family caregivers
576586|NCT00409279|Alzheimer's
576587|NCT00409279|Caregiving
576588|NCT00409253|PRE-ECLAMPSIA-URAPIDIL-NICARDIPINE
576589|NCT00409240|Group Intervention
576590|NCT00409240|Pharmacotherapy
576591|NCT00409240|Behavioral Modification
576592|NCT00409240|Diabetes
576593|NCT00409227|swl
576594|NCT00409227|lithotripsy
576595|NCT00409227|stone disease
576596|NCT00409227|urolithiasis
576597|NCT00409227|nephrolithiasis
576598|NCT00409214|Glioma
576599|NCT00409214|Litx™
576600|NCT00409214|LS11
576601|NCT00409214|Glioblastoma multiforme
576602|NCT00409214|Anaplastic Astrocytoma
576603|NCT00409214|GBM
576604|NCT00409214|AA
576605|NCT00409201|schizophrenia
576606|NCT00409201|reboxetine
576607|NCT00409201|cognitive
576608|NCT00409201|behavior
576609|NCT00409188|Non-Small Cell Lung Carcinoma;
576610|NCT00409188|stage III;
576611|NCT00409188|unresectable;
576612|NCT00409188|vaccine; Tecemotide; L-BLP25;
576613|NCT00409188|Cyclophosphamide;
576614|NCT00409188|placebo controlled;
576615|NCT00409188|randomized;
576616|NCT00409188|double blind;
576617|NCT00409188|immunotherapy;
576618|NCT00409175|FAP
576619|NCT00409175|Fx-1006A
576620|NCT00409175|transthyretin
576621|NCT00409175|TTR
576622|NCT00409175|amyloid
576623|NCT00409175|polyneuropathy
576624|NCT00409175|V30M
576625|NCT00409175|familial
576626|NCT00409175|hereditary
576627|NCT00409175|amyloidosis
576628|NCT00409175|FoldRx
576629|NCT00409162|Tattoo removal
576630|NCT00409149|Hypertension
576631|NCT00409149|Diet
576632|NCT00409149|physical exercise
576633|NCT00409149|naturopathic
576634|NCT00409149|group therapy
576635|NCT00409149|Qi Gong
576636|NCT00409136|Alert
576637|NCT00409136|Deep Vein Thrombosis
576638|NCT00409136|Pulmonary Embolism
576639|NCT00409136|Venous Thromboembolism
576640|NCT00409136|Prophylaxis
576641|NCT00409136|Anticoagulation
576642|NCT00409123|vasospastic women
576643|NCT00409123|controls
576644|NCT00409123|core cooling
576645|NCT00409123|core warming
576646|NCT00409123|external cooling
576647|NCT00409123|external warming
576648|NCT00409123|LDF
576649|NCT00409123|choroidal blood flow
576650|NCT00409123|temperature
576651|NCT00409123|vasospastic subjects
576652|NCT00409123|normal subjects
576653|NCT00409110|Ocular Pulse Amplitude
576654|NCT00409110|Dynamic Contour Tonometry
576655|NCT00409110|Pulsatility Index
576656|NCT00409110|Choroidal Laser Doppler Flowmetry
576657|NCT00409110|Finometer
576658|NCT00409097|ADMA
576659|NCT00409097|MOF
576660|NCT00409097|Critical illness
576661|NCT00409084|varices
576662|NCT00409084|band ligation
576663|NCT00409084|portal hypertension
576664|NCT00409084|primary prophylaxis
576665|NCT00409084|cirrhosis
576666|NCT00409084|beta blockers
576667|NCT00409071|Non metastatic breast cancer
576668|NCT00409071|Adjuvant chemotherapy
576669|NCT00409071|Nausea
576670|NCT00409071|Vomiting
576671|NCT00409071|Quality of life
576672|NCT00409071|Homeopathy
576673|NCT00409058|TBI (Traumatic Brain Injury)
576674|NCT00409058|Intracranial Edema
576675|NCT00409058|Brain Edema
576676|NCT00409058|Craniocerebral Trauma
576677|NCT00409058|Head Injury
576678|NCT00409058|Brain Hemorrhage, Traumatic
576679|NCT00409058|Subdural Hematoma
576680|NCT00409058|Brain Concussion
576681|NCT00409058|Head Injuries, Closed
576682|NCT00409045|Obstructive Sleep Apnea
576683|NCT00409045|Pulmonary Embolism
576684|NCT00409045|male and female patients suspected of having a pulmonary embolism.
576685|NCT00409032|osteoporosis
576686|NCT00409032|BMD
576687|NCT00409032|CTX
576688|NCT00409032|Post menopausal
576689|NCT00409032|strontium
576690|NCT00409032|bone turnover
576691|NCT00409032|clinical development
576692|NCT00408564|adenocarcinoma of the pancreas
576693|NCT00408564|stage II pancreatic cancer
576694|NCT00408564|stage III pancreatic cancer
576695|NCT00408551|stage IV colon cancer
576696|NCT00408551|stage IV rectal cancer
576697|NCT00408551|liver metastases
576698|NCT00408551|recurrent colon cancer
576699|NCT00408551|recurrent rectal cancer
576700|NCT00408538|Microbicide
576701|NCT00408538|HIV
576702|NCT00408538|Prevention
576703|NCT00408538|Rectal
576704|NCT00408538|HIV Prevention
576705|NCT00408525|memory loss
576706|NCT00408525|memory problems
576707|NCT00408525|alzheimer's
576708|NCT00408525|forgetfulness
576709|NCT00408525|forgetting
576710|NCT00408512|treatment
576711|NCT00408512|adverse events
576712|NCT00408512|adherence
576713|NCT00408512|gene
576714|NCT00408512|polymorphism
576715|NCT00408499|unspecified adult solid tumor, protocol specific
576716|NCT00408499|stage IIIA non-small cell lung cancer
576717|NCT00408499|stage IIIB non-small cell lung cancer
576718|NCT00408499|stage IV non-small cell lung cancer
576719|NCT00408499|recurrent non-small cell lung cancer
576720|NCT00408980|diet
576721|NCT00408980|breast milk fat
576722|NCT00408967|Ovarian
576723|NCT00408967|Cancer
576724|NCT00408967|Epithelial
576725|NCT00408967|Recurrent
576726|NCT00408967|Platinum
576727|NCT00408967|Second-line therapy
576728|NCT00408967|Maintenance Therapy
576729|NCT00408967|Biologic
576730|NCT00408967|Targeted Therapy
576731|NCT00408967|Antibody
576732|NCT00408941|EEG
576733|NCT00408941|AEP
576734|NCT00408941|Artefacts
576735|NCT00408941|Propofol
576736|NCT00408941|Local Anaesthesia
576737|NCT00408928|Graft-versus-Host Disease
576738|NCT00408928|bortezomib
576739|NCT00408915|Lisuride
576740|NCT00408915|Continuous Dopaminergic Stimulation
576741|NCT00408915|Motor Fluctuations
576742|NCT00408915|Off-Times
576743|NCT00408915|Troublesome Dyskinesia
576744|NCT00408915|Parkinson's Disease with motor fluctuations with OFF periods and/or troublesome dyskinesias of more than four hours per day
576745|NCT00408889|liver transplantation
576746|NCT00408889|organ failure
576747|NCT00408889|outcome
576748|NCT00408863|Breast cancer
576749|NCT00408863|Tibolone
576750|NCT00408863|Climacteric symptoms
576751|NCT00408850|sympathetic nervous system, pioglitazone, metabolic syndrome
576752|NCT00408824|insulin resistance
576753|NCT00408824|adipocytokine
576754|NCT00408824|Metabolic syndrome
576755|NCT00408824|Diabetes
576756|NCT00408798|Treatment of Alopecia areata with intracutaneous injections of Botulinum Toxin A
576757|NCT00408785|Botulinum Toxin Type A
576758|NCT00408785|safety
576759|NCT00408785|efficacy
576760|NCT00408785|glabellar lines
576761|NCT00408772|liver metastases
576762|NCT00408772|stage IV colon cancer
576763|NCT00408772|stage IV rectal cancer
576764|NCT00408772|adenocarcinoma of the colon
576765|NCT00408772|adenocarcinoma of the rectum
576766|NCT00408772|recurrent colon cancer
576767|NCT00408772|recurrent rectal cancer
576768|NCT00408759|xerostomia
576769|NCT00408759|hypnosis
576770|NCT00408759|dry mouth
576771|NCT00408759|radiotherapy
576772|NCT00408759|head and neck cancer
576773|NCT00408746|stomatognathic system
576774|NCT00408746|maxilla
576775|NCT00408746|palate
576776|NCT00408746|development
576777|NCT00408720|Spectral OCT
576778|NCT00408720|SLO
576779|NCT00408720|Retinal Imagining
576780|NCT00408707|local infiltration analgesia
576781|NCT00408707|postoperative pain
576782|NCT00408707|ropivacaine
576783|NCT00408668|Malaria Vaccine
576784|NCT00408642|adherence
576785|NCT00408642|treatment
576786|NCT00408642|antiretroviral
576787|NCT00408642|HAART
576788|NCT00408642|HIV
576789|NCT00408642|Treatment Naive
576790|NCT00408629|Ulcerative Colitis
576791|NCT00408629|Adalimumab
576792|NCT00408629|TNF Antagonist
576793|NCT00408629|Mayo Score
576794|NCT00408603|second line treatment
576795|NCT00408603|platinum resistant
576796|NCT00408603|ovary
576797|NCT00408603|ovaries
576798|NCT00408603|cancer
576799|NCT00408603|epithelial
576800|NCT00408603|carcinomas
576801|NCT00408603|tumor
576802|NCT00408590|ovarian clear cell cystadenocarcinoma
576803|NCT00408590|ovarian endometrioid adenocarcinoma
576804|NCT00408590|primary peritoneal cavity cancer
576805|NCT00408590|ovarian mixed epithelial carcinoma
576806|NCT00408590|ovarian mucinous cystadenocarcinoma
576807|NCT00408590|ovarian serous cystadenocarcinoma
576808|NCT00408590|ovarian undifferentiated adenocarcinoma
576809|NCT00408590|recurrent ovarian epithelial cancer
576810|NCT00408590|Brenner tumor
576811|NCT00408577|glucose intolerance
576812|NCT00408577|cardiovascular disease
576813|NCT00408577|insulin resistance
576814|NCT00408577|endothelial dysfunction
576815|NCT00408447|stem cell transplant
576816|NCT00408447|sickle cell disease
576817|NCT00408447|thalassemia
576818|NCT00408447|moderately ablative
576819|NCT00408447|cord blood transplant
576820|NCT00408447|matched family donor
576821|NCT00408434|PPARgamma agonist
576822|NCT00408434|advanced or metastatic malignancies
576823|NCT00408434|Tumor
576824|NCT00408434|Cancer
576825|NCT00408408|stage I breast cancer
576826|NCT00408408|stage II breast cancer
576827|NCT00408408|stage IIIA breast cancer
576828|NCT00408395|influenza
576829|NCT00408395|children
576830|NCT00408395|vaccine
576831|NCT00408395|influenza disease
576832|NCT00408382|Lipitor
576833|NCT00408382|atorvastatin
576834|NCT00408382|Hypercholesteremia
576835|NCT00408382|yellow coronary plaque
576836|NCT00408369|prophylactic
576837|NCT00408369|malaria
576838|NCT00408369|challenge
576839|NCT00408356|Zinc treatment
576840|NCT00408356|supplementation
576841|NCT00408356|Enterotoxigenic E. coli
576842|NCT00408356|diarrhoea
576843|NCT00408317|Cystic Fibrosis
576844|NCT00408317|Exocrine Pancreatic Insufficiency
576845|NCT00408317|Ultrase® MT20
576846|NCT00408304|interferon alpha
576847|NCT00408304|depression
576848|NCT00408304|omega 3
576849|NCT00408291|fracture
576850|NCT00408291|shoulder
576851|NCT00408291|bone density
576852|NCT00408291|healing
576853|NCT00408278|Acute Promyelocytic Leukemia
576854|NCT00408265|Nicotine Dependence
576855|NCT00408265|Contingency Management
576856|NCT00408252|recurrent or locally advanced
576857|NCT00408252|cytokine failure
576858|NCT00408239|Factor Xa inhibitor
576859|NCT00408239|Thromboembolism
576860|NCT00408239|Arthroplasty
576861|NCT00408239|Knee Replacement
576862|NCT00408239|Prevention and Control
576863|NCT00408200|Atrial fibrillation
576864|NCT00408200|Atrial arrhythmia
576865|NCT00408187|Randomized Controlled Trials
576866|NCT00408187|Immunosuppression
576867|NCT00408187|Adult
576868|NCT00408187|Chronic Disease
576869|NCT00408187|Dermatologic Agents
576870|NCT00408187|Female
576871|NCT00408187|Humans
576872|NCT00408187|Male
576873|NCT00408187|Middle Aged
576874|NCT00408187|Severity of Illness Index
576875|NCT00408187|Treatment Outcome
576876|NCT00408187|Quality of Life
576877|NCT00408187|Double-Blind Method
576878|NCT00408174|IBD
576879|NCT00408174|UC
576880|NCT00408174|Ulcerative Colitis
576881|NCT00408174|Inflammatory Bowel Disease
576882|NCT00408161|Contingency Management
576883|NCT00408161|Alcohol Dependence
576884|NCT00408135|Respiratory Tract Infections
576885|NCT00408135|Skin Diseases
576886|NCT00408135|Sinusitis
576887|NCT00408109|Avian Influenza
576888|NCT00408109|Healthy
576889|NCT00408109|Immunity
576890|NCT00408109|Preventive
576891|NCT00408109|Bird Flu
576892|NCT00408109|Healthy Volunteer
576893|NCT00408109|HV
576894|NCT00408096|osteoarthritis
576895|NCT00408096|shoulder
576896|NCT00408096|resurfacing
576897|NCT00408096|prosthesis
576898|NCT00408070|ovarian cancer
576899|NCT00408070|fallopian tube cancer
576900|NCT00408070|peritoneal cancer
576901|NCT00408057|lipid lowering
576902|NCT00408057|target achievement
576903|NCT00408057|Patients with established cardiovascular disease
576904|NCT00408031|Major depressive disorder
576905|NCT00408031|NMDA receptor
576906|NCT00408031|Treatment-Resistant
576907|NCT00408031|D-cycloserine
576908|NCT00407992|Headache
576909|NCT00407992|Migraine
576910|NCT00407953|prostate
576911|NCT00407953|BPH
576912|NCT00407953|Prolieve
576913|NCT00407953|AUA
576914|NCT00407953|hyperthermia
576915|NCT00407953|thermodilatation
576916|NCT00407953|benign hyperplastic hyperplasia
576917|NCT00407953|urology
576918|NCT00407953|microwave therapy
576919|NCT00407953|TUMT
576920|NCT00407940|Thrombosis
576921|NCT00407940|Claudication
576922|NCT00407914|wrinkles
576923|NCT00407914|soft tissue filler
576924|NCT00407914|Aquamid
576925|NCT00407901|Visually Challenged
576926|NCT00407901|Legally Blind
576927|NCT00407901|Functional Assessment Questionnaire
576928|NCT00407901|Low Functioning
576929|NCT00407901|High Functioning
576930|NCT00407875|Prostate
576931|NCT00407875|Cancer
576932|NCT00407875|Radiation
576933|NCT00407862|insulin resistance
576934|NCT00407862|beta cell function
576935|NCT00407862|endothelial dysfunction
576936|NCT00407836|HIV
576937|NCT00407836|CD4 T cell level
576938|NCT00407836|CD4 autoimmunity
576939|NCT00407836|Viral load
576940|NCT00407836|T cell vaccination
576941|NCT00407836|HIV Therapeutic Vaccine
576942|NCT00407823|Child
576943|NCT00407823|Septic shock
576944|NCT00407823|Resuscitation
576945|NCT00407823|Central venous oxygen saturation
576946|NCT00407823|Cardiac output
576947|NCT00407823|Goal-directed therapy
576948|NCT00407797|Lyrica
576949|NCT00407797|Epilepsies - Partial
576950|NCT00407784|primary aldosteronism
576951|NCT00407784|hypertension
576952|NCT00407784|aldosteron-renin ratio
576953|NCT00407784|eplerenone
576954|NCT00407784|aldosteron-receptor antagonist
576955|NCT00407784|screening
576956|NCT00407771|platelet function assay
576957|NCT00407771|Glycoprotein inhibitors
576958|NCT00407771|percutaneous coronary intervention
576959|NCT00407771|Diabetes Mellitus
576960|NCT00407758|recurrent ovarian epithelial cancer
576961|NCT00407758|primary peritoneal cavity cancer
576962|NCT00407745|Pain
576963|NCT00407745|central neuropathic pain
576964|NCT00407732|hepatitis C
576965|NCT00407732|mental disorder
576966|NCT00407732|substance use
576967|NCT00407732|psychosocial intervention
576968|NCT00407719|Choroidal Neovascularization
576969|NCT00407706|Breast Cancer, FACS, SCM, Malignant, Benign, Lymphocytes
576970|NCT00407693|Dosimetry
576971|NCT00407693|Effective Dose
576972|NCT00407693|Radiation-Absorbed Dose
576973|NCT00407680|Type 2 diabetes mellitus
576974|NCT00407680|Hypertension
576975|NCT00407680|Angiotensin II Receptor Blocker
576976|NCT00407680|Diabetic nephropathy
576977|NCT00407667|hemiparesis
576978|NCT00407667|rehabilitation
576979|NCT00407667|upper limb rehabilitation
576980|NCT00407667|arm therapy
576981|NCT00407641|diabetes mellitus
576982|NCT00407641|chronic hemodialysis
576983|NCT00407641|anticoagulation
576984|NCT00407641|outcome
576985|NCT00407628|Stroke
576986|NCT00407628|Diffusion spectrum tractography
576987|NCT00407628|Functional MRI (fMRI)
576988|NCT00407628|Lower extremity
576989|NCT00407602|retinitis pigmentosa
576990|NCT00407602|device
576991|NCT00407602|retinal implant
576992|NCT00407602|retinal prosthesis
576993|NCT00407602|RP
576994|NCT00407602|outer retinal degeneration
576995|NCT00407576|Alzheimer's Disease
576996|NCT00407576|Positron Emission Tomography
576997|NCT00407576|Brain
576998|NCT00407576|Neurochemistry
576999|NCT00407576|Beta-Amyloid Plaques
577000|NCT00407576|PET
577001|NCT00407576|MeS-IMPY
577002|NCT00407576|Alzheimer Disease
577003|NCT00407576|AD
577004|NCT00407576|Dementia
577005|NCT00407576|Healthy Volunteer
577006|NCT00407576|HV
577007|NCT00407550|stage IIIB non-small cell lung cancer
577008|NCT00407550|stage IV non-small cell lung cancer
577009|NCT00407550|recurrent non-small cell lung cancer
577010|NCT00407498|P 276-00
577011|NCT00407498|Advanced Refractory Neoplasm
577012|NCT00407498|Maximum Tolerated Dose
577013|NCT00407498|Dose Limiting Toxicity
577014|NCT00407498|Pharmacokinetics
577015|NCT00407472|Bio-equivalence study in healthy volunteers, indication
577016|NCT00407472|of product is growth hormone deficiency
577017|NCT00407446|PDE5 inhibition
577018|NCT00407446|chronic heart failure
577019|NCT00407446|endothelial function
577020|NCT00407446|exercise ventilation
577021|NCT00407433|Gemcitabine
577022|NCT00407433|Oxaliplatine
577023|NCT00407433|Paediatric solid tumors
577024|NCT00407433|Other CNS tumors
577025|NCT00407433|Other miscellaneous solid non-CNS tumours
577026|NCT00407420|Childhood
577027|NCT00407420|Obesity
577028|NCT00407420|Behavior modification
577029|NCT00407420|Insulin resistance
577030|NCT00407407|Epithelial ovarian
577031|NCT00407407|Primary peritoneal or fallopian tube carcinoma
577032|NCT00407407|Abraxane
577033|NCT00407407|Carboplatin
577034|NCT00407394|Pneumonia
577035|NCT00407394|Wheezing
577036|NCT00407394|Treatment
577037|NCT00407394|Children
577038|NCT00407394|India
577039|NCT00407381|DME
577040|NCT00407355|vein occlusion
577041|NCT00407355|macular edema
577042|NCT00407342|Psoriasis
577043|NCT00407342|biologics
577044|NCT00407342|alefacept
577045|NCT00407342|Narrowband UVB
577046|NCT00407342|Phototherapy
577047|NCT00407342|Half-side comparison
577048|NCT00407329|BPH
577049|NCT00407316|Uveitis
577050|NCT00407316|Quality of life
577051|NCT00407316|Visual function
577052|NCT00407290|pregnancy
577053|NCT00407290|vaginal delivery
577054|NCT00407277|nicotine dependence
577055|NCT00407277|smoking
577056|NCT00407277|nicotine patch
577057|NCT00407277|double-blind
577058|NCT00407277|randomized
577059|NCT00407277|placebo
577060|NCT00407277|psychosis
577061|NCT00407277|schizophrenia
577062|NCT00407277|schizophreniform
577063|NCT00407277|schizoaffective disorder
577064|NCT00407264|bronchial squamous metaplasia
577065|NCT00407264|bronchial squamous dysplasia
577066|NCT00407251|refractory
577067|NCT00407251|prostate
577068|NCT00407251|hormone
577069|NCT00407238|barrier function, multi-purpose solutions, silicone hydrogel contact lenses
577070|NCT00407212|early stage idiopathic Parkinson's disease
577071|NCT00407199|social phobia, anxiety, quetiapine
577072|NCT00407186|CRITICS
577073|NCT00407186|gastric cancer
577074|NCT00407186|surgery
577075|NCT00407186|adjuvant
577076|NCT00407186|chemotherapy
577077|NCT00407186|chemoradiotherapy
577078|NCT00407186|capecitabine
577079|NCT00407186|cisplatin
577080|NCT00407186|epirubicin
577081|NCT00407160|Kidney transplant
577082|NCT00407160|Tolerance induction
577083|NCT00407160|High PRA kidney recipients
577084|NCT00407147|bacterial infection
577085|NCT00407147|empiric antibiotic treatment
577086|NCT00407147|duration antibiotic treatment
577087|NCT00407147|reduce antibiotic treatment
577088|NCT00407147|procalcitonin
577089|NCT00407147|PCT Kryptor
577090|NCT00407147|sepsis
577091|NCT00407147|Intensive Care Unit
577092|NCT00407147|antibiotic treatment
577093|NCT00407121|Neovascular Membrane
577094|NCT00407121|Uveitis
577095|NCT00407121|Bevacizumab
577096|NCT00407108|vitreoretinal surgery
577097|NCT00407095|Parkinson Disease
577098|NCT00407043|Dry Eye Disease
577099|NCT00407043|Lotemax
577100|NCT00407043|Restasis
577101|NCT00407043|Loteprednol
577102|NCT00407043|Cyclosporine
577103|NCT00407004|acute-on-chronic liver failure, MARS, Prometheus, bilirubin, bile acids, cytokines
577104|NCT00406991|retinal blood flow
577105|NCT00406991|diabetic retinopathy
577106|NCT00406991|microthrombosis
577107|NCT00406991|aspirin
577108|NCT00406991|clopidogrel
577109|NCT00406978|MYELOMA
577110|NCT00406978|THALIDOMIDE
577111|NCT00406978|DEFIBRODITE
577112|NCT00406939|Gene Therapy
577113|NCT00406939|Immunology
577114|NCT00406939|Phase I Clinical Trial
577115|NCT00406900|uveal melanoma
577116|NCT00406900|metastatic disease
577117|NCT00406874|infertility
577118|NCT00406874|semen quality
577119|NCT00406874|sexual function
577120|NCT00406874|blood pressure
577121|NCT00406874|omega 3 fats
577122|NCT00406874|folic acid
577123|NCT00406861|reaction
577124|NCT00406861|ENL
577125|NCT00406861|leprosy
577126|NCT00406835|Whole Brain Radiation Therapy
577127|NCT00406835|Stereotactic Radiosurgery
577128|NCT00406835|Brain metastases
577129|NCT00406822|Glaucoma
577130|NCT00406822|collagen matrix
577131|NCT00406822|OculusGen
577132|NCT00406822|trabeculectomy
577133|NCT00406822|tissue engineering
577134|NCT00406809|Sezary syndrome
577135|NCT00406809|cutaneous T-cell lymphoma
577136|NCT00406809|follicular lymphoma
577137|NCT00406809|marginal zone lymphoma
577138|NCT00406809|indolent T-cell lymphoma
577139|NCT00406809|Navitoclax
577140|NCT00406809|Non-Hodgkin's lymphoma
577141|NCT00406809|peripheral T-cell lymphoma
577142|NCT00406809|ABT-263
577143|NCT00406809|lymphoid malignancies
577144|NCT00406809|chronic lymphoid leukemia
577145|NCT00406809|mycosis fungoides
577146|NCT00406809|mantle cell lymphoma
577147|NCT00406783|Allergic Rhinitis
577148|NCT00406783|Intermittent Allergic Rhinitis
577149|NCT00406770|Obesity
577150|NCT00406770|Light therapy
577151|NCT00406770|Hypocaloric diet
577152|NCT00406757|T-cell
577153|NCT00406757|T-ALL
577154|NCT00406757|T-LBL
577155|NCT00406757|506U78
577156|NCT00406757|ara-G
577157|NCT00406757|ara-GTP
577158|NCT00406757|Lymphoma
577159|NCT00406757|Leukemia
577160|NCT00406744|neovascularization
577161|NCT00406731|Endothelin-1
577162|NCT00406731|L-NG-Monomethyl Arginine
577163|NCT00406731|Optic Nerve Head blood flow
577164|NCT00406718|Medication Adherence
577165|NCT00406718|Psychosocial Treatment
577166|NCT00406718|Cognitive Adaptation Training
577167|NCT00406718|Med-e Monitor
577168|NCT00406718|Adaptive Function
577169|NCT00406705|Exercise Tolerance
577170|NCT00406705|Dyspnea
577171|NCT00406705|Rehabilitation
577172|NCT00406705|Helium
577173|NCT00406692|Zonisamide
577174|NCT00406692|Alcoholism
577175|NCT00406692|Alcohol
577176|NCT00406679|pain, postoperative
577177|NCT00406679|surgery, oral
577178|NCT00406679|surgery, dental
577179|NCT00406640|MDD
577180|NCT00406640|Major Depressive Disorder
577181|NCT00406640|Depression
577182|NCT00406627|filariasis, lymphatic filariasis, Egypt
577183|NCT00406614|High Blood Pressure
577184|NCT00406588|Parkinson Disease
577185|NCT00406575|Congestive heart failure
577186|NCT00406575|Relaxin
577187|NCT00406575|Hemodynamics
577188|NCT00406575|Renal function
577189|NCT00406562|uncontrolled
577190|NCT00406549|Staphylococcus aureus
577191|NCT00406549|Nasal colonization
577192|NCT00406549|pre-surgical patients
577193|NCT00406549|Sensitivity
577194|NCT00406549|Specificity
577195|NCT00406549|Nasal Staphylococcus aureus in pre-surgical patients
577196|NCT00406536|Cystic Fibrosis
577197|NCT00406536|Pancreatic Insufficiency
577198|NCT00406536|LYM-X-SORB™
577199|NCT00406536|LXS
577200|NCT00406484|Methadone
577201|NCT00406484|Counseling
577202|NCT00406484|HIV risk reduction
577203|NCT00406484|HIV Seronegativity
577204|NCT00406471|Ischemic
577205|NCT00406471|Central
577206|NCT00406471|Retinal
577207|NCT00406471|Vein
577208|NCT00406471|Occlusion
577209|NCT00406471|Ranibizumab
577210|NCT00406471|Lucentis
577211|NCT00406471|CRVO
577212|NCT00406471|ISCRVO
577213|NCT00406458|Diabetic neuropathy
577214|NCT00406458|Diabetes Type I or II
577215|NCT00406458|Mild to moderate sensorimotor diabetic polyneuropathy
577216|NCT00406445|Metabolism
577217|NCT00406445|Li-Fraumeni Syndrome
577218|NCT00406432|BRL029060/Paroxetine CR
577219|NCT00406432|pharmacokinetics
577220|NCT00406432|repeat dose
577221|NCT00406419|anti-CD20
577222|NCT00406419|stage
577223|NCT00406419|CD20
577224|NCT00406419|RA
577225|NCT00406393|Acute Myelogenous Leukemia
577226|NCT00406393|Acute Lymphoblastic Leukemia
577227|NCT00406393|Chronic Myelogenous Leukemia
577228|NCT00406380|Telangiectasias
577229|NCT00406380|Leakage
577230|NCT00406380|Bevacizumab
577231|NCT00406380|Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)
577232|NCT00406380|Idiopathic juxtafoveal retinal telangiectasias
577233|NCT00406315|ziprasidone, quetiapine (Seroquel) switch, open label, flexible dose, schizophrenia, schizoaffective disorder
577234|NCT00406302|NSCLC
577235|NCT00406302|non-small-cell lung cancer
577236|NCT00406276|Lung Cancer
577237|NCT00406263|nuclear sclerotic cataract
577238|NCT00406263|cataract
577239|NCT00406211|Rubella
577240|NCT00406211|Varicella
577241|NCT00406211|Measles
577242|NCT00406211|Mumps
577243|NCT00406211|Germany
577244|NCT00406211|Austria
577245|NCT00406198|Sepsis syndrom
577246|NCT00406198|severe sepsis
577247|NCT00406198|septic shock
577248|NCT00406198|hemofiltration
577249|NCT00406198|multiple organ failure
577250|NCT00406185|Registry
577251|NCT00406185|cardiac catheterization laboratory
577252|NCT00406185|coronary heart disease
577253|NCT00406185|cardiovascular disease
577254|NCT00406159|Autism
577255|NCT00406159|Hyperbaric Oxygen Therapy
577256|NCT00406159|Behavioral assessments
577257|NCT00406120|eye
577258|NCT00406120|uvea
577259|NCT00406120|iris
577260|NCT00406120|choroid
577261|NCT00406120|ciliary body
577262|NCT00406120|melanoma
577263|NCT00406120|iris melanoma
577264|NCT00406120|choroidal melanoma
577265|NCT00406120|ciliary body melanoma
577266|NCT00406120|uveal melanoma
577267|NCT00406120|posterior uveal melanoma
577268|NCT00406120|prognosis
577269|NCT00406120|metastasis
577270|NCT00406120|genetic testing
577271|NCT00406120|molecular testing
577272|NCT00406120|gene expression profiling
577273|NCT00406107|branch retinal vein occlusion
577274|NCT00406107|macular edema
577275|NCT00406107|pegaptanib sodium
577276|NCT00406107|vascular endothelial growth factor
577277|NCT00406094|NARES
577278|NCT00406094|eosinophils
577279|NCT00406094|nasal symptoms
577280|NCT00406068|Bladder neoplasm
577281|NCT00406068|Intravesical drug administration
577282|NCT00406068|Neoplasm recurrence, local
577283|NCT00406068|Transitional cell, carcinoma
577284|NCT00406068|Carcinoma in situ
577285|NCT00406068|Mycobacterium
577286|NCT00406042|glaucoma
577287|NCT00406042|trabeculoplasty
577288|NCT00406042|steroids
577289|NCT00406016|Acute spinal cord injury;
577290|NCT00406003|BRL029060/Paroxetine CR
577291|NCT00406003|pharmacokinetics
577292|NCT00406003|safety
577293|NCT00405990|HIV
577294|NCT00405990|MTCT
577295|NCT00405990|heterosexual behaviour
577296|NCT00405990|sexual risk behaviour
577297|NCT00405990|couple counselling
577298|NCT00405990|Voluntary counselling and testing
577299|NCT00405990|HIV Seronegativity
577300|NCT00405977|Neuromuscular block
577301|NCT00405977|Magnesium
577302|NCT00405977|Rocuronium
577303|NCT00405977|Time course of action
577304|NCT00405938|Breast cancer
577305|NCT00405938|Metastatic breast cancer
577306|NCT00405938|Bevacizumab
577307|NCT00405938|Anastrozole
577308|NCT00405938|Fulvestrant
577309|NCT00405925|AIDS
577310|NCT00405925|Treatment Naive
577311|NCT00405899|Allergy
577312|NCT00405899|Seasonal Allergic Rhinitis
577313|NCT00405899|Perennial Allergic Rhinitis
577314|NCT00405873|Primary hepatocellular carcinoma
577315|NCT00405873|Liver cancer
577316|NCT00405873|Tumour response
577317|NCT00405873|Quality of life
577318|NCT00405847|Sleep
577319|NCT00405847|Critical illness
577320|NCT00405847|Cytokine
577321|NCT00405834|Pressure Ulcers
577322|NCT00405821|AIDS
577323|NCT00405821|HIV Disease Progression
577324|NCT00405821|Quality of Life
577325|NCT00405821|HIV Viral Load
577326|NCT00405821|Genital Ulcers
577327|NCT00405821|HIV
577328|NCT00405821|Treatment Naive
577329|NCT00405795|Pressure Ulcer
577330|NCT00405782|metastatic breast cancer
577331|NCT00405782|exercise intervention
577332|NCT00405769|statin intolerance
577333|NCT00405769|hyperlipidemia
577334|NCT00405769|lifestyle changes
577335|NCT00405769|red yeast rice
577336|NCT00405756|Newly Diagnosed Multiple Myeloma
577337|NCT00405756|Celgene
577338|NCT00405756|CC-5013
577339|NCT00405756|Revlimid
577340|NCT00405756|Lenalidomide
577341|NCT00405756|Melphalan
577342|NCT00405756|Prednisone
577343|NCT00405756|Elderly
577344|NCT00405743|CP-4055
577345|NCT00405743|ELACYT™
577346|NCT00405743|Cancer
577347|NCT00405743|Refractory
577348|NCT00405743|Relapsed
577349|NCT00405743|Hematologic Malignancies
577350|NCT00405743|Leukemia
577351|NCT00405743|ALL
577352|NCT00405743|AML
577353|NCT00405743|AMM
577354|NCT00405743|CLL
577355|NCT00405743|CML
577356|NCT00405743|CMML
577357|NCT00405743|MDS
577358|NCT00405730|Cataracts
577359|NCT00405717|ischemic heart disease
577360|NCT00405717|acute coronary syndromes
577361|NCT00405717|percutaneous transluminal coronary angioplasty
577362|NCT00405717|statin
577363|NCT00405717|clopidogrel
577364|NCT00405704|Vesicoureteral Reflux
577365|NCT00405704|Urinary Tract Infections
577366|NCT00405704|Renal Scarring
577367|NCT00405704|Antibiotic Resistance
577368|NCT00405704|Controlled Clinical Trial
577369|NCT00405704|Trimethoprim-Sulfamethoxazole
577370|NCT00405704|Children
577371|NCT00405691|Medical Device
577372|NCT00405691|Spine
577373|NCT00405691|Lumbar Spinal Stenosis
577374|NCT00405691|Degenerative Spondylolisthesis
577375|NCT00405691|Facet Arthrosis
577376|NCT00405691|Back and Leg Pain
577377|NCT00405691|Spine Research
577378|NCT00405691|Medical Device Research
577379|NCT00405691|Impliant
577380|NCT00405691|Lumbar Treatment
577381|NCT00405691|Spinal Treatment
577382|NCT00405691|Spinal Device
577383|NCT00405678|Exercise Intervention
577384|NCT00405678|Breast Cancer
577385|NCT00405678|Neo-Adjuvant Therapy
577386|NCT00405678|Operable Breast Cancer Stage I-II receiving neo-adjuvant chemotherapy
577387|NCT00405665|Cystic Fibrosis
577388|NCT00405665|L-Arginine
577389|NCT00405665|Pediatrics
577390|NCT00405665|pulmonary function
577391|NCT00405652|Liver transplantation, mycophenolate, GI problems, Quality of Life
577392|NCT00405626|post partum hemmorhage,Arnica montana,Bellis Perenis
577393|NCT00405613|Aspirin
577394|NCT00405613|Bleeding
577395|NCT00405613|Clinical Trial
577396|NCT00405613|Dental Extraction
577397|NCT00405600|Lumbar degenerative disease
577398|NCT00405600|spinal stenosis
577399|NCT00405600|spondylolisthesis
577400|NCT00405600|non instrumented surgery
577401|NCT00405600|instrumented surgery
577402|NCT00405600|BMP-2
577403|NCT00405574|prostate
577404|NCT00405574|PSA
577405|NCT00405574|antiangiogenic
577406|NCT00405574|copper
577407|NCT00405574|ATN-224
577408|NCT00405561|Advanced Colorectal Carcinoma
577409|NCT00405535|OCD
577410|NCT00405535|Obsessive Compulsive Disorder
577411|NCT00405535|Glycine
577412|NCT00405522|Lumbar Puncture
577413|NCT00405522|Pediatrics
577414|NCT00405522|Propofol
577415|NCT00405522|Remifentanil
577416|NCT00405522|sedation
577417|NCT00405522|Oncology
577418|NCT00405509|Upper Respiratory Infection
577419|NCT00405509|Common Cold
577420|NCT00405483|arthroplasty
577421|NCT00405483|RSA
577422|NCT00405483|micromotion
577423|NCT00405483|osteoarthritis
577424|NCT00405483|minimally invasive
577425|NCT00405483|ProfemurZ
577426|NCT00405470|arthroplasty
577427|NCT00405470|RSA
577428|NCT00405470|micromotion
577429|NCT00405470|osteoarthritis
577430|NCT00405444|Pediatrics
577431|NCT00405444|Pain
577432|NCT00405444|Voiding Cystourethrogram
577433|NCT00405444|Catheterization
577434|NCT00405444|Fentanyl
577435|NCT00405431|glaucoma filtering surgery
577436|NCT00405431|restasis
577437|NCT00405431|conjunctival inflammation
577438|NCT00405405|Head and neck cancer
577439|NCT00405405|Parotid gland cancer
577440|NCT00405405|thyroid gland cancer
577441|NCT00405405|melanoma
577442|NCT00405405|Chemoradiotherapy
577443|NCT00405405|bevacizumab
577444|NCT00405405|erlotinib
577445|NCT00405392|Ibandronate
577446|NCT00405392|risedronate
577447|NCT00405392|Osteoporosis
577448|NCT00405392|preference
577449|NCT00405379|arthroplasty
577450|NCT00405379|RSA
577451|NCT00405379|Osteoarthritis
577452|NCT00405379|trabecular metal mesh
577453|NCT00405366|stage II renal cell cancer
577454|NCT00405366|stage III renal cell cancer
577455|NCT00405366|stage IV renal cell cancer
577456|NCT00405353|multiple sclerosis
577457|NCT00405353|testosterone
577458|NCT00405327|tumor vaccine
577459|NCT00405327|metastatic solid tumors
577460|NCT00405327|recurrent tumors
577461|NCT00405314|respiratory failure
577462|NCT00405314|non invasive ventilation
577463|NCT00405314|prehospital
577464|NCT00405314|endotracheal intubation
577465|NCT00405314|continuous positive airway pressure
577466|NCT00405301|Tuberculosis
577467|NCT00405301|Drug Induced Hepatotoxicity
577468|NCT00405301|Anti-tuberculosis drugs
577469|NCT00405301|India
577470|NCT00405288|Hemorrhoids
577471|NCT00405288|Pregnancy
577472|NCT00405288|antihemorrhoidal
577473|NCT00405288|Proctofoam
577474|NCT00405288|infants
577475|NCT00405275|antineoplastic
577476|NCT00405275|antiparasitics
577477|NCT00405275|antirheumatics
577478|NCT00405275|chronic diseases
577479|NCT00405275|clinical trial
577480|NCT00405275|connective tissue
577481|NCT00405275|double-blind
577482|NCT00405275|drug treatment
577483|NCT00405275|gastric medications
577484|NCT00405275|joint
577485|NCT00405275|multi-site trial
577486|NCT00405275|musculoskeletal
577487|NCT00405275|randomized
577488|NCT00405275|rheumatoid arthritis
577489|NCT00405262|Pediatrics
577490|NCT00405262|Postoperative Analgesia
577491|NCT00405262|orthopedic surgery
577492|NCT00405262|Iliac Crest Bone Graft
577493|NCT00405262|Osteotomy
577494|NCT00405262|cleft palate
577495|NCT00405249|HIV-1
577496|NCT00405249|Treatment Experienced
577497|NCT00405236|inflammation
577498|NCT00405236|exacerbations
577499|NCT00405210|hormone-resistant
577500|NCT00405210|metastatic prostatic cancer
577501|NCT00405210|pharmacokinetics
577502|NCT00405210|naïve patient
577503|NCT00405197|MUFA
577504|NCT00405197|Mediterranean diet
577505|NCT00405197|Insulin resistance
577506|NCT00405197|metabolic syndrome X
577507|NCT00405184|PID
577508|NCT00405184|IVIg
577509|NCT00405184|IntragamP
577510|NCT00405171|Efavirenz
577511|NCT00405171|Nevirapine
577512|NCT00405171|Dyslipidemia
577513|NCT00405171|HIV
577514|NCT00405158|Lactation mastitis
577515|NCT00405158|Breast inflammation
577516|NCT00405158|Breastfeeding
577517|NCT00405158|Care interventions
577518|NCT00405158|Acupuncture treatment
577519|NCT00405158|Antibiotic therapy
577520|NCT00405145|Epilepsy
577521|NCT00405145|MRI
577522|NCT00405145|EEG
577523|NCT00405145|Neuroimaging
577524|NCT00405119|tolerance
577525|NCT00405119|pharmacodynamics
577526|NCT00405119|ranitidine
577527|NCT00405119|esomeprazole
577528|NCT00405119|pharmacokinetics
577529|NCT00405119|gastroesophageal reflux disease (GERD)
577530|NCT00405119|AH23844
577531|NCT00405106|stress
577532|NCT00405106|anxiety
577533|NCT00405106|myopia progression
577534|NCT00405106|accommodation
577535|NCT00405106|vergence
577536|NCT00405093|cardiopulmonary bypass
577537|NCT00405093|circulatory arrest
577538|NCT00405093|aprotinin
577539|NCT00405093|thoracic aorta surgery
577540|NCT00405080|Rifampin GW679769
577541|NCT00405067|Cholesterol
577542|NCT00405015|rosiglitazone
577543|NCT00405015|ischemia-reperfusion injury
577544|NCT00405015|human
577545|NCT00405015|Annexin A5 scintigraphy
577546|NCT00405015|metabolic syndrome
577547|NCT00405002|Acute respiratory failure
577548|NCT00404989|HIV
577549|NCT00404989|HBV
577550|NCT00404989|Hepatitis
577551|NCT00404989|Pregnancy
577552|NCT00404989|Registry
577553|NCT00404976|inflammometry
577554|NCT00404976|exhaled breath condensate
577555|NCT00404976|fractional exhaled nitric oxide
577556|NCT00404976|asthma
577557|NCT00404976|children
577558|NCT00404963|GSK376501,
577559|NCT00404963|First Time in Human,
577560|NCT00404963|Single Dose,
577561|NCT00404963|Dose Escalation,
577562|NCT00404963|Healthy Overweight/Obese Volunteer
577563|NCT00404950|hyperglycemia
577564|NCT00404950|cardiopulmonary bypass
577565|NCT00404950|renal injury
577566|NCT00404950|diabetes
577567|NCT00404924|Non-Small-Cell Lung Carcinoma
577568|NCT00404924|Adenocarcinoma
577569|NCT00404924|Squamous Cell Carcinoma
577570|NCT00404924|Large Cell Carcinoma
577571|NCT00404911|Oppositional Defiant Disorder
577572|NCT00404898|World Trade Center dust
577573|NCT00404885|uveitis
577574|NCT00404885|calcineurin
577575|NCT00404885|inflammation
577576|NCT00404872|Stroke
577577|NCT00404859|inflammometry
577578|NCT00404859|exhaled breath condensate
577579|NCT00404859|fractional exhaled nitric oxide
577580|NCT00404859|asthma
577581|NCT00404859|cystic fibrosis
577582|NCT00404859|monitoring
577583|NCT00404859|exacerbations
577584|NCT00404859|paediatric
577585|NCT00404846|Hyperbaric oxygenation therapy
577586|NCT00404846|HBOT
577587|NCT00404846|Autism
577588|NCT00404833|idiopathic membranous nephropathy or focal segmental glomerulosclerosis
577589|NCT00404820|osteoporosis
577590|NCT00404820|bisphosphonate
577591|NCT00404820|biomarker
577592|NCT00404820|zoledronic acid
577593|NCT00404820|alendronate
577594|NCT00404820|postmenopausal
577595|NCT00404807|Continuous positive airway pressure
577596|NCT00404807|cardiovascular diseases
577597|NCT00404807|sleep apnea syndromes
577598|NCT00404807|sleep breathing disorders
577599|NCT00404807|sham CPAP
577600|NCT00404794|membranous lupus nephritis
577601|NCT00404781|ischemic heart disease
577602|NCT00404781|acute coronary syndromes
577603|NCT00404781|percutaneous transluminal coronary angioplasty
577604|NCT00404781|platelet function
577605|NCT00404781|aspirin
577606|NCT00404781|clopidogrel
577607|NCT00404781|cilostazol
577608|NCT00404768|Pre Term Labor
577609|NCT00404768|Premature Labor
577610|NCT00404768|fetal fibronectin
577611|NCT00404768|intravenous
577612|NCT00404755|Depression
577613|NCT00404742|uveitis
577614|NCT00404742|calcineurin
577615|NCT00404729|Glaucoma
577616|NCT00404729|Optic Neuropathy, Ischemic
577617|NCT00404729|Visual Pathways,
577618|NCT00404729|Optic nerve
577619|NCT00404729|Neural conduction
577620|NCT00404690|Gastroschisis
577621|NCT00404690|Silo
577622|NCT00404690|Operative closure
577623|NCT00404664|influenza vaccine
577624|NCT00404664|influenza immunization
577625|NCT00404664|reminder letters
577626|NCT00404664|raffle prize
577627|NCT00404651|Diphtheria
577628|NCT00404651|Tetanus
577629|NCT00404651|Pertussis
577630|NCT00404651|Hepatitis B
577631|NCT00404651|Poliomyelitis
577632|NCT00404651|Invasive Haemophilus influenzae type b.
577633|NCT00404638|Enuresis Nocturna
577634|NCT00404638|Paula Method
577635|NCT00404638|Circular muscle exercise
577636|NCT00404638|Sphincter
577637|NCT00404625|Bacteremia caused by ESBL-producing Enterobacteriaceae
577638|NCT00404625|Pneumonia caused by ESBL-producing Enterobacteriaceae
577639|NCT00404625|Abdomen infections due to ESBL-producing Enterobacteriaceae
577640|NCT00404625|Skin infections caused by ESBL-producing Enterobacteriaceae
577641|NCT00404625|Urinary infections due to ESBL-producing Enterobacteriaceae
577642|NCT00404612|uveitis
577643|NCT00404612|calcineurin
577644|NCT00404599|simvastatin, atorvastatin, oxidative stress
577645|NCT00404586|GW784568X
577646|NCT00404586|Intranasal
577647|NCT00404586|Environmental Challenge Chamber
577648|NCT00404573|Schizophrenia
577649|NCT00404560|CTLA4 Mutation
577650|NCT00404560|Recurrent Infections
577651|NCT00404560|Immunodeficiency
577652|NCT00404560|Phagocytes
577653|NCT00404560|PI3K
577654|NCT00404560|DOCK8
577655|NCT00404560|STAT 1
577656|NCT00404560|Genetic Mutation
577657|NCT00404560|Cytokines
577658|NCT00404560|Auto-antibodies
577659|NCT00404560|Infection Susceptibility
577660|NCT00404560|Immune Disorders
577661|NCT00404560|Immune Defects of Phagocytes
577662|NCT00404560|Unusual, Chronic Bacterial, Mycobacterial, and Fungal Infections
577663|NCT00404547|Asthma
577664|NCT00404547|Alvesco®
577665|NCT00404547|Ciclesonide
577666|NCT00404534|functional dyspepsia
577667|NCT00404534|Helicobacter pylori
577668|NCT00404534|Anti-Inflammatory Agents, Non-Steroidal
577669|NCT00404534|Gastritis
577670|NCT00404521|Tumor
577671|NCT00404521|PM02734
577672|NCT00404521|PharmaMar
577673|NCT00404508|Hydralazine
577674|NCT00404508|Magnesium Valproate
577675|NCT00404508|Chemotherapy resistance
577676|NCT00404508|Epigenetic therapy
577677|NCT00404482|uveitis
577678|NCT00404482|jia
577679|NCT00404482|Cyclosporine A
577680|NCT00404482|MTX
577681|NCT00404443|Acupuncture
577682|NCT00404443|Electroacupuncture
577683|NCT00404443|Rheumatoid arthritis
577684|NCT00404430|Endothelial function
577685|NCT00404430|Peripheral Arterial Tone
577686|NCT00404430|Systemic Inflammation
577687|NCT00404430|Oxidative Stress
577688|NCT00404430|Respiratory and peripheral muscular function
577689|NCT00404430|Cardiovascular risk
577690|NCT00404430|COPD severity
577691|NCT00404417|pain
577692|NCT00404417|lumbar
577693|NCT00404404|recurrent breast cancer
577694|NCT00404404|stage IV breast cancer
577695|NCT00404391|Moderate to severe pain following bunionectomy surgery
577696|NCT00404378|Healthy subjects
577697|NCT00404378|Pharmacokinetics
577698|NCT00404378|Drug interaction
577699|NCT00404378|Ketoconazole
577700|NCT00404378|Casopitant
577701|NCT00404365|depression
577702|NCT00404365|extensive stage small cell lung cancer
577703|NCT00404365|limited stage small cell lung cancer
577704|NCT00404365|recurrent small cell lung cancer
577705|NCT00404365|stage I non-small cell lung cancer
577706|NCT00404365|stage II non-small cell lung cancer
577707|NCT00404365|stage IIIA non-small cell lung cancer
577708|NCT00404365|stage IIIB non-small cell lung cancer
577709|NCT00404365|stage IV non-small cell lung cancer
577710|NCT00404365|recurrent non-small cell lung cancer
577711|NCT00404352|Rebif New Formulation
577712|NCT00404352|Clinical Isolated Syndrome
577713|NCT00404352|Multiple Sclerosis
577714|NCT00404339|recurrent squamous cell carcinoma of the lip and oral cavity
577715|NCT00404339|stage I squamous cell carcinoma of the lip and oral cavity
577716|NCT00404339|stage II squamous cell carcinoma of the lip and oral cavity
577717|NCT00404339|stage III squamous cell carcinoma of the lip and oral cavity
577718|NCT00404339|metastatic squamous neck cancer with occult primary squamous cell carcinoma
577719|NCT00404339|recurrent metastatic squamous neck cancer with occult primary
577720|NCT00404339|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
577721|NCT00404339|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
577722|NCT00404339|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
577723|NCT00404339|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
577724|NCT00404339|stage I squamous cell carcinoma of the hypopharynx
577725|NCT00404339|stage I squamous cell carcinoma of the larynx
577726|NCT00404339|stage I squamous cell carcinoma of the nasopharynx
577727|NCT00404339|stage I squamous cell carcinoma of the oropharynx
577843|NCT00403767|Stroke
577728|NCT00404339|stage II squamous cell carcinoma of the hypopharynx
577729|NCT00404339|stage II squamous cell carcinoma of the larynx
577730|NCT00404339|stage II squamous cell carcinoma of the nasopharynx
577731|NCT00404339|stage II squamous cell carcinoma of the oropharynx
577732|NCT00404339|stage III squamous cell carcinoma of the hypopharynx
577733|NCT00404339|stage III squamous cell carcinoma of the larynx
577734|NCT00404339|stage III squamous cell carcinoma of the nasopharynx
577735|NCT00404339|stage III squamous cell carcinoma of the oropharynx
577736|NCT00404339|recurrent squamous cell carcinoma of the hypopharynx
577737|NCT00404339|recurrent squamous cell carcinoma of the larynx
577738|NCT00404339|recurrent squamous cell carcinoma of the nasopharynx
577739|NCT00404339|recurrent squamous cell carcinoma of the oropharynx
577740|NCT00404339|stage IV squamous cell carcinoma of the hypopharynx
577741|NCT00404339|stage IV squamous cell carcinoma of the larynx
577742|NCT00404339|stage IV squamous cell carcinoma of the lip and oral cavity
577743|NCT00404339|stage IV squamous cell carcinoma of the nasopharynx
577744|NCT00404339|stage IV squamous cell carcinoma of the oropharynx
577745|NCT00404339|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
577746|NCT00404339|tongue cancer
577747|NCT00404326|Cervical carcinoma
577748|NCT00404326|Epigenetic therapy
577749|NCT00404326|Hydralazine
577750|NCT00404326|Valproate
577751|NCT00404326|Microarray analysis
577752|NCT00404287|C reactive protein
577753|NCT00404287|Inflammation
577754|NCT00404287|Aortic valve stenosis
577755|NCT00404287|progression
577756|NCT00404274|healthy human volunteer
577757|NCT00404274|GW679769
577758|NCT00404274|warfarin
577759|NCT00404274|casopitant
577760|NCT00404261|Fluticasone Propionate
577761|NCT00404261|healthcare professional satisfaction
577762|NCT00404261|patient satisfaction
577763|NCT00404261|metered dose inhaler with counter
577764|NCT00404261|Salmeterol
577765|NCT00404261|Chronic Obstructive Pulmonary Disease (COPD)
577766|NCT00404248|adult anaplastic astrocytoma
577767|NCT00404248|adult anaplastic oligodendroglioma
577768|NCT00404248|adult giant cell glioblastoma
577769|NCT00404248|recurrent adult brain tumor
577770|NCT00404248|adult glioblastoma
577771|NCT00404248|adult gliosarcoma
577772|NCT00404235|stage IV melanoma
577773|NCT00404235|recurrent melanoma
577774|NCT00404222|Acute Pain following Bunionectomy
577775|NCT00404183|Pain associated with osteoarthritis
577776|NCT00404170|imaging
577777|NCT00404170|Parkinson
577778|NCT00404170|progression
577779|NCT00404157|Lupus
577780|NCT00404157|U2970g
577781|NCT00404144|small vessel
577782|NCT00404144|paclitaxel coated balloon catheter
577783|NCT00404144|pepcad
577784|NCT00404144|drug eluting balloon
577785|NCT00404118|long-term care
577786|NCT00404118|satisfaction
577787|NCT00404118|cost
577788|NCT00404105|Excimer laser
577789|NCT00404092|aspergillosis
577790|NCT00404092|caspofungin
577791|NCT00404092|maximum tolerated dose
577792|NCT00404079|Chronic low back pain
577793|NCT00404014|MCI following CABG surgery
577794|NCT00404001|Microbia
577795|NCT00404001|MD-0727
577796|NCT00404001|Primary Hypercholesterolemia
577797|NCT00404001|Hypercholesterolemia
577798|NCT00404001|Hyperlipidemia
577799|NCT00404001|Dyslipidemia
577800|NCT00404001|Cholesterol
577801|NCT00404001|LDL
577802|NCT00403962|anxiety
577803|NCT00403962|Social Anxiety Disorder
577804|NCT00403962|SAD
577805|NCT00403936|osteopathic manipulation
577806|NCT00403936|autonomic nervous system
577807|NCT00403923|Lactose intolerance
577808|NCT00403923|Ulcerative colitis
577809|NCT00403923|Lactose
577810|NCT00403923|Threshold
577811|NCT00403897|Constipation
577812|NCT00403884|Drusen
577813|NCT00403884|Geographic atrophy
577814|NCT00403884|diabetes
577815|NCT00403884|macular edema
577816|NCT00403884|laser
577817|NCT00403884|retinal pigment epithelium
577818|NCT00403871|Anaesthesia
577819|NCT00403871|Pregnency
577820|NCT00403871|Heart disease
577821|NCT00403845|chronic obstructive pulmonary disease
577822|NCT00403845|COPD
577823|NCT00403845|QAB149
577824|NCT00403845|indacaterol
577825|NCT00403845|long acting β2-agonist
577826|NCT00403806|Adenotonsillectomy
577827|NCT00403806|Pediatrics
577828|NCT00403806|Postoperative Nausea and Vomiting
577829|NCT00403806|Pain
577830|NCT00403806|Oral intake
577831|NCT00403806|Dexamethasone
577832|NCT00403806|Dose finding
577833|NCT00403780|Critical limb ischemia
577834|NCT00403780|Pain control
577835|NCT00403780|Rest pain in lower limb ischemia
577836|NCT00403780|pregabalin
577837|NCT00403780|randomized controlled study
577838|NCT00403780|Ischemia, therapy
577839|NCT00403780|Lower extremity, blood supply
577840|NCT00403780|Pain, prevention & control
577841|NCT00403780|Pain, therapy
577842|NCT00403767|Atrial Fibrillation
577844|NCT00403767|Embolism
577845|NCT00403767|Non-central nervous system systemic embolism
577846|NCT00403767|Non-valvular atrial fibrillation
577847|NCT00403767|Blood Clot
577848|NCT00403767|Rivaroxaban
577849|NCT00403767|Warfarin
577850|NCT00403767|Anticoagulants
577851|NCT00403767|Arrhythmias, Cardiac
577852|NCT00403754|asthma
577853|NCT00403754|QAB149
577854|NCT00403754|indacaterol
577855|NCT00403754|long acting β2-agonist
577856|NCT00403754|bronchodilator
577857|NCT00403741|behavior
577858|NCT00403741|physical activity
577859|NCT00403741|motivation
577860|NCT00403728|Ischemia
577861|NCT00403728|Reperfusion
577862|NCT00403728|Myocardial infarction
577863|NCT00403728|ciclosporin A
577864|NCT00403728|acute myocardial infarction
577865|NCT00403702|Retinal detachment
577866|NCT00403702|proliferative vitreoretinopathy
577867|NCT00403702|heavier-than-water internal tamponades
577868|NCT00403689|Increased non-specific inflammatory markers
577869|NCT00403676|nurse practitioner
577870|NCT00403676|rheumatology care
577871|NCT00403676|outpatient clinic
577872|NCT00403676|patient satisfaction
577873|NCT00403663|Body mass index
577874|NCT00403663|Combined Spinal-Epidural Anesthesia
577875|NCT00403663|Cesarean section
577876|NCT00403663|Obesity
577877|NCT00403650|Sarcoidosis
577878|NCT00403650|Dyspnea
577879|NCT00403650|Interstitial lung disease
577880|NCT00403637|Asthma, indacaterol, long acting β2-agonist
577881|NCT00403585|Adefovir Dipivoxil(Hepsera)
577882|NCT00403585|Chronic Hepatitis B (CHB)
577883|NCT00403572|Preeclampsia
577884|NCT00403572|Trans cranial Doppler
577885|NCT00403572|Cardiac output
577886|NCT00403572|systemic vascular resistance
577887|NCT00403572|blood pressure
577888|NCT00403559|seborrheic dermatitis
577889|NCT00403546|Schizophrenia
577890|NCT00403533|Hepatitis C
577891|NCT00403533|viral load
577892|NCT00403533|antiviral therapy
577893|NCT00403533|cholesterol
577894|NCT00403533|atorvastatin
577895|NCT00403520|Alzheimer's disease
577896|NCT00403520|Mild cognitive impairment
577897|NCT00403507|Mild Dementia
577898|NCT00403507|Mild Alzheimer
577899|NCT00403507|Cognitive Impairment
577900|NCT00403507|Cholinesterase Inhibitor
577901|NCT00403507|Exercise
577902|NCT00403507|Physical activity
577903|NCT00403507|Behavior
577904|NCT00403507|Memory loss
577905|NCT00403494|Intermittent Claudication
577906|NCT00403494|IC
577907|NCT00403494|Symptomatic Peripheral Arterial Disease
577908|NCT00403494|Peripheral Arterial Disease
577909|NCT00403494|PAD
577910|NCT00403494|6R-BH4
577911|NCT00403494|BH4
577912|NCT00403494|sapropterin dihydrochloride
577913|NCT00403494|endothelial dysfunction
577914|NCT00403494|Nitric Oxide
577915|NCT00403494|NO
577916|NCT00403481|Hypertension
577917|NCT00403481|Angiotensin Receptor Blocker
577918|NCT00403481|Calcium Channel Blocker
577919|NCT00403481|Angiotensin Converting Enzyme Inhibitor
577920|NCT00403481|Hydrochlorothiazide
577921|NCT00403481|Stage I and II Hypertension
577922|NCT00403481|Type II Diabetes
577923|NCT00403455|Clinical
577924|NCT00403455|Genetics
577925|NCT00403455|Monoamine transporter
577926|NCT00403455|Pharmacogenetics
577927|NCT00403455|Post Traumatic Stress Disorder
577928|NCT00403442|Macular Degeneration
577929|NCT00403429|oral chemotherapy
577930|NCT00403429|platinum resistant
577931|NCT00403429|platinum refractory
577932|NCT00403429|second line
577933|NCT00403416|AEB071
577934|NCT00403416|Tacrolimus
577935|NCT00403416|Mycophenolic acid
577936|NCT00403416|Basiliximab
577937|NCT00403416|Rejection
577938|NCT00403416|Kidney function
577939|NCT00403416|Immunosuppression
577940|NCT00403403|SCLC
577941|NCT00403403|SALUTE
577942|NCT00403403|Lung Cancer
577943|NCT00403403|Avastin
577944|NCT00403377|melanoma
577945|NCT00403377|basal cell carcinoma of the skin
577946|NCT00403377|squamous cell carcinoma of the skin
577947|NCT00403364|Helicobacter pylori infection
577948|NCT00403364|Treatment
577949|NCT00403364|Double blind placebo controlled trial
577950|NCT00403351|Risk
577951|NCT00403351|Coronary artery disease
577952|NCT00403351|Heart Rate variability
577953|NCT00403351|Pulse wave analysis
577954|NCT00403351|BNP
577955|NCT00403351|CRP
577956|NCT00403338|myocardial ischemia
577957|NCT00403338|coronary disease
577958|NCT00403338|heart disease
577959|NCT00403338|Coronary Stenosis [MeSH heading: C14.280.647.250.285]
577960|NCT00403325|Central Serous Chorioretinopathy
577961|NCT00403312|Physical Activity
577962|NCT00403312|Wellness Programs
577963|NCT00403312|Pharmacological Smoking Cessation
577964|NCT00403299|Coronary artery disease
577965|NCT00403299|Cardiac transplantation
577966|NCT00403299|Coronary artery disease in heart transplanted patients
577967|NCT00403286|Chronic
577968|NCT00403286|Obstructive
577969|NCT00403286|Pulmonary
577970|NCT00403286|Disease
577971|NCT00403286|COPD
577972|NCT00403286|Safety
577973|NCT00403286|Efficacy
577974|NCT00403286|Pharmacokinetic
577975|NCT00403286|Dose-finding
577976|NCT00403273|Painful Knee Arthroplasty
577977|NCT00403273|Botulinum Toxin A
577978|NCT00403273|Randomized Controlled Trial
577979|NCT00403273|Pain and Function
577980|NCT00403260|malaria
577981|NCT00403260|ACT
577982|NCT00403260|P falciparum
577983|NCT00403260|pyronaridine
577984|NCT00403260|artesunate
577985|NCT00403247|Schizophrenia
577986|NCT00403247|Schizoaffective Disorder
577987|NCT00403247|Homocysteine
577988|NCT00403247|Vitamins
577989|NCT00403234|Postoperative pain
577990|NCT00403234|opioid
577991|NCT00403234|transdermal
577992|NCT00403234|TKA (total knee arthroplasty)
577993|NCT00403221|Gene therapy
577994|NCT00403221|Prostate cancer
577995|NCT00403221|Immunology, Angiogenesis inhibition
577996|NCT00403221|Phase I clinical trial
577997|NCT00403208|Ventilation, Mechanical
577998|NCT00403208|Sedation
577999|NCT00403195|Ocular Ischemic Syndrome
578000|NCT00403182|recurrent breast cancer
578001|NCT00403182|stage IIIA breast cancer
578002|NCT00403182|stage IIIB breast cancer
578003|NCT00403182|stage IIIC breast cancer
578004|NCT00403182|stage IV breast cancer
578005|NCT00403169|stage III renal cell cancer
578006|NCT00403169|stage IV renal cell cancer
578007|NCT00403169|recurrent renal cell cancer
578008|NCT00403156|Macular Degeneration
578009|NCT00403143|intraocular lens, colour vision, blue-light filtering
578010|NCT00403117|naltrexone
578011|NCT00403117|smoked marijuana
578012|NCT00403117|marijuana use
578013|NCT00403104|ONO-2506PO
578014|NCT00403104|Amyotrophic Lateral Sclerosis
578015|NCT00403104|ALS
578016|NCT00403091|Diabetes mellitus
578017|NCT00403091|Internet
578018|NCT00403091|Education, Professional
578019|NCT00403091|Quality Indicators, Health Care
578020|NCT00403091|Quality of Health Care
578021|NCT00403091|Hypertension
578022|NCT00403091|Hyperlipidemia
578023|NCT00403078|Carotid Artery Stenting (Endovascular)
578024|NCT00403065|recurrent non-small cell lung cancer
578025|NCT00403065|stage IV non-small cell lung cancer
578026|NCT00403065|tumors metastatic to brain
578027|NCT00403052|colorectal
578028|NCT00403052|cancer
578029|NCT00403052|carcinoma
578030|NCT00403052|metastatic
578031|NCT00403052|colon
578032|NCT00403052|rectal
578033|NCT00403052|neoplasm
578034|NCT00403052|cetuximab
578035|NCT00403052|irinotecan
578036|NCT00403052|1018 ISS
578037|NCT00403052|combination therapy
578038|NCT00403039|Central Retinal Vein Occlusion
578039|NCT00403026|Bevacizumab (Avastin)
578040|NCT00403026|Intravitreal injection
578041|NCT00403026|VEGF
578042|NCT00403026|CRVO
578043|NCT00403026|BRVO
578044|NCT00403026|PDR
578045|NCT00403026|CNVM
578046|NCT00403013|nerve block/*methods
578047|NCT00403013|Anesthetics, Local/pharmacokinetics
578048|NCT00403013|*Brachial Plexus
578049|NCT00403000|recurrent prostate cancer
578050|NCT00402987|sore throat
578051|NCT00402987|acute pain
578052|NCT00402974|osteocalcin
578053|NCT00402974|vitamin K
578054|NCT00402974|carboxylation
578055|NCT00402974|healthy children
578056|NCT00402961|Acupuncture
578057|NCT00402961|Post-Colectomy Ileus
578058|NCT00402961|Abdominal Surgery
578059|NCT00402961|Colon Surgery
578060|NCT00402948|High eosinophils level in sputum
578061|NCT00402935|long-term effects secondary to cancer therapy in adults
578062|NCT00402935|long-term effects secondary to cancer therapy in children
578063|NCT00402935|sexual dysfunction and infertility
578064|NCT00402935|sexuality and reproductive issues
578065|NCT00402935|adult acute lymphoblastic leukemia in remission
578066|NCT00402935|childhood acute lymphoblastic leukemia in remission
578067|NCT00402935|recurrent adult acute lymphoblastic leukemia
578068|NCT00402935|recurrent childhood acute lymphoblastic leukemia
578069|NCT00402935|untreated adult acute lymphoblastic leukemia
578070|NCT00402935|untreated childhood acute lymphoblastic leukemia
578071|NCT00402935|adult acute myeloid leukemia in remission
578072|NCT00402935|recurrent adult acute myeloid leukemia
578073|NCT00402935|recurrent childhood acute myeloid leukemia
578074|NCT00402935|untreated adult acute myeloid leukemia
578075|NCT00402935|untreated childhood acute myeloid leukemia and other myeloid malignancies
578076|NCT00402935|secondary acute myeloid leukemia
578077|NCT00402935|stage I adult Hodgkin lymphoma
578078|NCT00402935|stage I childhood Hodgkin lymphoma
578079|NCT00402935|stage II adult Hodgkin lymphoma
578080|NCT00402935|stage II childhood Hodgkin lymphoma
578081|NCT00402935|stage III adult Hodgkin lymphoma
578082|NCT00402935|stage III childhood Hodgkin lymphoma
578083|NCT00402935|stage IV adult Hodgkin lymphoma
578084|NCT00402935|stage IV childhood Hodgkin lymphoma
578085|NCT00402935|recurrent adult Hodgkin lymphoma
578086|NCT00402935|recurrent/refractory childhood Hodgkin lymphoma
578087|NCT00402935|unspecified adult solid tumor, protocol specific
578088|NCT00402935|unspecified childhood solid tumor, protocol specific
578089|NCT00402935|childhood acute myeloid leukemia in remission
578090|NCT00402935|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
578091|NCT00402935|adult acute myeloid leukemia with inv(16)(p13;q22)
578092|NCT00402935|adult acute myeloid leukemia with t(16;16)(p13;q22)
578093|NCT00402935|adult acute myeloid leukemia with t(15;17)(q22;q12)
578094|NCT00402935|adult acute myeloid leukemia with t(8;21)(q22;q22)
578095|NCT00402922|Coronary Heart Disease
578096|NCT00402909|Type 2 diabetes,
578097|NCT00402909|fasting glucose,
578098|NCT00402909|postprandial glucose,
578099|NCT00402909|blood sugar,
578100|NCT00402909|HbA1c,
578101|NCT00402909|insulin,
578102|NCT00402909|glargine,
578103|NCT00402909|metformin,
578104|NCT00402909|thiazolidinedione
578105|NCT00402896|Lung Cancer
578106|NCT00402896|Non-Small Cell Lung Cancer
578107|NCT00402896|Pleural Effusion
578108|NCT00402896|Indwelling Intrapleural Denver Catheter
578109|NCT00402896|ZD6474
578110|NCT00402896|Vascular Endothelial Growth Factor Receptor
578111|NCT00402896|VEGFR
578112|NCT00402896|Epidermal Growth factor Receptor
578113|NCT00402896|EGFR
578114|NCT00402896|Tyrosine Kinase Inhibitor
578115|NCT00402857|Parenting Education
578116|NCT00402857|Child, Preschool
578117|NCT00402857|Preventive Intervention
578118|NCT00402857|Primary Health Care
578119|NCT00402857|Pediatrics
578120|NCT00402857|Attention Deficit Disorders
578121|NCT00402857|Oppositional Defiant Disorder
578122|NCT00402857|Disruptive Behavior Disorder
578123|NCT00402844|Multicenter
578124|NCT00402844|Pelvic organ prolapse
578125|NCT00402844|Prospective
578126|NCT00402844|Transvaginal mesh
578127|NCT00402818|Moderate to severe plaque psoriasis
578128|NCT00402805|Influenza vaccine
578129|NCT00402805|Intradermal
578130|NCT00402805|Lung transplantation
578131|NCT00402792|Acute pain following bunionectomy surgery
578132|NCT00402779|Oral Cancer
578133|NCT00402779|Oral IEN Lesion with LOH
578134|NCT00402779|Loss of Heterozygosity
578135|NCT00402779|Intraepithelial Neoplasia
578136|NCT00402779|Placebo
578137|NCT00402779|Erlotinib
578138|NCT00402779|Tarceva
578139|NCT00402779|OSI-774
578140|NCT00402766|Mesothelioma
578141|NCT00402766|Pleural Mesothelioma
578142|NCT00402766|Peritoneal Mesothelioma
578143|NCT00402766|PDGF-R
578144|NCT00402766|Pemetrexed
578145|NCT00402766|Alimta
578146|NCT00402766|Cisplatin
578147|NCT00402766|Imatinib Mesylate
578148|NCT00402766|Gleevec
578149|NCT00402766|Platinol
578150|NCT00402766|Platinol-AQ
578151|NCT00402766|CDDP
578152|NCT00402766|Ly231514
578153|NCT00402766|Multitargeted Antifolate
578154|NCT00402766|NSC-698037
578155|NCT00402766|STI571
578156|NCT00402766|NSSC-716051
578157|NCT00402753|Cancer, Exercise, Health Related Quality of Life, PBSCT
578158|NCT00402740|Carotid
578159|NCT00402740|Artery
578160|NCT00402740|Disease
578161|NCT00402740|Stent
578162|NCT00402740|PROTECT
578163|NCT00402740|XACT
578164|NCT00402740|EMBOSHIELD
578165|NCT00402714|Allogeneic Stem Cell Transplant
578166|NCT00402701|walking
578167|NCT00402701|motor activity
578168|NCT00402701|students
578169|NCT00402701|schools
578170|NCT00402701|transportation
578171|NCT00402701|motor vehicles
578172|NCT00402688|Chronic Prostatitis
578173|NCT00402688|Prostatitis
578174|NCT00402688|levofloxacin
578175|NCT00402688|Levaquin
578176|NCT00402675|NSTEMI
578177|NCT00402675|infarction
578178|NCT00402675|treatment
578179|NCT00402675|percutaneous coronary intervention
578180|NCT00402675|non-ST-elevation myocardial infarction
578181|NCT00402662|everolimus
578182|NCT00402662|imatinib
578183|NCT00402649|influenza, A/H5N1, avian influenza, vaccine
578184|NCT00402623|sarcoidosis
578185|NCT00402623|quercetin
578186|NCT00402623|supplementation
578187|NCT00402623|oxidative stress
578188|NCT00402623|inflammation
578189|NCT00402610|HIV
578190|NCT00402610|Tuberculosis
578191|NCT00402610|Chemoprophylaxis
578192|NCT00402610|Anergy
578193|NCT00402610|AIDS
578194|NCT00402597|Acute Coronary Syndrome (ACS)
578195|NCT00402597|Myocardial Ischemia
578196|NCT00402597|Rivaroxaban (BAY59-7939)
578197|NCT00402597|Anti-platelet agents
578198|NCT00402597|Aspirin
578199|NCT00402597|Thienopyridine
578200|NCT00402597|Clopidogrel
578201|NCT00402571|acetaminophen
578202|NCT00402571|alcohol
578203|NCT00402571|liver injury
578204|NCT00402558|Acute Myeloid Leukemia
578205|NCT00402558|Chronic Myelogenous Leukemia
578206|NCT00402558|Myelodysplastic Syndrome
578207|NCT00402558|Leukemia
578208|NCT00402558|NK Cells
578209|NCT00402558|Natural Killer Cells
578210|NCT00402558|Fludarabine
578211|NCT00402558|Busulfan
578212|NCT00402558|Thymoglobulin
578213|NCT00402558|AML
578214|NCT00402558|CML
578215|NCT00402558|MDS
578216|NCT00402558|ATG
578217|NCT00402558|Antithymocyte globulin
578218|NCT00402558|Busulfex
578219|NCT00402558|Myleran®
578220|NCT00402558|Fludarabine Phosphate
578221|NCT00402558|G-CSF
578222|NCT00402558|Filgrastim
578223|NCT00402558|Neupogen
578224|NCT00402558|Interleukin-2
578225|NCT00402558|IL-2
578226|NCT00402558|Aldesleukin
578227|NCT00402558|Proleukin
578228|NCT00402558|Tacrolimus
578229|NCT00402558|Prograf
578230|NCT00402558|Methotrexate
578231|NCT00402545|SCCHN
578232|NCT00402545|C-TPF
578233|NCT00402545|5-FU
578234|NCT00402545|squamous cell carcinoma of the head and neck
578235|NCT00402532|Lung Transplantation
578236|NCT00402532|Immunosuppression
578237|NCT00402532|Mortality
578238|NCT00402532|Graft rejection
578239|NCT00402532|Bronchiolitis obliterans
578240|NCT00402532|Opportunistic infections
578241|NCT00402532|Nephrotoxicity
578242|NCT00402519|accelerated partial breast irradiation
578243|NCT00402519|multicatheter brachytherapy
578244|NCT00402519|high dose rate brachytherapy
578245|NCT00402519|pulsed dose rate brachytherapy
578246|NCT00402506|coronary
578247|NCT00402506|surgery
578248|NCT00402506|ischemia
578249|NCT00402506|reperfusion injury
578250|NCT00402506|cardiac
578251|NCT00402506|heart
578252|NCT00402506|neurological
578253|NCT00402506|cardiopulmonary bypass
578254|NCT00402506|cardioprotection
578255|NCT00402506|myocardium
578256|NCT00402506|myocardial
578257|NCT00402506|myocardial revascularization
578258|NCT00402493|Glaucoma
578259|NCT00402493|Ocular Hypertension
578260|NCT00402493|Xalatan
578261|NCT00402493|Alpahgan
578262|NCT00402493|Ibuprofen
578263|NCT00402493|Non-Steroidal Anti-Inflammatory
578264|NCT00402493|Brimonidine
578265|NCT00402493|Latanoprost
578266|NCT00402493|Eye Pressure
578267|NCT00402493|Intra-Ocular Pressure
578268|NCT00402480|Sickle Cell Anemia with Elevated TCD flow velocity
578269|NCT00402467|Prevention of venous thromboembolism
578270|NCT00402454|HIV
578271|NCT00402454|Tuberculosis
578272|NCT00402454|Prophylaxis
578273|NCT00402454|AIDS
578274|NCT00402428|Chronic Hepatitis C
578275|NCT00402428|Hepatitis C
578276|NCT00402428|CHC
578277|NCT00402428|HepC
578278|NCT00402428|Genotype 1
578279|NCT00402428|Hepatitis
578280|NCT00402428|HCV
578281|NCT00402415|metastatic
578282|NCT00402415|malignancy
578283|NCT00402415|advanced solid tumors
578284|NCT00402415|unresectable
578285|NCT00402415|Solid Tumors
578286|NCT00402402|Tuberculin skin test
578287|NCT00402402|Quantiferon-TB Gold assay
578288|NCT00402402|Chronic liver disease
578289|NCT00402402|Liver transplantation
578290|NCT00402402|Latent tuberculosis infection
578291|NCT00402389|Perinatal Depression
578292|NCT00402389|Postpartum Depression
578293|NCT00402389|Omega-3 Fatty Acids
578294|NCT00402389|Eicosapentaenoic Acid (EPA)
578295|NCT00402389|Docosahexaenoic Acid (DHA)
578296|NCT00402389|Pregnancy
578297|NCT00402389|Psychotherapy
578298|NCT00402376|End-stage heart failure
578299|NCT00402376|heart failure;
578300|NCT00402376|ventricular assist device;
578301|NCT00402376|statin;
578302|NCT00402376|heart transplantation;
578303|NCT00402376|myocardial function;
578304|NCT00402376|mitochondrial respiratory function;
578305|NCT00402363|Lovaza
578306|NCT00402363|Omega-3 fatty acids
578307|NCT00402363|Omacor
578308|NCT00402363|Paroxysmal atrial fibrillation
578309|NCT00402350|Staccato Fentanyl, Pharmacokinetics, Pharmacodynamics
578310|NCT00402337|Constipation
578311|NCT00402337|Chronic Constipation
578312|NCT00402337|Microbia
578313|NCT00402337|linaclotide
578314|NCT00402337|linaclotide acetate
578315|NCT00402337|MD-1100
578316|NCT00402324|Mixed episode associated with Bipolar I
578317|NCT00402311|Health Services for the Aged
578318|NCT00402311|Geriatric Psychiatry
578319|NCT00402298|PTSD
578320|NCT00402298|MDMA
578321|NCT00402298|psychotherapy
578322|NCT00402298|Posttraumatic stress disorder
578323|NCT00402298|Israel
578324|NCT00402285|adenocarcinoma of the prostate
578325|NCT00402285|stage I prostate cancer
578326|NCT00402285|stage IIB prostate cancer
578327|NCT00402285|stage IIA prostate cancer
578328|NCT00402272|drug eluting stents
578329|NCT00402272|stents
578330|NCT00402272|Angioplasty
578331|NCT00402272|coronary artery disease
578332|NCT00402272|total coronary occlusion
578333|NCT00402272|coronary artery restenosis
578334|NCT00402272|stent thrombosis
578335|NCT00402272|vascular disease
578336|NCT00402272|myocardial ischemia
578337|NCT00402272|coronary artery stenosis
578338|NCT00402259|acute non-variceal upper gastrointestinal bleeding
578339|NCT00402246|Randomized Controlled Trials
578340|NCT00402246|Defibrillators
578341|NCT00402246|Remote Consultation
578342|NCT00402207|asthma
578343|NCT00402207|non-invasive inflammometry
578344|NCT00402207|exhaled nitric oxide
578345|NCT00402207|exhaled breath condensate
578346|NCT00402207|paediatric
578347|NCT00402207|extrafine HFA-beclomethasone
578348|NCT00402207|HFA-fluticasone
578349|NCT00402194|Obesity
578350|NCT00402194|Insulin resistance
578351|NCT00402194|Impaired glucose tolerance
578352|NCT00402194|pre-diabetes
578353|NCT00402181|Myeloma
578354|NCT00402181|Intravenous
578355|NCT00402181|Monoclonal antibody
578356|NCT00402181|Siltuximab
578357|NCT00402181|Dexamethasone
578358|NCT00402181|CNTO 328
578359|NCT00402155|electroretinogram
578360|NCT00402155|visual evoked potential
578361|NCT00402155|contrast sensitivity
578362|NCT00402142|HIV Infection
578363|NCT00402142|Dendritic cell vaccine
578364|NCT00402142|Autologous virus
578365|NCT00402142|Heat inactivated
578366|NCT00402142|HIV Therapeutic Vaccine
578367|NCT00402129|Ethnic Skin
578368|NCT00402129|Laser
578369|NCT00402129|Photobiology
578370|NCT00402129|Quality of life
578371|NCT00402103|Hypertension, aliskiren, amlodipine, HCTZ, blood pressure
578372|NCT00402090|thiopurines
578373|NCT00402090|thiopurine methyl transferase
578374|NCT00402090|toxicity
578375|NCT00402090|pharmacogenomics
578376|NCT00402077|overweight
578377|NCT00402077|obesity
578378|NCT00402077|pramlintide
578379|NCT00402077|Symlin
578380|NCT00402077|sibutramine
578381|NCT00402077|Meridia
578382|NCT00402077|phentermine
578383|NCT00402077|Amylin
578384|NCT00402064|bisphosphonates
578385|NCT00402064|children
578386|NCT00402064|dental
578387|NCT00402064|Osteomyelitis
578388|NCT00402064|medication
578389|NCT00402025|Metastatic
578390|NCT00402025|Pancreas
578391|NCT00402025|Adenocarcinoma
578392|NCT00402012|Diabetes Mellitus, Type 2
578393|NCT00401999|PET
578394|NCT00401999|C-11 Raclopride
578395|NCT00401999|Dopamine
578396|NCT00401999|OPRM1
578397|NCT00401999|Alcohol
578398|NCT00401999|Healthy Volunteer
578399|NCT00401999|HV
578400|NCT00401986|Refractory Asthma
578401|NCT00401986|Bronchial Thermoplasty
578402|NCT00401986|Alair System
578403|NCT00401986|RISA (Research in Severe Asthma)
578404|NCT00401960|Enterococcus
578405|NCT00401960|Daptomycin
578406|NCT00401960|Endocarditis
578407|NCT00401947|HCV
578408|NCT00401947|Chronic
578409|NCT00401947|Hepatitis
578410|NCT00401934|cholera, Vibrio cholerae, diarrhea, Bangladesh, children
578411|NCT00401908|Acute gastrointestinal bleeding
578412|NCT00401908|Acute coronary syndrome
578413|NCT00401895|TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
578414|NCT00401895|Covered stents
578415|NCT00401895|portal hypertension
578416|NCT00401895|hepatic encephalopathy
578417|NCT00401882|Cardiac arrest
578418|NCT00401882|Sudden Cardiac Death
578419|NCT00401882|Ventricular Fibrillation
578420|NCT00401882|Pulseless Ventricular Tachycardia
578421|NCT00401882|Cardiopulmonary resuscitation
578422|NCT00401869|vigor
578423|NCT00401869|function
578424|NCT00401869|well-being
578425|NCT00401869|hand-strength
578426|NCT00401869|surgery
578427|NCT00401869|anemia
578428|NCT00401869|transfusion
578429|NCT00401869|strength
578430|NCT00401869|quality-of-life
578431|NCT00401856|Cardiomyopathy
578432|NCT00401856|Fibrosis
578433|NCT00401856|Magnetic-Resonance
578434|NCT00401856|Eplerenone
578435|NCT00401843|multiple myeloma
578436|NCT00401843|Monoclonal Antibody
578437|NCT00401843|Intravenous
578438|NCT00401843|refractory or relapsed multiple myeloma
578439|NCT00401843|velcade
578440|NCT00401843|bortezomib
578441|NCT00401830|Fibromyalgia Syndrome
578442|NCT00401830|Lacosamide
578443|NCT00401830|Vimpat
578444|NCT00401830|Harkoseride
578445|NCT00401804|Multiple Myeloma
578446|NCT00401804|renal impairment
578447|NCT00401804|Velcade
578448|NCT00401778|Lung Cancer
578449|NCT00401765|Prostatic neoplasm
578450|NCT00401765|intravenous
578451|NCT00401765|docetaxel
578452|NCT00401765|monoclonal antibody
578453|NCT00401752|NSAID-associated gastric ulcer
578454|NCT00401726|Major Depressive Disorder
578455|NCT00401726|Depression
578456|NCT00401726|Anxiety
578457|NCT00401713|submacular membrane
578458|NCT00401713|transplantation of RPE
578459|NCT00401713|translocation of RPE and Choroid
578460|NCT00401700|influenza
578461|NCT00401700|influenza vaccine
578462|NCT00401700|pregnancy
578463|NCT00401687|Reduced Heart Function
578464|NCT00401674|ovarian cancer
578465|NCT00401674|elderly
578466|NCT00401674|weekly chemotherapy
578467|NCT00401674|first-line
578468|NCT00401648|POC
578469|NCT00401648|photosensitive
578470|NCT00401648|epileptic
578471|NCT00401648|brivaracetam
578472|NCT00401648|PPR
578473|NCT00401648|AED
578474|NCT00401635|advanced
578475|NCT00401635|recurrent
578476|NCT00401635|chemotherapy
578477|NCT00401635|first-line
578478|NCT00401609|elderly
578479|NCT00401596|ALTO
578480|NCT00401583|GW786034 (pazopanib) cytochrome P450 interaction
578481|NCT00401570|Antibody
578482|NCT00401570|Pancreas
578483|NCT00401570|Carcinoma
578484|NCT00401570|Cancer
578485|NCT00401570|Pancreatic
578486|NCT00401557|Leishmaniasis, Leishmania (Viannia), Colombia
578487|NCT00401544|anemia
578488|NCT00401544|chemotherapy induced anemia
578489|NCT00401544|darbepoetin alfa
578490|NCT00401544|cancer
578491|NCT00401531|Hepatitis B
578492|NCT00401531|Polio
578493|NCT00401531|Diphtheria
578494|NCT00401531|Pertussis
578495|NCT00401531|H. influenzae type b
578496|NCT00401518|Spinal Stenosis
578497|NCT00401518|Lumbar Spinal Stenosis
578498|NCT00401518|Facet Arthroplasty
578499|NCT00401518|Posterior Fusion
578500|NCT00401518|Facet Arthritis
578501|NCT00401505|rubella
578502|NCT00401505|rubella vaccine
578503|NCT00401505|postpartum
578504|NCT00401505|immunity
578505|NCT00401492|elderly
578506|NCT00401492|chemotherapy
578507|NCT00401492|quality of life
578508|NCT00401492|ADL
578509|NCT00401492|toxicity
578510|NCT00401479|GW427353
578511|NCT00401479|b3-Adrenergic Receptor Agonist
578512|NCT00401479|Irritable Bowel Syndrome (IBS)
578513|NCT00401479|pharmacokinetics
578514|NCT00401479|tolerability
578515|NCT00401479|gastrointestinal transit
578516|NCT00401466|prophylactic ICD therapy
578517|NCT00401466|home monitoring
578518|NCT00401466|follow-up interval
578519|NCT00401466|remote follow-up
578520|NCT00401440|Medical termination of pregnancy
578521|NCT00401440|Induction of abortion
578522|NCT00401440|Misoprostol
578523|NCT00401440|MTP in second trimester
578524|NCT00401440|400 microgram vaginal misoprostol
578525|NCT00401427|HER2 overexpression
578526|NCT00401427|combination therapy
578527|NCT00401414|Warfarin
578528|NCT00401414|Thrombosis
578529|NCT00401414|Genetics
578530|NCT00401414|Nomogram
578531|NCT00401414|Pulmonary Embolism
578532|NCT00401414|Deep Vein Thrombosis
578533|NCT00401414|Dosing
578534|NCT00401414|INR
578535|NCT00401414|Anticoagulation
578536|NCT00401414|Therapy
578537|NCT00401414|Orthopedic Surgery
578538|NCT00401388|Chemo Insensitive Sarcomas
578539|NCT00401388|Chondrosarcomas
578540|NCT00401388|Alveolar soft part sarcomas
578541|NCT00401388|Extra skeletal myxoid chondrosarcomas
578542|NCT00401388|Perifosine
578543|NCT00401349|Leishmania
578544|NCT00401349|Mif Alleles
578545|NCT00401349|Colombia
578546|NCT00401349|children
578547|NCT00401336|Magnetic resonance imaging
578548|NCT00401336|Hepatic iron
578549|NCT00401336|Steatosis
578550|NCT00401297|Leishmaniasis
578551|NCT00401297|L. Viannia
578552|NCT00401297|Leishmania
578553|NCT00401297|Colombia
578554|NCT00401258|IBS
578555|NCT00401258|irritable bowel syndrome
578556|NCT00401258|irritable bowel
578557|NCT00401206|dexmedetomidine
578558|NCT00401206|sedation
578559|NCT00401206|bronchoscopy
578560|NCT00401206|COPD
578561|NCT00401193|Menorrhagia
578562|NCT00401193|Heavy Menstrual Bleeding
578563|NCT00401180|unspecified adult solid tumor, protocol specific
578564|NCT00401167|Alzheimer's disease
578565|NCT00401167|behavioral and psychological symptoms of dementia
578566|NCT00401167|severe Alzheimer's disease
578567|NCT00401167|memantine
578568|NCT00401167|agitation
578569|NCT00401167|aggression
578570|NCT00401154|Spastic Diplegia
578571|NCT00401154|Cerebral Palsy
578572|NCT00401154|Children
578573|NCT00401154|Adolescents
578574|NCT00401154|Strengthening
578575|NCT00401154|Endurance
578576|NCT00401141|Systemic lupus
578577|NCT00401141|B lymphocytes
578578|NCT00401141|transcriptomas
578579|NCT00401128|clear cell renal cell carcinoma
578580|NCT00401128|recurrent renal cell cancer
578581|NCT00401128|papillary renal cell carcinoma
578582|NCT00401128|stage IV renal cell cancer
578583|NCT00401102|self-injurious behavior
578584|NCT00401102|depression
578585|NCT00401102|adolescents
578586|NCT00401102|psychotherapy
578587|NCT00401089|negative symptoms schizophrenia
578588|NCT00401089|Atypical antipsychotics
578589|NCT00401089|Neurocognition impairment
578590|NCT00401089|obesity risk factor
578591|NCT00401089|Diabetes insulin resistance schizophrenia
578592|NCT00401076|SA-001
578593|NCT00401076|Pancreatic Exocrine Insufficiency
578594|NCT00401076|Chronic Pancreatitis
578595|NCT00401076|Pancreatectomy
578596|NCT00401063|Cancer
578597|NCT00401063|Acupuncture
578598|NCT00401063|Cancer Pain
578599|NCT00401063|Quality of life
578600|NCT00401050|patellofemoral pain syndrome
578601|NCT00401050|chiropractic
578602|NCT00401050|knee pain
578603|NCT00401050|chiropractic manipulation
578604|NCT00401050|Graston Instrument Soft Tissue Mobilization(GISTM)
578605|NCT00401024|adult anaplastic oligodendroglioma
578606|NCT00401024|adult oligodendroglioma
578607|NCT00401024|adult anaplastic astrocytoma
578608|NCT00401024|adult giant cell glioblastoma
578609|NCT00401024|adult gliosarcoma
578610|NCT00401024|recurrent adult brain tumor
578611|NCT00401024|adult brain stem glioma
578612|NCT00401024|adult mixed glioma
578613|NCT00401024|adult glioblastoma
578614|NCT00401024|adult pilocytic astrocytoma
578615|NCT00401024|adult diffuse astrocytoma
578616|NCT00401024|adult anaplastic ependymoma
578617|NCT00401024|adult ependymoma
578618|NCT00401024|adult myxopapillary ependymoma
578619|NCT00401024|adult subependymoma
578620|NCT00401024|adult pineal gland astrocytoma
578621|NCT00401024|adult subependymal giant cell astrocytoma
578622|NCT00401011|Perifosine
578623|NCT00401011|Bortezomib
578624|NCT00401011|Dexamethasone
578625|NCT00401011|Relapsed or Refractory Multiple Myeloma
578626|NCT00400998|Seasonal Allergic Rhinitis
578627|NCT00400998|Quality of Life
578628|NCT00400998|Efficacy
578629|NCT00400998|Validation
578630|NCT00400998|Fluticasone Propionate
578631|NCT00400985|Heart Failure, Congestive
578632|NCT00400985|Diagnostic
578633|NCT00400985|Ambulatory Monitoring
578634|NCT00400985|Intrathoracic Impedance
578635|NCT00400972|GlideScope
578636|NCT00400972|videolaryngoscopy
578637|NCT00400972|intubation
578638|NCT00400972|nasal
578639|NCT00400972|nasotracheal
578640|NCT00400972|laryngoscopy
578641|NCT00400972|anesthesia
578642|NCT00400959|cell therapy
578643|NCT00400959|acute myocardial infarction
578644|NCT00400946|drug/agent toxicity by tissue/organ
578645|NCT00400946|untreated childhood acute lymphoblastic leukemia
578646|NCT00400946|L1 childhood acute lymphoblastic leukemia
578647|NCT00400946|L2 childhood acute lymphoblastic leukemia
578648|NCT00400946|T-cell childhood acute lymphoblastic leukemia
578649|NCT00400933|Psycho-education
578650|NCT00400933|Eating disorders
578651|NCT00400933|Personality disorders
578652|NCT00400933|Relatives and close friends
578653|NCT00400933|Caregiver burden
578654|NCT00400907|long-term effects secondary to cancer therapy in adults
578655|NCT00400907|stage I adult diffuse large cell lymphoma
578656|NCT00400907|contiguous stage II adult diffuse large cell lymphoma
578657|NCT00400907|noncontiguous stage II adult diffuse large cell lymphoma
578658|NCT00400907|stage III adult diffuse large cell lymphoma
578659|NCT00400907|stage IV adult diffuse large cell lymphoma
578660|NCT00400894|prostate cancer
578661|NCT00400894|annexin A3
578662|NCT00400894|early detection
578663|NCT00400894|exprimate urine
578664|NCT00400881|mechanical ventilation
578665|NCT00400881|weaning
578666|NCT00400881|respiratory failure
578667|NCT00400881|spontaneous breathing trial
578668|NCT00400868|rheumatoid arthritis, occupational therapy, joint protection
578669|NCT00400855|Asthma
578670|NCT00400855|AMP challenge
578671|NCT00400842|SA-001
578672|NCT00400842|Pancreatic Exocrine Insufficiency
578673|NCT00400842|Pancreatectomy
578674|NCT00400816|adult anaplastic oligodendroglioma
578675|NCT00400816|adult mixed glioma
578676|NCT00400803|Carcinoma, Non-Small-Cell Lung
578677|NCT00400803|Gemcitabine
578678|NCT00400803|Carboplatin
578679|NCT00400803|Bevacizumab
578680|NCT00400803|Biological therapy
578681|NCT00400803|Drug therapy
578682|NCT00400790|neurocognitive decline
578683|NCT00400790|coronary artery bypass surgery
578684|NCT00400790|composite morbidity
578685|NCT00400790|postoperative care cost
578686|NCT00400777|Valsartan
578687|NCT00400777|hydrochlorothiazide
578688|NCT00400777|amlodipine
578689|NCT00400777|hypertension
578690|NCT00400777|high blood pressure
578691|NCT00400764|NHL
578692|NCT00400764|Follicular NHL
578693|NCT00400764|Rituxan
578694|NCT00400764|Apo2L/TRAIL
578695|NCT00400751|Health-compromised smokers, family cessation intervention
578696|NCT00400738|HIV-1 infection
578697|NCT00400738|pharmacokinetics
578698|NCT00400738|protease inhibitor
578699|NCT00400738|double boosted protease inhibitors
578700|NCT00400738|PIs
578701|NCT00400738|Treatment Naive
578702|NCT00400725|maintenance
578703|NCT00400725|scalp psoriasis
578704|NCT00400725|Galderma
578705|NCT00400712|mobility
578706|NCT00400712|strength
578707|NCT00400712|balance
578708|NCT00400712|function
578709|NCT00400712|reintegration
578710|NCT00400712|community
578711|NCT00400699|psychosocial effects of cancer and its treatment
578712|NCT00400699|unspecified adult solid tumor, protocol specific
578713|NCT00400686|anemia
578714|NCT00400686|stage I multiple myeloma
578715|NCT00400686|stage II multiple myeloma
578716|NCT00400686|stage III multiple myeloma
578717|NCT00400686|refractory multiple myeloma
578718|NCT00400673|Acute myelogenous leukemia
578719|NCT00400673|Adult patients
578720|NCT00400673|Cytogenetic risk class
578721|NCT00400673|Clinico-cytogenetic risk model
578722|NCT00400673|Risk-oriented therapy
578723|NCT00400660|GSK615915 asthma surfactant MDI
578724|NCT00400647|kidney transplant
578725|NCT00400647|enteric-coated mycophenolate sodium
578726|NCT00400647|quality of life
578727|NCT00400647|gastrointestinal symptoms
578728|NCT00400621|acetaminophen
578729|NCT00400621|alcohol
578730|NCT00400621|liver injury
578731|NCT00400608|pediatrics
578732|NCT00400608|ADVAIR Inhaler
578733|NCT00400608|Asthma
578734|NCT00400608|ADVAIR DISKUS
578735|NCT00400595|peritonitis
578736|NCT00400595|catheter related infection
578737|NCT00400595|exit site ointments
578738|NCT00400595|mupirocin
578739|NCT00400595|Polysporin Triple
578740|NCT00400582|Heart failure
578741|NCT00400582|Gene polymorphism
578742|NCT00400582|Candesartan
578743|NCT00400582|ACE inhibitors
578744|NCT00400582|BNP
578745|NCT00400582|Pharmacogenomics
578746|NCT00400569|Sunitinib malate
578747|NCT00400569|SUTENT
578748|NCT00400569|SU011248
578749|NCT00400569|Soft tissue sarcoma
578750|NCT00400569|Gastrointestinal stromal tumors (GIST)
578751|NCT00400569|MFH
578752|NCT00400569|Tyrosine kinase inhibitor
578753|NCT00400569|Imatinib mesylate
578754|NCT00400569|Phase II
578755|NCT00400556|mobilization
578756|NCT00400556|ATRA
578757|NCT00400556|G-CSF
578758|NCT00400556|filgrastim
578759|NCT00400556|retinoids
578760|NCT00400556|stem cell mobilization
578761|NCT00400556|hematopoietic stem and progenitor cells
578762|NCT00400543|obstructive sleep apnea
578763|NCT00400543|arterial stiffness
578764|NCT00400543|atherosclerosis
578765|NCT00400543|CPAP
578766|NCT00400543|heart disease
578767|NCT00400517|stage III prostate cancer
578768|NCT00400517|stage II prostate cancer
578769|NCT00400517|adenocarcinoma of the prostate
578770|NCT00400517|stage I prostate cancer
578771|NCT00400517|stage IV prostate cancer
578772|NCT00400504|Thrombelastograph
578773|NCT00400504|Cancer
578774|NCT00400504|Thromboembolism
578775|NCT00400504|Hypercoagulable
578776|NCT00400491|diabetes
578777|NCT00400491|insulin
578778|NCT00400491|glycated hemoglobin
578779|NCT00400491|cholecalciferol
578780|NCT00400491|vitamin D
578781|NCT00400478|DLBCL
578782|NCT00400478|NHL 13
578783|NCT00400478|Rituximab
578784|NCT00400478|maintenance
578785|NCT00400465|thyroid
578786|NCT00400465|thyroidectomy
578787|NCT00400465|dressing
578788|NCT00400452|wheelchair
578789|NCT00400452|skills
578790|NCT00400452|long-term-care
578791|NCT00400452|caregivers
578792|NCT00400426|Palliative radiotherapy
578793|NCT00400426|Recurrent
578794|NCT00400426|Head and neck Neoplasm
578795|NCT00400426|Quality of life
578796|NCT00400413|Neuropsychology
578797|NCT00400413|fMRI
578798|NCT00400413|Reading
578799|NCT00400413|Phonology
578800|NCT00400413|Deafness
578801|NCT00400400|RenalTransplantation
578802|NCT00400400|KidneyTransplantation
578803|NCT00400400|MPA
578804|NCT00400400|EC-MPS
578805|NCT00400387|recurrent pregnancy loss
578806|NCT00400374|Head and Neck Cancer
578807|NCT00400335|Testosterone
578808|NCT00400335|Men
578809|NCT00400335|Hypogonadism
578810|NCT00400335|Dutasteride
578811|NCT00400335|DHT
578812|NCT00400335|Androgen deficiency
578813|NCT00400322|glioblastoma multiforme
578814|NCT00400322|cytomegalovirus infection
578815|NCT00400322|antiviral treatment
578816|NCT00400322|valganciclovir
578817|NCT00400270|Asthma
578818|NCT00400270|Randomised controlled trial
578819|NCT00400270|Breathing exercises
578820|NCT00400270|Relaxation exercises
578821|NCT00400270|Primary care
578822|NCT00400257|Heart Failure
578823|NCT00400257|BNP
578824|NCT00400244|wheelchairs
578825|NCT00400244|skills
578826|NCT00400244|french
578827|NCT00400231|metabolic syndrome
578828|NCT00400231|Triglycerides
578829|NCT00400231|Insulin Resistance
578830|NCT00400231|inflammation
578831|NCT00400231|Cardiovascular Disease
578832|NCT00400231|Elevated triglycerides
578833|NCT00400231|without diabetes
578834|NCT00400205|Squamous Cell Carcinoma of the Oral Cavity
578835|NCT00400192|Microchimerism
578836|NCT00400192|Injuries
578837|NCT00400192|Leukocytes
578838|NCT00400192|Immunologic Techniques
578839|NCT00400179|Gastric Cancer
578840|NCT00400166|Peer support
578841|NCT00400166|Psychiatric disability
578842|NCT00400166|Mutual support
578843|NCT00400166|Psychiatric Rehabilitation
578844|NCT00400140|Myopia, defocus
578845|NCT00400127|transfemoral amputee
578846|NCT00400127|silicon suspension
578847|NCT00400127|balance
578848|NCT00400127|gait
578849|NCT00400114|esophageal
578850|NCT00400114|esophagus
578851|NCT00400114|cancer
578852|NCT00400114|sutent
578853|NCT00400114|sunitinib
578854|NCT00400101|Malaria
578855|NCT00400101|Vaccine
578856|NCT00400101|Plasmodium
578857|NCT00400101|falciparum
578858|NCT00400101|Phase I
578859|NCT00400101|Peptide
578860|NCT00400101|Virosome
578861|NCT00400101|safety
578862|NCT00400101|immunogenicity
578863|NCT00400088|Major Depressive Disorder
578864|NCT00400088|Depression
578865|NCT00400088|Bipolar Disorder
578866|NCT00400088|Manic Depressive Illness
578867|NCT00400088|Randomized Trial
578868|NCT00400088|Antidepressant Treatment
578869|NCT00400088|Lithium Treatment
578870|NCT00400075|Polyarteritis
578871|NCT00400075|Vasculitis
578872|NCT00400075|Therapy
578873|NCT00400075|Cyclophosphamide
578874|NCT00400075|Azathioprine
578875|NCT00400062|Critical care
578876|NCT00400062|delirium
578877|NCT00400062|long-term cognitive impairment
578878|NCT00400062|mechanical ventilation
578879|NCT00400062|critical illness
578880|NCT00400062|dementia
578881|NCT00400062|aging
578882|NCT00400062|sedatives and analgesics
578883|NCT00400036|cod protein
578884|NCT00400036|insulin sensitivity
578885|NCT00400036|plasma lipids
578886|NCT00400036|glucose tolerance
578887|NCT00400036|plasma inflammatory markers
578888|NCT00400036|skeletal muscle insulin signaling
578889|NCT00400036|type 2 diabetes
578890|NCT00400036|humans
578891|NCT00400023|Advanced Solid Tumors
578892|NCT00400010|Expert system
578893|NCT00400010|Transtheoretical Model of Behavior Change
578894|NCT00400010|Brief intervention
578895|NCT00400010|General hospital
578896|NCT00399997|Exercise
578897|NCT00399997|Exercise referral
578898|NCT00399997|Lifestyle diseases
578899|NCT00399997|Sedentary behavior
578900|NCT00399984|Continuing Medical Education
578901|NCT00399971|Idiopathic Aplastic Anemia
578902|NCT00399971|Has Failed Conventional Immunosuppressive Therapy
578903|NCT00399971|Not Eligible For Bone Marrow Transplantation
578904|NCT00399971|C15.378.071.085
578905|NCT00399945|Cystic fibrosis, tobramycin, PARI eFlow, PARI LC Plus, nebulizer, pharmacoscintigraphy
578906|NCT00399932|metabolic syndrome
578907|NCT00399932|insulin resistance
578908|NCT00399932|NASH
578909|NCT00399932|hepatic fibrosis
578910|NCT00399932|Fibroscan
578911|NCT00399932|elastography by MRI
578912|NCT00399919|Perhipheral Artery Disease
578913|NCT00399919|Claudication
578914|NCT00399919|Exercise
578915|NCT00399919|Intermittent Claudication due to Peripheral Artery Disease
578916|NCT00399893|Childhood obesity
578917|NCT00399893|Prader-Willi Syndrome
578918|NCT00399893|Octreotide
578919|NCT00399893|Ghrelin
578920|NCT00399893|Weight loss
578921|NCT00399893|Body composition
578922|NCT00399893|Energy expenditure
578923|NCT00399880|Clinical Trial
578924|NCT00399880|Behavioral/Social
578925|NCT00399880|Cardiovascular Disease
578926|NCT00399880|Risk Factors/Analysis
578927|NCT00399867|multiple myeloma
578928|NCT00399867|refractory
578929|NCT00399867|cell adhesion mediated drug resistance
578930|NCT00399841|Pain
578931|NCT00399841|Chronic Pain
578932|NCT00399841|Neurostimulation
578933|NCT00399815|Chronic viral hepatitis C
578934|NCT00399815|HCV RNA
578935|NCT00399815|Fibroscan
578936|NCT00399815|Fibrotest
578937|NCT00399815|hepatic elastography by MRI
578938|NCT00399789|Non-Small-Cell Lung
578939|NCT00399789|Perifosine
578940|NCT00399776|bone mineral
578941|NCT00399776|antipsychotic therapy
578942|NCT00399776|bone mineral accrual
578943|NCT00399776|bone mineral content
578944|NCT00399763|Adolescent
578945|NCT00399763|ADHD
578946|NCT00399763|SUD
578947|NCT00399737|ACE activity
578948|NCT00399737|Fermented milk peptides
578949|NCT00399737|Healthy male volunteers
578950|NCT00399698|Severe conduct problems
578951|NCT00399698|Risperidone
578952|NCT00399698|Risperdal
578953|NCT00399685|HIV
578954|NCT00399672|HCV
578955|NCT00399672|injection drug users
578956|NCT00399672|ribavirin
578957|NCT00399672|pegylated interferon
578958|NCT00399672|illicit drug users
578959|NCT00399659|Opioid, constipation, tegaserod
578960|NCT00399633|VIP
578961|NCT00399633|PACAP
578962|NCT00399633|CGRP
578963|NCT00399633|Prostanoids
578964|NCT00399620|Periodontitis
578965|NCT00399620|Diabetes
578966|NCT00399620|Gingival crevicular fluid
578967|NCT00399620|GCF
578968|NCT00399620|Saliva
578969|NCT00399620|Chromogranin
578970|NCT00399620|Electrophorèse
578971|NCT00399620|Western Blot
578972|NCT00399620|RT-HPLC
578973|NCT00399607|colonic neoplasms
578974|NCT00399607|colorectal adenoma
578975|NCT00399607|calcium
578976|NCT00399607|vitamin D
578977|NCT00399594|Mechanical dyssynchrony
578978|NCT00399594|Biventricular pacing
578979|NCT00399594|Cardiac resynchronization therapy
578980|NCT00399581|Acute Respiratory Distress Syndrome
578981|NCT00399581|Acute Lung Injury
578982|NCT00399581|Mechanical Ventilation
578983|NCT00399581|Lung
578984|NCT00399568|Pain
578985|NCT00399568|Gynecologic
578986|NCT00399568|IV Acetaminophen
578987|NCT00399568|Postoperative
578988|NCT00399568|Analgesic
578989|NCT00399555|Single Ventricle
578990|NCT00399555|Hypoplastic Left Heart
578991|NCT00399555|Developmental
578992|NCT00399542|Irritable Bowel Syndrome With Constipation
578993|NCT00399529|Stage IV HER-2/neu overexpressing breast cancer
578994|NCT00399516|Pain
578995|NCT00399516|Neurostimulation
578996|NCT00399516|Back pain
578997|NCT00399516|Chronic Pain
578998|NCT00399503|Noninvasive assessment
578999|NCT00399503|Combined parameter
579000|NCT00399503|Holter
579001|NCT00399490|Monoclonal antibody
579002|NCT00399464|Benign Prostatic Hyperplasia
579003|NCT00399464|Adrenergic alpha-Antagonists
579004|NCT00399464|alfuzosin
579005|NCT00399451|Sleep Apnea,Obstructive
579006|NCT00399451|apnea-hypopnea index (AHI)
579007|NCT00399451|polidocanol
579008|NCT00399451|sclerotherapy
579009|NCT00399451|pharynges
579010|NCT00399438|Diarrhea-predominant irritable bowel syndrome
579011|NCT00399425|Heparin, Low-Molecular-Weight
579012|NCT00399425|Bemiparin
579013|NCT00399425|Foot Ulcer, Diabetic
579014|NCT00399425|Diabetic Angiopathies
579015|NCT00399425|Primary Health Care
579016|NCT00399412|S-ICD
579017|NCT00399412|ICD
579018|NCT00399412|ECG signals
579019|NCT00399412|Resting
579020|NCT00399399|Churg-Strauss
579021|NCT00399399|Vasculitis
579022|NCT00399399|Therapy
579023|NCT00399399|Cyclophosphamide
579024|NCT00399399|Azathioprine
579025|NCT00399386|S ICD
579026|NCT00399386|ICD
579027|NCT00399386|Ablation
579028|NCT00399386|EP study
579029|NCT00399386|Paediatric
579030|NCT00399386|ECG
579031|NCT00399373|disease management
579032|NCT00399373|substance abuse
579033|NCT00399360|HIV
579034|NCT00399360|Metabolic Syndrome
579035|NCT00399360|Lifestyle Modification
579036|NCT00399360|Metformin
579037|NCT00399360|Treatment Experienced
579038|NCT00399347|Diabetes Mellitus, prevalence , Ethiopians Jews, Israel
579039|NCT00399334|Schizophrenia
579040|NCT00399334|Schizoaffective
579041|NCT00399334|relapse
579042|NCT00399334|risk factors
579043|NCT00399334|Observational study
579044|NCT00399334|Antipsychotic medication
579045|NCT00399321|Post menopause women receiving adjuvant care
579046|NCT00399308|wound
579047|NCT00399308|leg
579048|NCT00399308|venous
579049|NCT00399308|chronic
579050|NCT00399308|wound healing
579051|NCT00399295|Analgesia
579052|NCT00399282|Rheumatoid arthritis
579053|NCT00399282|Health related quality of life
579054|NCT00399282|Omega 3 fatty acids
579055|NCT00399282|Vitamin E
579056|NCT00399269|Anemia
579057|NCT00399256|contrast-induced nephropathy
579058|NCT00399256|Acetylcysteine
579059|NCT00399256|Zinc
579060|NCT00399256|Cystatin C
579061|NCT00399256|Creatinine
579062|NCT00399243|cluster headache
579063|NCT00399243|sumatriptan
579064|NCT00399217|subcutaneous ICD
579065|NCT00399217|ICD
579066|NCT00399217|DFT
579067|NCT00399217|Pacing threshold
579068|NCT00399217|Polarity
579069|NCT00399191|anemia
579070|NCT00399191|iron deficiency anemia
579071|NCT00399191|iron deficiency
579072|NCT00399191|absorption
579073|NCT00399191|iron absorption
579074|NCT00399191|iron uptake
579075|NCT00399178|Osteoarthritis
579076|NCT00399178|Norspan versus Tramadol
579077|NCT00399178|Randomised
579078|NCT00399178|Efficacy and safety
579079|NCT00399178|OA pain of the hip and/or knee
579080|NCT00399165|Oral Contraception for Men
579081|NCT00399165|Contraceptive agent
579082|NCT00399152|Perifosine
579083|NCT00399152|Sunitinib Malate
579084|NCT00399152|Renal cancer
579085|NCT00399152|GIST
579086|NCT00399152|advanced cancers
579087|NCT00399074|Sickle Cell anemia
579088|NCT00399074|Malaria
579089|NCT00399074|Presumptive treatment
579090|NCT00399074|Sulfadoxine- pyrimethamine
579091|NCT00399074|Children
579092|NCT00399074|Uganda
579093|NCT00399048|Pain
579094|NCT00399048|Osteoarthritis
579095|NCT00399048|knee Osteoarthritis
579096|NCT00399048|hip Osteoarthritis .
579097|NCT00399035|Colorectal Cancer
579098|NCT00399035|Cediranib
579099|NCT00399035|RECENTIN
579100|NCT00399009|Circular stapling devices
579101|NCT00399009|anastomotic leak
579102|NCT00399009|anastomotic dehiscence
579103|NCT00399009|rectal cancer
579104|NCT00398996|antiretroviral therapy
579105|NCT00398996|HIV
579106|NCT00398996|Opportunistic infections
579107|NCT00398996|CD4
579108|NCT00398996|Viral load
579109|NCT00398996|TB/HIV co infection
579110|NCT00398996|Treatment Naive
579111|NCT00398983|Acute Myelogenous Leukemia
579112|NCT00398983|AML
579113|NCT00398983|Remission
579114|NCT00398983|Decitabine
579115|NCT00398983|Maintenance Therapy
579116|NCT00398970|Endobronchial ultrasonography
579117|NCT00398970|Fluoroscopy
579118|NCT00398970|Guide sheath
579119|NCT00398970|Peripheral pulmonary lesion
579120|NCT00398970|Transbronchial biopsy
579121|NCT00398957|Analgesia
579122|NCT00398944|Guideline based decision support system, Hypertension, Diabetes
579123|NCT00398905|Prevention of venous thromboembolism
579124|NCT00398892|Type 2 diabetes mellitus
579125|NCT00398892|Glycaemic control
579126|NCT00398892|Lipoic acid
579127|NCT00398892|Diabetic nephropathy
579128|NCT00398879|Capecitabine
579129|NCT00398866|Hyaluronan
579130|NCT00398866|Carpometacarpal
579131|NCT00398866|Outcomes
579132|NCT00398866|Carpometacarpal Joints
579133|NCT00398853|insulin
579134|NCT00398853|glucose
579135|NCT00398853|chromium
579136|NCT00398840|Cancer
579137|NCT00398840|Solid Tumors
579138|NCT00398840|advanced solid tumors
579139|NCT00398827|American Society of Anesthesiologists (ASA)
579140|NCT00398827|Observer's Assessment of Alertness Scale (OAA/S)
579141|NCT00398827|Aldrete Scoring System
579142|NCT00398827|Surgery or procedure using monitored care anesthesia
579143|NCT00398827|Surgery or procedure at least 30 minutes in duration
579144|NCT00398814|Perifosine
579145|NCT00398814|Sorafenib
579146|NCT00398814|Renal cancer
579147|NCT00398814|Hepatocellular cancer
579148|NCT00398814|other advanced solid tumors
579149|NCT00398801|gastroparesis
579150|NCT00398788|Pain
579151|NCT00398775|procalcitonin guided antibiotic discontinuation
579152|NCT00398775|fever of unknown origin
579153|NCT00398749|Anemia
579154|NCT00398749|Neoplasms
579155|NCT00398749|Antineoplastic agents
579156|NCT00398749|Chemotherapy
579157|NCT00398749|Efficacy
579158|NCT00398749|Epoetin alfa
579159|NCT00398736|Presence of severe sepsis and septic shock, mechanical ventilation
579160|NCT00398723|Narrowband UBV Phototherapy
579161|NCT00398723|Skin biopsies
579162|NCT00398710|Waldenström's Macroglobulinemia
579163|NCT00398710|Perifosine
579164|NCT00398697|perifosine
579165|NCT00398697|gemcitabine
579166|NCT00398684|Thailand
579167|NCT00398684|Developing countries
579168|NCT00398684|prophylaxis
579169|NCT00398684|mother to child transmission
579170|NCT00398684|HIV-1
579171|NCT00398684|HIV-1 infection
579172|NCT00398684|HIV Seronegativity
579173|NCT00398671|primary successful cardio-pulmonary resuscitation
579174|NCT00398671|pre-hospital setting
579175|NCT00398658|Endophthalmitis
579176|NCT00398658|Post-traumatic Endophthalmitis
579177|NCT00398658|Bacterial Endophthalmitis
579178|NCT00398658|Prophylaxis of Endophthalmitis
579179|NCT00398658|Intra Ocular Injection of antibiotics
579180|NCT00398645|GW685698X
579181|NCT00398645|Adults
579182|NCT00398645|Pharmacokinetics
579183|NCT00398645|Pharmacogenetics
579184|NCT00398645|Asthma
579185|NCT00398645|Adolescents
579186|NCT00398593|Adherence with therapy
579187|NCT00398593|Adherence enhancing intervention
579188|NCT00398593|Nonadherence
579189|NCT00398593|Ulcerative colitis
579190|NCT00398580|DHT
579191|NCT00398580|Testosterone
579192|NCT00398580|Hypogonadism
579193|NCT00398580|Dutasteride
579194|NCT00398580|Androgen deficiency
579195|NCT00398567|HKI-272
579196|NCT00398567|neratinib
579197|NCT00398567|trastuzumab
579198|NCT00398567|Herceptin
579199|NCT00398567|breast cancer
579200|NCT00398554|stage II childhood Hodgkin lymphoma
579201|NCT00398554|stage III childhood Hodgkin lymphoma
579202|NCT00398554|stage IV childhood Hodgkin lymphoma
579203|NCT00398554|stage I childhood Hodgkin lymphoma
579204|NCT00398554|childhood lymphocyte depletion Hodgkin lymphoma
579205|NCT00398554|childhood mixed cellularity Hodgkin lymphoma
579206|NCT00398554|childhood nodular sclerosis Hodgkin lymphoma
579207|NCT00398528|Multiple Sclerosis
579208|NCT00398528|Disease Modifying Therapy
579209|NCT00398489|stage IIIA breast cancer
579210|NCT00398489|stage IIIB breast cancer
579211|NCT00398489|stage IIIC breast cancer
579212|NCT00398489|stage II breast cancer
579213|NCT00398489|inflammatory breast cancer
579214|NCT00398476|taste
579215|NCT00398476|questionnaire
579216|NCT00398476|preference
579217|NCT00398476|attributes
579218|NCT00398476|odor
579219|NCT00398476|after taste
579220|NCT00398476|scent
579221|NCT00398463|tirofiban
579222|NCT00398463|aspirin resistance
579223|NCT00398463|clopidogrel resistance
579224|NCT00398450|recurrent melanoma
579225|NCT00398450|stage IV melanoma
579226|NCT00398437|tumors metastatic to brain
579227|NCT00398437|stage IV breast cancer
579228|NCT00398424|Impaired Hepatic Function
579229|NCT00398411|prophylaxis
579230|NCT00398411|bacteremia
579231|NCT00398411|moxifloxacin
579232|NCT00398411|stem cell transplantation
579233|NCT00398411|Hodgkin disease
579234|NCT00398411|non-Hodgkin lymphoma
579235|NCT00398411|multiple myeloma
579236|NCT00398411|solid tumor
579237|NCT00398411|autologous stem cell transplantation
579238|NCT00398398|gastric cancer
579239|NCT00398398|chemotherapy
579240|NCT00398398|cetuximab
579241|NCT00398398|capecitabine
579242|NCT00398398|oxaliplatin
579243|NCT00398385|squamous cell lung cancer
579244|NCT00398385|adenocarcinoma of the lung
579245|NCT00398385|adenosquamous cell lung cancer
579246|NCT00398385|bronchoalveolar cell lung cancer
579247|NCT00398385|large cell lung cancer
579248|NCT00398385|stage IB non-small cell lung cancer
579249|NCT00398385|stage IIA non-small cell lung cancer
579250|NCT00398385|stage IIB non-small cell lung cancer
579251|NCT00398359|Obesity
579252|NCT00398359|Overweight
579253|NCT00398359|Children
579254|NCT00398359|Behavioral
579255|NCT00398359|Motivational
579256|NCT00398359|Family
579257|NCT00398359|Primary care
579258|NCT00398333|Colorectal Neoplasms
579259|NCT00398333|Eicosapentaenoic Acid
579260|NCT00398333|Quality of Life
579261|NCT00398333|Nutritional Status
579262|NCT00398307|Renal Impairment
579263|NCT00398281|prostate cancer
579264|NCT00398268|Fracture
579265|NCT00398268|Forearm
579266|NCT00398268|Distal
579267|NCT00398268|Child
579268|NCT00398268|Treatment
579269|NCT00398255|arthritis
579270|NCT00398255|self management
579271|NCT00398255|patient education
579272|NCT00398242|fracture
579273|NCT00398242|forearm
579274|NCT00398242|midshaft
579275|NCT00398242|child
579276|NCT00398242|treatment
579277|NCT00398229|In-Vitro Fertilization
579278|NCT00398229|human chorionic gonadotropin
579279|NCT00398229|frozen-thawed embryo transfer
579280|NCT00398229|implantation rate
579281|NCT00398216|Anti-coagulant
579282|NCT00398216|hip replacement
579283|NCT00398216|hip replacement surgery
579284|NCT00398216|unilateral hip replacement surgery
579285|NCT00398216|DeepVein Thrombosis
579286|NCT00398216|Venous Thromboembolism
579287|NCT00398216|pulmonary embolism
579288|NCT00398216|Prevention of Blood Clots
579289|NCT00398203|NaviAid™ BGE Device
579290|NCT00398203|Small Intestine
579291|NCT00398203|Intestinal Diseases
579292|NCT00398190|Smoking
579293|NCT00398190|Tobacco use disorder
579294|NCT00398138|adult acute myeloid leukemia in remission
579295|NCT00398138|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
579296|NCT00398138|adult acute myeloid leukemia with inv(16)(p13;q22)
579297|NCT00398138|adult acute myeloid leukemia with t(15;17)(q22;q12)
579298|NCT00398138|adult acute myeloid leukemia with t(16;16)(p13;q22)
579299|NCT00398138|adult acute myeloid leukemia with t(8;21)(q22;q22)
579300|NCT00398138|de novo myelodysplastic syndromes
579301|NCT00398138|previously treated myelodysplastic syndromes
579302|NCT00398138|secondary myelodysplastic syndromes
579303|NCT00398138|recurrent non-small cell lung cancer
579304|NCT00398138|stage IIIA non-small cell lung cancer
579305|NCT00398138|stage IIIB non-small cell lung cancer
579306|NCT00398138|stage IV non-small cell lung cancer
579307|NCT00398138|advanced malignant mesothelioma
579308|NCT00398138|recurrent malignant mesothelioma
579309|NCT00398138|primary peritoneal cavity cancer
579310|NCT00398125|GSK364735
579311|NCT00398125|HIV-1
579312|NCT00398125|integrase inhibitor
579313|NCT00398086|Metastatic Pancreatic Cancer, Abraxane, Gemcitabine
579314|NCT00398073|stage II melanoma
579315|NCT00398073|stage III melanoma
579316|NCT00398073|stage IV melanoma
579317|NCT00398073|recurrent melanoma
579318|NCT00398073|ciliary body and choroid melanoma, medium/large size
579319|NCT00398073|ciliary body and choroid melanoma, small size
579320|NCT00398073|recurrent intraocular melanoma
579321|NCT00398073|metastatic intraocular melanoma
579322|NCT00398060|life-style counseling
579323|NCT00398060|type 2 diabetes
579324|NCT00398060|prediabetes
579325|NCT00398060|physical activity
579326|NCT00398060|diet
579327|NCT00398060|cognitive-behavioral
579328|NCT00398047|de novo myelodysplastic syndromes
579329|NCT00398047|refractory anemia with ringed sideroblasts
579330|NCT00398047|refractory anemia with excess blasts
579331|NCT00398047|refractory anemia
579332|NCT00398047|refractory cytopenia with multilineage dysplasia
579333|NCT00398047|chronic myelomonocytic leukemia
579334|NCT00398047|secondary myelodysplastic syndromes
579335|NCT00398047|childhood myelodysplastic syndromes
579336|NCT00398034|opioids
579337|NCT00398034|pain
579338|NCT00398034|hypogonadism
579339|NCT00398034|depression
579340|NCT00398034|fatigue
579341|NCT00398034|cognition
579342|NCT00398034|libido
579343|NCT00398021|constipation
579344|NCT00398021|bowel habits
579345|NCT00398008|Buprenorphine
579346|NCT00398008|Naltrexone
579347|NCT00398008|HIV risk reduction behavior
579348|NCT00398008|Counseling
579349|NCT00398008|HIV Seronegativity
579350|NCT00397995|Fracture
579351|NCT00397995|Forearm
579352|NCT00397995|Distal
579353|NCT00397995|Child
579354|NCT00397995|Treatment
579355|NCT00397969|colon cancer
579356|NCT00397969|rectal cancer
579357|NCT00397969|precancerous condition
579358|NCT00397943|Tuberculosis
579359|NCT00397930|cancer-related sleep disturbance
579360|NCT00397930|fatigue
579361|NCT00397930|sleep disorders
579362|NCT00397904|adenocarcinoma of the esophagus
579363|NCT00397904|squamous cell carcinoma of the esophagus
579364|NCT00397904|recurrent esophageal cancer
579365|NCT00397904|recurrent gastric cancer
579366|NCT00397904|adenocarcinoma of the stomach
579367|NCT00397904|stage IV esophageal cancer
579368|NCT00397904|stage IV gastric cancer
579369|NCT00397865|Obesity
579370|NCT00397865|Overweight
579371|NCT00397852|Fracture
579372|NCT00397852|Forearm
579373|NCT00397852|Distal
579374|NCT00397852|Child
579375|NCT00397852|Treatment
579376|NCT00397839|male osteoporosis
579377|NCT00397839|osteoporosis
579378|NCT00397839|bisphonates
579379|NCT00397839|bone
579380|NCT00397800|recurrent grade 1 follicular lymphoma
579381|NCT00397800|recurrent grade 2 follicular lymphoma
579382|NCT00397800|Waldenstrom macroglobulinemia
579383|NCT00397800|recurrent mantle cell lymphoma
579384|NCT00397800|recurrent marginal zone lymphoma
579385|NCT00397800|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
579386|NCT00397800|nodal marginal zone B-cell lymphoma
579387|NCT00397800|splenic marginal zone lymphoma
579388|NCT00397774|Palliative care
579389|NCT00397774|Physical exercise
579390|NCT00397774|Physical function
579391|NCT00397761|inflammatory breast cancer
579392|NCT00397761|stage II breast cancer
579393|NCT00397761|stage IIIA breast cancer
579394|NCT00397761|stage IIIB breast cancer
579395|NCT00397748|Phospholipase A2
579396|NCT00397748|D2 Receptors
579397|NCT00397748|Apomorphine
579398|NCT00397748|Trimethobenzamide
579399|NCT00397748|Attention Deficit Hyperactivity Disorder
579400|NCT00397748|ADHD
579401|NCT00397748|Healthy Volunteer
579402|NCT00397748|HV
579403|NCT00397735|pregnancy
579404|NCT00397735|chorioamnionitis
579405|NCT00397735|preterm labor
579406|NCT00397735|preterm premature rupture of the membranes
579407|NCT00397735|Intra-amniotic infection
579408|NCT00397735|Intra-amniotic inflammation
579409|NCT00397722|effectiveness
579410|NCT00397722|safety
579411|NCT00397722|outpatients with a diagnosis of Social Anxiety disorder (SocAD).
579412|NCT00397709|Latent tuberculosis infection.
579413|NCT00397709|Isoniazid.
579414|NCT00397709|Rifampin.
579415|NCT00397709|Clinical trial.
579416|NCT00397709|treatment of latent tuberculosis infection
579417|NCT00397696|Parkinson
579418|NCT00397696|imaging
579419|NCT00397696|nicotinic receptors
579420|NCT00397657|carotid intima media thickness
579421|NCT00397657|atherosclerosis
579422|NCT00397657|niacin
579423|NCT00397657|coronary heart disease
579424|NCT00397657|HDL-C
579425|NCT00397657|LDL-C
579426|NCT00397644|pediatrician
579427|NCT00397644|well-child care visit
579428|NCT00397644|low-income children
579429|NCT00397644|family psychosocial problem
579430|NCT00397605|bipolar
579431|NCT00397605|therapeutic potential
579432|NCT00397605|neurocognitive performance
579433|NCT00397605|cannabinoids
579434|NCT00397592|Growth Hormone
579435|NCT00397592|Cardiovascular System
579436|NCT00397592|Endothelial Progenitor Cells
579437|NCT00397579|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
579438|NCT00397579|adult acute myeloid leukemia with inv(16)(p13;q22)
579439|NCT00397579|adult acute myeloid leukemia with t(15;17)(q22;q12)
579440|NCT00397579|adult acute myeloid leukemia with t(16;16)(p13;q22)
579441|NCT00397579|adult acute myeloid leukemia with t(8;21)(q22;q22)
579442|NCT00397579|recurrent adult acute myeloid leukemia
579443|NCT00397579|secondary acute myeloid leukemia
579444|NCT00397579|untreated adult acute myeloid leukemia
579445|NCT00397579|de novo myelodysplastic syndromes
579446|NCT00397579|previously treated myelodysplastic syndromes
579447|NCT00397579|secondary myelodysplastic syndromes
579448|NCT00397579|blastic plasmacytoid dendritic cell neoplasm
579449|NCT00397579|plasmacytoid dendritic cell leukemia
579450|NCT00397579|CD123+
579451|NCT00397566|HIV
579452|NCT00397566|Treatment Experienced
579453|NCT00397540|HBV DNA
579454|NCT00397540|HCC
579455|NCT00397540|recurrence
579456|NCT00397540|PEIT
579457|NCT00397540|RFTA
579458|NCT00397514|Biventricular pacing
579459|NCT00397514|Congenital heart disease
579460|NCT00397514|Tissue Doppler echocardiography
579461|NCT00397501|cognitive/functional effects
579462|NCT00397501|psychosocial effects of cancer and its treatment
579463|NCT00397501|drug/agent toxicity by tissue/organ
579464|NCT00397501|recurrent breast cancer
579465|NCT00397501|stage IV breast cancer
579466|NCT00397501|adult tumors metastatic to brain
579467|NCT00397488|recurrent bladder cancer
579468|NCT00397488|stage IV bladder cancer
579469|NCT00397488|transitional cell carcinoma of the bladder
579470|NCT00397488|anterior urethral cancer
579471|NCT00397488|posterior urethral cancer
579472|NCT00397488|recurrent urethral cancer
579473|NCT00397488|metastatic transitional cell cancer of the renal pelvis and ureter
579474|NCT00397488|recurrent transitional cell cancer of the renal pelvis and ureter
579475|NCT00397488|urethral cancer associated with invasive bladder cancer
579476|NCT00397462|Osteoporosis
579477|NCT00397462|Sarcopenia
579478|NCT00397462|Calf muscle pump
579479|NCT00397462|Venous insufficiency
579480|NCT00397462|DEXA
579481|NCT00397462|Soleus muscle
579482|NCT00397462|APG
579483|NCT00397449|Malaria, malaria vaccine, randomised, safety, immunogenicity
579484|NCT00397423|Amyotrophic Lateral Sclerosis
579485|NCT00397423|Granulocyte Colony Stimulating Factor
579486|NCT00397423|Randomized Control Trial Study
579487|NCT00397410|hip protectors
579488|NCT00397410|uptake and adherence
579489|NCT00397410|Nursing home residents
579490|NCT00397410|efficacy
579491|NCT00397410|prevention
579492|NCT00397397|Urinary Calculi
579493|NCT00397397|Rowatinex
579494|NCT00397397|Alfuzosin
579495|NCT00397397|Drug Therapy
579496|NCT00397358|Peritoneal Dialysis
579497|NCT00397358|Hypertriglyceridemia
579498|NCT00397358|Extraneal(7.5% icodextrin)Peritoneal Dialysis Solution
579499|NCT00397345|Renal
579500|NCT00397345|TroVax
579501|NCT00397345|survival
579502|NCT00397345|metastatic
579503|NCT00397345|Kidney
579504|NCT00397345|cancer
579505|NCT00397345|immunotherapy
579506|NCT00397345|Locally advanced or metastatic, measurable, histologically proven clear cell renal carcinoma.
579507|NCT00397332|GVHD
579508|NCT00397319|Growth Hormone
579509|NCT00397319|Cardiovascular System
579510|NCT00397293|AT101
579511|NCT00397293|AT-101
579512|NCT00397293|cancer
579513|NCT00397293|lung
579514|NCT00397293|small-cell
579515|NCT00397293|topotecan
579516|NCT00397280|Neutrophil
579517|NCT00397280|Immunity
579518|NCT00397280|Signal Transduction
579519|NCT00397280|Lipopolysaccharide
579520|NCT00397280|Cholesterol
579521|NCT00397280|Healthy Volunteer
579522|NCT00397280|HV
579523|NCT00397267|Dyspnea
579524|NCT00397267|Cough
579525|NCT00397254|Migraine
579526|NCT00397254|rizatriptan
579527|NCT00397228|Parkinson
579528|NCT00397228|imaging
579529|NCT00397228|dopamine transporter
579530|NCT00397215|H5N1
579531|NCT00397215|influenza
579532|NCT00397215|vaccine
579533|NCT00397202|Menstruation
579534|NCT00397189|Primary insomnia as defined by DSM IV criteria
579535|NCT00397163|Coronary artery bypass graft surgery
579536|NCT00397163|Remote ischemic preconditioning
579537|NCT00397163|Troponin-T
579538|NCT00397150|Infant Nutrition [G06.696.259.750]
579539|NCT00397150|Infant Care [N02.421.088.120] +
579540|NCT00397150|Diarrhea, Infantile [C23.888.821.214.500]
579541|NCT00397150|Child Health Services [N02.421.143.130] +
579542|NCT00397150|Counseling [N02.421.143.303]
579543|NCT00397150|Growth [G07.574.249] +
579544|NCT00397150|Micronutrients [D11.430]
579545|NCT00397150|Breast Feeding [G06.696.259.750.500]
579546|NCT00397137|Symptomatic haemorrhoids
579547|NCT00397137|haemorrhoidectomy
579548|NCT00397137|stapled anopexy
579549|NCT00397111|Morphometry
579550|NCT00397111|BOLD
579551|NCT00397111|fMRI
579552|NCT00397111|Spectrometry
579553|NCT00397111|Relaxometry
579554|NCT00397111|Healthy Volunteer
579555|NCT00397111|HV
579556|NCT00397098|Anxiety disorders, Relapse prevention
579557|NCT00397072|Glioblastoma recurrent,temozolomide, epothilone
579558|NCT00397059|Escitalopram
579559|NCT00397059|Pharmacokinetics
579560|NCT00397059|Pharmacodynamics
579561|NCT00397059|CYP2C19
579562|NCT00397059|Pupillometry
579563|NCT00397059|healthy volunteers
579564|NCT00397046|Advanced Malignant Solid Tumors
579565|NCT00397033|Schizoaffective Disorder
579566|NCT00397033|antipsychotic
579567|NCT00397033|paliperidone
579568|NCT00397033|placebo
579569|NCT00397020|quetiapine
579570|NCT00397020|divalproex
579571|NCT00397007|tinnitus
579572|NCT00397007|biofeedback
579573|NCT00397007|psychophysiological reactivity
579574|NCT00397007|intervention
579575|NCT00396994|biomechanics
579576|NCT00396994|osteogenesis
579577|NCT00396994|osteoporosis
579578|NCT00396994|bone regeneration
579579|NCT00396981|Intracranial saccular aneurysms
579580|NCT00396981|Endovascular coiling therapy
579581|NCT00396981|Retreatment
579582|NCT00396981|Raymond scale
579583|NCT00396981|Matrix
579584|NCT00396981|GDC
579585|NCT00396981|Guglielmi Detachable Coil
579586|NCT00396968|AMD3100
579587|NCT00396968|Acute Myelogenous Leukemai
579588|NCT00396968|Myelodysplastic Syndromes
579589|NCT00396968|Allogeneic stem cell transplantation
579590|NCT00396955|osteoarthritis
579591|NCT00396955|arthritis
579592|NCT00396955|pain
579593|NCT00396942|Electroencephalogram (EEG)
579594|NCT00396942|Nerve Conduction Study
579595|NCT00396942|Transcranial Magnetic Stimulation (TMS)
579596|NCT00396942|Motor Evoked Potential
579597|NCT00396942|Parkinson Disease
579598|NCT00396942|PD
579599|NCT00396942|Healthy Volunteer
579600|NCT00396942|HV
579601|NCT00396929|Paclitaxel
579602|NCT00396929|Restenosis
579603|NCT00396929|Stent
579604|NCT00396929|Intracoronary Dosis
579605|NCT00396929|Paclitaxel-eluting Stent
579606|NCT00396916|cancer patients
579607|NCT00396903|Anaesthetic techniques
579608|NCT00396903|epidural catheters
579609|NCT00396903|paraesthesia
579610|NCT00396903|side effects.
579611|NCT00396890|Theta Burst Stimulation
579612|NCT00396890|Repetitive TMS (rTMS)
579613|NCT00396890|Transcranial Magnetic Stimulation (TMS)
579614|NCT00396890|Primary Motor Cortex
579615|NCT00396890|Interhemispheric Disinhibition
579616|NCT00396890|Healthy Volunteer
579617|NCT00396890|HV
579618|NCT00396877|cyanotic congenital heart disease
579619|NCT00396877|shunt palliation
579620|NCT00396877|thrombosis
579621|NCT00396877|clopidogrel
579622|NCT00396864|cutaneous lymphoma
579623|NCT00396864|marginal zone lymphoma
579624|NCT00396825|Care giving
579625|NCT00396825|Alzheimer's Disease
579626|NCT00396825|Stress management
579627|NCT00396812|Autoimmune disease
579628|NCT00396812|Biologic response modifiers
579629|NCT00396812|Disease-modifying antirheumatic drugs (DMARDS)
579630|NCT00396812|Immune system
579631|NCT00396812|Rheumatoid arthritis (RA)
579632|NCT00396812|Rituximab (anti-CD20 monoclonal antibodies)
579633|NCT00396786|Prevention of venous thromboembolism
579634|NCT00396773|electrocoagulation,pregnancy,brian waves
579635|NCT00396760|cardiac surgery
579636|NCT00396760|blood transfusion
579637|NCT00396760|antifibrinolytics
579638|NCT00396760|aprotinin
579639|NCT00396760|tranexamic acid
579640|NCT00396747|Early rheumatoid arthritis,
579641|NCT00396747|glucocorticoids,
579642|NCT00396747|pulse therapy,
579643|NCT00396747|infliximab,
579644|NCT00396747|TNF blockade
579645|NCT00396734|Imaging
579646|NCT00396734|cocaine
579647|NCT00396734|methadone
579648|NCT00396734|craving
579649|NCT00396734|PET
579650|NCT00396734|FDG
579651|NCT00396734|D2
579652|NCT00396734|Modafinil
579653|NCT00396734|Topiramate
579654|NCT00396721|Nephropathy, IGA
579655|NCT00396721|Pilot trial
579656|NCT00396721|Sirolimus
579657|NCT00396721|Rapamune
579658|NCT00396708|Robotics
579659|NCT00396708|Rehabilitation
579660|NCT00396708|Arm
579661|NCT00396708|Stroke
579662|NCT00396708|Weakness
579663|NCT00396708|Outpatient
579664|NCT00396708|Chronic
579665|NCT00396695|PTSD, traumatic memory
579666|NCT00396682|HCC
579667|NCT00396682|T cell
579668|NCT00396669|Nicotine
579669|NCT00396669|Dopamine
579670|NCT00396669|Imaging
579671|NCT00396669|Raclopride
579672|NCT00396669|Addiction
579673|NCT00396669|Genetics
579674|NCT00396656|hypertension
579675|NCT00396656|valsartan
579676|NCT00396656|atenolol
579677|NCT00396656|hydrochlorothiazide
579678|NCT00396656|microcirculation
579679|NCT00396656|arterial compliance
579680|NCT00396656|pulse wave analysis
579681|NCT00396643|Ultra-High Risk
579682|NCT00396643|Psychosis
579683|NCT00396643|Schizophrenia
579684|NCT00396643|Omega-3 fatty acids
579685|NCT00396643|RCT
579686|NCT00396630|Transmission
579687|NCT00396630|Gastroenteritis
579688|NCT00396630|Shedding
579689|NCT00396630|rotavirus
579690|NCT00396630|HRV vaccine
579691|NCT00396617|Laryngeal or pharyngo-laryngeal's carcinoma,
579692|NCT00396617|voice prosthesis tracheooesophageal shunt,
579693|NCT00396617|titanium beads,
579694|NCT00396617|cellular colonization
579695|NCT00396617|Laryngeal or pharyngo-laryngeal's carcinoma
579696|NCT00396604|indacaterol
579697|NCT00396604|long acting beta agonist
579698|NCT00396591|Ovarian cancer
579699|NCT00396591|malignant ascites
579700|NCT00396591|angiogenesis
579701|NCT00396591|angiogenesis inhibition
579702|NCT00396591|VEGF-Trap fusion recombinant protein
579703|NCT00396578|aerosolized antibiotics
579704|NCT00396578|ventilator associated pneumonia
579705|NCT00396578|clinical pulmonary infection score
579706|NCT00396578|bacterial resistance
579707|NCT00396565|Schizophrenia
579708|NCT00396565|JNS007ER
579709|NCT00396565|Positive and Negative Syndrome Scale (PANSS)
579710|NCT00396565|Paliperidone
579711|NCT00396565|Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
579712|NCT00396552|refractory transcranial magnetic stimulation
579713|NCT00396552|obsessive compulsive disorder
579714|NCT00396552|randomized
579715|NCT00396552|placebo-controlled
579716|NCT00396552|double-blind
579717|NCT00395889|Lung Transplantation
579718|NCT00395889|Physical Activities in Daily Life
579719|NCT00395889|Pulmonary Rehabilitation
579720|NCT00395889|Functional Status
579721|NCT00395876|TNKase
579722|NCT00395876|CVA
579723|NCT00395876|CVAD
579724|NCT00395876|Central venous access catheter
579725|NCT00395876|CVA catheter
579726|NCT00395850|cocaine dependence
579727|NCT00395850|disulfiram
579728|NCT00395850|clinical trial
579729|NCT00395850|methadone maintenance
579730|NCT00395850|pharmacogenetics
579731|NCT00395850|dopamine beta-hydroxylase
579732|NCT00395837|Aging
579733|NCT00395837|Wellness
579734|NCT00395837|Aerobic exercise
579735|NCT00395837|Prevention
579736|NCT00395824|citrate
579737|NCT00395824|anticoagulation
579738|NCT00395824|heparin-coated membrane
579739|NCT00395811|Myocardial Infarction
579740|NCT00395811|stem cell therapy
579741|NCT00395811|Coronary Artery Bypass Grafting
579742|NCT00395798|cervical intervertebral disc displacement
579743|NCT00395798|cervical spondylosis
579744|NCT00395798|radiculopathy
579745|NCT00395798|neck collar
579746|NCT00395798|brace
579747|NCT00395798|physiotherapy
579748|NCT00395798|treatment
579749|NCT00395798|rehabilitation
579750|NCT00395785|Carotid stenosis
579751|NCT00395785|Intracranial Embolism
579752|NCT00395785|Carotid artery
579753|NCT00395785|Carotid stent
579754|NCT00395785|Embolic protection
579755|NCT00395785|TriActiv ProGuard System
579756|NCT00395785|Carotid angioplasty
579757|NCT00395772|Treatment of venous thromboembolism
579758|NCT00395759|contrast sensitivity
579759|NCT00395733|Gadovist
579760|NCT00395733|Gadavist
579761|NCT00395733|MRI Imaging
579762|NCT00395733|vascular diseases
579763|NCT00395733|Chinese
579764|NCT00395720|TB
579765|NCT00395720|Tuberculosis
579766|NCT00395720|HIV
579767|NCT00395720|Vaccine
579768|NCT00395720|MVA85A
579769|NCT00395720|HIV Therapeutic Vaccine
579770|NCT00395707|Macular Degeneration
579771|NCT00395707|Age Related Macular Degeneration
579772|NCT00395707|Retinal Angiomatous Proliferations
579773|NCT00395694|epilepsy
579774|NCT00395694|Incidence of rash
579775|NCT00395694|safety evaluation for initial dose
579776|NCT00395694|patients with Valproic acid
579777|NCT00395681|Obesity
579778|NCT00395681|Propofol
579779|NCT00395681|Morbidly obese
579780|NCT00395681|BMI
579781|NCT00396526|Nonsevere pneumonia
579782|NCT00396526|treatment
579783|NCT00396526|underfives
579784|NCT00396526|children
579785|NCT00396526|Community
579786|NCT00396526|India
579787|NCT00396513|PCOS
579788|NCT00396513|Statin
579789|NCT00396513|Metformin
579790|NCT00396513|Testosterone
579791|NCT00396513|Menstrual cycle
579792|NCT00396513|Lipids
579793|NCT00396500|Deworming
579794|NCT00396500|Malnutrition
579795|NCT00396500|children
579796|NCT00396500|Community
579797|NCT00396500|India
579798|NCT00396487|Metastatic colorectal cancer
579799|NCT00396487|tailored treatment
579800|NCT00396487|genetic markers
579801|NCT00396487|gene polymorphism
579802|NCT00396487|chemotherapy
579803|NCT00396474|Small for gestational age, Insulin Sensitivity Index, growth hormone treatment
579804|NCT00396461|Critical Illness
579805|NCT00396461|Fat Emulsions, Intravenous
579806|NCT00396461|Superinfection
579807|NCT00396461|Parenteral Nutrition
579808|NCT00396435|anaemia
579809|NCT00396435|renal transplantation
579810|NCT00396435|kidney failure
579811|NCT00396422|psoriasis
579812|NCT00396422|skin
579813|NCT00396422|auto immune
579814|NCT00396396|Creatinine clearance
579815|NCT00396396|Acetylcysteine
579816|NCT00396383|Multiple Myeloma
579817|NCT00396383|Stem cell mobilization
579818|NCT00396383|apheresis
579819|NCT00396370|tuberculosis, Bacillus Calmette-Guérin, parent protocol
579820|NCT00396357|Type 2 diabetes
579821|NCT00396357|vildagliptin
579822|NCT00396357|hemoglobin A1c
579823|NCT00396357|metformin
579824|NCT00396344|Systemic sepsis
579825|NCT00396331|Multiple Myeloma
579826|NCT00396331|Non-Hodgkin's Lymphoma
579827|NCT00396331|autologous transplantation
579828|NCT00396331|AMD3100
579829|NCT00396331|stem cell mobilization
579830|NCT00396331|plerixafor
579831|NCT00396318|TNKase
579832|NCT00396318|CVA
579833|NCT00396318|CVAD
579834|NCT00396318|Central venous access catheter
579835|NCT00396305|Influenza, vaccine, efficacy, elderly
579836|NCT00396292|Anemia
579837|NCT00396292|postpartum
579838|NCT00396292|Postpartum anemia
579839|NCT00396279|Giant Cell Tumor of Bone
579840|NCT00396266|Non-Hodgkin's Lymphoma
579841|NCT00396266|Multiple Myeloma
579842|NCT00396266|stem cell mobilization
579843|NCT00396266|AMD3100
579844|NCT00396266|autologous transplantation
579845|NCT00396253|HD
579846|NCT00396253|TNKase
579847|NCT00396253|Hemodialysis
579848|NCT00396253|Catheter clearance
579849|NCT00396240|rosuvastatin
579850|NCT00396240|hypercholesterolaemia
579851|NCT00396240|cholesterol
579852|NCT00396240|LDL-C
579853|NCT00396240|triglyceride
579854|NCT00396240|plasma lipids
579855|NCT00396240|compliance
579856|NCT00396227|Type 2 diabetes
579857|NCT00396227|vildagliptin
579858|NCT00396227|hemoglobin A1c
579859|NCT00396227|metformin
579860|NCT00396214|Schizophrenia
579861|NCT00396214|weight changes
579862|NCT00396201|Hodgkin's Disease
579863|NCT00396201|Stem cell mobilization
579864|NCT00396201|apheresis
579865|NCT00396188|Keratoconus
579866|NCT00396188|LASIK
579867|NCT00396188|Orthokeratology
579868|NCT00396188|Pellucid Marginal Degeneration
579869|NCT00396188|Refractive Surgery
579870|NCT00396188|normal cornea
579871|NCT00396188|post myopic LASIK
579872|NCT00396188|post hyperopic LASIK
579873|NCT00396188|corneal pathologies (e.g. pellucid marginal degeneration)
579874|NCT00396149|rBet v 1
579875|NCT00396149|Birch pollen allergy
579876|NCT00396149|Sublingual Immunotherapy
579877|NCT00396136|Congestive Heart Failure
579878|NCT00396136|Cardiac Resynchronization Therapy
579879|NCT00396136|Left Ventricular Lead
579880|NCT00396123|Chronic Kidney Disease
579881|NCT00396123|Anemia
579882|NCT00396110|cholesterol
579883|NCT00396110|coronary heart disease
579884|NCT00396110|rosuvastatin
579885|NCT00396110|LDL-C goal
579886|NCT00396110|hypercholesterolemia
579887|NCT00396097|ISS
579888|NCT00396097|human growth hormone
579889|NCT00396084|tuberculosis, linezolid, gatifloxacin, levofloxacin, isoniazid, moxifloxacin, Brazil
579890|NCT00396071|Type 2 diabetes
579891|NCT00396071|vildagliptin
579892|NCT00396071|incretin effect
579893|NCT00396071|metformin
579894|NCT00396045|Multiple Myeloma, Lenalidomide, elderly patients
579895|NCT00396032|HD
579896|NCT00396032|Hemodialysis
579897|NCT00396032|Catheter clearance
579898|NCT00396032|TNKase
579899|NCT00396032|Renal Insufficiency
579900|NCT00395993|anemia
579901|NCT00395993|heavy uterine bleeding
579902|NCT00395993|menorrhagia
579903|NCT00395993|Anemia secondary to heavy uterine bleeding
579904|NCT00395967|Non-Hodgkin's Lymphoma
579905|NCT00395967|Multiple Myeloma
579906|NCT00395967|stem cell mobilization
579907|NCT00395967|autologous transplantation
579908|NCT00395967|AMD3100
579909|NCT00395954|Lactose Intolerance
579910|NCT00395954|Lactose
579911|NCT00395954|Threshold
579912|NCT00395928|heart
579913|NCT00395928|echocardiography
579914|NCT00395928|diastolic function
579915|NCT00395928|left ventricle
579916|NCT00395928|right ventricle
579917|NCT00395928|cigarette smoking
579918|NCT00395928|Smoking
579919|NCT00395928|Heart Ventricles
579920|NCT00395928|Diastole
579921|NCT00395928|Doppler Echocardiography
579922|NCT00395915|schizophrenia
579923|NCT00395915|antipsychotics
579924|NCT00395915|treatment non response
579925|NCT00395915|pragmatic trial
579926|NCT00395902|Sensipar
579927|NCT00395902|cinacalcet
579928|NCT00395902|Mimpara
579929|NCT00395668|TETRA
579930|NCT00395668|EMF
579931|NCT00395668|Human exposure study
579932|NCT00395668|Symptoms
579933|NCT00395668|Well-being
579934|NCT00395668|Cognitive function
579935|NCT00395655|locally advanced breast cancer
579936|NCT00395655|hydralazine
579937|NCT00395655|magnesium valproate
579938|NCT00395655|epigenetic therapy
579939|NCT00395655|gene expression
579940|NCT00395642|Congestive Heart Failure
579941|NCT00395642|Cardiac Resynchronization Therapy
579942|NCT00395642|Home Monitoring
579943|NCT00395642|Telemonitoring
579944|NCT00395642|Remote Monitoring
579945|NCT00395629|Deferasirox
579946|NCT00395629|ICL670A
579947|NCT00395629|Iron chelators
579948|NCT00395629|Deferiprone
579949|NCT00395629|Transfusional Hemochromatosis
579950|NCT00395590|OSA inflammatory cytokines, metabolic syndrome
579951|NCT00395564|Urologic Surgery
579952|NCT00395551|choroidal neovascularization
579953|NCT00395551|Choroidal Neovascularization Not related to Age-Related Macular Degeneration
579954|NCT00395538|Parathyroid
579955|NCT00395538|Bone Biopsy
579956|NCT00395538|Calcium-Sensing Receptor
579957|NCT00395538|Bone Density
579958|NCT00395538|Bone Turnover
579959|NCT00395538|Hypoparathyroidism
579960|NCT00395512|Glucose Metabolism Disorder
579961|NCT00395512|Dysmetabolic Syndrome
579962|NCT00395512|Type II Diabetes
579963|NCT00395512|Diabetes Mellitus, Lipoatrophic
579964|NCT00395512|Dyslipidemia
579965|NCT00395512|Drug Therapy
579966|NCT00395499|Risperidone
579967|NCT00395499|9-Hydroxyrisperidone
579968|NCT00395499|Plasma
579969|NCT00395499|Saliva
579970|NCT00395499|children
579971|NCT00395486|rosuvastatin
579972|NCT00395486|lipoprotein
579973|NCT00395486|metabolic syndrome
579974|NCT00395460|Gadovist
579975|NCT00395460|Gadavist
579976|NCT00395460|Contrast agent
579977|NCT00395460|Brain
579978|NCT00395460|Spine disease
579979|NCT00395460|Magnetic Resonance Imaging
579980|NCT00395447|Cardiac Pacemaker
579981|NCT00395447|Defibrillator
579982|NCT00395447|Replacement
579983|NCT00395447|Upgrade
579984|NCT00395434|Advanced Solid Tumors
579985|NCT00395434|Advanced Solid Tumours
579986|NCT00395434|Advanced Solid Tumor
579987|NCT00395434|Advanced Solid Tumour
579988|NCT00395434|Advanced
579989|NCT00395434|Malignant
579990|NCT00395434|Solid
579991|NCT00395434|Tumors
579992|NCT00395434|Tumours
579993|NCT00395434|Tumor
579994|NCT00395434|Tumour
579995|NCT00395434|Cancer
579996|NCT00395434|Malignant Solid Tumors
579997|NCT00395434|Malignant Solid Tumours
579998|NCT00395434|Malignant Solid Tumor
579999|NCT00395434|Malignant Solid Tumour
580000|NCT00395434|Metastatic Cancer
580001|NCT00395434|Metastatic Disease
580002|NCT00395434|Advanced Cancer
580003|NCT00395434|Vascular Disrupting Agent
580004|NCT00395434|Anti-angiogenesis agent
580005|NCT00395434|Phase 1
580006|NCT00395421|treatment-naive
580007|NCT00395395|Postmenopausal
580008|NCT00395395|osteoporosis
580009|NCT00395395|Pharmacokinetics/dynamics
580010|NCT00395395|Calcitonin
580011|NCT00395382|Vascular calcification
580012|NCT00395382|Arterial stiffness
580013|NCT00395382|Cardiovascular risk
580014|NCT00395382|Bone mineral metabolism
580015|NCT00395382|Calcium
580016|NCT00395369|aprotinin
580017|NCT00395369|cardiac surgery
580018|NCT00395369|neurological dysfunction
580019|NCT00395369|optical coherance tomography
580020|NCT00395356|Diet
580021|NCT00395356|Caloric restriction
580022|NCT00395356|Intermittent diet
580023|NCT00395356|Obesity
580024|NCT00395356|Postmenopausal women
580025|NCT00395330|Respiratory Function Tests
580026|NCT00395330|Oscillometry
580027|NCT00395330|World Trade Center Disaster
580028|NCT00395330|Environmental Exposure
580029|NCT00395330|Distal Airways
580030|NCT00395317|magnetic resonance imaging
580031|NCT00395317|multiple sclerosis
580032|NCT00395317|SB-683699
580033|NCT00395291|Chronic kidney disease
580034|NCT00395291|End stage renal disease
580035|NCT00395278|KSHV
580036|NCT00395278|Kaposi's Sarcoma
580037|NCT00395278|HIV
580038|NCT00395278|Kaposi Sarcoma
580039|NCT00395265|Deep Vein Thrombosis
580040|NCT00395265|Chronic Venous Insufficiency
580041|NCT00395265|Post Thrombotic Syndrome
580042|NCT00395265|Blood Coagulation
580043|NCT00395265|Inflammation
580044|NCT00395252|pancreatic cancer
580045|NCT00395252|adjuvant chemotherapy
580046|NCT00395252|phase 2
580047|NCT00395252|R0 or R1 resected Adenocarcinoma of the Pancreas
580048|NCT00395239|Asthma
580049|NCT00395239|Inhaled corticosteroid
580050|NCT00395239|ICS
580051|NCT00395239|Metabolites
580052|NCT00395239|Induced sputum
580053|NCT00395239|Virtual Asthma Clinic
580054|NCT00395226|Rosacea
580055|NCT00395213|Anxiety
580056|NCT00395213|Major Depression
580057|NCT00395213|Anorexia
580058|NCT00395213|Bulimia
580059|NCT00395213|OCD
580060|NCT00395213|Antidepressant
580061|NCT00395213|SSRI
580062|NCT00395213|SNRI
580063|NCT00395200|Multiple Sclerosis
580064|NCT00395200|Safety
580065|NCT00395200|Therapeutics
580066|NCT00395200|Mesenchymal Stem Cells
580067|NCT00395200|Multipotent Mesenchymal Stromal Cells
580068|NCT00395200|Optic Neuritis
580069|NCT00395174|Influenza
580070|NCT00395161|sepsis
580071|NCT00395161|prevention
580072|NCT00395161|mineral supplementation
580073|NCT00395135|Obesity
580074|NCT00395135|Weight loss
580075|NCT00395135|lorcaserin
580076|NCT00395135|APD356
580077|NCT00395135|BLOOM
580078|NCT00395135|Hypertension
580079|NCT00395135|Dyslipidemia
580080|NCT00395135|Sleep apnea
580081|NCT00395135|glucose tolerance
580082|NCT00395135|cardiovascular disease
580083|NCT00395135|Arena
580084|NCT00395122|Band Atrophy
580085|NCT00395122|Optical Coherence Tomography
580086|NCT00395122|Scanning Laser Polarimetry
580087|NCT00395122|Chiasmal Lesions
580088|NCT00395109|cancer
580089|NCT00395109|hypoxia
580090|NCT00395109|PET scan
580091|NCT00395109|CT scan
580092|NCT00395096|Exhaled Nitric Oxide
580093|NCT00395096|Asthma
580094|NCT00395096|Tobacco Smoke
580095|NCT00395096|Allergen
580096|NCT00395070|Melanoma
580097|NCT00395070|DTIC
580098|NCT00395070|TMZ
580099|NCT00395070|Stage 3
580100|NCT00395070|Stage 4
580101|NCT00395070|Metastatic
580102|NCT00395070|Metastatic Melanoma (Stage 3, Stage 4 Melanoma)
580103|NCT00395044|Cannabis treatment
580104|NCT00395044|marijuana treatment
580105|NCT00395031|schizophrenia
580106|NCT00395031|Schizoaffective Disorder
580107|NCT00395031|metabolic markers
580108|NCT00395031|ziprasidone
580109|NCT00395031|diabetes
580110|NCT00395018|Chronic Hepatitis B Virus, Liver Transplant
580111|NCT00395005|Kallikrein
580112|NCT00395005|Cytokines
580113|NCT00395005|Proteinuria
580114|NCT00395005|Renal function
580115|NCT00395005|Chronic kidney disease
580116|NCT00394992|Colorectal cancer
580117|NCT00394992|Liver metastasis
580118|NCT00394992|Radical resection
580119|NCT00394992|Adjuvant therapy
580120|NCT00394992|Bevacizumab
580121|NCT00394992|Capecitabine
580122|NCT00394992|Oxaliplatin
580123|NCT00394992|Hepatica
580124|NCT00394940|COPD
580125|NCT00394940|Emphysema
580126|NCT00394940|Chronic Bronchitis
580127|NCT00394940|Inflammation
580128|NCT00394940|CD14
580129|NCT00394940|TLR4
580130|NCT00394940|Proteomics
580131|NCT00394927|Non-Interventional
580132|NCT00394927|Surveillance
580133|NCT00394927|Adverse Effects
580134|NCT00394927|AntiEpileptic Drug treatment
580135|NCT00394888|Hemangioma
580136|NCT00394888|PHACE
580137|NCT00394888|Lumbosacral hemangioma
580138|NCT00394888|Occult Spinal Dysraphism
580139|NCT00394875|Randomized controlled trial
580140|NCT00394875|Delegation, Professional
580141|NCT00394875|Nurses
580142|NCT00394849|Tonsillectomy
580143|NCT00394849|Suturing of tonsillar pillars
580144|NCT00394849|pain
580145|NCT00394849|postoperative hemorrhage, bleeding
580146|NCT00394836|ofatumumab
580147|NCT00394836|rituximab
580148|NCT00394836|NHL
580149|NCT00394836|CD20
580150|NCT00394836|refractory
580151|NCT00394823|Hypertension, valsartan, compliance
580152|NCT00394784|gram negative bacteria
580153|NCT00394784|culture
580154|NCT00394784|infection
580155|NCT00394771|oral contraceptives
580156|NCT00394771|breakthrough bleeding
580157|NCT00394771|spotting
580158|NCT00394758|ultrasonic surgical aspiration
580159|NCT00394758|CO2 laser surgery
580160|NCT00394758|vulvar dysplasia
580161|NCT00394758|vaginal dysplasia
580162|NCT00394758|recurrence
580163|NCT00394745|Hypertension, Metabolic Syndrome, lipid subfractions
580164|NCT00394732|chronic low back pain
580165|NCT00394732|total disc replacement
580166|NCT00394732|multidisciplinary rehabilitation
580167|NCT00394732|clinical effects
580168|NCT00394732|cost effectiveness
580169|NCT00394732|randomized controlled trial
580170|NCT00394732|multicenter study
580171|NCT00394706|cardiac arrest
580172|NCT00394706|cardiopulmonary resuscitation
580173|NCT00394693|Primary CBCL including (WHO/EORTC classification 2005)
580174|NCT00394693|Primary cutaneous marginal zone B-cell lymphoma
580175|NCT00394693|Primary cutaneous follicle center B-cell lymphoma
580176|NCT00394693|Primary cutaneous diffuse large B-cell other than leg type
580177|NCT00394693|Histologically consistent with primary CBCL
580178|NCT00394693|Relapse or active disease
580179|NCT00394680|coronary revascularization
580180|NCT00394680|stent inmplantation
580181|NCT00394680|coronary bypass
580182|NCT00394628|Glioblastoma Multiforme
580183|NCT00394628|Radiotherapy
580184|NCT00394628|temozolomide
580185|NCT00394628|adjuvant temozolomide
580186|NCT00394602|Gastric Cancer
580187|NCT00394602|Pancreatic Cancer
580188|NCT00394602|Cervical Cancer
580189|NCT00394602|Vulvar Cancer
580190|NCT00394602|Endometrial Cancer
580191|NCT00394602|Anal Cancer
580192|NCT00394602|Quality of Life
580193|NCT00394602|Questionnaire
580194|NCT00394602|Interview
580195|NCT00394602|Emesis
580196|NCT00394602|Nausea
580197|NCT00394602|Survey
580198|NCT00394576|Kidney School
580199|NCT00394576|Short Test of Functional Health Literacy
580200|NCT00394576|Chronic Kidney Disease Knowledge Assessment Tool of Nutrition
580201|NCT00394576|Short Form 12 version 2
580202|NCT00394576|Kidney Disease Self-Management Survey
580203|NCT00394576|Three Day Dietary Diary
580204|NCT00394563|osteoarthritis monoclonal antibody
580205|NCT00394550|laryngomalacia
580206|NCT00394550|supraglottoplasty
580207|NCT00394550|Tonsillectomy
580208|NCT00394550|Adenoidectomy
580209|NCT00394550|obstructive sleep apnea
580210|NCT00394550|Laser
580211|NCT00394550|Polysomnogram
580212|NCT00394550|airway obstruction
580213|NCT00394524|ICU
580214|NCT00394524|hyperglycemia
580215|NCT00394524|glucommander
580216|NCT00394498|Myocardial Infarction
580217|NCT00394498|Stem Cells
580218|NCT00394485|Chronic Obstructive Pulmonary Disease
580219|NCT00394485|Procaterol
580220|NCT00394485|Tiotropium
580221|NCT00394472|Heartburn
580222|NCT00394472|Patient reported symptoms
580223|NCT00394472|Proton pump inhibitor
580224|NCT00394459|Anaesthetic techniques
580225|NCT00394459|epidural
580226|NCT00394459|catheters
580227|NCT00394459|paraesthesia
580228|NCT00394459|side effects
580229|NCT00394459|Anesthesia, Epidural [E03.155.086.131]
580230|NCT00394446|Solid Tumors
580231|NCT00394446|Refractory
580232|NCT00394446|Brain
580233|NCT00394433|TPCA
580234|NCT00394433|Taxotere
580235|NCT00394433|Platinum
580236|NCT00394433|Avastin
580237|NCT00394433|Camptosar
580238|NCT00394433|gastric cancer
580239|NCT00394407|inpatient
580240|NCT00394407|diabetes management
580241|NCT00394407|insulin therapy
580242|NCT00394381|acute myeloid leukemia
580243|NCT00394381|myelodysplastic syndrome
580244|NCT00394381|autologous CIK cells
580245|NCT00394381|autologous peripheral blood stem cell transplant
580246|NCT00394368|asthma
580247|NCT00394368|combinations
580248|NCT00394368|inhaled therapy
580249|NCT00394368|corticosteroids
580250|NCT00394368|long acting bronchodilators
580251|NCT00394368|salmeterol
580252|NCT00394368|beclomethasone
580253|NCT00394368|formoterol
580254|NCT00394368|fluticasone
580255|NCT00394316|CD34 Stem Cells
580256|NCT00394316|Busulfan
580257|NCT00394316|Gene Therapy
580258|NCT00394316|Immune Reconstitution
580259|NCT00394316|Engraftment
580260|NCT00394316|Chronic Granulomatous Disease (CGD)
580261|NCT00394316|Gp91 Phox Deficiency
580262|NCT00394316|Peripheral Blood Stem Cells
580263|NCT00394316|Bone Marrow Transplantation
580264|NCT00394316|Chronic Granulomatous Disease
580265|NCT00394316|CGD
580266|NCT00394303|Open heart surgery
580267|NCT00394303|Diabetes mellitus
580268|NCT00394303|Hyperglycemia
580269|NCT00394303|Surgical site infection
580270|NCT00394303|Normoglycemia
580271|NCT00394290|Down Syndrome
580272|NCT00394290|Obstructive Sleep Apnea Syndrome
580273|NCT00394290|Continuous Positive Pressure
580274|NCT00394290|Hypersomnia
580275|NCT00394264|low back pain
580276|NCT00394264|active duty military personnel
580277|NCT00394264|manual/manipulative therapy
580278|NCT00394264|osteopathic manipulative treatment
580279|NCT00394264|physical medicine
580280|NCT00394251|Adjuvant therapy
580281|NCT00394251|Bevacizumab
580282|NCT00394251|Abraxane
580283|NCT00394251|Early stage breast cancer
580284|NCT00394225|6-Minute Walk Test
580285|NCT00394225|COPD
580286|NCT00394225|Helium-Hyperoxia
580287|NCT00394225|Exercise
580288|NCT00394225|Chronic Obstructive Pulmonary Disease (COPD)
580289|NCT00394212|Weight Loss
580290|NCT00394212|Transoral Suturing
580291|NCT00394212|Dilated gastrojejunostomy
580292|NCT00394212|Inadequate weight loss following primary RYGB
580293|NCT00394199|Asthma
580294|NCT00394199|Fluticasone Propionate
580295|NCT00394199|formoterol fumarate
580296|NCT00394199|Pressurized metered dose inhaler
580297|NCT00394199|Hydrofluoroalkane
580298|NCT00394199|Mild to Moderate Asthma
580299|NCT00394186|GW427353
580300|NCT00394186|b3-Adrenergic Receptor Agonist
580301|NCT00394186|Irritable Bowel Syndrome (IBS)
580302|NCT00394186|efficacy
580303|NCT00394186|tolerability
580304|NCT00394186|pharmacokinetics
580305|NCT00394173|IBS
580306|NCT00394173|diarrhea
580307|NCT00394173|gastrointestinal functional disorder
580308|NCT00394173|IBS-D
580309|NCT00394147|advanced
580310|NCT00394147|head
580311|NCT00394147|neck
580312|NCT00394147|cancer
580313|NCT00394134|Melanoma
580314|NCT00394134|Sun Exposure
580315|NCT00394134|Sun Protection
580316|NCT00394134|Interview
580317|NCT00394121|Asthma
580318|NCT00394121|Fluticasone Propionate
580319|NCT00394121|Formoterol Fumarate
580320|NCT00394121|Pressurized metered does inhaler
580321|NCT00394121|Hydrofluoroalkane
580322|NCT00394121|Mild to moderate-severe asthma
580323|NCT00394095|Bipolar Disorder
580324|NCT00394095|Weight Gain
580325|NCT00394082|Metastatic breast cancer, Abraxane, Bevacizumab
580326|NCT00394056|placebo
580327|NCT00394056|balanced
580328|NCT00394056|paroxetine
580329|NCT00394056|repeated dose
580330|NCT00394056|Hearing Loss
580331|NCT00394056|loudness
580332|NCT00394056|combination
580333|NCT00394056|Tinnitus
580334|NCT00394056|vestipitant (GW597599)
580335|NCT00394056|randomised
580336|NCT00394056|annoyance
580337|NCT00394056|crossover
580338|NCT00394043|Carpal Tunnel Sydrome
580339|NCT00394043|Osteopathic Manipulative Treatment
580340|NCT00394043|Osteopathic Manipulative Medicine
580341|NCT00394043|Physical Medicine
580342|NCT00394030|GSK716155 pharmacodynamics pharmacokinetics injection site
580343|NCT00394017|Heading Health Plan Implementation
580344|NCT00394017|Computer-Assisted Instruction
580345|NCT00394017|General Practice
580346|NCT00394017|Dementia
580347|NCT00394017|education
580348|NCT00394004|Decision Making
580349|NCT00394004|Health Disparities
580350|NCT00394004|Hispanic
580351|NCT00394004|African-American
580352|NCT00394004|Clinical Trials
580353|NCT00394004|HIV Positive
580354|NCT00393991|Asthma
580355|NCT00393991|Fluticasone Propionate
580356|NCT00393991|Formoterol Fumarate
580357|NCT00393991|Pressurized metered dose inhaler
580358|NCT00393991|Hydrofluoroalkane
580359|NCT00393991|Mild to Moderate Asthma
580360|NCT00393978|Bipolar mania
580361|NCT00393978|Cannabis consumption
580362|NCT00393965|Metastases
580363|NCT00393965|Refractory
580364|NCT00393965|Brain
580365|NCT00393952|Asthma
580366|NCT00393952|Fluticasone Propionate
580367|NCT00393952|Formoterol Fumarate
580368|NCT00393952|Pressurized metered dose inhaler
580369|NCT00393952|Hydrofluoroalkane
580370|NCT00393952|Moderate-Severe Asthma
580371|NCT00393939|advanced breast cancer
580372|NCT00393939|sunitinib
580373|NCT00393939|docetaxel
580374|NCT00393939|Phase 3
580375|NCT00393926|Robotics
580376|NCT00393926|Rehabilitation
580377|NCT00393926|Upper Extremity
580378|NCT00393926|CVA
580379|NCT00393913|Sleep Apnea
580380|NCT00393913|Sleep-Disordered Breathing
580381|NCT00393913|Snoring
580382|NCT00393900|otitis media
580383|NCT00393900|tympanostomy tube
580384|NCT00393900|eustachian tube function
580385|NCT00393900|gas exchange
580386|NCT00393900|tympanostomy tubes
580387|NCT00393887|Inguinal hernia
580388|NCT00393887|polypropylene
580389|NCT00393887|Biodesign IHM
580390|NCT00393887|lichtenstein
580391|NCT00393874|Anxiety D/O
580392|NCT00393874|Mood D/O
580393|NCT00393861|Germ Cell Tumor
580394|NCT00393861|Germ Cell Cancer
580395|NCT00393848|Hip Replacement Arthroplasty
580396|NCT00393848|Hip Replacement Surgery
580397|NCT00393848|Hip Surgery
580398|NCT00393848|Hip Rehabilitation
580399|NCT00393848|Avascular Necrosis
580400|NCT00393848|Knee replacement surgery
580401|NCT00393848|Total knee arthroplasty
580402|NCT00393822|KGF
580403|NCT00393822|Palifermin
580404|NCT00393822|Oral Mucositis
580405|NCT00393822|Clinical Trial
580406|NCT00393822|Amgen
580407|NCT00393822|Oncology
580408|NCT00393822|Colon Cancer
580409|NCT00393809|transitional cell carcinoma
580410|NCT00393809|H19 gene
580411|NCT00393809|plasmid
580412|NCT00393809|diphtheria toxin
580413|NCT00393783|Breast Cancer
580414|NCT00393783|Metastatic
580415|NCT00393783|HER2
580416|NCT00393783|04-101
580417|NCT00393770|Risk of type 2 diabetes
580418|NCT00393757|Malaria, Plasmodium falciparum, Kenya
580419|NCT00393731|labor
580420|NCT00393731|induction
580421|NCT00393731|misoprostol
580422|NCT00393731|oxytocin
580423|NCT00393705|diabetes
580424|NCT00393705|type 2
580425|NCT00393692|Age-related macular degeneration
580426|NCT00393692|Geographic atrophy
580427|NCT00393692|drusen
580428|NCT00393679|Children 6-59 months
580429|NCT00393679|P.falciparum
580430|NCT00393679|Haemoglobin
580431|NCT00393679|Informed consent
580432|NCT00393679|ACT
580433|NCT00393666|Absence
580434|NCT00393666|Epilepsy
580435|NCT00393666|Seizure
580436|NCT00393666|Brain
580437|NCT00393653|osteoarthritis
580438|NCT00393653|gastroesophageal reflux disease
580439|NCT00393653|practice-based research
580440|NCT00393653|N-of-1 trial
580441|NCT00393653|prescription
580442|NCT00393653|single-patient trial
580443|NCT00393640|Early Initiation of lactogenesis II
580444|NCT00393627|Dementia
580445|NCT00393627|Sleep disturbance
580446|NCT00393627|Behavioral strategies
580447|NCT00393627|Alzheimer's Disease
580448|NCT00393627|Adult Family Homes
580449|NCT00393614|CSWS, interiktal epileptiform activity
580450|NCT00393601|Cystectomy
580451|NCT00393588|Brain
580452|NCT00393588|Cognitive Deficits
580453|NCT00393588|Cognitive Testing
580454|NCT00393588|MRI
580455|NCT00393588|Multiple Sclerosis
580456|NCT00393588|MS
580457|NCT00393588|Healthy Volunteer
580458|NCT00393588|HV
580459|NCT00393575|HIV Prevention
580460|NCT00393575|HIV positive communities
580461|NCT00393562|excessive sleepiness
580462|NCT00393562|hypersomnolence
580463|NCT00393562|Parkinson's disease
580464|NCT00393549|Median Neuropathy at the wrist (MNW)
580465|NCT00393536|Depression
580466|NCT00393536|Guidelines
580467|NCT00393536|Educational outreach visiting
580468|NCT00393536|Prescribing
580469|NCT00393510|Diabetic Foot Ulcer
580470|NCT00393510|Traditional Chinese Medicine
580471|NCT00393497|Breast Cancer
580472|NCT00393497|lymphedema
580473|NCT00393471|Arthritis
580474|NCT00393471|Rheumatoid
580475|NCT00393471|Safety
580476|NCT00393458|chronic obstructive pulmonary disease
580477|NCT00393458|COPD
580478|NCT00393458|indacaterol
580479|NCT00393458|long-acting β2 agonist
580480|NCT00393445|GLP-1
580481|NCT00393445|Exendin(9-39)
580482|NCT00393445|Insulin
580483|NCT00393445|Glucagon
580484|NCT00393445|Human physiology
580485|NCT00393432|Action Observation
580486|NCT00393432|Motor Memory
580487|NCT00393432|Transcranial Magnetic Stimulation (TMS)
580488|NCT00393432|Use-Dependent Plasticity
580489|NCT00393432|Healthy Volunteer
580490|NCT00393432|HV
580491|NCT00393419|hypertension
580492|NCT00393419|hyperlipidemia
580493|NCT00393419|adherence
580494|NCT00393419|pharmacist
580495|NCT00393419|elderly
580496|NCT00393419|medication
580497|NCT00393406|Objective Risk
580498|NCT00393406|Gail Model
580499|NCT00393406|Subjective Risk
580500|NCT00393406|Medical Risk-Reducing Strategies
580501|NCT00393406|Physical Activity, Diet, Alcohol Use
580502|NCT00393406|Breast Cancer Risk
580503|NCT00393393|osteoarthritis
580504|NCT00393393|knee
580505|NCT00393393|hylan
580506|NCT00393380|Myelogenous Leukemia, Chronic
580507|NCT00393380|Myelodysplasia
580508|NCT00393380|Parathyroid Hormone
580509|NCT00393380|Umbilical Cord Blood Stem Cell Transplantation
580510|NCT00393367|Asthma
580511|NCT00393367|Acute
580512|NCT00393367|Treatment
580513|NCT00393367|Children
580514|NCT00393367|Pediatric
580515|NCT00393367|Inhaled corticosteroid
580516|NCT00393367|Budesonide
580517|NCT00393367|Budesonide inhalation suspension
580518|NCT00393367|Asthma score
580519|NCT00393367|Emergency
580520|NCT00393367|Emergency Department
580521|NCT00393367|Asthma flare
580522|NCT00393367|Clinical trial
580523|NCT00393367|Randomized clinical trial
580524|NCT00393367|Randomized trial
580525|NCT00393367|Pulmonary index score
580526|NCT00393367|Hospitalization
580527|NCT00393367|Moderate asthma
580528|NCT00393367|Severe asthma
580529|NCT00393367|Mixing budesonide
580530|NCT00393367|Budesonide admixture
580531|NCT00393367|Albuterol
580532|NCT00393367|Continuous albuterol
580533|NCT00393367|Ipratropium bromide
580534|NCT00393341|Breast Cancer
580535|NCT00393315|in stent restenosis
580536|NCT00393315|paclitaxel coated balloon catheter
580537|NCT00393315|pepcad
580538|NCT00393315|drug eluting balloon
580539|NCT00393302|HIV testing in pregnant women
580540|NCT00393289|Calcium absorption
580541|NCT00393289|D-vitamin status
580542|NCT00393289|Whole body calcium retention
580543|NCT00393289|Calcium intake
580544|NCT00393289|PTH status
580545|NCT00393276|Treatment Experienced
580546|NCT00393276|Treatment Naive
580547|NCT00393276|Immunizations
580548|NCT00393250|Hypnosis
580549|NCT00393250|Symptom Management
580550|NCT00393250|Pain Management
580551|NCT00393250|Sickle Cell Disease
580552|NCT00393250|Pain
580553|NCT00393224|Epidemiology
580554|NCT00393224|Nasopharyngeal Carcinoma
580555|NCT00393224|Genetic
580556|NCT00393224|Viruses
580557|NCT00393224|Cancer
580558|NCT00393224|NPC
580559|NCT00393198|Intrauterine System
580560|NCT00393198|Contraception
580561|NCT00393198|Menorrhagia
580562|NCT00393185|Immunosuppression
580563|NCT00393185|Primary Biliary Cirrhosis
580564|NCT00393185|Allogeneic Hematopoietic Stem Cell
580565|NCT00393172|exercise
580566|NCT00393172|breast cancer
580567|NCT00393172|prevention
580568|NCT00393172|obesity
580569|NCT00393172|estrogen metabolism
580570|NCT00393172|oxidative stress
580571|NCT00393172|IGF-1
580572|NCT00393159|Effusion
580573|NCT00393159|Otitis
580574|NCT00393159|Media
580575|NCT00393159|Ear
580576|NCT00393159|Popper
580577|NCT00393159|Children
580578|NCT00393146|Rheumatoid arthritis
580579|NCT00393146|MRI
580580|NCT00393120|HIV-infection
580581|NCT00393120|viral load
580582|NCT00393120|CCR5
580583|NCT00393120|viral tropism
580584|NCT00393120|HIV-1 infection
580585|NCT00393120|Treatment Naive
580586|NCT00393107|follicular lymphoma
580587|NCT00393107|non-Hodgkin lymphoma
580588|NCT00393107|Fludarabine
580589|NCT00393107|Cyclophosphamide
580590|NCT00393107|Rituximab
580591|NCT00393107|combination
580592|NCT00393107|immuno-chemotherapy
580593|NCT00393107|relapsed
580594|NCT00393094|Brain Tumor
580595|NCT00393094|Chemotherapy
580596|NCT00393094|Progression
580597|NCT00393094|Radiotherapy
580598|NCT00393094|Antiangiogenesis
580599|NCT00393094|Glioma
580600|NCT00393042|Attention Deficit Hyperactivity Disorder
580601|NCT00393042|sleep
580602|NCT00393042|side effects
580603|NCT00393042|stimulants
580604|NCT00393029|Tumor Regression
580605|NCT00393029|In Vivo Cell Survival
580606|NCT00393029|Toxicity Profile
580607|NCT00393029|Metastatic Renal Cell Cancer
580608|NCT00393029|Cancer
580609|NCT00393029|Metastatic Cancer
580610|NCT00393003|Anesthesia
580611|NCT00393003|Sedation
580612|NCT00392990|stage I adult Burkitt lymphoma
580613|NCT00392990|stage III adult Burkitt lymphoma
580614|NCT00392990|stage IV adult Burkitt lymphoma
580615|NCT00392990|contiguous stage II adult Burkitt lymphoma
580616|NCT00392990|noncontiguous stage II adult Burkitt lymphoma
580617|NCT00392990|AIDS-related peripheral/systemic lymphoma
580618|NCT00392977|Manganese
580619|NCT00392977|Neonatal Intensive Care
580620|NCT00392977|MRI
580621|NCT00392977|Parenteral Nutrition
580622|NCT00392977|Prematurity
580623|NCT00392964|Antacids
580624|NCT00392964|Proton pump inhibitors
580625|NCT00392964|aspirin
580626|NCT00392964|ischemic heart disease
580627|NCT00392964|Dyspepsia
580628|NCT00392951|ALPS
580629|NCT00392951|Autoimmune
580630|NCT00392951|Cytopenias
580631|NCT00392951|Treatment
580632|NCT00392951|Sirolimus
580633|NCT00392951|Rapamycin
580634|NCT00392951|Lymph Nodes
580635|NCT00392951|Spleen
580636|NCT00392951|Hemolytic Anemia
580637|NCT00392951|Immune Thrombocytopenia
580638|NCT00392951|Neutropenia
580639|NCT00392951|ITP
580640|NCT00392951|Lupus
580641|NCT00392938|recurrent prostate cancer
580642|NCT00392938|stage IV prostate cancer
580643|NCT00392938|bone metastases
580644|NCT00392925|overweight
580645|NCT00392925|obesity
580646|NCT00392925|pramlintide
580647|NCT00392925|leptin
580648|NCT00392925|Amylin
580649|NCT00392912|testosterone
580650|NCT00392912|hypogonadal
580651|NCT00392912|cerebral glucose metabolism
580652|NCT00392912|PET scan
580653|NCT00392912|Alzheimer's disease
580654|NCT00392899|stage II colon cancer
580655|NCT00392899|stage II rectal cancer
580656|NCT00392899|adenocarcinoma of the colon
580657|NCT00392899|adenocarcinoma of the rectum
580658|NCT00392886|untreated childhood medulloblastoma
580659|NCT00392886|untreated childhood supratentorial primitive neuroectodermal tumor
580660|NCT00392886|childhood infratentorial ependymoma
580661|NCT00392886|childhood supratentorial ependymoma
580662|NCT00392886|newly diagnosed childhood ependymoma
580663|NCT00392886|childhood high-grade cerebral astrocytoma
580664|NCT00392886|childhood oligodendroglioma
580665|NCT00392886|childhood atypical teratoid/rhabdoid tumor
580666|NCT00392886|childhood choroid plexus tumor
580667|NCT00392886|untreated childhood cerebellar astrocytoma
580668|NCT00392886|untreated childhood visual pathway and hypothalamic glioma
580669|NCT00392886|untreated childhood pineoblastoma
580670|NCT00392873|Amenorrhea
580671|NCT00392873|Energy deficiency
580672|NCT00392873|Resting energy expenditure
580673|NCT00392873|Bone metabolism
580674|NCT00392873|Bone mineral density
580675|NCT00392873|Exercise
580676|NCT00392860|Wheelchair
580677|NCT00392860|Handrims
580678|NCT00392860|Rehabilitation
580679|NCT00392860|Upper extremity
580680|NCT00392847|Child mental disorder
580681|NCT00392847|Home visit
580682|NCT00392847|Postnatal depression
580683|NCT00392847|Social Support
580684|NCT00392847|Random selection
580685|NCT00392834|stage I adult Burkitt lymphoma
580686|NCT00392834|stage III adult Burkitt lymphoma
580687|NCT00392834|stage IV adult Burkitt lymphoma
580688|NCT00392834|contiguous stage II adult Burkitt lymphoma
580689|NCT00392834|noncontiguous stage II adult Burkitt lymphoma
580690|NCT00392834|AIDS-related peripheral/systemic lymphoma
580691|NCT00392808|Meningococcal vaccine
580692|NCT00392808|Immunization, secondary
580693|NCT00392808|vaccines conjugated
580694|NCT00392808|Meningococcal disease
580695|NCT00392795|Critical Care
580696|NCT00392795|Delirium
580697|NCT00392795|Long-term cognitive impairment
580698|NCT00392795|mechanical ventilation
580699|NCT00392795|Critical illness
580700|NCT00392795|dementia
580701|NCT00392795|sedatives and analgesics
580702|NCT00392795|aging
580703|NCT00392782|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
580704|NCT00392782|adult acute myeloid leukemia in remission
580705|NCT00392782|childhood acute myeloid leukemia in remission
580706|NCT00392782|de novo myelodysplastic syndromes
580707|NCT00392782|previously treated myelodysplastic syndromes
580708|NCT00392782|adult acute myeloid leukemia with inv(16)(p13;q22)
580709|NCT00392782|adult acute myeloid leukemia with t(15;17)(q22;q12)
580710|NCT00392782|adult acute myeloid leukemia with t(16;16)(p13;q22)
580711|NCT00392782|adult acute myeloid leukemia with t(8;21)(q22;q22)
580712|NCT00392782|recurrent adult acute myeloid leukemia
580713|NCT00392782|recurrent childhood acute myeloid leukemia
580714|NCT00392782|secondary acute myeloid leukemia
580715|NCT00392782|accelerated phase chronic myelogenous leukemia
580716|NCT00392782|blastic phase chronic myelogenous leukemia
580717|NCT00392782|childhood chronic myelogenous leukemia
580718|NCT00392782|relapsing chronic myelogenous leukemia
580719|NCT00392782|secondary myelodysplastic syndromes
580720|NCT00392769|Endometrial Cancer
580721|NCT00392769|Progressive or Recurrent Endometrial Cancer
580722|NCT00392769|Cetuximab
580723|NCT00392769|C225
580724|NCT00392769|Erbitux™
580725|NCT00392769|IMC-C225
580726|NCT00392769|Epidermal growth factor receptor
580727|NCT00392769|EGFR
580728|NCT00392769|Endometrioid Tumor
580729|NCT00392769|Serous Tumor
580730|NCT00392769|Clear cell Tumor
580731|NCT00392769|Mixed malignant Mullerian Tumors
580732|NCT00392756|Kallmann Syndrome
580733|NCT00392756|Hypogonadotropic Hypogonadism
580734|NCT00392756|GnRH deficiency
580735|NCT00392756|Pulsatile GnRH
580736|NCT00392743|Bolus
580737|NCT00392743|11C-Raclopride
580738|NCT00392743|Schizophrenia
580739|NCT00392743|123I-IBZM
580740|NCT00392743|SPECT
580741|NCT00392743|Receptor Occupancy
580742|NCT00392743|PET
580743|NCT00392743|MRI
580744|NCT00392743|Antipsychotics
580745|NCT00392743|Bolus/Infusion
580746|NCT00392730|Manganese
580747|NCT00392730|Neonatal Intensive Care
580748|NCT00392730|MRI
580749|NCT00392730|Parenteral Nutrition
580750|NCT00392730|Prematurity
580751|NCT00392717|lipoprotein metabolism
580752|NCT00392717|cardiovascular disease
580753|NCT00392717|obesity
580754|NCT00392691|recurrent adult Burkitt lymphoma
580755|NCT00392691|recurrent adult diffuse large cell lymphoma
580756|NCT00392691|recurrent adult diffuse mixed cell lymphoma
580757|NCT00392691|recurrent adult diffuse small cleaved cell lymphoma
580758|NCT00392691|recurrent adult immunoblastic large cell lymphoma
580759|NCT00392691|recurrent adult lymphoblastic lymphoma
580760|NCT00392691|recurrent grade 1 follicular lymphoma
580761|NCT00392691|recurrent grade 2 follicular lymphoma
580762|NCT00392691|recurrent grade 3 follicular lymphoma
580763|NCT00392691|recurrent mantle cell lymphoma
580764|NCT00392691|recurrent marginal zone lymphoma
580765|NCT00392691|recurrent small lymphocytic lymphoma
580766|NCT00392691|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
580767|NCT00392691|nodal marginal zone B-cell lymphoma
580768|NCT00392691|splenic marginal zone lymphoma
580769|NCT00392691|Waldenström macroglobulinemia
580770|NCT00392678|Type 2 Diabetes
580771|NCT00392678|Inflammation
580772|NCT00392678|Obesity
580773|NCT00392678|Metabolic Syndrome
580774|NCT00392665|SCCHN
580775|NCT00392665|erlotinib
580776|NCT00392665|tarceva
580777|NCT00392639|Heart arrest
580778|NCT00392639|Cardiopulmonary resuscitation
580779|NCT00392639|Humans
580780|NCT00392639|Hypothermia
580781|NCT00392639|Brain diseases
580782|NCT00392639|Hypoxia-ischemia
580783|NCT00392639|Cost Benefit Analysis
580784|NCT00392639|Prospective study
580785|NCT00392639|Comparative study
580786|NCT00392639|Treatment outcome
580787|NCT00392639|Hypothermia for
580788|NCT00392639|out-of-hospital cardiac arrest
580789|NCT00392639|from cardiac origin
580790|NCT00392639|successfully resuscitated
580791|NCT00392587|Pharmacodynamics
580792|NCT00392587|Pharmacokinetics
580793|NCT00392587|Tolerability
580794|NCT00392587|COPD
580795|NCT00392587|Safety
580796|NCT00392574|Gastroenteritis
580797|NCT00392548|GBM
580798|NCT00392548|glioblastoma
580799|NCT00392548|urine
580800|NCT00392548|VEGF
580801|NCT00392548|radiation
580802|NCT00392548|Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
580803|NCT00392535|adenocarcinoma of the prostate
580804|NCT00392535|stage IIB prostate cancer
580805|NCT00392535|stage IIA prostate cancer
580806|NCT00392535|stage III prostate cancer
580807|NCT00392522|Anxiety
580808|NCT00392522|Cough
580809|NCT00392522|Number of general anaesthesias (due to procedure failure)
580810|NCT00392522|Patients satisfaction
580811|NCT00392522|Chest physician satisfaction
580812|NCT00392509|critical limb ischemia
580813|NCT00392509|cell therapy for angiogenesis
580814|NCT00392509|aldehyde dehydrogenase-bright cells
580815|NCT00392509|peripheral artery disease
580816|NCT00392509|peripheral vascular disease
580817|NCT00392509|leg pain
580818|NCT00392509|PVD
580819|NCT00392509|PAD
580820|NCT00392509|CLI
580821|NCT00392509|amputation
580822|NCT00392509|limb salvage
580823|NCT00392483|Heading Health Plan Implementation
580824|NCT00392483|Computer-Assisted Instruction
580825|NCT00392483|General Practice
580826|NCT00392483|Dementia
580827|NCT00392470|adenocarcinoma of the rectum
580828|NCT00392470|stage III rectal cancer
580829|NCT00392470|stage IV rectal cancer
580830|NCT00392457|Idiopathic Hypogonadotropic Hypogonadism
580831|NCT00392457|Kallmann Syndrome
580832|NCT00392457|Agonadal
580833|NCT00392418|iron deficiency anemia
580834|NCT00392418|hematologic disease
580835|NCT00392418|infancy
580836|NCT00392418|pediatrics
580837|NCT00392418|Sprinkles®
580838|NCT00392418|iron
580839|NCT00392418|micronutrient
580840|NCT00392405|Contrast Induced Nephropathy
580841|NCT00392392|Breast Cancer
580842|NCT00392379|Tobacco use disorder
580843|NCT00392379|Tobacco cessation
580844|NCT00392366|MRI guided Laser Therapy
580845|NCT00392366|Laser Interstitial Thermal Therapy
580846|NCT00392366|Magnetic Resonance Thermal Imaging
580847|NCT00392366|Liver Metastasis
580848|NCT00392340|recurrent neuroblastoma
580849|NCT00392340|disseminated neuroblastoma
580850|NCT00392314|hodgkin lymphoma
580851|NCT00392314|PET/CT
580852|NCT00392314|Therapy
580853|NCT00392301|wound healing
580854|NCT00392301|skin
580855|NCT00392301|graft donor site
580856|NCT00392301|donor site
580857|NCT00392301|transepidermal water loss
580858|NCT00392288|Bronchial Asthma
580859|NCT00392275|Cataract
580860|NCT00392275|Aqueous absorption
580861|NCT00392275|Funtioning Filtering Blebs
580862|NCT00392262|Moderate essential hypertension (WHO grade II)
580863|NCT00392249|Schizophrenia
580864|NCT00392249|Drug adherence
580865|NCT00392236|Schizoaffective Disorder
580866|NCT00392197|OPC-14597
580867|NCT00392197|Schizophrenia
580868|NCT00392184|accelerated partial breast irradiation
580869|NCT00392184|multicatheter brachytherapy
580870|NCT00392184|high dose rate brachytherapy
580871|NCT00392184|pulsed dose rate brachytherapy
580872|NCT00392145|Pediatrics
580873|NCT00392145|Gastroenteritis
580874|NCT00392145|Dehydration
580875|NCT00392145|IV Rehydration
580876|NCT00392132|HIV
580877|NCT00392119|MR-guided therapy
580878|NCT00392119|Laser interstitial thermal therapy
580879|NCT00392119|brain metastasis
580880|NCT00392119|Magnetic Resonance Thermal imaging (MRTI)
580881|NCT00392106|atrial fibrillation
580882|NCT00392106|arrhythmia
580883|NCT00392106|AF ablation
580884|NCT00392106|antiarrhythmic agent
580885|NCT00392106|catheter ablation
580886|NCT00392106|pulmonary veins
580887|NCT00392093|Systemic lupus erythematosus
580888|NCT00392093|Menopause hormonal therapy
580889|NCT00392093|Menopausal symptoms
580890|NCT00392093|Bone mineral density
580891|NCT00392054|Atrial Fibrillation
580892|NCT00392054|Paroxysmal
580893|NCT00392054|Pulmonary Vein Isolation
580894|NCT00392054|Ablation Catheter
580895|NCT00392054|Anti-arrhythmic Drug Therapy
580896|NCT00392054|First Line Therapy
580897|NCT00392041|Fibromyalgia
580898|NCT00392041|Insomnia
580899|NCT00392041|Sleep
580900|NCT00392041|Eszopiclone
580901|NCT00392041|Lunesta
580902|NCT00392028|Ertapenem
580903|NCT00392028|Bone drug level
580904|NCT00392028|Blood drug level
580905|NCT00392028|Tissue drug level
580906|NCT00392015|Malaria Vaccine
580907|NCT00392015|Adenovirus
580908|NCT00392015|Plasmodium falciparum
580909|NCT00392002|GERD
580910|NCT00391989|Ph+ Acute Lymphoblastic Leukaemia
580911|NCT00391989|Dasatinib
580912|NCT00391989|targeted therapy
580913|NCT00391989|Patients with Ph positive and or BCR ABL positive ALL
580914|NCT00391976|Cystic fibrosis
580915|NCT00391950|Prostate cancer
580916|NCT00391950|Cancer treatment induced bone loss (CTIBL)
580917|NCT00391950|Androgen deprivation therapy (ADT)
580918|NCT00391937|"resurfacing hip [MESH]"
580919|NCT00391937|"conventional position method"
580920|NCT00391937|"surgery, computer-assisted [MESH]"
580921|NCT00391924|Dehydroepiandrosterone
580922|NCT00391924|Fatigue
580923|NCT00391924|Quality of life
580924|NCT00391924|Lupus Erythematosus, Systemic
580925|NCT00391924|Sjogren's Syndrome
580926|NCT00391924|Bone mineral density
580927|NCT00391911|Rhabdomyolysis
580928|NCT00391911|CRRT
580929|NCT00391911|N-Acetylcysteine
580930|NCT00391898|Parkinson's disease, adults, levodopa/carbidopa/entacapone, wearing-off, activities of daily living
580931|NCT00391872|ACS
580932|NCT00391872|Acute coronary syndrome
580933|NCT00391872|Heart attack
580934|NCT00391872|Unstable angina
580935|NCT00391872|Coronary artery disease
580936|NCT00391859|Pharmacist-initiated Intervention Trial in OsteoArthritis
580937|NCT00391846|Heart Failure
580938|NCT00391846|Ventricular Dysfunction
580939|NCT00391846|NTproBNP
580940|NCT00391833|Alzheimer's disease, Ginseng, CD34
580941|NCT00391820|constipation
580942|NCT00391820|chronic
580943|NCT00391820|bowel function
580944|NCT00391807|Contraception
580945|NCT00391794|Memory
580946|NCT00391794|Alzheimer's disease
580947|NCT00391794|Dementia
580948|NCT00391794|Support Group
580949|NCT00391794|Psychosocial
580950|NCT00391781|mechanical infertility
580951|NCT00391781|hysterosalpingogram
580952|NCT00391781|hysterosalpingography
580953|NCT00391768|influenza, oseltamivir, Tamiflu®, antiviral, children, infants
580954|NCT00391755|Migraine Headache
580955|NCT00391742|Brief intervention
580956|NCT00391742|Motivational Interviewing
580957|NCT00391742|Primary care
580958|NCT00391742|Stepped-care
580959|NCT00391729|ADHD
580960|NCT00391716|Alcohol
580961|NCT00391716|Alcohol treatment
580962|NCT00391716|Alcoholism
580963|NCT00391716|Alcohol Dependence
580964|NCT00391703|Cystic fibrosis
580965|NCT00391703|mucoviscidosis
580966|NCT00391703|electrostimulation
580967|NCT00391703|retraining
580968|NCT00391690|Serum bone marker
580969|NCT00391690|Prostate cancer
580970|NCT00391690|Bisphosphonates
580971|NCT00391690|Early detection of metastasis
580972|NCT00391677|Cognitive Rehabilitation
580973|NCT00391677|Behavior Therapy
580974|NCT00391664|Endometrial cancer
580975|NCT00391664|Ovarian Cancer
580976|NCT00391664|Cervical Cancer
580977|NCT00391664|Genital Cancer
580978|NCT00391664|Vulvar Cancer
580979|NCT00391664|Vaginal Cancer
580980|NCT00391664|Other Gynecological Cancers
580981|NCT00391651|UTI
580982|NCT00391638|HIV and Hepatitis B coinfection
580983|NCT00391638|Peg interferon
580984|NCT00391638|tenofovir
580985|NCT00391638|emtricitabine
580986|NCT00391638|Hepatitis B e Antigens
580987|NCT00391638|Treatment Experienced
580988|NCT00391625|Gaucher disease, Enzyme Replacement Therapy
580989|NCT00391612|COPD (Chronic Obstructive Pulmonary Disease)
580990|NCT00391612|Emphysema
580991|NCT00391612|Hyperinflation
580992|NCT00391612|Minimally Invasive
580993|NCT00391599|Cesarean Section,
580994|NCT00391599|Enema
580995|NCT00391586|erlotinib
580996|NCT00391586|NSCLC
580997|NCT00391586|chemotherapy
580998|NCT00391586|platinum
580999|NCT00391586|lung
581000|NCT00391586|lung cancer
581001|NCT00391560|refractory leukemia
581002|NCT00391547|Gingivitis Disease
581003|NCT00391534|Epilepsy
581004|NCT00391534|oxcarbazepine
581005|NCT00391521|Oncology. All solid Tumour disease.
581006|NCT00391508|Ostomy
581007|NCT00391508|Peristomal skin
581008|NCT00391508|Skin complication
581009|NCT00391495|ADHD
581010|NCT00391495|Cytokines
581011|NCT00391495|CR-P
581012|NCT00391482|IV Drug Users
581013|NCT00391482|Hepatitis C Virus
581014|NCT00391482|Human Immunodeficiency Virus
581015|NCT00391482|Intervention
581016|NCT00391482|HIV Seronegativity
581017|NCT00391469|cardiac arrest
581018|NCT00391469|mild hypothermia
581019|NCT00391456|animal-assisted therapy
581020|NCT00391456|dog hospital visit
581021|NCT00391456|heart failure
581022|NCT00391443|BUILD 3
581023|NCT00391443|Idiopathic Pulmonary Fibrosis
581024|NCT00391443|Tracleer
581025|NCT00391443|Interstitial Lung Disease
581026|NCT00391443|bosentan
581027|NCT00391443|Actelion
581028|NCT00391430|PTSD
581029|NCT00391430|Trauma
581030|NCT00391430|Sexual Abuse
581031|NCT00391430|Sexual Assault
581032|NCT00391417|hot flush
581033|NCT00391417|hot flash
581034|NCT00391417|estrogen
581035|NCT00391417|vaginal atrophy
581036|NCT00391404|Childhood cancer survivors
581037|NCT00391404|Osteoporosis
581038|NCT00391404|Bone mineral density
581039|NCT00391404|Therapy
581040|NCT00391404|Bisphosphonate
581041|NCT00391404|Randomized controlled trial
581042|NCT00391391|Influenza
581043|NCT00391391|Orthomyxoviruses
581044|NCT00391391|Inactivated Split-virion influenza vaccine
581045|NCT00391391|Infants
581046|NCT00391391|children.
581047|NCT00391378|Diffusion-Weighted Magnetic Resonance Imaging
581048|NCT00391378|MRI (Magnetic Resonance Imaging)
581049|NCT00391378|Stroke
581050|NCT00391378|Cognition
581051|NCT00391378|Heart
581052|NCT00391365|ankle osteoarthritis
581053|NCT00391365|arthritis
581054|NCT00391365|arthrodesis
581055|NCT00391365|arthroplasty
581056|NCT00391365|Gait
581057|NCT00391365|step count
581058|NCT00391365|walking
581059|NCT00391352|Multiple Sclerosis
581060|NCT00391352|Disease Modifying Therapy
581061|NCT00391339|Bryophyllum p.
581062|NCT00391339|Nifedipine
581063|NCT00391339|Tocolysis
581064|NCT00391326|Bivalirudin
581065|NCT00391326|Heparin
581066|NCT00391326|Bleeding
581067|NCT00391326|TIMI flow
581068|NCT00391326|STEMI
581069|NCT00391313|Chikungunya
581070|NCT00391313|Chikungunya disease
581071|NCT00391300|melanoma
581072|NCT00391300|basal cell carcinoma of the skin
581073|NCT00391300|squamous cell carcinoma of the skin
581074|NCT00391287|Red-Cell Aplasia due to Chronic Kidney Failure
581075|NCT00391287|Aplastic Anemia
581076|NCT00391287|Recombinant Erythropoietin
581077|NCT00391287|Surveillance Registry
581078|NCT00391287|Registries
581079|NCT00391261|weight gain
581080|NCT00391261|obesity
581081|NCT00391261|metabolism
581082|NCT00391248|non-small cell lung cancer
581083|NCT00391248|palliative radiation
581084|NCT00391248|tarceva
581085|NCT00391248|palliative thoracic radiation therapy
581086|NCT00391235|bipolar disorder
581087|NCT00391235|magnetic resonance imaging
581088|NCT00391235|white matter
581089|NCT00391235|diffusion tensor imaging
581090|NCT00391235|children
581091|NCT00391235|adolescents
581092|NCT00391222|Bipolar I Disorder
581093|NCT00391222|Intramuscular injection
581094|NCT00391222|prevention of mood episodes
581095|NCT00391222|long acting injectable
581096|NCT00391222|risperidone
581097|NCT00391183|Gallbladder cancer
581098|NCT00391183|Quality of life
581099|NCT00391183|Stenting
581100|NCT00391183|Survival
581101|NCT00391183|Performance status
581102|NCT00391170|Oral Chronic GVHD
581103|NCT00391170|Topical Dexamethasone
581104|NCT00391170|Tissue Markers
581105|NCT00391170|Salivary Proteomics
581106|NCT00391170|Quality of Life
581107|NCT00391170|Oral Chronic Graft Versus Host Disease
581108|NCT00391170|Oral Pain
581109|NCT00391170|Mouth Pain
581110|NCT00391157|Múltiple Myeloma
581111|NCT00391157|Transplant
581112|NCT00391157|Patients <65 years.
581113|NCT00391144|Pattern Dystrophy
581114|NCT00391144|Choroidal Neovascularization
581115|NCT00391144|Intravitreal Avastin Injection
581116|NCT00391131|PID
581117|NCT00391131|SCIG
581118|NCT00391131|Ig
581119|NCT00391131|Quality of Life
581120|NCT00391131|Serious Bacterial Infections
581121|NCT00391105|intubation
581122|NCT00391105|Sedation
581123|NCT00391105|Analgesia
581124|NCT00391105|preterm neonate
581125|NCT00391105|remifentanil
581126|NCT00391105|morphine
581127|NCT00391105|respiratory distress syndrome
581128|NCT00391079|Central Neuropathic Pain
581129|NCT00391066|CD23+/CD20+ B-cell CLL
581130|NCT00391066|CLL
581131|NCT00391053|Influenza
581132|NCT00391053|Orthomyxoviruses
581133|NCT00391053|Inactivated Split-virion influenza vaccine
581134|NCT00391053|Adults
581135|NCT00391040|diabetes mellitus, structured treatment and teaching, education,
581136|NCT00391040|elderly patients, geriatrics
581137|NCT00391027|type 2 diabetes, insulin, glycemic control
581138|NCT00391014|Acute myeloid Leukemia
581139|NCT00391014|Allogeneic haematopoietic progenitor cell transplant
581140|NCT00391014|Acute Invasive Aspergillosis
581141|NCT00391001|mania
581142|NCT00391001|bipolar disorder
581143|NCT00391001|taurine
581144|NCT00391001|adolescents
581145|NCT00390988|blood count
581146|NCT00390988|capillary
581147|NCT00390988|venous
581148|NCT00390988|Adult
581149|NCT00390988|reference values
581150|NCT00390975|Tegaserod
581151|NCT00390975|diabetes
581152|NCT00390975|diabetic gastroparesis
581153|NCT00390975|gastric emptying
581154|NCT00390975|gastric retention
581155|NCT00390975|electrogastrography
581156|NCT00390962|copeptin
581157|NCT00390962|vasopressin
581158|NCT00390962|Adh
581159|NCT00390962|SIADH
581160|NCT00390962|diabetes insipidus
581161|NCT00390962|stroke
581162|NCT00390962|risk factors
581289|NCT00390520|hypoglycemia
581290|NCT00390507|Acceleromyography
581163|NCT00390962|Neurological patients with ischemic and hemorrhagic stroke and patients undergoing intracranial surgery.
581164|NCT00390949|HIV prevention
581165|NCT00390949|Zimbabwe
581166|NCT00390949|Core groups
581167|NCT00390949|Peer education
581168|NCT00390949|Syndromic management
581169|NCT00390949|Commercial sex workers
581170|NCT00390949|Condom distribution
581171|NCT00390949|HIV Seronegativity
581172|NCT00390923|smoking
581173|NCT00390923|nicotine dependence
581174|NCT00390923|double-blind
581175|NCT00390923|placebo-controlled
581176|NCT00390923|randomized
581177|NCT00390923|full substitution therapy
581178|NCT00390923|selegiline
581179|NCT00390910|Pneumococcal vaccine
581180|NCT00390910|Preterm
581181|NCT00390910|Safety
581182|NCT00390910|Pneumococcal disease
581183|NCT00390910|Immunogenicity
581184|NCT00390897|chronic myeloid leukaemia
581185|NCT00390897|Glivec
581186|NCT00390897|Interferon
581187|NCT00390884|Fluzone®
581188|NCT00390884|Influenza
581189|NCT00390884|Influenza virus infection
581190|NCT00390884|Influenza vaccine
581191|NCT00390871|Patient
581192|NCT00390871|Must be
581193|NCT00390871|Under
581194|NCT00390858|β-thalassemia major
581195|NCT00390858|iron overload
581196|NCT00390858|deferasirox
581197|NCT00390858|pediatric rare anemia
581198|NCT00390845|MAP kinase
581199|NCT00390845|SB681323
581200|NCT00390845|neuropathic pain
581201|NCT00390845|patients
581202|NCT00390845|P38
581203|NCT00390845|nerve trauma
581204|NCT00390832|STEMI
581205|NCT00390819|Community acquired pneumonia
581206|NCT00390806|Brain metastases from Non-Small Cell Lung Cancer
581207|NCT00390806|Brain metastases brain tumor lung cancer oral chemotherapy HYCAMTIN topotecan NSCLC WBRT whole brain radiation
581208|NCT00390793|Acute Lymphocytic Leukemia
581209|NCT00390793|Leukemia
581210|NCT00390793|ALL
581211|NCT00390793|Philadelphia-Positive ALL
581212|NCT00390793|BCR-ABL Positive ALL
581213|NCT00390793|Dasatinib
581214|NCT00390793|Hyper-CVAD
581215|NCT00390793|Cyclophosphamide
581216|NCT00390793|Cytoxan
581217|NCT00390793|Vincristine
581218|NCT00390793|Vincasar
581219|NCT00390793|Doxorubicin
581220|NCT00390793|Adriamycin
581221|NCT00390793|Dexamethasone
581222|NCT00390793|Decadron
581223|NCT00390793|Sprycel
581224|NCT00390780|Miconazole Lauriad
581225|NCT00390780|Oropharyngeal candidiasis
581226|NCT00390780|HIV patients
581227|NCT00390780|Mycology
581228|NCT00390780|Clinical picture of Oropharyngeal candidiasis
581229|NCT00390780|Candida culture positive
581230|NCT00390780|Treatment Experienced
581231|NCT00390767|Peripheral arterial disease
581232|NCT00390767|Peripheral vascular disease
581233|NCT00390767|Claudication
581234|NCT00390767|Cell therapy
581235|NCT00390767|Gene therapy
581236|NCT00390767|Endothelial cells
581237|NCT00390767|Smooth muscle cells
581238|NCT00390767|Angiogenesis
581239|NCT00390754|pregnancy
581240|NCT00390754|unintended
581241|NCT00390754|menses
581242|NCT00390741|hip fracture
581243|NCT00390741|bone mineral density
581244|NCT00390741|exercise
581245|NCT00390715|Acute Myeloblastic Leukemia
581246|NCT00390702|Ventricular septal defect
581247|NCT00390702|VSD
581248|NCT00390676|cancer
581249|NCT00390676|tumors
581250|NCT00390676|anticarcinogenic agents
581251|NCT00390676|antineoplastic agents
581252|NCT00390676|cadherins
581253|NCT00390676|solid tumors
581254|NCT00390663|Paediatric
581255|NCT00390663|Epistaxis
581256|NCT00390663|Nose bleed
581257|NCT00390663|Naseptin
581258|NCT00390650|Anxiety
581259|NCT00390650|clinical trials
581260|NCT00390637|Diogenes
581261|NCT00390637|Diet Intervention
581262|NCT00390637|Family
581263|NCT00390637|Glycemic Index
581264|NCT00390637|Protein
581265|NCT00390624|Urodilatin
581266|NCT00390624|Mannitol
581267|NCT00390624|Acute Kidney Failure
581268|NCT00390611|Ovarian Cancer
581269|NCT00390598|colonoscopy
581270|NCT00390598|large bowel preparation
581271|NCT00390598|bowel cleansing
581272|NCT00390598|randomized controlled trial
581273|NCT00390585|Renal Insufficiency
581274|NCT00390585|Angioplasty, Transluminal, Percutaneous Coronary
581275|NCT00390585|Contrast media
581276|NCT00390572|sleep
581277|NCT00390572|consultation and referral
581278|NCT00390572|outcome assessment
581279|NCT00390572|primary care
581280|NCT00390559|Nicotine Replacement Therapy
581281|NCT00390559|Tobacco Smoking
581282|NCT00390559|Smoking stimuli
581283|NCT00390559|Gender
581284|NCT00390533|Anxiety
581285|NCT00390533|clinical trials
581286|NCT00390520|Type 2 diabetes
581287|NCT00390520|vildagliptin
581288|NCT00390520|glucagon
581291|NCT00390507|TOF-Watch
581292|NCT00390507|Posttetanic count
581293|NCT00390507|Train of four
581294|NCT00390507|Neuromuscular blockade
581295|NCT00390494|Fibroids
581296|NCT00390494|Leiomyoma
581297|NCT00390494|Hysterectomy
581298|NCT00390494|Myomectomy
581299|NCT00390494|Uterine Fibroid Embolization
581300|NCT00390494|Questionnaire
581301|NCT00390481|Carotid Occlusion
581302|NCT00390481|Cognition
581303|NCT00390468|Tandutinib
581304|NCT00390468|MLN518
581305|NCT00390468|CT53518
581306|NCT00390468|pain
581307|NCT00390468|adenocarcinoma of the prostate
581308|NCT00390468|recurrent prostate cancer
581309|NCT00390468|stage IV prostate cancer
581310|NCT00390468|bone metastases
581311|NCT00390468|hormone-based castration
581312|NCT00390442|cardiogenic pulmonary edema
581313|NCT00390442|non invasive ventilation
581314|NCT00390442|CPAP
581315|NCT00390429|stage IIIB non-small cell lung cancer
581316|NCT00390429|stage IV non-small cell lung cancer
581317|NCT00390429|recurrent non-small cell lung cancer
581318|NCT00390429|unspecified adult solid tumor, protocol specific
581319|NCT00390416|Metastatic
581320|NCT00390416|Gastroesophageal
581321|NCT00390416|Docetaxel
581322|NCT00390416|Cisplatin
581323|NCT00390416|Fluorouracil
581324|NCT00390416|Bevacizumab
581325|NCT00390416|Metastatic Gastroesophageal Adenocarcinoma
581326|NCT00390416|06-096
581327|NCT00390403|adult glioblastoma
581328|NCT00390403|adult gliosarcoma
581329|NCT00390403|adult giant cell glioblastoma
581330|NCT00390390|Heartburn, frequent heartburn, proton pump inhibitor, lansoprazole
581331|NCT00390377|x-ray diffraction
581332|NCT00390377|hair
581333|NCT00390377|breast cancer
581334|NCT00390377|synchrotron
581335|NCT00390364|adenocarcinoma of the colon
581336|NCT00390364|adenocarcinoma of the rectum
581337|NCT00390364|recurrent colon cancer
581338|NCT00390364|stage III colon cancer
581339|NCT00390364|stage IV colon cancer
581340|NCT00390364|recurrent rectal cancer
581341|NCT00390364|stage III rectal cancer
581342|NCT00390364|stage IV rectal cancer
581343|NCT00390351|Optical coherence tomography
581344|NCT00390338|recurrent melanoma
581345|NCT00390338|stage IV melanoma
581346|NCT00390338|stage IIIA melanoma
581347|NCT00390338|stage IIIB melanoma
581348|NCT00390338|stage IIIC melanoma
581349|NCT00390312|Post operative pain
581350|NCT00390312|Third molar extraction
581351|NCT00390312|Dental surgery
581352|NCT00390312|Morphine
581353|NCT00390286|Telemedicine
581354|NCT00390273|diabetes
581355|NCT00390273|metformin
581356|NCT00390273|hyperlactatemia
581357|NCT00390221|MS
581358|NCT00390221|multiple sclerosis
581359|NCT00390208|Macular Degeneration
581360|NCT00390208|Degenerative changes in the macula lutea of the retina.
581361|NCT00390208|Maculopathy, Age-Related
581362|NCT00390208|Age-Related Maculopathies
581363|NCT00390208|Age-Related Maculopathy
581364|NCT00390208|Maculopathies, Age-Related
581365|NCT00390208|RETINAL DEGENERATION
581366|NCT00390208|ARMD
581367|NCT00390208|AMD
581368|NCT00390208|Lucentis
581369|NCT00390208|Visudyne
581370|NCT00390208|Photodynamic Therapy
581371|NCT00390208|Verteporfin
581372|NCT00390208|Ranibizumab
581373|NCT00390208|Intravitreal Dexamethasone
581374|NCT00390195|Hepatocellular carcinoma
581375|NCT00390195|RAD001
581376|NCT00390195|Rapamycin
581377|NCT00390195|Randomize
581378|NCT00390195|Phase I
581379|NCT00390195|Phase II
581380|NCT00390195|Pharmacokinetics
581381|NCT00390182|GI tumors
581382|NCT00390182|Locally Advanced
581383|NCT00390182|Metastatic
581384|NCT00390182|Hepatobiliary
581385|NCT00390182|Ovary
581386|NCT00390169|breast neoplasms
581387|NCT00390169|stress
581388|NCT00390169|personality
581389|NCT00390169|psychology
581390|NCT00390156|refractory
581391|NCT00390156|prior treatment
581392|NCT00390156|solid tumors
581393|NCT00390156|phase I
581394|NCT00390156|phase 1
581395|NCT00390143|Immunogenicity
581396|NCT00390143|Meningococcal vaccine
581397|NCT00390143|Conjugate vaccine
581398|NCT00390143|Persistence
581399|NCT00390130|Vaccination
581400|NCT00390130|Pediatrics
581401|NCT00390130|Pain
581402|NCT00390117|unspecified adult solid tumor, protocol specific
581403|NCT00390117|recurrent adult Burkitt lymphoma
581404|NCT00390117|recurrent adult diffuse large cell lymphoma
581405|NCT00390117|recurrent adult diffuse mixed cell lymphoma
581406|NCT00390117|recurrent adult immunoblastic large cell lymphoma
581407|NCT00390117|recurrent adult lymphoblastic lymphoma
581408|NCT00390117|recurrent adult diffuse small cleaved cell lymphoma
581409|NCT00390117|recurrent grade 1 follicular lymphoma
581410|NCT00390117|recurrent grade 2 follicular lymphoma
581767|NCT00388063|Carcinoma
581411|NCT00390117|recurrent grade 3 follicular lymphoma
581412|NCT00390117|recurrent mantle cell lymphoma
581413|NCT00390117|recurrent marginal zone lymphoma
581414|NCT00390117|recurrent small lymphocytic lymphoma
581415|NCT00390117|Waldenstrom macroglobulinemia
581416|NCT00390117|recurrent adult grade III lymphomatoid granulomatosis
581417|NCT00390117|adult nasal type extranodal NK/T-cell lymphoma
581418|NCT00390117|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
581419|NCT00390117|nodal marginal zone B-cell lymphoma
581420|NCT00390117|splenic marginal zone lymphoma
581421|NCT00390104|Neuromuscular Disease
581422|NCT00390104|Muscle weakness
581423|NCT00390104|Muscle atrophy
581424|NCT00390091|Lupus
581425|NCT00390091|Nephritis
581426|NCT00390091|Kidney
581427|NCT00390091|SLE
581428|NCT00390091|Systemic Lupus Erythematosus
581429|NCT00390091|Nephritis, Lupus
581430|NCT00390078|Vaccine
581431|NCT00390078|Safety
581432|NCT00390078|T-cell epitope
581433|NCT00390078|Acquired Immune Deficiency Syndrome Virus
581434|NCT00390078|HIV Therapeutic Vaccine
581435|NCT00390065|Follow-up
581436|NCT00390065|Premature infants
581437|NCT00390065|Nitric Oxide
581438|NCT00390065|Respiratory function testing
581439|NCT00390065|Neurodevelopmental outcomes
581440|NCT00390039|Pain, postoperative
581441|NCT00390039|Surgery, orthopedic
581442|NCT00390039|Morphine
581443|NCT00390026|Neovascular age-related macular degeneration
581444|NCT00390026|Bevacizumab
581445|NCT00390026|Photodynamic therapy
581446|NCT00390013|Vulvar Pain
581447|NCT00389948|Heartburn, frequent heartburn, proton pump inhibitor, lansoprazole
581448|NCT00389935|Gastrointestinal Bleeding
581449|NCT00389935|Arteriovenous Malformation
581450|NCT00389935|Angiodysplasia
581451|NCT00389935|Hereditary Hemorrhagic Telangiectasia
581452|NCT00389935|Obscure Bleeding
581453|NCT00389922|unspecified adult solid tumor, protocol specific
581454|NCT00389909|Premature infants
581455|NCT00389909|Apnea
581456|NCT00389909|Doxapram
581457|NCT00389909|pharmacokinetics
581458|NCT00389883|supratentorial brain tumors
581459|NCT00389883|propofol
581460|NCT00389883|sevoflurane
581461|NCT00389883|remifentanil
581462|NCT00389883|sufentanil.
581463|NCT00389870|recurrent colon cancer
581464|NCT00389870|stage IV colon cancer
581465|NCT00389870|recurrent rectal cancer
581466|NCT00389870|stage IV rectal cancer
581467|NCT00389870|adenocarcinoma of the colon
581468|NCT00389870|adenocarcinoma of the rectum
581469|NCT00389857|Influenza
581470|NCT00389857|Influenza Virus Vaccine
581471|NCT00389857|Fluzone®
581472|NCT00389844|hip fracture
581473|NCT00389844|exercise
581474|NCT00389844|motivation
581475|NCT00389831|Rotigotine
581476|NCT00389831|Rotigotine nasal spray
581477|NCT00389831|Efficacy, safety and tolerability
581478|NCT00389831|Restless Legs Syndrome
581479|NCT00389818|contiguous stage II grade 3 follicular lymphoma
581480|NCT00389818|noncontiguous stage II grade 3 follicular lymphoma
581481|NCT00389818|stage I grade 3 follicular lymphoma
581482|NCT00389818|stage III grade 3 follicular lymphoma
581483|NCT00389818|stage IV grade 3 follicular lymphoma
581484|NCT00389818|AIDS-related diffuse large cell lymphoma
581485|NCT00389818|contiguous stage II adult diffuse large cell lymphoma
581486|NCT00389818|noncontiguous stage II adult diffuse large cell lymphoma
581487|NCT00389818|stage I adult diffuse large cell lymphoma
581488|NCT00389818|stage III adult diffuse large cell lymphoma
581489|NCT00389818|stage IV adult diffuse large cell lymphoma
581490|NCT00389818|AIDS-related immunoblastic large cell lymphoma
581491|NCT00389818|contiguous stage II adult immunoblastic large cell lymphoma
581492|NCT00389818|noncontiguous stage II adult immunoblastic large cell lymphoma
581493|NCT00389818|stage I adult immunoblastic large cell lymphoma
581494|NCT00389818|stage III adult immunoblastic large cell lymphoma
581495|NCT00389818|stage IV adult immunoblastic large cell lymphoma
581496|NCT00389818|AIDS-related peripheral/systemic lymphoma
581497|NCT00389805|recurrent non-small cell lung cancer
581498|NCT00389805|stage IIIB non-small cell lung cancer
581499|NCT00389805|stage IV non-small cell lung cancer
581500|NCT00389805|unspecified adult solid tumor, protocol specific
581501|NCT00389766|localized unresectable neuroblastoma
581502|NCT00389766|recurrent neuroblastoma
581503|NCT00389766|regional neuroblastoma
581504|NCT00389766|localized resectable neuroblastoma
581505|NCT00389766|disseminated neuroblastoma
581506|NCT00389753|Scars
581507|NCT00389753|Hydratation
581508|NCT00389753|After Treatment
581509|NCT00389714|pedodontics
581510|NCT00389714|carious
581511|NCT00389714|dental restoration
581512|NCT00389714|antibacterial
581513|NCT00389714|nanoparticles
581514|NCT00389701|stage I multiple myeloma
581515|NCT00389701|stage II multiple myeloma
581516|NCT00389701|stage III multiple myeloma
581517|NCT00389701|refractory multiple myeloma
581518|NCT00389688|stage I non-small cell lung cancer
581768|NCT00388063|Atiprimod
581519|NCT00389688|stage II non-small cell lung cancer
581520|NCT00389649|congestive heart failure
581521|NCT00389649|pacemaker
581522|NCT00389649|heart rate
581523|NCT00389636|Diabetes
581524|NCT00389636|Foot
581525|NCT00389636|Extremity
581526|NCT00389636|Ulcer
581527|NCT00389636|Wound
581528|NCT00389636|Gauze
581529|NCT00389610|stage I pancreatic cancer
581530|NCT00389610|stage II pancreatic cancer
581531|NCT00389610|stage III pancreatic cancer
581532|NCT00389610|adenocarcinoma of the pancreas
581533|NCT00389597|degenerative disc disease
581534|NCT00389597|cervical arthroplasty
581535|NCT00389597|Mobi C
581536|NCT00389597|multilevel
581537|NCT00389597|anterior cervical discectomy and fusion
581538|NCT00389584|cognitive/functional effects
581539|NCT00389584|poor performance status
581540|NCT00389584|long-term effects secondary to cancer therapy in adults
581541|NCT00389584|long-term effects secondary to cancer therapy in children
581542|NCT00389584|adult tumors metastatic to brain
581543|NCT00389584|unspecified adult solid tumor, protocol specific
581544|NCT00389584|unspecified childhood solid tumor, protocol specific
581545|NCT00389558|Skin colonization
581546|NCT00389558|Antiseptic
581547|NCT00389558|Epicutaneocavous catheter dressing
581548|NCT00389558|Infant
581549|NCT00389532|Influenza
581550|NCT00389532|Influenza Vaccine
581551|NCT00389519|Hypertension/*etiology
581552|NCT00389519|Blood Pressure
581553|NCT00389519|Pediatric
581554|NCT00389519|Adolescent
581555|NCT00389519|Child
581556|NCT00389506|stage II adult Hodgkin lymphoma
581557|NCT00389506|stage III adult Hodgkin lymphoma
581558|NCT00389506|stage IV adult Hodgkin lymphoma
581559|NCT00389506|recurrent adult Hodgkin lymphoma
581560|NCT00389493|OCD
581561|NCT00389493|Augmentation
581562|NCT00389493|Antipsychotics
581563|NCT00389493|Cognitive-Behavioral Therapy
581564|NCT00389480|Solid Tumors
581565|NCT00389480|Solid Malignancies
581566|NCT00389480|Phase I
581567|NCT00389467|stroke
581568|NCT00389467|ischemic stroke
581569|NCT00389467|blood clot
581570|NCT00389467|Merci Retriever
581571|NCT00389467|Penumbra System
581572|NCT00389467|embolectomy
581573|NCT00389467|magnetic resonance imaging
581574|NCT00389467|MRI
581575|NCT00389467|CT
581576|NCT00389467|SPOTRIAS
581577|NCT00389454|Acetaminophen
581578|NCT00389454|Fever
581579|NCT00389454|cerebro spinal fluid
581580|NCT00389454|Infants
581581|NCT00389441|VEGFR inhibitor
581582|NCT00389441|tyrosine kinase inhibitor
581583|NCT00389441|anti-angiogenic
581584|NCT00389441|carcinoma
581585|NCT00389441|papillary
581586|NCT00389441|follicular
581587|NCT00389441|medullary
581588|NCT00389441|anaplastic
581589|NCT00389428|Hematologic malignancies
581590|NCT00389428|Malignancies, hematologic
581591|NCT00389428|Hematopoietic malignancies
581592|NCT00389415|Type 2 Diabetes
581593|NCT00389415|Vildagliptin
581594|NCT00389415|HbA1c
581595|NCT00389402|lipids
581596|NCT00389402|lipodystrophy
581597|NCT00389402|fat distribution
581598|NCT00389402|hiv-1
581599|NCT00389402|antiretroviral therapy
581600|NCT00389402|Treatment Naive
581601|NCT00389389|Advanced Solid Malignancies
581602|NCT00389389|Advanced solid tumors
581603|NCT00389389|Cancer
581604|NCT00389389|Phase I
581605|NCT00389389|Solid tumors
581606|NCT00389389|Solid malignancies
581607|NCT00389337|Sepsis
581608|NCT00389337|SIRS
581609|NCT00389337|Biomarkers
581610|NCT00389337|xMAP
581611|NCT00389324|Primary immune deficiency
581612|NCT00389311|Microbicide
581613|NCT00389311|Safety
581614|NCT00389311|HIV prevention
581615|NCT00389311|HIV Seronegativity
581616|NCT00389298|Chronic hepatitis C
581617|NCT00389298|Viral kinetics
581618|NCT00389298|Phase II
581619|NCT00389298|Pharmacokinetics (PK)
581620|NCT00389298|Safety and tolerability
581621|NCT00389285|Carcinoma, renal cell
581622|NCT00389285|interleukin-21
581623|NCT00389285|sorafenib
581624|NCT00389285|Immunotherapy
581625|NCT00389259|Insecticides
581626|NCT00389259|Organophosphate
581627|NCT00389259|Scopolamine
581628|NCT00389259|randomized control study
581629|NCT00389259|Organophosphate or carbamate intoxication
581630|NCT00389246|obesity
581631|NCT00389246|genetic consultation
581632|NCT00389246|randomized controlled trial
581633|NCT00389220|Coronary Disease
581634|NCT00389220|Coronary Stenosis
581635|NCT00389220|Angioplasty
581636|NCT00389220|Coronary Restenosis
581637|NCT00389220|Drug Eluting Stent
581638|NCT00389194|HIV-1 infection
581639|NCT00389194|fat distribution
581640|NCT00389194|lipodystrophy
581641|NCT00389194|lipids
581642|NCT00389194|kidney function
581643|NCT00389194|Treatment Experienced
581644|NCT00389181|Unruptured brain arteriovenous malformation
581645|NCT00389181|AVM
581646|NCT00389181|BAVM
581647|NCT00389181|Stroke
581648|NCT00389181|Intracranial Hemorrhage
581649|NCT00389168|Hypertension
581650|NCT00389168|Cardiac hypertrophy
581651|NCT00389168|Angiotensin
581652|NCT00389168|Human
581653|NCT00389155|Advanced or metastatic transitional cell carcinoma of the urothelium
581654|NCT00389142|pelvic pain
581655|NCT00389142|urinary frequency
581656|NCT00389142|painful bladder
581657|NCT00389142|urinary urgency
581658|NCT00389129|Platelets
581659|NCT00389129|Aspirin Resistance
581660|NCT00389129|Platelet aggregation
581661|NCT00389090|temozolomide resistant
581662|NCT00389090|anaplastic glioma
581663|NCT00389090|anaplastic astrocytoma
581664|NCT00389090|anaplastic oligodendroglioma
581665|NCT00389090|anaplastic oligoastrocytoma
581666|NCT00389077|perifosine
581667|NCT00389077|solid tumors
581668|NCT00389077|lymphomas
581669|NCT00389077|anticancer agent
581670|NCT00389064|Generalised Anxiety Disorder
581671|NCT00389064|GAD
581672|NCT00389051|Non-Hodgkin's Lymphoma
581673|NCT00389051|Malignant lymphoma
581674|NCT00389038|headache
581675|NCT00389038|coping skills training
581676|NCT00389038|amitriptyline
581677|NCT00389038|attention control
581678|NCT00389025|Subject with clinical history of seasonal allergic conjunctivitis
581679|NCT00389012|rehabilitation
581680|NCT00389012|hemiplegic gait
581681|NCT00389012|exercise therapy
581682|NCT00389012|physical therapy
581683|NCT00388999|Multiple Myeloma
581684|NCT00388999|Stem Cell Transplant
581685|NCT00388999|rhMBL
581686|NCT00388973|Major Depressive Disorder
581687|NCT00388973|MDD
581688|NCT00388960|small cell lung cancer
581689|NCT00388960|amrubicin
581690|NCT00388947|vaginal prolapse
581691|NCT00388947|cystocele
581692|NCT00388947|rectocele
581693|NCT00388947|enterocele
581694|NCT00388947|apical prolapse
581695|NCT00388947|vaginal vault prolapse
581696|NCT00388934|Percutaneous coronary intervention
581697|NCT00388934|Angina pectoris
581698|NCT00388934|Stent
581699|NCT00388921|Vitamin A
581700|NCT00388921|Children
581701|NCT00388921|Severe malnutrition
581702|NCT00388921|Retinol
581703|NCT00388921|Retinol binding protein
581704|NCT00388921|Diarrhoea
581705|NCT00388921|ALRI
581706|NCT00388921|Age 6-59 months
581707|NCT00388921|Either sex
581708|NCT00388921|Severe malnutrition as defined by the presence of any of the followings:
581709|NCT00388921|Bipedal oedema
581710|NCT00388921|Weight (measured after correction of dehydration) for height Z score <-3 of the National Center for Health Statistics (NCHS) reference
581711|NCT00388921|Written informed consent of respective parents/ guardians for participation of the children in the study.
581712|NCT00388921|Children having diarrhoea (watery or invasive) or cough and cold or both for the last 48 hours.
581713|NCT00388908|vertebral fractures
581714|NCT00388908|osteoporosis
581715|NCT00388908|prevention
581716|NCT00388908|case-finding
581717|NCT00388908|quality improvement
581718|NCT00388895|Acute lymphoblastic Leukemia
581719|NCT00388869|renal artery
581720|NCT00388869|calcium
581721|NCT00388869|CT
581722|NCT00388869|hypertension
581723|NCT00388856|antioxidant supplementation
581724|NCT00388856|preeclampsia
581725|NCT00388856|prevention
581726|NCT00388843|carotid atherosclerosis
581727|NCT00388843|magnetic resonance imaging
581728|NCT00388843|atherosclerosis
581729|NCT00388843|ultrasound
581730|NCT00388843|inflammation
581731|NCT00388843|statins
581732|NCT00388843|vulnerable plaque
581733|NCT00388843|stroke
581734|NCT00388830|Gallbladder
581735|NCT00388830|Ultrasound
581736|NCT00388830|Emergency Medicine
581737|NCT00388817|Hypertension
581738|NCT00388817|Blood pressure
581739|NCT00388817|Adherence
581740|NCT00388817|Compliance
581741|NCT00388817|Pharmacist
581742|NCT00388817|Pharmacy
581743|NCT00388817|Costs
581744|NCT00388804|Prostate Cancer
581745|NCT00388804|External Beam Radiotherapy
581746|NCT00388804|Radiation Therapy
581747|NCT00388804|Hormone Therapy
581748|NCT00388804|Bicalutamide
581749|NCT00388804|Casodex
581750|NCT00388804|Leuprolide
581751|NCT00388804|Lupron
581752|NCT00388804|Goserelin
581753|NCT00388804|Zoladex
581754|NCT00388804|Flutamide
581755|NCT00388804|EBRT
581756|NCT00388791|symptomatology
581757|NCT00388791|Schein questionnaire
581758|NCT00388791|fluoresceien staining
581759|NCT00388076|Pazopanib
581760|NCT00388076|paclitaxel
581761|NCT00388076|carboplatin
581762|NCT00388076|lapatinib
581763|NCT00388076|TAXOL
581764|NCT00388076|TYKERB
581765|NCT00388076|PARAPLATIN
581766|NCT00388063|Neuroendocrine
581769|NCT00388063|Carcinoid
581770|NCT00388050|Decision aid, diabetes, primary care
581771|NCT00388024|stage III squamous cell carcinoma of the hypopharynx
581772|NCT00388024|stage III squamous cell carcinoma of the larynx
581773|NCT00388024|stage III squamous cell carcinoma of the lip and oral cavity
581774|NCT00388024|stage III squamous cell carcinoma of the nasopharynx
581775|NCT00388024|stage III squamous cell carcinoma of the oropharynx
581776|NCT00388024|stage III lymphoepithelioma of the nasopharynx
581777|NCT00388024|stage III lymphoepithelioma of the oropharynx
581778|NCT00388024|squamous cell carcinoma of unknown primary
581779|NCT00388024|newly diagnosed carcinoma of unknown primary
581780|NCT00388024|metastatic squamous neck cancer with occult primary squamous cell carcinoma
581781|NCT00388024|untreated metastatic squamous neck cancer with occult primary
581782|NCT00388024|stage IV squamous cell carcinoma of the hypopharynx
581783|NCT00388024|stage IV squamous cell carcinoma of the larynx
581784|NCT00388024|stage IV squamous cell carcinoma of the lip and oral cavity
581785|NCT00388024|stage IV squamous cell carcinoma of the nasopharynx
581786|NCT00388024|stage IV squamous cell carcinoma of the oropharynx
581787|NCT00388024|stage IV lymphoepithelioma of the nasopharynx
581788|NCT00388024|stage IV lymphoepithelioma of the oropharynx
581789|NCT00388011|Post surgical pain
581790|NCT00388011|Bunionectomy
581791|NCT00388011|Hammer Toe Syndrome
581792|NCT00388011|Morphine
581793|NCT00387998|unspecified adult solid tumor, protocol specific
581794|NCT00387283|WNV
581795|NCT00387283|West Nile virus
581796|NCT00387283|WNV meningoencephalitis
581797|NCT00387270|Huntington's disease
581798|NCT00387270|Dimebon
581799|NCT00387270|dose-escalation
581800|NCT00387270|Phase 1-2a
581801|NCT00387270|randomized
581802|NCT00387270|controlled
581803|NCT00387270|double-blind
581804|NCT00387270|Unified Huntington's Disease Rating Scale
581805|NCT00387257|platelet aggregation
581806|NCT00387257|SB-659032
581807|NCT00387257|rilapladib
581808|NCT00387244|Pain;
581809|NCT00387244|Back Pain;
581810|NCT00387244|Neurostimulation
581811|NCT00387231|Myocardial Ischemia
581812|NCT00387231|Randomized Controlled Trials
581813|NCT00387231|Angioplasty, Transluminal, Percutaneous Coronary
581814|NCT00387231|Drug Therapy
581815|NCT00387218|Exercise
581816|NCT00387218|Physical Functional Ability
581817|NCT00387218|Spinal Range of Motion
581818|NCT00387218|Balance
581819|NCT00387218|Economy of Movement
581820|NCT00387218|Aerobic Conditioning
581821|NCT00387218|Quality of Life
581822|NCT00387218|Adherence
581823|NCT00387205|chronic administration
581824|NCT00387205|monotherapy and combination therapies
581825|NCT00387205|solid
581826|NCT00387205|lapatinib (TYKERB, TYVERB)
581827|NCT00387205|malignant tumor
581828|NCT00387205|Pazopanib
581829|NCT00387205|GW786034
581830|NCT00387205|cancer
581831|NCT00387205|safety
581832|NCT00387192|Von Willebrand Disease
581833|NCT00387192|Factor VIII
581834|NCT00387192|Von Willebrand Factor
581835|NCT00387192|Pharmacokinetics
581836|NCT00387179|Circadian Rhythm Sleep Disorders
581837|NCT00387166|Type 2 Diabetes
581838|NCT00387166|Cardiovascular
581839|NCT00387166|Blood Pressure
581840|NCT00387166|Hispanic
581841|NCT00387166|Women
581842|NCT00387166|Social Context
581843|NCT00387166|Psychosocial
581844|NCT00387153|Oncology
581845|NCT00387153|Cancer
581846|NCT00387153|Blood Cancers
581847|NCT00388765|bronchoscopy
581848|NCT00388765|sample bank
581849|NCT00388765|research study volunteer
581850|NCT00388752|Acupuncture
581851|NCT00388752|Phantom limb pain
581852|NCT00388752|Residual limb pain
581853|NCT00388752|amputation
581854|NCT00388752|amputee
581855|NCT00388752|traumatic
581856|NCT00388752|surgical
581857|NCT00388752|Traumatic amputation upper extremity
581858|NCT00388752|Traumatic amputation lower extremity
581859|NCT00388752|Surgical amputation upper extremity
581860|NCT00388752|Surgical amputation lower extremity
581861|NCT00388739|Pediatric Asthma
581862|NCT00388739|Pulmicort
581863|NCT00388739|TEDAS ED
581864|NCT00388739|Acute exacerbation of asthma
581865|NCT00388739|Chronic asthma
581866|NCT00388726|Locally recurrent breast cancer
581867|NCT00388726|metastatic breast cancer
581868|NCT00388713|Radiation therapy
581869|NCT00388713|Radiation-Induced Atherosclerosis
581870|NCT00388713|Carotid Artery Diseases
581871|NCT00388713|Breast Cancer
581872|NCT00388713|Intima Media thickening Ultrasound
581873|NCT00388700|Colorectal cancer, DAVANAT, colon cancer, 5-FU
581874|NCT00388687|Hypoxia
581875|NCT00388687|FAZA
581876|NCT00388687|PET
581877|NCT00388687|Radiochemotherapy
581878|NCT00388674|Chronic Hepatitis B Virus
581879|NCT00388661|sleep problems
581880|NCT00388661|quality of life
581881|NCT00388661|melatonin
581882|NCT00388661|sleep apnea
581883|NCT00388661|medication
581884|NCT00388661|preload
581885|NCT00388661|nutritional status
581886|NCT00388661|ProBNP
581887|NCT00388648|Dialysis
581888|NCT00388648|Vegan Diet
581889|NCT00388648|Mortality
581890|NCT00388648|Morbidity
581891|NCT00388648|Treatment outcome
581892|NCT00388635|Multiple Myeloma
581893|NCT00388635|Patients over 65 years old
581894|NCT00388622|Heart failure
581895|NCT00388622|Adherence
581896|NCT00388622|Compliance
581897|NCT00388622|Pharmacy
581898|NCT00388622|Pharmacist
581899|NCT00388622|Health-related quality of life
581900|NCT00388622|Clinical exacerbation
581901|NCT00388622|Costs
581902|NCT00388596|SB-751689
581903|NCT00388596|osteoporosis
581904|NCT00388596|drug interaction
581905|NCT00388596|ketoconazole
581906|NCT00388596|atorvastatin
581907|NCT00388596|rosuvastatin
581908|NCT00388583|Influenza
581909|NCT00388583|Orthomyxoviruses
581910|NCT00388583|Inactivated Split-virion influenza vaccine
581911|NCT00388583|Elderly.
581912|NCT00388570|Asthma
581913|NCT00388570|adult
581914|NCT00388570|paediatric
581915|NCT00388570|NIOX MINO®
581916|NCT00388570|NIOX®
581917|NCT00388570|nitric oxide
581918|NCT00388570|airway inflammation
581919|NCT00388570|open−label
581920|NCT00388570|single−cohort
581921|NCT00388531|Acute Lymphoblastic Leucemia
581922|NCT00388531|Aggressive Non-Hodgkin-Lymphoma
581923|NCT00388531|CNS relapse
581924|NCT00388531|Cytarabine liposome
581925|NCT00388505|tobramycin
581926|NCT00388492|HIV Infected
581927|NCT00388466|whole body vibration
581928|NCT00388466|muscle function
581929|NCT00388466|cystic fibrosis
581930|NCT00388466|mechanography
581931|NCT00388466|chair-rising-test
581932|NCT00388453|Healthy volunteers
581933|NCT00388440|Mumps
581934|NCT00388440|Singapore
581935|NCT00388440|Rubella
581936|NCT00388440|Measles
581937|NCT00388427|advanced cancer
581938|NCT00388427|solid tumor
581939|NCT00388427|solid malignancies
581940|NCT00388427|phase I
581941|NCT00388401|Postoperative Ileus
581942|NCT00388388|Remodeling
581943|NCT00388388|Resistance arteries
581944|NCT00388388|angiotensin receptor blocker
581945|NCT00388388|thiazide diuretic
581946|NCT00388362|GVHD
581947|NCT00388336|Anemia
581948|NCT00388336|Neoplasms, Hemoglobin values
581949|NCT00388336|PROCRIT
581950|NCT00388336|Epoetin alfa
581951|NCT00388323|Alcohol
581952|NCT00388323|Hepatitis
581953|NCT00388323|Cirrhosis
581954|NCT00388323|Inflammation
581955|NCT00388323|Cytokines
581956|NCT00388323|ADIPOKINES
581957|NCT00388323|Adipose tissue
581958|NCT00388310|cellulitis
581959|NCT00388310|furuncles
581960|NCT00388310|carbuncles
581961|NCT00388310|abscess
581962|NCT00388297|Subclinical Hypothyroidism
581963|NCT00388297|Hypothyroxinemia
581964|NCT00388297|Thyroid
581965|NCT00388297|Pregnancy
581966|NCT00388297|Intellectual Development
581967|NCT00388284|hemostasis
581968|NCT00388284|arterial sealing
581969|NCT00388271|Alpha-blocker
581970|NCT00388271|Alfuzosin
581971|NCT00388271|Xatral
581972|NCT00388271|ESWL
581973|NCT00388258|Postoperative ileus
581974|NCT00388245|PCI
581975|NCT00388245|CABG
581976|NCT00388245|Ejection Fraction
581977|NCT00388245|Myocardial Revascularization
581978|NCT00388232|COPD
581979|NCT00388232|prevalence
581980|NCT00388232|smoke
581981|NCT00388232|biomass
581982|NCT00388232|occupational
581983|NCT00388232|Malatya
581984|NCT00388232|Turkey
581985|NCT00388219|Buprenorphine
581986|NCT00388219|Transdermal patch
581987|NCT00388219|Centrally acting analgesic
581988|NCT00388219|Plasma level
581989|NCT00388219|Healthy volunteers
581990|NCT00388206|NSCLC
581991|NCT00388206|Avastin
581992|NCT00388206|anti-VEGF
581993|NCT00388206|lung cancer
581994|NCT00388206|colorectal cancer
581995|NCT00388206|ARIES
581996|NCT00388206|Colon Cancer
581997|NCT00388193|ALL (L3)
581998|NCT00388193|BURKITT's LYMPHOMA
581999|NCT00388193|RITUXIMAB
582000|NCT00388180|cholesterol
582001|NCT00388180|inflammation
582002|NCT00388180|fat
582003|NCT00388167|Invader fungal infection (IFI)
582004|NCT00388167|Invasive Aspergillosis (AI)
582005|NCT00388167|Invasive Candidiasis (CI)
582006|NCT00388167|Caspofungin acetate
582007|NCT00388154|Endometrial Cancer
582008|NCT00388154|Gemcitabine
582009|NCT00388154|Gemzar
582010|NCT00388154|Gemcitabine Hydrochloride
582011|NCT00388154|Cisplatin
582012|NCT00388154|Platinol-AQ
582013|NCT00388154|Platinol
582014|NCT00388154|CDDP
582015|NCT00388141|Preterm Infant;
582016|NCT00388141|NIDCAP;
582017|NCT00388141|Neonatal Care,
582018|NCT00388141|Intervention Study;
582019|NCT00388141|Growth and Development;
582020|NCT00388141|Maternal Self-esteem.
582021|NCT00388141|Maternal Social support
582022|NCT00388141|NICU
582023|NCT00388128|Intermittent Claudication
582024|NCT00388128|PAD
582025|NCT00388128|Caffeine
582026|NCT00388128|Walking capacity
582027|NCT00388128|ABI
582028|NCT00388128|QoL
582029|NCT00388128|Growth factor
582030|NCT00388115|ductal breast carcinoma in situ
582031|NCT00388115|stage I breast cancer
582032|NCT00388115|stage II breast cancer
582033|NCT00388115|breast cancer in situ
582034|NCT00388089|unspecified adult solid tumor, protocol specific
582035|NCT00388089|extensive stage small cell lung cancer
582036|NCT00388089|recurrent small cell lung cancer
582037|NCT00387972|Type 2 diabetes mellitus (T2DM)
582038|NCT00387972|glycosylated hemoglobin (HbA1c)
582039|NCT00387972|denagliptin
582040|NCT00387972|diabetes treatment
582041|NCT00387972|glycemic control
582042|NCT00387959|recurrent mantle cell lymphoma
582043|NCT00387959|stage III mantle cell lymphoma
582044|NCT00387959|stage IV mantle cell lymphoma
582045|NCT00387959|recurrent adult diffuse large cell lymphoma
582046|NCT00387959|stage III adult diffuse large cell lymphoma
582047|NCT00387959|stage IV adult diffuse large cell lymphoma
582048|NCT00387959|B-cell chronic lymphocytic leukemia
582049|NCT00387959|refractory chronic lymphocytic leukemia
582050|NCT00387959|stage III chronic lymphocytic leukemia
582051|NCT00387959|stage IV chronic lymphocytic leukemia
582052|NCT00387959|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
582053|NCT00387959|nodal marginal zone B-cell lymphoma
582054|NCT00387959|recurrent marginal zone lymphoma
582055|NCT00387959|recurrent adult diffuse small cleaved cell lymphoma
582056|NCT00387959|splenic marginal zone lymphoma
582057|NCT00387959|recurrent grade 1 follicular lymphoma
582058|NCT00387959|recurrent grade 2 follicular lymphoma
582059|NCT00387959|recurrent grade 3 follicular lymphoma
582060|NCT00387959|noncontiguous stage II grade 1 follicular lymphoma
582061|NCT00387959|noncontiguous stage II grade 2 follicular lymphoma
582062|NCT00387959|noncontiguous stage II grade 3 follicular lymphoma
582063|NCT00387959|stage III grade 1 follicular lymphoma
582064|NCT00387959|stage III grade 2 follicular lymphoma
582065|NCT00387959|stage III grade 3 follicular lymphoma
582066|NCT00387959|stage IV grade 1 follicular lymphoma
582067|NCT00387959|stage IV grade 2 follicular lymphoma
582068|NCT00387959|stage IV grade 3 follicular lymphoma
582069|NCT00387959|noncontiguous stage II marginal zone lymphoma
582070|NCT00387959|stage III marginal zone lymphoma
582071|NCT00387959|stage IV marginal zone lymphoma
582072|NCT00387959|noncontiguous stage II adult diffuse small cleaved cell lymphoma
582073|NCT00387959|stage III adult diffuse small cleaved cell lymphoma
582074|NCT00387959|stage IV adult diffuse small cleaved cell lymphoma
582075|NCT00387959|noncontiguous stage II adult diffuse large cell lymphoma
582076|NCT00387959|noncontiguous stage II mantle cell lymphoma
582077|NCT00387946|smoking
582078|NCT00387946|cessation
582079|NCT00387946|tobacco
582080|NCT00387933|recurrent adult brain tumor
582081|NCT00387933|adult glioblastoma
582082|NCT00387933|adult anaplastic astrocytoma
582083|NCT00387933|adult anaplastic oligodendroglioma
582084|NCT00387933|adult gliosarcoma
582085|NCT00387933|adult giant cell glioblastoma
582086|NCT00387933|adult anaplastic ependymoma
582087|NCT00387933|adult brain stem glioma
582088|NCT00387933|adult mixed glioma
582089|NCT00387933|adult pineal gland astrocytoma
582090|NCT00387907|Herceptin
582091|NCT00387907|Taxane
582092|NCT00387907|Breast Cancer
582093|NCT00387894|adult glioblastoma
582094|NCT00387894|adult gliosarcoma
582095|NCT00387894|recurrent adult brain tumor
582096|NCT00387881|sumatriptan succinate,
582097|NCT00387881|naproxen sodium,
582098|NCT00387881|parallel group,
582099|NCT00387881|double-blind,
582100|NCT00387881|placebo-controlled,
582101|NCT00387881|Combination product,
582102|NCT00387881|migrainous headache
582103|NCT00387881|Probable migraine, a sub-type of Migraine
582104|NCT00387881|probable migraine,
582105|NCT00387868|Thymoma
582106|NCT00387868|Thymic carcinoma
582107|NCT00387868|Preoperative chemotherapy and radiation
582108|NCT00387868|Response rate
582109|NCT00387855|suicide
582110|NCT00387855|depression
582111|NCT00387777|Buprenorphine
582112|NCT00387777|Transdermal patch
582113|NCT00387777|multidose
582114|NCT00387777|Centrally acting analgesic
582115|NCT00387777|Plasma level
582116|NCT00387777|Healthy volunteers
582117|NCT00387764|renal cell carcinoma
582118|NCT00387764|pazopanib
582119|NCT00387764|anti-angiogenic therapy
582120|NCT00387764|open label
582121|NCT00387738|Ragweed
582122|NCT00387738|Allergy
582123|NCT00387738|Allergic
582124|NCT00387738|Rhinitis
582125|NCT00387738|Hay Fever
582126|NCT00387738|Seasonal
582127|NCT00387738|Treatment
582128|NCT00387738|Immunotherapy
582129|NCT00387738|Vaccine
582130|NCT00387725|Adolescent
582131|NCT00387725|Meningococcal
582132|NCT00387725|Safety
582133|NCT00387712|exercise
582134|NCT00387712|inflammation
582135|NCT00387712|motor performance
582136|NCT00387712|skeletal muscle
582137|NCT00387712|chronic stroke survivors
582138|NCT00387712|treadmill exercise
582139|NCT00387699|limited stage small cell lung cancer
582140|NCT00387673|electrical stimulation
582141|NCT00387673|hand
582142|NCT00387673|Rehabilitation
582143|NCT00387673|spinal cord injury
582144|NCT00387660|extensive stage small cell lung cancer
582145|NCT00387660|limited stage small cell lung cancer
582146|NCT00387660|recurrent small cell lung cancer
582147|NCT00387647|myeloid
582148|NCT00387647|acute
582149|NCT00387647|monocytic
582150|NCT00387634|tick born encephalitis, TBE, adults
582151|NCT00387621|heart failure
582152|NCT00387621|diastolic dysfunction
582153|NCT00387621|systolic dysfunction
582154|NCT00387621|preclinical
582155|NCT00387621|natriuretic peptide
582156|NCT00387621|B-type natriuretic peptide
582157|NCT00387621|cyclic guanosine monophosphate
582158|NCT00387608|unspecified adult solid tumor, protocol specific
582159|NCT00387608|refractory chronic lymphocytic leukemia
582160|NCT00387608|stage III chronic lymphocytic leukemia
582161|NCT00387608|stage IV chronic lymphocytic leukemia
582162|NCT00387608|stage III grade 1 follicular lymphoma
582163|NCT00387608|stage III grade 2 follicular lymphoma
582164|NCT00387608|stage IV grade 1 follicular lymphoma
582165|NCT00387608|stage IV grade 2 follicular lymphoma
582166|NCT00387608|recurrent grade 1 follicular lymphoma
582167|NCT00387608|recurrent grade 2 follicular lymphoma
582168|NCT00387608|recurrent grade 3 follicular lymphoma
582169|NCT00387608|stage III grade 3 follicular lymphoma
582170|NCT00387608|stage IV grade 3 follicular lymphoma
582171|NCT00387595|Family History
582172|NCT00387595|CAD
582173|NCT00387595|CAC
582174|NCT00387595|cIMT
582175|NCT00387595|CV Risk Factors
582176|NCT00387582|Diabetes
582177|NCT00387582|Macular Edema
582178|NCT00387582|Diabetic Retinopathy
582179|NCT00387582|Lucentis
582180|NCT00387582|Ranibizumab
582181|NCT00387569|Toddlers
582182|NCT00387569|Vaccine
582183|NCT00387569|Safety
582184|NCT00387556|ketamine
582185|NCT00387556|children
582186|NCT00387556|emesis
582187|NCT00387530|recurrent lymphoepithelioma of the nasopharynx
582188|NCT00387530|post-transplant lymphoproliferative disorder
582189|NCT00387530|adult nasal type extranodal NK/T-cell lymphoma
582190|NCT00387530|recurrent adult Hodgkin lymphoma
582191|NCT00387530|AIDS-related peripheral/systemic lymphoma
582192|NCT00387530|AIDS-related primary CNS lymphoma
582193|NCT00387530|recurrent gastric cancer
582194|NCT00387517|Diastolic
582195|NCT00387517|systolic
582196|NCT00387517|hypertension
582197|NCT00387517|aliskiren
582198|NCT00387517|blood pressure
582199|NCT00387517|hydrochlorothiazide
582200|NCT00387517|HCTZ
582201|NCT00387504|unspecified adult solid tumor, protocol specific
582202|NCT00387478|Allergy
582203|NCT00387478|Specific Immunotherapy
582204|NCT00387478|Tree
582205|NCT00387478|Environmental Exposure Chamber
582206|NCT00387452|Aging
582207|NCT00387452|Type 2 diabetes
582208|NCT00387452|exercise
582209|NCT00387452|aerobic training
582210|NCT00387452|strength training
582211|NCT00387452|glucose metabolism arterial baroreceptors
582212|NCT00387452|heart rate variability
582213|NCT00387452|cerebral autoregulation
582214|NCT00387452|tilt table study
582215|NCT00387452|transcranial Doppler
582216|NCT00387452|autonomic nervous system
582217|NCT00387439|Anal incontinence
582218|NCT00387439|Gastroenterology
582219|NCT00387439|Anoperineal physiotherapy
582220|NCT00387439|Randomized clinical trial
582221|NCT00387413|Duloxetine
582222|NCT00387413|GSK189254
582223|NCT00387413|Healthy volunteers
582224|NCT00387413|Phase I.
582225|NCT00387413|Electrical hyperalgesia model
582226|NCT00387400|adult giant cell glioblastoma
582227|NCT00387400|adult gliosarcoma
582228|NCT00387400|recurrent adult brain tumor
582229|NCT00387400|adult glioblastoma
582230|NCT00387387|pharmacokinetics
582231|NCT00387387|colorectal cancer
582232|NCT00387387|pazopanib
582233|NCT00387387|capecitabine
582234|NCT00387387|CapeOx
582235|NCT00387387|5-fluorouracil
582236|NCT00387387|oxaliplatin
582237|NCT00387387|combination therapy
582238|NCT00387387|FOLFOX 6
582239|NCT00387361|Post-Operative Nausea
582240|NCT00387361|Nausea
582241|NCT00387361|Anesthesia
582242|NCT00387361|Osteopathic Manipulative Treatment
582243|NCT00387361|Osteopathic Manipulative Medicine
582244|NCT00387361|Manipulation, Osteopathic
582245|NCT00387361|Osteopathy
582246|NCT00387361|Texas College of Osteopathic Medicine
582247|NCT00387348|fatigue
582248|NCT00387348|psychosocial effects of cancer and its treatment
582249|NCT00387348|stage IIIB non-small cell lung cancer
582250|NCT00387348|stage IV non-small cell lung cancer
582251|NCT00387348|extensive stage small cell lung cancer
582252|NCT00387348|advanced adult primary liver cancer
582253|NCT00387348|depression
582254|NCT00387348|stage III pancreatic cancer
582255|NCT00387348|stage IV pancreatic cancer
582256|NCT00387348|stage IV esophageal cancer
582257|NCT00387348|stage IV gastric cancer
582258|NCT00387348|stage IVA colon cancer
582259|NCT00387348|stage IVB colon cancer
582260|NCT00387348|stage IVA rectal cancer
582261|NCT00387348|stage IVB rectal cancer
582262|NCT00387348|unresectable gallbladder cancer
582263|NCT00387348|unresectable extrahepatic bile duct cancer
582264|NCT00387322|unspecified adult solid tumor, protocol specific
582265|NCT00387322|recurrent non-small cell lung cancer
582266|NCT00387322|stage IIIB non-small cell lung cancer
582267|NCT00387322|stage IV non-small cell lung cancer
582268|NCT00387309|Bowel
582269|NCT00387140|Dental Pain, Postoperative
582270|NCT00387127|Neck Cancer
582271|NCT00387127|Locally advanced head and neck cancer
582272|NCT00387127|locally advanced
582273|NCT00387127|Head and Neck cancer
582274|NCT00387127|lapatinib
582275|NCT00387127|EGFR/ErbB2 inhibitor
582276|NCT00387127|Head Cancer
582277|NCT00387114|C-reactive protein
582278|NCT00387114|nitrotyrosine
582279|NCT00387114|oxidative stress
582280|NCT00387114|resistin
582281|NCT00387114|vitamin C
582282|NCT00387101|Diabetic Foot Ulcer
582283|NCT00387101|Diabetes Mellitus
582284|NCT00387101|Debridement
582285|NCT00387101|Dermal-LSR
582286|NCT00387101|Standard of Care
582287|NCT00387075|Parkinson Disease
582288|NCT00387075|SPECT imaging
582289|NCT00387062|Breast Cancer
582290|NCT00387062|Cognitive Impairment
582291|NCT00387062|Chemofog
582292|NCT00387062|Chemobrain
582293|NCT00387062|Post-chemotherapy cognitive impairment
582294|NCT00387049|Anxiety Sensitivity
582295|NCT00387023|Non-Hodgkin's Lymphoma
582296|NCT00387023|Orbital Lymphoma
582297|NCT00387023|Rituximab
582298|NCT00387023|Rituxan
582299|NCT00387023|Zevalin
582300|NCT00387023|Ibritumomab tiuxetan
582301|NCT00387023|IDEC-Y2B8
582302|NCT00387023|Eye
582303|NCT00386984|hepatocellular carcinoma; Sandostatin-LAR; RCT
582304|NCT00386971|L-carnitine
582305|NCT00386971|HIV
582306|NCT00386971|TGRL metabolism
582307|NCT00386971|postprandial
582308|NCT00386971|HIV Treatment Experienced
582309|NCT00386958|corneal ulcers
582310|NCT00386958|bacterial keratitis
582311|NCT00386958|childhood blindness
582312|NCT00386958|povidone-iodine
582313|NCT00386945|Tobacco
582314|NCT00386945|Cessation.
582315|NCT00386945|Chiropractic patients.
582316|NCT00386945|Doctors of Chiropractic.
582317|NCT00386945|Health care providers.
582318|NCT00386945|Behavioral intervention.
582319|NCT00386945|Tobacco intervention.
582320|NCT00386945|Cigarettes.
582321|NCT00386945|Smokeless tobacco.
582322|NCT00386945|Smoking intervention.
582323|NCT00386906|Melanoma
582324|NCT00386906|Conjunctival Melanoma
582325|NCT00386906|Malignant Melanoma of the Conjunctiva
582326|NCT00386906|Malignant Melanoma of the Eyelid
582327|NCT00386906|Sebaceous Cell Carcinoma
582328|NCT00386906|Sebaceous Cell Carcinoma of the Conjunctiva
582329|NCT00386906|Sebaceous Cell Carcinoma of the Eyelid
582330|NCT00386906|Sentinel Lymph Node
582331|NCT00386906|Lymphatic Mapping
582332|NCT00386906|Eyelid
582333|NCT00386906|Eyelid Lesion
582334|NCT00386867|medical abortion
582335|NCT00386867|mifepristone
582336|NCT00386867|misoprostol
582337|NCT00386867|buccal administration
582338|NCT00386854|exercise
582339|NCT00386854|lipid metabolism
582340|NCT00386854|lipoproteins
582341|NCT00386854|insulin resistance
582342|NCT00386854|inflammation
582343|NCT00386841|Major depression
582344|NCT00386841|First degree relatives
582345|NCT00386841|Escitalopram
582346|NCT00386841|Cortisol
582347|NCT00386841|Cognition
582348|NCT00386841|Personality
582349|NCT00386841|Endo-phenotype
582350|NCT00386828|colorectal cancer
582351|NCT00386828|advanced colorectal cancer
582352|NCT00386802|Neutropenia
582353|NCT00386802|Antifungals
582354|NCT00386789|Typhoid Fever
582355|NCT00386789|Serological Survey
582356|NCT00386789|Follow-Up
582357|NCT00386789|Protection
582358|NCT00386776|computers
582359|NCT00386776|diagnosis
582360|NCT00386776|medical records
582361|NCT00386776|physician patient relations
582362|NCT00386776|medical history taking
582363|NCT00386776|medical informatics applications
582364|NCT00386763|Marsh fever
582365|NCT00386763|Plasmodium infections
582366|NCT00386763|Remittent fever
582367|NCT00386763|Paludism
582368|NCT00386763|Artemether
582369|NCT00386763|Artemisinins
582370|NCT00386763|Malaria
582371|NCT00386763|Benflumetol
582372|NCT00386763|Lumefantrine
582373|NCT00386750|Malaria
582374|NCT00386750|hearing
582375|NCT00386750|co-artemether
582376|NCT00386750|auditory
582377|NCT00386750|Plasmodium falciparum
582378|NCT00386750|marsh fever
582379|NCT00386750|Plasmodium infections
582380|NCT00386750|remittent fever
582381|NCT00386750|paludism
582382|NCT00386750|artemether
582383|NCT00386750|artemisinins
582384|NCT00386750|benflumetol
582385|NCT00386750|lumefantrine
582386|NCT00386737|Asthma
582387|NCT00386737|Breath Testing
582388|NCT00386737|Laser Spectroscopy
582389|NCT00386737|eNO
582390|NCT00386737|Nitric Oxide
582391|NCT00386737|Lower Airway Inflammation
582392|NCT00386737|Carbon Dioxide
582393|NCT00386737|CO2
582394|NCT00386724|Pain
582395|NCT00386724|Neurostimulation
582396|NCT00386724|Leg Pain
582397|NCT00386724|Back Pain
582398|NCT00386711|suicide
582399|NCT00386711|depressed patients
582400|NCT00386711|primary care
582401|NCT00386698|Influenza,
582402|NCT00386698|improved vaccine,
582403|NCT00386698|influenza disease
582404|NCT00386698|elderly
582405|NCT00386685|Cancer
582406|NCT00386685|Breast
582407|NCT00386685|metastatic breast cancer
582408|NCT00386672|Calcium
582409|NCT00386672|Vitamin D
582410|NCT00386672|Weight Loss
582411|NCT00386672|Overweight
582412|NCT00386672|Obesity
582413|NCT00386672|Lite Orange Juice
582414|NCT00386646|Dry eye syndromes therapy
582415|NCT00386633|Vaccine
582416|NCT00386633|Safety
582417|NCT00386633|T-cell epitope
582418|NCT00386633|Acquired Immune Deficiency Syndrome Virus
582419|NCT00386633|HIV Preventive Vaccine
582420|NCT00386620|Breast Cancer
582421|NCT00386620|Cancer Control
582422|NCT00386620|Spousal Relationships
582423|NCT00386620|Questionnaire
582424|NCT00386620|Interview
582425|NCT00386620|Pain
582426|NCT00386607|Hypertension, aliskiren, valsartan, HCTZ, blood pressure
582427|NCT00386594|Barrett Esophagus
582428|NCT00386594|High grade dysplasia
582429|NCT00386594|Carcinoma in situ
582430|NCT00386594|825A
582431|NCT00386542|vaccination
582432|NCT00386542|influenza vaccine
582433|NCT00386542|jet injection
582434|NCT00386542|intradermal injection
582435|NCT00386542|infancy
582436|NCT00386542|children
582437|NCT00386542|dose-sparing
582438|NCT00386542|cutaneous vaccination
582439|NCT00386542|Dominican Republic
582440|NCT00386542|pandemic preparedness
582441|NCT00386542|jet injector
582442|NCT00386542|reduced dosage
582443|NCT00386542|immunogenicity
582444|NCT00386542|reactogenicity
582445|NCT00386542|safety
582446|NCT00386542|needle-free
582447|NCT00386542|immune response
582448|NCT00386542|hemagglutination inhibition
582449|NCT00386542|Infant
582450|NCT00386529|low dose aspirin
582451|NCT00386529|Hypertension
582452|NCT00386529|administration time dependent effect
582453|NCT00386516|cholangiocarcinoma
582454|NCT00386516|bile duct
582455|NCT00386516|biliary
582456|NCT00386516|intra-hepatic
582457|NCT00386516|extra-hepatic
582458|NCT00386516|gall bladder
582459|NCT00386516|cancer
582460|NCT00386516|carcinoma
582461|NCT00386516|metastatic
582462|NCT00386516|metastasis
582463|NCT00386516|advanced
582464|NCT00386516|recurrent
582465|NCT00386477|Povidone iodine
582466|NCT00386477|postoperative infection
582467|NCT00386477|presurgical cleansing
582468|NCT00386464|bipap
582469|NCT00386464|lou gehrigs disease
582470|NCT00386464|motor neuron disease
582471|NCT00386464|respiratory muscles
582472|NCT00386451|Intravenous chemotherapy
582473|NCT00386412|Cytomegalovirus infection
582474|NCT00386399|Advanced Pancreatic Cancer
582475|NCT00386399|Mutated BRCA2 Gene
582476|NCT00386399|Recurrent Pancreatic Cancer
582477|NCT00386386|hydration
582478|NCT00386386|prehospital
582479|NCT00386386|mass casualty incident
582480|NCT00386373|Chronic Myeloid Leukemia
582481|NCT00386373|CML
582482|NCT00386373|ALL
582483|NCT00386373|AML
582484|NCT00386373|Leukemia
582485|NCT00386373|Imatinib Mesylate
582486|NCT00386373|Gleevec
582487|NCT00386373|Philadelphia-Positive
582488|NCT00386373|Bone marrow transplant
582489|NCT00386373|BMT
582490|NCT00386373|Stem cell transplant
582491|NCT00386373|SCT
582492|NCT00386347|HIV
582493|NCT00386347|repeat dose
582494|NCT00386347|pharmacokinetics
582495|NCT00386347|bioavailability
582496|NCT00386347|single-dose
582497|NCT00386347|food effect
582498|NCT00386334|insomnia
582499|NCT00386334|chronic
582500|NCT00386334|primary
582501|NCT00386321|Zevalin
582502|NCT00386321|Zevalin plus CHOP
582503|NCT00386321|Diffuse large B-cell lymphoma
582504|NCT00386321|First line Diffuse large B-cell lymphoma
582505|NCT00386308|Heavy Menstrual Bleeding
582506|NCT00386308|Menorrhagia
582507|NCT00386282|Mifepristone
582508|NCT00386282|Misoprostol
582509|NCT00386282|Buccal administration
582510|NCT00386269|codeine phosphate analgesia
582511|NCT00386256|telehealth
582512|NCT00386256|telerehabilitation
582513|NCT00386256|deconditioning
582514|NCT00386256|exercise
582515|NCT00386243|analgesia
582516|NCT00386243|analgesics
582517|NCT00386243|cognitive behavioral therapy
582518|NCT00386243|Pain
582519|NCT00386243|self-management
582520|NCT00386243|stepped care
582521|NCT00386243|musculoskeletal pain
582522|NCT00386230|transmission
582523|NCT00386230|infant
582524|NCT00386230|HIV
582525|NCT00386230|pregnancy
582526|NCT00386230|HIV-1 infection
582527|NCT00386230|HIV Seronegativity
582528|NCT00386217|Cervical Cancer
582529|NCT00386217|Breast Cancer
582530|NCT00386217|Hodgkin's Disease
582531|NCT00386217|Non-Hodgkin's Lymphoma
582532|NCT00386217|Female Infertility
582533|NCT00386217|Telephone Survey
582534|NCT00386204|Q-switched Ruby laser
582535|NCT00386191|Platelet Aggregation Inhibitors
582536|NCT00386191|Ischemic cerebrovascular disease
582537|NCT00386178|vitamin E
582538|NCT00386178|gamma tocopherol
582539|NCT00386178|moderate to severe asthma
582540|NCT00386178|healthy subjects
582541|NCT00386152|Anemia
582542|NCT00386152|Cancer
582543|NCT00386152|Chemotherapy-Induced Anemia
582544|NCT00386152|Epoetin alfa
582545|NCT00386152|Darbepoetin alfa
582546|NCT00386139|Diastolic
582547|NCT00386139|systolic
582548|NCT00386139|hypertension
582549|NCT00386139|aliskiren
582550|NCT00386139|blood pressure
582551|NCT00386139|hydrochlorothiazide, HCTZ
582552|NCT00386126|Heart Failure
582553|NCT00386126|Anemia
582554|NCT00386126|Treatment
582555|NCT00386113|Influenza
582556|NCT00386113|improved vaccine
582557|NCT00386113|elderly
582558|NCT00386100|Fasting Plasma Glucose
582559|NCT00386100|Dual energy X ray absorptiometry (DXA)
582560|NCT00386100|Drug-naive
582561|NCT00386100|Type 2 diabetes mellitus
582562|NCT00386100|Bone Mineral Density
582563|NCT00386100|Hyperglycemia
582564|NCT00386100|HbA1c
582565|NCT00386087|Breast Cancer
582566|NCT00386087|Cancer of the Breast
582567|NCT00386074|NaFeEDTA
582568|NCT00386074|electrolytic iron
582569|NCT00386074|efficacy
582570|NCT00386074|whole maize flour
582571|NCT00386074|phytate
582572|NCT00386074|school-age children
582573|NCT00386074|controlled trial
582574|NCT00386074|Africa
582575|NCT00386061|Obesity
582576|NCT00386061|risk factors
582577|NCT00386048|Cognitive Behavioral Therapy
582578|NCT00386048|Pediatric Sickle Cell Disease
582579|NCT00386048|Pain Management
582580|NCT00386035|Treatment Experienced
582581|NCT00386022|Gonadotropin-releasing hormone
582582|NCT00386022|Estrogens
582583|NCT00386022|postmenopausal women
582584|NCT00386022|Pituitary hormones
582585|NCT00386009|Benign Prostatic Hyperplasia
582586|NCT00386009|Benign Prostatic Hypertrophy
582587|NCT00385996|Carcinoma,non-small cell lung
582588|NCT00385996|preoperative
582589|NCT00385996|Tarceva
582590|NCT00385996|Response rate
582591|NCT00385983|thyroidectomy
582592|NCT00385983|thyroid neoplasm
582593|NCT00385983|postoperative complications
582594|NCT00385983|cost effectiveness
582595|NCT00385957|Treatment Naive
582596|NCT00385931|Hypertension
582597|NCT00385931|high cholesterol
582598|NCT00385931|valsartan
582599|NCT00385931|simvastatin
582600|NCT00385918|Cardiovascular Fitness
582601|NCT00385918|Exercise
582602|NCT00385918|Gait
582603|NCT00385918|Spinal Cord Injury
582604|NCT00385918|Treadmill Training
582605|NCT00385892|Healthy volonteers
582606|NCT00385892|Abdominal binder
582607|NCT00385892|IAP
582608|NCT00385892|MAP
582609|NCT00385892|APP
582610|NCT00385866|Patient Navigator
582611|NCT00385866|Community health
582612|NCT00385866|Communication
582613|NCT00385853|PTK
582614|NCT00385853|temozolomide
582615|NCT00385853|glioblastoma
582616|NCT00385840|Influenza vaccine
582617|NCT00385840|Influenza
582618|NCT00385827|Cancer
582619|NCT00385827|Prostate
582620|NCT00385827|IL-6
582621|NCT00385827|Mitoxantrone
582622|NCT00385827|Metastatic prostate cancer
582623|NCT00385801|cocaine
582624|NCT00385801|dependence
582625|NCT00385801|risperidal
582626|NCT00385801|MRI
582627|NCT00385788|Hodgkin's Disease
582628|NCT00385788|Stem Cell Transplantation
582629|NCT00385788|Antithymocyte Globulin
582630|NCT00385788|Gemcitabine
582631|NCT00385788|Gemzar
582632|NCT00385788|Fludarabine
582633|NCT00385788|Fludarabine Phosphate
582634|NCT00385788|Melphalan
582635|NCT00385788|Allogeneic stem cell transplantation
582636|NCT00385788|AST
582637|NCT00385788|SCT
582638|NCT00385788|ATG
582639|NCT00385788|Thymoglobulin
582640|NCT00385775|Cancer
582641|NCT00385775|solid tumours
582642|NCT00385775|refractory
582643|NCT00385775|antisense
582644|NCT00385775|oligonucleotide
582645|NCT00385762|Human volunteers
582646|NCT00385749|Implanted cardioverter defibrillator
582647|NCT00385749|congestive heart failure
582648|NCT00385749|right ventricular lead placement
582649|NCT00385749|select site pacing
582650|NCT00385736|Moderate to Severe Ulcerative Colitis
582651|NCT00385736|Double-blind
582652|NCT00385736|Adalimumab
582653|NCT00385736|Induction of Clinical Remission
582654|NCT00385723|affect
582655|NCT00385723|inflammation
582656|NCT00385710|Progressive supranuclear palsy (PSP)
582657|NCT00385697|Randomized
582658|NCT00385697|Double Blind
582659|NCT00385697|Parallel Group
582660|NCT00385697|Controlled Clinical Trial
582661|NCT00385684|Agitation
582662|NCT00385684|Alzheimer Disease
582663|NCT00385684|Analgesics
582664|NCT00385684|Dementia
582665|NCT00385684|Narcotics
582666|NCT00385684|Opioid
582667|NCT00385684|Pain
582668|NCT00385684|Palliative Care
582669|NCT00385684|Psychomotor
582670|NCT00385684|Suffering, Physical
582671|NCT00385658|Dyslipidemia
582672|NCT00385658|metabolic syndrome
582673|NCT00385658|fluvastatin
582674|NCT00385658|fenofibrate
582675|NCT00385658|simvastatin
582676|NCT00385658|ezetimibe
582677|NCT00385645|HIV seronegativity
582678|NCT00385632|Treatment Experienced
582679|NCT00385606|prolonged continuous infusion
582680|NCT00385606|Cox-2 inhibitors
582681|NCT00385567|AIDS
582682|NCT00385567|Treatment Experienced
582683|NCT00385554|Microbicide
582684|NCT00385554|HIV prevention
582685|NCT00385554|Botswana
582686|NCT00385554|Preventing acquisition of HIV infection
582687|NCT00385554|HIV Seronegativity
582688|NCT00385541|pain
582689|NCT00385541|morphine
582690|NCT00385541|hydromorphone
582691|NCT00385541|nausea
582692|NCT00385541|vomiting
582693|NCT00385541|pruritis
582694|NCT00385528|Case complexity
582695|NCT00385528|INTERMED
582696|NCT00385528|Consultation liaison psychiatry
582697|NCT00385528|depression
582698|NCT00385502|toenail
582699|NCT00385502|fungus
582700|NCT00385502|onychomycosis
582701|NCT00385502|antifungal
582702|NCT00385502|anti-fungal
582703|NCT00385502|nail
582704|NCT00385476|Advanced Cancer
582705|NCT00385476|Medication Knowledge
582706|NCT00385476|Emergency Center
582707|NCT00385476|Questionnaire
582708|NCT00385476|Survey
582709|NCT00385463|Asthma
582710|NCT00385463|Rhinitis
582711|NCT00385463|Allergic Asthma
582712|NCT00385437|Driving safety
582713|NCT00385437|maintenance of wakefulness test
582714|NCT00385437|major depressive disorder
582715|NCT00385437|mirtazapine
582716|NCT00385398|tumors metastatic to brain
582717|NCT00385398|stage IV non-small cell lung cancer
582718|NCT00385372|low pseudoallergen diet
582719|NCT00385372|elimination diet
582720|NCT00385372|provocation diet
582721|NCT00385372|oral provocation
582722|NCT00385372|natural food ingredients
582723|NCT00385372|food additives
582724|NCT00385372|flavours
582725|NCT00385346|Expressive writing
582726|NCT00385346|Male infertility
582727|NCT00385333|Mitochondrion
582728|NCT00385333|Retina
582729|NCT00385333|Mitochondria
582730|NCT00385333|Metabolism
582731|NCT00385333|In Vivo Imaging
582732|NCT00385333|Age-Related Macular Degeneration
582733|NCT00385333|AMD
582734|NCT00385333|Diabetic Retinopathy
582735|NCT00385333|DR
582736|NCT00385333|Hippel-Lindau Disease
582737|NCT00385333|VHL
582738|NCT00385307|Depression
582739|NCT00385307|Clinical Trials
582740|NCT00385307|Major Depressive Disorder
582741|NCT00385294|Genetic
582742|NCT00385294|pain
582743|NCT00385294|obstetrical
582744|NCT00385281|proteomic profiling, influenza, vaccine, FluMist
582745|NCT00385268|cocaine
582746|NCT00385255|Immunogenicity,
582747|NCT00385255|Influenza
582748|NCT00385255|Co-administration,
582749|NCT00385255|Tdap,
582750|NCT00385242|coronary artery disease
582751|NCT00385242|left ventricular dysfunction
582752|NCT00385242|positron emission tomography
582753|NCT00385242|viable myocardium
582754|NCT00385242|revascularization
582755|NCT00385242|cost effectiveness
582756|NCT00385229|Asphyxia neonatorum
582757|NCT00385229|Birth Injury
582758|NCT00385229|Meconium Aspiration Syndrome
582759|NCT00385216|Third Molar
582760|NCT00385216|Pain
582761|NCT00385203|cancer
582762|NCT00385203|tumour
582763|NCT00385203|advanced cancer
582764|NCT00385203|Metastatic Gastro-Intestinal Stromal Tumours
582765|NCT00385203|gastro-intestinal cancer
582766|NCT00385203|RECENTIN
582767|NCT00385190|SAD
582768|NCT00385164|lung neoplasms
582769|NCT00385164|positron emissions tomography
582770|NCT00385164|radiotherapy planning
582771|NCT00385151|Post conditioning
582772|NCT00385138|Percutaneous Coronary Intervention (PCI)
582773|NCT00385138|ACS
582774|NCT00385125|relapsed
582775|NCT00385125|refractory
582776|NCT00385125|CD 20 positive
582777|NCT00385112|Cardiology
582778|NCT00385112|Echocardiograms
582779|NCT00385112|Surgery
582780|NCT00385112|Valve Disease
582781|NCT00385112|Heart Valve Disease
582782|NCT00385099|IBS
582783|NCT00385099|CRF1
582784|NCT00385099|stress
582785|NCT00385086|Sciatica
582786|NCT00385086|Pain
582787|NCT00385086|TNF-alpha
582788|NCT00385086|Discectomy
582789|NCT00385086|Fibrosis
582790|NCT00385086|Spine
582791|NCT00385047|malaria
582792|NCT00385047|vaccine
582793|NCT00385047|AMA-1 (apical membrane antigen-1)
582794|NCT00385047|efficacy
582795|NCT00385034|randomized controlled trial
582796|NCT00385034|RCT
582797|NCT00385034|partner violence
582798|NCT00385034|IPV
582799|NCT00385034|screening
582800|NCT00385034|family practice
582801|NCT00385034|computer
582802|NCT00385021|Advanced
582803|NCT00385021|metastatic
582804|NCT00385021|colorectal
582805|NCT00385021|cancer
582806|NCT00385021|Avastin
582807|NCT00385008|Combination product, sumatriptan succinate, naproxen sodium, absorption, pharmacokinetics, disintegration, gastric transit, gastric scintigraphy
582808|NCT00384995|Contrast Induced Nephropathy
582809|NCT00384995|Chronic Kidney Disease
582810|NCT00384995|Acute Renal Failure
582811|NCT00384995|End-stage Renal Disease
582812|NCT00384995|Cardiovascular diseases
582813|NCT00384995|Coronary catheterization
582814|NCT00384995|Percutaneous coronary intervention
582815|NCT00384995|Intra-arterial angiography
582816|NCT00384995|Bicarbonate
582817|NCT00384995|Saline
582818|NCT00384982|Bone marrow-derived stem cells
582819|NCT00384982|Acute myocardial infarction
582820|NCT00384969|RAD001
582821|NCT00384969|Sorafenib
582822|NCT00384969|Renal Cell Carcinoma
582823|NCT00384969|Metastatic
582824|NCT00384956|MDS either de novo or secondary, fitting any of the WHO classifications.
582825|NCT00384943|postpartum depression
582826|NCT00384943|exercise
582827|NCT00384891|Superficial urothelial cell carcinoma of bladder
582828|NCT00384891|NMIBC
582829|NCT00384891|Non Muscle Invasive Bladder Cancer
582830|NCT00384891|Hyperthermia
582831|NCT00384891|Bladder instillation
582832|NCT00384891|Mitomycin C
582833|NCT00384891|RITE
582834|NCT00384891|SHTC
582835|NCT00384891|Intravesical
582836|NCT00384865|Pulmonary Arterial Hypertension
582837|NCT00384852|Fracture
582838|NCT00384852|Humerus
582839|NCT00384826|Adenocarcinoma, Bronchiolo-Alveolar
582840|NCT00384787|HIV Seronegativity
582841|NCT00384787|Adenoviral Vector Vaccine
582842|NCT00384787|DNA Plasmid Vaccine
582843|NCT00384787|HIV Preventive Vaccine
582844|NCT00384774|Migraine
582845|NCT00384748|Cerebrovascular Accident
582846|NCT00384748|Rehabilitation
582847|NCT00384748|Telemedicine
582848|NCT00384735|bone tumor
582849|NCT00384735|soft tissue tumor
582850|NCT00384722|Left ventricular lead
582851|NCT00384722|Pacing
582852|NCT00384722|Heart Failure
582853|NCT00384709|Elderly
582854|NCT00384709|Hospitalization
582855|NCT00384709|Geriatrics
582856|NCT00384709|Mortality
582857|NCT00384709|Readmission
582858|NCT00384709|Length of Stay
582859|NCT00384696|Risk Perception
582860|NCT00384696|Smoking Cessation
582861|NCT00384696|Nicotine Replacement Therapy
582862|NCT00384696|Questionnaire
582863|NCT00384696|Nicotine
582864|NCT00384683|Endothelial Dysfunction
582865|NCT00384683|Endothelial Cells
582866|NCT00384683|Perioperative Outcome
582867|NCT00384683|Blood Sample
582868|NCT00384670|dengue
582869|NCT00384670|vaccine
582870|NCT00384657|chronic heart failure
582871|NCT00384657|chronic kidney disease
582872|NCT00384657|anemia
582873|NCT00384657|intravenous iron
582874|NCT00384644|heart failure
582875|NCT00384644|sepsis
582876|NCT00384644|septic shock
582877|NCT00384644|cardiogenic shock
582878|NCT00384631|Neovascular
582879|NCT00384631|Glaucoma
582880|NCT00384631|Bevacizumab
582881|NCT00384631|Avastin
582882|NCT00384631|Intravitreal
582883|NCT00384631|IOP
582884|NCT00384618|Kidney, Antioxidants, Statin, Carotid IMT
582885|NCT00384592|heartburn
582886|NCT00384592|reflux
582887|NCT00384592|proton pump inhibitor
582888|NCT00384592|GERD
582889|NCT00384592|GORD
582890|NCT00384579|back
582891|NCT00384579|pain
582892|NCT00384540|-Heart Transplant, Allograft Vasculopathy, Dobutamine Stress Echocardiography, Brain Natriuretic Peptide
582893|NCT00384540|Vasculopathy
582894|NCT00384527|Clostridium difficile
582895|NCT00384514|Coronary Artery disease with chronic stable angina
582896|NCT00384501|keratoconus
582897|NCT00384501|Intacs
582898|NCT00384488|Diabetes mellitus
582899|NCT00384488|Weight control
582900|NCT00384488|Healthy eating
582901|NCT00384488|Physical Activity
582902|NCT00384475|Seasonal Allergic Rhinitis
582903|NCT00384475|Ciclesonide
582904|NCT00384475|Hay Fever
582905|NCT00384475|SAR
582906|NCT00384462|Premature infants (32-35 weeks GA) <6 months of age at the start of the RSV season who are not receiving palivizumab and do not have CLD of prematurity
582907|NCT00384462|Respiratory Syncytial Viruses
582908|NCT00384449|Eales
582909|NCT00384436|Major Depressive Disorder
582910|NCT00384423|Alzheimer's Disease
582911|NCT00384423|AD
582912|NCT00384423|PRX-03140
582913|NCT00384423|Dementia
582914|NCT00384423|Epix
582915|NCT00384423|Predix
582916|NCT00384423|Cognition enhancing
582917|NCT00384410|Pain
582918|NCT00384410|Insomnia
582919|NCT00384410|Nabilone
582920|NCT00384397|Menactra vaccine
582921|NCT00384397|Meningococcal meningitis
582922|NCT00384397|Measles
582923|NCT00384397|Mumps
582924|NCT00384397|Rubella
582925|NCT00384397|Varicella virus
582926|NCT00384397|Haemophilus influenzae type b
582927|NCT00384397|Pneumococcal conjugate vaccine
582928|NCT00384384|Dialysis
582929|NCT00384384|Serum potassium
582930|NCT00384384|18b glycyrrhetinic acid
582931|NCT00384384|insulin sensitivity
582932|NCT00384371|back
582933|NCT00384371|pain
582934|NCT00384358|Fractures
582935|NCT00384345|bright light treatment
582936|NCT00384345|exercise
582937|NCT00384345|body fat index
582938|NCT00384345|mood
582939|NCT00384345|sleep
582940|NCT00384345|fatigue
582941|NCT00384332|Bipolar Depression
582942|NCT00384332|Weight gain bipolar medicine
582943|NCT00384332|side effects olanzapine
582944|NCT00384332|gastrointestinal hormones bipolar medicine
582945|NCT00384319|resuscitation
582946|NCT00384319|hypothermia
582947|NCT00384306|COPD
582948|NCT00384306|prednisolone
582949|NCT00384306|bone biopsy
582950|NCT00384306|tetracycline labelling
582951|NCT00383578|Type 2 diabetes
582952|NCT00383578|vildagliptin
582953|NCT00383578|hemoglobin A1c
582954|NCT00383578|metformin
582955|NCT00383539|Influenza
582956|NCT00383539|Orthomyxoviruses
582957|NCT00383539|Inactivated Split-virion influenza vaccine
582958|NCT00383539|Adults
582959|NCT00383526|Influenza
582960|NCT00383526|Orthomyxoviruses
582961|NCT00383526|Inactivated Split-virion influenza vaccine
582962|NCT00383526|elderly
582963|NCT00383513|Lupus
582964|NCT00383513|Antibody
582965|NCT00383513|B-Cell Immunotherapy
582966|NCT00384267|malaria, infants, preterm babies, neonates, Mali
582967|NCT00384254|Tobacco.
582968|NCT00384254|Cessation.
582969|NCT00384254|Dental patients.
582970|NCT00384254|Dentists.
582971|NCT00384254|Hygienists.
582972|NCT00384254|Dental assistants.
582973|NCT00384254|Health care providers.
582974|NCT00384254|Behavioral intervention.
582975|NCT00384254|Tobacco intervention.
582976|NCT00384254|Cigarettes.
582977|NCT00384254|Smokeless tobacco.
582978|NCT00384254|Smoking intervention.
582979|NCT00384241|Blood Pressure, High
582980|NCT00384241|Stress
582981|NCT00384241|Inflammation
582982|NCT00384228|Chronic Myelogenous Leukemia
582983|NCT00384228|Acute Lymphoblastic Leukemia
582984|NCT00384202|Tacrolimus
582985|NCT00384202|Liver Transplantation
582986|NCT00384189|Asthma
582987|NCT00384189|Ciclesonide
582988|NCT00384189|children
582989|NCT00384176|Metastatic Colorectal Cancer
582990|NCT00384176|RECENTIN
582991|NCT00384163|cardiac
582992|NCT00384163|adult
582993|NCT00384163|PVR
582994|NCT00384150|galiximab
582995|NCT00384150|antibody
582996|NCT00384150|refractory
582997|NCT00384150|follicular
582998|NCT00384150|relapsed
582999|NCT00384150|NHL
583000|NCT00384150|rituximab
583001|NCT00384150|retreatment
583002|NCT00384137|Tacrolimus
583003|NCT00384137|Kidney Transplantation
583004|NCT00384124|Bowens disease
583005|NCT00384124|Squamous cell carcinoma in situ of the skin
583006|NCT00384124|imiquimod
583007|NCT00384098|Psoriasis
583008|NCT00384072|postmenopausal
583009|NCT00384072|women
583010|NCT00384072|SERM
583011|NCT00384072|osteoporosis
583012|NCT00384033|MDD
583013|NCT00384033|Major Depressive Disorder
583014|NCT00384033|Depression
583015|NCT00384020|Major Depression Disorder
583016|NCT00384020|Antidepressant
583017|NCT00384020|Pharmacogenomics
583018|NCT00384020|Cytochrome P450
583019|NCT00384020|Serotonin Transporter
583020|NCT00384007|back pain
583021|NCT00384007|herniated disc
583022|NCT00384007|leg pain
583023|NCT00384007|pinched nerves
583024|NCT00384007|sciatica
583025|NCT00384007|radiculopathy
583026|NCT00383994|Chronic Lymphocytic Leukemia
583027|NCT00383994|CLL
583028|NCT00383994|Non-Hodgkin's Lymphoma
583029|NCT00383994|B-Cell Lymphoma
583030|NCT00383994|Lymphoma
583031|NCT00383994|granulocyte-macrophage colony-stimulating factor
583032|NCT00383994|Leukemia
583033|NCT00383994|NK Cells
583034|NCT00383994|Rituximab
583035|NCT00383994|GM-CSF
583036|NCT00383994|Non-myeloablative Allogeneic Stem Cell Transplantation
583037|NCT00383994|Stem Cell Transplant
583038|NCT00383981|malondialdehyde optoelectronic vitamin complex
583039|NCT00383942|pregnancy
583040|NCT00383942|induction of labor
583041|NCT00383929|Blood pressure reduction
583042|NCT00383929|combination therapy
583043|NCT00383929|candesartan cilexetil
583044|NCT00383929|hydrochlorothiazide
583045|NCT00383916|healthy
583046|NCT00383890|American Society of Anesthesiologists (ASA)
583047|NCT00383890|Mallampati Score
583048|NCT00383890|Ramsay Sedation Scale (RSS)
583049|NCT00383864|liver fibrosis
583050|NCT00383864|portal pressure
583051|NCT00383864|antiviral therapy
583052|NCT00383851|ATN-224
583053|NCT00383851|Temozolomide
583054|NCT00383851|Combination
583055|NCT00383851|Sequential
583056|NCT00383851|Anti-angiogenic
583057|NCT00383851|Copper
583058|NCT00383838|brief motivational intervention; teens; substance use
583059|NCT00383825|conjunctival autografts
583060|NCT00383825|amniotic membrane
583061|NCT00383825|indocyanine green angiography
583062|NCT00383825|pterygium surgery
583063|NCT00383812|Polypoidal choroidal vasculopathy
583064|NCT00383812|Intravitreal Bevacizumab
583065|NCT00383799|Ventricular tachycardia
583066|NCT00383786|PTSD
583067|NCT00383786|Substance P
583068|NCT00383786|Treatment Study
583069|NCT00383786|Placebo
583070|NCT00383786|Controlled
583071|NCT00383786|Post Traumatic Stress Disorder
583072|NCT00383773|retinal vein occlusion
583073|NCT00383773|rTPA
583074|NCT00383747|cognition
583075|NCT00383747|nicotine
583076|NCT00383747|schizophrenia
583077|NCT00383734|HIV-Associated Lipodystrophy Syndrome
583078|NCT00383734|polylactic acid
583079|NCT00383734|polyacrylamide gels
583080|NCT00383695|adenocarcinoma of the rectum
583081|NCT00383695|stage I rectal cancer
583082|NCT00383695|stage II rectal cancer
583083|NCT00383695|stage III rectal cancer
583084|NCT00383682|postamputation pain
583085|NCT00383682|phantom pain
583086|NCT00383682|stump pain
583087|NCT00383682|neuroma pain
583088|NCT00383682|opioid
583089|NCT00383682|mexiletine
583090|NCT00383669|HIV
583091|NCT00383669|AIDS
583092|NCT00383669|Disease Progression
583093|NCT00383669|Multivitamins
583094|NCT00383669|Anti-Retroviral Therapy
583095|NCT00383669|HAART
583096|NCT00383669|Tanzania
583097|NCT00383669|Africa
583098|NCT00383656|gonadotropin releasing hormone
583099|NCT00383656|GnRH deficiency
583100|NCT00383656|hypothalamic amenorrhea
583101|NCT00383656|hypogonadotropic hypogonadism
583102|NCT00383656|Kallman's syndrome
583103|NCT00383656|infertility
583104|NCT00383630|End Stage Heart Failure
583105|NCT00383630|LVAD
583106|NCT00383630|Bone Marrow Transplantation
583107|NCT00383630|Stem Cell Transplantation
583108|NCT00383617|pre-radiographic
583109|NCT00383617|screening
583110|NCT00383617|early diagnosis
583111|NCT00383461|tobacco use disorder
583112|NCT00383448|Stem cell transplantation
583113|NCT00383448|Inborn errors of metabolism
583114|NCT00383448|Adrenoleukodystrophy (ALD)
583115|NCT00383448|Metachromatic leukodystrophy (MLD)
583116|NCT00383448|Globoid cell leukodystrophy (GLD or Krabbe)
583117|NCT00383448|Tay Sachs
583118|NCT00383448|Sandhoff
583119|NCT00383448|Sanfilippo syndrome
583120|NCT00383448|Mucopolysaccharidosis III (MPS-III)
583121|NCT00383448|GM1 gangliosidosis
583122|NCT00383448|I-cell
583123|NCT00383448|mucolipidosis
583124|NCT00383409|breast
583125|NCT00383409|cancer
583126|NCT00383409|fatigue
583127|NCT00383409|multivitamins
583128|NCT00383357|Performance
583129|NCT00383357|Gait stability
583130|NCT00383357|sedative
583131|NCT00383357|hypnotic
583132|NCT00383357|quality of life
583133|NCT00383357|sleep disorder
583134|NCT00383357|wakefulness
583135|NCT00383357|sleeping pills
583136|NCT00383357|Cognitive function
583137|NCT00383344|Crohn Disease
583138|NCT00383344|Positron Emission Tomography
583139|NCT00383344|Colonoscopy
583140|NCT00383318|Neonate
583141|NCT00383318|Hyperbilirubinemia
583142|NCT00383318|Jaundice
583143|NCT00383318|G6PD Deficiency
583144|NCT00383318|Gilbert's Syndrome
583145|NCT00383305|neonatal
583146|NCT00383305|hypoxic
583147|NCT00383305|ischemic
583148|NCT00383305|encephalopathy
583149|NCT00383305|HIE
583150|NCT00383305|birth asphyxia
583151|NCT00383305|neonatal encephalopathy
583152|NCT00383305|Asphyxia Neonatorum
583153|NCT00383305|hypothermia, therapeutic
583154|NCT00383305|brain cooling
583155|NCT00383305|selective head cooling
583156|NCT00383279|recurrent cervical cancer
583157|NCT00383279|stage 0 cervical cancer
583158|NCT00383279|stage IA cervical cancer
583159|NCT00383279|stage IB cervical cancer
583160|NCT00383279|stage IIA cervical cancer
583161|NCT00383279|stage IIB cervical cancer
583162|NCT00383279|stage III cervical cancer
583163|NCT00383279|stage IVA cervical cancer
583164|NCT00383279|stage IVB cervical cancer
583165|NCT00383279|recurrent uterine sarcoma
583166|NCT00383279|stage I uterine sarcoma
583167|NCT00383279|stage II uterine sarcoma
583168|NCT00383279|stage III uterine sarcoma
583169|NCT00383279|stage IV uterine sarcoma
583170|NCT00383279|borderline ovarian surface epithelial-stromal tumor
583171|NCT00383279|ovarian sarcoma
583172|NCT00383279|ovarian stromal cancer
583173|NCT00383279|recurrent ovarian epithelial cancer
583174|NCT00383279|recurrent ovarian germ cell tumor
583175|NCT00383279|stage I ovarian epithelial cancer
583176|NCT00383279|stage I ovarian germ cell tumor
583177|NCT00383279|stage II ovarian epithelial cancer
583178|NCT00383279|stage II ovarian germ cell tumor
583179|NCT00383279|stage III ovarian epithelial cancer
583180|NCT00383279|stage III ovarian germ cell tumor
583181|NCT00383279|stage IV ovarian epithelial cancer
583182|NCT00383279|stage IV ovarian germ cell tumor
583183|NCT00383214|Lupus,
583184|NCT00383214|antibody,
583185|NCT00383214|B-cell immunotherapy
583186|NCT00383201|Contact Lens Care
583187|NCT00383188|Arthritis, Rheumatoid
583188|NCT00383175|Ocular Accommodation
583189|NCT00383175|Reading
583190|NCT00383162|Combination Product
583191|NCT00383162|naproxen sodium
583192|NCT00383162|sumatriptan succinate
583193|NCT00383162|short acting triptan
583194|NCT00383162|migraine, acute
583195|NCT00383162|Poor response
583196|NCT00383136|STEMI
583197|NCT00383136|Primary Angioplasty
583198|NCT00383136|Abciximab
583199|NCT00383136|Tirofiban
583200|NCT00383123|Fluarix
583201|NCT00383123|Influenza
583202|NCT00383110|Diabetes
583203|NCT00383110|Health Outcomes
583204|NCT00383110|Racial Preference
583205|NCT00383110|Clinical Trial
583206|NCT00383110|Ethnic Differences
583207|NCT00383097|CTLs
583208|NCT00383097|LMP1
583209|NCT00383097|LMP2
583210|NCT00383097|CYTOTOXIC T-LYMPHOCYTES
583211|NCT00383097|CD45
583212|NCT00383097|ANTIBODY
583213|NCT00383097|EBV-POSITIVE HODGKIN'S
583214|NCT00383097|NON-HODGKIN'S LYMPHOMA
583215|NCT00383084|Pain
583216|NCT00383084|Physical Activity
583217|NCT00383084|Fatigue
583218|NCT00383084|Lifestyle Activity
583219|NCT00383071|Apheresis
583220|NCT00383071|Avian Flu
583221|NCT00383071|Healthy Volunteers
583222|NCT00383071|Infectious Diseases
583223|NCT00383071|IVIG
583224|NCT00383071|Healthy Volunteer
583225|NCT00383071|HV
583226|NCT00383058|obesity
583227|NCT00383058|green tea
583228|NCT00383045|Buprenorphine
583229|NCT00383045|Naltrexone
583230|NCT00383045|HIV risk reduction behavior
583231|NCT00383045|Counseling
583232|NCT00383006|Psychotherapy, Group
583233|NCT00383006|Stress Disorders, Post-Traumatic
583234|NCT00383006|Ambulatory Care
583235|NCT00382993|migraine with or without aura
583236|NCT00382993|naproxen sodium
583237|NCT00382993|combination product
583238|NCT00382993|sumatriptan succinate
583239|NCT00382993|poor response
583240|NCT00382993|short acting triptan
583241|NCT00382993|migraine, acute
583242|NCT00382980|influenza, vaccine, A/H5N1, aluminum hydroxide, Vero cell
583243|NCT00382967|Parkinsonian Syndromes, Parkinsonism, DaTSCAN, SPECT, clinical management, quality of life, movement disorder
583244|NCT00382967|Clinically uncertain Parkinsonian Syndromes
583245|NCT00382954|Acute Myelogenous Leukemia
583246|NCT00382954|AML
583247|NCT00382954|Relapse
583248|NCT00382954|Elderly
583249|NCT00382954|Velcade
583250|NCT00382954|Idarubicin
583251|NCT00382954|Bortezomib
583252|NCT00382928|Randomized Controlled Trials
583253|NCT00382928|Defibrillators
583254|NCT00382928|Medical Devices
583255|NCT00382915|Smoking
583256|NCT00382915|Topography
583257|NCT00382915|Nicotine
583258|NCT00382902|Contact Lens Care
583259|NCT00382889|Anti-Asthmatic Agents
583260|NCT00382889|corticosteroids
583261|NCT00382889|symptom-driven
583262|NCT00382889|beclomethasone
583263|NCT00382889|salbutamol
583264|NCT00382876|apnea, hypoxia, car seat, car bed
583265|NCT00382863|heart failure
583266|NCT00382863|cardiac support
583267|NCT00382863|Paracor
583268|NCT00382863|HeartNet
583269|NCT00382863|PEERLESS-HF
583270|NCT00382850|Nissen fundoplication
583271|NCT00382850|gastroesophageal reflux
583272|NCT00382837|Lupus,
583273|NCT00382837|Antibody,
583274|NCT00382837|B-Cell immunotherapy
583275|NCT00382824|Progressive Supranuclear Palsy
583276|NCT00382824|Atypical Parkinsonism
583277|NCT00382824|CoQ10
583278|NCT00382811|Recurrent Ovarian Epithelial Cancer
583279|NCT00382811|Stage IV Ovarian Epithelial Cancer
583280|NCT00382811|Peritoneal Cavity Cancer
583281|NCT00382811|Stage III Ovarian Epithelial Cancer
583282|NCT00382785|online
583283|NCT00382785|support
583284|NCT00382785|breast cancer
583285|NCT00382772|HRV vaccine
583286|NCT00382772|Diarrhoea
583287|NCT00382772|Rotavirus
583288|NCT00382746|Congestive
583289|NCT00382746|Heart
583290|NCT00382746|Failure
583291|NCT00382746|CHF
583292|NCT00382733|Solid Tumors
583293|NCT00382707|repetitive transcranial magnetic stimulation
583294|NCT00382707|low frequency
583295|NCT00382707|frontal lobe epilepsy
583296|NCT00382707|brain excitability
583297|NCT00382707|electromyography
583298|NCT00382694|Myeloma
583299|NCT00382694|Induction therapy
583300|NCT00382694|High-dose melphalan
583301|NCT00382694|Autologous stem cell support
583302|NCT00382694|Fludarabine
583303|NCT00382694|Cyclophosphamide
583304|NCT00382694|Dexamethasone
583305|NCT00382694|Safety
583306|NCT00382694|Toxicity
583307|NCT00382681|Contact Lens Care
583308|NCT00382668|hepatically impaired
583309|NCT00382655|Prevention
583310|NCT00382655|Emergency Medical Services
583311|NCT00382655|Emergency Medical Technicians
583312|NCT00382642|alcoholism, alcohol disorder, drinking,alcohol
583313|NCT00382629|Multiple sclerosis
583314|NCT00382629|MS
583315|NCT00382629|Bayhill
583316|NCT00382629|BHT-3009
583317|NCT00382629|immunotherapy
583318|NCT00382616|behavioral problems
583319|NCT00382616|learning problems
583320|NCT00382616|inattentive
583321|NCT00382616|impulsive
583322|NCT00382616|hyperactive
583323|NCT00382616|children
583324|NCT00382616|phosphatidylserine
583325|NCT00382616|long-chain polyunsaturated fatty acid
583326|NCT00382616|eicosapentaenoic acid
583327|NCT00382616|docosahexaenoic acid
583328|NCT00382616|omega3:omega6 ratio
583329|NCT00382616|eicosapentaenoic acid:arachidonic acid ratio
583330|NCT00382616|Test of Variables of Attention
583331|NCT00382616|ADHD index scores
583332|NCT00382603|Contact Lens Care
583333|NCT00382590|Acute Myelogenous Leukemia
583334|NCT00382590|AML
583335|NCT00382590|Myelodysplastic Syndrome
583336|NCT00382590|Leukemia
583337|NCT00382590|MDS
583338|NCT00382590|Azacytidine
583339|NCT00382590|5-Azacytidine
583340|NCT00382590|5-aza
583341|NCT00382590|Vidaza
583342|NCT00382590|5-AZC
583343|NCT00382590|AZA-CR
583344|NCT00382590|Ladakamycin
583345|NCT00382590|Ara-C
583346|NCT00382590|Cytarabine
583347|NCT00382590|Cytosar
583348|NCT00382590|DepoCyt
583349|NCT00382590|Cytosine arabinosine hydrochloride
583350|NCT00382590|Valproic Acid
583351|NCT00382590|VPA
583352|NCT00382590|Depakene
583353|NCT00382564|Imaging
583354|NCT00382564|Arteriosclerosis
583355|NCT00382564|Hardening of the arteries
583356|NCT00382564|MRA
583357|NCT00382564|Narrowing of Vessels
583358|NCT00382564|Noninvasive Plaque Imaging
583359|NCT00382564|Atherosclerotic Disease
583360|NCT00382564|Plaque
583361|NCT00382564|Arteries
583362|NCT00382564|Diabetes
583363|NCT00382564|Hypertension
583364|NCT00382551|Alcohol
583365|NCT00382551|Red wine
583366|NCT00382551|Endothelial function
583367|NCT00382551|Flow-mediated vasodilation
583368|NCT00382551|Cardiovascular disease
583369|NCT00382538|mifepristone
583370|NCT00382538|induction
583371|NCT00382538|abortion
583372|NCT00382538|injection, intra-amniotic
583373|NCT00382525|Bradyarrhythmia
583374|NCT00382525|Atrial Fibrillation
583375|NCT00382525|Ventricular Tachycardia
583376|NCT00382525|Ventricular Fibrillation
583377|NCT00382525|Heart Failure
583378|NCT00382525|Pacemaker
583379|NCT00382525|Implantable Cardioverter Defibrillator
583380|NCT00382525|Cardiac Resynchronization Therapy
583381|NCT00382525|Loop recorder
583382|NCT00382525|Registry
583383|NCT00382512|Moderate Plaque Psoriasis
583384|NCT00382499|Intravenous Lidocaine
583385|NCT00382499|Lidocaine Infusion
583386|NCT00382499|Total Abdominal Hysterectomy
583387|NCT00382499|Analgesia
583388|NCT00382499|Anesthesia
583389|NCT00382499|Adjunct
583390|NCT00382486|Intestinal transplant
583391|NCT00382486|Bone marrow
583392|NCT00382486|Irradiation of allograft
583393|NCT00382473|Diabetes Mellitus, Type 2
583394|NCT00382473|Overweight
583395|NCT00382473|Fatty acid oxidation
583396|NCT00382473|Mitochondria
583397|NCT00382473|Exercise
583398|NCT00382447|breath actuated nebulizer
583399|NCT00382447|nebulizer
583400|NCT00382434|emergency pharmacist
583401|NCT00382434|emergency medicine
583402|NCT00382434|emergency department
583403|NCT00382434|medical error
583404|NCT00382434|adverse event
583405|NCT00382434|pharmacist
583406|NCT00382434|patient safety
583407|NCT00382421|Myocardial Ischemia
583408|NCT00382421|Randomized Controlled Trials
583409|NCT00382421|Drug Therapy
583410|NCT00382408|Acute respiratory disease prevention
583411|NCT00382408|Adenovirus
583412|NCT00382395|Glaucoma shunt
583413|NCT00382395|Ocular implant
583414|NCT00382395|Gold
583415|NCT00382395|trabeculectomy
583416|NCT00382382|Autism
583417|NCT00382382|Asperger Syndrome
583418|NCT00382382|Restricted repetitive behavior
583419|NCT00382382|Stereotyped patterns of behavior
583420|NCT00382382|Typically Developing children
583421|NCT00382382|Human Volunteers
583422|NCT00382369|familial vocal cord paralysis
583423|NCT00382369|genetic screening
583424|NCT00382356|Benign Prostatic Enlargement
583425|NCT00382356|Benign Prostatic Hypertrophy
583426|NCT00382356|Dutasteride
583427|NCT00382356|5-alpha reductase inhibitors
583428|NCT00382356|Hormonal therapy
583429|NCT00382343|Prevention
583430|NCT00382343|Pyelonephritis
583431|NCT00382343|Renal scars
583432|NCT00382343|Vesico-ureteral reflux
583433|NCT00382343|Dimercaptosuccinic acid renal scan (DMSA)
583434|NCT00382330|Vulva
583435|NCT00382317|MSCT indications
583436|NCT00382304|Clostridium difficile-associated diarrhea
583437|NCT00382304|C. difficile
583438|NCT00382304|CDAD
583439|NCT00382304|Clostridium difficile
583440|NCT00382304|Clostridium difficile Disease
583441|NCT00382304|Clostridium Enterocolitis
583442|NCT00382304|Antibiotic-Associated Colitis
583443|NCT00382304|Infectious diarrhea
583444|NCT00382291|OCD
583445|NCT00382291|Antidepressive Agents, Second-Generation
583446|NCT00382291|Placebos
583447|NCT00382291|Cognitive Behavior Therapy
583448|NCT00382291|Child Psychiatry
583449|NCT00382291|Activation Syndrome
583450|NCT00382291|Psychometrics
583451|NCT00382278|Stem cell
583452|NCT00382278|Liver cirrhosis
583453|NCT00382278|Cellular therapy
583454|NCT00382278|Autologous
583455|NCT00382278|Bone marrow
583456|NCT00382265|urolithiasis
583457|NCT00382265|renal colic
583458|NCT00382265|kidney stones
583459|NCT00382265|urinary stone disease
583460|NCT00382252|unspecified adult solid tumor, protocol specific
583461|NCT00382252|lung metastases
583462|NCT00382239|diabetes
583463|NCT00382239|exenatide
583464|NCT00382239|LY2148568
583465|NCT00382239|Lilly
583466|NCT00382239|Amylin
583467|NCT00382239|Japan
583468|NCT00382226|Glaucoma
583469|NCT00382200|de novo myelodysplastic syndromes
583470|NCT00382200|previously treated myelodysplastic syndromes
583471|NCT00382187|influenza
583472|NCT00382187|pandemic influenza
583473|NCT00382187|influenza vaccine
583474|NCT00382187|adjuvanted influenza vaccine
583475|NCT00382187|H5N1 influenza antigen
583476|NCT00382187|MF59
583477|NCT00382187|Pandemic influenza disease
583478|NCT00382174|pressure ulcers
583479|NCT00382174|cutaneous wound- healing
583480|NCT00382174|chronic wound-healing
583481|NCT00382174|Thymosin Beta 4
583482|NCT00382174|laminin-5
583483|NCT00382161|impotence
583484|NCT00382161|erectile dysfunction
583485|NCT00382161|cardiovascular risk factor
583486|NCT00382161|statin
583487|NCT00382148|TOPS
583488|NCT00382148|Peanut allergy
583489|NCT00382148|Peanut-induced allergy
583490|NCT00382148|Allergy
583491|NCT00382135|Impotence
583492|NCT00382135|erectile dysfunction
583493|NCT00382135|semen
583494|NCT00382135|sperm
583495|NCT00382135|Healthy male volunteers
583496|NCT00382135|men with mild erectile dysfunction
583497|NCT00382122|Glaucoma
583498|NCT00382122|Ocular hypertension
583499|NCT00382122|Dry eye
583500|NCT00382122|Ocular surface disease
583501|NCT00382096|Type 2 diabetes
583502|NCT00382096|vildagliptin
583503|NCT00382096|metformin
583504|NCT00382096|hemoglobin A1c
583505|NCT00382083|Mammogram
583506|NCT00382083|Pain
583507|NCT00382083|Discomfort
583508|NCT00382083|Breast
583509|NCT00382083|Pre-medication
583510|NCT00382070|stage I breast cancer
583511|NCT00382070|stage II breast cancer
583512|NCT00382070|stage IIIA breast cancer
583513|NCT00382057|Testosterone
583514|NCT00382057|Insulin resistance
583515|NCT00382057|Insulin sensitivity
583516|NCT00382057|Metabolic disorders
583517|NCT00382044|Kidney Failure, Chronic
583518|NCT00382044|Dialysis
583519|NCT00382044|Anemia
583520|NCT00382044|epoetin
583521|NCT00382018|recurrent breast cancer
583522|NCT00382018|stage IV breast cancer
583523|NCT00381992|sexual risk behavior
583524|NCT00381992|diabetes mellitus
583525|NCT00381992|hypertension
583526|NCT00381992|obesity
583527|NCT00381992|human immunodeficiency virus
583528|NCT00381992|hyperlipidemia
583529|NCT00381992|chlamydia
583530|NCT00381979|Depression
583531|NCT00381979|Anxiety
583532|NCT00381979|Adolescents
583533|NCT00381979|Treatment
583534|NCT00381979|Supportive Expressive Therapy
583535|NCT00381966|Prostate Cancer
583536|NCT00381966|Brachytherapy
583537|NCT00381927|Breast Cancer Risk
583538|NCT00381927|Counseling
583539|NCT00381927|Prevention
583540|NCT00381927|Anxiety
583541|NCT00381927|BRCA1 mutation
583542|NCT00381927|BRCA2 mutation
583543|NCT00381927|Tamoxifen
583544|NCT00381914|Infants
583545|NCT00381914|Vitamin D
583546|NCT00381914|Dose-response
583547|NCT00381901|stage II breast cancer
583548|NCT00381901|stage IIIA breast cancer
583549|NCT00381901|stage IIIB breast cancer
583550|NCT00381901|stage IA breast cancer
583551|NCT00381901|stage IB breast cancer
583552|NCT00381901|recurrent breast cancer
583553|NCT00381901|stage IIIC breast cancer
583554|NCT00381888|thromboembolism
583555|NCT00381888|cervical cancer
583556|NCT00381888|endometrial cancer
583557|NCT00381888|ovarian epithelial cancer
583558|NCT00381888|ovarian germ cell tumor
583559|NCT00381888|borderline ovarian surface epithelial-stromal tumor
583560|NCT00381888|ovarian sarcoma
583561|NCT00381888|ovarian stromal cancer
583562|NCT00381888|uterine sarcoma
583563|NCT00381888|vaginal cancer
583564|NCT00381888|vulvar cancer
583565|NCT00381888|fallopian tube cancer
583566|NCT00381875|HIV infection
583567|NCT00381862|nausea and vomiting
583568|NCT00381862|recurrent colon cancer
583569|NCT00381862|stage IV colon cancer
583570|NCT00381862|recurrent rectal cancer
583571|NCT00381862|stage IV rectal cancer
583572|NCT00381849|Cystone
583573|NCT00381849|Uricare
583574|NCT00381849|Computerized tomography
583575|NCT00381849|Kidney calculi
583576|NCT00381849|Supersaturation
583577|NCT00381849|Nephrolithiasis
583578|NCT00381849|Quantitative CT
583579|NCT00381836|Prostate Cancer
583580|NCT00381836|Anemia
583581|NCT00381836|Blood transfusion
583582|NCT00381836|Cancer
583583|NCT00381836|Critical illness
583584|NCT00381836|Drug efficacy
583585|NCT00381836|Drug safety
583586|NCT00381836|Drug tolerability
583587|NCT00381836|Erythropoietin
583588|NCT00381836|Fatigue
583589|NCT00381836|Hemoglobin
583590|NCT00381836|Human
583591|NCT00381836|Male
583592|NCT00381836|Multicenter study
583593|NCT00381836|Quality of life
583594|NCT00381836|Questionnaire
583595|NCT00381836|Randomized controlled trial
583596|NCT00381836|Recombinant erythropoietin
583597|NCT00381823|Pregnant women
583598|NCT00381823|Intervention Studies
583599|NCT00381823|African Americans
583600|NCT00381823|Infant Mortality
583601|NCT00381823|Environmental Tobacco Smoke Pollution
583602|NCT00381823|Depression
583603|NCT00381823|Partner Abuse
583604|NCT00381823|Tobacco Smoke
583605|NCT00381810|Rituxan
583606|NCT00381810|SLE
583607|NCT00381810|Lupus
583608|NCT00381784|YMSM
583609|NCT00381784|HIV/AIDS
583610|NCT00381784|Condom use
583611|NCT00381784|Drug users
583612|NCT00381784|Minority women
583613|NCT00381771|Globus Pharyngeus
583614|NCT00381771|Xerostomia
583615|NCT00381771|Salivary Hypofunction
583616|NCT00381771|Pharyngoxerosis
583617|NCT00381758|ADHD
583618|NCT00381758|Methylphenidate
583619|NCT00381758|Metadate CD
583620|NCT00381758|Concerta
583621|NCT00381758|COMACS
583622|NCT00381758|Attention Deficit Hyperactivity Disorder (ADHD)
583623|NCT00381732|Impotence
583624|NCT00381732|erectile dysfunction
583625|NCT00381706|squamous cell carcinoma of the esophagus
583626|NCT00381706|adenocarcinoma of the esophagus
583627|NCT00381706|stage IV esophageal cancer
583628|NCT00381706|recurrent esophageal cancer
583629|NCT00381693|primary myelofibrosis
583630|NCT00381693|polycythemia vera
583631|NCT00381693|essential thrombocythemia
583632|NCT00381693|secondary myelofibrosis
583633|NCT00381667|safety
583634|NCT00381667|GW642444M
583635|NCT00381667|Single Dose
583636|NCT00381667|pharmacodynamics
583637|NCT00381667|pharmacokinetics
583638|NCT00381667|GW642444H
583639|NCT00381667|tolerability
583640|NCT00381654|Solid Tumors
583641|NCT00381654|Tyrosine Kinases
583642|NCT00381628|Anatomy
583643|NCT00381628|cells
583644|NCT00381628|epithelial cells
583645|NCT00381628|blood cells
583646|NCT00381628|cystic fibrosis
583647|NCT00381628|equipment and supplies
583648|NCT00381628|disposable equipment
583649|NCT00381628|reagent kits
583650|NCT00381615|Meningococcal disease
583651|NCT00381615|prevention
583652|NCT00381615|vaccination
583653|NCT00381602|End stage renal disease
583654|NCT00381602|Hemodialysis
583655|NCT00381602|Malnutrition
583656|NCT00381602|End stage renal disease (ESRD)
583657|NCT00381589|clozapine-induced hypersalivation
583658|NCT00381576|Resistance training
583659|NCT00381576|Strength training
583660|NCT00381576|Training adaptations
583661|NCT00381576|CNS
583662|NCT00381563|Bracing
583663|NCT00381563|Patellofemoral
583664|NCT00381563|Osteoarthritis
583665|NCT00381537|childhood epilepsy
583666|NCT00381537|Active childhood epilepsy
583667|NCT00381524|human immunodeficiency virus
583668|NCT00381524|behavior change
583669|NCT00381511|pulmonary embolism,
583670|NCT00381511|deferred diagnosis,
583671|NCT00381511|protective anticoagulation
583672|NCT00381511|anticoagulants
583673|NCT00381472|Parkinson's Disease
583674|NCT00381472|Dyskinesia
583675|NCT00381472|Adjunctive Therapy with L-dopa
583676|NCT00381446|corneal staining
583677|NCT00381446|contact lens care
583678|NCT00381446|multipurpose solution
583679|NCT00381433|HCV
583680|NCT00381433|Hepatitis C virus
583681|NCT00381407|ADHD
583682|NCT00381407|Organizational Skills
583683|NCT00381407|Contingency Management
583684|NCT00381394|amphotericin B
583685|NCT00381394|safety
583686|NCT00381394|tolerability and pharmacokinetics of oral sitamaquine
583687|NCT00381394|Visceral leishmaniasis
583688|NCT00381381|Alzheimer's disease
583689|NCT00381368|breast cancer
583690|NCT00381368|skeletal metastases
583691|NCT00381368|bisphosphonate therapy
583692|NCT00381368|Breast cancer with painful skeletal metastases
583693|NCT00381355|asthma
583694|NCT00381355|children
583695|NCT00381355|written action plan
583696|NCT00381355|education
583697|NCT00381355|guided self-management
583698|NCT00381355|efficacy
583699|NCT00381355|compliance
583700|NCT00381355|b2-agonists
583701|NCT00381355|inhaled corticosteroids
583702|NCT00381355|oral steroids
583703|NCT00381355|relapse
583704|NCT00381355|randomised controlled trial
583705|NCT00381355|emergency department
583706|NCT00381342|diabetes
583707|NCT00381342|exenatide
583708|NCT00381342|Amylin
583709|NCT00381342|Lilly
583710|NCT00381342|monotherapy
583711|NCT00381329|Motivational Interviewing
583712|NCT00381329|Structured Brief Advice
583713|NCT00381329|Adolescent Smoking
583714|NCT00381329|Behavioral Intervention
583715|NCT00381329|Smoking
583716|NCT00381329|Primary Care
583717|NCT00381329|Tobacco
583718|NCT00381303|HIV
583719|NCT00381303|AIDS
583720|NCT00381303|Immunodeficiency Virus, Human
583721|NCT00381303|Females
583722|NCT00381303|Women
583723|NCT00381303|PREZISTA
583724|NCT00381303|darunavir
583725|NCT00381303|TMC114
583726|NCT00381303|Protease Inhibitor
583727|NCT00381290|Arthritis
583728|NCT00381290|Arthritis, Degenerative
583729|NCT00381290|Knee Health
583730|NCT00381290|Obesity
583731|NCT00381290|Overweight
583732|NCT00381290|Osteoarthritis
583733|NCT00381290|Weight Loss
583734|NCT00381290|Diet
583735|NCT00381290|Exercise
583736|NCT00381290|Knee Pain
583737|NCT00381277|nephrolithiasis
583738|NCT00381277|citrate
583739|NCT00381277|oxalate
583740|NCT00381251|vaginal atrophy
583741|NCT00381251|postmenopausal osteoporosis
583742|NCT00381251|menopause
583743|NCT00381251|hot flashes
583744|NCT00381238|Alzheimer's Disease
583745|NCT00381238|Rosiglitazone
583746|NCT00381225|radio-frequency
583747|NCT00381225|ablation
583748|NCT00381225|ultra-sound
583749|NCT00381225|guidance
583750|NCT00381225|papillary
583751|NCT00381225|thyroid
583752|NCT00381225|cancer
583753|NCT00381212|Immunotherapeutic injection
583754|NCT00381199|fibromyalgia
583755|NCT00381199|cannabinoid
583756|NCT00381199|chronic pain
583757|NCT00381199|sleep
583758|NCT00381199|insomnia
583759|NCT00381199|diffuse widespread pain
583760|NCT00381199|antidepressant
583761|NCT00381186|impaired glucose tolerance
583762|NCT00381186|type 2 diabetes
583763|NCT00381173|MGI PHARMA
583764|NCT00381173|ZYC3-002
583765|NCT00381173|ZYC300
583766|NCT00381173|plasmid DNA
583767|NCT00381173|cyclophosphamide
583768|NCT00381173|Cytoxan
583769|NCT00381173|advanced breast cancer
583770|NCT00381173|advanced ovarian cancer
583771|NCT00381173|hormone refractory prostate cancer
583772|NCT00381173|advanced colon cancer
583773|NCT00381173|advanced renal cancer
583774|NCT00381173|advanced stage malignancies
583775|NCT00381173|immune therapy
583776|NCT00381173|gene therapy
583777|NCT00381173|biologic therapy
583778|NCT00381173|T-regulatory cells
583779|NCT00381173|cancer vaccine
583780|NCT00381173|vaccine
583781|NCT00381173|Advanced stage malignancies-ovary, breast, colon, prostate
583782|NCT00381160|weight loss
583783|NCT00381160|obesity
583784|NCT00381160|sugar-sweetened beverages
583785|NCT00381160|diet
583786|NCT00381160|adolescence
583787|NCT00381134|double-blind
583788|NCT00381134|placebo-controlled
583789|NCT00381134|nephropathy
583790|NCT00381134|blood pressure
583791|NCT00381134|urine albumin to creatinine ratio
583792|NCT00381134|placebo
583793|NCT00381121|Tissue Biobank
583794|NCT00381121|molecular markers
583795|NCT00381121|molecular pathways
583796|NCT00381108|BPH
583797|NCT00381082|Pediculus
583798|NCT00381082|capitis
583799|NCT00381082|lice
583800|NCT00381069|Recreation Centers
583801|NCT00381069|Families
583802|NCT00381069|Obesity Prevention
583803|NCT00381056|labor and delivery care
583804|NCT00381056|teamwork training
583805|NCT00381056|crew resource management
583806|NCT00381056|cluster-randomized trial
583807|NCT00381043|Alcohol Dependence
583808|NCT00381043|Family Medicine Setting
583809|NCT00381043|University of North Carolina at Chapel Hill
583810|NCT00381030|beta-Adrenergic Blockers
583811|NCT00381030|Disease Management
583812|NCT00381004|Chronic Lymphocytic Leukemia
583813|NCT00381004|Leukemia
583814|NCT00381004|Cyclophosphamide
583815|NCT00381004|Fludarabine
583816|NCT00381004|Sargramostim
583817|NCT00381004|Rituximab
583818|NCT00381004|GM-CSF
583819|NCT00381004|FCR
583820|NCT00380978|labor pain
583821|NCT00380978|cesarean section
583822|NCT00380978|epidural analgesia
583823|NCT00380978|opioid analgesics
583824|NCT00380978|local anesthetics
583825|NCT00380978|labor induced
583826|NCT00380965|Chemotherapy-induced
583827|NCT00380965|neuropathy
583828|NCT00380965|cancer
583829|NCT00380952|IDC
583830|NCT00380952|DCIS
583831|NCT00380952|ILC
583832|NCT00380926|polyunsatturated fatty acids
583833|NCT00380926|nutrition
583834|NCT00380926|low-dose allergen challenge
583835|NCT00380926|exhaled nitric oxide
583836|NCT00380887|bioavailability
583837|NCT00380887|bioequivalence
583838|NCT00380887|marketed product
583839|NCT00380887|Premarin
583840|NCT00380887|Medroxyprogesterone acetate
583841|NCT00380887|MPA
583842|NCT00380887|Postmenopausal
583843|NCT00380887|vasomotor symptoms
583844|NCT00380874|Pain
583845|NCT00380874|chemotherapy
583846|NCT00380861|Total Knee Replacement
583847|NCT00380861|Flexion
583848|NCT00380861|Range of Motion
583849|NCT00380861|Activities of Daily Living
583850|NCT00380861|Implant design
583851|NCT00380861|Subject Satisfaction
583852|NCT00380861|Non-inflammatory arthritis
583853|NCT00380848|sleep apnea
583854|NCT00380848|end stage renal disease
583855|NCT00380848|hemodiafiltration
583856|NCT00380835|metastatic breast cancer
583857|NCT00380835|amrubicin
583858|NCT00380822|alpa-glucosidase inhibitor
583859|NCT00380796|Chronic Obstructive Pulmonary Disease
583860|NCT00380796|COPD
583861|NCT00380770|HIV
583862|NCT00380770|AIDS
583863|NCT00380770|Kaposi's sarcoma
583864|NCT00380770|Human herpesvirus 8
583865|NCT00380757|cardiac arrest
583866|NCT00380757|CPR
583867|NCT00380757|resuscitation
583868|NCT00380757|fatigue
583869|NCT00380757|quality
583870|NCT00380731|Social Anxiety Disorder
583871|NCT00380731|Magnetic Resonance Imaging
583872|NCT00380731|Cognitive Behavior Therapy
583873|NCT00380640|Pediatrics
583874|NCT00380640|Epidermolysis Bullosa
583875|NCT00380640|Trimethoprim
583876|NCT00380640|Wound Healing
583877|NCT00380614|Acute Hepatitis B, Lamivudine
583878|NCT00380575|hyponatremia
583879|NCT00380575|hypervolemic
583880|NCT00380575|euvolemic
583881|NCT00380575|vasopressins
583882|NCT00380575|YM087
583883|NCT00380562|Quality of life
583884|NCT00380562|Cognitive Functioning
583885|NCT00380562|Activities of Daily Living
583886|NCT00380562|Disability prevention
583887|NCT00380549|osteoarthritis, hip replacement
583888|NCT00380536|Peer-led Education
583889|NCT00380510|Family Physicians
583890|NCT00380510|Adolescents
583891|NCT00380510|Preventive Care
583892|NCT00380510|Health Behavior
583893|NCT00380497|Pediatrics
583894|NCT00380497|Colonoscopy
583895|NCT00380497|Bowel cleanout
583896|NCT00380497|Poly-Ethylene Glycol
583897|NCT00380497|Pico-Salax
583898|NCT00380471|bath PUVA
583899|NCT00380458|Obstructive
583900|NCT00380458|Sleep
583901|NCT00380458|Apnea
583902|NCT00380458|Pain
583903|NCT00380458|UPPP
583904|NCT00380458|Tonsillectomy
583905|NCT00380458|Narcotics
583906|NCT00380445|Vildagliptin, Type 2 diabetes
583907|NCT00380419|Pregnancy
583908|NCT00380419|Postpartum Depression
583909|NCT00380406|Gonadotropin releasing hormone agonist
583910|NCT00380406|GnRH
583911|NCT00380406|Fertility
583912|NCT00380406|Fertility preservation
583913|NCT00380406|Oncology
583914|NCT00380406|Cancer
583915|NCT00380406|Chemotherapy
583916|NCT00380393|RTS
583917|NCT00380393|S/AS01
583918|NCT00380393|Malaria
583919|NCT00380393|Plasmodium
583920|NCT00380393|Falciparum
583921|NCT00380380|Vildagliptin, type 2 diabetes, gastric emptying
583922|NCT00380354|allergen
583923|NCT00380354|methacholine
583924|NCT00380354|GSK256066
583925|NCT00380354|mild asthmatics
583926|NCT00380354|repeat dose
583927|NCT00380354|challenge
583928|NCT00380354|late asthmatic response
583929|NCT00380328|Pharmacokinetic
583930|NCT00380328|healthy subjects
583931|NCT00380315|Cough
583932|NCT00380315|Chronic bronchitis
583933|NCT00380315|PNDs
583934|NCT00380315|Post Nasal Drip syndrome
583935|NCT00380315|GERD
583936|NCT00380315|gastroesophageal reflux disease
583937|NCT00380315|bronchiectasis
583938|NCT00380302|Alzheimer's disease
583939|NCT00380302|symptomatic
583940|NCT00380302|cognition
583941|NCT00380289|Essential hypertension
583942|NCT00380289|Glucose metabolism
583943|NCT00380289|Thiazides
583944|NCT00380289|Beta blockers
583945|NCT00380276|Alzheimer's
583946|NCT00380276|Dementia
583947|NCT00380276|Dementia of Alzheimer Type
583948|NCT00380237|Bird Flu
583949|NCT00380237|Avian Flu
583950|NCT00380224|schizophrenia
583951|NCT00380211|Thimerosal reduced content
583952|NCT00380211|Immunogenicity, safety, reactogenicity
583953|NCT00380211|Young and elderly adults
583954|NCT00380211|Influenza vaccine
583955|NCT00380185|Peripheral Arterial Disease
583956|NCT00380185|Atherosclerosis
583957|NCT00380172|AMD
583958|NCT00380172|Macular Degeneration
583959|NCT00380172|Retinal Degeneration
583960|NCT00380159|Extension study to ACH443-014A
583961|NCT00380146|Malaria
583962|NCT00380146|Intermittent presumptive treatment
583963|NCT00380146|IPT
583964|NCT00380146|Pharmacokinetic
583965|NCT00380146|Efficacy
583966|NCT00380146|Gametocyte
583967|NCT00380146|Molecular markers
583968|NCT00380133|COPD SB-681323 prednisolone biomarkers
583969|NCT00380107|Minor surgery
583970|NCT00380107|Volume optimization
583971|NCT00380107|Volume deficit
583972|NCT00380107|Epidural anesthesia
583973|NCT00380094|ACS
583974|NCT00380094|NSTEMI
583975|NCT00380094|Myeloperoxidase
583976|NCT00380094|nonST segment elevation myocardial infarction
583977|NCT00380081|Insomnia
583978|NCT00380055|Cancer Screening
583979|NCT00380055|Navigators
583980|NCT00380055|Community Outreach
583981|NCT00380055|Behavioral Change
583982|NCT00380055|Access
583983|NCT00380042|Cortical Electrical Stimulation
583984|NCT00380042|Treatment Resistant Depression
583985|NCT00380042|Major Depressive Disorder
583986|NCT00380029|stage II bladder cancer
583987|NCT00380029|transitional cell carcinoma of the bladder
583988|NCT00380016|Angioplasty
583989|NCT00380016|Stent
583990|NCT00380016|Coronary Artery Disease
583991|NCT00380016|Peripheral Artery Disease
583992|NCT00380016|Percutaneous Coronary Intervention
583993|NCT00380016|CAD
583994|NCT00380016|PAD
583995|NCT00380016|Cardiovascular Disease
583996|NCT00379990|iNOS
583997|NCT00379990|Exhaled NO
583998|NCT00379990|Rheumatoid arthritis
583999|NCT00379938|Parvovirus B-19, Parvoviridae, vaccine
584000|NCT00379925|Physical Activity
584001|NCT00379925|Exercise
584002|NCT00379925|Dietary Habits
584003|NCT00379899|calcification
584004|NCT00379899|vascular calcification
584005|NCT00379899|coronary vascular calcification
584006|NCT00379899|chronic kidney disease
584007|NCT00379899|end stage renal disease
584008|NCT00379899|dialysis
584009|NCT00379886|ECT
584010|NCT00379886|Depression
584011|NCT00379886|Anesthiticum
584012|NCT00379886|Propofol
584013|NCT00379886|Thiopental
584014|NCT00378859|Children
584015|NCT00378859|Milk
584016|NCT00378859|Meat
584017|NCT00378859|Animal Protein
584018|NCT00378859|Growth Factors
584019|NCT00378859|IGF-I
584020|NCT00378859|IGFBP-3
584021|NCT00378859|Insulin
584022|NCT00378846|fever, sweats, and hot flashes
584023|NCT00378833|Primary Hypercholesterolemia or Mixed Hyperlipidemia
584024|NCT00379847|hyponatremia
584025|NCT00379847|hypervolemic
584026|NCT00379847|euvolemic
584027|NCT00379847|treatment outcomes
584028|NCT00379847|YM087
584029|NCT00379834|glaucoma
584030|NCT00379834|diurnal
584031|NCT00379834|intraocular pressure
584032|NCT00379821|chloroquine, malaria, Plasmodium falciparum, Malawi, children
584033|NCT00379808|coronary heart disease
584034|NCT00379808|montelukast
584035|NCT00379808|inflammation
584036|NCT00379795|CNV
584037|NCT00379795|Lucentis
584038|NCT00379795|AMD
584039|NCT00379795|Age-related macular degeneration
584040|NCT00379795|RVO
584041|NCT00379769|diabetes
584042|NCT00379769|CV outcomes
584043|NCT00379769|rosiglitazone
584044|NCT00379769|Type II diabetes
584045|NCT00379769|sulfonylurea
584046|NCT00379769|RECORD
584047|NCT00379769|metformin
584048|NCT00379756|Erectile dysfunction, impotence
584049|NCT00379730|CT scan
584050|NCT00379730|breathing tests
584051|NCT00379730|lung function tests
584052|NCT00379730|biomarkers
584053|NCT00379730|prednisolone
584054|NCT00379730|IOS
584055|NCT00379730|COPD
584056|NCT00379730|clinical outcomes
584057|NCT00379717|helical tomotherapy
584058|NCT00379717|dose escalation
584059|NCT00379717|chemotherapy
584060|NCT00379704|Tissue factor
584061|NCT00379704|Obesity
584062|NCT00379704|Adipose tissue
584063|NCT00379704|Microparticles
584064|NCT00379691|spinal
584065|NCT00379691|Cesarean section
584066|NCT00379691|hypotension
584067|NCT00379691|nausea
584068|NCT00379691|vomiting
584069|NCT00379691|phenylephrine
584070|NCT00379678|atopic dermatitis
584071|NCT00379665|Lung
584072|NCT00379665|Chemotherapy
584073|NCT00379665|Cisplatin
584074|NCT00379665|Intratumoral
584075|NCT00379665|Bronchoscope
584076|NCT00379665|Brachytherapy
584077|NCT00379652|Community Health Centers
584078|NCT00379652|Diabetes
584079|NCT00379652|Blood Pressure, High
584080|NCT00379639|Pancreatic cancer
584081|NCT00379639|advanced solid tumors
584082|NCT00379626|Paraphilia
584083|NCT00379626|Hormonal treatment
584084|NCT00379626|Cognitive treatment
584085|NCT00379600|Anti-inflammatory treatment
584086|NCT00379600|Rheumatoid Arthritis
584087|NCT00379587|Rituximab
584088|NCT00379587|Chronic GVHD
584089|NCT00379574|diffuse large B-cell lymphoma
584090|NCT00379574|Bortezomib
584091|NCT00379574|CHOP
584092|NCT00379574|Lenograstim
584093|NCT00379561|Prostate Cancer
584094|NCT00379561|Recurrent Prostate Cancer
584095|NCT00379561|Non-Metastatic prostate cancer
584096|NCT00379561|Recurrent Localized Prostate Cancer with Biochemical Failure
584097|NCT00379535|pregnancy , lack of iodine
584098|NCT00379535|lack of iodine during pregnancy
584099|NCT00379522|hemorrhagic
584100|NCT00379522|shock
584101|NCT00379522|traumatic
584102|NCT00379522|shock treatment
584103|NCT00379522|vasopressin
584104|NCT00379522|Circulatory Collapse
584105|NCT00379522|Hypovolemic Shock
584106|NCT00379509|recurrent breast cancer
584107|NCT00379509|stage IIIA breast cancer
584108|NCT00379509|stage IIIB breast cancer
584109|NCT00379509|stage IIIC breast cancer
584110|NCT00379509|stage IV breast cancer
584111|NCT00379509|male breast cancer
584112|NCT00379496|Fibromyalgia
584113|NCT00379496|Acupuncture
584114|NCT00379496|Randomized study
584115|NCT00379483|Transfusional iron overload
584116|NCT00379483|Deferasirox
584117|NCT00379470|Brain tumor
584118|NCT00379470|Treatment
584119|NCT00379470|Minimal toxicity
584120|NCT00379470|GBM
584121|NCT00379470|Glioblastoma
584122|NCT00379470|Recurrent
584123|NCT00379470|TTFields
584124|NCT00379457|alveolar childhood rhabdomyosarcoma
584125|NCT00379457|previously untreated childhood rhabdomyosarcoma
584126|NCT00379457|childhood malignant mesenchymoma
584127|NCT00379457|nonmetastatic childhood soft tissue sarcoma
584128|NCT00379457|embryonal childhood rhabdomyosarcoma
584129|NCT00379457|embryonal-botryoid childhood rhabdomyosarcoma
584130|NCT00379444|tobacco, intervention, tobacco cessation, ALaska Natives,
584131|NCT00379444|Native Americans, pregnancy, women
584132|NCT00379405|Saquinavir/ritonavir
584133|NCT00379405|Single therapy
584134|NCT00379405|Virological efficacy
584135|NCT00379405|Safety
584136|NCT00379405|HIV-1
584137|NCT00379392|Stroke
584138|NCT00379392|Mental Imagery
584139|NCT00379392|Constraint Induced Therapy
584140|NCT00379379|electroacupuncture, plasma glucose, plasma insulin
584141|NCT00379366|Randomized Controlled Trials
584142|NCT00379366|Renal Dialysis
584143|NCT00379366|Graft Occlusion, Vascular
584144|NCT00379366|Angioplasty
584145|NCT00379366|Vascular Patency
584146|NCT00379366|Radiation, Ionizing
584147|NCT00379353|Advanced Cancers
584148|NCT00379353|Anorexia
584149|NCT00379353|Fatigue
584150|NCT00379353|Thalidomide
584151|NCT00379353|Placebo
584152|NCT00379327|Pregnancy
584153|NCT00379327|Acupuncture
584154|NCT00379327|Pregnancy Outcome
584155|NCT00379327|Randomized Controlled Trial
584156|NCT00379327|Double-Blind Method
584157|NCT00379314|Incontinence
584158|NCT00379314|Urinary
584159|NCT00379314|Female
584160|NCT00379314|Surgery
584161|NCT00379314|Complications
584162|NCT00379301|Atrial Fibrillation
584163|NCT00379301|A-Fib
584164|NCT00379301|AF
584165|NCT00379301|Persistent
584166|NCT00379301|Permanent
584167|NCT00379301|Pulmonary Vein Isolation
584168|NCT00379301|Ablation
584169|NCT00379275|Sarcoidosis
584170|NCT00379275|Uveitis
584171|NCT00379275|Pulmonary Sarcoidosis
584172|NCT00379275|HLA-Typing
584173|NCT00379275|Cytokines
584174|NCT00379275|Serum Markers
584175|NCT00379262|Nasopharyngeal Carcinoma
584176|NCT00379262|Chemoradiotherapy
584177|NCT00379262|Accelerated Fractionation
584178|NCT00379249|hypercholesterolemia
584179|NCT00379249|statin
584180|NCT00379249|compliance
584181|NCT00379236|osteoarthritis
584182|NCT00379236|knee
584183|NCT00379223|retinal vein occlusion
584184|NCT00379223|vitrectomy
584185|NCT00379223|surgery
584186|NCT00379223|retinal disorders
584187|NCT00379223|vascular diseases
584188|NCT00379210|Attention
584189|NCT00379210|ERP
584190|NCT00379210|event-related potentials
584191|NCT00379210|fMRI
584192|NCT00379210|functional magnetic resonance imaging
584193|NCT00379210|MBSR
584194|NCT00379210|Mindfulness Based Stress Reduction
584195|NCT00379210|Mindfulness Meditation Training
584196|NCT00379210|MMT
584197|NCT00379197|stage IV breast cancer, estrogen receptor positive
584198|NCT00379197|recurrent breast cancer
584199|NCT00379197|hormone-refractory, metastatic breast cancer
584200|NCT00379184|arthritis
584201|NCT00379171|Children
584202|NCT00379171|Complementary feeding
584203|NCT00379171|Breast feeding
584204|NCT00379171|Cow's milk
584205|NCT00379171|Formula
584206|NCT00379171|Protein
584207|NCT00379171|LCPUFA
584208|NCT00379171|Fish oil
584209|NCT00379171|Lipid profile
584210|NCT00379171|Intestinal inflammation
584211|NCT00379171|Intestinal microbiota
584212|NCT00379158|multiple micronutrient supplements
584213|NCT00379158|home-fortification
584214|NCT00379158|complementary foods
584215|NCT00379158|infants
584216|NCT00379158|Ghana
584217|NCT00379145|uterine leiomyosarcoma
584218|NCT00379145|recurrent uterine sarcoma
584219|NCT00379145|stage III uterine sarcoma
584220|NCT00379145|stage IV uterine sarcoma
584221|NCT00379132|Glioma
584222|NCT00379132|prostatic
584223|NCT00379132|breast
584224|NCT00379132|non-small cell lung
584225|NCT00379132|melanoma
584226|NCT00379132|colorectal
584227|NCT00379132|pancreatic
584228|NCT00379119|adenocarcinoma of the prostate
584229|NCT00379119|recurrent prostate cancer
584230|NCT00379119|stage I prostate cancer
584231|NCT00379119|stage IIB prostate cancer
584232|NCT00379119|stage IIA prostate cancer
584233|NCT00379119|stage III prostate cancer
584234|NCT00379106|Supportive
584235|NCT00379106|Mastectomy
584236|NCT00379106|Quality of Life
584237|NCT00379106|Arm Function
584238|NCT00379093|Alcohol
584239|NCT00379093|Comorbidity
584240|NCT00379093|Aging
584241|NCT00379093|Brief Advice
584242|NCT00379093|Randomized Trial
584243|NCT00379067|Benign Prostatic Hyperplasia
584244|NCT00379067|Nocturia
584245|NCT00379067|Actigraphy
584246|NCT00379067|Tamsulosin
584247|NCT00379054|social support, smoking, smoking cessation, intervention,
584248|NCT00379054|telephone counseling
584249|NCT00379041|stage I adult Hodgkin lymphoma
584250|NCT00379041|stage II adult Hodgkin lymphoma
584251|NCT00379028|COPD
584252|NCT00379015|stage IIIB breast cancer
584253|NCT00379015|stage IIIC breast cancer
584254|NCT00379015|stage IV breast cancer
584255|NCT00379002|Interstitial Cystitis
584256|NCT00379002|Sexual Dysfunction
584257|NCT00379002|Vulvodynia
584258|NCT00379002|Pelvic Pain
584259|NCT00379002|incontinence
584260|NCT00378976|HIV infection
584261|NCT00378976|HIV shedding
584262|NCT00378976|HSV suppression
584263|NCT00378976|Co-infected
584264|NCT00378976|MSM
584265|NCT00378976|Reactivation
584266|NCT00378976|Valacyclovir
584267|NCT00378950|Congestive Heart Failure
584268|NCT00378937|unspecified adult solid tumor, protocol specific
584269|NCT00378937|pain
584270|NCT00378885|HIV-prevention
584271|NCT00378885|Internet Prevention intervention
584272|NCT00378885|Online randomized controlled trial
584273|NCT00378885|Effect evaluation
584274|NCT00378885|MSM
584275|NCT00378885|Steady relationships
584276|NCT00378820|Children
584277|NCT00378820|Whey
584278|NCT00378820|Casein
584279|NCT00378820|Milk minerals
584280|NCT00378820|Growth factors
584281|NCT00378820|IGF-I
584282|NCT00378820|Insulin
584283|NCT00378781|infection
584284|NCT00378781|poor vascular access
584285|NCT00378781|thromboembolism
584286|NCT00378781|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
584287|NCT00378781|adult acute myeloid leukemia with inv(16)(p13;q22)
584288|NCT00378781|adult acute myeloid leukemia with t(15;17)(q22;q12)
584289|NCT00378781|adult acute myeloid leukemia with t(16;16)(p13;q22)
584290|NCT00378781|adult acute myeloid leukemia with t(8;21)(q22;q22)
584291|NCT00378781|accelerated phase chronic myelogenous leukemia
584292|NCT00378781|adult acute lymphoblastic leukemia in remission
584293|NCT00378781|adult acute myeloid leukemia in remission
584294|NCT00378781|atypical chronic myeloid leukemia, BCR-ABL negative
584295|NCT00378781|blastic phase chronic myelogenous leukemia
584296|NCT00378781|childhood acute lymphoblastic leukemia in remission
584297|NCT00378781|childhood acute myeloid leukemia in remission
584298|NCT00378781|childhood chronic myelogenous leukemia
584299|NCT00378781|chronic eosinophilic leukemia
584300|NCT00378781|primary myelofibrosis
584301|NCT00378781|chronic myelomonocytic leukemia
584302|NCT00378781|chronic neutrophilic leukemia
584303|NCT00378781|chronic phase chronic myelogenous leukemia
584304|NCT00378781|de novo myelodysplastic syndromes
584305|NCT00378781|disseminated neuroblastoma
584306|NCT00378781|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
584307|NCT00378781|juvenile myelomonocytic leukemia
584308|NCT00378781|myelodysplastic/myeloproliferative neoplasm, unclassifiable
584309|NCT00378781|nodal marginal zone B-cell lymphoma
584310|NCT00378781|noncontiguous stage II adult Burkitt lymphoma
584311|NCT00378781|noncontiguous stage II adult diffuse large cell lymphoma
584312|NCT00378781|noncontiguous stage II adult diffuse mixed cell lymphoma
584313|NCT00378781|noncontiguous stage II adult diffuse small cleaved cell lymphoma
584314|NCT00378781|noncontiguous stage II adult immunoblastic large cell lymphoma
584315|NCT00378781|noncontiguous stage II adult lymphoblastic lymphoma
584316|NCT00378781|noncontiguous stage II grade 1 follicular lymphoma
584317|NCT00378781|noncontiguous stage II grade 2 follicular lymphoma
584318|NCT00378781|noncontiguous stage II grade 3 follicular lymphoma
584319|NCT00378781|noncontiguous stage II mantle cell lymphoma
584320|NCT00378781|noncontiguous stage II marginal zone lymphoma
584321|NCT00378781|noncontiguous stage II small lymphocytic lymphoma
584322|NCT00378781|poor prognosis metastatic gestational trophoblastic tumor
584323|NCT00378781|previously treated myelodysplastic syndromes
584324|NCT00378781|recurrent adult acute lymphoblastic leukemia
584325|NCT00378781|recurrent adult acute myeloid leukemia
584326|NCT00378781|recurrent adult Burkitt lymphoma
584327|NCT00378781|recurrent adult Hodgkin lymphoma
584328|NCT00378781|recurrent adult diffuse large cell lymphoma
584329|NCT00378781|recurrent adult diffuse mixed cell lymphoma
584330|NCT00378781|recurrent adult diffuse small cleaved cell lymphoma
584331|NCT00378781|recurrent adult immunoblastic large cell lymphoma
584332|NCT00378781|recurrent adult lymphoblastic lymphoma
584333|NCT00378781|recurrent breast cancer
584334|NCT00378781|recurrent/refractory childhood Hodgkin lymphoma
584335|NCT00378781|recurrent childhood acute lymphoblastic leukemia
584336|NCT00378781|recurrent childhood acute myeloid leukemia
584337|NCT00378781|recurrent childhood large cell lymphoma
584338|NCT00378781|recurrent childhood lymphoblastic lymphoma
584339|NCT00378781|recurrent childhood small noncleaved cell lymphoma
584340|NCT00378781|recurrent cutaneous T-cell non-Hodgkin lymphoma
584341|NCT00378781|recurrent grade 1 follicular lymphoma
584342|NCT00378781|recurrent grade 2 follicular lymphoma
584343|NCT00378781|recurrent grade 3 follicular lymphoma
584344|NCT00378781|recurrent mantle cell lymphoma
584345|NCT00378781|recurrent marginal zone lymphoma
584346|NCT00378781|recurrent mycosis fungoides/Sezary syndrome
584347|NCT00378781|recurrent neuroblastoma
584348|NCT00378781|recurrent ovarian epithelial cancer
584349|NCT00378781|recurrent ovarian germ cell tumor
584350|NCT00378781|recurrent small lymphocytic lymphoma
584351|NCT00378781|recurrent malignant testicular germ cell tumor
584352|NCT00378781|recurrent Wilms tumor and other childhood kidney tumors
584353|NCT00378781|refractory chronic lymphocytic leukemia
584354|NCT00378781|refractory hairy cell leukemia
584355|NCT00378781|refractory multiple myeloma
584356|NCT00378781|relapsing chronic myelogenous leukemia
584357|NCT00378781|secondary acute myeloid leukemia
584358|NCT00378781|secondary myelodysplastic syndromes
584359|NCT00378781|splenic marginal zone lymphoma
584360|NCT00378781|stage I multiple myeloma
584361|NCT00378781|stage II multiple myeloma
584362|NCT00378781|stage II ovarian epithelial cancer
584363|NCT00378781|stage III adult Burkitt lymphoma
584364|NCT00378781|stage III adult Hodgkin lymphoma
584365|NCT00378781|stage III adult diffuse large cell lymphoma
584366|NCT00378781|stage III adult diffuse mixed cell lymphoma
584367|NCT00378781|stage III adult diffuse small cleaved cell lymphoma
584368|NCT00378781|stage III adult immunoblastic large cell lymphoma
584369|NCT00378781|stage III adult lymphoblastic lymphoma
584370|NCT00378781|stage III chronic lymphocytic leukemia
584371|NCT00378781|stage III grade 1 follicular lymphoma
584372|NCT00378781|stage III grade 2 follicular lymphoma
584373|NCT00378781|stage III grade 3 follicular lymphoma
584374|NCT00378781|stage III mantle cell lymphoma
584375|NCT00378781|stage III marginal zone lymphoma
584376|NCT00378781|stage III multiple myeloma
584377|NCT00378781|stage III ovarian epithelial cancer
584378|NCT00378781|stage III small lymphocytic lymphoma
584379|NCT00378781|stage III malignant testicular germ cell tumor
584380|NCT00378781|stage IIIA breast cancer
584381|NCT00378781|stage IIIB breast cancer
584382|NCT00378781|stage IIIC breast cancer
584383|NCT00378781|stage IV adult Burkitt lymphoma
584384|NCT00378781|stage IV adult Hodgkin lymphoma
584385|NCT00378781|stage IV adult diffuse large cell lymphoma
584386|NCT00378781|stage IV adult diffuse mixed cell lymphoma
584387|NCT00378781|stage IV adult diffuse small cleaved cell lymphoma
584388|NCT00378781|stage IV adult immunoblastic large cell lymphoma
584389|NCT00378781|stage IV adult lymphoblastic lymphoma
584390|NCT00378781|stage IV breast cancer
584391|NCT00378781|stage IV chronic lymphocytic leukemia
584392|NCT00378781|stage IV grade 1 follicular lymphoma
584393|NCT00378781|stage IV grade 2 follicular lymphoma
584394|NCT00378781|stage IV grade 3 follicular lymphoma
584395|NCT00378781|stage IV mantle cell lymphoma
584396|NCT00378781|stage IV marginal zone lymphoma
584397|NCT00378781|stage IV ovarian epithelial cancer
584398|NCT00378781|stage IV small lymphocytic lymphoma
584399|NCT00378781|acute undifferentiated leukemia
584400|NCT00378781|mast cell leukemia
584401|NCT00378781|stage I adult T-cell leukemia/lymphoma
584402|NCT00378781|stage II adult T-cell leukemia/lymphoma
584403|NCT00378781|stage III adult T-cell leukemia/lymphoma
584404|NCT00378781|stage IV adult T-cell leukemia/lymphoma
584405|NCT00378781|recurrent adult T-cell leukemia/lymphoma
584406|NCT00378781|T-cell large granular lymphocyte leukemia
584407|NCT00378781|stage I chronic lymphocytic leukemia
584408|NCT00378781|stage II chronic lymphocytic leukemia
584409|NCT00378781|meningeal chronic myelogenous leukemia
584410|NCT00378781|prolymphocytic leukemia
584411|NCT00378781|stage I adult Hodgkin lymphoma
584412|NCT00378781|stage II adult Hodgkin lymphoma
584413|NCT00378781|stage I childhood Hodgkin lymphoma
584414|NCT00378781|stage II childhood Hodgkin lymphoma
584415|NCT00378781|stage III childhood Hodgkin lymphoma
584416|NCT00378781|stage IV childhood Hodgkin lymphoma
584417|NCT00378781|anaplastic large cell lymphoma
584418|NCT00378781|angioimmunoblastic T-cell lymphoma
584419|NCT00378781|stage I mycosis fungoides/Sezary syndrome
584420|NCT00378781|stage II mycosis fungoides/Sezary syndrome
584421|NCT00378781|stage III mycosis fungoides/Sezary syndrome
584422|NCT00378781|stage IV mycosis fungoides/Sezary syndrome
584423|NCT00378781|stage I cutaneous T-cell non-Hodgkin lymphoma
584424|NCT00378781|stage II cutaneous T-cell non-Hodgkin lymphoma
584425|NCT00378781|stage III cutaneous T-cell non-Hodgkin lymphoma
584426|NCT00378781|stage IV cutaneous T-cell non-Hodgkin lymphoma
584427|NCT00378781|adult grade III lymphomatoid granulomatosis
584428|NCT00378781|recurrent adult grade III lymphomatoid granulomatosis
584429|NCT00378781|childhood grade III lymphomatoid granulomatosis
584430|NCT00378781|recurrent childhood grade III lymphomatoid granulomatosis
584431|NCT00378781|Waldenstrom macroglobulinemia
584432|NCT00378781|stage I adult Burkitt lymphoma
584433|NCT00378781|stage I adult diffuse large cell lymphoma
584434|NCT00378781|stage I adult diffuse mixed cell lymphoma
584435|NCT00378781|stage I adult diffuse small cleaved cell lymphoma
584436|NCT00378781|stage I adult immunoblastic large cell lymphoma
584437|NCT00378781|stage I adult lymphoblastic lymphoma
584438|NCT00378781|stage I grade 1 follicular lymphoma
584439|NCT00378781|stage I grade 2 follicular lymphoma
584440|NCT00378781|stage I grade 3 follicular lymphoma
584441|NCT00378781|stage I mantle cell lymphoma
584442|NCT00378781|stage I marginal zone lymphoma
584443|NCT00378781|stage I small lymphocytic lymphoma
584444|NCT00378781|contiguous stage II adult Burkitt lymphoma
584445|NCT00378781|contiguous stage II adult diffuse large cell lymphoma
584446|NCT00378781|contiguous stage II adult diffuse mixed cell lymphoma
584447|NCT00378781|contiguous stage II adult diffuse small cleaved cell lymphoma
584448|NCT00378781|contiguous stage II adult immunoblastic large cell lymphoma
584449|NCT00378781|contiguous stage II adult lymphoblastic lymphoma
584450|NCT00378781|contiguous stage II grade 1 follicular lymphoma
584451|NCT00378781|contiguous stage II grade 2 follicular lymphoma
584452|NCT00378781|contiguous stage II grade 3 follicular lymphoma
584453|NCT00378781|contiguous stage II mantle cell lymphoma
584454|NCT00378781|contiguous stage II marginal zone lymphoma
584455|NCT00378781|contiguous stage II small lymphocytic lymphoma
584456|NCT00378781|stage I childhood large cell lymphoma
584457|NCT00378781|stage II childhood large cell lymphoma
584458|NCT00378781|stage III childhood large cell lymphoma
584459|NCT00378781|stage IV childhood large cell lymphoma
584460|NCT00378781|stage I childhood lymphoblastic lymphoma
584461|NCT00378781|stage II childhood lymphoblastic lymphoma
584462|NCT00378781|stage III childhood lymphoblastic lymphoma
584463|NCT00378781|stage IV childhood lymphoblastic lymphoma
584464|NCT00378781|stage I childhood small noncleaved cell lymphoma
584465|NCT00378781|stage II childhood small noncleaved cell lymphoma
584466|NCT00378781|stage III childhood small noncleaved cell lymphoma
584467|NCT00378781|stage IV childhood small noncleaved cell lymphoma
584468|NCT00378781|primary central nervous system non-Hodgkin lymphoma
584469|NCT00378781|post-transplant lymphoproliferative disorder
584470|NCT00378781|intraocular lymphoma
584471|NCT00378781|stage I melanoma
584472|NCT00378781|stage II melanoma
584473|NCT00378781|stage III melanoma
584474|NCT00378781|stage IV melanoma
584475|NCT00378781|recurrent melanoma
584476|NCT00378781|unspecified adult solid tumor, protocol specific
584477|NCT00378781|unspecified childhood solid tumor, protocol specific
584478|NCT00378781|stage I adult soft tissue sarcoma
584479|NCT00378781|stage II adult soft tissue sarcoma
584480|NCT00378781|stage III adult soft tissue sarcoma
584481|NCT00378781|stage IV adult soft tissue sarcoma
584482|NCT00378781|recurrent adult soft tissue sarcoma
584483|NCT00378781|metastatic childhood soft tissue sarcoma
584484|NCT00378781|nonmetastatic childhood soft tissue sarcoma
584485|NCT00378781|recurrent childhood soft tissue sarcoma
584486|NCT00378781|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
584487|NCT00378781|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
584488|NCT00378781|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
584489|NCT00378781|previously treated childhood rhabdomyosarcoma
584490|NCT00378781|previously untreated childhood rhabdomyosarcoma
584491|NCT00378781|recurrent childhood rhabdomyosarcoma
584492|NCT00378781|recurrent uterine sarcoma
584493|NCT00378781|stage I uterine sarcoma
584494|NCT00378781|stage II uterine sarcoma
584495|NCT00378781|stage III uterine sarcoma
584496|NCT00378781|stage IV uterine sarcoma
584497|NCT00378781|localized osteosarcoma
584498|NCT00378781|metastatic osteosarcoma
584499|NCT00378781|recurrent osteosarcoma
584500|NCT00378781|chondrosarcoma
584501|NCT00378781|small intestine leiomyosarcoma
584502|NCT00378781|recurrent small intestine cancer
584503|NCT00378781|childhood myelodysplastic syndromes
584504|NCT00378768|stage I multiple myeloma
584505|NCT00378768|stage II multiple myeloma
584506|NCT00378768|stage III multiple myeloma
584507|NCT00378768|refractory multiple myeloma
584508|NCT00378755|velcade
584509|NCT00378755|myeloma
584510|NCT00378755|VAD regimen
584511|NCT00378755|Transplantation, Autologous
584512|NCT00378742|Glaucoma
584513|NCT00378742|Gene
584514|NCT00378742|Phenotype-Genotype correlation
584515|NCT00378742|Molecular Diagnosis
584516|NCT00378742|Retinal Degeneration
584517|NCT00378742|Inherited Eye Disease
584518|NCT00378742|Retinitis Pigmentosa
584519|NCT00378742|Macular Dystrophy
584520|NCT00378742|Congenital Glaucoma
584521|NCT00378729|PCOS
584522|NCT00378729|FERTILOSCOPY
584523|NCT00378729|Ovarian hyperstimulation
584524|NCT00378729|Multiple pregnancies
584525|NCT00378729|Patient with PCOS (Rotterdam criteria)
584526|NCT00378729|Failure of treatment with Clomiphene Citrate
584527|NCT00378729|Age between 18 and 36 years old
584528|NCT00378729|Spermogram must be normal
584529|NCT00378729|Permeability of Fallopian tubes
584530|NCT00378716|stage II colon cancer
584531|NCT00378716|stage III colon cancer
584532|NCT00378716|adenocarcinoma of the colon
584533|NCT00378690|Prostate Cancer
584534|NCT00378690|Prostate Specific Antigen
584535|NCT00378677|Powder inhalation
584536|NCT00378677|Side effects
584537|NCT00378677|Nephrotoxicity
584538|NCT00378677|Calcineurin inhibitor
584539|NCT00378677|Bronchiolitis obliterans syndrome
584540|NCT00378677|Forced Expiratory Volume
584541|NCT00378664|urinary incontinence
584542|NCT00378664|spinal cord injury
584543|NCT00378664|spina bifida
584544|NCT00378651|Intubation, Endotracheal
584545|NCT00378651|Anesthesia, General
584546|NCT00378638|lymph
584547|NCT00378638|node
584548|NCT00378638|positive
584549|NCT00378638|breast
584550|NCT00378638|cancer
584551|NCT00378638|metastases
584552|NCT00378638|angiogenesis
584553|NCT00378638|bevacizumab
584554|NCT00378638|chemotherapy
584555|NCT00378612|trials
584556|NCT00378612|stents
584557|NCT00378612|coronary occlusions
584558|NCT00378547|Tonsillectomy
584559|NCT00378547|pregabalin
584560|NCT00378547|dexamethasone
584561|NCT00378547|multimodal postoperative analgesia
584562|NCT00378534|Chronic Myelogenous Leukemia (CML)
584563|NCT00378534|Acute Myelogenous Leukemia (AML)
584564|NCT00378534|Chronic Lymphocytic Leukemia (CLL)
584565|NCT00378534|Acute Lymphoblastic Leukemia (ALL)
584566|NCT00378534|Myelodysplastic Syndrome (MDS)
584567|NCT00378534|Leukemia
584568|NCT00378534|Chronic Myelogenous Leukemia
584569|NCT00378534|CML
584570|NCT00378534|Acute Myeloid Leukemia
584571|NCT00378534|AML
584572|NCT00378534|Chronic Lymphocytic Leukemia
584573|NCT00378534|CLL
584574|NCT00378534|Acute Lymphoblastic Leukemia
584575|NCT00378534|ALL
584576|NCT00378534|Myelodysplasia Syndrome
584577|NCT00378521|Raynaud's
584578|NCT00378521|Nitroglycerin
584579|NCT00378521|topical gel
584580|NCT00378521|cold hands
584581|NCT00378521|painful hands
584582|NCT00378521|scleroderma
584583|NCT00378508|immune therapy
584584|NCT00378508|autoimmunity
584585|NCT00378508|insulin secretion
584586|NCT00378508|diabetes mellitus
584587|NCT00378495|miltefosine
584588|NCT00378495|kala azar
584589|NCT00378495|Brazil
584590|NCT00378482|Melanoma and other tumors
584591|NCT00378469|Hepcidin
584592|NCT00378469|Hemojuvelin
584593|NCT00378469|Iron
584594|NCT00378469|Healthy volunteers
584595|NCT00378417|Otitis Media
584596|NCT00378417|Pneumococcal Infections
584597|NCT00378417|Pneumococcal Vaccines
584598|NCT00378417|Proportional Hazards Models
584599|NCT00378417|Prospective Studies
584600|NCT00378417|Streptococcus pneumoniae
584601|NCT00378417|Vaccines, Conjugate
584602|NCT00378404|NSCLC
584603|NCT00378404|Non-Small Cell Lung Cancer
584604|NCT00378404|Non-Small Cell
584605|NCT00378404|Lung Cancer
584606|NCT00378404|Docetaxel
584607|NCT00378404|Radiation
584608|NCT00378404|Metastatic
584609|NCT00378404|Recurrent
584610|NCT00378391|ST-Elevation Myocardial Infarction
584611|NCT00378391|upstream abciximab
584612|NCT00378391|guideline adherence
584613|NCT00378391|hospital networking
584614|NCT00378365|Acute promyelocytic leukaemia
584615|NCT00378365|ATRA
584616|NCT00378365|Idarubicin
584617|NCT00378365|Arsenic trioxide
584618|NCT00378365|Patient with a newly acute promyelocytic leukaemia (APL)
584619|NCT00378365|Unmapped MeSH term
584620|NCT00378352|Acute Myocardial Infarction
584621|NCT00378352|Left Ventricular Remodeling
584622|NCT00378352|Cardiac Magnetic Resonance Imaging
584623|NCT00378352|Endothelial Progenitor Cells
584624|NCT00378352|Infarct Size
584625|NCT00378339|arthrosis
584626|NCT00378339|gold
584627|NCT00378326|paraneoplastic syndrome
584628|NCT00378313|NSABP
584629|NCT00378313|gemcitabine
584630|NCT00378313|epirubicin
584631|NCT00378313|paclitaxel
584632|NCT00378313|Taxol
584633|NCT00378313|breast cancer
584634|NCT00378313|neoadjuvant chemotherapy
584635|NCT00378313|primary chemotherapy
584636|NCT00378300|Atopic Dermatitis
584637|NCT00378300|Probiotics
584638|NCT00378300|T Regulatory Cells
584639|NCT00378287|Acid Reflux
584640|NCT00378287|Proton Pump Inhibitor
584641|NCT00378287|GERD
584642|NCT00378274|Neuropathic pain
584643|NCT00378274|Chronic pain
584644|NCT00378274|Depression
584645|NCT00378274|Anxiety
584646|NCT00378261|Rheumatoid Arthritis
584647|NCT00378248|Personality disorders,
584648|NCT00378248|Day treatment,
584649|NCT00378248|Group psychotherapy,
584650|NCT00378248|Combined psychotherapy,
584651|NCT00378248|Outcome,
584652|NCT00378248|Attachment pattern
584653|NCT00378235|neurosurgery, craniotomy
584654|NCT00378235|convection-enhanced delivery
584655|NCT00378235|CNS interstitial infusion
584656|NCT00378235|recombinant toxins
584657|NCT00378235|malignant glioma, recurrent
584658|NCT00378235|catheter,
584659|NCT00378235|intratumoral therapy
584660|NCT00378235|positive pressure microinfusion
584661|NCT00378222|Myeloma previously untreated
584662|NCT00378222|Single autologous transplantation
584663|NCT00378222|Double autologous transplantation
584664|NCT00378222|Complete response
584665|NCT00378209|relapsed multiple myeloma
584666|NCT00378209|refractory multiple myeloma
584667|NCT00378196|Idiopathic Parafoveal Telangiectasia (IPT)
584668|NCT00378196|Also Known As Idiopathic Juxtafoveal Telangiectasia (IJFT)
584669|NCT00378183|weight loss
584670|NCT00378183|behavioral therapy
584671|NCT00378183|risperidone
584672|NCT00378183|switching antipsychotics
584673|NCT00378183|schizoaffective disorder
584674|NCT00378183|Risperdal
584675|NCT00378183|schizophrenia
584676|NCT00378183|olanzapine
584677|NCT00378183|Zyprexa
584678|NCT00378170|intubation
584679|NCT00378170|difficulty
584680|NCT00378170|Macintosh
584681|NCT00378170|dental damage
584682|NCT00378170|complications
584683|NCT00378157|autism
584684|NCT00378157|joint attention
584685|NCT00378157|intervention
584686|NCT00378157|joint engagement
584687|NCT00378157|language
584688|NCT00378118|HIV-1
584689|NCT00378118|HIV-2
584690|NCT00378105|newly diagnosed multiple myeloma
584691|NCT00378092|Schizophrenia
584692|NCT00378092|Risperidone
584693|NCT00378092|Risperdal consta
584694|NCT00378053|Radiation
584695|NCT00378053|Exposure
584696|NCT00378053|Hand
584697|NCT00378053|Orthopaedic
584698|NCT00378053|Surgeons
584699|NCT00378027|Pulmonary Embolism
584700|NCT00378027|PE
584701|NCT00378027|Outpatient
584702|NCT00378027|Anticoagulation
584703|NCT00378014|Liver transplantation, everolimus, CNI
584704|NCT00378001|Infertility, FSH, IVF, Ovarian stimulation
584705|NCT00377988|Contraception
584706|NCT00377988|Hormonal contraception
584707|NCT00377988|Oral contraception
584708|NCT00377988|Ethinyl estradiol
584709|NCT00377988|Progestin
584710|NCT00377988|Transdermal
584711|NCT00377988|Thrombosis
584712|NCT00377988|Venous thromboembolism
584713|NCT00377975|UCP-1
584714|NCT00377975|ephedrine
584715|NCT00377975|caffeine
584716|NCT00377975|pioglitazone
584717|NCT00377962|thoracic transplant recipients
584718|NCT00377962|everolimus
584719|NCT00377962|immunosuppressants
584720|NCT00377949|Systemic Sclerosis
584721|NCT00377949|Scleroderma
584722|NCT00377949|Pulmonary Hypertension
584723|NCT00377949|PHAROS
584724|NCT00377949|PHROS
584725|NCT00377949|Exercise Echocardiogram
584726|NCT00377949|Pulmonary Functional Tests
584727|NCT00377949|Six minute walk tests
584728|NCT00377949|6 minute walk tests
584729|NCT00377949|Right heart catheterization
584730|NCT00377936|Adenocarcinoma of the pancreas
584731|NCT00377936|Locally advanced
584732|NCT00377936|Metastatic
584733|NCT00377923|pharmacodynamic and pharmacokinetic study
584734|NCT00377923|Progesterone
584735|NCT00377923|healthy volunteers
584736|NCT00377923|Endometrial decidualisation
584737|NCT00377910|Chronic Achilles tendinopathy
584738|NCT00377910|Polidocanol
584739|NCT00377910|Ultrasound
584740|NCT00377910|Efficacy
584741|NCT00377910|RCT
584742|NCT00377897|critical leg ischemia
584743|NCT00377897|PAD
584744|NCT00377897|cell therapy
584745|NCT00377884|THA
584746|NCT00377871|Stentless
584747|NCT00377871|Biological
584748|NCT00377871|aortic
584749|NCT00377871|heart
584750|NCT00377871|valve
584751|NCT00377871|prosthesis
584752|NCT00377871|artificial
584753|NCT00377858|diabetes
584754|NCT00377858|type 2
584755|NCT00377845|self test
584756|NCT00377845|PAP smear
584757|NCT00377845|tampon test
584758|NCT00377845|cervical dysplasia
584759|NCT00377832|Fetal tachycardia
584760|NCT00377832|Fever in labor
584761|NCT00377832|Acetaminophen
584762|NCT00377832|Non reassuring fetal status
584763|NCT00377819|RANKL
584764|NCT00377819|RANK
584765|NCT00377819|denosumab
584766|NCT00377819|AMG 162
584767|NCT00377819|osteoporosis
584768|NCT00377819|bone turnover
584769|NCT00377819|bone mineral density
584770|NCT00377819|clinical trial
584771|NCT00377819|postmenopausal osteoporosis
584772|NCT00377819|alendronate
584773|NCT00377819|total hip bone mineral density
584774|NCT00377806|Superficial thrombophlebitis, diclofenac gel, non steroidal antiinflammatory drugs
584775|NCT00377780|Breast cancer
584776|NCT00377780|metastatic
584777|NCT00377780|cardiotoxicity
584778|NCT00377780|liposomal
584779|NCT00377780|doxorubicin
584780|NCT00377780|trastuzumab
584781|NCT00377780|docetaxel
584782|NCT00377780|HER2/neu positive metastatic breast cancer
584783|NCT00377767|Chronic Care Model
584784|NCT00377767|Obesity
584785|NCT00377767|Overweight
584786|NCT00377767|Children
584787|NCT00377767|Body Mass Index
584788|NCT00377767|Primary Care
584789|NCT00377754|dengue virus, immunity, hemorrhagic fever, Philippines
584790|NCT00377728|Seasonal Allergic Rhinitis Inflammation Vienna CHallenge Chamber
584791|NCT00377715|Dimebon, Alzheimer's Disease, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)
584792|NCT00377702|Coronary Heart Disease
584793|NCT00377702|Risk Factors
584794|NCT00377702|Heart Failure
584795|NCT00377689|Accidental falls
584796|NCT00377689|Cerebrovascular accident
584797|NCT00377689|Balance
584798|NCT00377689|ADL
584799|NCT00377689|Self efficacy
584800|NCT00377689|Quality of Life
584801|NCT00377689|Gait parameters
584802|NCT00377676|diabetes
584803|NCT00377676|diabetes mellitus
584804|NCT00377611|Influenza vaccine
584805|NCT00377598|Herpes Zoster
584806|NCT00377598|Neuralgia
584807|NCT00377598|Drug Therapy
584808|NCT00377585|Elderly
584809|NCT00377585|Improved vaccine
584810|NCT00377585|Influenza
584811|NCT00377585|Influenza disease
584812|NCT00377572|Immunoglobulins
584813|NCT00377572|Immunoglobulin E
584814|NCT00377572|omalizumab
584815|NCT00377572|anti-IgE
584816|NCT00377559|Breast cancer
584817|NCT00377559|metastatic
584818|NCT00377559|cardiotoxicity
584819|NCT00377559|liposomal
584820|NCT00377559|doxorubicin
584821|NCT00377559|docetaxel
584822|NCT00377559|HER2/neu negative metastatic breast cancer
584823|NCT00375583|Lymphatic Filariasis
584824|NCT00375583|Diethylcarbamazine
584825|NCT00375583|Microfilariae
584826|NCT00375583|Helminths
584827|NCT00375583|Nematode
584828|NCT00377546|Retinal Surgery
584829|NCT00377533|wheelchairs
584830|NCT00377533|caregivers
584831|NCT00377533|skills
584832|NCT00377507|catechin
584833|NCT00377507|elderly
584834|NCT00377507|mouth washing
584835|NCT00377507|disabled
584836|NCT00377507|colonized
584837|NCT00377494|malaria, Plasmodium falciparum, vaccine, Ghana
584838|NCT00377468|THC
584839|NCT00377468|CRPS
584840|NCT00377468|Pain
584841|NCT00377468|Complex Regional Pain Syndrome
584842|NCT00377468|Neuropathic Pain
584843|NCT00377468|Chronic
584844|NCT00377468|Prevention
584845|NCT00377455|scleroderma
584846|NCT00377455|systemic sclerosis
584847|NCT00377455|bosentan
584848|NCT00377455|pulmonary hypertension
584849|NCT00377455|PHAROS
584850|NCT00377455|PHROS
584851|NCT00377455|exercise echocardiogram
584852|NCT00377429|Epithelial Cancer
584853|NCT00377429|Epithelial Carcinoma
584854|NCT00377429|Epithelial Ovarian Cancer
584855|NCT00377429|Epithelial Ovarian Carcinoma
584856|NCT00377429|Fallopian Tube Cancer
584857|NCT00377429|Fallopian Tube Carcinoma
584858|NCT00377429|Ovarian Cancer
584859|NCT00377429|Ovarian Carcinoma
584860|NCT00377429|Ovarian Epithelial Cancer
584861|NCT00377429|Ovarian Epithelial Carcinoma
584862|NCT00377429|Peritoneal Cancer
584863|NCT00377429|Peritoneal Carcinoma
584864|NCT00377429|Advanced Epithelial Ovarian Cancer
584865|NCT00377416|Gene Transfer Techniques
584866|NCT00377416|Gene Therapy
584867|NCT00377403|rhinosinusitis, sinusitis, amoxicillin
584868|NCT00377390|Immunoglobulin
584869|NCT00377390|IgE
584870|NCT00377390|Omalizumab
584871|NCT00377377|GH release
584872|NCT00377377|Pharmacokinetics
584873|NCT00377377|Safety
584874|NCT00377364|Acetaminophen
584875|NCT00377364|corticosteroids
584876|NCT00377364|prednisone
584877|NCT00377351|Public Health
584878|NCT00377351|Elderly Population
584879|NCT00377351|Neurodegenerative Diseases
584880|NCT00377351|Exposure
584881|NCT00377351|Lifestyle
584882|NCT00377338|Bronchoscopy
584883|NCT00377338|Diagnostic imaging
584884|NCT00377338|Laser scanning confocal microscopy
584885|NCT00377338|Pulmonary Alveoli
584886|NCT00377338|Healthy volunteers
584887|NCT00377338|Diffuse peripheral lung disease
584888|NCT00377338|Focal peripheral lung disease
584889|NCT00377312|Endocrine System Diseases
584890|NCT00377312|MusculoSkeletal System Disease
584891|NCT00377312|Hormone
584892|NCT00377312|Physiologic Properties
584893|NCT00377299|Amphetamine Abuse
584894|NCT00377299|Amphetamine Dependence
584895|NCT00377299|Bipolar Disorder
584896|NCT00377299|Major Depressive Disorder
584897|NCT00377299|Citicoline
584898|NCT00377286|Osteoarthritis
584899|NCT00377286|Knee Pain
584900|NCT00377286|Glucosamine
584901|NCT00377286|MRI
584902|NCT00377286|CTX-II
584903|NCT00377286|Biomarkers
584904|NCT00377286|Skin quality
584905|NCT00377260|acute otitis media, infants, children
584906|NCT00377247|Carcinoma
584907|NCT00377247|Head
584908|NCT00377247|Neck
584909|NCT00377247|Oral Cavity
584910|NCT00377247|Oropharynx
584911|NCT00377247|Mouth
584912|NCT00377208|Blood Pressure, High
584913|NCT00377195|Marginal Zone Lymphoma
584914|NCT00377195|Involved field radiotherapy
584915|NCT00377195|H. pylori
584916|NCT00377169|Treatment Experienced
584917|NCT00377156|cognitive/functional effects
584918|NCT00377156|tumors metastatic to brain
584919|NCT00377156|stage IV breast cancer
584920|NCT00377156|stage IV prostate cancer
584921|NCT00377156|stage IV non-small cell lung cancer
584922|NCT00377156|male breast cancer
584923|NCT00377156|recurrent breast cancer
584924|NCT00377156|recurrent prostate cancer
584925|NCT00377156|recurrent non-small cell lung cancer
584926|NCT00377143|warfarin
584927|NCT00377143|pharmacogenomic
584928|NCT00377143|CYP2C9
584929|NCT00377143|VKORC1
584930|NCT00377143|polymorphism, single nucleotide
584931|NCT00377130|psychosocial effects of cancer and its treatment
584932|NCT00377130|unspecified adult solid tumor, protocol specific
584933|NCT00377091|pulmonary embolism
584934|NCT00377091|venous thromboembolism
584935|NCT00377091|pharmacoeconomic
584936|NCT00377091|heparin
584937|NCT00377091|unfractionated heparin
584938|NCT00377091|fondaparinux
584939|NCT00377091|length of stay
584940|NCT00377091|costs
584941|NCT00377091|bleeding
584942|NCT00377091|thrombosis
584943|NCT00377078|recombinant human lactoferrin
584944|NCT00377052|recurrent mantle cell lymphoma
584945|NCT00377039|ACR 1990 Fibromyalgia
584946|NCT00377039|Fibromyalgia Impact Questionnaire
584947|NCT00377026|weight loss
584948|NCT00377026|postpartum
584949|NCT00377026|weight retention
584950|NCT00376987|renal cell carcinoma
584951|NCT00376987|bladder cancer
584952|NCT00376987|cervical cancer
584953|NCT00376987|esophageal cancer
584954|NCT00376987|gastric cancer
584955|NCT00376987|adult acute myeloid leukemia
584956|NCT00376987|pancreatic cancer
584957|NCT00376987|hypopharyngeal cancer
584958|NCT00376987|lip and oral cavity cancer
584959|NCT00376987|laryngeal cancer
584960|NCT00376987|nasopharyngeal cancer
584961|NCT00376987|oropharyngeal cancer
584962|NCT00376987|paranasal sinus and nasal cavity cancer
584963|NCT00376987|non-small cell lung cancer
584964|NCT00376987|small cell lung cancer
584965|NCT00376987|adult primary liver cancer
584966|NCT00376987|tongue cancer
584967|NCT00376987|tobacco use disorder
584968|NCT00376974|glaucoma
584969|NCT00376974|compliance
584970|NCT00376974|intraocular pressure
584971|NCT00376974|video
584972|NCT00376961|contiguous stage II mantle cell lymphoma
584973|NCT00376961|noncontiguous stage II mantle cell lymphoma
584974|NCT00376961|stage III mantle cell lymphoma
584975|NCT00376961|stage IV mantle cell lymphoma
584976|NCT00376948|adenocarcinoma of the pancreas
584977|NCT00376948|stage III pancreatic cancer
584978|NCT00376948|stage IV pancreatic cancer
584979|NCT00376948|recurrent pancreatic cancer
584980|NCT00376935|Treatment Experienced
584981|NCT00376922|pain
584982|NCT00376922|psychosocial effects of cancer and its treatment
584983|NCT00376922|accelerated phase chronic myelogenous leukemia
584984|NCT00376922|acute undifferentiated leukemia
584985|NCT00376922|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
584986|NCT00376922|adult acute myeloid leukemia with inv(16)(p13;q22)
584987|NCT00376922|adult acute myeloid leukemia with t(15;17)(q22;q12)
584988|NCT00376922|adult acute myeloid leukemia with t(16;16)(p13;q22)
584989|NCT00376922|adult acute myeloid leukemia with t(8;21)(q22;q22)
584990|NCT00376922|atypical chronic myeloid leukemia, BCR-ABL1 negative
584991|NCT00376922|blastic phase chronic myelogenous leukemia
584992|NCT00376922|chronic eosinophilic leukemia
584993|NCT00376922|primary myelofibrosis
584994|NCT00376922|chronic myelomonocytic leukemia
584995|NCT00376922|chronic neutrophilic leukemia
584996|NCT00376922|chronic phase chronic myelogenous leukemia
584997|NCT00376922|de novo myelodysplastic syndromes
584998|NCT00376922|essential thrombocythemia
584999|NCT00376922|extramedullary plasmacytoma
585000|NCT00376922|meningeal chronic myelogenous leukemia
585001|NCT00376922|myelodysplastic/myeloproliferative neoplasm, unclassifiable
585002|NCT00376922|polycythemia vera
585003|NCT00376922|previously treated myelodysplastic syndromes
585004|NCT00376922|primary systemic amyloidosis
585005|NCT00376922|progressive hairy cell leukemia, initial treatment
585006|NCT00376922|prolymphocytic leukemia
585007|NCT00376922|secondary acute myeloid leukemia
585008|NCT00376922|secondary myelodysplastic syndromes
585009|NCT00376922|stage III adult T-cell leukemia/lymphoma
585010|NCT00376922|stage III chronic lymphocytic leukemia
585011|NCT00376922|stage III multiple myeloma
585012|NCT00376922|stage IV adult T-cell leukemia/lymphoma
585013|NCT00376922|stage IV chronic lymphocytic leukemia
585014|NCT00376922|relapsing chronic myelogenous leukemia
585015|NCT00376922|adult acute lymphoblastic leukemia in remission
585016|NCT00376922|recurrent adult acute lymphoblastic leukemia
585017|NCT00376922|untreated adult acute lymphoblastic leukemia
585018|NCT00376922|adult acute myeloid leukemia in remission
585019|NCT00376922|recurrent adult acute myeloid leukemia
585020|NCT00376922|untreated adult acute myeloid leukemia
585021|NCT00376922|mast cell leukemia
585022|NCT00376922|stage I adult T-cell leukemia/lymphoma
585023|NCT00376922|stage II adult T-cell leukemia/lymphoma
585024|NCT00376922|T-cell large granular lymphocyte leukemia
585025|NCT00376922|stage I chronic lymphocytic leukemia
585026|NCT00376922|stage II chronic lymphocytic leukemia
585027|NCT00376922|refractory hairy cell leukemia
585028|NCT00376922|recurrent adult T-cell leukemia/lymphoma
585029|NCT00376922|refractory chronic lymphocytic leukemia
585030|NCT00376922|untreated hairy cell leukemia
585031|NCT00376922|recurrent adult Hodgkin lymphoma
585032|NCT00376922|stage I adult Hodgkin lymphoma
585033|NCT00376922|stage II adult Hodgkin lymphoma
585034|NCT00376922|stage III adult Hodgkin lymphoma
585035|NCT00376922|stage IV adult Hodgkin lymphoma
585036|NCT00376922|anaplastic large cell lymphoma
585037|NCT00376922|angioimmunoblastic T-cell lymphoma
585038|NCT00376922|recurrent mycosis fungoides/Sezary syndrome
585039|NCT00376922|stage I mycosis fungoides/Sezary syndrome
585040|NCT00376922|stage II mycosis fungoides/Sezary syndrome
585041|NCT00376922|stage III mycosis fungoides/Sezary syndrome
585042|NCT00376922|stage IV mycosis fungoides/Sezary syndrome
585043|NCT00376922|recurrent cutaneous T-cell non-Hodgkin lymphoma
585044|NCT00376922|stage I cutaneous T-cell non-Hodgkin lymphoma
585045|NCT00376922|stage II cutaneous T-cell non-Hodgkin lymphoma
585046|NCT00376922|stage III cutaneous T-cell non-Hodgkin lymphoma
585047|NCT00376922|stage IV cutaneous T-cell non-Hodgkin lymphoma
585048|NCT00376922|adult grade III lymphomatoid granulomatosis
585049|NCT00376922|recurrent adult grade III lymphomatoid granulomatosis
585050|NCT00376922|Waldenström macroglobulinemia
585051|NCT00376922|contiguous stage II adult Burkitt lymphoma
585052|NCT00376922|noncontiguous stage II adult Burkitt lymphoma
585053|NCT00376922|recurrent adult Burkitt lymphoma
585054|NCT00376922|stage I adult Burkitt lymphoma
585055|NCT00376922|stage III adult Burkitt lymphoma
585056|NCT00376922|stage IV adult Burkitt lymphoma
585057|NCT00376922|contiguous stage II adult diffuse large cell lymphoma
585058|NCT00376922|contiguous stage II adult diffuse mixed cell lymphoma
585059|NCT00376922|contiguous stage II adult diffuse small cleaved cell lymphoma
585060|NCT00376922|noncontiguous stage II adult diffuse large cell lymphoma
585061|NCT00376922|noncontiguous stage II adult diffuse mixed cell lymphoma
585062|NCT00376922|noncontiguous stage II adult diffuse small cleaved cell lymphoma
585063|NCT00376922|recurrent adult diffuse large cell lymphoma
585064|NCT00376922|recurrent adult diffuse mixed cell lymphoma
585065|NCT00376922|recurrent adult diffuse small cleaved cell lymphoma
585066|NCT00376922|stage I adult diffuse large cell lymphoma
585067|NCT00376922|stage I adult diffuse mixed cell lymphoma
585068|NCT00376922|stage I adult diffuse small cleaved cell lymphoma
585069|NCT00376922|stage III adult diffuse large cell lymphoma
585070|NCT00376922|stage III adult diffuse mixed cell lymphoma
585071|NCT00376922|stage III adult diffuse small cleaved cell lymphoma
585072|NCT00376922|stage IV adult diffuse large cell lymphoma
585073|NCT00376922|stage IV adult diffuse mixed cell lymphoma
585074|NCT00376922|stage IV adult diffuse small cleaved cell lymphoma
585075|NCT00376922|contiguous stage II adult immunoblastic large cell lymphoma
585076|NCT00376922|noncontiguous stage II adult immunoblastic large cell lymphoma
585077|NCT00376922|recurrent adult immunoblastic large cell lymphoma
585078|NCT00376922|stage I adult immunoblastic large cell lymphoma
585079|NCT00376922|stage III adult immunoblastic large cell lymphoma
585080|NCT00376922|stage IV adult immunoblastic large cell lymphoma
585081|NCT00376922|contiguous stage II adult lymphoblastic lymphoma
585082|NCT00376922|noncontiguous stage II adult lymphoblastic lymphoma
585083|NCT00376922|recurrent adult lymphoblastic lymphoma
585084|NCT00376922|stage I adult lymphoblastic lymphoma
585085|NCT00376922|stage III adult lymphoblastic lymphoma
585086|NCT00376922|stage IV adult lymphoblastic lymphoma
585087|NCT00376922|contiguous stage II grade 1 follicular lymphoma
585088|NCT00376922|contiguous stage II grade 2 follicular lymphoma
585089|NCT00376922|contiguous stage II grade 3 follicular lymphoma
585090|NCT00376922|noncontiguous stage II grade 1 follicular lymphoma
585091|NCT00376922|noncontiguous stage II grade 2 follicular lymphoma
585092|NCT00376922|noncontiguous stage II grade 3 follicular lymphoma
585093|NCT00376922|recurrent grade 1 follicular lymphoma
585094|NCT00376922|recurrent grade 2 follicular lymphoma
585095|NCT00376922|recurrent grade 3 follicular lymphoma
585096|NCT00376922|stage I grade 1 follicular lymphoma
585097|NCT00376922|stage I grade 2 follicular lymphoma
585098|NCT00376922|stage I grade 3 follicular lymphoma
585099|NCT00376922|stage III grade 1 follicular lymphoma
585100|NCT00376922|stage III grade 2 follicular lymphoma
585101|NCT00376922|stage III grade 3 follicular lymphoma
585102|NCT00376922|stage IV grade 1 follicular lymphoma
585103|NCT00376922|stage IV grade 2 follicular lymphoma
585104|NCT00376922|stage IV grade 3 follicular lymphoma
585105|NCT00376922|contiguous stage II mantle cell lymphoma
585106|NCT00376922|noncontiguous stage II mantle cell lymphoma
585107|NCT00376922|recurrent mantle cell lymphoma
585108|NCT00376922|stage I mantle cell lymphoma
585109|NCT00376922|stage III mantle cell lymphoma
585110|NCT00376922|stage IV mantle cell lymphoma
585111|NCT00376922|contiguous stage II marginal zone lymphoma
585112|NCT00376922|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
585113|NCT00376922|nodal marginal zone B-cell lymphoma
585114|NCT00376922|noncontiguous stage II marginal zone lymphoma
585115|NCT00376922|recurrent marginal zone lymphoma
585116|NCT00376922|splenic marginal zone lymphoma
585117|NCT00376922|stage I marginal zone lymphoma
585118|NCT00376922|stage III marginal zone lymphoma
585119|NCT00376922|stage IV marginal zone lymphoma
585120|NCT00376922|contiguous stage II small lymphocytic lymphoma
585121|NCT00376922|noncontiguous stage II small lymphocytic lymphoma
585122|NCT00376922|recurrent small lymphocytic lymphoma
585123|NCT00376922|stage I small lymphocytic lymphoma
585124|NCT00376922|stage III small lymphocytic lymphoma
585125|NCT00376922|stage IV small lymphocytic lymphoma
585126|NCT00376922|isolated plasmacytoma of bone
585127|NCT00376922|monoclonal gammopathy of undetermined significance
585128|NCT00376922|refractory multiple myeloma
585129|NCT00376922|stage I multiple myeloma
585130|NCT00376922|stage II multiple myeloma
585131|NCT00376922|post-transplant lymphoproliferative disorder
585132|NCT00376922|primary central nervous system non-Hodgkin lymphoma
585133|NCT00376909|breast cancer
585134|NCT00376909|cervical cancer
585135|NCT00376909|colon cancer
585136|NCT00376909|rectal cancer
585137|NCT00376896|IBS fMRI
585138|NCT00376883|multiple myeloma
585139|NCT00376883|pamidronate prophylaxis
585140|NCT00376883|dose comparison
585141|NCT00376883|quality of life
585142|NCT00376883|skeletal event
585143|NCT00376883|response
585144|NCT00376883|survival
585145|NCT00376870|PCI
585146|NCT00376870|STENT
585147|NCT00376870|Coronary
585148|NCT00376870|Type 2 Diabetes Mellitus
585149|NCT00376857|Indocyanine green, toxicity, epiretinal membrane, visual field defect
585150|NCT00376844|stage I endometrial carcinoma
585151|NCT00376831|colonoscopy
585152|NCT00376831|conscious sedation
585153|NCT00376831|midazolam
585154|NCT00376831|ketamine
585155|NCT00376831|fentanyl
585156|NCT00376818|psychosocial effects of cancer and its treatment
585157|NCT00376818|adult anaplastic astrocytoma
585158|NCT00376818|adult anaplastic ependymoma
585159|NCT00376818|adult anaplastic oligodendroglioma
585160|NCT00376818|adult giant cell glioblastoma
585161|NCT00376818|adult gliosarcoma
585162|NCT00376818|adult medulloblastoma
585163|NCT00376818|adult anaplastic meningioma
585164|NCT00376818|adult papillary meningioma
585165|NCT00376818|adult mixed glioma
585166|NCT00376818|recurrent adult brain tumor
585167|NCT00376818|adult glioblastoma
585168|NCT00376818|adult grade III meningioma
585169|NCT00376805|stage IV breast cancer
585170|NCT00376805|male breast cancer
585171|NCT00376805|recurrent breast cancer
585172|NCT00376792|stage IIB prostate cancer
585173|NCT00376792|stage IIA prostate cancer
585174|NCT00376792|stage III prostate cancer
585175|NCT00376792|adenocarcinoma of the prostate
585176|NCT00376779|Haemophilus influenzae type b
585177|NCT00376779|Double-blind
585178|NCT00376779|Finland
585179|NCT00376779|randomized
585180|NCT00376779|phase 2
585181|NCT00376779|GSK Biologicals
585182|NCT00376779|DTPa-HBV-IPV/Hib
585183|NCT00376766|Cluster seizure
585184|NCT00376766|seizure clustering
585185|NCT00376766|repetitive seizure
585186|NCT00376766|Drug resistant epilepsy
585187|NCT00376766|Levetiracetam
585188|NCT00376766|keppra
585189|NCT00376753|Transcranial Magnetic Stimulation (TMS)
585190|NCT00376753|Writer's Cramp
585191|NCT00376753|Electromyogram
585192|NCT00376753|Focal Hand Dystonia
585193|NCT00376753|FHD
585194|NCT00376753|Healthy Volunteer
585195|NCT00376753|HV
585196|NCT00376740|breast cancer, postmenopausal, letrozole, zoledronic acid, adjuvant,bone mineral density
585197|NCT00376727|unspecified adult solid tumor, protocol specific
585198|NCT00376714|plethysmography
585199|NCT00376714|muscarinic receptor antagonist
585200|NCT00376714|COPD
585201|NCT00376714|repeat dosing
585202|NCT00376701|Choroidal Neovascularization
585203|NCT00376701|Photodynamic Therapy
585204|NCT00376701|Age Related Macular Degeneration
585205|NCT00376701|Triamcinolone Acetonide
585206|NCT00376701|Avastin
585207|NCT00376701|Visudyne
585208|NCT00376675|fatigue
585209|NCT00376675|unspecified adult solid tumor, protocol specific
585210|NCT00376662|HRT
585211|NCT00376662|Etidronate
585212|NCT00376662|Fractures
585213|NCT00376662|Osteoporosis
585214|NCT00376662|Asthma
585215|NCT00376662|Glucocorticoids
585216|NCT00376649|crohns
585217|NCT00376649|quality of life
585218|NCT00376649|lifestyle changing
585219|NCT00376649|remmision
585220|NCT00375544|Laser Therapy, Low-Level
585221|NCT00375544|Osteoarthritis
585222|NCT00375544|Phototherapy
585223|NCT00375544|Osteoarthritis, knee
585224|NCT00375544|Light-emitting diode
585225|NCT00376597|lymphedema
585226|NCT00376597|stage IA breast cancer
585227|NCT00376597|stage IB breast cancer
585228|NCT00376597|stage II breast cancer
585229|NCT00376597|stage IIIA breast cancer
585230|NCT00376597|stage IIIB breast cancer
585231|NCT00376597|stage IIIC breast cancer
585232|NCT00376584|Primary Hypercholesteremia
585233|NCT00376584|Mixed Hyperlipidemia
585234|NCT00376571|PCI
585235|NCT00376571|Bifurcation lesion
585236|NCT00376558|cocaine dependence
585237|NCT00376545|Functional Magnetic Resonance Imaging (fMRI)
585238|NCT00376545|Visuomotor
585239|NCT00376545|Occipital Cortex
585240|NCT00376545|Prefrontal Cortex
585241|NCT00376545|Healthy Volunteer
585242|NCT00376545|HV
585243|NCT00376532|Cardiac Ischemia
585244|NCT00376532|Cardiac Arrhythmia
585245|NCT00376532|Defibrillator
585246|NCT00376532|Matrix Metalloproteinase
585247|NCT00376532|Genetic Polymorphism
585248|NCT00376519|graft versus host disease
585363|NCT00376207|PASE
585249|NCT00376519|adult acute lymphoblastic leukemia in remission
585250|NCT00376519|adult acute myeloid leukemia in remission
585251|NCT00376519|secondary acute myeloid leukemia
585252|NCT00376519|refractory anemia with excess blasts
585253|NCT00376519|myelodysplastic syndromes
585254|NCT00376519|chronic myelogenous leukemia
585255|NCT00376519|refractory anemia
585256|NCT00376519|prolymphocytic leukemia
585257|NCT00376519|stage IV adult lymphoblastic lymphoma
585258|NCT00376519|recurrent adult Burkitt lymphoma
585259|NCT00376519|stage I adult Burkitt lymphoma
585260|NCT00376519|stage III adult Burkitt lymphoma
585261|NCT00376519|stage IV adult Burkitt lymphoma
585262|NCT00376519|follicular lymphoma
585263|NCT00376519|mantle cell lymphoma
585264|NCT00376519|chronic idiopathic myelofibrosis
585265|NCT00376519|secondary myelofibrosis
585266|NCT00376519|refractory chronic lymphocytic leukemia
585267|NCT00376519|recurrent small lymphocytic lymphoma
585268|NCT00376519|recurrent marginal zone lymphoma
585269|NCT00376519|marginal zone lymphoma
585270|NCT00376519|diffuse large cell lymphoma
585271|NCT00376519|anaplastic large cell lymphoma
585272|NCT00376519|lymphoblastic lymphoma
585273|NCT00376519|immunoblastic large cell lymphoma
585274|NCT00376519|multiple myeloma
585275|NCT00376506|Aspiration
585276|NCT00376506|Rehabilitation
585277|NCT00376506|Swallowing Disorders
585278|NCT00376506|Stroke
585279|NCT00376506|Parkinson's Disease
585280|NCT00376506|Dysphagia
585281|NCT00376506|Parkinson Disease
585282|NCT00376506|PD
585283|NCT00376493|Abortion
585284|NCT00376493|Infection
585285|NCT00376493|Antibiotics
585286|NCT00376493|Treatment
585287|NCT00376493|Pregnancy complications
585288|NCT00376480|refractory anemia with excess blasts in transformation
585289|NCT00376480|adult acute lymphoblastic leukemia in remission
585290|NCT00376480|refractory anemia with excess blasts
585291|NCT00376480|refractory anemia
585292|NCT00376480|adult acute myeloid leukemia in remission
585293|NCT00376480|childhood acute lymphoblastic leukemia in remission
585294|NCT00376480|childhood acute myeloid leukemia in remission
585295|NCT00376480|de novo myelodysplastic syndromes
585296|NCT00376480|previously treated myelodysplastic syndromes
585297|NCT00376480|secondary acute myeloid leukemia
585298|NCT00376480|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
585299|NCT00376480|adult acute myeloid leukemia with inv(16)(p13;q22)
585300|NCT00376480|adult acute myeloid leukemia with t(15;17)(q22;q12)
585301|NCT00376480|adult acute myeloid leukemia with t(16;16)(p13;q22)
585302|NCT00376480|adult acute myeloid leukemia with t(8;21)(q22;q22)
585303|NCT00376480|secondary myelodysplastic syndromes
585304|NCT00376480|childhood myelodysplastic syndromes
585305|NCT00376467|Acute Lymphoblastic Leukemia
585306|NCT00376467|Philadelphia positive
585307|NCT00376467|Adult
585308|NCT00376467|Elderly
585309|NCT00376467|Imatinib
585310|NCT00376454|neuropathic pain
585311|NCT00376441|vaginal
585312|NCT00376441|incontinence
585313|NCT00376441|sexual function
585314|NCT00376428|Cystic Fibrosis Transmembrane Conductance Regulator
585315|NCT00376428|Premature termination codon
585316|NCT00376428|Gentamicin-induced readthrough
585317|NCT00376415|Lessertia frutescens
585318|NCT00376415|Sutherlandia frutescens
585319|NCT00376415|Phase 1 clinical trial
585320|NCT00376415|Human safety study
585321|NCT00376402|Pandemic
585322|NCT00376402|Influenza
585323|NCT00376402|Prevention
585324|NCT00376402|Vaccine
585325|NCT00376402|Prevention of Pandemic Influenza
585326|NCT00376376|levofloxacin
585327|NCT00376376|pharmacodynamic
585328|NCT00376376|bactericidal
585329|NCT00376363|glaucoma
585330|NCT00376363|Ahmed implant
585331|NCT00376363|Baerveldt implant
585332|NCT00376350|Low Back Pain
585333|NCT00376350|Chronic
585334|NCT00376350|Manipulation
585335|NCT00376350|Chiropractic
585336|NCT00376350|Massage
585337|NCT00376337|Invasive Aspergillosis
585338|NCT00376337|Salvage Therapy
585339|NCT00376337|Micafungin
585340|NCT00376324|pharmacokinetics
585341|NCT00376324|human bone
585342|NCT00376311|Lequesne's algo-functional score
585343|NCT00376311|Biomarkers of joint metabolism
585344|NCT00376298|incontinence
585345|NCT00376298|prostate cancer
585346|NCT00376298|interstitial cystitis
585347|NCT00376272|atrial fibrillation,atrial remodeling,dysrhythmias,valsartan
585348|NCT00376259|lamivudine resistance
585349|NCT00376259|Hepatitis B virus
585350|NCT00376233|Schizophrenia,
585351|NCT00376233|Cannabinoids,
585352|NCT00376233|Arachidonic Acid,
585353|NCT00376233|Niacin,
585354|NCT00376233|Prostaglandins
585355|NCT00376220|Bipolar
585356|NCT00376220|Depression
585357|NCT00376207|Cerebral infarct
585358|NCT00376207|physical exercise
585359|NCT00376207|insulin sensitivity
585360|NCT00376207|low grade chronic inflammation
585361|NCT00376207|intervention
585362|NCT00376207|HOMA
585364|NCT00376194|Pervasive Developmental Disorder
585365|NCT00376194|Alternative Therapy
585366|NCT00376194|Autism
585367|NCT00376194|Asperger's Disorder
585368|NCT00376194|Clinical Trial
585369|NCT00376194|Autism Spectrum Disorder
585370|NCT00376194|ASD
585371|NCT00376194|Asperger Disorder
585372|NCT00376181|type 2 diabetes
585373|NCT00376181|hypertension
585374|NCT00376181|blood pressure
585375|NCT00376181|diastolic blood pressure
585376|NCT00376155|malaria
585377|NCT00376155|prevention
585378|NCT00376155|intermittent
585379|NCT00376155|drugs
585380|NCT00376142|Intention
585381|NCT00376142|Behaviour
585382|NCT00376142|Evidence-based practice
585383|NCT00376142|Intervention
585384|NCT00376116|Implantable cardioverter-defibrillator
585385|NCT00376116|Pacemaker
585386|NCT00376116|Cardiac resynchronisation therapy
585387|NCT00376116|Heart failure
585388|NCT00376116|Predictor
585389|NCT00376116|Mortality
585390|NCT00376116|Rehospitalization
585391|NCT00376116|Telemedicine
585392|NCT00376116|Home Monitoring
585393|NCT00376103|Brain Tumor
585394|NCT00376103|GBM
585395|NCT00376103|Glioblastoma Multiforme
585396|NCT00376103|Glioblastoma
585397|NCT00376103|Brachytherapy
585398|NCT00376103|Temozolomide
585399|NCT00376103|Temodar
585400|NCT00376090|MVA vector
585401|NCT00376090|Immunogenicity
585402|NCT00376090|HIV vaccine
585403|NCT00376090|HIV preventative vaccine
585404|NCT00376077|Thrombocytopenia
585405|NCT00376077|pediatric
585406|NCT00376077|methylprednisolone
585407|NCT00376077|intracranial hemorrhage
585408|NCT00376077|intravenous immune globulin
585409|NCT00376064|Growth hormone (GH)
585410|NCT00376064|IGF-1
585411|NCT00376064|Acromegaly
585412|NCT00376064|Pituitary adenoma
585413|NCT00376064|Brain tumor
585414|NCT00376064|Brain cancer
585415|NCT00376064|Octreotide acetate
585416|NCT00376051|frontotemporal lobar degeneration
585417|NCT00376051|frontotemporal dementia
585418|NCT00376051|serotonin
585419|NCT00376051|dementia
585420|NCT00376051|behavioural disturbances
585421|NCT00376038|GSK189074
585422|NCT00376038|T2DM
585423|NCT00376038|GSK189075
585424|NCT00376038|Glucophage
585425|NCT00376038|Obesity
585426|NCT00376038|Diabetes
585427|NCT00376038|Metformin
585428|NCT00376038|Type 2 Diabetes Mellitus
585429|NCT00376038|Drug Interaction
585430|NCT00376025|Kashin-Beck Disease
585431|NCT00376025|Kashin-Beck Osteoarthropathy
585432|NCT00376012|Chemotherapy for TB in HIV infection
585433|NCT00375986|Cesarean delivery
585434|NCT00375986|Placental removal
585435|NCT00375986|Blood loss
585436|NCT00375973|Fatigue
585437|NCT00375973|Fatigue syndrome, chronic
585438|NCT00375973|Chronic fatigue syndrome
585439|NCT00375973|CFS
585440|NCT00375973|Fibromyalgia
585441|NCT00375960|Pain associated with diabetes Type I or Type II
585442|NCT00375960|Neuropathic Pain due to diabetes
585443|NCT00375960|Diabetic peripheral neuropathic pain
585444|NCT00375960|Pain
585445|NCT00375960|Diabetes with burning sensation in the arms and/or legs
585446|NCT00375960|Diabetes with tingling sensation in the arms and/or legs
585447|NCT00375960|Neuropathic Pain Due to Diabetes Type I or Type II
585448|NCT00375947|exercise
585449|NCT00375947|hand disability
585450|NCT00375947|arthritis
585451|NCT00375947|AUSCAN
585452|NCT00375934|Bunionectomy
585453|NCT00375934|Bunion surgery
585454|NCT00375934|Post-operative pain
585455|NCT00375921|diet
585456|NCT00375921|food
585457|NCT00375921|taste
585458|NCT00375921|smell
585459|NCT00375921|head and neck
585460|NCT00375921|radiation
585461|NCT00375921|chemotherapy
585462|NCT00375908|Neonatal Encephalopathy
585463|NCT00375908|Hypoxic-Ischemic Brain Injury
585464|NCT00375908|Umbilical Cord Blood
585465|NCT00375908|Proteomics
585466|NCT00375895|Cyclosporin
585467|NCT00375895|Peginterferon
585468|NCT00375895|Ribavirin
585469|NCT00375895|Chronic hepatitis C
585470|NCT00375895|Liver transplantation
585471|NCT00375869|Neuroprotection
585472|NCT00375869|neuron specific enolase
585473|NCT00375869|CSF glutamate levels
585474|NCT00375869|Darbepoetin Alfa
585475|NCT00375856|arthroplasty
585476|NCT00375856|knee
585477|NCT00375856|computer-assist
585478|NCT00375856|gait
585479|NCT00375856|Total knee arthroplasty
585480|NCT00375856|knee prostheses
585481|NCT00375804|Endometrial Cancer
585482|NCT00375791|Relapsed Multiple Myeloma
585483|NCT00375791|Refractory Multiple Myeloma
585484|NCT00375778|Parkinson's Disease
585485|NCT00375778|Positron Emission Tomography
585486|NCT00375778|Memantine
585487|NCT00375778|NMDA antagonists
585488|NCT00375778|Cerebral Blood Flow
585489|NCT00375778|Cerebral Metabolic Rate of Oxygen
585490|NCT00375765|Dutasteride
585491|NCT00375765|BPH
585492|NCT00375765|Prostate cancer
585493|NCT00375765|Gene expression
585494|NCT00375765|PSA
585495|NCT00375752|Breast cancer
585496|NCT00375752|Anti tumor potential
585497|NCT00375752|Letrozole
585498|NCT00375752|Zoledronic acid
585499|NCT00375752|Neoadjuvant treatment
585500|NCT00375752|Hormone responsive breast cancer
585501|NCT00375739|Actinic Keratosis
585502|NCT00375739|Topical
585503|NCT00375739|Solar Keratosis
585504|NCT00375739|Sun Spots
585505|NCT00375739|Dermatology
585506|NCT00375726|Dengue Fever
585507|NCT00375726|Dengue Vaccine
585508|NCT00375726|Dengue Virus
585509|NCT00375726|Dengue Hemorrhagic Fever
585510|NCT00375726|Dengue Shock Syndrome
585511|NCT00375713|Dermatitis
585512|NCT00375713|Eczema
585513|NCT00375713|Pruritus
585514|NCT00375713|Xyzal
585515|NCT00375713|Zyrtec
585516|NCT00375713|Levocetirizine
585517|NCT00375713|Cetirizine
585518|NCT00375700|food
585519|NCT00375700|diet
585520|NCT00375700|oral supplement
585521|NCT00375700|head and neck cancer
585522|NCT00375700|radiation
585523|NCT00375687|Prostate cancer
585524|NCT00375661|hepatocellular carcinoma
585525|NCT00375648|Prostate
585526|NCT00375648|Cancer
585527|NCT00375648|Bone metastases
585528|NCT00375648|Zoledronic acid
585529|NCT00375648|Bone metastases-related pain
585530|NCT00375648|Prostate cancer
585531|NCT00375635|mFPSA
585532|NCT00375635|Uremic toxins
585533|NCT00375635|Protein bound toxins
585534|NCT00375635|Uremia
585535|NCT00375635|Chronic hemodialysis
585536|NCT00375622|HHT
585537|NCT00375622|Epistaxis
585538|NCT00375622|Tamoxifen
585539|NCT00375622|Hemoglobin
585540|NCT00375609|Prevention of Venous Thromboembolism
585541|NCT00375531|Post Traumatic Stress Disorder
585542|NCT00375531|Mindfulness Meditation
585543|NCT00375518|Thoracic Surgery
585544|NCT00375518|Cardiopulmonary complications
585545|NCT00375518|Atorvastatin
585546|NCT00375505|Breast Cancer
585547|NCT00375505|Premenopausal
585548|NCT00375505|Bone mineral density
585549|NCT00375505|Cancer therapy induced bone loss
585550|NCT00375505|zoledronic acid
585551|NCT00375492|diabetes
585552|NCT00375492|overweight
585553|NCT00375492|obesity
585554|NCT00375492|weight loss
585555|NCT00375492|exenatide
585556|NCT00375492|Amylin
585557|NCT00375492|Lilly
585558|NCT00375466|Hemorrhage
585559|NCT00375466|Transfusion
585560|NCT00375466|Blood components
585561|NCT00375466|Fibrinolysis
585562|NCT00375466|Platelet activation
585563|NCT00375453|Paclitaxel
585564|NCT00375453|Advanced Solid Tumors
585565|NCT00375440|Tranexamic Acid
585566|NCT00375440|Revision Total Hip Replacement
585567|NCT00375440|Reduction in Blood Loss
585568|NCT00375427|Breast cancer
585569|NCT00375427|Zoledronic acid
585570|NCT00375427|Skeletal related events (SRE)
585571|NCT00375414|Enteral tube feeding,
585572|NCT00375414|endoscopic gastropexy,
585573|NCT00375414|percutaneous endoscopic gastrostomy,
585574|NCT00375414|PEG
585575|NCT00375388|Type 2 diabetes mellitus
585576|NCT00375388|Metformin on top of insulin therapy
585577|NCT00375388|Randomized placebo-controlled trial
585578|NCT00375388|Diabetes regulation
585579|NCT00375388|Daily dose of insulin
585580|NCT00375388|Body Weight
585581|NCT00375388|Patients with type 2 diabetes
585582|NCT00375388|Intensive insulin therapy
585583|NCT00375388|Age: 30-80 years
585584|NCT00375388|Body mass index
585585|NCT00375388|Lipids
585586|NCT00375388|Blood Pressure
585587|NCT00375388|Endothelial function
585588|NCT00375388|Low grade inflammation
585589|NCT00375388|Fibrinolysis
585590|NCT00375388|Microvascular complications
585591|NCT00375388|Macrovascular complications
585592|NCT00375375|Minimal hepatic encephalopathy
585593|NCT00375375|Hepatic encephalopathy
585594|NCT00375375|Subclinical hepatic encephalopathy
585595|NCT00375375|Health related quality of life
585596|NCT00375362|nitroglycerin
585597|NCT00375362|morphine
585598|NCT00375362|patient controlled analgesia
585599|NCT00375362|total knee arthroplasty
585600|NCT00375349|fatty liver
585601|NCT00375349|statin
585602|NCT00375349|non-alcoholic
585603|NCT00375336|Aortic valve
585604|NCT00375336|Calcification
585605|NCT00375336|Endothelial dysfunction
585606|NCT00375336|Calcium metabolism
585607|NCT00375336|Coronary artery disease
585608|NCT00375323|factor VIII inhibitor
585609|NCT00375310|Phase I
585610|NCT00375310|Pancreas Cancer
585611|NCT00375310|Chemo-radiotherapy
585612|NCT00375297|antidepressants
585613|NCT00375297|sexual dysfunction
585614|NCT00375297|women
585615|NCT00375297|sildenafil
585616|NCT00375297|PDE5 inhibitors
585617|NCT00375297|serotonin reuptake inhibitor antidepressants
585618|NCT00375271|Monitoring, Intraoperative
585619|NCT00375271|Hemodynamic Processes
585620|NCT00375271|Treatment Protocols
585621|NCT00375258|Adult trauma patients with ongoing significant haemorrhage or at risk of significant haemorrhage
585622|NCT00375245|phase I
585623|NCT00375245|metastatic
585624|NCT00375245|advanced cancer
585625|NCT00375245|lung cancer
585626|NCT00375245|renal cancer
585627|NCT00375245|kidney cancer
585628|NCT00375245|head and neck cancer
585629|NCT00375245|bladder cancer
585630|NCT00375245|breast cancer
585631|NCT00375245|colorectal cancer
585632|NCT00375245|esophagus
585633|NCT00375245|GIST
585634|NCT00375245|liver cancer
585635|NCT00375245|melanoma
585636|NCT00375245|mesothelioma
585637|NCT00375245|lymphoma
585638|NCT00375245|ovary cancer
585639|NCT00375245|ovarian cancer
585640|NCT00375245|pancreas cancer
585641|NCT00375245|pancreatic cancer
585642|NCT00375245|prostate cancer
585643|NCT00375245|stomach cancer
585644|NCT00375245|thyroid cancer
585645|NCT00375245|Metastatic solid tumor
585646|NCT00375232|Exercise-Induced Bronchospasm
585647|NCT00375232|Asthma
585648|NCT00375232|Cardiopulmonary Stress Test
585649|NCT00375232|Eucapnic Voluntary Hyperventilation
585650|NCT00375232|Induced sputum
585651|NCT00375219|Chronic Myeloid Leukemia
585652|NCT00375219|CML
585653|NCT00375219|HHT
585654|NCT00375219|Homoharringtonine
585655|NCT00375219|Omacetaxine
585656|NCT00375219|T315i
585657|NCT00375219|ChemGenex
585658|NCT00375219|ChemGenex Pharmaceuticals
585659|NCT00375206|PowderMed, DNA vaccine, influenza
585660|NCT00375193|small cell lung cancer
585661|NCT00375193|amrubicin
585662|NCT00375180|food
585663|NCT00375180|diet
585664|NCT00375180|mucositis
585665|NCT00375180|xerostomia
585666|NCT00375180|dysphagia
585667|NCT00375180|taste
585668|NCT00375180|smell
585669|NCT00375180|head and neck
585670|NCT00375180|radiation
585671|NCT00375180|chemotherapy
585672|NCT00375167|Recovery, Hope, Empowerment, Randomized Control Trial
585673|NCT00375154|Acute respiratory failure
585674|NCT00375154|Prehospital care
585675|NCT00375154|Noninvasive ventilation
585676|NCT00375154|Emergency
585677|NCT00375128|Malaria
585678|NCT00375128|Vaccine
585679|NCT00375128|Prime-boost
585680|NCT00375128|Challenge
585681|NCT00375102|acupuncture
585682|NCT00375102|relaxation response
585683|NCT00375102|homeless
585684|NCT00375102|veterans
585685|NCT00375102|randomized trials
585686|NCT00375089|Early-onset Morbid Obesity
585687|NCT00375063|left main stenosis
585688|NCT00375063|Percutaneous Coronary Intervention
585689|NCT00375063|Coronary Artery Bypass Grafting
585690|NCT00375037|hand washing
585691|NCT00375037|cluster randomized trial
585692|NCT00375037|performance feedback
585693|NCT00375037|healthcare workers
585694|NCT00375037|Hand hygiene
585695|NCT00375037|hand washing adherence
585696|NCT00375024|Patient navigation
585697|NCT00375024|Breast cancer
585698|NCT00375024|Colon cancer
585699|NCT00375024|Questionnaire
585700|NCT00375011|MELD-Model of End Stage Liver Disease score
585701|NCT00375011|CTP-Child-Turcotte-Pugh score
585702|NCT00375011|MEGX-monoethylglycinexylidide-resultant of metabolism of lidocaine
585703|NCT00375011|HCC-Hepatocellular carcinoma
585704|NCT00375011|HCV-Hepatitis C virus
585705|NCT00375011|NASH-Non-alcoholic Steatohepatitis
585706|NCT00374998|Malaria
585707|NCT00374998|Vaccine
585708|NCT00374998|Prime-boost
585709|NCT00374985|chemoradiation
585710|NCT00374985|docetaxel
585711|NCT00374985|oxaliplatin
585712|NCT00374985|gastric
585713|NCT00374985|neoadjuvant
585714|NCT00374985|radiochemotherapy
585715|NCT00374959|Prevention of pneumonia
585716|NCT00374959|ceftriaxone
585717|NCT00374959|continuous aspiration
585718|NCT00374959|subglottic secretions
585719|NCT00374959|Mechanical ventilation with Endotracheal intubation.
585720|NCT00374959|Absence of infection
585721|NCT00374933|AML
585722|NCT00374933|ALL
585723|NCT00374933|MDS
585724|NCT00374933|Allogeneic transplant
585725|NCT00374933|Acute Myelogenous Leukemia
585726|NCT00374933|Acute Lymphoblastic Leukemia
585727|NCT00374933|Myelodysplastic Syndrome
585728|NCT00374933|Adoptive cell therapy
585729|NCT00374933|Non-myeloablative
585730|NCT00374920|bipolar
585731|NCT00374920|mania
585732|NCT00374920|mixed
585733|NCT00374894|2,3-dimercaptosuccinic acid
585734|NCT00374894|Blood Lead Levels
585735|NCT00374894|children
585736|NCT00374894|multi-nutrients
585737|NCT00374842|Influenza vaccine
585738|NCT00374842|Prophylaxis Influenza vaccine
585739|NCT00374829|randomised prospective trial
585740|NCT00374829|medication refill compliance
585741|NCT00374829|hypertension
585742|NCT00374829|ambulatory blood pressure monitoring
585743|NCT00374829|information technology based patient support system
585744|NCT00374829|process of care, quality of life, pharmacoeconomics
585745|NCT00374829|multidisciplinary patient management
585746|NCT00374803|Kidney
585747|NCT00374803|Transplant
585748|NCT00374803|Corticosteroid
585749|NCT00374803|Myfortic
585750|NCT00374790|Lead toxicity
585751|NCT00374777|Insomnia
585752|NCT00374777|schizophrenia
585753|NCT00374777|manic-depressive psychosis
585754|NCT00374777|zolpidem
585755|NCT00374764|Autism, Applied Behavioral Analysis, Risperidone
585756|NCT00374751|Samarium
585757|NCT00374751|Kyphoplasty
585758|NCT00374751|Pain management
585759|NCT00374751|Bone metastases
585760|NCT00374751|Histologically proven malignancy in the primary site
585761|NCT00374751|Radiographic evidence of bone metastasis
585762|NCT00374751|Significant pain equal or more than score 5
585763|NCT00374751|Karnofsky Performance status >40
585764|NCT00374751|The patient must sign a study specific informed consent
585765|NCT00374738|Guided Imagery for Trauma (GIFT)
585766|NCT00374738|Posttraumatic Stress Disorder (PTSD)
585767|NCT00374738|Military Sexual Trauma (MST)
585768|NCT00374738|Military Sexual Trauma - related PTSD
585769|NCT00374725|Ulcerative Colitis
585770|NCT00374725|Probiotic
585771|NCT00374725|Placebo controlled trial
585772|NCT00374725|Lactobacillus rhamnosus
585773|NCT00374725|Lactobacillus acidophilus
585774|NCT00374712|Phosphate
585775|NCT00374712|Dialysis
585776|NCT00374712|Klotho
585777|NCT00374712|Hemodialysis
585778|NCT00374699|Velcade
585779|NCT00374699|Bortezomib
585780|NCT00374699|CHOP
585781|NCT00374699|Peripheral T-cell lymphomas(PTCLs)
585782|NCT00374699|natural killer (NK)-cell lymphomas
585783|NCT00374686|cytomegalovirus
585784|NCT00374686|kidney
585785|NCT00374686|transplantation
585786|NCT00374686|valganciclovir
585787|NCT00374686|preemptive
585788|NCT00374673|TMS
585789|NCT00374673|chronic pain
585790|NCT00374673|fibromyalgia
585791|NCT00374673|IBS
585792|NCT00374673|burning mouth syndrome
585793|NCT00374673|predictive factors
585794|NCT00374660|Irofulven
585795|NCT00374660|Oxaliplatin
585796|NCT00374647|Renal
585797|NCT00374647|Kidney
585798|NCT00374647|Transplant
585799|NCT00374608|pediatric
585800|NCT00374608|congenital complete heart block
585801|NCT00374608|dual chamber pacemaker
585802|NCT00374595|Kidney Transplant
585803|NCT00374595|Vascular Risk
585804|NCT00374595|inflammation
585805|NCT00374595|Diabetes
585806|NCT00374595|Insulin resistance
585807|NCT00374595|Chronic kidney disease
585808|NCT00374582|Bioelectric impedance analysis
585809|NCT00374582|BIA
585810|NCT00374582|ESLD
585811|NCT00374582|LVP
585812|NCT00374582|Large volume paracentesis
585813|NCT00374582|Ascites
585814|NCT00374582|Liver
585815|NCT00374582|Hepatic
585816|NCT00374569|Gymnastics, Computerized Dynamic Posturography, Balance
585817|NCT00374556|eszopiclone
585818|NCT00374556|insomnia
585819|NCT00374543|Bipolar Disorder
585820|NCT00374543|Generalized Anxiety Disorder
585821|NCT00374543|Double-blind
585822|NCT00374543|Placebo-controlled
585823|NCT00374543|Ziprasidone
585824|NCT00374517|Mycobacterium Tuberculosis
585825|NCT00374517|Pimonidazole Hydrochloride
585826|NCT00374517|Recurrent Tuberculosis
585827|NCT00374517|Hypoxyprobe
585828|NCT00374517|mRNA Expression
585829|NCT00374517|Pulmonary Tuberculosis
585830|NCT00374491|ACL
585831|NCT00374491|Bone Screw
585832|NCT00374491|Knee
585833|NCT00374478|Scopolamine
585834|NCT00374478|Antiemetic
585835|NCT00374478|Task performance and analysis
585836|NCT00374478|Psychomotor vigilance test
585837|NCT00374465|Dilated Cardiomyopathy
585838|NCT00374465|Heart Failure
585839|NCT00374452|hypertension
585840|NCT00374452|practice guidelines
585841|NCT00374452|quality of health care
585842|NCT00374452|decision support systems
585843|NCT00374452|evidence-based medicine
585844|NCT00374452|medical informatics
585845|NCT00374439|depression
585846|NCT00374439|adolescents
585847|NCT00374439|prevention
585848|NCT00374439|schools
585849|NCT00374426|depression
585850|NCT00374426|diabetes mellitus
585851|NCT00374426|depression recurrence
585852|NCT00374413|DDD
585853|NCT00374413|artificial disc
585854|NCT00374400|Kidney
585855|NCT00374400|Transplant
585856|NCT00374400|Paired donation
585857|NCT00374400|Living donor
585858|NCT00374387|Healthy women
585859|NCT00374374|probiotic
585860|NCT00374361|insulin sensitivity
585861|NCT00374361|endothelial function
585862|NCT00374361|adolescence
585863|NCT00374361|lipids
585864|NCT00374361|puberty
585865|NCT00374348|Schizophrenia with OCD
585866|NCT00374348|Schizophrenia with-comorbid symptoms of Obsessive Compulsive Disorder(OCD)
585867|NCT00374335|prospective cohort study
585868|NCT00374322|Breast Cancer
585869|NCT00374322|ErbB2-overexpressing
585870|NCT00374322|early-stage breast cancer
585871|NCT00374322|adjuvant
585872|NCT00374309|Hemorrhagic Fever
585873|NCT00374309|Healthy
585874|NCT00374309|Immunity
585875|NCT00374309|T -Cells
585876|NCT00374309|Filovirus
585877|NCT00374309|Healthy Volunteer
585878|NCT00374309|HV
585879|NCT00374296|Leukemia
585880|NCT00374296|MDS
585881|NCT00374296|Phase II
585882|NCT00374296|Acute Myelogenous Leukemia (AML)
585883|NCT00374296|High Risk Myelodysplastic Syndromes (MDS)
585884|NCT00374283|Monitoring
585885|NCT00374283|Polyomavirus
585886|NCT00374283|Kidney
585887|NCT00374283|Pancreas
585888|NCT00374283|Transplant
585889|NCT00374270|Diabetes (type I and type II)
585890|NCT00374257|NB-UVB
585891|NCT00374257|cGVHD
585892|NCT00374244|schizophrenia
585893|NCT00374244|pimozide
585894|NCT00374244|clozapine
585895|NCT00374231|Liver
585896|NCT00374231|Transplant
585897|NCT00374231|Corticosteroid withdrawal
585898|NCT00374231|Tacrolimus
585899|NCT00374231|CellCept
585900|NCT00374231|MMF
585901|NCT00374231|Mycophenolate mofetil
585902|NCT00374218|Carbohydrate
585903|NCT00374218|Glycemic index
585904|NCT00374218|Randomized
585905|NCT00374218|Double-blind
585906|NCT00374218|Glucose
585907|NCT00374218|Insulin
585908|NCT00374218|C-reactive protein
585909|NCT00374205|Ghana
585910|NCT00374205|Effectiveness
585911|NCT00374205|Safety
585912|NCT00374205|Drug-Resistance
585913|NCT00374205|ACT
585914|NCT00374205|Coartem
585915|NCT00374205|Arsucam
585916|NCT00374192|Menopause
585917|NCT00374192|Insomnia
585918|NCT00374192|Depression
585919|NCT00374192|Anxiety
585920|NCT00374192|Sleep
585921|NCT00374192|Lunesta
585922|NCT00374192|Quality of Life
585923|NCT00374166|Anti-anxiety agents
585924|NCT00374166|antidepressive agents
585925|NCT00374166|controlled clinical trial
585926|NCT00374153|Alcohol
585927|NCT00374153|Drinking
585928|NCT00374153|College
585929|NCT00374153|Motivational
585930|NCT00374153|Feedback
585931|NCT00374153|Assessment
585932|NCT00374140|small cell
585933|NCT00374140|lung
585934|NCT00374127|Marijuana
585935|NCT00374127|Comparison between joints and blunts
585936|NCT00374127|Pharmacokinetic effects
585937|NCT00374114|cervical
585938|NCT00374114|dysplasia
585939|NCT00374101|PPIs,
585940|NCT00374101|endoscopic therapy,
585941|NCT00374101|peptic ulcers,
585942|NCT00374101|upper gastrointestinal bleeding,
585943|NCT00374101|non-variceal upper gastrointestinal bleeding
585944|NCT00374088|N-acetylcysteine
585945|NCT00374088|Myocardial dysfunction
585946|NCT00374088|Transposition of the Great Arteries
585947|NCT00374075|Spinal Muscular Atrophy (SMA)
585948|NCT00374075|Valproic Acid
585949|NCT00374062|Mohs Surgery
585950|NCT00374049|Prostate
585951|NCT00374049|vaccine
585952|NCT00374049|immunosuppression
585953|NCT00374049|dendritic cells
585954|NCT00374036|chemotherapy
585955|NCT00374036|stomach cancer metastatic
585956|NCT00374036|Capecitabine
585957|NCT00374036|Irinotecan
585958|NCT00374023|Zinc
585959|NCT00374023|vitamin A
585960|NCT00374023|immunity
585961|NCT00374023|morbidity
585962|NCT00374023|height gain
585963|NCT00374023|weight gain
585964|NCT00374023|Children aged between 1 and 3 years
585965|NCT00374023|Weight for age between 70% and 61% of NCHS standard
585966|NCT00374023|Acute diarrhoeal Patients
585967|NCT00374023|No signs of vitamin A deficiency
585968|NCT00374023|Who has not received measles vaccine
585969|NCT00374010|end-of-life decision making
585970|NCT00374010|advance care planning
585971|NCT00373984|shoulder
585972|NCT00373984|thoracotomy
585973|NCT00373971|Activities of daily living
585974|NCT00373971|Elderly
585975|NCT00373971|Nutrition
585976|NCT00373971|Postoperative
585977|NCT00373971|Hip fractures
585978|NCT00373971|Hip replacement
585979|NCT00373971|Knee replacement
585980|NCT00373945|HLA-B*5701
585981|NCT00373945|pharmacogenetic marker
585982|NCT00373945|hypersensitivity to abacavir,
585983|NCT00373945|retrospective analysis
585984|NCT00373932|Exercise
585985|NCT00373932|Physical Activity
585986|NCT00373932|Adherence
585987|NCT00373906|MALT Lymphoma, Bortezomib
585988|NCT00373893|Pain
585989|NCT00373893|Hyperalgesia
585990|NCT00373893|capsaicin
585991|NCT00373880|Aripiprazole
585992|NCT00373880|Cocaine abuse
585993|NCT00373867|Secondary prevention
585994|NCT00373867|Physical therapy
585995|NCT00373867|Fear-avoidance beliefs
585996|NCT00373867|Disability
585997|NCT00373854|Hypoglycemia
585998|NCT00373854|Endothelial function
585999|NCT00373841|Lung
586000|NCT00373841|Fibrosis
586001|NCT00373841|Idiopathic
586002|NCT00373841|Biomarkers
586003|NCT00373841|Genomics
586004|NCT00373841|Longitudinal
586005|NCT00373828|Chest Pain
586006|NCT00373828|Chest Wall
586007|NCT00373828|Angina Pectoris
586008|NCT00373828|Atypical Chest Pain
586009|NCT00373828|Physical Examination
586010|NCT00373828|Myocardial Perfusion Imaging
586011|NCT00373828|Observational Study
586012|NCT00373828|Non-Cardiac Chest Pain
586013|NCT00373828|Ischemic Heart Disease
586014|NCT00373815|acute GVHD
586015|NCT00373815|Immunosuppression
586016|NCT00373789|Botulinum Toxin A
586017|NCT00373789|Urinary Incontinence
586018|NCT00373789|Detrusor Overactivity
586019|NCT00373776|mucosal
586020|NCT00373776|leishmaniasis
586021|NCT00373776|miltefosine
586022|NCT00373763|Congenital diaphragmatic hernia
586023|NCT00373763|tracheal occlusion
586024|NCT00373763|fetus
586025|NCT00373763|fetal surgery
586026|NCT00373763|fetoscopy
586027|NCT00373750|Native American health
586028|NCT00373750|Teen pregnancy
586029|NCT00373750|Family strengthening
586030|NCT00373750|Substance abuse prevention
586031|NCT00373750|Injury prevention
586032|NCT00373724|sacroiliac joint
586033|NCT00373724|low back pain
586034|NCT00373724|radiofrequency
586035|NCT00373698|Stress Disorders, Posttraumatic
586036|NCT00373698|Delivery of Health Care, Integrated
586037|NCT00373698|Primary Health Care
586038|NCT00373698|Veterans
586039|NCT00373698|Depression
586040|NCT00373685|GI events in patients with moderate GI risk treated with NSAIDS
586041|NCT00373672|schizophrenia
586042|NCT00373672|cognition
586043|NCT00373659|Neovascularization
586044|NCT00373659|Age-related macular degeneration
586045|NCT00373659|Ranibizumab (Lucentis)
586046|NCT00373659|Optical coherence tomography
586047|NCT00373659|Intravitreal injection
586048|NCT00373646|MALT Lymphoma
586049|NCT00373646|thalidomide
586050|NCT00373646|disseminated MALT Lymphoma or at relapse following HP-eradication
586051|NCT00373646|or chemotherapy or radiation
586052|NCT00373633|THoracic Surgery
586053|NCT00373633|thoracic epidural
586054|NCT00373633|epidural
586055|NCT00373633|thoracotomy
586056|NCT00373633|intercostal nerve block
586057|NCT00373633|intercostal
586058|NCT00373633|nerve block
586059|NCT00373620|endometrial cancer
586060|NCT00373620|high risk
586061|NCT00373620|weekly paclitaxel
586062|NCT00373620|Cuncurrent chemoradiation
586063|NCT00373607|Non complicated malaria
586064|NCT00373607|Microscopy
586065|NCT00373607|Adult
586066|NCT00373607|Children
586067|NCT00373594|Cold agglutinin disease
586068|NCT00373594|Hemolytic
586069|NCT00373594|Anemia
586070|NCT00373594|Lymphoproliferative disease
586071|NCT00373594|Monoclonal antibodies
586072|NCT00373594|Rituximab
586073|NCT00373594|Fludarabine
586074|NCT00373581|Vigabatrin
586075|NCT00373581|GABA levels
586076|NCT00373581|Smoked cocaine
586077|NCT00372541|ceftriaxone
586078|NCT00372541|chloramphenicol
586079|NCT00372541|severe pneumonia
586080|NCT00372541|children
586081|NCT00372515|epidermal growth factor
586082|NCT00372515|EGFR
586083|NCT00372515|lung cancer
586084|NCT00372515|Iressa
586085|NCT00372515|Gefitinib
586086|NCT00372502|sepsis
586087|NCT00372502|shock
586088|NCT00372502|emergency department
586089|NCT00372502|resuscitation
586090|NCT00373568|mucosal
586091|NCT00373568|miltefosine
586092|NCT00373555|Sarcoidosis
586093|NCT00373555|mediastinal adenopathy
586094|NCT00373555|bronchoscopy
586095|NCT00373555|Transbronchial needle aspiration
586096|NCT00373555|endobronchial ultrasonography
586097|NCT00373542|Restless Legs Syndrome
586098|NCT00373542|ropinirole
586099|NCT00373542|polysomnography
586100|NCT00373542|RLS
586101|NCT00373542|PSG
586102|NCT00373529|Acute myelogenous leukemia
586103|NCT00373529|Acute myeloid leukemia
586104|NCT00373529|newly Diagnosed AML
586105|NCT00373529|Clofarabine
586106|NCT00373529|CLASSIC II
586107|NCT00373529|CLO243
586108|NCT00373516|psoriasis
586109|NCT00373516|topical therapy
586110|NCT00373503|Lofexidine
586111|NCT00373503|Oral THC
586112|NCT00373503|Cannabinoids
586113|NCT00373477|Depression
586114|NCT00373477|Primary Care
586115|NCT00373477|Care Manager
586116|NCT00373464|Postoperative pain
586117|NCT00373464|Opioid
586118|NCT00373464|Etoricoxib
586119|NCT00373464|Ketorolac
586120|NCT00373464|Laparoscopic Surgery
586121|NCT00373464|Surgical Procedures, Gynecologic
586122|NCT00373451|NSTEMI
586123|NCT00373438|Congenital diaphragmatic hernia
586124|NCT00373438|tracheal occlusion
586125|NCT00373438|fetus
586126|NCT00373438|fetal surgery
586127|NCT00373438|fetoscopy
586128|NCT00373438|ECMO
586129|NCT00373425|Adjuvant Non-small Cell Lung Cancer
586130|NCT00373425|Tarceva
586131|NCT00373425|Early-stage Lung Cancer
586132|NCT00373425|Adjuvant
586133|NCT00373425|RADIANT
586134|NCT00373425|NSCLC
586135|NCT00373425|EGFR-positive tumor
586136|NCT00373425|Stage IB Non-small Cell Lung Cancer
586137|NCT00373425|Stage II Non-small Cell Lung Cancer
586138|NCT00373425|Stage IIIA Non-small Cell Lung Cancer
586139|NCT00373412|cytomegalovirus
586140|NCT00373412|vaccine
586141|NCT00373412|T cell
586142|NCT00373412|antibodies
586143|NCT00373399|Cannabinoids
586144|NCT00373399|Risk taking
586145|NCT00373399|Decision making
586146|NCT00373386|growth hormone
586147|NCT00373386|endothelial function
586148|NCT00373373|Sorafenib
586149|NCT00373373|Acute Myeloid Leukemia
586150|NCT00373373|Flt3
586151|NCT00373373|AML
586152|NCT00373373|Kinase Inhibitor
586153|NCT00373360|pulmonary hypertension
586154|NCT00373360|PAH
586155|NCT00373360|Remodulin
586156|NCT00373360|treprostinil
586157|NCT00373360|Quality of Life
586158|NCT00373360|Rapid Switch
586159|NCT00373334|gastroesophageal reflux disease
586160|NCT00373334|GERD
586161|NCT00373334|heartburn
586162|NCT00373308|Quality of Life
586163|NCT00373295|Baclofen
586164|NCT00373295|Marijuana Dependence
586165|NCT00373295|Marijuana Withdrawal
586166|NCT00373282|PVR
586167|NCT00373282|Retinal detachment
586168|NCT00373282|Silicone oil
586169|NCT00373282|Triamcinolone
586170|NCT00373269|Acute ischemic stroke
586171|NCT00373269|Stroke
586172|NCT00373269|Hyperglycemia
586173|NCT00373269|Procoagulation
586174|NCT00373269|Diabetes
586175|NCT00373269|Blood coagulation
586176|NCT00373256|Breast cancer
586177|NCT00373256|advanced
586178|NCT00373256|sunitinib
586179|NCT00373256|bevacizumab
586180|NCT00373256|paclitaxel
586181|NCT00373256|Phase 3
586182|NCT00373243|hepatic impairment pharmacokinetics
586183|NCT00373230|weight loss
586184|NCT00373230|telemedicine
586185|NCT00373230|african-american
586186|NCT00373230|rural
586187|NCT00373217|fallopian tube cancer
586188|NCT00373217|stage III ovarian epithelial cancer
586189|NCT00373217|stage IV ovarian epithelial cancer
586190|NCT00373217|primary peritoneal cavity cancer
586191|NCT00373204|Advanced non-small cell lung cancer
586192|NCT00373204|Non-small cell lung cancer
586193|NCT00373204|Lung cancer
586194|NCT00373204|Metastatic lung cancer
586195|NCT00373204|Second line treatment for advanced lung cancer
586196|NCT00373204|Cancer
586197|NCT00373204|Advanced lung cancer
586198|NCT00373191|stage I breast cancer
586199|NCT00373191|stage II breast cancer
586200|NCT00373191|stage IIIA breast cancer
586201|NCT00373191|stage IIIB breast cancer
586202|NCT00373191|stage IIIC breast cancer
586203|NCT00373191|ductal breast carcinoma in situ
586204|NCT00373178|rosiglitazone
586205|NCT00373178|metformin
586206|NCT00373165|Renal Transplantation
586207|NCT00373165|CMV
586208|NCT00373165|Ganciclovir
586209|NCT00373165|Prophylaxis
586210|NCT00373165|Preemptive Therapy
586211|NCT00373165|Graft Survival
586212|NCT00373165|Proteomics
586213|NCT00373152|stage I breast cancer
586214|NCT00373152|stage II breast cancer
586215|NCT00373152|stage IIIA breast cancer
586216|NCT00373152|stage IIIC breast cancer
586217|NCT00373152|stage IV breast cancer
586218|NCT00373139|Pregnancy,
586219|NCT00373139|Screening,
586220|NCT00373139|Whole Blood
586221|NCT00373126|nicotine
586222|NCT00373126|schizophrenia
586223|NCT00373126|reward
586224|NCT00373126|withdrawal
586225|NCT00373113|advanced breast cancer
586226|NCT00373113|metastatic breast cancer
586227|NCT00373113|treatment resistant
586228|NCT00373113|treatment failure
586229|NCT00373100|Zinc
586230|NCT00373100|placebo
586231|NCT00373100|severe pneumonia
586232|NCT00373100|children
586233|NCT00373087|Parkinson's disease
586234|NCT00373087|Catechol O-methyltransferase
586235|NCT00373087|Entacapone
586236|NCT00373087|pharmacogenetic
586237|NCT00373074|Spinal Puncture Headache
586238|NCT00373061|Expect
586239|NCT00373048|HIV-1 malaria Clinical Trial
586240|NCT00373035|prostate cancer
586241|NCT00373022|depression
586242|NCT00373022|anxiety disorder
586243|NCT00373022|psychosocial effects of cancer and its treatment
586244|NCT00373022|stage II colon cancer
586245|NCT00373022|stage III colon cancer
586246|NCT00373022|stage II rectal cancer
586247|NCT00373022|stage III rectal cancer
586248|NCT00373009|Low back pain
586249|NCT00373009|Primary prevention
586250|NCT00373009|Secondary prevention
586251|NCT00373009|Lumbar stabilization
586252|NCT00373009|Psychosocial education
586253|NCT00372983|chronic HCV
586254|NCT00372983|Failed treatment
586255|NCT00372983|genotype 1
586256|NCT00372983|failed treatment with pegylated interferon plus ribavirin
586257|NCT00372970|gastroparesis
586258|NCT00372970|vomiting
586259|NCT00372970|nausea
586260|NCT00372970|bloating
586261|NCT00372970|dyspepsia
586262|NCT00372957|Diabetes
586263|NCT00372957|pharmacodynamics
586264|NCT00372957|pharmacokinetics
586265|NCT00372944|advanced pancreatic cancer
586266|NCT00372944|metastatic pancreatic cancer
586267|NCT00372944|AZD6244
586268|NCT00372905|follicular lymphoma
586269|NCT00372892|Idiopathic Thrombocytopenic Purpura
586270|NCT00372892|Rituximab
586271|NCT00372892|Feasibility study
586272|NCT00372879|amyotrophic lateral sclerosis
586273|NCT00372879|vitamin E
586274|NCT00372879|muscle cramp
586275|NCT00372840|psychosocial effects of cancer and its treatment
586276|NCT00372840|stage I breast cancer
586277|NCT00372840|stage II breast cancer
586278|NCT00372840|stage IIIA breast cancer
586279|NCT00372840|stage IIIA colon cancer
586280|NCT00372840|stage I prostate cancer
586281|NCT00372840|stage IIB prostate cancer
586282|NCT00372840|stage IIA prostate cancer
586283|NCT00372840|stage III prostate cancer
586284|NCT00372840|stage I non-small cell lung cancer
586285|NCT00372840|stage II non-small cell lung cancer
586286|NCT00372840|stage IIIA non-small cell lung cancer
586287|NCT00372840|limited stage small cell lung cancer
586288|NCT00372840|stage I rectal cancer
586289|NCT00372840|stage IIA rectal cancer
586290|NCT00372840|stage IIB rectal cancer
586291|NCT00372840|stage IIC rectal cancer
586292|NCT00372840|stage IIIA rectal cancer
586293|NCT00372840|pulmonary carcinoid tumor
586294|NCT00372840|stage I thymoma
586295|NCT00372840|stage II thymoma
586296|NCT00372840|stage III thymoma
586297|NCT00372840|stage I colon cancer
586298|NCT00372840|stage IIA colon cancer
586299|NCT00372840|stage IIB colon cancer
586300|NCT00372840|stage IIC colon cancer
586301|NCT00372840|stage IA malignant mesothelioma
586302|NCT00372840|stage IB malignant mesothelioma
586303|NCT00372840|stage II malignant mesothelioma
586304|NCT00372840|stage III malignant mesothelioma
586305|NCT00372814|diabetes
586306|NCT00372814|regimen adherence
586307|NCT00372814|metabolic control
586308|NCT00372814|adolescents
586309|NCT00372814|family therapy
586310|NCT00372801|Osteoarthritis
586311|NCT00372801|Ibuprofen
586312|NCT00372801|COX2
586313|NCT00372801|VAS
586314|NCT00372801|knee
586315|NCT00372801|single dose
586316|NCT00372788|NSCLC
586317|NCT00372788|Advanced Non-Small Cell Lung Cancer
586318|NCT00372788|AZD6244
586319|NCT00372775|brain metastases
586320|NCT00372775|Sunitinib
586321|NCT00372775|Phase 2
586322|NCT00372762|Insulin resistance
586323|NCT00372762|heart failure
586324|NCT00372762|diuretic therapy
586325|NCT00372749|Alcohol dependence
586326|NCT00372749|Craving
586327|NCT00372749|Disulfiram
586328|NCT00372749|Cue exposure
586329|NCT00372736|unspecified adult solid tumor, protocol specific
586330|NCT00372723|toxic epidermal necrlysis
586331|NCT00372723|ten
586332|NCT00372710|Breast cancer
586333|NCT00372710|Palliation
586334|NCT00372710|Bone metastasis
586335|NCT00372710|Zoledronic acid
586336|NCT00372697|acromegaly
586337|NCT00372697|octreotide acetate
586338|NCT00372697|partial responder patients
586339|NCT00372684|Plasmodium falciparum
586340|NCT00372684|Malaria
586341|NCT00372684|Imported malaria
586342|NCT00372684|Severe malaria
586343|NCT00372684|Uncomplicated malaria
586344|NCT00372684|Intensive Care Units
586345|NCT00372684|Polymorphism, Genetic
586346|NCT00372684|Parasitic Sensitivity Tests
586347|NCT00372684|Inflammation Mediators
586348|NCT00372671|Cardiac Rehabilitation
586349|NCT00372671|Improving Cardiac Rehabilitation Participation
586350|NCT00372658|hysterosalpingogram
586351|NCT00372658|intracervical local anesthesia
586352|NCT00372658|pain perception
586353|NCT00372658|visual analogue scale
586354|NCT00372645|Healthy
586355|NCT00372632|Pregnancy malaria prevention
586356|NCT00372619|recurrent childhood acute lymphoblastic leukemia
586357|NCT00372619|recurrent childhood acute myeloid leukemia
586358|NCT00372619|acute undifferentiated leukemia
586359|NCT00372619|adult acute minimally differentiated myeloid leukemia (M0)
586360|NCT00372619|childhood acute minimally differentiated myeloid leukemia (M0)
586361|NCT00372619|adult acute myeloblastic leukemia without maturation (M1)
586591|NCT00371865|Psychotherapy
586362|NCT00372619|childhood acute myeloblastic leukemia without maturation (M1)
586363|NCT00372619|adult acute myeloblastic leukemia with maturation (M2)
586364|NCT00372619|childhood acute myeloblastic leukemia with maturation (M2)
586365|NCT00372619|adult acute myelomonocytic leukemia (M4)
586366|NCT00372619|childhood acute myelomonocytic leukemia (M4)
586367|NCT00372619|adult acute monoblastic leukemia (M5a)
586368|NCT00372619|childhood acute monoblastic leukemia (M5a)
586369|NCT00372619|adult acute monocytic leukemia (M5b)
586370|NCT00372619|childhood acute monocytic leukemia (M5b)
586371|NCT00372619|adult erythroleukemia (M6a)
586372|NCT00372619|adult pure erythroid leukemia (M6b)
586373|NCT00372619|childhood acute erythroleukemia (M6)
586374|NCT00372619|adult acute megakaryoblastic leukemia (M7)
586375|NCT00372619|childhood acute megakaryocytic leukemia (M7)
586376|NCT00372619|recurrent adult acute lymphoblastic leukemia
586377|NCT00372619|recurrent adult acute myeloid leukemia
586378|NCT00372606|Obesity
586379|NCT00372606|Overweight
586380|NCT00372606|Hispanics
586381|NCT00372606|Online
586382|NCT00372606|Weight Loss
586383|NCT00372593|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
586384|NCT00372593|adult acute myeloid leukemia with inv(16)(p13;q22)
586385|NCT00372593|adult acute myeloid leukemia with t(16;16)(p13;q22)
586386|NCT00372593|adult acute myeloid leukemia with t(8;21)(q22;q22)
586387|NCT00372593|untreated adult acute myeloid leukemia
586388|NCT00372593|untreated childhood acute myeloid leukemia and other myeloid malignancies
586389|NCT00372593|adult acute basophilic leukemia
586390|NCT00372593|adult acute eosinophilic leukemia
586391|NCT00372593|adult acute minimally differentiated myeloid leukemia (M0)
586392|NCT00372593|adult acute myeloblastic leukemia without maturation (M1)
586393|NCT00372593|adult acute myeloblastic leukemia with maturation (M2)
586394|NCT00372593|adult acute myelomonocytic leukemia (M4)
586395|NCT00372593|adult acute monoblastic leukemia (M5a)
586396|NCT00372593|adult acute monocytic leukemia (M5b)
586397|NCT00372593|adult erythroleukemia (M6a)
586398|NCT00372593|adult pure erythroid leukemia (M6b)
586399|NCT00372593|adult acute megakaryoblastic leukemia (M7)
586400|NCT00372593|childhood acute basophilic leukemia
586401|NCT00372593|childhood acute eosinophilic leukemia
586402|NCT00372593|childhood acute minimally differentiated myeloid leukemia (M0)
586403|NCT00372593|childhood acute myeloblastic leukemia without maturation (M1)
586404|NCT00372593|childhood acute myeloblastic leukemia with maturation (M2)
586405|NCT00372593|childhood acute myelomonocytic leukemia (M4)
586406|NCT00372593|childhood acute monocytic leukemia (M5b)
586407|NCT00372593|childhood acute monoblastic leukemia (M5a)
586408|NCT00372593|childhood acute erythroleukemia (M6)
586409|NCT00372593|childhood acute megakaryocytic leukemia (M7)
586410|NCT00372489|anemia
586411|NCT00372489|chronic kidney disease
586412|NCT00372489|CKD
586413|NCT00372489|chronic renal failure
586414|NCT00372489|CRF
586415|NCT00372489|dialysis
586416|NCT00372489|erythropoietin
586417|NCT00372489|EPO
586418|NCT00372489|erythropoiesis stimulating agent
586419|NCT00372489|ESA
586420|NCT00372489|Hematide™
586421|NCT00372489|hemodialysis
586422|NCT00372489|hemoglobin
586423|NCT00372489|Hb
586424|NCT00372489|Hgb
586425|NCT00372489|Omontys
586426|NCT00372489|peginesatide
586427|NCT00372489|red blood cell
586428|NCT00372489|red blood cell production
586429|NCT00372476|Breast cancer
586430|NCT00372476|Tyrosine inhibitor
586431|NCT00372476|Chemotherapy
586432|NCT00372476|Imatinib
586433|NCT00372463|diabetes
586434|NCT00372463|type 2 diabetes
586435|NCT00372463|type II diabetes
586436|NCT00372463|diabetes mellitus
586437|NCT00372463|diabetes type 2
586438|NCT00372463|diabetes type II
586439|NCT00372463|diabetes education
586440|NCT00372463|patient education
586441|NCT00372463|workshop
586442|NCT00372463|class
586443|NCT00372463|education
586444|NCT00372463|online
586445|NCT00372463|on-line
586446|NCT00372463|internet
586447|NCT00372463|web
586448|NCT00372450|recurrent esophageal cancer
586449|NCT00372450|stage III esophageal cancer
586450|NCT00372450|stage IV esophageal cancer
586451|NCT00372450|squamous cell carcinoma of the esophagus
586452|NCT00372450|adenocarcinoma of the esophagus
586453|NCT00372450|gastrointestinal complications
586454|NCT00372437|Refractory solid tumors
586455|NCT00372437|Phase I/II
586456|NCT00372437|Refractory and solid tumors
586457|NCT00372424|Breast cancer over-expressing HER2. First-line treatment with sunitinib/docetaxel/trastuzumab.
586458|NCT00372411|Stroke
586459|NCT00372411|Rehabilitation
586460|NCT00372411|Single-blind
586461|NCT00372411|Clinical Trial
586462|NCT00372411|Randomized controlled trial
586463|NCT00372411|Upper extremity
586464|NCT00372411|Robotics
586465|NCT00372398|scleroderma
586466|NCT00372398|sclerosis
586467|NCT00372398|atherosclerosis
586468|NCT00372372|corticosteroids, bone mineral, risedronate, bisphosphonate
586469|NCT00372359|Attention Deficit Disorder
586470|NCT00372359|Hyperactivity
586471|NCT00372359|Methylphenidate
586472|NCT00372333|musculoskeletal pain; soft tissue inflammation; IDEA-033
586473|NCT00372320|Adenovirus
586474|NCT00372320|Aquaporin-1
586475|NCT00372320|Gene Transfer
586476|NCT00372320|Radiation-Induced Salivary Hypofunction
586477|NCT00372320|Salivary Gland
586478|NCT00372320|Xerostomia
586479|NCT00372320|Salivary Dysfunction
586480|NCT00372320|Hyposalivation
586481|NCT00372320|Dry mouth
586482|NCT00372320|head and neck cancer
586483|NCT00372320|side effects radiation damage
586484|NCT00372294|Toxoplasmosis
586485|NCT00372294|Chorioretinitis
586486|NCT00372294|Intravitreal Clindamycin
586487|NCT00372294|Dexamethasone in chorioretinitis
586488|NCT00372294|Toxoplasmic
586489|NCT00372281|MRI, CLIAVIST, MACROPHAGE, INFECTION, SPINE
586490|NCT00372268|Comparison of four conditionings of the insufflated gas during laparoscopy and their consequences on the core temperature and the post-operative pain.
586491|NCT00372268|Women with womb pathology needing laparoscopic surgery
586492|NCT00372268|No emergency
586493|NCT00372268|Aged over 18 years
586494|NCT00372242|Mal-nutrition
586495|NCT00372242|Morbidity
586496|NCT00372242|Nutrition Education
586497|NCT00372242|Complementary Feeding
586498|NCT00372242|Weight gain
586499|NCT00372242|Height
586500|NCT00372216|myocardial infarction
586501|NCT00372216|Clopidogrel
586502|NCT00372216|primary PCI
586503|NCT00372216|TIMI-flow
586504|NCT00372216|STEMI within 6 hrs.
586505|NCT00372203|Non-small cell lung cancer
586506|NCT00372203|NSCLC
586507|NCT00372203|EBUS
586508|NCT00372203|Endobronchial ultrasound
586509|NCT00372203|mediastinoscopy
586510|NCT00372190|Pelvic organ prolapse
586511|NCT00372190|recurrence
586512|NCT00372190|mesh
586513|NCT00372190|complications
586514|NCT00372190|treatment
586515|NCT00372177|monoclonal antibody
586516|NCT00372177|diagnostics
586517|NCT00372177|RA
586518|NCT00372177|Immunoglobulins
586519|NCT00372177|molecular target
586520|NCT00372177|Tc99m-pertechnetate
586521|NCT00372177|Fab-fragment of Anti-human CD4
586522|NCT00372177|Radiopharmaceutical
586523|NCT00372177|chronic inflammatory diseases
586524|NCT00372177|active Rheumatoid Arthritis
586525|NCT00372164|ASIPP
586526|NCT00372164|Guidelines
586527|NCT00372151|Schizophrenia
586528|NCT00372151|Schizoaffective disorders
586529|NCT00372151|Theonine
586530|NCT00372151|Augmentation
586531|NCT00372138|Abdominal aortic aneurysms
586532|NCT00372138|Endoleaks
586533|NCT00372138|Prevention
586534|NCT00372125|Prader-Willi syndrome
586535|NCT00372125|Growth hormone
586536|NCT00372125|Body composition
586537|NCT00372112|Chronic Obstructive Pulmonary Disease (COPD)
586538|NCT00372112|COPD
586539|NCT00372099|Postmenopausal women
586540|NCT00372099|bone microarchitecture
586541|NCT00372099|peripheral quantitative micro-CT
586542|NCT00372099|salmon calcitonin
586543|NCT00372034|contact lenses
586544|NCT00372034|intolerance
586545|NCT00372034|punctal plugs
586546|NCT00372034|tear volume
586547|NCT00372034|Intolerance to contact lens wear due to dryness symptoms
586548|NCT00372021|non arthritic ischemic optic neuropathy
586549|NCT00372021|anterior ischemic optic neuropathy
586550|NCT00372021|Optic nerve Neurotomy
586551|NCT00371995|Visceral leishmaniasis
586552|NCT00371995|kala-azar
586553|NCT00371995|miltefosine
586554|NCT00371995|AmBisome
586555|NCT00371982|Fish oil
586556|NCT00371982|Type 2 diabetic women
586557|NCT00371982|adiposity
586558|NCT00371982|adipose tissue inflammation
586559|NCT00371982|PAI-1
586560|NCT00371982|Insulin sensitivity
586561|NCT00371969|Unsafe drinking
586562|NCT00371969|Human Immunodeficiency Virus
586563|NCT00371969|Motivational Interviewing
586564|NCT00371956|raloxifene
586565|NCT00371956|estrogen
586566|NCT00371956|receptor
586567|NCT00371956|modulation
586568|NCT00371956|osteoporosis
586569|NCT00371956|steroid
586570|NCT00371956|Steroids
586571|NCT00371943|variceal bleeding,band ligation, beta-blocker
586572|NCT00371943|had history of esophageal variceal bleeding
586573|NCT00371904|Rituximab
586574|NCT00371904|donor
586575|NCT00371904|sensitised
586576|NCT00371904|antibody
586577|NCT00371904|rejection
586578|NCT00371878|Vaccine
586579|NCT00371878|Lung
586580|NCT00371878|Bronchoalveolar lavage
586581|NCT00371878|Lymphocyte
586582|NCT00371878|Immunoglobulin
586583|NCT00371878|HIV
586584|NCT00371878|Streptococcus pneumoniae
586585|NCT00371878|Conjugate vaccine
586586|NCT00371865|Behavior therapy
586587|NCT00371865|Chronic pain
586588|NCT00371865|Cognitive therapy
586589|NCT00371865|Meditation
586590|NCT00371865|Mindfulness
586592|NCT00371839|Hearing Loss
586593|NCT00371839|Hearing Aids
586594|NCT00371839|Rehabilitation of hearing impaired
586595|NCT00371826|Renal transplantation
586596|NCT00371826|everolimus
586597|NCT00371826|Immunosuppressants
586598|NCT00371800|Cinnamon
586599|NCT00371800|Type 1 Diabetes
586600|NCT00371800|Adolescent
586601|NCT00371800|HbA1c
586602|NCT00371774|Psoriasis
586603|NCT00371774|Plaque Psoriasis
586604|NCT00371774|Amevive®
586605|NCT00371774|alefacept
586606|NCT00371761|Hepatitis B virus
586607|NCT00371761|Pegylated interferon alfa-2b (PegIntron)
586608|NCT00371735|Malaria CDA LAPDAP Africa
586609|NCT00371722|Cesarean section
586610|NCT00371722|Appendectomy
586611|NCT00371683|Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery
586612|NCT00371670|Knee, osteoarthritis, pain, disease modifying
586613|NCT00371657|obesity
586614|NCT00371657|small for gestation age
586615|NCT00371657|intrauterine growth restriction
586616|NCT00371644|Stress Disorders, Post-Traumatic
586617|NCT00371644|Cognitive Processing Therapy
586618|NCT00371644|Military sexual trauma
586619|NCT00371644|Psychology, Military
586620|NCT00371644|Veterans
586621|NCT00371644|Rape
586622|NCT00371644|Veterans, psychology
586623|NCT00371644|Healthcare utilization
586624|NCT00371631|biofilm
586625|NCT00371631|clinical trial
586626|NCT00371631|Escherichia coli
586627|NCT00371631|urinary catheter
586628|NCT00371618|Fluoroscopy
586629|NCT00371618|Interventional Pain Management Procedures
586630|NCT00371605|Voriconazole
586631|NCT00371605|Liver Transplant
586632|NCT00371605|Fungal Infection
586633|NCT00371592|Treatment Naive
586634|NCT00371579|rosuvastatin
586635|NCT00371579|hepatitis C
586636|NCT00371579|geranylgeranylation
586637|NCT00371579|HCV-RNA load
586638|NCT00371566|squamous cell carcinoma of head and neck
586639|NCT00371566|lapatinib
586640|NCT00371566|ErbB1/ErbB2 inhibitor
586641|NCT00371566|apoptosis
586642|NCT00371553|relapsed or cisplatin-refractory germ cell cancer
586643|NCT00371553|germ cell cancer
586644|NCT00371553|SU011248 (Sunitinib)
586645|NCT00371540|Africa
586646|NCT00371540|Antiretrovirals
586647|NCT00371527|Bronchitis
586648|NCT00371527|Acute bronchitis
586649|NCT00371527|Ipratropium
586650|NCT00371527|Cough
586651|NCT00371527|Metered dose inhaler
586652|NCT00371527|Antibiotic prescriptions
586653|NCT00371527|Sputum production
586654|NCT00371501|lupus
586655|NCT00371501|atherosclerosis
586656|NCT00371501|thrombosis
586657|NCT00371501|statin
586658|NCT00371501|lipid
586659|NCT00371488|ErbB2
586660|NCT00371488|Stage IV breast cancer
586661|NCT00371488|ErbB1
586662|NCT00371488|breast cancer
586663|NCT00371488|lapatinib
586664|NCT00371488|Herceptin
586665|NCT00371488|trastuzumab
586666|NCT00371462|intervention study
586667|NCT00371462|technology
586668|NCT00371462|weight loss
586669|NCT00371449|hearing loss
586670|NCT00371449|hearing aids
586671|NCT00371436|Counseling
586672|NCT00371436|Education
586673|NCT00371436|Evaluation studies
586674|NCT00371436|Quality of health care
586675|NCT00371436|Rehabilitation of hearing impaired
586676|NCT00371436|Triage
586677|NCT00371410|Vitrectomy
586678|NCT00371410|Intravitreal triamcinolone acetonide
586679|NCT00371410|Macular focal laser photocoagulation
586680|NCT00371410|Best-corrected visual acuity
586681|NCT00371410|Central macular thickness
586682|NCT00371397|yoga
586683|NCT00371397|immune function
586684|NCT00371397|stress
586685|NCT00371397|health
586686|NCT00371397|mood
586687|NCT00371397|skin barrier repair
586688|NCT00371384|massage
586689|NCT00371384|back pain
586690|NCT00371384|effectiveness
586691|NCT00371371|clinical trial
586692|NCT00371371|chronic critical limb ischemia
586693|NCT00371371|leg pain
586694|NCT00371371|cell therapy
586695|NCT00371371|bone marrow
586696|NCT00371371|mononuclear
586697|NCT00371371|progenitor cell
586698|NCT00371371|stem cell
586699|NCT00371371|critical limb ischemia
586700|NCT00371371|nonhealing leg ulcer
586701|NCT00371345|Recurrent, locally-advanced, or metastatic breast cancer
586702|NCT00371332|chronic periodontitis, mouth
586703|NCT00371332|Moderate to advanced chronic periodontitis
586704|NCT00371319|lupus
586705|NCT00371319|nephritis
586706|NCT00371319|tacrolimus
586707|NCT00371319|mycophenolate mofetil
586708|NCT00371306|Diabetes
586709|NCT00371306|Pregnancy
586710|NCT00371293|Sleep Apnea
586711|NCT00371293|C-Reactive Protein
586712|NCT00371293|Obesity
586713|NCT00371293|Insulin Resistance
586714|NCT00371293|Arterial stiffness
586715|NCT00371280|hydroxyapatite
586716|NCT00371280|peg
586717|NCT00371280|prosthetic motility
586718|NCT00371280|orbital implant
586719|NCT00371267|cognitive behavioral therapy
586720|NCT00371267|pain
586721|NCT00371254|Recurrent, locally-advanced, or 'triple negative' metastatic breast cancer
586722|NCT00371241|ECMO
586723|NCT00371241|extracorporeal membrane oxygenation
586724|NCT00371241|cytokines
586725|NCT00371241|chemokines
586726|NCT00371228|cord clamping
586727|NCT00371228|hematocrit
586728|NCT00371228|hemoglobin
586729|NCT00371228|timing
586730|NCT00371215|hemostasis
586731|NCT00371215|grafting, skin
586732|NCT00371215|hemostatics
586733|NCT00371215|phase 2
586734|NCT00371202|keratoconus, penetrating keratoplasty,
586735|NCT00371202|deep lamellar keratoplasty
586736|NCT00371202|big bubble technique
586737|NCT00371189|circumsporozoite, malaria, vaccine
586738|NCT00371176|Cognitive Behavior Therapy
586739|NCT00371176|Cognitive enhancers
586740|NCT00371176|Combat Disorders
586741|NCT00371176|D-Cycloserine
586742|NCT00371176|Stress Disorders, Post-Traumatic
586743|NCT00371163|Identification of genes by microarray analyses.
586744|NCT00371137|FMS
586745|NCT00371137|Fibro
586746|NCT00371137|pain
586747|NCT00371137|Body pain
586748|NCT00371137|tenderness
586749|NCT00371137|joint pain
586750|NCT00371137|stiffness
586751|NCT00371137|muscular pain
586752|NCT00371124|Myopia treatment
586753|NCT00371124|Atropine
586754|NCT00371111|Resistant uveitic cystoid macular edema
586755|NCT00371111|intravitreal triamcinolone
586756|NCT00371111|intravitreal bevacizumab
586757|NCT00371098|influenza vaccination
586758|NCT00371098|coronary artery disease
586759|NCT00371098|prevention
586760|NCT00371098|acute coronary syndromes
586761|NCT00371085|heart failure
586762|NCT00371085|quality improvement
586763|NCT00371085|patient education
586764|NCT00371085|health care economics
586765|NCT00371072|Aphakic Glaucoma
586766|NCT00371072|trabeculectomy with mitomycin- C
586767|NCT00371072|Ahmed glaucoma implant
586768|NCT00371059|Agitation
586769|NCT00371059|Dementia
586770|NCT00371059|Alzheimer's
586771|NCT00371046|preterm labor
586772|NCT00371046|transvaginal ultrasound cervical length
586773|NCT00371046|fetal fibronectin
586774|NCT00371046|preterm birth
586775|NCT00371020|silicone oil
586776|NCT00371020|PVR
586777|NCT00371020|retinal redetachment
586778|NCT00371020|low molecular weight heparin
586779|NCT00371020|5-FU
586780|NCT00370994|post-lumbar surgery syndrome
586781|NCT00370994|percutaneous lumbar epidural adhesiolysis
586782|NCT00370994|hypertonic saline neurolysis
586783|NCT00370981|investigational drug
586784|NCT00370981|ejaculation
586785|NCT00370968|Children
586786|NCT00370968|India
586787|NCT00370968|Hospital
586788|NCT00370968|Zinc
586789|NCT00370968|Malnutrition
586790|NCT00370968|Treatment
586791|NCT00370955|Phacoemulsification
586792|NCT00370955|Corneal endothelial cell loss
586793|NCT00370955|Hydrodynamic parameters
586794|NCT00370955|Total ultrasound energy
586795|NCT00370955|Total infused fluids
586796|NCT00370942|GW823093C
586797|NCT00370942|diabetes
586798|NCT00370942|type 2 diabetes mellitus
586799|NCT00370942|DPP-IV inhibitor
586800|NCT00370916|Clinical Decision Support Systems
586801|NCT00370916|Continuity of Patient Care
586802|NCT00370916|Medication Errors
586803|NCT00370916|Drug Adverse Effects
586804|NCT00370903|cesarean
586805|NCT00370903|planned
586806|NCT00370903|emergent
586807|NCT00370903|postpartum depression
586808|NCT00370890|nasopharyngeal cancer
586809|NCT00370890|adjuvant chemotherapy
586810|NCT00370890|EBV DNA
586811|NCT00370890|PET CT scan
586812|NCT00370877|Post-partum hemorrhage
586813|NCT00370877|Arterial embolization
586814|NCT00370877|Surgery
586815|NCT00370877|Hysterectomy
586816|NCT00370877|Activated recombinant human factor VII
586817|NCT00370864|Pandemic
586818|NCT00370864|Influenza
586819|NCT00370864|Prevention
586820|NCT00370864|Vaccine
586821|NCT00370864|Prevention of Pandemic Influenza
586822|NCT00370851|intravitreal Avastin
586823|NCT00370851|BRVO
586824|NCT00370851|Macular edema
586825|NCT00370838|Tics
586826|NCT00370838|Tourette syndrome
586827|NCT00370838|levetiracetam
586828|NCT00370838|clonidine
586829|NCT00370825|Visceral leishmaniasis
586830|NCT00370825|miltefosine
586831|NCT00370825|AmBisome
586832|NCT00370825|Combination
586833|NCT00370812|amniotic membrane transplantation
586834|NCT00370812|ocular chemical burns
586835|NCT00370799|Caudal Epidural injections
586836|NCT00370799|lumbar disc herniation
586837|NCT00370799|spinal stenosis
586838|NCT00370799|discogenic pain
586962|NCT00370331|idiopathic
586839|NCT00370799|post-lumbar laminectomy syndrome
586840|NCT00370786|Choroidal neovascularization (CNV)
586841|NCT00370786|Bevacizumab
586842|NCT00370786|Non AMD
586843|NCT00370786|High myopia
586844|NCT00370786|angioid streaks
586845|NCT00370786|Ocular histoplasmosis
586846|NCT00370786|Idiopathic
586847|NCT00370773|Failed Back Surgery Syndrome
586848|NCT00370773|Back Pain
586849|NCT00370773|Chronic Pain
586850|NCT00370773|Spinal Cord Stimulation
586851|NCT00370760|PVR
586852|NCT00370760|Oral colchicine
586853|NCT00370760|Dexamethasone
586854|NCT00370760|low molecular weight heparin
586855|NCT00370760|5-FU
586856|NCT00370734|botulinum toxin
586857|NCT00370734|thyroid eye disease
586858|NCT00370734|lid retraction
586859|NCT00370721|Proliferative diabetic retinopathy(PDR)
586860|NCT00370721|Pan retinal photocoagulation (PRP)
586861|NCT00370721|Vitreous hemorrhage
586862|NCT00370721|Traction retinal detachment
586863|NCT00370721|Neovascularization on disc (NVD)
586864|NCT00370721|Neovascularization elsewhere (NVE)
586865|NCT00370721|Fibrous proliferation on disc (FPD)
586866|NCT00370721|Fibrous proliferaiton elsewhere (FPE)
586867|NCT00370708|Cesarean
586868|NCT00370708|Oral
586869|NCT00370708|Intake
586870|NCT00370695|Chronic back pain
586871|NCT00370695|Intractable neuropathic back pain
586872|NCT00370695|Lumbar radiculopathy
586873|NCT00370695|Spinal cord stimulation
586874|NCT00370669|Bevacizumab
586875|NCT00370669|CSME
586876|NCT00370669|MPC
586877|NCT00370669|Triamcinolone acetonide
586878|NCT00370656|Diabetic Peripheral Neuropathy
586879|NCT00370643|hyperglycaemia
586880|NCT00370643|open heart surgery
586881|NCT00370643|intensive care unit
586882|NCT00370630|CRVO
586883|NCT00370630|Intravitreal Avastin
586884|NCT00370630|Intravitreal triamcinolone
586885|NCT00370617|chronic hepatitis C
586886|NCT00370617|insulin resistance
586887|NCT00370617|therapy
586888|NCT00370604|Parturient
586889|NCT00370604|Obstetrics
586890|NCT00370604|Pregnancy
586891|NCT00370604|Labour
586892|NCT00370604|Labor
586893|NCT00370604|Headache
586894|NCT00370604|Epidural
586895|NCT00370604|Analgesia
586896|NCT00370604|Anesthesia
586897|NCT00370604|Anaesthesia
586898|NCT00370591|Inhaled corticosteroids
586899|NCT00370591|Asthma
586900|NCT00370578|STEMI, THROMBUS, ASPIRATION DEVICE, NO REFLOW
586901|NCT00370539|Photodynamic therapy,
586902|NCT00370539|Bevacizumab,
586903|NCT00370539|Triamcinolone,
586904|NCT00370539|Age-related macular degeneration,
586905|NCT00370539|Choroidal neovascular membrane
586906|NCT00370526|heart failure
586907|NCT00370526|resynchronization
586908|NCT00370526|CRT
586909|NCT00370526|Bi-V pacemaker
586910|NCT00370526|LV lead placement
586911|NCT00370526|hemodynamic assessment
586912|NCT00370526|CRT Outcomes
586913|NCT00370513|liver cancer
586914|NCT00370513|pazopanib
586915|NCT00370513|hepatocellular cancer
586916|NCT00370500|Schizophrenia
586917|NCT00370500|Dopamine transporter gene
586918|NCT00370500|DNA methylation
586919|NCT00370500|Epigenetics
586920|NCT00370487|Abortion
586921|NCT00370487|Midlevel providers
586922|NCT00370487|South Africa
586923|NCT00370487|Viet Nam
586924|NCT00370474|Bi-V lead
586925|NCT00370474|Magnetic Navigation
586926|NCT00370474|Cardiac Resynchronization Therapy
586927|NCT00370461|Basic Cardiac Life Support
586928|NCT00370461|Termination of Resuscitation
586929|NCT00370461|Emergency Medical Services
586930|NCT00370461|Primary Care Paramedics
586931|NCT00370461|Out of Hospital Cardiac Arrest
586932|NCT00370435|rheumatoid arthritis
586933|NCT00370435|safety
586934|NCT00370435|GW274150
586935|NCT00370435|pharmacokinetics
586936|NCT00370435|tolerability
586937|NCT00370422|Cystoid macular edema
586938|NCT00370422|Diabetic macular edema
586939|NCT00370422|Hard exudates
586940|NCT00370422|Intravitreal bevacizumab
586941|NCT00370422|Intravitreal triamcinolone
586942|NCT00370422|Macular thickness
586943|NCT00370409|Rebleeding
586944|NCT00370409|Diabetic vitreous hemorrhage
586945|NCT00370409|Cryotherapy
586946|NCT00370396|Streptococcus pneumonia, pneumococcal conjugate vaccine
586947|NCT00370383|Non Small Cell Lung Cancer
586948|NCT00370383|PATIENTS ≥ 70 YEARS WITH UNRESECTABLE STAGE 3 OR 4 NSCLC
586949|NCT00370370|Bevacizumab,
586950|NCT00370370|Triamcinolone
586951|NCT00370370|Age-related macular degeneration
586952|NCT00370370|Choroidal neovascular membrane
586953|NCT00370357|Microbicide
586954|NCT00370357|SPL7013
586955|NCT00370357|VivaGel
586956|NCT00370344|Gallbladder diseases
586957|NCT00370344|gallstones
586958|NCT00370344|cholecystectomy
586959|NCT00370344|minilaparotomy
586960|NCT00370344|laparoscopy
586961|NCT00370331|ITP
586963|NCT00370331|platelets
586964|NCT00370331|purpura
586965|NCT00370331|thrombocytopenia
586966|NCT00370331|Idiopathic Thrombocytopenic Purpura
586967|NCT00370331|thrombocytopenic
586968|NCT00370318|Pneumococcal Disease
586969|NCT00370305|11ß-hydroxysteroid dehydrogenase
586970|NCT00370305|rosiglitazone
586971|NCT00370305|insulin sensitivity
586972|NCT00370305|Impaired glucose tolerance
586973|NCT00370279|Pseudophakic retinal detachment,
586974|NCT00370279|Aphakic retinal detachment,
586975|NCT00370279|Scleral buckling,
586976|NCT00370279|Primary vitrectomy,
586977|NCT00370279|Proliferative vitreoretinopathy
586978|NCT00370266|Macular edema
586979|NCT00370266|Branch retinal vein occlusion
586980|NCT00370266|Intravitreal triamcinolone
586981|NCT00370266|Macular thickness
586982|NCT00370266|Retinal neovascularization
586983|NCT00370253|hepatorenal syndrome
586984|NCT00370253|ascites
586985|NCT00370253|portal hypertension
586986|NCT00370253|cirrhosis
586987|NCT00370240|Female
586988|NCT00370240|Anesthetics,local
586989|NCT00370227|Streptococcus pneumonia, pneumococcal conjugate vaccine
586990|NCT00370214|Pulmonary arterial hypertension
586991|NCT00370214|Lung diseases
586992|NCT00370214|Heart diseases
586993|NCT00370214|Pulmonary circulation
586994|NCT00370214|Vascular resistance
586995|NCT00370214|PAH
586996|NCT00370214|Hypertension
586997|NCT00370201|retinal detachment
586998|NCT00370201|proliferative vitreoretinopathy
586999|NCT00370188|problem gambling
587000|NCT00370188|topiramate
587001|NCT00370123|endometriosis
587002|NCT00370123|apoptosis
587003|NCT00370123|regulatory T cells
587004|NCT00370097|Asthma infants FLOVENT spacer
587005|NCT00370071|MS
587006|NCT00370058|ect
587007|NCT00370058|depression
587008|NCT00370058|homocysteine
587009|NCT00370058|mthfr genotype
587010|NCT00370032|mucosal blood flow d-IBS
587011|NCT00370019|Premature Ovarian Failure
587012|NCT00370019|Ovulation
587013|NCT00370019|Fertility
587014|NCT00370019|Estrogen Replacement
587015|NCT00370019|Follicle Function
587016|NCT00370019|Premature Menopause
587017|NCT00370019|POF
587018|NCT00370006|cytomegalovirus
587019|NCT00370006|vaccine
587020|NCT00370006|T cell
587021|NCT00370006|antibodies
587022|NCT00369993|asthma
587023|NCT00369993|spacer
587024|NCT00369967|Contraception
587025|NCT00369967|Adolescents
587026|NCT00369967|Contraceptive vaginal ring
587027|NCT00369967|Quick start
587028|NCT00369954|recurrent ovarian epithelial cancer
587029|NCT00369954|fallopian tube cancer
587030|NCT00369954|peritoneal cavity cancer
587031|NCT00369915|Cholinergic
587032|NCT00369915|Unipolar
587033|NCT00369915|Bipolar
587034|NCT00369915|Depression
587035|NCT00369915|Muscarinic
587036|NCT00369915|Scopolamine
587037|NCT00369915|Major Depressive Disorder
587038|NCT00369915|MDD
587039|NCT00369915|Bipolar Disorder
587040|NCT00369915|BP
587041|NCT00369902|pain
587042|NCT00369902|acupuncture
587043|NCT00369889|Thymoma
587044|NCT00369889|Thymic Cancer
587045|NCT00369876|Burns
587046|NCT00369876|Anorexia
587047|NCT00369876|Neuropeptide
587048|NCT00369876|Leptin
587049|NCT00369876|Adiponectin
587050|NCT00369876|Gherlin
587051|NCT00369863|Cystoid macular edema
587052|NCT00369863|Diabetic macular edema
587053|NCT00369863|Hard exudates
587054|NCT00369863|Intravitreal triamcinolone
587055|NCT00369863|Macular thickness
587056|NCT00369850|osteoporosis
587057|NCT00369850|stage I breast cancer
587058|NCT00369850|stage II breast cancer
587059|NCT00369850|stage IIIA breast cancer
587060|NCT00369824|HPV
587061|NCT00369824|HPV, diptheria, pertussis, tetanus, meningitis
587062|NCT00369811|Cholecystectomy, postoperative
587063|NCT00369798|Unipolar Depression
587064|NCT00369798|Phosphorylation
587065|NCT00369798|Affinity States
587066|NCT00369798|Compartment Analysis
587067|NCT00369798|(R)-(11)C Rolipram
587068|NCT00369798|Depression
587069|NCT00369798|Major Depressive Disorder
587070|NCT00369798|MDD
587071|NCT00369798|Healthy Volunteer
587072|NCT00369798|HV
587073|NCT00369785|cognitive/functional effects
587074|NCT00369785|fatigue
587075|NCT00369785|psychosocial effects of cancer and its treatment
587076|NCT00369785|radiation toxicity
587077|NCT00369785|tumors metastatic to brain
587078|NCT00369785|adult brain stem glioma
587079|NCT00369785|adult central nervous system germ cell tumor
587080|NCT00369785|adult choroid plexus tumor
587081|NCT00369785|adult craniopharyngioma
587082|NCT00369785|adult mixed glioma
587083|NCT00369785|adult anaplastic meningioma
587084|NCT00369785|meningeal melanocytoma
587085|NCT00369785|adult meningeal hemangiopericytoma
587086|NCT00369785|adult grade I meningioma
587087|NCT00369785|adult grade II meningioma
587088|NCT00369785|adult grade III meningioma
587089|NCT00369785|adult papillary meningioma
587090|NCT00369785|adult anaplastic oligodendroglioma
587091|NCT00369785|adult oligodendroglioma
587092|NCT00369785|adult pineoblastoma
587093|NCT00369785|adult pineocytoma
587094|NCT00369785|adult anaplastic astrocytoma
587095|NCT00369785|adult diffuse astrocytoma
587096|NCT00369785|adult glioblastoma
587097|NCT00369785|adult giant cell glioblastoma
587098|NCT00369785|adult gliosarcoma
587099|NCT00369785|adult pilocytic astrocytoma
587100|NCT00369785|adult ependymoblastoma
587101|NCT00369785|adult medulloblastoma
587102|NCT00369785|adult supratentorial primitive neuroectodermal tumor (PNET)
587103|NCT00369785|adult anaplastic ependymoma
587104|NCT00369785|adult ependymoma
587105|NCT00369785|adult myxopapillary ependymoma
587106|NCT00369785|adult subependymoma
587107|NCT00369772|Aranesp
587108|NCT00369772|Anemia
587109|NCT00369772|Kidney Disease
587110|NCT00369772|Hemoglobin
587111|NCT00369772|darbepoetin alfa
587112|NCT00369772|QoL
587113|NCT00369759|Acute Lower Respiratory Infection
587114|NCT00369759|Retractions
587115|NCT00369759|Bronchiolitis or pneumonia
587116|NCT00369759|Wheezing
587117|NCT00369759|Rales
587118|NCT00369759|Crackles
587119|NCT00369746|Depression
587120|NCT00369746|Alcohol Abuse
587121|NCT00369746|Alcohol Dependence
587122|NCT00369733|Aranesp
587123|NCT00369733|Anemia
587124|NCT00369733|Kidney Disease
587125|NCT00369733|Hemoglobin
587126|NCT00369733|darbepoetin alfa
587127|NCT00369733|QoL
587128|NCT00369720|Prematurity
587129|NCT00369720|Resuscitation
587130|NCT00369720|Room Air
587131|NCT00369707|Non-Hodgkin's Lymphoma
587132|NCT00369694|Esophageal varices
587133|NCT00369694|Portal Hypertension
587134|NCT00369694|Melena
587135|NCT00369694|Hematemesis
587136|NCT00369694|Gastrointestinal Hemorrhage
587137|NCT00369694|Terlipressin
587138|NCT00369694|Efficacy
587139|NCT00369694|Safety
587140|NCT00369681|stage II adult Hodgkin lymphoma
587141|NCT00369681|stage III adult Hodgkin lymphoma
587142|NCT00369681|stage IV adult Hodgkin lymphoma
587143|NCT00369681|adult lymphocyte depletion Hodgkin lymphoma
587144|NCT00369681|adult mixed cellularity Hodgkin lymphoma
587145|NCT00369681|adult nodular sclerosis Hodgkin lymphoma
587146|NCT00369668|Rehabilitation
587147|NCT00369668|Physical Therapy Techniques
587148|NCT00369668|Occupational Therapy
587149|NCT00369668|Upper Extremity; Motor skills
587150|NCT00369642|Cognitive-behavioral therapy
587151|NCT00369642|Children
587152|NCT00369642|Obsessive-compulsive disorder
587153|NCT00369642|Intensive Cognitive-behavioral therapy
587154|NCT00369642|Weekly Cognitive-behavioral therapy
587155|NCT00369629|recurrent mycosis fungoides/Sezary syndrome
587156|NCT00369629|stage I mycosis fungoides/Sezary syndrome
587157|NCT00369629|stage II mycosis fungoides/Sezary syndrome
587158|NCT00369629|stage III mycosis fungoides/Sezary syndrome
587159|NCT00369629|stage IV mycosis fungoides/Sezary syndrome
587160|NCT00369629|stage I cutaneous T-cell non-Hodgkin lymphoma
587161|NCT00369629|stage II cutaneous T-cell non-Hodgkin lymphoma
587162|NCT00369629|stage III cutaneous T-cell non-Hodgkin lymphoma
587163|NCT00369629|stage IV cutaneous T-cell non-Hodgkin lymphoma
587164|NCT00369629|recurrent cutaneous T-cell non-Hodgkin lymphoma
587165|NCT00369603|Alzheimer's Disease
587166|NCT00369603|fMRI
587167|NCT00369603|Functional Neuroimaging
587168|NCT00369603|Allosteric Nicotinic Receptor Modulation
587169|NCT00369603|Acetylcholinesterase Inhibition
587170|NCT00369603|Head to head
587171|NCT00369603|Dose escalation
587172|NCT00369603|Biomarker
587173|NCT00369577|Agitation
587174|NCT00369577|Schizophrenia
587175|NCT00369564|neurotoxicity
587176|NCT00369564|peripheral neuropathy
587177|NCT00369564|stage I Wilms tumor
587178|NCT00369564|stage II Wilms tumor
587179|NCT00369564|stage III Wilms tumor
587180|NCT00369564|stage IV Wilms tumor
587181|NCT00369564|stage V Wilms tumor
587182|NCT00369564|previously untreated childhood rhabdomyosarcoma
587183|NCT00369564|childhood grade III lymphomatoid granulomatosis
587184|NCT00369564|childhood diffuse large cell lymphoma
587185|NCT00369564|childhood immunoblastic large cell lymphoma
587186|NCT00369564|stage I childhood large cell lymphoma
587187|NCT00369564|stage II childhood large cell lymphoma
587188|NCT00369564|stage III childhood large cell lymphoma
587189|NCT00369564|stage IV childhood large cell lymphoma
587190|NCT00369564|stage I childhood lymphoblastic lymphoma
587191|NCT00369564|stage II childhood lymphoblastic lymphoma
587192|NCT00369564|stage III childhood lymphoblastic lymphoma
587193|NCT00369564|stage IV childhood lymphoblastic lymphoma
587194|NCT00369564|childhood Burkitt lymphoma
587195|NCT00369564|stage I childhood small noncleaved cell lymphoma
587196|NCT00369564|stage II childhood small noncleaved cell lymphoma
587197|NCT00369564|stage III childhood small noncleaved cell lymphoma
587198|NCT00369564|stage IV childhood small noncleaved cell lymphoma
587199|NCT00369564|untreated childhood acute lymphoblastic leukemia
587200|NCT00369538|Podocyte - podocyturia - microparticles - angiotensin receptor antagonist - glomerulosclerosis
587201|NCT00369538|Patients presenting with stable glomerular nephropathy with proteinuria, normal or slightly altered renal function, with hypertension
587202|NCT00369512|Phase II
587203|NCT00369512|Erlotinib
587204|NCT00369512|Radiotherapy
587205|NCT00369512|Squamous Cell Carcinomas
587206|NCT00369512|Cutaneous
587207|NCT00369512|Stage III
587208|NCT00369486|diabetic
587209|NCT00369486|macular
587210|NCT00369486|edema
587211|NCT00369486|peribulbar
587212|NCT00369486|triamcinolone
587213|NCT00369486|acetonide
587214|NCT00369486|laser
587215|NCT00369486|photocoagulation
587216|NCT00369486|intraocular
587217|NCT00369486|DME
587218|NCT00369473|rheumatoid arthritis
587219|NCT00369460|recurrent pancreatic cancer
587220|NCT00369460|stage III pancreatic cancer
587221|NCT00369460|adenocarcinoma of the pancreas
587222|NCT00369460|stage IV pancreatic cancer
587223|NCT00369447|Non small cell lung cancer
587224|NCT00369447|NSCLC
587225|NCT00369447|Nimotuzumab
587226|NCT00369447|TheraCIM
587227|NCT00369447|h-R3
587228|NCT00369447|YM BioSciences
587229|NCT00369447|Radiation
587230|NCT00369447|Non small cell lung cancer, Stage IIb, III and IV
587231|NCT00369421|Dietary Therapy
587232|NCT00369421|Biochemical Defects
587233|NCT00369421|Enzyme Defects
587234|NCT00369421|Transport
587235|NCT00369421|Rare Diseases
587236|NCT00369421|Varied Disorders
587237|NCT00369421|Screening
587238|NCT00369421|Relatives
587239|NCT00369408|Randomized Trial
587240|NCT00369408|Medication for Heavy Drinking
587241|NCT00369408|Naltrexone Treatment
587242|NCT00369408|Daily vs. Targeted Administration
587243|NCT00369395|melanoma
587244|NCT00369395|antibody
587245|NCT00369395|angiogenesis
587246|NCT00369395|volociximab
587247|NCT00369382|Heart Transplant
587248|NCT00369382|Kidney Failure
587249|NCT00369343|Major Depressive Disorder
587250|NCT00369343|vasomotor symptoms
587251|NCT00369343|menopause
587252|NCT00369343|diabetic neuropathy
587253|NCT00369343|fibromyalgia
587254|NCT00369330|atrial fibrillation
587255|NCT00369330|early cardioversion
587256|NCT00369330|electrical cardioversion
587257|NCT00369304|Health
587258|NCT00369278|Renal transplantation, mycophenolate
587259|NCT00369265|Gastroesophageal reflux
587260|NCT00369265|Laryngitis
587261|NCT00369265|Hoarseness
587262|NCT00369265|Dysphonia
587263|NCT00369265|Proton pump inhibitor
587264|NCT00369252|Nimotuzumab
587265|NCT00369252|TheraCIM
587266|NCT00369252|H-R3
587267|NCT00369252|Solid tumours
587268|NCT00369252|EGFR
587269|NCT00369252|Monoclonal antibody
587270|NCT00369239|Early psychosis
587271|NCT00369239|premorbid functioning
587272|NCT00369239|Scale for Assessment of Insight
587273|NCT00369239|Risperdal Consta
587274|NCT00369239|risperidone long acting injectable
587275|NCT00369226|Velcade
587276|NCT00369226|Bortezomib
587277|NCT00369226|Allogeneic Stem Cell Transplant
587278|NCT00369226|GVHD
587279|NCT00369213|Crossover trial
587280|NCT00369213|condom failure
587281|NCT00369213|additional spermicidal lubricant
587282|NCT00369148|glinides
587283|NCT00369148|premixed insulin
587284|NCT00369148|combination therapy
587285|NCT00369148|glycemic control
587286|NCT00369135|work
587287|NCT00369135|Musculoskeletal Disorders
587288|NCT00369109|recurrent colon cancer
587289|NCT00369109|stage III colon cancer
587290|NCT00369109|stage IV colon cancer
587291|NCT00369109|recurrent rectal cancer
587292|NCT00369109|stage III rectal cancer
587293|NCT00369109|stage IV rectal cancer
587294|NCT00369109|recurrent pancreatic cancer
587295|NCT00369109|stage II pancreatic cancer
587296|NCT00369109|stage III pancreatic cancer
587297|NCT00369109|stage IV pancreatic cancer
587298|NCT00369109|recurrent breast cancer
587299|NCT00369109|stage IIIA breast cancer
587300|NCT00369109|stage IIIB breast cancer
587301|NCT00369109|stage IIIC breast cancer
587302|NCT00369109|stage IV breast cancer
587303|NCT00369096|Peritoneal Dialysis
587304|NCT00369096|Bemiparin
587305|NCT00369096|Icodextrin
587306|NCT00369096|Peritoneal Transport Disorders
587307|NCT00369083|Frail elderly
587308|NCT00369083|Hospital at home
587309|NCT00369070|AMG 706
587310|NCT00369070|Bevacizumab
587311|NCT00369070|Paclitaxel and Carboplatin
587312|NCT00369070|Randomized
587313|NCT00369070|Non-Small Cell Lung Cancer
587314|NCT00369057|Intraocular pressure
587315|NCT00369057|Prostatectomy
587316|NCT00369057|Robotic
587317|NCT00369057|Glaucoma
587318|NCT00369057|Carbon dioxide
587319|NCT00369044|decompensated heart failure
587320|NCT00369044|prednisone
587321|NCT00369044|diuretics
587322|NCT00369044|diuresis
587323|NCT00369031|HIV
587324|NCT00369031|vaccine
587325|NCT00369031|nasal immunization
587326|NCT00369018|photodynamic therapy
587327|NCT00369018|methyl aminolevulinate
587328|NCT00369018|hexaminolevulinate
587329|NCT00369018|dose-finding
587330|NCT00369018|cervical dysplasia
587331|NCT00369005|Transfusions
587332|NCT00369005|Erythrocyte
587333|NCT00369005|Anemia
587334|NCT00369005|Brain
587335|NCT00369005|Infant, Premature
587336|NCT00368979|Benign Prostatic Hyperplasia BPH dutasteride
587337|NCT00368966|Pneumococcal
587338|NCT00368966|Pediatric
587339|NCT00368966|Vaccine
587340|NCT00368940|Memory Deficits
587341|NCT00368940|Geriatric Depression
587342|NCT00368940|Cognitive Impairment
587343|NCT00368940|Executive Dysfunction
587344|NCT00368940|Disability
587345|NCT00368940|Problem Solving Therapy
587346|NCT00368914|unspecified adult solid tumor, protocol specific
587347|NCT00368901|Aranesp
587348|NCT00368901|Anemia
587349|NCT00368901|Kidney Disease
587350|NCT00368901|Hemoglobin
587351|NCT00368901|darbepoetin alfa
587352|NCT00368901|QoL
587353|NCT00368862|Alcoholism
587354|NCT00368862|Depression
587355|NCT00368862|Efficacy study
587356|NCT00368862|Memantine
587357|NCT00368862|Escitalopram
587358|NCT00368849|Huntington Disease
587359|NCT00368849|Chorea
587360|NCT00368849|Attention
587361|NCT00368849|ADHD
587362|NCT00368849|ADD
587363|NCT00368849|Strattera
587364|NCT00368849|Atomoxetine
587365|NCT00368836|Capnography
587366|NCT00368836|Thromboembolism
587367|NCT00368836|Arthroplasty
587368|NCT00368836|D-dimer
587369|NCT00368823|point of care
587370|NCT00368823|evidence based medicine
587371|NCT00368810|Children
587372|NCT00368810|Cross-Sectional
587373|NCT00368810|Glycosylphosphatidylinositol
587374|NCT00368810|Cytokines
587375|NCT00368810|Peripheral Blood Mononuclear Cells
587376|NCT00368810|Malaria
587377|NCT00368797|Gene Therapy
587378|NCT00368797|PAOD
587379|NCT00368797|CLI
587380|NCT00368771|Irritable Bowel Syndrome
587381|NCT00368771|Abdominal Pain
587382|NCT00368771|Abdominal Discomfort
587383|NCT00368771|Diarrhea
587384|NCT00368771|Constipation
587385|NCT00368771|IBS
587386|NCT00368758|Meteorism
587387|NCT00368758|Bloating
587388|NCT00368758|Irritable bowel syndrome (IBS)
587389|NCT00368758|Probiotics
587390|NCT00368758|Bowel gas
587391|NCT00368732|Congenital Heart Defects
587392|NCT00368706|solifenacin
587393|NCT00368706|Overactive bladder
587394|NCT00368706|Urinary incontinence
587395|NCT00368706|Treatment outcomes
587396|NCT00368706|VESIcare
587397|NCT00368680|Respiratory Distress Syndrome
587398|NCT00368680|Early Bubble CPAP
587399|NCT00368680|Mechanical Ventilation
587400|NCT00368680|Surfactant
587401|NCT00368667|Anorexia Nervosa
587402|NCT00368667|Body Composition
587403|NCT00368667|Metabolic Rate
587404|NCT00368628|acute ischemic stroke
587405|NCT00368628|sleep apnea
587406|NCT00368628|continuous positive airway pressure
587407|NCT00368615|melanoma
587408|NCT00368615|malignant melanoma
587409|NCT00368589|atherosclerotic plaque
587410|NCT00368589|USPIO
587411|NCT00368589|Atheroma
587412|NCT00368589|thrombo-embolic stroke
587413|NCT00368589|magnetic resonance imaging
587414|NCT00368589|Ultra small Super-Paramagnetic Iron Oxide
587415|NCT00368576|SB-480848
587416|NCT00368576|methacholine challenge
587417|NCT00368576|asthma
587418|NCT00368576|inhaled steroid
587419|NCT00368550|Alcohol Drinking
587420|NCT00368550|Alcohol Dependence
587421|NCT00368550|Sertraline Pharmacotherapy
587422|NCT00368550|Alcoholism Subtypes
587423|NCT00368550|Early- versus Late-Onset Alcoholism
587424|NCT00368537|skin infection
587425|NCT00368537|antibiotics
587426|NCT00368524|cocaine dependence
587427|NCT00368524|mental disorder
587428|NCT00368524|dual diagnoses
587429|NCT00368524|homelessness
587430|NCT00368511|Fall Prevention
587431|NCT00368511|Dynamic Posturography
587432|NCT00368511|Nolwenn Effect
587433|NCT00368511|Music Listening
587434|NCT00368498|teicoplanin
587435|NCT00368485|diaphragm electrical activity
587436|NCT00368485|non invasive ventilation
587437|NCT00368485|patient ventilator interaction
587438|NCT00368472|Refractory
587439|NCT00368472|Partial
587440|NCT00368472|Seizures
587441|NCT00368459|raloxifene, women
587442|NCT00368446|Nontuberculous Mycobacterial Infection
587443|NCT00368446|Primary Ciliary Dyskinesia
587444|NCT00368446|Cystic Fibrosis
587445|NCT00368446|Pseudohypoaldosteronism
587446|NCT00368446|Chronic Granulomatous Disease
587447|NCT00368446|Mycobacterial Infection
587448|NCT00368446|PCD
587449|NCT00368446|CF
587450|NCT00368446|PHA
587451|NCT00368446|Healthy Volunteer
587452|NCT00368446|HV
587453|NCT00368433|Sensory Processing
587454|NCT00368433|Electromyogram
587455|NCT00368433|Tic Disorder
587456|NCT00368433|Tourette Syndrome
587457|NCT00368433|Tourette's Syndrome
587458|NCT00368433|Healthy Volunteer
587459|NCT00368433|HV
587460|NCT00368420|ovarian cancer
587461|NCT00368420|recurrence
587462|NCT00368420|surgery
587463|NCT00368407|308-nm excimer laser
587464|NCT00368407|vitiligo
587465|NCT00368394|Insulin glulisine
587466|NCT00368394|Euglycaemic clamp
587467|NCT00368394|Diabetes mellitus Type 1
587468|NCT00368381|sepsis
587469|NCT00368381|septicemia
587470|NCT00368381|sepsis syndrome
587471|NCT00368381|adrenal insufficiency
587472|NCT00368381|adrenal cortex hormones
587473|NCT00368381|hydrocortisone
587474|NCT00368381|fludrocortisone
587475|NCT00368355|haploidenticalstem cell transplant
587476|NCT00368355|acute lymphoblastic leukemia
587477|NCT00368355|Non Hodgkins Lymphoma
587478|NCT00368355|Myelodysplastic Syndrome
587479|NCT00368355|Acute myeloid leukemia
587480|NCT00368355|Chronic myelogenous leukemia
587481|NCT00368355|Hemophagocytic lymphohistiocytosis (HLH)
587482|NCT00368355|Familial hemophagocytic lymphohistiocytosis (FLH)
587483|NCT00368355|Viral-associated hemophagocytic syndrome (VAHS)
587484|NCT00368355|X-linked lymphoproliferative disease (XLP)
587485|NCT00368316|Dysentery
587486|NCT00368316|S. sonnei
587487|NCT00368316|Antibody Response
587488|NCT00368316|Protection
587489|NCT00368303|Major Depression
587490|NCT00368303|paroxetine controlled release (CR)
587491|NCT00368303|paroxetine immediate release (IR)
587492|NCT00368290|cocaine dependence
587493|NCT00368290|hiv prevention
587494|NCT00368277|Systolic hypertension
587495|NCT00368277|hypertension
587496|NCT00368277|aliskiren
587497|NCT00368277|blood pressure
587498|NCT00368277|ramipril
587499|NCT00368277|HTN
587500|NCT00368264|lupus
587501|NCT00368264|nephritis
587502|NCT00368264|membraneous
587503|NCT00368264|proteinuria
587504|NCT00368264|TNF
587505|NCT00368264|infliximab
587506|NCT00368264|azathioprine
587507|NCT00368264|autoantibodies
587508|NCT00368251|Unverricht-Lundborg Disease
587509|NCT00368251|Baltic Myoclonus
587510|NCT00368251|Progressive Myoclonic Epilepsies
587511|NCT00368251|Myoclonus
587512|NCT00368251|Brivaracetam
587513|NCT00368238|Platelet function tests
587514|NCT00368238|Erythropoietin
587515|NCT00368238|Aspirin
587516|NCT00368238|Clopidogrel
587517|NCT00368225|Viral Hepatitis
587518|NCT00368225|Hepatitis C
587519|NCT00368225|HCV
587520|NCT00368225|Liver Transplant
587521|NCT00368225|Renal Transplant
587522|NCT00368225|Kidney Transplant
587523|NCT00368212|Somatization
587524|NCT00368212|Refractory Symptoms
587525|NCT00368199|single photon emission computer tomography (SPECT)
587526|NCT00368199|transcranial sonography
587527|NCT00368199|transcranial duplex scanning
587528|NCT00368199|parkinson's disease
587529|NCT00368199|atypical parkinson syndromes
587530|NCT00368199|parkinsonism
587531|NCT00368199|parkinsonian
587532|NCT00368199|diagnostic
587533|NCT00368199|progressive supranuclear paralysis
587534|NCT00368160|Next day driving
587535|NCT00368147|Hemodialysis
587536|NCT00368147|Arteriovenous Fistula
587537|NCT00368147|Arteriovenous Graft
587538|NCT00368147|Left Ventricular Hypertrophy
587539|NCT00368147|Brain Natriuretic Peptide
587540|NCT00368134|Type 2 Diabetes
587541|NCT00368134|Vildagliptin
587542|NCT00368134|HbA1c
587543|NCT00368121|Multiple Myeloma
587544|NCT00368121|Cetuximab
587545|NCT00368095|DM
587546|NCT00368095|HT
587547|NCT00368095|Dyslipidemia
587548|NCT00368095|Obesity
587549|NCT00368095|Cardiovascular disease
587550|NCT00368095|Cerebrovascular disease
587551|NCT00368095|Myocardial infarction
587552|NCT00368095|stroke
587553|NCT00368095|Metabolic syndrome
587554|NCT00368095|CVD-CAD
587555|NCT00368082|EBV-Positive Lymphoma
587556|NCT00368082|Hodgkin´s Disease (HD)
587557|NCT00368082|Non-Hodgkin's lymphoma (NHL)
587558|NCT00368082|relapsed Hodgkin's disease
587559|NCT00368082|relapsed non-Hodgkin's disease
587560|NCT00368082|lymphoma
587561|NCT00368082|TGFbeta resistant LMP-specific CTLs
587562|NCT00368082|cytotoxic T cells
587563|NCT00368069|Epilepsy
587564|NCT00368069|Keppra® XR
587565|NCT00368069|Levetiracetam XR
587566|NCT00368069|Extended release
587567|NCT00368043|Pituitary
587568|NCT00368043|Adrenal
587569|NCT00368043|Growth
587570|NCT00368043|Cortisol
587571|NCT00368043|Stress Response
587572|NCT00368043|Adoption
587573|NCT00368043|Thyroid Hormone
587574|NCT00368043|Psychosocial Adjustment
587575|NCT00368043|Healthy Volunteer
587576|NCT00368043|HV
587577|NCT00368030|Insomnia related to major depressive disorder.
587578|NCT00368004|Coloboma
587579|NCT00368004|Genetics
587580|NCT00368004|Optic Nerve Coloboma
587581|NCT00368004|Chorioretinal Coloboma
587582|NCT00368004|Iris Coloboma
587583|NCT00368004|Uveal Coloboma
587584|NCT00367991|Platelet function tests
587585|NCT00367991|Erythropoietin
587586|NCT00367991|Myocardial infarction
587587|NCT00367978|Hypertension, diabetes, African-American, amlodipine/benazepril
587588|NCT00367965|Insomnia related to rheumatoid arthritis (RA)
587589|NCT00367952|HIV
587590|NCT00367952|apricitabine
587591|NCT00367952|drug resistance
587592|NCT00367952|reverse transcriptase
587593|NCT00367952|lamivudine
587594|NCT00367939|Hypertension
587595|NCT00367926|ginseng
587596|NCT00367926|polysaccharides
587597|NCT00367926|postprandial glycemia
587598|NCT00367926|area under the glucose curve
587599|NCT00367926|peak incremental glucose
587600|NCT00367913|pulmonary disease
587601|NCT00367913|Treatment of Opportunist Mycobacteria
587602|NCT00367913|Clarithromycin
587603|NCT00367913|Ciprofloxacin
587604|NCT00367913|M.vaccae
587605|NCT00367913|Pulmonary diseases caused by Opportunist Mycobacteria
587606|NCT00367900|Diet
587607|NCT00367900|Lifestyle
587608|NCT00367900|Neurodegenerative Diseases
587609|NCT00367900|Elderly Population
587610|NCT00367900|Public Health
587611|NCT00367900|Parkinson Disease
587612|NCT00367900|Environment
587613|NCT00367887|Hepatitis C
587614|NCT00367874|Opiate dependence
587615|NCT00367874|Benzodiazepine dependence
587616|NCT00367874|Polydrug Abuse
587617|NCT00367874|Detoxification
587618|NCT00367874|Withdrawal Treatment
587619|NCT00367861|GIST
587620|NCT00367861|Glivec®
587621|NCT00367861|randomized
587622|NCT00367861|phase III
587623|NCT00366873|Infant
587624|NCT00366873|Term
587625|NCT00366860|soy
587626|NCT00366860|isoflavones
587627|NCT00366860|bone resorption
587628|NCT00366860|osteogenesis
587629|NCT00366860|diet
587630|NCT00366860|hyperlipidemia
587631|NCT00366847|cardiac
587632|NCT00366847|MRI
587633|NCT00366847|pediatrics
587634|NCT00366834|Anthracycline
587635|NCT00366834|Cyclophosphamide
587636|NCT00366834|Moderately
587637|NCT00366834|Nausea
587638|NCT00366834|Emetogenic
587639|NCT00366834|Vomiting
587640|NCT00366821|cardiac
587641|NCT00366821|pediatric
587642|NCT00366821|genetic
587643|NCT00366782|Respiratory Tract Disease
587644|NCT00366782|Bovine
587645|NCT00366782|Chimeric Vaccine
587646|NCT00366756|Vision
587647|NCT00366756|Visual Acuity
587648|NCT00366730|Amebiasis
587649|NCT00366730|Entamoeba histolytica
587650|NCT00366717|Cancer under chemotherapy
587651|NCT00366704|Schizophrenia
587652|NCT00366691|cataract
587653|NCT00366678|Safety
587654|NCT00366678|Vaccine
587655|NCT00366652|Healthy
587656|NCT00366639|Heart failure, congestive
587657|NCT00366639|Heart decompensation
587658|NCT00366626|Alcohol dependence
587659|NCT00366626|Alcoholism
587660|NCT00366626|Craving
587661|NCT00366626|Genetic
587662|NCT00366613|Cataract
587663|NCT00366613|Cataract Extraction
587664|NCT00365898|Chronic non-malignant pain, opioid
587665|NCT00367848|suspected fractures in the ankle and wrist
587666|NCT00367822|Restless Legs Syndrome
587667|NCT00367822|dopamine agonist
587668|NCT00367822|lisuride
587669|NCT00367822|ropinirole
587670|NCT00367809|Meditation
587671|NCT00367809|Mindfulness
587672|NCT00367809|Organ Transplant
587673|NCT00367809|Transplantation
587674|NCT00367809|Minnesota
587675|NCT00367809|Immune suppressive therapy
587676|NCT00367796|Craniosynostosis
587677|NCT00367796|Philadelphia Type
587678|NCT00367770|bosentan
587679|NCT00367770|PAH related to Eisenmenger physiology
587680|NCT00367770|Tracleer
587681|NCT00367757|paroxysmal atrial fibrillation
587682|NCT00367757|persistent atrial fibrillation
587683|NCT00367757|high burden of atrial fibrillation
587684|NCT00367757|atrial fibrillation ablation
587685|NCT00367757|Pulmonary vein isolation
587686|NCT00367757|AF trigger
587687|NCT00367757|complex fractionated electrograms
587688|NCT00367757|CFE
587689|NCT00367757|CFAE
587690|NCT00367757|complex fractionated atrial electrograms
587691|NCT00367757|refractory antiarrhythmic medication
587692|NCT00367757|PVAI
587693|NCT00367757|Ensite NavX
587694|NCT00367757|NavX
587695|NCT00367757|CoolPath catheter
587696|NCT00367757|irrigated ablation catheter
587697|NCT00367757|high burden of paroxysmal or persistent atrial fibrillation
587698|NCT00367757|candidates for AF ablation
587699|NCT00367757|symptomatic AF
587700|NCT00367757|AF is refractory to at least one antiarrhythmic medication
587701|NCT00367744|mitochondria
587702|NCT00367744|HIV
587703|NCT00367744|lipoatrophy
587704|NCT00367731|HIV
587705|NCT00367731|AIDS
587706|NCT00367731|Neurological complications
587707|NCT00367731|HAART
587708|NCT00367692|Scleritis
587709|NCT00367679|pazopanib
587710|NCT00367679|I-ELCAP
587711|NCT00367679|non-small cell lung cancer
587712|NCT00367679|antiangiogenesis
587713|NCT00367679|NSCLC
587714|NCT00367679|GW786034
587715|NCT00367640|Sublingual immunotherapy
587716|NCT00367640|Grass pollen tablet
587717|NCT00367640|Allergic rhinoconjunctivitis
587718|NCT00367627|Children
587719|NCT00367627|Malnutrition
587720|NCT00367627|Ascaris Lumbricoides
587721|NCT00367627|Trichuris trichiura Morbidity
587722|NCT00367627|Helminthiasis
587723|NCT00367627|Children 2-5 years
587724|NCT00367627|Stool RME +ve for helminthiasis
587725|NCT00367614|Adolescents
587726|NCT00367614|GERD
587727|NCT00367588|chemotherapy
587728|NCT00367588|diet
587729|NCT00367588|hematological malignancy
587730|NCT00367588|infection prevention
587731|NCT00367588|protective isolation
587732|NCT00367588|Patients with cytopenia due to intensive chemotherapy for hematological malignancy
587733|NCT00367575|alcoholism
587734|NCT00367575|drinking
587735|NCT00367575|randomized
587736|NCT00367575|internet personalized alcohol feedback
587737|NCT00367562|IGA NEPHROPATHY
587738|NCT00367562|STEROIDS
587739|NCT00367562|ENALAPRIL
587740|NCT00367562|VALSARTAN
587741|NCT00367562|PROTEINURIA
587742|NCT00367562|IMMUNOGLOBULIN A NEPHROPATHY (IGA NEPHROPATHY)
587743|NCT00367549|Labor
587744|NCT00367549|instrumental delivery
587745|NCT00367549|nutrition
587746|NCT00367549|epidural anesthesia
587747|NCT00367549|oxytocin
587748|NCT00367536|Health
587749|NCT00367523|Echocardiogram
587750|NCT00367523|Nigeria
587751|NCT00367523|Screening
587752|NCT00367523|Sickle Cell Disease
587753|NCT00367523|Genetics
587754|NCT00367497|aggressive non-Hodgkin's lymphoma
587755|NCT00367497|salvage chemotherapy
587756|NCT00367497|rituximab
587757|NCT00367471|metastatic
587758|NCT00367471|paclitaxel
587759|NCT00367471|lapatinib
587760|NCT00367471|trastuzumab
587761|NCT00367471|carboplatin
587762|NCT00367471|breast cancer
587763|NCT00367458|Viremia
587764|NCT00367458|Statin
587765|NCT00367458|HIV Replication
587766|NCT00367458|Cholesterol
587767|NCT00367458|Lipid Raft
587768|NCT00367458|HIV Infection
587769|NCT00367458|HIV Positive
587770|NCT00367432|Epilepsies
587771|NCT00367432|Partial
587772|NCT00367432|Keppra
587773|NCT00367432|levetiracetam
587774|NCT00367393|Pimecrolimus, skin atrophy, dermoscopy, atopic dermatitis, eczema
587775|NCT00367380|Malaria
587776|NCT00367380|Sporozoite
587777|NCT00367380|Challenge Model
587778|NCT00367380|Plasmodium vivax
587779|NCT00367380|Human Volunteers
587780|NCT00367367|embryo transfer
587781|NCT00367367|hysteroscopy
587782|NCT00367367|curettage
587783|NCT00367367|iv-vitro fertilization
587784|NCT00367367|molecular markers
587785|NCT00367367|endometrial receptivity
587786|NCT00367367|endometrial dating
587787|NCT00367354|Imaging Technology
587788|NCT00367354|Cardiology
587789|NCT00367341|Depression, Treatment, Imaging
587790|NCT00367328|Hidradenitis Supperativa
587791|NCT00367315|Osteoarthritis, lumiracoxib, celecoxib, cyclooxygenase-2 inhibitors
587792|NCT00367302|addiction
587793|NCT00367302|jail
587794|NCT00367302|opiates
587795|NCT00367302|buprenorphine
587796|NCT00367302|clinical trial
587797|NCT00367276|Females requiring contraceptives
587798|NCT00367263|Asthma
587799|NCT00367224|vitiligo
587800|NCT00367224|tolerance
587801|NCT00367224|ultraviolet B.
587802|NCT00367211|Gastric Ulcers
587803|NCT00367211|NSAID
587804|NCT00367211|Arthritis
587805|NCT00367185|Multiple myeloma
587806|NCT00367185|Elderly patients
587807|NCT00367185|Thalidomide
587808|NCT00367185|Autologous transplantation
587809|NCT00367172|human immunodeficiency virus
587810|NCT00367172|acquired immunodeficiency syndrome
587811|NCT00367172|substance abuse
587812|NCT00367172|directly administered antiretroviral therapy
587813|NCT00367172|adherence, directly observed therapy
587814|NCT00367159|Vesico-ureteral reflux, autologous adipocytes, adipocytes graft
587815|NCT00367146|liver transplantation
587816|NCT00367146|children
587817|NCT00367146|immunosuppression
587818|NCT00367146|mycophenolatmofetil
587819|NCT00367146|calcineurin inhibitor
587820|NCT00367146|kidney disease
587821|NCT00367133|diabetic
587822|NCT00367133|macular
587823|NCT00367133|edema
587824|NCT00367133|intravitreal
587825|NCT00367133|triamcinolone
587826|NCT00367133|laser
587827|NCT00367133|photocoagulation
587828|NCT00367133|DME
587829|NCT00367107|Autism spectrum disorders
587830|NCT00367107|long-term outcomes
587831|NCT00367107|caregiver burden
587832|NCT00367107|birth cohort
587833|NCT00367107|nested case-control study
587834|NCT00367094|Hypertension, benazepril, hydrochlorothiazide, fixed combination
587835|NCT00367081|Toxoplasmic Encephalitis
587836|NCT00367081|AIDS
587837|NCT00367068|Cerebral palsy
587838|NCT00367068|Spasticity
587839|NCT00367068|Child
587840|NCT00367068|Baclofen
587841|NCT00367068|Intrathecal injection
587842|NCT00367055|Beta cell function
587843|NCT00367055|Type 2 diabetes
587844|NCT00367055|Combination treatment
587845|NCT00367029|Physical Activity
587846|NCT00367003|Depression, Unipolar, Bipolar-II, DBS, Imaging
587847|NCT00366990|Arterial Stiffening
587848|NCT00366977|Cessation
587849|NCT00366977|Smoking
587850|NCT00366977|Quitline
587851|NCT00366977|Policies
587852|NCT00366977|Counseling
587853|NCT00366951|Cervical Ripening
587854|NCT00366951|Labor, Induced
587855|NCT00366951|Balloon Dilation
587856|NCT00366951|Oxytocin
587857|NCT00366938|Osteoarthritis, lumiracoxib, celecoxib, Cox-2
587858|NCT00366912|work of breathing
587859|NCT00366912|pressure time product
587860|NCT00366912|muscle pressures
587861|NCT00366899|Vaccine
587862|NCT00366899|Infants
587863|NCT00366886|cardiac
587864|NCT00366886|pediatric
587865|NCT00366886|surgery
587866|NCT00366886|blood markers
587867|NCT00366600|Breast Cancer
587868|NCT00366600|Health
587869|NCT00366600|Pharmacokinetics
587870|NCT00366600|healthy subjects
587871|NCT00366561|neonates
587872|NCT00366561|neurological complications
587873|NCT00366561|surgery
587874|NCT00366548|Vaccine
587875|NCT00366548|Infant
587876|NCT00366535|Muscle Pain
587877|NCT00366535|Fibrositis Allodynia
587878|NCT00366535|Stiffness
587879|NCT00366535|Tender Points
587880|NCT00366535|Fibromyalgia
587881|NCT00366522|Safety
587882|NCT00366522|Healthy
587883|NCT00366522|healthy subjects
587884|NCT00366509|Vac A Toxin
587885|NCT00366509|Lung
587886|NCT00366509|Bronchoscopy
587887|NCT00366509|Endoscopy
587888|NCT00366509|Cytotoxin
587889|NCT00366509|Pulmonary Disease
587890|NCT00366509|Lung Disease
587891|NCT00366509|Genetic Disease
587892|NCT00366509|Oropharyngeal Disease
587893|NCT00366509|Pulmonary Fibrosis
587894|NCT00366509|Asthma
587895|NCT00366483|healthy young volunteers
587896|NCT00366483|healthy elderly volunteers
587897|NCT00366483|Alzheimer's disease
587898|NCT00366483|5HT1A antagonist
587899|NCT00366483|Health
587900|NCT00366483|Pharmacokinetics
587901|NCT00366444|Bunionectomy
587902|NCT00366444|Bunion surgery
587903|NCT00366444|Post-operative pain
587904|NCT00366431|OIBD
587905|NCT00366431|OIC
587906|NCT00366431|Opioid
587907|NCT00366431|Constipation
587908|NCT00366431|Laxative
587909|NCT00366418|CLL
587910|NCT00366418|Monoclonal Antibody Therapy
587911|NCT00366418|Anti CD20
587912|NCT00366418|Biologic Response Modifier Therapy
587913|NCT00366418|Fractionated-Dose
587914|NCT00366418|Low-Dose
587915|NCT00366418|Chronic Lymphocytic Leukemia
587916|NCT00366405|cataract
587917|NCT00366392|Low Vision
587918|NCT00366392|Optical Aids
587919|NCT00366353|Mechanical Ventilation
587920|NCT00366353|Spontaneous Breathing Trial
587921|NCT00366353|Sedation
587922|NCT00366340|safety
587923|NCT00366340|Vaccine
587924|NCT00366327|Schizophrenia
587925|NCT00366314|Blood samples
587926|NCT00366314|Medication administration
587927|NCT00366314|CICU
587928|NCT00366314|PICU
587929|NCT00366314|NICU
587930|NCT00366301|type 2 diabetes
587931|NCT00366301|insulin
587932|NCT00366301|insulin injection
587933|NCT00366301|metformin
587934|NCT00366301|C-reactive protein
587935|NCT00366301|insulin sensitivity
587936|NCT00366301|glycemic control
587937|NCT00366301|inflammation
587938|NCT00366288|Healthy
587939|NCT00366288|Safety
587940|NCT00366275|follicular lymphoma
587941|NCT00366275|rituximab
587942|NCT00366275|immunochemotherapy
587943|NCT00366275|peripheral blood stem cells (PBSC) mobilization
587944|NCT00366275|in vivo purging
587945|NCT00366275|autotransplant
587946|NCT00366275|bcl-2 rearrangement
587947|NCT00366275|molecular response
587948|NCT00366262|Health
587949|NCT00366249|Diabetic foot infection
587950|NCT00366249|Osteomyelitis
587951|NCT00366249|Diabetes Complications
587952|NCT00366249|Foot ulcer
587953|NCT00366249|Skin infection
587954|NCT00366236|Amebiasis
587955|NCT00366236|Entamoeba histolytica
587956|NCT00366223|infection
587957|NCT00366223|candida
587958|NCT00366210|stroke
587959|NCT00366210|rehabilitation
587960|NCT00366210|physical therapy
587961|NCT00366210|occupational therapy
587962|NCT00366210|arm
587963|NCT00366197|Rapid Shallow Breathing Index
587964|NCT00366197|Mechanical Ventilation
587965|NCT00366184|Neuromodulation
587966|NCT00366184|Stroke
587967|NCT00366184|Motor Cortex
587968|NCT00366184|Motor Learning
587969|NCT00366184|L-Dopa
587970|NCT00366184|Transcranial Magnetic Stimulation
587971|NCT00366184|Levodopa
587972|NCT00366184|Healthy Volunteer
587973|NCT00366184|HV
587974|NCT00366171|Schizophrenia
587975|NCT00366158|Patients with intact AV conduction
587976|NCT00366145|acute GVHD
587977|NCT00366145|steroid refractory GVHD
587978|NCT00366145|severe steroid refractory acute GVHD
587979|NCT00366145|steroid refractory
587980|NCT00366145|Steroid Refractory Acute Graft Versus Host Disease
587981|NCT00366132|Diabetic
587982|NCT00366132|Foot Ulcers
587983|NCT00366132|TRT
587984|NCT00366132|DermaGold
587985|NCT00366132|Shockwave
587986|NCT00366132|ESWT
587987|NCT00366132|Diabetes Mellitus
587988|NCT00366119|hypertension
587989|NCT00366119|ramipril
587990|NCT00366119|blood pressure
587991|NCT00366119|artery stiffness
587992|NCT00366119|BNP
587993|NCT00366119|CRP
587994|NCT00366106|Relapsed Multiple Myeloma
587995|NCT00366106|Refractory Multiple Myeloma
587996|NCT00366093|Menopause
587997|NCT00366093|Perimenopause
587998|NCT00366080|GSK189254 H3 Histamine Narcolepsy
587999|NCT00366067|Bronchial asthma
588000|NCT00366067|Phenytoin
588001|NCT00366067|Antiepileptic drugs
588002|NCT00366067|Efficacy
588003|NCT00366028|Organization Innovation
588004|NCT00366028|Diffusion of Innovation
588005|NCT00366028|Evidence-based Medicine
588006|NCT00366028|Infection Control
588007|NCT00366015|Coronary Artery Disease
588008|NCT00366015|PCI
588009|NCT00366015|Drug eluting stents
588010|NCT00366015|Coronary Hybrid Revascularization
588011|NCT00366015|Robotic CABG
588012|NCT00366002|Darifenacin,Overactive Bladder,antimuscarinic,M3 muscarinic receptor antagonist
588013|NCT00365989|Fibroids
588014|NCT00365989|leiomyoma
588015|NCT00365989|neoplasm
588016|NCT00365989|benign tumors
588017|NCT00365976|Insomnia
588018|NCT00365976|Low Back Pain
588019|NCT00365976|Hypnotics
588020|NCT00365976|Eszopiclone
588021|NCT00365976|Pain
588022|NCT00365976|Disability
588023|NCT00365963|lung cancer, caregivers, support, resources, education
588024|NCT00365950|Duration of anticoagulation
588025|NCT00365950|Deep vein thrombosis and/or pulmonary embolism
588026|NCT00365937|immunotherapy
588027|NCT00365937|adjuvants
588028|NCT00365937|IMP321
588029|NCT00365937|Montanide ISA51 VG
588030|NCT00365937|tumor-specific peptides
588031|NCT00365924|12 month therapy with postmenopausal women with osteoporosis to examine changes in bone quality parameters
588032|NCT00365911|No specific condition
588033|NCT00365885|Medical Informatics
588034|NCT00365885|Decision Support Systems, Clinical
588035|NCT00365885|Community Health Services
588036|NCT00365885|Costs and Cost analysis
588037|NCT00365872|Sarcoma
588038|NCT00365872|Intratumoral injection
588039|NCT00365872|Dendritic cells
588040|NCT00365872|Neo-adjuvant treatment
588041|NCT00365872|Immunotherapy
588042|NCT00365872|Pheresis
588043|NCT00365872|Radiation
588044|NCT00365859|Serious behavioral problems in children and adolescents with AD
588045|NCT00365859|behavioral problems
588046|NCT00365846|prevent kidney rejection
588047|NCT00365833|Transplantation
588048|NCT00365833|Cardiovascular
588049|NCT00365833|Renal
588050|NCT00365820|Opioid, constipation, tegaserod
588051|NCT00365820|Opioid-induced constipation
588052|NCT00365807|Obesity
588053|NCT00365807|Overweight
588054|NCT00365807|Behavioral treatment
588055|NCT00365807|Family involvement
588056|NCT00365794|Aging
588057|NCT00365794|Older men
588058|NCT00365794|Abdominal obesity
588059|NCT00365794|Central obesity
588060|NCT00365794|Insulin resistance
588061|NCT00365794|Low testosterone
588062|NCT00365781|Injection Site Reaction
588063|NCT00365781|Subcutaneous administration
588064|NCT00365781|Dermatological effects
588065|NCT00365781|Antisense
588066|NCT00365768|stage II childhood lymphoblastic lymphoma
588067|NCT00365768|stage III childhood lymphoblastic lymphoma
588068|NCT00365768|stage II childhood small noncleaved cell lymphoma
588069|NCT00365768|stage I Wilms tumor
588070|NCT00365768|stage II Wilms tumor
588071|NCT00365768|stage III Wilms tumor
588072|NCT00365768|stage IV Wilms tumor
588073|NCT00365768|stage V Wilms tumor
588074|NCT00365768|childhood grade III lymphomatoid granulomatosis
588075|NCT00365768|childhood diffuse large cell lymphoma
588076|NCT00365768|childhood immunoblastic large cell lymphoma
588077|NCT00365768|stage I childhood large cell lymphoma
588078|NCT00365768|stage I childhood lymphoblastic lymphoma
588079|NCT00365768|stage I childhood small noncleaved cell lymphoma
588080|NCT00365768|stage II childhood large cell lymphoma
588081|NCT00365768|stage III childhood large cell lymphoma
588082|NCT00365768|stage IV childhood large cell lymphoma
588083|NCT00365768|stage IV childhood lymphoblastic lymphoma
588084|NCT00365768|stage IV childhood small noncleaved cell lymphoma
588085|NCT00365768|childhood Burkitt lymphoma
588086|NCT00365768|stage III childhood small noncleaved cell lymphoma
588087|NCT00365768|untreated childhood acute lymphoblastic leukemia
588088|NCT00365768|childhood nasal type extranodal NK/T-cell lymphoma
588089|NCT00365768|previously untreated childhood rhabdomyosarcoma
588090|NCT00365768|localized Ewing sarcoma/PNET
588091|NCT00365768|metastatic Ewing sarcoma/PNET
588092|NCT00365768|neurotoxicity
588093|NCT00365768|peripheral neuropathy
588094|NCT00365755|disseminated neuroblastoma
588095|NCT00365742|red yeast rice
588096|NCT00365742|pharmaceutical grade fish oil
588097|NCT00365742|simvastatin
588098|NCT00365742|primary prevention
588099|NCT00365729|genitoanal HPV infection
588100|NCT00365729|HIV infection
588101|NCT00365716|HPV 6/11/16/18 infection and related genital disease
588102|NCT00365703|Infant, Premature
588103|NCT00365703|Tube feeding
588104|NCT00365690|AIDS
588105|NCT00365690|Older Adults
588106|NCT00365690|Telephone
588107|NCT00365690|Telemedicine
588108|NCT00365651|obesity
588109|NCT00365651|overweight
588110|NCT00365638|PCOS
588111|NCT00365638|statin
588112|NCT00365638|testosterone
588113|NCT00365638|lipids
588114|NCT00365625|Psoriasis
588115|NCT00365625|JAM3 protein, human
588116|NCT00365625|Cell Adhesion Molecules
588117|NCT00365625|Skin
588118|NCT00365625|Inflammation
588119|NCT00365625|Lymphocytes
588120|NCT00365612|HIV
588121|NCT00365612|HIV-1
588122|NCT00365612|AIDS
588123|NCT00365612|Human Immunodeficiency Virus
588124|NCT00365612|HIV-1 Infection
588125|NCT00365599|Breast cancer
588126|NCT00365599|Suberoylanilide hydroxamic acid (SAHA)
588127|NCT00365599|Vorinostat
588128|NCT00365599|Tamoxifen
588129|NCT00365599|Anti-hormonal therapy
588130|NCT00365599|Estrogen receptor positive
588131|NCT00365599|Progesterone receptor positive
588132|NCT00365599|Metastatic disease
588133|NCT00365599|Aromatase inhibitors (Ais)
588134|NCT00365599|Histone deacetylase (HDAC) inhibitors
588135|NCT00365599|Selective estrogen receptor modulators(SERMS)
588136|NCT00365586|Pain
588137|NCT00365586|Osteoarthritis
588138|NCT00365586|Knee
588139|NCT00365586|NSAID
588140|NCT00365547|recurrent non-small cell lung cancer
588141|NCT00365547|stage IIIB non-small cell lung cancer
588142|NCT00365547|stage IV non-small cell lung cancer
588143|NCT00365547|adenocarcinoma of the lung
588144|NCT00365547|bronchoalveolar cell lung cancer
588145|NCT00365547|large cell lung cancer
588146|NCT00365534|First colonoscopy examination
588147|NCT00365521|Organ transplant patients receiving immunosuppressive therapy
588148|NCT00365508|bladder cancer
588149|NCT00365508|cervical cancer
588150|NCT00365508|esophageal cancer
588151|NCT00365508|gastric cancer
588152|NCT00365508|renal cell carcinoma
588153|NCT00365508|adult primary liver cancer
588154|NCT00365508|non-small cell lung cancer
588155|NCT00365508|small cell lung cancer
588156|NCT00365508|pancreatic cancer
588157|NCT00365508|hypopharyngeal cancer
588158|NCT00365508|laryngeal cancer
588159|NCT00365508|lip and oral cavity cancer
588160|NCT00365508|nasopharyngeal cancer
588161|NCT00365508|oropharyngeal cancer
588162|NCT00365508|paranasal sinus and nasal cavity cancer
588163|NCT00365508|adult acute myeloid leukemia
588164|NCT00365508|tongue cancer
588165|NCT00365508|tobacco use disorder
588166|NCT00365495|Type 2 diabetes
588167|NCT00365495|physical training
588168|NCT00365495|mitochondrial function
588169|NCT00365482|Epilepsy
588170|NCT00365482|Bipolar Disorder
588171|NCT00365469|Probiotics
588172|NCT00365469|Eczema
588173|NCT00365469|Asthma
588174|NCT00365469|Allergic Rhinitis
588175|NCT00365469|Prevention
588176|NCT00365469|Immunological responses
588177|NCT00365456|Lumbar Spine Bone Mineral Density (BMD)
588178|NCT00365443|anogenital warts
588179|NCT00365443|premalignancy
588180|NCT00365443|HPV
588181|NCT00365443|Human papillomavirus
588182|NCT00365430|Patient safety
588183|NCT00365430|Adverse event
588184|NCT00365430|Prevention
588185|NCT00365430|Knowledge
588186|NCT00365430|Inpatient
588187|NCT00365430|Hospital
588188|NCT00365430|Nursing home
588189|NCT00365430|Long term care
588190|NCT00365430|Nurse
588191|NCT00365417|NSABP
588192|NCT00365417|Doxorubicin
588193|NCT00365417|Cyclophosphamide
588194|NCT00365417|Bevacizumab
588195|NCT00365417|Capecitabine
588196|NCT00365417|Docetaxel
588197|NCT00365417|Breast cancer
588198|NCT00365417|Locally advanced
588199|NCT00365417|Neoadjuvant
588200|NCT00365417|Locally advanced breast cancer
588201|NCT00365404|Behavioral change
588202|NCT00365404|Weight management
588203|NCT00365404|Physical activity
588204|NCT00365339|HIV
588205|NCT00365339|Protease Inhibitor
588206|NCT00365326|AC133
588207|NCT00365326|coronary
588208|NCT00365326|bone marrow
588209|NCT00365326|autologous
588210|NCT00365326|coronary artery disease
588211|NCT00365313|celecoxib
588212|NCT00365313|oesomeprazole
588213|NCT00365313|arthritis
588214|NCT00365313|ulcer bleeding
588215|NCT00365300|GERD
588216|NCT00365300|Infants
588217|NCT00365300|Gastroesophageal Reflux
588218|NCT00365287|stage IV breast cancer
588219|NCT00365287|recurrent renal cell cancer
588220|NCT00365287|stage III renal cell cancer
588221|NCT00365287|stage IV renal cell cancer
588222|NCT00365287|adult acute myeloid leukemia in remission
588223|NCT00365287|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
588224|NCT00365287|adult acute myeloid leukemia with inv(16)(p13;q22)
588225|NCT00365287|adult acute myeloid leukemia with t(15;17)(q22;q12)
588226|NCT00365287|adult acute myeloid leukemia with t(16;16)(p13;q22)
588227|NCT00365287|adult acute myeloid leukemia with t(8;21)(q22;q22)
588228|NCT00365287|recurrent adult acute myeloid leukemia
588229|NCT00365287|recurrent childhood acute myeloid leukemia
588230|NCT00365287|accelerated phase chronic myelogenous leukemia
588231|NCT00365287|chronic phase chronic myelogenous leukemia
588232|NCT00365287|relapsing chronic myelogenous leukemia
588233|NCT00365287|recurrent adult Hodgkin lymphoma
588234|NCT00365287|recurrent/refractory childhood Hodgkin lymphoma
588235|NCT00365287|stage III adult Hodgkin lymphoma
588236|NCT00365287|stage IV adult Hodgkin lymphoma
588237|NCT00365287|stage III chronic lymphocytic leukemia
588238|NCT00365287|stage IV chronic lymphocytic leukemia
588239|NCT00365287|stage I multiple myeloma
588240|NCT00365287|stage II multiple myeloma
588241|NCT00365287|stage III multiple myeloma
588242|NCT00365287|de novo myelodysplastic syndromes
588243|NCT00365287|previously treated myelodysplastic syndromes
588244|NCT00365287|secondary myelodysplastic syndromes
588245|NCT00365287|refractory anemia
588246|NCT00365287|adult acute lymphoblastic leukemia in remission
588247|NCT00365287|blastic phase chronic myelogenous leukemia
588248|NCT00365287|childhood acute lymphoblastic leukemia in remission
588249|NCT00365287|childhood acute myeloid leukemia in remission
588250|NCT00365287|childhood chronic myelogenous leukemia
588251|NCT00365287|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
588252|NCT00365287|nodal marginal zone B-cell lymphoma
588253|NCT00365287|noncontiguous stage II adult Burkitt lymphoma
588254|NCT00365287|noncontiguous stage II adult diffuse large cell lymphoma
588255|NCT00365287|noncontiguous stage II adult diffuse mixed cell lymphoma
588256|NCT00365287|noncontiguous stage II adult diffuse small cleaved cell lymphoma
588257|NCT00365287|noncontiguous stage II adult immunoblastic large cell lymphoma
588258|NCT00365287|noncontiguous stage II adult lymphoblastic lymphoma
588259|NCT00365287|noncontiguous stage II grade 1 follicular lymphoma
588260|NCT00365287|noncontiguous stage II grade 2 follicular lymphoma
588261|NCT00365287|noncontiguous stage II grade 3 follicular lymphoma
588262|NCT00365287|noncontiguous stage II mantle cell lymphoma
588263|NCT00365287|noncontiguous stage II marginal zone lymphoma
588264|NCT00365287|noncontiguous stage II small lymphocytic lymphoma
588265|NCT00365287|recurrent adult acute lymphoblastic leukemia
588266|NCT00365287|recurrent adult Burkitt lymphoma
588267|NCT00365287|recurrent adult diffuse large cell lymphoma
588268|NCT00365287|recurrent adult diffuse mixed cell lymphoma
588269|NCT00365287|recurrent adult diffuse small cleaved cell lymphoma
588270|NCT00365287|recurrent adult immunoblastic large cell lymphoma
588271|NCT00365287|recurrent adult lymphoblastic lymphoma
588272|NCT00365287|recurrent childhood acute lymphoblastic leukemia
588273|NCT00365287|recurrent childhood lymphoblastic lymphoma
588274|NCT00365287|recurrent childhood large cell lymphoma
588275|NCT00365287|recurrent childhood small noncleaved cell lymphoma
588276|NCT00365287|recurrent grade 1 follicular lymphoma
588277|NCT00365287|recurrent grade 2 follicular lymphoma
588278|NCT00365287|recurrent grade 3 follicular lymphoma
588279|NCT00365287|recurrent mantle cell lymphoma
588280|NCT00365287|recurrent marginal zone lymphoma
588281|NCT00365287|recurrent small lymphocytic lymphoma
588282|NCT00365287|refractory chronic lymphocytic leukemia
588283|NCT00365287|refractory multiple myeloma
588284|NCT00365287|secondary acute myeloid leukemia
588285|NCT00365287|splenic marginal zone lymphoma
588286|NCT00365287|stage III adult Burkitt lymphoma
588287|NCT00365287|stage III adult diffuse large cell lymphoma
588288|NCT00365287|stage III adult diffuse mixed cell lymphoma
588289|NCT00365287|stage III adult diffuse small cleaved cell lymphoma
588290|NCT00365287|stage III adult immunoblastic large cell lymphoma
588291|NCT00365287|stage III adult lymphoblastic lymphoma
588292|NCT00365287|stage III grade 1 follicular lymphoma
588293|NCT00365287|stage III grade 2 follicular lymphoma
588294|NCT00365287|stage III grade 3 follicular lymphoma
588295|NCT00365287|stage III mantle cell lymphoma
588296|NCT00365287|stage III marginal zone lymphoma
588297|NCT00365287|stage III small lymphocytic lymphoma
588298|NCT00365287|stage IV adult Burkitt lymphoma
588299|NCT00365287|stage IV adult diffuse large cell lymphoma
588300|NCT00365287|stage IV adult diffuse mixed cell lymphoma
588301|NCT00365287|stage IV adult diffuse small cleaved cell lymphoma
588302|NCT00365287|stage IV adult immunoblastic large cell lymphoma
588303|NCT00365287|stage IV adult lymphoblastic lymphoma
588304|NCT00365287|stage IV grade 1 follicular lymphoma
588305|NCT00365287|stage IV grade 2 follicular lymphoma
588306|NCT00365287|stage IV grade 3 follicular lymphoma
588307|NCT00365287|stage IV mantle cell lymphoma
588308|NCT00365287|stage IV marginal zone lymphoma
588309|NCT00365287|stage IV small lymphocytic lymphoma
588310|NCT00365287|refractory anemia with excess blasts in transformation
588311|NCT00365287|refractory anemia with ringed sideroblasts
588312|NCT00365287|refractory cytopenia with multilineage dysplasia
588313|NCT00365287|refractory anemia with excess blasts
588314|NCT00365287|childhood myelodysplastic syndromes
588315|NCT00365274|non-Hodgkin's lymphoma
588316|NCT00365274|NHL
588317|NCT00365274|murine monoclonal antibody
588318|NCT00365274|mAb
588319|NCT00365274|SGN-30
588320|NCT00365274|CHOP
588321|NCT00365274|Cyclophosphamide
588322|NCT00365274|Doxorubicin Hydrochloride
588323|NCT00365274|Vincristine
588324|NCT00365274|Prednisone
588325|NCT00365274|anaplastic large cell lymphoma
588326|NCT00365274|Lymphoma
588327|NCT00365274|Lymphoma, Large B-Cell, Diffuse
588328|NCT00365274|Lymphoma, Non-Hodgkin
588329|NCT00365274|Lymphoma, Large-Cell, Anaplastic
588330|NCT00365274|Neoplasms by Histologic Type
588331|NCT00365274|Neoplasms
588332|NCT00365274|Lymphoproliferative Disorders
588333|NCT00365274|Lymphatic Diseases
588334|NCT00365274|Immunoproliferative Disorders
588335|NCT00365274|Immune System Diseases
588336|NCT00365274|Lymphoma, B-Cell
588337|NCT00365274|Lymphoma, T-Cell
588338|NCT00365274|Antibodies
588339|NCT00365274|Antibodies, Monoclonal
588340|NCT00365274|Immunologic Factors
588341|NCT00365274|Physiological Effects of Drugs
588342|NCT00365274|Pharmacologic Actions
588343|NCT00365274|Immunosuppressive Agents
588344|NCT00365274|Antirheumatic Agents
588345|NCT00365274|Therapeutic Uses
588346|NCT00365274|Antineoplastic Agents, Alkylating
588347|NCT00365274|Alkylating Agents
588348|NCT00365274|Molecular Mechanisms of Pharmacological Action
588349|NCT00365274|Antineoplastic Agents
588350|NCT00365274|Myeloablative Agonists
588351|NCT00365274|Antibiotics
588352|NCT00365274|Antineoplastic
588353|NCT00365261|pain
588354|NCT00365261|fatigue
588355|NCT00365261|sleep
588356|NCT00365261|bone marrow transplant
588357|NCT00365261|cancer
588358|NCT00365248|Surgical resection of the liver with or without segmental transplantation
588359|NCT00365222|Temozolomide
588360|NCT00365222|Temodar
588361|NCT00365222|Glioblastoma
588362|NCT00365222|Gliosarcoma
588363|NCT00365222|Brain Tumor
588364|NCT00365222|Quality of Life
588365|NCT00365222|Neurological
588366|NCT00365196|Autonomic Nervous System
588367|NCT00365183|Non Small Cell Lung Cancer
588368|NCT00365183|Lung Cancer
588369|NCT00365183|Metastatic Lung Cancer
588370|NCT00365183|Inoperable Lung Cancer
588371|NCT00365183|Advanced Lung Cancer
588372|NCT00365183|Large Cell Lung Cancer
588373|NCT00365183|Adenocarcinoma, lung
588374|NCT00365183|Squamous Cell Carcinoma, lung
588375|NCT00365183|Squamous Cell Lung Cancer
588376|NCT00365183|Large Cell Carcinoma, lung
588377|NCT00365183|Cancer of the Lung
588378|NCT00365183|Carcinoma
588379|NCT00365183|Bronchogenic
588380|NCT00365144|stage IV pancreatic cancer
588381|NCT00365144|adenocarcinoma of the pancreas
588382|NCT00365144|recurrent pancreatic cancer
588383|NCT00365131|Type I Gaucher disease
588384|NCT00365131|Glucocerebrosidase Deficiency Disease
588385|NCT00365118|Port wine stains
588386|NCT00365118|naevus flammeus
588387|NCT00365105|pain
588388|NCT00365105|bone metastases
588389|NCT00365105|extensive stage small cell lung cancer
588390|NCT00365105|recurrent breast cancer
588391|NCT00365105|stage IV breast cancer
588392|NCT00365105|recurrent non-small cell lung cancer
588393|NCT00365105|stage IV non-small cell lung cancer
588394|NCT00365105|recurrent prostate cancer
588395|NCT00365105|stage IV prostate cancer
588396|NCT00365092|Insertion of tympanostomy tubes
588397|NCT00365092|Otitis media with effusion
588398|NCT00365092|Child development
588399|NCT00365092|Literacy
588400|NCT00365092|Attention
588401|NCT00365092|Middle-ear effusion
588402|NCT00365092|Educational status
588403|NCT00365092|Behavior
588404|NCT00365092|Social behavior
588405|NCT00365092|Achievement
588406|NCT00364338|gourmet healthy cooking
588407|NCT00364338|quality of life
588408|NCT00364338|preimenopause
588409|NCT00364338|weight
588410|NCT00364338|lipids
588411|NCT00364325|Heart failure, congestive
588412|NCT00364325|Heart decompensation
588413|NCT00364312|behavior therapy
588414|NCT00364312|dietary control
588415|NCT00364312|exercise
588416|NCT00364312|diabetes mellitus
588417|NCT00364312|behavior modification
588418|NCT00364312|blood glucose
588419|NCT00364312|clinical trial
588420|NCT00364312|diabetes education
588421|NCT00364312|health behavior
588422|NCT00364312|health care service utilization
588423|NCT00364312|obesity
588424|NCT00364312|quality of life
588425|NCT00364299|Ventilator-associated pneumonia
588426|NCT00364299|Mechanical ventilation
588427|NCT00364299|Tracheal tube cuff pressure
588428|NCT00364286|Chronic Lymphocytic Leukemia
588429|NCT00364286|Small Lymphocytic Lymphoma
588430|NCT00364286|Prolymphocytic Leukemia
588431|NCT00364286|Leukemia
588432|NCT00364286|Lymphoma
588433|NCT00364286|Dasatinib
588434|NCT00364286|BMS-354825
588435|NCT00364273|Asthma
588436|NCT00364260|Anemia
588437|NCT00364260|epoetin alfa
588438|NCT00364247|Acute pain
588439|NCT00364247|bunionectomy
588440|NCT00364234|Renal Osteodystrophy
588441|NCT00364195|Metastatic breast cancer
588442|NCT00364195|Tesmilifene
588443|NCT00364195|DPPE
588444|NCT00364182|Hemophilia B
588445|NCT00364182|BeneFIX
588446|NCT00364169|constipation
588447|NCT00364169|cancer
588448|NCT00364169|surgery
588449|NCT00364169|intervention
588450|NCT00364169|nursing
588451|NCT00364169|postoperative
588452|NCT00365040|myopia
588453|NCT00365040|excimer laser
588454|NCT00365027|GNRH agonist
588455|NCT00365027|ovarian hyperstimulation syndrome
588456|NCT00365027|Embryo cryopreservation
588457|NCT00365014|aplastic anemia
588458|NCT00365014|myelodysplastic syndromes
588459|NCT00365014|cytopenias
588460|NCT00365014|acute myeloid leukemia
588461|NCT00365014|myelodysplastic/myeloproliferative diseases
588462|NCT00365014|benzene poisoning
588463|NCT00364988|pioglitazone
588464|NCT00364988|losartan
588465|NCT00364988|proteinuria
588466|NCT00364988|end stage renal disease (ESRD)
588467|NCT00364975|gourmet healthy cooking
588468|NCT00364975|quality of life
588469|NCT00364975|adjuvant chemotherapy
588470|NCT00364975|weight
588471|NCT00364975|breast cancer
588472|NCT00364962|NPC
588473|NCT00364962|Nasopharyngectomy
588474|NCT00364962|KTP laser
588475|NCT00364962|recurrence
588476|NCT00364949|Polycystic Ovary Syndrome
588477|NCT00364949|PCOS
588478|NCT00364949|Pregnant
588479|NCT00364949|Cord Blood
588480|NCT00364936|palliative care
588481|NCT00364936|hospice
588482|NCT00364936|end-of-life
588483|NCT00364936|symptom control
588484|NCT00364936|evaluation
588485|NCT00364936|effectiveness
588486|NCT00364923|Peripheral T-cell Lymphoma
588487|NCT00364923|T-cell Lymphoma
588488|NCT00364923|Lymphoma
588489|NCT00364923|PDX
588490|NCT00364923|Pralatrexate
588491|NCT00364923|Vitamin B12
588492|NCT00364923|Folic acid
588493|NCT00364910|Myocardial Infarction (MI)
588494|NCT00364910|Cognitive Behavioral Therapy (CBT)
588495|NCT00364910|Adherence
588496|NCT00364910|Depression
588497|NCT00364884|chronic kidney disease
588498|NCT00364871|Obesity
588499|NCT00364858|Type 1 Gaucher Disease
588500|NCT00364858|Glucocerebrosidase Deficiency Disease
588501|NCT00364845|Quality of Life
588502|NCT00364845|Chronic Kidney Disease
588503|NCT00364845|Anemia
588504|NCT00364819|Primary Biliary Cirrhosis
588505|NCT00364806|Migraine
588506|NCT00364806|Headache
588507|NCT00364793|HIV, Pediatric
588508|NCT00364767|Moderate alcohol consumption
588509|NCT00364767|Fat and carbohydrate oxidative capacity
588510|NCT00364767|Postprandial glycemic response
588511|NCT00364754|Tesmilifene
588512|NCT00364754|DPPE
588513|NCT00364754|Breast cancer
588514|NCT00364754|Cyclophosphamide
588515|NCT00364754|Epirubicin
588516|NCT00364754|Pharmacokinetic
588517|NCT00364715|Nuclear localization, annexin A1, oral SCC
588518|NCT00364702|Virtual Reality
588519|NCT00364702|ADHD
588520|NCT00364702|Methylphenidate
588521|NCT00364689|Encephalopathy, Hepatic
588522|NCT00364689|Portosystemic Encephalopathy
588523|NCT00364689|Encephalopathy, Hepatocerebral
588524|NCT00364689|Encephalopathy, Portal-Systemic
588525|NCT00364689|Encephalopathy, Portosystemic
588526|NCT00364689|Hepatic Coma
588527|NCT00364689|Hepatic Stupor
588528|NCT00364689|Hepatocerebral Encephalopathy
588529|NCT00364689|Portal-Systemic Encephalopathy
588530|NCT00364676|Vinorelbine
588531|NCT00364676|solid tumors
588532|NCT00364676|Hodgkins
588533|NCT00364676|Non hodgkins
588534|NCT00364676|Lymphoma
588535|NCT00364676|Advanced solid tumors
588536|NCT00364663|NSCLC
588537|NCT00364663|staging
588538|NCT00364663|18F-FDG PET
588539|NCT00364663|decision tree model
588540|NCT00364663|cost-effectiveness
588541|NCT00364650|Renal transplantation
588542|NCT00364650|Diarrhea
588543|NCT00364650|Immunosuppression
588544|NCT00364650|Probiotics
588545|NCT00364637|Sevoflurane
588546|NCT00364637|Anesthesia
588547|NCT00364637|Troponin
588548|NCT00364637|Myocardial Preconditioning
588549|NCT00364637|Surgery, Cardiac
588550|NCT00364637|Stents
588551|NCT00364637|Non-cardiac Surgery
588552|NCT00364637|Surgery
588553|NCT00364624|lung cancer
588554|NCT00364624|adrenal insufficiency
588555|NCT00364598|Anginera
588556|NCT00364598|LVAD
588557|NCT00364598|Transplant
588558|NCT00364598|Histology
588559|NCT00364598|LVAD implantation as a bridge to transplant
588560|NCT00364572|sciatica
588561|NCT00364572|low back pain
588562|NCT00364572|epidural
588563|NCT00364572|tumor necrosis factor
588564|NCT00364559|intracerebral hemorrhage
588565|NCT00364559|statins
588566|NCT00364559|rosuvastatin
588567|NCT00364559|stroke
588568|NCT00364546|Osteoarthritis
588569|NCT00364546|Pain
588570|NCT00364546|Low Back Pain
588571|NCT00364546|Hip Pain
588572|NCT00364546|Knee Pain
588573|NCT00364546|Backache
588574|NCT00364546|tapentadol
588575|NCT00364533|Arthralgia
588576|NCT00364533|Pain
588577|NCT00364533|Pain Assessment
588578|NCT00364533|Hip Replacement
588579|NCT00364533|Tapentadol
588580|NCT00364520|Hematologic Diseases
588581|NCT00364520|Benzene
588582|NCT00364520|Genetic Polymorphisms
588583|NCT00364494|Hematocrit
588584|NCT00364494|Hemodilution
588585|NCT00364494|Blood Transfusion
588586|NCT00364494|Cardiopulmonary Bypass
588587|NCT00364494|Multiple Organ Failure
588588|NCT00364494|Surgery, Cardiac
588589|NCT00364494|Kidney Failure
588590|NCT00364494|Cardiac Surgical Procedures
588591|NCT00364481|apnea
588592|NCT00364481|tongue
588593|NCT00364481|exercises
588594|NCT00364481|reflux
588595|NCT00364481|airway
588596|NCT00364481|upper
588597|NCT00364481|fatigue
588598|NCT00364468|pegfilgrastim
588599|NCT00364468|neutropenia
588600|NCT00364468|cancer patients
588601|NCT00364468|lymphoma
588602|NCT00364455|Hormone refractory prostate cancer
588603|NCT00364455|Anemia
588604|NCT00364455|Quality-of-life
588605|NCT00364442|asthma
588606|NCT00364429|schizophrenic patients
588607|NCT00364429|SPET
588608|NCT00364429|NMDA receptor
588609|NCT00364429|ligand [123]I-CNS 1261
588610|NCT00364416|Heart Failure, congestive
588611|NCT00364416|Heart decompensation
588612|NCT00364403|Glycemic index
588613|NCT00364403|Glycemic load
588614|NCT00364403|Low fat
588615|NCT00364403|Impaired glucose tolerance
588616|NCT00364403|Large for gestational age infant
588617|NCT00364403|Excessive body weight
588618|NCT00364390|CABG
588619|NCT00364390|Anginera
588620|NCT00364390|CAD
588621|NCT00364351|Non Small Cell Lung Cancer
588622|NCT00364351|NSCLC
588623|NCT00364143|Cancer
588624|NCT00364143|Advanced Solid Tumor
588625|NCT00364143|Oncology
588626|NCT00364117|150 discharges
588627|NCT00364117|adults
588628|NCT00364117|Internal Medicine
588629|NCT00364104|Iron deficiency
588630|NCT00364104|Helicobacter infection
588631|NCT00364104|Epidemiology
588632|NCT00364091|allergic conjunctivitis, ophthalmology, multicenter, controlled
588633|NCT00364078|Cross-sectional correlational study
588634|NCT00364078|Uncertainty
588635|NCT00364078|Locus of Control
588636|NCT00364078|Quality of life
588637|NCT00364078|Transitoriness
588638|NCT00364078|Cancer care
588639|NCT00364052|Valganciclovir, Oral Ganciclovir, Liver transplant
588640|NCT00364013|Oncology
588641|NCT00364013|Cancer
588642|NCT00364013|metastatic colorectal cancer
588643|NCT00364013|EGFr
588644|NCT00364013|Panitumumab
588645|NCT00364013|Clinical Trail
588646|NCT00364013|Amgen
588647|NCT00364000|haemodialysis
588648|NCT00364000|hyperphosphatemia
588649|NCT00364000|sevelamer
588650|NCT00364000|calcium acetate
588651|NCT00363987|nephropathy with type 2 diabetes
588652|NCT00363974|AML
588653|NCT00363974|leukemia
588654|NCT00363974|relapse
588655|NCT00363974|refractory
588656|NCT00363974|antisense
588657|NCT00363974|oligonucleotide
588658|NCT00363961|End stage renal disease
588659|NCT00363961|Maintenance dialysis
588660|NCT00363961|Resistance exercise
588661|NCT00363961|Muscle wasting
588662|NCT00363961|Disability
588663|NCT00363948|MK-0431
588664|NCT00363948|ONO-5435
588665|NCT00363948|Type 2 diabetes mellitus
588666|NCT00363922|Coronary Artery Bypass [E04.100.376.719.332]
588667|NCT00363909|psychosocial effects of cancer and its treatment
588668|NCT00363909|hot flashes
588669|NCT00363909|breast cancer
588670|NCT00363896|COPD
588671|NCT00363896|Lung function
588672|NCT00363896|Exacerbations
588673|NCT00363896|Quality of Life
588674|NCT00363870|Influenza vaccine
588675|NCT00363870|Prophylaxis Influenza vaccine
588676|NCT00363857|fatigue
588677|NCT00363857|sleep
588678|NCT00363857|sleep disorder
588679|NCT00363857|Legs
588680|NCT00363857|RLS
588681|NCT00363857|Restless Legs Syndrome
588682|NCT00363857|Ropinirole
588683|NCT00363844|MK-0431
588684|NCT00363844|ONO-5435
588685|NCT00363844|Type 2 diabetes mellitus
588686|NCT00363818|Endothelial function
588687|NCT00363818|Platelet function
588688|NCT00363818|Coronary artery disease
588689|NCT00363818|Thrombosis
588690|NCT00363818|Aggregation
588691|NCT00363805|lung cancer
588692|NCT00363805|prevention
588693|NCT00363805|green tea
588694|NCT00363805|former smokers
588695|NCT00363792|Healthy subjects
588696|NCT00363779|Large Granular Lymphocyte (LGL)
588697|NCT00363779|LGL
588698|NCT00363779|Leukemia
588699|NCT00363779|Cyclosporine
588700|NCT00363779|Microarray
588701|NCT00363779|Gene Expression
588702|NCT00363779|Cyclosporin
588703|NCT00363779|Large Granular Lymphocyte Leukemia
588704|NCT00363779|LGL Leukemia
588705|NCT00363753|Transient ischemic attack
588706|NCT00363753|Stroke
588707|NCT00363753|Aspirin
588708|NCT00363753|Clopidogrel
588709|NCT00363740|GW685698X
588710|NCT00363740|allergic rhinitis
588711|NCT00363740|Seasonal Allergic Rhinitis
588712|NCT00363727|dyskinesia
588713|NCT00363727|SINEMET
588714|NCT00363727|Parkinson's disease
588715|NCT00363727|controlled release ropinirole
588716|NCT00363701|Protonpumpinhibitors
588717|NCT00363701|withdrawal
588718|NCT00363701|longterm treatment
588719|NCT00363701|dyspepsia
588720|NCT00363701|functional dyspepsia
588721|NCT00363701|gastrooesophageal reflux
588722|NCT00363701|upper endoscopy
588723|NCT00363688|Non life threatening allergic reaction
588724|NCT00363688|oral challenge
588725|NCT00363688|penicillin
588726|NCT00363688|skin testing
588727|NCT00363675|Hand Burns
588728|NCT00363675|Pediatrics
588729|NCT00363649|Philadelphia chromosome positive chronic myelogenous leukemia
588730|NCT00363649|chronic phase chronic myelogenous leukemia
588731|NCT00363636|relapsed
588732|NCT00363636|NHL
588733|NCT00363636|pharmacokinetics
588734|NCT00363636|antibody
588735|NCT00363636|safety
588736|NCT00363636|galiximab
588737|NCT00363636|efficacy
588738|NCT00363636|rituximab
588739|NCT00363636|refractory
588740|NCT00363610|Advanced and/or Metastatic Solid Tumors and Lymphoma
588741|NCT00363597|dyspepsia
588742|NCT00363597|gastrointestinal disease
588743|NCT00363597|indigestion
588744|NCT00363584|localized resectable adult primary liver cancer
588745|NCT00363584|cholangiocarcinoma of the extrahepatic bile duct
588746|NCT00363584|cholangiocarcinoma of the gallbladder
588747|NCT00363584|adenocarcinoma of the gallbladder
588748|NCT00363584|adenocarcinoma with squamous metaplasia of the gallbladder
588749|NCT00363584|anaplastic carcinoma of the gallbladder
588750|NCT00363584|localized gallbladder cancer
588751|NCT00363584|localized extrahepatic bile duct cancer
588752|NCT00363584|squamous cell carcinoma of the gallbladder
588753|NCT00363584|adult primary cholangiocellular carcinoma
588754|NCT00363558|skin graft
588755|NCT00363558|fixation
588756|NCT00363558|cyanoacrylate glue
588757|NCT00363558|skin staples
588758|NCT00363545|Prophylaxis against gastroenteritis caused by Rotavirus
588759|NCT00363532|migraine with out aura
588760|NCT00363519|MK-0431
588761|NCT00363519|ONO-5435
588762|NCT00363519|Type 2 diabetes mellitus
588763|NCT00363506|nutritional
588764|NCT00363506|C10.228.140.546.399.750
588765|NCT00363480|Asthma
588766|NCT00363480|Asthma Control Test
588767|NCT00363480|SERETIDE
588768|NCT00363467|Busulfan
588769|NCT00363467|Acute myeloid leukemia (AML)
588770|NCT00363467|Hematopoietic Stem Cell Transplantation (HSCT)
588771|NCT00363467|Dendritic cells
588772|NCT00363467|Bone marrow transplantation
588773|NCT00363467|PBSC mobilization
588774|NCT00363467|Autologous stem cells
588775|NCT00363454|Phase I
588776|NCT00363454|Pharmacokinetics
588777|NCT00363454|TCN-PM
588778|NCT00363454|VD-0002
588779|NCT00363454|Immunohistochemistry
588780|NCT00363454|Serum tumor marker
588781|NCT00363454|Akt phosphorylation
588782|NCT00363454|Ex vivo testing
588783|NCT00363454|metastatic
588784|NCT00363441|head and neck neoplasms
588785|NCT00363441|squamous cell cancer
588786|NCT00363441|intensity modulated radiotherapy
588787|NCT00363428|pulmonary complications
588788|NCT00363428|perioperative/postoperative complications
588789|NCT00363428|tobacco use disorder
588790|NCT00363428|non-small cell lung cancer
588791|NCT00363428|small cell lung cancer
588792|NCT00363402|Cystic Fibrosis
588793|NCT00363389|Hysteroscopy
588794|NCT00363389|Misoprostol
588795|NCT00363389|Uterine hemorrhage
588796|NCT00363389|Uterine cervix
588797|NCT00363389|Dilatation
588798|NCT00363376|olanzapine
588799|NCT00363376|zonisamide
588800|NCT00363376|weight gain
588801|NCT00363376|bipolar disorder
588802|NCT00363376|psychotic disorders
588803|NCT00363363|Pediatrics
588804|NCT00363363|Fontan Procedure
588805|NCT00363363|Physical Activity
588806|NCT00363363|Physical Fitness
588807|NCT00363363|Congenital Heart Defects
588808|NCT00363363|exercise rehabilitation
588809|NCT00363337|Adults
588810|NCT00363337|Bipolar Depression
588811|NCT00363337|Bipolar Disorder
588812|NCT00363337|Bipolar I
588813|NCT00363337|Bipolar II
588814|NCT00363337|Depression
588815|NCT00363324|stem cell
588816|NCT00363324|acute myocardial infarction
588817|NCT00363311|Dutasteride Prostate Cancer Expectant management REDEEM
588818|NCT00363285|adenocarcinoma of the prostate
588819|NCT00363285|stage III prostate cancer
588820|NCT00363285|stage IV prostate cancer
588821|NCT00363246|Elderly
588822|NCT00363246|Fall risk
588823|NCT00363246|Veterans
588824|NCT00363246|WheelChairs
588825|NCT00363246|Injury
588826|NCT00363233|type 2 diabetes
588827|NCT00363233|lignans
588828|NCT00363233|flaxseed
588829|NCT00363233|cholesterol
588830|NCT00363220|Infection
588831|NCT00363220|E coli
588832|NCT00363220|Klebsiella
588833|NCT00363220|ESBL
588834|NCT00363207|behavior
588835|NCT00363207|local anesthesia
588836|NCT00363207|behavior after dental local anesthesia
588837|NCT00363194|Pazopanib GW786034 Advanced cancer Metastatic cancer
588838|NCT00363181|Insulin resistance
588839|NCT00363181|Metabolic problems
588840|NCT00363181|Weight gain
588841|NCT00363181|Mental health problems
588842|NCT00363181|Mental disorders
588843|NCT00363181|Antipsychotic medication
588844|NCT00363181|Olanzapine
588845|NCT00363168|Hemorrhagic Choroidal Neovascularization
588846|NCT00363155|chronic
588847|NCT00363155|hepatitis b
588848|NCT00363142|HIV-1 LEXIVA Ritonavir Once-daily
588849|NCT00363129|neurotoxicity
588850|NCT00363129|unspecified adult solid tumor, protocol specific
588851|NCT00363116|Kidney transplant
588852|NCT00363116|Pancreas transplant
588853|NCT00363116|Daclizumab
588854|NCT00363116|Tacrolimus
588855|NCT00363116|Mycophenolate mofetil
588856|NCT00363116|Steroids
588857|NCT00363116|Immunosuppression
588858|NCT00363116|Acute allograft rejection
588859|NCT00363090|contiguous stage II adult diffuse large cell lymphoma
588860|NCT00363090|contiguous stage II adult diffuse mixed cell lymphoma
588861|NCT00363090|noncontiguous stage II adult diffuse large cell lymphoma
588862|NCT00363090|noncontiguous stage II adult diffuse mixed cell lymphoma
588863|NCT00363090|stage III adult diffuse large cell lymphoma
588864|NCT00363090|stage III adult diffuse mixed cell lymphoma
588865|NCT00363090|stage IV adult diffuse large cell lymphoma
588866|NCT00363090|stage IV adult diffuse mixed cell lymphoma
588867|NCT00363090|angioimmunoblastic T-cell lymphoma
588868|NCT00363090|anaplastic large cell lymphoma
588869|NCT00363090|stage II adult T-cell leukemia/lymphoma
588870|NCT00363090|stage III adult T-cell leukemia/lymphoma
588871|NCT00363090|stage IV adult T-cell leukemia/lymphoma
588872|NCT00363077|Influenza vaccine
588873|NCT00363077|Prophylaxis Influenza vaccine
588874|NCT00363051|Pancreatic
588875|NCT00363051|Tumor
588876|NCT00363051|Islet Cell
588877|NCT00363051|Carcinoma
588878|NCT00363051|Neuroendocrine
588879|NCT00363051|Endocrine
588880|NCT00363051|Atypical Carcinoid
588881|NCT00363051|RADIANT1
588882|NCT00363051|RADIANT-1
588883|NCT00363038|Bruising
588884|NCT00363038|Topical 20% arnica
588885|NCT00363025|Acute myeloid leukemia
588886|NCT00363025|Older patients
588887|NCT00363025|Patient aged 65 years or more
588888|NCT00363012|stage IIIA breast cancer
588889|NCT00363012|stage IIIB breast cancer
588890|NCT00363012|stage IIIC breast cancer
588891|NCT00363012|stage IV breast cancer
588892|NCT00363012|male breast cancer
588893|NCT00362999|Allergic
588894|NCT00362999|Rhinitis
588895|NCT00362999|Pharmacogenetics
588896|NCT00362999|Histamine
588897|NCT00362986|dermatologic complications
588898|NCT00362986|unspecified adult solid tumor, protocol specific
588899|NCT00362973|male breast cancer
588900|NCT00362973|recurrent breast cancer
588901|NCT00362973|stage I breast cancer
588902|NCT00362973|stage II breast cancer
588903|NCT00362973|stage IIIA breast cancer
588904|NCT00362973|stage IIIB breast cancer
588905|NCT00362973|stage IIIC breast cancer
588906|NCT00362973|stage IV breast cancer
588907|NCT00362960|Type 2 Diabetes Mellitus
588908|NCT00362960|Diabetic Nephropathy
588909|NCT00362960|Inflammatory Markers
588910|NCT00362960|Proteinuria
588911|NCT00362960|Renal Disease
588912|NCT00362947|Superficial vein thrombosis
588913|NCT00362947|thrombophlebitis
588914|NCT00362947|LMWH
588915|NCT00362947|parnaparin
588916|NCT00362934|Hyperlipidemia Combined
588917|NCT00362934|efficacy combination fenofibrate simvastatin versus atorvastatin
588918|NCT00362921|adult glioblastoma multiforme
588919|NCT00362921|adult gliosarcoma
588920|NCT00362921|recurrent adult brain tumor
588921|NCT00362908|Obesity
588922|NCT00362908|Hypertension
588923|NCT00362908|Insulin Resistance
588924|NCT00362869|Enteroaggregative Escherichia coli, diarrhea, challenge
588925|NCT00362843|11C-Leucine
588926|NCT00362843|Positron Emission Tomography (PET)
588927|NCT00362843|Cerebral Protein Synthesis
588928|NCT00362843|Propofol
588929|NCT00362843|Fragile X
588930|NCT00362843|Fragile X Syndrome
588931|NCT00362817|Recurrent
588932|NCT00362817|Symptomatic
588933|NCT00362804|tetrabenazine
588934|NCT00362804|partial response
588935|NCT00362804|psychosis
588936|NCT00362804|schizophrenia
588937|NCT00362804|schizoaffective disorder
588938|NCT00362804|partial response to antipsychotics
588939|NCT00362791|voluntary counseling and testing
588940|NCT00362791|HIV/STD prevention counseling
588941|NCT00362791|HIV/STD prevention intervention
588942|NCT00362791|counseling efficacy
588943|NCT00362765|Type 2 Diabetes
588944|NCT00362765|Dyslipidemia
588945|NCT00362765|Hyperinsulinemic
588946|NCT00362765|Clamp
588947|NCT00362765|Metformin
588948|NCT00362765|Fenofibrate
588949|NCT00362752|norfloxacin
588950|NCT00362752|hepatopulmonary syndrome
588951|NCT00362726|HIV
588952|NCT00362687|HIV, HAART
588953|NCT00362661|PTSD
588954|NCT00362661|cortisol
588955|NCT00362661|memory
588956|NCT00362661|treatment
588957|NCT00362622|Travalert
588958|NCT00362622|open angle glaucoma
588959|NCT00362609|Safety
588960|NCT00362596|Acyclovir
588961|NCT00362596|HIV
588962|NCT00362596|HSV
588963|NCT00362583|Cancer pain with breakthrough pain episodes
588964|NCT00362570|Newly diagnosed
588965|NCT00362544|antifungal prophylaxis
588966|NCT00362544|allogeneic stem-cell transplantation
588967|NCT00362544|acute leukaemia
588968|NCT00362544|antifungal prophylaxis treatment of allogeneic stem-cell transplantation and acute leukaemia
588969|NCT00362518|atherosclerosis
588970|NCT00362518|vitamin C
588971|NCT00362518|vitamin E
588972|NCT00362492|TKR
588973|NCT00362492|Ultrasonography
588974|NCT00362492|asymptomatic deep venous thrombosis
588975|NCT00362492|extended duration prophylaxis
588976|NCT00362492|short duration prophylaxis
588977|NCT00362479|pregnancy prevention
588978|NCT00362479|oral contraceptives
588979|NCT00362466|Leukemia (chronic myeloid leukemia - chronic phase)
588980|NCT00362440|HIV lipodystrophy
588981|NCT00362440|Leptin
588982|NCT00362440|Fat wasting
588983|NCT00362440|Pioglitazone
588984|NCT00362440|Insulin resistance
588985|NCT00362427|Hepatitis B
588986|NCT00362427|Pertussis
588987|NCT00362427|Diphtheria
588988|NCT00362427|Tetanus
588989|NCT00362427|H. influenzae type b
588990|NCT00362427|Polio
588991|NCT00362414|Stroke
588992|NCT00362401|Psychoacoustics
588993|NCT00362401|Quality of Life
588994|NCT00362401|Heart Valve Prosthesis
588995|NCT00362388|Coronary artery disease
588996|NCT00362388|Ischemic heart disease
588997|NCT00362388|Angiogenesis
588998|NCT00362388|Cells
588999|NCT00362388|Cardiac surgery
589000|NCT00362375|Adult
589001|NCT00362375|*HIV Infections/pc [Prevention & Control]
589002|NCT00362375|Female
589003|NCT00362375|Humans
589004|NCT00362375|Risk-Taking
589005|NCT00362375|Safe Sex
589006|NCT00362375|Sexual Behavior
589007|NCT00362375|HIV Testing
589008|NCT00362362|Amyotrophic Lateral Sclerosis
589009|NCT00362362|Primary Lateral Sclerosis
589010|NCT00362362|Genetics
589011|NCT00362362|Blood Sample
589012|NCT00362362|PLS
589013|NCT00362362|ALS
589014|NCT00362349|ITP
589015|NCT00362349|IVIg
589016|NCT00362349|Platelet count
589017|NCT00362349|Bleeding
589018|NCT00362336|Hepatitis B
589019|NCT00362336|Polio
589020|NCT00362336|Diphtheria
589021|NCT00362336|Pertussis
589022|NCT00362336|H. influenzae type b
589023|NCT00362323|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
589024|NCT00362310|classical kaposi's sarcoma
589025|NCT00362310|treatment
589026|NCT00362310|HIV protease inhibitor indinavir
589027|NCT00362284|Alzheimer's disease
589028|NCT00362284|coping
589029|NCT00362284|quality of life
589030|NCT00362284|caregiving
589031|NCT00362271|Healthy Subjects
589032|NCT00362245|Amikacin
589033|NCT00362245|Pharmacokinetics
589034|NCT00362245|Pharmacodynamics
589035|NCT00362245|Intra-Thecal injection
589036|NCT00362232|Prevention of venous thromboembolism
589037|NCT00362219|topical
589038|NCT00362219|morphine
589039|NCT00362219|pain
589040|NCT00362219|skin-wound
589041|NCT00362219|skin-graft
589042|NCT00362219|peripheral analgesia
589043|NCT00362219|burn
589044|NCT00362206|Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin versus pravastatin
589045|NCT00362206|Hyperlipidemia Combined
589046|NCT00362193|Diabetes
589047|NCT00362193|Chronic disease management
589048|NCT00362193|Relapse
589049|NCT00362180|LDL-cholesterol
589050|NCT00362180|apoB-100
589051|NCT00362180|apoB-48
589052|NCT00362180|triglyceride
589053|NCT00362180|HeFH
589054|NCT00362180|FHBL
589055|NCT00362167|Clinical Experience
589056|NCT00362167|Educational Training
589057|NCT00362167|Pain Syndromes
589058|NCT00362167|Analgesia
589059|NCT00362167|Pain Medicine
589060|NCT00362167|Therapy
589061|NCT00362167|Neuropathic
589062|NCT00362167|Chronic Pain
589063|NCT00362167|Acute Pain
589064|NCT00362167|Analgesics
589065|NCT00362167|Medication
589066|NCT00362167|Evaluation
589067|NCT00362141|levetiracetam
589068|NCT00362141|status
589069|NCT00362141|epilepticus
589070|NCT00362128|Blood Pressure, High
589071|NCT00362128|Obesity
589072|NCT00362128|Tobacco Use Disorder
589073|NCT00362115|hypertension
589074|NCT00362115|blood pressure
589075|NCT00362115|diastolic blood pressure
589076|NCT00362115|drug therapy
589077|NCT00362102|EGFR-detectable metastatic colorectal carcinoma with documented progressive disease to irinotecan-based chemotherapy and failure
589078|NCT00362089|n-3 fatty acids
589079|NCT00362089|n-6 fatty acids
589080|NCT00362089|long chain polyunsaturated fatty acids
589081|NCT00362089|pregnancy
589082|NCT00362089|lactation
589083|NCT00362089|breast feeding
589084|NCT00362089|breast milk
589085|NCT00362089|adipose tissue
589086|NCT00362089|newborn
589087|NCT00362089|fetal development
589088|NCT00362076|Perception
589089|NCT00362076|Development
589090|NCT00362076|Cognition
589091|NCT00362076|Vision
589092|NCT00362076|Infants
589093|NCT00362076|Autonomic Function
589094|NCT00362076|Cardiac Vagal Tone
589095|NCT00362076|Categorization
589096|NCT00362076|Habituation
589097|NCT00362076|Motion-Carried Information
589098|NCT00362063|growth hormone
589099|NCT00362050|malaria, falciparum
589100|NCT00362050|uncomplicated Plasmodium falciparum malaria
589101|NCT00361998|Uncomplicated Cystitis
589102|NCT00361998|Nitrofurantoin Macrocrystals
589103|NCT00361985|Gastric bypass
589104|NCT00361985|Anastomotic stricture
589105|NCT00361985|Morbid obesity
589106|NCT00361985|Bariatric surgery
589107|NCT00361985|Omeprazole
589108|NCT00361959|fluticasone propionate/salmeterol combination
589109|NCT00361959|tiotropium
589110|NCT00361959|SERETIDE
589111|NCT00361959|COPD exacerbation
589112|NCT00361946|Type 2 diabetes
589113|NCT00361946|Lean
589114|NCT00361946|Obese
589115|NCT00361920|steroid resistant asthma
589116|NCT00361907|Pulsatile intravenous insulin
589117|NCT00361907|Oral carbohydrate loading
589118|NCT00361907|Respiratory Quotients
589119|NCT00361907|Hypoglycemia
589120|NCT00361907|Diabetic Complications
589121|NCT00361907|Circulating vascular and inflammatory markers
589122|NCT00361868|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
589123|NCT00361855|MI
589124|NCT00361842|Colorectal cancer
589125|NCT00361842|Colorectal carcinoma
589126|NCT00361842|Colonic cancer
589127|NCT00361842|Rectal cancer
589128|NCT00361829|Development
589129|NCT00361829|Childhood Growth
589130|NCT00361816|Maternal Effect Gene
589131|NCT00361816|Embryonic Development
589132|NCT00361816|Infertility
589133|NCT00361803|chemotherapy
589134|NCT00361803|recurrent
589135|NCT00361803|refractory
589136|NCT00361803|research
589137|NCT00361803|cancer
589138|NCT00361803|pharmacokinetics
589139|NCT00361790|Healthy Subjects
589140|NCT00361777|Obesity
589141|NCT00361777|Pseudo-Cushing State
589142|NCT00361777|Hypercortisolism
589143|NCT00361777|Cushing's Syndrome
589144|NCT00361777|Cushing Syndrome
589145|NCT00361751|Glucose metabolism
589146|NCT00361751|Fat Metabolism
589147|NCT00361751|Insulin Resistance
589148|NCT00361751|Protein Metabolism
589149|NCT00361751|Tracer Methodology
589150|NCT00361738|Type 2 Diabetes Mellitus
589151|NCT00361725|severe sepsis
589152|NCT00361725|organ failure
589153|NCT00361725|activated protein C
589154|NCT00361725|thrombomodulin
589155|NCT00361725|EPCR
589156|NCT00361712|Epidural
589157|NCT00361712|analgesia
589158|NCT00361712|labor
589159|NCT00361712|cytokines
589160|NCT00361699|stroke
589161|NCT00361699|brain ischemia
589162|NCT00361699|cerebrovascular accident
589163|NCT00361699|statin
589164|NCT00361699|hydroxymethylglutaryl-CoA reductase inhibitors
589165|NCT00361699|cholesterol
589166|NCT00361699|hypercholesterolemia
589167|NCT00361699|hyperlipidemia
589168|NCT00361699|multicenter studies
589169|NCT00361699|prospective studies
589170|NCT00361699|endpoint determination
589171|NCT00361699|randomized controlled trials
589172|NCT00361699|recurrence
589173|NCT00361699|pravastatin
589174|NCT00361699|c-reactive Protein
589175|NCT00361686|tramadol
589176|NCT00361686|remifentanyl
589177|NCT00361686|patient controlled analgesia
589178|NCT00361686|abortion
589179|NCT00361673|Health Disparities
589180|NCT00361673|Built Environments
589181|NCT00361660|Motor skills
589182|NCT00361660|Occupational Therapy
589183|NCT00361660|Physical Therapy Techniques
589184|NCT00361660|Rehabilitation
589185|NCT00361660|Upper Extremity
589186|NCT00361660|Stroke
589187|NCT00361634|Etanercept
589188|NCT00361634|Enbrel
589189|NCT00361634|DCE-MRI
589190|NCT00361634|RA
589191|NCT00361621|VELCADE
589192|NCT00361608|diabetes
589193|NCT00361608|hypoglycemia
589194|NCT00361608|monitor
589195|NCT00361608|children with Type I Diabetes
589196|NCT00361595|osteoporosis
589197|NCT00361595|zoledronic acid
589198|NCT00361595|forteo
589199|NCT00361582|Osteoarthritis
589200|NCT00361582|tapentadol
589201|NCT00361582|knee-replacement
589202|NCT00361582|hip replacement
589203|NCT00361582|pain
589204|NCT00361569|vaginal atrophy
589205|NCT00361569|vaginal dryness
589206|NCT00361569|vaginal itching
589207|NCT00361569|vaginal pain
589208|NCT00361556|low back pain
589209|NCT00361556|disability
589210|NCT00361556|health education
589211|NCT00361556|primary care
589212|NCT00361543|Schizophrenia
589213|NCT00361543|Mental Illness
589214|NCT00361543|SERM
589215|NCT00361543|Raloxifene
589216|NCT00361543|Cognition
589217|NCT00361530|stroke
589218|NCT00361530|brain ischemia
589219|NCT00361530|cerebrovascular accident
589220|NCT00361530|statin
589221|NCT00361530|hydroxymethylglutaryl-CoA Reductase Inhibitors
589222|NCT00361530|cholesterol
589223|NCT00361530|hypercholesterolemia
589224|NCT00361530|hyperlipidemia
589225|NCT00361530|multicenter studies
589226|NCT00361530|prospective studies
589227|NCT00361530|endpoint determination
589228|NCT00361530|randomized controlled trials
589229|NCT00361530|recurrence
589230|NCT00361530|pravastatin
589231|NCT00361530|plaque
589232|NCT00361530|tunica intima
589233|NCT00361530|tunica media
589234|NCT00361530|ultrasonography
589235|NCT00361530|carotid arteries
589236|NCT00361517|GM monitoring
589237|NCT00361517|Immunocompromised
589238|NCT00361517|hematological disorder
589239|NCT00361517|Allogenic HSCT recipients
589240|NCT00361517|Aspergillus PCR assay
589241|NCT00361504|Osteoarthritis
589242|NCT00361504|Pain
589243|NCT00361504|Low Back Pain
589244|NCT00361504|Hip Pain
589245|NCT00361504|Knee Pain
589246|NCT00361504|Backache
589247|NCT00361504|Tapentadol
589248|NCT00361491|Depression
589249|NCT00361491|antidepressive disorders
589250|NCT00361491|controlled clinical trial
589251|NCT00361478|exercise
589252|NCT00361478|postnatal depression
589253|NCT00361478|psychological health
589254|NCT00361478|well-being
589255|NCT00361426|COPD
589256|NCT00361426|Respiration Rate
589257|NCT00361426|Monitoring
589258|NCT00361413|Stem cell transplantation
589259|NCT00361413|GVHD
589260|NCT00361413|Graft Versus Host Disease
589261|NCT00361400|pregnancy
589262|NCT00361400|hormonal contraception
589263|NCT00361387|Sarcoidosis
589264|NCT00361387|Sarcoid
589265|NCT00361374|Depression
589266|NCT00361374|Omega-3
589267|NCT00361374|Boston
589268|NCT00361348|Palifermin
589269|NCT00361348|drug interaction
589270|NCT00361335|Rheumatoid arthritis
589271|NCT00361335|Golimumab
589272|NCT00361335|Methotrexate
589273|NCT00361335|Tumor Necrosis Factor-alpha
589274|NCT00361335|Immunology
589275|NCT00361309|liver cancer
589276|NCT00361309|HCC
589277|NCT00361296|refractory anemia with excess blasts
589278|NCT00361296|refractory anemia with ringed sideroblasts
589279|NCT00361296|refractory anemia
589280|NCT00361296|refractory cytopenia with multilineage dysplasia
589281|NCT00361296|de novo myelodysplastic syndromes
589282|NCT00361296|previously treated myelodysplastic syndromes
589283|NCT00361296|secondary myelodysplastic syndromes
589284|NCT00361270|Biofeedback
589285|NCT00361270|Hypnosis
589286|NCT00361270|Low Back Pain, Recurrent
589287|NCT00361270|Pain beliefs
589288|NCT00361270|Pain coping strategies
589289|NCT00361270|Pain intensity
589290|NCT00361270|Pain interference
589291|NCT00361270|Pain quality
589292|NCT00361270|Self-help treatment
589293|NCT00361270|Sleep dysfunction
589294|NCT00361257|Treatment Experienced
589295|NCT00361244|Sutent
589296|NCT00361231|Avastin
589297|NCT00361231|GEMOX
589298|NCT00361218|depression
589299|NCT00361218|biology
589300|NCT00361205|Parkinson's Disease, pharmacology, compliance, dopaminergic
589301|NCT00361192|temporal arteritis
589302|NCT00361192|duplex of temporal artery
589303|NCT00361192|biopsy of temporal artery
589304|NCT00361179|Observation
589305|NCT00361179|Post-treatment
589306|NCT00361166|Schizophrenia
589307|NCT00361166|psychosis
589308|NCT00361166|delusions
589309|NCT00361166|hallucination
589310|NCT00361140|Busulfan
589311|NCT00361140|Fludarabine
589312|NCT00361140|Chimerism
589313|NCT00361140|Allogeneic stem cell transplantation (HCT)
589314|NCT00361140|Myelodysplastic Syndromes
589315|NCT00361140|Leukemia Myeloproliferative disorders (MPD)
589316|NCT00361140|Leukemia, Lymphocytic
589317|NCT00361140|Myeloma
589318|NCT00361140|Lymphoma
589319|NCT00361140|AUC
589320|NCT00361140|Hematologic malignancies
589321|NCT00361127|Heart failure
589322|NCT00361127|pulmonary edema
589323|NCT00361127|ACE-inhibitors
589324|NCT00361127|lung diffusion
589325|NCT00361127|exercise capacity
589326|NCT00361127|Chronic heart failure
589327|NCT00361101|HIV
589328|NCT00361101|X4 tropic virus
589329|NCT00361088|Velcade (PS-341)
589330|NCT00361088|Bortezomib
589331|NCT00361088|Zarnestra (R115777)
589332|NCT00361088|Tipifarnib
589333|NCT00361075|Perimenopause
589334|NCT00361075|Abdominal adipose tissue
589335|NCT00361075|Women's health
589336|NCT00361075|Cholesterol
589337|NCT00361075|Lipid Metabolism
589338|NCT00361062|aggressive
589339|NCT00361062|SSRI's
589340|NCT00361062|simulation
589341|NCT00361062|behavioral
589342|NCT00361062|Side Effects, Psychological
589343|NCT00361062|adverse effects
589344|NCT00361062|Serotonin Reuptake Inhibitors
589345|NCT00361062|aggressive behavior
589346|NCT00361062|computer simulation
589347|NCT00361049|graft versus host disease
589348|NCT00361049|unspecified adult solid tumor, protocol specific
589349|NCT00361049|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
589350|NCT00361049|adult acute myeloid leukemia with inv(16)(p13;q22)
589351|NCT00361049|adult acute myeloid leukemia with t(15;17)(q22;q12)
589352|NCT00361049|adult acute myeloid leukemia with t(16;16)(p13;q22)
589353|NCT00361049|adult acute myeloid leukemia with t(8;21)(q22;q22)
589354|NCT00361049|accelerated phase chronic myelogenous leukemia
589355|NCT00361049|adult acute lymphoblastic leukemia in remission
589356|NCT00361049|adult acute myeloid leukemia in remission
589357|NCT00361049|atypical chronic myeloid leukemia
589358|NCT00361049|blastic phase chronic myelogenous leukemia
589359|NCT00361049|chronic eosinophilic leukemia
589360|NCT00361049|primary myelofibrosis
589361|NCT00361049|chronic myelomonocytic leukemia
589362|NCT00361049|chronic neutrophilic leukemia
589363|NCT00361049|chronic phase chronic myelogenous leukemia
589364|NCT00361049|de novo myelodysplastic syndromes
589365|NCT00361049|disseminated neuroblastoma
589366|NCT00361049|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
589367|NCT00361049|myelodysplastic/myeloproliferative disease, unclassifiable
589368|NCT00361049|nodal marginal zone B-cell lymphoma
589369|NCT00361049|noncontiguous stage II adult Burkitt lymphoma
589370|NCT00361049|noncontiguous stage II adult diffuse large cell lymphoma
589371|NCT00361049|noncontiguous stage II adult diffuse mixed cell lymphoma
589372|NCT00361049|noncontiguous stage II adult diffuse small cleaved cell lymphoma
589373|NCT00361049|noncontiguous stage II adult immunoblastic large cell lymphoma
589374|NCT00361049|noncontiguous stage II adult lymphoblastic lymphoma
589375|NCT00361049|noncontiguous stage II grade 1 follicular lymphoma
589376|NCT00361049|noncontiguous stage II grade 2 follicular lymphoma
589377|NCT00361049|noncontiguous stage II grade 3 follicular lymphoma
589378|NCT00361049|noncontiguous stage II mantle cell lymphoma
589379|NCT00361049|noncontiguous stage II marginal zone lymphoma
589380|NCT00361049|noncontiguous stage II small lymphocytic lymphoma
589381|NCT00361049|poor prognosis metastatic gestational trophoblastic tumor
589382|NCT00361049|previously treated myelodysplastic syndromes
589383|NCT00361049|secondary acute myeloid leukemia
589384|NCT00361049|secondary myelodysplastic syndromes
589385|NCT00361049|splenic marginal zone lymphoma
589386|NCT00361049|stage I multiple myeloma
589387|NCT00361049|stage II multiple myeloma
589388|NCT00361049|stage II ovarian epithelial cancer
589389|NCT00361049|stage III adult Burkitt lymphoma
589390|NCT00361049|stage III adult Hodgkin lymphoma
589391|NCT00361049|stage III adult diffuse large cell lymphoma
589392|NCT00361049|stage III adult diffuse mixed cell lymphoma
589393|NCT00361049|stage III adult diffuse small cleaved cell lymphoma
589394|NCT00361049|stage III adult immunoblastic large cell lymphoma
589395|NCT00361049|stage III adult lymphoblastic lymphoma
589396|NCT00361049|stage III chronic lymphocytic leukemia
589397|NCT00361049|stage III grade 1 follicular lymphoma
589398|NCT00361049|stage III grade 2 follicular lymphoma
589399|NCT00361049|stage III grade 3 follicular lymphoma
589400|NCT00361049|stage III mantle cell lymphoma
589401|NCT00361049|stage III marginal zone lymphoma
589402|NCT00361049|stage III multiple myeloma
589403|NCT00361049|stage III ovarian epithelial cancer
589404|NCT00361049|stage III small lymphocytic lymphoma
589405|NCT00361049|stage III malignant testicular germ cell tumor
589406|NCT00361049|stage IIIA breast cancer
589407|NCT00361049|stage IIIB breast cancer
589408|NCT00361049|stage IIIC breast cancer
589409|NCT00361049|stage IV adult Burkitt lymphoma
589410|NCT00361049|stage IV adult Hodgkin lymphoma
589411|NCT00361049|stage IV adult diffuse large cell lymphoma
589412|NCT00361049|stage IV adult diffuse mixed cell lymphoma
589413|NCT00361049|stage IV adult diffuse small cleaved cell lymphoma
589414|NCT00361049|stage IV adult immunoblastic large cell lymphoma
589415|NCT00361049|stage IV adult lymphoblastic lymphoma
589416|NCT00361049|stage IV breast cancer
589417|NCT00361049|stage IV chronic lymphocytic leukemia
589418|NCT00361049|stage IV grade 1 follicular lymphoma
589419|NCT00361049|stage IV grade 2 follicular lymphoma
589420|NCT00361049|stage IV grade 3 follicular lymphoma
589421|NCT00361049|stage IV mantle cell lymphoma
589422|NCT00361049|stage IV marginal zone lymphoma
589423|NCT00361049|stage IV ovarian epithelial cancer
589424|NCT00361049|stage IV small lymphocytic lymphoma
589425|NCT00361036|Leiomyoma
589426|NCT00361036|Leiomyomatosis
589427|NCT00361036|Uterine Neoplasms
589428|NCT00361036|BeadBlock
589429|NCT00361036|Embsophere
589430|NCT00361036|Embolization
589431|NCT00361036|Uterine fibroid embolization
589432|NCT00361023|Angiotensin type 1 receptor blocker (ARB)
589433|NCT00361023|losartan
589434|NCT00361023|type 2 diabetes
589435|NCT00361023|insulin sensitivity and secretion
589436|NCT00361023|glucose metabolism
589437|NCT00361010|Keppra
589438|NCT00361010|Epilepsy
589439|NCT00361010|Childhood Absence Epilepsy
589440|NCT00361010|Seizures
589441|NCT00360997|Stroke rehabilitation
589442|NCT00360997|Physical therapy
589443|NCT00360984|CSII
589444|NCT00360984|insulin analog
589445|NCT00360984|severe hypoglycaemia
589446|NCT00360984|altered hypoglycaemia awareness
589447|NCT00360984|diabetes quality of life
589448|NCT00360984|CGMS
589449|NCT00360971|mucositis
589450|NCT00360971|pain
589451|NCT00360971|radiation toxicity
589452|NCT00360971|stage III squamous cell carcinoma of the hypopharynx
589453|NCT00360971|stage IV squamous cell carcinoma of the hypopharynx
589454|NCT00360971|stage III squamous cell carcinoma of the larynx
589455|NCT00360971|stage IV squamous cell carcinoma of the larynx
589456|NCT00360971|stage III squamous cell carcinoma of the lip and oral cavity
589457|NCT00360971|stage IV squamous cell carcinoma of the lip and oral cavity
589458|NCT00360971|stage III squamous cell carcinoma of the oropharynx
589459|NCT00360971|stage IV squamous cell carcinoma of the oropharynx
589460|NCT00360958|ultrafiltration
589461|NCT00360958|heart failure
589462|NCT00360958|fluid overload
589463|NCT00360945|childhood oligodendroglioma
589464|NCT00360945|untreated childhood cerebellar astrocytoma
589465|NCT00360945|childhood high-grade cerebral astrocytoma
589466|NCT00360945|childhood low-grade cerebral astrocytoma
589467|NCT00360945|recurrent childhood cerebellar astrocytoma
589468|NCT00360945|recurrent childhood cerebral astrocytoma
589469|NCT00360945|recurrent childhood brain tumor
589470|NCT00360932|facial lipoatrophy
589471|NCT00360932|HIV/AIDs
589472|NCT00360919|casomorphin
589473|NCT00360919|cheese
589474|NCT00360919|craving
589475|NCT00360919|casein
589476|NCT00360919|milk
589477|NCT00360906|RRMS
589478|NCT00360906|Omega-3
589479|NCT00360906|Treatment
589480|NCT00360867|Extension study
589481|NCT00360867|solid tumors
589482|NCT00360854|untreated childhood brain stem glioma
589483|NCT00360854|recurrent childhood cerebellar astrocytoma
589484|NCT00360854|recurrent childhood cerebral astrocytoma
589485|NCT00360854|recurrent childhood ependymoma
589486|NCT00360854|recurrent childhood medulloblastoma
589607|NCT00360425|pharmacokinetics
589487|NCT00360854|recurrent childhood supratentorial primitive neuroectodermal tumor
589488|NCT00360854|recurrent childhood visual pathway and hypothalamic glioma
589489|NCT00360854|childhood central nervous system germ cell tumor
589490|NCT00360854|childhood choroid plexus tumor
589491|NCT00360854|childhood craniopharyngioma
589492|NCT00360854|childhood grade I meningioma
589493|NCT00360854|childhood grade II meningioma
589494|NCT00360854|childhood grade III meningioma
589495|NCT00360854|childhood low-grade cerebral astrocytoma
589496|NCT00360854|childhood infratentorial ependymoma
589497|NCT00360854|childhood supratentorial ependymoma
589498|NCT00360854|recurrent childhood brain tumor
589499|NCT00360854|recurrent childhood subependymal giant cell astrocytoma
589500|NCT00360854|recurrent childhood pineoblastoma
589501|NCT00360841|auricular
589502|NCT00360841|acupuncture
589503|NCT00360828|Recurrent Anaplastic Astrocytoma
589504|NCT00360828|Mixed Malignant Glioma
589505|NCT00360828|Oligodendroglioma
589506|NCT00360828|Irinotecan
589507|NCT00360828|Brain tumor
589508|NCT00360828|Nitrosoureas
589509|NCT00360828|Brain and nervous system
589510|NCT00360802|chronic low back pain
589511|NCT00360802|cognitive-behavioral therapy
589512|NCT00360802|Mindful Based Stress Reduction
589513|NCT00360802|pain clinics
589514|NCT00360802|anxiety
589515|NCT00360802|quality of life
589516|NCT00360802|chronic pain
589517|NCT00360789|STROKE REHABILITATION
589518|NCT00360789|pHYSICAL THERAPY
589519|NCT00360750|intraocular retinoblastoma
589520|NCT00360750|extraocular retinoblastoma
589521|NCT00360737|Clinical Trials
589522|NCT00360737|Investigational Drug
589523|NCT00360737|Healthy Volunteers
589524|NCT00360737|Botulinum Antitoxin
589525|NCT00360737|Phoenix, Arizona
589526|NCT00360724|dysthymia
589527|NCT00360724|dysthymic disorder
589528|NCT00360724|chronic depression
589529|NCT00360724|chronic low-grade depression
589530|NCT00360724|atypical depression
589531|NCT00360724|minor depression
589532|NCT00360724|depression NOS
589533|NCT00360724|depression
589534|NCT00360724|depressive disorder
589535|NCT00360724|mood disorder
589536|NCT00360724|unipolar depression
589537|NCT00360724|low-grade depression
589538|NCT00360711|Moral Distress
589539|NCT00360711|Nondirectiveness
589540|NCT00360711|Ethical Dilemma
589541|NCT00360685|Tacrolimus
589542|NCT00360685|Methotrexate
589543|NCT00360685|Mycophenolate mofetil
589544|NCT00360685|Mucositis
589545|NCT00360685|Acute graft-versus-host disease (aGVHD)
589546|NCT00360685|Engraftment
589547|NCT00360685|hemolytic/uremic syndrome (HUS)
589548|NCT00360685|Thrombotic thrombocytopenic purpura (TTP)
589549|NCT00360672|Acute Myelogenous Leukemia
589550|NCT00360672|Myelodysplastic Syndrome
589551|NCT00360659|Obstructive sleep Apnea
589552|NCT00360659|Hypertension
589553|NCT00360659|Vasoactive hormones
589554|NCT00360646|LIVER DIS
589555|NCT00360646|CHEM IND
589556|NCT00360646|Drugs
589557|NCT00360646|Drug induced liver injury
589558|NCT00360646|phenotype
589559|NCT00360646|cholestatic liver injury
589560|NCT00360646|hepatocellular liver injury
589561|NCT00360646|mixed liver injury
589562|NCT00360646|genotype
589563|NCT00360633|Parkinson's Disease
589564|NCT00360633|Impulse control disorder
589565|NCT00360633|Dopamine agonist withdrawal syndrome
589566|NCT00360633|Anxiety
589567|NCT00360633|Depression
589568|NCT00360633|Healthcare Utilization
589569|NCT00360633|Disability
589570|NCT00360633|Quality of life
589571|NCT00360633|Cognitive function
589572|NCT00360633|Psychosis
589573|NCT00360633|Apathy
589574|NCT00360633|Dyskinesias
589575|NCT00360633|Wearing off
589576|NCT00360594|alcoholism
589577|NCT00360581|Smoking abstinence
589578|NCT00360568|carbidopa
589579|NCT00360568|severe motor fluctuations
589580|NCT00360568|intestinal gel
589581|NCT00360568|levodopa
589582|NCT00360568|efficacy
589583|NCT00360568|levodopa carbidopa intestinal gel
589584|NCT00360568|dyskinesia
589585|NCT00360568|Parkinson's Disease
589586|NCT00360568|Duodopa
589587|NCT00360568|levodopa-carbidopa
589588|NCT00360568|DUOPA
589589|NCT00360516|healthy volunteers
589590|NCT00360503|Cystic fibrosis
589591|NCT00360503|Antibiotic resistance
589592|NCT00360503|Microbiology
589593|NCT00360490|Idiopathic Menorrhagia
589594|NCT00360477|Kidney stone removal surgery
589595|NCT00360451|Prevention
589596|NCT00360451|Child
589597|NCT00360451|Adolescent
589598|NCT00360451|Parent
589599|NCT00360438|Leukemia
589600|NCT00360438|Lymphoma
589601|NCT00360438|Tumor Lysis Syndrome
589602|NCT00360438|TLS
589603|NCT00360438|Rasburicase
589604|NCT00360438|Elitek
589605|NCT00360425|anemia
589606|NCT00360425|intravenous iron
589608|NCT00360425|QTc
589609|NCT00360399|Escitalopram
589610|NCT00360399|Duloxetine
589611|NCT00360399|Cognitive Behavioral Therapy
589612|NCT00360399|PET
589613|NCT00360399|fMRI
589614|NCT00360373|bariatric
589615|NCT00360373|obesity
589616|NCT00360373|insulin resistance
589617|NCT00360373|gastric bypass
589618|NCT00360373|adolescent
589619|NCT00360360|Neoplasm, Unknown Primary
589620|NCT00360334|diabetes
589621|NCT00360334|exenatide
589622|NCT00360334|insulin glargine
589623|NCT00360334|Lilly
589624|NCT00360334|Amylin
589625|NCT00360282|Migraine
589626|NCT00360282|Triptans
589627|NCT00360282|Motion Sickness
589628|NCT00360256|Depression
589629|NCT00360256|Amplichip P450 tests
589630|NCT00360256|Antidepressants
589631|NCT00360230|Malaria
589632|NCT00360230|Plasmodium falciparum
589633|NCT00360230|Vaccine
589634|NCT00360230|Prophylaxis Plasmodium falciparum malaria
589635|NCT00360217|Omega-3
589636|NCT00360217|Triglyceride
589637|NCT00360217|Hyperlipidemia
589638|NCT00360217|Coronary Artery Disease
589639|NCT00360217|Fatty Acids
589640|NCT00360217|Safety
589641|NCT00360217|Fish Oil
589642|NCT00360217|Docosohexanoic Acid
589643|NCT00360204|Infant health
589644|NCT00360204|parenting competence
589645|NCT00360204|Home nurse visit
589646|NCT00360204|maternal post-partum care
589647|NCT00360204|postpartum health utilization
589648|NCT00360204|Breastfeeding
589649|NCT00360178|hypertension
589650|NCT00360178|valsartan
589651|NCT00360178|amlodipine
589652|NCT00360178|hydrochlorothiazide
589653|NCT00360152|Breast Cancer
589654|NCT00360152|Axilla
589655|NCT00360152|Ultrasound
589656|NCT00360152|FNA
589657|NCT00360152|Molecular Analysis
589658|NCT00360139|Sculptra
589659|NCT00360139|lipoatrophy
589660|NCT00360139|emaciation
589661|NCT00360139|facial
589662|NCT00360139|dermal filler
589663|NCT00360139|poly-L-lactic acid
589664|NCT00360139|Dermik
589665|NCT00360139|SpaMD
589666|NCT00360139|Sanofi
589667|NCT00360139|Facial lipoatrophy
589668|NCT00360139|Facial emaciation
589669|NCT00360126|Lamictal
589670|NCT00360126|lamotrigine
589671|NCT00360126|Open-Label Extension Study
589672|NCT00360126|Bipolar Disorder
589673|NCT00360087|Treatment Study
589674|NCT00360087|Sickle Cell Anemia
589675|NCT00360087|6-Minute Walk
589676|NCT00360087|Right Heart Catheterization
589677|NCT00360087|Tracleer
589678|NCT00360087|Sickle Cell
589679|NCT00360087|SCD
589680|NCT00360074|secondary hypothyroidism
589681|NCT00360074|body weight adjusted thyroxin dose
589682|NCT00360074|triiodothyronine supplementation
589683|NCT00360061|Type 1 Diabetes Mellitus
589684|NCT00360061|Adolescents
589685|NCT00360061|Cognitive Behaviour Therapy
589686|NCT00360048|oxytocin
589687|NCT00360048|tnf
589688|NCT00360048|sepsis
589689|NCT00360048|lps
589690|NCT00360009|Parkinson's disease
589691|NCT00360009|Parkinson disease
589692|NCT00360009|PD
589693|NCT00360009|deep brain stimulation
589694|NCT00360009|DBS
589695|NCT00360009|subthalamic nucleus
589696|NCT00360009|STN
589697|NCT00360009|globus pallidus interna
589698|NCT00360009|GPi
589699|NCT00360009|mood
589700|NCT00360009|motor symptoms
589701|NCT00360009|cognition
589702|NCT00360009|emotion
589703|NCT00360009|memory
589704|NCT00360009|attention
589705|NCT00360009|tremor
589706|NCT00360009|rigidity
589707|NCT00360009|bradykinesia
589708|NCT00359996|diabetes
589709|NCT00359996|quality improvement
589710|NCT00359996|community health center
589711|NCT00359996|health disparities
589712|NCT00359983|Humans
589713|NCT00359983|Meningococcal vaccines
589714|NCT00359983|Immunogenicity
589715|NCT00359983|Vaccines
589716|NCT00359983|H. influenzae type b vaccine
589717|NCT00359983|Conjugate
589718|NCT00359983|Toddlers
589719|NCT00359983|Comparative study
589720|NCT00359983|Neisseria meningitidis
589721|NCT00359970|Diarrhea
589722|NCT00359970|Travel
589723|NCT00359970|Travelers' diarrhea
589724|NCT00359970|Azithromycin
589725|NCT00359970|Loperamide
589726|NCT00359970|Treatment
589727|NCT00359970|Antibiotic
589728|NCT00359957|Pediatric obesity
589729|NCT00359957|Physical activity
589730|NCT00359957|Visceral fat
589731|NCT00359957|Weight
589732|NCT00359944|Alzheimer
589733|NCT00359944|Dementia
589734|NCT00359931|Neural Networks
589735|NCT00359931|Mathematical Modeling
589736|NCT00359931|Auditory Processing
589737|NCT00359931|Tinnitis
589738|NCT00359931|Hearing Loss
589739|NCT00359918|infarction
589740|NCT00359918|facilitated PCI
589741|NCT00359918|primary PCI
589742|NCT00359918|infarct size
589743|NCT00359918|fibrinolysis
589744|NCT00359918|ST-elevation myocardial infarction (STEMI)
589745|NCT00359905|Benign prostatic hyperplasia
589746|NCT00359905|alpha-blockers
589747|NCT00359879|diabetes
589748|NCT00359879|exenatide
589749|NCT00359879|Lilly
589750|NCT00359879|Amylin
589751|NCT00359853|Norfloxacin, primary prophylaxis, SBP
589752|NCT00359840|darbepoetin alfa
589753|NCT00359840|anemia
589754|NCT00359840|cancer patients
589755|NCT00359840|chemotherapy
589756|NCT00359814|Cyclosporine
589757|NCT00359814|renal insufficiency, chronic
589758|NCT00359814|long-term care
589759|NCT00359801|Large Simple Trial
589760|NCT00359775|Coping
589761|NCT00359775|psychosocial
589762|NCT00359775|Quality of Life
589763|NCT00359775|problem solving
589764|NCT00359762|exenatide
589765|NCT00359762|diabetes
589766|NCT00359762|Amylin
589767|NCT00359762|Lilly
589768|NCT00359762|glimepiride
589769|NCT00359736|alveolitis, fibrosing
589770|NCT00359736|exercise, aerobic
589771|NCT00359736|fibrosis, pulmonary
589772|NCT00359736|hypertension, pulmonary
589773|NCT00359723|Parkinson's disease
589774|NCT00359723|PD
589775|NCT00359723|methylphenidate
589776|NCT00359723|Ritalin
589777|NCT00359723|MPD
589778|NCT00359710|Multiracial Populations
589779|NCT00359710|Human Genetic Variation
589780|NCT00359710|Family History
589781|NCT00359710|Admixture
589782|NCT00359710|Physician-Patient Communication
589783|NCT00359710|Ancestry
589784|NCT00359710|Self-Identified Multiracial Adults
589785|NCT00359710|Interview
589786|NCT00359684|Cystinosis
589787|NCT00359684|Cystine
589788|NCT00359684|Lysomal Storage Disease
589789|NCT00359684|Mutation Analysis
589790|NCT00359684|Metabolic Disease
589791|NCT00359658|Cyclosporine
589792|NCT00359658|Glucocorticoids
589793|NCT00359658|renal insufficiency, chronic
589794|NCT00359658|long-term care
589795|NCT00359645|Screening
589796|NCT00359645|Upper aerodigestive tract cancer
589797|NCT00359645|Alcohol
589798|NCT00359645|Tobacco
589799|NCT00359645|Randomized trial
589800|NCT00359632|Optic neuropathy following long-term linezolid use
589801|NCT00359619|HPV vaccine
589802|NCT00359606|DNA Methylation
589803|NCT00359606|Advanced Cancer
589804|NCT00359606|Methyltransferase Inhibitor
589805|NCT00359606|Epigenetics
589806|NCT00359606|Gene Re-Expression
589807|NCT00359593|Stroke
589808|NCT00359593|Rehabilitation
589809|NCT00359593|Knowledge translation
589810|NCT00359593|Evidence based practice
589811|NCT00359593|Outcomes
589812|NCT00359580|Ancestry
589813|NCT00359567|nausea and vomiting
589814|NCT00359554|Influenza
589815|NCT00359541|CYP2C9
589816|NCT00359541|CYP2C19
589817|NCT00359541|Pharmacology
589818|NCT00359541|Genotype
589819|NCT00359541|Metabolism
589820|NCT00359515|Archived Samples
589821|NCT00359515|Mutation Screening
589822|NCT00359515|Genotype-Phenotype Correlation
589823|NCT00359515|Pediatric Developmental Disorder
589824|NCT00359515|Cataracts
589825|NCT00359515|Mutation Detection
589826|NCT00359515|Lowe Syndrome
589827|NCT00359515|Genotype
589828|NCT00359476|Locally advanced/metastatic gastric adenocarcinoma
589829|NCT00359476|adenocarcinoma-gastroesophageal junction
589830|NCT00359476|Gastric Adenocarcinoma
589831|NCT00359463|hepatitis C-associated thrombocytopenia
589832|NCT00359463|chemotherapy induced thrombocytopenia
589833|NCT00359463|thrombocytopenia
589834|NCT00359463|hepatic impairment
589835|NCT00359463|chronic immune thrombocytopenia purpura
589836|NCT00359450|Locally advanced or metastatic non-small cell lung cancer
589837|NCT00359424|acute ischemic stroke
589838|NCT00359424|rt-PA
589839|NCT00359424|thrombolytic
589840|NCT00359424|recombinant tissue plasminogen activator
589841|NCT00359424|recanalization
589842|NCT00359424|blood clot
589843|NCT00359424|stroke
589844|NCT00359424|clot-dissolving
589845|NCT00359424|Activase®
589846|NCT00359424|Actilyse®
589847|NCT00359424|Concentric Merci® Retriever
589848|NCT00359424|EKOS® Micro-Infusion catheter (MicroLysus)
589849|NCT00359424|The Penumbra System™
589850|NCT00359424|Standard microcatheter
589851|NCT00359411|Epstein-Barr Virus
589852|NCT00359411|B-Cell Lymphoma
589853|NCT00359411|Herpes Virus
589854|NCT00359411|Infectious Mononucleosis
589855|NCT00359398|Cardiopulmonary bypass
589856|NCT00359398|Blood component removal
589857|NCT00359385|primary hyperparathyroidism
589858|NCT00359385|hyperparathyroidism
589859|NCT00359385|PHPT
589860|NCT00359385|PTH
589861|NCT00359385|hypercalcemia
589862|NCT00359385|bone density
589863|NCT00359385|osteoporosis
589864|NCT00359385|bone turnover
589865|NCT00359385|DXA
589866|NCT00359385|pQCT
589867|NCT00359385|cQCT
589868|NCT00359385|alendronate
589869|NCT00359385|Fosamax
589870|NCT00359385|parathyroid hormone
589871|NCT00359385|parathyroid surgery
589872|NCT00359385|parathyroidectomy
589873|NCT00359385|Silverberg
589874|NCT00359385|Rubin
589875|NCT00359385|Bilezikian
589876|NCT00359385|treatment
589877|NCT00359372|Chronic Heart Failure
589878|NCT00359372|Cardiac Resynchronization
589879|NCT00359372|Magnetic Resonance Imaging
589880|NCT00359372|Biventricular Pacing
589881|NCT00359372|Heart Function
589882|NCT00359372|CRT
589883|NCT00359359|Small Cell Lung Cancer
589884|NCT00359346|Plasmapheresis
589885|NCT00359346|Auto-antibodies
589886|NCT00359346|Autonomic Nervous System
589887|NCT00359346|Dysautonomia
589888|NCT00359346|Sympathetic Nervous System
589889|NCT00359346|Autonomic Failure
589890|NCT00359320|Pancreaticoduodenectomy
589891|NCT00359320|Pancreaticojejunostomy
589892|NCT00359320|Pancreatic Cancer
589893|NCT00359307|Genetic
589894|NCT00359307|Longitudinal
589895|NCT00359307|Prospective
589896|NCT00359307|Epidemiology
589897|NCT00359307|Heart Attack
589898|NCT00359294|Tumor
589899|NCT00359294|Lymphoma
589900|NCT00359294|Zalypsis
589901|NCT00359294|PharmaMar
589902|NCT00359294|PM00104
589903|NCT00359281|healthy volunteers
589904|NCT00359268|Polymerase Chain Reaction
589905|NCT00359268|Random Priming
589906|NCT00359268|Nucleic Acid
589907|NCT00359268|Viral Genome
589908|NCT00359268|Virus
589909|NCT00359268|Identification
589910|NCT00359255|Exercise
589911|NCT00359255|rehabilitation
589912|NCT00359255|upper limb
589913|NCT00359255|inpatient
589914|NCT00359255|RCT
589915|NCT00359255|activities of daily living
589916|NCT00359242|Infant Sleep
589917|NCT00359242|Infant Diet
589918|NCT00359242|Infant Temperament
589919|NCT00359242|Rapid Infant weight gain
589920|NCT00359242|Infant Development
589921|NCT00359242|Parenting Competence
589922|NCT00359242|infant weight gain
589923|NCT00359216|Hypopnea Syndrome
589924|NCT00359203|syncope
589925|NCT00359203|implantable loop recorder
589926|NCT00359190|lapatinib
589927|NCT00359190|breast cancer
589928|NCT00359190|treatment-naive
589929|NCT00359177|emesis liver problems hepatic impairment GW679769
589930|NCT00359164|AMD
589931|NCT00359164|Avastin
589932|NCT00359164|Visudyne
589933|NCT00359164|Medical condition being studied AMD
589934|NCT00359151|Perioperative care of total arthroplasty assessing opioid consumption
589935|NCT00359138|Histamine H1 Antagonists
589936|NCT00359138|Anti-Allergic Agents
589937|NCT00359125|bipolar
589938|NCT00359125|RU-486
589939|NCT00359125|mifepristone
589940|NCT00359125|neurocognition
589941|NCT00359125|mood
589942|NCT00359125|cortisol
589943|NCT00359125|HPA axis
589944|NCT00359112|Type 2 diabetes
589945|NCT00359112|overweight
589946|NCT00359112|AVANDAMET
589947|NCT00359112|metformin
589948|NCT00359112|sulphonylurea
589949|NCT00359099|Hepatic Medicine
589950|NCT00359099|Surgery
589951|NCT00359086|Relapsed and Refractory Lymphoma
589952|NCT00359086|Phase II
589953|NCT00359073|asthma
589954|NCT00359073|leukotrienes
589955|NCT00359073|rhinovirus
589956|NCT00359060|Physical activity
589957|NCT00359060|Sex steroid hormones
589958|NCT00359060|Breast cancer risk
589959|NCT00359060|Intervention study
589960|NCT00359060|Postmenopausal women
589961|NCT00359047|Osteoporosis
589962|NCT00359047|Fragility fracture
589963|NCT00359047|Women
589964|NCT00359047|Randomised control trial
589965|NCT00359047|Patient education
589966|NCT00359047|Diagnosis
589967|NCT00359047|Treatment
589968|NCT00359034|Doppler ultrasound
589969|NCT00359034|pulsewave velocity
589970|NCT00359034|intrauterine growth restriction
589971|NCT00359034|Fetal Pulsewave Velocity
589972|NCT00359021|HIV-1
589973|NCT00359021|treatment experienced
589974|NCT00359021|virologic failure
589975|NCT00359008|AMD
589976|NCT00359008|CNV
589977|NCT00359008|PHP
589978|NCT00358995|Cognitive Behavioral Therapy
589979|NCT00358995|Primary Obsessions
589980|NCT00358995|Obsessive Compulsive Disorder
589981|NCT00358995|Compulsive Disorder
589982|NCT00358982|Relapsed or Refractory Hodgkin's Lymphoma
589983|NCT00358982|Phase II
589984|NCT00358969|borderline personality disorder
589985|NCT00358969|guanfacine
589986|NCT00358969|impulsivity
589987|NCT00358969|aggression
589988|NCT00358969|affective instability
589989|NCT00358956|medullary thyroid cancer
589990|NCT00358956|MTC
589991|NCT00358956|hereditary medullary thyroid cancer
589992|NCT00358956|thyroid cancer
589993|NCT00358943|Gaucher Disease
589994|NCT00358943|Glucocerebrosidase Deficiency Disease
589995|NCT00358930|squamous cell carcinoma of the head and neck
589996|NCT00358904|Hill Sachs
589997|NCT00358904|Weber osteotomy
589998|NCT00358904|shoulder dislocation
589999|NCT00358891|Prematurity
590000|NCT00358891|Chronic Lung Disease
590001|NCT00358891|Respiratory Health
590002|NCT00358891|Neurodevelopment
590003|NCT00358891|Preschool
590004|NCT00358891|Influencing Factors
590005|NCT00358878|Ascites
590006|NCT00358878|Liver Cirrhosis
590007|NCT00358865|Virtual Reality
590008|NCT00358865|ABI
590009|NCT00358865|Projected system
590010|NCT00358852|Schizophrenia
590011|NCT00358852|Mental disorder
590012|NCT00358852|Schizoaffective disorder
590013|NCT00358852|Schizophreniform disorder
590014|NCT00358852|Epidemiological study
590015|NCT00358852|Scale validation
590016|NCT00358852|Relapse
590017|NCT00358852|Short Term Hospitalization
590018|NCT00358852|PRE-COG
590019|NCT00358852|RISSCH4075
590020|NCT00358839|Familial hemiplegic migraine type 1 and 2
590021|NCT00358839|CGRP
590022|NCT00358839|middle cerebral artery
590023|NCT00358839|superficial temporal artery
590024|NCT00358839|headache
590025|NCT00358839|genotype
590026|NCT00358839|Healthy Volunteers
590027|NCT00358813|emesis
590028|NCT00358813|renal impairment
590029|NCT00358813|GW679769
590030|NCT00358813|kidney problems
590031|NCT00358800|OSAHS and REMStar Auto with C-Flex
590032|NCT00358787|Supracondylar fracture
590033|NCT00358787|humerus
590034|NCT00358787|ulnar nerve injury
590035|NCT00358787|Baumann's angle
590036|NCT00358787|Supracondylar fracture of the humerus
590037|NCT00358774|homeopathic
590038|NCT00358774|common cold
590039|NCT00358774|Research Subjects
590040|NCT00358761|Lone Star Tick
590041|NCT00358761|Borrelia
590042|NCT00358761|Skin Biopsy
590043|NCT00358761|Spirochete
590044|NCT00358761|Erythema Migrans
590045|NCT00358761|Southern Tick-Assoicated Rash Illness
590046|NCT00358761|STARI
590047|NCT00358748|Preterm
590048|NCT00358748|hypotension
590049|NCT00358748|steroids
590050|NCT00358748|hydrocortisone
590051|NCT00358735|SAFE
590052|NCT00358735|CECT
590053|NCT00358735|SFT
590054|NCT00358735|ActiveCare
590055|NCT00358735|ActiveCare+SFT
590056|NCT00358735|Deep Vein Thrombosis prevention
590057|NCT00358735|Total Hip Replacement
590058|NCT00358735|Total Hip Arthroplasty
590059|NCT00358735|Low Molecular Weight Heparin
590060|NCT00358735|MCS
590061|NCT00358709|Cognitive-behavioral therapy
590062|NCT00358709|symptom management
590063|NCT00358709|first psychotic episode
590064|NCT00358696|tenofovir
590065|NCT00358696|didanosine
590066|NCT00358696|hiv
590067|NCT00358696|hepatitis c virus infection
590068|NCT00358696|treatment
590069|NCT00358683|certolizunab pegol
590070|NCT00358683|long term safety follow-up
590071|NCT00358683|Chrohn's disease
590072|NCT00358683|infliximab failures patients
590073|NCT00358683|Greek population
590074|NCT00358644|Acute Myeloid Leukemia
590075|NCT00358644|AML
590076|NCT00358644|Decitabine
590077|NCT00358644|Dacogen
590078|NCT00358644|MGI PHARMA, INC.
590079|NCT00358631|depression
590080|NCT00358631|antidepressive agents
590081|NCT00358631|controlled clinical trial
590082|NCT00358618|Randomized
590083|NCT00358618|double-blind
590084|NCT00358618|3-group clinical interventional study
590085|NCT00358605|OSAHS
590086|NCT00358605|Oral Appliance
590087|NCT00358605|Hypopnoea Syndrome
590088|NCT00358592|surgical instruments
590089|NCT00358592|cesarean section
590090|NCT00358592|obesity
590091|NCT00358579|Vasopressin
590092|NCT00358579|Adrenaline
590093|NCT00358579|Survival
590094|NCT00358579|Return of spontaneous of circulation
590095|NCT00358566|Advanced
590096|NCT00358566|Unresesctable
590097|NCT00358566|Adenocarcinoma
590098|NCT00358566|Pancreatic cancer
590099|NCT00358553|Human Volunteers
590100|NCT00358540|sarcoma
590101|NCT00358540|thrombocytopenia
590102|NCT00358540|eltrombopag
590103|NCT00358540|thrombopoiesis
590104|NCT00358514|Tibia
590105|NCT00358514|fracture
590106|NCT00358514|compartment syndrome
590107|NCT00358514|fasciotomy
590108|NCT00358501|Defibrotide
590109|NCT00358501|Severe veno occlusive disease
590110|NCT00358501|Multi organ failure
590111|NCT00358501|Stem cell transplant
590112|NCT00358501|Liver
590113|NCT00358501|Regimen related toxicity
590114|NCT00358501|Day 100 survival
590115|NCT00358488|Safety
590116|NCT00358488|Asthmatic patients
590117|NCT00358488|GSK159797
590118|NCT00358488|Efficacy
590119|NCT00358475|perennial allergic rhinitis
590120|NCT00358462|NGU, M genitalium, Ureaplasma, azithromycin, doxycycline
590121|NCT00358449|eosinophilic
590122|NCT00358449|mepolizumab
590123|NCT00358449|esophagitis
590124|NCT00358436|COPD
590125|NCT00358436|Lung function
590126|NCT00358436|Exacerbations
590127|NCT00358436|Quality of Life
590128|NCT00358423|CME
590129|NCT00358423|Pegaptanib
590130|NCT00358423|Post-Surgical Ocular Inflammation
590131|NCT00358410|Functional Dyspepsia
590132|NCT00358410|Barostat
590133|NCT00358410|Stomach
590134|NCT00358397|Solid Tumor
590135|NCT00358397|Clostridial
590136|NCT00358397|Spore-forming bacteria
590137|NCT00358397|hypoxia
590138|NCT00358397|anaerobes
590139|NCT00358397|Clostridium novyi
590140|NCT00358397|Bacteria
590141|NCT00358397|Bacteriolytic
590142|NCT00358397|Tumor lysis
590143|NCT00358397|Necrosis
590144|NCT00358397|Colon Cancer
590145|NCT00358397|Lung Cancer
590146|NCT00358397|Sarcoma
590147|NCT00358397|Bladder Cancer
590148|NCT00358397|Rectal Cancer
590149|NCT00358397|Gastric Cancer
590150|NCT00358397|Pancreatic Cancer
590151|NCT00358397|Experimental Therapy
590152|NCT00358397|Solid Tumors
590153|NCT00358384|tolerability
590154|NCT00358384|safety
590155|NCT00358384|angiogenesis
590156|NCT00358384|vascular endothelial growth factor
590157|NCT00358384|pharmacodynamics
590158|NCT00358384|pharmacokinetics
590159|NCT00358384|microplaque
590160|NCT00358384|VEGF
590161|NCT00358384|GW786034
590162|NCT00358371|bioavailability flucloxacillin
590163|NCT00358358|COPD
590164|NCT00358358|Impulse Oscillometry System
590165|NCT00358358|Computerized Tomography
590166|NCT00358345|AMD
590167|NCT00358332|malaria, vaccine, Mali, children
590168|NCT00358319|Valproic Acid (VPA)
590169|NCT00358319|Karenitecin
590170|NCT00358319|Malignant Melanoma
590171|NCT00358319|Histone deacetylases (HDAC)inhibitors
590172|NCT00358319|Topoisomerase I inhibitor
590173|NCT00358319|metastatic
590174|NCT00358306|Endothelium
590175|NCT00358306|Chronic Kidney Disease
590176|NCT00358306|Acute Kidney Injury
590177|NCT00358306|Hemolytic-uremic syndrome (HUS)
590178|NCT00358293|Multiple Sclerosis
590179|NCT00358293|Spasticity
590180|NCT00358293|Sublingual Tizanidine
590181|NCT00358293|Ashworth Scores
590182|NCT00358293|Spasticity in Multiple Sclerosis Patients
590183|NCT00358280|Patients ASA category I ～ II
590184|NCT00358280|Unilateral Lower limb surgery
590185|NCT00358280|Spinal Anesthesia
590186|NCT00358267|Inferior Turbinate Reduction
590187|NCT00358267|Partial Resection of Inferior Turbinates (PRIT)
590188|NCT00358267|Radiofrequency Ablation (RFA)
590189|NCT00358267|NOSE scale
590190|NCT00358267|Nasal Obstruction
590191|NCT00358241|Nerve block, postoperative pain, analgesia
590192|NCT00358228|Smoking cessation
590193|NCT00358228|Abstinence
590194|NCT00358215|Survival study
590195|NCT00358215|morbidity and mortality
590196|NCT00358215|heart failure hospitalization
590197|NCT00358215|all-cause death
590198|NCT00358215|patient-reported outcomes
590199|NCT00358215|Kansas City Cardiomyopathy questionnaire
590200|NCT00358215|anemia treatment
590201|NCT00358202|intramuscular antibiotics
590202|NCT00358202|nursing home acquired pneumonia
590203|NCT00358202|nhap
590204|NCT00358202|pharmacoeconomics
590205|NCT00358202|cefepime
590206|NCT00358202|ceftriaxone
590207|NCT00358189|deep brain stimulation
590208|NCT00358189|gait
590209|NCT00358189|manual dexterity
590210|NCT00358189|parkinson's disease
590211|NCT00358176|Treatment osteoporosis postmenopausal
590212|NCT00358163|angiogenesis
590213|NCT00358163|taxane
590214|NCT00358163|tyrosine kinase
590215|NCT00358163|pharmacokinetics
590216|NCT00358163|Vatalanib
590217|NCT00358163|Taxol
590218|NCT00358150|Type 1 Gaucher Disease
590219|NCT00358150|Glucocerebrosidase Deficiency Disease
590220|NCT00358137|Blood Pressure, High
590221|NCT00358111|high-grade disease
590222|NCT00358111|Cervical examination
590223|NCT00358111|targeting biopsies
590224|NCT00358111|dysplasia
590225|NCT00358111|cancer
590226|NCT00358098|PET
590227|NCT00358098|hormone positive breast cancer
590228|NCT00358085|Endovascular
590229|NCT00358085|Vascular Surgical Procedures
590230|NCT00358085|Aneurysm
590231|NCT00358085|Expertise Based Methodology
590232|NCT00358072|Acute lymphoblastic leukemia
590233|NCT00358072|Adult patients
590234|NCT00358072|Minimal residual disease
590235|NCT00358072|Risk-oriented therapy
590236|NCT00358059|diabetes mellitus
590237|NCT00358059|adolescence
590238|NCT00358059|adherence
590239|NCT00358059|glycemic control
590240|NCT00358059|adaptation
590241|NCT00358059|communication
590242|NCT00358046|Hyperphosphatemia
590243|NCT00358046|Chronic kidney disease
590244|NCT00358046|Dialysis
590245|NCT00358046|Hyperphosphatemia in CKD patients on dialysis
590246|NCT00358020|MYELOMA, THALIDOMIDE, BORTEZOMIB
590247|NCT00358007|Kilovoltage Imaging
590248|NCT00358007|Cone-beam CT
590249|NCT00358007|CBCT
590250|NCT00358007|radiation therapy
590251|NCT00358007|head and neck neoplasms
590252|NCT00357994|carbidopa
590253|NCT00357994|levodopa-carbidopa
590254|NCT00357994|levodopa
590255|NCT00357994|levodopa/carbidopa suspension
590256|NCT00357994|dyskinesia
590257|NCT00357994|Duodopa
590258|NCT00357994|levodopa-carbidopa intestinal gel
590259|NCT00357994|Severe Motor Fluctuations
590260|NCT00357994|DUOPA
590261|NCT00357981|Contraceptive patch
590262|NCT00357981|menstruation
590263|NCT00357981|economics
590264|NCT00357942|Morphine
590265|NCT00357942|Mouthwash
590266|NCT00357942|Mucositis
590267|NCT00357942|Pain
590268|NCT00357942|Cancer
590269|NCT00357942|Child
590270|NCT00357942|Adolescent
590271|NCT00357929|permissive hypercarbia
590272|NCT00357929|weaning from mechanical ventilation
590273|NCT00357916|PEP005
590274|NCT00357916|Safety
590275|NCT00357903|Rheumatoid Arthritis, Etanercept, Long-term Safety, Enbrel
590276|NCT00357890|type 1 diabetes
590277|NCT00357890|diabetes
590278|NCT00357890|new onset
590279|NCT00357890|CSII
590280|NCT00357890|insulin glargine
590281|NCT00357890|insulin sensitivity
590282|NCT00357890|beta cell function
590283|NCT00357890|beta cell preservation
590284|NCT00357851|pancreatitis, blood loss
590285|NCT00357838|normal healthy women
590286|NCT00357812|Herpes Simplex Virus Type 1
590287|NCT00357812|Herpes Simplex Keratitis
590288|NCT00357812|Cornea
590289|NCT00357812|Dendretic Ulcer
590290|NCT00357812|In vivo Confocal Microscopy
590291|NCT00357812|Nested Multi-plex PCR
590292|NCT00357812|Monoclonal Antibody
590293|NCT00357812|Glycoprotein D
590294|NCT00357812|Glycoprotein C
590295|NCT00357799|Venipuncture
590296|NCT00357799|Randomized Controlled Trial
590297|NCT00357799|Intravenous Access
590298|NCT00357799|Children
590299|NCT00357799|Emergency Department Nursing
590300|NCT00357799|VeinViewer
590301|NCT00357799|Pediatrics
590302|NCT00357799|Emergency Nursing
590303|NCT00357786|Lysosomal Disease
590304|NCT00357786|Glycolipid
590305|NCT00357786|Stroke
590306|NCT00357786|Peripheral Neuropathy
590307|NCT00357786|Storage Disorder
590308|NCT00357747|unspecified adult solid tumor, protocol specific
590309|NCT00357734|lung cancer
590310|NCT00357734|breast cancer
590311|NCT00357695|Praxis
590312|NCT00357695|Grasping
590313|NCT00357695|Premotor Cortex
590314|NCT00357695|Visuo-Motor Integration
590315|NCT00357695|Motor Imagination
590316|NCT00357682|esophageal cancer
590317|NCT00357682|Barrett's esophagus
590318|NCT00357669|Unverricht-Lundborg disease
590319|NCT00357669|Baltic myoclonus
590320|NCT00357669|progressive myoclonic epilepsies
590321|NCT00357669|myoclonus
590322|NCT00357669|brivaracetam
590323|NCT00357656|Hemophilia A (severe or moderately severe)
590324|NCT00357643|calcium
590325|NCT00357643|vitamin D
590326|NCT00357643|bone loss
590327|NCT00357630|adenocarcinoma of unknown primary
590328|NCT00357630|newly diagnosed carcinoma of unknown primary
590329|NCT00357630|undifferentiated carcinoma of unknown primary
590330|NCT00357630|pain
590331|NCT00357617|stage I squamous cell carcinoma of the hypopharynx
590332|NCT00357617|stage II squamous cell carcinoma of the hypopharynx
590333|NCT00357617|stage III squamous cell carcinoma of the hypopharynx
590334|NCT00357617|stage IV squamous cell carcinoma of the hypopharynx
590335|NCT00357617|stage I squamous cell carcinoma of the larynx
590336|NCT00357617|stage II squamous cell carcinoma of the larynx
590337|NCT00357617|stage III squamous cell carcinoma of the larynx
590338|NCT00357617|stage IV squamous cell carcinoma of the larynx
590339|NCT00357617|stage I squamous cell carcinoma of the lip and oral cavity
590340|NCT00357617|stage II squamous cell carcinoma of the lip and oral cavity
590341|NCT00357617|stage III squamous cell carcinoma of the lip and oral cavity
590342|NCT00357617|stage IV squamous cell carcinoma of the lip and oral cavity
590343|NCT00357617|stage I squamous cell carcinoma of the oropharynx
590344|NCT00357617|stage II squamous cell carcinoma of the oropharynx
590345|NCT00357617|stage III squamous cell carcinoma of the oropharynx
590346|NCT00357617|stage IV squamous cell carcinoma of the oropharynx
590347|NCT00357617|recurrent squamous cell carcinoma of the hypopharynx
590348|NCT00357617|recurrent squamous cell carcinoma of the larynx
590349|NCT00357617|recurrent squamous cell carcinoma of the lip and oral cavity
590350|NCT00357617|recurrent squamous cell carcinoma of the oropharynx
590351|NCT00357604|HIV
590352|NCT00357604|Protease Inhibitor
590353|NCT00357591|Heart Failure
590354|NCT00357591|Acute Decompensation
590355|NCT00357591|Chronic Heart Failure
590356|NCT00357578|Macrophages
590357|NCT00357578|Biopsy
590358|NCT00357578|Genetic Analysis
590359|NCT00357578|Geographic Atrophy
590360|NCT00357578|Choroidal Neovascularization
590361|NCT00357578|Fibroblast
590362|NCT00357578|Disciform
590363|NCT00357578|Age-Related Macular Degeneration
590364|NCT00357565|childhood acute myeloid leukemia in remission
590365|NCT00357565|recurrent childhood acute myeloid leukemia
590366|NCT00357565|secondary acute myeloid leukemia
590367|NCT00357565|childhood acute lymphoblastic leukemia in remission
590368|NCT00357565|previously treated myelodysplastic syndromes
590369|NCT00357565|secondary myelodysplastic syndromes
590370|NCT00357565|refractory anemia with excess blasts in transformation
590371|NCT00357565|refractory anemia with excess blasts
590372|NCT00357565|refractory anemia
590373|NCT00357565|de novo myelodysplastic syndromes
590374|NCT00357565|childhood myelodysplastic syndromes
590375|NCT00357552|Treatment Experienced
590376|NCT00357526|vaginal ring
590377|NCT00357526|Oral contraceptive pills
590378|NCT00357526|Teenagers
590379|NCT00357526|Young women
590380|NCT00357526|Patient satisfaction
590381|NCT00357513|Cerebrovascular Disease
590382|NCT00357513|Gene Chip
590383|NCT00357513|Inflammation
590384|NCT00357513|Pathophysiology Stroke
590385|NCT00357513|Stroke Genomics
590386|NCT00357513|Stroke Subtypes
590387|NCT00357513|Neuroimaging
590388|NCT00357513|Clinical Outcome Measures
590389|NCT00357513|Stroke
590390|NCT00357513|CVA
590391|NCT00357513|Healthy Volunteer
590392|NCT00357513|HV
590393|NCT00357513|Normal Control
590394|NCT00357500|Metronomic
590395|NCT00357500|antiangiogenic
590396|NCT00357487|Sentinel lymph node
590397|NCT00357487|Breast cancer
590398|NCT00357487|Lymphoscintigraphy
590399|NCT00357487|Probe
590400|NCT00357487|Operative gamma camera
590401|NCT00357487|Breast cancer and sentinel lymph node biopsy
590402|NCT00357487|Use of lymphoscintigraphy
590403|NCT00357487|Use of intraoperative gamma camera
590404|NCT00357487|Use of intraoperative probe
590405|NCT00357474|HCC, TACE, PEIT
590406|NCT00357461|stage IV melanoma
590407|NCT00357461|recurrent melanoma
590408|NCT00357435|Cornea
590409|NCT00357435|Genetics
590410|NCT00357435|Dystrophy
590411|NCT00357435|Gene
590412|NCT00357435|Mapping
590413|NCT00357435|Molecular
590414|NCT00357435|Bietti
590415|NCT00357435|Fleck
590416|NCT00357435|Positional Cloning
590417|NCT00357435|Linkage
590418|NCT00357422|HCC, operation, percutaneous ethanol injection
590419|NCT00357409|GABA
590420|NCT00357409|Occipital
590421|NCT00357409|Vision
590422|NCT00357409|Plasticity
590423|NCT00357409|MRS
590424|NCT00357409|Blind
590425|NCT00357396|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
590426|NCT00357396|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
590427|NCT00357357|Alzheimer's disease
590428|NCT00357344|Obesity
590429|NCT00357344|Gray Matter
590430|NCT00357344|Eating Behavior
590431|NCT00357344|Brain MRI
590432|NCT00357344|Body Weight Regulation
590433|NCT00357331|postmenopausal osteopenia
590434|NCT00357331|treatment
590435|NCT00357331|bone loss
590436|NCT00357266|Uveitis
590437|NCT00357266|Interleukin 2
590438|NCT00357266|Interleukin 2 Receptor
590439|NCT00357266|Microarrays
590440|NCT00357266|Genetic Expression
590441|NCT00357266|Daclizumab
590442|NCT00357266|HAT
590443|NCT00357266|Zenapax
590444|NCT00357266|Proteins
590445|NCT00357266|RNA
590446|NCT00357266|Ocular Inflammatory Disease
590447|NCT00357253|untreated childhood brain stem glioma
590448|NCT00357253|childhood high-grade cerebral astrocytoma
590449|NCT00357253|untreated childhood cerebellar astrocytoma
590450|NCT00357240|Protease inhibitor
590451|NCT00357227|Atrial fibrillation
590452|NCT00357227|Stroke
590453|NCT00357227|Vascular Dementia
590454|NCT00357227|Mild Cognitive Impairment
590455|NCT00357214|bone turnover
590456|NCT00357214|calcium excretion
590457|NCT00357214|nitrogen excretion
590458|NCT00357214|potassium bicarbonate
590459|NCT00357214|muscle loss
590460|NCT00357214|muscle atrophy
590461|NCT00357214|bone loss
590462|NCT00357123|abdominal sepsis
590463|NCT00357123|sepsis
590464|NCT00357123|rosuvastatin
590465|NCT00357110|Breast neoplasms
590466|NCT00357110|breast cancer
590467|NCT00357110|early breast cancer
590468|NCT00357110|oncology
590469|NCT00357110|cancer
590470|NCT00357110|breast cancer micrometastasis
590471|NCT00357110|fulvestrant
590472|NCT00357097|randomised
590473|NCT00357097|ropinirole
590474|NCT00357097|depression
590475|NCT00357097|RLS
590476|NCT00357097|placebo
590477|NCT00357097|mood
590478|NCT00357097|double-blind
590479|NCT00357097|restless legs syndrome
590480|NCT00357097|germany
590481|NCT00357084|graft versus host disease
590482|NCT00357084|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
590483|NCT00357084|adult acute myeloid leukemia with inv(16)(p13;q22)
590484|NCT00357084|adult acute myeloid leukemia with t(15;17)(q22;q12)
590485|NCT00357084|adult acute myeloid leukemia with t(16;16)(p13;q22)
590486|NCT00357084|adult acute myeloid leukemia with t(8;21)(q22;q22)
590487|NCT00357084|accelerated phase chronic myelogenous leukemia
590488|NCT00357084|adult acute lymphoblastic leukemia in remission
590489|NCT00357084|adult acute myeloid leukemia in remission
590490|NCT00357084|atypical chronic myeloid leukemia
590491|NCT00357084|blastic phase chronic myelogenous leukemia
590492|NCT00357084|childhood acute lymphoblastic leukemia in remission
590493|NCT00357084|childhood acute myeloid leukemia in remission
590494|NCT00357084|childhood chronic myelogenous leukemia
590495|NCT00357084|chronic eosinophilic leukemia
590496|NCT00357084|chronic idiopathic myelofibrosis
590497|NCT00357084|chronic myelomonocytic leukemia
590498|NCT00357084|chronic neutrophilic leukemia
590499|NCT00357084|chronic phase chronic myelogenous leukemia
590500|NCT00357084|de novo myelodysplastic syndromes
590501|NCT00357084|disseminated neuroblastoma
590502|NCT00357084|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
590503|NCT00357084|juvenile myelomonocytic leukemia
590504|NCT00357084|myelodysplastic/myeloproliferative disease, unclassifiable
590505|NCT00357084|nodal marginal zone B-cell lymphoma
590506|NCT00357084|noncontiguous stage II adult Burkitt lymphoma
590507|NCT00357084|noncontiguous stage II adult diffuse large cell lymphoma
590508|NCT00357084|noncontiguous stage II adult diffuse mixed cell lymphoma
590509|NCT00357084|noncontiguous stage II adult diffuse small cleaved cell lymphoma
590510|NCT00357084|noncontiguous stage II adult immunoblastic large cell lymphoma
590511|NCT00357084|noncontiguous stage II adult lymphoblastic lymphoma
590512|NCT00357084|noncontiguous stage II grade 1 follicular lymphoma
590513|NCT00357084|noncontiguous stage II grade 2 follicular lymphoma
590514|NCT00357084|noncontiguous stage II grade 3 follicular lymphoma
590515|NCT00357084|noncontiguous stage II mantle cell lymphoma
590516|NCT00357084|noncontiguous stage II marginal zone lymphoma
590517|NCT00357084|noncontiguous stage II small lymphocytic lymphoma
590518|NCT00357084|poor prognosis metastatic gestational trophoblastic tumor
590519|NCT00357084|previously treated childhood rhabdomyosarcoma
590520|NCT00357084|previously treated myelodysplastic syndromes
590521|NCT00357084|recurrent adult acute lymphoblastic leukemia
590522|NCT00357084|recurrent adult acute myeloid leukemia
590523|NCT00357084|recurrent adult Burkitt lymphoma
590524|NCT00357084|recurrent adult Hodgkin lymphoma
590525|NCT00357084|recurrent adult diffuse large cell lymphoma
590526|NCT00357084|recurrent adult diffuse mixed cell lymphoma
590527|NCT00357084|recurrent adult diffuse small cleaved cell lymphoma
590528|NCT00357084|recurrent adult immunoblastic large cell lymphoma
590529|NCT00357084|recurrent adult lymphoblastic lymphoma
590530|NCT00357084|recurrent/refractory childhood Hodgkin lymphoma
590531|NCT00357084|recurrent childhood acute lymphoblastic leukemia
590532|NCT00357084|recurrent childhood acute myeloid leukemia
590533|NCT00357084|recurrent childhood large cell lymphoma
590534|NCT00357084|recurrent childhood lymphoblastic lymphoma
590535|NCT00357084|recurrent childhood rhabdomyosarcoma
590536|NCT00357084|recurrent childhood small noncleaved cell lymphoma
590537|NCT00357084|recurrent cutaneous T-cell non-Hodgkin lymphoma
590538|NCT00357084|recurrent grade 1 follicular lymphoma
590539|NCT00357084|recurrent grade 2 follicular lymphoma
590540|NCT00357084|recurrent grade 3 follicular lymphoma
590541|NCT00357084|recurrent mantle cell lymphoma
590542|NCT00357084|recurrent marginal zone lymphoma
590543|NCT00357084|recurrent mycosis fungoides/Sezary syndrome
590544|NCT00357084|recurrent small lymphocytic lymphoma
590545|NCT00357084|recurrent Wilms tumor and other childhood kidney tumors
590546|NCT00357084|refractory chronic lymphocytic leukemia
590547|NCT00357084|refractory hairy cell leukemia
590548|NCT00357084|refractory multiple myeloma
590549|NCT00357084|relapsing chronic myelogenous leukemia
590550|NCT00357084|secondary acute myeloid leukemia
590551|NCT00357084|secondary myelodysplastic syndromes
590552|NCT00357084|splenic marginal zone lymphoma
590553|NCT00357084|stage I multiple myeloma
590554|NCT00357084|stage II multiple myeloma
590555|NCT00357084|stage II ovarian epithelial cancer
590556|NCT00357084|stage III adult Burkitt lymphoma
590557|NCT00357084|stage III adult Hodgkin lymphoma
590558|NCT00357084|stage III adult diffuse large cell lymphoma
590559|NCT00357084|stage III adult diffuse mixed cell lymphoma
590560|NCT00357084|stage III adult diffuse small cleaved cell lymphoma
590561|NCT00357084|stage III adult immunoblastic large cell lymphoma
590562|NCT00357084|stage III adult lymphoblastic lymphoma
590563|NCT00357084|stage III chronic lymphocytic leukemia
590564|NCT00357084|stage III grade 1 follicular lymphoma
590565|NCT00357084|stage III grade 2 follicular lymphoma
590566|NCT00357084|stage III grade 3 follicular lymphoma
590567|NCT00357084|stage III mantle cell lymphoma
590568|NCT00357084|stage III marginal zone lymphoma
590569|NCT00357084|stage III multiple myeloma
590570|NCT00357084|stage III small lymphocytic lymphoma
590571|NCT00357084|stage III malignant testicular germ cell tumor
590572|NCT00357084|stage IV adult Burkitt lymphoma
590573|NCT00357084|stage IV adult Hodgkin lymphoma
590574|NCT00357084|stage IV adult diffuse large cell lymphoma
590575|NCT00357084|stage IV adult diffuse mixed cell lymphoma
590576|NCT00357084|stage IV adult diffuse small cleaved cell lymphoma
590577|NCT00357084|stage IV adult immunoblastic large cell lymphoma
590578|NCT00357084|stage IV adult lymphoblastic lymphoma
590579|NCT00357084|stage IV chronic lymphocytic leukemia
590580|NCT00357084|stage IV grade 1 follicular lymphoma
590581|NCT00357084|stage IV grade 2 follicular lymphoma
590582|NCT00357084|stage IV grade 3 follicular lymphoma
590583|NCT00357084|stage IV mantle cell lymphoma
590584|NCT00357084|stage IV marginal zone lymphoma
590585|NCT00357084|stage IV small lymphocytic lymphoma
590586|NCT00357084|Waldenstrom macroglobulinemia
590587|NCT00357084|childhood myelodysplastic syndromes
590588|NCT00357071|Autoimmunity
590589|NCT00357071|Cell Mediated Immunity
590590|NCT00357071|S Antigen
590591|NCT00357071|Cell Proliferation
590592|NCT00357071|Uveitis
590593|NCT00357071|Cell Proliferation Assays
590594|NCT00357071|Auto-Antibody
590595|NCT00357071|Auto-Antigens
590596|NCT00357058|Deafferentiation-Induced Plasticity
590597|NCT00357058|fMRI
590598|NCT00357058|Cortical Reorganization
590599|NCT00357058|Tactile Performance
590600|NCT00357058|Transcranial Magnetic Stimulation
590601|NCT00357058|Tactile Discrimination
590602|NCT00357058|Plasticity
590603|NCT00357058|Healthy Volunteer
590604|NCT00357058|HV
590605|NCT00357058|Normal Control
590606|NCT00357006|Schizophrenia
590607|NCT00357006|Estrogen
590608|NCT00357006|Psychosis
590609|NCT00356993|nicotine replacement therapy
590610|NCT00356993|smoking cessation
590611|NCT00356980|unspecified adult solid tumor, protocol specific
590612|NCT00356967|smoking
590613|NCT00356967|cessation
590614|NCT00356967|tobacco
590615|NCT00356967|smoking cessation
590616|NCT00356967|tobacco use cessation
590617|NCT00356954|Kidney failure
590618|NCT00356954|Contrast media
590619|NCT00356954|Antioxidant
590620|NCT00356954|Prevention
590621|NCT00356941|recurrent non-small cell lung cancer
590622|NCT00356941|stage II non-small cell lung cancer
590623|NCT00356941|stage IIIA non-small cell lung cancer
590624|NCT00356941|stage IIIB non-small cell lung cancer
590625|NCT00356928|previously treated myelodysplastic syndromes
590626|NCT00356928|secondary myelodysplastic syndromes
590627|NCT00356928|secondary acute myeloid leukemia
590628|NCT00356928|chronic myelomonocytic leukemia
590629|NCT00356928|de novo myelodysplastic syndromes
590630|NCT00356915|Nail fungus
590631|NCT00356915|Onychomycosis
590632|NCT00356915|Itraconazole
590633|NCT00356915|Toenail
590634|NCT00356863|Intervention
590635|NCT00356863|Awareness
590636|NCT00356863|Cardiac Rehabilitation (CR)
590637|NCT00356863|Coronary Artery Patients
590638|NCT00356863|Coronary Artery Bypass Grafting Surgery (CABG)
590639|NCT00356824|Child
590640|NCT00356811|Lapatinib
590641|NCT00356811|Metastatic breast cancer
590642|NCT00356811|Paclitaxel
590643|NCT00356811|ErbB2-amplification
590644|NCT00356811|GW572016
590645|NCT00356798|pandemic
590646|NCT00356798|influenza
590647|NCT00356798|H5N1
590648|NCT00356798|vaccine
590649|NCT00356785|lifestyle
590650|NCT00356785|diet
590651|NCT00356785|exercise
590652|NCT00356785|physical activity
590653|NCT00356785|obesity
590654|NCT00356759|warfarin
590655|NCT00356759|prothrombin time
590656|NCT00356759|monitoring
590657|NCT00356746|Perioperative inflammatory response
590658|NCT00356746|General anesthesia
590659|NCT00356746|Toll-Like Receptors
590660|NCT00356733|cardiorenal syndrome
590661|NCT00356733|erythropoietin
590662|NCT00356733|Heart Failure, Congestive
590663|NCT00356733|Renal Insufficiency, Chronic
590664|NCT00356707|Body Mass Index
590665|NCT00356681|AMG 706
590666|NCT00356681|Paclitaxel
590667|NCT00356681|Metastatic Breast Cancer
590668|NCT00356681|Antiangiogenic
590669|NCT00356681|Bevacizumab
590670|NCT00356668|HFNC
590671|NCT00356668|NCPAP
590672|NCT00356668|nasal continuous positive airway pressure
590673|NCT00356668|humidified high flow nasal cannula
590674|NCT00356668|esophageal pressure
590675|NCT00356668|gas flow
590676|NCT00356655|Depressive disorder
590677|NCT00356655|Patient compliance
590678|NCT00356655|Antidepressive Agents
590679|NCT00356655|Patient education
590680|NCT00356655|Community pharmacy services
590681|NCT00356655|Counseling
590682|NCT00356642|PK
590683|NCT00356642|GW842470X
590684|NCT00356642|safety
590685|NCT00356642|tolerability
590686|NCT00356642|PD
590687|NCT00356642|Atopic Dermatitis
590688|NCT00356629|bronchopulmonary ignition
590689|NCT00356629|condensate of exhaled air
590690|NCT00356629|Mucoviscidosis
590691|NCT00356629|Asthma
590692|NCT00356616|Antiretroviral treatment
590693|NCT00356616|virological failure
590694|NCT00356616|HIV
590695|NCT00356603|Migraine
590696|NCT00356603|Sumatriptan Succinate Injection Kit
590697|NCT00356603|Cluster Headache
590698|NCT00356603|self-injection
590699|NCT00356590|Rheumatoid Arthritis
590700|NCT00356590|Etanercept
590701|NCT00356590|Long-term Safety
590702|NCT00356590|Enbrel
590703|NCT00356564|Prophylaxis for hepatitis B disease
590704|NCT00356551|Teen pregnancy
590705|NCT00356551|Family strengthening
590706|NCT00356551|Substance abuse prevention
590707|NCT00356551|Depression prevention
590708|NCT00356551|Parent involvement
590709|NCT00356512|Phosphate
590710|NCT00356512|Vitamin D
590711|NCT00356512|Hypoparathyroidism
590712|NCT00356512|Phosphatonin
590713|NCT00356512|Clamp
590714|NCT00356486|Chronic Hepatitis C
590715|NCT00356486|Co-infection
590716|NCT00356486|Induction dose
590717|NCT00356486|HIV
590718|NCT00356486|HIV Infections
590719|NCT00356473|Rheumatoid arthritis
590720|NCT00356473|Atherosclerosis
590721|NCT00356473|High density lipoprotein (HDL) cholesterol
590722|NCT00356473|Statins
590723|NCT00356473|HDL anti-inflammatory properties
590724|NCT00356473|Atorvastatin
590725|NCT00356434|deep vein thrombosis
590726|NCT00356434|thrombophilia
590727|NCT00356434|pregnancy
590728|NCT00356434|thromboprophylaxis
590729|NCT00356434|decreased mobility
590730|NCT00356434|hospitalization
590731|NCT00356408|CDP870
590732|NCT00356408|certolizumab pegol
590733|NCT00356408|Crohn's Disease
590734|NCT00356395|endothelial function, insulin resistance, adipocytokines
590735|NCT00356382|probiotic
590736|NCT00356382|Lactobacillus (L.) casei
590737|NCT00356382|cultured dairy drink
590738|NCT00356382|Health
590739|NCT00356369|Immunogenicity
590740|NCT00356369|Healthy
590741|NCT00356369|Persistence
590742|NCT00356369|Meningococcal vaccine
590743|NCT00356369|Non-inferiority
590744|NCT00356369|Meningococcal A C W Y Diseases
590745|NCT00356369|meningococcal serogroups A, C, W & Y diseases
590746|NCT00356343|NMES
590747|NCT00356343|Cerebral Palsy
590748|NCT00356343|Spastic Diplegia
590749|NCT00356343|Electrical Stimulation
590750|NCT00356343|Children
590751|NCT00356330|pacemaker
590752|NCT00356330|magnetic resonance imaging
590753|NCT00356330|safety
590754|NCT00356317|Culture
590755|NCT00356317|Family
590756|NCT00356317|Therapy
590757|NCT00356304|Dysthymia
590758|NCT00356304|Major Depression
590759|NCT00356304|Hispanics
590760|NCT00356304|Latinos
590761|NCT00356304|Motivational Interviewing
590762|NCT00356304|Adherence
590763|NCT00356291|HIV
590764|NCT00356291|AIDS
590765|NCT00356291|Prevention
590766|NCT00356291|Serious Mental Illness
590767|NCT00356278|D-Cycloserine
590768|NCT00356278|Virtual Reality
590769|NCT00356278|Exposure Therapy
590770|NCT00356278|Veterans
590771|NCT00356278|Cognitive Behavior Therapy
590772|NCT00356278|Translational Research
590773|NCT00356265|Blood Pressure Nitric Oxide
590774|NCT00356265|L-NMMA
590775|NCT00356265|Phenylephrine
590776|NCT00356265|Vasoreactivity
590777|NCT00356265|Blood Pressure
590778|NCT00356239|Defibrillators, Implantable
590779|NCT00356239|Heart Failure, Congestive
590780|NCT00356239|Magnetic Resonance Imaging
590781|NCT00356226|norepinephrine
590782|NCT00356226|renin
590783|NCT00356226|aldosterone
590784|NCT00356226|hemodynamics
590785|NCT00356226|spironolactone
590786|NCT00356213|morbid obesity
590787|NCT00356213|bariatric surgery
590788|NCT00356213|sleeve-gastrectomy
590789|NCT00356213|Roux-Y-gastric bypass
590790|NCT00356213|outcome
590791|NCT00356213|weight loss
590792|NCT00356174|Food Allergy
590793|NCT00356161|colorectal neoplasms
590794|NCT00356161|hepatocellular carcinoma
590795|NCT00356161|gallbladder cancer
590796|NCT00356161|bile duct cancer
590797|NCT00356161|hepatic arterial infusion
590798|NCT00356148|breast cancer
590799|NCT00356148|breast surgery
590800|NCT00356148|clean wound
590801|NCT00356148|overweight
590802|NCT00356148|prophylaxis
590803|NCT00356148|antibiotics
590804|NCT00356122|Lung
590805|NCT00356122|non-small cell
590806|NCT00356122|chemotherapy
590807|NCT00356122|tumor
590808|NCT00356122|advanced
590809|NCT00356122|recurrent
590810|NCT00356122|metastatic
590811|NCT00356122|Non-Small Cell Lung Cancer (NSCLC)
590812|NCT00356070|Attention Deficit Hyperactivity Disorder, treatment,
590813|NCT00356070|Strattera,
590814|NCT00356070|rehabilitation
590815|NCT00356057|atrial fibrillation
590816|NCT00356057|AV node ablation
590817|NCT00356057|pacemaker
590818|NCT00356057|congestive heart failure
590819|NCT00356044|Transradial access
590820|NCT00356044|Femoral access
590821|NCT00356044|Femoral vs radial access
590822|NCT00356031|Avastin
590823|NCT00356018|Epilepsy
590824|NCT00356018|Compliance
590825|NCT00356005|falciparum malaria
590826|NCT00356005|therapy
590827|NCT00356005|azithromycin
590828|NCT00356005|artesunate
590829|NCT00356005|Coartem
590830|NCT00356005|Bangladesh
590831|NCT00355992|Myocardial Ischemia
590832|NCT00355992|Chest pain
590833|NCT00355992|Ischemia Modified Albumin
590834|NCT00355992|Acute Coronary Syndrome
590835|NCT00355979|Obesity, intragastric balloon, Pharmacotherapy
590836|NCT00355966|Premature rupture of membranes
590837|NCT00355966|Induction of labour with Misoprostol
590838|NCT00355966|Induction of labour with PGE2 gel
590839|NCT00355953|Post-Menopausal Women
590840|NCT00355953|Osteoporosis
590841|NCT00355953|Phytoestrogen
590842|NCT00355953|Genistein
590843|NCT00355940|endovascular
590844|NCT00355940|aortic
590845|NCT00355940|repair
590846|NCT00355940|navigation
590847|NCT00355940|DynaCT
590848|NCT00355940|position
590849|NCT00355940|sensor
590850|NCT00355927|Deep brain stimulation
590851|NCT00355927|Microelectrode recordings
590852|NCT00355927|Basal Ganglia
590853|NCT00355927|Sedation
590854|NCT00355927|Propofol
590855|NCT00355914|Lumbar Facet Joint Nerve Block
590856|NCT00355901|Ulcerative Colitis
590857|NCT00355901|Colitis
590858|NCT00355901|Steroid-Refractory
590859|NCT00355901|Visilizumab
590860|NCT00355901|Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
590861|NCT00355888|Cancer
590862|NCT00355888|Advanced or Metastatic Solid Tumor
590863|NCT00355875|newborn
590864|NCT00355875|preterm
590865|NCT00355875|resuscitation
590866|NCT00355875|oxidative injury
590867|NCT00355875|protein carbonyl
590868|NCT00355862|Sirolimus
590869|NCT00355862|mTOR
590870|NCT00355862|HCC-recurrence free survival
590871|NCT00355862|Liver transplant recipients
590872|NCT00355862|HCC recurrence free survival
590873|NCT00355836|Motor Imagery
590874|NCT00355836|Stroke
590875|NCT00355836|Neuro-rehabilitation
590876|NCT00355836|health psychology
590877|NCT00355836|neuroscience
590878|NCT00355836|randomised controlled trial
590879|NCT00355823|electric field
590880|NCT00355823|wound current
590881|NCT00355823|wound healing
590882|NCT00355823|bioelectric field
590883|NCT00355823|chronic ulcer
590884|NCT00355823|diabetic
590885|NCT00355823|Diabetes
590886|NCT00355823|aging
590887|NCT00355810|Probiotics
590888|NCT00355797|Bradycardia
590889|NCT00355797|Sinus Node Dysfunction
590890|NCT00355797|Chronotropic incompetence
590891|NCT00355797|Pacemaker
590892|NCT00355797|Rate adaptive
590893|NCT00355784|growth hormone
590894|NCT00355784|overfeeding
590895|NCT00355784|energy expenditure
590896|NCT00355784|protein metabolism
590897|NCT00355784|lipid metabolism
590898|NCT00355771|allergic rhinitis
590899|NCT00355771|histamine antagonist
590900|NCT00355771|sleep disorder
590901|NCT00355758|Prostate Cancer Detection by Serum Proteomic Profiling
590902|NCT00355745|Breast
590903|NCT00355745|tumor
590904|NCT00355745|ultrasound
590905|NCT00355745|biopsy
590906|NCT00355745|Breast mammographic or ultrasound findings
590907|NCT00355732|Respiration
590908|NCT00355732|COPD
590909|NCT00355732|Mechanical Ventilation
590910|NCT00355732|Ventilator Weaning
590911|NCT00355732|Respiratory Failure
590912|NCT00355732|ICU
590913|NCT00355732|Pressure Support Ventilation
590914|NCT00355719|Nevirapine
590915|NCT00355719|Atazanavir
590916|NCT00355719|Pharmacokinetics
590917|NCT00355719|Interactions
590918|NCT00355706|chronic low back pain
590919|NCT00355706|thoracic facet joint
590920|NCT00355706|nerve block
590921|NCT00355693|Anxiety
590922|NCT00355693|Dental
590923|NCT00355693|Oral
590924|NCT00355693|Surgery
590925|NCT00355693|Colonoscopy
590926|NCT00355693|Propofol
590927|NCT00355693|Sedation
590928|NCT00355693|Effect
590929|NCT00355693|Reaction
590930|NCT00355680|Retina
590931|NCT00355680|Retinal Diseases
590932|NCT00355680|Retinal Vessels
590933|NCT00355680|Laser Coagulation
590934|NCT00355667|diuretics
590935|NCT00355667|furosemide
590936|NCT00355667|azosemide
590937|NCT00355667|congestive heart failure
590938|NCT00355654|Diphtheria
590939|NCT00355654|Tetanus
590940|NCT00355654|Pertussis
590941|NCT00355654|Poliomyelitis
590942|NCT00355654|Haemophilus influenzae type b
590943|NCT00355654|Hepatitis B
590944|NCT00355641|Ropinirole
590945|NCT00355641|Restless Legs Syndrome
590946|NCT00355641|RLS
590947|NCT00355628|Pain
590948|NCT00355628|Cancer
590949|NCT00355628|Neoplasm
590950|NCT00355628|Continual Reassessment Method
590951|NCT00355628|Pain Associated with Cancer/Neoplasms
590952|NCT00355615|Heterozygous Familial Hypercholesterolemia
590953|NCT00355602|Antibiotics
590954|NCT00355602|Controlled Clinical Trial
590955|NCT00355589|Hypertension
590956|NCT00355589|High Blood Pressure
590957|NCT00355589|Diuretic
590958|NCT00355589|Angiotensin converting enzyme inhibitor
590959|NCT00355589|Ambulatory blood pressure monitoring
590960|NCT00355576|Amyotrophic Lateral Sclerosis
590961|NCT00355576|Celecoxib
590962|NCT00355576|Creatine
590963|NCT00355576|Minocycline
590964|NCT00355576|Combination
590965|NCT00355576|Selection
590966|NCT00355576|ALS
590967|NCT00355576|Motor Neuron Disease
590968|NCT00355550|Mild Cognitive Impairment
590969|NCT00355550|Cognition disorders
590970|NCT00355550|nutritional supplement
590971|NCT00355550|dietary supplement
590972|NCT00355524|HIV-1
590973|NCT00355524|Darunavir
590974|NCT00355524|Ritonavir
590975|NCT00355524|TMC114
590976|NCT00355511|heart failure, congestive
590977|NCT00355511|patient care team
590978|NCT00355511|randomized controlled trial
590979|NCT00355511|disease management
590980|NCT00355511|drug therapy
590981|NCT00355511|diet therapy
590982|NCT00355511|hospitalization
590983|NCT00355511|mortality
590984|NCT00355498|functional magnetic resonance imaging
590985|NCT00355498|positron emission tomography
590986|NCT00355498|beta-amyloid
590987|NCT00355498|tau
590988|NCT00355485|Acne
590989|NCT00355485|Microdermabrasion
590990|NCT00355472|Adult T-Cell Leukemia
590991|NCT00355472|ATL
590992|NCT00355472|Adult Peripheral T-Cell Lymphoma
590993|NCT00355472|PTCL
590994|NCT00355459|Meibomian Gland Dystrophy
590995|NCT00355446|Cataract
590996|NCT00355446|Human Aqueous
590997|NCT00355433|urinary incontinence
590998|NCT00355433|urodynamics
590999|NCT00355433|temperature
591000|NCT00355407|Aranesp
591001|NCT00355407|allogeneic stem cell transplant
591002|NCT00355381|Information Services
591003|NCT00355381|Randomized Controlled Trials
591004|NCT00355381|Medical Records Systems, Computerized
591005|NCT00355381|Internet
591006|NCT00355381|Librarians
591007|NCT00355381|Breast Neoplasms
591008|NCT00355381|Patient Satisfaction
591009|NCT00355381|Health Personnel
591010|NCT00355381|Costs and Cost Analysis
591011|NCT00355381|Premature Birth
591012|NCT00355368|intubation
591013|NCT00355368|intensive care
591014|NCT00355368|neuromuscular depolarizing agents
591015|NCT00355368|neuromuscular nondepolarizing agents
591016|NCT00355368|neuromuscular blocking agents
591017|NCT00355355|Hepatocellular carcinoma
591018|NCT00355355|HCC
591019|NCT00355355|Liver Neoplasms
591020|NCT00355355|Talaporfin Sodium (LS11)
591021|NCT00355355|Light emitting diodes (LEDs)
591022|NCT00355355|Light activation
591023|NCT00355342|Osteoporosis
591024|NCT00355342|Bone Mineral Density
591025|NCT00355342|Osteopenia
591026|NCT00355342|Chronic Obstructive Pulmonary Disease
591027|NCT00355342|COPD
591028|NCT00355329|Traditional Chinese Medicine (TCM)
591029|NCT00355329|Autism
591030|NCT00355329|Autistic Spectrum Disorder
591031|NCT00355329|Tongue Acupuncture (TAC)
591032|NCT00355329|18F-fluorodeoxyglucose Positron Emission Tomography (PET)
591033|NCT00355329|children
591034|NCT00355316|Breast Cancer
591035|NCT00355316|Peripheral
591036|NCT00355316|Blood
591037|NCT00355303|Premature rupture of membranes at term
591038|NCT00355303|Induction of labour
591039|NCT00355303|Misoprostol
591040|NCT00355303|PGE2 gel
591041|NCT00355303|Immediate induction with PGE2 gel
591042|NCT00355303|Immediate induction with Misoprostol
591043|NCT00355290|Chronic Oral Anticoagulation
591044|NCT00355277|Tricyclic antidepressants
591045|NCT00355277|Neuropathic pain
591046|NCT00355277|Local anaesthesia
591047|NCT00355277|Transcutaneous
591048|NCT00355251|Atorvastatin
591049|NCT00355251|Viral replication
591050|NCT00355251|HIV-1
591051|NCT00355251|plasma cholesterol
591052|NCT00355251|Cell membrane cholesterol
591053|NCT00355225|insecticide-treated bednets
591054|NCT00355225|malaria
591055|NCT00355225|africa
591056|NCT00355225|social marketing
591057|NCT00355225|ante-natal care
591058|NCT00355225|ITN coverage
591059|NCT00355225|ITn use
591060|NCT00355212|percutaneous ethanol injection
591061|NCT00355212|radiofrequency
591062|NCT00355212|liver cirrhosis
591063|NCT00355212|carcinoma, hepatocellular
591064|NCT00355199|DLBCL
591065|NCT00355199|R-HDS
591066|NCT00355199|R-CHOP14
591067|NCT00355186|acute myocardial infarction
591068|NCT00355186|MRI
591069|NCT00355186|bone marrow cells
591070|NCT00355186|stem cells
591071|NCT00355186|remodeling
591072|NCT00355160|Headache
591073|NCT00355160|Sinusitis
591074|NCT00355160|Rhinitis
591075|NCT00355160|Facial Pain
591076|NCT00355147|Ischemic stroke
591077|NCT00355147|Preventive medicine
591078|NCT00355147|Transient Ischemic Attack
591079|NCT00355147|Neurology
591080|NCT00355147|Risk management
591081|NCT00355134|fingolimod
591082|NCT00355134|FTY720
591083|NCT00355134|relapsing-remitting multiple sclerosis
591084|NCT00355134|MS
591085|NCT00355134|RRMS
591086|NCT00355121|Meningococcal meningitis
591087|NCT00355121|Tetanus
591088|NCT00355121|Diphtheria
591089|NCT00355121|Pertussis
591090|NCT00355121|Poliomyelitis
591091|NCT00355121|Neisseria meningitidis
591092|NCT00355108|Rendu Osler syndrome
591093|NCT00355108|Epistaxis
591094|NCT00355108|Tranexamic acid
591095|NCT00355108|clinical trial
591096|NCT00355095|multiple sclerosis
591097|NCT00355095|add-on Therapy
591098|NCT00355095|erythropoietin
591099|NCT00355095|methylprednisolone
591100|NCT00355095|autoimmune optic neuritis
591101|NCT00355082|epilepsy
591102|NCT00355082|lamotrigine
591103|NCT00355082|Lamictal
591104|NCT00355082|monotherapy
591105|NCT00355069|pediatric
591106|NCT00355069|asthma
591107|NCT00355069|translational research
591108|NCT00355069|health information technology
591109|NCT00355056|Migraine
591110|NCT00355056|PFO
591111|NCT00355056|Migraine Headache
591112|NCT00355056|patent foramen ovale
591113|NCT00355043|Zinc treatment
591114|NCT00355043|Bronchiolitis
591115|NCT00355043|Wheezing
591116|NCT00355043|Children aged 2 months to 23 months
591117|NCT00355043|Diagnosed case of acute bronchiolitis
591118|NCT00355004|colon cancer
591119|NCT00355004|rectal cancer
591120|NCT00354978|Colorectal Cancer
591121|NCT00354978|FOLFIRI
591122|NCT00354978|Irinotecan
591123|NCT00354978|CPT-11
591124|NCT00354978|Leucovorin
591125|NCT00354978|LV
591126|NCT00354978|Folinic Acid
591127|NCT00354978|Fluorouracil
591128|NCT00354978|5-FU
591129|NCT00354978|Adrucil
591130|NCT00354978|Efudex
591131|NCT00354978|Bevacizumab
591132|NCT00354978|Avastin
591133|NCT00354978|Anti-VEGF monoclonal antibody
591134|NCT00354978|rhuMAb-VEGF
591135|NCT00354965|ABS
591136|NCT00354965|Acute Bacterial
591137|NCT00354965|Sinusitis
591138|NCT00354965|Bacterial Sinusitis
591139|NCT00354952|Healthy volunteers
591140|NCT00354952|Antibiotic exposure
591141|NCT00354952|Resistance selection
591142|NCT00354926|Non-Hodgkin's Lymphoma
591143|NCT00354926|rituximab
591144|NCT00354926|humanized monoclonal antibody
591145|NCT00354926|anti-CD20 monoclonal antibody
591146|NCT00354913|adult grade I meningioma
591147|NCT00354913|adult grade II meningioma
591148|NCT00354913|adult grade III meningioma
591149|NCT00354913|adult papillary meningioma
591150|NCT00354913|adult anaplastic meningioma
591151|NCT00354913|recurrent adult brain tumor
591152|NCT00354913|glioblastoma multiforme (GBM)
591153|NCT00354913|Imatinib
591154|NCT00354913|Imatinib mesylate
591155|NCT00354913|Hydroxyurea
591156|NCT00354913|Droxia
591157|NCT00354913|Hydrea
591158|NCT00354913|Hydroxycarbamide
591159|NCT00354913|Gleevec
591160|NCT00354913|Meningioma
591161|NCT00354900|breast cancer
591162|NCT00354900|fibrinolysis
591163|NCT00354900|urokinase-type plasminogen activator
591164|NCT00354900|plasminogen activator inhibitor
591165|NCT00354900|aprotinin
591166|NCT00354900|plasmin/alpha-2-antiplasmin complex
591167|NCT00354887|Gastrointestinal Cancer
591168|NCT00354887|Small Bowel Cancer
591169|NCT00354887|Ampulla of Vater
591170|NCT00354887|Capecitabine
591171|NCT00354887|Xeloda
591172|NCT00354887|Oxaliplatin
591173|NCT00354887|Eloxatin
591174|NCT00354874|GW642444 asthmatic subjects safety tolerability PD and PK
591175|NCT00354861|Healthy volunteers
591176|NCT00354861|IMP321
591177|NCT00354861|Adjuvant
591178|NCT00354861|Pharmacodynamics
591179|NCT00354822|Zevalin
591180|NCT00354822|Lymphoma, Non-Hodgkin
591181|NCT00354809|cognition
591182|NCT00354809|Primary Insomnia
591183|NCT00354809|sleep
591184|NCT00354809|polysomnography
591185|NCT00354796|bleeding
591186|NCT00354796|anticoagulation
591187|NCT00354796|LMWH
591188|NCT00354796|Enoxaparin
591189|NCT00354783|Very low birth weight premature infants
591190|NCT00354783|Kicking
591191|NCT00354783|Stepping
591192|NCT00354783|Walking
591193|NCT00354783|Motor development
591194|NCT00354783|Kinematics
591195|NCT00354770|Trichotillomania
591196|NCT00354770|Hair-pulling
591197|NCT00354757|gastroesophageal reflux disease, proton-pump inhibitor test
591198|NCT00354744|adult rhabdomyosarcoma
591199|NCT00354744|previously untreated childhood rhabdomyosarcoma
591200|NCT00354744|adult malignant mesenchymoma
591201|NCT00354744|childhood malignant mesenchymoma
591202|NCT00354744|metastatic childhood soft tissue sarcoma
591203|NCT00354744|stage IV adult soft tissue sarcoma
591204|NCT00354731|nephrotic syndrome, pentoxifylline, corticosteroid
591205|NCT00354705|Colon Cancer
591206|NCT00354705|Adenocarcinoma of the Colon
591207|NCT00354705|Cancer Recurrence
591208|NCT00354705|Survey
591209|NCT00354705|Chemotherapy
591210|NCT00354705|Surgery
591211|NCT00354679|adenocarcinoma of the esophagus
591212|NCT00354679|recurrent esophageal cancer
591213|NCT00354679|stage III esophageal cancer
591214|NCT00354679|stage II esophageal cancer
591215|NCT00354666|inhaled
591216|NCT00354666|asthmatic subjects
591217|NCT00354666|GSK159797
591218|NCT00354666|safety and tolerability
591219|NCT00354666|efficacy
591220|NCT00354666|dry powder
591221|NCT00354653|HBeAg
591222|NCT00354653|HBV
591223|NCT00354653|CHRONIC HEPATITIS
591224|NCT00354653|lamivudine
591225|NCT00354640|breast cancer
591226|NCT00354640|breast cancer in situ
591227|NCT00354640|ductal breast carcinoma in situ
591228|NCT00354640|stage I breast cancer
591229|NCT00354640|stage II breast cancer
591230|NCT00354640|stage IIIA breast cancer
591231|NCT00354640|stage IIIB breast cancer
591232|NCT00354640|stage IIIC breast cancer
591233|NCT00354627|HIV-1
591234|NCT00354627|Early Access Program (EAP)
591235|NCT00354627|TMC125
591236|NCT00354627|treatment-experienced
591237|NCT00354627|failing multiple antiretroviral (ARV) regimens
591238|NCT00354627|limited to no treatment options
591239|NCT00354601|fallopian tube cancer
591240|NCT00354601|peritoneal cavity cancer
591241|NCT00354601|recurrent ovarian epithelial cancer
591242|NCT00354601|ovarian clear cell cystadenocarcinoma
591243|NCT00354601|ovarian endometrioid adenocarcinoma
591244|NCT00354601|ovarian mucinous cystadenocarcinoma
591245|NCT00354601|ovarian serous cystadenocarcinoma
591246|NCT00354601|ovarian undifferentiated adenocarcinoma
591247|NCT00354588|chronic renal failure
591248|NCT00354588|arterial stiffness
591249|NCT00354588|arterial wave reflections
591250|NCT00354575|Constipation;
591251|NCT00354575|Chinese herb;
591252|NCT00354575|Long-term care;
591253|NCT00354575|Integrative Chinese Medicine and Western Medicine;
591254|NCT00354562|Lung Cancer
591255|NCT00354562|Non-Small Cell Lung Cancer
591256|NCT00354562|NSCLC
591257|NCT00354562|ABT-751
591258|NCT00354562|docetaxel
591259|NCT00354562|Taxotere
591260|NCT00354549|recurrent non-small cell lung cancer
591261|NCT00354549|stage IIIB non-small cell lung cancer
591262|NCT00354549|stage IV non-small cell lung cancer
591263|NCT00354549|adenocarcinoma of the lung
591264|NCT00354549|bronchoalveolar cell lung cancer
591265|NCT00354549|large cell lung cancer
591266|NCT00354536|GSK716155
591267|NCT00354536|albiglutide
591268|NCT00354536|pharmacodynamics
591269|NCT00354536|pharmacokinetics
591270|NCT00354523|Solid Tumor
591271|NCT00354523|Thyroid Cancer
591272|NCT00354523|Medullary Thyroid Cancer
591273|NCT00354523|MTC
591274|NCT00354523|Advanced Metastatic Medullary Thyroid Carcinoma
591275|NCT00354523|Capecitabine
591276|NCT00354523|Dacarbazine
591277|NCT00354523|Imatinib
591278|NCT00354523|Gleevec
591279|NCT00354523|Imatinib Mesylate
591280|NCT00354523|DTIC-Dome
591281|NCT00354523|Xeloda
591282|NCT00354510|atopic dermatitis
591283|NCT00354510|GW842470X
591284|NCT00354510|PDE4 inhibitor
591285|NCT00354497|prostate cancer
591286|NCT00354484|anemia
591287|NCT00354484|postpartum
591288|NCT00354458|heart failure
591289|NCT00354458|diuretic
591290|NCT00354458|renal impairment
591291|NCT00354458|renal function
591292|NCT00354445|Age-Related Macular Degeneration (AMD)
591293|NCT00354445|pegaptanib sodium
591294|NCT00354445|subfoveal CNV
591295|NCT00354445|macugen
591296|NCT00354432|recurrent prostate cancer
591297|NCT00354432|stage I prostate cancer
591298|NCT00354432|stage IIB prostate cancer
591299|NCT00354432|stage IIA prostate cancer
591300|NCT00354432|stage III prostate cancer
591301|NCT00354432|stage IV prostate cancer
591302|NCT00354432|hot flashes
591303|NCT00354406|Abciximab
591304|NCT00354406|Magnetic Resonance Imaging
591305|NCT00354406|Percutaneous Transluminal Coronary Angioplasty
591306|NCT00354393|localized malignant mesothelioma
591307|NCT00354393|sarcomatous mesothelioma
591308|NCT00354393|advanced malignant mesothelioma
591309|NCT00354393|epithelial mesothelioma
591310|NCT00354380|Malaria
591311|NCT00354380|Africa
591312|NCT00354380|Methalyne-blue
591313|NCT00354380|Artesunate
591314|NCT00354380|Amodiaquine
591315|NCT00354367|Crohn Disease
591316|NCT00354367|Certolizumab pegol
591317|NCT00354367|Fistula
591318|NCT00354354|COPD
591319|NCT00354354|Combivent
591320|NCT00354354|Exercise
591321|NCT00354354|Bronchodilator
591322|NCT00354354|Kinetics
591323|NCT00354328|HCM
591324|NCT00354328|Echocardiography
591325|NCT00354328|Diastolic Dysfunction
591326|NCT00354328|Enalapril
591327|NCT00354315|Shared decision making
591328|NCT00354315|Optimal drug prescription
591329|NCT00354302|osteoporosis
591330|NCT00354302|stage I breast cancer
591331|NCT00354302|stage II breast cancer
591332|NCT00354302|stage IIIA breast cancer
591333|NCT00354276|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
591334|NCT00354276|adult acute myeloid leukemia with t(16;16)(p13;q22)
591335|NCT00354276|untreated adult acute myeloid leukemia
591336|NCT00354276|adult acute myelomonocytic leukemia (M4)
591337|NCT00354276|adult acute monocytic leukemia (M5b)
591338|NCT00354276|adult erythroleukemia (M6a)
591339|NCT00354276|adult pure erythroid leukemia (M6b)
591340|NCT00354276|adult acute monoblastic leukemia (M5a)
591341|NCT00354276|adult acute megakaryoblastic leukemia (M7)
591342|NCT00354276|adult acute basophilic leukemia
591343|NCT00354276|adult acute myeloblastic leukemia without maturation (M1)
591344|NCT00354276|adult acute myeloblastic leukemia with maturation (M2)
591345|NCT00354276|adult acute eosinophilic leukemia
591346|NCT00354276|adult acute minimally differentiated myeloid leukemia (M0)
591347|NCT00354263|Healthy male volunteers
591348|NCT00354263|IMP321
591349|NCT00354263|Adjuvant
591350|NCT00354263|Monotherapy
591351|NCT00354263|Pharmacokinetics/Pharmacodynamics
591352|NCT00354237|diabetes mellitus
591353|NCT00354237|cardiac rehabilitation
591354|NCT00354237|insulin
591355|NCT00354224|recurrent gastric cancer
591356|NCT00354224|stage III gastric cancer
591357|NCT00354224|stage IV gastric cancer
591358|NCT00354211|Cardiac Output
591359|NCT00354211|Hemodynamic Phenomena
591360|NCT00354198|rapidly progressive glomerulonephritis
591361|NCT00354198|pentoxifylline
591362|NCT00354172|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
591363|NCT00354172|adult acute myeloid leukemia with inv(16)(p13;q22)
591364|NCT00354172|adult acute myeloid leukemia with t(15;17)(q22;q12)
591365|NCT00354172|adult acute myeloid leukemia with t(16;16)(p13;q22)
591366|NCT00354172|adult acute myeloid leukemia with t(8;21)(q22;q22)
591367|NCT00354172|atypical chronic myeloid leukemia
591368|NCT00354172|blastic phase chronic myelogenous leukemia
591369|NCT00354172|childhood chronic myelogenous leukemia
591370|NCT00354172|previously treated myelodysplastic syndromes
591371|NCT00354172|recurrent adult acute myeloid leukemia
591372|NCT00354172|recurrent childhood acute myeloid leukemia
591373|NCT00354172|relapsing chronic myelogenous leukemia
591374|NCT00354172|secondary acute myeloid leukemia
591375|NCT00354172|secondary myelodysplastic syndromes
591376|NCT00354172|childhood myelodysplastic syndromes
591377|NCT00354159|Implantable cardioverter defibrillator
591378|NCT00354159|Intracardiac pressures
591379|NCT00354146|Farnesyl transferase inhibitor
591380|NCT00354146|relapsed or refractory acute myeloid leukemia
591381|NCT00354133|Parkinson Disease
591382|NCT00354133|Deep Brain Stimulation
591383|NCT00354133|PDQ-39
591384|NCT00354081|Coronary Artery Disease
591385|NCT00354081|Myocardial Infarction
591386|NCT00354081|Cerebrovascular Stroke
591387|NCT00354081|Homocysteine
591388|NCT00354081|Folic Acid
591389|NCT00354081|Vitamin B 12
591390|NCT00354081|Vitamin B 6
591391|NCT00354068|adult anaplastic oligodendroglioma
591392|NCT00354068|adult giant cell glioblastoma
591393|NCT00354068|adult gliosarcoma
591394|NCT00354068|adult mixed glioma
591395|NCT00354068|adult anaplastic astrocytoma
591396|NCT00354068|recurrent adult brain tumor
591397|NCT00354068|adult glioblastoma
591398|NCT00354042|GW597901X
591399|NCT00354042|Asthma
591400|NCT00354042|Crossover
591401|NCT00354042|dose ascending
591402|NCT00354042|repeat dose
591403|NCT00354042|inhaled
591404|NCT00354029|hemorrhoids
591405|NCT00354029|hemorrhoidectomy
591406|NCT00354029|S (+) ketamine
591407|NCT00354029|pain
591408|NCT00354016|influenza
591409|NCT00354016|vaccine
591410|NCT00354003|Parkinson
591411|NCT00354003|Imaging
591412|NCT00353990|insulin
591413|NCT00353990|bioavailability
591414|NCT00353990|duodenum
591415|NCT00353990|infusion
591416|NCT00353990|healthy
591417|NCT00353990|diabetes
591418|NCT00353990|absorption
591419|NCT00353977|Cytomegalovirus
591420|NCT00353977|Vaccine
591421|NCT00353977|CMV
591422|NCT00353977|Immunization
591423|NCT00353977|Peripheral Blood Stem Cell Transplantation
591424|NCT00353977|Stem Cell Allotransplant
591425|NCT00353951|primary care
591426|NCT00353951|lower respiratory tract infection
591427|NCT00353951|antibiotics
591428|NCT00353951|cough
591429|NCT00353938|PTSD, MDMA, psychotherapy, Switzerland
591430|NCT00353925|Hypertrophy
591431|NCT00353925|LVH
591432|NCT00353925|Cardiac
591433|NCT00353925|Blood Pressure
591434|NCT00353925|Papillary Muscle
591435|NCT00353912|Blood
591436|NCT00353912|Venous
591437|NCT00353912|Systolic
591438|NCT00353912|Diastolic
591439|NCT00353912|Pulse
591440|NCT00353912|Pressure
591441|NCT00353899|Magnetic Resonance Imaging
591442|NCT00353899|Pediatric
591443|NCT00353899|Normal Volunteer
591444|NCT00353899|Electrocardiogram
591445|NCT00353899|Cardiac
591446|NCT00353899|Healthy Volunteer
591447|NCT00353899|HV
591448|NCT00353886|Retrospective
591449|NCT00353886|Epilepsy
591450|NCT00353886|Antiepileptic Drugs
591451|NCT00353886|Behavioral Development
591452|NCT00353886|Intellectual Development
591453|NCT00353873|FLIXOTIDE
591454|NCT00353873|asthmatics children 4-11 years
591455|NCT00353873|SERETIDE
591456|NCT00353873|asthma-control
591457|NCT00353860|Leukemia
591458|NCT00353860|Transplant - Mortality
591459|NCT00353860|Immunosuppression
591460|NCT00353860|Radiation
591461|NCT00353860|Cure
591462|NCT00353860|Peripheral Blood Stem Cells
591463|NCT00353860|Graft-Versus Leukemia/Myeloma
591464|NCT00353860|Graft-Versus-Host Disease
591465|NCT00353860|Cyclosporine
591466|NCT00353860|Fludarabine
591467|NCT00353847|acupuncture, RCTs, chronic LBP
591468|NCT00353834|endothelial dysfunction
591469|NCT00353834|subclinical inflammation
591470|NCT00353834|flow mediated brachial artery dilation
591471|NCT00353834|pulse wave analysis
591472|NCT00353834|glucagon like polypeptide mimetics
591473|NCT00353834|type 2 diabetes mellitus
591474|NCT00353821|Tumor Necrosis Factor Alpha (TNF-Alpha)
591475|NCT00353821|Interferon-Gamma (IFN-Gamma)
591476|NCT00353821|Interleukin-10 (IL-10)
591477|NCT00353821|Interleukin-6 (IL-6)
591478|NCT00353821|Interleukin-1 (IL-1 Ra)
591479|NCT00353821|Interleukin-1 Receptor Antagonist (IL-1 Ra)
591480|NCT00353821|Vitamin D Receptor (VitD R)
591481|NCT00353795|MESA
591482|NCT00353795|MRI
591483|NCT00353795|Cardiovascular
591484|NCT00353795|Cardiac
591485|NCT00353795|Coronary
591486|NCT00353795|Atherosclerosis
591487|NCT00353782|Dyslipidemia
591488|NCT00353782|Hypertriglyceridemia
591489|NCT00353782|Hyperalphalipoproteinemia
591490|NCT00353782|Atheroembolism
591491|NCT00353782|Atherosclerosis
591492|NCT00353782|Dyslipoproteinemia
591493|NCT00353782|Hypercholesterolemia
591494|NCT00353782|hypoalphalipoproteinemia
591495|NCT00353769|scalp laceration
591496|NCT00353769|tissue adhesive
591497|NCT00353769|wound care
591498|NCT00353769|cost effectiveness
591499|NCT00353743|infected abortion
591500|NCT00353743|treatment period
591501|NCT00353743|doxycycline
591502|NCT00353743|metronidazole
591503|NCT00353743|placebo
591504|NCT00353730|Serial Analysis of Gene Expression
591505|NCT00353730|Carotid Artery Plaque
591506|NCT00353730|Atherosclerosis
591507|NCT00353717|breast
591508|NCT00353717|basal like
591509|NCT00353717|carcinoma
591510|NCT00353717|metastatic
591511|NCT00353717|EGFR
591512|NCT00353704|Intervertebral disk displacement
591513|NCT00353704|disk prolapse
591514|NCT00353704|pregabalin
591515|NCT00353678|Hip replacement
591516|NCT00353678|Arthroplasty
591517|NCT00353678|Prevention
591518|NCT00353678|Thromboembolism
591519|NCT00353678|Treatment outcomes
591520|NCT00353678|Arthroplasty, replacement, hip
591521|NCT00353665|amyotrophic lateral sclerosis
591522|NCT00353665|motor neuron disease
591523|NCT00353665|memantine
591524|NCT00353665|clinical trial
591525|NCT00353652|Blood Pressure, High
591526|NCT00353639|Ulcera
591527|NCT00353639|Telomerase
591528|NCT00353639|TERT
591529|NCT00353639|TERC
591530|NCT00353639|SBDS
591531|NCT00353639|DNA Helicase
591532|NCT00353639|Inflammatory Bowel Disease
591533|NCT00353639|IBD
591534|NCT00353626|Amputation
591535|NCT00353626|trans tibial
591536|NCT00353626|prosthesis
591537|NCT00353626|motion analysis
591538|NCT00353613|Antibiotic prophylaxis
591539|NCT00353600|Proteinuria
591540|NCT00353600|Renal Failure
591541|NCT00353600|Angiotension Converting Enzyme Inhibitor
591542|NCT00353600|Glomerular Filtration Rate
591543|NCT00353587|insulin sensitizer
591544|NCT00353587|type 2 diabetes
591545|NCT00353587|diabetes
591546|NCT00353587|glucose control
591547|NCT00353574|Resistant Hypertension
591548|NCT00353548|Bulimia Nervosa
591549|NCT00353548|Binge Eating Disorder
591550|NCT00353548|Obesity
591551|NCT00353548|Anorexia Nervosa
591552|NCT00353535|glomerulosclerosis, focal
591553|NCT00353535|pretransplant immunosuppression
591554|NCT00353535|total lymphoid irradiation
591555|NCT00353535|renal transplant
591556|NCT00353535|recurrence
591557|NCT00353496|Non functioning entero-pancreatic tumours
591558|NCT00353483|Breast Cancer
591559|NCT00353483|Neoadjuvant
591560|NCT00353470|PD
591561|NCT00353470|CBT
591562|NCT00353470|PFPP
591563|NCT00353457|Adjuvant therapy
591564|NCT00353457|Rectal cancer
591565|NCT00353457|Capecitabine
591566|NCT00353457|Oxaliplatin
591567|NCT00353457|Cetuximab
591568|NCT00353457|Erbitux
591569|NCT00353444|head injury
591570|NCT00353444|transcranial Doppler
591571|NCT00353444|pulsatility index
591572|NCT00353444|vasospasm in head injury
591573|NCT00353431|Hyperglycaemia
591574|NCT00353431|algorithm
591575|NCT00353431|emergency
591576|NCT00353431|s.c. insulin therapy
591577|NCT00353431|Emergency patient
591578|NCT00353405|Adolescents
591579|NCT00353405|Sexually Transmitted Infections
591580|NCT00353405|Gonorrhea
591581|NCT00353405|Chlamydia Infections
591582|NCT00353366|safety
591583|NCT00353366|Post-marketing surveillance (PMS)
591584|NCT00353366|Rotarix
591585|NCT00353366|oral
591586|NCT00353366|Filipino
591587|NCT00353366|Rotavirus
591588|NCT00353366|Gastroenteritis
591589|NCT00353366|Human Rotavirus (HRV) vaccine
591590|NCT00353353|no specific conditions
591591|NCT00353340|sodium bicarbonate,
591592|NCT00353340|n-acetylcisteine,
591593|NCT00353340|contrast nephropathy,
591594|NCT00353340|cardiac catheterisation
591595|NCT00353327|HIV
591596|NCT00353327|Passive immunotherapy
591597|NCT00353301|Carcinoma, Renal Cell
591598|NCT00353301|Receptor, Epidermal Growth Factor
591599|NCT00353301|mTOR protein
591600|NCT00353301|Sirolimus
591601|NCT00353301|Erlotinib
591602|NCT00353275|Strict glycemic control
591603|NCT00353249|Cognitive Behavioral Therapy
591604|NCT00353249|CBT
591605|NCT00353249|Homeless Women
591606|NCT00352235|Chronic hepatitis C
591607|NCT00352235|KRN7000
591608|NCT00352235|a-GalCer
591609|NCT00352235|immunotherapy
591610|NCT00352235|Natural Killer T cells
591611|NCT00352235|interferon
591612|NCT00352222|iliac arteries
591613|NCT00352222|implantation
591614|NCT00352222|treatment of atherosclerotic disease
591615|NCT00352222|stenosed
591616|NCT00352222|occlusive
591617|NCT00352209|Cyclophosphamide
591618|NCT00352209|Preparative Regimens
591619|NCT00352209|Risk Factors
591620|NCT00352209|Chart Review
591621|NCT00352209|Incidence
591622|NCT00352196|Asperger's Disorder
591623|NCT00352196|Risperidone
591624|NCT00352196|Magnetic Resonance Spectroscopy
591625|NCT00352196|Social Skills
591626|NCT00352183|Hyperlipidemia Combined
591627|NCT00352183|Combination of fenofibrate and simvastatin
591628|NCT00352170|calcium
591629|NCT00352170|vitamin D
591630|NCT00352170|secondary hyperparathyroidism
591631|NCT00352170|osteoporotic fractures
591632|NCT00352157|Soy
591633|NCT00352157|Dermatology
591634|NCT00352157|Skin
591635|NCT00352157|Hair
591636|NCT00352157|Finger Nails
591637|NCT00352157|Weight Loss
591638|NCT00352157|Body Mass Index
591639|NCT00352157|Photoaging of Skin
591640|NCT00352157|Skin Wrinkling
591641|NCT00352131|unspecified adult solid tumor, protocol specific
591642|NCT00352131|stage II pancreatic cancer
591643|NCT00352131|stage III pancreatic cancer
591644|NCT00352131|stage IV pancreatic cancer
591645|NCT00352131|recurrent pancreatic cancer
591646|NCT00352118|oral complications of radiation therapy
591647|NCT00352118|oral complications of chemotherapy
591648|NCT00352118|mucositis
591649|NCT00352118|xerostomia
591650|NCT00352118|stage III squamous cell carcinoma of the hypopharynx
591651|NCT00352118|stage IV squamous cell carcinoma of the hypopharynx
591652|NCT00352118|stage III squamous cell carcinoma of the larynx
591653|NCT00352118|stage IV squamous cell carcinoma of the larynx
591654|NCT00352118|stage III squamous cell carcinoma of the lip and oral cavity
591655|NCT00352118|stage IV squamous cell carcinoma of the lip and oral cavity
591656|NCT00352118|stage III squamous cell carcinoma of the oropharynx
591657|NCT00352118|stage IV squamous cell carcinoma of the oropharynx
591658|NCT00352105|stage III squamous cell carcinoma of the hypopharynx
591659|NCT00352105|stage IV squamous cell carcinoma of the hypopharynx
591660|NCT00352105|stage III squamous cell carcinoma of the larynx
591661|NCT00352105|stage IV squamous cell carcinoma of the larynx
591662|NCT00352105|stage III squamous cell carcinoma of the lip and oral cavity
591663|NCT00352105|stage IV squamous cell carcinoma of the lip and oral cavity
591664|NCT00352105|stage III squamous cell carcinoma of the oropharynx
591665|NCT00352105|stage IV squamous cell carcinoma of the oropharynx
591666|NCT00352092|Kidney disease
591667|NCT00352092|Renal transplant
591668|NCT00352092|HLA Identical
591669|NCT00352092|Living Donor
591670|NCT00352092|Corticosteroid free
591671|NCT00352092|Calcineurin sparing
591672|NCT00352092|Adults
591673|NCT00352079|transitional cell carcinoma of the bladder
591674|NCT00352079|stage 0 bladder cancer
591675|NCT00352079|stage I bladder cancer
591676|NCT00352079|recurrent bladder cancer
591677|NCT00352066|Human Immunodeficiency Virus
591678|NCT00352066|anti-retroviral therapy
591679|NCT00352066|nucleoside analogue
591680|NCT00352066|reverse transcriptase
591681|NCT00352066|apricitabine
591682|NCT00352066|tipranavir
591683|NCT00352066|bioequivalence
591684|NCT00352066|drug-drug interaction
591685|NCT00352066|pharmacokinetics
591686|NCT00352053|Phase 3
591687|NCT00352053|Randomized, Double-Blind
591688|NCT00352053|Control
591689|NCT00352053|Treatment-Experienced
591690|NCT00352053|OBR
591691|NCT00352053|Optimized background regimen
591692|NCT00352053|Highly Active Antiretroviral Therapy
591693|NCT00352053|HAART
591694|NCT00352053|HIV
591695|NCT00352053|HIV-1
591696|NCT00352053|AIDS Virus
591697|NCT00352053|Human Immunodeficiency Virus
591698|NCT00352053|Acquired Immune Deficiency Syndrome Virus
591699|NCT00352053|Virus
591700|NCT00352053|Human Immunodeficiency
591701|NCT00352053|Pediatrics
591702|NCT00352027|Hodgkin's Disease
591703|NCT00353236|delivery of preterm infant and/or twins
591704|NCT00353223|Heart Failure
591705|NCT00353223|Functional Impairment
591706|NCT00353223|Health-Related Quality of Life
591707|NCT00353223|Telemedicine
591708|NCT00353210|IVF
591709|NCT00353210|embryos
591710|NCT00353210|research
591711|NCT00353210|donation
591712|NCT00353210|surplus
591713|NCT00353210|stem cells
591714|NCT00353210|abnormal embryo
591715|NCT00353210|screening
591716|NCT00353197|IVF
591717|NCT00353197|embryos
591718|NCT00353197|research
591719|NCT00353197|donation
591720|NCT00353197|surplus
591721|NCT00353197|stem cells
591722|NCT00353184|Acute
591723|NCT00353184|Asthma
591724|NCT00353184|Child
591725|NCT00353184|Pediatric
591726|NCT00353184|Emergency
591727|NCT00353184|Oral
591728|NCT00353184|Montelukast
591729|NCT00353184|Forced Expiratory Volume in One Second
591730|NCT00353184|FEV1
591731|NCT00353171|Smoking
591732|NCT00353171|PCB
591733|NCT00353171|DDE
591734|NCT00353171|Menstrual Cycle
591735|NCT00353171|NC Infant Feeding Study
591736|NCT00353158|Phototesting
591737|NCT00353158|UVR/UVA
591738|NCT00353158|Sunburn
591739|NCT00353158|Doxycycline
591740|NCT00353158|Voriconazole
591741|NCT00353158|Phototoxicity
591742|NCT00353158|Healthy Volunteer
591743|NCT00353158|HV
591744|NCT00353145|Unknown Primary Neoplasms
591745|NCT00353145|UPC
591746|NCT00353145|Unknown Primary Cancer
591747|NCT00353145|Questionnaire
591748|NCT00353145|Gemcitabine
591749|NCT00353145|Gemcitabine Hydrochloride
591750|NCT00353145|Gemzar
591751|NCT00353145|Oxaliplatin
591752|NCT00353145|Eloxatin
591753|NCT00353145|Gemox
591754|NCT00353119|Palmoplantar pustulosis
591755|NCT00353119|Psoriasis
591756|NCT00353119|Etanercept
591757|NCT00353106|Graft-Versus-Host Disease
591758|NCT00353106|GVHD
591759|NCT00353106|Chronic Graft-Versus-Host Disease
591760|NCT00353106|cGVHD
591761|NCT00353106|Interview
591762|NCT00353106|Questionnaire
591763|NCT00353106|Survey
591764|NCT00353106|Caregiver
591765|NCT00353093|deep vein thrombosis,D-dimer,ultrasonography
591766|NCT00353080|Prevention of postmenopausal osteoporosis
591767|NCT00353067|unstable angina
591768|NCT00353067|myocardial infarction
591769|NCT00353067|coronary thrombosis
591770|NCT00353067|coronary atherosclerosis
591771|NCT00353054|Caltrate
591772|NCT00353054|Lipoproteins
591773|NCT00353054|Glucose
591774|NCT00353054|Insulin
591775|NCT00353054|Blood pressure
591776|NCT00353054|Body fat
591777|NCT00353054|Body weight
591778|NCT00353054|Women
591779|NCT00353054|Diet
591780|NCT00353054|Macronutrients
591781|NCT00353041|topical
591782|NCT00353041|anesthetic
591783|NCT00353041|pain
591784|NCT00353028|Fluvoxamine Maleate
591785|NCT00353028|Depression
591786|NCT00353028|Children and Adolescents
591787|NCT00353015|Gastrointestinal cancer
591788|NCT00353015|high grade gastrointestinal neuroendocrine carcinoma
591789|NCT00353015|High grade neuroendocrine carcinoma of unknown primary site
591790|NCT00353015|Cisplatin
591791|NCT00353015|Platinol-AQ
591792|NCT00353015|Platinol
591793|NCT00353015|CDDP
591794|NCT00353015|CPT-11
591795|NCT00353015|Irinotecan
591796|NCT00353002|Pain
591797|NCT00353002|Ametop
591798|NCT00353002|Liposomal Lidocaine
591799|NCT00353002|Venous cannulation
591800|NCT00352976|Bone Marrow transplant
591801|NCT00352976|stem cell transplant
591802|NCT00352976|cord blood transplant
591803|NCT00352976|total body irradiation
591804|NCT00352976|thymic shielding
591805|NCT00352963|Open, phase 3, Infanrix hexa™, Hib-MenC, co-administered
591806|NCT00352950|NSCLC, Lung cancer
591807|NCT00352950|Panitumumab
591808|NCT00352950|Sirolimus
591809|NCT00352950|mTOR
591810|NCT00352950|Monoclonal antibody
591811|NCT00352937|Coronary Arteriosclerosis
591812|NCT00352937|Tomography, X-Ray Computed
591813|NCT00352937|Tomography, Emission-Computed, Single-Photon
591814|NCT00352924|Cancer
591815|NCT00352924|Pesticides
591816|NCT00352924|Agriculture
591817|NCT00352911|HIV-1
591818|NCT00352885|Cancer
591819|NCT00352885|IL-2 therapy
591820|NCT00352885|Antidepressant
591821|NCT00352885|Immune system
591822|NCT00352885|Neuroendocrine response
591823|NCT00352872|Pharmacogenetics
591824|NCT00352872|Toxicity
591825|NCT00352872|Pre-Menopausal
591826|NCT00352872|Women
591827|NCT00352872|Doxorubicin
591828|NCT00352872|Cyclophosphamide
591829|NCT00352872|Breast Cancer
591830|NCT00352872|Chemotherapy
591831|NCT00352859|Cancer
591832|NCT00352859|Renal Cell Cancer
591833|NCT00352859|RCC
591834|NCT00352846|Non-Hodgkin's Lymphoma
591835|NCT00352846|Lymphoma
591836|NCT00352846|Zoledronic Acid
591837|NCT00352846|Zoledronate
591838|NCT00352846|Zometa
591839|NCT00352846|Vitamin D
591840|NCT00352846|Calcium Carbonate
591841|NCT00352846|Bone Loss
591842|NCT00352833|gastric cancer
591843|NCT00352833|investigational drug
591844|NCT00352833|adjuvant therapy
591845|NCT00352833|intraoperative
591846|NCT00352833|intraperitoneal
591847|NCT00352833|EpCAM-positive tumor
591848|NCT00352820|Caregiver
591849|NCT00352820|Brain cancer
591850|NCT00352820|Glioma
591851|NCT00352820|Questionnaire
591852|NCT00352820|Survey
591853|NCT00352820|Interview
591854|NCT00352807|Cataract
591855|NCT00352794|Combination chemotherapy
591856|NCT00352794|Myelofibrosis (MF)
591857|NCT00352781|nicotine replacement therapy
591858|NCT00352781|smoking cessation
591859|NCT00352768|Fluvoxamine Maleate
591860|NCT00352768|OCD
591861|NCT00352768|Children and Adolescents
591862|NCT00352742|Multiple myeloma
591863|NCT00352742|bortezomib
591864|NCT00352742|ATN-224
591865|NCT00352742|refractory
591866|NCT00352742|relapsed
591867|NCT00352742|antiangiogenic
591868|NCT00352729|Burns
591869|NCT00352729|ACell
591870|NCT00352729|Donor Site
591871|NCT00352703|Oral mucositis
591872|NCT00352703|Non-Hodgkin's lymphoma (NHL)
591873|NCT00352703|conditioning chemotherapy
591874|NCT00352703|autologous PBSCT
591875|NCT00352703|multiple myeloma (MM)
591876|NCT00352703|Melphalan
591877|NCT00352664|Advanced Cancer
591878|NCT00352664|Cancer Pain
591879|NCT00352664|Donepezil
591880|NCT00352664|Sedation
591881|NCT00352664|Placebo
591882|NCT00352651|Acute Herpes Zoster (AHZ)
591883|NCT00352651|Postherpetic Neuralgia (PHN)
591884|NCT00352651|Pregabalin
591885|NCT00352651|Lyrica
591886|NCT00352651|Pain
591887|NCT00352638|colon cancer
591888|NCT00352638|rectal cancer
591889|NCT00352625|Tendonitis
591890|NCT00352625|Bursitis
591891|NCT00352625|Pain
591892|NCT00352625|Shoulder Pain
591893|NCT00352625|Elbow Pain
591894|NCT00352625|Knee Pain
591895|NCT00352625|Tendon Injury
591896|NCT00352625|Muscle, Bone and Cartilage Disorders
591897|NCT00352612|clinical trial
591898|NCT00352612|randomized
591899|NCT00352612|blinded
591900|NCT00352612|controlled
591901|NCT00352599|Neurofibromatosis Type 1
591902|NCT00352599|NF1
591903|NCT00352599|Lovastatin
591904|NCT00352599|statin
591905|NCT00352586|Classical Conditioning
591906|NCT00352586|Learning
591907|NCT00352586|NMDA
591908|NCT00352586|Startle
591909|NCT00352586|Eyeblink
591910|NCT00352586|Anxiety
591911|NCT00352586|Fear Conditioning
591912|NCT00352586|Fear Potentiated Startle
591913|NCT00352586|Extinction
591914|NCT00352586|D-cycloserine
591915|NCT00352586|Healthy Volunteer
591916|NCT00352586|HV
591917|NCT00352586|Normal Control
591918|NCT00352573|Ethics, Clinical
591919|NCT00352573|Physician's Role
591920|NCT00352573|Health Care Rationing
591921|NCT00352573|Knowledge, Attitudes, Practices
591922|NCT00352573|Questionnaires
591923|NCT00352573|Survey
591924|NCT00352573|Ethics
591925|NCT00352560|Patients with Paroxysmal Atrial Fibrillation (PAF)
591926|NCT00352547|Immunosuppresant
591927|NCT00352547|Genetic Polymorphism
591928|NCT00352547|Drug Metabolism
591929|NCT00352547|Pharmacogenetics
591930|NCT00352547|Rapamycin
591931|NCT00352521|adult anaplastic astrocytoma
591932|NCT00352521|adult mixed glioma
591933|NCT00352521|adult giant cell glioblastoma
591934|NCT00352521|adult gliosarcoma
591935|NCT00352521|recurrent adult brain tumor
591936|NCT00352521|adult glioblastoma
591937|NCT00352521|adult anaplastic ependymoma
591938|NCT00352521|adult anaplastic oligodendroglioma
591939|NCT00352521|adult pineal gland astrocytoma
591940|NCT00352508|Internet, dietary advice, saturated fat
591941|NCT00352495|childhood low-grade cerebral astrocytoma
591942|NCT00352495|recurrent childhood cerebellar astrocytoma
591943|NCT00352495|recurrent childhood cerebral astrocytoma
591944|NCT00352495|childhood oligodendroglioma
591945|NCT00352495|neurofibromatosis type 1
591946|NCT00352495|recurrent childhood visual pathway and hypothalamic glioma
591947|NCT00352495|untreated childhood visual pathway and hypothalamic glioma
591948|NCT00352482|Pulmonary Hypertension
591949|NCT00352482|Idiopathic Pulmonary Fibrosis
591950|NCT00352469|Alcoholism
591951|NCT00352469|Anxiety
591952|NCT00352469|GAD
591953|NCT00352469|PTSD
591954|NCT00352469|Panic Disorder
591955|NCT00352469|OCD
591956|NCT00352456|Amygdala
591957|NCT00352456|Facial Affect
591958|NCT00352456|Instrumental Learning
591959|NCT00352456|Psychopathy
591960|NCT00352456|Emotion
591961|NCT00352456|Orbitofrontal Cortex
591962|NCT00352456|Healthy Volunteer
591963|NCT00352456|HV
591964|NCT00352443|adult grade III lymphomatoid granulomatosis
591965|NCT00352443|recurrent adult grade III lymphomatoid granulomatosis
591966|NCT00352443|Waldenstrom macroglobulinemia
591967|NCT00352443|recurrent adult Burkitt lymphoma
591968|NCT00352443|stage IV adult Burkitt lymphoma
591969|NCT00352443|recurrent adult diffuse large cell lymphoma
591970|NCT00352443|recurrent adult diffuse mixed cell lymphoma
591971|NCT00352443|recurrent adult diffuse small cleaved cell lymphoma
591972|NCT00352443|recurrent adult immunoblastic large cell lymphoma
591973|NCT00352443|recurrent adult lymphoblastic lymphoma
591974|NCT00352443|recurrent grade 1 follicular lymphoma
591975|NCT00352443|recurrent grade 2 follicular lymphoma
591976|NCT00352443|recurrent grade 3 follicular lymphoma
591977|NCT00352443|recurrent mantle cell lymphoma
591978|NCT00352443|recurrent marginal zone lymphoma
591979|NCT00352443|recurrent small lymphocytic lymphoma
591980|NCT00352443|stage IV adult diffuse large cell lymphoma
591981|NCT00352443|stage IV adult diffuse mixed cell lymphoma
591982|NCT00352443|stage IV adult diffuse small cleaved cell lymphoma
591983|NCT00352443|stage IV adult immunoblastic large cell lymphoma
591984|NCT00352443|stage IV adult lymphoblastic lymphoma
591985|NCT00352443|stage IV grade 1 follicular lymphoma
591986|NCT00352443|stage IV grade 2 follicular lymphoma
591987|NCT00352443|stage IV grade 3 follicular lymphoma
591988|NCT00352443|stage IV mantle cell lymphoma
591989|NCT00352443|stage IV marginal zone lymphoma
591990|NCT00352443|stage IV small lymphocytic lymphoma
591991|NCT00352443|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
591992|NCT00352443|nodal marginal zone B-cell lymphoma
591993|NCT00352443|splenic marginal zone lymphoma
591994|NCT00352443|unspecified adult solid tumor, protocol specific
591995|NCT00352443|anaplastic large cell lymphoma
591996|NCT00352443|angioimmunoblastic T-cell lymphoma
591997|NCT00352443|adult nasal type extranodal NK/T-cell lymphoma
591998|NCT00352430|Nitric Oxide
591999|NCT00352430|PDE Inhibitors
592000|NCT00352430|Pulmonary Hypertension
592001|NCT00352430|Sickle Cell
592002|NCT00352430|Thalassemia
592003|NCT00352430|Sickle Cell Anemia
592004|NCT00352404|Endomicroscopy
592005|NCT00352404|Chromoendoscopy
592006|NCT00352404|Chromoscopy
592007|NCT00352404|Ulcerative Colitis
592008|NCT00352404|Intraepithelial Neoplasia
592009|NCT00352391|Non-Small Cell Lung Cancer
592010|NCT00352391|Head And Neck Cancer
592011|NCT00352391|Lung Cancer
592012|NCT00352391|Bronchoscopy
592013|NCT00352391|Laryngoscopy
592014|NCT00352391|NSCLC
592015|NCT00352391|Disease Free Survival
592016|NCT00352391|Current Smoker
592017|NCT00352391|Former Smoker
592018|NCT00352378|Primary
592019|NCT00352352|Traditional Chinese Medicine (TCM)
592020|NCT00352352|Alternative Medicine (AM)
592021|NCT00352352|Tongue Acupuncture (TAC)
592022|NCT00352352|Autism Spectrum Disorder (ASD)
592023|NCT00352352|Autism
592024|NCT00352352|Children
592025|NCT00352339|Schizophrenia
592026|NCT00352339|Switching
592027|NCT00352339|Early stage
592028|NCT00352339|Risperidone
592029|NCT00352339|Aripirazole
592030|NCT00352313|adult anaplastic oligodendroglioma
592031|NCT00352313|adult gliosarcoma
592032|NCT00352313|adult mixed glioma
592033|NCT00352313|adult anaplastic astrocytoma
592034|NCT00352313|recurrent adult brain tumor
592035|NCT00352313|adult glioblastoma
592036|NCT00352313|adult giant cell glioblastoma
592037|NCT00352287|Visceral fat
592038|NCT00352287|Impaired glucose tolerance
592039|NCT00352287|Insulin resistance
592040|NCT00352287|Growth hormone
592041|NCT00352287|Thiazolidinedione
592042|NCT00352261|Barrett's Esophagus
592043|NCT00352248|Alternative Medicine (AM)
592044|NCT00352248|Traditional Chinese Medicine
592045|NCT00352248|Tongue Acupuncture
592046|NCT00352248|Autistic Spectrum Disorder
592047|NCT00352248|Autism
592048|NCT00352248|Children
592049|NCT00352014|Monitoring of antiplatelet therapy
592050|NCT00352014|antiplatelet therapy
592051|NCT00352014|platelet function assays
592052|NCT00352014|Aspirin
592053|NCT00352014|Clopidogrel
592054|NCT00352014|elective PCI
592055|NCT00352001|refractory anemia with excess blasts
592056|NCT00352001|previously treated myelodysplastic syndromes
592057|NCT00352001|chronic myelomonocytic leukemia
592058|NCT00352001|de novo myelodysplastic syndromes
592059|NCT00352001|secondary myelodysplastic syndromes
592060|NCT00351988|Lung Cancer
592061|NCT00351988|Non-Small Cell Lung Cancer
592062|NCT00351988|Breast Cancer
592063|NCT00351988|Psychosocial
592064|NCT00351988|Behavioral
592065|NCT00351988|Caregiver
592066|NCT00351988|Interview
592067|NCT00351988|Questionnaire
592068|NCT00351988|Minority Caregiver
592069|NCT00351988|Non-Minority Caregiver
592070|NCT00351988|Survey
592071|NCT00351962|lung neoplasms
592072|NCT00351962|metastatic lung cancer
592073|NCT00351962|stereotactic radiation
592074|NCT00351949|Advanced or metastatic renal cell carcinoma
592075|NCT00351949|IMP321
592076|NCT00351949|Monotherapy
592077|NCT00351949|LAG-3
592078|NCT00351949|CD223
592079|NCT00351936|Schizophrenia
592080|NCT00351936|Diabetes
592081|NCT00351936|Obesity
592082|NCT00351936|Olanzapine
592083|NCT00351936|Insulin Resistance
592084|NCT00351910|Major Depressive Disorder
592085|NCT00351910|MDD
592086|NCT00351884|Type 2 diabetes
592087|NCT00351884|vildagliptin
592088|NCT00351884|Hemoglobin A1c
592089|NCT00351871|HCV
592090|NCT00351858|Breast Cancer
592091|NCT00351858|investigational drug
592092|NCT00351858|drug therapy
592093|NCT00351858|Antineoplastic Protocols
592094|NCT00351858|Immunotherapy
592095|NCT00351858|Metastatic breast cancer
592096|NCT00351858|Advanced breast cancer
592097|NCT00351858|Stage III to IV breast cancer
592098|NCT00351858|Hormonal therapy refractory
592099|NCT00351858|Failure of hormonal therapy
592100|NCT00351858|Her-2/neu expressing breast cancer
592101|NCT00351858|low to moderate Her-2/neu expression
592102|NCT00351832|Type 2 diabetes
592103|NCT00351832|Vildagliptin
592104|NCT00351832|Hemoglobin A1c
592105|NCT00351819|Testosterone
592106|NCT00351819|Pain
592107|NCT00351819|Opioid
592108|NCT00351819|Hypogonadism
592109|NCT00351806|acute intracerebral infarction
592110|NCT00351780|fractional flow reserve
592111|NCT00351780|bifurcation
592112|NCT00351780|stent
592113|NCT00351767|Diabetes
592114|NCT00351767|Dabetic Feet
592115|NCT00351741|Burns
592116|NCT00351715|Sublingual Methadone
592117|NCT00351715|Cancer related breakthrough pain
592118|NCT00351715|feasibility study
592119|NCT00351715|Phase II/open label
592120|NCT00351715|Outpatients
592121|NCT00351715|Safety/ efficacy
592122|NCT00351715|previously receiving opioids
592123|NCT00351715|speak English
592124|NCT00351702|Preventive therapy
592125|NCT00351689|Probiotic bacteria
592126|NCT00351689|cutaneous immune homeostasis
592127|NCT00351689|UV radiation
592128|NCT00351689|dietary supplement
592129|NCT00351676|Drug Therapy
592130|NCT00351676|Hospitals, Teaching
592131|NCT00351676|Hospitals, Community
592132|NCT00351676|Interprofessional relations
592133|NCT00351676|Patient Care Team
592134|NCT00351676|Pharmacists
592135|NCT00351676|Pharmacy Service, Hospital
592136|NCT00351676|Comparative Study
592137|NCT00351676|Hospitalization
592138|NCT00351663|Venous Thrombosis
592139|NCT00351663|Critical Illness
592140|NCT00351663|Blood Coagulation
592141|NCT00351663|Factor Xa
592142|NCT00351650|Imaging
592143|NCT00351650|Type 1 Diabetes Mellitus (T1DM)
592144|NCT00351650|Islet
592145|NCT00351650|B Cell Mass
592146|NCT00351650|Pet Scan
592147|NCT00351650|Type 1 Diabetes
592148|NCT00351650|T1DM
592149|NCT00351650|Pancreas
592150|NCT00351650|Healthy Volunteer
592151|NCT00351650|HV
592152|NCT00351637|Sublingual methadone
592153|NCT00351637|iatrogenic
592154|NCT00351637|treatment related incident breakthrough pain
592155|NCT00351637|feasibility study
592156|NCT00351637|Phase II/open-label
592157|NCT00351637|inpatients
592158|NCT00351637|Safety/efficacy
592159|NCT00351637|Cancer related breakthrough pain
592160|NCT00351637|previously receiving opioids
592161|NCT00351637|speak English
592162|NCT00351624|DHA supplementation
592163|NCT00351624|Cognitive function
592164|NCT00351624|Preschool children
592165|NCT00351624|Attention and behavior
592166|NCT00351624|Healthy Children
592167|NCT00351611|epilepsy partial seizure treatment with pregabalin or placebo
592168|NCT00351611|vision testing
592169|NCT00351598|Tumour Volume
592170|NCT00351598|Prognostic value
592171|NCT00351585|Vildagliptin
592172|NCT00351585|Type 2 diabetes
592173|NCT00351585|Insulin secretion
592174|NCT00351585|Beta cell
592175|NCT00351572|colon cancer
592176|NCT00351559|allograft
592177|NCT00351559|rejection
592178|NCT00351559|biopsy
592179|NCT00351559|gene
592180|NCT00351559|expression
592181|NCT00351559|cardiac
592182|NCT00351559|heart
592183|NCT00351559|transplant
592184|NCT00351546|Vildagliptin
592185|NCT00351546|Type 2 diabetes
592186|NCT00351546|Insulin sensitivity
592187|NCT00351546|Insulin action
592188|NCT00351533|Respiratory distress syndrome, adult
592189|NCT00351533|Acute lung injury
592190|NCT00351533|Acute respiratory distress syndrome
592191|NCT00351533|ARDS, human
592192|NCT00351533|Fish oils
592193|NCT00351533|Fatty Acids, Omega-3
592194|NCT00351533|Docosahexaenoic Acids
592195|NCT00351533|Eicosapentaenoic Acid
592196|NCT00351520|Anthoponotic Cutaneous leishmaniasis
592197|NCT00351520|Glucantime
592198|NCT00351520|Miltefosine
592199|NCT00351507|Vildagliptin
592200|NCT00351507|Type 2 diabetes
592201|NCT00351494|embolization
592202|NCT00351494|contrast enhanced ultrasound
592203|NCT00351494|myoma
592204|NCT00351494|uterine artery
592205|NCT00351494|microvascularisation
592206|NCT00351481|IVF
592207|NCT00351481|endometrial receptivity
592208|NCT00351481|embryo implantation
592209|NCT00351481|recurrent implantation failure
592210|NCT00351468|eltrombopag olamine
592211|NCT00351468|SB-497115-GR
592212|NCT00351468|idiopathic thrombocytopenic purpura
592213|NCT00351468|thrombocytopenia
592214|NCT00351468|ITP
592215|NCT00351468|platelets
592216|NCT00351455|hernia
592217|NCT00351455|incisional hernia
592218|NCT00351455|ventral hernia
592219|NCT00351455|umbilical hernia
592220|NCT00351442|Host Resistance
592221|NCT00351429|Glaucoma
592222|NCT00351429|Trabeculectomy
592223|NCT00351429|Sutures
592224|NCT00351416|GnRH deficiency
592225|NCT00351416|GnRH antagonist
592226|NCT00351416|Letrozole
592227|NCT00351416|GnRH
592228|NCT00351416|FSH
592229|NCT00351416|LH
592230|NCT00351416|Inhibins
592231|NCT00351403|Chronic HCV infection
592232|NCT00351403|Genotype 1
592233|NCT00351403|Individually adapted therapy
592234|NCT00351403|Peginterferon alfa-2b
592235|NCT00351403|Ribavirin
592236|NCT00351403|Sustained viral response (SVR)
592237|NCT00351390|congestive heart failure treatment
592238|NCT00351390|congestive heart failure, prognosis
592239|NCT00351390|NT-proBNP testing
592240|NCT00351377|Autoimmune disease, mycophenolate, GI problems
592241|NCT00351364|atherosclerosis
592242|NCT00351364|inflammation
592243|NCT00351364|leukotriene blockade
592244|NCT00351364|endothelial function
592245|NCT00351351|Kidney Stones
592246|NCT00351351|Renal Calculi
592247|NCT00351312|Pressure ulcers
592248|NCT00351312|socks
592249|NCT00351312|foot pressure
592250|NCT00351299|Delirium
592251|NCT00351299|Agitation
592252|NCT00351299|Sedation
592253|NCT00351299|Dexmedetomidine
592254|NCT00351299|Surgical
592255|NCT00351286|peripheral arterial disease
592256|NCT00351286|peripheral vascular disease
592257|NCT00351286|claudication
592258|NCT00351273|Chlamydia
592259|NCT00351260|Bifurcation
592260|NCT00351260|Coronary
592261|NCT00351260|Stenosis
592262|NCT00351260|Stent
592263|NCT00351260|drug elution
592264|NCT00351247|Myocardial Infarction
592265|NCT00351247|Primary PCI
592266|NCT00351247|Postconditioning
592267|NCT00351247|MRI
592268|NCT00351234|Diabetes Mellitus Type I,
592269|NCT00351234|Hypoglycemia,
592270|NCT00351234|Carnitine
592271|NCT00351208|Spinal cord stimulation
592272|NCT00351208|Spinal cord stimulation efficacy
592273|NCT00351208|Spinal cord stimulators
592274|NCT00351208|Stimulation frequencies
592275|NCT00351208|Stimulation pulse-widths
592276|NCT00351208|Varying settings
592277|NCT00351195|Hepatocellular carcinoma
592278|NCT00351195|Etoposide
592279|NCT00351195|Oxaliplatin
592280|NCT00351195|Capecitabine
592281|NCT00351182|Scrub typhus
592282|NCT00351182|Telithromycin
592283|NCT00351182|Doxycycline
592284|NCT00351182|5 day Course of Telithromycin versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus
592285|NCT00351169|Major Depressive Disorder
592286|NCT00351169|MDD
592287|NCT00351156|Gaucher Disease
592288|NCT00351156|Gaucher Disease, Type 1
592289|NCT00351156|Gaucher Disease, Type 2
592290|NCT00351156|Gaucher Disease, Type 3
592291|NCT00351156|Neuronopathic Gaucher Disease
592292|NCT00351156|Non-Neuronopathic Gaucher Disease
592293|NCT00351156|Lysosomal Storage Disease
592294|NCT00351156|Metabolism, Inborn Errors
592295|NCT00351156|Metabolic Diseases
592296|NCT00351156|Sphingolipidoses
592297|NCT00351156|Genetic Diseases, Inborn
592298|NCT00351143|QoL
592299|NCT00351143|Asthma
592300|NCT00351143|asthma compliance enhancement
592301|NCT00351143|Salmeterol/fluticasone
592302|NCT00351143|Total control
592303|NCT00351143|SERETIDE
592304|NCT00351143|FEV1
592305|NCT00351130|Hypertension,
592306|NCT00351130|stage 1 hypertension,
592307|NCT00351130|stage 2 hypertension,
592308|NCT00351130|valsartan,
592309|NCT00351130|amlodipine,
592310|NCT00351117|St. John's Wort
592311|NCT00351117|Selective Serotonin Receptor Inhibitor
592312|NCT00351117|Microvasculature
592313|NCT00351117|Natural Health Products
592314|NCT00351104|Sprain
592315|NCT00351104|Strain
592316|NCT00351104|Pain
592317|NCT00351104|Ankle Pain
592318|NCT00351104|Muscle, Bone and Cartilage Disorders
592319|NCT00351078|Cystic fibrosis
592320|NCT00351078|Nonsense mutation
592321|NCT00351078|Premature stop codon
592322|NCT00351078|CF
592323|NCT00351078|PTC124
592324|NCT00351065|erectile dysfunction, PDE-5 inhibitor
592325|NCT00351052|Pimecrolimus, Atopic Dermatitis, Eczema, Pediatric
592326|NCT00351026|opioid dependence
592327|NCT00351026|methadone
592328|NCT00351026|HIV
592329|NCT00351013|malaria
592330|NCT00351013|Plasmodium falciparum
592331|NCT00351013|Tropica Nosode
592332|NCT00351013|Homeopathy
592333|NCT00351000|Schizophrenia
592334|NCT00351000|Ziprasidone
592335|NCT00351000|Diabetes
592336|NCT00351000|Insulin Resistance
592337|NCT00350987|Procalcitonin, guidelines, LRTI, non-inferiority
592338|NCT00350987|COLD
592339|NCT00350961|Cholangiocarcinoma
592340|NCT00350961|Fixed dose rate
592341|NCT00350961|Gemcitabine
592342|NCT00350961|Oxaliplatin
592343|NCT00350961|Capecitabine
592344|NCT00350948|Ovary
592345|NCT00350935|fMRI
592346|NCT00350935|Visual perception
592347|NCT00350935|Attention
592348|NCT00350909|drug abuse
592349|NCT00350896|trapezotrapezoidial
592350|NCT00350896|scaphotrapezial
592351|NCT00350896|thumb
592352|NCT00350896|pain
592353|NCT00350896|orthoses
592354|NCT00350896|Osteoarthritis in the BTOA concerns the trapezometacarpal joint
592355|NCT00350883|Cognitive Therapy
592356|NCT00350883|Negative Symptoms
592357|NCT00350883|Functional Outcomes
592358|NCT00350883|Schizophrenia
592359|NCT00350883|Schizoaffective Disorder
592360|NCT00350870|disulfiram
592361|NCT00350870|cognitive behavioral therapy
592362|NCT00350870|contingency management
592363|NCT00350870|drug abuse therapy
592364|NCT00350870|educational/resource design/development
592365|NCT00350844|Sickle Cell Disease
592366|NCT00350844|Pulmonary Hypertension
592367|NCT00350831|Solid tumor
592368|NCT00350818|Acute Myelogenous Leukemia
592369|NCT00350818|Myelodysplastic Syndrome
592370|NCT00350818|Allogeneic Transplantation
592371|NCT00350818|Leukemia
592372|NCT00350818|Azacitidine
592373|NCT00350818|Vidaza
592374|NCT00350805|Schizophrenia
592375|NCT00350805|Time perception
592376|NCT00350805|Cortical synchronization
592377|NCT00350805|Electroencephalography
592378|NCT00350779|Type 2 Diabetes Mellitus
592379|NCT00350766|Myocardial Infarction
592380|NCT00350766|Myocardial Ischemia
592381|NCT00350766|Ventricular Remodeling
592382|NCT00350766|Bone Marrow Cell Transplantation
592383|NCT00350766|Stem cells
592384|NCT00350753|Cholangiocarcinoma
592385|NCT00350727|relapsed
592386|NCT00350727|lapatinib
592387|NCT00350727|Pazopanib
592388|NCT00350727|glioblastoma
592389|NCT00350714|HCV (Hepatitis C Virus)
592390|NCT00350714|MBT (Methacetin Breath Test)
592391|NCT00350714|Hepatitis C Virus Patients
592392|NCT00350701|DM type 2
592393|NCT00350701|Hypogonadism
592394|NCT00350701|Testosterone
592395|NCT00350701|AndroGel
592396|NCT00350688|Bladder,
592397|NCT00350688|Cancer,
592398|NCT00350688|Chemoradiation,
592399|NCT00350688|IMRT,
592400|NCT00350688|tomotherapy
592401|NCT00350662|Deferiprone
592402|NCT00350662|L1
592403|NCT00350662|Desferrioxamine
592404|NCT00350662|Hemochromatosis
592405|NCT00350662|Iron overload
592406|NCT00350662|Thalassemia
592407|NCT00350649|behavior modification
592408|NCT00350649|cognitive behavioral therapy
592409|NCT00350649|combination therapy
592410|NCT00350649|drug abuse therapy
592411|NCT00350649|drug addition
592412|NCT00350649|human therapy evaluation
592413|NCT00350649|psychotherapy
592414|NCT00350649|clinical trial phase II
592415|NCT00350649|coping
592416|NCT00350649|drug and alcohol abstinence
592417|NCT00350649|longitudinal human study
592418|NCT00350649|outcomes research
592419|NCT00350649|outpatient care
592420|NCT00350649|psychological reinforcement
592421|NCT00350649|therapy compliance
592422|NCT00350649|behavior and social research tag
592423|NCT00350649|human subjects
592424|NCT00350649|neuropsychological test
592425|NCT00350649|patient oriented research
592426|NCT00350636|OAB, anticholineric, oxybutynin, urge urinary incontinence
592427|NCT00350623|AIDS
592428|NCT00350610|cognitive behavior therapy
592429|NCT00350610|computer assisted instruction
592430|NCT00350610|drug abuse therapy
592431|NCT00350610|educational resource design and development
592432|NCT00350597|Malignant Melanoma
592433|NCT00350597|Adjuvant Therapy
592434|NCT00350597|Cytokine Therapy
592435|NCT00350597|Immunologic Testing
592436|NCT00350584|Mindfulness
592437|NCT00350584|Psychoeducation
592438|NCT00350584|Telehealth Intervention
592439|NCT00350571|behavior therapy
592440|NCT00350571|counseling
592441|NCT00350571|drug abuse therapy
592442|NCT00350571|outpatient care
592443|NCT00350571|therapy compliance
592444|NCT00350571|clinical trial phase I
592445|NCT00350571|coping
592446|NCT00350571|outcomes research
592447|NCT00350571|satisfaction
592448|NCT00350571|social psychology
592449|NCT00350571|patient oriented research
592450|NCT00350532|pain, chronic pain
592451|NCT00350532|acetylcholine
592452|NCT00350532|clonidine
592453|NCT00350532|a2-adrenergic agonists
592454|NCT00350532|alpha2-adrenergic agonists
592455|NCT00350519|Hemostasis, Surgical
592456|NCT00350519|Epoetin alfa
592457|NCT00350519|Surgery
592458|NCT00350519|Abdomen
592459|NCT00350519|Pelvis
592460|NCT00350519|PROCRIT
592461|NCT00350519|pRBC
592462|NCT00350519|Blood transfusion
592463|NCT00350519|Packed red blood cell transfusion
592464|NCT00350480|acute uterine bleeding
592465|NCT00350467|Schizophrenia
592466|NCT00350467|DSM-IV
592467|NCT00350467|PANSS
592468|NCT00350467|informed consent
592469|NCT00350441|Sildenafil Citrate
592470|NCT00350441|Cardiopulmonary bypass
592471|NCT00350441|Open heart surgery
592472|NCT00350428|Acute primary angle closure
592473|NCT00350428|Laser preipheral iridotomy
592474|NCT00350428|Phacoemulsification
592475|NCT00350415|ulcerative colitis, inflammatory bowel disease
592476|NCT00350402|Parkinson's disease
592477|NCT00350402|PD
592478|NCT00350402|masked faces
592479|NCT00350402|diminished facial expressivity
592480|NCT00350402|diminished facial expression
592481|NCT00350402|high intensity respiratory muscle strength training
592482|NCT00350402|MST
592483|NCT00350389|Falls, Older persons
592484|NCT00350376|asthma
592485|NCT00350376|allergies
592486|NCT00350376|Xolair
592487|NCT00350376|Advair
592488|NCT00350350|XEROSTOMIA
592489|NCT00350350|MOUTH DRYNESS
592490|NCT00350350|ELDERLY
592491|NCT00350350|ORAL LUBRICANT
592492|NCT00350298|Monoclonal antibody,
592493|NCT00350298|Clostridium difficile Associated Diarrhea
592494|NCT00350285|cannabis
592495|NCT00350285|marijuana
592496|NCT00350272|HIV-1 treatment naive
592497|NCT00349219|first-line
592498|NCT00349219|second-line
592499|NCT00349219|targeted therapy
592500|NCT00349193|Relapsing Remitting Multiple Sclerosis
592501|NCT00348452|osteoarthritis pain; knee; hip; extended release analgesia; opioid
592502|NCT00348426|Food Borne Botulism
592503|NCT00348413|Graves ophthalmopathy/therapy
592504|NCT00348413|Randomized controlled trial
592505|NCT00348413|Methylprednisolone
592506|NCT00348413|Methotrexate
592507|NCT00348387|Imovax polio
592508|NCT00348387|poliomyelitis
592509|NCT00348374|type two diabetes, insulin, HbA1c
592510|NCT00348361|Hay fever
592511|NCT00348361|biomarkers
592512|NCT00348309|apolipoprotein E
592513|NCT00348309|Alzheimer's disease
592514|NCT00348309|cognition
592515|NCT00348309|rosiglitazone
592516|NCT00348309|adjunctive therapy
592517|NCT00348296|Scleroderma, Systemic
592518|NCT00350233|Bone Tumors
592519|NCT00350233|Bone Cancer
592520|NCT00350233|Prostate Cancer
592521|NCT00350233|lung cancer
592522|NCT00350220|Single ventricle
592523|NCT00350220|Bidirectional Glenn
592524|NCT00350220|Fontan
592525|NCT00350220|Congenital cardiac disease
592526|NCT00350220|Red blood cell transfusion
592527|NCT00350220|oxygen utilization
592528|NCT00350220|lactate level
592529|NCT00350220|hemoglobin level
592530|NCT00350194|Fatty Acids, Omega-3
592531|NCT00350168|Blood pressure
592532|NCT00350168|Venous pressure
592533|NCT00350168|Systolic pressure
592534|NCT00350168|Diastolic pressure
592535|NCT00350168|Pulse pressure
592536|NCT00350155|Video capsule endoscopy, healthy volunteers, naproxen, omeprazole, lumiracoxib, small bowel
592537|NCT00350142|Stereotactic Body Radiotherapy (SBRT)
592538|NCT00350142|pancreas cancer
592539|NCT00350142|locally advanced
592540|NCT00350142|local control
592541|NCT00350142|Gemcitabine
592542|NCT00350129|glucose
592543|NCT00350129|vasospasm
592544|NCT00350129|RVA
592545|NCT00350129|LDF
592546|NCT00350129|vasospastic subjects
592547|NCT00350129|non-vasospastic subjects
592548|NCT00350116|plaque psoriasis
592549|NCT00350116|Vitamin B12
592550|NCT00350090|Anemia
592551|NCT00350090|Neoplasms
592552|NCT00350090|Hemoglobin values
592553|NCT00350077|Burns
592554|NCT00350064|Metabolic Syndrome
592555|NCT00350064|Obesity
592556|NCT00350064|Exercise
592557|NCT00350064|Diabetes
592558|NCT00350064|Physical Activity
592559|NCT00350051|Prostate cancer
592560|NCT00350051|Metastatic androgen-independent prostate cancer
592561|NCT00350025|urothelial
592562|NCT00350025|urologic
592563|NCT00350025|neoplasm
592564|NCT00350025|advanced
592565|NCT00350025|metastatic
592566|NCT00350012|stroke
592567|NCT00350012|visual
592568|NCT00350012|spatial neglect
592569|NCT00349999|Vibrio cholerae, Cholera, Bangladesh, esophagogastroduodenoscopy, sub-study
592570|NCT00349973|Schizophrenia
592571|NCT00349973|Positive symptoms
592572|NCT00349973|Negative symptoms
592573|NCT00349973|Cognitive deficits
592574|NCT00349960|Erythropoiesis stimulating agent
592575|NCT00349960|Dosing frequency
592576|NCT00349960|Hemodialysis
592577|NCT00349960|Therapeutic equivalence
592578|NCT00349934|Metastatic breast cancer
592579|NCT00349934|IMP321
592580|NCT00349934|hLAG-3Ig
592581|NCT00349934|LAG-3
592582|NCT00349934|CD223
592583|NCT00349934|Chemotherapy
592584|NCT00349934|Paclitaxel
592585|NCT00349934|Combination therapy
592586|NCT00349921|pain
592587|NCT00349921|chronic pain
592588|NCT00349921|clonidine
592589|NCT00349921|adenosine
592590|NCT00349921|complex regional pain syndrome
592591|NCT00349921|CRPS
592592|NCT00349921|a2-adrenergic agonists
592593|NCT00349921|alpha2-adrenergic agonists
592594|NCT00349908|Atherosclerosis,Wide Neck Aneurysm
592595|NCT00349895|Percutaneous Transluminal Coronary Angioplasty
592596|NCT00349895|Stent implantation
592597|NCT00349869|inflammatory arthritis
592598|NCT00349869|rheumatoid arthritis
592599|NCT00349869|knee osteoarthritis
592600|NCT00349869|arthritis
592601|NCT00349869|yoga
592602|NCT00349804|temperature
592603|NCT00349804|Temperature Homeostasis
592604|NCT00349791|Natural Menopause
592605|NCT00349765|cardiovascular disease
592606|NCT00349765|saturated fat
592607|NCT00349765|trans fat
592608|NCT00349765|polyunsaturated fat
592609|NCT00349765|diet
592610|NCT00349765|intramyocellular lipid
592611|NCT00349752|certolizumab pegol
592612|NCT00349752|Cimzia
592613|NCT00349752|Crohn's Disease
592614|NCT00349752|Inflammatory Bowel Disease
592615|NCT00349739|age related macular degeneration
592616|NCT00349726|NICHD Neonatal Research Network
592617|NCT00349726|Pharmacokinetics
592618|NCT00349726|Inositol
592619|NCT00349726|Very Low Birth Weight (VLBW)
592620|NCT00349726|Extremely Low Birth Weight (ELBW)
592621|NCT00349726|Prematurity
592622|NCT00349713|Plasmodium falciparum Malaria, Mali, adjuvant
592623|NCT00349700|healing
592624|NCT00349700|skin
592625|NCT00349700|infection
592626|NCT00349700|wound therapy
592627|NCT00349674|Wegener's granulomatosis,
592628|NCT00349674|microscopic polyangiitis,
592629|NCT00349674|ANCA-associated vasculitis,
592630|NCT00349674|methotrexate,
592631|NCT00349674|azathioprine
592632|NCT00349661|clopidogrel
592633|NCT00349661|omeprazole
592634|NCT00349648|subacromial
592635|NCT00349648|impingement
592636|NCT00349648|acromioplasty
592637|NCT00349648|physiotherapy
592638|NCT00349635|Weight loss and diet.
592639|NCT00349622|amyotrophic lateral sclerosis
592640|NCT00349622|ALS
592641|NCT00349622|ceftriaxone
592642|NCT00349622|cephalosporin antibiotic
592643|NCT00349622|motor neurons
592644|NCT00349596|Hypomethylating agent
592645|NCT00349596|Chemotherapy
592646|NCT00349596|Relapsed or refractory ALL
592647|NCT00349596|Acute Lymphocytic Leukemia (ALL)
592648|NCT00349570|thrombus
592649|NCT00349570|aspiration catheter
592650|NCT00349557|Prostate Cancer
592651|NCT00349557|High-Risk Prostate Cancer
592652|NCT00349557|1st line therapy
592653|NCT00349544|Neck pain
592654|NCT00349544|Cervicalgia
592655|NCT00349544|Quality of life
592656|NCT00349544|Disability
592657|NCT00349518|Chronic and Advanced Phase CML and
592658|NCT00349518|Philadelphia Chromosome Positive ALL with imatinib intolerance or resistance
592659|NCT00349505|previous treatment surgery + 6 cycles of platinum based chemotherapy
592660|NCT00349492|Small Cell Lung Cancer
592661|NCT00349492|Extensive Disease
592662|NCT00349492|Chemotherapy
592663|NCT00349492|Randomisation
592664|NCT00349479|stroke
592665|NCT00349479|tissue plasminogen activator
592666|NCT00349479|t-PA
592667|NCT00349479|barrier assessment and interactive educational intervention
592668|NCT00349479|BA-IEI
592669|NCT00349466|Keratoconjunctivitis Sicca
592670|NCT00349466|KCS
592671|NCT00349466|Dry Eye
592672|NCT00349453|Deferiprone
592673|NCT00349453|L1
592674|NCT00349453|Desferrioxamine
592675|NCT00349453|Hemochromatosis
592676|NCT00349453|Iron overload
592677|NCT00349453|Thalassemia
592678|NCT00349440|Dry eye
592679|NCT00349427|Insulin
592680|NCT00349427|BRL49653 /rosiglitazone
592681|NCT00349427|Type 2 Diabetes Mellitus
592682|NCT00349414|Advanced glaucoma
592683|NCT00349414|Refractory glaucoma
592684|NCT00349414|Cyclophotocoagulation
592685|NCT00349414|Transscleral cyclophotocoagulation
592686|NCT00349414|Micropulse transscleral cyclophotocoagulation
592687|NCT00349401|pain
592688|NCT00349401|chronic pain
592689|NCT00349401|morphine
592690|NCT00349401|ketorolac
592691|NCT00349388|Mesalamine
592692|NCT00349388|Ulcerative Colitis
592693|NCT00349375|Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin
592694|NCT00349323|Community directed treatment,
592695|NCT00349323|soil-transmitted helminth infections,
592696|NCT00349323|treatment coverage,
592697|NCT00349323|Zambia
592698|NCT00349284|Hyperlipidemia Combined and features of the metabolic syndrome, efficacy combination fenofibrate ezetimibe
592699|NCT00349271|Chagas Cardiomyopathy
592700|NCT00349271|Dilated Cardiomyopathy
592701|NCT00349271|stem cells
592702|NCT00349271|Therapeutics
592703|NCT00349271|Randomized Controlled Trials
592704|NCT00349258|OHSS
592705|NCT00349258|PCOS
592706|NCT00349258|Previous high response
592707|NCT00349258|GnRH antagonist
592708|NCT00349258|GnRH agonist
592709|NCT00349258|IVF
592710|NCT00349245|Endotracheal
592711|NCT00349245|Awake fiberoptic intubation
592712|NCT00349245|Dexmedetomidine
592713|NCT00349245|Remifentanil
592714|NCT00349232|childhood obesity
592715|NCT00349232|lifestyle intervention
592716|NCT00349232|school health program
592717|NCT00349232|special primary education
592718|NCT00349180|Total Hip Replacement
592719|NCT00349180|Enoxaparin
592720|NCT00349167|unspecified adult solid tumor, protocol specific
592721|NCT00349141|Pandemic influenza
592722|NCT00349128|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
592723|NCT00349102|Non-small-cell lung cancer
592724|NCT00349102|Breath-hold
592725|NCT00349102|Radiation pneumonitis
592726|NCT00349102|Serum cytokines
592727|NCT00349102|LENT-SOMA scale
592728|NCT00349102|Non-metastatic non-small-cell lung cancer
592729|NCT00349089|Non-small cell lung cancer
592730|NCT00349089|adjuvant therapy
592731|NCT00349089|clinical feasibility rate
592732|NCT00349050|trigeminal neuralgia
592733|NCT00349050|neuropathic pain
592734|NCT00349050|complex regional pain syndrome
592735|NCT00349050|reflex sympathetic dystrophy
592736|NCT00349050|pain
592737|NCT00349050|chronic pain
592738|NCT00349050|transcranial magnetic stimulation
592739|NCT00349050|TMS
592740|NCT00349050|laboratory pain assessment
592741|NCT00349037|DNA vaccine
592742|NCT00349037|influenza
592743|NCT00349037|immunogenicity
592744|NCT00349037|tolerability
592745|NCT00349037|PMED
592746|NCT00349037|efficacy
592747|NCT00349037|challenge virus
592748|NCT00349024|unspecified childhood solid tumor, protocol specific
592749|NCT00349024|pain
592750|NCT00349024|childhood acute lymphoblastic leukemia
592751|NCT00349024|childhood Hodgkin lymphoma
592752|NCT00349024|chondrosarcoma
592753|NCT00349024|osteosarcoma
592754|NCT00349024|childhood soft tissue sarcoma
592755|NCT00349024|Wilms tumor and other childhood kidney tumors
592756|NCT00349024|neuroblastoma
592757|NCT00349024|childhood acute myeloid leukemia/other myeloid malignancies
592758|NCT00349024|childhood large cell lymphoma
592759|NCT00349024|childhood lymphoblastic lymphoma
592760|NCT00349024|childhood small noncleaved cell lymphoma
592761|NCT00349024|childhood rhabdomyosarcoma
592762|NCT00349024|childhood brain stem glioma
592763|NCT00349024|childhood central nervous system germ cell tumor
592764|NCT00349024|childhood cerebellar astrocytoma
592765|NCT00349024|childhood cerebral astrocytoma/malignant glioma
592766|NCT00349024|childhood choroid plexus tumor
592767|NCT00349024|childhood craniopharyngioma
592768|NCT00349024|childhood ependymoma
592769|NCT00349024|childhood medulloblastoma
592770|NCT00349024|childhood meningioma
592771|NCT00349024|childhood oligodendroglioma
592772|NCT00349024|childhood atypical teratoid/rhabdoid tumor
592773|NCT00349024|childhood spinal cord neoplasm
592774|NCT00349024|childhood supratentorial primitive neuroectodermal tumor
592775|NCT00349024|childhood visual pathway and hypothalamic glioma
592776|NCT00349024|chordoma
592777|NCT00349024|mucositis
592778|NCT00349024|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
592779|NCT00349011|menopause
592780|NCT00349011|genetic counseling
592781|NCT00349011|breast cancer
592782|NCT00349011|tamoxifen
592783|NCT00349011|chemoprevention
592784|NCT00348998|adenocarcinoma of the prostate
592785|NCT00348998|stage IIB prostate cancer
592786|NCT00348998|stage IIA prostate cancer
592787|NCT00348998|stage III prostate cancer
592788|NCT00348998|stage IV prostate cancer
592789|NCT00348972|Glargine
592790|NCT00348972|prediabetes
592791|NCT00348972|impaired glucose tolerance
592792|NCT00348972|impaired fasting glucose
592793|NCT00348959|Haematological Malignancies
592794|NCT00348959|Autologous Stem Cell Transplantation
592795|NCT00348959|Allogeneic Stem Cell Transplantation
592796|NCT00348959|Quality of Life
592797|NCT00348959|Life Threatening Illness
592798|NCT00348959|Art in Health Care
592799|NCT00348959|Randomised Controlled Trial
592800|NCT00348959|Mixed Methods Research
592801|NCT00348946|Klinefelter syndrome
592802|NCT00348946|androgen
592803|NCT00348946|androgen oxandrolone
592804|NCT00348933|Developmental Delay
592805|NCT00348933|Mental Retardation
592806|NCT00348933|Ataxia
592807|NCT00348933|Microcephaly
592808|NCT00348933|Seizures
592809|NCT00348920|Aortic Valve
592810|NCT00348920|Aortic Stenosis
592811|NCT00348920|High Spinal Anesthesia
592812|NCT00348920|Total Spinal Anesthesia
592813|NCT00348920|Stress Response
592814|NCT00348920|Inflammatory Mediators
592815|NCT00348920|Renal Function
592816|NCT00348920|Hemodynamic Stability
592817|NCT00348907|doppler
592818|NCT00348907|CIVIQ quality of life
592819|NCT00348907|Hydrotherapy
592820|NCT00348907|anticoagulants
592821|NCT00348881|Diphtheria
592822|NCT00348881|Tetanus
592823|NCT00348881|Pertussis
592824|NCT00348881|Hepatitis B Hansenula (HB)
592825|NCT00348881|Haemophilus influenzae type b
592826|NCT00348868|HIV Infection
592827|NCT00348868|Opioid dependence
592828|NCT00348868|DSM-IV criteria for opioid dependence
592829|NCT00348855|High Blood Pressure
592830|NCT00348855|High cardiovascular risk
592831|NCT00348855|Type 2 diabetes
592832|NCT00348855|Reaching goals
592833|NCT00348842|Immunotherapy
592834|NCT00348829|CHF
592835|NCT00348829|mitral insufficiency
592836|NCT00348829|conductance catheter
592837|NCT00348829|mitral valve repair
592838|NCT00348816|stage I prostate cancer
592839|NCT00348816|stage IIB prostate cancer
592840|NCT00348816|stage IIA prostate cancer
592841|NCT00348816|stage III prostate cancer
592842|NCT00348816|stage IV prostate cancer
592843|NCT00348790|adult grade I meningioma
592844|NCT00348790|adult grade II meningioma
592845|NCT00348790|adult grade III meningioma
592846|NCT00348790|adult malignant hemangiopericytoma
592847|NCT00348790|adult anaplastic meningioma
592848|NCT00348790|adult papillary meningioma
592849|NCT00348790|adult melanocytic lesion
592850|NCT00348790|recurrent adult brain tumor
592851|NCT00348777|Visual analogic Scale of pain
592852|NCT00348777|Womac indice
592853|NCT00348777|SF-36 quality of life
592854|NCT00348777|Hydrotherapy
592855|NCT00348764|lauromacrogol
592856|NCT00348764|Sclerotherapy
592857|NCT00348738|radiotherapy
592858|NCT00348738|clinical trial
592859|NCT00348738|erythropoietin
592860|NCT00348738|cervix cancer
592861|NCT00348738|Phase III
592862|NCT00348738|2 Arms
592863|NCT00348725|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
592864|NCT00348686|LVH
592865|NCT00348660|Screening for Hepatitis C in Pregnancy
592866|NCT00348647|Prevention
592867|NCT00348647|Exercise
592868|NCT00348647|Overuse
592869|NCT00348647|Anterior knee pain syndrome
592870|NCT00348647|Exertional lower leg pain
592871|NCT00348647|Prospective
592872|NCT00348647|Risk factors
592873|NCT00348647|Hip
592874|NCT00348634|Constipation, Tegaserod, orocecal transit, colonic transit, gastric emptying
592875|NCT00348621|cataract surgery
592876|NCT00348621|refractive correction
592877|NCT00348621|low vision services
592878|NCT00348621|nursing home
592879|NCT00348621|visual impairment
592880|NCT00348608|Coronary
592881|NCT00348608|Angiography
592882|NCT00348608|X-ray
592883|NCT00348608|CAD
592884|NCT00348595|Prostate Cancer
592885|NCT00348569|CT
592886|NCT00348569|Coronary
592887|NCT00348569|Cardiac
592888|NCT00348569|Angiography
592889|NCT00348569|X-ray
592890|NCT00348569|CAD
592891|NCT00348569|Chest pain
592892|NCT00348543|age-related macula degeneration
592893|NCT00348543|prophylactic laser treatment
592894|NCT00348543|exudative complication
592895|NCT00348530|Systolic heart failure; Therapy; Cardiomyopathy
592896|NCT00348491|Dental surgery
592897|NCT00348491|acute pain
592898|NCT00348491|lumiracoxib
592899|NCT00348491|celecoxib
592900|NCT00348491|Moderate to severe pain following dental surgery
592901|NCT00348478|trachoma
592902|NCT00348478|chlamydia trachomatis
592903|NCT00348478|water
592904|NCT00348478|health education
592905|NCT00348478|face washing
592906|NCT00348465|Brachytherapy
592907|NCT00348465|Prostate volume
592908|NCT00348270|Cataract
592909|NCT00348270|Intraocular lens
592910|NCT00348270|Aberration
592911|NCT00348270|Wavefront
592912|NCT00348231|diabetes mellitus, biphasic insulin analogue
592913|NCT00348218|Neurovision
592914|NCT00348218|Myopia Therapy
592915|NCT00348192|Alzheimer's Disease
592916|NCT00348192|cognition global functioning
592917|NCT00348192|symptomatic
592918|NCT00348192|SB-742457
592919|NCT00348179|Vascular abnormalities
592920|NCT00348179|Type 1 diabetes
592921|NCT00348179|Healthy control subjects
592922|NCT00348153|Uveitis
592923|NCT00348153|Adalimumab
592924|NCT00348153|TNF alpha
592925|NCT00348140|adjunctive therapy
592926|NCT00348140|moderate
592927|NCT00348140|Alzheimer's disease
592928|NCT00348140|apolipoprotein E
592929|NCT00348140|mild
592930|NCT00348140|rosiglitazone
592931|NCT00348140|cognition
592932|NCT00348127|Neurovision
592933|NCT00348127|Myopia Therapy
592934|NCT00348114|autologous
592935|NCT00348114|transplantation ex-vivo expanded limbal epithelium
592936|NCT00348114|limbal deficiency
592937|NCT00348101|Patients undergoing major vascular surgery having documented CAD or risk factors for CAD
592938|NCT00348088|Metastatic
592939|NCT00348088|Melanoma
592940|NCT00348088|Untreated
592941|NCT00348088|Biomarker
592942|NCT00348075|Neurovision
592943|NCT00348075|Adult myopia
592944|NCT00348075|Therapy
592945|NCT00348049|LASIK
592946|NCT00348049|PRK
592947|NCT00348049|Myopia
592948|NCT00348036|Major Depression
592949|NCT00348036|Trauma
592950|NCT00348036|Primary Care
592951|NCT00348036|Low-Income Patients
592952|NCT00348010|osteoarthritis
592953|NCT00348010|knee pain
592954|NCT00348010|extended release analgesia
592955|NCT00348010|opioid
592956|NCT00347971|Lymphoma, Non-Hodgkin
592957|NCT00347971|interleukin-21
592958|NCT00347971|rituximab
592959|NCT00347971|Immunotherapy
592960|NCT00347958|Tetanus,
592961|NCT00347958|Diphtheria,
592962|NCT00347958|Pertussis
592963|NCT00347945|convergence insufficiency, vision therapy, orthoptics
592964|NCT00347919|GW786034
592965|NCT00347919|Quality of Life
592966|NCT00347919|GW572016
592967|NCT00347919|Lapatinib
592968|NCT00347919|Pazopanib
592969|NCT00347919|Metastatic
592970|NCT00347919|Breast cancer
592971|NCT00347919|Genetics
592972|NCT00347919|FISH
592973|NCT00347919|Advanced
592974|NCT00347893|Primary open angle glaucoma
592975|NCT00347893|Ocular hypertension
592976|NCT00347893|Pseudo-exfoliative glaucoma
592977|NCT00347893|Pigment Dispersion glaucoma
592978|NCT00347893|selective laser trabeculoplasty
592979|NCT00347893|intraocular pressure
592980|NCT00347880|Bronchiolitis
592981|NCT00347880|ANP
592982|NCT00347880|BNP
592983|NCT00347880|Atrial Natriuretic Peptide
592984|NCT00347880|Brain Natriuretic Peptide
592985|NCT00347880|Vasopressin
592986|NCT00347880|ADH
592987|NCT00347880|Pediatric
592988|NCT00347880|Respiratory Distress
592989|NCT00347880|Fluid Balance
592990|NCT00347867|IUGR
592991|NCT00347867|PET
592992|NCT00347867|Pregnancy
592993|NCT00347867|Viagra
592994|NCT00347867|Sildenafil citrate
592995|NCT00347854|Normal, healthy eyes (other than correction for visual acuity)
592996|NCT00347828|Antibiotic prophylaxis
592997|NCT00347828|Vigamox
592998|NCT00347828|Moxifloxacin
592999|NCT00347828|Zymar
593000|NCT00347828|Gatifloxacin
593001|NCT00347828|Preoperative antibiotic
593002|NCT00347828|Eye infection
593003|NCT00347789|glaucoma
593004|NCT00347789|trabeculectomy
593005|NCT00347789|filtering bleb revision
593006|NCT00347789|intraocular pressure
593007|NCT00347789|needling procedure
593008|NCT00347789|mitomycin C
593009|NCT00347776|trichiasis
593010|NCT00347776|azithromycin
593011|NCT00347776|trichiasis surgery
593012|NCT00347776|topical tetracycline
593013|NCT00347763|trachoma
593014|NCT00347763|chlamydia
593015|NCT00347763|flies
593016|NCT00347763|permethrin
593017|NCT00347750|Lopinavir
593018|NCT00347750|Pharmacokinetic
593019|NCT00347750|Pharmacodynamic
593020|NCT00347750|Ethiopian population
593021|NCT00347750|Caucasian population
593022|NCT00347724|chronic low back pain; chronic pain; low back pain; extended-release analgesia; opioid
593023|NCT00345800|Endocrine Evaluation cataplexy
593024|NCT00345800|sodium oxybate (xyrem)
593025|NCT00345787|Osteoarthritic Pain
593026|NCT00345774|Pulmonary Hypertension
593027|NCT00345774|PH
593028|NCT00345774|Pulmonary Arterial Hypertension
593029|NCT00345774|PAH
593030|NCT00345774|Chronic Obstructive Pulmonary Disease
593031|NCT00345774|COPD
593032|NCT00345774|PRX-08066
593033|NCT00345774|Predix
593034|NCT00345761|Advanced and/or metastatic colorectal cancer
593035|NCT00345735|Cancer pain with breakthrough pain episodes
593036|NCT00345722|Strawberry
593037|NCT00345722|Almond
593038|NCT00345722|Soy protein
593039|NCT00345722|viscous dietary fibre
593040|NCT00345722|plant sterols
593041|NCT00345722|portfolio diet
593042|NCT00345722|blood lipids
593043|NCT00345722|compliance
593044|NCT00345722|blood pressure
593045|NCT00345709|Ovarian Cancer
593046|NCT00345709|Peritoneal Cancer
593047|NCT00345709|Fallopian Tube Cancer
593048|NCT00345709|Elizabeth Registry
593049|NCT00345709|Questionnaire
593050|NCT00345709|Registry
593051|NCT00345709|Survey
593052|NCT00347698|diabetic retinopathy
593053|NCT00347698|bevacizumab
593054|NCT00347698|photocoagulation
593055|NCT00347685|chronic non-malignant pain; chronic pain; non-malignant
593056|NCT00347685|pain; moderate pain; severe pain
593057|NCT00347672|Bird Flu
593058|NCT00347659|Lung volume reduction
593059|NCT00347659|Bronchoscopy
593060|NCT00347659|Emphysema
593061|NCT00347659|COPD
593062|NCT00347659|NETT
593063|NCT00347659|Lung disease
593064|NCT00347659|COLD
593065|NCT00347659|BLVR
593066|NCT00347607|trachoma
593067|NCT00347607|chlamydia trachomatis
593068|NCT00347607|surveillance
593069|NCT00347607|azithromycin
593070|NCT00347594|Corneal surface topography
593071|NCT00347594|Ocular aberrations
593072|NCT00347581|convergence insufficiency
593073|NCT00347581|base-in prism
593074|NCT00347581|orthoptics
593075|NCT00347581|vision therapy
593076|NCT00347568|decision aids
593077|NCT00347568|high risk
593078|NCT00347568|breast cancer
593079|NCT00347568|breast cancer prevention
593080|NCT00347555|malaria, falciparum, Plasmodium falciparum malaria, vaccine
593081|NCT00347542|Vitamin D
593082|NCT00347542|Diabetes
593083|NCT00347542|Insulin sensitivity
593084|NCT00347542|Obesity
593085|NCT00347529|DNA vaccine, influenza, immunogenicity, tolerability, PMED, pandemic
593086|NCT00347516|IOL formula
593087|NCT00347516|High myopia
593088|NCT00347516|axial length
593089|NCT00347477|cardiac arrest
593090|NCT00347477|hypothermia
593091|NCT00347477|neurologic outcome
593092|NCT00347477|edema
593093|NCT00347464|Kleinfelter
593094|NCT00347451|myopia
593095|NCT00347451|optical coherence tomography
593096|NCT00347438|breast cancer
593097|NCT00347438|neoadjuvant
593098|NCT00347438|locally advanced
593099|NCT00347425|Switch Study
593100|NCT00347425|Schizophrenia
593101|NCT00347425|Atypical Antipsychotics
593102|NCT00347412|NSCLC
593103|NCT00347412|Stage IIIb
593104|NCT00347412|Stage IV
593105|NCT00347412|Non Small Cell Lung Cancer (NSCLC)
593106|NCT00347412|NSCLC Stage IIIb with malignant pleural/pericardial effusion
593107|NCT00347412|NSCLC Stage IV
593108|NCT00347399|macular degeneration
593109|NCT00347399|antibodies
593110|NCT00347399|angiogenesis inhibitor
593111|NCT00347386|Infants
593112|NCT00347386|India
593113|NCT00347386|Zinc
593114|NCT00347386|Bacterial illness
593115|NCT00347386|Treatment
593116|NCT00347373|conjugated linoleic acid
593117|NCT00347373|obesity
593118|NCT00347373|body composition
593119|NCT00347373|body fat mass
593120|NCT00347373|lean body mass
593121|NCT00347360|carvedilol
593122|NCT00347360|hypertension
593123|NCT00347360|lisinopril
593124|NCT00347360|factorial
593125|NCT00347334|Torticollis
593126|NCT00347334|infant home positioning
593127|NCT00347334|head control
593128|NCT00347321|Percutaneous tracheostomy
593129|NCT00347321|Endotracheal intubation
593130|NCT00347321|Mechanical ventilation
593131|NCT00347321|Cardiac surgery
593132|NCT00347321|Ventilator-free days
593133|NCT00347308|brow ptosis, facial aesthetics, browlift, facelift
593134|NCT00347282|Post enucleation socket syndrome
593135|NCT00347282|Multi-slice computed tomography scan
593136|NCT00347282|Prospective studies
593137|NCT00347282|Tomography, X Ray Computed
593138|NCT00347269|Anxiety Disorders
593139|NCT00347269|Post-traumatic Stress Disorder
593140|NCT00347269|Generalized Anxiety Disorder
593141|NCT00347269|Panic Disorder
593142|NCT00347269|Social Anxiety Disorder
593143|NCT00347269|Stress
593144|NCT00347269|Stress Disorders, Traumatic
593145|NCT00347269|Stress Disorders, Post-Traumatic
593146|NCT00347269|Mental Health Disorders
593147|NCT00347230|Intacs ring segments
593148|NCT00347230|Keratoconus
593149|NCT00347217|Cholesterol
593150|NCT00347217|rosuvastatin
593151|NCT00347217|LDL-C goal
593152|NCT00347217|observational study
593153|NCT00347217|primary prevention
593154|NCT00347217|secondary prevention
593155|NCT00347204|PRK
593156|NCT00347204|laser vision correction
593157|NCT00347204|surface ablation
593158|NCT00347204|pain
593159|NCT00347204|wound healing
593160|NCT00347204|corneal haze
593161|NCT00347191|Corneal thickness
593162|NCT00347191|Intraocular pressure
593163|NCT00347191|Instrumentation
593164|NCT00347191|Glaucoma
593165|NCT00347191|Keratoconus
593166|NCT00347178|Asymptomatic Narrow Angles
593167|NCT00347178|Primary Angle Closure Suspects
593168|NCT00347178|Laser Peripheral Iridotomy
593169|NCT00347178|Randomised Controlled Trial
593170|NCT00347165|macular degeneration
593171|NCT00347165|angiogenesis
593172|NCT00347165|antibodies
593173|NCT00347152|Intellectual disabilities
593174|NCT00347152|development disabilities
593175|NCT00347152|behavior disorders
593176|NCT00347152|stable epilepsy
593177|NCT00347139|Tolerability
593178|NCT00347139|Pharmacodynamics
593179|NCT00347139|Safety
593180|NCT00347139|Pharmacokinetics
593181|NCT00347139|GW642444
593182|NCT00347139|Asthmatic patients
593183|NCT00347139|Efficacy
593184|NCT00347126|Glaucoma
593185|NCT00347126|Latanoprost
593186|NCT00347126|Travoprost
593187|NCT00347126|Intraocular pressure
593188|NCT00347126|Hyperemia
593189|NCT00347113|P. falciparum
593190|NCT00347113|malaria
593191|NCT00347113|schistosome infections
593192|NCT00347113|soil-transmitted helminths infection
593193|NCT00347113|anaemia
593194|NCT00347113|immune response
593195|NCT00347113|Tanzania
593196|NCT00347087|Insulin sensitivity
593197|NCT00347087|chronic heart failure
593198|NCT00347087|metabolism
593199|NCT00347074|Keratoconus, corneal topography, ocular aberrometry, visual outcome, contact lens wear, quality of life
593200|NCT00347061|Benign Prostatic Hyperplasiam
593201|NCT00347061|Adrenergic alpha-antagonist
593202|NCT00347048|Ulcerative colitis
593203|NCT00347048|tacrolimus
593204|NCT00347048|FK506
593205|NCT00347048|treatment outcome
593206|NCT00347022|Multislice computed tomography (MSCT)indications
593207|NCT00347009|Cirrhosis
593208|NCT00347009|Advanced Fibrosis
593209|NCT00347009|Chronic Hepatitis B
593210|NCT00347009|Adefovir Dipivoxil
593211|NCT00346996|diabetes
593212|NCT00346996|insulin
593213|NCT00346996|insulin analogues
593214|NCT00346996|hypoglycaemia
593215|NCT00346996|severe hypoglycaemia
593216|NCT00346970|Metabolic Syndrome
593217|NCT00346970|High Density Lipoprotein
593218|NCT00346970|Extended-Release Niacin
593219|NCT00346970|Endothelial Function
593220|NCT00346970|Endothelial Progenitor Cells
593221|NCT00346931|glaucoma
593222|NCT00346931|cataract
593223|NCT00346931|surgery
593224|NCT00346931|intraocular pressure
593225|NCT00346931|phacoemulsification
593226|NCT00346931|trabeculotomy
593227|NCT00346918|ADPKD
593228|NCT00346918|autosomal dominant polycystic kidney disease
593229|NCT00346918|Sirolimus
593230|NCT00346918|volumetry
593231|NCT00346905|GERD
593232|NCT00346905|Gastroesophageal Reflux Disease
593233|NCT00346905|Reflux
593234|NCT00346905|Enteryx
593235|NCT00346892|Prophylaxis rotavirus
593236|NCT00346879|fondaparinux for prevention of blood clots
593237|NCT00346853|Dark adaptation inhibition
593238|NCT00346853|Stargardt macular dystrophy
593239|NCT00346853|4-Methylpyrazole (4-MP)
593240|NCT00346853|Antizol
593241|NCT00346853|Fomepizole
593242|NCT00346840|Labor induction
593243|NCT00346840|cervical ripening
593244|NCT00346840|misoprostol
593245|NCT00346840|vaginal insert
593246|NCT00345696|Capecitabine
593247|NCT00345696|Oxaliplatin
593248|NCT00345696|Bevacizumab
593249|NCT00345696|First line
593250|NCT00345683|H. influenzae type B vaccine
593251|NCT00345683|Infants
593252|NCT00345683|Neisseria meningitidis
593253|NCT00345683|Vaccines, conjugate
593254|NCT00345683|Meningococcal vaccines
593255|NCT00345683|Prophylaxis
593256|NCT00345683|Comparative study
593257|NCT00345683|Safety
593258|NCT00345683|Humans
593259|NCT00345670|Lower respiratory tract illness
593260|NCT00345670|RSV and PIV3 infection
593261|NCT00345657|Hyperlipidemia
593262|NCT00345657|Dyslipidemia
593263|NCT00345657|Niacin
593264|NCT00345657|Hydroxymethylglutaryl-CoA Reductase Inhibitors
593265|NCT00345657|Combination lipid therapy
593266|NCT00345657|Lovastatin
593267|NCT00345644|Postmenopausal
593268|NCT00345631|Closure Device
593269|NCT00345631|Angiography
593270|NCT00345631|Angioplasty
593271|NCT00345631|Hemostasis
593272|NCT00345631|Heart Catheterization
593273|NCT00345631|Peripheral Angiography
593274|NCT00345631|Femoral Closure
593275|NCT00345631|Vascular Closure
593276|NCT00345631|Coronary Angiography
593277|NCT00345618|Deep venous thrombosis
593278|NCT00345618|pulmonary embolism
593279|NCT00345618|anticoagulant drugs
593280|NCT00345605|Argininosuccinic Acid Lyase Deficiency
593281|NCT00345605|ASA
593282|NCT00346814|Retinopathy of prematurity
593283|NCT00346814|antiangiogenic therapy
593284|NCT00346801|Non-Small Cell Lung Cancer
593285|NCT00346801|Lung Cancer
593286|NCT00346801|Celecoxib
593287|NCT00346801|Cisplatin
593288|NCT00346801|Platinol
593289|NCT00346801|CPT-11
593290|NCT00346801|Irinotecan
593291|NCT00346801|SC-58635
593292|NCT00346801|Celebrex
593293|NCT00346801|Radiation Therapy
593294|NCT00346775|questionnaire
593295|NCT00346775|nasal spray
593296|NCT00346775|Seasonal allergic rhinitis
593297|NCT00346775|nasal spray questionnaire
593298|NCT00346775|allergic rhinitis
593299|NCT00346762|Former Plasma Donors
593300|NCT00346762|Commercial Plasma Donors
593301|NCT00346762|Long-Term Nonprogressors
593302|NCT00346762|Host Factors
593303|NCT00346762|Viral Factors
593304|NCT00346762|HIV
593305|NCT00346749|Inflammation
593306|NCT00346749|FEV1
593307|NCT00346749|Sputum
593308|NCT00346736|Alternative medicine
593309|NCT00346736|Traditional Chinese medicine
593310|NCT00346736|Acupuncture
593311|NCT00346736|Autistic Spectrum Disorder
593312|NCT00346736|Autism
593313|NCT00346736|Children
593314|NCT00346723|Influenza, Vaccine, CHMP criteria
593315|NCT00346710|communication
593316|NCT00346710|patient experience
593317|NCT00346710|fellowship training
593318|NCT00346697|AIDS
593319|NCT00346697|HIV
593320|NCT00346697|HAART
593321|NCT00346697|Lipids
593322|NCT00346697|Triglycerides
593323|NCT00346697|Cholesterol
593324|NCT00346697|omega-3 fatty acids
593325|NCT00346697|bone turnover
593326|NCT00346697|inflammation
593327|NCT00346697|insulin resistance
593328|NCT00346684|Lymphoma
593329|NCT00346684|LPHD
593330|NCT00346684|Rituximab
593331|NCT00346671|Reiki
593332|NCT00346671|Stress
593333|NCT00346671|CAM
593334|NCT00346658|Osteoporosis
593335|NCT00346658|bone density
593336|NCT00346658|magnesium
593337|NCT00346658|vitamin D
593338|NCT00346645|NON-SMALL CELL LUNG CANCER METASTATIC
593339|NCT00346632|AML
593340|NCT00346632|ALL
593341|NCT00346632|MDS
593342|NCT00346632|CML
593343|NCT00346632|Kinase Inhibitor
593344|NCT00346606|Chronic Idiopathic Urticaria
593345|NCT00346606|Desloratadine
593346|NCT00346606|Denosin
593347|NCT00346606|Levocetirizine
593348|NCT00346567|mother-to-child-transmission
593349|NCT00346567|PMTCT
593350|NCT00346567|HIV
593351|NCT00346567|resistance
593352|NCT00346567|NNRTI
593353|NCT00346554|COPD
593354|NCT00346554|Sleep disorders
593355|NCT00346554|pulmonary rehabilitation
593356|NCT00346541|glaucoma
593357|NCT00346541|polymorphism, genetic
593358|NCT00346515|carotid artery
593359|NCT00346515|carotid stenosis
593360|NCT00346515|carotid stenting
593361|NCT00346515|embolic protection
593362|NCT00346489|Trabeculectomy
593363|NCT00346489|5-fluorouracil
593364|NCT00346489|Mitomycin C
593365|NCT00346476|TB
593366|NCT00346476|Transmission
593367|NCT00346476|Genetic Diversity
593368|NCT00346476|Genetic Testing
593369|NCT00346476|RFLP
593370|NCT00346463|Allopurinol
593371|NCT00346463|Fetal Growth Retardation
593372|NCT00346463|Oxidative Stress
593373|NCT00346463|Placental Insufficiency
593374|NCT00346450|Culture
593375|NCT00346450|Conjunctiva
593376|NCT00346450|transplantation
593377|NCT00346450|pterygium
593378|NCT00346450|ocular surface
593379|NCT00346437|angina
593380|NCT00346437|FGF-4
593381|NCT00346437|angiogenesis
593382|NCT00346437|adenovector
593383|NCT00346437|growth factor
593384|NCT00346437|myocardial ischemia
593385|NCT00346437|revascularization
593386|NCT00346424|occluded central catheter
593387|NCT00346424|central venous access devices dysfunction
593388|NCT00346424|withdrawal occlusion
593389|NCT00346424|Thrombosis
593390|NCT00346424|Venous thrombosis
593391|NCT00346411|rheumatoid arthritis
593392|NCT00346411|mood
593393|NCT00346411|adherence
593394|NCT00346411|medication
593395|NCT00346398|asthma
593396|NCT00346398|allergen
593397|NCT00346398|allergic disease
593398|NCT00346398|allergen immunotherapy
593399|NCT00346398|allergic sensitization
593400|NCT00346398|atopic dermatitis
593401|NCT00346398|eczema
593402|NCT00346398|food allergy
593403|NCT00346398|oral mucosal immunoprophylaxis (OMIP)
593404|NCT00346385|recurrent small cell lung cancer
593405|NCT00346385|merkel cell carcinoma
593406|NCT00346385|ovarian cancer
593407|NCT00346372|Ocular Melanoma
593408|NCT00346372|Optical Coherence Tomography
593409|NCT00346372|Eye Tumor
593410|NCT00346372|Choroidal Melanoma
593411|NCT00346372|Uveal Melanoma
593412|NCT00346359|graft versus host disease
593413|NCT00346359|chronic phase chronic myelogenous leukemia
593414|NCT00346359|childhood chronic myelogenous leukemia
593415|NCT00346359|blastic phase chronic myelogenous leukemia
593416|NCT00346359|accelerated phase chronic myelogenous leukemia
593417|NCT00346359|relapsing chronic myelogenous leukemia
593418|NCT00346359|adult acute myeloid leukemia in remission
593419|NCT00346359|recurrent adult acute myeloid leukemia
593420|NCT00346359|childhood acute myeloid leukemia in remission
593421|NCT00346359|recurrent childhood acute myeloid leukemia
593422|NCT00346359|de novo myelodysplastic syndromes
593423|NCT00346359|previously treated myelodysplastic syndromes
593424|NCT00346359|secondary myelodysplastic syndromes
593425|NCT00346359|atypical chronic myeloid leukemia
593426|NCT00346359|chronic myelomonocytic leukemia
593427|NCT00346359|juvenile myelomonocytic leukemia
593428|NCT00346359|myelodysplastic/myeloproliferative disease, unclassifiable
593429|NCT00346359|secondary acute myeloid leukemia
593430|NCT00346359|chronic eosinophilic leukemia
593431|NCT00346359|chronic idiopathic myelofibrosis
593432|NCT00346359|chronic neutrophilic leukemia
593433|NCT00346359|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
593434|NCT00346359|adult acute myeloid leukemia with inv(16)(p13;q22)
593435|NCT00346359|adult acute myeloid leukemia with t(15;17)(q22;q12)
593436|NCT00346359|adult acute myeloid leukemia with t(16;16)(p13;q22)
593437|NCT00346359|adult acute myeloid leukemia with t(8;21)(q22;q22)
593438|NCT00346359|childhood myelodysplastic syndromes
593439|NCT00346346|Immunity
593440|NCT00346346|Memory
593441|NCT00346346|ELISPOT
593442|NCT00346346|Malaria
593443|NCT00346346|Prospective
593444|NCT00346333|Retinitis Pigmentosa, Inherited Retinal Degeneration
593445|NCT00346320|stage I non-small cell lung cancer
593446|NCT00346320|stage II non-small cell lung cancer
593447|NCT00346320|adenocarcinoma of the lung
593448|NCT00346320|adenosquamous cell lung cancer
593449|NCT00346320|bronchoalveolar cell lung cancer
593450|NCT00346320|large cell lung cancer
593451|NCT00346320|squamous cell lung cancer
593452|NCT00346294|Rheumatoid Arthritis
593453|NCT00346294|Device
593454|NCT00346294|Auto-injector
593455|NCT00346294|SureClick
593456|NCT00346294|Enbrel
593457|NCT00346294|Etanercept
593458|NCT00346281|unresectable pancreatic cancer
593459|NCT00346281|brachytherapy
593460|NCT00346281|32P
593461|NCT00346281|BioSilicon
593462|NCT00346281|locally advanced
593463|NCT00346281|gemcitabine
593464|NCT00346281|intratumourally
593465|NCT00346281|unresectable
593466|NCT00346255|stage I multiple myeloma
593467|NCT00346255|stage II multiple myeloma
593468|NCT00346255|stage III multiple myeloma
593469|NCT00346242|thalassemia
593470|NCT00346242|zoledronic acid
593471|NCT00346242|skeletal events
593472|NCT00346229|stage III B breast cancer
593473|NCT00346229|stage III C breast cancer
593474|NCT00346229|stage IV breast cancer
593475|NCT00346229|inflammatory breast cancer
593476|NCT00346229|recurrent breast cancer
593477|NCT00346177|heart
593478|NCT00346177|stem Cells
593479|NCT00346177|low EF
593480|NCT00346177|heart attack
593481|NCT00346177|cardiomyopathy
593482|NCT00346177|congestive heart failure
593483|NCT00346177|cardiovascular disease
593484|NCT00346177|Heart Failure
593485|NCT00346177|Low Ejection Fraction
593486|NCT00346151|renal transplantation
593487|NCT00346151|kidney transplantation
593488|NCT00346151|renal allograft recipient
593489|NCT00346151|anti-rejection drugs
593490|NCT00346151|immunosuppression protocol
593491|NCT00346151|immunosuppression withdrawal
593492|NCT00346125|soft tissue sarcoma
593493|NCT00346125|Malignant fibrous histiocytoma
593494|NCT00346125|Liposarcoma
593495|NCT00346125|Fibrosarcoma
593496|NCT00346125|Leiomyosarcoma
593497|NCT00346125|Synovial sarcoma
593498|NCT00346125|Malignant peripheral nerve sheath tumor (MPNST)
593499|NCT00346125|Epithelioid sarcoma
593500|NCT00346112|ICD
593501|NCT00346112|distress
593502|NCT00346112|anxiety
593503|NCT00346112|quality-of-life
593504|NCT00346099|NSABP
593505|NCT00346099|panitumumab
593506|NCT00346099|rectal cancer
593507|NCT00346099|colorectal cancer
593508|NCT00346099|oxaliplatin
593509|NCT00346099|capecitabine
593510|NCT00346099|combined modality therapy
593511|NCT00346099|combined pelvic radiation therapy
593512|NCT00346099|Rectal cancer with or without metastasis
593513|NCT00346086|CpG oligonucleotide vaccine
593514|NCT00346086|ragweed immunotherapy
593515|NCT00346073|Prophylaxis for diphtheria, tetanus, pertussis
593516|NCT00346073|Immunogenicity, booster, dTpa
593517|NCT00346060|Dry age related macular degeneration.
593518|NCT00346060|Retinal Transplant
593519|NCT00346060|Fetal Tissue
593520|NCT00346060|Early treatment diabetic retinopathy study
593521|NCT00346060|20/200 or worse.
593522|NCT00346021|Children's behavior towards hat use
593523|NCT00346008|melanoma
593524|NCT00346008|recurrent melanoma
593525|NCT00346008|stage I melanoma
593526|NCT00346008|stage II melanoma
593527|NCT00346008|stage III melanoma
593528|NCT00346008|stage IV melanoma
593529|NCT00345982|Schizophrenia
593530|NCT00345982|Treatment-resistant
593531|NCT00345982|sertindole
593532|NCT00345982|clozapine
593533|NCT00345969|Testosterone Replacement Therapy
593534|NCT00345969|Physical Frailty
593535|NCT00345969|Hip Fracture
593536|NCT00345956|Prophylaxis against gastroenteritis caused by Rotavirus
593537|NCT00345943|Eating Disorders
593538|NCT00345943|Bulimia Nervosa
593539|NCT00345943|Bulimia
593540|NCT00345943|fMRI
593541|NCT00345943|Magnetic Resonance Imaging
593542|NCT00345930|Complementary and alternative medicine
593543|NCT00345930|Complementary therapies
593544|NCT00345930|Alternative therapies
593545|NCT00345930|Prescription Drugs
593546|NCT00345930|Non prescription Drugs
593547|NCT00345930|Liver Disease
593548|NCT00345930|Chemical Ind
593549|NCT00345930|Phenotype
593550|NCT00345930|Proteomics
593551|NCT00345930|Metabolomics
593552|NCT00345930|Cholestatic Liver Injury
593553|NCT00345930|Hepatocellular Liver Injury
593554|NCT00345930|Mixed Liver Injury
593555|NCT00345930|Matched Case Control Studies
593556|NCT00345930|Genotype
593557|NCT00345930|Liver Dis
593558|NCT00345930|Chem Ind
593559|NCT00345917|Retinitis Pigmentosa
593560|NCT00345917|Retinal Transplant
593561|NCT00345917|Fetal Tissue
593562|NCT00345917|Early treatment diabetic retinopathy study
593563|NCT00345917|20/200 or worse.
593564|NCT00345904|influenza, vaccine
593565|NCT00345904|prophylaxis of influenza
593566|NCT00345891|Lung neoplasms
593567|NCT00345891|Family
593568|NCT00345891|Stress
593569|NCT00345878|HPV-16/18 L1 VLP AS04
593570|NCT00345878|Cervical neoplasia
593571|NCT00345878|Cervical cancer
593572|NCT00345878|Human Papillomavirus (HPV)
593573|NCT00345878|Double-blind
593574|NCT00345878|AS04
593575|NCT00345865|Hodgkin lymphoma
593576|NCT00345865|non-Hodgkin lymphoma
593577|NCT00345865|HIV-associated lymphoma
593578|NCT00345852|twin to twin transfusion syndrome
593579|NCT00345852|fetoscopic selective laser photocoagulation
593580|NCT00345852|amnioreduction
593581|NCT00345839|Cinacalcet HCl
593582|NCT00345839|Cinacalcet
593583|NCT00345839|AMG 073
593584|NCT00345839|Sensipar
593585|NCT00345839|Mimpara
593586|NCT00345839|Calcimimetic
593587|NCT00345839|Hemodialysis
593588|NCT00345839|CKD
593589|NCT00345839|Secondary hyperparathyroidism (HPT)
593590|NCT00345826|accelerated phase chronic myelogenous leukemia
593591|NCT00345826|blastic phase chronic myelogenous leukemia
593592|NCT00345826|chronic phase chronic myelogenous leukemia
593593|NCT00345826|relapsing chronic myelogenous leukemia
593594|NCT00345826|recurrent adult acute lymphoblastic leukemia
593595|NCT00345826|chronic myelogenous leukemia, BCR-ABL1 positive
593596|NCT00345813|adenocarcinoma of the prostate
593597|NCT00345813|stage I prostate cancer
593598|NCT00345813|stage IIB prostate cancer
593599|NCT00345813|stage IIA prostate cancer
593600|NCT00345813|stage III prostate cancer
593601|NCT00345813|stage IV prostate cancer
593602|NCT00345579|Prophylaxis
593603|NCT00345579|Neisseria meningitidis Vaccines, conjugate
593604|NCT00345579|Infants
593605|NCT00345579|Meningococcal vaccines
593606|NCT00345579|H. influenzae type B vaccine
593607|NCT00345579|Humans
593608|NCT00345579|Safety
593609|NCT00345566|cerebral palsy
593610|NCT00345566|protein composition
593611|NCT00345566|gastric emptying rate
593612|NCT00345566|tube feeding
593613|NCT00345553|Biliary Atresia
593614|NCT00345553|Cholestasis
593615|NCT00345540|Platinum Resistant Tumors of Ovarian Origin
593616|NCT00345527|Problem gambling
593617|NCT00345527|Clinically significant anger
593618|NCT00345514|Children
593619|NCT00345514|Self-efficacy
593620|NCT00345514|Organization
593621|NCT00345514|Process of care
593622|NCT00345501|contrast media
593623|NCT00345501|contrast nephropathy
593624|NCT00345475|Birth Defects
593625|NCT00345475|Epilepsy
593626|NCT00345475|High Risk Pregnancy
593627|NCT00345462|Influenza, Vaccine, CHMP criteria
593628|NCT00345449|cystic fibrosis,
593629|NCT00345449|lung disease,
593630|NCT00345449|lung transplantation,
593631|NCT00345449|decision aid
593632|NCT00345436|Insulin Sensitivity
593633|NCT00345436|Moderate intensity
593634|NCT00345436|Insulin Resistance
593635|NCT00345436|Exercise Intervention
593636|NCT00345410|obesity and dyslipidemia
593637|NCT00345397|cecostomy
593638|NCT00345397|colonoscopy
593639|NCT00345397|colostomy
593640|NCT00345397|constipation
593641|NCT00345397|endoscopy, gastrointestinal
593642|NCT00345397|fecal incontinence
593643|NCT00345397|percutaneous
593644|NCT00345397|quality of life
593645|NCT00345397|spinal cord injury
593646|NCT00345384|Dexmedetomidine
593647|NCT00345384|Sedation
593648|NCT00345384|Opioid
593649|NCT00345384|Respiratory depression
593650|NCT00345358|Booster vaccination
593651|NCT00345358|Catch-up vaccination
593652|NCT00345358|Pneumococcal vaccine
593653|NCT00345358|Immunogenicity
593654|NCT00345358|Safety
593655|NCT00345358|Pneumococcal disease
593656|NCT00345345|Neutropenia
593657|NCT00345345|Monoclonal Antibody Therapy
593658|NCT00345345|Anti-CD52
593659|NCT00345345|T-LGL Leukemia
593660|NCT00345345|LGL Leukemia
593661|NCT00345345|Anemia
593662|NCT00345345|Immunosuppression
593663|NCT00345345|Chronic T Cell Lymphocytosis with Neutropenia
593664|NCT00345345|Leukemia
593665|NCT00345319|rabies
593666|NCT00345319|vaccine
593667|NCT00345319|post-exposure prophylaxis
593668|NCT00345306|endometrial preparation
593669|NCT00345306|Utrogestan
593670|NCT00345306|Endometrin
593671|NCT00345293|Prostate Cancer
593672|NCT00345280|Cystic fibrosis
593673|NCT00345280|eye
593674|NCT00345280|inflammation
593675|NCT00345280|apoptosis
593676|NCT00345280|C11+
593677|NCT00345267|Asthma
593678|NCT00345267|Children
593679|NCT00345267|Integrated Care Pathway
593680|NCT00345267|Evidence based medicine
593681|NCT00345267|Prescribing errors
593682|NCT00345241|Blepharitis
593683|NCT00345228|High myopia
593684|NCT00345228|Choroidal neovascularisation
593685|NCT00345228|Lacquer crack
593686|NCT00345228|Fundus fluorescein angiography
593687|NCT00345228|Indocyanine green angiography
593688|NCT00345228|Axial length
593689|NCT00345215|Urinary Aquaporin 2
593690|NCT00345215|High/low Sodium Diet
593691|NCT00345215|Fractional Sodium Excretion
593692|NCT00345202|HMG-COA reductase inhibition
593693|NCT00345202|GFR
593694|NCT00345202|RPF
593695|NCT00345202|FE
593696|NCT00345202|CL
593697|NCT00345189|Hsp90 inhibitor
593698|NCT00345189|CNF2024
593699|NCT00345189|Advanced Solid Tumors
593700|NCT00345176|age-related macular degeneration
593701|NCT00345176|AMD
593702|NCT00345176|lutein
593703|NCT00345176|zeaxanthin
593704|NCT00345176|docosahexaenoic acid
593705|NCT00345176|eicosapentaenoic acid
593706|NCT00345163|Glioblastoma Multiforme
593707|NCT00345163|Avastin
593708|NCT00345163|Brain Cancer
593709|NCT00345163|GBM
593710|NCT00345150|hypertension
593711|NCT00345150|nitric oxide
593712|NCT00345150|renal hemodynamics
593713|NCT00345137|Renal hemodynamics
593714|NCT00345137|Nitric oxide
593715|NCT00345124|urinary aquaporin-2
593716|NCT00345124|ENaC
593717|NCT00345124|fractional sodium excretion
593718|NCT00345124|High/low sodium diet
593719|NCT00345111|Restor IOL versus Conventional IOL
593720|NCT00345098|Depression, Antidepressive agents
593721|NCT00345098|Clinical Trial
593722|NCT00345098|Phase III
593723|NCT00345098|Multicenter study
593724|NCT00345072|Menopause
593725|NCT00345072|Decision aids
593726|NCT00345072|Internet
593727|NCT00345072|Hormone Replacement Therapy
593728|NCT00345072|Breast Cancer
593729|NCT00345072|Cardiovascular Disease
593730|NCT00345072|Osteoporosis
593731|NCT00345059|second line
593732|NCT00345059|monochemotherapy
593733|NCT00345059|combination chemotherapy
593734|NCT00345059|platinum refractory
593735|NCT00345059|previously treated
593736|NCT00345046|Glaucoma
593737|NCT00345046|Cataract
593738|NCT00345033|Glucose Metabolism
593739|NCT00345020|Deep Lamellar Endotheliam Keratoplasty
593740|NCT00345007|Retinal detachment
593741|NCT00345007|Macular function
593742|NCT00345007|Multifocal electrophysiology
593743|NCT00344994|Restless Legs Syndrome
593744|NCT00344994|Mirapex (pramipexole)
593745|NCT00344994|Requip(Ropinirole)
593746|NCT00344994|Dopamine Agonist
593747|NCT00344981|Cell Cycle Agents
593748|NCT00344955|HMG-COA reductase inhibition
593749|NCT00344955|GFR
593750|NCT00344955|RPF
593751|NCT00344955|FE
593752|NCT00344955|CL
593753|NCT00344916|Renal hemodynamics
593754|NCT00344916|Nitric oxide
593755|NCT00344903|Atherosclerosis
593756|NCT00344903|Heart Failure
593757|NCT00344903|Ventricular Hypertrophy
593758|NCT00344903|Myocardial Infarction
593759|NCT00344903|Screening
593760|NCT00344903|Hypertension
593761|NCT00344903|Diabetes
593762|NCT00344903|Obesity
593763|NCT00344903|Metabolic Syndrome
593764|NCT00344890|Cervical fusion
593765|NCT00344890|Anterior Cervical Discectomy and Fusion
593766|NCT00344890|ACDF
593767|NCT00344877|Epilepsy
593768|NCT00344877|Temporal Lobe Epilepsy
593769|NCT00344877|Cortical Excitability
593770|NCT00344877|Transcranial Direct Current Stimulation (tDCS)
593771|NCT00344877|Memory Testing
593772|NCT00344877|Seizures
593773|NCT00344877|Transcranial Magnetic Stimulation (TMS)
593774|NCT00344877|Memory
593775|NCT00344877|Plasticity
593776|NCT00344864|Contact Lenses Higher Order Aberrations
593777|NCT00344851|menstrual cyclicity
593778|NCT00344851|insulin resistance
593779|NCT00344851|body fat distribution
593780|NCT00344851|pancreatic ß-cell function
593781|NCT00344851|inflammatory markers
593782|NCT00344851|liver function tests
593783|NCT00344838|LADARWave™
593784|NCT00344838|WaveScan Wavefront™ Systems
593785|NCT00344825|B- Chronic Lymphocytic Leukemia
593786|NCT00344799|Choroidal Melanoma
593787|NCT00344799|Choroidal Malignant Melanoma
593788|NCT00344799|Ocular Melanoma
593789|NCT00344799|Uveal Melanoma
593790|NCT00344786|CLL
593791|NCT00344786|CNF2024
593792|NCT00344786|Hsp90 inhibitor
593793|NCT00344773|Locally advanced (IIIB) pulmonary adenocarcinoma with EGFR mutation
593794|NCT00344773|Metastatic (IV) pulmonary adenocarcinoma with EGFR mutation
593795|NCT00344773|Recurrent pulmonary adenocarcinoma with EGFR mutation
593796|NCT00344747|intervention program
593797|NCT00344747|diet
593798|NCT00344747|physical activity
593799|NCT00344747|adolescents
593800|NCT00344747|obesity
593801|NCT00344734|Nitric oxide
593802|NCT00344734|Renal hemodynamics
593803|NCT00344721|Meibomian Gland Syndrome
593804|NCT00344721|Blepharitis
593805|NCT00344708|Tissue-Cultured Human Amniotic Epithelial Cells onto damaged corneal surface
593806|NCT00344682|memantine
593807|NCT00344682|Namenda
593808|NCT00344682|augmentation
593809|NCT00344682|add-on
593810|NCT00344682|depression
593811|NCT00344682|MDD (major depressive disorder)
593812|NCT00344682|unipolar depression
593813|NCT00344682|NMDA
593814|NCT00344682|ketamine
593815|NCT00344682|uncompetitive NMDA receptor antagonist
593816|NCT00344669|underweight
593817|NCT00344669|preschool
593818|NCT00344669|mass deworming
593819|NCT00344656|Eating Disorders
593820|NCT00344656|Anorexia Nervosa
593821|NCT00344643|Comparison of Daily wear versus Extended wear in bacterial binding and corneal epithelial thickness
593822|NCT00344617|Choroidal neovascularisation
593823|NCT00344617|Polypoidal choroidal vasculopathy
593824|NCT00344617|Intravitreal injection
593825|NCT00344617|Avastin
593826|NCT00344604|Patients who have undergone routine LASIK as a primary refractive procedure for myopia, hyperopia, or astigmatism.
593827|NCT00344591|HIV
593828|NCT00344591|AIDS
593829|NCT00344578|Higher Order Abberations
593830|NCT00344539|asexual blood stage vaccine, Plasmodium falciparum malaria
593831|NCT00344526|AL amyloidosis
593832|NCT00344526|Autologous stem cell transplantation
593833|NCT00344526|Melphalan
593834|NCT00344526|Dexamethasone
593835|NCT00344513|registry
593836|NCT00344513|OPTIMIZE
593837|NCT00344513|Heart failure
593838|NCT00344513|OPTIMIZE-HF
593839|NCT00344500|Antipsychotic
593840|NCT00344500|Bipolar
593841|NCT00344500|Diabetes
593842|NCT00344500|Mental Illness
593843|NCT00344500|Nutrition
593844|NCT00344500|Obesity
593845|NCT00344500|Schizoaffective
593846|NCT00344500|Schizophrenia
593847|NCT00344500|Weight Gain
593848|NCT00344500|Weight Loss
593849|NCT00344474|Prevention
593850|NCT00344474|Addiction
593851|NCT00344474|Personality
593852|NCT00344474|Adolescents
593853|NCT00344474|Binge Drinking
593854|NCT00344474|Alcohol Abuse
593855|NCT00344474|Comorbidity
593856|NCT00344474|Depression
593857|NCT00344474|Anxiety
593858|NCT00344474|Antisocial Behaviour
593859|NCT00344448|Adhesion Molecule
593860|NCT00344448|Interventional Study
593861|NCT00344448|Immunomodulation
593862|NCT00344448|Autoimmunity
593863|NCT00344448|Sjogren Syndrome
593864|NCT00344448|SS
593865|NCT00344435|Hemophilia
593866|NCT00344435|Antibody
593867|NCT00344435|Mutations
593868|NCT00344435|SNP
593869|NCT00344435|clotting
593870|NCT00344422|Anthracyclines
593871|NCT00344422|Liposomes
593872|NCT00344422|Liposomal
593873|NCT00344422|Vincristine
593874|NCT00344422|Doxorubicin
593875|NCT00344422|Dexamethasone
593876|NCT00344422|Pegylated Liposomal Doxorubicin
593877|NCT00344422|DOXIL
593878|NCT00344422|drug resistant myeloma
593879|NCT00344409|darbepoetin alfa
593880|NCT00344409|anemia
593881|NCT00344409|cancer patients
593882|NCT00344409|platinum containing chemotherapy
593883|NCT00344383|oral contraceptive
593884|NCT00344383|breakthrough bleeding
593885|NCT00344383|spotting
593886|NCT00344370|Pitavastatin
593887|NCT00344370|Type II Diabetes Mellitus
593888|NCT00344370|Combined Dyslipidemia
593889|NCT00344344|Asthma
593890|NCT00344344|Cockroach
593891|NCT00344344|Dust Mite
593892|NCT00344344|Extermination
593893|NCT00344344|Targeted Cleaning
593894|NCT00344344|Allergy
593895|NCT00344344|Prevention
593896|NCT00344331|Lysosomal Storage
593897|NCT00344331|Biomarkers
593898|NCT00344331|Longitudinal
593899|NCT00344331|Niemann Pick Type C
593900|NCT00344331|NPC
593901|NCT00344331|Lysosomal Storage Disorder
593902|NCT00344318|Immunogenicity
593903|NCT00344318|Safety
593904|NCT00344318|Pneumococcal vaccine
593905|NCT00344318|Pneumococcal disease
593906|NCT00344305|children, FluMist, shedding,
593907|NCT00344292|Polymorphism, Genetic
593908|NCT00344292|Coronary Artery Disease
593909|NCT00344292|Coronary Arteriosclerosis
593910|NCT00344292|Polymorphism, Single Nucleotide
593911|NCT00344292|SNPs
593912|NCT00344279|Coinfection
593913|NCT00344279|AIDS
593914|NCT00344279|Lymphatic Filariasis
593915|NCT00344279|Diethylcarbamazine (DEC)
593916|NCT00344279|Albendazole
593917|NCT00344266|Obesity
593918|NCT00344266|Adipose Tissue
593919|NCT00344266|Microarrays
593920|NCT00344266|Cytokines
593921|NCT00344266|Eicosanoids
593922|NCT00344266|Gene Expression
593923|NCT00344266|Adipokines
593924|NCT00344266|Inflammation
593925|NCT00344266|Weight Loss
593926|NCT00344266|Lipid Products
593927|NCT00344253|Uveitis
593928|NCT00344253|Macular Edema
593929|NCT00344253|Interferon
593930|NCT00344253|Multiple Sclerosis
593931|NCT00344253|Encephalomyelitis disseminata (ED)
593932|NCT00344240|type 2 diabetes
593933|NCT00344240|exercise
593934|NCT00344240|activity guidance
593935|NCT00344240|health education
593936|NCT00344227|neovascularization
593937|NCT00344227|age-related macular degeneration
593938|NCT00344227|vascular endothelial growth factor (VEGF)
593939|NCT00344227|antigen-binding fragment (Fab)
593940|NCT00344227|antiangiogenesis
593941|NCT00344227|optical coherence tomography (OCT)
593942|NCT00344214|HIV
593943|NCT00344214|STDs
593944|NCT00344214|Methamphetamine
593945|NCT00344201|Pterygium
593946|NCT00344201|Fibrin adhesive
593947|NCT00344201|Conjunctival graft
593948|NCT00344201|Ocular surface reconstruction
593949|NCT00344188|Cutaneous
593950|NCT00344188|Visceral
593951|NCT00344188|PCR
593952|NCT00344188|Mucocutaneous
593953|NCT00344188|Biopsy
593954|NCT00344188|Leishmanial Infection
593955|NCT00344188|Leishmaniasis
593956|NCT00344175|hypercholesterolemia
593957|NCT00344175|dyslipidemia
593958|NCT00344175|CHD
593959|NCT00344175|pitavastatin
593960|NCT00344175|simvastatin
593961|NCT00344175|2 or more risk factors for coronary heart disease
593962|NCT00344175|combined dyslipidemia
593963|NCT00344162|Epidemiology
593964|NCT00344162|Population
593965|NCT00344162|Pregnancy
593966|NCT00344162|Preeclampsia
593967|NCT00344149|Idiopathic Thrombocytopenic Purpura
593968|NCT00344149|Rituximab
593969|NCT00344149|Splenectomy
593970|NCT00344149|Response
593971|NCT00344149|Treatment
593972|NCT00344149|treatment of Idiopathic Thrombocytopenic Purpura
593973|NCT00344136|Blood Pressure, High
593974|NCT00344136|Stroke
593975|NCT00344136|Hypertension
593976|NCT00344136|Diabetes Mellitus
593977|NCT00344136|Obesity
593978|NCT00344136|Cerebrovascular Accident
593979|NCT00344136|Atherosclerosis
593980|NCT00344123|HIV
593981|NCT00344110|Hypertension, aliskiren, blood pressure, renin
593982|NCT00344097|soy protein
593983|NCT00344097|pain
593984|NCT00344097|thoracotomy
593985|NCT00344084|Leishmania Major
593986|NCT00344084|Phlebotomus Duboscqi
593987|NCT00344084|Dermatology
593988|NCT00344084|Vector-Transmitted Disease
593989|NCT00344084|Africa
593990|NCT00344084|Cutaneous Leishmaniasis
593991|NCT00344084|CL
593992|NCT00344071|Clinical
593993|NCT00344071|Tissue
593994|NCT00344071|Photographs
593995|NCT00344071|Women
593996|NCT00344071|Case-Control
593997|NCT00344058|pregnancy
593998|NCT00344058|preeclampsia
593999|NCT00344058|treatment
594000|NCT00344045|Subjects with postoperative pain after Total Hip Arthroplasty
594001|NCT00344032|Double-blind
594002|NCT00344032|Human Papillomavirus
594003|NCT00344032|Phase IIIb
594004|NCT00344032|Controlled
594005|NCT00344032|Randomized
594006|NCT00344032|India
594007|NCT00344019|Acute coronary syndrome
594008|NCT00344019|Percutaneous coronary intervention
594009|NCT00344019|Peri-procedure myocardial infarction
594010|NCT00344006|Malaria CDA COARTEM Africa pediatrics children
594011|NCT00343993|noninvasive positive pressure ventilation
594012|NCT00343993|acute lung injury
594013|NCT00343993|acute respiratory distress syndrome
594014|NCT00343954|sickle cell disease
594015|NCT00343941|HIV-1 infection
594016|NCT00343941|Tucaresol
594017|NCT00343941|Viral suppression
594018|NCT00343915|Persistence
594019|NCT00343915|Hepatitis B vaccine
594020|NCT00343902|Hawthorn
594021|NCT00343902|Crataegus
594022|NCT00343902|Herbs
594023|NCT00343889|Diphtheria
594024|NCT00343889|Tetanus
594025|NCT00343889|Pertussis
594026|NCT00343889|Hepatitis B Hansenula (HB)
594027|NCT00343889|Haemophilus influenzae type b
594028|NCT00343889|Haemophilus Influenzae
594029|NCT00343876|hs-CRP
594030|NCT00343876|aspirin
594031|NCT00343876|clopidogrel
594032|NCT00343850|idiopathic chronic inflammatory disease of large intestine
594033|NCT00343850|ulcerative colitis
594034|NCT00343850|inactive ulcerative colitis
594035|NCT00343850|chronic disease of large intestine
594036|NCT00343850|medication adherence
594037|NCT00343850|Asacol
594038|NCT00343850|mesalamine
594039|NCT00343824|Burn wounds - Silver Dressings - Bacterial Control
594040|NCT00343811|Attention-Deficit/Hyper Activity Disorder
594041|NCT00343811|ADHD
594042|NCT00343759|Breast cancer
594043|NCT00343759|Tyrosine kinase inhibitors
594044|NCT00343759|Lapatinib
594045|NCT00343759|Biologic response modifiers
594046|NCT00343759|Magnetic resonance imaging
594047|NCT00343759|Treatment-naive, operable
594048|NCT00343746|macular degeneration
594049|NCT00343746|glaucoma
594050|NCT00343746|diabetic retinopathy
594051|NCT00343746|retinopathy, eye diseases
594052|NCT00343733|diabetic peripheral neuropathy
594053|NCT00343733|postherpetic neuralgia
594054|NCT00343733|traumatic injury
594055|NCT00343733|complex regional pain syndrome
594056|NCT00343733|back pain
594057|NCT00343733|neck pain
594058|NCT00343733|fibromyalgia
594059|NCT00343733|chronic pancreatitis
594060|NCT00343733|osteoarthritis
594061|NCT00343720|VELCADE
594062|NCT00343720|Alimta
594063|NCT00343720|locally advanced
594064|NCT00343720|metastatic
594065|NCT00343720|non-small cell lung cancer
594066|NCT00343720|complete response
594067|NCT00343720|partial response
594068|NCT00343720|Locally Advanced or Metastatic Non-Small Cell Lung Cancer
594069|NCT00343707|Social Anxiety Disorder
594070|NCT00343707|brain imaging
594071|NCT00343707|Positron Emission Tomography
594072|NCT00343707|antidepressant
594073|NCT00343681|Influenza
594074|NCT00343681|Orthomyxoviridae Infections
594075|NCT00343681|Orthomyxoviruses
594076|NCT00343681|Split-virion influenza vaccine
594077|NCT00343668|advanced gastric cancer
594078|NCT00343668|First-line therapy
594079|NCT00343668|S-1
594080|NCT00343668|irinotecan
594081|NCT00343655|Hypercholesterolemia
594082|NCT00343642|Crohn's disease
594083|NCT00343642|Fructooligosaccharide
594084|NCT00343642|Inulin
594085|NCT00343642|Diet
594086|NCT00343642|Treatment
594087|NCT00343642|Bacterial flora
594088|NCT00343642|Oxidative stress
594089|NCT00343629|unspecified adult solid tumor, protocol specific
594090|NCT00343616|cognitive/functional effects
594091|NCT00343616|fatigue
594092|NCT00343616|psychosocial effects of cancer and its treatment
594093|NCT00343616|stage I breast cancer
594094|NCT00343616|stage II breast cancer
594095|NCT00343616|stage IIIA breast cancer
594096|NCT00343603|maculopathy
594097|NCT00343577|proteinuria
594098|NCT00343577|ARBs
594099|NCT00343577|agalsidase-beta
594100|NCT00343577|MDRD estimated GFR
594101|NCT00343577|Chronic kidney disease
594102|NCT00343551|Hypertension, ambulatory blood pressure, missed dose, aliskiren
594103|NCT00343525|HCV
594104|NCT00343525|monoclonal antibody
594105|NCT00343525|phase 1
594106|NCT00343512|inflammatory breast cancer
594107|NCT00343512|stage II breast cancer
594108|NCT00343512|stage IIIA breast cancer
594109|NCT00343512|stage IIIB breast cancer
594110|NCT00343512|stage IIIC breast cancer
594111|NCT00343499|atrial fibrillation
594112|NCT00343499|valsartan
594113|NCT00343499|sinus rhythm
594114|NCT00343499|persistent atrial fibrillation undergoing electrical cardioversion to restore normal sinus rhythm
594115|NCT00343486|Overactive Bladder
594116|NCT00343473|Fuch's dystrophy
594117|NCT00343473|corneal disorders
594118|NCT00343473|cornea
594119|NCT00343473|lasik
594120|NCT00343473|refractive surgery
594121|NCT00343460|nausea and vomiting
594122|NCT00343460|unspecified adult solid tumor, protocol specific
594123|NCT00343447|stage I chronic lymphocytic leukemia
594124|NCT00343447|stage II chronic lymphocytic leukemia
594125|NCT00343447|stage III chronic lymphocytic leukemia
594126|NCT00343447|stage IV chronic lymphocytic leukemia
594127|NCT00343434|stage I breast cancer
594128|NCT00343434|stage II breast cancer
594129|NCT00343434|stage IIIA breast cancer
594130|NCT00343434|stage IIIB breast cancer
594131|NCT00343434|stage IIIC breast cancer
594132|NCT00343434|obesity
594133|NCT00343421|Diphtheria
594134|NCT00343421|Tetanus
594135|NCT00343421|Pertussis
594136|NCT00343421|Poliomyelitis
594137|NCT00343421|Haemophilus influenzae type b
594138|NCT00343421|Pneumococcal infections
594139|NCT00343408|recurrent non-small cell lung cancer
594140|NCT00343408|stage IIIB non-small cell lung cancer
594141|NCT00343408|stage IV non-small cell lung cancer
594142|NCT00343408|recurrent colon cancer
594143|NCT00343408|stage III colon cancer
594144|NCT00343408|stage IV colon cancer
594145|NCT00343408|recurrent rectal cancer
594146|NCT00343408|stage III rectal cancer
594147|NCT00343408|stage IV rectal cancer
594148|NCT00343395|rosiglitazone
594149|NCT00343395|metformin
594150|NCT00343395|hs-CRP
594151|NCT00343395|inflammation
594152|NCT00343382|sexuality and reproductive issues
594153|NCT00343382|sexual dysfunction
594154|NCT00343382|recurrent breast cancer
594155|NCT00343382|stage I breast cancer
594156|NCT00343382|stage II breast cancer
594157|NCT00343382|stage IIIA breast cancer
594158|NCT00343382|stage IIIB breast cancer
594159|NCT00343382|stage IIIC breast cancer
594160|NCT00343382|stage IV breast cancer
594161|NCT00343369|B-cell childhood acute lymphoblastic leukemia
594162|NCT00343369|recurrent childhood acute lymphoblastic leukemia
594163|NCT00343369|T-cell childhood acute lymphoblastic leukemia
594164|NCT00343369|untreated childhood acute lymphoblastic leukemia
594165|NCT00343356|Bladder neoplasm;
594166|NCT00343356|Carcinoma;
594167|NCT00343356|Epirubicin;
594168|NCT00343356|BCG;
594169|NCT00343356|Perfusion
594170|NCT00343317|puerperal sepsis
594171|NCT00343317|HIV infection
594172|NCT00343317|prophylactic antibiotics
594173|NCT00343304|Stroke.Robot.Ergometer.Group OT
594174|NCT00343291|Non-Small Cell Lung Cancer
594175|NCT00343291|Malignant pleural effusions
594176|NCT00343278|Valaciclovir Hydrochloride
594177|NCT00343278|hemodialysis patient
594178|NCT00343278|ALDH
594179|NCT00343278|pharmacokinetics
594180|NCT00343278|Japanese
594181|NCT00343265|Preterm birth
594182|NCT00343265|Multiple pregnancy
594183|NCT00343265|Vaginal progesterone
594184|NCT00343265|Preterm birth in multiple pregnancy
594185|NCT00343226|Basiliximab, transplantation, liver, renal function
594186|NCT00343213|Prognostic value of p16INK4a
594187|NCT00343213|CIN 1
594188|NCT00343213|LSIL
594189|NCT00343213|HPV
594190|NCT00343187|Tarceva
594191|NCT00343187|Rash
594192|NCT00343187|EGFR-1 Rash
594193|NCT00343187|erlotinib
594194|NCT00343187|Aczone
594195|NCT00343187|Dapsone
594196|NCT00343187|Non-small Cell Lung Cancer
594197|NCT00343187|subjects treated with Tarceva for non-small cell lung cancer (NSCLC) who subsequently develop a rash suspected to be related to Tarceva
594198|NCT00343174|stroke
594199|NCT00343174|vascular diseases
594200|NCT00343161|Nexium
594201|NCT00343135|Skin
594202|NCT00343135|AUGMENTIN
594203|NCT00343135|1gm
594204|NCT00343135|Soft
594205|NCT00343135|tissue
594206|NCT00343135|Infections
594207|NCT00343122|liver
594208|NCT00343122|cirrhosis
594209|NCT00343122|hepatopulmonary syndrome
594210|NCT00343096|intranasal
594211|NCT00343096|buccal
594212|NCT00343096|lorazepam
594213|NCT00343096|paediatric
594214|NCT00343096|convulsions
594215|NCT00343083|Head and Neck Neoplasms
594216|NCT00343044|platinum resistant ovarian cancer
594217|NCT00343044|recurrent ovarian cancer
594218|NCT00343044|platinum resistant cancer
594219|NCT00343031|Insecticides
594220|NCT00343031|Children
594221|NCT00343031|Women
594222|NCT00343031|Infection
594223|NCT00343031|DDT
594224|NCT00343031|Contaminant
594225|NCT00343018|Preschoolers
594226|NCT00343018|Young Children
594227|NCT00343018|Eyewitness
594228|NCT00343018|Memory
594229|NCT00343005|Blood-Stage
594230|NCT00343005|Investigational
594231|NCT00343005|Endemic
594232|NCT00343005|Malaria
594233|NCT00343005|Vaccine
594234|NCT00342992|Vitamin E
594235|NCT00342992|Micronutrients
594236|NCT00342992|Genetics
594237|NCT00342992|Smoking
594238|NCT00342992|Biomarkers
594239|NCT00342966|Metabolism
594240|NCT00342966|Tracer Studies
594241|NCT00342966|Chemoprevention
594242|NCT00342966|Selenomethionine
594243|NCT00342966|Plasma Selenoproteins
594244|NCT00342953|saline
594245|NCT00342953|silicone
594246|NCT00342953|Breast Implants
594247|NCT00342953|augmentation mammoplasty
594248|NCT00342953|visk
594249|NCT00342940|influenza
594250|NCT00342940|influenza vaccine
594251|NCT00342940|flu
594252|NCT00342940|vaccination
594253|NCT00342940|immunogenicity
594254|NCT00342927|American Indians
594255|NCT00342927|Complications
594256|NCT00342927|Genetics
594257|NCT00342927|Linkage
594258|NCT00342927|Type 2 Diabetes
594259|NCT00342927|Diabetic Kidney Disease
594260|NCT00342888|Childhood Cancer
594261|NCT00342888|Pesticides
594262|NCT00342888|Polychlorinated Biphenyls
594263|NCT00342888|Organochlorines
594264|NCT00342888|Polybrominated Diphenyl Ethers
594265|NCT00342875|Bladder Cancer
594266|NCT00342875|Exposure
594267|NCT00342875|Drinking Water
594268|NCT00342862|Pregnancy
594269|NCT00342862|Amevive
594270|NCT00342862|alefacept
594271|NCT00342862|Registry
594272|NCT00342862|Psoriasis
594273|NCT00342849|Clinical Trial
594274|NCT00342849|Low-level Lead Poisoning
594275|NCT00342849|Chelation
594276|NCT00342849|Developmental Assessment
594277|NCT00342849|Succimer
594278|NCT00342836|Akt
594279|NCT00342836|Immunohistochemistry
594280|NCT00342836|Myoinositol
594281|NCT00342836|Bronchial Specimens
594282|NCT00342836|Phosphorylation
594283|NCT00342823|Linkage Analysis
594284|NCT00342823|Canidate Gene Analysis
594285|NCT00342823|Genome Scan
594286|NCT00342823|L. Chagasi
594287|NCT00342823|Visceral Leishmania
594288|NCT00342810|Eye Diseases
594289|NCT00342797|second primary cancer
594290|NCT00342797|retinoblastoma
594291|NCT00342797|RB1 germline mutation
594292|NCT00342784|Mutation
594293|NCT00342784|Cancer Genetics
594294|NCT00342771|Tobacco Use
594295|NCT00342771|Tumor Biology
594296|NCT00342771|Biomarker
594297|NCT00342771|Risk Factor
594298|NCT00342771|Health Disparity
594299|NCT00342758|Asthma
594300|NCT00342758|Wheeze
594301|NCT00342758|Environment
594302|NCT00342758|Diet
594303|NCT00342758|Infection
594304|NCT00342732|Genetics
594305|NCT00342732|Fat Intake
594306|NCT00342732|Pima Indians
594307|NCT00342732|Weight Control
594308|NCT00342732|Appetite Control
594309|NCT00342706|Teen Pregnancy
594310|NCT00342706|Short Inter-Pregnancy Intervals
594311|NCT00342693|Radiation
594312|NCT00342693|Screening
594313|NCT00342693|Cancer
594314|NCT00342693|Nodules
594315|NCT00342693|Nuclear
594316|NCT00342693|Thyroid Screening
594317|NCT00342693|Thyroid Gland
594318|NCT00342667|Preterm Birth
594319|NCT00342667|Predictors of Outcome
594320|NCT00342667|Neonatal/Infant Complications
594321|NCT00342667|Neurologic Development
594322|NCT00342667|(SqrRoot) mniotic Fluid
594323|NCT00342667|Cerebral Palsy
594324|NCT00342667|Risk Factors
594325|NCT00342654|Epidemiology
594326|NCT00342654|Cancer
594327|NCT00342654|Environment
594328|NCT00342654|Genetics
594329|NCT00342654|Nutrition
594330|NCT00342641|Lymphoma
594331|NCT00342641|Multiple Myeloma
594332|NCT00342641|Thyroiditis
594333|NCT00342641|Cohort Study
594334|NCT00342641|Record linkage study
594335|NCT00342641|Hepatitis C
594336|NCT00342628|Antibody
594337|NCT00342628|Reactions
594338|NCT00342628|Vaccine
594339|NCT00342628|Conjugate Vaccine
594340|NCT00342628|Typhoid Fever
594341|NCT00342628|Trial
594342|NCT00342628|Safety
594343|NCT00342628|Immunogenicity
594344|NCT00342628|Comparability
594345|NCT00342628|DTP
594346|NCT00342602|JC Virus
594347|NCT00342602|Opportunistic Infection
594348|NCT00342602|Single Nucleotide Polymorphism
594349|NCT00342602|Genotype
594350|NCT00342602|Sequencing
594351|NCT00342589|Pneumocystis
594352|NCT00342589|HIV
594353|NCT00342589|Oral Wash
594354|NCT00342589|PCR
594355|NCT00342589|Drug Resistance
594356|NCT00342576|Filarial Parasites
594357|NCT00342576|Wuchereria Bancrofti
594358|NCT00342576|Brugia Malayi
594359|NCT00342576|Diethylcarbamazine (DEC)
594360|NCT00342576|Ivermectin
594361|NCT00342563|mecamylamine
594362|NCT00342563|treatment
594363|NCT00342563|alcohol dependence
594364|NCT00342563|smoking
594365|NCT00342550|Pregnancy
594366|NCT00342550|Preterm Birth
594367|NCT00342550|Pregnancy Complications
594368|NCT00342537|Pathology
594369|NCT00342537|Genetics
594370|NCT00342537|Testicular Cancer
594371|NCT00342537|Familial
594372|NCT00342537|Cancer Epidemiology
594373|NCT00342524|IVIG
594374|NCT00342524|Plasmapheresis
594375|NCT00342524|Blood Collection
594376|NCT00342524|Immune Globulin
594377|NCT00342524|Severe Acute Respiratory Syndrome
594378|NCT00342524|SARS
594379|NCT00342511|Pap
594380|NCT00342511|Hybrid Capture 2
594381|NCT00342511|HSIL
594382|NCT00342511|Colposcopy
594383|NCT00342511|CIN
594384|NCT00342511|Specimen Collection
594385|NCT00342498|DNA
594386|NCT00342498|Hormone
594387|NCT00342498|Resistance
594388|NCT00342498|Skeleton
594389|NCT00342485|Cellular Immunity
594390|NCT00342485|HIV-infected
594391|NCT00342485|Immune Deficiency
594392|NCT00342485|Cancer
594393|NCT00342485|Transplantation
594394|NCT00342472|Esophageal Cancer
594395|NCT00342472|Polycyclic Aromatic Hydrocarbons
594396|NCT00342446|GONADOTROPIN
594397|NCT00342446|CLOMIPHENE
594398|NCT00342446|Ovulation-Stimulating Drugs
594399|NCT00342433|Androgens
594400|NCT00342433|Serum
594401|NCT00342433|Tissue
594402|NCT00342407|Cancer Risk
594403|NCT00342407|Cosmic Radiation
594404|NCT00342407|Airlines
594405|NCT00342407|Flight Attendants
594406|NCT00342407|Circadian Rhythm
594407|NCT00342394|Biological Monitoring
594408|NCT00342394|Exposure Determinants
594409|NCT00342394|Exposure Validation
594410|NCT00342394|Occupational Exposure
594411|NCT00342394|Pesticides
594412|NCT00342394|Agriculture
594413|NCT00342381|Motor fatigue
594414|NCT00342381|Cognitive fatigue
594415|NCT00342368|CPAP
594416|NCT00342368|ARDS
594417|NCT00342368|ALI
594418|NCT00342368|Hypoxemia
594419|NCT00342368|Intubation
594420|NCT00342355|Protease Inhibitors
594421|NCT00342355|Reverse Transcriptase Inhibitors
594422|NCT00342355|AIDS
594423|NCT00342355|Opportunistic Infections
594424|NCT00342355|Resource-Poor
594425|NCT00342342|Genetics
594426|NCT00342329|Case-Control
594427|NCT00342329|Hydrocarbons
594428|NCT00342329|Metals
594429|NCT00342329|Silica
594430|NCT00342329|Tobacco Smoke
594431|NCT00342329|Lupus Nephritis
594432|NCT00342329|Environmental Exposures
594433|NCT00342329|Occupational Exposures
594434|NCT00342316|Acute Myeloid Leukemia
594435|NCT00342316|Stem Cell Transplantation
594436|NCT00342316|Reduced Intensity Conditioning
594437|NCT00342316|Survival
594438|NCT00342316|Relapse
594439|NCT00342303|Premature Infants
594440|NCT00342303|Fatty Acid Metabolism
594441|NCT00342303|Polyunsaturated Fatty Acids
594442|NCT00342303|Infant Formula
594443|NCT00342303|Gas-chromatography
594444|NCT00342303|Mass Spectrometry
594445|NCT00342290|Pathophysiological Volume Measurement
594446|NCT00342290|Power Doppler Ultrasound
594447|NCT00342290|Prediction of Adverse Pregnancy Outcome
594448|NCT00342290|Subchorionic Hemorrhage
594449|NCT00342277|Premature Rupture of Membranes
594450|NCT00342277|Genetic Risk Factors
594451|NCT00342277|Tissue Specific Expression
594452|NCT00342277|Quantitative Real Time PCR
594453|NCT00342277|Preterm Birth
594454|NCT00342277|Expression Profiling
594455|NCT00342277|Microarrays
594456|NCT00342264|Lung Cancer
594457|NCT00342264|Smoking
594458|NCT00342264|Diesel Exhaust
594459|NCT00342251|Macular Degeneration
594460|NCT00342251|Retinal Images
594461|NCT00342251|Risk Factors
594462|NCT00342251|Linkage Analysis
594463|NCT00342251|Gene
594464|NCT00342251|Mutation
594465|NCT00342225|Observation
594466|NCT00342225|Mothers
594467|NCT00342225|Description
594468|NCT00342212|Walking
594469|NCT00342212|Jogging
594470|NCT00342212|Bridging Study
594471|NCT00342212|Data Comparability
594472|NCT00342212|Healthy Adults
594473|NCT00342212|Healthy Volunteer
594474|NCT00342212|HV
594475|NCT00342199|Incidence
594476|NCT00342199|Prevalence
594477|NCT00342199|Immunity
594478|NCT00342199|Bacteriology
594479|NCT00342199|Pathogenesis
594480|NCT00342186|China
594481|NCT00342186|Cancer
594482|NCT00342186|Hepatitis B
594483|NCT00342186|Genetics
594484|NCT00342186|Liver Disease
594485|NCT00342186|HBV
594486|NCT00342173|Cervix
594487|NCT00342173|Natural History
594488|NCT00342173|Neoplasia
594489|NCT00342173|HPV
594490|NCT00342173|Costa Rica
594491|NCT00342160|AIDS
594492|NCT00342160|HIV Infectiousness
594493|NCT00342160|Immunity
594494|NCT00342160|CTL
594495|NCT00342160|Epidemiology
594496|NCT00342147|EBV
594497|NCT00342147|NPC
594498|NCT00342134|Demyelination
594499|NCT00342134|Inflammation
594500|NCT00342134|Immunosuppression
594501|NCT00342134|Autoimmunity
594502|NCT00342134|Bone Marrow
594503|NCT00342134|Multiple Sclerosis
594504|NCT00342121|Cancer
594505|NCT00342121|NHL
594506|NCT00342121|Pesticides
594507|NCT00342121|Atrazine
594508|NCT00342121|Organophosphates
594509|NCT00342121|Cancer Risk
594510|NCT00342121|Normal Control
594511|NCT00342095|Autoimmune Diseases
594512|NCT00342095|Estrogen
594513|NCT00342095|Silica
594514|NCT00342095|Pesticides
594515|NCT00342095|Major Histocompatibility Complex
594516|NCT00342095|Genetic Susceptibility
594517|NCT00342082|Zidovudine
594518|NCT00342082|HIV
594519|NCT00342082|Cord Blood
594520|NCT00342069|Decision Making
594521|NCT00342069|Genetic Counseling
594522|NCT00342069|Pregnancy Options
594523|NCT00342069|Attitudes Toward Reproductive Options
594524|NCT00342069|Beliefs About Down Syndrome Risk
594525|NCT00342069|Down Syndrome Risk
594526|NCT00342069|Pregnancy
594527|NCT00342056|Pharmacogenetics
594528|NCT00342056|Transporter Proteins
594529|NCT00342056|Drug Exposure
594530|NCT00342056|Imatinib
594531|NCT00342056|Retrospective
594532|NCT00342056|Cancer
594533|NCT00342043|Sickle Trait
594534|NCT00342043|Fetal Hemoglobin
594535|NCT00342043|Hemoglobin C
594536|NCT00342043|Beta-Thalassemia
594537|NCT00342043|Artesunate-Amodiaquine
594538|NCT00342030|Respiratory
594539|NCT00342030|Polymorphism
594540|NCT00342030|Fruit
594541|NCT00342030|COPD
594542|NCT00342030|Prospective
594543|NCT00342030|Diet
594544|NCT00342017|Filarial Infections
594545|NCT00342017|Helminths
594546|NCT00342017|Tuberculosis
594547|NCT00342017|Filarial Infection
594548|NCT00342004|Shanghai
594549|NCT00342004|Residential History
594550|NCT00342004|Exposure Assessment
594551|NCT00342004|Cohort Study
594552|NCT00342004|Molecular Epidemiology
594553|NCT00341991|DNA Repair
594554|NCT00341991|Genes
594555|NCT00341991|Pigmentation
594556|NCT00341991|Skin Cancer
594557|NCT00341991|Sun Exposure
594558|NCT00341965|DDT
594559|NCT00341965|DDE
594560|NCT00341965|Androgen Levels
594561|NCT00341965|Farming
594562|NCT00341965|Antiandrogen
594563|NCT00341952|Case-Control Study
594564|NCT00341952|Non-Hodgkin Lymphoma
594565|NCT00341939|Drug Therapy
594566|NCT00341939|Pharmacogenetics
594567|NCT00341939|Cancer
594568|NCT00341939|Pharmacodynamics
594569|NCT00341939|Parmacokinetics
594570|NCT00341913|Research
594571|NCT00341913|Repository
594572|NCT00341913|Registry
594573|NCT00341913|Surveillance
594574|NCT00341913|Databases
594575|NCT00341900|Chromosome Translocations
594576|NCT00341900|Cosmic Radiation
594577|NCT00341900|Airline Flight Crew
594578|NCT00341900|Airlines
594579|NCT00341900|Flight Crew
594580|NCT00341900|Occupational Exposure
594581|NCT00341887|Screening
594582|NCT00341887|AIDS
594583|NCT00341887|Antiretrovirals
594584|NCT00341887|Military
594585|NCT00341887|Force readiness
594586|NCT00341874|DNA Mutations
594587|NCT00341874|Genetic Variation
594588|NCT00341874|GENETIC LINKAGE
594589|NCT00341874|Gene Expression Patterns
594590|NCT00341874|Hereditary Hearing Disorder
594591|NCT00341861|Bladder Cancer
594592|NCT00341861|Occupational and Environmental Risks
594593|NCT00341861|Lifestyle Factors
594594|NCT00341861|Epidemiology
594595|NCT00341861|Genetic Susceptibility
594596|NCT00341848|Apoptosis
594597|NCT00341848|Environment
594598|NCT00341848|Infection
594599|NCT00341848|Inflammation
594600|NCT00341848|Leiomyoma
594601|NCT00341848|Uterine Leiomyoma
594602|NCT00341848|Uterus
594603|NCT00341835|Linkage Analysis
594604|NCT00341835|Cancer Susceptibility Alleles
594605|NCT00341835|Cancer Genetics
594606|NCT00341835|Linkage Mapping
594607|NCT00341835|Linkage Disequilibrium
594608|NCT00341822|Amniocentesis
594609|NCT00341822|Chorionic Villus Sampling
594610|NCT00341822|Fertility
594611|NCT00341822|Genetic Counseling
594612|NCT00341822|Decisional Conflict
594613|NCT00341822|Prenatal Testing
594614|NCT00341822|Questionnaire
594615|NCT00341809|Natural Killer Cells
594616|NCT00341809|Autoimmune Disease
594617|NCT00341809|Chronic Inflammation
594618|NCT00341809|Two-Locus Interaction
594619|NCT00341809|Allele/Haplotype Analysis
594620|NCT00341796|AIDS
594621|NCT00341796|HIV
594622|NCT00341796|Perinatal
594623|NCT00341796|Transmission
594624|NCT00341796|Antiretroviral
594625|NCT00341796|Outcomes
594626|NCT00341783|Plasmodium
594627|NCT00341783|Falciparum
594628|NCT00341783|Screening
594629|NCT00341783|Malaria
594630|NCT00341757|Family Reports
594631|NCT00341757|Cancer
594632|NCT00341757|Questionnaire
594633|NCT00341757|Validity
594634|NCT00341757|Surveillance
594635|NCT00341744|Vision
594636|NCT00341744|Aids
594637|NCT00341731|Cystic Ovaries
594638|NCT00341731|Environmental Factors
594639|NCT00341731|Heritability
594640|NCT00341731|Hyperandrogenism
594641|NCT00341731|Twin Study
594642|NCT00341718|Interview
594643|NCT00341718|Genetics
594644|NCT00341705|AIDS
594645|NCT00341705|Cancer
594646|NCT00341705|Hepatitis C Virus
594647|NCT00341705|HIV
594648|NCT00341705|Natural History
594649|NCT00341705|Hemophilia
594650|NCT00341705|Hepatitis C
594651|NCT00341692|Mammary
594652|NCT00341692|Development
594653|NCT00341692|Cancer
594654|NCT00341692|Risk
594655|NCT00341692|Genes
594656|NCT00341679|Autoimmune Diseases
594657|NCT00341679|Genetic Risk Factors
594658|NCT00341679|Polymyositis
594659|NCT00341679|Dermatomyositis
594660|NCT00341679|Connective Tissue Disorders
594661|NCT00341679|Idiopathic Inflammatory Myopathies
594662|NCT00341679|Inclusion Body Myositis
594663|NCT00341679|Pathogenesis
594664|NCT00341679|Environmental Risk Factor
594665|NCT00341679|IIM
594666|NCT00341666|Immune Regulation
594667|NCT00341666|Co-Infection
594668|NCT00341666|Filariasis
594669|NCT00341666|Immunology
594670|NCT00341666|Filarial Infection
594671|NCT00341653|Asthma
594672|NCT00341653|Pulmonary Function
594673|NCT00341653|Air Pollution
594674|NCT00341653|Genetic Polymorphism
594675|NCT00341653|Environmental Tobacco Agents
594676|NCT00341640|Teen Pregnancy
594677|NCT00341627|Bone Tumor
594678|NCT00341627|Familial Chordoma
594679|NCT00341627|Gene Mapping
594680|NCT00341627|Genetics
594681|NCT00341627|Sporadic Chordoma
594682|NCT00341614|Exercise
594683|NCT00341614|Diabetes Mellitus, Type 2
594684|NCT00341614|Postmenopause
594685|NCT00341614|Diet
594686|NCT00341601|Mycobacterium Tuberculosis
594687|NCT00341601|TLR-2
594688|NCT00341601|Recurrent Tuberculosis
594689|NCT00341601|Phenolic Glycolipid
594690|NCT00341601|mRNA Expression Profiles
594691|NCT00341588|Testicular Cancer
594692|NCT00341588|Epidemiology
594693|NCT00341588|Testicular Germ Cell Cancer
594694|NCT00341588|TGCT
594695|NCT00341588|Healthy Volunteer
594696|NCT00341575|Family Systems
594697|NCT00341575|Communication
594698|NCT00341575|Information Diffusion
594699|NCT00341575|Social Networks
594700|NCT00341575|Family Dynamics
594701|NCT00341562|Gene Expression Profiling
594702|NCT00341562|Vascular Disease
594703|NCT00341549|Linkage
594704|NCT00341549|Genetics
594705|NCT00341549|Mapping
594706|NCT00341549|Gene
594707|NCT00341549|Susceptibility
594708|NCT00341549|Myopia
594709|NCT00341549|Nearsightedness
594710|NCT00341549|Refraction
594711|NCT00341549|Eye
594712|NCT00341536|Diet
594713|NCT00341536|Pilot
594714|NCT00341536|Cohort
594715|NCT00341536|Environmental
594716|NCT00341536|Chronic Disease
594717|NCT00341523|Cytology
594718|NCT00341523|Endoscopy
594719|NCT00341523|Esophageal Cancer
594720|NCT00341523|Early Detection
594721|NCT00341523|Treatment
594722|NCT00341510|Risk Behavior
594723|NCT00341510|Health Status
594724|NCT00341510|Adolescence
594725|NCT00341510|Positive Health Behaviors
594726|NCT00341510|Social Support
594727|NCT00341510|Health Behavior
594728|NCT00341510|Survey
594729|NCT00341497|Leukoplakia
594730|NCT00341497|Oral Mucosa
594731|NCT00341497|Biomarkers
594732|NCT00341484|Genetics
594733|NCT00341484|Liver Cancer
594734|NCT00341484|HIV
594735|NCT00341471|School
594736|NCT00341471|Sixth Grade
594737|NCT00341471|Curricular
594738|NCT00341471|Howard University
594739|NCT00341471|D.C.
594740|NCT00341471|Adolescent Pregnancy
594741|NCT00341471|Intervention
594742|NCT00341458|Breast Cancer
594743|NCT00341458|Environment
594744|NCT00341458|Genetics
594745|NCT00341458|Epidemiology
594746|NCT00341445|Environmental Intervention
594747|NCT00341445|Indoor Allergens
594748|NCT00341445|Environment
594749|NCT00341432|NRT Study
594750|NCT00341432|Smoking Cessation
594751|NCT00341419|ABC Transporter
594752|NCT00341419|ABCC6
594753|NCT00341419|Slkin Laxity
594754|NCT00341419|Genetic Association
594755|NCT00341419|Angiod Streaks
594756|NCT00341419|Pseudoxanthoma Elasticum
594757|NCT00341419|PXE
594758|NCT00341406|Obesity
594759|NCT00341406|Type 2 Diabetes Mellitus
594760|NCT00341406|Adipose Cell Turn Over
594761|NCT00341393|HIV Infection
594762|NCT00341393|AIDS
594763|NCT00341393|Viral Load
594764|NCT00341393|Retroviral Treatment
594765|NCT00341393|Uganda
594766|NCT00341380|Cancer
594767|NCT00341380|Lung Cancer
594768|NCT00341380|Surgical Resection
594769|NCT00341380|Non-Small Cell Lung Cancer
594770|NCT00341380|NSCLC
594771|NCT00341367|Analgesic
594772|NCT00341367|Back Pain
594773|NCT00341367|Lumbar Disc
594774|NCT00341367|Nerve
594775|NCT00341367|Radiculopathy
594776|NCT00341354|Pneumonia
594777|NCT00341354|Bacterial Infection
594778|NCT00341354|Nosocomial Infection
594779|NCT00341354|Trachea
594780|NCT00341354|Biofilm
594781|NCT00341354|Mucus Shaver
594782|NCT00341341|Smoking
594783|NCT00341341|Smoking Cessation
594784|NCT00341341|GSTM1
594785|NCT00341341|Glutathione S. Transferase
594786|NCT00341341|Lung Cancer
594787|NCT00341341|Smokers
594788|NCT00341341|Genetic Risk Communication
594789|NCT00341328|India
594790|NCT00341328|Pulmonary Tuberculosis
594791|NCT00341328|Category-I Pulmonary Tuberculosis
594792|NCT00341328|Immunomodulator
594793|NCT00341328|Mycobacterium w
594794|NCT00341315|Epidemiology
594795|NCT00341315|DDT
594796|NCT00341315|BMI
594797|NCT00341315|Serum
594798|NCT00341315|Case-Control Study
594799|NCT00341302|HIV
594800|NCT00341302|AIDS
594801|NCT00341302|Perinatal
594802|NCT00341302|Transmission
594803|NCT00341302|Antiretroviral
594804|NCT00341302|Outcomes
594805|NCT00341289|Submersion
594806|NCT00341289|Epidemiology
594807|NCT00341289|Fatal
594808|NCT00341289|Child
594809|NCT00341289|Swim
594810|NCT00341289|Drowning
594811|NCT00341289|Survey
594812|NCT00341276|Esophageal Cancer
594813|NCT00341276|Genetics
594814|NCT00341276|Polymorphism
594815|NCT00341276|Susceptibility Genes
594816|NCT00341276|Tumor
594817|NCT00341263|Twins
594818|NCT00341263|Clinical Research
594819|NCT00341263|Endocrinology
594820|NCT00341263|Breast Cancer
594821|NCT00341263|Biochemical Epidemiology
594822|NCT00341250|Blood Stage
594823|NCT00341250|Investigational
594824|NCT00341250|Endemic
594825|NCT00341250|Malaria
594826|NCT00341237|Polymorphism
594827|NCT00341237|Genotype
594828|NCT00341237|Phenotype
594829|NCT00341237|Environmental Factor
594830|NCT00341237|Single Nucleotide Polymorphism
594831|NCT00341224|Aggression
594832|NCT00341224|Violence
594833|NCT00341224|Adolescents
594834|NCT00341224|Randomized Trial
594835|NCT00341224|Behavioral Intervention
594836|NCT00341211|AIDS
594837|NCT00341211|Cancer
594838|NCT00341211|Epidemiology
594839|NCT00341211|Immunology
594840|NCT00341211|Virology
594841|NCT00341198|Rheumatoid Arthritis
594842|NCT00341198|Lupus
594843|NCT00341198|Scleroderma
594844|NCT00341198|Sjogren's Syndrome
594845|NCT00341198|Farming
594846|NCT00341198|Autoimmune Disease
594847|NCT00341198|Exposure
594848|NCT00341185|Biodosimetry
594849|NCT00341185|Dose Reconstruction
594850|NCT00341185|Radioactive Fallout
594851|NCT00341185|Thyroid Screening
594852|NCT00341185|Ultrasound
594853|NCT00341172|Retinitis
594854|NCT00341172|Cytomegalovirus
594855|NCT00341172|HIV-1
594856|NCT00341172|Polymorphisms
594857|NCT00341172|HAART
594858|NCT00341159|Breast
594859|NCT00341159|BRCA1
594860|NCT00341159|BRCA2
594861|NCT00341159|Inherited
594862|NCT00341159|Association
594863|NCT00341159|Breast Cancer
594864|NCT00341159|Population-Based
594865|NCT00341159|Cancer Susceptibility Alleles
594866|NCT00341146|Cancer
594867|NCT00341146|Catonese Chinese
594868|NCT00341146|Genetic Predisposition
594869|NCT00341146|Genotyping
594870|NCT00341146|Triad analysis
594871|NCT00341146|Nasopharyngeal Cancer
594872|NCT00341146|NPC
594873|NCT00341133|Laterality
594874|NCT00341133|Heterotaxy
594875|NCT00341133|Holoprosencephaly
594876|NCT00341133|Genetic Testing
594877|NCT00341133|Congential Cardiac Malformations
594878|NCT00341133|Disturbed Internal Organ Positioning
594879|NCT00341120|Genotypes
594880|NCT00341120|Mutation
594881|NCT00341120|Folate
594882|NCT00341120|Male Infertility
594883|NCT00341120|Nutrition
594884|NCT00341107|Cancer
594885|NCT00341107|Genes
594886|NCT00341107|Screening
594887|NCT00341107|Primary Care
594888|NCT00341107|Inherited Susceptibility
594889|NCT00341094|Cohort
594890|NCT00341094|Radiation
594891|NCT00341094|In Utero
594892|NCT00341094|Genomic
594893|NCT00341081|Short Tandem Repeat
594894|NCT00341081|Molecular Epidemiology
594895|NCT00341081|Viral Infection
594896|NCT00341081|Mixture Detection
594897|NCT00341081|Intervention & Education
594898|NCT00341081|Intervention
594899|NCT00341081|Education
594900|NCT00341068|Birth Defects
594901|NCT00341068|Genetics
594902|NCT00341068|Folic Acid
594903|NCT00341068|Gene-Environment Interactions
594904|NCT00341068|Neural Tube Defects
594905|NCT00341068|Cleft Lip
594906|NCT00341068|Cleft Palate
594907|NCT00341068|Mutations
594908|NCT00341055|Anemia
594909|NCT00341055|Hemoglobin
594910|NCT00341055|Chemotherapy
594911|NCT00341055|Epoetin alfa
594912|NCT00341042|Normal Values
594913|NCT00341042|Complete Blood Count
594914|NCT00341042|HIV
594915|NCT00341042|Tuberculosis
594916|NCT00341042|Flow Cytometry
594917|NCT00341029|Longitudinal Study
594918|NCT00341029|Chromosomal Effects
594919|NCT00341029|Sister Chromatid Exchanges
594920|NCT00341029|Micronuclei
594921|NCT00341029|Stimulants
594922|NCT00341029|Attention Deficit Hyperactivity Disorder
594923|NCT00341029|ADHD
594924|NCT00341016|Radiation
594925|NCT00341003|Plasmodium Falciparum
594926|NCT00341003|Hemoglobin E
594927|NCT00341003|Mefloquine
594928|NCT00341003|Artemisinin
594929|NCT00341003|Piperaquine
594930|NCT00341003|Malaria
594931|NCT00340990|Tuberculosis
594932|NCT00340990|HIV
594933|NCT00340990|CD4+ T Cell
594934|NCT00340990|Interferon-Gamma
594935|NCT00340990|Lymphocyte Proliferation
594936|NCT00340977|Birth Defects
594937|NCT00340977|Case-Control Studies
594938|NCT00340977|Genetic Susceptibility
594939|NCT00340964|Photography
594940|NCT00340964|Self-Esteem
594941|NCT00340964|Perceived Social Stigma
594942|NCT00340964|Hopefulness
594943|NCT00340964|Cleft Lip and Palate
594944|NCT00340964|Hemifacial Microsomia
594945|NCT00340964|Treacher Collins Syndrome
594946|NCT00340964|Mobius Syndrome
594947|NCT00340964|Apert Syndrome
594948|NCT00340964|Videography
594949|NCT00340964|Craniofacial Differences
594950|NCT00340964|Self -Esteem
594951|NCT00340951|Regulatory T Cells
594952|NCT00340951|Bronchiolitis Obliterans Syndrome
594953|NCT00340951|Genetic Polymorphism
594954|NCT00340951|Innate Immunity
594955|NCT00340951|Transplantation
594956|NCT00340951|Lung Transplantation
594957|NCT00340938|Adherence
594958|NCT00340938|Education
594959|NCT00340938|Problem Solving
594960|NCT00340938|Motivation
594961|NCT00340938|Locus of Responsibility
594962|NCT00340912|Skin Biopsy
594963|NCT00340899|Perinatal Mortality
594964|NCT00340899|Perinatal Morbidity
594965|NCT00340899|Preterm Birth
594966|NCT00340899|Pregnancy Complications
594967|NCT00340899|Pregnancy
594968|NCT00340886|Genetic Susceptibility
594969|NCT00340886|Single Nucleotide Polymorphism
594970|NCT00340886|Environmental Risk Factor
594971|NCT00340886|Allelic Variants
594972|NCT00340886|Ascertainment by Genotype
594973|NCT00340873|Molecular Epidemiology
594974|NCT00340873|Cross-Sectional
594975|NCT00340873|Gene-Enviroment Interaction
594976|NCT00340860|Ultrasound
594977|NCT00340860|Biobank
594978|NCT00340860|Urine
594979|NCT00340860|Blood
594980|NCT00340860|Exposure
594981|NCT00340860|Norway Mother and Child Study
594982|NCT00340847|Molecular Profiling
594983|NCT00340847|In Situ Hybridization
594984|NCT00340847|SAGE
594985|NCT00340847|Tumor Markers
594986|NCT00340847|IHC
594987|NCT00340847|Lung Cancer
594988|NCT00340847|Genetics
594989|NCT00340834|FTY720
594990|NCT00340834|Interferon
594991|NCT00340834|RRMS
594992|NCT00340834|Multiple Sclerosis
594993|NCT00340834|Efficacy
594994|NCT00340821|HTLV-I
594995|NCT00340808|Endometrial Cancer
594996|NCT00340808|Epidemiology
594997|NCT00340808|Questionnaire
594998|NCT00340808|Etiology
594999|NCT00340808|Biomarkers
595000|NCT00340795|Media Analysis
595001|NCT00340795|Nutrition
595002|NCT00340795|Physical Activity
595003|NCT00340795|After-School
595004|NCT00340795|Exercise
595005|NCT00340782|Menstrual Cycles
595006|NCT00340782|Early Pregnancy
595007|NCT00340782|Reproductive Hormones
595008|NCT00340782|Stress
595009|NCT00340782|Adrenal Function
595010|NCT00340769|Cytokines
595011|NCT00340769|Inflammation
595012|NCT00340769|mRNA Stability
595013|NCT00340769|Pygmy
595014|NCT00340769|Zinc Finger Proteins
595015|NCT00340769|Ethnic Group
595016|NCT00340756|GCMS
595017|NCT00340756|LCMS-MS
595018|NCT00340743|Heterocyclic Aminos
595019|NCT00340743|Cruciferous Vegetables
595020|NCT00340743|Yogurt
595021|NCT00340743|Chlorophyllin
595022|NCT00340743|Comet Assay
595023|NCT00340743|Diet
595024|NCT00340743|Healthy Volunteer
595025|NCT00340730|Health Education
595026|NCT00340730|Mentoring
595027|NCT00340730|Parenting
595028|NCT00340730|Social Skills Training
595029|NCT00340730|Violence
595030|NCT00340730|Intervention
595031|NCT00340730|Youth Injury
595032|NCT00340717|Methylation
595033|NCT00340717|Genes
595034|NCT00340717|Screening
595035|NCT00340717|Prospective
595036|NCT00340717|Diagnosis
595037|NCT00340704|tamsulosin
595038|NCT00340704|pediatric
595039|NCT00340704|neurogenic bladder
595040|NCT00340691|Parasite
595041|NCT00340691|Chemotherapy
595042|NCT00340691|Wuchereria Bancrofti
595043|NCT00340678|Angiotensin II Receptor Antagonist
595044|NCT00340678|Therapeutic Trial
595045|NCT00340678|Glomerular Filtration Rate
595046|NCT00340678|Kidney Biopsy
595047|NCT00340678|Non-Insulin Dependent Diabetes Mellitus
595048|NCT00340665|Soy
595049|NCT00340665|Infant Formula
595050|NCT00340665|Sexual Development
595051|NCT00340665|Hormone
595052|NCT00340665|Isoflavones
595053|NCT00340652|Soy
595054|NCT00340652|Isoflavones
595055|NCT00340652|Infant Formula
595056|NCT00340652|Sexual Development
595057|NCT00340652|Hormone
595058|NCT00340639|Adherence
595059|NCT00340639|Chronic Illness
595060|NCT00340639|Adolescent
595061|NCT00340639|Family
595062|NCT00340639|Self-Regulation
595063|NCT00340626|Whole Genome Sequencing
595064|NCT00340626|Cleft Palate
595065|NCT00340613|Type 1 Diabetes
595066|NCT00340613|Poorly controlled glucose
595067|NCT00340613|adolescents
595068|NCT00340600|Cancer
595069|NCT00340600|DES
595070|NCT00340600|Endocrine Disrupting Chemicals
595071|NCT00340600|In Utero
595072|NCT00340587|Zona Pellucida
595073|NCT00340587|Human Eggs
595074|NCT00340587|ZP1, ZP2, ZP3
595075|NCT00340587|Fertilization
595076|NCT00340574|Human
595077|NCT00340574|Clinical Trial
595078|NCT00340574|Mosquito
595079|NCT00340574|Healthy Volunteer
595080|NCT00340574|HV
595081|NCT00340561|Test Track
595082|NCT00340561|Distraction
595083|NCT00340561|Motor Vehicle
595084|NCT00340561|Learning
595085|NCT00340561|Inexperience
595086|NCT00340548|Genotyping
595087|NCT00340548|Polymorphisms
595088|NCT00340548|Co-Infection
595089|NCT00340548|Chemokines
595090|NCT00340548|Associations
595091|NCT00340548|HIV
595092|NCT00340548|HCV
595093|NCT00340548|Hepatitis C
595094|NCT00340548|Hemophilia
595095|NCT00340535|Disinfection byproducts
595096|NCT00340535|Genetic Variation
595097|NCT00340535|Trihalomethanes
595098|NCT00340522|Sarcoma
595099|NCT00340522|Brain Tumor
595100|NCT00340522|Embryonal Tumor
595101|NCT00340522|Tumor Array
595102|NCT00340522|Childhood Cancer
595103|NCT00340522|Plexiform Neurofibromas
595104|NCT00340522|Drug Screening
595105|NCT00340522|Immunohistochemistry
595106|NCT00340509|Genetics
595107|NCT00340509|Population
595108|NCT00340509|CHD Risk
595109|NCT00340509|Epidemiology
595110|NCT00340509|Gene Mapping
595111|NCT00340496|Schwannoma
595112|NCT00340496|Meningioma
595113|NCT00340496|Follow-Up
595114|NCT00340496|Radiation Therapy
595115|NCT00340496|Cohort
595116|NCT00340483|Smoking Cessation
595117|NCT00340483|Young Adults
595118|NCT00340483|Quit Smoking
595119|NCT00340483|Email
595120|NCT00340483|Social Marketing
595121|NCT00340470|Injury
595122|NCT00340470|Motor Vehicle
595123|NCT00340470|Parenting
595124|NCT00340470|Randomized Trial
595125|NCT00340470|Behavioral Intervention
595126|NCT00340457|Case-Control Study
595127|NCT00340457|Renal Cell Carcinoma
595128|NCT00340457|Kidney Cancer
595129|NCT00340457|Diet
595130|NCT00340457|Occupation
595131|NCT00340444|Linkage
595132|NCT00340444|Covariates
595133|NCT00340444|Association
595134|NCT00340444|Fine Mapping
595135|NCT00340444|Inflammatory Bowel Disease
595136|NCT00340444|Ulcerative Colitis
595137|NCT00340444|Crohn's Disease
595138|NCT00340431|Human
595139|NCT00340431|Clinical Trial
595140|NCT00340431|Mosquito
595141|NCT00340418|Bronchoalveolar Lavage
595142|NCT00340418|Acute Rejection
595143|NCT00340418|Chronic Rejection
595144|NCT00340418|Genetic Polymorphisms
595145|NCT00340418|Innate Immunity
595146|NCT00340418|Lung Transplantation
595147|NCT00340418|Lung Allograft Rejection
595148|NCT00340405|Blood
595149|NCT00340405|Lung Cancer
595150|NCT00340405|Occupational Exposure
595151|NCT00340405|Radon
595152|NCT00340405|Arsenic
595153|NCT00340392|Mammary Stem Cells
595154|NCT00340392|Breast Cancer
595155|NCT00340392|Cancer Stem Cells
595156|NCT00340392|Gene Expression Profiling
595157|NCT00340379|Psychotic
595158|NCT00340366|Homocysteine
595159|NCT00340366|Vitamin B12
595160|NCT00340366|Birth Defects
595161|NCT00340366|Pregnancy
595162|NCT00340366|Folate
595163|NCT00340366|Irish Individuals
595164|NCT00340353|Gene Expression
595165|NCT00340353|Drug Sensitivity
595166|NCT00340353|TFE3
595167|NCT00340353|ASPL-TFE3
595168|NCT00340353|NOD-SCID Mice
595169|NCT00340353|Sarcoma
595170|NCT00340353|Alveolar Soft Part Sarcoma
595171|NCT00340353|ASPS
595172|NCT00340340|Population-Based Case Control Study
595173|NCT00340340|Lung Cancer
595174|NCT00340340|Epidemiology
595175|NCT00340340|Smoking
595176|NCT00340340|Smokers
595177|NCT00340340|Genetics
595178|NCT00340327|healthy subjects
595179|NCT00340314|symptomatic
595180|NCT00340314|paroxysmal
595181|NCT00340314|atrial fibrillation
595182|NCT00340301|Polymorphism
595183|NCT00340301|Neurodegenerative Diseases
595184|NCT00340301|ALS
595185|NCT00340288|Fibroids
595186|NCT00340288|Life Style/Endrocrinology
595187|NCT00340288|Magnetic Resonance Imaging
595188|NCT00340288|Molecular Characterization
595189|NCT00340288|Symptoms/Clinical Outcome
595190|NCT00340288|Uterine Fibroids
595191|NCT00340275|Bacterial Vaginosis
595192|NCT00340275|Vaginal Infection
595193|NCT00340275|Vaginitis
595194|NCT00340275|Cohort Study
595195|NCT00340275|Sexually Transmitted Disease
595196|NCT00340262|Supplemental Hormone Use
595197|NCT00340262|Osteoporosis
595198|NCT00340262|Endogenous Sex Hormones
595199|NCT00340249|Premature Rupture of the Membranes (PROM)
595200|NCT00340249|Preterm Delivery
595201|NCT00340249|In-Utero Fetal Demise
595202|NCT00340249|Chorioamnionitis
595203|NCT00340249|Spontaneous Abortion
595204|NCT00340223|Immunity
595205|NCT00340223|Mutations
595206|NCT00340223|Viral Selection
595207|NCT00340223|Disease Progression
595208|NCT00340223|RNA
595209|NCT00340210|Biomarkers
595210|NCT00340210|Breast Cancer
595211|NCT00340210|Etiology
595212|NCT00340210|Hormones
595213|NCT00340210|Prospective Study
595214|NCT00340184|concurrent
595215|NCT00340184|chemoradiation
595216|NCT00340184|paclitaxel
595217|NCT00340184|carboplatin
595218|NCT00340171|Intrauterine Growth Retardation
595219|NCT00340171|Macrosomia
595220|NCT00340171|Fetal Volume
595221|NCT00340171|Fetal Anatomy
595222|NCT00340171|Prediction of Birthweight
595223|NCT00340171|3D Ultrasonography
595224|NCT00340171|Fetus
595225|NCT00340171|Prenatal Diagnosis
595226|NCT00340158|Mammary
595227|NCT00340158|Diagnosis
595228|NCT00340158|Aggressive
595229|NCT00340158|Pathology
595230|NCT00340158|Epidemiology
595231|NCT00340132|Non-Insulin Dependent Diabetes
595232|NCT00340132|Insulin Resistance
595233|NCT00340132|Insulin Secretion
595234|NCT00340132|Glucose Tolerance
595235|NCT00340132|Adipose Tissue
595236|NCT00340132|Preadipocytes
595237|NCT00340119|CHOICE Cohort
595238|NCT00340119|End Stage Renal Disease
595239|NCT00340119|Epidemiology
595240|NCT00340119|Prevention
595241|NCT00340119|Single Nucleotide Polymorphisms
595242|NCT00340119|ESRD
595243|NCT00340106|Infant Health Study
595244|NCT00340106|Environmental Tobacco Smoke
595245|NCT00340106|Infant Health
595246|NCT00340093|Adherence
595247|NCT00340093|Behavioral Intervention
595248|NCT00340093|Adolescence
595249|NCT00340093|Self-Regulation
595250|NCT00340093|Behavioral Medicine
595251|NCT00340093|Diabetes
595252|NCT00340080|Abacavir
595253|NCT00340080|Pharmacogenetics
595254|NCT00340080|hypersensitivity
595255|NCT00340080|HLA-B*5701
595256|NCT00340054|brain tumor
595257|NCT00340028|Ovulation
595258|NCT00340028|Diary Record
595259|NCT00340028|Urine Collection
595260|NCT00340028|Leutinizing Hormone
595261|NCT00340028|Blood Collection
595262|NCT00340028|Pregnancy
595263|NCT00340015|Cancer
595264|NCT00340015|Mortality
595265|NCT00340015|Lifestyle Factors
595266|NCT00340015|Cohort
595267|NCT00340002|Fetal Anatomy
595268|NCT00340002|Pregnancy
595269|NCT00340002|Prenatal Diagnosis
595270|NCT00339989|Molecular Markers
595271|NCT00339989|Human Papillomavirus
595272|NCT00339989|Cervix
595273|NCT00339989|Cancer
595274|NCT00339989|Microarray
595275|NCT00339976|Case-Control Study
595276|NCT00339976|Death Certificates
595277|NCT00339976|National Death Index
595278|NCT00339976|Cause of Death Information
595279|NCT00339976|Lead Exposure
595280|NCT00339976|Amyotrophic Lateral Sclerosis
595281|NCT00339976|ALS
595282|NCT00339963|Microarray
595283|NCT00339963|Lymphoma
595284|NCT00339963|Gene Expression
595285|NCT00339963|Molecular Diagnosis
595286|NCT00339963|Prognosis
595287|NCT00339963|Leukemia
595288|NCT00339963|Myeloma
595289|NCT00339963|Lymphoid Malignancy
595290|NCT00339950|Colorectal adenoma
595291|NCT00339950|Screening
595292|NCT00339950|Polyp
595293|NCT00339950|Diet
595294|NCT00339950|Nutrition
595295|NCT00339950|Polymorphism
595296|NCT00339950|Cooking
595297|NCT00339950|Risk Factors
595298|NCT00339937|Human Herpes virus 8 (HHV8)
595299|NCT00339937|Kaposi sarcoma (KS)
595300|NCT00339924|Clinical Decision-Making
595301|NCT00339924|Physician Bias
595302|NCT00339924|Genetics
595303|NCT00339924|Race
595304|NCT00339924|Ethnicity
595305|NCT00339924|Human Genetic Variation
595306|NCT00339911|Repository
595307|NCT00339911|Phlebotomy
595308|NCT00339911|Venipuncture
595309|NCT00339911|Anemia
595310|NCT00339911|Occupational Health Services
595311|NCT00339898|Minimal Residual Disease
595312|NCT00339898|Ewings Sarcoma
595313|NCT00339885|Type 2 Diabetes
595314|NCT00339872|healthy subjects
595315|NCT00339859|Molecular Epidemiology of Lung Cancer
595316|NCT00339859|Health Disparities
595317|NCT00339846|Craniosynostosis
595318|NCT00339846|Craniofrontonasal Syndrome
595319|NCT00339846|CFNS
595320|NCT00339833|Salsalate
595321|NCT00339833|Insulin Resistance
595322|NCT00339833|Diabetes Mellitus
595323|NCT00339833|Inflammation
595324|NCT00339833|Diabetes
595325|NCT00339833|HCV
595326|NCT00339807|Retrovirus
595327|NCT00339807|Caribbean
595328|NCT00339807|Transmission
595329|NCT00339807|Genetic
595330|NCT00339807|Viral Markers
595331|NCT00339807|HTLV-1
595332|NCT00339794|Racial Profiling
595333|NCT00339794|Genomics
595334|NCT00339794|Genetic Testing
595335|NCT00339794|Family History
595336|NCT00339794|Family Physician
595337|NCT00339781|Fetomaternal Microchimerism
595338|NCT00339781|Cell Trafficking
595339|NCT00339781|Discordant Twins
595340|NCT00339781|Maternofetal Microchimerism
595341|NCT00339781|Diabetes Type I
595342|NCT00339781|Twins
595343|NCT00339768|Helicobacter Pylori
595344|NCT00339768|Gastric Cancer Prevention
595345|NCT00339768|Precancerous Gastric Lesions
595346|NCT00339742|Esophageal Cancer
595347|NCT00339742|Case-Control Study
595348|NCT00339742|Environmental Risk Factors
595349|NCT00339742|Genetic Risk Factors
595350|NCT00339729|Children
595351|NCT00339729|Behavior
595352|NCT00339729|Epidemiology
595353|NCT00339729|Lead
595354|NCT00339729|Learning Disorder
595355|NCT00339716|Cohort
595356|NCT00339716|Radiation
595357|NCT00339716|In Utero
595358|NCT00339703|Resistin
595359|NCT00339703|Asthma
595360|NCT00339703|CRP
595361|NCT00339703|Diabetes
595362|NCT00339703|FIZZ
595363|NCT00339690|Asthma
595364|NCT00339690|Allergy
595365|NCT00339690|Intervention
595366|NCT00339690|Behaviors
595367|NCT00339690|Test-Kit
595368|NCT00339690|Dust Mites Allergen
595369|NCT00339677|Measurement Error
595370|NCT00339677|Dietary Assessment
595371|NCT00339677|Dietary Intake
595372|NCT00339677|Energy
595373|NCT00339677|Protein
595374|NCT00339664|Pharmacokinetics
595375|NCT00339664|Quantify
595376|NCT00339664|HPLC
595377|NCT00339664|LC/MS
595378|NCT00339664|Pharmacodynamics
595379|NCT00339651|Precursors
595380|NCT00339651|Endometrial Cancer
595381|NCT00339651|Hyperplasia
595382|NCT00339651|Progression
595383|NCT00339638|Epidemiology
595384|NCT00339638|Risk Prediction
595385|NCT00339638|Biomarkers
595386|NCT00339638|Nested Case Control
595387|NCT00339625|Intervention
595388|NCT00339625|Diet
595389|NCT00339625|Colon
595390|NCT00339612|Perinatal
595391|NCT00339612|HIV
595392|NCT00339612|AIDS
595393|NCT00339599|Atherosclerosis
595394|NCT00339599|Single Nucleotide Polymorphisms
595395|NCT00339599|Monocyte Chemotactic Protein-1
595396|NCT00339599|Inflammation
595397|NCT00339599|Eotaxin
595398|NCT00339586|Non-small cell lung cancer
595399|NCT00339586|tyrosine kinase inhibition
595400|NCT00339586|first-line treatment
595401|NCT00339586|mutant EGFR-gene
595402|NCT00339573|Asthma
595403|NCT00339573|Dust Mite
595404|NCT00339573|Cockroach
595405|NCT00339573|Lead Toxicity
595406|NCT00339573|Allergy
595407|NCT00339560|Ampulla of Vater
595408|NCT00339560|Gallbaldder
595409|NCT00339560|Cancer
595410|NCT00339560|Extrahepatic Bile Duct
595411|NCT00339547|Leiomyomas
595412|NCT00339547|Ultrasound
595413|NCT00339547|Hysterectomy
595414|NCT00339547|Epidemiology
595415|NCT00339547|Hyperinsulinemia
595416|NCT00339534|African Men
595417|NCT00339534|Case-Control Study
595418|NCT00339534|Prostate Cancer
595419|NCT00339534|Cancer
595420|NCT00339521|Asthma
595421|NCT00339521|Mexico
595422|NCT00339521|Candidate Genes
595423|NCT00339521|Triads
595424|NCT00339521|Polymorphism
595425|NCT00339508|Linkage Analysis
595426|NCT00339508|Cancer Genetics
595427|NCT00339508|Software
595428|NCT00339508|Bug Reports
595429|NCT00339508|Computer Programs
595430|NCT00339508|Data Analysis
595431|NCT00339495|Prostate
595432|NCT00339495|Screening Trail
595433|NCT00339495|Ovarian
595434|NCT00339495|Lung
595435|NCT00339495|Colorectal
595436|NCT00339482|Epidemiology
595437|NCT00339482|Type 2 Diabetes
595438|NCT00339482|Vascular Complications
595439|NCT00339482|Retinopathy
595440|NCT00339482|Nephropathy
595441|NCT00339482|Genetics
595442|NCT00339469|Prevention
595443|NCT00339469|Colorectal Neoplasms
595444|NCT00339469|Insulin Resistance
595445|NCT00339469|Inflammation Obesity
595446|NCT00339469|Adenoma
595447|NCT00339456|Therapy
595448|NCT00339456|Africa
595449|NCT00339456|Structured
595450|NCT00339456|Interruption
595451|NCT00339456|Antiretroviral
595452|NCT00339456|HIV
595453|NCT00339443|Buccal Cells
595454|NCT00339443|Concordance
595455|NCT00339443|DNA Yields
595456|NCT00339443|pH Meter
595457|NCT00339443|Urine pH
595458|NCT00339443|Calibration
595459|NCT00339430|Genotyping
595460|NCT00339430|HIV
595461|NCT00339430|HPV
595462|NCT00339430|HCV
595463|NCT00339430|HBV
595464|NCT00339417|Lymphatic Filariasis
595465|NCT00339417|Chemotherapy
595466|NCT00339404|Genotyping
595467|NCT00339404|Linkage Analysis
595468|NCT00339404|Cancer
595469|NCT00339404|Hereditary Melanoma
595470|NCT00339391|Adjustment
595471|NCT00339391|Environmental Complexity
595472|NCT00339391|Mental Illness
595473|NCT00339391|Non-literate
595474|NCT00339391|West Africa
595475|NCT00339391|Stress
595476|NCT00339391|Knowledge
595477|NCT00339391|Mental Health
595478|NCT00339391|AIDS
595479|NCT00339378|Record Linkage
595480|NCT00339378|Retrospective
595481|NCT00339378|Cohort
595482|NCT00339378|Registries
595483|NCT00339378|Agricultural
595484|NCT00339365|Infants
595485|NCT00339365|Toddlers
595486|NCT00339365|Attachment
595487|NCT00339365|Maltreatment
595488|NCT00339365|Foster Care
595489|NCT00339352|Brain
595490|NCT00339352|Exposures
595491|NCT00339352|Genetics
595492|NCT00339352|Glioma
595493|NCT00339352|Occupations
595494|NCT00339339|Dental Materials
595495|NCT00339339|Resins
595496|NCT00339339|BisDMA
595497|NCT00339339|Absorption
595498|NCT00339339|Systemic
595499|NCT00339326|Human Herpes virus 8 (HHV8)
595500|NCT00339326|Kaposis sarcoma (KS)
595501|NCT00339326|Kaposi Sarcoma
595502|NCT00339326|Karposi Sarcoma-Associated Herpesvirus
595503|NCT00339326|KSHV
595504|NCT00339326|KS
595505|NCT00339313|Obesity
595506|NCT00339313|Etiology
595507|NCT00339313|Macronutrient Selection
595508|NCT00339313|Taste Preference
595509|NCT00339313|Mixed Meal Test
595510|NCT00339300|Etiology
595511|NCT00339300|Brain Cancer
595512|NCT00339300|Epidemiology
595513|NCT00339300|Brain Tumors
595514|NCT00339300|Glioma
595515|NCT00339287|Inflammation
595516|NCT00339287|Innate Immunity
595517|NCT00339287|Macrophages
595518|NCT00339287|Neutrophils
595519|NCT00339287|Pathogenesis
595520|NCT00339274|Repositories
595521|NCT00339274|Pathology
595522|NCT00339274|Belarus
595523|NCT00339274|Russia
595524|NCT00339274|Ukraine
595525|NCT00339261|Cardiovascular
595526|NCT00339261|Renal
595527|NCT00339261|Autoimmune Disease
595528|NCT00339261|Genetics
595529|NCT00339261|Mortality
595530|NCT00339248|Hyperplasia
595531|NCT00339248|Atypia
595532|NCT00339248|Polymorphism
595533|NCT00339248|Progression
595534|NCT00339248|Epidemiology
595535|NCT00339235|Preterm Birth Prevention
595536|NCT00339235|Preterm Birth
595537|NCT00339235|Pregnancy
595538|NCT00339235|Pregnancy Complications
595539|NCT00339222|Genetics
595540|NCT00339222|Kindreds
595541|NCT00339222|Mediterranean Population
595542|NCT00339222|Nevi
595543|NCT00339222|Pigmentation
595544|NCT00339222|Melanoma-Prone Families
595545|NCT00339222|Sun Exposure
595546|NCT00339222|Melanoma
595547|NCT00339209|Genetic Polymorphisms
595548|NCT00339209|Acute Rejection
595549|NCT00339209|Bronchiolitis Obliterans Syndrome
595550|NCT00339209|Transplant Rejection
595551|NCT00339209|Innate Immunity
595552|NCT00339209|Lung Transplantation Rejection
595553|NCT00339196|AML
595554|NCT00339196|MDS High risk
595555|NCT00339196|Demethylating agents
595556|NCT00339196|HDAC Inhibitors
595557|NCT00339183|Oncology
595558|NCT00339183|Cancer
595559|NCT00339183|Metastatic Colorectal Cancer
595560|NCT00339183|EGFr
595561|NCT00339183|Panitumumab
595562|NCT00339183|Clinical Trial
595563|NCT00339183|Amgen
595564|NCT00339170|Schizoaffective Disorder
595565|NCT00339170|Schizophrenic Disorders
595566|NCT00339170|Psychotic Disorders
595567|NCT00339170|Cognition
595568|NCT00339157|IDIOPATHIC JUVENILE ARTHRITIS
595569|NCT00339157|PEDIATRICS
595570|NCT00339157|ORPHAN DISEASE
595571|NCT00339157|INTERLEUKIN - 1
595572|NCT00339157|RECEPTORS , INTERLEUKINS
595573|NCT00339157|ANTAGONISTS
595574|NCT00339144|Solid tumors (including relapsed disease) that are refractory to standard therapies or for which no effective standard therapy exists
595575|NCT00339131|radiopharmaceutical
595576|NCT00339131|radiation dosimetry
595577|NCT00339131|iodine
595578|NCT00339131|MIBG
595579|NCT00339131|iobenguane
595580|NCT00339131|Ultratrace
595581|NCT00339131|neuroendocrine tumors
595582|NCT00339105|Acute
595583|NCT00339105|Coronary
595584|NCT00339105|Syndrome
595585|NCT00339105|HyperQ
595586|NCT00339105|High
595587|NCT00339105|Frequency
595588|NCT00339105|ECG
595589|NCT00339105|chest
595590|NCT00339105|pain
595591|NCT00339092|HIV
595592|NCT00339092|ART
595593|NCT00339066|Late-Life Depression
595594|NCT00339053|thoracic aortic aneurysm
595595|NCT00339053|immunonutrition
595596|NCT00339053|respiratory failure
595597|NCT00339053|lenght of stay ICU
595598|NCT00339040|HPV
595599|NCT00339027|child care centers
595600|NCT00339027|community based research
595601|NCT00339027|behavioral health
595602|NCT00339027|health literacy
595603|NCT00339027|unmet healthcare needs
595604|NCT00339001|Erythropoietin
595605|NCT00339001|Iron
595606|NCT00339001|Retinopathy of prematurity
595607|NCT00338988|Gastrointestinal
595608|NCT00338988|Capecitabine
595609|NCT00338988|Oxaliplatin
595610|NCT00338988|Carcinoma of the Gallbladder
595611|NCT00338988|Carcinoma of the Intrahepatic or Extrahepatic Biliary Tract
595612|NCT00338988|Xeloda
595613|NCT00338988|Eloxatin
595614|NCT00338975|Psychotic Disorders
595615|NCT00338975|Schizoaffective Disorder
595616|NCT00338975|Cognitive Behavioral Therapy
595617|NCT00338975|Social Skills Training
595618|NCT00338962|SSRI
595619|NCT00338962|treatment
595620|NCT00338962|naltrexone
595621|NCT00338962|alcohol dependence
595622|NCT00338962|Desipramine
595623|NCT00338962|depression
595624|NCT00338962|PTSD
595625|NCT00338949|Ziprasidone
595626|NCT00338949|Olanzapine
595627|NCT00338949|Risperidone
595628|NCT00338949|Schizoaffective Disorder
595629|NCT00338949|Insulin Sensitivity
595630|NCT00338949|Visceral Adiposity
595631|NCT00338949|Metabolic Syndrome
595632|NCT00338936|Hypertension
595633|NCT00338936|Valsartan
595634|NCT00338936|Hydrochlorothiazide
595635|NCT00338910|healthy volunteers
595636|NCT00338897|Venous Thromboembolism
595637|NCT00338897|Prevention
595638|NCT00338897|Arthroplasty
595639|NCT00338897|Replacement
595640|NCT00338897|Hip
595641|NCT00338897|orthopedic surgery
595642|NCT00338845|STDs
595643|NCT00338832|Lifestyle Intervention
595644|NCT00338832|Schizoaffective Disorder
595645|NCT00337766|Blood Loss
595646|NCT00337766|Postoperative Blood loss
595647|NCT00338819|DVT prevention
595648|NCT00338819|Hemodynamic study
595649|NCT00338819|IPC
595650|NCT00338819|CECT
595651|NCT00338806|Prevention
595652|NCT00338806|Mood Disorders
595653|NCT00338806|Unipolar Depression
595654|NCT00338793|Tuberculosis;
595655|NCT00338793|Pleural effusion;
595656|NCT00338793|Corticosteroids.
595657|NCT00338780|Chronic Hepatitis B
595658|NCT00338780|Lamivudine
595659|NCT00338780|HBeAg negative
595660|NCT00338767|AIDS
595661|NCT00338767|DOT
595662|NCT00338767|Directly Observed Therapy
595663|NCT00338728|Breast Cancer
595664|NCT00338728|Letrozole
595665|NCT00338728|Imatinib Mesylate
595666|NCT00338728|Gleevec
595667|NCT00338728|Femara
595668|NCT00338715|Effectiveness
595669|NCT00338715|Pulmonary Vein Isolation Procedure
595670|NCT00338715|Coronary Artery Bypass Surgery
595671|NCT00338715|Atrial Fibrillation
595672|NCT00338702|Diabetic
595673|NCT00338702|Foot
595674|NCT00338702|Ulcer
595675|NCT00338702|Autologous
595676|NCT00338702|Platelet
595677|NCT00338702|Gel
595678|NCT00338689|infant formula
595679|NCT00338689|protein content
595680|NCT00338689|growth
595681|NCT00338689|obesity
595682|NCT00338689|breast feeding
595683|NCT00338676|Aortic stenosis
595684|NCT00338676|Elderly
595685|NCT00338663|anterior cruciate ligament reconstruction
595686|NCT00338663|knee immobilization
595687|NCT00338663|postoperative pain
595688|NCT00338624|lower urinary tract symptoms
595689|NCT00338624|DITROPAN XL
595690|NCT00338624|oxybutynin extended release tablets
595691|NCT00338611|vision therapy
595692|NCT00338611|orthoptics
595693|NCT00338611|pencil push-up therapy
595694|NCT00338598|glycine
595695|NCT00338598|treatment
595696|NCT00338598|alcohol dependence
595697|NCT00338598|schizophrenia
595698|NCT00338585|PAO
595699|NCT00338585|acute peripheral arterial occlusion
595700|NCT00338585|thrombolysis
595701|NCT00338585|blood clot
595702|NCT00338585|leg attack
595703|NCT00338585|alfimeprase
595704|NCT00338585|thrombus
595705|NCT00338585|embolism
595706|NCT00338585|thromboembolism
595707|NCT00338585|claudication
595708|NCT00338585|thrombolytic
595709|NCT00338585|thrombosis
595710|NCT00338585|plasminogen activator
595711|NCT00338585|arterial flow
595712|NCT00338572|Inflammation
595713|NCT00338572|Blood Pressure, High
595714|NCT00338559|Strabismus
595715|NCT00338559|LMA
595716|NCT00338559|ET Tube
595717|NCT00338559|POV
595718|NCT00338546|Cocaine
595719|NCT00338546|Sympathetic nerve activity
595720|NCT00338546|Blood pressure
595721|NCT00338546|Cutaneous vasoconstriction
595722|NCT00338546|Coronary vasoconstriction
595723|NCT00338533|childhood glaucoma
595724|NCT00338520|Cerebral malaria, phenylalanine, Tanzania
595725|NCT00338507|Chronic Bronchitis
595726|NCT00338507|Chronic Obstructive Pulmonary Disease
595727|NCT00338468|Anemia
595728|NCT00338468|Elderly
595729|NCT00338468|Hemoglobin level
595730|NCT00338468|Chronic Kidney Disease
595731|NCT00338455|Congestive heart failure
595732|NCT00338455|cardiac transplantation
595733|NCT00338455|renal insufficiency
595734|NCT00338455|renal failure
595735|NCT00338455|dialysis
595736|NCT00338455|ultrafiltration
595737|NCT00338455|vasodilator
595738|NCT00338455|Natrecor (nesiritide)
595739|NCT00338442|Immune compromised
595740|NCT00338442|Varicella Zoster Virus ( VZV) Infection
595741|NCT00338442|Pediatric
595742|NCT00338429|sleep onset latency
595743|NCT00338429|bedtime resistance
595744|NCT00338416|Chemotherapy Induced Anemia
595745|NCT00338416|PROCRIT (Epoetin alfa)
595746|NCT00338416|Chemotherapy
595747|NCT00338416|Epoetin alfa
595748|NCT00338403|CPAP pressure of -5cm/water during cold, dry air exposure
595749|NCT00338403|CPAP pressure of 0cm/water during cold, dry air exposure
595750|NCT00338403|CPAP pressure of 5cm/water during cold, dry air exposure
595751|NCT00338403|CPAP pressure of 10cm/water during cold, dry air exposure
595752|NCT00338390|Antiretrovirals
595753|NCT00338390|CD4 cell count
595754|NCT00338390|toxicity
595755|NCT00338377|Melanoma
595756|NCT00338377|Regional nodal disease
595757|NCT00338377|Dendritic Cell Immunization
595758|NCT00338377|Lymphodepletion
595759|NCT00338377|Adoptive Cell Transfer
595760|NCT00338377|T Cells
595761|NCT00338377|Vaccine
595762|NCT00338377|Cyclosphosphamide
595763|NCT00338377|Cytoxan
595764|NCT00338377|Neosar
595765|NCT00338377|Dendritic Cells
595766|NCT00338377|Tumor Infiltrating Lymphocytes
595767|NCT00338377|TIL Cells
595768|NCT00338377|MART Peptide
595769|NCT00338377|Fludarabine
595770|NCT00338377|Fludarabine Phosphate
595771|NCT00338377|Fludara
595772|NCT00338377|Proleukin
595773|NCT00338377|IL-2
595774|NCT00338377|Interleukin-2
595775|NCT00338377|Leptomeningeal disease
595776|NCT00338364|Pediatric pain
595777|NCT00338364|Pediatric anxiety
595778|NCT00338364|Painful procedures
595779|NCT00338338|essential hypertension
595780|NCT00338338|Amlodipine
595781|NCT00338338|blood pressure
595782|NCT00338338|lacidipine
595783|NCT00338325|Pediatric Anxiety
595784|NCT00338325|Pediatric Pain
595785|NCT00338312|Natural Menopause
595786|NCT00338312|HSDD
595787|NCT00338299|Anemia
595788|NCT00338299|hemoglobin
595789|NCT00338299|chemotherapy
595790|NCT00338299|subcutaneous injection
595791|NCT00338299|Epoetin alfa
595792|NCT00338286|anemia
595793|NCT00338286|metastatic breast cancer
595794|NCT00338286|Hemoglobin
595795|NCT00338286|progression-free survival (PFS)
595796|NCT00338286|erythropoiesis-stimulating agents (ESA)
595797|NCT00338273|Bipolar I disorder with major depressive episode
595798|NCT00338247|advanced
595799|NCT00338247|TYKERB
595800|NCT00338247|HER2 positive
595801|NCT00338247|Stage IIIc
595802|NCT00338247|ErbB2 positive
595803|NCT00338247|GW572016
595804|NCT00338247|metastatic
595805|NCT00338247|Stage IIIb
595806|NCT00338247|breast cancer
595807|NCT00338234|anemia
595808|NCT00338234|intensive care
595809|NCT00338234|cardiac surgery
595810|NCT00338234|iron metabolism
595811|NCT00338234|hepcidin
595812|NCT00338221|Diarrhea, Malnutrition, Brazil
595813|NCT00338208|low vision
595814|NCT00338208|glaucoma
595815|NCT00338195|Caffeine dependence
595816|NCT00338195|Caffeine withdrawal
595817|NCT00338182|Solid tumor
595818|NCT00338156|Left Ventricle Remodelling
595819|NCT00338156|Collagen markers
595820|NCT00338156|Neurohormones
595821|NCT00338156|Cardiac MRI
595822|NCT00338143|Plaque psoriasis
595823|NCT00338143|Antipsoriatic
595824|NCT00338130|Melanoma
595825|NCT00338130|Phase II
595826|NCT00338130|AZD6244
595827|NCT00338130|temozolomide
595828|NCT00338117|Dementia
595829|NCT00338117|neurodegenerative disorder
595830|NCT00338117|impairment of memory
595831|NCT00338117|galantamine
595832|NCT00338117|galanthamine
595833|NCT00338117|acetylcholinesterase inhibitor
595834|NCT00338117|Mini Mental State Examination score
595835|NCT00338104|insulin
595836|NCT00338104|glargine
595837|NCT00338104|intravenous
595838|NCT00338104|subcutaneous
595839|NCT00338104|hospital
595840|NCT00338104|diabetes
595841|NCT00338104|glucose
595842|NCT00338104|inpatient
595843|NCT00338091|Renal Insufficiency,Chronic
595844|NCT00338091|Disease Progression
595845|NCT00338091|Proteinuria
595846|NCT00338091|Dose-Response Relationship,Drug
595847|NCT00338091|Benazepril
595848|NCT00338091|Losartan
595849|NCT00338065|Intraocular Pressure
595850|NCT00338052|Contraception
595851|NCT00338039|Pancreatic Cancer
595852|NCT00338039|Cetuximab
595853|NCT00338039|C225
595854|NCT00338039|Erbitux
595855|NCT00338039|Gemcitabine
595856|NCT00338039|Oxaliplatin
595857|NCT00338039|Eloxatin
595858|NCT00338039|Capecitabine
595859|NCT00338039|Xeloda
595860|NCT00338026|Solid Tumors
595861|NCT00338026|Thallion
595862|NCT00338026|TLN-4601
595863|NCT00338026|Ecopia
595864|NCT00338026|ECO-4601
595865|NCT00338026|Patients with histologically confirmed solid tumors:
595866|NCT00338026|High Grade Glioma
595867|NCT00338026|Colorectal
595868|NCT00338026|Lung
595869|NCT00338026|Breast
595870|NCT00338026|Ovarian
595871|NCT00338026|Pancreatic
595872|NCT00338026|Prostate
595873|NCT00338013|sleep
595874|NCT00338000|Chronic renal failure
595875|NCT00338000|left ventricular hypertrophy
595876|NCT00338000|epoetin alfa
595877|NCT00337974|cognitive enhancement
595878|NCT00337974|memory
595879|NCT00337974|auditory memory
595880|NCT00337974|speech
595881|NCT00337974|computerized
595882|NCT00337961|Optic Nerve Sheath Fenestration
595883|NCT00337948|Anemia
595884|NCT00337948|Epoetin Alfa
595885|NCT00337948|Chemotherapy
595886|NCT00337948|Anemia due to Cancer
595887|NCT00337935|Long Term Care Facilities
595888|NCT00337935|subcutaneous injections
595889|NCT00337935|PROCRIT
595890|NCT00337935|Epoetin alfa
595891|NCT00337935|Anemia
595892|NCT00337922|EPZICOM
595893|NCT00337922|Lamivudine
595894|NCT00337922|Abacavir
595895|NCT00337922|pharmacokinetics
595896|NCT00337922|Japanese
595897|NCT00337909|cognitive enhancement
595898|NCT00337909|memory
595899|NCT00337909|auditory memory
595900|NCT00337909|speech
595901|NCT00337909|computerized
595902|NCT00337896|vaccine, influenza, A/H5N1, CMI, sub-study
595903|NCT00337883|Glioblastoma Multiforme
595904|NCT00337883|glioma
595905|NCT00337883|Grade IV glioma
595906|NCT00337870|Pediatric Anxiety
595907|NCT00337870|Pediatric Pain
595908|NCT00337870|Emergency room procedures
595909|NCT00337818|Non-inferiority
595910|NCT00337818|Immunogenicity
595911|NCT00337818|HPV Vaccine Consistency
595912|NCT00337805|colloid
595913|NCT00337805|crystalloid
595914|NCT00337805|hemodynamics
595915|NCT00337805|flow-directed
595916|NCT00337805|resuscitation
595917|NCT00337753|Gambling
595918|NCT00337714|Central venous catheter,
595919|NCT00337714|bloodstream infections,
595920|NCT00337714|intensive care unit
595921|NCT00337688|Cerebral Palsy
595922|NCT00337688|Spasticity
595923|NCT00337688|Joystick
595924|NCT00337688|Wheelchair
595925|NCT00337688|rehabilitation
595926|NCT00337636|NCL
595927|NCT00337636|INCL
595928|NCT00337636|LINCL
595929|NCT00337636|Batten disease
595930|NCT00337636|Infantile Neuronal Ceroid Lipofuscinosis (INCL)
595931|NCT00337636|Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
595932|NCT00337623|Cataracts
595933|NCT00337623|Corticosteroids
595934|NCT00337623|Scheimpflug
595935|NCT00337623|Lens autofluorescence
595936|NCT00337597|Normal saline
595937|NCT00337597|Dextrose 5% in water
595938|NCT00337597|neurostimulation
595939|NCT00337597|Continuous regional analgesia after total knee arthroplasty
595940|NCT00337584|out patient surgery
595941|NCT00337584|quality improvement
595942|NCT00337571|Serious behavioral problems in children and adolescents with AD
595943|NCT00337558|treatment outcomes
595944|NCT00337558|Overactive bladder
595945|NCT00337558|Solifenacin succinate
595946|NCT00337558|urinary incontinence
595947|NCT00337558|urge incontinence
595948|NCT00337558|frequency
595949|NCT00337545|Metastatic
595950|NCT00337545|Refractory
595951|NCT00337519|chronic lymphocytic leukemia
595952|NCT00337519|reduced intensity conditioning
595953|NCT00337519|alemtuzumab
595954|NCT00337519|allogeneic stem cell transplantation
595955|NCT00337506|the efficacy and safety of Velcade plus dexamethasone
595956|NCT00337506|Multiple Myeloma
595957|NCT00337480|acute coronary syndrome
595958|NCT00337480|cardiovascular risk factors
595959|NCT00337480|smoking habits
595960|NCT00337480|obesity
595961|NCT00337480|sedentary lifestyle
595962|NCT00337480|overweight
595963|NCT00337480|education
595964|NCT00337480|follow up after hospitalization
595965|NCT00337467|HIV-Infected Patients Evidencing Virologic Suppression
595966|NCT00337454|Imatinib resistant or intolerant CML
595967|NCT00337454|Treatment resistant or intolerant Ph+ALL
595968|NCT00337441|Chronic Anemia
595969|NCT00337441|Anemia
595970|NCT00337441|Chronic Diseases
595971|NCT00337441|Elderly
595972|NCT00337441|Epoetin alfa
595973|NCT00337441|Fatigue
595974|NCT00337441|Quality of life
595975|NCT00337441|Mobility
595976|NCT00337402|Gastrostomy
595977|NCT00337402|Quality of life
595978|NCT00337389|Metastatic
595979|NCT00337389|Colorectal
595980|NCT00337389|Cancer
595981|NCT00337389|CoFactor
595982|NCT00337389|Stage IV
595983|NCT00337350|Schizophrenia
595984|NCT00337350|Glucose Metabolism
595985|NCT00337350|Insulin Resistance
595986|NCT00337337|Diabetes
595987|NCT00337337|rice
595988|NCT00337337|fiber
595989|NCT00337324|Diabetic neuropathy
595990|NCT00337324|Complications of diabetes
595991|NCT00337324|Neuropathies
595992|NCT00337324|Electromagnetic stimulation
595993|NCT00337324|Neuropathic pain
595994|NCT00337298|Diabetes
595995|NCT00337298|Retinopathy
595996|NCT00337298|Blood Pressure
595997|NCT00337298|Amlodipine
595998|NCT00337298|Lisinopril
595999|NCT00337285|Attention Deficit Hyperactivity Disorder
596000|NCT00337285|Attention Deficit Disorders with Hyperactivity
596001|NCT00337285|Attention Deficit Hyperactivity Disorders
596002|NCT00337272|chronic insomnia
596003|NCT00337259|marginal zone lymphoma
596004|NCT00337259|gemcitabine
596005|NCT00337246|refractory chronic lymphocytic leukemia
596006|NCT00337246|stage I chronic lymphocytic leukemia
596007|NCT00337246|stage II chronic lymphocytic leukemia
596008|NCT00337246|stage III chronic lymphocytic leukemia
596009|NCT00337246|stage IV chronic lymphocytic leukemia
596010|NCT00337233|fatigue
596011|NCT00337233|psychosocial effects of cancer and its treatment
596012|NCT00337233|recurrent breast cancer
596013|NCT00337233|stage I breast cancer
596014|NCT00337233|stage II breast cancer
596015|NCT00337233|stage IIIA breast cancer
596016|NCT00337233|stage IIIB breast cancer
596017|NCT00337233|stage IIIC breast cancer
596018|NCT00337233|stage IV breast cancer
596019|NCT00337233|recurrent ovarian epithelial cancer
596020|NCT00337233|recurrent ovarian germ cell tumor
596021|NCT00337233|stage I ovarian epithelial cancer
596022|NCT00337233|stage I ovarian germ cell tumor
596023|NCT00337233|stage II ovarian epithelial cancer
596024|NCT00337233|stage II ovarian germ cell tumor
596025|NCT00337233|stage III ovarian epithelial cancer
596026|NCT00337233|stage III ovarian germ cell tumor
596027|NCT00337233|stage IV ovarian epithelial cancer
596028|NCT00337233|stage IV ovarian germ cell tumor
596029|NCT00337220|allograft
596030|NCT00337220|graft
596031|NCT00337207|adult glioblastoma
596032|NCT00337207|adult gliosarcoma
596033|NCT00337207|recurrent adult brain tumor
596034|NCT00337207|adult anaplastic astrocytoma
596035|NCT00337207|adult giant cell glioblastoma
596036|NCT00337181|HIV-1
596037|NCT00337181|Natural History
596038|NCT00337181|HIV vaccine
596039|NCT00337181|Thailand
596040|NCT00337168|recurrent adult acute lymphoblastic leukemia
596041|NCT00337168|L1 adult acute lymphoblastic leukemia
596042|NCT00337168|L2 adult acute lymphoblastic leukemia
596043|NCT00337168|B-cell adult acute lymphoblastic leukemia
596044|NCT00337168|T-cell adult acute lymphoblastic leukemia
596045|NCT00337155|Recurrent Prostate Cancer
596046|NCT00337155|metastatic Cancer
596047|NCT00337142|gestational diabetes
596048|NCT00337142|newborn
596049|NCT00337142|hypoglycemia
596050|NCT00337129|metastatic squamous neck cancer with occult primary squamous cell carcinoma
596051|NCT00337129|recurrent metastatic squamous neck cancer with occult primary
596052|NCT00337129|recurrent squamous cell carcinoma of the hypopharynx
596053|NCT00337129|recurrent squamous cell carcinoma of the larynx
596054|NCT00337129|recurrent squamous cell carcinoma of the lip and oral cavity
596055|NCT00337129|recurrent squamous cell carcinoma of the oropharynx
596056|NCT00337129|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
596057|NCT00337129|stage IV squamous cell carcinoma of the hypopharynx
596058|NCT00337129|stage IV squamous cell carcinoma of the larynx
596059|NCT00337129|stage IV squamous cell carcinoma of the lip and oral cavity
596060|NCT00337129|stage IV squamous cell carcinoma of the oropharynx
596061|NCT00337129|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
596062|NCT00337129|untreated metastatic squamous neck cancer with occult primary
596063|NCT00337129|salivary gland squamous cell carcinoma
596064|NCT00337090|Over Active Bladder
596065|NCT00337090|Urinary incontinence
596066|NCT00337090|YM178
596067|NCT00337090|Symptomatic Over Active Bladder
596068|NCT00337077|Eribulin Mesylate
596069|NCT00337077|metastatic hormone refractory prostate cancer
596070|NCT00337077|Halichondrin B Analog
596071|NCT00337064|Breast cancer treatment
596072|NCT00337064|Partial breast radiation
596073|NCT00337064|Radiation Therapy
596074|NCT00337064|Adjuvant Treatment
596075|NCT00337051|Renal transplantation
596076|NCT00337051|renal allograft
596077|NCT00337051|end-stage renal disease
596078|NCT00337051|renal failure
596079|NCT00337051|general anaesthesia
596080|NCT00337051|inhaled anaesthetic
596081|NCT00337051|Sevoflurane
596082|NCT00337051|ischemia
596083|NCT00337051|reperfusion
596084|NCT00337051|ischemic lesions
596085|NCT00336973|Plaque Psoriasis
596086|NCT00336973|Raptiva
596087|NCT00336973|Anti-TNF
596088|NCT00336960|stage II rectal cancer
596089|NCT00336960|stage III rectal cancer
596090|NCT00336960|adenocarcinoma of the rectum
596091|NCT00336947|stage III squamous cell carcinoma of the hypopharynx
596092|NCT00336947|stage IV squamous cell carcinoma of the hypopharynx
596093|NCT00336947|stage III squamous cell carcinoma of the larynx
596094|NCT00336947|stage IV squamous cell carcinoma of the larynx
596095|NCT00336947|stage III squamous cell carcinoma of the lip and oral cavity
596096|NCT00336947|stage IV squamous cell carcinoma of the lip and oral cavity
596097|NCT00336947|stage III squamous cell carcinoma of the oropharynx
596098|NCT00336947|stage IV squamous cell carcinoma of the oropharynx
596099|NCT00336947|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
596100|NCT00336947|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
596101|NCT00336934|adenocarcinoma of the prostate
596102|NCT00336934|recurrent prostate cancer
596103|NCT00336934|stage I prostate cancer
596104|NCT00336934|stage II prostate cancer
596105|NCT00336934|stage III prostate cancer
596106|NCT00336934|stage IV prostate cancer
596107|NCT00336908|Intensive Care,Neonatal
596108|NCT00336908|Parenteral nutrition
596109|NCT00336908|Fat emulsions,Intravenous
596110|NCT00336895|Liver transplantation
596111|NCT00336895|mycophenolate mofetil
596112|NCT00336895|gastrointestinal
596113|NCT00336895|adverse effects
596114|NCT00336882|traumatic brain injury
596115|NCT00336882|propofol
596116|NCT00336882|oxidative stress
596117|NCT00336882|microdialysis
596118|NCT00336856|Colon Cancer
596119|NCT00336843|Zevalin
596120|NCT00336843|B-cell non-Hodgkin's lymphoma
596121|NCT00336843|autologous stem cell transplantation
596122|NCT00336843|BuCyE regimen
596123|NCT00336830|Cardiac Rehabilitation
596124|NCT00336830|Improving Cardiac Rehabilitation Participation
596125|NCT00336830|coronary angioplasty
596126|NCT00336830|coronary artery bypass surgery
596127|NCT00336817|Liver transplantation
596128|NCT00336817|mycophenolate mofetil
596129|NCT00336817|gastrointestinal
596130|NCT00336817|adverse effects
596131|NCT00336791|Breast Cancer
596132|NCT00336791|Gene Expression
596133|NCT00336791|Fluorouracil
596134|NCT00336791|Cyclophosphamide
596135|NCT00336791|Doxorubicin
596136|NCT00336791|Paclitaxel
596137|NCT00336765|solid tumors
596138|NCT00336752|undisplaced ,unstable wEBER B ankle fractures
596139|NCT00336752|operative intervention
596140|NCT00336752|non operative intervention
596141|NCT00336739|Gastric acidity determination
596142|NCT00336739|Calcium sensing receptor
596143|NCT00336713|depression
596144|NCT00336713|antidepressive agents
596145|NCT00336713|controlled clinical trial
596146|NCT00336700|Pancreas
596147|NCT00336700|Cancer
596148|NCT00336700|Pancreatic
596149|NCT00336687|Thrombopenia
596150|NCT00336687|Reanimation
596151|NCT00336687|Thrombopenia in reanimation
596152|NCT00336674|Type 1 diabetes
596153|NCT00336661|Periodontitis
596154|NCT00336661|Chronic Periodontitis
596155|NCT00336661|Gingivitis
596156|NCT00336661|PERIOWAVE
596157|NCT00336661|Photodynamic Disinfection
596158|NCT00336648|Pancreatic Neoplasms
596159|NCT00336648|Bevacizumab
596160|NCT00336648|Gemcitabine
596161|NCT00336648|Radiation Therapy
596162|NCT00336648|adenocarcinoma of the pancreatic head
596163|NCT00336648|adenocarcinoma of the uncinate process
596164|NCT00336635|smallpox, vaccine, immunity
596165|NCT00336622|Carpal Tunnel Syndrome
596166|NCT00336622|Splints
596167|NCT00336596|middle cerebral artery occlusion
596168|NCT00336596|intracranial embolism and thrombosis
596169|NCT00336596|ultrasound enhanced thrombolysis
596170|NCT00336596|Patients receiving iv thrombolytic therapy (t-PA)
596171|NCT00336583|oxaliplatin
596172|NCT00336583|ESHAOX
596173|NCT00336583|refractory
596174|NCT00336583|relapsed
596175|NCT00336583|non-hodgkin's lymphoma
596176|NCT00336570|Oxidative Stress
596177|NCT00336570|Endothelial Function
596178|NCT00336570|Flow Mediated Dilation
596179|NCT00336557|High-Dose Interferon
596180|NCT00336557|Neutralizing Antibodies
596181|NCT00336544|Pneumonia
596182|NCT00336544|Respiratory
596183|NCT00336544|Infection
596184|NCT00336544|Infectious
596185|NCT00336544|Advanced
596186|NCT00336544|Life
596187|NCT00336544|Sciences
596188|NCT00336544|Lung
596189|NCT00336544|Pulmonary
596190|NCT00336544|Cethromycin
596191|NCT00336544|Clarithromycin
596192|NCT00336544|Biaxin
596193|NCT00336531|prophylactic itraconazole
596194|NCT00336531|Relapsed pediatric solid tumors
596195|NCT00336531|Embryonal brain tumor
596196|NCT00336505|Pneumonia
596197|NCT00336505|Respiratory
596198|NCT00336505|Infection
596199|NCT00336505|Infectious
596200|NCT00336505|Advanced
596201|NCT00336505|Life
596202|NCT00336505|Sciences
596203|NCT00336505|Lung
596204|NCT00336505|Pulmonary
596205|NCT00336505|Cethromycin
596206|NCT00336505|Restanza
596207|NCT00336505|Clarithromycin
596208|NCT00336505|Biaxin
596209|NCT00336492|Ulcerative colitis
596210|NCT00336492|inflammatory bowel disease
596211|NCT00336492|children
596212|NCT00336466|Cardiac bypass surgery
596213|NCT00336453|Influenza
596214|NCT00336427|MRSA
596215|NCT00336427|Colonization
596216|NCT00336427|Pregnancy
596217|NCT00336427|Neonates
596218|NCT00336414|Juvenile Systemic Lupus Erythematosus nephritis
596219|NCT00336414|randomised actively controlled clinical trial
596220|NCT00336414|cyclophosphamide
596221|NCT00336414|prednisone
596222|NCT00336414|azathioprine
596223|NCT00336414|methylprednisolone
596224|NCT00336401|anesthesia
596225|NCT00336401|non cardiac surgery
596226|NCT00336401|cardiac outcomes
596227|NCT00336388|Malaria
596228|NCT00336362|Beta Thalassemia Major
596229|NCT00336362|Hematopoietic Stem Cell Mobilization
596230|NCT00336362|Gene Transfer Techniques
596231|NCT00336349|diabetes mellitus
596232|NCT00336349|neuropathic pain
596233|NCT00336323|diabetic
596234|NCT00336323|macular
596235|NCT00336323|edema
596236|NCT00336323|avastin
596237|NCT00336323|bevacizumab
596238|NCT00336323|anti-VEGF
596239|NCT00336323|retinal thickness
596240|NCT00336323|visual acuity
596241|NCT00336323|DME
596242|NCT00336310|Diabetes Mellitus
596243|NCT00336310|Treatment
596244|NCT00336310|Repaglinide
596245|NCT00336297|screening
596246|NCT00336297|screening methods
596247|NCT00336297|intimate partner violence
596248|NCT00336284|Telemonitoring
596249|NCT00336284|ICD
596250|NCT00336284|Reduction of office follow-ups
596251|NCT00336271|coffee
596252|NCT00336271|caffeine
596253|NCT00336271|healthy subjects
596254|NCT00336258|Deep Vein Thrombosis
596255|NCT00336258|Cancer
596256|NCT00336258|US- Doppler
596257|NCT00336258|Procoagulant Microparticles
596258|NCT00336258|Asymptomatic
596259|NCT00336245|Contraception
596260|NCT00336245|Women
596261|NCT00336245|HIV/AIDS
596262|NCT00336245|IUD
596263|NCT00336245|IUCD
596264|NCT00336232|Vitamin K metabolism
596265|NCT00336232|Bone health
596266|NCT00336232|Metabolism
596267|NCT00336219|GERD
596268|NCT00336219|Pantoprazole
596269|NCT00336206|Low dose Alemtuzumab
596270|NCT00336206|Chronic lymphocytic leukemia
596271|NCT00336206|B-Cell
596272|NCT00336193|home visitation
596273|NCT00336193|family outcomes
596274|NCT00336193|competency training
596275|NCT00336180|Adolescent
596276|NCT00336180|Adolescent behavior
596277|NCT00336180|Adolescent development
596278|NCT00336180|Drinking behavior
596279|NCT00336180|Health behavior
596280|NCT00336180|Reproductive Behavior
596281|NCT00336180|Sexual Behavior
596282|NCT00336180|South Africa
596283|NCT00336167|carnitine palmitoyl transferase 2 deficiency
596284|NCT00336167|Fatty acid oxidation
596285|NCT00336167|Mitochondria
596286|NCT00336128|infant
596287|NCT00336128|kindergarten
596288|NCT00336128|obesity
596289|NCT00336128|adiposity
596290|NCT00336115|pertussis
596291|NCT00336115|bone marrow transplant
596292|NCT00336102|fatigue
596293|NCT00336102|hypothyroidism
596294|NCT00336102|stage I breast cancer
596295|NCT00336102|stage II breast cancer
596296|NCT00336102|stage IIIA breast cancer
596297|NCT00336102|stage IIIB breast cancer
596298|NCT00336089|fatigue
596299|NCT00336089|pain
596300|NCT00336089|cancer survivor
596301|NCT00336089|breast cancer in situ
596302|NCT00336089|inflammatory breast cancer
596303|NCT00336089|stage IA breast cancer
596304|NCT00336089|stage IB breast cancer
596305|NCT00336089|stage II breast cancer
596306|NCT00336089|stage IIIA breast cancer
596307|NCT00336089|stage IIIB breast cancer
596308|NCT00336089|stage IIIC breast cancer
596309|NCT00336089|stage IV breast cancer
596310|NCT00336089|recurrent breast cancer
596311|NCT00336076|Mast cell disease
596312|NCT00336076|Anaphylaxis
596313|NCT00336076|c-kit
596314|NCT00336076|Mutation
596315|NCT00336076|Mastocytosis (suspected or proven)
596316|NCT00336050|Air Pollution
596317|NCT00336050|Pulmonary Function
596318|NCT00336011|pacemaker
596319|NCT00336011|magnetic resonance imaging
596320|NCT00336011|safety
596321|NCT00335985|polymyositis, dermatomyositis
596322|NCT00335985|High-dose intravenous immunoglobulin
596323|NCT00335985|Venoglobulin-IH
596324|NCT00335985|Steroid-resistant polymyositis(PM) and dermatomyositis(DM)
596325|NCT00335972|Carotid Endarterectomy patients
596326|NCT00335959|adenocarcinoma of the stomach
596327|NCT00335959|stage I gastric cancer
596328|NCT00335959|stage II gastric cancer
596329|NCT00335959|stage III gastric cancer
596330|NCT00335933|Postherpetic Neuralgia (PHN)
596331|NCT00335920|Sudden Hearing Loss
596332|NCT00335920|intratympanic
596333|NCT00335920|steroids
596334|NCT00335907|Clinical trial
596335|NCT00335907|Controlled clinical trial
596336|NCT00335907|Shock, Septic
596337|NCT00335894|Infertility
596338|NCT00335894|IVF
596339|NCT00335894|ART
596340|NCT00335894|hMG
596341|NCT00335881|Prophylaxis for hepatitis B disease
596342|NCT00335868|accelerated phase chronic myelogenous leukemia
596343|NCT00335868|blastic phase chronic myelogenous leukemia
596344|NCT00335868|chronic phase chronic myelogenous leukemia
596345|NCT00335868|relapsing chronic myelogenous leukemia
596346|NCT00335855|Device, influenza
596347|NCT00335829|localized unresectable adult primary liver cancer
596348|NCT00335829|adult primary hepatocellular carcinoma
596349|NCT00335829|advanced adult primary liver cancer
596350|NCT00335829|recurrent adult primary liver cancer
596351|NCT00335816|stage II rectal cancer
596352|NCT00335816|stage III rectal cancer
596353|NCT00335816|adenocarcinoma of the rectum
596354|NCT00335751|recurrent adult soft tissue sarcoma
596355|NCT00335751|stage I adult soft tissue sarcoma
596356|NCT00335751|localized osteosarcoma
596357|NCT00335751|metastatic osteosarcoma
596358|NCT00335751|recurrent osteosarcoma
596359|NCT00335751|stage II adult soft tissue sarcoma
596360|NCT00335751|stage III adult soft tissue sarcoma
596361|NCT00335751|stage IV adult soft tissue sarcoma
596362|NCT00335725|Ovarian stimulation
596363|NCT00335725|Infertility
596364|NCT00335725|ICSI
596365|NCT00335725|FSH
596366|NCT00335712|ONO-5129
596367|NCT00335712|type 2 diabetes mellitus
596368|NCT00335699|Hypercholesterolemia with nondiabetic metabolic syndrome
596369|NCT00335686|Mitochondrial toxicity
596370|NCT00335686|Lopinavir-rtv
596371|NCT00335686|Nevirapine
596372|NCT00335686|DNA mitochondrial/DNA nuclear
596373|NCT00335660|Idiopathic Detrusor Overactivity
596374|NCT00335660|NK-1 Receptor Antagonist
596375|NCT00335660|Neurokinin
596376|NCT00335660|Urge Incontinence
596377|NCT00335647|stage III multiple myeloma
596378|NCT00335647|refractory multiple myeloma
596379|NCT00335647|stage II multiple myeloma
596380|NCT00335634|Prostate Cancer
596381|NCT00335634|Radical Prostatectomy
596382|NCT00335634|Sexual Dysfunction
596383|NCT00335634|Intimacy
596384|NCT00335634|Adaptation
596385|NCT00335634|Psychosocial Oncology
596386|NCT00335621|COPD
596387|NCT00335621|ipratropium
596388|NCT00335621|tiotropium
596389|NCT00335595|colorectal cancer
596390|NCT00335595|Bevacizumab
596391|NCT00335595|capecitabine
596392|NCT00335595|oxaliplatin
596393|NCT00335582|alpha 2 agonists
596394|NCT00335582|cardiac events
596395|NCT00335582|non cardiac surgery
596396|NCT00335569|Infertility, sterility, hCG, IVF
596397|NCT00335543|adenocarcinoma of the pancreas
596398|NCT00335543|stage I pancreatic cancer
596399|NCT00335543|stage II pancreatic cancer
596400|NCT00335543|stage III pancreatic cancer
596401|NCT00335517|Lumbar surgery
596402|NCT00335517|Surgery L3-S1
596403|NCT00335517|DepoDur
596404|NCT00335517|Post-operative pain
596405|NCT00335517|Pain control
596406|NCT00335517|Pain relief
596407|NCT00335491|small cell lung cancer
596408|NCT00335491|non-small cell lung cancer
596409|NCT00335491|colon cancer
596410|NCT00335491|prostate cancer
596411|NCT00335491|breast cancer
596412|NCT00335491|male breast cancer
596413|NCT00335491|fatigue
596414|NCT00335491|lymphoma
596415|NCT00335491|ovarian epithelial cancer
596416|NCT00335491|bladder cancer
596417|NCT00335491|esophageal cancer
596418|NCT00335478|neutropenia
596419|NCT00335478|infection
596420|NCT00335478|unspecified adult solid tumor, protocol specific
596421|NCT00335478|fever, sweats, and hot flashes
596422|NCT00335452|platelet aggregation inhibitors
596423|NCT00335452|acute coronary disease
596424|NCT00335452|percutaneous coronary
596425|NCT00335413|Renal autoregulation
596426|NCT00335413|Glomerular filtration rate
596427|NCT00335413|Type 1 diabetes
596428|NCT00335374|Parkinson's disease
596429|NCT00335361|Male Contraceptive Devices
596430|NCT00335361|Intra Vas Device (IVD)
596431|NCT00335361|Male Sterilization
596432|NCT00335361|Vasectomy
596433|NCT00335361|Intra Vas Deferens Occlusion
596434|NCT00335361|Vas Occlusion
596435|NCT00335348|Multiple Myeloma
596436|NCT00335348|Relapse
596437|NCT00335348|Bortezomib
596438|NCT00335348|Dexamethasone
596439|NCT00335348|Maintenance
596440|NCT00335335|Coronary
596441|NCT00335335|Angiography
596442|NCT00335335|X-ray
596443|NCT00335335|CAD
596444|NCT00335322|Human Immunodeficiency Virus (HIV)
596445|NCT00335309|chronic rhinosinusitis
596446|NCT00335309|sinus irrigation
596447|NCT00335296|PFO
596448|NCT00335296|Migraine
596449|NCT00335296|Stroke
596450|NCT00335296|TIA (transient ischemic attack)
596451|NCT00335296|Decompression Illness
596452|NCT00335270|HIV Type 1
596453|NCT00335257|Drospirenone
596454|NCT00335257|Safety
596455|NCT00335257|INAS
596456|NCT00335231|Post-cataract surgery endophthalmitis
596457|NCT00335218|Early postmenopausal state
596458|NCT00335218|Climacteric symptoms
596459|NCT00335218|Hormone replacement therapy
596460|NCT00335205|ropinirole
596461|NCT00335205|dopamine
596462|NCT00335205|D2
596463|NCT00335205|depression
596464|NCT00335205|bipolar
596465|NCT00335192|Intracellular concentrations
596466|NCT00335192|Plasma concentration
596467|NCT00335192|Abacavir
596468|NCT00335192|Tenofovir
596469|NCT00335192|Lamivudine (3TC)
596470|NCT00335192|Pharmacokinetic interactions
596471|NCT00335179|Actinic keratosis
596472|NCT00335179|AK
596473|NCT00335179|imiquimod
596474|NCT00335179|confocal microscopy
596475|NCT00335179|gene microarray
596476|NCT00335166|Parkinson Disease
596477|NCT00335153|severe motor fluctuations
596478|NCT00335153|levodopa
596479|NCT00335153|levodopa/carbidopa intestinal gel
596480|NCT00335153|efficacy
596481|NCT00335153|dyskinesia
596482|NCT00335153|Parkinson's Disease
596483|NCT00335153|carbidopa
596484|NCT00335153|DUOPA
596485|NCT00335140|primary central nervous system non-Hodgkin lymphoma
596486|NCT00335114|cyclosporine, dry eye syndrome, contact lens
596487|NCT00335101|Coronary Artery Disease (CAD), Renal Impairment, Serum creatinine (SCr), Iodixanol, Ioversol, Iopromide, Contrast Induced Nephropathy (CIN)
596488|NCT00335088|Prophylaxis,
596489|NCT00335088|Intraocular surgery
596490|NCT00335088|Lacrimal sac
596491|NCT00335088|Eye lid
596492|NCT00335088|No conditions
596493|NCT00335062|Autoimmune thyroid disease
596494|NCT00335062|Children and Adolescents
596495|NCT00335062|TSH Receptor Antibodies
596496|NCT00335049|myopia progression
596497|NCT00335049|bifocal
596498|NCT00335036|Implantable Cardioverter Defibrillator
596499|NCT00335036|Ventricular Arrhythmia
596500|NCT00335036|Sudden Cardiac Death
596501|NCT00335036|Congenital Heart Disease
596502|NCT00335036|Pediatric Electrophysiology
596503|NCT00335023|postpartum hemorrhage
596504|NCT00335023|red blood cell transfusion
596505|NCT00335023|health related quality of life
596506|NCT00335010|Nitroglycerine
596507|NCT00335010|gastroesophageal anastomosis
596508|NCT00335010|microvascular bloodflow
596509|NCT00335010|microvascular hemoglobinsaturation
596510|NCT00334997|stage I squamous cell carcinoma of the larynx
596511|NCT00334997|stage II squamous cell carcinoma of the larynx
596512|NCT00334997|stage 0 laryngeal cancer
596513|NCT00334984|childhood fibrosarcoma
596514|NCT00334984|childhood neurofibrosarcoma
596515|NCT00334984|childhood synovial sarcoma
596516|NCT00334984|chondrosarcoma
596517|NCT00334984|localized osteosarcoma
596518|NCT00334984|metastatic osteosarcoma
596519|NCT00334984|metastatic childhood soft tissue sarcoma
596520|NCT00334984|nonmetastatic childhood soft tissue sarcoma
596521|NCT00334984|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
596522|NCT00334984|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
596523|NCT00334984|previously treated childhood rhabdomyosarcoma
596524|NCT00334984|previously untreated childhood rhabdomyosarcoma
596525|NCT00334984|childhood alveolar soft-part sarcoma
596526|NCT00334984|childhood angiosarcoma
596527|NCT00334984|childhood epithelioid sarcoma
596528|NCT00334984|childhood leiomyosarcoma
596529|NCT00334984|childhood liposarcoma
596530|NCT00334984|localized childhood malignant fibrous histiocytoma of bone
596531|NCT00334984|metastatic childhood malignant fibrous histiocytoma of bone
596532|NCT00334984|childhood malignant mesenchymoma
596533|NCT00334984|dermatofibrosarcoma protuberans
596534|NCT00334984|childhood desmoplastic small round cell tumor
596535|NCT00334971|African-American
596536|NCT00334971|estradiol
596537|NCT00334971|luteinizing hormone
596538|NCT00334971|follicle stimulating hormone
596539|NCT00334971|androstenedione
596540|NCT00334971|aromatase
596541|NCT00334971|inhibins
596542|NCT00334971|ovarian
596543|NCT00334971|Healthy volunteers
596544|NCT00334971|Fragile X
596545|NCT00334945|Fibroblast Growth Factors
596546|NCT00334945|Bone development
596547|NCT00334932|refractory multiple myeloma
596548|NCT00334932|stage I multiple myeloma
596549|NCT00334932|stage II multiple myeloma
596550|NCT00334932|stage III multiple myeloma
596551|NCT00334919|Diabetes
596552|NCT00334919|Pre-Diabetes
596553|NCT00334919|Anti-Inflammatory Diet
596554|NCT00334919|Diet Study
596555|NCT00334919|Inflammation
596556|NCT00334919|Diabetic Diet
596557|NCT00334906|memantine
596558|NCT00334906|Alzheimer's disease
596559|NCT00334906|MRI
596560|NCT00334906|moderate Alzheimer's disease
596561|NCT00334880|Attention Deficit Hyperactivity Disorder
596562|NCT00334880|Attention Deficit Disorders with Hyperactivity
596563|NCT00334880|Attention Deficit Hyperactivity Disorders
596564|NCT00334867|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
596565|NCT00334854|childhood synovial sarcoma
596566|NCT00334854|nonmetastatic childhood soft tissue sarcoma
596567|NCT00334854|childhood alveolar soft-part sarcoma
596568|NCT00334854|childhood angiosarcoma
596569|NCT00334854|childhood epithelioid sarcoma
596570|NCT00334854|childhood fibrosarcoma
596571|NCT00334854|childhood leiomyosarcoma
596572|NCT00334854|childhood liposarcoma
596573|NCT00334854|childhood neurofibrosarcoma
596574|NCT00334854|localized childhood malignant fibrous histiocytoma of bone
596575|NCT00334854|childhood malignant hemangiopericytoma
596576|NCT00334854|dermatofibrosarcoma protuberans
596577|NCT00334854|chondrosarcoma
596578|NCT00334828|Severe sepsis
596579|NCT00334828|septic shock
596580|NCT00334828|sepsis
596581|NCT00334776|recurrent melanoma
596582|NCT00334776|stage IV melanoma
596583|NCT00334776|ciliary body and choroid melanoma, medium/large size
596584|NCT00334776|iris melanoma
596585|NCT00334776|recurrent intraocular melanoma
596586|NCT00334776|extraocular extension melanoma
596587|NCT00334763|recurrent non-small cell lung cancer
596588|NCT00334763|stage IIIB non-small cell lung cancer
596589|NCT00334763|stage IV non-small cell lung cancer
596590|NCT00334763|squamous cell lung cancer
596591|NCT00334750|Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian
596592|NCT00334737|erythropoietin
596593|NCT00334737|darbepoetin
596594|NCT00334737|transfusions
596595|NCT00334737|neonates
596596|NCT00334737|outcomes
596597|NCT00334737|neurodevelopment
596598|NCT00334724|Cardiovascular disease
596599|NCT00334724|Vascular disease
596600|NCT00334724|Hypertension
596601|NCT00334724|Home blood pressure measurement
596602|NCT00334711|Permanent Neonatal Diabetes
596603|NCT00334711|Kir6.2
596604|NCT00334711|KCNJ11
596605|NCT00334711|Infancy onset diabetes
596606|NCT00334711|Sulfonylurea
596607|NCT00334672|hemophagocytic lymphohistiocytosis
596608|NCT00334659|HIV-1 Infection
596609|NCT00334646|cyclophosphamide
596610|NCT00334646|CINV
596611|NCT00334646|Chemotherapy induced nausea and vomiting
596612|NCT00334633|bacterial vaginosis
596613|NCT00334633|tinidazole
596614|NCT00334620|randomised double-blinded trial
596615|NCT00334620|rehabilitation
596616|NCT00334620|radon spa therapy
596617|NCT00334620|long-term effectiveness
596618|NCT00334607|HRV vaccine
596619|NCT00334607|diarrhoea
596620|NCT00334607|rotavirus
596621|NCT00334594|epithelial mesothelioma
596622|NCT00334594|sarcomatous mesothelioma
596623|NCT00334594|stage IA malignant mesothelioma
596624|NCT00334594|stage IB malignant mesothelioma
596625|NCT00334594|stage II malignant mesothelioma
596626|NCT00334594|stage III malignant mesothelioma
596627|NCT00334568|AVANDIA
596628|NCT00334568|Alzheimers Disease
596629|NCT00334555|trichomoniasis
596630|NCT00334555|partner notification
596631|NCT00334542|breast cancer
596632|NCT00334542|ductal breast carcinoma in situ
596633|NCT00334542|breast cancer in situ
596634|NCT00334542|stage I breast cancer
596635|NCT00334542|stage II breast cancer
596636|NCT00334542|stage IIIA breast cancer
596637|NCT00334542|stage IIIB breast cancer
596638|NCT00334542|stage IIIC breast cancer
596639|NCT00334529|Tamiflu
596640|NCT00334529|Flu
596641|NCT00334529|Antiviral
596642|NCT00334529|Neuraminidase Inhibitor
596643|NCT00334529|Pharmacokinetic Trial
596644|NCT00334529|Healthy Volunteer
596645|NCT00334529|HV
596646|NCT00334516|Motor Neuron Disease
596647|NCT00334516|Cognitive Testing
596648|NCT00334516|Movement-Related Potential
596649|NCT00334516|MRI
596650|NCT00334516|Neuropsychologic Testing
596651|NCT00334516|Primary Lateral Sclerosis
596652|NCT00334516|PLS
596653|NCT00334516|Amyotrophic Lateral Sclerosis
596654|NCT00334516|ALS
596655|NCT00334516|Healthy Volunteer
596656|NCT00334516|HV
596657|NCT00334503|alpa-glucosidase inhibitor,Biguanide
596658|NCT00334490|Pulmonary Hypertension
596659|NCT00334490|Sildenafil
596660|NCT00334490|Viagra
596661|NCT00334490|Cardiac Surgery
596662|NCT00334490|Cardiopulmonary Bypass
596663|NCT00334477|erectile dysfunction
596664|NCT00334477|chronic renal dysfunction
596665|NCT00334477|tadalafil
596666|NCT00334464|warfarin metabolism
596667|NCT00334464|CYP2C0
596668|NCT00334464|anticoagulation
596669|NCT00334464|genotyping
596670|NCT00334464|DVT
596671|NCT00334464|PE
596672|NCT00334451|Heart Failure
596673|NCT00334451|Remote Monitoring
596674|NCT00334451|Implantable Device
596675|NCT00334438|recurrent grade 1 follicular lymphoma
596676|NCT00334438|recurrent grade 2 follicular lymphoma
596677|NCT00334438|recurrent grade 3 follicular lymphoma
596678|NCT00334438|recurrent mantle cell lymphoma
596679|NCT00334438|recurrent small lymphocytic lymphoma
596680|NCT00334399|alpa-glucosidase inhibitor,Biguanide
596681|NCT00334386|Hypertension
596682|NCT00334386|Anti-hypertensive effect
596683|NCT00334386|Diuretic
596684|NCT00334373|Myocardial infarction
596685|NCT00334373|Magnetic Resonance Imaging
596686|NCT00334373|Coronary Angioplasty
596687|NCT00334334|Streptococcus pneumonia, vaccine
596688|NCT00334321|IMRT
596689|NCT00334321|Tomotherapy
596690|NCT00334321|Post-Hysterectomy
596691|NCT00334321|Endometrial Cancer
596692|NCT00334295|Recurrent or metastatic endometrial carcinoma
596693|NCT00334282|Metastatic
596694|NCT00334282|Anti-angiogenesis
596695|NCT00334282|GW786034
596696|NCT00334282|Pazopanib
596697|NCT00334269|obesity
596698|NCT00334269|physical activity
596699|NCT00334269|daily energy intake
596700|NCT00334269|nutrition
596701|NCT00334269|healthy lifestyle
596702|NCT00334269|Aboriginal
596703|NCT00334269|body fat
596704|NCT00334269|exercise
596705|NCT00334269|education
596706|NCT00334269|family
596707|NCT00334269|body mass index
596708|NCT00334269|knowledge
596709|NCT00334269|randomized controlled trial
596710|NCT00334269|community
596711|NCT00334269|intervention
596712|NCT00334269|Six Nations Indian Reserve
596713|NCT00334269|household
596714|NCT00334269|health counselling
596715|NCT00334256|PMTCT
596716|NCT00334256|Resistance
596717|NCT00334256|HIV infection
596718|NCT00334256|Pregnancy
596719|NCT00334243|in vitro fertilization
596720|NCT00334243|infertile
596721|NCT00334243|infertility
596722|NCT00334243|pregnancy
596723|NCT00334243|pregnancy rates
596724|NCT00334243|microflare protocol
596725|NCT00334243|antagonist protocol
596726|NCT00334243|demi-halt protocol
596727|NCT00334243|poor responders
596728|NCT00334243|low antral follicle count
596729|NCT00334243|Infertile Patients undergoing in vitro fertilization (IVF)
596730|NCT00334243|Patients with a previous poor response to ovarian stimulation
596731|NCT00334243|Patients with an antral follicle count of less than 10
596732|NCT00334230|Functional Magnetic Resonance Imaging (fMRI)
596733|NCT00334230|Transcranial Magnetic Stimulation (TMS)
596734|NCT00334230|Locomotion
596735|NCT00334230|Cortical Reorganization
596736|NCT00334230|Rehabilitation
596737|NCT00334230|fMRI
596738|NCT00334230|Stroke
596739|NCT00334230|Healthy Volunteer
596740|NCT00334230|HV
596741|NCT00334217|Psychology: cognitive aspects
596742|NCT00334217|Substance-Related Disorders
596743|NCT00334217|treatment efficacy
596744|NCT00334204|Platelet Function Analyser-100 (PFA-100)
596745|NCT00334204|renal failure
596746|NCT00334204|kidney biopsy
596747|NCT00334204|bleeding
596748|NCT00334204|hematoma
596749|NCT00334191|Cardiac surgery,
596750|NCT00334191|Cardiopulmonary bypass,
596751|NCT00334191|Oxidative stress,
596752|NCT00334191|Acute renal dysfunction,
596753|NCT00334191|Sodium Bicarbonate
596754|NCT00334178|Migraine
596755|NCT00334178|Migraine prophylaxis
596756|NCT00334152|NK-1
596757|NCT00334152|antiemetics
596758|NCT00334152|casopitant mesylate
596759|NCT00334152|postoperative nausea and vomiting
596760|NCT00334152|ondansetron hydrochloride
596761|NCT00334152|5HT3
596762|NCT00334152|ZOFRAN
596763|NCT00334152|PONV
596764|NCT00334139|serum bone markers
596765|NCT00334139|bone metastasis
596766|NCT00334139|prostate cancer
596767|NCT00334139|breast cancer
596768|NCT00334139|quality of life
596769|NCT00334139|bisphosphonates
596770|NCT00334126|Schizophrenia
596771|NCT00334126|Antipsychotic
596772|NCT00334126|paliperidone
596773|NCT00334126|quetiapine
596774|NCT00334126|Seroquel
596775|NCT00334126|placebo
596776|NCT00334113|Diabetes Mellitus
596777|NCT00334113|Exercise
596778|NCT00334113|Obesity
596779|NCT00334113|Telemedicine
596780|NCT00334100|Exercise
596781|NCT00334100|multiple sclerosis
596782|NCT00334100|treadmill
596783|NCT00334087|primary dental prevention
596784|NCT00334087|early childhood caries
596785|NCT00334087|prenatal oral care
596786|NCT00334074|AML
596787|NCT00334074|MDS
596788|NCT00334074|CML
596789|NCT00334074|Relapsed
596790|NCT00334074|Refractory
596791|NCT00334074|Chemo treatment
596792|NCT00334074|Clofarabine
596793|NCT00334074|Cytarabine
596794|NCT00334074|standard or poor cytogenetic risk AML
596795|NCT00334074|untreated high-risk (>10% blasts) MDS
596796|NCT00334074|CML in accelerated phase or blast crisis
596797|NCT00334074|Elderly AML patients with risk of anthracycline toxicity
596798|NCT00334061|Penumbra
596799|NCT00334061|Ischemic
596800|NCT00334061|Stroke
596801|NCT00334061|Intervention
596802|NCT00334061|Neurovascular
596803|NCT00334061|Thrombus
596804|NCT00334061|Embolectomy
596805|NCT00334061|Ischemic stroke
596806|NCT00334048|Medication-induced sexual dysfunction
596807|NCT00334048|SSRI-induced sexual dysfunction
596808|NCT00334048|Anorgasmia
596809|NCT00334048|Delayed ejaculation
596810|NCT00334048|Sexual dysfunction
596811|NCT00334048|Antidepressant-induced sexual dysfunction
596812|NCT00334048|Requip
596813|NCT00334048|Ropinirole
596814|NCT00334048|Dopamine agonist
596815|NCT00334048|Serotonin reuptake inhibitor
596816|NCT00334048|Sexual dysfunction, physiological, medication-induced
596817|NCT00334022|Fuzeon
596818|NCT00334022|Viral Decay
596819|NCT00334009|Cardiac Surgery
596820|NCT00334009|Cardiopulmonary Bypass
596821|NCT00334009|COMT-Polymorphism
596822|NCT00334009|Vasoplegia
596823|NCT00334009|Catecholamines
596824|NCT00334009|Acute Renal Failure
596825|NCT00333970|cognition
596826|NCT00333970|neuropsychology
596827|NCT00333970|Rehabilitation
596828|NCT00333970|treatment efficacy
596829|NCT00333970|cognitive remediation
596830|NCT00333957|capsule endoscopy
596831|NCT00333944|Organophosphorus poisoning
596832|NCT00333944|Atropine
596833|NCT00333944|Pralidoxime
596834|NCT00333944|Intermediate syndrome.
596835|NCT00333931|Impulsive Aggression
596836|NCT00333931|Posttraumatic Stress Disorder
596837|NCT00333918|Cataract Extraction
596838|NCT00333918|Anti-Inflammatory Agents, Non-Steroidal
596839|NCT00333905|Exercise
596840|NCT00333905|Exercise Therapy
596841|NCT00333892|primary HIV infection
596842|NCT00333892|chronic HIV infection
596843|NCT00333879|Rehabilitation
596844|NCT00333879|Sensory Aid
596845|NCT00333840|CML
596846|NCT00333840|STI571
596847|NCT00333840|imatinib
596848|NCT00333840|interferon
596849|NCT00333840|interferon alpha
596850|NCT00333840|cytosine arabinoside
596851|NCT00333840|chronic myeloid leukemia
596852|NCT00333840|Philadelphia chromosome positive
596853|NCT00333827|Dilated Cardiomyopathy
596854|NCT00333827|stem cells
596855|NCT00333827|Therapeutics
596856|NCT00333827|Randomized Controlled Trials
596857|NCT00333801|Posttraumatic Stress Disorder
596858|NCT00333801|Veterans
596859|NCT00333801|Vocational Rehabilitation
596860|NCT00333801|Supported Employment
596861|NCT00333801|Individual Placement and Support
596862|NCT00333788|Crohn's Disease
596863|NCT00333788|Certolizumab pegol
596864|NCT00333788|CDP870
596865|NCT00333788|Cimzia
596866|NCT00333762|aging
596867|NCT00333762|blindness
596868|NCT00333762|wheelchairs
596869|NCT00333762|spinal cord injury
596870|NCT00333749|children
596871|NCT00333736|Injection site reactions
596872|NCT00333736|enfuvirtide administration
596873|NCT00333723|Rosiglitazone
596874|NCT00333723|Glyburide
596875|NCT00333723|Type 2 Diabetes Mellitus
596876|NCT00333723|African American
596877|NCT00333723|Hispanic
596878|NCT00333710|Rehabilitation
596879|NCT00333710|Telecommunication
596880|NCT00333697|Deep vein thrombosis
596881|NCT00333697|Duplex ultrasound
596882|NCT00333697|Pulmonary embolism
596883|NCT00333671|Macular oedema
596884|NCT00333671|Diabetes
596885|NCT00333671|Pathogenesis
596886|NCT00333671|Osmolality
596887|NCT00333671|Retinal thickness
596888|NCT00333658|psychotherapy, group
596889|NCT00333658|rehabilitation, vocational
596890|NCT00333658|treatment outcome
596891|NCT00333645|Liver transplantation
596892|NCT00333645|Invasive fungal infection
596893|NCT00333645|Invasive aspergillosis
596894|NCT00333645|Prophylaxis
596895|NCT00333645|Caspofungin
596896|NCT00333632|Sleep
596897|NCT00333632|Dexmedetomidine
596898|NCT00333632|Postoperative care
596899|NCT00333632|Sedation
596900|NCT00333619|sleep disorders
596901|NCT00333619|rehabilitation
596902|NCT00333619|rehabilitation outcomes
596903|NCT00333593|Dialysis
596904|NCT00333593|Large pore dialyser
596905|NCT00333593|Cytokines
596906|NCT00333593|Noradrenaline
596907|NCT00333580|Ethnography
596908|NCT00333580|Psychometrics
596909|NCT00333580|Qualitative Research
596910|NCT00333567|arthroscopic knee surgery
596911|NCT00333567|cyclooxygenase-2 inhibitors
596912|NCT00333567|lumiracoxib
596913|NCT00333567|COX189
596914|NCT00333567|Ambulatory arthroscopic knee surgery
596915|NCT00333554|DHA
596916|NCT00333554|docosahexaenoic acid
596917|NCT00333554|omega-3 fatty acid
596918|NCT00333554|fish oil
596919|NCT00333554|pregnancy
596920|NCT00333554|infancy
596921|NCT00333554|prevention
596922|NCT00333554|"at risk for developing type 1 diabetes"
596923|NCT00333554|juvenile diabetes
596924|NCT00333554|T1D
596925|NCT00333554|diabetes mellitus
596926|NCT00333554|Type 1 diabetes TrialNet
596927|NCT00333554|TrialNet
596928|NCT00333554|dietary supplementation
596929|NCT00333554|nutrition
596930|NCT00333541|Contraceptive behavior
596931|NCT00333541|Internet Use
596932|NCT00333541|Adolescent pregnancy
596933|NCT00333541|Unintended pregnancy
596934|NCT00333528|Chemical Nerve Agent Intoxication
596935|NCT00333528|Chemical Warfare Agents
596936|NCT00333528|Chemical Terrorism
596937|NCT00333515|Chemical nerve agent intoxication
596938|NCT00333502|Cancer, Neoplasms, Solid Tumor, Ovarian Cancer, Lung Cancer,
596939|NCT00333502|Non Small Cell Lung Cancer, Pancreatic Cancer,
596940|NCT00333502|Breast Cancer, Colon Cancer, Endometrial Cancer,
596941|NCT00333502|Kidney (Renal Cell) Cancer, Melanoma, Prostate Cancer,
596942|NCT00333502|Skin Cancer, Thyroid Cancer,
596943|NCT00333502|Solid Malignancies
596944|NCT00333489|valsartan
596945|NCT00333489|amlodipine
596946|NCT00333489|hypertension
596947|NCT00333437|Scleroderma, Systemic
596948|NCT00333424|HIV
596949|NCT00333424|Human Immunodeficiency Virus
596950|NCT00333424|Prophylactic vaccine
596951|NCT00333398|CSL Influenza Vaccine, influenza, vaccine, immunogenicity
596952|NCT00333385|Ceftazidime
596953|NCT00333385|Continuous infusion
596954|NCT00333385|Antibiotic course
596955|NCT00333333|Thrombocytopenia
596956|NCT00333333|Small for Gestational Age (SGA)
596957|NCT00333333|Preeclampsia
596958|NCT00333320|acute myocardial infarction
596959|NCT00333320|postconditioning
596960|NCT00333320|coronary reserve
596961|NCT00333320|ejection fraction
596962|NCT00333307|relaxin
596963|NCT00333307|preeclampsia
596964|NCT00333281|Healthy Volunteers
596965|NCT00333242|Pain
596966|NCT00333242|opioid
596967|NCT00333242|hyperalgesia
596968|NCT00333242|methadone
596969|NCT00333229|Breast Cancer
596970|NCT00333229|premenopausal
596971|NCT00333229|Bone Mineral density
596972|NCT00333229|Cancer therapy induced bone loss
596973|NCT00333229|zoledronic acid
596974|NCT00333203|epimacular membrane
596975|NCT00333190|stem cell transplant
596976|NCT00333190|graft versus host disease
596977|NCT00333190|GVHD
596978|NCT00333190|CD+8 T cell depletion
596979|NCT00333177|Schizoaffective Disorder, Depressed Type
596980|NCT00333177|Schizophreniform Disorder
596981|NCT00333177|First-Episode Schizophrenia
596982|NCT00333177|Supported Employment
596983|NCT00333177|Cognitive Remediation
596984|NCT00333177|Health Behavior Training
596985|NCT00333177|Antipsychotic Medication
596986|NCT00333164|intracranial arteriosclerosis
596987|NCT00333164|cilostazol
596988|NCT00333164|Platelete aggrigation inhibitors dual antiplatelet therapy
596989|NCT00333164|Drug therapy, combination
596990|NCT00333164|Clinical trials
596991|NCT00333138|FTY720
596992|NCT00333138|MS
596993|NCT00333138|Multiple Sclerosis
596994|NCT00333138|RRMS
596995|NCT00333112|Treatment Outcome
596996|NCT00333112|Urology
596997|NCT00333112|Solifenacin succinate
596998|NCT00333112|Urinary Incontinence
596999|NCT00333099|Enteral nutrition
597000|NCT00333099|immunonutrients
597001|NCT00333099|head and neck cancer
597002|NCT00333099|esophageal cancer
597003|NCT00333099|chemoradiotherapy
597004|NCT00333099|H&N or esophageal cancer patients with a chemoradiotherapy treatment.
597005|NCT00333086|Endometrial Cancer
597006|NCT00333086|Aromatase inhibitor
597007|NCT00333086|Letrozole
597008|NCT00333073|urinary incontinence
597009|NCT00333073|Bulkamid
597010|NCT00333047|Metastatic breast cancer
597011|NCT00333047|Aromatase inhibitor
597012|NCT00333047|Letrozole
597013|NCT00333034|Psoriasis
597014|NCT00333021|Fondaparinux Abdominal surgery Japanese VTE
597015|NCT00333008|Diffuse Large B Cell Lymphoma
597016|NCT00333008|CDOP
597017|NCT00333008|Dose Dense
597018|NCT00333008|Anne Arbor Stage I-IV
597019|NCT00333008|Any IPI score
597020|NCT00332995|HIV Seronegativity
597021|NCT00332982|best practices, performance improvement, intensive care, measurement
597022|NCT00332969|Open label
597023|NCT00332969|phase II
597024|NCT00332969|disease
597025|NCT00332969|clinical trial
597026|NCT00332969|Octreotide
597027|NCT00332969|thymoma
597028|NCT00332969|cancer
597029|NCT00332969|tumor
597030|NCT00332943|colorectal polyps
597031|NCT00332943|colorectal cancer
597032|NCT00332943|Virtual colonoscopy
597033|NCT00332943|Fecal tagging
597034|NCT00332943|MR colonography
597035|NCT00332930|HIV
597036|NCT00332930|Therapeutic vaccine
597037|NCT00332917|Parkinson's disease
597038|NCT00332904|betablocker
597039|NCT00332904|aldosterone antagonist
597040|NCT00332904|peripheral haemodynamics
597041|NCT00332904|cardiac haemodynamics
597042|NCT00332904|oxygenation
597043|NCT00332891|Anxiety
597044|NCT00332891|Anti-Anxiety Agents
597045|NCT00332891|controlled Clinical Trials
597046|NCT00332878|Behavioral Intervention
597047|NCT00332878|HIV
597048|NCT00332878|HSV2
597049|NCT00332865|Head and neck cancer
597050|NCT00332865|Radiotherapy
597051|NCT00332865|Dysphagia
597052|NCT00332865|Exercise
597053|NCT00332865|Deglutition
597054|NCT00332865|Randomized controlled trial
597055|NCT00332865|Quality of life
597056|NCT00332865|Tube feeding
597057|NCT00332852|Postive breast cancer
597058|NCT00332852|postmenopausal
597059|NCT00332852|disease free survival
597060|NCT00332852|letrozole
597061|NCT00332852|early adjuvant treatment
597062|NCT00332852|primary hormone receptor
597063|NCT00332839|enteric-coated mycophenolate sodium, everolimus, CNI-free regimen
597064|NCT00332826|Inhaled insulin
597065|NCT00332826|Diabetes Type I and II with Asthma
597066|NCT00332813|HIV Risk Behavior
597067|NCT00332813|Pregnancy
597068|NCT00332813|Drug Abuse
597069|NCT00332800|Stroke-Nutritional Supplementation-Functional Recovery
597070|NCT00332787|Major Depressive Disorder
597071|NCT00332735|spinal
597072|NCT00332735|anesthesia
597073|NCT00332735|articaine
597074|NCT00332735|bupivacaine
597075|NCT00332735|outpatient
597076|NCT00332735|surgery
597077|NCT00332735|limbs
597078|NCT00332709|Breast cancer
597079|NCT00332709|postmenopausal
597080|NCT00332709|bone mineral density
597081|NCT00332709|Zoledronic acid
597082|NCT00332709|Letrozole
597083|NCT00332709|extended adjuvant treatment.
597084|NCT00332709|Postmenopausal women with primary hormone receptor positive breast cancer
597085|NCT00332696|bowel obstruction,
597086|NCT00332696|peritoneal carcinomatosis
597087|NCT00332696|Octreotide
597088|NCT00332696|inoperable
597089|NCT00332683|Dysphagia
597090|NCT00332683|spine surgery
597091|NCT00332683|cuff pressure
597092|NCT00332670|(Non-seasonal) Depression
597093|NCT00332670|bright light therapy
597094|NCT00332670|randomized controlled trial
597095|NCT00332670|suprachiasmatic nucleus
597096|NCT00332670|HPA-axis
597097|NCT00332670|DHEA
597098|NCT00332670|melatonin
597099|NCT00332670|actigraphy
597100|NCT00332670|elderly
597101|NCT00332670|self-efficacy
597102|NCT00332670|social support
597103|NCT00332631|Cardiac surgery,
597104|NCT00332631|Cardiopulmonary bypass,
597105|NCT00332631|Oxidative stress,
597106|NCT00332631|Acute renal dysfunction,
597107|NCT00332631|N-acetylcysteine
597108|NCT00332618|MULTICENTER
597109|NCT00332618|CONTROLLED
597110|NCT00332618|PARALLEL GROUPS
597111|NCT00332605|Methamphetamine Dependence
597112|NCT00332592|Necrotizing Enterocolitis
597113|NCT00332592|Intragastric microdialysis
597114|NCT00332592|Peritoneal microdialysis
597115|NCT00332592|Infants
597116|NCT00332579|Compulsive Shoplifting
597117|NCT00332579|Kleptomania
597118|NCT00332579|Compulsive Stealing
597119|NCT00330824|prevention of post inflammation in LASIK surgery
597120|NCT00330811|Pediatrics
597121|NCT00330811|Non-cardiac Illness
597122|NCT00330811|B-type Natriuretic Peptide (BNP)
597123|NCT00330798|Photorefractive Keratectomy
597124|NCT00332514|pharmacist intervention
597125|NCT00332514|post-discharge telephone call
597126|NCT00332514|black hole
597127|NCT00332462|Liver transplantation, Cyclosporine
597128|NCT00332449|early breast feeding
597129|NCT00332449|hypoglycemia
597130|NCT00332449|newborn
597131|NCT00332410|Voriconazole
597132|NCT00332410|renal transplant
597133|NCT00332410|kidney function
597134|NCT00332410|kidneys
597135|NCT00332371|Intensive Care
597136|NCT00332371|Shock, Septic
597137|NCT00332371|Adsorption
597138|NCT00332371|Sorption Detoxification
597139|NCT00330772|Cardiac Surger
597140|NCT00330772|Coronary Artery Bypass Grafting
597141|NCT00330772|Graft patency
597142|NCT00330772|Aspirin
597143|NCT00330772|Clopidogrel
597144|NCT00330772|Hemorrhage
597145|NCT00330772|Transfusion
597146|NCT00330759|Bone metastases
597147|NCT00330759|lytic bone lesions
597148|NCT00330759|advanced cancer
597149|NCT00330759|multiple myeloma
597150|NCT00330759|lymphoma
597151|NCT00330759|solid tumors
597152|NCT00330759|skeletal related events
597153|NCT00330759|skeletal fractures
597154|NCT00330759|spinal cord compressions, radiation to bone
597155|NCT00330759|surgery to bone, bisphosphonates
597156|NCT00330759|denosumab
597157|NCT00330746|elderly
597158|NCT00330746|chemotherapy
597159|NCT00330746|targeted therapy
597160|NCT00330746|combination therapy
597161|NCT00330746|sequential therapy
597162|NCT00330746|randomized phase II
597163|NCT00330746|one year survival
597164|NCT00330733|Cardiovascular Disease
597165|NCT00330733|Inflammation
597166|NCT00330733|Insulin Resistance
597167|NCT00330733|Type 2 DM
597168|NCT00330720|Personal Emergency Response System
597169|NCT00330720|Anxiety
597170|NCT00330720|Fear of Falling
597171|NCT00330720|RCT
597172|NCT00330707|bladder cancer
597173|NCT00330707|BCG
597174|NCT00330707|interferon alpha
597175|NCT00330694|Physical Therapy
597176|NCT00330694|Organisation of care
597177|NCT00330681|Amyotrophic lateral sclerosis
597178|NCT00330681|free radical scavenger
597179|NCT00330668|Insulin-like Growth Factor Deficiency
597180|NCT00330668|IGF-1
597181|NCT00330668|Short Stature
597182|NCT00330655|Binge eating
597183|NCT00330655|Obesity
597184|NCT00330655|Eating disorder
597185|NCT00330642|Streptococcus Group B
597186|NCT00330642|Pregnancy
597187|NCT00330616|WELLBUTRIN
597188|NCT00330616|elderly
597189|NCT00330616|depression
597190|NCT00330616|Pharmacokinetics
597191|NCT00330603|Cough
597192|NCT00330603|Gastroesophageal Reflux
597193|NCT00330590|Central Venous
597194|NCT00330590|Ultrasonography
597195|NCT00330590|Catheterization
597196|NCT00330564|VHL Syndrome
597197|NCT00330564|Von Hippel-Lindau Syndrome
597198|NCT00330564|VHL Disease
597199|NCT00330564|Kidney
597200|NCT00330564|Retina
597201|NCT00330564|Brain
597202|NCT00330564|Spinal cord
597203|NCT00330564|Pancreas
597204|NCT00330564|Inner ear
597205|NCT00330564|Cysts
597206|NCT00330564|Tumors
597207|NCT00330564|Sunitinib Malate
597208|NCT00330564|SU011248
597209|NCT00330564|Sutent
597210|NCT00330564|VHL
597211|NCT00330564|Sunitinib
597212|NCT00330564|Renal cell carcinoma
597213|NCT00330564|Hemangioblastoma
597214|NCT00330564|Endothelium
597215|NCT00330551|Schizoaffective Disorder, Depressed Type
597216|NCT00330551|Schizophreniform Disorder
597217|NCT00330551|First-episode Schizophrenia
597218|NCT00330551|Injectable Risperidone
597219|NCT00332332|Phase IV
597220|NCT00332332|Psoriasis
597221|NCT00332332|Inflammation
597222|NCT00332319|spinal cord injury
597223|NCT00332319|urgency
597224|NCT00332319|Overactive bladder
597225|NCT00332319|neurogenic
597226|NCT00332319|neurometry
597227|NCT00332319|frequency
597228|NCT00332319|urge incontinence
597229|NCT00332306|Once daily antiretroviral treatment
597230|NCT00332306|Concomitant antituberculosis treatment
597231|NCT00332306|HIV Infections
597232|NCT00332280|solid tumors
597233|NCT00332280|clinical benefit
597234|NCT00332280|quality of life
597235|NCT00332280|esophageal cancer
597236|NCT00332280|colon cancer
597237|NCT00332280|pancreatic cancer
597238|NCT00332280|gastric cancer
597239|NCT00332280|liver cancer
597240|NCT00332280|gall bladder cancer
597241|NCT00332280|prostate cancer
597242|NCT00332280|gynecological cancer
597243|NCT00332280|lung cancer
597244|NCT00332280|Tumors of GI tract, prostate and gynaecological
597245|NCT00332267|Sepsis
597246|NCT00332267|Hypoxia
597247|NCT00332267|Altitude Sickness
597248|NCT00332267|Endotoxin
597249|NCT00332267|Cytokines
597250|NCT00332267|Cerebral blood flow
597251|NCT00332267|Cerebral metabolism
597252|NCT00332267|Reactive oxygen species
597253|NCT00332254|Anterior cruciate ligament tear
597254|NCT00332254|Meniscus tear
597255|NCT00332254|Chondral injury
597256|NCT00332241|Serious behavioral problems in children and adolescents with AD
597257|NCT00332241|Behavioral Problems
597258|NCT00332228|opiate dependence
597259|NCT00332228|heroin dependence
597260|NCT00332228|naltrexone
597261|NCT00332228|cognitive behavioral therapy
597262|NCT00332215|Cystic Fibrosis
597263|NCT00332215|Antioxidants
597264|NCT00332215|Inhalational therapy
597265|NCT00332215|Induced sputum
597266|NCT00332215|Airway inflammation
597267|NCT00332189|PKU
597268|NCT00332176|Hepatitis C
597269|NCT00332176|Celgosivir
597270|NCT00332176|HCV
597271|NCT00332176|Genotype 1
597272|NCT00332176|Treatment-naive
597273|NCT00332176|Early viral kinetics
597274|NCT00332163|STEPP
597275|NCT00332163|STEP
597276|NCT00332163|STEEP
597277|NCT00332163|mCRC
597278|NCT00332163|Skin Toxicities
597279|NCT00332163|Skin Rash
597280|NCT00332163|Metastatic Colorectal Cancer
597281|NCT00332163|Anti-EGFr Skin Rash
597282|NCT00332163|colon cancer
597283|NCT00332163|colorectal cancer
597284|NCT00332163|rectal cancer
597285|NCT00332150|parents
597286|NCT00332150|newborn
597287|NCT00332150|clinical trials
597288|NCT00332111|transplant
597289|NCT00332111|pancreas
597290|NCT00332098|Childhood Mood Disorders
597291|NCT00332098|Family Treatment
597292|NCT00332098|Psychoeducation
597293|NCT00332098|Pharmacotherapy
597294|NCT00332098|Family Functioning
597295|NCT00332098|Psychosocial Intervention
597296|NCT00332046|fMRI placebo GW679769 Social Anxiety Disorder SAD
597297|NCT00332033|Fibroids
597298|NCT00332033|Leiomyoma
597299|NCT00332033|Pirfenidone
597300|NCT00332033|Misoprostol
597301|NCT00332033|Non-Surgical
597302|NCT00332033|Collagen
597303|NCT00332033|Uterus
597304|NCT00332033|Uterine Fibroids
597305|NCT00332033|Uterine Leiomyoma
597306|NCT00331942|Breast
597307|NCT00331942|Cancer
597308|NCT00331942|Associated
597309|NCT00331942|Antibodies
597310|NCT00331929|Asthma
597311|NCT00331929|Allergy
597312|NCT00331929|Respiratory
597313|NCT00331929|Pollution
597314|NCT00331929|Children
597315|NCT00331929|Air pollution
597316|NCT00330538|Osteoporosis
597317|NCT00330538|Childhood acute lymphoblastic leukemia
597318|NCT00330512|regional anestesia
597319|NCT00330512|cesarean section
597320|NCT00330512|hypotention
597321|NCT00330512|newborn
597322|NCT00330499|Locally invasive
597323|NCT00330499|Bladder cancer
597324|NCT00330499|Chemoradiotherapy
597325|NCT00330499|Efficacy
597326|NCT00330499|Organ conservation
597327|NCT00330486|Acamprosate
597328|NCT00330486|Addiction
597329|NCT00330486|Alcoholism
597330|NCT00330486|Alcohol dependence
597331|NCT00330486|Bipolar disorder
597332|NCT00330486|Depression
597333|NCT00330486|Impulsivity
597334|NCT00330486|Mania
597335|NCT00330486|Substance abuse
597336|NCT00330460|Osteoporosis
597337|NCT00330460|Osteopenia
597338|NCT00330460|AMG 162
597339|NCT00330460|Fracture - hip
597340|NCT00330460|Postmenopausal
597341|NCT00330447|pregnancy
597342|NCT00330447|in utero
597343|NCT00330447|chemotherapy
597344|NCT00330447|radiotherapy
597345|NCT00330447|cancer
597346|NCT00330447|offspring
597347|NCT00330447|neonatal
597348|NCT00330447|long term
597349|NCT00330447|follow up
597350|NCT00330447|cancer during pregnancy
597351|NCT00330447|chemotherapy and radiotherapy during pregnancy
597352|NCT00330447|long term follow up of children
597353|NCT00330434|Alcohol
597354|NCT00330434|Bupropion
597355|NCT00330434|Chlorzoxazone
597356|NCT00330434|Interaction
597357|NCT00330434|Induction
597358|NCT00330434|Depression
597359|NCT00330434|Smoking
597360|NCT00330434|Drinking
597361|NCT00330434|Cytochrome P450 Enzyme
597362|NCT00330434|CYP2B6
597363|NCT00330434|CYP2E1
597364|NCT00330434|Pharmacogenetics
597365|NCT00330434|Pharmacokinetics
597366|NCT00330434|Pharmacodynamics
597367|NCT00330434|Boston
597368|NCT00330434|Tufts University
597369|NCT00330408|Adherence
597370|NCT00330408|GP training
597371|NCT00330408|Medication Event Monitoring System(MEMS)
597372|NCT00330408|Antihypertensive Medication
597373|NCT00330408|Hypertension
597374|NCT00330356|Dietary Salt
597375|NCT00330356|Blood Pressure
597376|NCT00330356|Normotensives
597377|NCT00330343|morphine
597378|NCT00330343|naloxone
597379|NCT00330343|pediatrics
597380|NCT00330343|adverse effects
597381|NCT00330343|pain
597382|NCT00330330|Fasting plasma glucose
597383|NCT00330330|HbA1c
597384|NCT00330317|Letrozole
597385|NCT00330317|Breast Conserving Surgery
597386|NCT00330317|NeoAdjuvant
597387|NCT00330317|Early Breast Cancer
597388|NCT00330304|Tuberculosis
597389|NCT00330304|Child
597390|NCT00330304|HIV
597391|NCT00330304|prophylaxis
597392|NCT00330304|mortality
597393|NCT00330291|PTSD
597394|NCT00330291|Xyrem
597395|NCT00330291|Sleep problems
597396|NCT00331890|Neuroprotection
597397|NCT00331890|Acute ischemic stroke
597398|NCT00331890|Cerebral infarction
597399|NCT00331877|family
597400|NCT00331877|end-of-life
597401|NCT00331877|intensive care unit
597402|NCT00331864|AMD, ranibizumab
597403|NCT00331838|Prevention
597404|NCT00331838|Venous Thrombosis
597405|NCT00331838|Orthopedic Surgery
597406|NCT00331825|Schizophrenia, EPS, risperidone, olanzapine
597407|NCT00331812|Hypermetabolism
597408|NCT00331812|Mitochondrial abnormalities
597409|NCT00331812|Oxidant/antioxidant status
597410|NCT00331799|Depression
597411|NCT00331799|Pharmacotherapy
597412|NCT00331799|Duloxetine
597413|NCT00331786|colon cancer
597414|NCT00331786|rectal cancer
597415|NCT00331773|adenocarcinoma of the prostate
597416|NCT00331773|stage IIB prostate cancer
597417|NCT00331773|stage IIA prostate cancer
597418|NCT00331760|stage I endometrial carcinoma
597419|NCT00331760|stage II endometrial carcinoma
597420|NCT00331760|stage III endometrial carcinoma
597421|NCT00331760|endometrial adenoacanthoma
597422|NCT00331760|endometrial adenocarcinoma
597423|NCT00331760|endometrial adenosquamous cell carcinoma
597424|NCT00331760|stage IB cervical cancer
597425|NCT00331760|stage IIA cervical cancer
597426|NCT00331760|stage IIB cervical cancer
597427|NCT00331760|cervical adenocarcinoma
597428|NCT00331760|cervical adenosquamous cell carcinoma
597429|NCT00331760|cervical squamous cell carcinoma
597430|NCT00331721|Acute Ischemic Stroke
597431|NCT00331708|Malaria
597432|NCT00331708|Efficacy
597433|NCT00331708|Pharmacokinetic
597434|NCT00331708|Gametocyte
597435|NCT00331708|Molecular markers
597436|NCT00331708|Sulfadoxine-pyrimethamine
597437|NCT00331708|Artesunate
597438|NCT00331708|Artemisinin
597439|NCT00331695|Progesterone
597440|NCT00331695|Preterm delivery
597441|NCT00331695|Preterm labor
597442|NCT00331695|Cervical length
597443|NCT00331695|ultrasonography
597444|NCT00331669|deep brain stimulation
597445|NCT00331669|pallidum
597446|NCT00331669|tardive dystonia
597447|NCT00331669|randomized
597448|NCT00331669|double blind
597449|NCT00331669|multicenter
597450|NCT00331656|noninvasive
597451|NCT00331656|positive
597452|NCT00331656|cuirass
597453|NCT00331656|ventilation
597454|NCT00331656|respiratory
597455|NCT00331656|failure
597456|NCT00331630|stage I breast cancer
597457|NCT00331630|stage II breast cancer
597458|NCT00331630|stage IIIA breast cancer
597459|NCT00331630|stage IIIB breast cancer
597460|NCT00331630|stage IIIC breast cancer
597461|NCT00331565|Bariatric surgery
597462|NCT00331565|Bioavailability
597463|NCT00331565|Bioequivalence
597464|NCT00331565|Atorvastatin
597465|NCT00331565|CYP's
597466|NCT00331565|P-gp
597467|NCT00331565|OATP
597468|NCT00331539|Cochlear implant
597469|NCT00331539|threshold (T) measurement
597470|NCT00331539|comfort (C) level
597471|NCT00331539|profound hearing loss
597472|NCT00331539|auditory stimuli
597473|NCT00331539|profound hearing loss patients eligible for the study should be capable of providing reliable
597474|NCT00331539|subjective counted thresholds and has good NRT recordings, implanted with
597475|NCT00331539|the Nucleus Freedom system
597476|NCT00331526|adult glioblastoma
597477|NCT00331526|adult gliosarcoma
597478|NCT00331526|adult giant cell glioblastoma
597479|NCT00331487|Glucose Metabolism Disorder
597480|NCT00331487|Dysmetabolic Syndrome
597481|NCT00331487|Type II Diabetes
597482|NCT00331487|Diabetes Mellitus
597483|NCT00331487|Lipoatrophic
597484|NCT00331487|Dyslipidemia
597485|NCT00331487|Drug Therapy
597486|NCT00331474|BCG
597487|NCT00331474|HIV
597488|NCT00331474|Immune responses
597489|NCT00331474|Delayed vaccination
597490|NCT00331474|Infant morbidity
597491|NCT00331474|Nutritional status
597492|NCT00331474|Morbidity
597493|NCT00331474|Mortality
597494|NCT00331448|Treatment Experienced
597495|NCT00331448|Lipoatrophy
597496|NCT00331448|Lipohypertrophy
597497|NCT00331448|Glucose
597498|NCT00331448|Cholesterol
597499|NCT00331448|Triglycerides
597500|NCT00331448|MRI
597501|NCT00331448|DXA
597502|NCT00331448|Carotid IMT
597503|NCT00331448|LDL
597504|NCT00331448|HDL
597505|NCT00331435|AMD
597506|NCT00331435|PCV
597507|NCT00331435|PDT
597508|NCT00331422|ovarian clear cell cystadenocarcinoma
597509|NCT00331422|ovarian endometrioid adenocarcinoma
597510|NCT00331422|ovarian mixed epithelial carcinoma
597511|NCT00331422|ovarian mucinous cystadenocarcinoma
597512|NCT00331422|ovarian serous cystadenocarcinoma
597513|NCT00331422|ovarian undifferentiated adenocarcinoma
597514|NCT00331422|stage III ovarian epithelial cancer
597515|NCT00331422|stage IV ovarian epithelial cancer
597516|NCT00331422|peritoneal cavity cancer
597517|NCT00331422|fallopian tube cancer
597518|NCT00331422|Brenner tumor
597519|NCT00331409|stage III renal cell cancer
597520|NCT00331409|stage IV renal cell cancer
597521|NCT00331409|clear cell renal cell carcinoma
597522|NCT00331409|recurrent renal cell cancer
597523|NCT00331357|acute idiopathic thrombocytopenic purpura
597524|NCT00331357|paediatric
597525|NCT00331357|quality of life
597526|NCT00331331|Uveitis
597527|NCT00331331|Intermediate Uveitis
597528|NCT00331331|Pars Planitis
597529|NCT00331331|Macular Edema
597530|NCT00331331|Vasculitis
597531|NCT00331331|Ocular Inflammatory Disease
597532|NCT00331318|Transcranial Direct Current Stimulation (tDCS)
597533|NCT00331318|Transcranial Magnetic Stimulation (TMS)
597534|NCT00331318|Motor Learning
597535|NCT00331318|Brain Plasticity
597536|NCT00331318|Healthy Volunteer
597537|NCT00331318|HV
597538|NCT00331305|Exercise
597539|NCT00331292|Asthma bronchoscopy
597540|NCT00331279|polycystic ovary syndrome
597541|NCT00331279|insulin resistance
597542|NCT00331279|cinnamon
597543|NCT00331253|Indocyanine Green-Mediated Photothrombosis
597544|NCT00331253|Neovascular
597545|NCT00331253|Age-Related Macular Degeneration
597546|NCT00331227|flavonoids
597547|NCT00331227|food supplements
597548|NCT00331227|endothelial function
597549|NCT00331227|no conditions allowed, healthy volunteers only
597550|NCT00331214|Surgical menopause
597551|NCT00331214|HSDD
597552|NCT00331201|NEC
597553|NCT00331188|Esophageal Variceal Bleeding
597554|NCT00331188|Portal Hypertension
597555|NCT00331188|Hepatic Cirrhosis
597556|NCT00331188|Cirrhosis
597557|NCT00331188|Liver Cirrhosis
597558|NCT00331188|Somatostatin Analog
597559|NCT00331188|Vapreotide
597560|NCT00331188|Acute Esophageal Variceal Bleeding
597561|NCT00331162|Renal Transplantation
597562|NCT00331162|Pancreas Transplantation
597563|NCT00331162|Graft Rejection
597564|NCT00331162|Immunosuppression
597565|NCT00331162|Kidney failure, chronic
597566|NCT00331162|Diabetes Mellitus, Type 1
597567|NCT00331162|Diabetes Mellitus, Type 2
597568|NCT00331149|safety
597569|NCT00331149|efficacy
597570|NCT00331149|L-dopa
597571|NCT00331149|ropinirole PR
597572|NCT00331149|Parkinson's disease
597573|NCT00331149|ropinirole IR
597574|NCT00331149|adjunctive therapy
597575|NCT00331149|superiority
597576|NCT00331149|REQUIP
597577|NCT00331149|health outcomes
597578|NCT00331136|malaria
597579|NCT00331136|pyronaridine
597580|NCT00331136|artesunate
597581|NCT00331136|falciparum
597582|NCT00331136|ACT
597583|NCT00331123|Surgical menopause
597584|NCT00331123|HSDD
597585|NCT00331097|elderly
597586|NCT00331097|adjuvant therapy
597587|NCT00331097|intermediate risk
597588|NCT00331097|high risk
597589|NCT00331084|prevention of post inflammation in cataract surgery
597590|NCT00331071|Contraception
597591|NCT00331071|Hormonal contraception
597592|NCT00331071|Oral contraception
597593|NCT00331071|Ethinyl estradiol, Progestin, Contraception
597594|NCT00331071|Transdermal
597595|NCT00331058|Severe Asthma bronchoscopy
597596|NCT00331045|Opioids
597597|NCT00331045|cancer
597598|NCT00331045|constipation
597599|NCT00331032|VivaGel™, sexually transmitted, microbicide, herpes simplex
597600|NCT00331019|Streptococcus Group B
597601|NCT00331019|Pregnancy
597602|NCT00331006|Blood Coagulation Factor Inhibitors
597603|NCT00330993|mifepristone
597604|NCT00330993|misoprostol
597605|NCT00330993|medical abortion
597606|NCT00330993|buccal administration
597607|NCT00330980|Cognition
597608|NCT00330980|Statins
597609|NCT00330980|Serotonin
597610|NCT00330980|Cholesterol
597611|NCT00330967|Fat Emulsions, Intravenous
597612|NCT00330967|Free Fatty Acids
597613|NCT00330967|Glucose Clamp Technique
597614|NCT00330967|Inflammation
597615|NCT00330967|Insulin Resistance
597616|NCT00330967|Muscle, Skeletal
597617|NCT00330967|NF-Kappa B
597618|NCT00330954|viral response genes
597619|NCT00330902|malaria
597620|NCT00330902|subpatent parasitaemia
597621|NCT00330902|dry season
597622|NCT00330902|primaquine
597623|NCT00330902|Plasmodium falciparum infection detected by PCR
597624|NCT00330889|Rheumatoid Arthritis
597625|NCT00330876|pitavastatin
597626|NCT00330876|hypercholesterolemia
597627|NCT00330876|combined dyslipidemia
597628|NCT00330863|Relapse
597629|NCT00330863|Prevention
597630|NCT00330863|Schizophrenia
597631|NCT00330863|Injectable Medication
597632|NCT00330850|Migraine
597633|NCT00330850|Photophobia
597634|NCT00330850|Phonophobia
597635|NCT00330850|Aura
597636|NCT00330278|Cesarean section
597637|NCT00330278|Antibiotic prophylaxis
597638|NCT00330278|Cefazolin
597639|NCT00330252|Chronic Lymphocytic Leukemia
597640|NCT00330252|Relapsed Chronic Lymphocytic Leukemia
597641|NCT00330252|Alemtuzumab
597642|NCT00330252|Campath
597643|NCT00330252|Rituximab
597644|NCT00330252|Rituxan
597645|NCT00330239|Substance Abuse
597646|NCT00330239|Trauma
597647|NCT00330239|Dependence
597648|NCT00330226|schizophrenia
597649|NCT00330226|bipolar disorder
597650|NCT00330226|atypical antipsychotics
597651|NCT00330226|mood stabilizers
597652|NCT00330226|biological markers
597653|NCT00330213|transthoracic
597654|NCT00330213|echocardiography
597655|NCT00330213|red wine
597656|NCT00330213|cognac
597657|NCT00330213|coronary reactivity
597658|NCT00330200|Fasting plasma glucose
597659|NCT00330200|HbA1c
597660|NCT00330200|Metabolism
597661|NCT00330187|nicotine dependence
597662|NCT00330187|bupropion SR
597663|NCT00330187|smoking cessation
597664|NCT00330187|adolescents
597665|NCT00330187|contingency management
597666|NCT00330174|Alcoholism
597667|NCT00330174|Mood
597668|NCT00330174|Anxiety
597669|NCT00330174|Acamprosate
597670|NCT00330148|trypanosomiasis
597671|NCT00330148|gambiense
597672|NCT00330148|combination drug therapy
597673|NCT00330148|sleeping sickness
597674|NCT00330148|Uganda
597675|NCT00330135|hip osteoarthritis
597676|NCT00330135|Hyaluronic acid
597677|NCT00330135|Viscosupplementation
597678|NCT00330135|intra-articular injections
597679|NCT00330122|radius articular displaced fractures
597680|NCT00330122|fore locked plate
597681|NCT00330122|external radiocarpal fixer
597682|NCT00330109|glioma
597683|NCT00330109|machine learning
597684|NCT00330109|advanced diagnostic imaging
597685|NCT00330096|bone loss, osteoporosis, prevention, hesperidin
597686|NCT00330070|8-week treatment
597687|NCT00330070|oral tablets
597688|NCT00330070|persistent moderate to severe asthma
597689|NCT00330070|AQLQ
597690|NCT00330070|asthma control
597691|NCT00330070|quality of life
597692|NCT00330018|BMT
597693|NCT00330018|CMV
597694|NCT00330018|GVHD
597695|NCT00330005|psychotherapy
597696|NCT00330005|bipolar disorder
597697|NCT00330005|psychodynamic
597698|NCT00330005|psychoeducation
597699|NCT00330005|illness management
597700|NCT00330005|controlled trial
597701|NCT00330005|pilot study
597702|NCT00329979|aortic stenosis
597703|NCT00329979|radial
597704|NCT00329979|femoral
597705|NCT00329979|vascular access site
597706|NCT00329979|embolism
597707|NCT00329979|cerebral
597708|NCT00329979|MRI
597709|NCT00329979|stroke
597710|NCT00329966|Influenza
597711|NCT00329966|adult
597712|NCT00329966|elderly
597713|NCT00329966|vaccine
597714|NCT00329940|Letrozole
597715|NCT00329940|breast cancer
597716|NCT00329940|critical musculoskeletal
597717|NCT00329940|postmenopausal
597718|NCT00329940|rheumatologic tolerance
597719|NCT00329927|Adjuvanted Influenza Vaccine
597720|NCT00329914|Preterm delivery
597721|NCT00329914|Prevention
597722|NCT00329914|Twins
597723|NCT00329914|Progesterone
597724|NCT00329901|Meningitis
597725|NCT00329901|healthy subject
597726|NCT00329901|vaccine
597727|NCT00329888|Endoscopic papillary balloon dilatation
597728|NCT00329888|Endoscopic sphincterotomy
597729|NCT00329862|Laparoscopic Adjustable Gastric Banding
597730|NCT00329862|Truncal Vagotomy
597731|NCT00329862|Lap Band
597732|NCT00329862|Lap Banding
597733|NCT00329862|Obesity Surgery
597734|NCT00329862|Bariatric surgery
597735|NCT00329862|Weight Loss Surgery
597736|NCT00329849|Meningitis
597737|NCT00329849|children
597738|NCT00329849|vaccine
597739|NCT00329849|safety
597740|NCT00329849|efficacy
597741|NCT00329823|Hidradenitis suppurativa, etanercept
597742|NCT00329797|osteoporosis
597743|NCT00329797|adenocarcinoma of the prostate
597744|NCT00329797|stage IIB prostate cancer
597745|NCT00329797|stage IIA prostate cancer
597746|NCT00329797|stage III prostate cancer
597747|NCT00329797|stage IV prostate cancer
597748|NCT00329784|peanut allergy
597749|NCT00329784|egg allergy
597750|NCT00329784|eczema
597751|NCT00329784|peanut
597752|NCT00329784|allergy
597753|NCT00329784|allergies
597754|NCT00329784|allergic reaction
597755|NCT00329784|anaphylaxis
597756|NCT00329784|infants
597757|NCT00329784|children
597758|NCT00329758|moderate head injury
597759|NCT00329758|rosuvastatin
597760|NCT00329758|statin
597761|NCT00329758|amnesia
597762|NCT00329758|orientation
597763|NCT00329745|Rotavirus Gastroenteritis
597764|NCT00329745|Human rotavirus vaccine, efficacy, infants
597765|NCT00329706|mild cognitive impairment
597766|NCT00329706|Alzheimer's disease
597767|NCT00329706|dementia
597768|NCT00329706|FDG
597769|NCT00329706|PET
597770|NCT00329680|Sepsis
597771|NCT00329680|Severe Sepsis
597772|NCT00329680|Septic Shock
597773|NCT00329680|Enteral Nutrition
597774|NCT00329680|Antioxidants
597775|NCT00329680|EPA
597776|NCT00329680|GLA
597777|NCT00329680|Nutrition
597778|NCT00329680|Intensive Care
597779|NCT00329680|ICU
597780|NCT00329667|heart valve
597781|NCT00329667|mitral
597782|NCT00329667|aortic
597783|NCT00329667|valvular disease
597784|NCT00329654|Burn wounds, light therapy
597785|NCT00329628|Prevention
597786|NCT00329628|Thromboembolism
597787|NCT00329615|Cancer cachexia
597788|NCT00329615|Tumor host metabolism
597789|NCT00329602|Moderate
597790|NCT00329602|Restless Legs Syndrome
597791|NCT00329602|Severe
597792|NCT00329602|ropinirole
597793|NCT00329589|Malignancies of the central nervous system, head and neck area
597794|NCT00329589|and cervix
597795|NCT00329563|Cardiac Arrest
597796|NCT00329563|Hypothermia
597797|NCT00329550|Certolizumab pegol
597798|NCT00329550|Cimzia
597799|NCT00329550|CZP
597800|NCT00329537|Crohn's Disease
597801|NCT00329537|Sargramostim
597802|NCT00329537|CDAI
597803|NCT00329537|Moderately to severely active Crohn's Disease
597804|NCT00329524|Tinnitus
597805|NCT00329524|TMS
597806|NCT00329524|Transcranial Magnetic Stimulation
597807|NCT00329511|pregnancy
597808|NCT00329511|hypertension
597809|NCT00329511|compliance
597810|NCT00329511|clonidine patch
597811|NCT00329511|methyldopa
597812|NCT00329498|ascorbic acid
597813|NCT00329485|Elevated BNP Levels in CHF patients
597814|NCT00329459|menstrual migraine
597815|NCT00329459|headache
597816|NCT00329459|early intervention
597817|NCT00329459|dysmenorrhea
597818|NCT00329446|GAD
597819|NCT00329446|anxiety
597820|NCT00329433|Deep venous thrombosis
597821|NCT00329433|DVT
597822|NCT00329433|Heparin induced thrombocytopenia
597823|NCT00329433|HIT
597824|NCT00329433|Direct thrombin inhibitor
597825|NCT00329420|Crohn's Disease
597826|NCT00329420|CDP870
597827|NCT00329420|Certolizumab pegol
597828|NCT00329420|CZP
597829|NCT00329407|Alcoholism
597830|NCT00329407|Heavy Drinking
597831|NCT00329407|Alcohol Dependence
597832|NCT00329394|Ketamine
597833|NCT00329394|Analgesia
597834|NCT00329394|Alcool-dependent
597835|NCT00329394|carcinological surgery
597836|NCT00329381|Allergic
597837|NCT00329381|Asthma
597838|NCT00329381|Immunotherapy
597839|NCT00329368|Cancer
597840|NCT00329368|Vaccine
597841|NCT00329368|Phase I
597842|NCT00329368|FolateImmune
597843|NCT00329368|Recurrent
597844|NCT00329368|Refractory
597845|NCT00329368|Experimental
597846|NCT00329355|menstrual migraine
597847|NCT00329355|headache
597848|NCT00329355|early intervention
597849|NCT00329355|dysmenorrhea
597850|NCT00329342|Low back pain;
597851|NCT00329342|Return to work;
597852|NCT00329342|Posture
597853|NCT00329329|Advanced solid malignancies
597854|NCT00329316|Pre-term labor
597855|NCT00329316|progesterone
597856|NCT00329303|Moderate to severe chronic plaque psoriasis
597857|NCT00329303|anti TNF α
597858|NCT00329303|CDP 870
597859|NCT00329303|Cimzia®
597860|NCT00329303|certolizumab pegol
597861|NCT00329303|retreatment
597862|NCT00329290|pregnancy
597863|NCT00329290|anticoagulation
597864|NCT00329290|enoxaparin
597865|NCT00329290|prosthetic heart valves
597866|NCT00329277|age-related macular degeneration
597867|NCT00329277|preferred retinal locus
597868|NCT00329277|macular perimetry
597869|NCT00329264|GAD
597870|NCT00329264|anxiety
597871|NCT00329251|HIV
597872|NCT00329251|Viral load
597873|NCT00329251|Vaccines
597874|NCT00329251|Immunotherapy
597875|NCT00329225|Type 2 Diabetes Mellitus Thiazolidinediones Insulin
597876|NCT00329212|Pharmacokinetics
597877|NCT00329212|Bioavailability
597878|NCT00329212|Therapeutic Equivalency
597879|NCT00329199|Depression
597880|NCT00329199|Adolescents
597881|NCT00329199|Family Therapy
597882|NCT00329199|Primary Care
597883|NCT00329199|Family Conflict
597884|NCT00329186|Healthy Subjects
597885|NCT00329186|Major Depressive Disorder
597886|NCT00329186|Depression
597887|NCT00329186|Cytochrome P-450 CYP2D6
597888|NCT00329186|Pharmacokinetics
597889|NCT00329186|Health
597890|NCT00329147|Healthy Subjects
597891|NCT00329147|Major Depressive Disorder
597892|NCT00329147|Depression
597893|NCT00329121|SCCIS
597894|NCT00329121|Bowens disease
597895|NCT00329121|PEP005
597896|NCT00329121|Topical
597897|NCT00329121|Dermatology
597898|NCT00329121|Cutaneous Squamous Cell Carcinoma in situ
597899|NCT00329095|Glaucoma
597900|NCT00329095|Compliance
597901|NCT00329069|statin
597902|NCT00329069|atorvastatin
597903|NCT00329069|hypercholesterolemia
597904|NCT00329069|coronary artery disease
597905|NCT00329069|monocyte
597906|NCT00329069|collateral formation
597907|NCT00329069|arteriogenesis
597908|NCT00329069|chemotaxis
597909|NCT00329069|migration
597910|NCT00329069|growth factors
597911|NCT00329069|vascular endothelial growth factor A
597912|NCT00329069|placenta growth factor 1
597913|NCT00329069|hepatocyte growth factor
597914|NCT00329069|monocyte chemotactic protein 1
597915|NCT00329056|Parkinson's disease
597916|NCT00329056|MitoQ
597917|NCT00329056|UPDRS
597918|NCT00329043|Prostate Cancer
597919|NCT00329043|Adenocarcinoma of the Prostate
597920|NCT00329043|Ductal Adenocarcinoma of the Prostate
597921|NCT00329043|Hormonal Ablation
597922|NCT00329043|Radical Prostatectomy
597923|NCT00329043|LHRH Agonist
597924|NCT00329043|Lupron
597925|NCT00329043|Leuprolide
597926|NCT00329043|Sunitinib Malate
597927|NCT00329043|SU011248
597928|NCT00329030|Large B-Cell Lymphoma
597929|NCT00329030|Non-Hodgkin's Lymphoma
597930|NCT00329017|SNPs
597931|NCT00329017|single nucleotide polymorphism
597932|NCT00329017|breast atypia
597933|NCT00329017|breast epithelial hyperplasia
597934|NCT00329017|high risk for breast cancer
597935|NCT00329004|Solid Tumors
597936|NCT00328991|wart
597937|NCT00328991|common wart
597938|NCT00328991|verruca vulgaris
597939|NCT00328991|verruca plantaris
597940|NCT00328991|plantar wart
597941|NCT00328991|duct tape
597942|NCT00328991|occlusion therapy
597943|NCT00328978|schizophrenia
597944|NCT00328978|schizoaffective disorders
597945|NCT00328965|Korean patients
597946|NCT00328965|Type 2 diabetes
597947|NCT00328965|Endothelial function
597948|NCT00328965|lacidipine
597949|NCT00328965|Essential hypertension
597950|NCT00328952|schizophrenia
597951|NCT00328952|auditory verbal hallucination
597952|NCT00328952|antipsychotic treatment
597953|NCT00328939|ARIXTRA
597954|NCT00328939|prevention of DVT
597955|NCT00328926|Hypogonadotropic Hypogonadism (LH <1.2 IU/L)
597956|NCT00328926|Placebo
597957|NCT00328926|Luveris® 75 IU
597958|NCT00328926|Luveris® 25 IU
597959|NCT00328926|Recombinant human chorionic gonadotropin (r-hCG)
597960|NCT00328913|satiety
597961|NCT00328913|food intake
597962|NCT00328913|mood
597963|NCT00328913|wellness
597964|NCT00328913|weight management
597965|NCT00328900|Galvanic skin response
597966|NCT00328900|Anesthesia
597967|NCT00328900|Atropine
597968|NCT00328887|Esophageal Neoplasms
597969|NCT00328874|Progressive Supranuclear Palsy
597970|NCT00328874|Coenzyme Q10
597971|NCT00328861|Adoptive Cell Therapy
597972|NCT00328861|Cutaneous Melanoma
597973|NCT00328861|Clinical Response
597974|NCT00328861|Rate of Repopulation
597975|NCT00328861|Toxicity Profile
597976|NCT00328861|Metastatic Melanoma
597977|NCT00328861|Metastatic Kidney Cancer
597978|NCT00328848|patient care management
597979|NCT00328848|chronic disease
597980|NCT00328835|Optic Nerve
597981|NCT00328835|Glaucoma
597982|NCT00328822|Primary insomnia
597983|NCT00328822|Quetiapine
597984|NCT00328822|Randomized controlled trial
597985|NCT00328822|Double blind
597986|NCT00328796|Perineal
597987|NCT00328796|repair
597988|NCT00328796|episiotomies
597989|NCT00328796|midwives
597990|NCT00328796|pain relief
597991|NCT00328796|Episiotomy
597992|NCT00328783|Breast cancer
597993|NCT00328783|Active Breathing Control
597994|NCT00328783|Active Breathing Coordinator
597995|NCT00328783|ABC
597996|NCT00328770|liver transplant
597997|NCT00328770|hepatocellular carcinoma
597998|NCT00328770|sirolimus
597999|NCT00328757|gynecologic cancer
598000|NCT00328757|cervical cancer
598001|NCT00328757|ovarian cancer
598002|NCT00328757|endometrial cancer
598003|NCT00328757|radical abdominal hysterectomy
598004|NCT00328757|pelvic lymphadenectomy
598005|NCT00328757|surgical staging
598006|NCT00328757|postoperative feeding
598007|NCT00328757|Early-stage gynecologic cancer patients
598008|NCT00328744|Weight
598009|NCT00328744|Dietary intake
598010|NCT00328744|Energy
598011|NCT00328744|Hedonics
598012|NCT00328744|Behavioral
598013|NCT00328744|Sensory-specific satiety
598014|NCT00328744|Monotony
598015|NCT00328731|Allergy
598016|NCT00328731|NAET
598017|NCT00328718|Persistent Asthma
598018|NCT00328718|pediatric asthmatic
598019|NCT00328718|asthma control
598020|NCT00328705|Sensing
598021|NCT00328705|Capture Management
598022|NCT00328705|Heart Failure
598023|NCT00328705|ICD Indication
598024|NCT00328692|heart failure
598025|NCT00328692|diuretic
598026|NCT00328692|renal impairment
598027|NCT00328692|renal function
598028|NCT00328679|abdominal
598029|NCT00328679|stomach
598030|NCT00328679|dyspepsia
598031|NCT00328679|food allergy
598032|NCT00328653|vernal keratoconjunctivitis (VKC), eye, allergy, cyclosporin
598033|NCT00328640|CVA
598034|NCT00328640|Ischemic stroke
598035|NCT00328627|Diabetes Mellitus, Type 2
598036|NCT00328627|Drug Therapy
598037|NCT00328627|Diabetes Mellitus, Non Insulin Dependent
598038|NCT00328627|Glucose Intolerance
598039|NCT00328627|Hyperglycemia
598040|NCT00328614|Locally advanced prostate cancer
598041|NCT00328614|positive lymph nodes
598042|NCT00328588|Treatment Efficacy
598043|NCT00328588|Treatment Effectiveness
598044|NCT00328588|Disease Management
598045|NCT00328588|Treatment
598046|NCT00328588|Safety
598047|NCT00328575|Brain metastases
598048|NCT00328575|Parenchymal
598049|NCT00328575|Neoplasm
598050|NCT00328575|IMRT
598051|NCT00328575|Intensity Modulated Radiation Therapy
598052|NCT00328562|Advanced NSCLC
598053|NCT00328562|Non-Small Cell Lung Carcinoma
598054|NCT00328562|Stage IV NSCLC
598055|NCT00328549|Natural History,
598056|NCT00328549|Hepatitis C Infection
598057|NCT00328549|Ribavirin
598058|NCT00328549|Pegylated Interferon
598059|NCT00328549|Interferon
598060|NCT00328536|flow-mediated vasodilatation
598061|NCT00328536|endothelial dysfunction
598062|NCT00328536|omega-3 fatty acids
598063|NCT00328536|type 2 diabetes mellitus
598064|NCT00328536|postprandial state
598065|NCT00328510|Stereotactic radiotherapy
598066|NCT00328484|COPD
598067|NCT00328484|Chronic Obstructive Pulmonary Disease
598068|NCT00328484|Exercise
598069|NCT00328484|Emphysema
598070|NCT00328484|Chronic Bronchitis
598071|NCT00328471|patient care management
598072|NCT00328471|cerebrovascular accident
598073|NCT00328458|CNS and head and neck cancers
598074|NCT00328458|Histologically confirmed CNS malignancy head and neck
598075|NCT00328458|there is on standard therapy or
598076|NCT00328458|have failed standard therapy
598077|NCT00328445|Curriculum
598078|NCT00328445|Classroom management
598079|NCT00328445|School-wide climate
598080|NCT00328445|Parent involvement
598081|NCT00328432|early breast cancer
598082|NCT00328432|double-blind randomized placebo-controlled
598083|NCT00328432|RCT
598084|NCT00328432|pre-surgical model
598085|NCT00328432|DCIS model
598086|NCT00328432|COX-2 inhibitor
598087|NCT00328432|celecoxib
598088|NCT00328432|Ki-67 placebo
598089|NCT00328419|Photoprotection,
598090|NCT00328419|Parenteral nutrition
598091|NCT00328419|Oxidant stress
598092|NCT00328419|Infant, Premature
598093|NCT00328393|Hypertension
598094|NCT00328380|Travelers' Diarrhea
598095|NCT00328380|Xifaxan
598096|NCT00328380|Rifaximin
598097|NCT00328380|Escherichia coli
598098|NCT00328380|E coli
598099|NCT00328380|EAEC
598100|NCT00328380|Enteroaggregative E coli
598101|NCT00328380|ETEC
598102|NCT00328380|Enterotoxigenic E coli
598103|NCT00328367|schizophrenia
598104|NCT00328367|aripiprazole
598105|NCT00328367|clozapine
598106|NCT00328341|traumatic brain injury
598107|NCT00328341|hemorrhagic shock
598108|NCT00328341|multisystem trauma
598109|NCT00328341|under resuscitation
598110|NCT00328341|tissue oxygen monitoring
598111|NCT00328315|Myocardial Perfusion SPECT
598112|NCT00328302|Diabetes
598113|NCT00328302|Kidney function
598114|NCT00328302|24 ambulatory blood pressure
598115|NCT00328302|Kidney biopsy
598116|NCT00328289|Dialysis associated hypotension
598117|NCT00328289|Urea removal
598118|NCT00328263|Bio-K+CL1285
598119|NCT00328263|Probiotics
598120|NCT00328263|Antibiotics-associated diarrhea
598121|NCT00328263|Clostridium difficile-associated diarrhea
598122|NCT00328263|Lactobacillus acidophilus
598123|NCT00328263|Clostridium Difficile
598124|NCT00328250|Internet
598125|NCT00328250|CBT
598126|NCT00328250|Insomnia
598127|NCT00328250|Sleep
598128|NCT00328237|Cord Blood Transplant
598129|NCT00328237|Umbilical cord blood transplant
598130|NCT00328237|Transplant
598131|NCT00328237|Fludarabine
598132|NCT00328237|Total Body Irradiation
598133|NCT00328237|Cyclophosphamide
598134|NCT00328224|ritalin
598135|NCT00328224|ADHA
598136|NCT00328224|dental status
598137|NCT00328224|periodontal status
598138|NCT00328224|Attention-Deficit Hyperactivity Disorder
598139|NCT00328224|Dental trauma
598140|NCT00328198|CAMPATH
598141|NCT00328198|Alemtuzumab
598142|NCT00328198|Leukemia
598143|NCT00328198|MabCampath
598144|NCT00328198|Chronic
598145|NCT00328198|Subcutaneous
598146|NCT00328198|CLL
598147|NCT00328198|C-CLL
598148|NCT00328198|Relapsed
598149|NCT00328198|Refractory
598150|NCT00328198|Chronic Lymphocytic Leukemia
598151|NCT00328185|pediatric
598152|NCT00328185|heart disease
598153|NCT00328185|orthotopic heart transplantation
598154|NCT00328185|allograft fibrosis
598155|NCT00328159|FAO disorders
598156|NCT00328159|long-chain FAO enzyme defects
598157|NCT00328159|inborn errors of metabolism
598158|NCT00328159|carnitine palmitoyltransferase 1 (CPT1),
598159|NCT00328159|carnitine-acylcarnitine translocase (CAT),
598160|NCT00328159|carnitine palmitoyltransferase 2 (CPT2),
598161|NCT00328159|very-long chain acyl-CoA dehydrogenase (VLCAD),
598162|NCT00328159|L-3-hydroxy-acyl-CoA dehydrogenase (LCHAD)
598163|NCT00328159|or trifunctional protein (MTP).
598164|NCT00328146|pediatric
598165|NCT00328146|cardiac
598166|NCT00328146|re-operative surgery
598167|NCT00328133|recombinant Factor VIIa
598168|NCT00328133|traumatic hemorrhage
598169|NCT00328133|hemorrhagic shock
598170|NCT00328133|coagulopathy
598171|NCT00328120|Advanced breast cancer
598172|NCT00328120|Faslodex
598173|NCT00328107|Influenza
598174|NCT00328094|Tight
598175|NCT00328094|Glycemic
598176|NCT00328094|control
598177|NCT00328094|outcomes
598178|NCT00328094|peripheral vascular disease
598179|NCT00328094|infection
598180|NCT00328094|cardiovascular
598181|NCT00328094|morbidity
598182|NCT00328094|mortality
598183|NCT00328081|Obesity
598184|NCT00328081|Weight gain
598185|NCT00328081|Anti-obesity medication
598186|NCT00328081|Anti-obesity management strategies
598187|NCT00328081|Body Weight
598188|NCT00328068|ASAS classification
598189|NCT00328068|ASAS diagnostic criteria
598190|NCT00328068|spondyloarthritis
598191|NCT00328068|spondyloarthropathy
598192|NCT00328068|spondylitis, ankylosing
598193|NCT00328068|modified New York criteria for AS
598194|NCT00328068|ESSG criteria for SpA
598195|NCT00328068|Amor criteria for SpA
598196|NCT00328068|arthritis
598197|NCT00328068|enthesitis
598198|NCT00328068|magnetic resonance imaging
598199|NCT00328055|functional ability
598200|NCT00328055|patient care management
598201|NCT00328055|communication
598202|NCT00328055|literacy
598203|NCT00328042|Self-care
598204|NCT00328042|Quality of Life
598205|NCT00328042|Chronic disease
598206|NCT00328029|Busulfan
598207|NCT00328029|pharmacokinetic
598208|NCT00328029|respiratory function assessment
598209|NCT00328029|Busulfan pharmacokinetic and respiratory function tests
598210|NCT00328016|hypertension
598211|NCT00328016|high blood pressure
598212|NCT00328016|meditation
598213|NCT00327990|ibandronate
598214|NCT00327990|osteoporosis
598215|NCT00327990|preference
598216|NCT00327990|case-finding
598217|NCT00327990|post-menopausal
598218|NCT00327990|alendronate
598219|NCT00327977|hypoxemia
598220|NCT00327977|palliative neonatal surgery
598221|NCT00327964|malaria
598222|NCT00327964|fever
598223|NCT00327964|Uganda
598224|NCT00327964|children
598225|NCT00327964|rapid diagnostic tests
598226|NCT00327964|RDTs
598227|NCT00327964|Africa
598228|NCT00327951|pediatric
598229|NCT00327951|cardiac
598230|NCT00327951|weight gain pre-operative
598231|NCT00327951|trisomy 21
598232|NCT00327951|complete atrioventricular canal
598233|NCT00327938|Remifentanil
598234|NCT00327938|Skin Conductance
598235|NCT00327938|Anesthesia
598236|NCT00327938|Analgesics, Opioid
598237|NCT00327925|Ovarian
598238|NCT00327925|Cancer
598239|NCT00327925|Antibodies
598240|NCT00327925|Ovarian Cancer Associated Antibodies
598241|NCT00327912|Obesity
598242|NCT00327912|Surgery
598243|NCT00327912|Gastric bypass
598244|NCT00327912|Biliopancreatic diversion with Duodenal switch
598245|NCT00327912|Laparoscopy
598246|NCT00327899|pediatric
598247|NCT00327899|congestive heart failure
598248|NCT00327899|inotropes
598249|NCT00327886|pediatric
598250|NCT00327886|Glenn operation
598251|NCT00327886|Cyanosis
598252|NCT00327873|breathlessness
598253|NCT00327873|shortness of breath
598254|NCT00327873|end-of-life care
598255|NCT00327873|hospice
598256|NCT00327808|Smokers
598257|NCT00327808|Adults
598258|NCT00327808|Inflammatory markers
598259|NCT00327795|congenital heart disease
598260|NCT00327795|pediatric
598261|NCT00327795|surgical outcomes
598262|NCT00327782|pediatric
598263|NCT00327782|palliative care
598264|NCT00327782|end stage heart failure
598265|NCT00327769|Advanced breast cancer
598266|NCT00327769|fulvestrant
598267|NCT00327769|anastrozole
598268|NCT00327756|Depression
598269|NCT00327756|Magnetic Resonance Spectroscopy
598270|NCT00327756|Mitochondrial Enhancer
598271|NCT00327756|Manic Depressive
598272|NCT00327756|Bioenergetics
598273|NCT00327756|Bipolar Disorder
598274|NCT00327756|Manic Depression
598275|NCT00327743|Cancer Alternative Therapies
598276|NCT00327743|Metastatic Breast Cancer
598277|NCT00327730|Muscle
598278|NCT00327730|Spasm
598279|NCT00327730|Back
598280|NCT00327730|Pain
598281|NCT00327717|Epilepsy
598282|NCT00327717|Partial seizures
598283|NCT00327704|Septic Shock
598284|NCT00327691|Major cardiovascular event
598285|NCT00327691|Major Coronary event
598286|NCT00327691|Revascularization
598287|NCT00327678|ALL,
598288|NCT00327678|young patients,
598289|NCT00327678|chemotherapy,
598290|NCT00327678|Mabtera,
598291|NCT00327678|Imatinib,
598292|NCT00327678|allogeneic transplant
598293|NCT00327665|pneumonia
598294|NCT00327665|pneumococcal vaccine
598295|NCT00327665|elderly subjects
598296|NCT00327665|invasive pneumococcal diseases
598297|NCT00327665|Prophylaxis
598298|NCT00327652|carcinoma
598299|NCT00327652|liver
598300|NCT00327652|hepatic
598301|NCT00327652|metastasis
598302|NCT00327652|Listeria
598303|NCT00327626|Fasting plasma glucose
598304|NCT00327626|HbA1c
598305|NCT00327626|Oral antidiabetic agent(s)
598306|NCT00327613|PEX
598307|NCT00327613|glaucoma
598308|NCT00327613|MMP
598309|NCT00327613|DNA degradation
598310|NCT00327613|POAG
598311|NCT00327613|Healthy subjects
598312|NCT00327587|hypertension
598313|NCT00327587|valsartan
598314|NCT00327587|amlodipine
598315|NCT00327587|HCTZ
598316|NCT00327561|Inflammation
598317|NCT00327561|Periodontitis
598318|NCT00327561|Endothelial function
598319|NCT00327561|Atherosclerosis
598320|NCT00327561|Controlled trial
598321|NCT00327509|mRNA
598322|NCT00327509|glaucoma
598323|NCT00327483|Transplant
598324|NCT00327483|Medication error
598325|NCT00327483|Patient Safety
598326|NCT00327483|Information technology
598327|NCT00327470|neovascular age related macular degeneration
598328|NCT00327470|choroidal neovascularization
598329|NCT00327457|colorectal cancer screening
598330|NCT00327457|sigmoidoscopy
598331|NCT00327457|colonoscopy
598332|NCT00327444|Ovarian neoplasm
598333|NCT00327444|Ascites
598334|NCT00327444|Angiogenesis inhibitor
598335|NCT00327444|Vascular Endothelial Growth Factor A
598336|NCT00327444|Recombinant fusion protein
598337|NCT00327431|Hypertension
598338|NCT00327431|Blood Pressure
598339|NCT00327431|Psychosocial Factors
598340|NCT00327405|POAG
598341|NCT00327405|Primary Open Angle Glaucoma
598342|NCT00327405|Trabeculectomy
598343|NCT00327405|Combined Phacotrabeculectomy
598344|NCT00327405|Combined Glaucoma Cataract Surgery
598345|NCT00327405|Releasable Suture
598346|NCT00327405|Ocular Compresssion
598347|NCT00327392|Arthroscopy
598348|NCT00327392|AV Shunt
598349|NCT00327392|Bunion
598350|NCT00327392|Dilatation and Curettage
598351|NCT00327392|Esophagogastroduodenoscopy
598352|NCT00327392|Hysteroscopy
598353|NCT00327392|Lithotripsy
598354|NCT00327392|Rotator Cuff/ Shoulder
598355|NCT00327392|Transesophageal Echocardiography
598356|NCT00327392|Ureteroscopy
598357|NCT00327392|AQUAVAN
598358|NCT00327392|Sedation
598359|NCT00327379|Bloodloss
598360|NCT00327379|Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
598361|NCT00327366|Menstrual Cycle
598362|NCT00327366|Light Therapy
598363|NCT00327366|Sex Hormones
598364|NCT00327366|Ovulation
598365|NCT00327353|Asthma
598366|NCT00327353|Salmeterol
598367|NCT00327353|Formoterol
598368|NCT00327353|Airway resistance
598369|NCT00327340|Metastatic hormone refractory prostate cancer (HRPC)
598370|NCT00327301|POAG
598371|NCT00327301|Parkinson's disease
598372|NCT00327301|cellular proteome
598373|NCT00327301|human leucocytes
598374|NCT00327301|vasospasm
598375|NCT00327301|POAG patients
598376|NCT00327301|Patients with Parkinson's disease
598377|NCT00327301|Healthy subjects
598378|NCT00327288|Hormone refractory prostate cancer
598379|NCT00327262|chronic myeloid leukemia
598380|NCT00327262|Ph+
598381|NCT00327262|bcr/abl+
598382|NCT00327262|imatinib
598383|NCT00327236|Paraneoplastic Neurologic Syndromes
598384|NCT00327223|Metastatic cancer
598385|NCT00327223|Disseminated malignant disease
598386|NCT00327210|BGAT
598387|NCT00327210|Blood Glucose Awareness Training
598388|NCT00327210|Diabetes
598389|NCT00327210|T1DM
598390|NCT00327210|Internet
598391|NCT00327210|Web
598392|NCT00327210|Intervention
598393|NCT00327210|Treatment
598394|NCT00327210|Behavior
598395|NCT00327210|Education
598396|NCT00327210|Awareness
598397|NCT00327197|bronchoscopy
598398|NCT00327197|Sputum induction
598399|NCT00327197|Prednisolone
598400|NCT00327197|Asthma
598401|NCT00327197|biomarkers
598402|NCT00327171|ovarian cancer
598403|NCT00327171|angiogenesis
598404|NCT00327171|angiogenesis inhibition
598405|NCT00327171|VEGF-Trap fusion recombinant protein
598406|NCT00327171|Cancer and other neoplasms
598407|NCT00327158|Reaming
598408|NCT00327158|fracture
598409|NCT00327158|emboli
598410|NCT00327145|HCTZ
598411|NCT00327145|hypertension
598412|NCT00327145|valsartan
598413|NCT00327145|amlodipine
598414|NCT00327132|Early-stage Lg/Hg Gastric MALT Lymphoma
598415|NCT00327132|Eradication of Helicobacter pylori (Hp)
598416|NCT00327119|EGFR
598417|NCT00327119|Fully human
598418|NCT00327119|Monoclonal antibody
598419|NCT00327119|Panitumumab
598420|NCT00327119|ABX-EGF
598421|NCT00327119|AMG954
598422|NCT00327119|Colorectal Cancer
598423|NCT00327119|Japan
598424|NCT00327106|hip fracture
598425|NCT00327106|transfusion
598426|NCT00327106|tranexamic acid
598427|NCT00327106|fondaparinux
598428|NCT00327093|Colorectal cancer,
598429|NCT00327093|immunohistochemistry,
598430|NCT00327093|monoclonal antibodies,
598431|NCT00327093|predictive model,
598432|NCT00327093|antiangiogenic agents,
598433|NCT00327093|medical imaging
598434|NCT00327093|Colorectal cancer with liver metastases
598435|NCT00327080|HIV
598436|NCT00327080|AIDS
598437|NCT00327080|Pulmonary Hypertension
598438|NCT00327080|Blood Flow Studies
598439|NCT00327080|Right Heart Catheterization
598440|NCT00327080|HIV Infection
598441|NCT00327080|HIV Associated Pulmonary Hypertension
598442|NCT00327080|Healthy Volunteer
598443|NCT00327080|HV
598444|NCT00327067|Hemoglobin
598445|NCT00327067|Iron Supplementation
598446|NCT00327067|Donor Retention
598447|NCT00327067|Iron Stores
598448|NCT00327067|Ferritin
598449|NCT00327067|Transferrin Saturation
598450|NCT00327067|Healthy Volunteer
598451|NCT00327067|HV
598452|NCT00327067|Blood Donors
598453|NCT00327054|Dyslipidaemia
598454|NCT00327054|Herbal medicine
598455|NCT00327054|Home remedy
598456|NCT00327054|Alternative medicine
598457|NCT00327054|Metabolic syndrome
598458|NCT00327041|Aspirin
598459|NCT00327041|Clopidogrel
598460|NCT00327041|Balloon Angioplasty
598461|NCT00327041|Coronary Thrombosis
598462|NCT00327028|Bronchial asthma
598463|NCT00327028|Phenytoin, Diphenine
598464|NCT00327028|Antiepileptic drugs
598465|NCT00327028|Efficacy
598466|NCT00327002|Low HDL
598467|NCT00327002|Metabolic syndrome
598468|NCT00327002|low HDL Cholesterol in setting of metabolic syndrome
598469|NCT00326989|Extracorporal shock wave therapy
598470|NCT00326989|Cell therapy
598471|NCT00326976|Angioplasty, Transluminal, Percutaneous Coronary
598472|NCT00326976|Myocardial Revascularization
598473|NCT00326950|Cancer
598474|NCT00326950|Tumors
598475|NCT00326950|Phase I
598476|NCT00326950|E7389
598477|NCT00326924|Transfusion
598478|NCT00326898|Sorafenib
598479|NCT00326898|Sunitinib
598480|NCT00326898|Renal Carcinoma
598481|NCT00326885|Ascites
598482|NCT00326885|Epithelial Cancer
598483|NCT00326885|Epithelial Carcinoma
598484|NCT00326885|Epithelial Ovarian Cancer
598485|NCT00326885|Epithelial Ovarian Carcinoma
598486|NCT00326885|Fallopian Tube Cancer
598487|NCT00326885|Fallopian Tube Carcinoma
598488|NCT00326885|Malignant Ascites
598489|NCT00326885|Ovarian Cancer
598490|NCT00326885|Ovarian Carcinoma
598491|NCT00326885|Ovarian Epithelial Cancer
598492|NCT00326885|Ovarian Epithelial Carcinoma
598493|NCT00326885|Peritoneal Cancer
598494|NCT00326885|Peritoneal Carcinoma
598495|NCT00326885|Recurrent Ascites
598496|NCT00326885|Recurrent Malignant Ascites
598497|NCT00326885|Recurrent Symptomatic Malignant Ascites
598498|NCT00326885|Symptomatic Malignant Ascites
598499|NCT00326885|Symptomatic Ascites
598500|NCT00326885|Neoplasms, Glandular and Epithelial
598501|NCT00326885|Ovarian Neoplasms
598502|NCT00326885|Fallopian Tube Neoplasms
598503|NCT00326885|Peritoneal Neoplasms
598504|NCT00326859|analgesia strategies
598505|NCT00326859|pain
598506|NCT00326859|extensive dressing change
598507|NCT00326833|Vitamin B12 deficiency
598508|NCT00326833|Vitamin B12 absorption
598509|NCT00326833|Holotranscobalamin
598510|NCT00326820|hypercalcemia of malignancy
598511|NCT00326820|stage IV breast cancer
598512|NCT00326820|bone metastases
598513|NCT00326820|recurrent breast cancer
598514|NCT00326820|male breast cancer
598515|NCT00326807|naltrexone
598516|NCT00326807|alcohol
598517|NCT00326807|gambling
598518|NCT00326807|concurrent
598519|NCT00326794|Nonsurgical proximal humerus fracture
598520|NCT00326794|Rehabilitation
598521|NCT00326794|Physiotherapy
598522|NCT00326794|randomised controlled trial
598523|NCT00326781|Nicotine nasal spray + counseling
598524|NCT00326781|Transdermal nicotine + counseling
598525|NCT00326742|Alcoholism
598526|NCT00326742|Risk factors
598527|NCT00326742|Adolescence
598528|NCT00326742|Stress test
598529|NCT00326742|HPA system
598530|NCT00326742|Family adversity
598531|NCT00326742|Candidate genes
598532|NCT00326742|Cortisol
598533|NCT00326742|Adrenocorticotrophin
598534|NCT00326729|burns
598535|NCT00326729|thermal injury
598536|NCT00326729|hemodynamics
598537|NCT00326729|microcirculation
598538|NCT00326716|HIV-1 infected pregnant women, either treatment naive or on ATV/RTV combined with ZDV/3TC
598539|NCT00326703|hypoxia
598540|NCT00326703|hypobaric
598541|NCT00326703|altitude
598542|NCT00326690|Congestive Heart Failure
598543|NCT00326690|Coronary Artery Disease
598544|NCT00326690|Ischemic Cardiomyopathy
598545|NCT00326690|Idiopathic Cardiomyopathy
598546|NCT00326677|Depression Prevention
598547|NCT00326677|Prevention of Depression
598548|NCT00326677|Depression in the Elderly
598549|NCT00326677|Late Life Depression
598550|NCT00326677|Depression in Old Age
598551|NCT00326677|Treatment of Depression in Primary Care Patients
598552|NCT00326677|Sub syndromal depression
598553|NCT00326677|Minor Depression
598554|NCT00326651|infertility
598555|NCT00326651|pregnancy
598556|NCT00326651|conception
598557|NCT00326651|conceive
598558|NCT00326651|conceiving
598559|NCT00326651|trying to conceive
598560|NCT00326651|get pregnant
598561|NCT00326651|conception kit
598562|NCT00326651|conception cap
598563|NCT00326651|fertility
598564|NCT00326651|Women who are actively trying to become pregnant
598565|NCT00326638|prostate, IMRT, tomotherapy, radiation, cancer
598566|NCT00326612|Seizures
598567|NCT00326599|recurrent non-small cell lung cancer
598568|NCT00326599|stage IIIB non-small cell lung cancer
598569|NCT00326599|stage IV non-small cell lung cancer
598570|NCT00326599|squamous cell lung cancer
598571|NCT00326573|Diabetes
598572|NCT00326573|Teenagers
598573|NCT00326573|Motivational Interviewing
598574|NCT00326560|Pterygium excision
598575|NCT00326560|Cut and paste
598576|NCT00326560|Tisseel fibrin glue
598577|NCT00326560|Conjunctival autograft
598578|NCT00326534|Sarcoidosis
598579|NCT00326534|Rickettsia
598580|NCT00326534|Serological reactions
598581|NCT00326534|Polymerase chain reaction
598582|NCT00326521|Pregnant Women
598583|NCT00326521|Epidural Anesthesia
598584|NCT00326521|Fever
598585|NCT00326521|Chorioamnionitis
598586|NCT00326521|Intrauterine pressure catheter
598587|NCT00326521|Pregnancy
598588|NCT00326508|T Lymphocytes
598589|NCT00326508|IL-2 Conjugate
598590|NCT00326508|CD25
598591|NCT00326508|T Regulatory Cells
598592|NCT00326508|Autoimmunity
598593|NCT00326508|Uveitis
598594|NCT00326508|Daclizumab
598595|NCT00326508|Denileukin Diftitox
598596|NCT00326508|Immune Tolerance
598597|NCT00326508|T Cell
598598|NCT00326495|Sorafenib
598599|NCT00326495|Cetuximab
598600|NCT00326495|Advanced Cancer
598601|NCT00326495|Phase II
598602|NCT00326495|Colorectal Cancer
598603|NCT00326495|Colon Cancer
598604|NCT00326495|Rectal Cancer
598605|NCT00326495|CRC
598606|NCT00326495|Metastatic Colorectal Cancer
598607|NCT00326482|Drug Toxicity
598608|NCT00326482|Steatohepatitis
598609|NCT00326482|Hepatotoxicity
598610|NCT00326482|Liver Biopsy
598611|NCT00326482|Elevated transaminases
598612|NCT00326482|HIV
598613|NCT00326482|Liver Fibrosis
598614|NCT00326456|ovarian cancer
598615|NCT00326456|chemotherapy
598616|NCT00326456|first-line
598617|NCT00326443|Salmonella, vaccine, typhoid fever, S. Typhi
598618|NCT00326430|Social Phobia
598619|NCT00326430|Cognitive Therapy
598620|NCT00326430|Interpersonal Therapy
598621|NCT00326430|Efficacy
598622|NCT00326430|Process-Outcome
598623|NCT00326417|Severe Aplastic Anemia
598624|NCT00326404|Oral Contraceptives
598625|NCT00326404|Adolescents
598626|NCT00326404|Compliance
598627|NCT00326391|Attention Deficit Disorder with Hyperactivity, ADHD, Attention Deficit Disorder Adult
598628|NCT00326365|mechanical ventilation
598629|NCT00326365|secretions
598630|NCT00326365|viscosity
598631|NCT00326365|homeopathy
598632|NCT00326365|kalium bichromate
598633|NCT00326365|extubation
598634|NCT00326352|Sedation
598635|NCT00326352|Propofol
598636|NCT00326352|Remifentanil
598637|NCT00326352|recovery
598638|NCT00326339|R935788
598639|NCT00326339|Rheumatoid Arthritis
598640|NCT00326339|Syk Kinase
598641|NCT00326313|Group B streptococci
598642|NCT00326313|virulent
598643|NCT00326313|morbidity
598644|NCT00326313|mortality
598645|NCT00326300|Attention Deficit Hyperactivity Disorder, ADHD, Attention Deficit Disorder Adult
598646|NCT00326287|Community-Acquired Pneumonia
598647|NCT00326287|Cephalosporins
598648|NCT00326287|Methicillin-Resistant Staphylococcus Aureus
598649|NCT00326248|postoperative nausea and vomiting PONV antiemetics NK-1 5HT3 casopitant mesylate ZOFRAN ondansetron hydrochloride
598650|NCT00326235|Opioid withdrawal
598651|NCT00326235|Buspirone
598652|NCT00326235|Methadone taper
598653|NCT00326222|Patient Education as a Topic
598654|NCT00326222|Self-Management Program
598655|NCT00326222|Health promotion
598656|NCT00326222|Self Efficacy
598657|NCT00326222|Quality of life
598658|NCT00326209|UC
598659|NCT00326209|Ulcerative colitis
598660|NCT00326209|Inflammatory bowel disease
598661|NCT00326209|IBD
598662|NCT00326196|CABG
598663|NCT00326196|Coronary Disease
598664|NCT00326196|Diabetes
598665|NCT00326196|PCI
598666|NCT00326170|Combination Chemotherapy
598667|NCT00326170|MDS
598668|NCT00326170|High-Risk Myelodysplastic Syndrome
598669|NCT00326170|AML
598670|NCT00326170|Acute myelogenous leukemia
598671|NCT00326170|valproic acid
598672|NCT00326170|VPA
598673|NCT00326170|Depakene
598674|NCT00326170|5-azacytidine
598675|NCT00326170|5-aza
598676|NCT00326170|Azacitidine
598677|NCT00326170|5-AZC
598678|NCT00326170|Vidaza
598679|NCT00326170|AZA-CR
598680|NCT00326170|Ladakamycin
598681|NCT00326170|NSC-102816
598682|NCT00326170|All-trans retinoic acid
598683|NCT00326170|ATRA
598684|NCT00326170|Tretinoin
598685|NCT00326170|Vesanoid
598686|NCT00326157|antifungal primary prophylaxis treatment
598687|NCT00326157|allogeneic stem-cell transplantation
598688|NCT00326157|antifungal primary prophylaxis treatment of high risk patients undergoing allogeneic stem-cell transplantation
598689|NCT00326144|MDD
598690|NCT00326144|Depression
598691|NCT00326118|Meningococcal serogroup C diseases
598692|NCT00326118|H.influenzae type b diseases
598693|NCT00326105|MDD
598694|NCT00326105|Depression
598695|NCT00326079|Open angle
598696|NCT00326079|Glaucoma
598697|NCT00326079|Surgery
598698|NCT00326066|Open angle
598699|NCT00326066|Glaucoma
598700|NCT00326066|Surgery
598701|NCT00326066|Cataract
598702|NCT00326053|Asthma Reoccurrence
598703|NCT00326053|Acute Asthma
598704|NCT00326053|Patient Discharge
598705|NCT00326053|Emergency Service, Hospital
598706|NCT00326053|Asthma Exacerbation
598707|NCT00326053|Asthma Relapse
598708|NCT00326040|Open angle
598709|NCT00326040|Glaucoma
598710|NCT00326040|Refractory
598711|NCT00326040|Surgery
598712|NCT00326027|GERD
598713|NCT00326027|Pantoprazole
598714|NCT00326027|NERD
598715|NCT00326014|Open angle
598716|NCT00326014|Glaucoma
598717|NCT00326014|Cataract
598718|NCT00326014|Surgery
598719|NCT00326001|Transvenous Catheter Ablation
598720|NCT00326001|Radiofrequency Catheter Ablation
598721|NCT00326001|Atrial flutter
598722|NCT00326001|Catheter Ablation
598723|NCT00325988|Neuroimmunology
598724|NCT00325988|Demyelinating Disease
598725|NCT00325988|Genetics
598726|NCT00325988|Proteins
598727|NCT00325975|Smallpox
598728|NCT00325975|Variola
598729|NCT00325975|Orthopoxvirus
598730|NCT00325975|Virus
598731|NCT00325975|Immunogenicity
598732|NCT00325975|Smallpox Vaccine
598733|NCT00325962|Hypertension
598734|NCT00325962|Type 2 Diabetes
598735|NCT00325962|6R-BH4
598736|NCT00325962|BH4
598737|NCT00325962|BH4 deficiency
598738|NCT00325962|sapropterin dihydrochloride
598739|NCT00325962|endothelial dysfunction
598740|NCT00325962|NO
598741|NCT00325962|Nitric Oxide
598742|NCT00325936|metabolic syndrome
598743|NCT00325936|Hypertension
598744|NCT00325936|CCB
598745|NCT00325936|cilnidipine
598746|NCT00325923|Decision making
598747|NCT00325923|Decision support
598748|NCT00325923|Decisional conflict
598749|NCT00325923|Menopause
598750|NCT00325923|Natural health products
598751|NCT00325923|Herbs
598752|NCT00325923|Complementary medicine
598753|NCT00325923|Complementary therapies
598754|NCT00325910|Diabetes
598755|NCT00325910|Heart Failure
598756|NCT00325910|Mortality
598757|NCT00325910|Hospitalization
598758|NCT00325910|Feasability
598759|NCT00325884|coronary artery disease
598760|NCT00325884|bifurcation lesions
598761|NCT00325884|percutaneous interventions
598762|NCT00325884|stenting
598763|NCT00325884|outcomes
598764|NCT00325884|death
598765|NCT00325884|myocardial infarction
598766|NCT00325858|osteoarthritis pain
598767|NCT00325858|knee
598768|NCT00325858|hip
598769|NCT00325858|extended-release analgesia
598770|NCT00325858|opioid
598771|NCT00325845|Investigational
598772|NCT00325845|Therapeutic
598773|NCT00325845|Efficacy
598774|NCT00325845|Safety
598775|NCT00325845|Outcomes
598776|NCT00325845|Lumbar facet joint arthrosis
598777|NCT00325845|Lumbar facet joint arthropathy
598778|NCT00325832|Hypertension
598779|NCT00325832|Blood Pressure
598780|NCT00325832|Systolic Pressure
598781|NCT00325832|Diastolic Pressure
598782|NCT00325832|Blood Pressure Monitoring, Ambulatory
598783|NCT00325819|Acetaminophen
598784|NCT00325819|Vaccination
598785|NCT00325819|Immunization
598786|NCT00325793|nicardipine
598787|NCT00325793|hypertension
598788|NCT00325793|intracerebral hemorrhage
598789|NCT00325793|ischemic stroke
598790|NCT00325780|Kowa
598791|NCT00325780|Hypercholesterolemia
598792|NCT00325780|dyslipidemia
598793|NCT00325780|pitavastatin
598794|NCT00325780|NK-104
598795|NCT00325780|Hypercholesterolemia or combined dyslipidemia
598796|NCT00325767|mucociliary clearance
598797|NCT00325767|beta-adrenergic drugs
598798|NCT00325767|inhalation
598799|NCT00325767|aerosol
598800|NCT00325754|Chronic Obstructive Pulmonary Disease
598801|NCT00325754|COPD
598802|NCT00325741|Lupus
598803|NCT00325741|Systemic Lupus Erythematosus
598804|NCT00325741|Blood Stem Cell Transplantation
598805|NCT00325728|Chronic Insomnia
598806|NCT00325728|Sleep Initiation and Maintenance Disorder
598807|NCT00325728|Drug Therapy
598808|NCT00325728|Alzheimer disease
598809|NCT00325702|HIV
598810|NCT00325702|prevention
598811|NCT00325676|GERD
598812|NCT00325676|Pantoprazole
598813|NCT00325676|Complete Remission
598814|NCT00325663|acupuncture
598815|NCT00325663|double-blind
598816|NCT00325663|sham control
598817|NCT00325663|osteoarthritis
598818|NCT00325663|pain
598819|NCT00325650|Prediabetic state
598820|NCT00325650|Impaired fasting glucose
598821|NCT00325650|Impaired glucose Tolerance
598822|NCT00325637|CHERISH
598823|NCT00325637|Ischemic Stroke
598824|NCT00325624|Blood Pressure
598825|NCT00325624|Diabetes mellitus
598826|NCT00325624|Hypertension
598827|NCT00325624|Home Care
598828|NCT00325624|Glucometer
598829|NCT00325611|Palliative care
598830|NCT00325611|End of life care
598831|NCT00325585|Human Immunodeficiency Viruses
598832|NCT00325585|Acquired Immunodeficiency Syndrome
598833|NCT00325585|Substance Abuse
598834|NCT00325585|Sexually Transmitted Disease, Viral
598835|NCT00325585|Intervention Studies
598836|NCT00325585|Women's Health
598837|NCT00325546|Obesity
598838|NCT00325533|Blood Pressure, High
598839|NCT00325533|Blacks
598840|NCT00325533|African Americans
598841|NCT00325507|Renal cell cancer
598842|NCT00325507|requiring IL-2 treatment
598843|NCT00325507|Locally advanced or metastatic renal cell carcinoma
598844|NCT00325494|Pancreatic Cancer
598845|NCT00325494|Mesothelioma
598846|NCT00325494|Ovarian Cancer
598847|NCT00325494|Non-Small Cell Lung Cancer
598848|NCT00325494|Mesothelin
598849|NCT00325468|bone loss
598850|NCT00325468|osteoporosis
598851|NCT00325442|Pulmonary Arterial Hypertension
598852|NCT00325429|Type 2 diabetes
598853|NCT00325429|Vildagliptin
598854|NCT00325429|HbA1c
598855|NCT00325416|melphalan
598856|NCT00325416|topotecan
598857|NCT00325416|topoisomerase
598858|NCT00325416|bone marrow transplant
598859|NCT00325416|drug sequence
598860|NCT00325403|Pulmonary Arterial Hypertension
598861|NCT00325390|SR25990C
598862|NCT00325390|Platelet Aggregation Inhibitors
598863|NCT00325390|NSTEACS
598864|NCT00325377|low back pain
598865|NCT00325377|pain
598866|NCT00325377|magnetism
598867|NCT00325377|electromagnetic fields
598868|NCT00325377|visual analogue pain scale
598869|NCT00325351|Ovarian cancer
598870|NCT00325351|Ovarian neoplasms, epithelium
598871|NCT00325338|Allergy
598872|NCT00325338|Specific Immunotherapy
598873|NCT00325338|Ragweed
598874|NCT00325338|Environmental Exposure Chamber
598875|NCT00325325|Kidney Transplantation
598876|NCT00325312|Neck Pain
598877|NCT00325312|Complementary Therapies
598878|NCT00325312|Subcutaneous Carbon Dioxide Insufflations
598879|NCT00325312|Acute Treatment
598880|NCT00325273|Lactobacillus rhamnosus
598881|NCT00325273|Atopic dermatitis
598882|NCT00325273|Allergic rhinitis
598883|NCT00325273|Asthma
598884|NCT00325273|Infant
598885|NCT00325273|Pregnancy
598886|NCT00325260|influenza
598887|NCT00325260|non-inferiority
598888|NCT00325260|Influvac
598889|NCT00325260|Agrippal
598890|NCT00325260|healthy subjects
598891|NCT00325247|ZINC SUPPLEMENTATION
598892|NCT00325247|ACUTE DIARRHOEA
598893|NCT00325247|UNDER FIVE CHILDREN
598894|NCT00325247|RURAL BANGLADESH
598895|NCT00325221|implantable cardioverter-defibrillator
598896|NCT00325221|telemedicine
598897|NCT00325221|Home Monitoring
598898|NCT00325221|psychosomatic
598899|NCT00325221|ventricular tachyarrhythmia
598900|NCT00325221|quality of life
598901|NCT00325221|Electric Countershock
598902|NCT00325182|Alcoholism
598903|NCT00325169|Cross-over
598904|NCT00325169|Tiotropium
598905|NCT00325169|Triple
598906|NCT00325169|COPD
598907|NCT00325169|SERETIDE 50/500
598908|NCT00325169|Dyspnoea
598909|NCT00325169|Impulse oscillometry
598910|NCT00325169|Plethysmography
598911|NCT00325117|Type 2 diabetes
598912|NCT00325117|Vildagliptin
598913|NCT00325117|HbA1c
598914|NCT00325104|Multiple Endocrine Neoplasia
598915|NCT00325104|Gastrinoma
598916|NCT00325104|Prolacinoma
598917|NCT00325104|Medullary Thyroid Cancer
598918|NCT00325104|Insulinoma
598919|NCT00325104|MEN1
598920|NCT00325104|MEN2A
598921|NCT00325104|Familial Primary Hyperparathytoidism
598922|NCT00325091|Writer's Cramp
598923|NCT00325091|Electroencephalogram (EEG)
598924|NCT00325091|Transcranial Magnetic Stimulation (TMS)
598925|NCT00325091|Fine Motor Skills
598926|NCT00325091|Focal Hand Dystonia
598927|NCT00325091|Writer Cramp
598928|NCT00325091|Healthy Volunteer
598929|NCT00325091|HV
598930|NCT00325078|Remicade
598931|NCT00325078|Crohn's Disease
598932|NCT00325078|IBD
598933|NCT00325078|CGD Infection
598934|NCT00325078|Infliximab
598935|NCT00325078|Chorionic Granulomatous Disease
598936|NCT00325078|CGD
598937|NCT00325078|Inflammatory Bowel Disease
598938|NCT00325065|Amygdala
598939|NCT00325065|Emotion
598940|NCT00325065|Memory
598941|NCT00325065|Threat
598942|NCT00325065|Peptides
598943|NCT00325065|Neuropeptides
598944|NCT00325065|Oxytocin
598945|NCT00325065|Vasopressin
598946|NCT00325065|Mood Disorder
598947|NCT00325039|Urinary Incontinence, Stress
598948|NCT00325039|Surgery
598949|NCT00325026|Preterm gestation
598950|NCT00325026|Cervical ripening
598951|NCT00325026|Labor induction
598952|NCT00325026|Misoprostol
598953|NCT00325026|Foley bulb
598954|NCT00325013|Primary Sclerosing Cholangitis
598955|NCT00325013|PSC
598956|NCT00325013|DHA
598957|NCT00325013|Docosahexaenoic Acid
598958|NCT00324974|Gastroesophageal Reflux Disease
598959|NCT00324974|infant
598960|NCT00324974|lansoprazole oral suspension
598961|NCT00324974|PPI
598962|NCT00324961|adefovir dipivoxil
598963|NCT00324961|e Antigen negative
598964|NCT00324961|chronic hepatitis B
598965|NCT00324961|Chinese
598966|NCT00324948|Female sexual arousal disorder
598967|NCT00324948|Female sexual dysfunction
598968|NCT00324922|Vancomycin
598969|NCT00324922|Trimethoprim-Sulfamethoxazole Combination
598970|NCT00324896|Parkinson's
598971|NCT00324896|insomnia
598972|NCT00324896|drug
598973|NCT00324896|eszopiclone
598974|NCT00324896|placebo
598975|NCT00324883|sodium intake
598976|NCT00324883|sodium excretion
598977|NCT00324883|chloride excretion
598978|NCT00324883|creatinine
598979|NCT00324883|hypertension
598980|NCT00324857|Osteoarthritis, Knee
598981|NCT00324857|race
598982|NCT00324857|ethnicity
598983|NCT00324857|knee replacement
598984|NCT00324831|contiguous stage II adult diffuse large cell lymphoma
598985|NCT00324831|noncontiguous stage II adult diffuse large cell lymphoma
598986|NCT00324831|stage III adult diffuse large cell lymphoma
598987|NCT00324831|stage IV adult diffuse large cell lymphoma
598988|NCT00324818|bacterial vaginosis
598989|NCT00324818|treatment
598990|NCT00324779|B-cell childhood acute lymphoblastic leukemia
598991|NCT00324779|untreated childhood acute lymphoblastic leukemia
598992|NCT00324779|stage I childhood large cell lymphoma
598993|NCT00324779|stage II childhood large cell lymphoma
598994|NCT00324779|stage III childhood large cell lymphoma
598995|NCT00324779|stage IV childhood large cell lymphoma
598996|NCT00324779|stage I childhood lymphoblastic lymphoma
598997|NCT00324779|stage II childhood lymphoblastic lymphoma
598998|NCT00324779|stage III childhood lymphoblastic lymphoma
598999|NCT00324779|stage IV childhood lymphoblastic lymphoma
599000|NCT00324779|stage I childhood small noncleaved cell lymphoma
599001|NCT00324779|stage II childhood small noncleaved cell lymphoma
599002|NCT00324779|stage III childhood small noncleaved cell lymphoma
599003|NCT00324779|stage IV childhood small noncleaved cell lymphoma
599004|NCT00324753|cancer
599005|NCT00324753|screening
599006|NCT00324753|communication
599007|NCT00324753|prevention
599008|NCT00324727|liver metastases
599009|NCT00324727|extraocular extension melanoma
599010|NCT00324727|stage IV melanoma
599011|NCT00324727|recurrent melanoma
599012|NCT00324727|recurrent intraocular melanoma
599013|NCT00324727|metastatic intraocular melanoma
599014|NCT00324727|iris melanoma
599015|NCT00324727|ciliary body and choroid melanoma, medium/large size
599016|NCT00324714|osteoporosis
599017|NCT00324714|ductal breast carcinoma in situ
599018|NCT00324714|breast cancer in situ
599019|NCT00324701|Mental Health
599020|NCT00324701|Geriatric Medicine
599021|NCT00324701|Depression
599022|NCT00324701|Health Service Delivery
599023|NCT00324701|Aged
599024|NCT00324688|HIV-1
599025|NCT00324688|Methadone
599026|NCT00324688|HIV-1 infection
599027|NCT00324675|type 2 diabetes,
599028|NCT00324675|glomerular filtration rate,
599029|NCT00324675|renal plasma flow,
599030|NCT00324675|endothelial dysfunction,
599031|NCT00324675|proteinuria,
599032|NCT00324675|diabetic nephropathy
599033|NCT00324662|Implantable cardioverter-defibrillator
599034|NCT00324662|Ventricular tachyarrhythmia
599035|NCT00324662|Supraventricular tachyarrhythmia
599036|NCT00324662|Electric Countershock
599037|NCT00324649|HIV-1
599038|NCT00324623|stage IV melanoma
599039|NCT00324623|recurrent melanoma
599040|NCT00324610|fluoropyrimidines
599041|NCT00324610|metastases
599042|NCT00324610|pharmacokinetics
599043|NCT00324610|phase 1-2 study
599044|NCT00324597|unspecified adult solid tumor, protocol specific
599045|NCT00324597|recurrent adult grade III lymphomatoid granulomatosis
599046|NCT00324597|stage III grade 1 follicular lymphoma
599047|NCT00324597|stage III grade 2 follicular lymphoma
599048|NCT00324597|stage III grade 3 follicular lymphoma
599049|NCT00324597|stage IV grade 1 follicular lymphoma
599050|NCT00324597|stage IV grade 2 follicular lymphoma
599051|NCT00324597|stage IV grade 3 follicular lymphoma
599052|NCT00324597|stage III mantle cell lymphoma
599053|NCT00324597|stage IV mantle cell lymphoma
599054|NCT00324597|stage III marginal zone lymphoma
599055|NCT00324597|stage IV marginal zone lymphoma
599056|NCT00324597|stage III small lymphocytic lymphoma
599057|NCT00324597|stage III cutaneous T-cell non-Hodgkin lymphoma
599058|NCT00324597|stage IV cutaneous T-cell non-Hodgkin lymphoma
599059|NCT00324597|stage III adult T-cell leukemia/lymphoma
599060|NCT00324597|recurrent adult Hodgkin lymphoma
599061|NCT00324597|recurrent adult immunoblastic large cell lymphoma
599062|NCT00324597|recurrent adult lymphoblastic lymphoma
599063|NCT00324597|recurrent adult T-cell leukemia/lymphoma
599064|NCT00324597|recurrent cutaneous T-cell non-Hodgkin lymphoma
599065|NCT00324597|recurrent grade 1 follicular lymphoma
599066|NCT00324597|recurrent grade 2 follicular lymphoma
599067|NCT00324597|recurrent grade 3 follicular lymphoma
599068|NCT00324597|recurrent mantle cell lymphoma
599069|NCT00324597|recurrent marginal zone lymphoma
599070|NCT00324597|recurrent small lymphocytic lymphoma
599071|NCT00324597|splenic marginal zone lymphoma
599072|NCT00324597|stage III adult Burkitt lymphoma
599073|NCT00324597|stage III adult diffuse large cell lymphoma
599074|NCT00324597|stage III adult diffuse mixed cell lymphoma
599075|NCT00324597|stage III adult diffuse small cleaved cell lymphoma
599076|NCT00324597|stage III adult Hodgkin lymphoma
599077|NCT00324597|stage III adult immunoblastic large cell lymphoma
599078|NCT00324597|stage III adult lymphoblastic lymphoma
599079|NCT00324597|Waldenström macroglobulinemia
599080|NCT00324597|recurrent mycosis fungoides/Sezary syndrome
599081|NCT00324597|stage III mycosis fungoides/Sezary syndrome
599082|NCT00324597|stage IV mycosis fungoides/Sezary syndrome
599083|NCT00324597|stage IV adult Burkitt lymphoma
599084|NCT00324597|stage IV adult diffuse large cell lymphoma
599085|NCT00324597|stage IV adult diffuse mixed cell lymphoma
599086|NCT00324597|stage IV adult diffuse small cleaved cell lymphoma
599087|NCT00324597|stage IV adult Hodgkin lymphoma
599088|NCT00324597|stage IV adult immunoblastic large cell lymphoma
599089|NCT00324597|stage IV adult lymphoblastic lymphoma
599090|NCT00324597|stage IV adult T-cell leukemia/lymphoma
599091|NCT00324597|adenocarcinoma of the lung
599092|NCT00324597|bronchoalveolar cell lung cancer
599093|NCT00324597|large cell lung cancer
599094|NCT00324597|stage IIIA non-small cell lung cancer
599095|NCT00324597|stage IIIB non-small cell lung cancer
599096|NCT00324597|stage IV non-small cell lung cancer
599097|NCT00324597|recurrent adult Burkitt lymphoma
599098|NCT00324597|recurrent adult diffuse large cell lymphoma
599099|NCT00324597|recurrent adult diffuse mixed cell lymphoma
599100|NCT00324597|recurrent adult diffuse small cleaved cell lymphoma
599101|NCT00324597|stage IV small lymphocytic lymphoma
599102|NCT00324597|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
599103|NCT00324597|nodal marginal zone B-cell lymphoma
599104|NCT00324597|anaplastic large cell lymphoma
599105|NCT00324597|angioimmunoblastic T-cell lymphoma
599106|NCT00324597|post-transplant lymphoproliferative disorder
599107|NCT00324597|recurrent non-small cell lung cancer
599108|NCT00324584|type 1 diabetes mellitus
599109|NCT00324584|telecare
599110|NCT00324584|telemedicine
599111|NCT00324584|insulin pump therapy
599112|NCT00324558|Bemiparin
599113|NCT00324558|small cell lung carcinoma
599114|NCT00324545|Obesity
599115|NCT00324545|Diets
599116|NCT00324545|Heart Disease
599117|NCT00324545|Randomized controlled trial
599118|NCT00324545|Ischemia.
599119|NCT00324519|second trimester
599120|NCT00324519|pregnancy termination
599121|NCT00324519|misoprostol
599122|NCT00324519|foley bulb
599123|NCT00324493|Severe Hemophilia
599124|NCT00324493|Musculoskeletal Function
599125|NCT00324493|Factor Replacement
599126|NCT00324467|NON-HODGKIN'S LYMPHOMA
599127|NCT00324467|POSITRON EMISSION TOMOGRAPHY
599128|NCT00324467|PET
599129|NCT00324467|DLBCL
599130|NCT00324467|R-CHOP
599131|NCT00324467|R-ICE
599132|NCT00324454|motor neuron disease
599133|NCT00324454|amyotrophic lateral sclerosis primary lateral
599134|NCT00324454|sclerosis; progressive muscular atrophy
599135|NCT00324454|cramps
599136|NCT00324454|spasticity
599137|NCT00324441|Fibromyalgia
599138|NCT00324441|Rehabilitation
599139|NCT00324441|Physical Medicine
599140|NCT00324441|Whole-Body Hyperthermia
599141|NCT00324441|Water-Filtered Near Infrared
599142|NCT00324428|TMS
599143|NCT00324428|Visceral Pain
599144|NCT00324428|Analgesia
599145|NCT00324428|Pancreatic Cancer
599146|NCT00324428|Cancer
599147|NCT00324428|Electric stimulation therapy
599148|NCT00324428|Electric stimulation
599149|NCT00324428|Pain
599150|NCT00324428|Safety
599151|NCT00324415|stage I anal cancer
599152|NCT00324415|stage II anal cancer
599153|NCT00324415|stage IIIA anal cancer
599154|NCT00324415|stage IIIB anal cancer
599155|NCT00324415|squamous cell carcinoma of the anus
599156|NCT00324415|basaloid carcinoma of the anus
599157|NCT00324415|cloacogenic carcinoma of the anus
599158|NCT00324402|brain natriuretic peptide
599159|NCT00324402|pregnancy
599160|NCT00324402|biomarker
599161|NCT00324389|Interferon, Gene Expression in Liver, Lymphocytes, High Density Oligonucleotide Microarray Expression Analysis, African American, Hepatitis C
599162|NCT00324363|exenatide
599163|NCT00324363|diabetes
599164|NCT00324363|Amylin
599165|NCT00324363|Lilly
599166|NCT00324363|China
599167|NCT00324350|Diabetes Mellitus
599168|NCT00324350|Fracture
599169|NCT00324350|Falls
599170|NCT00324350|Height Loss
599171|NCT00324324|infection
599172|NCT00324324|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
599173|NCT00324324|adult acute myeloid leukemia with inv(16)(p13;q22)
599174|NCT00324324|adult acute myeloid leukemia with t(15;17)(q22;q12)
599175|NCT00324324|adult acute myeloid leukemia with t(16;16)(p13;q22)
599176|NCT00324324|adult acute myeloid leukemia with t(8;21)(q22;q22)
599177|NCT00324324|accelerated phase chronic myelogenous leukemia
599178|NCT00324324|adult acute lymphoblastic leukemia in remission
599179|NCT00324324|adult acute myeloid leukemia in remission
599180|NCT00324324|atypical chronic myeloid leukemia, BCR-ABL negative
599181|NCT00324324|blastic phase chronic myelogenous leukemia
599182|NCT00324324|chronic eosinophilic leukemia
599183|NCT00324324|primary myelofibrosis
599184|NCT00324324|chronic myelomonocytic leukemia
599185|NCT00324324|chronic neutrophilic leukemia
599186|NCT00324324|chronic phase chronic myelogenous leukemia
599187|NCT00324324|de novo myelodysplastic syndromes
599188|NCT00324324|disseminated neuroblastoma
599189|NCT00324324|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
599190|NCT00324324|myelodysplastic/myeloproliferative neoplasm, unclassifiable
599191|NCT00324324|nodal marginal zone B-cell lymphoma
599192|NCT00324324|noncontiguous stage II adult Burkitt lymphoma
599193|NCT00324324|noncontiguous stage II adult diffuse large cell lymphoma
599194|NCT00324324|noncontiguous stage II adult diffuse mixed cell lymphoma
599195|NCT00324324|noncontiguous stage II adult diffuse small cleaved cell lymphoma
599196|NCT00324324|noncontiguous stage II adult immunoblastic large cell lymphoma
599197|NCT00324324|noncontiguous stage II adult lymphoblastic lymphoma
599198|NCT00324324|noncontiguous stage II grade 1 follicular lymphoma
599199|NCT00324324|noncontiguous stage II grade 2 follicular lymphoma
599200|NCT00324324|noncontiguous stage II grade 3 follicular lymphoma
599201|NCT00324324|noncontiguous stage II mantle cell lymphoma
599202|NCT00324324|noncontiguous stage II marginal zone lymphoma
599203|NCT00324324|noncontiguous stage II small lymphocytic lymphoma
599204|NCT00324324|poor prognosis metastatic gestational trophoblastic tumor
599205|NCT00324324|previously treated myelodysplastic syndromes
599206|NCT00324324|recurrent adult acute lymphoblastic leukemia
599207|NCT00324324|recurrent adult acute myeloid leukemia
599208|NCT00324324|recurrent adult Burkitt lymphoma
599209|NCT00324324|recurrent adult Hodgkin lymphoma
599210|NCT00324324|recurrent adult diffuse large cell lymphoma
599211|NCT00324324|recurrent adult diffuse mixed cell lymphoma
599212|NCT00324324|recurrent adult diffuse small cleaved cell lymphoma
599213|NCT00324324|recurrent adult immunoblastic large cell lymphoma
599214|NCT00324324|recurrent adult lymphoblastic lymphoma
599215|NCT00324324|recurrent cutaneous T-cell non-Hodgkin lymphoma
599216|NCT00324324|recurrent grade 1 follicular lymphoma
599217|NCT00324324|recurrent grade 2 follicular lymphoma
599218|NCT00324324|recurrent grade 3 follicular lymphoma
599219|NCT00324324|recurrent mantle cell lymphoma
599220|NCT00324324|recurrent marginal zone lymphoma
599221|NCT00324324|recurrent mycosis fungoides/Sezary syndrome
599222|NCT00324324|recurrent neuroblastoma
599223|NCT00324324|recurrent ovarian epithelial cancer
599224|NCT00324324|recurrent ovarian germ cell tumor
599225|NCT00324324|recurrent small lymphocytic lymphoma
599226|NCT00324324|recurrent malignant testicular germ cell tumor
599227|NCT00324324|refractory chronic lymphocytic leukemia
599228|NCT00324324|refractory hairy cell leukemia
599229|NCT00324324|refractory multiple myeloma
599230|NCT00324324|relapsing chronic myelogenous leukemia
599231|NCT00324324|secondary acute myeloid leukemia
599232|NCT00324324|secondary myelodysplastic syndromes
599233|NCT00324324|splenic marginal zone lymphoma
599234|NCT00324324|stage I multiple myeloma
599235|NCT00324324|stage II multiple myeloma
599236|NCT00324324|stage II ovarian epithelial cancer
599237|NCT00324324|stage III adult Burkitt lymphoma
599238|NCT00324324|stage III adult Hodgkin lymphoma
599239|NCT00324324|stage III adult diffuse large cell lymphoma
599240|NCT00324324|stage III adult diffuse mixed cell lymphoma
599241|NCT00324324|stage III adult diffuse small cleaved cell lymphoma
599242|NCT00324324|stage III adult immunoblastic large cell lymphoma
599243|NCT00324324|stage III adult lymphoblastic lymphoma
599244|NCT00324324|stage III chronic lymphocytic leukemia
599245|NCT00324324|stage III grade 1 follicular lymphoma
599246|NCT00324324|stage III grade 2 follicular lymphoma
599247|NCT00324324|stage III grade 3 follicular lymphoma
599248|NCT00324324|stage III mantle cell lymphoma
599249|NCT00324324|stage III marginal zone lymphoma
599250|NCT00324324|stage III multiple myeloma
599251|NCT00324324|stage III ovarian epithelial cancer
599252|NCT00324324|stage III small lymphocytic lymphoma
599253|NCT00324324|stage III malignant testicular germ cell tumor
599254|NCT00324324|stage IIIA breast cancer
599255|NCT00324324|stage IIIB breast cancer
599256|NCT00324324|stage IIIC breast cancer
599257|NCT00324324|stage IV adult Burkitt lymphoma
599258|NCT00324324|stage IV adult Hodgkin lymphoma
599259|NCT00324324|stage IV adult diffuse large cell lymphoma
599260|NCT00324324|stage IV adult diffuse mixed cell lymphoma
599261|NCT00324324|stage IV adult diffuse small cleaved cell lymphoma
599262|NCT00324324|stage IV adult immunoblastic large cell lymphoma
599263|NCT00324324|stage IV adult lymphoblastic lymphoma
599264|NCT00324324|stage IV breast cancer
599265|NCT00324324|stage IV chronic lymphocytic leukemia
599266|NCT00324324|stage IV grade 1 follicular lymphoma
599267|NCT00324324|stage IV grade 2 follicular lymphoma
599268|NCT00324324|stage IV grade 3 follicular lymphoma
599269|NCT00324324|stage IV mantle cell lymphoma
599270|NCT00324324|stage IV marginal zone lymphoma
599271|NCT00324324|stage IV ovarian epithelial cancer
599272|NCT00324324|stage IV small lymphocytic lymphoma
599273|NCT00324298|drug/agent toxicity by tissue/organ
599274|NCT00324298|stage III malignant testicular germ cell tumor
599275|NCT00324285|Diarrhoea
599276|NCT00324285|severe malnutrition
599277|NCT00324285|amylase resistant starch
599278|NCT00324285|ORS
599279|NCT00324272|Groin dissection
599280|NCT00324272|Axilla (or axillary) dissection
599281|NCT00324272|Lymph node dissection
599282|NCT00324272|Lymphadenectomy
599283|NCT00324272|Seroma
599284|NCT00324272|Wound drainage
599285|NCT00324272|Fibrin sealant
599286|NCT00324272|Malignant melanoma
599287|NCT00324272|Squamous cell carcinoma
599288|NCT00324246|vaginal infection
599289|NCT00324246|color appearance
599290|NCT00324246|new developed indicator strips (NEW NORMA-SENSE)
599291|NCT00324246|in-vitro
599292|NCT00324246|vaginal secretion
599293|NCT00324246|elevated pH
599294|NCT00324233|Residual urine
599295|NCT00324233|Hematuria
599296|NCT00324233|Ultra sound
599297|NCT00324220|Phase I/II
599298|NCT00324207|Type 1 diabetes mellitus
599299|NCT00324207|Insulin mRNA
599300|NCT00324194|Leukemia
599301|NCT00324194|Myelodysplastic Syndromes
599302|NCT00324194|Phase I
599303|NCT00324181|normal-tension glaucoma
599304|NCT00324181|psychopathology
599305|NCT00324181|Hong Kong
599306|NCT00324168|Bacterial Infections
599307|NCT00324168|Eye Diseases
599308|NCT00324168|Bacterial Keratitis
599309|NCT00324168|Visual Acuity
599310|NCT00324155|Stage IIIc N3 (unresectable)
599311|NCT00324155|Stage IV melanoma
599312|NCT00324142|Bacterial vaginosis
599313|NCT00324142|Tinidazole
599314|NCT00324142|Vaginitis
599315|NCT00324129|Leukemia
599316|NCT00324129|Myelodysplastic Syndromes
599317|NCT00324129|Phase I
599318|NCT00324103|HIV
599319|NCT00324103|Chronic Infection
599320|NCT00324103|Clinical Trial
599321|NCT00324103|Structured Treatment Interruption
599322|NCT00324077|Chronic phase chronic myelogenous leukemia (CML)
599323|NCT00324064|Growth hormone deficiency
599324|NCT00324038|OA
599325|NCT00324038|Elderly
599326|NCT00324038|Pain
599327|NCT00324038|OA of the hips and/or knees
599328|NCT00324025|Cryptococcal meningitis
599329|NCT00324012|Adrenocortical Carcinoma
599330|NCT00324012|cisplatin
599331|NCT00324012|taxotere
599332|NCT00323999|Hysteroscopic resection
599333|NCT00323999|Menorrhagia
599334|NCT00323999|fibroids
599335|NCT00323999|polyps
599336|NCT00323986|COPD
599337|NCT00323986|tracheotomy
599338|NCT00323986|azithromycin
599339|NCT00323986|exacerbation
599340|NCT00323986|hospitalisation
599341|NCT00323986|exhaled breath condensate
599342|NCT00323973|Chagas, Heart failure, Cardiomiopathy
599343|NCT00323960|Juvenile dermatomyositis
599344|NCT00323960|randomised actively controlled clinical trial
599345|NCT00323960|prednisone
599346|NCT00323960|cyclosporine
599347|NCT00323960|methotrexate
599348|NCT00323960|effectiveness
599349|NCT00323947|ADHD
599350|NCT00323947|Seizures
599351|NCT00323947|Methylphenidate
599352|NCT00323947|Stimulant
599353|NCT00323934|metastatic solid tumor
599354|NCT00323934|aggressive non Hodgkin's Lymphoma
599355|NCT00323934|Phase I
599356|NCT00323934|Advanced Solid Tumors
599357|NCT00323908|Breast Cancer
599358|NCT00323908|prevention
599359|NCT00323908|tissue sampling
599360|NCT00323908|polymorphisms
599361|NCT00323908|steroid and carcinogen metabolism
599362|NCT00323882|Prostate Cancer
599363|NCT00323882|Oncology
599364|NCT00323882|Prostate
599365|NCT00323882|Cancer
599366|NCT00323882|Metastatic
599367|NCT00323882|Hormone
599368|NCT00323882|PSA
599369|NCT00323882|Metastatic Hormone-Refractory Prostate Cancer (HRPC)
599370|NCT00323856|Hemophilia A
599371|NCT00323856|Plasma-derived treatment
599372|NCT00323856|Factor VIII
599373|NCT00323856|Inhibitor
599374|NCT00323843|Kidney stone
599375|NCT00323843|ureteropyeloscopy
599376|NCT00323843|renal pelvic pressure
599377|NCT00323830|gastric cancer
599378|NCT00323830|radiotherapy
599379|NCT00323830|postoperative therapy
599380|NCT00323830|chemotherapy
599381|NCT00321802|atrial fibrillation
599382|NCT00321802|statin therapy
599383|NCT00321802|CRP levels
599384|NCT00321802|Paroxysmal Atrial Fibrillation
599385|NCT00321789|self care
599386|NCT00321789|social support
599387|NCT00321763|Influenza
599388|NCT00321763|Influenza vaccine
599389|NCT00321750|Oral erosive lichen planus
599390|NCT00321750|pimecrolimus cream
599391|NCT00321737|Erosive Esophagitis
599392|NCT00321711|MDS
599393|NCT00321711|Myelodysplastic Syndromes
599394|NCT00321711|Refractory Cytopenias
599395|NCT00321711|Thrombocytopenia
599396|NCT00321698|adenocarcinoma of the prostate
599397|NCT00321698|stage II prostate cancer
599398|NCT00321698|stage III prostate cancer
599399|NCT00321672|Analgesics
599400|NCT00321672|Capsaicin
599401|NCT00321672|Neuropathic pain
599402|NCT00321672|Neuropathy
599403|NCT00321672|Distal sensory polyneuropathy
599404|NCT00321672|Peripheral neuropathy
599405|NCT00321672|Dermal assessment
599406|NCT00321672|Pain measurement
599407|NCT00321659|fibromyalgia
599408|NCT00321659|self-management
599409|NCT00321659|exercise
599410|NCT00321659|patient education
599411|NCT00323804|Maintenance therapy
599412|NCT00323804|Non-responder patients
599413|NCT00323804|Ribavirin/peginterferon combination therapy
599414|NCT00323804|Hepatitis C, Chronic
599415|NCT00323791|recurrent renal cell cancer
599416|NCT00323791|clear cell renal cell carcinoma
599417|NCT00323791|papillary renal cell carcinoma
599418|NCT00323791|stage IV renal cell cancer
599419|NCT00323778|hyalgan
599420|NCT00323778|knee
599421|NCT00323778|osteoarthritis
599422|NCT00323778|MRI
599423|NCT00323765|Transcranial Magnetic Stimulation (TMS)
599424|NCT00323765|Cervical Dystonia
599425|NCT00323765|Plasticity
599426|NCT00323765|Healthy Volunteer
599427|NCT00323765|HV
599428|NCT00323752|Blood loss, Erythropoetin
599429|NCT00323739|kidney cancer
599430|NCT00323739|bevacizumab
599431|NCT00323713|Chronic renal insufficiency
599432|NCT00323713|CKD stage 4
599433|NCT00323713|CKD stage 5
599434|NCT00323713|Protein intake
599435|NCT00323713|Low protein diet
599436|NCT00323713|Very low protein diet
599437|NCT00323713|Ketoanalogs
599438|NCT00323713|Renal death
599439|NCT00323700|ADHD
599440|NCT00323700|Effectiveness
599441|NCT00323700|ODD
599442|NCT00323687|HIV-1 Infection
599443|NCT00323674|Hernia Inguinalis
599444|NCT00323661|Pacing
599445|NCT00323661|Rate-adaptive
599446|NCT00323661|Quality of life
599447|NCT00323661|Cognitive performance
599448|NCT00323661|Atrial fibrillation
599449|NCT00323661|Pacemaker sensor
599450|NCT00323635|nocturia
599451|NCT00323635|urinary incontinence
599452|NCT00323635|overactive bladder
599453|NCT00323635|tolterodine
599454|NCT00323635|sleep
599455|NCT00323635|sleep disorder
599456|NCT00323635|menopause
599457|NCT00323635|midlife women
599458|NCT00323635|psychological tests
599459|NCT00323609|Kyphoplasty
599460|NCT00323609|Vertebroplasty
599461|NCT00323609|Balloon Kyphoplasty
599462|NCT00323609|Inflatable Bone Tamp
599463|NCT00323609|Spine
599464|NCT00323609|Back Pain
599465|NCT00323609|Vertebral Compression Fracture
599466|NCT00323609|Vertebral Body Compression Fracture
599467|NCT00323583|Cancer
599468|NCT00323583|Pancreatic Cancer
599469|NCT00323583|Cancer Alternative Therapies
599470|NCT00323583|Living with Cancer
599471|NCT00323557|Chronic Lymphocytic Leukemia
599472|NCT00323557|Leukemia
599473|NCT00323557|Sargramostim
599474|NCT00323557|Pneumococcal Pneumonia
599475|NCT00323557|Pneumococcal Vaccine
599476|NCT00323557|Prevnar
599477|NCT00323557|GM-CSF
599478|NCT00323557|CLL
599479|NCT00323544|HIV 1
599480|NCT00323544|HIV 1 infection
599481|NCT00323531|thoracoscopy
599482|NCT00323531|fibrinolysis
599483|NCT00323531|empyema
599484|NCT00323531|children
599485|NCT00323518|oral mucositis
599486|NCT00323518|hematologic
599487|NCT00323518|autologous stem cell transplant
599488|NCT00323518|velafermin
599489|NCT00323518|stomatitis
599490|NCT00323518|oncology - supportive care
599491|NCT00323518|mouth diseases
599492|NCT00323492|HIV 1 Infection
599493|NCT00323479|breast cancer treatment
599494|NCT00323479|joint disorders
599495|NCT00323453|Appendectomy
599496|NCT00323453|Surgery
599497|NCT00323453|Infection
599498|NCT00323440|Familial Mediterranean fever
599499|NCT00323440|Inflammation
599500|NCT00323440|Attacks
599501|NCT00323440|Remission
599502|NCT00323440|RNA
599503|NCT00323440|Cytokines
599504|NCT00323440|Inflammatory proteins
599505|NCT00323440|MEFV
599506|NCT00323440|mutations
599507|NCT00323440|Colchicine
599508|NCT00323440|Treatment
599509|NCT00323440|microarray RNA analysis
599510|NCT00323427|Audiology
599511|NCT00323427|Coping behaviors
599512|NCT00323427|Counseling
599513|NCT00323427|Hearing aids
599514|NCT00323427|Hearing impairment
599515|NCT00323427|Patient-centered care
599516|NCT00323427|Psychological adaptation
599517|NCT00323427|Psychological adjustment
599518|NCT00323427|Rehabilitation
599519|NCT00323427|Social adjustment
599520|NCT00323427|Aural Rehabilitation
599521|NCT00323414|PUFA
599522|NCT00323414|NASH
599523|NCT00323414|Fatty Liver
599524|NCT00323414|Insulin resistance
599525|NCT00323414|Metabolic syndrome
599526|NCT00323414|Nonalcoholic fatty liver disease
599527|NCT00323414|Nonalcoholic steatohepatitis
599528|NCT00323414|Type 2 Diabetes Mellitus
599529|NCT00323401|Pregnancy
599530|NCT00323401|Parturition
599531|NCT00323401|Depression
599532|NCT00323401|Randomized
599533|NCT00323401|Antenatal classes
599534|NCT00321646|prostate cancer
599535|NCT00321646|bevacizumab
599536|NCT00321646|docetaxel
599537|NCT00321646|radical prostatectomy
599538|NCT00321633|stage IV breast cancer
599539|NCT00321633|recurrent breast cancer
599540|NCT00321633|hereditary breast/ovarian cancer (BRCA1, BRCA2)
599541|NCT00321633|BRCA1 mutation carrier
599542|NCT00321633|BRCA2 mutation carrier
599543|NCT00321620|Bone metastases
599544|NCT00321620|Hormone-refractory prostate cancer
599545|NCT00321620|Skeletal
599546|NCT00321620|Fractures
599547|NCT00321620|Compressions
599548|NCT00321620|Bisphosphonates
599549|NCT00321581|VEGFR2
599550|NCT00321581|Tyrosine Kinase Inhibitor
599551|NCT00321581|Antiangiogenesis
599552|NCT00321581|Solid Tumors
599553|NCT00321581|Childhood Cancer
599554|NCT00321581|Solid Tumor
599555|NCT00321581|Recurrent Solid Tumor
599556|NCT00321581|Treatment Resistant Solid Tumor
599557|NCT00321581|Acute Myelogenous Leukemia
599558|NCT00321581|AML
599559|NCT00321568|Multiple Sclerosis
599560|NCT00321568|Magnetic Resonance
599561|NCT00321568|MRI
599562|NCT00321568|Magnetic Field
599563|NCT00321568|MS
599564|NCT00321555|Biologic Therapy
599565|NCT00321555|Monoclonal Antibody
599566|NCT00321555|Immunotherapy
599567|NCT00321555|Pseudomonas Exotoxin
599568|NCT00321555|Targeted Therapy
599569|NCT00321555|Hairy Cell Leukemia
599570|NCT00321555|HCL
599571|NCT00321542|Computed tomography
599572|NCT00321542|Diabetes mellitus
599573|NCT00321542|Coronary atherosclerosis
599574|NCT00321542|Non-invasive imaging
599575|NCT00321529|Cervical spine instability
599576|NCT00321529|Penning Study
599577|NCT00321516|Bipolar type I Disorder
599578|NCT00321503|acid reflux
599579|NCT00321503|LPR
599580|NCT00321503|gastroesophageal reflux
599581|NCT00321503|GERD
599582|NCT00321503|pH probe
599583|NCT00321503|proton pump inhibitor
599584|NCT00321503|PPI
599585|NCT00321490|MDD
599707|NCT00322894|Clinico-pathologic
599586|NCT00321490|Quetiapine fumarate, sustained release
599587|NCT00321490|Depression
599588|NCT00321477|Overactive Bladder
599589|NCT00321464|Fractures
599590|NCT00321464|Compressions
599591|NCT00321464|Bisphosphonates
599592|NCT00321464|Bone metastases
599593|NCT00321464|Breast cancer
599594|NCT00321464|Skeletal
599595|NCT00321464|Radiation
599596|NCT00321464|Surgery to Bone
599597|NCT00321451|insomnia
599598|NCT00321451|cognitive behavior therapy
599599|NCT00321438|HIV-1
599600|NCT00321438|GW873140
599601|NCT00321438|CCR5 antagonist
599602|NCT00321438|experienced
599603|NCT00321438|treatment experienced
599604|NCT00321412|Crohn's disease
599605|NCT00321412|IBD
599606|NCT00321412|Inflammatory Bowel Disease
599607|NCT00321412|Fistula
599608|NCT00323375|Malaria
599609|NCT00323375|Aminoquinolines
599610|NCT00323375|Drug Resistance
599611|NCT00323375|Chloroquine Resistance
599612|NCT00323362|recurrent non-small cell lung cancer
599613|NCT00323362|stage IV non-small cell lung cancer
599614|NCT00323349|Glucose Tolerance Test
599615|NCT00323349|Health Knowledge, Attitudes, Practice
599616|NCT00323349|Motivation
599617|NCT00323349|Communication
599618|NCT00323349|Health Behavior
599619|NCT00323323|Untreated
599620|NCT00323323|CD-20 Negative
599621|NCT00323323|Large B-Cell Lymphomas
599622|NCT00323310|disease of the central nervous system (brain or spine)
599623|NCT00323284|Open angle
599624|NCT00323284|Glaucoma
599625|NCT00323284|Cataract
599626|NCT00323284|Surgery
599627|NCT00323271|Chronic pain
599628|NCT00323271|Cognitive behavioral therapy
599629|NCT00323271|Multiple sclerosis
599630|NCT00323271|Randomized controlled trial
599631|NCT00323258|Heart disease
599632|NCT00323258|Coronary disease
599633|NCT00323258|Patient compliance
599634|NCT00323258|Treatment refusal
599635|NCT00323258|Pharmacists
599636|NCT00323258|Continuity of patient care
599637|NCT00323258|Evidence-based medicine
599638|NCT00323258|Patient education
599639|NCT00323258|Adherence
599640|NCT00323245|Randomized clinical trial
599641|NCT00323245|osteoporosis
599642|NCT00323245|urinary incontinence
599643|NCT00323245|physiotherapy
599644|NCT00323245|education
599645|NCT00323232|DHS, Intertrochanteric
599646|NCT00323219|Cellulitis, RCT, emergency Department, Double-blind, Equivalence trial, Moxifloxacin, Cefazolin, Probenecid.
599647|NCT00323206|melanoma
599648|NCT00323206|electroporation
599649|NCT00323206|IL-12
599650|NCT00323193|Behavioral interventions
599651|NCT00323193|Mental Illness
599652|NCT00323193|Obesity
599653|NCT00323193|Psycho-educational interventions
599654|NCT00323193|Weight management
599655|NCT00323167|Variant Cystic Fibrosis
599656|NCT00323167|Primary Ciliary Dyskinesia
599657|NCT00323154|Morphine, analgesia
599658|NCT00323141|Hernia umbilicalis
599659|NCT00323115|immunotherapy
599660|NCT00323115|cancer vaccine
599661|NCT00323115|glioblastoma multiforme
599662|NCT00323089|microcoil
599663|NCT00323089|subcentimetre nodules
599664|NCT00323063|recurrent breast cancer
599665|NCT00323063|stage IV breast cancer
599666|NCT00323063|male breast cancer
599667|NCT00323063|stage IIIA breast cancer
599668|NCT00323063|stage IIIB breast cancer
599669|NCT00323063|stage IIIC breast cancer
599670|NCT00323037|heart failure
599671|NCT00323024|Pulmonary Arterial Hypertension
599672|NCT00323024|Pulmonary Hypertension
599673|NCT00323024|Idiopathic PAH
599674|NCT00323024|PH associated with connective tissue disease (CTD)
599675|NCT00323024|PH associated with interstitial lung disease (ILD)
599676|NCT00323024|PH associated with congestive heart failure (CHF)
599677|NCT00323024|PH associated with chronic obstructive pulmonary disease (COPD)
599678|NCT00322985|T-cell lymphoma
599679|NCT00322985|lenalidomide
599680|NCT00322972|Bacterial Infections
599681|NCT00322972|Chlamydia Infections
599682|NCT00322972|Eye Diseases
599683|NCT00322959|dendritic cells
599684|NCT00322959|Tai-Chi-Chuan
599685|NCT00322946|Dengue Fever
599686|NCT00322946|Dengue Vaccine
599687|NCT00322946|Dengue Virus
599688|NCT00322946|Dengue Hemorrhagic Fever
599689|NCT00322946|Dengue Shock Syndrome
599690|NCT00322933|intermittent renal replacement therapy
599691|NCT00322933|continuous renal replacement therapy
599692|NCT00322933|acute renal failure
599693|NCT00322933|renal recovery
599694|NCT00322933|mortality
599695|NCT00322920|cervical cancer
599696|NCT00322920|topotecan
599697|NCT00322920|Stage IVB cervical cancer
599698|NCT00322920|Persistent or recurrent cervical cancer
599699|NCT00322907|malaria
599700|NCT00322907|treatment
599701|NCT00322907|cotrifazid
599702|NCT00322907|clinical trial
599703|NCT00322907|efficacy
599704|NCT00322894|Breast cancer
599705|NCT00322894|Risk factors
599706|NCT00322894|Treatment
599708|NCT00322894|Outcomes
599709|NCT00322894|Tissue repository
599710|NCT00322894|Registry
599711|NCT00322881|carboplatin
599712|NCT00322881|paclitaxel
599713|NCT00322881|elderly women
599714|NCT00322868|Prescription drugs
599715|NCT00322868|Administration, oral
599716|NCT00322868|Durable medical equipment
599717|NCT00322868|Kinetics
599718|NCT00322842|Non-Hodgkin's lymphoma
599719|NCT00322842|Multiple Myeloma
599720|NCT00322842|Stem cell mobilization
599721|NCT00322829|Group B Streptococcus, Strepotococcus agalactiae, detection
599722|NCT00322816|Malaria, Plasmodium falciparum, Gambia, larvicides
599723|NCT00322803|panic disorder
599724|NCT00322803|proof of concept
599725|NCT00321399|CORONARY ANATOMY
599726|NCT00321399|Coronary Artery Disease
599727|NCT00321399|SPECT
599728|NCT00321399|PET
599729|NCT00321399|PET/CT
599730|NCT00321399|CTA
599731|NCT00321386|Glaucoma
599732|NCT00321386|Open Angle
599733|NCT00321386|Normal Tension
599734|NCT00321373|Influenza
599735|NCT00321373|Influenza vaccine
599736|NCT00321360|propofol
599737|NCT00321360|sedation
599738|NCT00321347|Cancer
599739|NCT00321347|Pain
599740|NCT00321347|Lidocaine
599741|NCT00321334|non-small cell lung cancer
599742|NCT00321334|Chemotherapy
599743|NCT00321334|surgery
599744|NCT00321334|neo-adjuvant
599745|NCT00321334|adjuvant
599746|NCT00321334|RCT
599747|NCT00321321|Type 2 diabetes mellitus
599748|NCT00321321|Glucose dependent insulinotropic polypeptide
599749|NCT00321321|Sulfonylurea compounds
599750|NCT00321321|insulin secretion
599751|NCT00321321|Sulfonylurea receptor subunit-SUR1
599752|NCT00321321|Impaired incretin effect
599753|NCT00321308|advanced carcinoma, non-small cell lung cancer, phase II, pemetrexed, Alimta, PF-3512676, immunotherapy, immunomodulator
599754|NCT00321295|Bi-ventricular pacing
599755|NCT00321295|Cardiac Surgery
599756|NCT00321295|Cardiomyopahty
599757|NCT00321295|Heart Failure
599758|NCT00321282|Atrial Fibrillation
599759|NCT00321282|Coronary Artery Bypass Graft
599760|NCT00321282|Risk Stratification
599761|NCT00322777|Major depression
599762|NCT00322777|Spirituality
599763|NCT00322777|Randomized clinical trial
599764|NCT00322764|manic depression
599765|NCT00322764|bipolar disorder
599766|NCT00322764|depression
599767|NCT00322764|uridine
599768|NCT00322764|RG2417
599769|NCT00322738|malaria, Plasmodium falciparum, Gambia, larvicides, vector
599770|NCT00322699|Bladder Cancer
599771|NCT00322699|Photodynamic Therapy
599772|NCT00322699|Photofrin
599773|NCT00322699|Photosensitization
599774|NCT00322699|Photoradiation
599775|NCT00322686|oglemilast
599776|NCT00322686|asthma
599777|NCT00322686|allergen
599778|NCT00322686|prevention
599779|NCT00322686|prophylaxis
599780|NCT00322686|Allergen-Induced Asthma
599781|NCT00322673|acute myeloid leukemia
599782|NCT00322673|AML
599783|NCT00322608|Solid Tumors
599784|NCT00322608|Lymphomas
599785|NCT00322595|Anxiety
599786|NCT00322595|GAD
599787|NCT00322582|familial cardiomyopathy
599788|NCT00322582|genetics analysis
599789|NCT00322569|Percutaneous coronary intervention (PCI)
599790|NCT00322569|Drug eluting stent (DES)
599791|NCT00322556|Immunoglobulin Intravenous
599792|NCT00322556|Agammaglobulinemia
599793|NCT00322556|Hypogammaglobulinemia
599794|NCT00322556|Common variable immunodeficiency
599795|NCT00322556|Immunoglobulin G
599796|NCT00322556|Children
599797|NCT00322543|Percutaneous coronary intervention (PCI)
599798|NCT00322543|Drug eluting stent (DES)
599799|NCT00322491|Non-Hodgkin's Lymphoma
599800|NCT00322491|Multiple Myeloma
599801|NCT00322491|Stem cell mobilization
599802|NCT00322465|non-gonococcal urethritis, doxycycline, azithromycin, sexually transmitted, tinidazole
599803|NCT00322452|NSCLC
599804|NCT00322452|Gefitinib
599805|NCT00322439|plaque Psoriasis patients
599806|NCT00322439|TNF-inhibitor naïve
599807|NCT00322426|Freezing of Gait
599808|NCT00322426|Parkinson's Disease
599809|NCT00322426|Sensory Cues
599810|NCT00322413|Epoetin alfa
599811|NCT00322413|Epoetin omega
599812|NCT00322413|Comparative efficacy trial
599813|NCT00322413|Renal anemia
599814|NCT00322400|Clinical trial
599815|NCT00322400|AMG 706
599816|NCT00322400|Anti-angiogenesis
599817|NCT00322400|Locally Recurrent
599818|NCT00322400|Metastatic
599819|NCT00322400|Breast Cancer
599820|NCT00322400|VEGF
599821|NCT00322400|Angiogenesis Inhibitor
599822|NCT00322400|Oral
599823|NCT00322400|Multi-kinase Inhibitor
599824|NCT00322400|Anti-tumor
599825|NCT00322400|PDGF receptor
599826|NCT00322400|Paclitaxel
599827|NCT00322400|Docetaxel
599828|NCT00322400|Targeted Therapy
599829|NCT00322400|Oncology
599830|NCT00322400|Amgen
599831|NCT00322400|c-Kit
599832|NCT00322387|Non-Hodgkin's Lymphoma
599833|NCT00322387|Multiple Myeloma
599834|NCT00322387|Stem cell mobilization
599835|NCT00322348|oncology
599836|NCT00322348|cancer
599837|NCT00322348|breast cancer
599838|NCT00322335|H.influenzae type b Disease
599839|NCT00322322|L-carnitine supplementation
599840|NCT00322322|Hemodialysis
599841|NCT00322322|Anaemia
599842|NCT00322322|Erythropoietin responsiveness
599843|NCT00322309|Cocaine
599844|NCT00322309|Substance Abuse
599845|NCT00322296|Parapsoriasis
599846|NCT00322296|Cutaneous T-cell lymphoma
599847|NCT00322296|Mycosis fungoides
599848|NCT00322296|Bexarotene
599849|NCT00322296|Retinoids
599850|NCT00322283|oglemilast
599851|NCT00322283|asthma
599852|NCT00322283|exercise
599853|NCT00322283|prevention
599854|NCT00322283|prophylaxis
599855|NCT00322270|Occluded Central Venous Access Devices
599856|NCT00322270|Occluded Catheters
599857|NCT00322270|Thrombosis
599858|NCT00322270|thrombosis, catheter
599859|NCT00322270|alfimeprase
599860|NCT00322270|thrombotic occlusion
599861|NCT00322270|thrombosis, CVAD
599862|NCT00322270|thrombosis, catheters
599863|NCT00322244|Osteoarthritis
599864|NCT00322244|Massage therapy
599865|NCT00322192|Stroke rehabilitation
599866|NCT00322192|Physical Therapy
599867|NCT00322179|Microarray Analysis
599868|NCT00322179|Obesity
599869|NCT00322179|Chronic Hepatitis C
599870|NCT00322166|accidental falls
599871|NCT00322166|vitamin D
599872|NCT00322166|parathyroid hormone
599873|NCT00322166|osteoporosis
599874|NCT00322153|memantine
599875|NCT00322153|Alzheimer's disease
599876|NCT00322153|moderate to severe Alzheimer's disease
599877|NCT00322140|Metastatic
599878|NCT00322140|Triterpenoids
599879|NCT00322140|2-Cyano-3,12-Dioxooleana-1,9(11)Dien-28oic Acid
599880|NCT00322140|Dose-Limiting
599881|NCT00322140|Pharmacokinetic
599882|NCT00322140|Solid Tumor
599883|NCT00322140|Lymphoma
599884|NCT00322127|Hematopoietic Stem Cells
599885|NCT00322127|Stem Cell Mobilization
599886|NCT00322127|CXCR4
599887|NCT00322127|SDF-1
599888|NCT00322127|Healthy Volunteer
599889|NCT00322127|HV
599890|NCT00322114|prostate cancer
599891|NCT00322062|Colon cleansing
599892|NCT00322049|Dengue, Vaccine, Thailand
599893|NCT00322036|Alzheimer Disease
599894|NCT00322036|Dementia
599895|NCT00322023|Negative symptoms
599896|NCT00322023|NMDA
599897|NCT00322023|Glutamate
599898|NCT00322023|Glycine
599899|NCT00322010|mechanical ventilation
599900|NCT00322010|physical therapy
599901|NCT00322010|occupational therapy
599902|NCT00322010|mobilization
599903|NCT00322010|clinical protocols
599904|NCT00322010|ICU acquired weakness
599905|NCT00322010|critical illness myopathy
599906|NCT00322010|muscle atrophy
599907|NCT00322010|intensive care unit
599908|NCT00322010|randomized controlled trial
599909|NCT00321997|AMD
599910|NCT00321997|Age-Related Macular Degeneration
599911|NCT00321997|Macular Degeneration
599912|NCT00321997|Macugen
599913|NCT00321997|pegaptanib sodium
599914|NCT00321984|Gastroesophageal Reflux Disease(GERD)
599915|NCT00321984|Heartburn
599916|NCT00321971|Anxiety
599917|NCT00321971|Mild Cognitive Impairment
599918|NCT00321971|MCI
599919|NCT00321971|Cognitive Impairment
599920|NCT00321971|Alzheimer's Disease
599921|NCT00321971|Caregiver Burden
599922|NCT00321971|Caregiver Stress
599923|NCT00321971|Family Dementia Caregiving
599924|NCT00321971|Spousal Dementia Caregiving
599925|NCT00321958|Barrett Esophagus
599926|NCT00321958|Esophageal Neoplasm
599927|NCT00321958|Deglutition disorders
599928|NCT00321958|Cryotherapy
599929|NCT00321958|Cryosurgery
599930|NCT00321958|GERD
599931|NCT00321958|Neoplasm
599932|NCT00321958|Esophagus
599933|NCT00321958|Endoscopy, Digestive System
599934|NCT00321945|Atrial Fibrillation
599935|NCT00321945|Atrial Flutter
599936|NCT00321945|Angiotensin Converting Enzyme Inhibitor
599937|NCT00321945|Angiotensin Receptor Blocker
599938|NCT00321906|Rejection in lung transplant
599939|NCT00321893|Small cell lung cancer
599940|NCT00321893|Non-small cell lung cancer
599941|NCT00321893|Budesonide
599942|NCT00321893|Entocort EC
599943|NCT00321893|Pulmicort Respules
599944|NCT00321893|Rhinocort aqua
599945|NCT00321893|Aerosol budesonide treatment
599946|NCT00321893|Smoking
599947|NCT00321880|fatigue
599948|NCT00321880|psychosocial effects of cancer and its treatment
599949|NCT00321880|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
599950|NCT00321880|adult acute myeloid leukemia with inv(16)(p13;q22)
599951|NCT00321880|adult acute myeloid leukemia with t(15;17)(q22;q12)
599952|NCT00321880|adult acute myeloid leukemia with t(16;16)(p13;q22)
599953|NCT00321880|adult acute myeloid leukemia with t(8;21)(q22;q22)
599954|NCT00321880|recurrent adult acute lymphoblastic leukemia
599955|NCT00321880|recurrent adult acute myeloid leukemia
599956|NCT00321880|untreated adult acute lymphoblastic leukemia
599957|NCT00321880|untreated adult acute myeloid leukemia
599958|NCT00321867|rectocele
599959|NCT00321867|pelvic prolapse
599960|NCT00321867|graft
599961|NCT00321867|surgical repair
599962|NCT00321828|adenocarcinoma of the colon
599963|NCT00321828|stage IV colon cancer
599964|NCT00321815|advanced carcinoma non-small cell lung EGFR positive Erlotinib Tarceva PF-3512676 Phase II immunotherapy immune modulator
599965|NCT00321269|Home Monitoring
599966|NCT00321269|Heart Failure
599967|NCT00321269|Depression
599968|NCT00321256|islet transplantation
599969|NCT00321256|brittle diabetes
599970|NCT00321256|severe hypoglycemia
599971|NCT00321256|type 1 diabetes mellitus
599972|NCT00321243|triage
599973|NCT00321230|Colon cleansing
599974|NCT00321217|rheumatoid arthritis
599975|NCT00321217|pharmacogenetics
599976|NCT00321217|anti-TNF
599977|NCT00321217|high throughput genotyping
599978|NCT00321204|Atrial Fibrillation
599979|NCT00321204|Atrial Flutter
599980|NCT00321204|Cardiac Surgery
599981|NCT00321204|Thiazolidinediones
599982|NCT00321178|Mycobacterium ulcerans
599983|NCT00321178|Buruli ulcer
599984|NCT00321178|Ghana
599985|NCT00321178|randomized comparison
599986|NCT00321178|streptomycin
599987|NCT00321178|rifampicin
599988|NCT00321178|clarithromycin
599989|NCT00321165|nutrition
599990|NCT00321165|parenteral
599991|NCT00321165|infection
599992|NCT00321165|katheter
599993|NCT00321165|taurolidine
599994|NCT00321165|acridine orange
599995|NCT00321165|prevention
599996|NCT00321139|biomarkers
599997|NCT00321139|oxidative stress
599998|NCT00321139|intravascular ultrasound
599999|NCT00321126|Zinc
600000|NCT00321126|Shigella
600001|NCT00321126|Children
600002|NCT00321126|Bangladesh
600003|NCT00321113|IMMUNOSUPPRESSION
600004|NCT00321113|TACROLIMUS
600005|NCT00321113|ELDERLY RECEPIENTS
600006|NCT00321113|MARGINAL KIDNEY
600007|NCT00321100|metastatic
600008|NCT00321100|colorectal
600009|NCT00321100|cancer
600010|NCT00321100|initial therapy
600011|NCT00321087|Movement Disorder
600012|NCT00321074|IMMUNOSUPPRESSION
600013|NCT00321074|TACROLIMUS
600014|NCT00321074|MARGINAL LIVERS
600015|NCT00321074|PHARMACOKINETICS
600016|NCT00321061|HIV Negative
600017|NCT00321061|Healthy
600018|NCT00321061|Immunity
600019|NCT00321061|Preventive
600020|NCT00321061|Virus
600021|NCT00321061|Healthy Volunteer
600022|NCT00321061|HV
600023|NCT00321048|breast cancer
600024|NCT00321048|SPECT
600025|NCT00321048|ABC device
600026|NCT00321048|Invasive adenocarcinoma of the left breast
600027|NCT00321048|Ductal Carcinoma In Situ of the left breast
600028|NCT00321035|Glaucoma
600029|NCT00321035|Pterygium
600030|NCT00321035|collagen matrix
600031|NCT00321035|oculusgen
600032|NCT00321035|ologen
600033|NCT00321035|trabeculectomy
600034|NCT00321035|anti scarring
600035|NCT00321035|prevent recurrence
600036|NCT00321035|tissue engineering
600037|NCT00321035|Aeon Astron
600038|NCT00321022|Transient Ischemic Attack (TIA)
600039|NCT00321022|Diagnostic Protocol
600040|NCT00321022|Observational Medicine
600041|NCT00321022|Emergency Department Observational Unit
600042|NCT00321009|Myocardial Infarction
600043|NCT00321009|Left Ventricular Mural Thrombus
600044|NCT00321009|Low Molecular Weight Heparin
600045|NCT00321009|Enoxaparin
600046|NCT00321009|Warfarin
600047|NCT00321009|Echocardiograms
600048|NCT00320996|Pelvic mass
600049|NCT00320983|Cancer
600050|NCT00320983|Cervix
600051|NCT00320970|TGF-Beta 1
600052|NCT00320970|Angiotensin II
600053|NCT00320970|Advanced glycation end products
600054|NCT00320957|Glaucoma
600055|NCT00320957|Pterygium
600056|NCT00320957|collagen matrix
600057|NCT00320957|OculusGen
600058|NCT00320957|trabeculectomy
600059|NCT00320957|Anti scarring
600060|NCT00320957|pterygium recurrence
600061|NCT00320957|tissue engineering
600062|NCT00320957|Aeon Astron
600063|NCT00320957|ologen
600064|NCT00320931|Coronary artery disease
600065|NCT00320931|PET CT scan
600066|NCT00320931|Stress test
600067|NCT00320931|Rubudium
600068|NCT00320918|Unresectable/metastatic cholangiocarcinoma
600069|NCT00320918|Cancer
600070|NCT00320918|Chart Review
600071|NCT00320905|Cardiac Rehabilitation
600072|NCT00320905|Cognitive functioning
600073|NCT00320905|Cardiovascular disease
600074|NCT00320892|Death Rattle
600075|NCT00320892|Noise level
600076|NCT00320892|Primary Care
600077|NCT00320879|diabetes
600078|NCT00320879|microalbuminuria
600079|NCT00320879|angiotensin II receptor blockade
600080|NCT00320879|irbesartan
600081|NCT00320879|dose-response
600082|NCT00320879|randomized
600083|NCT00320879|double-blind
600084|NCT00320879|renin-angiotensin-aldosterone system
600085|NCT00320879|clinical
600086|NCT00320879|hypertension
600087|NCT00320866|Hypodermoclysis
600088|NCT00320866|Evaluation of Symptoms
600089|NCT00320853|Diabetes
600090|NCT00320853|Vitamin D
600091|NCT00320853|Insulin sensitivity
600092|NCT00320853|Insulin secretion
600093|NCT00320840|preterm infants
600094|NCT00320840|twins
600095|NCT00320840|motherhood
600096|NCT00320840|internal resources
600097|NCT00320840|familial resources
600098|NCT00320827|Apoptosis
600099|NCT00320827|Death receptor 5
600100|NCT00320827|Cancer
600101|NCT00320827|Advanced solid malignancies and lymphomas (without leukemic component)
600102|NCT00320801|Chronic pain
600103|NCT00320801|osteoarthritis
600104|NCT00320801|transdermal
600105|NCT00320788|Neovascular Age-Related Macular Degeneration
600106|NCT00320775|Neovascular Age-Related Macular Degeneration
600107|NCT00320762|Glaucoma
600108|NCT00320762|Pterygium
600109|NCT00320762|collagen matrix
600110|NCT00320762|OculusGen
600111|NCT00320762|trabeculectomy
600112|NCT00320762|Anti scarring
600113|NCT00320762|pterygium recurrence
600114|NCT00320762|tissue engineering
600115|NCT00320762|Aeon Astron
600116|NCT00320749|Advanced Pancreatic Cancer
600117|NCT00320736|schizophrenia
600118|NCT00320736|cognitive function
600119|NCT00320736|cholinergic medication
600120|NCT00320736|nicotinic receptor agonist
600121|NCT00320723|schizophrenia
600122|NCT00320723|smoking cessation
600123|NCT00320723|nicotine
600124|NCT00320723|patch
600125|NCT00320723|bupropion
600126|NCT00320723|nicotine replacement therapy
600127|NCT00320723|cognitive behavioral therapy
600128|NCT00320710|Breast cancer
600129|NCT00320710|zoledronic acid
600130|NCT00320710|bone metastases
600131|NCT00320697|schizophrenia
600132|NCT00320697|smoking cessation
600133|NCT00320697|relapse prevention
600134|NCT00320697|nicotine
600135|NCT00320697|bupropion
600136|NCT00320697|cognitive behavioral therapy
600137|NCT00320697|nicotine replacement therapy
600138|NCT00320684|Serotonin Transporter
600139|NCT00320684|Positron-Emission Tomography
600140|NCT00320671|First-episode
600141|NCT00320671|Schizoaffective Disorder
600142|NCT00320671|Schizophreniform Disorder
600143|NCT00320671|Psychotic Disorder Not Otherwise Specified NOS
600144|NCT00320671|Aripiprazole
600145|NCT00320671|Clozapine
600146|NCT00320671|Risperidone
600147|NCT00320658|Plasmodium falciparum
600148|NCT00320632|Major Depressive Disorder
600149|NCT00320632|MDD
600150|NCT00320619|Aminocaproic Acids
600151|NCT00320619|Blood Transfusion
600152|NCT00320606|allograft function
600153|NCT00320606|anti-rejection
600154|NCT00320606|immunosuppression withdrawal
600155|NCT00320606|liver transplant
600156|NCT00320606|liver transplantation
600157|NCT00320606|living donor transplant
600158|NCT00320593|Myopia
600159|NCT00320593|Progressive Addition Lenses (PALs)
600160|NCT00320593|Single Vision Lenses (SVLs)
600161|NCT00320593|Accommodative lags
600162|NCT00320593|Near esophoria
600163|NCT00320593|Refractive error
600164|NCT00320580|Metrorrhagia
600165|NCT00320580|oral contraception
600166|NCT00320580|breakthrough bleeding
600167|NCT00320580|spotting
600168|NCT00320567|osteoporosis
600169|NCT00320567|anorexia nervosa
600170|NCT00320567|pediatric
600171|NCT00320541|Breast Cancer
600172|NCT00320541|Cancer of Breast
600173|NCT00320541|Cancer of the breast
600174|NCT00320541|Breast Neoplasms
600175|NCT00320476|Multiple myeloma
600176|NCT00320450|SB-681323
600177|NCT00320450|CRP
600178|NCT00320450|Rheumatoid Arthritis SB-681323 CRP RA
600179|NCT00320450|Rheumatoid Arthritis
600180|NCT00320450|RA
600181|NCT00320437|trauma
600182|NCT00320437|anxiety
600183|NCT00320437|antenatal
600184|NCT00320437|mothers
600185|NCT00320437|children
600186|NCT00320437|Gene x Environment Interaction
600187|NCT00320424|MOSLL
600188|NCT00320424|VTE
600189|NCT00320424|Xa factor
600190|NCT00320424|pentasaccharide
600191|NCT00320411|Stage IV breast cancer
600192|NCT00320411|Herceptin
600193|NCT00320411|metastatic breast cancer
600194|NCT00320411|ErbB1
600195|NCT00320411|ErbB2
600196|NCT00320411|trastuzumab
600197|NCT00320411|lapatinib
600198|NCT00320398|Fondaparinux
600199|NCT00320398|MOSLL
600200|NCT00320398|THR
600201|NCT00320398|VTE
600202|NCT00320398|Xa factor
600203|NCT00320398|pentasaccharide
600204|NCT00320398|Hip Replacement Arthroplasty
600205|NCT00320385|lapatinib
600206|NCT00320385|GW572016
600207|NCT00320385|ErbB2
600208|NCT00320385|EGFR
600209|NCT00320385|ErbB1
600210|NCT00320385|MBC
600211|NCT00320385|FISH amplification
600212|NCT00320385|Metastatic Breast Cancer
600213|NCT00320385|dual tyrosine kinase inhibitor
600214|NCT00320385|Her-2/neu
600215|NCT00320372|Major Depressive Disorder
600216|NCT00320372|Treatment-resistant Depression
600217|NCT00320359|First-line Cisplatin
600218|NCT00320359|Small Cell Lung Cancer
600219|NCT00320359|topotecan
600220|NCT00320359|etoposide
600221|NCT00320359|Extensive Disease
600222|NCT00320346|Pandemic
600223|NCT00320346|Influenza
600224|NCT00320346|Prevention
600225|NCT00320346|Vaccine
600226|NCT00320346|Prevention of Pandemic Influenza
600227|NCT00319670|constipation
600228|NCT00319670|pediatric
600229|NCT00319657|Kidney Transplantation
600230|NCT00319657|Blood Stem Cell Transplantation
600231|NCT00319631|Respiratory Distress Syndrome, Adult
600232|NCT00319605|Cross sectional study
600233|NCT00319605|acceptability
600234|NCT00319605|levetiracetam
600235|NCT00319605|oral solution
600236|NCT00319605|Keppra
600237|NCT00320333|COPD
600238|NCT00320333|rehabilitation
600239|NCT00320333|health services research
600240|NCT00320320|No prior chemotherapy
600241|NCT00320307|Human Immunodeficiency Virus
600242|NCT00320307|HIV
600243|NCT00320307|Abacavir regime
600244|NCT00320307|ABC
600245|NCT00320281|Botox
600246|NCT00320268|MDD
600247|NCT00320268|Quetiapine fumarate, sustained release
600248|NCT00320268|Depression
600249|NCT00320255|anticoagulant
600250|NCT00320242|Parkinson's disease
600251|NCT00320242|laser cane
600252|NCT00320242|freezing of gait
600253|NCT00320242|visual cues
600254|NCT00320229|angioplasty
600255|NCT00320229|stent
600256|NCT00320229|abciximab
600257|NCT00320229|Platelet Glycoprotein GPIIb-IIIa Complex
600258|NCT00320229|myocardial infarction
600259|NCT00320216|Psoriasis
600260|NCT00320216|CNTO 1275
600261|NCT00320216|Ustekinumab
600262|NCT00320216|Stelara
600263|NCT00320216|Interleukin-12
600264|NCT00320216|IL-12
600265|NCT00320216|Interleukin-23
600266|NCT00320216|IL-23
600267|NCT00320203|open-angle
600268|NCT00320203|glaucoma
600269|NCT00320190|Chronic phase CML, with a suboptimal response after treatment with imatinib
600270|NCT00320177|Binge Eating
600271|NCT00320177|Food Intake
600272|NCT00320177|Obesity
600273|NCT00320177|Melanocortin-4 Receptor Gene
600274|NCT00320177|Child
600275|NCT00320177|Macronutrient Composition
600276|NCT00320164|Healthy Volunteers
600277|NCT00320151|chronic lung disease
600278|NCT00320138|PTSD
600279|NCT00320138|Posttraumatic Stress
600280|NCT00320138|Acupuncture
600281|NCT00320138|Randomized Controlled Trial
600282|NCT00320138|Complementary medicine
600283|NCT00320138|Alternative medicine
600284|NCT00320138|Chinese medicine
600285|NCT00320138|military healthcare
600286|NCT00320125|Dairy
600287|NCT00320125|Calcium
600288|NCT00320125|Pregnancy
600289|NCT00320125|Fetus
600290|NCT00320125|Bone mineralization
600291|NCT00320112|telemedicine
600292|NCT00320112|case management
600293|NCT00320112|insulin
600294|NCT00320112|self-care
600295|NCT00320099|septic shock
600296|NCT00320099|adrenal insufficiency
600297|NCT00320099|glucose control
600298|NCT00320099|mineralocorticoids
600299|NCT00320073|unspecified adult solid tumor, protocol specific
600300|NCT00320060|Diabetic nephropathy
600301|NCT00320060|Advanced Glycation Endproduct Inhibitor
600302|NCT00320060|Pyridorin
600303|NCT00320060|Pyridoxamine
600304|NCT00320047|Binge Eating Disorder
600305|NCT00320034|levalbuterol
600306|NCT00320034|asthma
600307|NCT00320034|allergen provocation
600308|NCT00320034|airway inflammation
600309|NCT00320034|clinical trial
600310|NCT00320021|Diabetic nephropathy
600311|NCT00320021|Advanced Glycation Endproduct Inhibitor
600312|NCT00320021|Pyridorin
600313|NCT00320021|Pyridoxamine
600314|NCT00319982|Hypertrophic Cardiomyopathy
600315|NCT00319982|Left ventricular hypertrophy
600316|NCT00319982|Diltiazem
600317|NCT00319969|small cell lung cancer
600318|NCT00319969|amrubicin
600319|NCT00319956|premature infant
600320|NCT00319956|respiratory distress syndrome
600321|NCT00319956|mechanical ventilation
600322|NCT00319943|Cognitive remediation
600323|NCT00319943|Cognitive impairment
600324|NCT00319943|computer
600325|NCT00319943|training
600326|NCT00319930|Chronic lymphocytic leukemia
600327|NCT00319930|CLL
600328|NCT00319930|ZAP-70
600329|NCT00319930|Hsp90 inhibitor
600330|NCT00319917|Tacrolimus
600331|NCT00319917|Rheumatoid Arthritis
600332|NCT00319917|Tacrolimus anhydrous
600333|NCT00319904|Schizophrenia
600334|NCT00319904|DNA
600335|NCT00319891|Alzheimer's
600336|NCT00319891|AD
600337|NCT00319891|Mild Cognitive Impairment
600338|NCT00319891|Dementia
600339|NCT00319891|Cognitive remediation
600340|NCT00319891|computer-based training
600341|NCT00319865|Multiple Myeloma Relapsed
600342|NCT00319852|Diphteria;
600343|NCT00319852|Tetanus;
600344|NCT00319852|Pertussis;
600345|NCT00319852|Poliomyelitis;
600346|NCT00319852|acellular
600347|NCT00319839|Head cancer
600348|NCT00319839|Neck cancer
600349|NCT00319826|Staphylococcus aureus, S. aureus, bacteremia, sepsis
600350|NCT00319774|End-stage renal disease
600351|NCT00319774|Hemodialysis
600352|NCT00319774|Hypertension
600353|NCT00319774|Hypotension
600354|NCT00319774|Blood volume
600355|NCT00319774|Hypervolemia
600356|NCT00319774|Quality of life
600357|NCT00319774|Biofeedback system
600358|NCT00319761|glomerulonephritis
600359|NCT00319761|proteinuria
600360|NCT00319761|chronic kidney diseases
600361|NCT00319748|Breast
600362|NCT00319748|Ovarian
600363|NCT00319748|Endometrial
600364|NCT00319748|Cervical
600365|NCT00319748|Metastatic
600366|NCT00319748|852A
600367|NCT00319748|IRM
600368|NCT00319748|Oncology
600369|NCT00319748|Metastatic Cervical Cancer
600370|NCT00319748|Metastatic Ovarian Cancer
600371|NCT00319748|Metastatic Breast Cancer
600372|NCT00319748|Metastatic Endometrial Cancer
600373|NCT00319722|autism
600374|NCT00319722|pervasive developmental disorder
600375|NCT00319722|evoked potentials
600376|NCT00319722|EEG
600377|NCT00319722|Coherence
600378|NCT00319709|depression
600379|NCT00319709|antidepressive agents
600380|NCT00319709|controlled clinical trial
600381|NCT00319696|systemic sclerosis
600382|NCT00319696|digital ulcers
600383|NCT00319696|bosentan
600384|NCT00319696|open label
600385|NCT00319696|finger ulcers
600386|NCT00319683|Cancer
600387|NCT00319683|Tumors
600388|NCT00319683|Neoplasms
600389|NCT00319683|Anticarcinogenic Agents
600390|NCT00319683|Antineoplastic Agents
600391|NCT00319683|Dihydrouracil Dehydrogenase (NADP)
600392|NCT00319592|Japanese encephalitis
600393|NCT00319592|ChimeriVax™-JE
600394|NCT00319592|JE-VAX®
600395|NCT00319579|living kidney donors
600396|NCT00319579|prospective
600397|NCT00319579|medical
600398|NCT00319579|psychosocial
600399|NCT00319566|Coronary Heart Disease
600400|NCT00319566|Hormone replacement therapy
600401|NCT00319566|Estrogen
600402|NCT00319566|Postmenopausal women
600403|NCT00319553|Tetanus
600404|NCT00319553|diphtheria
600405|NCT00319553|acellular pertussis
600406|NCT00319540|Depression
600407|NCT00319540|psychoeducation
600408|NCT00319540|RCT
600409|NCT00319540|primary health services
600410|NCT00319527|long term outcome
600411|NCT00319527|living kidney donor
600412|NCT00319501|Acute Repetitive Seizures
600413|NCT00319501|ARS
600414|NCT00319501|Diazepam
600415|NCT00319501|Cluster Seizures
600416|NCT00319488|Wheezing
600417|NCT00319488|Respiratory Tract Illness
600418|NCT00319462|point A, cervical cancer, radiotherapy
600419|NCT00319436|parenting intervention
600420|NCT00319436|family intervention
600421|NCT00319436|maternal substance abuse
600422|NCT00319436|mother-child relations
600423|NCT00319436|parent-child relations
600424|NCT00319423|Hip Osteoarthritis, Exercise therapy, Patient Education
600425|NCT00319410|Menorrhagia
600426|NCT00319410|intrauterine diagnosis
600427|NCT00319410|visual analogue scale
600428|NCT00319397|vascular resistance
600429|NCT00319397|vasomotion
600430|NCT00319397|coronary disorder
600431|NCT00319397|hemodynamics
600432|NCT00319397|physical fitness
600433|NCT00319384|congestive heart failure
600434|NCT00319384|heart failure
600435|NCT00319384|ultrafiltration therapy
600436|NCT00319384|fluid overload
600437|NCT00319371|vasospasm
600438|NCT00319371|circadian
600439|NCT00319371|sleep-disorders
600440|NCT00319358|chronic pancreatitis
600441|NCT00319358|antioxidant supplementation
600442|NCT00319358|oxidative stress
600443|NCT00319345|Traumatic brain injury
600444|NCT00319345|Intracranial pressure
600445|NCT00319345|Osmotherapy
600446|NCT00319345|Glasgow outcome score
600447|NCT00319345|Mannitol
600448|NCT00319345|Sodium-Lactate
600449|NCT00319332|non-Hodgkin's Lymphoma
600450|NCT00319332|follicular lymphoma
600451|NCT00319332|BEXXAR
600452|NCT00319332|ZEVALIN
600453|NCT00319332|Iodine I 131 Tositumomab
600454|NCT00319332|Ibritumomab Tiuxetan
600455|NCT00319332|Follicular, mixed small-cleaved and large-cell
600456|NCT00319332|Diffuse large cell non-Hodgkin's lymphoma following or concurrent with a diagnosis of follicular lymphoma
600457|NCT00319319|major depressive disorder,
600458|NCT00319319|serotonin selective reuptake inhibitor,
600459|NCT00319319|mecamylamine,
600460|NCT00319319|controlled trial,
600461|NCT00319319|cigarette smoking
600462|NCT00319306|Respiratory Tract Diseases
600463|NCT00319306|Bronchial Diseases
600464|NCT00319306|Anti-asthmatic agents
600465|NCT00319306|Anti-asthmatic drugs
600466|NCT00319306|Bronchodilators
600467|NCT00319280|Osteoarthritis, Knee
600468|NCT00319280|Osteotomy
600469|NCT00319280|Healing
600470|NCT00319280|Roentgen Stereometric Analysis
600471|NCT00319267|bosentan
600472|NCT00319267|children
600473|NCT00319267|pharmacokinetics
600474|NCT00319267|pulmonary arterial hypertension
600475|NCT00319254|Advanced Breast Cancer
600476|NCT00319241|parenting intervention
600477|NCT00319241|substance abuse treatment
600478|NCT00319241|mother-child relations
600479|NCT00319241|parent-child relations
600480|NCT00319241|child abuse and neglect
600481|NCT00319228|AT-III deficiency
600482|NCT00319228|AT-III concentrate
600483|NCT00319228|Bleeding disorders
600484|NCT00319228|Blood disorders
600485|NCT00319215|ramelteon
600486|NCT00319215|zopiclone
600487|NCT00319215|driving
600488|NCT00319215|memory
600489|NCT00319215|balance
600490|NCT00319215|psychomotor
600491|NCT00319202|Impaired fasting glucose
600492|NCT00319202|Abdominal obesity
600493|NCT00319202|HOMA
600494|NCT00319202|Angiotensin-receptor blocker
600495|NCT00319189|Nateglinide
600496|NCT00319189|Renal
600497|NCT00319189|Kidney
600498|NCT00319189|Transplantation
600499|NCT00319189|Diabets
600500|NCT00319189|Glucose
600501|NCT00319176|Pregnancy
600502|NCT00319176|Enoxaparin
600503|NCT00319176|Anticoagulation
600504|NCT00319163|oral contraceptive
600505|NCT00319163|therapeutic equivalency
600506|NCT00319163|contraceptives, oral, combined
600507|NCT00319150|Erythropoetin resistance
600508|NCT00319150|End Stage Renal Disease on hemodialysis
600509|NCT00319137|GW274150
600510|NCT00319137|Nitric Oxide
600511|NCT00319137|acute migraine
600512|NCT00319124|Hip Osteoarthritis, muscle strength, range of motion, aerobic capacity, functional capacity, health-related quality of life
600513|NCT00319111|pulmonary hypertension
600514|NCT00319111|bosentan
600515|NCT00319111|BENEFIT
600516|NCT00319111|CTEPH
600517|NCT00319111|inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
600518|NCT00319098|Adjuvanted pandemic influenza candidate vaccine
600519|NCT00319098|Influenza
600520|NCT00319085|Arthroplasty,
600521|NCT00319085|Hip,
600522|NCT00319085|Pre-heating,
600523|NCT00319085|Radiostereometric analysis,
600524|NCT00319085|Dual-Energy Radiographic Absorptiometry,
600525|NCT00319046|Type 1 Gaucher Disease
600526|NCT00319046|miglustat
600527|NCT00319046|enzyme replacement therapy
600528|NCT00319033|interstitial lung disease
600529|NCT00319033|scleroderma
600530|NCT00319033|bosentan
600531|NCT00319020|bosentan
600532|NCT00319020|pulmonary arterial hypertension
600533|NCT00319020|children
600534|NCT00319020|FUTURE 1
600535|NCT00318981|Medication trial
600536|NCT00318981|ADHD
600537|NCT00318981|Concerta
600538|NCT00318981|Efficacy trial
600539|NCT00318968|Acid Reflux
600540|NCT00318968|Nexium
600541|NCT00318968|Esomeprazole
600542|NCT00318955|Dexmedetomidine, Sedation, Extubation, Phase 4
600543|NCT00318942|Sepsis
600544|NCT00318942|Multiple Trauma
600545|NCT00318942|Hypovolemic Shock
600546|NCT00318929|Treatment Efficacy
600547|NCT00318929|pharmacokinetics
600548|NCT00318903|Chemotherapy for cancer of the esophagus
600549|NCT00318903|Radiotherapy for cancer of the esophagus
600550|NCT00318903|Surgery for cancer of the esophagus
600551|NCT00318903|Chemotherapy, radiotherapy, surgery for esophageal cancer
600552|NCT00318890|Chemotherapy and Radiotherapy for Head and Neck Cancer
600553|NCT00318890|Chemotherapy, Radiotherapy Squamous Cell Carcinoma Head Neck
600554|NCT00318877|Obesity
600555|NCT00318877|Physical activity
600556|NCT00318864|depression
600557|NCT00318864|cardiovascular risk
600558|NCT00318864|mechanisms
600559|NCT00318851|Carotid Artery stenting
600560|NCT00318851|Stroke
600561|NCT00318825|Pain
600562|NCT00318825|Colonoscopy
600563|NCT00318825|Sedation
600564|NCT00318812|Randomized controlled trial (RCT)
600565|NCT00318812|Prospective Studies
600566|NCT00318812|ferric oxide, saccharated
600567|NCT00318812|Peptides
600568|NCT00318812|Heme
600569|NCT00318812|Iron
600570|NCT00318812|Erythropoietin,
600571|NCT00318812|Recombinant
600572|NCT00318812|Ferritin
600573|NCT00318812|Transferrin
600574|NCT00318812|Treatment Outcome
600703|NCT00318227|Postoperative care
600575|NCT00318799|prevention of unintended pregnancies
600576|NCT00318773|PMS
600577|NCT00318773|PMDD
600578|NCT00318773|sertraline
600579|NCT00318773|antidepressant
600580|NCT00318773|extended treatment
600581|NCT00318773|relapse
600582|NCT00318760|Drug Cue
600583|NCT00318760|Relapse
600584|NCT00318760|Stress
600585|NCT00318760|Craving
600586|NCT00318747|Amb a 1-Immunostimulatory Oligodeoxyribonucleotide Conjugate
600587|NCT00318747|AIC
600588|NCT00318747|Amb a I Protein
600589|NCT00318747|Ragweed Allergy
600590|NCT00318747|Hay Fever
600591|NCT00318747|Wheeze
600592|NCT00318747|Immunotherapy
600593|NCT00318747|Tolerance
600594|NCT00318747|Immunostimulatory
600595|NCT00318747|Ragweed Season
600596|NCT00318747|Asthma
600597|NCT00318747|Asthmatics
600598|NCT00318747|Asthmatic
600599|NCT00318721|Leishmania donovani
600600|NCT00318721|cluster-randomised control trial
600601|NCT00318721|Long Lasting Impregnated Nets
600602|NCT00318721|Bednets
600603|NCT00318721|Sandflies
600604|NCT00318695|Probiotics
600605|NCT00318695|Eczema
600606|NCT00318695|Asthma
600607|NCT00318695|Allergic Rhinitis
600608|NCT00318695|Prevention
600609|NCT00318695|Immunological responses
600610|NCT00318682|biopsy
600611|NCT00318682|FIBROSCAN
600612|NCT00318669|Anxiety
600613|NCT00318669|SAD
600614|NCT00318669|Social
600615|NCT00318669|Disorder
600616|NCT00318656|type 2 diabetes
600617|NCT00318656|rosiglitazone
600618|NCT00318656|metformin
600619|NCT00318656|glimepiride
600620|NCT00318656|glycemia
600621|NCT00318643|Non-invasive bladder cancer
600622|NCT00318643|Chemophase
600623|NCT00318643|Intravesical administration
600624|NCT00318643|Superficial Bladder Cancer
600625|NCT00318630|Asthma AVANDIA Inflammation
600626|NCT00318617|peroxisome proliferator activated receptors,
600627|NCT00318617|PPARs,
600628|NCT00318617|Heart Failure,
600629|NCT00318617|cardiac energetics,
600630|NCT00318617|MRI,
600631|NCT00318617|GW501516X
600632|NCT00318617|fatty acid metabolism,
600633|NCT00318604|plasma circulating DNA
600634|NCT00318604|hean and neck cancers
600635|NCT00318604|esophageal cancer
600636|NCT00318604|localized head and neck cancers
600637|NCT00318604|localized esophageal cancer
600638|NCT00318578|convulsive status epilepticus
600639|NCT00318578|outcome
600640|NCT00318578|prognosis factors
600641|NCT00318578|seizure duration
600642|NCT00318578|adult
600643|NCT00318578|electroencephalogram
600644|NCT00318578|intensive care unit
600645|NCT00318565|Heart Disease
600646|NCT00318565|Atrial Flutter
600647|NCT00318565|Typical Atrial Flutter
600648|NCT00318552|Antibiotic Therapy
600649|NCT00318552|sepsis treatment
600650|NCT00318552|Meropenem
600651|NCT00318539|Obsessive Compulsive Disorder
600652|NCT00318513|breast cancer
600653|NCT00318513|lymphedema
600654|NCT00318513|extremity
600655|NCT00318513|women
600656|NCT00318500|Endometriosis
600657|NCT00318500|Dysmenorrhea
600658|NCT00318500|Pelvic pain
600659|NCT00318500|Dyspareunia
600660|NCT00318487|Dental implants
600661|NCT00318474|Proteinuria
600662|NCT00318474|Immunoglobulin A
600663|NCT00318448|Child Psychology
600664|NCT00318448|Pediatric Psychology
600665|NCT00318448|Insomnia
600666|NCT00318448|Sleeplessness
600667|NCT00318409|Methamphetamine
600668|NCT00318409|HIV
600669|NCT00318396|THA
600670|NCT00318383|Vaccine
600671|NCT00318383|Immunogenicity
600672|NCT00318383|Randomized Controlled Trial
600673|NCT00318370|Ovarian Cancer
600674|NCT00318370|Primary Fallopian Tube Cancer
600675|NCT00318370|Peritoneal Cancer
600676|NCT00318357|Cardiac Resynchronization therapy (CRT)
600677|NCT00318357|All-cause mortality
600678|NCT00318357|Long-term follow-up
600679|NCT00318331|Glutamine
600680|NCT00318331|Critical Illness
600681|NCT00318331|Enteral Feeding
600682|NCT00318331|Blood Volume Analysis
600683|NCT00318318|Premarin,
600684|NCT00318318|HRT,
600685|NCT00318318|RNA,
600686|NCT00318318|Gene Expression.
600687|NCT00318318|Postmenopausal Women
600688|NCT00318292|preemptive analgesia
600689|NCT00318292|paracervical block
600690|NCT00318292|vaginal hysterectomy
600691|NCT00318279|Surgical education
600692|NCT00318279|Vascular anastomosis
600693|NCT00318279|Simulator
600694|NCT00318279|Randomized controlled trial
600695|NCT00318266|Detection of Bladder Cancer using NMP22 Urine Test Kit
600696|NCT00318253|Cranberry juice
600697|NCT00318253|Antiadhesion
600698|NCT00318253|Urinary tract infection
600699|NCT00318253|vaginosis
600700|NCT00318240|High Intensity Focused Ultrasound
600701|NCT00318240|Men
600702|NCT00318240|Locally recurrent prostate cancer.
600704|NCT00318227|Cardiac Surgery
600705|NCT00318227|Blood Transfusion
600706|NCT00318214|toe ulcer
600707|NCT00318214|heel ulcer
600708|NCT00318214|foot ulcer
600709|NCT00318214|diabetic feet
600710|NCT00318214|diabetic foot
600711|NCT00318214|complications of diabetes
600712|NCT00318201|Healthy Subjects
600713|NCT00318188|scleroderma
600714|NCT00318188|HAQ
600715|NCT00318188|Intensive care reeducation, readaptation
600716|NCT00318175|Systemic Scleroderma
600717|NCT00318175|Dermal Sclerosis
600718|NCT00318175|Bosentan
600719|NCT00318175|Endothelin Receptor Antagonist
600720|NCT00318175|Rodnan Skin Score
600721|NCT00318162|autism
600722|NCT00318162|PDD
600723|NCT00318162|LDN
600724|NCT00318162|naltrexone
600725|NCT00318136|BRIDGE
600726|NCT00318136|NSCLC
600727|NCT00318136|Lung Cancer
600728|NCT00318136|Avastin
600729|NCT00318123|Simplification therapy
600730|NCT00318123|Efficacy
600731|NCT00318123|Safety
600732|NCT00318123|Virological effectiveness
600733|NCT00318123|Immunological effectiveness
600734|NCT00318123|HIV
600735|NCT00318110|Metastatic
600736|NCT00318110|Renal
600737|NCT00318110|Cell
600738|NCT00318110|Carcinoma
600739|NCT00318110|Unrelated
600740|NCT00318110|Donor
600741|NCT00318110|Transplant
600742|NCT00318110|stage IV
600743|NCT00318110|clear cell
600744|NCT00318097|McCune Albright Syndrome
600745|NCT00318097|Histamine regulation
600746|NCT00318084|Gastroesophageal reflux disease
600747|NCT00318084|Heartburn
600748|NCT00318084|Acid-related diseases
600749|NCT00318084|Acid reflux disease
600750|NCT00318084|Nexium
600751|NCT00318071|Stroke
600752|NCT00318071|Ischemic
600753|NCT00318071|Thrombus
600754|NCT00318071|Embolectomy
600755|NCT00318071|Thrombectomy
600756|NCT00318071|Merci
600757|NCT00318071|Concentric
600758|NCT00318071|Embolus
600759|NCT00318071|Embolism
600760|NCT00318071|Mechanical
600761|NCT00318045|Refractive error
600762|NCT00318045|Asthenopia
600763|NCT00318032|Randomised control trial
600764|NCT00318032|Screening
600765|NCT00318032|Intensive management
600766|NCT00318032|Diabetes mellitus
600767|NCT00318032|Type 2 diabetes
600768|NCT00318019|Energy
600769|NCT00318019|Energy Level
600770|NCT00318006|chronic
600771|NCT00318006|nasal
600772|NCT00318006|sinus
600773|NCT00318006|symptoms
600774|NCT00317980|Cutaneous leishmaniasis
600775|NCT00317980|Leishmania braziliensis
600776|NCT00317980|Pentavalent antimony
600777|NCT00317980|Meglumine antimoniate
600778|NCT00317967|Hypertrophic cardiomyopathy
600779|NCT00317967|Statin therapy
600780|NCT00317967|Regression
600781|NCT00317967|Heart failure
600782|NCT00317967|Arrhythmias
600783|NCT00317967|Sudden cardiac death
600784|NCT00317954|Diabetic nephropathy
600785|NCT00317954|Spironolactone
600786|NCT00317954|Aldosterone antagonism
600787|NCT00317954|Renoprotection
600788|NCT00317941|Multiple Sclerosis
600789|NCT00317941|RRMS
600790|NCT00317928|Polycystic Ovary Syndrome
600791|NCT00317928|Metformin
600792|NCT00317928|Metabolic Syndrome
600793|NCT00317928|Hyperandrogenism
600794|NCT00317928|Ovulation
600795|NCT00317902|Anemia
600796|NCT00317902|erythropoetin
600797|NCT00317902|Epoetin alfa
600798|NCT00317902|erythropoetin recombinant
600799|NCT00317902|HIV, AIDS
600800|NCT00317889|THA
600801|NCT00317876|Fanconi anemia
600802|NCT00317837|Fracture of Femoral Neck
600803|NCT00317811|stage I multiple myeloma
600804|NCT00317811|stage II multiple myeloma
600805|NCT00317811|stage III multiple myeloma
600806|NCT00317798|drug/agent toxicity by tissue/organ
600807|NCT00317798|stage I multiple myeloma
600808|NCT00317798|stage II multiple myeloma
600809|NCT00317798|stage III multiple myeloma
600810|NCT00317798|refractory multiple myeloma
600811|NCT00317785|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
600812|NCT00317785|adult acute myeloid leukemia with inv(16)(p13;q22)
600813|NCT00317785|adult acute myeloid leukemia with t(15;17)(q22;q12)
600814|NCT00317785|adult acute myeloid leukemia with t(16;16)(p13;q22)
600815|NCT00317785|adult acute myeloid leukemia with t(8;21)(q22;q22)
600816|NCT00317785|accelerated phase chronic myelogenous leukemia
600817|NCT00317785|adult acute lymphoblastic leukemia in remission
600818|NCT00317785|adult acute myeloid leukemia in remission
600819|NCT00317785|blastic phase chronic myelogenous leukemia
600820|NCT00317785|chronic phase chronic myelogenous leukemia
600821|NCT00317785|de novo myelodysplastic syndromes
600822|NCT00317785|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
600823|NCT00317785|nodal marginal zone B-cell lymphoma
600824|NCT00317785|noncontiguous stage II adult Burkitt lymphoma
600825|NCT00317785|noncontiguous stage II adult diffuse large cell lymphoma
600826|NCT00317785|noncontiguous stage II adult diffuse mixed cell lymphoma
600827|NCT00317785|noncontiguous stage II adult diffuse small cleaved cell lymphoma
600828|NCT00317785|noncontiguous stage II adult immunoblastic large cell lymphoma
600829|NCT00317785|noncontiguous stage II adult lymphoblastic lymphoma
600830|NCT00317785|noncontiguous stage II grade 1 follicular lymphoma
600831|NCT00317785|noncontiguous stage II grade 2 follicular lymphoma
600832|NCT00317785|noncontiguous stage II grade 3 follicular lymphoma
600833|NCT00317785|noncontiguous stage II mantle cell lymphoma
600834|NCT00317785|noncontiguous stage II marginal zone lymphoma
600835|NCT00317785|noncontiguous stage II small lymphocytic lymphoma
600836|NCT00317785|previously treated myelodysplastic syndromes
600837|NCT00317785|recurrent adult acute lymphoblastic leukemia
600838|NCT00317785|recurrent adult acute myeloid leukemia
600839|NCT00317785|recurrent adult Burkitt lymphoma
600840|NCT00317785|recurrent adult Hodgkin lymphoma
600841|NCT00317785|recurrent adult diffuse large cell lymphoma
600842|NCT00317785|recurrent adult diffuse mixed cell lymphoma
600843|NCT00317785|recurrent adult diffuse small cleaved cell lymphoma
600844|NCT00317785|recurrent adult immunoblastic large cell lymphoma
600845|NCT00317785|recurrent adult lymphoblastic lymphoma
600846|NCT00317785|recurrent cutaneous T-cell non-Hodgkin lymphoma
600847|NCT00317785|recurrent grade 1 follicular lymphoma
600848|NCT00317785|recurrent grade 2 follicular lymphoma
600849|NCT00317785|recurrent grade 3 follicular lymphoma
600850|NCT00317785|recurrent mantle cell lymphoma
600851|NCT00317785|recurrent marginal zone lymphoma
600852|NCT00317785|recurrent mycosis fungoides/Sezary syndrome
600853|NCT00317785|recurrent small lymphocytic lymphoma
600854|NCT00317785|relapsing chronic myelogenous leukemia
600855|NCT00317785|secondary acute myeloid leukemia
600856|NCT00317785|secondary myelodysplastic syndromes
600857|NCT00317785|splenic marginal zone lymphoma
600858|NCT00317785|stage III adult Burkitt lymphoma
600859|NCT00317785|stage III adult Hodgkin lymphoma
600860|NCT00317785|stage III adult diffuse large cell lymphoma
600861|NCT00317785|stage III adult diffuse mixed cell lymphoma
600862|NCT00317785|stage III adult diffuse small cleaved cell lymphoma
600863|NCT00317785|stage III adult immunoblastic large cell lymphoma
600864|NCT00317785|stage III adult lymphoblastic lymphoma
600865|NCT00317785|stage III grade 1 follicular lymphoma
600866|NCT00317785|stage III grade 2 follicular lymphoma
600867|NCT00317785|stage III grade 3 follicular lymphoma
600868|NCT00317785|stage III mantle cell lymphoma
600869|NCT00317785|stage III marginal zone lymphoma
600870|NCT00317785|stage III small lymphocytic lymphoma
600871|NCT00317785|stage IV adult Burkitt lymphoma
600872|NCT00317785|stage IV adult Hodgkin lymphoma
600873|NCT00317785|stage IV adult diffuse large cell lymphoma
600874|NCT00317785|stage IV adult diffuse mixed cell lymphoma
600875|NCT00317785|stage IV adult diffuse small cleaved cell lymphoma
600876|NCT00317785|stage IV adult immunoblastic large cell lymphoma
600877|NCT00317785|stage IV adult lymphoblastic lymphoma
600878|NCT00317785|stage IV grade 1 follicular lymphoma
600879|NCT00317785|stage IV grade 2 follicular lymphoma
600880|NCT00317785|stage IV grade 3 follicular lymphoma
600881|NCT00317785|stage IV mantle cell lymphoma
600882|NCT00317785|stage IV marginal zone lymphoma
600883|NCT00317785|stage IV small lymphocytic lymphoma
600884|NCT00317772|Epithelial Ovarian Cancer
600885|NCT00317772|Peritoneal Cancer
600886|NCT00317772|Fallopian Tube Cancer
600887|NCT00317772|Epidermal Growth Factor
600888|NCT00317772|Platinum Hypersensitivity
600889|NCT00317772|Hycamtin
600890|NCT00317772|Gefitinib
600891|NCT00317772|Iressa
600892|NCT00317772|Topotecan
600893|NCT00317772|EGFR
600894|NCT00317759|stage IV melanoma
600895|NCT00317759|recurrent melanoma
600896|NCT00317746|HIV/HCV Co-infection
600897|NCT00317746|Depression
600898|NCT00317746|Citalopram
600899|NCT00317733|Ketoprofen
600900|NCT00317733|Transfersome
600901|NCT00317733|Osteoarthritis, Knee
600902|NCT00317720|Breast Cancer
600903|NCT00317720|Metastatic Breast Cancer
600904|NCT00317720|Trastuzumab
600905|NCT00317720|RAD001
600906|NCT00317720|Herceptin
600907|NCT00317707|cardiovascular risk
600908|NCT00317707|cardiovascular diseases
600909|NCT00317707|cardiovascular prevention
600910|NCT00317707|polyunsaturated fatty acids
600911|NCT00317707|diabetes
600912|NCT00317707|hypertension
600913|NCT00317707|hypercholesterolemia
600914|NCT00317707|obesity
600915|NCT00317694|Hyperphosphatemia
600916|NCT00317694|Phosphate binder
600917|NCT00317681|Cutaneous lupus erythematosus
600918|NCT00317681|Tacrolimus ointment
600919|NCT00317681|Topical treatment
600920|NCT00317681|Skin lesions
600921|NCT00317655|back pain
600922|NCT00317642|acute myelogenous leukemia
600923|NCT00317642|acute myeloid leukemia
600924|NCT00317642|relapsed AML
600925|NCT00317642|refractory AML
600926|NCT00317642|clofarabine
600927|NCT00317642|cytarabine
600928|NCT00317642|CLO341
600929|NCT00317642|clolar
600930|NCT00317629|leishmaniasis
600931|NCT00317629|nitric oxide
600932|NCT00317629|treatment
600933|NCT00317629|donor
600934|NCT00317629|controlled trial
600935|NCT00317616|FALS
600936|NCT00317616|SOD1
600937|NCT00317616|familial
600938|NCT00317616|genetic testing
600939|NCT00317616|genetic counseling
600940|NCT00317616|ALS
600941|NCT00317616|C9ORF72
600942|NCT00317603|autologous vaccination
600943|NCT00317603|GM-CSF
600944|NCT00317603|adenoviral mediated gene transfer
600945|NCT00317603|Stage IV breast cancer
600946|NCT00317590|Diagnosis
600947|NCT00317590|Rapid Diagnostic Test
600948|NCT00317590|Management
600949|NCT00317590|Attributable Fraction
600950|NCT00317590|Threshold
600951|NCT00317577|Low-pressure glaucoma
600952|NCT00317577|Normal tension glaucoma
600953|NCT00317577|Neuroprotection
600954|NCT00317577|Brimonidine
600955|NCT00317577|Visual field progression
600956|NCT00317564|Birth Defects
600957|NCT00317564|High Risk Pregnancy
600958|NCT00317564|Multiple Sclerosis
600959|NCT00317551|Aberration control
600960|NCT00317551|Accommodative facility
600961|NCT00317551|Accommodative response
600962|NCT00317551|Peripheral refraction
600963|NCT00317551|Accommodative convergence to accommodation ratio
600964|NCT00317538|Rheumatoid Arthritis
600965|NCT00317538|Switching
600966|NCT00317538|Structural Damage
600967|NCT00317538|MRI
600968|NCT00317525|Refractive error
600969|NCT00317525|Asthenopia
600970|NCT00317512|Hemoglobin Based Oxygen carrier
600971|NCT00317512|HBOC 201
600972|NCT00317512|Percutaneous Revascularization
600973|NCT00317512|Percutaneous Coronary Intervention
600974|NCT00317512|Non ST-segment Elevation Myocardial Infarction
600975|NCT00317512|Tissue Oxygenation
600976|NCT00317512|Transluminal Percutaneous Coronary Angioplasty
600977|NCT00317486|pulmonary arterial hypertension
600978|NCT00317486|Eisenmenger physiology
600979|NCT00317486|bosentan
600980|NCT00317473|Vaccine
600981|NCT00317473|Phase 1
600982|NCT00317473|Plasmodium falciparum
600983|NCT00317473|Malaria
600984|NCT00317473|Merozoite surface protein-1
600985|NCT00317473|MSP-1
600986|NCT00317473|Falciparum malaria protein 1
600987|NCT00317473|FMP-1
600988|NCT00317473|AS02A
600989|NCT00317460|Drug Abuse
600990|NCT00317460|Drug Addiction
600991|NCT00317460|Drug Dependence
600992|NCT00317460|Drug Use Disorders
600993|NCT00317460|Drug Use Disorder
600994|NCT00317460|Substance Abuse
600995|NCT00317460|Substance Use Disorder
600996|NCT00317460|Buprenorphine
600997|NCT00317460|Opiate Addiction
600998|NCT00317447|Sciatica
600999|NCT00317447|Lower back pain
601000|NCT00317447|Prednisone
601001|NCT00317447|Randomized, controlled clinical trial
601002|NCT00317434|ovarian cancer
601003|NCT00317421|Phosphodiesterase 5
601004|NCT00317421|Sildenafil
601005|NCT00317421|Hypertension
601006|NCT00317421|Blood pressure
601007|NCT00317421|Arterial stiffness
601008|NCT00317421|Endothelial function
601009|NCT00317408|anaplastic large cell lymphoma
601010|NCT00317408|recurrent childhood anaplastic large cell lymphoma
601011|NCT00317408|stage III childhood anaplastic large cell lymphoma
601012|NCT00317408|stage IV childhood anaplastic large cell lymphoma
601013|NCT00317395|Non ST elevation Acute Coronary Syndrome
601014|NCT00317395|Early invasive strategy
601015|NCT00317395|Percutaneous Coronary Intervention
601016|NCT00317382|lumbar puncture
601017|NCT00317382|headache
601018|NCT00317382|traumatic tap
601019|NCT00317369|OPC-6535
601020|NCT00317369|Crohn's disease
601021|NCT00317356|OPC-6535
601022|NCT00317356|ulcerative colitis
601023|NCT00317343|Patients candidate to a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy
601024|NCT00317317|IVF
601025|NCT00317317|Acupuncture
601026|NCT00317317|Pregnant
601027|NCT00317304|Hot flashes
601028|NCT00317304|vasomotor symptoms
601029|NCT00317304|menopause
601030|NCT00317304|mindfulness based stress reduction
601031|NCT00317304|meditation
601032|NCT00317291|Acupuncture
601033|NCT00317291|HIV
601034|NCT00317291|AIDS
601035|NCT00317291|Symptom management
601036|NCT00317291|Non-invasive
601037|NCT00317291|Complementary Therapies
601038|NCT00317291|Treatment Experienced
601039|NCT00317278|Massage
601040|NCT00317278|immune system
601041|NCT00317278|preterm infants
601042|NCT00317265|coronary artery disease
601043|NCT00317265|coronary bypass surgery
601044|NCT00317265|complete arterial coronary surgery
601045|NCT00317265|internal mammary artery
601046|NCT00317252|contrast induced nephropathy
601047|NCT00317252|contrast nephropathy
601048|NCT00317252|contrast media
601049|NCT00317252|kidney diseases
601050|NCT00317252|angiotensin converting enzyme inhibitors
601051|NCT00317239|Anemia
601052|NCT00317239|Chronic Kidney Disease
601053|NCT00317239|Iron
601054|NCT00317226|Anemia
601055|NCT00317226|CKD
601056|NCT00317226|Chronic Kidney Disease
601057|NCT00317226|Iron
601058|NCT00317226|Maintenance Dose
601059|NCT00317213|Smoking
601060|NCT00317213|Nicotine
601061|NCT00317213|Withdrawal
601062|NCT00317213|Phospholipids
601063|NCT00317213|Cell membrane fluidity
601064|NCT00317213|Smoking cessation
601065|NCT00317148|Hot Flashes
601066|NCT00317148|Menopause
601067|NCT00317148|Quality of Life
601068|NCT00317109|meningococcal serogroups A and C diseases
601069|NCT00317109|tetanus
601070|NCT00317109|hepatitis B
601071|NCT00317109|pertussis
601072|NCT00317109|Haemophilus influenzae type b
601073|NCT00317109|meningococcal vaccine
601074|NCT00317109|Prophylaxis diphtheria
601075|NCT00317096|Drug Therapy
601076|NCT00317096|Maintenance
601077|NCT00317096|rituximab
601078|NCT00317083|Cough Reflex
601079|NCT00317083|Citric acid
601080|NCT00317083|Obesity
601081|NCT00317083|Sleep apnea syndrome
601082|NCT00317070|PBS/IC
601083|NCT00317070|Painful bladder syndrome including Interstitial cystitis
601084|NCT00317057|chronic obstructive pulmonary disease
601085|NCT00317057|Outpatient management
601086|NCT00317057|nurse-lead patient education
601087|NCT00317044|Moderate to severe Asthma
601088|NCT00317044|Gastroesophageal Reflux Disease
601089|NCT00317044|esomeprazole
601090|NCT00317044|GERD
601091|NCT00317031|Alcoholism
601092|NCT00317031|Drug Therapy
601093|NCT00317018|depression
601094|NCT00317018|quality improvement
601095|NCT00317018|implementation
601096|NCT00317018|translation
601097|NCT00317018|evidence-based practice
601098|NCT00317018|collaborative care
601099|NCT00317018|adoption
601100|NCT00317018|sustainability
601101|NCT00317018|cost-effectiveness
601102|NCT00317018|rural
601103|NCT00317005|hemodialysis
601104|NCT00317005|chronic uremia
601105|NCT00317005|hyperhomocysteinemia
601106|NCT00317005|folate
601107|NCT00316992|Insomnia
601108|NCT00316992|Chronic Obstructive Pulmonary Disease
601109|NCT00316992|Drug Therapy
601110|NCT00316979|migraine
601111|NCT00316979|transcranial magnetic stimulation
601112|NCT00316979|repetitive transcranial magnetic stimulation
601113|NCT00316979|rTMS
601114|NCT00316966|Nutritional status, dietary intervention, health care use, costs
601115|NCT00316940|stage I multiple myeloma
601116|NCT00316940|stage II multiple myeloma
601117|NCT00316940|stage III multiple myeloma
601118|NCT00316940|refractory multiple myeloma
601119|NCT00316927|adenocarcinoma of the prostate
601120|NCT00316927|stage III prostate cancer
601121|NCT00316927|stage IV prostate cancer
601122|NCT00316914|neurotoxicity
601123|NCT00316914|stage II colon cancer
601124|NCT00316914|stage III colon cancer
601125|NCT00316914|adenocarcinoma of the colon
601126|NCT00316914|stage II rectal cancer
601127|NCT00316914|stage III rectal cancer
601128|NCT00316914|stage IV rectal cancer
601129|NCT00316914|stage IV colon cancer
601130|NCT00316914|adenocarcinoma of the rectum
601131|NCT00316901|stage IV renal cell cancer
601132|NCT00316901|stage IV melanoma
601133|NCT00316901|recurrent melanoma
601134|NCT00316901|recurrent renal cell cancer
601135|NCT00316888|squamous cell carcinoma of the anus
601136|NCT00316888|stage I anal cancer
601137|NCT00316888|stage II anal cancer
601138|NCT00316888|stage IIIA anal cancer
601139|NCT00316888|stage IIIB anal cancer
601140|NCT00316888|basaloid carcinoma of the anus
601141|NCT00316888|cloacogenic carcinoma of the anus
601142|NCT00316875|stage IV breast cancer
601143|NCT00316875|recurrent breast cancer
601144|NCT00316875|male breast cancer
601145|NCT00316862|adenocarcinoma of the esophagus
601146|NCT00316862|stage II esophageal cancer
601147|NCT00316862|stage III esophageal cancer
601148|NCT00316836|stage I breast cancer
601149|NCT00316836|stage II breast cancer
601150|NCT00316836|stage IIIA breast cancer
601151|NCT00316823|thyroid cancer
601152|NCT00316810|Campath 1H
601153|NCT00316810|Alemtuzumab
601154|NCT00316810|Tacrolimus
601155|NCT00316810|Pancreas-kidney transplantation
601156|NCT00316810|immunosuppression
601157|NCT00316810|prevention of acute rejection
601158|NCT00316797|SPECT
601159|NCT00316797|Nuclear Medicine
601160|NCT00316784|osteoarthritis; knee; IDEA-033
601161|NCT00316745|irinotecan
601162|NCT00316745|S-1
601163|NCT00316745|Oxaliplatin
601164|NCT00316745|l-leucovorin
601165|NCT00316745|Fluorouracil
601166|NCT00316745|Metastatic colorectal cancer
601167|NCT00316745|phase III
601168|NCT00316732|Avodart
601169|NCT00316732|IPSS
601170|NCT00316732|BPH
601171|NCT00316732|dutasteride
601172|NCT00316732|EQ-5D
601173|NCT00316732|Observational
601174|NCT00316719|treatment naive
601175|NCT00316719|CHB
601176|NCT00316719|adefovir
601177|NCT00316719|monotherapy
601178|NCT00316706|Prophylaxis HPV-16/18 infections and cervical neoplasia
601179|NCT00316693|HPV Vaccine Efficacy
601180|NCT00316667|epidemiology
601181|NCT00316667|risk factors
601182|NCT00316654|Prevention of Meningococcal Meningitis
601183|NCT00316654|vaccines, conjugate
601184|NCT00316654|immunology
601185|NCT00316654|child
601186|NCT00316654|antibody persistence
601187|NCT00316628|influenza
601188|NCT00316628|elderly
601189|NCT00316628|vaccine
601190|NCT00316615|influenza
601191|NCT00316615|non elderly adult and elderly
601192|NCT00316615|vaccine
601193|NCT00316602|Atopic dermatitis
601194|NCT00316602|Smallpox
601195|NCT00316602|Vaccination
601196|NCT00316589|HIV
601197|NCT00316589|treatment experienced
601198|NCT00316589|treatment vaccinia naive
601199|NCT00316576|Kidney failure, Acute
601200|NCT00316576|Genetic Polymorphism
601201|NCT00316576|Angiotensin-converting enzyme
601202|NCT00316563|cannabinoids
601203|NCT00316563|taste disorders
601204|NCT00316563|olfaction disorders
601205|NCT00316563|cancer
601206|NCT00316563|palliative medicine
601207|NCT00316563|caloric intake
601208|NCT00316563|appetite
601209|NCT00316563|reward
601210|NCT00316563|tetrahydrocannabinol/therapeutic use
601211|NCT00316563|anorexia/drug therapy
601212|NCT00316563|quality of life
601213|NCT00316563|chemosensory changes/drug therapy
601214|NCT00316550|Irritable Bowel Syndrome (IBS)
601215|NCT00316537|diabetes
601216|NCT00316537|foot ulcers
601217|NCT00316537|nicotine gel
601218|NCT00316537|wound healing
601219|NCT00316524|Smallpox
601220|NCT00316524|Vaccination
601221|NCT00316524|Prevention
601222|NCT00316511|advanced solid malignancies
601223|NCT00316511|B-cell lymphoma
601224|NCT00316511|Aroplatin
601225|NCT00316511|L-NDDP
601226|NCT00316511|MTD
601227|NCT00316511|advanced solid malignancies or B-cell lymphoma
601228|NCT00316498|Eye Movement
601229|NCT00316498|Niemann Pick C
601230|NCT00316485|Bone
601231|NCT00316485|Microbiology
601232|NCT00316485|Dental Pulp Stem Cell
601233|NCT00316485|Wisdom Teeth
601234|NCT00316485|Biopsy
601235|NCT00316485|Third Molar Extraction
601236|NCT00316472|Hyperphosphatemia
601237|NCT00316472|End Stage Renal Disease
601238|NCT00316472|Renal Osteodystrophy
601239|NCT00316459|Healthy
601240|NCT00316459|Cardiac
601241|NCT00316459|Pharmacokinetics
601242|NCT00316394|Preventive Health Care
601243|NCT00316394|Annual Health Check-up
601244|NCT00316394|Primary Care
601245|NCT00316394|Reminders
601246|NCT00316381|stem cells
601247|NCT00316381|acute myocardial infarction
601248|NCT00316381|regeneration
601249|NCT00316381|left ventricular ejection fraction
601250|NCT00316368|Bi-Ventricular pacing post coronary artery bypass graft
601251|NCT00316368|coronary artery bypass graft
601252|NCT00316355|Anxiety
601253|NCT00316355|Behavior therapy
601254|NCT00316355|Cognitive-behavioral therapy
601255|NCT00316355|Stepped care
601256|NCT00316355|Cost-effectiveness
601257|NCT00316342|Low back pain
601258|NCT00316342|Industrial workers
601259|NCT00316342|Recurrent back pain
601260|NCT00316342|Back supports
601261|NCT00316342|Back health education
601262|NCT00316342|Rehabilitation
601263|NCT00316316|OCD
601264|NCT00316303|Serious Mental Illness
601265|NCT00316303|Dual Diagnosis
601266|NCT00316303|Mental Disorders
601267|NCT00316303|Substance-Related Disorders
601268|NCT00316290|ADHD
601269|NCT00316290|Cognitive Behavioral Therapy
601270|NCT00316290|Parent Training
601271|NCT00316277|Opiate Analgesic Dependence
601272|NCT00316264|Respiratory Syncytial Virus
601273|NCT00316264|Premature and under 6 mos. of age
601274|NCT00316264|Chronic Lung Disease over 6 mos. of age
601275|NCT00316264|palivizumab
601276|NCT00316264|motavizumab
601277|NCT00316264|RSV
601278|NCT00316251|Somatosensory dysfunction
601279|NCT00316212|Coronary Artery Bypass Graft Surgery involving Cardiopulmonary Bypass
601280|NCT00316186|chemonaive
601281|NCT00316186|small cell lung cancer
601282|NCT00316186|untreated
601283|NCT00316186|Lung cancer
601284|NCT00316186|HYCAMTIN
601285|NCT00316186|first-line
601286|NCT00316186|extensive disease
601287|NCT00316173|HYCAMTIN
601288|NCT00316173|ovarian cancer
601289|NCT00316173|recurrent
601290|NCT00316173|relapsed
601291|NCT00316173|carboplatin
601292|NCT00316173|topotecan
601293|NCT00316173|potentially platinum-sensitive
601294|NCT00316160|sexual dysfunction
601295|NCT00316160|Depression
601296|NCT00316160|MDD
601297|NCT00316147|diphtheria
601298|NCT00316147|tetanus
601299|NCT00316147|poliomyelitis
601300|NCT00316147|pertussis
601301|NCT00316147|hepatitis B
601302|NCT00316147|Prophylaxis
601303|NCT00316147|Haemophilus influenza type b diseases
601304|NCT00316134|Pleural Diseases
601305|NCT00316134|Pleural Effusion
601306|NCT00316134|Pleural Effusion, Malignant
601307|NCT00316134|Pleural Neoplasms
601308|NCT00316134|Neoplasms, Pleural
601309|NCT00316121|One or Two Level Degenerative Disc Disease
601310|NCT00316108|Carotid
601311|NCT00316108|Carotid Artery Stenting
601312|NCT00316108|Stent
601313|NCT00316108|Carotid Endarterectomy
601314|NCT00316108|Stroke
601315|NCT00316108|Transient Ischemic Attack
601316|NCT00316108|Stenosis
601317|NCT00316108|Atherosclerotic Disease
601318|NCT00316069|Erythropoiesis
601319|NCT00316069|Leukapheresis
601320|NCT00316069|G-CSF
601321|NCT00316069|Mobilization
601322|NCT00316069|Stem Cells
601323|NCT00316069|Apheresis
601324|NCT00316069|Blood Donation
601325|NCT00316069|Healthy Volunteer
601326|NCT00316069|HV
601327|NCT00316056|Genetic Literacy
601328|NCT00316056|Learning
601329|NCT00316056|Genetic Knowledge
601330|NCT00316056|Public Understanding of Science
601331|NCT00316056|Science Education
601332|NCT00316056|Healthy Volunteer
601333|NCT00316056|HV
601334|NCT00316043|Urinary tract infections
601335|NCT00316043|Renal failure
601336|NCT00316043|Renal scarring
601337|NCT00316043|Prevention
601338|NCT00316043|Primary Care
601339|NCT00316043|General Practice
601340|NCT00316043|Intervention Studies
601341|NCT00316043|Children
601342|NCT00316030|AML
601343|NCT00316030|Acute Myeloid Leukemia
601344|NCT00316030|Bexarotene
601345|NCT00316030|Leukemia
601346|NCT00316017|Trauma
601347|NCT00316017|Shock
601348|NCT00316004|Traumatic
601349|NCT00316004|Brain injury
601350|NCT00315991|BG perception
601351|NCT00315991|hypoglycemic awareness
601352|NCT00315991|pediatric T1DM
601353|NCT00315978|Risk Assessment
601354|NCT00315978|Decision Support Technique
601355|NCT00315978|Physician-Patient Relations
601356|NCT00315978|Prevention and Control
601357|NCT00315965|Diffusion
601358|NCT00315965|Membrane diffusing capacity
601359|NCT00315965|Alveolar capillary gas diffusion
601360|NCT00315965|Transfer factor
601361|NCT00315965|Nitric oxide diffusion
601362|NCT00315952|type 1 diabetes mellitus
601363|NCT00315952|inhaled insulin
601364|NCT00315952|Positron Emission Tomography
601365|NCT00315939|Diabetes
601366|NCT00315939|hypoglycemic episodes
601367|NCT00315926|Cardiac morbidity
601368|NCT00315926|Melatonin
601369|NCT00315926|Surgery
601370|NCT00315926|Postoperative
601371|NCT00315913|Labor
601372|NCT00315913|Dysfunctional Labor
601373|NCT00315913|Labor Arrest
601374|NCT00315913|Primary Cesarean Section Prevention
601375|NCT00315900|Seroquel
601376|NCT00315900|Depakote ER
601377|NCT00315900|Nursing Home
601378|NCT00315900|Quetiapine
601379|NCT00315900|Divalproex ER
601380|NCT00315900|Agitation
601381|NCT00315887|low back pain
601382|NCT00315887|opioid
601383|NCT00315887|transdermal
601384|NCT00315874|chronic back pain
601385|NCT00315874|opioid
601386|NCT00315874|transdermal
601387|NCT00315861|ovarian carcinoma
601388|NCT00315861|endometrial carcinoma
601389|NCT00315861|cervical carcinoma
601390|NCT00315861|lung carcinoma
601391|NCT00315848|chronic pain
601392|NCT00315848|osteoarthritis
601393|NCT00315848|opioid
601394|NCT00315848|transdermal
601395|NCT00315835|postoperative pain
601396|NCT00315835|opioid
601397|NCT00315835|transdermal
601398|NCT00315822|Surgery
601399|NCT00315822|colon
601400|NCT00315809|leprosy, Philippines
601401|NCT00315796|Mind-Body Intervention
601402|NCT00315796|Distraction
601403|NCT00315796|Biophilic
601404|NCT00315796|Cancer
601405|NCT00315796|pain
601406|NCT00315796|Bedscapes
601407|NCT00315796|procedures
601408|NCT00315796|bone marrow aspirate
601409|NCT00315796|bone marrow biopsy
601410|NCT00315783|hypertrophic cardiomyopathy
601411|NCT00315783|echocardiography
601412|NCT00315783|magnetic resonance imaging
601413|NCT00315770|overweight
601414|NCT00315770|Metabolic syndrome
601415|NCT00315744|moderate asthma
601416|NCT00315744|fluticasone
601417|NCT00315744|children
601418|NCT00315744|salmeterol
601419|NCT00315744|steroid-sparing
601420|NCT00315744|Asthma
601421|NCT00315731|Bexxar
601422|NCT00315731|tositumomab and iodine I 131 tositumomab therapeutic regiment
601423|NCT00315731|fission
601424|NCT00315731|Non-Hodgkin's lymphoma
601425|NCT00315731|Iodine I 131 Tositumomab
601426|NCT00315731|pharmacokinetics
601427|NCT00315731|tellurium
601428|NCT00315718|Hintonia latiflora extract
601429|NCT00315718|Diabetes mellitus type 2
601430|NCT00315718|HbA1c
601431|NCT00315718|Safety
601432|NCT00315718|Liver function tests
601433|NCT00315705|clofarabine
601434|NCT00315705|acute leukemia
601435|NCT00315705|ALL
601436|NCT00315705|AML
601437|NCT00315705|clolar
601438|NCT00315705|CLO218
601439|NCT00315692|Ovarian Neoplasms
601440|NCT00315679|recurrent aphthous stomatitis
601441|NCT00315679|recurrent mouth ulcers
601442|NCT00315679|pentoxifylline
601443|NCT00315679|clinical trial
601444|NCT00315679|double blind
601445|NCT00315679|placebo controlled
601446|NCT00315679|randomized
601447|NCT00315666|Chronic tension-type headache
601448|NCT00315653|Bladder Cancer
601449|NCT00315653|Cancer of Bladder
601450|NCT00315653|Bladder Tumors
601451|NCT00315653|Cancer of the Bladder
601452|NCT00315653|Neoplasms, Bladder
601453|NCT00315640|Elevated IOP due to intravitreal triamcinolone therapy
601454|NCT00315627|Islet Transplantation
601455|NCT00315614|Islet Transplantation
601456|NCT00315601|Telithromycin (drug)
601457|NCT00315601|Azithromycin (drug)
601458|NCT00315601|Bronchoalveolar lavage (procedure)
601459|NCT00315601|Pharmacokinetics
601460|NCT00315588|Islet Transplantation
601461|NCT00315575|Dementia
601462|NCT00315575|brain circulation
601463|NCT00315575|disease /disorder proneness /risk
601464|NCT00315575|neuropathology
601465|NCT00315575|neurophysiology
601466|NCT00315575|aging
601467|NCT00315575|apolipoprotein E
601468|NCT00315575|genotype
601469|NCT00315575|hemodynamics
601470|NCT00315575|memory
601471|NCT00315575|temporal lobe /cortex
601472|NCT00315562|stroke
601473|NCT00315562|carotid stenosis
601474|NCT00315562|carotid endarterectomy
601475|NCT00315562|timing
601476|NCT00315549|Tonsillitis
601477|NCT00315549|pharyngitis
601478|NCT00315549|penicillin
601479|NCT00315549|telithromycin
601480|NCT00315549|ketolides
601481|NCT00315549|clinical trials
601482|NCT00315523|Levocetirizine
601483|NCT00315523|Xyzal
601484|NCT00315523|Rhinitis
601485|NCT00315523|Allergic
601486|NCT00315523|Seasonal
601487|NCT00315523|Ragweed
601488|NCT00315510|Ischemia-reperfusion
601489|NCT00315510|Annexin A5
601490|NCT00315497|Giant Cell Arteritis
601491|NCT00315484|Anemia
601492|NCT00315484|chemotherapy
601493|NCT00315484|hemoglobin level
601494|NCT00315484|recombinant human erythropoietin
601495|NCT00315484|epoetin alfa
601496|NCT00315484|darbepoetin alfa
601497|NCT00315471|Vasculitis
601498|NCT00315458|osteoarthritis
601499|NCT00315458|opioid
601500|NCT00315458|transdermal
601501|NCT00315445|chronic back pain
601502|NCT00315445|opioid
601503|NCT00315445|transdermal
601504|NCT00315432|Natural History, Hepatitis C Infection, HIV Infection, HCV/HIV co-infection Ribavirin, Pegylated Interferon, Interferon
601505|NCT00315419|Large Granular Lymphocyte Leukemia
601506|NCT00315419|Amegakaryocytic Thrombocytopenic Purpura
601507|NCT00315419|Idiopathic Pure Red Cell Aplasia
601508|NCT00315419|Paroxysmal Nocturnal Hemoglobinuria
601509|NCT00315406|PAN
601510|NCT00315406|Periarteritis Nodosa
601511|NCT00315393|GPA
601512|NCT00315393|MPA
601513|NCT00315393|WG
601514|NCT00315380|EGPA
601515|NCT00315380|CSS
601516|NCT00315367|Multiple Sclerosis
601517|NCT00315367|Memory impairment
601518|NCT00315354|obesity
601519|NCT00315354|nutrition
601520|NCT00315328|Amblyopia
601521|NCT00315328|Atropine
601522|NCT00315328|Patching
601523|NCT00315315|Nasolacrimal duct obstruction
601524|NCT00315315|Balloon catheter nasolacrimal duct dilation
601525|NCT00315315|Nasolacrimal intubation
601526|NCT00315315|Simple Nasolacrimal duct probing
601527|NCT00315302|Amblyopia
601528|NCT00315302|Atropine
601529|NCT00315302|Plano lens
601530|NCT00315289|Nasolacrimal duct obstruction
601531|NCT00315289|Simple probing
601532|NCT00315289|Balloon catheter dilation
601533|NCT00315289|Nasolacrimal intubation
601534|NCT00315276|ADHD
601535|NCT00315263|DNA
601536|NCT00315263|Genomics
601537|NCT00315263|SNPs
601538|NCT00315263|Neonatology
601539|NCT00315263|Chronic Lung Disease
601540|NCT00315263|Periventricular Brain Injury
601541|NCT00315263|Hypoxic Respiratory Failure
601542|NCT00315250|Parkinson
601543|NCT00315224|Isolated systolic Hypertension
601544|NCT00315224|exercise
601545|NCT00315224|pulse pressure
601546|NCT00315224|endothelium
601547|NCT00315211|Small Cell Lung Cancer Recurrent
601548|NCT00315198|amblyopia
601549|NCT00315198|patching
601550|NCT00315198|visual activities
601551|NCT00315185|Advanced Non-small Cell Lung Cancer
601552|NCT00315185|First Line Treatment
601553|NCT00315172|Adipose Tissue
601554|NCT00315172|Weight Gain
601555|NCT00315172|Pediatric
601556|NCT00315172|Body Composition
601557|NCT00315172|Thermogenesis
601558|NCT00315172|Exercise
601559|NCT00315172|Healthy Volunteer
601560|NCT00315172|HV
601561|NCT00315159|Squamous
601562|NCT00315159|Cell
601563|NCT00315159|Carcinoma
601564|NCT00315159|Vulva
601565|NCT00315159|Sentinel Node
601566|NCT00315146|Body Composition
601567|NCT00315146|Sarcopenia
601568|NCT00315146|Weight loss trials
601569|NCT00315146|Intervention studies
601570|NCT00315146|Elderly
601571|NCT00315133|Diabetes mellitus
601572|NCT00315133|Stem cells
601573|NCT00315133|Autologous stem cell transplantation
601574|NCT00315133|Autoimmune diseases
601575|NCT00315120|Randomized controlled trial
601576|NCT00315120|Low back pain
601577|NCT00315120|Spinal manipulative therapy
601578|NCT00315120|Spinal manipulation
601579|NCT00315120|Osteopathic manipulation
601580|NCT00315120|Osteopathic medicine
601581|NCT00315120|Physical therapy modalities
601582|NCT00315094|home parenteral nutrition
601583|NCT00315081|Schizophrenia
601584|NCT00315081|Hyperprolactinemia
601585|NCT00315081|Risperidone
601586|NCT00315081|Bromocriptin
601587|NCT00315068|arrythmia
601588|NCT00315068|atrial fibrillation
601589|NCT00315068|proteins
601590|NCT00315055|Hepatitis B
601591|NCT00315055|Polio
601592|NCT00315055|Diphtheria
601593|NCT00315055|Pertussis
601594|NCT00315055|H influenzae type b
601595|NCT00315042|Tonsillitis
601596|NCT00315042|pharyngitis
601597|NCT00315042|penicillin
601598|NCT00315042|telithromycin
601599|NCT00315042|ketolides
601600|NCT00315042|clinical trials
601601|NCT00315029|Implementation
601602|NCT00315029|Single embryo transfer
601603|NCT00315029|ICSI
601604|NCT00315029|IVF
601605|NCT00315029|prevention
601606|NCT00315016|albuminuria
601607|NCT00315016|eplerenone
601608|NCT00315016|ACE inhibition
601609|NCT00315016|renal function
601610|NCT00315016|endothelial function
601611|NCT00315003|Otitis Media
601612|NCT00315003|Suppurative
601613|NCT00315003|Purulent
601614|NCT00315003|Ketolide
601615|NCT00315003|Azithromycin
601616|NCT00315003|Telithromycin
601617|NCT00315003|Controlled Clinical Trials
601618|NCT00314990|Venous thrombosis
601619|NCT00314990|Deep-vein thrombosis
601620|NCT00314990|Pulmonary embolism
601621|NCT00314990|Homocysteine
601622|NCT00314990|B-vitamins
601623|NCT00314990|Folate
601624|NCT00314990|Vitamin B12
601625|NCT00314990|Vitamin B6
601626|NCT00314977|Large resectable breast cancer
601627|NCT00314977|Locally advanced breast cancer
601628|NCT00314977|Neoadjuvant therapy
601629|NCT00314951|CDAD, Clostridium difficile, diarrhea
601630|NCT00314951|Clostridium difficile-Associated Diarrhea
601631|NCT00314925|advanced carcinoma
601632|NCT00314925|carcinoid
601633|NCT00314925|neuroendocrine features
601634|NCT00314925|oncolytic virus
601635|NCT00314925|phase I study
601636|NCT00314925|dose escalation study
601637|NCT00314925|rhabdomyosarcoma
601638|NCT00314925|alveolar rhabdomyosarcoma
601639|NCT00314925|medulloblastoma
601640|NCT00314925|rhabdoid
601641|NCT00314925|glioblastoma
601642|NCT00314925|ewing's sarcoma
601643|NCT00314925|pediatric oncologies
601644|NCT00314925|neuroblastoma
601645|NCT00314925|wilms' tumor
601646|NCT00314925|retinoblastoma
601647|NCT00314925|Large cell lung cancer
601648|NCT00314899|Malaria, Plasmodium falciparum, Kenya, immunity
601649|NCT00314886|Diet
601650|NCT00314886|Fiber
601651|NCT00314886|Irritable Bowel Syndrome
601652|NCT00314886|Colonic Flora
601653|NCT00314873|Thymic malignancy
601654|NCT00314873|Thymic Carcinoma
601655|NCT00314860|Restless Legs Syndrome
601656|NCT00314847|Myocardial infarction
601657|NCT00314847|Cardiogenic shock
601658|NCT00314847|Extracorporeal Life Support-Impella
601659|NCT00314834|hemodialysis
601660|NCT00314834|intradialytic parenteral nutrition
601661|NCT00314834|oral supplementation
601662|NCT00314834|survival
601663|NCT00314834|hospitalization
601664|NCT00314834|serum albumin
601665|NCT00314834|prealbumin
601666|NCT00314834|transthyretin
601667|NCT00314821|bipolar disorder, ropinirole, depression
601668|NCT00314808|primary gliomas
601669|NCT00314808|brain tumors
601670|NCT00314808|vomiting
601671|NCT00314808|appetite suppression
601672|NCT00314808|appetite
601673|NCT00314795|pure red cell aplasia
601674|NCT00314795|PRCA
601675|NCT00314795|chronic kidney disease
601676|NCT00314795|CKD
601677|NCT00314795|chronic renal failure
601678|NCT00314795|CRF
601679|NCT00314795|anemia
601680|NCT00314795|erythropoietin
601681|NCT00314795|EPO
601682|NCT00314795|erythropoiesis stimulating agent
601683|NCT00314795|ESA
601684|NCT00314795|hemoglobin
601685|NCT00314795|Hb
601686|NCT00314795|Hgb
601687|NCT00314795|red blood cell
601688|NCT00314795|red blood cell production
601689|NCT00314782|metastatic hormone-refractory prostate cancer (HRPC)
601690|NCT00314769|Transcranial Direct Current Stimulation (TDCS)
601691|NCT00314769|Motor Learning
601692|NCT00314769|Transcranial Magnetic Stimulation (TMS)
601693|NCT00314769|Cortical Re-Organization
601694|NCT00314769|Neuroplasticity
601695|NCT00314769|Neurorehabilitation
601696|NCT00314769|TBI
601697|NCT00314769|Stroke
601698|NCT00314769|Healthy Volunteer
601699|NCT00314769|HV
601700|NCT00314756|imiquimod cream
601701|NCT00314756|nodular basal cell carcinoma
601702|NCT00314756|curettage
601703|NCT00314743|Patients with Non-Hodgkins Lymphoma or Multiple Myeloma
601704|NCT00314704|shock
601705|NCT00314704|hypotension
601706|NCT00314704|circulatory failure
601707|NCT00314704|septic shock
601708|NCT00314704|cardiogenic shock
601709|NCT00314691|fetal DNA
601710|NCT00314691|prenatal diagnosis
601711|NCT00314691|maternal plasma
601712|NCT00314691|Diagnostic potential of cell-free fetal DNA circulating in maternal blood
601713|NCT00314678|Ovarian
601714|NCT00314678|Peritoneal
601715|NCT00314665|Sarcoidosis
601716|NCT00314665|Chronic Uveitis
601717|NCT00314665|Uveitis
601718|NCT00314665|Thalidomide
601719|NCT00314652|Osteoarthritis
601720|NCT00314652|chronic pain
601721|NCT00314652|opioid
601722|NCT00314652|transdermal
601723|NCT00314626|Antiviral efficacy
601724|NCT00314626|Tolerability
601725|NCT00314626|Immunologic response
601726|NCT00314626|Virologic response
601727|NCT00314626|HIV
601728|NCT00314613|Schizophreniform; Schizophrenia; Schizoaffective Disorders
601729|NCT00314600|Fracture
601730|NCT00314600|Forearm
601731|NCT00314600|Midshaft
601732|NCT00314600|Child
601733|NCT00314600|Cast
601734|NCT00314587|fracture
601735|NCT00314587|forearm
601736|NCT00314587|midshaft
601737|NCT00314587|child
601738|NCT00314587|treatment
601739|NCT00314574|Persistent Asthma
601740|NCT00314574|EXTRA
601741|NCT00314574|Xolair
601742|NCT00314574|Difficult Breathing
601743|NCT00314561|Rosiglitazone
601744|NCT00314561|Pioglitazone
601745|NCT00314561|FMD
601746|NCT00314561|PWV
601747|NCT00314561|atherosclerosis
601748|NCT00314548|ARDS
601749|NCT00314548|pulmonary hypertension
601750|NCT00314548|prostacyclins
601751|NCT00314119|Tumor Imaging
601752|NCT00314119|NF1
601753|NCT00314119|Neurofibromatosis
601754|NCT00314106|Clinical Response
601755|NCT00314106|Stage IV Melanoma
601756|NCT00314106|Adoptive Cell Therapy
601757|NCT00314106|Tumor Infiltrating Lymphocytes
601758|NCT00314106|Immunologic Response
601759|NCT00314106|Metastatic Melanoma
601760|NCT00314093|Clinical Response
601761|NCT00314093|Stage IV Melanoma
601762|NCT00314093|Immunotoxin
601763|NCT00314093|T Regulatory Cells
601764|NCT00314093|CD25+ Cells
601765|NCT00314093|Metastatic Melanoma
601766|NCT00314080|Botulism
601767|NCT00314080|Botulinum anti-toxin
601768|NCT00314080|Repetitive nerve stimulation
601769|NCT00314080|Respiratory failure
601770|NCT00314067|Quality of Health Care
601771|NCT00314067|Primary Health Care
601772|NCT00314067|Education
601773|NCT00314067|E-Learning
601774|NCT00314067|Alcohol-related Disorders
601775|NCT00314054|Hepatitis C
601776|NCT00314054|Hepatic Impairment
601777|NCT00314054|Healthy Volunteer
601778|NCT00314054|Phase 1
601779|NCT00314054|Hepacivirus
601780|NCT00314041|Infant
601781|NCT00314041|Conjugate vaccine
601782|NCT00314041|Meningococcal
601783|NCT00314041|Antibody
601784|NCT00314041|Immune memory
601785|NCT00314041|Health
601786|NCT00314041|Meningococcal Vaccines
601787|NCT00314028|African American
601788|NCT00314028|Men
601789|NCT00314028|Sexually Transmitted Diseases
601790|NCT00314028|Condoms
601791|NCT00314002|Massive pulmonary embolism
601792|NCT00314002|Catheter thrombectomy
601793|NCT00314509|Asthma
601794|NCT00314509|Ciclesonide
601795|NCT00314509|Formoterol Fumarate
601796|NCT00314509|Long-acting beta2-agonists
601797|NCT00314509|LABA
601798|NCT00314509|Steroids
601799|NCT00314483|Mesenchymal stem cells
601800|NCT00314483|GVHD
601801|NCT00314483|Treatment
601802|NCT00314483|Steroid refractory GVHD
601803|NCT00314457|pain control
601804|NCT00314457|intra-articular pain control device
601805|NCT00314457|ACL repair
601806|NCT00314457|Bankart Repair
601807|NCT00314444|Psychogenic
601808|NCT00314444|Psychogenic Movement Disorders
601809|NCT00314431|neonatal chronic lung disease
601810|NCT00314431|bronchopulmonary dysplasia
601811|NCT00314431|prematurity
601812|NCT00314431|telephone follow up
601813|NCT00314431|care coordination
601814|NCT00314431|children with special health care needs
601815|NCT00314418|Colonoscopy
601816|NCT00314418|technique
601817|NCT00314418|time
601818|NCT00314418|duration
601819|NCT00314418|position
601820|NCT00314418|abdominal pressure
601821|NCT00314405|sentinel lymph node
601822|NCT00314405|SLN
601823|NCT00314405|probe
601824|NCT00314405|breast cancer
601825|NCT00314405|lymphoscintigraphy
601826|NCT00314405|methylene blue dye
601827|NCT00314392|Experimental pain
601828|NCT00314392|Placebo analgesia
601829|NCT00314392|Heart rate variability
601830|NCT00314392|Skin conductance
601831|NCT00314379|Diabetes
601832|NCT00314379|Endothelial Function
601833|NCT00314379|Haptoglobin
601834|NCT00314366|stem cell
601835|NCT00314366|autologous
601836|NCT00314366|ischemia
601837|NCT00314353|NSABP
601838|NCT00314353|bevacizumab
601839|NCT00314353|capecitabine
601840|NCT00314353|oxaliplatin
601841|NCT00314353|irinotecan
601842|NCT00314353|rectal cancer
601843|NCT00314353|colon cancer
601844|NCT00314353|colorectal cancer
601845|NCT00314340|Chronic Pain
601846|NCT00314340|Opioids
601847|NCT00314327|first episode
601848|NCT00314327|schizophrenia
601849|NCT00314327|risperidone
601850|NCT00314314|Bipolar Disorder, memory, executive functioning
601851|NCT00314301|cerebral palsy
601852|NCT00314301|resistance
601853|NCT00314301|movement
601854|NCT00314301|biomechanics
601855|NCT00314288|Parkinson's Disease
601856|NCT00314288|Dyskinesia
601857|NCT00314288|L-dopa-induced dyskinesia
601858|NCT00314275|Pharmacokinetics
601859|NCT00314275|Coronary Artery Disease
601860|NCT00314275|PCI
601861|NCT00314275|Drug Eluting Stent
601862|NCT00314262|Skin Lesions
601863|NCT00314262|Premalignant Lesion
601864|NCT00314249|Fibromyalgia
601865|NCT00314236|Cartilage repair
601866|NCT00314236|Cartilage
601867|NCT00314236|Knee
601868|NCT00314236|Knee Pain
601869|NCT00314236|Microfracture
601870|NCT00314236|arthroscopy
601871|NCT00314236|bone marrow stimulation
601872|NCT00314236|Chondrogenesis
601873|NCT00314236|Scaffold
601874|NCT00314236|Chitosan
601875|NCT00314236|A02.165.165
601876|NCT00314236|A10.165.382.332
601877|NCT00314236|G07.574.500.325.377.625.180
601878|NCT00314236|A10.165.382.400
601879|NCT00314236|Articular Cartilage Repair
601880|NCT00314210|Generalised Anxiety Disorder
601881|NCT00314197|automated counseling system
601882|NCT00314197|telephone-based intervention
601883|NCT00314197|behavior change
601884|NCT00314184|Bipolar I disorder.
601885|NCT00314171|open-angle glaucoma
601886|NCT00314171|ocular hypertension
601887|NCT00314132|Japanese Encephalitis
601888|NCT00314132|Encephalitis virus
601889|NCT00314132|ChimeriVax™-JE Vaccine
601890|NCT00313976|Multiple Sclerosis
601891|NCT00313976|Early secondary progressive Multiple Sclerosis
601892|NCT00313963|Anemia, Sickle Cell
601893|NCT00313963|Magnesium Sulfate
601894|NCT00313963|pediatric
601895|NCT00313950|measles
601896|NCT00313950|rubella
601897|NCT00313950|mumps
601898|NCT00313950|hepatitis A
601899|NCT00313924|URGENCY FREQUENCY SYNDROME
601900|NCT00313924|URGE INCONTINENCE
601901|NCT00313911|Diphtheria
601902|NCT00313911|Tetanus
601903|NCT00313911|Pertussis
601904|NCT00313911|Recombinant Hepatitis B
601905|NCT00313911|Poliomyelitis
601906|NCT00313911|Haemophilus influenzae type b
601907|NCT00313911|Tetanus protein
601908|NCT00313898|quality of sexual life, Mild erectile dysfunction
601909|NCT00313872|gastric cancer
601910|NCT00313872|chemotherapy
601911|NCT00313872|irinotecan
601912|NCT00313872|docetaxel
601913|NCT00313859|colorectal cancer
601914|NCT00313859|metastatic
601915|NCT00313846|Chronic pain
601916|NCT00313846|opioid
601917|NCT00313846|transdermal
601918|NCT00313846|osteoarthritis
601919|NCT00313833|Chronic pain
601920|NCT00313833|elderly
601921|NCT00313833|supervised living
601922|NCT00313833|opioid
601923|NCT00313833|transdermal
601924|NCT00313820|Post-stroke pain, pregabalin
601925|NCT00313807|contrast nephropathy
601926|NCT00313807|renal failure
601927|NCT00313807|Travasol
601928|NCT00313781|randomized
601929|NCT00313781|non-comparative
601930|NCT00313781|efficacy
601931|NCT00313768|advanced carcinoma, non-small cell lung, Phase II, paclitaxel, Taxol, carboplatin, Paraplatin, bevacizumab, Avastin, PF-3512676, immunotherapy, immunomodulator
601932|NCT00313755|colonoscopy, narrow band imaging,
601933|NCT00313755|high definition endoscopy
601934|NCT00313755|colorectal cancer
601935|NCT00313755|dysplasia
601936|NCT00313755|hereditary non-polyposis colorectal cancer
601937|NCT00313755|Lynch Syndrome
601938|NCT00313755|HNPCC
601939|NCT00313729|adult oligodendroglioma
601940|NCT00313729|adult mixed glioma
601941|NCT00313729|adult diffuse astrocytoma
601942|NCT00313729|adult pilocytic astrocytoma
601943|NCT00313729|adult pineal gland astrocytoma
601944|NCT00313716|anemia
601945|NCT00313716|traumatic brain injury
601946|NCT00313716|recombinant human erythropoietin
601947|NCT00313716|rhEpo
601948|NCT00313716|erythropoietin
601949|NCT00313716|TBI
601950|NCT00313716|Epo
601951|NCT00313703|headache
601952|NCT00313703|emergency department
601953|NCT00313703|migraine
601954|NCT00313703|recurrent headache
601955|NCT00313690|Lung Cancer
601956|NCT00313677|muscular dystrophy
601957|NCT00313677|MD
601958|NCT00313677|fukutin-related protein gene
601959|NCT00313677|limb girdle
601960|NCT00313677|FKRP gene
601961|NCT00313677|congenital muscular dystrophy
601962|NCT00313677|childhood onset LGMD
601963|NCT00313677|adult onset LGMD
601964|NCT00313677|POMT1
601965|NCT00313677|POMT2
601966|NCT00313677|POMGnT
601967|NCT00313677|LARGE
601968|NCT00313677|alpha dystroglycan
601969|NCT00313677|dystroglycanopathy
601970|NCT00313677|ISPD
601971|NCT00313677|DPM
601972|NCT00313677|GMPPB
601973|NCT00313677|B3GNT1
601974|NCT00313677|B3GALNT2
601975|NCT00313677|GTDC2
601976|NCT00313677|TMEM5
601977|NCT00313677|Fukutin
601978|NCT00313677|DAG1
601979|NCT00313677|POMK
601980|NCT00313625|stage I multiple myeloma
601981|NCT00313625|stage II multiple myeloma
601982|NCT00313625|stage III multiple myeloma
601983|NCT00313625|refractory multiple myeloma
601984|NCT00313599|recurrent breast cancer
601985|NCT00313599|stage IV breast cancer
601986|NCT00313599|recurrent non-small cell lung cancer
601987|NCT00313599|stage IV non-small cell lung cancer
601988|NCT00313599|recurrent prostate cancer
601989|NCT00313599|stage IV prostate cancer
601990|NCT00313599|recurrent bladder cancer
601991|NCT00313599|stage IV bladder cancer
601992|NCT00313599|recurrent gastric cancer
601993|NCT00313599|stage IV gastric cancer
601994|NCT00313599|recurrent esophageal cancer
601995|NCT00313599|stage IV esophageal cancer
601996|NCT00313599|recurrent ovarian germ cell tumor
601997|NCT00313599|stage IV ovarian germ cell tumor
601998|NCT00313599|adult central nervous system germ cell tumor
601999|NCT00313599|ovarian choriocarcinoma
602000|NCT00313599|ovarian dysgerminoma
602001|NCT00313599|ovarian embryonal carcinoma
602002|NCT00313599|ovarian yolk sac tumor
602003|NCT00313599|ovarian mixed germ cell tumor
602004|NCT00313599|recurrent ovarian epithelial cancer
602005|NCT00313599|stage IV ovarian epithelial cancer
602006|NCT00313599|recurrent extragonadal non-seminomatous germ cell tumor
602007|NCT00313599|recurrent extragonadal seminoma
602008|NCT00313599|stage IV extragonadal non-seminomatous germ cell tumor
602009|NCT00313599|stage IV extragonadal seminoma
602010|NCT00313599|recurrent extragonadal germ cell tumor
602011|NCT00313573|unspecified adult solid tumor, protocol specific
602012|NCT00313573|pain
602013|NCT00313573|depression
602014|NCT00313560|adenocarcinoma of the pancreas
602015|NCT00313560|stage I pancreatic cancer
602016|NCT00313560|stage II pancreatic cancer
602017|NCT00313547|Blood pressure
602018|NCT00313547|Hypertension
602019|NCT00313547|Renin
602020|NCT00313547|Aldosterone
602021|NCT00313547|Heart rate variability
602022|NCT00313534|recurrent prostate cancer
602023|NCT00313534|stage IIB prostate cancer
602024|NCT00313534|stage IIA prostate cancer
602025|NCT00313534|stage III prostate cancer
602026|NCT00313534|stage I prostate cancer
602027|NCT00313521|untreated childhood cerebellar astrocytoma
602028|NCT00313521|childhood high-grade cerebral astrocytoma
602029|NCT00313508|stage IV melanoma
602030|NCT00313508|recurrent melanoma
602031|NCT00313508|ciliary body and choroid melanoma, medium/large size
602032|NCT00313508|recurrent intraocular melanoma
602033|NCT00313508|metastatic intraocular melanoma
602034|NCT00313508|extraocular extension melanoma
602035|NCT00313508|iris melanoma
602036|NCT00313495|Huntington disease, observational, family members, biomarker
602037|NCT00313469|Pharmacokinetics/Pharmacodynamics
602038|NCT00313469|Elderly
602039|NCT00313469|Anticoagulants
602040|NCT00313443|Anti-Arrhythmia Agents
602041|NCT00313443|Amiodarone, chronic treatment
602042|NCT00313443|Amiodarone, adverse effects
602043|NCT00313443|Biopsy, Fine-Needle, Adipose tissue
602044|NCT00313443|Drug concentrations in tissues
602045|NCT00313443|Drug accumulation in tissues
602046|NCT00313430|Urine concentration ability
602047|NCT00313430|chronic renal insufficiency
602048|NCT00313430|hypertension
602049|NCT00313430|aquaporin2
602050|NCT00313430|Patients with chronic renal insufficiency
602051|NCT00313430|Patients with hypertension
602052|NCT00313430|Healthy volunteers
602053|NCT00313417|Creatine
602054|NCT00313417|major depressive disorders
602055|NCT00313404|Norovirus
602056|NCT00313404|Gastroenteritis
602057|NCT00313404|Clinical Trial
602058|NCT00313404|Stomach flu
602059|NCT00313378|Thoracotomy
602060|NCT00313378|Neuropathic pain
602061|NCT00313378|Nerve trauma
602062|NCT00313378|Ketamine
602063|NCT00313378|NMDA receptors
602064|NCT00313352|adult
602065|NCT00313352|cardiac
602066|NCT00313352|transposition of great arteries
602067|NCT00313352|beta-adrenergic blockers
602068|NCT00313339|myocardial infarction
602069|NCT00313339|bone marrow
602070|NCT00313339|cd34+
602071|NCT00313339|stem cells
602072|NCT00313326|Adaptive Support ventilation
602073|NCT00313326|Weaning
602074|NCT00313248|Breast Cancer
602075|NCT00313248|Metastatic Breast Cancer
602076|NCT00313235|Dendritic Vaccine
602077|NCT00313235|Melanoma
602078|NCT00313235|Cyclophosphamide (CPA)
602079|NCT00313222|CTEPH
602080|NCT00313222|bosentan
602081|NCT00313209|Roflumilast
602082|NCT00313209|Salmeterol
602083|NCT00313209|COPD
602084|NCT00313209|Chronic obstructive pulmonary disease
602085|NCT00313196|Pulmonary Hypertension
602086|NCT00313196|Sickle Cell Disease
602087|NCT00313196|Sickle cell anemia
602088|NCT00313196|bosentan
602089|NCT00313196|ASSET
602090|NCT00313196|ASSET-2
602091|NCT00313183|Type 1 Diabetes
602092|NCT00313183|pediatric
602093|NCT00313183|pramlintide
602094|NCT00313183|Symlin
602095|NCT00313183|Amylin
602096|NCT00313170|oncology
602097|NCT00313170|cancer
602098|NCT00313170|breast cancer
602099|NCT00313157|Atrial fibrillation
602100|NCT00313131|bacterial vaginosis
602101|NCT00313131|vaginal candidiasis
602102|NCT00313131|trichomoniasis
602103|NCT00313131|vaginitis
602104|NCT00313131|Ghana
602105|NCT00313131|Togo
602106|NCT00313131|Mali
602107|NCT00313131|Guinea
602108|NCT00313118|oxidative stress parameters
602109|NCT00313105|smoking cessation
602110|NCT00313105|smokeless tobacco
602111|NCT00313105|nicotine patch
602112|NCT00313105|nicotine buccal tablets
602113|NCT00313105|retreatment
602114|NCT00313105|adherence
602115|NCT00313092|OSAS
602116|NCT00313092|glaucoma
602117|NCT00313092|MMP
602118|NCT00313066|CTGF
602119|NCT00313066|fibrogenic cytokine
602120|NCT00313066|FGF
602121|NCT00313066|pleural fibrosis
602122|NCT00313040|physical activity
602123|NCT00313040|sedentary
602124|NCT00313040|behavioral medicine
602125|NCT00313040|motivational interviewing
602126|NCT00313014|Low back pain
602127|NCT00313014|opioid
602128|NCT00313014|transdermal
602129|NCT00313014|Butrans
602130|NCT00312988|Ovarian cancer
602131|NCT00312962|Schizoaffective Disorder
602132|NCT00312962|Cognitive Remediation
602133|NCT00312962|fMRI
602134|NCT00312949|Patient participation
602135|NCT00312949|Patient education
602136|NCT00312949|Consumer involvement
602137|NCT00312936|Medication adherence
602138|NCT00312936|Medication compliance
602139|NCT00312936|Quality of Life
602140|NCT00312936|Stress reduction
602141|NCT00312936|mindfulness based stress reduction
602142|NCT00312936|HIV/AIDS
602143|NCT00312936|treatment experienced
602144|NCT00312923|HIV
602145|NCT00312923|lipids
602146|NCT00312923|dyslipidemia
602147|NCT00312923|policosanol
602148|NCT00312923|treatment experienced
602149|NCT00312910|Cirrhosis
602150|NCT00312910|Probiotics
602151|NCT00312910|Hepatic encephalopathy
602152|NCT00312910|Ammonia
602153|NCT00312897|Adolescents
602154|NCT00312897|Depression
602155|NCT00312897|Fish Oil
602156|NCT00312897|Omega-3 Fatty Acids
602157|NCT00312897|Psychiatry
602158|NCT00312884|telemonitoring
602159|NCT00312884|heart failure
602160|NCT00312884|randomised
602161|NCT00312884|hospitalisation
602162|NCT00312884|HomMed
602163|NCT00312871|Chronic renal failure
602164|NCT00312871|Anemia
602165|NCT00312871|Renal replacement therapy
602166|NCT00312871|Epoetin
602167|NCT00312871|Epoetin alfa
602168|NCT00312871|erythropoietin
602169|NCT00312871|Chronic kidney failure
602170|NCT00312871|end-stage renal disease
602171|NCT00312858|Hepatitis A Virus
602172|NCT00312845|B-cell Non-Hodgkin's Lymphoma
602173|NCT00312832|HIV
602174|NCT00312832|d4T
602175|NCT00312832|TDF
602176|NCT00312832|lipoatrophy
602177|NCT00312832|treatment experienced
602178|NCT00312832|HIV-infection
602179|NCT00312819|Non-small cel lung cancer
602180|NCT00312819|chemotherapy
602181|NCT00312819|randomized phaseII
602182|NCT00312819|disulfiram
602183|NCT00312819|antiangiogenesis
602184|NCT00312819|placebo
602185|NCT00312806|Gastroesophageal Reflux Disease
602186|NCT00312806|GERD
602187|NCT00312806|Pantoprazole
602188|NCT00312806|ReQuestTM
602189|NCT00312793|Anterior Cruciate Ligament reconstruction surgery
602190|NCT00312780|albuminuria
602191|NCT00312780|diabetic nephropathy
602192|NCT00312780|diabetes
602193|NCT00312767|Agalsidase beta
602194|NCT00312767|alpha Galactosidase A
602195|NCT00312767|aGAL
602196|NCT00312767|rh aGAL
602197|NCT00312767|Fabry
602198|NCT00312767|GL3
602199|NCT00312767|Fabrazyme
602200|NCT00312767|dialysis
602201|NCT00312767|hemodialysis
602202|NCT00312741|community-acquired pneumonia
602203|NCT00312741|microbiological tests
602204|NCT00312741|urinary antigen
602205|NCT00312741|selection of antibiotic treatment
602206|NCT00312728|Brain Cancer
602207|NCT00312728|Brain Metastases
602208|NCT00312728|Avastin
602209|NCT00312728|NSCLC
602210|NCT00312728|Lung Cancer
602211|NCT00312728|PASSPORT
602212|NCT00312715|Deiodinase
602213|NCT00312715|Levothyroxine
602214|NCT00312715|Liothyronine
602215|NCT00312715|Lipid Metabolism
602216|NCT00312715|Healthy Volunteer
602217|NCT00312715|HV
602218|NCT00312702|Vaccine
602219|NCT00312702|Malaria
602220|NCT00312702|Liver Stage Antigen-1
602221|NCT00312702|Falciparum Malaria Protein-11
602222|NCT00312702|AS02A
602223|NCT00312702|adjuvant
602224|NCT00312689|congenital
602225|NCT00312689|lacrimal
602226|NCT00312689|stenosis
602227|NCT00312689|bacteria
602228|NCT00312689|microbiological
602229|NCT00312676|Tolerability
602230|NCT00312676|Depakote DR
602231|NCT00312676|Depakote ER
602232|NCT00312676|Elderly
602233|NCT00312676|Conversion
602234|NCT00312663|Vaccine
602235|NCT00312663|Phase I/II
602236|NCT00312663|Malaria
602237|NCT00312663|Liver Stage Antigen -1
602238|NCT00312663|Falciparum Malaria Protein -11
602239|NCT00312663|AS01B
602240|NCT00312663|adjuvant
602241|NCT00312650|ovarian cancer
602242|NCT00312650|recurrent
602243|NCT00312650|progressive
602244|NCT00312637|Breast Cancer Staging
602245|NCT00312624|ICD implantation
602246|NCT00312624|cardiac MRI
602247|NCT00312624|cardiomyopathy
602248|NCT00312624|ventricular arrhythmias
602249|NCT00312624|LVEF 35% or less
602250|NCT00312624|indication for ICD implantation as part of standard of care
602251|NCT00312611|Gastric pacing device
602252|NCT00312611|Obesity
602253|NCT00312598|schizophrenia
602254|NCT00312598|BMI
602255|NCT00312598|weight
602256|NCT00312598|aripiprazole
602257|NCT00312598|antipsychotic
602258|NCT00312598|Mood Disorders with psychotic features
602259|NCT00312585|pregnancy
602260|NCT00312585|acupuncture
602261|NCT00312572|Osteoarthritis, opioid, transdermal
602262|NCT00312559|Parkinson's Disease
602263|NCT00312546|Virus Latency
602264|NCT00312546|Valproic Acid
602265|NCT00312546|Histone Deacetylase
602266|NCT00312533|knee
602267|NCT00312533|injection
602268|NCT00312533|function
602269|NCT00312533|osteoarthritis
602270|NCT00312507|Meconium Aspiration Syndrome
602271|NCT00312507|Surfactant
602272|NCT00312507|Bronchoalveolar Lavage
602273|NCT00312507|newborns
602274|NCT00312468|AIDS
602275|NCT00312455|Substance abuse
602276|NCT00312455|Depression
602277|NCT00312455|Aggression
602278|NCT00312442|Prostate cancer after radiation therapy
602279|NCT00312429|Hematological Malignancies
602280|NCT00312429|Leukemia
602281|NCT00312429|Lymphoma
602282|NCT00312429|Myelodysplasia
602283|NCT00312429|Multiple Myeloma
602284|NCT00312416|Choroidal blood flow
602285|NCT00312416|Clonidin
602286|NCT00312416|Brimonidin
602287|NCT00312403|Glaucoma
602288|NCT00312403|Gene Polymorphism
602289|NCT00312403|Metalloproteinase
602290|NCT00312390|Amblyopia
602291|NCT00312390|Retinal vessel diameters
602292|NCT00312390|Retinal blood flow
602293|NCT00312390|Flicker
602294|NCT00312377|Non-small cell lung cancer
602295|NCT00312377|NSCLC
602296|NCT00312364|toe ulcer
602297|NCT00312364|heel ulcer
602298|NCT00312364|foot ulcer
602299|NCT00312364|diabetic feet
602300|NCT00312364|diabetic foot
602301|NCT00312364|complications of diabetes
602302|NCT00312351|AMD
602303|NCT00312351|Age-Related Macular Degeneration
602304|NCT00312351|Macular Degeneration
602305|NCT00312351|Macugen
602306|NCT00312351|pegaptanib sodium
602307|NCT00312351|ERG
602308|NCT00312351|specular microscopy
602437|NCT00311883|Cystic Fibrosis
602309|NCT00312351|Age-Related Mcular Degeneration (AMD)
602310|NCT00312325|Optic nerve head blood flow
602311|NCT00312325|Choroidal blood flow
602312|NCT00312325|Prednisolone
602313|NCT00312325|Graves´ Ophthalmopathy
602314|NCT00312325|optic neuritis
602315|NCT00312312|Asthma
602316|NCT00312312|Allergic rhinitis
602317|NCT00312312|Atopy
602318|NCT00312312|Exhaled nitric oxide
602319|NCT00312312|Specific immunotherapy
602320|NCT00312312|Atopic diseases
602321|NCT00312299|Double-Blind Method
602322|NCT00312299|Clinical Trials, Randomized
602323|NCT00312299|Lenses, Intraocular
602324|NCT00312299|Prospective Studies
602325|NCT00312299|PMMA
602326|NCT00312299|Visual acuity
602327|NCT00312286|Cervical Neoplasms
602328|NCT00312286|Drug Therapy
602329|NCT00312286|Human Papillomavirus
602330|NCT00312286|Cervical Human Papillomavirus
602331|NCT00312286|Cervical Dysplasia
602332|NCT00312286|Chemoprevention
602333|NCT00312286|High Risk Cervical Human Papillomavirus
602334|NCT00312286|Atypical Squamous Cells of Undetermined Significance
602335|NCT00312286|Low Grade Intraepithelial Lesions
602336|NCT00312273|Heart Arrest
602337|NCT00312273|Cardiopulmonary Resuscitation
602338|NCT00312273|Aminophylline
602339|NCT00312273|Bradycardia
602340|NCT00312273|Humans
602341|NCT00312273|Emergency Medical Services
602342|NCT00312260|Pain
602343|NCT00312260|Analgesia
602344|NCT00312260|Gabapentin
602345|NCT00312260|Amitriptyline
602346|NCT00312260|Pediatrics
602347|NCT00312247|Walking
602348|NCT00312247|Muscle Strength
602349|NCT00312247|Energy Cost
602350|NCT00312247|Quality of Life
602351|NCT00312234|Muscular Disease
602352|NCT00312234|Fibromyalgia
602353|NCT00312234|Exercise Therapy
602354|NCT00312234|Qigong
602355|NCT00312234|Aerobic Exercise
602356|NCT00312234|pediatrics
602357|NCT00312221|Osteoarthritis, opioid, transdermal
602358|NCT00312195|Chronic pain
602359|NCT00312195|opioid
602360|NCT00312195|transdermal
602361|NCT00312195|Butrans™ [BTDS]
602362|NCT00312169|HIV
602363|NCT00312169|NNRTI
602364|NCT00312169|Incomplete virologic suppression
602365|NCT00312169|treatment experienced
602366|NCT00312143|De novo Kidney Transplant recipients, enteric-coated mycophenolate sodium
602367|NCT00312130|Vildaglptin
602368|NCT00312130|Pre-diabetes
602369|NCT00312117|contrast induced nephropathy
602370|NCT00312117|sodium bicarbonate
602371|NCT00312117|cardiac catheterization
602372|NCT00312091|Pharmacokinetics
602373|NCT00312091|Treatment Experienced
602374|NCT00312078|Minimal Hepatic Encephalopathy
602375|NCT00312078|Cirrhosis
602376|NCT00312065|servocontrolled
602377|NCT00312065|radiant warmer
602378|NCT00312065|thermistor
602379|NCT00312065|heat shield
602380|NCT00312052|Coronary Artery Disease
602381|NCT00312039|HIV-1
602382|NCT00312039|treatment experienced
602383|NCT00312026|Plaque Psoriasis
602384|NCT00312026|Hands
602385|NCT00312026|Feet
602386|NCT00312026|Hand
602387|NCT00312013|low molecular weight heparin
602388|NCT00312013|nadroparin
602389|NCT00312013|non-small cell lung cancer
602390|NCT00312013|cancer survival
602391|NCT00312013|prostate cancer
602392|NCT00312013|pancreatic cancer
602393|NCT00312000|colorectal
602394|NCT00312000|cancer
602395|NCT00312000|capecitabine
602396|NCT00312000|irinotecan
602397|NCT00312000|oxaliplatin
602398|NCT00311987|Hypercholesterolemia
602399|NCT00311987|Thyroid hormone
602400|NCT00311987|Diiodothyropropionic acid
602401|NCT00311987|Therapy
602402|NCT00311974|Dihydralazine
602403|NCT00311974|Sympathetic activation
602404|NCT00311974|Fractional sodium excretion
602405|NCT00311961|COPD
602406|NCT00311961|Exacerbations
602407|NCT00311961|Corticosteroids
602408|NCT00311961|Oral
602409|NCT00311961|Intravenous
602410|NCT00311961|Chronic Obstructive Pulmonary Disease (COPD)
602411|NCT00311948|Teen smokers
602412|NCT00311948|Quithelper
602413|NCT00311948|Tobacco
602414|NCT00311948|Tobacco Website
602415|NCT00311948|Website Intervention
602416|NCT00311948|Tobacco counseling
602417|NCT00311948|Tobacco abstinence
602418|NCT00311935|Hernia
602419|NCT00311935|Inguinal
602420|NCT00311935|Groin
602421|NCT00311935|Laparoscopic
602422|NCT00311935|Open
602423|NCT00311935|Abdominal wall
602424|NCT00311922|Diabetes
602425|NCT00311922|Education
602426|NCT00311922|Health Literacy
602427|NCT00311909|Tourette Syndrome
602428|NCT00311909|Deep Brain Stimulation
602429|NCT00311909|Video assessment
602430|NCT00311909|YGTSS
602431|NCT00311909|TSSL
602432|NCT00311896|Cancer
602433|NCT00311896|Thrombosis
602434|NCT00311896|Catheter
602435|NCT00311896|Bemiparin
602436|NCT00311896|Prophylaxis
602438|NCT00311883|Induced sputum
602439|NCT00311883|Lung inflammation
602440|NCT00311857|Cetuximab
602441|NCT00311831|Pediatrics
602442|NCT00311831|Gastroenteritis
602443|NCT00311831|Education
602444|NCT00311792|training
602445|NCT00311792|teaching
602446|NCT00311792|curriculum
602447|NCT00311779|Pediculosis capitis
602448|NCT00311779|Head Lice
602449|NCT00311779|Crawlers
602450|NCT00311779|Ova
602451|NCT00311766|Epidermolysis Bullosa
602452|NCT00311766|cutaneous wound-healing
602453|NCT00311766|chronic wound-healing
602454|NCT00311766|Thymosin Beta 4
602455|NCT00311766|laminin-5
602456|NCT00311753|heparin, thromboprophylaxis, medical patients, acutely ill
602457|NCT00311753|Acutely ill non surgical patients
602458|NCT00311753|Immobilization
602459|NCT00311740|Hypertension,
602460|NCT00311740|Valsartan,
602461|NCT00311740|Hydrochlorothiazide
602462|NCT00311727|Cell-Mediated Immune Responses, Influenza, A/H5N1, Vaccine, sub-study
602463|NCT00311714|Influenza, United Kingdom
602464|NCT00311701|Influenza, pediatric
602465|NCT00311688|IL-2
602466|NCT00311688|Immunomodulatory Therapies
602467|NCT00311675|influenza, A/H5N1, vaccine
602468|NCT00311649|H5N1, Influenza
602469|NCT00311636|stage I breast cancer
602470|NCT00311636|stage II breast cancer
602471|NCT00311636|stage IIIA breast cancer
602472|NCT00311636|stage IIIB breast cancer
602473|NCT00311636|stage IIIC breast cancer
602474|NCT00311623|stage III prostate cancer
602475|NCT00311623|stage I prostate cancer
602476|NCT00311623|stage IIB prostate cancer
602477|NCT00311623|stage IIA prostate cancer
602478|NCT00311623|adenocarcinoma of the prostate
602479|NCT00311610|recurrent colon cancer
602480|NCT00311610|stage IV colon cancer
602481|NCT00311610|recurrent rectal cancer
602482|NCT00311610|stage IV rectal cancer
602483|NCT00311597|unspecified adult solid tumor, protocol specific
602484|NCT00311584|recurrent neuroblastoma
602485|NCT00311571|bedrest
602486|NCT00311571|spaceflight
602487|NCT00311571|Weightlessness
602488|NCT00311571|Countermeasure
602489|NCT00311558|stage IV melanoma
602490|NCT00311558|stage IV adult soft tissue sarcoma
602491|NCT00311558|recurrent melanoma
602492|NCT00311545|recurrent renal cell cancer
602493|NCT00311545|stage IV renal cell cancer
602494|NCT00311545|stage III renal cell cancer
602495|NCT00311519|Subcutaneous hydration
602496|NCT00311519|Hylenex
602497|NCT00311519|Hyaluronidase
602498|NCT00311506|Pulmozyme
602499|NCT00311493|TBE
602500|NCT00311493|vaccine
602501|NCT00311493|adults
602502|NCT00311480|influenza
602503|NCT00311480|pandemic influenza
602504|NCT00311480|influenza vaccine
602505|NCT00311480|adjuvanted influenza vaccine
602506|NCT00311467|renal cell cancer
602507|NCT00311441|TBE, children, vaccine
602508|NCT00311428|Influenza
602509|NCT00311428|Children
602510|NCT00311428|Vaccine
602511|NCT00311415|Prevention of Meningococcal Meningitis
602512|NCT00311415|meningococcal vaccines
602513|NCT00311415|conjugate
602514|NCT00311415|immunology
602515|NCT00311415|infant
602516|NCT00311415|antibody persistence
602517|NCT00311389|Glaucoma
602518|NCT00311389|POAG
602519|NCT00311389|OAG
602520|NCT00311389|OHT
602521|NCT00311350|Safety
602522|NCT00311350|Health
602523|NCT00311350|Pharmacokinetics
602524|NCT00311350|ileus
602525|NCT00311337|VELCADE
602526|NCT00311337|bortezomib
602527|NCT00311337|maintenance treatment
602528|NCT00311337|multiple myeloma
602529|NCT00311337|primary disease
602530|NCT00311324|behavioral intervention
602531|NCT00311311|Kidney transplant
602532|NCT00311311|Renal transplant
602533|NCT00311311|Immunosuppression
602534|NCT00311311|Atherosclerosis
602535|NCT00311311|Graft Rejection
602536|NCT00311298|tuberculosis
602537|NCT00311298|hiv
602538|NCT00311298|diabetes
602539|NCT00311298|protein-energy
602540|NCT00311298|micronutrients
602541|NCT00311285|Electromyography
602542|NCT00311285|Glucocorticoids
602543|NCT00311285|Heart Rate
602544|NCT00311285|Physical workload
602545|NCT00311285|Mental workload
602546|NCT00311285|Ergonomics
602547|NCT00311285|Laparoscopy
602548|NCT00311285|Workload
602549|NCT00311285|Biomechanics
602550|NCT00311272|dendritic cells
602551|NCT00311272|antigens, neoplasm
602552|NCT00311246|Sarcoidosis
602553|NCT00311246|Humira
602554|NCT00311246|Adalimumab
602555|NCT00311246|Tumor Necrosis Factor Inhibitors
602556|NCT00311233|child
602557|NCT00311233|psychosocial
602558|NCT00311233|predictors
602559|NCT00311233|cohort
602560|NCT00311233|recurrent
602561|NCT00311220|tuberculosis
602562|NCT00311220|latent tuberculosis
602563|NCT00311220|tuberculin skin test
602564|NCT00311220|quantiferon TB-RD1
602565|NCT00311220|contact screening
602566|NCT00311220|elderly
602567|NCT00311207|diagnostic kit
602568|NCT00311207|immunochromatography test
602569|NCT00311207|PCR detection kit
602570|NCT00311207|luminex
602571|NCT00311194|Heart failure
602572|NCT00311194|Education
602573|NCT00311194|CD-ROM
602574|NCT00311194|Randomization
602575|NCT00311194|Hospitalization
602576|NCT00311194|Readmission
602577|NCT00311194|Death
602578|NCT00311194|Knowledge
602579|NCT00311181|ICD
602580|NCT00311181|Defibrillation
602581|NCT00311181|ULV
602582|NCT00311181|Tuned
602583|NCT00311155|Olmesartan medoxomil
602584|NCT00311155|Hypertension
602585|NCT00311142|Sleep pattern
602586|NCT00311142|newborn
602587|NCT00311142|actigraphy
602588|NCT00311142|delivery mode
602589|NCT00311142|Parents' approval
602590|NCT00311116|Vitamin E
602591|NCT00311116|Cancer
602592|NCT00311116|pediatrics
602593|NCT00311116|supportive care
602594|NCT00311116|oral mucositis
602595|NCT00311116|Bayesian analysis
602596|NCT00311116|N-of-1 trial
602597|NCT00311116|prophylaxis
602598|NCT00311103|Elderly
602599|NCT00311103|Disability
602600|NCT00311103|Musculoskeletal diseases
602601|NCT00311090|Deep Venous Thrombosis
602602|NCT00311051|Asthma
602603|NCT00311051|Allergens
602604|NCT00311051|house dust mites
602605|NCT00311051|Ramatroban
602606|NCT00311051|Montelukast
602607|NCT00311051|Bronchial Provocation Tests
602608|NCT00311038|ONO-1101
602609|NCT00311038|Landiolol Hydrochloride
602610|NCT00311038|Multi-slice CT
602611|NCT00311038|Coronary Artery Disease
602612|NCT00311025|stroke
602613|NCT00311025|physical therapy
602614|NCT00311025|rehabilitation
602615|NCT00311025|exercise
602616|NCT00311025|longterm follow-up
602617|NCT00311012|Hypertension, Aliskiren
602618|NCT00310999|Cervical Vertebrae
602619|NCT00310999|Intubation, Intratracheal
602620|NCT00310999|Laryngoscopes
602621|NCT00310999|Fluoroscopy
602622|NCT00310986|Attention Deficit Disorder with Hyperactivity
602623|NCT00310986|meditation
602624|NCT00310986|breathing meditation
602625|NCT00310986|Anapanasathi
602626|NCT00310986|randomized controlled trial
602627|NCT00310986|nonpharmacologic treatment
602628|NCT00310986|complementary and alternative medicine
602629|NCT00310973|HIV
602630|NCT00310973|Prevention
602631|NCT00310973|Risk Behavior Reduction
602632|NCT00310973|Roma
602633|NCT00310973|Bulgaria
602634|NCT00310973|HIV seronegativity
602635|NCT00310960|infantile esotropia
602636|NCT00310960|acquired non-accommodative esotropia
602637|NCT00310960|acquired partially accommodative esotropia
602638|NCT00310947|Coronary artery disease
602639|NCT00310947|Coronary flow reserve
602640|NCT00310947|Heart failure
602641|NCT00310947|prospective randomised
602642|NCT00310934|heroin dependence
602643|NCT00310934|methadone
602644|NCT00310934|buprenorphine
602645|NCT00310934|contingency management
602646|NCT00310934|relapse prevention
602647|NCT00310908|Renal
602648|NCT00310908|Colic
602649|NCT00310908|Calculi
602650|NCT00310908|Treatment
602651|NCT00310895|Refractory
602652|NCT00310895|Relapsed
602653|NCT00310882|breast cancer
602654|NCT00310882|digitalis like compounds
602655|NCT00310882|prognostic factor
602656|NCT00310869|Preterm Birth
602657|NCT00310869|Prematurity
602658|NCT00310869|NIDCAP
602659|NCT00310869|Adolescence
602660|NCT00310869|Developmental Care
602661|NCT00310869|Follow-up
602662|NCT00310869|Neurobehavior
602663|NCT00310856|meningitis
602664|NCT00310856|children
602665|NCT00310856|vaccine
602666|NCT00310830|Pulmonary Arterial Hypertension
602667|NCT00310830|Pulmonary hypertension
602668|NCT00310830|Sickle Cell Disease
602669|NCT00310830|Sickle cell anemia
602670|NCT00310830|ASSET
602671|NCT00310830|ASSET-1
602672|NCT00310817|meningitis
602673|NCT00310817|children
602674|NCT00310817|vaccine
602675|NCT00310804|Influenza
602676|NCT00310804|Flu
602677|NCT00310804|Cell-Derived
602678|NCT00310804|Egg-Derived
602679|NCT00310804|Healthy Adults
602680|NCT00310804|Safety
602681|NCT00310804|Immunogenicity
602682|NCT00310804|Vaccination
602683|NCT00310791|anorexia nervosa
602684|NCT00310791|adolescents
602685|NCT00310791|dual-energy x-ray absorptiometry
602686|NCT00310791|dehydroepiandrosterone (DHEA)
602687|NCT00310791|osteoporosis
602688|NCT00310778|High sodium diet
602689|NCT00310778|Low sodium diet
602690|NCT00310778|Renin-angiotensin system blockers
602691|NCT00310778|AT1 receptor (AT1R) antagonist
602692|NCT00310778|ACE inhibition
602693|NCT00310765|abdominal pain
602694|NCT00310765|surgical adhesions
602695|NCT00310011|metastatic transitional cell cancer of the renal pelvis and ureter
602696|NCT00310011|recurrent transitional cell cancer of the renal pelvis and ureter
602697|NCT00310011|transitional cell carcinoma of the bladder
602698|NCT00310011|regional transitional cell cancer of the renal pelvis and ureter
602699|NCT00310011|stage IV bladder cancer
602700|NCT00310011|recurrent bladder cancer
602701|NCT00309998|stage IIIB non-small cell lung cancer
602702|NCT00309998|stage IV non-small cell lung cancer
602703|NCT00309998|adenocarcinoma of the lung
602704|NCT00309998|bronchoalveolar cell lung cancer
602705|NCT00309998|large cell lung cancer
602706|NCT00309998|recurrent non-small cell lung cancer
602707|NCT00309985|metastatic hormone-sensitive prostate cancer
602708|NCT00309985|docetaxel
602709|NCT00309972|stage IIIA non-small cell lung cancer
602710|NCT00309972|stage IIIB non-small cell lung cancer
602711|NCT00309933|cognitive/functional effects
602712|NCT00309933|spiritual concerns
602713|NCT00309933|sexuality and reproductive issues
602714|NCT00309933|psychosocial effects of cancer and its treatment
602715|NCT00309933|cancer survivor
602716|NCT00309933|stage I breast cancer
602717|NCT00309933|stage II breast cancer
602718|NCT00309933|stage IIIA breast cancer
602719|NCT00309933|stage IIIB breast cancer
602720|NCT00309933|stage IIIC breast cancer
602721|NCT00309920|stage IIIA breast cancer
602722|NCT00309920|stage IIIC breast cancer
602723|NCT00309894|adenocarcinoma of the prostate
602724|NCT00309894|recurrent prostate cancer
602725|NCT00309881|refractory chronic lymphocytic leukemia
602726|NCT00309881|stage I chronic lymphocytic leukemia
602727|NCT00309881|stage II chronic lymphocytic leukemia
602728|NCT00309881|stage III chronic lymphocytic leukemia
602729|NCT00309881|stage IV chronic lymphocytic leukemia
602730|NCT00309868|heart catheterization
602731|NCT00309868|echocardiogram
602732|NCT00309868|nesiritide
602733|NCT00309842|blastic phase chronic myelogenous leukemia
602734|NCT00309842|primary myelofibrosis
602735|NCT00309842|chronic myelomonocytic leukemia
602736|NCT00309842|myelodysplastic syndromes
602737|NCT00309842|juvenile myelomonocytic leukemia
602738|NCT00309842|recurrent adult Burkitt lymphoma
602739|NCT00309842|recurrent adult immunoblastic large cell lymphoma
602740|NCT00309842|recurrent lymphoblastic lymphoma
602741|NCT00309842|recurrent childhood acute myeloid leukemia
602742|NCT00309842|recurrent childhood large cell lymphoma
602743|NCT00309842|recurrent follicular lymphoma
602744|NCT00309842|recurrent marginal zone lymphoma
602745|NCT00309842|recurrent small lymphocytic lymphoma
602746|NCT00309842|refractory chronic lymphocytic leukemia
602747|NCT00309842|refractory multiple myeloma
602748|NCT00309842|chronic myelogenous leukemia
602749|NCT00309842|secondary acute myeloid leukemia
602750|NCT00309842|secondary myelodysplastic syndromes
602751|NCT00309842|multiple myeloma
602752|NCT00309842|adult lymphoblastic lymphoma
602753|NCT00309842|refractory anemia with excess blasts
602754|NCT00309842|refractory anemia
602755|NCT00309842|Burkitt lymphoma
602756|NCT00309842|childhood large cell lymphoma
602757|NCT00309842|adult Burkitt lymphoma
602758|NCT00309842|mantle cell lymphoma
602759|NCT00309842|childhood lymphoblastic lymphoma
602760|NCT00309842|childhood myelodysplastic syndromes
602761|NCT00309816|Exercise stress test
602762|NCT00309803|Carotid artery
602763|NCT00309803|distal protection device
602764|NCT00309790|exercise stress test
602765|NCT00309777|hypercholesterolemia
602766|NCT00309777|kowa
602767|NCT00309777|dyslipidemia
602768|NCT00309777|pitavastatin
602769|NCT00309777|NK-104
602770|NCT00309777|Primary Hypercholesterolemia or Combined Dyslipidemia
602771|NCT00310726|Mother to Child Transmission of HIV
602772|NCT00310726|Postnatal HIV transmission
602773|NCT00310726|HIV
602774|NCT00310726|Breastfeeding
602775|NCT00310726|Perinatal HIV Transmission
602776|NCT00310726|HIV Seronegativity
602777|NCT00310713|Prevention of Meningococcal Meningitis
602778|NCT00310713|vaccines
602779|NCT00310713|conjugate
602780|NCT00310713|immunology
602781|NCT00310713|children
602782|NCT00310713|antibody persistence
602783|NCT00310700|Prevention of Meningococcal Meningitis
602784|NCT00310700|vaccines, conjugate
602785|NCT00310700|immunology
602786|NCT00310700|infant
602787|NCT00310700|antibody persistence
602788|NCT00310687|Prevention of Meningococcal Meningitis
602789|NCT00310687|vaccines
602790|NCT00310687|conjugate
602791|NCT00310687|immunology
602792|NCT00310687|antibody persistence
602793|NCT00310674|Prevention of Meningococcal Meningitis
602794|NCT00310674|meningococcal vaccines
602795|NCT00310674|conjugate
602796|NCT00310674|Immunology
602797|NCT00310674|infant
602798|NCT00310661|sarizotan
602799|NCT00310661|neuroleptic-induced tardive dyskinesia
602800|NCT00310648|Influenza, elderly, vaccine
602920|NCT00310167|Marginal zone lymphoma
602801|NCT00310635|Prevention of meningococcal infection
602802|NCT00310622|HyperQ
602803|NCT00310622|Ischemia
602804|NCT00310622|dobutamine
602805|NCT00310609|Structural abnormalities of the aortic arch and cerebral branches
602806|NCT00310596|ECG safety
602807|NCT00310583|tactile hyperalgesia
602808|NCT00310583|neuropathic pain
602809|NCT00310583|enriched design
602810|NCT00310583|peripheral nerve lesion
602811|NCT00310583|plexus lesion
602812|NCT00310583|radicular lesion
602813|NCT00310583|spinal lesion
602814|NCT00310583|polyneuropathy
602815|NCT00310583|postzosteric neuralgia
602816|NCT00310570|distal
602817|NCT00310570|interphalangeal
602818|NCT00310570|extensor tendon
602819|NCT00310570|avulsion
602820|NCT00310505|visceral leishmaniasis
602821|NCT00310505|amphotericin B
602822|NCT00310505|Kala-azar
602823|NCT00310479|Magnetic Resonance Imaging
602824|NCT00310479|prostate cancer imaging
602825|NCT00310479|3T MRS
602826|NCT00310479|functional imaging
602827|NCT00310440|Degenerative disc disease
602828|NCT00310440|P-15 Bone Putty
602829|NCT00310440|Bone graft
602830|NCT00310440|Cervical discectomy
602831|NCT00310440|Cervical spine
602832|NCT00310427|Anxiety
602833|NCT00310427|Alcohol Dependence
602834|NCT00310427|Alcoholism
602835|NCT00310414|Imaging Studies
602836|NCT00310414|Botulinum Toxin
602837|NCT00310414|Writer's Cramp
602838|NCT00310414|Focal Hand Dystonia
602839|NCT00310414|FHD
602840|NCT00310414|Writer Cramp
602841|NCT00310414|Healthy Volunteer
602842|NCT00310414|HV
602843|NCT00310401|brain death
602844|NCT00310401|organ donor
602845|NCT00310401|pulmonary edema
602846|NCT00310401|albuterol
602847|NCT00310401|hypoxia
602848|NCT00310401|lung transplantation
602849|NCT00310401|infiltrates
602850|NCT00310388|Partial Seizures
602851|NCT00310388|Epilepsy
602852|NCT00310388|RTG115097
602853|NCT00310388|Complex Partial Seizures
602854|NCT00310388|Anticonvulsant
602855|NCT00310388|Potassium Channels
602856|NCT00310388|Epilepsies, Partial
602857|NCT00310375|Epilepsy
602858|NCT00310375|Partial Seizures
602859|NCT00310375|Potassium Channels
602860|NCT00310375|Anticonvulsant
602861|NCT00310375|Complex Partial Seizures
602862|NCT00310375|Epilepsies, Partial
602863|NCT00310375|RTG115098
602864|NCT00310362|telephone
602865|NCT00310362|telemedicine
602866|NCT00310362|mass screening
602867|NCT00310362|patient education
602868|NCT00310362|Patient compliance
602869|NCT00310349|pneumococcal vaccine
602870|NCT00310349|clinical trial
602871|NCT00310349|Indigenous
602872|NCT00310349|Maternal
602873|NCT00310349|Streptococcus pneumoniae
602874|NCT00310323|sleep apnea
602875|NCT00310323|phenotyping
602876|NCT00310323|cytochrome P450
602877|NCT00310323|drug metabolism
602878|NCT00310323|child
602879|NCT00310310|Continuous positive airway pressure
602880|NCT00310310|Patient compliance
602881|NCT00310310|Self-care
602882|NCT00310284|Insomnia
602883|NCT00310284|Sleep
602884|NCT00310271|DNA vaccine, immunotherapy, HSV-2, PMED
602885|NCT00310245|CD4-guided STI
602886|NCT00310245|Keywords:
602887|NCT00310245|HAART
602888|NCT00310245|Clinical outcome
602889|NCT00310245|Resistance
602890|NCT00310245|Costs
602891|NCT00310245|Prognostic factors
602892|NCT00310245|pulse therapy
602893|NCT00310245|treatment experienced
602894|NCT00310245|treatment interruption
602895|NCT00310232|Quality of Life
602896|NCT00310232|Blood transfusion
602897|NCT00310219|stage II non-small cell lung cancer
602898|NCT00310219|stage IIIA non-small cell lung cancer
602899|NCT00310219|stage IIIB non-small cell lung cancer
602900|NCT00310219|recurrent non-small cell lung cancer
602901|NCT00310206|Influenza, pandemic, H5N1, vaccine
602902|NCT00310167|stage I grade 1 follicular lymphoma
602903|NCT00310167|stage I grade 2 follicular lymphoma
602904|NCT00310167|stage I grade 3 follicular lymphoma
602905|NCT00310167|contiguous stage II grade 1 follicular lymphoma
602906|NCT00310167|noncontiguous stage II grade 1 follicular lymphoma
602907|NCT00310167|contiguous stage II grade 2 follicular lymphoma
602908|NCT00310167|noncontiguous stage II grade 2 follicular lymphoma
602909|NCT00310167|contiguous stage II grade 3 follicular lymphoma
602910|NCT00310167|noncontiguous stage II grade 3 follicular lymphoma
602911|NCT00310167|stage III grade 1 follicular lymphoma
602912|NCT00310167|stage III grade 2 follicular lymphoma
602913|NCT00310167|stage III grade 3 follicular lymphoma
602914|NCT00310167|stage IV grade 1 follicular lymphoma
602915|NCT00310167|stage IV grade 2 follicular lymphoma
602916|NCT00310167|stage IV grade 3 follicular lymphoma
602917|NCT00310167|recurrent grade 1 follicular lymphoma
602918|NCT00310167|recurrent grade 2 follicular lymphoma
602919|NCT00310167|recurrent grade 3 follicular lymphoma
602921|NCT00310154|stage IIIA non-small cell lung cancer
602922|NCT00310154|stage IIIB non-small cell lung cancer
602923|NCT00310154|adenosquamous cell lung cancer
602924|NCT00310154|bronchoalveolar cell lung cancer
602925|NCT00310154|large cell lung cancer
602926|NCT00310154|squamous cell lung cancer
602927|NCT00310154|adenocarcinoma of the lung
602928|NCT00310141|non-small cell lung cancer
602929|NCT00310141|small cell lung cancer
602930|NCT00310128|AIDS-related diffuse large cell lymphoma
602931|NCT00310128|AIDS-related peripheral/systemic lymphoma
602932|NCT00310128|AIDS-related small noncleaved cell lymphoma
602933|NCT00310128|AIDS-related diffuse mixed cell lymphoma
602934|NCT00310128|AIDS-related immunoblastic large cell lymphoma
602935|NCT00310128|contiguous stage II grade 2 follicular lymphoma
602936|NCT00310128|contiguous stage II grade 3 follicular lymphoma
602937|NCT00310128|noncontiguous stage II grade 2 follicular lymphoma
602938|NCT00310128|noncontiguous stage II grade 3 follicular lymphoma
602939|NCT00310128|recurrent grade 2 follicular lymphoma
602940|NCT00310128|recurrent grade 3 follicular lymphoma
602941|NCT00310128|stage I grade 2 follicular lymphoma
602942|NCT00310128|stage I grade 3 follicular lymphoma
602943|NCT00310128|stage III grade 2 follicular lymphoma
602944|NCT00310128|stage III grade 3 follicular lymphoma
602945|NCT00310128|stage IV grade 2 follicular lymphoma
602946|NCT00310128|stage IV grade 3 follicular lymphoma
602947|NCT00310128|contiguous stage II adult Burkitt's lymphoma
602948|NCT00310128|noncontiguous stage II adult Burkitt's lymphoma
602949|NCT00310128|recurrent adult Burkitt's lymphoma
602950|NCT00310128|stage I adult Burkitt's lymphoma
602951|NCT00310128|stage III adult Burkitt's lymphoma
602952|NCT00310128|stage IV adult Burkitt's lymphoma
602953|NCT00310128|anaplastic large cell lymphoma
602954|NCT00310128|contiguous stage II adult diffuse large cell lymphoma
602955|NCT00310128|noncontiguous stage II adult diffuse large cell lymphoma
602956|NCT00310128|recurrent adult diffuse large cell lymphoma
602957|NCT00310128|stage I adult diffuse large cell lymphoma
602958|NCT00310128|stage III adult diffuse large cell lymphoma
602959|NCT00310128|stage IV adult diffuse large cell lymphoma
602960|NCT00310128|contiguous stage II adult diffuse mixed cell lymphoma
602961|NCT00310128|noncontiguous stage II adult diffuse mixed cell lymphoma
602962|NCT00310128|recurrent adult diffuse mixed cell lymphoma
602963|NCT00310128|stage I adult diffuse mixed cell lymphoma
602964|NCT00310128|stage III adult diffuse mixed cell lymphoma
602965|NCT00310128|stage IV adult diffuse mixed cell lymphoma
602966|NCT00310128|contiguous stage II adult immunoblastic large cell lymphoma
602967|NCT00310128|noncontiguous stage II adult immunoblastic large cell lymphoma
602968|NCT00310128|recurrent adult immunoblastic large cell lymphoma
602969|NCT00310128|stage I adult immunoblastic large cell lymphoma
602970|NCT00310128|stage III adult immunoblastic large cell lymphoma
602971|NCT00310128|stage IV adult immunoblastic large cell lymphoma
602972|NCT00310115|non-small cell lung cancer
602973|NCT00310115|small cell lung cancer
602974|NCT00310115|bladder cancer
602975|NCT00310115|cervical cancer
602976|NCT00310115|esophageal cancer
602977|NCT00310115|gastric cancer
602978|NCT00310115|renal cell carcinoma
602979|NCT00310115|adult primary liver cancer
602980|NCT00310115|pancreatic cancer
602981|NCT00310115|hypopharyngeal cancer
602982|NCT00310115|lip and oral cavity cancer
602983|NCT00310115|laryngeal cancer
602984|NCT00310115|nasopharyngeal cancer
602985|NCT00310115|oropharyngeal cancer
602986|NCT00310115|paranasal sinus and nasal cavity cancer
602987|NCT00310115|adult acute myeloid leukemia
602988|NCT00310115|tobacco use disorder
602989|NCT00310089|stage IIIA breast cancer
602990|NCT00310089|stage IIIB breast cancer
602991|NCT00310089|stage IIIC breast cancer
602992|NCT00310089|inflammatory breast cancer
602993|NCT00310076|carcinoma of the appendix
602994|NCT00310076|stage II colon cancer
602995|NCT00310076|stage III colon cancer
602996|NCT00310076|stage IV colon cancer
602997|NCT00310076|recurrent colon cancer
602998|NCT00310076|stage II rectal cancer
602999|NCT00310076|stage III rectal cancer
603000|NCT00310076|stage IV rectal cancer
603001|NCT00310076|recurrent rectal cancer
603002|NCT00310063|nausea and vomiting
603003|NCT00310063|unspecified childhood solid tumor, protocol specific
603004|NCT00310050|stage II pancreatic cancer
603005|NCT00310050|stage III pancreatic cancer
603006|NCT00310050|stage IV pancreatic cancer
603007|NCT00309751|Kowa
603008|NCT00309751|Type II Diabetes Mellitus
603009|NCT00309751|Combined Dyslipidemia
603010|NCT00309751|pitavastatin
603011|NCT00309751|NK-104
603012|NCT00309751|Atorvastatin
603013|NCT00309738|Kowa
603014|NCT00309738|KRE
603015|NCT00309738|Hypercholesterolemia
603016|NCT00309738|combined dyslipidemia
603017|NCT00309738|dyslipidemia
603018|NCT00309738|pitavastatin
603019|NCT00309738|NK-104
603020|NCT00309738|simvastatin
603021|NCT00309725|Alzheimer's Disease
603022|NCT00309725|cardiac arrhythmias
603023|NCT00309712|diabetes
603149|NCT00309010|Motor Planning
603024|NCT00309712|combination lipid treatment
603025|NCT00309712|statin
603026|NCT00309712|fibrate
603027|NCT00309712|hypercholesteremia
603028|NCT00309712|mixed dyslipidemia
603029|NCT00309699|Affective psychosis
603030|NCT00309699|mixed-state
603031|NCT00309699|bipolar disorder
603032|NCT00309699|manic disorder
603033|NCT00309699|manic-depressive psychosis
603034|NCT00309699|mania
603035|NCT00309699|manic state
603036|NCT00309699|paliperidone
603037|NCT00309699|paliperidone ER.
603038|NCT00309686|Affective psychosis
603039|NCT00309686|bipolar disorder
603040|NCT00309686|manic disorder
603041|NCT00309686|manic-depressive psychosis
603042|NCT00309686|mania
603043|NCT00309686|manic state
603044|NCT00309686|paliperidone
603045|NCT00309686|paliperidone ER
603046|NCT00309686|adjunctive therapy
603047|NCT00309673|tuberculosis, tuberculin, childhood, pain
603048|NCT00309660|PPARgamma ligand
603049|NCT00309660|Rosiglitazone
603050|NCT00309660|Enema
603051|NCT00309647|prophylaxis of pandemic influenza
603052|NCT00309634|prophylaxis of pandemic influenza
603053|NCT00309621|Hand Dermatoses,
603054|NCT00309621|hand dermatitis
603055|NCT00309621|hand eczema
603056|NCT00309621|chronic hand dermatitis
603057|NCT00309621|retinoid
603058|NCT00309569|Cyclophosphamide
603059|NCT00309569|Methotrexate
603060|NCT00309569|Fluorouracil
603061|NCT00309569|Epirubicine
603062|NCT00309569|Breast Cancer
603063|NCT00309556|Epirubicin
603064|NCT00309556|Docetaxel
603065|NCT00309556|Capecitabine
603066|NCT00309556|Herceptin
603067|NCT00309556|Breast cancer
603068|NCT00309543|Fluorouracil
603069|NCT00309543|Leucovorin
603070|NCT00309543|Colon cancer
603071|NCT00309530|Fluorouracil
603072|NCT00309530|Levamisol
603073|NCT00309530|Interferon
603074|NCT00309530|Colon cancer
603075|NCT00309517|Fluorouracil
603076|NCT00309517|Leucovorin
603077|NCT00309517|MAb 17-1A
603078|NCT00309517|Rectal cancer
603079|NCT00309504|magnetic resonance imaging
603080|NCT00309504|magnetic resonance spectroscopy
603081|NCT00309491|Tamoxifen
603082|NCT00309491|Aminoglutethimide
603083|NCT00309491|Breast cancer
603084|NCT00309478|Cyclophosphamide
603085|NCT00309478|Methotrexate
603086|NCT00309478|Fluorouracil
603087|NCT00309478|Goserelin
603088|NCT00309478|Tamoxifen
603089|NCT00309478|Breast cancer
603090|NCT00309465|Diabetes
603091|NCT00309465|Insulin Glargine
603092|NCT00309465|Surgery
603093|NCT00309452|First episode psychosis
603094|NCT00309452|Specialized care
603095|NCT00309452|Phase-specific treatment
603096|NCT00309452|Schizophrenia
603097|NCT00309452|Disorders with psychotic features
603098|NCT00309426|atherosclerosis
603099|NCT00309413|Schizophrenia and Disorders with Psychotic Features
603100|NCT00309400|History
603101|NCT00309400|Phenylketonuria
603102|NCT00309400|Galactosemia
603103|NCT00309400|Screening
603104|NCT00309400|Treatment
603105|NCT00309387|Cataract
603106|NCT00309387|Nutritional supplements
603107|NCT00309374|LPS
603108|NCT00309374|Statins
603109|NCT00309374|leukocyte mRNA expression profiles
603110|NCT00309361|Soft Tissue Anesthesia (Numbness)
603111|NCT00309335|Soft Tissue Anesthesia (Numbness)
603112|NCT00309322|Soft Tissue Anesthesia (Numbness)
603113|NCT00309296|smoking cessation
603114|NCT00309296|smoking reduction
603115|NCT00309296|nicotine replacement therapy
603116|NCT00309270|Campath-1H, low-dose immunosuppression, T regulatives cells
603117|NCT00309231|diabetes mellitus
603118|NCT00309231|islet transplantation
603119|NCT00309218|Pediatric renal transplantation
603120|NCT00309218|Steroid withdrawal
603121|NCT00309218|Mycophenolate Mofetil
603122|NCT00309218|Cyclosporine A
603123|NCT00309218|Stable graft function
603124|NCT00309218|children
603125|NCT00309218|renal transplantation
603126|NCT00309205|HIV seronegativity
603127|NCT00309192|Diabetes, Macular Edema, Triamcinolone
603128|NCT00309179|Advanced colorectal cancer
603129|NCT00309127|Type 2 Diabetes Mellitus
603130|NCT00309127|DM Nephropathy
603131|NCT00309127|Structured care
603132|NCT00309114|UTI
603133|NCT00309114|SCI
603134|NCT00309114|E coli
603135|NCT00309114|Prevention
603136|NCT00309101|Tacrolimus
603137|NCT00309101|Myasthenia Gravis
603138|NCT00309088|Tacrolimus
603139|NCT00309088|Myasthenia Gravis
603140|NCT00309075|Stenosis of the calf and/or pedal arteries
603141|NCT00309062|Allergy
603142|NCT00309062|Birch pollen
603143|NCT00309062|Recombinant
603144|NCT00309036|Allergy
603145|NCT00309036|Grass pollen
603146|NCT00309036|Recombinant
603147|NCT00309023|Advanced Solid Tumors
603148|NCT00309010|Focal Hand Dystonia
603150|NCT00309010|Transcranial Magnetic Stimulation (TMS)
603151|NCT00309010|MRI (Magnetic Resonance Imaging)
603152|NCT00309010|FHD
603153|NCT00309010|Writer's Cramp
603154|NCT00309010|Healthy Volunteer
603155|NCT00309010|HV
603156|NCT00308997|Auditory Hallucinations
603157|NCT00308997|Schizophrenia
603158|NCT00308997|Schizoaffective Disorder
603159|NCT00308997|Repetitive Transcranial Magnetic Stimulation
603160|NCT00308997|Wernicke's Area
603161|NCT00308997|Superior Temporal Gyrus
603162|NCT00308984|Pediatrics
603163|NCT00308984|Intraoperative Awareness
603164|NCT00308984|Pediatric Anesthesia
603165|NCT00308958|cystic fibrosis
603166|NCT00308958|chest physiotherapy
603167|NCT00308958|airway clearance
603168|NCT00308958|bronchiectasis
603169|NCT00308945|Glaucoma
603170|NCT00308945|Blood flow
603171|NCT00308945|Choroid
603172|NCT00308945|Retina
603173|NCT00308945|Prostaglandin analogues
603174|NCT00308932|fluticasone
603175|NCT00308932|asthma therapy
603176|NCT00308932|spacer inhaler
603177|NCT00308932|HFA-134a
603178|NCT00308906|infection
603179|NCT00308906|renal dysfunction
603180|NCT00308906|aminoglycoside
603181|NCT00308906|protein
603182|NCT00308906|child
603183|NCT00308893|Antidepressants
603184|NCT00308893|escitalopram
603185|NCT00308893|Genetic polymorphism
603186|NCT00308880|Tranexamic acid
603187|NCT00308880|head neck surgery
603188|NCT00308867|PDT
603189|NCT00308867|AK
603190|NCT00308867|Cryosurgery
603191|NCT00308854|AK
603192|NCT00308854|PDT
603193|NCT00308841|"Objective: To evaluate the efficacy of intrauterine lidocaine instillation in reducing patient discomfort during the removal of a lost IUD"
603194|NCT00308815|Resuscitation
603195|NCT00308815|Out-of-hospital cardiac arrest
603196|NCT00308815|cardiac arrest
603197|NCT00308815|CPR
603198|NCT00308802|Kidney
603199|NCT00308802|Transplant
603200|NCT00308802|Rejection
603201|NCT00308802|Kidney Disease
603202|NCT00308802|Kidney Failure
603203|NCT00308802|End Stage Renal Disease
603204|NCT00308789|Continuous Positive Airway Pressure
603205|NCT00308789|Infant,newborn
603206|NCT00308789|Artificial respiration
603207|NCT00308763|Smoking Cessation
603208|NCT00308763|Nicotine Dependence
603209|NCT00308724|Generalized Anxiety Disorder
603210|NCT00308724|Geriatric
603211|NCT00308711|Cervical ripening
603212|NCT00308711|Induction of labor
603213|NCT00308711|Dinoprostone vaginal insert
603214|NCT00308711|Cervidil
603215|NCT00308711|Misoprostol vaginal insert
603216|NCT00308711|Modified Bishop's Score
603217|NCT00308711|PGE2
603218|NCT00308711|PGE1
603219|NCT00308711|Uterine Hyperstimulation
603220|NCT00308711|Cesarean section
603221|NCT00308698|recombinant human erythropoietin
603222|NCT00308698|adiponectin
603223|NCT00308698|mortality
603224|NCT00308685|Asthma
603225|NCT00308685|Pediatric asthma
603226|NCT00308633|Cardiac Rehabilitation
603227|NCT00308633|Apoptosis
603228|NCT00308633|Gene Expression
603229|NCT00308633|Nitric Oxide
603230|NCT00308633|Reactive Oxygen Species
603231|NCT00308633|Coronary Artery Disease
603232|NCT00308633|CAD
603233|NCT00308620|HIV
603234|NCT00308620|chloroquine
603235|NCT00308620|disease progression
603236|NCT00308620|inflammation
603237|NCT00308620|treatment naive
603238|NCT00308607|melanoma
603239|NCT00308607|metastatic
603240|NCT00308607|bevacizumab
603241|NCT00308594|cervical radiculopathy
603242|NCT00308594|dexamethasone
603243|NCT00308594|corticosteroid
603244|NCT00308594|oral
603245|NCT00308581|Crohn's Disease
603246|NCT00308581|Certolizumab pegol
603247|NCT00308568|screening colonoscopy
603248|NCT00308568|adherence
603249|NCT00308555|Cannabis
603250|NCT00308555|Morphine
603251|NCT00308555|Oxycodone
603252|NCT00308555|Marijuana
603253|NCT00308555|chronic pain
603254|NCT00308542|eye diseases
603255|NCT00308542|diabetic eye problems
603256|NCT00308529|Carcinoma Small Cell Lung
603257|NCT00308529|Lung Cancer
603258|NCT00308516|Rectal Cancer
603259|NCT00308516|Cancer of the Rectum
603260|NCT00308516|Colorectal Cancer
603261|NCT00308516|Bevacizumab
603262|NCT00308503|Primary Insomnia
603263|NCT00308503|Sleep Maintenance Insomnia
603264|NCT00308503|Awakening
603265|NCT00308477|eye diseases
603266|NCT00308451|chromium
603267|NCT00308451|chromium picolinate
603268|NCT00308451|type 2 diabetes mellitus
603269|NCT00308451|fructosamine
603270|NCT00308451|glycemic control
603271|NCT00308451|OGTT
603272|NCT00308438|Crohn Disease
603273|NCT00308438|Crohn's Disease
603274|NCT00308425|Renal transplantation, EC-MPS
603275|NCT00308412|Respiratory Tract Infection
603276|NCT00308386|Nurse Case Management
603277|NCT00308386|Diabetes
603278|NCT00308386|Hypertension
603279|NCT00308386|Hyperlipidemia
603280|NCT00308386|Behavior therapy
603281|NCT00308386|Motivational interviewing
603282|NCT00308360|Hostility
603283|NCT00308360|Impulsivity
603284|NCT00308360|Aggression
603285|NCT00308334|Domperidone
603286|NCT00308334|breast milk
603287|NCT00308334|breast milk composition
603288|NCT00308334|preterm infant
603289|NCT00308334|neonate
603290|NCT00308334|nutrition
603291|NCT00308269|Cancer
603292|NCT00308269|Phase I
603293|NCT00308269|EC145
603294|NCT00308269|Recurrent
603295|NCT00308269|Refractory
603296|NCT00308269|Solid Tumors
603297|NCT00308269|Experimental
603298|NCT00308256|Type1 diabetes;
603299|NCT00308256|nurse-counselling;
603300|NCT00308256|adolescent
603301|NCT00308243|Cystic Fibrosis
603302|NCT00308243|Sodium Pyruvate
603303|NCT00308243|Reactive Oxygen Species
603304|NCT00308243|Inflammation of Lung
603305|NCT00308230|Congenital, BNP
603306|NCT00308217|Heart Disease, Congenital
603307|NCT00308217|Single Ventricle
603308|NCT00308217|Hypoplastic Left Heart Syndrome
603309|NCT00308204|discoid lupus
603310|NCT00308204|lupus
603311|NCT00308204|discoid lupus erythematosus
603312|NCT00308204|lupus of the scalp
603313|NCT00308191|COPD
603314|NCT00308191|Formoterol
603315|NCT00308191|Tiotropium
603316|NCT00308178|Abraxane
603317|NCT00308178|dose-dense chemotherapy
603318|NCT00308178|taxol
603319|NCT00308165|Recurrent Primary Malignant Brain Tumors
603320|NCT00308165|Brain Tumors
603321|NCT00308165|Neoplasms, Brain
603322|NCT00308165|Brain Cancer
603323|NCT00308165|Brain cancer treatment
603324|NCT00308165|Topotecan
603325|NCT00308152|Colonoscopy
603326|NCT00308152|Rehydration
603327|NCT00308152|Sedation
603328|NCT00308139|diabetes
603329|NCT00308139|exenatide
603330|NCT00308139|long acting release
603331|NCT00308139|LAR
603332|NCT00308139|Amylin
603333|NCT00308139|Lilly
603334|NCT00308126|Abdominal operation
603335|NCT00308113|Muscular dystrophy
603336|NCT00308113|Duchenne
603337|NCT00308113|CoQ10
603338|NCT00308113|prednisone
603339|NCT00308100|Liver Transplantation
603340|NCT00308087|Sargramostim
603341|NCT00308087|Leukine
603342|NCT00308087|NHL
603343|NCT00308074|behavioral problems
603344|NCT00308074|aggression
603345|NCT00308074|autism
603346|NCT00308074|aripiprazole
603347|NCT00308061|Plasmodium falciparum
603348|NCT00308061|malaria
603349|NCT00308061|merozoite surface protein-1
603350|NCT00308048|Interferon
603351|NCT00308048|Pegylated interferon
603352|NCT00308048|Pegylated interferon alfa 2b
603353|NCT00308048|Hepatitis C
603354|NCT00308048|Genotype 2
603355|NCT00308048|Genotype 3
603356|NCT00308048|Rapid virological response
603357|NCT00308048|Short treatment
603358|NCT00308048|14 weeks treatment
603359|NCT00308048|health related quality of life
603360|NCT00308048|sick leave
603361|NCT00308048|Injecting drug use
603362|NCT00308022|Acute Lung Injury
603363|NCT00308022|Acute Respiratory Distress Syndrome
603364|NCT00308022|High Frequency Percussive Ventilation
603365|NCT00308022|Ventilator Associated Pneumonia
603366|NCT00308009|Pelvic Organ Prolapse
603367|NCT00308009|Urinary stress incontinence
603368|NCT00308009|Surgery
603369|NCT00307996|CoQ10
603370|NCT00307996|hemodialysis
603371|NCT00307996|oxidative marker
603372|NCT00307996|antioxidant
603373|NCT00307970|fluticasone
603374|NCT00307970|asthma therapy
603375|NCT00307970|spacer inhaler
603376|NCT00307970|HFA-134a
603377|NCT00307957|Obstructive Sleep Apnea
603378|NCT00307957|Daytime Sleepiness
603379|NCT00307957|Pillar Palatal Implants
603380|NCT00307944|Acid Reflux
603381|NCT00307944|Obstructive Sleep Apnea
603382|NCT00307944|Daytime Sleepiness
603383|NCT00307931|Certolizumab pegol
603384|NCT00307931|Cimzia
603385|NCT00307931|Crohn's disease
603386|NCT00307931|Greek patients
603387|NCT00307918|acupuncture, intraocular pressure, glaucoma
603388|NCT00307905|homeopathy
603389|NCT00307905|pain
603390|NCT00307905|traumeel s
603391|NCT00307905|Fracture of neck of femur
603392|NCT00307905|Surgical correction of fracture of neck of hip
603393|NCT00307892|Homeopathy
603394|NCT00307892|Traumeel S
603395|NCT00307892|Arthroscopy
603396|NCT00307892|Pain management
603397|NCT00307892|Post-operative pain following arthroscopy
603398|NCT00307879|Myocardial infarction
603399|NCT00307879|revascularization
603400|NCT00307879|granulocyte colony stimulating factor (G-CSF)
603401|NCT00307866|Known or suspected focal liver lesions detected by spiral CT
603402|NCT00307853|homeopathy
603403|NCT00307853|pain
603404|NCT00307853|traumeel s
603405|NCT00307853|total knee arthroplasty
603406|NCT00307853|total hip arthroplasty
603407|NCT00307840|hemodialysis; secondary hyperparathyroidism; hypercalcemia; hyperphosphatemia; vitamin D
603408|NCT00307827|Steroid-Refractory
603409|NCT00307827|IVSR-UC
603410|NCT00307827|Ulcerative Colitis
603411|NCT00307814|Anemia
603412|NCT00307814|Low Blood Count
603413|NCT00307814|Chronic Kidney Failure
603414|NCT00307814|Chronic Kidney Disease
603415|NCT00307814|epoetin alfa
603416|NCT00307814|recombinant human erythropoietin
603417|NCT00307801|Dysfunctional uterine bleeding
603418|NCT00307788|Psychiatric Comorbidity
603419|NCT00307788|Acupuncture
603420|NCT00307788|expectancy
603421|NCT00307775|oestradiol, faecal incontinence, post menopausal
603422|NCT00307775|post menopausal women with faecal incontinence
603423|NCT00307762|Stroke
603424|NCT00307762|Physiotherapy
603425|NCT00307762|Effectiveness
603426|NCT00307762|Gait trainer
603427|NCT00307749|Neuropathy
603428|NCT00307749|Nerve Conduction
603429|NCT00307736|Fluorouracil
603430|NCT00307736|bevacizumab
603431|NCT00307736|erlotinib
603432|NCT00307736|external beam radiation therapy
603433|NCT00307736|EBRT
603434|NCT00307723|EBRT
603435|NCT00307723|advanced pancreatic cancer
603436|NCT00307710|Non-Hodgkin's Lymphoma
603437|NCT00307710|Influenza Vaccination
603438|NCT00307710|Trivalent Baculovirus-Expressed Influenza HA vaccine
603439|NCT00307710|Antineoplastic Therapy
603440|NCT00307697|Letter intervention
603441|NCT00307697|Depression
603442|NCT00307697|Anxiety
603443|NCT00307697|Primary health care
603444|NCT00307684|Attention Deficit Hyperactivity Disorder
603445|NCT00307684|Adult
603446|NCT00307684|Long term safety
603447|NCT00307684|Efficacy
603448|NCT00307684|Quality of life
603449|NCT00307671|Systemic necrotizing vasculitides
603450|NCT00307671|corticosteroids; azathioprine; mycophenolate mofetil;
603451|NCT00307671|cyclophosphamide
603452|NCT00307671|Elderly patients
603453|NCT00307671|Randomized controlled trial
603454|NCT00307658|ANCA associated Vasculitides
603455|NCT00307658|Relapse
603456|NCT00307658|intravenous Immunoglobulins
603457|NCT00307658|Corticosteroid
603458|NCT00307658|Immunosuppressant
603459|NCT00307645|ANCA associated systemic vasculitis
603460|NCT00307645|Maintenance therapy
603461|NCT00307645|Azathioprine
603462|NCT00307645|Mycophenolate mofetil
603463|NCT00307632|Contraception
603464|NCT00307632|Hormonal patch
603465|NCT00307632|Norelgestromine
603466|NCT00307632|Ethinyl estradiol
603467|NCT00307619|Binge-Eating Disorder
603468|NCT00307606|Mastectomy
603469|NCT00307606|Seroma
603470|NCT00307606|Breast cancer
603471|NCT00307606|Glucocorticoid
603472|NCT00307593|Systemic ANCA+ vascularizes
603473|NCT00307593|Relapse
603474|NCT00307593|Corticosteroids
603475|NCT00307593|Immunosuppressant
603476|NCT00307593|Infliximab/rituximab
603477|NCT00307593|Patients with relapsing or refractory forms of ANCA
603478|NCT00307593|associated vasculitides Microscopic polyangiitis
603479|NCT00307580|CVADS
603480|NCT00307502|protease inhibitors
603481|NCT00307502|non-nucleoside analog reverse transcriptase inhibitors
603482|NCT00307502|pharmacokinetic models
603483|NCT00307502|treatment experienced
603484|NCT00307502|HIV
603485|NCT00307476|Fecal Incontinence
603486|NCT00307476|Fecal Containment Devices
603487|NCT00307476|Skin Integrity
603488|NCT00307463|end-stage renal disease
603489|NCT00307463|hemodialysis
603490|NCT00307463|volume control
603491|NCT00307463|ultrafiltration
603492|NCT00307463|inflammation
603493|NCT00307463|cardiovascular disease
603494|NCT00307463|left ventricular hypertrophy
603495|NCT00307463|dietary salt restriction
603496|NCT00307450|Dyskinesias
603497|NCT00307450|Parkinson's disease
603498|NCT00307450|Levetiracetam
603499|NCT00307450|Treatment
603500|NCT00307437|Moderate to Severe Plaque-Type Psoriasis
603501|NCT00307437|interleukin 23
603502|NCT00307437|IL-12
603503|NCT00307437|interleukin-12
603504|NCT00307437|interleukin-23
603505|NCT00307437|CNTO1275
603506|NCT00307437|biologic
603507|NCT00307437|Psoriasis
603508|NCT00307437|CNTO 1275
603509|NCT00307437|IL23
603510|NCT00307437|interleukin 12
603511|NCT00307437|IL-23
603512|NCT00307437|IL12
603513|NCT00307437|ustekinumab
603514|NCT00307411|Metabolic syndrome
603515|NCT00307398|AMD
603516|NCT00307398|Dry AMD
603517|NCT00307398|Drusen
603518|NCT00307398|CNV
603519|NCT00307385|Motor Recovery
603520|NCT00307385|Transcranial Direct Current Stimulation (tDCS)
603521|NCT00307385|Homeostatic Plasticity
603522|NCT00307385|Ipsilesional Primary Motor Cortex
603523|NCT00307385|Paretic Fingers Motor Sequence
603524|NCT00307385|Motor Cortex
603525|NCT00307385|Motor Function
603526|NCT00307385|Motor Learning
603527|NCT00307385|Premotor Cortex
603528|NCT00307385|Primary Motor Cortex
603529|NCT00307385|Stroke
603530|NCT00307385|Healthy Volunteer
603531|NCT00307385|HV
603532|NCT00307346|Movement-Related Potential
603533|NCT00307346|Electroencephalogram
603534|NCT00307346|Psychogenic Movement Disorders
603535|NCT00307346|Psychogenic Movement Disorder
603536|NCT00307346|Healthy Volunteer
603537|NCT00307346|HV
603538|NCT00307333|very low birth weight infants
603539|NCT00307333|heart rate characteristics
603540|NCT00307320|pregnancy
603541|NCT00307320|stress
603542|NCT00307320|anxiety
603543|NCT00307307|atherosclerosis
603544|NCT00307307|HDL cholesterol
603545|NCT00307307|niacin
603546|NCT00307307|MR imaging
603547|NCT00307294|Prostate
603548|NCT00307294|Androgen
603549|NCT00307294|AIPC
603550|NCT00307294|Doxil
603551|NCT00307268|ADHD Effectiveness
603552|NCT00307255|unspecified adult solid tumor
603553|NCT00307255|protocol specific
603554|NCT00307255|Paclitaxel
603555|NCT00307255|Abraxane
603556|NCT00307255|Gemcitabine
603557|NCT00307255|Gemzar
603558|NCT00307255|Phase I
603559|NCT00307255|Lineberger
603560|NCT00307242|Adefovir Dipivoxil
603561|NCT00307242|Lamivudine
603562|NCT00307242|Hepatitis B
603563|NCT00307229|metastatic breast cancer
603564|NCT00307229|recurrent breast cancer
603565|NCT00307216|First Episode Psychosis
603566|NCT00307216|Early Psychosis
603567|NCT00307216|Psychosocial Intervention
603568|NCT00307203|Bupropion
603569|NCT00307203|Zyban
603570|NCT00307203|Wellbutrin
603571|NCT00307203|Smoking cessation
603572|NCT00307203|Schizophrenia
603573|NCT00307203|Schizoaffective disorder
603574|NCT00307203|Cognitive Behavioral Therapy
603575|NCT00307190|BED
603576|NCT00307177|influenza vaccine, baculovirus, immunogenicity, lymphoma
603577|NCT00307164|Treatment Experienced
603578|NCT00307164|Uridine
603579|NCT00307151|Treatment Naive
603580|NCT00307151|Mother-To-Child Transmission
603581|NCT00307151|MTCT
603582|NCT00307151|Pediatrics
603583|NCT00307151|Viral resistance
603584|NCT00307138|Coronary artery bypass, Off-pump
603585|NCT00307138|Hetastarch
603586|NCT00307138|Plasma substitutes
603587|NCT00307138|Equivalence
603588|NCT00307125|Organ Transplantation
603589|NCT00307125|Graft function/survival
603590|NCT00307125|Immunosuppression
603591|NCT00307125|anti-CD20 (rituximab)
603592|NCT00307112|Group A streptococcus, Nicaragua, Rheumatic Heart Disease
603593|NCT00307099|bacterial diseases
603594|NCT00307073|Pacemaker
603595|NCT00307073|Managed Ventricular Pacing
603596|NCT00307073|Ventricular Pacing
603597|NCT00307047|Stents
603598|NCT00307047|Angioplasty
603599|NCT00307047|Total coronary occlusion
603600|NCT00307047|coronary restenosis
603601|NCT00307047|stent thrombosis
603602|NCT00307034|Primary vaccination
603603|NCT00307034|Pneumococcal disease
603604|NCT00307034|Safety
603605|NCT00307034|Booster vaccination
603606|NCT00307034|Immunogenicity
603607|NCT00307034|Pneumococcal vaccine
603608|NCT00307034|Dose comparison
603609|NCT00307021|Parasitic Diseases
603610|NCT00307021|Malaria, Falciparum
603611|NCT00307021|Malaria
603612|NCT00307021|Coccidiosis
603613|NCT00307008|Prophylaxis Invasive pneumococcal diseases and pneumonia
603614|NCT00306995|prophylaxis of pandemic influenza
603615|NCT00306982|Prophylaxis Influenza vaccine
603616|NCT00306969|mycosis fungoides, Sézary Syndrome
603617|NCT00306956|Infant
603618|NCT00306956|Newborn
603619|NCT00306956|pacifier
603620|NCT00306956|dummies
603621|NCT00306956|breastfeeding
603622|NCT00306956|Sudden Infant Death
603623|NCT00306956|SIDS
603624|NCT00306956|Pacifiers
603625|NCT00306930|Total Hip Replacement
603626|NCT00306930|post-traumatic arthritis
603627|NCT00306917|Total Hip Replacement
603628|NCT00306904|Macular
603629|NCT00306904|Edema
603630|NCT00306904|Diabetic
603631|NCT00306904|Retinopathy
603632|NCT00306891|Advanced solid tumours
603633|NCT00306891|Advanced cancer
603634|NCT00306891|tumor
603635|NCT00306891|tumour
603636|NCT00306891|RECENTIN
603637|NCT00306865|Neurotransmitter
603638|NCT00306865|Neuroimaging
603639|NCT00306865|Movement Disorder
603640|NCT00306865|Focal Hand Dystonia
603641|NCT00306865|FHD
603642|NCT00306865|HV
603643|NCT00306852|Glaucoma
603644|NCT00306852|Trabeculectomy
603645|NCT00306852|Tube shunt surgery
603646|NCT00306839|Tissucol
603647|NCT00306839|Tisseel
603648|NCT00306839|Lichtenstein
603649|NCT00306839|hernia
603650|NCT00306839|inguinal
603651|NCT00306826|Impaired glucose tolerance
603652|NCT00306813|refractory or relapsed multiple myeloma
603653|NCT00306813|CC-5013
603654|NCT00306813|Revlimid
603655|NCT00306813|lenalidomide
603656|NCT00306813|RAD
603657|NCT00306800|Methyl aminolevulinate
603658|NCT00306800|Photodynamic therapy
603659|NCT00306800|Aktilite CL128 LED light source
603660|NCT00306800|Multiple Actinic Keratosis
603661|NCT00306787|Herpes simplex
603662|NCT00306787|genital herpes
603663|NCT00306787|famciclovir
603664|NCT00306787|valacyclovir
603665|NCT00306787|Recurrent genital herpes
603666|NCT00306774|osteoarthritis
603667|NCT00306774|vitamin D
603668|NCT00306774|knee pain
603669|NCT00306774|cartilage loss
603670|NCT00306774|WOMAC
603671|NCT00306774|MRI
603672|NCT00306774|cartilage volume
603673|NCT00306774|OA
603674|NCT00306774|physical function
603675|NCT00306774|web-based
603676|NCT00306774|internet-based
603677|NCT00306748|Chronic Constipation
603678|NCT00306748|Chronic Idiopathic Constipation
603679|NCT00306748|Constipation
603680|NCT00306748|CIC
603681|NCT00306748|CC
603682|NCT00306748|MD-1100
603683|NCT00306748|MD-1100 Acetate
603684|NCT00306748|Microbia
603685|NCT00306748|Microbia, Inc.
603686|NCT00306748|linaclotide
603687|NCT00306748|linaclotide acetate
603688|NCT00306735|Multiple Myeloma
603689|NCT00306735|Stem Cell Transplantation
603690|NCT00306735|CINV
603691|NCT00306722|Bronchoscopy
603692|NCT00306722|Sedation
603693|NCT00306722|AQUAVAN
603694|NCT00306722|fospropofol disodium
603695|NCT00306722|Flexible bronchoscopy
603696|NCT00306709|obesity
603697|NCT00306709|behavior change
603698|NCT00306709|cultural adaptations
603699|NCT00306709|weight loss
603700|NCT00306696|rosiglitazone
603701|NCT00306696|fluid retention
603702|NCT00306696|Type 2 diabetes
603703|NCT00306696|diuretics
603704|NCT00306683|Hypothalamic-pituitary lesions
603705|NCT00306683|Craniopharyngioma
603706|NCT00306683|Obesity
603707|NCT00306683|Diazoxide
603708|NCT00306683|Hyperinsulinemia
603709|NCT00306683|Pediatric neurosurgery
603710|NCT00306683|Oncology
603711|NCT00306683|Pituitary
603712|NCT00306683|Hypothalamus
603713|NCT00306670|Acquired Hemophilia A
603714|NCT00306670|Anti-Factor VIII antibodies
603715|NCT00306670|Anti-Factor VIII inhibitors
603716|NCT00306670|Hemophilia A
603717|NCT00306670|Factor VIII inhibitors
603718|NCT00306657|Glaucoma Open-Angle
603719|NCT00306657|Normal tension glaucoma progressive
603720|NCT00306657|chronic open angle glaucoma progressive
603721|NCT00306657|optic nerve sheath fenestration
603722|NCT00306657|cerebrospinal fluid
603723|NCT00306657|Beta-Trace Protein
603724|NCT00306644|rosiglitazone
603725|NCT00306644|Type 2 diabetes
603726|NCT00306644|intima media thickness
603727|NCT00306644|Insulin resistance
603728|NCT00306631|Advanced and Metastatic Breast Cancer
603729|NCT00306605|Emotional experiences
603730|NCT00306605|fathers
603731|NCT00306605|stress
603732|NCT00306605|depressive symptomatology
603733|NCT00306605|NICU
603734|NCT00306605|preterm birth
603735|NCT00306592|Multiple Sclerosis
603736|NCT00306592|MS
603737|NCT00306579|Ischemic Stroke
603738|NCT00306579|Myocardial ischemia
603739|NCT00306579|Myocardial necrosis
603740|NCT00306527|Influenza
603741|NCT00306527|adult/elderly
603742|NCT00306527|flu cell culture
603743|NCT00306527|vaccine
603744|NCT00306514|metastatic malignant melanoma of the skin
603745|NCT00306501|Training
603746|NCT00306501|Cortical Stimulation
603747|NCT00306501|Sensory Stimulation
603748|NCT00306501|Brain Imaging
603749|NCT00306501|Transcranial Magnetic Stimulation (TMS)
603750|NCT00306501|Swallowing
603751|NCT00306501|Dysphagia
603752|NCT00306501|Stroke
603753|NCT00306501|CVA
603754|NCT00306501|Cerebral Vascular Accident
603755|NCT00306501|Healthy Volunteer
603756|NCT00306501|HV
603757|NCT00306488|Retinal Pigment Epithelium
603758|NCT00306488|Dynamic Light Scattering (DLS)
603759|NCT00306488|Visual Acuity Decrease
603760|NCT00306488|Intra-ocular Pressure
603761|NCT00306488|Autofluorescence of Retina
603762|NCT00306488|Age-Related Macular Degeneration
603763|NCT00306488|AMD
603764|NCT00306475|schizophrenia, cognition, mood stabilizer
603765|NCT00306462|Premature Labor
603766|NCT00306462|Premature Birth
603767|NCT00306462|Magnesium sulfate
603768|NCT00306462|Nifedipine
603769|NCT00306449|Weight gain
603770|NCT00306449|obesity
603771|NCT00306449|overweight
603772|NCT00306449|young adults
603773|NCT00306449|lipid disorders
603774|NCT00306449|insulin resistance
603775|NCT00306449|randomized controled study
603776|NCT00306436|Diabetes
603777|NCT00306436|renal deficiency
603778|NCT00306436|hypertension
603779|NCT00306423|exercise
603780|NCT00306410|Vitamin D deficiency
603781|NCT00306410|HIV/AIDS
603782|NCT00306410|HAART
603783|NCT00306410|T-Lymphocytes, Regulatory
603784|NCT00306410|insulin resistance
603785|NCT00306410|bone density
603786|NCT00306397|Kidney transplantation
603787|NCT00306397|Steroid free
603788|NCT00306397|Calcineurin inhibitor free
603789|NCT00306397|Tacrolimus
603790|NCT00306397|Sirolimus
603791|NCT00306384|Glucose Metabolism Disorder
603792|NCT00306384|Dysmetabolic Syndrome
603793|NCT00306384|Type II Diabetes
603794|NCT00306384|Diabetes Mellitus,
603795|NCT00306384|Lipoatrophic
603796|NCT00306384|Dyslipidemia
603797|NCT00306384|Drug Therapy
603798|NCT00306371|diode
603799|NCT00306371|laser
603800|NCT00306371|acne
603801|NCT00306371|acne scar
603802|NCT00306358|absorption test
603803|NCT00306358|cobalamin
603804|NCT00306358|holotranscobalamin
603805|NCT00306358|vitamin B12
603806|NCT00306345|Outreach
603807|NCT00306345|Major general surgery
603808|NCT00306345|Intensive care
603809|NCT00306345|Serious adverse events
603810|NCT00306332|Allogeneic Stem cell transplantation
603811|NCT00306332|T-cell depletion
603812|NCT00306332|B-cell depletion
603813|NCT00306332|Immunomagnetic selection
603814|NCT00306319|Tuberculosis
603815|NCT00306293|Recurrent Genital Herpes
603816|NCT00306280|Helicobacter pylori
603817|NCT00306280|phototherapy
603818|NCT00306280|peptic ulcer
603819|NCT00306280|gastric cancer
603820|NCT00306267|Anemia
603821|NCT00306267|non-chemotherapy-induced
603822|NCT00306267|non-radiation therapy-induced
603823|NCT00306267|cancer
603824|NCT00306267|non-myeloid
603825|NCT00306241|Cervical neoplasia
603826|NCT00306241|Cervical cancer
603827|NCT00306241|Double-blind
603828|NCT00306241|HPV-16/18 L1 VLP AS04
603829|NCT00306241|HPV
603830|NCT00306241|AS04
603831|NCT00306228|ST elevation acute myocardial infarction
603832|NCT00306228|Thrombolysis
603833|NCT00306228|Early routine percutaneous coronary intervention
603834|NCT00306228|tirofiban
603835|NCT00306228|paclitaxel
603836|NCT00306215|double-blind
603837|NCT00306215|placebo-controlled
603838|NCT00306215|multicenter
603839|NCT00306215|efficacy
603840|NCT00306215|safety
603841|NCT00306202|Relapsed and Refractory Leukemia
603842|NCT00306189|RANKL
603843|NCT00306189|RANK
603844|NCT00306189|denosumab
603845|NCT00306189|AMG 162
603846|NCT00306189|osteoporosis
603847|NCT00306189|bone turnover
603848|NCT00306189|bone mineral density
603849|NCT00306189|Japanese
603850|NCT00306176|rosiglitazone,exercise,cardiovascular risk factors
603851|NCT00306163|Asthma
603852|NCT00306163|AMP
603853|NCT00306163|Ciclesonide
603854|NCT00306163|Fluticasone propionate
603855|NCT00306150|Prevention of blood loss
603856|NCT00306150|Blood Loss, Surgical
603857|NCT00306150|Blood Loss, Postoperative
603858|NCT00306124|Dementia
603859|NCT00306124|Mild Cognitive Impairment
603860|NCT00306124|MCI
603861|NCT00306124|levodopa
603862|NCT00306124|learning
603863|NCT00306124|enhancement
603864|NCT00306111|stem cell transplantation
603865|NCT00306111|stem cell mobilization
603866|NCT00306111|high-dose therapy
603867|NCT00306098|Transplantation, Islets of Langerhans
603868|NCT00306085|Peripheral arterial disease,
603869|NCT00306085|blood marrow cells,
603870|NCT00306085|therapeutic angiogenesis.
603871|NCT00306046|PETScan
603872|NCT00306046|Positron-Emission Tomography
603873|NCT00306046|Bisphosphonate
603874|NCT00306046|Biochemical Markers
603875|NCT00306046|Paget's Disease of Bone (monostotic and polyostotic)
603876|NCT00306033|myasthenia gravis
603877|NCT00306033|immunoglobulin
603878|NCT00306033|intravenous immunoglobulin
603879|NCT00306033|treatment
603880|NCT00306020|Skin ulcers
603881|NCT00306020|Topical morphine
603882|NCT00306020|Chronic pain
603883|NCT00306020|Cancer
603884|NCT00306007|Pregnancy
603885|NCT00306007|Unplanned pregnancy
603886|NCT00306007|Psychosocial
603887|NCT00306007|Measure
603888|NCT00305968|Quality of life
603889|NCT00305968|Gastrointestinal symptoms
603890|NCT00305968|Health related costs
603891|NCT00305955|amblyopia
603892|NCT00305955|bilateral amblyopia
603893|NCT00305955|refractive error
603894|NCT00305942|Lung Cancer
603895|NCT00305942|Carcinoma, Small Cell
603896|NCT00305929|Treatment of localized prostate cancer
603897|NCT00305929|Localized prostate cancer
603898|NCT00305916|MSCT
603899|NCT00305916|Idiopathic Cardiomyopathy
603900|NCT00305916|Sinus rhythm
603901|NCT00305903|Dementia,
603902|NCT00305903|Alzheimer's,
603903|NCT00305903|Rivastigmine,
603904|NCT00305903|Memantine
603905|NCT00305851|fatigue
603906|NCT00305851|pain
603907|NCT00305851|psychosocial effects of cancer and its treatment
603908|NCT00305851|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
603909|NCT00305851|adult acute myeloid leukemia with inv(16)(p13;q22)
603910|NCT00305851|adult acute myeloid leukemia with t(15;17)(q22;q12)
603911|NCT00305851|adult acute myeloid leukemia with t(16;16)(p13;q22)
603912|NCT00305851|adult acute myeloid leukemia with t(8;21)(q22;q22)
603913|NCT00305851|accelerated phase chronic myelogenous leukemia
603914|NCT00305851|adult acute lymphoblastic leukemia in remission
603915|NCT00305851|adult acute myeloid leukemia in remission
603916|NCT00305851|atypical chronic myeloid leukemia, BCR-ABL1 negative
603917|NCT00305851|blastic phase chronic myelogenous leukemia
603918|NCT00305851|childhood acute lymphoblastic leukemia in remission
603919|NCT00305851|childhood acute myeloid leukemia in remission
603920|NCT00305851|childhood chronic myelogenous leukemia
603921|NCT00305851|chronic eosinophilic leukemia
603922|NCT00305851|primary myelofibrosis
603923|NCT00305851|chronic myelomonocytic leukemia
603924|NCT00305851|chronic neutrophilic leukemia
603925|NCT00305851|chronic phase chronic myelogenous leukemia
603926|NCT00305851|de novo myelodysplastic syndromes
603927|NCT00305851|disseminated neuroblastoma
603928|NCT00305851|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
603929|NCT00305851|juvenile myelomonocytic leukemia
603930|NCT00305851|myelodysplastic/myeloproliferative neoplasm, unclassifiable
603931|NCT00305851|nodal marginal zone B-cell lymphoma
603932|NCT00305851|noncontiguous stage II adult Burkitt lymphoma
603933|NCT00305851|noncontiguous stage II adult diffuse large cell lymphoma
603934|NCT00305851|noncontiguous stage II adult diffuse mixed cell lymphoma
603935|NCT00305851|noncontiguous stage II adult diffuse small cleaved cell lymphoma
603936|NCT00305851|noncontiguous stage II adult immunoblastic large cell lymphoma
603937|NCT00305851|noncontiguous stage II adult lymphoblastic lymphoma
603938|NCT00305851|noncontiguous stage II grade 1 follicular lymphoma
603939|NCT00305851|noncontiguous stage II grade 2 follicular lymphoma
603940|NCT00305851|noncontiguous stage II grade 3 follicular lymphoma
603941|NCT00305851|noncontiguous stage II mantle cell lymphoma
603942|NCT00305851|noncontiguous stage II marginal zone lymphoma
603943|NCT00305851|noncontiguous stage II small lymphocytic lymphoma
603944|NCT00305851|high risk metastatic gestational trophoblastic tumor
603945|NCT00305851|previously treated childhood rhabdomyosarcoma
603946|NCT00305851|previously treated myelodysplastic syndromes
603947|NCT00305851|recurrent adult acute lymphoblastic leukemia
603948|NCT00305851|recurrent adult acute myeloid leukemia
603949|NCT00305851|recurrent adult Burkitt lymphoma
603950|NCT00305851|recurrent adult Hodgkin lymphoma
603951|NCT00305851|recurrent adult diffuse large cell lymphoma
603952|NCT00305851|recurrent adult diffuse mixed cell lymphoma
603953|NCT00305851|recurrent adult diffuse small cleaved cell lymphoma
603954|NCT00305851|recurrent adult immunoblastic large cell lymphoma
603955|NCT00305851|recurrent adult lymphoblastic lymphoma
603956|NCT00305851|recurrent/refractory childhood Hodgkin lymphoma
603957|NCT00305851|recurrent childhood acute lymphoblastic leukemia
603958|NCT00305851|recurrent childhood acute myeloid leukemia
603959|NCT00305851|recurrent childhood large cell lymphoma
603960|NCT00305851|recurrent childhood lymphoblastic lymphoma
603961|NCT00305851|recurrent childhood rhabdomyosarcoma
603962|NCT00305851|recurrent childhood small noncleaved cell lymphoma
603963|NCT00305851|recurrent cutaneous T-cell non-Hodgkin lymphoma
603964|NCT00305851|recurrent grade 1 follicular lymphoma
603965|NCT00305851|recurrent grade 2 follicular lymphoma
603966|NCT00305851|recurrent grade 3 follicular lymphoma
603967|NCT00305851|recurrent mantle cell lymphoma
603968|NCT00305851|recurrent marginal zone lymphoma
603969|NCT00305851|recurrent mycosis fungoides/Sezary syndrome
603970|NCT00305851|recurrent neuroblastoma
603971|NCT00305851|recurrent ovarian epithelial cancer
603972|NCT00305851|recurrent ovarian germ cell tumor
603973|NCT00305851|recurrent small lymphocytic lymphoma
603974|NCT00305851|recurrent malignant testicular germ cell tumor
603975|NCT00305851|recurrent Wilms tumor and other childhood kidney tumors
603976|NCT00305851|refractory chronic lymphocytic leukemia
603977|NCT00305851|refractory hairy cell leukemia
603978|NCT00305851|relapsing chronic myelogenous leukemia
603979|NCT00305851|secondary acute myeloid leukemia
603980|NCT00305851|secondary myelodysplastic syndromes
603981|NCT00305851|splenic marginal zone lymphoma
603982|NCT00305851|stage III adult Burkitt lymphoma
603983|NCT00305851|stage III adult Hodgkin lymphoma
603984|NCT00305851|stage III adult diffuse large cell lymphoma
603985|NCT00305851|stage III adult diffuse mixed cell lymphoma
603986|NCT00305851|stage III adult diffuse small cleaved cell lymphoma
603987|NCT00305851|stage III adult immunoblastic large cell lymphoma
603988|NCT00305851|stage III adult lymphoblastic lymphoma
603989|NCT00305851|stage III chronic lymphocytic leukemia
603990|NCT00305851|stage III grade 1 follicular lymphoma
603991|NCT00305851|stage III grade 2 follicular lymphoma
603992|NCT00305851|stage III grade 3 follicular lymphoma
603993|NCT00305851|stage III mantle cell lymphoma
603994|NCT00305851|stage III marginal zone lymphoma
603995|NCT00305851|stage III small lymphocytic lymphoma
603996|NCT00305851|stage III malignant testicular germ cell tumor
603997|NCT00305851|stage IV adult Burkitt lymphoma
603998|NCT00305851|stage IV adult Hodgkin lymphoma
603999|NCT00305851|stage IV adult diffuse large cell lymphoma
604000|NCT00305851|stage IV adult diffuse mixed cell lymphoma
604001|NCT00305851|stage IV adult diffuse small cleaved cell lymphoma
604002|NCT00305851|stage IV adult immunoblastic large cell lymphoma
604003|NCT00305851|stage IV adult lymphoblastic lymphoma
604004|NCT00305851|stage IV chronic lymphocytic leukemia
604005|NCT00305851|stage IV grade 1 follicular lymphoma
604006|NCT00305851|stage IV grade 2 follicular lymphoma
604007|NCT00305851|stage IV grade 3 follicular lymphoma
604008|NCT00305851|stage IV mantle cell lymphoma
604009|NCT00305851|stage IV marginal zone lymphoma
604010|NCT00305851|stage IV ovarian epithelial cancer
604011|NCT00305851|stage IV small lymphocytic lymphoma
604012|NCT00305851|stage II ovarian epithelial cancer
604013|NCT00305851|stage III ovarian epithelial cancer
604014|NCT00305851|childhood myelodysplastic syndromes
604015|NCT00305851|Ewing sarcoma
604016|NCT00305851|childhood brain tumor
604017|NCT00305851|adult brain tumor
604018|NCT00305851|osteosarcoma
604019|NCT00305838|stage IV ovarian epithelial cancer
604020|NCT00305838|recurrent ovarian epithelial cancer
604021|NCT00305838|stage IIIA ovarian epithelial cancer
604022|NCT00305838|stage IIIB ovarian epithelial cancer
604023|NCT00305838|stage IIIC ovarian epithelial cancer
604024|NCT00305838|recurrent fallopian tube cancer
604025|NCT00305838|stage IIIA fallopian tube cancer
604026|NCT00305838|stage IIIB fallopian tube cancer
604027|NCT00305838|stage IIIC fallopian tube cancer
604028|NCT00305838|stage IV fallopian tube cancer
604029|NCT00305838|recurrent primary peritoneal cavity cancer
604030|NCT00305838|stage IIIA primary peritoneal cavity cancer
604031|NCT00305838|stage IIIB primary peritoneal cavity cancer
604032|NCT00305838|stage IIIC primary peritoneal cavity cancer
604033|NCT00305838|stage IV primary peritoneal cavity cancer
604034|NCT00305825|recurrent breast cancer
604035|NCT00305825|stage IIIA breast cancer
604036|NCT00305825|stage IIIB breast cancer
604037|NCT00305825|stage IIIC breast cancer
604038|NCT00305825|stage IV breast cancer
604039|NCT00305812|stage I multiple myeloma
604040|NCT00305812|stage II multiple myeloma
604041|NCT00305812|stage III multiple myeloma
604042|NCT00305799|neurotoxicity
604043|NCT00305799|unspecified adult solid tumor, protocol specific
604044|NCT00305786|recurrent non-small cell lung cancer
604045|NCT00305786|stage IIIB non-small cell lung cancer
604046|NCT00305786|stage IV non-small cell lung cancer
604047|NCT00305760|stage III pancreatic cancer
604048|NCT00305760|recurrent pancreatic cancer
604049|NCT00305760|duct cell adenocarcinoma of the pancreas
604050|NCT00305760|adenocarcinoma of the pancreas
604051|NCT00305760|stage IV pancreatic cancer
604052|NCT00305747|recurrent prostate cancer
604053|NCT00305747|stage I prostate cancer
604054|NCT00305747|stage II prostate cancer
604055|NCT00305747|stage III prostate cancer
604056|NCT00305747|adenocarcinoma of the prostate
604057|NCT00305747|stage IV prostate cancer
604058|NCT00305708|thrombocytopenia
604059|NCT00305708|childhood acute myeloid leukemia in remission
604060|NCT00305708|childhood chronic myelogenous leukemia
604061|NCT00305708|Diamond-Blackfan anemia
604062|NCT00305708|congenital amegakaryocytic thrombocytopenia
604063|NCT00305708|Fanconi anemia
604064|NCT00305708|severe congenital neutropenia
604065|NCT00305708|chronic phase chronic myelogenous leukemia
604066|NCT00305695|osteoporosis
604067|NCT00305695|hereditary breast/ovarian cancer (BRCA1, BRCA2)
604068|NCT00305695|ovarian epithelial cancer
604069|NCT00305669|adenocarcinoma of the prostate
604070|NCT00305669|stage I prostate cancer
604071|NCT00305669|stage IIB prostate cancer
604072|NCT00305669|stage IIA prostate cancer
604073|NCT00305669|stage III prostate cancer
604074|NCT00305643|Hand-Foot Syndrome
604075|NCT00305643|cancer-related problem/condition
604076|NCT00305643|drug/agent toxicity by tissue/organ
604077|NCT00305643|pain
604078|NCT00305643|palmar-plantar erythrodysesthesia
604079|NCT00305643|stage IV breast cancer
604080|NCT00305643|male breast cancer
604081|NCT00305643|recurrent breast cancer
604082|NCT00305643|stage IV colon cancer
604083|NCT00305643|stage IV rectal cancer
604084|NCT00305643|recurrent colon cancer
604085|NCT00305643|recurrent rectal cancer
604086|NCT00305643|Celecoxib
604087|NCT00305643|Celebrex
604088|NCT00305643|Capecitabine
604089|NCT00305643|Xeloda
604090|NCT00305630|Corticosteroids
604091|NCT00305630|Triamcinolone
604092|NCT00305630|Photodynamic therapy
604093|NCT00305630|Choroidal neovascularization
604094|NCT00305630|Age-related macular degeneration
604095|NCT00305617|stage IIIA non-small cell lung cancer
604096|NCT00305617|stage IIIB non-small cell lung cancer
604097|NCT00305591|magnetic resonance imaging
604098|NCT00305591|magnetic resonance spectroscopy
604099|NCT00305591|functional magnetic resonance imaging
604100|NCT00305591|cirrhosis
604101|NCT00305591|hepatic encephalopathy
604102|NCT00305591|l-ornithine l-aspartate
604103|NCT00305578|Bipolar
604104|NCT00305578|Depression
604105|NCT00305578|Incomplete Response
604106|NCT00305565|Depression
604107|NCT00305565|Chronic Depression
604108|NCT00305565|Bipolar Disorder
604109|NCT00305552|Randomized controlled trial
604110|NCT00305552|Thalidomide vs placebo
604111|NCT00305552|skin sarcoidosis
604112|NCT00305552|Thalidomide
604113|NCT00305539|Giant Cell Arteritis
604114|NCT00305539|Placebo
604115|NCT00305539|Anti-TNF
604116|NCT00305539|Multicenter-randomized-trial
604117|NCT00305539|Proved GCA according to ACR criteria (HUNDER et al 1990)
604118|NCT00305513|right hemispheric CVA
604119|NCT00305513|neglect
604120|NCT00305513|phasic alert treatment
604121|NCT00305513|PET scan
604122|NCT00305513|patients post right hemispheric CVA (stroke)
604123|NCT00305500|OCD
604124|NCT00305500|Escitalopram
604125|NCT00305487|Hay Fever
604126|NCT00305487|Seasonal Allergic Rhinitis
604127|NCT00305487|Nasal spray
604128|NCT00305487|Ciclesonide
604129|NCT00305487|Allergic Rhinitis
604130|NCT00305474|Negative symptoms
604131|NCT00305474|neuropsychological deficits
604132|NCT00305474|Cognitive function
604133|NCT00305474|diagnostic
604134|NCT00305474|prevention
604135|NCT00305461|Asthma
604136|NCT00305461|Quality of Life
604137|NCT00305461|Ciclesonide
604138|NCT00305448|oncology
604139|NCT00305448|cancer
604140|NCT00305448|breast cancer
604141|NCT00305435|AMG 531, ITP, Phase 2, Japanese
604142|NCT00305409|Crohn's
604143|NCT00305409|TNF-alpha
604144|NCT00305409|Synbiotic
604145|NCT00305409|Probiotic
604146|NCT00305396|Kidney transplantation
604147|NCT00305396|immunosuppression
604148|NCT00305396|sirolimus
604149|NCT00305396|Thymoglobulin
604150|NCT00305383|Viramidine
604151|NCT00305383|Peginterferon alfa-2b
604152|NCT00305383|Valeant
604153|NCT00305383|Hepatitis C
604154|NCT00305383|Rapid virologic response
604155|NCT00305383|HCV RNA
604156|NCT00305370|clinical trial
604157|NCT00305370|aripiprazole
604158|NCT00305370|methylphenidate
604159|NCT00305370|Bipolar Disorder
604160|NCT00305370|Attention-Deficit Hyperactivity Disorder
604161|NCT00305370|ADHD
604162|NCT00305357|Post-Herpetic Neuralgia
604163|NCT00305357|Acute Herpes Zoster
604164|NCT00305344|Type 1 Diabetes Mellitus
604165|NCT00305344|Umbilical Cord
604166|NCT00305344|Regeneration
604167|NCT00305344|Insulin
604168|NCT00305344|Islets of Langerhans
604169|NCT00305331|Parkinson's disease
604170|NCT00305331|Domperidone
604171|NCT00305331|Peripheral edema
604172|NCT00305331|Pramipexole
604173|NCT00305331|Ropinirole
604174|NCT00305305|Agenesis Corpus Callosum
604175|NCT00305305|Polymicrogyria
604176|NCT00305305|Dandy-Walker
604177|NCT00305305|Brain Malformation
604178|NCT00305305|Autism
604179|NCT00305305|Epilepsy
604180|NCT00305305|Mental Retardation
604181|NCT00305305|MRI
604182|NCT00305305|Agenesis of the Corpus Callosum (complete or partial)
604183|NCT00305305|Confirmed by a brain MRI.
604184|NCT00305305|Aicardi Syndrome.
604185|NCT00305266|CIDP
604186|NCT00305266|IVIG
604187|NCT00305266|gammaglobulin
604188|NCT00305266|Chronic Inflammatory Demyelinating Polyradiculoneuropathy
604189|NCT00305253|maternal mortality
604190|NCT00305253|obstetric hemorrhage
604191|NCT00305240|Myocardial Infarction
604192|NCT00305240|Microvolt T Wave Alternans Test
604193|NCT00305240|Implantable Cardioverter Defibrillator (ICD)
604194|NCT00305240|Ventricular Arrythmias
604195|NCT00305227|urinary tract infection
604196|NCT00305227|cystitis
604197|NCT00305227|Lactobacillus
604198|NCT00305227|probiotic
604199|NCT00305227|prevention
604200|NCT00305214|Myocardial Infarction
604201|NCT00305214|Microvolt T Wave Alternans Test
604202|NCT00305214|Implantable Cardioverter Defibrillator (ICD)
604203|NCT00305214|Ventricular Arrhythmia
604204|NCT00305201|Mucocutaneous Lymph Node Syndrome
604205|NCT00305201|Kawasaki disease
604206|NCT00305201|Endothelial dysfunction
604207|NCT00305201|Pravastatin
604208|NCT00305201|Statin therapy
604209|NCT00305188|Neurotoxicity syndromes
604210|NCT00305188|Paresthesia
604211|NCT00305188|Oxaliplatin
604212|NCT00305188|Xaliproden
604213|NCT00305175|Hydroxyurea
604214|NCT00305175|Sickle Cell Anemia
604215|NCT00305162|Acute Coronary Syndrome (ACS)
604216|NCT00305162|Percutaneous Coronary Intervention (PCI)
604217|NCT00305162|non-ST-segment elevation myocardial infarction (NSTEMI)
604218|NCT00305162|ST-segment elevation myocardial infarction (STEMI)
604219|NCT00305149|Hodgkin Lymphoma
604220|NCT00305149|BEACOPP
604221|NCT00305149|PET
604222|NCT00305149|Gallium
604223|NCT00305149|Tailored therapy
604224|NCT00305136|thoracotomy
604225|NCT00305136|post-operative pain
604226|NCT00305136|chronic pain
604227|NCT00305136|endogenous analgesia
604228|NCT00305136|temporal summation
604229|NCT00305136|central sensitization
604230|NCT00305136|prediction
604231|NCT00305136|Patients Who Should Undergo Thoracotomy
604232|NCT00305123|Pharyngitis, Mali, Group A Streptococcus, Children
604233|NCT00305110|Pain
604234|NCT00305110|Acute
604235|NCT00305110|Emergency Department
604236|NCT00305110|Severe
604237|NCT00305110|Hydromorphone
604238|NCT00305110|Dilaudid
604239|NCT00305110|Adult
604240|NCT00305097|coffee
604241|NCT00305097|caffeine
604242|NCT00305097|glucose tolerance
604243|NCT00305097|body weight
604244|NCT00305097|insulin sensitivity
604245|NCT00305097|randomized controlled trial
604246|NCT00305084|NGR-hTNF
604247|NCT00305084|doxorubicin
604248|NCT00305084|solid tumors
604249|NCT00305071|pyuria
604250|NCT00305071|urinary tract infections
604251|NCT00305071|Vaccinium macrocarpon
604252|NCT00305058|Elderly
604253|NCT00305058|Hydromorphone
604254|NCT00305058|Morphine
604255|NCT00305058|Pain
604256|NCT00305058|Acute
604257|NCT00305058|Emergency Department
604258|NCT00305045|Major Depressive Disorder
604259|NCT00305045|Repetitive Transcranial Magnetic Stimulation
604260|NCT00305045|Treatment resistance
604261|NCT00305006|cerebral palsy
604262|NCT00305006|constraint-induced therapy
604263|NCT00305006|constraint-induced movement therapy
604264|NCT00305006|CP
604265|NCT00305006|hemiplegia
604266|NCT00305006|hand
604267|NCT00305006|forced use
604268|NCT00305006|motor control
604269|NCT00305006|children
604270|NCT00305006|HABIT
604271|NCT00305006|Hand-arm bimanual intensive therapy
604272|NCT00305006|Bilateral training
604273|NCT00305006|Bimanual training
604274|NCT00305006|functional therapy
604275|NCT00305006|physical therapy
604276|NCT00305006|occupational therapy
604277|NCT00305006|intensive
604278|NCT00305006|pediatric
604279|NCT00305006|development
604280|NCT00305006|upper extremity
604281|NCT00305006|hemiplegic
604282|NCT00304993|fenofibrate
604283|NCT00304993|niacin
604284|NCT00304993|rosiglitazone
604285|NCT00304993|LDL phenotype pattern B
604286|NCT00304993|small, dense LDL
604287|NCT00304993|insulin resistance
604288|NCT00304993|Metabolic Syndrome
604289|NCT00304967|Cataract
604290|NCT00304967|Normal Lenses
604291|NCT00304967|Lens Crystallines
604292|NCT00304967|Dynamic or Quasielastic Light Scattering (DLS)
604293|NCT00304967|Eye Examinations
604294|NCT00304967|Healthy Volunteer
604295|NCT00304967|HV
604296|NCT00304967|Eye Examination
604297|NCT00304954|Age-Related Macular Degeneration
604298|NCT00304954|Rapamycin
604299|NCT00304954|Remicade
604300|NCT00304954|Daclizumab
604301|NCT00304954|Immunosuppression
604302|NCT00304954|Infliximab
604303|NCT00304954|Choroidal Neovascularization
604304|NCT00304954|Sirolimus
604305|NCT00304954|AMD
604306|NCT00304954|Ocular Inflammation
604307|NCT00304941|Breast Cancer
604308|NCT00304941|Family History
604309|NCT00304941|Pre/Post Menopausal
604310|NCT00304941|Prevention
604311|NCT00304941|Risk-Factor
604312|NCT00304941|Body-Mass-Index
604313|NCT00304941|BRCA1
604314|NCT00304941|Insulin
604315|NCT00304941|Genetic Counseling
604316|NCT00304941|Penetrance
604317|NCT00304941|Risk Assessment
604318|NCT00304941|Healthy Volunteer
604319|NCT00304941|HV
604320|NCT00304915|HIV, depression
604321|NCT00304915|patient care management
604322|NCT00304915|patient care team
604323|NCT00304902|MRSA
604324|NCT00304902|Methicillin Resistant Staphylococcus aureus
604325|NCT00304902|Staphylococcus aureus Bacteremia
604326|NCT00304889|Clostridium difficile
604327|NCT00304876|Clostridium difficile associated diarrhea
604328|NCT00304863|CDAD
604329|NCT00304863|Clostridium difficile Associated Diarrhea
604330|NCT00304850|polyamines
604331|NCT00304850|pain
604332|NCT00304850|breast cancer
604333|NCT00304850|mastectomy
604334|NCT00304850|post operative pain
604335|NCT00304837|Nonhealing leg ulcers
604336|NCT00304837|Ischemic rest pain
604337|NCT00304824|Glaucoma
604338|NCT00304824|Olfactory functions
604339|NCT00304824|Sniffing Sticks Test
604340|NCT00304811|MRSA
604341|NCT00304811|Methicillin Resistant Staphylococcus aureus
604342|NCT00304798|Transient Ischemic Attack (TIA).
604343|NCT00304798|Stroke.
604344|NCT00304798|Hospital admission.
604345|NCT00304772|Candida
604346|NCT00304772|bloodstream infection
604347|NCT00304772|fluconazole
604348|NCT00304772|micafungin
604349|NCT00304772|randomized controlled trial
604350|NCT00304759|prostate cancer
604351|NCT00304759|localized prostate cancer
604352|NCT00304759|intermediate risk
604353|NCT00304759|prostate specific antigen
604354|NCT00304759|PSA
604355|NCT00304759|radiation fractionation
604356|NCT00304759|shorter schedule
604357|NCT00304759|quality of life
604358|NCT00304733|neuropathic foot ulcerations - total contact cast - custom -made footwear - off-loading
604359|NCT00304720|Lymphoma
604360|NCT00304720|Leukemia
604361|NCT00304694|NPC
604362|NCT00304694|Induction chemotherapy
604363|NCT00304694|Therapeutic response
604364|NCT00304694|18F-FDG PET
604365|NCT00304681|Attention Deficit Hyperactivity Disorder
604366|NCT00304681|OROS* Methylphenidate
604367|NCT00304668|HIV-1
604368|NCT00304668|HIV Seronegativity
604369|NCT00304655|Schizophrenia
604370|NCT00304655|Schizoaffective disorder
604371|NCT00304655|Aripiprazole
604372|NCT00304642|HIV-1
604373|NCT00304642|HIV Seronegativity
604374|NCT00304629|Alzheimer's disease
604375|NCT00304629|cholinesterase inhibitors
604376|NCT00304629|galantamine
604377|NCT00304616|Schizophrenia
604378|NCT00304616|Aripiprazole
604379|NCT00304603|Obesity
604380|NCT00304603|Type 2 Diabetes Mellitus
604381|NCT00304603|Topiramate
604382|NCT00304603|Pharmacogenomics
604383|NCT00304603|DNA Polymorphism
604384|NCT00304577|Strabismus
604385|NCT00304577|Esotropia
604386|NCT00304577|Surgical techniques
604387|NCT00304564|Posturography, Fall Prevention, Geriatrics, Nolwenn Effect
604388|NCT00304551|CHC with compensated LC
604389|NCT00304538|diabetes
604390|NCT00304525|Anti-angiogenesis therapy
604391|NCT00304525|Kinase inhibitor therapy
604392|NCT00304525|Raf inhibitor
604393|NCT00304525|Locally Advanced Melanoma
604394|NCT00304499|OROS®
604395|NCT00304499|middle age
604396|NCT00304499|elderly
604397|NCT00304499|oxybutynin
604398|NCT00304499|urinary incontinenence
604399|NCT00304499|women
604400|NCT00304473|Schizophrenia
604401|NCT00304460|Serum Protein Levels
604402|NCT00304460|Lymphocyte Phenotypes
604403|NCT00304460|Predictive Analysis
604404|NCT00304460|Serum Cytokines
604405|NCT00304460|Kidney Cancer
604406|NCT00304460|Renal Cell Cancer
604407|NCT00304460|Melanoma
604408|NCT00304460|Metastatic Melanoma
604409|NCT00304447|Leukemia
604410|NCT00304447|Mylotarg
604411|NCT00304447|Safety
604412|NCT00304447|Adverse Events
604413|NCT00304434|Adverse effects
604414|NCT00304434|Antiviral
604415|NCT00304434|Clinical trial
604416|NCT00304434|Oseltamivir
604417|NCT00304434|Pharmacokinetics
604418|NCT00304434|Probenecid
604419|NCT00304421|Gastroesophageal Reflux Disease
604420|NCT00304421|Proton Pump Inhibitors
604421|NCT00304421|Gastric pH
604422|NCT00304421|Gastric Acid Secretion
604423|NCT00304408|Clostridium difficile
604424|NCT00304395|Community Acquired Pneumonia
604425|NCT00304395|CAP
604426|NCT00304382|Pneumococcus
604427|NCT00304382|Pneumococcal pneumonia
604428|NCT00304369|Clostridium difficile
604429|NCT00304356|Clostridium difficile Associated Diarrhea
604430|NCT00304330|gram negative infection
604431|NCT00304317|calculi
604432|NCT00304317|ureteral calculi
604433|NCT00304317|ureter
604434|NCT00304304|child care centers
604435|NCT00304304|asthma triggers
604436|NCT00304304|community-based research
604437|NCT00304291|Novantrone
604438|NCT00304278|Head and Neck Cancer
604439|NCT00304278|Erlotinib
604440|NCT00304278|RADPLAT
604441|NCT00304265|Pertussis,
604442|NCT00304265|Diphtheria,
604443|NCT00304265|Tetanus,
604444|NCT00304265|Poliomyelitis
604445|NCT00304239|Methyl aminolevulinate
604446|NCT00304239|Photodynamic therapy
604447|NCT00304239|Aktilite CL128 LED light source
604448|NCT00304239|Multiple Actinic Keratosis
604449|NCT00304226|Valsartan,
604450|NCT00304226|amlodipine,
604451|NCT00304226|hydrochlorothiazide
604452|NCT00304213|hypogonadism
604453|NCT00304213|testosterone
604454|NCT00304213|aging
604455|NCT00304213|Total testosterone < 300 ng/dL
604456|NCT00304213|Bioavailable testosterone < 70 ng/dL
604457|NCT00304200|Metastatic Malignant Melanoma
604458|NCT00304187|Binge-Eating Disorder
604459|NCT00304161|Depression
604460|NCT00304161|Parkinson's Disease
604461|NCT00304161|Atomoxetine
604462|NCT00304148|Renal Insufficiency Chronic
604463|NCT00304135|localized unresectable adult primary liver cancer
604464|NCT00304135|unresectable extrahepatic bile duct cancer
604465|NCT00304135|unresectable gallbladder cancer
604466|NCT00304096|recurrent breast cancer
604467|NCT00304096|stage IIIA breast cancer
604468|NCT00304096|stage IIIB breast cancer
604469|NCT00304096|stage IIIC breast cancer
604470|NCT00304096|stage IV breast cancer
604471|NCT00304096|male breast cancer
604472|NCT00304096|invasive lobular breast carcinoma
604473|NCT00304083|adult neurofibrosarcoma
604474|NCT00304083|childhood neurofibrosarcoma
604475|NCT00304083|metastatic childhood soft tissue sarcoma
604476|NCT00304083|nonmetastatic childhood soft tissue sarcoma
604477|NCT00304083|stage IV adult soft tissue sarcoma
604478|NCT00304083|neurofibromatosis type 1
604479|NCT00304031|adult glioblastoma
604480|NCT00304031|adult giant cell glioblastoma
604481|NCT00304031|adult gliosarcoma
604482|NCT00304018|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
604483|NCT00304018|recurrent adult acute myeloid leukemia
604484|NCT00304018|secondary acute myeloid leukemia
604485|NCT00304018|adult acute myeloid leukemia in remission
604486|NCT00304018|adult acute erythroid leukemia (M6)
604487|NCT00304018|adult acute megakaryoblastic leukemia (M7)
604488|NCT00304018|adult acute monoblastic leukemia (M5a)
604489|NCT00304018|adult acute monocytic leukemia (M5b)
604490|NCT00304018|refractory multiple myeloma
604491|NCT00304018|adult acute lymphoblastic leukemia in remission
604492|NCT00304018|accelerated phase chronic myelogenous leukemia
604493|NCT00304018|blastic phase chronic myelogenous leukemia
604494|NCT00304018|relapsing chronic myelogenous leukemia
604495|NCT00304018|chronic phase chronic myelogenous leukemia
604496|NCT00304018|stage II multiple myeloma
604497|NCT00304018|stage III multiple myeloma
604498|NCT00304018|recurrent adult acute lymphoblastic leukemia
604499|NCT00304018|recurrent adult diffuse large cell lymphoma
604500|NCT00304018|stage III adult diffuse large cell lymphoma
604501|NCT00304018|recurrent mantle cell lymphoma
604502|NCT00304018|stage III mantle cell lymphoma
604503|NCT00304018|recurrent adult Hodgkin lymphoma
604504|NCT00304018|stage III adult Hodgkin lymphoma
604505|NCT00304018|adult acute myeloid leukemia with inv(16)(p13;q22)
604506|NCT00304018|adult acute myeloid leukemia with t(15;17)(q22;q12)
604507|NCT00304018|adult acute myeloid leukemia with t(16;16)(p13;q22)
604508|NCT00304018|adult acute myeloid leukemia with t(8;21)(q22;q22)
604509|NCT00304018|de novo myelodysplastic syndromes
604510|NCT00304018|previously treated myelodysplastic syndromes
604511|NCT00304018|secondary myelodysplastic syndromes
604512|NCT00304018|recurrent adult T-cell leukemia/lymphoma
604513|NCT00304018|stage IV adult diffuse large cell lymphoma
604514|NCT00304018|stage IV adult Hodgkin lymphoma
604515|NCT00304018|stage IV adult T-cell leukemia/lymphoma
604516|NCT00304018|stage IV mantle cell lymphoma
604517|NCT00304018|stage III adult T-cell leukemia/lymphoma
604518|NCT00304018|stage I multiple myeloma
604519|NCT00304005|refractory chronic lymphocytic leukemia
604520|NCT00304005|recurrent adult diffuse large cell lymphoma
604521|NCT00304005|recurrent adult Hodgkin lymphoma
604522|NCT00303992|stage IV breast cancer
604523|NCT00303992|recurrent breast cancer
604524|NCT00303979|Systolic Heart Failure
604525|NCT00303979|Quality of Care
604526|NCT00303979|Outcomes
604527|NCT00303979|Evidence-based Guidelines
604528|NCT00303979|Recommended Therapies
604529|NCT00303940|unspecified childhood solid tumor, protocol specific
604530|NCT00303940|recurrent childhood rhabdomyosarcoma
604531|NCT00303940|recurrent childhood soft tissue sarcoma
604532|NCT00303940|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
604533|NCT00303940|recurrent osteosarcoma
604534|NCT00303940|recurrent neuroblastoma
604535|NCT00303940|recurrent Wilms tumor and other childhood kidney tumors
604536|NCT00303940|recurrent childhood malignant germ cell tumor
604537|NCT00303940|recurrent childhood liver cancer
604538|NCT00303940|recurrent childhood brain stem glioma
604539|NCT00303940|recurrent childhood cerebellar astrocytoma
604540|NCT00303940|recurrent childhood cerebral astrocytoma
604541|NCT00303940|recurrent childhood ependymoma
604542|NCT00303940|recurrent childhood medulloblastoma
604543|NCT00303940|recurrent childhood supratentorial primitive neuroectodermal tumor
604544|NCT00303940|childhood atypical teratoid/rhabdoid tumor
604545|NCT00303940|childhood low-grade cerebral astrocytoma
604546|NCT00303940|childhood high-grade cerebral astrocytoma
604547|NCT00303940|childhood choroid plexus tumor
604548|NCT00303940|childhood craniopharyngioma
604549|NCT00303940|childhood infratentorial ependymoma
604550|NCT00303940|childhood supratentorial ependymoma
604551|NCT00303940|childhood oligodendroglioma
604552|NCT00303940|recurrent childhood visual pathway and hypothalamic glioma
604553|NCT00303940|recurrent childhood brain tumor
604554|NCT00303940|childhood central nervous system germ cell tumor
604555|NCT00303940|childhood grade I meningioma
604556|NCT00303940|childhood grade II meningioma
604557|NCT00303940|childhood grade III meningioma
604558|NCT00303940|childhood malignant ovarian germ cell tumor
604559|NCT00303940|childhood malignant testicular germ cell tumor
604560|NCT00303940|childhood teratoma
604561|NCT00303927|recurrent pancreatic cancer
604562|NCT00303927|stage IV pancreatic cancer
604563|NCT00303914|pain
604564|NCT00303914|psychosocial effects of cancer and its treatment
604565|NCT00303914|cognitive/functional effects
604566|NCT00303914|recurrent breast cancer
604567|NCT00303914|stage I breast cancer
604568|NCT00303914|stage II breast cancer
604569|NCT00303914|stage IIIA breast cancer
604570|NCT00303914|stage IIIB breast cancer
604571|NCT00303914|stage IIIC breast cancer
604572|NCT00303914|stage IV breast cancer
604573|NCT00303914|recurrent colon cancer
604574|NCT00303914|stage I colon cancer
604575|NCT00303914|stage II colon cancer
604576|NCT00303914|stage III colon cancer
604577|NCT00303914|stage IV colon cancer
604578|NCT00303914|recurrent rectal cancer
604579|NCT00303914|stage I rectal cancer
604580|NCT00303914|stage II rectal cancer
604581|NCT00303914|stage III rectal cancer
604582|NCT00303914|stage IV rectal cancer
604583|NCT00303914|extensive stage small cell lung cancer
604584|NCT00303914|limited stage small cell lung cancer
604585|NCT00303914|recurrent small cell lung cancer
604586|NCT00303914|recurrent non-small cell lung cancer
604587|NCT00303914|stage I non-small cell lung cancer
604588|NCT00303914|stage II non-small cell lung cancer
604589|NCT00303914|stage IIIA non-small cell lung cancer
604590|NCT00303914|stage IIIB non-small cell lung cancer
604591|NCT00303914|stage IV non-small cell lung cancer
604592|NCT00303914|recurrent prostate cancer
604593|NCT00303914|stage I prostate cancer
604594|NCT00303914|stage IIB prostate cancer
604595|NCT00303914|stage IIA prostate cancer
604596|NCT00303914|stage III prostate cancer
604597|NCT00303914|stage IV prostate cancer
604598|NCT00303914|male breast cancer
604599|NCT00303914|pulmonary carcinoid tumor
604600|NCT00303901|lung metastases
604601|NCT00303901|recurrent non-small cell lung cancer
604602|NCT00303901|recurrent small cell lung cancer
604603|NCT00303901|stage I non-small cell lung cancer
604604|NCT00303901|stage II non-small cell lung cancer
604605|NCT00303901|stage IIIA non-small cell lung cancer
604606|NCT00303901|stage IIIB non-small cell lung cancer
604607|NCT00303901|stage IV non-small cell lung cancer
604608|NCT00303901|extensive stage small cell lung cancer
604609|NCT00303901|limited stage small cell lung cancer
604610|NCT00303901|pulmonary carcinoid tumor
604611|NCT00303888|recurrent ovarian epithelial cancer
604612|NCT00303888|fallopian tube cancer
604613|NCT00303888|peritoneal cavity cancer
604614|NCT00303888|stage III ovarian epithelial cancer
604615|NCT00303888|stage IV ovarian epithelial cancer
604616|NCT00303875|recurrent prostate cancer
604617|NCT00303875|stage I prostate cancer
604618|NCT00303875|stage IIB prostate cancer
604619|NCT00303875|stage IIA prostate cancer
604620|NCT00303875|stage III prostate cancer
604621|NCT00303875|stage IV prostate cancer
604622|NCT00303875|recurrent breast cancer
604623|NCT00303875|stage I breast cancer
604624|NCT00303875|stage II breast cancer
604625|NCT00303875|stage IIIA breast cancer
604626|NCT00303875|stage IIIB breast cancer
604627|NCT00303875|stage IIIC breast cancer
604628|NCT00303875|stage IV breast cancer
604629|NCT00303875|recurrent colon cancer
604630|NCT00303875|stage I colon cancer
604631|NCT00303875|stage II colon cancer
604632|NCT00303875|stage III colon cancer
604633|NCT00303875|stage IV colon cancer
604634|NCT00303875|recurrent rectal cancer
604635|NCT00303875|stage I rectal cancer
604636|NCT00303875|stage II rectal cancer
604637|NCT00303875|stage III rectal cancer
604638|NCT00303875|stage IV rectal cancer
604639|NCT00303810|childhood infratentorial ependymoma
604640|NCT00303810|childhood supratentorial ependymoma
604641|NCT00303810|untreated childhood medulloblastoma
604642|NCT00303810|newly diagnosed childhood ependymoma
604643|NCT00303810|untreated childhood supratentorial primitive neuroectodermal tumor
604644|NCT00303784|hot flashes
604645|NCT00303784|anemia
604646|NCT00303784|osteoporosis
604647|NCT00303784|cardiovascular complications
604648|NCT00303784|recurrent prostate cancer
604649|NCT00303784|stage III prostate cancer
604650|NCT00303784|stage IV prostate cancer
604651|NCT00303784|adenocarcinoma of the prostate
604652|NCT00303771|adenocarcinoma of the rectum
604653|NCT00303771|stage IV rectal cancer
604654|NCT00303771|stage IV colon cancer
604655|NCT00303771|adenocarcinoma of the colon
604656|NCT00303771|recurrent colon cancer
604657|NCT00303771|recurrent rectal cancer
604658|NCT00303758|adenocarcinoma of the pancreas
604659|NCT00303758|recurrent pancreatic cancer
604660|NCT00303758|stage IV pancreatic cancer
604661|NCT00303745|adenocarcinoma of the colon
604662|NCT00303745|recurrent colon cancer
604663|NCT00303745|stage IV colon cancer
604664|NCT00303745|adenocarcinoma of the rectum
604665|NCT00303745|recurrent rectal cancer
604666|NCT00303745|stage IV rectal cancer
604667|NCT00303732|unspecified adult solid tumor, protocol specific
604668|NCT00303732|recurrent renal cell cancer
604669|NCT00303732|stage IV renal cell cancer
604670|NCT00303719|leukemia
604671|NCT00303719|lymphoma
604672|NCT00303719|myeloma
604673|NCT00303706|CABG, Endoscopic, Radial Artery
604674|NCT00303706|Radial Artery Conduit
604675|NCT00303706|Coronary Artery Bypass Surgery
604676|NCT00303706|Endoscopic technique
604677|NCT00303667|NK cells
604678|NCT00303667|natural killer cells
604679|NCT00303667|immunotherapy
604680|NCT00303667|hematopoietic cell transplant
604681|NCT00303667|acute myelogenous leukemia
604682|NCT00303654|recurrent bladder cancer
604683|NCT00303654|stage I bladder cancer
604684|NCT00303654|stage II bladder cancer
604685|NCT00303654|stage III bladder cancer
604686|NCT00303654|stage IV bladder cancer
604687|NCT00303641|Cardiopulmonary bypass
604688|NCT00303641|Inflammatory reaction
604689|NCT00303628|Rectal cancer
604690|NCT00303628|Bevacizumab
604691|NCT00303615|ER (-) and PR (-)
604692|NCT00303576|HIV-1
604693|NCT00303576|HIV Seronegativity
604694|NCT00303550|skin infection
604695|NCT00303550|complicated skin infection
604696|NCT00303550|skin structure infection
604697|NCT00303550|Complicated Skin and Skin Structure Infection
604698|NCT00303537|hepatitis
604699|NCT00303537|metformin
604700|NCT00303537|non-alcoholic fatty liver (NAFLD)
604701|NCT00303537|non-alcoholic steatohepatitis (NASH)
604702|NCT00303537|Nonalcoholic fatty liver disease
604703|NCT00303511|adult
604704|NCT00303511|pacemaker
604705|NCT00303511|bradycardia
604706|NCT00303511|tachycardia
604707|NCT00303511|heart failure
604708|NCT00303472|MDS
604709|NCT00303472|Myelodysplastic Syndromes
604710|NCT00303472|Refractory Cytopenias
604711|NCT00303472|Thrombocytopenia
604712|NCT00303459|sildenafil
604713|NCT00303459|Combination Drug Therapy
604714|NCT00303459|bosentan
604715|NCT00303459|Pulmonary Hypertension
604716|NCT00303459|Pulmonary Arterial Hypertension
604717|NCT00303459|Multicenter Study
604718|NCT00303459|Antihypertensive Agents
604719|NCT00303459|Tracleer
604720|NCT00303459|endothelin receptor antagonist
604721|NCT00303459|Randomized Controlled Trial
604722|NCT00303459|Phosphodiesterase type 5 inhibitor (PDE5i)
604723|NCT00303459|Outcome Assessment
604724|NCT00303446|Motor Neuron
604725|NCT00303446|Androgen Receptor
604726|NCT00303446|Polyglutamine
604727|NCT00303446|X-Linked
604728|NCT00303446|Ligand Dependency
604729|NCT00303446|Spinal and Bulbar Muscular Atrophy
604730|NCT00303446|SBMA
604731|NCT00303446|Kennedy Disease
604732|NCT00303433|Prevention
604733|NCT00303433|Post-Operative tates
604734|NCT00303433|Delirium
604735|NCT00303433|Namenda
604736|NCT00303420|catheter
604737|NCT00303420|hemodialysis
604738|NCT00303420|dysfunction
604739|NCT00303420|thrombolytic
604740|NCT00303420|alteplase
604741|NCT00303394|Type 2 Diabetes, IL-1, inflammation, glucotoxicity, insulin
604742|NCT00303368|Neurofibromatosis (NF1)
604743|NCT00303368|Tibial Dysplasia (TD)
604744|NCT00303355|jugular venous pulse
604745|NCT00303342|sleep
604746|NCT00303342|arousal
604747|NCT00303342|stress
604748|NCT00303342|cortisol
604749|NCT00303342|catecholamines
604750|NCT00303329|β-thalassemia
604751|NCT00303329|rare chronic anemia
604752|NCT00303329|iron overload
604753|NCT00303329|deferasirox
604754|NCT00303329|chronic anemias
604755|NCT00303329|transfusional hemosiderosis
604756|NCT00303316|Diphtheria
604757|NCT00303316|Tetanus
604758|NCT00303316|Pertussis
604759|NCT00303316|whooping cough
604760|NCT00303316|Haemophilus influenzae type b
604761|NCT00303316|Hepatitis B
604762|NCT00303316|Poliomyelitis
604763|NCT00303303|Snake envenomation
604764|NCT00303303|Antivenins
604765|NCT00303303|Disability evaluation
604766|NCT00303303|Activities of daily living
604767|NCT00303290|Early Chronic Phase CML
604768|NCT00303290|Peg Interferon Alpha 2b
604769|NCT00303290|Peg Intron
604770|NCT00303290|Ara-C
604771|NCT00303290|Cytosine Arabinoside
604772|NCT00303277|Alzheimer's disease
604773|NCT00303277|beta-amyloid
604774|NCT00303277|statins
604775|NCT00303264|functional dyspepsia
604776|NCT00303264|cholecystokinin
604777|NCT00303264|CCK
604778|NCT00303264|gastrointestinal
604779|NCT00303264|intestinal transit
604780|NCT00303264|GI motility
604781|NCT00303264|bloating
604782|NCT00303264|upper GI discomfort
604783|NCT00303264|upper GI
604784|NCT00303264|early satiety
604785|NCT00303264|nausea
604786|NCT00303264|belching
604787|NCT00303264|retching
604788|NCT00303264|vomiting
604789|NCT00303264|GERD
604790|NCT00303251|Locally Advanced or Metastatic Melanoma
604791|NCT00303238|Inflammation
604792|NCT00303238|Interleukin-1
604793|NCT00303238|C-reactive protein
604794|NCT00303238|Genotype
604795|NCT00303238|Rose Hips
604796|NCT00303238|Blueberry
604797|NCT00303238|Blackberry
604798|NCT00303238|Aframomum melegueta
604799|NCT00303238|Resveravine
604800|NCT00303225|Biodefense
604801|NCT00303225|Smallpox
604802|NCT00303225|Monkeypox
604803|NCT00303225|Vaccinia
604804|NCT00303225|Prophylaxis
604805|NCT00303225|Healthy Volunteer
604806|NCT00303225|HV
604807|NCT00303212|heart failure
604808|NCT00303212|CHF
604809|NCT00303212|telemedicine
604810|NCT00303212|disease management
604811|NCT00303199|Multiple Myeloma
604812|NCT00303199|Arsenic
604813|NCT00303199|Cancer study
604814|NCT00303199|Failed treatment
604815|NCT00303186|Rheumatoid Arthritis
604816|NCT00303173|Pre-eclampsia
604817|NCT00303173|hypertension
604818|NCT00303173|blood pressure
604819|NCT00303173|pregnancy
604820|NCT00303173|randomized clinical trial
604821|NCT00303173|guided imagery
604822|NCT00303173|relaxation
604823|NCT00303173|psychophysiology
604824|NCT00303173|mind-body
604825|NCT00303160|heliobacter pylori infection
604826|NCT00303160|reactive oxygen species
604827|NCT00303160|antioxidants
604828|NCT00303147|Expressive Writing
604829|NCT00303147|Written Emotional Expression
604830|NCT00303147|Caregiver Stress
604831|NCT00303147|Cognition
604832|NCT00303134|islet cell
604833|NCT00303134|diabetes
604834|NCT00303134|transplant
604835|NCT00303134|immunosuppression
604836|NCT00303134|autoimmunity
604837|NCT00303134|alloimmunity
604838|NCT00303121|Glaucoma
604839|NCT00303121|Compliance
604840|NCT00303121|Therapy
604841|NCT00303121|Administration technique
604842|NCT00303082|Probiotics
604843|NCT00303082|Bacterial Vaginosis
604844|NCT00303082|Premature birth
604845|NCT00303082|Intra-uterine Infection
604846|NCT00303082|Periventricular leukomalacia
604847|NCT00303069|S. aureus;
604848|NCT00303069|Vaccine
604849|NCT00303069|FIM
604850|NCT00303056|Osteoarthritis
604851|NCT00303056|knee
604852|NCT00303043|Hemodynamic monitoring
604853|NCT00303043|Mixed venous saturation
604854|NCT00303043|Critically ill patients
604855|NCT00303030|Fecal incontinence
604856|NCT00303030|Biofeedback
604857|NCT00303030|Patient Satisfaction
604858|NCT00303030|Quality of LifeTreatment Outcome
604859|NCT00303030|Injections
604860|NCT00302991|Observational
604861|NCT00302991|cross-sectional
604862|NCT00302991|health-related quality of life
604863|NCT00302991|adverse effects
604864|NCT00302991|Baker´s AEP scale validation
604865|NCT00302991|epilepsy
604866|NCT00302978|Height phobia
604867|NCT00302978|fear of heights
604868|NCT00302978|specific phobia
604869|NCT00302965|Plasma
604870|NCT00302965|Trauma
604871|NCT00302965|Critical Care
604872|NCT00302952|Arthritis, Rheumatoid
604873|NCT00302939|Aging
604874|NCT00302926|Weight loss
604875|NCT00302926|obesity
604876|NCT00302926|energy restriction
604877|NCT00302913|Clopidogrel
604878|NCT00302913|Coronary Artery Disease
604879|NCT00302913|Dose-Response Relationship, Drug
604880|NCT00302913|Drug Resistance
604881|NCT00302913|PCI
604882|NCT00302900|Blood Donation
604883|NCT00302900|Syncope
604884|NCT00302900|Vasovagal Reactions
604885|NCT00302887|fibromyalgia
604886|NCT00302887|connective tissue manipulation
604887|NCT00302887|ultrasound therapy
604888|NCT00302887|high voltage pulsed galvanic stimulation
604889|NCT00302874|diabetes
604890|NCT00302874|hyperglycemia
604891|NCT00302874|hospital
604892|NCT00302874|medicine ward
604893|NCT00302861|B-Cll
604894|NCT00302848|Venous thromboembolism
604895|NCT00302848|Drospirenone
604896|NCT00302835|Analgesics
604897|NCT00302835|Chronic Kidney Failure
604898|NCT00302822|HIV infections
604899|NCT00302822|Fuzeon
604900|NCT00302822|Truvada
604901|NCT00302822|AIDS
604902|NCT00302822|Treatment Naive
604903|NCT00302809|Flavonoids
604904|NCT00302809|Arterial stiffness
604905|NCT00302809|Blood pressure
604906|NCT00302809|Endothelium
604907|NCT00302809|Inflammation
604908|NCT00302796|Low Back Pain,
604909|NCT00302783|Education, Medical
604910|NCT00302783|Education, Competency-Based
604911|NCT00302783|Multi-Source Feedback
604912|NCT00302783|Communication
604913|NCT00302783|Professionalism
604914|NCT00302770|Patients with SAD
604915|NCT00302757|NHL
604916|NCT00302757|low and high grade non-Hodgkin lymphoma
604917|NCT00302744|Anxiety
604918|NCT00302744|Depression
604919|NCT00302744|Mood
604920|NCT00302744|Cancer
604921|NCT00302744|Quality of Life
604922|NCT00302744|Psychiatric
604923|NCT00302744|Psilocybin
604924|NCT00302744|Alternative
604925|NCT00302744|Los Angeles
604926|NCT00302718|Physician Incentive Plan
604927|NCT00302718|Quality of Health Care
604928|NCT00302718|Reimbursement, Incentive
604929|NCT00302718|Randomized Controlled Trial
604930|NCT00302718|Physicians
604931|NCT00302718|Reward
604932|NCT00302705|Ambulatory blood pressure monitoring
604933|NCT00302705|Valsartan
604934|NCT00302705|Enalapril
604935|NCT00302705|Missing dose
604936|NCT00302679|Colonoscopy
604937|NCT00302679|Sigmoidoscopy
604938|NCT00302679|Colon cancer screening
604939|NCT00302679|Pain
604940|NCT00302679|Screening
604941|NCT00302666|Contraception, Bleeding pattern
604942|NCT00302627|bisphosphonates
604943|NCT00302627|vitamin D
604944|NCT00302627|calcium supplement
604945|NCT00302627|corticosteroid therapy
604946|NCT00302627|fractures
604947|NCT00302614|obstructive sleep apnea
604948|NCT00302614|snoring
604949|NCT00302614|collapsibility
604950|NCT00302614|upper airway
604951|NCT00302601|Pulmonary embolism
604952|NCT00302601|Right heart strain
604953|NCT00302601|Lung scintigraphy
604954|NCT00302601|Pulmonary angiography
604955|NCT00302588|metastatic carcinoma
604956|NCT00302588|cervical lymph nodes
604957|NCT00302588|unknown primary
604958|NCT00302588|diagnosis
604959|NCT00302588|result
604960|NCT00302575|Substance-Related Disorders
604961|NCT00302575|Prisoners
604962|NCT00302562|laryngeal cancer
604963|NCT00302562|hypopharyngeal cancer
604964|NCT00302562|CXCR4
604965|NCT00302562|CXCL12
604966|NCT00302562|matrix metalloproteinases(MMPs)
604967|NCT00302562|metastasis
604968|NCT00302549|Tacrolimus
604969|NCT00302549|Cyclophosphamide
604970|NCT00302549|Treatment
604971|NCT00302549|Lupus Nephritis
604972|NCT00302536|Idiopathic Focal Segmental Glomerulosclerosis
604973|NCT00302536|Treatment
604974|NCT00302536|Steroids
604975|NCT00302523|Idiopathic Membranous Nephropathy
604976|NCT00302523|Treatment
604977|NCT00302523|Tacrolimus
604978|NCT00302523|Cyclophosphamide
604979|NCT00302510|lipoprotein glomerulopathy
604980|NCT00302510|treatment
604981|NCT00302510|immunoadsorption
604982|NCT00302510|apolipoprotein E
604983|NCT00302458|healthy volunteers
604984|NCT00302432|smoking reduction
604985|NCT00302432|group therapy
604986|NCT00302432|cigarette holders
604987|NCT00302432|"Flowers Menthol"
604988|NCT00302419|Acute myocardial infarction
604989|NCT00302419|primary angioplasty
604990|NCT00302419|streptokinase
604991|NCT00302419|microvasculature
604992|NCT00302393|healthy volunteers
604993|NCT00302341|Pulmonary disease
604994|NCT00302341|Dyspnea
604995|NCT00302341|Hypoxemia
604996|NCT00302341|AIDS
604997|NCT00302341|Pneumocystis jiroveci
604998|NCT00302315|postcesarean physiotherapy
604999|NCT00302315|incisional pain
605000|NCT00302315|functional activity
605001|NCT00302315|connective tissue manipulation
605002|NCT00302315|transcutaneous electrical nerve stimulation
605003|NCT00302302|Blood glucose
605004|NCT00302302|Insulin
605005|NCT00302302|Triglyceride
605006|NCT00302302|GIP
605007|NCT00302302|GLP-1
605008|NCT00302302|L-arabinose
605009|NCT00302302|Appetite
605010|NCT00302302|Energy intake
605011|NCT00302289|green tea
605012|NCT00302289|caffeine
605013|NCT00302289|tyrosine
605014|NCT00302289|energy expenditure
605015|NCT00302289|energy intake
605016|NCT00302276|Body fat loss
605017|NCT00302276|energy expenditure
605018|NCT00302276|capsaicin
605019|NCT00302276|caffeine
605020|NCT00302276|green tea
605021|NCT00302276|calcium
605022|NCT00302276|fecal fat
605023|NCT00302276|fecal energy
605024|NCT00302263|Green tea
605025|NCT00302263|capsaicin
605026|NCT00302263|tyrosine
605027|NCT00302263|caffeine
605028|NCT00302263|energy expenditure
605029|NCT00302263|catecholamines
605030|NCT00302250|Cardiovascular
605031|NCT00302250|Flow-mediated vasodilation (FMD)
605032|NCT00302250|Pulse perfusion-mediated vasodilation (PPMV)
605033|NCT00302250|Endothelial function
605034|NCT00302250|Heart failure
605035|NCT00302237|carotid, stenting, angioplasty
605036|NCT00302224|safety
605037|NCT00302224|type 2 diabetes
605038|NCT00302211|PAH
605039|NCT00302211|Pulmonary Arterial Hypertension
605040|NCT00302198|Amyotrophic Lateral Sclerosis
605041|NCT00302185|Palliative Care
605042|NCT00302185|Acupuncture
605043|NCT00302185|Symptom Management
605044|NCT00302185|Quality of Life
605045|NCT00302172|Cancer
605046|NCT00302172|solid tumor
605047|NCT00302172|metastatic
605048|NCT00302172|primary tumor
605049|NCT00302159|Chemotherapy
605050|NCT00302159|Radiation
605051|NCT00302159|Brain Tumor
605052|NCT00302159|GBM
605053|NCT00302159|Radiosensitizer
605054|NCT00302159|Glioblastoma
605055|NCT00302159|Glioblastoma Multiforme
605056|NCT00302146|Lysosomal Storage Disorder
605057|NCT00302146|Carrier
605058|NCT00302146|L-Dopa Uptake
605059|NCT00302146|Glucocerebrosidase
605060|NCT00302146|Pathogenesis
605061|NCT00302146|Carbidopa
605062|NCT00302146|Gaucher Disease
605063|NCT00302146|Parkinson Disease
605064|NCT00302146|[O-15]-Water
605065|NCT00302146|6-[F-18]Fluoro-L-dopa
605066|NCT00302146|Healthy Volunteer
605067|NCT00302146|HV
605068|NCT00302133|Alcoholism Bipolar Disorder Pharmacotherapy Naltrexone
605069|NCT00302120|Magnetic Resonance Imaging
605070|NCT00302120|Breast Neoplasms
605071|NCT00302120|Diagnostic Trial
605072|NCT00302107|Mirtazapine
605073|NCT00302107|PTSD
605074|NCT00302107|Veterans
605075|NCT00302107|antidepressant
605076|NCT00302081|Hepatitis C, Chronic
605077|NCT00302081|Genotype 2 and Genotype 3
605078|NCT00302068|Exercise
605079|NCT00302029|Cytomegalovirus, risk factors, seroprevalence
605080|NCT00302016|Chronic myeloid leukemia
605081|NCT00302016|AMN 107
605082|NCT00302016|Imatinib resistant or intolerant
605083|NCT00302016|nilotinib
605084|NCT00302016|enact
605085|NCT00301990|stage IV renal cell cancer
605086|NCT00301990|recurrent renal cell cancer
605087|NCT00301990|clear cell renal cell carcinoma
605088|NCT00301951|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
605089|NCT00301951|adult acute myeloid leukemia with inv(16)(p13;q22)
605090|NCT00301951|adult acute myeloid leukemia with t(15;17)(q22;q12)
605091|NCT00301951|adult acute myeloid leukemia with t(16;16)(p13;q22)
605092|NCT00301951|adult acute myeloid leukemia with t(8;21)(q22;q22)
605093|NCT00301951|accelerated phase chronic myelogenous leukemia
605094|NCT00301951|adult acute lymphoblastic leukemia in remission
605095|NCT00301951|adult acute myeloid leukemia in remission
605096|NCT00301951|angioimmunoblastic T-cell lymphoma
605097|NCT00301951|blastic phase chronic myelogenous leukemia
605098|NCT00301951|chronic myelomonocytic leukemia
605099|NCT00301951|chronic phase chronic myelogenous leukemia
605100|NCT00301951|de novo myelodysplastic syndromes
605101|NCT00301951|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
605102|NCT00301951|anaplastic large cell lymphoma
605103|NCT00301951|nodal marginal zone B-cell lymphoma
605104|NCT00301951|previously treated myelodysplastic syndromes
605105|NCT00301951|recurrent adult acute lymphoblastic leukemia
605106|NCT00301951|recurrent adult acute myeloid leukemia
605107|NCT00301951|recurrent adult T-cell leukemia/lymphoma
605108|NCT00301951|recurrent adult Hodgkin lymphoma
605109|NCT00301951|recurrent adult diffuse large cell lymphoma
605110|NCT00301951|recurrent cutaneous T-cell non-Hodgkin lymphoma
605111|NCT00301951|recurrent grade 1 follicular lymphoma
605112|NCT00301951|recurrent grade 2 follicular lymphoma
605113|NCT00301951|recurrent grade 3 follicular lymphoma
605114|NCT00301951|recurrent mantle cell lymphoma
605115|NCT00301951|recurrent marginal zone lymphoma
605116|NCT00301951|recurrent mycosis fungoides/Sezary syndrome
605117|NCT00301951|recurrent small lymphocytic lymphoma
605118|NCT00301951|refractory chronic lymphocytic leukemia
605119|NCT00301951|stage III adult T-cell leukemia/lymphoma
605120|NCT00301951|refractory multiple myeloma
605121|NCT00301951|relapsing chronic myelogenous leukemia
605122|NCT00301951|secondary acute myeloid leukemia
605123|NCT00301951|secondary myelodysplastic syndromes
605124|NCT00301951|splenic marginal zone lymphoma
605125|NCT00301951|stage I multiple myeloma
605126|NCT00301951|stage II multiple myeloma
605127|NCT00301951|stage IV adult T-cell leukemia/lymphoma
605128|NCT00301951|stage III adult Hodgkin lymphoma
605129|NCT00301951|stage III adult diffuse large cell lymphoma
605130|NCT00301951|stage III chronic lymphocytic leukemia
605131|NCT00301951|stage III grade 1 follicular lymphoma
605132|NCT00301951|stage III grade 2 follicular lymphoma
605133|NCT00301951|stage III grade 3 follicular lymphoma
605134|NCT00301951|stage III mantle cell lymphoma
605135|NCT00301951|stage III marginal zone lymphoma
605136|NCT00301951|stage III multiple myeloma
605137|NCT00301951|stage III small lymphocytic lymphoma
605138|NCT00301951|stage IV adult Hodgkin lymphoma
605139|NCT00301951|stage IV adult diffuse large cell lymphoma
605140|NCT00301951|stage IV chronic lymphocytic leukemia
605141|NCT00301951|stage IV grade 1 follicular lymphoma
605142|NCT00301951|stage IV grade 2 follicular lymphoma
605143|NCT00301951|stage IV grade 3 follicular lymphoma
605144|NCT00301951|stage IV mantle cell lymphoma
605145|NCT00301951|stage IV marginal zone lymphoma
605146|NCT00301951|stage IV small lymphocytic lymphoma
605147|NCT00301925|stage I breast cancer
605148|NCT00301925|stage II breast cancer
605149|NCT00301925|stage IIIA breast cancer
605150|NCT00301925|male breast cancer
605151|NCT00301912|chronic phase chronic myelogenous leukemia
605152|NCT00301912|accelerated phase chronic myelogenous leukemia
605153|NCT00301912|blastic phase chronic myelogenous leukemia
605154|NCT00301912|adult acute myeloid leukemia in remission
605155|NCT00301912|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
605156|NCT00301912|adult acute myeloid leukemia with inv(16)(p13;q22)
605157|NCT00301912|adult acute myeloid leukemia with t(15;17)(q22;q12)
605158|NCT00301912|adult acute myeloid leukemia with t(16;16)(p13;q22)
605159|NCT00301912|adult acute myeloid leukemia with t(8;21)(q22;q22)
605160|NCT00301912|recurrent adult acute myeloid leukemia
605161|NCT00301912|secondary acute myeloid leukemia
605162|NCT00301912|de novo myelodysplastic syndromes
605163|NCT00301912|previously treated myelodysplastic syndromes
605164|NCT00301912|secondary myelodysplastic syndromes
605165|NCT00301912|atypical chronic myeloid leukemia
605166|NCT00301912|myelodysplastic/myeloproliferative disease, unclassifiable
605167|NCT00301912|adult acute lymphoblastic leukemia in remission
605168|NCT00301912|recurrent adult lymphoblastic lymphoma
605169|NCT00301912|anemia
605170|NCT00301912|refractory chronic lymphocytic leukemia
605171|NCT00301912|stage III chronic lymphocytic leukemia
605172|NCT00301912|stage IV chronic lymphocytic leukemia
605173|NCT00301912|Waldenstrom macroglobulinemia
605174|NCT00301912|stage II multiple myeloma
605175|NCT00301912|stage III multiple myeloma
605176|NCT00301912|refractory multiple myeloma
605177|NCT00301912|polycythemia vera
605178|NCT00301912|essential thrombocythemia
605179|NCT00301912|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
605180|NCT00301912|nodal marginal zone B-cell lymphoma
605181|NCT00301912|splenic marginal zone lymphoma
605182|NCT00301912|recurrent adult Burkitt lymphoma
605183|NCT00301912|recurrent adult diffuse large cell lymphoma
605184|NCT00301912|recurrent adult diffuse mixed cell lymphoma
605185|NCT00301912|recurrent adult immunoblastic large cell lymphoma
605186|NCT00301912|recurrent grade 3 follicular lymphoma
605187|NCT00301912|recurrent mantle cell lymphoma
605188|NCT00301912|recurrent adult diffuse small cleaved cell lymphoma
605189|NCT00301912|recurrent grade 1 follicular lymphoma
605190|NCT00301912|recurrent grade 2 follicular lymphoma
605191|NCT00301912|recurrent marginal zone lymphoma
605192|NCT00301912|recurrent small lymphocytic lymphoma
605193|NCT00301912|relapsing chronic myelogenous leukemia
605194|NCT00301912|chronic eosinophilic leukemia
605195|NCT00301912|chronic idiopathic myelofibrosis
605196|NCT00301912|chronic myelomonocytic leukemia
605197|NCT00301912|chronic neutrophilic leukemia
605198|NCT00301912|noncontiguous stage II adult Burkitt lymphoma
605199|NCT00301912|noncontiguous stage II adult diffuse large cell lymphoma
605200|NCT00301912|noncontiguous stage II adult diffuse mixed cell lymphoma
605201|NCT00301912|noncontiguous stage II adult diffuse small cleaved cell lymphoma
605202|NCT00301912|noncontiguous stage II adult immunoblastic large cell lymphoma
605203|NCT00301912|noncontiguous stage II adult lymphoblastic lymphoma
605204|NCT00301912|noncontiguous stage II grade 1 follicular lymphoma
605205|NCT00301912|noncontiguous stage II grade 2 follicular lymphoma
605206|NCT00301912|noncontiguous stage II grade 3 follicular lymphoma
605207|NCT00301912|noncontiguous stage II mantle cell lymphoma
605208|NCT00301912|noncontiguous stage II marginal zone lymphoma
605209|NCT00301912|noncontiguous stage II small lymphocytic lymphoma
605210|NCT00301912|stage III adult Burkitt lymphoma
605211|NCT00301912|stage III adult diffuse large cell lymphoma
605212|NCT00301912|stage III adult diffuse mixed cell lymphoma
605213|NCT00301912|stage III adult diffuse small cleaved cell lymphoma
605214|NCT00301912|stage III adult immunoblastic large cell lymphoma
605215|NCT00301912|stage III adult lymphoblastic lymphoma
605216|NCT00301912|stage III grade 1 follicular lymphoma
605217|NCT00301912|stage III grade 2 follicular lymphoma
605218|NCT00301912|stage III grade 3 follicular lymphoma
605219|NCT00301912|stage III mantle cell lymphoma
605220|NCT00301912|stage III marginal zone lymphoma
605221|NCT00301912|stage III small lymphocytic lymphoma
605222|NCT00301912|stage IV adult Burkitt lymphoma
605223|NCT00301912|stage IV adult diffuse large cell lymphoma
605224|NCT00301912|stage IV adult diffuse mixed cell lymphoma
605225|NCT00301912|stage IV adult diffuse small cleaved cell lymphoma
605226|NCT00301912|stage IV adult immunoblastic large cell lymphoma
605227|NCT00301912|stage IV adult lymphoblastic lymphoma
605228|NCT00301912|stage IV grade 1 follicular lymphoma
605229|NCT00301912|stage IV grade 2 follicular lymphoma
605230|NCT00301912|stage IV grade 3 follicular lymphoma
605231|NCT00301912|stage IV mantle cell lymphoma
605232|NCT00301912|stage IV marginal zone lymphoma
605233|NCT00301912|stage IV small lymphocytic lymphoma
605234|NCT00301912|recurrent adult acute lymphoblastic leukemia
605235|NCT00301912|stage I multiple myeloma
605236|NCT00301912|childhood myelodysplastic syndromes
605237|NCT00301899|recurrent breast cancer
605238|NCT00301899|male breast cancer
605239|NCT00301899|stage IIIA breast cancer
605240|NCT00301899|stage IIIB breast cancer
605241|NCT00301899|stage IIIC breast cancer
605242|NCT00301899|stage IV breast cancer
605243|NCT00301886|pain
605244|NCT00301886|hypercalcemia of malignancy
605245|NCT00301886|stage IV breast cancer
605246|NCT00301886|bone metastases
605247|NCT00301886|recurrent breast cancer
605248|NCT00301873|osteoporosis
605249|NCT00301873|adult anaplastic astrocytoma
605250|NCT00301873|adult giant cell glioblastoma
605251|NCT00301873|adult anaplastic oligodendroglioma
605252|NCT00301873|adult gliosarcoma
605253|NCT00301873|adult mixed glioma
605254|NCT00301873|recurrent adult brain tumor
605255|NCT00301873|adult glioblastoma
605256|NCT00301860|childhood acute lymphoblastic leukemia in remission
605362|NCT00301483|blunt trauma
605257|NCT00301860|childhood acute myeloid leukemia in remission
605258|NCT00301860|recurrent childhood acute lymphoblastic leukemia
605259|NCT00301860|recurrent childhood acute myeloid leukemia
605260|NCT00301860|recurrent childhood small noncleaved cell lymphoma
605261|NCT00301860|juvenile myelomonocytic leukemia
605262|NCT00301860|chronic phase chronic myelogenous leukemia
605263|NCT00301860|accelerated phase chronic myelogenous leukemia
605264|NCT00301860|relapsing chronic myelogenous leukemia
605265|NCT00301860|recurrent childhood large cell lymphoma
605266|NCT00301860|recurrent childhood lymphoblastic lymphoma
605267|NCT00301860|recurrent/refractory childhood Hodgkin lymphoma
605268|NCT00301860|childhood chronic myelogenous leukemia
605269|NCT00301847|tumors metastatic to brain
605270|NCT00301847|recurrent renal cell cancer
605271|NCT00301847|stage IV renal cell cancer
605272|NCT00301834|de novo myelodysplastic syndromes
605273|NCT00301834|previously treated myelodysplastic syndromes
605274|NCT00301834|secondary myelodysplastic syndromes
605275|NCT00301834|childhood acute myeloid leukemia in remission
605276|NCT00301834|childhood chronic myelogenous leukemia
605277|NCT00301834|congenital amegakaryocytic thrombocytopenia
605278|NCT00301834|Diamond-Blackfan anemia
605279|NCT00301834|severe congenital neutropenia
605280|NCT00301834|secondary acute myeloid leukemia
605281|NCT00301834|chronic phase chronic myelogenous leukemia
605282|NCT00301834|childhood myelodysplastic syndromes
605283|NCT00301821|contiguous stage II adult diffuse large cell lymphoma
605284|NCT00301821|noncontiguous stage II adult diffuse large cell lymphoma
605285|NCT00301821|stage III adult diffuse large cell lymphoma
605286|NCT00301821|stage IV adult diffuse large cell lymphoma
605287|NCT00301808|stage IIIA non-small cell lung cancer
605288|NCT00301808|stage IIIB non-small cell lung cancer
605289|NCT00301782|testicular choriocarcinoma and embryonal carcinoma
605290|NCT00301782|testicular choriocarcinoma and teratoma
605291|NCT00301782|testicular choriocarcinoma and yolk sac tumor
605292|NCT00301782|testicular choriocarcinoma
605293|NCT00301782|testicular embryonal carcinoma and teratoma
605294|NCT00301782|testicular embryonal carcinoma and yolk sac tumor
605295|NCT00301782|testicular embryonal carcinoma
605296|NCT00301782|testicular yolk sac tumor
605297|NCT00301782|testicular yolk sac tumor and teratoma
605298|NCT00301782|stage I malignant testicular germ cell tumor
605299|NCT00301782|stage II malignant testicular germ cell tumor
605300|NCT00301782|stage III malignant testicular germ cell tumor
605301|NCT00301782|recurrent malignant testicular germ cell tumor
605302|NCT00301782|recurrent extragonadal non-seminomatous germ cell tumor
605303|NCT00301782|stage I extragonadal non-seminomatous germ cell tumor
605304|NCT00301782|stage II extragonadal non-seminomatous germ cell tumor
605305|NCT00301782|stage III extragonadal non-seminomatous germ cell tumor
605306|NCT00301782|stage IV extragonadal non-seminomatous germ cell tumor
605307|NCT00301782|recurrent extragonadal germ cell tumor
605308|NCT00301782|testicular immature teratoma
605309|NCT00301782|testicular mature teratoma
605310|NCT00301782|adult teratoma
605311|NCT00301730|lung metastases
605312|NCT00301730|stage IV breast cancer
605313|NCT00301730|recurrent breast cancer
605314|NCT00301691|unspecified adult solid tumor, protocol specific
605315|NCT00301678|unspecified adult solid tumor, protocol specific
605316|NCT00301652|ANCA
605317|NCT00301652|vasculitis
605318|NCT00301652|mycophenolate mofetil
605319|NCT00301652|cyclophosphamide
605320|NCT00301652|treatment
605321|NCT00301626|tobacco
605322|NCT00301626|nicotine
605323|NCT00301626|smoking reduction
605324|NCT00301613|Henoch-Schonlein purpura nephritis Mycophenolate mofetil
605325|NCT00301613|Cyclophosphamide
605326|NCT00301613|treatment
605327|NCT00301600|Crescentic IgA nephropathy
605328|NCT00301600|Mycophenolate mofetil
605329|NCT00301600|Cyclophosphamide
605330|NCT00301600|treatment
605331|NCT00301587|spina bifida
605332|NCT00301587|birth defects
605333|NCT00301587|folic acid
605334|NCT00301587|nervous system diseases
605335|NCT00301587|folate
605336|NCT00301587|Vitamin B
605337|NCT00301574|Alzheimer's disease
605338|NCT00301574|Cognitive dysfunction
605339|NCT00301561|Antiretroviral treatment
605340|NCT00301561|Expanded access
605341|NCT00301561|Africa
605342|NCT00301561|Treatment Naive
605343|NCT00301548|antineoplastic protocols
605344|NCT00301548|neoadjuvant therapy
605345|NCT00301548|perioperative chemotherapy
605346|NCT00301548|fluorouracil
605347|NCT00301535|Coronary Artery Bypass Graft
605348|NCT00301535|memory loss after cardiac surgery
605349|NCT00301535|side effects of bypass
605350|NCT00301522|Coronary
605351|NCT00301522|Artery
605352|NCT00301522|Stenosis
605353|NCT00301522|Drug-eluting
605354|NCT00301522|stent
605355|NCT00301522|restenosis
605356|NCT00301522|revascularization
605357|NCT00301483|multiple trauma
605358|NCT00301483|bleeding injuries
605359|NCT00301483|gunshot wounds
605360|NCT00301483|stab wounds
605361|NCT00301483|penetrating injuries
605363|NCT00301483|multiple wounds
605364|NCT00301470|Ureter, obstruction
605365|NCT00301470|Diagnostic techniques, urological
605366|NCT00301470|MRI, functional
605367|NCT00301457|Hormone Sensitive Primary Breast Cancer
605368|NCT00301457|Adjuvant Treatment
605369|NCT00301457|Aromatase Inhibitor
605370|NCT00301444|phantom limb pain
605371|NCT00301444|limb amputation
605372|NCT00301431|Fibromyalgia
605373|NCT00301431|Adults
605374|NCT00301431|Outpatients
605375|NCT00301431|Adult
605376|NCT00301431|Double-Blind Method
605377|NCT00301418|Glioblastoma Multiforme
605378|NCT00301418|Anaplastic Astrocytoma
605379|NCT00301418|High Grade Glial Neoplasms
605380|NCT00301418|Brain Tumor
605381|NCT00301405|prostatitis
605382|NCT00301405|pelvic pain
605383|NCT00301392|Glucose intolerance
605384|NCT00301392|Diabetes mellitus
605385|NCT00301392|Statins,HMG-CoA
605386|NCT00301379|Cholangiocarcinoma
605387|NCT00301379|Observational
605388|NCT00301366|alpha 1-Antitrypsin Deficiency
605389|NCT00301366|alpha 1-Antitrypsin
605390|NCT00301366|pulmonary emphysema
605391|NCT00301353|early menopause
605392|NCT00301353|isoflavones/phyto-estrogens
605393|NCT00301353|bone metabolism
605394|NCT00301353|bone mineral density
605395|NCT00301353|hormones
605396|NCT00301249|Diabetes
605397|NCT00301249|Nephropathy
605398|NCT00301249|Diabetic Nephropathy
605399|NCT00301249|Genome Scan
605400|NCT00301249|Genetic Research
605401|NCT00301236|ADHD, children, CADS-T, Dexmethylphenidate-HCl, extended release
605402|NCT00301197|Childhood obesity
605403|NCT00301197|intervention
605404|NCT00301197|obesity
605405|NCT00301197|weight loss
605406|NCT00301197|behavior therapy
605407|NCT00301197|peer group
605408|NCT00301197|social support network
605409|NCT00301197|child
605410|NCT00301197|clinical research
605411|NCT00301197|human subject
605412|NCT00301184|HIV Seronegativity
605413|NCT00301184|HIV Preventive Vaccine
605414|NCT00301184|HIV DNA Vaccine
605415|NCT00301184|Modified Vaccinia Ankara Vaccine
605416|NCT00301171|Wheezing
605417|NCT00301158|unspecified adult solid tumor, protocol specific
605418|NCT00301145|unspecified adult solid tumor, protocol specific
605419|NCT00301119|small cell lung cancer
605420|NCT00301119|non-small cell lung cancer
605421|NCT00301119|smoker lung cancer screening
605422|NCT00301119|low dose spiral CT screening
605423|NCT00301106|stage IV breast cancer
605424|NCT00301106|liver metastases
605425|NCT00301093|chronic phase chronic myelogenous leukemia
605426|NCT00301093|Philadelphia chromosome positive chronic myelogenous leukemia
605427|NCT00301080|pain
605428|NCT00301080|neurotoxicity
605429|NCT00301080|breast cancer
605430|NCT00301067|stage IV melanoma
605431|NCT00301067|recurrent melanoma
605432|NCT00301054|Anaemia
605433|NCT00301054|Malaria
605434|NCT00301054|Rural Area in Ghana
605435|NCT00301041|invasive ductal breast carcinoma
605436|NCT00301041|invasive lobular breast carcinoma
605437|NCT00301041|stage I breast cancer
605438|NCT00301041|stage II breast cancer
605439|NCT00301041|stage IIIA breast cancer
605440|NCT00301028|stage IV squamous cell carcinoma of the oropharynx
605441|NCT00301028|stage IV squamous cell carcinoma of the hypopharynx
605442|NCT00301028|stage IV squamous cell carcinoma of the larynx
605443|NCT00301028|stage IV squamous cell carcinoma of the nasopharynx
605444|NCT00301028|stage IV squamous cell carcinoma of the lip and oral cavity
605445|NCT00301002|safety
605446|NCT00301002|effectiveness
605447|NCT00301002|Alefacept
605448|NCT00301002|Palmar
605449|NCT00301002|Plantar
605450|NCT00301002|Pustulosis
605451|NCT00300976|Blood glucose
605452|NCT00300976|Blood pressure
605453|NCT00300976|Lipids
605454|NCT00300963|psychosis
605455|NCT00300963|cognition
605456|NCT00300950|Pancreas Cancer
605457|NCT00300950|resected pancreas cancer
605458|NCT00300950|non-metastatic pancreas cancer
605459|NCT00300911|Natriuretic Peptide, Brain
605460|NCT00300911|Heart Failure, Congestive
605461|NCT00300898|contained lumbar herniated disc
605462|NCT00300898|nucleoplasty
605463|NCT00300898|percutaneous decompression
605464|NCT00300898|Dekompressor
605465|NCT00300898|intervertebral electrothermal disc decompression
605466|NCT00300898|IDET
605467|NCT00300885|Non-Small Cell Lung Cancer
605468|NCT00300885|NSCLC
605469|NCT00300820|Bipolar Disorder
605470|NCT00300820|Affected Adults and Adult Siblings
605471|NCT00300820|Interest in Genetic Counseling
605472|NCT00300820|Bipolar
605473|NCT00300820|Genes
605474|NCT00300820|Familial
605475|NCT00300820|Education
605476|NCT00300820|Testing
605477|NCT00300820|BP
605478|NCT00300820|Adult Siblings
605479|NCT00300807|Hepatitis C
605480|NCT00300807|Monoclonal Antibody
605481|NCT00300807|failed IFN/RBV treatment
605482|NCT00300781|phase 2
605483|NCT00300781|HER2+ breast cancer
605484|NCT00300781|monotherapy neratinib
605485|NCT00300768|onchocerciasis
605486|NCT00300768|onchocerca volvulus
605487|NCT00300768|river blindness
605488|NCT00300768|ivermectin
605489|NCT00300768|moxidectin
605490|NCT00300755|GERD
605491|NCT00300755|Children
605492|NCT00300755|Child
605493|NCT00300755|Child, Preschool
605494|NCT00300742|drinking
605495|NCT00300742|eating
605496|NCT00300742|obesity
605497|NCT00300742|alcohol
605498|NCT00300742|binge eating
605499|NCT00300729|Cyclooxygenase-2 inhibitors
605500|NCT00300729|Celecoxib
605501|NCT00300729|Carcinoma, non-small-cell lung
605502|NCT00300729|Antineoplastic agents
605503|NCT00300729|Therapy, palliative
605504|NCT00300729|Survival
605505|NCT00300716|Multiple Sclerosis
605506|NCT00300716|Cognitive impairment
605507|NCT00300716|Memantine
605508|NCT00300716|Placebo
605509|NCT00300716|Neuropsychological tests
605510|NCT00300716|Quality of life
605511|NCT00300716|Fatigue
605512|NCT00300703|Cardiac Arrest
605513|NCT00300690|Lower extremity bypass surgery
605514|NCT00300690|femoro-popliteal bypass
605515|NCT00300690|Dacron material
605516|NCT00300690|PTFE material
605517|NCT00300677|Pharmacokinetics
605518|NCT00300677|Voriconazole
605519|NCT00300677|Magnetic Resonance Spectroscopy
605520|NCT00300651|Cognitive Behavioral Therapy
605521|NCT00300651|Schizophrenia
605522|NCT00300651|Cognitive Biases
605523|NCT00300651|Efficacy
605524|NCT00300638|Alcoholism
605525|NCT00300638|Emotion
605526|NCT00300638|Cognition
605527|NCT00300638|Brain scans
605528|NCT00300625|Syncope
605529|NCT00300625|Near syncope
605530|NCT00300625|San Francisco Syncope rule
605531|NCT00300586|Non-small cell lung cancer ;
605532|NCT00300586|metastatic ;
605533|NCT00300586|chemotherapy ;
605534|NCT00300586|erlotinib
605535|NCT00300573|dexelvucitabine
605536|NCT00300573|DFC
605537|NCT00300573|Treatment Experienced
605538|NCT00300573|HIV-1
605539|NCT00300560|ESBL-producing E.coli Infections
605540|NCT00300560|ESBL-producing Klebsiella pneumoniae Infections
605541|NCT00300560|Colistin
605542|NCT00300547|colorectal cancer
605543|NCT00300547|polyps
605544|NCT00300547|Virtual colonoscopy
605545|NCT00300547|synchronous carcinoma
605546|NCT00300547|MR colonography
605547|NCT00300534|Diagnosis
605548|NCT00300521|hepatocellular carcinoma
605549|NCT00300521|liver transplantation
605550|NCT00300521|adenovirus-thymidine kinase enzyme
605551|NCT00300521|gene therapy
605552|NCT00300521|immunosuppression
605553|NCT00300508|Hormone receptor positive breast cancer
605554|NCT00300495|Atrial fibrillation
605555|NCT00300495|Lung cancer
605556|NCT00300495|Pulmonary resection
605557|NCT00300495|Post-operative complications
605558|NCT00300482|Dyslipidemia
605559|NCT00300482|Coronary Heart Disease
605560|NCT00300482|Mixed Dyslipidemia
605561|NCT00300469|Mixed Dyslipidemia
605562|NCT00300469|Coronary Heart Disease
605563|NCT00300469|Dyslipidemia
605564|NCT00300456|Dyslipidemia
605565|NCT00300456|Coronary Heart Disease
605566|NCT00300456|Mixed Dyslipidemia
605567|NCT00300417|Flavivirus
605568|NCT00300417|Mosquito
605569|NCT00300417|Immunity
605570|NCT00300417|Preventive
605571|NCT00300417|West Nile Fever
605572|NCT00300417|West Nile Virus
605573|NCT00300417|Vaccine
605574|NCT00300417|Healthy Volunteer
605575|NCT00300417|HV
605576|NCT00300404|Schizophrenia
605577|NCT00300404|Psychosis
605578|NCT00300404|Depression
605579|NCT00300404|Affective Disorder
605580|NCT00300391|Delirium
605581|NCT00300391|Mechanical ventilation
605582|NCT00300391|Intensive care
605583|NCT00300391|Haloperidol
605584|NCT00300378|Depression
605585|NCT00300378|Adult
605586|NCT00300378|Outpatients
605587|NCT00300365|HDL cholesterol
605588|NCT00300365|Metabolic syndrome
605589|NCT00300352|Coronary artery disease
605590|NCT00300352|Folic acid
605591|NCT00300352|Endothelial function
605592|NCT00300300|ACL computer-assisted surgery graft
605593|NCT00300287|Type 2 diabetes
605594|NCT00300287|Vildagliptin
605595|NCT00300274|Everolimus
605596|NCT00300274|heart transplant
605597|NCT00300274|heart disease
605598|NCT00300274|transplantation
605599|NCT00300274|heart IVUS assessment at 12 months
605600|NCT00300274|rate of graft loss
605601|NCT00300274|acute rejection episodes
605602|NCT00300274|survival
605603|NCT00300261|Heart Failure
605604|NCT00300248|Acute Respiratory Distress Syndrome
605605|NCT00300248|Acute Lung Injury
605606|NCT00300248|Respiratory Failure
605607|NCT00300248|ARDS, Human
605608|NCT00300235|Sickle Cell Anemia
605609|NCT00300222|dermal assessment
605610|NCT00300222|pain measurement
605611|NCT00300222|diary
605612|NCT00300222|PHN
605613|NCT00300222|shingles
605614|NCT00300222|neuropathy
605615|NCT00300222|analgesics
605616|NCT00300222|capsaicin
605617|NCT00300222|postherpetic neuralgia
605618|NCT00300196|Stroke
605619|NCT00300196|Fibrinogen
605620|NCT00300196|Reperfusion
605621|NCT00300196|Thrombolysis
605622|NCT00300183|HIV
605623|NCT00300183|health services accessibility
605624|NCT00300183|health services research
605625|NCT00300183|homeless
605626|NCT00300183|social support
605627|NCT00300183|AIDS
605628|NCT00300183|substance abuse
605629|NCT00300183|mental health
605630|NCT00300183|quality of life
605631|NCT00300183|outreach
605632|NCT00300183|harm reduction
605633|NCT00300170|HIV
605634|NCT00300170|race
605635|NCT00300170|unstable housing
605636|NCT00300170|health services accessibility
605637|NCT00300170|health services utilization
605638|NCT00300170|substance abuse
605639|NCT00300170|AIDS
605640|NCT00300170|health services research
605641|NCT00300170|social support
605642|NCT00300170|depression
605643|NCT00300170|trust
605644|NCT00300170|discrimination
605645|NCT00300157|Left main coronary artery stenosis, stent, Taxus
605646|NCT00300157|Unprotected left main coronary artery disease
605647|NCT00300157|Percutaneous coronary intervention with Taxus stent
605648|NCT00300131|Bioabsorbable
605649|NCT00300131|Coronary Stent
605650|NCT00300131|Everolimus
605651|NCT00300131|drug eluting stents
605652|NCT00300131|stents
605653|NCT00300131|angioplasty
605654|NCT00300131|coronary artery disease
605655|NCT00300131|total coronary occlusion
605656|NCT00300131|coronary artery restenosis
605657|NCT00300131|stent thrombosis
605658|NCT00300131|vascular disease
605659|NCT00300131|myocardial ischemia
605660|NCT00300131|coronary artery stenosis
605661|NCT00300105|Patients diagnosed with type 2 diabetes who have participated in and completed the randomized, double-blind, parallel-group, multi-center study GALLANT 4
605662|NCT00300079|Ocular Hypertension Patients
605663|NCT00300066|Glomerular Filtration Rate
605664|NCT00300066|Serum Cystatin C
605665|NCT00300066|Body Composition
605666|NCT00300066|bioelectrical impedance spectroscopy
605667|NCT00300053|angina
605668|NCT00300040|Amputation
605669|NCT00300040|Lower limb
605670|NCT00300040|Critical Limb Ischemia
605671|NCT00300040|residual limb
605672|NCT00300040|Peripheral Vascular Disease
605673|NCT00300040|re-amputation
605674|NCT00300040|Lower Limb Ischemia
605675|NCT00300040|PVD
605676|NCT00300027|Advanced Gastrointestinal Malignancies
605677|NCT00300014|Post vitrectomy
605678|NCT00300014|Recurrent diabetic vitreous hemorrhage
605679|NCT00300014|Intravitreal triamcinolone injection
605680|NCT00300001|Cancer
605681|NCT00300001|Symptom Management
605682|NCT00300001|Supportive Symptom Interventions
605683|NCT00300001|Symptom Severity
605684|NCT00300001|quality of life
605685|NCT00300001|Home-based symptom monitoring
605686|NCT00299988|Immunotherapy
605687|NCT00299988|Amyloid beta protein
605688|NCT00299988|Antibodies
605689|NCT00299988|Alzheimer's
605690|NCT00299988|Dementia
605691|NCT00299975|Randomized Controlled Trials
605692|NCT00299975|Medicine, Chinese Traditional
605693|NCT00299975|Medicine, Herbal
605694|NCT00299975|Constipation
605695|NCT00299962|gene therapy
605696|NCT00299962|immunotherapy
605697|NCT00299936|hepatitis C
605698|NCT00299936|chronic hepatitis C
605699|NCT00299936|ribavirin
605700|NCT00299936|WIN-R
605701|NCT00299923|drug therapy
605702|NCT00299923|Interferon
605703|NCT00299897|HIV
605704|NCT00299897|AIDS
605705|NCT00299897|Treatment Resistance
605706|NCT00299897|Treatment Failure
605707|NCT00299897|Mutations
605708|NCT00299897|GP120
605709|NCT00299897|Entry Inhibitors
605710|NCT00299897|HAART
605711|NCT00299897|antiretroviral
605712|NCT00299897|antiviral
605713|NCT00299897|ARV
605714|NCT00299897|CCR5
605715|NCT00299897|CXCR4
605716|NCT00299897|receptors
605717|NCT00299897|intracellular fluid
605718|NCT00299897|lipid rafts
605719|NCT00299897|cholesterol
605720|NCT00299897|chemokine
605721|NCT00299897|Treatment Experienced
605722|NCT00299884|Randomized
605723|NCT00299884|non-blinded
605724|NCT00299884|prospective
605725|NCT00299884|open-label
605726|NCT00299884|LDL-C
605727|NCT00299884|HDL-C
605728|NCT00299871|Type 2 diabetes
605729|NCT00299858|Chronic Obstructive Pulmonary Disease
605730|NCT00299858|Theophylline
605731|NCT00299858|Exercise testing
605732|NCT00299845|gastroesophageal reflux
605733|NCT00299845|children
605734|NCT00299845|lansoprazole
605735|NCT00299845|cytochrome P450 2C19 (CYP2C19)
605736|NCT00299845|pharmacogenomics
605737|NCT00299845|genetic polymorphisms
605738|NCT00299845|individualized medicine
605739|NCT00299845|pharmacokinetics/dynamics
605740|NCT00299832|Hypertension, aliskiren, blood pressure, rennin
605741|NCT00299819|Lupus
605742|NCT00299806|Hypertension, aliskiren, blood pressure, rennin
605743|NCT00299793|Epilepsy
605744|NCT00299793|Quality of life
605745|NCT00299780|Mobilization
605746|NCT00299780|Stem Cell
605747|NCT00299780|Parathyroid Hormone
605748|NCT00299754|Low dose misoprostol
605749|NCT00299754|dinoprostone
605750|NCT00299754|cervical priming
605751|NCT00299741|Sutent
605752|NCT00299741|Sunitinib
605753|NCT00299741|Bone
605754|NCT00299741|Metastatic
605755|NCT00299741|Hormone-refractory
605756|NCT00299741|Biomarkers
605757|NCT00299728|NY-ESO-1
605758|NCT00299728|Vaccine
605759|NCT00299728|Adjuvant or metastatic setting
605760|NCT00299728|Several tumor types eligible
605761|NCT00299715|Affective psychosis
605762|NCT00299715|mixed-state
605763|NCT00299715|bipolar disorder
605764|NCT00299715|manic disorder
605765|NCT00299715|manic-depressive
605766|NCT00299715|psychosis
605767|NCT00299715|mania
605768|NCT00299715|manic state
605769|NCT00299715|paliperidone
605770|NCT00299715|paliperidone ER.
605771|NCT00299702|Schizophrenia
605772|NCT00299702|Relapse
605773|NCT00299702|Remission
605774|NCT00299702|Treatment Outcome
605775|NCT00299702|long-acting injectable
605776|NCT00299689|Melanoma
605777|NCT00299689|Metastatic
605778|NCT00299689|Stage IV
605779|NCT00299689|Ontak
605780|NCT00299676|Alzheimer's Disease
605781|NCT00299676|Dementia
605782|NCT00299676|Post Marketing
605783|NCT00299676|Prospective Studies
605784|NCT00299676|Longitudinal Studies
605785|NCT00299676|New Zealand
605786|NCT00299676|Cholinesterase Inhibitors
605787|NCT00299676|Observational
605788|NCT00299676|Outcomes
605789|NCT00299663|group A streptococcal infection
605790|NCT00299663|genital tract
605791|NCT00299663|CARRIER
605792|NCT00299663|patients with GAS isolation
605793|NCT00299663|Streptococcus Group A
605794|NCT00299650|ARDS
605795|NCT00299650|mortality
605796|NCT00299650|mechanical ventilation
605797|NCT00299650|pneumonia
605798|NCT00299650|muscle relaxants
605799|NCT00299624|venous thromboembolism risk,
605800|NCT00299624|elderly,
605801|NCT00299624|hypercoagulability
605802|NCT00299624|fibrinolysis
605803|NCT00299624|microparticles
605804|NCT00299611|OCD
605805|NCT00299611|Anxiety
605806|NCT00299611|Pharmacotherapy
605807|NCT00299611|Sertraline
605808|NCT00299611|Levetiracetam
605809|NCT00299598|antibacterial
605810|NCT00299598|composite
605811|NCT00299598|polyethylenimine
605812|NCT00299598|nanoparticle
605813|NCT00299585|dental implant
605814|NCT00299585|dental implantation
605815|NCT00299585|osseointegration
605816|NCT00299585|bone cement
605817|NCT00299585|osteoconductivity
605818|NCT00299585|brushite
605819|NCT00299585|calcium phosphate
605820|NCT00299585|bone augmentation
605821|NCT00299585|primary stability
605822|NCT00299585|immediate implantation
605823|NCT00299585|Mandibular Ridge Augmentation
605824|NCT00299585|Maxillary Ridge Augmentation
605825|NCT00299585|synthetic implants for rebuilding the alveolar ridge
605826|NCT00299572|alendronate
605827|NCT00299572|peritoneal dialysis
605828|NCT00299572|vascular calcification
605829|NCT00299572|bone mineral density
605830|NCT00299559|common cold
605831|NCT00299559|organic chemicals
605832|NCT00299559|menthol
605833|NCT00299559|cineole
605834|NCT00299559|camphor
605835|NCT00299559|etheric oils
605836|NCT00299559|alternative medicine
605837|NCT00299559|smart textiles
605838|NCT00299546|Rheumatoid Arthritis
605839|NCT00299546|Anti-TNFa agents
605840|NCT00299546|subcutaneous injection
605841|NCT00299520|skin infection
605842|NCT00299520|complicated skin infection
605843|NCT00299520|skin structure infection
605844|NCT00299507|exudative AMD
605845|NCT00299507|age-related macular degeneration (AMD)
605846|NCT00299494|Lymphoma
605847|NCT00299494|NHL
605848|NCT00299481|Tissue Bank
605849|NCT00299481|Endometrial neoplasm
605850|NCT00299481|uterine cervical neoplasm
605851|NCT00299481|ovarian neoplasm
605852|NCT00299481|leiomyoma
605853|NCT00299481|DNA
605854|NCT00299481|RNA
605855|NCT00299481|Protein
605856|NCT00299481|Serum
605857|NCT00299468|hypertension
605858|NCT00299468|home care
605859|NCT00299468|patient activation
605860|NCT00299468|stages-of-change
605861|NCT00299442|behavior
605862|NCT00299442|conduct
605863|NCT00299442|child
605864|NCT00299442|parenting
605865|NCT00299442|self-help
605866|NCT00299442|media-based
605867|NCT00299429|Stent
605868|NCT00299429|drug-eluting stent
605869|NCT00299429|Minimally invasive bypass surgery
605870|NCT00299429|left anterior descending
605871|NCT00299416|Stroke
605872|NCT00299416|Nonhemorrhagic
605873|NCT00299416|hypothermia
605874|NCT00299403|Depressive disorder,
605875|NCT00299403|Antidepressant effect,
605876|NCT00299403|rTMS,
605877|NCT00299403|ECT,
605878|NCT00299403|cognition,
605879|NCT00299403|Saliva cortisol
605880|NCT00299403|noninferiority trial
605881|NCT00299390|Sagopilone
605882|NCT00299390|Epothilone
605883|NCT00299390|SCLC
605884|NCT00299390|Small Cell Lung Cancer
605885|NCT00299390|Lung Cancer
605886|NCT00299377|STEMI
605887|NCT00299377|infarct size
605888|NCT00299377|primary PCI
605889|NCT00299377|no-reflow
605890|NCT00299377|ST-elevation myocardial infarction
605891|NCT00299364|Climacteric symptoms
605892|NCT00299364|Black Cohosh
605893|NCT00299364|Efficacy
605894|NCT00299364|Safety
605895|NCT00299338|HIV
605896|NCT00299338|AIDS
605897|NCT00299338|CD4
605898|NCT00299338|HAART
605899|NCT00299338|antiretroviral
605900|NCT00299338|treatment failure
605901|NCT00299338|resistance
605902|NCT00299338|CCR4
605903|NCT00299338|CXCR5
605904|NCT00299338|gp120
605905|NCT00299338|gp41
605906|NCT00299338|cholesterol
605907|NCT00299338|lipid rafts
605908|NCT00299338|intracellular fluid
605909|NCT00299338|receptors
605910|NCT00299338|chemokine
605911|NCT00299338|antigens
605912|NCT00299338|Treatment Experienced
605913|NCT00299312|Loss of Purposeful Hand Use Syndrome
605914|NCT00299312|Loss of Communication
605915|NCT00299312|Stereotypic Hand Movements
605916|NCT00299312|MECP2 mutation
605917|NCT00299312|MECP2 duplication
605918|NCT00299312|CDKL5 mutation
605919|NCT00299312|FOXG1 mutation
605920|NCT00299286|Ki67
605921|NCT00299286|Molecular
605922|NCT00299286|antiproliferative
605923|NCT00299273|Obesity;
605924|NCT00299273|Low calorie high fat/protein diet;
605925|NCT00299273|Low-carbohydrate diet
605926|NCT00299273|Weight Loss
605927|NCT00299260|cytomegalovirus, glycoprotein B vaccine, allograft
605928|NCT00299247|Malaria, Plasmodium falciparum, drug resistance, Colombia
605929|NCT00299234|Attention Deficit Hyperactivity Disorder
605930|NCT00299221|immunosuppression
605931|NCT00299221|steroid withdrawal
605932|NCT00299221|rejection
605933|NCT00299221|coronary disease
605934|NCT00299221|cytomegalovirus infection
605935|NCT00299208|Malaria
605936|NCT00299195|Oral Leukoplakia
605937|NCT00299195|Benign Neoplasms
605938|NCT00299195|Chemoprevention
605939|NCT00299195|Pan-cyclooxygenase (COX) inhibitor
605940|NCT00299195|sulindac
605941|NCT00299195|04-099
605942|NCT00299182|Non-Hodgkin's Lymphoma
605943|NCT00299182|Lymphoma
605944|NCT00299182|Mantle Cell Lymphoma
605945|NCT00299182|AMG 531
605946|NCT00299182|Romiplostim
605947|NCT00299182|Placebo
605948|NCT00299182|R-HyperCVAD
605949|NCT00299182|R-Ara-C/MTX
605950|NCT00299182|Cyclophosphamide
605951|NCT00299182|Cytarabine
605952|NCT00299182|Dexamethasone
605953|NCT00299182|Doxorubicin
605954|NCT00299182|Methotrexate
605955|NCT00299182|Rituximab
605956|NCT00299182|Vincristine
605957|NCT00299182|Decadron
605958|NCT00299182|Neosar
605959|NCT00299182|AD
605960|NCT00299182|Hydroxydaunomycin hydrocholoride
605961|NCT00299182|Ara-C
605962|NCT00299182|Cytosar
605963|NCT00299182|DepoCyt
605964|NCT00299182|Cytosine arabinosine hydrochloride
605965|NCT00299169|N of 1 trial
605966|NCT00299169|diabetes mellitus
605967|NCT00299169|HMG CoA Reductase Inhibitors
605968|NCT00299169|cardiovascular disease
605969|NCT00299156|Myelodysplastic Syndrome
605970|NCT00299156|MDS
605971|NCT00299156|Chronic Myelomonocytic Leukemia
605972|NCT00299156|CMML
605973|NCT00299156|Clofarabine
605974|NCT00299156|Clofarex
605975|NCT00299156|Clolar
605976|NCT00299156|Chemotherapy
605977|NCT00299143|SIPA
605978|NCT00299143|acute coronary syndrome
605979|NCT00299130|RA
605980|NCT00299130|Rituxan
605981|NCT00299130|SERENE
605982|NCT00299117|Smoking cessation
605983|NCT00299117|Stress
605984|NCT00299117|Nicotine dependence
605985|NCT00299117|Complication, postoperative
605986|NCT00299104|Rituxan
605987|NCT00299104|MTX
605988|NCT00299104|RA
605989|NCT00299104|IMAGE
605990|NCT00299104|WA17047
605991|NCT00299091|Therapeutic drug monitoring
605992|NCT00299091|Treatment Naive
605993|NCT00299091|Treatment Experienced
605994|NCT00299091|HIV
605995|NCT00299065|Asthma, bronchial
605996|NCT00299065|Asthma, exercise-induced
605997|NCT00299065|Anti-asthmatic agents
605998|NCT00299052|Tibia
605999|NCT00299052|Fracture
606000|NCT00299052|DBM
606001|NCT00299039|Randomized controlled trial
606002|NCT00299039|Clinical trial
606003|NCT00299039|Breast tumor surgery
606004|NCT00299039|Outpatient surgery
606005|NCT00299039|Analgesia
606006|NCT00299039|Outpatient analgesia
606007|NCT00299039|Post surgical analgesia
606008|NCT00299039|≥ 18 and ≤ 70 years of age
606009|NCT00299039|Elective outpatient breast surgery for:
606010|NCT00299039|lumpectomy/quadrantectomy +/- Sentinel Lymph Node Biopsy
606011|NCT00299039|lumpectomy/quadrantectomy with Axillary Node Dissection
606012|NCT00299039|simple mastectomy +/- Sentinel Lymph Node Biopsy
606013|NCT00299039|Modified Radical mastectomy
606014|NCT00299026|Coronary Artery Disease
606015|NCT00299026|Percutaneous Coronary Intervention
606016|NCT00299026|Stent Implant
606017|NCT00299026|Drug-coated Stent
606018|NCT00299013|Ulcerative colitis
606019|NCT00298987|Chronic Myeloid Leukemia Accelerated and Blast Phase
606020|NCT00298987|Leukemia, Acute, Philadelphia-Positive
606021|NCT00298974|Osteoarthritis of the hip or knee
606022|NCT00298935|Randomized Controlled Trial
606023|NCT00298935|Pregnant Women
606024|NCT00298922|Cystic Fibrosis
606025|NCT00298922|Burkholderia cepacia complex
606026|NCT00298896|Lung
606027|NCT00298896|Squamous Cell
606028|NCT00298896|Small Cell
606029|NCT00298896|Carcinoma
606030|NCT00298896|Cancer
606031|NCT00298896|Small Cell Lung Cancer
606032|NCT00298883|Renal
606033|NCT00298883|Transplant
606034|NCT00298883|PRA
606035|NCT00298870|pulmonary tuberculosis
606036|NCT00298870|isoniazid
606037|NCT00298870|arylamine N-acetyltransferase 2
606038|NCT00298870|pharmacogenomics
606039|NCT00298870|genetic polymorphisms
606040|NCT00298870|individualized medicine
606041|NCT00298870|drug-induced hepatotoxity
606042|NCT00298857|Healthy
606043|NCT00298857|Obesity
606044|NCT00298857|Pharmacokinetics
606045|NCT00298844|Type 2 diabetes mellitus
606046|NCT00298844|Macrovascular disease
606047|NCT00298844|Diastolic dysfunction
606048|NCT00298844|Intima media thickness
606049|NCT00298844|Single- photon emission computed tomography (SPECT)
606050|NCT00298818|Epilepsy
606051|NCT00298818|Mental Retardation
606052|NCT00298818|Developmental Disabilities
606053|NCT00298805|Migraine
606054|NCT00298805|Headache
606055|NCT00298805|Depression
606056|NCT00298805|Quality of Life
606057|NCT00298792|Cognitive Behavioral Treatment
606058|NCT00298792|Alcohol Dependence
606059|NCT00298792|Functional Analysis
606060|NCT00298792|Experience Sampling
606061|NCT00298792|Interactive Voice Response
606062|NCT00298779|patients with advanced solid tumors or Non-Hodgkins's Lymphoma
606063|NCT00298727|Knowledge transfer
606064|NCT00298727|Clinical decision-making
606065|NCT00298727|Outcome measures
606066|NCT00298714|Hepatitis C, Chronic
606067|NCT00298701|Allergy
606068|NCT00298662|Multiple Sclerosis
606069|NCT00298662|Betaseron-Prograf
606070|NCT00298662|patients of Multiple Sclerosis
606071|NCT00298662|Secondary Progressive type
606072|NCT00298662|Relapsing-Remitting type
606073|NCT00298649|pesticide safety
606074|NCT00298649|migrant and seasonal farmworkers
606075|NCT00298649|Latino/Hispanic
606076|NCT00298649|agricultural health
606077|NCT00298649|occupational health
606078|NCT00298610|Uncomplicated Malaria
606079|NCT00298610|GMP artesunate
606080|NCT00298584|Diagnostic techniques, urological
606081|NCT00298584|urinary catheterization
606082|NCT00298584|Aspiration
606083|NCT00298584|Neonates
606084|NCT00298584|Neonatal Intensive Care Unit
606085|NCT00298584|Infant, Newborn
606086|NCT00298584|Infant, Premature
606087|NCT00298584|Infant, Low-birth weight
606088|NCT00298571|Cesarean Delivery
606089|NCT00298571|Post-operative
606090|NCT00298571|Pain
606091|NCT00298571|Local Anesthetic
606092|NCT00298558|cognition disorder
606093|NCT00298558|cognitive behavior therapy
606094|NCT00298558|functional ability
606095|NCT00298532|Pediatrics
606096|NCT00298532|Seizure
606097|NCT00298532|Trauma
606098|NCT00298532|Respiratory
606099|NCT00298532|Cardiac
606100|NCT00298532|Arrest
606101|NCT00298506|Tacrolimus
606102|NCT00298506|Mycophenolate mofetil
606103|NCT00298506|Cyclophosphamide
606104|NCT00298506|Lupus nephritis
606105|NCT00298506|Treatment
606106|NCT00298493|ICU
606107|NCT00298493|Sedation strategies
606108|NCT00298493|Daily sedative interruption
606109|NCT00298493|Sedation protocols
606110|NCT00298480|preterm labor
606111|NCT00298480|transvaginal ultrasound
606112|NCT00298480|dynamic cervical change
606113|NCT00298467|ALCL
606114|NCT00298467|csALCL
606115|NCT00298467|pcALCL
606116|NCT00298467|Lymphoma
606117|NCT00298467|Non-Hodgkin's Lymphoma
606118|NCT00298467|Anaplastic Large Cell Lymphoma
606119|NCT00298467|classic systemci Anaplastic Large Cell Lymphoma (csALCL)
606120|NCT00298467|primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL)
606121|NCT00298454|renal failure
606122|NCT00298454|oliguric
606123|NCT00298454|critically ill
606124|NCT00298454|furosemide
606125|NCT00298441|intravenous iron administration
606126|NCT00298428|stent
606127|NCT00298428|percutaneous coronary intervention
606128|NCT00298428|platelet aggregation
606129|NCT00298428|clopidogrel
606130|NCT00298428|shear
606131|NCT00298428|metabolic syndrome
606132|NCT00298415|2-years survival
606133|NCT00298402|macrophage
606134|NCT00298402|MMP
606135|NCT00298402|CT scan
606136|NCT00298389|macrophage
606137|NCT00298389|phagocytosis
606138|NCT00298389|exacerbation
606139|NCT00298376|Cow’s milk allergy,
606140|NCT00298376|food allergy
606141|NCT00298376|oral tolerance,
606142|NCT00298376|infant,
606143|NCT00298376|regulatory T cells,
606144|NCT00298376|intestinal microflora
606145|NCT00298363|Hepatitis; Hepatitis B virus; Tenofovir
606146|NCT00298350|Phase 2
606147|NCT00298350|Phase II
606148|NCT00298350|Randomized
606149|NCT00298350|Controlled
606150|NCT00298350|Comparator
606151|NCT00298350|Partially Blind
606152|NCT00298350|Protease Inhibitors
606153|NCT00298350|Integrase Inhibitors
606154|NCT00298350|Antiviral Agents
606155|NCT00298350|Antiretroviral Agents
606156|NCT00298350|ART
606157|NCT00298350|ARV
606158|NCT00298350|Highly Activity Antiretroviral Therapy
606159|NCT00298350|HAART
606160|NCT00298350|Treatment Experienced
606161|NCT00298324|GvHD
606162|NCT00298324|graft versus host disease
606163|NCT00298324|extensive
606164|NCT00298324|myfortic
606165|NCT00298298|lung cancer
606166|NCT00298298|non-small cell lung cancere
606167|NCT00298298|vaccine
606168|NCT00298298|immunotherapy
606169|NCT00298285|mechanical valve replacement
606170|NCT00298285|warfarin
606171|NCT00298246|Neurodevelopmental Disorders
606172|NCT00298246|Neurological Disorder
606173|NCT00298246|Children- Onset
606174|NCT00298246|Children
606175|NCT00298246|Pervasive Developmental Disorder
606176|NCT00298246|PDD
606177|NCT00298246|Autism
606178|NCT00298246|Healthy Volunteer
606179|NCT00298246|HV
606180|NCT00298233|Antibody Response
606181|NCT00298233|Antiviral Efficacy
606182|NCT00298233|Bird Flu
606183|NCT00298233|Severe Respiratory Distress
606184|NCT00298233|Viral Replication and Shedding
606185|NCT00298220|Family Practice
606186|NCT00298220|Intervention Studies
606187|NCT00298220|Prevention and Control
606188|NCT00298207|high blood pressure
606189|NCT00298207|hypertension
606190|NCT00298207|adult
606191|NCT00298207|African Americans
606192|NCT00298207|Walking
606193|NCT00298168|Delayed Graft Function
606194|NCT00298142|Cervicogenic Headache
606195|NCT00298142|Migraine
606196|NCT00298142|Tension Type Headache
606197|NCT00298103|Antibiotic resistant
606198|NCT00298103|Infection
606199|NCT00298090|Oxygenation
606200|NCT00298077|Infection
606201|NCT00298077|transplant recipients
606202|NCT00298064|Cervical cancer
606203|NCT00298064|EGFR
606204|NCT00298064|cervical
606205|NCT00298064|genomic
606206|NCT00298064|DNA
606207|NCT00298064|markers
606208|NCT00298064|prognostic
606209|NCT00298064|gene
606210|NCT00298064|epidermal growth factor
606211|NCT00298051|Iron-deficiency anemia
606212|NCT00298051|Umbilical cord clamping
606213|NCT00298051|Infant
606214|NCT00298025|Infertility
606215|NCT00298025|Cetrotide
606216|NCT00298025|Antagon
606217|NCT00298025|Recombinant human follicle stimulating hormone (r-hFSH)
606218|NCT00298025|Human Menopausal Gonadotropin (hMG)
606219|NCT00298025|Recombinant Human Choriogonadotropin (r-hCG)
606220|NCT00298012|Methotrexate
606221|NCT00298012|Magnetic Resonance Imaging
606222|NCT00298012|Anterior uveitis
606223|NCT00297947|schizophrenia
606224|NCT00297947|quetiapine
606225|NCT00297947|schizoaffective disorder
606226|NCT00297934|dual-task
606227|NCT00297934|postural control
606228|NCT00297934|cognitive
606229|NCT00297908|Ethanol levels
606230|NCT00297908|Dermal absorbtion
606231|NCT00297895|sentinel lymph node dissection
606232|NCT00297895|complete lymph node dissection
606233|NCT00297895|surgical
606234|NCT00297882|Efficacy
606235|NCT00297882|Safety
606236|NCT00297882|Children
606237|NCT00297882|Cameroon
606238|NCT00297856|Boostrix
606239|NCT00297830|Heart Transplantation
606240|NCT00297830|Liver Transplantation
606241|NCT00297830|Immunosuppression
606242|NCT00297830|Bone Density/drug effects
606243|NCT00297830|Alendronate
606244|NCT00297830|Zoledronic acid
606245|NCT00297830|Comparative study
606246|NCT00297830|Humans
606247|NCT00297817|Meningococcal Disease; Meningococcal Meningitis; Vaccine
606248|NCT00297804|Coronary Artery Disease
606249|NCT00297804|Percutaneous Coronary Intervention
606250|NCT00297804|Stent Implant
606251|NCT00297804|Drug-coated Stent
606252|NCT00297791|rectal cancer
606253|NCT00297791|laparoscopic technique
606254|NCT00297791|open technique
606255|NCT00297791|clinical trial
606256|NCT00297791|multicenter study
606257|NCT00297791|randomized controlled trial
606258|NCT00297791|Tumor Below 15cm
606259|NCT00297791|curative surgical resection
606260|NCT00297791|no evidence for distant metastases
606261|NCT00297765|Renal Transplantation
606262|NCT00297765|Therapeutics
606263|NCT00297765|Treatment Outcome
606264|NCT00297765|Safety
606265|NCT00297752|facial burns
606266|NCT00297752|cerium flammazine
606267|NCT00297752|quality of life
606268|NCT00297752|randomised clinical trial
606269|NCT00297739|Aggression
606270|NCT00297739|ADHD
606271|NCT00297739|Antipsychotic
606272|NCT00297726|Osteoarthritis, Knee
606273|NCT00297726|Osteoarthritis, Hip
606274|NCT00297726|Osteoarthritis, Ankle
606275|NCT00297726|Arthritis
606276|NCT00297726|Self-Management
606277|NCT00297700|Smoking
606278|NCT00297700|Dental
606279|NCT00297700|Cessation
606280|NCT00297700|Prevention
606281|NCT00297700|Control
606282|NCT00297700|Quitline
606283|NCT00297700|5A-Model
606284|NCT00297700|Cost-effective
606285|NCT00297687|Vaccines
606286|NCT00297687|Healthy Adults
606287|NCT00297687|Health
606288|NCT00297687|Adult
606289|NCT00297687|Meningococcal Vaccines
606290|NCT00297674|clarithromycin
606291|NCT00297674|sepsis
606292|NCT00297674|immunomodulation
606293|NCT00297661|Coronary Revascularization
606294|NCT00297661|Sirolimus-eluting stents
606295|NCT00297661|Paclitaxel-eluting stents
606296|NCT00297648|Certolizumab pegol
606297|NCT00297648|Crohn's disease
606298|NCT00297648|Mucosal healing
606299|NCT00297635|Hyperglycemia
606300|NCT00297635|Insulin Infusion Systems
606301|NCT00297635|Blood Glucose Self-Monitoring
606302|NCT00297609|Resuscitation medication errors
606303|NCT00297609|critical care
606304|NCT00297609|pediatrics
606305|NCT00297609|clinical decision support systems
606306|NCT00297609|computerized physician order entry
606307|NCT00297596|Metastatic
606308|NCT00297596|HER2/neu+
606309|NCT00297570|CML
606310|NCT00297570|Imatinib
606311|NCT00297570|Pegylated Interferon
606312|NCT00297570|Philadelphia Positive CML
606313|NCT00297544|impotence
606314|NCT00297544|endothelial function
606315|NCT00297544|autonomic nervous system
606316|NCT00297531|Chronic Periodontitis
606317|NCT00297531|Periodontitis
606318|NCT00297531|Photodynamic disinfection
606319|NCT00297531|PDD
606320|NCT00297531|PDT
606321|NCT00297531|Periowave
606322|NCT00297531|Scaling and Root Planing
606323|NCT00297531|SRP
606324|NCT00297518|Adult Periodontitis
606325|NCT00297518|Chronic Periodontitis
606326|NCT00297518|PDD
606327|NCT00297518|PDT
606328|NCT00297518|Photodynamic Disinfection
606329|NCT00297518|SRP
606330|NCT00297518|Scaling and Root Planing
606331|NCT00297505|Cocaine; citalopram; impulsivity; serotonin
606332|NCT00297492|Smoking Cessation
606333|NCT00297492|Tobacco
606334|NCT00297479|Tobacco Cessation
606335|NCT00297479|Smoking Cessation
606336|NCT00297466|tobacco use
606337|NCT00297466|smoking cessation
606338|NCT00297466|emergency department
606339|NCT00297440|Smoking
606340|NCT00297440|Exercise
606341|NCT00297440|Adolescent
606342|NCT00297440|Girls
606343|NCT00297427|urinary incontinence
606344|NCT00297414|Mild Cognitive Impairment
606345|NCT00297414|Dementia
606346|NCT00297414|Galantamine
606347|NCT00297414|Memory disorders
606348|NCT00297414|Isolated memory impairment
606349|NCT00297414|Alzheimer's disease
606350|NCT00297388|schizophrenia
606351|NCT00297388|schizoaffective disorder
606352|NCT00297388|long-acting risperidone
606353|NCT00297388|intramuscular injection risperidone
606354|NCT00297388|risperidone
606355|NCT00297375|treatment
606356|NCT00297375|Pain
606357|NCT00297375|acute
606358|NCT00297375|migraine
606359|NCT00297375|headache
606360|NCT00297362|Alzheimer Disease
606361|NCT00297362|Dementia
606362|NCT00297362|Brain Disease
606363|NCT00297362|Memory Loss
606364|NCT00297362|Caregiver
606365|NCT00297362|Galantamine hydrobromide
606366|NCT00297362|Nervous System Diseases
606367|NCT00297362|Mental Disorders
606368|NCT00297349|Seizures
606369|NCT00297349|Epilepsy
606370|NCT00297349|Tonic-clonic
606371|NCT00297349|Lennox-Gastaut Syndrome
606372|NCT00297349|Focal Epilepsy
606373|NCT00297349|Topiramate
606374|NCT00297349|Epilepsy in Children
606375|NCT00297336|Topiramate
606376|NCT00297336|Migraine
606377|NCT00297336|Headache
606378|NCT00297336|Chronic headache
606379|NCT00297336|Chronic migraine
606380|NCT00297323|Seizures
606381|NCT00297323|Epilepsy
606382|NCT00297323|Topiramate
606383|NCT00297323|Epilepsy in Children
606384|NCT00297310|Tacrolimus
606385|NCT00297310|Kidney transplantation
606386|NCT00297310|Transplantation
606387|NCT00297310|Kidney failure
606388|NCT00297310|chronic
606389|NCT00297310|P-Glycoprotein
606390|NCT00297297|Solitary solid and scintigraphically cold thyroid nodules
606391|NCT00297284|systemic lupus erythematosus
606392|NCT00297284|cognitive efficiency
606393|NCT00297284|cognitive dysfunction
606394|NCT00297284|cognition
606395|NCT00297284|memory
606396|NCT00297284|attention
606397|NCT00297284|modafinil
606398|NCT00297284|provigil
606399|NCT00297271|Dementia
606400|NCT00297271|Mild Cognitive Impairment
606401|NCT00297271|Patient Registries
606402|NCT00297271|Prospective Studies
606403|NCT00297271|Longitudinal Studies
606404|NCT00297271|Australia
606405|NCT00297271|Cholinesterase Inhibitors
606406|NCT00297271|Observational
606407|NCT00297271|Non-randomized
606408|NCT00297258|Sarcoma
606409|NCT00297258|Synovial sarcoma
606410|NCT00297258|Pazopanib(GW786034)
606411|NCT00297258|Adipocytic tumors
606412|NCT00297258|Leiomyosarcoma
606413|NCT00297258|Phase II
606414|NCT00297245|gastrodin
606415|NCT00297232|Multiple Sclerosis
606416|NCT00297232|MS
606417|NCT00297219|Hemodialysis
606418|NCT00297219|Coronary artery calcification
606419|NCT00297219|Adynamic bone disease
606420|NCT00297219|Dialysate calcium
606421|NCT00297219|Bone mineral density
606422|NCT00297219|Bone histomorphometry
606423|NCT00297206|pharmacokinetics herpes varicella herpes labialis Epstein-Barr virus
606424|NCT00297193|Crohn's Disease
606425|NCT00297193|HSCT
606426|NCT00297193|Autologous
606427|NCT00297193|EBMT
606428|NCT00297193|ECCO
606429|NCT00297180|hunger
606430|NCT00297180|obesity
606431|NCT00297180|sodium-dependent glucose transporter
606432|NCT00297180|GW869682
606433|NCT00297180|body composition
606434|NCT00297180|SGLT2 inhibitor
606435|NCT00297180|weight loss
606436|NCT00297167|CF
606437|NCT00297167|Cystic Fibrosis
606438|NCT00297167|EPI
606439|NCT00297167|Exocrine Pancreatic Insufficiency
606440|NCT00297167|Pancreatic
606441|NCT00297167|Enzyme
606442|NCT00297167|PEP
606443|NCT00297154|Heart failure, congestive
606444|NCT00297154|Metabolic Syndrome X
606445|NCT00297154|Obesity
606446|NCT00297141|Preoperative
606447|NCT00297141|Radiochemotherapy
606448|NCT00297141|Newly Diagnosed
606449|NCT00297141|Primary Operable
606450|NCT00297141|Locally Advanced
606451|NCT00297141|Rectal Carcinoma
606452|NCT00297141|T3
606453|NCT00297141|Lower Rectum
606454|NCT00297141|Middle Rectum
606455|NCT00297141|ABCSG
606456|NCT00297141|TAKO
606457|NCT00297141|95
606458|NCT00297141|05
606459|NCT00297128|pilot study
606460|NCT00297128|rectal
606461|NCT00297128|cancer
606462|NCT00297128|phase II
606463|NCT00297128|preoperative
606464|NCT00297128|chemoradiation
606465|NCT00297128|capecitabine
606466|NCT00297128|cetuximab
606467|NCT00297128|operable
606468|NCT00297128|T4
606469|NCT00297128|ABCSG
606470|NCT00297128|TAKO
606471|NCT00297128|R03
606472|NCT00297128|96
606473|NCT00297128|06
606474|NCT00297115|Roflumilast
606475|NCT00297115|COPD
606476|NCT00297115|Chronic obstructive pulmonary disease
606477|NCT00297102|Roflumilast
606478|NCT00297102|COPD
606479|NCT00297102|Chronic obstructive pulmonary disease
606480|NCT00297089|Lung Cancer
606481|NCT00297089|ABT-751
606482|NCT00297089|NSCLC
606483|NCT00297089|Alimta
606484|NCT00297089|Non-Small-Cell Lung Cancer
606485|NCT00297089|pemetrexed
606486|NCT00297076|HIV-1
606487|NCT00297076|GW873140
606488|NCT00297076|CCR5 antagonist
606489|NCT00297076|experienced
606490|NCT00297076|Treatment Experienced
606491|NCT00297063|rosiglitazone
606492|NCT00297063|vandia
606493|NCT00297063|Type 2 diabetes mellitus
606494|NCT00297063|diabetes;
606495|NCT00297050|Influenza Virus
606496|NCT00297050|Avian Influenza
606497|NCT00297050|Normal Volunteers
606498|NCT00297050|Neuraminidase Inhibitor
606499|NCT00297050|Viral Disease
606500|NCT00297050|Healthy Volunteer
606501|NCT00297050|HV
606502|NCT00297037|oral lichen planus, pimecrolimus 1% cream
606503|NCT00296985|Cardiac surgery
606504|NCT00296985|Cellsaver
606505|NCT00296985|Neurocognitive Function
606506|NCT00296985|Neuronal Protection
606507|NCT00296985|Quality of Life
606508|NCT00296972|peg interferon
606509|NCT00296972|ribavirin
606510|NCT00296972|HAART
606511|NCT00296972|HIV
606512|NCT00296972|Chronic Hepatitis C
606513|NCT00296972|Treatment Experienced
606514|NCT00296959|Dyskinesia
606515|NCT00296959|AMPA receptor antagonists
606516|NCT00296946|Sialorrhoea
606517|NCT00296933|Major Depression
606518|NCT00296933|Antidepressant
606519|NCT00296933|Pharmacotherapy
606520|NCT00296933|Memory functioning
606521|NCT00296933|Memory Impairment
606522|NCT00296920|Deep Brain Stimulation
606523|NCT00296920|Treatment failure
606524|NCT00296907|cancer
606525|NCT00296907|siblings
606526|NCT00296907|behavior
606527|NCT00296907|psychological adaptation
606528|NCT00296907|intervention
606529|NCT00296881|Periodontitis
606530|NCT00296881|Photodynamic Disinfection
606531|NCT00296881|PERIOWAVE
606532|NCT00296881|Scaling and Root Planing
606533|NCT00296881|SRP
606534|NCT00296868|reflex sympathetic dystrophy
606535|NCT00296868|ascorbic acid
606536|NCT00296868|primary prevention
606537|NCT00296868|radius fractures
606538|NCT00296855|Peripheral artery disease
606539|NCT00296842|posttraumatic stress disorder
606540|NCT00296842|children
606541|NCT00296842|injury
606542|NCT00296842|road traffic accident
606543|NCT00296829|Influenza;
606544|NCT00296829|Orthomyxoviruses;
606545|NCT00296829|Inactivated Split-virion influenza vaccine;
606546|NCT00296829|Elderly.
606547|NCT00296803|metabolic syndrome
606548|NCT00296777|Major Depression
606549|NCT00296777|Dysthymia
606550|NCT00296777|f-MRI
606551|NCT00296777|Escitalopram
606552|NCT00296777|Bupropion
606553|NCT00296777|Imipramine
606554|NCT00296777|Neuropsychologic test
606555|NCT00296777|Dichotic listening
606556|NCT00296777|EEG
606557|NCT00296777|ERP
606558|NCT00296764|Happy Puppet Syndrome
606559|NCT00296764|Developmental Disorders
606560|NCT00296725|Major Depression
606561|NCT00296725|Dysthymia
606562|NCT00296725|Depression NOS
606563|NCT00296725|Dichotic Listening
606564|NCT00296725|Fluoxetine
606565|NCT00296725|Imipramine
606566|NCT00296725|Placebo
606567|NCT00296725|Predictors
606568|NCT00296712|Major Depression
606569|NCT00296712|Dysthymia
606570|NCT00296712|Depression NOS
606571|NCT00296712|Escitalopram
606572|NCT00296712|Bupropion
606573|NCT00296712|Dual Therapy
606574|NCT00296712|Combination Therapy
606575|NCT00296699|Atypical Depression
606576|NCT00296699|Major Depressive Disorder
606577|NCT00296699|Dysthymic Disorder
606578|NCT00296699|Atypical Features
606579|NCT00296699|Duloxetine
606580|NCT00296686|Major Depression
606581|NCT00296686|Refractory Depression
606582|NCT00296686|Tranylcypromine
606583|NCT00296686|Dextroamphetamine
606584|NCT00296686|Triiodothyronine
606585|NCT00296673|Rehabilitation, Side Bridge test, Muscular endurance
606586|NCT00296660|Acute Infection
606587|NCT00296634|H5N1, Influenza, vaccine
606588|NCT00296621|glutamine
606589|NCT00296621|nutrition
606590|NCT00296621|children
606591|NCT00296621|pediatrics
606592|NCT00296621|randomized controlled clinical trial
606593|NCT00296621|therapy
606594|NCT00296621|supplement
606595|NCT00296621|oral administration
606596|NCT00296621|handicap
606597|NCT00296608|stage II rectal cancer
606598|NCT00296608|stage III rectal cancer
606599|NCT00296608|adenocarcinoma of the rectum
606600|NCT00296556|Ulcerative colitis
606601|NCT00296556|EP4 agonist
606602|NCT00296556|PGE2
606603|NCT00296543|hemodialysis
606604|NCT00296543|sudden cardiac death
606605|NCT00296530|Asthma
606606|NCT00296530|Allergic Rhinitis
606607|NCT00296517|bupropion hydrochloride
606608|NCT00296517|SSRI
606609|NCT00296517|non-responder
606610|NCT00296517|depression
606611|NCT00296517|placebo-controlled
606612|NCT00296517|double-blind
606613|NCT00296517|comparative study
606614|NCT00296504|antiretroviral therapy naive subjects
606615|NCT00296504|fosamprenavir
606616|NCT00296504|HIV-1
606617|NCT00296504|protease inhibitor
606618|NCT00296504|pro-drug
606619|NCT00296504|antiretroviral therapy
606620|NCT00296504|LEXIVA
606621|NCT00296504|AGENERASE
606622|NCT00296504|GW433908
606623|NCT00296504|amprenavir
606624|NCT00296491|Allergic Rhinitis
606625|NCT00296491|Asthma
606626|NCT00296452|cancer
606627|NCT00296452|nutrition
606628|NCT00296426|Adverse Drug Event
606629|NCT00296426|Inpatients
606630|NCT00296426|Outcome assessment
606631|NCT00296413|epilepsy
606632|NCT00296413|menstrual cycle
606633|NCT00296413|valproate
606634|NCT00296413|lamotrigine
606635|NCT00296413|oral contraceptive
606636|NCT00296400|Hyperlipidemia
606637|NCT00296400|Proteinuria
606638|NCT00296400|Diabetes Mellitus
606639|NCT00296374|Hyperlipidemia
606640|NCT00296374|Proteinuria
606641|NCT00296374|Diabetes Mellitus
606642|NCT00296361|Tacrolimus
606643|NCT00296361|Kidney Transplantation
606644|NCT00296361|Immunosuppression
606645|NCT00296361|Adult
606646|NCT00296361|Treatment Outcomes
606647|NCT00296348|Tacrolimus
606648|NCT00296348|Kidney Transplantation
606649|NCT00296348|Child
606650|NCT00296348|Treatment Outcome
606651|NCT00296348|Immunosuppression
606652|NCT00296335|Stomach cancer
606653|NCT00296335|Adjuvant chemotherapy
606654|NCT00296335|Mitomycin
606655|NCT00296335|Cisplatin
606656|NCT00296335|Doxifluridine
606657|NCT00296322|stomach cancer
606658|NCT00296322|adjuvant chemotherapy
606659|NCT00296322|mitomycin
606660|NCT00296322|cisplatin
606661|NCT00296322|doxifluridine
606662|NCT00296309|Tacrolimus
606663|NCT00296309|Kidney Transplantation
606664|NCT00296309|Immunosuppression
606665|NCT00296309|Adult
606666|NCT00296309|Treatment Outcomes
606667|NCT00296296|kidney Transplant
606668|NCT00296296|Type II Diabetes
606669|NCT00296296|Diabetic Nephropathy
606670|NCT00296296|Immunosuppression
606671|NCT00296296|Cyclosporin
606672|NCT00296296|Tacrolimus
606673|NCT00296283|Relatives
606674|NCT00296283|Bipolar Disorder
606675|NCT00296283|Psychoeducation
606676|NCT00296244|steroid-free immunosuppression
606677|NCT00296244|liver transplantation
606678|NCT00296231|premature infants
606679|NCT00296231|very low birthweight infants
606680|NCT00296231|high frequency ventilation
606681|NCT00296231|nasal ventilation
606682|NCT00296205|Multiple Sclerosis
606683|NCT00296205|Cyclophosphamide
606684|NCT00296205|autoimmune
606685|NCT00296192|Rotigotine
606686|NCT00296192|Rotigotine nasal spray
606687|NCT00296192|Efficacy, safety and tolerability
606688|NCT00296192|Parkinson's disease
606689|NCT00296166|Atrial fibrillation
606690|NCT00296166|Permanent Atrial fibrillation
606691|NCT00296166|catheter ablation
606692|NCT00296166|thoracoscopy
606693|NCT00296166|Arrhythmia
606694|NCT00296166|Heart
606695|NCT00296153|Human immunodeficiency Virus (HIV)
606696|NCT00296153|Highly Active Antiviral Therapy (HAART)
606697|NCT00296153|Ischemic Heart Disease
606698|NCT00296153|OMACOR
606699|NCT00296153|Triglycerides
606700|NCT00296153|Endothelial function
606701|NCT00296153|Treatment Experienced
606702|NCT00296114|Cancer
606703|NCT00296114|Pancreas
606704|NCT00296101|Physical Inactivity
606705|NCT00296088|Mechanical Ventilation
606706|NCT00296088|Critical Care
606707|NCT00296088|Respiratory Failure
606708|NCT00296062|unspecified adult solid tumor, protocol specific
606709|NCT00296062|stage III colon cancer
606710|NCT00296062|stage IV colon cancer
606711|NCT00296062|stage III rectal cancer
606712|NCT00296062|stage IV rectal cancer
606713|NCT00296062|recurrent colon cancer
606714|NCT00296062|recurrent rectal cancer
606715|NCT00296049|unspecified adult solid tumor, protocol specific
606716|NCT00296049|infection
606717|NCT00296049|neutropenia
606718|NCT00296049|unspecified childhood solid tumor, protocol specific
606719|NCT00296036|drug/agent toxicity by tissue/organ
606720|NCT00296036|stage I breast cancer
606721|NCT00296036|stage II breast cancer
606722|NCT00296036|stage IIIA breast cancer
606723|NCT00296036|stage IIIB breast cancer
606724|NCT00296036|stage IIIC breast cancer
606725|NCT00296036|stage IV breast cancer
606726|NCT00296036|unspecified adult solid tumor, protocol specific
606727|NCT00296023|stage III chronic lymphocytic leukemia
606728|NCT00296023|stage IV chronic lymphocytic leukemia
606729|NCT00296023|stage III adult diffuse small cleaved cell lymphoma
606730|NCT00296023|stage IV adult diffuse small cleaved cell lymphoma
606731|NCT00296023|noncontiguous stage II grade 1 follicular lymphoma
606732|NCT00296023|noncontiguous stage II grade 2 follicular lymphoma
606733|NCT00296023|noncontiguous stage II grade 3 follicular lymphoma
606734|NCT00296023|stage III grade 1 follicular lymphoma
606735|NCT00296023|stage III grade 2 follicular lymphoma
606736|NCT00296023|stage III grade 3 follicular lymphoma
606737|NCT00296023|stage IV grade 1 follicular lymphoma
606738|NCT00296023|stage IV grade 2 follicular lymphoma
606739|NCT00296023|stage IV grade 3 follicular lymphoma
606740|NCT00296023|noncontiguous stage II marginal zone lymphoma
606741|NCT00296023|stage III marginal zone lymphoma
606742|NCT00296023|stage IV marginal zone lymphoma
606743|NCT00296023|noncontiguous stage II small lymphocytic lymphoma
606744|NCT00296023|stage III small lymphocytic lymphoma
606745|NCT00296023|stage IV small lymphocytic lymphoma
606746|NCT00296023|noncontiguous stage II adult Burkitt lymphoma
606747|NCT00296023|stage III adult Burkitt lymphoma
606748|NCT00296023|stage IV adult Burkitt lymphoma
606749|NCT00296023|stage III adult diffuse large cell lymphoma
606750|NCT00296023|stage IV adult diffuse large cell lymphoma
606751|NCT00296023|noncontiguous stage II adult diffuse mixed cell lymphoma
606752|NCT00296023|stage III adult diffuse mixed cell lymphoma
606753|NCT00296023|stage IV adult diffuse mixed cell lymphoma
606754|NCT00296023|noncontiguous stage II adult immunoblastic large cell lymphoma
606755|NCT00296023|stage III adult immunoblastic large cell lymphoma
606756|NCT00296023|stage IV adult immunoblastic large cell lymphoma
606757|NCT00296023|noncontiguous stage II adult lymphoblastic lymphoma
606758|NCT00296023|stage III adult lymphoblastic lymphoma
606759|NCT00296023|stage IV adult lymphoblastic lymphoma
606760|NCT00296023|noncontiguous stage II mantle cell lymphoma
606761|NCT00296023|stage III mantle cell lymphoma
606762|NCT00296023|stage IV mantle cell lymphoma
606763|NCT00296023|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
606764|NCT00296023|nodal marginal zone B-cell lymphoma
606765|NCT00296023|splenic marginal zone lymphoma
606766|NCT00296023|stage II multiple myeloma
606767|NCT00296023|stage III multiple myeloma
606768|NCT00296023|chronic phase chronic myelogenous leukemia
606769|NCT00296023|primary myelofibrosis
606770|NCT00296023|polycythemia vera
606771|NCT00296023|prolymphocytic leukemia
606772|NCT00296023|stage II adult Hodgkin lymphoma
606773|NCT00296023|stage III adult Hodgkin lymphoma
606774|NCT00296023|stage IV adult Hodgkin lymphoma
606775|NCT00296023|de novo myelodysplastic syndromes
606776|NCT00296023|previously treated myelodysplastic syndromes
606777|NCT00296023|secondary myelodysplastic syndromes
606778|NCT00296023|refractory anemia with excess blasts in transformation
606779|NCT00296023|refractory anemia with excess blasts
606780|NCT00296023|chronic myelomonocytic leukemia
606781|NCT00296023|adult acute myeloid leukemia in remission
606782|NCT00296023|secondary acute myeloid leukemia
606783|NCT00296023|Waldenström macroglobulinemia
606784|NCT00296023|essential thrombocythemia
606785|NCT00296023|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
606786|NCT00296023|adult acute myeloid leukemia with inv(16)(p13;q22)
606787|NCT00296023|adult acute myeloid leukemia with t(15;17)(q22;q12)
606788|NCT00296023|adult acute myeloid leukemia with t(16;16)(p13;q22)
606789|NCT00296023|adult acute myeloid leukemia with t(8;21)(q22;q22)
606790|NCT00296023|noncontiguous stage II adult diffuse large cell lymphoma
606791|NCT00296023|noncontiguous stage II adult diffuse small cleaved cell lymphoma
606792|NCT00296023|stage I multiple myeloma
606793|NCT00296010|stage I breast cancer
606794|NCT00296010|stage II breast cancer
606795|NCT00296010|stage IIIA breast cancer
606796|NCT00295997|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
606797|NCT00295997|adult acute myeloid leukemia with inv(16)(p13;q22)
606798|NCT00295997|adult acute myeloid leukemia with t(15;17)(q22;q12)
606799|NCT00295997|adult acute myeloid leukemia with t(16;16)(p13;q22)
606800|NCT00295997|accelerated phase chronic myelogenous leukemia
606801|NCT00295997|adult acute lymphoblastic leukemia in remission
606802|NCT00295997|adult acute myeloid leukemia in remission
606803|NCT00295997|atypical chronic myeloid leukemia, BCR-ABL1 negative
606804|NCT00295997|blastic phase chronic myelogenous leukemia
606805|NCT00295997|childhood acute lymphoblastic leukemia in remission
606806|NCT00295997|childhood acute myeloid leukemia in remission
606807|NCT00295997|childhood chronic myelogenous leukemia
606808|NCT00295997|chronic eosinophilic leukemia
606809|NCT00295997|primary myelofibrosis
606810|NCT00295997|chronic myelomonocytic leukemia
606811|NCT00295997|chronic neutrophilic leukemia
606812|NCT00295997|chronic phase chronic myelogenous leukemia
606813|NCT00295997|de novo myelodysplastic syndromes
606814|NCT00295997|essential thrombocythemia
606815|NCT00295997|juvenile myelomonocytic leukemia
606816|NCT00295997|myelodysplastic/myeloproliferative neoplasm, unclassifiable
606817|NCT00295997|polycythemia vera
606818|NCT00295997|previously treated myelodysplastic syndromes
606819|NCT00295997|recurrent adult acute myeloid leukemia
606820|NCT00295997|prolymphocytic leukemia
606821|NCT00295997|recurrent adult Hodgkin lymphoma
606822|NCT00295997|recurrent adult diffuse large cell lymphoma
606823|NCT00295997|recurrent adult immunoblastic large cell lymphoma
606824|NCT00295997|recurrent adult lymphoblastic lymphoma
606825|NCT00295997|recurrent/refractory childhood Hodgkin lymphoma
606826|NCT00295997|recurrent childhood acute lymphoblastic leukemia
606827|NCT00295997|recurrent childhood acute myeloid leukemia
606828|NCT00295997|recurrent childhood large cell lymphoma
606829|NCT00295997|recurrent grade 1 follicular lymphoma
606830|NCT00295997|recurrent grade 2 follicular lymphoma
606831|NCT00295997|recurrent grade 3 follicular lymphoma
606832|NCT00295997|recurrent mantle cell lymphoma
606833|NCT00295997|refractory chronic lymphocytic leukemia
606834|NCT00295997|refractory multiple myeloma
606835|NCT00295997|relapsing chronic myelogenous leukemia
606836|NCT00295997|secondary acute myeloid leukemia
606837|NCT00295997|secondary myelodysplastic syndromes
606838|NCT00295997|stage II multiple myeloma
606839|NCT00295997|stage III chronic lymphocytic leukemia
606840|NCT00295997|stage III grade 1 follicular lymphoma
606841|NCT00295997|stage III grade 2 follicular lymphoma
606842|NCT00295997|stage III grade 3 follicular lymphoma
606843|NCT00295997|stage III multiple myeloma
606844|NCT00295997|stage IV chronic lymphocytic leukemia
606845|NCT00295997|stage IV grade 1 follicular lymphoma
606846|NCT00295997|stage IV grade 2 follicular lymphoma
606847|NCT00295997|stage IV grade 3 follicular lymphoma
606848|NCT00295997|recurrent renal cell cancer
606849|NCT00295997|stage IV renal cell cancer
606850|NCT00295997|noncontiguous stage II grade 1 follicular lymphoma
606851|NCT00295997|noncontiguous stage II grade 2 follicular lymphoma
606852|NCT00295997|noncontiguous stage II grade 3 follicular lymphoma
606853|NCT00295997|recurrent adult acute lymphoblastic leukemia
606854|NCT00295997|childhood myelodysplastic syndromes
606855|NCT00295984|classic Kaposi sarcoma
606856|NCT00295984|recurrent Kaposi sarcoma
606857|NCT00295971|childhood acute lymphoblastic leukemia in remission
606858|NCT00295971|childhood acute myeloid leukemia in remission
606859|NCT00295971|de novo myelodysplastic syndromes
606860|NCT00295971|previously treated myelodysplastic syndromes
606861|NCT00295971|secondary myelodysplastic syndromes
606862|NCT00295971|secondary acute myeloid leukemia
606863|NCT00295971|juvenile myelomonocytic leukemia
606864|NCT00295971|chronic phase chronic myelogenous leukemia
606865|NCT00295971|refractory anemia with excess blasts in transformation
606866|NCT00295971|refractory anemia with excess blasts
606867|NCT00295971|severe congenital neutropenia
606868|NCT00295971|congenital amegakaryocytic thrombocytopenia
606869|NCT00295971|childhood chronic myelogenous leukemia
606870|NCT00295971|childhood myelodysplastic syndromes
606871|NCT00295958|recurrent melanoma
606872|NCT00295958|stage IV melanoma
606873|NCT00295958|skin cancer
606874|NCT00295945|pain
606875|NCT00295945|perioperative/postoperative complications
606876|NCT00295945|stage III cervical cancer
606877|NCT00295945|recurrent cervical cancer
606878|NCT00295945|stage IB cervical cancer
606879|NCT00295945|stage IIB cervical cancer
606880|NCT00295945|stage IVB cervical cancer
606881|NCT00295945|stage IA cervical cancer
606882|NCT00295945|stage IIA cervical cancer
606883|NCT00295945|stage IVA cervical cancer
606884|NCT00295945|stage I endometrial carcinoma
606885|NCT00295945|stage II endometrial carcinoma
606886|NCT00295945|stage III endometrial carcinoma
606887|NCT00295945|stage IV endometrial carcinoma
606888|NCT00295945|recurrent endometrial carcinoma
606889|NCT00295945|stage I uterine sarcoma
606890|NCT00295945|stage II uterine sarcoma
606891|NCT00295945|stage III uterine sarcoma
606892|NCT00295945|stage IV uterine sarcoma
606893|NCT00295945|recurrent uterine sarcoma
606894|NCT00295945|ovarian sarcoma
606895|NCT00295945|recurrent ovarian epithelial cancer
606896|NCT00295945|recurrent ovarian germ cell tumor
606897|NCT00295945|stage IV ovarian epithelial cancer
606898|NCT00295945|stage IV ovarian germ cell tumor
606899|NCT00295945|ovarian stromal cancer
606900|NCT00295945|recurrent fallopian tube cancer
606901|NCT00295945|stage IA fallopian tube cancer
606902|NCT00295945|stage IB fallopian tube cancer
606903|NCT00295945|stage IC fallopian tube cancer
606904|NCT00295945|stage IIA fallopian tube cancer
606905|NCT00295945|stage IIB fallopian tube cancer
606906|NCT00295945|stage IIC fallopian tube cancer
606907|NCT00295945|stage IIIA fallopian tube cancer
606908|NCT00295945|stage IIIB fallopian tube cancer
606909|NCT00295945|stage IIIC fallopian tube cancer
606910|NCT00295945|stage IV fallopian tube cancer
606911|NCT00295945|stage IA ovarian epithelial cancer
606912|NCT00295945|stage IB ovarian epithelial cancer
606913|NCT00295945|stage IC ovarian epithelial cancer
606914|NCT00295945|stage IIA ovarian epithelial cancer
606915|NCT00295945|stage IIB ovarian epithelial cancer
606916|NCT00295945|stage IIC ovarian epithelial cancer
606917|NCT00295945|stage IIIA ovarian epithelial cancer
606918|NCT00295945|stage IIIB ovarian epithelial cancer
606919|NCT00295945|stage IIIC ovarian epithelial cancer
606920|NCT00295945|stage IA ovarian germ cell tumor
606921|NCT00295945|stage IB ovarian germ cell tumor
606922|NCT00295945|stage IC ovarian germ cell tumor
606923|NCT00295945|stage IIA ovarian germ cell tumor
606924|NCT00295945|stage IIB ovarian germ cell tumor
606925|NCT00295945|stage IIC ovarian germ cell tumor
606926|NCT00295945|stage IIIA ovarian germ cell tumor
606927|NCT00295945|stage IIIB ovarian germ cell tumor
606928|NCT00295945|stage IIIC ovarian germ cell tumor
606929|NCT00295932|recurrent grade 1 follicular lymphoma
606930|NCT00295932|recurrent grade 2 follicular lymphoma
606931|NCT00295932|recurrent grade 3 follicular lymphoma
606932|NCT00295932|recurrent small lymphocytic lymphoma
606933|NCT00295932|recurrent marginal zone lymphoma
606934|NCT00295932|Waldenstrom macroglobulinemia
606935|NCT00295932|recurrent mantle cell lymphoma
606936|NCT00295932|refractory chronic lymphocytic leukemia
606937|NCT00295932|B-cell chronic lymphocytic leukemia
606938|NCT00295932|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
606939|NCT00295932|nodal marginal zone B-cell lymphoma
606940|NCT00295932|splenic marginal zone lymphoma
606941|NCT00295919|recurrent neuroblastoma
606942|NCT00295906|melanoma
606943|NCT00295906|skin cancer
606944|NCT00295893|inflammatory breast cancer
606945|NCT00295893|stage II breast cancer
606946|NCT00295893|stage IIIA breast cancer
606947|NCT00295893|stage IIIB breast cancer
606948|NCT00295893|stage IIIC breast cancer
606949|NCT00295893|male breast cancer
606950|NCT00295893|Paget disease of the breast with invasive ductal carcinoma
606951|NCT00295893|invasive ductal breast carcinoma with predominant intraductal component
606952|NCT00295893|invasive ductal breast carcinoma
606953|NCT00295893|medullary ductal breast carcinoma with lymphocytic infiltrate
606954|NCT00295893|comedo ductal breast carcinoma
606955|NCT00295893|invasive lobular breast carcinoma with predominant in situ component
606956|NCT00295893|invasive lobular breast carcinoma
606957|NCT00295893|mucinous ductal breast carcinoma
606958|NCT00295893|papillary ductal breast carcinoma
606959|NCT00295893|tubular ductal breast carcinoma
606960|NCT00295880|adult acute myeloid leukemia in remission
606961|NCT00295880|adult acute myeloid leukemia
606962|NCT00295880|childhood acute myeloid leukemia in remission
606963|NCT00295880|secondary acute myeloid leukemia
606964|NCT00295880|accelerated phase chronic myelogenous leukemia
606965|NCT00295880|childhood chronic myelogenous leukemia
606966|NCT00295880|chronic phase chronic myelogenous leukemia
606967|NCT00295880|relapsing chronic myelogenous leukemia
606968|NCT00295880|refractory anemia with excess blasts
606969|NCT00295880|de novo myelodysplastic syndromes
606970|NCT00295880|myelodysplastic syndromes
606971|NCT00295880|adult diffuse large cell lymphoma
606972|NCT00295880|adult diffuse mixed cell lymphoma
606973|NCT00295880|adult diffuse small cleaved cell lymphoma
606974|NCT00295880|adult lymphoblastic lymphoma
606975|NCT00295880|grade 3 follicular lymphoma
606976|NCT00295880|mantle cell lymphoma
606977|NCT00295880|childhood large cell lymphoma
606978|NCT00295880|childhood lymphoblastic lymphoma
606979|NCT00295880|adult acute lymphoblastic leukemia
606980|NCT00295880|acute lymphoblastic leukemia
606981|NCT00295880|refractory anemia
606982|NCT00295880|refractory cytopenia
606983|NCT00295880|childhood acute myeloid leukemia
606984|NCT00295880|adult immunoblastic large cell lymphoma
606985|NCT00295880|blastic phase chronic myelogenous leukemia
606986|NCT00295880|chronic eosinophilic leukemia
606987|NCT00295880|chronic neutrophilic leukemia
606988|NCT00295880|childhood small noncleaved cell lymphoma
606989|NCT00295880|childhood myelodysplastic syndromes
606990|NCT00295867|stage I breast cancer
606991|NCT00295867|stage II breast cancer
606992|NCT00295867|stage IIIA breast cancer
606993|NCT00295867|stage IIIB breast cancer
606994|NCT00295867|stage IIIC breast cancer
606995|NCT00295854|Interstitial Cystitis
606996|NCT00295854|urgency
606997|NCT00295854|frequency
606998|NCT00295854|MN-001
606999|NCT00295854|Global Response Assessment
607000|NCT00295854|bladder pain/urgency
607001|NCT00295854|O'Leary Sant IC Symptom and Problem Index
607002|NCT00295841|recurrent adult acute lymphoblastic leukemia
607003|NCT00295841|recurrent adult acute myeloid leukemia
607004|NCT00295841|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
607005|NCT00295841|adult acute myeloid leukemia with inv(16)(p13;q22)
607006|NCT00295841|adult acute myeloid leukemia with t(16;16)(p13;q22)
607007|NCT00295841|adult acute myeloid leukemia with t(8;21)(q22;q22)
607008|NCT00295841|adult acute basophilic leukemia
607009|NCT00295841|adult acute eosinophilic leukemia
607010|NCT00295841|adult erythroleukemia (M6a)
607011|NCT00295841|adult pure erythroid leukemia (M6b)
607012|NCT00295841|adult acute megakaryoblastic leukemia (M7)
607013|NCT00295841|adult acute minimally differentiated myeloid leukemia (M0)
607014|NCT00295841|adult acute monoblastic leukemia (M5a)
607015|NCT00295841|adult acute monocytic leukemia (M5b)
607016|NCT00295841|adult acute myeloblastic leukemia with maturation (M2)
607017|NCT00295841|adult acute myeloblastic leukemia without maturation (M1)
607018|NCT00295841|adult acute myelomonocytic leukemia (M4)
607019|NCT00295828|VEGF
607020|NCT00295828|iris neovascularization
607021|NCT00295828|diabetic retinopathy
607022|NCT00295828|Macugen
607023|NCT00295802|Prostate Cancer
607024|NCT00295802|HIFU
607025|NCT00295802|EDAP
607026|NCT00295802|Low Risk, Localized Prostate Cancer
607027|NCT00295789|cervical cancer
607028|NCT00295789|palliative chemotherapy
607029|NCT00295789|recurrent
607030|NCT00295789|persistent
607031|NCT00295789|stageⅣb
607032|NCT00295789|cisplatin
607033|NCT00295789|carboplatin
607034|NCT00295789|paclitaxel
607156|NCT00295360|bile acids
607157|NCT00295360|ABCG2
607035|NCT00295776|Inclusion Criteria:Minimum of 4 on the Likert Pain Scale.If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks.
607036|NCT00295776|Exclusion Criteria:
607037|NCT00295776|Currently on any antiepilepic drugs (AED), except for Gabapentin.
607038|NCT00295776|Currently taking opioid or unwilling to washout prior to the study,
607039|NCT00295776|Pregnant and lactating,
607040|NCT00295776|Have active severe systemic disease,
607041|NCT00295776|History of Stevens-Johnson syndrome or TEN,
607042|NCT00295763|papillary thyroid cancer
607043|NCT00295763|follicular thyroid cancer
607044|NCT00295763|recombinant human TSH
607045|NCT00295763|Thyrogen
607046|NCT00295763|thyroid stimulating hormone
607047|NCT00295763|thyroid remnant ablation
607048|NCT00295763|radioiodine
607049|NCT00295750|Prostate Cancer
607050|NCT00295737|allergic rhinitis
607051|NCT00295724|bicifadine
607052|NCT00295724|chronic low back pain
607053|NCT00295711|bicifadine
607054|NCT00295711|chronic low back pain
607055|NCT00295698|HIV
607056|NCT00295698|Lymphatic filariasis
607057|NCT00295698|Diethylcarbamazine
607058|NCT00295698|Interaction
607059|NCT00295698|Tanzania
607060|NCT00295685|Reflux
607061|NCT00295685|GERD
607062|NCT00295672|Non-Small-Cell Lung,radiotherapy, Chemotherapy, vinorelbine
607063|NCT00295659|Gestational Diabetes
607064|NCT00295659|Screening
607065|NCT00295659|Cost-effectiveness
607066|NCT00295659|obstetrical outcomes
607067|NCT00295646|ABCSG
607068|NCT00295646|12
607069|NCT00295646|Phase 3
607070|NCT00295646|breast cancer
607071|NCT00295646|anastrozole
607072|NCT00295646|tamoxifen
607073|NCT00295646|zoledronic acid
607074|NCT00295646|premenopausal
607075|NCT00295646|hormone receptor-positive
607076|NCT00295646|Stage I
607077|NCT00295646|Stage II
607078|NCT00295646|bone mineral density
607079|NCT00295646|BMD
607080|NCT00295646|bisphosphonate
607081|NCT00295646|zoledronate
607082|NCT00295620|Hormone receptor positive breast cancer
607083|NCT00295607|Tacrolimus
607084|NCT00295607|Liver Transplantation
607085|NCT00295607|Immunosuppression
607086|NCT00295607|Adult
607087|NCT00295607|Treatment Outcome
607088|NCT00295594|Tacrolimus
607089|NCT00295594|Liver Transplantation
607090|NCT00295594|Treatment Outcome
607091|NCT00295594|Immunosuppression
607092|NCT00295581|Human
607093|NCT00295581|Clinical Trial
607094|NCT00295581|Mosquito
607095|NCT00295581|Healthy Volunteer
607096|NCT00295581|HV
607097|NCT00295568|Transcranial Magnetic Stimulation (TMS)
607098|NCT00295568|Motor Learning
607099|NCT00295568|Accuracy
607100|NCT00295568|Tracking Motor Task
607101|NCT00295568|Healthy Volunteer
607102|NCT00295568|HV
607103|NCT00295555|ambulatory blood pressure monitoring
607104|NCT00295555|doxazosin
607105|NCT00295555|alpha1-adrenergic antagonists
607106|NCT00295555|sympathetic nervous activity
607107|NCT00295555|diabetic nephropathy
607108|NCT00295555|essential hypertension
607109|NCT00295555|power spectral analysis
607110|NCT00295555|morning surge
607111|NCT00295542|ambulatory blood pressure monitoring
607112|NCT00295542|cardiovascular risk
607113|NCT00295542|chronotherapy
607114|NCT00295542|circadian pattern
607115|NCT00295529|Primary health care
607116|NCT00295529|Breast neoplasm
607117|NCT00295529|Education
607118|NCT00295516|Rhesus
607119|NCT00295516|Isoimmunization
607120|NCT00295516|Red Cell Alloimmunization
607121|NCT00295516|Fetal Hemolytic Anemia
607122|NCT00295516|Erythroblastosis fetalis
607123|NCT00295503|mesothelioma
607124|NCT00295503|bevacizumab
607125|NCT00295503|chemotherapy
607126|NCT00295490|double blind randomised controlled trial
607127|NCT00295490|phase II
607128|NCT00295490|Devil's Claw
607129|NCT00295490|osteoarthritis of the knee
607130|NCT00295490|osteoarthritis of the hip
607131|NCT00295477|HIV
607132|NCT00295477|Treatment Experienced
607133|NCT00295464|Antenatal glucocorticoid
607134|NCT00295464|Premature birth
607135|NCT00295438|robot-based tele-echography
607136|NCT00295438|tele-medicine
607137|NCT00295425|psoriasis
607138|NCT00295425|randomized clinical trial
607139|NCT00295425|cyclosporine A
607140|NCT00295425|mycophenolate mofetil
607141|NCT00295425|immunosuppression
607142|NCT00295399|cerebrovascular accident
607143|NCT00295399|traumatic brain injury
607144|NCT00295399|stroke
607145|NCT00295399|telerehabilitation
607146|NCT00295373|Hypercholesterolemia
607147|NCT00295373|Exercise
607148|NCT00295373|Statin
607149|NCT00295373|Rosuvastatin
607150|NCT00295373|TLR4
607151|NCT00295373|Inflammation
607152|NCT00295360|cholestasis
607153|NCT00295360|BCRP
607154|NCT00295360|multidrug resistance
607155|NCT00295360|duodenum
607158|NCT00295334|adherence
607159|NCT00295334|glycemic control
607160|NCT00295308|Opioid Dependence
607161|NCT00295308|Clonidine
607162|NCT00295308|Buprenorphine
607163|NCT00295308|Opioid Abstinence
607164|NCT00295308|Relapse
607165|NCT00295295|vibration
607166|NCT00295295|bone density
607167|NCT00295282|Ulcerative Colitis
607168|NCT00295282|UC
607169|NCT00295282|Colitis
607170|NCT00295256|randomized trial
607171|NCT00295256|diabetes
607172|NCT00295256|pregnancy
607173|NCT00295230|respiratory distress syndrome
607174|NCT00295230|very low birth weight infant
607175|NCT00295230|mechanical ventilation
607176|NCT00295217|Fibroids
607177|NCT00295217|Uterine Leiomyomas
607178|NCT00295217|ExAblate
607179|NCT00295217|MrgFUS
607180|NCT00295204|Syncope
607181|NCT00295204|pre-syncope
607182|NCT00295204|palpitations
607183|NCT00295191|end-stage renal disease
607184|NCT00295191|hemodialysis
607185|NCT00295191|cardiovascular morbidity and mortality
607186|NCT00295191|high flux dialyser
607187|NCT00295191|ultrapure dialysate
607188|NCT00295191|coronary vascular calcifications
607189|NCT00295191|carotid intima-media thickness
607190|NCT00295191|atherosclerosis
607191|NCT00295152|elderly/aged
607192|NCT00295152|occupational therapy
607193|NCT00295152|daily activities
607194|NCT00295152|caregivers
607195|NCT00295152|sense of competence
607196|NCT00295139|treatment
607197|NCT00295139|dual diagnosis
607198|NCT00295126|Edentulous
607199|NCT00295126|Tooth Loss
607200|NCT00295126|APC
607201|NCT00295126|Autologous platelet concentrate
607202|NCT00295113|Pulmonary arterial pressure
607203|NCT00295113|COPD
607204|NCT00295113|Cardiac output
607205|NCT00295113|pulmonary and cardiac functions
607206|NCT00295113|pulmonary arterial pressure measurements
607207|NCT00295100|Tamoxifen
607208|NCT00295100|Prevention
607209|NCT00295100|Breast Cancer
607210|NCT00295100|MRI
607211|NCT00295087|Premature Ovarian Failure
607212|NCT00295087|X-Chromosome Inactivation
607213|NCT00295074|traumatic brain injury
607214|NCT00295074|head injury
607215|NCT00295074|concussion
607216|NCT00295074|neuropsychologic test
607217|NCT00295061|alpha 1-Antitrypsin Deficiency
607218|NCT00295061|alpha 1-Antitrypsin
607219|NCT00295061|pulmonary emphysema
607220|NCT00295048|treatment
607221|NCT00295048|cognition
607222|NCT00295048|schizophrenia
607223|NCT00295022|Levocetirizine
607224|NCT00295022|Xyzal
607225|NCT00295022|Rhinitis
607226|NCT00295022|Allergic
607227|NCT00295022|Seasonal
607228|NCT00295022|Ragweed
607229|NCT00294996|Metastatic Her2+ Breast cancer
607230|NCT00294996|Myocet
607231|NCT00294996|liposomal doxorubicin
607232|NCT00294996|trastuzumab
607233|NCT00294931|Lung Cancer, Small Cell
607234|NCT00294931|Extensive
607235|NCT00294918|Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
607236|NCT00294918|Human Immunodeficiency Virus Infections
607237|NCT00294918|Serostim®
607238|NCT00294918|recombinant human growth hormone (r-hGH)
607239|NCT00294905|COPD
607240|NCT00294905|smoking cessation
607241|NCT00294905|implementation
607242|NCT00294905|patient counseling
607243|NCT00294905|general practice
607244|NCT00294892|HIV
607245|NCT00294892|mother to child transmission; MTCT
607246|NCT00294892|nevirapine resistance
607247|NCT00294892|pharmacokinetics
607248|NCT00294892|Treatment Naive
607249|NCT00294866|End Stage Renal Disease
607250|NCT00294866|Inflammation
607251|NCT00294853|Coronary calcium score
607252|NCT00294853|Coronary artery disease
607253|NCT00294853|Cardiac transplantation
607254|NCT00294853|Coronary calcium score in heart transplanted patients
607255|NCT00294853|Coronary artery disease in heart transplanted patients
607256|NCT00294827|Liver transplantation
607257|NCT00294814|Cardiac Surgery
607258|NCT00294814|CABG
607259|NCT00294814|Microemboli
607260|NCT00294814|Transcranial Doppler
607261|NCT00294814|Cognitive Decline
607262|NCT00294814|Anastomotic Device
607263|NCT00294814|Proximal Anastomosis
607264|NCT00294814|Coronary Artery Bypass Graft (CABG)
607265|NCT00294801|knee osteoarthritis
607266|NCT00294788|Influenza
607267|NCT00294788|bioadjuvant
607268|NCT00294788|probiotic
607269|NCT00294788|HAI
607270|NCT00294788|immunity
607271|NCT00294788|vaccine
607272|NCT00294788|Immune response to influenza vaccine
607273|NCT00294775|diastolic dysfunction
607274|NCT00294775|Reverse Remodelling
607275|NCT00294762|NSCLC
607276|NCT00294762|Erlotinib
607277|NCT00294762|Tarceva
607278|NCT00294762|Lung Cancer
607279|NCT00294749|Prostate,
607280|NCT00294749|Infection,
607281|NCT00294749|Biopsy,
607282|NCT00294749|Antibiotic,
607283|NCT00294749|Prophylaxis
607284|NCT00294736|lung cancer
607285|NCT00294736|erlotinib
607286|NCT00294736|NSCLC
607287|NCT00294736|smokers
607288|NCT00294710|Hypertension, aliskiren, hydrochlorothiazide, amlodipine
607289|NCT00294697|polymorphisms
607290|NCT00294697|innate immune response
607291|NCT00294697|immunomonitoring
607292|NCT00294697|immuno paralysis
607293|NCT00294684|biliary atresia
607294|NCT00294684|hepatoportoenterostomy
607295|NCT00294684|corticosteroids
607296|NCT00294671|familial amyloid polyneuropathy
607297|NCT00294671|familial amyloidosis
607298|NCT00294671|diflunisal
607299|NCT00294671|amyloidosis
607300|NCT00294671|transthyretin
607301|NCT00294671|peripheral neuropathy
607302|NCT00294671|autonomic neuropathy
607303|NCT00294671|amyloid cardiomyopathy
607304|NCT00294658|myasthenia gravis
607305|NCT00294658|thymectomy
607306|NCT00294658|prednisone
607307|NCT00294658|corticosteroid
607308|NCT00294658|extended transsternal thymectomy
607309|NCT00294658|ETTX
607310|NCT00294658|MG
607311|NCT00294658|thymus
607312|NCT00294658|thymoma
607313|NCT00294645|Remote Follow Up
607314|NCT00294645|Diagnostic
607315|NCT00294645|Bradycardia
607316|NCT00294632|Mantle Cell Lymphoma
607317|NCT00294632|B-Cell Non-Hodgkin's Lymphoma
607318|NCT00294632|Transformed Large Cell Lymphoma
607319|NCT00294632|Follicular Lymphoma
607320|NCT00294632|Lymphoma
607321|NCT00294632|MCL
607322|NCT00294632|Lenalidomide
607323|NCT00294632|CC-5013
607324|NCT00294632|Revlimid™
607325|NCT00294632|Rituximab
607326|NCT00294632|Rituxan
607327|NCT00294619|Growth hormone deficiency
607328|NCT00294606|vasopressor agents
607329|NCT00294606|carotid endarterectomy
607330|NCT00294606|cardiac function
607331|NCT00294606|transesophageal echocardiography
607332|NCT00294606|wall motion abnormalities
607333|NCT00294593|Down syndrome
607334|NCT00294593|folinic acid therapy
607335|NCT00294593|cognitive functions
607336|NCT00294580|Malaria
607337|NCT00294580|Cognition
607338|NCT00294580|Prevention & control
607339|NCT00294580|Anemia
607340|NCT00294580|Chemoprophylaxis
607341|NCT00294580|Mortality
607342|NCT00294580|Children
607343|NCT00294580|Randomized controlled trial
607344|NCT00294580|Education
607345|NCT00294580|Long-term effects
607346|NCT00294580|The Gambia
607347|NCT00294580|Africa, West
607348|NCT00294567|Hypertension
607349|NCT00294567|PCI
607350|NCT00294567|Calcium Channel Blockers
607351|NCT00294567|IVUS
607352|NCT00294567|Plaque
607353|NCT00294554|Parkinson's Disease
607354|NCT00294554|Cognitive Impairment
607355|NCT00294554|Dementia
607356|NCT00294554|Memory
607357|NCT00294541|sickle cell disease
607358|NCT00294541|sickle cell anemia
607359|NCT00294528|osteoarthritis, knee
607360|NCT00294528|total knee arthroplasty
607361|NCT00294528|range of motion
607362|NCT00294528|satisfaction
607363|NCT00294489|HCV
607364|NCT00294489|Fibrosis
607365|NCT00294489|Breath test
607366|NCT00294476|IVIg
607367|NCT00294476|Cancer
607368|NCT00294476|Melanoma
607369|NCT00294463|postmenopause
607370|NCT00294463|endometrium
607371|NCT00294463|Gene Expression Profiling
607372|NCT00294463|Histology, Comparative
607373|NCT00294463|Hormone Replacement Therapy
607374|NCT00294463|Hormones
607375|NCT00294437|Prostate Cancer
607376|NCT00294437|Zometa
607377|NCT00294424|Waiting time
607378|NCT00294424|Total hip replacement
607379|NCT00294424|Total knee replacement
607380|NCT00294424|Quality of life
607381|NCT00294424|The15D
607382|NCT00294424|Harris Hip Score
607383|NCT00294424|Knee Score
607384|NCT00294424|Pain measurement
607385|NCT00294424|Cost-effectiveness
607386|NCT00294424|Medication
607387|NCT00294424|Health services
607388|NCT00294424|Social services
607389|NCT00294424|Randomized Controlled Trial
607390|NCT00294398|Asthma, Controller Medications
607391|NCT00294385|Breast Cancer
607392|NCT00294385|Docetaxel
607393|NCT00294359|colorectal neoplasm
607394|NCT00294346|Social Anxiety Disorder
607395|NCT00294346|Social Phobia
607396|NCT00294320|Aldara
607397|NCT00294320|Actinic Keratosis
607398|NCT00294307|Nursing Models of Care
607399|NCT00294307|Collaborative Care
607400|NCT00294307|Care Management
607401|NCT00294307|Transitional Care
607402|NCT00294307|Advanced Practice Nurse Care Interventions
607403|NCT00294307|Cognitive Impairment
607404|NCT00294307|Dementia
607405|NCT00294307|Delirium
607406|NCT00294294|vaccine
607407|NCT00294294|infant
607408|NCT00294281|Pain
607409|NCT00294281|Tenderness
607410|NCT00294281|Depression
607411|NCT00294281|Work Disability
607412|NCT00294281|Physical Function
607413|NCT00294281|Quality of Life
607414|NCT00294281|Chronic Pain
607415|NCT00294268|obesity
607416|NCT00294268|CBT
607417|NCT00294268|motivational enhancement therapy
607418|NCT00294268|weight loss maintenance
607419|NCT00294255|mixed mania
607420|NCT00294255|depression
607421|NCT00294255|irritability
607422|NCT00294242|pregnancy
607423|NCT00294242|membranes sweeping
607424|NCT00294242|prelabor rupture of membranes
607425|NCT00294229|Low back pain
607426|NCT00294229|Spinal manipulative therapy
607427|NCT00294229|Randomised controlled trial
607428|NCT00294216|Omacor
607429|NCT00294216|Omega-3 PUFA
607430|NCT00294216|Endarterectomy
607431|NCT00294216|Carotid Plaque stability
607432|NCT00294216|Structural changes
607433|NCT00294216|inflammation
607434|NCT00294203|Digestive System Surgical Procedures
607435|NCT00294203|Post-Operative Care
607436|NCT00294203|Fatigue
607437|NCT00294203|Quality of Life
607438|NCT00294203|Erythrocyte Transfusion
607439|NCT00294203|Esophagectomy
607440|NCT00294203|Gastric Cancer
607441|NCT00294203|Hepatectomy
607442|NCT00294203|Pancreatic Cancer
607443|NCT00294203|Rectum
607444|NCT00294190|Lung Cancer
607445|NCT00294190|Extensive stage
607446|NCT00294190|Small Cell Lung Cancer
607447|NCT00294177|Trophoblastic Neoplasms
607448|NCT00294177|Chorionic Gonadotropin
607449|NCT00294177|Molecular Conformation
607450|NCT00294164|Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
607451|NCT00294164|Human Immunodeficiency Virus Infections
607452|NCT00294164|recombinant human growth hormone (r-hGH)
607453|NCT00294164|Serostim®
607454|NCT00294164|Placebo
607455|NCT00294151|breast cancer
607456|NCT00294151|prostate cancer
607457|NCT00294151|vertebral metastasis
607458|NCT00294151|vertebroplasty
607459|NCT00294151|vertebral metastasis from breast cancer
607460|NCT00294151|vertebral metastasis from prostate cancer
607461|NCT00294125|Medical Food
607462|NCT00294125|Botanicals
607463|NCT00294125|Phytochemicals
607464|NCT00294112|mesenchymal stem cells
607465|NCT00294099|A/H5N1, Influenza, Vaccine
607466|NCT00294086|valsartan,
607467|NCT00294086|chronic heart failure,
607468|NCT00294073|femoral block
607469|NCT00294073|fascia iliaca block
607470|NCT00294073|ACL repair
607471|NCT00294073|post-operative analgesia
607472|NCT00294073|knee surgery
607473|NCT00294073|ACL damage
607474|NCT00294073|knee damage
607475|NCT00294060|Pacemaker
607476|NCT00294060|Bradycardia
607477|NCT00294047|Vaccine
607478|NCT00294047|Human papillomavirus
607479|NCT00294047|Cervical Cancer
607480|NCT00294047|Cervical Infection
607481|NCT00294034|Registry
607482|NCT00294034|Pacemaker
607483|NCT00294034|Diagnostics
607484|NCT00294008|Schizophrenia
607485|NCT00294008|Treatment adherence
607486|NCT00294008|Antipsychotic agents
607487|NCT00294008|Risperidone
607488|NCT00294008|Long-acting injectable
607489|NCT00294008|Risperdal tablet
607490|NCT00294008|Risperidal Consta
607491|NCT00293982|Patient satisfaction
607492|NCT00293982|Patient expectations
607493|NCT00293982|Pediatric emergency department
607494|NCT00293969|Pain
607495|NCT00293969|Morphine
607496|NCT00293956|hypothyroxinemia
607497|NCT00293956|full term infants
607498|NCT00293956|near term infants
607499|NCT00293956|respiratory distress
607500|NCT00293956|thyroid disease
607501|NCT00293943|Atrial fibrillation
607502|NCT00293943|Pulmonary vein ablation
607503|NCT00293943|Linear lesions
607504|NCT00293930|Treatment Outcome
607505|NCT00293930|Tacrolimus
607506|NCT00293930|Safety
607507|NCT00293930|Psoriasis
607508|NCT00293917|Treatment Outcome
607509|NCT00293917|Tacrolimus
607510|NCT00293917|Safety
607511|NCT00293917|Psoriasis
607512|NCT00293904|Allergy
607513|NCT00293904|Grass Pollen
607514|NCT00293904|Systemic Immunotherapy
607515|NCT00293891|Treatment Outcome
607516|NCT00293891|Tacrolimus
607517|NCT00293891|Safety
607518|NCT00293891|Psoriasis
607519|NCT00293865|Breast infiltrative cancer
607520|NCT00293852|Heart failure, Congestive
607521|NCT00293852|Metabolic Syndrome X
607522|NCT00293852|Ambulatory Care
607523|NCT00293852|Health behavior
607524|NCT00293839|bladder
607525|NCT00293839|overactive
607526|NCT00293826|ACR criteria
607527|NCT00293826|methotrexate
607528|NCT00293826|DMARDs
607529|NCT00293826|patient reported outcomes
607530|NCT00293826|joint assessment
607531|NCT00293813|Post Menopausal
607532|NCT00293813|Osteoporosis
607533|NCT00293813|MicroCT
607534|NCT00293813|Amgen
607535|NCT00293813|denosumab
607536|NCT00293813|Extreme CT
607537|NCT00293813|XCT
607538|NCT00293813|Fosamax
607539|NCT00293813|Alendronate
607540|NCT00293800|Open-angle
607541|NCT00293800|glaucoma
607542|NCT00293800|ocular
607543|NCT00293800|hypertension
607544|NCT00293787|Open-angle
607545|NCT00293787|glaucoma
607546|NCT00293787|ocular
607547|NCT00293787|hypertension
607548|NCT00293774|Prospective
607549|NCT00293774|Conventional therapy
607550|NCT00293774|Registry
607551|NCT00293774|Metal-on-metal
607552|NCT00293774|Ceramic-on-ceramic
607553|NCT00293774|Hip Arthroplasty
607554|NCT00293761|open-angle
607555|NCT00293761|glaucoma
607556|NCT00293761|ocular
607557|NCT00293761|hypertension
607558|NCT00293748|Genomics
607559|NCT00293748|Statins
607560|NCT00293748|Coronary Heart Disease
607561|NCT00293748|Stroke
607562|NCT00293748|Inflammation
607563|NCT00293748|Gene Expression
607564|NCT00293748|Vascular Risk
607565|NCT00293748|Peripheral Blood Mononuclear Cells
607566|NCT00293748|Atorvastatin
607567|NCT00293748|Vascular Disease
607568|NCT00293748|Vascular Disease Risk
607569|NCT00293735|Preeclampsia
607570|NCT00293735|Pregnancy
607571|NCT00293735|Hypertension
607572|NCT00293735|Eclampsia
607573|NCT00293735|HELLP Syndrome
607574|NCT00293735|Seizures
607575|NCT00293735|Prevention
607576|NCT00293722|Arthritis
607577|NCT00293709|Arthritis
607578|NCT00293696|biomarker study
607579|NCT00293696|Patients with clinically localised prostate cancer
607580|NCT00293683|cesarean
607581|NCT00293683|closure
607582|NCT00293683|skin
607583|NCT00293683|staple
607584|NCT00293683|absorbable
607585|NCT00293683|metal
607586|NCT00293644|Pregnancy Complications
607587|NCT00293644|Hyperemesis Gravidarum
607588|NCT00293644|Diclectin
607589|NCT00293644|doxylamine succinate
607590|NCT00293644|pyridoxine hydrochloride
607591|NCT00293618|Implementation of prediction rules
607592|NCT00293618|Decision Support Systems, Clinical
607593|NCT00293618|PONV
607594|NCT00293618|Emesis
607595|NCT00293618|Nausea
607596|NCT00293618|Vomiting
607597|NCT00293618|Postoperative
607598|NCT00293618|Implementation
607599|NCT00293618|prediction rule
607600|NCT00293618|impact study
607601|NCT00293618|decision support
607602|NCT00293618|clinical decision support
607603|NCT00293605|aseptic loosening
607604|NCT00293605|femoral stem design
607605|NCT00293592|Heart surgery
607606|NCT00293592|Cardiopulmonary bypass
607607|NCT00293592|Systemic Inflammatory Response Syndrome (SIRS)
607608|NCT00293579|head and neck cancer
607609|NCT00293540|metastatic
607610|NCT00293540|secondary
607611|NCT00293540|Hormone Receptor-Positive Breast Cancer
607612|NCT00293527|Metastatic
607613|NCT00293514|standard surgical treatment for air leakage in pulmonary lobectomy
607614|NCT00293501|clear cell renal cell carcinoma
607615|NCT00293501|stage IV renal cell cancer
607616|NCT00293501|recurrent renal cell cancer
607617|NCT00293488|anaplastic large cell lymphoma
607618|NCT00293488|angioimmunoblastic T-cell lymphoma
607619|NCT00293488|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
607620|NCT00293488|nodal marginal zone B-cell lymphoma
607621|NCT00293488|recurrent adult Burkitt lymphoma
607622|NCT00293488|recurrent adult diffuse large cell lymphoma
607623|NCT00293488|recurrent adult Hodgkin lymphoma
607624|NCT00293488|recurrent adult T-cell leukemia/lymphoma
607625|NCT00293488|recurrent cutaneous T-cell non-Hodgkin lymphoma
607626|NCT00293488|recurrent grade 1 follicular lymphoma
607627|NCT00293488|recurrent grade 2 follicular lymphoma
607628|NCT00293488|recurrent grade 3 follicular lymphoma
607629|NCT00293488|recurrent mantle cell lymphoma
607630|NCT00293488|recurrent marginal zone lymphoma
607631|NCT00293488|recurrent mycosis fungoides/Sezary syndrome
607632|NCT00293488|splenic marginal zone lymphoma
607633|NCT00293462|mucositis
607634|NCT00293462|radiation toxicity
607635|NCT00293462|recurrent squamous and basal cell carcinoma of the hypopharynx,larynx,lip,nasopharynx
607636|NCT00293462|oropharynx, paranasal sinus and nasal cavity
607637|NCT00293462|stage I-IV lymphoepithelioma of the nasopharynx
607638|NCT00293462|stage I-IV lymphoepithelioma of the oropharynx
607639|NCT00293462|Recurrent and stage I-IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
607640|NCT00293462|Recurrent and stage I-IV inverted papilloma of the paranasal sinus and nasal cavity
607641|NCT00293462|Recurrent and stage I-IV midline lethal granuloma of the paranasal sinus and nasal cavity
607642|NCT00293462|untreated, current,metastatic squamous neck cancer with occult primary
607643|NCT00293462|recurrent verrucous carcinoma of the larynx
607644|NCT00293462|recurrent lymphoepithelioma of the oropharynx
607645|NCT00293462|stage I verrucous carcinoma of the larynx
607646|NCT00293462|recurrent verrucous carcinoma of the oral cavity
607647|NCT00293462|stage I verrucous carcinoma of the oral cavity
607648|NCT00293462|stage II verrucous carcinoma of the larynx
607649|NCT00293462|stage II verrucous carcinoma of the oral cavity
607831|NCT00293319|recurrent neuroblastoma
607650|NCT00293462|stage III verrucous carcinoma of the larynx
607651|NCT00293462|stage III verrucous carcinoma of the oral cavity
607652|NCT00293462|stage IV verrucous carcinoma of the larynx
607653|NCT00293462|stage IV verrucous carcinoma of the oral cavity
607654|NCT00293462|recurrent adenoid cystic carcinoma of the oral cavity
607655|NCT00293462|stage I adenoid cystic carcinoma of the oral cavity
607656|NCT00293462|stage II adenoid cystic carcinoma of the oral cavity
607657|NCT00293462|stage III adenoid cystic carcinoma of the oral cavity
607658|NCT00293462|stage IV adenoid cystic carcinoma of the oral cavity
607659|NCT00293462|recurrent mucoepidermoid carcinoma of the oral cavity
607660|NCT00293462|stage I mucoepidermoid carcinoma of the oral cavity
607661|NCT00293462|stage II mucoepidermoid carcinoma of the oral cavity
607662|NCT00293462|stage III mucoepidermoid carcinoma of the oral cavity
607663|NCT00293462|stage IV mucoepidermoid carcinoma of the oral cavity
607664|NCT00293462|recurrent squamous cell carcinoma of the lip and oral cavity
607665|NCT00293462|stage I squamous cell carcinoma of the lip and oral cavity
607666|NCT00293462|stage II squamous cell carcinoma of the lip and oral cavity
607667|NCT00293462|stage III squamous cell carcinoma of the lip and oral cavity
607668|NCT00293462|stage IV squamous cell carcinoma of the lip and oral cavity
607669|NCT00293462|tongue cancer
607670|NCT00293436|adult primary hepatocellular carcinoma
607671|NCT00293436|advanced adult primary liver cancer
607672|NCT00293436|localized resectable adult primary liver cancer
607673|NCT00293423|adult glioblastoma
607674|NCT00293423|recurrent adult brain tumor
607675|NCT00293410|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
607676|NCT00293410|adult acute myeloid leukemia with inv(16)(p13;q22)
607677|NCT00293410|adult acute myeloid leukemia with t(15;17)(q22;q12)
607678|NCT00293410|adult acute myeloid leukemia with t(16;16)(p13;q22)
607679|NCT00293410|adult acute myeloid leukemia with t(8;21)(q22;q22)
607680|NCT00293410|recurrent adult acute myeloid leukemia
607681|NCT00293410|recurrent childhood acute myeloid leukemia
607682|NCT00293410|secondary acute myeloid leukemia
607683|NCT00293410|myelodysplastic/myeloproliferative disease, unclassifiable
607684|NCT00293410|accelerated phase chronic myelogenous leukemia
607685|NCT00293410|chronic idiopathic myelofibrosis
607686|NCT00293410|chronic myelomonocytic leukemia
607687|NCT00293410|juvenile myelomonocytic leukemia
607688|NCT00293410|recurrent adult acute lymphoblastic leukemia
607689|NCT00293410|recurrent childhood acute lymphoblastic leukemia
607690|NCT00293410|acute undifferentiated leukemia
607691|NCT00293410|blastic phase chronic myelogenous leukemia
607692|NCT00293410|childhood chronic myelogenous leukemia
607693|NCT00293410|adult acute basophilic leukemia
607694|NCT00293410|adult acute eosinophilic leukemia
607695|NCT00293410|adult acute megakaryoblastic leukemia (M7)
607696|NCT00293410|adult acute minimally differentiated myeloid leukemia (M0)
607697|NCT00293410|adult acute monoblastic leukemia (M5a)
607698|NCT00293410|adult acute monocytic leukemia (M5b)
607699|NCT00293410|adult acute myeloblastic leukemia with maturation (M2)
607700|NCT00293410|adult acute myeloblastic leukemia without maturation (M1)
607701|NCT00293410|adult acute myelomonocytic leukemia (M4)
607702|NCT00293410|adult acute promyelocytic leukemia (M3)
607703|NCT00293410|adult erythroleukemia (M6a)
607704|NCT00293410|adult pure erythroid leukemia (M6b)
607705|NCT00293410|childhood acute basophilic leukemia
607706|NCT00293410|childhood acute monocytic leukemia (M5b)
607707|NCT00293410|childhood acute eosinophilic leukemia
607708|NCT00293410|childhood acute erythroleukemia (M6)
607709|NCT00293410|childhood acute megakaryocytic leukemia (M7)
607710|NCT00293410|childhood acute minimally differentiated myeloid leukemia (M0)
607711|NCT00293410|childhood acute myeloblastic leukemia with maturation (M2)
607712|NCT00293410|childhood acute myeloblastic leukemia without maturation (M1)
607713|NCT00293410|childhood acute myelomonocytic leukemia (M4)
607714|NCT00293410|childhood acute monoblastic leukemia (M5a)
607715|NCT00293410|childhood acute promyelocytic leukemia (M3)
607716|NCT00293397|adult primary hepatocellular carcinoma
607717|NCT00293397|localized unresectable adult primary liver cancer
607718|NCT00293384|nausea and vomiting
607719|NCT00293384|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
607720|NCT00293384|adult acute myeloid leukemia with inv(16)(p13;q22)
607721|NCT00293384|adult acute myeloid leukemia with t(15;17)(q22;q12)
607722|NCT00293384|adult acute myeloid leukemia with t(16;16)(p13;q22)
607723|NCT00293384|adult acute myeloid leukemia with t(8;21)(q22;q22)
607724|NCT00293384|accelerated phase chronic myelogenous leukemia
607725|NCT00293384|adult acute lymphoblastic leukemia in remission
607726|NCT00293384|adult acute myeloid leukemia in remission
607727|NCT00293384|atypical chronic myeloid leukemia, BCR-ABL negative
607728|NCT00293384|blastic phase chronic myelogenous leukemia
607729|NCT00293384|chronic eosinophilic leukemia
607730|NCT00293384|primary myelofibrosis
607731|NCT00293384|chronic myelomonocytic leukemia
607732|NCT00293384|chronic neutrophilic leukemia
607733|NCT00293384|chronic phase chronic myelogenous leukemia
607734|NCT00293384|de novo myelodysplastic syndromes
607735|NCT00293384|disseminated neuroblastoma
607736|NCT00293384|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
607737|NCT00293384|myelodysplastic/myeloproliferative neoplasm, unclassifiable
607738|NCT00293384|nodal marginal zone B-cell lymphoma
607739|NCT00293384|noncontiguous stage II adult Burkitt lymphoma
607740|NCT00293384|noncontiguous stage II adult diffuse large cell lymphoma
607741|NCT00293384|noncontiguous stage II adult diffuse mixed cell lymphoma
607742|NCT00293384|noncontiguous stage II adult diffuse small cleaved cell lymphoma
607743|NCT00293384|noncontiguous stage II adult immunoblastic large cell lymphoma
607744|NCT00293384|noncontiguous stage II adult lymphoblastic lymphoma
607745|NCT00293384|noncontiguous stage II grade 1 follicular lymphoma
607746|NCT00293384|noncontiguous stage II grade 2 follicular lymphoma
607747|NCT00293384|noncontiguous stage II grade 3 follicular lymphoma
607748|NCT00293384|noncontiguous stage II mantle cell lymphoma
607749|NCT00293384|noncontiguous stage II marginal zone lymphoma
607750|NCT00293384|noncontiguous stage II small lymphocytic lymphoma
607751|NCT00293384|poor prognosis metastatic gestational trophoblastic tumor
607752|NCT00293384|previously treated myelodysplastic syndromes
607753|NCT00293384|recurrent adult acute lymphoblastic leukemia
607754|NCT00293384|recurrent adult acute myeloid leukemia
607755|NCT00293384|recurrent adult Burkitt lymphoma
607756|NCT00293384|recurrent adult Hodgkin lymphoma
607757|NCT00293384|recurrent adult diffuse large cell lymphoma
607758|NCT00293384|recurrent adult diffuse mixed cell lymphoma
607759|NCT00293384|recurrent adult diffuse small cleaved cell lymphoma
607760|NCT00293384|recurrent adult immunoblastic large cell lymphoma
607761|NCT00293384|recurrent adult lymphoblastic lymphoma
607762|NCT00293384|recurrent cutaneous T-cell non-Hodgkin lymphoma
607763|NCT00293384|recurrent grade 1 follicular lymphoma
607764|NCT00293384|recurrent grade 2 follicular lymphoma
607765|NCT00293384|recurrent grade 3 follicular lymphoma
607766|NCT00293384|recurrent mantle cell lymphoma
607767|NCT00293384|recurrent marginal zone lymphoma
607768|NCT00293384|recurrent mycosis fungoides/Sezary syndrome
607769|NCT00293384|recurrent neuroblastoma
607770|NCT00293384|recurrent ovarian epithelial cancer
607771|NCT00293384|recurrent ovarian germ cell tumor
607772|NCT00293384|recurrent small lymphocytic lymphoma
607773|NCT00293384|recurrent malignant testicular germ cell tumor
607774|NCT00293384|refractory chronic lymphocytic leukemia
607775|NCT00293384|refractory hairy cell leukemia
607776|NCT00293384|refractory multiple myeloma
607777|NCT00293384|relapsing chronic myelogenous leukemia
607778|NCT00293384|secondary acute myeloid leukemia
607779|NCT00293384|secondary myelodysplastic syndromes
607780|NCT00293384|splenic marginal zone lymphoma
607781|NCT00293384|stage I multiple myeloma
607782|NCT00293384|stage II multiple myeloma
607783|NCT00293384|stage II ovarian epithelial cancer
607784|NCT00293384|stage III adult Burkitt lymphoma
607785|NCT00293384|stage III adult Hodgkin lymphoma
607786|NCT00293384|stage III adult diffuse large cell lymphoma
607787|NCT00293384|stage III adult diffuse mixed cell lymphoma
607788|NCT00293384|stage III adult diffuse small cleaved cell lymphoma
607789|NCT00293384|stage III adult immunoblastic large cell lymphoma
607790|NCT00293384|stage III adult lymphoblastic lymphoma
607791|NCT00293384|stage III chronic lymphocytic leukemia
607792|NCT00293384|stage III grade 1 follicular lymphoma
607793|NCT00293384|stage III grade 2 follicular lymphoma
607794|NCT00293384|stage III grade 3 follicular lymphoma
607795|NCT00293384|stage III mantle cell lymphoma
607796|NCT00293384|stage III marginal zone lymphoma
607797|NCT00293384|stage III multiple myeloma
607798|NCT00293384|stage III ovarian epithelial cancer
607799|NCT00293384|stage III small lymphocytic lymphoma
607800|NCT00293384|stage III malignant testicular germ cell tumor
607801|NCT00293384|stage IIIA breast cancer
607802|NCT00293384|stage IIIB breast cancer
607803|NCT00293384|stage IIIC breast cancer
607804|NCT00293384|stage IV adult Burkitt lymphoma
607805|NCT00293384|stage IV adult Hodgkin lymphoma
607806|NCT00293384|stage IV adult diffuse large cell lymphoma
607807|NCT00293384|stage IV adult diffuse mixed cell lymphoma
607808|NCT00293384|stage IV adult diffuse small cleaved cell lymphoma
607809|NCT00293384|stage IV adult immunoblastic large cell lymphoma
607810|NCT00293384|stage IV adult lymphoblastic lymphoma
607811|NCT00293384|stage IV breast cancer
607812|NCT00293384|stage IV chronic lymphocytic leukemia
607813|NCT00293384|stage IV grade 1 follicular lymphoma
607814|NCT00293384|stage IV grade 2 follicular lymphoma
607815|NCT00293384|stage IV grade 3 follicular lymphoma
607816|NCT00293384|stage IV mantle cell lymphoma
607817|NCT00293384|stage IV marginal zone lymphoma
607818|NCT00293384|stage IV ovarian epithelial cancer
607819|NCT00293384|stage IV small lymphocytic lymphoma
607820|NCT00293371|adenocarcinoma of the prostate
607821|NCT00293371|recurrent prostate cancer
607822|NCT00293371|stage IV prostate cancer
607823|NCT00293358|childhood central nervous system germ cell tumor
607824|NCT00293358|adult central nervous system germ cell tumor
607825|NCT00293358|childhood central nervous system choriocarcinoma
607826|NCT00293358|childhood central nervous system embryonal tumor
607827|NCT00293358|childhood central nervous system yolk sac tumor
607828|NCT00293332|stage I non-small cell lung cancer
607829|NCT00293332|stage II non-small cell lung cancer
607830|NCT00293332|stage IIIA non-small cell lung cancer
607832|NCT00293293|stage I ovarian epithelial cancer
607833|NCT00293293|stage II ovarian epithelial cancer
607834|NCT00293293|stage III ovarian epithelial cancer
607835|NCT00293293|stage IV ovarian epithelial cancer
607836|NCT00293293|peritoneal cavity cancer
607837|NCT00293280|stage IIIB non-small cell lung cancer
607838|NCT00293280|stage IV non-small cell lung cancer
607839|NCT00293280|adenocarcinoma of the lung
607840|NCT00293280|adenosquamous cell lung cancer
607841|NCT00293280|bronchoalveolar cell lung cancer
607842|NCT00293280|large cell lung cancer
607843|NCT00293280|recurrent non-small cell lung cancer
607844|NCT00293280|squamous cell lung cancer
607845|NCT00293267|Treatment Experienced
607846|NCT00293254|Treatment Experienced
607847|NCT00293241|Pacemaker or ICD replacement
607848|NCT00293228|Latent tuberculosis
607849|NCT00293228|biomarkers
607850|NCT00293228|isoniazid
607851|NCT00293228|ELISPOT
607852|NCT00293228|PPD positive individuals
607853|NCT00293202|etanercept
607854|NCT00293202|malnutrition
607855|NCT00293202|inflammation
607856|NCT00293202|hemodialysis
607857|NCT00293189|hip fracture
607858|NCT00293189|epidemiology
607859|NCT00293189|genetics
607860|NCT00293189|p2x7
607861|NCT00293176|Cognitive impairment
607862|NCT00293176|Memory Loss
607863|NCT00293150|diastolic heart failure
607864|NCT00293150|heart failure
607865|NCT00293137|Chronic systolic heart failure
607866|NCT00293137|Heart Failure
607867|NCT00293124|Gastrointestinal Stromal Tumors
607868|NCT00293124|Glivec
607869|NCT00293111|Multiple Myeloma
607870|NCT00293111|Relapsed Multiple Myeloma
607871|NCT00293111|Refractory Multiple Myeloma
607872|NCT00293098|Iron overload
607873|NCT00293098|Thalassemia
607874|NCT00293098|Iron induced heart disease
607875|NCT00293098|deferoxamine (Desferal)
607876|NCT00293098|Deferiprone
607877|NCT00293085|NSCLC
607878|NCT00293085|Docetaxel
607879|NCT00293072|Rituximab, ANCA, vasculitis, lupus,
607880|NCT00293059|Dysfunctional Uterine Bleeding
607881|NCT00291954|Dialysis
607882|NCT00291954|Pre-dialysis
607883|NCT00291954|Hepatitis B vaccine
607884|NCT00291954|Prophylaxis hepatitis B infection
607885|NCT00291941|Dialysis
607886|NCT00291941|Pre-dialysis
607887|NCT00291941|Hepatitis B vaccine
607888|NCT00291941|Prophylaxis
607889|NCT00291915|early arthritis, methotrexate, adalimumab
607890|NCT00291902|CHD
607891|NCT00291902|coronary heart disease
607892|NCT00291902|atherosclerosis
607893|NCT00291902|inflammation
607894|NCT00291876|HAVRIX™
607895|NCT00291876|Hepatitis A
607896|NCT00291863|end stage renal failure
607897|NCT00291863|peritoneal dialysis
607898|NCT00291863|simvastatin
607899|NCT00291863|endothelium
607900|NCT00291863|vasodilation
607901|NCT00291850|NSCLC
607902|NCT00291837|ovarian
607903|NCT00291837|CT-2106
607904|NCT00291824|Cardiovascular risks
607905|NCT00291824|Motivational interviewing
607906|NCT00291824|Behavior change
607907|NCT00291824|Primary care setting
607908|NCT00291811|AMD3100
607909|NCT00291811|G-CSF
607910|NCT00291798|pilot study
607911|NCT00291798|exemestane
607912|NCT00291798|endocrinotherapy
607913|NCT00291798|mamma carcinoma
607914|NCT00291798|neoadjuvant
607915|NCT00291798|ABCSG
607916|NCT00291798|17
607917|NCT00291785|colorectal cancer
607918|NCT00291785|camptothecin
607919|NCT00291772|Type 1 Diabetes
607920|NCT00291772|hypoglycemia
607921|NCT00291772|hyperglycemia
607922|NCT00291746|GERD
607923|NCT00291733|Levetiracetam
607924|NCT00291733|Levodopa-induced dyskinesias
607925|NCT00291733|Parkinson's
607926|NCT00291720|Aldosterone
607927|NCT00291720|Spironolactone
607928|NCT00291720|Chronic Kidney Disease
607929|NCT00291720|Arterial Stiffness
607930|NCT00291707|head
607931|NCT00291707|neck
607932|NCT00291707|Cetuximab
607933|NCT00291707|Pemetrexed
607934|NCT00293046|Allergy
607935|NCT00293033|Breakthrough Pain in Cancer Patients
607936|NCT00293020|Breakthrough Pain in Cancer Patients
607937|NCT00292994|Metabolic Syndrome
607938|NCT00292994|Hyperlipidemia
607939|NCT00292994|Type 2 diabetes mellitus
607940|NCT00292994|Insulin resistance
607941|NCT00292994|Weight loss
607942|NCT00292994|Obesity
607943|NCT00292994|Exercise
607944|NCT00292994|Hypertension
607945|NCT00292981|C1 Inhibitor
607946|NCT00292981|Hereditary angioedema
607947|NCT00292981|Acute HAE attack
607948|NCT00292968|Health Behavior
607949|NCT00292968|Prevention
607950|NCT00292968|Informatics
607951|NCT00292968|Electronic Health Record
607952|NCT00292955|Cervical Cancer, Cetuximab, Phase II Clinical Trials
607953|NCT00292955|Stage IB2-IVB Carcinoma of the Cervix
607954|NCT00292942|artesunate
607955|NCT00292942|artemisinin
607956|NCT00292942|falciparum
607957|NCT00292929|artesunate
607958|NCT00292929|artemisinin
607959|NCT00292929|falciparum
607960|NCT00292916|whole body vibration
607961|NCT00292916|exercise
607962|NCT00292916|elderly woman
607963|NCT00292916|Bone Mineral Density
607964|NCT00292916|falls
607965|NCT00292916|higher age
607966|NCT00292903|Perinatal Depression
607967|NCT00292903|Interpersonal Psychotherapy
607968|NCT00292890|injection devices
607969|NCT00292890|injection technique
607970|NCT00292890|insulin needles
607971|NCT00292890|insulin administration
607972|NCT00292877|1. Eosinophilic bronchitis, 2. Asthma, 3. Steroid dependent asthma, 4. Sputum eosinophils, 5. SB-240563 (Mepolizumab)
607973|NCT00292864|Cancer
607974|NCT00292864|Carcinoma
607975|NCT00292864|Adenocarcinoma
607976|NCT00292864|Tumor
607977|NCT00292864|Advanced solid tumors
607978|NCT00292838|Eosinophilic bronchitis with asthma
607979|NCT00292838|Eosinophilic bronchitis without asthma
607980|NCT00292825|vasovagal syncope
607981|NCT00292825|syncope
607982|NCT00292825|cardioinhibitory syncope
607983|NCT00292825|neurocardiogenic syncope
607984|NCT00292825|pacing
607985|NCT00292825|closed loop pacing
607986|NCT00292825|tilt table
607987|NCT00292812|Infant nutrition
607988|NCT00292812|Nucleotides
607989|NCT00292812|Infant formula
607990|NCT00292799|Polycystic ovary syndrome
607991|NCT00292799|Obesity
607992|NCT00292799|metformin
607993|NCT00292799|orlistat
607994|NCT00292786|Functional Electrical Stimulation
607995|NCT00292786|FES
607996|NCT00292786|Walking
607997|NCT00292786|Practice
607998|NCT00292786|Coordination
607999|NCT00292786|Posture
608000|NCT00292773|Anovulation
608001|NCT00292773|Obesity
608002|NCT00292773|bariatric surgery
608003|NCT00292708|Antibiotics
608004|NCT00292708|Prophylaxis
608005|NCT00292708|Surgical wound infection
608006|NCT00292656|Allergy
608007|NCT00292591|vitamin D
608008|NCT00292591|cholecalciferol
608009|NCT00292591|pregnancy
608010|NCT00292591|bone mineral density
608011|NCT00292578|Allergy
608012|NCT00292578|Sugar Intolerance
608013|NCT00292578|Fatigue
608014|NCT00292552|Chronic Obstructive Pulmonary Disease (COPD)
608015|NCT00292552|longitudinal
608016|NCT00292552|eclipse
608017|NCT00292539|Pacemaker
608018|NCT00292539|NYHA class
608019|NCT00292539|Ejection fraction
608020|NCT00292539|Heart Failure
608021|NCT00292526|Chemotherapy induced cardiotoxicity
608022|NCT00292526|Troponin
608023|NCT00292526|Heart failure
608024|NCT00292500|CABG, anastomotic device; myocardial revascularization
608025|NCT00292474|coronary artery disease
608026|NCT00292474|percutaneous coronary interventions
608027|NCT00292474|stent implant
608028|NCT00292474|drug-coated stent
608029|NCT00292461|Epilepsy
608030|NCT00292461|seizures
608031|NCT00292422|Arthritis, Rheumatoid
608032|NCT00292422|Methotrexate
608033|NCT00292422|Antirheumatic Agents
608034|NCT00292383|Cardiac Pacing, artificial
608035|NCT00292383|Atrial Fibrillation
608036|NCT00292383|Heart failure
608037|NCT00292383|Pacemaker leads
608038|NCT00292383|Lead position
608039|NCT00292383|Higher degree AV-Block
608040|NCT00292370|Atypical Antipsychotics
608041|NCT00292370|Controlled Trial
608042|NCT00292370|Paroxetine
608043|NCT00292370|Quetiapine
608044|NCT00292370|Stress Disorders, Post-Traumatic
608045|NCT00292370|Treatment refractory
608046|NCT00292370|Treatment resistant
608047|NCT00292344|Travelers' diarrhea
608048|NCT00292344|rifaximin
608049|NCT00292344|loperamide
608050|NCT00292344|enterotoxigenic E. coli
608051|NCT00292331|gastric varices
608052|NCT00292331|liver cirrhosis
608053|NCT00292331|hepatocelluar carcinoma
608054|NCT00292331|rebleeding
608055|NCT00292331|long-term
608056|NCT00292318|adequate relief
608057|NCT00292318|anorectal manometry
608058|NCT00292318|biofeedback therapy
608059|NCT00292318|fecal incontinence
608060|NCT00292305|PCI
608061|NCT00292305|Bifurcation lesion
608062|NCT00292279|Impact of Omega 3 fatty acid on outcome
608063|NCT00292279|Omega-3 fatty acid
608064|NCT00292279|Carcinoma surgery
608065|NCT00292279|Digestive System
608066|NCT00292279|Parenteral Nutrition
608067|NCT00292279|Fat Emulsions, Intravenous
608068|NCT00292279|Clinical outcome
608069|NCT00292279|SIRS
608070|NCT00292279|Infectious complication
608071|NCT00292279|Postoperative hospital stay
608072|NCT00292279|Cost of postoperative period
608073|NCT00292279|Post-operative nutritional cost & total treatment cost
608074|NCT00292266|Relapsing-remitting Multiple Sclerosis
608075|NCT00292266|Rebif®
608076|NCT00292266|Avonex®
608077|NCT00292266|interferon-beta-1a
608078|NCT00292253|MS
608202|NCT00291421|Primary Caregiver
608079|NCT00292240|brief motivational intervention; teens; substance use
608080|NCT00292227|advanced-stage idiopathic Parkinson's disease
608081|NCT00292214|paracetamol
608082|NCT00292214|acetaminophen
608083|NCT00292214|pharmacokinetic
608084|NCT00292214|intravenous
608085|NCT00292214|oral
608086|NCT00292214|analgesia
608087|NCT00292214|pain
608088|NCT00292214|opioid
608089|NCT00292201|Asthma
608090|NCT00292201|Statin
608091|NCT00292188|Phase 4, post-traumatic neuropathic pain, neuropathic pain, Nep, post surgical pain, nerve injury, phantom limb pain, international
608092|NCT00292175|colonoscopy, narrow band imaging (NBI), ulcerative colitis
608093|NCT00292162|Chronic Heart Failure
608094|NCT00292162|Atrial Fibrillation
608095|NCT00292162|Radiofrequency Ablation
608096|NCT00292136|Cocaine Dependence
608097|NCT00292136|Drug Relapse
608098|NCT00292136|Pharmacokinetics
608099|NCT00292136|EMA
608100|NCT00292136|Polydrug Abuse
608101|NCT00292110|HIV
608102|NCT00292110|Opiate Substitution
608103|NCT00292110|Pharmacokinetics
608104|NCT00292110|ECG
608105|NCT00292110|Polydrug Abuse
608106|NCT00292097|Respiratory failure
608107|NCT00292097|Tracheostomy
608108|NCT00292097|Percutaneous dilatation tracheostomy
608109|NCT00292097|Endotracheal Conversion
608110|NCT00292097|Traumatic brain injury
608111|NCT00292084|Hepatitis C
608112|NCT00292084|Celgosivir
608113|NCT00292084|HCV
608114|NCT00292084|Genotype 1
608115|NCT00292084|Non-responders
608116|NCT00292084|End of Treatment Response
608117|NCT00292084|Sustained Viral Response
608118|NCT00292058|Telepsychiatry
608119|NCT00292058|Videoconference
608120|NCT00292058|Psychiatric consultation
608121|NCT00292058|Equivalence trial
608122|NCT00292045|NY-ESO-1 protein, immunization, advanced prostate cancer
608123|NCT00292032|cardiac arrest
608124|NCT00292032|diagnosis
608125|NCT00292032|genetics
608126|NCT00292032|testing
608127|NCT00292006|clinical scaphoid fracture
608128|NCT00292006|pediatric
608129|NCT00291993|Obstructive sleep apnea
608130|NCT00291993|Vasoactive hormones
608131|NCT00291993|Blood pressure
608132|NCT00291980|Dialysis
608133|NCT00291980|Pre-dialysis
608134|NCT00291980|Hepatitis B vaccine
608135|NCT00291980|Prophylaxis hepatitis B infection
608136|NCT00291694|breast atypia
608137|NCT00291694|double-blind randomized clinical trial
608138|NCT00291694|RCT
608139|NCT00291694|celecoxib
608140|NCT00291694|COX-2 inhibitor
608141|NCT00291694|placebo
608142|NCT00291694|high risk for breast cancer
608143|NCT00291694|breast epithelial hyperplasia
608144|NCT00291694|ki-67
608145|NCT00291694|chemoprevention
608146|NCT00291681|Inflammatory Bowel Disease
608147|NCT00291681|B cell selection
608148|NCT00291668|Crohn's Disease
608149|NCT00291668|CDP870, Certolizumab pegol
608150|NCT00291655|NEWLY DIAGNOSED EPILEPSY
608151|NCT00291655|LEVETIRACETAM
608152|NCT00291655|KEPPRA
608153|NCT00291655|N01175 (NCT00175903)
608154|NCT00291642|Levocetirizine, Xyzal, Rhinitis, Allergic, Seasonal, Ragweed
608155|NCT00291629|Myocardial infarction
608156|NCT00291629|revascularization
608157|NCT00291629|drug eluting stents
608158|NCT00291616|chronic hepatitis B, pegylated interferon, thymosin alpha
608159|NCT00291603|dialysis
608160|NCT00291603|Renal Dialysis
608161|NCT00291603|inflammation
608162|NCT00291603|quality of life
608163|NCT00291603|End Stage Kidney Failure
608164|NCT00291590|diabetes
608165|NCT00291590|behavioral change
608166|NCT00291590|chronic care model
608167|NCT00291590|stage of change
608168|NCT00291590|Medicaid
608169|NCT00291590|Dual eligible
608170|NCT00291590|ethnic
608171|NCT00291590|self-care
608172|NCT00291577|advanced
608173|NCT00291577|sunitinib (Sutent)
608174|NCT00291577|docetaxel
608175|NCT00291577|Phase 1B
608176|NCT00291564|Observational
608177|NCT00291564|Heart Failure
608178|NCT00291564|Continuous Cardiac Resynchronization Therapy
608179|NCT00291525|valve
608180|NCT00291525|prosthesis
608181|NCT00291525|antithrombotics
608182|NCT00291525|randomized
608183|NCT00291512|HIV
608184|NCT00291512|STDs
608185|NCT00291512|Methamphetamine abuse
608186|NCT00291512|MSM
608187|NCT00291499|symptomatic OA of the hand
608188|NCT00291460|COPD
608189|NCT00291460|respiratory failure
608190|NCT00291460|inspiratory muscle training
608191|NCT00291434|Head and neck cancer
608192|NCT00291434|Fractionation
608193|NCT00291434|Radiotherapy
608194|NCT00291434|Conventional fractionation
608195|NCT00291434|Hyperfractionation
608196|NCT00291434|Accelerated fractionation
608197|NCT00291421|Alzheimer's Disease
608198|NCT00291421|Dementia
608199|NCT00291421|Brain Disease
608200|NCT00291421|Memory Loss
608201|NCT00291421|Caregiver
608203|NCT00291421|Observation
608204|NCT00291421|galantamine
608205|NCT00291421|donepezil
608206|NCT00291421|rivastigmine
608207|NCT00291421|Quality of life
608208|NCT00291382|Total asthma control
608209|NCT00291382|airway hyper-responsiveness
608210|NCT00291382|adult
608211|NCT00291382|Asthma
608212|NCT00291369|Metastatic renal cell carcinoma
608213|NCT00291369|Interleukin-2
608214|NCT00291369|Interferon alfa
608215|NCT00291369|Cytokines
608216|NCT00291369|Survival
608217|NCT00291356|Diabetes
608218|NCT00291356|sodium dependent glucose transporter
608219|NCT00291356|SGLT2
608220|NCT00291356|GSK189075
608221|NCT00291356|GSK189074
608222|NCT00291356|SGLT1
608223|NCT00291356|GW869683
608224|NCT00291343|hepatitis B
608225|NCT00291343|meningococcal vaccine
608226|NCT00291343|pertussis
608227|NCT00291343|Prophylaxis diphtheria
608228|NCT00291343|meningococcal serogroups A and C diseases
608229|NCT00291343|tetanus
608230|NCT00291343|Haemophilus influenzae type b
608231|NCT00291317|pediatric spinal cord injury
608232|NCT00291317|FES cycling
608233|NCT00291317|bone mineral density
608234|NCT00291317|quality of life
608235|NCT00291304|Magnetic Resonance Imaging
608236|NCT00291304|Pathology
608237|NCT00291278|Endometriosis
608238|NCT00291278|Bone Mineral Density
608239|NCT00291278|Osteopenia
608240|NCT00291278|Osteoporosis
608241|NCT00291278|DEXA Scan
608242|NCT00291278|Menopause
608243|NCT00291278|Screening
608244|NCT00291278|Healthy Volunteer
608245|NCT00291278|HV
608246|NCT00291265|Bradykinesia
608247|NCT00291265|Tremor
608248|NCT00291265|Speech
608249|NCT00291265|Rigidity
608250|NCT00291265|Neurodegeneration
608251|NCT00291265|Parkinson Disease
608252|NCT00291265|PD
608253|NCT00291226|schizophrenia prodrome
608254|NCT00291200|Psychosis
608255|NCT00291200|Basic Symptoms
608256|NCT00291174|Ventricular Arrhythmia
608257|NCT00291174|Myocardial Infarction
608258|NCT00291174|Ventricular Dysfunction
608259|NCT00291174|Coronary Artery Disease
608260|NCT00291174|Structural Heart Disease
608261|NCT00291174|Arrhythmia
608262|NCT00291174|Cardiomyopathies
608263|NCT00291161|Delivery of Health Care, Integrated
608264|NCT00291161|United States Department of Veterans Affairs
608265|NCT00291161|Dementia
608266|NCT00291161|Patient Care Management
608267|NCT00291148|Neuropathic pain
608268|NCT00291148|Multiple Sclerosis
608269|NCT00291148|pregabalin
608270|NCT00291148|paroxetine
608271|NCT00291135|breast atypia
608272|NCT00291135|open label pilot study
608273|NCT00291135|letrozole
608274|NCT00291135|fine needle aspiration
608275|NCT00291135|high risk for breast cancer
608276|NCT00291135|breast epithelial hyperplasia
608277|NCT00291135|Ki-67
608278|NCT00291135|hormones plus chemoprevention
608279|NCT00291135|chemoprevention
608280|NCT00291122|breast atypia
608281|NCT00291122|breast epithelial hyperplasia
608282|NCT00291122|ki-67
608283|NCT00291122|RTPCR
608284|NCT00291122|microdissection
608285|NCT00291109|breast atypia
608286|NCT00291109|breast epithelial hyperplasia
608287|NCT00291109|Ki-67
608288|NCT00291109|RTPCR
608289|NCT00291109|microdissection
608290|NCT00291096|breast atypia
608291|NCT00291096|fine needle aspiration
608292|NCT00291096|high risk for breast cancer
608293|NCT00291096|breast epithelial hyperplasia
608294|NCT00291083|NAF
608295|NCT00291083|nipple aspirate fluid
608296|NCT00291083|breast atypia
608297|NCT00291083|high risk for breast cancer
608298|NCT00291083|breast epithelial hyperplasia
608299|NCT00291083|Ki-67
608300|NCT00291083|hormones plus chemoprevention
608301|NCT00291083|chemoprevention
608302|NCT00291070|ADHD
608303|NCT00291070|attention
608304|NCT00291070|insomnia
608305|NCT00291070|hyperactivity
608306|NCT00291070|anxiety
608307|NCT00291057|Pediculosis
608308|NCT00291057|Head Lice
608309|NCT00291044|pregnancy, genital herpes
608310|NCT00291031|nightmare
608311|NCT00291031|sleep disorder
608312|NCT00291031|sleep
608313|NCT00291031|imagery rehearsal
608314|NCT00291031|anxiety disorders
608315|NCT00291031|mood disorders
608316|NCT00291031|personality disorders
608317|NCT00291018|ProDisc
608318|NCT00291018|ProDisc-C
608319|NCT00291018|Spinal Fusion
608320|NCT00291018|Anterior cervical diskectomy
608321|NCT00291018|Cervical spine
608322|NCT00291018|Disc disease
608323|NCT00291018|Implant
608324|NCT00291018|Degenerative disc disease
608325|NCT00291018|Intervertebral disc
608326|NCT00291005|Prostate cancer
608327|NCT00291005|HRPC
608328|NCT00291005|AIPC
608329|NCT00291005|Hormone refractory
608330|NCT00291005|Androgen independent
608331|NCT00291005|Docetaxel
608332|NCT00291005|Taxotere
608333|NCT00291005|prednisolone
608334|NCT00290992|urate oxidase, hyperuricemia, lymphoma, leukemia
608335|NCT00290979|HMR1964, insulin glulisine, Diabetes Mellitus, Type 1
608336|NCT00290966|docetaxel
608337|NCT00290966|stomach neoplasm
608338|NCT00290953|Metastases
608339|NCT00290940|Diabetes mellitus, Type 2
608340|NCT00290940|High blood sugar
608341|NCT00290940|Hyperglycemia
608342|NCT00290940|Antihyperglycemic agents
608343|NCT00290940|CS-917
608344|NCT00290927|HMR1964, insulin glulisine, Diabetes Mellitus, Type 2
608345|NCT00289835|Coronary Artery Bypass Grafting
608346|NCT00289835|Drug Eluting Stent
608347|NCT00289835|Saphenous Vein Graft
608348|NCT00289822|chronic heart failure
608349|NCT00289822|myocardial infarction
608350|NCT00289783|Primary and booster vaccination
608351|NCT00289783|Neisseria meningitidis
608352|NCT00289783|Hib disease
608353|NCT00289783|Meningococcal vaccine
608354|NCT00289783|Meningococcal disease
608355|NCT00289783|Children
608356|NCT00289783|Immunogenicity
608357|NCT00289783|Safety
608358|NCT00289783|Infants
608359|NCT00289770|TWINRIX™ ADULT
608360|NCT00289770|Hepatitis A
608361|NCT00289770|Hepatitis B
608362|NCT00289757|Havrix™
608363|NCT00289757|Hepatitis A
608364|NCT00289744|Hepatitis B
608365|NCT00289744|TWINRIX™ ADULT
608366|NCT00289744|Hepatitis A
608367|NCT00289731|Combined hepatitis A and hepatitis B vaccine
608368|NCT00289731|Hepatitis B
608369|NCT00289731|Hepatitis A
608370|NCT00289731|Monovalent hepatitis A and hepatitis B vaccines
608371|NCT00289718|Combined Hepatitis A and B vaccine
608372|NCT00289718|Hepatitis A
608373|NCT00289718|Hepatitis B
608374|NCT00289705|Obesity
608375|NCT00289705|Surgery
608376|NCT00289705|Adolescent
608377|NCT00289705|Roux-en-Y gastric bypass
608378|NCT00289705|Laparoscopic
608379|NCT00288964|balloon
608380|NCT00288964|fiber
608381|NCT00288964|respiratory
608382|NCT00288964|oxygenator
608383|NCT00288964|Heart Failure
608384|NCT00288964|ARDS
608385|NCT00288964|COPD
608386|NCT00288236|Type 2 diabetes mellitus
608387|NCT00288210|Myocardial Infarction
608388|NCT00288210|Stents
608389|NCT00288210|Sirolimus
608390|NCT00288210|abciximab
608391|NCT00290888|Rotator Cuff Tear
608392|NCT00290888|Tendon Repair
608393|NCT00290888|Acromioplasty
608394|NCT00290888|Arthroscopy
608395|NCT00290888|Orthopedic Surgery
608396|NCT00290875|cspine injury
608397|NCT00290875|radiography
608398|NCT00290875|clinical impact
608399|NCT00290875|dissemination
608400|NCT00290862|Osteoporosis
608401|NCT00290862|Spine fracture
608402|NCT00290862|Back Pain
608403|NCT00290862|Vertebroplasty
608404|NCT00290862|Vertebral compression fractures related to osteoporosis
608405|NCT00290823|Taenia
608406|NCT00290823|Seizures
608407|NCT00290823|Tapeworm
608408|NCT00290823|Parasite
608409|NCT00290771|imatinib mesylate
608410|NCT00290771|hydroxyurea
608411|NCT00290771|protein tyrosine kinases
608412|NCT00290771|glioma
608413|NCT00290771|glioblastoma multiforme
608414|NCT00290771|recurrent glioblastoma multiforme
608415|NCT00290771|GBM
608416|NCT00290771|MacDonald criteria
608417|NCT00290745|breast cancer in situ
608418|NCT00290745|ductal breast carcinoma in situ
608419|NCT00290732|stage I breast cancer
608420|NCT00290732|stage II breast cancer
608421|NCT00290732|stage IIIA breast cancer
608422|NCT00290732|stage IIIC breast cancer
608423|NCT00290732|stage IV breast cancer
608424|NCT00290732|breast cancer in situ
608425|NCT00290732|ductal breast carcinoma in situ
608426|NCT00290719|adenocarcinoma of the esophagus
608427|NCT00290719|squamous cell carcinoma of the esophagus
608428|NCT00290719|stage II esophageal cancer
608429|NCT00290719|stage III esophageal cancer
608430|NCT00290706|recurrent adult diffuse large cell lymphoma
608431|NCT00290706|recurrent adult diffuse mixed cell lymphoma
608432|NCT00290706|recurrent adult immunoblastic large cell lymphoma
608433|NCT00290706|recurrent adult lymphoblastic lymphoma
608434|NCT00290706|recurrent grade 3 follicular lymphoma
608435|NCT00290706|recurrent cutaneous T-cell non-Hodgkin lymphoma
608436|NCT00290706|recurrent mycosis fungoides/Sezary syndrome
608437|NCT00290693|recurrent pancreatic cancer
608438|NCT00290693|adenocarcinoma of the pancreas
608439|NCT00290693|stage IV pancreatic cancer
608440|NCT00290680|unspecified adult solid tumor, protocol specific
608441|NCT00290667|contiguous stage II adult diffuse large cell lymphoma
608442|NCT00290667|noncontiguous stage II adult diffuse large cell lymphoma
608443|NCT00290667|stage I adult diffuse large cell lymphoma
608444|NCT00290667|stage III adult diffuse large cell lymphoma
608445|NCT00290667|stage IV adult diffuse large cell lymphoma
608446|NCT00290667|contiguous stage II adult immunoblastic large cell lymphoma
608983|NCT00289289|Cardiac Pacemaker
608447|NCT00290667|noncontiguous stage II adult immunoblastic large cell lymphoma
608448|NCT00290667|stage I adult immunoblastic large cell lymphoma
608449|NCT00290667|stage III adult immunoblastic large cell lymphoma
608450|NCT00290667|stage IV adult immunoblastic large cell lymphoma
608451|NCT00290667|contiguous stage II adult Burkitt lymphoma
608452|NCT00290667|noncontiguous stage II adult Burkitt lymphoma
608453|NCT00290667|stage I adult Burkitt lymphoma
608454|NCT00290667|stage III adult Burkitt lymphoma
608455|NCT00290667|stage IV adult Burkitt lymphoma
608456|NCT00290667|contiguous stage II adult diffuse mixed cell lymphoma
608457|NCT00290667|noncontiguous stage II adult diffuse mixed cell lymphoma
608458|NCT00290667|stage I adult diffuse mixed cell lymphoma
608459|NCT00290667|stage III adult diffuse mixed cell lymphoma
608460|NCT00290667|stage IV adult diffuse mixed cell lymphoma
608461|NCT00290667|contiguous stage II adult diffuse small cleaved cell lymphoma
608462|NCT00290667|noncontiguous stage II adult diffuse small cleaved cell lymphoma
608463|NCT00290667|stage I adult diffuse small cleaved cell lymphoma
608464|NCT00290667|stage III adult diffuse small cleaved cell lymphoma
608465|NCT00290667|stage IV adult diffuse small cleaved cell lymphoma
608466|NCT00290667|contiguous stage II grade 1 follicular lymphoma
608467|NCT00290667|contiguous stage II grade 2 follicular lymphoma
608468|NCT00290667|contiguous stage II grade 3 follicular lymphoma
608469|NCT00290667|noncontiguous stage II grade 1 follicular lymphoma
608470|NCT00290667|noncontiguous stage II grade 2 follicular lymphoma
608471|NCT00290667|noncontiguous stage II grade 3 follicular lymphoma
608472|NCT00290667|stage I grade 1 follicular lymphoma
608473|NCT00290667|stage I grade 2 follicular lymphoma
608474|NCT00290667|stage I grade 3 follicular lymphoma
608475|NCT00290667|stage III grade 1 follicular lymphoma
608476|NCT00290667|stage III grade 2 follicular lymphoma
608477|NCT00290667|stage III grade 3 follicular lymphoma
608478|NCT00290667|stage IV grade 1 follicular lymphoma
608479|NCT00290667|stage IV grade 2 follicular lymphoma
608480|NCT00290667|stage IV grade 3 follicular lymphoma
608481|NCT00290654|ductal breast carcinoma in situ
608482|NCT00290654|breast cancer in situ
608483|NCT00290641|adult acute myeloid leukemia in remission
608484|NCT00290641|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
608485|NCT00290641|adult acute myeloid leukemia with inv(16)(p13;q22)
608486|NCT00290641|adult acute myeloid leukemia with t(15;17)(q22;q12)
608487|NCT00290641|adult acute myeloid leukemia with t(16;16)(p13;q22)
608488|NCT00290641|adult acute myeloid leukemia with t(8;21)(q22;q22)
608489|NCT00290641|childhood acute myeloid leukemia in remission
608490|NCT00290641|secondary acute myeloid leukemia
608491|NCT00290641|accelerated phase chronic myelogenous leukemia
608492|NCT00290641|childhood chronic myelogenous leukemia
608493|NCT00290641|chronic phase chronic myelogenous leukemia
608494|NCT00290641|relapsing chronic myelogenous leukemia
608495|NCT00290641|refractory anemia with excess blasts
608496|NCT00290641|de novo myelodysplastic syndromes
608497|NCT00290641|previously treated myelodysplastic syndromes
608498|NCT00290641|secondary myelodysplastic syndromes
608499|NCT00290641|noncontiguous stage II adult Burkitt lymphoma
608500|NCT00290641|recurrent adult Burkitt lymphoma
608501|NCT00290641|stage III adult Burkitt lymphoma
608502|NCT00290641|stage IV adult Burkitt lymphoma
608503|NCT00290641|noncontiguous stage II adult diffuse large cell lymphoma
608504|NCT00290641|recurrent adult diffuse large cell lymphoma
608505|NCT00290641|stage III adult diffuse large cell lymphoma
608506|NCT00290641|stage IV adult diffuse large cell lymphoma
608507|NCT00290641|noncontiguous stage II adult diffuse mixed cell lymphoma
608508|NCT00290641|recurrent adult diffuse mixed cell lymphoma
608509|NCT00290641|stage III adult diffuse mixed cell lymphoma
608510|NCT00290641|stage IV adult diffuse mixed cell lymphoma
608511|NCT00290641|noncontiguous stage II adult diffuse small cleaved cell lymphoma
608512|NCT00290641|recurrent adult diffuse small cleaved cell lymphoma
608513|NCT00290641|stage III adult diffuse small cleaved cell lymphoma
608514|NCT00290641|stage IV adult diffuse small cleaved cell lymphoma
608515|NCT00290641|contiguous stage II adult lymphoblastic lymphoma
608516|NCT00290641|noncontiguous stage II adult lymphoblastic lymphoma
608517|NCT00290641|stage III adult lymphoblastic lymphoma
608518|NCT00290641|stage IV adult lymphoblastic lymphoma
608519|NCT00290641|noncontiguous stage II grade 3 follicular lymphoma
608520|NCT00290641|recurrent grade 3 follicular lymphoma
608521|NCT00290641|stage III grade 3 follicular lymphoma
608522|NCT00290641|stage IV grade 3 follicular lymphoma
608523|NCT00290641|noncontiguous stage II mantle cell lymphoma
608524|NCT00290641|recurrent mantle cell lymphoma
608525|NCT00290641|stage III mantle cell lymphoma
608526|NCT00290641|stage IV mantle cell lymphoma
608527|NCT00290641|recurrent childhood large cell lymphoma
608528|NCT00290641|recurrent childhood lymphoblastic lymphoma
608529|NCT00290641|recurrent childhood small noncleaved cell lymphoma
608530|NCT00290641|adult acute lymphoblastic leukemia in remission
608531|NCT00290641|childhood acute lymphoblastic leukemia in remission
608532|NCT00290641|refractory anemia with excess blasts in transformation
608533|NCT00290641|refractory cytopenia with multilineage dysplasia
608534|NCT00290641|recurrent adult acute myeloid leukemia
608984|NCT00289289|IPG Indication
608535|NCT00290641|recurrent childhood acute myeloid leukemia
608536|NCT00290641|noncontiguous stage II adult immunoblastic large cell lymphoma
608537|NCT00290641|recurrent adult immunoblastic large cell lymphoma
608538|NCT00290641|stage III adult immunoblastic large cell lymphoma
608539|NCT00290641|stage IV adult immunoblastic large cell lymphoma
608540|NCT00290641|blastic phase chronic myelogenous leukemia
608541|NCT00290641|chronic idiopathic myelofibrosis
608542|NCT00290641|chronic eosinophilic leukemia
608543|NCT00290641|chronic neutrophilic leukemia
608544|NCT00290641|contiguous stage II adult Burkitt lymphoma
608545|NCT00290641|stage I adult Burkitt lymphoma
608546|NCT00290641|contiguous stage II adult diffuse large cell lymphoma
608547|NCT00290641|stage I adult diffuse large cell lymphoma
608548|NCT00290641|contiguous stage II adult diffuse mixed cell lymphoma
608549|NCT00290641|stage I adult diffuse mixed cell lymphoma
608550|NCT00290641|contiguous stage II adult diffuse small cleaved cell lymphoma
608551|NCT00290641|stage I adult diffuse small cleaved cell lymphoma
608552|NCT00290641|contiguous stage II adult immunoblastic large cell lymphoma
608553|NCT00290641|stage I adult immunoblastic large cell lymphoma
608554|NCT00290641|stage I adult lymphoblastic lymphoma
608555|NCT00290641|stage I childhood lymphoblastic lymphoma
608556|NCT00290641|stage II childhood lymphoblastic lymphoma
608557|NCT00290641|stage I childhood small noncleaved cell lymphoma
608558|NCT00290641|stage II childhood small noncleaved cell lymphoma
608559|NCT00290641|stage III childhood small noncleaved cell lymphoma
608560|NCT00290641|stage IV childhood small noncleaved cell lymphoma
608561|NCT00290641|contiguous stage II grade 3 follicular lymphoma
608562|NCT00290641|stage I grade 3 follicular lymphoma
608563|NCT00290641|contiguous stage II mantle cell lymphoma
608564|NCT00290641|stage I mantle cell lymphoma
608565|NCT00290641|stage I childhood large cell lymphoma
608566|NCT00290641|stage II childhood large cell lymphoma
608567|NCT00290641|stage III childhood large cell lymphoma
608568|NCT00290641|stage IV childhood large cell lymphoma
608569|NCT00290641|stage III childhood lymphoblastic lymphoma
608570|NCT00290641|stage IV childhood lymphoblastic lymphoma
608571|NCT00290641|recurrent adult lymphoblastic lymphoma
608572|NCT00290641|childhood myelodysplastic syndromes
608573|NCT00290628|graft versus host disease
608574|NCT00290628|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
608575|NCT00290628|adult acute myeloid leukemia with inv(16)(p13;q22)
608576|NCT00290628|adult acute myeloid leukemia with t(15;17)(q22;q12)
608577|NCT00290628|adult acute myeloid leukemia with t(16;16)(p13;q22)
608578|NCT00290628|adult acute myeloid leukemia with t(8;21)(q22;q22)
608579|NCT00290628|accelerated phase chronic myelogenous leukemia
608580|NCT00290628|adult acute lymphoblastic leukemia in remission
608581|NCT00290628|adult acute myeloid leukemia in remission
608582|NCT00290628|atypical chronic myeloid leukemia
608583|NCT00290628|blastic phase chronic myelogenous leukemia
608584|NCT00290628|childhood acute lymphoblastic leukemia in remission
608585|NCT00290628|childhood acute myeloid leukemia in remission
608586|NCT00290628|childhood chronic myelogenous leukemia
608587|NCT00290628|chronic eosinophilic leukemia
608588|NCT00290628|chronic idiopathic myelofibrosis
608589|NCT00290628|chronic myelomonocytic leukemia
608590|NCT00290628|chronic neutrophilic leukemia
608591|NCT00290628|chronic phase chronic myelogenous leukemia
608592|NCT00290628|de novo myelodysplastic syndromes
608593|NCT00290628|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
608594|NCT00290628|juvenile myelomonocytic leukemia
608595|NCT00290628|myelodysplastic/myeloproliferative disease, unclassifiable
608596|NCT00290628|nodal marginal zone B-cell lymphoma
608597|NCT00290628|noncontiguous stage II adult Burkitt lymphoma
608598|NCT00290628|noncontiguous stage II adult diffuse large cell lymphoma
608599|NCT00290628|noncontiguous stage II adult diffuse mixed cell lymphoma
608600|NCT00290628|noncontiguous stage II adult diffuse small cleaved cell lymphoma
608601|NCT00290628|noncontiguous stage II adult immunoblastic large cell lymphoma
608602|NCT00290628|noncontiguous stage II adult lymphoblastic lymphoma
608603|NCT00290628|noncontiguous stage II grade 1 follicular lymphoma
608604|NCT00290628|noncontiguous stage II grade 2 follicular lymphoma
608605|NCT00290628|noncontiguous stage II grade 3 follicular lymphoma
608606|NCT00290628|noncontiguous stage II mantle cell lymphoma
608607|NCT00290628|noncontiguous stage II marginal zone lymphoma
608608|NCT00290628|noncontiguous stage II small lymphocytic lymphoma
608609|NCT00290628|previously treated myelodysplastic syndromes
608610|NCT00290628|recurrent adult acute lymphoblastic leukemia
608611|NCT00290628|recurrent adult acute myeloid leukemia
608612|NCT00290628|recurrent adult Burkitt lymphoma
608613|NCT00290628|recurrent adult Hodgkin lymphoma
608614|NCT00290628|recurrent adult diffuse large cell lymphoma
608615|NCT00290628|recurrent adult diffuse mixed cell lymphoma
608616|NCT00290628|recurrent adult diffuse small cleaved cell lymphoma
608617|NCT00290628|recurrent adult immunoblastic large cell lymphoma
608618|NCT00290628|recurrent adult lymphoblastic lymphoma
608619|NCT00290628|recurrent/refractory childhood Hodgkin lymphoma
608620|NCT00290628|recurrent childhood acute lymphoblastic leukemia
608621|NCT00290628|recurrent childhood acute myeloid leukemia
608985|NCT00289289|Pacing
608622|NCT00290628|recurrent childhood large cell lymphoma
608623|NCT00290628|recurrent childhood lymphoblastic lymphoma
608624|NCT00290628|recurrent childhood small noncleaved cell lymphoma
608625|NCT00290628|recurrent cutaneous T-cell non-Hodgkin lymphoma
608626|NCT00290628|recurrent grade 1 follicular lymphoma
608627|NCT00290628|recurrent grade 2 follicular lymphoma
608628|NCT00290628|recurrent grade 3 follicular lymphoma
608629|NCT00290628|recurrent mantle cell lymphoma
608630|NCT00290628|recurrent marginal zone lymphoma
608631|NCT00290628|recurrent mycosis fungoides/Sezary syndrome
608632|NCT00290628|recurrent small lymphocytic lymphoma
608633|NCT00290628|refractory chronic lymphocytic leukemia
608634|NCT00290628|refractory hairy cell leukemia
608635|NCT00290628|refractory multiple myeloma
608636|NCT00290628|relapsing chronic myelogenous leukemia
608637|NCT00290628|secondary acute myeloid leukemia
608638|NCT00290628|secondary myelodysplastic syndromes
608639|NCT00290628|splenic marginal zone lymphoma
608640|NCT00290628|stage III adult Burkitt lymphoma
608641|NCT00290628|stage III adult Hodgkin lymphoma
608642|NCT00290628|stage III adult diffuse large cell lymphoma
608643|NCT00290628|stage III adult diffuse mixed cell lymphoma
608644|NCT00290628|stage III adult diffuse small cleaved cell lymphoma
608645|NCT00290628|stage III adult immunoblastic large cell lymphoma
608646|NCT00290628|stage III adult lymphoblastic lymphoma
608647|NCT00290628|stage III chronic lymphocytic leukemia
608648|NCT00290628|stage III grade 1 follicular lymphoma
608649|NCT00290628|stage III grade 2 follicular lymphoma
608650|NCT00290628|stage III grade 3 follicular lymphoma
608651|NCT00290628|stage III mantle cell lymphoma
608652|NCT00290628|stage III marginal zone lymphoma
608653|NCT00290628|stage III small lymphocytic lymphoma
608654|NCT00290628|stage IV adult Burkitt lymphoma
608655|NCT00290628|stage IV adult Hodgkin lymphoma
608656|NCT00290628|stage IV adult diffuse large cell lymphoma
608657|NCT00290628|stage IV adult diffuse mixed cell lymphoma
608658|NCT00290628|stage IV adult diffuse small cleaved cell lymphoma
608659|NCT00290628|stage IV adult immunoblastic large cell lymphoma
608660|NCT00290628|stage IV adult lymphoblastic lymphoma
608661|NCT00290628|stage IV chronic lymphocytic leukemia
608662|NCT00290628|stage IV grade 1 follicular lymphoma
608663|NCT00290628|stage IV grade 2 follicular lymphoma
608664|NCT00290628|stage IV grade 3 follicular lymphoma
608665|NCT00290628|stage IV mantle cell lymphoma
608666|NCT00290628|stage IV marginal zone lymphoma
608667|NCT00290628|stage IV small lymphocytic lymphoma
608668|NCT00290628|Diamond-Blackfan anemia
608669|NCT00290628|Fanconi anemia
608670|NCT00290628|childhood myelodysplastic syndromes
608671|NCT00290615|adenocarcinoma of the colon
608672|NCT00290615|recurrent colon cancer
608673|NCT00290615|stage IV colon cancer
608674|NCT00290615|adenocarcinoma of the rectum
608675|NCT00290615|recurrent rectal cancer
608676|NCT00290615|stage IV rectal cancer
608677|NCT00290602|Acute respiratory distress syndrome
608678|NCT00290602|corticosteroids
608679|NCT00290602|postoperative complications
608680|NCT00290602|cytokines
608681|NCT00290589|low back pain
608682|NCT00290589|emergency department
608683|NCT00290589|corticosteroids
608684|NCT00290576|Digestive and Nutritional Effects
608685|NCT00290576|Safety and Growth
608686|NCT00290576|Feeding Tolerance
608687|NCT00290550|Advanced Non-Small Cell Lung Cancer
608688|NCT00290550|NSCLC
608689|NCT00290537|Non-Small Cell Lung Cancer
608690|NCT00290537|Lung Cancer
608691|NCT00290537|Carboplatin
608692|NCT00290537|Paclitaxel
608693|NCT00290537|ZD6474
608694|NCT00290537|NSCLC
608695|NCT00290524|Oral alimentation following colorectal surgery
608696|NCT00290524|anastomosis
608697|NCT00290524|laparoscopy
608698|NCT00290524|hospitalization stay
608699|NCT00290511|Follicular Lymphoma
608700|NCT00290511|Zevalin
608701|NCT00290511|Ibritumomab Tiuxetan
608702|NCT00290511|IDEC-Y2B8
608703|NCT00290511|Fludarabine
608704|NCT00290511|Fludara
608705|NCT00290511|Dexamethasone
608706|NCT00290511|Mitoxantrone
608707|NCT00290511|Rituximab
608708|NCT00290511|Rituxan
608709|NCT00290511|R-FND
608710|NCT00290511|Fludarabine Phosphate
608711|NCT00290511|Decadron
608712|NCT00290498|Non-Hodgkin's Lymphoma
608713|NCT00290498|B-Cell Non-Hodgkin's Lymphoma
608714|NCT00290498|Lymphoma
608715|NCT00290498|Cyclophosphamide
608716|NCT00290498|Cytarabine
608717|NCT00290498|Doxorubicin
608718|NCT00290498|Hyper-CVAD
608719|NCT00290498|Methotrexate
608720|NCT00290498|Prednisone
608721|NCT00290498|Rituximab
608722|NCT00290498|Vincristine
608723|NCT00290498|R-CHOP
608724|NCT00290498|R-HCVAD
608725|NCT00290498|Dexamethasone
608726|NCT00290498|Decadron
608727|NCT00290498|Leucovorin
608728|NCT00290498|Ara-C
608729|NCT00290498|Cytosar
608730|NCT00290498|Cytoxan
608731|NCT00290498|DepoCyt
608732|NCT00290498|Cytosine arabinosine hydrochloride
608733|NCT00290498|AD
608734|NCT00290498|Hydroxydaunomycin hydrochloride
608735|NCT00290498|Neosar
608736|NCT00290485|non-resectable tumor
608737|NCT00290485|high-risk tumor
608738|NCT00290485|metastasis
608739|NCT00290485|Response Evaluation Criteria in Solid Tumors (RECIST)
608740|NCT00290485|Gleevec
608741|NCT00290485|Imatinib mesylate
608742|NCT00290459|Gynecologic Disease
608743|NCT00290459|Gynecologic Cancer
608744|NCT00290459|Prognostic Markers
608745|NCT00290433|Lymphoma
608746|NCT00290433|Peripheral T Cell
608747|NCT00290433|HCVIDDOXIL Regimen
608748|NCT00290433|ARA-C
608749|NCT00290433|Cytosar
608750|NCT00290433|DepoCyt
608751|NCT00290433|Cytosine arabinosine hydrochloride
608752|NCT00290433|Pegylated Liposomal Doxorubicin
608753|NCT00290433|Doxorubicin hydrochloride
608754|NCT00290433|Doxil
608755|NCT00290433|Cyclophosphamide
608756|NCT00290433|Cytoxan
608757|NCT00290433|Neosar
608758|NCT00290433|Dexamethasone
608759|NCT00290433|Decadron
608760|NCT00290433|Mesna
608761|NCT00290433|Methotrexate
608762|NCT00290433|Vincristine
608763|NCT00290433|G-CSF
608764|NCT00290433|Filgrastim
608765|NCT00290433|Neupogen
608766|NCT00290420|malaria
608767|NCT00290420|Plasmodium vivax
608768|NCT00290420|pregnancy
608769|NCT00290420|chemoprophylaxis
608770|NCT00290407|chronic lymphocytic leukemia
608771|NCT00290407|small lymphocytic lymphoma
608772|NCT00290407|rituximab
608773|NCT00290407|beta-glucan
608774|NCT00290394|Blood Pressure,
608775|NCT00290394|rosiglitazone,Diabetes Mellitus, Type 2,
608776|NCT00290381|Allergic rhinitis
608777|NCT00290368|Nasal allergen challenge
608778|NCT00290368|Allergic rhinitis
608779|NCT00290368|Timothy grass pollen
608780|NCT00290368|inflammatory mediators
608781|NCT00290329|Safety
608782|NCT00290329|Meningococcal disease
608783|NCT00290329|Meningitidis serogroups A, C,W & Y diseases
608784|NCT00290329|Meningococcal vaccine
608785|NCT00290316|Hepatocellular carcinoma
608786|NCT00290316|Cholangiocarcinoma
608787|NCT00290316|Metastasis
608788|NCT00290316|Liver neoplasm
608789|NCT00290290|Prevention
608790|NCT00290290|Antiseptic Preoperative Scrub
608791|NCT00290290|Postoperative Wound Infection
608792|NCT00290251|Endometrium
608793|NCT00290251|Progesterone
608794|NCT00290251|Estrogen
608795|NCT00290251|Fibroid
608796|NCT00290251|Hysterectomy
608797|NCT00290251|Leiomyoma
608798|NCT00290251|Uterine Fibroids
608799|NCT00290251|Fibroids
608800|NCT00290238|Chronic Low Back Pain
608801|NCT00290238|Lower Extremity Pain
608802|NCT00290238|Central Sensitization
608803|NCT00290238|Percutaneous Neuromodulation Therapy
608804|NCT00290225|Posttraumatic stress disorder
608805|NCT00290225|depression
608806|NCT00290225|disaster mental health
608807|NCT00290225|yoga
608808|NCT00290225|Breathwork
608809|NCT00290225|exposure treatments
608810|NCT00290212|Women
608811|NCT00290212|Bone density
608812|NCT00290212|Menopause
608813|NCT00290212|Dietary Supplements
608814|NCT00290212|Vitamin K2
608815|NCT00290199|Fetal Membranes, Premature Rupture
608816|NCT00290199|Labor, Induced
608817|NCT00290199|Foley Catheter
608818|NCT00290186|Cerebral Palsy
608819|NCT00290186|Spastic Cerebral Palsy
608820|NCT00290186|CP
608821|NCT00290186|Hyperbaric
608822|NCT00290186|HBOT
608823|NCT00290173|pre term labor
608824|NCT00290173|therapy
608825|NCT00290173|maintenance
608826|NCT00290160|Hyperkalemia
608827|NCT00290160|Protein
608828|NCT00290160|Hyperglycemia
608829|NCT00290160|ELBW
608830|NCT00290147|Dengue
608831|NCT00290147|DNA vaccine
608832|NCT00290134|Hypogonadism
608833|NCT00290134|Testosterone
608834|NCT00290121|Schizophrenia
608835|NCT00290121|Atypical antipsychotics
608836|NCT00290121|Weight gain
608837|NCT00290121|Appetite
608838|NCT00290121|fMRI
608839|NCT00290108|BIS
608840|NCT00290108|Propofol
608841|NCT00290108|hemodynamic
608842|NCT00290108|pharmacokinetic
608843|NCT00290095|Multiple Myeloma
608844|NCT00290095|Quality of Life
608845|NCT00290095|Response Shift
608846|NCT00290095|Clinically Important Difference
608847|NCT00290082|sedation
608848|NCT00290082|midazolam
608849|NCT00290082|loxapine
608850|NCT00290082|agitation
608851|NCT00290082|emergency department
608852|NCT00290082|toxicological analysis
608853|NCT00290069|Renal function
608854|NCT00290069|Serum creatinine
608855|NCT00290069|Immunosuppression
608856|NCT00290069|Rejection
608857|NCT00290056|CHD
608858|NCT00290056|Arrhythmia
608859|NCT00290056|ICD
608860|NCT00290056|Omega-3 PUFA
608861|NCT00290056|Nutrition
608862|NCT00290043|Insulin glulisine
608863|NCT00290043|Diabetes mellitus Type 1
608864|NCT00290043|Postprandial Period
608865|NCT00290043|Pharmacokinetics
608866|NCT00290043|Glucodynamics
608867|NCT00290030|acute urinary retention
608868|NCT00290030|International Prostate Symptom Score (IPSS)
608869|NCT00290004|Chronic Lymphocytic Leukemia
608870|NCT00290004|Small Lymphocytic Lymphoma
608871|NCT00290004|Leukemia
608872|NCT00290004|Lymphoma
608873|NCT00290004|Motexafin Gadolinium
608874|NCT00290004|Relapsed Chronic Lymphocytic Leukemia
608875|NCT00290004|Relapsed Small Lymphocytic Lymphoma
608876|NCT00290004|Refractory Chronic Lymphocytic Leukemia
608877|NCT00290004|Refractory Small Lymphocytic Lymphoma
608878|NCT00289978|Multiple Sclerosis
608879|NCT00289978|FTY720
608880|NCT00289978|Fingolimod
608881|NCT00289965|Alcohol Abuse
608882|NCT00289965|Alcohol Drinking
608883|NCT00289965|Intervention Studies
608884|NCT00289965|Computer-Assisted Instruction
608885|NCT00289965|College Students
608886|NCT00289952|HIV infections
608887|NCT00289952|Histone deacetylase Inhibitor
608888|NCT00289952|HIV Reservoirs
608889|NCT00289952|Peripheral Blood Mononuclear Cells
608890|NCT00289952|Valproic Acid
608891|NCT00289952|Treatment Experienced
608892|NCT00289939|women
608893|NCT00289939|women's health
608894|NCT00289939|HIV
608895|NCT00289939|risk factors
608896|NCT00289939|risk behaviors
608897|NCT00289939|prevention
608898|NCT00289939|motivational interviewing
608899|NCT00289939|domestic violence
608900|NCT00289939|partner violence
608901|NCT00289939|behavioral trial
608902|NCT00289939|community justice
608903|NCT00289939|criminal justice
608904|NCT00289926|low libido
608905|NCT00289926|lack of wellbeing
608906|NCT00289913|Hepatitis A virus
608907|NCT00289861|Schizophrenia
608908|NCT00289861|risperidone
608909|NCT00289861|prolactin
608910|NCT00289861|clozapine
608911|NCT00289666|Sleep Disorder
608912|NCT00289666|CPAP
608913|NCT00289653|nicotine dependence,
608914|NCT00289653|transdermal nicotine patch,
608915|NCT00289653|smoking while receiving nicotine replacement,
608916|NCT00289653|comorbidities
608917|NCT00289640|Stage III (unresectable)
608918|NCT00289640|Stage IV melanoma
608919|NCT00289627|Previously treated melanoma
608920|NCT00289627|Unresectable Stage III
608921|NCT00289627|Stage IV
608922|NCT00289614|contrast induced nephropathy
608923|NCT00289601|aspirin
608924|NCT00289601|clopidogrel
608925|NCT00289601|resistance
608926|NCT00289601|angioplasty
608927|NCT00289601|percutaneous coronary intervention
608928|NCT00289601|myocardial infarction
608929|NCT00289588|Methicillin-resistant Staphylococcus aureus
608930|NCT00289588|Staphylococcus aureus
608931|NCT00289588|MRSA
608932|NCT00289588|CA-MRSA
608933|NCT00289575|Femur head aseptic osteonecrosis
608934|NCT00289575|Bone reconstruction
608935|NCT00289575|Macroporous biphasic calcium phosphate granules
608936|NCT00289562|B-cell
608937|NCT00289562|leukemia
608938|NCT00289562|B-lymphoblastic leukemia
608939|NCT00289562|lymphoma
608940|NCT00289562|B-All
608941|NCT00289549|CLL
608942|NCT00289549|Chronic lymphocytic leukemia
608943|NCT00289549|leukemia
608944|NCT00289549|Advanced, fludarabine-refractory CLL
608945|NCT00289523|Major Depressive Disorder, Depressive Disorder, Unipolar Depression, Antidepressants, Electroencephalography
608946|NCT00289497|Charcot
608947|NCT00289497|foot
608948|NCT00289497|ulceration
608949|NCT00289497|neuropathy
608950|NCT00289484|Mood disorder
608951|NCT00289471|Sensitivity and specificity
608952|NCT00289471|Physician's practice patterns
608953|NCT00289471|Health Care costs
608954|NCT00289471|Quality of Health Care
608955|NCT00289458|older adults, falls, arthritis, aquatic, exercise
608956|NCT00289419|Arthroplasty, Replacement, Hip
608957|NCT00289419|Anesthetics, Local
608958|NCT00289419|Pain, Postoperative
608959|NCT00289406|hypertension
608960|NCT00289380|Nutritional Risk Screening(NRS)
608961|NCT00289380|Malnutrition
608962|NCT00289380|Overweight
608963|NCT00289380|Obesity
608964|NCT00289380|Clinical nutritional support
608965|NCT00289380|Clinical outcome
608966|NCT00289380|Cost effectiveness
608967|NCT00289380|Complication
608968|NCT00289380|Infective complications
608969|NCT00289354|chromium
608970|NCT00289354|chromium picolinate
608971|NCT00289354|type 2 diabetes mellitus
608972|NCT00289354|HbA1c
608973|NCT00289354|hyperglycemia
608974|NCT00289354|cholesterol
608975|NCT00289302|Heart Failure
608976|NCT00289302|Cardiac pacing
608977|NCT00289302|Cardiac resynchronization therapy
608978|NCT00289302|Implantable Cardioverter Defibrillator
608979|NCT00289289|Atrial Fibrillation
608980|NCT00289289|Atrial Tachyarrhythmia
608981|NCT00289289|Arrhythmia
608982|NCT00289289|Bradycardia
608986|NCT00289276|Cardiomyopathy
608987|NCT00289276|Ventricular Ejection Fraction
608988|NCT00289276|Congestive Heart Failure
608989|NCT00289276|Impedance
608990|NCT00289263|metastatic breast cancer
608991|NCT00289263|maintenance chemotherapy
608992|NCT00289250|Malaria
608993|NCT00289250|Gametocytes
608994|NCT00289250|Asymptomatic carriers
608995|NCT00289237|Lifestyle intervention
608996|NCT00289237|Behavioural changes
608997|NCT00289237|CHD
608998|NCT00289237|Type 2 diabetes
608999|NCT00289224|bivalent killed whole cell oral cholera vaccine
609000|NCT00289224|double blind randomized clinical trial
609001|NCT00289211|Hereditary angioedema
609002|NCT00289211|HAE
609003|NCT00289211|C1 esterase inhibitor (human)
609004|NCT00289211|C1INH-nf
609005|NCT00289198|GW685698X
609006|NCT00289198|perennial allergic rhinitis
609007|NCT00289198|allergic rhinitis
609008|NCT00289185|Coccidiosis
609009|NCT00289185|Parasitic Diseases
609010|NCT00289185|Malaria, Falciparum
609011|NCT00289185|Malaria
609012|NCT00289159|aged 18-50
609013|NCT00289159|remitting evolution
609014|NCT00289159|less than two years of evolution
609015|NCT00289159|MS patients
609016|NCT00289146|kidney cancer, immunology
609017|NCT00289133|Arthroplasty, Replacement, Knee
609018|NCT00289120|urolithiasis, cola
609019|NCT00289107|Total Knee Replacement
609020|NCT00289107|Knee Prosthesis
609021|NCT00289081|Total Knee Replacement
609022|NCT00289068|cataract surgery
609023|NCT00289068|phacoemulsification sleeve
609024|NCT00289055|Peripheral Artery Occlusive Disease
609025|NCT00289042|atrial fibrillation
609026|NCT00289042|atrial thrombus
609027|NCT00289042|cardioversion
609028|NCT00289042|enoxaparin
609029|NCT00289042|low molecular weight heparin
609030|NCT00289042|transesophageal echocardiography
609031|NCT00289016|gene transfer
609032|NCT00289016|gene therapy
609033|NCT00289016|oncolytic virus
609034|NCT00289016|GM-CSF
609035|NCT00289016|melanoma
609036|NCT00288990|MS
609037|NCT00288977|Diabetes
609038|NCT00288977|Islet Transplantation
609039|NCT00288938|Suspicious mole
609040|NCT00288938|Congenital Nevus
609041|NCT00288938|Skin Cancer
609042|NCT00288938|Moles
609043|NCT00288938|Pigmented lesion
609044|NCT00288938|LCMN
609045|NCT00288912|Self-Care
609046|NCT00288912|Telemedicine
609047|NCT00288912|Pain
609048|NCT00288912|Veterans
609049|NCT00288899|Informed Consent
609050|NCT00288899|Medical Record Systems, computerized
609051|NCT00288899|Comprehension
609052|NCT00288899|Anxiety
609053|NCT00288899|Personal Satisfactin
609054|NCT00288886|Compliance
609055|NCT00288886|Aftercare
609056|NCT00288886|Reinforcement, social
609057|NCT00288886|Alcoholics Anonymous
609058|NCT00288886|Support Groups
609059|NCT00288886|Treatment Outcome
609060|NCT00288873|Vitamin D deficiency
609061|NCT00288873|Secondary hyperparathyroidism
609062|NCT00288873|Obesity
609063|NCT00288860|telemedicine
609064|NCT00288860|treatment compliance
609065|NCT00288860|mental health
609066|NCT00288847|Patella Dislocation
609067|NCT00288847|Surface EMG
609068|NCT00288847|Gender difference
609069|NCT00288834|stroke
609070|NCT00288834|dysphagia
609071|NCT00288834|rehabilitation
609072|NCT00288834|biofeedback
609073|NCT00288821|Gynaecological malignancy
609074|NCT00288821|Diagnostic Accuracy
609075|NCT00288821|DWIBS
609076|NCT00288821|Lymph Nodes
609077|NCT00288821|Metastasis
609078|NCT00288808|Blood
609079|NCT00288808|Coagulation
609080|NCT00288808|PT/InR
609081|NCT00288808|Warfarin
609082|NCT00288808|Mechanical Valve
609083|NCT00288795|Fatigue
609084|NCT00288795|Polarity
609085|NCT00288795|Massage
609086|NCT00288782|Mirtazapine
609087|NCT00288782|Antidepressant
609088|NCT00288782|Positron Emission Tomography
609089|NCT00288769|Recurrent aphthous stomatitis
609090|NCT00288769|vitamin B12
609091|NCT00288756|arrythmias
609092|NCT00288730|Heart Failure
609093|NCT00288730|Renal Dysfunction
609094|NCT00288730|Cardiomyopathy
609095|NCT00288730|Heart Decompensation
609096|NCT00288730|Dyspnea Paroxysmal
609097|NCT00288704|Familial Cold Autoinflammatory Syndrome (FCAS)
609098|NCT00288704|Muckle-Wells Syndrome (MWS)
609099|NCT00288704|CIAS1
609100|NCT00288704|NLRP-3
609101|NCT00288704|PYPAF1
609102|NCT00288704|Cryopyrin
609103|NCT00288704|CAPS
609104|NCT00288704|Interleukin-1
609105|NCT00288691|Treatment-resistant menorrhagia
609106|NCT00288678|Diabetic shared care
609107|NCT00288678|Health manager
609108|NCT00288678|Prospective Study
609109|NCT00288678|Health Care Quality, Access, and Evaluation
609110|NCT00288665|Myocardial infarction
609111|NCT00288665|aspiration
609112|NCT00288665|thrombectomy
609113|NCT00288665|ventricular remodeling
609114|NCT00288639|Pregabalin for partial seizures
609115|NCT00288626|hematopoietic stem cell transplantation
609116|NCT00288626|autologous hematopoietic cell transplant (HCT)
609117|NCT00288626|high-dose immunosuppressive therapy(HDIT)
609118|NCT00288613|ESRD
609119|NCT00288613|Daily Hemodialysis
609120|NCT00288613|Hemodialysis
609121|NCT00288613|Kidney Failure
609122|NCT00288613|Kidney Disease
609123|NCT00288600|Immunoglobulins, Intravenous
609124|NCT00288600|Hyperbilirubinemia
609125|NCT00288600|Erythroblastosis, Fetal
609126|NCT00288600|Exchange Transfusion, Whole Blood
609127|NCT00288587|Heart Failure
609128|NCT00288587|Congestive Heart Failure
609129|NCT00288587|CHF
609130|NCT00288574|Depression
609131|NCT00288561|ARMD, ranibizumab, verteporfin
609132|NCT00288535|coronary bifurcation ; PCI; modified T-Stenting; sirolimus stent
609133|NCT00288496|mechanical bowel preparation, colorectal surgery, anastomotic dehiscence
609134|NCT00288444|Advanced malignancies.
609135|NCT00288431|cancer
609136|NCT00288431|sarcoma
609137|NCT00288418|Colonization of the catheter
609138|NCT00288418|Catheter related bloodstream infection
609139|NCT00288405|Intracranial
609140|NCT00288405|Wide-neck
609141|NCT00288405|Saccular
609142|NCT00288405|Aneurysms
609143|NCT00288379|Asthma
609144|NCT00288379|allergen challenge
609145|NCT00288379|airway responsiveness
609146|NCT00288379|airway inflammation
609147|NCT00288379|Symbicort®
609148|NCT00288366|schizophrenia
609149|NCT00288366|schizoaffective disorder
609150|NCT00288366|bipolar disorder
609151|NCT00288366|metabolic syndrome
609152|NCT00288353|schizophrenia
609153|NCT00288353|schizoaffective disorder
609154|NCT00288353|bipolar disorder
609155|NCT00288353|metabolic syndrome
609156|NCT00288340|psychotic disorders
609157|NCT00288340|auditory hallucinations
609158|NCT00288340|brain structure
609159|NCT00288340|psychiatric disorder with auditory hallucinations (at least one every 20 minutes)
609160|NCT00288340|schizophrenia/schizoaffective disorder without auditory hallucinations
609161|NCT00288327|diet
609162|NCT00288327|physical activity
609163|NCT00288327|smoking cessation
609164|NCT00288314|PTSD
609165|NCT00288314|MRI, Functional
609166|NCT00288314|Anxiety
609167|NCT00288314|Working Memory
609168|NCT00288314|Processing speed
609169|NCT00288301|diet
609170|NCT00288301|physical activity
609171|NCT00288301|weight management
609172|NCT00288275|Ovarian Cancer
609173|NCT00288275|Fallopian Tube Cancer
609174|NCT00288275|Peritoneal Cancer
609175|NCT00288275|Assay
609176|NCT00288275|Chemotherapy
609177|NCT00288275|Recurrent
609178|NCT00288275|Refractory
609179|NCT00288275|Persistent
609180|NCT00288275|Chemoresponse
609181|NCT00288275|Sensitivity
609182|NCT00288275|Precision Therapeutics
609183|NCT00288262|hot flashes
609184|NCT00288262|melatonin
609185|NCT00288262|depression
609186|NCT00288262|sleep
609187|NCT00288262|luteinizing hormone
609188|NCT00288262|postmenopause
609189|NCT00288249|Breast Cancer
609190|NCT00288249|Breast Neoplasms
609191|NCT00288145|worksite
609192|NCT00288145|weight gain prevention (among adults)
609193|NCT00288145|obesity (among adults)
609194|NCT00288145|physical activity
609195|NCT00288145|nutrition
609196|NCT00288132|Diabetes
609197|NCT00288132|self-management
609198|NCT00288132|telemedicine
609199|NCT00288132|retinal
609200|NCT00288132|screening
609201|NCT00288119|Barrett's Esophagus
609202|NCT00288106|recurrent prostate cancer
609203|NCT00288106|stage I prostate cancer
609204|NCT00288106|stage II prostate cancer
609205|NCT00288106|stage III prostate cancer
609206|NCT00288106|stage IV prostate cancer
609207|NCT00288080|stage III prostate cancer
609208|NCT00288080|stage IIB prostate cancer
609209|NCT00288080|stage IIA prostate cancer
609210|NCT00288080|stage IV prostate cancer
609211|NCT00288054|stage IIIA non-small cell lung cancer
609212|NCT00288054|stage IIIB non-small cell lung cancer
609213|NCT00288054|adenocarcinoma of the lung
609214|NCT00288054|large cell lung cancer
609215|NCT00288054|squamous cell lung cancer
609216|NCT00288028|stage I multiple myeloma
609217|NCT00288028|stage II multiple myeloma
609218|NCT00288028|stage III multiple myeloma
609219|NCT00288028|refractory multiple myeloma
609220|NCT00288015|adult angiosarcoma
609221|NCT00288015|recurrent adult soft tissue sarcoma
609222|NCT00288015|stage I adult soft tissue sarcoma
609223|NCT00288015|stage II adult soft tissue sarcoma
609224|NCT00288015|stage III adult soft tissue sarcoma
609225|NCT00288015|stage IV adult soft tissue sarcoma
609226|NCT00288002|inflammatory breast cancer
609227|NCT00288002|stage II breast cancer
609228|NCT00288002|stage IIIA breast cancer
609229|NCT00288002|stage IIIB breast cancer
609230|NCT00288002|stage IIIC breast cancer
609231|NCT00288002|stage IA breast cancer
609232|NCT00288002|stage IB breast cancer
609233|NCT00288002|estrogen receptor-negative breast cancer
609234|NCT00288002|estrogen receptor-positive breast cancer
609235|NCT00288002|HER2-negative breast cancer
609236|NCT00288002|HER2-positive breast cancer
609237|NCT00287989|recurrent non-small cell lung cancer
609238|NCT00287989|stage IIIB non-small cell lung cancer
609239|NCT00287989|stage IV non-small cell lung cancer
609240|NCT00287976|childhood hepatoblastoma
609241|NCT00287976|recurrent childhood liver cancer
609242|NCT00287963|adenocarcinoma of the lung
609243|NCT00287963|adenosquamous cell lung cancer
609244|NCT00287963|bronchoalveolar cell lung cancer
609245|NCT00287963|combined type small cell lung cancer
609246|NCT00287963|intermediate type small cell lung cancer
609247|NCT00287963|large cell lung cancer
609248|NCT00287963|lymphocyte-like type small cell lung cancer
609249|NCT00287963|recurrent non-small cell lung cancer
609250|NCT00287963|recurrent small cell lung cancer
609251|NCT00287963|squamous cell lung cancer
609252|NCT00287950|disseminated neuroblastoma
609253|NCT00287950|localized resectable neuroblastoma
609254|NCT00287950|localized unresectable neuroblastoma
609255|NCT00287950|regional neuroblastoma
609256|NCT00287950|stage 4S neuroblastoma
609257|NCT00287924|childhood infratentorial ependymoma
609258|NCT00287924|childhood supratentorial ependymoma
609259|NCT00287924|newly diagnosed childhood ependymoma
609260|NCT00287911|cervical adenocarcinoma
609261|NCT00287911|cervical adenosquamous cell carcinoma
609262|NCT00287911|cervical squamous cell carcinoma
609263|NCT00287911|stage IB cervical cancer
609264|NCT00287911|stage IIA cervical cancer
609265|NCT00287911|stage IIB cervical cancer
609266|NCT00287911|stage III cervical cancer
609267|NCT00287911|stage IVA cervical cancer
609268|NCT00287898|breast cancer
609269|NCT00287885|recurrent cervical cancer
609270|NCT00287885|stage III cervical cancer
609271|NCT00287885|stage IVA cervical cancer
609272|NCT00287885|stage IVB cervical cancer
609273|NCT00287885|stage III endometrial carcinoma
609274|NCT00287885|recurrent endometrial carcinoma
609275|NCT00287885|stage IV endometrial carcinoma
609276|NCT00287885|fallopian tube cancer
609277|NCT00287885|stage III ovarian epithelial cancer
609278|NCT00287885|stage IV ovarian epithelial cancer
609279|NCT00287885|stage III ovarian germ cell tumor
609280|NCT00287885|recurrent ovarian germ cell tumor
609281|NCT00287885|stage IV ovarian germ cell tumor
609282|NCT00287885|recurrent ovarian epithelial cancer
609283|NCT00287885|recurrent uterine sarcoma
609284|NCT00287885|stage III uterine sarcoma
609285|NCT00287885|stage IV uterine sarcoma
609286|NCT00287885|stage III vaginal cancer
609287|NCT00287885|recurrent vaginal cancer
609288|NCT00287885|stage IVA vaginal cancer
609289|NCT00287885|stage IVB vaginal cancer
609290|NCT00287885|stage III vulvar cancer
609291|NCT00287885|recurrent vulvar cancer
609292|NCT00287885|stage IV vulvar cancer
609293|NCT00287885|ovarian sarcoma
609294|NCT00287885|ovarian stromal cancer
609295|NCT00287885|peritoneal cavity cancer
609296|NCT00287872|stage II multiple myeloma
609297|NCT00287872|stage III multiple myeloma
609298|NCT00287859|fallopian tube cancer
609299|NCT00287859|peritoneal cavity cancer
609300|NCT00287859|recurrent ovarian epithelial cancer
609301|NCT00287846|desmoid tumor
609302|NCT00287820|schizophrenia
609303|NCT00287820|diabetes
609304|NCT00287820|metabolic syndrome
609305|NCT00287820|hyperglycemia
609306|NCT00287820|glucose
609307|NCT00287820|insulin
609308|NCT00287820|lipids
609309|NCT00287820|IL-6
609310|NCT00287820|prolactin
609311|NCT00287807|Diabetes mellitus, type 2
609312|NCT00287807|Blood Glucose Self-Monitoring
609313|NCT00287807|life style
609314|NCT00287794|rheumatoid arthritis
609315|NCT00287794|sleep disturbance
609316|NCT00287781|Migraine
609317|NCT00287781|Lidocaine
609318|NCT00287781|Headache
609319|NCT00287768|gastric cancer
609320|NCT00287768|advanced gastric cancer
609321|NCT00287768|S-1
609322|NCT00287768|docetaxel
609323|NCT00287768|phase III study
609324|NCT00287755|gastric cancer
609325|NCT00287755|S-1
609326|NCT00287755|chemosensitivity
609327|NCT00287755|adjuvant
609328|NCT00287742|risperidone
609329|NCT00287742|antipsychotic agents
609330|NCT00287742|Alzheimer's disease
609331|NCT00287742|dementia
609332|NCT00287742|psychosis
609333|NCT00287729|Idiopathic
609334|NCT00287729|Pulmonary
609335|NCT00287729|Fibrosis
609336|NCT00287729|Lung
609337|NCT00287729|Pirfenidone
609338|NCT00287729|InterMune
609339|NCT00287716|Idiopathic
609340|NCT00287716|Pulmonary
609341|NCT00287716|Fibrosis
609342|NCT00287716|Lung
609343|NCT00287716|Pirfenidone
609344|NCT00287716|InterMune
609345|NCT00287703|Major depression
609346|NCT00287703|Treatment resistant
609347|NCT00287703|PEMF
609348|NCT00287703|AQT
609349|NCT00287703|Hamilton
609350|NCT00287690|arteries
609351|NCT00287690|blood flow
609352|NCT00287690|coronary artery disease
609353|NCT00287690|diet
609354|NCT00287677|Growth Hormone
609355|NCT00287677|HIV-1
609356|NCT00287677|Vaccination
609357|NCT00287677|Thymopoiesis
609358|NCT00287677|HIV-specific responses
609359|NCT00287677|Treatment Experienced
609360|NCT00287664|hepatorenal syndrome
609361|NCT00287664|terlipressin
609362|NCT00287664|albumin
609363|NCT00287664|cirrhosis
609364|NCT00287651|Pulsatile intravenous insulin
609365|NCT00287651|Oral carbohydrate loading
609366|NCT00287651|Respiratory Quotients
609367|NCT00287651|Hypoglycemia
609368|NCT00287638|Obstructive sleep apnea
609369|NCT00287625|Chronic obstructive pulmonary disease
609370|NCT00287625|Pulmonary rehabilitation
609371|NCT00287612|GERD
609372|NCT00287612|Hiatal Hernia
609373|NCT00287612|Recurrence
609374|NCT00287599|Surgical wound infections
609375|NCT00287599|Real-time PCR
609376|NCT00287599|Rapid identification of bacteria
609377|NCT00287599|Cloning
609378|NCT00287599|16S rRNA sequencing
609379|NCT00287586|Testosterone Replacement
609380|NCT00287586|Heart Disease
609381|NCT00287586|Vascular Disease
609382|NCT00287586|Risk Factors for Cardiovascular Disease
609383|NCT00287586|Cholesterol
609384|NCT00287586|Obesity
609385|NCT00287586|Blood pressure
609386|NCT00287586|Quality of Life
609387|NCT00287534|Early Breast Cancer
609388|NCT00287521|open
609389|NCT00287521|angle
609390|NCT00287521|glaucoma
609391|NCT00287521|ocular
609392|NCT00287521|hypertension
609393|NCT00287508|Carotid stenting
609394|NCT00287508|Carotid endarterectomy
609395|NCT00287508|Carotid artery disease with severe narrowing of the artery
609396|NCT00287508|Stroke prevention
609397|NCT00287508|cerebral infarction
609398|NCT00287495|AIDS
609399|NCT00287495|HIV
609400|NCT00287495|Antiangiogenesis
609401|NCT00287495|VEGF
609402|NCT00287495|AIDS Malignancy
609403|NCT00287495|Kaposi Sarcoma
609404|NCT00287495|KS
609405|NCT00287482|Treatment side effects
609406|NCT00287482|Quality of Life
609407|NCT00287482|Transition
609408|NCT00287482|Survivorship
609409|NCT00287469|Hepatitis E
609410|NCT00287469|clinical hepatitis
609411|NCT00287469|vaccine
609412|NCT00287469|efficacy
609413|NCT00287469|Nepal
609414|NCT00287417|Nucal translucency
609415|NCT00287417|Down syndrome
609416|NCT00287417|MSS
609417|NCT00287417|Risk assessment
609418|NCT00287404|type 2 diabetes
609419|NCT00287404|hyperlipidemia
609420|NCT00287404|dyslipidemia
609421|NCT00287404|fasting lipids
609422|NCT00287404|postprandial lipids
609423|NCT00287404|Non-HDL cholesterol
609424|NCT00287404|NMR lipoanalysis
609425|NCT00287404|ATP III guidelines
609426|NCT00287391|Insomnia
609427|NCT00287391|Gastroesophageal Reflux Disease (GERD)
609428|NCT00287391|Sleep Disturbance
609429|NCT00287352|First episode psychosis
609430|NCT00287339|Cough
609431|NCT00287339|GERD
609432|NCT00287326|Epidural
609433|NCT00287326|Bupivacaine
609434|NCT00287326|Clonidine
609435|NCT00287313|Unstable INRs
609436|NCT00287313|Warfarin
609437|NCT00287313|Vitamin K
609438|NCT00287300|Malaria
609439|NCT00287300|Pregnancy
609440|NCT00287300|Efficacy
609441|NCT00287300|Azithromycin
609442|NCT00287300|Artesunate
609443|NCT00287287|Lenalidomide
609444|NCT00287287|Clinical Trials phase II
609445|NCT00287287|Carcinomas, thyroid
609446|NCT00287287|Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
609447|NCT00287261|myelofibrosis
609448|NCT00287261|D009191
609449|NCT00287248|Alzheimer
609450|NCT00287248|Alzheimer disease
609451|NCT00287248|Alzheimer disease (AD)
609452|NCT00287235|Hepatic Encephalopathy
609453|NCT00287235|End Stage Liver Disease
609454|NCT00287235|Cirrhosis
609455|NCT00287235|MARS
609456|NCT00287235|Albumin Dialysis
609457|NCT00287222|Inoperable and Metastatic Hepatocellular Carcinoma
609458|NCT00287209|RASCABG 1 - study
609459|NCT00287209|Postoperative atrial fibrillation
609460|NCT00287209|Randomized, controlled trial
609461|NCT00287209|Amiodarone
609462|NCT00287196|Melanoma
609463|NCT00287196|Lymph node disease
609464|NCT00287196|Adjuvant radiotherapy
609465|NCT00287196|Lymphoedema
609466|NCT00287170|Crohn's Disease
609467|NCT00287170|Local Ileal Delivery
609468|NCT00287170|Delayed-Release Formulations
609469|NCT00287170|6-Mercaptopurine
609470|NCT00287170|Calcitriol
609471|NCT00287157|Traumatic Brain Injury
609472|NCT00287157|Actigraphy
609473|NCT00287157|Spasticity, Cognition and Functioning
609474|NCT00287144|Hypothyroidism
609475|NCT00287131|melanoma
609476|NCT00287131|metastatic melanoma
609477|NCT00287131|adoptive immunotherapy
609478|NCT00287131|IL-2
609479|NCT00287105|Chemotherapy
609480|NCT00287105|Leukemia
609481|NCT00287105|Children
609482|NCT00287105|Philadelphia chromosome
609483|NCT00287105|Protein-tyrosine kinase inhibitor
609484|NCT00287092|Haemophilus influenzae type b;
609485|NCT00287092|Corynebacterium diphtheriae;
609486|NCT00287092|Clostridium tetani;
609487|NCT00287092|Bordetella pertussis;
609488|NCT00287092|poliovirus types 1, 2 and 3;
609489|NCT00287092|Vero cell;
609490|NCT00287092|Influenza;
609491|NCT00287092|Diphtheria
609492|NCT00287053|divalproex sodium
609493|NCT00287053|valproic acid
609494|NCT00287053|food intake
609495|NCT00287053|energy expenditure
609496|NCT00287053|posture allocation
609497|NCT00287053|None, the population of study is healthy
609498|NCT00287040|Breast Cancer
609499|NCT00287040|Mammography
609500|NCT00287027|psychotic disorders
609501|NCT00287027|family burden
609502|NCT00287027|long acting injectible antipsychotic medication
609503|NCT00287014|Rift valley fever, Kenya
609504|NCT00287001|Acquired bilateral nevus of Ota-like macules
609505|NCT00287001|Postinflammatory hyperpigmentation
609506|NCT00287001|Cold air cooling
609507|NCT00286988|Preventative
609508|NCT00286988|Open-Label
609509|NCT00286988|Safety/Efficacy
609510|NCT00286975|Leadership skills
609511|NCT00286975|Management skills
609512|NCT00286975|Postgraduate medical education
609513|NCT00286962|Diabetes mellitus, type 1
609514|NCT00286962|insulin infusion systems
609515|NCT00286962|continuous intraperitoneal insulin infusion
609516|NCT00286962|cross-over studies
609517|NCT00286949|Parkinson's disease
609518|NCT00286949|executive dysfunction
609519|NCT00286949|impairment
609520|NCT00286949|motor skills
609521|NCT00286949|cognitive
609522|NCT00286936|Hip fracture
609523|NCT00286936|delirium
609524|NCT00286936|sleep disturbance
609525|NCT00286936|hypnotic
609526|NCT00286923|migraine
609527|NCT00286923|chronic headache
609528|NCT00286923|hyperexcitability
609529|NCT00286923|Magnetic stimulation
609530|NCT00286910|AQP-2
609531|NCT00286910|NPHS2-gene
609532|NCT00286845|Chemosensitivity
609533|NCT00286845|Acute Myeloid Leukemia
609534|NCT00286845|Apoptosis
609535|NCT00286845|MiCK Assay
609536|NCT00286832|Non-Hodgkin's lymphoma
609537|NCT00286832|Diffuse large B-cell lymphoma
609538|NCT00286832|PET
609539|NCT00286832|Prognosis
609540|NCT00286819|early breast cancer,
609541|NCT00286819|Fluorouracil
609542|NCT00286793|at-101
609543|NCT00286793|at101
609544|NCT00286793|cancer
609545|NCT00286793|hormone refractory
609546|NCT00286793|prostate
609547|NCT00286793|docetaxel
609548|NCT00286793|prednisone
609549|NCT00286780|AT101
609550|NCT00286780|AT-101
609551|NCT00286780|cancer
609552|NCT00286780|lymphoctic
609553|NCT00286780|lukemia
609554|NCT00286780|Rituximab
609555|NCT00286767|Opportunistic Infections
609556|NCT00286767|Immune Restoration Disease
609557|NCT00286767|Mycobacterial Infections
609558|NCT00286767|HIV-1 Infection
609559|NCT00286767|HIV
609560|NCT00286767|ART Naive
609561|NCT00286754|Hypertension
609562|NCT00286754|Behavior modification
609563|NCT00286754|Randomized controlled trial
609564|NCT00286754|Treatment effectiveness
609565|NCT00286754|Telemedicine
609566|NCT00286754|Prevention
609567|NCT00286741|Diabetes
609568|NCT00286741|Hypertension
609569|NCT00286741|Randomized controlled trials
609570|NCT00286741|cost-effectiveness
609571|NCT00286741|health services
609572|NCT00286728|self-help groups
609573|NCT00286728|referral and consultation
609574|NCT00286702|splints
609575|NCT00286702|Occupational Therapy
609576|NCT00286663|AIH, Autoimmune Hepatitis
609577|NCT00286650|Paracetamol
609578|NCT00286637|OCT
609579|NCT00286637|CSLO
609580|NCT00286637|SLP
609581|NCT00286637|Perimetry
609582|NCT00286637|electrophysiology
609583|NCT00286637|glaucoma
609584|NCT00286637|macular degeneration
609585|NCT00286637|retinopathy
609586|NCT00286637|diabetes
609587|NCT00286637|macular hole
609588|NCT00286611|Amifostine
609589|NCT00286598|foot ulcer
609590|NCT00286598|diabetes mellitus
609591|NCT00286598|motor activity
609592|NCT00286598|randomized controlled trial
609593|NCT00286598|prevention
609594|NCT00286585|preconditioning
609595|NCT00286585|cardiac protection
609596|NCT00286585|morbidity
609597|NCT00286585|mortality
609598|NCT00286585|major non-cardiac surgery
609599|NCT00286585|cardiac mortality and morbidity
609600|NCT00286585|high cardiac perioperative risk
609601|NCT00286572|insulin-dependent diabetes mellitus
609602|NCT00286572|non-insulin-dependent diabetes mellitus
609603|NCT00286572|coronary artery disease
609604|NCT00286572|long-term mortality
609605|NCT00286559|Coronary artery disease
609606|NCT00286559|Coronary artery bypass graft surgery
609607|NCT00286559|SPECT
609608|NCT00286559|Adenosin
609609|NCT00286546|Testosterone
609610|NCT00286546|Major Depression
609611|NCT00286546|Men
609612|NCT00286533|Implant
609613|NCT00286520|Constipation
609614|NCT00286520|Fecal incontinence
609615|NCT00286520|Spinal cord injury
609616|NCT00286520|transanal irrigation
609617|NCT00286520|quality of life
609618|NCT00286507|Full thickness macular hole
609619|NCT00286507|Internal limiting membrane (ILM)
609620|NCT00286507|Vitreo retinal surgery
609621|NCT00286507|Vitrectomy
609622|NCT00286494|Glucose Metabolism Disorder
609623|NCT00286494|Dysmetabolic Syndrome
609624|NCT00286494|Type II Diabetes
609625|NCT00286494|Diabetes Mellitus
609626|NCT00286494|Lipoatrophic
609627|NCT00286494|Dyslipidemia
609628|NCT00286494|Drug Therapy
609629|NCT00286481|Hyperlipidemia
609630|NCT00286481|Drug Therapy
609631|NCT00286468|Glucose Metabolism Disorder
609632|NCT00286468|Dysmetabolic Syndrome
609633|NCT00286468|Type II Diabetes
609634|NCT00286468|Diabetes Mellitus
609635|NCT00286468|Lipoatrophic
609636|NCT00286468|Dyslipidemia
609637|NCT00286468|Drug Therapy
609638|NCT00286455|Glucose Metabolism Disorder
609639|NCT00286455|Dysmetabolic Syndrome
609640|NCT00286455|Type II Diabetes; Diabetes Mellitus
609641|NCT00286455|Lipoatrophic
609642|NCT00286455|Dyslipidemia
609643|NCT00286455|Drug Therapy
609644|NCT00286442|Glucose Metabolism Disorder
609645|NCT00286442|Dysmetabolic Syndrome
609646|NCT00286442|Type II Diabetes
609647|NCT00286442|Diabetes Mellitus
609648|NCT00286442|Lipoatrophic
609649|NCT00286442|Dyslipidemia
609650|NCT00286442|Drug Therapy
609651|NCT00286429|Glucose Metabolism Disorder
609652|NCT00286429|Dysmetabolic Syndrome
609653|NCT00286429|Type II Diabetes
609654|NCT00286429|Diabetes Mellitus
609655|NCT00286429|Lipoatrophic
609656|NCT00286429|Dyslipidemia
609657|NCT00286429|Drug Therapy
609658|NCT00286416|AERD
609659|NCT00286416|aspirin
609660|NCT00286416|allergy
609661|NCT00286416|omalizumab
609662|NCT00286403|Acute Tubular Necrosis
609663|NCT00286403|antioxidants
609664|NCT00286403|Fenoldopam
609665|NCT00286338|Fluid therapy
609666|NCT00286338|Monitoring
609667|NCT00286312|Acute myocardial infarction
609668|NCT00286312|Primary angioplasty
609669|NCT00286312|Reperfusion damage
609670|NCT00286312|Atorvastatin
609671|NCT00286312|Placebo
609672|NCT00286312|Early left ventricular remodelling
609673|NCT00286312|Late left ventricular remodelling
609674|NCT00286312|Cardiac MRI
609675|NCT00286312|Statin
609676|NCT00286312|Transluminal, Percutaneous Coronary
609677|NCT00286312|Angioplasty
609678|NCT00286299|Schizophrenia
609679|NCT00286299|Cardiovascular disease
609680|NCT00286299|Aerobic capacity
609681|NCT00286299|Mortality
609682|NCT00286299|Exercise
609683|NCT00286286|Laparoscopy
609684|NCT00286286|Laparoscopic Surgical Procedures
609685|NCT00286286|Laparoscopic Surgery
609686|NCT00286286|Gastric Bypass
609687|NCT00286286|Drug Delivery Systems
609688|NCT00286286|Pain Measurement
609689|NCT00286273|kidney failure, acute
609690|NCT00286273|venovenous hemofiltration
609691|NCT00286273|hemorrhage
609692|NCT00286273|heparin, low-molecular-weight
609693|NCT00286273|nadroparin
609694|NCT00286273|citrates
609695|NCT00286260|polyneuropathy
609696|NCT00286260|neuropathic pain
609697|NCT00286260|levetiracetam
609698|NCT00286234|triglycerides
609699|NCT00286234|HDL-cholesterol
609700|NCT00286234|insulin resistance
609701|NCT00286234|omega-3 fatty acids
609702|NCT00286234|niacin
609703|NCT00286208|Medical abortion
609704|NCT00286208|mifepristone
609705|NCT00286208|misoprostol
609706|NCT00286182|Heart Failure
609707|NCT00286182|Elderly
609708|NCT00286182|Diastolic Dysfunction
609709|NCT00286182|Anemia
609710|NCT00286182|Ventricular End Diastolic Volume
609711|NCT00286182|Aged
609712|NCT00286169|Extensive-disease small-cell lung cancer (ED-SCLC)
609713|NCT00286156|ADPKD
609714|NCT00286130|metastatic colorectal cancer
609715|NCT00286130|FOLFOX 6
609716|NCT00286130|FOLFIRI
609717|NCT00286117|Breast Cancer
609718|NCT00286104|Ventriculitis
609719|NCT00286104|External ventricular catheter
609720|NCT00286104|Antibiotic-impregnated
609721|NCT00286091|Hormone refractory prostate cancer
609722|NCT00286091|androgen independent
609723|NCT00286091|ADT
609724|NCT00286091|bone metastasis
609725|NCT00286078|Headache
609726|NCT00286078|Migraine
609727|NCT00286078|Refractory
609728|NCT00286078|Chronic
609729|NCT00286078|Pain
609730|NCT00286065|Pain
609731|NCT00286065|Fentanyl
609732|NCT00286065|Analgesics
609733|NCT00286065|Opioid
609734|NCT00286065|Inhalation
609735|NCT00286026|Chlamydia trachomatis
609736|NCT00285961|Fractures of the wrist, forearm, elbow, ankle, foot
609737|NCT00285961|Distortions of the wrist, elbow, ankle
609738|NCT00285961|Wounds without tendon injuries
609739|NCT00285935|Major Depressive Disorder
609740|NCT00285935|MDD
609741|NCT00285935|Neurobiology
609742|NCT00285935|Selective Serotonin Reuptake Inhibitor
609743|NCT00285935|SSRI
609744|NCT00285935|Depression
609745|NCT00285922|myocardial infarction
609746|NCT00285922|electrocardiography
609747|NCT00285922|myocardial ischemia
609748|NCT00285922|emergency medicine
609749|NCT00285922|monitoring, physiologic
609750|NCT00285909|Moderate alcohol consumption
609751|NCT00285909|Alcohol dehydrogenase 1c polymorphism
609752|NCT00285909|PPAR-gamma activated gene expression
609753|NCT00285896|GLP-1
609754|NCT00285896|fasting
609755|NCT00285896|hypoglycaemia
609756|NCT00285883|Invirase
609757|NCT00285883|HIV
609758|NCT00285883|DOT
609759|NCT00285883|Treatment Experienced
609760|NCT00285857|breast cancer
609761|NCT00285857|lovastatin
609762|NCT00285857|duct cytology
609763|NCT00285844|obesity
609764|NCT00285844|insulin resistance
609765|NCT00285844|thiazolidinedione
609766|NCT00285844|weight loss
609767|NCT00285844|adipose tissue
609768|NCT00285844|metabolic syndrome
609769|NCT00285844|diabetes prevention
609770|NCT00285844|cardiovascular disease prevention
609771|NCT00285805|Rosiglitazone
609772|NCT00285805|Furosemide
609773|NCT00285805|Amiloride
609774|NCT00285805|Epithelial sodium channel
609775|NCT00285805|Sodium excretion
609776|NCT00285792|Preschool, Physical Activity
609777|NCT00285766|Depression
609778|NCT00285753|psychosocial intervention
609779|NCT00285753|mild cognitive impairment
609780|NCT00285753|support group
609781|NCT00285753|caregivers
609782|NCT00285753|Mild Cognitive Impairment (MCI)
609783|NCT00285753|Cognitive Impairment No Dementia (CIND)
609784|NCT00285714|3D computer assisted imaging
609785|NCT00285714|maxillofacial surgery
609786|NCT00285714|cephalometry
609787|NCT00285714|normative value
609788|NCT00285688|H. Pylori, Clarithromycin resistant, gene
609789|NCT00285675|Calcitriol, DN-101, Androgen Independent Prostate Cancer (AIPC), Prostate Cancer, Non Small Cell Lung Cancer (NSCLC)
609790|NCT00285662|IPTi
609791|NCT00285662|Malaria
609792|NCT00285662|Anemia
609793|NCT00285662|Prevention
609794|NCT00285662|Infant
609795|NCT00285662|Artesunate
609796|NCT00285662|SP
609797|NCT00285662|Amodiaquine
609798|NCT00285662|Papua New Guinea
609799|NCT00285649|Spinal Manipulation
609800|NCT00285636|Long Term Follow-Up
609801|NCT00285623|Collection of all thromboembolic events,
609802|NCT00285623|immunological events and drug interactions leading to thromboembolic events or major
609803|NCT00285623|bleeding after exposure to TachoSil®.
609804|NCT00285584|HIV infection
609805|NCT00285584|Depression
609806|NCT00285584|Men who have sex with men
609807|NCT00285584|Drug abuse
609808|NCT00285558|obesity
609809|NCT00285558|adolescent
609810|NCT00285558|weight loss
609811|NCT00285558|body mass index
609812|NCT00285558|evaluation studies
609813|NCT00285558|peer group
609814|NCT00285558|behavior therapy
609815|NCT00285558|diet
609816|NCT00285558|exercise
609817|NCT00285558|self efficacy
609818|NCT00285558|parents
609819|NCT00285545|Blood Supply
609820|NCT00285545|Mesentery
609821|NCT00285532|Blood Lead
609822|NCT00285532|Pesticides
609823|NCT00285532|Community-based
609824|NCT00285532|Sampling Kits
609825|NCT00285519|Morning hypertension
609826|NCT00285506|Healthy Volunteers
609827|NCT00285493|low back pain
609828|NCT00285467|kidney, parathyroid hormone, vitamin d
609829|NCT00285441|HIV
609830|NCT00285428|treatment
609831|NCT00285428|NHL
609832|NCT00285428|CD20+ B-cell NHL
609833|NCT00285428|Lymphoma
609834|NCT00285415|Advanced endometrial adenocarcinoma, stage III A, B, C
609835|NCT00285402|Migraine
609836|NCT00285402|Migraine prophylaxis
609837|NCT00285402|Migraine prevention
609838|NCT00285402|Chronic migraine treatment
609839|NCT00285389|Mantle cell lymphoma
609840|NCT00285389|Chemotherapy
609841|NCT00285389|Autologous PBSCT
609842|NCT00285389|Molecular evaluation
609843|NCT00285376|Depression. Genetics, Pharmacogenetics
609844|NCT00285363|cancer
609845|NCT00285363|quality of life
609846|NCT00285363|adolescents
609847|NCT00285350|myasthenia gravis
609848|NCT00285337|Myelopathy
609849|NCT00285337|Laminectomy
609850|NCT00285337|Laminoplasty
609851|NCT00285337|Decompression of Spinal Cord
609852|NCT00285337|Cervical Spondylosis
609853|NCT00285324|Glioma
609854|NCT00285324|Glioblastoma Multiforme
609855|NCT00285324|Brain Cancer
609856|NCT00285324|Diffusion-Weighted Magnetic Resonance Imaging
609857|NCT00285324|Brain Tumor
609858|NCT00285298|proteinuria
609859|NCT00285298|Kidney failure, chronic
609860|NCT00285285|Point-of-care Testing
609861|NCT00285285|Pediatric Emergency Department
609862|NCT00285285|Length of Stay
609863|NCT00285285|Efficiency
609864|NCT00285259|cytomegalovirus infection
609865|NCT00285259|infectious disease
609866|NCT00285259|viremia
609867|NCT00285259|cytomegalovirus disease
609868|NCT00285259|stem cell transplant
609869|NCT00285259|allogeneic
609870|NCT00285259|bone marrow transplant
609871|NCT00285259|hematopoietic cell transplant
609872|NCT00285259|Acute Lymphoblastic Leukemia
609873|NCT00285259|Chronic Myelogenous Leukemia
609874|NCT00285259|Acute Myelogenous Leukemia
609875|NCT00285259|Hodgkin's Lymphoma
609876|NCT00285259|Non-Hodgkin's Lymphoma
609877|NCT00285259|Myelodysplastic Syndrome
609878|NCT00285246|combat disorders
609879|NCT00285246|stress, psychological
609880|NCT00285246|somatoform disorders
609881|NCT00285246|life change events
609882|NCT00285246|utilization
609883|NCT00285207|Cervical Intraepithelial Neoplasia (CIN)
609884|NCT00285207|High-grade Cervical Intraepithelial Neoplasia
609885|NCT00285207|High-grade Squamous Intraepithelial Lesions (HSIL)
609886|NCT00285207|Human Papilloma Virus (HPV)
609887|NCT00285207|High-Grade Cervical Intraepithelial Lesions (CIN 2/3)
609888|NCT00285181|persons
609889|NCT00285168|Osteoporosis
609890|NCT00285168|Fractures, Bone
609891|NCT00285168|Bone Mineral Density
609892|NCT00285155|bupropion
609893|NCT00285155|repeated dose
609894|NCT00285155|healthy volunteers
609895|NCT00285155|cognitive function
609896|NCT00285155|behaviour
609897|NCT00285155|tolerance
609898|NCT00285155|Persons
609899|NCT00285142|rosiglitazone
609900|NCT00285142|insulin secretion
609901|NCT00285142|clinical trial
609902|NCT00285142|healthy
609903|NCT00285142|persons
609904|NCT00284245|Chronic Pain
609905|NCT00284245|Pain
609906|NCT00284245|Computer Analysis
609907|NCT00284245|Pain Diagrams
609908|NCT00284232|HbA1c
609909|NCT00284232|Self-monitoring blood glucose (SMBG)
609910|NCT00284232|Diabetes treatment
609911|NCT00284232|quality of care
609912|NCT00284219|rTMS, smoking, dopamine, acotinine
609913|NCT00284206|methamphetamine, cognition, outpatient, risperidone
609914|NCT00284180|Breast Neoplasms
609915|NCT00284180|Breast Cancer
609916|NCT00284180|Vinflunine
609917|NCT00284180|Vinca Alkaloid
609918|NCT00284180|Javlor
609919|NCT00284167|tailored
609920|NCT00284167|web-based
609921|NCT00284167|weight management
609922|NCT00284167|obesity
609923|NCT00284167|efficacy
609924|NCT00284154|Extensive stage
609925|NCT00284154|Relapsed
609926|NCT00284141|lung
609927|NCT00284141|cancer
609928|NCT00284141|non-small-cell lung cancer
609929|NCT00284141|metastatic
609930|NCT00284141|carcinoma
609931|NCT00284141|lung neoplasm
609932|NCT00284141|lung diseases
609933|NCT00284141|angiogenesis
609934|NCT00284141|anti-angiogenesis
609935|NCT00284141|anti-angiogenesis inhibitors
609936|NCT00284141|cancer and other neoplasms
609937|NCT00284141|respiratory tract
609938|NCT00284141|(lung and bronchial) diseases
609939|NCT00284128|Cardiovascular Disease C14
609940|NCT00284128|vascular disease C14.907
609941|NCT00284128|hypertension C14.907.489
609942|NCT00284115|Gait trainer
609943|NCT00284115|Hemiplegia
609944|NCT00284115|Rehabilitation
609945|NCT00284115|Stroke
609946|NCT00284102|gas exchange
609947|NCT00284102|dead space
609948|NCT00284102|respiratory failure
609949|NCT00284102|ALI/ARDS patients
609950|NCT00284089|Subfoveal CNV, AMD, ranibizumab
609951|NCT00284063|spinal manipulation, zygapophysial joints
609952|NCT00285103|Antisense, mRNA antagonist, Bcl-2, CLL
609953|NCT00285090|Burn Injury
609954|NCT00285090|Calcium
609955|NCT00285090|Vitamin D
609956|NCT00285090|Bone Mineral Density
609957|NCT00285077|Alzheimer disease
609958|NCT00285077|nerve growth factors
609959|NCT00285077|Clinical Trial
609960|NCT00285064|MDCT
609961|NCT00285064|viability
609962|NCT00285051|emesis, nausea,
609963|NCT00285038|Deep vein thrombosis
609964|NCT00285038|Gynecological cancer
609965|NCT00285025|Alzheimer disease
609966|NCT00285025|nerve growth factors
609967|NCT00285025|Clinical Trial
609968|NCT00285012|smoking cessation
609969|NCT00285012|smoking cessation in COPD
609970|NCT00284986|GVHD
609971|NCT00284986|Graft vs Host Disease
609972|NCT00284986|Graft versus Host Disease
609973|NCT00284973|malaria
609974|NCT00284960|erectile dysfunction
609975|NCT00284960|metabolic syndrome
609976|NCT00284960|insulin resistance
609977|NCT00284960|etiology
609978|NCT00284947|Side effects
609979|NCT00284947|calcineurin inhibitors
609980|NCT00284947|maintenance
609981|NCT00284947|basiliximab
609982|NCT00284947|Kidney maintenance transplant
609983|NCT00284934|Dose optimization
609984|NCT00284934|immune suppressive regimen
609985|NCT00284934|enteric-coated mycophenolate sodium
609986|NCT00284934|EC-MPS
609987|NCT00284934|renal transplantation
609988|NCT00284934|kidney
609989|NCT00284934|transplant
609990|NCT00284934|maintenance patients
609991|NCT00284934|Renal transplantation in maintenance
609992|NCT00284921|kidney transplant, hepatitis C, enteric-coated mycophenolate sodium
609993|NCT00284908|S-Tenatoprazole-Na
609994|NCT00284908|Pharmacokinetic
609995|NCT00284908|intragastric pH recording
609996|NCT00284908|dose-response
609997|NCT00284895|Obesity
609998|NCT00284895|Bariatric Surgery
609999|NCT00284895|Weight Loss Surgery
610000|NCT00284895|Asthma
610001|NCT00284882|Streptococcus, Fiji, pyoderma, pharyngitis, scabies
610002|NCT00284869|LPS
610003|NCT00284869|ethnicity
610004|NCT00284869|neutrophils
610005|NCT00284869|TNF
610006|NCT00284843|Streptococcus, Fiji, pyoderma, scabies, rheumatic disease
610007|NCT00284830|Right Ventricular Pacing
610008|NCT00284830|Persistent Atrial Fibrillation
610009|NCT00284830|Atrioventricular Conduction
610010|NCT00284830|Heart Failure Hospitalization
610011|NCT00284830|Cardiovascular Health Care Utilization
610012|NCT00284830|Sinus-node Disease
610013|NCT00284830|Minimized Ventricular Pacing
610014|NCT00284804|relapsed or refractory Hodgkin's Disease
610015|NCT00284778|lung cancer
610016|NCT00284778|second line treatment
610017|NCT00284778|cost-minimization trial
610018|NCT00284778|Pharmaco-economic study
610019|NCT00284778|docetaxel
610020|NCT00284778|pemetrexed
610021|NCT00284752|Prostate
610022|NCT00284752|Cancer
610023|NCT00284752|Metastatic
610024|NCT00284726|Cytokines in lung transplantation
610025|NCT00284726|Cold storage solutions
610026|NCT00284726|Ischemic reperfusion injury
610027|NCT00284700|Helicobacter pylori
610028|NCT00284700|Iron deficiency anemia
610029|NCT00284700|children
610030|NCT00284687|bone marrow transplantation
610031|NCT00284687|CMV disease
610032|NCT00284661|Meniscal repair
610033|NCT00284661|Meniscal suturing
610034|NCT00284661|Meniscal tear
610035|NCT00284648|Achilles tendon
610036|NCT00284648|Rupture
610037|NCT00284648|Non-operative
610038|NCT00284648|Operative
610039|NCT00284622|HTO
610040|NCT00284622|Arthroscopy
610041|NCT00284622|Osteoarthritis
610042|NCT00284622|Alignement
610043|NCT00284622|Varus gonarthrosis
610044|NCT00284609|Type 2 diabetes,
610045|NCT00284609|rehabilitation,
610046|NCT00284609|quality of life,
610047|NCT00284609|glycaemic control,
610048|NCT00284609|lifestyle intervention,
610049|NCT00284609|patient education,
610050|NCT00284609|physical training,
610051|NCT00284609|group visits,
610052|NCT00284609|reminders
610053|NCT00284596|Opening wedge high tibial osteotomy
610054|NCT00284596|Radio Sterometric Analysis
610055|NCT00284596|Locking screw fixation
610056|NCT00284583|Morton's Neuroma
610057|NCT00284583|Alcohol
610058|NCT00284583|Steroid
610059|NCT00284570|pediatrics
610060|NCT00284570|congenital heart disease
610061|NCT00284570|cardiac
610062|NCT00284570|cardiopulmonary bypass
610063|NCT00284570|infection
610064|NCT00284570|sepsis
610065|NCT00284570|postoperative
610066|NCT00284570|marker for infection
610067|NCT00284570|inflammation
610068|NCT00284570|cardiac surgery
610069|NCT00284557|Behavioral/Social
610070|NCT00284557|Obesity
610071|NCT00284557|Pediatrics
610072|NCT00284557|Preventive Medicine
610073|NCT00284531|cardiac transplantation
610074|NCT00284531|allograft rejection
610075|NCT00284531|anti-CD25
610076|NCT00284505|cytokine
610077|NCT00284505|arachnoiditis
610078|NCT00284505|neuropathic pain
610079|NCT00284505|tumor necrosis factor
610080|NCT00284492|Women
610081|NCT00284492|Acupuncture
610082|NCT00284492|Menopause
610083|NCT00284492|Hot flashes
610084|NCT00284492|Health related quality of life
610085|NCT00284479|walking intervention
610086|NCT00284479|cardiovascular risk
610087|NCT00284479|inflammatory markers
610088|NCT00284479|aerobic fitness
610089|NCT00284479|fatness
610090|NCT00284466|coronary artery disease
610091|NCT00284466|cardiac catheterization
610092|NCT00284466|CT coronary angiography
610093|NCT00284466|coronary angiography
610094|NCT00284453|ventricular
610095|NCT00284453|arrhythmias
610096|NCT00284453|ICD
610097|NCT00284453|VT storm
610098|NCT00284453|ICD patients with VT storm
610099|NCT00284440|Visual field progression
610100|NCT00284440|Choroidal blood flow
610101|NCT00284050|DME
610102|NCT00284050|Diabetic macular edema
610103|NCT00284050|ranibizumab
610104|NCT00284050|Diabetic macular edema with center involvement
610105|NCT00284037|obstructive sleep apnea,
610106|NCT00284037|baroreceptors
610107|NCT00284024|breastfeeding
610108|NCT00284024|domperidone
610109|NCT00284024|efficacy
610110|NCT00284024|randomized controlled trial
610111|NCT00284024|compliance
610112|NCT00284011|SAMe
610113|NCT00284011|AdoMet
610114|NCT00284011|Methylation
610115|NCT00284011|Homocysteine
610116|NCT00284011|Dietary Supplement
610117|NCT00284011|S-Adenosyl-L-Methionine
610118|NCT00283998|Odontoid
610119|NCT00283998|Type II fractures
610120|NCT00283998|Elderly patients
610121|NCT00283998|Surgical vs. conservative treatment
610122|NCT00283985|NK/T-cell lymphoma
610123|NCT00283985|Lymphoma
610124|NCT00283985|L-asparaginase
610125|NCT00283985|Nasal NK-cell lymphoma
610126|NCT00283985|Nasal-type NK-cell Lymphoma
610127|NCT00283972|Health Outcome Study
610128|NCT00283946|zolpidem
610129|NCT00283946|sleep initiation and maintenance disorders Hypnotics and sedatives
610130|NCT00283946|double-blind study
610131|NCT00283946|comparative study
610132|NCT00284401|Reversed prosthesis
610133|NCT00283920|Pharmacokinetics
610134|NCT00283920|Compartmental Analysis
610135|NCT00283920|Distribution Volume
610136|NCT00283920|Identitiability
610137|NCT00283920|Healthy Volunteer
610138|NCT00283920|HV
610139|NCT00283907|Electroencephalogram (EEG)
610140|NCT00283907|Sense of Agency
610141|NCT00283907|Coherence
610142|NCT00283907|Voluntary Movement
610143|NCT00283907|Self-Agency
610144|NCT00283907|Healthy Volunteer
610145|NCT00283907|HV
610146|NCT00283894|Obesity
610147|NCT00283894|Leptin
610148|NCT00283894|Sleep Attacks
610149|NCT00283894|Energy Metabolism
610150|NCT00283894|Healthy Control
610151|NCT00283894|Narcolepsy
610152|NCT00283894|Healthy Volunteer
610153|NCT00283894|HV
610154|NCT00283881|Haptic Skills
610155|NCT00283881|Implicit Tactile Learning
610156|NCT00283881|Functional Magnetic Resonance Imaging (fMRI)
610157|NCT00283881|Transcranial Magnetic Stimulation (TMS)
610158|NCT00283881|Transcranial Direct Current Stimulation (tDCS)
610159|NCT00283881|Stroke
610160|NCT00283881|Healthy Volunteer
610161|NCT00283881|HV
610162|NCT00284336|breast cancer
610163|NCT00284336|elderly
610164|NCT00284336|adjuvant chemotherapy
610165|NCT00284336|Caelyx
610166|NCT00284323|Acute Myocardial Infarction
610167|NCT00284323|PCI
610168|NCT00284323|Adenosine
610169|NCT00284323|Postconditioning
610170|NCT00284310|Wrist surgery: 4-corner arthrodesis or proximal row carpectomy
610171|NCT00284271|Hodgkin´s Lymphoma
610172|NCT00284271|eldery patients
610173|NCT00284271|primary diagnosis
610174|NCT00284258|Colorectal Cancer
610175|NCT00283868|stroke
610176|NCT00283868|digital video
610177|NCT00283868|SPOTRIAS
610178|NCT00283855|Rheumatoid Arthritis
610179|NCT00283855|Self-Management
610180|NCT00283855|Internet
610181|NCT00283842|neuropathic pain
610182|NCT00283842|diabetic peripheral neuropathy
610183|NCT00283829|Immunotherapy
610184|NCT00283816|Polycystic Ovary Syndrome
610185|NCT00283816|Overweight Adolescent Girls
610186|NCT00283816|Irregular Menstrual Cycles
610187|NCT00283777|insulin
610188|NCT00283777|glucose
610189|NCT00283777|body weight
610190|NCT00283777|chromium
610191|NCT00283738|migraine
610192|NCT00283738|aura
610193|NCT00283738|Patent Foramen Ovale (PFO)
610194|NCT00283738|cardiac defects
610195|NCT00283738|Heart Septal Defects, Atrial
610196|NCT00283738|Cephalalgia
610197|NCT00283725|Dementia
610198|NCT00283725|Alzheimer's Disease
610199|NCT00283725|Acetylcholinesterase inhibitor
610200|NCT00283725|Galantamine
610201|NCT00283725|Nursing Home Admission
610202|NCT00283712|Skin Diseases
610203|NCT00283712|Autoimmune Diseases
610204|NCT00283699|neurocysticercosis
610205|NCT00283699|albendazole
610206|NCT00283699|tape worm
610207|NCT00283686|polycystic kidney disease
610208|NCT00283686|polycystic
610209|NCT00283686|kidney
610210|NCT00283686|disease
610211|NCT00283686|adpkd
610212|NCT00283686|halt
610213|NCT00283686|pkd
610214|NCT00283686|blood pressure
610215|NCT00283686|bp
610216|NCT00283686|hypertension
610217|NCT00283686|renal
610218|NCT00283686|renin-angiotensin-aldosterone-system
610219|NCT00283686|RAAS
610220|NCT00283660|Zinc
610221|NCT00283660|Dietary Supplements
610222|NCT00283660|Nutritional Supplements
610223|NCT00283660|Child
610224|NCT00283660|Mental Health
610225|NCT00283660|School
610226|NCT00283660|Guatemala
610227|NCT00283647|lead exposure
610228|NCT00283647|magnetic resonance imaging
610229|NCT00283647|magnetic resonance spectroscopy
610230|NCT00283647|functional magnetic resonance
610231|NCT00283647|brain development
610232|NCT00283621|Aranesp
610233|NCT00283621|Darbepoetin Alfa
610234|NCT00283621|Pegfilgrastim
610235|NCT00283621|Neulasta
610236|NCT00283621|Sarcoma
610237|NCT00283621|Adriamycin
610238|NCT00283621|Doxorubicin Hydrocholoride
610239|NCT00283621|Adriamycin PFS
610240|NCT00283621|Adriamycin RDF
610241|NCT00283621|Ifosfamide
610242|NCT00283608|stage I breast cancer
610243|NCT00283608|stage II breast cancer
610244|NCT00283608|stage IIIA breast cancer
610245|NCT00283608|stage IIIB breast cancer
610246|NCT00283608|stage IIIC breast cancer
610247|NCT00283595|Anorexia Nervosa
610248|NCT00283595|Eating disorder
610249|NCT00283595|Bone
610250|NCT00283595|Growth hormone
610251|NCT00283595|Osteopenia
610252|NCT00283595|Osteoporosis
610253|NCT00283569|Glioma
610254|NCT00283556|High Dose Irinotecan
610255|NCT00283556|CPT-11
610256|NCT00283556|Camptosar
610257|NCT00283556|Malignant Glioma
610258|NCT00283556|Unresectable
610259|NCT00283543|Glioma
610260|NCT00283543|Gliadel Wafer
610261|NCT00283530|Cancer
610262|NCT00283530|Cancer receiving chemotherapy
610263|NCT00283530|Tumor biopsy
610264|NCT00283517|Risperidone long-acting injection
610265|NCT00283517|Antipsychotic medication
610266|NCT00283517|Schizophrenia
610267|NCT00283517|Treatment retention
610268|NCT00283517|Observational study
610269|NCT00283491|Iron absorption
610270|NCT00283491|Organic acids
610271|NCT00283491|Lactobacillus
610272|NCT00283491|Probiotic
610273|NCT00283478|Advanced stage
610274|NCT00283478|Lung cancer
610275|NCT00283465|Anemia
610276|NCT00283465|cancer
610277|NCT00283465|neoplasm
610278|NCT00283465|transfusion
610279|NCT00283465|quality of life
610280|NCT00283465|tumor response
610281|NCT00283465|survival
610282|NCT00283465|chemotherapy
610283|NCT00283465|hemoglobin
610284|NCT00283465|standard care
610285|NCT00283465|epoetin alfa
610286|NCT00283465|epoetin
610287|NCT00283465|erythropoietin
610288|NCT00283452|Physical activity maintenance
610289|NCT00283452|Interactive phone and mail-based intervention
610290|NCT00283452|Older adults
610291|NCT00283439|NHL
610292|NCT00283439|chemotherapy induced thrombocytopenia
610293|NCT00283439|CIT
610294|NCT00283439|ICE
610295|NCT00283439|RICE
610296|NCT00283439|Hodgkin's Lymphoma
610297|NCT00283439|Non-Hodgkin's Lymphoma
610298|NCT00283439|CHOP
610299|NCT00283439|ESHAP
610300|NCT00283439|DHAP
610301|NCT00283439|R-CHOP
610302|NCT00283439|R-ESHAP
610303|NCT00283439|R-DHAP
610304|NCT00283413|Covered Stent System
610305|NCT00283413|Saphenous Vein Graft
610306|NCT00283413|Coronary Artery Bypass[MeSH]
610307|NCT00283413|Stents[MeSH]
610308|NCT00283400|subarachnoid hemorrhage
610309|NCT00283400|SAH
610310|NCT00283400|human albumin
610311|NCT00283400|HA
610312|NCT00283400|cerebral vasospasm
610313|NCT00283400|aneurysm
610314|NCT00283400|neuroprotective
610315|NCT00283387|Primary Hyperoxaluria
610316|NCT00283374|Metabolic Syndrome
610317|NCT00283374|Obesity
610318|NCT00283374|Nonalcoholic fatty liver disease
610319|NCT00283374|Nonalcoholic steatohepatitis
610320|NCT00283374|Bariatric Surgery
610321|NCT00283348|Renal Transplantation
610322|NCT00283348|Immunosuppression
610323|NCT00283348|Chronic Rejection
610324|NCT00283322|Heparin Induced Thrombocytopenia
610325|NCT00283322|HIT
610326|NCT00283322|HITT
610327|NCT00283322|Thrombosis
610328|NCT00283322|Thromboembolism
610329|NCT00283309|Corticosteroids
610330|NCT00283309|Riluzole
610331|NCT00283309|Memantine
610332|NCT00283309|Memory
610333|NCT00283296|manual wheelchair
610334|NCT00283296|assistive technology
610335|NCT00283296|travel wheelchair
610336|NCT00283283|Influenza
610337|NCT00283270|Mental health
610338|NCT00283270|Screening
610339|NCT00283270|Elderly
610340|NCT00283270|Chinese
610341|NCT00283270|Problem-solving counselling
610342|NCT00283257|Problem solving
610343|NCT00283257|psychosocial support
610344|NCT00283244|stage IIIB non-small cell lung cancer
610345|NCT00283244|stage IV non-small cell lung cancer
610346|NCT00283231|Hot Flashes
610347|NCT00283231|Menopausal Symptoms
610348|NCT00283231|Paced respiration
610349|NCT00283231|RESPeRATE
610350|NCT00283205|Menopausal Symptoms
610351|NCT00283205|Hot Flashes
610352|NCT00283205|Yoga
610353|NCT00283192|Menopausal Symptoms
610354|NCT00283192|Hot flashes
610355|NCT00283179|Aripiprazole
610356|NCT00283179|Risperidone
610357|NCT00283179|Schizophrenia
610358|NCT00283179|Schizoaffective disorder
610359|NCT00283166|Palliative Care
610360|NCT00283153|Traumatic Brain Injury
610361|NCT00283153|Stroke
610362|NCT00283153|Emotion Recognition
610363|NCT00283153|Affect
610364|NCT00283153|Interventions
610365|NCT00283127|Chlamydia trachomatis
610366|NCT00283127|Mass screening
610367|NCT00283127|Home sampling
610368|NCT00283127|Urine test
610369|NCT00283114|Lintuzumab
610370|NCT00283114|Antigens, CD33
610371|NCT00283114|Antibodies, Monoclonal
610372|NCT00283114|Leukemia, Myeloid, Acute
610373|NCT00283114|Myelodysplastic Syndromes
610374|NCT00283114|Hematologic Diseases
610375|NCT00283114|Myeloproliferative Disorders
610376|NCT00283114|Leukemia
610377|NCT00283101|Antigens, CD40
610378|NCT00283101|Antibody, Monoclonal
610379|NCT00283101|Leukemia, Lymphocytic, Chronic, B-Cell
610380|NCT00283101|Hematologic Diseases
610381|NCT00283101|Immunoproliferatic Disorders
610382|NCT00283101|Lymphatic Diseases
610383|NCT00283101|Lymphoproliferative Disorders
610384|NCT00283101|Leukemia
610385|NCT00283088|stroke
610386|NCT00283088|hypothermia
610387|NCT00283088|cooling
610388|NCT00283088|tissue plasminogen activator
610389|NCT00283088|tPA
610390|NCT00283088|thrombolysis
610391|NCT00283075|intraabdominal cancer (carcinomas)
610392|NCT00283075|agarose macrobeads
610393|NCT00283075|mouse kidney cancer cells
610394|NCT00283075|cancer cell growth inhibition
610395|NCT00283023|All selective craniotomy
610396|NCT00283010|cognitive enhancement
610397|NCT00283010|memory
610398|NCT00283010|auditory memory
610399|NCT00283010|speech
610400|NCT00283010|computerized
610401|NCT00283010|cognitive decline
610402|NCT00282971|Type 2 diabetes melllitus
610403|NCT00282893|aneurysm
610404|NCT00282893|vasospasm
610405|NCT00282893|subarachnoid hemorrhage
610406|NCT00282893|transluminal ballooning
610407|NCT00282867|stroke
610408|NCT00282867|acute ischemic stroke
610409|NCT00282867|hyperglycemia
610410|NCT00282867|glucose
610411|NCT00282867|insulin
610412|NCT00282867|insulin and potassium therapy
610413|NCT00282867|GIK
610414|NCT00282854|epilepsy
610415|NCT00282854|Rolandic epilepsy
610416|NCT00282841|stroke
610417|NCT00282841|ultrasound
610418|NCT00282841|occlusion
610419|NCT00282841|blockage
610420|NCT00282841|contrast solution
610421|NCT00282828|Social Anxiety Disorder
610422|NCT00282828|Pharmacotherapy
610423|NCT00282828|Genetics
610424|NCT00282828|Treatment Refractory
610425|NCT00282815|obstructive sleep apnea
610426|NCT00282815|stroke
610427|NCT00282815|OSA
610428|NCT00282815|CPAP
610429|NCT00282815|continuous positive airway pressure
610430|NCT00282802|Parkinson's Disease
610431|NCT00282802|twins
610432|NCT00282802|SPECT
610433|NCT00282802|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort Registry
610434|NCT00282802|NAS/NRC
610435|NCT00282802|World War II Veteran Twins
610436|NCT00281814|psychosocial effects of cancer and its treatment
610437|NCT00281814|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
610438|NCT00281814|adult acute myeloid leukemia with inv(16)(p13;q22)
610439|NCT00281814|adult acute myeloid leukemia with t(15;17)(q22;q12)
610440|NCT00281814|adult acute myeloid leukemia with t(16;16)(p13;q22)
610441|NCT00281814|adult acute myeloid leukemia with t(8;21)(q22;q22)
610442|NCT00281814|accelerated phase chronic myelogenous leukemia
610443|NCT00281814|adult acute lymphoblastic leukemia in remission
610444|NCT00281814|adult acute myeloid leukemia in remission
610445|NCT00281814|atypical chronic myeloid leukemia
610446|NCT00281814|blastic phase chronic myelogenous leukemia
610447|NCT00281814|chronic idiopathic myelofibrosis
610448|NCT00281814|chronic myelomonocytic leukemia
610449|NCT00281814|chronic phase chronic myelogenous leukemia
610450|NCT00281814|de novo myelodysplastic syndromes
610451|NCT00281814|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
610452|NCT00281814|myelodysplastic/myeloproliferative disease, unclassifiable
610453|NCT00281814|nodal marginal zone B-cell lymphoma
610454|NCT00281814|noncontiguous stage II adult Burkitt lymphoma
610455|NCT00281814|noncontiguous stage II adult diffuse large cell lymphoma
610456|NCT00281814|noncontiguous stage II adult diffuse mixed cell lymphoma
610457|NCT00281814|noncontiguous stage II adult diffuse small cleaved cell lymphoma
610458|NCT00281814|noncontiguous stage II adult immunoblastic large cell lymphoma
610459|NCT00281814|noncontiguous stage II adult lymphoblastic lymphoma
610460|NCT00281814|noncontiguous stage II grade 1 follicular lymphoma
610461|NCT00281814|noncontiguous stage II grade 2 follicular lymphoma
610462|NCT00281814|noncontiguous stage II grade 3 follicular lymphoma
610463|NCT00281814|noncontiguous stage II mantle cell lymphoma
610464|NCT00281814|noncontiguous stage II marginal zone lymphoma
610465|NCT00281814|noncontiguous stage II small lymphocytic lymphoma
610466|NCT00281814|previously treated myelodysplastic syndromes
610467|NCT00281814|recurrent adult acute lymphoblastic leukemia
610468|NCT00281814|recurrent adult acute myeloid leukemia
610469|NCT00281814|recurrent adult Burkitt lymphoma
610470|NCT00281814|recurrent adult Hodgkin lymphoma
610471|NCT00281814|recurrent adult diffuse large cell lymphoma
610472|NCT00281814|recurrent adult diffuse mixed cell lymphoma
610473|NCT00281814|recurrent adult diffuse small cleaved cell lymphoma
610474|NCT00281814|recurrent adult immunoblastic large cell lymphoma
610475|NCT00281814|recurrent adult lymphoblastic lymphoma
610476|NCT00281814|recurrent cutaneous T-cell non-Hodgkin lymphoma
610477|NCT00281814|recurrent grade 1 follicular lymphoma
610478|NCT00281814|recurrent grade 2 follicular lymphoma
610479|NCT00281814|recurrent grade 3 follicular lymphoma
610480|NCT00281814|recurrent mantle cell lymphoma
610481|NCT00281814|recurrent marginal zone lymphoma
610482|NCT00281814|recurrent small lymphocytic lymphoma
610483|NCT00281814|refractory chronic lymphocytic leukemia
610484|NCT00281814|refractory hairy cell leukemia
610485|NCT00281814|relapsing chronic myelogenous leukemia
610486|NCT00281814|secondary acute myeloid leukemia
610487|NCT00281814|secondary myelodysplastic syndromes
610488|NCT00281814|splenic marginal zone lymphoma
610489|NCT00281814|stage I multiple myeloma
610490|NCT00281814|stage II multiple myeloma
610491|NCT00281814|stage III adult Burkitt lymphoma
610492|NCT00281814|stage III adult Hodgkin lymphoma
610493|NCT00281814|stage III adult diffuse large cell lymphoma
610494|NCT00281814|stage III adult diffuse mixed cell lymphoma
610495|NCT00281814|stage III adult diffuse small cleaved cell lymphoma
610496|NCT00281814|stage III adult immunoblastic large cell lymphoma
610497|NCT00281814|stage III adult lymphoblastic lymphoma
610498|NCT00281814|stage III chronic lymphocytic leukemia
610499|NCT00281814|stage III grade 1 follicular lymphoma
610500|NCT00281814|stage III grade 2 follicular lymphoma
610501|NCT00281814|stage III grade 3 follicular lymphoma
610502|NCT00281814|stage III mantle cell lymphoma
610503|NCT00281814|stage III marginal zone lymphoma
610504|NCT00281814|stage III multiple myeloma
610505|NCT00281814|stage III small lymphocytic lymphoma
610506|NCT00281814|stage IV adult Burkitt lymphoma
610507|NCT00281814|stage IV adult Hodgkin lymphoma
610508|NCT00281814|stage IV adult diffuse large cell lymphoma
610509|NCT00281814|stage IV adult diffuse mixed cell lymphoma
610510|NCT00281814|stage IV adult diffuse small cleaved cell lymphoma
610511|NCT00281814|stage IV adult immunoblastic large cell lymphoma
610512|NCT00281814|stage IV adult lymphoblastic lymphoma
610513|NCT00281814|stage IV chronic lymphocytic leukemia
610514|NCT00281814|stage IV grade 1 follicular lymphoma
610515|NCT00281814|stage IV grade 2 follicular lymphoma
610516|NCT00281814|stage IV grade 3 follicular lymphoma
610517|NCT00281814|stage IV mantle cell lymphoma
610518|NCT00281814|stage IV marginal zone lymphoma
610519|NCT00281814|stage IV small lymphocytic lymphoma
610520|NCT00281801|psychosocial effects of cancer and its treatment
610521|NCT00281801|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
610522|NCT00281801|adult acute myeloid leukemia with inv(16)(p13;q22)
610523|NCT00281801|adult acute myeloid leukemia with t(15;17)(q22;q12)
610524|NCT00281801|adult acute myeloid leukemia with t(16;16)(p13;q22)
610525|NCT00281801|adult acute myeloid leukemia with t(8;21)(q22;q22)
610526|NCT00281801|accelerated phase chronic myelogenous leukemia
610527|NCT00281801|adult acute lymphoblastic leukemia in remission
610528|NCT00281801|adult acute myeloid leukemia in remission
610529|NCT00281801|atypical chronic myeloid leukemia
610530|NCT00281801|blastic phase chronic myelogenous leukemia
610531|NCT00281801|chronic idiopathic myelofibrosis
610532|NCT00281801|chronic myelomonocytic leukemia
610533|NCT00281801|chronic phase chronic myelogenous leukemia
610534|NCT00281801|de novo myelodysplastic syndromes
610535|NCT00281801|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
610536|NCT00281801|myelodysplastic/myeloproliferative disease, unclassifiable
610537|NCT00281801|nodal marginal zone B-cell lymphoma
610538|NCT00281801|noncontiguous stage II adult Burkitt lymphoma
610539|NCT00281801|noncontiguous stage II adult diffuse large cell lymphoma
610540|NCT00281801|noncontiguous stage II adult diffuse mixed cell lymphoma
610541|NCT00281801|noncontiguous stage II adult diffuse small cleaved cell lymphoma
610542|NCT00281801|noncontiguous stage II adult immunoblastic large cell lymphoma
610543|NCT00281801|noncontiguous stage II adult lymphoblastic lymphoma
610544|NCT00281801|noncontiguous stage II grade 1 follicular lymphoma
610545|NCT00281801|noncontiguous stage II grade 2 follicular lymphoma
610546|NCT00281801|noncontiguous stage II grade 3 follicular lymphoma
610547|NCT00281801|noncontiguous stage II mantle cell lymphoma
610548|NCT00281801|noncontiguous stage II marginal zone lymphoma
610549|NCT00281801|noncontiguous stage II small lymphocytic lymphoma
610550|NCT00281801|previously treated myelodysplastic syndromes
610551|NCT00281801|recurrent adult acute lymphoblastic leukemia
610552|NCT00281801|recurrent adult acute myeloid leukemia
610553|NCT00281801|recurrent adult Burkitt lymphoma
610554|NCT00281801|recurrent adult Hodgkin lymphoma
610555|NCT00281801|recurrent adult diffuse large cell lymphoma
610556|NCT00281801|recurrent adult diffuse mixed cell lymphoma
610557|NCT00281801|recurrent adult diffuse small cleaved cell lymphoma
610558|NCT00281801|recurrent adult immunoblastic large cell lymphoma
610559|NCT00281801|recurrent adult lymphoblastic lymphoma
610560|NCT00281801|recurrent cutaneous T-cell non-Hodgkin lymphoma
610561|NCT00281801|recurrent grade 1 follicular lymphoma
610562|NCT00281801|recurrent grade 2 follicular lymphoma
610563|NCT00281801|recurrent grade 3 follicular lymphoma
610564|NCT00281801|recurrent mantle cell lymphoma
610565|NCT00281801|recurrent marginal zone lymphoma
610566|NCT00281801|recurrent small lymphocytic lymphoma
610567|NCT00281801|refractory chronic lymphocytic leukemia
610568|NCT00281801|refractory hairy cell leukemia
610569|NCT00281801|relapsing chronic myelogenous leukemia
610570|NCT00281801|secondary acute myeloid leukemia
610571|NCT00281801|secondary myelodysplastic syndromes
610572|NCT00281801|splenic marginal zone lymphoma
610573|NCT00281801|stage I multiple myeloma
610574|NCT00281801|stage II multiple myeloma
610575|NCT00281801|stage III adult Burkitt lymphoma
610576|NCT00281801|stage III adult Hodgkin lymphoma
610577|NCT00281801|stage III adult diffuse large cell lymphoma
610578|NCT00281801|stage III adult diffuse mixed cell lymphoma
610579|NCT00281801|stage III adult diffuse small cleaved cell lymphoma
610580|NCT00281801|stage III adult immunoblastic large cell lymphoma
610581|NCT00281801|stage III adult lymphoblastic lymphoma
610582|NCT00281801|stage III chronic lymphocytic leukemia
610583|NCT00281801|stage III grade 1 follicular lymphoma
610584|NCT00281801|stage III grade 2 follicular lymphoma
610585|NCT00281801|stage III grade 3 follicular lymphoma
610586|NCT00281801|stage III mantle cell lymphoma
610587|NCT00281801|stage III marginal zone lymphoma
610588|NCT00281801|stage III multiple myeloma
610589|NCT00281801|stage III small lymphocytic lymphoma
610590|NCT00281801|stage IV adult Burkitt lymphoma
610591|NCT00281801|stage IV adult Hodgkin lymphoma
610592|NCT00281801|stage IV adult diffuse large cell lymphoma
610593|NCT00281801|stage IV adult diffuse mixed cell lymphoma
610594|NCT00281801|stage IV adult diffuse small cleaved cell lymphoma
610595|NCT00281801|stage IV adult immunoblastic large cell lymphoma
610596|NCT00281801|stage IV adult lymphoblastic lymphoma
610597|NCT00281801|stage IV chronic lymphocytic leukemia
610598|NCT00281801|stage IV grade 1 follicular lymphoma
610599|NCT00281801|stage IV grade 2 follicular lymphoma
610600|NCT00281801|stage IV grade 3 follicular lymphoma
610601|NCT00281801|stage IV mantle cell lymphoma
610602|NCT00281801|stage IV marginal zone lymphoma
610603|NCT00281801|stage IV small lymphocytic lymphoma
610604|NCT00281788|stage I esophageal cancer
610605|NCT00281788|stage II esophageal cancer
610606|NCT00281788|stage III esophageal cancer
610607|NCT00281762|AQP-2
610608|NCT00281762|NSAID
610609|NCT00281762|Urinary concentrating ability
610610|NCT00281749|ALZHEIMER'S D-SE
610611|NCT00281749|PARKINSON'S D-SE
610612|NCT00281749|FRAILTY
610613|NCT00281736|adenocarcinoma of the esophagus
610614|NCT00281736|recurrent esophageal cancer
610615|NCT00281736|stage 0 esophageal cancer
610616|NCT00281736|stage I esophageal cancer
610617|NCT00281736|precancerous condition
610618|NCT00281723|Aphthous
610619|NCT00281723|oral
610620|NCT00281710|AQP-2
610621|NCT00281710|Methylprednisolone
610622|NCT00281710|Urinary concentrating ability
610623|NCT00281697|Ribbon 2
610624|NCT00281697|Avastin
610625|NCT00281697|MBC
610626|NCT00281697|Breast cancer
610627|NCT00281684|Acute Pain
610628|NCT00281684|Dental Pain
610629|NCT00281684|Vanilloid
610630|NCT00281684|VR1
610631|NCT00281684|TRPV1
610632|NCT00281684|Inflammation
610633|NCT00281671|Nesiritide
610634|NCT00281671|Natriuretic Peptide, Brain
610635|NCT00281671|Heart Defects, Congenital
610636|NCT00281671|Cardiopulmonary Bypass
610637|NCT00281671|Diuretics
610638|NCT00281658|ErbB2 positive
610639|NCT00281658|Her2+
610640|NCT00281658|metastatic breast cancer
610641|NCT00281658|FISH positive
610642|NCT00281658|Stage IV
610643|NCT00281632|Pazopanib
610644|NCT00281632|Fallopian tube cancer
610645|NCT00281632|Ovarian epithelial cancer
610646|NCT00281632|Peritoneal cancer
610647|NCT00281619|Pediatric Kidney Transplant
610648|NCT00281619|Kidney Transplant
610649|NCT00281619|CellCept
610650|NCT00281619|Mycophenolate mofetil
610651|NCT00281619|Mycophenolic Acid
610652|NCT00281619|MPA
610653|NCT00281606|Lopinavir
610654|NCT00281606|antiretroviral therapy
610655|NCT00281606|cross-over
610656|NCT00281606|tolerability
610657|NCT00282776|Postpartum Depression
610658|NCT00282776|Telephone Care Management
610659|NCT00282776|Screening for Postpartum Depression
610660|NCT00282750|"Surgery[MeSH]"
610661|NCT00282750|"Surgical Sponges[MeSH]"
610662|NCT00282750|"Automatic Data Processing[MeSH]"
610663|NCT00282724|Lamellar ichthyosis
610664|NCT00282724|Liarozole
610665|NCT00282724|Investigator's Global Assessment
610666|NCT00282724|Scaling
610667|NCT00282711|Diagnostic Techniques, Radioisotope
610668|NCT00282711|Radionuclide Imaging
610669|NCT00282711|Diagnostic Techniques, Cardiovascular
610670|NCT00282711|Heart Function tests
610671|NCT00282685|Patients with symmetric peripheral diabetic neuropathy
610672|NCT00282672|Barrett's Esophagus
610673|NCT00282672|Dysplasia
610674|NCT00282672|Radiofrequency Ablation
610675|NCT00282659|Hemodynamics
610676|NCT00282659|Hypertension
610677|NCT00282659|Dyslipidemia
610678|NCT00282659|Diabetes
610679|NCT00282659|Implantable Cardioverter Defibrillator
610680|NCT00282659|Blood Pressure
610681|NCT00282646|critical limb ischemia
610682|NCT00282646|peripheral arterial occlusive disease
610683|NCT00282646|[C14.907.137]
610684|NCT00282633|Cesarean Delivery
610685|NCT00282633|Wound closure
610686|NCT00282633|Suture
610687|NCT00282633|Alternative therapy
610688|NCT00282633|Surgery
610689|NCT00282620|Implantable Cardioverter Defibrillator
610690|NCT00282620|Magnesium
610691|NCT00282620|Electrocardiogram
610692|NCT00282620|Ventricular Arrhythmia
610693|NCT00282607|Erectile Dysfunction
610694|NCT00282594|Intensive Insulin Therapy
610695|NCT00282594|General Surgical
610696|NCT00282594|Vascular Surgical
610697|NCT00282594|Tight Glycemic Control
610698|NCT00282581|HIV
610699|NCT00282581|Smallpox
610700|NCT00282581|MVA
610701|NCT00282568|Pharmacokinetics
610702|NCT00282568|Therapy
610703|NCT00282568|Immunosuppression
610704|NCT00282568|Drugs, Investigational
610705|NCT00282568|Adult
610706|NCT00282555|Esophagitis, Reflux
610707|NCT00282555|S-Tenatoprazole-Na
610708|NCT00282555|Heartburn
610709|NCT00282555|Esophageal endoscopy
610710|NCT00282542|Hepatocytes
610711|NCT00282529|lymphedema, screening, treatment
610712|NCT00282516|asthma
610713|NCT00282516|telemedicine
610714|NCT00282516|case management
610715|NCT00282516|clinic
610716|NCT00282516|children
610717|NCT00282516|pediatric
610718|NCT00282503|aGvHD
610719|NCT00282490|Overactive bladder
610720|NCT00282490|Children
610721|NCT00282490|Nerve stimulation
610722|NCT00282490|TENS
610723|NCT00282477|cyclist
610724|NCT00282464|Bipolar I Depression
610725|NCT00282399|Myelodysplastic Syndrome
610726|NCT00282399|MGI Pharma
610727|NCT00282399|Decitabine
610728|NCT00282399|Dacogen
610729|NCT00282360|coronary artery disease
610730|NCT00282360|diabetes mellitus
610731|NCT00282347|Class IV LN
610732|NCT00282347|Lupus
610733|NCT00282347|LUNAR
610734|NCT00282347|LN
610735|NCT00282334|Telemedicine
610736|NCT00282334|Blood pressure
610737|NCT00282334|Quality of life
610738|NCT00282334|Cost-effectiveness
610739|NCT00282308|RA
610740|NCT00282308|Rituxan
610741|NCT00282308|SIERRA
610742|NCT00282295|tetanus
610743|NCT00282295|pertussis
610744|NCT00282295|Prophylaxis
610745|NCT00282295|meningococcus
610746|NCT00282295|diptheria
610747|NCT00282282|non-myeloablative peripheral blood stem cell
610748|NCT00282282|PBSCT
610749|NCT00282282|tacrolimus
610750|NCT00282282|sirolimus
610751|NCT00282269|Traumatic Brain Injury
610752|NCT00282269|Children
610753|NCT00282269|Hypothermia
610754|NCT00282269|Outcome
610755|NCT00282269|Intensive Care
610756|NCT00282269|Magnetic resonance Imaging
610757|NCT00282256|Child
610758|NCT00282256|Pharmacokinetics
610759|NCT00282256|Immunosuppression Drugs
610760|NCT00282256|Hepatic transplant
610761|NCT00282256|Liver Transplantation
610762|NCT00282243|Pharmacokinetics
610763|NCT00282243|Therapy
610764|NCT00282243|Immunosuppression
610765|NCT00282243|Drugs, Investigational
610766|NCT00282243|Adult
610767|NCT00282230|Malononitrilamide
610768|NCT00282230|immunosuppression
610769|NCT00282230|treatment efficacy
610770|NCT00282230|treatment outcome
610771|NCT00282217|Kidney Failure
610772|NCT00282217|Kidney Transplant
610773|NCT00282217|Graft Rejection
610774|NCT00282217|Kidney Transplantation
610775|NCT00282204|Hypnosis
610776|NCT00282204|Hypnotherapy
610777|NCT00282204|Childbirth
610778|NCT00282204|Analgesia
610779|NCT00282191|spasticity
610780|NCT00282191|mental retardation
610781|NCT00282178|Metabolic
610782|NCT00282178|Hypertension
610783|NCT00282178|Abdominal obesity
610784|NCT00282178|Insulin sensitivity
610785|NCT00282178|Hyperinsulinemic euglycemic clamp
610786|NCT00282152|Early Stage Parkinson's Disease
610787|NCT00282152|Parkinson's Disease
610788|NCT00282152|Deep Brain Stimulation
610789|NCT00282152|PD
610790|NCT00282152|DBS
610791|NCT00282126|Calcium balance
610792|NCT00282113|Probiotic
610793|NCT00282113|Prebiotic
610794|NCT00282113|NEC
610795|NCT00282113|Premature infants
610796|NCT00282113|commensal flora
610797|NCT00282087|early stage
610798|NCT00282087|high grade
610799|NCT00282087|uterine leiomyosarcoma
610800|NCT00282087|adjuvant treatment
610801|NCT00282061|3 conditions in a within-subject design:
610802|NCT00282061|1-ad-lib sleep wake
610803|NCT00282061|2-forced morning wake-up
610804|NCT00282061|3- ad-lib sleep wake after treatment with melatonin
610805|NCT00282035|breast cancer
610806|NCT00282035|breast tumour
610807|NCT00282035|DCIS
610808|NCT00282035|female
610809|NCT00282035|breast conserving surgery
610810|NCT00282035|irradiation
610811|NCT00282035|whole breast irradiation
610812|NCT00282035|3D CRT accelerated partial breast irradiation
610813|NCT00282035|cosmetic outcome
610814|NCT00282035|quality of life
610815|NCT00282022|recurrent small cell lung cancer
610816|NCT00282022|extensive stage small cell lung cancer
610817|NCT00282022|limited stage small cell lung cancer
610818|NCT00282009|unspecified adult solid tumor, protocol specific
610819|NCT00281996|recurrent pancreatic cancer
610820|NCT00281996|stage III pancreatic cancer
610821|NCT00281996|stage IV pancreatic cancer
610822|NCT00281983|B-cell chronic lymphocytic leukemia
610823|NCT00281983|refractory chronic lymphocytic leukemia
610824|NCT00281983|stage III chronic lymphocytic leukemia
610825|NCT00281983|stage IV chronic lymphocytic leukemia
610826|NCT00281983|Waldenström macroglobulinemia
610827|NCT00281970|stage I non-small cell lung cancer
610828|NCT00281970|stage II non-small cell lung cancer
610829|NCT00281970|stage IIIA non-small cell lung cancer
610830|NCT00281970|stage IIIB non-small cell lung cancer
610831|NCT00281931|prolymphocytic leukemia
610832|NCT00281918|B-cell chronic lymphocytic leukemia
610833|NCT00281918|stage I chronic lymphocytic leukemia
610834|NCT00281918|stage II chronic lymphocytic leukemia
610835|NCT00281918|stage III chronic lymphocytic leukemia
610836|NCT00281918|stage IV chronic lymphocytic leukemia
610837|NCT00281905|untreated childhood brain stem glioma
610838|NCT00281905|childhood high-grade cerebral astrocytoma
610839|NCT00281905|childhood low-grade cerebral astrocytoma
610840|NCT00281905|untreated childhood cerebellar astrocytoma
610841|NCT00281905|childhood choroid plexus tumor
610842|NCT00281905|childhood infratentorial ependymoma
610843|NCT00281905|childhood supratentorial ependymoma
610844|NCT00281905|newly diagnosed childhood ependymoma
610845|NCT00281905|untreated childhood medulloblastoma
610846|NCT00281905|childhood oligodendroglioma
610847|NCT00281905|untreated childhood supratentorial primitive neuroectodermal tumor
610848|NCT00281905|disseminated neuroblastoma
610849|NCT00281905|localized resectable neuroblastoma
610850|NCT00281905|localized unresectable neuroblastoma
610851|NCT00281905|regional neuroblastoma
610852|NCT00281905|stage 4S neuroblastoma
610853|NCT00281892|anemia
610854|NCT00281892|refractory chronic lymphocytic leukemia
610855|NCT00281892|stage 0 chronic lymphocytic leukemia
610856|NCT00281892|stage I chronic lymphocytic leukemia
610857|NCT00281892|stage II chronic lymphocytic leukemia
610858|NCT00281892|stage III chronic lymphocytic leukemia
610859|NCT00281892|stage IV chronic lymphocytic leukemia
610860|NCT00281879|adult acute lymphoblastic leukemia in remission
610861|NCT00281879|L1 adult acute lymphoblastic leukemia
610862|NCT00281879|L2 adult acute lymphoblastic leukemia
610863|NCT00281879|L3 adult acute lymphoblastic leukemia
610864|NCT00281879|recurrent adult acute lymphoblastic leukemia
610865|NCT00281879|accelerated phase chronic myelogenous leukemia
610866|NCT00281879|blastic phase chronic myelogenous leukemia
610867|NCT00281879|chronic phase chronic myelogenous leukemia
610868|NCT00281879|relapsing chronic myelogenous leukemia
610869|NCT00281879|childhood acute lymphoblastic leukemia in remission
610870|NCT00281879|L1 childhood acute lymphoblastic leukemia
610871|NCT00281879|L2 childhood acute lymphoblastic leukemia
610872|NCT00281879|L3 childhood acute lymphoblastic leukemia
610873|NCT00281879|recurrent childhood acute lymphoblastic leukemia
610874|NCT00281879|recurrent adult Hodgkin lymphoma
610875|NCT00281879|recurrent/refractory childhood Hodgkin lymphoma
610876|NCT00281879|stage IV adult Hodgkin lymphoma
610877|NCT00281879|stage IV childhood Hodgkin lymphoma
610878|NCT00281879|adult acute myeloid leukemia in remission
610879|NCT00281879|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
610880|NCT00281879|adult acute myeloid leukemia with t(15;17)(q22;q12)
610881|NCT00281879|adult acute myeloid leukemia with t(16;16)(p13;q22)
610882|NCT00281879|childhood acute myeloid leukemia in remission
610883|NCT00281879|recurrent adult acute myeloid leukemia
610884|NCT00281879|recurrent childhood acute myeloid leukemia
610885|NCT00281879|myelodysplastic/myeloproliferative neoplasm, unclassifiable
610886|NCT00281879|previously treated myelodysplastic syndromes
610887|NCT00281879|secondary myelodysplastic syndromes
610888|NCT00281879|secondary acute myeloid leukemia
610889|NCT00281879|refractory anemia with excess blasts in transformation
610890|NCT00281879|refractory anemia with excess blasts
610891|NCT00281879|refractory anemia
610892|NCT00281879|chronic myelomonocytic leukemia
610893|NCT00281879|childhood chronic myelogenous leukemia
610894|NCT00281879|chronic eosinophilic leukemia
610895|NCT00281879|primary myelofibrosis
610896|NCT00281879|chronic neutrophilic leukemia
610897|NCT00281879|de novo myelodysplastic syndromes
610898|NCT00281879|atypical chronic myeloid leukemia, BCR-ABL negative
610899|NCT00281879|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
610900|NCT00281879|juvenile myelomonocytic leukemia
610901|NCT00281879|nodal marginal zone B-cell lymphoma
610902|NCT00281879|noncontiguous stage II adult Burkitt lymphoma
610903|NCT00281879|noncontiguous stage II adult diffuse large cell lymphoma
610904|NCT00281879|noncontiguous stage II adult diffuse mixed cell lymphoma
610905|NCT00281879|noncontiguous stage II adult diffuse small cleaved cell lymphoma
610906|NCT00281879|noncontiguous stage II adult immunoblastic large cell lymphoma
610907|NCT00281879|noncontiguous stage II adult lymphoblastic lymphoma
610908|NCT00281879|noncontiguous stage II grade 1 follicular lymphoma
610909|NCT00281879|noncontiguous stage II grade 2 follicular lymphoma
610910|NCT00281879|noncontiguous stage II grade 3 follicular lymphoma
610911|NCT00281879|noncontiguous stage II mantle cell lymphoma
610912|NCT00281879|noncontiguous stage II marginal zone lymphoma
610913|NCT00281879|noncontiguous stage II small lymphocytic lymphoma
610914|NCT00281879|recurrent adult Burkitt lymphoma
610915|NCT00281879|recurrent adult diffuse large cell lymphoma
610916|NCT00281879|recurrent adult diffuse mixed cell lymphoma
610917|NCT00281879|recurrent adult diffuse small cleaved cell lymphoma
610918|NCT00281879|recurrent adult immunoblastic large cell lymphoma
610919|NCT00281879|recurrent adult lymphoblastic lymphoma
610920|NCT00281879|recurrent childhood large cell lymphoma
610921|NCT00281879|recurrent childhood lymphoblastic lymphoma
610922|NCT00281879|recurrent childhood small noncleaved cell lymphoma
610923|NCT00281879|recurrent grade 1 follicular lymphoma
610924|NCT00281879|recurrent grade 2 follicular lymphoma
610925|NCT00281879|recurrent grade 3 follicular lymphoma
610926|NCT00281879|recurrent mantle cell lymphoma
610927|NCT00281879|recurrent marginal zone lymphoma
610928|NCT00281879|recurrent small lymphocytic lymphoma
610929|NCT00281879|refractory chronic lymphocytic leukemia
610930|NCT00281879|refractory hairy cell leukemia
610931|NCT00281879|refractory multiple myeloma
610932|NCT00281879|splenic marginal zone lymphoma
610933|NCT00281879|stage I multiple myeloma
610934|NCT00281879|stage II multiple myeloma
610935|NCT00281879|stage III adult Burkitt lymphoma
610936|NCT00281879|stage III adult Hodgkin lymphoma
610937|NCT00281879|stage III adult diffuse large cell lymphoma
610938|NCT00281879|stage III adult diffuse mixed cell lymphoma
610939|NCT00281879|stage III adult diffuse small cleaved cell lymphoma
610940|NCT00281879|stage III adult immunoblastic large cell lymphoma
610941|NCT00281879|stage III adult lymphoblastic lymphoma
610942|NCT00281879|stage III chronic lymphocytic leukemia
610943|NCT00281879|stage III grade 1 follicular lymphoma
610944|NCT00281879|stage III grade 2 follicular lymphoma
610945|NCT00281879|stage III grade 3 follicular lymphoma
610946|NCT00281879|stage III mantle cell lymphoma
610947|NCT00281879|stage III marginal zone lymphoma
610948|NCT00281879|stage III multiple myeloma
610949|NCT00281879|stage III small lymphocytic lymphoma
610950|NCT00281879|stage IV adult Burkitt lymphoma
610951|NCT00281879|stage IV adult diffuse large cell lymphoma
610952|NCT00281879|stage IV adult diffuse mixed cell lymphoma
610953|NCT00281879|stage IV adult diffuse small cleaved cell lymphoma
610954|NCT00281879|stage IV adult immunoblastic large cell lymphoma
610955|NCT00281879|stage IV adult lymphoblastic lymphoma
610956|NCT00281879|stage IV chronic lymphocytic leukemia
610957|NCT00281879|stage IV grade 1 follicular lymphoma
610958|NCT00281879|stage IV grade 2 follicular lymphoma
610959|NCT00281879|stage IV grade 3 follicular lymphoma
610960|NCT00281879|stage IV mantle cell lymphoma
610961|NCT00281879|stage IV marginal zone lymphoma
610962|NCT00281879|stage IV small lymphocytic lymphoma
610963|NCT00281879|stage III childhood Hodgkin lymphoma
610964|NCT00281879|stage III childhood large cell lymphoma
610965|NCT00281879|stage III childhood lymphoblastic lymphoma
610966|NCT00281879|stage III childhood small noncleaved cell lymphoma
610967|NCT00281879|stage IV childhood large cell lymphoma
610968|NCT00281879|stage IV childhood lymphoblastic lymphoma
610969|NCT00281879|stage IV childhood small noncleaved cell lymphoma
610970|NCT00281879|unusual cancers of childhood
610971|NCT00281879|childhood myelodysplastic syndromes
610972|NCT00281866|stage IV squamous cell carcinoma of the hypopharynx
610973|NCT00281866|stage IV squamous cell carcinoma of the larynx
610974|NCT00281866|stage IV squamous cell carcinoma of the lip and oral cavity
610975|NCT00281866|stage IV squamous cell carcinoma of the nasopharynx
610976|NCT00281866|stage IV squamous cell carcinoma of the oropharynx
610977|NCT00281866|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
610978|NCT00281866|recurrent squamous cell carcinoma of the hypopharynx
610979|NCT00281866|recurrent squamous cell carcinoma of the larynx
610980|NCT00281866|recurrent squamous cell carcinoma of the lip and oral cavity
610981|NCT00281866|recurrent squamous cell carcinoma of the nasopharynx
610982|NCT00281866|recurrent squamous cell carcinoma of the oropharynx
610983|NCT00281866|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
610984|NCT00281866|recurrent metastatic squamous neck cancer with occult primary
610985|NCT00281866|metastatic squamous neck cancer with occult primary squamous cell carcinoma
610986|NCT00281853|neurotoxicity
610987|NCT00281853|unspecified adult solid tumor, protocol specific
610988|NCT00281840|stage III squamous cell carcinoma of the hypopharynx
610989|NCT00281840|stage IV squamous cell carcinoma of the hypopharynx
610990|NCT00281840|stage III squamous cell carcinoma of the larynx
610991|NCT00281840|stage IV squamous cell carcinoma of the larynx
610992|NCT00281840|stage III squamous cell carcinoma of the lip and oral cavity
610993|NCT00281840|stage IV squamous cell carcinoma of the lip and oral cavity
610994|NCT00281840|stage III squamous cell carcinoma of the nasopharynx
610995|NCT00281840|stage IV squamous cell carcinoma of the nasopharynx
610996|NCT00281840|stage III squamous cell carcinoma of the oropharynx
610997|NCT00281840|stage IV squamous cell carcinoma of the oropharynx
610998|NCT00281827|adenocarcinoma of the lung
610999|NCT00281827|squamous cell lung cancer
611000|NCT00281827|large cell lung cancer
611001|NCT00281827|stage II non-small cell lung cancer
611002|NCT00281827|stage IIIA non-small cell lung cancer
611003|NCT00281554|Investigational Therapies
611004|NCT00281554|Atrial Fibrillation
611005|NCT00281554|Treatment Efficacy
611006|NCT00281554|Treatment Effectiveness
611007|NCT00281554|Safety
611008|NCT00281554|RSD1235
611009|NCT00281541|Treatment Efficacy
611010|NCT00281541|Treatment Effectiveness
611011|NCT00281541|Disease Management
611012|NCT00281541|Treatment
611013|NCT00281541|Safety
611014|NCT00281541|Malignant Melanoma
611015|NCT00281528|First Line Metastatic Breast Cancer
611016|NCT00281502|Hepatic Encephalopathy
611017|NCT00281502|Hepatitis C
611018|NCT00281502|Liver Cirrhosis
611019|NCT00281502|Bacterial Overgrowth
611020|NCT00281489|Recall
611021|NCT00281489|Awareness
611022|NCT00281489|BIS
611023|NCT00281489|Anesthesia
611024|NCT00281489|Explicit Recall
611025|NCT00281476|multiple myeloma
611026|NCT00281476|statins
611027|NCT00281476|bone
611028|NCT00281463|wheelchair
611029|NCT00281463|spinal cord injury
611030|NCT00281463|rehabilitation
611031|NCT00281437|exercise
611032|NCT00281437|adherence
611033|NCT00281437|lifestyle
611034|NCT00281437|choice
611035|NCT00281437|autonomy
611036|NCT00281424|exercise adherence
611037|NCT00281424|cardiac patients
611038|NCT00281424|walking
611039|NCT00281411|Blood Vessel Prosthesis Implantation
611040|NCT00281411|Endovascular aneurysm repair
611041|NCT00281411|Magnetic Resonance Angiography
611042|NCT00281411|Computed Tomography Angiography
611043|NCT00281411|Endoleak
611044|NCT00281398|homelessness
611045|NCT00281398|Attitudes of medical trainees towards the homeless
611046|NCT00281385|adherence
611047|NCT00281385|lifestyle
611048|NCT00281385|exercise
611049|NCT00281385|pedometer
611050|NCT00281385|training
611051|NCT00281372|sexual dysfunction
611052|NCT00281372|male
611053|NCT00281372|female
611054|NCT00281372|dental care
611055|NCT00281372|need of control
611056|NCT00281359|cerebral palsy
611057|NCT00281359|dynamic splinting
611058|NCT00281359|contractures
611059|NCT00281359|heat therapy
611060|NCT00281346|Doppler echocardiography
611061|NCT00281346|coronary stenosis
611062|NCT00281346|Coronary angiography
611063|NCT00281307|Rhinitis
611064|NCT00281307|Vitamin E
611065|NCT00281307|Intranasal
611066|NCT00281294|Arthritis, Rheumatoid
611067|NCT00281281|Extracorporeal Membrane Oxygenation
611068|NCT00281281|vancomycin
611069|NCT00281242|Chronic Obstructive Pulmonary Disease
611070|NCT00281242|COPD
611071|NCT00281229|Chronic Obstructive Pulmonary Disease
611072|NCT00281229|COPD
611073|NCT00281216|Chronic Obstructive Pulmonary Disease
611074|NCT00281216|COPD
611075|NCT00281203|Chronic Obstructive Pulmonary Disease
611076|NCT00281203|COPD
611077|NCT00281190|Chronic Obstructive Pulmonary Disease
611078|NCT00281190|COPD
611079|NCT00281125|Non-Small Cell Lung Cancer
611080|NCT00281125|Pleural Mesothelioma
611081|NCT00281099|ICD
611082|NCT00281099|Pacing
611083|NCT00281099|Heart Failure
611084|NCT00281073|Intra-Cardiac Echocardiography
611085|NCT00281073|Cardioversion
611086|NCT00281060|endovascular
611087|NCT00281060|balloon angioplasty
611088|NCT00281060|stents
611089|NCT00281047|Helicobacter pylori (H. pylori)
611090|NCT00281047|FP-10
611091|NCT00281047|amoxicillin
611092|NCT00281047|clarithromycin
611093|NCT00281047|lansoprazole
611094|NCT00281034|brain infarction
611095|NCT00281034|SF-36
611096|NCT00281034|HRQOL
611097|NCT00281034|Japan
611098|NCT00281034|Post-stroke syndrome
611099|NCT00281021|non-small cell lung cancer
611100|NCT00281021|Erlotinib
611101|NCT00281021|Digoxin
611102|NCT00281008|LDL-cholesterol
611103|NCT00281008|apoB-100
611104|NCT00281008|Heterozygous Familial Hypercholesterolemia
611105|NCT00280995|LDL-cholesterol
611106|NCT00280995|apoB-100
611107|NCT00280995|Homozygous Familial Hypercholesterolemia
611108|NCT00280982|dendritic cells, immunotherapy, vaccination, mesothelioma
611109|NCT00280969|HIV infection
611110|NCT00280969|treatment
611111|NCT00280969|efavirenz
611112|NCT00280969|atazanavir
611113|NCT00280969|ritonavir
611114|NCT00280943|All NC LTC facilities having ten residents with a hip fracture or osteoporosis on the MDS will be invited to participate in the trial
611115|NCT00280930|letrozole
611116|NCT00280930|breast cancer
611117|NCT00280930|menopause
611118|NCT00280917|Rheumatoid Arthritis
611119|NCT00280917|RA
611120|NCT00280904|Hydrocephalus
611121|NCT00280904|Shunt
611122|NCT00280891|head and neck
611123|NCT00280891|cancer
611124|NCT00280891|palliation
611125|NCT00280891|radiotherapy
611126|NCT00280878|Lymphoma
611127|NCT00280878|CD20+
611128|NCT00280865|Tesaglitazar
611129|NCT00280865|type 2 diabetes
611130|NCT00280176|recurrent rectal cancer
611131|NCT00280176|stage II rectal cancer
611132|NCT00280176|stage III rectal cancer
611133|NCT00280176|stage IV rectal cancer
611134|NCT00280176|adenocarcinoma of the rectum
611135|NCT00280163|Genomics, cardiac surgery
611136|NCT00280150|stage IIIA non-small cell lung cancer
611137|NCT00280150|stage IIIB non-small cell lung cancer
611138|NCT00280150|recurrent non-small cell lung cancer
611139|NCT00280150|squamous cell lung cancer
611140|NCT00280137|Quality of Life
611141|NCT00280137|Pediatric Systemic Lupus Erythematosus
611142|NCT00280111|rotavirus
611143|NCT00280111|vaccine
611144|NCT00280111|safety
611145|NCT00280111|immunogenicity
611146|NCT00280111|infants
611147|NCT00280072|Renal Failure, Acute
611148|NCT00280072|Acute Kidney Failure
611149|NCT00280072|Acute Renal Failure
611150|NCT00280072|Acute Tubular Necrosis
611151|NCT00280072|Anuria
611152|NCT00280072|Renal Dialysis
611153|NCT00280072|Acute Kidney Injury
611154|NCT00280059|Epilepsy
611155|NCT00280059|partial seizures
611156|NCT00280059|pregabalin monotherapy
611157|NCT00280059|lamotrigine comparator
611158|NCT00280059|double-blind and randomized trial
611159|NCT00280033|H5N1, Influenza, vaccine, parent protocol
611160|NCT00280020|sleep disorders
611161|NCT00280020|meditation
611162|NCT00280020|cognitive behavior therapy
611163|NCT00280007|hepatocellular carcinoma
611164|NCT00280007|TACE
611165|NCT00280007|transarterial chemoembolisation
611166|NCT00280007|portal hypertension
611167|NCT00280007|angiogenesis
611168|NCT00280007|VEGF
611169|NCT00280007|bevacizumab
611170|NCT00279994|Intermittent claudication
611171|NCT00279994|Exercise therapy
611172|NCT00279994|Therapy feedback
611173|NCT00279994|Accelerometer
611174|NCT00279994|Physiotherapy
611175|NCT00279994|PAD;
611176|NCT00279994|peripheral arterial disease according to Fontaine stage II)
611177|NCT00279981|Atrial fibrillation
611178|NCT00279981|Stroke
611179|NCT00279981|Pacemaker
611180|NCT00279981|Implantable Cardiac Defibrillator
611181|NCT00279981|Resynchronization systems
611182|NCT00279968|ICD
611183|NCT00279968|Registry
611184|NCT00279968|Ventricular tachycardia
611185|NCT00279968|Ventricular Fibrillation
611186|NCT00279955|Heart Failure, Congestive
611187|NCT00279955|Implantable Cardioverter-Defibrillators
611188|NCT00279942|Fibromyalgia
611189|NCT00279942|Dietary Supplements
611190|NCT00279942|Rheumatologic Diseases
611191|NCT00279942|Complementary and Alternative Medicine
611192|NCT00280852|anaplastic thyroid cancer
611193|NCT00280852|chemotherapy
611194|NCT00280852|radiotherapy
611195|NCT00280826|OCT
611196|NCT00280826|Retinal Disease
611197|NCT00280826|Adhesion Molecule
611198|NCT00280826|Ocular Inflammation
611199|NCT00280826|Raptiva
611200|NCT00280826|Macular Edema
611201|NCT00280826|Uveitis
611202|NCT00280826|Immunosuppression
611203|NCT00280813|treatment
611204|NCT00280813|dual diagnosis
611205|NCT00280800|randomized
611206|NCT00280800|controlled
611207|NCT00280800|double blind
611208|NCT00280800|effectiveness
611209|NCT00280800|auto CPAP
611210|NCT00280800|treatment
611211|NCT00280800|sleep apnea
611212|NCT00280787|unresectable
611213|NCT00280787|induction
611214|NCT00280787|radiotherapy
611215|NCT00280787|ZD1839
611216|NCT00280774|corticosteroid
611217|NCT00280774|prednisone
611218|NCT00280774|memantine
611219|NCT00280774|Patients who are taking a corticosteroid for a
611220|NCT00280774|pulmonary illness
611221|NCT00280774|rheumatic illness
611222|NCT00280774|kidney transplant
611223|NCT00280761|adenocarcinoma of the rectum
611224|NCT00280761|recurrent rectal cancer
611225|NCT00280761|stage II rectal cancer
611226|NCT00280761|stage III rectal cancer
611227|NCT00280761|stage IV rectal cancer
611228|NCT00280748|recurrent non-small cell lung cancer
611229|NCT00280748|stage IV non-small cell lung cancer
611230|NCT00280748|tumors metastatic to brain
611231|NCT00280735|stage I non-small cell lung cancer
611232|NCT00280735|stage III non-small cell lung cancer
611233|NCT00280735|stage IIIA non-small cell lung cancer
611234|NCT00280722|Randomised
611235|NCT00280722|Intervention
611236|NCT00280722|Leaflet
611237|NCT00280722|Information
611238|NCT00280722|Awareness
611239|NCT00280722|Behaviour
611240|NCT00280722|Research
611241|NCT00280709|Bile duct
611242|NCT00280709|Bile duct obstruction
611243|NCT00280709|Biliary stent
611244|NCT00280709|Metal stent
611245|NCT00280709|ERCP
611246|NCT00280709|Patency
611247|NCT00280709|Complication
611248|NCT00280709|Stent occlusion
611249|NCT00280696|Epilepsies, Partial,
611250|NCT00280696|Keppra, levetiracetam
611251|NCT00280683|Airway Inflammation
611252|NCT00280683|Moderate persistent asthma
611253|NCT00280683|Severe Persistent Asthma
611254|NCT00280657|Acne papulopustulosa
611255|NCT00280592|Prophylaxis
611256|NCT00280592|Cranberry
611257|NCT00280592|Neurogenic bladder
611258|NCT00280553|analgesia
611259|NCT00280553|laparoscopic surgical procedures
611260|NCT00280553|length of stay
611261|NCT00280540|Hypertension
611262|NCT00280540|High blood pressure
611263|NCT00280540|Blood pressure control
611264|NCT00280540|Blood pressure reduction
611265|NCT00280540|Valsartan
611266|NCT00280527|NAFLD
611267|NCT00280527|NASH
611268|NCT00280527|Obesity
611269|NCT00280527|Bariatric Surgery
611270|NCT00280527|Weight Reduction
611271|NCT00280514|abscess
611272|NCT00280514|penetration
611273|NCT00280514|antibiotics
611274|NCT00280514|cefpirome
611275|NCT00280514|moxifloxacin
611276|NCT00280514|abdominal cyst
611277|NCT00280501|Sulpiride
611278|NCT00280501|Quetiapine
611279|NCT00280501|Light/dark transition
611280|NCT00280501|Choroidal blood flow
611281|NCT00280488|Motivational Interviewing
611282|NCT00280488|Alcohol Abuse
611283|NCT00280488|Alcohol Dependence
611284|NCT00280488|Emergency Care Setting
611285|NCT00280475|Randomized Controlled Trials
611286|NCT00280475|Brain Neoplasms/Secondary
611287|NCT00280475|Brain Neoplasms/Radiotherapy
611288|NCT00280475|Radiosurgery
611289|NCT00280462|Nifedipine
611290|NCT00280462|Choroidal blood flow
611291|NCT00280462|Choroidal autoregulation
611292|NCT00280462|Isometric exercise
611293|NCT00280449|people living with HIV
611294|NCT00280449|quality of life
611295|NCT00280436|Polysomnography
611296|NCT00280436|Electroencephalography
611297|NCT00280436|Primary Insomnia
611298|NCT00280436|Cognition
611299|NCT00280436|Sleep
611300|NCT00280423|Cognition
611301|NCT00280423|Polysomnography
611302|NCT00280423|Primary Insomnia
611303|NCT00280423|Electroencephalography
611304|NCT00280423|Sleep
611305|NCT00280397|Cancer, solid tumors
611306|NCT00280371|COPD
611307|NCT00280371|Chronic Obstructive Pulmonary Disease
611308|NCT00280371|formoterol
611309|NCT00280358|Fluticasone
611310|NCT00280358|Formoterol
611311|NCT00280358|PK Study
611312|NCT00280358|Pharmacokinetics
611313|NCT00280345|pigmentary glaucoma
611314|NCT00280345|primary open angle glaucoma
611315|NCT00280345|cataract
611316|NCT00280345|trabeculectomy
611317|NCT00280345|cataract surgery
611318|NCT00280332|colonic adenoma, colonic advanced neoplasm
611319|NCT00280319|randomized controlled trial
611320|NCT00280319|depression
611321|NCT00280319|Uganda
611322|NCT00280319|adolescents
611323|NCT00280293|Bipolar Disorder
611324|NCT00280293|Cocaine Dependence
611325|NCT00280293|Dual Diagnosis
611326|NCT00280280|spasticity
611327|NCT00280280|Botox
611328|NCT00280280|baclofen
611329|NCT00280267|hip fracture
611330|NCT00280267|testosterone
611331|NCT00280267|muscle weakness
611332|NCT00280267|frail elderly
611333|NCT00280267|aging
611334|NCT00280254|Heart Failure
611335|NCT00280254|Hemodynamics
611336|NCT00280254|Echocardiography
611337|NCT00280241|Chronic
611338|NCT00280241|Lymphocytic
611339|NCT00280241|Leukemia
611340|NCT00280241|Fludarabine
611341|NCT00280241|Cyclophosphamide
611342|NCT00280241|Rituximab
611343|NCT00280228|ADHD
611344|NCT00280228|Oppositional Defiant Disorder
611345|NCT00280228|Conduct Disorder
611346|NCT00280228|Substance Use
611347|NCT00280228|Drug and Alcohol Use
611348|NCT00280215|Primary Hyperoxaluria
611349|NCT00280202|Non-small cell lung cancer
611350|NCT00280202|Carcinogenesis
611351|NCT00280202|Genomic changes leading to malignant phenotypes in NSCLC.
611352|NCT00280202|Simultaneous mutagenesis of epithelial cells.
611353|NCT00280202|Chromosomal abnormalities/mutations in bronchial tissues.
611354|NCT00280202|Detect micrometastases in histologically neg. lymph nodes
611355|NCT00280189|Radiofrequency ablation
611356|NCT00280189|Pulmonary malignancies
611357|NCT00280189|Primary lung cancer
611358|NCT00280189|Pulmonary metastasis
611359|NCT00280189|Primary lung tumors
611360|NCT00280189|Secondary lung tumors
611361|NCT00280189|Coagulation necrosis of soft tissue tumors
611362|NCT00279851|idiopathic seizure
611363|NCT00279851|hypoglycemia
611364|NCT00279851|hyperammonemia/hyperinsulinism syndrome
611365|NCT00279812|Immune response
611366|NCT00279812|Selenomethionine
611367|NCT00279812|Selenium enriched foods
611368|NCT00279812|Selenium status
611369|NCT00279812|Selenium biomarkers
611370|NCT00279799|Sexually Transmitted Diseases, HIV, condom use, adolescents
611371|NCT00279786|pediatric
611372|NCT00279773|Acute
611373|NCT00279773|Myeloid
611374|NCT00279773|Leukemia
611375|NCT00279734|Rheumatoid Arthritis
611376|NCT00279721|thyroid neoplasms
611377|NCT00279721|intensity modulated radiation
611378|NCT00279721|radiotherapy
611379|NCT00279708|Granulomatous Inflammation
611380|NCT00279708|Steroid-Sparing
611381|NCT00279708|Pulmonary Function
611382|NCT00279708|Sarcoidosis, Pulmonary
611383|NCT00279708|Statins (Atorvastatin)
611384|NCT00279708|Biomarkers
611385|NCT00279708|Nitric Oxide
611386|NCT00279708|Disease Activity
611387|NCT00279708|Quality of Life
611388|NCT00279708|Corticosteroids
611389|NCT00279708|Pulmonary Sarcoidosis
611390|NCT00279708|Sarcoidosis
611391|NCT00279695|Glaucoma
611392|NCT00279695|Accommodation
611393|NCT00279695|Ocular Tumors
611394|NCT00279695|Age-Related Macular Degeneration
611395|NCT00279695|Ultrasound
611396|NCT00279695|Eye
611397|NCT00279682|depression
611398|NCT00279682|suicide
611399|NCT00279682|geriatric
611400|NCT00279682|elderly
611401|NCT00279682|primary care
611402|NCT00279669|Retinopathy of Prematurity
611403|NCT00279669|Ultrasound
611404|NCT00279669|Eye
611405|NCT00279656|Frail elderly
611406|NCT00279656|Pharmaceutical services
611407|NCT00279656|Drug therapy
611408|NCT00279656|Geriatrics
611409|NCT00279656|Randomized controlled trial
611410|NCT00279656|Hospitals, teaching
611411|NCT00279643|Laser
611412|NCT00279643|immunohistochemical staining
611413|NCT00279643|Laser Hair Removal
611414|NCT00279643|follicular stem cells
611415|NCT00279643|keratin 15
611416|NCT00279630|Tibialis Posterior Tendinopathy
611417|NCT00279578|haemophilia A
611418|NCT00279578|thrombelastography
611419|NCT00279578|recombinant factor VIII
611420|NCT00279578|thrombin generation
611421|NCT00279565|buprenorphine
611422|NCT00279565|methadone
611423|NCT00279565|Peg-Intron
611424|NCT00279565|Rebetol
611425|NCT00279552|Vitamin B12 deficiency
611426|NCT00279552|Vitamin B12 malabsorption
611427|NCT00279552|Intrinsic factor
611428|NCT00279552|Holotranscobalamin
611429|NCT00279539|Cardiovascular
611430|NCT00279539|Gene Therapy
611431|NCT00279539|DNA
611432|NCT00279539|Stem Cells
611433|NCT00279539|Congestive Heart Failure
611434|NCT00279539|Coronary Artery Disease
611435|NCT00279539|CHF
611436|NCT00279539|Cardiomyopathy
611437|NCT00279526|Depression
611438|NCT00279526|Health services utilization
611439|NCT00279526|Elderly
611440|NCT00279526|Primary Care
611441|NCT00279513|homeopathy
611442|NCT00279513|hallux valgus
611443|NCT00279513|pain
611444|NCT00279513|traumeel s
611445|NCT00279487|Patients undergoing total knee replacement who received pain management by the following modality:
611446|NCT00279487|IV PCA opioid
611447|NCT00279487|Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine
611448|NCT00279474|cancer patients
611449|NCT00279474|family
611450|NCT00279474|cognitive behavior
611451|NCT00279474|distress
611452|NCT00279461|Rheumatoid Arthritis
611453|NCT00279461|Vitamin D
611454|NCT00279435|Intravenous, Steroid-Refractory, Ulcerative Colitis
611455|NCT00279422|Intravenous, Steroid-Refractory, Ulcerative Colitis
611456|NCT00279409|Attention Deficit Hyperactivity Disorder
611457|NCT00279409|ADHD
611458|NCT00279409|Treatment resistant
611459|NCT00279409|Partial responder
611460|NCT00279409|Non-responder
611461|NCT00279409|Atypical Antipsychotic
611462|NCT00279383|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
611463|NCT00279370|SSRI Exposure
611464|NCT00279370|Pregnancy
611465|NCT00279370|Infant Development
611466|NCT00279357|NBI
611467|NCT00279357|high risk group for adenomas
611468|NCT00279331|HIV Seronegativity
611469|NCT00279331|Men who have Sex with Men
611470|NCT00279331|MSM
611471|NCT00279331|Peru
611472|NCT00279331|Ecuador
611473|NCT00279331|Incidence
611474|NCT00279331|Prevalence
611475|NCT00279331|Drug resistance, viral
611476|NCT00279318|Environment
611477|NCT00279318|Exposures
611478|NCT00279318|Diet
611479|NCT00279318|Toxins
611480|NCT00279318|Psychosocial
611481|NCT00279318|Infectious Agents
611482|NCT00279318|Bacterial
611483|NCT00279318|Viral
611484|NCT00279318|Immunizations
611485|NCT00279318|Autoantibody
611486|NCT00279305|Newly diagnosed type 1 diabetes
611487|NCT00279305|New Onset type 1 diabetes
611488|NCT00279305|Preservation of insulin secretion
611489|NCT00279305|Type 1 diabetes
611490|NCT00279305|Juvenile Onset Diabetes
611491|NCT00279305|Insulin Dependent Diabetes
611492|NCT00279305|T1D
611493|NCT00279292|Pancreatic neoplasm
611494|NCT00279279|Implantable cardioverter defibrillator (ICD)
611495|NCT00279279|Sudden Cardiac Death
611496|NCT00279279|Primary Prevention
611497|NCT00279266|Diabetic Peripheral Neuropathy
611498|NCT00279266|Peripheral Neuropathy
611499|NCT00279266|Diabetes Mellitus
611500|NCT00279253|clonidine
611501|NCT00279253|glaucoma
611502|NCT00279240|Impaired glucose tolerance
611503|NCT00279240|Intervention
611504|NCT00279240|Prevention
611505|NCT00279227|coronary artery disease
611506|NCT00279227|epicardial adipose tissue
611507|NCT00279227|epicardial fat
611508|NCT00279227|obesity
611509|NCT00279201|diabetes
611510|NCT00279201|type 2
611511|NCT00279188|Bronchial hyperresponsiveness
611512|NCT00279188|Atopy
611513|NCT00279188|Inhaled steroids
611514|NCT00279188|Exacerbations
611515|NCT00279188|Lung function decline
611516|NCT00279188|Prognosis
611517|NCT00279175|Acute myocardial infarction
611518|NCT00279149|Telemedicine
611519|NCT00279149|TELESTROKE
611520|NCT00279149|symptoms of ischemic stroke since less than 3 hours
611521|NCT00279136|Bronchial hyperresponsiveness,
611522|NCT00279136|lung function,
611523|NCT00279136|airway inflammation,
611524|NCT00279136|deep inspiration,
611525|NCT00279136|bronchial biopsies
611526|NCT00279136|airway smooth muscle
611527|NCT00279110|HIV
611528|NCT00279110|Antiretroviral therapy
611529|NCT00279110|Heroin dependence
611530|NCT00279110|Methadone
611531|NCT00279110|Buprenorphine
611532|NCT00279097|Intracranial pressure
611533|NCT00279097|High Frequency Chest Wall Oscillation
611534|NCT00279097|Neurosurgery
611535|NCT00279084|Anaemia
611536|NCT00279084|Chronic kidney disease
611537|NCT00279084|Type 2 diabetes
611538|NCT00279084|Randomized trial
611539|NCT00279071|dystocia
611540|NCT00279071|stimulation
611541|NCT00279071|acupuncture
611542|NCT00279071|oxytocin
611543|NCT00279045|type 2 diabetes monotherapy treatment naive
611544|NCT00279032|GW406381
611545|NCT00279032|peripheral nerve injury
611546|NCT00279032|patients
611547|NCT00279032|allodynia
611548|NCT00279032|hyperalgesia
611549|NCT00279032|randomised
611550|NCT00279032|placebo-controlled
611551|NCT00279019|GSK233705
611552|NCT00279019|Chronic Obstructive Pulmonary Disease (COPD)
611553|NCT00279019|COPD
611554|NCT00279006|DES (drug eluting stents)
611555|NCT00279006|CAD (cornary artery disease)
611556|NCT00279006|stent retrieval
611557|NCT00278993|Prostate cancer
611558|NCT00278993|metastatic disease
611559|NCT00278967|colonoscopy
611560|NCT00278967|preparation
611561|NCT00278954|Primary Antibody Deficiency
611562|NCT00278954|Common variable hypogammaglobulinemia
611563|NCT00278954|X-linked hypogammaglobulinemia
611564|NCT00278954|Hypogammaglobulinemia
611565|NCT00278954|Immunodeficiency with hyper-IgM
611566|NCT00278954|Wiskott-Aldrich Syndrome
611567|NCT00278941|Seroquel SR™
611568|NCT00278941|Major Depressive Disorder
611569|NCT00278928|Hypertriglyceridemia
611570|NCT00278928|Infant, Premature
611571|NCT00278915|Progressive Precocious Puberty
611572|NCT00278915|PPP
611573|NCT00278915|McCune-Albright Syndrome
611574|NCT00278915|MAS
611575|NCT00278902|ErbB2+ Breast Cancer
611576|NCT00278902|HER2+ Breast Cancer
611577|NCT00278889|Colorectal Cancer
611578|NCT00278889|phase II
611579|NCT00278889|metastatic colorectal cancer
611580|NCT00278889|AZD2171
611581|NCT00278889|RECENTIN
611582|NCT00278876|GIST
611583|NCT00278876|Imatinib
611584|NCT00278876|Adjuvant therapy
611585|NCT00278876|Kit mutation
611586|NCT00278863|Stomach cancer
611587|NCT00278863|Palliative chemotherapy
611588|NCT00278863|Capecitabine
611589|NCT00278863|S-1
611590|NCT00278850|Vulvar vestibulitis
611591|NCT00278850|Treatment
611592|NCT00278850|Education
611593|NCT00278837|Meditation
611594|NCT00278837|Stress-reduction
611595|NCT00278837|Cognitive-affective behavior learning
611596|NCT00278824|Chronic Pain
611597|NCT00278824|Pain
611598|NCT00278811|Mental Health Services
611599|NCT00278811|Suicide
611600|NCT00278811|Suicide ideation
611601|NCT00278798|tracehelectomy
611602|NCT00278798|radical hysterectomy
611603|NCT00278785|interviews
611604|NCT00278785|brief intervention
611605|NCT00278785|drinking
611606|NCT00278785|alcohol
611607|NCT00278785|injuries
611608|NCT00278785|wounds
611609|NCT00278785|intervention studies
611610|NCT00278759|rapid viral diagnosis
611611|NCT00278759|respiratory infection
611612|NCT00278759|pediatric emergency department
611613|NCT00278759|febrile respiratory infection
611614|NCT00278746|zinc
611615|NCT00278746|diarrhea
611616|NCT00278746|cluster randomization
611617|NCT00278746|hospitalization
611618|NCT00278733|Randomized controlled trial
611619|NCT00278733|brief intervention
611620|NCT00278733|university students
611621|NCT00278733|physician advice
611622|NCT00278733|high risk drinking
611623|NCT00278707|Canavan Disease
611624|NCT00278707|Aspartoacylase Deficiency
611625|NCT00278707|NAA
611626|NCT00278707|Acetate
611627|NCT00278707|Glyceryltriacetate
611628|NCT00278694|Oxaliplatin, radiation
611629|NCT00278681|zinc
611630|NCT00278681|diarrhea
611631|NCT00278681|hospitalization
611632|NCT00278681|programme
611633|NCT00278538|Stem cell, Autoimmune disease, Systemic Lupus Erythematosus
611634|NCT00278473|Primarily Inattentive
611635|NCT00278473|Hyperactive Impulsive Type
611636|NCT00278473|Combined Type
611637|NCT00278473|ADHD
611638|NCT00278473|Adults
611639|NCT00278473|Psychological
611640|NCT00278473|CBT
611641|NCT00278460|stage IIIB non-small cell lung cancer
611642|NCT00278460|stage IV non-small cell lung cancer
611643|NCT00278460|adenocarcinoma of the lung
611644|NCT00278460|bronchoalveolar cell lung cancer
611645|NCT00278460|large cell lung cancer
611646|NCT00278460|recurrent non-small cell lung cancer
611647|NCT00278460|squamous cell lung cancer
611648|NCT00278447|Alcohol
611649|NCT00278447|Alcohol use
611650|NCT00278447|Alcohol dependence
611651|NCT00278447|Drug
611652|NCT00278447|Drug use
611653|NCT00278447|Drug dependence
611654|NCT00278447|Utilization
611655|NCT00278447|Hospitalization
611656|NCT00278447|Primary care
611657|NCT00278447|Chronic disease management
611658|NCT00278447|Care management
611659|NCT00278447|Comorbidity
611660|NCT00278434|cervical cancer
611661|NCT00278434|cervical intraepithelial neoplasia grade 2
611662|NCT00278434|cervical intraepithelial neoplasia grade 3
611663|NCT00278421|contiguous stage II grade 3 follicular lymphoma
611664|NCT00278421|noncontiguous stage II grade 3 follicular lymphoma
611665|NCT00278421|stage I grade 3 follicular lymphoma
611666|NCT00278421|contiguous stage II adult diffuse large cell lymphoma
611667|NCT00278421|contiguous stage II adult diffuse mixed cell lymphoma
611668|NCT00278421|noncontiguous stage II adult diffuse large cell lymphoma
611669|NCT00278421|noncontiguous stage II adult diffuse mixed cell lymphoma
611670|NCT00278421|stage I adult diffuse large cell lymphoma
611671|NCT00278421|stage I adult diffuse mixed cell lymphoma
611672|NCT00278421|nodal marginal zone B-cell lymphoma
611673|NCT00278421|anaplastic large cell lymphoma
611674|NCT00278421|contiguous stage II adult immunoblastic large cell lymphoma
611675|NCT00278421|noncontiguous stage II adult immunoblastic large cell lymphoma
611676|NCT00278421|stage I adult immunoblastic large cell lymphoma
611677|NCT00278421|contiguous stage II adult Burkitt lymphoma
611678|NCT00278421|contiguous stage II mantle cell lymphoma
611679|NCT00278421|noncontiguous stage II adult Burkitt lymphoma
611680|NCT00278421|noncontiguous stage II mantle cell lymphoma
611681|NCT00278421|stage I adult Burkitt lymphoma
611682|NCT00278421|stage I mantle cell lymphoma
611683|NCT00278421|contiguous stage II marginal zone lymphoma
611684|NCT00278421|noncontiguous stage II marginal zone lymphoma
611685|NCT00278421|stage I marginal zone lymphoma
611686|NCT00278421|stage III marginal zone lymphoma
611687|NCT00278421|stage IV marginal zone lymphoma
611688|NCT00278421|stage III adult Burkitt lymphoma
611689|NCT00278421|stage III adult diffuse large cell lymphoma
611690|NCT00278421|stage III adult diffuse mixed cell lymphoma
611691|NCT00278421|stage III adult immunoblastic large cell lymphoma
611692|NCT00278421|stage III grade 3 follicular lymphoma
611693|NCT00278421|stage III mantle cell lymphoma
611694|NCT00278421|stage IV adult Burkitt lymphoma
611695|NCT00278421|stage IV adult diffuse large cell lymphoma
611696|NCT00278421|stage IV adult diffuse mixed cell lymphoma
611697|NCT00278421|stage IV adult immunoblastic large cell lymphoma
611698|NCT00278421|stage IV grade 3 follicular lymphoma
611699|NCT00278421|stage IV mantle cell lymphoma
611700|NCT00278408|contiguous stage II grade 3 follicular lymphoma
611701|NCT00278408|noncontiguous stage II grade 3 follicular lymphoma
611702|NCT00278408|stage I grade 3 follicular lymphoma
611703|NCT00278408|stage III grade 3 follicular lymphoma
611704|NCT00278408|stage IV grade 3 follicular lymphoma
611705|NCT00278408|contiguous stage II adult diffuse large cell lymphoma
611706|NCT00278408|contiguous stage II adult diffuse mixed cell lymphoma
611707|NCT00278408|noncontiguous stage II adult diffuse large cell lymphoma
611708|NCT00278408|noncontiguous stage II adult diffuse mixed cell lymphoma
611709|NCT00278408|stage I adult diffuse large cell lymphoma
611710|NCT00278408|stage I adult diffuse mixed cell lymphoma
611711|NCT00278408|stage III adult diffuse large cell lymphoma
611712|NCT00278408|stage III adult diffuse mixed cell lymphoma
611713|NCT00278408|stage IV adult diffuse large cell lymphoma
611714|NCT00278408|stage IV adult diffuse mixed cell lymphoma
611715|NCT00278408|nodal marginal zone B-cell lymphoma
611716|NCT00278408|anaplastic large cell lymphoma
611717|NCT00278408|contiguous stage II adult immunoblastic large cell lymphoma
611718|NCT00278408|noncontiguous stage II adult immunoblastic large cell lymphoma
611719|NCT00278408|stage I adult immunoblastic large cell lymphoma
611720|NCT00278408|stage III adult immunoblastic large cell lymphoma
611721|NCT00278408|stage IV adult immunoblastic large cell lymphoma
611722|NCT00278408|contiguous stage II adult Burkitt lymphoma
611723|NCT00278408|contiguous stage II mantle cell lymphoma
611724|NCT00278408|noncontiguous stage II adult Burkitt lymphoma
611725|NCT00278408|noncontiguous stage II mantle cell lymphoma
611726|NCT00278408|stage I adult Burkitt lymphoma
611727|NCT00278408|stage I mantle cell lymphoma
611728|NCT00278408|stage III adult Burkitt lymphoma
611729|NCT00278408|stage III mantle cell lymphoma
611730|NCT00278408|stage IV adult Burkitt lymphoma
611731|NCT00278408|stage IV mantle cell lymphoma
611732|NCT00278408|contiguous stage II marginal zone lymphoma
611733|NCT00278408|noncontiguous stage II marginal zone lymphoma
611734|NCT00278408|stage I marginal zone lymphoma
611735|NCT00278408|stage III marginal zone lymphoma
611736|NCT00278408|stage IV marginal zone lymphoma
611737|NCT00278369|recurrent renal cell cancer
611738|NCT00278369|stage IV renal cell cancer
611739|NCT00278369|clear cell renal cell carcinoma
611740|NCT00278304|cervical adenocarcinoma
611741|NCT00278304|cervical adenosquamous cell carcinoma
611742|NCT00278304|cervical squamous cell carcinoma
611743|NCT00278304|stage IB cervical cancer
611744|NCT00278304|stage IIA cervical cancer
611745|NCT00278304|stage IIB cervical cancer
611746|NCT00278304|stage III cervical cancer
611747|NCT00278304|stage IVA cervical cancer
611748|NCT00278304|stage IVB cervical cancer
611749|NCT00278278|untreated childhood brain stem glioma
611750|NCT00278278|untreated childhood cerebellar astrocytoma
611751|NCT00278278|childhood high-grade cerebral astrocytoma
611752|NCT00278278|childhood spinal cord neoplasm
611753|NCT00278265|T-cell large granular lymphocyte leukemia
611754|NCT00278265|anemia
611755|NCT00278265|neutropenia
611756|NCT00278252|recurrent childhood ependymoma
611757|NCT00278252|childhood infratentorial ependymoma
611758|NCT00278252|childhood supratentorial ependymoma
611759|NCT00278239|long-term effects secondary to cancer therapy in children
611760|NCT00278239|psychosocial effects of cancer and its treatment
611761|NCT00278239|cognitive/functional effects
611762|NCT00278239|childhood supratentorial primitive neuroectodermal tumor
611763|NCT00278226|unspecified adult solid tumor, protocol specific
611764|NCT00278213|prolymphocytic leukemia
611765|NCT00278213|refractory chronic lymphocytic leukemia
611766|NCT00278213|stage I chronic lymphocytic leukemia
611767|NCT00278213|stage II chronic lymphocytic leukemia
611768|NCT00278213|stage III chronic lymphocytic leukemia
611769|NCT00278213|stage IV chronic lymphocytic leukemia
611770|NCT00278213|T-cell large granular lymphocyte leukemia
611771|NCT00278200|post-transplant lymphoproliferative disorder
611772|NCT00278187|stage IIIB non-small cell lung cancer
611773|NCT00278187|stage IV non-small cell lung cancer
611774|NCT00278187|recurrent non-small cell lung cancer
611775|NCT00278174|stage IV renal cell cancer
611776|NCT00278174|recurrent renal cell cancer
611777|NCT00278174|clear cell renal cell carcinoma
611778|NCT00278161|stage 0 chronic lymphocytic leukemia
611779|NCT00278161|stage I chronic lymphocytic leukemia
611780|NCT00278161|stage II chronic lymphocytic leukemia
611781|NCT00278161|stage III chronic lymphocytic leukemia
611782|NCT00278161|stage IV chronic lymphocytic leukemia
611783|NCT00278161|small lymphocytic lymphoma
611784|NCT00278161|stage I small lymphocytic lymphoma
611785|NCT00278161|stage III small lymphocytic lymphoma
611786|NCT00278161|stage IV small lymphocytic lymphoma
611787|NCT00278161|B-cell chronic lymphocytic leukemia
611788|NCT00278161|splenic marginal zone lymphoma
611789|NCT00278161|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
611790|NCT00278161|nodal marginal zone B-cell lymphoma
611791|NCT00278161|stage I grade 1 follicular lymphoma
611792|NCT00278161|stage I grade 2 follicular lymphoma
611793|NCT00278161|stage III grade 1 follicular lymphoma
611794|NCT00278161|stage III grade 2 follicular lymphoma
611795|NCT00278161|stage IV grade 1 follicular lymphoma
611796|NCT00278161|stage IV grade 2 follicular lymphoma
611797|NCT00278161|stage I mantle cell lymphoma
611798|NCT00278161|stage III mantle cell lymphoma
611799|NCT00278161|stage IV mantle cell lymphoma
611800|NCT00278161|Waldenstrom macroglobulinemia
611801|NCT00278161|prolymphocytic leukemia
611802|NCT00278161|stage I marginal zone lymphoma
611803|NCT00278161|contiguous stage II adult diffuse small cleaved cell lymphoma
611804|NCT00278161|contiguous stage II grade 1 follicular lymphoma
611805|NCT00278161|contiguous stage II grade 2 follicular lymphoma
611806|NCT00278161|contiguous stage II mantle cell lymphoma
611807|NCT00278161|contiguous stage II marginal zone lymphoma
611808|NCT00278161|contiguous stage II small lymphocytic lymphoma
611809|NCT00278161|noncontiguous stage II adult diffuse small cleaved cell lymphoma
611810|NCT00278161|noncontiguous stage II grade 1 follicular lymphoma
611811|NCT00278161|noncontiguous stage II grade 2 follicular lymphoma
611812|NCT00278161|noncontiguous stage II mantle cell lymphoma
611813|NCT00278161|noncontiguous stage II marginal zone lymphoma
611814|NCT00278161|noncontiguous stage II small lymphocytic lymphoma
611815|NCT00278161|stage III marginal zone lymphoma
611816|NCT00278161|recurrent grade 1 follicular lymphoma
611817|NCT00278161|recurrent grade 2 follicular lymphoma
611818|NCT00278161|recurrent mantle cell lymphoma
611819|NCT00278161|recurrent marginal zone lymphoma
611820|NCT00278161|recurrent small lymphocytic lymphoma
611821|NCT00278161|refractory chronic lymphocytic leukemia
611822|NCT00278161|stage IV marginal zone lymphoma
611823|NCT00278148|stage IIIA non-small cell lung cancer
611824|NCT00278148|stage IIIB non-small cell lung cancer
611825|NCT00278135|Cognition
611826|NCT00278135|Memory
611827|NCT00278135|Nutrition
611828|NCT00278135|Omega-3
611829|NCT00278135|DHA
611830|NCT00278122|stage III melanoma
611831|NCT00278122|stage IV melanoma
611832|NCT00278122|recurrent melanoma
611833|NCT00278109|stage I breast cancer
611834|NCT00278109|stage II breast cancer
611835|NCT00278096|disability
611836|NCT00278096|occupational therapy
611837|NCT00278083|Pharmacology
611838|NCT00278083|Asthma
611839|NCT00278083|TNF-alpha
611840|NCT00278070|Metronomic-therapy
611841|NCT00278070|vinorelbine
611842|NCT00278070|Recurrent Breast Cancer
611843|NCT00278070|Recurrent Non Small Cell Lung Cancer
611844|NCT00278070|Metastatic prostate cancer
611845|NCT00278057|Blood pressure;
611846|NCT00278057|chronic renal failure;
611847|NCT00278057|diabetes mellitus;
611848|NCT00278057|dialysis fluid; glucose;
611849|NCT00278057|hemodialysis;
611850|NCT00278057|hypertension;
611851|NCT00278057|uremia.
611852|NCT00278044|Search as text words in Annotation & Scope Note
611853|NCT00278031|Retinoblastoma
611854|NCT00278031|Quality of life
611855|NCT00278005|pediatric
611856|NCT00278005|DiGeorge Syndrome
611857|NCT00278005|Congenital heart defects
611858|NCT00278005|Infections
611859|NCT00278005|Cardiac surgery
611860|NCT00277992|Pediatric
611861|NCT00277992|Cardiac
611862|NCT00277992|Norwood operation modification
611863|NCT00277992|GT/Nissen operation
611864|NCT00277992|Po feed
611865|NCT00277992|GT fed
611866|NCT00277979|pediatric
611867|NCT00277979|cardiac
611868|NCT00277979|Infantile Pompe's Disease
611869|NCT00277979|3D Echocardiography
611870|NCT00277966|Pediatric
611871|NCT00277966|Cardiac Catheterization
611872|NCT00277966|Fluoroscopy time
611873|NCT00277953|Pediatric
611874|NCT00277953|Cardiac
611875|NCT00277953|Tracheal Dimensions
611876|NCT00277953|MRI
611877|NCT00277940|Pediatric
611878|NCT00277940|Cardiac
611879|NCT00277940|Neoaortic Elastic Properties
611880|NCT00277940|Aortic Arch Reconstruction
611881|NCT00277927|Pediatric
611882|NCT00277927|Cardiac
611883|NCT00277927|Valvar Pulmonary Stenosis
611884|NCT00277901|cardiac
611885|NCT00277901|pediatric
611886|NCT00277901|MRI
611887|NCT00277901|Tetralogy of Fallot TOF
611888|NCT00277901|Aortic Coarctation
611889|NCT00277888|Dialysis
611890|NCT00277888|Hemodialysis
611891|NCT00277888|Catheterization
611892|NCT00277875|Cardiovascular
611893|NCT00277875|Flow-Mediated Vasodilation (FMD)
611894|NCT00277875|Pulse Perfusion-Mediated Vasodilation (PPMV)
611895|NCT00277875|Endothelial Function
611896|NCT00277875|Heart Failure
611897|NCT00277875|Local Distensibility
611898|NCT00277875|Arterial Stiffening
611899|NCT00277875|Augmentation Index (AI)
611900|NCT00277875|Aging
611901|NCT00277875|Isolated Systolic Hypertension
611902|NCT00277875|Advanced Glycation Endproducts
611903|NCT00277875|Vascular Stiffness
611904|NCT00277862|chronic hepatitis C;
611905|NCT00277862|peg-interferon alfa-2b;
611906|NCT00277862|ribavirin,
611907|NCT00277862|rapid virologic response,
611908|NCT00277862|sustained virological response
611909|NCT00277849|Sickle
611910|NCT00277849|Hemoglobinopathy
611911|NCT00277849|Thalassemia
611912|NCT00277849|G6PD
611913|NCT00277849|Plasmodium
611914|NCT00277849|Erythrocyte Variant
611915|NCT00277849|Hemoglobin Variant
611916|NCT00277849|Healthy Volunteer
611917|NCT00277849|HV
611918|NCT00277836|malignant tumor
611919|NCT00277823|Depression
611920|NCT00277823|Adult
611921|NCT00277823|Outpatients
611922|NCT00277810|Alzheimer's Disease
611923|NCT00277810|Cholinesterase Inhibitors
611924|NCT00277810|Outpatients
611925|NCT00277797|Low Back Pain
611926|NCT00277784|Age Related Macular Degeneration
611927|NCT00277784|Ultrasound
611928|NCT00277784|OCT
611929|NCT00277784|Eye
611930|NCT00277771|technology in weight loss
611931|NCT00277771|standard behavioral therapy for obesity
611932|NCT00277758|Interleukin-2
611933|NCT00277745|periodontitis
611934|NCT00277745|microfluidics
611935|NCT00277745|saliva diagnostics
611936|NCT00277706|periodontitis
611937|NCT00277706|bone regeneration
611938|NCT00277706|Parathyroid Hormone
611939|NCT00277706|moderate to advanced periodontitis
611940|NCT00277693|hemodialysis
611941|NCT00277693|aldosterone
611942|NCT00277693|heart failure
611943|NCT00277693|spironolactone
611944|NCT00277680|uterine fibroids
611945|NCT00277680|leiomyoma
611946|NCT00277680|laparoscopy
611947|NCT00277680|menorrhagia
611948|NCT00277667|currently experiencing hypomania or mild mania
611949|NCT00277654|Bipolar Disorder with Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
611950|NCT00277641|Binge Eating Disorder Associated with Obesity
611951|NCT00277615|Children
611952|NCT00277615|Bladder volume
611953|NCT00277615|Ultrasound
611954|NCT00277576|DNA vaccine
611955|NCT00277576|immunotherapy
611956|NCT00277576|Hepatitis B Virus
611957|NCT00277576|Particle Mediated Epidermal Delivery
611958|NCT00277563|Carpal Tunnel Syndrome
611959|NCT00277563|Neuropathic Pain
611960|NCT00277563|Neuromodulation
611961|NCT00277563|PEMF
611962|NCT00277563|Magnetic Field Therapy
611963|NCT00277563|Magnetotherapy
611964|NCT00277550|Constipation, Tegaserod, Dyspepsia
611965|NCT00277537|Mannitol
611966|NCT00277524|Pacemaker
611967|NCT00277524|Defibrillator
611968|NCT00277524|Cardiac Resynchronization
611969|NCT00277524|Dysynchrony
611970|NCT00277524|Heart failure
611971|NCT00277524|Arrhythmia
611972|NCT00277524|Tachycardia
611973|NCT00277524|Bradycardia
611974|NCT00277472|Hypertension
611975|NCT00277472|High blood pressure
611976|NCT00277472|diuretics
611977|NCT00277472|valsartan
611978|NCT00277446|Asthma
611979|NCT00277446|Soy isoflavones
611980|NCT00277446|Eosinophils
611981|NCT00277446|Exhaled nitric oxide
611982|NCT00277433|Atopic Dermatitis
611983|NCT00277433|Eczema
611984|NCT00277433|Genetics
611985|NCT00277433|Histamine
611986|NCT00277407|NAET
611987|NCT00277407|Chiropractic procedures
611988|NCT00277407|Acupuncture/acupressure
611989|NCT00277407|Treatment of Autism by holistic procedures
611990|NCT00277407|Food and Vaccination allergy
611991|NCT00277394|Acute, symptomatic and objectively confirmed DVT
611992|NCT00277381|Adherence
611993|NCT00277381|Hypertension
611994|NCT00277381|Telemedicine
611995|NCT00277368|Epilepsy
611996|NCT00277368|Headache
611997|NCT00277368|Seizure
611998|NCT00277355|Study of Minocycline in Huntington's Disease
611999|NCT00277342|lipid induced hepatic insulin resistance
612000|NCT00277342|polymorphisms liver fatty-acid-binding-protein
612001|NCT00277342|gluconeogenesis
612002|NCT00277342|glycogenolysis
612003|NCT00277342|endogenous glucose production
612004|NCT00277316|Kidney cancer
612005|NCT00277316|Metastatic
612006|NCT00277303|Colon Cancer
612007|NCT00277290|Cancer
612008|NCT00277290|Recurrent
612009|NCT00277290|Platinum-resistant
612010|NCT00277290|Platinum-sensitive
612011|NCT00277277|Telemedicine
612012|NCT00277277|Biobehavioral weight loss program
612013|NCT00277277|Body Mass Index
612014|NCT00277277|Blood Glucose
612015|NCT00277277|Diabetes Management
612016|NCT00277251|Crohn’s disease
612017|NCT00277251|systemic-onset juvenile rheumatoid arthritis
612018|NCT00277251|juvenile dermatomyositis
612019|NCT00277251|systemic lupus erythematosus (SLE)
612020|NCT00277251|Mixed connective tissue disease (MCTD)
612021|NCT00277251|vasculitis
612022|NCT00277238|HCV
612023|NCT00277238|Hepatitis c virus
612024|NCT00277238|Virus diseases
612025|NCT00277238|Interferon-alpha
612026|NCT00277238|Interferons
612027|NCT00277238|Liver diseases
612028|NCT00277212|Bipolar I Disorder with a recent manic or mixed episode
612029|NCT00277186|Arthroplasty
612030|NCT00277186|Health services research
612031|NCT00277186|Intent to treat
612032|NCT00277186|Randomized
612033|NCT00277186|Controlled
612034|NCT00277173|Medication Safety
612035|NCT00277173|Adverse Drug Events
612036|NCT00277173|Preventable Adverse Drug Events
612037|NCT00277173|Culture of Safety
612038|NCT00277173|Failure Modes and Effects Analysis
612039|NCT00277173|Teambuilding
612040|NCT00277147|Typhoid Fever
612041|NCT00277147|Immunogenicity
612042|NCT00277147|Safety
612043|NCT00277147|Vaccine
612044|NCT00277147|Conjugate
612045|NCT00277147|Healthy Volunteer
612046|NCT00277121|Lipid disorder
612047|NCT00277121|Gene mutation
612048|NCT00277108|postpartum depression
612049|NCT00277108|postnatal depression
612050|NCT00277108|PPD
612051|NCT00277095|Urinary Incontinence
612052|NCT00277082|Metastatic or Recurrent Cancer of the Endometrium or the Lung (NSCLC)
612053|NCT00277082|Aerosolized Liposomal 9-Nitro 20
612054|NCT00277082|Camptothecin (L9NC)
612055|NCT00277069|Breast metastatic
612056|NCT00277056|leukemia
612057|NCT00277043|Taxane
612058|NCT00277043|Test Dose
612059|NCT00277030|Respiratory Distress Syndrome
612060|NCT00277030|Surfactant
612061|NCT00277030|Nasal CPAP
612062|NCT00277017|Combination Therapy
612063|NCT00277017|5-Fluorouracil
612064|NCT00277017|Interferon-a Interleukin-2
612065|NCT00277017|Thalidomide
612066|NCT00277017|Renal Cell Carcinoma
612067|NCT00276991|Prolonged Viral Suppression
612068|NCT00276991|HIV Infections
612069|NCT00276978|Therapy-resistant Depression
612070|NCT00276978|add-on therapy depression
612071|NCT00276965|Bipolar II Depression
612072|NCT00276952|Gonyautoxins
612073|NCT00276952|Tension-type Headache
612074|NCT00276952|Human Treatment
612075|NCT00276939|Diabetes Mellitus, Type 2
612076|NCT00276939|Diet, Vegetarian
612077|NCT00276939|Diet, Fat-Restricted
612078|NCT00276939|Glycemic Index
612079|NCT00276926|Hypereosinophilic Syndrome
612080|NCT00276926|Eosinophilic leukemias
612081|NCT00276926|STI571 (Gleevec)
612082|NCT00276926|PDGF receptor alpha
612083|NCT00276926|Familiar hypereosinophilia
612084|NCT00276926|Myeloproliferative disorder (MPD) with eosinophilia
612085|NCT00276926|myeloproliferative disorders/myelodysplastic syndromes
612086|NCT00276900|Postpartum Depression
612087|NCT00276900|Recurrent Depression
612088|NCT00276887|Somatization Disorder
612089|NCT00276887|Multiple Medically Unexplained Symptoms
612090|NCT00276887|Cognitive Behavior Therapy
612091|NCT00276887|Mental Health
612092|NCT00276874|Cocaine Addiction
612093|NCT00276874|Cocaine Dependence
612094|NCT00276861|adenocarcinoma of the colon
612095|NCT00276861|recurrent colon cancer
612096|NCT00276861|stage IV colon cancer
612097|NCT00276848|stage III chronic lymphocytic leukemia
612098|NCT00276848|stage IV chronic lymphocytic leukemia
612099|NCT00276835|recurrent renal cell cancer
612100|NCT00276835|clear cell renal cell carcinoma
612101|NCT00276835|stage IV renal cell cancer
612102|NCT00276835|recurrent melanoma
612103|NCT00276835|stage IV melanoma
612104|NCT00276822|stage I breast cancer
612105|NCT00276822|stage II breast cancer
612106|NCT00276822|stage IIIA breast cancer
612107|NCT00276822|stage IIIB breast cancer
612108|NCT00276822|stage IIIC breast cancer
612109|NCT00276822|stage IV breast cancer
612110|NCT00276809|stage 0 chronic lymphocytic leukemia
612111|NCT00276809|stage I chronic lymphocytic leukemia
612112|NCT00276809|stage II chronic lymphocytic leukemia
612113|NCT00276809|stage III chronic lymphocytic leukemia
612114|NCT00276809|stage IV chronic lymphocytic leukemia
612115|NCT00276796|cervical squamous cell carcinoma
612116|NCT00276796|stage III cervical cancer
612117|NCT00276796|recurrent cervical cancer
612118|NCT00276796|cervical adenocarcinoma
612119|NCT00276796|cervical adenosquamous cell carcinoma
612120|NCT00276796|cervical small cell carcinoma
612121|NCT00276796|stage IVA cervical cancer
612122|NCT00276796|stage IVB cervical cancer
612123|NCT00276783|primary central nervous system lymphoma
612124|NCT00276783|tumors metastatic to brain
612125|NCT00276783|recurrent adult brain tumor
612126|NCT00276783|adult giant cell glioblastoma
612127|NCT00276783|adult gliosarcoma
612128|NCT00276783|adult mixed glioma
612129|NCT00276783|adult anaplastic astrocytoma
612130|NCT00276783|adult anaplastic oligodendroglioma
612131|NCT00276783|adult glioblastoma
612132|NCT00276770|adult anaplastic astrocytoma
612133|NCT00276770|adult anaplastic ependymoma
612134|NCT00276770|adult anaplastic oligodendroglioma
612135|NCT00276770|adult diffuse astrocytoma
612136|NCT00276770|adult glioblastoma
612137|NCT00276770|adult giant cell glioblastoma
612138|NCT00276770|adult gliosarcoma
612139|NCT00276770|adult ependymoma
612140|NCT00276770|adult oligodendroglioma
612141|NCT00276770|recurrent adult brain tumor
612142|NCT00276770|adult mixed glioma
612143|NCT00276757|childhood Langerhans cell histiocytosis
612144|NCT00276744|recurrent pancreatic cancer
612145|NCT00276744|stage III pancreatic cancer
612146|NCT00276744|adenocarcinoma of the pancreas
612147|NCT00276744|stage I pancreatic cancer
612148|NCT00276744|stage II pancreatic cancer
612149|NCT00276731|localized resectable neuroblastoma
612150|NCT00276731|localized unresectable neuroblastoma
612151|NCT00276731|regional neuroblastoma
612152|NCT00276718|childhood malignant ovarian germ cell tumor
612153|NCT00276718|childhood malignant testicular germ cell tumor
612154|NCT00276718|childhood central nervous system germ cell tumor
612155|NCT00276718|childhood extragonadal germ cell tumor
612156|NCT00276718|childhood teratoma
612157|NCT00276705|adult primary hepatocellular carcinoma
612158|NCT00276705|childhood hepatocellular carcinoma
612159|NCT00276705|advanced adult primary liver cancer
612160|NCT00276705|localized resectable adult primary liver cancer
612161|NCT00276705|localized unresectable adult primary liver cancer
612162|NCT00276705|stage I childhood liver cancer
612163|NCT00276705|stage II childhood liver cancer
612164|NCT00276705|stage III childhood liver cancer
612165|NCT00276705|stage IV childhood liver cancer
612166|NCT00276692|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
612167|NCT00276679|recurrent neuroblastoma
612168|NCT00276679|disseminated neuroblastoma
612169|NCT00276679|localized unresectable neuroblastoma
612170|NCT00276666|untreated childhood medulloblastoma
612171|NCT00276640|recurrent childhood brain stem glioma
612172|NCT00276640|untreated childhood brain stem glioma
612173|NCT00276640|recurrent childhood cerebellar astrocytoma
612174|NCT00276640|untreated childhood cerebellar astrocytoma
612175|NCT00276640|childhood low-grade cerebral astrocytoma
612176|NCT00276640|recurrent childhood cerebral astrocytoma
612177|NCT00276640|childhood oligodendroglioma
612178|NCT00276640|recurrent childhood visual pathway and hypothalamic glioma
612179|NCT00276640|untreated childhood visual pathway and hypothalamic glioma
612180|NCT00276640|childhood spinal cord neoplasm
612181|NCT00276627|unspecified adult solid tumor, protocol specific
612182|NCT00276614|stage IV renal cell cancer
612183|NCT00276614|recurrent renal cell cancer
612184|NCT00276614|papillary renal cell carcinoma
612185|NCT00276601|untreated adult acute myeloid leukemia
612186|NCT00276601|untreated childhood acute myeloid leukemia and other myeloid malignancies
612187|NCT00276601|adult acute promyelocytic leukemia (M3)
612188|NCT00276601|childhood acute promyelocytic leukemia (M3)
612189|NCT00276601|adult acute myeloid leukemia with t(15;17)(q22;q12)
612190|NCT00276588|adenocarcinoma of the lung
612191|NCT00276588|adenosquamous cell lung cancer
612192|NCT00276588|large cell lung cancer
612193|NCT00276588|recurrent non-small cell lung cancer
612194|NCT00276588|squamous cell lung cancer
612195|NCT00276588|stage IIIB non-small cell lung cancer
612196|NCT00276588|stage IV non-small cell lung cancer
612197|NCT00276575|unspecified adult solid tumor, protocol specific
612198|NCT00276549|adenocarcinoma of the prostate
612199|NCT00276549|stage IV prostate cancer
612200|NCT00276536|stage IV melanoma
612201|NCT00276536|unspecified adult solid tumor, protocol specific
612202|NCT00276523|stage II squamous cell carcinoma of the lip and oral cavity
612203|NCT00276523|stage III squamous cell carcinoma of the lip and oral cavity
612204|NCT00276523|stage IV squamous cell carcinoma of the lip and oral cavity
612205|NCT00276523|stage II squamous cell carcinoma of the oropharynx
612206|NCT00276523|stage III squamous cell carcinoma of the oropharynx
612207|NCT00276523|stage IV squamous cell carcinoma of the oropharynx
612208|NCT00276523|stage II squamous cell carcinoma of the hypopharynx
612209|NCT00276523|stage III squamous cell carcinoma of the hypopharynx
612210|NCT00276523|stage IV squamous cell carcinoma of the hypopharynx
612211|NCT00276523|stage II squamous cell carcinoma of the larynx
612212|NCT00276523|stage III squamous cell carcinoma of the larynx
612213|NCT00276523|stage IV squamous cell carcinoma of the larynx
612214|NCT00276523|recurrent squamous cell carcinoma of the hypopharynx
612215|NCT00276523|recurrent squamous cell carcinoma of the larynx
612216|NCT00276523|recurrent squamous cell carcinoma of the lip and oral cavity
612217|NCT00276523|recurrent squamous cell carcinoma of the oropharynx
612218|NCT00276497|Impaired glucose tolerance
612219|NCT00276497|Intervention
612220|NCT00276497|Prevention
612221|NCT00276445|allergy
612222|NCT00276445|Allergy conjunctivitis
612223|NCT00276445|beta-1-3glucan
612224|NCT00276445|Th1/Th2
612225|NCT00276341|cognitive impairment
612226|NCT00276289|nephrolithiasis
612227|NCT00276289|hypercalciuria
612228|NCT00276289|hypokalemia
612229|NCT00276289|thiazide diuretics
612230|NCT00276276|relapsed
612231|NCT00276276|lung cancer
612232|NCT00276276|resistant
612233|NCT00276276|small cel
612234|NCT00276276|topotecan (HYCAMTIN)
612235|NCT00276263|Schizophrenia prodrome
612236|NCT00276263|Sarcosine
612237|NCT00276263|Psychosis
612238|NCT00276263|NMDA receptor
612239|NCT00276263|Prevention
612240|NCT00276237|Congenital Heart Disease
612241|NCT00276237|Pulmonary Valve Replacement
612242|NCT00276224|iron deficiency schistosomiasis soil transmitted helminths
612243|NCT00276211|MRI diffusion mamma cancer
612244|NCT00276198|Clinical trial, controlled
612245|NCT00276198|Micronutrients
612246|NCT00276198|Dietary Supplementation
612247|NCT00276198|Infants
612248|NCT00276185|spasticity ;
612249|NCT00276185|Botulinum toxin ;
612250|NCT00276185|Upper limb ;
612251|NCT00276185|motor function.
612252|NCT00276185|spastic hemiplegia after stoke
612253|NCT00276159|Leukemia
612254|NCT00276159|Lymphoma
612255|NCT00276159|Myeloma
612256|NCT00276159|Hematology
612257|NCT00276159|852A
612258|NCT00276159|IRM
612259|NCT00276159|Oncology
612260|NCT00276146|dipyridamole
612261|NCT00276146|magnesium
612262|NCT00276146|sickle cell
612263|NCT00276146|anemia
612264|NCT00276146|red blood cells
612265|NCT00276133|small dense LDL
612266|NCT00276120|Breast
612267|NCT00276120|Cancer
612268|NCT00276120|Young
612269|NCT00276120|Women
612270|NCT00276107|Vaccine
612271|NCT00276107|Healthy Infants
612272|NCT00276094|Urogenital atrophy
612273|NCT00276094|Vaginal atrophy
612274|NCT00276094|Vulvar and vaginal atrophy in postmenopausal women
612275|NCT00276094|Menopausal symptoms
612276|NCT00276081|Hot flashes
612277|NCT00276081|postmenopausal
612278|NCT00276081|climacteric symptoms
612279|NCT00276081|hormone replacement therapy
612280|NCT00276081|gabapentin
612281|NCT00276068|Vulvar vestibulitis
612282|NCT00276068|Vulvodynia
612283|NCT00276068|Desipramine
612284|NCT00276068|Lidocaine
612285|NCT00276068|Genetics
612286|NCT00276055|Soft Tissue Sarcoma
612287|NCT00276055|Phase I
612288|NCT00276055|Gemcitabine
612289|NCT00276055|Docetaxel
612290|NCT00276055|Bevacizumab
612291|NCT00276055|vascular endothelial growth factor
612292|NCT00276042|AOM
612293|NCT00276029|Asthma
612294|NCT00276029|Refractory
612295|NCT00276003|Lymphoma-Non Hodgkins
612296|NCT00276003|Phase II
612297|NCT00276003|Gemcitabine
612298|NCT00276003|Irinotecan
612299|NCT00275990|coronary thrombectomy
612300|NCT00275990|thrombectomy for acute myocardial infarction
612301|NCT00275990|C14.280.647.500
612302|NCT00275990|C14.907.553.355.500
612303|NCT00275977|"Stem cell"
612304|NCT00275977|"autologous bone marrow transplantation"
612305|NCT00275977|"Myocardial infarction"
612306|NCT00275951|Combination
612307|NCT00275951|Chemotherapy
612308|NCT00275951|Gastric cancer
612309|NCT00275938|hepatitis B virus
612310|NCT00275938|e antigen
612311|NCT00275938|interferon
612312|NCT00275938|ribavirin
612313|NCT00275925|partial epilepsy, oxcarbazepine, adults
612314|NCT00275834|obesity treatment
612315|NCT00275834|weight loss
612316|NCT00275834|antiobesity drugs
612317|NCT00275834|zonisamide
612318|NCT00275821|Age-related macular degeneration, ranibizumab
612319|NCT00275795|NST-NAET testing
612320|NCT00275795|Food Ssensitivities
612321|NCT00275795|Eczema
612322|NCT00275795|Acne
612323|NCT00275795|Indigestion
612324|NCT00275769|Arrhythmia
612325|NCT00275769|Bradycardia
612326|NCT00275769|Cardiac Pacemaker Artificial
612327|NCT00275756|Ocular Physiology
612328|NCT00275756|Brimonidine
612329|NCT00275756|Timoptic
612330|NCT00275756|Dorzolamide
612331|NCT00275756|ocular blood flow
612332|NCT00275756|Regional Blood Flow
612333|NCT00275730|indometacine
612334|NCT00275730|retinal blood flow
612335|NCT00275730|choroidal blood flow
612336|NCT00275561|Eosinophilic Esophagitis
612337|NCT00275561|Fluticasone
612338|NCT00275561|Dysphagia
612339|NCT00275535|kidney transplantation
612340|NCT00275535|immunosuppression
612341|NCT00275535|calcineurin inhibitor
612342|NCT00275535|sirolimus
612343|NCT00275535|chronic allograft nephropathy
612344|NCT00275509|kidney
612345|NCT00275509|transplantation
612346|NCT00275509|positive crossmatch
612347|NCT00275509|antibody mediated rejection
612348|NCT00275509|rejection
612349|NCT00275509|induction
612350|NCT00275509|therapy
612351|NCT00275509|trial
612352|NCT00275496|SLND
612353|NCT00275496|Sentinel
612354|NCT00275496|Melanoma
612355|NCT00275496|Surgical
612356|NCT00275431|cancer
612357|NCT00275431|AT-101
612358|NCT00275431|AT101
612359|NCT00275431|B-cell malignancies
612360|NCT00275431|Non-Hodgkin
612361|NCT00275431|lymphoma
612362|NCT00275431|lukemia
612363|NCT00275418|Crohn's disease
612364|NCT00275418|remission
612365|NCT00275418|beta carotene
612366|NCT00275405|Effects of Garlic
612367|NCT00275392|Dizziness
612368|NCT00275392|Geriatrics
612369|NCT00275392|Rehabilitation
612370|NCT00275392|Vestibular rehabilitation
612371|NCT00275379|Cystitis
612372|NCT00275366|cuff, rotator
612373|NCT00275366|Rotator cuff
612374|NCT00275340|Pain
612375|NCT00275340|Depressive Symptoms
612376|NCT00275340|Coronary Artery Bypass
612377|NCT00275340|Convalescence
612378|NCT00275340|Quality of Life
612379|NCT00275340|Human Activities
612380|NCT00275327|antibiotics
612381|NCT00275314|transplantation
612382|NCT00275301|Borderline Personality Disorder
612383|NCT00275301|BPD
612384|NCT00275301|PET
612385|NCT00275301|olanzapine
612386|NCT00275301|brain
612387|NCT00275288|Borderline Personality Disorder
612388|NCT00275288|BPD
612389|NCT00275288|amygdala
612390|NCT00275288|facial expression response
612391|NCT00275288|MRI
612392|NCT00275275|PD
612393|NCT00275275|Parkinson's
612394|NCT00275262|Bone marrow transplantation
612395|NCT00275262|Hematopoietic stem cell transplantation
612396|NCT00275262|Hodgkin's disease
612397|NCT00275262|non-Hodgkin's lymphoma
612398|NCT00275262|multiple myeloma
612399|NCT00275249|Chronic Pain
612400|NCT00275236|Idiopthic Restless Legs Syndrome
612401|NCT00275223|adipose tissue
612402|NCT00275223|adipocytokines
612403|NCT00275210|Oxaliplatin
612404|NCT00275210|Chemotherapy,adjuvant
612405|NCT00275210|Colonic Neoplasms
612406|NCT00275184|Bowel preparation
612407|NCT00275184|capsule endoscopy
612408|NCT00275184|randomised
612409|NCT00275184|Citramag
612410|NCT00275184|Senna
612411|NCT00275184|Metoclopramide
612412|NCT00275184|Patients referred for Capsule endoscopy
612413|NCT00275184|occult/overt gastrointestinal bleeding
612414|NCT00275184|other suspected small bowel pathology
612415|NCT00275171|Nontoxic nodular goiter
612416|NCT00275171|131I therapy
612417|NCT00275171|thyroid radioiodine uptake
612418|NCT00275171|optimal time-interval
612419|NCT00275171|reduced 131I activity
612420|NCT00275171|goiter reduction
612421|NCT00275158|Pre-Eclampsia
612422|NCT00275158|Glomerular Filtration Rate (GFR)
612423|NCT00275158|Inulin clearance
612424|NCT00275158|Hypertension
612425|NCT00275158|L-Arginine
612426|NCT00275158|Nitric Oxide
612427|NCT00275158|cGMP
612428|NCT00275158|Endothelin
612429|NCT00275158|ADMA
612430|NCT00275132|stage IIIB non-small cell lung cancer
612431|NCT00275132|stage IV non-small cell lung cancer
612432|NCT00275119|adenocarcinoma of the pancreas
612433|NCT00275119|stage II pancreatic cancer
612434|NCT00275119|stage III pancreatic cancer
612435|NCT00275119|recurrent pancreatic cancer
612436|NCT00275106|stage I childhood lymphoblastic lymphoma
612437|NCT00275106|stage II childhood lymphoblastic lymphoma
612438|NCT00275106|stage III childhood lymphoblastic lymphoma
612439|NCT00275106|stage IV childhood lymphoblastic lymphoma
612440|NCT00275067|adult anaplastic astrocytoma
612441|NCT00275067|adult gliosarcoma
612442|NCT00275067|adult anaplastic oligodendroglioma
612443|NCT00275067|adult mixed glioma
612444|NCT00275067|adult glioblastoma
612445|NCT00275067|adult giant cell glioblastoma
612446|NCT00275067|recurrent adult brain tumor
612447|NCT00275054|stage 0 chronic lymphocytic leukemia
612448|NCT00275054|B-cell chronic lymphocytic leukemia
612449|NCT00275054|stage I chronic lymphocytic leukemia
612450|NCT00275054|stage II chronic lymphocytic leukemia
612451|NCT00275041|recurrent breast cancer
612452|NCT00275041|stage IV breast cancer
612453|NCT00275041|male breast cancer
612454|NCT00275015|stage 0 chronic lymphocytic leukemia
612455|NCT00275015|stage I chronic lymphocytic leukemia
612456|NCT00275015|stage II chronic lymphocytic leukemia
612457|NCT00275015|stage III chronic lymphocytic leukemia
612458|NCT00275015|stage IV chronic lymphocytic leukemia
612459|NCT00275015|refractory chronic lymphocytic leukemia
612460|NCT00275002|recurrent childhood brain stem glioma
612461|NCT00275002|recurrent childhood brain tumor
612462|NCT00274989|B-cell chronic lymphocytic leukemia
612463|NCT00274989|relapsed refractory chronic lymphocytic leukemia
612464|NCT00274989|previously untreated chronic lymphocytic leukemia
612465|NCT00274976|refractory chronic lymphocytic leukemia
612466|NCT00274976|stage III chronic lymphocytic leukemia
612467|NCT00274976|stage IV chronic lymphocytic leukemia
612468|NCT00274963|B-cell chronic lymphocytic leukemia
612469|NCT00274963|refractory chronic lymphocytic leukemia
612470|NCT00274950|childhood extragonadal germ cell tumor
612471|NCT00274950|childhood malignant ovarian germ cell tumor
612472|NCT00274950|childhood malignant testicular germ cell tumor
612473|NCT00274950|recurrent childhood malignant germ cell tumor
612474|NCT00274950|childhood teratoma
612475|NCT00274950|childhood extracranial germ cell tumor
612476|NCT00274924|contiguous stage II adult diffuse large cell lymphoma
612477|NCT00274924|noncontiguous stage II adult diffuse large cell lymphoma
612478|NCT00274924|stage III adult diffuse large cell lymphoma
612479|NCT00274924|stage IV adult diffuse large cell lymphoma
612480|NCT00274911|untreated childhood supratentorial primitive neuroectodermal tumor
612684|NCT00274690|GW679769
612481|NCT00274898|stage II non-small cell lung cancer
612482|NCT00274898|stage IIIA non-small cell lung cancer
612483|NCT00274898|stage IIIB non-small cell lung cancer
612484|NCT00274898|recurrent non-small cell lung cancer
612485|NCT00274885|neurotoxicity
612486|NCT00274885|carcinoma of the appendix
612487|NCT00274885|recurrent anal cancer
612488|NCT00274885|stage I anal cancer
612489|NCT00274885|stage II anal cancer
612490|NCT00274885|stage IIIA anal cancer
612491|NCT00274885|stage IIIB anal cancer
612492|NCT00274885|stage IV anal cancer
612493|NCT00274885|localized extrahepatic bile duct cancer
612494|NCT00274885|recurrent extrahepatic bile duct cancer
612495|NCT00274885|unresectable extrahepatic bile duct cancer
612496|NCT00274885|localized gallbladder cancer
612497|NCT00274885|recurrent gallbladder cancer
612498|NCT00274885|unresectable gallbladder cancer
612499|NCT00274885|recurrent gastric cancer
612500|NCT00274885|stage IV gastric cancer
612501|NCT00274885|recurrent colon cancer
612502|NCT00274885|recurrent rectal cancer
612503|NCT00274885|recurrent esophageal cancer
612504|NCT00274885|localized gastrointestinal carcinoid tumor
612505|NCT00274885|metastatic gastrointestinal carcinoid tumor
612506|NCT00274885|recurrent gastrointestinal carcinoid tumor
612507|NCT00274885|regional gastrointestinal carcinoid tumor
612508|NCT00274885|gastrointestinal stromal tumor
612509|NCT00274885|advanced adult primary liver cancer
612510|NCT00274885|localized resectable adult primary liver cancer
612511|NCT00274885|localized unresectable adult primary liver cancer
612512|NCT00274885|recurrent adult primary liver cancer
612513|NCT00274885|recurrent pancreatic cancer
612514|NCT00274885|stage I pancreatic cancer
612515|NCT00274885|stage II pancreatic cancer
612516|NCT00274885|stage III pancreatic cancer
612517|NCT00274885|recurrent small intestine cancer
612518|NCT00274885|small intestine adenocarcinoma
612519|NCT00274885|small intestine leiomyosarcoma
612520|NCT00274885|small intestine lymphoma
612521|NCT00274885|stage IV pancreatic cancer
612522|NCT00274885|metastatic extrahepatic bile duct cancer
612523|NCT00274885|metastatic gallbladder cancer
612524|NCT00274885|stage IA gastric cancer
612525|NCT00274885|stage IB gastric cancer
612526|NCT00274885|stage IIA gastric cancer
612527|NCT00274885|stage IIB gastric cancer
612528|NCT00274885|stage IIIA gastric cancer
612529|NCT00274885|stage IIIB gastric cancer
612530|NCT00274885|stage IIIC gastric cancer
612531|NCT00274885|stage I colon cancer
612532|NCT00274885|stage IIA colon cancer
612533|NCT00274885|stage IIB colon cancer
612534|NCT00274885|stage IIIA colon cancer
612535|NCT00274885|stage IIIB colon cancer
612536|NCT00274885|stage IIIC colon cancer
612537|NCT00274885|stage IVA colon cancer
612538|NCT00274885|stage IVB colon cancer
612539|NCT00274885|stage I rectal cancer
612540|NCT00274885|stage IIA rectal cancer
612541|NCT00274885|stage IIB rectal cancer
612542|NCT00274885|stage IIC rectal cancer
612543|NCT00274885|stage IIIA rectal cancer
612544|NCT00274885|stage IIIB rectal cancer
612545|NCT00274885|stage IIIC rectal cancer
612546|NCT00274885|stage IVA rectal cancer
612547|NCT00274885|stage IVB rectal cancer
612548|NCT00274885|stage IA esophageal cancer
612549|NCT00274885|stage IB esophageal cancer
612550|NCT00274885|stage IIA esophageal cancer
612551|NCT00274885|stage IIB esophageal cancer
612552|NCT00274885|stage IIIA esophageal cancer
612553|NCT00274885|stage IIIB esophageal cancer
612554|NCT00274885|stage IIIC esophageal cancer
612555|NCT00274885|stage IV esophageal cancer
612556|NCT00274872|recurrent rectal cancer
612557|NCT00274872|stage IV rectal cancer
612558|NCT00274872|recurrent colon cancer
612559|NCT00274872|stage IV colon cancer
612560|NCT00274872|adenocarcinoma of the colon
612561|NCT00274872|adenocarcinoma of the rectum
612562|NCT00274859|unspecified adult solid tumor, protocol specific
612563|NCT00274846|recurrent adult acute myeloid leukemia
612564|NCT00274846|recurrent childhood acute myeloid leukemia
612565|NCT00274846|secondary acute myeloid leukemia
612566|NCT00274846|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
612567|NCT00274846|adult acute myeloid leukemia with inv(16)(p13;q22)
612568|NCT00274846|adult acute myeloid leukemia with t(15;17)(q22;q12)
612569|NCT00274846|adult acute myeloid leukemia with t(16;16)(p13;q22)
612570|NCT00274846|adult acute myeloid leukemia with t(8;21)(q22;q22)
612571|NCT00274833|adult glioblastoma
612572|NCT00274833|adult giant cell glioblastoma
612573|NCT00274833|adult gliosarcoma
612574|NCT00274820|chronic idiopathic myelofibrosis
612575|NCT00274820|chronic myelomonocytic leukemia
612576|NCT00274820|atypical chronic myeloid leukemia
612577|NCT00274820|myelodysplastic/myeloproliferative disease, unclassifiable
612578|NCT00274820|de novo myelodysplastic syndromes
612579|NCT00274820|previously treated myelodysplastic syndromes
612580|NCT00274820|secondary myelodysplastic syndromes
612581|NCT00274807|untreated adult acute myeloid leukemia
612582|NCT00274807|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
612583|NCT00274807|adult acute myeloid leukemia with inv(16)(p13;q22)
612685|NCT00274690|Post-operative Nausea
612584|NCT00274807|adult acute myeloid leukemia with t(15;17)(q22;q12)
612585|NCT00274807|adult acute myeloid leukemia with t(16;16)(p13;q22)
612586|NCT00274807|adult acute myeloid leukemia with t(8;21)(q22;q22)
612587|NCT00274794|noncontiguous stage II adult Burkitt lymphoma
612588|NCT00274794|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
612589|NCT00274794|nodal marginal zone B-cell lymphoma
612590|NCT00274794|stage III adult Burkitt lymphoma
612591|NCT00274794|stage IV adult Burkitt lymphoma
612592|NCT00274794|noncontiguous stage II adult diffuse large cell lymphoma
612593|NCT00274794|noncontiguous stage II adult diffuse mixed cell lymphoma
612594|NCT00274794|noncontiguous stage II adult diffuse small cleaved cell lymphoma
612595|NCT00274794|recurrent adult diffuse large cell lymphoma
612596|NCT00274794|recurrent adult diffuse mixed cell lymphoma
612597|NCT00274794|recurrent adult diffuse small cleaved cell lymphoma
612598|NCT00274794|stage III adult diffuse large cell lymphoma
612599|NCT00274794|stage III adult diffuse mixed cell lymphoma
612600|NCT00274794|stage III adult diffuse small cleaved cell lymphoma
612601|NCT00274794|stage IV adult diffuse large cell lymphoma
612602|NCT00274794|stage IV adult diffuse mixed cell lymphoma
612603|NCT00274794|stage IV adult diffuse small cleaved cell lymphoma
612604|NCT00274794|noncontiguous stage II adult immunoblastic large cell lymphoma
612605|NCT00274794|recurrent adult immunoblastic large cell lymphoma
612606|NCT00274794|stage III adult immunoblastic large cell lymphoma
612607|NCT00274794|stage IV adult immunoblastic large cell lymphoma
612608|NCT00274794|noncontiguous stage II adult lymphoblastic lymphoma
612609|NCT00274794|recurrent adult lymphoblastic lymphoma
612610|NCT00274794|stage III adult lymphoblastic lymphoma
612611|NCT00274794|stage IV adult lymphoblastic lymphoma
612612|NCT00274794|noncontiguous stage II grade 1 follicular lymphoma
612613|NCT00274794|noncontiguous stage II grade 2 follicular lymphoma
612614|NCT00274794|noncontiguous stage II grade 3 follicular lymphoma
612615|NCT00274794|recurrent grade 1 follicular lymphoma
612616|NCT00274794|recurrent grade 2 follicular lymphoma
612617|NCT00274794|recurrent grade 3 follicular lymphoma
612618|NCT00274794|stage III grade 1 follicular lymphoma
612619|NCT00274794|stage III grade 2 follicular lymphoma
612620|NCT00274794|stage III grade 3 follicular lymphoma
612621|NCT00274794|stage IV grade 1 follicular lymphoma
612622|NCT00274794|stage IV grade 2 follicular lymphoma
612623|NCT00274794|stage IV grade 3 follicular lymphoma
612624|NCT00274794|noncontiguous stage II mantle cell lymphoma
612625|NCT00274794|recurrent mantle cell lymphoma
612626|NCT00274794|stage III mantle cell lymphoma
612627|NCT00274794|stage IV mantle cell lymphoma
612628|NCT00274794|noncontiguous stage II marginal zone lymphoma
612629|NCT00274794|recurrent marginal zone lymphoma
612630|NCT00274794|splenic marginal zone lymphoma
612631|NCT00274794|stage III marginal zone lymphoma
612632|NCT00274794|stage IV marginal zone lymphoma
612633|NCT00274794|noncontiguous stage II small lymphocytic lymphoma
612634|NCT00274794|recurrent small lymphocytic lymphoma
612635|NCT00274794|stage III small lymphocytic lymphoma
612636|NCT00274794|stage IV small lymphocytic lymphoma
612637|NCT00274781|refractory anemia with excess blasts in transformation
612638|NCT00274781|refractory anemia with excess blasts
612639|NCT00274781|chronic myelomonocytic leukemia
612640|NCT00274781|secondary acute myeloid leukemia
612641|NCT00274781|previously treated myelodysplastic syndromes
612642|NCT00274781|secondary myelodysplastic syndromes
612643|NCT00274781|de novo myelodysplastic syndromes
612644|NCT00274768|stage IV breast cancer
612645|NCT00274768|male breast cancer
612646|NCT00274768|recurrent breast cancer
612647|NCT00274755|adult anaplastic astrocytoma
612648|NCT00274755|adult diffuse astrocytoma
612649|NCT00274755|adult glioblastoma
612650|NCT00274755|adult giant cell glioblastoma
612651|NCT00274755|adult gliosarcoma
612652|NCT00274755|adult pilocytic astrocytoma
612653|NCT00274755|adult anaplastic ependymoma
612654|NCT00274755|adult ependymoma
612655|NCT00274755|adult myxopapillary ependymoma
612656|NCT00274755|adult subependymoma
612657|NCT00274755|adult anaplastic oligodendroglioma
612658|NCT00274755|adult oligodendroglioma
612659|NCT00274755|adult mixed glioma
612660|NCT00274742|Non-Hodgkin's Lymphoma
612661|NCT00274742|Cancer immunotherapy
612662|NCT00274742|Monoclonal antibody
612663|NCT00274742|anti-CD19
612664|NCT00274742|anti-CD3
612665|NCT00274742|BiTE
612666|NCT00274742|Blinatumomab
612667|NCT00274729|Dietary intervention
612668|NCT00274729|High-carbohydrate diet
612669|NCT00274729|High-fat diet
612670|NCT00274729|Moderate-fat diet
612671|NCT00274729|Obesity
612672|NCT00274729|Weight maintenance
612673|NCT00274729|Body composition
612674|NCT00274729|Glucose metabolism
612675|NCT00274729|Cardiovascular disease
612676|NCT00274729|Appetite regulation
612677|NCT00274729|Energy expenditure
612678|NCT00274703|anti IL-5
612679|NCT00274703|oesophagitis
612680|NCT00274703|eosinophils
612681|NCT00274703|mepolizumab
612682|NCT00274703|adults
612683|NCT00274690|Neurokinin-1 Receptor Antagonist
612686|NCT00274690|NK-1 Receptor Antagonist
612687|NCT00274690|PONV
612688|NCT00274690|Post-discharge Nausea and Vomiting
612689|NCT00274690|PDNV
612690|NCT00274690|Vomiting
612691|NCT00274677|Bipolar Disorder
612692|NCT00274664|Amblyopia
612693|NCT00274664|Occlusion dose monitoring
612694|NCT00274664|Refractive adaptation
612695|NCT00274664|Dose-response
612696|NCT00274651|CTCL
612697|NCT00274651|PTCL
612698|NCT00274651|lymphoma
612699|NCT00274651|Non-Hodgkin's Lymphoma
612700|NCT00274651|Cutaneous T-Cell Lymphomas (CTCL)
612701|NCT00274651|Peripheral T-Cell Lymphomas (PTCL)
612702|NCT00274651|Other Types of Non-Hodgkin's Lymphoma
612703|NCT00274651|belinostat
612704|NCT00274625|Biomaterials
612705|NCT00274625|Bariatric Surgery
612706|NCT00274625|Hernia, Prevention of
612707|NCT00274625|Obesity
612708|NCT00274625|Bypass Surgery
612709|NCT00274625|Incisional Hernia
612710|NCT00274625|Ventral Hernia
612711|NCT00274495|Genotype 1
612712|NCT00274495|Metabolic syndrome
612713|NCT00274495|Insulin resistance
612714|NCT00274469|oncology
612715|NCT00274469|cancer
612716|NCT00274469|breast cancer
612717|NCT00274456|Metastatic breast cancer, nab paclitaxel, docetaxel,
612718|NCT00274404|infectious mononucleosis
612719|NCT00274404|Epstein-Barr virus
612720|NCT00274404|valacyclovir
612721|NCT00274404|quantitative PCR
612722|NCT00274378|radius fracture
612723|NCT00274378|fracture fixation
612724|NCT00274378|homologous bone transplantation
612725|NCT00274365|general practitioners, psychiatry, videoconference
612726|NCT00274352|sarcoidosis
612727|NCT00274352|adalimumab
612728|NCT00274352|skin diseases
612729|NCT00274339|Laryngopharyngeal Reflux
612730|NCT00274339|Prevacid
612731|NCT00274339|Lifestyle changes
612732|NCT00274339|Reflux Finding Score
612733|NCT00274339|Reflux Symptom Index
612734|NCT00274339|Laryngoscopy
612735|NCT00274326|Hyponatremia
612736|NCT00274313|Cystic Fibrosis
612737|NCT00274300|DNA vaccine
612738|NCT00274300|immunotherapy
612739|NCT00274300|Herpes Simplex Virus Type 2 (HSV2)
612740|NCT00274300|Particle Mediated Epidermal Delivery
612741|NCT00274261|contraception
612742|NCT00274235|Malaria
612743|NCT00274235|Prevention
612744|NCT00274235|Pregnancy
612745|NCT00274235|Low birthweight
612746|NCT00274235|Anemia
612747|NCT00274235|Africa
612748|NCT00274222|COPD, nebulized budesonide, systemic corticosteroids
612749|NCT00274209|Ulcerative colitis
612750|NCT00274209|Crohn's disease
612751|NCT00274209|Chromoendoscopy
612752|NCT00274209|Dysplasia
612753|NCT00274209|Neoplasia
612754|NCT00274196|fractures, occult
612755|NCT00274196|hip
612756|NCT00274196|ultrasound examination
612757|NCT00274196|MRI
612758|NCT00274196|sensitivity
612759|NCT00274196|specificity
612760|NCT00274170|Migraine
612761|NCT00274170|Octreotide
612762|NCT00274170|Prochlorperazine
612763|NCT00274157|Peripheral Vascular Disease
612764|NCT00274157|Intermittent Claudication
612765|NCT00274157|Catheter-based Arterial Revascularization
612766|NCT00274157|Peripheral angioplasty
612767|NCT00274157|Peripheral stenting
612768|NCT00274157|Functional capacity
612769|NCT00274157|Quality of life
612770|NCT00273949|Lactulose
612771|NCT00273949|Prebiotics
612772|NCT00273949|Nosocomial infection
612773|NCT00273949|children
612774|NCT00273949|infants
612775|NCT00273910|Disease Free Survival
612776|NCT00273910|gp 100:209-217 (210m)
612777|NCT00273910|Immunologic Response
612778|NCT00273910|Adjuvant Therapy
612779|NCT00273910|Cutaneous Melanoma
612780|NCT00273910|Melanoma
612781|NCT00273897|Dementia Treatment
612782|NCT00273897|Hand Function
612783|NCT00273897|Clinical Trials
612784|NCT00273897|Dementia
612785|NCT00273897|Cortical Syndrome
612786|NCT00273897|CBS
612787|NCT00273897|Apraxia
612788|NCT00273884|AML
612789|NCT00273884|Secondary AML
612790|NCT00273884|Leukemia
612791|NCT00273871|kidney transplant
612792|NCT00273858|Rheumatoid Arthritis
612793|NCT00273858|Ankylosing Spondylitis
612794|NCT00273858|Psoriatic Arthritis
612795|NCT00273845|case management
612796|NCT00273845|substance abuse treatment
612797|NCT00273845|linkage
612798|NCT00273832|Chest pain
612799|NCT00273832|Angina pectoris
612800|NCT00273832|Emergency medicine
612801|NCT00273832|Spiral computed tomography
612802|NCT00273832|Length of stay
612803|NCT00273832|Cost analysis
612804|NCT00273819|Congestive heart failure, LV dysfunction
612805|NCT00273806|Behavioral risk factors
612806|NCT00273806|Primary Care
612807|NCT00273806|Health services research
612808|NCT00273780|Patient compliance
612809|NCT00273767|troponin T
612810|NCT00273767|CK-MB
612811|NCT00273767|protein S-100
612812|NCT00273767|Cardiopulmonary Bypass
612813|NCT00273767|Erythropoietin
612814|NCT00273754|Obstructive Sleep Apnea (OSA)
612815|NCT00273754|Tonsillectomy and Adenoidectomy (T&A)
612816|NCT00273754|Postoperative Complications
612817|NCT00273754|Recovery
612818|NCT00273741|palliative care
612819|NCT00273741|methylphenidate
612820|NCT00273728|Hydroxyethyl Starch
612821|NCT00273728|shock, septic
612822|NCT00273728|infusion, intravenous
612823|NCT00273728|mortality
612824|NCT00273715|Comparative
612825|NCT00273715|Randomized
612826|NCT00273715|Suture
612827|NCT00273715|Staples, surgical
612828|NCT00273715|Skin
612829|NCT00273715|Surgical procedures, operative
612830|NCT00273715|Orthopedics
612831|NCT00273715|Joint, hip
612832|NCT00273715|Surgical procedures of Hip, Operative
612833|NCT00273702|Gambling
612834|NCT00273702|Gambler
612835|NCT00273702|Gamble
612836|NCT00273702|Pathological
612837|NCT00273676|Community-acquired pneumonia
612838|NCT00273676|Treatment
612839|NCT00273676|Antibiotics
612840|NCT00273663|cerebral blood flow
612841|NCT00273663|electrical stimulation
612842|NCT00273663|Computed Tomography Scanner, X-Ray
612843|NCT00273663|Brain Mapping
612844|NCT00273650|Autism
612845|NCT00273650|Placebo
612846|NCT00273650|B12
612847|NCT00273650|Controlled
612848|NCT00273650|Complementary Alternative Medicine
612849|NCT00273650|Vitamin Supplement
612850|NCT00273637|heart failure
612851|NCT00273637|peripartum cardiomyopathy
612852|NCT00273637|pregnancy-associated cardiomyopathy
612853|NCT00273637|pregnancy complications
612854|NCT00273637|nonischemic cardiomyopathy
612855|NCT00273624|Therapy-resistant depression
612856|NCT00273624|add-on therapy depression
612857|NCT00273611|vitamin D deficiency
612858|NCT00273611|geriatric patients
612859|NCT00273598|Scoliosis
612860|NCT00273598|spinal disease
612861|NCT00273598|pediatrics
612862|NCT00273598|Adolescents
612863|NCT00273598|Universal Spinal Instrumentation System
612864|NCT00273598|Moss Miami Spinal Instrumentation System
612865|NCT00273598|Orthopedic Surgery
612866|NCT00273585|Fecal occult blood testing
612867|NCT00273585|Flexible sigmoidoscopy
612868|NCT00273585|Colonoscopy
612869|NCT00273585|Self-efficacy
612870|NCT00273572|Obesity
612871|NCT00273572|Women
612872|NCT00273572|Arab
612873|NCT00273572|Metabolic syndrome
612874|NCT00273572|Lifestyle intervention
612875|NCT00273572|Quality of life
612876|NCT00273559|Renal Transplantation
612877|NCT00273546|Head and Neck Cancer
612878|NCT00273546|Induction
612879|NCT00273546|Chemotherapy
612880|NCT00273546|Chemoradiotherapy
612881|NCT00273507|Non-small cell lung cancer
612882|NCT00273507|neoadjuvant
612883|NCT00273507|resection
612884|NCT00273494|N2 disease
612885|NCT00273494|Non-small cell lung cancer
612886|NCT00273494|Surgery
612887|NCT00273494|Neoadjuvant chemotherapy
612888|NCT00273403|HIV
612889|NCT00273403|Minority Groups
612890|NCT00273403|Health Services Accessibility
612891|NCT00273403|Quality of Life
612892|NCT00273377|Anesthesia
612893|NCT00273377|Oxygen
612894|NCT00273377|Carbon dioxide
612895|NCT00273377|Hypercapnia
612896|NCT00273377|Hypercarbia
612897|NCT00273377|Dexamethasone
612898|NCT00273377|Steroid
612899|NCT00273377|Postoperative nausea and vomiting (PONV)
612900|NCT00273364|stem cell, autoimmune disease, multiple sclerosis
612901|NCT00273351|Parkinson
612902|NCT00273351|family history
612903|NCT00273351|diagnosis
612904|NCT00273338|Androgen-independent Prostate Cancer (AIPC)
612905|NCT00273338|Prostate Cancer
612906|NCT00273338|DN-101
612907|NCT00273338|calcitriol
612908|NCT00273338|Taxotere
612909|NCT00273338|docetaxel
612910|NCT00273325|NICHD Neonatal Research Network
612911|NCT00273325|Very Low Birth Weight (VLBW)
612912|NCT00273325|Extremely Low Birth Weight (ELBW)
612913|NCT00273325|Prematurity
612914|NCT00273325|Pneumococcal Vaccines
612915|NCT00273325|Vaccines, Conjugate
612916|NCT00273325|Immunogenicity
612917|NCT00273325|Vaccine Response
612918|NCT00273325|Heptavalent pneumococcal conjugate vaccine (PCV-7)
612919|NCT00273325|pneumococcal polysaccharide, type 6B
612920|NCT00273325|Pneumococcal polysaccharide, type 14
612921|NCT00273325|Pneumococcal polysaccharide, type 19F,
612922|NCT00273325|Pneumococcal polysaccharide, 23F
612923|NCT00273325|Pneumococcal polysaccharide, 18C
612924|NCT00273325|Pneumococcal polysaccharide, 4
612925|NCT00273325|Pneumococcal polysaccharide, 9V
612926|NCT00273312|Advanced unresectable metastatic hepatocellular carcinoma
612927|NCT00273312|Liver cancer
612928|NCT00273299|hypertension
612929|NCT00273299|high blood pressure
612930|NCT00273299|valsartan/hydrochlorozide
612931|NCT00273299|severe hypertension
612932|NCT00273286|Diabetes Mellitus, Insulin-Dependent
612933|NCT00273286|Diabetes Mellitus, Juvenile-Onset
612934|NCT00273286|IDDM
612935|NCT00273286|Type 1 Diabetes Mellitus
612936|NCT00273273|HIV
612937|NCT00273273|Atazanavir
612938|NCT00273273|ritonavir
612939|NCT00273273|tenofovir
612940|NCT00273273|Adolescent
612941|NCT00273273|Treatment Experienced
612942|NCT00273234|Venous
612943|NCT00273234|Ulcer
612944|NCT00273234|autologous
612945|NCT00273234|platelet
612946|NCT00273234|healing
612947|NCT00273221|Glaucoma
612948|NCT00273221|Cataract
612949|NCT00273208|breast cancer
612950|NCT00273208|fatigue
612951|NCT00273195|Implantable Cardioverter Defibrillator, Anti-tachycardia pacing (ATP)
612952|NCT00273182|Heart Failure
612953|NCT00273182|Cardiomyopathy
612954|NCT00273182|Cardiac pacing
612955|NCT00273182|Cardiac resynchronization therapy
612956|NCT00273130|transnasal gastroscopy, stress response, ischaemia
612957|NCT00273117|transnasal gastroscopy
612958|NCT00273117|tachycardia
612959|NCT00273117|hypoxemia
612960|NCT00273078|Speech,
612961|NCT00273078|tongue,
612962|NCT00273078|pressure,
612963|NCT00273078|transducer,
612964|NCT00273078|complete denture
612965|NCT00273065|Local Anesthetic
612966|NCT00273065|Neosaxitoxin
612967|NCT00273052|hypertension
612968|NCT00273039|Social Anxiety Disorder
612969|NCT00273039|Anxiety
612970|NCT00273039|Psychiatry
612971|NCT00273026|Asthma Advair
612972|NCT00273013|asthma
612973|NCT00273013|allergen challenge
612974|NCT00272987|trastuzumab
612975|NCT00272987|ErbB2
612976|NCT00272987|paclitaxel
612977|NCT00272987|Herceptin
612978|NCT00272987|Taxol
612979|NCT00272987|ErbB1
612980|NCT00272987|metastatic breast cancer
612981|NCT00272987|Stage IV breast cancer
612982|NCT00272987|lapatinib
612983|NCT00272974|AE adverse event
612984|NCT00272974|DCF data collection forms
612985|NCT00272974|IRB Institutional Review Board
612986|NCT00272974|SAE serious adverse event
612987|NCT00272948|Venoocclusive disease
612988|NCT00272948|Pediatric
612989|NCT00272948|myeloablative conditioning
612990|NCT00272948|stem cell transplant
612991|NCT00272935|menopause
612992|NCT00272935|vasomotor symptoms
612993|NCT00272922|Biomaterials
612994|NCT00272922|Paraesophageal Hernia
612995|NCT00272922|Laparoscopy
612996|NCT00272909|Acute Ischemic Stroke
612997|NCT00272909|9-Hour window MRI
612998|NCT00272909|Serotonin receptor agonist
612999|NCT00272896|Migraine
613000|NCT00272896|VIP
613001|NCT00272896|Transcranial Doppler
613002|NCT00272896|Headache
613003|NCT00272883|central core
613004|NCT00272883|centronuclear
613005|NCT00272883|multiminicore
613006|NCT00272883|multicore
613007|NCT00272883|minicore
613008|NCT00272883|congenital fiber type disproportion
613009|NCT00272883|myotubular
613010|NCT00272883|nemaline
613011|NCT00272883|congenital myopathy
613012|NCT00272883|neuromuscular
613013|NCT00272883|rigid spine
613014|NCT00272844|cholesterol
613015|NCT00272844|Smith-Lemli-Opitz syndrome
613016|NCT00272844|mental retardation
613017|NCT00272844|sterols
613018|NCT00272844|congenital anomalies
613019|NCT00272831|Diabetic nephropathy
613020|NCT00272831|Macroalbuminuria
613021|NCT00272831|Pletaal
613022|NCT00272818|Colitis
613023|NCT00272818|Esophagitis
613024|NCT00272818|CD23
613025|NCT00272805|chronic heart failure
613026|NCT00272805|left ventricular systolic dysfunction
613027|NCT00272779|HIV
613028|NCT00272779|Treatment Naive
613029|NCT00272766|Ocular histoplasmosis
613030|NCT00272766|Macugen
613031|NCT00272766|Photodynamic therapy with Visudyne
613032|NCT00272766|Best-corrected visual acuity scores between 20/40-20/200
613033|NCT00272766|classic or occult choroidal neovascularization
613034|NCT00272740|breast cancer
613035|NCT00272740|fulvestrant
613036|NCT00272740|Faslodex
613037|NCT00272740|hormonotherapy
613038|NCT00272740|aromatase inhibitor failure
613039|NCT00272740|Advanced breast cancer
613040|NCT00271726|distal radius fracture
613041|NCT00271726|extraarticular Colles fracture
613042|NCT00271713|bone structure
613043|NCT00271713|ibandronate
613044|NCT00271700|Diabetes Mellitus
613045|NCT00271700|Outcome Assessment (Healthcare)
613046|NCT00271700|Inpatients
613047|NCT00271700|Hospital Information Systems
613048|NCT00271700|Education
613049|NCT00271687|exercise
613050|NCT00271687|exercise therapy
613051|NCT00271687|activities of daily living
613052|NCT00271687|quality of life
613053|NCT00270699|Dengue Vaccine
613054|NCT00270699|Dengue Virus
613055|NCT00270699|Dengue Hemorrhagic Fever
613056|NCT00270699|Dengue Shock Syndrome
613057|NCT00272727|Asthma
613058|NCT00272727|dialog tool
613059|NCT00272727|compliance
613060|NCT00272714|breast pain, tenderness, benign breast conditions
613061|NCT00272675|Nosocomial infection,
613062|NCT00272675|Decontamination,
613063|NCT00272675|Randomized placebo-controlled trial,
613064|NCT00272675|Cardiac surgery,
613065|NCT00272675|Chlorhexidine,
613066|NCT00272675|Prevention
613067|NCT00272662|anemia
613068|NCT00272662|cancer
613069|NCT00272662|chemotherapy
613070|NCT00272662|chemotherapy induced anemia
613071|NCT00272662|CIA
613072|NCT00272662|hemoglobin
613073|NCT00272662|Hb
613074|NCT00272662|Hgb
613075|NCT00272662|erythropoietin
613076|NCT00272662|EPO
613077|NCT00272662|erythropoiesis stimulating agent
613078|NCT00272662|ESA
613079|NCT00272662|Hematide
613080|NCT00272662|Omontys
613081|NCT00272662|peginesatide
613082|NCT00272662|red blood cell
613083|NCT00272662|red blood cell production
613084|NCT00272649|Kidney cancer
613085|NCT00272649|Renal cancer
613086|NCT00272636|atrial fibrillation
613087|NCT00272636|catheter ablation
613088|NCT00272636|amiodarone
613089|NCT00272636|cardioversion
613090|NCT00272623|Catheter, Indwelling
613091|NCT00272623|Indwelling Catheter
613092|NCT00272623|Indwelling Catheters
613093|NCT00272623|Implantable Catheters
613094|NCT00272623|Catheter, Implantable
613095|NCT00272623|Catheters, Implantable
613096|NCT00272623|Implantable Catheter
613097|NCT00272623|In-Dwelling Catheters
613098|NCT00272623|Catheter, In-Dwelling
613099|NCT00272623|Catheters, In-Dwelling
613100|NCT00272623|In Dwelling Catheters
613101|NCT00272623|In-Dwelling Catheter
613102|NCT00272623|Venous Reservoirs
613103|NCT00272623|Reservoir, Venous
613104|NCT00272623|Reservoirs, Venous
613105|NCT00272623|Venous Reservoir
613106|NCT00272623|Vascular Access Ports
613107|NCT00272623|Access Port, Vascular
613108|NCT00272623|Access Ports, Vascular
613109|NCT00272623|Port, Vascular Access
613110|NCT00272623|Ports, Vascular Access
613111|NCT00272623|Vascular Access Port
613112|NCT00272610|Skin Aging
613113|NCT00272610|Bateman's Purpura
613114|NCT00272597|Psychosis
613115|NCT00272597|schizophrenia
613116|NCT00272597|schizoaffective
613117|NCT00272597|risperidone
613118|NCT00272584|Psychosis, schizophrenia, schizoaffective, clozapine, risperidone
613119|NCT00272571|ECPT, endothelial progenitor cells
613120|NCT00272558|Malignant Pleural Mesothelioma
613121|NCT00272558|Chemotherapy
613122|NCT00272545|Anorexia Nervosa
613123|NCT00272545|Bulimia Nervosa
613124|NCT00272545|Cognitive Behavioral Therapy
613125|NCT00272519|HIV
613126|NCT00272519|AIDS
613127|NCT00272519|Adolescent
613128|NCT00272519|HIV Positive
613129|NCT00272493|Treatment Experienced
613130|NCT00272493|Treatment Naive
613131|NCT00272480|HAM/TSP
613132|NCT00272480|HTLV-I-associated myelopathy
613133|NCT00272480|zidovudine
613134|NCT00272480|lamivudine
613135|NCT00272480|antiretroviral therapy
613136|NCT00272467|Helicobacter pylori
613137|NCT00272467|Stomach ulcer
613138|NCT00272467|Rebamipide
613139|NCT00272467|Omeprazole
613140|NCT00272454|cilostazol
613141|NCT00272454|aspirin
613142|NCT00272454|cerebral infarction
613143|NCT00272428|Prevention trial
613144|NCT00272428|Antioxydant vitamins and minerals
613145|NCT00272428|Cancer
613146|NCT00272428|Ischemic disease
613147|NCT00272428|Mortality
613148|NCT00272428|Health related quality of life
613149|NCT00272415|INO4136g
613150|NCT00272415|inotek
613151|NCT00272415|Parp
613152|NCT00272415|Temodar
613153|NCT00272402|physician decision support
613154|NCT00272402|diabetes mellitus
613155|NCT00272402|electronic medical records
613156|NCT00272402|office systems redesign
613157|NCT00272376|Myopia
613158|NCT00272376|Nearsightedness
613159|NCT00272363|Glaucoma
613160|NCT00272350|Brain
613161|NCT00272350|Tumor
613162|NCT00272350|Therapy
613163|NCT00272350|Progression
613164|NCT00272350|Antiangiogenesis
613165|NCT00272350|Brain Tumor
613166|NCT00272350|Malignant Glioma
613167|NCT00272337|Cardiovascular diseases
613168|NCT00272337|Aspirin
613169|NCT00272337|Atherosclerosis
613170|NCT00272337|Myocardial Infarction
613171|NCT00272324|Colorectal neoplasms
613172|NCT00272324|Adenomatous polyps
613173|NCT00272311|Primary prevention
613174|NCT00272311|Cardiovascular diseases
613175|NCT00272311|Aspirin
613176|NCT00272311|Metabolic Syndrome X
613177|NCT00272311|Atherosclerosis
613178|NCT00272285|Serotonin antagonists
613179|NCT00272285|Combination drug therapy
613180|NCT00272285|Randomized controlled trial
613181|NCT00272285|Double-blind method
613182|NCT00272272|Fall Prevention, Music Therapy, Geriatric, Nursing Home
613183|NCT00272246|dystonia
613184|NCT00272233|Inflammation Mediators [D23.469]
613185|NCT00272233|Cardiovascular Physiologic Phenomena [G09.330.553]
613186|NCT00272220|Acquired Immunodeficiency Syndrome
613187|NCT00272220|Antiretroviral Therapy, Highly Active
613188|NCT00272220|Randomized Controlled Trials
613189|NCT00272220|Africa
613190|NCT00272220|Adherence
613191|NCT00272220|Treatment Naive
613192|NCT00272207|Fibromyalgia
613193|NCT00272207|Cannabinoids
613194|NCT00272207|Nabilone
613195|NCT00272207|Cesamet
613196|NCT00272207|Pain
613197|NCT00272194|Endotracheal Intubation
613198|NCT00272194|Supraglottic Airway
613199|NCT00272168|Cognitive behavioral therapy
613200|NCT00272168|Social Skills training
613201|NCT00272168|Vocational Rehabilitation
613202|NCT00272142|mortality
613203|NCT00272142|hospitalization
613204|NCT00272142|diarrhea
613205|NCT00272142|respiratory infection
613206|NCT00272142|low birth weight
613207|NCT00272142|morbidity
613208|NCT00272116|zinc
613209|NCT00272116|diarrhea
613210|NCT00272116|severe diarrhea
613211|NCT00272116|recurrent diarrhea
613212|NCT00272116|acute lower respiratory infection
613213|NCT00272116|pneumonia
613214|NCT00272103|functional dyspepsia
613215|NCT00272103|non ulcer dyspepsia
613216|NCT00272103|drug treatment
613217|NCT00272051|Neurotoxicity syndromes
613218|NCT00272051|Paresthesia
613219|NCT00272051|Oxaliplatin
613220|NCT00272051|Xaliproden
613221|NCT00272025|Bipolar Depression
613222|NCT00272025|Escitalopram
613223|NCT00272025|Mood Stabilizer
613224|NCT00272025|Atypical Antipsychotic
613225|NCT00271999|randomized controlled clinical trial
613226|NCT00271999|hemodialysis
613227|NCT00271999|End Stage Renal Disease
613228|NCT00271986|Peritoneal microdialysis
613229|NCT00271986|Low anterior resection
613230|NCT00271986|Recto-sigmoid cancer
613231|NCT00271986|Anastomotic leakage
613232|NCT00271960|Pregnancy
613233|NCT00271960|Birth Weight
613234|NCT00271960|Gestational Age
613235|NCT00271960|Preterm Delivery
613236|NCT00271960|HIV Seronegativity
613237|NCT00271921|eating disorders
613238|NCT00271921|anorexia nervosa
613239|NCT00271921|body fat distribution
613240|NCT00271921|metabolic syndrome
613241|NCT00271921|visceral adipose tissue
613242|NCT00271908|HIV
613243|NCT00271908|AIDS
613244|NCT00271908|Adolescent
613245|NCT00271908|Community
613246|NCT00271908|Structural Changes
613247|NCT00271908|HIV Seronegativity
613248|NCT00271882|Adolescent Females
613249|NCT00271882|HIV positive
613250|NCT00271882|PTSD
613251|NCT00271882|Sexual Abuse
613252|NCT00271869|hematopoietic stem cell transplantation
613253|NCT00271869|graft-versus-host disease
613254|NCT00271869|treatment
613255|NCT00271856|HIV
613256|NCT00271856|Meditation
613257|NCT00271856|Stress
613258|NCT00271856|Randomized Controlled Trial
613259|NCT00271856|Complementary Therapies
613260|NCT00271856|MBSR
613261|NCT00271856|Not on ART medications
613262|NCT00271830|renal
613263|NCT00271830|transplant
613264|NCT00271830|sexual dysfunction
613265|NCT00271830|male
613266|NCT00271830|dialysis free
613267|NCT00271804|Myelodysplastic syndrome
613268|NCT00271804|Myelodysplasia
613269|NCT00271804|MDS
613270|NCT00271804|Velcade
613271|NCT00271804|Thalidomide
613272|NCT00271804|Bortezomib
613273|NCT00271791|Vestibular Neuronitis
613274|NCT00271791|Vestibular Function Tests
613275|NCT00271791|Vestibular Adaptation
613276|NCT00271791|Steroids
613277|NCT00271778|Otitis media suppurative
613278|NCT00271778|surgery ear
613279|NCT00271765|Myocardial infarction
613280|NCT00271765|Coronary angioplasty
613281|NCT00271765|PARP inhibitor
613282|NCT00271765|PARP inhibition
613283|NCT00271765|Heart Attack
613284|NCT00271752|Procalcitonin
613285|NCT00271752|Sepsis
613286|NCT00271752|Intensive Care Unit
613287|NCT00271752|Sepsis and Complications
613288|NCT00271752|Organ Failure
613289|NCT00271739|Telemedicine
613290|NCT00271739|Diabetes Mellitus
613291|NCT00271661|presbyopia; breast cancer survivors
613292|NCT00271635|Charcot-Marie-Tooth Disease
613293|NCT00271635|Hereditary Motor and Sensory Neuropathies
613294|NCT00271635|Ascorbic Acid
613295|NCT00271635|Vitamin C
613296|NCT00271622|Screening
613297|NCT00271622|Pediatric
613298|NCT00271622|Pervasive Developmental Disorder
613299|NCT00271622|Early Development
613300|NCT00271622|Children
613301|NCT00271622|Autism Spectrum Disorders
613302|NCT00271622|Healthy Volunteer
613303|NCT00271622|HV
613304|NCT00271609|AVASTIN
613305|NCT00271609|Recurrence
613306|NCT00271609|Chemotherapy
613307|NCT00271609|Anti-Angiogenesis
613308|NCT00271609|Radiotherapy
613309|NCT00271609|Brain Tumor
613310|NCT00271609|Malignant Glioma
613311|NCT00271596|Huntington Disease
613312|NCT00271596|Citalopram
613313|NCT00271596|Celexa
613314|NCT00271596|Chorea
613315|NCT00271596|Focus
613316|NCT00271596|ADD
613317|NCT00271596|ADHD
613318|NCT00271596|HD
613319|NCT00271596|SSRI
613320|NCT00271583|emergency contraception
613321|NCT00271583|antiprogestin
613322|NCT00271557|Heart Failure
613323|NCT00271557|Renal Dysfunction
613324|NCT00271557|Cardiomyopathy
613325|NCT00271557|Heart Decompensation
613326|NCT00271557|Dyspnea Paroxysmal.
613327|NCT00271544|heart failure
613328|NCT00271544|cardiac pacing
613329|NCT00271544|left ventricular lead
613330|NCT00271544|cardiac resynchronization therapy
613331|NCT00271531|bacterial infection, pneumonia, ventilation, children
613332|NCT00271505|Non-Small Cell Lung Cancer
613333|NCT00271505|Lung Cancer
613334|NCT00271505|Bevacizumab
613335|NCT00271505|Carboplatin
613336|NCT00271505|Docetaxel
613337|NCT00271505|Avastin
613338|NCT00271505|NSCLC
613339|NCT00271505|Anti-VEGF monoclonal antibody
613340|NCT00271505|rhuMAb-VEGF
613341|NCT00271505|Paraplatin®
613342|NCT00271505|Taxotere
613343|NCT00271479|Meningitis
613344|NCT00271479|Dose-Response Relationship, Immunologic
613345|NCT00271479|Neisseria meningitidis
613346|NCT00271479|Outbreaks
613347|NCT00271479|Vaccine
613348|NCT00271479|Africa
613349|NCT00271479|Uganda
613350|NCT00271479|Prevention of Neisseria meningitidis infections
613351|NCT00271479|In outbreak contexts in developing countries
613352|NCT00271466|opioid
613353|NCT00271466|fentanyl
613354|NCT00271466|Duragesic
613355|NCT00271466|transdermal
613356|NCT00271466|chronic pain
613357|NCT00271466|morphine
613358|NCT00271453|chronic pain
613359|NCT00271453|opioid
613360|NCT00271453|fentanyl
613361|NCT00271453|transdermal
613362|NCT00271453|Durogesic
613363|NCT00271453|morphine
613364|NCT00271440|chlorhexidine
613365|NCT00271440|neonatal
613366|NCT00271440|skin flora
613367|NCT00271440|skin cleansing
613368|NCT00271440|bacterial colonization
613369|NCT00271427|Thyroiditis
613370|NCT00271427|Autoimmune
613371|NCT00271427|Hashimoto's
613372|NCT00271427|TPOAb
613373|NCT00271427|Selenium
613374|NCT00271414|chronic pain
613375|NCT00271414|opioid
613376|NCT00271414|fentanyl
613377|NCT00271414|transdermal
613378|NCT00271414|Duragesic
613379|NCT00271414|morphine
613380|NCT00271401|Stents
613381|NCT00271401|Angioplasty, Transluminal, Percutaneous Coronary
613382|NCT00271388|Galvanic Vestibular Stimulation
613383|NCT00271388|Hemispatial Neglect
613384|NCT00271388|Stroke
613385|NCT00271375|Age
613386|NCT00271375|Caregivers
613387|NCT00271375|Family
613388|NCT00271375|Intervention Studies
613389|NCT00271362|Exercise
613390|NCT00271362|Physical function
613391|NCT00271362|Prosthetic mobility
613392|NCT00271362|Rehabilitation
613393|NCT00271349|Eosinophilic Esophagitis
613394|NCT00271349|Budesonide
613395|NCT00271336|NEC
613396|NCT00271336|Premature Infants
613397|NCT00271336|TNF
613398|NCT00271336|Pentoxifylline
613399|NCT00271297|pelvic floor
613400|NCT00271297|exercise therapy
613401|NCT00271297|prevention
613402|NCT00271297|ultrasonography
613403|NCT00271297|risk factors
613404|NCT00271245|cirrhosis
613405|NCT00271245|liver disease
613406|NCT00271245|selenium
613407|NCT00271245|selenoproteins
613408|NCT00271245|selenoprotein P
613409|NCT00271245|biomarkers
613410|NCT00271232|Heart Failure, Cardiac Resynchronization
613411|NCT00271219|opiate addiction
613412|NCT00271219|opiate dependence
613413|NCT00271219|substance abuse
613414|NCT00271219|addiction
613415|NCT00271219|substance addiction
613416|NCT00271219|pregnancy
613417|NCT00271219|buprenorphine
613418|NCT00271219|methadone
613419|NCT00271219|fetal
613420|NCT00271219|neonatal
613421|NCT00271219|post-partum
613422|NCT00271206|Nicotine Dependence
613423|NCT00271206|Tobacco Dependence
613424|NCT00271180|Cardiac Pacing
613425|NCT00271180|Implantable Cardioverter Defibrillator
613426|NCT00271180|pacemaker
613427|NCT00271180|Sinus Bradycardia
613428|NCT00271167|Cardiac surgery
613429|NCT00271167|PARP inhibitor
613430|NCT00271167|PARP inhibition
613431|NCT00271167|Bypass surgery
613432|NCT00271167|CPB surgery
613433|NCT00271167|Cardiopulmonary bypass
613434|NCT00271167|Coronary revascularization
613435|NCT00271167|Cardiac valve replacement
613436|NCT00271154|Heart Failure
613437|NCT00271154|Implantable Cardioverter Defibrillator
613689|NCT00270218|HIV Seronegativity
613438|NCT00271154|Cardiac Resynchronization Therapy
613439|NCT00271141|Parkinson's disease
613440|NCT00271141|Oxidative stress
613441|NCT00271141|Marker
613442|NCT00271128|NT-proBNP
613443|NCT00271128|Heart failure
613444|NCT00271128|Dyspnea
613445|NCT00271115|Kangaroo holding
613446|NCT00271115|Kangaroo care
613447|NCT00271115|Maternal stress levels
613448|NCT00271115|Premature birth
613449|NCT00271102|Cystocele, prolapse, anterior repair, colporrhaphy
613450|NCT00271076|CAD
613451|NCT00271076|CEA
613452|NCT00271076|CAS
613453|NCT00271076|IVUS
613454|NCT00271076|symptomatic
613455|NCT00271076|asymptomatic
613456|NCT00271076|Cerebral Protection Device
613457|NCT00271076|TIA
613458|NCT00271076|Stroke
613459|NCT00271076|plaque morphology
613460|NCT00271063|Refractory or Relapsed Acute Lymphocytic Leukemia
613461|NCT00271050|non-Hodgkin's lymphoma
613462|NCT00271050|external beam radiotherapy (EBRT)
613463|NCT00271050|radio-immunotherapy (RIT)
613464|NCT00271050|Zevalin
613465|NCT00271037|Pelvic organ prolapse
613466|NCT00271037|Stress urinary incontinence
613467|NCT00271037|Surgery
613468|NCT00271037|Colpocleisis
613469|NCT00271037|Urinary retention
613470|NCT00271024|Smoking
613471|NCT00271024|Smoking Cessation
613472|NCT00270998|Stress urinary incontinence
613473|NCT00270985|almonds
613474|NCT00270985|pre-diabetes
613475|NCT00270985|inflammatory
613476|NCT00270985|CRP
613477|NCT00270972|Venous leg ulcer
613478|NCT00270972|Venous insufficiency
613479|NCT00270972|OrCel
613480|NCT00270959|PTSD
613481|NCT00270946|Venous leg ulcer
613482|NCT00270946|OrCel
613483|NCT00270946|Compression therapy
613484|NCT00270933|defibrillators
613485|NCT00270933|LLECG
613486|NCT00270933|ventricular tachycardia
613487|NCT00270933|ventricular fibrillation
613488|NCT00270920|Initiation, Maintenance, Breastfeeding
613489|NCT00270907|Metastatic Breast Cancer
613490|NCT00270907|Breast Cancer
613491|NCT00270907|CT-2103
613492|NCT00270907|Gemcitabine
613493|NCT00270907|Xyotax
613494|NCT00270907|Gemzar
613495|NCT00270894|neoadjuvant chemotherapy
613496|NCT00270894|HER2 positive breast cancer
613497|NCT00270894|stage II - III breast cancer
613498|NCT00270881|cord blood transplantation
613499|NCT00270881|myeloablative regimen
613500|NCT00270881|hematologic malignancies
613501|NCT00270868|Double guide wire technique
613502|NCT00270868|Difficult selective biliary cannulation
613503|NCT00270868|ERCP
613504|NCT00270868|Attempts of cannulation
613505|NCT00270868|Post-ERCP complications.
613506|NCT00270855|Body Composition
613507|NCT00270855|Exercise
613508|NCT00270855|Glucose Tolerance
613509|NCT00270855|Insulin Sensitivity
613510|NCT00270855|Functional Electric Stimulation
613511|NCT00270842|Education
613512|NCT00270842|Exercise
613513|NCT00270842|Gait
613514|NCT00270842|Peripheral Nervous System
613515|NCT00270842|Postural Balance
613516|NCT00270842|Self Efficacy
613517|NCT00270842|Tai Chi Chuan
613518|NCT00270829|renal function
613519|NCT00270816|Multiple Sclerosis
613520|NCT00270816|Interferon-ß-1b
613521|NCT00270816|Therapy
613522|NCT00270803|Marijuana, FDG, PET, maze, THC, motor coordination.
613523|NCT00270790|Head and Neck cancer
613524|NCT00270777|Controlled trial
613525|NCT00270777|Snake bite
613526|NCT00270777|Safety
613527|NCT00270777|Antivenom
613528|NCT00270764|HIV/AIDS
613529|NCT00270764|Antiretroviral therapy
613530|NCT00270764|Quality of life
613531|NCT00270764|South Africa
613532|NCT00270764|Treatment Naive
613533|NCT00270751|Video-Assisted Thoracoscopic Surgery
613534|NCT00270751|Spontaneous pneumothorax
613535|NCT00270751|Pleurectomy
613536|NCT00270751|Pleural abrasion
613537|NCT00270751|Minocycline
613538|NCT00270738|urinary incontinence
613539|NCT00270738|transversus abdominis
613540|NCT00270738|pelvic floor muscles
613541|NCT00270738|randomized controlled trial
613542|NCT00270725|HIV
613543|NCT00270725|AIDS
613544|NCT00270725|Labor productivity
613545|NCT00270725|Antiretroviral therapy
613546|NCT00270725|South Africa
613547|NCT00270712|kidney
613548|NCT00270712|transplant
613549|NCT00270712|dysfunction
613550|NCT00270712|chronic
613551|NCT00270712|deterioration
613552|NCT00270712|loss of function
613553|NCT00270686|Ehlers-Danlos Syndrome
613554|NCT00270686|Stickler Syndrome
613555|NCT00270686|Marfan Syndrome
613556|NCT00270686|Genetics
613557|NCT00270686|Aneurysm
613558|NCT00270673|Lactate
613559|NCT00270673|Tissue hypoxia
613560|NCT00270673|Intensive care
613561|NCT00270673|Goal- directed therapy
613562|NCT00270660|retraction pockets ear
613563|NCT00270660|unsafe otitis media
613564|NCT00270660|otitis media complications
613565|NCT00270647|cancer
613566|NCT00270647|prostate cancer
613567|NCT00270647|colorectal cancer
613568|NCT00270647|cardiovascular disease
613569|NCT00270647|eye disease
613570|NCT00270647|cognitive decline
613571|NCT00270634|Randomized Controlled Trials
613572|NCT00270634|Immunosuppression
613573|NCT00270634|Adult
613574|NCT00270634|Kidney Transplantation
613575|NCT00270634|Treatment Outcome
613576|NCT00270608|Hypertension
613577|NCT00270608|Peripheral vascular disease
613578|NCT00270608|Diabetes
613579|NCT00270608|Total body fat percentage
613580|NCT00270556|Treatment Experienced
613581|NCT00270543|Stomach Neoplasms
613582|NCT00270530|Malaria
613583|NCT00270530|Placental diseases
613584|NCT00270530|Birth complications
613585|NCT00270530|Plasmodium falciparum
613586|NCT00270530|Zambia
613587|NCT00270530|HIV-seropositive
613588|NCT00270530|HIV
613589|NCT00270504|Memokath
613590|NCT00270504|Urethral stricture
613591|NCT00270504|urethral stent
613592|NCT00270504|Bulbar urethral stricture
613593|NCT00270478|Erythropoietin Therapy
613594|NCT00270478|Fetal Hemoglobin Induction
613595|NCT00270478|Sickle Cell Disease
613596|NCT00270478|Pulmonary Hypertension
613597|NCT00270478|Chronic Kidney Disease
613598|NCT00270478|SCD
613599|NCT00270465|HIV-positive
613600|NCT00270465|Treatment Interruption
613601|NCT00270465|Therapeutic Vaccine
613602|NCT00270465|HIV/AIDS
613603|NCT00270465|Virologic Response
613604|NCT00270465|HIV Positive
613605|NCT00270452|Myelodyplastic Syndrome (MDS)
613606|NCT00270452|Wilm's tumor-1
613607|NCT00270452|Proteinase-3
613608|NCT00270452|Vaccine Therapy
613609|NCT00270452|Acute Myeloid Leukemia
613610|NCT00270452|Chronic Myeloid Leukemias
613611|NCT00270452|Myelodysplastic Syndrome
613612|NCT00270452|MDS
613613|NCT00270439|Obesity
613614|NCT00270439|Omentectomy
613615|NCT00270439|Diabetes Mellitus Type 2
613616|NCT00270439|Laparoscopic
613617|NCT00270439|Dyslipidemia
613618|NCT00270426|Advanced Chronic Renal Insufficiency
613619|NCT00270426|Benazepril
613620|NCT00270413|breast cancer
613621|NCT00270413|metastatic
613622|NCT00270413|taxanes
613623|NCT00270413|SU11248
613624|NCT00270400|Heart Failure
613625|NCT00270400|Renal Dysfunction
613626|NCT00270400|Cardiomyopathy
613627|NCT00270400|Heart Decompensation
613628|NCT00270400|Dyspnea Paroxsymal.
613629|NCT00270387|Acutely Decompensated Congestive Heart Failure
613630|NCT00270387|Heart Failure
613631|NCT00270387|Renal Impairment
613632|NCT00270387|Kidney Failure
613633|NCT00270387|Myocardial Infarction.
613634|NCT00270374|Congestive heart failure
613635|NCT00270374|CHF
613636|NCT00270374|Left-sided heart failure
613637|NCT00270374|Right-sided heart failure
613638|NCT00270374|Systolic Heart Failure
613639|NCT00270361|Heart Failure
613640|NCT00270361|Renal Dysfunction
613641|NCT00270361|Cardiomyopathy
613642|NCT00270361|Heart Decompensation
613643|NCT00270361|Dyspnea Paroxsymal
613644|NCT00270361|Outpatient Therapy.
613645|NCT00270348|Asthma
613646|NCT00270348|Safety
613647|NCT00270348|Pediatrics
613648|NCT00270322|total knee replacement
613649|NCT00270322|orthopedic surgery
613650|NCT00270322|post operative analgesia
613651|NCT00270322|continuous epidural
613652|NCT00270322|patients controlled analgesia
613653|NCT00270322|morphine
613654|NCT00270322|combined spinal epidural anesthesia
613655|NCT00270322|anesthesia
613656|NCT00270322|analgesia
613657|NCT00270322|epidural marcaine
613658|NCT00270322|epidural fentanyl
613659|NCT00270322|pain
613660|NCT00270309|lower urinary tract symptoms, self-management
613661|NCT00270296|Treatment Naive
613662|NCT00270296|MTCT
613663|NCT00270296|HIV Seronegativity
613664|NCT00270283|Anemia
613665|NCT00270283|AIDS
613666|NCT00270283|erythropoietin
613667|NCT00270283|epoetin alfa
613668|NCT00270283|Quality of Life
613669|NCT00270283|Zidovudine
613670|NCT00270283|HIV
613671|NCT00270270|erythropoietin
613672|NCT00270270|Anemia
613673|NCT00270270|Quality of Life
613674|NCT00270270|epoetin alfa
613675|NCT00270270|HIV
613676|NCT00270270|Zidovudine
613677|NCT00270270|AIDS
613678|NCT00270257|HIV Seronegativity
613679|NCT00270257|Opiate Addiction
613680|NCT00270257|Opiate Dependence
613681|NCT00270244|Major Depression
613682|NCT00270244|Dysthymic Disorder
613683|NCT00270244|Adjustment Disorder With Depressed Mood
613684|NCT00270244|Depressive Disorder Not Otherwise Specified
613685|NCT00270244|Adolescent
613686|NCT00270244|Psychotherapy
613687|NCT00270231|within-subjects, crossover, laboratory study
613688|NCT00270231|Naltrexone vs. Placebo
613690|NCT00270218|Adenoviral Vector Vaccine
613691|NCT00270218|DNA Plasmid Vaccine
613692|NCT00270205|Treatment Experienced
613693|NCT00270205|HIV Therapeutic Vaccine
613694|NCT00270192|Breastfeeding
613695|NCT00270192|exclusive
613696|NCT00270192|education
613697|NCT00270192|counseling
613698|NCT00270179|Anemia
613699|NCT00270179|blood transfusion
613700|NCT00270179|epoetin alfa
613701|NCT00270179|erythropoietin
613702|NCT00270179|surgery
613703|NCT00270179|self-blood donation
613704|NCT00270166|cancer
613705|NCT00270166|malignancy
613706|NCT00270166|red cell transfusion
613707|NCT00270166|epoetin alfa
613708|NCT00270166|epoetin
613709|NCT00270166|erythropoietin
613710|NCT00270166|red blood cells
613711|NCT00270153|renal transplant, ACE inhibitor
613712|NCT00270140|anemia
613713|NCT00270140|blood transfusion
613714|NCT00270140|epoetin alfa
613715|NCT00270140|erythropoietin
613716|NCT00270140|surgery
613717|NCT00270140|blood donation
613718|NCT00270140|blood
613719|NCT00270127|Anemia
613720|NCT00270127|cancer
613721|NCT00270127|quality of life
613722|NCT00270127|chemotherapy
613723|NCT00270127|hemoglobin
613724|NCT00270127|transfusion
613725|NCT00270127|epoetin alfa
613726|NCT00270127|epoetin
613727|NCT00270127|erythropoietin
613728|NCT00270114|Anemia
613729|NCT00270114|blood transfusion, autologous
613730|NCT00270114|epoetin alfa
613731|NCT00270114|epogen
613732|NCT00270114|erythropoietin
613733|NCT00270114|orthopedic procedures
613734|NCT00270114|orthopedic surgery
613735|NCT00270101|anemia
613736|NCT00270101|cancer
613737|NCT00270101|quality of life
613738|NCT00270101|chemotherapy
613739|NCT00270101|hemoglobin
613740|NCT00270101|multiple myeloma
613741|NCT00270101|transfusion
613742|NCT00270101|epoetin alfa
613743|NCT00270101|epoetin
613744|NCT00270101|erythropoietin
613745|NCT00270088|Anemia
613746|NCT00270088|blood transfusion
613747|NCT00270088|epoetin alfa
613748|NCT00270088|epogen
613749|NCT00270088|erythropoietin
613750|NCT00270088|orthopedic procedures
613751|NCT00270088|orthopedic surgery
613752|NCT00270075|epogen
613753|NCT00270075|erythropoietin
613754|NCT00270075|orthopedic procedures
613755|NCT00270075|orthopedic surgery
613756|NCT00270075|cardiovascular surgical procedures
613757|NCT00270075|Blood transfusion
613758|NCT00270075|epoetin alfa
613759|NCT00270062|anemia
613760|NCT00270062|blood transfusion
613761|NCT00270062|epoetin alfa
613762|NCT00270062|erythropoietin
613763|NCT00270062|surgery
613764|NCT00270062|blood donation
613765|NCT00270062|blood
613766|NCT00270049|Anemia
613767|NCT00270049|cancer
613768|NCT00270049|leukemia
613769|NCT00270049|chronic lymphocytic leukemia
613770|NCT00270049|lymphocytic leukemia
613771|NCT00270049|epoetin alfa
613772|NCT00270049|erythropoietin
613773|NCT00270049|red blood cells
613774|NCT00270049|transfusions
613775|NCT00270049|quality of life
613776|NCT00270036|Blood transfusion
613777|NCT00270036|epoetin alfa
613778|NCT00270036|epogen
613779|NCT00270036|erythropoietin
613780|NCT00270036|orthopedic procedures
613781|NCT00270036|orthopedic surgery
613782|NCT00270023|Blood transfusion
613783|NCT00270023|epoetin alfa
613784|NCT00270023|epogen
613785|NCT00270023|erythropoietin
613786|NCT00270023|orthopedic procedures
613787|NCT00270023|orthopedic surgery
613788|NCT00270023|cardiovascular surgical procedures
613789|NCT00270023|breast reduction
613790|NCT00270010|Anemia
613791|NCT00270010|AIDS
613792|NCT00270010|HIV
613793|NCT00270010|Zidovudine
613794|NCT00270010|Quality of Life
613795|NCT00270010|erythropoietin
613796|NCT00270010|epoetin alfa
613797|NCT00269997|Anemia
613798|NCT00269997|chemotherapy
613799|NCT00269997|epoetin alfa
613800|NCT00269997|epogen
613801|NCT00269997|erythropoietin
613802|NCT00269997|neoplasms
613803|NCT00269997|cancer
613804|NCT00269984|Anemia
613805|NCT00269984|Blood transfusion
613806|NCT00269984|Epoetin alfa
613807|NCT00269984|Erythropoietin
613808|NCT00269984|Neoplasm
613809|NCT00269984|Epogen
613810|NCT00269984|Cancer
613811|NCT00269971|hip replacement
613812|NCT00269971|hip replacement surgery
613813|NCT00269971|surgery
613814|NCT00269971|anemia
613815|NCT00269971|transfusions
613816|NCT00269971|blood
613817|NCT00269971|blood transfusions
613818|NCT00269958|hip replacement
613819|NCT00269958|hip replacement surgery
613820|NCT00269958|surgery
613821|NCT00269958|anemia
613822|NCT00269958|transfusions
613823|NCT00269958|blood transfusions
613824|NCT00269945|Anemia
613825|NCT00269945|AIDS
613826|NCT00269945|HIV
613827|NCT00269945|Zidovudine
613828|NCT00269945|Quality of Life
613829|NCT00269945|erythropoietin
613830|NCT00269945|epoetin alfa
613831|NCT00269932|Bronchitis
613832|NCT00269932|chronic bronchitis
613833|NCT00269932|lung diseases
613834|NCT00269932|respiratory tract infections
613835|NCT00269932|bronchial diseases
613836|NCT00269932|antibacterial agents
613837|NCT00269932|quinolones
613838|NCT00269932|levofloxacin
613839|NCT00269919|Schizophrenia
613840|NCT00269919|Risperidone
613841|NCT00269919|Risperidal Consta
613842|NCT00269906|Angina, unstable
613843|NCT00269906|Angioplasty, transluminal, percutaneous coronary
613844|NCT00269906|Abciximab
613845|NCT00269893|Abciximab
613846|NCT00269893|Angina, unstable
613847|NCT00269893|Angioplasty, transluminal, Percutaneous coronary
613848|NCT00269880|Angioplasty, Transluminal, Percutaneous coronary
613849|NCT00269867|Rheumatoid Arthritis
613850|NCT00269867|infliximab
613851|NCT00269867|methotrexate
613852|NCT00269854|Crohn's Disease
613853|NCT00269841|fistulae
613854|NCT00269841|Crohn's Disease
613855|NCT00269828|Non-small cell lung cancer
613856|NCT00269828|NSCLC
613857|NCT00269828|PS 2
613858|NCT00269828|female
613859|NCT00269828|chemotherapy
613860|NCT00269815|ADHD
613861|NCT00269815|Attention Deficit Hyperactivity Disorder
613862|NCT00269815|OROS®
613863|NCT00269815|children
613864|NCT00269815|methylphenidate
613865|NCT00269802|ADHD
613866|NCT00269802|Attention Deficit Hyperactivity Disorder
613867|NCT00269802|OROS®
613868|NCT00269802|Ritalin®
613869|NCT00269802|children
613870|NCT00269802|methylphenidate
613871|NCT00269789|Attention Deficit Hyperactivity Disorder
613872|NCT00269789|OROS®
613873|NCT00269789|Ritalin®
613874|NCT00269789|children
613875|NCT00269789|methylphenidate
613876|NCT00269789|ADHD
613877|NCT00269776|ADHD
613878|NCT00269776|Attention Deficit Hyperactivity Disorder
613879|NCT00269776|OROS
613880|NCT00269776|children
613881|NCT00269776|methylphenidate
613882|NCT00269776|Ritalin
613883|NCT00269763|patch
613884|NCT00269763|pain
613885|NCT00269763|fentanyl
613886|NCT00269763|narcotic
613887|NCT00269763|Cancer
613888|NCT00269750|Ditropan®
613889|NCT00269750|OROS®
613890|NCT00269750|urge
613891|NCT00269750|oxybutynin
613892|NCT00269750|mixed urinary incontinence
613893|NCT00269737|fentanyl
613894|NCT00269737|pain
613895|NCT00269737|Cancer
613896|NCT00269737|patch
613897|NCT00269724|urinary incontinence
613898|NCT00269724|oxybutynin
613899|NCT00269724|OROS®
613900|NCT00269685|Septic shock
613901|NCT00269685|catecholamine
613902|NCT00269685|vasopressin
613903|NCT00269685|tonometria
613904|NCT00269685|lactate
613905|NCT00269672|vaccine
613906|NCT00269659|Left Bundle Branch Block
613907|NCT00269659|Regional cardiac function
613908|NCT00269659|Global cardiac function
613909|NCT00269659|Mechanical asynchrony
613910|NCT00269659|Echocardiography
613911|NCT00269659|2D echocardiography
613912|NCT00269659|Tissue Doppler Imaging
613913|NCT00269659|Real-time 3D echocardiography
613914|NCT00269659|Cardiovascular Magnetic Resonance Imaging-tagging
613915|NCT00269646|Diet
613916|NCT00269646|Low-carbohydrate
613917|NCT00269646|Insulin
613918|NCT00269646|Dietary fiber
613919|NCT00269646|Diabetes
613920|NCT00269646|Cardiovascular disease
613921|NCT00269633|Seasonal Affective Disorder
613922|NCT00269620|contraceptive vaginal ring
613923|NCT00269620|contraceptive patch
613924|NCT00269620|oral contraceptives
613925|NCT00269620|acceptability
613926|NCT00269607|Substance abuse
613927|NCT00269607|Treatment
613928|NCT00269607|Relapse prevention
613929|NCT00269607|opioid antagonist
613930|NCT00269594|Skin
613931|NCT00269594|Picking
613932|NCT00269594|Pick
613933|NCT00269594|Neurotic Excoriation
613934|NCT00269581|migraine
613935|NCT00269581|tension headaches
613936|NCT00269581|chronic daily headaches
613937|NCT00269568|medical abortion
613938|NCT00269568|mifepristone
613939|NCT00269568|misoprostol
613940|NCT00269555|Prostate
613941|NCT00269555|Cancer
613942|NCT00269555|Prostate Specific Antigen
613943|NCT00269555|C04.588.945.440.770
613944|NCT00269542|zinc supplementation
613945|NCT00269542|hospitalisations
613946|NCT00269542|children
613947|NCT00269542|mortality
613948|NCT00269542|iron folic acid
613949|NCT00269529|postoperative pain
613950|NCT00269529|knee arthroplasty
613951|NCT00269529|analgesia
613952|NCT00269529|infiltration
613953|NCT00269529|femoral nerve block
613954|NCT00269516|Parkinson's disease
613955|NCT00269490|Post-Traumatic Stress Disorder
613956|NCT00269490|Yoga Nidra
613957|NCT00269477|Meningitis
613958|NCT00269477|Meningococcal infection
613959|NCT00269477|Neisseria meningitidis
613960|NCT00269477|Menactra®
613961|NCT00269477|Menomune®
613962|NCT00268658|Arthroplasty, Replacement, Hip
613963|NCT00268658|Arthroplasty, Replacement, Knee
613964|NCT00268658|Arthroscopy
613965|NCT00269425|Cardiovascular disease
613966|NCT00269425|Nutrition
613967|NCT00269425|Mediterranean diet
613968|NCT00269425|Low fat diet
613969|NCT00269425|American Heart Association diet
613970|NCT00269425|Monounsaturated fats
613971|NCT00269425|Omega-3 fats
613972|NCT00269425|Outcomes
613973|NCT00269412|Irritable bowel syndrome
613974|NCT00269399|Clostridium difficile-associated Diarrhea (CDAD)
613975|NCT00269399|CDAD
613976|NCT00269399|C diff
613977|NCT00269386|Clarithromycin
613978|NCT00269386|Crohn's
613979|NCT00269373|Unknown primary tumor
613980|NCT00269373|PET-CT
613981|NCT00269360|Chiropractic
613982|NCT00269360|Manual Therapies
613983|NCT00269360|Exercise
613984|NCT00269360|Randomized
613985|NCT00269360|Clinical Trial
613986|NCT00269360|Neck Pain
613987|NCT00269347|Chiropractic
613988|NCT00269347|Manual Therapy
613989|NCT00269347|Exercise
613990|NCT00269347|Randomized
613991|NCT00269347|Clinical Trial
613992|NCT00269347|Back Pain
613993|NCT00269334|antidepressant,major depression,CYP2D6,CYP2C19,SSRI
613994|NCT00269321|Randomized
613995|NCT00269321|Clinical Trial
613996|NCT00269321|Low Back Pain
613997|NCT00269321|Chiropractic
613998|NCT00269321|Manual Therapies
613999|NCT00269321|Exercise
614000|NCT00269308|Randomized
614001|NCT00269308|Clinical Trial
614002|NCT00269308|Neck Pain
614003|NCT00269308|Chiropractic
614004|NCT00269308|Manual Therapies
614005|NCT00269308|Exercise
614006|NCT00269295|Typhoid fever, S typhi, vaccine
614007|NCT00269230|cardiac resynchronization therapy, left ventricular Lead, Heart Failure
614008|NCT00269191|Arcoxia
614009|NCT00269178|malaria
614010|NCT00269178|knowledge attitudes and practice (KAP)
614011|NCT00269178|bednets
614012|NCT00269178|peer health education
614013|NCT00269139|Behavioral crisis
614014|NCT00269139|Perception of social crisis
614015|NCT00269139|Repetition compulsion
614016|NCT00269139|Intrusive mental events
614017|NCT00269139|Uncontrollable urges
614018|NCT00269126|COPD
614019|NCT00269126|Chronic Bronchitis
614020|NCT00269126|Emphysema
614021|NCT00268606|fibromyalgia
614022|NCT00268606|cognitive-behavioral therapy
614023|NCT00268606|tailored treatment
614024|NCT00268593|heparanase
614025|NCT00268593|angiogenesis
614026|NCT00268580|Asthma
614027|NCT00268580|Care map
614028|NCT00268580|Clinical pathway
614029|NCT00268580|Education
614030|NCT00268580|Emergency department
614031|NCT00268554|adenosine
614032|NCT00268554|caffeine
614033|NCT00268554|dipyridamole
614034|NCT00268541|exercise
614035|NCT00268541|physical activity
614036|NCT00268541|insulin resistance
614037|NCT00268541|adipose tissue
614038|NCT00268541|gene expression
614039|NCT00268502|fatigue
614040|NCT00268502|depression
614041|NCT00268502|spiritual concerns
614042|NCT00268502|sexual dysfunction
614043|NCT00268502|sleep disorders
614044|NCT00268502|cancer survivor
614045|NCT00268502|stage IA breast cancer
614046|NCT00268502|stage IB breast cancer
614047|NCT00268502|stage II breast cancer
614048|NCT00268502|stage IIIA breast cancer
614049|NCT00268502|stage IIIB breast cancer
614050|NCT00268502|stage IIIC breast cancer
614051|NCT00268489|recurrent non-small cell lung cancer
614052|NCT00268489|squamous cell lung cancer
614053|NCT00268489|stage IIIB non-small cell lung cancer
614054|NCT00268489|stage IV non-small cell lung cancer
614055|NCT00268476|stage III prostate cancer
614056|NCT00268476|stage IV prostate cancer
614057|NCT00268476|recurrent prostate cancer
614058|NCT00268476|adenocarcinoma of the prostate
614059|NCT00269100|Debridement
614060|NCT00269087|Chronic Bronchitis
614061|NCT00269087|COPD
614062|NCT00269087|Emphysema
614063|NCT00269061|pioglitazone
614064|NCT00269061|diabetes
614065|NCT00269061|fluid
614066|NCT00269048|CHD
614067|NCT00269048|Lp-PLA2
614068|NCT00269048|SB-480848
614069|NCT00269035|SB-773812
614070|NCT00269035|SPECT
614071|NCT00269035|D2 RO
614072|NCT00269035|pharmacokinetics
614073|NCT00269035|schizophrenic patients
614074|NCT00269035|5HT2A RO
614075|NCT00269022|SB-705498 acute migraine single dose TRPV1 combination inpatient outpatient study
614076|NCT00269009|Tobacco use
614077|NCT00268996|Lipoprotein-associated Phospholipase A2
614078|NCT00268996|palpography
614079|NCT00268996|hs-CRP
614080|NCT00268996|Coronary artery disease
614081|NCT00268996|endothelial function
614082|NCT00268996|intravascular ultrasound
614083|NCT00268983|rituximab
614084|NCT00268983|tositumomab and iodine I 131 tositumomab
614085|NCT00268983|non-Hodgkins lymphoma
614086|NCT00268983|radioimmunotherapy
614087|NCT00268983|anti-B1 antibody
614088|NCT00268983|Bexxar
614089|NCT00268983|NHL
614090|NCT00268983|Tositumomab
614091|NCT00268970|Advanced non-small cell lung cancer (NSCLC)
614092|NCT00268957|Chronic
614093|NCT00268957|Hemodialysis
614094|NCT00268957|Kidney
614095|NCT00268957|Hyperphosphatemia
614096|NCT00268957|Chronic kidney disease
614097|NCT00268957|Chronic Renal Insufficiency
614098|NCT00268944|Glycogen Storage Disease Type II
614099|NCT00268944|GSD-II
614100|NCT00268944|Pompe Disease
614101|NCT00268931|premature birth
614102|NCT00268931|motor skills
614103|NCT00268931|learning
614104|NCT00268931|reaching
614105|NCT00268918|PTK787
614106|NCT00268918|Metastatic breast cancer
614107|NCT00268918|Refractory gynecological cancer
614108|NCT00268892|Prostate Cancer
614109|NCT00268892|Androgen ablation therapy
614110|NCT00268879|Irritable bowel syndrome
614111|NCT00268879|Constipation-predominant irritable bowel syndrome
614112|NCT00268853|lymphoma
614113|NCT00268853|NHL
614114|NCT00268853|large cell
614115|NCT00268853|phase II
614116|NCT00268853|CHOP R
614117|NCT00268853|CPOP R
614118|NCT00268853|non Hodgkins
614119|NCT00268840|Pancreas or biliary cancer
614120|NCT00268827|Kaletra
614121|NCT00268827|Comparison
614122|NCT00268827|Quality of Life
614123|NCT00268827|African American
614124|NCT00268788|multifocal motor neuropathy
614125|NCT00268788|subcutaneous
614126|NCT00268788|IVIG
614127|NCT00268788|gammaglobulin
614128|NCT00268775|community pharmacy services
614129|NCT00268775|patient care
614130|NCT00268775|outcome assessment
614131|NCT00268775|benzodiazepines therapeutic use
614132|NCT00268762|stroke
614133|NCT00268762|thrombin inhibition
614134|NCT00268762|thrombolysis
614135|NCT00268762|bleeding
614136|NCT00268762|outcome
614137|NCT00268697|Hyperlipidemia
614138|NCT00268697|Drug Therapy
614139|NCT00268463|liver metastases
614140|NCT00268463|stage IV colon cancer
614141|NCT00268463|stage IV rectal cancer
614142|NCT00268463|adenocarcinoma of the colon
614143|NCT00268463|adenocarcinoma of the rectum
614144|NCT00268450|transitional cell carcinoma of the bladder
614145|NCT00268450|stage III bladder cancer
614146|NCT00268450|stage II bladder cancer
614147|NCT00268450|recurrent bladder cancer
614148|NCT00268437|adenocarcinoma of the esophagus
614149|NCT00268437|squamous cell carcinoma of the esophagus
614150|NCT00268437|stage III esophageal cancer
614151|NCT00268437|stage II esophageal cancer
614152|NCT00268411|adenocarcinoma of the pancreas
614153|NCT00268411|stage IV pancreatic cancer
614154|NCT00268398|adenocarcinoma of the colon
614155|NCT00268398|stage IV colon cancer
614156|NCT00268398|adenocarcinoma of the rectum
614157|NCT00268398|stage IV rectal cancer
614158|NCT00268398|resectable metastases
614159|NCT00268372|stage III squamous cell carcinoma of the oropharynx
614160|NCT00268372|stage IV squamous cell carcinoma of the oropharynx
614161|NCT00268359|adult anaplastic astrocytoma
614162|NCT00268359|adult anaplastic oligodendroglioma
614163|NCT00268359|adult glioblastoma
614164|NCT00268359|adult gliosarcoma
614165|NCT00268359|recurrent adult brain tumor
614166|NCT00268359|adult giant cell glioblastoma
614167|NCT00268346|adenocarcinoma of the esophagus
614168|NCT00268346|recurrent esophageal cancer
614169|NCT00268346|squamous cell carcinoma of the esophagus
614170|NCT00268346|stage IV esophageal cancer
614171|NCT00268333|adenocarcinoma of the colon
614172|NCT00268333|adenocarcinoma of the rectum
614173|NCT00268333|stage IV colon cancer
614174|NCT00268333|stage III colon cancer
614175|NCT00268333|stage III rectal cancer
614176|NCT00268333|stage IV rectal cancer
614177|NCT00268320|congestive heart failure, atrial arrhythmia, cardiac resynchronization therapy, implantable cardioverter defibrillator
614178|NCT00268307|Cell therapy
614179|NCT00268294|cardiac resynchronization therapy, atrial arrhythmia
614180|NCT00268281|cardiac resynchronization therapy
614181|NCT00268255|stage I non-small cell lung cancer
614182|NCT00268255|stage II non-small cell lung cancer
614183|NCT00268255|adenosquamous cell lung cancer
614184|NCT00268255|bronchoalveolar cell lung cancer
614185|NCT00268255|large cell lung cancer
614186|NCT00268255|squamous cell lung cancer
614187|NCT00268255|adenocarcinoma of the lung
614188|NCT00268242|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
614189|NCT00268242|adult acute myeloid leukemia with inv(16)(p13;q22)
614190|NCT00268242|adult acute myeloid leukemia with t(16;16)(p13;q22)
614191|NCT00268242|adult acute myeloid leukemia with t(8;21)(q22;q22)
614192|NCT00268242|recurrent adult acute myeloid leukemia
614193|NCT00268242|adult acute minimally differentiated myeloid leukemia (M0)
614194|NCT00268242|adult acute myeloblastic leukemia without maturation (M1)
614195|NCT00268242|adult acute myeloblastic leukemia with maturation (M2)
614196|NCT00268242|adult acute myelomonocytic leukemia (M4)
614197|NCT00268242|adult acute monoblastic leukemia (M5a)
614198|NCT00268242|adult acute monocytic leukemia (M5b)
614199|NCT00268242|adult erythroleukemia (M6a)
614200|NCT00268242|adult pure erythroid leukemia (M6b)
614201|NCT00268242|adult acute megakaryoblastic leukemia (M7)
614202|NCT00268229|recurrent adult acute myeloid leukemia
614203|NCT00268229|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
614204|NCT00268229|adult acute myeloid leukemia with inv(16)(p13;q22)
614205|NCT00268229|adult acute myeloid leukemia with t(16;16)(p13;q22)
614206|NCT00268229|adult acute myeloid leukemia with t(8;21)(q22;q22)
614207|NCT00268229|adult acute minimally differentiated myeloid leukemia (M0)
614208|NCT00268229|adult acute megakaryoblastic leukemia (M7)
614209|NCT00268229|adult acute monoblastic leukemia (M5a)
614210|NCT00268229|adult acute monocytic leukemia (M5b)
614211|NCT00268229|adult acute myeloblastic leukemia with maturation (M2)
614212|NCT00268229|adult acute myeloblastic leukemia without maturation (M1)
614213|NCT00268229|adult acute myelomonocytic leukemia (M4)
614214|NCT00268229|adult erythroleukemia (M6a)
614215|NCT00268229|adult pure erythroid leukemia (M6b)
614216|NCT00268216|mortality
614217|NCT00268216|TORCH
614218|NCT00268216|SERETIDE
614219|NCT00268216|ADVAIR
614220|NCT00268216|COPD
614221|NCT00268203|expanded access study
614222|NCT00268203|refractory low-grade non-Hodgkin's Lymphoma
614223|NCT00268203|Bexxar®
614224|NCT00268203|Iodine I 131 Tositumomab
614225|NCT00268203|EAP
614226|NCT00268203|relapsed low-grade non-Hodgkin's lymphoma
614227|NCT00268177|Airways
614228|NCT00268177|Pulmonary
614229|NCT00268177|Obstructive
614230|NCT00268177|Chronic
614231|NCT00268177|inflammation
614232|NCT00268177|salmeterol/fluticasone propionate
614233|NCT00268151|non-small cell lung cancer
614234|NCT00268151|oxaliplatin
614235|NCT00268151|capecitabine
614236|NCT00268151|XELOX-RT
614237|NCT00268138|amine fluoride
614238|NCT00268138|white spot lesions
614239|NCT00268138|qlf
614240|NCT00268125|Breast Neoplasm
614241|NCT00268125|FEC100
614242|NCT00268125|Chemotherapy
614243|NCT00268125|acupression
614244|NCT00268125|bracelet
614245|NCT00268125|nausea
614246|NCT00268125|vomiting
614247|NCT00268112|pediatric
614248|NCT00268112|cardiac
614249|NCT00268112|ALCAPA
614250|NCT00268112|Tissue Doppler Imaging
614251|NCT00268099|pediatric
614252|NCT00268099|cardiac
614253|NCT00268099|repair of right to left shunt lesions
614254|NCT00268099|Tetralogy of Fallot defects
614255|NCT00268086|constrictive pericarditis
614256|NCT00268086|adult congenital patients
614257|NCT00268086|pulmonary insufficiency
614258|NCT00268073|Pediatric
614259|NCT00268073|cardiac
614260|NCT00268073|neo-aortic insufficience
614261|NCT00268073|Norwood standard Stage I procedure
614262|NCT00268073|Norwood Sano procedure
614263|NCT00268060|pediatric
614264|NCT00268060|cardiac
614265|NCT00268060|Long QT Syndrome
614266|NCT00268060|Pacemaker
614267|NCT00268060|Herg mutation
614268|NCT00268047|pediatric
614269|NCT00268047|cardiac
614270|NCT00268047|surgery
614271|NCT00268047|transplantation
614272|NCT00268047|pulmonary vascular resistance in Fontan patients
614273|NCT00268034|pediatric
614274|NCT00268034|cardiac
614275|NCT00268034|aneurysms
614276|NCT00268034|left ventricular aneurysms
614277|NCT00268034|surgical repair for LV aneurysms
614278|NCT00268021|pediatric
614279|NCT00268021|biventricular pacemaker
614280|NCT00268021|automated implantable cardioverter defibrillator
614281|NCT00268021|AICD
614282|NCT00268008|aortic valve replacement
614283|NCT00268008|mitral valve replacement
614284|NCT00268008|valvular stenosis
614285|NCT00268008|Ross procedure
614286|NCT00268008|Homograft valves
614287|NCT00268008|Bio-prosthetic valves
614288|NCT00268008|Mechanical valves
614289|NCT00267995|Pediatric
614290|NCT00267995|cardiac
614291|NCT00267995|Ross procedure
614292|NCT00267995|Aortic valve replacement
614293|NCT00267995|Proximal buttressing technique
614294|NCT00267982|pediatric
614295|NCT00267982|cardiac
614296|NCT00267982|Radiofrequency Ablation
614297|NCT00267982|Ectopic Atrial Tachycardia
614298|NCT00267969|Ustekinumab
614299|NCT00267969|CNTO1275
614300|NCT00267969|Plaque type Psoriasis
614301|NCT00267969|Interleukin-23
614302|NCT00267969|IL-23
614303|NCT00267969|Psoriasis
614304|NCT00267969|Interleukin 12
614305|NCT00267969|IL-12
614306|NCT00267956|Psoriatic arthritis
614307|NCT00267956|CNTO 1275
614308|NCT00267956|Ustekinumab
614309|NCT00267956|Interleukin-23, IL-12, IL-23
614310|NCT00267956|Monoclonal antibodies
614311|NCT00267930|AFib
614312|NCT00267930|AF
614313|NCT00267904|Normal Physiology
614314|NCT00267904|Catecholamines
614315|NCT00267904|Catechols
614316|NCT00267904|Healthy Volunteer
614317|NCT00267904|HV
614318|NCT00267891|Healthy Control Subjects
614319|NCT00267891|Aggression
614320|NCT00267891|Prefrontal Cortex Function
614321|NCT00267891|Children and Adolescents
614322|NCT00267891|Healthy Volunteer
614323|NCT00267891|HV
614324|NCT00267865|HIV
614325|NCT00267865|AIDS-Related-Primary Central Nervous System Lymphoma
614326|NCT00267865|High Dose Methotrexate
614327|NCT00267865|Rituximab
614328|NCT00267865|Highly Active Antiretroviral Therapy
614329|NCT00267865|AIDS Related-Primary Central Nervous System Lymphoma
614330|NCT00267865|AR-PCNSL
614331|NCT00267852|Arthritis
614332|NCT00267839|exercise
614333|NCT00267839|intervention
614334|NCT00267839|elderly woman
614335|NCT00267839|risk factors
614336|NCT00267839|health costs
614337|NCT00267839|Osteoporosis
614338|NCT00267839|cardiovascular diseases
614339|NCT00267839|diabetes
614340|NCT00267839|Higher Age
614341|NCT00267826|Anti-CD20 antibody treatment
614342|NCT00267826|Atopic dermatitis
614343|NCT00267826|B cells
614344|NCT00267826|Cytokines
614345|NCT00267826|Immunopathology
614346|NCT00267813|craving
614347|NCT00267813|nicotine
614348|NCT00267813|imaging
614349|NCT00267813|FDG
614350|NCT00267813|PET
614351|NCT00267813|smoking
614352|NCT00267813|Bupropion
614353|NCT00267800|Lung disease, Interstitial
614354|NCT00267800|Sarcoidosis
614355|NCT00267800|Pulmonary fibrosis
614356|NCT00267735|pregnancy
614357|NCT00267735|repeat cesarean
614358|NCT00267735|vaginal birth after cesarean
614359|NCT00267696|ovarian cancer
614360|NCT00267696|platinum sensitive cancer
614361|NCT00267696|fallopian tube cancer
614362|NCT00267696|peritoneal cancer
614363|NCT00267670|Fatty Liver Disease
614364|NCT00267670|Liver
614365|NCT00267670|NASH
614366|NCT00267670|Nonalcoholic Steatohepatitis
614367|NCT00267670|Nonalcoholic Fatty Liver Disease (NAFLD)
614368|NCT00267670|Pentoxifylline
614369|NCT00267644|Children, dehydration, Ultrasound
614370|NCT00267631|children, obesity, emergency medicine
614371|NCT00267553|Atamestane
614372|NCT00267553|Breast neoplasms
614373|NCT00267553|Combined hormonal therapy
614374|NCT00267553|Complete estrogen blockade
614375|NCT00267553|Ductal breast carcinoma
614376|NCT00267553|Estrogen blocker
614377|NCT00267553|Fareston®
614378|NCT00267553|Femara®
614379|NCT00267553|First line therapy
614380|NCT00267553|Letrozole
614381|NCT00267553|Lobular breast carcinoma
614382|NCT00267553|Locally advanced breast cancer
614383|NCT00267553|Locally recurrent breast cancer
614384|NCT00267553|Maximal estrogen inhibition
614385|NCT00267553|Metastatic breast cancer
614386|NCT00267553|Neoplasms, Hormone-dependent
614387|NCT00267553|Receptor-positive
614388|NCT00267553|Stage IIIA breast cancer
614389|NCT00267553|Stage IIIB breast cancer
614390|NCT00267553|Stage IV breast cancer
614391|NCT00267553|Toremifene
614392|NCT00267540|Vitamin D
614393|NCT00267540|adolescent girls
614394|NCT00267540|bone accretion
614395|NCT00267540|bone turn over
614396|NCT00267540|vitamin D status
614397|NCT00267540|Vitamin D insufficiency in young girls
614398|NCT00267527|Treatment Experienced
614399|NCT00267527|HIV Visceral Obesity
614400|NCT00267514|Hemodialysis
614401|NCT00267501|Eosinophilic Disorders
614402|NCT00267488|Hycamtin
614403|NCT00267488|endometrial cancer
614404|NCT00267488|topotecan
614405|NCT00267475|eosinophilic esophagitis
614406|NCT00267475|eosinophilic gastritis
614407|NCT00267475|eosinophilic enteritis
614408|NCT00267475|eosinophilic colitis
614409|NCT00267475|eosinophilic gastroenteritis
614410|NCT00267462|pediatric
614411|NCT00267462|cardiac
614412|NCT00267462|hypertrophic Myopathy
614413|NCT00267449|Spectroscopy, Near-Infrared
614414|NCT00267449|Mammography
614415|NCT00267449|Breast Cancer
614416|NCT00267436|adaptation
614417|NCT00267436|HIV prevention
614418|NCT00267436|HIV positive
614419|NCT00267436|evidence based interventions
614420|NCT00267436|HIV Seronegativity
614421|NCT00267423|pediatric
614422|NCT00267423|cardiac
614423|NCT00267423|electrophysiology
614424|NCT00267423|epicardial biventricular pacing
614425|NCT00267410|HIV
614426|NCT00267410|Adaptation
614427|NCT00267410|Behavioral interventions
614428|NCT00267410|Seropositive
614429|NCT00267410|MSM
614430|NCT00267410|HIV Seronegativity
614431|NCT00267397|infant
614432|NCT00267397|prenatal
614433|NCT00267397|birth defects
614434|NCT00267397|22Q11 deletion
614435|NCT00267384|Aminoglycosides
614436|NCT00267371|Migraine headache
614437|NCT00267371|Patent Foramen Ovale
614438|NCT00267371|Patent Foramen Ovale Closure
614439|NCT00265057|Cancer;
614440|NCT00265057|Tumors;
614441|NCT00265057|Neoplasms;
614442|NCT00265057|Anticarcinogenic Agents;
614443|NCT00265057|Antineoplastic Agents;
614444|NCT00265057|Cadherins;
614445|NCT00265057|Non-Small-Cell Lung Carcinoma;
614446|NCT00265057|Ovarian Cancer
614447|NCT00265044|Behavior Change
614448|NCT00265044|patient Education
614449|NCT00265031|Hodgkin´s Lymphoma
614450|NCT00265031|advanced stages
614451|NCT00265018|Hodgkin´s lymphoma
614452|NCT00265018|early stages
614453|NCT00265005|alteplase
614454|NCT00265005|occluded central venous catheter
614455|NCT00265005|occluded arterial catheter
614456|NCT00265005|occluded PICC
614457|NCT00265005|neonates
614458|NCT00265005|infants
614459|NCT00264992|embryo implantation, in vitro fertilization,
614460|NCT00264992|cytokine expression
614461|NCT00264979|Colorectal cancer
614462|NCT00264979|Sequential or simultaneous surgery
614463|NCT00264979|Synchronous hepatic metastases
614464|NCT00264966|Mild asthma
614465|NCT00264953|Hodgkin´s lymphoma
614466|NCT00264953|intermediate stages
614467|NCT00264927|Inappropriate ADH Syndrome
614468|NCT00264927|Hyponatremia
614469|NCT00264914|Inappropriate ADH Syndrome
614470|NCT00264914|Hyponatremia
614471|NCT00264888|Duchenne muscular dystrophy
614472|NCT00264888|Nonsense mutation
614473|NCT00264888|Premature stop codon
614474|NCT00267332|Sedation
614475|NCT00267332|Pain
614476|NCT00267332|modafinil
614477|NCT00267332|opioids
614478|NCT00267293|fever treatment
614479|NCT00267293|children
614480|NCT00267241|ARDS
614481|NCT00267241|ALI
614482|NCT00267241|respiratory mechanics
614483|NCT00267241|gas exchange
614484|NCT00267241|assisted ventilation
614485|NCT00267228|Anorexia Nervosa
614486|NCT00267228|Eating disorder
614487|NCT00267228|Quality of life
614488|NCT00267215|Lumiracoxib
614489|NCT00267215|osteoarthritis
614490|NCT00267202|Allergic Asthma, IgE, immunotherapy, omalizumab
614491|NCT00267189|Liver transplantation, everolimus, calcineurin inhibitor, renal function
614492|NCT00267176|Osteoarthritis,
614493|NCT00267176|hypertension,
614494|NCT00267176|lumiracoxib,
614495|NCT00267176|ibuprofen,
614496|NCT00267176|24-hour blood pressure profile
614497|NCT00267163|Alzheimer's disease
614498|NCT00267163|Mild Cognitive Impairment
614499|NCT00267150|Simultaneous Pancreas-Kidney Transplantation
614500|NCT00267150|mycophenolate
614501|NCT00267150|GI problems
614502|NCT00267137|Pacemaker, Atrial Fibrillation/Therapy
614503|NCT00267124|cognitive decline
614504|NCT00267124|dementia
614505|NCT00267124|neuroimaging
614506|NCT00267111|Infant,newborn
614507|NCT00267111|Topical anesthesia
614508|NCT00267111|Intramuscular injection
614509|NCT00267098|Atrioventricular block
614510|NCT00267098|Cardiac Resynchronization Therapy
614511|NCT00267098|Pacemaker
614512|NCT00267098|Defibrillator
614513|NCT00267098|NYHA Class I, II or III Heart failure
614514|NCT00267085|Chronic Myeloid Leukemia
614515|NCT00267085|Minimal Residual Disease
614516|NCT00267085|Peptide Vaccine
614517|NCT00267072|Ovarian Cancer
614518|NCT00267059|Chronic Lymphocytic Leukemia
614519|NCT00267059|Lenalidomide
614520|NCT00267059|Revlimid
614521|NCT00267059|CLL
614522|NCT00267046|Sarcoma
614523|NCT00267046|Soft Tissue Sarcoma
614524|NCT00267046|Oral Mucositis
614525|NCT00267046|Doxorubicin
614526|NCT00267046|Adriamycin
614527|NCT00267046|Ifosfamide
614528|NCT00267046|Palifermin
614529|NCT00267046|Vincristine
614530|NCT00267046|Cisplatin
614531|NCT00267046|Placebo
614532|NCT00267033|Neoplasm Metastasis
614533|NCT00267033|Bone Neoplasms
614534|NCT00267033|Pain
614535|NCT00267033|Radiotherapy
614536|NCT00267033|Vertebroplasty
614537|NCT00267033|Combined modality therapy
614538|NCT00267007|Peripheral neuropathy
614539|NCT00267007|Chemotherapy-induced
614540|NCT00267007|Hemoglobin level
614541|NCT00267007|Cancer
614542|NCT00267007|Taxane
614543|NCT00267007|Platinum-based chemotherapy
614544|NCT00266994|Thrombosis
614545|NCT00266968|pediatric
614546|NCT00266968|cardiac
614547|NCT00266968|single ventricle
614548|NCT00266955|pediatric
614549|NCT00266955|cardiac
614550|NCT00266955|ADHD
614551|NCT00266955|Adderall
614552|NCT00266955|Straterra
614553|NCT00266942|Fontan procedure
614554|NCT00266942|single ventricle physiology
614555|NCT00266942|intra-atrial
614556|NCT00266942|extracardiac technique
614557|NCT00266929|odontoid fx
614558|NCT00266929|surgical intervention
614559|NCT00266929|conservative treatment
614560|NCT00266929|nonunion
614561|NCT00266929|odontoid fractures
614562|NCT00266929|surgical treatment
614563|NCT00266916|adult
614564|NCT00266916|congenital heart disease
614565|NCT00266916|percutaneous occlusion
614566|NCT00266916|percutaneous balloon valvotomy
614567|NCT00266916|balloon angioplasty
614568|NCT00266916|complex cyanotic congenital heart defects (CCHD)
614569|NCT00266903|adult
614570|NCT00266903|congenital heart disease
614571|NCT00266903|Eisenmenger's Syndrome
614572|NCT00266903|Bosentan
614573|NCT00266903|Sitaxsetan
614574|NCT00266903|Sildenafil
614575|NCT00266877|Lung Cancer
614576|NCT00266864|Spinal Cord Injury
614577|NCT00266864|Testosterone Replacement Therapy
614578|NCT00266864|Dual Energy X ray Absorptiometry
614579|NCT00266864|Lean Tissue Mass
614580|NCT00266851|Randomized clinical trial
614581|NCT00266851|Asthma
614582|NCT00266851|Adults
614583|NCT00266851|Azithromycin
614584|NCT00266838|Lacrimal Obstruction
614585|NCT00266838|Epiphora
614586|NCT00266812|temozolomide
614587|NCT00266812|radiotherapy
614588|NCT00266773|Chronic Pain
614589|NCT00266773|Cognitive Therapy
614590|NCT00266773|Cognitive Behavioral Therapy
614591|NCT00266773|Recurrence
614592|NCT00266773|Relapse Prevention
614593|NCT00266773|Educational Technology
614594|NCT00266773|CBT
614595|NCT00266773|CST
614596|NCT00266773|IVR
614597|NCT00266773|TIVR
614598|NCT00266747|Anxiety
614599|NCT00266747|Anti-Anxiety Agents
614600|NCT00266747|Controlled Clinical Trial
614601|NCT00266734|Adenoviral conjunctivitis
614602|NCT00266734|Viral conjunctivitis
614603|NCT00266734|conjunctivitis
614604|NCT00266721|Pancrelipase
614605|NCT00266721|Abdominal bloating
614606|NCT00266721|Abdominal pain
614607|NCT00266721|Eructation
614608|NCT00266708|renal transplant
614609|NCT00266708|post-transplant osteoporosis
614610|NCT00266682|Bradycardia
614611|NCT00266669|Raynaud's Phenomenon
614612|NCT00266669|Raynaud's Disease
614613|NCT00266669|Scleroderma
614614|NCT00266669|Raynaud's Disease Secondary to Scleroderma
614615|NCT00266669|Raynaud's Disease Secondary to Other Autoimmune Disease
614616|NCT00266617|Anemia
614617|NCT00266617|chemotherapy
614618|NCT00266617|epoetin alfa
614619|NCT00266617|epogen
614620|NCT00266617|erythropoietin
614621|NCT00266617|neoplasms
614622|NCT00266617|cancer
614623|NCT00266604|Epilepsy
614624|NCT00266604|seizures
614625|NCT00266604|new-onset epilepsy
614626|NCT00266604|epilepsy relapse
614627|NCT00266604|epilepsy monotherapy
614628|NCT00266591|Epilepsy
614629|NCT00266591|Seizures
614630|NCT00266591|Topiramate
614631|NCT00266591|Prophylaxis
614632|NCT00266591|Antiepileptic
614633|NCT00266591|Epileptic seizures
614634|NCT00266591|Partial seizure disorder
614635|NCT00266591|Brain disease
614636|NCT00266578|Eosinophilic Esophagitis
614637|NCT00266552|conduct disorder
614638|NCT00266552|oppositional defiant disorder
614639|NCT00266552|disruptive behavior disorder not otherwise specified
614640|NCT00266552|ADHD
614641|NCT00266552|risperidone
614642|NCT00266552|antipsychotropic agents
614643|NCT00266552|children
614644|NCT00266539|Postoperative pain
614645|NCT00266539|patient-controlled analgesia
614646|NCT00266526|Allergy
614647|NCT00266526|Birch pollen
614648|NCT00266526|Recombinant
614649|NCT00266513|CD40 Ligand
614650|NCT00266513|Nemo
614651|NCT00266513|Genetics
614652|NCT00266513|Hyper-IGM
614653|NCT00266513|Ectodermal Dysplasia
614654|NCT00266513|CVID
614655|NCT00266513|Hyper-IgM Syndrome
614656|NCT00266513|Primary Immune Deficiency Disorders
614657|NCT00266513|Common Variable Immune Deficiency
614658|NCT00266500|Adipose Tissue
614659|NCT00266500|Weight Gain
614660|NCT00266500|Overweight
614661|NCT00266500|Thermogenesis
614662|NCT00266500|Deep Body Temperature
614663|NCT00266500|Adult
614664|NCT00266500|Exercise
614665|NCT00266487|Homocysteine
614666|NCT00266487|B vitamins
614667|NCT00266487|Folic acid
614668|NCT00266487|Randomized trial
614669|NCT00266487|Secondary prevention
614670|NCT00266474|Cystic Fibrosis with Chronic Rhinosinusitis
614671|NCT00266461|Postoperative Ileus
614672|NCT00266448|MRSA
614673|NCT00266448|eradication
614674|NCT00266448|chlorhexidine
614675|NCT00266435|Asymptomatic subjects
614676|NCT00266435|Moderate to high risk for cardiovascular event
614677|NCT00264849|Asthma
614678|NCT00264849|omalizumab
614679|NCT00264849|Severe persistent allergic asthma
614680|NCT00264823|HIV
614681|NCT00264823|Mental Illness
614682|NCT00264810|Responsive Stimulation
614683|NCT00264810|Brain Stimulator
614684|NCT00264810|Epilepsy
614685|NCT00264810|Seizures
614686|NCT00266396|Total Hip Arthroplasty
614687|NCT00266396|THA
614688|NCT00266396|Total Knee Arthroplasty
614689|NCT00266396|TKA
614690|NCT00266396|Total Hip Replacement
614691|NCT00266396|THR
614692|NCT00266396|Total Knee Replacement
614693|NCT00266396|TKR
614694|NCT00266331|Breast cancer
614695|NCT00266331|Radiation skin protection
614696|NCT00266318|Hepatitis C Nonresponder
614697|NCT00266318|Genotype 1
614698|NCT00266318|Interferon Alfacon-1
614699|NCT00266318|Consensus Interferon
614700|NCT00266318|CIFN
614701|NCT00266318|Infergen
614702|NCT00266318|Ribavirin
614703|NCT00266305|n-3 LCPUFA
614704|NCT00266305|Infant development
614705|NCT00266305|Visual acuity
614706|NCT00266305|Immune function
614707|NCT00266305|Breast milk
614708|NCT00266292|Fish oil
614709|NCT00266292|Polyunsaturated fatty acid
614710|NCT00266292|Immune function
614711|NCT00266292|Endothelial function
614712|NCT00266292|Cardiovascular risk factors
614713|NCT00266266|Human Papilloma Virus
614714|NCT00266214|lidocaine patch 5%
614715|NCT00266214|Lidoderm
614716|NCT00266214|carpal tunnel syndrome
614717|NCT00266214|pain
614718|NCT00266214|nerve compression injury
614719|NCT00266214|topical analgesic
614720|NCT00266201|Heart Defects, Congenital
614721|NCT00266201|Right Ventricular Dysfunction
614722|NCT00266201|Low Cardiac Output
614723|NCT00266201|Biochemical markers
614724|NCT00266201|Neurohumoral activity
614725|NCT00266188|Heart Defects, Congenital
614726|NCT00266188|Tetralogy of Fallot
614727|NCT00266188|Heart Septal Defects, Ventricular
614728|NCT00266188|Pulmonary Valve Diseases
614729|NCT00266188|Magnetic Resonance Imaging
614730|NCT00266188|Heart Catheterization
614731|NCT00266188|Echocardiography
614732|NCT00266175|Pulmonary heart disease
614733|NCT00266175|Pulmonary hypertension
614734|NCT00266175|Stent implantation
614735|NCT00266175|Balloon dilatation
614736|NCT00266175|Surgery
614737|NCT00266162|Heart Defects, Congenital
614738|NCT00266162|Eisenmenger Complex
614739|NCT00266162|Hypertension, Pulmonary
614740|NCT00266162|Pulmonary Heart Disease
614741|NCT00266162|Pulmonary Circulation
614742|NCT00266162|Vascular Resistance
614743|NCT00266149|Pharmacokinetics
614744|NCT00266149|Lamotrigine
614745|NCT00266149|Oral Contraceptives
614746|NCT00266149|UGT
614747|NCT00266149|Glucuronidation.
614748|NCT00266136|AML treatment, de-novo, secondary, high-risk MDS, chemotherapy, autologous SCT, adult
614749|NCT00266123|Kidney Failure
614750|NCT00266123|Kidney Transplant
614751|NCT00266110|stage IV breast cancer
614752|NCT00266110|recurrent breast cancer
614753|NCT00266097|stage III pancreatic cancer
614754|NCT00266097|stage IV pancreatic cancer
614755|NCT00266097|unresectable extrahepatic bile duct cancer
614756|NCT00266097|unresectable gallbladder cancer
614757|NCT00266097|adenocarcinoma of the extrahepatic bile duct
614758|NCT00266097|adenocarcinoma of the gallbladder
614759|NCT00266097|adenocarcinoma of the pancreas
614760|NCT00266097|recurrent pancreatic cancer
614761|NCT00266097|recurrent extrahepatic bile duct cancer
614762|NCT00266097|recurrent gallbladder cancer
614763|NCT00266084|Cervix
614764|NCT00266084|Uterus
614765|NCT00266084|Dysplasia
614766|NCT00266084|Cancer
614767|NCT00266084|Collector
614768|NCT00264784|Streptococcus, Group A, Fiji, epidemiology
614769|NCT00264771|Fiji, Group A streptococcus, rheumatic, glomerulonephritis
614770|NCT00264758|randomized controlled clinical trial
614771|NCT00264758|hemodialysis
614772|NCT00264758|end stage renal disease
614773|NCT00264745|Caregiver
614774|NCT00264745|Stroke
614775|NCT00264732|cervical lesions
614776|NCT00264732|cervical dysplasia
614777|NCT00264732|Human papilloma virus
614778|NCT00264732|abnormal Pap
614779|NCT00264732|High-grade cervical intraepithelial lesions (CIN 2/3)
614780|NCT00266071|skin
614781|NCT00266071|pressure
614782|NCT00266071|age
614783|NCT00266058|healthy
614784|NCT00266058|controls
614785|NCT00266058|research
614786|NCT00266058|clinical
614787|NCT00266058|study
614788|NCT00266058|pharmacokinetic
614789|NCT00266058|PK
614790|NCT00266058|HIV
614791|NCT00266058|malaria
614792|NCT00266045|Deep Vein Thrombosis
614793|NCT00266045|Pulmonary Embolism
614794|NCT00266045|D-dimer
614795|NCT00266045|Recurrence
614796|NCT00266045|Duration of Anticoagulation
614797|NCT00266045|Vitamin K Antagonists
614798|NCT00266019|nonalcoholic steatohepatitis
614799|NCT00266019|nonalcoholic fatty liver disease
614800|NCT00266019|Fatty liver
614801|NCT00266019|Cirrhosis
614802|NCT00266019|Obesity
614803|NCT00266019|Weight Reduction
614804|NCT00266019|Weight Management
614805|NCT00265980|Leptin
614806|NCT00265980|Obesity
614807|NCT00265980|Energy
614808|NCT00265980|Autonomics
614809|NCT00265980|Neuroendocrine
614810|NCT00265941|stage III squamous cell carcinoma of the hypopharynx
614811|NCT00265941|stage IV squamous cell carcinoma of the hypopharynx
614812|NCT00265941|stage III squamous cell carcinoma of the larynx
614813|NCT00265941|stage IV squamous cell carcinoma of the larynx
614814|NCT00265941|stage III squamous cell carcinoma of the oropharynx
614815|NCT00265941|stage IV squamous cell carcinoma of the oropharynx
614816|NCT00265928|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
614817|NCT00265928|recurrent grade 1 follicular lymphoma
614818|NCT00265928|recurrent grade 2 follicular lymphoma
614819|NCT00265928|recurrent grade 3 follicular lymphoma
614820|NCT00265928|recurrent mantle cell lymphoma
614821|NCT00265928|recurrent marginal zone lymphoma
614822|NCT00265928|recurrent small lymphocytic lymphoma
614823|NCT00265928|splenic marginal zone lymphoma
614824|NCT00265928|recurrent adult diffuse small cleaved cell lymphoma
614825|NCT00265928|nodal marginal zone B-cell lymphoma
614826|NCT00265928|Waldenstrom's macroglobulinemia
614827|NCT00265915|B-cell chronic lymphocytic leukemia
614828|NCT00265915|refractory chronic lymphocytic leukemia
614829|NCT00265915|stage 0 chronic lymphocytic leukemia
614830|NCT00265915|stage I chronic lymphocytic leukemia
614831|NCT00265915|stage II chronic lymphocytic leukemia
614832|NCT00265915|stage III chronic lymphocytic leukemia
614833|NCT00265915|stage IV chronic lymphocytic leukemia
614834|NCT00265902|Kaposi sarcoma
614835|NCT00265889|recurrent adult Hodgkin lymphoma
614836|NCT00265889|stage III adult Hodgkin lymphoma
614837|NCT00265889|stage IV adult Hodgkin lymphoma
614838|NCT00265876|adenocarcinoma of the pancreas
614839|NCT00265876|stage III pancreatic cancer
614840|NCT00265876|recurrent pancreatic cancer
614841|NCT00265876|stage IV pancreatic cancer
614842|NCT00265863|malignant ascites
614843|NCT00265850|recurrent colon cancer
614844|NCT00265850|stage III colon cancer
614845|NCT00265850|stage III rectal cancer
614846|NCT00265850|stage IV colon cancer
614847|NCT00265850|recurrent rectal cancer
614848|NCT00265850|stage IV rectal cancer
614849|NCT00265850|adenocarcinoma of the colon
614850|NCT00265850|adenocarcinoma of the rectum
614851|NCT00265837|graft versus host disease
614852|NCT00265837|adult acute myeloid leukemia in remission
614853|NCT00265837|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
614854|NCT00265837|adult acute myeloid leukemia with inv(16)(p13;q22)
614855|NCT00265837|adult acute myeloid leukemia with t(15;17)(q22;q12)
614856|NCT00265837|adult acute myeloid leukemia with t(16;16)(p13;q22)
614857|NCT00265837|adult acute myeloid leukemia with t(8;21)(q22;q22)
614858|NCT00265837|recurrent adult acute myeloid leukemia
614859|NCT00265837|recurrent childhood acute myeloid leukemia
614860|NCT00265837|childhood acute myeloid leukemia in remission
614861|NCT00265837|adult acute lymphoblastic leukemia in remission
614862|NCT00265837|recurrent adult acute lymphoblastic leukemia
614863|NCT00265837|childhood acute lymphoblastic leukemia in remission
614864|NCT00265837|recurrent childhood acute lymphoblastic leukemia
614865|NCT00265837|accelerated phase chronic myelogenous leukemia
614866|NCT00265837|blastic phase chronic myelogenous leukemia
614867|NCT00265837|childhood chronic myelogenous leukemia
614868|NCT00265837|chronic phase chronic myelogenous leukemia
614869|NCT00265837|relapsing chronic myelogenous leukemia
614870|NCT00265837|secondary acute myeloid leukemia
614871|NCT00265837|de novo myelodysplastic syndromes
614872|NCT00265837|previously treated myelodysplastic syndromes
614873|NCT00265837|secondary myelodysplastic syndromes
614874|NCT00265837|chronic myelomonocytic leukemia
614875|NCT00265837|juvenile myelomonocytic leukemia
614876|NCT00265837|atypical chronic myeloid leukemia
614877|NCT00265837|myelodysplastic/myeloproliferative disease, unclassifiable
614878|NCT00265837|Philadelphia chromosome negative chronic myelogenous leukemia
614879|NCT00265837|stage I multiple myeloma
614880|NCT00265837|stage II multiple myeloma
614881|NCT00265837|stage III multiple myeloma
614882|NCT00265837|refractory multiple myeloma
614883|NCT00265837|stage III adult Hodgkin lymphoma
614884|NCT00265837|stage IV adult Hodgkin lymphoma
614885|NCT00265837|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
614886|NCT00265837|nodal marginal zone B-cell lymphoma
614887|NCT00265837|noncontiguous stage II adult Burkitt lymphoma
614888|NCT00265837|noncontiguous stage II adult diffuse large cell lymphoma
614889|NCT00265837|noncontiguous stage II adult diffuse mixed cell lymphoma
614890|NCT00265837|noncontiguous stage II adult diffuse small cleaved cell lymphoma
614891|NCT00265837|noncontiguous stage II adult immunoblastic large cell lymphoma
614892|NCT00265837|noncontiguous stage II adult lymphoblastic lymphoma
614893|NCT00265837|noncontiguous stage II grade 1 follicular lymphoma
614894|NCT00265837|noncontiguous stage II grade 2 follicular lymphoma
614895|NCT00265837|noncontiguous stage II grade 3 follicular lymphoma
614896|NCT00265837|noncontiguous stage II mantle cell lymphoma
614897|NCT00265837|noncontiguous stage II marginal zone lymphoma
614898|NCT00265837|recurrent adult Hodgkin lymphoma
614899|NCT00265837|recurrent adult Burkitt lymphoma
614900|NCT00265837|recurrent adult diffuse large cell lymphoma
614901|NCT00265837|recurrent adult diffuse mixed cell lymphoma
614902|NCT00265837|recurrent adult diffuse small cleaved cell lymphoma
614903|NCT00265837|recurrent adult immunoblastic large cell lymphoma
614904|NCT00265837|recurrent adult lymphoblastic lymphoma
614905|NCT00265837|recurrent/refractory childhood Hodgkin lymphoma
614906|NCT00265837|recurrent childhood large cell lymphoma
614907|NCT00265837|recurrent childhood lymphoblastic lymphoma
614908|NCT00265837|recurrent childhood small noncleaved cell lymphoma
614909|NCT00265837|recurrent grade 1 follicular lymphoma
614910|NCT00265837|recurrent grade 2 follicular lymphoma
614911|NCT00265837|recurrent grade 3 follicular lymphoma
614912|NCT00265837|recurrent mantle cell lymphoma
614913|NCT00265837|recurrent marginal zone lymphoma
614914|NCT00265837|recurrent small lymphocytic lymphoma
614915|NCT00265837|splenic marginal zone lymphoma
614916|NCT00265837|stage III adult Burkitt lymphoma
614917|NCT00265837|stage III adult diffuse large cell lymphoma
614918|NCT00265837|stage III adult diffuse mixed cell lymphoma
614919|NCT00265837|stage III adult diffuse small cleaved cell lymphoma
614920|NCT00265837|stage IV adult diffuse large cell lymphoma
614921|NCT00265837|stage IV adult diffuse mixed cell lymphoma
614922|NCT00265837|stage IV adult diffuse small cleaved cell lymphoma
614923|NCT00265837|stage III adult lymphoblastic lymphoma
614924|NCT00265837|stage IV adult lymphoblastic lymphoma
614925|NCT00265837|stage III grade 1 follicular lymphoma
614926|NCT00265837|stage III grade 2 follicular lymphoma
614927|NCT00265837|stage III grade 3 follicular lymphoma
614928|NCT00265837|stage IV grade 1 follicular lymphoma
614929|NCT00265837|stage IV grade 2 follicular lymphoma
614930|NCT00265837|stage IV grade 3 follicular lymphoma
614931|NCT00265837|stage III mantle cell lymphoma
614932|NCT00265837|stage III marginal zone lymphoma
614933|NCT00265837|stage IV mantle cell lymphoma
614934|NCT00265837|stage IV marginal zone lymphoma
614935|NCT00265837|stage III small lymphocytic lymphoma
614936|NCT00265837|stage IV small lymphocytic lymphoma
614937|NCT00265837|stage IV adult Burkitt lymphoma
614938|NCT00265837|stage IV adult immunoblastic large cell lymphoma
614939|NCT00265837|childhood myelodysplastic syndromes
614940|NCT00265824|stage IV colon cancer
614941|NCT00265824|stage IV rectal cancer
614942|NCT00265824|adenocarcinoma of the colon
614943|NCT00265824|adenocarcinoma of the rectum
614944|NCT00265824|chemotherapy
614945|NCT00265811|stage III colon cancer
614946|NCT00265811|adenocarcinoma of the colon
614947|NCT00265785|bronchoalveolar cell lung cancer
614948|NCT00265785|stage IIIB non-small cell lung cancer
614949|NCT00265785|stage IV non-small cell lung cancer
614950|NCT00265785|recurrent non-small cell lung cancer
614951|NCT00265772|enteral nutrition
614952|NCT00265772|steroids
614953|NCT00265772|mucosal healing
614954|NCT00265759|stage II breast cancer
614955|NCT00265759|stage IIIA breast cancer
614956|NCT00265759|stage IIIB breast cancer
614957|NCT00265759|stage IIIC breast cancer
614958|NCT00265759|estrogen receptor-positive breast cancer
614959|NCT00265746|metformin
614960|NCT00265746|gestational diabetes
614961|NCT00265746|lifestyle
614962|NCT00265733|male breast cancer
614963|NCT00265733|recurrent breast cancer
614964|NCT00265733|stage IV breast cancer
614965|NCT00265720|African Americans
614966|NCT00265720|Colorectal Cancer Screening
614967|NCT00265720|Colorectal Cancer
614968|NCT00265720|Colorectal Cancer and African Americans
614969|NCT00265720|Cancer Disparities
614970|NCT00265707|Hypertension
614971|NCT00265707|Hypotension
614972|NCT00265681|smokeless tobacco cessation
614973|NCT00265681|chewing tobacco
614974|NCT00265681|oral tobacco
614975|NCT00265681|smokeless tobacco
614976|NCT00265681|telephone
614977|NCT00265681|counseling
614978|NCT00265642|Hepatitis C, Chronic
614979|NCT00265642|irbesartan
614980|NCT00265629|Atrial fibrillation
614981|NCT00265616|Refractory status epilepticus,
614982|NCT00265616|coma-induction,
614983|NCT00265616|treatment,
614984|NCT00265616|propofol,
614985|NCT00265616|barbiturates,
614986|NCT00265616|efficacy,
614987|NCT00265616|safety.
614988|NCT00265590|Aniridia
614989|NCT00265590|PAX6
614990|NCT00265590|Keratopathy
614991|NCT00265590|Limbal Stem Cell Deficiency
614992|NCT00265590|Molecular Genetics
614993|NCT00265564|outcomes assessment
614994|NCT00265564|substance use disorders
614995|NCT00265564|stress disorders, post-traumatic
614996|NCT00265564|screening
614997|NCT00265551|Schizophrenia
614998|NCT00265538|Hypertension
614999|NCT00265538|Diuretics
615000|NCT00265538|Drug Therapy
615001|NCT00265538|Anti-Hypertensive Agents
615002|NCT00265538|Patient Intervention
615003|NCT00265525|Randomized Control Trial
615004|NCT00265525|Exercise Intervention
615005|NCT00265525|Prevention
615006|NCT00265525|Rehabilitation
615007|NCT00265512|Telemedicine
615008|NCT00265512|Aftercare
615009|NCT00265499|Coronary Artery Bypass
615010|NCT00265499|Skeletonization
615011|NCT00265499|Internal Thoracic Artery
615012|NCT00265499|Flow
615013|NCT00265499|Length
615014|NCT00265499|Pain
615015|NCT00265486|Divers
615016|NCT00265486|Brain
615017|NCT00265486|Flow
615018|NCT00265486|Blood
615019|NCT00265486|EPO
615020|NCT00265486|Dive
615021|NCT00265486|reflex
615022|NCT00265460|smoking cessation,
615023|NCT00265460|nicotine,
615024|NCT00265460|smokeless tobacco,
615025|NCT00265460|cigarettes
615026|NCT00265447|knee osteoarthritis
615027|NCT00265447|exercise
615028|NCT00265447|aerobic exercise
615029|NCT00265447|strengthening exercise
615030|NCT00265447|exercise prescription
615031|NCT00265447|rehabilitation
615032|NCT00265447|physical disability
615033|NCT00265447|physical function
615034|NCT00265447|physical activity
615035|NCT00265447|physical fitness
615036|NCT00265421|Suture Techniques
615037|NCT00265408|Cervicocephalic Arterial Dissection
615038|NCT00265382|Adolescent Subjects
615039|NCT00265356|Positron Emission Tomography (PET)
615040|NCT00265356|Diagnostic Investigation
615041|NCT00265356|Colorectal cancer
615042|NCT00265356|Liver metastases
615043|NCT00265356|Liver surgery
615044|NCT00265330|Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
615045|NCT00265317|Non-small cell lung cancer
615046|NCT00265317|sunitinib
615047|NCT00265317|erlotinib
615048|NCT00265317|Phase 2
615049|NCT00265304|Osteoarthritis
615050|NCT00265291|Depression
615051|NCT00265291|mood disorders
615052|NCT00265291|affective disorders
615053|NCT00265291|pharmacogenetics
615054|NCT00265291|pharmacogenomics
615055|NCT00265265|Cocaine Dependence
615056|NCT00265252|osteonecrosis
615057|NCT00265252|total hip replacement
615058|NCT00265239|Edaravone
615059|NCT00265239|Randomized Control Trial
615060|NCT00265239|ST-Elevation Myocardial Infarction
615061|NCT00265239|Coronary Angioplasty
615062|NCT00265226|India
615063|NCT00265226|Pulmonary Tuberculosis
615064|NCT00265226|Category-II tuberculosis
615065|NCT00265226|Immunomodulator
615066|NCT00265226|Mycobacterium w
615067|NCT00265226|Revised National Tuberculosis Control Programme
615068|NCT00265226|Category-II Pulmonary Tuberculosis
615069|NCT00265213|breast conservative surgery
615070|NCT00265213|shoulder functional outcome questionnaire
615071|NCT00265213|disability questionnaire
615072|NCT00265200|Zometa
615073|NCT00265200|bone metastasis
615074|NCT00265200|lung cancer
615075|NCT00265200|non-small cell lung cancer
615076|NCT00265200|small cell lung cancer
615077|NCT00265200|bone metabolic markers
615078|NCT00265200|tartrate resistant acid phosphatase
615079|NCT00265187|child, bronchiolitis,
615080|NCT00265174|SERUM DNA
615081|NCT00265174|LOH
615082|NCT00265174|METHYLATION
615083|NCT00265174|GLIOMA
615084|NCT00265174|MGMT
615085|NCT00265161|influenza vaccine
615086|NCT00265161|effectiveness
615087|NCT00265161|health care worker
615088|NCT00265161|OBSERVATIONAL STUDY
615089|NCT00265148|rosiglitazone
615090|NCT00265148|cognition
615091|NCT00265148|cerebral glucose metabolism
615092|NCT00265148|positron emission tomography (PET)
615093|NCT00265148|Alzheimer's Disease
615094|NCT00265135|Renal cell carcinoma
615095|NCT00265135|CNTO 328
615096|NCT00265135|Infusions
615097|NCT00265135|Renal cell cancer
615098|NCT00265122|Crohn Disease
615099|NCT00265122|Biologic
615100|NCT00265122|Infusion
615101|NCT00265122|Injection
615102|NCT00265122|CNTO 1275
615103|NCT00265122|Ustekinumab
615104|NCT00265122|C01275
615105|NCT00265122|IL-12p40
615106|NCT00265109|body dysmorphic disorder
615107|NCT00265109|levetiracetam
615108|NCT00265096|Psoriatic Arthritis
615109|NCT00265096|Spondyloarthritis
615110|NCT00265096|Spondyloarthropathy
615111|NCT00265096|subcutaneous injection
615112|NCT00265083|Spondylitis
615113|NCT00265083|subcutaneous injection
615114|NCT00265083|Bechterew's Disease
615115|NCT00265083|Spondyloarthritis
615116|NCT00265083|Spondyloarthropathy
615117|NCT00264719|A drug is administered to initiate breastfeeding
615118|NCT00264680|Validation of questionnaire
615119|NCT00264680|qolie-10
615120|NCT00264680|epilepsy
615121|NCT00264680|lamotrigine
615122|NCT00264680|quality of life
615123|NCT00264667|Dyslipidaemia
615124|NCT00264654|Social
615125|NCT00264654|(SAD)
615126|NCT00264654|Anxiety
615127|NCT00264654|Disorder
615128|NCT00264641|Hypoglycemia
615129|NCT00264641|Cognitive impairment
615130|NCT00264641|PET
615131|NCT00264641|CalCAP
615132|NCT00264628|NK1-antagonist
615133|NCT00264628|Depression
615134|NCT00264628|Fibromyalgia
615135|NCT00264628|GW679769
615136|NCT00264628|Outpatient
615137|NCT00264615|once daily dosing
615138|NCT00264615|seizure
615139|NCT00264615|pharmacokinetics
615140|NCT00264615|epilepsy
615141|NCT00264602|Lymphatic mapping
615142|NCT00264602|nodal targeting
615143|NCT00264602|indocyanine green
615144|NCT00264602|near infrared imaging
615145|NCT00264589|vascular function
615146|NCT00264589|cardiac function
615147|NCT00264589|individualized training
615148|NCT00264589|ultrasonography
615149|NCT00264589|body composition
615150|NCT00264550|Rheumatoid Arthritis
615151|NCT00264550|Golimumab
615152|NCT00264550|Methotrexate
615153|NCT00264550|Fully Human anti-TNFa monoclonal antibody
615154|NCT00264550|Simpony
615155|NCT00264537|Rheumatoid Arthritis
615156|NCT00264537|Methotrexate Naïve
615157|NCT00264537|subcutaneous injection
615158|NCT00264524|Rheumatic heart disease, HLA, Genetics, Taiwan
615159|NCT00264511|Hyperbaric oxygen
615160|NCT00264511|Crush injury
615161|NCT00264511|Tibial fracture
615162|NCT00264511|Gustillo 3
615163|NCT00264511|soft tissue injury
615164|NCT00264511|complications
615165|NCT00264511|outcomes
615166|NCT00264511|randomised controlled trial
615167|NCT00264498|Non-Small-Cell Lung Cancer
615168|NCT00264498|NSCLC
615169|NCT00264498|Lung Cancer
615170|NCT00264485|Postoperative pain
615171|NCT00264485|patient-controlled analgesia
615172|NCT00264472|Cancer
615173|NCT00264472|Tumors
615174|NCT00264472|Neoplasms
615175|NCT00264472|Anticarcinogenic Agents
615176|NCT00264472|Antineoplastic Agents
615177|NCT00264472|Dihydrouracil Dehydrogenase (NADP)
615178|NCT00264459|Sublingual immunotherapy
615179|NCT00264459|Rhinoconjunctivitis
615180|NCT00264459|Rhinitis
615181|NCT00264459|Asthma
615182|NCT00264446|Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents;
615183|NCT00264446|Dihydrouracil dehydrogenase (NADP); Colorectal Carcinoma; Liver Cancer
615184|NCT00264433|Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents
615185|NCT00264433|Cadherins; Non-Small-Cell Lung Carcinoma; Esophageal Cancer; Gastric Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Adrenocortical Carcinoma
615186|NCT00264420|bone metastases
615187|NCT00264420|breast cancer
615188|NCT00264420|lung cancer
615189|NCT00264420|prostate cancer
615190|NCT00264420|zoledronic acid
615191|NCT00264420|radiation therapy
615192|NCT00264407|Hearing Loss, Central
615193|NCT00264407|Presbycusis
615194|NCT00264407|Hearing Loss, Sensorineural
615195|NCT00264407|Hearing Loss, Cochlear
615196|NCT00264407|Hearing Loss, Bilateral
615197|NCT00264407|Sex Steroid Hormones
615198|NCT00264407|Estradiol
615199|NCT00264394|Computer generated reminder system
615200|NCT00264394|quality control
615201|NCT00264394|dyslipidemia
615202|NCT00264394|antiretroviral therapy
615203|NCT00264394|HIV infection
615204|NCT00264381|Superficial Thrombophlebitis
615205|NCT00264381|STP
615206|NCT00264381|Fragmin
615207|NCT00264381|Ibuprofen
615208|NCT00264381|Superficial Thrombus
615209|NCT00264381|Superficial Phlebitis
615210|NCT00264381|phlebitis
615211|NCT00264368|Renal replacement therapy
615212|NCT00264368|CMV disease
615213|NCT00264355|cyclosporine
615214|NCT00264355|metabolites
615215|NCT00264355|metabolic pattern
615216|NCT00264355|genotypes
615217|NCT00264342|Smoking
615218|NCT00264342|Tobacco
615219|NCT00264342|Nicotine
615220|NCT00264316|bone marrow cell transfer
615221|NCT00264316|acute myocardial infarction
615222|NCT00264316|left ventricular function
615223|NCT00264303|Chronic Idiopathic Urticaria
615224|NCT00264303|CUTE Levocetirizine Xyzal®
615225|NCT00264290|HIV
615226|NCT00264290|CMV
615227|NCT00264290|T Cell activation
615228|NCT00264290|Valganciclovir
615229|NCT00264277|D-dimer
615230|NCT00264277|Recurrence
615231|NCT00264277|Venous Thromboembolism
615232|NCT00264277|Anticoagulation
615233|NCT00264277|Duration
615234|NCT00264264|Closure device
615235|NCT00264264|Stenting
615236|NCT00264264|Percutaneous coronary intervention
615237|NCT00264251|HIV
615238|NCT00264251|Body composition
615239|NCT00264251|Weight reduction
615240|NCT00264251|Insulin resistance/sensitivity
615241|NCT00264251|Exercise
615242|NCT00264251|Diet
615243|NCT00264251|Visceral adiposity
615244|NCT00264225|osteoarthritis, pain
615245|NCT00264199|Chronic Congestive heart failure
615246|NCT00264199|Ischemic heart disease
615247|NCT00264199|insulin resistance
615248|NCT00264160|AMN107
615249|NCT00264160|CML
615250|NCT00264160|Bcr Abl
615251|NCT00264160|cytogenetic response
615870|NCT00260975|chemotherapy
615252|NCT00264160|Chronic Myelogenous Leukemia (CML)
615253|NCT00264160|imatinib mesylate
615254|NCT00264147|Arcoxia
615255|NCT00264134|Non-Small Cell Lung Cancer
615256|NCT00264121|congenital, high scrotal
615257|NCT00264108|Antineoplastic agents
615258|NCT00264108|Chemotherapy
615259|NCT00264108|Cost-effectiveness
615260|NCT00264108|Epoetin alfa
615261|NCT00264108|Darbepoetin alfa
615262|NCT00264095|Anemia
615263|NCT00264095|Blood loss
615264|NCT00264095|Transfusion
615265|NCT00264095|Blood transfusion
615266|NCT00264095|Erythropoietin
615267|NCT00264095|Surgery
615268|NCT00264095|Surgical blood loss
615269|NCT00264095|Tumor
615270|NCT00264095|Cancer
615271|NCT00264095|Surgical resection
615272|NCT00264095|Tumor resection
615273|NCT00264069|Adherence
615274|NCT00264069|Compliance
615275|NCT00264069|Schizophrenia
615276|NCT00264069|Bipolar Disorder
615277|NCT00264069|Depression
615278|NCT00264069|Personality Disorders
615279|NCT00264069|Registry
615280|NCT00264056|malignant melanoma
615281|NCT00264056|hyperthermia
615282|NCT00264056|chemotherapy
615283|NCT00264004|Advanced Solid Tumours
615284|NCT00264004|phase II
615285|NCT00264004|Hypertension
615286|NCT00264004|RECENTIN
615287|NCT00263978|Venous occlusive disease
615288|NCT00263978|VOD
615289|NCT00263952|Bee venom allergy
615290|NCT00263952|Specific immunotherapy
615291|NCT00263939|chronic disease
615292|NCT00263939|patient education
615293|NCT00263939|self-efficacy
615294|NCT00263939|self-management
615295|NCT00263926|Wasp venom allergy,
615296|NCT00263926|specific immunotherapy
615297|NCT00263900|Influenza A
615298|NCT00263900|Influenza B
615299|NCT00263900|RSV
615300|NCT00263887|alpha 1 proteinase inhibitor
615301|NCT00263887|alpha1 proteinase inhibitor
615302|NCT00263887|congenital emphysema
615303|NCT00263887|replacement therapy
615304|NCT00263861|neurotoxicity
615305|NCT00263861|unspecified adult solid tumor, protocol specific
615306|NCT00263822|stage I ovarian epithelial cancer
615307|NCT00263822|stage II ovarian epithelial cancer
615308|NCT00263822|stage III ovarian epithelial cancer
615309|NCT00263822|stage IV ovarian epithelial cancer
615310|NCT00263822|primary peritoneal cavity cancer
615311|NCT00263822|fallopian tube cancer
615312|NCT00263731|lung cancer
615313|NCT00263731|non-small cell lung cancer
615314|NCT00263731|small cell lung cancer
615315|NCT00263731|cancer metabolism
615316|NCT00263640|House dust mite
615317|NCT00263640|Bronchial Asthma
615318|NCT00263640|Allergy
615319|NCT00263640|House Dust Mite Allergy
615320|NCT00263627|specific immunotherapy
615321|NCT00263627|birch pollen allergy
615322|NCT00263627|Allergovit
615323|NCT00263601|Allergovit
615324|NCT00263601|Grass pollen allergy
615325|NCT00263588|breast cancer brain metastases ErbB2 positive HER2 positive
615326|NCT00263575|EN3267
615327|NCT00263575|Breakthrough Pain
615328|NCT00263575|Safety Study
615329|NCT00263575|Fentanyl Tablets
615330|NCT00263562|Sickle cell disease
615331|NCT00263562|vaso-occlusive crisis
615332|NCT00263562|steroid treatment
615333|NCT00263549|House dust mite,
615334|NCT00263549|Allergy
615335|NCT00263536|Obesity
615336|NCT00263536|Adiposity
615337|NCT00263536|Binge Eating
615338|NCT00263536|Social Functioning
615339|NCT00263536|Eating Disorders
615340|NCT00263536|Prevention
615341|NCT00263536|Adolescence
615342|NCT00263536|Adolescent Weight Gain
615343|NCT00263536|Overweight
615344|NCT00263523|Serotonin
615345|NCT00263523|Positron Emission Tomograhy
615346|NCT00263523|Brain
615347|NCT00263523|Neurochemistry
615348|NCT00263523|Neurotransmitter
615349|NCT00263523|Healthy Volunteer
615350|NCT00263523|HV
615351|NCT00263497|Postinjury chronic pain
615352|NCT00263497|Transtibial amputation
615353|NCT00263497|Physical rehabilitation
615354|NCT00263497|Immediate temporary prosthesis
615355|NCT00263484|Steroids, Fluorinated
615356|NCT00263484|Thalidomide
615357|NCT00263484|Bisphosphonates
615358|NCT00263458|HIV
615359|NCT00263458|acquired immunodeficiency syndrome
615360|NCT00263458|buprenorphine
615361|NCT00263458|opioid dependence
615362|NCT00263458|opioid-related disorders
615363|NCT00263458|integrated care
615364|NCT00263458|primary care
615365|NCT00263445|Growth hormone dosing
615366|NCT00263445|IGF-I
615367|NCT00263419|Diabetes Type 2
615368|NCT00263419|Late Complications
615369|NCT00263419|Stress relief management
615370|NCT00263419|psychosocial stress
615371|NCT00263393|Myocardial Infarction
615372|NCT00263393|Angina Pectoris
615373|NCT00263393|Cerebrovascular Accident
615374|NCT00263393|Diabetes Mellitus
615375|NCT00263393|Cluster randomized design
615376|NCT00263393|Community-based intervention trial
615377|NCT00263393|Primary Healthcare intervention
615378|NCT00263393|Lifestyle advice
615379|NCT00263380|COPD
615380|NCT00263380|cytokines
615381|NCT00263380|corticosteroids
615382|NCT00263380|beta agonists
615383|NCT00263380|synergistic effect
615384|NCT00263367|Autism
615385|NCT00263367|Oxidative Stress
615386|NCT00263367|Hyperbaric Oxygen
615387|NCT00263367|Reduced Glutathione
615388|NCT00263367|Lipid Peroxides
615389|NCT00263341|Contraceptive agents
615390|NCT00263341|Female contraception
615391|NCT00263341|Progestins
615392|NCT00263328|immunosuppression
615393|NCT00263328|JAK3 inhibitor
615394|NCT00263328|kidney transplant
615395|NCT00263328|tofacitinib
615396|NCT00263328|Xeljanz
615397|NCT00263328|CP-690
615398|NCT00263328|550
615399|NCT00263328|tacromilus
615400|NCT00263328|mycophenolate mofetil
615401|NCT00263315|aspergillosis
615402|NCT00263315|mycosis
615403|NCT00263315|neutropenia
615404|NCT00263315|primary prevention
615405|NCT00263315|hematologic diseases
615406|NCT00263315|amphotericin B
615407|NCT00263315|AmBisome
615408|NCT00263315|liposomal amphotericin B
615409|NCT00263302|dexamethasone, diuretic, congestive heart failure
615410|NCT00263250|inguinal hernia
615411|NCT00263250|asymptomatic
615412|NCT00263250|watchful waiting
615413|NCT00263250|tension-free hernia repair
615414|NCT00263237|T Cell
615415|NCT00263237|Lymphocyte
615416|NCT00263237|Lamina Propria
615417|NCT00263237|Malabsorption
615418|NCT00263237|Colonoscopy
615419|NCT00263237|Common Variable Immunodeficiency
615420|NCT00263237|CVID
615421|NCT00263237|Gastrointestinal Inflammation
615422|NCT00263211|Breast Cancer
615423|NCT00263211|Metastatic
615424|NCT00263211|Platelet
615425|NCT00263172|internet
615426|NCT00263172|weight management
615427|NCT00263172|behavior therapy
615428|NCT00263172|self-help
615429|NCT00263172|commercial program
615430|NCT00263172|obesity
615431|NCT00263133|Depression
615432|NCT00263133|SSRI
615433|NCT00263133|Sertraline
615434|NCT00263133|synaptic plasticity
615435|NCT00263133|visually evoked potentials
615436|NCT00263107|telerounding
615437|NCT00263107|minimally invasive surgery
615438|NCT00263094|Fasting
615439|NCT00263094|Headache
615440|NCT00263094|Cox 2 Inhibitors
615441|NCT00263094|Pain
615442|NCT00263094|Prophylaxis
615443|NCT00263081|Hyperlipidemia
615444|NCT00263081|Dyslipidemia
615445|NCT00263081|Drug Therapy
615446|NCT00263068|IDIOPATHIC RESTLESS LEGS SYNDROME
615447|NCT00263042|Myocardial infarction
615448|NCT00263042|cerebrovascular accident
615449|NCT00263042|obesity
615450|NCT00262990|Epithelial ovarian cancer
615451|NCT00262990|fallopian tube cancer
615452|NCT00262990|peritoneal cancer
615453|NCT00262990|primary cancer
615454|NCT00262990|recurrent cancer
615455|NCT00262990|doxorubicin
615456|NCT00262990|taxane chemotherapy
615457|NCT00262990|platinum chemotherapy
615458|NCT00262990|Patupilone
615459|NCT00262990|taxane platinum resistant
615460|NCT00262977|diabetes mellitus
615461|NCT00262977|cardiovascular diseases
615462|NCT00262977|aspirin
615463|NCT00262977|quality of healthcare
615464|NCT00262964|non-alcoholic fatty liver disease
615465|NCT00262964|obesity
615466|NCT00262964|fatty liver disease
615467|NCT00262951|stage I pancreatic cancer
615468|NCT00262951|stage II pancreatic cancer
615469|NCT00262951|stage III pancreatic cancer
615470|NCT00262951|adenocarcinoma of the pancreas
615471|NCT00262938|stage I endometrial carcinoma
615472|NCT00262938|stage II endometrial carcinoma
615473|NCT00262938|weight changes
615474|NCT00262925|MOAD
615475|NCT00262925|Methotrexate
615476|NCT00262925|Vincristine
615477|NCT00262925|L-asparaginase
615478|NCT00262925|Dexamethasone
615479|NCT00262925|Subcutaneous Campath
615480|NCT00262899|psychosocial effects of cancer and its treatment
615481|NCT00262899|ductal breast carcinoma in situ
615482|NCT00262899|breast cancer in situ
615483|NCT00262899|stage IA breast cancer
615484|NCT00262899|stage IB breast cancer
615485|NCT00262899|stage II breast cancer
615486|NCT00262899|stage IIIA breast cancer
615487|NCT00262886|recurrent renal cell cancer
615488|NCT00262886|stage IV renal cell cancer
615489|NCT00262873|previously treated myelodysplastic syndromes
615490|NCT00262873|refractory anemia with excess blasts
615491|NCT00262873|refractory anemia with ringed sideroblasts
615492|NCT00262873|refractory anemia
615493|NCT00262873|secondary myelodysplastic syndromes
615494|NCT00262873|de novo myelodysplastic syndromes
615495|NCT00262860|recurrent adult Hodgkin lymphoma
615496|NCT00262808|stage II colon cancer
615497|NCT00262808|stage III colon cancer
615498|NCT00262808|adenocarcinoma of the colon
615499|NCT00262795|stage 0 chronic lymphocytic leukemia
615500|NCT00262795|stage I chronic lymphocytic leukemia
615501|NCT00262795|stage II chronic lymphocytic leukemia
615502|NCT00262795|stage III chronic lymphocytic leukemia
615503|NCT00262795|stage IV chronic lymphocytic leukemia
615504|NCT00262782|B-cell chronic lymphocytic leukemia
615505|NCT00262782|stage 0 chronic lymphocytic leukemia
615506|NCT00262782|stage I chronic lymphocytic leukemia
615507|NCT00262782|stage II chronic lymphocytic leukemia
615508|NCT00262769|cholangiocarcinoma of the extrahepatic bile duct
615509|NCT00262769|recurrent extrahepatic bile duct cancer
615510|NCT00262769|unresectable extrahepatic bile duct cancer
615511|NCT00262769|cholangiocarcinoma of the gallbladder
615512|NCT00262769|recurrent gallbladder cancer
615513|NCT00262769|unresectable gallbladder cancer
615514|NCT00262769|metastatic extrahepatic bile duct cancer
615515|NCT00262769|metastatic gallbladder cancer
615516|NCT00262743|B-cell chronic lymphocytic leukemia
615517|NCT00262743|stage 0 chronic lymphocytic leukemia
615518|NCT00262743|stage I chronic lymphocytic leukemia
615519|NCT00262743|stage II chronic lymphocytic leukemia
615520|NCT00262730|adult glioblastoma
615521|NCT00262730|adult giant cell glioblastoma
615522|NCT00262730|adult gliosarcoma
615523|NCT00262717|HIV drug resistance testing
615524|NCT00262717|Treatment Experienced
615525|NCT00262704|physician intervention
615526|NCT00262704|diabetes mellitus
615527|NCT00262704|primary care
615528|NCT00262704|quality improvement
615529|NCT00262704|disease management
615530|NCT00262652|sodium pyruvate
615531|NCT00262652|anti-inflammatory
615532|NCT00262652|bronchodilation
615533|NCT00262652|asthma
615534|NCT00262652|asthmatics
615535|NCT00262639|Alcoholism
615536|NCT00262639|Alcohol Dependence
615537|NCT00262639|Alcohol Withdrawal
615538|NCT00262639|Treatment
615539|NCT00262639|Pharmacotherapy
615540|NCT00262613|Sodium Pyruvate
615541|NCT00262613|COPD
615542|NCT00262613|Chronic Obstructive Pulmonary Disease
615543|NCT00262587|Sport
615544|NCT00262587|Asthma
615545|NCT00262587|Treatment
615546|NCT00262587|Airway inflammation
615547|NCT00262574|endothelial disfunction
615548|NCT00262574|BNP
615549|NCT00262574|PCI
615550|NCT00262574|coronary artery disease
615551|NCT00262561|Intermittent Claudication
615552|NCT00262561|Aspirin resistance
615553|NCT00262561|Clopidogrel resistance
615554|NCT00262548|Obesity
615555|NCT00262548|Menopause
615556|NCT00262522|Human Immunodeficiency Virus Infections
615557|NCT00262509|Rehabilitation
615558|NCT00262509|Sensory Aid
615559|NCT00262496|Botox
615560|NCT00262496|Overactive bladder
615561|NCT00262496|Incontinence
615562|NCT00262496|Spinal Cord Injury
615563|NCT00262470|tachycardia
615564|NCT00262470|sinus tachycardia
615565|NCT00262470|postural tachycardia syndrome (POTS)
615566|NCT00262457|electrical stimulation
615567|NCT00262457|Pressure Ulcers
615568|NCT00262457|Spinal Cord Injury
615569|NCT00262431|Tracheostomy
615570|NCT00262431|Tracheostomy timing
615571|NCT00262431|Ventilator associated pneumonia
615572|NCT00262431|Mechanical ventilation
615573|NCT00262392|heterotopic ossification,
615574|NCT00262392|prevention,
615575|NCT00262392|high risk,
615576|NCT00262392|bisphosphonates,
615577|NCT00262392|radiotherapy
615578|NCT00262379|Chronic hepatitis C
615579|NCT00262379|peginterferon
615580|NCT00262379|ribavirin
615581|NCT00262379|epoetin beta
615582|NCT00262340|Asthma
615583|NCT00262340|Pediatrics
615584|NCT00262340|Airway
615585|NCT00262340|Inflammation
615586|NCT00262327|antiangiogenesis
615587|NCT00262327|endostatin
615588|NCT00262327|adenovirus
615589|NCT00262327|gene therapy
615590|NCT00262327|cancer
615591|NCT00262236|Hypertension, Aliskiren, Atenolol, Blood Pressure
615592|NCT00262223|Co-morbid alcohol dependence and PTSD
615593|NCT00262223|Alcohol and other drug use disorders
615594|NCT00262223|Treatment outcome
615595|NCT00262197|Diabetes mellitus
615596|NCT00262197|Medical error rates
615597|NCT00262197|Pharmacotherapy
615598|NCT00262184|Post-Menopausal osteopenia
615599|NCT00262158|smoking status
615600|NCT00262158|cigarette consumption
615601|NCT00262145|glucose
615602|NCT00262145|lipid
615603|NCT00262145|diabetes
615604|NCT00262145|overweight
615605|NCT00262119|Physiological pacing
615606|NCT00262119|Antitachycardia pacing therapies
615607|NCT00262106|Administration, intravaginal
615608|NCT00262106|Anti-infective agents
615609|NCT00262106|Double blind method
615610|NCT00262106|Drug evaluation
615611|NCT00262106|Female
615612|NCT00262106|Gels
615613|NCT00262106|HIV infections/prevention and control
615614|NCT00262106|Microbicide
615615|NCT00262106|Naphthalenesulfonates/administration and dosage
615871|NCT00260975|hormonal therapy
615616|NCT00262106|Polymers/administration and dosage
615617|NCT00262106|Sexual behavior
615618|NCT00262106|Vaginal creams, foams and jellies
615619|NCT00262106|HIV Seronegativity
615620|NCT00262106|Genital Herpes Infections
615621|NCT00262093|preeclampsia
615622|NCT00262093|sFlt1
615623|NCT00262093|PlGF
615624|NCT00262093|parity
615625|NCT00262093|angiogenesis
615626|NCT00262054|coronary disease
615627|NCT00261989|pulse oximetry readings
615628|NCT00261989|pediatrics
615629|NCT00261989|cardiac
615630|NCT00261989|congenital heart disease
615631|NCT00261976|Rheumatoid arthritis
615632|NCT00261976|Crohn's disease
615633|NCT00261976|Psoriasis
615634|NCT00261950|Cinacalcet HCl, Cinacalcet, Amgen (AMG) 073, Sensipar, Mimpara, Calcimimetic
615635|NCT00261924|Thrombocytopenic patients
615636|NCT00261911|Meridia
615637|NCT00261911|Sibutramine
615638|NCT00261911|Obesity
615639|NCT00261911|Adolescent
615640|NCT00261911|BMI
615641|NCT00261898|Sleep Deprivation
615642|NCT00261898|Obesity
615643|NCT00261898|Metabolic Syndrome
615644|NCT00261898|Hormones
615645|NCT00261898|Public Health
615646|NCT00261898|Overweight
615647|NCT00261898|Sleep
615648|NCT00261872|Alcoholism
615649|NCT00261872|Attention Deficit Disorder
615650|NCT00261872|ADHD
615651|NCT00261859|hazardous drinking
615652|NCT00261846|Leukemia
615653|NCT00261846|tyrosine kinase inhibitor
615654|NCT00261846|philadelphia chromosome
615655|NCT00261846|Myeloid
615656|NCT00261846|Philadelphia Positive
615657|NCT00261833|Alpha1-proteinase inhibitor deficiency
615658|NCT00261833|Emphysema
615659|NCT00261833|Chronic augmentation and maintenance therapy
615660|NCT00261820|Kidney Transplant
615661|NCT00261807|severe
615662|NCT00261807|skin
615663|NCT00261807|infections
615664|NCT00261794|cognition
615665|NCT00261794|schizophrenia
615666|NCT00261794|treatment
615667|NCT00261781|Treadmill
615668|NCT00261781|Walking
615669|NCT00261781|Exercise
615670|NCT00261781|Automaticity
615671|NCT00261781|Quality of Life
615672|NCT00261768|Aging
615673|NCT00261768|hearing aids
615674|NCT00261768|hearing loss, sensorineural
615675|NCT00261768|speech recognition
615676|NCT00261755|Acupuncture
615677|NCT00261755|pain relief
615678|NCT00261755|labour
615679|NCT00261755|randomized controlled trial
615680|NCT00261755|TENS
615681|NCT00261742|perianal
615682|NCT00261742|dermatitis
615683|NCT00261742|streptococcus pyogenes
615684|NCT00261729|Paroxetine
615685|NCT00261729|Prazosin
615686|NCT00261729|Sleep Disorders
615687|NCT00261729|Stress Disorders, Post-Traumatic
615688|NCT00261716|clinical trial
615689|NCT00261716|employment
615690|NCT00261716|schizoaffective disorder
615691|NCT00261716|schizophrenia
615692|NCT00261690|Virtual Reality Distraction
615693|NCT00261677|Anemia
615694|NCT00261677|cancer
615695|NCT00261677|solid tumor
615696|NCT00261677|Hodgkin's Disease
615697|NCT00261677|Acute Lymphocytic Leukemia (ALL)
615698|NCT00261677|Non-Hodgkin's Lymphoma (NHL)
615699|NCT00261677|Quality of Life
615700|NCT00261677|hemoglobin
615701|NCT00261677|Epoetin alfa
615702|NCT00261638|Mental Health Promotion
615703|NCT00261638|Mental Health Index
615704|NCT00261638|Taiwan Mental Health Index scale
615705|NCT00261638|psychophysical health
615706|NCT00261638|education years over 9 years
615707|NCT00261638|normal people, especially joining Mental Health Foundation Promotions
615708|NCT00261625|peritoneal dialysis
615709|NCT00261625|artery calcification
615710|NCT00261625|bone mineral density
615711|NCT00261612|relapsed or chemotherapy-refractory disease
615712|NCT00261599|Colonoscopy
615713|NCT00261599|Sedation
615714|NCT00261599|AQUAVAN
615715|NCT00261599|Fospropofol disodium
615716|NCT00261599|Colon polyps
615717|NCT00261599|Endoscopic outcomes
615718|NCT00261599|Endoscopic sedation
615719|NCT00261599|Endoscopy
615720|NCT00261586|aspirin
615721|NCT00261586|analgesics
615722|NCT00261586|cyclooxygenase activity
615723|NCT00261586|non-steroidal antiinflammatory drugs
615724|NCT00261573|"Alzheimer's disease with cerebrovascular disease (mixed dementia)"
615725|NCT00261573|probable vascular dementia
615726|NCT00261573|galantamine
615727|NCT00261560|ankle sprain
615728|NCT00261560|acetaminophen extended release, ibuprofen
615729|NCT00261547|Kidney transplantation
615730|NCT00261547|HLA
615731|NCT00261534|Chemotherapy
615732|NCT00261521|Kidney failure, Chronic
615733|NCT00261521|End-stage renal disease
615734|NCT00261521|Kidney failure
615735|NCT00261521|Anemia
615736|NCT00261521|Dialysis
615737|NCT00261521|Epoetin
615738|NCT00261521|Erythropoetin
615739|NCT00261521|Epoetin alfa
615740|NCT00261508|Risperidone
615741|NCT00261508|child development disorders
615742|NCT00261508|pervasive development disorders
615743|NCT00261508|autistic disorder
615744|NCT00261508|autism
615745|NCT00261508|developmental disabilities
615746|NCT00261508|antipsychotropic agents
615747|NCT00261495|chronic noncancer pain
615748|NCT00261495|pain
615749|NCT00261495|analgesia
615750|NCT00261495|analgesic opioid
615751|NCT00261495|oxycodone
615752|NCT00261495|hydromorphone
615753|NCT00261482|contraception
615754|NCT00261482|female contraception
615755|NCT00261482|hormonal contraception
615756|NCT00261482|transdermal contraception
615757|NCT00261482|EVRA
615758|NCT00261482|estrogen
615759|NCT00261482|progestin
615760|NCT00261482|ethinyl estradiol
615761|NCT00261482|norelgestromin
615762|NCT00261469|Migraine
615763|NCT00261469|Headache
615764|NCT00261456|Prostate cancer
615765|NCT00261456|BRCA1
615766|NCT00261456|BRCA2
615767|NCT00261456|prostate screening
615768|NCT00261456|PSA
615769|NCT00261456|prostate biopsy
615770|NCT00261443|Bipolar I Disorder with a recent manic or mixed episode
615771|NCT00261430|Schizophrenia
615772|NCT00261430|acceptance
615773|NCT00261430|motivational enhancement therapy
615774|NCT00261430|long-acting risperidone
615775|NCT00261430|intramuscular injection
615776|NCT00261430|Treatment Guidebook
615777|NCT00261430|GAIN Acceptance Approach
615778|NCT00261391|Arteriovenous Malformation
615779|NCT00261391|Lymphatic Malformation
615780|NCT00261391|Gorham
615781|NCT00261378|Hepatocellular Carcinoma (HCC)
615782|NCT00261339|Gastroesophageal Reflux
615783|NCT00261339|Gastroesophageal Reflux Disease
615784|NCT00261339|Pantoprazole
615785|NCT00261326|Simvastatin
615786|NCT00261326|Optic Neuritis
615787|NCT00261326|Multiple Sclerosis
615788|NCT00261313|Breast cancer
615789|NCT00261313|Doses dense chemotherapy
615790|NCT00261313|Growth factor support
615791|NCT00261313|Adjuvant Breast Cancer
615792|NCT00261300|Gastric acid
615793|NCT00261300|GERD
615794|NCT00261300|Gastroesophageal reflux disease
615795|NCT00261300|Pantoprazole
615796|NCT00261300|Proton pump inhibitor
615797|NCT00261287|Hay Fever
615798|NCT00261287|Allergic Rhinitis
615799|NCT00261287|Perennial Allergic Rhinitis
615800|NCT00261287|Ciclesonide
615801|NCT00261274|transfusion; red blood cells
615802|NCT00261261|children
615803|NCT00261261|anxiety
615804|NCT00261261|behavioral preparation
615805|NCT00261261|family
615806|NCT00261261|surgery
615807|NCT00261261|parents
615808|NCT00261248|Phase 2
615809|NCT00261248|Vaccine
615810|NCT00261248|Urinary Tract Infection
615811|NCT00261248|Vaginal Mucosal
615812|NCT00261235|Rehabilitation, Vocational
615813|NCT00261235|Virtues
615814|NCT00261235|Employment, supported
615815|NCT00261235|veterans
615816|NCT00261235|Mentally Ill Persons
615817|NCT00261222|Amodiaquine
615818|NCT00261222|Efficacy
615819|NCT00261222|Malaria
615820|NCT00261222|Burkina Faso
615821|NCT00261209|Flexor Tendon Adhesions
615822|NCT00261209|Zone II of the Hand
615823|NCT00261196|Frozen Shoulder
615824|NCT00261170|smoking
615825|NCT00261157|nephrectomy
615826|NCT00261157|Safety
615827|NCT00261157|Laparoscopy
615828|NCT00261157|telerounding
615829|NCT00261157|prostatectomy
615830|NCT00261131|cerebral palsy
615831|NCT00261131|spasticity
615832|NCT00261131|diplegia
615833|NCT00261118|colitis
615834|NCT00261118|rituximab
615835|NCT00261066|functional outcome
615836|NCT00261066|orthopaedic surgery
615837|NCT00261040|Osteoarthritis
615838|NCT00261040|Total Hip Arthroplasty
615839|NCT00261040|Minimally Invasive Surgery
615840|NCT00261027|ovarian cancer
615841|NCT00261014|Recurrent
615842|NCT00261014|Idiopathic
615843|NCT00261014|Deep Vein Thrombosis
615844|NCT00261014|Pulmonary Embolism
615845|NCT00261014|Clinical Prediction Rule
615846|NCT00261014|Venous Thromboembolism
615847|NCT00261014|Risk Factors
615848|NCT00261001|Transcutaneous
615849|NCT00261001|Vaccination
615850|NCT00261001|Safety
615851|NCT00261001|Immunogenicity
615852|NCT00261001|HIV
615853|NCT00261001|Treatment Experienced
615854|NCT00260988|Prophylaxis
615855|NCT00260988|Thromboembolic disease
615856|NCT00260988|End stage renal disease
615857|NCT00260988|Hemodialysis
615858|NCT00260988|Pharmacokinetics
615859|NCT00260988|Low Molecular Weight Heparin
615860|NCT00260988|Innohep
615861|NCT00260988|Tinzaparin
615862|NCT00260988|Fragmin
615863|NCT00260988|Dalteparin
615864|NCT00260988|Anti Xa
615865|NCT00260988|INR
615866|NCT00260988|Oral anticoagulation
615867|NCT00260988|warfarin
615868|NCT00260988|Coumadin
615869|NCT00260975|breast cancer
615872|NCT00260975|cognitive function
615873|NCT00260975|chemo fog
615874|NCT00260962|Pilot Project,
615875|NCT00260962|Clinical Trial,
615876|NCT00260962|Treatment Outcome,
615877|NCT00260962|Psychopharmacology
615878|NCT00260949|rotator cuff tear
615879|NCT00260949|arthroscopic repair
615880|NCT00260936|HIV
615881|NCT00260936|AIDS
615882|NCT00260936|Adolescent Males
615883|NCT00260936|HIV positive
615884|NCT00260936|Treatment Naive
615885|NCT00260936|Treatment Experienced
615886|NCT00260923|hypertension
615887|NCT00260923|aliskiren
615888|NCT00260923|blood pressure
615889|NCT00260897|avascular necrosis of the femoral head
615890|NCT00260897|genotyping
615891|NCT00260897|linkage analysis
615892|NCT00260897|pathogenesis
615893|NCT00260897|therapy
615894|NCT00260871|lung adenocarcinoma
615895|NCT00260871|genetic epidemiology
615896|NCT00260871|environmental factors
615897|NCT00260871|genetic map
615898|NCT00260871|coordination center
615899|NCT00260858|Glycemic index
615900|NCT00260858|Nutrition
615901|NCT00260858|Carbohydrates
615902|NCT00260858|Glycemic responses
615903|NCT00260858|Methodology
615904|NCT00260858|Healthy human subjects
615905|NCT00260832|Acute Myeloid Leukemia
615906|NCT00260832|Dacogen
615907|NCT00260832|Decitabine
615908|NCT00260832|Poor or intermediate-risk cytogenetics
615909|NCT00260819|Hypoxia-induced pulmonary artery hypertension
615910|NCT00260819|High-altitude pulmonary oedema
615911|NCT00260819|ETA receptor antagonist
615912|NCT00260793|Ropinirole
615913|NCT00260793|Parkinson's disease
615914|NCT00260793|dopamine agonist
615915|NCT00260780|sexually transmitted diseases
615916|NCT00260780|Risk Behavior
615917|NCT00260754|Risk behavior
615918|NCT00260754|Sexually transmitted diseases
615919|NCT00260741|cannabis
615920|NCT00260741|marijuana
615921|NCT00260741|Multiple Sclerosis
615922|NCT00260741|Spasticity
615923|NCT00260728|vascular access
615924|NCT00260728|hemodialysis
615925|NCT00260715|Risk behavior
615926|NCT00260715|Sexually Transmitted Diseases
615927|NCT00260702|Phenotype
615928|NCT00260702|Monoclonal
615929|NCT00260702|Immunoglobulin
615930|NCT00260702|Immunodeficiency
615931|NCT00260702|Dermatitis
615932|NCT00260702|Job's Syndrome
615933|NCT00260702|Hyper-IgE Syndrome
615934|NCT00260702|HIES
615935|NCT00260689|Immunosuppression
615936|NCT00260689|T-cells
615937|NCT00260689|Hematopoiesis
615938|NCT00260689|Autoimmunity
615939|NCT00260689|Thrombocytopenia
615940|NCT00260689|Severe Aplastic Anemia
615941|NCT00260689|SAA
615942|NCT00260676|brain death
615943|NCT00260676|lung transplantation
615944|NCT00260676|organ donors
615945|NCT00260676|potential organ donors
615946|NCT00260663|Hearing Impaired Rehabilitation
615947|NCT00260663|Hearing Aids
615948|NCT00260663|Randomized Controlled Trials
615949|NCT00260663|Cost Effectiveness
615950|NCT00260663|Quality of life
615951|NCT00260663|Patient Compliance
615952|NCT00260650|heart failure, congestive
615953|NCT00260650|self-care
615954|NCT00260650|quality of life
615955|NCT00260650|health behavior
615956|NCT00260637|Prostatitis
615957|NCT00260624|agitation
615958|NCT00260624|dementia
615959|NCT00260624|Alzheimer's Disease
615960|NCT00260611|prostate
615961|NCT00260598|Non-small cell lung cancer
615962|NCT00260598|Head and neck squamous cell cancer
615963|NCT00260598|White light bronchoscopy
615964|NCT00260598|Imaging Elastic Scattering Spectroscopy (IESS)
615965|NCT00260598|Fluorescence Bronchoscopy
615966|NCT00260598|COPD
615967|NCT00260598|Helium-Cadmium Laser Bronchoscopy
615968|NCT00260598|Autofluorescence spectra of dysplasia & cancer in situ (CIS)
615969|NCT00260598|Severe Chronic Obstructive Pulmonary Disorders(COPD)
615970|NCT00260585|gastroesophageal reflux disease
615971|NCT00260585|GERD
615972|NCT00260585|hiatal hernia
615973|NCT00260585|achalasia
615974|NCT00260585|Barrett's metaplasia
615975|NCT00260585|Anti-Reflux Surgery
615976|NCT00260585|Known/suspected esophageal/gastroesophageal junction tumor
615977|NCT00260585|Esophageal disorders such as Barrett's metaplasia
615978|NCT00260585|Symptomatic gastroesophageal reflux disease
615979|NCT00260572|GERD
615980|NCT00260572|nissen
615981|NCT00260572|fundoplication
615982|NCT00260572|reflux
615983|NCT00260572|toupet
615984|NCT00260572|QOL
615985|NCT00260572|dyspepsia
615986|NCT00260572|heartburn
615987|NCT00260572|Patients with reflux symptoms for at least 6 months
615988|NCT00260572|Patients scheduled for lap nissen or toupet fundoplication
615989|NCT00260572|Reflux diagnosed by either endoscopy, upper GI, or 24hr. pH
615990|NCT00260572|On or starting treatment with PPI or pro-motility agents
615991|NCT00260559|Esophagectomy
615992|NCT00260559|Esophageal Cancer
615993|NCT00260559|Quality of Life
615994|NCT00260559|Minimally Invasive Esophagectomy
615995|NCT00260559|Laparoscopic Transhiatal Esophagectomy
615996|NCT00260559|Open Esophagectomy
615997|NCT00260559|Karnofsky Score
615998|NCT00260559|Dysphagia score
615999|NCT00260559|Heartburn Scale
616000|NCT00260559|Nutrition Score
616001|NCT00260546|Ventricular dyssynchrony
616002|NCT00260520|Low molecular weight heparin
616003|NCT00260520|Preeclampsia
616004|NCT00260520|Fetal Growth Restriction
616005|NCT00260520|Thrombophilia
616006|NCT00260520|Factor V Leiden
616007|NCT00260520|G20210A prothrombin gene mutation
616008|NCT00260507|Post Traumatic Stress Disorder
616009|NCT00260507|Veteran's
616010|NCT00260507|Vocational Rehabilitation
616011|NCT00260494|Cardiac Surgical Procedures
616012|NCT00260494|open saphenous vein graft harvest wounds
616013|NCT00260494|Postoperative Complications
616014|NCT00260494|Surgical Wound Infection
616015|NCT00260494|Surgical Wound Dehiscence
616016|NCT00260481|Methamphetamine Dependence
616017|NCT00260481|Pharmacotherapy
616018|NCT00260468|Major depression
616019|NCT00260468|Magnetic resonance imaging
616020|NCT00260468|White matter lesions
616021|NCT00260468|Perfusion
616022|NCT00260468|Diffusion
616023|NCT00260468|Magnetization transfer
616024|NCT00260468|Vascular risk factors
616025|NCT00260442|sarcopenia
616026|NCT00260442|resistance training
616027|NCT00260442|strength training
616028|NCT00260442|skeletal muscle
616029|NCT00260442|elderly
616030|NCT00260442|cholesterol
616031|NCT00260442|aging
616032|NCT00260442|cardiovascular disease
616033|NCT00260442|nutrition
616034|NCT00260442|inflammation
616035|NCT00260442|lipids
616036|NCT00260429|Dupuytren's contracture
616037|NCT00260429|fixed flexion contracture
616038|NCT00260416|Acute myocardial infarction
616039|NCT00260416|Symptom duration
616040|NCT00260416|Primary angioplasty
616041|NCT00260416|Infarct size
616042|NCT00260416|Myocardial scintigraphy
616043|NCT00260390|Dysthymic Disorder
616044|NCT00260390|HPG hypofunctioning
616045|NCT00260390|Testosterone replacement
616046|NCT00260377|Aspirin treatment
616047|NCT00260377|Aspirin resistance
616048|NCT00260377|Coronary bypass surgery
616049|NCT00260364|Recurrent carcinoma of the pancreas
616050|NCT00260364|Adenocarcinoma of the pancreas
616051|NCT00260364|Stage II carcinoma of the pancreas
616052|NCT00260364|Stage III carcinoma of the pancreas
616053|NCT00260364|Stage IVA carcinoma of the pancreas
616054|NCT00260364|Stage IVB carcinoma of the pancreas
616055|NCT00260351|rabies;
616056|NCT00260351|rabies post-exposure;
616057|NCT00260351|category III
616058|NCT00260338|myocardial ischemia
616059|NCT00260338|stem cell
616060|NCT00260338|mesenchymal
616061|NCT00260338|myocardial perfusion
616062|NCT00260325|pretreatment
616063|NCT00260325|healthy volunteers
616064|NCT00260312|inactived
616065|NCT00260312|polio
616066|NCT00260312|vaccine
616067|NCT00260312|cuba
616068|NCT00260312|trial
616069|NCT00260312|randomized
616070|NCT00260312|eradication
616071|NCT00260299|cholesterol defects
616072|NCT00260299|Mevalonic Aciduria
616073|NCT00260299|Mevalonate Kinase Deficiency
616074|NCT00260299|HIDS
616075|NCT00260299|Hyperimmunoglobulinemia with periodic fever syndrome
616076|NCT00260299|MKD
616077|NCT00260299|Lipid Metabolism, Inborn Errors
616078|NCT00260299|Periodic Fever Syndromes, hereditary
616079|NCT00260299|mevalonic acid
616080|NCT00260299|mevalonate kinase
616081|NCT00260299|cholesterol, dietary
616082|NCT00260299|Hyper IgD
616083|NCT00260299|Multiple malformations
616084|NCT00260299|Fever
616085|NCT00260286|LH pulsatility
616086|NCT00260286|energy availability
616087|NCT00260286|exercise
616088|NCT00260286|diet
616089|NCT00260286|gynecological age
616090|NCT00260273|Preventive Therapy
616091|NCT00260273|Psychoses
616092|NCT00260273|Cognitive Behaviour Therapy
616093|NCT00260247|CYP3A4
616094|NCT00260247|Induction
616095|NCT00260247|Oxcarbazepine
616096|NCT00260247|Carbamazepine
616097|NCT00260247|Quinidine
616098|NCT00260247|Human
616099|NCT00260247|In vivo
616100|NCT00260234|Transplantation, Pancreatic Islets
616101|NCT00260234|Diabetes Mellitus, Type 1
616102|NCT00260234|Insulin Dependent
616103|NCT00260234|Islet Transplant
616104|NCT00260221|Virtual Reality Hypnosis
616105|NCT00260208|Liver transplant, adults, hepatitis C, liver fibrosis, cyclosporine microemulsion, tacrolimus
616106|NCT00260195|Trauma
616107|NCT00260195|Violence
616108|NCT00260195|Adolescent
616109|NCT00260195|Schools
616110|NCT00260195|Cognitive behavioral therapy
616111|NCT00260182|Depressive Disorder
616112|NCT00260182|Family
616113|NCT00260182|Genetics
616114|NCT00260169|Treatment Preferences
616115|NCT00260169|Public sector
616116|NCT00260169|Latino
616117|NCT00260156|Type 2 diabetes
616118|NCT00260156|vildagliptin
616119|NCT00260143|HIV+ men
616120|NCT00260143|Treatment Experienced
616121|NCT00260130|obesity
616122|NCT00260130|food intake
616123|NCT00260130|human
616124|NCT00260130|energy balance
616125|NCT00260130|beverage
616126|NCT00260117|Exercise
616127|NCT00260117|Physical activity
616128|NCT00260117|walking
616129|NCT00260117|running
616130|NCT00260091|Infertility
616131|NCT00260091|Advanced maternal age
616132|NCT00260091|Pregnancy
616133|NCT00260091|Reproductive health
616134|NCT00260091|Fertility treatment
616135|NCT00260091|Reproduction
616136|NCT00260078|Treatment Experienced
616137|NCT00260078|Pharmacokinetics
616138|NCT00260078|PK
616139|NCT00260065|Myelodysplastic Syndrome
616140|NCT00260065|Decitabine
616141|NCT00260065|Dacogen
616142|NCT00260065|MGI Pharma
616143|NCT00260052|traumatic brain injury
616144|NCT00260026|Lung Cancer
616145|NCT00260013|chronic mental illness
616146|NCT00260000|mild PKU
616147|NCT00260000|Y414C
616148|NCT00260000|5,6,7,8-tetrahydrobiopterin, BH4
616149|NCT00260000|treatment without protein restriction
616150|NCT00259987|relapsed adenocarcinoma
616151|NCT00259987|esophagus
616152|NCT00259987|tumors
616153|NCT00259987|GE junction
616154|NCT00259987|cancer
616155|NCT00259987|lapatinib
616156|NCT00259987|gastric cardia
616157|NCT00259974|Anti-MAG monoclonal gammopathy
616158|NCT00259974|Polyneuropathy
616159|NCT00259974|Rituximab
616160|NCT00259948|HR variability, CVA, Myocardial infarction, aerobic exercise training
616161|NCT00259935|Any Solid Tumor
616162|NCT00259922|constipation
616163|NCT00259922|gastrointestinal
616164|NCT00259922|opioids
616165|NCT00259922|pain
616166|NCT00259922|non-cancer pain
616167|NCT00259922|opioid-induced
616168|NCT00259922|bowel dysfunction
616169|NCT00259909|Patient reported outcomes
616170|NCT00259909|acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
616171|NCT00259909|COPD
616172|NCT00259896|exenatide
616173|NCT00259896|pharmacokinetics
616174|NCT00259896|pharmacodynamics
616175|NCT00259883|depressive episodes
616176|NCT00259883|paroxetine
616177|NCT00259883|PAXIL
616178|NCT00259883|depression
616179|NCT00259883|benzodiazepine
616180|NCT00259883|combination
616181|NCT00259870|Schizophrenia
616182|NCT00259870|PANSS
616183|NCT00259870|Acute
616184|NCT00259870|Cognition
616185|NCT00259857|Fracture
616186|NCT00259857|Bone Mineral Density
616187|NCT00259857|DXA
616188|NCT00259844|Colorectal
616189|NCT00259844|Liver Metastases
616190|NCT00259844|Vaccine
616191|NCT00259844|Colorectal Liver Metastases
616192|NCT00259831|cold
616193|NCT00259831|influenza
616194|NCT00259818|Refractory
616195|NCT00259818|Solid Tumors
616196|NCT00259805|encephalitis
616197|NCT00259805|epilepsy
616198|NCT00259805|Rasmussens
616199|NCT00259805|rituximab
616200|NCT00259805|autoimmune
616201|NCT00259779|COPD
616202|NCT00259753|Wet Age-Related Macular Degeneration
616203|NCT00259740|Multiple Myeloma, Relapsed, Plateau-Phase
616204|NCT00259727|Amprenavir
616205|NCT00259727|Glucagon
616206|NCT00259727|HIV Protease inhibitors
616207|NCT00259727|Indinavir
616208|NCT00259727|Lopinavir
616209|NCT00259727|Ritonavir
616210|NCT00259714|hypertension
616211|NCT00259714|hemodialysis
616212|NCT00259714|sodium
616213|NCT00259714|dialysate
616214|NCT00259714|hemodynamics
616215|NCT00259701|endothelium
616216|NCT00259701|iontophoresis
616217|NCT00259701|acetylcholine
616218|NCT00259701|nitroglycerin
616219|NCT00259701|vasodilation
616220|NCT00259688|Preeclampsia
616221|NCT00259688|Sleep Apnea
616222|NCT00259688|CPAP
616223|NCT00259662|cancer--ovarian
616224|NCT00259662|cancer--endometria
616225|NCT00259662|deep vein thrombosis
616226|NCT00259662|statin therapy in perioperative period
616227|NCT00259623|Cardiac surgery
616228|NCT00259623|Radiofrequency ablation
616229|NCT00259623|Atrial fibrillation
616230|NCT00259610|RA
616231|NCT00259610|painful joints
616232|NCT00259610|swollen joints
616233|NCT00259597|nuclear morphology
616234|NCT00259597|image analysis
616235|NCT00259597|lipid peroxidation
616236|NCT00259597|diet
616237|NCT00259597|proliferative breast disease
616238|NCT00259571|remission
616239|NCT00259571|mesalazin
616240|NCT00259571|non-inferiority study
616241|NCT00259571|relapse
616242|NCT00259558|Ulcerative Colitis
616243|NCT00259558|Dose Finding
616244|NCT00259558|Phosphatidylcholine
616245|NCT00259545|retarded phosphatidylcholine
616246|NCT00259545|chronic active
616247|NCT00259545|steroid
616248|NCT00259519|premature or preterm birth
616249|NCT00259519|chorioamnionitis
616250|NCT00259519|neonatal sepsis
616251|NCT00259519|labour
616252|NCT00259519|Cesarean Section
616253|NCT00259519|delivery
616254|NCT00259519|length of stay
616255|NCT00259519|pregnancy
616256|NCT00259506|Recurrent depression
616257|NCT00259506|Mental Health
616258|NCT00259493|Coronary Artery Disease
616259|NCT00259493|Coronary Artery Bypass Graft Surgery
616260|NCT00259493|Off-pump CABG
616261|NCT00259493|Cardiac CT
616262|NCT00259493|Bypass Graft CT angiography
616263|NCT00259467|Activity, Dementia, Caregiving
616264|NCT00259454|Caregivers
616265|NCT00259454|in-home care occupational therapy
616266|NCT00259441|Kidney failure
616267|NCT00259441|Contrast media
616268|NCT00259441|Prevention
616269|NCT00259441|Simvastatin
616270|NCT00259428|Atrial Fibrillation
616271|NCT00259428|Atrial Flutter
616272|NCT00259428|Arrhythmia
616273|NCT00259428|Anti-Arrhythmia agents
616274|NCT00259415|Support groups
616275|NCT00259415|Alzheimer's Disease
616276|NCT00259389|Treatment Experienced
616277|NCT00259389|Adherence
616278|NCT00259389|Compliance
616279|NCT00259389|Directly Observed Therapy
616280|NCT00259389|DOT
616281|NCT00259389|Treatment Naive
616282|NCT00259376|Atrial Fibrillation
616283|NCT00259376|Atrial Flutter
616284|NCT00259376|Arrhythmia
616285|NCT00259376|Anti-Arrhythmia agents
616286|NCT00259350|Central venous catheter
616287|NCT00259350|Skin disinfection
616288|NCT00259350|Antisepsis
616289|NCT00259350|Nosocomial infection
616290|NCT00259350|Catheter infection
616291|NCT00259337|Diphteria
616292|NCT00259337|Tetanus
616293|NCT00259337|Polio
616294|NCT00259337|Acellular Pertussis
616295|NCT00259337|Hib
616296|NCT00259337|Haemophilus influenzae type B
616297|NCT00259259|Appetite regulation
616298|NCT00259259|Hormones
616299|NCT00259259|Energy intake
616300|NCT00259220|Bleeding
616301|NCT00259220|Endoscopy
616302|NCT00259220|Gastric tube
616303|NCT00259220|Erythromycin
616304|NCT00259220|Randomized
616305|NCT00259207|Pulmonary valve regurgitation
616306|NCT00259207|Valve replacement
616307|NCT00259207|Hybrid procedure
616308|NCT00259194|Coronary angiography
616309|NCT00259194|Complications
616310|NCT00259194|Observation
616311|NCT00259181|chlorhexidine gluconate
616312|NCT00259181|polymethylmethacrylate
616313|NCT00259181|Anti-Bacterial Agents
616314|NCT00259168|Postprandial endothelial function
616315|NCT00259155|Irritable bowel syndrome, Bacterial overgrowth
616316|NCT00259142|home management of fever, malaria, Uganda
616317|NCT00259116|Congestive heart failure
616318|NCT00259116|Relaxin
616319|NCT00259116|Cardiac hemodynamics
616320|NCT00259103|relaxin
616321|NCT00259103|pregnancy
616322|NCT00259103|cervical ripening
616323|NCT00259103|normal pregnancy at least at 40 weeks of gestation
616324|NCT00259038|Carperitide
616325|NCT00259038|Atrial Natriuretic Peptide
616326|NCT00259038|Treatment efficacy
616327|NCT00259038|Safety
616328|NCT00259038|Heart failure, Congestive
616329|NCT00259038|Pulmonary Artery Catheterization
616330|NCT00259025|Renal failure, chronic
616331|NCT00259025|Death, sudden, cardiac
616332|NCT00259025|Heart rate variability
616333|NCT00259025|Tachycardia, ventricular
616334|NCT00259025|Ventricular premature complexes
616335|NCT00259025|Ventricular repolarization
616336|NCT00259025|Eicosapentaenoic acid
616337|NCT00259025|Docosahexaenoic acid
616338|NCT00259012|GERD
616339|NCT00259012|Infant
616340|NCT00258999|Skin Cholesterol
616341|NCT00258999|Carotid Plaque
616342|NCT00258999|Carotid Intima-Media Thickness
616343|NCT00258986|Living donors
616344|NCT00258986|Nephrectomy
616345|NCT00258986|Kidney transplantation
616346|NCT00258986|Randomized Controlled Trial
616347|NCT00258986|Laparoscopy
616348|NCT00258973|Hand held Ultrasound
616349|NCT00258973|Office practice
616350|NCT00258973|Atherosclerosis prevention
616351|NCT00258973|Ultrasound training
616352|NCT00258960|HER2 positive breast cancer
616353|NCT00258960|Metastatic breast cancer
616354|NCT00258947|Smallpox
616355|NCT00258947|Orthopoxvirus
616356|NCT00258947|Poxvirus
616357|NCT00258947|Vaccina Virus
616358|NCT00258947|LISTER Strain
616359|NCT00258947|Bioterrorism
616360|NCT00258934|Influenza
616361|NCT00258934|Orthomyxoviruses
616362|NCT00258934|Inactivated
616363|NCT00258934|Split-virion influenza vaccine
616364|NCT00258934|adults
616365|NCT00258934|Myxovirus Infection
616366|NCT00258934|Orthomyxovirus Infection
616367|NCT00258908|ADACEL™
616368|NCT00258908|Tetanus
616369|NCT00258908|Diphteria
616370|NCT00258908|Acellular pertussis
616371|NCT00258895|DAPTACEL®
616372|NCT00258895|Pentacel™
616373|NCT00258895|Diphtheria
616374|NCT00258895|Tetanus
616375|NCT00258895|Pertussis
616376|NCT00258895|Whooping cough
616377|NCT00258895|Acellular Pertussis Vaccine Adsorbed
616378|NCT00258882|Tetanus Toxoid,
616379|NCT00258882|acellular pertussis,
616380|NCT00258882|diphtheria toxoid
616381|NCT00258869|prospective studies
616382|NCT00258869|biological assay
616383|NCT00258869|body weights and measures
616384|NCT00258869|chemistry, analytical
616385|NCT00258869|microchip analytical procedures
616386|NCT00258869|spectrum analysis, mass
616387|NCT00258869|molecular diagnostic techniques
616388|NCT00258869|microbiological techniques
616389|NCT00258869|drug administration schedule
616390|NCT00258869|data collection
616391|NCT00258869|statistics
616392|NCT00258869|gene expression profiling
616393|NCT00258869|sequence analysis
616394|NCT00258869|human experimentation
616395|NCT00258869|immunoassay
616396|NCT00258869|Trauma severity indices
616397|NCT00258869|Glasgow Coma score
616398|NCT00258869|Outcome assessment
616399|NCT00258869|mortality
616400|NCT00258869|computer models
616401|NCT00258869|decision modeling
616402|NCT00258869|linear models
616403|NCT00258869|logistic models
616404|NCT00258869|immunologic model
616405|NCT00258869|mathematical model
616406|NCT00258869|non-linear models
616407|NCT00258869|early diagnosis
616408|NCT00258869|diagnosis, computer assisted
616409|NCT00258869|medical informatics
616410|NCT00258869|prognosis
616411|NCT00258869|registries
616412|NCT00258869|computational biology
616413|NCT00258869|systems biology
616414|NCT00258856|Meningitis
616415|NCT00258856|Meningococcal infection
616416|NCT00258856|Neisseria meningitidis
616417|NCT00258856|Menactra®
616418|NCT00258856|Menomune®
616419|NCT00258843|IMOVAX;
616420|NCT00258843|poliomyelitis
616421|NCT00258830|Influenza vaccine
616422|NCT00258817|Fluzone®
616423|NCT00258817|Influenza Virus Vaccine
616424|NCT00258791|Psychiatric disorders
616425|NCT00258791|ECT
616426|NCT00258791|Headache
616427|NCT00258791|Ibuprofen
616428|NCT00258765|zoledronic acid
616429|NCT00258765|prostate cancer
616430|NCT00258765|high risk
616431|NCT00258765|PSA
616432|NCT00258765|docetaxel
616433|NCT00258752|Prevention
616434|NCT00258752|Adolescent
616435|NCT00258726|Measels, Mumps, Varicella, Rubella, vaccine, children
616436|NCT00258713|Randomized Controlled Trials
616437|NCT00258713|Immunosuppression
616438|NCT00258713|Adult
616439|NCT00258713|Chronic Disease
616440|NCT00258713|Dermatologic Agents
616441|NCT00258713|Female
616442|NCT00258713|Humans
616443|NCT00258713|Male
616444|NCT00258713|Middle Aged
616445|NCT00258713|Severity of Illness Index
616446|NCT00258713|Treatment Outcome
616447|NCT00258713|Quality of Life
616448|NCT00258713|Double-Blind Method
616449|NCT00258687|GVAX
616450|NCT00258687|GM-CSF
616451|NCT00258687|Adenoviral mediated gene transfer
616452|NCT00258687|Pediatric Melanoma
616453|NCT00258674|Diabetes
616454|NCT00258674|Care coordination
616455|NCT00258674|Case management
616456|NCT00258674|Physician profiling
616457|NCT00258661|Pneumonia
616458|NCT00258661|Osteopathic
616459|NCT00258661|Manipulation
616460|NCT00258661|Multi-center
616461|NCT00258661|Elderly
616462|NCT00258635|Allergy
616463|NCT00258635|Specific Immunotherapy
616464|NCT00258622|Peripheral neuropathic pain
616465|NCT00258622|Neuropathic pain
616466|NCT00258622|Chronic pain
616467|NCT00258609|Botulinum toxin type A,
616468|NCT00258609|Dysport®,Dysport
616469|NCT00258609|Migraine without aura,
616470|NCT00258609|Migraine prophylaxis.
616471|NCT00258596|drug-eluting stent
616472|NCT00258596|chronic total occlusion
616473|NCT00258596|sirolimus-eluting stent
616474|NCT00258596|zotarolimus-eluting stent
616475|NCT00258596|QCA
616476|NCT00258583|"Lung[A04.400]"
616477|NCT00258570|"Lung[A04.400]"
616478|NCT00258557|HIV
616479|NCT00258557|Anti-Retroviral agents
616480|NCT00258557|HIV-1
616481|NCT00258557|TMC114/r
616482|NCT00258557|Treatment naïve patients
616483|NCT00258544|Lung
616484|NCT00258544|Fibrosis
616485|NCT00258544|Idiopathic
616486|NCT00258544|Microarray
616487|NCT00258544|Tissue
616488|NCT00258544|Biopsy
616489|NCT00258518|Critically ill patients
616490|NCT00258505|Spreading depression
616491|NCT00258505|Seizures
616492|NCT00258505|Blood-brain barrier
616493|NCT00258492|Restless legs syndrome
616494|NCT00258492|Insomnia
616495|NCT00258492|Daytime sleepiness
616496|NCT00258492|Exercise
616497|NCT00258479|Nicotine Dependence
616498|NCT00258479|Nicotine Use Disorder
616499|NCT00258479|Tobacco Dependence
616500|NCT00258466|adenocarcinoma of the prostate
616501|NCT00258466|stage I prostate cancer
616502|NCT00258466|stage II prostate cancer
616503|NCT00258466|stage III prostate cancer
616504|NCT00258453|psychosocial effects of cancer and its treatment
616505|NCT00258453|long-term effects secondary to cancer therapy in children
616506|NCT00258453|perioperative/postoperative complications
616507|NCT00258453|weight changes
616508|NCT00258453|childhood craniopharyngioma
616509|NCT00258440|fatigue
616510|NCT00258440|anemia
616511|NCT00258440|unspecified adult solid tumor, protocol specific
616512|NCT00258427|Fanconi anemia
616513|NCT00258401|diarrhea
616514|NCT00258401|radiation toxicity
616515|NCT00258401|recurrent uterine sarcoma
616516|NCT00258401|stage I uterine sarcoma
616517|NCT00258401|stage II uterine sarcoma
616518|NCT00258401|stage III uterine sarcoma
616519|NCT00258401|stage IV uterine sarcoma
616520|NCT00258401|recurrent prostate cancer
616521|NCT00258401|stage I prostate cancer
616522|NCT00258401|stage II prostate cancer
616523|NCT00258401|stage III prostate cancer
616524|NCT00258401|stage IV prostate cancer
616525|NCT00258401|recurrent cervical cancer
616526|NCT00258401|stage 0 cervical cancer
616527|NCT00258401|stage IA cervical cancer
616528|NCT00258401|stage IB cervical cancer
616529|NCT00258401|stage IIA cervical cancer
616530|NCT00258401|stage IIB cervical cancer
616531|NCT00258401|stage III cervical cancer
616532|NCT00258401|stage IVA cervical cancer
616533|NCT00258401|stage IVB cervical cancer
616534|NCT00258388|adenocarcinoma of the prostate
616535|NCT00258388|recurrent prostate cancer
616536|NCT00258388|stage IV prostate cancer
616537|NCT00258375|stage IIIA breast cancer
616538|NCT00258375|stage IIIB breast cancer
616539|NCT00258375|stage IIIC breast cancer
616540|NCT00258375|stage IV breast cancer
616541|NCT00258375|recurrent breast cancer
616542|NCT00258362|recurrent endometrial carcinoma
616543|NCT00258362|stage III endometrial carcinoma
616544|NCT00258362|stage IV endometrial carcinoma
616545|NCT00258336|recurrent grade 1 follicular lymphoma
616546|NCT00258336|recurrent grade 2 follicular lymphoma
616547|NCT00258336|stage III grade 1 follicular lymphoma
616548|NCT00258336|stage III grade 2 follicular lymphoma
616549|NCT00258336|stage IV grade 1 follicular lymphoma
616550|NCT00258336|stage IV grade 2 follicular lymphoma
616551|NCT00258336|contiguous stage II grade 1 follicular lymphoma
616552|NCT00258336|contiguous stage II grade 2 follicular lymphoma
616553|NCT00258336|noncontiguous stage II grade 1 follicular lymphoma
616554|NCT00258336|noncontiguous stage II grade 2 follicular lymphoma
616555|NCT00258336|stage I grade 1 follicular lymphoma
616556|NCT00258336|stage I grade 2 follicular lymphoma
616557|NCT00258323|adenocarcinoma of the esophagus
616558|NCT00258323|squamous cell carcinoma of the esophagus
616559|NCT00258323|stage II esophageal cancer
616560|NCT00258323|stage III esophageal cancer
616561|NCT00258323|stage IV esophageal cancer
616562|NCT00258310|stage I squamous cell carcinoma of the hypopharynx
616563|NCT00258310|stage I squamous cell carcinoma of the larynx
616564|NCT00258310|stage I squamous cell carcinoma of the lip and oral cavity
616565|NCT00258310|stage I squamous cell carcinoma of the nasopharynx
616566|NCT00258310|stage I squamous cell carcinoma of the oropharynx
616567|NCT00258310|stage II squamous cell carcinoma of the hypopharynx
616568|NCT00258310|stage II squamous cell carcinoma of the larynx
616569|NCT00258310|stage II squamous cell carcinoma of the lip and oral cavity
616570|NCT00258310|stage II squamous cell carcinoma of the nasopharynx
616571|NCT00258310|stage II squamous cell carcinoma of the oropharynx
616572|NCT00258310|stage III squamous cell carcinoma of the hypopharynx
616573|NCT00258310|stage III squamous cell carcinoma of the larynx
616574|NCT00258310|stage III squamous cell carcinoma of the lip and oral cavity
616575|NCT00258310|stage III squamous cell carcinoma of the nasopharynx
616576|NCT00258310|stage III squamous cell carcinoma of the oropharynx
616577|NCT00258310|stage IV squamous cell carcinoma of the hypopharynx
616578|NCT00258310|stage IV squamous cell carcinoma of the larynx
616579|NCT00258310|stage IV squamous cell carcinoma of the lip and oral cavity
616580|NCT00258310|stage IV squamous cell carcinoma of the nasopharynx
616581|NCT00258310|stage IV squamous cell carcinoma of the oropharynx
616582|NCT00258297|stage I esophageal cancer
616583|NCT00258297|stage II esophageal cancer
616584|NCT00258297|stage III esophageal cancer
616585|NCT00258297|adenocarcinoma of the esophagus
616586|NCT00258297|squamous cell carcinoma of the esophagus
616587|NCT00258284|recurrent prostate cancer
616588|NCT00258284|stage IV prostate cancer
616589|NCT00258284|adenocarcinoma of the prostate
616590|NCT00258271|recurrent adult acute myeloid leukemia
616591|NCT00258271|adult acute basophilic leukemia
616592|NCT00258271|adult acute eosinophilic leukemia
616593|NCT00258271|adult acute megakaryoblastic leukemia (M7)
616594|NCT00258271|adult acute myeloblastic leukemia with maturation (M2)
616595|NCT00258271|adult acute myelomonocytic leukemia (M4)
616596|NCT00258271|adult acute monoblastic leukemia (M5a)
616597|NCT00258271|adult acute monocytic leukemia (M5b)
616598|NCT00258271|adult acute myeloblastic leukemia without maturation (M1)
616599|NCT00258271|adult erythroleukemia (M6a)
616600|NCT00258271|adult pure erythroid leukemia (M6b)
616601|NCT00258271|blastic phase chronic myelogenous leukemia
616602|NCT00258271|relapsing chronic myelogenous leukemia
616603|NCT00258258|refractory multiple myeloma
616604|NCT00258245|stage II multiple myeloma
616605|NCT00258245|stage III multiple myeloma
616606|NCT00258245|refractory multiple myeloma
616607|NCT00258245|stage I multiple myeloma
616608|NCT00258232|adenocarcinoma of the colon
616609|NCT00258232|adenocarcinoma of the rectum
616610|NCT00258232|recurrent colon cancer
616611|NCT00258232|recurrent rectal cancer
616612|NCT00258232|stage IV colon cancer
616613|NCT00258232|stage IV rectal cancer
616614|NCT00258206|stage I multiple myeloma
616615|NCT00258206|stage II multiple myeloma
616616|NCT00258206|stage III multiple myeloma
616617|NCT00258206|refractory multiple myeloma
616618|NCT00258193|C-IBS
616619|NCT00258193|IBS-C
616620|NCT00258193|Constipation-predominant Irritable Bowel Syndrome
616621|NCT00258193|Constipation Predominant Irritable Bowel Syndrome
616622|NCT00258193|Irritable Bowel Syndrome
616623|NCT00258193|IBS
616624|NCT00258193|Transit
616625|NCT00258193|Scintigraphy
616626|NCT00258193|Gastroenterology
616627|NCT00258193|Gastrointestinal
616628|NCT00258193|GC
616629|NCT00258193|MD-1100 Acetate
616630|NCT00258193|MD-1100
616631|NCT00258193|linaclotide
616632|NCT00258193|linaclotide acetate
616633|NCT00258180|unspecified childhood solid tumor, protocol specific
616634|NCT00258180|gastrointestinal complications
616635|NCT00258180|diarrhea
616636|NCT00258167|Family members
616637|NCT00258167|Illness burden
616638|NCT00258167|Mental Disorders
616639|NCT00258167|Family intervention
616640|NCT00258115|Obesity
616641|NCT00258115|Metabolic Syndrome
616642|NCT00258115|Diabetes
616643|NCT00258115|Inflammation
616644|NCT00258102|levofloxacin
616645|NCT00258102|urinary tract infections
616646|NCT00258102|bacterial infections
616647|NCT00258102|bacteriuria
616648|NCT00258102|urinary anti-infective agents
616649|NCT00258102|urinary infections
616650|NCT00258102|quinolones
616651|NCT00258089|levofloxacin
616652|NCT00258089|urinary tract infections
616653|NCT00258089|bacterial infections
616654|NCT00258089|bacteriuria
616655|NCT00258089|urinary anti-infective agents
616656|NCT00258089|urinary infections
616657|NCT00258089|quinolones
616658|NCT00258076|Transdermal contraception
616659|NCT00258076|contraceptive
616660|NCT00258076|hormonal, steroid contraception
616661|NCT00258076|ethinyl estradiol
616662|NCT00258076|progesterone
616663|NCT00258076|EVRA
616664|NCT00258063|Transdermal contraception
616665|NCT00258063|contraceptive
616666|NCT00258063|hormonal, steroid contraception
616667|NCT00258063|ethinyl estradiol
616668|NCT00258063|progesterone
616669|NCT00258063|EVRA
616670|NCT00258063|CILEST
616671|NCT00258063|ORTHO EVRA
616672|NCT00258050|lapatinib
616673|NCT00258050|midazolam
616674|NCT00258050|pharmacokinetics
616675|NCT00258037|Physiotherapy
616676|NCT00258037|Stroke
616677|NCT00258037|Urinary Incontinence
616678|NCT00258037|quality of Life
616679|NCT00258024|IPT-SP, pregnancy, malaria,Ghana
616680|NCT00258011|MPS I Disease
616681|NCT00257985|Familial hemiplegic migraine type 1 and 2
616682|NCT00257985|GTN
616683|NCT00257985|middle cerebral artery
616684|NCT00257985|superficial temporal artery
616685|NCT00257985|headache
616686|NCT00257985|genotype
616687|NCT00257972|Bipolar Mania
616688|NCT00257946|Diaphragm
616689|NCT00257946|Hernia
616690|NCT00257946|Congenital
616691|NCT00257933|Corticosteroids
616692|NCT00257933|Treatment
616693|NCT00257933|Pediatric
616694|NCT00257920|Stage 5 Chronic Kidney Disease (CKD)
616695|NCT00257907|Latent Tuberculosis
616696|NCT00257907|PPD
616697|NCT00257907|Antigen Specific T-Cells
616698|NCT00257907|Lymphocyte Proliferation Assay
616699|NCT00257907|HIV
616700|NCT00257907|LPA
616701|NCT00257894|Baclofen
616702|NCT00257894|Conditioning, Classical
616703|NCT00257894|Nicotine
616704|NCT00257894|Smoking
616705|NCT00257881|Tumor
616706|NCT00257855|Secondary Progressive Multiple Sclerosis
616707|NCT00257855|Neuroprotection
616708|NCT00257855|Axonal loss
616709|NCT00257855|Brain atrophy
616710|NCT00257855|MRI
616711|NCT00257855|Lamotrigine
616712|NCT00257855|Sodium Channel Blockers
616713|NCT00257829|Cervical Cancer
616714|NCT00257816|Cervical Cancer
616715|NCT00257803|Oxytocin, bolus, postpartum hemorrhage
616716|NCT00257790|Fever
616717|NCT00257790|Neutropenia
616718|NCT00257790|Tobramycin
616719|NCT00257790|Aminoglycoside
616720|NCT00257790|Penicillin
616721|NCT00257764|Swallowing disorder
616722|NCT00257764|Stroke
616723|NCT00257764|Standardized swallowing therapy
616724|NCT00257764|Randomized controlled trial
616725|NCT00257725|ADHD
616726|NCT00257725|Attention-deficit/hyperactivity disorder (ADHD)
616727|NCT00257712|Alzheimer's disease
616728|NCT00257712|cognition disorders
616729|NCT00257699|Crohn's Disease
616730|NCT00257699|Randomized
616731|NCT00257699|Ciprofloxacin
616732|NCT00257699|Metronidazole
616733|NCT00257699|Antibiotic
616734|NCT00257686|Kowa
616735|NCT00257686|Hypercholesterolemia
616736|NCT00257686|combined
616737|NCT00257686|dyslipidemia
616738|NCT00257686|elderly
616739|NCT00257686|pitavastatin
616740|NCT00257686|NK-104
616741|NCT00257673|Cognition
616742|NCT00257673|Alzheimer's
616743|NCT00257673|Cognitive impairment
616744|NCT00257634|lateral epicondylitis
616745|NCT00257634|iontophoresis
616746|NCT00257634|dexamethasone
616747|NCT00257621|HIV-1 protease inhibitor GW640385 ritonavir RTV
616748|NCT00257608|NSCLC
616749|NCT00257608|Lung Cancer
616750|NCT00257608|ATLAS
616751|NCT00257608|Avastin
616752|NCT00257608|Tarceva
616753|NCT00257595|Perennial Allergic Rhinitis pediatric
616754|NCT00257582|cetirizine
616755|NCT00257582|various type of cutaneous disease accompanied with Pruritus
616756|NCT00257582|pediatrics
616757|NCT00257569|Atopic
616758|NCT00257569|Pediatric
616759|NCT00257569|Dermatitis
616760|NCT00257543|sickle cell disease
616761|NCT00257543|bone marrow transplant
616762|NCT00257517|Congenital heart disease
616763|NCT00257517|Single ventricle
616764|NCT00257517|Infant feeding
616765|NCT00257478|Treatment Efficacy
616766|NCT00257478|Treatment Effectiveness
616767|NCT00257478|Disease Management
616768|NCT00257478|Treatment
616769|NCT00257478|Safety
616770|NCT00257465|melanoma
616771|NCT00257465|metastatic
616772|NCT00257465|vaccine
616773|NCT00257465|immunotherapy
616774|NCT00257465|autologous
616775|NCT00257439|Vitamin B12
616776|NCT00257439|Folic Acid
616777|NCT00257426|adult primary hepatocellular carcinoma
616778|NCT00257426|advanced adult primary liver cancer
616779|NCT00257426|localized unresectable adult primary liver cancer
616780|NCT00257426|recurrent adult primary liver cancer
616781|NCT00257400|major depressive disorder
616782|NCT00257400|psychotherapy
616783|NCT00257400|childhood sexual abuse
616784|NCT00257400|trauma
616785|NCT00257387|Kidney
616786|NCT00257387|Kidney Transplant
616787|NCT00257348|Advanced Cervical Carcinoma
616788|NCT00257348|Recurrent Cervical Carcinoma
616789|NCT00257335|Carcinoma of the head and neck
616790|NCT00257322|Metastatic colon cancer
616791|NCT00257322|Metastatic rectal cancer
616792|NCT00257309|Acute myocardial infarction
616793|NCT00257309|Elderly
616794|NCT00257309|Thrombolysis
616795|NCT00257309|Primary angioplasty
616796|NCT00257309|Randomized trial
616797|NCT00257309|Efficacy
616798|NCT00257309|Safety
616799|NCT00257283|Chronic renal failure
616800|NCT00257283|Hemodialysis
616801|NCT00257283|OMACOR (omega-3-acid ethyl ester 90)
616802|NCT00257283|intervention study
616803|NCT00257283|cardiovascular events
616804|NCT00257283|mortality
616805|NCT00257270|Chronic
616806|NCT00257270|Tinnitus
616807|NCT00257270|Acoustic trauma
616808|NCT00257270|Psychophysics
616809|NCT00257270|Loudness match
616810|NCT00257270|gabapentin
616811|NCT00257257|Type 2 diabetes mellitus
616812|NCT00257244|Immunity, innate
616813|NCT00257244|Inflammation
616814|NCT00257244|Genomics
616815|NCT00257244|Proteomics
616816|NCT00257231|Immunity, innate
616817|NCT00257231|Inflammation
616818|NCT00257231|Genomics
616819|NCT00257231|Proteomics
616820|NCT00257192|Adolescent Subjects With Schizophrenia
616821|NCT00257179|Tissue factor
616822|NCT00257179|Lung cancer
616823|NCT00257179|Tissue factor protein inhibitor
616824|NCT00257179|Factor VII
616825|NCT00257179|Factor X
616826|NCT00257153|Acute myocardial infarction
616827|NCT00257153|primary angioplasty
616828|NCT00257153|myocardial reperfusion
616829|NCT00257153|thrombus aspiration
616830|NCT00257140|Bronchitis
616831|NCT00257140|chronic bronchitis
616832|NCT00257140|lung diseases
616833|NCT00257140|respiratory tract infections
616834|NCT00257140|bronchial diseases
616835|NCT00257140|antibacterial agents
616836|NCT00257140|quinolones
616837|NCT00257140|levofloxacin
616838|NCT00257127|Vaccination
616839|NCT00257114|Multiple Myeloma
616840|NCT00257114|Retreatment
616841|NCT00257114|VELCADE
616842|NCT00257088|development
616843|NCT00257088|epidemiology
616844|NCT00257088|risk factors
616845|NCT00257088|randomized field trials
616846|NCT00257075|risperidone
616847|NCT00257075|antipsychotic agents
616848|NCT00257075|bipolar disorders
616849|NCT00257075|manic episode
616850|NCT00257062|Infectious skin diseases
616851|NCT00257062|skin diseases
616852|NCT00257062|bacterial skin diseases
616853|NCT00257062|antibacterial agents
616854|NCT00257062|quinolones
616855|NCT00257062|levofloxacin
616856|NCT00257049|Pneumonia
616857|NCT00257049|lung inflammation
616858|NCT00257049|bacterial pneumonia
616859|NCT00257049|lung diseases
616860|NCT00257049|respiratory tract infections
616861|NCT00257049|antibacterial agents
616862|NCT00257049|quinolones
616863|NCT00257049|levofloxacin
616864|NCT00257036|Infectious skin diseases
616865|NCT00257036|skin diseases
616866|NCT00257036|bacterial skin diseases
616867|NCT00257036|cellulitis
616868|NCT00257036|quinolones
616869|NCT00257036|levofloxacin
616870|NCT00257023|Schizophrenia
616871|NCT00257023|Risperidone
616872|NCT00257023|Positive and Negative Syndrome Scale (PANSS)
616873|NCT00257023|Clinical Global Impression (CGI)
616874|NCT00257023|Positron Emission Tomography (PET)
616875|NCT00257010|Migraine
616876|NCT00257010|Almotriptan Malate
616877|NCT00257010|Headache
616878|NCT00257010|Triptan
616879|NCT00256997|Schizophrenia
616880|NCT00256997|Risperidone
616881|NCT00256997|Risperdal Consta
616882|NCT00256984|Obstructive Defecation Syndrome
616883|NCT00256984|Colorectal Surgery
616884|NCT00256984|Defecography
616885|NCT00256984|Constipation
616886|NCT00256984|Rectocele
616887|NCT00256984|Intussusception
616888|NCT00256984|Quality of Life
616889|NCT00256945|biofilm formation
616890|NCT00256945|dental plaque
616891|NCT00256945|surface roughness
616892|NCT00256945|dental restoration
616893|NCT00256945|dental materials
616894|NCT00256932|bowel dysfunction
616895|NCT00256932|constipation
616896|NCT00256932|gastrointestinal
616897|NCT00256932|opioids
616898|NCT00256932|pain
616899|NCT00256932|non-cancer pain
616900|NCT00256932|Opioid-induced
616901|NCT00256919|GW856553
616902|NCT00256919|biomarkers
616903|NCT00256919|CRP
616904|NCT00256919|rheumatoid arthritis
616905|NCT00256906|lateral ventricles
616906|NCT00256906|fetal ventriculomegaly
616907|NCT00256893|pain intensity
616908|NCT00256893|numerical rating scale
616909|NCT00256893|fibromyalgia
616910|NCT00256880|Pazopanib(GW786034)
616911|NCT00256880|Solid Tumors
616912|NCT00256880|Myeloma
616913|NCT00256867|Type 2 diabetes Type II
616914|NCT00256854|RLS
616915|NCT00256854|Ropinirole
616916|NCT00256854|Restless Legs Syndrome
616917|NCT00256841|Hypofractionated Chest Radiation
616918|NCT00256841|Taxotere
616919|NCT00256841|5-FU
616920|NCT00256828|HIV infection
616921|NCT00256828|Highly active antiretroviral therapy
616922|NCT00256828|Treatment Naive
616923|NCT00256815|Hypofractionated chest radiation
616924|NCT00256815|Oral Navelbine
616925|NCT00256802|Headache
616926|NCT00256802|migraine
616927|NCT00256802|MR-angiography
616928|NCT00256802|healthy volunteers
616929|NCT00256802|GTN
616930|NCT00256802|Middle cerebral artery
616931|NCT00256789|NSCLC, Non-Small Cell Lung Cancer,Weekly Radiation, Taxotere
616932|NCT00256776|Multiple Myeloma
616933|NCT00256776|Velcade
616934|NCT00256776|Autologous transplantation
616935|NCT00256776|Relapse
616936|NCT00256776|Disease progress
616937|NCT00256737|Maintenance of healed erosive esophagitis
616938|NCT00256724|hypotension
616939|NCT00256724|hypovolemia
616940|NCT00256724|dehydration
616941|NCT00256724|sepsis
616942|NCT00256724|blood loss
616943|NCT00256711|Locally advanced or metastatic NSCLC.
616944|NCT00256711|Stage IIIb or Stage IV lung cancer
616945|NCT00256698|Hormone
616946|NCT00256698|receptor
616947|NCT00256698|positive
616948|NCT00256698|breast
616949|NCT00256698|cancer
616950|NCT00256698|first
616951|NCT00256698|relapse
616952|NCT00256685|Menopause
616953|NCT00256672|Spinal Cord Injury
616954|NCT00256672|TLSO brace
616955|NCT00256672|Spine curvature
616956|NCT00256672|Child
616957|NCT00256672|Effectiveness of bracing
616958|NCT00256659|Medical inpatients
616959|NCT00256659|Social Work
616960|NCT00256659|Physical therapy
616961|NCT00256659|Occupational therapy
616962|NCT00256659|Psychiatry
616963|NCT00256659|Early intervention
616964|NCT00256659|Iatrogenic complications
616965|NCT00256620|Cardiopulmonary bypass
616966|NCT00256620|Coronary artery disease
616967|NCT00256620|Cardiac morbidity
616968|NCT00256620|Neurologic morbidity
616969|NCT00256620|Neurocognitive function
616970|NCT00256620|Autoregulation
616971|NCT00256594|Medical Errors
616972|NCT00256594|Medication Errors
616973|NCT00256594|Prescriptions, Drug
616974|NCT00256581|myocardial perfusion
616975|NCT00256581|Imaging
616976|NCT00256568|Medical Errors
616977|NCT00256568|Medication Errors
616978|NCT00256568|Prescriptions, Drug
616979|NCT00256568|Pharmacies
616980|NCT00256568|Ambulatory Care Facilities
616981|NCT00256542|interstitial cystitis
616982|NCT00256542|pelvic pain
616983|NCT00256542|urgency
616984|NCT00256542|frequency
616985|NCT00256542|Pelvic Pain and/or Urgency of Bladder Origin
616986|NCT00256529|dysphagia
616987|NCT00256529|eosinophilic esophagitis
616988|NCT00256516|Diet Therapy
616989|NCT00256503|Primary Insomnia
616990|NCT00256503|Insomnia
616991|NCT00256503|Sleep
616992|NCT00256490|Diffuse large B cells lymphoma
616993|NCT00256490|PET/CT
616994|NCT00256490|FDG
616995|NCT00256464|PTSD
616996|NCT00256451|Naltrexone
616997|NCT00256451|Endophenotype
616998|NCT00256438|Depression
616999|NCT00256438|Transcranial Direct Current Stimulation
617000|NCT00256425|glioma
617001|NCT00256425|brain tumor
617002|NCT00256425|cognit
617003|NCT00256425|neuropsycholog
617004|NCT00256425|attention
617005|NCT00256425|memory
617006|NCT00256425|executive function
617007|NCT00256425|rehabilitation
617008|NCT00256425|remediation
617009|NCT00256425|training
617010|NCT00256386|Baseline
617011|NCT00256386|Laboratory
617012|NCT00256386|Drug
617013|NCT00256373|Low Back Pain
617014|NCT00256373|Dynamic Back-Muscle exercise Treatment
617015|NCT00256373|Interdisciplinary Treatment
617016|NCT00256373|Roland Morris Disability Questionnaire
617017|NCT00256373|SF-36
617018|NCT00256373|Low Back Pain Rating Scale
617019|NCT00256360|breast cancer
617020|NCT00256360|adjuvant
617021|NCT00256360|dose dense
617022|NCT00256360|docetaxel
617023|NCT00256360|pegfilgrastim
617024|NCT00256334|Colon Cancer
617025|NCT00256334|Resveratrol
617026|NCT00256334|Clinical Trial
617027|NCT00256334|WnT signaling
617028|NCT00256334|Grapes
617029|NCT00256334|Cancer prevention
617030|NCT00256321|Gastric Carcinoma
617031|NCT00256321|Gastroesophageal junction Carcinoma
617032|NCT00256308|Head and Neck Cancer
617033|NCT00256295|Cancer of the Head and Neck
617034|NCT00256282|Metastatic Melanoma
617035|NCT00256269|Esophageal Cancer
617036|NCT00256269|Gastroesophageal junction cancer
617037|NCT00256256|type 2 diabetes
617038|NCT00256256|GLP-1
617039|NCT00256256|PET
617040|NCT00256256|brain
617041|NCT00256256|heart
617042|NCT00256204|Parkinson's
617043|NCT00256204|Rasagiline Mesylate
617044|NCT00256191|taxanes
617045|NCT00256191|multidrug resistance
617046|NCT00256191|mutant tubulin binding
617047|NCT00256191|Hodgkin's or Non-Hodgkin's Lymphoma
617048|NCT00256178|Hyperlipidemia
617049|NCT00256178|Drug Therapy
617050|NCT00256165|Aortic valve replacement
617051|NCT00256152|Atrial fibrillation
617052|NCT00256152|Pacemaker
617053|NCT00256152|AF suppression pacing
617054|NCT00256152|Indications for Pacemaker Implantation due to sinus node or atrio-ventricular node disease
617055|NCT00256113|depression
617056|NCT00256113|antidepressive agents
617057|NCT00256113|controlled clinical trial
617058|NCT00256087|Nosocomial rates in critically ill patients
617059|NCT00256009|Late abortion
617060|NCT00255983|bronchitis
617061|NCT00255983|AECB
617062|NCT00255970|Periodontal Treatment of Intraosseous Vertical Defects
617063|NCT00255957|Stroke, HES, Coagulation, Kinetics, Hemorehology
617064|NCT00255944|HIV Prevention
617065|NCT00255944|Internet Intervention
617066|NCT00255944|STDs
617067|NCT00255931|Heart Failure
617068|NCT00255931|Biofeedback-Relaxation
617069|NCT00255931|Cognitive Behavioral Therapy
617070|NCT00255918|Evoked Potentials
617071|NCT00255918|3-(2,4-dimethoxybenzylidene)anabaseine
617072|NCT00255918|DMXB-A
617073|NCT00255918|Receptors, Nicotinic
617074|NCT00255905|Depression
617075|NCT00255905|Insomnia
617076|NCT00255892|HIV
617077|NCT00255879|Schizophrenia
617078|NCT00255879|Neuroleptic
617079|NCT00255879|Tardive dyskinesia
617080|NCT00255866|Assisted Living Facilities
617081|NCT00255866|Aged
617082|NCT00255866|Elderly
617083|NCT00255866|Caregivers
617084|NCT00255840|Treatment Naive
617085|NCT00255814|liver metastases
617086|NCT00255801|stage I cutaneous T-cell non-Hodgkin lymphoma
617087|NCT00255801|stage II cutaneous T-cell non-Hodgkin lymphoma
617088|NCT00255801|stage III cutaneous T-cell non-Hodgkin lymphoma
617089|NCT00255801|stage IV cutaneous T-cell non-Hodgkin lymphoma
617090|NCT00255801|recurrent cutaneous T-cell non-Hodgkin lymphoma
617091|NCT00255801|stage I mycosis fungoides/Sezary syndrome
617092|NCT00255801|stage II mycosis fungoides/Sezary syndrome
617093|NCT00255801|stage III mycosis fungoides/Sezary syndrome
617094|NCT00255801|stage IV mycosis fungoides/Sezary syndrome
617095|NCT00255801|recurrent mycosis fungoides/Sezary syndrome
617096|NCT00255788|recurrent breast cancer
617097|NCT00255788|stage IV breast cancer
617098|NCT00255788|male breast cancer
617099|NCT00255775|non-small cell lung cancer
617100|NCT00255775|small cell lung cancer
617101|NCT00255749|adult acute lymphoblastic leukemia in remission
617102|NCT00255749|progressive hairy cell leukemia, initial treatment
617103|NCT00255749|stage 0 chronic lymphocytic leukemia
617104|NCT00255749|anemia
617105|NCT00255749|extramedullary plasmacytoma
617106|NCT00255749|isolated plasmacytoma of bone
617107|NCT00255749|refractory multiple myeloma
617108|NCT00255749|monoclonal gammopathy of undetermined significance
617109|NCT00255749|primary systemic amyloidosis
617110|NCT00255749|stage I multiple myeloma
617111|NCT00255749|stage II multiple myeloma
617112|NCT00255749|stage III multiple myeloma
617113|NCT00255749|AIDS-related peripheral/systemic lymphoma
617114|NCT00255749|AIDS-related primary CNS lymphoma
617115|NCT00255749|anaplastic large cell lymphoma
617116|NCT00255749|angioimmunoblastic T-cell lymphoma
617117|NCT00255749|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
617118|NCT00255749|nodal marginal zone B-cell lymphoma
617119|NCT00255749|recurrent adult Burkitt lymphoma
617120|NCT00255749|recurrent adult diffuse large cell lymphoma
617121|NCT00255749|recurrent adult diffuse mixed cell lymphoma
617122|NCT00255749|recurrent adult diffuse small cleaved cell lymphoma
617123|NCT00255749|recurrent adult Hodgkin lymphoma
617124|NCT00255749|recurrent adult immunoblastic large cell lymphoma
617125|NCT00255749|recurrent adult lymphoblastic lymphoma
617126|NCT00255749|recurrent adult T-cell leukemia/lymphoma
617127|NCT00255749|recurrent cutaneous T-cell non-Hodgkin lymphoma
617128|NCT00255749|recurrent grade 1 follicular lymphoma
617129|NCT00255749|recurrent grade 2 follicular lymphoma
617130|NCT00255749|recurrent grade 3 follicular lymphoma
617131|NCT00255749|recurrent mantle cell lymphoma
617132|NCT00255749|recurrent marginal zone lymphoma
617133|NCT00255749|recurrent mycosis fungoides/Sezary syndrome
617134|NCT00255749|recurrent small lymphocytic lymphoma
617135|NCT00255749|splenic marginal zone lymphoma
617136|NCT00255749|stage III adult Burkitt lymphoma
617137|NCT00255749|stage III adult diffuse large cell lymphoma
617138|NCT00255749|stage III adult diffuse mixed cell lymphoma
617139|NCT00255749|stage III adult diffuse small cleaved cell lymphoma
617140|NCT00255749|stage III adult Hodgkin lymphoma
617141|NCT00255749|stage III adult immunoblastic large cell lymphoma
617142|NCT00255749|stage III adult lymphoblastic lymphoma
617143|NCT00255749|stage III adult T-cell leukemia/lymphoma
617144|NCT00255749|stage III cutaneous T-cell non-Hodgkin lymphoma
617145|NCT00255749|stage III grade 1 follicular lymphoma
617146|NCT00255749|stage III grade 2 follicular lymphoma
617147|NCT00255749|stage III grade 3 follicular lymphoma
617148|NCT00255749|stage III mantle cell lymphoma
617149|NCT00255749|stage III marginal zone lymphoma
617150|NCT00255749|stage III mycosis fungoides/Sezary syndrome
617151|NCT00255749|stage III small lymphocytic lymphoma
617152|NCT00255749|stage IV adult Burkitt lymphoma
617153|NCT00255749|stage IV adult diffuse large cell lymphoma
617154|NCT00255749|stage IV adult diffuse mixed cell lymphoma
617155|NCT00255749|stage IV adult diffuse small cleaved cell lymphoma
617156|NCT00255749|stage IV adult Hodgkin lymphoma
617157|NCT00255749|stage IV adult immunoblastic large cell lymphoma
617158|NCT00255749|stage IV adult lymphoblastic lymphoma
617159|NCT00255749|stage IV adult T-cell leukemia/lymphoma
617160|NCT00255749|stage IV cutaneous T-cell non-Hodgkin lymphoma
617161|NCT00255749|stage IV grade 1 follicular lymphoma
617162|NCT00255749|stage IV grade 2 follicular lymphoma
617163|NCT00255749|stage IV grade 3 follicular lymphoma
617164|NCT00255749|stage IV mantle cell lymphoma
617165|NCT00255749|stage IV marginal zone lymphoma
617166|NCT00255749|stage IV mycosis fungoides/Sezary syndrome
617167|NCT00255749|stage IV small lymphocytic lymphoma
617168|NCT00255749|Waldenström macroglobulinemia
617169|NCT00255749|contiguous stage II adult Burkitt lymphoma
617170|NCT00255749|contiguous stage II adult diffuse large cell lymphoma
617171|NCT00255749|contiguous stage II adult diffuse mixed cell lymphoma
617172|NCT00255749|contiguous stage II adult diffuse small cleaved cell lymphoma
617173|NCT00255749|contiguous stage II adult immunoblastic large cell lymphoma
617174|NCT00255749|contiguous stage II adult lymphoblastic lymphoma
617175|NCT00255749|contiguous stage II grade 1 follicular lymphoma
617176|NCT00255749|contiguous stage II grade 2 follicular lymphoma
617177|NCT00255749|contiguous stage II grade 3 follicular lymphoma
617178|NCT00255749|contiguous stage II mantle cell lymphoma
617179|NCT00255749|contiguous stage II marginal zone lymphoma
617180|NCT00255749|contiguous stage II small lymphocytic lymphoma
617181|NCT00255749|noncontiguous stage II adult Burkitt lymphoma
617182|NCT00255749|noncontiguous stage II adult diffuse large cell lymphoma
617183|NCT00255749|noncontiguous stage II adult diffuse mixed cell lymphoma
617184|NCT00255749|noncontiguous stage II adult diffuse small cleaved cell lymphoma
617185|NCT00255749|noncontiguous stage II adult immunoblastic large cell lymphoma
617186|NCT00255749|noncontiguous stage II adult lymphoblastic lymphoma
617187|NCT00255749|noncontiguous stage II grade 1 follicular lymphoma
617188|NCT00255749|noncontiguous stage II grade 2 follicular lymphoma
617189|NCT00255749|noncontiguous stage II grade 3 follicular lymphoma
617190|NCT00255749|noncontiguous stage II mantle cell lymphoma
617191|NCT00255749|noncontiguous stage II marginal zone lymphoma
617192|NCT00255749|noncontiguous stage II small lymphocytic lymphoma
617193|NCT00255749|post-transplant lymphoproliferative disorder
617194|NCT00255749|stage I adult Burkitt lymphoma
617195|NCT00255749|stage I adult diffuse large cell lymphoma
617196|NCT00255749|stage I adult diffuse mixed cell lymphoma
617197|NCT00255749|stage I adult diffuse small cleaved cell lymphoma
617198|NCT00255749|stage I adult Hodgkin lymphoma
617199|NCT00255749|stage I adult immunoblastic large cell lymphoma
617200|NCT00255749|stage I adult lymphoblastic lymphoma
617201|NCT00255749|stage I adult T-cell leukemia/lymphoma
617202|NCT00255749|stage I cutaneous T-cell non-Hodgkin lymphoma
617203|NCT00255749|stage I grade 1 follicular lymphoma
617204|NCT00255749|stage I grade 2 follicular lymphoma
617205|NCT00255749|stage I grade 3 follicular lymphoma
617206|NCT00255749|stage I mantle cell lymphoma
617207|NCT00255749|stage I marginal zone lymphoma
617208|NCT00255749|stage I small lymphocytic lymphoma
617209|NCT00255749|stage II adult Hodgkin lymphoma
617210|NCT00255749|stage II adult T-cell leukemia/lymphoma
617211|NCT00255749|stage II cutaneous T-cell non-Hodgkin lymphoma
617212|NCT00255749|stage I mycosis fungoides/Sezary syndrome
617213|NCT00255749|stage II mycosis fungoides/Sezary syndrome
617214|NCT00255749|recurrent adult acute lymphoblastic leukemia
617215|NCT00255749|refractory chronic lymphocytic leukemia
617216|NCT00255749|stage I chronic lymphocytic leukemia
617217|NCT00255749|stage II chronic lymphocytic leukemia
617218|NCT00255749|stage III chronic lymphocytic leukemia
617219|NCT00255749|stage IV chronic lymphocytic leukemia
617220|NCT00255749|refractory hairy cell leukemia
617221|NCT00255749|prolymphocytic leukemia
617222|NCT00255749|unspecified adult solid tumor, protocol specific
617223|NCT00255749|T-cell large granular lymphocyte leukemia
617224|NCT00255723|adult lymphocyte depletion Hodgkin lymphoma
617225|NCT00255723|adult mixed cellularity Hodgkin lymphoma
617226|NCT00255723|adult nodular sclerosis Hodgkin lymphoma
617227|NCT00255723|recurrent adult Hodgkin lymphoma
617228|NCT00255710|graft versus host disease
617229|NCT00255710|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
617230|NCT00255710|adult acute myeloid leukemia with inv(16)(p13;q22)
617231|NCT00255710|adult acute myeloid leukemia with t(15;17)(q22;q12)
617232|NCT00255710|adult acute myeloid leukemia with t(16;16)(p13;q22)
617233|NCT00255710|adult acute myeloid leukemia with t(8;21)(q22;q22)
617234|NCT00255710|adult acute lymphoblastic leukemia in remission
617235|NCT00255710|adult acute myeloid leukemia in remission
617236|NCT00255710|chronic idiopathic myelofibrosis
617237|NCT00255710|chronic myelomonocytic leukemia
617238|NCT00255710|chronic phase chronic myelogenous leukemia
617239|NCT00255710|myelodysplastic/myeloproliferative disease, unclassifiable
617240|NCT00255710|previously treated myelodysplastic syndromes
617241|NCT00255710|recurrent adult Burkitt lymphoma
617242|NCT00255710|recurrent adult diffuse large cell lymphoma
617243|NCT00255710|recurrent adult diffuse mixed cell lymphoma
617244|NCT00255710|recurrent adult immunoblastic large cell lymphoma
617245|NCT00255710|recurrent adult lymphoblastic lymphoma
617246|NCT00255710|recurrent grade 3 follicular lymphoma
617247|NCT00255710|recurrent mantle cell lymphoma
617248|NCT00255710|stage II multiple myeloma
617249|NCT00255710|stage III adult Hodgkin lymphoma
617250|NCT00255710|stage III chronic lymphocytic leukemia
617251|NCT00255710|stage III grade 1 follicular lymphoma
617252|NCT00255710|stage III grade 2 follicular lymphoma
617253|NCT00255710|stage III multiple myeloma
617254|NCT00255710|stage III small lymphocytic lymphoma
617255|NCT00255710|stage IV adult Hodgkin lymphoma
617256|NCT00255710|stage IV chronic lymphocytic leukemia
617257|NCT00255710|stage IV grade 1 follicular lymphoma
617258|NCT00255710|stage IV grade 2 follicular lymphoma
617259|NCT00255710|stage IV small lymphocytic lymphoma
617260|NCT00255710|stage II mycosis fungoides/Sezary syndrome
617261|NCT00255710|stage III mycosis fungoides/Sezary syndrome
617262|NCT00255710|stage IV mycosis fungoides/Sezary syndrome
617263|NCT00255710|refractory anemia with excess blasts in transformation
617264|NCT00255710|refractory anemia with excess blasts
617265|NCT00255710|refractory cytopenia with multilineage dysplasia
617266|NCT00255710|primary systemic amyloidosis
617267|NCT00255710|de novo myelodysplastic syndromes
617268|NCT00255710|secondary acute myeloid leukemia
617269|NCT00255710|secondary myelodysplastic syndromes
617270|NCT00255710|atypical chronic myeloid leukemia
617271|NCT00255697|psychosocial effects of cancer and its treatment
617272|NCT00255697|unspecified adult solid tumor, protocol specific
617273|NCT00255684|graft versus host disease
617274|NCT00255684|adult acute myeloid leukemia in remission
617483|NCT00255242|Rho GTP-ase
617275|NCT00255684|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
617276|NCT00255684|adult acute myeloid leukemia with t(16;16)(p13;q22)
617277|NCT00255684|adult acute myeloid leukemia with t(8;21)(q22;q22)
617278|NCT00255684|recurrent adult acute myeloid leukemia
617279|NCT00255684|childhood acute myeloid leukemia in remission
617280|NCT00255684|recurrent childhood acute myeloid leukemia
617281|NCT00255684|adult acute lymphoblastic leukemia in remission
617282|NCT00255684|recurrent adult acute lymphoblastic leukemia
617283|NCT00255684|childhood acute lymphoblastic leukemia in remission
617284|NCT00255684|recurrent childhood acute lymphoblastic leukemia
617285|NCT00255684|acute undifferentiated leukemia
617286|NCT00255684|accelerated phase chronic myelogenous leukemia
617287|NCT00255684|chronic phase chronic myelogenous leukemia
617288|NCT00255684|childhood chronic myelogenous leukemia
617289|NCT00255684|refractory anemia with excess blasts
617290|NCT00255684|refractory anemia
617291|NCT00255684|chronic myelomonocytic leukemia
617292|NCT00255684|atypical chronic myeloid leukemia, BCR-ABL1 negative
617293|NCT00255684|juvenile myelomonocytic leukemia
617294|NCT00255684|primary myelofibrosis
617295|NCT00255684|refractory hairy cell leukemia
617296|NCT00255684|stage I multiple myeloma
617297|NCT00255684|stage II multiple myeloma
617298|NCT00255684|stage III multiple myeloma
617299|NCT00255684|refractory multiple myeloma
617300|NCT00255684|refractory chronic lymphocytic leukemia
617301|NCT00255684|stage III adult Hodgkin lymphoma
617302|NCT00255684|stage IV adult Hodgkin lymphoma
617303|NCT00255684|recurrent/refractory childhood Hodgkin lymphoma
617304|NCT00255684|stage III adult Burkitt lymphoma
617305|NCT00255684|stage IV adult Burkitt lymphoma
617306|NCT00255684|stage III adult diffuse large cell lymphoma
617307|NCT00255684|stage III adult diffuse mixed cell lymphoma
617308|NCT00255684|stage III adult diffuse small cleaved cell lymphoma
617309|NCT00255684|stage IV adult diffuse large cell lymphoma
617310|NCT00255684|stage IV adult diffuse mixed cell lymphoma
617311|NCT00255684|stage IV adult diffuse small cleaved cell lymphoma
617312|NCT00255684|stage III adult immunoblastic large cell lymphoma
617313|NCT00255684|stage IV adult immunoblastic large cell lymphoma
617314|NCT00255684|stage III adult lymphoblastic lymphoma
617315|NCT00255684|stage IV adult lymphoblastic lymphoma
617316|NCT00255684|stage III grade 1 follicular lymphoma
617317|NCT00255684|stage III grade 2 follicular lymphoma
617318|NCT00255684|stage III grade 3 follicular lymphoma
617319|NCT00255684|stage IV grade 1 follicular lymphoma
617320|NCT00255684|stage IV grade 2 follicular lymphoma
617321|NCT00255684|stage IV grade 3 follicular lymphoma
617322|NCT00255684|stage III mantle cell lymphoma
617323|NCT00255684|stage III marginal zone lymphoma
617324|NCT00255684|stage IV mantle cell lymphoma
617325|NCT00255684|stage IV marginal zone lymphoma
617326|NCT00255684|stage III small lymphocytic lymphoma
617327|NCT00255684|stage IV small lymphocytic lymphoma
617328|NCT00255684|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
617329|NCT00255684|nodal marginal zone B-cell lymphoma
617330|NCT00255684|splenic marginal zone lymphoma
617331|NCT00255684|adult acute myeloid leukemia with inv(16)(p13;q22)
617332|NCT00255684|adult acute myeloid leukemia with t(15;17)(q22;q12)
617333|NCT00255684|de novo myelodysplastic syndromes
617334|NCT00255684|recurrent mycosis fungoides/Sezary syndrome
617335|NCT00255684|recurrent cutaneous T-cell non-Hodgkin lymphoma
617336|NCT00255684|recurrent childhood large cell lymphoma
617337|NCT00255684|recurrent childhood lymphoblastic lymphoma
617338|NCT00255684|recurrent childhood small noncleaved cell lymphoma
617339|NCT00255684|recurrent adult diffuse large cell lymphoma
617340|NCT00255684|recurrent adult diffuse mixed cell lymphoma
617341|NCT00255684|recurrent adult diffuse small cleaved cell lymphoma
617342|NCT00255684|recurrent grade 1 follicular lymphoma
617343|NCT00255684|recurrent grade 2 follicular lymphoma
617344|NCT00255684|recurrent grade 3 follicular lymphoma
617345|NCT00255684|recurrent marginal zone lymphoma
617346|NCT00255684|recurrent small lymphocytic lymphoma
617347|NCT00255684|recurrent adult Burkitt lymphoma
617348|NCT00255684|recurrent adult immunoblastic large cell lymphoma
617349|NCT00255684|recurrent adult lymphoblastic lymphoma
617350|NCT00255684|recurrent mantle cell lymphoma
617351|NCT00255684|relapsing chronic myelogenous leukemia
617352|NCT00255684|myelodysplastic/myeloproliferative neoplasm, unclassifiable
617353|NCT00255684|previously treated myelodysplastic syndromes
617354|NCT00255684|recurrent adult Hodgkin lymphoma
617355|NCT00255684|secondary acute myeloid leukemia
617356|NCT00255684|secondary myelodysplastic syndromes
617357|NCT00255684|noncontiguous stage II adult Burkitt lymphoma
617358|NCT00255684|noncontiguous stage II adult diffuse large cell lymphoma
617359|NCT00255684|noncontiguous stage II adult diffuse mixed cell lymphoma
617360|NCT00255684|noncontiguous stage II adult diffuse small cleaved cell lymphoma
617361|NCT00255684|noncontiguous stage II adult immunoblastic large cell lymphoma
617362|NCT00255684|noncontiguous stage II adult lymphoblastic lymphoma
617363|NCT00255684|noncontiguous stage II grade 1 follicular lymphoma
617364|NCT00255684|noncontiguous stage II grade 2 follicular lymphoma
617365|NCT00255684|noncontiguous stage II grade 3 follicular lymphoma
617366|NCT00255684|noncontiguous stage II mantle cell lymphoma
617367|NCT00255684|noncontiguous stage II marginal zone lymphoma
617368|NCT00255684|noncontiguous stage II small lymphocytic lymphoma
617369|NCT00255684|childhood myelodysplastic syndromes
617370|NCT00255671|radiation toxicity
617371|NCT00255671|tumors metastatic to brain
617372|NCT00255671|adult anaplastic astrocytoma
617373|NCT00255671|adult anaplastic ependymoma
617374|NCT00255671|adult anaplastic meningioma
617375|NCT00255671|adult anaplastic oligodendroglioma
617376|NCT00255671|adult brain stem glioma
617377|NCT00255671|adult central nervous system germ cell tumor
617378|NCT00255671|adult choroid plexus tumor
617379|NCT00255671|adult craniopharyngioma
617380|NCT00255671|adult diffuse astrocytoma
617381|NCT00255671|adult ependymoblastoma
617382|NCT00255671|adult ependymoma
617383|NCT00255671|adult giant cell glioblastoma
617384|NCT00255671|adult gliosarcoma
617385|NCT00255671|adult medulloblastoma
617386|NCT00255671|adult melanocytic lesion
617387|NCT00255671|adult meningeal hemangiopericytoma
617388|NCT00255671|adult meningioma
617389|NCT00255671|adult myxopapillary ependymoma
617390|NCT00255671|adult oligodendroglioma
617391|NCT00255671|adult papillary meningioma
617392|NCT00255671|adult pineoblastoma
617393|NCT00255671|adult pineocytoma
617394|NCT00255671|adult subependymoma
617395|NCT00255671|adult supratentorial primitive neuroectodermal tumor (PNET)
617396|NCT00255671|adult grade I meningioma
617397|NCT00255671|adult grade II meningioma
617398|NCT00255671|adult grade III meningioma
617399|NCT00255671|adult mixed glioma
617400|NCT00255671|recurrent adult brain tumor
617401|NCT00255671|adult pilocytic astrocytoma
617402|NCT00255671|adult glioblastoma
617403|NCT00255671|ACTH-producing pituitary tumor
617404|NCT00255671|growth hormone-producing pituitary tumor
617405|NCT00255671|nonfunctioning pituitary tumor
617406|NCT00255671|prolactin-producing pituitary tumor
617407|NCT00255671|recurrent pituitary tumor
617408|NCT00255671|TSH producing pituitary tumor
617409|NCT00255619|Continuous ambulatory peritoneal dialysis (CAPD)
617410|NCT00255619|Peritonitis
617411|NCT00255619|ANDY-disc® (Fresenius Medical care)
617412|NCT00255619|Ultra® (Baxter)
617413|NCT00255619|Twin bag System
617414|NCT00255606|adenocarcinoma of the prostate
617415|NCT00255606|stage IV prostate cancer
617416|NCT00255606|recurrent prostate cancer
617417|NCT00255593|Kidney
617418|NCT00255593|Transplantation
617419|NCT00255593|Immunosuppression
617420|NCT00255593|Rituximab
617421|NCT00255580|neuropathy
617422|NCT00255580|cannabis
617423|NCT00255580|marijuana
617424|NCT00255580|HIV
617425|NCT00255580|DSPN
617426|NCT00255567|Visceral Leishmaniasis
617427|NCT00255567|Combination
617428|NCT00255554|Borderline Personality Disorder
617429|NCT00255554|BPD
617430|NCT00255554|Dialectical Behavior Therapy
617431|NCT00255554|DBT
617432|NCT00255554|Escitalopram
617433|NCT00255554|Lexapro
617434|NCT00255528|Pediatric hypertension
617435|NCT00255502|Pediatric hypertension
617436|NCT00255450|anemia
617437|NCT00255411|Conversion Disorder
617438|NCT00255411|Somatoform Disorder
617439|NCT00255411|Involuntary Movement
617440|NCT00255411|Childhood Abuse
617441|NCT00255411|Depression
617442|NCT00255411|Psychogenic Movement Disorder
617443|NCT00255411|PMD
617444|NCT00255411|Non-Epileptic Seizure
617445|NCT00255411|NES
617446|NCT00255411|Healthy Volunteer
617447|NCT00255411|HV
617448|NCT00255398|Focal Segmental Glomerulosclerosis
617449|NCT00255398|Minimal Change Disease
617450|NCT00255398|Diabetic Nephropathy
617451|NCT00255398|Mass Spectrometry
617452|NCT00255398|Proteinuria
617453|NCT00255398|Idiopathic Nephrotic Syndrome
617454|NCT00255398|Glomerular Disease
617455|NCT00255398|FSG
617456|NCT00255398|Kidney Disease
617457|NCT00255385|Zinc
617458|NCT00255385|Iron
617459|NCT00255385|Probiotics
617460|NCT00255385|Prebiotics
617461|NCT00255385|Child health
617462|NCT00255385|Milk fortification
617463|NCT00255385|Randomized controlled trial
617464|NCT00255346|targeted therapy
617465|NCT00255346|leukemia
617466|NCT00255346|Acute myeloid leukemia (AML)
617467|NCT00255346|Myelodysplastic syndrome (MDS)
617468|NCT00255346|Agnogenic myeloid metaplasia - myelofibrosis (MMM)
617469|NCT00255346|Hypereosinophilic syndrome (HES)
617470|NCT00255346|Polycythemia vera (PV)
617471|NCT00255346|Mastocytosis
617472|NCT00255346|CMML
617473|NCT00255320|healthy volunteers, headache, migraine, hemodynamics, VIP, SPECT, ultrasound
617474|NCT00255307|cold
617475|NCT00255307|flu
617476|NCT00255307|respiratory tract infection
617477|NCT00255255|Asthma
617478|NCT00255242|Cystic Fibrosis
617479|NCT00255242|Airway Inflammation
617480|NCT00255242|Cytokines
617481|NCT00255242|Simvastatin
617482|NCT00255242|HMG-CoA reductase inhibitors
617484|NCT00255229|irinotecan
617485|NCT00255229|5FU
617486|NCT00255229|amino acids
617487|NCT00255229|heat shock protein
617488|NCT00255190|Gastroesophageal Reflux Disease
617489|NCT00255177|Hepatitis C
617490|NCT00255164|Erosive Esophagitis
617491|NCT00255151|Erosive Esophagitis
617492|NCT00255138|Cancer
617493|NCT00255138|Cognitive Late Effects
617494|NCT00255138|Stimulants
617495|NCT00255138|Atomoxetine
617496|NCT00255138|Attention
617497|NCT00255138|Children
617498|NCT00255125|Estrogen Receptor
617499|NCT00255125|Isoflavones
617500|NCT00255125|Prostate Neoplasm
617501|NCT00255125|Soy Supplementation
617502|NCT00255112|SAD
617503|NCT00255112|treatment
617504|NCT00255112|cognitive behavior therapy
617505|NCT00255112|family
617506|NCT00255112|children
617507|NCT00255112|anxiety
617508|NCT00255099|HIV
617509|NCT00255099|HIV-1
617510|NCT00255099|TMC125
617511|NCT00255047|Pertussis
617512|NCT00255047|Whooping cough
617513|NCT00255047|Filamentous Haemagglutinin
617514|NCT00255047|Fimbriae Types 2 and 3;
617515|NCT00255047|Pertactin
617516|NCT00255047|Diphtheria
617517|NCT00255047|Tetanus
617518|NCT00255047|Poliovirus Types 1, 2, and 3.
617519|NCT00255034|chronic hepatitis C
617520|NCT00255034|pegylated interferon alfa-2b
617521|NCT00255034|ribavirin
617522|NCT00255034|Australia
617523|NCT00255021|Diphteria
617524|NCT00255021|Tetanus
617525|NCT00255021|Pertussis
617526|NCT00255021|Poliomyelitis
617527|NCT00255021|Haemophilus influenzae type b
617528|NCT00255021|acellular
617529|NCT00255008|chronic hepatitis C
617530|NCT00255008|pegylated interferon alfa-2b
617531|NCT00255008|ribavirin
617532|NCT00255008|Asia
617533|NCT00254995|Meningitis
617534|NCT00254995|Meningococcal disease
617535|NCT00254995|Menactra vaccine
617536|NCT00254969|Diphteria
617537|NCT00254969|tetanus
617538|NCT00254969|haemophilus influenzae type b
617539|NCT00254969|poliomyelitis
617540|NCT00254969|pertussis
617541|NCT00254956|Diseases
617542|NCT00254956|respiratory tract diseases
617543|NCT00254956|respiratory hypersensitivity
617544|NCT00254956|asthma
617545|NCT00254930|learning disorder
617546|NCT00254930|children
617547|NCT00254930|behaviour disorder
617548|NCT00254930|risperidone
617549|NCT00254917|Pentaxim
617550|NCT00254904|advanced carcinoma, non-small cell lung, Phase III, Gemcitabine, Gemzar, Cisplatin, Platinol, PF-3512676, immunotherapy, immune modulator
617551|NCT00254891|advanced carcinoma, non-small cell lung, Phase III, Paclitaxel, Taxol, Carboplatin, Paraplatin, PF-3512676, immunotherapy, immune modulator
617552|NCT00254878|ADHD, Methylphenidate hydrochloride, modified-release
617553|NCT00254865|Transdermal contraception
617554|NCT00254865|contraceptive
617555|NCT00254865|hormonal, steroid contraception
617556|NCT00254865|ethinyl estradiol
617557|NCT00254865|progesterone
617558|NCT00254865|EVRA
617559|NCT00254865|CILEST
617560|NCT00254852|Primary lumbar fusion
617561|NCT00254852|Demineralized Bone Matrix
617562|NCT00254852|DBM
617563|NCT00254852|Optecure
617564|NCT00254852|Allograft
617565|NCT00254852|Autograft
617566|NCT00254852|Lumbar fusion
617567|NCT00254852|Interbody fusion
617568|NCT00254852|Instrumented fusion
617569|NCT00254852|Non-instrumented fusion
617570|NCT00254852|Exactech
617571|NCT00254852|Spinal fusion
617572|NCT00253864|shoulder surgery
617573|NCT00253864|prospective database
617574|NCT00253864|long term outcome
617575|NCT00253851|DVT
617576|NCT00253851|Osteoarthritis
617577|NCT00253851|Total Knee Arthroplasty
617578|NCT00253838|revision hip arthroplasty
617579|NCT00253838|bone mineral density
617580|NCT00253812|colonoscopy, sigmoidoscopy, chromoendoscopy, autofluorescence, narrow band imaging, colorectal cancer, polyp, adenoma,rectal remnant, FAP
617581|NCT00253786|diabetes
617582|NCT00253786|nephropathy
617583|NCT00253773|sulfer amino acids
617584|NCT00253773|redox status
617585|NCT00253760|redox
617586|NCT00253760|sulfur amino acids
617587|NCT00253760|glutathione
617588|NCT00253760|aging
617589|NCT00253734|Influenza
617590|NCT00253721|adult anaplastic astrocytoma
617591|NCT00253721|adult brain stem glioma
617592|NCT00253721|adult diffuse astrocytoma
617593|NCT00253721|adult central nervous system germ cell tumor
617594|NCT00253721|adult medulloblastoma
617595|NCT00253721|adult supratentorial primitive neuroectodermal tumor (PNET)
617596|NCT00253721|adult anaplastic oligodendroglioma
617597|NCT00253721|adult oligodendroglioma
617598|NCT00253721|adult pineoblastoma
617599|NCT00253721|tumors metastatic to brain
617600|NCT00253721|adult mixed glioma
617601|NCT00253721|recurrent adult brain tumor
617602|NCT00253721|primary central nervous system non-Hodgkin lymphoma
617603|NCT00253708|depression
617604|NCT00253708|nausea and vomiting
617605|NCT00253708|pain
617606|NCT00253708|psychosocial effects of cancer and its treatment
617607|NCT00253708|stage IIIA non-small cell lung cancer
617608|NCT00253708|stage IIIB non-small cell lung cancer
617609|NCT00253708|stage IV non-small cell lung cancer
617610|NCT00253708|extensive stage small cell lung cancer
617611|NCT00253708|stage III gastric cancer
617612|NCT00253708|stage III esophageal cancer
617613|NCT00253708|localized unresectable adult primary liver cancer
617614|NCT00253708|stage III colon cancer
617615|NCT00253708|stage IV renal cell cancer
617616|NCT00253708|stage IV bladder cancer
617617|NCT00253708|stage IV prostate cancer
617618|NCT00253708|stage IV breast cancer
617619|NCT00253708|stage IV ovarian epithelial cancer
617620|NCT00253708|advanced adult primary liver cancer
617621|NCT00253708|stage IV melanoma
617622|NCT00253708|stage IV ovarian germ cell tumor
617623|NCT00253708|ovarian sarcoma
617624|NCT00253708|ovarian stromal cancer
617625|NCT00253708|recurrent small cell lung cancer
617626|NCT00253708|recurrent adult primary liver cancer
617627|NCT00253708|recurrent colon cancer
617628|NCT00253708|recurrent esophageal cancer
617629|NCT00253708|recurrent gastric cancer
617630|NCT00253708|recurrent non-small cell lung cancer
617631|NCT00253708|recurrent bladder cancer
617632|NCT00253708|recurrent breast cancer
617633|NCT00253708|recurrent ovarian epithelial cancer
617634|NCT00253708|recurrent ovarian germ cell tumor
617635|NCT00253708|recurrent prostate cancer
617636|NCT00253708|recurrent renal cell cancer
617637|NCT00253708|recurrent melanoma
617638|NCT00253669|thromboembolism
617639|NCT00253669|adult anaplastic astrocytoma
617640|NCT00253669|adult anaplastic oligodendroglioma
617641|NCT00253669|adult glioblastoma
617642|NCT00253669|adult giant cell glioblastoma
617643|NCT00253669|adult gliosarcoma
617644|NCT00253643|prostate cancer
617645|NCT00253643|precancerous condition
617646|NCT00253591|stage I non-small cell lung cancer
617647|NCT00253591|stage II non-small cell lung cancer
617648|NCT00253591|stage IIIA non-small cell lung cancer
617649|NCT00253591|stage IIIB non-small cell lung cancer
617650|NCT00254839|Oral malodor
617651|NCT00254839|Dental implants
617652|NCT00254826|Yellow Fever Virus Vaccination
617653|NCT00254813|Schizophrenia
617654|NCT00254813|Schizoaffective disorder
617655|NCT00254800|diabetes
617656|NCT00254800|exenatide
617657|NCT00254800|Amylin
617658|NCT00254800|Lilly
617659|NCT00254787|Schizophrenia
617660|NCT00254774|Bipolar Disorder I or II with Rapid Cycling
617661|NCT00254761|cannabis
617662|NCT00254761|marijuana
617663|NCT00254761|neuropathy
617664|NCT00254761|antinociception
617665|NCT00254761|mood
617666|NCT00254761|cognition
617667|NCT00254748|Borderline personality disorder
617668|NCT00254735|Obsessive Compulsive Disorder (OCD)
617669|NCT00254722|Traumatic Brain Injury
617670|NCT00254722|Stem Cell
617671|NCT00254709|kidney transplant
617672|NCT00254709|elderly
617673|NCT00254696|bacterial infection
617674|NCT00254683|Rectal Cancer
617675|NCT00254683|Positron Emission Tomography
617676|NCT00254683|Fluorodeoxyglucose F18
617677|NCT00254683|Computed Tomography
617678|NCT00254683|Neoadjuvant Therapy
617679|NCT00254683|Chemotherapy
617680|NCT00254683|Radiotherapy
617681|NCT00254670|Alcohol
617682|NCT00254670|Naltrexone
617683|NCT00254657|Fibromyalgia
617684|NCT00254657|Fibro
617685|NCT00254657|Keppra
617686|NCT00254657|Levetiracetam
617687|NCT00254644|phonological treatment
617688|NCT00254644|language
617689|NCT00254644|fMRI
617690|NCT00254631|long bone fracture
617691|NCT00254631|open fractures
617692|NCT00254631|closed fractures
617693|NCT00254631|trauma
617694|NCT00254618|ulcerative colitis; pharmacokinetics; pediatrics
617695|NCT00254605|imaging
617696|NCT00254605|adaptive optics scanning laser ophthalmoscope
617697|NCT00254605|optical coherence tomography
617698|NCT00254605|electroretinography
617699|NCT00254592|Inflammatory
617700|NCT00254592|Breast Cancer
617701|NCT00254592|Female
617702|NCT00254592|Neo-adjuvant
617703|NCT00254592|HER-2 positive
617704|NCT00254592|Hormone receptor
617705|NCT00254579|refractory melanoma
617706|NCT00254579|malignant melanoma
617707|NCT00254566|Azithromycin SR; Moxifloxacin; Acute exacerbation of chronic bronchitis (AECB)
617708|NCT00254540|Ph2, RCC, SU011248, SUNITINIB
617709|NCT00254527|Methicillin Resistant Staphylococcus aureus
617710|NCT00254527|Children
617711|NCT00254527|Colonization
617712|NCT00254527|Risk Factor
617713|NCT00254501|diabetes
617714|NCT00254475|Valsartan
617715|NCT00254475|simvastatin
617716|NCT00254475|hypertension
617717|NCT00254475|hypercholesterolemia
617718|NCT00254475|angiotensin II receptor blocker
617719|NCT00254462|ADHD
617720|NCT00254462|Atomoxetine
617721|NCT00254436|Epoetin Alfa
617722|NCT00254436|Epogen
617723|NCT00254436|Erythropoietin
617724|NCT00254423|Chronic Myelogenous Leukemia
617725|NCT00254423|CML
617726|NCT00254423|Dasatinib
617727|NCT00254423|BMS-354825
617728|NCT00254410|Chronic Lymphocytic Leukemia
617729|NCT00254410|Untreated
617730|NCT00254410|Fludarabine
617731|NCT00254410|Fludara
617732|NCT00254410|Cyclophosphamide
617733|NCT00254410|Cytoxan
617734|NCT00254410|Mitoxantrone
617735|NCT00254410|Novantrone
617736|NCT00254410|Rituximab
617737|NCT00254410|Rituxan
617738|NCT00254410|Pegylated Filgrastim
617739|NCT00254410|Neupogen
617740|NCT00254397|Melanoma
617741|NCT00254397|Uveal Melanoma
617742|NCT00254397|Peptide Vaccine
617743|NCT00254397|LHRH-agonist
617744|NCT00254397|Leuprolide
617745|NCT00254397|Lupron
617746|NCT00254397|MAGE-3 Peptide
617747|NCT00254397|MAGE-3
617748|NCT00254397|GP100 Peptide
617749|NCT00254397|Melanoma vaccines
617750|NCT00254397|Tumor fighting immune cells
617751|NCT00254397|T cells
617752|NCT00254397|Skin Cancer
617753|NCT00254397|Eye Cancer
617754|NCT00254384|Non-Small Cell Lung Cancer
617755|NCT00254384|Lung Cancer
617756|NCT00254384|Cisplatin
617757|NCT00254384|Platinol
617758|NCT00254384|Platinol-AQ
617759|NCT00254384|CDDP
617760|NCT00254384|Docetaxel
617761|NCT00254384|Taxotere
617762|NCT00254384|Erlotinib
617763|NCT00254384|Tarceva
617764|NCT00254384|OSI-774
617765|NCT00254384|NSCLC
617766|NCT00254358|Nicotine
617767|NCT00254358|Dopamine
617768|NCT00254358|IBZM
617769|NCT00254345|biofilm
617770|NCT00254345|adhesion
617771|NCT00254345|liquid polish
617772|NCT00254345|bonding resin
617773|NCT00254345|PMMA Polymethylmetacrylate
617774|NCT00254345|provisional crown
617775|NCT00254345|no antibiotics treatment three months prior to experiment
617776|NCT00254345|no mouth rinse with oral solutions one month prior to experiment
617777|NCT00254332|Cutaneous T-cell Lymphoma
617778|NCT00254332|Sezary Syndrome
617779|NCT00254332|Mycosis Fungoides
617780|NCT00254332|Denileukin Diftitox
617781|NCT00254306|Ecstasy
617782|NCT00254306|D2 Dopamine Receptor
617783|NCT00254306|IBZM
617784|NCT00254306|MDMA
617785|NCT00254280|Warts
617786|NCT00254280|Intense pulsed light
617787|NCT00254280|RCT
617788|NCT00254280|Recalcitrant hand and foot warts
617789|NCT00254267|Gastrointestinal Stromal Tumor, Imatinib Mesylate Resistance, Phase2 study, AMG 706
617790|NCT00254254|diabetes
617791|NCT00254254|adolescents
617792|NCT00254254|exenatide
617793|NCT00254254|Amylin
617794|NCT00254254|Lilly
617795|NCT00254241|Schizophrenia
617796|NCT00254228|Balance
617797|NCT00254228|Vestibular
617798|NCT00254228|Electrotactile
617799|NCT00254228|BrainPort
617800|NCT00254228|Sensory substitution
617801|NCT00254228|Tongue
617802|NCT00254215|overweight
617803|NCT00254215|obesity
617804|NCT00254215|glycemic index
617805|NCT00254215|glycemic load
617806|NCT00254215|high protein diet
617807|NCT00254215|blood cholesterol
617808|NCT00254202|Schizophrenia
617809|NCT00254202|Atypical antipsychotic
617810|NCT00254202|psychosis
617811|NCT00254189|Ovulation
617812|NCT00254189|Oral Contraceptive
617813|NCT00254176|Neonate
617814|NCT00254176|Glutathione
617815|NCT00254176|Cysteine
617816|NCT00254176|Sepsis
617817|NCT00254176|Stable Isotope
617818|NCT00254137|capecitabine
617819|NCT00254137|irinotecan
617820|NCT00254137|cetuximab
617821|NCT00254137|oxaliplatin
617822|NCT00254137|colorectal cancer
617823|NCT00254124|obesity
617824|NCT00254124|type 2 diabetes mellitus
617825|NCT00254124|portion control
617826|NCT00254111|osteoarthritis
617827|NCT00254111|hand
617828|NCT00254111|laser
617829|NCT00254111|device
617830|NCT00254111|hand pain
617831|NCT00254111|stiffness
617832|NCT00254085|Type 2 diabtes
617833|NCT00254085|Postprandial hyperglycemia
617834|NCT00254085|Insulin treatment
617835|NCT00254072|Morbid Obesity
617836|NCT00254072|Laparoscopic Gastric Bypass
617837|NCT00254072|Staple Line Hemorrhage
617838|NCT00254059|OSAHS, OSA, CPAP, polysomnography, overnight oximetry, Obstructive sleep apnea, apnea hypopnea index, AHI, Obstructive Sleep Apnea Hypopnea Syndrome
617839|NCT00254046|HIV
617840|NCT00254046|HIV-1
617841|NCT00254046|TMC125
617842|NCT00254033|Alzheimer's Disease
617843|NCT00254033|Apathy
617844|NCT00254033|Brain Reward System
617845|NCT00254033|Dopamine
617846|NCT00254033|Dextroamphetamine Challenge
617847|NCT00254033|Methylphenidate
617848|NCT00254020|stroke
617849|NCT00254020|depression
617850|NCT00254020|cytokines
617851|NCT00254020|serotonin
617852|NCT00254020|citalopram
617853|NCT00254007|depression
617854|NCT00254007|traumatic brain injury
617855|NCT00254007|serotonin transporter
617856|NCT00254007|genetic polymorphisms
617857|NCT00254007|citalopram
617858|NCT00253981|Pain, Intractable
617859|NCT00253981|Infrared Rays
617860|NCT00253981|Leg
617861|NCT00253968|Primary Insomnia
617862|NCT00253968|Sleeplessness
617863|NCT00253968|Early Awakening
617864|NCT00253968|Chronic Insomnia
617865|NCT00253929|adenosine
617866|NCT00253929|polymorphisms
617867|NCT00253929|blood flow
617868|NCT00253929|adenosine A2a receptor
617869|NCT00253929|AMP deaminase
617870|NCT00253903|Primary Insomnia
617871|NCT00253903|Sleeplessness
617872|NCT00253903|Early Awakening
617873|NCT00253903|Chronic Insomnia
617874|NCT00253890|sleep quality
617875|NCT00253890|methadone
617876|NCT00253890|substance use
617877|NCT00253877|osteoarthritis
617878|NCT00253877|hip resurfacing
617879|NCT00253565|unspecified adult solid tumor, protocol specific
617880|NCT00253552|graft versus host disease
617881|NCT00253552|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
617882|NCT00253552|adult acute myeloid leukemia with inv(16)(p13;q22)
617883|NCT00253552|adult acute myeloid leukemia with t(15;17)(q22;q12)
617884|NCT00253552|adult acute myeloid leukemia with t(16;16)(p13;q22)
617885|NCT00253552|adult acute myeloid leukemia with t(8;21)(q22;q22)
617886|NCT00253552|accelerated phase chronic myelogenous leukemia
617887|NCT00253552|adult acute lymphoblastic leukemia in remission
617888|NCT00253552|adult acute myeloid leukemia in remission
617889|NCT00253552|atypical chronic myeloid leukemia
617890|NCT00253552|blastic phase chronic myelogenous leukemia
617891|NCT00253552|childhood acute lymphoblastic leukemia in remission
617892|NCT00253552|childhood acute myeloid leukemia in remission
617893|NCT00253552|childhood chronic myelogenous leukemia
617894|NCT00253552|chronic eosinophilic leukemia
617895|NCT00253552|chronic idiopathic myelofibrosis
617896|NCT00253552|chronic myelomonocytic leukemia
617897|NCT00253552|chronic neutrophilic leukemia
617898|NCT00253552|chronic phase chronic myelogenous leukemia
617899|NCT00253552|de novo myelodysplastic syndromes
617900|NCT00253552|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
617901|NCT00253552|juvenile myelomonocytic leukemia
617902|NCT00253552|myelodysplastic/myeloproliferative disease, unclassifiable
617903|NCT00253552|nodal marginal zone B-cell lymphoma
617904|NCT00253552|noncontiguous stage II adult Burkitt lymphoma
617905|NCT00253552|noncontiguous stage II adult diffuse large cell lymphoma
617906|NCT00253552|noncontiguous stage II adult diffuse mixed cell lymphoma
617907|NCT00253552|noncontiguous stage II adult diffuse small cleaved cell lymphoma
617908|NCT00253552|noncontiguous stage II adult immunoblastic large cell lymphoma
617909|NCT00253552|noncontiguous stage II adult lymphoblastic lymphoma
617910|NCT00253552|noncontiguous stage II grade 1 follicular lymphoma
617911|NCT00253552|noncontiguous stage II grade 2 follicular lymphoma
617912|NCT00253552|noncontiguous stage II grade 3 follicular lymphoma
617913|NCT00253552|noncontiguous stage II mantle cell lymphoma
617914|NCT00253552|noncontiguous stage II marginal zone lymphoma
617915|NCT00253552|noncontiguous stage II small lymphocytic lymphoma
617916|NCT00253552|previously treated myelodysplastic syndromes
617917|NCT00253552|recurrent adult acute lymphoblastic leukemia
617918|NCT00253552|recurrent adult acute myeloid leukemia
617919|NCT00253552|recurrent adult Burkitt lymphoma
617920|NCT00253552|recurrent adult Hodgkin lymphoma
617921|NCT00253552|recurrent adult diffuse large cell lymphoma
617922|NCT00253552|recurrent adult diffuse mixed cell lymphoma
617923|NCT00253552|recurrent adult diffuse small cleaved cell lymphoma
617924|NCT00253552|recurrent adult immunoblastic large cell lymphoma
617925|NCT00253552|recurrent adult lymphoblastic lymphoma
617926|NCT00253552|recurrent/refractory childhood Hodgkin lymphoma
617927|NCT00253552|recurrent childhood acute lymphoblastic leukemia
617928|NCT00253552|recurrent childhood acute myeloid leukemia
617929|NCT00253552|recurrent childhood large cell lymphoma
617930|NCT00253552|recurrent childhood lymphoblastic lymphoma
617931|NCT00253552|recurrent childhood rhabdomyosarcoma
617932|NCT00253552|recurrent childhood small noncleaved cell lymphoma
617933|NCT00253552|recurrent cutaneous T-cell non-Hodgkin lymphoma
617934|NCT00253552|recurrent grade 1 follicular lymphoma
617935|NCT00253552|recurrent grade 2 follicular lymphoma
617936|NCT00253552|recurrent grade 3 follicular lymphoma
617937|NCT00253552|recurrent mantle cell lymphoma
617938|NCT00253552|recurrent marginal zone lymphoma
617939|NCT00253552|recurrent mycosis fungoides/Sezary syndrome
617940|NCT00253552|recurrent small lymphocytic lymphoma
617941|NCT00253552|refractory chronic lymphocytic leukemia
617942|NCT00253552|refractory hairy cell leukemia
617943|NCT00253552|refractory multiple myeloma
617944|NCT00253552|relapsing chronic myelogenous leukemia
617945|NCT00253552|secondary acute myeloid leukemia
617946|NCT00253552|secondary myelodysplastic syndromes
617947|NCT00253552|splenic marginal zone lymphoma
617948|NCT00253552|stage I multiple myeloma
617949|NCT00253552|stage II multiple myeloma
617950|NCT00253552|stage III adult Burkitt lymphoma
617951|NCT00253552|stage III adult Hodgkin lymphoma
617952|NCT00253552|stage III adult diffuse large cell lymphoma
617953|NCT00253552|stage III adult diffuse mixed cell lymphoma
617954|NCT00253552|stage III adult diffuse small cleaved cell lymphoma
617955|NCT00253552|stage III adult immunoblastic large cell lymphoma
617956|NCT00253552|stage III adult lymphoblastic lymphoma
617957|NCT00253552|stage III chronic lymphocytic leukemia
617958|NCT00253552|stage III grade 1 follicular lymphoma
617959|NCT00253552|stage III grade 2 follicular lymphoma
617960|NCT00253552|stage III grade 3 follicular lymphoma
617961|NCT00253552|stage III mantle cell lymphoma
617962|NCT00253552|stage III marginal zone lymphoma
617963|NCT00253552|stage III multiple myeloma
617964|NCT00253552|stage III small lymphocytic lymphoma
617965|NCT00253552|stage IV adult Burkitt lymphoma
617966|NCT00253552|stage IV adult Hodgkin lymphoma
617967|NCT00253552|stage IV adult diffuse large cell lymphoma
617968|NCT00253552|stage IV adult diffuse mixed cell lymphoma
617969|NCT00253552|stage IV adult diffuse small cleaved cell lymphoma
617970|NCT00253552|stage IV adult immunoblastic large cell lymphoma
617971|NCT00253552|stage IV adult lymphoblastic lymphoma
617972|NCT00253552|stage IV chronic lymphocytic leukemia
617973|NCT00253552|stage IV grade 1 follicular lymphoma
617974|NCT00253552|stage IV grade 2 follicular lymphoma
617975|NCT00253552|stage IV grade 3 follicular lymphoma
617976|NCT00253552|stage IV mantle cell lymphoma
617977|NCT00253552|stage IV marginal zone lymphoma
617978|NCT00253552|stage IV small lymphocytic lymphoma
617979|NCT00253552|childhood myelodysplastic syndromes
617980|NCT00253539|hereditary breast/ovarian cancer (BRCA1, BRCA2)
617981|NCT00253539|breast cancer
617982|NCT00253513|adult acute lymphoblastic leukemia in remission
617983|NCT00253513|adult acute myeloid leukemia in remission
617984|NCT00253513|childhood acute lymphoblastic leukemia in remission
617985|NCT00253513|recurrent adult acute lymphoblastic leukemia
617986|NCT00253513|recurrent adult acute myeloid leukemia
617987|NCT00253513|recurrent childhood acute lymphoblastic leukemia
617988|NCT00253513|recurrent childhood acute myeloid leukemia
617989|NCT00253513|secondary acute myeloid leukemia
617990|NCT00253513|myelodysplastic syndromes
617991|NCT00253513|childhood myelodysplastic syndromes
617992|NCT00253500|stage II breast cancer
617993|NCT00253500|stage I breast cancer
617994|NCT00253500|stage IIIA breast cancer
617995|NCT00253500|stage IIIB breast cancer
617996|NCT00253487|adult glioblastoma
617997|NCT00253487|adult anaplastic astrocytoma
617998|NCT00253487|childhood high-grade cerebral astrocytoma
617999|NCT00253487|adult giant cell glioblastoma
618000|NCT00253487|adult gliosarcoma
618001|NCT00253474|neoplasm of uncertain malignant potential
618002|NCT00253474|unspecified childhood solid tumor, protocol specific
618003|NCT00253461|stage IV ovarian epithelial cancer
618004|NCT00253461|stage IV ovarian germ cell tumor
618005|NCT00253461|extensive stage small cell lung cancer
618006|NCT00253461|recurrent small cell lung cancer
618007|NCT00253461|unspecified adult solid tumor, protocol specific
618008|NCT00253461|recurrent ovarian epithelial cancer
618009|NCT00253461|recurrent ovarian germ cell tumor
618010|NCT00253461|tumors metastatic to brain
618011|NCT00253448|adult glioblastoma
618012|NCT00253448|adult giant cell glioblastoma
618013|NCT00253448|adult gliosarcoma
618014|NCT00253435|recurrent neuroblastoma
618015|NCT00253422|recurrent breast cancer
618016|NCT00253422|stage IV breast cancer
618017|NCT00253422|stage IIIB breast cancer
618018|NCT00253422|stage IIIC breast cancer
618019|NCT00253409|localized malignant mesothelioma
618020|NCT00253396|warfarin
618021|NCT00253396|clinical trial
618022|NCT00253396|pain measurement
618023|NCT00253396|heparin
618024|NCT00253396|heparin, low-molecular-weight
618025|NCT00253396|Anticoagulants
618026|NCT00253383|transitional care planning
618027|NCT00253383|stage IIIB non-small cell lung cancer
618028|NCT00253383|stage IV non-small cell lung cancer
618029|NCT00253383|extensive stage small cell lung cancer
618030|NCT00253383|stage IV breast cancer
618031|NCT00253383|recurrent breast cancer
618032|NCT00253383|male breast cancer
618033|NCT00253383|stage IIIB anal cancer
618034|NCT00253383|stage IV anal cancer
618035|NCT00253383|carcinoma of the appendix
618036|NCT00253383|stage III colon cancer
618037|NCT00253383|stage IV colon cancer
618038|NCT00253383|stage III rectal cancer
618039|NCT00253383|stage IV rectal cancer
618040|NCT00253383|stage III esophageal cancer
618041|NCT00253383|stage IV esophageal cancer
618042|NCT00253383|unresectable extrahepatic bile duct cancer
618043|NCT00253383|unresectable gallbladder cancer
618044|NCT00253383|stage III gastric cancer
618045|NCT00253383|stage IV gastric cancer
618046|NCT00253383|metastatic gastrointestinal carcinoid tumor
618047|NCT00253383|regional gastrointestinal carcinoid tumor
618048|NCT00253383|gastrointestinal stromal tumor
618049|NCT00253383|advanced adult primary liver cancer
618295|NCT00252395|electronic prescribing
618050|NCT00253383|localized unresectable adult primary liver cancer
618051|NCT00253383|stage III pancreatic cancer
618052|NCT00253383|recurrent small intestine cancer
618053|NCT00253383|small intestine adenocarcinoma
618054|NCT00253383|small intestine leiomyosarcoma
618055|NCT00253383|small intestine lymphoma
618056|NCT00253383|stage IV bladder cancer
618057|NCT00253383|stage IV renal cell cancer
618058|NCT00253383|clear cell sarcoma of the kidney
618059|NCT00253383|peripheral primitive neuroectodermal tumor of the kidney
618060|NCT00253383|rhabdoid tumor of the kidney
618061|NCT00253383|metastatic transitional cell cancer of the renal pelvis and ureter
618062|NCT00253383|anterior urethral cancer
618063|NCT00253383|posterior urethral cancer
618064|NCT00253383|urethral cancer associated with invasive bladder cancer
618065|NCT00253383|stage IV penile cancer
618066|NCT00253383|stage IV prostate cancer
618067|NCT00253383|stage III malignant testicular germ cell tumor
618068|NCT00253383|stage IV endometrial carcinoma
618069|NCT00253383|fallopian tube cancer
618070|NCT00253383|ovarian sarcoma
618071|NCT00253383|ovarian stromal cancer
618072|NCT00253383|stage IV pancreatic cancer
618073|NCT00253370|Sorafenib
618074|NCT00253370|Docetaxel
618075|NCT00253370|Cisplatin
618076|NCT00253370|gastric cancer
618077|NCT00253370|gastroesophageal junction adenocarcinoma
618078|NCT00253357|Heart Failure
618079|NCT00253357|Congestive Heart Failure
618080|NCT00253357|Fluid overload
618081|NCT00253357|Left sided heart failure
618082|NCT00253357|Pacemaker
618083|NCT00253357|Defibrillator
618084|NCT00253344|unspecified adult solid tumor, protocol specific
618085|NCT00253331|Raynaud's
618086|NCT00253331|sclerderma
618087|NCT00253331|systemic sclerosis
618088|NCT00253331|autoimmune disease
618089|NCT00253318|Neoplasm Metastasis
618090|NCT00253318|Breast Cancer
618091|NCT00253318|Docetaxel
618092|NCT00253318|RAD001
618093|NCT00253318|Taxotere
618094|NCT00253305|tinea unguium
618095|NCT00253305|onychomycosis
618096|NCT00253292|Burns
618097|NCT00253292|Trauma
618098|NCT00253292|Outcomes
618099|NCT00253292|Quality of Life
618100|NCT00253279|Protein Synthesis Rate
618101|NCT00253279|Burn Injury
618102|NCT00253279|PET Scan
618103|NCT00253266|Treatment resistant depression
618104|NCT00253266|Augmentation
618105|NCT00253266|Pharmacogenetics
618106|NCT00253253|orchidopexy, long-term outcome, congenital
618107|NCT00253227|Alzheimer's disease
618108|NCT00253227|dementia
618109|NCT00253227|brain disease
618110|NCT00253227|memory loss
618111|NCT00253227|galantamine
618112|NCT00253227|placebo
618113|NCT00253214|Alzheimer's disease
618114|NCT00253214|dementia
618115|NCT00253214|galantamine hydrobromide
618116|NCT00253214|controlled-release
618117|NCT00253214|once-daily dosing
618118|NCT00253201|Alzheimer's disease
618119|NCT00253201|dementia
618120|NCT00253201|brain disease
618121|NCT00253201|memory loss
618122|NCT00253201|galantamine
618123|NCT00253201|placebo
618124|NCT00253201|caregiver
618125|NCT00253201|quality of life
618126|NCT00253201|resource utilization
618127|NCT00253188|Alzheimer's disease
618128|NCT00253188|dementia
618129|NCT00253188|brain disease
618130|NCT00253188|memory loss
618131|NCT00253188|galantamine
618132|NCT00253188|placebo
618133|NCT00253188|caregiver
618134|NCT00253188|quality of life
618135|NCT00253188|resource utilization
618136|NCT00253175|topiramate
618137|NCT00253175|migraine headache
618138|NCT00253175|migraine prevention
618139|NCT00253175|migraine
618140|NCT00253162|risperidone
618141|NCT00253162|antipsychotic agents
618142|NCT00253162|bipolar disorders
618143|NCT00253162|manic episode
618144|NCT00253149|risperidone
618145|NCT00253149|antipsychotic agents
618146|NCT00253149|bipolar disorders
618147|NCT00253149|manic episode
618148|NCT00253136|schizophrenia
618149|NCT00253136|schizoaffective disorder
618150|NCT00253136|psychotic disorder
618151|NCT00253136|risperidone
618152|NCT00253136|long-acting injectable
618153|NCT00253136|intramuscular injection
618154|NCT00253136|antipsychotic agents
618155|NCT00253123|Dementia
618156|NCT00253123|Alzheimer's disease
618157|NCT00253123|vascular dementia
618158|NCT00253123|mixed dementia
618159|NCT00253123|risperidone
618160|NCT00253123|nursing home
618161|NCT00253110|Schizophrenia, Psychotic Disorders
618162|NCT00253110|Haloperidol
618163|NCT00253110|Risperidone
618164|NCT00253110|Schizoaffective disorder
618165|NCT00253097|stroke recurrence
618166|NCT00253097|risk factors
618167|NCT00253097|health behavior
618168|NCT00253097|intervention
618169|NCT00253097|tertiary prevention
618170|NCT00253071|Prophylactic treatment
618171|NCT00253071|Pharmacological treatment
618172|NCT00253071|Psychological treatment
618173|NCT00253058|Allergic
618174|NCT00253058|pediatric
618175|NCT00253058|Rhinitis
618176|NCT00253058|Perennial
618177|NCT00253045|Motivational Interviewing
618178|NCT00253045|antiretroviral therapy
618179|NCT00253045|medication adherence
618180|NCT00253045|risk reduction behaviors
618181|NCT00253045|women
618182|NCT00253045|HIV
618183|NCT00253045|AIDS
618184|NCT00253019|birth control
618185|NCT00253019|continuation
618186|NCT00253019|abortion
618187|NCT00253019|contraception
618188|NCT00253006|NO
618189|NCT00253006|mRNA-expression
618190|NCT00253006|pathophysiology
618191|NCT00253006|painful bladder syndrome
618192|NCT00252993|Nausea
618193|NCT00252993|Vomiting
618194|NCT00252993|Chronic Functional Vomiting
618195|NCT00252993|Functional Vomiting
618196|NCT00252993|Cyclic Vomiting
618197|NCT00252980|Cannabis
618198|NCT00252980|Dependence
618199|NCT00252980|Marijuana
618200|NCT00252980|Substance Abuse Treatment
618201|NCT00252980|Psychotherapy,
618202|NCT00252967|Reactive Oxgen Speers
618203|NCT00252967|Atrial Fibrillation
618204|NCT00252967|Oxidative Stress
618205|NCT00252967|Inflammation
618206|NCT00252954|Spinal cord injury
618207|NCT00252954|Neuropathic pain
618208|NCT00252954|Spasms
618209|NCT00252941|prostate cancer
618210|NCT00252941|brachytherapy
618211|NCT00252941|urethral stenting
618212|NCT00252928|sodium dichloroisocyanurate
618213|NCT00252928|water purification
618214|NCT00252928|disinfection
618215|NCT00252928|Ghana
618216|NCT00252902|tobacco; emergency department; motivation; counseling
618217|NCT00252889|Metastatic cancer
618218|NCT00252889|Metastatic gastric and esophagus adenocarcinoma
618219|NCT00252889|Unresectable pancreatic cancer
618220|NCT00252889|Unresectable head and neck cancer
618221|NCT00252889|Cancer of undetermined primary
618222|NCT00252850|Parkinson's Disease
618223|NCT00252850|Gene Transfer
618224|NCT00252798|Non Small Cell Lung Cancer
618225|NCT00252785|Asthma
618226|NCT00252746|NSCLC
618227|NCT00252746|Non Small Cell Lung Cancer
618228|NCT00252733|Diabetes Mellitus, Insulin-Dependent
618229|NCT00252720|Diabetes mellitus type 1
618230|NCT00252694|Diabetes mellitus type 2
618231|NCT00252681|randomized
618232|NCT00252681|controlled
618233|NCT00252681|trial
618234|NCT00252681|necrotizing
618235|NCT00252681|enterocolitis
618236|NCT00252681|premature
618237|NCT00252681|infants
618238|NCT00252681|laparotomy
618239|NCT00252681|peritoneal
618240|NCT00252681|drainage
618241|NCT00252668|Rheumatoid Arthritis
618242|NCT00252642|Hepatitis C
618243|NCT00252642|Interferon
618244|NCT00252642|Cirrhosis
618245|NCT00252642|Liver Disease
618246|NCT00252642|Portal Hypertension
618247|NCT00252642|Portal Pressure
618248|NCT00252629|Fatigue
618249|NCT00252629|Functional Somatic Syndrome
618250|NCT00252629|Gulf War Syndrome
618251|NCT00252629|Sleep apnea
618252|NCT00252629|Upper Airway Resistance Syndrome
618253|NCT00252616|Mechanical ventilation
618254|NCT00252616|acute respiratory failure
618255|NCT00252616|early nutrition
618256|NCT00252603|Autism
618257|NCT00252603|Childhood Autism
618258|NCT00252590|Psychotherapy motivational intervention
618259|NCT00252577|Lithium
618260|NCT00252577|Pharmacogenetics
618261|NCT00252551|spondylolisthesis, decompressive surgery, osteosynthesis
618262|NCT00252538|Cortisol
618263|NCT00252538|Depression
618264|NCT00252538|Hepatitis C
618265|NCT00252538|Interferon
618266|NCT00252538|Polymorphism
618267|NCT00252538|Serotonin
618268|NCT00252538|Tryptophan
618269|NCT00252512|Contingency management interventions
618270|NCT00252512|Substance use disorders treatment
618271|NCT00252512|Treatment effectiveness
618272|NCT00252512|Randomized clinical trial
618273|NCT00252512|Behavioral research
618274|NCT00252499|beta cell function
618275|NCT00252499|fenofibrate
618276|NCT00252499|non-alcoholic steatohepatitis
618277|NCT00252499|rosiglitazone
618278|NCT00252499|insulin sensitivity
618279|NCT00252486|Bipolar
618280|NCT00252486|Omega-3 Fatty acids
618281|NCT00252434|high-risk sexual behavior
618282|NCT00252434|methamphetamine use
618283|NCT00252434|drug craving
618284|NCT00252434|addiction behaviors
618285|NCT00252421|osteoporosis
618286|NCT00252421|bone mineral density
618287|NCT00252421|nitrates
618288|NCT00252408|Fracture
618289|NCT00252408|Osteoporosis
618290|NCT00252408|Bone mineral density
618291|NCT00252408|Hormone replacement therapy
618292|NCT00252408|Estrogen
618293|NCT00252408|Breast cancer
618294|NCT00252395|medication error
618296|NCT00252395|patient safety
618297|NCT00252382|Lung
618298|NCT00252382|Squamous Cell
618299|NCT00252382|Large Cell
618300|NCT00252382|Adenocarcinoma
618301|NCT00252382|Carcinoma
618302|NCT00252382|Cancer
618303|NCT00252356|major depressive disorder
618304|NCT00252356|depression
618305|NCT00252356|major depressive episode
618306|NCT00252356|antidepressive agents
618307|NCT00252343|anxiety disorder
618308|NCT00252330|major depressive disorder
618309|NCT00252330|depression
618310|NCT00252330|major depressive episode
618311|NCT00252330|antidepressive agents
618312|NCT00252317|Aortic stenosis
618313|NCT00252317|ACE-inhibitores
618314|NCT00252304|Child, severe pneumonia, Zinc, Nepal, therapeutic
618315|NCT00252291|bronchial
618316|NCT00252291|hyperresponsiveness
618317|NCT00252239|stroke
618318|NCT00252239|tenecteplase
618319|NCT00252239|TNK
618320|NCT00252239|ischemic
618321|NCT00252239|tissue plasminogen activator
618322|NCT00252239|tPA
618323|NCT00252226|Quetiapine
618324|NCT00252226|bipolar spectrum disorders
618325|NCT00252187|Heart failure
618326|NCT00252187|Natriuretic peptides
618327|NCT00252187|B-type natriuretic peptide
618328|NCT00252187|Kidney
618329|NCT00252187|Nesiritide
618330|NCT00252187|Natrecor
618331|NCT00252187|CHF
618332|NCT00252174|MDMA
618333|NCT00252174|cancer
618334|NCT00252174|anxiety
618335|NCT00252174|psychotherapy
618336|NCT00252174|quality of life
618337|NCT00252161|Neoadjuvant Therapy
618338|NCT00252161|Stomach Neoplasms
618339|NCT00252161|Cisplatin
618340|NCT00252161|S-1(combination)
618341|NCT00252148|HIV Preventive Vaccine
618342|NCT00252135|Moderate to severe asthma
618343|NCT00252109|HIV
618344|NCT00252109|Seropositive
618345|NCT00252109|MSM
618346|NCT00252109|African American
618347|NCT00252109|Popular Opinion Leader
618348|NCT00252096|Diagnosis
618349|NCT00252096|Chlamydia trachomatis
618350|NCT00252096|Neisseria gonorrhoeae
618351|NCT00252096|Nucleic acid amplification test
618352|NCT00252096|Rectum
618353|NCT00252096|Pharynx
618354|NCT00252083|Seropositive
618355|NCT00252083|MSM
618356|NCT00252083|Hispanic
618357|NCT00252083|Popular Opinion Leader
618358|NCT00252083|HIV
618359|NCT00252070|arthritis
618360|NCT00252070|exercise
618361|NCT00252070|function
618362|NCT00252070|pain
618363|NCT00252057|rehospitalization
618364|NCT00252057|readmission
618365|NCT00252057|adverse events
618366|NCT00252057|discharge
618367|NCT00252031|Borderline Personality Disorder
618368|NCT00252031|BPD
618369|NCT00252031|Dialectical Behavior Therapy
618370|NCT00252031|DBT
618371|NCT00252018|Nutritional supplement
618372|NCT00252018|Prevention
618373|NCT00252018|Endothelial function
618374|NCT00252018|Flow mediated dilation
618375|NCT00251966|Prevention of gastroduodenal lesions
618376|NCT00251966|erosive oesophagitis
618377|NCT00251966|upper GI symptoms
618378|NCT00251927|Acid reflux disease
618379|NCT00251927|Gastroesophageal Reflux Disease
618380|NCT00251901|Gastroesophageal reflux disease
618381|NCT00251901|GERD
618382|NCT00251888|cervix cancer
618383|NCT00251888|advanced cervix cancer
618384|NCT00251888|radiochemotherapy
618385|NCT00251888|pelvic radiotherapy
618386|NCT00251888|campto
618387|NCT00251888|cisplatin
618388|NCT00251888|irinotecan
618389|NCT00251888|cisplatyl
618390|NCT00251888|maximum dose search
618391|NCT00251875|patient portals
618392|NCT00251875|electronic health records
618393|NCT00251875|family history
618394|NCT00251875|health maintenance
618395|NCT00251875|medications
618396|NCT00251875|diabetes
618397|NCT00251862|Colorectal cancer screening
618398|NCT00251862|Shared decision-making
618399|NCT00251862|Decision aid
618400|NCT00251849|Intermittent Claudication
618401|NCT00251836|Kidney donation
618402|NCT00251836|Organ Donation
618403|NCT00251836|Vascular anatomy
618404|NCT00251836|Adrenal Insufficiency
618405|NCT00251823|ST-Elevation Myocardial Infarction
618406|NCT00251810|general anaesthesia
618407|NCT00251810|depth of hypnosis
618408|NCT00251810|Cerebral State Monitor
618409|NCT00251810|CSM
618410|NCT00251810|Bispectral Index
618411|NCT00251810|BIS
618412|NCT00251797|Phase I
618413|NCT00251797|Brain cancer
618414|NCT00251797|Recurrent CNS tumors
618415|NCT00251082|hormone replacement
618416|NCT00251082|vasomotoric symptoms
618417|NCT00251082|bleeding pattern
618418|NCT00251069|glucosamine sulphate, osteoarthritis, cholesterol,
618419|NCT00251043|Pregnancy
618420|NCT00251043|Antepartum Depression
618421|NCT00251043|Major Depression
618422|NCT00251017|single nucleotide polymorphisms (SNPs)
618423|NCT00251017|personalized medicines
618424|NCT00251017|Subjects 16 years of age or older, of either sex.
618425|NCT00251017|Subjects have a medication including vancomycin
618426|NCT00251004|Renal transplantation, kidney, and organ transplant
618427|NCT00251004|Renal transplant rejection
618428|NCT00250991|stroke
618429|NCT00250991|integrilin
618430|NCT00250991|eptifibatide
618431|NCT00250991|activase
618432|NCT00250991|recombinant tissue plasminogen activator
618433|NCT00250991|rt-PA
618434|NCT00250991|recombinant t-PA
618435|NCT00250991|SPOTRIAS
618436|NCT00250978|Advanced Non Small Cell Lung Cancer
618437|NCT00250952|Clinical Practice Variations
618438|NCT00250939|Glycogen Storage Disease Type II
618439|NCT00250939|GSD-II
618440|NCT00250939|Pompe Disease
618441|NCT00250926|bortezomib
618442|NCT00250926|dexamethasone
618443|NCT00250926|rituximab
618444|NCT00250913|motor activity
618445|NCT00250913|determinants
618446|NCT00250913|psychology
618447|NCT00250913|health care costs
618448|NCT00250913|quality of life
618449|NCT00250913|Angioplasty
618450|NCT00250900|Otitis
618451|NCT00250900|Antibiotic
618452|NCT00250900|Prescription
618453|NCT00250887|recurrent Glioblastoma, Gefitinib
618454|NCT00250848|Lung Diseases
618455|NCT00250848|Cancer
618456|NCT00250835|Resectable Rectal Cancer
618457|NCT00250835|Radiation
618458|NCT00250835|Neoadjuvant
618459|NCT00250835|Rectum
618460|NCT00250835|GI - Colorectal Neoadjuvant
618461|NCT00250835|Cancer
618462|NCT00251771|Thrombolytic therapy
618463|NCT00251771|Postphlebitic syndrome
618464|NCT00251771|Venous thrombosis
618465|NCT00251758|Non-Erosive Gastroesophageal Reflux Disease(GERD),heartburn
618466|NCT00251745|Non-Erosive Gastroesophageal Reflux Disease (GERD)
618467|NCT00251745|Heartburn
618468|NCT00251732|acid reflux studies
618469|NCT00251732|efficacy of PPI therapy
618470|NCT00251732|failing PPI therapy
618471|NCT00251732|GERD
618472|NCT00251732|Acid Reflux Disease
618473|NCT00251719|Erosive Esophagitis
618474|NCT00251706|atrial fibrillation
618475|NCT00251706|atrial flutter
618476|NCT00251706|amiodarone
618477|NCT00251706|post-operative
618478|NCT00251706|coronary artery bypass surgery
618479|NCT00251706|valve replacement or repair
618480|NCT00251693|Erosive Esophagitis
618481|NCT00251680|Hyperlipidemia
618482|NCT00251680|Drug Therapy
618483|NCT00251654|complications
618484|NCT00251654|adverse events
618485|NCT00251654|regional anesthesia
618486|NCT00251654|adverse effects
618487|NCT00251628|Tonsils
618488|NCT00251628|Tonsillectomy
618489|NCT00251615|vascular surgery
618490|NCT00251615|vascular aging
618491|NCT00251615|arterial aging
618492|NCT00251615|surgical tissue
618493|NCT00251615|Aging
618494|NCT00251602|heart rate variability
618495|NCT00251602|gene response
618496|NCT00251589|Relapsed Non-Small-Cell Lung Cancer
618497|NCT00251589|Refractory Non-Small-Cell Lung Cancer
618498|NCT00251563|Cancer,Risk factors
618499|NCT00251537|Pilot study
618500|NCT00251537|Randomized
618501|NCT00251537|Placebo-controlled
618502|NCT00251537|Double-blind
618503|NCT00251537|Effect on viral load
618504|NCT00251537|LTB4
618505|NCT00251537|HIV-1 infection
618506|NCT00251498|Metastatic 1st line NSCLC
618507|NCT00251485|Metastatic 1st line colorectal cancer
618508|NCT00251459|SAILOR
618509|NCT00251459|CNV
618510|NCT00251459|AMD
618511|NCT00251459|CNV secondary to AMD
618512|NCT00251433|ErbB1
618513|NCT00251433|ErbB2
618514|NCT00251433|trastuzumab (Herceptin)
618515|NCT00251433|lapatinib
618516|NCT00251433|Stage IV breast cancer
618517|NCT00251433|metastatic breast cancer
618518|NCT00251433|overexpression of ErbB2 receptors
618519|NCT00251433|docetaxel (Taxotere)
618520|NCT00251420|copd
618521|NCT00251420|asthma
618522|NCT00251420|QoL
618523|NCT00251420|Perceived health status
618524|NCT00251420|Trait anxiety
618525|NCT00251407|Advanced solid tumor malignancy
618526|NCT00251407|cisplatin
618527|NCT00251407|CPT-11
618528|NCT00251407|taxotere
618529|NCT00251394|B-Cell follicular non-Hodgkin's lymphoma
618530|NCT00251394|Rituxan
618531|NCT00251394|Rituximab
618532|NCT00251394|1018 ISS
618533|NCT00251394|CD 20 +
618534|NCT00251381|Oropharyngeal Neoplasms
618535|NCT00251381|Cetuximab
618536|NCT00251381|Concomitant-boost accelerated radiotherapy
618537|NCT00251368|leukemia
618538|NCT00251368|9-Aminocamptothecin
618539|NCT00251368|AML
618540|NCT00251368|ALL
618541|NCT00251368|refractory leukemia
618542|NCT00251368|relapsed leukemia
618543|NCT00251355|gemcitabine
618544|NCT00251355|5-fluorouracil
618545|NCT00251355|5-FU
618546|NCT00251355|unresectable pancreatic cancer
618674|NCT00250627|depression
618547|NCT00251355|non-metastatic pancreatic cancer
618548|NCT00251342|Postnatal depression
618549|NCT00251342|Randomized controlled trial
618550|NCT00251342|Screening
618551|NCT00251342|Outcome
618552|NCT00251342|Edinburgh Postnatal Depression Scale
618553|NCT00251329|Neoadjuvant
618554|NCT00251329|Breast Cancer
618555|NCT00251329|pCR
618556|NCT00251329|Capecitabine
618557|NCT00251329|Carboplatin
618558|NCT00251329|Docetaxel
618559|NCT00251316|Thyroid Neoplasm
618560|NCT00251316|I-131
618561|NCT00251316|Radiation Dose
618562|NCT00251316|Radiation Effect
618563|NCT00251316|Pharmaceutical Adjuvant
618564|NCT00251316|Thyroid Cancer
618565|NCT00251303|Clinical Trial
618566|NCT00251303|Glutamate Antagonist
618567|NCT00251303|Pediatrics
618568|NCT00251303|Basal Ganglia
618569|NCT00251303|Neuropsychological
618570|NCT00251303|Obsessive Compulsive Disorder
618571|NCT00251303|OCD
618572|NCT00251303|Riluzole
618573|NCT00251303|Rilutek
618574|NCT00251290|transient ischemic attack
618575|NCT00251290|sleep apnea
618576|NCT00251277|Thrombotic Thrombocytopenic Purpura
618577|NCT00251277|TTP
618578|NCT00251277|Hematology
618579|NCT00251264|Shoulder instability
618580|NCT00251264|Traumatic
618581|NCT00251264|Anterior
618582|NCT00251264|Unidirectional
618583|NCT00251264|Open stabilization
618584|NCT00251264|Arthroscopic
618585|NCT00251264|Bankart repair
618586|NCT00251264|Shoulder instability, traumatic
618587|NCT00251264|Anterior, unidirectional instability
618588|NCT00251264|Bankart
618589|NCT00251251|Congestive heart failure
618590|NCT00251251|Multicentre randomized controlled trial
618591|NCT00251251|Defibrillator
618592|NCT00251251|Cardiac resynchronization
618593|NCT00251251|Sudden death/mortality
618594|NCT00251251|Hospitalization
618595|NCT00251251|ICD indication
618596|NCT00251251|NYHA Class II
618597|NCT00251251|LVEF </equal to 30%
618598|NCT00251251|QRS >/equal to 120 ms
618599|NCT00251238|Raynaud´s phenomenon
618600|NCT00251238|Vasospastic attacks
618601|NCT00251238|Ginkgo biloba
618602|NCT00251225|prostate
618603|NCT00251212|Alcohol
618604|NCT00251212|Violence
618605|NCT00251212|Alcohol consumption
618606|NCT00251212|Alcohol, drinking
618607|NCT00251160|Multi-directional instability
618608|NCT00251160|MDI
618609|NCT00251160|Ligamentous laxity
618610|NCT00251160|Multi-directional laxity
618611|NCT00251160|MDL-AII
618612|NCT00251160|Shoulder instability
618613|NCT00251160|electrothermal capsulorrhaphy, ETAC
618614|NCT00251160|inferior capsular shift, ICS
618615|NCT00251160|capsular redundancy
618616|NCT00251147|rotator cuff
618617|NCT00251147|open
618618|NCT00251147|arthroscopic
618619|NCT00251147|mini-open
618620|NCT00251147|acromioplasty
618621|NCT00251147|quality of life
618622|NCT00251147|shoulder
618623|NCT00251134|myocardial infarction
618624|NCT00251134|omega 3-fatty acids
618625|NCT00251121|Electrophysiological study
618626|NCT00251121|paroxysmal tachycardia
618627|NCT00251108|'traumatic brain injury'
618628|NCT00251108|'head injury'
618629|NCT00251108|'brain injuries'
618630|NCT00251108|'exercise therapy'
618631|NCT00251108|'physical fitness'
618632|NCT00251095|Metastatic Breast Cancer
618633|NCT00250822|Liver
618634|NCT00250822|hepatocellular
618635|NCT00250822|Gem-Ox
618636|NCT00250822|Cancer
618637|NCT00250796|Phase II
618638|NCT00250796|Hepatocellular carcinoma
618639|NCT00250783|Corpus Uteri
618640|NCT00250783|Endometrium
618641|NCT00250783|Cancer
618642|NCT00250770|Corpus Uteri
618643|NCT00250770|Endometrium
618644|NCT00250770|Cancer
618645|NCT00250757|prostate
618646|NCT00250757|NMR Spectroscopy
618647|NCT00250744|delayed nausea and vomiting
618648|NCT00250744|Emetogenic Chemotherapy
618649|NCT00250744|Pilot Trial
618650|NCT00250731|diabetes
618651|NCT00250731|relationship
618652|NCT00250731|social support
618653|NCT00250731|behavior change
618654|NCT00250731|telemedicine
618655|NCT00250718|Non Hodgkin's Lymphoma
618656|NCT00250718|Phase II
618657|NCT00250718|Lymphoid malignancies
618658|NCT00250705|Aripiprazole
618659|NCT00250679|COPD
618660|NCT00250679|chronic bronchitis
618661|NCT00250679|emphysema
618662|NCT00250666|Biological Markers
618663|NCT00250666|Procalcitonin
618664|NCT00250666|Critical Care
618665|NCT00250666|Diagnosis, Differential
618666|NCT00250666|Prospective Study
618667|NCT00250666|Sepsis
618668|NCT00250666|Antibiotic stewardship
618669|NCT00250666|Antimicrobial resistance
618670|NCT00250653|depression
618671|NCT00250653|antidepressive agents
618672|NCT00250653|clinical trial
618673|NCT00250640|Primary Pulmonary hypertension
618675|NCT00250627|antidepressive agents
618676|NCT00250627|controlled clinical trial
618677|NCT00250614|depression
618678|NCT00250614|antidepressive agents
618679|NCT00250614|controlled clinical trial
618680|NCT00250601|depression
618681|NCT00250601|antidepressive agents
618682|NCT00250601|controlled clinical trial
618683|NCT00250588|Asthma
618684|NCT00250588|Child
618685|NCT00250588|Problem-solving
618686|NCT00250588|Quality of Life
618687|NCT00250588|Barriers to Care
618688|NCT00250575|Schizophrenia, treatment-resistant, clozapine
618689|NCT00250562|Hypertension
618690|NCT00250562|Angiotensin II receptor blocker
618691|NCT00250562|fixed combination
618692|NCT00250562|diuretics
618693|NCT00250549|HIV
618694|NCT00250549|Prevention
618695|NCT00250549|Rapid HIV testing
618696|NCT00250523|trauma
618697|NCT00250523|critical illness
618698|NCT00250523|injury
618699|NCT00250510|Obesity treatment
618700|NCT00250510|Insurance reimbursement
618701|NCT00250510|Health care utilization
618702|NCT00250510|Health care costs
618703|NCT00250497|Adolescent
618704|NCT00250497|Girls
618705|NCT00250497|Physical Activity
618706|NCT00250497|Exercise
618707|NCT00250497|Diet
618708|NCT00250497|Body image
618709|NCT00250484|analgesia
618710|NCT00250484|electric stimulation therapy
618711|NCT00250484|electric stimulation
618712|NCT00250484|pain
618713|NCT00250484|safety
618714|NCT00250471|GP IIb/IIIa inhibitors
618715|NCT00250471|eptifibatide
618716|NCT00250471|Anti-thrombotic agents
618717|NCT00250445|Arcoxia
618718|NCT00250406|urolithiasis
618719|NCT00250406|ureteral stent
618720|NCT00250406|triclosan
618721|NCT00250406|drug eluting
618722|NCT00250393|Parkinson's disease
618723|NCT00250393|monotherapy
618724|NCT00250380|Aspirin
618725|NCT00250380|Platelet Aggregation Inhibitors
618726|NCT00250367|risperidone
618727|NCT00250367|antipsychotic agents
618728|NCT00250367|bipolar disorders
618729|NCT00250367|manic episode
618730|NCT00250354|conduct disorder
618731|NCT00250354|oppositional deficit disorder
618732|NCT00250354|disruptive behavior disorder not otherwise specified
618733|NCT00250354|ADHD
618734|NCT00250354|risperidone
618735|NCT00250354|antipsychotropic agents
618736|NCT00250354|children
618737|NCT00250289|malodor
618738|NCT00250289|halitosis
618739|NCT00250289|herbal formulation
618740|NCT00250289|natural medicinals
618741|NCT00250289|slow release delivery system
618742|NCT00250263|rhinitis
618743|NCT00250263|asthma
618744|NCT00250263|atopy
618745|NCT00250263|house dust mite
618746|NCT00250263|immunotherapy
618747|NCT00250263|SLIT
618748|NCT00250237|Post-operative delirium
618749|NCT00250237|hip fracture
618750|NCT00250224|Radiotherapy
618751|NCT00250224|image guided
618752|NCT00250224|marker
618753|NCT00250211|magnetic resonance imaging, functional
618754|NCT00250211|radiation therapy
618755|NCT00250211|temozolomide
618756|NCT00250211|functional imaging
618757|NCT00250211|concurrent chemoradiation
618758|NCT00250198|T Cell
618759|NCT00250198|Lymphocyte
618760|NCT00250198|Lamina Propria
618761|NCT00250198|Colonoscopy
618762|NCT00250198|Placebo
618763|NCT00250198|Crohn's Disease
618764|NCT00250198|Crohns Disease
618765|NCT00250185|Ischemia Tolerance
618766|NCT00250185|Endothelial Function
618767|NCT00250185|Forearm Blood Flow
618768|NCT00250185|Muscle Recovery
618769|NCT00250185|Inflammation
618770|NCT00250185|Healthy Volunteer
618771|NCT00250185|HV
618772|NCT00250172|Dosimetry
618773|NCT00250172|Pharmacokinetics
618774|NCT00250172|Compartment Analysis
618775|NCT00250172|Reproducibility
618776|NCT00250172|Healthy Volunteer
618777|NCT00250172|HV
618778|NCT00250159|Congenital Adrenal Hyperplasia (CAH)
618779|NCT00250159|Familial Male Precocious Puberty (FMPP)
618780|NCT00250159|21-hydroxylast deficiency
618781|NCT00250159|Congenital Adrenal Hyperplasia
618782|NCT00250159|CAH
618783|NCT00250159|Familial Male Precocious Puberty
618784|NCT00250159|FMPP
618785|NCT00250146|Celiac Disease
618786|NCT00250146|Gluten
618787|NCT00250146|Toxicity
618788|NCT00250146|Small bowel morphometry
618789|NCT00250133|selective decontamination of the digestive tract
618790|NCT00250120|NSCLC
618791|NCT00250120|L9NC
618792|NCT00250120|Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin
618793|NCT00250094|Phase I
618794|NCT00250094|Ovarian Cancer
618795|NCT00250094|Ovary
618796|NCT00250094|Cancer
618797|NCT00250081|Cerebral Palsy
618798|NCT00250081|Tendon Transfer
618799|NCT00250081|Botulinum Toxin Type A
618800|NCT00250081|Occupational Therapy
618801|NCT00250081|Child
618802|NCT00250068|Phase II
618803|NCT00250068|Aerosol Delivery
618804|NCT00250068|NSCLC
618805|NCT00250068|9-Nitrocamptothecin
618806|NCT00250055|NIH
618807|NCT00250055|Non-Invasive diagnosis of cervical tissue
618808|NCT00250055|Los Alamos/NIH
618809|NCT00250029|Colorectal Cancer
618810|NCT00250029|Pilot Study
618811|NCT00250029|Oxaliplatin
618812|NCT00250016|Endometrium
618813|NCT00250016|Tissue
618814|NCT00250016|L9NC
618815|NCT00250003|Elderly
618816|NCT00250003|Preventive home visits
618817|NCT00249990|Uterus
618818|NCT00249990|Recurrent disease
618819|NCT00249990|Treatment
618820|NCT00249990|9-Nitrocamptothecin
618821|NCT00249990|Endometrium
618822|NCT00249977|Phase I
618823|NCT00249977|solid tumors
618824|NCT00249977|DNA repair
618825|NCT00249964|Extensive or recurrent small cell lung cancer Phase I
618826|NCT00249964|Paclitaxel, Carboplatin, Temozolomide
618827|NCT00249951|nephrocalcinosis
618828|NCT00249951|premature infants
618829|NCT00249951|hypocitraturia
618830|NCT00249951|alcaline citrate therapy
618831|NCT00249951|Nephrocalcinosis in premature infants
618832|NCT00249938|Antilipemic agents
618833|NCT00249938|hyperlipidemia
618834|NCT00249925|Home modification
618835|NCT00249925|Occupational Therapy
618836|NCT00249925|Physical Therapy
618837|NCT00249925|Home care
618838|NCT00249912|Hyperlipidemia
618839|NCT00249912|Drug Therapy
618840|NCT00249899|Hyperlipidemia
618841|NCT00249899|Drug Therapy
618842|NCT00249873|Atrial fibrillation
618843|NCT00249873|Anticoagulant therapy
618844|NCT00249873|Thromboembolic prevention
618845|NCT00249860|Subjects with chronic hepatitis C who have never previously received interferon therapy.
618846|NCT00249847|Hot flashes, vasomotor symptoms, estrogen, paroxetine
618847|NCT00249834|Healthy female partners of infertile couples justifying Assisted Reproductive Technology (ART) treatment.
618848|NCT00249808|Candidates for systemic therapy for psoriasis
618849|NCT00249795|Atrial fibrillation
618850|NCT00249795|Cardiovascular disease
618851|NCT00249795|angiotensin II blocker
618852|NCT00249782|rosacea, Papulopustular Rosacea,erythema, dapsone
618853|NCT00249769|Japanese Encephalitis
618854|NCT00249769|Japanese B Encephalitis
618855|NCT00249769|Japanese B Viral Encephalitis
618856|NCT00249769|Viral Encephalitis, Japanese B
618857|NCT00249756|Criminal Justice
618858|NCT00249743|fall prevention
618859|NCT00249743|fall risk management
618860|NCT00249743|RCT
618861|NCT00249743|cost
618862|NCT00249717|Contingency management
618863|NCT00249717|Substance abuse treatment
618864|NCT00249691|cocaine addiction
618865|NCT00249691|cocaine dependence
618866|NCT00249678|Behavior Therapy
618867|NCT00249678|methamphetamine
618868|NCT00249652|End stage liver disease
618869|NCT00249652|End stage renal disease
618870|NCT00249652|Substance-Related Disorders
618871|NCT00249639|Contingency Management
618872|NCT00249639|Substance Abuse Treatment
618873|NCT00249626|Contingency management
618874|NCT00249626|substance abuse treatment
618875|NCT00249613|gender-responsive substance abuse treatment
618876|NCT00249600|contingency management
618877|NCT00249600|substance abuse
618878|NCT00249574|heroin addiction
618879|NCT00249548|contingency management
618880|NCT00249548|substance abuse
618881|NCT00249535|Substance Abuse
618882|NCT00249535|Contingency Management
618883|NCT00249522|contingency management
618884|NCT00249522|substance abuse treatment
618885|NCT00249509|marijuana dependence
618886|NCT00249496|cocaine
618887|NCT00249496|opioids
618888|NCT00249496|contingency management
618889|NCT00249496|sexual risk
618890|NCT00249496|HIV
618891|NCT00249483|Cocaine Addiction
618892|NCT00249483|Cocaine Dependence
618893|NCT00249470|HIV
618894|NCT00249470|HIV risk behaviors
618895|NCT00249470|Heroin
618896|NCT00249470|Cocaine
618897|NCT00249470|Methadone
618898|NCT00249470|Opioid Dependence
618899|NCT00249470|Cocaine Abuse
618900|NCT00249470|Contingency management
618901|NCT00249470|alcohol & drug use
618902|NCT00249470|sexual risk behaviors
618903|NCT00249457|Behavior Therapy
618904|NCT00249457|Cocaine Abuse
618905|NCT00249457|Cocaine Dependence
618906|NCT00249457|Contingency Management
618907|NCT00249457|Heroin Dependence
618908|NCT00249457|Methadone
618909|NCT00249457|Opioid Dependence
618910|NCT00249418|Contingency Management
618911|NCT00249418|Substance Abuse Treatment
618912|NCT00249405|Clinical trial
618913|NCT00249405|Alcoholism
618914|NCT00249405|Alcohol
618915|NCT00249405|Pharmacogenetics
618916|NCT00249405|Citalopram
618917|NCT00249405|Genotype
618918|NCT00249405|Therapy compliance
618919|NCT00249405|Serotonin inhibitor
618920|NCT00249405|Alcoholism/alcohol abuse therapy
618921|NCT00249392|ocular diseases
618922|NCT00249392|risk factors
618923|NCT00249392|genetic factors
618924|NCT00249379|Alcohol dependence
618925|NCT00249379|Acamprosate(drug)
618926|NCT00249379|Drug Court
618927|NCT00249379|Probation
618928|NCT00249379|Parole
618929|NCT00249379|Criminal justice
618930|NCT00249366|Alcohol withdrawal
618931|NCT00249366|Symptom-triggered therapy
618932|NCT00249366|Fixed-schedule therapy
618933|NCT00249366|CIWA-Ar
618934|NCT00249366|Lorazepam (drug)
618935|NCT00249353|Attention Deficit Hyperactivity Disorder
618936|NCT00249353|ADHD
618937|NCT00249353|Concerta
618938|NCT00249340|behavioral weight loss treatment
618939|NCT00249340|brief behavioral treatment
618940|NCT00249340|commercial weight loss programs
618941|NCT00249340|Weight Watchers
618942|NCT00249327|HIV testing
618943|NCT00249327|HIV disclosure
618944|NCT00249327|HIV Seronegativity
618945|NCT00249314|South Asians
618946|NCT00249314|European Caucasians
618947|NCT00249314|ethnic differences
618948|NCT00249314|body composition
618949|NCT00249314|body fat distribution
618950|NCT00249314|adipose tissue
618951|NCT00249314|visceral fat
618952|NCT00249314|myocellular lipids
618953|NCT00249314|skeletal muscle
618954|NCT00249301|Breast Cancer
618955|NCT00249301|Colon Cancer
618956|NCT00249301|Pancreatic Cancer
618957|NCT00249301|Bladder Cancer
618958|NCT00249288|Schizophrenia
618959|NCT00249288|Negative Symptoms
618960|NCT00249288|Folate
618961|NCT00249275|significant refractive errors
618962|NCT00249275|children
618963|NCT00249275|spectacles
618964|NCT00249275|Africa
618965|NCT00249249|hypercholesterolemia
618966|NCT00249249|dyslipidemia
618967|NCT00249249|kowa
618968|NCT00249249|KRE
618969|NCT00249249|pitavastatin
618970|NCT00249249|NK-104
618971|NCT00249236|risperidone
618972|NCT00249236|antipsychotic agents
618973|NCT00249236|bipolar disorders
618974|NCT00249236|manic episode
618975|NCT00249223|chronic schizophrenia, psychotic disorder, risperidone, long-acting injectable, intramuscular injection, antipsychotic agents
618976|NCT00249210|Sinusitis
618977|NCT00249210|respiratory tract diseases
618978|NCT00249210|nose diseases
618979|NCT00249210|respiratory tract infections
618980|NCT00249210|paranasal sinus diseases
618981|NCT00249210|antibacterial agents
618982|NCT00249210|quinolones
618983|NCT00249210|levofloxacin
618984|NCT00249197|skin infection
618985|NCT00249197|bacterial infection
618986|NCT00249197|levofloxacin
618987|NCT00249197|quinolones
618988|NCT00249197|skin
618989|NCT00249197|infection
618990|NCT00249171|acute schizophrenia
618991|NCT00249171|psychosis
618992|NCT00249171|risperidone
618993|NCT00249171|lorazepam, antipsychotic agents
618994|NCT00249171|emergency treatment
618995|NCT00249158|Dementia
618996|NCT00249158|Alzheimer's Disease
618997|NCT00249158|vascular dementia
618998|NCT00249158|mixed dementia
618999|NCT00249158|risperidone
619000|NCT00249158|nursing home
619001|NCT00249145|Dementia
619002|NCT00249145|Alzheimer's Disease
619003|NCT00249145|vascular dementia
619004|NCT00249145|mixed dementia, risperidone
619005|NCT00249145|nursing home
619006|NCT00249132|chronic schizophrenia
619007|NCT00249132|psychotic disorder
619008|NCT00249132|risperidone
619009|NCT00249132|antipsychotic agents
619010|NCT00249119|chronic schizophrenia
619011|NCT00249119|psychotic disorders
619012|NCT00249119|risperidone
619013|NCT00249119|antipsychotic agents
619014|NCT00248066|Coronary artery disease
619015|NCT00248066|Restenosis
619016|NCT00248066|Coronary stent restenosis
619017|NCT00248053|Familial adenomatous polyposis patient with 5 or more adenomatous polyps in the colon or ileoanal pouch
619018|NCT00248040|Kidney transplantation
619019|NCT00248040|Reperfusion Injury
619020|NCT00248040|Survival
619021|NCT00248027|early intervention,program evaluation
619022|NCT00248014|CLASS II
619023|NCT00248014|FUNCTIONAL APPLIANCE
619024|NCT00248014|MANDIBULAR ADVANCEMENT STABILITY
619025|NCT00247988|Ovarian
619026|NCT00247988|Relapsed
619027|NCT00247975|L-carnitine
619028|NCT00247975|Breast cancer
619029|NCT00247975|Anthracycline Cardiotoxicity
619030|NCT00247975|Primary prevention
619031|NCT00247975|Anthracycline induced cardiotoxicity
619032|NCT00247975|Left Ventricular Ejection Fraction
619033|NCT00247962|Ankylosing Spondylitis (AS)
619034|NCT00247949|carbon dioxide
619035|NCT00247949|monitoring
619036|NCT00247949|major surgery
619037|NCT00247949|repeated blood gas testing
619038|NCT00247949|carbon dioxide monitoring
619039|NCT00247936|Adenocarcinoma, Esophagectomy
619040|NCT00247923|Endometrial polyps.
619041|NCT00247923|Angiogenesis.
619042|NCT00247923|Asymptomatic.
619043|NCT00247923|Symptoms.
619044|NCT00247923|Malignancy.
619045|NCT00247923|Treatment efficiency.
619046|NCT00247923|Vaginal bleeding.
619047|NCT00247910|hypertension, ambulatory BP, office resting BP, hydrochlorothiazide, stress reduction, self-help, psychotherapy, efficacy
619048|NCT00247884|Injection drug users
619049|NCT00247884|pegylated interferon
619050|NCT00247884|ribavirin,
619051|NCT00247884|HCV
619052|NCT00247871|MRSA, USA300, CMRSA-10, CMRSA-6, soft tissue abscesses
619053|NCT00247858|MRSA, USA300, CMRSA-10, CMRSA-6, soft tissue abscesses
619054|NCT00247845|HIV
619055|NCT00247845|Atazanavir
619056|NCT00247845|quality of life
619057|NCT00247845|Treatment Experienced
619058|NCT00247832|Monitoring, early mobilization, motivation modality, visitation rate, step rates, anxiety, pain
619059|NCT00247832|Elective lobectomy
619060|NCT00247819|Substance abuse
619061|NCT00247806|Pilot, pediatric, stem cell transplant, lactose intolerance
619062|NCT00249080|3T MRI
619063|NCT00249080|neurodegenerative disease
619064|NCT00249080|Alzheimer's disease
619065|NCT00249080|spectroscopy
619066|NCT00249080|Normal, healthy subject without memory complaint
619067|NCT00249080|Not pregnant
619068|NCT00249080|MR compatible
619069|NCT00249067|Congestive Heart Failure, Left-to-Right Shunt
619070|NCT00249041|Rheumatoid Arthritis, Enbrel liquid, antibodies
619071|NCT00249015|aerobic exercise
619072|NCT00249015|resistance exercise
619073|NCT00249015|physical fitness
619074|NCT00249015|body composition
619075|NCT00249015|quality of life
619076|NCT00249015|rehabilitation
619077|NCT00249015|psychosocial oncology
619078|NCT00249015|adherence
619079|NCT00249002|Vascular Access Graft Failure
619080|NCT00249002|Venous Neointimal Hyperplasia(VNH)
619081|NCT00249002|Hemodialysis
619082|NCT00248989|Skin aging
619083|NCT00248989|Menopausal symptoms
619084|NCT00248976|Angioplasty
619085|NCT00248976|Motivating behavior change
619086|NCT00248976|Reducing risk factors
619087|NCT00248976|Enhancing quality of life
619088|NCT00248976|Improving treatment outcomes
619089|NCT00248963|Oral Contraceptive
619090|NCT00248950|Angioplasty
619091|NCT00248950|Behavior Change
619092|NCT00248937|African-American
619093|NCT00248937|Hypertension
619094|NCT00248937|Medication adherence
619095|NCT00248937|Risk reduction
619096|NCT00248924|Social service intervention
619097|NCT00248924|Social support
619098|NCT00248924|Elderly
619099|NCT00248924|Homebound
619100|NCT00248924|Quality of life
619101|NCT00248911|Breast cancer
619102|NCT00248911|Gynecologic cancers
619103|NCT00248911|Meditation
619104|NCT00248911|Stress-reduction
619105|NCT00248911|Cognitive-affective behavioral learning
619106|NCT00248898|nonagenarians
619107|NCT00248898|quality of life
619108|NCT00248898|cardiothoracic surgery
619109|NCT00248898|long term survival
619110|NCT00248885|Coronary artery bypass graft surgery
619111|NCT00248885|Perioperative complications
619112|NCT00248885|Neurocognitive function
619113|NCT00248885|Quality of life
619114|NCT00248885|Blood pressure
619115|NCT00248872|African-American
619116|NCT00248872|Hypertension
619117|NCT00248872|Medication adherence
619118|NCT00248872|Risk reduction
619119|NCT00248859|Coronary artery disease
619120|NCT00248859|Depressive symptoms
619121|NCT00248859|Latino American
619122|NCT00248846|Angioplasty patients
619123|NCT00248846|Behavior change
619124|NCT00248846|Physical activity
619125|NCT00248846|Risk reduction
619126|NCT00248820|Contrast-enhanced Ultrasound
619127|NCT00248820|Ultrasound Contrast agent, microbubbles
619128|NCT00248820|Ovarian tumor
619129|NCT00248820|vascularization
619130|NCT00248807|Blood Pressure, Low
619131|NCT00248807|Hypotension, Postural
619132|NCT00248807|Injuries, Spinal Cord
619133|NCT00248807|Spinal Cord Transection
619134|NCT00248807|Spinal Cord Trauma
619135|NCT00248794|Cognitive Impairment
619136|NCT00248794|Rehabilitation
619137|NCT00248781|Activities of daily living
619138|NCT00248781|Aging
619139|NCT00248781|Exercise
619140|NCT00248781|Weight lifting
619141|NCT00248768|Depression
619142|NCT00248768|Parkinson Disease
619143|NCT00248768|Transcranial Magnetic Stimulation
619144|NCT00248755|cystic fibrosis
619145|NCT00248755|mucociliary clearance
619146|NCT00248755|nuclear medicine
619147|NCT00248742|IBD, psychological, stress management
619148|NCT00248703|Disseminating tumor cells,breast cancer,docetaxel,adjuvant
619149|NCT00248690|Subarachnoid hemorrhage
619150|NCT00248690|Intracranial hypertension
619151|NCT00248690|Intracranial pressure
619152|NCT00248690|Diagnostic techniques and procedures
619153|NCT00248690|Compliance
619154|NCT00248690|Treatment outcome
619155|NCT00248690|Intensive care, surgical
619156|NCT00248664|Cystitis, Interstitial
619157|NCT00248664|Case-Control Studies
619158|NCT00248664|Risk Factors
619159|NCT00248651|Bloating
619160|NCT00248651|Early Fullness
619161|NCT00248651|Nausea
619162|NCT00248651|Upper Abdominal Discomfort
619163|NCT00248651|dyspepsia
619164|NCT00248651|stomach pain
619165|NCT00248651|stomach discomfort
619166|NCT00248625|acute liver failure
619167|NCT00248625|hepatic encephalopathy
619168|NCT00248625|acetaminophen toxicity
619169|NCT00248625|N-acetylcysteine
619170|NCT00248612|Venlafaxine
619171|NCT00248612|Alcoholism
619172|NCT00248612|Anxiety Disorders
619173|NCT00248612|Alcohol-Use Disorders
619174|NCT00248612|Alcohol Abuse
619175|NCT00248612|Alcohol Dependence
619176|NCT00248612|Cognitive Behavioral Treatment
619177|NCT00248560|recurrent squamous cell carcinoma of the hypopharynx
619178|NCT00248560|stage IV squamous cell carcinoma of the hypopharynx
619179|NCT00248560|recurrent squamous cell carcinoma of the larynx
619180|NCT00248560|stage IV squamous cell carcinoma of the larynx
619181|NCT00248560|recurrent squamous cell carcinoma of the lip and oral cavity
619182|NCT00248560|stage IV squamous cell carcinoma of the lip and oral cavity
619183|NCT00248560|metastatic squamous neck cancer with occult primary squamous cell carcinoma
619184|NCT00248560|recurrent metastatic squamous neck cancer with occult primary
619185|NCT00248560|recurrent squamous cell carcinoma of the nasopharynx
619186|NCT00248560|stage IV squamous cell carcinoma of the nasopharynx
619187|NCT00248560|recurrent squamous cell carcinoma of the oropharynx
619188|NCT00248560|stage IV squamous cell carcinoma of the oropharynx
619189|NCT00248560|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
619190|NCT00248560|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
619191|NCT00248547|nausea and vomiting
619192|NCT00248547|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
619193|NCT00248547|adult acute myeloid leukemia with inv(16)(p13;q22)
619194|NCT00248547|adult acute myeloid leukemia with t(15;17)(q22;q12)
619195|NCT00248547|adult acute myeloid leukemia with t(16;16)(p13;q22)
619196|NCT00248547|adult acute myeloid leukemia with t(8;21)(q22;q22)
619197|NCT00248547|accelerated phase chronic myelogenous leukemia
619198|NCT00248547|adult acute lymphoblastic leukemia in remission
619199|NCT00248547|adult acute myeloid leukemia in remission
619200|NCT00248547|atypical chronic myeloid leukemia
619201|NCT00248547|blastic phase chronic myelogenous leukemia
619202|NCT00248547|chronic eosinophilic leukemia
619203|NCT00248547|chronic idiopathic myelofibrosis
619204|NCT00248547|chronic myelomonocytic leukemia
619205|NCT00248547|chronic neutrophilic leukemia
619206|NCT00248547|chronic phase chronic myelogenous leukemia
619207|NCT00248547|de novo myelodysplastic syndromes
619208|NCT00248547|disseminated neuroblastoma
619209|NCT00248547|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
619210|NCT00248547|myelodysplastic/myeloproliferative disease, unclassifiable
619211|NCT00248547|nodal marginal zone B-cell lymphoma
619212|NCT00248547|noncontiguous stage II adult Burkitt lymphoma
619213|NCT00248547|noncontiguous stage II adult diffuse large cell lymphoma
619214|NCT00248547|noncontiguous stage II adult diffuse mixed cell lymphoma
619215|NCT00248547|noncontiguous stage II adult diffuse small cleaved cell lymphoma
619216|NCT00248547|noncontiguous stage II adult immunoblastic large cell lymphoma
619217|NCT00248547|noncontiguous stage II adult lymphoblastic lymphoma
619218|NCT00248547|noncontiguous stage II grade 1 follicular lymphoma
619219|NCT00248547|noncontiguous stage II grade 2 follicular lymphoma
619220|NCT00248547|noncontiguous stage II grade 3 follicular lymphoma
619221|NCT00248547|noncontiguous stage II mantle cell lymphoma
619222|NCT00248547|noncontiguous stage II marginal zone lymphoma
619223|NCT00248547|noncontiguous stage II small lymphocytic lymphoma
619224|NCT00248547|poor prognosis metastatic gestational trophoblastic tumor
619225|NCT00248547|previously treated myelodysplastic syndromes
619226|NCT00248547|recurrent adult acute lymphoblastic leukemia
619227|NCT00248547|recurrent adult acute myeloid leukemia
619228|NCT00248547|recurrent adult Burkitt lymphoma
619229|NCT00248547|recurrent adult Hodgkin lymphoma
619230|NCT00248547|recurrent adult diffuse large cell lymphoma
619231|NCT00248547|recurrent adult diffuse mixed cell lymphoma
619232|NCT00248547|recurrent adult diffuse small cleaved cell lymphoma
619233|NCT00248547|recurrent adult immunoblastic large cell lymphoma
619234|NCT00248547|recurrent adult lymphoblastic lymphoma
619235|NCT00248547|recurrent cutaneous T-cell non-Hodgkin lymphoma
619236|NCT00248547|recurrent grade 1 follicular lymphoma
619237|NCT00248547|recurrent grade 2 follicular lymphoma
619238|NCT00248547|recurrent grade 3 follicular lymphoma
619239|NCT00248547|recurrent mantle cell lymphoma
619240|NCT00248547|recurrent marginal zone lymphoma
619241|NCT00248547|recurrent mycosis fungoides/Sezary syndrome
619242|NCT00248547|recurrent neuroblastoma
619243|NCT00248547|recurrent ovarian epithelial cancer
619244|NCT00248547|recurrent ovarian germ cell tumor
619245|NCT00248547|recurrent small lymphocytic lymphoma
619246|NCT00248547|recurrent malignant testicular germ cell tumor
619247|NCT00248547|refractory chronic lymphocytic leukemia
619248|NCT00248547|refractory hairy cell leukemia
619249|NCT00248547|refractory multiple myeloma
619250|NCT00248547|relapsing chronic myelogenous leukemia
619251|NCT00248547|secondary acute myeloid leukemia
619252|NCT00248547|secondary myelodysplastic syndromes
619253|NCT00248547|splenic marginal zone lymphoma
619254|NCT00248547|stage I multiple myeloma
619255|NCT00248547|stage II multiple myeloma
619256|NCT00248547|stage II ovarian epithelial cancer
619257|NCT00248547|stage III adult Burkitt lymphoma
619258|NCT00248547|stage III adult Hodgkin lymphoma
619259|NCT00248547|stage III adult diffuse large cell lymphoma
619260|NCT00248547|stage III adult diffuse mixed cell lymphoma
619261|NCT00248547|stage III adult diffuse small cleaved cell lymphoma
619262|NCT00248547|stage III adult immunoblastic large cell lymphoma
619263|NCT00248547|stage III adult lymphoblastic lymphoma
619264|NCT00248547|stage III chronic lymphocytic leukemia
619265|NCT00248547|stage III grade 1 follicular lymphoma
619266|NCT00248547|stage III grade 2 follicular lymphoma
619267|NCT00248547|stage III grade 3 follicular lymphoma
619268|NCT00248547|stage III mantle cell lymphoma
619269|NCT00248547|stage III marginal zone lymphoma
619270|NCT00248547|stage III multiple myeloma
619271|NCT00248547|stage III ovarian epithelial cancer
619272|NCT00248547|stage III small lymphocytic lymphoma
619273|NCT00248547|stage III malignant testicular germ cell tumor
619274|NCT00248547|stage IIIA breast cancer
619275|NCT00248547|stage IIIB breast cancer
619276|NCT00248547|stage IIIC breast cancer
619277|NCT00248547|stage IV adult Burkitt lymphoma
619278|NCT00248547|stage IV adult Hodgkin lymphoma
619279|NCT00248547|stage IV adult diffuse large cell lymphoma
619280|NCT00248547|stage IV adult diffuse mixed cell lymphoma
619281|NCT00248547|stage IV adult diffuse small cleaved cell lymphoma
619282|NCT00248547|stage IV adult immunoblastic large cell lymphoma
619283|NCT00248547|stage IV adult lymphoblastic lymphoma
619284|NCT00248547|stage IV breast cancer
619285|NCT00248547|stage IV chronic lymphocytic leukemia
619286|NCT00248547|stage IV grade 1 follicular lymphoma
619287|NCT00248547|stage IV grade 2 follicular lymphoma
619288|NCT00248547|stage IV grade 3 follicular lymphoma
619289|NCT00248547|stage IV mantle cell lymphoma
619290|NCT00248547|stage IV marginal zone lymphoma
619291|NCT00248547|stage IV ovarian epithelial cancer
619292|NCT00248547|stage IV small lymphocytic lymphoma
619293|NCT00248547|unspecified adult solid tumor, protocol specific
619294|NCT00248534|primary central nervous system non-Hodgkin lymphoma
619295|NCT00248521|unspecified adult solid tumor, protocol specific
619296|NCT00248495|stage IIIA non-small cell lung cancer
619297|NCT00248495|stage IIIB non-small cell lung cancer
619298|NCT00248495|stage II non-small cell lung cancer
619299|NCT00248495|stage I non-small cell lung cancer
619300|NCT00248482|extensive stage small cell lung cancer
619301|NCT00248482|recurrent small cell lung cancer
619302|NCT00248469|Community randomised trial
619303|NCT00248469|Sexual behavior
619304|NCT00248469|Intervention
619305|NCT00248469|Evaluation
619306|NCT00248469|Sexual health education
619307|NCT00248469|Youth-friendly health services
619308|NCT00248469|Adolescents
619309|NCT00248469|Behavior change
619310|NCT00248469|HIV Seronegativity
619311|NCT00248469|HIV
619312|NCT00248443|Haematology and cancer patients
619313|NCT00248443|Acute respiratory failure
619314|NCT00248443|Bronchoalveolar lavage
619315|NCT00248443|Non invasive diagnostic tools
619316|NCT00248443|Mechanical ventilation
619317|NCT00248443|Intensive Care
619318|NCT00248430|graft versus host disease
619319|NCT00248430|stage II multiple myeloma
619320|NCT00248430|stage III multiple myeloma
619321|NCT00248430|refractory multiple myeloma
619322|NCT00248430|refractory chronic lymphocytic leukemia
619323|NCT00248430|stage III chronic lymphocytic leukemia
619324|NCT00248430|stage IV chronic lymphocytic leukemia
619325|NCT00248430|recurrent small lymphocytic lymphoma
619326|NCT00248430|stage III small lymphocytic lymphoma
619327|NCT00248430|stage IV small lymphocytic lymphoma
619328|NCT00248430|recurrent mantle cell lymphoma
619329|NCT00248430|stage III mantle cell lymphoma
619330|NCT00248430|stage IV mantle cell lymphoma
619331|NCT00248430|recurrent grade 1 follicular lymphoma
619332|NCT00248430|recurrent grade 2 follicular lymphoma
619333|NCT00248430|recurrent grade 3 follicular lymphoma
619334|NCT00248430|stage III grade 1 follicular lymphoma
619335|NCT00248430|stage III grade 2 follicular lymphoma
619336|NCT00248430|stage III grade 3 follicular lymphoma
619337|NCT00248430|stage IV grade 1 follicular lymphoma
619338|NCT00248430|stage IV grade 2 follicular lymphoma
619339|NCT00248430|stage IV grade 3 follicular lymphoma
619340|NCT00248404|colorectal cancer
619341|NCT00248404|ovarian cancer
619342|NCT00248404|lung cancer
619343|NCT00248404|breast cancer
619344|NCT00248404|small bowel cancer
619345|NCT00248404|Advanced, recurrent, or metastatic solid tumors of any type
619346|NCT00248404|TS overexpression confirmed by fresh biopsy (RTPCR)
619347|NCT00248404|Suitable for experimental monotherapy
619348|NCT00248391|adenoid hypertrophy
619349|NCT00248391|feeding position
619350|NCT00248391|supine
619351|NCT00248391|upright
619352|NCT00248391|pneumonia
619353|NCT00248391|wheezing
619354|NCT00248391|otitis
619355|NCT00248391|adenoid
619356|NCT00248391|tonsil
619357|NCT00248391|caries
619358|NCT00248378|Multiple Sclerosis
619359|NCT00248378|Cannabis
619360|NCT00248378|Spasticity
619361|NCT00248378|Tolerability
619362|NCT00248365|Chronic GvHD
619363|NCT00248365|Extensive chronic GvHD
619364|NCT00248365|Resistant chronic GvHD
619365|NCT00248352|Coronary Artery Disease
619366|NCT00248352|Diabetes Mellitus
619367|NCT00248352|Type 2
619368|NCT00248352|Chronic Disease
619369|NCT00248339|Hepatitis C
619370|NCT00248339|Peginterferon
619371|NCT00248339|Ribavirin
619372|NCT00248339|Procrit
619373|NCT00248339|Epoetin-alpha
619374|NCT00248326|atrial fibrillation
619375|NCT00248326|genetics
619376|NCT00248326|genetic polymorphisms
619377|NCT00248313|Kidney Disease
619378|NCT00248300|ventilator-associated pneumonia
619379|NCT00248300|hospital acquired pneumonia
619380|NCT00248274|atrial fibrillation
619381|NCT00248274|genetics
619382|NCT00248261|ziprasidone, sertraline, PTSD
619383|NCT00248248|Consolidation
619384|NCT00248248|Ovarian cancer
619385|NCT00248248|DOXIL
619386|NCT00248248|Hand-foot syndrome
619387|NCT00248235|exercise
619388|NCT00248235|rehabilitation
619389|NCT00248235|head and neck neoplasms
619390|NCT00248222|Exercise
619391|NCT00248222|Rehabilitation
619392|NCT00248222|Aerobic training
619393|NCT00248209|Female Orgasmic Disorder
619394|NCT00248209|Female Sexual Dysfunction
619395|NCT00248170|Breast cancer
619396|NCT00248170|letrozole
619397|NCT00248170|anastrozole
619398|NCT00248170|adjuvant
619399|NCT00248170|postmenopausal
619400|NCT00248170|FACE
619401|NCT00248157|Diabetic retinopathy
619402|NCT00248157|Octreotide acetate in microspheres
619403|NCT00248144|Herpes labialis
619404|NCT00248131|Diabetic retinopathy, octreotide acetate in microspheres
619405|NCT00248118|Randomized
619406|NCT00248118|Double-blind
619407|NCT00248118|Placebo-controlled
619408|NCT00248105|Arthritis
619409|NCT00248105|Physical Activity
619410|NCT00248092|d-Amphetamine
619411|NCT00248092|Diethylpropion
619412|NCT00248092|Diethylpropion Hydrochloride
619413|NCT00248092|Attention Deficit Hyperactivity Disorder
619414|NCT00248092|Attention Deficit Disorders with Hyperactivity
619415|NCT00248092|Attention Deficit Hyperactivity Disorders
619416|NCT00248092|Amphetamine Abuse
619417|NCT00248092|Amphetamine Dependence
619418|NCT00248092|Amphetamine Addiction
619419|NCT00248092|Amphetamine Users
619420|NCT00248092|Drug Abuse
619421|NCT00248092|Drug Addiction
619422|NCT00248092|Drug Dependence
619423|NCT00248092|Drug Habituation
619424|NCT00248092|Drug Use Disorders
619425|NCT00248092|Substance Abuse
619426|NCT00248092|Substance Dependence
619427|NCT00248092|Substance Use Disorders
619428|NCT00248092|Drug Usage
619429|NCT00248092|Substance Addiction
619430|NCT00248079|Coronary Disease
619431|NCT00247793|immunonutrition
619432|NCT00247793|preoperative optimization
619433|NCT00247793|preoperative enteral nutritional supplement
619434|NCT00247793|high risk
619435|NCT00247793|cardiac surgery
619436|NCT00247793|arginine
619437|NCT00247793|omega-3 polyunsaturated fatty acids
619438|NCT00247793|nucleotides
619439|NCT00247793|glycine
619440|NCT00247793|immune enhancing nutritional supplement
619441|NCT00247793|immune enhancing formula
619442|NCT00247780|Atrial fibrillation
619443|NCT00247780|Pulmonary vein isolation
619444|NCT00247780|Tissue Doppler echocardiography
619445|NCT00247754|Anxiety
619446|NCT00247754|Therapy
619447|NCT00247754|Behaviour
619448|NCT00247741|spinal anesthesia
619449|NCT00247741|lidocaine
619450|NCT00247741|articaine
619451|NCT00247741|intrathecal
619452|NCT00247728|PI-88
619453|NCT00247728|post resection hepatoma
619454|NCT00247728|adjuvant therapy
619455|NCT00247728|hepatectomy
619456|NCT00247728|hepatoma
619457|NCT00247715|uninvestigated dyspepsia
619458|NCT00247715|cost effectiveness
619459|NCT00247715|acid suppressive medicine
619460|NCT00247715|primary care
619461|NCT00247715|gastrointestinal complaints
619462|NCT00247715|Gastrointestinal drugs
619463|NCT00247702|CYP2C9
619464|NCT00247702|VKORC1
619465|NCT00247702|polymorphism
619466|NCT00247702|warfarin
619467|NCT00247689|Ritalin
619468|NCT00247689|Substance Abuse
619469|NCT00247689|Allelic Variants
619470|NCT00247689|Genotype
619471|NCT00247689|Addiction-Associated Human Gene Variants
619472|NCT00247689|Methylphenidate
619473|NCT00247676|Liver neoplasms, sunitinib, Phase 2
619474|NCT00247663|Aromatase inhibitor
619475|NCT00247663|letrozole
619476|NCT00247663|breast cancer
619477|NCT00247650|neoadjuvant, postmenopausal women, breast cancer, hormonal therapy, bisphosphonate
619478|NCT00247637|Mental Health
619479|NCT00247637|Psychosis
619480|NCT00247637|Genetics
619481|NCT00247637|Heredity
619482|NCT00247624|Depression
619483|NCT00247624|Hypnotics
619484|NCT00247624|Sleep
619485|NCT00247624|Quality of Life
619486|NCT00247624|Insomnia
619487|NCT00247624|Suicide
619488|NCT00247611|HIV
619489|NCT00247611|AIDS
619490|NCT00247611|Antiretroviral Medication Adherence
619491|NCT00247585|Alcohol
619492|NCT00247585|Alcohol abuse
619493|NCT00247585|Alcohol consumption
619494|NCT00247585|Unhealthy alcohol use
619495|NCT00247585|Residual effects
619496|NCT00247585|Sleep Stages
619497|NCT00247585|Respiratory Physiology
619498|NCT00247572|d-Amphetamine
619499|NCT00247572|Attention Deficit Hyperactivity Disorder
619500|NCT00247572|Attention Deficit Disorders with Hyperactivity
619501|NCT00247572|Attention Deficit Hyperactivity Disorders
619502|NCT00247572|Amphetamine Abuse
619503|NCT00247572|Amphetamine Dependence
619504|NCT00247572|Amphetamine Addiction
619505|NCT00247572|Amphetamine Users
619506|NCT00247572|Drug Abuse
619507|NCT00247572|Drug Addiction
619508|NCT00247572|Drug Dependence
619509|NCT00247572|Drug Habituation
619510|NCT00247572|Drug Use Disorders
619511|NCT00247572|Substance Abuse
619512|NCT00247572|Substance Dependence
619513|NCT00247572|Substance Use Disorders
619514|NCT00247572|Drug Usage
619515|NCT00247572|Substance Addiction
619516|NCT00247572|Drug Abuse, Intravenous
619517|NCT00247572|Intravenous Drug Abuse
619518|NCT00247559|crow's feet
619519|NCT00247559|cosmesis
619520|NCT00247559|ageing
619521|NCT00247546|Falls
619522|NCT00247546|Accidental falls
619523|NCT00247546|Prevention
619524|NCT00247546|Aged
619525|NCT00247546|Multifactorial trial
619526|NCT00247533|coronary disease
619527|NCT00247533|cerebrovascular disorders
619528|NCT00247533|angiography
619529|NCT00247533|cerebral ischemia
619530|NCT00247533|intracranial atherosclerosis
619531|NCT00247533|Coronary artery disease
619532|NCT00247533|cerebral artery stenosis
619533|NCT00247533|percutaneous coronary balloon angioplasty
619534|NCT00247533|coronary artery bypass surgery
619535|NCT00247533|ischemic stroke
619536|NCT00247533|electrocardiograph
619537|NCT00247533|electroencephalograph
619538|NCT00247533|Nuclear brain scan
619539|NCT00247533|cognition decline
619540|NCT00247533|atrial fibrillation
619541|NCT00247533|undetermined ischemic stroke
619542|NCT00247520|Seasonal allergic rhinitis (SAR), rhinoconjunctivitis, allergy
619543|NCT00247507|Anemia
619544|NCT00247507|atherosclerosis
619545|NCT00247507|End-stage renal disease
619546|NCT00247507|Erythropoietin
619547|NCT00247507|Hemodialysis
619548|NCT00247507|Oxidative stress
619549|NCT00247507|Pro-inflammation
619550|NCT00247494|HIV-1
619551|NCT00247494|atherosclerosis
619552|NCT00247494|immunomodulation
619553|NCT00247481|Metastatic Breast Cancer
619554|NCT00247455|Human nutrition
619555|NCT00247455|Dietary fibre
619556|NCT00247455|Insulin resistance
619557|NCT00247455|Obesity
619558|NCT00247455|Glucose
619559|NCT00247455|Colonic fermentation
619560|NCT00247455|Short chain fatty acids
619561|NCT00247455|GLP-1
619562|NCT00247455|Appetite
619563|NCT00247455|Abdominal fat
619564|NCT00247442|Mammography screening
619565|NCT00247442|Breast cancer screening
619566|NCT00247442|Screening outcomes
619567|NCT00247442|Decision aid
619568|NCT00247442|Decision support tool
619569|NCT00247442|Informed choice
619570|NCT00247429|depression
619571|NCT00247429|anxiety
619572|NCT00247429|elderly
619573|NCT00247416|Untreated
619574|NCT00247416|Lung
619575|NCT00247416|Cancer
619576|NCT00247416|non-small cell
619577|NCT00247416|gemcitabine
619578|NCT00247416|gemzar
619579|NCT00247416|carboplatin
619580|NCT00247416|dexamethasone
619581|NCT00247403|Intracranial cancer
619582|NCT00247403|Cancer
619583|NCT00247403|2DG
619584|NCT00247403|2-deoxyglucose
619585|NCT00247403|Intracranial metastatic cancer
619586|NCT00247390|Chronic Insomnia
619587|NCT00247390|Sleep Initiation and Maintenance Disorder
619588|NCT00247390|Drug Therapy
619589|NCT00247377|Morbid Obesity
619590|NCT00247377|Laparoscopic Gastric Bypass
619591|NCT00247377|Laparoscopic Gastric Banding
619592|NCT00247364|RLS
619593|NCT00247338|parenteral nutrition
619594|NCT00247338|low calorie
619595|NCT00247338|low nitrogen
619596|NCT00247338|gastrointestinal neoplasms
619597|NCT00247338|gastrointestinal diseases
619598|NCT00247338|gastrectomy
619599|NCT00247338|colectomy
619600|NCT00247338|rectectomy
619601|NCT00247338|operations
619602|NCT00247325|Kidney failure
619603|NCT00247325|Contrast media
619604|NCT00247325|Iodixanol
619605|NCT00247325|Ioxaglate
619606|NCT00247312|Prostate cancer
619607|NCT00247312|brachytherapy
619608|NCT00247312|palladium 103
619609|NCT00247312|I-125
619610|NCT00247299|Vascular lesions
619611|NCT00247299|Intense pulse light
619612|NCT00247299|phototermolysis
619613|NCT00247299|wavelength
619614|NCT00247299|filters
619615|NCT00247299|non coherent
619616|NCT00247286|urodynamic stress incontinence
619617|NCT00247286|weighted vaginal cones
619618|NCT00247286|pelvic floor biofeedback
619619|NCT00247286|randomized controlled trial
619620|NCT00247273|randomized controlled trial, osteoporosis, risedronate
619621|NCT00247260|HCC
619622|NCT00247260|Primary Liver Cancer
619623|NCT00247221|Alcohol
619624|NCT00247221|Substance abuse
619625|NCT00247221|Adolescent
619626|NCT00247221|Family functioning
619627|NCT00247208|Coronary artery bypass
619628|NCT00247208|Stents
619629|NCT00247208|Angioplasty, Transluminal, Percutaneous Coronary
619630|NCT00247208|Coronary Restenosis
619631|NCT00247208|Paclitaxel
619632|NCT00247195|Major Depression
619633|NCT00247195|MDD
619634|NCT00247195|Hispanic
619635|NCT00247195|Primary Care
619636|NCT00247195|Cultural Congruence
619637|NCT00247182|Stepped Care
619638|NCT00247182|Brief Motivational Intervention
619639|NCT00247182|Minimal Intervention
619640|NCT00247182|Treatment response
619641|NCT00247182|College Students
619642|NCT00247169|cervical intraepithelial neoplasia (CIN)
619643|NCT00247169|progesterone
619644|NCT00247156|Autism
619645|NCT00247156|eye contact
619646|NCT00247156|Noncommunicable
619647|NCT00247143|Protease Inhibitor
619648|NCT00247143|Antiretroviral Agents
619649|NCT00247143|Treatment Experienced
619650|NCT00247130|Omeprazole
619651|NCT00247130|Ranitidine
619652|NCT00247130|Endoscopic treatment
619653|NCT00247130|Hemostasis
619654|NCT00247130|Peptic ulcer
619655|NCT00247117|non-alcoholic fatty liver disease
619656|NCT00247117|insulin resistance
619657|NCT00247117|metformin
619658|NCT00247104|Urinary tract infection
619659|NCT00247104|Endometritis
619660|NCT00247104|Respiratory Distress Syndrome
619661|NCT00247104|Necrotizing enterocolitis
619662|NCT00247104|Intraventricular hemorrhage
619663|NCT00247104|Latent period
619664|NCT00247104|Neonatal infection
619665|NCT00247091|HIV
619666|NCT00247091|measles
619667|NCT00247091|measles vaccine
619668|NCT00247091|children
619669|NCT00247091|Zambia
619670|NCT00247078|black
619671|NCT00247078|widow
619672|NCT00247078|spider
619673|NCT00247078|antivenom
619674|NCT00247052|post operative pericardial effusion
619675|NCT00247052|NSAID
619676|NCT00247039|neutropenia
619677|NCT00247039|fever
619678|NCT00247039|garlic
619679|NCT00247039|infection
619680|NCT00247026|myelodysplasia
619681|NCT00247026|curcumin
619682|NCT00247026|coenzyme Q10
619683|NCT00247026|cytopenia
619684|NCT00247013|automated telephone system
619685|NCT00247013|breast cancer
619686|NCT00247013|cancer prevention
619687|NCT00247013|intervention
619688|NCT00247013|mammography
619689|NCT00247013|screening
619690|NCT00247000|Cardiovascular Diseases
619691|NCT00247000|Heart Disease
619692|NCT00247000|Heart Failure,Congestive
619693|NCT00247000|Health Outcomes
619694|NCT00247000|Disease Management
619695|NCT00247000|Telehomecare
619696|NCT00247000|Home Telehealth
619697|NCT00246974|bladder cancer
619698|NCT00246974|Transitionel cell cancer of the urothelium
619699|NCT00246961|Adjuvant
619700|NCT00246948|Physical therapy
619701|NCT00246935|COPD
619702|NCT00246935|Phosphodiesterase 4 inhibitor
619703|NCT00246935|Roflumilast
619704|NCT00246922|Asthma
619705|NCT00246922|Roflumilast
619706|NCT00246922|phosphodiesterase 4 inhibitor
619707|NCT00246909|Gastroesophageal Reflux
619708|NCT00246909|Gastroesophageal Reflux Disease
619709|NCT00246909|Pantoprazole
619710|NCT00246883|Endothelial Progenitor Cells
619711|NCT00246883|Nitric Oxide
619712|NCT00246883|Brachial Artery Reactivity
619713|NCT00246883|Physical Fitness
619714|NCT00246883|C-reactive Protein
619715|NCT00246883|Exercise
619716|NCT00246883|Vascular Function
619717|NCT00246870|Seizures
619718|NCT00246870|Development
619719|NCT00246870|Pediatric
619720|NCT00246870|Benzodiazepine Receptors
619721|NCT00246870|Neurotransmission
619722|NCT00246870|Succinic Semialdehyde Dehydrogenase
619723|NCT00246870|Deficiency
619724|NCT00246870|SSADH Deficiency
619725|NCT00246870|Healthy Volunteer
619726|NCT00246870|HV
619727|NCT00246857|Apoptosis
619728|NCT00246857|T-cell
619729|NCT00246857|Autoimmunity
619730|NCT00246857|Immunodeficiency
619731|NCT00246857|B-Cell
619855|NCT00246350|chiropractic
619732|NCT00246857|Inherited Lymphhocyte Homeostasis
619733|NCT00246857|Genetic Disease
619734|NCT00246844|Transplant
619735|NCT00246844|Diabetes
619736|NCT00246844|C-Peptide
619737|NCT00246844|B Cell
619738|NCT00246844|Immunosuppression
619739|NCT00246844|Type 1 Diabetes
619740|NCT00246844|Pancreas Transplant
619741|NCT00246831|fMRI
619742|NCT00246831|Self-Agency
619743|NCT00246831|Functional Magnetic Resonance Imaging (fMRI)
619744|NCT00246831|Voluntary Movement
619745|NCT00246831|Healthy Volunteer
619746|NCT00246831|HV
619747|NCT00246818|Mind-Body
619748|NCT00246818|Stress Reduction
619749|NCT00246818|Complementary Medicine
619750|NCT00246818|Quality of Life
619751|NCT00246818|Well-being
619752|NCT00246818|Psychoneuroimmunology
619753|NCT00246818|Tai Chi
619754|NCT00246818|Aerobic Exercise
619755|NCT00246818|Cancer Survivor
619756|NCT00246805|Permanent atrial fibrillation
619757|NCT00246805|VVI(R) pacing
619758|NCT00246805|rate regularization
619759|NCT00246792|School-based intervention
619760|NCT00246792|Learning disabilities
619761|NCT00246792|ecological intervention
619762|NCT00246779|transfusion
619763|NCT00246779|cardiac surgery
619764|NCT00246779|modified ultrafiltration
619765|NCT00246779|Cardiopulmonary bypass
619766|NCT00246766|Maternal's movements recorded by a specific sensor
619767|NCT00246766|Parameters of fetal distress (umbilical and cerebral Doppler) and new-born parameters.
619768|NCT00246753|adenocarcinoma of the prostate
619769|NCT00246753|recurrent prostate cancer
619770|NCT00246753|stage I prostate cancer
619771|NCT00246753|stage II prostate cancer
619772|NCT00246753|stage III prostate cancer
619773|NCT00246753|stage IV prostate cancer
619774|NCT00246740|Doxycycline
619775|NCT00246740|coronary artery bypass grafting
619776|NCT00246714|endotoxin tolerance
619777|NCT00246714|humans
619778|NCT00246714|cross-tolerance
619779|NCT00246714|pro and anti-inflammatory cytokines
619780|NCT00246701|High triglycerides
619781|NCT00246701|omega-3-acid ethyl esters
619782|NCT00246701|simvastatin
619783|NCT00246701|Lovaza
619784|NCT00246662|Leukemia
619785|NCT00246662|Hematologic
619786|NCT00246662|Blood
619787|NCT00246662|Cancer
619788|NCT00246662|Malignancy
619789|NCT00246662|Myelodysplastic Syndromes
619790|NCT00246649|Mafosfamide
619791|NCT00246649|Growth Factor
619792|NCT00246649|Stem Cell
619793|NCT00246649|Bone Marrow
619794|NCT00246636|Very high triglycerides
619795|NCT00246636|omega-3-acid ethyl esters
619796|NCT00246636|fenofibrate
619797|NCT00246636|Lovaza
619798|NCT00246610|Non-randomized open-label single-arm study of Nelfinavir plus Combivir in pregnant females infected with HIV-1 virus.
619799|NCT00246597|Anemia
619800|NCT00246597|Breast cancer
619801|NCT00246597|Hemoglobin
619802|NCT00246597|Quality of Life
619803|NCT00246597|Adjuvant Chemotherapy
619804|NCT00246597|Pure red cell aplasia (PRCA)
619805|NCT00246597|Cognitive and executive function
619806|NCT00246584|Hypertension
619807|NCT00246584|angiotensin
619808|NCT00246584|renin
619809|NCT00246584|aliskiren
619810|NCT00246558|Tight Achilles Tendon
619811|NCT00246558|Hyperpronation of the foot
619812|NCT00246519|hypertension
619813|NCT00246519|pharmacogenetics
619814|NCT00246519|pharmacogenomics
619815|NCT00246519|beta-blocker
619816|NCT00246519|atenolol
619817|NCT00246519|diuretic
619818|NCT00246519|hydrochlorothiazide
619819|NCT00246519|blood pressure
619820|NCT00246519|metabolic adverse effects
619821|NCT00246506|Infertility
619822|NCT00246506|Fertility
619823|NCT00246506|Reproduction
619824|NCT00246506|Advanced Maternal Age
619825|NCT00246506|Reproductive Medicine
619826|NCT00246506|Reproductive Techniques
619827|NCT00246506|Pregnancy
619828|NCT00246493|Coronary
619829|NCT00246493|Endothelial
619830|NCT00246493|Vascular
619831|NCT00246493|Atherosclerosis
619832|NCT00246493|Arterial
619833|NCT00246480|Respiratory Syncytial Virus Infections, RSV, elderly
619834|NCT00246467|plague
619835|NCT00246454|circadian
619836|NCT00246454|advanced sleep phase
619837|NCT00246454|delayed sleep phase
619838|NCT00246441|Pharmacotherapy
619839|NCT00246441|Self medication
619840|NCT00246428|Motivational Interviewing
619841|NCT00246428|Alcohol Abuse
619842|NCT00246428|Alcohol Dependence
619843|NCT00246428|Emergency Care Setting
619844|NCT00246415|Alcohol Dependence
619845|NCT00246415|Alcohol Abuse
619846|NCT00246415|Memantine
619847|NCT00246415|Alcohol Treatment
619848|NCT00246389|muscle spasm
619849|NCT00246389|cyclobenzaprine hydrochloride
619850|NCT00246363|HIV
619851|NCT00246363|Hepatitis C
619852|NCT00246350|Headaches
619853|NCT00246350|Spinal manipulation
619854|NCT00246350|Massage
619856|NCT00246298|Anemia
619857|NCT00246298|erythropoetin
619858|NCT00246298|Epoetin alfa
619859|NCT00246298|erythropoietin recombinant
619860|NCT00246298|HIV infection
619861|NCT00246298|HIV
619862|NCT00246298|AIDS
619863|NCT00246285|schizophrenia
619864|NCT00246285|antipsychotic agents
619865|NCT00246285|risperidone
619866|NCT00246285|adolescents
619867|NCT00246272|risperidone
619868|NCT00246272|schizophrenia
619869|NCT00246272|rapidly-dissolving
619870|NCT00246259|Schizophrenia
619871|NCT00246259|Schizoaffective disorder
619872|NCT00246259|Schizophreniform disorder
619873|NCT00246259|Risperidone
619874|NCT00246259|Risperdal Consta
619875|NCT00246246|risperidone
619876|NCT00246246|long-acting injectable
619877|NCT00246246|bipolar disorder
619878|NCT00246246|intramuscular injection
619879|NCT00246233|methylphenidate hydrochloride
619880|NCT00246233|oral tablets
619881|NCT00246233|Major Depressive Disorder
619882|NCT00246220|Attention deficit/hyperactivity disorder
619883|NCT00246220|methylphenidate
619884|NCT00246220|central nervous system stimulants
619885|NCT00246207|Attention Deficit Hyperactivity Disorder
619886|NCT00246207|once-day oral tablets
619887|NCT00246194|Schizophrenia
619888|NCT00246194|Mental disorder
619889|NCT00246194|DSM-IV
619890|NCT00246194|RISPERDAL CONSTA
619891|NCT00246194|Risperidone
619892|NCT00246194|Long-acting risperidone
619893|NCT00246194|Disorganized
619894|NCT00246194|Catatonic
619895|NCT00246194|Paranoid
619896|NCT00246181|Lung cancer
619897|NCT00246181|stereotactic body radiotherapy
619898|NCT00246168|Rheumatoid arthritis
619899|NCT00246168|NSAID add-on therapy
619900|NCT00246168|tramadol
619901|NCT00246168|acetaminophen
619902|NCT00246155|chronic
619903|NCT00246155|muscular
619904|NCT00246129|Kidney Transplantation
619905|NCT00246129|Kidney Disease
619906|NCT00246129|Kidney Failure
619907|NCT00246129|Graft Rejection
619908|NCT00246116|Lung Cancer
619909|NCT00246116|Radiation Oncology
619910|NCT00246116|Treated with Stereostatic Body Radiation
619911|NCT00246103|Valproic Acid
619912|NCT00246103|Epirubicin
619913|NCT00246103|Solid Tumor
619914|NCT00246103|Malignancies
619915|NCT00246077|chronic transfusion therapy
619916|NCT00246077|quality of life
619917|NCT00246064|Rheumatoid Arthritis
619918|NCT00246064|Infliximab infusions
619919|NCT00246064|Methotrexate
619920|NCT00246064|Remicade
619921|NCT00246051|Police
619922|NCT00246051|Sleep
619923|NCT00246051|Fatigue
619924|NCT00246051|Work Hours
619925|NCT00246051|Sleep disorder
619926|NCT00246051|Performance
619927|NCT00246038|Abdominal Aortic Aneurysm
619928|NCT00246038|Aortic Aneurysm
619929|NCT00246038|AAA
619930|NCT00246038|Endovascular
619931|NCT00246038|Stent Graft
619932|NCT00246038|Endograft
619933|NCT00246038|Vascular Prostheses
619934|NCT00246012|Melanoma
619935|NCT00246012|Neoplasm
619936|NCT00246012|CNTO 95
619937|NCT00246012|Dacarbazine
619938|NCT00246012|Intetumumab
619939|NCT00245986|Pharmacokinetics
619940|NCT00245986|Cytochrome P450
619941|NCT00245986|HIV Resistance
619942|NCT00245986|Drug Interaction
619943|NCT00245986|Non-Nucleoside Reverse Transcriptase Inhibitors
619944|NCT00245986|HIV Positive
619945|NCT00245986|Healthy Volunteer
619946|NCT00245986|HV
619947|NCT00245960|Psoriatic Arthritis
619948|NCT00245960|Skin Disease
619949|NCT00245960|Joint Disease
619950|NCT00245947|Crohn's Disease
619951|NCT00245947|Inflammation
619952|NCT00245934|Rheumatoid Arthritis
619953|NCT00245921|contraception
619954|NCT00245908|Asthma
619955|NCT00245908|Chlamydia pneumoniae
619956|NCT00245908|Chlamydophila pneumoniae
619957|NCT00245908|Azithromycin
619958|NCT00245895|Anemia,
619959|NCT00245895|Prostate Cancer
619960|NCT00245882|Telehealth
619961|NCT00245882|Veterans
619962|NCT00245882|Glycemic control
619963|NCT00245882|Active care management
619964|NCT00245882|Care coordination
619965|NCT00245869|Contrast-enhanced Ultrasound
619966|NCT00245869|Ultrasound Contrast agents, microbubbles
619967|NCT00245869|breast cancer
619968|NCT00245869|chemotherapy
619969|NCT00245869|vascularization
619970|NCT00245856|Upper Extremity Deep-Vein Thrombosis
619971|NCT00245856|DVT
619972|NCT00245856|Fragmin
619973|NCT00245856|Deep-Vein Thrombosis
619974|NCT00245856|Thrombosis
619975|NCT00245843|Premature birth
619976|NCT00245843|moderate preterm
619977|NCT00245843|late preterm
619978|NCT00245843|Joint attention
619979|NCT00245843|Social interaction
619980|NCT00245843|Child development
619981|NCT00245843|Parent
619982|NCT00245843|infant
619983|NCT00245830|Ischemia/reperfusion of the liver
619984|NCT00245830|Ischemic Preconditioning
619985|NCT00245830|Cadaver organ donor
619986|NCT00245817|Anxiety. Depression. HRQOL. Psycho-educative intervention
619987|NCT00245791|Complicated Urinary Infection
619988|NCT00245765|chronic plaque psoriasis, anti TNFα
619989|NCT00245765|CDP870, Cimzia
619990|NCT00245752|post term pregnancy
619991|NCT00245752|acupuncture
619992|NCT00245752|induction
619993|NCT00245739|HIV infections
619994|NCT00245739|HIV-1
619995|NCT00245739|TMC114
619996|NCT00245739|Early access
619997|NCT00245739|Highly antiretroviral treatment experienced patients
619998|NCT00245739|Anti-retroviral agents
619999|NCT00245713|Levetiracetam, adult, partial-onset epilepsy, antiepileptic
620000|NCT00245687|feeding tube, nutrition, gastric, jejunal
620001|NCT00245661|COPD
620002|NCT00245661|respiratory
620003|NCT00245661|sleep quality
620004|NCT00245661|temazepam
620005|NCT00245661|dyspnea
620006|NCT00245635|Body Dysmorphic Disorder
620007|NCT00245635|BDD
620008|NCT00245635|BDD treatment
620009|NCT00245635|delusionality variant
620010|NCT00245635|OCD
620011|NCT00245622|Phase 2b Tovaxin
620012|NCT00245622|Clinically Isolated Syndrome (CIS)
620013|NCT00245622|Relapse-Remitting Multiple Sclerosis (RR-MS)
620014|NCT00245583|Pathological Gambling
620015|NCT00245583|Compulsive Gambling
620016|NCT00245583|Gambling
620017|NCT00245583|topiramate
620018|NCT00245557|Depression
620019|NCT00245557|Geriatric
620020|NCT00245557|MRI
620021|NCT00245557|Sertraline
620022|NCT00245531|endocrine abnormalities
620023|NCT00245531|cognitive performance
620024|NCT00245518|prostate cancer
620025|NCT00245518|soy
620026|NCT00245518|androgen deprivation
620027|NCT00245518|quality of life
620028|NCT00245518|isoflavones
620029|NCT00245492|Colonoscopy
620030|NCT00245492|Chromoscopy
620031|NCT00245492|Prevention
620032|NCT00245479|Primary nocturnal enuresis
620033|NCT00245466|Prostate Cancer
620034|NCT00245466|Androgen ablation therapy
620035|NCT00245453|pneumonia
620036|NCT00245453|Spneumoniae
620037|NCT00245453|bronchitis
620038|NCT00245453|telithromycin
620039|NCT00245453|azithromycin
620040|NCT00245440|S.pneumonia
620041|NCT00245440|sinusitis
620042|NCT00245440|ams
620043|NCT00245440|azithromycin
620044|NCT00245427|beta-lactam
620045|NCT00245427|macrolide
620046|NCT00245427|antibiotics
620047|NCT00245388|Mixed Dyslipidemia
620048|NCT00245375|Outpatient Surgery for:
620049|NCT00245375|inguinal hernia repair
620050|NCT00245375|abdominal hernia repair
620051|NCT00245375|umbilical hernia repair
620052|NCT00245362|cancer vaccine
620053|NCT00245362|pancreatic cancer
620054|NCT00245362|metastatic pancreatic cancer
620055|NCT00245362|unresectable pancreatic cancer
620056|NCT00245362|immunotherapy
620057|NCT00245349|Head and Neck cancer
620058|NCT00245349|Squamous cell carcinoma
620059|NCT00245349|FLT
620060|NCT00245349|Fluorothymidine
620061|NCT00245349|F-18
620062|NCT00245336|hemostasis
620063|NCT00245336|surgery
620064|NCT00245336|hemostatics
620065|NCT00245336|randomized controlled trial
620066|NCT00245336|phase 3
620067|NCT00245323|smoking
620068|NCT00245310|ICG clearance
620069|NCT00245310|liver cirrhosis
620070|NCT00245310|acute liver failure
620071|NCT00245310|prognosis
620072|NCT00245297|Bleeding disorder
620073|NCT00245297|severe Haemophilia A
620074|NCT00245297|Prophylaxis
620075|NCT00245271|Knee
620076|NCT00245271|Musculoskeletal System
620077|NCT00245271|Ligament
620078|NCT00245271|ACL reconstruction
620079|NCT00245245|hemophilia A
620080|NCT00245245|inhibitor
620081|NCT00245245|treatment
620082|NCT00245232|PTSD
620083|NCT00245232|Cognitive therapy
620084|NCT00245232|Rape
620085|NCT00245206|Antipsychotic
620086|NCT00245206|Diabetes
620087|NCT00245206|Hyperlipidemia
620088|NCT00245206|Stroke
620089|NCT00245193|Major Depression
620090|NCT00245154|stage IIIB non-small cell lung cancer
620091|NCT00245154|stage IV non-small cell lung cancer
620092|NCT00245141|embryonal childhood rhabdomyosarcoma
620093|NCT00245141|embryonal-botryoid childhood rhabdomyosarcoma
620094|NCT00245141|previously untreated childhood rhabdomyosarcoma
620095|NCT00245128|chronic idiopathic myelofibrosis
620096|NCT00245128|polycythemia vera
620097|NCT00245128|essential thrombocythemia
620098|NCT00245115|adult acute myeloblastic leukemia without maturation (M1)
620099|NCT00245115|childhood acute myeloblastic leukemia without maturation (M1)
620100|NCT00245115|adult acute myeloblastic leukemia with maturation (M2)
620101|NCT00245115|childhood acute myeloblastic leukemia with maturation (M2)
620102|NCT00245115|adult acute promyelocytic leukemia (M3)
620103|NCT00245115|childhood acute promyelocytic leukemia (M3)
620104|NCT00245115|adult acute myelomonocytic leukemia (M4)
620105|NCT00245115|childhood acute myelomonocytic leukemia (M4)
620106|NCT00245115|adult acute monoblastic leukemia (M5a)
620107|NCT00245115|adult acute monocytic leukemia (M5b)
620108|NCT00245115|childhood acute monoblastic leukemia (M5a)
620109|NCT00245115|childhood acute monocytic leukemia (M5b)
620110|NCT00245115|adult erythroleukemia (M6a)
620111|NCT00245115|adult pure erythroid leukemia (M6b)
620112|NCT00245115|childhood acute erythroleukemia (M6)
620113|NCT00245115|adult acute megakaryoblastic leukemia (M7)
620114|NCT00245115|childhood acute megakaryocytic leukemia (M7)
620115|NCT00245115|adult acute lymphoblastic leukemia in remission
620116|NCT00245115|adult acute myeloid leukemia in remission
620117|NCT00245115|childhood acute lymphoblastic leukemia in remission
620118|NCT00245115|childhood acute myeloid leukemia in remission
620119|NCT00245115|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
620120|NCT00245115|adult acute myeloid leukemia with inv(16)(p13;q22)
620121|NCT00245115|adult acute myeloid leukemia with t(15;17)(q22;q12)
620122|NCT00245115|adult acute myeloid leukemia with t(16;16)(p13;q22)
620123|NCT00245115|adult acute myeloid leukemia with t(8;21)(q22;q22)
620124|NCT00245115|secondary acute myeloid leukemia
620125|NCT00245089|embryonal childhood rhabdomyosarcoma
620126|NCT00245089|embryonal-botryoid childhood rhabdomyosarcoma
620127|NCT00245089|previously untreated childhood rhabdomyosarcoma
620128|NCT00245076|unspecified adult solid tumor, protocol specific
620129|NCT00245050|drug/agent toxicity by tissue/organ
620130|NCT00245050|fallopian tube cancer
620131|NCT00245050|peritoneal cavity cancer
620132|NCT00245050|recurrent ovarian epithelial cancer
620133|NCT00245050|recurrent endometrial carcinoma
620134|NCT00245050|stage III endometrial carcinoma
620135|NCT00245050|stage IV endometrial carcinoma
620136|NCT00245050|stage IV breast cancer
620137|NCT00245050|male breast cancer
620138|NCT00245050|recurrent breast cancer
620139|NCT00245037|recurrent adult acute lymphoblastic leukemia
620140|NCT00245037|recurrent adult acute myeloid leukemia
620141|NCT00245037|de novo myelodysplastic syndromes
620142|NCT00245037|previously treated myelodysplastic syndromes
620143|NCT00245037|secondary myelodysplastic syndromes
620144|NCT00245037|atypical chronic myeloid leukemia, breakpoint cluster region-Abelson (BCR-ABL) negative
620145|NCT00245037|refractory chronic lymphocytic leukemia
620146|NCT00245037|stage III chronic lymphocytic leukemia
620147|NCT00245037|stage IV chronic lymphocytic leukemia
620148|NCT00245037|accelerated phase chronic myelogenous leukemia
620149|NCT00245037|blastic phase chronic myelogenous leukemia
620150|NCT00245037|chronic phase chronic myelogenous leukemia
620151|NCT00245037|relapsing chronic myelogenous leukemia
620152|NCT00245037|stage II multiple myeloma
620153|NCT00245037|stage III multiple myeloma
620154|NCT00245037|primary systemic amyloidosis
620155|NCT00245037|refractory multiple myeloma
620156|NCT00245037|myelodysplastic/myeloproliferative neoplasm, unclassifiable
620157|NCT00245037|chronic eosinophilic leukemia
620158|NCT00245037|primary myelofibrosis
620159|NCT00245037|chronic neutrophilic leukemia
620160|NCT00245037|essential thrombocythemia
620161|NCT00245037|polycythemia vera
620162|NCT00245037|chronic myelomonocytic leukemia
620163|NCT00245037|acute undifferentiated leukemia
620164|NCT00245037|extramedullary plasmacytoma
620165|NCT00245037|isolated plasmacytoma of bone
620166|NCT00245037|monoclonal gammopathy of undetermined significance
620167|NCT00245037|stage I multiple myeloma
620168|NCT00245037|secondary acute myeloid leukemia
620169|NCT00245037|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
620170|NCT00245037|adult acute myeloid leukemia with inv(16)(p13;q22)
620171|NCT00245037|adult acute myeloid leukemia with t(15;17)(q22;q12)
620172|NCT00245037|adult acute myeloid leukemia with t(16;16)(p13;q22)
620173|NCT00245037|adult acute myeloid leukemia with t(8;21)(q22;q22)
620174|NCT00245037|nodal marginal zone B-cell lymphoma
620175|NCT00245037|noncontiguous stage II adult Burkitt lymphoma
620176|NCT00245037|noncontiguous stage II adult diffuse large cell lymphoma
620177|NCT00245037|noncontiguous stage II adult diffuse mixed cell lymphoma
620178|NCT00245037|noncontiguous stage II adult diffuse small cleaved cell lymphoma
620179|NCT00245037|noncontiguous stage II adult immunoblastic large cell lymphoma
620180|NCT00245037|noncontiguous stage II adult lymphoblastic lymphoma
620181|NCT00245037|noncontiguous stage II grade 1 follicular lymphoma
620182|NCT00245037|noncontiguous stage II grade 2 follicular lymphoma
620183|NCT00245037|noncontiguous stage II grade 3 follicular lymphoma
620184|NCT00245037|noncontiguous stage II mantle cell lymphoma
620185|NCT00245037|noncontiguous stage II marginal zone lymphoma
620186|NCT00245037|noncontiguous stage II small lymphocytic lymphoma
620187|NCT00245037|recurrent adult Burkitt lymphoma
620188|NCT00245037|recurrent adult Hodgkin lymphoma
620189|NCT00245037|recurrent adult diffuse large cell lymphoma
620190|NCT00245037|recurrent adult diffuse mixed cell lymphoma
620191|NCT00245037|recurrent adult diffuse small cleaved cell lymphoma
620192|NCT00245037|recurrent adult immunoblastic large cell lymphoma
620193|NCT00245037|recurrent adult lymphoblastic lymphoma
620194|NCT00245037|recurrent cutaneous T-cell non-Hodgkin lymphoma
620195|NCT00245037|recurrent grade 1 follicular lymphoma
620410|NCT00244569|Cirrhosis
620196|NCT00245037|recurrent grade 2 follicular lymphoma
620197|NCT00245037|recurrent grade 3 follicular lymphoma
620198|NCT00245037|recurrent mantle cell lymphoma
620199|NCT00245037|recurrent marginal zone lymphoma
620200|NCT00245037|recurrent small lymphocytic lymphoma
620201|NCT00245037|splenic marginal zone lymphoma
620202|NCT00245037|stage III adult Burkitt lymphoma
620203|NCT00245037|stage III adult Hodgkin lymphoma
620204|NCT00245037|stage III adult diffuse large cell lymphoma
620205|NCT00245037|stage III adult diffuse mixed cell lymphoma
620206|NCT00245037|stage III adult diffuse small cleaved cell lymphoma
620207|NCT00245037|stage III adult immunoblastic large cell lymphoma
620208|NCT00245037|stage III adult lymphoblastic lymphoma
620209|NCT00245037|stage III grade 1 follicular lymphoma
620210|NCT00245037|stage III grade 2 follicular lymphoma
620211|NCT00245037|stage III grade 3 follicular lymphoma
620212|NCT00245037|stage III mantle cell lymphoma
620213|NCT00245037|stage III marginal zone lymphoma
620214|NCT00245037|stage III small lymphocytic lymphoma
620215|NCT00245037|stage IV adult Burkitt lymphoma
620216|NCT00245037|stage IV adult Hodgkin lymphoma
620217|NCT00245037|stage IV adult diffuse large cell lymphoma
620218|NCT00245037|stage IV adult diffuse mixed cell lymphoma
620219|NCT00245037|stage IV adult diffuse small cleaved cell lymphoma
620220|NCT00245037|stage IV adult immunoblastic large cell lymphoma
620221|NCT00245037|stage IV adult lymphoblastic lymphoma
620222|NCT00245037|stage IV grade 1 follicular lymphoma
620223|NCT00245037|stage IV grade 2 follicular lymphoma
620224|NCT00245037|stage IV grade 3 follicular lymphoma
620225|NCT00245037|stage IV mantle cell lymphoma
620226|NCT00245037|stage IV marginal zone lymphoma
620227|NCT00245037|stage IV small lymphocytic lymphoma
620228|NCT00245037|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
620229|NCT00245024|breast cancer
620230|NCT00245024|ductal breast carcinoma in situ
620231|NCT00245024|lobular breast carcinoma in situ
620232|NCT00245024|breast cancer in situ
620233|NCT00245011|recurrent osteosarcoma
620234|NCT00245011|metastatic osteosarcoma
620235|NCT00245011|localized osteosarcoma
620236|NCT00244998|adenocarcinoma of the prostate
620237|NCT00244998|stage III prostate cancer
620238|NCT00244998|stage IV prostate cancer
620239|NCT00244985|recurrent grade 1 follicular lymphoma
620240|NCT00244985|recurrent grade 2 follicular lymphoma
620241|NCT00244985|recurrent grade 3 follicular lymphoma
620242|NCT00244985|recurrent mantle cell lymphoma
620243|NCT00244985|recurrent small lymphocytic lymphoma
620244|NCT00244985|recurrent adult diffuse large cell lymphoma
620245|NCT00244985|recurrent adult diffuse mixed cell lymphoma
620246|NCT00244985|recurrent marginal zone lymphoma
620247|NCT00244985|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
620248|NCT00244985|nodal marginal zone B-cell lymphoma
620249|NCT00244985|splenic marginal zone lymphoma
620250|NCT00244959|stage I breast cancer
620251|NCT00244959|stage II breast cancer
620252|NCT00244959|stage IIIA breast cancer
620253|NCT00244959|stage IIIB breast cancer
620254|NCT00244959|stage IIIC breast cancer
620255|NCT00244959|ductal breast carcinoma in situ
620256|NCT00244959|breast cancer in situ
620257|NCT00244946|nodal marginal zone B-cell lymphoma
620258|NCT00244946|recurrent adult Burkitt lymphoma
620259|NCT00244946|recurrent adult diffuse large cell lymphoma
620260|NCT00244946|recurrent adult diffuse mixed cell lymphoma
620261|NCT00244946|recurrent adult diffuse small cleaved cell lymphoma
620262|NCT00244946|recurrent adult immunoblastic large cell lymphoma
620263|NCT00244946|recurrent adult lymphoblastic lymphoma
620264|NCT00244946|recurrent grade 1 follicular lymphoma
620265|NCT00244946|recurrent grade 2 follicular lymphoma
620266|NCT00244946|recurrent grade 3 follicular lymphoma
620267|NCT00244946|recurrent mantle cell lymphoma
620268|NCT00244946|recurrent marginal zone lymphoma
620269|NCT00244946|splenic marginal zone lymphoma
620270|NCT00244946|stage III adult Burkitt lymphoma
620271|NCT00244946|stage III adult diffuse large cell lymphoma
620272|NCT00244946|stage III adult diffuse mixed cell lymphoma
620273|NCT00244946|stage III adult diffuse small cleaved cell lymphoma
620274|NCT00244946|stage III adult immunoblastic large cell lymphoma
620275|NCT00244946|stage III adult lymphoblastic lymphoma
620276|NCT00244946|stage III grade 1 follicular lymphoma
620277|NCT00244946|stage III grade 2 follicular lymphoma
620278|NCT00244946|stage III grade 3 follicular lymphoma
620279|NCT00244946|stage III mantle cell lymphoma
620280|NCT00244946|stage III marginal zone lymphoma
620281|NCT00244946|stage IV adult Burkitt lymphoma
620282|NCT00244946|stage IV adult diffuse large cell lymphoma
620283|NCT00244946|stage IV adult diffuse mixed cell lymphoma
620284|NCT00244946|stage IV adult diffuse small cleaved cell lymphoma
620285|NCT00244946|stage IV adult immunoblastic large cell lymphoma
620286|NCT00244946|stage IV adult lymphoblastic lymphoma
620287|NCT00244946|stage IV grade 1 follicular lymphoma
620288|NCT00244946|stage IV grade 2 follicular lymphoma
620289|NCT00244946|stage IV grade 3 follicular lymphoma
620290|NCT00244946|stage IV mantle cell lymphoma
620291|NCT00244946|stage IV marginal zone lymphoma
620292|NCT00244946|recurrent small lymphocytic lymphoma
620293|NCT00244946|stage III small lymphocytic lymphoma
620294|NCT00244946|stage IV small lymphocytic lymphoma
620295|NCT00244946|noncontiguous stage II adult Burkitt lymphoma
620296|NCT00244946|noncontiguous stage II adult diffuse large cell lymphoma
620297|NCT00244946|noncontiguous stage II adult diffuse mixed cell lymphoma
620298|NCT00244946|noncontiguous stage II adult diffuse small cleaved cell lymphoma
620299|NCT00244946|noncontiguous stage II adult immunoblastic large cell lymphoma
620300|NCT00244946|noncontiguous stage II adult lymphoblastic lymphoma
620301|NCT00244946|noncontiguous stage II grade 1 follicular lymphoma
620302|NCT00244946|noncontiguous stage II grade 2 follicular lymphoma
620303|NCT00244946|noncontiguous stage II grade 3 follicular lymphoma
620304|NCT00244946|noncontiguous stage II mantle cell lymphoma
620305|NCT00244946|noncontiguous stage II marginal zone lymphoma
620306|NCT00244946|noncontiguous stage II small lymphocytic lymphoma
620307|NCT00244933|stage IV breast cancer
620308|NCT00244933|recurrent breast cancer
620309|NCT00244920|adenocarcinoma of the prostate
620310|NCT00244920|stage III prostate cancer
620311|NCT00244907|Bone Resorption
620312|NCT00244907|Phytoestrogens
620313|NCT00244907|Calcium
620314|NCT00244907|Genistein
620315|NCT00244907|Equol
620316|NCT00244894|fatigue
620317|NCT00244894|recurrent prostate cancer
620318|NCT00244894|stage II prostate cancer
620319|NCT00244894|stage III prostate cancer
620320|NCT00244894|stage IV prostate cancer
620321|NCT00244894|hot flashes
620322|NCT00244868|unspecified adult solid tumor, protocol specific
620323|NCT00244868|metastatic cancer
620324|NCT00244842|Randomized Controlled Trials
620325|NCT00244842|Immunosuppression
620326|NCT00244842|Adult
620327|NCT00244842|Chronic Disease
620328|NCT00244842|Dermatologic Agents
620329|NCT00244842|Female
620330|NCT00244842|Humans
620331|NCT00244842|Male
620332|NCT00244842|Middle Aged
620333|NCT00244842|Severity of Illness Index
620334|NCT00244842|Treatment Outcome
620335|NCT00244842|Quality of Life
620336|NCT00244842|Double-Blind Method
620337|NCT00244829|accelerated phase chronic myelogenous leukemia
620338|NCT00244829|blastic phase chronic myelogenous leukemia
620339|NCT00244829|childhood chronic myelogenous leukemia
620340|NCT00244829|chronic phase chronic myelogenous leukemia
620341|NCT00244829|Philadelphia chromosome positive chronic myelogenous leukemia
620342|NCT00244829|adult acute lymphoblastic leukemia in remission
620343|NCT00244829|childhood acute lymphoblastic leukemia in remission
620344|NCT00244803|Human Immunodeficiency Virus
620345|NCT00244803|FRAM 1
620346|NCT00244790|glomerular hyperfiltration
620347|NCT00244790|proteinuria
620348|NCT00244777|Seizure
620349|NCT00244777|Altered consciousness
620350|NCT00244777|Hyponatraemia
620351|NCT00244777|Diarrhoea
620352|NCT00244777|Hypo osmolar ORS
620353|NCT00244764|Solid tumors
620354|NCT00244764|Pazopanib(GW786034)
620355|NCT00244764|Angiogenesis
620356|NCT00244764|Renal Cell Carcinoma
620357|NCT00244751|Hepatitis C liver fibrosis
620358|NCT00244738|pregnancy
620359|NCT00244738|post-date
620360|NCT00244738|induction of labor
620361|NCT00244738|castor oil
620362|NCT00244725|PE
620363|NCT00244725|total knee replacement
620364|NCT00244725|Venous thromboembolism
620365|NCT00244725|VTE
620366|NCT00244725|pulmonary embolism
620367|NCT00244725|DVT
620368|NCT00244725|deep vein thrombosis
620369|NCT00244712|HEAT
620370|NCT00244712|Antiretroviral-naive
620371|NCT00244712|HIV
620372|NCT00244712|EPZICOM
620373|NCT00244712|TRUVADA
620374|NCT00244712|KALETRA
620375|NCT00244712|once-daily
620376|NCT00244699|youth
620377|NCT00244699|drug addiction
620378|NCT00244699|substance abuse
620379|NCT00244699|mindfulness
620380|NCT00244699|motivational interviewing
620381|NCT00244699|brief treatment
620382|NCT00244699|skills training
620383|NCT00244699|group therapy
620384|NCT00244699|emotion regulation
620385|NCT00244686|Hypereosinophilic Syndrome
620386|NCT00244686|Mepo
620387|NCT00244686|HES
620388|NCT00244686|Compassionate Use
620389|NCT00244686|Mepolizumab
620390|NCT00244673|Vaccination
620391|NCT00244673|DTP
620392|NCT00244673|Child mortality
620393|NCT00244673|Sex
620394|NCT00244673|Non-specific effects
620395|NCT00244647|restenosis
620396|NCT00244647|in-stent restenosis
620397|NCT00244621|Pediatric hypertension
620398|NCT00244595|Pediatric hypertension
620399|NCT00244595|Hypertension in children
620400|NCT00244582|Central Nervous System
620401|NCT00244582|Enzyme Replacement Therapy
620402|NCT00244582|Convection
620403|NCT00244582|Gaucher Disease
620404|NCT00244582|Neuronopathic Gaucher Disease
620405|NCT00244582|Type 2 Gaucher Disease
620406|NCT00244569|Nonalcoholic Fatty Liver Disease
620407|NCT00244569|Nonalcoholic Steatohepatitis
620408|NCT00244569|Liver Function
620409|NCT00244569|Metabolism
620411|NCT00244569|Fibrosis
620412|NCT00244569|Liver
620413|NCT00244556|Rheumatoid Arthritis
620414|NCT00244543|ocular, allergic conjunctivitis, ophthalmic
620415|NCT00244530|Preventive Therapy
620416|NCT00244530|Calcium Channel Blockers
620417|NCT00244530|Kidney Failure, Chronic
620418|NCT00244530|Coronary Artery Bypass
620419|NCT00244530|Heart Valve Prosthesis Implantation
620420|NCT00244517|ventricular function
620421|NCT00244517|diastolic function
620422|NCT00244517|inhalative anaesthetics
620423|NCT00244491|care transitions
620424|NCT00244491|geriatric
620425|NCT00244491|care coordination
620426|NCT00244491|self-management
620427|NCT00244491|chronic illness
620428|NCT00244491|patient-centered care
620429|NCT00244465|Narcolepsy
620430|NCT00244465|Cataplexy
620431|NCT00244465|Oxybate
620432|NCT00244465|Xyrem
620433|NCT00244465|Misuse
620434|NCT00244465|Safety
620435|NCT00244452|Endometriosis
620436|NCT00244452|Cetrorelix
620437|NCT00244452|Hormone
620438|NCT00244452|Symptoms relief
620439|NCT00244452|Safety
620440|NCT00244452|Tolerability
620441|NCT00244452|Pharmacodynamic
620442|NCT00244452|Pharmacokinetic
620443|NCT00244439|Head Lice
620444|NCT00244439|Pediculosis capitis
620445|NCT00244426|Prevention of thromboembolic events in patients with non valvular atrial fibrillation
620446|NCT00244413|Myotonia
620447|NCT00244413|Paramyotonia Congenita
620448|NCT00244413|Thomsen's Disease
620449|NCT00244400|Femur Head Necrosis
620450|NCT00244400|CYP3A
620451|NCT00244387|advanced stage idiopathic Parkinson's disease
620452|NCT00244361|opsoclonus
620453|NCT00244361|myoclonus
620454|NCT00244348|hepatic artery infusion
620455|NCT00244348|colorectal cancer
620456|NCT00244348|liver metastasis
620457|NCT00244348|oxaliplatin
620458|NCT00244348|5 fluorouracil
620459|NCT00244335|Post-Traumatic Stress Disorders
620460|NCT00244335|PTSD
620461|NCT00244309|brachytherapy
620462|NCT00244309|urinary symptoms
620463|NCT00244283|Myocardial preconditioning
620464|NCT00244283|anesthetics
620465|NCT00244283|epidural anesthesia
620466|NCT00244283|sevoflurane
620467|NCT00244283|NT proBNP
620468|NCT00244270|totally implantable vascular access devices
620469|NCT00244270|thromboembolism
620470|NCT00244270|genetic susceptibility to venous thrombosis.
620471|NCT00244257|idiopathic thrombocytopenia purpura
620472|NCT00244231|Niacin
620473|NCT00244231|Hyperlipidemia
620474|NCT00244218|phenylketonuria
620475|NCT00244218|hyperphenylalaninemia
620476|NCT00244192|COPD
620477|NCT00244192|infliximab
620478|NCT00244192|Remicade
620479|NCT00244192|inflammation
620480|NCT00244192|cachexia
620481|NCT00244192|fat-free mass
620482|NCT00244192|health status
620483|NCT00244192|exercise capacity
620484|NCT00244179|reactive arthritis
620485|NCT00244179|trial
620486|NCT00244179|interferon-gamma
620487|NCT00244179|infliximab
620488|NCT00244179|chronic
620489|NCT00244179|tnf-blocker
620490|NCT00244166|treatment
620491|NCT00244166|ankylosing spondylitis
620492|NCT00244166|prednisolone
620493|NCT00244166|trial
620494|NCT00244166|steroid
620495|NCT00244153|intraarticular morphine, steroids, arthroscopy
620496|NCT00244140|Ultravist 370
620497|NCT00244140|CECT
620498|NCT00244140|CT Scan
620499|NCT00244114|Hemophilia B
620500|NCT00244114|Allergic Reaction
620501|NCT00244101|Prematurity
620502|NCT00244101|respiratory distress syndrome
620503|NCT00244101|surfactant
620504|NCT00244101|nasal continuous positive airway pressure
620505|NCT00244088|Abdominal infection
620506|NCT00244023|Erectile Dysfunction
620507|NCT00244023|Testosterone
620508|NCT00244023|Testosterone Therapy
620509|NCT00244023|PDE V Inhibitor
620510|NCT00244023|Tadalafil
620511|NCT00244010|Aplastic anemia
620512|NCT00244010|Amegakaryocytic thrombocytopenia
620513|NCT00244010|Diamond-Blackfan Anemia
620514|NCT00244010|Kostmann syndrome
620515|NCT00244010|Allogeneic stem cell transplantation
620516|NCT00244010|Haploidentical stem cell transplant
620517|NCT00244010|T-cell depletion
620518|NCT00244010|Partially matched family member donor transplant
620519|NCT00244010|Refractory cytopenia
620520|NCT00243997|parents
620521|NCT00243997|fathers
620522|NCT00243997|mothers
620523|NCT00243984|metabolic syndrome
620524|NCT00243984|type 2 diabetes
620525|NCT00243984|topiramate
620526|NCT00243984|weight loss
620527|NCT00243971|EARLY-STAGE, IDIOPATHIC PARKINSON'S DISEASE
620528|NCT00243932|amyotrophic lateral sclerosis
620529|NCT00243932|ALS
620530|NCT00243932|Lou Gehrig's disease
620531|NCT00243932|CoQ10
620532|NCT00243932|coenzyme Q10
620533|NCT00243932|antioxidants
620534|NCT00243932|free radicals
620535|NCT00243932|mitochondrial dysfunction
620536|NCT00243919|stroke
620537|NCT00243919|locomotor
620538|NCT00243919|exercise
620539|NCT00243919|walking
620540|NCT00243919|training program
620541|NCT00243919|body weight support training
620542|NCT00243919|physical therapy
620543|NCT00243906|acute ischemic stroke
620544|NCT00243906|stroke
620545|NCT00243906|rt-PA
620546|NCT00243906|thrombolytic
620547|NCT00243906|recombinant tissue plasminogen activator
620548|NCT00243893|giant aneurysms
620549|NCT00243893|arteriovenous malformations
620550|NCT00243893|minocycline
620551|NCT00243893|doxycycline
620552|NCT00243893|BAVM
620553|NCT00243880|acute ischemic stroke
620554|NCT00243880|lovastatin
620555|NCT00243880|statin
620556|NCT00243880|neuroprotection
620557|NCT00243880|SPOTRIAS
620558|NCT00243867|Advanced Non-Small Cell Lung Cancer
620559|NCT00243854|Pancreatic Cancer
620560|NCT00243854|Resectable Pancreatic Cancer
620561|NCT00243854|adenocarcinoma of the pancreas
620562|NCT00243828|Noninvasive Mechanical Ventilation
620563|NCT00243828|Acute Respiratory Failure
620564|NCT00243828|Intubation
620565|NCT00243815|randomized controlled trial
620566|NCT00243815|prophylactic nonsteroidal antiflammatory drug
620567|NCT00243815|IUD removal
620568|NCT00243802|Atrial Fibrillation
620569|NCT00243802|Oxidative Stress
620570|NCT00243802|Atrial Flutter
620571|NCT00243789|Duchenne
620572|NCT00243789|Genetic
620573|NCT00243789|Muscular Dystrophy
620574|NCT00243789|DMD
620575|NCT00243763|Refractory Multiple Myeloma or
620576|NCT00243763|Relapsed Multiple Myeloma
620577|NCT00243750|ankylosing spondylitis
620578|NCT00243750|trial
620579|NCT00243750|methotrexate
620580|NCT00243737|Malaria
620581|NCT00243737|falciparum
620582|NCT00243737|Mefloquine
620583|NCT00243737|Artesunate
620584|NCT00243737|Artemisinin
620585|NCT00243724|immunohistochemical
620586|NCT00243724|erosive esophagitis
620587|NCT00243724|Acid reflux disease
620588|NCT00243698|Contrast-enhanced Ultrasound Sonography
620589|NCT00243698|Ultrasound Contrast agents, microbubbles
620590|NCT00243698|Breast tumors
620591|NCT00243685|Chemosensitivity
620592|NCT00243685|Chemotherapy
620593|NCT00243685|Lung cancer
620594|NCT00243685|Ovarian Cancer
620595|NCT00243685|Breast Cancer
620596|NCT00243685|Sarcoma
620597|NCT00243685|Apoptosis
620598|NCT00243685|MiCK Assay
620599|NCT00243685|New Technology
620600|NCT00243685|Patients with pathological diagnoses of breast, lung, and ovarian adenocarcinomas and soft tissue sarcoma
620601|NCT00243659|Hemophilia A
620602|NCT00243659|bleeding disorder
620603|NCT00243646|Radiation therapy
620604|NCT00243646|Brachytherapy
620605|NCT00243646|Prostatic neoplasm
620606|NCT00243633|focal liver lesions
620607|NCT00243633|contrast-enhanced ultrasound sonography
620608|NCT00243633|cirrhosis
620609|NCT00243633|suspected liver metastases
620610|NCT00243633|suspected liver cirrhosis
620611|NCT00243620|Chronic leg ulcers; wound healing; wound care; Vacuum Assisted Closure; topical negative Pressure
620612|NCT00243607|climacteric symptoms
620613|NCT00243607|breast cancer
620614|NCT00243607|hydrotherapy
620615|NCT00243594|Dendritic cells
620616|NCT00243594|Immunotherapy
620617|NCT00243594|Vaccination
620618|NCT00243594|Melanoma
620619|NCT00243594|Peptides
620620|NCT00243594|MRI
620621|NCT00243594|Scintigraphy
620622|NCT00243594|Immune response
620623|NCT00243568|HIV Infections
620624|NCT00243568|Acquired Immunodeficiency Syndrome
620625|NCT00243568|CCR5/CXCR4 mixed tropism
620626|NCT00243568|R5/X4 mixed tropism
620627|NCT00243568|CCR5 inhibitor
620628|NCT00243568|vicriviroc
620629|NCT00243568|treatment-experienced
620630|NCT00243555|peanut hypersensitivity
620631|NCT00243555|chemokines
620632|NCT00243555|cytokines
620633|NCT00243555|RNA,messenger
620634|NCT00243555|monocytes
620635|NCT00243542|Acne, G6PD deficiency, Dapsone
620636|NCT00243529|Dendritic cells
620637|NCT00243529|Melanoma
620638|NCT00243529|Vaccine
620639|NCT00243529|Immunotherapy
620640|NCT00243529|RNA
620641|NCT00243529|Peptides
620642|NCT00243516|Acute Coronary Syndrome
620643|NCT00243516|Emergency Department
620644|NCT00243516|Chest Pain Evaluation Unit
620645|NCT00243516|Overtesting
620646|NCT00243516|Chest Pain Protocol
620647|NCT00243516|Myocardial Infarction
620648|NCT00243516|Medical Malpractice
620649|NCT00243503|Breast Cancer Metastatic
620650|NCT00243490|Photodynamic therapy
620651|NCT00243490|Malignant glioma
620652|NCT00243490|Photosan
620653|NCT00243477|Coronary Artery Bypass
620654|NCT00243477|Surgery
620655|NCT00243425|Major Depressive Disorder;
620656|NCT00243425|African Americans;
620657|NCT00243425|Disparities;
620658|NCT00243425|Quality Improvement;
620659|NCT00243425|Patient Centered Care;
620660|NCT00243425|Primary Care;
620661|NCT00243425|Patient-Physician Relationship;
620662|NCT00243412|Rituxan
620663|NCT00243412|RA
620664|NCT00243399|Fanconi anemia
620665|NCT00243399|FA
620666|NCT00243373|Patient safety
620667|NCT00243373|Medication safety
620668|NCT00243373|Barcode technology
620669|NCT00243360|Urinary tract infections,
620670|NCT00243360|antibiotic use,
620671|NCT00243360|long term care facilities
620672|NCT00243347|RECENTIN
620673|NCT00243334|Ambulatory Care Information Systems
620674|NCT00243334|Clinical Decision Support Systems
620675|NCT00243334|Medication Systems
620676|NCT00243334|Medication Errors
620677|NCT00243334|Reminder Systems
620678|NCT00243334|Drug Monitoring
620679|NCT00243334|Preventive Health Services
620680|NCT00243334|Time and Motion Studies
620681|NCT00243334|Efficiency
620682|NCT00243334|Cost-Benefit Analysis
620683|NCT00243321|brachytherapy
620684|NCT00243321|intensity-modulated radiation therapy
620685|NCT00243321|prostate specific antigen
620686|NCT00243308|Anti-inflammatory agents
620687|NCT00243308|unstable plaque
620688|NCT00243308|acute coronary syndrome
620689|NCT00243295|osteoarthritis
620690|NCT00243295|deformity of knee
620691|NCT00243282|Complementary Therapies
620692|NCT00243282|Dyspnea
620693|NCT00243282|Palliative Care
620694|NCT00243282|Meditation
620695|NCT00243282|Quality of Life
620696|NCT00243269|nausea, acupressure bands, relaxation
620697|NCT00243243|Burns
620698|NCT00243204|Stage IIIb/IV non-small cell lung cancer
620699|NCT00243204|NSCLC
620700|NCT00243204|Lung Cancer
620701|NCT00243191|newly diagnosed or recurrent
620702|NCT00243178|Atrial fibrillation
620703|NCT00243178|Anticoagulant therapy
620704|NCT00243178|Thromboembolic prevention
620705|NCT00243165|breast cancer
620706|NCT00243165|honey
620707|NCT00243165|myelosuppression
620708|NCT00243165|chemotherapy
620709|NCT00243152|pain
620710|NCT00243152|neuropathic
620711|NCT00243152|face
620712|NCT00243152|trigeminal
620713|NCT00243139|Oral appliances
620714|NCT00243139|Obstructive sleep apnea
620715|NCT00243139|Epworth Sleepiness Scale
620716|NCT00243139|SF-36
620717|NCT00243126|HIV prevention
620718|NCT00243126|HIV Seronegativity
620719|NCT00243126|HIV negative
620720|NCT00243113|stage II squamous cell carcinoma of the hypopharynx
620721|NCT00243113|stage II squamous cell carcinoma of the larynx
620722|NCT00243113|stage III squamous cell carcinoma of the hypopharynx
620723|NCT00243113|stage III squamous cell carcinoma of the larynx
620724|NCT00243087|stage IV adult diffuse large cell lymphoma
620725|NCT00243087|recurrent adult diffuse large cell lymphoma
620726|NCT00243087|recurrent adult Burkitt lymphoma
620727|NCT00243087|stage IV adult Burkitt lymphoma
620728|NCT00243087|stage IV grade 3 follicular lymphoma
620729|NCT00243087|recurrent grade 3 follicular lymphoma
620730|NCT00243087|stage IV mantle cell lymphoma
620731|NCT00243087|recurrent mantle cell lymphoma
620732|NCT00243087|recurrent adult immunoblastic large cell lymphoma
620733|NCT00243087|stage IV adult immunoblastic large cell lymphoma
620734|NCT00243087|anaplastic large cell lymphoma
620735|NCT00243087|recurrent adult T-cell leukemia/lymphoma
620736|NCT00243087|stage IV adult T-cell leukemia/lymphoma
620737|NCT00243087|stage III adult Burkitt lymphoma
620738|NCT00243087|stage III adult diffuse large cell lymphoma
620739|NCT00243087|stage III adult immunoblastic large cell lymphoma
620740|NCT00243087|stage III adult T-cell leukemia/lymphoma
620741|NCT00243087|stage III grade 3 follicular lymphoma
620742|NCT00243087|stage III mantle cell lymphoma
620743|NCT00243048|stage I prostate cancer
620744|NCT00243048|stage II prostate cancer
620745|NCT00243022|cerebral edema
620746|NCT00243022|adult glioblastoma
620747|NCT00243022|adult giant cell glioblastoma
620748|NCT00243022|adult gliosarcoma
620749|NCT00243022|adult anaplastic astrocytoma
620750|NCT00243022|adult anaplastic oligodendroglioma
620751|NCT00243009|recurrent renal cell cancer
620752|NCT00243009|stage IV renal cell cancer
620753|NCT00243009|clear cell renal cell carcinoma
620754|NCT00242996|recurrent adult diffuse large cell lymphoma
620755|NCT00242983|adenocarcinoma of the lung
620756|NCT00242983|large cell lung cancer
620757|NCT00242983|recurrent non-small cell lung cancer
620758|NCT00242983|squamous cell lung cancer
620759|NCT00242983|stage IIIB non-small cell lung cancer
620760|NCT00242983|stage IV non-small cell lung cancer
620761|NCT00242957|HIV/AIDS
620762|NCT00242957|Gender Based Violence
620763|NCT00242957|Structural Interventions
620764|NCT00242957|South Africa
620765|NCT00242957|HIV Seronegativity
620766|NCT00242944|Acute coronary syndrome
620767|NCT00242944|Hypercholesterolemia
620768|NCT00242944|Primary coronary intervention
620769|NCT00242944|Hydroxymethylglutaryl-CoA reductase inhibitors
620770|NCT00242944|coronary plaque
620897|NCT00242489|Arcoxia
620771|NCT00242944|Angioplasty, Transluminal, Percutaneous Coronary
620772|NCT00242944|Ultrasonography, Interventional
620773|NCT00242931|adenocarcinoma of the prostate
620774|NCT00242931|recurrent prostate cancer
620775|NCT00242931|stage IV prostate cancer
620776|NCT00242918|High risk
620777|NCT00242918|adenocarcinoma
620778|NCT00242918|prostate cancer
620779|NCT00242918|neoadjuvant
620780|NCT00242905|Memory
620781|NCT00242905|Epilepsy
620782|NCT00242905|Children
620783|NCT00242905|Magnetic resonance imaging
620784|NCT00242905|Functional magnetic resonance imaging
620785|NCT00242892|Deployment stent optimisation
620786|NCT00242892|Fractional Flow Reserve
620787|NCT00242892|Stent
620788|NCT00242892|Restenosis
620789|NCT00242892|Coronary
620790|NCT00242879|treatment-experienced
620791|NCT00242879|RTV
620792|NCT00242879|protease inhibitor
620793|NCT00242879|ritonavir
620794|NCT00242879|GW640385
620795|NCT00242879|HIV-1
620796|NCT00242866|Productivity
620797|NCT00242866|Efficacy
620798|NCT00242866|without aura
620799|NCT00242866|iNOS
620800|NCT00242866|Safety
620801|NCT00242866|Nitric Oxide
620802|NCT00242866|Pharmacokinetics
620803|NCT00242866|GW274150
620804|NCT00242866|with aura
620805|NCT00242866|Migraine
620806|NCT00242866|Prophylaxis
620807|NCT00242866|Quality of Life
620808|NCT00242853|iNOS
620809|NCT00242853|Rheumatoid arthritis
620810|NCT00242853|Exhaled NO
620811|NCT00242840|protease inhibitor
620812|NCT00242840|ritonavir
620813|NCT00242840|GW433908
620814|NCT00242840|HIV-1
620815|NCT00242840|fosamprenavir
620816|NCT00242788|Colorectal Cancer
620817|NCT00242775|Asthma
620818|NCT00242762|Head and Neck Neoplasms
620819|NCT00242762|Cancer of Head and Neck
620820|NCT00242762|Head and Neck Cancer
620821|NCT00242762|Head Cancer
620822|NCT00242762|Neck Cancer
620823|NCT00242749|Head and Neck Cancer Disease
620824|NCT00242749|Head Cancer
620825|NCT00242749|Neck Cancer
620826|NCT00242749|Cancer of Head
620827|NCT00242749|Cancer of Neck
620828|NCT00242749|Cancer of the Head
620829|NCT00242749|Cancer of the Head and Neck
620830|NCT00242749|Cancer of the Neck
620831|NCT00242749|Neoplasms, Head and Neck
620832|NCT00242723|Lung Cancers
620833|NCT00242723|Esophageal Cancer
620834|NCT00242723|Malignant Pleural Mesothelioma
620835|NCT00242723|Biopsy
620836|NCT00242723|Staging Studies
620837|NCT00242723|Lung Cancer
620838|NCT00242710|Endometrium
620839|NCT00242710|Uterus
620840|NCT00242710|Menopause
620841|NCT00242697|coronary artery bypass surgery
620842|NCT00242697|anesthesia, general
620843|NCT00242697|anesthesia, spinal
620844|NCT00242697|heart-lung machine
620845|NCT00242684|Aging
620846|NCT00242684|Undernutrition
620847|NCT00242684|Inflammation
620848|NCT00242684|Frail Elderly
620849|NCT00242671|general anesthesia, hyperventilation, carbon dioxide, isocapnic hyperponea
620850|NCT00242658|Physical Activity
620851|NCT00242658|Wellness Programs
620852|NCT00242658|Health Promotion
620853|NCT00242658|Blood Pressure, High
620854|NCT00242645|Doctor-Patient relation
620855|NCT00242645|Physician-Patient relation
620856|NCT00242645|Diabetes
620857|NCT00242645|Office visits
620858|NCT00242645|Comparative Study
620859|NCT00242645|Health behavior
620860|NCT00242645|Randomized controlled trials
620861|NCT00242645|Health Promotion
620862|NCT00242645|Health Education
620863|NCT00242645|Computer-tailor information
620864|NCT00242606|Newly diagnosed epilepsy
620865|NCT00242606|Initial monotherapy
620866|NCT00242606|Levetiracetam
620867|NCT00242606|Lamotrigine
620868|NCT00242593|cognition disorders
620869|NCT00242593|Alzheimer's disease
620870|NCT00242593|memory
620871|NCT00242580|AMD
620872|NCT00242580|age-related macular degeneration
620873|NCT00242580|choroidal neovascularization
620874|NCT00242567|zoledronic acid
620875|NCT00242567|bone metastases
620876|NCT00242567|prostate cancer
620877|NCT00242567|hormone-sensitive
620878|NCT00242554|Prostate Cancer
620879|NCT00242554|Bone Metastases
620880|NCT00242554|Zoledronic acid
620881|NCT00242541|microadenoma
620882|NCT00242541|macroadenoma
620883|NCT00242528|Bone Lesions
620884|NCT00242528|Multiple Myeloma
620885|NCT00242528|zoledronic acid
620886|NCT00242515|High risk Myelodysplastic Syndrome (MDS)
620887|NCT00242502|Hepatocellular Carcinoma
620888|NCT00242502|Liver Cancer
620889|NCT00242502|Bevacizumab
620890|NCT00242502|Anti-VEGF monoclonal antibody
620891|NCT00242502|rhuMAb-VEGF
620892|NCT00242502|Erlotinib Hydrochloride
620893|NCT00242502|OSI-774
620894|NCT00242502|Tarceva
620895|NCT00242502|Erlotinib
620896|NCT00242502|Avastin
620898|NCT00242463|malnutrition
620899|NCT00242463|anabolic steroids
620900|NCT00242463|intensive care unit
620901|NCT00242463|rehabilitation
620902|NCT00242450|metoclopramide
620903|NCT00242450|feeding
620904|NCT00242450|very low birthweightnewborn
620905|NCT00242424|influenza vaccine
620906|NCT00242424|infants
620907|NCT00242424|safety
620908|NCT00242424|immunogenicity
620909|NCT00242398|Intensive care unit
620910|NCT00242398|Patients with bleeding high risk
620911|NCT00242398|Intermittent hemodialysis without anticoagulation
620912|NCT00242398|Blood lost
620913|NCT00242385|Severe congenital Alpha1-Proteinase Inhibitor (Alpha1-PI) deficiency
620914|NCT00242372|Insulin dependent Type 2 diabetes
620915|NCT00242346|Hypertension
620916|NCT00242333|COPD
620917|NCT00242333|COAD
620918|NCT00242333|Chronic obstructive pulmonary disease
620919|NCT00242333|emphysema
620920|NCT00242333|chronic bronchitis
620921|NCT00242320|COPD
620922|NCT00242320|chronic obstructive pulmonary disease
620923|NCT00242320|Roflumilast
620924|NCT00242307|Asthma
620925|NCT00242307|Roflumilast
620926|NCT00242307|phosphodiesterase 4 inhibitor
620927|NCT00242294|COPD
620928|NCT00242294|Phosphodiesterase 4 inhibitor
620929|NCT00242294|Roflumilast
620930|NCT00242281|Sore Throat
620931|NCT00242281|Pharyngitis
620932|NCT00242281|Tonsillitis
620933|NCT00242255|Histone
620934|NCT00242255|Chromatin
620935|NCT00242255|Epigenome
620936|NCT00242255|Senescence
620937|NCT00242255|Acetylation
620938|NCT00242255|Aging
620939|NCT00242255|Tissue Sample
620940|NCT00242242|Stroke
620941|NCT00242242|BCI
620942|NCT00242242|Healthy Volunteer
620943|NCT00242242|HV
620944|NCT00242229|Depression
620945|NCT00242216|HIV-1 infected people
620946|NCT00242216|Antiretroviral treatment-naïve
620947|NCT00242216|Atazanavir
620948|NCT00242216|Fosamprenavir
620949|NCT00242216|ARV Treatment Naive
620950|NCT00242203|Breast Cancer
620951|NCT00242203|Neoadjuvant
620952|NCT00242203|Micrometastasis
620953|NCT00242190|drug therapy
620954|NCT00242190|radiotherapy
620955|NCT00242190|clinical trial
620956|NCT00242177|Multiple Sclerosis
620957|NCT00242177|Relapsing, Remitting
620958|NCT00242177|Autoimmune disease
620959|NCT00242164|Hemodialysis
620960|NCT00242164|Magnesium
620961|NCT00242164|Arrhythmia
620962|NCT00242164|QTc interval
620963|NCT00242164|QT dispersion
620964|NCT00242151|Delirium, Confusion, Cardiac Surgery, Organic Brain Injury, Diffusion Weighted Magnetic Resonance Imaging (DW-MRI)
620965|NCT00242125|Primary biliary Cirrhosis
620966|NCT00242125|genes
620967|NCT00242125|DNA
620968|NCT00242099|liver transplant
620969|NCT00242099|HHV-6
620970|NCT00242099|HHV-7
620971|NCT00242099|Human Herpesvirus-6
620972|NCT00242099|Human Herpesvirus-7
620973|NCT00242047|Tuberculosis.
620974|NCT00242047|Children.
620975|NCT00242047|Vaccine.
620976|NCT00242047|BCG.
620977|NCT00242021|Satiety, ad libitum food intake, fatty acids, hormones
620978|NCT00242008|IDIOPATHIC PARKINSON'S DISEASE
620979|NCT00241982|rheumatoid arthritis
620980|NCT00241982|long circulating liposomes
620981|NCT00241969|nutrition therapy
620982|NCT00241969|preschool children
620983|NCT00241969|cystic fibrosis
620984|NCT00241943|Hepatitis C
620985|NCT00241943|Heroin
620986|NCT00241943|Populations at risk
620987|NCT00241943|testing
620988|NCT00241943|vaccination
620989|NCT00241930|Heroin
620990|NCT00241930|HIV
620991|NCT00241930|buprenorphine
620992|NCT00241930|integration
620993|NCT00241930|drug treatment
620994|NCT00241917|hepatitis C
620995|NCT00241917|heroin
620996|NCT00241917|populations at risk
620997|NCT00241917|testing
620998|NCT00241917|vaccination
620999|NCT00241722|bowel dysfunction
621000|NCT00241722|constipation
621001|NCT00241722|gastrointestinal
621002|NCT00241722|opioids
621003|NCT00241722|pain
621004|NCT00241722|non-cancer pain
621005|NCT00241722|opioid-induced
621006|NCT00241644|Rotavirus gastroenteritis
621007|NCT00241644|HRV vaccine
621008|NCT00241618|Clinical trial
621009|NCT00241618|Randomized
621010|NCT00241618|Treatment
621011|NCT00241618|Prospective
621012|NCT00241618|Parallel Assignment
621013|NCT00241618|Efficacy Safety Study
621014|NCT00241605|Metformin
621015|NCT00241605|AVANDAMET
621016|NCT00241605|Type 2 diabetes
621017|NCT00241592|Cannabis
621018|NCT00241592|Marijuana
621019|NCT00241592|Vaporization
621020|NCT00241592|Volcano
621021|NCT00241592|THC
621022|NCT00241579|Pain
621023|NCT00241579|Cannabis
621024|NCT00241579|Analgesic
621025|NCT00241566|Neuropathic pain
621026|NCT00241566|Electric cortical stimulation
621027|NCT00241566|Economic Medical evaluation
621028|NCT00241540|NSAIDs
621029|NCT00241540|Upper GI symptoms
621030|NCT00241514|NSAIDs
621031|NCT00241514|Upper GI symptoms
621032|NCT00241475|Cancer of the Prostate
621033|NCT00241462|Advanced Breast Cancer
621034|NCT00241449|Locally advanced breast cancer or metastatic breast cancer
621035|NCT00241423|exenatide
621036|NCT00241423|diabetes
621037|NCT00241423|Amylin
621038|NCT00241423|Lilly
621039|NCT00241410|Allergy
621040|NCT00241410|Specific Immunotherapy
621041|NCT00241410|Sublingual Immunotherapy
621042|NCT00241397|pain
621043|NCT00241397|depression
621044|NCT00241397|anxiety disorder
621045|NCT00241384|Prostatic Cancer
621046|NCT00241384|Brachytherapy
621047|NCT00241384|Prostatic neoplasm
621048|NCT00241384|Radiation therapy
621049|NCT00241371|Multiple Myeloma
621050|NCT00241358|Plerixafor
621051|NCT00241358|Stem cell transplantation
621052|NCT00241358|Stem cells
621053|NCT00241358|Mobilization
621054|NCT00241345|post transplant
621055|NCT00241345|Any patient receiving an allogeneic bone marrow or peripheral blood stem cell transplant at Washington University Medical Center
621056|NCT00241332|pain
621057|NCT00241332|hyperalgesia
621058|NCT00241332|drug tolerance
621059|NCT00241332|remifentanil
621060|NCT00241332|fentanyl
621061|NCT00241332|Anterior Cruciate Ligament
621062|NCT00241332|Posterior Cruciate Ligament
621063|NCT00241332|Medial Collateral Ligament, Knee
621064|NCT00241319|ocular, allergic conjunctivitis, ophthalmic
621065|NCT00241306|aging
621066|NCT00241306|language
621067|NCT00241306|gender
621068|NCT00241293|language
621069|NCT00241267|Pulmonary
621070|NCT00241267|Neoplasms
621071|NCT00241267|Endobronchial
621072|NCT00241267|Ultrasonography
621073|NCT00241267|Primary
621074|NCT00241254|Multiple Sclerosis, Chronic Progressive
621075|NCT00241254|Cyclophosphamide
621076|NCT00241254|Methylprednisolone
621077|NCT00241254|Randomized Controlled Trials
621078|NCT00241254|Double-Blind Study
621079|NCT00241241|myeloproliferative disorder
621080|NCT00241241|polycythemia vera
621081|NCT00241241|interferon
621082|NCT00241228|Shock, Septic
621083|NCT00241228|Renal Failure, Acute
621084|NCT00241228|Venovenous Hemofiltration
621085|NCT00241228|Randomized Controlled Trial
621086|NCT00241228|Multicenter Study
621087|NCT00241228|Mortality
621088|NCT00241215|Botulinum toxin serotype A
621089|NCT00241215|Cervicobrachial syndrome
621090|NCT00241215|Myofascial pain
621091|NCT00241215|Cervicothoracic myofascial pain
621092|NCT00241215|Propulsion
621093|NCT00241215|Postural abnormality
621094|NCT00241202|signs and symptoms
621095|NCT00241202|self care
621096|NCT00241202|patient compliance
621097|NCT00241202|quality of life
621098|NCT00241189|Systemic sclerosis
621099|NCT00241189|Scleroderma
621100|NCT00241189|Rapamycin
621101|NCT00241189|Methotrexate
621102|NCT00241176|Psychiatric
621103|NCT00241176|Clinical Trial
621104|NCT00241176|Pediatrics
621105|NCT00241176|Tourette's Disorder
621106|NCT00241176|Tic Disorder
621107|NCT00241150|valsartan
621108|NCT00241150|hypertension
621109|NCT00241150|metabolic syndrome
621110|NCT00241150|endothelial function
621111|NCT00241137|hypertension
621112|NCT00241137|valsartan
621113|NCT00241124|hypertension
621114|NCT00241124|valsartan
621115|NCT00241124|morning/evening dosing
621116|NCT00241124|lisinopril
621117|NCT00241111|Prostate
621118|NCT00241111|cancer
621119|NCT00241111|bone metastasis
621120|NCT00241111|zoledronic acid
621121|NCT00241098|HYPERTENSION
621122|NCT00241098|HEART FAILURE
621123|NCT00241098|PEPTIDE
621124|NCT00241098|valsartan
621125|NCT00241085|proteinuria
621126|NCT00241085|hypertension
621127|NCT00241085|valsartan
621128|NCT00241085|type 2 diabetes
621129|NCT00241059|Renal transplantation, maintenance patients, tolerability, EC-MPS
621130|NCT00241046|Breast cancer
621131|NCT00241046|Machine learning techniques
621132|NCT00241046|Aromatase inhibitors
621133|NCT00241046|1st line treatment
621134|NCT00241046|2nd line treatment
621135|NCT00241020|hepatocellular carcinoma
621136|NCT00241020|Octreotide
621137|NCT00241007|HYPERTENSION, VALSARTAN
621138|NCT00240994|End stage renal disease
621139|NCT00240994|Kidney transplantation
621140|NCT00240994|Renal transplantation
621141|NCT00240994|Kidney failure
621142|NCT00240994|Pediatric renal transplant recipients
621143|NCT00240994|Alemtuzumab
621144|NCT00240994|Campath
621145|NCT00240994|Mycophenolate mofetil
621146|NCT00240994|MMF
621147|NCT00240994|CellCept
621148|NCT00240994|Tacrolimus
621149|NCT00240994|Prograf
621150|NCT00240994|Sirolimus
621151|NCT00240994|Rapamycin
621152|NCT00240981|Andropause
621153|NCT00240981|frailty
621154|NCT00240981|hormone replacement therapy
621155|NCT00240981|Aging
621156|NCT00240968|Avian influenza, vaccine, A/H5N1, sub-study
621157|NCT00240955|Renal/Kidney, Transplantation, steroids, EC-MPS
621158|NCT00240942|Endometriosis
621159|NCT00240942|GnRH analog
621160|NCT00240942|Aromataseinhibitor
621161|NCT00240942|Letrozole
621162|NCT00240903|revaccination, vaccination, influenza, H5N1 vaccine
621163|NCT00240864|postoperative dental pain
621164|NCT00240864|acetaminophen
621165|NCT00240864|ibuprofen
621166|NCT00240851|muscle ache
621167|NCT00240851|pain
621168|NCT00240851|soreness
621169|NCT00240851|acetaminophen
621170|NCT00240838|muscle soreness
621171|NCT00240838|pain, acetaminophen
621172|NCT00240838|ibuprofen
621173|NCT00240825|postoperative dental pain
621174|NCT00240825|acetaminophen
621175|NCT00240825|ibuprofen
621176|NCT00240812|nocturnal enuresis
621177|NCT00240812|bedwetting
621178|NCT00240812|ibuprofen
621179|NCT00240799|osteoarthritis hip
621180|NCT00240799|osteoarthritis knee
621181|NCT00240799|acetaminophen
621182|NCT00240786|osteoarthritis hip
621183|NCT00240786|osteoarthritis knee
621184|NCT00240786|acetaminophen
621185|NCT00240773|osteoarthritis hip
621186|NCT00240773|osteoarthritis knee
621187|NCT00240773|acetaminophen, naproxen
621188|NCT00240760|Memantine
621189|NCT00240760|Down syndrome
621190|NCT00240760|Dementia
621191|NCT00240760|learning Disability
621192|NCT00240760|Treatment of Dementia
621193|NCT00240734|Anemia
621194|NCT00240734|Chronic renal failure
621195|NCT00240734|pre-dialysis
621196|NCT00240734|diabetic
621197|NCT00240721|topiramate
621198|NCT00240721|bipolar disorders
621199|NCT00240721|mood disorders
621200|NCT00240721|manic state
621201|NCT00240721|depression
621202|NCT00240721|manic-depressive psychoses
621203|NCT00240708|Schizophrenia
621204|NCT00240708|intramuscular injection
621205|NCT00240708|antipsychotic agents
621206|NCT00240708|risperidone
621207|NCT00240708|long-acting injectable
621208|NCT00240695|Alzheimer's disease
621209|NCT00240695|Dementia
621210|NCT00240695|Brain Disease
621211|NCT00240695|Memory Loss
621212|NCT00240695|galantamine
621213|NCT00240695|Nervous System Diseases
621214|NCT00240695|open-label
621215|NCT00240695|elderly
621216|NCT00240682|Carcinoma, Squamous Cell
621217|NCT00240682|Skin
621218|NCT00240682|cetuximab
621219|NCT00240682|epidermal growth factor receptor
621220|NCT00240669|Maxillo facial surgery,
621221|NCT00240669|osteosynthesis,
621222|NCT00240669|resorbable device
621223|NCT00240656|aldosterone antagonists, spironolactone, captopril carvedilol
621224|NCT00240643|non valvular atrial fibrillation
621225|NCT00240643|stroke
621226|NCT00240643|aspirin
621227|NCT00240630|acute migraine
621228|NCT00240630|consistency of response
621229|NCT00240630|satisfaction
621230|NCT00240630|migraine
621231|NCT00240630|early intervention
621232|NCT00240617|consistency of response
621233|NCT00240617|migraine
621234|NCT00240617|satisfaction
621235|NCT00240617|early intervention
621236|NCT00240604|corticosteroid treatment
621237|NCT00240604|inflammatory diseases
621238|NCT00240591|BEXXAR
621239|NCT00240591|Tositumomab
621240|NCT00240591|Iodine I 131 Tositumomab
621241|NCT00240591|low-grade follicular lymphomas
621242|NCT00240578|Long-Term Follow-up
621243|NCT00240578|BEXXAR
621244|NCT00240578|Iodine I 131 Tositumomab
621245|NCT00240578|Low-grade lymphoma
621246|NCT00240565|BEXXAR
621247|NCT00240565|non-Hodgkin's Lymphoma
621248|NCT00240565|tositumomab
621249|NCT00240565|I-131
621250|NCT00240552|protease inhibitor
621251|NCT00240552|Treatment Experienced
621252|NCT00240552|amprenavir
621253|NCT00240552|fosamprenavir
621254|NCT00240552|GW433908
621255|NCT00240552|HIV
621256|NCT00240552|pro drug
621257|NCT00240539|Hepatitis B
621258|NCT00240526|Hepatitis B immunoglobulin
621259|NCT00240526|Hepatitis B antibody persistence
621260|NCT00240513|Acne
621261|NCT00240500|Long-term follow-up
621262|NCT00240500|Hepatitis B antibody persistence
621263|NCT00240487|Acute Respiratory Distress Syndrome
621264|NCT00240487|ARDS
621265|NCT00240487|Nitric Oxide
621266|NCT00240461|respiratory
621267|NCT00240461|infection
621268|NCT00240461|influenza
621269|NCT00240396|fracture
621270|NCT00240396|Tibia
621271|NCT00240396|femur
621272|NCT00240396|humerus
621273|NCT00240396|narcotics
621274|NCT00240396|bimodal
621275|NCT00240396|analgesia
621276|NCT00240396|long-bone
621277|NCT00240396|NSAIDS
621278|NCT00240344|High risk patients
621279|NCT00240344|Crestor
621280|NCT00240344|Rosuvastatin
621281|NCT00240344|LDL cholesterol
621282|NCT00240344|observational
621283|NCT00240331|End Stage Renal Failure
621284|NCT00240318|Coronary Artery Disease
621285|NCT00240305|Metabolic Syndrome
621286|NCT00240305|Dyslipidaemia
621287|NCT00240292|Ischaemic or non-ischaemic systolic congestive heart failure
621288|NCT00240279|high blood cholesterol levels
621289|NCT00240266|Metabolic Syndrome
621290|NCT00240266|Dyslipaemia
621291|NCT00240253|diabetes
621292|NCT00240253|Amylin
621293|NCT00240253|Symlin
621294|NCT00240253|pramlintide
621295|NCT00240253|insulin glargine
621296|NCT00240227|Alcoholism
621297|NCT00240227|Cocaine Dependence
621298|NCT00240227|Prazosin
621299|NCT00240227|Substance use disorders
621300|NCT00240214|Kidney transplants
621301|NCT00240188|Hernia
621302|NCT00240188|Incisional
621303|NCT00240188|Laparoscopic
621304|NCT00240188|Mesh
621305|NCT00240188|Repair
621306|NCT00240188|Ventral
621307|NCT00240162|Myeloma
621308|NCT00240162|PTK
621309|NCT00240136|Early, severe
621310|NCT00240123|ERCP
621311|NCT00240123|EUS
621312|NCT00240110|Bipolar
621313|NCT00240110|Cocaine
621314|NCT00240110|Comorbidity
621315|NCT00240071|Breast cancer
621316|NCT00240071|Metastatic breast cancer
621317|NCT00240071|Hormonal therapy
621318|NCT00240071|Bevacizumab
621319|NCT00240058|Blood Pressure
621320|NCT00240058|Nitric Oxide
621321|NCT00240058|L-NMMA
621322|NCT00240058|Phenylephrine
621323|NCT00240058|Nitroprusside
621324|NCT00240058|Vasoreactivity
621325|NCT00240045|Hepatorenal syndrome
621326|NCT00240045|Refractory ascites
621327|NCT00240045|Midodrine
621328|NCT00240045|Octreotide
621329|NCT00240045|Albumin
621330|NCT00240045|Cirrhosis
621331|NCT00240006|Multiple Sclerosis
621332|NCT00240006|Copaxone®
621333|NCT00240006|Shared Solutions®
621334|NCT00239980|antineoplastic agent
621335|NCT00239980|ovarian cancer
621336|NCT00239980|fragmin
621337|NCT00239980|dalteparin
621338|NCT00239967|dyslipidemia
621339|NCT00239967|obesity
621340|NCT00239928|Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
621341|NCT00239902|Transplantation, kidney, and organ transplantation
621342|NCT00239889|Forearm fracture
621343|NCT00239889|Postmenopausal women
621344|NCT00239889|Pain
621345|NCT00239889|Grip strength
621346|NCT00239889|Salmon calcitonin
621347|NCT00239876|Transplantation, kidney, and organ transplant
621348|NCT00239863|Transplantation, kidney,organ transplant
621349|NCT00239850|obesity
621350|NCT00239850|lifestyle
621351|NCT00239850|treatment
621352|NCT00239850|Complications
621353|NCT00239850|endocrine changes
621354|NCT00239850|Lipids
621355|NCT00239850|C18.654.726.500.495
621356|NCT00239837|Adolescent
621357|NCT00239837|Foster Care
621358|NCT00239837|Female
621359|NCT00239824|urinary incontinence
621360|NCT00239824|pelvic floor muscle training
621361|NCT00239824|radical prostatectomy
621362|NCT00239824|physiotherapy
621363|NCT00239811|Transplantation, kidney, and organ transplant.
621364|NCT00239798|Transplantation, kidney, organ transplant
621365|NCT00239785|Transplantation, kidney, and organ transplant.
621366|NCT00239772|Cognitive Therapy
621367|NCT00239772|PTSD
621368|NCT00239772|Females
621369|NCT00239772|Rape
621370|NCT00239772|Trauma
621371|NCT00239759|Epidemiological study
621372|NCT00239746|Nonsteroidal Anti-inflammatories
621373|NCT00239746|NSAIDS
621374|NCT00239733|HIV
621375|NCT00239733|HCV
621376|NCT00239733|Hepatitis C
621377|NCT00239733|Thrombocytopenia
621378|NCT00239720|Psoriatic Arthritis
621379|NCT00239720|Arthritis
621380|NCT00239720|Psoriasis
621381|NCT00239720|Psoriatic
621382|NCT00239720|PsA
621383|NCT00239707|insulin sensitivity
621384|NCT00239707|blood sugar
621385|NCT00239694|Immune response
621386|NCT00239694|Antibody response
621387|NCT00239681|Primary prevention
621388|NCT00239681|Cardiovascular disease
621389|NCT00239681|Statin therapy
621390|NCT00239681|C-reactive protein
621391|NCT00239668|Burns
621392|NCT00239668|Functional
621393|NCT00239668|Psychosocial
621394|NCT00239668|Recovery
621395|NCT00239668|Long-term
621396|NCT00239668|Pediatric
621397|NCT00239668|Surgical
621398|NCT00239668|Outcomes
621399|NCT00239668|Benchmarking
621400|NCT00239642|Iron
621401|NCT00239642|Anemia
621402|NCT00239642|CKD
621403|NCT00239616|Anemia
621404|NCT00239616|Pharmacokinetics
621405|NCT00239603|OV-Watch
621406|NCT00239603|fertility monitor
621407|NCT00239603|ovulation induction
621408|NCT00239603|clomiphene citrate
621409|NCT00239603|anovulation
621410|NCT00239603|infertility
621411|NCT00239577|Dengue infection
621412|NCT00239564|IPX054
621413|NCT00239564|Parkinson disease
621414|NCT00239564|Levodopa
621415|NCT00239551|gastric stress ulcer
621416|NCT00239551|Prevacid
621417|NCT00239551|Prostaglandin
621418|NCT00239525|Cerebrovascular Accident
621419|NCT00239525|Intracranial Hypertension
621420|NCT00239512|PDA
621421|NCT00239512|VLBW infants
621422|NCT00239512|Indomethacin
621423|NCT00239512|Ibuprofen
621424|NCT00239330|high blood cholesterol levels
621425|NCT00239317|tamsulosin
621426|NCT00239317|urinary tract diseases
621427|NCT00239317|male
621428|NCT00239304|Stage III Head and Neck Cancer
621429|NCT00239304|Stage IV Head and Neck Cancer
621430|NCT00239265|tamsulosin
621431|NCT00239265|urinary tract diseases
621432|NCT00239265|female
621433|NCT00239252|Interferon alfacon-1
621434|NCT00239252|Virus disease
621435|NCT00239252|Hepatitis C
621436|NCT00239239|Non-myeloid malignancy
621437|NCT00239239|Chemotherapy-induced anemia
621438|NCT00239239|Oncology
621439|NCT00239239|Clinical Trials
621440|NCT00239239|Pharmacokinetics
621441|NCT00239239|Darbepoetin alfa
621442|NCT00239239|Aranesp
621443|NCT00239239|Amgen
621444|NCT00239226|atrial fibrillation
621445|NCT00239226|interatrial septum
621446|NCT00239226|atrial pacing
621447|NCT00239226|symptomatic sinus node dysfunction,
621448|NCT00239226|pacemaker indication class I
621449|NCT00239213|catechins
621450|NCT00239213|gargling
621451|NCT00239213|healthy volunteers
621452|NCT00239187|Type 2 diabetes
621453|NCT00239174|obesity
621454|NCT00239161|Pyelonephritis
621455|NCT00239148|Type 1 diabetes
621456|NCT00239135|Actinic Keratosis
621457|NCT00239135|Topical
621458|NCT00239135|Maximum Tolerated Dose
621459|NCT00239135|Solar Keratosis
621460|NCT00239135|Sun Spots
621461|NCT00239135|Dermatology
621462|NCT00239122|Cognitive Therapy
621463|NCT00239122|Psychotic Disorders
621464|NCT00239122|Treatment Outcome
621465|NCT00239096|alcoholic liver cirrhosis
621466|NCT00239096|ascites
621467|NCT00239096|sodium retention
621468|NCT00239083|MYFORMS, Kidney Transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS), Cyclosporine microemulsion (CsA-ME)
621469|NCT00239070|EC-MPS, renal transplantation, de novo patients
621470|NCT00239057|Renal transplantation, EC-MPS
621471|NCT00239044|Kidney transplant recipients; Enteric-coated Mycophenolate sodium (EC-MPS)
621472|NCT00239031|Renal transplantation, EC-MPS
621473|NCT00239018|Enteric-Coated Mycophenolate Sodium (EC-MPS), de novo, kidney transplantation, long-term safety.
621474|NCT00239005|QoL
621475|NCT00239005|GI Side Effects
621476|NCT00239005|MPA
621477|NCT00238992|Kidney, de novo transplant, steroid withdrawal, adults, EC-MPS and cyclosporine
621478|NCT00238979|Renal transplantation, Enteric-coated mycophenolate sodium
621479|NCT00238966|Renal transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS)
621480|NCT00238953|Kidney transplantation
621481|NCT00238953|enteric-coated mycophenolate sodium
621482|NCT00238940|Renal transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS)
621483|NCT00238927|asthma
621484|NCT00238927|preschool
621485|NCT00238927|viral
621486|NCT00238927|upper respiratory track infection
621487|NCT00238927|fluticasone
621488|NCT00238927|inhaled corticosteroids
621489|NCT00238927|placebo
621490|NCT00238927|exacerbations
621491|NCT00238927|severity
621492|NCT00238927|safety
621493|NCT00238927|growth
621494|NCT00238927|bone mineral density
621495|NCT00238927|adrenal function
621496|NCT00238927|rescue beta2-agonists
621497|NCT00238901|Liver transplant, HCV+, steroid free
621498|NCT00238888|asthma
621499|NCT00238888|children
621500|NCT00238888|adolescent
621501|NCT00238888|education
621502|NCT00238888|medical review
621503|NCT00238888|asthma control
621504|NCT00238888|questionnaire
621505|NCT00238888|quality of life
621506|NCT00238888|emergency department visit
621507|NCT00238888|use of medication
621508|NCT00238888|adherence to treatment
621509|NCT00238875|stereotactic body radiation therapy
621510|NCT00238875|T1N0M0 non-small cell lung cancer
621511|NCT00238875|radiotherapy
621512|NCT00238862|Diabetes
621513|NCT00238862|Corneal transplant
621514|NCT00238862|Neurotrophic keratitis
621515|NCT00238862|Post-bacterial keratitis
621516|NCT00238862|Metaherpetic keratitis
621517|NCT00238849|Non-small cell lung cancer
621518|NCT00238823|cryoablation
621519|NCT00238823|radiofrequency ablation
621520|NCT00238823|pediatrics
621521|NCT00238823|cardiology
621522|NCT00238810|BNP
621523|NCT00238810|Pediatrics
621524|NCT00238810|Congenital heart disease
621525|NCT00238810|b-type natriuretic peptide
621526|NCT00238797|Glioblastoma multiforme
621527|NCT00238797|Brain tumour
621528|NCT00238758|Mood Disorder
621529|NCT00238745|Postmenopausal Osteoporosis
621530|NCT00238732|Vaginal Atrophy
621531|NCT00238732|Postmenopause
621532|NCT00238719|Social Anxiety
621533|NCT00238719|Children Disorders
621534|NCT00238706|Radiofrequency catheter ablation
621535|NCT00238706|Atrial fibrillation
621536|NCT00238706|Randomized trial
621537|NCT00238693|transplant
621538|NCT00238693|transplantation of liver, kidney, pancreas
621539|NCT00238680|Overactive bladder
621540|NCT00238680|Children
621541|NCT00238680|Bladder rehabilitation
621542|NCT00238667|Extracranial carotid artery dissection
621543|NCT00238667|Dissection and stroke
621544|NCT00238550|Diabetes
621545|NCT00238550|Pain
621546|NCT00238550|Peripheral neuropathy
621547|NCT00238537|Stroke
621548|NCT00238537|Thrombolysis
621549|NCT00238537|MRI
621550|NCT00238537|Echoplanar
621551|NCT00238537|Penumbra
621552|NCT00238524|painful distal diabetic neuropathy
621553|NCT00238498|Type 2 diabetes
621554|NCT00238498|vildagliptin
621555|NCT00238498|HbA1c
621556|NCT00238485|Bipolar I Disorder
621557|NCT00238472|Type 2 diabetes
621558|NCT00238472|nateglinide
621559|NCT00238459|Immunity to HIV
621560|NCT00238459|Acute Infection
621561|NCT00238459|Treatment Naive
621562|NCT00238459|Treatment Interruption
621563|NCT00238459|Structured Treatment Interruption
621564|NCT00238459|STI
621565|NCT00238446|Enteric-coated mycophenolate sodium, heart transplant recipients, long term safety
621566|NCT00238433|recurrent adult Hodgkin lymphoma
621567|NCT00238433|recurrent adult diffuse small cleaved cell lymphoma
621568|NCT00238433|stage III adult diffuse small cleaved cell lymphoma
621569|NCT00238433|stage IV adult diffuse small cleaved cell lymphoma
621570|NCT00238433|recurrent grade 3 follicular lymphoma
621571|NCT00238433|stage III grade 3 follicular lymphoma
621572|NCT00238433|stage IV grade 3 follicular lymphoma
621573|NCT00238433|recurrent adult diffuse mixed cell lymphoma
621574|NCT00238433|stage III adult diffuse mixed cell lymphoma
621575|NCT00238433|stage IV adult diffuse mixed cell lymphoma
621576|NCT00238433|recurrent adult diffuse large cell lymphoma
621577|NCT00238433|stage III adult diffuse large cell lymphoma
621578|NCT00238433|stage IV adult diffuse large cell lymphoma
621579|NCT00238433|recurrent adult immunoblastic large cell lymphoma
621580|NCT00238433|stage III adult immunoblastic large cell lymphoma
621581|NCT00238433|stage IV adult immunoblastic large cell lymphoma
621582|NCT00238433|recurrent adult lymphoblastic lymphoma
621583|NCT00238433|stage III adult lymphoblastic lymphoma
621584|NCT00238433|stage IV adult lymphoblastic lymphoma
621585|NCT00238433|recurrent adult Burkitt lymphoma
621586|NCT00238433|stage III adult Burkitt lymphoma
621587|NCT00238433|stage IV adult Burkitt lymphoma
621588|NCT00238433|recurrent mantle cell lymphoma
621589|NCT00238433|stage III mantle cell lymphoma
621590|NCT00238433|stage IV mantle cell lymphoma
621591|NCT00238433|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
621592|NCT00238433|nodal marginal zone B-cell lymphoma
621593|NCT00238433|recurrent marginal zone lymphoma
621594|NCT00238433|splenic marginal zone lymphoma
621595|NCT00238433|recurrent small lymphocytic lymphoma
621596|NCT00238433|recurrent grade 1 follicular lymphoma
621597|NCT00238433|recurrent grade 2 follicular lymphoma
621598|NCT00238433|recurrent/refractory childhood Hodgkin lymphoma
621599|NCT00238433|stage III childhood Hodgkin lymphoma
621600|NCT00238433|stage IV childhood Hodgkin lymphoma
621601|NCT00238433|recurrent childhood anaplastic large cell lymphoma
621602|NCT00238433|stage III childhood anaplastic large cell lymphoma
621603|NCT00238433|stage IV childhood anaplastic large cell lymphoma
621604|NCT00238433|childhood grade III lymphomatoid granulomatosis
621605|NCT00238433|recurrent childhood large cell lymphoma
621606|NCT00238433|stage III childhood large cell lymphoma
621607|NCT00238433|stage IV childhood large cell lymphoma
621608|NCT00238433|recurrent childhood lymphoblastic lymphoma
621609|NCT00238433|stage III childhood lymphoblastic lymphoma
621610|NCT00238433|stage IV childhood lymphoblastic lymphoma
621611|NCT00238433|recurrent childhood small noncleaved cell lymphoma
621612|NCT00238433|stage III childhood small noncleaved cell lymphoma
621613|NCT00238433|stage IV childhood small noncleaved cell lymphoma
621614|NCT00238433|recurrent cutaneous T-cell non-Hodgkin lymphoma
621615|NCT00238433|stage III cutaneous T-cell non-Hodgkin lymphoma
621616|NCT00238433|stage IV cutaneous T-cell non-Hodgkin lymphoma
621617|NCT00238407|adenocarcinoma of the esophagus
621618|NCT00238407|squamous cell carcinoma of the esophagus
621619|NCT00238407|stage III esophageal cancer
621620|NCT00238407|stage IV esophageal cancer
621621|NCT00238381|adenocarcinoma of the rectum
621622|NCT00238381|stage 0 rectal cancer
621623|NCT00238381|stage I rectal cancer
621624|NCT00238381|stage II rectal cancer
621625|NCT00238381|stage III rectal cancer
621626|NCT00238381|stage IV rectal cancer
621627|NCT00238381|recurrent rectal cancer
621628|NCT00238368|contiguous stage II adult diffuse large cell lymphoma
621629|NCT00238368|noncontiguous stage II adult diffuse large cell lymphoma
621630|NCT00238368|stage I adult diffuse large cell lymphoma
621631|NCT00238368|stage III adult diffuse large cell lymphoma
621632|NCT00238368|stage IV adult diffuse large cell lymphoma
621633|NCT00238368|contiguous stage II grade 3 follicular lymphoma
621634|NCT00238368|noncontiguous stage II grade 3 follicular lymphoma
621635|NCT00238368|stage I grade 3 follicular lymphoma
621636|NCT00238368|stage III grade 3 follicular lymphoma
621637|NCT00238368|stage IV grade 3 follicular lymphoma
621638|NCT00238368|anaplastic large cell lymphoma
621639|NCT00238368|stage I adult T-cell leukemia/lymphoma
621640|NCT00238368|stage II adult T-cell leukemia/lymphoma
621641|NCT00238368|stage III adult T-cell leukemia/lymphoma
621642|NCT00238368|stage IV adult T-cell leukemia/lymphoma
621643|NCT00238355|infection
621644|NCT00238355|unspecified adult solid tumor, protocol specific
621645|NCT00238342|stage I ovarian epithelial cancer
621646|NCT00238342|stage II ovarian epithelial cancer
621647|NCT00238342|stage III ovarian epithelial cancer
621648|NCT00238342|stage IV ovarian epithelial cancer
621649|NCT00238342|fallopian tube cancer
621650|NCT00238342|ovarian clear cell cystadenocarcinoma
621651|NCT00238342|ovarian endometrioid adenocarcinoma
621652|NCT00238342|ovarian mucinous cystadenocarcinoma
621653|NCT00238342|ovarian serous cystadenocarcinoma
621654|NCT00238342|ovarian undifferentiated adenocarcinoma
621655|NCT00238329|recurrent melanoma
621656|NCT00238329|stage IV melanoma
621657|NCT00238329|ciliary body and choroid melanoma, medium/large size
621658|NCT00238329|extraocular extension melanoma
621659|NCT00238329|iris melanoma
621660|NCT00238329|recurrent intraocular melanoma
621661|NCT00238316|breast cancer
621662|NCT00238290|recurrent breast cancer
621663|NCT00238290|stage IIIA breast cancer
621664|NCT00238290|stage IIIB breast cancer
621665|NCT00238290|stage IIIC breast cancer
621666|NCT00238290|stage IV breast cancer
621667|NCT00238277|adult glioblastoma
621668|NCT00238277|adult giant cell glioblastoma
621669|NCT00238277|adult gliosarcoma
621670|NCT00238264|childhood oligodendroglioma
621671|NCT00238264|recurrent childhood cerebellar astrocytoma
621672|NCT00238264|recurrent childhood cerebral astrocytoma
621673|NCT00238264|childhood low-grade cerebral astrocytoma
621674|NCT00238264|recurrent childhood visual pathway and hypothalamic glioma
621675|NCT00238264|untreated childhood cerebellar astrocytoma
621676|NCT00238264|untreated childhood visual pathway and hypothalamic glioma
621677|NCT00238251|stage IV non-small cell lung cancer
621678|NCT00238251|recurrent non-small cell lung cancer
621679|NCT00238251|tumors metastatic to brain
621680|NCT00238238|recurrent grade 1 follicular lymphoma
621681|NCT00238238|recurrent grade 2 follicular lymphoma
621682|NCT00238238|recurrent grade 3 follicular lymphoma
621683|NCT00238225|unspecified adult solid tumor, protocol specific
621684|NCT00238199|stage III pancreatic cancer
621685|NCT00238199|stage IV pancreatic cancer
621686|NCT00238173|drug/agent toxicity by tissue/organ
621687|NCT00238173|bone marrow suppression
621688|NCT00238173|long-term effects secondary to cancer therapy in children
621689|NCT00238173|recurrent childhood brain stem glioma
621690|NCT00238173|untreated childhood brain stem glioma
621691|NCT00238173|childhood central nervous system germ cell tumor
621692|NCT00238173|recurrent childhood supratentorial primitive neuroectodermal tumor
621693|NCT00238173|recurrent childhood visual pathway and hypothalamic glioma
621694|NCT00238173|recurrent childhood brain tumor
621695|NCT00238173|recurrent childhood cerebellar astrocytoma
621696|NCT00238173|childhood high-grade cerebral astrocytoma
621697|NCT00238173|childhood low-grade cerebral astrocytoma
621698|NCT00238173|recurrent childhood cerebral astrocytoma
621699|NCT00238173|recurrent childhood medulloblastoma
621700|NCT00238173|childhood oligodendroglioma
621701|NCT00238173|childhood infratentorial ependymoma
621702|NCT00238173|childhood supratentorial ependymoma
621703|NCT00238173|recurrent childhood ependymoma
621704|NCT00238173|childhood central nervous system choriocarcinoma
621705|NCT00238173|childhood central nervous system embryonal tumor
621706|NCT00238173|childhood central nervous system germinoma
621707|NCT00238173|childhood central nervous system mixed germ cell tumor
621708|NCT00238173|childhood central nervous system teratoma
621709|NCT00238173|childhood central nervous system yolk sac tumor
621710|NCT00238173|recurrent childhood central nervous system embryonal tumor
621711|NCT00238147|stage II esophageal cancer
621712|NCT00238147|stage III esophageal cancer
621713|NCT00238108|Sleep disorders
621714|NCT00238108|High blood pressure
621715|NCT00238082|COPD
621716|NCT00238082|Chronic Obstructive Pulmonary Disease
621717|NCT00238082|Emphysema
621718|NCT00238082|Chronic Bronchitis
621719|NCT00238069|Asthma
621720|NCT00238069|Sleep Apnea
621721|NCT00238069|Obesity
621722|NCT00238069|CPAP
621723|NCT00238056|Domperidone, QT, prematurity
621724|NCT00238043|Biogeneric Epoetin treatment
621725|NCT00238043|Renal anaemia
621726|NCT00238043|Chronic Kidney Disease
621727|NCT00238043|Pure Red Blood Cell Aplasia
621728|NCT00238043|Hemodialysis
621729|NCT00238030|organ donation
621730|NCT00238030|thyroid replacement
621731|NCT00238017|malaria, amodiaquine, artesunate, safety, efficacy
621732|NCT00238004|Niacin
621733|NCT00237965|Skin Self Examination
621734|NCT00237965|Mole Mapping Diagram
621735|NCT00237965|Melanoma
621736|NCT00237926|Sleep
621737|NCT00237926|Fatigue
621738|NCT00237926|Exercise tolerance
621739|NCT00237926|Quality of life
621740|NCT00237926|Health status
621741|NCT00237887|Psoriasis
621742|NCT00237887|adalimumab
621743|NCT00237874|prodrome
621744|NCT00237874|ultra high risk
621745|NCT00237874|aripiprazole
621746|NCT00237822|Treatment Adherence
621747|NCT00237822|Co-Occurring Disorders
621748|NCT00237822|Motivational Enhancement Therapy
621749|NCT00237822|Contingency Management
621750|NCT00237822|MEMS Caps
621751|NCT00237796|Behavioral
621752|NCT00237796|Cognitive
621753|NCT00237796|Functioning
621754|NCT00237796|Older
621755|NCT00237796|CBT
621756|NCT00237796|Rehabilitation
621757|NCT00237796|Schizophrenia
621758|NCT00237796|Skills
621759|NCT00237796|Social
621760|NCT00237796|Training
621761|NCT00237783|Renal dialysis
621762|NCT00237783|Hypotension
621763|NCT00237783|Dialysis solutions
621764|NCT00237770|Blood Pressure
621765|NCT00237770|Cardiovascular Autonomic Control
621766|NCT00237770|Nitric Oxide
621767|NCT00237770|NOS Inhibitor
621768|NCT00237770|Orthostatic Hypotension
621769|NCT00237770|Spinal Cord Injury
621770|NCT00237770|Tetraplegia
621771|NCT00237757|Patient Care Team
621772|NCT00237757|Rehabilitation outcomes
621773|NCT00237757|Treatment outcomes
621774|NCT00237744|Motor Learning
621775|NCT00237744|Rehabilitation
621776|NCT00237744|Robotics
621777|NCT00237744|Therapeutic Electric Stimulation
621778|NCT00237731|Acute pain
621779|NCT00237731|Morphine titration
621780|NCT00237731|Analgesia
621781|NCT00237731|Pre-hospital care
621782|NCT00237705|Headache
621783|NCT00237705|Concussion
621784|NCT00237705|Post concussive syndrome
621785|NCT00237705|Head trauma
621786|NCT00237692|Telemedicine
621787|NCT00237692|Adherence
621788|NCT00237692|Tailored Nurse Intervention
621789|NCT00237692|Home Blood Pressure Monitoring
621790|NCT00237692|cardiovascular disease
621791|NCT00237679|behavior therapy
621792|NCT00237679|combination therapy
621793|NCT00237679|gastrointestinal disorder chemotherapy
621794|NCT00237679|human therapy evaluation
621795|NCT00237679|larynx disorder
621796|NCT00237679|middle childhood (6-11)
621797|NCT00237679|lansoprazole
621798|NCT00237679|reflux esophagitis
621799|NCT00237679|quality of life
621800|NCT00237679|clinical research
621801|NCT00237679|human subject
621802|NCT00237679|laryngoscopy
621803|NCT00237679|patient oriented research
621804|NCT00237679|questionnaire
621805|NCT00237666|Bipolar II Disorder
621806|NCT00237666|Major Depressive Episode
621807|NCT00237653|Valganciclovir
621808|NCT00237653|Cytomegalovirus
621809|NCT00237653|Cryptogenic inflammatory bowel diseases
621810|NCT00237653|Crohn Disease
621811|NCT00237653|colitis, ulcerative
621812|NCT00237640|Cinnamon
621813|NCT00237640|Diabetes mellitus
621814|NCT00237640|Hyperlipidemia
621815|NCT00237640|Insulin Resistance
621816|NCT00237627|stage IIIA breast cancer
621817|NCT00237627|stage IIIB breast cancer
621818|NCT00237627|stage IIIC breast cancer
621819|NCT00237627|stage IV breast cancer
621820|NCT00237627|male breast cancer
621821|NCT00237627|recurrent ovarian epithelial cancer
621822|NCT00237627|stage III ovarian epithelial cancer
621823|NCT00237627|stage IV ovarian epithelial cancer
621824|NCT00237627|recurrent adult acute lymphoblastic leukemia
621825|NCT00237627|recurrent adult acute myeloid leukemia
621826|NCT00237627|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
621827|NCT00237627|adult acute myeloid leukemia with inv(16)(p13;q22)
621828|NCT00237627|adult acute myeloid leukemia with t(15;17)(q22;q12)
621829|NCT00237627|adult acute myeloid leukemia with t(16;16)(p13;q22)
621830|NCT00237627|adult acute myeloid leukemia with t(8;21)(q22;q22)
621831|NCT00237627|secondary acute myeloid leukemia
621832|NCT00237627|mast cell leukemia
621833|NCT00237627|stage III chronic lymphocytic leukemia
621834|NCT00237627|stage IV chronic lymphocytic leukemia
621835|NCT00237627|refractory chronic lymphocytic leukemia
621836|NCT00237627|T-cell large granular lymphocyte leukemia
621837|NCT00237627|atypical chronic myeloid leukemia
621838|NCT00237627|accelerated phase chronic myelogenous leukemia
621839|NCT00237627|blastic phase chronic myelogenous leukemia
621840|NCT00237627|chronic phase chronic myelogenous leukemia
621841|NCT00237627|meningeal chronic myelogenous leukemia
621842|NCT00237627|relapsing chronic myelogenous leukemia
621843|NCT00237627|chronic myelomonocytic leukemia
621844|NCT00237627|refractory hairy cell leukemia
621845|NCT00237627|progressive hairy cell leukemia, initial treatment
621846|NCT00237627|stage III adult T-cell leukemia/lymphoma
621847|NCT00237627|stage IV adult T-cell leukemia/lymphoma
621848|NCT00237627|recurrent adult T-cell leukemia/lymphoma
621849|NCT00237627|stage III adult Hodgkin lymphoma
621850|NCT00237627|stage IV adult Hodgkin lymphoma
621851|NCT00237627|recurrent adult Hodgkin lymphoma
621852|NCT00237627|anaplastic large cell lymphoma
621853|NCT00237627|angioimmunoblastic T-cell lymphoma
621854|NCT00237627|stage III cutaneous T-cell non-Hodgkin lymphoma
621855|NCT00237627|stage IV cutaneous T-cell non-Hodgkin lymphoma
621856|NCT00237627|stage III mycosis fungoides/Sezary syndrome
621857|NCT00237627|stage IV mycosis fungoides/Sezary syndrome
621858|NCT00237627|recurrent cutaneous T-cell non-Hodgkin lymphoma
621859|NCT00237627|recurrent mycosis fungoides/Sezary syndrome
621860|NCT00237627|adult grade III lymphomatoid granulomatosis
621861|NCT00237627|adult nasal type extranodal NK/T-cell lymphoma
621862|NCT00237627|Waldenstrom macroglobulinemia
621863|NCT00237627|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
621864|NCT00237627|splenic marginal zone lymphoma
621865|NCT00237627|stage III adult Burkitt lymphoma
621866|NCT00237627|stage III adult diffuse large cell lymphoma
621867|NCT00237627|stage III adult diffuse mixed cell lymphoma
621868|NCT00237627|stage III adult diffuse small cleaved cell lymphoma
621869|NCT00237627|stage III adult immunoblastic large cell lymphoma
621870|NCT00237627|stage III adult lymphoblastic lymphoma
621871|NCT00237627|stage III grade 1 follicular lymphoma
621872|NCT00237627|stage III grade 2 follicular lymphoma
621873|NCT00237627|stage III grade 3 follicular lymphoma
621874|NCT00237627|stage III mantle cell lymphoma
621875|NCT00237627|stage III marginal zone lymphoma
621876|NCT00237627|stage III small lymphocytic lymphoma
621877|NCT00237627|stage IV adult Burkitt lymphoma
621878|NCT00237627|stage IV adult diffuse large cell lymphoma
621879|NCT00237627|stage IV adult diffuse mixed cell lymphoma
621880|NCT00237627|stage IV adult diffuse small cleaved cell lymphoma
621881|NCT00237627|stage IV adult immunoblastic large cell lymphoma
621882|NCT00237627|stage IV adult lymphoblastic lymphoma
621883|NCT00237627|stage IV grade 1 follicular lymphoma
621884|NCT00237627|stage IV grade 2 follicular lymphoma
621885|NCT00237627|stage IV grade 3 follicular lymphoma
621886|NCT00237627|stage IV mantle cell lymphoma
621887|NCT00237627|stage IV marginal zone lymphoma
621888|NCT00237627|stage IV small lymphocytic lymphoma
621889|NCT00237627|recurrent adult Burkitt lymphoma
621890|NCT00237627|recurrent adult diffuse large cell lymphoma
621891|NCT00237627|recurrent adult diffuse mixed cell lymphoma
621892|NCT00237627|recurrent adult diffuse small cleaved cell lymphoma
621893|NCT00237627|recurrent adult grade III lymphomatoid granulomatosis
621894|NCT00237627|recurrent adult immunoblastic large cell lymphoma
621895|NCT00237627|recurrent adult lymphoblastic lymphoma
621896|NCT00237627|recurrent grade 1 follicular lymphoma
621897|NCT00237627|recurrent grade 2 follicular lymphoma
621898|NCT00237627|recurrent grade 3 follicular lymphoma
621899|NCT00237627|recurrent mantle cell lymphoma
621900|NCT00237627|recurrent marginal zone lymphoma
621901|NCT00237627|recurrent small lymphocytic lymphoma
621902|NCT00237627|intraocular lymphoma
621903|NCT00237627|primary central nervous system lymphoma
621904|NCT00237627|stage III multiple myeloma
621905|NCT00237627|stage II multiple myeloma
621906|NCT00237627|refractory multiple myeloma
621907|NCT00237627|cutaneous B-cell non-Hodgkin lymphoma
621908|NCT00237627|recurrent ovarian germ cell tumor
621909|NCT00237627|stage III ovarian germ cell tumor
621910|NCT00237627|stage IV ovarian germ cell tumor
621911|NCT00237627|unspecified adult solid tumor, protocol specific
621912|NCT00237627|recurrent breast cancer
621913|NCT00237627|nodal marginal zone B-cell lymphoma
621914|NCT00237614|Contrast-induced nephropathy
621915|NCT00237614|Acute myocardial infarction
621916|NCT00237614|Primary coronary angioplasty
621917|NCT00237601|Home birth
621918|NCT00237601|Hospital birth
621919|NCT00237601|Midwifery
621920|NCT00237601|Effectivity
621921|NCT00237601|Efficiency
621922|NCT00237588|Angiotensin II Type I Receptor Blockers
621923|NCT00237588|Amlodipine
621924|NCT00237588|Calcium Channel Blockers
621925|NCT00237588|Diabetes Mellitus
621926|NCT00237588|Hypertension
621927|NCT00237588|Insulin Resistance
621928|NCT00237588|Losartan
621929|NCT00237575|urothelial
621930|NCT00237575|bladder
621931|NCT00237575|gemcitabine
621932|NCT00237575|cisplatin
621933|NCT00237575|leukine
621934|NCT00237575|neupogen
621935|NCT00237575|filgrastim
621936|NCT00237575|sargramostim
621937|NCT00237575|metastatic
621938|NCT00237575|Regionally Advanced
621939|NCT00237575|Advanced
621940|NCT00237549|Type 2 diabetes
621941|NCT00237549|Screening
621942|NCT00237549|Intensive treatment
621943|NCT00237549|Polypharmacy
621944|NCT00237549|Primary care
621945|NCT00237536|Benign Prostatic Hyperplasia
621946|NCT00237536|BPH
621947|NCT00237536|Enlarged Prostate
621948|NCT00237523|Breast pain
621949|NCT00237523|Mastalgia
621950|NCT00237523|Cyclic mastalgia
621951|NCT00237523|Periodic mastalgia
621952|NCT00237523|Non-cyclic mastalgia
621953|NCT00237523|Fibrosis
621954|NCT00237523|Nodularity
621955|NCT00237523|Cysts
621956|NCT00237523|Fibrocystic breast disease
621957|NCT00237523|Fibrocystic breast condition
621958|NCT00237523|Fibocystic breast syndrome
621959|NCT00237510|Antidepressant induced excessive sweating
621960|NCT00237497|Insomnia
621961|NCT00237497|Center of Pressure
621962|NCT00237497|Postural Sway
621963|NCT00237497|Drug Therapy
621964|NCT00237497|Balance and Stability
621965|NCT00237484|pegylated interferon alfa-2b
621966|NCT00237484|ribavirin
621967|NCT00237484|infliximab
621968|NCT00237484|chronic hepatitis C
621969|NCT00237471|Acute Myocardial Infarction
621970|NCT00237471|Hyperglycaemia
621971|NCT00237471|Insulin Infusion
621972|NCT00237419|Ankylosing spondylitis
621973|NCT00237419|Long-term therapy with infliximab
621974|NCT00237419|Radiographic progression
621975|NCT00237406|IVR, methadone
621976|NCT00237406|methadone maintenance
621977|NCT00237393|PTSD
621978|NCT00237393|Posttraumatic stress disorder
621979|NCT00237393|Treatment
621980|NCT00237393|Quetiapine
621981|NCT00237380|Cystic fibrosis
621982|NCT00237380|Nonsense mutation
621983|NCT00237380|Premature stop codon
621984|NCT00237367|Gastroesophageal Reflux
621985|NCT00237367|GERD
621986|NCT00237367|Nighttime heartburn
621987|NCT00237367|heartburn
621988|NCT00237367|esophagus
621989|NCT00237367|esophageal acid exposure
621990|NCT00237367|EAE
621991|NCT00237367|Aciphex
621992|NCT00237367|Pariet
621993|NCT00237367|rabeprazole
621994|NCT00237367|Protonix
621995|NCT00237367|pantoprazole
621996|NCT00237354|Recurrent soft tissue breast carcinoma
621997|NCT00237341|chronic low back pain
621998|NCT00237341|opioid
621999|NCT00237341|fentanyl
622000|NCT00237328|Heparin resistance
622001|NCT00237328|Blood clotting
622002|NCT00237328|Heart surgery
622003|NCT00237328|Cardiopulmonary bypass
622004|NCT00237315|Urea
622005|NCT00237315|Inherited metabolic disorders
622006|NCT00237302|pediatric migraine
622007|NCT00237302|migraine headache
622008|NCT00237302|migraine prophylaxis
622009|NCT00237302|migraine prevention
622010|NCT00237302|migraine
622011|NCT00237289|Manic depression
622012|NCT00237289|Mania
622013|NCT00237289|Depression
622014|NCT00237289|Bipolar disorder
622015|NCT00237289|Psychosis
622016|NCT00237276|colonoscopy, chromoendoscopy, autoflurescence, narrow band imaging, high definition endoscopy, colorectal cancer, colitis, polyp, DALM, adenoma, video
622017|NCT00237263|Parkinson's disease, end-of -dose wearing-off, entacapone
622018|NCT00237250|Pre-diabetes
622019|NCT00237250|vildagliptin
622020|NCT00237250|IGT
622021|NCT00237237|Type 2 diabetes
622022|NCT00237237|vildagliptin
622023|NCT00237224|Breast Cancer, ER and/or PgR positive, Letrozole
622024|NCT00237211|Aromatase inhibitor
622025|NCT00237211|letrozole
622026|NCT00237211|breast cancer
622027|NCT00237198|Aromatase inhibitor
622028|NCT00237198|letrozole
622029|NCT00237198|breast cancer
622030|NCT00237185|GIST
622031|NCT00237185|c-kit
622032|NCT00237185|imatinib mesylate
622033|NCT00237172|GIST
622034|NCT00237172|Imatinib
622035|NCT00237172|STI571
622036|NCT00237172|Gastrointestinal Stromal Tumors
622037|NCT00237159|Prostate cancer
622038|NCT00237159|Bone metastasis
622039|NCT00237159|Skeletal related event
622040|NCT00237146|Prostate cancer
622041|NCT00237146|Zoledronic acid
622042|NCT00237146|Bone metastasis
622043|NCT00237133|Breast cancer,
622044|NCT00237133|Letrozole,
622045|NCT00237133|Hormonal receptors
622046|NCT00237120|Chronic Myelogenous Leukemia
622047|NCT00237120|Imatinib
622048|NCT00237120|CML
622049|NCT00237107|Cytoreduction Surgical Procedures
622050|NCT00237107|Curretage
622051|NCT00237107|Photochemotherapy
622052|NCT00237094|Diabetes
622053|NCT00237094|Self Management
622054|NCT00237094|Interdisciplinary team
622055|NCT00237081|Interstitial Cystitis
622056|NCT00237081|Painful Bladder Syndrome
622057|NCT00237081|Genetics
622058|NCT00237081|Risk factors
622059|NCT00237081|Family history
622060|NCT00237068|Gastroesophageal Reflux
622061|NCT00237055|Children
622062|NCT00237055|Crohn's disease
622063|NCT00237055|Inflammatory bowel disease
622064|NCT00237055|Infectious agents
622065|NCT00237055|Colonoscopy
622066|NCT00237042|Temporomandibular Disorders
622067|NCT00237042|TMJ Disorders
622068|NCT00237003|women
622069|NCT00237003|incarceration
622070|NCT00237003|alcohol use
622071|NCT00237003|motivational interviewing
622072|NCT00236990|prostatitis
622073|NCT00236990|Elmiron
622074|NCT00236990|pentosan polysulfate sodium
622075|NCT00236977|CKD
622076|NCT00236977|iron
622077|NCT00236977|anemia
622078|NCT00236964|Anemia
622079|NCT00236964|Chronic Kidney Disease
622080|NCT00236951|Anemia
622081|NCT00236951|Cancer
622082|NCT00236951|Chemotherapy
622083|NCT00236938|iron
622084|NCT00236938|peritoneal dialysis
622085|NCT00236938|anemia
622086|NCT00236925|Fibromyalgia
622087|NCT00236925|Cortisol
622088|NCT00236925|Hydrocortisone
622089|NCT00236925|Stress
622090|NCT00236912|complicated appendicitis
622091|NCT00236912|antibiotics
622092|NCT00236912|appendicitis
622093|NCT00236912|infection
622094|NCT00236886|Epilepsy
622095|NCT00236886|Partial Epilepsy
622096|NCT00236886|Secondary Generalized Epilepsy
622097|NCT00236886|Primary Generalized Epilepsy
622098|NCT00236886|Tonic-Clonic Seizures
622099|NCT00236886|Topiramate
622100|NCT00236886|Weight Loss
622101|NCT00236873|topiramate
622102|NCT00236873|epilepsy
622103|NCT00236873|partial epilepsies
622104|NCT00236873|partial epilepsy
622105|NCT00236873|seizures
622106|NCT00236873|epileptic seizures
622107|NCT00236873|partial seizure disorder
622108|NCT00236873|brain diseases
622109|NCT00236860|partial seizure disorder
622110|NCT00236860|brain diseases
622111|NCT00236860|topiramate
622112|NCT00236860|epilepsy
622113|NCT00236860|partial epilepsies
622114|NCT00236860|partial epilepsy
622115|NCT00236860|seizures
622116|NCT00236860|epileptic seizures
622117|NCT00236847|topiramate
622118|NCT00236847|epilepsy
622119|NCT00236847|partial epilepsy
622120|NCT00236847|seizures
622121|NCT00236847|epileptic seizures
622122|NCT00236847|partial seizure disorder
622123|NCT00236847|brain diseases
622124|NCT00236834|respiratory tract diseases
622125|NCT00236834|levofloxacin
622126|NCT00236834|pneumonia
622127|NCT00236834|quinolones, hospital-acquired pneumonia
622128|NCT00236834|lung diseases
622129|NCT00236821|respiratory tract diseases
622130|NCT00236821|pneumonia
622131|NCT00236821|levofloxacin
622132|NCT00236821|community-acquired pneumonia
622133|NCT00236821|lung diseases
622134|NCT00236821|quinolones
622135|NCT00236808|quinolones, ciprofloxacin
622136|NCT00236808|levofloxacin
622137|NCT00236808|chronic bacterial prostatitis
622138|NCT00236808|inflammation
622139|NCT00236808|chronic prostatitis
622140|NCT00236808|prostatitis
622141|NCT00236808|prostate
622142|NCT00236808|antibiotic
622143|NCT00236795|contraception
622144|NCT00236795|hormonal contraception
622145|NCT00236795|oral contraception
622146|NCT00236795|steroid, ethinyl estradiol, horgestimate, levonorgestrel contraception
622147|NCT00236795|transdermal.
622148|NCT00236782|contraception
622149|NCT00236782|hormonal contraception
622150|NCT00236782|oral contraception
622151|NCT00236782|steroid, ethinyl estradiol, progestin contraception
622152|NCT00236782|transdermal.
622153|NCT00236769|contraception
622154|NCT00236769|transdermal contraception
622155|NCT00236769|hormonal, steroidal contraception
622156|NCT00236769|ethinyl estradiol
622157|NCT00236769|progesterone
622158|NCT00236756|Epilepsy
622159|NCT00236756|Seizures
622160|NCT00236756|Topiramate
622161|NCT00236756|Prophylaxis
622162|NCT00236756|Antiepileptic
622163|NCT00236756|Lennox-Gastaut syndrome
622164|NCT00236756|Seizures, tonic
622165|NCT00236743|topiramate
622166|NCT00236743|epilepsy
622167|NCT00236743|partial epilepsies
622168|NCT00236743|partial epilepsy
622169|NCT00236743|seizures
622170|NCT00236743|epileptic seizures
622171|NCT00236743|partial seizure disorder
622172|NCT00236743|children
622173|NCT00236743|pediatric
622174|NCT00236730|topiramate
622175|NCT00236730|epilepsy
622176|NCT00236730|partial epilepsies
622177|NCT00236730|partial epilepsy
622178|NCT00236730|seizures
622179|NCT00236730|epileptic seizures
622180|NCT00236730|partial seizure disorder
622181|NCT00236730|brain diseases
622182|NCT00236717|Epilepsy
622183|NCT00236717|Seizures
622184|NCT00236717|Topiramate
622185|NCT00236717|Prophylaxis
622186|NCT00236717|Antiepileptic
622187|NCT00236704|Epilepsy
622188|NCT00236704|Seizures
622189|NCT00236704|Topiramate
622190|NCT00236704|Prophylaxis
622191|NCT00236704|Antiepileptic
622192|NCT00236704|Tonic-clonic seizures
622193|NCT00236704|Grand mal seizures
622194|NCT00236691|topiramate
622195|NCT00236691|epilepsy
622196|NCT00236691|partial epilepsies
622197|NCT00236691|partial epilepsy
622198|NCT00236691|seizures
622199|NCT00236691|epileptic seizures
622200|NCT00236691|partial seizure disorder
622201|NCT00236691|brain diseases
622202|NCT00236678|Anemia
622203|NCT00236678|Rheumatoid arthritis
622204|NCT00236678|Hemoglobin level
622205|NCT00236665|Obesity
622206|NCT00236665|Essential Hypertension
622207|NCT00236665|Mild Hypertension
622208|NCT00236665|Moderate Hypertension
622209|NCT00236665|High Blood Pressure
622210|NCT00236652|Maxillary Sinusitis
622211|NCT00236652|Infection
622212|NCT00236639|Obesity
622213|NCT00236639|Hypertension
622214|NCT00236639|Hyperlipidemia
622215|NCT00236639|Type 2 Diabetes Mellitus
622216|NCT00236639|Body Mass Index
622217|NCT00236626|Type 2 Diabetes
622218|NCT00236626|Obesity
622219|NCT00236626|Insulin Resistance
622220|NCT00236626|Body Mass Index
622221|NCT00236626|Hypertension
622222|NCT00236626|Hyperlipidemia
622223|NCT00236626|Sulfonylurea
622224|NCT00236626|Topiramate
622225|NCT00236626|Adult-Onset Diabetes Mellitus
622226|NCT00236626|Metabolic Syndrome
622227|NCT00236613|Obesity
622228|NCT00236613|Hypertension
622229|NCT00236613|Hyperlipidemia
622230|NCT00236613|Body Mass Index
622231|NCT00236600|Obesity
622232|NCT00236600|Hypertension
622233|NCT00236600|Hyperlipidemia
622234|NCT00236600|Type 2 Diabetes
622235|NCT00236600|Life style modification
622236|NCT00236587|Schizophrenia
622237|NCT00236587|Intramuscular injection
622238|NCT00236587|Antipsychotic agents
622239|NCT00236587|Long-acting risperidone
622240|NCT00236574|Dementia
622241|NCT00236574|Alzheimer disease
622242|NCT00236574|Mild cognitive impairment
622243|NCT00236574|Galantamine hydrobromide
622244|NCT00236574|Memory disorder
622245|NCT00236561|Migraine
622246|NCT00236561|Common Migraine
622247|NCT00236561|Classic Migraine
622248|NCT00236561|Headache
622249|NCT00236561|Topiramate
622250|NCT00236561|Propranolol
622251|NCT00236561|Prophylaxis
622252|NCT00236561|Prevention
622253|NCT00236548|Schizophrenia
622254|NCT00236548|schizoaffective disorder
622255|NCT00236548|patient compliance
622256|NCT00236548|long-acting risperidone
622257|NCT00236548|intramuscular injection
622258|NCT00236548|Treatment Guidebook
622259|NCT00236535|musculoskeletal
622260|NCT00236535|Pain
622261|NCT00236535|sprained ankle
622262|NCT00236535|ligament
622263|NCT00236535|sprain
622264|NCT00236535|ankle
622265|NCT00236522|sinus infection
622266|NCT00236522|acute bacterial sinusitis
622267|NCT00236522|sinusitis
622268|NCT00236522|bacterial sinus infection
622269|NCT00236509|Migraine
622270|NCT00236509|Common Migraine
622271|NCT00236509|Classic Migraine
622272|NCT00236509|Headache
622273|NCT00236509|Topiramate
622274|NCT00236509|Prophylaxis
622275|NCT00236496|tremor
622276|NCT00236496|essential tremor
622277|NCT00236483|Oral Surgery
622278|NCT00236483|Analgesics
622279|NCT00236483|Postoperative Pain
622280|NCT00236483|dental
622281|NCT00236470|Disruptive behavior disorder
622282|NCT00236470|risperidone
622283|NCT00236470|antipsychotropic agents
622284|NCT00236470|child
622285|NCT00236470|adolescent
622286|NCT00236457|Schizophrenia
622287|NCT00236457|Intramuscular injection
622288|NCT00236457|Antipsychotic agents
622289|NCT00236457|Long-acting risperidone
622290|NCT00236457|Olanzapine
622291|NCT00236444|Child
622292|NCT00236444|adolescent
622293|NCT00236444|disruptive behavior disorders
622294|NCT00236444|risperidone
622295|NCT00236444|antipsychotropic agents
622296|NCT00236431|Mild cognitive impairment
622297|NCT00236431|Galantamine hydrobromide
622298|NCT00236431|Memory disorders
622299|NCT00236418|Epilepsy
622300|NCT00236418|Seizures
622301|NCT00236418|Topiramate
622302|NCT00236418|Prophylaxis
622303|NCT00236418|Antiepileptic
622304|NCT00236418|Tonic-clonic seizures
622305|NCT00236418|Grand mal seizures
622306|NCT00236405|Anemia
622307|NCT00236405|erythropoetin
622308|NCT00236405|quality-of-life outcomes
622309|NCT00236392|Gastroesophageal reflux
622310|NCT00236392|Heartburn
622311|NCT00236392|Rabeprazole
622312|NCT00236392|Anti-ulcer agents
622313|NCT00236392|GERD
622314|NCT00236392|Proton pump inhibitor
622315|NCT00236392|GORD
622316|NCT00236392|Non-Erosive Reflux Disease
622317|NCT00236392|NERD
622318|NCT00236379|schizophrenia
622319|NCT00236379|blood glucose
622320|NCT00236379|glucose metabolism
622321|NCT00236379|diabetes mellitus
622322|NCT00236379|risperidone
622323|NCT00236379|olanzapine
622324|NCT00236366|Fentanyl
622325|NCT00236366|opioid analgesics
622326|NCT00236366|osteoarthritis
622327|NCT00236366|arthritis
622328|NCT00236366|transdermal administration
622329|NCT00236353|schizophrenia
622330|NCT00236353|schizoaffective disorder
622331|NCT00236353|long-acting risperidone
622332|NCT00236353|intramuscular injection
622333|NCT00236340|Amniodrainage
622334|NCT00236340|Pregnancy
622335|NCT00236340|Amniocentesis
622336|NCT00236327|Fentanyl
622337|NCT00236327|Analgesia
622338|NCT00236327|Pain
622339|NCT00236327|Cancer pain
622340|NCT00236327|Opioid analgesia
622341|NCT00236327|Transdermal fentanyl
622342|NCT00236327|Patient-controlled analgesia
622343|NCT00236301|Hormone
622344|NCT00236301|Menopause
622345|NCT00236301|Inflammation
622346|NCT00236301|Dose effects
622347|NCT00236301|Apoptosis
622348|NCT00236288|Cancer treatment and tobacco abuse
622349|NCT00236275|Comparison of imaging modalities
622350|NCT00236275|predict the effectiveness of neoadjuvant chemotherapy
622351|NCT00236262|SDRA
622352|NCT00236262|Distress
622353|NCT00236262|Expiratory
622354|NCT00236262|Pressure
622355|NCT00236262|Ventilatory
622356|NCT00236249|Double blind method
622357|NCT00236249|Prospective study
622358|NCT00236249|Lidocaine/administration and dosage/therapeutic use
622359|NCT00236249|Anaesthetics local/administration and dosage
622360|NCT00236249|Opioids/administration and dosage
622361|NCT00236249|Pain, postoperative
622362|NCT00236249|Perioperative care
622363|NCT00236249|Postoperative care
622364|NCT00236249|Analgesia, Patient-controlled
622365|NCT00236249|Length of stay
622366|NCT00236249|Survival analysis
622367|NCT00236249|Patient satisfaction
622368|NCT00236249|Surgery
622369|NCT00236249|Middle age
622370|NCT00236249|Adult
622371|NCT00236249|Aged
622372|NCT00236223|Primary hip replacement
622373|NCT00236223|Gabapentin
622374|NCT00236223|Dexamethasone
622375|NCT00236223|Ketamine
622376|NCT00236223|Multimodal postoperative analgesia.
622377|NCT00236210|Vascular Intervention Program
622378|NCT00236210|Vascular Disease
622379|NCT00236210|Coronary Artery Disease
622380|NCT00236210|Diabetes
622381|NCT00236210|Lifestyle Modification
622382|NCT00236210|Modifiable Risk Factors
622383|NCT00236197|Heartburn
622384|NCT00236197|Rabeprazole
622385|NCT00236171|topical therapy
622386|NCT00236171|Psoriasis Plaque Test
622387|NCT00236145|BTP
622388|NCT00236145|Break through pain
622389|NCT00236145|breakthrough pain
622390|NCT00236093|Sickle Cell
622391|NCT00236041|Breakthrough Pain
622392|NCT00236041|Cancer
622393|NCT00236041|Sickle Cell
622394|NCT00236041|Severe Burns
622395|NCT00236041|Children
622396|NCT00236041|Adolescents
622397|NCT00236041|Analgesia
622398|NCT00236041|Sickle Cell Disease
622399|NCT00236041|Non-Cancer
622400|NCT00236028|Early Rheumatoid Arthritis
622401|NCT00235989|Relapsing multiple sclerosis
622402|NCT00235989|interferon beta 1b
622403|NCT00235989|Betaferon
622404|NCT00235989|Betaseron
622405|NCT00235976|Neuromuscular Blocking Agent
622406|NCT00235976|Anesthesia
622407|NCT00235976|Succinylcholine
622408|NCT00235976|Tracheal Intubation
622409|NCT00235976|Adjunct for tracheal intubation
622410|NCT00235950|Coronary Heart Disease
622411|NCT00235950|Percutaeous Coronary Intervention (PCI)
622412|NCT00235937|Premenopausal
622413|NCT00235937|Advanced Breast Cancer
622414|NCT00235937|Metastatic Breast Cancer
622415|NCT00235924|menopause
622416|NCT00235924|isoflavone
622417|NCT00235924|endometrial safety
622418|NCT00235924|breast innocuity assessment
622419|NCT00235924|hot flushes
622420|NCT00235885|Psoriatic Arthritis
622421|NCT00235885|adalimumab
622422|NCT00235872|Rheumatoid arthritis
622423|NCT00235859|Rheumatoid Arthritis
622424|NCT00235859|adalimumab
622425|NCT00235846|Endoscopic vein harvesting
622426|NCT00235846|Saphenous vein
622427|NCT00235833|Rheumatoid Arthritis
622428|NCT00235820|Psoriasis
622429|NCT00235820|adalimumab
622430|NCT00235807|Audiology
622431|NCT00235807|Rehabilitation
622432|NCT00235807|Tinnitus
622433|NCT00235781|Kidney Transplantation
622434|NCT00235781|Antilymphocyte Serum
622435|NCT00235781|Induction
622436|NCT00235781|Graft Rejection
622437|NCT00235768|Ecstasy
622438|NCT00235768|MDMA
622439|NCT00235768|Cognition
622440|NCT00235768|Brain function
622441|NCT00235768|Neuroimaging
622442|NCT00235755|Partial Seizures
622443|NCT00235755|Complex Partial Seizures
622444|NCT00235755|Epilepsy
622445|NCT00235755|Potassium Channels
622446|NCT00235755|Anticonvulsant
622447|NCT00235729|Opiate addiction
622448|NCT00235729|Opiate dependence
622449|NCT00235729|Withdrawal symptoms
622450|NCT00235716|Alzheimer's Disease
622451|NCT00235716|clinical trial
622452|NCT00235716|randomized controlled trial
622453|NCT00235716|alpha-tocopherol
622454|NCT00235716|vitamin E
622455|NCT00235716|Namenda
622456|NCT00235716|memantine
622457|NCT00235677|Endoscopic antireflux treatment
622458|NCT00235677|GERD
622459|NCT00235677|Sham-controlled
622460|NCT00235677|Endocinch
622461|NCT00235664|liver transplant recipients
622462|NCT00235664|intestinal transplant recipients
622463|NCT00235664|multivisceral transplant recipients
622464|NCT00235651|Lung transplant recipient
622465|NCT00235625|Alternative Medicine
622466|NCT00235625|Psoriasis
622467|NCT00235625|Turmeric
622468|NCT00235625|Curcumin
622469|NCT00235625|Dermatology
622470|NCT00235599|Growth
622471|NCT00235599|Hormone
622472|NCT00235599|Deficiency
622473|NCT00235586|vitamin D deficiency postmenopausal women
622474|NCT00235573|Vitamin B12 absorption
622475|NCT00235573|Holo-transcobalamin
622476|NCT00235560|AML
622477|NCT00235560|Rapamycin
622478|NCT00235560|Elderly
622479|NCT00235560|Elderly patients not eligible for intensive chemotherapy
622480|NCT00235547|abortion
622481|NCT00235547|randomized
622482|NCT00235547|contraception
622483|NCT00235547|pregnancy
622484|NCT00235547|compliance
622485|NCT00235547|continuation
622486|NCT00235547|contraceptive patch
622487|NCT00235547|transdermal hormonal contraception
622488|NCT00235534|abortion
622489|NCT00235534|randomized
622490|NCT00235534|contraception
622491|NCT00235534|pregnancy
622492|NCT00235534|compliance
622493|NCT00235534|continuation
622494|NCT00235534|oral contraceptive pills
622495|NCT00235521|Pulmonary hypertension
622496|NCT00235521|Cardiac Surgery
622497|NCT00235521|Children
622498|NCT00235521|Pediatric Patients
622499|NCT00235521|Iloprost
622500|NCT00235521|NO
622501|NCT00235521|nitric oxide
622502|NCT00235521|Pulmonary hypertension after cardiac surgery in pediatric patients, 0 - 2 years old
622503|NCT00235508|Insomnia
622504|NCT00235508|Anxiety
622505|NCT00235508|Generalized Anxiety Disorder
622506|NCT00235495|stroke
622507|NCT00235469|PAINFUL DISTAL DIABETIC NEUROPATHY
622508|NCT00235456|oxygen
622509|NCT00235456|surgical complications
622510|NCT00235456|colo-rectal resections
622511|NCT00235443|Painful Distal Diabetic Neuropathy
622512|NCT00235417|Bone Marrow Transplantation
622513|NCT00235404|Treatment of elderly.
622514|NCT00235404|Nursing home.
622515|NCT00235404|Rehabilitation.
622516|NCT00235404|Readmissions.
622517|NCT00235391|Deferasirox
622518|NCT00235391|Congenital Anemias
622519|NCT00235391|Anemias
622520|NCT00235391|Red Blood Cell Disorders
622521|NCT00235391|Chronic Iron Overload
622522|NCT00235391|Transfusional Iron Overload
622523|NCT00235391|Iron Chelators
622524|NCT00235391|Oral Iron Chelators
622525|NCT00235391|Thalassemia
622526|NCT00235391|Sickle Cell Disease
622527|NCT00235391|Diamond Blackfan Anemia
622528|NCT00235391|Myelofibrosis
622529|NCT00235391|ICL670A
622530|NCT00235378|Lupus
622531|NCT00235378|SLE
622532|NCT00235352|Schizphrenia
622533|NCT00235352|Cognition
622534|NCT00235352|Negative Symptoms
622535|NCT00235339|Oxygen Consumption
622536|NCT00235339|Exercise
622537|NCT00235339|Rehabilitation
622538|NCT00235326|residents of Walkerton ontario at outbreak
622539|NCT00235313|Nicotine replacement therapies
622540|NCT00235313|Smoking
622541|NCT00235313|Smoking related diseases
622542|NCT00235313|Saliva cotinine
622543|NCT00235313|Dose adjustment
622544|NCT00235313|Smoker; patients with smoking related disease conditions
622545|NCT00235300|Anti-T cells antibodies
622546|NCT00235300|Cadaveric Donor Renal Transplantation
622547|NCT00235300|Acute Renal Allograft Rejection
622548|NCT00235300|Induction Therapy
622549|NCT00235287|Angiotensin-Converting Enzyme Inhibitors
622550|NCT00235287|type 1 angiotensin receptor antagonists
622551|NCT00235287|blood pressure
622552|NCT00235274|Schizophrenia
622553|NCT00235274|Secretin
622554|NCT00235261|Total hip replacement
622555|NCT00235261|Pregablin
622556|NCT00235261|Dexamethasone
622557|NCT00235261|Multimodal postoperative analgesia.
622558|NCT00235248|TIA/Brain infarct
622559|NCT00235248|and plaque>4mm in the aortic arch
622560|NCT00235248|Or peripheral embolism
622561|NCT00235248|and plaque>4 mm in the thoracic aorta
622562|NCT00235222|Stavudine
622563|NCT00235222|Reduced dose of stavudine
622564|NCT00235222|Viral load
622565|NCT00235222|Peripheral neuropathy
622566|NCT00235222|Treatment Experienced
622567|NCT00235183|plasma
622568|NCT00235183|bleeding
622569|NCT00235183|liver transplantation
622570|NCT00235131|Peripheral Artery Occlusive Disease
622571|NCT00235105|early ankylosing spondylitis
622572|NCT00235105|spondyloarthritis
622573|NCT00235105|trial
622574|NCT00235105|adalimumab
622575|NCT00235079|Pericarditis
622576|NCT00235079|Recurrence
622577|NCT00235079|Therapeutics
622578|NCT00235079|Prevention
622579|NCT00235079|Colchicine
622580|NCT00235053|asthma
622581|NCT00235053|candidiasis, oral
622582|NCT00235053|voice disorders
622583|NCT00235040|Upper Respiratory Infections
622584|NCT00235040|Respiratory Tract Infections
622585|NCT00235040|Tree Number C01.539.739
622586|NCT00235040|Tree Number C08.730
622587|NCT00235040|Unique ID D012141
622588|NCT00235014|hypertension
622589|NCT00235014|diabetes
622590|NCT00235014|trandolapril
622591|NCT00235014|verapamil
622592|NCT00235014|albuminuria
622593|NCT00235001|Hypertension
622594|NCT00235001|Tarka
622595|NCT00234988|Sibutramine
622596|NCT00234988|Obesity
622597|NCT00234975|Lopinavir
622598|NCT00234975|Ritonavir
622599|NCT00234975|Phase 4
622600|NCT00234975|HIV
622601|NCT00234962|HIV Infection
622602|NCT00234962|HAART
622603|NCT00234962|Lopinavir
622604|NCT00234962|Ritonavir
622605|NCT00234962|Treatment Experienced
622606|NCT00234962|Treatment Naive
622607|NCT00234949|Cefdinir
622608|NCT00234949|Cephalexin
622609|NCT00234949|Skin Infection
622610|NCT00234936|rheumatoid arthritis
622611|NCT00234936|adalimumab
622612|NCT00234936|quality of life
622613|NCT00234923|HIV Infection
622614|NCT00234923|Kaletra
622615|NCT00234923|Lopinavir
622616|NCT00234923|Ritonavir
622617|NCT00234923|Treatment Naive
622618|NCT00234910|Lopinavir
622619|NCT00234910|Ritonavir
622620|NCT00234910|Kaletra
622621|NCT00234910|Tenofovir
622622|NCT00234910|HIV infection
622623|NCT00234910|Treatment Naive
622624|NCT00234897|adalimumab
622625|NCT00234897|rheumatoid arthritis
622626|NCT00234884|rheumatoid arthritis
622627|NCT00234884|adalimumab
622628|NCT00234871|Hypertension
622629|NCT00234871|Diabetes
622630|NCT00234871|Proteinuria
622631|NCT00234871|Tarka
622632|NCT00234871|Lotrel
622633|NCT00234858|Hypertension
622634|NCT00234858|Metabolic Syndrome
622635|NCT00234858|Tarka
622636|NCT00234858|Hyzaar
622637|NCT00234832|Obesity
622638|NCT00234832|Sibutramine
622639|NCT00234819|Menopause
622640|NCT00234806|telehealth
622641|NCT00234806|telemedicine
622642|NCT00234793|childhood cancer
622643|NCT00234793|intervention
622644|NCT00234793|maternal coping
622645|NCT00234793|problem solving skills
622646|NCT00234793|anxiety
622647|NCT00234793|cope
622648|NCT00234793|problem solving
622649|NCT00234780|acute home care
622650|NCT00234767|Acute Respiratory Distress Syndrome
622651|NCT00234767|ARDS
622652|NCT00234767|Acute Lung Injury
622653|NCT00234767|ALI
622654|NCT00234767|Cost-effectiveness
622655|NCT00234767|Pharmacoeconomics
622656|NCT00234767|Long-term follow-up
622657|NCT00234754|Incontinence
622658|NCT00234754|Surgery
622659|NCT00234754|Trans-vaginal tape
622660|NCT00234754|Trans-obturator tape
622661|NCT00234728|psoriasis
622662|NCT00234728|hydrogel
622663|NCT00234728|occlusive dressing
622664|NCT00234728|occlusion
622665|NCT00234728|hydrocortisone
622666|NCT00234728|tacrolimus
622667|NCT00234728|Protopic
622668|NCT00234728|triamcinolone
622669|NCT00234728|calcipotriene
622670|NCT00234728|Dovonex
622671|NCT00234728|halobetasol
622672|NCT00234728|Ultravate
622673|NCT00234715|Breast Cancer
622674|NCT00234715|Breast Cancer Risk
622675|NCT00234715|Breast Cancer Risk Assessment
622676|NCT00234715|Psychosocial
622677|NCT00234715|Acceptance
622678|NCT00234676|Parkinson disease
622679|NCT00234676|women
622680|NCT00234676|postmenopause
622681|NCT00234676|estrogen replacement therapy
622682|NCT00234676|clinical trials
622683|NCT00234663|Cystic fibrosis
622684|NCT00234663|Nonsense mutation
622685|NCT00234663|Premature stop codon
622686|NCT00234650|position change
622687|NCT00234650|adenoma
622688|NCT00234650|colonoscopy
622689|NCT00234637|Alzheimer's disease,
622690|NCT00234637|switch,
622691|NCT00234637|rivastigmine,
622692|NCT00234637|memantine
622693|NCT00234598|Pneumonia
622694|NCT00234598|Dental Health
622695|NCT00234598|Critical Care
622696|NCT00234559|Angiogenesis
622697|NCT00234559|Post surgical dehisced wounds of the lower extremity
622698|NCT00234533|growth
622699|NCT00234533|child development
622700|NCT00234533|growth hormone
622701|NCT00234533|inadequate growth hormone secretion
622702|NCT00234533|growth failure
622703|NCT00234468|Locally Advanced Non Small Cell Lung Cancer (Stage IIIA and IIIB)
622704|NCT00234442|Non symptomatic brain metastases
622705|NCT00234442|Iressa
622706|NCT00234429|Colorectal carcinoma advanced disease
622707|NCT00234416|Pancreatic Cancer
622708|NCT00234416|EGF-R
622709|NCT00234403|Advanced breast cancer
622710|NCT00234403|Metastatic breast cancer
622711|NCT00234403|ER positive breast cancer
622712|NCT00234403|PR positive breast cancer
622713|NCT00234377|Schizophrenia
622714|NCT00234364|Pergolide
622715|NCT00234364|Ergotamine derivates
622716|NCT00234364|Valvular heart disease
622717|NCT00233610|Casodex monotherapy
622718|NCT00233597|anemia
622719|NCT00233597|iron
622720|NCT00233584|Children of asthmatic mothers
622721|NCT00233545|cutaneous
622722|NCT00233545|leishmaniasis
622723|NCT00233545|drug
622724|NCT00233545|miltefosine
622725|NCT00233532|Hypertension
622726|NCT00233532|Trandolapril
622727|NCT00233506|CpG 7909
622728|NCT00233506|CLL
622729|NCT00233493|dermatophytes
622730|NCT00233480|Randomized Controlled Trial
622731|NCT00233480|Hydroxymethylglutaryl-CoA Reductase Inhibitors
622732|NCT00233480|Sympathetic Nervous System
622733|NCT00233480|Ventricular Remodeling
622734|NCT00233480|Chemokines
622735|NCT00233467|antipsychotics
622736|NCT00233467|PTSD
622737|NCT00233467|posttraumatic stress disorder
622738|NCT00233441|Atrial Fibrillation
622739|NCT00233441|Atrial Flutter
622740|NCT00233441|Arrhythmia
622741|NCT00233441|Anti-Arrhythmia Agents
622742|NCT00233428|Healthy volunteers
622743|NCT00233402|Bladder Cancer
622744|NCT00233402|Hexvix
622745|NCT00233402|Fluorescence
622746|NCT00233402|Cystoscopy
622747|NCT00234338|Children
622748|NCT00234338|Vaccine
622749|NCT00234338|Prevenar
622750|NCT00234312|Depressive Disorders
622751|NCT00234299|Cancer
622752|NCT00234299|Prostate
622753|NCT00234299|Preventive Therapy
622754|NCT00234286|Palliative Care
622755|NCT00234286|Terminal Care
622756|NCT00234286|Hospice Care
622757|NCT00234286|Patient Care Planning
622758|NCT00234286|Nursing Care Plans
622759|NCT00234286|Quality of Health Care
622760|NCT00234286|Inpatients
622761|NCT00234286|Professional education
622762|NCT00234286|Resuscitation orders
622763|NCT00234286|Pastoral Care
622764|NCT00234273|Adapted Physical Activity
622765|NCT00234273|Quality of life
622766|NCT00234273|cardiovascular risk
622767|NCT00234273|teaching
622768|NCT00234273|Directly Observed Therapy
622769|NCT00234273|Physical activity
622770|NCT00234260|Genetics
622771|NCT00234234|Biologics
622772|NCT00234208|Complicated parapneumonic effusion
622773|NCT00234208|Pleural empyema
622774|NCT00234208|Intervention
622775|NCT00234208|Medical thoracoscopy
622776|NCT00234208|Chest tube drainage
622777|NCT00234195|Breast Cancer
622778|NCT00234195|Major Depressive Disorder
622779|NCT00234182|liver cancer
622780|NCT00234182|hepatectomy
622781|NCT00234182|survival
622782|NCT00234182|recurrence
622783|NCT00234169|Multiple Myeloma
622784|NCT00234169|Lymphoma
622785|NCT00234156|Fructose
622786|NCT00234156|Lipogenesis
622787|NCT00234156|Triglycerides
622788|NCT00234156|Dialysis
622789|NCT00234143|MDS
622790|NCT00234143|EPO
622791|NCT00234143|G-CSF
622792|NCT00234143|REGiM
622793|NCT00234130|Dialysis
622794|NCT00234130|Cytokines
622795|NCT00234130|Triglycerides
622796|NCT00234130|Insulin
622797|NCT00234104|OPC-41061
622798|NCT00234104|Tolvaptan
622799|NCT00234104|Heart Failure
622800|NCT00234104|Edema
622801|NCT00234104|Extracellular volume expansion
622802|NCT00234091|Treatment Naive
622803|NCT00234091|Treatment Initiation
622804|NCT00234091|Infant
622805|NCT00234091|Preschool Child
622806|NCT00234091|Child
622807|NCT00234091|Zidovudine
622808|NCT00234091|AZT
622809|NCT00234091|Retrovir
622810|NCT00234091|3TC
622811|NCT00234091|Lamivudine
622812|NCT00234091|Epivir
622813|NCT00234091|Nevirapine
622814|NCT00234091|NVP
622815|NCT00234091|Viramune
622816|NCT00234091|Efavirenz
622817|NCT00234091|EFV
622818|NCT00234091|Sustiva
622819|NCT00234091|Lopinavir/Ritonavir
622820|NCT00234091|LPV/r
622821|NCT00234091|Kaletra
622822|NCT00234091|Nelfinavir
622823|NCT00234091|NFV
622824|NCT00234091|Viracept
622825|NCT00234091|ABC
622826|NCT00234091|Abacavir
622827|NCT00234091|Ziagen
622828|NCT00234078|OPC-12759
622829|NCT00234078|Dry eye syndromes
622830|NCT00234052|recurrent non-small cell lung cancer
622831|NCT00234052|stage IIIB non-small cell lung cancer
622832|NCT00234052|stage IV non-small cell lung cancer
622833|NCT00234052|adenocarcinoma of the lung
622834|NCT00234052|bronchoalveolar cell lung cancer
622835|NCT00234052|large cell lung cancer
622836|NCT00234039|recurrent bladder cancer
622837|NCT00234039|stage 0 bladder cancer
622838|NCT00234039|stage I bladder cancer
622839|NCT00234039|transitional cell carcinoma of the bladder
622840|NCT00234026|recurrent mantle cell lymphoma
622841|NCT00234026|stage I mantle cell lymphoma
622842|NCT00234026|contiguous stage II mantle cell lymphoma
622843|NCT00234026|noncontiguous stage II mantle cell lymphoma
622844|NCT00234026|stage III mantle cell lymphoma
622845|NCT00234026|stage IV mantle cell lymphoma
622846|NCT00234000|refractory anemia with excess blasts in transformation
622847|NCT00234000|refractory anemia with excess blasts
622848|NCT00234000|refractory anemia with ringed sideroblasts
622849|NCT00234000|refractory anemia
622850|NCT00234000|chronic myelomonocytic leukemia
622851|NCT00234000|de novo myelodysplastic syndromes
622852|NCT00234000|previously treated myelodysplastic syndromes
622853|NCT00234000|secondary myelodysplastic syndromes
622854|NCT00233987|recurrent adult Hodgkin lymphoma
622855|NCT00233974|stage IIIA breast cancer
622856|NCT00233974|stage IIIB breast cancer
622857|NCT00233974|stage IIIC breast cancer
622858|NCT00233974|stage IV breast cancer
622859|NCT00233961|chronic phase chronic myelogenous leukemia
622860|NCT00233922|orbit
622861|NCT00233922|orbital
622862|NCT00233922|trauma
622863|NCT00233922|fractures
622864|NCT00233922|facial
622865|NCT00233909|Leukemia, Myeloid
622866|NCT00233909|Relapse
622867|NCT00233909|Chemotherapy
622868|NCT00233909|Zosuquidar
622869|NCT00233909|gemtuzumab ozogamicin (GO)
622870|NCT00233896|Hematopoietic cell transplant
622871|NCT00233896|Acute graft-vs.-host disease
622872|NCT00233896|Gastrointestinal tract
622873|NCT00233896|Randomized trial
622874|NCT00233896|Topical corticosteroid
622875|NCT00233896|Beclomethasone dipropionate
622876|NCT00233896|Prednisone
622877|NCT00233896|Survival
622878|NCT00233857|Acute pain
622879|NCT00233857|postoperative pain
622880|NCT00233857|auricular acupuncture
622881|NCT00233844|Acute pain
622882|NCT00233844|pain on venipuncture
622883|NCT00233844|"cough-trick"
622884|NCT00233844|distraction
622885|NCT00233831|Postoperative pain
622886|NCT00233831|analgesia
622887|NCT00233831|total knee arthroplasty
622888|NCT00233753|Intracranial
622889|NCT00233753|Wide-neck
622890|NCT00233753|Saccular
622891|NCT00233753|Aneurysms
622892|NCT00233727|cervical cancer
622893|NCT00233727|cervical intraepithelial neoplasia
622894|NCT00233727|prevention
622895|NCT00233727|cryotherapy
622896|NCT00233727|HPV testing
622897|NCT00233727|cytology
622898|NCT00233701|NPH
622899|NCT00233701|Hydrocephalus
622900|NCT00233636|Squamous Cell Carcinoma of Head and Neck
622901|NCT00233636|Inoperable locally advanced Squamous Cell Carcinoma of Head and Neck
622902|NCT00233623|Metastatic Colorectal Cancer
622903|NCT00233376|Decision support system
622904|NCT00233376|Causal probabilistic network
622905|NCT00233376|Antibiotics
622906|NCT00233376|Antibiotic resistance
622907|NCT00233376|Community-acquired infections
622908|NCT00233376|Cross-infections
622909|NCT00233350|Neuronavigation
622910|NCT00233350|Ultrasound
622911|NCT00233350|Brain tumour surgery
622912|NCT00233350|Biopsy
622913|NCT00233350|Histopathology
622914|NCT00233350|Intraoperative imaging
622915|NCT00233350|3D ultrasound imaging
622916|NCT00233337|Malaria, non-immune travelers
622917|NCT00233324|NICHD Neonatal Research Network
622918|NCT00233324|Extremely Low Birth Weight (ELBW)
622919|NCT00233324|Very Low Birth Weight (VLBW)
622920|NCT00233324|Prematurity
622921|NCT00233324|Mechanical ventilation
622922|NCT00233324|Surfactant
622923|NCT00233324|Intubation
622924|NCT00233324|Neurodevelopmental impairment
622925|NCT00233324|Pulse oximetry
622926|NCT00233324|Oxygen saturation
622927|NCT00233324|Positive-Pressure Respiration
622928|NCT00233311|high fat diet
622929|NCT00233311|inflammation
622930|NCT00233311|inflammatory markers
622931|NCT00233311|C-reactive protein
622932|NCT00233311|Aging
622933|NCT00233298|Hypoglycemia
622934|NCT00233298|Blood Sugar
622935|NCT00233298|Blood Glucose Level
622936|NCT00233298|Insulin Sensitivity
622937|NCT00233298|Metabolism
622938|NCT00233298|Type 2 Diabetes
622939|NCT00233298|Healthy
622940|NCT00233272|Frailty
622941|NCT00233272|Disease Processes
622942|NCT00233155|Analgesics
622943|NCT00233155|Capsaicin
622944|NCT00233155|Neuropathic pain
622945|NCT00233155|Neuropathy
622946|NCT00233155|PHN
622947|NCT00233155|Shingles
622948|NCT00233142|Diabetes
622949|NCT00233142|Emotions
622950|NCT00233142|Blood glucose
622951|NCT00233142|Expressive Writing
622952|NCT00233129|Day treatment
622953|NCT00233129|executive function
622954|NCT00233129|problem solving
622955|NCT00233129|attention
622956|NCT00233129|participation
622957|NCT00233129|TBI
622958|NCT00233129|brain injury
622959|NCT00233129|traumatic brain injury
622960|NCT00233103|Sertraline
622961|NCT00233103|TBI
622962|NCT00233103|depression
622963|NCT00233103|SSRI
622964|NCT00233103|brain injury
622965|NCT00233090|Fatigue
622966|NCT00233090|TBI
622967|NCT00233090|brain injury
622968|NCT00233090|Modafinil
622969|NCT00233090|traumatic brain injury
622970|NCT00233077|breast cancer
622971|NCT00233077|adjuvant treatment
622972|NCT00233077|racial disparities
622973|NCT00233051|Chronic Obstructive Pulmonary Disease (COPD)
622974|NCT00233051|Emphysema
622975|NCT00233051|Chronic Bronchitis
622976|NCT00233051|Inhaled Steroid
622977|NCT00233051|Salmeterol
622978|NCT00233038|Pancreatic cancer
622979|NCT00233038|Pancreatic adenoma
622980|NCT00233038|Ethanol
622981|NCT00233038|Endoscopic ultrasound
622982|NCT00233038|Cyst ablation
622983|NCT00233012|Refractory partial-onset seizures
622984|NCT00233012|Infants aged 1-24 months
622985|NCT00233012|Pharmacokinetics
622986|NCT00233012|Topiramate
622987|NCT00232999|Allergic asthma
622988|NCT00232999|Allergen challenge
622989|NCT00232999|Bronchial hyperresponsiveness
622990|NCT00232960|oral and oropharynx carcinoma
622991|NCT00232960|surgery
622992|NCT00232960|postoperative radiotherapy
622993|NCT00232960|molecular analysis
622994|NCT00232960|microsatellite instability
622995|NCT00232947|vaccine
622996|NCT00232947|elderly
622997|NCT00232947|immunogenicity
622998|NCT00232947|safety
622999|NCT00232934|Myeloma
623000|NCT00232934|Thalidomide
623001|NCT00232934|Diagnosis
623002|NCT00232934|Elderly patients
623003|NCT00232882|Hypertension
623004|NCT00232882|Blood pressure
623005|NCT00232882|Antihypertensive drugs
623006|NCT00232882|Clinical Pharmacology
623007|NCT00232882|Autonomic nervous system
623008|NCT00232882|Renin angiotensin system
623009|NCT00232882|Oxidative stress
623010|NCT00232882|Inflammatory markers
623011|NCT00232843|Peripheral Artery Occlusive Disease
623012|NCT00232817|Postoperative pain
623013|NCT00232726|Malignant melanoma
623014|NCT00232726|CP-4055
623015|NCT00232726|Chemotherapy-naïve patients
623016|NCT00232726|Phase II
623017|NCT00232726|Chemotherapy-naive patients
623018|NCT00232726|Metastatic malignant melanoma
623019|NCT00232713|Birth Defects
623020|NCT00232713|Pregnancy
623021|NCT00232713|Uterine Fibroids
623022|NCT00232713|Fibroids
623023|NCT00232700|Major depressive disorder
623024|NCT00232700|Repetitive transcranial magnetic stimulation
623025|NCT00232674|Chronic Obstructive Pulmonary Disease
623026|NCT00232635|RSV
623027|NCT00232635|HSCT
623028|NCT00232635|HEMATOPOIETIC STEM CELL TRANSPL
623029|NCT00232622|Prosthetic valve thrombosis
623030|NCT00232622|Fibrinolysis
623031|NCT00232622|Streptokinase
623032|NCT00232609|Wheelchair
623033|NCT00232609|Exercise
623034|NCT00232609|Cardiovascular Disease
623035|NCT00232596|Partial Seizures
623036|NCT00232596|Anticonvulsant
623037|NCT00232596|Complex Partial Seizures
623038|NCT00232596|Potassium Channels
623039|NCT00232596|Epilepsy
623040|NCT00232583|TYpe 2 diabetes mellitus
623041|NCT00232583|Newly diagnosed
623042|NCT00232583|Beta-cell function
623043|NCT00232570|sleep disturbance
623044|NCT00232570|dementia
623045|NCT00232557|Asthma
623046|NCT00232557|Disease Management
623047|NCT00232557|Telecommunications
623048|NCT00232557|Health Services
623049|NCT00232557|Quality of Life
623050|NCT00232557|Patient Compliance
623051|NCT00232544|sleep apnea, obstructive
623052|NCT00232544|Quality of Life
623053|NCT00232544|Depression
623054|NCT00232544|Patient Compliance
623055|NCT00232518|immune system
623056|NCT00232518|infection
623057|NCT00232518|allergic rhinitis
623058|NCT00232505|recurrent breast cancer
623059|NCT00232505|stage IV breast cancer
623060|NCT00232492|Wisdom
623061|NCT00232492|Tooth
623062|NCT00232492|Teeth
623063|NCT00232492|Third
623064|NCT00232492|Molar
623065|NCT00232466|Vertebroplasty
623066|NCT00232466|Vertebral fracture
623067|NCT00232466|Actonel
623068|NCT00232466|Osteoporotic
623069|NCT00232466|vertebral
623070|NCT00232466|fractures
623071|NCT00232427|Liver cirrhosis
623072|NCT00232427|Hemodynamics
623073|NCT00232427|Fluid balance
623074|NCT00232414|bipolar
623075|NCT00232414|with acute depressive episode
623076|NCT00232401|urine
623077|NCT00232401|circadian rhythm
623078|NCT00232388|Ejection Fraction <35%
623079|NCT00232375|SPIDDM
623080|NCT00232375|LADA
623081|NCT00232375|GAD antibody
623082|NCT00232375|Beta cell function
623083|NCT00232375|Insulin
623084|NCT00232349|schizophrenia
623085|NCT00232349|galantamine
623086|NCT00232349|cholinesterase inhibitors
623087|NCT00232349|quality of life
623088|NCT00232349|cognition
623089|NCT00232336|cocaine
623090|NCT00232336|drug
623091|NCT00232336|substance
623092|NCT00232336|abuse
623093|NCT00232336|addiction
623094|NCT00232336|dependence
623095|NCT00232336|quetiapine
623096|NCT00232336|antipsychotic
623097|NCT00232336|treatment
623098|NCT00232323|intensive care
623099|NCT00232323|stress
623100|NCT00232323|education
623101|NCT00232323|simulation
623102|NCT00232310|Atrial Fibrillation
623103|NCT00232310|Atrial Flutter
623104|NCT00232310|Electric Countershock
623105|NCT00232297|Tachycardia, Ventricular
623106|NCT00232297|Ventricular Fibrillation
623107|NCT00232297|Defibrillators Implantable
623108|NCT00232297|Arrhythmia
623109|NCT00232297|Anti-arrhythmia agents
623110|NCT00232258|NK1 Antagonist
623111|NCT00232258|Inflammatory Bowel Disease
623112|NCT00232258|Mesalamine
623113|NCT00232232|Atrial mechanical stunning and
623114|NCT00232232|atrial electrical remodeling
623115|NCT00232206|NSCLC
623116|NCT00232206|Lung
623117|NCT00232206|Cancer
623118|NCT00232206|Metastatic
623119|NCT00232206|Neoadjuvant
623120|NCT00232206|Stage IB Non-Small Cell Lung Cancer (NSCLC)
623121|NCT00232206|IIA Non-Small Cell Lung Cancer (NSCLC)
623122|NCT00232206|IIB Non-Small Cell Lung Cancer (NSCLC)
623123|NCT00232206|Some IIIA Non-Small Cell Lung Cancer (NSCLC)
623124|NCT00232193|Multiple Sclerosis
623125|NCT00232193|Interferon Beta 1-a
623126|NCT00232193|Pulsed steroids
623127|NCT00232180|Open-label
623128|NCT00232180|single arm mortality/morbidity trial eplerenone chronic systolic heart failure
623129|NCT00232115|Perioral Dermatitis, pimecrolimus cream
623130|NCT00232102|Dyspepsia, gastrointestinal, tegaserod
623131|NCT00232089|Dyspepsia, gastrointestinal, tegaserod
623132|NCT00232076|Atopic Dermatitis, Ciclosporin,
623133|NCT00232063|Atopic Dermatitis, Ciclosporin,
623134|NCT00232050|Asthma, IgE, Omalizumab
623135|NCT00232037|Dyspepsia, gastrointestinal, tegaserod
623136|NCT00232024|Dyspepsia, gastrointestinal, tegaserod
623137|NCT00232011|Atopic dermatitis, ASM981, pimecrolimus
623138|NCT00231998|Atopic dermatitis, ASM981, pimecrolimus
623139|NCT00231985|Habit-reversal Therapy
623140|NCT00231985|Behavior Therapy
623141|NCT00231985|Supportive Therapy
623142|NCT00231972|HIV
623143|NCT00231972|MSM
623144|NCT00231959|Depression, Treatment-Resistant
623145|NCT00231946|gonadotropins
623146|NCT00231946|hormone therapy
623147|NCT00231946|HRT
623148|NCT00231946|Antigonadotropin
623149|NCT00231946|Leuprolide
623150|NCT00231933|Person-centered Care
623151|NCT00231933|Recovery
623152|NCT00231933|Disparities
623153|NCT00231933|Culturally Responsive Care
623154|NCT00231933|Psychosis
623155|NCT00231920|Influenza, Vaccine, Infants
623156|NCT00231907|influenza, vaccine, TIV, LAIV, booster, children
623157|NCT00231894|atypical antipsychotics
623158|NCT00231894|hyperglycemia
623159|NCT00231894|triglycerides
623160|NCT00231894|HDL
623161|NCT00231894|cholesterol
623162|NCT00231894|insulin resistance
623163|NCT00231894|schizophrenia
623164|NCT00231894|verbal memory
623165|NCT00231881|GORD – Oesophageal sensitivity- Oesophageal permeability
623166|NCT00231868|Uterine Papillary Serous Carcinoma
623167|NCT00231868|UPSC
623168|NCT00231868|Radiation Therapy
623169|NCT00231868|Chemotherapy
623170|NCT00231855|Epithelial Ovarian Cancer
623171|NCT00231855|Uterine Cancer
623172|NCT00231855|Prior Therapy
623173|NCT00231855|Chemotherapy
623174|NCT00231855|Recurrence
623175|NCT00231842|Mixed Mesodermal Tumor
623176|NCT00231842|MMT
623177|NCT00231842|Uterine Cancer
623178|NCT00231842|Radiation Therapy
623179|NCT00231842|Chemotherapy
623180|NCT00231829|Treatment
623181|NCT00231829|Uterine Papillary Serous Carcinoma
623182|NCT00231829|Clear Cell Carcinoma
623183|NCT00231829|COX-2 Inhibitors
623184|NCT00231816|Prevention of Herpes Zoster
623185|NCT00231764|Renal transplantation
623186|NCT00231764|Immunosuppression
623187|NCT00231764|Daclizumab
623188|NCT00231764|GFR
623189|NCT00231751|Hemophilia A
623190|NCT00231751|Inhibitors
623191|NCT00231738|Eicosapentaenoic acid
623192|NCT00231738|Coronary artery disease
623193|NCT00231712|prospective analysis of immune function,
623194|NCT00231712|spectratype
623195|NCT00231712|immunoscope
623196|NCT00231712|TREC analysis
623197|NCT00231712|solid tumor
623198|NCT00231699|Prevention of Hypothermia
623199|NCT00231699|Pediatric Patient
623200|NCT00231699|Cotton
623201|NCT00231699|Plastic wrap
623202|NCT00231686|Lung function test
623203|NCT00231686|Physical conditioning, human
623204|NCT00231686|Physical fitness
623205|NCT00231686|Quality of life
623206|NCT00231673|Diabetic peripheral polyneuropathy
623207|NCT00231673|Electrophysiology
623208|NCT00231673|Nerve Conduction Study
623209|NCT00231673|Neurological Examination
623210|NCT00231673|Quantitative Sensory Testing
623211|NCT00231673|Topiramate
623212|NCT00231660|Type 2 Diabetes
623213|NCT00231660|Obesity
623214|NCT00231660|Metformin
623215|NCT00231660|Hemoglobin A1c
623216|NCT00231660|Adult-Onset Diabetes Mellitus (AODM)
623217|NCT00231647|Obesity
623218|NCT00231647|Type 2 Diabetes Mellitus
623219|NCT00231647|Metformin
623220|NCT00231647|Diabetic Diet
623221|NCT00231647|Topiramate
623222|NCT00231647|Adult-Onset Diabetes Mellitus (AODM)
623223|NCT00231634|Obesity
623224|NCT00231634|Type 2 Diabetes Mellitus
623225|NCT00231634|HbA1c
623226|NCT00231634|Sulfonylurea
623227|NCT00231634|Topiramate
623228|NCT00231634|Adult-Onset Diabetes Mellitus (AODM)
623229|NCT00231621|Obesity
623230|NCT00231621|Dyslipidemia
623231|NCT00231621|Hyperlipidemia
623232|NCT00231621|Triglyceride
623233|NCT00231621|HDL
623234|NCT00231621|LDL
623235|NCT00231621|Diabetes
623236|NCT00231608|Obesity
623237|NCT00231608|Abdominal Obesity
623238|NCT00231608|Visceral Fat
623239|NCT00231608|Subcutaneous Fat
623240|NCT00231608|Dislipidemia
623241|NCT00231608|Hypertension
623242|NCT00231608|Type 2 Diabetes Mellitus
623243|NCT00231595|Migraine
623244|NCT00231595|Common Migraine
623245|NCT00231595|Classic Migraine
623246|NCT00231595|Headache
623247|NCT00231595|Topiramate
623248|NCT00231595|Prophylaxis
623249|NCT00231595|Prevention
623250|NCT00231582|High-dose with autologous germ-cell tumors
623251|NCT00231569|LDL-cholesterol
623252|NCT00231569|apoB-100
623253|NCT00231569|apoB-48
623254|NCT00231556|Epilepsy
623255|NCT00231556|Seizures
623256|NCT00231556|Parital Epilepsies
623257|NCT00231556|Generalized Epilepsy
623258|NCT00231556|Tonic-Clonic Epilepsy
623259|NCT00231556|Topiramate
623260|NCT00231530|Type 2 Diabetes Mellitus
623261|NCT00231530|Obesity
623262|NCT00231530|Diabetic Diet
623263|NCT00231530|Hypertension
623264|NCT00231530|Hyperlipidemia
623265|NCT00231530|Adult-Onset Diabetes Mellitus(AODM)
623266|NCT00231504|Polymorphism P1
623267|NCT00231504|Polymorphism P2
623268|NCT00231504|FSH Receptor
623269|NCT00231504|Antral follicle count
623270|NCT00231504|FSH receptor polymorphism
623271|NCT00231491|Overactive bladder
623272|NCT00231491|Urgency
623273|NCT00231491|Urge incontinence
623274|NCT00231491|Botulinum toxin A
623275|NCT00231491|Quality of life
623276|NCT00231465|elderly
623277|NCT00231465|malignant pleural effusion
623278|NCT00231452|natural acquired immunity,
623279|NCT00231452|clinical malaria,
623280|NCT00231452|P. falciparum,
623281|NCT00231452|age,
623282|NCT00231452|exposure,
623283|NCT00231452|neonatal immunology,
623284|NCT00231452|infants
623285|NCT00231439|Post-polio syndrome
623286|NCT00231439|IvIg
623287|NCT00231400|Glycogen Storage Disease Type II (GSD-II)
623288|NCT00231400|GSD-II
623289|NCT00231400|Pompe Disease
623290|NCT00231400|Pompe Disease (late-onset)
623291|NCT00231400|Acid Maltase Deficiency Disease
623292|NCT00231400|Glycogenosis II
623293|NCT00231387|diabetes rosiglitazone plaque
623294|NCT00231374|cerebrospinal fluid
623295|NCT00231374|pain in cervical spine
623296|NCT00231374|pain in lumbar spine
623297|NCT00231374|myelogram
623298|NCT00231348|Social anxiety disorder
623299|NCT00231348|social phobia
623300|NCT00231348|positron emission tomography (PET
623301|NCT00231348|regional cerebral blood flow (rCBF)
623302|NCT00231348|nefazodone
623303|NCT00231348|amygdala
623304|NCT00231335|schizophrenia
623305|NCT00231335|depression
623306|NCT00231335|anxiety
623307|NCT00231335|negative symptoms
623308|NCT00231322|Schistosoma haematobium
623309|NCT00231322|haematuria
623310|NCT00231322|ultrasonography
623311|NCT00231322|Uganda
623312|NCT00231322|Vesical polyps
623313|NCT00231309|G-CSF
623314|NCT00231309|Bone Marrow
623315|NCT00231309|Hematologic malignancies
623316|NCT00231309|Non-malignancies
623317|NCT00231309|Matched sibling donor
623318|NCT00231309|Allogeneic BMT
623319|NCT00231296|cryoablation
623320|NCT00231296|atrial fibrillation
623321|NCT00231218|vitamin c
623322|NCT00231218|echinacea
623323|NCT00231218|propolis
623324|NCT00231218|upper respiratory tract infection
623325|NCT00231218|common cold
623326|NCT00231218|gastroenteritis
623327|NCT00231218|dietary supplement
623328|NCT00231218|herbal remedy
623329|NCT00231205|viability
623330|NCT00231205|myocardium
623331|NCT00231205|preejection velocity
623332|NCT00231205|CAD
623333|NCT00231205|echocardiography
623334|NCT00231205|tissue Doppler
623335|NCT00231192|Diabetes
623336|NCT00231192|Adolescents
623337|NCT00231192|Cystic Fibrosis
623338|NCT00231192|Insulin
623339|NCT00231192|Repaglinide
623340|NCT00231179|child, preschool
623341|NCT00231179|intelligence
623342|NCT00231179|environment
623343|NCT00231179|home visiting
623344|NCT00231166|dose-finding
623345|NCT00231166|monoclonal antibody
623346|NCT00231166|Multiple Myeloma
623347|NCT00231153|catheter site infection
623348|NCT00231153|catheter colonization
623349|NCT00231153|catheter related blood stream infection
623350|NCT00231153|patients with central venous catheters
623351|NCT00231140|ALS, motor neuron disease
623352|NCT00231127|COPD
623353|NCT00231127|Osteoporosis
623354|NCT00231127|Osteopenia
623355|NCT00231127|Glucocorticoids
623356|NCT00231127|GOLD
623357|NCT00231127|BODE
623358|NCT00231114|Asthma
623359|NCT00231101|Smoking
623360|NCT00231101|Schizophrenia
623361|NCT00231075|Epithelial ovary cancer F.I.G.O. stages III or IV
623362|NCT00231075|70 years or older
623363|NCT00231062|sinusitis
623364|NCT00231062|rhinitis
623365|NCT00231062|sinus surgery
623366|NCT00231062|maxillary
623367|NCT00231062|ethmoid
623368|NCT00231062|sphenoid
623369|NCT00231062|frontal
623370|NCT00231062|FESS
623371|NCT00231062|sinuplasty
623372|NCT00231049|Genital Herpes
623373|NCT00231049|HSV-2 Seropositive
623374|NCT00231049|Vaccine
623375|NCT00231023|Anterior Subtenon
623376|NCT00231023|Posterior Peribulbar
623377|NCT00231023|Laser Photocoagulation
623378|NCT00231023|Diabetes
623379|NCT00231023|Diabetic Retinopathy
623380|NCT00231023|Diabetic Macular Edema
623381|NCT00231023|DME
623382|NCT00231010|Retnitis Pigmentosa
623383|NCT00231010|Retinal Degeneration
623384|NCT00231010|Retinitis Pigmentosa
623385|NCT00231010|RP
623386|NCT00231010|Usher Syndrome
623387|NCT00231010|USH
623388|NCT00231010|Bietti Crystalline Dystrophy
623389|NCT00231010|BCD
623390|NCT00230997|Galantamine
623391|NCT00230997|Dementia with Lewy Bodies
623392|NCT00230997|Treatment
623393|NCT00230984|Chronic Respiratory Failure
623394|NCT00230984|Pulmonary Rehabilitation
623395|NCT00230984|Nutritional Depletion
623396|NCT00230984|Home
623397|NCT00230984|COPD
623398|NCT00230984|Oral Dietary Supplements
623399|NCT00230984|Therapeutic Education
623400|NCT00230984|Androgens
623401|NCT00230984|Exacerbation
623402|NCT00230984|Survival
623403|NCT00230971|Intra-Abdominal Infections
623404|NCT00230971|Abscess
623405|NCT00230958|Viramidine
623406|NCT00230958|Ribavirin
623407|NCT00230958|Valeant
623408|NCT00230958|Hepatitis C
623409|NCT00230958|Pegylated interferon alfa-2b
623410|NCT00230932|Veterans
623411|NCT00230932|Pain
623412|NCT00230932|Palliative Care
623413|NCT00230932|Cardiology
623414|NCT00230932|Reproducibility of Results
623415|NCT00230932|Health Personnel
623416|NCT00230932|Heart Failure, Congestive
623417|NCT00230919|Obesity,
623418|NCT00230919|weight loss,
623419|NCT00230919|diet counseling
623420|NCT00230919|low-glycemic load
623421|NCT00230893|Antipsychotics
623422|NCT00230893|PTSD
623423|NCT00230893|Post Traumatic Stress Disorder
623424|NCT00230893|monotherapy
623425|NCT00230893|adjunct therapy
623426|NCT00230880|Contraception behavior
623427|NCT00230880|Condoms
623428|NCT00230880|Unsafe sex
623429|NCT00230880|Pregnancy unwanted
623430|NCT00230880|Adolescent pregnancy
623431|NCT00230880|Condom use
623432|NCT00230880|Unprotected sex
623433|NCT00230880|Unintended pregnancy
623434|NCT00230867|herpes labialis
623435|NCT00230867|cold sore
623436|NCT00230867|acyclovir
623437|NCT00230867|iontophoresis
623438|NCT00230867|topical
623439|NCT00230854|hepatitis C
623440|NCT00230854|genotype 1
623441|NCT00230854|non-responders
623442|NCT00230854|viral hepatitis
623443|NCT00230841|croup
623444|NCT00230841|humidity therapy
623445|NCT00230841|pediatrics
623446|NCT00230815|Oligoanovulatory infertility
623447|NCT00230815|Follitropin alfa
623448|NCT00230815|Pen device
623449|NCT00230815|Gonal-f®
623450|NCT00230815|Recombinant Human Choriogonadotropin (r-hCG)
623451|NCT00230815|Ovidrel®
623452|NCT00230802|pregnancy
623453|NCT00230802|hypothyroidism
623454|NCT00230802|levothyroxine
623455|NCT00230750|influenza, elderly, vaccine, H5N1, parent protocol
623456|NCT00230737|Aged
623457|NCT00230737|Sleep
623458|NCT00230737|Insomnia
623459|NCT00230737|Melatonin
623460|NCT00230737|Neurobehavioral Manifestations
623461|NCT00230737|Circadian Rhythms
623462|NCT00230737|Human
623463|NCT00230737|Polysomnography
623464|NCT00230737|Elderly
623465|NCT00230724|Exercise maintenance
623466|NCT00230711|Physical activity
623467|NCT00230711|Cancer follow-up care
623468|NCT00230698|Epilepsy
623469|NCT00230698|Partial Epilepsies
623470|NCT00230698|Seizures
623471|NCT00230698|Topiramate
623472|NCT00230685|Pulmonary arteriovenous malformations
623473|NCT00230646|cancer recovery
623474|NCT00230646|physical activity
623475|NCT00230607|alpha Galactosidase A
623476|NCT00230607|aGAL
623477|NCT00230607|rh aGAL
623478|NCT00230607|Fabry
623479|NCT00230607|GL3
623480|NCT00230607|Fabrazyme
623481|NCT00230607|Lysosomal Storage Disorder
623482|NCT00230607|Enzyme Replacement Therapy (ERT)
623483|NCT00230581|IBS-d, IBS
623484|NCT00230568|Mild to Moderate Alzheimer's Disease
623485|NCT00230568|Hispanic
623486|NCT00230568|Latino
623487|NCT00230568|Spanish-speaking
623488|NCT00230555|child, preschool
623489|NCT00230555|environment
623490|NCT00230555|intelligence
623491|NCT00230542|platinum-sensitive recurrence
623492|NCT00230542|carboplatin
623493|NCT00230542|pemetrexed
623494|NCT00230529|Plaque-type Psoriasis
623495|NCT00230529|infliximab
623496|NCT00230529|Remicade
623497|NCT00230529|biologics
623498|NCT00230516|N/A this study is being conducted with healthy volunteers
623499|NCT00230503|Hepatitis B, Chronic
623500|NCT00230503|Hepatitis B Virus
623501|NCT00230503|Pradefovir Mesylate
623502|NCT00230503|Adefovir Dipivoxyl
623503|NCT00230490|Hepatitis B, Chronic
623504|NCT00230490|Hepatitis B Virus
623505|NCT00230490|Pradefovir Mesylate
623506|NCT00230490|Adefovir Dipivoxyl
623507|NCT00230477|Hepatitis B
623508|NCT00230464|diabetes
623509|NCT00230464|rate of appearance of glucose
623510|NCT00230464|insulin secretion
623511|NCT00230464|glucagon
623512|NCT00230425|Alcohol Abuse
623513|NCT00230425|Anxiety Disorders
623514|NCT00230425|Mood Disorders
623515|NCT00230412|Kidney Failure, Acute
623516|NCT00230412|Acute Renal Failure
623517|NCT00230412|Kidney Failure
623518|NCT00230412|Heat-Shock Proteins
623519|NCT00230412|Children
623520|NCT00230373|Localized scleroderma
623521|NCT00230360|constipation
623522|NCT00230360|fecal incontinence
623523|NCT00230360|diagnosis
623524|NCT00230360|children
623525|NCT00230308|Head and Neck Cancer
623526|NCT00228488|advanced non-nasopharyngeal head and neck carcinoma
623527|NCT00228462|Schizophrenia
623528|NCT00228449|anemia
623529|NCT00228449|chronic kidney disease
623530|NCT00228449|CKD
623531|NCT00228449|chronic renal failure
623532|NCT00228449|CRF
623533|NCT00228449|dialysis
623534|NCT00228449|erythropoietin
623535|NCT00228449|EPO
623536|NCT00228449|erythropoiesis stimulating agent
623537|NCT00228449|ESA
623538|NCT00228449|Hematide™
623539|NCT00228449|hemodialysis
623540|NCT00228449|hemoglobin
623541|NCT00228449|Hb
623542|NCT00228449|Hgb
623543|NCT00228449|Omontys
623544|NCT00228449|peginesatide
623545|NCT00228449|red blood cell
623546|NCT00228449|red blood cell production
623547|NCT00230243|Aspergillosis
623548|NCT00230243|CandidiasisMucormycosis
623549|NCT00230243|FusariosisCryptococcosis
623550|NCT00230243|Endemic Fungal infections
623551|NCT00230243|Phaeohyphomycosis
623552|NCT00230217|Relapse
623553|NCT00230217|Refracturing
623554|NCT00230217|Leukemia
623555|NCT00230217|Lymphoma
623556|NCT00230217|Solid Tumor
623557|NCT00230204|Multiple sclerosis
623558|NCT00230204|Antibodies
623559|NCT00230204|Serum
623560|NCT00230204|Infectious agents
623561|NCT00230204|Immunoglobulin G
623562|NCT00230204|Immunoglobulin M
623563|NCT00230191|Oral
623564|NCT00230191|Mucositis
623565|NCT00230191|Stomatitis
623566|NCT00230191|Head and Neck Cancer
623567|NCT00230178|Hyperuricemia
623568|NCT00230178|Tumor lysis syndrome
623569|NCT00230178|Leukemia
623570|NCT00230178|Lymphoma
623571|NCT00230178|Myelodysplastic Syndromes
623572|NCT00230178|Solid tumor cancers
623573|NCT00230178|Solid Tumor cancers with hyperuricemia Hyperuricemia (cancer patients only)
623574|NCT00230178|Tumor lysis syndrome (cancer patients only)
623575|NCT00230165|Platelets
623576|NCT00230165|Erythrocytes
623577|NCT00230165|Leukocytes
623578|NCT00230165|Coagulation
623579|NCT00230165|Thrombosis
623580|NCT00230126|African Americans
623581|NCT00230113|NAFLD
623582|NCT00230113|NASH
623583|NCT00230113|Fatty Liver Disease
623584|NCT00230113|Omega-3 Fatty Acid
623585|NCT00230113|Fish oil
623586|NCT00230100|Gender differences
623587|NCT00230100|Women
623588|NCT00230100|Substance use disorders
623589|NCT00230100|Alcohol use disorders
623590|NCT00230100|Treatment outcomes
623591|NCT00230100|Group therapy
623592|NCT00230087|diabetes
623593|NCT00230087|nafld
623594|NCT00230087|nash
623595|NCT00230087|phlebotomy
623596|NCT00230074|Amyotrophic Lateral Sclerosis; ALS
623597|NCT00230061|HIV
623598|NCT00230009|child abuse, child neglect, substance use, violence exposure, brief intervention
623599|NCT00229996|endometriosis
623600|NCT00229996|pelvic pain
623601|NCT00229996|treatment
623602|NCT00229983|Substance use disorders
623603|NCT00229983|Substance abuse
623604|NCT00229983|Alcohol abuse
623605|NCT00229983|Drug abuse
623606|NCT00229957|Occupational therapy
623607|NCT00229957|Physical therapy techniques
623608|NCT00229957|Primary health care
623609|NCT00229957|Chronic disease
623610|NCT00229957|Rehabilitation
623611|NCT00229957|Disease management
623612|NCT00229957|Self care
623613|NCT00229944|Azithromycin
623614|NCT00229944|V. cholerae O1 / O139
623615|NCT00229944|adults
623616|NCT00229944|Bangladesh
623617|NCT00229944|Clinical trial
623618|NCT00229931|CATARACT EXTRACTION
623619|NCT00229931|MACULAR EDEMA
623620|NCT00229931|DIABETES
623621|NCT00229931|FOCAL LASER
623622|NCT00229931|TRIAMCINOLONE
623623|NCT00229918|Diabetic macular edema
623624|NCT00229918|Clinically significant macular edema
623625|NCT00229905|pediatric health
623626|NCT00229905|children
623627|NCT00229905|single case study
623628|NCT00229892|pediatric health
623629|NCT00229892|cardiac
623630|NCT00229892|small incisions
623631|NCT00229892|operations
623632|NCT00229892|minimally invasive
623633|NCT00229879|pediatric health
623634|NCT00229879|rare tumor
623635|NCT00229879|children
623636|NCT00229879|cardiac
623637|NCT00229866|newborn
623638|NCT00229866|pediatric health
623639|NCT00229866|Feeding difficulty
623640|NCT00229866|discharge with a NG tube
623641|NCT00229866|G-tube placement
623642|NCT00229866|Nissen fundoplication
623643|NCT00229853|Children's Healthcare of Atlanta
623644|NCT00229853|pediatric
623645|NCT00229853|Thoracoscopic Vascular ring
623646|NCT00229853|diverticulopexy
623647|NCT00229853|Vascular Ring Division
623648|NCT00229840|MRI, fMRI, Epilepsy, Pediatric
623649|NCT00229827|pediatric health
623650|NCT00229827|cardiac
623651|NCT00229827|pediatric population
623652|NCT00229827|congenital heart surgery
623653|NCT00229827|left to right shunt lesions
623654|NCT00229827|heart surgery
623655|NCT00229827|Atrioventricular canal defects
623656|NCT00229814|Tectal Plate Glioma
623657|NCT00229814|Tumor
623658|NCT00229814|Brain
623659|NCT00229814|MRI
623660|NCT00229814|Spectroscopy
623661|NCT00229801|Renal Function, MRI
623662|NCT00229788|orthotopic heart transplantation
623663|NCT00229775|Plasmodium falciparum malaria
623664|NCT00229775|malaria
623665|NCT00229775|artemether lumafantrine
623666|NCT00229775|chloroquine
623667|NCT00229775|sulfadoxine pyrimethamine
623668|NCT00229775|Coartem
623669|NCT00229762|pneumococcal vaccination coverage with no disease or efficacy outcomes recorded
623670|NCT00229749|HCV
623671|NCT00229723|Head and Neck Squamous Cell Carcinoma
623672|NCT00229723|Head and Neck Squamous Cell Cancer
623673|NCT00229723|Squamous Cell Carcinoma
623674|NCT00229723|Squamous Cell Cancer
623675|NCT00229710|Diabetes Mellitus, Type II
623676|NCT00229710|Type 2 Diabetes Mellitus
623677|NCT00229697|Breast cancer
623678|NCT00229697|metastatic breast cancer
623679|NCT00229684|Type 2 Diabetes
623680|NCT00229658|diabetes
623681|NCT00229658|pramlintide
623682|NCT00229658|Symlin
623683|NCT00229658|Amylin
623684|NCT00229658|phase 4
623685|NCT00229645|Major Depression
623686|NCT00229645|Anxiety
623687|NCT00229632|Friedreich's Ataxia
623688|NCT00229632|Idebenone
623689|NCT00229632|Ataxia
623690|NCT00229632|Drug Trial
623691|NCT00229632|Randomized Trial
623692|NCT00229632|Friedreich Ataxia
623693|NCT00229632|FA
623694|NCT00229619|rituxan
623695|NCT00229619|Immunosuppression
623696|NCT00229619|Bone Marrow Failure
623697|NCT00229619|Monoclonal Antibody Therapy
623698|NCT00229619|Diamond Blackfan Anemia (DBA)
623699|NCT00229619|T -Cells
623700|NCT00229619|B-Cells
623701|NCT00229619|Hematopoiesis
623702|NCT00229619|Moderate Aplastic Anemia (MAA)
623703|NCT00229619|Diamond-Blackfan Anemia
623704|NCT00229619|DBA
623705|NCT00229619|Pure Red Cell Aplasia
623706|NCT00229619|PRCA
623707|NCT00229593|Male contraception
623708|NCT00229593|Androgen
623709|NCT00229593|Progestin
623710|NCT00229593|Spermatogenesis
623711|NCT00229593|Gonadotropin suppression
623712|NCT00229593|Testosterone
623713|NCT00229593|Nestorone
623714|NCT00229580|Brief Intervention
623715|NCT00229580|Motivational Interviewing
623716|NCT00229580|Health Psychology
623717|NCT00229580|Alcohol
623718|NCT00229580|Hepatitis C
623719|NCT00229580|Patient Education
623720|NCT00229567|ketamine
623721|NCT00229567|lidocaine
623722|NCT00229567|postoperative ileus
623723|NCT00229567|randomized controlled trial
623724|NCT00229567|acute postoperative pain
623725|NCT00229554|health surveys
623726|NCT00229554|questionnaires
623727|NCT00229541|Medical in-patient rehabilitation
623728|NCT00229541|Gainfully employed
623729|NCT00229541|Work incapacity
623730|NCT00229515|Myocardial infarction
623731|NCT00229515|Revascularization
623732|NCT00229515|Stent
623733|NCT00229515|ST segment elevation
623734|NCT00229476|Depression
623735|NCT00229476|EEG
623736|NCT00229476|QEEG
623737|NCT00229476|cordance
623738|NCT00229476|Zoloft
623739|NCT00229476|sertraline
623740|NCT00229476|placebo
623741|NCT00229476|electroencephalogram
623742|NCT00229476|brain
623743|NCT00229476|antidepressants
623744|NCT00229463|Depression
623745|NCT00229463|genetic
623746|NCT00229463|gene
623747|NCT00229463|antidepressant
623748|NCT00229463|research
623749|NCT00229450|depression
623750|NCT00229450|menopause
623751|NCT00229450|perimenopause
623752|NCT00229450|mood
623753|NCT00229450|memory
623754|NCT00229450|perimenopausal
623755|NCT00229450|antidepressant
623756|NCT00229450|estrogen
623757|NCT00229437|Diabetic Mononeuropathy
623758|NCT00229437|Diabetic Neuralgia
623759|NCT00229437|Mononeuropathy, Diabetic
623760|NCT00229437|Neuralgia, Diabetic
623761|NCT00229437|Diabetic Polyneuropathy
623762|NCT00229437|Drug Therapy
623763|NCT00229424|lafutidine
623764|NCT00229424|reflux oesophagitis
623765|NCT00229424|Gastroesophageal Reflux
623766|NCT00229424|famotidine
623767|NCT00229424|Double Blind
623768|NCT00229424|Controlled Study
623769|NCT00229424|H2 receptor antagonist
623770|NCT00229424|H2-blocker
623771|NCT00229411|intensive care
623772|NCT00229411|teamwork
623773|NCT00229411|medical errors
623774|NCT00229411|education
623775|NCT00229411|simulation
623776|NCT00228865|Pulsatile intravenous insulin
623777|NCT00228865|Oral carbohydrate loading
623778|NCT00228865|Mindstream testing
623779|NCT00228865|Wechsler Memory Scale II
623780|NCT00228865|Respiratory Quotients
623781|NCT00228865|Hypoglycemia
623782|NCT00228865|Diabetes Mellitus with cognitive impairment
623783|NCT00228865|Diabetes Mellitus with complications
623784|NCT00228852|Patients with severe T-cell immune deficiency diseases
623785|NCT00228839|Recipients of an allogeneic hematopoietic stem cell transplant who have acute GVHD
623786|NCT00228696|late effects
623787|NCT00228670|Idiopathic Pulmonary Fibrosis
623788|NCT00228670|herpesvirus
623789|NCT00228670|lung biopsy
623790|NCT00228670|Having diagnosed lung disease
623791|NCT00228670|Scheduled to have a lung biopsy as part of the evaluation for your lung disease
623792|NCT00228644|oxidative stress
623793|NCT00228644|amino acids
623794|NCT00228644|acetaminophen
623795|NCT00228644|dietary requirements
623796|NCT00228631|sickle
623797|NCT00228631|cell
623798|NCT00229333|Escitalopram
623799|NCT00229333|Depression
623800|NCT00229333|Dementia
623801|NCT00229333|Treatment
623802|NCT00229333|Depressive Syndrome in Alzheimer’s Disease
623803|NCT00229333|Depressive Syndrome in Vascular Dementia
623804|NCT00229333|Depressive Syndrome in Mixed Vascular and Alzheimer’s Dementia
623805|NCT00229307|Post traumatic stress disorder
623806|NCT00228618|oxidative stress
623807|NCT00228618|amino acids
623808|NCT00228618|dietary requirements
623809|NCT00228605|Pain
623810|NCT00228605|Sudden Pain
623811|NCT00228605|Flares
623812|NCT00228605|noncancer
623813|NCT00228605|low back pain
623814|NCT00228605|neuropathic pain
623815|NCT00228605|osteoarthritis pain
623816|NCT00228605|migraine
623817|NCT00228605|chronic headache
623818|NCT00228605|diabetic peripheral neuropathy
623819|NCT00228579|diabetes
623820|NCT00228579|insulin resistance
623821|NCT00229268|Healthy Volunteers
623822|NCT00229255|Non-Alcoholic hepatic steatosis
623823|NCT00229242|Ambulatory blood pressure monitoring
623824|NCT00229242|Echocardiography
623825|NCT00229242|Diastolic function
623826|NCT00229242|Left ventricular mass regression
623827|NCT00229229|Obesity
623828|NCT00229229|Cardiovascular Disease
623829|NCT00229229|Metabolic Syndrome
623830|NCT00229229|Canada Food Guide
623831|NCT00229229|Glycemic Index
623832|NCT00229229|Glycemic Load
623833|NCT00229203|Myeloma
623834|NCT00229203|Aplidin
623835|NCT00229203|Plitidepsin
623836|NCT00229203|PharmaMar
623837|NCT00229190|Nasal lavage fluid
623838|NCT00229190|Eosinophils
623839|NCT00229190|Reproducibility of results
623840|NCT00229177|ONO-2506
623841|NCT00229177|stroke
623842|NCT00229177|Acute ischemic stroke
623843|NCT00229164|Primary Dysmenorrhea,
623844|NCT00229164|Transcutaneous Electric Nerve Stimulation
623845|NCT00229138|De novo kidney recipients,
623846|NCT00229138|EC-MPS,
623847|NCT00229138|tacrolimus,
623848|NCT00229138|efficacy,
623849|NCT00229138|safety,
623850|NCT00229138|glomerular filtration rate
623851|NCT00229138|Treatment in de novo kidney recipients
623852|NCT00229125|Alcohol Withdrawal Syndrome
623853|NCT00229125|CIWA-Ar
623854|NCT00229125|Acoustic Startle Procedure
623855|NCT00229125|Rebound Effect
623856|NCT00229073|dapoxetine
623857|NCT00229073|premature ejaculation
623858|NCT00229073|ejaculation
623859|NCT00229073|sexual dysfunction
623860|NCT00229073|orgasmic disorder
623861|NCT00229073|sexual intercourse
623862|NCT00229060|Complicated Intra-Abdominal Infections
623863|NCT00229060|Appendicitis
623864|NCT00229060|Cholecystitis
623865|NCT00229060|Peritonitis
623866|NCT00229047|Ischemic Preconditioning
623867|NCT00229047|Microvascular Perfusion
623868|NCT00229047|Inflammation
623869|NCT00229047|Ischemia and Reperfusion
623870|NCT00229047|Chronic Limb Ischemia
623871|NCT00229034|Systemic Inflammation
623872|NCT00229034|Microvascular Perfusion
623873|NCT00229034|Septic Shock
623874|NCT00229021|Complicated Urinary Tract Infection
623875|NCT00229021|Pyelonephritis
623876|NCT00229008|Ceftobiprole medocaril
623877|NCT00229008|Nosocomial Pneumonia
623878|NCT00229008|Ventilator-Associated Pneumonia
623879|NCT00229008|Cephalosporins
623880|NCT00229008|Methicillin-Resistant Staphylococcus Aureus
623881|NCT00228995|Anemia
623882|NCT00228995|Subcutaneous injection
623883|NCT00228995|PROCRIT
623884|NCT00228995|Erythropoietin
623885|NCT00228995|Epoetin Alfa
623886|NCT00228995|Hemoglobin Level
623887|NCT00228995|Elderly
623888|NCT00228982|Complicated Skin Infections
623889|NCT00228982|Infectious Skin Diseases
623890|NCT00228982|Bacterial Skin Diseases
623891|NCT00228982|Staphylococcal Skin Infections
623892|NCT00228982|Cephalosporin
623893|NCT00228956|Breast Cancer
623894|NCT00228956|Aromatase Inhibitor
623895|NCT00228956|Letrozole
623896|NCT00228956|Exemestane
623897|NCT00228943|Breast cancer survivorship
623898|NCT00228943|Hot Flashes
623899|NCT00228943|Serotonin
623900|NCT00228930|Breast Cancer
623901|NCT00228930|Tamoxifen
623902|NCT00228930|Prevention
623903|NCT00228917|Hib & Neisseria meningitidis serogroups A & C diseases
623904|NCT00228904|Pulsatile intravenous insulin
623905|NCT00228904|Oral carbohydrate loading
623906|NCT00228904|Respiratory Quotients
623907|NCT00228904|Hypoglycemia
623908|NCT00228904|Diabetic Neuropathy
623909|NCT00228904|Diabetes Mellitus, with complications
623910|NCT00228891|Pulsatile intravenous insulin
623911|NCT00228891|Oral carbohydrate loading
623912|NCT00228891|Respiratory Quotients
623913|NCT00228891|Hypoglycemia
623914|NCT00228891|Diabetic Neuropathy
623915|NCT00228878|Diabetes
623916|NCT00228878|Pulsatile intravenous insulin
623917|NCT00228878|Oral carbohydrate loading
623918|NCT00228878|Respiratory Quotients
623919|NCT00228878|Hypoglycemia
623920|NCT00228878|Diabetes Mellitus, with complications
623921|NCT00228436|anemia
623922|NCT00228436|chronic kidney disease
623923|NCT00228436|CKD
623924|NCT00228436|chronic renal failure
623925|NCT00228436|CRF
623926|NCT00228436|dialysis
623927|NCT00228436|erythropoietin
623928|NCT00228436|EPO
623929|NCT00228436|erythropoiesis stimulating agent
623930|NCT00228436|ESA
623931|NCT00228436|Hematide™
623932|NCT00228436|hemoglobin
623933|NCT00228436|Hb
623934|NCT00228436|Hgb
623935|NCT00228436|Omontys
623936|NCT00228436|peginesatide
623937|NCT00228436|red blood cell
623938|NCT00228436|red blood cell production
623939|NCT00228423|Saphenous vein
623940|NCT00228423|Intimal hyperplasia
623941|NCT00228423|Coronary artery bypass graft surgery
623942|NCT00228423|Antiplatelet therapy
623943|NCT00228423|Clopidogrel
623944|NCT00228423|Saphenous vein graft disease
623945|NCT00228410|Skin Infections
623946|NCT00228410|Skin Disease
623947|NCT00228397|Multiple Sclerosis
623948|NCT00228371|Epilepsy
623949|NCT00228371|deep brain stimulation
623950|NCT00228371|Subthalamic nucleus
623951|NCT00228371|Drug resistant epilepsy
623952|NCT00228345|Idiopathic Axonal Polyneuropathy
623953|NCT00228345|abnormal OGTT
623954|NCT00228293|cardiac arrest
623955|NCT00228293|CPR
623956|NCT00228280|Apicoectomy
623957|NCT00228280|Retrograde
623958|NCT00228280|MTA
623959|NCT00228267|Chronic Headache
623960|NCT00228267|Analgesic Rebound Headache
623961|NCT00228267|Chronic Daily Headache
623962|NCT00228267|Headache, Intractable
623963|NCT00228267|Randomised controlled trial
623964|NCT00228267|Propofol
623965|NCT00228254|acute respiratory infection
623966|NCT00228254|acute lower respiratory infection
623967|NCT00228254|diarrhea
623968|NCT00228241|Sick sinus syndrome
623969|NCT00228241|AV-block
623970|NCT00228228|Multiple Sclerosis
623971|NCT00228228|T-cell vaccination
623972|NCT00228228|Autoreactive T cells
623973|NCT00228215|sleep
623974|NCT00228215|neonates
623975|NCT00228215|mothers
623976|NCT00228215|behavioural intervention
623977|NCT00228202|cytomegalovirus
623978|NCT00228202|CMV
623979|NCT00228202|pregnancy
623980|NCT00228202|amniotic fluid
623981|NCT00228202|bone marrow
623982|NCT00228202|transplantation
623983|NCT00228202|viral load
623984|NCT00228202|glycoprotein B
623985|NCT00228202|genotyping
623986|NCT00228202|PCR
623987|NCT00228202|real-time PCR
623988|NCT00228202|CMV disease
623989|NCT00228202|Congenital CMV infection
623990|NCT00228189|Dendritic cells
623991|NCT00228189|Colorectal cancer
623992|NCT00228189|Carcinoembryonic antigen
623993|NCT00228189|Vaccine
623994|NCT00228189|Immunotherapy
623995|NCT00228176|Metabolic syndrome
623996|NCT00228176|Carotid Atherosclerosis
623997|NCT00228163|Multiple Sclerosis Relapsing Remitting
623998|NCT00228163|Secondary Progressive
623999|NCT00228163|Progressive Relapsing
624000|NCT00228150|Parkinson Disease
624001|NCT00228150|levodopa
624002|NCT00228150|dopamine agonists
624003|NCT00228124|Prostate cancer
624004|NCT00228124|Continuous androgen suppression
624005|NCT00228124|Intermittent androgen suppression
624006|NCT00228124|Bone loss
624007|NCT00228124|Osteoporosis
624008|NCT00228111|Computed tomography
624009|NCT00228111|wounds and injuries,non penetrating
624010|NCT00228111|algorithms
624011|NCT00228111|Blunt trauma of the thorax and abdomen
624012|NCT00228072|Hyperhidrosis
624013|NCT00228072|Axillary
624014|NCT00228072|Excision
624015|NCT00228072|Suction-curettage
624016|NCT00228072|Outcome
624017|NCT00228059|Bipolar disorder, manic episode/treatment/licarbazepine
624018|NCT00228046|ADHD
624019|NCT00228046|ODD
624020|NCT00228046|Conduct Disorder
624021|NCT00228046|CD
624022|NCT00228033|Calcium
624023|NCT00228033|Pregnancy
624024|NCT00228033|Postpartum Depression
624025|NCT00228033|Depression
624026|NCT00228020|pediatric, kidney transplantation, basiliximab
624027|NCT00228007|Injection Drug Use
624028|NCT00228007|HIV Risk Behavior
624029|NCT00228007|HIV Seronegativity
624030|NCT00227994|Cholinesterase Inhibitors
624031|NCT00227994|Elderly
624032|NCT00227994|Stroke
624033|NCT00227994|Cognition
624034|NCT00227981|Depression Relapse
624035|NCT00227981|Maintenance Therapy
624036|NCT00227968|Manic-depressive psychosis
624037|NCT00227968|Depression, bipolar
624038|NCT00227955|Major depression
624039|NCT00227942|Women
624040|NCT00227942|Menopause
624041|NCT00227942|Depression
624042|NCT00227942|Hot flash
624043|NCT00227942|Insomnia
624044|NCT00227942|Sleep Disruption
624045|NCT00227942|Estrogen Replacement Therapy
624046|NCT00227929|Major Depressive Disorder
624047|NCT00227929|MDD
624048|NCT00227916|alcohol, marijuana
624049|NCT00227890|substance abuse
624050|NCT00227877|alcohol abuse
624051|NCT00227877|substance abuse
624052|NCT00227877|substance related disorders
624053|NCT00227864|marijuana
624054|NCT00227864|sexual risk
624055|NCT00227838|substance abuse
624056|NCT00227825|Behavioral Intervention
624057|NCT00227812|cocaine dependence
624058|NCT00227786|unspecified adult solid tumor, protocol specific
624059|NCT00227786|tobacco use disorder
624060|NCT00227773|localized gastrointestinal carcinoid tumor
624061|NCT00227773|metastatic gastrointestinal carcinoid tumor
624062|NCT00227773|recurrent gastrointestinal carcinoid tumor
624063|NCT00227773|regional gastrointestinal carcinoid tumor
624064|NCT00227773|recurrent islet cell carcinoma
624065|NCT00227773|gastrinoma
624066|NCT00227773|insulinoma
624067|NCT00227773|WDHA syndrome
624068|NCT00227773|glucagonoma
624069|NCT00227773|pancreatic polypeptide tumor
624070|NCT00227773|somatostatinoma
624071|NCT00227747|adenocarcinoma of the rectum
624072|NCT00227747|stage II rectal cancer
624073|NCT00227747|stage III rectal cancer
624074|NCT00227734|stage IV colon cancer
624075|NCT00227734|stage IV rectal cancer
624076|NCT00227734|recurrent colon cancer
624077|NCT00227734|recurrent rectal cancer
624078|NCT00227721|recurrent ovarian epithelial cancer
624079|NCT00227721|peritoneal cavity cancer
624080|NCT00227708|adenocarcinoma of the lung
624081|NCT00227708|adenosquamous cell lung cancer
624082|NCT00227708|large cell lung cancer
624083|NCT00227708|squamous cell lung cancer
624084|NCT00227708|stage IIIB non-small cell lung cancer
624085|NCT00227708|stage IV non-small cell lung cancer
624086|NCT00227708|recurrent non-small cell lung cancer
624087|NCT00227695|stage I grade 1 follicular lymphoma
624088|NCT00227695|stage I grade 2 follicular lymphoma
624089|NCT00227695|stage I grade 3 follicular lymphoma
624090|NCT00227695|stage III grade 1 follicular lymphoma
624091|NCT00227695|stage III grade 2 follicular lymphoma
624092|NCT00227695|stage III grade 3 follicular lymphoma
624093|NCT00227695|stage IV grade 1 follicular lymphoma
624094|NCT00227695|stage IV grade 2 follicular lymphoma
624095|NCT00227695|stage IV grade 3 follicular lymphoma
624096|NCT00227695|contiguous stage II grade 1 follicular lymphoma
624097|NCT00227695|contiguous stage II grade 2 follicular lymphoma
624098|NCT00227695|contiguous stage II grade 3 follicular lymphoma
624099|NCT00227695|noncontiguous stage II grade 1 follicular lymphoma
624100|NCT00227695|noncontiguous stage II grade 2 follicular lymphoma
624101|NCT00227695|noncontiguous stage II grade 3 follicular lymphoma
624102|NCT00227695|recurrent grade 1 follicular lymphoma
624103|NCT00227695|recurrent grade 2 follicular lymphoma
624104|NCT00227695|recurrent grade 3 follicular lymphoma
624105|NCT00227682|refractory multiple myeloma
624106|NCT00227669|uterine leiomyosarcoma
624107|NCT00227669|stage III adult soft tissue sarcoma
624108|NCT00227669|stage IV adult soft tissue sarcoma
624109|NCT00227669|recurrent adult soft tissue sarcoma
624110|NCT00227669|stage III uterine sarcoma
624111|NCT00227669|stage IV uterine sarcoma
624112|NCT00227669|recurrent uterine sarcoma
624113|NCT00227669|adult leiomyosarcoma
624114|NCT00227656|stage IV breast cancer
624115|NCT00227656|recurrent breast cancer
624116|NCT00227656|male breast cancer
624117|NCT00227656|tumors metastatic to brain
624118|NCT00227630|epithelial mesothelioma
624119|NCT00227630|sarcomatous mesothelioma
624120|NCT00227630|localized malignant mesothelioma
624121|NCT00227630|recurrent malignant mesothelioma
624122|NCT00227617|recurrent gastrointestinal carcinoid tumor
624123|NCT00227617|regional gastrointestinal carcinoid tumor
624124|NCT00227617|pulmonary carcinoid tumor
624125|NCT00227617|gastrinoma
624126|NCT00227617|insulinoma
624127|NCT00227617|WDHA syndrome
624128|NCT00227617|glucagonoma
624129|NCT00227617|pancreatic polypeptide tumor
624130|NCT00227617|somatostatinoma
624131|NCT00227617|recurrent islet cell carcinoma
624132|NCT00227617|metastatic gastrointestinal carcinoid tumor
624133|NCT00227565|extensive stage small cell lung cancer
624134|NCT00227539|stage I non-small cell lung cancer
624135|NCT00227539|stage II non-small cell lung cancer
624136|NCT00227539|stage IIIA non-small cell lung cancer
624137|NCT00227539|stage IIIB non-small cell lung cancer
624138|NCT00227526|Colon
624139|NCT00227526|Surgery
624140|NCT00227526|Prehabilitation
624141|NCT00227526|Exercise
624142|NCT00227500|Hyperlipidaemia
624143|NCT00227500|Lipid metabolism
624144|NCT00227500|Glucose metabolism
624145|NCT00227500|HMG CoA reductase inhibitors
624146|NCT00227500|Lipodystrophy
624147|NCT00227500|Cardiovascular disease
624148|NCT00227500|Treatment Experienced
624149|NCT00227500|HIV
624150|NCT00227487|autism
624151|NCT00227487|intestine
624152|NCT00227487|disaccharidases
624153|NCT00227487|inflammation
624154|NCT00227487|permeability
624155|NCT00227474|stage IIIB breast cancer
624156|NCT00227474|stage IIIC breast cancer
624157|NCT00227474|stage IV breast cancer
624158|NCT00227461|Aphasia
624159|NCT00227461|Stroke
624160|NCT00227448|Ischemic
624161|NCT00227448|Stroke
624162|NCT00227422|Neisseria meningitidis serogroups A & C diseases
624163|NCT00227422|Hib diseases
624164|NCT00227409|Repeated chelation therapy
624165|NCT00227409|Progressive renal insufficiency
624166|NCT00227409|Body lead burden
624167|NCT00227409|Long-term outcome
624168|NCT00227409|Glomerular filtration rate
624169|NCT00227383|Diabetes
624170|NCT00227383|gastroparesis
624171|NCT00227383|electroacupuncture
624172|NCT00227370|Acute rejection
624173|NCT00227370|Non-CMV infections
624174|NCT00227370|Resistance
624175|NCT00227357|HIV
624176|NCT00227357|AIDS
624177|NCT00227357|Buprenorphine
624178|NCT00227357|Methadone
624179|NCT00227357|Primary care
624180|NCT00227357|dual diagnosis
624181|NCT00227357|ptsd
624182|NCT00227331|Pneumonia
624183|NCT00227305|Schizophrenia
624184|NCT00227305|Bipolar I Disorder
624185|NCT00227292|Low back pain
624186|NCT00227292|Depression
624187|NCT00227279|Grass pollen allergy
624188|NCT00227279|Hayfever
624189|NCT00227279|Allergen immunotherapy
624190|NCT00227279|Specific immunotherapy
624191|NCT00227266|Spinal Muscular Atrophy (SMA)
624192|NCT00227266|SMA Type 2
624193|NCT00227266|SMA Type 3
624194|NCT00227253|Phenotype
624195|NCT00227253|Growth
624196|NCT00227253|Genotype
624197|NCT00227253|Chromosome 18
624198|NCT00227201|African-American
624199|NCT00227201|Hypertension
624200|NCT00227201|Complementary medicine
624201|NCT00227201|Medication adherence
624202|NCT00227175|African American
624203|NCT00227175|Hypertension
624204|NCT00227175|Medication adherence
624205|NCT00227175|Risk reduction
624206|NCT00227162|Asthma
624207|NCT00227162|Behavior change
624208|NCT00227162|Physical activity
624209|NCT00227162|Risk reduction
624210|NCT00227149|C06.552.380.705.440
624211|NCT00227136|5Hydroxytryptamine
624212|NCT00227136|Chromogranin A
624213|NCT00227136|5HIAA
624214|NCT00227136|carcinoid
624215|NCT00227123|Bipolar, cocaine, methamphetamine,quetiapine,risperidone
624216|NCT00227110|NASH, IGT, T2DM
624217|NCT00227097|therapeutic education
624218|NCT00227097|thrombi embolic disease
624219|NCT00227084|Mammary glands
624220|NCT00227084|hemostasis
624221|NCT00227084|Mammaplasty
624222|NCT00227071|accidental falls
624223|NCT00227071|osteoporosis
624224|NCT00227071|risk factors
624225|NCT00227058|allergic rhinitis
624226|NCT00227045|Kidney Transplantation
624227|NCT00227032|adult giant cell glioblastoma
624228|NCT00227032|adult gliosarcoma
624229|NCT00227032|adult glioblastoma
624230|NCT00227032|recurrent adult brain tumor
624231|NCT00226915|ovarian neoplasms
624232|NCT00226915|randomized controlled trial
624233|NCT00226915|paclitaxel
624234|NCT00226915|carboplatin
624235|NCT00226902|Diabetes
624236|NCT00226902|Hemoglobin
624237|NCT00226902|Dialysis
624238|NCT00226902|Vascular reactivity
624239|NCT00226889|Scleroderma
624240|NCT00226889|Fibrosis
624241|NCT00226889|Therapy
624242|NCT00226889|Bosentan
624243|NCT00226889|Endothelin-1
624244|NCT00226876|dreaming
624245|NCT00226876|anaesthesia
624246|NCT00226876|electroencephalography
624247|NCT00226876|bispectral index
624248|NCT00226876|awareness
624249|NCT00226824|Tourette's disorder
624250|NCT00226824|tic
624251|NCT00226772|Anterior cruciate ligament reconstruction
624252|NCT00226772|ACL reconstruction
624253|NCT00226759|Anterior cruciate ligament reconstruction
624254|NCT00226759|ACL reconstruction
624255|NCT00226746|Pancreatic Cancer
624256|NCT00226746|Hyperfractionated Radiation Therapy
624257|NCT00226746|Gemcitabine
624258|NCT00226746|Paclitaxel
624259|NCT00226746|Carcinoma, Pancreatic Ductal
624260|NCT00226733|Coronary Artery Bypass (E04.928.220.520.220)
624261|NCT00226733|Exercise Test [E01.370.370.380.250]
624262|NCT00226733|Echocardiography [E01.370.370.380.220]
624263|NCT00226733|Quality of Life [K01.752.400.750]
624264|NCT00226720|alcoholism
624265|NCT00226720|Alcohol dependence
624266|NCT00226720|Detoxification
624267|NCT00226720|Abstinence maintain
624268|NCT00226720|Efficacy
624269|NCT00226720|Ambulatory detoxification
624270|NCT00226707|Chronic hand dermatitis, pimecrolimus, dermatitis
624271|NCT00226694|Alcoholism
624272|NCT00226694|Stress
624273|NCT00226694|Gender Differences
624274|NCT00226694|Addiction
624275|NCT00226694|Alcohol Dependence
624276|NCT00226668|peritumoral brain edema
624277|NCT00226668|edema
624278|NCT00226668|malignant brain tumor
624279|NCT00226668|astrocytoma
624280|NCT00226668|brain tumor
624281|NCT00226668|dexamethasone
624282|NCT00226668|Decadron
624283|NCT00226655|peritumoral brain edema
624284|NCT00226655|edema
624285|NCT00226655|malignant brain tumor
624286|NCT00226655|astrocytoma
624287|NCT00226655|brain tumor
624288|NCT00226655|dexamethasone
624289|NCT00226655|Decadron
624290|NCT00226642|depression
624291|NCT00226642|primary care
624292|NCT00226616|Zinc
624293|NCT00226616|cholera
624294|NCT00226616|children
624295|NCT00226616|Bangladesh
624296|NCT00226603|groin injury
624297|NCT00226603|football
624298|NCT00226603|prevention
624299|NCT00226603|traing programme
624300|NCT00226603|cluster randomized study
624301|NCT00226590|non-small cell lung cancer
624302|NCT00226590|carcinoma
624303|NCT00226590|unresectable
624304|NCT00226590|Stage IIIA
624305|NCT00226590|Stage IIIB
624306|NCT00226590|thoracic radiation
624307|NCT00226577|Non-Small-Cell Lung Cancer
624308|NCT00226577|resectable
624309|NCT00226577|NSCLC
624310|NCT00225823|Seasonal Allergic Rhinitis Intranasal Corticosteroid
624311|NCT00225797|chronic pain
624312|NCT00225797|lower back
624313|NCT00225797|opioid
624314|NCT00225797|efficacy
624315|NCT00225797|safety
624316|NCT00225784|Stage I, II, III pancreatic adenocarcinoma
624317|NCT00225784|Radiographically measurable disease
624318|NCT00225758|breast cancer
624319|NCT00225758|endocrine therapy
624320|NCT00225758|drug resistance
624321|NCT00225758|lapatinib
624322|NCT00225758|epidermal growth factor receptor
624323|NCT00225745|Ghrelin
624324|NCT00225693|coronary artery
624325|NCT00225693|restenosis
624326|NCT00225693|patency
624327|NCT00225693|drug eluting
624328|NCT00225693|stent
624329|NCT00226525|Restenosis, skin metal allergy
624330|NCT00226473|malignant Melanoma
624331|NCT00226473|Chemotherapy
624332|NCT00226473|Metastasis
624333|NCT00226473|standard palliative care
624334|NCT00226473|best supportive care
624335|NCT00226447|Chronic Hepatitis B
624336|NCT00226447|Pegylated Interferon
624337|NCT00226447|Lamivudine
624338|NCT00226434|HIV infection
624339|NCT00226434|Tuberculosis
624340|NCT00226434|Paradoxical reaction
624341|NCT00226434|Treatment Naive
624342|NCT00226421|opioid
624343|NCT00226421|oxymorphone
624344|NCT00226421|chronic pain
624345|NCT00226421|randomized, double-blind trial
624346|NCT00226421|low back pain
624347|NCT00226408|melanoma,adjuvant therapy,stageIII Interferon
624348|NCT00226408|high dose
624349|NCT00226395|oxymorphone
624350|NCT00226395|acute pain
624351|NCT00226395|abdominal surgery
624352|NCT00226395|opioids
624353|NCT00226382|Chronic Hepatitis B
624354|NCT00226382|Pegylated Interferon-alfa-2a
624355|NCT00226382|Pegasys
624356|NCT00226369|Pediatric
624357|NCT00226369|Cardiopulmonary bypass
624358|NCT00226369|Congenital heart disease
624359|NCT00226369|Reperfusion injury
624360|NCT00226330|Patients diagnosed with type 2 diabetes who have participated in and completed the randomized, double-blind, parallel-group, multi-center study GALLANT 6.
624361|NCT00226304|Focal Brain Lesions
624362|NCT00226304|AIDS
624363|NCT00226304|Lymphoma
624364|NCT00226304|EBV
624365|NCT00226304|FDG-PET
624366|NCT00226304|HIV Infection
624367|NCT00226304|Brain Lesion
624368|NCT00226291|EBM
624369|NCT00226291|evidence based medicine
624370|NCT00226291|informationist
624371|NCT00226291|clinical medical librarian
624372|NCT00226265|Cardiac surgery patients
624373|NCT00226265|Quality of Life
624374|NCT00226265|Recall bias
624375|NCT00226265|Aortic valve replacement
624376|NCT00226265|Mitral valve replacement
624377|NCT00226265|Tricuspid valve replacement
624378|NCT00226265|Coronary artery bypass graft surgery
624379|NCT00226252|Wheelchair
624380|NCT00226252|Propulsion
624381|NCT00226252|Biomechanics
624382|NCT00226239|head
624383|NCT00226239|neck
624384|NCT00226200|Allergic
624385|NCT00226200|Non allergic
624386|NCT00226187|Fatty acids
624387|NCT00226187|Human milk
624388|NCT00226187|Infant development
624389|NCT00226187|Very low birthweight infants
624390|NCT00226174|Curcuminoids
624391|NCT00226174|Oral Lichen Planus
624392|NCT00226148|Implant
624393|NCT00226148|Immediate placement
624394|NCT00226148|Molar tooth
624395|NCT00226135|Bipolar disorder
624396|NCT00226135|Treatment
624397|NCT00226135|Long-term
624398|NCT00226135|Lithium
624399|NCT00226135|Lamotrigine
624400|NCT00226135|Randomised Clinical Trial
624401|NCT00226122|Enuresis
624402|NCT00226122|Nocturnal
624403|NCT00226122|Monosymptomatic
624404|NCT00226122|DDAVP
624405|NCT00226122|Indomethacin
624406|NCT00226122|Randomized
624407|NCT00226109|Alcoholism
624408|NCT00226109|cardiomyopathy
624409|NCT00226109|skeletal muscle
624410|NCT00226109|spironolactone
624411|NCT00226109|Na,K-pumps
624412|NCT00226109|Magnesium
624413|NCT00226096|Clinical Trial
624414|NCT00226096|Blood Pressure
624415|NCT00226096|CVA (Cerebrovascular Accident)
624416|NCT00226070|selfrated health,
624417|NCT00226070|SF-36,
624418|NCT00226070|rehabilitation,
624419|NCT00226070|total hip replacement,
624420|NCT00226070|patients above 65
624421|NCT00226057|Atopic dermatitis
624422|NCT00226057|Raptiva
624423|NCT00226044|Omeprazole, suppository, infants
624424|NCT00226031|Osteoporosis
624425|NCT00226031|Wrist fractures
624426|NCT00226031|Knowledge translation
624427|NCT00226031|Implementation
624428|NCT00226031|Educational reminder
624429|NCT00226005|pancreas
624430|NCT00226005|adenocarcinoma
624431|NCT00226005|cancer
624432|NCT00226005|metastatic
624433|NCT00226005|advanced cancer
624434|NCT00226005|Phase II
624435|NCT00226005|growth factor
624436|NCT00226005|VEGF
624437|NCT00226005|angiogenesis
624438|NCT00225979|Acromegaly
624439|NCT00225979|Untreated
624440|NCT00225979|Newly diagnosed
624441|NCT00225979|Octreotide LAR
624442|NCT00225979|Pituitary surgery
624443|NCT00225966|Urinary urgency-frequency
624444|NCT00225927|invasive breast cancer
624445|NCT00225927|in situ breast cancer
624446|NCT00225927|radioguided seed localization
624447|NCT00225927|nonpalpable tumour
624448|NCT00225927|needle localization
624449|NCT00225927|margin status
624450|NCT00225914|Menopause
624451|NCT00225914|Hormone Therapy
624452|NCT00225914|Paxil
624453|NCT00225914|Hot Flash
624454|NCT00225914|Sleep Disturbance
624455|NCT00225914|Night Sweats
624456|NCT00225914|Antidepressants
624457|NCT00225888|Diabetes
624458|NCT00225888|Nutrition
624459|NCT00225888|Digital photography
624460|NCT00225888|Self-management
624461|NCT00225875|Autoimmune thrombocytopenic purpura
624462|NCT00225875|Rituximab
624463|NCT00225862|RLS
624464|NCT00225862|Restless Legs Syndrome
624465|NCT00225849|Aspirin
624466|NCT00225849|Primary prevention
624467|NCT00225836|Dysmenorrhoea
624468|NCT00225836|Women
624469|NCT00225836|Pain
624470|NCT00225836|TENS
624471|NCT00225680|coronary artery
624472|NCT00225680|stent
624473|NCT00225680|drug eluting
624474|NCT00225680|patency
624475|NCT00225680|restenosis
624476|NCT00225667|Atrial Fibrillation
624477|NCT00225667|Arrhythmia
624478|NCT00225667|Pacemaker, Artificial
624479|NCT00225667|Atrial High Rate Episodes
624480|NCT00225667|Electrophysiology
624481|NCT00225667|Renin-Angiotensin System
624482|NCT00225667|Hypertension
624483|NCT00225667|Cardiac Remodeling
624484|NCT00225654|coronary artery
624485|NCT00225654|stent
624486|NCT00225654|drug eluting
624487|NCT00225654|patency
624488|NCT00225654|restenosis
624489|NCT00225641|Follow-up
624490|NCT00225628|Computerized clinical decision support
624491|NCT00225628|Patient Safety
624492|NCT00225628|Quality of Care
624493|NCT00225628|Electronic Medical Records
624494|NCT00225628|Chronic Disease Management
624495|NCT00225628|Drug Monitoring
624496|NCT00225628|Guideline Adherence
624497|NCT00225628|Reminder Systems
624498|NCT00225615|Phenylalanine Hydroxylase
624499|NCT00225602|Schizophrenia
624500|NCT00225602|Assertive community treatment
624501|NCT00225589|Hypercholesteremia
624502|NCT00225576|medication errors
624503|NCT00225576|adverse drug events
624504|NCT00225576|electronic health records
624505|NCT00225563|Electronic medical records
624506|NCT00225563|Electronic prescribing
624507|NCT00225563|Quality measures
624508|NCT00225550|Cancer;
624509|NCT00225550|Tumors;
624510|NCT00225550|Neoplasms;
624511|NCT00225550|Anticarcinogenic Agents;
624512|NCT00225550|Antineoplastic Agents;
624513|NCT00225550|Cadherins
624514|NCT00225537|hcv
624515|NCT00225537|hbv
624516|NCT00225537|methylumbelliferone
624517|NCT00225537|liver
624518|NCT00225537|hepatitis
624519|NCT00225537|viral
624520|NCT00225537|heparvit
624521|NCT00225537|hiv
624522|NCT00225537|aids
624523|NCT00225524|Depression
624524|NCT00225511|Depression
624525|NCT00225485|Depression
624526|NCT00225459|Religious psychology
624527|NCT00225459|Anxiety disorder
624528|NCT00225459|Mood disorder
624529|NCT00225459|Suicide
624530|NCT00225446|Orthognathic surgery.
624531|NCT00225446|optic repositioning system.
624532|NCT00225433|infertility
624533|NCT00225433|in vitro fertilization
624534|NCT00225420|adenocarcinoma of the prostate
624535|NCT00225420|stage I prostate cancer
624536|NCT00225420|stage II prostate cancer
624537|NCT00225420|stage III prostate cancer
624538|NCT00225420|stage IV prostate cancer
624539|NCT00225407|Cannabis
624540|NCT00225407|Tetrahydrocannabinol
624541|NCT00225407|Pharmacokinetics
624542|NCT00225407|Psychomotor tests
624543|NCT00225407|Event related potentials
624544|NCT00225394|CMV
624545|NCT00225394|Kidney Transplant
624546|NCT00225394|Pancreas Transplant
624547|NCT00225394|Ganciclovir-resistance
624548|NCT00225394|Valganciclovir
624549|NCT00225394|CMV Disease
624550|NCT00225381|Oxygen consumption
624551|NCT00225381|CO2 production
624552|NCT00225381|Indirect calorimetry
624553|NCT00225381|Non steady state
624554|NCT00225381|Anesthesia monitoring
624555|NCT00225381|Critical events during anesthesia
624556|NCT00225381|Acid base balance
624557|NCT00225381|Metabolism during anesthesia
624558|NCT00225368|Malaria
624559|NCT00225368|All-cause mortality
624560|NCT00225368|Africa
624561|NCT00225368|Burkina Faso
624562|NCT00225355|Angina pectoris
624563|NCT00225355|Metabolic syndrome
624564|NCT00225355|Ischaemic heart disease
624565|NCT00225342|Angina
624566|NCT00225342|Ischaemic heart disease
624567|NCT00225342|Diabetes
624568|NCT00225329|RCT
624569|NCT00225329|intervention study
624570|NCT00225329|labour management
624571|NCT00225329|assessment
624572|NCT00225316|RCT
624573|NCT00225316|intervention study
624574|NCT00225316|addiction
624575|NCT00225316|substance use
624576|NCT00225316|pregnancy
624577|NCT00225303|HIV infection
624578|NCT00225303|TMC125
624579|NCT00225303|Non-Nucleoside reverse transcriptase inhibitor
624580|NCT00225303|Protease inhibitor
624581|NCT00225303|TMC125-C227
624582|NCT00225290|Phase III
624583|NCT00225290|Hepatocellular Carcinoma
624584|NCT00225277|Glucose Metabolism Disorder
624585|NCT00225277|Dysmetabolic Syndrome
624586|NCT00225277|Type II Diabetes
624587|NCT00225277|Diabetes Mellitus, Lipoatrophic
624588|NCT00225277|Dyslipidemia
624589|NCT00225277|Drug Therapy
624590|NCT00225277|Atherosclerosis
624591|NCT00225264|Glucose Metabolism Disorder
624592|NCT00225264|Dysmetabolic Syndrome
624593|NCT00225264|Type II Diabetes
624594|NCT00225264|Diabetes Mellitus, Lipoatrophic
624595|NCT00225264|Dyslipidemia
624596|NCT00225264|Drug Therapy
624597|NCT00225251|Dysthymic Disorder
624598|NCT00225251|Dysthymia
624599|NCT00225251|Depression
624600|NCT00225251|Chronic Depression
624601|NCT00225251|Wellbutrin XL
624602|NCT00225238|colonoscopy prep
624603|NCT00225212|non-Hodgkin's lymphoma
624604|NCT00225212|diffuse large cell lymphoma
624605|NCT00225212|mantle cell lymphoma
624606|NCT00225212|transformed lymphoma
624607|NCT00225212|other subtypes of B cell lymphoma
624608|NCT00225212|recurrent lymphoma
624609|NCT00225173|nodular sclerosis
624610|NCT00225173|lymphocyte rich
624611|NCT00225173|lymphocyte depleted
624612|NCT00225173|mixed cellularity
624613|NCT00225160|HIV
624614|NCT00225160|poly neuropathy
624615|NCT00225160|acetyl L-carnitine
624616|NCT00225160|treatment naïve
624617|NCT00225160|combination antiretroviral therapy
624618|NCT00225160|Lipid abnormalities
624619|NCT00225108|Deep vein thrombosis
624620|NCT00225108|bleeding
624621|NCT00225095|meniscectomy
624622|NCT00225095|Chondrogen
624623|NCT00225095|Mesenchymal Stem Cells
624624|NCT00225095|Osiris
624625|NCT00225082|Lipoatrophy
624626|NCT00225082|Mitochondrial function
624627|NCT00225082|Nucleoside analogue switch
624628|NCT00225082|Treatment Experienced
624629|NCT00225069|Facial blushing
624630|NCT00225069|Sympathectomy
624631|NCT00225017|Atazanavir
624632|NCT00225017|Endothelial function
624633|NCT00225017|Treatment Experienced
624634|NCT00225004|Colles Fracture
624635|NCT00225004|Osteoporosis
624636|NCT00225004|BMD
624637|NCT00225004|Quality assurance
624638|NCT00224991|osteoporosis
624639|NCT00224991|fall frequency
624640|NCT00224991|medical treatment
624641|NCT00224991|compliance
624642|NCT00224991|quality of life
624643|NCT00224991|systematic education
624644|NCT00224965|nicotine dependence
624645|NCT00224952|seizures
624646|NCT00224952|Epilepsy
624647|NCT00224926|Tinea Capitis
624648|NCT00224913|osteoarthritis
624649|NCT00224913|quadriceps
624650|NCT00224913|inhibition
624651|NCT00224913|functional outcome
624652|NCT00224913|electrical stimulation
624653|NCT00224900|Perinatally-acquired HIV infection
624654|NCT00224900|Life Skills
624655|NCT00224900|Focus Group
624656|NCT00224900|Young adolescents
624657|NCT00224900|Caregivers
624658|NCT00224874|Acute Graft vs Host Disease
624659|NCT00224874|GVHD
624660|NCT00224822|Psychiatry
624661|NCT00224822|Antipsychotic
624662|NCT00224822|Psychopharmacology
624663|NCT00224822|Clinical Trial
624664|NCT00224822|Open Label
624665|NCT00224822|Schizophrenia
624666|NCT00224822|Schizoaffective Disorder
624667|NCT00224822|Bipolar Disorder
624668|NCT00224822|Metabolic Syndrome
624669|NCT00224796|Wound closure
624670|NCT00224796|Foot salvage
624671|NCT00224796|Accelerated healing
624672|NCT00224796|Amputation Wounds of the Diabetic Foot
624673|NCT00224757|Echocardiography
624674|NCT00224744|Vulvar Neoplasms
624675|NCT00224744|Skin Neoplasms
624676|NCT00224744|Ultracision
624677|NCT00224744|Lymphadenectomy
624678|NCT00224731|Attention disorder with hyperactivity
624679|NCT00224731|sleep
624680|NCT00224731|stimulants
624681|NCT00224731|actigraphy
624682|NCT00224718|Abdominal aortic aneurysm
624683|NCT00224718|Endograft
624684|NCT00224718|Open repair
624685|NCT00224718|Endovascular repair
624686|NCT00224718|AAA
624687|NCT00224705|Albumin dialysis
624688|NCT00224705|MARS system
624689|NCT00224705|Extracorporeal artificial liver support
624690|NCT00224705|Fulminant hepatitis
624691|NCT00224705|Subfulminant hepatitis
624692|NCT00224705|Acute liver failure
624693|NCT00224692|Mucositis
624694|NCT00224692|Pain
624695|NCT00224692|Morphine
624696|NCT00224692|Ketamine
624697|NCT00224679|Colon cancer
624698|NCT00224679|Aspirin
624699|NCT00224679|Adenomas
624700|NCT00224679|Prevention
624701|NCT00224666|Cortex stimulation ,Rebel neuropathic pains
624702|NCT00224653|Obesity.
624703|NCT00224653|Respiration. Respiration, artificial.
624704|NCT00224653|Ventilation. Pressure controlled. Volume controlled.
624705|NCT00224640|Iron-chelating treatment
624706|NCT00224627|Randomized study
624707|NCT00224627|Capsule endoscopy
624708|NCT00224627|Push enteroscopy
624709|NCT00224627|Occult gastrointestinal bleeding
624710|NCT00224627|Endoscopy
624711|NCT00224614|stem cell transplantation
624712|NCT00224614|reduced-intensity conditioning regimen
624713|NCT00224614|acute myeloid leukemia
624714|NCT00224601|Colorectal cancer
624715|NCT00224601|HNPCC
624716|NCT00224601|Diagnosis
624717|NCT00224601|Coloscopy
624718|NCT00224601|Chromoscopy
624719|NCT00224601|Indigo carmine
624720|NCT00224601|Colorectal Neoplasms
624721|NCT00224601|Hereditary Nonpolyposis
624722|NCT00224588|Ketamine
624723|NCT00224588|Chronic post thoracotomy pain
624724|NCT00224588|NMDA
624725|NCT00224588|Post operative
624726|NCT00224575|Veterans
624727|NCT00224562|TNF alpha antagonists
624728|NCT00224562|infections
624729|NCT00224562|lymphoma
624730|NCT00224562|safety
624731|NCT00224549|Resistant hypertension
624732|NCT00224549|Combined diuretic therapy
624733|NCT00224549|Combined RAS blockers
624734|NCT00224536|Myocardial infarction
624735|NCT00224536|Bone marrow cells
624736|NCT00224536|Intracoronary
624737|NCT00224523|perennial allergic rhinitis
624738|NCT00224523|nasal biopsy
624739|NCT00224523|GW685698X
624740|NCT00224510|bipolar disorder bipolar depression lamotrigine
624741|NCT00224497|Alzheimer's disease
624742|NCT00224497|cognition global functioning
624743|NCT00224497|symptomatic
624744|NCT00224497|B-742457
624745|NCT00224484|Herpes Simplex vaccine
624746|NCT00224484|Safety
624747|NCT00224484|Adolescents
624748|NCT00224484|Immunogenicity
624749|NCT00224471|Adolescents
624750|NCT00224471|Immunogenicity
624751|NCT00224471|Safety
624752|NCT00224471|Herpes Simplex vaccine
624753|NCT00224458|Treatment Experienced
624754|NCT00224458|HIV-1
624755|NCT00224445|Treatment Naive
624756|NCT00224445|HIV-1
624757|NCT00224432|Atopic Dermatitis
624758|NCT00224432|SCORAD
624759|NCT00224432|probiotics
624760|NCT00224432|cytokines
624761|NCT00224432|Infant
624762|NCT00224419|Smoking cessation
624763|NCT00224419|Pregnancy
624764|NCT00224419|Nicotine replacement therapy
624765|NCT00224419|Motivational interviewing
624766|NCT00224406|Lung transplantation
624767|NCT00224406|Reperfusion Injury
624768|NCT00224406|Survival
624769|NCT00224393|Amyloidosis
624770|NCT00224393|Enbrel
624771|NCT00224380|Serious mental illness
624772|NCT00224380|medication adherence
624773|NCT00224367|fracture
624774|NCT00224367|hip
624775|NCT00224367|ambulation
624776|NCT00224354|LYMPHOCYTIC
624777|NCT00224354|B-LEUKEMIA
624778|NCT00224354|B-CLL
624779|NCT00224341|Pacemaker
624780|NCT00224341|Atrial Fibrillation
624781|NCT00224341|Prevention pacing
624782|NCT00224341|Algorithms
624783|NCT00224341|Sick sinus syndrome + Atrial Fibrillation
624784|NCT00224328|Tissue Oxygen Saturation
624785|NCT00224328|Peripheral Arterial Disease
624786|NCT00224328|Critical Limb Ischemia
624787|NCT00224328|Near-infrared Spectroscopy
624788|NCT00224315|Schizophrenia,
624789|NCT00224315|schizoaffective disorder,
624790|NCT00224315|treatment resistancy
624791|NCT00224315|clozapine,
624792|NCT00224315|ziprasidone
624793|NCT00224315|risperidone
624794|NCT00224315|combination
624795|NCT00224302|Schizophrenia,
624796|NCT00224302|schizoaffective disorder,
624797|NCT00224302|major depressive episode,
624798|NCT00224302|combination,
624799|NCT00224302|duloxetine
624800|NCT00224289|Latanoprost
624801|NCT00224289|Glaucoma
624802|NCT00224289|Intraocular pressure
624803|NCT00224263|Traditional Chinese Medicine
624804|NCT00224263|Lingzhi
624805|NCT00224237|Latino patients
624806|NCT00224237|Health practices
624807|NCT00224237|Culture influences
624808|NCT00224224|Clinical performance
624809|NCT00224224|Continuity of care
624810|NCT00224224|Utilization of resources
624811|NCT00224185|Healthy individuals
624812|NCT00224185|smokers
624813|NCT00224185|ex-smokers
624814|NCT00224185|non-smokers
624815|NCT00224172|Pre-hospitalization characteristics
624816|NCT00224172|Post-hospitalization characteristics
624817|NCT00224172|Psychosocial measures
624818|NCT00224172|Predict re-hospitalization
624819|NCT00224159|Statin therapy
624820|NCT00224159|Dietary behavior
624821|NCT00224159|Attitudes and beliefs
624822|NCT00224159|Self efficacy
624823|NCT00224146|Oxytrol(r)
624824|NCT00224146|transdermal oxybutynin
624825|NCT00224146|overactive bladder
624826|NCT00224133|benign prostatic hyperplasia, alpha blocker
624827|NCT00224120|Benign prostatic hyperplasia, alpha blocker
624828|NCT00224107|Benign prostatic hyperplasia, BPH, alpha blocker
624829|NCT00224094|Menopause
624830|NCT00224094|Testosterone
624831|NCT00224094|Androgens
624832|NCT00224094|Sex Hormone Binding Globulin
624833|NCT00224094|Thyroid function
624834|NCT00224094|Cortisol
624835|NCT00224081|iron deficiency anemia
624836|NCT00224081|ferritin
624837|NCT00224081|hemodialysis
624838|NCT00224081|sodium ferric gluconate
624839|NCT00224081|epoetin alfa
624840|NCT00224068|Iron deficiency
624841|NCT00224068|Sodium ferric gluconate
624842|NCT00224068|anemia
624843|NCT00224068|cancer chemotherapy
624844|NCT00224068|epoetin alfa
624845|NCT00224068|Anemia/drug therapy
624846|NCT00224068|Anemia, Iron-Deficiency/drug therapy/etiology
624847|NCT00224068|Hematinics/administration & dosage/pharmacology
624848|NCT00224068|Antineoplastic Agents/adverse effects
624849|NCT00224068|Erythropoietin, Recombinant/therapeutic use/adverse effects
624850|NCT00224055|Iron deficiency
624851|NCT00224055|Anemia
624852|NCT00224055|Chronic kidney disease
624853|NCT00224055|Sodium Ferric Gluconate
624854|NCT00224055|Anemia, Iron-Deficiency/drug therapy/etiology
624855|NCT00224055|Kidney Failure, Chronic/blood/complications/therapy
624856|NCT00224042|Iron deficiency
624857|NCT00224042|Anemia
624858|NCT00224042|Chronic kidney disease
624859|NCT00224042|Erythropoietic agents
624860|NCT00224042|Sodium Ferric Gluconate
624861|NCT00224042|Anemia, Iron-Deficiency/drug therapy/etiology
624862|NCT00224042|Kidney Failure, Chronic/blood/complications/therapy
624863|NCT00224042|Erythropoietin, Recombinant/adverse effects/therapeutic use
624864|NCT00224003|Anemia
624865|NCT00223990|Plasmodium
624866|NCT00223990|falciparum
624867|NCT00223990|malaria
624868|NCT00223990|vaccine
624869|NCT00223990|AS02A adjuvant
624870|NCT00223990|FMP1
624871|NCT00223990|Merozoite surface protein-1
624872|NCT00223977|Anemia.
624873|NCT00223964|Iron Deficiency
624874|NCT00223964|Anemia in Pediatric Hemodialysis
624875|NCT00223951|Healthy volunteers, safety, ocular, allergic conjunctivitis, ophthalmic
624876|NCT00223925|Stem cell transplantation
624877|NCT00223925|Allogeneic transplantation
624878|NCT00223912|Cardiovascular Disease
624879|NCT00223912|Exercise
624880|NCT00223912|Functional electrical stimulation
624881|NCT00223912|hemostasis
624882|NCT00223912|Spinal cord injury
624883|NCT00223899|Melanoma
624884|NCT00223899|Electroporation
624885|NCT00223899|IL-2
624886|NCT00223873|Penile Vibratory Stimulation
624887|NCT00223873|Muscles Spasticity
624888|NCT00223873|Spasms
624889|NCT00223873|Ferti Care Vibrator
624890|NCT00223873|Antispasmotic treatment
624891|NCT00223860|Hypogonadal
624892|NCT00223860|Hypothalamus
624893|NCT00223860|Pituitary
624894|NCT00223860|Spinal Cord Injury
624895|NCT00223860|Testes
624896|NCT00223860|Testosterone
624897|NCT00223847|Aphasia rehabilitation
624898|NCT00223847|Aphasia therapy
624899|NCT00223847|Constraint therapy
624900|NCT00223847|Language therapy
624901|NCT00223834|Counseling
624902|NCT00223834|Motivation
624903|NCT00223834|Psychotherapy, brief
624904|NCT00223821|Behavior Therapy
624905|NCT00223821|Behavioral Medicine
624906|NCT00223821|Behavioral Research
624907|NCT00223821|Behavioral Sciences
624908|NCT00223821|Combined Modality Therapy
624909|NCT00223821|Drug Therapy
624910|NCT00223821|Overactive bladder
624911|NCT00223821|Treatment Outcome
624912|NCT00223821|Urge incontinence
624913|NCT00223821|Urinary incontinence
624914|NCT00223808|Rehabilitation
624915|NCT00223808|Robotics
624916|NCT00223795|Cane
624917|NCT00223795|Gait
624918|NCT00223795|Obesity
624919|NCT00223795|Osteoarthritis
624920|NCT00223795|Walking Aids
624921|NCT00223782|Diabetes
624922|NCT00223782|Peripheral Neuropathy
624923|NCT00223782|Walking
624924|NCT00223769|oxandrolone
624925|NCT00223769|oxandrin
624926|NCT00223769|lean body mass
624927|NCT00223769|functional recovery
624928|NCT00223769|resistance training
624929|NCT00223756|Vision, Low
624930|NCT00223743|essential tremor
624931|NCT00223743|zonisamide
624932|NCT00223743|clinical trial
624933|NCT00223730|Peripheral Blood Stem Cell Transplant
624934|NCT00223730|Bone Marrow Transplant
624935|NCT00223730|Citrulline
624936|NCT00223730|Urea Cycle
624937|NCT00223730|Hepatic Injury
624938|NCT00223730|Allogeneic PBSCT
624939|NCT00223730|Matched-Unrelated PBSCT
624940|NCT00223717|Supine Hypertension
624941|NCT00223717|Hypertension
624942|NCT00223717|Treatment
624943|NCT00223717|Autonomic failure
624944|NCT00223717|Pure autonomic failure
624945|NCT00223717|Multiple System Atrophy
624946|NCT00223717|Shy-Drager Syndrome
624947|NCT00223704|Coronary Artery Bypass
624948|NCT00223704|Blood Transfusion
624949|NCT00223704|Bradykinin Receptor Antagonism
624950|NCT00223704|Anti-Inflammatory Agents
624951|NCT00223704|Antifibrinolytic Agents
624952|NCT00223691|orthostatic hypotension
624953|NCT00223691|autonomic failure
624954|NCT00223665|Intermittent Hormone Therapy
624955|NCT00223652|Cognitive-Behavioral Therapy
624956|NCT00223652|Telephone psychotherapy
624957|NCT00223652|Clinical Trial
624958|NCT00223652|Primary Care Clinic
624959|NCT00223652|Treatment for Depression
624960|NCT00223639|alcoholism /alcohol abuse
624961|NCT00223639|alcoholism antagonist
624962|NCT00223639|anticonvulsant
624963|NCT00223639|cognition
624964|NCT00223639|neuropharmacology
624965|NCT00223639|substance abuse related behavior
624966|NCT00223639|craving
624967|NCT00223639|euphoria
624968|NCT00223639|relapse /recurrence
624969|NCT00223639|patient oriented research
624970|NCT00223626|Cocaine Addiction
624971|NCT00223626|Cocaine Dependence
624972|NCT00223613|diabetes
624973|NCT00223613|juvenile diabetes
624974|NCT00223613|insulin deficiency
624975|NCT00223600|lipids
624976|NCT00223600|lipoproproteins
624977|NCT00223600|growth
624978|NCT00223600|neurological development
624979|NCT00223600|vascular wall
624980|NCT00223600|blood pressure
624981|NCT00223600|nutrient intake
624982|NCT00223587|driving
624983|NCT00223587|memory
624984|NCT00223561|adult
624985|NCT00223548|prophylaxis
624986|NCT00223548|contrast-induced nephropathy
624987|NCT00223548|mesna
624988|NCT00223548|acute renal failure
624989|NCT00223535|Schizophrenia
624990|NCT00223535|Cognitive Remediation
624991|NCT00223535|Social Skills Training
624992|NCT00223535|Psychosocial
624993|NCT00223522|Schizophrenia
624994|NCT00223522|Schizoaffective
624995|NCT00223522|MEMS
624996|NCT00223522|adherence to antipsychotic medication
624997|NCT00223509|mixed mania
624998|NCT00223509|lamotrigine
624999|NCT00223496|Bipolar Depression
625000|NCT00223496|Refractory
625001|NCT00223483|Hematologic Diseases
625002|NCT00223483|Genomics
625003|NCT00223483|Cytokines
625004|NCT00223483|Chemokines
625005|NCT00223483|Receptors
625006|NCT00223470|pain
625007|NCT00223457|multiple sclerosis
625008|NCT00223457|compliance
625009|NCT00223457|adherence
625010|NCT00223457|disease modifying therapy
625011|NCT00223457|depression
625012|NCT00223457|hope
625013|NCT00223457|quality of life
625014|NCT00223444|alcohol
625015|NCT00223444|GABA
625016|NCT00223444|genetic variation
625017|NCT00223418|aripiprazole
625018|NCT00223418|olanzapine
625019|NCT00223418|vocational
625020|NCT00223418|learning
625021|NCT00223418|cognition
625022|NCT00223418|cognitive
625023|NCT00223405|enamel wear against ceramic crowns
625024|NCT00223379|Apical Periodontitis, Root Canal Therapy, Apical Preparation
625025|NCT00223366|Pain in teeth
625026|NCT00223353|Biomechanics
625027|NCT00223353|Gait
625028|NCT00223353|Balance
625029|NCT00223340|patient activation
625030|NCT00223340|primary care
625031|NCT00223340|diabetes
625032|NCT00223340|cardiovascular risk
625033|NCT00223327|pain
625034|NCT00223327|Normal pulp and normal periodontal status
625035|NCT00223327|Chronic apical periodontitis of pulpal origin
625036|NCT00223314|HIV
625037|NCT00223314|Sexually Transmitted Diseases
625038|NCT00223314|Pregnancy
625039|NCT00223314|HIV Seronegativity
625040|NCT00223275|Bipolar Disorder
625041|NCT00223275|Alcohol Dependence
625042|NCT00223275|Dual Diagnosis
625043|NCT00223275|Naltrexone
625044|NCT00223210|bipolar disorder
625045|NCT00223210|cocaine dependence
625046|NCT00223210|quetiapine
625047|NCT00223197|Bipolar with depression
625048|NCT00223197|Recurrent major depressive disorder
625049|NCT00223197|substance abuse dependence
625050|NCT00223171|Stage T3 T4
625051|NCT00223171|PSA > 20
625052|NCT00223171|Gleason Score > 7
625053|NCT00223158|Thyroid cancer
625054|NCT00223158|Hypothyroidism
625055|NCT00223158|Whole Body Scintigraphy
625056|NCT00223158|Liothyronine
625057|NCT00223158|TSH elevation
625058|NCT00223145|Prostate adenocarcinoma
625059|NCT00223145|Gleason score <= 6 and PSA 10-20
625060|NCT00223145|Gleason score = 7 and PSA <=20
625061|NCT00223132|bariatric surgery
625062|NCT00223132|body contouring
625063|NCT00223132|skin laxity
625064|NCT00223132|plastic surgery
625065|NCT00223132|suture granuloma
625066|NCT00223132|absorbable sutures
625067|NCT00223119|perineal trauma
625068|NCT00223119|perineal laceration
625069|NCT00223119|persistent perineal pain
625070|NCT00223106|urge incontinence
625071|NCT00223106|urinary incontinence
625072|NCT00223106|vault prolapse
625073|NCT00223106|stess incontinence
625074|NCT00223106|mixed incontinence
625075|NCT00223106|urine leakage
625076|NCT00223106|enterocele
625077|NCT00223106|rectocele
625078|NCT00223106|cystocele
625079|NCT00223093|renal transplantation, TAIZ-moncytes
625080|NCT00223080|HIV Seronegativity
625081|NCT00223067|renal transplantation
625082|NCT00223067|TAIZ
625083|NCT00223054|cyclosporin A
625084|NCT00223054|Tacrolimus
625085|NCT00223054|Everolimus
625086|NCT00223054|Sirolimus
625087|NCT00223054|Fluvastatin
625088|NCT00223041|renal transplantation
625089|NCT00223041|cardiovasculary disease
625090|NCT00223041|statin
625091|NCT00223028|fluvastain
625092|NCT00223028|sirolimus
625093|NCT00223028|mycophenolat mofetil
625094|NCT00223028|renal transplantation
625095|NCT00223015|renal transplantation
625096|NCT00223015|pharmacokinetics
625097|NCT00223015|Fluvastatin
625098|NCT00223015|Mycophenolat mofetil
625099|NCT00223015|tacrolimus
625100|NCT00222989|GERD
625101|NCT00222989|PPI
625102|NCT00222989|Functional heartburn
625103|NCT00222963|Obesity
625104|NCT00222963|Obstructive Sleep Apnea Syndrome
625105|NCT00222963|Children
625106|NCT00222963|Adolescents
625107|NCT00222963|Adenotonsillectomy
625108|NCT00222950|plant sterols, serum, aortic valve cusps
625109|NCT00222937|Voice Problems
625110|NCT00222937|Voice Disorders
625111|NCT00222924|Mitochondria
625112|NCT00222911|plantar fasciitis
625113|NCT00222911|heel pain
625114|NCT00222911|heel spur
625115|NCT00222911|night splint
625116|NCT00222911|arch support
625117|NCT00222911|foot orthosis
625118|NCT00222911|physical therapy
625119|NCT00222898|Pancreatic Cyst
625120|NCT00222898|PANDA Study
625121|NCT00222885|PET imaging
625122|NCT00222885|Skeletal muscle
625123|NCT00222885|In vivo insulin-stimulated tissue perfusion
625124|NCT00222885|Glucose transport
625125|NCT00222885|Glucose phosphorylation
625126|NCT00222872|Endocrine System Diseases
625127|NCT00222872|MusculoSkeletal System Diseases
625128|NCT00222872|Hormone
625129|NCT00222872|Postmenopausal Women
625130|NCT00222859|HIV
625131|NCT00222859|HCV
625132|NCT00222846|Clinical trial
625133|NCT00222846|Behavioral research
625134|NCT00222846|Patient compliance
625135|NCT00222833|Schizophrenia
625136|NCT00222833|Schizoaffective disorder
625137|NCT00222833|Aripiprazole
625138|NCT00222833|Obese
625139|NCT00222833|Overweight
625140|NCT00222833|Heart Health
625141|NCT00222833|Antipsychotic
625142|NCT00222833|Heart Health Factors
625143|NCT00222833|Cardiovascular Health Indices
625144|NCT00222833|Cardiovascular health
625145|NCT00222807|schizophrenia, psychosis, type 2 diabetes mellitus
625146|NCT00222794|Schizophrenia
625147|NCT00222794|Schizo-Affective Disorder
625148|NCT00222794|Negative Symptoms
625149|NCT00222794|Atomoxetine
625150|NCT00222794|Strattera
625151|NCT00222781|Skeletal muscle
625152|NCT00222781|Triple-tracer PET imaging
625153|NCT00222768|Adipose tissue
625154|NCT00222768|PET imaging
625155|NCT00222755|Mood disorders-bipolar
625156|NCT00222755|Disease management
625157|NCT00222755|Quality of care
625158|NCT00222742|hypothermia
625159|NCT00222742|pediatric TBI
625160|NCT00222729|head
625161|NCT00222729|neck
625162|NCT00222716|Treatment adherence
625163|NCT00222716|HIV
625164|NCT00222716|Self-efficacy
625165|NCT00222716|Treatment Experienced
625166|NCT00222703|nicotine addiction
625167|NCT00222703|relapse
625168|NCT00222703|smoking
625169|NCT00222703|chronic disorders
625170|NCT00222703|randomized controlled trial
625171|NCT00222703|intervention
625172|NCT00222690|qualitative interview
625173|NCT00222690|symptom triggers
625174|NCT00222690|activity and participation
625175|NCT00222677|venous thromboembolism
625176|NCT00222677|deep vein thrombosis
625177|NCT00222677|pulmonary embolism
625178|NCT00222677|antithrombotic agents
625179|NCT00222664|hepatitis B
625180|NCT00222664|hepatocellular carcinoma
625181|NCT00222664|prevention
625182|NCT00222664|vaccination
625183|NCT00222651|pulmonary embolism
625184|NCT00222651|right ventricular dysfunction
625185|NCT00222651|thrombolysis
625186|NCT00222651|echocardiography
625187|NCT00222638|Oral anticoagulants
625188|NCT00222638|Influenza virus
625189|NCT00222638|Influenza vaccine
625190|NCT00222638|Pharmacological interference
625191|NCT00222625|Intracerebral Hemorrhage
625192|NCT00222625|Oral Anticoagulants
625193|NCT00222625|Antiplatelet Agents
625194|NCT00222625|Recombinant Activated Factor VII
625195|NCT00222573|clopidogrel
625196|NCT00222573|metoprolol
625197|NCT00222573|myocardial infarction
625198|NCT00222573|randomised trial
625199|NCT00222560|physical activity counselling
625200|NCT00222560|physical activity behavior change intervention
625201|NCT00222560|prevention
625202|NCT00222560|collaborative health care
625203|NCT00222560|physical inactivity
625204|NCT00222560|motivation
625205|NCT00222560|fitness
625206|NCT00222560|randomized controlled trial
625207|NCT00222534|Respiratory Insufficiency
625208|NCT00222534|Alkalosis
625209|NCT00222521|Cystic Fibrosis
625210|NCT00222521|Diabetes
625211|NCT00222508|Cystic Fibrosis
625212|NCT00222508|Diabetes
625213|NCT00222508|Complications
625214|NCT00222495|Psychotic Disorders in adolescents
625215|NCT00222495|Schizophrenia in adolescents
625216|NCT00222495|Schizophreniform Disorders in adolescents
625217|NCT00222495|Schizoaffective Disorders in adolescents
625218|NCT00222482|Borderline Personality Disorder
625219|NCT00222469|pancreatic cancer
625220|NCT00222469|unresectable pancreatic cancer
625221|NCT00222469|metastatic pancreatic cancer
625222|NCT00222469|bevacizumab
625223|NCT00222469|oxaliplatin
625224|NCT00222469|gemcitabine
625225|NCT00222469|1st line treatment
625226|NCT00222469|first line treatment
625227|NCT00222469|locally advanced (unresectable) pancreatic cancer
625228|NCT00222456|preterm infants
625229|NCT00222456|early intervention
625230|NCT00222456|outcome
625231|NCT00222456|behavioral problems
625232|NCT00222456|parenting stress
625233|NCT00222443|Recurrent solid tumors
625234|NCT00222443|recurrent lymphomas
625235|NCT00222443|Pediatrics
625236|NCT00222443|Adolescents
625237|NCT00222430|Fluoroscopy
625238|NCT00222430|Femoral Artery
625239|NCT00222430|Arterial Vascular Access
625240|NCT00222404|Carcinoma, Non-Small-Cell Lung
625241|NCT00222404|Pharmacogenomic
625242|NCT00222378|Crohn's disease
625243|NCT00222378|ulcerative colitis
625244|NCT00222378|cytomegalovirus
625245|NCT00222378|Epstein Bar Virus
625246|NCT00222378|Human Herpes virus 6
625247|NCT00222365|homeopathy
625248|NCT00222365|assessment
625249|NCT00222365|pain
625250|NCT00222365|ligamentoplasty
625251|NCT00222352|Unstable Angina
625252|NCT00222352|Non-ST-segment Myocardial Infarction
625253|NCT00222352|Myocardial Necrosis
625254|NCT00222352|Troponin I
625255|NCT00222339|Stroke
625256|NCT00222339|Hand function
625257|NCT00222339|Task-specific training
625258|NCT00222326|Hysterectomy,
625259|NCT00222326|Prolapse,
625260|NCT00222326|Pelvic floor muscles,
625261|NCT00222326|Bladder,
625262|NCT00222326|Bowel.
625263|NCT00222300|Total hip replacement
625264|NCT00222300|Strength training
625265|NCT00222300|Gait analysis
625266|NCT00222287|Feldenkrais Method
625267|NCT00222287|movement class
625268|NCT00222287|balance
625269|NCT00222287|Four square step test
625270|NCT00222287|Activities Specific Balance Confidence Scale
625271|NCT00222287|systems theory
625272|NCT00222274|fibromyalgia
625273|NCT00222274|pain
625274|NCT00222274|biofeedback
625275|NCT00222274|heart rate variability
625276|NCT00222261|antiplatelet therapy
625277|NCT00222261|aspirin non-responders
625278|NCT00222261|aspirin resistance
625279|NCT00222261|clopidogrel
625280|NCT00222261|coronary heart disease
625281|NCT00222261|stable angina pectoris
625282|NCT00222248|Stress urinary incontinence
625283|NCT00222248|Pelvic floor muscle training
625284|NCT00222248|Bladder training
625285|NCT00222248|Older women
625286|NCT00222235|schizophrenia
625287|NCT00222235|schizoaffective disorder
625288|NCT00222235|negative symptoms
625289|NCT00222235|cognitive impairments
625290|NCT00222222|severe sepsis
625291|NCT00222222|prognostic markers
625292|NCT00222222|polymorphisms
625293|NCT00222222|SIRS
625294|NCT00222209|Experimental study
625295|NCT00222209|chronic pain
625296|NCT00222209|operant learning
625297|NCT00222209|comorbidity
625298|NCT00222209|stress
625299|NCT00222209|Fibromyalgia w visceral hypersensitivity
625300|NCT00222209|Fibromyalgia w/o visceral hypersensitivity
625301|NCT00222196|atherosclerosis
625302|NCT00222196|quality of life
625303|NCT00222196|pain-score
625304|NCT00222196|biomarkers
625305|NCT00222183|Lupus erythematodes
625306|NCT00222183|Elidel
625307|NCT00222183|Pimecrolimus
625308|NCT00222183|Chronic discoid lupus erythematosus (dLE)
625309|NCT00222183|subacute cutaneous lupus erythematosus (scLE)
625310|NCT00222131|Epigastric Pain
625311|NCT00222131|Non-Ulcer Dyspepsia (NUD)
625312|NCT00222092|post-ERCP pancreatitis
625313|NCT00222092|prophylaxis
625314|NCT00222092|prognosis
625315|NCT00222092|natural course
625316|NCT00222092|molecular markers
625317|NCT00222066|Aspiration
625318|NCT00222066|Fetal ovarian cyst
625319|NCT00222066|Ovarian torsion
625320|NCT00222053|Myeloma
625321|NCT00222053|Autologous transplantation
625322|NCT00222053|Maintenance therapy
625323|NCT00222053|Thalidomide
625324|NCT00222040|Stroke
625325|NCT00222040|thrombolysis
625326|NCT00222040|ultrasound
625327|NCT00222040|microbubbles
625328|NCT00222040|alteplase
625329|NCT00222027|Acute lymphoblastic leukemia
625330|NCT00222027|adult patient
625331|NCT00222027|chemotherapy
625332|NCT00222027|stem cell transplantation
625333|NCT00222027|Young adult patients
625334|NCT00222014|Refractory ascites
625335|NCT00222014|Cirrhosis
625336|NCT00222014|Paracentesesis
625337|NCT00221988|Elderly
625338|NCT00221988|Epilepsy
625339|NCT00221988|Cognition
625340|NCT00221988|Health Outcome
625341|NCT00221962|ADHD
625342|NCT00221923|Primary open angle glaucoma
625343|NCT00221923|African American
625344|NCT00221923|Glaucoma/pathology
625345|NCT00221923|Glaucoma/ physiopathology
625346|NCT00221923|Nerve Fibers/pathology
625347|NCT00221923|Risk factor glaucoma
625348|NCT00221897|Primary open angle glaucoma
625349|NCT00221897|Glaucoma/pathology
625350|NCT00221897|Glaucoma/physiopathology
625351|NCT00221897|Nerve Fibers/pathology
625352|NCT00221897|Risk factors glaucoma
625353|NCT00221845|Ramipril
625354|NCT00221845|Hypertension
625355|NCT00221845|Chronic renal failure
625356|NCT00221845|Disease progression
625357|NCT00221845|Left ventricular hypertrophy
625358|NCT00221845|Intima media thickness
625359|NCT00221845|Cardiovascular disease
625360|NCT00221845|Biomarkers
625361|NCT00221845|Gene polymorphisms
625362|NCT00221832|Long QT Syndrome
625363|NCT00221832|Hypertrophic cardiomyopathy
625364|NCT00221832|arrhythmogenic right ventricular dysplasia
625365|NCT00221832|Short QT Syndrome
625366|NCT00221832|Brugada Syndrome
625367|NCT00221819|Humidification
625368|NCT00221819|Heat and moisture exchanger
625369|NCT00221819|Heated humidifier, non invasive ventilation
625370|NCT00221806|Arteritis, femoro popliteal bypass, endothelialised prosthesis, saphenous vein graft, permeability, Doppler echography
625371|NCT00221793|Parkinson
625372|NCT00221793|deep subthalamic stimulation
625373|NCT00221793|pharmacological treatment
625374|NCT00221780|Heart failure
625375|NCT00221780|Cardiomyopathy, dilated
625376|NCT00221780|Coronary disease
625377|NCT00221780|Cardiac Pacing, Artificial
625378|NCT00221780|Hemodynamics
625379|NCT00221780|Randomized Controlled Trials
625380|NCT00221780|Single-Blind Study
625381|NCT00221767|Neurogenic bladder
625382|NCT00221767|electric stimulation therapy
625383|NCT00221767|urinary tract infection
625384|NCT00221767|urinary incontinence
625385|NCT00221767|spinal cord injuries
625386|NCT00221767|spinal nerve roots
625387|NCT00221767|nonRandomized Controlled Trials
625388|NCT00221767|open Study
625389|NCT00221754|HIV,
625390|NCT00221754|protease inhibitors
625391|NCT00221754|pravastatin
625392|NCT00221754|Treatment Experienced
625393|NCT00221741|Heart surgery
625394|NCT00221741|Blood Loss, Surgical
625395|NCT00221741|Mortality
625396|NCT00221741|Blood Transfusion
625397|NCT00221741|Cohort Studies
625398|NCT00221728|Kidney Neoplasms
625399|NCT00221728|Surgery
625400|NCT00221728|Catheter Ablation
625401|NCT00221728|Randomized controlled trials
625402|NCT00221728|Kidney Failure, Chronic
625403|NCT00221715|arteritis
625404|NCT00221715|lower limb ischemia
625405|NCT00221715|femoropopliteal artery bypass
625406|NCT00221715|blood vessel prothesis implantation
625407|NCT00221715|saphenous vein
625408|NCT00221715|vascular permeability
625409|NCT00221715|doppler ultrasonography
625410|NCT00221715|randomized clinical trials
625411|NCT00221715|efficacy study
625412|NCT00221702|Melanoma
625413|NCT00221702|Neoplasm metastasis
625414|NCT00221702|Interferon alfa-2b
625415|NCT00221702|Adjuvants
625416|NCT00221702|Randomized clinical trial
625417|NCT00221702|Disease-free survival time
625418|NCT00221702|Safety
625419|NCT00221702|Drug toxicity
625420|NCT00221702|Quality of life
625421|NCT00221689|Severe brain injury
625422|NCT00221689|Coma
625423|NCT00221689|Hypertonia
625424|NCT00221689|Dysautonomia
625425|NCT00221689|Baclofen
625426|NCT00221689|Randomized Controlled Trials
625427|NCT00221676|influenza vaccine
625428|NCT00221676|general practitioner
625429|NCT00221663|Cardiac surgery
625430|NCT00221663|Aortic valve replacement
625431|NCT00221663|Minimally invasive surgery
625432|NCT00221663|Perioperative course
625433|NCT00221650|Hepatitis C, Chronic
625434|NCT00221650|HCV infection
625435|NCT00221650|HIV infection
625436|NCT00221650|Treatment Failure
625437|NCT00221650|PEG interferon
625438|NCT00221650|Interferons/therapeutic use
625439|NCT00221650|Interferon Alfa-2a/adverse effects
625440|NCT00221650|Ribavirin/therapeutic use
625441|NCT00221650|Ribavirin/adverse effects
625442|NCT00221650|Drug Therapy, Combination
625443|NCT00221650|Treatment Experienced
625444|NCT00221650|Treatment Naive
625445|NCT00221637|Neuralgia
625446|NCT00221637|Valproate
625447|NCT00221637|Anticonvulsant Drugs
625448|NCT00221637|Pain Measurement
625449|NCT00221637|Randomized Controlled Trials
625450|NCT00221624|Hepatitis C, chronic
625451|NCT00221624|HCV infection
625452|NCT00221624|Treatment failure
625453|NCT00221624|PEG Interferon
625454|NCT00221624|(Interferons/therapeutic use
625455|NCT00221624|Interferon Alfa-2a/adverse effects)
625456|NCT00221624|ribavirin
625457|NCT00221624|(Ribavirin/therapeutic use
625458|NCT00221624|Ribavirin/adverse effects)
625459|NCT00221624|Amantadine
625460|NCT00221624|Drug Therapy, Combination
625461|NCT00221520|Sedation, mechanical ventilation
625462|NCT00221507|Vaccination
625463|NCT00221507|Prevention & Control
625464|NCT00221494|depression
625465|NCT00221481|Bipolar
625466|NCT00221481|Alcohol
625467|NCT00221468|Adolescents
625468|NCT00221455|Diabetes Mellitus
625469|NCT00221455|Chronic disease management
625470|NCT00221455|Patient portal
625471|NCT00221455|Patient empowerment
625472|NCT00221442|Adults
625473|NCT00221442|Binge eating disorder
625474|NCT00221442|Blood draw
625475|NCT00221442|E.Coli enterprotoxin
625476|NCT00221442|Eating disorders
625477|NCT00221442|Electrocardiogram
625478|NCT00221442|Females
625479|NCT00221442|Males
625480|NCT00221442|Physical exam
625481|NCT00221442|Psychiatric evaluation
625482|NCT00221442|Questionnaire
625483|NCT00221429|child
625484|NCT00221429|adolescent
625485|NCT00221416|child
625486|NCT00221416|adolescent
625487|NCT00221403|child
625488|NCT00221403|adolescent
625489|NCT00221403|bipolar disorder
625490|NCT00221390|stroke
625491|NCT00221390|Chronic stroke with hemiparesis
625492|NCT00221377|intubation
625493|NCT00221377|trachea
625494|NCT00221377|tube
625495|NCT00221377|cuff
625496|NCT00221377|children
625497|NCT00221364|Trachoma
625498|NCT00221364|Chlamydia
625499|NCT00221364|Azithromycin
625500|NCT00221351|cough
625501|NCT00221351|acute bronchitis
625502|NCT00221351|upper respiratory tract infection
625503|NCT00221351|pneumonia
625504|NCT00221351|lower respiratory tract infection
625505|NCT00221338|gabapentin
625506|NCT00221338|pain
625507|NCT00221338|surgery
625508|NCT00221338|delirium
625509|NCT00221338|cognitive decline
625510|NCT00221325|Phase I Clinical Trial
625511|NCT00221325|Pharmacokinetics
625512|NCT00221325|Pharmacodynamics
625513|NCT00221325|CNS Lymphoma
625514|NCT00221325|Ocular Lymphoma
625515|NCT00221312|Perimenopausal bone loss
625516|NCT00221299|Osteoporosis
625517|NCT00221299|Steroids
625518|NCT00221299|Prednisone
625519|NCT00221286|chronic hepatitis B
625520|NCT00221286|human immunodeficiency virus
625521|NCT00221286|pegylated interferon
625522|NCT00221286|tenofovir DF
625523|NCT00221286|emtricitabine
625524|NCT00221260|Analgesia
625525|NCT00221260|anesthesia
625526|NCT00221247|cerebral palsy; acupuncture
625527|NCT00221234|Diabetes
625528|NCT00221234|Physical Activity
625529|NCT00221221|breast cancer survivors
625530|NCT00221221|physical activity
625531|NCT00221221|health promotion
625532|NCT00221208|Diabetes
625533|NCT00221208|Resistance Training
625534|NCT00221182|Angina
625535|NCT00221182|Heart diseases
625536|NCT00221182|Pain
625537|NCT00221182|Vascular diseases
625538|NCT00221169|Non-small cell lung cancer
625539|NCT00221169|Positron emission tomography
625540|NCT00221169|Gross tumor volume
625541|NCT00221169|Radiation therapy
625542|NCT00221156|Abnormal Glucose Tolerance
625543|NCT00221156|coronary artery disease
625544|NCT00221156|diabetes mellitus
625545|NCT00221156|clinical outcome
625546|NCT00221143|Ulcer/ gangrene
625547|NCT00221143|Leg diseases
625548|NCT00221143|Pain
625549|NCT00221143|Vascular diseases
625550|NCT00221143|Chronic limb ischemia
625551|NCT00221143|Peripheral artery disease
625552|NCT00221130|Regenerative medicine
625553|NCT00221130|Periodontal tissue
625554|NCT00221117|Spinal Cord Injuries
625555|NCT00221104|stroke
625556|NCT00221104|brain ischemia
625557|NCT00221104|cerebrovascular accident
625558|NCT00221104|statin
625559|NCT00221104|hydroxymethylglutaryl-CoA reductase inhibitors
625560|NCT00221104|cholesterol
625561|NCT00221104|hypercholesterolemia
625562|NCT00221104|hyperlipidemia
625563|NCT00221104|multicenter studies
625564|NCT00221104|prospective studies
625565|NCT00221104|endpoint determination
625566|NCT00221104|randomized controlled trials
625567|NCT00221104|recurrence
625568|NCT00221104|pravastatin
625569|NCT00221091|idiopathic normal pressure hydrocephalus
625570|NCT00221091|shunt
625571|NCT00221078|Cerebrovascular Accident
625572|NCT00221078|Stroke
625573|NCT00221065|Sleep Apnea Syndromes
625574|NCT00221065|Cerebrovascular Accident
625575|NCT00221039|ECP
625576|NCT00221039|Photopheresis
625577|NCT00221039|CTCL
625578|NCT00221039|Cutaneous T Cell Lymphoma
625579|NCT00221039|Mycosis Fungoides
625580|NCT00221013|Acute Renal Failure
625581|NCT00221013|Continuous Renal Replacement Therapy
625582|NCT00221013|Continuous Veno-Venous Haemofiltration
625583|NCT00221013|Continuous Veno-Venous Haemodiafiltration
625584|NCT00221013|Renal Replacement Therapy
625585|NCT00221000|Rheumatoid Arthritis
625586|NCT00220987|Hyperglycemia in the critically ill patient
625587|NCT00220987|Intensive Insulin Therapy
625588|NCT00220987|Conventional insulin therapy
625589|NCT00220987|Hypoglycaemia
625590|NCT00220961|Impaired Glucose Tolerance
625591|NCT00220961|Type 2 Diabetes
625592|NCT00220961|Prevention
625593|NCT00220961|Pioglitazone
625594|NCT00220948|discogenic pain
625595|NCT00220948|myoelectric activity
625596|NCT00220935|Randomized controlled clinical trial
625597|NCT00220922|Copaxone
625598|NCT00220909|Gastric erosions
625599|NCT00220909|Proton pump inhibitors
625600|NCT00220896|Delirium
625601|NCT00220896|Prevention
625602|NCT00220896|Donepezil
625603|NCT00220883|Functional Dyspepsia
625604|NCT00220883|Electrogastrography
625605|NCT00220870|schizophrenia
625606|NCT00220870|shared decision making
625607|NCT00220870|compliance
625608|NCT00220870|maintenance therapy
625609|NCT00220857|Rabeprazole
625610|NCT00220857|Nonsteroidal Antiinflammatory Drugs
625611|NCT00220857|Gastric erosions
625612|NCT00220831|Diabetes
625613|NCT00220831|MI
625614|NCT00220831|CVD disease
625615|NCT00220818|Pediatric GERD
625616|NCT00220818|Pediatric Gastroesophageal Reflux Disease
625617|NCT00220818|lansoprazole
625618|NCT00220792|Primary breast cancer
625619|NCT00220792|support groups
625620|NCT00220792|mood disturbance
625621|NCT00220766|Primary Immune Deficiency
625622|NCT00220766|IGIV
625623|NCT00220766|Immunoglobulin G
625624|NCT00220753|Dog allergy
625625|NCT00220753|Pet allergy
625626|NCT00220753|Air cleaners
625627|NCT00220753|HEPA filters
625628|NCT00220753|Air filtration
625629|NCT00220753|Can f1
625630|NCT00220753|Asthma
625631|NCT00220753|Children
625632|NCT00220753|Adolescents
625633|NCT00220753|Indoor environment
625634|NCT00220753|Indoor allergy
625635|NCT00220753|Perennial allergy
625636|NCT00220740|Immunoglobulin G
625637|NCT00220727|Idiopathic (Immune) Thrombocytopenic Purpura
625638|NCT00220727|Immunoglobulin G
625639|NCT00220714|schizophrenia
625640|NCT00220714|first-episode
625641|NCT00220714|patient compliance
625642|NCT00220714|long-acting risperidone
625643|NCT00220714|relapse
625644|NCT00220701|Dysthymic Disorder
625645|NCT00220701|Depression
625646|NCT00220701|Chronic Depression
625647|NCT00220701|Escitalopram
625648|NCT00220688|nausea
625649|NCT00220688|vomiting
625650|NCT00220688|palliative
625651|NCT00220688|acupressure
625652|NCT00220675|Malignant extradural spinal cord compression
625653|NCT00220675|Erythropoietin
625654|NCT00220675|Neuroprotectant
625655|NCT00220675|Radiotherapy
625656|NCT00220675|Palliation
625657|NCT00220662|anorexia nervosa
625658|NCT00220662|bulimia nervosa
625659|NCT00220662|readiness and motivation
625660|NCT00220649|solid tumors or adenocarcinoma of the exocrine pancreas
625661|NCT00220636|Major Depression
625662|NCT00220636|Depression
625663|NCT00220636|Unipolar Depression
625664|NCT00220636|Treatment Resistant Depression
625665|NCT00220636|Adjunctive treatment
625666|NCT00220623|major depression
625667|NCT00220623|psychotherapy
625668|NCT00220623|antidepressant medications
625669|NCT00220623|clincial trial
625670|NCT00220597|group therapy
625671|NCT00220597|sexual revictimization
625672|NCT00220597|risky sex
625673|NCT00220597|addiction
625674|NCT00220571|AMI
625675|NCT00220571|stent
625676|NCT00220571|PTCA
625677|NCT00220571|abciximab
625678|NCT00220571|reteplase
625679|NCT00220571|combo therapy
625680|NCT00220558|Percutaneous Transluminal Coronary Angioplasty
625681|NCT00220558|Bare metal stents
625682|NCT00220558|drug eluting stents
625683|NCT00220545|Polycystic ovarY
625684|NCT00220545|Laparoscopic ovarian diathermy
625685|NCT00220545|Induction of ovulation
625686|NCT00220545|Clomiphene citrate
625687|NCT00220532|Randomised placebo controlled intervention trial
625688|NCT00220532|Folic acid
625689|NCT00220532|Riboflavin
625690|NCT00220532|cervical cancer
625691|NCT00220506|provigil
625692|NCT00220506|fatigue
625693|NCT00220506|Multiple Sclerosis
625694|NCT00220506|cognition
625695|NCT00220493|MS
625696|NCT00220493|RITALIN
625697|NCT00220493|PASAT
625698|NCT00220493|COGNITION
625699|NCT00220493|ATTENTION
625700|NCT00220493|Relapsing remitting
625701|NCT00220493|Secondary progressive
625702|NCT00220493|Primary progressive
625703|NCT00220467|MCI
625704|NCT00220467|aging
625705|NCT00220467|cognition
625706|NCT00220467|exercise
625707|NCT00220467|aerobic
625708|NCT00220467|insulin
625709|NCT00220454|cognition
625710|NCT00220454|estradiol
625711|NCT00220454|cortisol
625712|NCT00220454|postmenopause
625713|NCT00220441|IGT
625714|NCT00220441|exercise
625715|NCT00220441|cognition
625716|NCT00220441|insulin
625717|NCT00220441|aging
625718|NCT00220441|aerobic
625719|NCT00220428|T cell
625720|NCT00220350|arousal
625721|NCT00220350|sex offender
625722|NCT00220350|suppression of arousal
625723|NCT00220350|pedohilia
625724|NCT00220350|leuprolide acetate
625725|NCT00220324|Contraception
625726|NCT00220285|Antigen
625727|NCT00220285|CD20
625728|NCT00220272|Parkinson Disease
625729|NCT00220272|5-fluorodopa
625730|NCT00220259|Cystic Fibrosis, inhaled corticosteroids
625731|NCT00220246|Hereditary colorectal cancer
625732|NCT00220246|Microsatellite instability
625733|NCT00220246|Chromosomal instability
625734|NCT00220207|Diabetes
625735|NCT00220207|Health Education
625736|NCT00220207|Information Technology
625737|NCT00220207|African Americans
625738|NCT00220207|Disease Management
625739|NCT00220207|Internet
625740|NCT00220207|Patient Education
625741|NCT00220181|Nutritional status
625742|NCT00220181|Bowel symptoms
625743|NCT00220181|Radical radiotherapy to pelvis
625744|NCT00220181|Gynaecological, urological or rectal cancer
625745|NCT00220090|Irritable Bowel Syndrome
625746|NCT00220090|Cholecystokinin
625747|NCT00220090|Dexloxiglumide
625748|NCT00220090|Randomized/withdrawal
625749|NCT00219999|Hepatitis
625750|NCT00219999|Hepacivirus
625751|NCT00219999|B Lymphocytes
625752|NCT00219999|Chemokines
625753|NCT00219999|Antibodies
625754|NCT00219986|Treatment Experienced
625755|NCT00219986|HIV
625756|NCT00219973|venous thromboembolism
625757|NCT00219973|deep vein thrombosis
625758|NCT00219973|pulmonary embolism
625759|NCT00219973|bleeding
625760|NCT00219973|low-molecular-weight heparin
625761|NCT00219973|cancer
625762|NCT00219973|surgery
625763|NCT00219960|Hypertension
625764|NCT00219960|Blood Pressure
625765|NCT00219960|Ambulatory Blood Pressure Monitoring
625766|NCT00219960|Complementary and Alternative Medicine
625767|NCT00219960|Herbal
625768|NCT00219960|North American Ginseng
625769|NCT00219960|Panax Quinquefolius
625770|NCT00219947|HIV Infection
625771|NCT00219947|Acute HIV Infection
625772|NCT00219947|Primary HIV Infection
625773|NCT00219947|Acute Seroconversion Syndrome
625774|NCT00219934|New HIV Infection
625775|NCT00219934|Acute HIV Infection
625776|NCT00219934|Primary HIV Infection
625777|NCT00219934|Acute Seroconversion Syndrome
625778|NCT00219921|total hip replacement
625779|NCT00219921|pain treatment
625780|NCT00219908|Multiple sclerosis
625781|NCT00219908|Mitoxantrone
625782|NCT00219908|Methylprednisolone
625783|NCT00219908|Interferon beta1b
625784|NCT00219908|Relapse
625785|NCT00219908|MRI
625786|NCT00219908|EDSS
625787|NCT00219895|Cystic Fibrosis
625788|NCT00219895|Anti-inflammatory Agents
625789|NCT00219895|Ibuprofen
625790|NCT00219882|Cystic Fibrosis
625791|NCT00219882|curcuminoids
625792|NCT00219882|turmeric root extract
625793|NCT00219882|nasal potential difference (NPD)
625794|NCT00219882|sweat chloride
625795|NCT00219869|Post
625796|NCT00219869|Traumatic
625797|NCT00219869|Headache
625798|NCT00219869|Cognitive
625799|NCT00219856|Propofol
625800|NCT00219856|Hepatectomy
625801|NCT00219856|Oxidative stress
625802|NCT00219843|Stage III and IV melanoma
625803|NCT00219830|Cardiac Rehabilitation
625804|NCT00219830|Walking
625805|NCT00219830|Acute Myocardial Infarction
625806|NCT00219830|Secondary Prevention
625807|NCT00219817|Anorexia
625808|NCT00219817|Cachexia
625809|NCT00219791|methotrexate
625810|NCT00219791|delayed elimination
625811|NCT00219791|renal insufficiency
625812|NCT00219791|CPG2
625813|NCT00219791|Voraxaze
625814|NCT00219765|CML
625815|NCT00219765|Acute Phase
625816|NCT00219765|Imatinib mesylate
625817|NCT00219765|Cytarabine
625818|NCT00219765|Daunorubicine
625819|NCT00219752|CML - ederly patients - Imatinib mesylate
625820|NCT00219739|CML
625821|NCT00219739|Imatinib
625822|NCT00219739|Interferon
625823|NCT00219739|Cytarabine
625824|NCT00219726|CML
625825|NCT00219726|Imatinib mesylate
625826|NCT00219726|Stem cell transplantation
625827|NCT00219713|Nitrous oxide and oxygen
625828|NCT00219713|Pain
625829|NCT00219713|Bone marrow biopsy
625830|NCT00219713|Bone marrow aspiration
625831|NCT00219700|NSAID-PC
625832|NCT00219700|IBU-PC
625833|NCT00219687|Heart arrest
625834|NCT00219687|Cardiopulmonary resuscitation
625835|NCT00219687|Dispatcher
625836|NCT00219674|education
625837|NCT00219674|training, defibrillators
625838|NCT00219674|home defibrillators
625839|NCT00219674|automated external defibrillators
625840|NCT00219674|psychological adjustment
625841|NCT00219661|randomised control trial
625842|NCT00219661|intensive care unit
625843|NCT00219661|mechanical ventilation
625844|NCT00219661|ventilator-associated pneumonia
625845|NCT00219661|drainage of subglottic secretions
625846|NCT00219557|Randomized Phase 2 Study of AG-013736 in Combination with Gemcitabine versus Gemcitabine Alone in Advanced Pancreatic Cancer
625847|NCT00219531|functional MRI
625848|NCT00219531|pain perception
625849|NCT00219531|anxiety
625850|NCT00219531|brain-gut axis
625851|NCT00219518|Defecography
625852|NCT00219518|Pelvic floor dyssynergia
625853|NCT00219518|Anismus
625854|NCT00219505|Diarrhea-predominant irritable bowel syndrome
625855|NCT00219505|Acupuncture
625856|NCT00219505|abdominal pain
625857|NCT00219492|NCCP, mast cell, esophagus
625858|NCT00219479|seizure prophylaxis
625859|NCT00219479|enteral nutrition
625860|NCT00219453|Pilot Projects
625861|NCT00219453|Injections, Jet
625862|NCT00219453|Injections, Jet/instrumentation
625863|NCT00219453|Equipment Contamination/prevention and control
625864|NCT00219453|Blood-Borne Pathogens
625865|NCT00219453|Disease Transmission, Horizontal
625866|NCT00219427|Low vision
625867|NCT00219401|Pneumococcal vaccine
625868|NCT00219401|Antibody responses
625869|NCT00219401|Cellular immunology
625870|NCT00219401|Th1/Th2 immune responses
625871|NCT00219401|Paediatric
625872|NCT00219401|Neonatal
625873|NCT00219401|Infectious diseases
625874|NCT00219401|Papua New Guinea
625875|NCT00219388|Safety
625876|NCT00219388|Efficacy
625877|NCT00219388|Levosimendan
625878|NCT00219388|Dobutamine
625879|NCT00219388|Intravenous
625880|NCT00219388|Invasive hemodynamics
625881|NCT00219388|Decompensated Heart Failure
625882|NCT00219375|sivelestat sodium hydrate
625883|NCT00219375|acute lung injury
625884|NCT00219375|systemic inflammatory response syndrome
625885|NCT00219375|Elaspol
625886|NCT00219375|Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS)
625887|NCT00219362|HIV-1 infection
625888|NCT00219362|therapeutic vaccine
625889|NCT00219362|Treatment Experienced
625890|NCT00219349|Anxiety Disorders
625891|NCT00219349|Anxiety Neuroses
625892|NCT00219349|Behavior Therapy, Cognitive
625893|NCT00219349|Escitalopram
625894|NCT00219336|Prevent Alcohol Exposed Pregnancies
625895|NCT00219336|Reduced Alcohol Used
625896|NCT00219336|Self-Guided Motivational Intervention
625897|NCT00219336|Effective Contraception
625898|NCT00219336|Contraception
625899|NCT00219336|College Students
625900|NCT00219323|Asthma, IgE, Omalizumab
625901|NCT00219310|Recurrent Genital Herpes (RGH), famciclovir, episodic treatment, suppressive treatment, Polymerase Chain Reaction (PCR).
625902|NCT00219297|EPO
625903|NCT00219297|EPO906
625904|NCT00219297|Brain cancer
625905|NCT00219297|Brain metastasis
625906|NCT00219297|Lung cancer
625907|NCT00219297|Lung metastasis
625908|NCT00219297|Brain metastasis from non-small cell lung cancer
625909|NCT00219284|Parkinson's disease, tremor
625910|NCT00219271|Prostate cancer
625911|NCT00219271|molecular staging
625912|NCT00219271|antitumor potential
625913|NCT00219245|Traumatic brain injury, head trauma, rivastigmine, cognitive deficits
625914|NCT00219232|Alzheimer's disease
625915|NCT00219232|Dementia
625916|NCT00219219|zoledronic acid
625917|NCT00219219|prostate cancer
625918|NCT00219219|SRE
625919|NCT00219193|Hypertension, aliskiren, blood pressure, valsartan, HCTZ
625920|NCT00219180|Hypertension, Aliskiren
625921|NCT00219167|hypertension
625922|NCT00219167|aliskiren
625923|NCT00219167|age
625924|NCT00219128|Hypertension, aliskiren, blood pressure, placebo
625925|NCT00219115|Hypertension, aliskiren, blood pressure, irbesartan, amlodipine, hydrochlorothiazide
625926|NCT00219102|Hypertension,
625927|NCT00219102|diabetes,
625928|NCT00219102|aliskiren,
625929|NCT00219102|blood pressure,
625930|NCT00219102|valsartan,
625931|NCT00219102|hydrochlorothiazide
625932|NCT00219089|Hypertension, aliskiren, blood pressure, diabetes mellitus, ramipril
625933|NCT00219076|Hypertension, aliskiren, blood pressure, amlodipine
625934|NCT00219063|Hypertension, aliskiren, blood pressure, Ramipril, hydrochlorothiazide
625935|NCT00219037|Hypertension, blood pressure, aliskiren
625936|NCT00219024|Hypertension, aliskiren, blood pressure, hydrochlorothiazide (HCTZ).
625937|NCT00219011|Aliskiren, heart failure,hypertension
625938|NCT00218985|Aerobic capacity
625939|NCT00218985|Exercise training
625940|NCT00218985|CABG
625941|NCT00218985|Endothelial function
625942|NCT00218972|Hypertension
625943|NCT00218972|endurance training
625944|NCT00218972|endothelial function
625945|NCT00218972|left ventricular function
625946|NCT00218972|Echocardiography
625947|NCT00218972|Quality of life
625948|NCT00218972|Essential hypertension grade 1 - 2
625949|NCT00218959|PTSD
625950|NCT00218959|trauma treatment
625951|NCT00218959|refugees
625952|NCT00218959|randomized controlled
625953|NCT00218946|pain
625954|NCT00218946|infant, premature
625955|NCT00218946|intubation, gastrointestinal
625956|NCT00218946|Neonatal nursing
625957|NCT00218933|Interval training
625958|NCT00218933|Endothelial dysfunction
625959|NCT00218933|Aerobic capacity
625960|NCT00218933|Exercise
625961|NCT00218920|aerobic capacity
625962|NCT00218920|endothelial function
625963|NCT00218920|obesity
625964|NCT00218920|exercise training
625965|NCT00218907|HIV prevention
625966|NCT00218907|HIV counseling
625967|NCT00218907|HIV testing
625968|NCT00218907|Emergency Medicine
625969|NCT00218907|HIV Seronegativity
625970|NCT00218894|Effect
625971|NCT00218894|Balance
625972|NCT00218894|Gait
625973|NCT00218894|Falls
625974|NCT00218881|HIV prevention
625975|NCT00218881|HIV screening
625976|NCT00218881|Emergency Medicine
625977|NCT00218881|HIV counseling and Testing
625978|NCT00218881|HIV Seronegativity
625979|NCT00218868|Cytodiagnosis
625980|NCT00218868|Skin Scrape
625981|NCT00218868|Touch Imprint
625982|NCT00218868|Papanicolaou
625983|NCT00218868|May-Grunvald-Giemsa
625984|NCT00218855|Multiple Myeloma
625985|NCT00218855|Phase 3, randomised, double blind study
625986|NCT00218855|thalidomide
625987|NCT00218842|exercise
625988|NCT00218842|functioning
625989|NCT00218842|frail elderly
625990|NCT00218829|Photodynamic treatment
625991|NCT00218829|Basal cell carcinoma
625992|NCT00218829|DMSO
625993|NCT00218790|Sleep
625994|NCT00218790|Renal failure
625995|NCT00218790|Dialysis
625996|NCT00218777|Chronic tic disorder
625997|NCT00218777|Motor tics
625998|NCT00218777|Vocal tics
625999|NCT00218764|MDDRU
626000|NCT00218764|Major Depressive Disorder Recurrent Unipolar
626001|NCT00218751|Child abuse
626002|NCT00218751|Neglect
626003|NCT00218751|Home Visitation
626004|NCT00218751|Program Evaluation
626005|NCT00218725|Cognitive Therapy
626006|NCT00218725|Suicide
626007|NCT00218725|Addictions
626008|NCT00218725|Substance Abuse
626009|NCT00218712|HIV
626010|NCT00218712|AIDS
626011|NCT00218712|MSM
626012|NCT00218712|Cognitive-Behavioral
626013|NCT00218712|HIV Seronegativity
626014|NCT00218699|HIV
626015|NCT00218699|MSM Men Who Have Sex with Men
626016|NCT00218699|Men Who Have Sex With Men
626017|NCT00218699|Cognitive-Behavioral
626018|NCT00218699|HIV Counseling and Testing
626019|NCT00218699|HIV Seronegativity
626020|NCT00218686|HIV
626021|NCT00218686|injection drug use
626022|NCT00218686|social networks
626023|NCT00218673|HIV
626024|NCT00218673|injection drug use
626025|NCT00218673|social networks
626026|NCT00218621|Buprenorphine
626027|NCT00218621|Methadone
626028|NCT00218608|Cocaine Abuse
626029|NCT00218582|12 step groups
626030|NCT00218582|self help
626031|NCT00218582|psychiatric day treatment
626032|NCT00218582|co-occurring disorders
626033|NCT00218582|dual diagnosis
626034|NCT00218569|Alcohol Dependence
626035|NCT00218569|Cocaine Dependence
626036|NCT00218556|Hepatitis C, Depressive Symptoms
626037|NCT00218543|ADHD
626038|NCT00218543|Cocaine Abuse
626039|NCT00218517|cannabis use disorder
626040|NCT00218465|Drugs, Investigational
626041|NCT00218465|Therapies for Relapse to Nicotine
626042|NCT00218465|Relapse Prevention
626043|NCT00218465|Nicotine Cessation Therapies
626044|NCT00218465|Smoking Cessation
626045|NCT00218465|Nicotine Dependence
626046|NCT00218452|Tobacco use cessation
626047|NCT00218439|Smoking
626048|NCT00218413|Vaccine
626049|NCT00218413|Immunogenicity
626050|NCT00218413|Randomized Controlled Trial
626051|NCT00218413|Addiction
626052|NCT00218374|Opiate Addiction
626053|NCT00218374|Opiate Dependence
626054|NCT00218361|Behavioral economics
626055|NCT00218361|Drug self administration
626056|NCT00218361|Opioid
626057|NCT00218348|Cocaine Abuse
626058|NCT00218348|Dextro-Amphetamine Sulfate
626059|NCT00218335|HIV prevention Intervention, injection drug user,peer-oriented, randomized controlled trial, social network
626060|NCT00218309|opiate dependence
626061|NCT00218296|Nicotine Dependence
626062|NCT00218296|Tobacco Dependence
626063|NCT00218283|Nicotine Dependence
626064|NCT00218283|Tobacco Dependence
626065|NCT00218270|Smokeless tobacco, harm reduction
626066|NCT00218257|Cocaine
626067|NCT00218244|Brand Switching, smokeless tobacco use
626068|NCT00218231|schizophrenia
626069|NCT00218231|tobacco dependence
626070|NCT00218231|nicotine
626071|NCT00218218|Nicotine Dependence
626072|NCT00218218|Tobacco Dependence
626073|NCT00218205|Epirubicin
626074|NCT00218205|Estramustine Phosphate
626075|NCT00218205|Celecoxib
626076|NCT00218205|Hormone Refractory Prostate Cancer
626077|NCT00218192|hepatitis c
626078|NCT00218192|injection drug use
626079|NCT00218179|Lung Cancer
626080|NCT00218179|Cotinine
626081|NCT00218179|NNAL
626082|NCT00218179|Carcinogens
626083|NCT00218179|Case-control
626084|NCT00218179|SNPs
626085|NCT00218166|cocaine
626086|NCT00218166|tiagabine
626087|NCT00218166|baclofen
626088|NCT00218153|nicotine dependence
626089|NCT00218140|tobacco
626090|NCT00218127|Heroin dependence
626091|NCT00218101|opioid dependence
626092|NCT00218075|Cocaine addiction
626093|NCT00218075|cocaine treatment
626094|NCT00218036|Cocaine Abuse
626095|NCT00218036|Opiate Abuse
626096|NCT00218010|methadone
626097|NCT00218010|lactation
626098|NCT00218010|breastfeeding
626099|NCT00218010|maternal opioid dependency
626100|NCT00217984|Tobacco use disorder
626101|NCT00217984|Alcohol dependence
626102|NCT00217971|cannabis dependence
626103|NCT00217971|dronabinol
626104|NCT00217971|treatment
626105|NCT00217932|Behavioral Disorders
626106|NCT00217854|asthma, corticosteroids
626107|NCT00217841|MRSA
626108|NCT00217763|Dementia
626109|NCT00217763|Alzheimer's disease
626110|NCT00217724|unspecified adult solid tumor, protocol specific
626111|NCT00217724|pain
626112|NCT00217711|stage III colon cancer
626113|NCT00217711|stage IV colon cancer
626114|NCT00217711|stage III rectal cancer
626115|NCT00217711|stage IV rectal cancer
626116|NCT00217698|recurrent non-small cell lung cancer
626117|NCT00217698|stage IIIB non-small cell lung cancer
626118|NCT00217698|stage IV non-small cell lung cancer
626119|NCT00217698|adenocarcinoma of the lung
626120|NCT00217698|large cell lung cancer
626121|NCT00217698|squamous cell lung cancer
626122|NCT00217672|stage IV breast cancer
626123|NCT00217672|recurrent breast cancer
626124|NCT00217659|male breast cancer
626125|NCT00217659|recurrent breast cancer
626126|NCT00217659|stage IV breast cancer
626127|NCT00217620|adult angiosarcoma
626128|NCT00217620|adult leiomyosarcoma
626129|NCT00217620|adult liposarcoma
626130|NCT00217620|adult malignant hemangiopericytoma
626131|NCT00217620|recurrent adult soft tissue sarcoma
626132|NCT00217620|stage III adult soft tissue sarcoma
626133|NCT00217620|stage IV adult soft tissue sarcoma
626134|NCT00217607|adult angiosarcoma
626135|NCT00217607|recurrent adult soft tissue sarcoma
626136|NCT00217607|stage III adult soft tissue sarcoma
626137|NCT00217607|stage IV adult soft tissue sarcoma
626138|NCT00217594|Immunosuppression
626139|NCT00217594|T Cells
626140|NCT00217594|Hematopoiesis
626141|NCT00217594|Anti-CD52
626142|NCT00217594|Monoclonal Antibody Therapy
626143|NCT00217581|recurrent gastric cancer
626144|NCT00217581|stage III gastric cancer
626145|NCT00217581|stage IV gastric cancer
626146|NCT00217581|recurrent esophageal cancer
626147|NCT00217581|stage III esophageal cancer
626148|NCT00217581|stage IV esophageal cancer
626149|NCT00217581|adenocarcinoma of the stomach
626150|NCT00217568|recurrent ovarian epithelial cancer
626151|NCT00217568|stage III ovarian epithelial cancer
626152|NCT00217568|stage IV ovarian epithelial cancer
626153|NCT00217568|peritoneal cavity cancer
626154|NCT00217555|recurrent ovarian epithelial cancer
626155|NCT00217555|fallopian tube cancer
626156|NCT00217555|peritoneal cavity cancer
626157|NCT00217529|stage III ovarian epithelial cancer
626158|NCT00217529|stage IV ovarian epithelial cancer
626159|NCT00217529|peritoneal cavity cancer
626160|NCT00217529|ovarian clear cell cystadenocarcinoma
626161|NCT00217529|ovarian endometrioid adenocarcinoma
626162|NCT00217529|ovarian undifferentiated adenocarcinoma
626163|NCT00217529|ovarian mucinous cystadenocarcinoma
626164|NCT00217529|ovarian serous cystadenocarcinoma
626165|NCT00217529|Brenner tumor
626166|NCT00217529|fallopian tube cancer
626167|NCT00217529|ovarian mixed epithelial carcinoma
626168|NCT00217516|adenocarcinoma of the prostate
626169|NCT00217516|stage I prostate cancer
626170|NCT00217516|stage II prostate cancer
626171|NCT00217503|AIDS-related peripheral/systemic lymphoma
626172|NCT00217490|unspecified adult solid tumor, protocol specific
626173|NCT00217477|unspecified adult solid tumor, protocol specific
626174|NCT00217464|adenocarcinoma of the prostate
626175|NCT00217464|recurrent prostate cancer
626176|NCT00217451|Malaria
626177|NCT00217451|Fosmidomycin
626178|NCT00217451|Clindamycin
626179|NCT00217451|Gabon
626180|NCT00217425|anaplastic large cell lymphoma
626181|NCT00217425|stage I adult T-cell leukemia/lymphoma
626182|NCT00217425|stage II adult T-cell leukemia/lymphoma
626183|NCT00217425|stage III adult T-cell leukemia/lymphoma
626184|NCT00217425|stage IV adult T-cell leukemia/lymphoma
626185|NCT00217425|peripheral T-cell lymphoma
626186|NCT00217386|de novo myelodysplastic syndromes
626187|NCT00217386|previously treated myelodysplastic syndromes
626188|NCT00217386|secondary myelodysplastic syndromes
626189|NCT00217386|myelodysplastic/myeloproliferative disease, unclassifiable
626190|NCT00217386|atypical chronic myeloid leukemia
626191|NCT00217347|Gastroesophageal reflux
626192|NCT00217347|Dyspepsia
626193|NCT00217347|Esophageal Capsule Endoscopy
626194|NCT00217334|Hypertension
626195|NCT00217334|Cardiovascular diseases
626196|NCT00217334|Randomized controlled trial
626197|NCT00217334|Cluster randomization
626198|NCT00217334|Primary care
626199|NCT00217321|Parkinson's disease
626200|NCT00217321|Parkinson disease
626201|NCT00217321|Registry
626202|NCT00217321|quality of life
626203|NCT00217321|database
626204|NCT00217295|Relapsing-remitting multiple sclerosis
626205|NCT00217295|Brain atrophy
626206|NCT00217295|Disease progression
626207|NCT00217269|Restenosis
626208|NCT00217256|Restenosis
626209|NCT00217243|Pain
626210|NCT00217243|Magnetoencephalography
626211|NCT00217243|Median
626212|NCT00217243|Ulnar
626213|NCT00217243|Causalgia
626214|NCT00217243|Complex regional pain syndrome
626215|NCT00217243|Evoked fields
626216|NCT00217243|Nerve injury
626217|NCT00217243|Neuropathic pain
626218|NCT00217217|non-pharmaceutical
626219|NCT00217217|alternative
626220|NCT00217217|imaging
626221|NCT00217217|magnetic resonance imaging
626222|NCT00217217|low field magnetic stimulation
626223|NCT00217217|bipolar disorder
626224|NCT00217217|depression
626225|NCT00217217|bipolar depression
626226|NCT00217204|Cystic fibrosis
626227|NCT00217204|Pancreatic insufficiency
626228|NCT00217204|Steatorrhea
626229|NCT00217204|Fat malabsorption
626230|NCT00217204|Pancrelipase
626231|NCT00217191|Premature Infants
626232|NCT00217191|Patent ductus arteriosus
626233|NCT00217191|Renal function
626234|NCT00217191|Ibuprofen
626235|NCT00217178|Atherosclerosis
626236|NCT00217178|CV Risk Factors
626237|NCT00217178|Homocysteine
626238|NCT00217178|CV disease
626239|NCT00217178|Cardiovascular disease
626240|NCT00217165|bipolar
626241|NCT00217165|mania
626242|NCT00217165|depression
626243|NCT00217165|taurine
626244|NCT00217165|alternative
626245|NCT00217152|Kidney Transplant
626246|NCT00217139|Hepatitis C
626247|NCT00217139|Celgosivir
626248|NCT00217139|HCV
626249|NCT00217139|Genotype 1
626250|NCT00217139|Non-responders
626251|NCT00217139|Early Viral Response
626252|NCT00217139|EVR
626253|NCT00217035|parenteral nutrition
626254|NCT00217035|burn injury
626255|NCT00217035|stable isotopes
626256|NCT00217035|Proline Metabolic Kinetics
626257|NCT00217035|Ornithine Metabolic Kinetics
626258|NCT00217035|Glutamate Metabolic Kinetics
626259|NCT00217035|Glutamine Metabolic Kinetics
626260|NCT00217022|Lymphocytic Colitis
626261|NCT00217022|diarrhea
626262|NCT00217022|budesonide
626263|NCT00216996|parenteral nutrition
626264|NCT00216996|burn injury
626265|NCT00216996|stable isotopes
626266|NCT00216996|Glutamate Metabolic Kinetics
626267|NCT00216996|Glutamine Metabolic Kinetics
626268|NCT00216983|parenteral nutrition
626269|NCT00216983|burn injury
626270|NCT00216983|stable isotopes
626271|NCT00216983|Proline Metabolic Kinetics
626272|NCT00216983|Ornithine Metabolic Kinetics
626273|NCT00216983|Glutamate Metabolic Kinetics
626274|NCT00216983|Glutamine Metabolic Kinetics
626275|NCT00216970|parenteral nutrition
626276|NCT00216970|burn injury
626277|NCT00216970|stable isotopes
626278|NCT00216970|Arginine Metabolic Kinetics
626279|NCT00216970|Nitric Oxide Formation
626280|NCT00216970|Glutamine Metabolic Kinetics
626281|NCT00216944|Intubation
626282|NCT00216944|premedication
626283|NCT00216905|Patients with alcoholism according to ICD-10 after detoxification
626284|NCT00216866|Embolism
626285|NCT00216866|Thrombosis
626286|NCT00216814|antiangiogenic effects of bcg treatment and prognosis
626287|NCT00216801|Upper Tract Transitional Cell (TCC)
626288|NCT00216788|Sucrose
626289|NCT00216788|Barrett's esophagus
626290|NCT00216788|Esophagitis
626291|NCT00216788|GERD
626292|NCT00216788|Reflux
626293|NCT00216788|Esophagus
626294|NCT00216788|Esomeprazole
626295|NCT00216762|Urticaria
626296|NCT00216762|Hives
626297|NCT00216749|Cerebral Infarction Prevention
626298|NCT00216749|Cilostazol
626299|NCT00216736|Migraine
626300|NCT00216736|Headache
626301|NCT00216736|Rebound headache
626302|NCT00216723|Aripiprazole
626303|NCT00216723|Schizophrenia
626304|NCT00216723|Bipolar Disorder
626305|NCT00216710|Child abuse
626306|NCT00216710|Neglect
626307|NCT00216710|Home visitation
626308|NCT00216710|Program evaluation
626309|NCT00216697|Multiple myeloma
626310|NCT00216697|Proteasome inhibitor
626311|NCT00216697|Ubiquitin
626312|NCT00216697|Boronic acids
626313|NCT00216697|Bortezomib
626314|NCT00216684|Fentanyl, Chronic intractable pain, Japanese patients
626315|NCT00216671|Schizophrenia
626316|NCT00216671|intramuscular injection
626317|NCT00216671|antipsychotic agents
626318|NCT00216671|long-acting risperidone
626319|NCT00216658|Fentanyl
626320|NCT00216658|Cancer pain
626321|NCT00216658|Japanese patients
626322|NCT00216645|Müllerian Carcinoma
626323|NCT00216645|Doxil
626324|NCT00216645|Japanese Patients
626325|NCT00216632|Schizophrenia, Schizoaffective disorder
626326|NCT00216632|antipsychotic agents
626327|NCT00216632|long-acting risperidone
626328|NCT00216632|intramuscular injection
626329|NCT00216619|chronic migraine
626330|NCT00216619|Topiramate
626331|NCT00216619|migraine
626332|NCT00216619|headache
626333|NCT00216619|chronic headache
626334|NCT00216606|Chronic migraine
626335|NCT00216606|Migraine
626336|NCT00216606|Headache
626337|NCT00216606|Migraine headache
626338|NCT00216606|Topiramate
626339|NCT00216593|dementia
626340|NCT00216593|cognition function
626341|NCT00216593|Alzheimer disease
626342|NCT00216593|behavioral symptoms
626343|NCT00216593|galantamine hydrobromide
626344|NCT00216580|Schizophrenia
626345|NCT00216580|Intramuscular injection
626346|NCT00216580|Antipsychotic agents
626347|NCT00216580|Long-acting risperidone
626348|NCT00216580|Schizophreniform disorders
626349|NCT00216580|Schizoaffective disorder
626350|NCT00216567|Benign rolandic epilepsy
626351|NCT00216567|Topiramate
626352|NCT00216554|Bipolar
626353|NCT00216554|risperidone
626354|NCT00216554|Adjunctive therapy
626355|NCT00216541|Anemia
626356|NCT00216541|cancer
626357|NCT00216541|transfusion
626358|NCT00216541|chemotherapy
626359|NCT00216541|hemoglobin
626360|NCT00216541|standard care
626361|NCT00216541|epoetin alfa
626362|NCT00216541|epoetin
626363|NCT00216541|erythropoietin
626364|NCT00216528|Schizophrenia
626365|NCT00216528|risperidone
626366|NCT00216528|Intramuscular injection, long-acting risperidone
626367|NCT00216515|Alzheimer's disease
626368|NCT00216515|galantamine
626369|NCT00216515|attention
626370|NCT00216515|executive function
626371|NCT00216502|Alzheimer's disease
626372|NCT00216502|Dementia
626373|NCT00216502|galantamine
626374|NCT00216502|placebo
626375|NCT00216502|Caregiver
626376|NCT00216502|Brain disease
626377|NCT00216502|Memory loss
626378|NCT00216489|gastroesophageal reflux
626379|NCT00216489|heartburn
626380|NCT00216489|rabeprazole
626381|NCT00216489|GERD
626382|NCT00216489|anti-ulcer agents
626383|NCT00216489|proton pump inhibitor
626384|NCT00216476|Schizophrenia, relapse prevention
626385|NCT00216476|Antipsychotic agents
626386|NCT00216476|Long-acting risperidone
626387|NCT00216476|Quetiapine
626388|NCT00216476|Aripiprazole
626389|NCT00216463|LDL-cholesterol
626390|NCT00216463|apoB-100
626391|NCT00216463|apoB-48
626392|NCT00216450|rabeprazole
626393|NCT00216450|proton pump inhibitor
626394|NCT00216450|Helicobacter infections
626395|NCT00216450|Helicobacter pylori
626396|NCT00216450|H pylori
626397|NCT00216450|bacterial infections
626398|NCT00216437|Liver cancer
626399|NCT00216424|Colon cancer
626400|NCT00216424|Rectal cancer
626401|NCT00216398|acromegaly
626402|NCT00216398|growth hormone
626403|NCT00216385|Tuberculosis
626404|NCT00216385|Treatment
626405|NCT00216385|Quinolone
626406|NCT00216385|Short course chemotherapy
626407|NCT00216372|carcinomatosis
626408|NCT00216359|Treatment Experienced
626409|NCT00216333|tuberculosis
626410|NCT00216333|fixed dose combination
626411|NCT00216333|DOT
626412|NCT00216333|shot-course chemotherapy
626413|NCT00216320|electrical stimulation
626414|NCT00216294|Obsessive Compulsive Disorder
626415|NCT00216294|RG 1068 (Synthetic Human Secretin)
626416|NCT00216281|Schizophrenia
626417|NCT00216281|Clozapine
626418|NCT00216281|Atomoxetine
626419|NCT00216255|Persistent Developmental Stuttering
626420|NCT00216242|influenza
626421|NCT00216242|vaccine
626422|NCT00216242|efficacy
626423|NCT00216242|safety
626424|NCT00216242|immunogenicity
626425|NCT00216229|combined hepatitis A and B vaccine
626426|NCT00216229|hepatitis B virus
626427|NCT00216229|immunity
626428|NCT00216203|Non-Small Cell Lung Cancer
626429|NCT00216190|Sedation, ICU, Anesthesia, Dexmedetomidine, Midazolam
626430|NCT00216164|Lymphoma
626431|NCT00216151|Multiple Myeloma
626432|NCT00216151|Bisphosphonates
626433|NCT00216138|Head and Neck Cancer
626434|NCT00216125|Non-Small Cell Lung Cancer
626435|NCT00216112|Ovarian Cancer
626436|NCT00216099|Prostate Cancer
626437|NCT00216086|Rectal Cancer
626438|NCT00216073|Breast Cancer
626439|NCT00216047|Breast Cancer
626440|NCT00216034|Gastric Cancer
626441|NCT00216034|TS-1
626442|NCT00216034|PSK
626443|NCT00216034|Disease-free survival
626444|NCT00216034|Overall survival
626445|NCT00216021|Breast Cancer
626446|NCT00215995|esophageal cancer
626447|NCT00215995|esophagogastric cancer
626448|NCT00215995|gastric cancer
626449|NCT00215982|advanced
626450|NCT00215982|colon
626451|NCT00215982|rectal
626452|NCT00215969|Pre-eclampsia
626453|NCT00215969|Pregnancy
626454|NCT00215969|Hypercoagulation
626455|NCT00215969|Screening
626456|NCT00215969|Cardiovascular complications
626457|NCT00215956|Topotecan
626458|NCT00215956|Rectal Neoplasms
626459|NCT00215956|Radiosensitizing
626460|NCT00215943|hematologic malignancy
626461|NCT00215930|malignant pleural effusion
626462|NCT00215917|Schizophrenia
626463|NCT00215917|NMDA
626464|NCT00215917|D-serine
626465|NCT00215891|Treatment Experienced
626466|NCT00215852|Alferon LDO
626467|NCT00215852|Low Dose Oral Interferon
626468|NCT00215852|Alfa-n3
626469|NCT00215852|Human Leukocyte Derived
626470|NCT00215852|HIV
626471|NCT00215852|Asymptomatic HIV
626472|NCT00215852|Treatment Experienced
626473|NCT00215839|Treatment Experienced
626474|NCT00215826|SARS
626475|NCT00215826|Alferon LDO
626476|NCT00215826|Low Dose Oral Interferon ALFA-n3
626477|NCT00215826|Human Leukocyte Derived
626478|NCT00215826|Exposure to SARS
626479|NCT00215826|Possible SARS
626480|NCT00215813|Chronic Fatigue Syndrome
626481|NCT00215813|CFS
626482|NCT00215813|ME
626483|NCT00215813|Ampligen
626484|NCT00215813|poly I:poly C12U
626485|NCT00215813|Rintatolimod
626486|NCT00215800|Chronic Fatigue Syndrome
626487|NCT00215800|Myalgic Encephalomyelitis
626488|NCT00215800|CFS
626489|NCT00215800|Ampligen
626490|NCT00215800|Poly I:ploy C12U
626491|NCT00215787|Nasal polyps
626492|NCT00215787|Gastroesophageal Reflux
626493|NCT00215774|Atrial fibrillation
626494|NCT00215761|Atrial fibrillation
626495|NCT00215761|Preventive stimulation
626496|NCT00215761|Pacemaker
626497|NCT00215748|Elderly
626498|NCT00215748|Weekly
626499|NCT00215735|diabetes
626500|NCT00215735|Ulcer
626501|NCT00215735|APC
626502|NCT00215709|elderly
626503|NCT00215683|Prostate Cancer
626504|NCT00215683|Androgen ablation therapy
626505|NCT00215670|AMD
626506|NCT00215670|Macugen
626507|NCT00215670|Pharmacokinetics
626508|NCT00215670|Age-Related Macular Degeneration
626509|NCT00215670|PK
626510|NCT00215644|Esophagus
626511|NCT00215644|Gastric
626512|NCT00215644|Adenocarcinoma
626513|NCT00215644|EGFR
626514|NCT00215644|matuzumab
626515|NCT00215644|EMD 72000
626516|NCT00215644|randomized
626517|NCT00215644|Epirubicin
626518|NCT00215644|cisplatin
626519|NCT00215644|capecitabine
626520|NCT00215644|Metastatic Esophago-Gastric cancer
626521|NCT00215631|prostate cancer
626522|NCT00215631|radiotherapy
626523|NCT00215631|erectile dysfunction
626524|NCT00215631|tadalafil
626525|NCT00215605|Advanced Malignancies
626526|NCT00215605|Solid Tumor
626527|NCT00215605|Medullary Thyroid Cancer
626528|NCT00215566|IBS
626529|NCT00215566|IBS-c
626530|NCT00215540|Double-blind
626531|NCT00215540|Low Birth Weight
626532|NCT00215540|Surfactant
626533|NCT00215540|Placebo-Controlled
626534|NCT00215540|Premature Birth
626535|NCT00215527|mucopolysaccharidosis
626536|NCT00215527|Hurler-Scheie
626537|NCT00215527|Scheie
626538|NCT00215527|laronidase
626539|NCT00215527|spinal cord compression
626540|NCT00215527|central nervous system
626541|NCT00215527|enzyme replacement therapy
626542|NCT00215527|intrathecal
626543|NCT00215527|LA Biomed
626544|NCT00215514|adjuvant chemoradiation
626545|NCT00215514|GE junction
626546|NCT00215514|epirubicin
626547|NCT00215501|advanced solid tumor malignancy
626548|NCT00215501|capecitabine
626549|NCT00215501|continuous infusion
626550|NCT00215501|5-FU
626551|NCT00215501|irinotecan
626552|NCT00215501|5-fluorouracil
626553|NCT00215501|cisplatin
626554|NCT00215462|gastric adenocarcinoma
626555|NCT00215462|esophageal adenocarcinoma
626556|NCT00215462|vinorelbine
626557|NCT00215449|Chronic Obstructive Pulmonary Disease
626558|NCT00215449|COPD
626559|NCT00215449|formoterol
626560|NCT00215449|formoterol fumarate
626561|NCT00215436|Chronic Obstructive Pulmonary Disease
626562|NCT00215436|COPD
626563|NCT00215436|formoterol
626564|NCT00215423|COPD
626565|NCT00215423|Chronic Obstructive Pulmonary Disease
626566|NCT00215423|Formoterol Fumarate
626567|NCT00215423|Formoterol
626568|NCT00215410|Asthma
626569|NCT00215410|Formoterol
626570|NCT00215410|Fumarate
626571|NCT00215397|Asthma
626572|NCT00215397|Formoterol
626573|NCT00215397|Fumarate
626574|NCT00215384|COPD
626575|NCT00215384|formoterol
626576|NCT00215371|Asthma
626577|NCT00215371|Pediatric
626578|NCT00215371|Formoterol Fumarate
626579|NCT00215371|Foradil
626580|NCT00215358|Asthma
626581|NCT00215358|Formoterol
626582|NCT00215358|Fumarate
626583|NCT00215358|Foradil
626584|NCT00215345|Celecoxib
626585|NCT00215345|Taxotere
626586|NCT00215345|Hormone Refractory Prostate Cancer
626587|NCT00215332|arthroplasty
626588|NCT00215332|lumbar
626589|NCT00215332|disc
626590|NCT00215319|Degenerative disc disease at up to 2 levels (L2-S1)
626591|NCT00215306|arthroplasty
626592|NCT00215306|lumbar
626593|NCT00215306|spine
626594|NCT00215293|fusion
626595|NCT00215293|cervical
626596|NCT00215293|spine
626597|NCT00215280|Mansonella perstans
626598|NCT00215280|microfilaraemia
626599|NCT00215280|ivermectin
626600|NCT00215280|albendazole
626601|NCT00215280|Uganda
626602|NCT00215267|Schistosoma mansoni
626603|NCT00215267|hepatosplenomegaly
626604|NCT00215267|malaria
626605|NCT00215267|Uganda
626606|NCT00215254|quetiapine
626607|NCT00215254|social anxiety disorder
626608|NCT00215254|antipsychotic
626609|NCT00215254|pilot study
626610|NCT00215241|PTSD
626611|NCT00215241|sertraline
626612|NCT00215241|risperidone
626613|NCT00215241|antidepressant
626614|NCT00215241|antipsychotic
626615|NCT00215241|anxiety
626616|NCT00215241|trauma
626617|NCT00215215|Vagus Nerve Stimulation Therapy
626618|NCT00215215|Epilepsies, Partial
626619|NCT00215215|Seizures
626620|NCT00215215|Antiepileptic Drugs
626621|NCT00215215|Refractory Partial Seizures
626622|NCT00215202|Adrenocortical Cancer
626623|NCT00215202|Iressa
626624|NCT00215202|Adrenal Cancer
626625|NCT00215189|health
626626|NCT00215189|mental illness
626627|NCT00215189|fitness
626628|NCT00215176|atypical depression
626629|NCT00215176|psychostimulants
626630|NCT00215176|modafinil
626631|NCT00215163|PTSD
626632|NCT00215163|Anxiety
626633|NCT00215163|CBT
626634|NCT00215163|Exposure
626635|NCT00215163|Paroxetine
626636|NCT00215163|Paroxetine-CR
626637|NCT00215150|anxiety disorder
626638|NCT00215150|SAD
626639|NCT00215150|ziprasidone
626640|NCT00215150|sertraline
626641|NCT00215150|antidepressant
626642|NCT00215150|antipsychotic
626643|NCT00215137|OCD
626644|NCT00215137|SSRI
626645|NCT00215137|escitalopram
626646|NCT00215137|relapse
626647|NCT00215111|childhood obesity
626648|NCT00215111|weight management
626649|NCT00215111|dietary interventions
626650|NCT00215111|cardiovascular disease risk factors
626651|NCT00215098|pediatric health
626652|NCT00215098|cardiac
626653|NCT00215098|congenital heart surgery
626654|NCT00215098|post-operative chylous effusions
626655|NCT00215098|heart defects
626656|NCT00215098|children
626657|NCT00215085|pediatric health
626658|NCT00215085|cardiac
626659|NCT00215085|cardiac tumor
626660|NCT00215085|children
626661|NCT00215072|Death after heart surgery
626662|NCT00215072|surgical mortality
626663|NCT00215072|post-operative mortality
626664|NCT00215072|pediatric health
626665|NCT00215072|cardiac
626666|NCT00215059|angiogenic related growth factor
626667|NCT00215046|vinblastine
626668|NCT00215046|methotrexate
626669|NCT00215033|Epstein-Barr virus
626670|NCT00215033|pediatric health
626671|NCT00215033|cardiac
626672|NCT00215033|heart transplant
626673|NCT00215033|lymphoproliferative disease
626674|NCT00215033|post-transplant
626675|NCT00215033|pediatric transplant
626676|NCT00215020|Isoprostanes
626677|NCT00214227|patient who will undergo definitive radiotherapy
626678|NCT00214175|low grade gliomas and benign CNS lesions
626679|NCT00214981|ADHD
626680|NCT00214981|Attention Deficit/Hyperactivity Disorder
626681|NCT00214929|Pulmonary Embolism
626682|NCT00214929|Therapy
626683|NCT00214929|Home Nursing
626684|NCT00214929|Economics
626685|NCT00214916|Tight glycemic control with
626686|NCT00214916|intensive insulin treatment
626687|NCT00214916|versus conventional glycemic control
626688|NCT00214916|in infant or child in ICU
626689|NCT00214903|Postmenopause
626690|NCT00214903|HRT
626691|NCT00214890|HIV
626692|NCT00214890|nucleoside pharmacology
626693|NCT00214890|drug-drug interaction
626694|NCT00214890|Treatment Naive
626695|NCT00214890|Drug resistance
626696|NCT00214890|Drug pharmacokinetics
626697|NCT00214877|methylene blue for cognitive dysfunction in bipolar disorder
626698|NCT00214864|Metastatic Breast Cancer
626699|NCT00214864|Taxotere (docetaxel)
626700|NCT00214864|Xeloda (capecitabine)
626701|NCT00214851|Familial Cold Urticaria
626702|NCT00214851|Kineret (anakinra)
626703|NCT00214851|Interleukin 1 beta
626704|NCT00214851|C-Reactive Protein
626705|NCT00214851|Serum Amyloid A protein
626706|NCT00214838|cancer, atiprimod
626707|NCT00214812|HIV Seronegativity
626708|NCT00214812|HIV
626709|NCT00214786|Diabetes Mellitus
626710|NCT00214786|Hypoglycemia
626711|NCT00214786|Hyperglycemia
626712|NCT00214760|Hip prosthesis
626713|NCT00214760|Centralizer
626714|NCT00214760|Uncemented
626715|NCT00214747|HIV Seronegativity
626716|NCT00214747|HIV
626717|NCT00214708|Tuberculosis
626718|NCT00214708|Screening
626719|NCT00214708|Heaf
626720|NCT00214708|BCG
626721|NCT00214682|Depression
626722|NCT00214682|Cognition
626723|NCT00214682|Depressive disorder
626724|NCT00214682|Mental health literacy
626725|NCT00214682|Older adults
626726|NCT00214682|Randomzed controlled trial
626727|NCT00214669|ethnicity
626728|NCT00214669|primary care
626729|NCT00214669|education
626730|NCT00214656|Cardiac surgical procedures
626731|NCT00214656|Surgical blood loss
626732|NCT00214656|Surgical haemostasis
626733|NCT00214656|Factor VIIa
626734|NCT00214656|Anaesthesia
626735|NCT00214643|Malaria
626736|NCT00214643|Fosmidomycin
626737|NCT00214643|Clindamycin
626738|NCT00214643|Chemotherapy
626739|NCT00214643|Gabon
626740|NCT00214617|hypercholesterolemia
626741|NCT00214617|HMG CoA Reductase Inhibtors
626742|NCT00214617|tracer kinetics
626743|NCT00214617|Apolipoproteins
626744|NCT00214591|Type 2 diabetes
626745|NCT00214578|Schizophrenia
626746|NCT00214565|Type 2 diabetes
626747|NCT00214552|GERD
626748|NCT00214552|Gastroesophageal reflux disease
626749|NCT00214552|Asthma symptoms
626750|NCT00214539|Asthma
626751|NCT00214539|Bronchial Thermoplasty
626752|NCT00214526|Asthma
626753|NCT00214526|Bronchial Thermoplasty
626754|NCT00214526|Airway Hyperresponsiveness
626755|NCT00214487|Myopia Progression
626756|NCT00214487|Myopia Control
626757|NCT00214487|Bifocal Contact Lenses
626758|NCT00214487|Esophoria
626759|NCT00214487|Fixation Disparity
626760|NCT00214474|Disease Management
626761|NCT00214474|Health Literacy
626762|NCT00214474|Telephone Care
626763|NCT00214474|Group Medical Visits
626764|NCT00214474|Type 2 Diabetes
626765|NCT00214474|Access to Care
626766|NCT00214474|Technology
626767|NCT00214474|Language Barriers
626768|NCT00214461|Clostridium difficile
626769|NCT00214448|Multiple genetic conditions will be studied
626770|NCT00214435|HIV infection
626771|NCT00214435|AIDS
626772|NCT00214435|Adherence
626773|NCT00214435|MEMS caps
626774|NCT00214435|Treatment Experienced
626775|NCT00214422|Prostate
626776|NCT00214422|Radiation
626777|NCT00214422|Cancer
626778|NCT00214422|Prostate Cancer
626779|NCT00214383|pediatric asthma
626780|NCT00214370|pediatric
626781|NCT00214370|acute leukemia/lymphoma
626782|NCT00214344|dying
626783|NCT00214045|Bladder cancer surveillance
626784|NCT00214045|Voiding dysfunction
626785|NCT00214045|Cystoscopy
626786|NCT00214032|lymphedema of the arm in breast cancer survivors
626787|NCT00213980|bone mineral density
626788|NCT00213980|postmenopausal women
626789|NCT00213967|Influenza vaccine
626790|NCT00213954|Nerve block anaesthesia
626791|NCT00213954|ultrasound-guidance
626792|NCT00213941|transient tachypnoea of the newborn
626793|NCT00213941|surfactant deficiency
626794|NCT00213941|persistant pulmonary hypertension of the neonate
626795|NCT00213941|lung maturity tests
626796|NCT00213915|L-arginine
626797|NCT00213915|exercise capacity
626798|NCT00213915|renal function
626799|NCT00213915|nitric oxide
626800|NCT00213915|exercise capacity using a maximal exercise test
626801|NCT00213915|urinary elimination of a saline load using blood and urinary samples
626802|NCT00213902|Heart failure
626803|NCT00213902|Diastolic
626804|NCT00213902|functionClonidine
626805|NCT00213902|Left ventricular diastolic dysfunction with preserved ejection fraction
626806|NCT00213889|Facial clefting
626807|NCT00213889|twist
626808|NCT00213889|craniofacial development genes
626809|NCT00213889|Human cleft lip and palate
626810|NCT00213889|cleft lip and palate
626811|NCT00213876|Brain tumours
626812|NCT00213876|oligodendrogliomas
626813|NCT00213876|allelotyping
626814|NCT00213876|SAGE
626815|NCT00213876|Presence of molecular abnormalities statistically linked to survival or response to chemotherapy
626816|NCT00213863|porous titanium implants
626817|NCT00213863|thyroplasty
626818|NCT00213863|vocal cord paralysis
626819|NCT00213863|male or female more than 18 years old
626820|NCT00213850|Interrupter technique
626821|NCT00213850|Respiratory resistance
626822|NCT00213850|Normal adults
626823|NCT00213837|porous titanium implants
626824|NCT00213837|thyroplasty
626825|NCT00213837|vocal cord paralysis
626826|NCT00213837|male or female more than 18 years old
626827|NCT00213824|Amyotrophic lateral sclerosis
626828|NCT00213824|Nogo gene
626829|NCT00213824|reticulon genes
626830|NCT00213811|Bardet-Biedl syndrome, retinitis pigmentosa, obesity, genes
626831|NCT00213798|Lung cancer
626832|NCT00213798|plasma DNA
626833|NCT00213798|allelotyping
626834|NCT00213798|follow-up
626835|NCT00213798|Prospective Study
626836|NCT00213798|Non-Small Cell Lung Cancer
626837|NCT00213798|Small Cell Lung Cancer
626838|NCT00213785|AreET1
626839|NCT00213785|ANP
626840|NCT00213785|BNP pronostic markers of stroke
626841|NCT00213772|Porphyria cutanea tarda
626842|NCT00213772|hepatitis C
626843|NCT00213772|hemochromatosis
626844|NCT00213759|neutropenia
626845|NCT00213759|prematurity
626846|NCT00213759|nosocomial infection
626847|NCT00213759|G-CSF
626848|NCT00213746|Coronary Arteriosclerosis
626849|NCT00213746|Heart Failure, Congestive
626850|NCT00213746|Myocardial Infarction
626851|NCT00213746|Myocardial Revascularization
626852|NCT00213746|Tomography, Emission-Computed, Single-Photon
626853|NCT00213746|Dobutamine
626854|NCT00213746|Myocardial Stunning
626855|NCT00213746|Myocardial Hibernation
626856|NCT00213733|Lung cancer patients
626857|NCT00213733|non-small cell lung cancer
626858|NCT00213733|molecular marker
626859|NCT00213733|lymph node completed resected
626860|NCT00213733|Lung cancer samples and paired lymph node resected
626861|NCT00213720|Hyperthyroidism
626862|NCT00213720|atrial fibrillation
626863|NCT00213720|quality of life
626864|NCT00213720|radioiodine treatment
626865|NCT00213707|Dendritic cells
626866|NCT00213707|liver transplantation
626867|NCT00213707|hepatitis C virus
626868|NCT00213707|quasispecies
626869|NCT00213707|virological markers
626870|NCT00213707|biochemical markers
626871|NCT00213707|immunological markers
626872|NCT00213707|clinical markers
626873|NCT00213304|organ transplantation
626874|NCT00213304|immunosuppression
626875|NCT00213304|vaccine
626876|NCT00213304|varicella
626877|NCT00213304|pediatrics
626878|NCT00213291|chronic kidney failure
626879|NCT00213291|darbepoetin
626880|NCT00213291|pediatrics
626881|NCT00213291|anemia
626882|NCT00213278|glioma
626883|NCT00213278|brain tumour
626884|NCT00213278|cancer
626885|NCT00213278|pediatrics
626886|NCT00213278|vinblastine sulfate
626887|NCT00213265|organ transplantation
626888|NCT00213265|immunosuppression
626889|NCT00213265|vaccine
626890|NCT00213265|pneumococcal conjugate vaccine
626891|NCT00213265|pediatrics
626892|NCT00213252|asthma, randomized trial, pediatrics
626893|NCT00213239|spinal puncture
626894|NCT00213239|remifentanil
626895|NCT00213239|propofol
626896|NCT00213239|anesthesia
626897|NCT00213239|dose finding
626898|NCT00213239|pediatrics
626899|NCT00213226|bronchiolitis
626900|NCT00213226|pediatrics
626901|NCT00213226|corticosteroids
626902|NCT00213213|sucrose
626903|NCT00213213|analgesia
626904|NCT00213213|pain
626905|NCT00213213|neonates
626906|NCT00213213|diabetes
626907|NCT00213200|pain
626908|NCT00213200|analgesia
626909|NCT00213200|morphine
626910|NCT00213200|amethocaine
626911|NCT00213200|neonate
626912|NCT00213187|Juvenile Rheumatoid Arthritis,
626913|NCT00213187|Randomized Control Trial,
626914|NCT00213187|attention placebo,
626915|NCT00213187|exercise testing,
626916|NCT00213187|aerobics,
626917|NCT00213187|Qi Gong,
626918|NCT00213187|exercise video,
626919|NCT00213187|activities of daily living,
626920|NCT00213187|quality of life,
626921|NCT00213187|economy of walking,
626922|NCT00213187|fitness
626923|NCT00213187|pediatrics
626924|NCT00213174|pediatrics
626925|NCT00213174|injury
626926|NCT00213174|arm fractures
626927|NCT00213174|trauma
626928|NCT00213174|playground surfaces
626929|NCT00213174|fractures
626930|NCT00213161|anemia
626931|NCT00213161|iron deficiency
626932|NCT00213161|iron drops
626933|NCT00213161|iron supplement
626934|NCT00213161|malnutrition
626935|NCT00213161|pediatrics
626936|NCT00211302|Cognition
626937|NCT00211302|Schizophrenia
626938|NCT00211302|Schizoaffective disorder
626939|NCT00211289|Educational Interventions
626940|NCT00211289|Heart Failure
626941|NCT00211289|Compliance
626942|NCT00213681|Pulmonary edema, respiratory failure, pressure support ventilation, continuous positive pressure
626943|NCT00213668|glutamine
626944|NCT00213668|premature neonate
626945|NCT00213668|gastric emptying
626946|NCT00213642|Technetium Tc 99m Mertiatide
626947|NCT00213642|Radionuclide Imaging
626948|NCT00213642|Cisplatin
626949|NCT00213642|Kidney failure
626950|NCT00213642|Drug Toxicity
626951|NCT00213642|Cancer
626952|NCT00213629|myositis
626953|NCT00213629|cDNA arrays
626954|NCT00213629|Genes, T-Cell Receptor beta
626955|NCT00213616|bilateral vocal cord paralysis
626956|NCT00213616|reinnervation
626957|NCT00213616|phrenic nerve
626958|NCT00213603|precancerous lesions
626959|NCT00213603|Lung cancer
626960|NCT00213603|Follow-up
626961|NCT00213603|Randomized study
626962|NCT00213603|Autofluorescence endoscopy
626963|NCT00213603|precancerous conditions
626964|NCT00213577|overactive neurogenic bladder
626965|NCT00213499|Mechanical ventilation
626966|NCT00213499|Weaning
626967|NCT00213499|Noninvasive ventilation
626968|NCT00213499|Acute on chronic respiratory failure
626969|NCT00213473|acquired haemophilia
626970|NCT00213434|prospective
626971|NCT00213434|randomized
626972|NCT00213434|polysomnography
626973|NCT00213434|orthodontic appliance, removable
626974|NCT00213408|Arrhythmia
626975|NCT00213408|atrial flutter
626976|NCT00213408|catheter ablation
626977|NCT00213395|Noninvasive ventilation
626978|NCT00213395|Acute hypercapnic respiratory failure
626979|NCT00213395|Cephalic mask
626980|NCT00213395|Facial Mask
626981|NCT00213382|swallowing
626982|NCT00213382|ventilation
626983|NCT00213382|pressure
626984|NCT00213382|EMG
626985|NCT00213382|cortical magnetic stimulation
626986|NCT00213382|Brain Mapping
626987|NCT00213369|aspiration
626988|NCT00213369|stroke
626989|NCT00213369|motor evoked potential
626990|NCT00213369|cortical evoked potential
626991|NCT00213369|neuromodulation
626992|NCT00213356|spinal cord injuries - anal sphincter - evoked potentials
626993|NCT00213343|aspiration
626994|NCT00213343|phrenic nerve
626995|NCT00213343|magnetic stimulation
626996|NCT00213330|cerebral activity
626997|NCT00213330|rectal distension
626998|NCT00213330|colitis ulcerative
626999|NCT00213330|irritable bowel syndrome
627000|NCT00213330|magnetic resonance imaging
627001|NCT00213317|sacral magnetic stimulation
627002|NCT00213317|fecal incontinence
627003|NCT00213317|constipation
627004|NCT00213122|alpha-glucosidase inhibitor,Insulin
627005|NCT00213109|alpha-glucosidase inhibitor,Insulin
627006|NCT00213096|Contraceptive agents
627007|NCT00213096|female
627008|NCT00213083|Microbicide
627009|NCT00213083|HIV
627010|NCT00213083|AIDS
627011|NCT00213083|STIs
627012|NCT00213083|STDs
627013|NCT00213083|Efficacy
627014|NCT00213083|HSV
627015|NCT00213083|Women
627016|NCT00213083|South Africa
627017|NCT00213083|seroconversion
627018|NCT00213083|condom
627019|NCT00213083|safe-sex
627020|NCT00213083|vaginal intercourse
627021|NCT00213083|prevention
627022|NCT00213083|HIV Seronegativity
627023|NCT00213070|alpha-glucosidase inhibitor,Insulin
627024|NCT00213057|Microbicides
627025|NCT00213057|HIV prevention
627026|NCT00213057|sexually transmitted infections
627027|NCT00213057|carrageenan
627028|NCT00213057|sero-concordant couples
627029|NCT00213057|HIV Seronegativity
627030|NCT00213057|HIV
627031|NCT00213044|Microbicides
627032|NCT00213044|HIV prevention
627033|NCT00213044|HIV-positive women
627034|NCT00213044|safety
627035|NCT00213044|carrageenan
627036|NCT00213044|HIV
627037|NCT00213031|microbicides
627038|NCT00213031|HIV prevention
627039|NCT00213031|sexually transmitted infections
627040|NCT00213031|female-initiated protection
627041|NCT00213031|carrageenan
627042|NCT00213031|expanded safety trial
627043|NCT00213031|HIV Seronegativity
627044|NCT00213031|HIV
627045|NCT00213018|microbicides
627046|NCT00213018|HIV prevention
627047|NCT00213018|sexually transmitted infections
627048|NCT00213018|female-initiated protection
627049|NCT00213018|carrageenan
627050|NCT00213018|expanded safety trial
627051|NCT00213018|HIV Seronegativity
627052|NCT00213018|HIV
627053|NCT00213005|Microbicides
627054|NCT00213005|HIV prevention
627055|NCT00213005|HIV positive
627056|NCT00213005|carrageenan
627057|NCT00213005|safety trial
627058|NCT00213005|Treatment Experienced
627059|NCT00213005|HIV
627060|NCT00212992|defibrillation
627061|NCT00212992|ventricular fibrillation
627062|NCT00212992|heart arrest
627063|NCT00212979|glomerular filtration rate
627064|NCT00212979|cystatin C
627065|NCT00212979|creatinine
627066|NCT00211588|cognition
627067|NCT00211562|weight gain
627068|NCT00211562|weight gain supplementation
627069|NCT00211562|antioxidants
627070|NCT00211562|olanzapine
627071|NCT00211549|Osteoarthritis
627072|NCT00211536|Diabetes
627073|NCT00211536|Implantable Insulin Pump
627074|NCT00211536|Intraperitoneal Insulin Delivery
627075|NCT00211523|acne
627076|NCT00211523|acne vulgaris
627077|NCT00211523|MBI 226
627078|NCT00211523|Propionibacterium acnes
627079|NCT00211523|lesion counts
627080|NCT00211523|lesions
627081|NCT00211523|inflammatory
627082|NCT00211523|non-inflammatory
627083|NCT00211523|topical
627084|NCT00211510|Diabetes
627085|NCT00211510|Continuous Glucose Monitoring
627086|NCT00211510|Glycemic Control
627087|NCT00211497|acne vulgaris
627088|NCT00211497|acne
627089|NCT00211497|Propionibacterium acnes
627090|NCT00211497|topical
627091|NCT00211497|inflammatory
627092|NCT00211497|non-inflammatory
627093|NCT00211497|lesion counts
627094|NCT00211497|lesions
627095|NCT00211458|Age-Related Macular Degeneration
627096|NCT00211419|Exudative Age-Related Macular Degeneration
627097|NCT00211419|AMD
627098|NCT00211380|cognition
627099|NCT00211380|schizophrenia
627100|NCT00211380|schizoaffective disorder
627101|NCT00211367|Radiation Retinopathy
627102|NCT00212966|psychosocial
627103|NCT00212953|Chest Pain,
627104|NCT00212953|Shortness of breath,
627105|NCT00212953|Injury,
627106|NCT00212953|Trauma
627107|NCT00212940|Treatment Naive
627108|NCT00212940|HIV
627109|NCT00212901|Diabetes
627110|NCT00212901|Proteinuria
627111|NCT00212901|Angiotensin converting enzyme inhibitors
627112|NCT00212901|Angiotensin receptor antagonists
627113|NCT00212888|HIV
627114|NCT00212888|Vaccination
627115|NCT00212875|Chronic Kidney disease
627116|NCT00212875|anemia
627117|NCT00212862|Anemia
627118|NCT00212862|Cancer
627119|NCT00212862|Epoetin alfa
627120|NCT00212862|Darbepoetin alfa
627121|NCT00212862|Registry
627122|NCT00212849|Articular Cartilage Lesions
627123|NCT00212849|Patellar lesions
627124|NCT00212849|Trochlear lesions
627125|NCT00212849|Patellofemoral joint
627126|NCT00212849|Carticel
627127|NCT00212849|Autologous Chondrocyte Implantation
627128|NCT00212823|Migraine
627129|NCT00212810|Migraine
627130|NCT00212810|Headache
627131|NCT00212810|Migraine Headache
627132|NCT00212758|Short stature
627133|NCT00212758|children
627134|NCT00212758|kidney failure, chronic
627135|NCT00212758|Growth
627136|NCT00212745|Behavior Therapy
627137|NCT00212745|Relaxation Techniques
627138|NCT00212732|ONO-8025, KRP-197, overactive bladder, antimuscarinic
627139|NCT00212719|ONO-5920, osteoporosis, bisphosphonate
627140|NCT00212706|ONO-8025, KRP-197, overactive bladder, antimuscarinic
627141|NCT00212693|ONO-2506PO, Parkinson's disease
627142|NCT00212680|ONO-1101,Landiolol Hydrochloride, Postoperative, Supraventricular Tachyarrhythmia
627143|NCT00212667|ONO-5920, osteoporosis, bisphosphonate
627144|NCT00212654|ONO-1101
627145|NCT00212654|Landiolol Hydrochloride
627146|NCT00212654|Postoperative
627147|NCT00212654|supraventricular tachyarrhythmia
627148|NCT00212628|ONO-5920
627149|NCT00212628|osteoporosis
627150|NCT00212628|bisphosphonate
627151|NCT00212615|Colorectal neoplasm
627152|NCT00212615|Capecitabine (Xeloda)
627153|NCT00212615|Oxaliplatin (Eloxatin)
627154|NCT00212615|Advanced disease
627155|NCT00212615|Metastatic disease
627156|NCT00212615|First-line treatment
627157|NCT00212615|Phase II study
627158|NCT00212602|ONO-7436, Aprepitant, Vomiting, Nausea
627159|NCT00212589|Patients preference
627160|NCT00212589|Colorectal cancer
627161|NCT00212589|Capecitabine
627162|NCT00212589|Fluorouracil + folinic acid
627163|NCT00212589|Cross-over study
627164|NCT00212576|Child development
627165|NCT00212576|Language Development
627166|NCT00212576|Parenting
627167|NCT00212537|Asthma and normal
627168|NCT00212485|Hemophilia
627169|NCT00212485|Factor Deficiency
627170|NCT00212485|synovitis
627171|NCT00212485|sonogram
627172|NCT00212459|Bleeding logs
627173|NCT00212459|Factor Infusions
627174|NCT00212446|Tocolysis
627175|NCT00212446|Electrical Pacemaker
627176|NCT00212433|colorectal neoplasia
627177|NCT00212433|CT colonography
627178|NCT00212433|faecal tagging
627179|NCT00212420|fistula; enterocutaneous; nutrition;enteral; parenteral; TPN
627180|NCT00212407|Cord blood transplantation
627181|NCT00212407|bone marrow transplantation
627182|NCT00212394|Tourniquet
627183|NCT00212394|paresis
627184|NCT00212381|cervical dysplasia, diindolylmethane, pap smear
627185|NCT00212329|Type 1 Diabetes
627186|NCT00212329|Juvenile Onset Diabetes
627187|NCT00212329|Insulin Dependent Diabetes
627188|NCT00212329|T1D
627189|NCT00212316|Huntington's Disease
627190|NCT00212316|phenylbutyrate
627191|NCT00212316|HDAC inhibitors
627192|NCT00212316|transcription
627193|NCT00212303|type 2 diabetes
627194|NCT00212303|hypertension
627195|NCT00212303|exercise training
627196|NCT00212303|cardiac, peripheral
627197|NCT00212303|body composition
627198|NCT00212303|physical fitness
627199|NCT00212303|inflammation
627200|NCT00212290|impaired glucose tolerance
627201|NCT00211341|Pregnancy
627202|NCT00211341|Mortality
627203|NCT00211341|Maternal
627204|NCT00211341|Vitamin A
627205|NCT00212264|urinary incontinence
627206|NCT00212264|therapy
627207|NCT00212264|prostatectomy
627208|NCT00212264|prostate cancer
627209|NCT00212251|obesity
627210|NCT00212251|postpartum period
627211|NCT00212251|exercise
627212|NCT00212251|diet
627213|NCT00212251|motivation
627214|NCT00212238|obesity
627215|NCT00212238|weight loss
627216|NCT00212238|Internet
627217|NCT00212238|cognitive behavior therapy
627218|NCT00212238|computer assisted patient care
627219|NCT00212238|human therapy evaluation
627220|NCT00212238|physical activity
627221|NCT00212238|clinical trial
627222|NCT00212238|nutrient intake activity
627223|NCT00212238|outcomes research
627224|NCT00212238|personal log /diary
627225|NCT00212238|reinforcer
627226|NCT00212238|self care
627227|NCT00212238|social support network
627228|NCT00212238|weight control
627229|NCT00212238|behavioral /social science research tag
627230|NCT00212238|clinical research
627231|NCT00212238|human subject
627232|NCT00212238|questionnaire
627233|NCT00212225|gastric disease
627234|NCT00212225|H. pylori
627235|NCT00212225|children
627236|NCT00212225|Helicobacter pylori
627237|NCT00212225|child
627238|NCT00212225|epidemiology
627239|NCT00212212|selenium supplements
627240|NCT00212212|selenate
627241|NCT00212212|selenomethionine
627242|NCT00212212|biomarkers
627243|NCT00212212|plasma selenium concentration
627244|NCT00212212|plasma glutathione peroxidase
627245|NCT00212212|selenoprotein P
627246|NCT00212199|Obesity Treatment
627247|NCT00212199|Effectiveness of weight management treatment
627248|NCT00212199|Counseling for weight management
627249|NCT00212173|Adolescent
627250|NCT00212173|Weight Management
627251|NCT00212173|Obesity Treatment
627252|NCT00212173|Behavioral Treatment
627253|NCT00212147|cobalamin
627254|NCT00212147|anesthesia
627255|NCT00212147|cognition
627256|NCT00212134|cataract surgery
627257|NCT00212134|intraocular lens
627258|NCT00212134|contact lens
627259|NCT00212134|infants
627260|NCT00212134|aphakia
627261|NCT00212121|breast cancer
627262|NCT00212121|radiotherapy
627263|NCT00212121|microarrays
627264|NCT00212108|celecoxib, NPC, gefitinib
627265|NCT00212095|breast cancer
627266|NCT00212095|docetaxel
627267|NCT00212095|gene expression
627268|NCT00212095|proteomics
627269|NCT00212082|breast cancer
627270|NCT00212082|chemotherapy response
627271|NCT00212082|gene expression profiles
627272|NCT00212082|proteomics
627273|NCT00212069|breast cancer
627274|NCT00212069|serum proteomics
627275|NCT00212069|gemcitabine
627276|NCT00212069|carboplatin
627277|NCT00212069|chemotherapy sensitivity
627278|NCT00212056|Acute myocardial infarction
627279|NCT00212056|Atrial natriuretic peptide
627280|NCT00212056|Data mining
627281|NCT00212056|Randomized clinical trial
627282|NCT00212056|SNPs
627283|NCT00212043|randomised phase II trial gemcitabine and carboplatin
627284|NCT00212030|Acute myocardial infarction
627285|NCT00212030|Data mining
627286|NCT00212030|Nicorandil
627287|NCT00212030|Randomized clinical trial
627288|NCT00212030|SNPs
627289|NCT00212017|IGT
627290|NCT00212017|Myocardial Infarction
627291|NCT00212017|alpha-glucosidase inhibitor
627292|NCT00212017|re-infarction prevention
627293|NCT00212004|diabetes mellitus
627294|NCT00212004|myocardial infarction
627295|NCT00212004|pioglitazone
627296|NCT00211978|PhosLo (Calcium acetate)
627297|NCT00211965|Knee replacement surgery
627298|NCT00211965|hip replacement surgery
627299|NCT00211965|nosocomial infections
627300|NCT00211965|Arthroplasty
627301|NCT00211939|PhosLo (Calcium acetate)
627302|NCT00211939|Renagel (sevelamer, polyallylamine HCL)
627303|NCT00211939|kidney dialysis
627304|NCT00211939|hyperphosphatemia
627305|NCT00211939|Kidney failure
627306|NCT00211926|vaccine
627307|NCT00211926|Staphylococcus aureus vaccine
627308|NCT00211887|Multiple Sclerosis
627309|NCT00211887|Clinical trial
627310|NCT00211887|treatment trial
627311|NCT00211887|autoimmune disease
627312|NCT00211887|Relapsing Remitting
627313|NCT00211887|MS Treatment
627314|NCT00211887|interferon beta-1a
627315|NCT00211887|glatiramer acetate
627316|NCT00211874|Congestive heart failure
627317|NCT00211874|nurse management
627318|NCT00211874|effectiveness trial
627319|NCT00211874|quality improvement
627320|NCT00211874|minority communities
627321|NCT00211874|disease management
627322|NCT00211848|Chemical Compounds-drugs
627323|NCT00211848|Human Subjects- adults
627324|NCT00211848|Gastrointestinal System-liver
627325|NCT00211848|Pathology
627326|NCT00211835|TBI
627327|NCT00211835|traumatic brain injury
627328|NCT00211835|depression
627329|NCT00211835|cognitive behavioral therapy
627330|NCT00211835|supportive psychotherapy
627331|NCT00211835|psychotherapy
627332|NCT00211822|Pathological Gambling
627333|NCT00211822|Obsessive-Compulsive Disorder
627334|NCT00211822|Go No-go
627335|NCT00211822|Monetary incentives delay
627336|NCT00211822|fMRI
627337|NCT00211809|Body Dysmorphic Disorder
627338|NCT00211809|SRIs
627339|NCT00211809|Cognitive Behavioral Therapy
627340|NCT00211796|autism
627341|NCT00211796|divalproex sodium ER
627342|NCT00211796|aggression
627343|NCT00211796|irritability
627344|NCT00211783|autism
627345|NCT00211783|fMRI
627346|NCT00211783|response inhibition
627347|NCT00211783|face processing
627348|NCT00211783|linguistic processing
627349|NCT00211770|Autism
627350|NCT00211770|Functional Behavioral Assessment
627351|NCT00211770|Citalopram
627352|NCT00211757|autism
627353|NCT00211757|aggression
627354|NCT00211757|irritability
627355|NCT00211757|divalproex sodium
627356|NCT00211744|OCD
627357|NCT00211744|Obsessive-Compulsive Disorder
627358|NCT00211744|OCD treatment
627359|NCT00211731|Acute stroke
627360|NCT00211731|recurrent stroke preventive measures
627361|NCT00211731|racial disparities
627362|NCT00211718|shoulder pain
627363|NCT00211718|arthritis
627364|NCT00211718|intra-articular botulinum toxin a
627365|NCT00211718|joint pain
627366|NCT00211705|Hyperlipidemia
627367|NCT00211705|coronary heart disease
627368|NCT00211705|prevention
627369|NCT00211705|stroke
627370|NCT00211705|pravastatin
627371|NCT00211692|Hepatitis C
627372|NCT00211692|interferon alfa
627373|NCT00211692|ribavirin
627374|NCT00211692|interferon alfacon-1
627375|NCT00211692|antiviral therapy
627376|NCT00211679|Joint pain
627377|NCT00211679|Knee Pain
627378|NCT00211679|Arthritis
627379|NCT00211679|Intra-articular Botulinum Toxin Type A
627380|NCT00211666|Hypertension
627381|NCT00211666|blood pressure
627382|NCT00211666|self management
627383|NCT00211666|nurse management
627384|NCT00211666|racial disparities
627385|NCT00211666|cardiovascular disease
627386|NCT00211653|Kidney failure
627387|NCT00211653|Thoracic surgery
627388|NCT00211653|Acetylcysteine
627389|NCT00211614|Obstructive Sleep Apnea
627390|NCT00211614|Gastroesophageal Reflux
627391|NCT00211614|Proton Pump Inhibitor
627392|NCT00211614|Lansoprazole (Prevacid)
627393|NCT00211614|Quality of Life
627394|NCT00211263|Bipolar Disorder
627395|NCT00211250|Depakote Er and Valproic Acid
627396|NCT00211237|Balloon Kyphoplasty
627397|NCT00211237|Cancer
627398|NCT00211237|Vertebral Compression Fracture
627399|NCT00211237|Back Pain
627400|NCT00211237|Spine
627401|NCT00211224|multiple system atrophy
627402|NCT00211224|progressive supranuclear palsy
627403|NCT00211224|riluzole
627404|NCT00211224|MSA
627405|NCT00211224|PSP
627406|NCT00211211|Osteopenia
627407|NCT00211211|Osteoporosis
627408|NCT00211211|Multiple Myeloma
627409|NCT00211211|Osteolytic Metastatic Tumors
627410|NCT00211211|Vertebral Compression Fracture
627411|NCT00211211|Back Pain
627412|NCT00211211|Spine
627413|NCT00211198|Cutaneous
627414|NCT00211198|T-cell lymphoma
627415|NCT00211198|ONTAK
627416|NCT00211198|CD25
627417|NCT00211172|Acute Myocardial Infarction (AMI)
627418|NCT00211172|Heart Attack
627419|NCT00211172|Adherence
627420|NCT00211172|Beta-blocker
627421|NCT00211172|Behavior change
627422|NCT00211159|Alzheimer's disease
627423|NCT00211159|Omega-3 fatty acid
627424|NCT00211159|Dietary supplementation
627425|NCT00211159|Cognition
627426|NCT00211159|Safety
627427|NCT00211146|Anemia, erythropoetin, PROCRIT, deep vein thrombosis, thrombovascular event
627428|NCT00211133|Anemia
627429|NCT00211133|Breast Cancer
627430|NCT00211133|Breast Tumor
627431|NCT00211133|Quality of Life
627432|NCT00211133|Women
627433|NCT00211133|Female
627434|NCT00211133|Chemotherapy
627435|NCT00211133|Hemoglobin
627436|NCT00211133|Survival
627437|NCT00211133|Epoetin
627438|NCT00211133|Epoetin alfa
627439|NCT00211133|erythropoietin
627440|NCT00211120|Anemia
627441|NCT00211120|Low Blood Count
627442|NCT00211120|Chronic Kidney Failure
627443|NCT00211120|Chronic Kidney Disease
627444|NCT00211107|dapoxetine
627445|NCT00211107|rapid ejaculation
627446|NCT00211107|premature ejaculation
627447|NCT00211107|ejaculation
627448|NCT00211107|sexual dysfunction
627449|NCT00211107|orgasmic disorder
627450|NCT00211107|sexual intercourse
627451|NCT00211094|dapoxetine
627452|NCT00211094|premature ejaculation
627453|NCT00211094|ejaculation
627454|NCT00211094|sexual dysfunction
627455|NCT00211094|orgasmic disorder
627456|NCT00211094|sexual intercourse
627457|NCT00211081|Congenital Heart Disease
627458|NCT00211081|Spironolactone
627459|NCT00211081|>17 years old
627460|NCT00211081|undergone Fontan procedure
627461|NCT00211081|endothelial function
627462|NCT00211068|Pure red-cell aplasia
627463|NCT00211068|Chronic kidney failure
627464|NCT00211068|Epoetin alfa (Eprex)
627465|NCT00211068|Erythropoietin
627466|NCT00211068|Kidney disease
627467|NCT00211068|Anemia
627468|NCT00211055|Critically Ill
627469|NCT00211055|Intensive Care Unit
627470|NCT00211055|Blood transfusion
627471|NCT00211055|Blood loss
627472|NCT00211055|Pediatric
627473|NCT00211055|Children
627474|NCT00211055|Anemia, Pediatric Intensive Care Unit
627475|NCT00211055|Hemoglobin
627476|NCT00211055|Transfusion
627477|NCT00211042|Pure red-cell aplasia
627478|NCT00211042|Anemia
627479|NCT00211042|Red blood cells
627480|NCT00211042|Epoetin alfa (Eprex)
627481|NCT00211042|Anti-erythropoietin antibodies
627482|NCT00211042|Recombinant human erythropoietin
627483|NCT00211029|Anemia, Hemoglobin, Red Blood Cells, Epoetin alfa
627484|NCT00211029|Epoetin
627485|NCT00211029|erythropoietin
627486|NCT00211029|Red Cell Aplasia, Pure Red Cell Aplasia
627487|NCT00211029|Chronic Renal Failure
627488|NCT00211029|Kidney Failure
627489|NCT00211016|Ventilator-Associated Pneumonia
627490|NCT00211003|Hospital-Acquired Pneumonia
627491|NCT00211003|Mechanical Ventilation
627492|NCT00210990|Complicated Urinary Tract Infections
627493|NCT00210990|Pyelonephritis
627494|NCT00210977|Anemia
627495|NCT00210977|Erythropoietin
627496|NCT00210977|Epoetin alfa
627497|NCT00210977|Erythropoietin receptor agonist (ERA) therapy
627498|NCT00210977|Anti-erythropoietin antibodies (anti-EPO Ab)
627499|NCT00210977|Recombinant human erythropoietin
627500|NCT00210977|Pure red cell aplasia
627501|NCT00210977|Darbepoetin
627502|NCT00210964|Ceftobiprole medocaril
627503|NCT00210964|Nosocominal Pneumonia
627504|NCT00210964|Ventilator-Associated Pneumonia
627505|NCT00210964|Cephalosporins
627506|NCT00210964|Methicillin-Resistant Staphylococcus Aureus
627507|NCT00210951|Epoetin alfa
627508|NCT00210951|Erythropoietin
627509|NCT00210951|Red Cell Aplasia, Pure
627510|NCT00210951|Chronic Renal Failure
627511|NCT00210938|Complicated Intra-Abdominal Infections
627512|NCT00210938|Appendicitis
627513|NCT00210938|Cholecystitis
627514|NCT00210938|Peritonitis
627515|NCT00210925|alcoholism
627516|NCT00210925|alcohol dependence
627517|NCT00210925|medication treatment.
627518|NCT00210912|prevention
627519|NCT00210912|Migraine
627520|NCT00210912|chronic
627521|NCT00210912|headache
627522|NCT00210899|Complicated Skin Infections
627523|NCT00210899|Infectious Skin Diseases
627524|NCT00210899|Bacterial Skin Diseases
627525|NCT00210899|Staphylococcal Skin Infections
627526|NCT00210899|Cephalosporin
627527|NCT00210886|complicated urinary tract infection
627528|NCT00210886|urinary tract infection
627529|NCT00210886|acute pyelonephritis
627530|NCT00210886|pyelonephritis
627531|NCT00210886|kidney infection
627532|NCT00210886|bladder infection
627533|NCT00210873|Migraine
627534|NCT00210873|headache
627535|NCT00210873|chronic
627536|NCT00210873|prevention
627537|NCT00210860|chronic
627538|NCT00210860|headache
627539|NCT00210860|prevention
627540|NCT00210860|Migraine
627541|NCT00210847|peripheral neuropathy
627542|NCT00210847|Diabetic neuropathy
627543|NCT00210847|pain
627544|NCT00210847|diabetes
627545|NCT00210847|extremities
627546|NCT00210847|neuropathy
627547|NCT00210847|diabetic
627548|NCT00210834|PROCRIT, Erythropoietin, Epoetin alfa, Hemoglobin level
627549|NCT00210821|migraine
627550|NCT00210821|headache
627551|NCT00210821|analgesics
627552|NCT00210821|prophylaxis
627553|NCT00210821|prevention
627554|NCT00210808|Binge-Eating Disorder
627555|NCT00210808|medication treatment
627556|NCT00210808|obesity
627557|NCT00210808|bingeing
627558|NCT00210795|Anemia
627559|NCT00210795|Subcutaneous injection
627560|NCT00210795|PROCRIT
627561|NCT00210795|Erythropoietin
627562|NCT00210795|Epoetin Alfa
627563|NCT00210795|Hemoglobin Level
627564|NCT00210795|Elderly
627565|NCT00210782|epilepsy
627566|NCT00210782|seizures
627567|NCT00210782|epileptic seizures
627568|NCT00210782|complex partial seizures
627569|NCT00210782|generalized tonic-clonic seizures
627570|NCT00210769|schizophrenia
627571|NCT00210769|extended release
627572|NCT00210769|oral administration
627573|NCT00210769|antipsychotic agents
627574|NCT00210769|dementia praecox
627575|NCT00210769|mental disorders
627576|NCT00210769|paliperidone
627577|NCT00210769|PANSS
627578|NCT00210756|Anemia
627579|NCT00210756|pharmacokinetics
627580|NCT00210756|erythropoetin
627581|NCT00210756|Epoetin alfa
627582|NCT00210756|erythropoetin recombinant
627583|NCT00210756|Critical care
627584|NCT00210756|critical illness, intensive care,
627585|NCT00210743|Anemia
627586|NCT00210743|chronic kidney disease
627587|NCT00210743|erythropoetin, Epoetin alfa
627588|NCT00210743|erythropoetin recombinant
627589|NCT00210743|pre-dialysis
627590|NCT00210730|Anemia
627591|NCT00210730|Neoplasm
627592|NCT00210730|Hemoglobin Level
627593|NCT00210717|schizophrenia
627594|NCT00210717|intramuscular injection
627595|NCT00210717|antipsychotic agents
627596|NCT00210717|risperidone
627597|NCT00210717|paliperidone palmitate
627598|NCT00210717|dementia praecox
627599|NCT00210717|mental disorders
627600|NCT00210717|PANSS
627601|NCT00210704|dapoxetine
627602|NCT00210704|premature ejaculation
627603|NCT00210704|ejaculation
627604|NCT00210704|sexual dysfunction
627605|NCT00210704|orgasmic disorder
627606|NCT00210704|sexual intercourse
627607|NCT00210691|Schizophrenia
627608|NCT00210691|intramuscular injection
627609|NCT00210691|psychotropic agents
627610|NCT00210691|long-acting risperidone
627611|NCT00210678|Erectile Dysfunction
627612|NCT00210678|Dapoxetine
627613|NCT00210678|Premature ejaculation
627614|NCT00210678|Ejaculation
627615|NCT00210678|Sexual dysfunction
627616|NCT00210678|Orgasmic disorder
627617|NCT00210665|Sarcoma
627618|NCT00210665|Soft tissue sarcoma
627619|NCT00210665|Standard care
627620|NCT00210665|Trabectedin
627621|NCT00210665|Antitumor agent
627622|NCT00210665|Safety
627623|NCT00210652|Epilepsy
627624|NCT00210652|Refractory partial epilepsy
627625|NCT00210652|seizure disorder
627626|NCT00210652|antiepileptic drugs
627627|NCT00210639|Musculoskeletal Diseases
627628|NCT00210639|Musculoskeletal Disorders
627629|NCT00210639|Childhood Disease
627630|NCT00210639|Bone Diseases
627631|NCT00210639|Joint Diseases
627632|NCT00210639|Levofloxacin
627633|NCT00210639|Quinolones
627634|NCT00210639|Bacterial infections
627635|NCT00210626|Anemia, erythropoetin, Epoetin alfa, erythropoetin recombinant, Critical care, critical illness, intensive care
627636|NCT00210613|dapoxetine
627637|NCT00210613|premature ejaculation
627638|NCT00210613|sexual dysfunction
627639|NCT00210613|orgasmic disorder
627640|NCT00210613|sexual intercourse
627641|NCT00210613|ejaculation
627642|NCT00210600|Anemia
627643|NCT00210600|Hemoglobin level
627644|NCT00210587|Anemia
627645|NCT00210587|Neoplasms
627646|NCT00210587|hemoglobin level
627647|NCT00210574|childhood absence epilepsy
627648|NCT00210574|epilepsy
627649|NCT00210574|seizures
627650|NCT00210574|absence seizures
627651|NCT00210561|Pain
627652|NCT00210561|Acute Low Back Pain
627653|NCT00210561|Back
627654|NCT00210561|Lower back
627655|NCT00210548|schizophrenia
627656|NCT00210548|intramuscular injection
627657|NCT00210548|antipsychotic agents
627658|NCT00210548|dementia praecox
627659|NCT00210548|paliperidone palmitate
627660|NCT00210548|mental disorders
627661|NCT00210548|PANSS.
627662|NCT00210535|Topiramate
627663|NCT00210535|Migraine
627664|NCT00210535|Migraine headache
627665|NCT00210535|Migraine prevention
627666|NCT00210535|Pediatric
627667|NCT00210522|RWJ-333369
627668|NCT00210522|Anticonvulsants
627669|NCT00210522|Epilepsy
627670|NCT00210522|Refractory partial epilepsy
627671|NCT00210522|Seizure disorder
627672|NCT00210522|Antiepileptic drugs
627673|NCT00210509|aura
627674|NCT00210509|Migraine
627675|NCT00210509|pain
627676|NCT00210509|headache
627677|NCT00210496|Migraine headache
627678|NCT00210496|Topiramate, Almotriptan malate
627679|NCT00210483|pain
627680|NCT00210483|Migraine
627681|NCT00210483|aura
627682|NCT00210483|headache
627683|NCT00210470|Head and Neck Cancer
627684|NCT00210470|Immunotherapy
627685|NCT00210470|IRX-2
627686|NCT00210470|Mouth Cancer
627687|NCT00210470|Throat Cancer
627688|NCT00210418|Malnutrition
627689|NCT00210418|Infant nutrition
627690|NCT00210418|Food, fortified
627691|NCT00210418|Growth
627692|NCT00210418|Randomized controlled trials
627693|NCT00210418|Evaluation studies
627694|NCT00210418|Haiti
627695|NCT00210405|Anemia
627696|NCT00210405|Infant nutrition
627697|NCT00210405|Dietary supplements
627698|NCT00210405|Randomized controlled trials
627699|NCT00210405|Evaluation studies
627700|NCT00210405|Haiti
627701|NCT00210301|MS
627702|NCT00210301|cognition
627703|NCT00210301|attention
627704|NCT00210301|fatigue
627705|NCT00210288|Healthy Volunteer
627706|NCT00210288|Shigella
627707|NCT00210288|Oral Vaccine
627708|NCT00210288|Double Blind
627709|NCT00210288|Placebo
627710|NCT00210288|Immunogenicity
627711|NCT00210288|Safety
627712|NCT00210249|Cancer
627713|NCT00210249|elderly
627714|NCT00210249|geriatric evaluation
627715|NCT00210249|safety
627716|NCT00210249|chemotherapy
627717|NCT00210236|Breast neoplasms
627718|NCT00210236|Local recurrence
627719|NCT00210236|Survival
627720|NCT00210236|Surgery
627721|NCT00210223|Radiofrequency
627722|NCT00210223|Percutaneous technique
627723|NCT00210223|breast cancer
627724|NCT00210223|tolerance
627725|NCT00210210|Post-operative-pain
627726|NCT00210210|Breast cancer
627727|NCT00210210|Morphine
627728|NCT00210210|Analgesia
627729|NCT00210197|Hypercoagulability
627730|NCT00210197|Plasma coagulation parameters
627731|NCT00210197|Breast cancer
627732|NCT00210184|Chemotherapy
627733|NCT00210184|gastric cancer
627734|NCT00210184|geriatric evaluation
627735|NCT00210184|efficacy
627736|NCT00210184|safety
627737|NCT00210171|Carcinoma
627738|NCT00210171|Stage IIIA Non Small Cell Lung
627739|NCT00210171|Stage IIIB Non-Small-Cell Lung
627740|NCT00210171|Concomitant chemo-radiotherapy
627741|NCT00210171|Consolidation chemotherapy
627742|NCT00210158|Current opioid treatment
627743|NCT00210158|Nitrous oxide
627744|NCT00210158|Chronic pain
627745|NCT00210158|Opioid therapy
627746|NCT00210158|Postoperative hyperalgesia
627747|NCT00210158|Acute opioid tolerance
627748|NCT00210145|Aesthetic care,
627749|NCT00210145|Mastectomy,
627750|NCT00210145|Breast cancer,
627751|NCT00210145|Quality of life,
627752|NCT00210145|Body image,
627753|NCT00210145|Psychological adjustment
627754|NCT00210132|Thoracic surgery
627755|NCT00210132|postoperative pain
627756|NCT00210132|ropivacaine
627757|NCT00210132|inter pleural analgesia
627758|NCT00210119|Chronic myeloid leukemia
627759|NCT00210119|imatinib mesylate
627760|NCT00210119|zoledronate
627761|NCT00210119|molecular response
627762|NCT00210106|Radiofrequency ablation
627763|NCT00210106|Colorectal cancer
627764|NCT00210106|Liver metastases
627765|NCT00210041|Genital Neoplasms, Male
627766|NCT00210028|Breast Neoplasms
627767|NCT00210028|Zarnestra
627768|NCT00210028|Tamoxifen
627769|NCT00210028|estrogen receptor
627770|NCT00210028|progesterone receptor
627771|NCT00210002|Neoplasms
627772|NCT00210002|Solid
627773|NCT00210002|Anemia
627774|NCT00210002|darbepoetin alfa
627775|NCT00210002|ferric saccharose
627776|NCT00210002|Venofer®
627777|NCT00210002|Aranesp®
627778|NCT00209989|Glioblastoma Multiforme
627779|NCT00209989|Zarnestra
627780|NCT00209989|Radiation therapy
627781|NCT00209963|Primary insomnia
627782|NCT00209950|Primary insomnia
627783|NCT00209937|Primary insomnia
627784|NCT00209924|Primary insomnia
627785|NCT00209911|atrial volume
627786|NCT00209911|ventricular volume
627787|NCT00209911|atrial function
627788|NCT00209911|ventricular function
627789|NCT00209911|magnetic resonance imaging
627790|NCT00209911|cardioversion
627791|NCT00209911|natriuretic peptides
627792|NCT00209898|Chronic hepatits C
627793|NCT00209898|peginterferon
627794|NCT00209898|ribavirin
627795|NCT00209898|inmate
627796|NCT00209898|fast initiation procedure
627797|NCT00209846|Primary insomnia
627798|NCT00209820|low back pain
627799|NCT00209820|randomized clinical trial
627800|NCT00209820|Nordic walking
627801|NCT00209820|supervision
627802|NCT00209820|Advice to stay active
627803|NCT00209807|major depression
627804|NCT00209807|pain
627805|NCT00209807|escitalopram
627806|NCT00209807|reboxetine
627807|NCT00209807|visceral sensitivity
627808|NCT00209807|somatic sensitivity
627809|NCT00209768|pediatric intensive care
627810|NCT00209768|critically ill children
627811|NCT00209768|in-line filtration
627812|NCT00209768|prospective randomized study
627813|NCT00209768|complications
627814|NCT00209768|sepsis
627815|NCT00209768|SIRS
627816|NCT00209768|thrombosis
627817|NCT00209768|organ failure
627818|NCT00209755|chronic hepatitis C
627819|NCT00209742|Colorectal Cancer,UFT,LV,Krestin,adjuvant therapy,phase III
627820|NCT00209729|Docetaxel
627821|NCT00209729|S-1
627822|NCT00209729|Elderly Patients
627823|NCT00209729|Gastric cancer
627824|NCT00209664|Irinotecan, S-1, Phase II, gastric cancer
627825|NCT00209651|Irinotecan, S-1, Phase II, colorectal cancer,
627826|NCT00209638|Irinotecan,
627827|NCT00209638|S-1,
627828|NCT00209638|Phase I/II,
627829|NCT00209638|gastric cancer
627830|NCT00209625|Irinotecan, leucovorin, fluorouracil, PhaseI/II, colorectal cancer,
627831|NCT00209599|Colonoscopy
627832|NCT00209599|Seadation
627833|NCT00209586|Bronchoscopy
627834|NCT00209586|Sedation
627835|NCT00209573|Colonoscopy
627836|NCT00209573|Sedation
627837|NCT00209560|AQUAVAN® Injection
627838|NCT00209560|Midazolam
627839|NCT00209560|Minor surgical procedures
627840|NCT00209560|Sedation
627841|NCT00209547|AQUAVAN® Injection
627842|NCT00209547|Midazolam
627843|NCT00209547|Angioplasty
627844|NCT00209547|Coronary catheterization
627845|NCT00209521|Coronary Artery Bypass Surgery
627846|NCT00209521|AQUAVAN® Injection
627847|NCT00209521|DISOPRIVAN® Injectable Emulsion.
627848|NCT00209521|ischemic coronary artery disease
627849|NCT00209508|Parkinson's Disease
627850|NCT00209508|SPECT Scanning
627851|NCT00209495|Abdominal hysterectomy
627852|NCT00209495|Pregabalin
627853|NCT00209495|Dexamethasone
627854|NCT00209495|Multimodal postoperative analgesia
627855|NCT00209456|Lewy Body Dementia
627856|NCT00209456|non-DLB dementia
627857|NCT00209456|Dopamine Transporter
627858|NCT00209456|Striatal Uptake
627859|NCT00209443|Aorto-iliac Stenosis
627860|NCT00209443|Occlusion
627861|NCT00209443|Diagnostic Imaging
627862|NCT00209443|Omniscan
627863|NCT00209443|Magnetic Resonance Angiography
627864|NCT00209443|Contrast Media
627865|NCT00209430|Iodixanol
627866|NCT00209430|Iopamidol
627867|NCT00209430|coronary angiography
627868|NCT00209430|Contrast media-induced nephropathy
627869|NCT00209417|Iodixanol
627870|NCT00209417|Iopamidol
627871|NCT00209417|computed tomography
627872|NCT00209417|Patients with pre-existing renal impairment and diabetes
627873|NCT00209404|MDCT
627874|NCT00209404|Coronary Artery
627875|NCT00209404|Heart Rate
627876|NCT00209404|Image Quality
627877|NCT00209404|Diagnostic Quality
627878|NCT00209391|Renal Artery Stenosis
627879|NCT00209391|Occlusion
627880|NCT00209391|Diagnostic Imaging
627881|NCT00209391|Omniscan
627882|NCT00209391|Magnetic Resonance Angiography
627883|NCT00209391|Contrast Media
627884|NCT00209378|Continuous venovenous hemofiltration (CVVH)
627885|NCT00209378|Continuous renal replacement therapy (CRRT)
627886|NCT00209378|Acute Kidney Injury
627887|NCT00209378|Regional citrate anticoagulation
627888|NCT00209378|filter survival
627889|NCT00209378|trisodium citrate
627890|NCT00209378|bleeding complication
627891|NCT00209378|Hemofiltration
627892|NCT00209352|Varicella Zoster Virus Infection
627893|NCT00209352|VZV infection
627894|NCT00209352|Oral Acyclovir
627895|NCT00209352|Allogeneic Bone Marrow Transplantation
627896|NCT00209352|Allogeneic Hematopoietic Cell Transplantation
627897|NCT00209339|Mitral Valve Insufficiency
627898|NCT00209339|Mitral Valve Regurgitation
627899|NCT00209339|Mitral Valve Incompetence
627900|NCT00209339|Mitral Regurgitation
627901|NCT00209339|Mitral Insufficiency
627902|NCT00209339|Mitral Valve
627903|NCT00209339|MR
627904|NCT00209339|Mitral Valve Prolapse
627905|NCT00209339|E2E - Edge to Edge
627906|NCT00209339|Alfieri Technique
627907|NCT00209339|MitraClip
627908|NCT00209339|Functional MR
627909|NCT00209339|Degenerative MR
627910|NCT00209339|Echocardiogram
627911|NCT00209339|CAD - Coronary Artery Disease
627912|NCT00209339|Heart Failure
627913|NCT00209339|Heart Attack
627914|NCT00209339|EVEREST
627915|NCT00209339|EVEREST I
627916|NCT00209339|EVEREST II
627917|NCT00209313|HIV-1
627918|NCT00209313|HSV-2
627919|NCT00209313|Coinfection
627920|NCT00209313|Africa
627921|NCT00209313|Cameroon
627922|NCT00209300|Ulcerative Colitis for Maintenance of Remission
627923|NCT00209287|Ulcerative Colitis for Maintenance of Remission
627924|NCT00209274|Mitral Valve Insufficiency
627925|NCT00209274|Mitral Valve Regurgitation
627926|NCT00209274|Mitral Valve Incompetence
627927|NCT00209274|Mitral Regurgitation
627928|NCT00209274|Mitral Insufficiency
627929|NCT00209274|Mitral Valve
627930|NCT00209274|MR
627931|NCT00209274|Mitral Valve Prolapse
627932|NCT00209274|Edge to Edge (E2E)
627933|NCT00209274|Alfieri Technique
627934|NCT00209274|MitraClip
627935|NCT00209274|Functional MR
627936|NCT00209274|Degenerative MR
627937|NCT00209274|Echocardiogram
627938|NCT00209274|CAD - Coronary Artery Disease
627939|NCT00209274|Heart Failure
627940|NCT00209274|Heart Attack
627941|NCT00209274|EVEREST
627942|NCT00209274|EVEREST I
627943|NCT00209274|EVEREST II
627944|NCT00209274|REALISM
627945|NCT00209235|Pseudohypoparathyroidism Type 1a (PHP 1a)
627946|NCT00209235|Albright Hereditary Osteodystrophy
627947|NCT00209235|Growth Hormone Deficiency
627948|NCT00209222|Lymphoma, Mantle-Cell
627949|NCT00209222|younger patients
627950|NCT00209222|chemotherapy
627951|NCT00209222|high dose therapy
627952|NCT00209222|C04.557.386.480.300.725.500
627953|NCT00209222|C15.604.515.569.480.300.725.500
627954|NCT00209222|C20.683.515.761.480.300.725.500
627955|NCT00209209|Lymphoma, Mantle-Cell
627956|NCT00209209|Elderly patients
627957|NCT00209209|Chemotherapy
627958|NCT00209209|Maintenance therapy
627959|NCT00209209|C04.557.386.480.300.725.500
627960|NCT00209209|C15.604.515.569.480.300.725.500
627961|NCT00209209|C20.683.515.761.480.300.725.500
627962|NCT00209196|pediatric
627963|NCT00209196|transplantation
627964|NCT00209196|psychosocial
627965|NCT00209196|kidney transplant recipient
627966|NCT00209196|liver transplant recipient
627967|NCT00209196|heart transplant recipient
627968|NCT00209196|lung transplant recipient
627969|NCT00209196|heart-lung transplant recipient
627970|NCT00209144|Inflammation
627971|NCT00209144|Thrombosis
627972|NCT00209144|Hyperglycemia
627973|NCT00209144|Myocardial Infarction
627974|NCT00209144|Angioplasty
627975|NCT00209131|urolithiasis
627976|NCT00209118|Hepatitis C
627977|NCT00209118|Interferon-alpha associated side effects
627978|NCT00209118|Antidepressants
627979|NCT00209118|Prevention
627980|NCT00209105|Child Abuse
627981|NCT00209105|Hypothalamic-Pituitary-Adrenal Axis
627982|NCT00209105|Brain Imaging
627983|NCT00209105|Depression
627984|NCT00209092|Breast Cancer
627985|NCT00209079|Gastric Adenocarcinoma
627986|NCT00209066|Major Depressive Disorder
627987|NCT00209066|Electroconvulsive Therapy
627988|NCT00209066|Platelet Activation
627989|NCT00209040|PTSD
627990|NCT00209040|Acoustic startle
627991|NCT00209027|schizophrenia
627992|NCT00209027|reward
627993|NCT00209027|fMRI
627994|NCT00209014|B-Cell Lymphoma
627995|NCT00209014|Hodgkin's Disease
627996|NCT00209001|Breast Cancer
627997|NCT00208988|Health literacy
627998|NCT00208988|Physician-Patient Relationship
627999|NCT00208988|Prostate Cancer
628000|NCT00208975|Lymphoma
628001|NCT00208962|Hematologic Diseases
628002|NCT00208949|Hematologic Diseases
628003|NCT00208936|Esophageal Diseases
628004|NCT00208923|Hematologic Malignancies
628005|NCT00208910|Anxiety
628006|NCT00208910|Mental Health
628007|NCT00208897|Early Life Stress
628008|NCT00208897|HPA-axis
628009|NCT00208897|CRF
628010|NCT00208884|pediatric
628011|NCT00208884|orthotopic heart transplantation
628012|NCT00208884|graft failure
628013|NCT00208871|Stereoscopic digital mammography
628014|NCT00208871|Breast cancer detection
628015|NCT00208871|Reduced rate of recall
628016|NCT00208871|Focal abnormalities detection
628017|NCT00208832|Medication Compliance
628018|NCT00208832|Health Literacy
628019|NCT00208819|Alzheimer's Disease
628020|NCT00208819|Geriatric
628021|NCT00208819|Dementia
628022|NCT00208819|Agitation
628023|NCT00208819|Behavioral Disturbances
628024|NCT00208819|Psychosis
628025|NCT00208806|Dilated Cardiomyopathy
628026|NCT00208806|Pediatric
628027|NCT00208806|Bi-ventricular Pacemaker
628028|NCT00208793|colonic polyps
628029|NCT00208793|adenomatous polyps
628030|NCT00208793|colon cancer prevention
628031|NCT00208793|dietary supplements
628032|NCT00208780|Oxidative Stress
628033|NCT00208780|Endothelium
628034|NCT00208767|Angiotensin receptor blockade
628035|NCT00208767|Oxidative stress
628036|NCT00208767|Endothelial dysfunction
628037|NCT00208754|heart defects
628038|NCT00208754|cardiology
628039|NCT00208754|adults who have congenital heart defects
628040|NCT00208741|Social Anxiety Disorder
628041|NCT00208741|Mental Health
628042|NCT00208728|pediatric
628043|NCT00208728|congenital heart disease
628044|NCT00208728|cardiac surgery
628045|NCT00208715|Depression
628174|NCT00208117|placebo
628046|NCT00208702|Major Depressive Disorder
628047|NCT00208702|Mental Health
628048|NCT00208702|Depression
628049|NCT00208689|pediatric
628050|NCT00208689|congenital heart disease
628051|NCT00208676|heart defects
628052|NCT00208676|pediatrics
628053|NCT00208650|pediatrics
628054|NCT00208650|transplant
628055|NCT00208650|cardiac
628056|NCT00208637|Maori
628057|NCT00208637|insulin sensitivity
628058|NCT00208637|cardiovascular risk
628059|NCT00208637|diabetes prevention
628060|NCT00208637|diet modification
628061|NCT00208624|arrhythmia
628062|NCT00208624|pediatrics
628063|NCT00208624|cardiac
628064|NCT00208598|Maori
628065|NCT00208598|Body Composition
628066|NCT00208598|DEXA
628067|NCT00208598|Cardiovascular disease
628068|NCT00208598|Diabetes
628069|NCT00208572|Traumatic Brain Injury; Anxiety Disorders; SRI Treatment
628070|NCT00208559|Autism
628071|NCT00208559|Pervasive Developmental Disorder
628072|NCT00208559|Ziprasidone
628073|NCT00208559|Adolescents
628074|NCT00208546|capecitabine
628075|NCT00208546|oxaliplatin
628076|NCT00208546|bevacizumab
628077|NCT00208546|cetuximab
628078|NCT00208546|advanced colorectal cancer
628079|NCT00208533|Autism
628080|NCT00208533|Pervasive developmental disorder
628081|NCT00208533|Aripiprazole
628082|NCT00208533|Antipsychotic medication
628083|NCT00208533|Adolescents
628084|NCT00208520|Epilepsy
628085|NCT00208520|Valproate
628086|NCT00208520|Levetiracetam
628087|NCT00208520|Lamotrigine
628088|NCT00208520|Carbamazepine
628089|NCT00208507|Joint Diseases
628090|NCT00208507|Non-Inflammatory Degenerative Joint Disease
628091|NCT00208494|Non-Inflammatory Degenerative Joint Disease
628092|NCT00208468|Hip
628093|NCT00208468|Cementless
628094|NCT00208455|Arthroplasty
628095|NCT00208455|Replacement
628096|NCT00208455|Hip
628097|NCT00208455|Conservative
628098|NCT00208455|Anatomic
628099|NCT00208455|Cementless
628100|NCT00208442|Hip
628101|NCT00208442|Cemented
628102|NCT00208429|Hip
628103|NCT00208429|Cementless
628104|NCT00208416|Hip
628105|NCT00208416|Surgical Technique
628106|NCT00208403|Hip
628107|NCT00208403|Cement
628108|NCT00208390|Hip
628109|NCT00208390|Cementless
628110|NCT00208377|Hip
628111|NCT00208377|Conservative
628112|NCT00208377|Metal-on-Metal
628113|NCT00208377|Resurfacing
628114|NCT00208364|Hip
628115|NCT00208364|Cementless
628116|NCT00208364|Metal-on-Metal
628117|NCT00208351|Hip
628118|NCT00208351|Cemented
628119|NCT00208338|Rotator cuff tear repair
628120|NCT00208312|Lexiscan
628121|NCT00208312|Regadenoson
628122|NCT00208312|Adenoscan®
628123|NCT00208312|Adenosine
628124|NCT00208312|SPECT Myocardial Perfusion Imaging
628125|NCT00208312|Reversible Perfusion Defect
628126|NCT00208299|Lexiscan
628127|NCT00208299|Regadenoson
628128|NCT00208299|Adenoscan®
628129|NCT00208299|Adenosine
628130|NCT00208299|SPECT Myocardial Perfusion Imaging
628131|NCT00208299|Reversible Perfusion Defect
628132|NCT00208273|Postmenopausal breast cancer, radiohormonotherapy sequences
628133|NCT00208273|ER+ and/or PgR+,
628134|NCT00208273|Postmenopausal Breast cancer,
628135|NCT00208273|Adjuvant setting
628136|NCT00208234|asthma
628137|NCT00208221|Hypertension
628138|NCT00208221|Diabetes
628139|NCT00208221|Microalbuminuria
628140|NCT00208221|Blood pressure
628141|NCT00208208|Posttraumatic Stress Disorder
628142|NCT00208208|Post-traumatic Stress Disorder
628143|NCT00208208|PTSD
628144|NCT00208208|Geodon
628145|NCT00208208|Ziprasidone
628146|NCT00208195|Bipolar Disorder
628147|NCT00208195|Mania
628148|NCT00208195|Substance Abuse
628149|NCT00208195|Substance Dependence
628150|NCT00208195|Comorbid
628151|NCT00208169|Comorbid substance abuse/dependence
628152|NCT00208169|Comorbid diagnoses
628153|NCT00208169|Substance abuse and/or dependence
628154|NCT00208156|Depression
628155|NCT00208156|Major Depression
628156|NCT00208156|Psychotic Major Depression
628157|NCT00208156|PMD
628158|NCT00208156|Psychosis
628159|NCT00208143|Cocaine Abuse
628160|NCT00208143|Cocaine Dependence
628161|NCT00208143|Amphetamine Abuse
628162|NCT00208143|Amphetamine Dependence
628163|NCT00208143|Schizophrenia
628164|NCT00208143|Comorbid
628165|NCT00208143|Schizoaffective Disorder
628166|NCT00208130|PTSD
628167|NCT00208130|trauma
628168|NCT00208117|depression
628169|NCT00208117|inflammation
628170|NCT00208117|heart disease
628171|NCT00208117|randomized clinical trial
628172|NCT00208117|sertraline
628173|NCT00208117|simvastatin
628175|NCT00208104|Hypertension
628176|NCT00208104|African Americans
628177|NCT00208104|Adherence
628178|NCT00208104|Motivational Interviewing
628179|NCT00208091|Myloboc
628180|NCT00208091|Botulinum Toxin Type B
628181|NCT00208091|Focal Dystonia
628182|NCT00208091|Musicians
628183|NCT00208091|Muscle Relaxants
628184|NCT00208091|Motor Impairments
628185|NCT00208091|Motor Performance
628186|NCT00208091|Tremor
628187|NCT00208091|Abnormal Postures
628188|NCT00208078|Hypercapnia
628189|NCT00208078|Non-Invasive Ventilation
628190|NCT00208065|migraine
628191|NCT00208065|biological markers
628192|NCT00208065|rhinosinusitis
628193|NCT00208065|CGRP
628194|NCT00208065|histamine
628195|NCT00208065|VIP
628196|NCT00208039|Prematurity
628197|NCT00208039|Lung Disease
628198|NCT00208039|Hyaline Membrane
628199|NCT00208039|Surfactant
628200|NCT00208013|resting energy expenditure
628201|NCT00208013|cachexia
628202|NCT00208013|advanced cancer
628203|NCT00208013|advanced cancer patients
628204|NCT00207987|controlled hypotension
628205|NCT00207974|Hyperuricemia, Anserine, Pharmacokinetic
628206|NCT00207948|Human Immunodeficiency Virus
628207|NCT00207948|Protease Inhibitors
628208|NCT00207948|Pharmacogenetics
628209|NCT00207948|Genes, MDR1, Cytochrome P-450 enzymes
628210|NCT00207948|Pharmacokinetics
628211|NCT00207948|Pediatrics
628212|NCT00207948|Treatment Experienced
628213|NCT00207935|Seizures
628214|NCT00207935|Depakote
628215|NCT00207935|Developmental Delay
628216|NCT00207935|Mental Retardation
628217|NCT00207935|Swallow
628218|NCT00207922|cytokine
628219|NCT00207922|T-cell
628220|NCT00207922|chemokine
628221|NCT00207922|graft-versus-host disease
628222|NCT00207909|Acute Renal Failure
628223|NCT00207909|Contiuous Veno Venous Hemofiltration
628224|NCT00207896|Pediatric Intensive Care
628225|NCT00207896|Neuroendocrine Dysfunction
628226|NCT00207883|Vascular Access
628227|NCT00207883|Ultrasound
628228|NCT00207883|Pediatric
628229|NCT00207883|Pediatric intensive care patient
628230|NCT00207870|Type II Supracondylar Fracture
628231|NCT00207870|Orthopaedics
628232|NCT00207857|Duchenne's Muscular Dystrophy
628233|NCT00207857|Scoliosis
628234|NCT00207844|Selenium
628235|NCT00207844|Oxidative stress
628236|NCT00207844|Septic shock
628237|NCT00207844|Sodium selenite
628238|NCT00207831|rectal cancer
628239|NCT00207831|neoadjuvant therapy
628240|NCT00207831|UFT
628241|NCT00207831|radiochemotherapy
628242|NCT00207818|tissue engineered wound dressing; autologous skin substitute; biological dressing; wound care
628243|NCT00207792|Granulocyte colony stimulating factor
628244|NCT00207779|central venous catheter
628245|NCT00207779|catheter related bloodstream infection
628246|NCT00207779|heparin
628247|NCT00207766|Crohn's Disease
628248|NCT00207766|infusions
628249|NCT00207753|ascaris
628250|NCT00207753|trichuris
628251|NCT00207753|strongyloides
628252|NCT00207753|hookworm
628253|NCT00207753|head lice
628254|NCT00207740|Asthma
628255|NCT00207740|Severe Persistent Asthma
628256|NCT00207740|Subcutaneous injections
628257|NCT00207740|Immunology disorder
628258|NCT00207740|Breathlesness
628259|NCT00207727|Multiple Sclerosis
628260|NCT00207714|Rheumatoid Arthritis
628261|NCT00207714|CNTO 148
628262|NCT00207714|Methotrexate
628263|NCT00207714|Joint pain
628264|NCT00207714|Arthritis
628265|NCT00207701|Ankylosing Spondylitis
628266|NCT00207701|infusion
628267|NCT00207688|Ulcerative Colitis
628268|NCT00207688|Infliximab
628269|NCT00207688|Remicade
628270|NCT00207688|Safety
628271|NCT00207675|Crohn's Disease
628272|NCT00207675|pediatric Crohn's Disease
628273|NCT00207662|Crohn's Disease
628274|NCT00207649|shared decision-making
628275|NCT00207649|prostate cancer screening
628276|NCT00207649|evidence-based medicine
628277|NCT00207649|computer-assisted learning tools
628278|NCT00207649|standardized patients
628279|NCT00207649|randomized controlled trial
628280|NCT00207649|educational intervention
628281|NCT00207649|patient education
628282|NCT00207649|physician education
628283|NCT00207636|Computer-Assisted Decision Making
628284|NCT00207636|Workplace
628285|NCT00207636|Screening
628286|NCT00207623|arthritis
628287|NCT00207623|self management
628288|NCT00207623|patient education
628289|NCT00207610|Anemia
628290|NCT00207610|Postpartum
628291|NCT00207610|iron
628292|NCT00207610|supplements
628293|NCT00206557|Schizophrenia
628294|NCT00206557|Mental Illness
628295|NCT00206557|Hormone Therapy
628296|NCT00206557|Post-menopausal
628297|NCT00206557|SERM
628298|NCT00206557|Raloxifene
628299|NCT00206544|Bipolar Affective Disorder
628300|NCT00206544|Mania
628301|NCT00206544|Anti-Estrogen
628302|NCT00206544|Schizoaffective Disorder
628303|NCT00206544|Mood
628304|NCT00206531|HIV-1
628305|NCT00206531|Naive T-cells
628306|NCT00206531|CD31
628307|NCT00206531|Treatment Naive
628308|NCT00206518|Breast
628309|NCT00206518|Cancer
628310|NCT00206518|Taxotere
628311|NCT00206518|AC
628312|NCT00206518|Validation
628313|NCT00206518|Neoadjuvant
628314|NCT00206505|Breast
628315|NCT00206505|Cancer
628316|NCT00206505|Neoadjuvant
628317|NCT00206505|Taxotere
628318|NCT00206492|Breast
628319|NCT00206492|Cancer
628320|NCT00206492|Neoadjuvant
628321|NCT00206492|HER2
628322|NCT00206492|Overexpressing
628323|NCT00206466|neoadjuvant
628324|NCT00206466|chemosensitivity
628325|NCT00206466|chemotherapy
628326|NCT00206466|breast cancer
628327|NCT00206466|tumor
628328|NCT00206466|taxotere
628329|NCT00206466|AC
628330|NCT00206453|Breast
628331|NCT00206453|Cancer
628332|NCT00206453|Gene
628333|NCT00206453|Expression
628334|NCT00206453|Taxotere
628335|NCT00206440|chemotherapy
628336|NCT00206440|nausea
628337|NCT00206440|vomiting
628338|NCT00206440|breast cancer
628339|NCT00206427|Advanced
628340|NCT00206427|Breast
628341|NCT00206427|Cancer
628342|NCT00206427|Neoadjuvant
628343|NCT00206427|HER2
628344|NCT00207571|computer
628345|NCT00207571|video
628346|NCT00207571|partner notification
628347|NCT00207519|overweight
628348|NCT00207519|obesity
628349|NCT00207519|adolescent
628350|NCT00207506|Latino
628351|NCT00207506|Lay Health
628352|NCT00207506|Access
628353|NCT00207506|Prevention
628354|NCT00207506|HIV Seronegativity
628355|NCT00207506|HIV
628356|NCT00207493|sexually transmitted disease
628357|NCT00207493|structural intervention
628358|NCT00207493|behavioral intervention
628359|NCT00207467|patient-delivered partner treatment
628360|NCT00207467|partner referral
628361|NCT00207467|sexually transmitted diseases
628362|NCT00207454|Partner Referral
628363|NCT00207454|Social Cognitive Intervention
628364|NCT00207454|Partner Delivered Medication
628365|NCT00207441|arthritis
628366|NCT00207441|chronic disease
628367|NCT00207441|self management
628368|NCT00207441|self efficacy
628369|NCT00207428|Bronchial asthma
628370|NCT00207428|Carbamazepine
628371|NCT00207428|Efficacy
628372|NCT00207415|arthritis
628373|NCT00207415|self management
628374|NCT00207402|Hepatitis C
628375|NCT00207402|Insulin resistance
628376|NCT00207389|Incretins:GIP , GLP-1
628377|NCT00207389|Gastric bypass surgery
628378|NCT00207389|Laparoscopic gastric bypass surgery
628379|NCT00207389|Postprandial expression of GIP
628380|NCT00207363|Hepatitis C
628381|NCT00207350|Brain Tumor
628382|NCT00207337|COPD (Chronic Obstructive Pulmonary Disease)
628383|NCT00207337|Emphysema
628384|NCT00207337|Minimally invasive
628385|NCT00207311|Hepatitis C
628386|NCT00207311|Fatty Liver
628387|NCT00207311|NASH
628388|NCT00207311|Steatohepatitis
628389|NCT00207285|Police
628390|NCT00207285|Sleep
628391|NCT00207285|Fatigue
628392|NCT00207285|Work Hours
628393|NCT00207285|Sleep disorder
628394|NCT00207285|Performance
628395|NCT00207272|Hypocaloric MCT oil liquid diet
628396|NCT00207272|Hypocaloric LCT oil liquid diet
628397|NCT00207272|Visceral and omental adipose tissue
628398|NCT00207272|Subcutaneous abdominal adipose tissue
628399|NCT00207272|Gastric bypass surgery
628400|NCT00207259|Prostate Cancer
628401|NCT00207259|Reiki
628402|NCT00207259|Relaxation Response
628403|NCT00207259|Cognitive Restructuring
628404|NCT00207259|Feasibility
628405|NCT00207233|Weight loss
628406|NCT00207233|MCT oil hypocaloric liquid diet
628407|NCT00207233|LCT oil hypocaloric liquid diet
628408|NCT00207233|Gastric Bypass
628409|NCT00207220|heart failure
628410|NCT00207220|preserved ejection fraction
628411|NCT00207220|vascular stiffness
628412|NCT00207207|Alternate Site
628413|NCT00207207|Blood Glucose Testing
628414|NCT00207207|Blood Sugar Testing
628415|NCT00207207|Hemoglobin A1C
628416|NCT00207181|Cancer prevention
628417|NCT00207181|Physical activity
628418|NCT00207181|Self-report
628419|NCT00207181|Paper diary
628420|NCT00207181|Electronic
628421|NCT00207181|Computerized
628422|NCT00207181|Measurement
628423|NCT00207181|PDA
628424|NCT00207181|Accelerometer
628425|NCT00207142|Treatment Naive
628426|NCT00207142|HIV-1 infected treatment naive patients
628427|NCT00207116|Metastatic Non Small Cell Lung Cancer
628428|NCT00207103|Advanced metastatic or solid tumors
628429|NCT00207077|Advanced Solid Tumors
628430|NCT00207064|first-episode
628431|NCT00207064|altanserin
628432|NCT00207064|5-HT2A receptors
628433|NCT00207064|MRI
628434|NCT00207064|fMRI
628435|NCT00207064|PPI
628436|NCT00207064|P300
628437|NCT00207064|P50 gating
628438|NCT00207064|endophenotypes
628439|NCT00207064|vulnerability indicators
628440|NCT00207064|quetiapine
628441|NCT00207051|Advanced Gastrointestinal Malignancies
628442|NCT00207038|Asthma
628443|NCT00207038|Airway inflammation
628444|NCT00207038|Sport
628445|NCT00207025|Patients with advanced solid tumors
628446|NCT00206999|Psychophysiology
628447|NCT00206999|PPI
628448|NCT00206999|P50 suppression
628449|NCT00206999|Imipramine
628450|NCT00206986|Schizophrenia
628451|NCT00206986|Information processing
628452|NCT00206986|PPI
628453|NCT00206986|P50 gating
628454|NCT00206986|P300
628455|NCT00206986|mismatch negativity
628456|NCT00206986|clonidine
628457|NCT00206414|HORMONE RECEPTOR POSITIVE BREAST CANCER
628458|NCT00206401|Adolescents
628459|NCT00206401|Lantus
628460|NCT00206388|NEUROBLASTOMA
628461|NCT00206388|RECURRENT
628462|NCT00206388|REFRACTORY
628463|NCT00206388|CORTICAL
628464|NCT00206388|BONE
628465|NCT00206375|Hypothyroidism
628466|NCT00206375|Growth hormone
628467|NCT00206362|Depression
628468|NCT00206362|Socioeconomic status
628469|NCT00206362|Type 1 diabetes mellitus
628470|NCT00206362|Children
628471|NCT00206362|Adolescents
628472|NCT00206349|Depression
628473|NCT00206349|Socioeconomic status
628474|NCT00206349|Type 1 diabetes mellitus
628475|NCT00206349|Children
628476|NCT00206349|Adolescents
628477|NCT00206960|drug-naive
628478|NCT00206960|epidepride
628479|NCT00206960|single tomography
628480|NCT00206960|D2 receptor
628481|NCT00206960|information processing
628482|NCT00206960|PPI
628483|NCT00206960|antipsychotic treatment
628484|NCT00206960|MRI
628485|NCT00206960|fMRI
628486|NCT00206960|cognitive disturbances
628487|NCT00206947|Cognitive deficits
628488|NCT00206947|Cholinergic Augmentation
628489|NCT00206947|Schizophrenia
628490|NCT00206934|PPI
628491|NCT00206934|P50 suppression
628492|NCT00206934|P300
628493|NCT00206934|mismatch negativity
628494|NCT00206934|escitalopram
628495|NCT00206921|Telangiectasia
628496|NCT00206921|Skin redness
628497|NCT00206882|sunburn
628498|NCT00206882|corticosteroids
628499|NCT00206791|bone substitutes
628500|NCT00206791|Bone Replacement Materials
628501|NCT00206791|bone void filler
628502|NCT00206791|Grafting, Bone
628503|NCT00206791|Bone Cysts
628504|NCT00206778|Mixed mania
628505|NCT00206778|Bipolar Disorder
628506|NCT00206765|panic
628507|NCT00206739|Malaria
628508|NCT00206739|Anemia
628509|NCT00206739|IPTi
628510|NCT00206739|Intermittent Preventive Treatment in Infants
628511|NCT00206739|Sulfadoxine-Pyrimethamine
628512|NCT00206739|Chemoprophylaxis
628513|NCT00206739|Ghana
628514|NCT00206713|Crohn Disease
628515|NCT00206674|Morbus Crohn
628516|NCT00206674|Sargramostim
628517|NCT00206674|Phase III
628518|NCT00206674|Placebo Controlled
628519|NCT00206661|Crohn Disease
628520|NCT00206609|Cancer
628521|NCT00206609|palliative care
628522|NCT00206609|dyspnoea
628523|NCT00206609|oxygen
628524|NCT00206570|Schizophrenia
628525|NCT00206570|Gender differences
628526|NCT00206570|Hormones
628527|NCT00206570|Estradiol
628528|NCT00206570|PANSS
628529|NCT00206297|Type 1 diabetes
628530|NCT00206297|hypoglycemia
628531|NCT00206297|hyperglycemia
628532|NCT00206284|GERD without erosive esophagitis
628533|NCT00206271|whiplash injuries
628534|NCT00206271|neck pain
628535|NCT00206271|exercise movement techniques
628536|NCT00206271|immobilisation
628537|NCT00206258|type 1 diabetes
628538|NCT00206258|hypoglycemia
628539|NCT00206258|hyperglycemia
628540|NCT00206245|GERD with erosive esophagitis
628541|NCT00206232|Diastolic Heart Failure
628542|NCT00206219|Squamous cell carcinoma of the head and neck
628543|NCT00206193|termination of pregnancy
628544|NCT00206141|Bipolar disorder
628545|NCT00206141|bipolar depression
628546|NCT00206141|depression
628547|NCT00206128|Schizophrenia
628548|NCT00206115|Schizophrenic disorder
628549|NCT00206102|Schizophrenia
628550|NCT00206102|Schizoaffective Disorder
628551|NCT00206089|Prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery
628552|NCT00206076|Liver transplantation
628553|NCT00206076|Calcineurin inhibitor withdraw
628554|NCT00206076|mycophenolate mofetil
628555|NCT00206076|Immunosuppression side effects
628556|NCT00206076|Graft rejection
628557|NCT00206037|Tibia osteotomy
628558|NCT00206037|Bone healing
628559|NCT00206037|Bone filler
628560|NCT00206037|Equine Protein
628561|NCT00206037|COLLOSS E
628562|NCT00206037|TomoFix
628563|NCT00206011|Condylar neck
628564|NCT00206011|fractures
628565|NCT00206011|endoscopic
628566|NCT00206011|Helkimo Dysfunction index
628567|NCT00205998|Locking Compression Plate
628568|NCT00205998|Conservative treatment
628569|NCT00205998|Surgical treatment
628570|NCT00205998|Radius fractures
628571|NCT00205998|AO 23
628572|NCT00205985|Return to work
628573|NCT00205985|Scaphoid fracture
628574|NCT00205985|Operative treatment
628575|NCT00205985|Activity level
628576|NCT00205972|Fractures
628577|NCT00205972|Humerus
628578|NCT00205972|Conservative treatment
628579|NCT00205972|Operative treatment
628580|NCT00205959|Humerus
628581|NCT00205959|Fractures
628582|NCT00205959|Locking Plates
628583|NCT00205959|Nail System
628584|NCT00205946|Reward Processing
628585|NCT00205946|Wellbutrin
628586|NCT00205946|Bupropion
628587|NCT00205933|Depression
628588|NCT00205933|Bipolar Disorder
628589|NCT00205933|Reward Processing
628590|NCT00205920|emphysema
628591|NCT00205920|pulmonary emphysema
628592|NCT00205920|COPD
628593|NCT00205920|COLD
628594|NCT00205920|chronic obstructive pulmonary disease
628595|NCT00205907|BLVR
628596|NCT00205907|emphysema
628597|NCT00205907|COPD
628598|NCT00205907|COLD
628599|NCT00205907|chronic obstructive pulmonary disease
628600|NCT00205907|pulmonary emphysema
628601|NCT00205894|Headache
628602|NCT00205894|Chronic headache
628603|NCT00205894|Migraine
628604|NCT00205894|Pain
628605|NCT00205894|Cluster headache
628606|NCT00205881|HiResolution Bionic Ear
628607|NCT00205881|severe to profound hearing loss
628608|NCT00205881|bilateral implantation
628609|NCT00205868|Back Pain
628610|NCT00205868|Low Back Pain
628611|NCT00205868|Chronic Pain
628612|NCT00205868|Spinal Cord Stimulation
628613|NCT00205855|Pain
628614|NCT00205855|Chronic Pain
628615|NCT00205855|Neurostimulation
628616|NCT00205829|Chronic headaches
628617|NCT00205829|greater occipital nerve stimulation
628618|NCT00205816|Bacterial Infections
628619|NCT00205803|Infant Vaccine
628620|NCT00205777|Osteoporosis
628621|NCT00205777|Postmenopause
628622|NCT00205764|Multiple Myeloma
628623|NCT00205764|first line tretment
628624|NCT00205764|high dose chemotherapy
628625|NCT00205764|stem cell transplantation
628626|NCT00205764|maintenance therapy
628627|NCT00205751|Multiple Myeloma
628628|NCT00205751|first line treatment
628629|NCT00205751|thalidomide
628630|NCT00205751|melphalan
628631|NCT00205738|Schizophrenia
628632|NCT00205738|BMI
628633|NCT00205738|T2DM
628634|NCT00205725|Schizophrenia
628635|NCT00205725|BMI
628636|NCT00205725|T2DM
628637|NCT00205712|NMDA antagonist-induced psychosis
628638|NCT00205712|Children
628639|NCT00205712|Memory Impairment
628640|NCT00205712|Decreased cognitive function
628641|NCT00205712|Increased memory impairment
628642|NCT00205699|Antipsychotic treatment
628643|NCT00205699|Insulin action/secretion
628644|NCT00205699|Abdominal fat mass, total body fat
628645|NCT00205699|Aggression
628646|NCT00205699|Resting metabolic rates
628647|NCT00205686|Aging, dhea, bone density, muscle mass, insulin action
628648|NCT00205660|Schizophrenia
628649|NCT00205660|Obesity
628650|NCT00205660|Hyperglycemia
628651|NCT00205660|Dyslipidemia
628652|NCT00205660|Type 2 Diabetes Mellitus
628653|NCT00205647|Chronic Bronchitis
628654|NCT00205647|N-acetylcysteine (NAC)
628655|NCT00205647|Quality of Life
628656|NCT00205647|Mucus
628657|NCT00205634|Cystic Fibrosis (CF)
628658|NCT00205634|Macrolide antiobiotics
628659|NCT00205634|airway inflammation
628660|NCT00205621|Alzheimer's disease
628661|NCT00205621|amyloid
628662|NCT00205621|PET
628663|NCT00205621|PIB
628664|NCT00205621|FDDNP
628665|NCT00205608|schizophrenia
628666|NCT00205608|microglia
628667|NCT00205608|PET
628668|NCT00205595|microglia
628669|NCT00205595|PET
628670|NCT00205595|PK11195
628671|NCT00205582|Traumatic Brain Injury
628672|NCT00205582|PET
628673|NCT00205582|microglia
628674|NCT00205569|brain injury, acute rehabilitation
628675|NCT00205556|online hemodiafiltration
628676|NCT00205556|low flux hemodialysis
628677|NCT00205556|cardiovascular disease
628678|NCT00205556|endothelial dysfunction
628679|NCT00205556|uremic toxicity
628680|NCT00205556|quality of life
628681|NCT00205556|nutritional status
628682|NCT00205543|obstructive sleep apnea
628683|NCT00205543|airway obstruction
628684|NCT00205543|sleep-disordered breathing
628807|NCT00204412|Triglyceride
628685|NCT00205530|brain injury, family treatment
628686|NCT00205504|Inflammatory markers, oral contraceptions, obesity, metabolic syndrome X
628687|NCT00205491|depression after brain injury
628688|NCT00205491|traumatic brain injury
628689|NCT00205491|Venlafaxine
628690|NCT00205426|Pulmonary hypertension in lung transplant recipients
628691|NCT00205413|surveillance for lung cancer
628692|NCT00205387|echocardiography
628693|NCT00205387|cardiac elastography
628694|NCT00205387|Normal volunteers
628695|NCT00205309|intubated patients
628696|NCT00205283|HIV
628697|NCT00205270|Pre or post-lung transplant
628698|NCT00205270|Healthy
628699|NCT00205231|HIV
628700|NCT00205192|Heart Failure
628701|NCT00205192|Cardiac resynchronization
628702|NCT00205192|echocardiography
628703|NCT00205166|adenosine tracer scans
628704|NCT00205166|coronary artery disease
628705|NCT00205166|caffeine
628706|NCT00205153|hypertension in African Americans
628707|NCT00205127|Cardiac PET imaging
628708|NCT00205127|Radiopharmaceutical tracers
628709|NCT00205101|Transforaminal lumbar interbody fusion
628710|NCT00205101|Posterior lumbar interbody fusion
628711|NCT00205101|Isthmic spondylolisthesis, degenerative spondylolisthesis
628712|NCT00205101|Pseudoarthritis
628713|NCT00205101|Severe Foraminal Stenosis
628714|NCT00205049|acute alcoholic hepatitis
628715|NCT00204997|Cervical Cancer
628716|NCT00204997|Squamous Cell
628717|NCT00204997|Laparoscopy
628718|NCT00204997|Ovarian Function
628719|NCT00204984|arterial stiffness
628720|NCT00204984|echocardiography
628721|NCT00204984|nesiritide
628722|NCT00204958|bone marrow transplant (BMT)
628723|NCT00204958|hematopoietic stem cell transplant (HSCT)
628724|NCT00204945|arterial stiffness
628725|NCT00204945|echocardiography
628726|NCT00204945|nesiritide
628727|NCT00204945|high heart pressures
628728|NCT00204945|cardiac catheterization
628729|NCT00204919|osteoporosis
628730|NCT00204919|vitamin D deficiency
628731|NCT00204867|colorectal
628732|NCT00204867|polyps
628733|NCT00204763|manometry catheters
628734|NCT00204763|diffuse esophageal spasm or hypertensive LES
628735|NCT00204763|incontinence
628736|NCT00204750|lower esophageal ring
628737|NCT00204750|dysphagia
628738|NCT00204750|electrosurgical incision
628739|NCT00204750|bougie dilation
628740|NCT00204750|GERD
628741|NCT00204711|patients having outpatient surgery with sedation
628742|NCT00204711|patients having procedures with sedation
628743|NCT00204672|Asthma
628744|NCT00204659|Rituximab
628745|NCT00204659|CHOP
628746|NCT00204659|DLBCL
628747|NCT00204659|gastric lymphoma
628748|NCT00204594|mRNA
628749|NCT00204594|vaccination
628750|NCT00204594|melanoma
628751|NCT00204581|Melanoma
628752|NCT00204581|Soft tissue metastases
628753|NCT00204581|Interleukin-2
628754|NCT00204555|nodular basal cell carcinoma
628755|NCT00204555|Imiquimod
628756|NCT00204555|topical treatment
628757|NCT00204555|Adjuvants, Immunologic
628758|NCT00204555|Antineoplastic Agents
628759|NCT00204555|Interferon Inducers
628760|NCT00204542|actinic keratosis
628761|NCT00204542|diclofenac sodium
628762|NCT00204529|malignant melanoma
628763|NCT00204529|adjuvant therapy
628764|NCT00204529|Adjuvants, Immunologic
628765|NCT00204516|vaccination
628766|NCT00204516|mRNA
628767|NCT00204503|Bipolar I or II
628768|NCT00204503|Depression
628769|NCT00204503|Alcohol Abuse or Dependence
628770|NCT00204503|Mental Health Issues
628771|NCT00204490|soy
628772|NCT00204490|isoflavones
628773|NCT00204490|phytoestrogens
628774|NCT00204490|prevention
628775|NCT00204490|mammographic density
628776|NCT00204490|bone density
628777|NCT00204477|soy diet
628778|NCT00204477|breast cancer
628779|NCT00204477|ovarian hormones
628780|NCT00204477|breast density
628781|NCT00204477|prevention
628782|NCT00204464|Amyotrophic Lateral Sclerosis
628783|NCT00204464|Exercise
628784|NCT00204451|emergency contraception
628785|NCT00204451|follicle
628786|NCT00204451|ovulation
628787|NCT00204451|blood pressure
628788|NCT00204451|Fertility Control
628789|NCT00204451|Inhibition of fertilization
628790|NCT00204438|female contraception
628791|NCT00204438|oral contraceptive
628792|NCT00204438|emergency contraceptive
628793|NCT00204438|ovary
628794|NCT00204438|follicle
628795|NCT00204438|ovulation
628796|NCT00204425|Osteoporosis
628797|NCT00204425|Bone
628798|NCT00204425|Exercise
628799|NCT00204425|Soy
628800|NCT00204425|Isoflavone
628801|NCT00204425|Phytoestrogen
628802|NCT00204425|Menopause
628803|NCT00204425|Lipids
628804|NCT00204412|Cholesterol
628805|NCT00204412|High density lipoprotein
628806|NCT00204412|Low density lipoprotein
628808|NCT00204412|Glucose
628809|NCT00204412|Exercise
628810|NCT00204412|Fitness
628811|NCT00204412|Flax
628812|NCT00204412|Lignan
628813|NCT00204412|Phytoestrogen
628814|NCT00204412|bone
628815|NCT00204386|Posttraumatic Stress Disorder
628816|NCT00204360|epilepsy
628817|NCT00204347|risperidone
628818|NCT00204334|Kidney transplantation
628819|NCT00204334|anemia
628820|NCT00204334|vascular endothelium
628821|NCT00204334|monocytes
628822|NCT00204334|apoptosis
628823|NCT00204321|rejection
628824|NCT00204321|vesselwall function
628825|NCT00204321|endothelial cell function
628826|NCT00204321|monocytes
628827|NCT00204308|HIV
628828|NCT00204308|Pregnancy
628829|NCT00204308|Mother-to-child transmission of HIV
628830|NCT00204308|Drug resistance
628831|NCT00204308|Nevirapine resistance
628832|NCT00204308|NNRTI resistance
628833|NCT00204295|Brain neoplasms
628834|NCT00204295|Positron-Emission Tomography
628835|NCT00204295|Amino Acids
628836|NCT00204295|Magnetic Resonance Imaging
628837|NCT00204282|Diabetes prevention
628838|NCT00204269|Hypogonadism
628839|NCT00204269|Testosterone
628840|NCT00204269|Substitution
628841|NCT00204256|chronic kidney disease
628842|NCT00204256|anemia
628843|NCT00204256|intravenous iron
628844|NCT00204256|recombinant human erythropoetin
628845|NCT00204243|naltrexone implant
628846|NCT00204243|methadone
628847|NCT00204243|inmates
628848|NCT00204243|randomized controlled trial
628849|NCT00204230|Kidney Failure, Chronic
628850|NCT00204230|Kidney Transplantation
628851|NCT00204217|cardiac arrest
628852|NCT00204217|resuscitation
628853|NCT00204217|ventilation
628854|NCT00204217|impedance
628855|NCT00204204|multiple trauma
628856|NCT00204204|traffic accident
628857|NCT00204204|outcome
628858|NCT00204204|safety
628859|NCT00204204|injury severity
628860|NCT00204191|kidney transplantation
628861|NCT00204191|Immunosuppression
628862|NCT00204191|Cyclosporine
628863|NCT00204191|Tacrolimus
628864|NCT00204178|Kidney transplantation
628865|NCT00204178|Reperfusion injury
628866|NCT00204152|Early onset depression
628867|NCT00204152|early adversity
628868|NCT00204126|exercise testing
628869|NCT00204126|treadmill
628870|NCT00204126|incomplete spinal cord injury
628871|NCT00204126|novel methods
628872|NCT00204113|spinal cord injury
628873|NCT00204113|standing
628874|NCT00204113|balance
628875|NCT00204113|functional electrical stimulation
628876|NCT00204100|paraplegia
628877|NCT00204100|spinal cord injury
628878|NCT00204100|functional electrical stimulation
628879|NCT00204100|cycling
628880|NCT00204100|exercise
628881|NCT00204100|cardiopulmonary fitness
628882|NCT00204087|Schizophrenia
628883|NCT00204087|Psychosis
628884|NCT00204087|Prodrome
628885|NCT00204087|Early Initial Prodromal State
628886|NCT00204087|Early Intervention
628887|NCT00204087|Cognitive Behavioral Therapy
628888|NCT00204074|Migraine
628889|NCT00204074|Menstrual cycle
628890|NCT00204074|17 beta-estradiol
628891|NCT00204074|Transdermal administration
628892|NCT00204061|schizophrenia
628893|NCT00204061|psychosis
628894|NCT00204061|ultra high risk
628895|NCT00204061|prodromal state
628896|NCT00204061|early intervention
628897|NCT00204061|amisulpride
628898|NCT00204048|Hospitalists
628899|NCT00204035|Training early achievers for careers in health
628900|NCT00204022|Lupus nephritis
628901|NCT00204022|Treatment
628902|NCT00204022|Maintenance therapy
628903|NCT00204022|Mycophenolate mofetil
628904|NCT00204022|Azathioprine
628905|NCT00204009|children and adolescents
628906|NCT00204009|epidemiology
628907|NCT00203996|polycystic ovary syndrome
628908|NCT00203996|metabolic syndrome
628909|NCT00203996|obstructive sleep apnea
628910|NCT00203996|impaired glucose tolerance
628911|NCT00203996|insulin resistance
628912|NCT00203970|Thrombosis
628913|NCT00203970|Low Molecular Weight Heparin
628914|NCT00203957|Parkinson's Disease
628915|NCT00203944|Adoption
628916|NCT00203944|Stress Response
628917|NCT00203944|Child Development
628918|NCT00203931|Non-small cell lung cancer
628919|NCT00203918|Prostate Cancer
628920|NCT00203918|Cost-Effectiveness Analysis
628921|NCT00203918|Utility Assessment
628922|NCT00203905|Head and Neck Cancer
628923|NCT00203892|Adenocarcinoma
628924|NCT00203892|Pancreas
628925|NCT00203879|metastatic melanoma
628926|NCT00203866|Metastatic Renal Cell Carcinoma
628927|NCT00203853|HIV
628928|NCT00203853|HAART
628929|NCT00203853|medication adherance
628930|NCT00203853|pillbox
628931|NCT00203853|wristwatch
628932|NCT00203840|Sleep Disorders
628933|NCT00203827|Sleep Disorders
628934|NCT00203814|Malaria
628935|NCT00203814|Efficacy
628936|NCT00203814|Pharmacokinetic
628937|NCT00203814|Gametocyte
628938|NCT00203814|Molecular markers
628939|NCT00203814|Sulfadoxine-pyrimethamine
628940|NCT00203814|Artesunate
628941|NCT00203814|Artemisinin
628942|NCT00203801|Malaria
628943|NCT00203801|Efficacy
628944|NCT00203801|Pharmacokinetic
628945|NCT00203801|Gametocyte
628946|NCT00203801|Molecular markers
628947|NCT00203801|Sulfadoxine-pyrimethamine
628948|NCT00203801|Artesunate
628949|NCT00203801|Artemisinin
628950|NCT00203788|work outcome
628951|NCT00203788|supported employment
628952|NCT00203788|social skills training
628953|NCT00203788|risperidone
628954|NCT00203788|cognition
628955|NCT00203788|first-episode schizophrenia
628956|NCT00203762|Pragmatic cluster non-randomized controlled trial
628957|NCT00203762|antiretroviral treatment
628958|NCT00203762|tuberculosis
628959|NCT00203762|childhood immunization
628960|NCT00203762|primary care
628961|NCT00203762|resource-restricted settings
628962|NCT00203749|HIV
628963|NCT00203749|Testing
628964|NCT00203749|Counseling
628965|NCT00203736|Malaria
628966|NCT00203736|Efficacy
628967|NCT00203736|Pharmacokinetic
628968|NCT00203736|Gametocyte
628969|NCT00203736|Molecular Markers
628970|NCT00203736|Sulfadoxine-pyrimethamine
628971|NCT00203736|Artesunate
628972|NCT00203736|Artemisinin
628973|NCT00203723|mood disorder
628974|NCT00203723|affective disorder
628975|NCT00203723|depression
628976|NCT00203723|treatment-resistant
628977|NCT00203710|Concentric Retriever Device
628978|NCT00203710|embolectomy
628979|NCT00203710|acute ischemic stroke
628980|NCT00203710|treatment
628981|NCT00203697|Eric Kleerup
628982|NCT00203697|Idiopathic Pulmonary Fibrosis
628983|NCT00203671|renal
628984|NCT00203671|transplant
628985|NCT00203671|kidney
628986|NCT00203671|rejection
628987|NCT00203671|MMF
628988|NCT00203671|Mycophenolate Mofetil
628989|NCT00203671|outcomes
628990|NCT00203671|Kidney Transplantation
628991|NCT00203645|Problem gambling
628992|NCT00203645|Self-help manual
628993|NCT00203645|Motivation enhancement
628994|NCT00203645|Telephone support
628995|NCT00203645|Treatment
628996|NCT00203645|Pathological gambling
628997|NCT00203632|diabetes mellitus
628998|NCT00203632|endothelium
628999|NCT00203632|thiazolidinediones
629000|NCT00203632|atherosclerosis
629001|NCT00203593|exercise
629002|NCT00203593|total peripheral resistance
629003|NCT00203593|venoconstriction
629004|NCT00203593|blood volume expansion
629005|NCT00203593|orthostatic tolerance
629006|NCT00203580|venous thromboembolism
629007|NCT00203580|low-molecular-weight heparin
629008|NCT00203567|bipolar depression
629009|NCT00203567|carbamazepine ER
629010|NCT00203567|Equetro
629011|NCT00203554|osteoporosis
629012|NCT00203554|vertebra
629013|NCT00203554|fracture
629014|NCT00203554|pain
629015|NCT00203554|percutaneous
629016|NCT00203554|vertebroplasty
629017|NCT00203554|polymethylmetacrylate
629018|NCT00203528|divalproex sodium
629019|NCT00203528|risperidone
629020|NCT00203528|dual diagnosis
629021|NCT00203528|substance use
629022|NCT00203528|bipolar
629023|NCT00203515|Urinary Catheterization
629024|NCT00203502|Operable and Locally advanced Breast Cancer
629025|NCT00203476|ezetimibe
629026|NCT00203476|niacin
629027|NCT00203476|colestipol
629028|NCT00203476|hyperlipidemia
629029|NCT00203476|adjunct therapy
629030|NCT00203476|zetia
629031|NCT00203463|topiramate
629032|NCT00203463|PTSD
629033|NCT00203463|posttraumatic stress disorder
629034|NCT00203463|topamax
629035|NCT00203450|obesity
629036|NCT00203450|zonisamide
629037|NCT00203450|zonegran
629038|NCT00203450|psychotropic weight gain
629039|NCT00203450|psychotropic
629040|NCT00203385|divalproex sodium, depakote, ptsd, long-term ptsd treatments
629041|NCT00203333|Epilepsy
629042|NCT00203281|renal transplantation
629043|NCT00203268|migraine
629044|NCT00203268|cutaneous allodynia
629045|NCT00203255|Menstrually-Associated Migraine
629046|NCT00203229|Double-Blind
629047|NCT00203229|Placebo-Controlled
629048|NCT00203203|Autologous
629049|NCT00203203|Cardiac
629050|NCT00203203|Stem Cell
629051|NCT00203203|Transplant
629052|NCT00203047|Multiple Sclerosis
629053|NCT00203047|brain atrophy
629054|NCT00203047|Glatiramer Acetate
629055|NCT00203047|Copaxone
629056|NCT00203047|Steroids
629057|NCT00203047|Prednisone
629058|NCT00202969|Stomach cancer
629059|NCT00202943|TCRFVR, LAUP, Snorer
629060|NCT00202930|neuroblastoma
629061|NCT00202930|Opsoclonus-myoclonus
629062|NCT00202930|rituximab
629063|NCT00202917|haploidentical transplantation
629064|NCT00202917|immunomagnetic cell sorting
629065|NCT00202917|allogeneic hematopoietic cell transplantation
629066|NCT00202917|dose reduced conditioning
629067|NCT00202904|ezetimibe
629068|NCT00202904|atorvastatin
629069|NCT00202904|hypercholesterolemia
629070|NCT00202904|coronary heart disease
629071|NCT00202891|pyoderma
629072|NCT00202891|sisomicin
629073|NCT00202891|nadifloxacin
629074|NCT00202878|hypercholesterolemia
629075|NCT00202878|myocardial infarction
629076|NCT00202878|cholesterol
629077|NCT00202878|randomized controlled trials
629078|NCT00202878|acute coronary syndrome
629079|NCT00202878|angina
629080|NCT00202813|CVC
629081|NCT00202813|central venous catheter
629082|NCT00202813|infection
629083|NCT00202813|bloodstream infection
629084|NCT00202813|catheter infection
629085|NCT00202813|pediatric
629086|NCT00202813|children
629087|NCT00202813|antibiotic impregnated catheters
629088|NCT00202800|Pancreatic Cancer
629089|NCT00202800|Gemcitabine/Etoposide
629090|NCT00202800|Ras-mutation
629091|NCT00202787|colorectal cancer
629092|NCT00202787|cetuximab
629093|NCT00202787|FOLFOX4
629094|NCT00202774|colorectal cancer, capecitabine, oxaliplatin, 5-fluorouracil
629095|NCT00202761|Cerebral palsy
629096|NCT00202761|Functional training
629097|NCT00202761|preschool children
629098|NCT00202761|Gross Motor Functional Classification Level
629099|NCT00202761|Gross motor functional Measure test
629100|NCT00202761|Pediatric Evaluation of Disability Inventory
629101|NCT00202761|Parental Stress Index
629102|NCT00202748|metabolic syndrome
629103|NCT00202748|lifestyle
629104|NCT00202748|obesity
629105|NCT00202735|shoulder dislocation
629106|NCT00202735|anterior
629107|NCT00202735|traumatic
629108|NCT00202735|primary
629109|NCT00202735|first time
629110|NCT00202735|initial
629111|NCT00202735|immobilization
629112|NCT00202735|external
629113|NCT00202735|rotation
629114|NCT00202722|Remifentanil, parenteral opioids, obstetric analgesia, IVPCA
629115|NCT00202709|Anxiety disorder
629116|NCT00202709|Thought Field Therapy
629117|NCT00202709|Psychotherapy
629118|NCT00202709|Agoraphobia
629119|NCT00202709|Social Phobia
629120|NCT00202709|Post Traumatic Stress Disorder
629121|NCT00202683|Altitude
629122|NCT00202683|Anoxemia
629123|NCT00202683|Mitochondria
629124|NCT00202683|Reflex
629125|NCT00202683|Genetic research
629126|NCT00202670|coronary artery disease
629127|NCT00202670|stress myocardial scintigraphy
629128|NCT00202670|stress echocardiography
629129|NCT00202657|parkinson's disease
629130|NCT00202657|pergolide
629131|NCT00202657|heart valve disease
629132|NCT00202631|tetraplegia
629133|NCT00202631|quadriplegia
629134|NCT00202631|spinal cord injury
629135|NCT00202631|functional electrical stimulation
629136|NCT00202631|abdominal stimulation
629137|NCT00202618|Hypertension
629138|NCT00202618|Type 2 diabetes mellitus
629139|NCT00202618|Microalbuminuria
629140|NCT00202618|Amlodipine
629141|NCT00202618|Calcium channel blocker
629142|NCT00202618|Valsartan
629143|NCT00202618|Angiotensin type 2 receptor blocker
629144|NCT00202527|Sleep apnea
629145|NCT00202527|Hypertension
629146|NCT00202527|CPAP
629147|NCT00202514|alcoholism
629148|NCT00202514|alcohol related disorders
629149|NCT00202514|mood disorders
629150|NCT00202514|anticonvulsants
629151|NCT00202514|divalproex sodium
629152|NCT00202488|anemia, iron-deficiency
629153|NCT00202488|Helicobacter pylori
629154|NCT00202475|Dubble eerythrocytapheresis
629155|NCT00202462|testosterone
629156|NCT00202462|depression
629157|NCT00202462|subsyndromal depression
629158|NCT00202462|quality of life
629159|NCT00202449|Prazosin
629160|NCT00202449|Paroxetine
629161|NCT00202449|Stress Disorders, Post-Traumatic
629162|NCT00202449|Sleep Disorders
629163|NCT00202423|Multiple sclerosis
629164|NCT00202423|Cannabinoids
629165|NCT00202423|Spasticity
629166|NCT00202423|fMRI
629167|NCT00202423|TMS
629168|NCT00202410|Multiple Sclerosis
629169|NCT00202410|Tuberculosis vaccine
629170|NCT00202410|Therapy
629171|NCT00202397|cerebellar ataxia
629172|NCT00202397|deep cerebellar nuclei (DCN)
629173|NCT00202397|small-conductance calcium-activated potassium(SK)channels
629174|NCT00202397|riluzole
629175|NCT00202397|Sporadic ataxia
629176|NCT00202397|Multiple system atrophy type C
629177|NCT00202384|Multiple Sclerosis
629178|NCT00202384|microarrays
629179|NCT00202371|MDS, Fatigue, RBC transfusion
629180|NCT00202358|perioperative
629181|NCT00202358|beta-blockers
629182|NCT00202358|inflammation
629183|NCT00202358|outcomes
629184|NCT00202345|Creatinine Clearance
629185|NCT00202345|Hemoglobin
629186|NCT00202345|Iron sucrose
629187|NCT00202345|Oral iron therapy
629188|NCT00202345|Ferritin
629189|NCT00202345|Transferrin saturation
629190|NCT00202345|Iron
629191|NCT00202319|sedation
629192|NCT00202319|mechanical ventilation
629193|NCT00202319|sedation protocols
629194|NCT00202319|critical care
629195|NCT00202319|intensive care outcomes
629196|NCT00202319|staffing
629197|NCT00202306|at risk mental state
629198|NCT00202306|prodrome
629199|NCT00202306|ultra high risk
629200|NCT00202306|first episode psychosis
629201|NCT00202306|schizophrenia
629202|NCT00202306|bipolar disorder
629203|NCT00202293|Bipolar
629204|NCT00202293|Mania
629205|NCT00202293|Drug treatment
629206|NCT00202293|First episode
629207|NCT00202293|Psychosis
629208|NCT00202293|Therapy
629209|NCT00202293|Antipsychotic
629210|NCT00202267|leg ulcer, compression, bandage, APBI, venous insufficiency
629211|NCT00202254|Mulitple Sclerosis
629212|NCT00202254|MS
629213|NCT00202241|HIV
629214|NCT00202241|AIDS
629215|NCT00202241|testosterone
629216|NCT00202241|anabolic steroid
629217|NCT00202241|body composition
629218|NCT00202241|lipodystrophy
629219|NCT00202241|MRI
629220|NCT00202241|BIA
629221|NCT00202241|skinfold measurements
629222|NCT00202241|protease inhibitors
629223|NCT00202228|HIV
629224|NCT00202228|HIV/AIDS
629225|NCT00202228|Lactic Acidosis
629226|NCT00202228|Supplementation
629227|NCT00202228|Lactate Clearance
629228|NCT00202228|Mitochondrial Toxicity
629229|NCT00202228|HAART
629230|NCT00202215|Day hospital treatment
629231|NCT00202202|personality disorder
629232|NCT00202202|user satisfaction
629233|NCT00202189|COPD
629234|NCT00202189|Pulmicort
629235|NCT00202189|Budesonide
629236|NCT00202189|Chronic
629237|NCT00202189|Obstructive
629238|NCT00202189|Pulmonary
629239|NCT00202189|Disease
629240|NCT00202189|Exercise
629241|NCT00202189|Emphysema
629242|NCT00202176|Chronic
629243|NCT00202176|Obstructive
629244|NCT00202176|Pulmonary
629245|NCT00202176|Disease
629246|NCT00202176|COPD
629247|NCT00202176|Atrovent
629248|NCT00202176|Ipratropium
629249|NCT00202176|Bromide
629250|NCT00202176|Exercise
629251|NCT00202176|Dyspnea
629252|NCT00202163|ED
629253|NCT00202163|DHEA
629254|NCT00202163|testosterone
629255|NCT00202150|Advanced chronic diseases
629256|NCT00202150|Heart failure
629257|NCT00202150|Chronic obstructive lung disease
629258|NCT00202150|primary care
629259|NCT00202150|Chronic Care
629260|NCT00202137|Home Blood Pressure, Hypertension, Blood Pressure Control
629261|NCT00202111|Clinical Trial
629262|NCT00202111|Colonic Neoplasms
629263|NCT00202111|Laparoscopic Surgery
629264|NCT00202111|Morbidity
629265|NCT00202111|Port Site Metastasis
629266|NCT00202111|Disease-Free Survival
629267|NCT00202098|ARDS
629268|NCT00202098|mechanical ventilation
629269|NCT00202098|variable ventilation
629270|NCT00202098|chaotic ventilation
629271|NCT00202072|lung
629272|NCT00202072|airway
629273|NCT00202072|pulmonary exacerbation
629274|NCT00202072|mucus
629275|NCT00202059|Breast cancer
629276|NCT00202059|Bone mineral density
629277|NCT00202059|Chemotherapy
629278|NCT00202046|Breast cancer
629279|NCT00202046|Lymphedema
629280|NCT00202046|Quality of life
629281|NCT00202033|referred to
629282|NCT00202033|comprehensive
629283|NCT00202033|diabetes
629284|NCT00202033|education
629285|NCT00202033|program
629286|NCT00202020|Cerebral infarction
629287|NCT00202020|Prevention
629288|NCT00202020|Cilostazol
629289|NCT00202020|Aspirin
629290|NCT00202020|Stroke
629291|NCT00202020|Clinical trial
629292|NCT00202007|Aripiprazole
629293|NCT00202007|Schizophrenia
629294|NCT00202007|Clinical trial
629295|NCT00202007|Risperidone
629296|NCT00201994|Sodium
629297|NCT00201994|SIADH
629298|NCT00201994|Vasopressin
629299|NCT00201994|CHF
629300|NCT00201994|Cirrhosis
629301|NCT00201994|salt
629302|NCT00201994|water
629303|NCT00201994|electrolyte
629304|NCT00201981|dry eye
629305|NCT00201981|keratoconjunctivitis sicca
629306|NCT00201955|dry eye
629307|NCT00201955|keratoconjunctivitis sicca
629308|NCT00201942|Breast Cancer
629309|NCT00201942|Diagnosis
629310|NCT00201942|PET
629311|NCT00201942|Positronic Emission Tomography
629312|NCT00201942|fluorodeoxyglucose
629313|NCT00201929|breast cancer
629314|NCT00201929|decision aid
629315|NCT00201929|Decision Board
629316|NCT00201929|information transfer
629317|NCT00201916|prostate cancer
629318|NCT00201916|prostate specific antigen
629319|NCT00201916|PSA
629320|NCT00201916|radiation fractionation
629321|NCT00201903|venous thromboembolism
629322|NCT00201903|brain tumours
629323|NCT00201903|glioma
629324|NCT00201903|tissue factor
629325|NCT00201903|blood coagulation
629326|NCT00201903|tumour progression
629327|NCT00201903|low molecular weight heparin
629328|NCT00201890|Breast Cancer
629329|NCT00201890|Lymphedema
629330|NCT00201890|Treatment
629331|NCT00201890|Massage
629332|NCT00201890|Randomized
629333|NCT00201890|DLT therapy
629334|NCT00201890|Quality of Life
629335|NCT00201890|Decongestive Therapy
629336|NCT00201890|Breast Cancer related Lymphedema
629337|NCT00201877|Relapsed/Refractory
629338|NCT00201877|NHL
629339|NCT00201877|Follicular
629340|NCT00201877|Mantle Cell
629341|NCT00201877|non-Hodgkin's lymphoma
629342|NCT00201864|Postmenopausal
629343|NCT00201864|Women
629344|NCT00201851|Asian
629345|NCT00201851|Premenopausal
629346|NCT00201851|Women
629347|NCT00201851|Oophorectomy
629348|NCT00201838|Advanced Stage
629349|NCT00201838|Chemotherapy Naive
629350|NCT00201825|Previously Untreated
629351|NCT00201825|Advanced
629352|NCT00201812|Advanced Solid Tumors
629353|NCT00201799|Hematopoietic Stem Cell Transplantation
629354|NCT00201786|Corticosteroids
629355|NCT00201773|Post-Menopause
629356|NCT00201773|Neoadjuvant Therapy
629357|NCT00201760|metastatic
629358|NCT00201747|Advanced
629359|NCT00201734|Adenocarcinoma
629360|NCT00201721|Previously Untreated
629361|NCT00201708|Adjuvant Trial
629362|NCT00201708|Dose-Dense
629363|NCT00201708|Axillary Node-Positive
629364|NCT00201695|Untreated Patients
629365|NCT00201695|Symptomatic
629366|NCT00201682|Leukemia
629367|NCT00201682|Lymphoma
629368|NCT00201669|Aggressive
629369|NCT00201669|Clofarabine
629370|NCT00201656|PPROM
629371|NCT00201656|Cerclage
629372|NCT00201656|Preterm Premature Rupture of the Membranes with Cerclage
629373|NCT00201643|Preterm Labor
629374|NCT00201643|Preterm delivery
629375|NCT00201630|Prostate
629376|NCT00201630|cancer
629377|NCT00201630|Brachytherapy
629378|NCT00201630|Alpha Blocker
629379|NCT00201617|Unilateral hearing loss
629380|NCT00201617|Unilateral deafness
629381|NCT00201617|Bone anchored hearing aid
629382|NCT00201591|Coronary artery disease
629383|NCT00201591|Exercise training
629384|NCT00201591|Intensity
629385|NCT00201591|Randomized
629386|NCT00201591|echocardiography
629387|NCT00201591|Aerobic Exercise
629388|NCT00201578|Herbal Drugs
629389|NCT00201578|Alternative medicine
629390|NCT00201565|pulse wave velocity
629391|NCT00201565|cardiovascular disease
629392|NCT00201539|analgesics, opioid/pharmacokinetics
629393|NCT00201539|humans
629394|NCT00201539|morphine/therapeutic use*
629395|NCT00201539|neoplasms
629396|NCT00201539|pain/drugtherapy
629397|NCT00201526|Bipolar Disorder
629398|NCT00201513|Muscle, Skeletal
629399|NCT00201513|Neuromuscular control
629400|NCT00201513|Stability
629401|NCT00201513|Exercise
629402|NCT00201513|Anticipatory muscle control
629403|NCT00201474|brief depressive episodes
629404|NCT00201474|affective disorders
629405|NCT00201474|EEG and QEEG
629406|NCT00201474|epilepsy
629407|NCT00201474|organic brain disorders
629408|NCT00201474|acute psychiatry
629409|NCT00201461|Patent Foramen Ovale
629410|NCT00201461|STARFlex
629411|NCT00201461|CLOSURE I
629412|NCT00201461|Septal Closure System
629413|NCT00201461|Stroke
629414|NCT00201461|Cerebrovascular Accident
629415|NCT00201461|Transient Ischemic Attack
629416|NCT00201461|Heart Septal Defects, Atrial
629417|NCT00201448|CMV, cytomegalovirus, vaccine, Towne strain
629418|NCT00201435|Breast
629419|NCT00201435|Cancer
629420|NCT00201435|Paclitaxel
629421|NCT00201435|Docetaxel
629422|NCT00201435|Qulaity of life
629423|NCT00201422|MALT lymphoma
629424|NCT00201422|diffuse large B-cell lymphoma,
629425|NCT00201422|stomach
629426|NCT00201422|Helicobacter pylori
629427|NCT00201422|antibiotic therapy
629428|NCT00201396|A Multicenter Phase III Trial
629429|NCT00201396|Induction Chemotherapy
629430|NCT00201396|Concurrent Chemoradiotherapy
629431|NCT00201396|Stage IV Nasopharyngeal Carcinoma (NPC)
629432|NCT00201396|randomization
629433|NCT00201396|disease-free survival
629434|NCT00201370|cervical neoplasia;
629435|NCT00201370|human papillomavirus,
629436|NCT00201370|PCR,
629437|NCT00201370|risk factors,
629438|NCT00201370|Taiwan
629439|NCT00201357|hormone-refractory prostate cancer
629440|NCT00201357|thalidomide
629441|NCT00201357|quality of life
629442|NCT00201344|Radiotherapy
629443|NCT00201344|Adjuvant chemotherapy
629444|NCT00201344|Chemtherapy
629445|NCT00201344|Nasopharyngeal Carcinoma
629446|NCT00201292|Metabolic syndrome
629447|NCT00201292|Diabetes
629448|NCT00201292|Insulin resistance
629449|NCT00201292|pharmacogenetics
629450|NCT00201201|Older Adults
629451|NCT00201201|Primary Care
629452|NCT00201201|Hypertension
629453|NCT00201201|Adherence
629454|NCT00201136|Behavioral intervention
629455|NCT00201136|Lifestyle modification
629456|NCT00201136|Guidelines
629457|NCT00201110|African Americans
629458|NCT00201058|urban
629459|NCT00201058|adolescents
629460|NCT00201058|African American
629461|NCT00201058|web-based
629462|NCT00201058|computer tailoring
629463|NCT00201058|school based
629464|NCT00201045|Hypertension management
629465|NCT00201045|Pharmacist management
629466|NCT00201045|Physician pharmacist collaboration
629467|NCT00201045|Blood pressure control
629468|NCT00200954|prospective
629469|NCT00200954|intervention
629470|NCT00200954|randomised
629471|NCT00200954|probiotics
629472|NCT00200954|atopy
629473|NCT00200941|Restless Legs Syndrome
629474|NCT00200941|Topiramate
629475|NCT00200941|Actigraphy
629476|NCT00200941|Polysomnography
629477|NCT00200928|prospective
629478|NCT00200928|randomised
629479|NCT00200928|intervention
629480|NCT00200928|BCG
629481|NCT00200928|atopy
629482|NCT00200902|Major depressive disorder
629483|NCT00200902|MDD
629484|NCT00200902|Antidepressant
629485|NCT00200889|Acupuncture
629486|NCT00200889|Magnetic Resonance Imaging, Functional
629487|NCT00200889|Brain Mapping
629488|NCT00200889|normal volunteers
629489|NCT00200876|Positron-Emission Tomography
629490|NCT00200876|Endorphins
629491|NCT00200876|Pain Relief
629492|NCT00200876|Opioid Receptors
629493|NCT00200876|Stress
629494|NCT00200876|Analgesia
629495|NCT00200863|light
629496|NCT00200863|wavelength
629497|NCT00200863|action spectrum
629498|NCT00200863|circadian
629499|NCT00200863|melatonin
629500|NCT00200863|alertness
629501|NCT00200863|performance
629502|NCT00200863|arousal
629503|NCT00200850|Breathing
629504|NCT00200850|Allergy
629505|NCT00200850|Mites, House Dust
629506|NCT00200837|oral mucosal pain
629507|NCT00200837|oral inflammations
629508|NCT00200837|anisillo
629509|NCT00200837|cordonsillo
629510|NCT00200837|Piperaceae
629511|NCT00200837|oral ulcers
629512|NCT00200837|oral tumors
629513|NCT00200837|mucosal pain
629514|NCT00200837|mucosal inflammations
629515|NCT00200837|cordoncillo
629516|NCT00200824|isoflavones
629517|NCT00200824|soy
629518|NCT00200824|postmenopausal
629519|NCT00200824|men
629520|NCT00200824|prostate
629521|NCT00200824|breast
629522|NCT00200824|bone
629523|NCT00200798|Milk Thistle
629524|NCT00200798|Silymarin
629525|NCT00200798|pharmacokinetics
629526|NCT00200798|drug interactions
629527|NCT00200798|Normal volunteers
629528|NCT00200785|garlic
629529|NCT00200759|Vaccinium macrocarpon
629530|NCT00200759|Antioxidants
629531|NCT00200759|Drug Interactions
629532|NCT00200746|Hepatitis
629533|NCT00200746|Liver Diseases
629534|NCT00200746|Alcoholism
629535|NCT00200746|Arginine
629536|NCT00200733|acupuncture
629537|NCT00200733|patient narratives
629538|NCT00200733|qualitative methods
629539|NCT00200720|Diet
629540|NCT00200720|Carbohydrates
629541|NCT00200720|Weight Loss
629542|NCT00200707|Cell therapy
629543|NCT00200707|bone marrow mononuclear cells
629544|NCT00200707|myocardial infarction
629545|NCT00200694|Proteinuria
629546|NCT00200694|ACEI
629547|NCT00200694|ARB
629548|NCT00200694|diuretics
629549|NCT00200694|blood pressure
629550|NCT00200694|renal failure
629551|NCT00200681|Secretory Multiple Myeloma
629552|NCT00200681|First line treatment
629553|NCT00200681|Velcade®
629554|NCT00200681|autograft
629555|NCT00200681|Newly diagnosed secretory Multiple Myeloma (MM)
629556|NCT00200642|Gastroesophageal reflux. PPI. Radiofrequency
629557|NCT00200629|Women
629558|NCT00200629|Diagnostic Testing
629559|NCT00200629|Radionuclide Imaging
629560|NCT00200629|Stress Testing
629561|NCT00200629|Adenosine
629562|NCT00200616|Urinary tract infection
629563|NCT00200616|Vesico-renal reflux
629564|NCT00200616|Child
629565|NCT00200616|Antimicrobial prophylaxis
629566|NCT00200616|Recurrence of urinary tract infection
629567|NCT00200603|Calcium phosphate ceramic
629568|NCT00200603|tibial osteotomy
629569|NCT00200603|osteoarthritis
629570|NCT00200590|prostaglandin
629571|NCT00200590|analgesia
629572|NCT00200590|congenital
629573|NCT00200590|heart
629574|NCT00200590|defect
629575|NCT00200590|induced
629576|NCT00200577|Adjuvant therapy
629577|NCT00200577|immunotherapy
629578|NCT00200577|TIL
629579|NCT00200577|melanoma
629580|NCT00200564|Pediatrics
629581|NCT00200564|ketamine
629582|NCT00200564|postoperative analgesia
629583|NCT00200564|nalbuphine
629584|NCT00200564|Postoperative analgesia in children
629585|NCT00200538|frontotemporal dementia
629586|NCT00200538|Mémantine
629587|NCT00200538|Patients with frontotemporal dementia
629588|NCT00200499|Nebivolol
629589|NCT00200499|Hypertension
629590|NCT00200499|Beta-Blocker
629591|NCT00200486|genetic microarray
629592|NCT00200486|head and neck cancer
629593|NCT00200473|Nebivolol
629594|NCT00200473|Hypertension
629595|NCT00200473|Beta-Blockers
629596|NCT00200460|Nebivolol
629597|NCT00200460|Hypertension
629598|NCT00200460|Beta-Blocker
629599|NCT00200447|Parkinson
629600|NCT00200447|brain imaging
629601|NCT00200434|Nebivolol
629602|NCT00200434|Beta-Blocker
629603|NCT00200434|Hypertension
629604|NCT00200421|Nebivolol
629605|NCT00200421|Atenolol
629606|NCT00200421|Exercise
629607|NCT00200421|Hypertension
629608|NCT00200408|cancer of head and neck
629609|NCT00200408|smoking
629610|NCT00200369|HIV
629611|NCT00200369|Adherence
629612|NCT00200369|Antiretroviral therapy
629613|NCT00200369|Protease inhibitor
629614|NCT00200369|Lopinavir
629615|NCT00200343|Chronic hepatitis C, Ursodeoxycholic acid
629616|NCT00200330|weight loss
629617|NCT00200330|physical activity
629618|NCT00200330|diet
629619|NCT00200330|home environment
629620|NCT00200317|Exercise
629621|NCT00200317|Internet
629622|NCT00200317|Print
629623|NCT00200317|Randomized Controlled Trial
629624|NCT00200317|Exercise Intervention
629625|NCT00200304|Obesity
629626|NCT00200304|Weight loss
629627|NCT00200304|Internet
629628|NCT00200278|Exercise
629629|NCT00200278|Intervention studies
629630|NCT00200278|Decision-making
629631|NCT00200278|computer assisted Expert systems
629632|NCT00200278|telephone
629633|NCT00200252|oxytocin
629634|NCT00200252|third stage
629635|NCT00200252|dose
629636|NCT00200252|route
629637|NCT00200252|blood loss
629638|NCT00200226|pain/discomfort
629639|NCT00200226|cervical dilatation
629640|NCT00200226|side effects
629641|NCT00200200|BEVACIZUMAB (AVASTIN)
629642|NCT00200200|DEXAMETHASONE
629643|NCT00200200|FLOXURIDINE
629644|NCT00200200|FLUOROURACIL
629645|NCT00200200|IRINOTECAN (CPT-11) CAMPTOSAR
629646|NCT00200200|LEUCOVORIN
629647|NCT00200200|OXALIPLATIN
629648|NCT00200200|Colon
629649|NCT00200200|Rectal
629650|NCT00200200|04-086
629651|NCT00200200|Adjuvant postoperative chemo for CLM
629652|NCT00200187|Prostatectomy
629653|NCT00200187|Anesthesia
629654|NCT00200187|Blood Loss
629655|NCT00200174|Breast cancer
629656|NCT00200174|estrogen
629657|NCT00200174|postmenopausal
629658|NCT00200148|Pancreaticoduodenectomy
629659|NCT00200148|Hepatectomy
629660|NCT00200148|Major Hepatic resection
629661|NCT00200148|Acute Normovolemic Hemodilution
629662|NCT00200135|motorcycle accident
629663|NCT00200135|helmet
629664|NCT00200135|traumatic brain injury
629665|NCT00200135|financial burden
629666|NCT00200096|Cancer
629667|NCT00200096|Fatigue
629668|NCT00200083|Obesity
629669|NCT00200083|Morbid Obesity
629670|NCT00200083|SHAPE
629671|NCT00200083|IGS
629672|NCT00200083|Implantable Gastric Stimulator
629673|NCT00200070|Angina Pectoris Pain
629674|NCT00200057|Fecal Incontinence
629675|NCT00200057|InterStim
629676|NCT00200044|GERD
629677|NCT00200018|Obesity
629678|NCT00200018|Morbid obesity
629679|NCT00200018|Diabetes
629680|NCT00200005|Slow transit constipation
629681|NCT00200005|Fecal incontinence
629682|NCT00200005|Constipation
629683|NCT00200005|Idiopathic slow transit constipation
629684|NCT00200005|Chronic constipation
629685|NCT00199992|acute wounds
629686|NCT00199992|wounds
629687|NCT00199992|platelets
629688|NCT00199992|platelet gel
629689|NCT00199979|Antiretroviral Therapy
629690|NCT00199979|Nevirapine
629691|NCT00199979|HIV Viral Load
629692|NCT00199979|Adherence
629693|NCT00199979|Quality of Life
629694|NCT00199979|Resistance Mutations
629695|NCT00199966|Bipolar Disorder; Pediatric Bipolar Disorder; Depakote ER
629696|NCT00199953|Postnasal drainage
629697|NCT00199953|Extraesophageal reflux
629698|NCT00199940|Schizophrenia
629699|NCT00199940|Pediatric psychotic disorders
629700|NCT00199940|Ziprasidone
629701|NCT00199914|Diathermy
629702|NCT00199914|Short-wave therapy
629703|NCT00199914|Osteoarthritis
629704|NCT00199914|Knee
629705|NCT00199901|Phase II
629706|NCT00199901|Randomized Controlled Trial
629707|NCT00199901|Double-Blind
629708|NCT00199901|Cancer Vaccine
629709|NCT00199901|NY-ESO-1 protein, human
629710|NCT00199901|ISCOMATRIX, immunological adjuvant
629711|NCT00199888|Kidney Cancer
629712|NCT00199888|Renal Cancer
629713|NCT00199888|Neoplasms, Kidney
629714|NCT00199888|cG250
629715|NCT00199888|antibody
629716|NCT00199888|Iodine 124
629717|NCT00199875|antibody
629718|NCT00199875|renal cell carcinoma
629719|NCT00199875|advanced renal cancer
629720|NCT00199875|cG250
629721|NCT00199875|90Y
629722|NCT00199862|huA33
629723|NCT00199862|antibody
629724|NCT00199862|colorectal cancer
629725|NCT00199862|Iodine 124
629726|NCT00199862|124I
629727|NCT00199862|03-124
629728|NCT00199849|NY-ESO-1
629729|NCT00199849|DNA
629730|NCT00199836|cancer vaccine
629731|NCT00199836|NY-ESO-1b peptide
629732|NCT00199836|CpG 7909
629733|NCT00199836|Montanide ISA-51
629734|NCT00199836|LAGE-1
629735|NCT00199836|immune response
629736|NCT00199836|safety
629737|NCT00199823|Myocardial infarction
629738|NCT00199823|bone marrow cells
629739|NCT00199823|cell transplantation
629740|NCT00199810|Cardiac output
629741|NCT00199810|Preeclamptic women
629742|NCT00199810|systemic vascular resistance
629743|NCT00199810|blood pressure
629744|NCT00199797|Colorectal Cancer
629745|NCT00199797|huA33
629746|NCT00199797|antibody
629747|NCT00199797|chemotherapy
629748|NCT00199784|Hemodynamic
629749|NCT00199784|Hypotension
629750|NCT00199784|Spinal
629751|NCT00199784|Anesthesia
629752|NCT00199784|Healthy pregnant women for elective cesarean section
629753|NCT00199771|Cardiac Surgery
629754|NCT00199771|Infant
629755|NCT00199771|Infant, Newborn
629756|NCT00199771|Hypertonic Solutions
629757|NCT00199771|Saline Solution, Hypertonic
629758|NCT00199771|Capillary leak
629759|NCT00199771|Inflammation Mediators
629760|NCT00199758|Non small cell lung carcinoma
629761|NCT00199758|Cisplatin
629762|NCT00199758|Gemcitabine
629763|NCT00199758|Paclitaxel
629764|NCT00199745|statin
629765|NCT00199745|statins
629766|NCT00199745|statin therapy
629767|NCT00199745|adverse events
629768|NCT00199745|side effect
629769|NCT00199745|Myotoxicity
629770|NCT00199745|atorvastatin
629771|NCT00199745|Atorvastatin Therapy
629772|NCT00199732|Chronic hepatitis B
629773|NCT00199732|CCC DNA kinetics
629774|NCT00199732|Total HBV DNA kinetics
629775|NCT00199732|Adefovir-Dipovixil
629776|NCT00199732|Peg interferon alpha 2a
629777|NCT00199719|drug monitoring
629778|NCT00199719|ribavirin-pharmacokinetic
629779|NCT00199719|pharmacodynamics
629780|NCT00199719|chronic hepatitis C
629781|NCT00199719|non 2 non 3 genotype
629782|NCT00199706|Intracranial Pressure
629783|NCT00199706|Intracranial Hypertension
629784|NCT00199706|Hypertonic Solutions
629785|NCT00199706|Saline Solutions, Hypertonic
629786|NCT00199693|Hemodynamic and respiratory changes and pregnancy
629787|NCT00199693|Healthy pregnant women
629788|NCT00199680|PETscan, cervical cancer
629789|NCT00199667|MMF, Monitoring, area under curve (AUC), kidney transplantation
629790|NCT00199654|colorectal cancer stage II and III
629791|NCT00199628|fetomaternal tissular alloimmunization
629792|NCT00199628|Mothers having a child suffering from:
629793|NCT00199628|neonatal membranous glomerulonephritis
629794|NCT00199628|unexplained neonatal tubular defect
629795|NCT00199628|unexplained thrombotic microangiopathy
629796|NCT00199628|neonatal hemochromatosis
629797|NCT00199615|lung cancer, 18 FDG, PET
629798|NCT00199589|Spastic equinovarus
629799|NCT00199589|Botox
629800|NCT00199589|Ankle foot orthosis
629801|NCT00199576|Corticosteroids
629802|NCT00199576|Laryngotracheal injury
629803|NCT00199576|Intubation-extubation
629804|NCT00199563|Viagra
629805|NCT00199563|sildenafil
629806|NCT00199550|Transurethral Resection of Prostate
629807|NCT00199550|TURP
629808|NCT00199524|ureteroscopy
629809|NCT00199524|stone free
629810|NCT00199511|Brain Tumor
629811|NCT00199511|Intracranial Pressure
629812|NCT00199511|Osmolarity
629813|NCT00199511|Seric
629814|NCT00199511|Hypertonic Solution
629815|NCT00199498|Permanent Pacemaker Implantation- Lead Position
629816|NCT00199485|prostate cancer
629817|NCT00199485|Luteinizing Hormone Releasing Hormone
629818|NCT00199485|LHRH
629819|NCT00199459|calculi
629820|NCT00199459|proteomics
629821|NCT00199446|Sleep -Sleep Disorder
629822|NCT00199446|Sleep- Restless Legs Syndrome
629823|NCT00199446|Clinical Trial
629824|NCT00199433|Parkinson's Disease
629825|NCT00199433|Movement Disorder
629826|NCT00199433|Neurology,
629827|NCT00199433|Clinical Trial
629828|NCT00199420|levodopa
629829|NCT00199420|end of dose wearing off
629830|NCT00199420|OFF time
629831|NCT00199407|Parkinson's disease
629832|NCT00199407|levodopa
629833|NCT00199407|end of dose wearing off
629834|NCT00199407|OFF time
629835|NCT00199394|KW-6002 (istradefylline)
629836|NCT00199394|Entacapone
629837|NCT00199394|Placebo
629838|NCT00199394|Parkinson's Disease
629839|NCT00199394|Motor Response Complications
629840|NCT00199394|Levodopa Therapy
629841|NCT00199381|Parkinson's Disease
629842|NCT00199381|levodopa
629843|NCT00199381|end of dose wearing off
629844|NCT00199381|OFF time
629845|NCT00199368|Parkinson's disease
629846|NCT00199368|levodopa
629847|NCT00199368|end of dose wearing off
629848|NCT00199368|OFF time
629849|NCT00199355|Parkinson's Disease
629850|NCT00199355|levodopa
629851|NCT00199355|end of dose wearing off
629852|NCT00199355|OFF time
629853|NCT00199342|Melanoma
629854|NCT00199342|Monoclonal Antibody
629855|NCT00199342|Anti-GD-3
629856|NCT00199329|ondansetron
629857|NCT00199329|PCA
629858|NCT00199316|patient who recieve kidney surgery and Patient controlled anesthesia with spinal morphine, intrathecal
629859|NCT00199303|NMDAreceptor antagonist, dextromethorphan
629860|NCT00199303|pain, post-operative
629861|NCT00199303|opioid consumption, morphine
629862|NCT00199290|Trafermin
629863|NCT00199290|Periodontitis
629864|NCT00199264|antifungal oral therapy
629865|NCT00199264|efficacy acute candidiasis vulvaginitis
629866|NCT00199251|URTICARIA, WHEALS, FLARE, ANTIHISTAMINE, ANTIHISTAMINE
629867|NCT00199238|ANTIHISTAMINE
629868|NCT00199238|RUPATADINE
629869|NCT00199238|WHEAL
629870|NCT00199238|FLARE
629871|NCT00199238|DERMATOLOGY
629872|NCT00199225|Thorough study QT/QTc
629873|NCT00199225|Cardiac repolarization
629874|NCT00199225|QT prolongation
629875|NCT00199212|HER-2 positive
629876|NCT00199212|metastatic breast cancer patients
629877|NCT00199173|colorectal cancer
629878|NCT00199173|liver metastasis
629879|NCT00199173|intraarterial hepatic injection
629880|NCT00199173|yttrium loaded microspheres
629881|NCT00199173|colorectal neoplasm metastatic to the liver
629882|NCT00199160|local recurrence and or metastatic disease
629883|NCT00199160|Previously treated with platinum
629884|NCT00199160|carcinoma of the head and neck
629885|NCT00199134|neoadjuvant treatment
629886|NCT00199108|CNS relapse
629887|NCT00199108|ALL
629888|NCT00199108|Treatment
629889|NCT00199095|ALL
629890|NCT00199095|Elderly
629891|NCT00199095|Chemotherapy
629892|NCT00199082|High-grade NHL
629893|NCT00199082|De novo
629894|NCT00199082|Mature B-ALL
629895|NCT00199082|Burkitt'S NHL
629896|NCT00199082|Chemotherapy
629897|NCT00199082|Rituximab
629898|NCT00199082|Primary mediastinal diffuse large cell lymphoma
629899|NCT00199082|B-precursor lymphoblastic lymphoma
629900|NCT00199069|ALL
629901|NCT00199069|Treatment
629902|NCT00199069|De Novo
629903|NCT00199069|Adult
629904|NCT00199056|ALL
629905|NCT00199056|Treatment
629906|NCT00199056|De Novo
629907|NCT00199056|Adult
629908|NCT00199030|Relapse
629909|NCT00199030|T-ALL
629910|NCT00199030|T-LBL
629911|NCT00199030|MabCampath
629912|NCT00199030|Minimal residual disease
629913|NCT00199030|Lymphoma, lymphoblastic, T-cell
629914|NCT00199017|T-LBL
629915|NCT00199017|Treatment
629916|NCT00199017|De novo
629917|NCT00199017|Chemotherapy
629918|NCT00199017|Adult
629919|NCT00199017|Lymphoma, lymphoblastic, T-cell
629920|NCT00199004|ALL
629921|NCT00199004|Treatment
629922|NCT00199004|De novo
629923|NCT00199004|Minimal residual disease
629924|NCT00199004|Rituximab
629925|NCT00199004|Adult
629926|NCT00198991|ALL
629927|NCT00198991|Treatment
629928|NCT00198991|de novo
629929|NCT00198991|Minimal residual disease
629930|NCT00198991|Adult
629931|NCT00198978|ALL
629932|NCT00198978|Treatment
629933|NCT00198978|Elderly
629934|NCT00198978|De novo
629935|NCT00198939|drug prevention
629936|NCT00198939|adolescence
629937|NCT00198939|middle school
629938|NCT00198939|randomized trial
629939|NCT00198939|family therapy
629940|NCT00198939|cognitive-behavioral
629941|NCT00198939|efficacy
629942|NCT00198939|selected youth
629943|NCT00198939|indicated youth
629944|NCT00198887|newborn
629945|NCT00198887|operations research
629946|NCT00198887|newborn survival
629947|NCT00198887|Neonatal illness/mortality
629948|NCT00198887|Delivery complications
629949|NCT00198874|drug abuse
629950|NCT00198874|drug dependence
629951|NCT00198874|treatment
629952|NCT00198874|randomized trial
629953|NCT00198874|stage II study
629954|NCT00198874|adolescents
629955|NCT00198874|young adults
629956|NCT00198874|efficacy study
629957|NCT00198861|HIV Epidemiology
629958|NCT00198861|Neurology
629959|NCT00198861|Neuropsychological
629960|NCT00198861|HIV Risk Factors
629961|NCT00198861|Cognitive Risk Factors
629962|NCT00198861|HIV
629963|NCT00198848|Iron deficiency anemia
629964|NCT00198848|Adolescent girls
629965|NCT00198848|India
629966|NCT00198835|malnutrition
629967|NCT00198835|anemia
629968|NCT00198835|infants
629969|NCT00198835|children
629970|NCT00198835|India
629971|NCT00198822|Maternal mortality
629972|NCT00198822|Infant mortality
629973|NCT00198822|Vitamin A
629974|NCT00198822|Beta-carotene
629975|NCT00198822|Micronutrients
629976|NCT00198822|Bangladesh
629977|NCT00198822|Neonatal mortality
629978|NCT00198731|maternal health
629979|NCT00198731|Bangladesh
629980|NCT00198731|care seeking
629981|NCT00198718|Vitamin A supplementation
629982|NCT00198718|HIV
629983|NCT00198718|Mother to child transmission of HIV
629984|NCT00198718|Breastfeeding
629985|NCT00198692|amputation
629986|NCT00198692|depression
629987|NCT00198692|pain
629988|NCT00198692|anxiety
629989|NCT00198692|self-management
629990|NCT00198692|secondary conditions
629991|NCT00198679|skin cleansing
629992|NCT00198679|Bangladesh
629993|NCT00198679|Skin Flora
629994|NCT00198679|Newborn
629995|NCT00198679|infectious disease
629996|NCT00198679|chlorhexidine
629997|NCT00198666|Pneumonia
629998|NCT00198666|zinc
629999|NCT00198653|Hypothermia
630000|NCT00198653|Newborn
630001|NCT00198653|India
630002|NCT00198653|Maternal/Child Health
630003|NCT00198653|Infant
630004|NCT00198653|Kangaroo Mother Care
630005|NCT00197145|HIV-1 GW873140 CCR5 antagonist experienced
630006|NCT00197132|Insulin resistance vasodilatory response
630007|NCT00197119|Hepatitis B
630008|NCT00197119|TWINRIX™ Adult
630009|NCT00197119|Hepatitis A
630010|NCT00197119|TWINRIX™ Junior
630011|NCT00197106|salmeterol/fluticasone combination
630012|NCT00197106|Asthma
630013|NCT00197106|bronchial hyperresponsiveness
630014|NCT00197106|Children
630015|NCT00197106|symptom control
630016|NCT00197093|Schizophrenia
630017|NCT00197093|safety
630018|NCT00197093|tolerability
630019|NCT00197093|pharmacokinetics
630020|NCT00197080|Restless Legs Syndrome
630021|NCT00197080|RLS
630022|NCT00198640|animal antibiotics
630023|NCT00198640|human antibiotics
630024|NCT00198627|Neonatal bacterial infection
630025|NCT00198614|Adrenergic beta-Antagonists
630026|NCT00198614|Carvedilol
630027|NCT00198614|Metoprolol
630028|NCT00198614|Coronary Artery Bypass
630029|NCT00198614|Atrial Fibrillation
630030|NCT00198601|meningitis
630031|NCT00198601|neonatal deaths
630032|NCT00198601|gentamicin
630033|NCT00198601|Uniject
630034|NCT00198601|aminoglycoside
630035|NCT00198588|heparin-induced thrombocytopenia
630036|NCT00198588|argatroban
630037|NCT00198588|cardiac surgery
630038|NCT00198588|acute coronary syndrome
630039|NCT00198588|thrombosis
630040|NCT00198588|amputation
630041|NCT00198588|anticoagulation
630042|NCT00198575|heparin-induced thrombocytopenia
630043|NCT00198575|cardiovascular surgery
630044|NCT00198575|percutaneous coronary intervention
630045|NCT00198562|Antihypertensive therapy
630046|NCT00198562|Home blood pressure
630047|NCT00198562|Systolic blood pressure
630048|NCT00198562|Morning blood pressure
630049|NCT00198562|Calcium antagonist
630050|NCT00198562|Angiotensin receptor antagonist
630051|NCT00198549|Adjuvants, Anesthesia
630052|NCT00198549|hyaluronate lyase
630053|NCT00198523|Cataract Extraction
630054|NCT00198523|Anti-Bacterial Agents
630055|NCT00198523|Steroids
630056|NCT00198484|Adjuvants, Anesthesia
630057|NCT00198484|Spreading Factor
630058|NCT00198445|Cataract Extraction
630059|NCT00198445|Anti-Inflammatory Agents, Non-Steroidal
630060|NCT00198393|stage IIIB/IV NSCLC
630061|NCT00198393|patients with performance status 2 or 3.
630062|NCT00198380|Adenocarcinoma, Bronchiolo-Alveolar
630063|NCT00198367|operable and resectable stage IIIA (T1-3, N2) NSCLC
630064|NCT00198341|Post-surgical Non-small cell lung cancer
630065|NCT00198328|Squamous Cell Carcinoma
630066|NCT00198328|carcinoma
630067|NCT00198328|head and neck cancer
630068|NCT00198328|larynx
630069|NCT00198328|electroporation
630070|NCT00198328|medpulser
630071|NCT00198328|bleomycin
630072|NCT00198328|cancer
630073|NCT00198328|Locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx, or larynx
630074|NCT00198315|Squamous Cell Carcinoma
630075|NCT00198315|Carcinoma
630076|NCT00198315|Head and Neck Cancer
630077|NCT00198315|Oral
630078|NCT00198315|Soft Palate
630079|NCT00198315|Cancer
630080|NCT00198315|Medpulser
630081|NCT00198315|Electroporation
630082|NCT00198315|Local recurrent or second primary squamous cell carcinoma of anterior oral cavity, soft palate, or tonsil
630083|NCT00198302|staphylococcus aureus
630084|NCT00198302|bacteremia
630085|NCT00198302|sepsis
630086|NCT00198289|Cystic Fibrosis
630087|NCT00198289|Staphylococcus aureus
630088|NCT00198289|lungs
630089|NCT00198276|cancer
630090|NCT00198276|cutaneous
630091|NCT00198276|subcutaneous
630092|NCT00198276|MedPulser
630093|NCT00198276|bleomycin
630094|NCT00198276|electroporation
630095|NCT00198276|Cutaneous or subcutaneous cancer
630096|NCT00198263|head and neck cancer
630097|NCT00198263|cancer
630098|NCT00198263|bleomycin
630099|NCT00198263|medpulser
630100|NCT00198263|electroporation
630101|NCT00198263|primary oral cavity, primary pharyngeal, primary laryngeal, salivary gland, limited recurrent and second primary tumors
630102|NCT00198250|Breast cancer survivorship
630103|NCT00198250|hot flashes
630104|NCT00198250|treatment
630105|NCT00198237|Breast Cancer
630106|NCT00198237|Stage II Breast Cancer
630107|NCT00198237|Stage III Breast Cancer
630108|NCT00198224|immunosuppression
630109|NCT00198185|Full Thickness Tendon Defect of Rotator Cuff
630110|NCT00198172|Germ Cell Tumor
630111|NCT00198172|Refractory Germ Cell Tumors
630112|NCT00198172|Cisplatin plus Epirubicin Salvage Chemotherapy
630113|NCT00198159|Refractory Germ Cell Tumors
630114|NCT00198159|Germ Cell Tumors
630115|NCT00198133|Thymoma
630116|NCT00198133|Thymic Carcinoma
630117|NCT00198120|Autistic Disorder
630118|NCT00198120|cycloserine
630119|NCT00198120|pharmacology
630120|NCT00198120|glutamatergic agents
630121|NCT00198120|communication
630122|NCT00198120|social interaction
630123|NCT00198120|Double-Blind Method
630124|NCT00198107|Children
630125|NCT00198107|Adolescents
630126|NCT00198107|Aripiprazole
630127|NCT00198107|Cycloserine
630128|NCT00198107|Aggression
630129|NCT00198107|Irritability
630130|NCT00198107|Self-Injurious Behavior
630131|NCT00198107|Social Interaction
630132|NCT00198107|Antipsychotics
630133|NCT00198107|Pharmacology
630134|NCT00198107|Glutamatergic Agents
630135|NCT00198081|celecoxib for pancreas lesions
630136|NCT00198068|Pregnancy outcomes
630137|NCT00198068|Systemic lupus erythematosus
630138|NCT00198068|Antiphospholipid syndrome
630139|NCT00198055|Aggression
630140|NCT00198055|Behavioral symptoms
630141|NCT00198042|ACL
630142|NCT00198042|Tunnel
630143|NCT00198042|Widening
630144|NCT00198029|Osteoarthritis
630145|NCT00198029|Hyaluronan
630146|NCT00198029|Carpometacarpal
630147|NCT00198029|Outcomes
630148|NCT00198016|coronary fistulas.
630149|NCT00198016|coils embolization.
630150|NCT00198003|hip arthritis
630151|NCT00198003|total hip arthroplasty
630152|NCT00198003|expectations
630153|NCT00198003|education
630154|NCT00197990|total hip arthroplasty
630155|NCT00197990|expectations
630156|NCT00197990|satisfaction
630157|NCT00197990|quality of life
630158|NCT00197977|knee arthritis
630159|NCT00197977|total knee arthroplasty
630160|NCT00197977|expectations
630161|NCT00197977|education
630162|NCT00197964|Self-management
630163|NCT00197964|Self-efficacy
630164|NCT00197964|Quality of life
630165|NCT00197964|Resource utilization
630166|NCT00197951|Psychiatric symptoms associated to alcoholism recovery
630167|NCT00197951|Alcoholism treatment
630168|NCT00197951|Alcohol craving
630169|NCT00197951|Relapse to heavy drinking
630170|NCT00197951|Abuse of other substances during alcoholism recovery
630171|NCT00197925|breast cancer
630172|NCT00197925|dendritic cells
630173|NCT00197925|vaccine
630174|NCT00197912|dendritic cell
630175|NCT00197912|cancer vaccine
630176|NCT00197912|cyclophosphamide
630177|NCT00197912|melanoma
630178|NCT00196989|Efficacy
630179|NCT00196989|PPARpan
630180|NCT00196989|Type 2 Diabetes Mellitus
630181|NCT00196989|Phase IIb
630182|NCT00196989|Safety
630183|NCT00196989|Pharmacokinetics
630184|NCT00196989|GW677954
630185|NCT00196989|Pharmacodynamics
630186|NCT00196989|Tolerability
630187|NCT00196989|Dose-Ranging
630188|NCT00196976|Safety
630189|NCT00196976|Meningococcal vaccine
630190|NCT00196976|Dose selection
630191|NCT00196976|Toddlers
630192|NCT00196976|Immunogenicity
630193|NCT00196976|Conjugate vaccine
630194|NCT00196976|Reactogenicity
630195|NCT00196976|Children
630196|NCT00196937|HPV Vaccine Safety
630197|NCT00196898|Parkinson´s disease
630198|NCT00196898|fibrotic valvular heart fibrosis
630199|NCT00196898|ergot dopamine agonists
630200|NCT00196898|non-ergot dopamine agonists
630201|NCT00196885|cancer cachexia
630202|NCT00196885|muscle wasting
630203|NCT00196885|weight loss
630204|NCT00196885|proteolysis
630205|NCT00196872|dose dense sequence
630206|NCT00196872|dose dense combination
630207|NCT00196872|node positive disease
630208|NCT00196859|Early Breast Cancer in elderly Patients
630209|NCT00196859|Ibandronate plus/minus Capecitabine in elderly patients
630210|NCT00196846|hormone insensitive breast cancer
630211|NCT00196846|Prevention of Chemotherapy induced ovarian failure
630212|NCT00196846|P.O.F.
630213|NCT00196846|GnRH-Agonist Goserelin
630214|NCT00196833|Breast Cancer in Pregnancy
630215|NCT00196833|Prospective and Retrospective Register
630216|NCT00196833|Study
630217|NCT00196820|Metastatic breast cancer
630218|NCT00196820|HER2 negative, medium-risk, metastatic breast cancer
630219|NCT00196807|prostate cancer screening
630220|NCT00196807|medical decision making
630221|NCT00196807|informed decision making
630222|NCT00196807|patient education
630223|NCT00196807|male
630224|NCT00197873|colorectal cancer
630225|NCT00197873|probiotics
630226|NCT00197873|chemotherapy
630227|NCT00197873|prevention
630228|NCT00197873|adverse effects
630229|NCT00197873|diarrhoea
630230|NCT00197860|dendritic cell
630231|NCT00197860|vaccine
630232|NCT00197860|renal cell carcinoma
630233|NCT00197834|Depakote
630234|NCT00197834|Agitation
630235|NCT00197834|Dementia
630236|NCT00197834|Atypical antipsychotic
630237|NCT00197834|Behavioral Symptoms
630238|NCT00197834|Psychiatric Symptoms
630239|NCT00197834|Psychological Symptoms
630240|NCT00197834|Geriatric
630241|NCT00197834|Behavioral and Psychological Symptoms
630242|NCT00197808|Streptococcus pneumoniae
630243|NCT00197808|Neisseria meningitidis
630244|NCT00197756|HIV
630245|NCT00197756|Breastfeeding
630246|NCT00197756|Vitamins
630247|NCT00197756|Tanzania
630248|NCT00197756|Children
630249|NCT00197743|HIV
630250|NCT00197743|Multivitamins
630251|NCT00197743|Pregnancy outcomes
630252|NCT00197743|Tanzania
630253|NCT00197743|Women
630254|NCT00197730|Birth Outcomes
630255|NCT00197730|Nutrition
630256|NCT00197730|HIV
630257|NCT00197730|AIDS
630258|NCT00197730|Vitamins
630259|NCT00197730|Multivitamins
630260|NCT00197730|Maternal and child health outcomes
630261|NCT00197730|Tanzania
630262|NCT00197730|Africa
630263|NCT00197704|Tuberculosis
630264|NCT00197704|HIV
630265|NCT00197704|Tanzania
630266|NCT00197704|multivitamins
630267|NCT00197691|HIV infected mothers
630268|NCT00197691|Infants at risk of HIV-infection
630269|NCT00197691|Infant lower respiratory tract disease
630270|NCT00197691|Infant bloodstream infection
630271|NCT00197678|HIV
630272|NCT00197678|AIDS
630273|NCT00197678|Multivitamins
630274|NCT00197678|Pregnancy Outcomes
630275|NCT00197678|Women
630276|NCT00197678|Tanzania
630277|NCT00197678|Africa
630278|NCT00197652|Prevention of Mother-Infant HIV Transmission
630279|NCT00197639|indinavir, HIV, ritonavir, pharmacokinetics, Thailand
630280|NCT00197561|HIV
630281|NCT00197561|Selenium
630282|NCT00197561|Nutrition
630283|NCT00197561|Women
630284|NCT00197561|Pregnancy
630285|NCT00197561|Tanzania
630286|NCT00197561|Maternal and child health outcomes
630287|NCT00197561|HIV/AIDS
630288|NCT00197561|Pregnancy Outcome
630289|NCT00197548|Women
630290|NCT00197548|Pregnancy Outcomes
630291|NCT00197548|Nutrition
630292|NCT00197548|Vitamins
630293|NCT00197548|Tanzania
630294|NCT00197548|Maternal and Child Health Outcomes
630295|NCT00197522|breast cancer
630296|NCT00197522|vaccination
630297|NCT00197522|dendritic cells
630298|NCT00197522|HER-2
630299|NCT00197522|CD34+ stem cells
630300|NCT00197509|Long-Term Care
630301|NCT00197509|Clinical Protocols
630302|NCT00197509|Sit-To-Stand
630303|NCT00197483|Pergolide
630304|NCT00197483|Dopamine D1
630305|NCT00197483|Schizophrenia
630306|NCT00197483|Cognitive disturbance
630307|NCT00197483|Negative symptoms
630308|NCT00197444|esophageal cancer
630309|NCT00197444|Nedaplatin
630310|NCT00197444|5-FU
630311|NCT00197444|chemotherapy
630312|NCT00197444|radiation
630313|NCT00197444|chemoradiotherapy
630314|NCT00197418|H. pylori infection
630315|NCT00197392|Ventriculostomy
630316|NCT00197392|EVD
630317|NCT00197379|androgenetic alopecia
630318|NCT00197379|roxitromycin
630319|NCT00197379|apoptosis
630320|NCT00197366|pregnancy
630321|NCT00197366|HIV-positive
630322|NCT00197366|HIV resistance
630323|NCT00197366|HIV
630324|NCT00197353|Anesthesia, Epidural
630325|NCT00197353|Pharmacology
630326|NCT00197353|Dose-Response Relationship, Drug
630327|NCT00197353|Sympathectomy
630328|NCT00197353|Photoplethysmography
630329|NCT00197340|Pre-Eclampsia
630330|NCT00197340|Fetal Growth Retardation
630331|NCT00197340|Anesthesia, Epidural
630332|NCT00197340|Placental Circulation
630333|NCT00197340|Dose-Response Relationship, Drug
630334|NCT00197327|Labor Pain
630335|NCT00197327|Analgesia, Obstetrical
630336|NCT00197327|Pharmacology
630337|NCT00197327|Treatment Outcome
630338|NCT00197314|Urinary stress incontinence
630339|NCT00197314|Randomized trial
630340|NCT00197314|circular muscle training
630341|NCT00197314|pelvic floor training
630342|NCT00197314|bioequivalence
630343|NCT00197301|Intranasal vaccination, Influenza
630344|NCT00197288|Prophylaxis: Influenza virus infection
630345|NCT00197275|Haemophilus influenzae type b
630346|NCT00197275|diphtheria
630347|NCT00197275|tetanus
630348|NCT00197275|Prophylaxis diphtheria
630349|NCT00197275|pertussis
630350|NCT00197275|hepatitis B
630351|NCT00197275|meningococcal serogroups A & C diseases
630352|NCT00197262|Seasonal Allergic Rhinitis
630353|NCT00197262|GW685698X
630354|NCT00197262|allergic rhinitis
630355|NCT00197262|Hayfever
630356|NCT00197249|Hepatitis A & B
630357|NCT00197249|Typhoid
630358|NCT00197236|Hepatitis A
630359|NCT00197197|HIV-1 GW873140 CCR5 antagonist treatment experienced
630360|NCT00197184|Combined hepatitis A and B vaccine
630361|NCT00197184|Twinrix™
630362|NCT00196794|Pseudomembranous Colitis
630363|NCT00196794|Clostridium difficile-associated diarrhea
630364|NCT00196794|C. difficile
630365|NCT00196794|CDAD
630366|NCT00196781|prostate cancer treatment
630367|NCT00196781|medical decision making
630368|NCT00196781|informed decision making
630369|NCT00196781|shared decision making
630370|NCT00196781|decision aid
630371|NCT00196781|patient education
630372|NCT00196768|relapsed
630373|NCT00196768|acute promyelocytic leukemia
630374|NCT00196768|arsenic
630375|NCT00196742|alpha Galactosidase A
630376|NCT00196742|aGAL (alpha-galactosidase)
630377|NCT00196742|Fabry
630378|NCT00196742|GL3 (globotriaosylceramide)
630379|NCT00196742|Anderson-Fabry Disease
630380|NCT00196742|angiokeratomas
630381|NCT00196742|GLA deficiency (gene deficiency)
630382|NCT00196742|errors in metabolism
630383|NCT00196716|alpha Galactosidase A
630384|NCT00196716|aGAL
630385|NCT00196716|rh aGAL
630386|NCT00196716|Fabry
630387|NCT00196716|GL3
630388|NCT00196716|Fabrazyme
630389|NCT00196703|Aphasia
630390|NCT00196703|Memantine
630391|NCT00196703|Constraint-induced language therapy
630392|NCT00196703|Event-related potentials
630393|NCT00196690|Aphasia
630394|NCT00196690|Donepezil
630395|NCT00196664|Chronic Hepatitis C
630396|NCT00196664|Paroxetine
630397|NCT00196664|Depression
630398|NCT00196651|HIV infection
630399|NCT00196651|AIDS Vaccines
630400|NCT00196651|ALVAC vaccine
630401|NCT00196651|Interleukin-2
630402|NCT00196651|Antiretroviral Therapy, Highly Active
630403|NCT00196638|HIV infections
630404|NCT00196638|Primary acute infection
630405|NCT00196638|Interferon-alpha
630406|NCT00196625|HIV infections
630407|NCT00196625|Salvage therapy
630408|NCT00196625|Amprenavir
630409|NCT00196625|Lopinavir
630410|NCT00196625|Ritonavir
630411|NCT00196612|HIV Infections
630412|NCT00196612|Reverse Transcriptase Inhibitors
630413|NCT00196612|Treatment simplification
630414|NCT00196599|HIV infections
630415|NCT00196599|Reverse Transcriptase Inhibitors
630416|NCT00196586|Chronic Hepatitis C
630417|NCT00196586|HIV infection
630418|NCT00196586|Interleukin-2
630419|NCT00196586|Pegylated interferon alpha 2 a
630420|NCT00196586|ribavirin
630421|NCT00196573|Rotator Cuff
630422|NCT00196573|Tendinosis
630423|NCT00196573|Impingement Syndrome
630424|NCT00196573|Partial Thickness Tears
630425|NCT00196573|Rotator Cuff Tendinosis
630426|NCT00196573|Partial Thickness Rotator Cuff Tears
630427|NCT00196560|Immobilization in External Rotation
630428|NCT00196560|Acute primary anterior shoulder dislocation
630429|NCT00196547|Asthma
630430|NCT00196547|Respiratory viral infections
630431|NCT00196547|Exacerbations
630432|NCT00196547|Pediatric
630433|NCT00196547|Leukotriene receptor antagonists
630434|NCT00196547|School
630435|NCT00196508|Childbirth
630436|NCT00196482|growth
630437|NCT00196482|oral feeding
630438|NCT00196482|nutrition
630439|NCT00196456|Photodynamic lasertherapy
630440|NCT00196456|Periodontol disease
630441|NCT00196417|heparin-induced thrombocytopenia
630442|NCT00196417|HIT
630443|NCT00196417|unfractionated heparin
630444|NCT00196417|UFH
630445|NCT00196417|low-molecular-weight heparin
630446|NCT00196417|LMWH
630447|NCT00196417|thrombosis prophylaxis
630448|NCT00196417|HIT-antibody
630449|NCT00196404|overactive bladder
630450|NCT00196404|urge incontinence
630451|NCT00196404|urinary incontinence
630452|NCT00196391|secondary amenorrhea
630453|NCT00196391|progesterone
630454|NCT00196378|vaginal atrophy
630455|NCT00196378|vaginal dryness
630456|NCT00196378|vaginal itching
630457|NCT00196378|vaginal pain
630458|NCT00196378|dyspareunia
630459|NCT00196365|cyclic pelvic pain
630460|NCT00196365|dysmenorrhea
630461|NCT00196352|oral contraceptives
630462|NCT00196352|birth control
630463|NCT00196352|ethinyl estradiol
630464|NCT00196352|pregnancy prevention
630465|NCT00196339|prostate cancer
630466|NCT00196339|hot flashes
630467|NCT00196339|hot flushes
630468|NCT00196339|vasomotor symptoms
630469|NCT00196326|pregnancy prevention
630470|NCT00196326|oral contraceptives
630471|NCT00196313|cyclic pelvic pain
630472|NCT00196313|dysmenorrhea
630473|NCT00196313|oral contraceptives
630474|NCT00196300|Assessment, Risk
630475|NCT00196300|Autonomic nervous system
630476|NCT00196300|Aged
630477|NCT00196287|Assessment, risk
630478|NCT00196287|autonomic nervous system
630479|NCT00196287|Gender
630480|NCT00196274|AUTONOMIC NERVOUS SYSTEM
630481|NCT00196274|Assessment, Risk
630482|NCT00196261|Assessment, Risk
630483|NCT00196261|Autonomic nervous system
630484|NCT00196235|Assessment, Risk
630485|NCT00196235|Diabetes mellitus
630486|NCT00196235|Autonomic nervous system
630487|NCT00196209|atrial fibrillation
630488|NCT00196209|catheter ablation
630489|NCT00196196|Hydrocephalus
630490|NCT00196196|Codman Hakim Programmable Valve
630491|NCT00196196|Programmable Valve
630492|NCT00196196|Shunt System
630493|NCT00196131|morphine
630494|NCT00196131|head injury
630495|NCT00196131|SAH
630496|NCT00196118|Pulmonary Embolism
630497|NCT00196118|Venous Thromboembolism
630498|NCT00196118|Inferior Vena Cava Filter
630499|NCT00196118|IVC
630500|NCT00196118|PE
630501|NCT00196105|Stents
630502|NCT00196105|Stent-graft
630503|NCT00196105|Minimally invasive
630504|NCT00196105|Biliary Tract Cancer
630505|NCT00196105|Pancreatic Cancer
630506|NCT00196105|Jaundice
630507|NCT00196105|Biliary Tract Neoplasms
630508|NCT00196105|Pancreatic Neoplasms
630509|NCT00196105|Jaundice, Obstructive
630510|NCT00196105|Zilver
630511|NCT00196079|coronary artery
630512|NCT00196079|stenosis
630513|NCT00196079|drug eluting stent
630514|NCT00196079|stent
630515|NCT00196053|Intrathecal pain management
630516|NCT00196053|constant flow pump
630517|NCT00196014|Registered Nurses
630518|NCT00196014|Workload
630519|NCT00196014|Clinical staff nurses that are currently working
630520|NCT00196001|Adrenal sufficiency
630521|NCT00196001|Low-dose ACTH stimulation
630522|NCT00196001|G proteins
630523|NCT00195988|immunosuppression,
630524|NCT00195988|steroid avoidance,
630525|NCT00195988|liver transplantation,
630526|NCT00195988|children
630527|NCT00195975|Abdominal Pain
630528|NCT00195975|Functional Gastrointestinal Disorders
630529|NCT00195975|Stress
630530|NCT00195975|Anxiety
630531|NCT00195975|Autonomic Nervous System
630532|NCT00195962|Breastfeeding
630533|NCT00195962|Post-partum mothers of healthy breast-fed newborns
630534|NCT00195949|Pyloric Stenosis
630535|NCT00195949|Laparoscopy
630536|NCT00195949|Idiopathic Hypertrophic Pyloric Stenosis
630537|NCT00195936|Cinacalcet
630538|NCT00195936|PTH
630539|NCT00195936|XLH
630540|NCT00195936|children and adolescents with hypophosphatemic rickets (XLH)
630541|NCT00195923|appendicitis
630542|NCT00195923|perforation
630543|NCT00195910|Acute
630544|NCT00195910|Pain
630545|NCT00195910|Emergency Department
630546|NCT00195910|Morphine
630547|NCT00195910|Hydromorphone
630548|NCT00195910|Dilaudid
630549|NCT00195897|Lymphoma
630550|NCT00195897|Anthracyclines
630551|NCT00195897|Heart Failure
630552|NCT00195897|Radionuclide
630553|NCT00195897|Magnetic Resonance Imaging
630554|NCT00195897|Troponin
630555|NCT00195897|Natriuretic Peptide, Brain
630556|NCT00195884|Diabetes Mellitus
630557|NCT00195884|Type 2 Diabetes
630558|NCT00195884|Aerobic
630559|NCT00195884|Resistance
630560|NCT00195884|weight training
630561|NCT00195884|Exercise
630562|NCT00195871|Non-Hodgkin
630563|NCT00195871|Lymphoma
630564|NCT00195871|Lymphoblastic
630565|NCT00195858|Youth
630566|NCT00195858|Exercise
630567|NCT00195858|Physical Activity
630568|NCT00195858|Aerobic
630569|NCT00195858|Resistance
630570|NCT00195858|Overweight
630571|NCT00195858|obese
630572|NCT00195858|Canada
630573|NCT00195858|Sigal
630574|NCT00195819|ankylosing spondylitis
630575|NCT00195819|adalimumab
630576|NCT00195806|Migraine
630577|NCT00195806|Depakote ER
630578|NCT00195806|Divalproex sodium
630579|NCT00195793|Hyperlipidemia
630580|NCT00195793|fenofibrate
630581|NCT00195793|ezetimibe
630582|NCT00195793|atorvastatin
630583|NCT00195780|Bipolar I Disorder
630584|NCT00195780|Depakote
630585|NCT00195767|Bipolar I Disorder
630586|NCT00195767|Depakote ER
630587|NCT00195767|divalproex sodium
630588|NCT00195754|Migraines
630589|NCT00195754|Depakote ER
630590|NCT00195754|divalproex sodium
630591|NCT00195741|Migraine
630592|NCT00195741|Depakote ER
630593|NCT00195728|Hydrocodone/Acetaminophen
630594|NCT00195728|Vicodin CR
630595|NCT00195702|Rheumatoid Arthritis
630596|NCT00195663|Early Rheumatoid Arthritis
630597|NCT00195650|Rheumatoid Arthritis
630598|NCT00195637|GNE Gene
630599|NCT00195637|Alpha-Dystroglycan
630600|NCT00195637|Sialic Acid
630601|NCT00195637|Glycosylation
630602|NCT00195637|Dystroglycanopathy
630603|NCT00195637|Hereditary Inclusion Body Myopathy
630604|NCT00195637|Immune Globulin
630605|NCT00195637|HIBM
630606|NCT00195624|Immunosuppression
630607|NCT00195624|Alemtuzumab/Campath
630608|NCT00195624|Severe Aplastic Anemia
630609|NCT00195624|T-cells
630610|NCT00195624|Hematopoiesis
630611|NCT00195624|Autoimmunity
630612|NCT00195624|Thrombocytopenia
630613|NCT00195624|Neutropenia
630614|NCT00195624|SAA
630615|NCT00195611|Middle Ear Infection
630616|NCT00195598|Panic Disorders
630617|NCT00195585|Colon Cancer
630618|NCT00195572|Gastric Cancer
630619|NCT00195572|Advanced/Recurrent Gastric Cancer
630620|NCT00195559|Premenstrual Syndrome (PMS)
630621|NCT00195559|Hormone Therapy
630622|NCT00195546|Menopause
630623|NCT00195533|Leukemia
630624|NCT00195533|Lymphoma
630625|NCT00195533|Myeloma
630626|NCT00195520|Menopause
630627|NCT00195520|Sleep Disorder
630628|NCT00195520|Hot Flashes
630629|NCT00195507|Psoriasis
630630|NCT00195494|Rheumatoid Arthritis
630631|NCT00195481|Kidney
630632|NCT00195481|Transplant
630633|NCT00195468|Kidney Failure
630634|NCT00195468|Transplant
630635|NCT00195455|Postmenopause
630636|NCT00195442|Hemophilia A
630637|NCT00195429|Kidney
630638|NCT00195429|Transplant
630639|NCT00195416|Ankylosing Spondylitis
630640|NCT00195403|Rheumatoid Arthritis
630641|NCT00195390|Vaccine
630642|NCT00195390|heptavalent pneumococcal conjugate vaccine
630643|NCT00195364|Rheumatoid Arthritis
630644|NCT00195351|Complicated intra-abdominal infection
630645|NCT00195351|Appendicitis with abscess
630646|NCT00195351|Perforated diverticulitis
630647|NCT00195351|Purulent peritonitis
630648|NCT00195351|Complicated cholecystitis
630649|NCT00195338|Rheumatoid Arthritis
630650|NCT00195325|Advanced Malignant Solid Tumors
630651|NCT00195312|HIV
630652|NCT00195312|Vaccine
630653|NCT00195312|Treatment Experienced
630654|NCT00195299|Carcinoma
630655|NCT00195299|Head
630656|NCT00195299|Neck
630657|NCT00195286|Urinary Infections
630658|NCT00195273|Kidney
630659|NCT00195273|Transplant
630660|NCT00195260|Solid tumors
630661|NCT00195247|Tumors
630662|NCT00195247|Advanced malignant solid tumors
630663|NCT00195234|HIV
630664|NCT00195234|Treatment Experienced
630665|NCT00195221|Hemophilia B
630666|NCT00195208|Gastroesophageal Reflux Disease (GERD)
630667|NCT00195195|Transplantation
630668|NCT00195182|Hypertension
630669|NCT00195182|African-American
630670|NCT00195182|Perceived Racism
630671|NCT00195182|Psychological Stress
630672|NCT00195182|Medication Adherence
630673|NCT00195169|Myocardial Infarction
630674|NCT00195169|Social support
630675|NCT00195156|Solid Tumor Malignancies
630676|NCT00195143|Parkinson's disease
630677|NCT00195143|GABA
630678|NCT00195143|Subthalamic nucleus
630679|NCT00195143|Adeno-associated virus
630680|NCT00195143|AAV
630681|NCT00195143|Gene therapy
630682|NCT00195130|prognosis
630683|NCT00195130|risk of death
630684|NCT00195130|morbidity
630685|NCT00195130|mortality
630686|NCT00195130|quality of life
630687|NCT00195117|Asthma
630688|NCT00195117|Behavior change
630689|NCT00195117|Physical activity
630690|NCT00195117|Risk reduction
630691|NCT00195104|Myelodysplastic Syndrome
630692|NCT00195078|head and neck cancer
630693|NCT00195078|squamous cell carcinoma of the oral cavity
630694|NCT00195078|squamous cell carcinoma of the oropharynx
630695|NCT00195078|squamous cell carcinoma of the larynx
630696|NCT00195078|squamous cell carcinoma of the hypopharynx
630697|NCT00195065|Asthma
630698|NCT00195065|Behavior change
630699|NCT00195065|Physical activity
630700|NCT00195065|Risk reduction
630701|NCT00195052|epilepsy
630702|NCT00195052|optical imaging
630703|NCT00195052|optical mapping
630704|NCT00195039|Prostate Cancer
630705|NCT00195000|Acute Myeloid Leukemia
630834|NCT00194350|Factor V Leiden
630706|NCT00195000|Myelodysplastic Syndrome
630707|NCT00194987|Alloimmune thrombocytopenia
630708|NCT00194987|Fetal alloimmune thrombocytopenia
630709|NCT00194974|pregnancy
630710|NCT00194974|chronic hypertension
630711|NCT00194974|Toxemia
630712|NCT00194974|Blood Pressure
630713|NCT00194961|Chronic Kidney Disease
630714|NCT00194961|Growth Failure
630715|NCT00194961|Cytokines
630716|NCT00194961|leptin
630717|NCT00194935|Ovarian Cancer
630718|NCT00194935|Cancer of the Ovary
630719|NCT00194896|type 2 diabetes mellitus
630720|NCT00194896|autoantibodies
630721|NCT00194896|islet proteins
630722|NCT00194896|rosiglitazone
630723|NCT00194896|glyburide
630724|NCT00194896|c-peptide
630725|NCT00194883|Recombinant Human Growth Hormone
630726|NCT00194883|Leptin
630727|NCT00194883|Cytokines
630728|NCT00194883|Chronic Renal Insufficiency
630729|NCT00194883|Children
630730|NCT00194870|EEG
630731|NCT00194870|DBS
630732|NCT00194857|anemia
630733|NCT00194857|dose reduction
630734|NCT00194857|neutropenia
630735|NCT00194857|hepatitis C virus
630736|NCT00194857|human immunodeficiency virus
630737|NCT00194844|caring
630738|NCT00194844|miscarriage
630739|NCT00194844|grief
630740|NCT00194844|couples
630741|NCT00194844|counseling
630742|NCT00194805|Internet
630743|NCT00194805|Diabetes
630744|NCT00194805|Education
630745|NCT00194805|Social Support
630746|NCT00194766|Breast cancer
630747|NCT00194766|Soft tissue sarcoma
630748|NCT00194753|Breast cancer
630749|NCT00194740|Breast cancer
630750|NCT00194727|Breast cancer
630751|NCT00194701|heart failure
630752|NCT00194701|sleep
630753|NCT00194701|exercise
630754|NCT00194701|heart rate variability
630755|NCT00194688|ammonia
630756|NCT00194675|androgen deficiency
630757|NCT00194675|testosterone
630758|NCT00194675|Benign Prostatic Hyperplasia
630759|NCT00194675|hypogonadism
630760|NCT00194675|prostate
630761|NCT00194675|BPH
630762|NCT00194649|Glycosphingolipids (GSL)
630763|NCT00194636|Prostatitis
630764|NCT00194636|Chronic Male Pelvic Pain Syndrome
630765|NCT00194623|prostatitis
630766|NCT00194597|Prostatitis
630767|NCT00194584|children
630768|NCT00194584|chronic illness
630769|NCT00194584|parent education
630770|NCT00194584|parent support
630771|NCT00194571|breast cancer,
630772|NCT00194571|child functioning,
630773|NCT00194571|parenting,
630774|NCT00194571|self-efficacy,
630775|NCT00194571|psychoeducational intervention
630776|NCT00194571|counseling
630777|NCT00194558|Diabetes
630778|NCT00194558|Health Education
630779|NCT00194558|Information Technology
630780|NCT00194558|Disease Management
630781|NCT00194558|Internet
630782|NCT00194558|Patient Education
630783|NCT00194545|HIV-1
630784|NCT00194545|pediatric adherence
630785|NCT00194545|medication diaries
630786|NCT00194545|HAART
630787|NCT00194545|Treatment Naive
630788|NCT00194532|UTI
630789|NCT00194519|HIV infection
630790|NCT00194519|HIV transmission
630791|NCT00194519|genital herpes
630792|NCT00194519|sexual intercourse
630793|NCT00194519|sexual transmitted infection
630794|NCT00194519|acyclovir
630795|NCT00194519|HIV Seronegativity
630796|NCT00194519|Treatment Naive
630797|NCT00194519|HIV-discordant couples
630798|NCT00194519|HIV serodiagnosis
630799|NCT00194506|Diabetes
630800|NCT00194506|Health Education
630801|NCT00194506|Information Technology
630802|NCT00194506|Disease Management
630803|NCT00194506|Internet
630804|NCT00194506|Patient Education
630805|NCT00194493|Cancer
630806|NCT00194493|Quality of Life
630807|NCT00194493|Signs and Symptoms
630808|NCT00194493|Computers
630809|NCT00194493|Patient-Reported Outcomes
630810|NCT00194480|Hepatitis C, peg-Interferon, drug abuse
630811|NCT00194454|Depressive symptoms
630812|NCT00194454|Behavior and behavior mechanisms
630813|NCT00194454|Recovery
630814|NCT00194441|cerebral circulation
630815|NCT00194441|monitoring, physiologic
630816|NCT00194441|informatics
630817|NCT00194441|nursing care
630818|NCT00194441|physiologic variability
630819|NCT00194441|outcome
630820|NCT00194441|quality adjusted life years
630821|NCT00194428|Obesity,
630822|NCT00194428|Metabolic Syndrome,
630823|NCT00194428|BMI
630824|NCT00194402|cholesterol
630825|NCT00194402|dyslipidemia
630826|NCT00194402|hypercholesterolemia
630827|NCT00194402|C-reactive protein
630828|NCT00194363|breast cancer
630829|NCT00194363|breast cancer survivors
630830|NCT00194363|lymphedema
630831|NCT00194363|strength training
630832|NCT00194363|breast cancer survivorship
630833|NCT00194350|Infertility
630835|NCT00194337|stage I breast cancer
630836|NCT00194337|stage II breast cancer
630837|NCT00194337|stage IIIA breast cancer
630838|NCT00194337|stage IIIB breast cancer
630839|NCT00194337|stage IIIC breast cancer
630840|NCT00194337|stage IV breast cancer
630841|NCT00194311|HPV
630842|NCT00194311|Pregnancy
630843|NCT00194298|diabetic foot disease
630844|NCT00194298|osteomyelitis
630845|NCT00194298|charcot
630846|NCT00194298|neuropathy
630847|NCT00194298|hypoxia
630848|NCT00194298|[18 F] Fluorodeoxyglucose
630849|NCT00194298|Positron Emission Tomography Imaging
630850|NCT00194285|Prosthesis
630851|NCT00194285|[18 F] Fluorodeoxyglucose
630852|NCT00194285|Positron Emission Tomography Imaging
630853|NCT00194272|Ectopic pregnancy
630854|NCT00194272|Methotrexate
630855|NCT00194233|Endometriosis
630856|NCT00194220|Infertility
630857|NCT00194220|Oxidative stress
630858|NCT00194207|Ectopic pregnancy
630859|NCT00194194|BMI
630860|NCT00194194|RMR
630861|NCT00194194|Personal Computer
630862|NCT00194181|dialysis
630863|NCT00194181|fibrin
630864|NCT00194181|sheath
630865|NCT00194181|clot
630866|NCT00194181|tpa
630867|NCT00194168|ectopic pregnancy
630868|NCT00194155|cytomegalovirus
630869|NCT00194155|pregnancy
630870|NCT00194155|placenta
630871|NCT00194142|Pregnancy
630872|NCT00194142|Cytomegalovirus
630873|NCT00194090|pain
630874|NCT00194090|osteoarthritis
630875|NCT00194051|obesity
630876|NCT00194051|gait biomechanics
630877|NCT00194051|knee osteoarthritis
630878|NCT00194038|Bipolar Disorder
630879|NCT00194038|Geriatric Psychiatry
630880|NCT00194038|Aripiprazole
630881|NCT00194025|Schizophrenia
630882|NCT00194025|Anticonvulsants
630883|NCT00194025|Valproic Acid
630884|NCT00194025|Valproate
630885|NCT00194012|bipolar disorder
630886|NCT00193999|Nasogastric Tubes
630887|NCT00193999|Nausea
630888|NCT00193999|Vomiting
630889|NCT00193999|Cardiac surgery
630890|NCT00193986|Prepulse
630891|NCT00193986|Defibrillator
630892|NCT00193973|Lymphoma
630893|NCT00193973|PCNSL
630894|NCT00193973|Primary CNS lymphoma
630895|NCT00193960|Seton surgery, glaucoma, Ahmed valve, intraocular pressure
630896|NCT00193934|Women's Health
630897|NCT00193934|Multidisciplinary, multicentre prospective study
630898|NCT00193934|Cancer:mechanisms of growth, invasion, metastases
630899|NCT00193934|Figo Stages cervical cancer
630900|NCT00193934|Advances in diagnosis using radiological methods
630901|NCT00193934|Quantitative Magnetic Resonance Imaging
630902|NCT00193934|Patient Management Strategies
630903|NCT00193934|Selecting patients for therapy
630904|NCT00193921|Chemoradiotherapy
630905|NCT00193921|High dose
630906|NCT00193921|palliative radiotherapy
630907|NCT00193921|Quality of life
630908|NCT00193908|Skin care
630909|NCT00193908|Radiotherapy
630910|NCT00193895|Skin cancer
630911|NCT00193895|radiotherapy
630912|NCT00193895|chemotherapy
630913|NCT00193895|surgery
630914|NCT00193882|Oesophageal
630915|NCT00193882|Dysphagia
630916|NCT00193882|Palliation
630917|NCT00193882|Quality of Life
630918|NCT00193882|Radiotherapy
630919|NCT00193882|Chemotherapy
630920|NCT00193869|Radiotherapy
630921|NCT00193869|Dose fractionation
630922|NCT00193856|Prostate Cancer
630923|NCT00193856|Androgen Deprivation
630924|NCT00193856|Hormone Therapy
630925|NCT00193856|RadiotherapyBisphosphonate
630926|NCT00193856|Prostate Specific Antigen (PSA)
630927|NCT00193843|Oral cancer
630928|NCT00193843|Head and neck surgery
630929|NCT00193843|Accelerated radiotherapy
630930|NCT00193843|Chemo-radiotherapy
630931|NCT00193830|Cervical Cancer
630932|NCT00193830|High Dose Rate (HDR) Brachytherapy
630933|NCT00193830|Low Dose Rate (LDR) Brachytherapy
630934|NCT00193830|Acute Toxicities
630935|NCT00193830|Late Radiation Sequelae
630936|NCT00193817|Cancer
630937|NCT00193817|Esophagus
630938|NCT00193817|Lymphadenectomy
630939|NCT00193804|Cervical Cancer
630940|NCT00193804|FIGO STAGE IIB
630941|NCT00193804|CHEMORADIATION
630942|NCT00193804|Intensity Modulated Radiation Therapy(IMRT)
630943|NCT00193804|Conventional Radiation Therapy
630944|NCT00193804|Cancer of the Cervix
630945|NCT00193804|Cervix Cancer
630946|NCT00193791|Carcinoma Cervix
630947|NCT00193791|FIGO Stage IIIB
630948|NCT00193791|Radiation therapy
630949|NCT00193791|Chemoradiation
630950|NCT00193791|Treatment related toxicities
630951|NCT00193791|Cervical Cancer
630952|NCT00193791|Cervix Cancer
630953|NCT00193778|Metastatic breast cancer
630954|NCT00193778|Locoregional treatment
630955|NCT00193778|Survival
630956|NCT00193765|neck dissection
630957|NCT00193765|survival
630958|NCT00193765|early oral cancer
631208|NCT00190450|cellular therapy
630959|NCT00193765|Early oral cavity squamous cancer with node negative neck
630960|NCT00193752|FDG-PET Imaging
630961|NCT00193752|Cervical Cancer
630962|NCT00193752|Post-treatment evaluation
630963|NCT00193752|Para-aortic Nodal Staging
630964|NCT00193752|Extended field Radiation
630965|NCT00193752|Extended field IMRT
630966|NCT00193752|Cancer of the Cervix
630967|NCT00193752|Cervix Cancer
630968|NCT00193739|Neoadjuvant chemotherapy
630969|NCT00193739|Surgery
630970|NCT00193739|Cervix cancer
630971|NCT00193739|Concurrent chemoradiation
630972|NCT00193726|Estrogen
630973|NCT00193726|Priming
630974|NCT00193726|Adjuvant chemotherapy
630975|NCT00193726|Breast cancer
630976|NCT00193713|double-blind study in the treatment of schizophrenia
630977|NCT00193700|Hypogonadism
630978|NCT00193687|open-label study in the treatment of schizophrenia
630979|NCT00193674|Pregnancy
630980|NCT00193674|Immunology
630981|NCT00193674|Unexplained recurrent miscarriage
630982|NCT00193661|Hypogonadism
630983|NCT00193648|FSGS
630984|NCT00193648|Pharmacokinetics
630985|NCT00193648|Rosiglitazone
630986|NCT00193648|PPAR-gamma agonist
630987|NCT00193648|Adalimumab
630988|NCT00193648|TNF-alpha antagonist
630989|NCT00193648|Steroid and immunosuppressive drug resistance
630990|NCT00193648|Resistant primary FSGS
630991|NCT00193635|Congenital uropathies
630992|NCT00193635|Mycophenolate mofetil
630993|NCT00193635|GFR
630994|NCT00193635|Iothalamate clearance
630995|NCT00193635|Urine cytometry
630996|NCT00193635|Children
630997|NCT00193635|Congenital urological abnormalities which represent stuctural defects in the genitourinary system
630998|NCT00193609|Neoplasms, Unknown Primary
630999|NCT00193596|Neoplasms, Unknown Primary
631000|NCT00193492|Lymphoma
631001|NCT00193492|Bevacizumab
631002|NCT00193492|Rituximab
631003|NCT00193453|Lung Cancer
631004|NCT00193336|NSCLC Lung Cancer
631005|NCT00193336|Non Small Cell Lung Cancer
631006|NCT00193297|Ovary Cancer
631007|NCT00193258|Recurrent clear cell renal cell carcinoma
631008|NCT00193258|Bevacizumab
631009|NCT00193258|Erlotinib
631010|NCT00193258|Imatinib
631011|NCT00193219|Colon Cancer
631012|NCT00193206|Locally Advanced Breast Cancer
631013|NCT00193206|Inflammatory Breast Cancer
631014|NCT00193206|Breast Cancer
631015|NCT00193206|Abraxane
631016|NCT00193206|nab Paclitaxel
631017|NCT00193206|Epirubicin
631018|NCT00193206|Gemcitabine
631019|NCT00193206|Gemzar
631020|NCT00193180|Breast Cancer
631021|NCT00193154|Kidney Cancer
631022|NCT00193128|Esophagus Cancer
631023|NCT00193037|Breast Cancer
631024|NCT00192998|Affective disorder
631025|NCT00192998|Alzheimer dementia
631026|NCT00192998|healthy controls
631027|NCT00192972|Catheter ablation
631028|NCT00192972|Atrial fibrillation
631029|NCT00192959|Anaesthesia
631030|NCT00192959|Surgery
631031|NCT00192959|Postoperative
631032|NCT00192959|Neuropsychological test
631033|NCT00192946|Cardiac resynchronization
631034|NCT00192946|Heart failure
631035|NCT00192946|open heart surgery
631036|NCT00192946|surgery
631037|NCT00192881|Percutaneous coronary intervention
631038|NCT00192881|Balloon angioplasty
631039|NCT00192881|Restenosis
631040|NCT00192881|Stents
631041|NCT00192868|primary PCI
631042|NCT00192868|distal protection
631043|NCT00192868|drug eluting stent
631044|NCT00192868|restenosis
631045|NCT00192855|schizophrenia
631046|NCT00192855|negative symptoms
631047|NCT00192855|entacapone
631048|NCT00192842|carcinoma
631049|NCT00192842|pancreas
631050|NCT00192842|gemcitabine
631051|NCT00192842|curcumin
631052|NCT00192829|Lung cancer
631053|NCT00192829|Thrombosis
631054|NCT00192829|Hypercoagulable
631055|NCT00192803|niddm
631056|NCT00192803|ace2
631057|NCT00192803|NIDDM patients
631058|NCT00192790|Therma,pain, Silent myocardial ischemia, catastrophizing
631059|NCT00192777|Solid Tumors
631060|NCT00192777|Bone Metastases
631061|NCT00192777|Radiotherapy
631062|NCT00192777|Xeloda
631063|NCT00192777|Concurrent
631064|NCT00192777|Radiosensitization
631065|NCT00192764|large cell lymphoma
631066|NCT00192764|CHOP
631067|NCT00192764|cyclophosphamide
631068|NCT00192764|high-dose
631069|NCT00192751|Schizophrenia
631070|NCT00192751|Major depression
631071|NCT00192751|Bipolar disorder
631072|NCT00192751|Compliance
631073|NCT00192751|Relapse prevention
631074|NCT00192738|telephone,
631075|NCT00192738|internal medicine,
631076|NCT00192738|readmission,
631077|NCT00192738|patients' satisfaction
631078|NCT00192725|bipolar disorder
631079|NCT00192725|acute mania
631080|NCT00192725|tryptophan depletion
631081|NCT00192725|placebo controlled add-on
631082|NCT00192725|Bipolar disorder- manic type
631083|NCT00192712|carcinoma
631084|NCT00192712|pancreas
631085|NCT00192712|chemotherapy
631086|NCT00192712|radiotherapy
631087|NCT00192699|Osteoarthritis
631088|NCT00192673|Asparaginase
631089|NCT00192673|intramuscular administration
631090|NCT00192673|Silent antibodies
631091|NCT00192673|Childhood acute lymphoblastic leukemia
631092|NCT00192673|Side effects
631093|NCT00192673|5-year EFS
631094|NCT00192660|HIV
631095|NCT00192660|Metabolic abnormality
631096|NCT00192660|Lipodystrophy
631097|NCT00192660|Cardiovascular disease
631098|NCT00192660|Treatment Naive
631099|NCT00192660|Treatment Experienced
631100|NCT00192660|HIV Infections
631101|NCT00192634|HIV
631102|NCT00192634|Antiretroviral therapy
631103|NCT00192634|nucleoside analogue reverse transcriptase
631104|NCT00192634|fixed dose combination
631105|NCT00192634|Treatment Experienced
631106|NCT00192621|HIV negative healthy subjects
631107|NCT00192621|Lipid metabolism
631108|NCT00192621|Glucose metabolism
631109|NCT00192621|Metabolic abnormality
631110|NCT00192621|Lipodystrophy
631111|NCT00192621|Cardiovascular disease
631112|NCT00192621|Treatment Naive
631113|NCT00192621|HIV
631114|NCT00192608|Pharmacokinetics, atazanavir, saquinavir, ritonavir, HIV
631115|NCT00192595|Hepatitis B
631116|NCT00192595|HIV
631117|NCT00192595|Treatment Naive
631118|NCT00192582|Motivational interview
631119|NCT00192582|Care plan
631120|NCT00192582|Relapse prevention
631121|NCT00192582|Psychoeducation
631122|NCT00192582|Indigenous mental health
631123|NCT00192569|Acute Hepatitis C
631124|NCT00192556|tuberculosis
631125|NCT00192556|nutrition
631126|NCT00192556|directly observed therapy
631127|NCT00192556|Timor Leste
631128|NCT00192556|cost-effectiveness
631129|NCT00192543|dialysis
631130|NCT00192543|omega-3 fatty acids
631131|NCT00192543|antioxidants
631132|NCT00192543|cardiovascular markers
631133|NCT00192543|Mortality
631134|NCT00192543|End-stage renal disease
631135|NCT00191971|Transitional cell carcinoma of urothelium
631136|NCT00191282|diabetes
631137|NCT00191282|MI
631138|NCT00191282|heart attack
631139|NCT00191269|after
631140|NCT00191269|anthracycline
631141|NCT00191269|taxane
631142|NCT00191269|regimen
631143|NCT00191243|breast cancer
631144|NCT00191113|syndrome
631145|NCT00191113|Turner
631146|NCT00191113|Turner's
631147|NCT00191113|height
631148|NCT00191113|growth
631149|NCT00191113|growth hormone
631150|NCT00191113|somatropin
631151|NCT00191113|short stature
631152|NCT00191113|short
631153|NCT00191113|hearing
631154|NCT00191113|glucose metabolism
631155|NCT00190671|Advanced Breast Cancer
631156|NCT00190580|CKD
631157|NCT00190580|chronic kidney disease
631158|NCT00190580|hypertension
631159|NCT00190580|angiotensin II receptor blocker
631160|NCT00190580|cardiovascular disease
631161|NCT00190580|valsartan
631162|NCT00190580|KVT
631163|NCT00190554|esophageal cancer
631164|NCT00190554|squamous cell carcinoma
631165|NCT00190554|esophagectomy
631166|NCT00190554|neoadjuvant chemotherapy
631167|NCT00190554|esophageal squamous cell carcinoma
631168|NCT00190541|Rectal Cancer
631169|NCT00190541|Lymph Node Dissection
631170|NCT00190541|Rectal Surgery
631171|NCT00190541|Autonomic Nerves
631172|NCT00190541|Stage II, III lower rectal cancer
631173|NCT00190528|cervical cancer
631174|NCT00190528|drug therapy
631175|NCT00190528|cisplatin
631176|NCT00190528|bleomycin
631177|NCT00190528|mitomycin
631178|NCT00190528|vincristine
631179|NCT00190515|adjuvant chemotherapy
631180|NCT00190515|Stage III colorectal cancer
631181|NCT00190515|5-FU+l-LV
631182|NCT00190515|UFT+LV
631183|NCT00190515|randomized controlled trial
631184|NCT00190502|Type 1 diabetes mellitus
631185|NCT00190502|Immune intervention
631186|NCT00190502|Polyclonal antibodies
631187|NCT00190502|Type 1 diabetes of recent onset
631188|NCT00190502|C-peptide level 0.3 pmol/l or higher
631189|NCT00190502|Positivity of at least one marker of autoimmunity (diabetes)
631190|NCT00190489|metastatic breast cancer
631191|NCT00190489|drug therapy
631192|NCT00190489|doxorubicin
631193|NCT00190489|docetaxel
631194|NCT00190476|Elderly
631195|NCT00190476|advanced
631196|NCT00190476|non-small-cell lung cancer
631197|NCT00190476|cisplatin
631198|NCT00190476|docetaxel
631199|NCT00190476|weekly
631200|NCT00190476|combination
631201|NCT00190476|chemotherapy
631202|NCT00190476|randomized trial
631203|NCT00190463|aspergillosis
631204|NCT00190463|antifungal therapy
631205|NCT00190463|empirical antifungal treatment
631206|NCT00190450|Huntington
631207|NCT00190450|graft
631209|NCT00190450|striatum
631210|NCT00190437|Chronic Obstructive Lung Disease (COLD)
631211|NCT00190437|Randomized Clinical Trial
631212|NCT00190437|Antibiotics
631213|NCT00190437|Acute Exacerbation
631214|NCT00190437|Mechanical
631215|NCT00190437|Ventilation
631216|NCT00190437|Intensive Care
631217|NCT00190437|Length of Stay
631218|NCT00190437|Mortality
631219|NCT00190424|Glioblastoma
631220|NCT00190424|Immunotherapy
631221|NCT00190411|Arteries
631222|NCT00190411|ultrasonography
631223|NCT00190411|Ehlers Danlos syndrome
631224|NCT00190411|Cardiovascular disease
631225|NCT00190411|beta adrenergic antagonists
631226|NCT00190398|Prospective
631227|NCT00190398|Randomised
631228|NCT00190398|Open
631229|NCT00190398|Blinded End-point
631230|NCT00190398|PROBE Study
631231|NCT00190398|Ischemic stroke
631232|NCT00190385|Cirrhosis
631233|NCT00190385|Hepatocellular carcinoma
631234|NCT00190385|Screening
631235|NCT00190385|Randomized
631236|NCT00190385|HBV
631237|NCT00190385|HCV
631238|NCT00190385|alcohol
631239|NCT00190385|hemochromatosis
631240|NCT00190372|Alzheimer's disease training programme
631241|NCT00190372|educational programme caregivers carers dementia treatment
631242|NCT00190372|Dementia Cognitive disorder
631243|NCT00190359|heart failure
631244|NCT00190359|hormones
631245|NCT00190359|growth substances
631246|NCT00190346|Acute respiratory distress
631247|NCT00190346|with hypercapnia
631248|NCT00190346|with hypoxemia
631249|NCT00190346|requiring NIV
631250|NCT00190333|pulmonary hypertension
631251|NCT00190333|6 minutes walking test
631252|NCT00190333|serotonin
631253|NCT00190333|primary or associated pulmonary hypertension
631254|NCT00190320|Fetal macrosomia
631255|NCT00190320|Neonatal traumatism
631256|NCT00190320|Maternal morbidity
631257|NCT00190307|Long term antiplatelet therapy
631258|NCT00190307|Scheduled surgery
631259|NCT00190294|Pregnancy Complications
631260|NCT00190281|FUNCTIONAL STUDY
631261|NCT00190281|CONTRAST-ENHANCED US
631262|NCT00190281|PERFUSION
631263|NCT00190268|multiple sclerosis
631264|NCT00190268|fatigue
631265|NCT00190268|3,4-diaminopyridine
631266|NCT00190255|gastrointestinal haemorrhage
631267|NCT00190255|stomach ulcer
631268|NCT00190255|anti-inflammatory agents, non-steroidal
631269|NCT00190255|CYP2C9 protein, human
631270|NCT00190255|genotype
631271|NCT00190255|pharmacogenetics
631272|NCT00190242|HIV
631273|NCT00190242|hepatitis A
631274|NCT00190242|vaccine
631275|NCT00190242|HBV and/or HCV co-infection
631276|NCT00190229|Vasculitis
631277|NCT00190229|Cyclophosphamide
631278|NCT00190229|Renal failure
631279|NCT00190216|Resistant depression
631280|NCT00190216|Transcranial Magnetic Stimulation,
631281|NCT00190216|Neuroimaging
631282|NCT00190203|Malignant middle cerebral artery infarction
631283|NCT00190203|Decompressive surgery
631284|NCT00190203|Hemicraniectomy
631285|NCT00190203|Brain edema
631286|NCT00190190|Macular hole
631287|NCT00190190|internal limiting membrane
631288|NCT00190190|retina
631289|NCT00190190|surgery
631290|NCT00190164|Macular hole
631291|NCT00190164|Vitrectomy
631292|NCT00190164|positioning
631293|NCT00190164|retina
631294|NCT00190164|surgery
631295|NCT00190151|ciprofloxacin
631296|NCT00190151|commensal flora
631297|NCT00190151|resistance
631298|NCT00190151|Pharmacokinetic
631299|NCT00190138|Bi-ventricular pacing
631300|NCT00190138|ventricular resynchronization
631301|NCT00190138|baroreflex sensitivity
631302|NCT00190138|heart rate variability
631303|NCT00190125|Hemodialysis
631304|NCT00190125|Malnutrition
631305|NCT00190125|Inflammation
631306|NCT00190099|In-stent restenosis,
631307|NCT00190099|Drug eluting stent,
631308|NCT00190099|dexamethasone,
631309|NCT00190099|Acute coronary syndrome
631310|NCT00190073|Epidermal nerves;protein gene product 9.5; ethanol
631311|NCT00190060|Frailty
631312|NCT00190060|Muscle strength
631313|NCT00190060|Physical performance
631314|NCT00190060|Bone mineral density
631315|NCT00190060|Quality of life
631316|NCT00190047|Cerebral Ischemia
631317|NCT00190047|Ischemic Brain Injury
631318|NCT00190047|Brain Infarction
631319|NCT00190047|Brain Ischemia
631320|NCT00190034|Acetylcysteine
631321|NCT00190034|cardiac surgery
631322|NCT00190034|cardiopulmonary bypass
631323|NCT00190034|acute renal insufficiency
631324|NCT00190021|Alzheimer's type dementia
631325|NCT00190021|donepezil
631326|NCT00190021|double-blind
631327|NCT00190008|tardive dyskinesia
631328|NCT00190008|piracetam
631329|NCT00189995|schizophrenia
631330|NCT00189995|aggression
631331|NCT00189995|clozapine
631332|NCT00189995|efficacy
631333|NCT00189995|double-blind
631334|NCT00189982|Factor VIII Deficiency
631335|NCT00189930|Treatment Experienced
631336|NCT00189904|HIV
631337|NCT00189878|chronic idiopathic urticaria
631338|NCT00189878|methotrexate
631339|NCT00189852|Telecare
631340|NCT00189852|chronic
631341|NCT00189852|older people
631342|NCT00189852|heart failure
631343|NCT00189839|Tacrolimus
631344|NCT00189839|Kidney transplantation
631345|NCT00189839|Transplantation, kidney
631346|NCT00189839|Renal Transplantation
631347|NCT00189839|Transplantation, renal
631348|NCT00189826|Tacrolimus
631349|NCT00189826|Liver transplantation
631350|NCT00189813|Irritable Bowel Syndrome
631351|NCT00189813|Diarrhea
631352|NCT00189813|Nasea®
631353|NCT00189813|Irribow®
631354|NCT00189813|ramosetron
631355|NCT00189800|Solifenacin
631356|NCT00189800|tolterodine
631357|NCT00189800|randomized controlled trial
631358|NCT00189800|double-blind method
631359|NCT00189787|Tacrolimus
631360|NCT00189787|Immunosuppressant
631361|NCT00189787|Anti-asthmatic drug
631362|NCT00189787|Administration, inhalation
631363|NCT00188500|epilepsy
631364|NCT00188500|atkins diet
631365|NCT00188253|Nasopharyngeal carcinoma
631366|NCT00188253|PET scan
631367|NCT00188253|MRI
631368|NCT00188253|EBV virus
631369|NCT00188240|hepatitis C
631370|NCT00188240|insulin resistance
631371|NCT00188240|antiviral therapy
631372|NCT00188227|Bone marrow puncture
631373|NCT00188227|Pain
631374|NCT00188214|perfusion
631375|NCT00188214|CT
631376|NCT00188214|CAT
631377|NCT00188214|non-small
631378|NCT00188214|lung
631379|NCT00188201|Hepatitis C
631380|NCT00188201|neucognitive functions
631381|NCT00188201|neuropsychological testing
631382|NCT00188201|antiviral treatment
631383|NCT00188188|Endothelial
631384|NCT00188188|Dysfunction
631385|NCT00188188|Systemic
631386|NCT00188188|Lupus
631387|NCT00187759|Abscess
631388|NCT00187759|Antibitoics
631389|NCT00187759|Methicillin-resistant Staphylococcus aureus
631390|NCT00187746|Healthy Control
631391|NCT00187733|L-carnitine
631392|NCT00187720|Healthy Control
631393|NCT00187681|Healthy controls
631394|NCT00187668|Healthy Cohort
631395|NCT00187655|Healthy volunteers willing to be dosed with cefotaxime
631396|NCT00189774|nateglinide
631397|NCT00189774|pioglitazone
631398|NCT00189774|combination drug therapy
631399|NCT00189774|treatment
631400|NCT00189761|Tacrolimus
631401|NCT00189761|Immunosuppression
631402|NCT00189761|Bone Marrow Transplantation
631403|NCT00189761|Graft versus Host Disease
631404|NCT00189748|Tacrolimus
631405|NCT00189748|Immunosuppression
631406|NCT00189748|Bone Marrow Transplantation
631407|NCT00189748|Graft versus Host Disease
631408|NCT00189735|Treatment Efficacy
631409|NCT00189735|Treatment Effectiveness
631410|NCT00189735|Anti-rejection therapy
631411|NCT00189735|Immunosuppression
631412|NCT00189735|Antirejection
631413|NCT00189735|Malononitrilamide
631414|NCT00189722|Tacrolimus
631415|NCT00189722|Immunosuppressant
631416|NCT00189722|Anti-asthmatic drug
631417|NCT00189722|Administration, inhalation
631418|NCT00189709|micafungin
631419|NCT00189709|fluconazole
631420|NCT00189709|invasive candidiasis
631421|NCT00189709|candidemia
631422|NCT00189696|Irritable Bowel Syndrome, Diarrhea
631423|NCT00189618|Peripheral vascular disease
631424|NCT00189618|Peripheral arterial disease
631425|NCT00189618|Walking Capacity
631426|NCT00189618|Aspirin
631427|NCT00189618|Clopidogrel
631428|NCT00189605|Plasma disc decompression
631429|NCT00189605|Intradiscal Pressure
631430|NCT00189605|Steroid Injection
631431|NCT00189605|Epidural Steroid Injection
631432|NCT00189605|Selective Nerve Root Injection
631433|NCT00189605|Leg Pain
631434|NCT00189605|Radicular Pain
631435|NCT00189605|Coblation
631436|NCT00189605|SNRI
631437|NCT00189592|plantar fascia
631438|NCT00189592|plantar fasciitis
631439|NCT00189592|Coblation
631440|NCT00189592|fasciotomy
631441|NCT00189592|conventional surgical fasciotomy
631442|NCT00189592|heel spur
631443|NCT00189592|heel pain
631444|NCT00189592|aponeurosis
631445|NCT00189592|plasma based radiofrequency
631446|NCT00189592|angiogenesis
631447|NCT00189579|HERCEPTIN
631448|NCT00189579|Carboplatin
631449|NCT00189579|Paclitaxel
631450|NCT00189579|Relapse
631451|NCT00189566|Relapse within 6 months
631452|NCT00189566|Previously received taxane derivative
631453|NCT00189553|Extra-ovarian papillary serous tumors
631454|NCT00189553|Relapse over 6 months
631455|NCT00189553|Previously received taxane derivative
631456|NCT00189540|Ischemic ulcers
631457|NCT00189540|Critical Limb Ischemia
631458|NCT00189514|obesity
631459|NCT00189514|weight loss
631460|NCT00189514|Amylin
631461|NCT00189514|pramlintide
631462|NCT00189501|Chronic Kidney Disease, CKD,
631463|NCT00189501|Secondary Hyperparathyroidism, HPT
631464|NCT00189488|Hematological Malignancies
631465|NCT00189488|Graft-versus-host-disease
631466|NCT00189488|Oral Mucositis
631467|NCT00189488|Allogeneic Transplantation
631468|NCT00189475|Cold
631469|NCT00189475|Upper Respiratory Infection
631470|NCT00189462|Ear Infections
631471|NCT00189462|Otitis Media
631472|NCT00189449|Allergic Rhinitis
631473|NCT00189449|Allergy
631474|NCT00189449|Growth
631475|NCT00189436|Asthma
631476|NCT00189423|Heart Arrest
631477|NCT00189423|Cardiac Arrest
631478|NCT00189423|Cardiopulmonary Resuscitation
631479|NCT00189423|Impedance Threshold Device
631480|NCT00189423|Active Compression Decompression
631481|NCT00189423|ResQPOD
631482|NCT00189423|ResQPump
631483|NCT00189423|Survival
631484|NCT00189423|Out-of-hospital
631485|NCT00189423|Prehospital
631486|NCT00189423|ResQCPR System
631487|NCT00189397|Parthenium dermatitis
631488|NCT00189384|Neonatal sepsis
631489|NCT00189384|Neonatal pneumonia
631490|NCT00189384|Bacterial infections
631491|NCT00189384|Young infants
631492|NCT00189384|Neonate
631493|NCT00189384|Community
631494|NCT00189384|Developing country
631495|NCT00189358|cancer
631496|NCT00189358|cancer alternative therapies
631497|NCT00189358|ovarian cancer
631498|NCT00189358|tyrosine kinase inhibitor
631499|NCT00189345|Cancer
631500|NCT00189345|Cancer alternative therapies
631501|NCT00189345|ovarian cancer
631502|NCT00189332|Oncology
631503|NCT00189332|Melanoma
631504|NCT00189319|Tambocor
631505|NCT00189319|Paroxysmal Atrial Fibrillation
631506|NCT00189319|Quality of Life
631507|NCT00189306|Superficial Basal Cell Carcinoma
631508|NCT00189306|Aldara
631509|NCT00189293|External Ano-Genital Warts
631510|NCT00189293|Ablative Therapy
631511|NCT00189293|Aldara
631512|NCT00189280|Aldara, sBCC
631513|NCT00189267|Aldara
631514|NCT00189267|Actinic Keratosis
631515|NCT00189267|Graft Recipients
631516|NCT00189254|1 year follow up
631517|NCT00189241|Aldara
631518|NCT00189241|Superficial Basal Cell Carcinoma
631519|NCT00189241|Long-Term Study
631520|NCT00189215|coronary artery disease
631521|NCT00189215|cardiopulmonary bypass
631522|NCT00189215|cognition disorders
631523|NCT00189189|prevention
631524|NCT00189189|oppositional defiant disorder
631525|NCT00189189|conduct disorder
631526|NCT00189163|Hepatitis C
631527|NCT00189163|Genotype 1
631528|NCT00189163|Insulin Resistance
631529|NCT00189163|Pioglitazone
631530|NCT00189150|Valganciclovir
631531|NCT00189150|Mycophenolate Mofetil
631532|NCT00189150|Pharmacokinetic
631533|NCT00189150|Interaction
631534|NCT00189150|MPA
631535|NCT00189124|Systemic Lupus Erythematosus
631536|NCT00189124|Dehydroepiandrosterone (DHEA)
631537|NCT00189124|DHEA
631538|NCT00189124|SLE
631539|NCT00189124|Lupus
631540|NCT00189111|peripheral arterial disease
631541|NCT00189111|computed tomography
631542|NCT00189111|cardiac asymptomatic
631543|NCT00189111|dobutamine magnetic resonance imaging
631544|NCT00189085|Metabolic syndrome
631545|NCT00189072|gabapentin
631546|NCT00189072|neuropathic pain
631547|NCT00189072|driving
631548|NCT00189072|attention
631549|NCT00189059|neuropathic pain
631550|NCT00189059|erp
631551|NCT00189059|driving
631552|NCT00189059|attention
631553|NCT00189059|amitriptyline
631554|NCT00189046|driving, chronic pain, attention
631555|NCT00189033|Irritable Bowel Syndrome
631556|NCT00189033|Diet Therapy
631557|NCT00189033|Dietary Fiber
631558|NCT00189033|Randomized Controlled Trial
631559|NCT00189033|Family Practice
631560|NCT00189020|pneumococcal conjugate vaccination
631561|NCT00189020|nasopharyngeal carriage
631562|NCT00189020|herd immunity
631563|NCT00189020|antipneumococcal antibodies
631564|NCT00189020|respiratory tract infections
631565|NCT00189020|National infant vaccination program
631566|NCT00189007|allopurinol
631567|NCT00189007|neuroprotection
631568|NCT00189007|reperfusion injury
631569|NCT00189007|fetal hypoxia
631570|NCT00189007|post hypoxic-ischemic reperfusion damage
631571|NCT00188994|Myocardial Protection
631572|NCT00188994|Myocardial Metabolism
631573|NCT00188994|Ventricular Function
631574|NCT00188994|Cardiovascular Disease
631575|NCT00188994|Cardioplegic Additives
631576|NCT00188981|psychosis
631577|NCT00188981|high risk
631578|NCT00188981|prodrome
631579|NCT00188981|Multiple Complex Developmental Disorder
631580|NCT00188968|Xanthines
631581|NCT00188968|Reintubation
631582|NCT00188968|Nasal Intermittent Ventilation
631707|NCT00188110|coloscopy or surgery
631583|NCT00188968|Nasal continous positive airway pressure
631584|NCT00188955|pediatric
631585|NCT00188955|chronic allograft nephropathy
631586|NCT00188955|chronic rejection
631587|NCT00188955|interstitial fibrosis
631588|NCT00188942|Magnetic Resonance Imaging
631589|NCT00188942|Diagnostic Imaging
631590|NCT00188942|Mood Disorders
631591|NCT00188942|Major Depressive Disorder
631592|NCT00188942|Antipsychotic
631593|NCT00188942|Olanzapine
631594|NCT00188942|Fluoxetine
631595|NCT00188344|laparoscopic myotomy
631596|NCT00188344|pneumatic dilatation
631597|NCT00188344|motility disorder
631598|NCT00188344|dysphasia
631599|NCT00188344|health-related quality of life
631600|NCT00188331|cognitive function
631601|NCT00188331|fatigue
631602|NCT00188331|colorectal cancer
631603|NCT00188331|chemotherapy
631604|NCT00188331|cognitive impairment
631605|NCT00188305|Risk counselling
631606|NCT00188305|Health education
631607|NCT00188305|Prevention
631608|NCT00188305|Behavioral
631609|NCT00188305|Screening
631610|NCT00188305|Intervention
631611|NCT00188305|Telephone vs in person
631612|NCT00188292|Human Papillomavirus
631613|NCT00188292|Anal
631614|NCT00188292|Cancer screening
631615|NCT00188292|Immunodeficiency
631616|NCT00188292|HIV
631617|NCT00188279|ct
631618|NCT00188279|scan
631619|NCT00188279|lung
631620|NCT00188279|follow-up
631621|NCT00188916|Bronchial blockers
631622|NCT00188916|Lung isolation
631623|NCT00188916|Thoracic Anesthesia
631624|NCT00188903|Cardiac Surgery
631625|NCT00188903|Diastolic Dysfunction
631626|NCT00188903|Atrial Fibrillation
631627|NCT00188890|Lung Cancer
631628|NCT00188890|Mesothelioma
631629|NCT00188890|Asbestos
631630|NCT00188890|Screening
631631|NCT00188890|Early Diagnosis
631632|NCT00188851|HIV
631633|NCT00188851|salvage regimen
631634|NCT00188851|virologic failure
631635|NCT00188851|treatment interruption
631636|NCT00188851|ARV experienced
631637|NCT00188838|Bipolar Disorder
631638|NCT00188838|Psychosocial Factors
631639|NCT00188838|Mania
631640|NCT00188838|Depression
631641|NCT00188838|Social Adjustment
631642|NCT00188838|Coping Skills
631643|NCT00188825|Lung
631644|NCT00188825|Transplant
631645|NCT00188825|Rejection
631646|NCT00188825|BOS
631647|NCT00188812|dementia
631648|NCT00188812|stroke
631649|NCT00188773|n-acetylcysteine,
631650|NCT00188773|free fatty acid,
631651|NCT00188773|glucose stimulated insulin secretion,
631652|NCT00188773|insulin resistance syndrome
631653|NCT00188773|antioxidant therapy
631654|NCT00188773|Insulin Resistance
631655|NCT00188760|Breast Transillumination Spectroscopy
631656|NCT00188760|Optical Transillumination Spectroscopy
631657|NCT00188760|Breast Cancer Risk
631658|NCT00188747|Coagulopathy
631659|NCT00188747|Cardiac Surgery
631660|NCT00188747|Point of Care
631661|NCT00188747|Monitoring
631662|NCT00188734|Lung Cancer
631663|NCT00188734|Eary Diagnosis
631664|NCT00188734|Screening
631665|NCT00188721|Breast Cancer Risk
631666|NCT00188721|Optical Transillumination Spectroscopy
631667|NCT00188721|Transillumination Breast Spectroscopy
631668|NCT00188682|Optical Transillumination Spectroscopy
631669|NCT00188682|Transillumination Breast Spectroscopy
631670|NCT00188682|Breast Cancer Risk
631671|NCT00188643|Bipolar Disorder, Depression, Anticonvulsants, Antidepressants
631672|NCT00188630|Cardiac Surgery
631673|NCT00188630|Acute Renal Failure
631674|NCT00188630|N-acetylcysteine
631675|NCT00188630|Cardiopulmonary bypass
631676|NCT00188617|LUNG CANCER
631677|NCT00188617|IRESSA
631678|NCT00188617|GEFITINIB
631679|NCT00188617|STAGE 1A & 1B
631680|NCT00188617|NEOADJUVANT
631681|NCT00188617|PHASE 2
631682|NCT00188591|Optical Transillumination Spectroscopy
631683|NCT00188591|Breast Cancer Risk
631684|NCT00188396|Major Depressive Disorder
631685|NCT00188396|Women's Mental Health
631686|NCT00188396|Hormones
631687|NCT00188396|Citalopram
631688|NCT00188396|Antidepressive agents
631689|NCT00188396|Mental Health
631690|NCT00188383|Hyperalgesia
631691|NCT00188383|Quantitative Sensory Testing
631692|NCT00188383|Pain
631693|NCT00188383|Opioid use
631694|NCT00188383|Elderly
631695|NCT00188149|Hodgkin's Lymphoma
631696|NCT00188149|Chemotherapy
631697|NCT00188149|Radiation therapy
631698|NCT00188149|PET
631699|NCT00188136|AML, allogeneic transplantation, high-risk, karyotype
631700|NCT00188123|Myocardial infarction
631701|NCT00188123|MRI late enhancement
631702|NCT00188123|Atrial fibrillation
631703|NCT00188110|Water-Enema Computed Tomography
631704|NCT00188110|colon tumor
631705|NCT00188110|coloscopy
631706|NCT00188110|suspicion of colon tumor
631708|NCT00188071|medical abortion
631709|NCT00188071|analgesia
631710|NCT00188058|Acute respiratory distress syndrome
631711|NCT00188058|Positive end-expiratory pressure
631712|NCT00188058|Acute lung injury
631713|NCT00188058|Mechanical ventilation
631714|NCT00188058|Randomized controlled trial
631715|NCT00188045|Portal hypertension, alcoholic cirrhosis, Hepatic venous pressure gradient, hemodynamic, spironolactone, propranolol
631716|NCT00188032|pulmonary embolism
631717|NCT00188032|clinical practice
631718|NCT00188032|quality of health care
631719|NCT00188032|diagnostic criteria
631720|NCT00188032|Computer-Assisted Decision Support
631721|NCT00188032|reminders
631722|NCT00188006|cardiopulmonary bypass, inflammatory response
631723|NCT00188006|neurologic injury
631724|NCT00188006|neurocognitive deficit
631725|NCT00188006|biomaterials
631726|NCT00188006|coronary artery bypass surgery
631727|NCT00187993|growth hormone deficiency
631728|NCT00187993|growth hormone
631729|NCT00187993|energy expenditure
631730|NCT00187993|body composition
631731|NCT00187954|women
631732|NCT00187954|chest pain
631733|NCT00187954|microvascular dysfunction
631734|NCT00187954|retinal photography
631735|NCT00187954|Retinal vascular function
631736|NCT00187941|transplant
631737|NCT00187941|renal
631738|NCT00187941|Cellcept
631739|NCT00187941|therapeutic drug level
631740|NCT00187941|MMF
631741|NCT00187941|MPA
631742|NCT00187941|immunosuppression
631743|NCT00187928|Obsessive-Compulsive Disorder
631744|NCT00187928|Obsessions
631745|NCT00187928|Compulsions
631746|NCT00187928|Adjunctive treatment
631747|NCT00187915|Renal transplant
631748|NCT00187915|Cellcept
631749|NCT00187915|Therapeutic drug level
631750|NCT00187915|Mycophenolate mofetil (MMF)
631751|NCT00187915|Mycophenolate Acid (MPA)
631752|NCT00187915|Oral Bioavailability
631753|NCT00187915|Immunosuppression
631754|NCT00187902|Sexually Transmitted Diseases
631755|NCT00187902|Chlamydia trachomatis
631756|NCT00187902|Neisseria gonorrhoeae
631757|NCT00187889|Microvascular Disease
631758|NCT00187889|Women
631759|NCT00187889|Ischemic Heart Disease
631760|NCT00187889|WISE
631761|NCT00187850|Pulp capping
631762|NCT00187850|partial pulpotomy
631763|NCT00187850|Exposure of the pulp
631764|NCT00187837|Stepwise excavation
631765|NCT00187824|prospective
631766|NCT00187824|observational
631767|NCT00187824|hormonal
631768|NCT00187824|inflammatory
631769|NCT00187824|vioenergetic
631770|NCT00187824|immune
631771|NCT00187824|sepsis
631772|NCT00187811|Angioplasty,
631773|NCT00187811|Restenosis,
631774|NCT00187811|Photodynamic therapy
631775|NCT00187798|Healthy Control Twins
631776|NCT00187785|Hispanic
631777|NCT00187785|communication
631778|NCT00187772|domestic violence
631779|NCT00187772|preschoolers
631780|NCT00187772|trauma
631781|NCT00187772|intervention
631782|NCT00187616|adverse events
631783|NCT00187616|clinical trial methodology
631784|NCT00187603|tobacco
631785|NCT00187603|cessation
631786|NCT00187603|smoking
631787|NCT00187603|smoking cessation
631788|NCT00187590|HIV
631789|NCT00187590|case management
631790|NCT00187577|Alopecia areata
631791|NCT00187577|Eyelash growth
631792|NCT00187577|Latanoprost
631793|NCT00187577|Bimatoprost
631794|NCT00187564|Diabetes Mellitus, Type 1
631795|NCT00187564|lipoic acid
631796|NCT00187564|oxidative stress
631797|NCT00187551|enfuvirtide
631798|NCT00187551|T20
631799|NCT00187551|Fuzeon
631800|NCT00187551|Treatment
631801|NCT00187551|Interruption
631802|NCT00187551|Resistance
631803|NCT00187551|HIV Drug Resistance
631804|NCT00187551|Antiretroviral Agents
631805|NCT00187551|Salvage Therapy
631806|NCT00187551|Drug Resistance, Multiple
631807|NCT00187551|Human Immunodeficiency virus
631808|NCT00187512|HIV
631809|NCT00187512|Antiretroviral Agents
631810|NCT00187512|Drug Resistance, Multiple
631811|NCT00187512|Long Term Non Progression
631812|NCT00187512|Long Term Non Progressor
631813|NCT00187512|Elite Suppression
631814|NCT00187512|Elite Suppressor
631815|NCT00187512|Natural History
631816|NCT00187512|Observational
631817|NCT00187499|Asthma
631818|NCT00187499|Corticosteroid
631819|NCT00187499|Gene expression
631820|NCT00187486|Glioblastoma Multiforme
631821|NCT00187486|Gliosarcoma
631822|NCT00187486|GBM
631823|NCT00187486|GS
631824|NCT00187486|Tarceva
631825|NCT00187486|Temodar
631826|NCT00187486|Radiation
631827|NCT00187486|Newly Diagnosed
631828|NCT00187473|hepatitis C
631829|NCT00187473|HCV
631830|NCT00187473|natural history
631831|NCT00187460|Acute myocardial infarction
631832|NCT00187460|Congestive heart failure
631833|NCT00187460|Quality of care
631834|NCT00187460|Reperfusion
631835|NCT00187460|Report cards
631836|NCT00187460|Quality indicators
631837|NCT00187447|prematurity
631838|NCT00187447|chronic lung disease
631839|NCT00187447|necrotizing enterocolitis
631840|NCT00187447|indomethacin
631841|NCT00187447|ductus arteriosus
631842|NCT00187434|premature infant
631843|NCT00187434|supporting extubation
631844|NCT00187421|coronary disease
631845|NCT00187421|angiography
631846|NCT00187421|intraoperative care
631847|NCT00187421|vascular patency
631848|NCT00187408|Thrombosis
631849|NCT00187408|Pulmonary Embolism
631850|NCT00187408|Low Molecular Weight Heparin
631851|NCT00187408|Tibial Fractures
631852|NCT00187395|hypertension
631853|NCT00187395|blood pressure
631854|NCT00187395|pregnancy
631855|NCT00187382|antenatal corticosteroids
631856|NCT00187382|preterm birth
631857|NCT00187382|multiple versus single doses
631858|NCT00187382|follow-up
631859|NCT00187369|twins
631860|NCT00187369|twin births
631861|NCT00187369|multiples
631862|NCT00187356|Coronary Bypass Surgery
631863|NCT00187356|Coronary Artery Disease
631864|NCT00187356|Angiography
631865|NCT00187356|Arterial Grafts
631866|NCT00187356|Radial Artery
631867|NCT00187356|Saphenous Vein
631868|NCT00187343|Radiotherapy
631869|NCT00187343|IMRT
631870|NCT00187330|cardiopulmonary bypass
631871|NCT00187330|renal insufficiency
631872|NCT00187330|cardiac surgery
631873|NCT00187330|n-acetylcysteine
631874|NCT00187317|Exercise
631875|NCT00187317|Rehabilitation
631876|NCT00187317|Postural Balance
631877|NCT00187317|Accidental Falls
631878|NCT00187317|Geriatrics
631879|NCT00187291|T-Wave Alternans
631880|NCT00187291|ICD
631881|NCT00187291|Primary Prevention
631882|NCT00187278|Standard pacing indication
631883|NCT00187252|Ventricular Dyssynchrony
631884|NCT00187239|ICDs
631885|NCT00187239|Ventricular pacing
631886|NCT00187239|Patient has been implanted with a dual chamber SJM ICD with AICS for 1 month (± 2 weeks).
631887|NCT00187239|At the time of enrollment, patient is paced in the RV ≤25% of the time as determined by the device diagnostics.
631888|NCT00187239|Patient is medically stable.
631889|NCT00187226|Brain neoplasm
631890|NCT00187226|Brain cancer
631891|NCT00187226|Neoplasm intracranial
631892|NCT00187213|Ventricular Dyssynchrony
631893|NCT00187174|Brain tumors
631894|NCT00187174|Soft Tissue Sarcomas
631895|NCT00187174|Refractory solid tumors
631896|NCT00187174|Recurrent or Refractory Rhabdomyosarcomatous Soft Tissue and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
631897|NCT00187161|Mature B-Cell Leukemia
631898|NCT00187161|Non-Hodgkin Lymphoma
631899|NCT00187161|Burkitt's lymphoma
631900|NCT00187161|Small noncleaved cell non Hodgkin lymphoma
631901|NCT00187161|Large cell lymphoma
631902|NCT00187148|Vaccine
631903|NCT00187148|Prevention
631904|NCT00187148|HIV
631905|NCT00187148|AIDS
631906|NCT00187135|Pain Management
631907|NCT00187135|Bone Marrow Aspiration
631908|NCT00187122|Non-Hodgkin
631909|NCT00187122|Lymphoma
631910|NCT00187109|Thrombocytopenia
631911|NCT00187109|Platelets
631912|NCT00187109|Thrombopoietin
631913|NCT00187096|Leukemia
631914|NCT00187096|Myeloid
631915|NCT00187096|Acute
631916|NCT00187083|Leukemia
631917|NCT00187083|Acute Lymphoblastic Leukemia
631918|NCT00187083|Refractory Acute Lymphoblastic Leukemia
631919|NCT00187083|Relapsed Acute Lymphoblastic Leukemia
631920|NCT00187057|Ataxia
631921|NCT00187057|alphafetoprotein
631922|NCT00187044|Vaccine
631923|NCT00187044|Prevention
631924|NCT00187044|HIV
631925|NCT00187044|AIDS
631926|NCT00187031|Wilms Tumor
631927|NCT00187018|Collagen Disease
631928|NCT00187005|Leukemia
631929|NCT00186992|Sarcoma
631930|NCT00186992|radiation therapy
631931|NCT00186992|Other musculoskeletal tumors
631932|NCT00186979|Refractory Childhood Solid Tumors
631933|NCT00186953|Ultrasound
631934|NCT00186953|Abdominal tumors
631935|NCT00186953|Pelvic tumors
631936|NCT00186940|leukemia
631937|NCT00186927|Vaccine
631938|NCT00186927|Sendai virus vaccine
631939|NCT00186914|Bone marrow transplant
631940|NCT00186914|bone marrow stromal cells
631941|NCT00186914|allogeneic transplant
631942|NCT00186914|Osteodysplasia
631943|NCT00186914|Osteogenesis imperfecta
631944|NCT00186914|Gene marking
631945|NCT00186914|Stromal cell
631946|NCT00186901|Bone Density
631947|NCT00186888|Cancer of the Eye
631948|NCT00186888|Eye Enucleation
631949|NCT00186875|Leukemia
631950|NCT00186875|Lymphoblastic
631951|NCT00186875|Acute
631952|NCT00186875|Lymphoma
631953|NCT00186875|Non-Hodgkin's
631954|NCT00186862|Neuroblastoma
631955|NCT00186862|Immunotherapy
631956|NCT00186862|Gene therapy
631957|NCT00186849|Neuroblastoma
631958|NCT00186836|Hepatitis A
631959|NCT00186836|Hepatitis B
631960|NCT00186836|Hemodialysis
631961|NCT00186836|Vaccine
631962|NCT00186823|Haploidentical stem cell transplant
631963|NCT00186823|Allogeneic stem cell transplant
631964|NCT00186823|Mismatched family member stem cell donor transplant
631965|NCT00186823|Bone marrow transplantHigh risk hematologic malignancies
631966|NCT00186810|Anemia
631967|NCT00186810|Sickle Cell
631968|NCT00186797|Aplastic Anemia
631969|NCT00186784|Repetitive Transcranial Magnetic Stimulation
631970|NCT00186784|TMS
631971|NCT00186771|Transcranial Magnetic Stimulation
631972|NCT00186771|Paired Pulse
631973|NCT00186758|Transcranial Magnetic Stimulation
631974|NCT00186758|TMS
631975|NCT00186745|Venous thrombosis
631976|NCT00186745|Pulmonary embolism
631977|NCT00186745|Kidney failure
631978|NCT00186745|Anticoagulants
631979|NCT00186745|Heparin, Low-Molecular-Weight
631980|NCT00186732|wound closure
631981|NCT00186732|Pfannenstiel incision
631982|NCT00186732|surgical staples
631983|NCT00186732|subcuticular suture
631984|NCT00186719|Chronic Obstructive Pulmonary Disease
631985|NCT00186719|Smoking Related Disease
631986|NCT00186719|Immune System Changes
631987|NCT00186706|Selenium
631988|NCT00186706|Chronic Obstructive Pulmonaary Disease
631989|NCT00186706|Cardiovascular Disease
631990|NCT00186706|Anti-oxidant
631991|NCT00186706|Pulmonary
631992|NCT00186693|Airway remodeling
631993|NCT00186693|Asthma
631994|NCT00186693|Hyper-responsiveness
631995|NCT00186641|chronic Graft vs Host Disease
631996|NCT00186537|Insulin resistance
631997|NCT00186537|Insulin resistance syndrome
631998|NCT00186537|dyslipidemia
631999|NCT00186537|atherogenic dyslipidemia
632000|NCT00186537|triglyceride/HDL-C ratio
632001|NCT00186420|Prostate Cancer
632002|NCT00186420|Taxotere
632003|NCT00186368|Prostate cancer
632004|NCT00186368|Gene expression
632005|NCT00186368|tumor markers
632006|NCT00186368|microarray analysis
632007|NCT00186329|Vasodilation
632008|NCT00186329|Congestive heart failure
632009|NCT00186329|Renal insufficiency
632010|NCT00186329|Diuresis
632011|NCT00186329|Serum creatinine
632012|NCT00186199|voiding patterns
632013|NCT00186199|flow rate
632014|NCT00186199|ultrasound
632015|NCT00186173|Obesity
632016|NCT00186173|Physical activity
632017|NCT00186134|Physical Activity
632018|NCT00186134|Walking
632019|NCT00186134|Primary Schools
632020|NCT00186134|Transportation
632021|NCT00186108|Oral Triamcinalone
632022|NCT00186108|Prostate Cancer
632023|NCT00186095|Amyloidosis
632024|NCT00186095|nonmyeloablative
632025|NCT00186095|hematopoietic
632026|NCT00186095|cell transplantation
632027|NCT00186056|Mifepristone
632028|NCT00186056|Depression
632029|NCT00186056|Mifeprex
632030|NCT00186056|RU 486
632031|NCT00186030|HIV
632032|NCT00186030|AIDS
632033|NCT00186030|PTSD
632034|NCT00186030|Prevention
632035|NCT00185978|obesity prevention
632036|NCT00185978|preadolescents
632037|NCT00185978|schools
632038|NCT00185965|non-Hodgkin
632039|NCT00185965|lymphoma
632040|NCT00185965|mycosis
632041|NCT00185965|fungoides
632042|NCT00185939|dog bites
632043|NCT00185939|infection
632044|NCT00185939|prophylactic antibiotics
632045|NCT00185939|cost effectiveness
632046|NCT00185783|Sepsis
632047|NCT00185783|Adrenal Insufficiency
632048|NCT00185783|Hydrocortisone
632049|NCT00185783|Gene Expression
632050|NCT00185783|Microarray
632051|NCT00185783|RNA
632052|NCT00185783|Critically Ill
632053|NCT00185770|Obesity prevention
632054|NCT00185770|Television
632055|NCT00185770|Screen time
632056|NCT00185770|Schools
632057|NCT00185770|Preadolescents
632058|NCT00185705|Insulin resistance
632059|NCT00185705|obesity
632060|NCT00185705|hypertension
632061|NCT00185705|adolescents
632062|NCT00185705|telmisartan
632063|NCT00185705|lifestyle intervention
632064|NCT00185562|Osteoarthritis
632065|NCT00185549|Cystic Fibrosis;
632066|NCT00185549|patient education,
632067|NCT00185549|Internet
632068|NCT00185536|Taste
632069|NCT00185536|preschool children
632070|NCT00185536|fast food
632071|NCT00185484|Oral contraception
632072|NCT00185445|Non Hodgkin Lymphoma
632073|NCT00185393|Follicular Non Hodgkin lymphoma
632074|NCT00185354|FC patch
632075|NCT00185354|comparator study
632076|NCT00185341|Endometriosis associated pelvic pain
632077|NCT00185328|Postmenopause
632078|NCT00185302|Non-resectable metastatic melanoma
632079|NCT00185276|Structural abnormalities of the infrarenal aorta and peripheral arteries
632080|NCT00185263|angina
632081|NCT00185263|FGF-4
632082|NCT00185263|angiogenesis
632083|NCT00185263|adenovector
632084|NCT00185263|growth factor
632085|NCT00185263|myocardial ischemia
632086|NCT00185263|revascularization
632087|NCT00185250|Cardiomyopathy
632088|NCT00185250|idiopathic chronic heart failure
632089|NCT00185250|Adenovirus
632090|NCT00185250|Enterovirus
632091|NCT00185250|Parvovirus
632092|NCT00185237|Menopause
632093|NCT00185198|Partial androgen deficiency of aging males (PADAM)
632094|NCT00185159|Microalbuminuria
632095|NCT00185133|Treatment of high blood pressure in mild to severe hypertensive patients
632096|NCT00185120|Hypertension
632097|NCT00185120|angiotensin receptor blocker
632098|NCT00185120|calcium channel blocker
632099|NCT00185120|angiotensin converting enzyme inhibitor hydroclorothiazide
632100|NCT00185107|Safety
632101|NCT00185107|Efficacy
632102|NCT00185107|WelChol®
632103|NCT00185107|Zocor®
632104|NCT00185107|Zetia®
632105|NCT00185081|colon cancer
632106|NCT00185081|radioimmunoscintigraphy
632107|NCT00185081|colon-specific antigen,
632108|NCT00185081|radioimmunotherapy,
632109|NCT00185081|radioimmunodetection
632110|NCT00185068|Systolic hypertension, Angiotensin receptor blocker
632111|NCT00184392|Sinus surgery
632112|NCT00184392|endoscopic
632113|NCT00184392|postoperative care
632114|NCT00184392|debridement
632115|NCT00184392|randomized
632116|NCT00184392|acute recurrent rhinosinusitis
632117|NCT00184392|chronic rhinosinusitis
632118|NCT00184392|nasal polyps
632119|NCT00184392|Chronic rhinosinusitis with nasal polyps
632120|NCT00184392|Chronic rhinosinusitis without nasal polyps
632121|NCT00184379|Relatives to
632122|NCT00184379|patients
632123|NCT00184379|with
632124|NCT00184379|serious
632125|NCT00184379|mental
632126|NCT00184379|illness
632127|NCT00184379|Psychoeducation
632128|NCT00184366|drug therapy
632129|NCT00184366|efalizumab
632130|NCT00184353|brain metastasis
632131|NCT00184353|signal to noise ratio
632132|NCT00184353|spectral resolution
632133|NCT00184340|eTherapy supplementary
632134|NCT00184327|Severe and longstanding psychiatric symptoms in children
632135|NCT00185055|olmesartan
632136|NCT00185055|valsartan
632137|NCT00185055|irbesartan
632138|NCT00185055|renin-angiotensin-aldosterone system
632139|NCT00185042|Atherosclerosis, intravascular ultrasound
632140|NCT00185029|prostate
632141|NCT00185029|ferumoxtran-10
632142|NCT00185029|lymph nodes
632143|NCT00185029|USPIO
632144|NCT00185016|intimate partner abuse
632145|NCT00185016|gender
632146|NCT00185016|education
632147|NCT00185016|attitude
632148|NCT00185016|family doctor
632149|NCT00185016|health care utilisation
632150|NCT00185016|abused women
632151|NCT00185003|Endotoxemia
632152|NCT00185003|vascular potassium channels
632153|NCT00185003|cytokine
632154|NCT00185003|norepinephrine
632155|NCT00185003|regional blood flow,
632156|NCT00185003|inflammation,
632157|NCT00185003|ion channels,
632158|NCT00185003|nitric oxide synthase,
632159|NCT00185003|pharmacology.
632160|NCT00184990|Endotoxemia
632161|NCT00184990|Aminoguanidine
632162|NCT00184977|Pulmonary Disease, Chronic Obstructive
632163|NCT00184977|Randomized Controlled Trial
632164|NCT00184977|Family Practice
632165|NCT00184977|Respiratory Function Tests
632166|NCT00184977|Health Status
632167|NCT00184951|HIV
632168|NCT00184938|opioids
632169|NCT00184938|ischemic preconditioning
632170|NCT00184938|morphine
632171|NCT00184899|free fatty acids
632172|NCT00184899|vasodilation
632173|NCT00184899|sympathetic activity
632174|NCT00184873|randomized controlled trial
632175|NCT00184873|health-counseling
632176|NCT00184873|multi-center study
632177|NCT00184847|acetylcholine
632178|NCT00184847|adenosine
632179|NCT00184847|caffeine
632180|NCT00184847|ischemic preconditioning
632181|NCT00184834|colorectal
632182|NCT00184834|liver
632183|NCT00184834|metastases
632184|NCT00184834|health-related quality of life
632185|NCT00184834|surgery
632186|NCT00184821|Diabetes
632187|NCT00184821|Ischemia
632188|NCT00184821|Annexin A5 scintigraphy
632189|NCT00184795|Hot flashes
632190|NCT00184782|colorectal cancer
632191|NCT00184782|liver metastases
632192|NCT00184782|metabolic activity
632193|NCT00184587|prophylactic
632194|NCT00184587|episodic
632195|NCT00184587|cluster
632196|NCT00184587|candesartan
632197|NCT00184587|angiotensin II receptor blocker
632198|NCT00184587|randomized placebo controlled parallel study
632199|NCT00184587|headache diary
632200|NCT00184535|Low back pain
632201|NCT00184535|Neuromuscular control
632202|NCT00184535|Anticipatory motor control
632203|NCT00184535|Musculoskeletal Physiologic Processes
632204|NCT00184535|Muscle, Skeletal
632205|NCT00184535|Ultrasonography
632206|NCT00184535|Electromyography
632207|NCT00184522|Gastroesophageal Reflux
632208|NCT00184522|Esomeprazole
632209|NCT00184522|Drug treatment
632210|NCT00184509|schizophrenia
632211|NCT00184509|psychosocial treatment
632212|NCT00184509|outcome
632213|NCT00184496|Analgesics, Opioid/pharmacokinetics
632214|NCT00184496|Humans
632215|NCT00184496|Methadone/therapeutic use
632216|NCT00184496|Neoplasms/complications
632217|NCT00184496|pain/drug therapy
632218|NCT00184483|Surgery
632219|NCT00184483|Lichtenstein
632220|NCT00184483|Prolene Hernia System
632221|NCT00184483|Postoperative pain
632222|NCT00184483|Recurrence
632223|NCT00184470|Adult
632224|NCT00184470|Child
632225|NCT00184470|Hospitalization/statistics & numerical data
632226|NCT00184470|Retrospective studies
632227|NCT00184457|Cardiac heart failure
632228|NCT00184457|Leg press
632229|NCT00184457|Maximal strength training
632230|NCT00184457|Serum testosterone
632231|NCT00184457|Work economy
632232|NCT00184444|angina pectoris
632233|NCT00184444|hyperoxia
632234|NCT00184444|endurance training
632235|NCT00184444|stroke volume
632236|NCT00184444|cardiac perfusion
632237|NCT00184431|Cerebrovascular Accident
632238|NCT00184431|Physical Therapy Techniques
632239|NCT00184431|Musculoskeletal Equilibrium
632240|NCT00184431|Rehabilitation
632241|NCT00184418|Immunological
632242|NCT00184418|Immune system
632243|NCT00184418|Psychiatric
632244|NCT00184418|Stress
632245|NCT00184418|Psychic trauma
632246|NCT00184418|Depression
632247|NCT00184418|Mania
632248|NCT00184418|Psychoses
632249|NCT00184418|Personality disorder
632250|NCT00184418|Schizophrenia
632251|NCT00184418|Bipolar disorder
632252|NCT00184418|Cytokine
632253|NCT00184405|Parents with psychiatric or addictive problems
632254|NCT00184301|Eating disorders
632255|NCT00184301|Anorexia nervosa
632256|NCT00184301|Bulimia nervosa
632257|NCT00184301|Personality disorders
632258|NCT00184301|In-patient treatment
632259|NCT00184301|out-patient treatment
632260|NCT00184301|group therapy
632261|NCT00184288|Lipid
632262|NCT00184288|choline
632263|NCT00184288|metastasis
632264|NCT00184288|magnetic resonance spectroscopy
632265|NCT00184288|treatment response
632266|NCT00184275|Brain metastasis
632267|NCT00184275|HR MAS spectroscopy
632268|NCT00184275|Tissue micro array
632269|NCT00184275|DNA micro array
632270|NCT00184249|Catheter ablation
632271|NCT00184249|Heart/surgery
632272|NCT00184249|Cardial surgical procedures
632273|NCT00184236|Exercise Training
632274|NCT00184236|Cardiovascular diseases
632275|NCT00184236|Risk factors
632276|NCT00184223|Motivational Interviewing
632277|NCT00184223|Substance abuse
632278|NCT00184223|Acuteley admitted psychiatric patients
632279|NCT00184223|Emergency Services, Psychiatric
632280|NCT00184210|Magnetic Resonance Spectroscopy
632281|NCT00184197|Injection
632282|NCT00184197|Headache
632283|NCT00184197|Cervical muscles
632284|NCT00184184|Emergency Services, Psychiatric
632285|NCT00184184|Tobacco use cessation
632286|NCT00184184|Coffee use cessation
632287|NCT00184184|substance use detection
632288|NCT00184184|Substance Abuse Detection
632289|NCT00184171|Microscopic colitis
632290|NCT00184171|Drug treatment
632291|NCT00184171|Diarrhoea
632292|NCT00184158|Cubital tunnel
632293|NCT00184158|treatment
632294|NCT00184158|nerve compression
632295|NCT00184145|Specific (Animal) Phobia
632296|NCT00184145|EMDR
632297|NCT00184145|Exposure therapy
632298|NCT00184132|Psychiatric Intensive Care Unit
632299|NCT00184132|Psychiatry
632300|NCT00184132|Interior decoration
632301|NCT00184132|Seclusion
632302|NCT00184119|psychiatry
632303|NCT00184119|acute
632304|NCT00184119|emergency services
632305|NCT00184119|seclusion
632306|NCT00184119|Psychiatric Intensive Care
632307|NCT00184106|Phobic disorders
632308|NCT00184106|Therapy, cognitive
632309|NCT00184106|Paroxetine
632310|NCT00184093|Cervical Carcinoma
632311|NCT00183976|Diffuse mixed NHL
632312|NCT00183976|Diffuse or follicular large B-cell NHL
632313|NCT00183976|Immunoblastic NHL
632314|NCT00183976|Burkitt or Burkitt-like lymphomas
632315|NCT00183898|Gastroesophageal Junction Cancer
632316|NCT00183872|Gastroesophageal cancer
632317|NCT00183872|Gastric Adenocarcinoma
632318|NCT00183872|Gastroesophageal Junction Adenocarcinoma
632319|NCT00183859|solid tumor
632320|NCT00183859|phase I
632321|NCT00183859|phase one
632322|NCT00183846|pancreas
632323|NCT00183846|stomach
632324|NCT00183846|common bile duct cancer
632325|NCT00183846|ampulla of Vater cancer
632326|NCT00183833|phase 1
632327|NCT00183833|phase I
632328|NCT00183833|phase one
632329|NCT00183833|colon cancer
632330|NCT00183833|colorectal cancer
632331|NCT00183820|Testicular
632332|NCT00183820|Extra gonadal germ cell neoplasm
632333|NCT00183794|Primary Peritoneal
632334|NCT00183781|HIV
632335|NCT00183781|Telephone intervention
632336|NCT00183768|Cognitive Behavioral Treatment For Depression
632337|NCT00183768|Antidepressant Psychopharmacology
632338|NCT00183768|HIV Risk Behavior
632339|NCT00183768|Injection Drug Use
632340|NCT00183755|Reward Processing
632341|NCT00183755|Anhedonia
632342|NCT00183755|Major Depressive Disorder
632343|NCT00183755|Depression
632344|NCT00183742|Phase 1
632345|NCT00183742|Phase I
632346|NCT00183742|Phase one
632347|NCT00183742|Solid tumor
632348|NCT00183729|Major depressive disorder
632349|NCT00183729|Rehabilitating
632350|NCT00183729|Elderly
632351|NCT00183729|Apathy
632352|NCT00183716|PTSD
632353|NCT00183716|Physical Abuse
632354|NCT00183716|Sexual Abuse
632355|NCT00183716|Women
632356|NCT00183716|Trauma
632357|NCT00183716|Group Therapy
632358|NCT00183716|Substance Abuse
632359|NCT00183703|Depression, Bipolar
632360|NCT00183703|Manic-Depressive Psychosis
632361|NCT00183690|PTSD
632362|NCT00183690|Anxiety Disorder
632363|NCT00183690|Trauma
632364|NCT00183690|Adolescents
632365|NCT00183690|Cognitive Behavioral Therapy
632366|NCT00183677|Brain Bioenergetic Metabolism
632367|NCT00183677|Magnetic Resonance Spectroscopy
632368|NCT00183677|Major Depressive Disorder
632369|NCT00183677|Treatment Response
632370|NCT00183664|Depression
632371|NCT00183664|Cognitive Therapy
632372|NCT00183664|Relapse Prevention
632373|NCT00183651|Suicide
632374|NCT00183651|Women
632375|NCT00183651|Emotions
632376|NCT00183651|Psychotherapy, Group
632377|NCT00183638|Internet
632378|NCT00183638|Interactive Computer Program
632379|NCT00183638|HIV Prevention
632380|NCT00183625|Antipsychotic Agents
632381|NCT00183625|Employment
632382|NCT00183612|Child
632383|NCT00183612|Adolescent
632384|NCT00183612|Mental Health
632385|NCT00183612|Olanzapine
632386|NCT00183612|Pharmacokinetics
632387|NCT00183612|Pharmacology
632388|NCT00183599|Brief interventions
632389|NCT00183599|Motivational Enhancement Therapy
632390|NCT00183599|Cognitive Behavioral Therapy
632391|NCT00183586|Treatment outcomes study
632392|NCT00183586|Anorexia
632393|NCT00183586|Anorexia nervosa
632394|NCT00183573|STDs
632395|NCT00183573|Sexual Behavior
632396|NCT00183573|Health Behavior
632397|NCT00183573|HIV Seronegativity
632398|NCT00183560|Depression Recurrence
632399|NCT00183560|Drug Therapy
632400|NCT00183560|Cognitive Therapy
632401|NCT00183560|Relapse
632402|NCT00183560|Antidepressants
632403|NCT00183547|Postpartum Depression
632404|NCT00183547|Postpartum Period
632405|NCT00183547|Indians, North American
632406|NCT00183547|Adolescent
632407|NCT00183547|Female
632408|NCT00183547|CBT
632409|NCT00183521|Hyperventilation
632410|NCT00183521|Breathing Exercises
632411|NCT00183521|Carbon Dioxide
632412|NCT00183521|Panic Attack
632413|NCT00183508|PTSD
632414|NCT00183508|Occupational Health
632415|NCT00183508|Trauma
632416|NCT00183508|Job
632417|NCT00183508|CBT
632418|NCT00183495|Depression, Bipolar
632419|NCT00183495|Manic-Depressive Psychosis
632420|NCT00183482|Parents
632421|NCT00183482|Child
632422|NCT00183482|Stress
632423|NCT00183482|CBT
632424|NCT00183469|Lamotrigine
632425|NCT00183469|Divalproex
632426|NCT00183469|Antidepressant
632427|NCT00183456|Sex Education
632428|NCT00183456|Peer Group
632429|NCT00183456|Social Identity Theory
632430|NCT00183456|HIV Seronegativity
632431|NCT00183456|Intervention
632432|NCT00183456|women
632433|NCT00183456|Social Networks
632434|NCT00183456|Peer Education
632435|NCT00183443|Mania
632436|NCT00183443|Manic-depressive
632437|NCT00183443|Psychotic disorder
632438|NCT00183430|Prazosin
632439|NCT00183430|Sleep Disorders
632440|NCT00183417|Adolescent
632441|NCT00183417|CBT
632442|NCT00183404|Drug Treatment
632443|NCT00183404|Child
632444|NCT00183404|Olanzapine
632445|NCT00183391|ADHD
632446|NCT00183391|Child
632447|NCT00183391|Adolescent
632448|NCT00183391|School
632449|NCT00183378|Alzheimer's Disease
632450|NCT00183378|Insomnia
632451|NCT00183378|Sleep Problems
632452|NCT00183378|Elderly
632453|NCT00183378|Caregivers
632454|NCT00183365|Family
632455|NCT00183365|Parenting
632456|NCT00183365|Depression
632457|NCT00183365|Group Intervention
632458|NCT00183352|Women
632459|NCT00183352|Mood
632460|NCT00183352|Menarche
632461|NCT00183352|Menstruation
632462|NCT00183339|Autism
632463|NCT00183326|Posttraumatic Stress Disorder
632464|NCT00183326|Domestic Violence
632465|NCT00183326|Children
632466|NCT00183326|Cognitive Behavioral Therapy
632467|NCT00183326|CBT
632468|NCT00183313|Mental Health
632469|NCT00183313|Primary health care
632470|NCT00183313|Case management
632471|NCT00183300|Post-traumatic stress disorder
632472|NCT00183300|PTSD
632473|NCT00183300|Prolonged Exposure
632474|NCT00183300|Cognitive-Behavior Therapy
632475|NCT00183274|Generalized Anxiety Disorder
632476|NCT00183274|Chronic Mediation Treatment
632477|NCT00183274|Double-Blind
632478|NCT00183274|Placebo Controlled
632479|NCT00183274|Venlafaxine XR
632480|NCT00183274|Relapse
632481|NCT00183261|Treatment Interruption
632482|NCT00183261|HIV Therapeutic Vaccine
632483|NCT00183261|Acute Infection
632484|NCT00183261|Acute Retroviral Syndrome
632485|NCT00183248|kidney
632486|NCT00183248|kidney transplant
632487|NCT00183248|kidney transplantation
632488|NCT00183248|transplant
632489|NCT00183248|transplantation
632490|NCT00183248|renal
632491|NCT00183248|renal transplant
632492|NCT00183248|renal transplantation
632493|NCT00183248|kidney disease
632494|NCT00183248|chronic
632495|NCT00183248|renal failure
632496|NCT00183248|kidney failure
632497|NCT00183235|Alcohol dependence
632498|NCT00183235|Alcoholism
632499|NCT00183235|Craving
632500|NCT00183222|Alcohol dependence
632501|NCT00183222|Alcoholism
632502|NCT00183222|Craving
632503|NCT00183209|Substance use disorders
632504|NCT00183209|Parent child relationship
632505|NCT00183196|Alcohol dependence
632506|NCT00183196|Alcoholism
632507|NCT00183196|Heavy drinking
632508|NCT00183183|Alcohol Abuse
632509|NCT00183183|Harm Reduction
632510|NCT00183183|Motivational Interviewing
632511|NCT00183183|Emergency Department
632512|NCT00183183|Risky Drinking
632513|NCT00183183|Prevention
632514|NCT00183170|Alcohol abuse
632515|NCT00183170|Alcoholic beverages (beer)
632516|NCT00183170|Residual effects
632517|NCT00183170|Psychomotor performance
632518|NCT00183170|Psychomotor vigilance test
632519|NCT00183170|Neurobehavioral Evaluation System
632520|NCT00183170|Family history of alcohol use
632521|NCT00183170|Alcoholic Consumption
632522|NCT00183170|Unhealthy alcohol use
632523|NCT00183170|Alcohol
632524|NCT00183157|High risk drinking
632525|NCT00183157|Alcohol dependence
632526|NCT00183157|Alcohol related injury
632527|NCT00183144|contingency management
632528|NCT00183144|reinforcement
632529|NCT00183144|employment
632530|NCT00183144|Therapeutic Workplace
632531|NCT00183131|Alcohol
632532|NCT00183131|Alcohol abuse
632533|NCT00183131|Alcohol dependence
632534|NCT00183131|Alcohol consumption
632535|NCT00183131|Unhealthy alcohol use
632536|NCT00183131|Screening
632537|NCT00183131|Brief Intervention
632538|NCT00183131|Effectiveness
632539|NCT00183131|Electronic intervention
632540|NCT00183131|Web-based intervention
632541|NCT00183131|College students
632542|NCT00183118|HIV
632543|NCT00183118|Russia
632544|NCT00183118|Prevention
632545|NCT00183118|Behavioral intervention
632546|NCT00183118|Alcohol dependence
632547|NCT00183105|Alcohol
632548|NCT00183105|Alcohol abuse
632549|NCT00183105|Alcohol dependence
632550|NCT00183105|Utilization
632551|NCT00183105|Alcohol consumption
632552|NCT00183105|Unhealthy alcohol use
632553|NCT00183105|Hospitalization
632554|NCT00183105|Screening
632555|NCT00183105|Brief Intervention
632556|NCT00183105|Motivational Interviewing
632557|NCT00183105|Randomized trial
632558|NCT00183105|Effectiveness
632559|NCT00183105|Unhealthy alcohol use (Risky alcohol consumption amounts, problem alcohol use, hazardous alcohol use, alcohol abuse and alcohol dependence)
632560|NCT00183092|dementia
632561|NCT00183092|spongiform encephalopathy
632562|NCT00183092|nervous system disorder
632563|NCT00183092|acridine
632564|NCT00183092|prion
632565|NCT00183092|neuropharmacologic agent
632566|NCT00183079|Depression
632567|NCT00183079|Alcohol Use
632568|NCT00183079|Motivational Interviewing
632569|NCT00183053|Hospitalization
632570|NCT00183053|Fall Risk
632571|NCT00183053|Frailty
632572|NCT00183040|andropause
632573|NCT00183040|hormone therapy
632574|NCT00183040|HRT
632575|NCT00183027|Dietary restriction
632576|NCT00183027|Caloric restriction
632577|NCT00183014|behavior therapy
632578|NCT00183014|exercise
632579|NCT00183014|gait
632580|NCT00183014|physical activity
632581|NCT00183001|nutritional supplement
632582|NCT00183001|dietary supplement
632583|NCT00183001|vitamin therapy
632584|NCT00183001|Vitamin K deficiency
632585|NCT00183001|bone density
632586|NCT00182988|communication behavior
632587|NCT00182988|coping
632588|NCT00182988|functional ability
632589|NCT00182988|quality of life
632590|NCT00182988|caregiving
632591|NCT00182975|Metabolic syndrome
632592|NCT00182962|Activities of Daily Living
632593|NCT00182962|Low-income
632594|NCT00182962|geriatric medicine
632595|NCT00182962|computer assisted patient care
632596|NCT00182949|Epidemiology
632597|NCT00182949|Genetics
632598|NCT00182949|Aging
632599|NCT00182949|Sardinian Population
632600|NCT00182949|Cardiovascular Diseases
632601|NCT00182949|Personality Traits
632602|NCT00182949|Frailty
632603|NCT00182936|Cognition disorder
632604|NCT00182936|organic brain syndrome
632605|NCT00182936|patient care management
632606|NCT00182936|long term care
632607|NCT00182936|extended care facility
632608|NCT00182923|Blood pressure
632609|NCT00182923|genetics
632610|NCT00182897|caregiver
632611|NCT00182897|home health care
632612|NCT00182897|coping
632613|NCT00182884|Hospital acquired complications
632614|NCT00182884|adverse effects
632615|NCT00182884|Cognitive Impairment
632616|NCT00182884|Aging
632617|NCT00182871|geriatric medicine
632618|NCT00182871|hormone therapy
632619|NCT00182871|HT
632620|NCT00182871|andropause
632621|NCT00182858|Tissue
632622|NCT00182858|Procurement
632623|NCT00182858|Exploratory Methods
632624|NCT00182858|Disease Correlation
632625|NCT00182858|Sampling
632626|NCT00182845|dementia
632627|NCT00182845|MCI
632628|NCT00182845|Aricept
632629|NCT00182845|Adverse Effects
632630|NCT00182845|Hospital Acquired Complications
632631|NCT00182845|Cognitive Impairment
632632|NCT00182845|Aging
632633|NCT00182832|Physician Behavior
632634|NCT00182832|Hospital Acquired Complications
632635|NCT00182832|MCI
632636|NCT00182832|Mild Cognitive Impairment
632637|NCT00182819|adult oligodendroglioma
632638|NCT00182819|adult diffuse astrocytoma
632639|NCT00182819|adult mixed glioma
632640|NCT00182806|recurrent non-small cell lung cancer
632641|NCT00182806|stage IIIA non-small cell lung cancer
632642|NCT00182806|stage IIIB non-small cell lung cancer
632643|NCT00182806|stage IV non-small cell lung cancer
632644|NCT00182793|stage IIIB breast cancer
632645|NCT00182793|stage IIIC breast cancer
632646|NCT00182793|stage IV breast cancer
632647|NCT00182793|inflammatory breast cancer
632648|NCT00182793|male breast cancer
632649|NCT00182793|recurrent breast cancer
632650|NCT00182793|invasive ductal breast carcinoma with predominant intraductal component
632651|NCT00182793|invasive ductal breast carcinoma
632652|NCT00182793|medullary ductal breast carcinoma with lymphocytic infiltrate
632653|NCT00182793|mucinous ductal breast carcinoma
632654|NCT00182793|Paget disease of the breast with invasive ductal carcinoma
632655|NCT00182793|papillary ductal breast carcinoma
632656|NCT00182793|tubular ductal breast carcinoma
632657|NCT00182793|invasive lobular breast carcinoma with predominant in situ component
632658|NCT00182793|invasive lobular breast carcinoma
632659|NCT00182793|comedo ductal breast carcinoma
632660|NCT00182780|fatigue
632661|NCT00182780|unspecified adult solid tumor, protocol specific
632662|NCT00182754|unspecified adult solid tumor, protocol specific
632663|NCT00182754|malignant ascites
632664|NCT00182741|recurrent prostate cancer
632665|NCT00182741|stage IV prostate cancer
632666|NCT00182728|invasive ductal breast carcinoma
632667|NCT00182728|stage I breast cancer
632668|NCT00182728|stage II breast cancer
632669|NCT00182715|adenocarcinoma of the colon
632670|NCT00182715|stage IV colon cancer
632671|NCT00182715|adenocarcinoma of the rectum
632672|NCT00182715|stage IV rectal cancer
632673|NCT00182650|recurrent grade 1 follicular lymphoma
632674|NCT00182650|recurrent grade 2 follicular lymphoma
632675|NCT00182650|recurrent grade 3 follicular lymphoma
632676|NCT00182637|recurrent mycosis fungoides/Sezary syndrome
632677|NCT00182637|stage I mycosis fungoides/Sezary syndrome
632678|NCT00182637|stage II mycosis fungoides/Sezary syndrome
632679|NCT00182637|stage III mycosis fungoides/Sezary syndrome
632680|NCT00182637|stage IV mycosis fungoides/Sezary syndrome
632681|NCT00182637|stage I cutaneous T-cell non-Hodgkin lymphoma
632682|NCT00182637|stage II cutaneous T-cell non-Hodgkin lymphoma
632683|NCT00182637|stage III cutaneous T-cell non-Hodgkin lymphoma
632684|NCT00182637|stage IV cutaneous T-cell non-Hodgkin lymphoma
632685|NCT00182637|recurrent cutaneous T-cell non-Hodgkin lymphoma
632686|NCT00182624|Prostate Cancer
632687|NCT00182624|Magnetic Resonance Imaging
632688|NCT00182624|Spectroscopy
632689|NCT00182611|stage III gastric cancer
632690|NCT00182611|adenocarcinoma of the stomach
632691|NCT00182598|buprenorphine
632692|NCT00182598|computer
632693|NCT00182598|treatment
632694|NCT00182598|opioid
632695|NCT00182598|heroin
632696|NCT00182585|HIV
632697|NCT00182585|hepatitis
632698|NCT00182585|STDs
632699|NCT00182585|adolescents
632700|NCT00182585|addiction
632701|NCT00182585|treatment
632702|NCT00182585|prevention
632703|NCT00182585|HIV and related risk behavior among youth in drug treatment
632704|NCT00182572|heroin
632705|NCT00182572|opiate
632706|NCT00182572|addiction
632707|NCT00182572|adolescent
632708|NCT00182572|treatment
632709|NCT00182559|kidney
632710|NCT00182559|transplantation
632711|NCT00182559|tacrolimus
632712|NCT00182559|cyclosporine
632713|NCT00182559|conversion
632714|NCT00182546|Pulmonary Embolism
632715|NCT00182546|DVT
632716|NCT00182546|Venous Thrombosis
632717|NCT00182546|D dimer
632718|NCT00182546|DD
632719|NCT00182546|Thrombosis
632720|NCT00182546|Diagnosis
632721|NCT00182533|Generalized social phobia
632722|NCT00182533|Comorbid panic disorder with agoraphobia
632723|NCT00182533|Comorbid obsessive compulsive disorder
632724|NCT00182533|Comorbid generalized anxiety disorder
632725|NCT00182533|Comorbid major depressive disorder/Dysthymia
632726|NCT00182520|Treatment Refractory Obsessive Compulsive Disorder
632727|NCT00182494|Schizophrenia, Diabetes, Weight gain, Antipsychotic drugs
632728|NCT00182481|asthma treatment
632729|NCT00182481|induced sputum cell counts
632730|NCT00182481|asthma exacerbations
632731|NCT00182481|eosinophilic bronchitis
632732|NCT00182481|non-eosinophilic bronchitis
632733|NCT00182468|Domestic violence
632734|NCT00182468|Spouse Abuse
632735|NCT00182455|Treatment Refractory Generalized Social Phobia
632736|NCT00182442|Cognitive deficits
632737|NCT00182442|Psychosocial functioning
632738|NCT00182442|Quality of Life
632739|NCT00182429|Antibiotic associated diarrhea
632740|NCT00182429|C. difficile
632741|NCT00182429|Metronidazole
632742|NCT00182429|Rifampin
632743|NCT00182416|pacemakers
632744|NCT00182416|atrial fibrillation
632745|NCT00182416|stroke
632746|NCT00182416|cardiovascular death
632747|NCT00182403|Unfractionated Heparin
632748|NCT00182403|Low Molecular Weight Heparin
632749|NCT00182403|Venous Thromboembolism
632750|NCT00182403|APTT
632751|NCT00182403|Treatment
632752|NCT00182390|ELBW premature infants
632753|NCT00182390|neonatal transfusion
632754|NCT00182390|bronchopulmonary dysplasia
632755|NCT00182390|periventricular leukomalacia
632756|NCT00182390|ventriculomegaly
632757|NCT00182390|retinopathy of prematurity
632758|NCT00182377|patients undergoing cardiac surgery requiring cardiopulmonary bypass
632759|NCT00182364|Critically Ill
632760|NCT00182364|Deep Venous Thrombosis
632761|NCT00182364|Randomized Control Trial
632762|NCT00182364|Pilot Study
632763|NCT00182351|deep vein thrombosis
632764|NCT00182351|d-dimer
632765|NCT00182351|serial compression ultrasound
632766|NCT00182338|cardiovascular outcomes
632767|NCT00182338|congestive heart failure
632768|NCT00182338|Peritoneal Membrane transport properties
632769|NCT00182338|Arterial stiffening
632770|NCT00182338|Inflammatory markers
632771|NCT00182325|medical record
632772|NCT00182325|pregnancy
632773|NCT00182325|Internet
632774|NCT00182312|preterm infants
632775|NCT00182312|very low birthweight
632776|NCT00182312|apnea of prematurity
632777|NCT00182312|methylxanthines
632778|NCT00182312|developmental disabilities
632779|NCT00182286|Diabetes
632780|NCT00182286|Continuity of Care
632781|NCT00182286|Patient Perspective
632782|NCT00182286|Health Service Organization
632783|NCT00182273|Benign paroxysmal positional vertigo
632784|NCT00182273|Canalith repositioning maneuver
632785|NCT00182273|Dizziness
632786|NCT00182273|Primary Care
632787|NCT00182247|deep vein thrombosis
632788|NCT00182247|DVT
632789|NCT00182247|pulmonary embolism
632790|NCT00182247|PE
632791|NCT00182247|venous thromboembolism
632792|NCT00182247|VTE
632793|NCT00182247|d-dimer
632794|NCT00182247|IPG
632795|NCT00182234|unmet supportive care needs
632796|NCT00182221|Pulmonary Embolism
632797|NCT00182221|Deep Vein Thrombosis
632798|NCT00182221|MDA D-Dimer Testing
632799|NCT00182221|Diagnostic Algorithm
632800|NCT00182208|PTS
632801|NCT00182208|Post phlebitic Syndrome
632802|NCT00182208|Activities of Daily Living
632803|NCT00182208|Quality of Life
632804|NCT00182182|Heart Failure
632805|NCT00182182|Family physicians
632806|NCT00182182|academic detailing
632807|NCT00182182|process of care
632808|NCT00182169|Severe heart failure
632809|NCT00182169|Growth hormone
632810|NCT00182169|exercise capacity
632811|NCT00182169|quality of life
632812|NCT00182169|cardiac function
632813|NCT00182156|hemodialysis
632814|NCT00182156|platelet function analyzer
632815|NCT00182156|bioimpedance
632816|NCT00182156|pulse wave velocity
632817|NCT00182156|end stage renal disease
632818|NCT00182143|Critically Ill
632819|NCT00182143|Deep Venous ThromboEmbolism
632820|NCT00182143|Randomized Controlled Trial
632821|NCT00182130|rectal cancer
632822|NCT00182130|surgery
632823|NCT00182130|physician behaviour
632824|NCT00182130|knowledge translation
632825|NCT00182117|bleeding
632826|NCT00182117|end stage renal disease
632827|NCT00182117|antiplatelet therapy
632828|NCT00182117|anticoagulant therapy
632829|NCT00182117|hemodialysis
632830|NCT00182104|Fontan procedure
632831|NCT00182104|Anticoagulation
632832|NCT00182104|Thrombosis
632833|NCT00182104|Thromboembolism
632834|NCT00182104|Prevention
632835|NCT00182091|Acromegaly
632836|NCT00182091|Growth Hormone Deficiency
632837|NCT00182091|Cardiovascular Risk
632838|NCT00182091|Pituitary
632839|NCT00182091|Hypothalamic
632840|NCT00182078|sertraline
632841|NCT00182078|children
632842|NCT00182078|adolescents
632843|NCT00182078|posttraumatic stress disorder
632844|NCT00182078|depression
632845|NCT00182078|prevention
632846|NCT00182078|burns
632847|NCT00182078|injuries
632848|NCT00182065|Heart failure
632849|NCT00182065|Functional decline
632850|NCT00182065|Cognitive impairment
632851|NCT00182065|Neuropsychiatric health
632852|NCT00182065|Longitudinal
632853|NCT00182065|Long-term care
632854|NCT00182065|Elderly
632855|NCT00182052|rosiglitazone
632856|NCT00182052|Avandia
632857|NCT00182052|androgen dependant prostate cancer
632858|NCT00182039|randomized controlled trial
632859|NCT00182039|blinded
632860|NCT00182039|noncardiac surgery
632861|NCT00182039|cardiovascular events
632862|NCT00182026|diabetes
632863|NCT00182026|community intervention
632864|NCT00182026|self-management
632865|NCT00182026|prevention
632866|NCT00182000|OCD
632867|NCT00181987|ADHD
632868|NCT00181987|bipolar disorder
632869|NCT00181987|children
632870|NCT00181987|Concerta
632871|NCT00181974|burns
632872|NCT00181974|hemostasis
632873|NCT00181974|skin graft
632874|NCT00181974|Surgical Hemostasis
632875|NCT00181974|Grafting, Skin
632876|NCT00181961|antidepressant-induced sexual dysfunction
632877|NCT00181948|ADHD
632878|NCT00181948|children
632879|NCT00181948|stimulant non-responders
632880|NCT00181948|Strattera
632881|NCT00181935|bipolar disorder
632882|NCT00181935|preschoolers
632883|NCT00181935|risperdal
632884|NCT00181935|zyprexa
632885|NCT00181922|bipolar disorder
632886|NCT00181922|children
632887|NCT00181922|ziprasidone
632888|NCT00181922|mania
632889|NCT00181909|Pregnancy
632890|NCT00181909|Smoking cessation
632891|NCT00181896|depression
632892|NCT00181896|bipolar disorder
632893|NCT00181896|children
632894|NCT00181896|bupropion SR
632895|NCT00181883|children
632896|NCT00181883|bipolar disorder
632897|NCT00181883|quetiapine
632898|NCT00181883|preschoolers
632899|NCT00181870|bipolar disorder
632900|NCT00181870|children
632901|NCT00181870|mania
632902|NCT00181870|Equetro
632903|NCT00181857|ADHD NOS
632904|NCT00181857|familial risk
632905|NCT00181857|children
632906|NCT00181844|bipolar disorder
632907|NCT00181844|lamotrigine
632908|NCT00181844|children
632909|NCT00181844|mania
632910|NCT00181831|SPECT
632911|NCT00181831|bipolar disorder
632912|NCT00181831|ADHD
632913|NCT00181831|children
632914|NCT00181818|Smoking cessation
632915|NCT00181818|Bupropion SR
632916|NCT00181818|Hospital intervention
632917|NCT00181818|Myocardial infarction
632918|NCT00181818|Unstable angina
632919|NCT00181805|GER
632920|NCT00181792|ADHD
632921|NCT00181792|smoking
632922|NCT00181792|familial risk
632923|NCT00181779|mania
632924|NCT00181779|Abilify
632925|NCT00181779|children
632926|NCT00181779|bipolar disorder
632927|NCT00181766|ADHD NOS
632928|NCT00181766|Adults
632929|NCT00181766|Strattera (atomoxetine)
632930|NCT00181766|Open-Label
632931|NCT00181753|glutamine metabolic kinetics
632932|NCT00181753|glutamate metabolic kinetics
632933|NCT00181753|enteral nutrition
632934|NCT00181753|parenteral nutrition
632935|NCT00181753|burn injury
632936|NCT00181753|stable isotopes
632937|NCT00181740|ADHD NOS
632938|NCT00181740|Adults
632939|NCT00181740|Concerta
632940|NCT00181740|Open-Label
632941|NCT00181727|bipolar disorder
632942|NCT00181727|mania
632943|NCT00181727|depakote ER
632944|NCT00181727|children
632945|NCT00181714|cigarette smoking
632946|NCT00181714|ADHD
632947|NCT00181714|adolescents
632948|NCT00181714|Concerta
632949|NCT00181701|Ovarian cancer
632950|NCT00181701|Epithelial carcinoma of mullerian origin
632951|NCT00181701|Intraperitoneal paclitaxel
632952|NCT00181701|Intraperitoneal carboplatin
632953|NCT00181701|Primary peritoneal carcinoma
632954|NCT00181701|Tubal carcinoma
632955|NCT00181688|Iressa
632956|NCT00181688|ZD1839
632957|NCT00181688|Anastrozole
632958|NCT00181688|Arimidex
632959|NCT00181675|Adult
632960|NCT00181675|ADHD
632961|NCT00181675|galantamine
632962|NCT00181675|double-blind
632963|NCT00181662|Curcumin
632964|NCT00181662|Piperine
632965|NCT00181662|Silybin
632966|NCT00181662|Healthy volunteer
632967|NCT00181662|Female
632968|NCT00181649|Lactation
632969|NCT00181649|Breastfeeding
632970|NCT00181649|Adoptive mothers
632971|NCT00181649|Prolactin
632972|NCT00181649|Relative lactation insufficiency
632973|NCT00181623|Lactation
632974|NCT00181623|Breastfeeding
632975|NCT00181623|Prolactin
632976|NCT00181623|Primary lactation insufficiency
632977|NCT00181610|Lactation
632978|NCT00181610|Breastfeeding
632979|NCT00181610|Premature infants
632980|NCT00181610|Prolactin
632981|NCT00181610|Primary lactation insufficiency
632982|NCT00181597|Trilostane
632983|NCT00181597|Androgen-independent prostate cancer
632984|NCT00181584|Androgen deprivation therapy
632985|NCT00181584|bone loss
632986|NCT00181584|prostate cancer
632987|NCT00181584|Zoledronic Acid
632988|NCT00181584|Zometa
632989|NCT00181571|ADHD
632990|NCT00181571|Adults
632991|NCT00181571|Concerta
632992|NCT00181571|Double-Blind
632993|NCT00181558|Prostate Cancer
632994|NCT00181558|bone metastases
632995|NCT00181558|Atrasentan
632996|NCT00181558|Zometa
632997|NCT00181558|Androgen Independent Prostate Cancer
632998|NCT00181545|Non-small cell lung carcinoma
632999|NCT00181545|radiotherapy
633000|NCT00181545|mean lung dose
633001|NCT00181532|NSCLC
633002|NCT00181532|cox-2-inhibitor
633003|NCT00181532|radiosensitizer
633004|NCT00181532|radiotherapy
633005|NCT00181506|radiotherapy
633006|NCT00181506|radiation dose
633007|NCT00181506|lung cancer
633008|NCT00181363|Breast cancer
633009|NCT00181363|Breast conserving surgery
633010|NCT00181363|Radiotherapy
633011|NCT00181363|Pendulous breasts
633012|NCT00181350|brain tumor
633013|NCT00181350|fractionated stereotactic radiotherapy
633014|NCT00181350|fixationsystems
633015|NCT00181350|repositioning
633016|NCT00181311|vaginal hysterectomy
633017|NCT00181311|abdominal hysterectomy
633018|NCT00181311|complications
633019|NCT00181311|physical well being
633020|NCT00181311|mental well being
633021|NCT00181298|Memantine
633022|NCT00181298|SLE
633023|NCT00181298|Anti NR2
633024|NCT00181298|ANAM
633025|NCT00181298|Cognitive functioning
633026|NCT00181272|chronic obstructive pulmonary disease (COPD)
633027|NCT00181272|undifferentiated asthma/COPD
633028|NCT00181246|Neuropathic pain
633029|NCT00181246|Efficacy
633030|NCT00181207|COPD
633031|NCT00181194|Asthma
633032|NCT00181181|Hypertension
633033|NCT00181168|thyroid cancer
633034|NCT00181168|PET scan
633035|NCT00181168|recombinant thyrotropin
633036|NCT00181168|thyroglobulin
633037|NCT00181168|Thyroid cancer, differentiated epithelial
633038|NCT00181155|metabolism
633039|NCT00181155|congestive heart failure
633040|NCT00181155|allopurinol
633041|NCT00181155|Adenosine triphosphate (ATP)
633042|NCT00181142|Induciton therapy, Daclizumab, Thymoglobulin, lung transplantation
633043|NCT00181129|Fatigue
633044|NCT00181129|Cancer treatment
633045|NCT00181116|Epilepsy
633046|NCT00181116|Benign rolandic
633047|NCT00181116|Levetiracetam
633048|NCT00181090|Epilepsy
633049|NCT00181090|Ketosis
633050|NCT00181090|Atkins
633051|NCT00181090|seizures
633052|NCT00181077|preeclampsia, hypertonic saline, diuresis
633053|NCT00181064|headache
633054|NCT00181064|Atkins
633055|NCT00181064|ketosis
633056|NCT00181064|intractable
633057|NCT00181038|Oro-Pharyngeal Carcinoma Surgery
633058|NCT00181025|Limbs’ girdle
633059|NCT00181012|Cancer Related Visceral Pain Resistant to Morphinics
633060|NCT00180947|Soft parts tissue
633061|NCT00180921|Adenoid cystic carcinoma of the head and neck
633062|NCT00180908|Osteosarcoma
633063|NCT00180895|Burkitt lymphoma
633064|NCT00180895|B-cell non Hodgkin lymphoma
633065|NCT00180895|B-cell ALL
633066|NCT00180895|Refractory
633067|NCT00180895|Relapse
633068|NCT00180895|Rituximab
633069|NCT00180895|Children
633070|NCT00180869|cancer
633071|NCT00180869|peroperative transfusion
633072|NCT00180869|allogeneic red blood cell concentrate
633073|NCT00180869|leuko-reduced red blood cell concentrate
633074|NCT00180856|Lung metastasis
633075|NCT00180856|Lung cancer
633076|NCT00180856|Radiofrequency ablation
633077|NCT00180791|Brain PNET
633078|NCT00180765|Leukocytes
633079|NCT00180765|Eosinophils
633080|NCT00180765|Neutrophils
633081|NCT00180765|Chronic Obstructive Airway Disease
633082|NCT00180765|Apoptosis
633083|NCT00180765|Signal Transduction
633084|NCT00180739|MR guided FUS
633085|NCT00180739|Uterine Fibroids
633086|NCT00180739|Fertility
633087|NCT00180739|Pregnancy
633088|NCT00180726|asthma, inflammatory, corticosteroid
633089|NCT00180713|Pulmonary hypertension
633090|NCT00180713|Simvastatin
633091|NCT00180713|Statins
633092|NCT00180700|HIV
633093|NCT00180700|Stress
633094|NCT00180700|Psychoneuroimmunology
633095|NCT00180700|stress management
633096|NCT00180700|hypnosis
633097|NCT00180700|Johrei
633098|NCT00180700|psychological intervention
633099|NCT00180687|Pain
633100|NCT00180687|Nebulisation
633101|NCT00180687|Cholecystectomy
633102|NCT00180687|Laparoscopic
633103|NCT00180687|Bupivacaine
633104|NCT00180687|Local Anaesthetic
633105|NCT00180674|Hepatic fibrosis
633106|NCT00180674|anticoagulation
633107|NCT00180674|Coumarin
633108|NCT00180674|Warfarin
633109|NCT00180674|Chronic hepatitis C virus infection
633110|NCT00180661|Severe asthma
633111|NCT00180661|corticosteroid responsiveness
633112|NCT00180648|Short Bowel Syndrome
633113|NCT00180648|Intestinal Failure
633114|NCT00180648|Glucagon Like Peptide 2
633115|NCT00180648|Parenteral Nutrition
633116|NCT00180518|Carotid artery disease
633117|NCT00180518|High risk
633118|NCT00180518|High surgical risk
633119|NCT00180505|Peripheral Artery Disease
633120|NCT00180505|Restenosis Rate
633121|NCT00180505|Patency Rates
633122|NCT00180505|Self-Expandable Nitinol Stents
633123|NCT00180505|Stent Fractures
633124|NCT00180492|Atherosclerotic disease
633125|NCT00180479|Everolimus
633126|NCT00180466|drug eluting stents
633127|NCT00180466|stents
633128|NCT00180466|angioplasty
633129|NCT00180466|coronary artery disease
633130|NCT00180466|total coronary occlusion
633131|NCT00180466|coronary artery restenosis
633132|NCT00180466|stent thrombosis
633133|NCT00180466|vascular disease
633134|NCT00180466|myocardial ischemia
633135|NCT00180466|coronary artery stenosis
633136|NCT00180453|Cardiovascular disease
633137|NCT00180453|Ischemia
633138|NCT00180414|heart failure
633139|NCT00180388|cardiovascular system
633140|NCT00180388|veins
633141|NCT00180388|saphenous vein
633142|NCT00180336|Heart Failure
633143|NCT00180336|Tachycardia
633144|NCT00180336|Atrial Fibrillation
633145|NCT00180336|Atrial Flutter
633146|NCT00180336|Ventricular Fibrillation
633147|NCT00180310|drug eluting stents
633148|NCT00180310|stents
633149|NCT00180310|angioplasty
633150|NCT00180310|coronary artery disease
633151|NCT00180310|total coronary occlusion
633152|NCT00180310|coronary artery restenosis
633153|NCT00180310|stent thrombosis
633154|NCT00180310|vascular disease
633155|NCT00180310|myocardial ischemia
633156|NCT00180310|coronary artery stenosis
633157|NCT00180284|Pacemaker leads
633158|NCT00180284|Electrodes, implantable
633159|NCT00180284|Cardiac pacing, aritificial
633160|NCT00180271|Defibrillator
633161|NCT00180271|Cardiac Resynchronization Therapy
633162|NCT00180271|MADIT
633163|NCT00180258|Cardiac Resynchronization Therapy (CRT)
633164|NCT00180258|Heart Failure
633165|NCT00180258|Defibrillator
633166|NCT00180258|Pacemaker
633167|NCT00180245|Radiation therapy
633168|NCT00180245|F-18-FDG
633169|NCT00180219|G08.520.769.550.408
633170|NCT00180219|G08.520.769.550.490
633171|NCT00180219|G08.520.769.550.520
633172|NCT00180206|Arthritis
633173|NCT00180206|Hip
633174|NCT00180206|Hip arthroplasty
633175|NCT00180206|Hip resurfacing arthroplasty
633176|NCT00180193|Radiotherapy
633177|NCT00180193|F-18-OMFD
633178|NCT00180180|head-and-neck cancer
633179|NCT00180180|radiation therapy
633180|NCT00180180|F-18-FMISO
633181|NCT00180167|Chemotherapy
633182|NCT00180167|elderly
633183|NCT00180154|radiation therapy
633184|NCT00180154|F-18-FDG
633185|NCT00180154|NSCLC
633186|NCT00180141|Atopic dermatitis on both lower arm.
633187|NCT00180128|acute promyelocytic leukemia
633188|NCT00180128|risk adapted therapy
633189|NCT00180115|acute myeloid leukemia
633190|NCT00180115|cytarabine postremission dosage
633191|NCT00180115|risk adapted treatment strategy
633192|NCT00180115|allogeneic stem cell transplantation
633193|NCT00180115|autologous stem cell transplantation
633194|NCT00180102|acute myeloid leukemia
633195|NCT00180102|risk adapted treatment
633196|NCT00180102|early allogeneic stem cell transplantation
633197|NCT00180102|autologous stem cell transplantation
633198|NCT00180089|graft-versus-host disease
633199|NCT00180089|budesonide
633200|NCT00180089|stem cell transplantation
633201|NCT00180076|collagenous colitis
633202|NCT00180076|microscopic colitis
633203|NCT00180076|budesonide
633204|NCT00180050|lymphocytic colitis
633205|NCT00180050|microscopic colitis
633206|NCT00180050|budesonide
633207|NCT00180037|Parkinson's disease
633208|NCT00180037|Coenzyme Q10
633209|NCT00180037|Treatment
633210|NCT00180037|Neuroprotection
633211|NCT00180024|AT1-receptor
633212|NCT00180024|AT2-receptor
633213|NCT00180024|human pharmacology
633214|NCT00180011|omalizumab
633215|NCT00180011|severe asthma
633216|NCT00180011|moderate asthma
633217|NCT00180011|injectable asthma medication
633218|NCT00180011|Xolair
633219|NCT00179998|Cystic fibrosis
633220|NCT00179998|Infants
633221|NCT00179998|Children
633222|NCT00179998|Pulmozyme
633223|NCT00179998|Pulmonary function
633224|NCT00179998|Computed tomography
633225|NCT00179985|Developmental Care
633226|NCT00179985|Neonatal Intensive Care Unit (NICU)
633227|NCT00179972|Pulse oximetry
633228|NCT00179972|Pulse oximetry sensors
633229|NCT00179972|Skin Integrity
633230|NCT00179972|Prematurity
633231|NCT00179972|Neonatal Intensive Care Unit
633232|NCT00179972|Infant, premature
633233|NCT00179933|developmental care
633234|NCT00179933|Neonatal Intensive Care Unit
633235|NCT00179894|ADHD
633236|NCT00179894|Attention Deficit Hyperactivity Disorder
633237|NCT00179881|Brain stem glioma
633238|NCT00179868|cancer
633239|NCT00179868|leukemia
633240|NCT00179868|stem cell transplant
633241|NCT00179868|complications
633242|NCT00179855|graft versus host disease
633243|NCT00179855|ECP
633244|NCT00179855|extracorporeal photopheresis
633245|NCT00179855|allogeneic transplantation
633246|NCT00179829|leukemia
633247|NCT00179829|acute lymphocytic leukemia
633248|NCT00179829|chronic myelogenous leukemia
633249|NCT00179829|acute myelogenous leukemia
633250|NCT00179816|wilm's tumor
633251|NCT00179816|stem cell transplantation
633252|NCT00179816|solid tumor
633253|NCT00179803|brain tumor
633254|NCT00179803|medulloblastoma
633255|NCT00179803|germ cell tumor
633256|NCT00179803|CNS tumor
633257|NCT00179803|glioblastoma
633258|NCT00179803|astrocytoma
633259|NCT00179803|pineoblastoma
633260|NCT00179803|rhabdoid tumor
633261|NCT00179803|supratentorial PNET
633262|NCT00179803|high grade astrocytoma
633263|NCT00179790|cancer
633264|NCT00179790|hemoglobinopathy
633265|NCT00179790|immune deficiency
633266|NCT00179790|photopheresis
633267|NCT00179790|ECP
633268|NCT00179790|extracorporeal photopheresis
633269|NCT00179777|Diabetes Mellitus, Type 1
633270|NCT00179777|Genetic Predisposition to Disease
633271|NCT00179777|Infant Nutrition
633272|NCT00179777|Primary Prevention
633273|NCT00179764|Patients with recurrent solid tumors
633274|NCT00179764|Patients with malignant melanoma
633275|NCT00179764|Patients with hematological malignancies
633276|NCT00179764|Acute lymphoblastic leukemia (ALL)
633277|NCT00179764|Acute myelogenous leukemia (AML)
633278|NCT00179751|cc-5013
633279|NCT00179751|revlimid
633280|NCT00179751|pancreatic cancer
633281|NCT00179738|Androgen Independent Prostate Cancer
633282|NCT00179725|cc-5013
633283|NCT00179725|revlimid
633284|NCT00179725|ovarian cancer
633285|NCT00179725|celgene
633286|NCT00179712|cc-5013
633287|NCT00179712|revlimid
633288|NCT00179712|ovarian cancer
633289|NCT00179712|celgene
633290|NCT00179699|cc-5013
633291|NCT00179699|Non Small Cell Lung Cancer
633292|NCT00179699|revlimid
633293|NCT00179699|celgene
633294|NCT00179699|cc5013
633295|NCT00179686|celgene
633296|NCT00179686|cc-5013
633297|NCT00179686|NSCLC
633298|NCT00179686|CC5013
633299|NCT00179686|Revlimid
633300|NCT00179686|Non-Small Cell Lung Cancer
633301|NCT00179673|NHL
633302|NCT00179673|CC5013
633303|NCT00179673|Non-Hodgkins Lymphoma
633304|NCT00179673|revlimid
633305|NCT00179673|cc-5013
633306|NCT00179673|celgene
633307|NCT00179660|celgene
633308|NCT00179660|cc-5013
633309|NCT00179660|CC5013
633310|NCT00179660|NHL
633311|NCT00179660|Non-Hodgkins Lymphoma
633312|NCT00179660|Revlimid
633313|NCT00179647|Multiple Myeloma
633314|NCT00179647|MM
633315|NCT00179647|Revlimid
633316|NCT00179647|CC5013
633317|NCT00179647|celgene
633318|NCT00179647|cc-5013
633319|NCT00179647|relapsed/refractory
633320|NCT00179647|lenalidomide
633321|NCT00179647|dexamethasone
633322|NCT00179647|Decadron
633323|NCT00179634|Mastectomy
633324|NCT00179634|Randomized Controlled Trial
633325|NCT00179634|Imagery
633326|NCT00179621|MDS
633327|NCT00179621|transfusion dependent
633328|NCT00179621|anaemia
633329|NCT00179621|cytogenetic abnormality 5q-
633330|NCT00179621|erythroid response
633331|NCT00179621|leukaemia
633332|NCT00179621|CC-5013
633333|NCT00179621|Celgene
633334|NCT00179621|revlimid
633335|NCT00179621|lenalidomide
633336|NCT00179608|CC-5013
633337|NCT00179608|CC5013
633338|NCT00179608|celgene
633339|NCT00179608|Melanoma
633340|NCT00179608|Revlimid
633341|NCT00179608|Metastatic Malignant Melanoma
633342|NCT00179608|Lenalidomide
633343|NCT00179595|nitric oxide, volumetric oxygen consumption
633344|NCT00179582|IBS
633345|NCT00179582|Functional bowel disorder
633346|NCT00179582|Diarrhea
633347|NCT00179582|probiotic
633348|NCT00179556|Hot flashes
633349|NCT00179556|Menopausal symptoms
633350|NCT00179556|Soybean germ
633351|NCT00179556|Aglycones
633352|NCT00179556|Menopause
633353|NCT00179517|Seizure
633354|NCT00179517|Epilepsy
633355|NCT00179517|Testosterone
633356|NCT00179517|Hormone
633357|NCT00179517|Sexual Dysfunction
633358|NCT00179517|Hypogonadism
633359|NCT00179517|Men
633360|NCT00179491|coronary artery bypass grafting surgery
633361|NCT00179478|Multiple sclerosis
633362|NCT00179478|Interferon Beta
633363|NCT00179478|MRI
633364|NCT00179478|Optic neuritis
633365|NCT00179478|Transverse Myelitis
633366|NCT00179465|Treatment
633367|NCT00179465|fMRI
633368|NCT00179465|Cognition
633369|NCT00179465|Brain development
633370|NCT00179452|epilepsy, yoga
633371|NCT00179439|PSC
633372|NCT00179439|IBD
633373|NCT00179439|CFTR
633374|NCT00179426|Seizure Disorder
633375|NCT00179426|Hypogonadism
633376|NCT00179426|Sexual Function
633377|NCT00179426|Epilepsy
633378|NCT00179413|hepatitis C
633379|NCT00179413|cirrhosis
633380|NCT00179413|interferon
633381|NCT00179413|colchicine
633382|NCT00179387|Neoplasms
633383|NCT00179387|Needs Assessment
633384|NCT00179387|Adaptation Psychological
633385|NCT00179387|Minority Groups
633386|NCT00179387|Psychotherapy, Group
633387|NCT00179387|Program Evaluation
633388|NCT00179387|Spirituality
633389|NCT00179387|Spiritual Therapies
633390|NCT00179374|Medication adherence
633391|NCT00179374|Self-care behaviors
633392|NCT00179374|Telephonic intervention
633393|NCT00179374|Diabetes
633394|NCT00179374|Nutrition
633395|NCT00179374|Exercise
633396|NCT00179335|Regular lopinavir/ritonavir or Efavirenz use
633397|NCT00179335|Age >/= 55 y or </= 35 y
633398|NCT00179335|HIV+
633399|NCT00179322|Sleep Architecture
633400|NCT00179322|Sleep Measures
633401|NCT00179322|Speech Articulation
633402|NCT00179322|Cerebral Perfusion
633403|NCT00179322|Neuroimaging
633404|NCT00179322|Healthy Volunteer
633405|NCT00179322|HV
633406|NCT00179309|CEA
633407|NCT00179309|MUC-1
633408|NCT00179309|Immunotherapy
633409|NCT00179309|GM-CSF
633410|NCT00179309|Vaccine
633411|NCT00179309|Breast Cancer
633412|NCT00179309|Metastatic Breast Cancer
633413|NCT00179257|Failure to Escitalopram
633414|NCT00179244|Treatment Resistant Depression
633415|NCT00179192|End Stage Renal Disease
633416|NCT00179192|ESRD
633417|NCT00179192|Chronic Maintenance Hemodialysis
633418|NCT00179127|Pediatrics
633419|NCT00179127|Diabetes
633420|NCT00179127|Emergency Care
633421|NCT00179127|Endocrinology
633422|NCT00179127|Critical Care
633423|NCT00179114|Spasticity
633424|NCT00179114|Developmental Disabilities
633425|NCT00179114|Intrathecal baclofen (ITB)
633426|NCT00179114|Botulinum Toxin Type A (Botox)
633427|NCT00179101|Parkinson's Disease
633428|NCT00179101|Depression
633429|NCT00179101|Quality of Life
633430|NCT00179101|Deep Brain Stimulation
633431|NCT00179088|Weight-Bearing
633432|NCT00179088|Total Hip Replacement
633433|NCT00179088|Non-cemented
633434|NCT00179088|Randomized
633435|NCT00179088|Fiber-Metal-Taper-Stem
633436|NCT00179088|Hip
633437|NCT00179088|Osteoarthritis
633438|NCT00179075|T-Lymphocyte Subsets
633439|NCT00179062|major depression with psychotic features
633440|NCT00179062|bipolar disorder with psychotic features
633441|NCT00179049|T-Lymphocyte Subsets
633442|NCT00179036|Blood supply
633443|NCT00179036|Mesentery
633444|NCT00179023|OBESITY
633445|NCT00179023|RESTING ENERGY EXPENDITURE
633446|NCT00179023|SYMPATHETIC NERVOUS SYSTEM
633447|NCT00179023|HYPERTENSION
633448|NCT00179023|AUTONOMIC FAILURE
633449|NCT00179010|Adenosine
633450|NCT00179010|AMP
633451|NCT00179010|Microdialysis
633452|NCT00179010|Blood Flow
633453|NCT00178997|Blood supply
633454|NCT00178997|Mesentery
633455|NCT00178984|Blood supply
633456|NCT00178984|Mesentery
633457|NCT00178919|Endothelial Nitric Oxide
633458|NCT00178919|L-NMMA
633459|NCT00178919|Trimethaphan
633460|NCT00178919|Autonomic Nervous System
633461|NCT00178919|Nitric Oxide Inhibition
633462|NCT00178906|depression
633463|NCT00178906|suicide
633464|NCT00178906|voice
633465|NCT00178880|depression
633466|NCT00178880|MRI
633467|NCT00178880|imaging
633468|NCT00178841|Cutaneous T-cell Lymphoma
633469|NCT00178841|CTCL
633470|NCT00178841|Mycosis Fungoides
633471|NCT00178841|Sezary Syndrome
633472|NCT00178841|Bexarotene
633473|NCT00178841|Targretin
633474|NCT00178841|Rosiglitazone
633475|NCT00178841|Avandia
633476|NCT00178828|Depression
633477|NCT00178828|antidepressant
633478|NCT00178828|SSRI
633479|NCT00178802|breast cancer
633480|NCT00178802|endometrial cancer
633481|NCT00178802|cervical cancer
633482|NCT00178802|ovarian cancer
633483|NCT00178789|Deep Venous Thrombosis
633484|NCT00178789|Blood Clot
633485|NCT00178789|Lower Extremity
633486|NCT00178789|Sonography
633487|NCT00178776|Group
633488|NCT00178776|Therapy
633489|NCT00178776|Cocaine
633490|NCT00178776|Drugs
633491|NCT00178776|Trial
633492|NCT00178776|Outcome
633493|NCT00178776|Study
633494|NCT00178776|Feasibility
633495|NCT00178776|Transtheoretical
633496|NCT00178776|Stages
633497|NCT00178776|Motivation
633498|NCT00178776|Change
633499|NCT00178763|Cancer
633500|NCT00178763|Pancreatic Cancer
633501|NCT00178763|Pancreas
633502|NCT00178763|Neoplasms
633503|NCT00178750|Epidural placement
633504|NCT00178750|CompuFlo®
633505|NCT00178724|spinal cord injury
633506|NCT00178724|SCI
633507|NCT00178724|traumatic spinal cord injury
633508|NCT00178724|acute spinal cord injury
633509|NCT00178724|paralysis
633510|NCT00178711|Traumatic Brain Injury
633511|NCT00178711|Hypothermia
633512|NCT00178698|thermochemotherapy
633513|NCT00178698|fever range whole body
633514|NCT00178698|cisplatin
633515|NCT00178698|gemcitabine
633516|NCT00178698|daily low dose interferon alpha
633517|NCT00178685|Self-determination
633518|NCT00178685|motivation
633519|NCT00178685|adherence
633520|NCT00178685|competence
633521|NCT00178685|autonomy
633522|NCT00178685|tobacco dependence
633523|NCT00178685|Tobacco use and dependence
633524|NCT00178685|Behavior change
633525|NCT00178672|CVA
633526|NCT00178672|TIA
633527|NCT00178672|Carotid disease
633528|NCT00178672|Stroke
633529|NCT00178672|Neurology
633530|NCT00178672|Carotid Stenting
633531|NCT00178659|Traumatic Brain Injury
633532|NCT00178659|TBI (Traumatic Brain Injury)
633533|NCT00178659|Proteomics
633534|NCT00178646|Stroke
633535|NCT00178646|Brain Injuries
633536|NCT00178646|Spasticity
633537|NCT00178646|Botulinum Toxins
633538|NCT00178633|Obesity
633539|NCT00178633|Insulin Resistance
633540|NCT00178633|Free Fatty Acids
633541|NCT00178633|Heart Failure
633542|NCT00178620|Heart Disease
633543|NCT00178620|Heart Attack
633544|NCT00178620|Myocardial Infarction
633545|NCT00178620|Thrombolytic Therapy
633546|NCT00178620|Emergency Medicine
633547|NCT00178607|Inhibitors
633548|NCT00178594|Hereditary Bleeding disorder
633549|NCT00178594|Thrombotic Disorder
633550|NCT00178581|Trauma
633551|NCT00178581|Critical Illness
633552|NCT00178581|Shock
633553|NCT00178581|Enteral Nutrition
633554|NCT00178581|Glutamine
633555|NCT00178568|Caregiving
633556|NCT00178568|Spousal
633557|NCT00178568|Sleep disturbances
633558|NCT00178568|Progressive dementia
633559|NCT00178568|Stress
633560|NCT00178568|Health outcomes
633561|NCT00178568|Intervention
633562|NCT00178568|Affective self-management
633563|NCT00178568|Caregivers M01.526.485.200
633564|NCT00178568|Spouses F01.829.263.500.660
633565|NCT00178568|Alzheimer's disease C10.574.945.249
633566|NCT00178568|Parkinson's disease C10.574.812
633567|NCT00178568|Sleep disorder C10.886.425.800.800
633568|NCT00178555|Endotracheal Intubation, Video Laryngoscopy
633569|NCT00178542|von Willebrand Disease
633570|NCT00178542|Healthy Women and Women with von Willebrand Disease
633571|NCT00178529|Stroke
633572|NCT00178529|Caregivers
633573|NCT00178516|male
633574|NCT00178516|infertility
633575|NCT00178490|Neurocognitive Function
633576|NCT00178464|sickle cell disease
633577|NCT00178464|hemoglobin SS disease
633578|NCT00178464|hemoglobin S Beta-0 Thalassemia
633579|NCT00178464|silent infarction in sickle cell disease
633580|NCT00178464|overt stroke in sickle cell disease
633581|NCT00178464|aspirin
633582|NCT00178464|transcranial Doppler ultrasound
633583|NCT00178464|neurocognitive testing
633584|NCT00178438|capsule endoscopy in small bowel
633585|NCT00178425|mycophenolate mofetil hydrochloride
633586|NCT00178425|pharmacokinetics
633587|NCT00178425|tacrolimus
633588|NCT00178412|Hospitalized elders
633589|NCT00178412|Family caregivers
633590|NCT00178412|Acute care
633591|NCT00178386|cancer
633592|NCT00178386|education
633593|NCT00178386|learning
633594|NCT00178386|brain tumor
633595|NCT00178386|school
633596|NCT00178373|cancer-related fatigue
633597|NCT00178373|chemotherapy
633598|NCT00178373|modafinil
633599|NCT00178360|Huntington's Disease, Music Therapy, quality of life
633600|NCT00178321|Sleep
633601|NCT00178321|Criticall Ill
633602|NCT00178321|Children
633603|NCT00178321|Earplugs
633604|NCT00177320|Rheumatic Disorders
633605|NCT00177320|Computer Use
633606|NCT00178217|Botulinum Toxin
633607|NCT00178217|Music Therapy
633608|NCT00178217|Cerebral Palsy
633609|NCT00178217|Procedural Support
633610|NCT00178204|delta sleep
633611|NCT00178204|Cancer-related fatigue
633612|NCT00178204|Sleep Disturbance
633613|NCT00178204|chemotherapy
633614|NCT00178178|anterior cruciate ligament reconstruction
633615|NCT00178178|Pain Care 3000
633616|NCT00178178|Catheter Placement
633617|NCT00178178|Pain
633618|NCT00178178|Breg, Inc
633619|NCT00178165|Family Caregivers
633620|NCT00178165|Dementia
633621|NCT00178165|Alzheimer Disease
633622|NCT00178165|Randomized Controlled Trial
633623|NCT00178165|Intervention Studies
633624|NCT00178139|Music Therapy
633625|NCT00178139|Mechanical ventilation
633626|NCT00178139|Weaning from mechanical ventilation
633627|NCT00178139|complementary and alternative therapy
633628|NCT00178126|pressure ulcer
633629|NCT00178113|Prostatic Intraepithelial Neoplasia
633630|NCT00178113|Prostate-Specific Antigen
633631|NCT00178113|lycopene
633632|NCT00178100|Depression
633633|NCT00178100|Elderly
633634|NCT00178100|Late Life
633635|NCT00178087|late-life depression
633636|NCT00178087|mild cognitive impairment
633637|NCT00178087|dementia
633638|NCT00178074|depression
633639|NCT00178074|imaging
633640|NCT00178074|PET
633641|NCT00178074|elderly
633642|NCT00178074|late life
633643|NCT00178074|sleep deprivation
633644|NCT00178048|primary insomnia
633645|NCT00178048|insomnia
633646|NCT00178048|depression
633647|NCT00178048|late life
633648|NCT00178048|elderly
633649|NCT00178048|sleep disorders
633650|NCT00178035|Depression
633651|NCT00178035|Unipolar Depression
633652|NCT00178035|Elderly depression
633653|NCT00178035|Late-Life
633654|NCT00178022|tbi
633655|NCT00178022|intervention
633656|NCT00178022|depression
633657|NCT00178022|anxiety
633658|NCT00178009|computer-assisted instruction
633659|NCT00178009|instruction (video)
633660|NCT00177996|depression
633661|NCT00177996|anxiety
633662|NCT00177983|Schizophrenia
633663|NCT00177983|Relapse
633664|NCT00177983|Psychological distress
633665|NCT00177957|Gram negative bacteremia
633666|NCT00177944|invasive fungal infection
633667|NCT00177931|Liver transplant
633668|NCT00177931|cefepime
633669|NCT00177931|antibiotics
633670|NCT00177918|Lung Transplant
633671|NCT00177892|Sleep fragmentation
633672|NCT00177892|Intermittent hypoxia
633673|NCT00177892|Obstructive Sleep Apnea
633674|NCT00177892|Metabolic Syndrome
633675|NCT00177892|Insulin resistance
633676|NCT00177879|website
633677|NCT00177879|comparison
633678|NCT00177853|Locally advanced pancreatic cancer
633679|NCT00177853|invasion of major arteries and veins around pancreas
633680|NCT00177853|No prior radiation or chemo
633681|NCT00177840|cancer-related fatigue
633682|NCT00177840|acupuncture
633683|NCT00177840|breast cancer
633684|NCT00177814|pipercillin
633685|NCT00177814|gram negative bacteria infections
633686|NCT00177788|liver transplant
633687|NCT00177788|voriconazole prophylaxis
633688|NCT00177788|liver transplantation
633689|NCT00177788|voriconazole
633690|NCT00177749|invasive fungal infections
633691|NCT00177736|ventilator associated pneumonia
633692|NCT00177723|receiving antibiotic Linezolid clinically
633693|NCT00177671|Depression
633694|NCT00177671|Dementia
633695|NCT00177671|Alzheimer's Disease
633696|NCT00177671|Cognitive
633697|NCT00177671|Donepezil
633698|NCT00177671|Memory
633699|NCT00177671|Function
633700|NCT00177671|Elderly
633701|NCT00177671|Late-Life
633702|NCT00177658|Salmonella
633703|NCT00177645|cystic fibrosis
633704|NCT00177645|mucus clearance
633705|NCT00177619|Prostatic neoplasms
633706|NCT00177619|Bisphosphonates
633707|NCT00177619|Hypogonadism
633708|NCT00177606|withdrawal
633709|NCT00177606|life-sustaining
633710|NCT00177606|treatments
633711|NCT00177606|UNOS
633712|NCT00177606|organ donation
633713|NCT00177580|schizophrenia
633714|NCT00177580|schizoaffective disorder
633715|NCT00177580|positive symptoms
633716|NCT00177580|negative symptoms
633717|NCT00177580|cognitive functioning
633718|NCT00177580|pravastatin
633719|NCT00177567|Bipolar Disorder
633720|NCT00177567|Manic Depression
633721|NCT00177567|Elderly
633722|NCT00177567|Late-Life
633723|NCT00177554|Non-Hodgkin Lymphoma
633724|NCT00177541|urge incontinence
633725|NCT00177541|biofeedback
633726|NCT00177541|pelvic floor muscle training
633727|NCT00177541|behavior modification
633728|NCT00177528|Elderly
633729|NCT00177515|emergency contraception
633730|NCT00177515|folic acid
633731|NCT00177515|education
633732|NCT00177515|preventive health
633733|NCT00177489|Family Caregivers
633734|NCT00177489|Dementia
633735|NCT00177489|Alzheimer Disease
633736|NCT00177489|Randomized Controlled Trial
633737|NCT00177489|Intervention Studies
633738|NCT00177463|L-carnosine
633739|NCT00177463|Bipolar I disorder
633740|NCT00177463|Cognitive enhancement
633741|NCT00177424|Rehabilitation
633742|NCT00177411|Endocrine System Diseases
633743|NCT00177411|MusculoSkeletal System Diseases
633744|NCT00177411|Hormone
633745|NCT00177411|Postmenopausal Women
633746|NCT00177398|Type 2 diabetes
633747|NCT00177398|Hyperglycemia
633748|NCT00177398|Enteral nutrition
633749|NCT00177385|Sleep
633750|NCT00177385|Sleep Hygiene
633751|NCT00177385|Modest sleep deprivation
633752|NCT00177385|Healthy Aging and sleep
633753|NCT00177385|Health Promotion
633754|NCT00177359|gait impairment
633755|NCT00177333|Abortion, Induced
633756|NCT00177333|Doxycycline
633757|NCT00177333|Antibiotic Prophylaxis
633758|NCT00177333|Vomiting
633759|NCT00177333|Abortion, Therapeutic
633760|NCT00177307|colon
633761|NCT00177307|rectum
633762|NCT00177294|Elderly
633763|NCT00177294|Remission
633764|NCT00177294|Escitalopram
633765|NCT00177294|Interpersonal Psychotherapy
633766|NCT00177294|Psychotherapy
633767|NCT00177294|Caregiving
633768|NCT00177294|Late-Life
633769|NCT00177268|Cutaneous T-cell Lymphoma
633770|NCT00177268|Sezary Syndrome
633771|NCT00177268|Mycosis Fungoides
633772|NCT00177268|Blood/tissue banking
633773|NCT00177268|eczema
633774|NCT00177268|atopic dermatitis
633775|NCT00177255|gastric
633776|NCT00177255|stomach
633777|NCT00177255|esophagus
633778|NCT00177255|esophageal
633779|NCT00177242|pancreas
633780|NCT00177242|pancreatic
633781|NCT00177216|Primary Insomnia
633782|NCT00177216|Insomnia
633783|NCT00177216|Placebo-Controlled
633784|NCT00177216|Double-Blind
633785|NCT00177216|Polysomnography
633786|NCT00177216|PET Studies
633787|NCT00177216|Escitalopram
633788|NCT00177216|Zolpidem
633789|NCT00177203|Insomnia
633790|NCT00177203|Sleep Disorders
633791|NCT00177203|Sleeplessness
633792|NCT00177203|Chronic Insomnia
633793|NCT00177203|Sleep Studies
633794|NCT00177203|Disorders of Initiating and Maintaining Sleep
633795|NCT00177203|Primary Care
633796|NCT00177190|Cutaneous T-cell Lymphoma
633797|NCT00177190|Sezary Syndrome
633798|NCT00177190|Mycosis Fungoides
633799|NCT00177190|Immune Responses
633800|NCT00177177|L-carnosine
633801|NCT00177177|Schizophrenia
633802|NCT00177177|Schizoaffective disorder
633803|NCT00177177|Cognitive enhancement
633804|NCT00177164|Bipolar I Disorder
633805|NCT00177164|Risperidone Consta - Long Acting Injection
633806|NCT00177164|Oral second generation antipsychotic agents
633807|NCT00177138|Campath Study
633808|NCT00177138|Pancreas After Kidney Transplantation
633809|NCT00177138|Alemtuzumab
633810|NCT00177112|Cystoscopy
633811|NCT00177047|stem cell transplantation
633812|NCT00177047|chemotherapy
633813|NCT00177047|multiple myeloma
633814|NCT00177047|autologous
633815|NCT00177034|Keratinocyte
633816|NCT00177008|Schizophrenia
633817|NCT00177008|Schizoaffective Disorder
633818|NCT00177008|Social Anxiety Disorder
633819|NCT00176982|treatment of alopecia areata
633820|NCT00176956|Post Pediatric Heart Transplant
633821|NCT00176930|stem cell transplant
633822|NCT00176930|chronic leukemia
633823|NCT00176930|acute leukemia
633824|NCT00176930|irradiation
633825|NCT00176930|chemotherapy
633826|NCT00176917|stem cell transplant
633827|NCT00176917|storage disease
633828|NCT00176917|errors of metabolism
633829|NCT00176904|Inborn errors
633830|NCT00176904|Storage disease
633831|NCT00176904|errors of metabolism
633832|NCT00176904|stem cell transplant
633833|NCT00176891|Laronidase ERT
633834|NCT00176891|Stem cell transplant
633835|NCT00176891|storage disease
633836|NCT00176891|inborn errors of metabolism
633837|NCT00176891|hurler syndrome
633838|NCT00176891|glycosaminoglycans
633839|NCT00176891|enzyme replacement
633840|NCT00176878|Stem cell transplant
633841|NCT00176878|T-cell depletion
633842|NCT00176878|TLI
633843|NCT00176878|bone marrow failure disorders
633844|NCT00176865|Stem cell transplant
633845|NCT00176865|immunodeficiency
633846|NCT00176865|donor lymphocyte infusion
633847|NCT00176852|high risk hemoglobinopathy
633848|NCT00176852|stem cell transplant
633849|NCT00176852|donor lymphocyte infusion
633850|NCT00176852|transfusion dependent
633851|NCT00176852|stem cell donor
633852|NCT00176852|cord blood
633853|NCT00176852|marrow
633854|NCT00176852|transfusion dependent non-malignant hematologic disorders
633855|NCT00176839|Stem Cell transplant
633856|NCT00176839|retransplant
633857|NCT00176839|hematological malignancies
633858|NCT00176826|Stem Cell Transplant
633859|NCT00176826|T-cell depletion
633860|NCT00176826|immune deficiencies
633861|NCT00176826|Busulfan pharmacokinetics
633862|NCT00176826|Non-Malignant Hematological Disorders
633863|NCT00176722|Spine Surgery
633864|NCT00176722|Intraocular Pressure
633865|NCT00176722|lumbar or thoracic Spine Surgery in the prone position
633866|NCT00176722|and its association with visual change
633867|NCT00176696|general anesthesia
633868|NCT00176696|pain
633869|NCT00176696|depth of anesthesia
633870|NCT00176683|intubation
633871|NCT00176683|capnography
633872|NCT00176670|presurgical anxiety, children,
633873|NCT00176657|cardiac surgery
633874|NCT00176657|transfusion
633875|NCT00176644|prostate cancer
633876|NCT00176631|adenocarcinoma of the prostate
633877|NCT00176631|recurrent prostate cancer
633878|NCT00176631|stage IV prostate cancer
633879|NCT00176618|Aberrant Crypt Foci
633880|NCT00176605|prostate cancer
633881|NCT00176605|recurrent prostate cancer
633882|NCT00176605|stage IV prostate cancer
633883|NCT00176592|Multiple Sclerosis
633884|NCT00176592|Brain
633885|NCT00176592|Betaseron
633886|NCT00176592|Copaxone
633887|NCT00176592|MRI
633888|NCT00176579|osteoporosis
633889|NCT00176579|stage I prostate cancer
633890|NCT00176566|oral leukoplakia
633891|NCT00176553|methotrexate neurotoxicity
633892|NCT00176540|unspecified adult solid tumor, protocol specific
633893|NCT00176540|unspecified childhood solid tumor, protocol specific
633894|NCT00176540|fatigue
633895|NCT00176527|recurrent prostate cancer
633896|NCT00176527|stage IV prostate cancer
633897|NCT00176514|mucositis
633898|NCT00176501|recurrent renal cell cancer
633899|NCT00176501|clear cell renal cell carcinoma
633900|NCT00176501|stage IV renal cell cancer
633901|NCT00176488|recurrent breast cancer
633902|NCT00176488|stage II breast cancer
633903|NCT00176488|stage IIIA breast cancer
633904|NCT00176488|stage IIIB breast cancer
633905|NCT00176488|stage IV breast cancer
633906|NCT00176488|male breast cancer
633907|NCT00176475|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
633908|NCT00176475|nodal marginal zone B-cell lymphoma
633909|NCT00176475|recurrent adult Burkitt lymphoma
633910|NCT00176475|recurrent adult diffuse large cell lymphoma
633911|NCT00176475|recurrent adult Hodgkin lymphoma
633912|NCT00176475|recurrent adult lymphoblastic lymphoma
633913|NCT00176475|recurrent adult acute lymphoblastic leukemia
633914|NCT00176475|refractory chronic lymphocytic leukemia
633915|NCT00176475|recurrent small lymphocytic lymphoma
633916|NCT00176475|refractory hairy cell leukemia
633917|NCT00176475|prolymphocytic leukemia
633918|NCT00176475|recurrent marginal zone lymphoma
633919|NCT00176475|recurrent grade 1 follicular lymphoma
633920|NCT00176475|recurrent grade 2 follicular lymphoma
633921|NCT00176475|recurrent grade 3 follicular lymphoma
633922|NCT00176475|refractory multiple myeloma
633923|NCT00176475|recurrent mantle cell lymphoma
633924|NCT00176475|recurrent adult grade III lymphomatoid granulomatosis
633925|NCT00176475|Waldenstrom macroglobulinemia
633926|NCT00176475|splenic marginal zone lymphoma
633927|NCT00176475|stage II multiple myeloma
633928|NCT00176475|stage III multiple myeloma
633929|NCT00176475|stage IV adult Burkitt lymphoma
633930|NCT00176475|stage IV adult diffuse large cell lymphoma
633931|NCT00176475|stage IV adult Hodgkin lymphoma
633932|NCT00176475|stage IV adult lymphoblastic lymphoma
633933|NCT00176475|stage III adult Burkitt lymphoma
633934|NCT00176475|stage III adult diffuse large cell lymphoma
633935|NCT00176475|stage III adult Hodgkin lymphoma
633936|NCT00176475|stage III adult lymphoblastic lymphoma
633937|NCT00176475|stage III grade 1 follicular lymphoma
633938|NCT00176475|stage III grade 2 follicular lymphoma
633939|NCT00176475|stage III grade 3 follicular lymphoma
633940|NCT00176475|stage IV grade 1 follicular lymphoma
633941|NCT00176475|stage IV grade 2 follicular lymphoma
633942|NCT00176475|stage IV grade 3 follicular lymphoma
633943|NCT00176475|stage III mantle cell lymphoma
633944|NCT00176475|stage IV mantle cell lymphoma
633945|NCT00176475|stage III marginal zone lymphoma
633946|NCT00176475|stage IV marginal zone lymphoma
633947|NCT00176475|stage III small lymphocytic lymphoma
633948|NCT00176475|stage IV small lymphocytic lymphoma
633949|NCT00176475|stage III chronic lymphocytic leukemia
633950|NCT00176475|stage IV chronic lymphocytic leukemia
633951|NCT00176475|progressive hairy cell leukemia, initial treatment
633952|NCT00176462|Acute Lymphocytic Leukemia
633953|NCT00176462|Leukemia
633954|NCT00176449|Nicotine Dependence
633955|NCT00176449|Nicotine Use Disorder
633956|NCT00176449|Tobacco Dependence
633957|NCT00176449|Tobacco-Use Disorder
633958|NCT00176449|Smoking Cessation
633959|NCT00176436|Weight loss
633960|NCT00176436|Support group
633961|NCT00176436|Exercise
633962|NCT00176436|Atomoxetine
633963|NCT00176423|schizophrenia
633964|NCT00176423|acetylcholine
633965|NCT00176423|cognitive impairments
633966|NCT00176423|attention
633967|NCT00176423|processing speed
633968|NCT00176423|sensory gating
633969|NCT00176423|eye-tracking
633970|NCT00176410|aortic valve stenosis
633971|NCT00176410|statin therapy
633972|NCT00176397|left main coronary artery
633973|NCT00176397|coronary artery disease
633974|NCT00176384|chronic heart failure
633975|NCT00176384|exercise training
633976|NCT00176371|Physical fitness
633977|NCT00176345|exercise training
633978|NCT00176345|endothelial function
633979|NCT00176332|chronic heart failure
633980|NCT00176332|rosuvastatin
633981|NCT00176332|endothelial function
633982|NCT00176332|skeletal muscle
633983|NCT00176319|heart failure
633984|NCT00176319|ageing
633985|NCT00176293|prostate
633986|NCT00176293|prostate cancer
633987|NCT00176293|doxil
633988|NCT00176293|dexamethasone
633989|NCT00176293|metastatic
633990|NCT00176293|hormone refractory
633991|NCT00176280|Renal
633992|NCT00176280|Carcinoma
633993|NCT00176280|Renal Cell Carcinoma
633994|NCT00176280|RCC
633995|NCT00176280|Leukine
633996|NCT00176280|Dexamethasone
633997|NCT00176280|Gemcitabine
633998|NCT00176280|5 Fluorouracil
633999|NCT00176280|5 FU
634000|NCT00176280|Metastatic
634001|NCT00176267|head and neck
634002|NCT00176267|squamous cell carcinoma
634003|NCT00176267|squamous cell
634004|NCT00176267|carcinoma
634005|NCT00176267|paclitaxel
634006|NCT00176267|carboplatin
634007|NCT00176267|radiotherapy
634008|NCT00176267|induction therapy
634009|NCT00176254|head and neck
634010|NCT00176254|squamous cell carcinoma
634011|NCT00176254|squamous cell
634012|NCT00176254|carcinoma
634013|NCT00176254|paclitaxel
634014|NCT00176254|carboplatin
634015|NCT00176254|radiotherapy
634016|NCT00176254|induction therapy
634017|NCT00176241|head and neck
634018|NCT00176241|Gemcitabine
634019|NCT00176241|Paclitaxel
634020|NCT00176241|radiation
634021|NCT00176241|low-dose radiation
634022|NCT00176241|recurrent
634023|NCT00176241|metastatic
634024|NCT00176189|FPD, all-ceramic
634025|NCT00176176|cerebral circulation
634026|NCT00176163|Fibromyalgia
634027|NCT00176163|Back pain
634028|NCT00176163|Behavior Therapy
634029|NCT00176163|Operant learning
634030|NCT00176163|Tetrahydrocannabinol
634031|NCT00176150|anorexia nervosa
634032|NCT00176150|multidrug resistance
634033|NCT00176150|cholesterol metabolism
634034|NCT00176137|multimodality treatment
634035|NCT00176124|leukocyte depletion, autologous transfusion,
634036|NCT00176124|infection
634037|NCT00176124|bacterial infection
634038|NCT00176124|sepsis, antibiotics
634039|NCT00176111|peripheral nerve stimulation
634040|NCT00176111|saline
634041|NCT00176111|local anesthestics
634042|NCT00176111|regional anesthestia
634043|NCT00176111|nerve damage
634044|NCT00176098|Cataract surgery
634045|NCT00176098|Hypnosis
634046|NCT00176098|C11.510.245
634047|NCT00176098|F04.754.424.771
634048|NCT00176098|Suggestion
634049|NCT00176059|immunoglobulins, intravenous
634050|NCT00176059|kidney transplantation
634051|NCT00176059|acute rejection
634052|NCT00176059|chronic rejection
634053|NCT00176059|regulatory autoantibodies
634054|NCT00176059|Th1
634055|NCT00176059|Th2
634056|NCT00176059|B Cell
634057|NCT00176059|Monokines
634058|NCT00176059|Cytokine promoter gene polymorphisms
634059|NCT00176046|breast cancer
634060|NCT00176046|mistletoe
634061|NCT00176046|complementary therapy
634062|NCT00176046|quality of life
634063|NCT00176046|immune function
634064|NCT00176046|breast cancer (UICC stage I/II)
634065|NCT00176033|ritonavir
634066|NCT00176033|lopinavir
634067|NCT00176033|HIV Infections
634068|NCT00176020|nicotinic acid
634069|NCT00176020|flush symptom
634070|NCT00176020|pharmacodynamic
634071|NCT00176020|pharmacokinetic
634072|NCT00175994|voriconazole
634073|NCT00175994|genotype
634074|NCT00175994|bioavailability
634075|NCT00175994|metabolic clearance
634076|NCT00175955|Neuroleptic-induced tardive dyskinesia
634077|NCT00175955|Keppra, Levetiracetam
634078|NCT00175942|acute myocardial infarction
634079|NCT00175942|ventricular fibrillation
634080|NCT00175942|coagulation
634081|NCT00175942|inflammation
634082|NCT00175929|Epilepsy
634083|NCT00175929|Focal Epilepsy
634084|NCT00175929|Partial Onset Seizures
634085|NCT00175929|Brivaracetam
634086|NCT00175916|Brivaracetam
634087|NCT00175916|Epilepsy
634088|NCT00175916|long term
634089|NCT00175903|Newly Diagnosed Epilepsy
634090|NCT00175903|Levetiracetam
634091|NCT00175903|Keppra
634092|NCT00175903|Carbamazepine
634093|NCT00175903|Valproate
634094|NCT00175890|Partial Onset Seizure
634095|NCT00175890|levetiracetam
634096|NCT00175890|Video Electroencephalogram
634097|NCT00175890|Keppra
634098|NCT00175877|Rheumatoid Arthritis
634099|NCT00175877|CDP870
634100|NCT00175877|Certolizumab Pegol
634101|NCT00175877|Cimzia
634102|NCT00175864|Partial Onset, Primary Generalized Seizures, Seletracetam
634103|NCT00175851|Partial onset, primary generalized seizures, seletracetam
634104|NCT00175838|Primary Thrombocythmeia
634105|NCT00175838|Hydroxyurea
634106|NCT00175838|Randomised
634107|NCT00175838|Thrombosis
634108|NCT00175838|Haemorrhage
634109|NCT00175825|Epilepsy: partial onset seizures
634110|NCT00175825|brivaracetam
634111|NCT00175812|Acute myelogenous leukemia
634112|NCT00175812|Differentiation
634113|NCT00175812|All trans retinoic acid
634114|NCT00175812|Valproic acid
634115|NCT00175812|Theophyllamin
634116|NCT00175799|Observational study of physiological status at entry into PICU as a predictor of outcome, comparison of two commonly used scores (PRISM and PIM)
634117|NCT00175799|Data from children admitted to a Paediatric Intensive Care unit
634118|NCT00175786|Glaucoma
634119|NCT00175786|Normal Tensions Glaucoma
634120|NCT00175786|Neuroradiology
634121|NCT00175786|Tumor
634122|NCT00175786|MRI
634123|NCT00175786|Magnetic Resonance Imaging
634124|NCT00175786|Compressive Lesion
634125|NCT00175773|Orthostatic stress
634126|NCT00175760|TTG
634127|NCT00175760|pediatric
634128|NCT00175760|comparison study
634129|NCT00175747|dysplasia
634130|NCT00175747|lung cancer
634131|NCT00175747|chemoprevention
634132|NCT00175734|Vascular Reactivity
634133|NCT00175734|Anemia Correction Therapy
634134|NCT00175734|Hemodialysis patients
634135|NCT00175734|Diabetic and non-diabetic patients
634136|NCT00175734|Diabetes in Hemodialysis patients
634137|NCT00175721|Combined Clinic
634138|NCT00175721|Chronic Kidney Disease
634139|NCT00175721|Diabetes
634140|NCT00175708|Evaluation of an outcome tool
634141|NCT00175708|clubfoot
634142|NCT00175708|foot pressure profiles
634143|NCT00175708|pedobarographs
634144|NCT00175682|Autonomic Dysreflexia
634145|NCT00175682|SCI
634146|NCT00175682|Vibrostimulation
634147|NCT00175682|Ejaculation
634148|NCT00175669|Randomized control trial; placebo-control study
634149|NCT00175656|Femur fracture
634150|NCT00175656|titanium elastic nails
634151|NCT00175643|actinic keratoses
634152|NCT00175643|imiquimod
634153|NCT00175643|pre-malignant
634154|NCT00175643|squamous cell carcinoma
634155|NCT00175643|immunosuppression
634156|NCT00175630|ACL reconstruction
634157|NCT00175630|morphine sparing
634158|NCT00175630|preemptive analgesia
634159|NCT00175630|Post-operative pain and post- operative opioid use
634160|NCT00175604|Botox
634161|NCT00175604|torticollis
634162|NCT00175604|Congenital Muscular Torticollis (CMT)
634163|NCT00175591|Femur fracture
634164|NCT00175591|morphine sparing
634165|NCT00175591|preemptive analgesia
634166|NCT00175591|Post-operative pain and post- operative opioid use
634167|NCT00175578|Early stage (0/I) non-small cell lung cancer
634168|NCT00175565|inflammation
634169|NCT00175565|trial
634170|NCT00175565|fluticasone
634171|NCT00175552|Depression
634172|NCT00175552|Adolescents
634173|NCT00175552|IPT
634174|NCT00175552|Knowledge translation
634175|NCT00175552|Psychotherapy
634176|NCT00175539|sexual dysfunction
634177|NCT00175539|group treatment
634178|NCT00175513|Psychosis
634179|NCT00175513|early psychosis
634180|NCT00175513|first episode psychosis
634181|NCT00175513|schizophrenia
634182|NCT00175513|schizoaffective
634183|NCT00175513|schizophreniform
634184|NCT00175513|bipolar disorder
634185|NCT00175513|valtrex
634186|NCT00175513|valacyclovir.
634187|NCT00175500|Post-Arthroplasty Hip Dislocation
634188|NCT00175487|Osteoarthritis/Avascular Necrosis
634189|NCT00175487|Hip
634190|NCT00175435|Topical Immune Modulator
634191|NCT00175435|resiquimod gel
634192|NCT00175435|Hepatitis B booster response
634193|NCT00175435|Vaccine Evaluation
634194|NCT00175435|Prevention of Hepatitis B disease
634195|NCT00175422|Prevention
634196|NCT00175422|Randomized controlled trial
634197|NCT00175422|Community education
634198|NCT00175422|Shaken Baby Syndrome
634199|NCT00175422|Crying
634200|NCT00175422|Colic
634201|NCT00175409|Pain Response
634202|NCT00175396|ASCENDE-RT
634203|NCT00175383|Prostate cancer, LHRH, hormone therapy, testosterone level
634204|NCT00175370|Vancomycin
634205|NCT00175370|Coagulase Negative Staphylococcus
634206|NCT00175370|Central Venous Catheter
634207|NCT00175370|Bloodstream infection
634208|NCT00175370|CNS bloodstream infection
634209|NCT00175357|Opiate addiction
634210|NCT00175357|medical heroin
634211|NCT00175357|methadoneRCT
634212|NCT00175344|Breast cancer
634213|NCT00175344|scar massage
634214|NCT00175344|breast conserving surgery
634215|NCT00175344|scar pain
634216|NCT00175344|quality of life
634217|NCT00175344|Breast cancer treated with breast conserving surgery with or without axillary dissection or sentinel node sampling.
634218|NCT00175318|Motivational interviewing
634219|NCT00175318|behavioural modification
634220|NCT00175318|maternal counseling
634221|NCT00175305|Prader-Willi Syndrome
634222|NCT00175305|Somatostatin
634223|NCT00175305|Ghrelin
634224|NCT00175305|Obesity
634225|NCT00175305|Hyperphagia
634226|NCT00175305|Hyperphagia in Prader-Willi syndrome
634227|NCT00175279|coronary disease
634228|NCT00175279|heart failure
634229|NCT00175279|quality improvement
634230|NCT00175279|knowledge translation
634231|NCT00175279|opinion leaders
634232|NCT00175266|islet
634233|NCT00175266|transplantation
634234|NCT00175253|islet
634235|NCT00175253|transplantation
634236|NCT00175240|Coronary disease
634237|NCT00175240|quality improvement
634238|NCT00175240|knowledge translation
634239|NCT00175227|contrast-induced nephropathy
634240|NCT00175227|prevention
634241|NCT00175227|renal failure
634242|NCT00175227|cardiac angiogram
634243|NCT00175214|osteoporosis
634244|NCT00175214|wrist fractures
634245|NCT00175214|quality improvement
634246|NCT00175214|knowledge translation
634247|NCT00175188|RSA
634248|NCT00175188|DEXA
634249|NCT00175188|Osteoarthritis
634250|NCT00175188|Finger implant
634251|NCT00175188|Micromotion
634252|NCT00175188|Bone density
634253|NCT00175188|Cement
634254|NCT00175175|osteoporosis treatment
634255|NCT00175175|osteoporosis testing
634256|NCT00175175|hip fracture
634257|NCT00175175|quality improvement
634258|NCT00175162|RSA
634259|NCT00175162|DEXA
634260|NCT00175162|Genoarthrosis
634261|NCT00175162|Knee Arthroplasty
634262|NCT00175162|Micromotion of polyethylene liner
634263|NCT00175162|Cement
634264|NCT00175149|CKD 3-4
634265|NCT00175136|RSA
634266|NCT00175136|DEXA
634267|NCT00175136|Gonarthrosis
634268|NCT00175136|Knee Arthroplasty
634269|NCT00175136|Micromotion of polyethylen liner
634270|NCT00175136|Stem arthroplasty design
634271|NCT00175123|Myelomeningocele
634272|NCT00175123|Neurogenic Bladder
634273|NCT00175123|Intervention
634274|NCT00175123|Botulinum A toxin
634275|NCT00175123|Oxybutynin
634276|NCT00175110|pre-hypertension
634277|NCT00175110|mild hypertension
634278|NCT00175097|soy protein
634279|NCT00175097|lipids
634280|NCT00175097|lipoproteins
634281|NCT00175097|apolipoproteins
634282|NCT00175097|cholesterol
634283|NCT00175097|endothelial function
634284|NCT00175058|Heart Attack
634285|NCT00175045|Intravenous
634286|NCT00175045|gastric acid secretion
634287|NCT00175045|Lansoprazole
634288|NCT00175045|Esophagitis
634289|NCT00175045|reflux
634290|NCT00175032|Low dose aspirin
634291|NCT00175032|Peptic Ulcer
634292|NCT00175032|gastric ulcer
634293|NCT00175032|duodenal ulcer
634294|NCT00175032|NSAIDs
634295|NCT00175019|uric acid
634296|NCT00175019|xanthine oxidase
634297|NCT00175019|hyperuricemia
634298|NCT00175019|tophi
634299|NCT00175019|Drug Therapy
634300|NCT00175006|Hyperuricemia
634301|NCT00175006|Tophi
634302|NCT00175006|Tophus
634303|NCT00175006|Drug Therapy
634304|NCT00174993|Glucose Metabolism Disorder
634305|NCT00174993|Dysmetabolic Syndrome
634306|NCT00174993|Type II Diabetes; Diabetes Mellitus
634307|NCT00174993|Lipoatrophic
634308|NCT00174993|Dyslipidemia
634309|NCT00174993|Drug Therapy
634310|NCT00174980|Oxycyte
634311|NCT00174980|perfluorocarbon oxygen carrier
634312|NCT00174980|brain oxygen tension
634313|NCT00174967|Uric Acid
634314|NCT00174967|xanthine oxidase
634315|NCT00174967|tophi
634316|NCT00174967|Drug Therapy
634317|NCT00174954|Gout
634318|NCT00174954|Tophus
634319|NCT00174954|MRI
634320|NCT00174941|Uric acid
634321|NCT00174941|xanthine oxidase
634322|NCT00174941|tophi
634323|NCT00174941|Drug Therapy
634324|NCT00174928|Pediatric GERD
634325|NCT00174928|Pediatric Gastroesophageal Reflux Disease
634326|NCT00174928|Neonates
634327|NCT00174928|lansoprazole
634328|NCT00174915|Uric Acid, gout, xanthine oxidase, febuxostat, tophi
634329|NCT00174902|Randomized controlled trial
634330|NCT00174902|Blood platelets
634331|NCT00174902|Hemostasis
634332|NCT00174902|Stress, psychological
634333|NCT00174902|Adrenergic beta-antagonists
634334|NCT00174902|Aspirin
634335|NCT00174902|Endothelium
634336|NCT00174902|Arteriosclerosis
634337|NCT00174889|Schizophrenia
634338|NCT00174889|Pregnenolone
634339|NCT00174889|Neurosteroids
634340|NCT00174876|depression
634341|NCT00174850|anxiety
634342|NCT00174850|sexual dysfunction
634343|NCT00174850|ssri
634344|NCT00174837|Tirapazamine
634345|NCT00174837|Head and Neck Cancer
634346|NCT00174837|Cisplatin
634347|NCT00174837|Radiation
634348|NCT00174824|Diabetes
634349|NCT00174824|Diabetic Retinopathy
634350|NCT00174811|acute otitis media
634351|NCT00174811|controlled clinical trial
634352|NCT00174811|telithromycin
634353|NCT00174811|cefuroxime axetil
634354|NCT00174811|middle ear infections
634355|NCT00174811|tympanocentecis
634356|NCT00174798|Cystometry NK1 Antagonist SSR240600C
634357|NCT00174785|Mortality, Hospitalization
634358|NCT00174746|Glucocorticosteroid; Dose response; Bronchospasm
634359|NCT00174733|Glucocorticosteroid. Bronchospasm
634360|NCT00174720|Glucocorticosteroid. Bronchospasm
634361|NCT00174603|depression
634362|NCT00174603|psychosis
634363|NCT00174590|depression
634364|NCT00174538|codeine
634365|NCT00174538|pain
634366|NCT00174538|CYP2D6
634367|NCT00174538|genotype
634368|NCT00174538|morphine
634369|NCT00174538|sickle cell
634370|NCT00174538|pharmacokinetic
634371|NCT00174525|Alzheimer's Caregivers
634372|NCT00174525|Alzheimer disease
634373|NCT00174499|Tooth stain
634374|NCT00174213|iliotibial tract
634375|NCT00174161|Premenstrual Syndrome,Health Related Quality of Life
634376|NCT00174135|Sarcopenia
634377|NCT00174135|exercise
634378|NCT00174122|Emergency department
634379|NCT00174122|Blood culture
634380|NCT00174122|Antimicrobial therapy
634381|NCT00174109|arecoline, oral cancer, MAP2, cell migration
634382|NCT00174096|laryngeal cancer
634383|NCT00174096|hypopharyngeal cancer
634384|NCT00174096|CXCR4
634385|NCT00174096|stromal-cell-derived factor-1(SDF-1)
634386|NCT00174096|metastasis
634387|NCT00174083|Tuberculosis, TB-ELISPOT, active tuberculosis latent infection interferon
634388|NCT00174070|Respiratory failure
634389|NCT00174070|Community
634390|NCT00174057|Graves' ophthalmopathy
634391|NCT00174057|real time PCR
634392|NCT00174057|cytokines
634393|NCT00174057|Tsh receptor
634394|NCT00174031|baseball
634395|NCT00174031|injury
634396|NCT00174018|subacrominal space
634397|NCT00173914|1. Transplant vasculopathy
634398|NCT00173914|2. Endothelial dysfunction
634399|NCT00173914|3. Myocardial perfusion imaging
634400|NCT00173914|4. Intravascular vascular ultrasound
634401|NCT00173901|ceftazidime
634402|NCT00173901|safety
634403|NCT00173901|infection
634404|NCT00173888|Combination, Chemotherapy,non-small cell lung cancer
634405|NCT00173875|EGFR Non-small cell lung cancer
634406|NCT00173862|Combination, Chemotherapy,transitional cell carcinoma
634407|NCT00173849|oral cancer
634408|NCT00173849|CXCR4
634409|NCT00173849|stromal-cell-derived factor-1(SDF-1)
634410|NCT00173849|metastasis
634411|NCT00173836|Nasopharyngeal carcinoma
634412|NCT00173836|Saliva
634413|NCT00173836|Swallowing
634414|NCT00173836|Videofluoroscopy
634415|NCT00173836|Radiation
634416|NCT00174005|muscle
634417|NCT00174005|tendon
634418|NCT00173992|Stroke
634419|NCT00173992|Balance
634420|NCT00173992|Proactive control
634421|NCT00173992|Reactive control
634422|NCT00173992|Recovery
634423|NCT00173992|Training
634424|NCT00173992|Fall
634425|NCT00173979|muscle
634426|NCT00173979|tendon
634427|NCT00173953|H. pylori、immune response、lymphocytic subsets、cytokine
634428|NCT00173940|chronic diseases, such as hypertension, diabetes, obesity, chronic renal failure, and so on
634429|NCT00173927|extracranial atherosclerosis
634430|NCT00173927|imaging
634431|NCT00173927|biomarkers
634432|NCT00173810|stroke
634433|NCT00173810|movement
634434|NCT00173810|psychomterics
634435|NCT00173797|depression
634436|NCT00173797|psychometrics
634437|NCT00173784|psychometrics
634438|NCT00173784|activities of daily living
634439|NCT00173771|stroke
634440|NCT00173771|activities of daily living
634441|NCT00173771|psychometrics
634442|NCT00173758|IL-15
634443|NCT00173758|IL-15 receptor
634444|NCT00173758|decidual natural killer cells
634445|NCT00173758|endometrium
634446|NCT00173745|cerebral palsy
634447|NCT00173745|drooling
634448|NCT00173745|botulinum toxin
634449|NCT00173732|Preimplantation genetic diagnosis (PGD)
634450|NCT00173732|single cell
634451|NCT00173732|Multiple displacement amplification (MDA)
634452|NCT00173719|Hemiplegia
634453|NCT00173719|Assisstive device
634454|NCT00173719|Walking
634455|NCT00173719|Dynamic equilibrium
634456|NCT00173719|Reaction time
634457|NCT00173719|Attention
634458|NCT00173719|Dual task
634459|NCT00173706|L-Carnitine
634460|NCT00173706|hemodialysis
634461|NCT00173706|cardiac complications
634462|NCT00173706|impaired exercise and functional capacities
634463|NCT00173706|muscle symptoms
634464|NCT00173706|intradialytic hypotension
634465|NCT00173706|erythropoietin-resistant anemia
634466|NCT00173693|CEA, Osteoporosis, Fracture, Prevention, Exercise
634467|NCT00173615|ECMO
634468|NCT00173615|CPR
634469|NCT00173602|Peritoneal Dialysis
634470|NCT00173563|Immunology
634471|NCT00173550|Menopause, premature
634472|NCT00173550|Hysterectomy
634473|NCT00173550|Ovariectomy
634474|NCT00173550|Estrogen Replacement Therapy
634475|NCT00173550|Knowledge
634476|NCT00173550|Perception
634477|NCT00173550|Attitude
634478|NCT00173537|idiopathic pulmonary artery hypertension
634479|NCT00173524|EGFR Non-small cell lung cancer
634480|NCT00173498|atopic dermatitis, skin test
634481|NCT00173485|peritonitis, peritoneal dialysis, dialysate
634482|NCT00173472|colorectal cancer, MSI, TS, DPD, EGFR, chemotherapy.
634483|NCT00173446|Normal part of the adrenal gland
634484|NCT00173433|tuberculosis
634485|NCT00173433|relapse
634486|NCT00173433|reinfection
634487|NCT00173433|reactivation
634488|NCT00173433|dormancy
634489|NCT00173433|tuberculin skin test
634490|NCT00173420|Normal Controls
634491|NCT00173407|Ovarian endometrioid carcinoma
634492|NCT00173407|invasion
634493|NCT00173407|IGFBP-3
634494|NCT00173407|transfection
634495|NCT00173407|signal transduction
634496|NCT00173407|PTEN
634497|NCT00173407|methylation
634498|NCT00173394|ovarian cancer
634499|NCT00173394|immunotherapy
634500|NCT00173394|mesothelin
634501|NCT00173394|normal volunteer
634502|NCT00173381|lymphangiogenesis
634503|NCT00173381|head and neck squamous cell carcinoma (HNSCC)
634504|NCT00173381|vascular endothelial growth factor-C (VEGF-C)
634505|NCT00173381|cyclooxygenase-2 (COX-2)
634506|NCT00173381|interleukin-6 (IL-6)
634507|NCT00173368|Sphincterotomy
634508|NCT00173368|needle knife
634509|NCT00173368|hemorrhage
634510|NCT00173368|complication
634511|NCT00173355|pediatric Dermatofibrosarcoma Protuberans
634512|NCT00173342|Right bundle branch block
634513|NCT00173342|Electrocardiography
634514|NCT00173342|Ion channel
634515|NCT00173329|HIV
634516|NCT00173316|vascular endothelial growth factor-C
634517|NCT00173316|VEGF-CR
634518|NCT00173316|lymphangiogenesis
634519|NCT00173316|host inflammatory responses
634520|NCT00173316|oral carcinogenesis
634521|NCT00173316|oral cancers
634522|NCT00173316|oral premalignant lesions
634523|NCT00173303|Breast neoplasms
634524|NCT00173303|Breast radiography
634525|NCT00173303|Cancer screening
634526|NCT00173290|Cervical cancer
634527|NCT00173290|Breast cancer
634528|NCT00173290|T lymphocyte
634529|NCT00173290|NK receptor
634530|NCT00173277|colorectal cancer screening
634531|NCT00173277|colonoscopy
634532|NCT00173238|atherosclerosis
634533|NCT00173238|optical coherence tomography
634534|NCT00173238|polarization
634535|NCT00173238|phase retardation
634536|NCT00173238|birefringence
634537|NCT00173225|nociceptin
634538|NCT00173225|sunstance P
634539|NCT00173225|asthma
634540|NCT00173225|COPD
634541|NCT00173225|cough
634542|NCT00173212|adenomyosis
634543|NCT00173212|cell proliferation
634544|NCT00173212|Immunocytochemistry
634545|NCT00173186|ventricular septal defect
634546|NCT00173186|aortic regurgitation
634547|NCT00173173|Gifted dance students
634548|NCT00173173|eating disorders
634549|NCT00173173|prevalence
634550|NCT00173173|risk factors
634551|NCT00173173|BITE
634552|NCT00173160|Eating disorders
634553|NCT00173160|risk factors
634554|NCT00173160|prospective study
634555|NCT00173160|case-controled study
634556|NCT00173160|outcome
634557|NCT00173160|gifted dance students
634558|NCT00173134|diabetes
634559|NCT00173134|erectile dysfunction
634560|NCT00173134|erectile dysfunction related quality of life
634561|NCT00173121|enterovirus, environment, aerosol, air
634562|NCT00173108|Prematurity
634563|NCT00173108|Early intervention
634564|NCT00173108|Neurodevelopment
634565|NCT00173108|Cost-effectiveness
634566|NCT00173082|primary aldosteronism
634567|NCT00173082|Insulin resistance
634568|NCT00173082|Metabolic syndrome
634569|NCT00173082|OGTT
634570|NCT00173069|Schizophrenia
634571|NCT00173069|PPI
634572|NCT00173069|P50I
634573|NCT00173069|MRS
634574|NCT00173069|Niacin
634575|NCT00173069|Candidate Genes
634576|NCT00173056|Peritoneal dialysis
634577|NCT00173017|N95 mask
634578|NCT00173017|medical staff
634579|NCT00173017|hypoxemia
634580|NCT00173017|hypercapnia
634581|NCT00173017|neurological study
634582|NCT00172055|Zoledronic acid
634583|NCT00172055|Zometa
634584|NCT00172055|prostate cancer
634585|NCT00172055|osteoporosis
634586|NCT00172042|Non-Small-Cell Lung Cancer
634587|NCT00172042|Bisphosphonates
634588|NCT00172042|Zoledronic acid
634589|NCT00172042|Bone metastases
634590|NCT00172042|Prevention of bone metastases
634591|NCT00172029|Zoledronic acid
634592|NCT00172029|Radiotherapy
634593|NCT00172029|Bone pain
634594|NCT00172029|Breast cancer
634595|NCT00172016|Zoledronic acid
634596|NCT00172016|SRE
634597|NCT00172016|Prostate cancer
634598|NCT00172003|Renal Cell Cancer
634599|NCT00172003|Bone metastasis
634600|NCT00172003|Skeletal related event
634601|NCT00172003|Renal Cell Cancer patients with bone metastasis
634602|NCT00171990|genital herpes
634603|NCT00171990|herpes
634604|NCT00171990|famciclovir
634605|NCT00171977|GIST
634606|NCT00171977|Imatinib
634607|NCT00171977|Postoperative Adjuvant
634608|NCT00171964|Pain
634609|NCT00171964|Bone metastasis
634610|NCT00171964|Analgesic consumption
634611|NCT00171964|Cancer patients
634612|NCT00171964|Cancer patients with painful bone metastasis
634613|NCT00171951|Cushing's disease
634614|NCT00171951|ACTH
634615|NCT00171951|Cortisol
634616|NCT00171951|ACTH dependent Cushing's disease
634617|NCT00171938|Glioblastoma
634618|NCT00171938|Brain tumors
634619|NCT00171938|Imatinib
634620|NCT00171938|PDGFR
634621|NCT00171925|Multiple Myeloma
634622|NCT00171925|Stage I
634623|NCT00171925|Zoledronic acid
634624|NCT00171925|Progression
634625|NCT00171912|Imatinib mesylate
634626|NCT00171912|tyrosine kinases
634627|NCT00171912|imatinib sensitivity
634628|NCT00171912|Diverse malignancies either associated with
634629|NCT00171912|or thought to be associated with
634630|NCT00171912|activated tyrosine kinase enzymes
634631|NCT00171912|including hypereosinophilic syndrome
634632|NCT00171912|systemic mastocytosis
634633|NCT00171912|chronic myelomonocytic leukaemia,
634634|NCT00171912|dermatofibrosarcoma protuberans and other diseases.
634635|NCT00171912|Not included:
634636|NCT00171912|patients with chronic myeloid leukemia,
634637|NCT00171912|some other types of leukemias (abl-mutated)
634638|NCT00171912|some types of gastrointestinal stromal tumours (c-KIT-positive),
634639|NCT00171912|some systemic mastocytosis (if c-KIT D816V mutation),
634640|NCT00171912|brain,
634641|NCT00171912|prostate,
634642|NCT00171912|breast or lung cancers.
634643|NCT00171899|Chronic Myelogenous Leukemia
634644|NCT00171899|Complete cytogenetic response
634645|NCT00171899|Imatinib mesylate
634646|NCT00171899|Major molecular response
634647|NCT00171899|Chronic phase Ph+ Chronic Myelogenous Leukemia
634648|NCT00171886|Acromegaly
634649|NCT00171886|Otreotide
634650|NCT00171886|Tumor reduction
634651|NCT00172965|Optic coherence tomography
634652|NCT00172965|oral cancer
634653|NCT00172965|oral precancers
634654|NCT00172952|high myopia, genomic
634655|NCT00172926|Physical Constitution
634656|NCT00172926|Disease Pattern
634657|NCT00172926|Laboratory Data
634658|NCT00172926|Integrative Chinese Medicine and Western Medicine
634659|NCT00172913|Wavefront Aberration
634660|NCT00172913|LASIK
634661|NCT00172913|Contrast Sensitivity
634662|NCT00172913|Visual Performance
634663|NCT00172913|Ablation Profile
634664|NCT00172900|Diffusion tensor imaging
634665|NCT00172900|MR spectroscopy
634666|NCT00172900|dementia
634667|NCT00172900|white matter
634668|NCT00172887|Psychiatrists
634669|NCT00172874|cross-cultural,
634670|NCT00172874|eating disorders,
634671|NCT00172874|EDI,
634672|NCT00172874|psychometrics
634673|NCT00172861|gastric cancer, cyclooxygenase-2, microarray
634674|NCT00172835|pleural effusion
634675|NCT00172835|procalcitonin
634676|NCT00172822|appendicitis
634677|NCT00172809|Chronic Hepatitis C
634678|NCT00172809|End stage renal disease
634679|NCT00172809|Hemodialysis
634680|NCT00172809|Interferon
634681|NCT00172809|Pegylated interferon
634682|NCT00172796|Metabolic syndrome
634683|NCT00172783|TB
634684|NCT00172783|PPD
634685|NCT00172783|ELISPOT
634686|NCT00172783|BCG
634687|NCT00172757|MSI, TS, Colorectal Cancer, DM.
634688|NCT00171873|Double blind
634689|NCT00171873|Phase III
634690|NCT00171873|Disease
634691|NCT00171873|Clinical trial
634692|NCT00171873|Octreotide
634693|NCT00171873|Neuroendocrine tumor
634694|NCT00171873|Cancer
634695|NCT00171873|Tumor
634696|NCT00171873|Midgut
634697|NCT00171860|Hypereosinophilic syndrome
634698|NCT00171860|Imatinib
634699|NCT00171847|Breast cancer
634700|NCT00171847|Metastatic
634701|NCT00171847|Trastuzumab
634702|NCT00171847|Letrozole
634703|NCT00171834|EPO
634704|NCT00171834|EPO906
634705|NCT00171834|Brain metastasis
634706|NCT00171834|Lung cancer
634707|NCT00171834|Lung metastasis
634708|NCT00171834|NSCLC
634709|NCT00171821|Thalassemia
634710|NCT00171821|Myelodysplastic Syndrome
634711|NCT00171821|MDS
634712|NCT00171821|Sickle cell
634713|NCT00171821|Diamond-Blackfan anemia
634714|NCT00171821|Transfusion
634715|NCT00171821|Anemia
634716|NCT00171821|Fanconi
634717|NCT00171821|Chelation
634718|NCT00171821|Deferasirox
634719|NCT00171808|Endometrial Cancer
634720|NCT00171808|Aromatase inhibitor
634721|NCT00171808|Advanced or recurrent
634722|NCT00171808|hormone receptor positive
634723|NCT00171795|Traumatic brain injury,
634724|NCT00171795|cognitive impairment,
634725|NCT00171795|rivastigmine
634726|NCT00171782|HYPERTENSION
634727|NCT00171782|VALSARTAN
634728|NCT00171782|VALSARTAN AND HYDROCHLOROTHIAZIDE
634729|NCT00171782|RISK FACTORS
634730|NCT00171756|hypertension
634731|NCT00171756|valsartan
634732|NCT00171743|Adults
634733|NCT00171743|Post transplant diabetes
634734|NCT00171730|Acromegaly
634735|NCT00171730|Pasireotide
634736|NCT00171730|GH
634737|NCT00171730|IGF-1
634738|NCT00171717|Cyclosporine, liver transplantation, maintenance, diabetes
634739|NCT00171704|Breast Cancer
634740|NCT00171704|Letrozole
634741|NCT00171704|Bone Mineral Density
634742|NCT00171704|Bone Markers
634743|NCT00171704|Serum lipid
634744|NCT00171704|Postmenopausal
634745|NCT00171691|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
634746|NCT00171678|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
634747|NCT00171665|Hand osteoarthritis, Topical NSAID, Diclofenac sodium
634748|NCT00172744|stem cells
634749|NCT00172744|periodontal cells
634750|NCT00172744|mechanical stress
634751|NCT00172744|differentiation
634752|NCT00172744|periodontal ligament
634753|NCT00172692|Chewing efficiency,
634754|NCT00172692|Gum chewing
634755|NCT00172692|Chewing velocity
634756|NCT00172692|Occlusal surface area
634757|NCT00172692|EMG
634758|NCT00172692|Jaw movement
634759|NCT00172679|Tai Chi
634760|NCT00172679|NK Cells
634761|NCT00172679|T lymphocytes
634762|NCT00172679|Exercise
634763|NCT00172666|SLE
634764|NCT00172666|healthy subjects
634765|NCT00172653|shoulder, reliability, validity
634766|NCT00172614|metabolic syndrome
634767|NCT00172588|adenomyosis
634768|NCT00172588|apoptosis
634769|NCT00172588|flowcytometry
634770|NCT00172575|Lung neoplasms
634771|NCT00172575|Magnetic resonance imaging
634772|NCT00172562|acute myeloid leukemia
634773|NCT00172562|age and sex matched normal subjects
634774|NCT00172562|dynamic MRI
634775|NCT00172562|bone marrow perfusion
634776|NCT00172562|tumor angiogenesis
634777|NCT00172497|aggressive acts
634778|NCT00172484|cerebrovascular accident
634779|NCT00172484|stroke center
634780|NCT00172484|stroke team
634781|NCT00172484|intensive care of stroke
634782|NCT00172484|rehabilitation of stroke
634783|NCT00172419|statin, inflammation, FDG, positron emission tomography
634784|NCT00172393|EV71,
634785|NCT00172393|CNS,
634786|NCT00172393|Outcome,
634787|NCT00172393|Neurological,
634788|NCT00172393|Psychiatric
634789|NCT00172367|Urothelial carcinoma
634790|NCT00172367|Lycopene
634791|NCT00172367|uremia
634792|NCT00172367|prevention
634793|NCT00172367|biomarker
634794|NCT00172367|progression
634795|NCT00172367|anti-oxidant
634796|NCT00172328|Hepatitis B
634797|NCT00172328|vaccine
634798|NCT00172315|acquired immunodeficiency syndrome
634799|NCT00172315|lipodystrophy
634800|NCT00172315|MR spectroscopy
634801|NCT00172289|pulse wave velocity
634802|NCT00172289|sympathetic nerve activity
634803|NCT00172289|spinal cord injury
634804|NCT00172289|cerebrovascular accident
634805|NCT00172263|Immunology
634806|NCT00172237|eye-head coordination
634807|NCT00172237|proprioception
634808|NCT00172237|cervical spine with degenerative disease
634809|NCT00172237|degenerated cervical spine
634810|NCT00172224|osteoporosis
634811|NCT00172224|compression fracture
634812|NCT00172224|bone marrow perfusion
634813|NCT00172224|MR spectroscopy
634814|NCT00172224|hormone therapy
634815|NCT00172211|Physioneal
634816|NCT00172211|Peritoneal dialysis
634817|NCT00172211|Oxidative stress
634818|NCT00172211|insulin resistance
634819|NCT00172198|w-3 fish oil
634820|NCT00172198|Nutrition
634821|NCT00172198|immune
634822|NCT00172198|intensive care
634823|NCT00172198|patients
634824|NCT00172185|Short Bowel Syndrome
634825|NCT00172185|Parenteral Nutrition
634826|NCT00172185|SBS
634827|NCT00172185|Teduglutide
634828|NCT00172172|Post-menopausal
634829|NCT00172172|Osteoporosis
634830|NCT00172172|Parathyroid Hormone
634831|NCT00172172|PTH
634832|NCT00172172|ALX1-11
634833|NCT00172159|Colorectal cancer
634834|NCT00172159|Chemotherapy
634835|NCT00172159|Surgery
634836|NCT00172159|Liver metastasis
634837|NCT00172146|Hemiplegia
634838|NCT00172146|Regular cane
634839|NCT00172146|Volitional stepping
634840|NCT00172146|Dynamic equilibrium
634841|NCT00172146|Attention
634842|NCT00172146|Dual task
634843|NCT00172133|Post-menopausal
634844|NCT00172133|Osteoporosis
634845|NCT00172133|Parathyroid Hormone
634846|NCT00172133|PTH
634847|NCT00172133|ALX1-11
634848|NCT00172120|Post-menopausal
634849|NCT00172120|Osteoporosis
634850|NCT00172120|Parathyroid Hormone
634851|NCT00172120|PTH
634852|NCT00172120|ALX1-11
634853|NCT00172107|Post-menopausal
634854|NCT00172107|Osteoporosis
634855|NCT00172107|Parathyroid Hormone
634856|NCT00172107|PTH
634857|NCT00172107|ALX1-11
634858|NCT00172094|Migraine
634859|NCT00172081|Post-menopausal
634860|NCT00172081|Osteoporosis
634861|NCT00172081|Parathyroid Hormone
634862|NCT00172081|PTH
634863|NCT00172081|ALX1-11
634864|NCT00172068|Primary breast cancer
634865|NCT00172068|Bone metastases
634866|NCT00172068|Minimal residual disease
634867|NCT00172068|Bisphosphonates
634868|NCT00171652|Hand osteoarthritis, Topical NSAID, Diclofenac sodium
634869|NCT00171626|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
634870|NCT00171613|Obesity
634871|NCT00171600|valsartan
634872|NCT00171600|lisinopril
634873|NCT00171600|albuminuria
634874|NCT00171600|diabetic nephropathy
634875|NCT00171587|Metastatic solid tumors
634876|NCT00171587|PTK787/ZK 222584
634877|NCT00171587|Vatalanib
634878|NCT00171587|Capecitabine
634879|NCT00171587|VEGF (vascular endothelial growth factor)
634880|NCT00171587|Histologically confirmed metastatic solid tumors
634881|NCT00171574|valsartan
634882|NCT00171574|lisinopril
634883|NCT00171574|antiproteinuric
634884|NCT00171574|diabetic nephropathy
634885|NCT00171561|hypertension
634886|NCT00171561|diabetes
634887|NCT00171561|albuminuria
634888|NCT00171561|valsartan
634889|NCT00171561|hydrochlorothiazide
634890|NCT00171561|amlodipine
634891|NCT00171548|Metabolic syndrome, cardiovascular risk reduction
634892|NCT00171535|hypertension
634893|NCT00171535|high blood pressure
634894|NCT00171535|valsartan
634895|NCT00171535|amlodipine
634896|NCT00171522|Constipation
634897|NCT00171522|Tegaserod
634898|NCT00171522|Polyethylene Glycol 3350
634899|NCT00171522|PEG
634900|NCT00171509|Liver transplant, adults, once a day administration, Immunosuppressants
634901|NCT00171496|Kidney transplant, adults, NODM, immunosuppressants
634902|NCT00171483|GERD
634903|NCT00171483|PPI
634904|NCT00171483|heartburn
634905|NCT00171483|regurgitation
634906|NCT00171470|dyspepsia
634907|NCT00171470|hearburn
634908|NCT00171470|female
634909|NCT00171470|PPI
634910|NCT00171457|functional heartburn
634911|NCT00171457|dyspepsia
634912|NCT00171457|male
634913|NCT00171457|female
634914|NCT00171457|visceral sensitivity
634915|NCT00171444|hypertension,
634916|NCT00171444|valsartan+hydrochlorothiazide
634917|NCT00171431|IBS-C
634918|NCT00171431|female
634919|NCT00171418|GERD
634920|NCT00171418|PPI
634921|NCT00171405|hypertension
634922|NCT00171405|aliskiren
634923|NCT00171405|hydrochlorothiazide
634924|NCT00171392|Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium, tacrolimus.
634925|NCT00171379|Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium.
634926|NCT00171366|amlodipine
634927|NCT00171366|benazepril
634928|NCT00171366|hypertension
634929|NCT00171366|diastolic
634930|NCT00171353|arterial hypertension
634931|NCT00171353|albuminuria
634932|NCT00171353|valsartan
634933|NCT00171340|Bone Loss
634934|NCT00171340|Osteopenia
634935|NCT00171340|Breast cancer
634936|NCT00171340|letrozole
634937|NCT00171340|zoledronic acid
634938|NCT00171340|postmenopausal
634939|NCT00171327|arterial hypertension
634940|NCT00171327|dyslipidemia
634941|NCT00171327|valsartan
634942|NCT00171327|fluvastatin
634943|NCT00171314|breast cancer
634944|NCT00171314|letrozole
634945|NCT00171314|zoledronic acid
634946|NCT00171314|adjuvant
634947|NCT00171314|postmenopausal
634948|NCT00171301|Transfusional hemosiderosis
634949|NCT00171301|Beta-thalassemia major
634950|NCT00171301|Deferasirox
634951|NCT00171301|iron overload
634952|NCT00171301|rare anemia
634953|NCT00171301|iron overload due to transfusion
634954|NCT00171288|Dyslipidemia, ezetimibe, inflammatory markers, fluvastatin
634955|NCT00171275|Coronary disease
634956|NCT00171275|Myocardial infarction
634957|NCT00171275|Statins
634958|NCT00171262|Dyslipidemia, chronic renal disease, fluvastatin
634959|NCT00171249|Chronic Myelogenous Leukemia
634960|NCT00171249|CML
634961|NCT00171249|Philadelphia Chromosome
634962|NCT00171249|Accelerated phase
634963|NCT00171249|Acute Myelogenous Leukemia
634964|NCT00171249|AML
634965|NCT00171249|Acute Lymphoblastic Leukemia
634966|NCT00171249|ALL
634967|NCT00171249|Imatinib mesylate
634968|NCT00171236|Heterozygous familial hypercholesterolemia
634969|NCT00171236|mixed dyslipidemia
634970|NCT00171223|Chronic Myelogenous Leukemia
634971|NCT00171223|CML
634972|NCT00171223|Philadelphia Chromosome
634973|NCT00171223|Accelerated phase
634974|NCT00171223|Acute Myelogenous Leukemia
634975|NCT00171223|AML
634976|NCT00171223|Acute Lymphoblastic Leukemia
634977|NCT00171223|ALL
634978|NCT00171223|Imatinib mesylate
634979|NCT00171210|β-thalassemia
634980|NCT00171210|iron overload
634981|NCT00171210|deferasirox
634982|NCT00171184|Overactive bladder, Darifenacin, M3 muscarinic receptor antagonist, elderly population
634983|NCT00171171|Thalassemia (beta-thal. major)
634984|NCT00171171|Transfusional hemosiderosis
634985|NCT00171171|Deferasirox
634986|NCT00171171|Beta-thalassemia major patients
634987|NCT00171171|Unable to be chelated with deferoxamine or deferiprone
634988|NCT00171158|Chronic Myelogenous Leukemia
634989|NCT00171158|CML
634990|NCT00171158|Philadelphia Chromosome
634991|NCT00171158|Blast crisis
634992|NCT00171158|Imatinib mesylate
634993|NCT00171145|Overactive Bladder, incontinence, antimuscarinic, warning time, darifenacin
634994|NCT00171132|Postmenopausal
634995|NCT00171132|women
634996|NCT00171132|overweight
634997|NCT00171132|hypertension
634998|NCT00171132|impaired
634999|NCT00171132|exercise
635000|NCT00171132|capacity
635001|NCT00171132|valsartan
635002|NCT00171132|atenolol
635003|NCT00171132|hydrochlorothiazide
635004|NCT00171119|HYPERTENSION
635005|NCT00171119|DIABETES MELLITUS TYPE II
635006|NCT00171119|VALSARTAN
635007|NCT00171119|BENAZAPRIL
635008|NCT00171106|diastolic dysfunction
635009|NCT00171106|heart failure
635010|NCT00171106|exercise tolerance
635011|NCT00171106|valsartan
635012|NCT00171093|HYPERTENSION
635013|NCT00171093|HYPERCHOLESTEROLEMIA
635014|NCT00171093|BLOOD PRESSURE
635015|NCT00171093|CHOLESTEROL
635016|NCT00171093|VALSARTAN
635017|NCT00171093|SIMVASTATIN
635018|NCT00171080|Hypertension
635019|NCT00171080|Valsartan
635020|NCT00171080|Dialysis
635021|NCT00171080|Renal Disease
635022|NCT00171067|Microalbuminuria, urinary albumin excretion, urinary albumin creatinine ratio, hypertension, valsartan, lisinopril, combination
635023|NCT00171054|hypertension
635024|NCT00171054|postmenopausal
635025|NCT00171054|valsartan
635026|NCT00171054|amlodipine
635027|NCT00171054|hydrochlorothiazide
635028|NCT00171041|PEDIATRIC HYPERTENSION
635029|NCT00171041|PEDIATRIC
635030|NCT00171041|VALSARTAN
635031|NCT00171028|PEDIATRIC HYPERTENSION
635032|NCT00171028|PEDIATRIC
635033|NCT00171028|VALSARTAN
635034|NCT00171015|VALSARTAN
635035|NCT00171015|HYDROCHLOROTHIAZIDE
635036|NCT00171015|OLMESARTAN
635037|NCT00171015|HYPERTENSION
635038|NCT00171002|Hypertension, high blood pressure, valsartan, amlodipine
635039|NCT00170989|hypertension
635040|NCT00170989|high blood pressure
635041|NCT00170989|valsartan
635042|NCT00170989|hydrochlorothiazide
635043|NCT00170976|HYPERTENSION, VALSARTAN, AMLODIPINE< SAFETY
635044|NCT00170963|Hypertension, high blood pressure, valsartan, amlodipine
635045|NCT00170950|cardiovascular morbidity
635046|NCT00170950|cardiovascular mortality
635047|NCT00170950|benazepril
635048|NCT00170950|amlodipine
635049|NCT00170950|high risk population
635050|NCT00170937|METABOLIC SYNDROME, VALSARTAN, HYDROCHLOROTHIAZIDE, HYPERTENSION,
635051|NCT00170924|Hypertension, High Blood Pressure, Diastolic Dysfunction,
635052|NCT00170924|Heart Disease
635053|NCT00170911|Osteoporosis
635054|NCT00170911|Postmenopausal women
635055|NCT00170911|Cathepsin K inhibitor
635056|NCT00170898|Musculoskeletal pain
635057|NCT00170898|cyclooxygenase-2 inhibitors
635058|NCT00170898|lumiracoxib
635059|NCT00170898|naproxen
635060|NCT00170885|acute rejection
635061|NCT00170885|renal function
635062|NCT00170885|everolimus
635063|NCT00170885|cyclosporine microemulsion
635064|NCT00170872|Osteoarthritis
635065|NCT00170872|Rheumatoid Arthritis
635066|NCT00170872|Cox-2
635067|NCT00170872|lumiracoxib
635068|NCT00170859|everolimus
635069|NCT00170859|cyclosporine microemulsion
635070|NCT00170859|renal function
635071|NCT00170846|Renal transplantation, everolimus, calcineurin inhibitors, GFR
635072|NCT00170833|Renal/Kidney, transplantation, everolimus, calcineurin sparing
635073|NCT00170820|Renal transplantation, maintenance, switch, everolimus, CNI-free
635074|NCT00170794|cardiac transplantation, everolimus, cyclosporine microemulsion, GFR
635075|NCT00170781|Pain, acute gout, arthritis, cyclooxygenase-2 inhibitors, lumiracoxib, indomethacin
635076|NCT00170768|Darifenacin, oxybutynin, cognition, memory
635077|NCT00170755|Overactive Bladder, incontinence, antimuscarinic, darifenacin, long-term treatment
635078|NCT00170742|Open label,
635079|NCT00170742|phase III,
635080|NCT00170742|disease,
635081|NCT00170742|clinical trial,
635082|NCT00170742|octreotide,
635083|NCT00170742|proliferative diabetic retinopathy, lasercoagulation
635084|NCT00170729|Prednisolone acetate,
635085|NCT00170729|efficacy,
635086|NCT00170729|cataract,
635087|NCT00170729|eye drops,
635088|NCT00170729|tolerability,
635089|NCT00170729|inflammation
635090|NCT00170716|Motor Cortex Electrical Stimulation
635091|NCT00170716|Ischemic Stroke
635092|NCT00170716|Upper Extremity Hemiparesis
635093|NCT00170716|Rehabilitation
635094|NCT00170716|Motor Recovery
635095|NCT00170716|Functional MRI
635096|NCT00170703|Cortical Electrical Stimulation
635097|NCT00170703|Ischemic Stroke
635098|NCT00170703|Broca's Aphasia
635099|NCT00170703|Speech Rehabilitation
635100|NCT00170703|Functional MRI
635101|NCT00170664|Ovarian neoplasms
635102|NCT00170664|paclitaxel, carboplatin
635103|NCT00170664|clinical trials, phase II
635104|NCT00170664|first-line chemotherapy
635105|NCT00170664|weekly therapy schedule
635106|NCT00170638|Tuberculosis, children, infants
635107|NCT00170625|platin-resistant
635108|NCT00170612|Pneumococcal infections
635109|NCT00170612|Fiji
635110|NCT00170612|infants
635111|NCT00170612|vaccine
635112|NCT00170586|Underglove, polyvinylidene fluoride, acrylic polymer
635113|NCT00170573|biweekly schedule of PLD - Ovarian cancer - pegylated liposomal doxorubicin -quality of life - Toxic skin reactions
635114|NCT00170560|hospital, acquired, infections, mortality
635115|NCT00170547|inactivated, trivalent, influenza, vaccine, Fluzone
635116|NCT00170534|India, male, sexually transmitted infection, STI, STD
635117|NCT00170521|group A streptococci, pharyngitis, epidemiology, Streptococcus pyogenes, children, Nicaragua
635118|NCT00170508|Influenza, sub-study
635119|NCT00170495|respiratory illness, influenza, bronchitis, pneumonia, cold
635120|NCT00170482|influenza vaccine, Fluzone, inactivated, trivalent
635121|NCT00170469|Anthrax
635122|NCT00170456|Anthrax vaccine
635123|NCT00170443|Influenza, Baculovirus, Immunogenicity, Geriatrics
635124|NCT00170430|HIV-1, sexually transmitted diseases, females, Kenya
635125|NCT00170404|HIV Infections, Tuberculosis, Malnutrition, Tanzania
635126|NCT00170391|Insomnia
635127|NCT00170391|Sleep
635128|NCT00170391|PSG
635129|NCT00170391|Behavioural treatment
635130|NCT00170378|Enoxaparin
635131|NCT00170378|Safety
635132|NCT00170365|Stress
635133|NCT00170365|Yoga
635134|NCT00170352|hyperbaric oxygen
635135|NCT00170352|cerebral metabolism
635136|NCT00170352|hyperoxia
635137|NCT00170352|traumatic brain injury
635138|NCT00170339|Opiate Dependence
635139|NCT00170339|Methadone Maintenance
635140|NCT00170339|Osteoporosis
635141|NCT00170339|Hypogonadism
635142|NCT00170326|Permanent Pacing artificial internal
635143|NCT00170313|Heart Failure
635144|NCT00170313|Primary Prevention of Sudden Cardiac Death
635145|NCT00170313|Secondary Prevention of Sudden Cardiac Death
635146|NCT00170313|Cardiac Desynchronization
635147|NCT00170313|CRT-D
635148|NCT00170313|Cardiac Dyssynchrony
635149|NCT00170300|Cardiac resynchronisation therapy (CRT therapy),
635150|NCT00170300|all-cause mortality,
635151|NCT00170300|quality of life assesment,
635152|NCT00170300|echocardiographic left ventricular function,
635153|NCT00170300|CRT and neurohormonal activation,
635154|NCT00170300|CRT and health economics
635155|NCT00170287|Unstable Ventricular Tachycardia
635156|NCT00170274|Indication for cardiac pacing
635157|NCT00170274|Atrial Arrhythmia
635158|NCT00170274|Indication for the implantation of a pacemaker according to the German guidelines
635159|NCT00170274|Documented (ECG) atrial tachyarrhythmia within the last three months before enrollment
635160|NCT00170261|Syncope of uncertain etiology
635161|NCT00170261|Repeated presyncopes
635162|NCT00170248|Asthma
635163|NCT00170248|Primary Care
635164|NCT00170248|Computer-Based Decision Support
635165|NCT00170248|Outcome Evaluation
635166|NCT00170235|Breast cancer
635167|NCT00170235|Prehabilitation
635168|NCT00170235|Rehabilitation
635169|NCT00170235|Exercise
635170|NCT00170222|Acute bronchitis
635171|NCT00170222|antibiotics
635172|NCT00170209|Tuberculosis
635173|NCT00170209|Children
635174|NCT00170196|pneumonia
635175|NCT00170196|corticosteroids
635176|NCT00170183|Heart failure
635177|NCT00170183|Renal dysfunction
635178|NCT00170170|cytomegalovirus
635179|NCT00170105|Age 18 years or older
635180|NCT00170105|No cognitive impairment or altered mental status
635181|NCT00170105|Stable
635182|NCT00170105|No aphasia
635183|NCT00170105|English-speaking
635184|NCT00170053|Kidney Transplantation
635185|NCT00170001|supraesophageal reflux
635186|NCT00170001|laryngopharyngeal symptoms
635187|NCT00170001|pharynx
635188|NCT00170001|esophagus
635189|NCT00169988|clinical high risk
635190|NCT00169988|attenuated positive symptoms
635191|NCT00169988|attenuated negative symptoms
635192|NCT00169988|cognition
635193|NCT00169988|functional status
635194|NCT00169988|prodromal psychosis
635195|NCT00169962|acute disease
635196|NCT00169949|early intervention
635197|NCT00169949|social functioning
635198|NCT00169949|role functioning
635199|NCT00169949|cognition
635200|NCT00169910|Renal Transplantation
635201|NCT00169910|Calcineurin Inhibitor
635202|NCT00169910|Mycophenolate Mofetil
635203|NCT00169910|Cardiovascular Disease
635204|NCT00169897|COPD
635205|NCT00169897|Exercise
635206|NCT00169897|Self-management
635207|NCT00169897|Rehabilitation
635208|NCT00169897|Quality of life
635209|NCT00169897|Health economy
635210|NCT00169897|Cost effectiveness
635211|NCT00169897|Health care utilization
635212|NCT00169884|Deliberate Self-Harm,
635213|NCT00169884|cognitive-behavioural therapy,
635214|NCT00169884|integrative approach
635215|NCT00169858|Hepatitis B
635216|NCT00169858|Vaccination
635217|NCT00169858|Engerix-B
635218|NCT00169858|Immunogenicity
635219|NCT00169858|Long-term immunity
635220|NCT00169858|Booster dose
635221|NCT00169858|Safety
635222|NCT00169845|chemoprevention trial
635223|NCT00169845|antioxidant
635224|NCT00169845|alpha-tocopherol
635225|NCT00169845|beta-carotene
635226|NCT00169845|second primary cancer
635227|NCT00169845|head and neck cancer
635228|NCT00169845|adverse effect of radiation therapy
635229|NCT00169845|quality of life
635230|NCT00169845|mortality
635231|NCT00169845|cancer free survival
635232|NCT00169845|cancer recurrence
635233|NCT00169832|Atherosclerosis progression
635234|NCT00169832|Ischemic heart disease
635235|NCT00169832|Saphenous vein graft
635236|NCT00169832|Metabolic risk factors
635237|NCT00169832|Rosiglitazone
635238|NCT00169819|Same day discharge
635239|NCT00169819|Trans-radial
635240|NCT00169819|Coronary artery stenting
635241|NCT00169819|Abciximab bolus
635242|NCT00169806|Randall's Plaque
635243|NCT00169806|Kidney stones
635244|NCT00169793|Obesity
635245|NCT00169793|Nephrolithiasis
635246|NCT00169780|Renal Calculi
635247|NCT00169780|Radiology
635248|NCT00169780|High Reslolution CT
635249|NCT00169767|Enlarged Prostate
635250|NCT00169767|BPH
635251|NCT00169754|Nephrolithiasis
635252|NCT00169754|Renal Calculi
635253|NCT00169754|Perc
635254|NCT00169754|Attached Stones
635255|NCT00169741|Nephrolithiasis
635256|NCT00169741|Renal Calculi
635257|NCT00169728|allogeneic haematopoietic stem cell transplantation
635258|NCT00169728|bone marrow transplantation
635259|NCT00169728|children
635260|NCT00169728|vaccination
635261|NCT00169728|invasive pneumococcal disease
635262|NCT00169728|tetanus
635263|NCT00169728|diphtheria
635264|NCT00169728|poliomyelitis
635265|NCT00169728|pertussis
635266|NCT00169728|Hepatitis B
635267|NCT00169728|Haemophilus influenzae type B infection
635268|NCT00169715|Kidney stones
635269|NCT00169715|renal Calculi
635270|NCT00169715|Tic
635271|NCT00169715|Caliceal Diverticula
635272|NCT00169702|Schizophrenia, weight management programme
635273|NCT00169689|schizophrenia, rTMS
635274|NCT00169676|Prostate Cancer
635275|NCT00169663|Brushite Kidney Stones
635276|NCT00169663|Nephrolithiasis
635277|NCT00169650|UPJ Obstruction
635278|NCT00169650|Renal Obstruction
635279|NCT00169650|Delayed Renal Flow
635280|NCT00169637|Short bowel syndrome
635281|NCT00169637|Growth hormone
635282|NCT00169637|Children
635283|NCT00169624|Diabetes,
635284|NCT00169624|coronary endothelial dysfunction,
635285|NCT00169624|metformin,
635286|NCT00169624|glyclazide,
635287|NCT00169624|MRI.
635288|NCT00169611|Neurofibromatosis type 1
635289|NCT00169611|Attention deficit with hyperactivity disorder school difficulties
635290|NCT00169611|methylphenidate
635291|NCT00169598|Lymphoma
635292|NCT00169598|positron emission tomography
635293|NCT00169598|stem cell transplantation
635294|NCT00169598|therapeutic impact
635295|NCT00169585|diagnostic-therapeutic pathway
635296|NCT00169585|PSA
635297|NCT00169585|DRE
635298|NCT00169585|Levofloxacin
635299|NCT00169572|Nausea
635300|NCT00169572|Vomiting
635301|NCT00169572|Emesis
635302|NCT00169572|Chemotherapy-induced Nausea and Vomiting
635303|NCT00169572|CINV
635304|NCT00169559|triglycerides
635305|NCT00169559|Hypertriglyceridemia
635306|NCT00169559|cholesterol
635307|NCT00169559|LDL
635308|NCT00169559|HDL
635309|NCT00169546|Asthma
635310|NCT00169546|inhaled corticosteroids
635311|NCT00169533|safety
635312|NCT00169533|tolerating lapatinib
635313|NCT00169533|Lapatinib
635314|NCT00169520|Safety
635315|NCT00169520|tolerability
635316|NCT00169520|dose limiting toxicity
635317|NCT00169520|solid tumors
635318|NCT00169520|docetaxel
635319|NCT00169468|B Lymphoma
635320|NCT00169468|Velcade
635321|NCT00169468|Chemotherapy
635322|NCT00169416|chicken pox
635323|NCT00169416|varicella
635324|NCT00169416|VZV
635325|NCT00169416|pharmacokinetics
635326|NCT00169403|Idiopathic dystonia
635327|NCT00169403|deep brain stimulation
635328|NCT00169403|globus pallidus
635329|NCT00169403|generalised Idiopathic dystonia
635330|NCT00169390|smoking
635331|NCT00169390|pregnancy
635332|NCT00169390|newborns
635333|NCT00169390|monoamine oxidases
635334|NCT00169377|Obsessive compulsive disorder
635335|NCT00169377|deep brain stimulation
635336|NCT00169377|subthalamic nucleus
635337|NCT00169364|Parkinson's disease
635338|NCT00169364|parkin mutation
635339|NCT00169364|Juvenile parkinson's disease
635340|NCT00169364|positron emission tomography
635341|NCT00169338|Dystonia
635342|NCT00169338|deep brain stimulation
635343|NCT00169338|globus pallidus
635344|NCT00169338|Post-anoxic dystonia
635345|NCT00169325|basal ganglia
635346|NCT00169325|loss of psychic self-activation
635347|NCT00169312|unspecified adult solid tumor, protocol specific
635348|NCT00169299|Menopause
635349|NCT00169299|Vasomotor
635350|NCT00169299|Black cohosh
635351|NCT00169299|Herbs
635352|NCT00169299|Hot flashes
635353|NCT00169299|HT
635354|NCT00169299|CAM
635355|NCT00169273|Obesity
635356|NCT00169273|Depression
635357|NCT00169273|Behavioral
635358|NCT00169273|Cognitive
635359|NCT00169273|Treatment
635360|NCT00169260|smoking
635361|NCT00169260|tobacco
635362|NCT00169260|behavior therapy
635363|NCT00169247|larynx cancer
635364|NCT00169247|hypopharynx cancer
635365|NCT00169247|larynx preservation
635366|NCT00169247|concomitant radiochemotherapy
635367|NCT00169247|cisplatin
635368|NCT00169247|cetuximab
635369|NCT00169247|randomized trial
635370|NCT00169234|Pneumococcal disease
635371|NCT00169234|Vaccination
635372|NCT00169234|Immunization
635373|NCT00169234|PPV23
635374|NCT00169234|PCV7
635375|NCT00169208|relapsed/refractory.
635376|NCT00169208|lymphoma, follicular
635377|NCT00169208|rituximab
635378|NCT00169208|chemotherapy
635379|NCT00169195|B-cell lymphoma
635380|NCT00169195|Salvage Therapy
635381|NCT00169195|rituximab
635382|NCT00169195|oxaliplatine
635383|NCT00169195|gemcitabine
635384|NCT00169182|Larynx cancer
635385|NCT00169182|Hypopharynx cancer
635386|NCT00169182|Chemotherapy
635387|NCT00169182|Randomized trial
635388|NCT00169182|Larynx preservation
635389|NCT00169169|Diffuse large B cell lymphoma
635390|NCT00169169|Rituximab
635391|NCT00169169|Autotransplant
635392|NCT00169156|T-cell angioimmunoblastic lymphoma
635393|NCT00169156|Rituximab
635394|NCT00169143|Diffuse large B cell lymphoma
635395|NCT00169143|Pegfilgrastim
635396|NCT00169143|Autotransplant
635397|NCT00169130|lymphoma
635398|NCT00169130|autologous stem cell transplant
635399|NCT00169130|chemotherapy
635400|NCT00169130|BCL2
635401|NCT00169117|Mosquito nets
635402|NCT00169117|Malaria prevention
635403|NCT00169117|Songs
635404|NCT00169117|Posters
635405|NCT00169117|Net repair
635406|NCT00169117|Bednets
635407|NCT00169104|Breast cancer
635408|NCT00169104|Her-2/neu
635409|NCT00169104|Granulocyte Colony Stimulating Factor
635410|NCT00169104|Trastuzumab
635411|NCT00169104|Vinorelbine
635412|NCT00169104|Antibody-dependent cellular cytotoxicity
635413|NCT00169104|Effector cells
635414|NCT00169091|Clozapine
635415|NCT00169091|Haloperidol
635416|NCT00169091|Schizophrenia
635417|NCT00169078|Transmission intensity
635418|NCT00169078|Insecticide-treated materials
635419|NCT00169078|antimalarial drug resistance
635420|NCT00169065|Clozapine
635421|NCT00169065|olanzapine
635422|NCT00169052|geriatric,
635423|NCT00169052|older
635424|NCT00169052|serious mental illness
635425|NCT00169052|SMI
635426|NCT00169039|Clozapine
635427|NCT00169039|Chlorpromazine
635428|NCT00169039|Schizophrenia
635429|NCT00169039|Biochemistry
635430|NCT00169026|Clozapine
635431|NCT00169026|Atypical Antipsychotic
635432|NCT00169026|Conventional antipsychotic
635433|NCT00169026|Schizophrenia
635434|NCT00169026|Dual Diagnosis
635435|NCT00169026|Substance Abuse
635436|NCT00169026|Alcohol Abuse
635437|NCT00169000|breast cancer
635438|NCT00169000|capecitabine
635439|NCT00169000|docetaxel
635440|NCT00169000|pharmacokinetic/pharmacodynamic
635441|NCT00169000|bcl-2
635442|NCT00169000|bax
635443|NCT00168987|oral nutritional supplement
635444|NCT00168987|eicosapentanoic acid
635445|NCT00168987|gastroenterological tumors
635446|NCT00168987|muscle function
635447|NCT00168987|quality of life
635448|NCT00168987|body composition
635449|NCT00168961|liver cirrhosis Child B or C
635450|NCT00168948|Intermittent preventive treatment
635451|NCT00168948|IPTi
635452|NCT00168948|Malaria control
635453|NCT00168948|Ghana
635454|NCT00168922|recurrent SCLC
635455|NCT00168909|osteoporosis
635456|NCT00168909|frailty
635457|NCT00168909|falls
635458|NCT00168896|SCLC
635459|NCT00168883|NSCLC
635460|NCT00168883|curative non-treatable NSCLC UICC stage IIIB and IV
635461|NCT00168870|metastatic ocular melanoma
635462|NCT00168766|Combination therapy for multiple sclerosis
635463|NCT00168753|Extended dosing
635464|NCT00168753|alefacept
635465|NCT00168740|rituximab
635466|NCT00168740|Rituxan
635467|NCT00168740|B-cell lymphoma
635468|NCT00168740|low-grade
635469|NCT00168740|follicular
635470|NCT00168740|anti-CD20 monoclonal antibody
635471|NCT00168727|Radioimmunotherapy
635472|NCT00168727|Antigens, CD20
635473|NCT00168714|AVONEX
635474|NCT00168714|Pregnancy
635475|NCT00168701|Multiple Sclerosis
635476|NCT00168701|MRI
635477|NCT00168688|micronutrient supplementation
635478|NCT00168688|pregnancy
635479|NCT00168688|birth weight
635480|NCT00168688|perinatal mortality
635481|NCT00168662|Non-specific effects of vaccines
635482|NCT00168662|Infant mortality
635483|NCT00168662|Child mortality
635484|NCT00168662|Mortality
635485|NCT00168662|Morbidity
635486|NCT00168662|Measles vaccine
635487|NCT00168662|Measles
635488|NCT00168662|Immunisation
635489|NCT00168662|Low income country
635490|NCT00168662|Guinea-Bissau
635491|NCT00168662|Bandim Health Project
635492|NCT00168662|Immunology
635493|NCT00168649|Vitamin A
635494|NCT00168649|Endotoxin
635495|NCT00168649|TNF-alfa
635496|NCT00168636|Vitamin A
635497|NCT00168636|Mortality
635498|NCT00168636|Morbidity
635499|NCT00168636|OPV
635500|NCT00168636|Sex
635501|NCT00168623|Vitamin A
635502|NCT00168623|Vaccines
635503|NCT00168623|Mortality
635504|NCT00168623|Morbidity
635505|NCT00168610|Vitamin A
635506|NCT00168610|BCG
635507|NCT00168610|Infant mortality
635508|NCT00168610|Morbidity
635509|NCT00168610|Low-income country
635510|NCT00168610|Mortality
635511|NCT00168597|Vitamin A
635512|NCT00168597|BCG
635513|NCT00168597|Infant mortality
635514|NCT00168597|Morbidity
635515|NCT00168597|Low-income country
635516|NCT00168584|Vitamin A
635517|NCT00168584|Mortality
635518|NCT00168584|Morbidity
635519|NCT00168584|Doses
635520|NCT00168584|OPV
635521|NCT00168571|Measles vaccine
635522|NCT00168571|Measles
635523|NCT00168571|Measles antibodies
635524|NCT00168571|Immunisation
635525|NCT00168571|Low income country
635526|NCT00168571|Guinea-Bissau
635527|NCT00168571|Bandim Health Project
635528|NCT00168571|Measles antibody level
635529|NCT00168558|Non-specific effects of vaccines
635530|NCT00168558|Infant mortality
635531|NCT00168558|Child mortality
635532|NCT00168558|Mortality
635533|NCT00168558|Morbidity
635534|NCT00168558|Diphtheria-tetanus-pertussis vaccine
635535|NCT00168558|Measles vaccine
635536|NCT00168558|Measles
635537|NCT00168558|Immunisation
635538|NCT00168558|Low income country
635539|NCT00168558|Guinea-Bissau
635540|NCT00168558|Bandim Health Project
635541|NCT00168558|Immunology
635542|NCT00168545|Non-specific effects of vaccines
635543|NCT00168545|Immunology
635544|NCT00168545|Cytokines
635545|NCT00168545|Infant mortality
635546|NCT00168545|Child mortality
635547|NCT00168545|Mortality
635548|NCT00168545|Morbidity
635549|NCT00168545|Diphtheria-tetanus-pertussis vaccine
635550|NCT00168545|Measles vaccine
635551|NCT00168545|Measles
635552|NCT00168545|Immunisation
635553|NCT00168545|Low income country
635554|NCT00168545|Guinea-Bissau
635555|NCT00168545|Bandim Health Project
635679|NCT00168038|Thrombocytopenia
635556|NCT00168545|Immunology of measles and DTP vaccination
635557|NCT00168532|Prophylactic antibiotics
635558|NCT00168532|Measles
635559|NCT00168532|Pneumonia
635560|NCT00168532|Post-measles pneumonia
635561|NCT00168532|Low income country
635562|NCT00168532|Guinea-Bissau
635563|NCT00168532|Bandim Health Project
635564|NCT00168519|Diabetes Mellitus, Type 2
635565|NCT00168519|Blood Glucose
635566|NCT00168519|Exercise
635567|NCT00168519|Muscle Contraction
635568|NCT00168519|Nitric Oxide
635569|NCT00168519|Nitrates
635570|NCT00168506|panic disorder
635571|NCT00168506|cardiac risk
635572|NCT00168493|Major Depression
635573|NCT00168493|Cardiac disease
635574|NCT00168402|Axillary Hyperhidrosis
635575|NCT00168376|Transcranial Magnetic Stimulation
635576|NCT00168376|Depression
635577|NCT00166348|Cognitive Rehabilitation
635578|NCT00166322|IBZM-SPECT
635579|NCT00166322|Amphetamine Challenge
635580|NCT00166322|Schizophrenia
635581|NCT00166322|dopaminergic neurotransmission
635582|NCT00166322|Persons at risk for the development of schizophrenia
635583|NCT00166322|healthy subjects
635584|NCT00166309|Hemophilia A
635585|NCT00166309|Inhibitors
635586|NCT00166296|Major depressive disorder, chemically induced.
635587|NCT00166296|Peginterferon alfa-2a.
635588|NCT00166296|Escitalopram.
635589|NCT00166296|Chronic hepatitis C, psychology.
635590|NCT00166296|Prophylactic treatment.
635591|NCT00166283|memory
635592|NCT00166283|learning
635593|NCT00166283|Multiple Sclerosis
635594|NCT00166283|Cognition
635595|NCT00166283|treatment
635596|NCT00166283|therapy
635597|NCT00166270|Fibroids
635598|NCT00166270|ExAblate
635599|NCT00166270|MrgFus
635600|NCT00166270|Uterine Fibroids
635601|NCT00166257|Paradoxical embolism, Patent foramen ovale,
635602|NCT00166244|Mycophenolate mofetil
635603|NCT00166244|Therapeutic Drug Monitoring
635604|NCT00166244|Adult kidney transplantation
635605|NCT00166244|Paediatric kidney transplantation
635606|NCT00166231|Innocent heart murmurs
635607|NCT00166231|Chest pain
635608|NCT00166231|pediatric Cardiology
635609|NCT00166231|Somatization
635610|NCT00166231|life stress
635611|NCT00166218|pediatrics
635612|NCT00166218|cardiac defects
635613|NCT00166205|Obesity, Morbid
635614|NCT00166205|Obesity
635615|NCT00166205|Body Weight
635616|NCT00166192|Melasma
635617|NCT00166192|Jessner's solution
635618|NCT00166192|Trichloroacetic acid (TCA)
635619|NCT00168311|Transcranial Magnetic Stimulation
635620|NCT00168311|Schizophrenia
635621|NCT00168311|Negative Symptoms
635622|NCT00168285|Exercise
635623|NCT00168285|Pulmonary rehabilitation
635624|NCT00168285|Idiopathic pulmonary fibrosis
635625|NCT00168285|Connective tissue disorders
635626|NCT00168272|Transcranial Magnetic Stimulation
635627|NCT00168272|Depression
635628|NCT00168259|Treatment Naive
635629|NCT00168259|HIV
635630|NCT00168246|HIV
635631|NCT00168233|Treatment Naive
635632|NCT00168233|HIV
635633|NCT00168220|Treatment Experienced
635634|NCT00168220|HIV
635635|NCT00168207|Treatment Experienced
635636|NCT00168207|HIV
635637|NCT00168194|HIV
635638|NCT00168181|salagen
635639|NCT00168181|gland transfer
635640|NCT00168181|randomized
635641|NCT00168181|xerostomia
635642|NCT00168168|G-CSF
635643|NCT00168168|Filgrastim
635644|NCT00168168|Engraftment time
635645|NCT00168168|Autologus transplant
635646|NCT00168155|resectable liver metastases
635647|NCT00168155|colorectal adenocarcinoma
635648|NCT00168155|survival
635649|NCT00168155|neoadjuvant chemotherapy
635650|NCT00168142|Helical tomotherapy
635651|NCT00168142|Megavoltage imaging
635652|NCT00168129|tomotherapy
635653|NCT00168129|bone metastases
635654|NCT00168129|radiotherapy
635655|NCT00168129|intensity modulated
635656|NCT00168116|nasopharynx
635657|NCT00168116|xerostomia
635658|NCT00168116|prevention
635659|NCT00168103|C1 Inhibitor
635660|NCT00168103|Hereditary angioedema
635661|NCT00168103|Acute HAE attack
635662|NCT00168090|von Willebrand Factor
635663|NCT00168090|Blood Coagulation Disorders
635664|NCT00168090|Factor VIII
635665|NCT00168077|Prothrombin Complex Concentrate
635666|NCT00168077|Anticoagulant reversal
635667|NCT00168064|Mycosis Fungoides
635668|NCT00168064|Nitrogen Mustard
635669|NCT00168064|Cutaneous T-Cell Lymphoma
635670|NCT00168064|CTCL - Mycosis Fungoides
635671|NCT00168051|Hemophilia A
635672|NCT00168038|Chronic Immune Thrombocytopenic Purpura
635673|NCT00168038|Chronic Idiopathic Thrombocytopenic Purpura
635674|NCT00168038|Werlhofs Disease
635675|NCT00168038|Autoimmune Thrombocytopenia
635676|NCT00168038|Immunglobulin Intravenous
635677|NCT00168038|Chronic ITP
635678|NCT00168038|Platelet count
635680|NCT00168025|Immunoglobulin Intravenous
635681|NCT00168025|Agammaglobulinemia
635682|NCT00168025|Hypogammaglobulinemia
635683|NCT00168025|Common variable immunodeficiency
635684|NCT00168025|Immunoglobulin G
635685|NCT00168025|Children
635686|NCT00168012|Immunoglobulin intravenous
635687|NCT00168012|Agammaglobulinemia
635688|NCT00168012|Hypogammaglobulinemia
635689|NCT00168012|Common variable immunodeficiency
635690|NCT00168012|Immunoglobulin G
635691|NCT00168012|Children
635692|NCT00167999|Bacterial Infections
635693|NCT00167986|Bacterial Infections
635694|NCT00167973|Hemophilia B
635695|NCT00167960|Bacterial Infections
635696|NCT00167947|Kidney
635697|NCT00167947|Transplant
635698|NCT00167934|Diabetes
635699|NCT00167934|Metabolic
635700|NCT00167895|osteoarthritis
635701|NCT00167895|knee
635702|NCT00167895|platelet concentrate
635703|NCT00167882|Crohn's disease
635704|NCT00167882|Ulcerative colitis
635705|NCT00167882|Inflammatory bowel disease
635706|NCT00167882|azathioprine
635707|NCT00167882|6-mercaptopurine
635708|NCT00167882|5-aminosalicylate
635709|NCT00167882|metabolism
635710|NCT00167869|hypertension
635711|NCT00167869|blood pressure
635712|NCT00167869|dairy peptides
635713|NCT00167869|bioactive peptides
635714|NCT00167869|randomized controlled trial
635715|NCT00167856|Burning pain
635716|NCT00167856|Clinical trial
635717|NCT00167856|Effexor
635718|NCT00167856|Pain
635719|NCT00167856|Spinal cord injury
635720|NCT00167856|Venalafaxine
635721|NCT00167856|Neuropathic Pain
635722|NCT00167843|Malaria
635723|NCT00167843|Anemia
635724|NCT00167843|Children
635725|NCT00167843|Gabon
635726|NCT00167843|Intermittent preventive treatment
635727|NCT00167830|Pediatric Overweight,
635728|NCT00167830|African American;
635729|NCT00167830|Adolescent;
635730|NCT00167830|Intervention,
635731|NCT00167830|Teasing;
635732|NCT00167830|Self-esteem
635733|NCT00167830|Quality of Life
635734|NCT00167830|Metabolic syndrome
635735|NCT00167830|Insulin resistance
635736|NCT00167830|Diabetes
635737|NCT00167830|Nutrition
635738|NCT00167830|Motivation
635739|NCT00167830|Culture
635740|NCT00167830|BMI
635741|NCT00167830|Cardiorespiratory fitness
635742|NCT00167830|Resistance Training
635743|NCT00167830|Compliance
635744|NCT00167817|Schizophrenia
635745|NCT00167817|Smoking
635746|NCT00167817|Metabolic
635747|NCT00167817|Health
635748|NCT00167817|Glucose
635749|NCT00167817|Lipids
635750|NCT00167804|Exposure Therapy
635751|NCT00167804|Post Traumatic Stress Disorder
635752|NCT00167804|Treatment Outcome
635753|NCT00167804|Veterans
635754|NCT00167804|Virtual Reality
635755|NCT00167791|transplant
635756|NCT00167791|desensitization
635757|NCT00167791|kidney transplant
635758|NCT00167778|Amputation
635759|NCT00167778|Amputee
635760|NCT00167778|Artificial limbs
635761|NCT00167778|Gait
635762|NCT00167778|Locomotion
635763|NCT00167778|Walking
635764|NCT00167765|stroke, ischemic
635765|NCT00167765|acute ischemic stroke
635766|NCT00166179|CAD
635767|NCT00166166|hyperlipidaemia
635768|NCT00166166|EDHF
635769|NCT00166166|FMD
635770|NCT00166153|cardiac transplantation
635771|NCT00166153|pediatrics
635772|NCT00166153|cardiology
635773|NCT00166153|drug metabolism
635774|NCT00166140|pediatrics
635775|NCT00166140|cardiac
635776|NCT00166140|surgery
635777|NCT00166127|heart failure
635778|NCT00166127|cardiac surgery
635779|NCT00166127|pharmacokinetics
635780|NCT00166127|pharmacodynamics
635781|NCT00166114|platelet function
635782|NCT00166114|childhood abuse
635783|NCT00166114|depression
635784|NCT00166114|antidepressants
635785|NCT00166114|immune function
635786|NCT00166114|stress response
635787|NCT00166101|pediatric
635788|NCT00166101|cardiac surgery
635789|NCT00166088|Oxidative Stress
635790|NCT00166088|Diet, Mediterranean
635791|NCT00166075|Suicidality
635792|NCT00166075|PTSD
635793|NCT00166075|depression
635794|NCT00166062|intimate partner violence
635795|NCT00166062|perpetration
635796|NCT00167739|Malaria
635797|NCT00167739|Quinine
635798|NCT00167739|Sulfadoxine-pyrimethamine
635799|NCT00167739|Gabon
635800|NCT00167713|Malaria
635801|NCT00167713|Fever
635802|NCT00167713|Ibuprofen
635803|NCT00167713|Gabon
635804|NCT00167700|atopic disease
635805|NCT00167700|probiotics
635806|NCT00167700|gut microbiota
635807|NCT00167700|allergy
635808|NCT00167700|nutrition
635809|NCT00167700|growth
635810|NCT00167700|allergic rhinitis
635811|NCT00167700|atopic sensitization
635812|NCT00167700|risk-markers of life-style related diseases
635813|NCT00167687|Alcoholism
635814|NCT00167687|Randomized Controlled Trial
635815|NCT00167674|breastmilk
635816|NCT00167674|HIV-1
635817|NCT00167674|antiretroviral
635818|NCT00167674|mother-to-child
635819|NCT00167674|transmission
635820|NCT00167661|living or deceased donor renal transplant recipient
635821|NCT00167635|Irritable Bowel Syndrome
635822|NCT00167635|Cognitive-behavioral intervention
635823|NCT00167635|Psychological distress
635824|NCT00167635|Quality of life
635825|NCT00167622|Guillain Barré
635826|NCT00167622|Mechanical ventilation, invasive
635827|NCT00167622|Mechanical ventilation, non invasive
635828|NCT00167622|Pneumonia
635829|NCT00167609|myotonic dystrophy
635830|NCT00167609|hypersomnia
635831|NCT00167609|dehydroepiandrosterone
635832|NCT00167596|near infrared spectroscopy
635833|NCT00167596|tissue oxygenation
635834|NCT00167596|organ dysfunction
635835|NCT00167596|mortality
635836|NCT00167583|Ocular Behcet`s disease
635837|NCT00167583|Panuveitis
635838|NCT00167583|Posterior Uveitis
635839|NCT00167583|Retinal vasculitis
635840|NCT00167583|Treatment
635841|NCT00167583|Interferon-alpha
635842|NCT00167583|Cyclosporin A
635843|NCT00167570|Artificial Limbs
635844|NCT00167570|Amputees
635845|NCT00167570|Computer-Aided Design
635846|NCT00167557|Liver Transplantation
635847|NCT00167544|Bronchopulmonary Dysplasia
635848|NCT00167544|Encephalomalacia
635849|NCT00167544|Brain injury
635850|NCT00167544|Neurosensory impairment
635851|NCT00167544|Corticosteroids
635852|NCT00167544|Anti-Inflammatory Agents
635853|NCT00167544|Extremely Low Birth Weight (ELBW) infants
635854|NCT00167544|Premature Birth
635855|NCT00167544|Magnetic Resonance Imaging
635856|NCT00167531|Stroke
635857|NCT00167531|health outcomes
635858|NCT00167531|physiotherapy
635859|NCT00167531|rehabilitation
635860|NCT00167531|treadmill
635861|NCT00167518|Diabetic macular oedema
635862|NCT00167518|Triamcinolone acetate
635863|NCT00167518|Intravitreal injection
635864|NCT00167518|Clinical trial
635865|NCT00167518|Laser treatment
635866|NCT00167505|adolescents
635867|NCT00167505|sexual health
635868|NCT00167505|HIV
635869|NCT00167505|STD
635870|NCT00167505|pregnancy prevention
635871|NCT00167505|abstinence education
635872|NCT00167505|HIV Seronegativity
635873|NCT00167505|human immunodeficiency virus
635874|NCT00167479|Bipolar Anxiety
635875|NCT00167479|Bipolar Disorder
635876|NCT00167479|Anxiety
635877|NCT00167479|Panic Disorder
635878|NCT00167479|Generalized Anxiety Disorder
635879|NCT00167479|GAD
635880|NCT00167479|Risperidone
635881|NCT00167479|Double-Blind
635882|NCT00167479|Placebo Controlled
635883|NCT00167466|periodontal disease
635884|NCT00167466|toothbrush
635885|NCT00167466|titanium dioxide semiconductor
635886|NCT00167466|mild-to-moderate periodontal disease
635887|NCT00167466|adult patients 18 to 70 years of age
635888|NCT00167453|Nervous system disease
635889|NCT00167453|movement disorder
635890|NCT00167453|exercise
635891|NCT00167453|balance
635892|NCT00167453|education
635893|NCT00167440|cardiac index
635894|NCT00167440|cardiac output
635895|NCT00167440|indwelling central venous catheter
635896|NCT00167440|indwelling arterial catheter
635897|NCT00167414|conformal radiotherapy
635898|NCT00167388|anemia
635899|NCT00167388|prematurity
635900|NCT00167388|blood flow velocity
635901|NCT00167388|superior mesenteric artery
635902|NCT00167388|intestinal blood flow in premature infants
635903|NCT00167375|Insomnia
635904|NCT00167375|polysomnography
635905|NCT00167375|sleep onset
635906|NCT00167375|time series analysis
635907|NCT00167362|Schizophrenia
635908|NCT00167362|Cognition
635909|NCT00167362|Enhancement
635910|NCT00167362|Randomized
635911|NCT00167349|cardiac surgery
635912|NCT00167349|cardiopulmonary bypass
635913|NCT00167349|cytokines
635914|NCT00167336|Computer
635915|NCT00167336|Kinematics
635916|NCT00167336|Instrument development
635917|NCT00167336|Reliability
635918|NCT00167336|Cumulative Trauma Disorder
635919|NCT00167323|Bipolar
635920|NCT00167323|Alcoholism
635921|NCT00167310|Omega-3 fatty acids
635922|NCT00167310|Statins
635923|NCT00167310|Antipsychotic drug
635924|NCT00167310|Antidepressant drug
635925|NCT00167310|Antimanic drug
635926|NCT00167310|Placebos
635927|NCT00167310|Double-blind method
635928|NCT00167310|Bipolar (depressed phase)
635929|NCT00167297|atomoxetine
635930|NCT00167297|cannabis dependence
635931|NCT00167297|treatment
636058|NCT00166855|multiple myeloma
635932|NCT00167284|chronic care model, diabetes, community, diabetes education
635933|NCT00167271|Cognitive therapy
635934|NCT00167245|Topiramate
635935|NCT00167245|alcoholism
635936|NCT00167245|cocaine dependence
635937|NCT00167232|naltrexone
635938|NCT00167232|cocaine dependence
635939|NCT00167232|alcohol dependence
635940|NCT00167232|psychosocial treatment
635941|NCT00167219|Stem cell transplant
635942|NCT00167219|long term survival
635943|NCT00167219|retinoic acid
635944|NCT00167206|Stem Cell Transplant
635945|NCT00167206|Thymic Shielding
635946|NCT00167206|Total Body Irradiation
635947|NCT00167206|Chemotherapy
635948|NCT00167180|donor lymphocyte infusions
635949|NCT00167180|BMT
635950|NCT00167180|bone marrow transplant
635951|NCT00167167|Donor Lymphocyte Infusion
635952|NCT00167167|relapse
635953|NCT00167167|post-transplant
635954|NCT00167154|suicidality
635955|NCT00167154|antipsychotic
635956|NCT00167154|antidepressant
635957|NCT00167154|treatment
635958|NCT00167141|male fertility
635959|NCT00167141|semen parameters
635960|NCT00167128|Auditory Processing Disorder
635961|NCT00167128|speech-in-noise intelligibility
635962|NCT00167115|Alcohol
635963|NCT00167115|Type 2 diabetes mellitus
635964|NCT00167115|Plama glucose
635965|NCT00167115|HDL cholesterol
635966|NCT00167102|Alopecia Areata
635967|NCT00167089|Stroke
635968|NCT00167089|Hemiplegia
635969|NCT00167089|Gait
635970|NCT00167089|Ambulation training
635971|NCT00167089|Neurologic physical therapy
635972|NCT00167076|Stroke
635973|NCT00167076|Foot pressure
635974|NCT00167076|Walking speed
635975|NCT00167076|Gait
635976|NCT00167063|Stroke
635977|NCT00167063|Fall
635978|NCT00167063|Fall prediction
635979|NCT00167063|Clinical manifestations
635980|NCT00167063|Frequent faller
635981|NCT00167037|Hemiplegia
635982|NCT00167037|Waist pulling perturbation
635983|NCT00167037|Reactive balance strategy
635984|NCT00167037|Trajectory of center of pressure
635985|NCT00167037|Parameters of center of pressure
635986|NCT00167024|prostate cancer, DNA repair gene, genetic polymorphism
635987|NCT00166049|Heart failure
635988|NCT00166049|Family partnership
635989|NCT00166049|Patient family education
635990|NCT00166023|pediatric
635991|NCT00166023|cardiology
635992|NCT00166010|drug
635993|NCT00166010|pediatrics
635994|NCT00166010|cardiac
635995|NCT00166010|Children with Cardiac Ventricular Failure
635996|NCT00165997|pediatrics
635997|NCT00165997|cardiology
635998|NCT00165997|Radiofrequency ablation
635999|NCT00165997|structurally normal heart
636000|NCT00165984|cardiac
636001|NCT00165984|hypoplastic
636002|NCT00165984|pediatric
636003|NCT00165984|hypoplastic heart ventricle
636004|NCT00165971|Cognitive decline
636005|NCT00165971|Inflammation
636006|NCT00165971|Monitoring
636007|NCT00165971|Recovery
636008|NCT00165971|Bispectral index
636009|NCT00165958|Epidermal cyst
636010|NCT00165958|Epidermoid cyst
636011|NCT00165958|Sebaceous cyst
636012|NCT00165958|Pilar cyst
636013|NCT00165945|pediatric, cardiology, diagnostic imaging using MRI
636014|NCT00165932|tachycardia
636015|NCT00165932|pediatrics
636016|NCT00165919|Hepatitis C
636017|NCT00165919|HIV
636018|NCT00165919|Immunopathogenesis
636019|NCT00165919|HIV-1
636020|NCT00165906|neonates
636021|NCT00165906|cardiac
636022|NCT00165906|non-cardiac
636023|NCT00165906|surgery
636024|NCT00165906|anticoagulation
636025|NCT00165893|low back pain
636026|NCT00165893|DDD
636027|NCT00165841|non-erosive symptomatic GERD
636028|NCT00165841|GERD
636029|NCT00165828|Epilepsy
636030|NCT00165802|Cancer
636031|NCT00165802|malignant tumors
636032|NCT00167011|coronary artery
636033|NCT00166998|Breast neoplasms
636034|NCT00166998|diagnosis
636035|NCT00166985|endometrial cancer, MRI, Doppler sonography, angiogenesis
636036|NCT00166972|metastasis, survival, malignancy, female, trophinin
636037|NCT00166959|Stroke patients
636038|NCT00166959|Falls
636039|NCT00166959|Reliability
636040|NCT00166959|Validity
636041|NCT00166933|minimal erythema dose
636042|NCT00166933|UVB
636043|NCT00166933|normal
636044|NCT00166907|Stroke
636045|NCT00166907|Balance
636046|NCT00166907|Proactive control
636047|NCT00166907|Reactive control
636048|NCT00166907|Recovery
636049|NCT00166907|Training
636050|NCT00166907|Fall
636051|NCT00166894|pleural effusion
636052|NCT00166894|TREM-1
636053|NCT00166881|Combination, Chemotherapy, Inoperable Gastric Cancer
636054|NCT00166868|Biliary atresia, cholangitis, probiotics, prophylaxis
636055|NCT00166855|angiogenesis
636056|NCT00166855|bone marrow perfusion
636057|NCT00166855|dynamic MRI
636059|NCT00166855|prognosis
636060|NCT00166842|Pharmacokinetics
636061|NCT00166842|Sirolimus
636062|NCT00166842|Cyclosporine
636063|NCT00166842|Tacrolimus
636064|NCT00166842|Immunosuppressive Agents
636065|NCT00166842|Immunosuppression
636066|NCT00166842|Transplantation
636067|NCT00166842|Kidney Transplantation
636068|NCT00166829|Tacrolimus
636069|NCT00166829|Sirolimus
636070|NCT00166829|Mycophenolic acid
636071|NCT00166829|Immunosuppressive Agents
636072|NCT00166829|Immunosuppression
636073|NCT00166829|Kidney Transplantation
636074|NCT00166829|Transplantation
636075|NCT00166816|Sirolimus
636076|NCT00166816|Tacrolimus
636077|NCT00166816|Cyclosporine
636078|NCT00166816|Pharmacokinetics
636079|NCT00166816|Immunosuppressive Agents
636080|NCT00166816|Immunosuppression
636081|NCT00166816|Kidney Transplantation
636082|NCT00166816|Transplantation
636083|NCT00166803|Diabetes Mellitus, PPARγ agonist, FDG PET
636084|NCT00166790|Human Chorionic Gonadotropin
636085|NCT00166790|Dual Polarization Interferometry,
636086|NCT00166790|Gestational Trophoblastic Neoplasms
636087|NCT00166764|Psychiatric Disorders
636088|NCT00166764|Evaluation of Mental Health Index
636089|NCT00166751|Videofluoroscopic examination,
636090|NCT00166751|ultrasound
636091|NCT00166751|laryngeal elevation
636092|NCT00166751|dysphagia
636093|NCT00166738|Schizophrenia
636094|NCT00166738|multiple genes
636095|NCT00166738|array-comparative genomic hybridization (CGH)
636096|NCT00166738|genomic DNA
636097|NCT00166738|Chinese Han People
636098|NCT00166725|HRPC
636099|NCT00166725|octreotide LAR
636100|NCT00166725|CgA
636101|NCT00166712|Kidney Transplant
636102|NCT00166712|Living Donor Kidney Transplant Recipients
636103|NCT00166699|ultrasonography
636104|NCT00166699|obesity
636105|NCT00166699|Cesarean Section
636106|NCT00166699|Anesthesia
636107|NCT00166699|Epidural
636108|NCT00166686|Cancer
636109|NCT00166686|Clonidine
636110|NCT00166686|Neurocognitive sequelae
636111|NCT00166673|Diabetes Mellitus, Insulin-Dependent
636112|NCT00166673|Type 1 Diabetes
636113|NCT00166673|Continuous Glucose Monitoring Devices
636114|NCT00166673|Electronic Data Collection
636115|NCT00166660|Preterm infants
636116|NCT00166660|Developmental Care
636117|NCT00166660|NIDCAP
636118|NCT00166660|Fetal Growth Restriction
636119|NCT00166660|Neurobehavior
636120|NCT00166660|APIB
636121|NCT00166660|MRI
636122|NCT00166660|EEG
636123|NCT00166660|Parent Stress
636124|NCT00166647|Cancer
636125|NCT00166647|Chemotherapy
636126|NCT00166647|Hematological disorder
636127|NCT00166634|Hypertension
636128|NCT00166634|ABPM
636129|NCT00166634|Ambulatory Blood Pressure Monitoring
636130|NCT00166621|Autism
636131|NCT00166621|Neuroplasticity
636132|NCT00166608|acetaminophen toxicity
636133|NCT00166608|liver damage
636134|NCT00166608|tylenol overdose
636135|NCT00166595|Risperidone
636136|NCT00166595|Autism
636137|NCT00166595|Pervasive Developmental Disorder (PDD)
636138|NCT00166582|pediatric asthma, medication adherence, adolescents
636139|NCT00166569|Polycystic Ovary Syndrome
636140|NCT00166543|locally advanced breast carcinoma
636141|NCT00166543|locally recurrent inoperable breast carcinoma
636142|NCT00166543|progressive metastatic breast carcinoma
636143|NCT00166517|Gastrointestinal Rotavirus
636144|NCT00166439|C04.557.386
636145|NCT00166387|Hemophilia
636146|NCT00166387|Inhibitors
636147|NCT00166361|Extrinsic ureteral obstruction
636148|NCT00166361|Memokath 051 Ureteral Stent
636149|NCT00166361|JJ Stent
636150|NCT00166361|Stent
636151|NCT00165763|Vascular Dementia
636152|NCT00165737|Dementia cerebrovascular disease
636153|NCT00165698|Postmenopausal
636154|NCT00165698|osteoporosis
636155|NCT00165672|24-hour esophageal pH monitoring
636156|NCT00165672|non-erosive gastroesophageal reflux disease
636157|NCT00165672|NERD
636158|NCT00165672|proton pump inhibitor
636159|NCT00165672|rabeprazole
636160|NCT00165646|non-erosive gastroesophageal reflux disease
636161|NCT00165646|NERD
636162|NCT00165646|proton pump inhibitor
636163|NCT00165646|rabeprazole
636164|NCT00165633|Hepatocellular
636165|NCT00165633|Carcinoma
636166|NCT00165633|Hepatitis C Virus
636167|NCT00165633|Hepatitis B Virus
636168|NCT00165633|recurrence
636169|NCT00165633|Vitamin K2
636170|NCT00165633|E0167
636171|NCT00165594|gastric cancer
636172|NCT00165594|Phase I
636173|NCT00165594|Phase IIa
636174|NCT00165594|E7070
636175|NCT00165594|Indisulam
636176|NCT00165594|Pharmacogenomic
636177|NCT00165594|2C19
636178|NCT00165581|Intracavitary brachytherapy
636179|NCT00165581|radiation therapy
636180|NCT00165581|Stage I breast cancer
636181|NCT00165581|Stage II breast cancer
636182|NCT00165568|Positron emission tomography
636183|NCT00165568|PET
636184|NCT00165568|bevacizumab
636185|NCT00165568|5fluorouracil
636186|NCT00165568|Metastatic colorectal cancer
636187|NCT00165555|cisplatin
636188|NCT00165555|pleurectomy
636189|NCT00165555|decortication
636190|NCT00165555|heated cisplatin
636191|NCT00165542|A-protein level
636192|NCT00165542|brain tumor
636193|NCT00165516|Extrapleural pneumonectomy
636194|NCT00165516|cisplatin
636195|NCT00165516|heated cisplatin
636196|NCT00165503|pleurectomy
636197|NCT00165503|decortication
636198|NCT00165503|cisplatin
636199|NCT00165503|ALIMTA
636200|NCT00165490|adenocarcinoma of esophagus
636201|NCT00165490|squamous cell carcinoma of esophagus
636202|NCT00165490|combination chemotherapy
636203|NCT00165490|cisplatin
636204|NCT00165490|irinotecan
636205|NCT00165490|radiation therapy
636206|NCT00165490|resectable esophageal cancer
636207|NCT00165477|Glioblastoma
636208|NCT00165477|Gliosarcoma
636209|NCT00165477|Malignant Gliomas
636210|NCT00165477|Radiation Therapy
636211|NCT00165477|IMiD
636212|NCT00165477|Lenalidomide
636213|NCT00165464|Esophageal Cancer
636214|NCT00165464|Gastric Cancer
636215|NCT00165464|GE Junction
636216|NCT00165464|Cisplatin
636217|NCT00165464|Taxotere
636218|NCT00165464|CPT-11
636219|NCT00165464|Irinotecan
636220|NCT00165451|Relapsed tumors
636221|NCT00165451|Progressive Poor Prognosis Tumors
636222|NCT00165451|Thalidomide
636223|NCT00165451|Celecoxib
636224|NCT00165451|Etoposide
636225|NCT00165451|Cyclophosphamide
636226|NCT00165438|Pulmonary function
636227|NCT00165438|Bleomycin-based chemotherapy
636228|NCT00165438|mediastinal irradiation
636229|NCT00165425|Cardiac screening
636230|NCT00165425|Cardiac stress test
636231|NCT00165425|Echocardiogram
636232|NCT00165412|Breast screening
636233|NCT00165412|Breast MRI
636234|NCT00165412|Mammogram
636235|NCT00165412|Mammography
636236|NCT00165399|Prostate cancer
636237|NCT00165399|PSA level
636238|NCT00165399|docetaxel
636239|NCT00165399|estramustine
636240|NCT00165399|hormone therapy
636241|NCT00165399|androgen withdrawal
636242|NCT00165386|MRI-guided bone marrow biopsy
636243|NCT00165373|pediatric solid tumors
636244|NCT00165373|rhEndostatin
636245|NCT00165360|low-grade glioma
636246|NCT00165360|astrocytoma
636247|NCT00165360|oligodendroglioma
636248|NCT00165360|oligoastrocytoma
636249|NCT00165360|temozolomide
636250|NCT00165360|mixed oligoastrocytoma
636251|NCT00165347|Multiple myeloma
636252|NCT00165347|PTK
636253|NCT00165347|Relapsed multiple myeloma
636254|NCT00165347|Refractory Multiple myeloma
636255|NCT00165347|Myeloma
636256|NCT00165334|Non-small cell lung cancer
636257|NCT00165334|Cetuximab
636258|NCT00165334|Vinorelbine
636259|NCT00165334|Navelbine
636260|NCT00165334|Previously untreated lung cancer
636261|NCT00165308|Hodgkin's disease
636262|NCT00165308|breast cancer prevention
636263|NCT00165308|tamoxifen
636264|NCT00165295|sildenafil citrate
636265|NCT00165295|Viagra
636266|NCT00165295|Waldenstrom's macroglobulinemia
636267|NCT00165282|Meditation
636268|NCT00165282|Mindfulness meditation
636269|NCT00165282|Bone Marrow Transplant
636270|NCT00165282|Stem Cell Transplant
636271|NCT00165269|Hodgkin's Disease Stage IA-IIA
636272|NCT00165269|mantle irradiation
636273|NCT00165256|Ductal carcinoma in situ
636274|NCT00165256|DCIS
636275|NCT00165256|wide excision
636276|NCT00165243|Axillary Dissection
636277|NCT00165243|Tangential Radiation
636278|NCT00165243|Breast Cancer
636279|NCT00165230|thalidomide
636280|NCT00165230|temodar
636281|NCT00165230|metastatic neuroendocrine tumor
636282|NCT00165230|unresectable neuroendocrine tumor
636283|NCT00165217|capecitabine
636284|NCT00165217|thalidomide
636285|NCT00165217|colorectal cancer
636286|NCT00165204|Tibolone
636287|NCT00165204|High risk women
636288|NCT00165204|Oophorectomy
636289|NCT00165204|Breast Density
636290|NCT00165204|Bone Density
636291|NCT00165191|doxorubicin
636292|NCT00165191|cisplatin
636293|NCT00165191|5-fluorouracil
636294|NCT00165191|stomach cancer
636295|NCT00165191|esophagus cancer
636296|NCT00165178|Acute lymphoblastic leukemia in children
636297|NCT00165178|High Risk ALL
636298|NCT00165178|Standard Risk ALL
636299|NCT00165178|E. coli asparaginase
636300|NCT00165152|Genetic testing
636301|NCT00165152|BRCA1 gene
636302|NCT00165152|BRCA2 gene
636303|NCT00165152|Counseling interventions
636304|NCT00165152|Genetic counseling
636305|NCT00165139|Stem cell transplant
636306|NCT00165139|High-risk pediatric tumors
636307|NCT00165126|dosimetric analysis
636308|NCT00165126|vaginal cuff brachytherapy
636309|NCT00165100|DAT
636310|NCT00165100|imaging modality
636311|NCT00165087|childhood ALL
636312|NCT00165087|standard risk
636313|NCT00165087|high risk
636314|NCT00165087|infant/high risk
636315|NCT00165074|Prematurity
636316|NCT00165074|Lung Disease
636317|NCT00165074|Hyaline Membrane
636318|NCT00165074|Surfactant
636319|NCT00165035|Percutaneous coronary intervention (PCI)
636320|NCT00165035|Drug eluting stent (DES)
636321|NCT00165009|Bleeding Peptic Ulcer
636322|NCT00165009|Endoscopic treatment
636323|NCT00164996|upper endoscopy
636324|NCT00164996|local pharyngeal anaesthesia
636325|NCT00164996|ultrathin endoscope
636326|NCT00164944|Colonoscopy
636327|NCT00164944|First degree relatives
636328|NCT00164931|Peptic ulcer hemorrhage
636329|NCT00164931|Omeprazole
636330|NCT00164931|Scheduled second endoscopy
636331|NCT00164905|Peptic ulcer hemorrhage
636332|NCT00164905|Doppler ultrasound
636333|NCT00164879|Obstructing
636334|NCT00164879|Left-sided
636335|NCT00164879|Colorectal neoplasms
636336|NCT00164879|Obstructing left-sided colorectal cancers
636337|NCT00164866|Peptic ulcer
636338|NCT00164866|IVPPI prior endoscopy
636339|NCT00164840|GERD
636340|NCT00164788|24 hours pH monitoring
636341|NCT00164775|Functional dyspepsia, refractory, antidepressant
636342|NCT00164762|HIV
636343|NCT00164762|drug resistance
636344|NCT00164762|nevirapine
636345|NCT00164762|anti-retroviral drugs
636346|NCT00164762|mother-to-child transmission
636347|NCT00164762|Treatment Naive
636348|NCT00164762|pregnancy
636349|NCT00164749|dementia
636350|NCT00164749|cognition
636351|NCT00164749|memory
636352|NCT00164749|neurodegenerative disease
636353|NCT00164749|brain
636354|NCT00164736|HIV
636355|NCT00164736|Clinical trial
636356|NCT00164736|breastfeeding
636357|NCT00164736|mother-to-child-transmission
636358|NCT00164736|nutrition
636359|NCT00164736|HIV Seronegativity
636360|NCT00164723|Capsule Endoscopy
636361|NCT00164710|antimalarials
636362|NCT00164697|Child Development
636363|NCT00164697|Parenting
636364|NCT00164697|Child Rearing
636365|NCT00164697|Parent-Child Relations
636366|NCT00164684|batterers
636367|NCT00164684|prevention
636368|NCT00164684|African American
636369|NCT00164684|Latino
636370|NCT00164671|Male condoms
636371|NCT00164671|Female condoms
636372|NCT00164671|Self-efficacy
636373|NCT00164658|family history
636374|NCT00164658|familial risk
636375|NCT00164658|behavior change
636376|NCT00164645|Emotional outcomes
636377|NCT00164645|health outcomes
636378|NCT00164645|traumatic brain injury
636379|NCT00164645|caregiving
636380|NCT00164619|controlled clinical trial
636381|NCT00164619|behavioral intervention
636382|NCT00164619|prevention intervention
636383|NCT00164606|child maltreatment
636384|NCT00164606|child abuse
636385|NCT00164606|prevention
636386|NCT00164593|Youth Violence
636387|NCT00164593|Prevention
636388|NCT00164580|Homosexuality, Male
636389|NCT00164580|Adolescents
636390|NCT00164580|Minority Groups
636391|NCT00164580|Community Participation
636392|NCT00164580|Community Surveys
636393|NCT00164580|HIV Seronegativity
636394|NCT00164580|HIV
636395|NCT00164567|partner abuse
636396|NCT00164567|screening
636397|NCT00164567|intimate partner violence
636398|NCT00164554|treatment
636399|NCT00164554|control
636400|NCT00164541|dating violence
636401|NCT00164541|violence against women
636402|NCT00164515|obesity, mobility limitations, women, physical activity
636403|NCT00164463|tuberculosis
636404|NCT00164463|TB
636405|NCT00164450|tuberculosis
636406|NCT00164450|TB
636407|NCT00164450|pharmacokinetics
636408|NCT00164450|children
636409|NCT00164437|screening
636410|NCT00164437|community healt education
636411|NCT00164437|decision making
636412|NCT00164437|computer-assisted decision making
636413|NCT00164424|HSV2
636414|NCT00164424|genital ulcer
636415|NCT00164424|HIV
636416|NCT00164424|South Africa
636417|NCT00164424|Treatment
636418|NCT00164424|Acyclovir
636419|NCT00164424|Prevention
636420|NCT00164411|Diptheria-Tetanus vaccine
636421|NCT00164411|Pneumococcal vaccine
636422|NCT00164411|Adverse events following vaccination
636423|NCT00164411|Immunization
636424|NCT00164411|Immunogenicity
636425|NCT00164398|HIV
636426|NCT00164385|HIV/AIDS
636427|NCT00164372|IV Drug users
636428|NCT00164372|HIV
636429|NCT00164372|hepatitis C virus
636430|NCT00164372|HIV Seronegativity
636431|NCT00164359|malaria, falciparum
636432|NCT00164359|antimalarials
636433|NCT00164346|fetal alcohol syndrome (FAS)
636434|NCT00164346|alcohol-related neurodevelopmental disorder (ARND)
636435|NCT00164281|TB
636436|NCT00164281|Tuberculosis
636437|NCT00164281|INH
636438|NCT00164281|Isoniazid
636439|NCT00164281|Preventive therapy
636440|NCT00164281|HIV
636441|NCT00164281|AIDS
636442|NCT00164281|Botswana
636443|NCT00164281|LTBI
636444|NCT00164281|Latent TB Infection
636445|NCT00164268|Intimate partner violence
636446|NCT00164268|Sexual violence
636447|NCT00164268|Cultural intervention
636448|NCT00164268|Native Hawaiian
636449|NCT00164255|malaria
636450|NCT00164255|birthweight
636451|NCT00164255|placental malaria
636452|NCT00164255|intermittent protective treatment
636453|NCT00164255|sulfadoxine/ pyrimethamine
636454|NCT00164255|artesuate
636455|NCT00164255|combination therapy
636456|NCT00164255|Pregnancy
636457|NCT00164242|Tardive dyskinesia
636458|NCT00164242|Galantamine
636459|NCT00164242|Cholinesterase inhibitors
636460|NCT00164229|treatment
636461|NCT00164229|control
636462|NCT00164216|malaria
636463|NCT00164216|combination therapy
636464|NCT00164216|mefloquine
636465|NCT00164216|artesunate
636466|NCT00164216|Peru
636467|NCT00164216|malaria, uncomplicated
636468|NCT00164190|Myocardial Infarction
636469|NCT00164190|Thrombolysis
636470|NCT00164190|Angioplasty
636471|NCT00164190|ST Elevation Myocardial Infarction
636472|NCT00164177|virtual colonoscopy
636473|NCT00164177|colonoscopy preparation
636474|NCT00164177|bowel prep
636475|NCT00164164|colonoscopy preparation
636476|NCT00164164|prep
636477|NCT00164151|colonoscopy preparation
636478|NCT00164151|prep
636479|NCT00164138|Incontinence
636480|NCT00164138|physiotherapy
636481|NCT00164138|treatment
636482|NCT00164138|pelvic floor muscle function
636483|NCT00164138|coughing
636484|NCT00164138|forced expirations
636485|NCT00164138|lung disease
636486|NCT00164112|Cooperstown Cocktail
636487|NCT00164112|Drug Metabolizing Enzymes
636488|NCT00164112|Drug Interactions
636489|NCT00164112|Phenotyping
636490|NCT00164099|Coronary Artery Bypass
636491|NCT00164099|Postoperative Complications
636492|NCT00164099|Probiotics
636493|NCT00164099|Surgical Wound infection
636494|NCT00164099|cystitis
636495|NCT00164099|bacteremia
636496|NCT00164099|pneumonia
636497|NCT00164099|Enterocolitis, Pseudomembranous
636498|NCT00164073|HCV and microarray
636499|NCT00164073|HCV
636500|NCT00164060|HCV
636501|NCT00164060|HIV co-infection
636502|NCT00164047|Nitrous Oxide
636503|NCT00164047|Anaesthesia
636504|NCT00164047|Anesthesia
636505|NCT00164047|Recovery
636506|NCT00164047|Quality
636507|NCT00164034|Trauma
636508|NCT00164034|Wounds
636509|NCT00164034|Injuries
636510|NCT00164021|gastroesophageal reflux, gastric reflux, acid reflux, lung transplantation, physiotherapy, anti-reflux medication
636511|NCT00163995|Chronic Liver Disease
636512|NCT00163514|Allergy
636513|NCT00163514|Perennial Allergic Rhinitis
636514|NCT00163514|Allergic Rhinitis
636515|NCT00163514|Hay Fever
636516|NCT00163501|Allergy
636517|NCT00163501|Perennial Allergic Rhinitis
636518|NCT00163501|Allergic Rhinitis
636519|NCT00163501|Hay Fever
636520|NCT00163488|Allergy
636521|NCT00163488|Perennial Allergic Rhinitis
636522|NCT00163488|Allergic Rhinitis
636523|NCT00163488|Hay Fever
636524|NCT00163475|Asthma
636525|NCT00163475|Roflumilast
636526|NCT00163462|Asthma
636527|NCT00163462|Ciclesonide
636528|NCT00163462|Child
636529|NCT00163462|Fluticasone propionate
636530|NCT00163462|Pediatric
636531|NCT00163449|Asthma
636532|NCT00163449|Ciclesonide
636533|NCT00163449|Child
636534|NCT00163449|Pediatric
636535|NCT00163436|Asthma
636536|NCT00163436|Ciclesonide
636537|NCT00163423|Asthma
636538|NCT00163423|Ciclesonide
636539|NCT00163423|Fluticasone propionate
636540|NCT00163410|Asthma
636541|NCT00163410|Ciclesonide
636542|NCT00163410|Child
636543|NCT00163410|Fluticasone propionate
636544|NCT00163410|Pediatric
636545|NCT00163397|Asthma
636546|NCT00163397|Ciclesonide
636547|NCT00163397|Budesonide
636548|NCT00163384|Asthma
636549|NCT00163384|Ciclesonide
636550|NCT00163384|Budesonide
636551|NCT00163371|Asthma
636552|NCT00163371|Ciclesonide
636553|NCT00163371|Child
636554|NCT00163371|Fluticasone propionate
636555|NCT00163371|HPA-axis
636556|NCT00163371|Pediatric
636557|NCT00163371|Linear growth rate
636558|NCT00163358|Asthma
636559|NCT00163358|Ciclesonide
636560|NCT00163358|Fluticasone propionate
636561|NCT00163358|Salmeterol
636562|NCT00163345|Asthma
636563|NCT00163345|Ciclesonide
636564|NCT00163345|Small Airways
636565|NCT00163332|Asthma
636566|NCT00163332|Ciclesonide
636567|NCT00163332|Fluticasone propionate
636568|NCT00163319|Asthma
636569|NCT00163319|Ciclesonide
636570|NCT00163319|Fluticasone propionate
636571|NCT00163306|Gastroesophageal Reflux
636572|NCT00163306|Gastroesophageal Reflux Disease
636573|NCT00163306|Pantoprazole
636574|NCT00163293|Asthma
636575|NCT00163293|Ciclesonide
636576|NCT00163293|Exacerbation
636577|NCT00163982|HVPG > 12 mmHg
636578|NCT00163969|Pain
636579|NCT00163969|Wind-up
636580|NCT00163969|opioid
636581|NCT00163969|ketamine
636582|NCT00163969|pre-emptive
636583|NCT00163956|IVC filters
636584|NCT00163956|failed retrieval
636585|NCT00163943|Metabolic syndrome
636586|NCT00163943|Sympathetic nervous system activity
636587|NCT00163943|Insulin sensitivity
636588|NCT00163943|weight loss
636589|NCT00163943|aerobic exercise
636590|NCT00163930|Uterine Fibroids
636591|NCT00163930|embolisation
636592|NCT00163930|pain management
636593|NCT00163917|Hypnosis
636594|NCT00163917|Analgesia
636595|NCT00163904|Heart Failure
636596|NCT00163904|Inflammatory mediators
636597|NCT00163904|insulin sensitivity
636598|NCT00163904|overweight
636599|NCT00163904|high monounsaturated diet
636600|NCT00163891|Respiratory Therapy
636601|NCT00163891|Postoperative Care
636602|NCT00163891|Treatment Outcome
636603|NCT00163878|Sensory Stimulation Programs
636604|NCT00163865|Boredom
636605|NCT00163865|Adolescent
636606|NCT00163865|Mental illness
636607|NCT00163865|Depression
636608|NCT00163865|Anxiety
636609|NCT00163852|Cystic fibrosis
636610|NCT00163852|Metabolic alkalosis
636611|NCT00163852|Hypercapnia
636612|NCT00163852|Salt replacement
636613|NCT00163839|Dietary Intervention
636614|NCT00163839|Pseudoallergen free diet
636615|NCT00163826|cervical spine injury
636616|NCT00163826|multiple trauma
636617|NCT00163813|Mechanically-ventilated
636618|NCT00163813|medical-surgical critically ill patients
636619|NCT00163813|reduced gastric motility
636620|NCT00163800|Outcome predictors
636621|NCT00163800|Acute brain injury
636622|NCT00163787|mobility
636623|NCT00163787|falls
636624|NCT00163787|activity level
636625|NCT00163761|Lymphoma
636626|NCT00163748|Lymphoma
636627|NCT00163735|Food allergy
636628|NCT00163735|wine
636629|NCT00163735|milk allergy
636630|NCT00163735|egg allergy
636631|NCT00163735|nut allergy
636632|NCT00163735|fish allergy
636633|NCT00163709|Atrial natriuretic factor.
636634|NCT00163709|Biochemistry.
636635|NCT00163709|Cardiac failure.
636636|NCT00163709|Randomised trials.
636637|NCT00163709|Hormones.
636638|NCT00163709|Systolic heart failure.
636639|NCT00163709|Diastolic heart failure.
636640|NCT00163709|Ischaemic cardiomyopathy.
636641|NCT00163709|Ventricular hypertrophy.
636642|NCT00163709|AMI
636643|NCT00163696|MBNW
636644|NCT00163696|Ventilation
636645|NCT00163696|small airways
636646|NCT00163696|Lung Transplant recipients (Bronchiolitis Obliterans syndrome)
636647|NCT00163683|Dietary Intervention
636648|NCT00163657|Hepatitis C Virus
636649|NCT00163657|Immunosuppressive Agents
636650|NCT00163644|Hematological malignancies.
636651|NCT00163644|Bone- marrow/ haemopoetic transplant
636652|NCT00163644|Exercise
636653|NCT00163618|tick-borne encephalitis
636654|NCT00163605|Sinus augmentation
636655|NCT00163605|Alloplastic bone substitute
636656|NCT00163605|Hydroxyl apatite
636657|NCT00163592|Vascular reconstruction
636658|NCT00163592|Polytetraflouroethylene (PTFE) prosthesis
636659|NCT00163579|premature birth
636660|NCT00163579|cerclage
636661|NCT00163579|tocolysis
636662|NCT00163579|drug therapy
636663|NCT00163566|libido
636664|NCT00163566|depression strength
636665|NCT00163566|testosterone
636666|NCT00163566|dihydrotestosterone
636667|NCT00163553|spinal surgery
636668|NCT00163553|pethidine
636669|NCT00163553|analgesia
636670|NCT00163540|tick-borne encephalitis
636671|NCT00163527|Asthma
636672|NCT00163527|Roflumilast
636673|NCT00163527|Corticosteroids
636674|NCT00163280|Mucositis
636675|NCT00163280|Peripheral blood stem cell transplant
636676|NCT00163267|peripheral arterial intervention
636677|NCT00163267|atherosclerosis
636678|NCT00163267|platelets
636679|NCT00163267|Age above 18
636680|NCT00163254|Chronic limb ischemia
636681|NCT00163254|Intervention
636682|NCT00163254|Restenosis
636683|NCT00163254|Patients above 18 years
636684|NCT00163228|C05.550.114.606.500
636685|NCT00163228|C05.550.114.606.508
636686|NCT00163176|cell proliferation
636687|NCT00163176|PET
636688|NCT00163176|radiotherapy
636689|NCT00163124|chiropractic
636690|NCT00163124|spinal manipulation
636691|NCT00163124|low back pain
636692|NCT00163072|transdermal
636693|NCT00163072|Megace
636694|NCT00163072|pharmacokinetics
636695|NCT00163033|phase I study
636696|NCT00163020|Preterm Birth
636697|NCT00163020|Preterm Delivery
636698|NCT00163020|Multiple gestation
636699|NCT00163020|17-alpha-hydroxyprogesterone caproate
636700|NCT00163020|Progesterone
636701|NCT00162994|recurrent otitis media
636702|NCT00162994|adenoidectomy
636703|NCT00162994|tympanostomy
636704|NCT00162994|young children
636705|NCT00162994|prevention
636706|NCT00162994|quality of life
636707|NCT00162968|polyneuropathies
636708|NCT00162968|pain
636709|NCT00162968|drug effects
636710|NCT00162968|escitalopram
636711|NCT00162968|serotonin uptake inhibitors
636712|NCT00162955|untreated adult Non-Hodgkin's Lymphoma
636713|NCT00162955|CHOP protocol
636714|NCT00162955|Angiotensin II Type 1 Receptor Blockers
636715|NCT00162955|Cardiomyopathy
636716|NCT00162942|Crohn's Disease
636717|NCT00162929|metastatic breast cancer
636718|NCT00162929|locally recurrent breast cancer
636719|NCT00162916|Traumatic Brain Injury
636720|NCT00162916|Depression
636721|NCT00162916|Antidepressant medication
636722|NCT00162916|Double-Blind Study
636723|NCT00162916|Brain Injuries
636724|NCT00162916|Antidepressive Agents
636725|NCT00162916|Citalopram
636726|NCT00162916|Double-Blind Method
636727|NCT00162903|Preterm infant, Patent ductus arteriosus, Nitric oxide,Endothelin-1
636728|NCT00162890|degenerated cervical spine
636729|NCT00162890|assessment
636730|NCT00162890|physical therapy
636731|NCT00162877|rabeprazole, omeprazole, CYP2C19, H. pylori, PK/PD
636732|NCT00162864|asthma
636733|NCT00162864|COPD
636734|NCT00162864|montelukast sodium
636735|NCT00162864|leukotriene modifier
636736|NCT00162864|older adults
636737|NCT00162825|Psoriasis, T cell, inflammation, CD7, cytokine
636738|NCT00162812|neoadjuvant chemotherapy
636739|NCT00162812|early breast cancer
636740|NCT00162812|inflammatory breast cancer
636741|NCT00162799|insulin resistance and inflamation
636742|NCT00162799|insulin sensitibity
636743|NCT00162799|obesity-induced insuline resistence
636744|NCT00162799|obesity-diabetes link
636745|NCT00162799|salicylate
636746|NCT00162799|insulin resistance in obesity health adults
636747|NCT00162786|Driving performance
636748|NCT00162786|Antihistamine
636749|NCT00162773|asthma
636750|NCT00162747|Pre-term infants
636751|NCT00162747|skin infections
636752|NCT00162747|infant skin
636753|NCT00162747|Aquaphor
636754|NCT00162747|sunflower seed oil
636755|NCT00162747|nutrition
636756|NCT00162747|skin care
636757|NCT00162734|Chronic Hepatitis C
636758|NCT00162734|Liver
636759|NCT00162734|Pegylated
636760|NCT00162734|Interferon
636761|NCT00162734|Alpha
636762|NCT00162734|Ribavirin
636763|NCT00162734|Combination
636764|NCT00162734|Nonresponder
636765|NCT00162734|HCV
636766|NCT00162734|Infergen
636767|NCT00162734|SVR
636768|NCT00162721|Uterine sarcoma non metastatic
636769|NCT00162708|Head and neck squamous cell carcinoma
636770|NCT00162708|Radiotherapy
636771|NCT00162708|Chemotherapy
636772|NCT00162682|HIV
636773|NCT00162682|Highly Active Antiretroviral Therapy
636774|NCT00162682|Monitoring
636775|NCT00162682|Viral load
636776|NCT00162682|CD4
636777|NCT00162682|Thailand
636778|NCT00162682|Future Drug Options
636779|NCT00162682|Resistance
636780|NCT00162682|Developing Country
636781|NCT00162682|Acquired Immunodeficiency Syndrome
636782|NCT00162669|Hepatocellular carcinoma, advanced, bevacizumab, phase II, VGEF, neovascularization
636783|NCT00162656|B-Cell Lymphoma
636784|NCT00162643|Acquired Immunodeficiency Syndrome
636785|NCT00162643|Antiretroviral Therapy, Highly Active
636786|NCT00162643|Protease Inhibitors
636787|NCT00162643|Reverse Transcriptase Inhibitors
636788|NCT00162630|Hip fracture, pain, regional anaesthesia, analgesia
636789|NCT00162617|Hip fracture
636790|NCT00162617|Rehabilitation
636791|NCT00162617|Transfusion
636792|NCT00162617|Outcome
636793|NCT00162604|Prophylactic antibiotic
636794|NCT00162604|Postoperative infections
636795|NCT00162604|Uterine prolapse grade I - II
636796|NCT00162604|cystocele
636797|NCT00162604|rectocele
636798|NCT00162604|enterocele
636799|NCT00162604|defects of the perineal body
636800|NCT00162591|Bispectral index
636801|NCT00162591|sedation
636802|NCT00162591|remifentanyl
636803|NCT00162591|Bronchoalveolar lavage
636804|NCT00162591|Intensive care
636805|NCT00162591|Nociceptive stimuli
636806|NCT00162591|Sedated patient
636807|NCT00162591|BIS variation
636808|NCT00162578|pneumococcal meningitis
636809|NCT00162578|intensive care unit
636810|NCT00162578|vancomycin
636811|NCT00162578|dexamethasone
636812|NCT00162578|drug diffusion in cerebrospinal fluid
636813|NCT00162565|Heart Failure, Congestive
636814|NCT00162565|beta-Adrenergic Blockers
636815|NCT00162552|multicenter-randomized-trial
636816|NCT00162552|pentoxifyllinE
636817|NCT00162552|placebo
636818|NCT00162552|cirrhosis
636819|NCT00162552|liver failure
636820|NCT00162552|cytokine
636821|NCT00162539|foetal thyroid mensuration
636822|NCT00162500|Metastatic solid tumors
636823|NCT00162474|Healthy Volunteers
636824|NCT00162461|Healthy Volunteers
636825|NCT00162448|Patients requiring dual-chamber pacemakers or defibrillators
636826|NCT00162396|Albuterol
636827|NCT00162396|β2 Adrenergic receptor
636828|NCT00162396|Polymorphism
636829|NCT00162240|Metabolics Diabetes New Onset
636830|NCT00162214|Advanced Solid Tumors
636831|NCT00162123|ipilimumab
636832|NCT00162123|previously treated
636833|NCT00162019|Factor VIII Deficiency
636834|NCT00162006|Chronic idiopathic thrombocytopenic purpura
636835|NCT00161993|Gammaglobulin
636836|NCT00161980|Axillary wound
636837|NCT00161980|Seroma
636838|NCT00161980|Fistulae
636839|NCT00161967|tick-borne encephalitis
636840|NCT00161954|Tick-Borne Encephalitis
636841|NCT00161941|Meningococcal Vaccine
636842|NCT00161941|Meningococcal Meningitis, Serogroup C
636843|NCT00161941|Neisseria Meningitidis
636844|NCT00161928|Meningococcal Vaccine
636845|NCT00161928|Meningococcal Meningitis, Serogroup C
636846|NCT00161928|Neisseria Meningitidis
636847|NCT00161915|Liver cirrhosis
636848|NCT00161902|Arthroplasty
636849|NCT00161902|Hip Prosthesis
636850|NCT00161902|Cement Free Hip Prosthesis
636851|NCT00161902|Femur Head Necrosis
636852|NCT00161902|Coxarthrosis
636853|NCT00161876|tick-borne encephalitis
636854|NCT00161837|Influenza
636855|NCT00161837|Vaccine
636856|NCT00161746|Tick-Borne Encephalitis
636857|NCT00161733|Cardiopulmonary bypass
636858|NCT00161733|Median sternotomy
636859|NCT00161733|Fibrin sealant
636860|NCT00161733|Clot
636861|NCT00161733|Cardiac surgery
636862|NCT00161720|Severe Congenital Protein C Deficiency
636863|NCT00161694|pain control
636864|NCT00161681|Levonorgestrel
636865|NCT00161681|ethinyl estradiol
636866|NCT00161681|premenstrual syndrome
636867|NCT00161681|menstrual cycle related symptoms
636868|NCT00161668|Leukemia
636869|NCT00161655|Psoriasis
636870|NCT00161655|Arthritis
636871|NCT00161642|Malignant Tumors
636872|NCT00161629|Distal Radius Fractures
636873|NCT00161616|Open Diaphyseal Tibia Fractures
636874|NCT00161603|Angioplasty
636875|NCT00161603|Behavior change
636876|NCT00161603|Physical activity
636877|NCT00161603|Risk reduction
636878|NCT00161590|NK cell lymphoma
636879|NCT00161590|Null cell lymphoma
636880|NCT00161577|Ketorolac
636881|NCT00161564|Idiopathic Thrombocytopenic Purpura
636882|NCT00161564|ITP
636883|NCT00161564|Non-Malignant Hematology
636884|NCT00161551|Cardiac Pacing, artificial
636885|NCT00161551|Atrial Fibrillation
636886|NCT00161551|Heart Failure
636887|NCT00161551|Pacemaker leads
636888|NCT00161551|Pacing Mode
636889|NCT00161538|Cardiac Pacing, artificial
636890|NCT00161538|Atrial fibrillation
636891|NCT00161538|Pacemaker leads
636892|NCT00161538|Lead positions
636893|NCT00161525|Subretinal Hemorrhage, Perfluorocarbon gas
636894|NCT00161486|Male contraception
636895|NCT00161486|Prostate
636896|NCT00161486|Acyline
636897|NCT00161486|Androgen replacement
636898|NCT00161473|double-blind
636899|NCT00161473|treatment
636900|NCT00161473|prazosin
636901|NCT00161460|Colorectal cancer
636902|NCT00161460|Mass screening
636903|NCT00161447|Male contraception
636904|NCT00161447|testosterone
636905|NCT00161447|acyline
636906|NCT00161434|HIV-1
636907|NCT00161421|Male Contraception
636908|NCT00161421|Testosterone
636909|NCT00161421|Hypogonadism
636910|NCT00161408|schizophrenia, first episode, cognitive behavioural therapy, psychoeducation
636911|NCT00161395|fertility
636912|NCT00161395|pregnancy
636913|NCT00161382|HIV Seronegativity
636914|NCT00161382|HIV
636915|NCT00161369|homocysteine
636916|NCT00161369|asymmetric dimethylarginine
636917|NCT00161369|atherosclerosis
636918|NCT00161369|cardiovascular event
636919|NCT00161369|hemodialysis
636920|NCT00161343|HIV
636921|NCT00161343|Prevention Intervention
636922|NCT00161343|Female
636923|NCT00161343|Adolescents
636924|NCT00161343|STD
636925|NCT00161343|HIV Seronegativity
636926|NCT00161330|urinary tract infection,
636927|NCT00161330|antibiotic treatment
636928|NCT00161330|childhood
636929|NCT00161330|amoxicilline/clavulanic acid
636930|NCT00161330|ceftriaxone
636931|NCT00161330|renal ultrasonography
636932|NCT00161330|renal scintigraphy
636933|NCT00161291|Carcinoma of the breast
636934|NCT00161291|Breast cancer
636935|NCT00161252|Prostate Cancer
636936|NCT00161239|T-Cell Lymphomas
636937|NCT00161226|endometrial cancer
636938|NCT00161213|recurrent pancreatic cancer
636939|NCT00161213|stage IV pancreatic cancer
636940|NCT00161213|stage III pancreatic cancer
636941|NCT00161213|adenocarcinoma of the pancreas
636942|NCT00161213|stage II pancreatic cancer
636943|NCT00161200|Esophageal Metaplasia
636944|NCT00161187|refractory chronic lymphocytic leukemia
636945|NCT00161187|recurrent small lymphocytic lymphoma
636946|NCT00161187|prolymphocytic leukemia
636947|NCT00161187|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
636948|NCT00161187|nodal marginal zone B-cell lymphoma
636949|NCT00161187|recurrent marginal zone lymphoma
636950|NCT00161187|splenic marginal zone lymphoma
636951|NCT00161187|recurrent grade 1 follicular lymphoma
636952|NCT00161187|recurrent grade 2 follicular lymphoma
636953|NCT00161187|recurrent grade 3 follicular lymphoma
636954|NCT00161187|stage I multiple myeloma
636955|NCT00161187|stage II multiple myeloma
636956|NCT00161187|stage III multiple myeloma
636957|NCT00161187|recurrent mantle cell lymphoma
636958|NCT00161187|childhood diffuse large cell lymphoma
636959|NCT00161187|recurrent adult diffuse large cell lymphoma
636960|NCT00161187|recurrent adult Burkitt lymphoma
636961|NCT00161187|recurrent adult grade III lymphomatoid granulomatosis
636962|NCT00161187|recurrent childhood grade III lymphomatoid granulomatosis
636963|NCT00161187|adult nasal type extranodal NK/T-cell lymphoma
636964|NCT00161187|childhood nasal type extranodal NK/T-cell lymphoma
636965|NCT00161187|recurrent mycosis fungoides/Sezary syndrome
636966|NCT00161187|anaplastic large cell lymphoma
636967|NCT00161187|angioimmunoblastic T-cell lymphoma
636968|NCT00161187|recurrent adult T-cell leukemia/lymphoma
636969|NCT00161187|recurrent adult Hodgkin lymphoma
636970|NCT00161187|recurrent/refractory childhood Hodgkin lymphoma
636971|NCT00161187|recurrent adult acute myeloid leukemia
636972|NCT00161187|recurrent childhood acute myeloid leukemia
636973|NCT00161187|childhood chronic myelogenous leukemia
636974|NCT00161187|chronic phase chronic myelogenous leukemia
636975|NCT00161187|relapsing chronic myelogenous leukemia
636976|NCT00161187|recurrent renal cell cancer
636977|NCT00161187|stage IV renal cell cancer
636978|NCT00161187|recurrent bladder cancer
636979|NCT00161187|stage IV bladder cancer
636980|NCT00161187|recurrent prostate cancer
636981|NCT00161187|stage IV prostate cancer
636982|NCT00161187|recurrent malignant testicular germ cell tumor
636983|NCT00161187|stage III malignant testicular germ cell tumor
636984|NCT00161187|recurrent gastric cancer
636985|NCT00161187|stage IV gastric cancer
636986|NCT00161187|recurrent pancreatic cancer
636987|NCT00161187|stage IV pancreatic cancer
636988|NCT00161187|localized unresectable adult primary liver cancer
636989|NCT00161187|recurrent adult primary liver cancer
636990|NCT00161187|recurrent childhood liver cancer
636991|NCT00161187|recurrent colon cancer
636992|NCT00161187|stage IV colon cancer
636993|NCT00161187|recurrent rectal cancer
636994|NCT00161187|stage IV rectal cancer
636995|NCT00161187|recurrent breast cancer
636996|NCT00161187|stage IV breast cancer
636997|NCT00161187|extensive stage small cell lung cancer
636998|NCT00161187|recurrent non-small cell lung cancer
636999|NCT00161187|recurrent small cell lung cancer
637000|NCT00161187|stage IV non-small cell lung cancer
637001|NCT00161187|recurrent ovarian epithelial cancer
637002|NCT00161187|recurrent cervical cancer
637003|NCT00161187|recurrent adult soft tissue sarcoma
637004|NCT00161187|stage IV adult soft tissue sarcoma
637005|NCT00161187|chondrosarcoma
637006|NCT00161187|recurrent osteosarcoma
637007|NCT00161187|previously treated childhood rhabdomyosarcoma
637008|NCT00161187|recurrent childhood rhabdomyosarcoma
637009|NCT00161187|ovarian sarcoma
637010|NCT00161187|recurrent uterine sarcoma
637011|NCT00161187|stage IV uterine sarcoma
637012|NCT00161187|stage I small lymphocytic lymphoma
637013|NCT00161187|contiguous stage II small lymphocytic lymphoma
637014|NCT00161187|noncontiguous stage II small lymphocytic lymphoma
637015|NCT00161187|stage III small lymphocytic lymphoma
637016|NCT00161187|stage IV small lymphocytic lymphoma
637017|NCT00161187|accelerated phase chronic myelogenous leukemia
637018|NCT00161187|blastic phase chronic myelogenous leukemia
637019|NCT00161187|recurrent childhood large cell lymphoma
637020|NCT00161187|stage I childhood large cell lymphoma
637021|NCT00161187|stage II childhood large cell lymphoma
637022|NCT00161187|stage III childhood large cell lymphoma
637023|NCT00161187|stage IV childhood large cell lymphoma
637024|NCT00161187|adult primary hepatocellular carcinoma
637025|NCT00161187|advanced adult primary liver cancer
637026|NCT00161187|ovarian stromal cancer
637027|NCT00161187|stage IA cervical cancer
637028|NCT00161187|stage IB cervical cancer
637029|NCT00161187|stage IIA cervical cancer
637030|NCT00161187|stage IIB cervical cancer
637031|NCT00161187|stage III cervical cancer
637032|NCT00161187|stage IVA cervical cancer
637033|NCT00161187|stage IVB cervical cancer
637034|NCT00161187|recurrent adult acute lymphoblastic leukemia
637035|NCT00161187|untreated adult acute lymphoblastic leukemia
637036|NCT00161187|recurrent childhood acute lymphoblastic leukemia
637037|NCT00161187|untreated childhood acute lymphoblastic leukemia
637038|NCT00161187|recurrent endometrial carcinoma
637039|NCT00161187|stage I endometrial carcinoma
637040|NCT00161187|stage II endometrial carcinoma
637041|NCT00161187|stage III endometrial carcinoma
637042|NCT00161187|stage IV endometrial carcinoma
637043|NCT00161187|childhood hepatocellular carcinoma
637044|NCT00161187|stage III childhood liver cancer
637045|NCT00161187|stage IV childhood liver cancer
637046|NCT00161187|previously untreated childhood rhabdomyosarcoma
637047|NCT00161187|metastatic childhood soft tissue sarcoma
637048|NCT00161187|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
637049|NCT00161187|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
637050|NCT00161187|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
637051|NCT00161187|contiguous stage II grade 1 follicular lymphoma
637052|NCT00161187|contiguous stage II grade 2 follicular lymphoma
637053|NCT00161187|contiguous stage II grade 3 follicular lymphoma
637054|NCT00161187|noncontiguous stage II grade 1 follicular lymphoma
637055|NCT00161187|noncontiguous stage II grade 2 follicular lymphoma
637056|NCT00161187|noncontiguous stage II grade 3 follicular lymphoma
637057|NCT00161187|stage I grade 1 follicular lymphoma
637058|NCT00161187|stage I grade 2 follicular lymphoma
637059|NCT00161187|stage I grade 3 follicular lymphoma
637060|NCT00161187|stage III grade 1 follicular lymphoma
637061|NCT00161187|stage III grade 2 follicular lymphoma
637062|NCT00161187|stage III grade 3 follicular lymphoma
637063|NCT00161187|stage IV grade 1 follicular lymphoma
637064|NCT00161187|stage IV grade 2 follicular lymphoma
637065|NCT00161187|stage IV grade 3 follicular lymphoma
637066|NCT00161187|contiguous stage II marginal zone lymphoma
637067|NCT00161187|noncontiguous stage II marginal zone lymphoma
637068|NCT00161187|stage I marginal zone lymphoma
637069|NCT00161187|stage III marginal zone lymphoma
637070|NCT00161187|stage IV marginal zone lymphoma
637071|NCT00161187|localized osteosarcoma
637072|NCT00161187|metastatic osteosarcoma
637073|NCT00161187|stage I ovarian epithelial cancer
637074|NCT00161187|stage II ovarian epithelial cancer
637075|NCT00161187|stage III ovarian epithelial cancer
637076|NCT00161187|stage IV ovarian epithelial cancer
637077|NCT00161187|recurrent ovarian germ cell tumor
637078|NCT00161187|stage I ovarian germ cell tumor
637079|NCT00161187|stage II ovarian germ cell tumor
637080|NCT00161187|stage III ovarian germ cell tumor
637081|NCT00161187|stage IV ovarian germ cell tumor
637082|NCT00161187|limited stage small cell lung cancer
637083|NCT00161187|refractory multiple myeloma
637084|NCT00161187|stage II malignant testicular germ cell tumor
637085|NCT00161187|stage I adult soft tissue sarcoma
637086|NCT00161187|stage II adult soft tissue sarcoma
637087|NCT00161187|stage III adult soft tissue sarcoma
637088|NCT00161187|stage I bladder cancer
637089|NCT00161187|stage II bladder cancer
637090|NCT00161187|stage III bladder cancer
637091|NCT00161187|male breast cancer
637092|NCT00161187|stage I breast cancer
637093|NCT00161187|stage II breast cancer
637094|NCT00161187|stage IIIA breast cancer
637095|NCT00161187|stage IIIB breast cancer
637096|NCT00161187|stage IIIC breast cancer
637097|NCT00161187|stage I colon cancer
637098|NCT00161187|stage II colon cancer
637099|NCT00161187|stage III colon cancer
637100|NCT00161187|stage I gastric cancer
637101|NCT00161187|stage II gastric cancer
637102|NCT00161187|stage III gastric cancer
637103|NCT00161187|stage I non-small cell lung cancer
637104|NCT00161187|stage II non-small cell lung cancer
637105|NCT00161187|stage IIIA non-small cell lung cancer
637106|NCT00161187|stage IIIB non-small cell lung cancer
637107|NCT00161187|stage I pancreatic cancer
637108|NCT00161187|stage II pancreatic cancer
637109|NCT00161187|stage III pancreatic cancer
637110|NCT00161187|stage I prostate cancer
637111|NCT00161187|stage II prostate cancer
637112|NCT00161187|stage III prostate cancer
637113|NCT00161187|stage I rectal cancer
637114|NCT00161187|stage II rectal cancer
637115|NCT00161187|stage III rectal cancer
637116|NCT00161187|stage I renal cell cancer
637117|NCT00161187|stage II renal cell cancer
637118|NCT00161187|stage III renal cell cancer
637119|NCT00161187|stage I uterine sarcoma
637120|NCT00161187|stage II uterine sarcoma
637121|NCT00161187|stage III uterine sarcoma
637122|NCT00161187|stage I chronic lymphocytic leukemia
637123|NCT00161187|stage II chronic lymphocytic leukemia
637124|NCT00161187|stage III chronic lymphocytic leukemia
637125|NCT00161187|stage IV chronic lymphocytic leukemia
637126|NCT00161187|contiguous stage II mantle cell lymphoma
637127|NCT00161187|noncontiguous stage II mantle cell lymphoma
637128|NCT00161187|stage I mantle cell lymphoma
637129|NCT00161187|stage III mantle cell lymphoma
637130|NCT00161187|stage IV mantle cell lymphoma
637131|NCT00161187|Waldenstrom macroglobulinemia
637132|NCT00161187|contiguous stage II adult diffuse large cell lymphoma
637133|NCT00161187|noncontiguous stage II adult diffuse large cell lymphoma
637134|NCT00161187|stage I adult diffuse large cell lymphoma
637135|NCT00161187|stage III adult diffuse large cell lymphoma
637136|NCT00161187|stage IV adult diffuse large cell lymphoma
637137|NCT00161187|contiguous stage II adult Burkitt lymphoma
637138|NCT00161187|noncontiguous stage II adult Burkitt lymphoma
637139|NCT00161187|stage I adult Burkitt lymphoma
637140|NCT00161187|stage III adult Burkitt lymphoma
637141|NCT00161187|stage IV adult Burkitt lymphoma
637142|NCT00161187|stage I mycosis fungoides/Sezary syndrome
637143|NCT00161187|stage II mycosis fungoides/Sezary syndrome
637144|NCT00161187|stage III mycosis fungoides/Sezary syndrome
637145|NCT00161187|stage IV mycosis fungoides/Sezary syndrome
637146|NCT00161187|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
637147|NCT00161187|adult acute myeloid leukemia with inv(16)(p13;q22)
637148|NCT00161187|adult acute myeloid leukemia with t(15;17)(q22;q12)
637149|NCT00161187|adult acute myeloid leukemia with t(16;16)(p13;q22)
637150|NCT00161187|adult acute myeloid leukemia with t(8;21)(q22;q22)
637151|NCT00161187|untreated adult acute myeloid leukemia
637152|NCT00161187|untreated childhood acute myeloid leukemia and other myeloid malignancies
637153|NCT00161187|de novo myelodysplastic syndromes
637154|NCT00161187|secondary myelodysplastic syndromes
637155|NCT00161187|previously treated myelodysplastic syndromes
637156|NCT00161187|nonmetastatic childhood soft tissue sarcoma
637157|NCT00161187|recurrent childhood soft tissue sarcoma
637158|NCT00161187|stage I childhood Hodgkin lymphoma
637159|NCT00161187|stage II childhood Hodgkin lymphoma
637160|NCT00161187|stage III childhood Hodgkin lymphoma
637161|NCT00161187|stage IV childhood Hodgkin lymphoma
637162|NCT00161187|stage I adult Hodgkin lymphoma
637163|NCT00161187|stage II adult Hodgkin lymphoma
637164|NCT00161187|stage III adult Hodgkin lymphoma
637165|NCT00161187|stage IV adult Hodgkin lymphoma
637166|NCT00161187|recurrent childhood small noncleaved cell lymphoma
637167|NCT00161187|stage I childhood small noncleaved cell lymphoma
637168|NCT00161187|stage II childhood small noncleaved cell lymphoma
637169|NCT00161187|stage III childhood small noncleaved cell lymphoma
637170|NCT00161187|stage IV childhood small noncleaved cell lymphoma
637171|NCT00161187|Burkitt lymphoma
637172|NCT00161187|stage I adult T-cell leukemia/lymphoma
637173|NCT00161187|stage II adult T-cell leukemia/lymphoma
637174|NCT00161187|stage III adult T-cell leukemia/lymphoma
637175|NCT00161187|stage IV adult T-cell leukemia/lymphoma
637176|NCT00161187|stage I malignant testicular germ cell tumor
637177|NCT00161187|childhood myelodysplastic syndromes
637178|NCT00161187|childhood renal cell carcinoma
637179|NCT00161187|stage IA melanoma
637180|NCT00161187|stage IB melanoma
637181|NCT00161187|stage IIA melanoma
637182|NCT00161187|stage IIB melanoma
637183|NCT00161187|stage IIC melanoma
637184|NCT00161187|stage IIIA melanoma
637185|NCT00161187|stage IIIB melanoma
637186|NCT00161187|stage IIIC melanoma
637187|NCT00161187|stage IV melanoma
637188|NCT00161187|recurrent melanoma
637189|NCT00161174|testicular cancer
637190|NCT00161174|cardiovascular morbidity
637191|NCT00161174|cardiovascular risk factors
637192|NCT00161174|pharmacogenomic determinants
637193|NCT00161161|ADHD; MRI; genetics
637194|NCT00161148|PSC
637195|NCT00161148|Liver biochemistry
637196|NCT00161148|Probiotics
637197|NCT00161148|Pruritus
637198|NCT00161135|MRI
637199|NCT00161135|PDD-NOS, MCDD
637200|NCT00161109|22q11.2 deletion syndrome
637201|NCT00161109|Psychopathology
637202|NCT00161109|Psychiatry
637203|NCT00161109|Neuropsychology
637204|NCT00161109|Psychiophysiology
637205|NCT00161109|Autism
637206|NCT00161109|Psychosis
637207|NCT00161109|Deletion size
637208|NCT00161109|Candidate genes
637209|NCT00161109|Psychiatric symptoms
637210|NCT00161109|Neuropsychological impairments
637211|NCT00161109|Psychophysiological performance
637212|NCT00161096|on-demand therapy
637213|NCT00161096|pantoprazole
637214|NCT00161096|gastro-oesophageal reflux disease
637215|NCT00161096|proton pump inhibitor
637216|NCT00161096|acid suppression
637217|NCT00161096|intermittent
637218|NCT00161083|ursodeoxycholic acid
637219|NCT00161083|gallstone
637220|NCT00161083|complications
637221|NCT00161083|pancreatitis
637222|NCT00161083|gallbladder motility
637223|NCT00161083|colic
637224|NCT00161070|secondary prevention
637225|NCT00161070|TIA / minor stroke
637226|NCT00161070|atherosclerotic origin
637227|NCT00161070|TIA (Transient Ischemic Attack)
637228|NCT00161070|prevention & control
637229|NCT00161057|Schizophrenia
637230|NCT00161057|Medication-naive
637231|NCT00161057|Functional MRI
637232|NCT00161057|Working memory
637233|NCT00161057|Language lateralization
637234|NCT00161057|schizoaffective disorder
637235|NCT00161057|psychotic disorder Not Otherwise Specified
637236|NCT00161005|Acute myocardial infarction
637237|NCT00161005|Fibrinolysis
637238|NCT00161005|Health effects /Quality of life
637239|NCT00160992|Adoptive cell transfer
637240|NCT00160992|peptide vaccination
637241|NCT00160992|melanoma
637242|NCT00160992|immunosuppression and homeostatic proliferation
637243|NCT00160966|kidney transplantation
637244|NCT00160966|polyoma virus associated transplant nephropathy
637245|NCT00160966|tacrolimus
637246|NCT00160966|mycophenolate mofetil
637247|NCT00160966|everolimus
637248|NCT00160966|cyclosporin A
637249|NCT00160966|BK virus PCR
637250|NCT00160966|viruria screening
637251|NCT00160966|BK polyomavirus
637252|NCT00160966|immunosuppression
637253|NCT00160940|gene expression
637254|NCT00160940|viral hepatitis
637255|NCT00160940|autoimmune disease
637256|NCT00160927|microcirculation
637257|NCT00160927|Laser doppler flowmetry
637258|NCT00160927|neuropathy
637259|NCT00160927|endothelial function
637260|NCT00160914|Childhood obesity
637261|NCT00160901|Breast cancer
637262|NCT00160901|Chemotherapy
637263|NCT00160901|Phytotherapy
637264|NCT00160901|Nutritional counseling
637265|NCT00160875|esophageal
637266|NCT00160875|esophagus
637267|NCT00160875|irinotecan
637268|NCT00160875|CPT11
637269|NCT00160875|cisplatin
637270|NCT00160849|Treatment Experienced
637271|NCT00160836|Tissue diagnosis
637272|NCT00160823|Colon cleansing
637273|NCT00160823|Quality
637274|NCT00160823|Cost-effectiveness
637275|NCT00160810|distal
637276|NCT00160810|radius
637277|NCT00160810|fractures
637278|NCT00160745|endothelium, NO, renal, statins
637279|NCT00160732|Islet Cell Transplant
637280|NCT00160732|Human islet cell infusion
637281|NCT00160732|Juvenile-onset diabetes
637282|NCT00160693|Rheumatoid Arthritis
637283|NCT00160693|America College of Rheumatology
637284|NCT00160693|Disease modifying anti-rheumatic drug
637285|NCT00160693|Certolizumab Pegol (CDP870)
637286|NCT00160680|Persistent Allergic Rhinitis, HDM, Parietaria, sneezing, rhinorrhea, ocular pruritus, Rhinasthma, inflammatory cells, ICAM-1, ATAREAL, Xyzal, Levocetirizine
637287|NCT00160667|Post-herpetic Neuralgia (PHN)
637288|NCT00160667|Brivaracetam
637289|NCT00160654|Epilepsy
637290|NCT00160654|Partial Onset Seizures
637291|NCT00160654|Keppra
637292|NCT00160654|Levetiracetam
637293|NCT00160641|Rheumatoid Arthritis
637294|NCT00160641|CDP870
637295|NCT00160641|Certolizumab Pegol
637296|NCT00160641|Cimzia
637297|NCT00160628|Epilepsy
637298|NCT00160628|Partial Onset Seizures
637299|NCT00160628|Keppra
637300|NCT00160628|Levetiracetam
637301|NCT00160615|Epilepsy, Partial,
637302|NCT00160615|Keppra, levetiracetam
637303|NCT00160602|Rheumatoid Arthritis
637304|NCT00160602|Certolizumab Pegol, Cimzia
637305|NCT00160589|Allergic Rhinits, Symptoms (sneezing, rhinorrhea, nasal/ocular pruritus, nasal congestion), LEADER, Xyzal, Levocetirizine
637306|NCT00160576|Idiopathic Parkinson's Disease, levodopa induced dyskinesia,
637307|NCT00160576|Levetiracetam, Keppra
637308|NCT00160563|Pediatry
637309|NCT00160563|EPAAC
637310|NCT00160563|atopic Children
637311|NCT00160563|prevention of asthma
637312|NCT00160563|Levocetirizine
637313|NCT00160563|Xyzal
637314|NCT00160550|Idiopathic Generalized Epilepsy, tonic-clonic seizures
637315|NCT00160550|Levetiracetam, Keppra
637316|NCT00160537|Seasonal Allergic Rhinitis (SAR), Grass pollen, SAR Symptoms (sneezing, rhinorrhea, nasal / ocular pruritus, nasal congestion)
637317|NCT00160537|POPULAR, Xyzal, Levocetirizine
637318|NCT00160524|Certolizumab Pegol
637319|NCT00160524|Cimzia
637320|NCT00160524|CDP870
637321|NCT00160524|CZP
637322|NCT00160511|Postherpetic Neuralgia (PHN)
637323|NCT00160511|Levetiracetam
637324|NCT00160511|Keppra
637325|NCT00160511|Nerve Pain
637326|NCT00160498|Lercanidipine, calcium antagonist, hypertension, obesity
637327|NCT00160485|Gestational Diabetes
637328|NCT00160485|Pregnancy
637329|NCT00160485|Glyburide
637330|NCT00160485|Insulin
637331|NCT00160472|vasopressin
637332|NCT00160472|ovarian
637333|NCT00160472|neoplasm
637334|NCT00160459|Fibroid Uterus
637335|NCT00160459|Leiomyoma
637336|NCT00160459|Uterine Fibroids
637337|NCT00160459|asoprisnil
637338|NCT00160446|Pelvic pain
637339|NCT00160446|Dysmenorrhea
637340|NCT00160446|Dyspareunia
637341|NCT00160446|Infertility
637342|NCT00160446|Asoprisnil
637343|NCT00160433|Pelvic pain
637344|NCT00160433|Dysmenorrhea
637345|NCT00160433|Dyspareunia
637346|NCT00160433|Infertility
637347|NCT00160433|asoprisnil
637348|NCT00160420|Pelvic pain
637349|NCT00160420|Dysmenorrhea
637350|NCT00160420|Dyspareunia
637351|NCT00160420|Infertility
637352|NCT00160420|asoprisnil
637353|NCT00160407|nonalcoholic steatohepatitis
637354|NCT00160407|enzyme inhibitors
637355|NCT00160407|lipase
637356|NCT00160407|obesity
637357|NCT00160407|insulin resistance
637358|NCT00160394|Mild to Moderate
637359|NCT00160381|Symptomatic Uterine Fibroids
637360|NCT00160381|Excessive Uterine Bleeding
637361|NCT00160381|Uterine Hemorrhage
637362|NCT00160381|asoprisnil
637363|NCT00160368|Hypertension, potassium salts
637364|NCT00160355|Wiskott-Aldrich Syndrome
637365|NCT00160355|Immunodeficiency
637366|NCT00160355|Haploidentical transplantation
637367|NCT00160342|Hormone replacement therapy, hot flushes, postmenopause
637368|NCT00160303|Prolotherapy
637369|NCT00160303|Lateral Epicondylitis
637370|NCT00160303|Tennis Elbow
637371|NCT00160303|Corticosteroid Therapy
637372|NCT00160290|lactulose
637373|NCT00160290|randomised clinical trial
637374|NCT00160290|hemorrhoids
637375|NCT00160290|anal fissures
637376|NCT00160277|Efficacy and safety of moxonidine in Indian hypertensives
637377|NCT00160264|lactulose; randomised clinical trial; osteopenia; postmenopause
637378|NCT00160251|PEG-Intron
637379|NCT00160251|Ribavirin
637380|NCT00160251|Protease Inhibitor
637381|NCT00160238|Meniere's disease
637382|NCT00160238|Vestibular neurotomy
637383|NCT00160225|blood pressure, diabetic nephropathy, proteinuria
637384|NCT00160212|blood pressure
637385|NCT00160199|To collect additional data on 300 and 400 mg doses of PROMETRIUM in women with secondary amenorrhea
637386|NCT00160173|Post menopausal vasomotor symptoms
637387|NCT00160160|comparator trial
637388|NCT00160160|hypertension
637389|NCT00160160|diabetes
637390|NCT00160160|blood pressure
637391|NCT00160134|congestive heart failure, adenosine receptor blocker, cardiac hemodynamic
637392|NCT00160095|larynx carcinoma
637393|NCT00160095|Tumor hypoxia
637394|NCT00160095|microregional imaging
637395|NCT00160095|hypoxia modifying treatment
637396|NCT00160082|Post Polio Syndrome
637397|NCT00160082|PPS
637398|NCT00160082|Poliomyelitis
637399|NCT00160082|Paralylic Polio
637400|NCT00160082|Late effects of polio
637401|NCT00160082|Late onset polio sequele
637402|NCT00160082|Xepol
637403|NCT00160082|IvIg
637404|NCT00160082|Intravenous Immunoglobuline
637405|NCT00160069|Stage IIIB or stage IV non-small-cell lung cancer.
637406|NCT00160056|Hypoglycemia unawareness
637407|NCT00160056|Diabetes
637408|NCT00160056|adrenal receptor
637409|NCT00160056|adrenerg respons
637410|NCT00160056|adrenergic beta-agonists
637411|NCT00160056|salbutamol
637412|NCT00160017|Quality assurance health care
637413|NCT00160017|Diabetes
637414|NCT00160017|Breakthrough collaborative (IHI)
637415|NCT00160017|Evaluation
637416|NCT00160004|Amyotrophic Lateral Sclerosis
637417|NCT00160004|Exercise
637418|NCT00160004|Fatigue
637419|NCT00160004|Quality-of-life
637420|NCT00159991|Coronary artery bypass grafting
637421|NCT00159991|Total arterial revascularization
637422|NCT00159991|Internal mammary artery grafting
637423|NCT00159991|Radial artery grafting
637424|NCT00159978|head and neck cancer
637425|NCT00159978|hypoxia
637426|NCT00159978|tumor cell proliferation
637427|NCT00159978|PET
637428|NCT00159965|nonepileptic seizure
637429|NCT00159965|pseudoseizure
637430|NCT00159965|conversion disorder
637431|NCT00159965|psychogenic
637432|NCT00159965|Depression
637433|NCT00159965|Anxiety
637434|NCT00159965|Abuse
637435|NCT00159965|post-traumatic stress disorder
637436|NCT00159965|sertraline
637437|NCT00159965|serotonin
637438|NCT00159965|randomized controlled trial
637439|NCT00159952|Sepsis
637440|NCT00159952|Septic shock
637441|NCT00159952|Hyperglycemia
637442|NCT00159952|Fibrinolysis
637443|NCT00159952|PAI 1
637444|NCT00159939|ARDS
637445|NCT00159939|prone position
637446|NCT00159926|systemic inflammatory response syndrome
637447|NCT00159926|coronary artery bypass grafting
637448|NCT00159926|cell saver
637449|NCT00159926|interleukins
637450|NCT00159926|tumor necrosis factor alfa
637451|NCT00159900|Impotence
637452|NCT00159874|children
637453|NCT00159627|heart failure, congestive
637454|NCT00159627|diuretic
637455|NCT00159614|renal insufficiency
637456|NCT00159614|diuretic
637457|NCT00159614|heart failure, congestive
637458|NCT00159601|Quality of Life
637459|NCT00159601|Mental health
637460|NCT00159601|Children
637461|NCT00159601|Adolescents
637462|NCT00159601|Normal population
637463|NCT00159588|Medication-overuse headache
637464|NCT00159588|preventative medication
637465|NCT00159588|controls
637466|NCT00159588|follow-up
637467|NCT00159588|randomized
637468|NCT00159588|abrupt withdrawal
637469|NCT00159575|Polycystic ovarian syndrome
637470|NCT00159575|Clinical pregnancy rate
637471|NCT00159575|Oligo- or anovulation
637472|NCT00159562|Bipolar Disorder
637473|NCT00159562|Psycho-education
637474|NCT00159549|Patient education
637475|NCT00159536|PCOS
637476|NCT00159536|metformin
637477|NCT00159536|pregnancy
637478|NCT00159536|preeclampsia
637479|NCT00159536|diabetes
637480|NCT00159536|preterm delivery
637481|NCT00159523|Prevention
637482|NCT00159523|Probiotics
637483|NCT00159523|Allergy
637484|NCT00159523|Hypersensitivity
637485|NCT00159510|sepsis, methylene blue, nitric oxide, acute lung injury
637486|NCT00159497|THA
637487|NCT00159484|phase 1
637488|NCT00159484|phase one
637489|NCT00159484|phase I
637490|NCT00159432|colorectal
637491|NCT00159432|cancer
637492|NCT00159419|Osteogenesis Imperfecta
637493|NCT00159419|Fractures
637494|NCT00159419|Pediatric
637495|NCT00159419|Osteoporosis
637496|NCT00159419|Juvenile Pagets
637497|NCT00159406|BPH treatment
637498|NCT00159406|Laser Prostatectomy
637499|NCT00159406|Treatment of enlarged Prostates
637500|NCT00159406|BPH
637501|NCT00159393|Kidney stones
637502|NCT00159393|nephrolithotripsy percutaneous
637503|NCT00159380|Healthy Volunteers
637504|NCT00159367|Neuromuscular electrical stimulation
637505|NCT00159354|FDG−PET
637506|NCT00159354|pulmonary inflammation,
637507|NCT00159354|smoking,
637508|NCT00159354|COPD
637509|NCT00159354|steroid intervention
637510|NCT00159341|cigarette smoke
637511|NCT00159341|nasal
637512|NCT00159341|whole blood
637513|NCT00159341|cytokines
637514|NCT00159341|chemokines
637515|NCT00159341|nasal fluid
637516|NCT00159341|filter paper
637517|NCT00159328|Magnetic Resonance Guided Focused Ultrasound
637518|NCT00159328|Gonadotrophin Releasing Hormone Agonist
637519|NCT00159328|Uterine Fibroids
637520|NCT00159315|Healthy Volunteers (smokers)
637521|NCT00159315|Healthy Volunteers (Non-smokers)
637522|NCT00159315|Asthma Patients
637523|NCT00159315|COPD Patients
637524|NCT00159289|Mild to moderate Chronic Obstructive Pulmonary Disease (COPD)
637525|NCT00159289|Volunteers (healthy non-smokers)
637526|NCT00159289|Volunteers (current or ex-smokers)
637527|NCT00159250|Duchenne muscular dystrophy;
637528|NCT00159250|antisense oligonucleotides;
637529|NCT00159250|gene restoration;
637530|NCT00159250|deletion
637531|NCT00159224|HIV
637532|NCT00159224|Simplification
637533|NCT00159224|Monotherapy
637534|NCT00159224|Treatment Naive
637535|NCT00159224|HIV-1 infection
637536|NCT00159211|type 2 diabetes
637537|NCT00159198|Amyotrophic lateral sclerosis
637538|NCT00159198|Frontotemporal dementia
637539|NCT00159198|Mutations spectrum
637540|NCT00159198|Linkage studies
637541|NCT00159198|Genetic epidemiology
637542|NCT00159185|Arthroplasty, Replacement, Hip
637543|NCT00159185|Epidemiology
637544|NCT00159172|Advanced parkinson disease
637545|NCT00159172|Stimulation
637546|NCT00159172|Motor Cortex
637547|NCT00159172|Parkinson disease C10.574.812
637548|NCT00159172|Electric Stimulation Therapy E02.831.580.438
637549|NCT00159172|Neuronavigation E05.873.249
637550|NCT00159159|Cardiac Transplant
637551|NCT00159159|ciclosporine
637552|NCT00159159|immunosuppressive
637553|NCT00159146|Major Depression
637554|NCT00159146|Pindolol
637555|NCT00159146|Venlafaxine
637556|NCT00159146|Augmentation
637557|NCT00159146|Major depression (DSM-IVR)
637558|NCT00159133|Schizophrenia
637559|NCT00159133|first episode
637560|NCT00159133|prodrome based early intervention
637561|NCT00159133|antipsychotics - benzodiazepine
637562|NCT00159133|maintenance treatment
637563|NCT00159133|drug discontinuation
637564|NCT00159120|Schizophrenia
637565|NCT00159120|first episode
637566|NCT00159120|neuroleptic maintenance treatment
637567|NCT00159120|drug discontinuation
637568|NCT00159120|prodrome based early intervention
637569|NCT00159107|alcoholism
637570|NCT00159107|abstinence enhancement
637571|NCT00159107|psychotherapy
637572|NCT00159107|cognitive behavior therapy vs. supportive counseling
637573|NCT00159107|Acamprosate vs. Placebo
637574|NCT00159107|multi-center study
637575|NCT00159081|Schizophrenia
637576|NCT00159081|first episode
637577|NCT00159081|long-term treatment
637578|NCT00159081|typical vs. atypical neuroleptics
637579|NCT00159003|drug metabolism and disposition enzymes
637580|NCT00158990|major depression
637581|NCT00158990|bipolar disorder
637582|NCT00158990|unipolar depression
637583|NCT00158990|sertraline
637584|NCT00158990|triiodothyronine
637585|NCT00158977|heart failure
637586|NCT00158977|atrial fibrillation
637587|NCT00158977|cardiac resynchronization therapy defibrillator
637588|NCT00158964|left ventricular lead
637589|NCT00158964|pacing
637590|NCT00158964|heart failure
637591|NCT00158951|Left Ventricular Lead
637592|NCT00158951|Cardiac Resynchronization Therapy
637593|NCT00158951|Congestive Heart Failure
637594|NCT00158938|Artificial Cardiac Pacemaker
637595|NCT00158938|Implanted Electrodes
637596|NCT00158925|Artificial Cardiac Pacing
637597|NCT00158925|Implanted Electrodes
637598|NCT00158899|HDLc
637599|NCT00158899|high-density lipoprotein
637600|NCT00158899|Dyslipidemia
637601|NCT00158886|oral topotecan rectal cancer pelvic radiation
637602|NCT00158873|ICU mechanical ventilation analgesia sedation
637603|NCT00158860|valaciclovir
637604|NCT00158860|genital herpes
637605|NCT00158860|HSV-2
637606|NCT00158860|Valtrex
637607|NCT00158860|suppression
637608|NCT00158847|COPD inflammation sputum lung function biopsy
637609|NCT00158834|Children
637610|NCT00158834|Asthma
637611|NCT00158834|bronchial hyperresponsiveness
637612|NCT00158834|symptoms
637613|NCT00158821|HIV
637614|NCT00158821|Antiretroviral
637615|NCT00158821|Treatment Experienced
637616|NCT00158821|HIV-1
637617|NCT00158782|Cancer GW786034 Lapatinib Pazopanib
637618|NCT00158769|Hepatic Impairment
637619|NCT00158769|Emulsion
637620|NCT00158769|GR270773
637621|NCT00158756|Diphtheria
637622|NCT00158756|Pertussis
637623|NCT00158756|Prophylaxis
637624|NCT00158756|Hepatitis B diseases
637625|NCT00158756|Tetanus
637626|NCT00158743|Pre-eclampsia
637627|NCT00158743|Hypertension
637628|NCT00158743|Endogenous digitalis-like factor
637629|NCT00158743|Anti-digoxin antibody
637630|NCT00158743|Digibind
637631|NCT00158717|Chronic Hepatitis B
637632|NCT00158704|Chronic Hepatitis B
637633|NCT00158691|Head and Neck cancer
637634|NCT00158691|Radiotherapy
637635|NCT00158691|Xerostomia
637636|NCT00158691|Randomized trial
637637|NCT00158678|oral cancer
637638|NCT00158678|oropharynx cancer
637639|NCT00158678|hypopharynx cancer
637640|NCT00158678|IMRT
637641|NCT00158665|Influenza
637642|NCT00158665|Vaccination
637643|NCT00158665|Immunization
637644|NCT00158665|Flu
637645|NCT00158665|Immunogenicity
637646|NCT00158652|Head and neck squamous cell carcinoma
637647|NCT00158652|Radiotherapy
637648|NCT00158652|Chemotherapy
637649|NCT00158639|Blood Pressure Monitoring, home
637650|NCT00158639|Pharmaceutical services
637651|NCT00158639|Self care
637652|NCT00158626|physical therapy
637653|NCT00158626|physiotherapy
637654|NCT00158626|pelvic organ prolapse
637655|NCT00158600|Glycogen Storage Disease Type II
637656|NCT00158600|GSD-II
637657|NCT00158600|Pompe Disease
637658|NCT00158587|Vivax
637659|NCT00158587|Treatment
637660|NCT00158587|Primaquine
637661|NCT00158587|Asia
637662|NCT00158574|intermittent preventive treatment
637663|NCT00158574|malaria
637664|NCT00158574|efficacy
637665|NCT00158574|safety
637666|NCT00158574|drug options
637667|NCT00158561|vivax
637668|NCT00158561|treatment
637669|NCT00158561|Asia
637670|NCT00158548|Falciparum
637671|NCT00158548|Vivax
637672|NCT00158548|Treatment
637673|NCT00158548|Asia
637674|NCT00158535|Liver Transplantation
637675|NCT00158535|Hepatitis C
637676|NCT00158535|HIV Infections
637677|NCT00158522|Acute hepatitis C
637678|NCT00158522|Genotype 4
637679|NCT00158522|Pegylated Interferon
637680|NCT00158522|Egypt
637681|NCT00158509|Valacyclovir
637682|NCT00158509|HIV-1
637683|NCT00158509|HSV-2
637684|NCT00158509|genital shedding
637685|NCT00158509|herpes genitalis
637686|NCT00158509|HIV infection
637687|NCT00158496|Chronic Hepatitis C
637688|NCT00158496|Genotype 4
637689|NCT00158496|Pegylated Interferon
637690|NCT00158496|Ribavirin
637691|NCT00158496|Egypt
637692|NCT00158483|Genital herpes
637693|NCT00158483|Cofactors of sexual transmission
637694|NCT00158483|Syndromic treatment
637695|NCT00158483|Genital viral load
637696|NCT00158483|Ulcer
637697|NCT00158470|HIV infection
637698|NCT00158470|injecting drug users
637699|NCT00158470|HAART
637700|NCT00158470|once daily regimen
637701|NCT00158470|Treatment Naive
637702|NCT00158457|Simplification regimen
637703|NCT00158457|HIV infection
637704|NCT00158457|Once a day
637705|NCT00158457|Naive patients
637706|NCT00158457|Sub-saharian Africa
637707|NCT00158457|Treatment Naive
637708|NCT00158444|arthroplasty
637709|NCT00158444|Resurfacing
637710|NCT00158444|implant
637711|NCT00158431|osteoarthritis
637712|NCT00158431|randomized trial
637713|NCT00158431|knee
637714|NCT00158431|quality of life
637715|NCT00158418|osteoarthritis
637716|NCT00158418|shoulder
637717|NCT00158418|randomized trial
637718|NCT00158418|cement
637719|NCT00158405|HIV
637720|NCT00158405|Structured treatment interruption
637721|NCT00158405|HAART
637722|NCT00158405|Sub-saharian africa
637723|NCT00158405|Treatment Interruption
637724|NCT00158405|Treatment Naive
637725|NCT00158366|Weight Loss
637726|NCT00158353|Mentors
637727|NCT00158353|Self-esteem
637728|NCT00158353|Adolescent
637729|NCT00158353|Mental health
637730|NCT00158353|Social support
637731|NCT00158353|Substance use
637732|NCT00158353|Violence
637733|NCT00158353|Exercise
637734|NCT00158353|Nutrition
637735|NCT00158353|Sexual behavior
637736|NCT00158353|Female
637737|NCT00158340|Binge Eating
637738|NCT00158340|Overeating
637739|NCT00158340|Compulsive Eating
637740|NCT00158340|Hyperphagia
637741|NCT00158327|Primary Health Care
637742|NCT00158314|Pathological gambling
637743|NCT00158314|Gambler's anonymous
637744|NCT00158314|Cognitive behavioral therapy
637745|NCT00158314|CBT
637746|NCT00158301|Child
637747|NCT00158301|Adolescent
637748|NCT00158301|CBT
637749|NCT00158301|Drug Therapy
637750|NCT00158288|Substance Use Disorders
637751|NCT00158275|Cognitive behavioral therapy
637752|NCT00158275|Problem solving therapy
637753|NCT00158275|CBT
637754|NCT00158262|Post-Traumatic Stress Disorder
637755|NCT00158262|Prevention
637756|NCT00158262|Propranolol
637757|NCT00158262|Psychophysiology
637758|NCT00158249|citicoline, drug abuse, marijuana
637759|NCT00158236|Opiate Addiction
637760|NCT00158236|Opiate Dependence
637761|NCT00158223|Schizophrenia
637762|NCT00158223|Clozapine
637763|NCT00158223|Treatment
637764|NCT00158223|Combination
637765|NCT00158223|Unresponsive
637766|NCT00158223|Schizoaffective Disorders
637767|NCT00158197|Adherence
637768|NCT00158197|Amphetamine-Related Disorders
637769|NCT00158197|Behavior Therapy
637770|NCT00158197|Contingency management
637771|NCT00158197|Drug Counseling
637772|NCT00158197|health behaviors
637773|NCT00158197|methamphetamine
637774|NCT00158197|sexual risk behaviors
637775|NCT00158197|substance dependence
637776|NCT00158171|smoking addiction
637777|NCT00158158|smoking addiction
637778|NCT00158132|cocaine
637779|NCT00158119|strength training
637780|NCT00158119|power training
637781|NCT00158119|exercise training
637782|NCT00158119|functional performance tasks
637783|NCT00158106|functional communicative ability
637784|NCT00158106|cost effectiveness
637785|NCT00158106|service user preferences
637786|NCT00158067|Epilepsy
637787|NCT00158067|Neurostimulation
637788|NCT00158054|depression
637789|NCT00158054|acute coronary syndrome
637790|NCT00158054|clinical trials
637791|NCT00158041|Amifostine
637792|NCT00158041|Mucositis
637793|NCT00158041|Nausea
637794|NCT00158041|Hypotension
637795|NCT00158041|Rash
637796|NCT00158028|Schizotypal Personality Disorder
637797|NCT00158028|Risperidone
637798|NCT00158028|Treatment
637799|NCT00158028|Cognitive
637800|NCT00158015|Echocardiography
637801|NCT00158015|tissue Doppler Imaging
637802|NCT00158015|Cardiac Resynchronization Therapy
637803|NCT00158002|Basilar/Hemiplegic Migraine
637804|NCT00158002|Prophylaxis
637805|NCT00157989|Infant, Premature
637806|NCT00157976|Macular Degeneration
637807|NCT00157976|AMD
637808|NCT00157976|Visual Acuity
637809|NCT00157950|Human Papilloma Virus
637810|NCT00157885|Falciparum
637811|NCT00157885|Vivax
637812|NCT00157885|Papua
637813|NCT00157885|Amodiaquine
637814|NCT00157885|Artekin
637815|NCT00157885|Artemisinin Combination Therapy
637816|NCT00157885|Dihydroartemisinin
637817|NCT00157885|Piperaquine
637818|NCT00157885|Lumefantrine
637819|NCT00157885|Artemether
637820|NCT00157859|Falciparum
637821|NCT00157859|Vivax
637822|NCT00157859|Papua
637823|NCT00157859|Chloroquine
637824|NCT00157859|Sulphadoxine-pyrimethamine
637825|NCT00157846|Heart Failure
637826|NCT00157846|LVEF < 35%
637827|NCT00157846|Bradycardia
637828|NCT00157833|Coartemether
637829|NCT00157833|Artekin
637830|NCT00157833|Papua
637831|NCT00157833|Uncomplicated malaria
637832|NCT00157820|Defibrillators, Implantable
637833|NCT00157820|Atrial Fibrillation
637834|NCT00157820|Ventricular Tachyarrhythmias
637835|NCT00157820|Clinical Trial
637836|NCT00157807|Persistent Atrial Fibrillation
637837|NCT00157807|Permanent Atrial Fibrillation
637838|NCT00157807|Mitral Valve Defect
637839|NCT00157807|Tricuspid Valve Defect
637840|NCT00157807|Aortic Valve Defect
637841|NCT00157794|Sinus Node Disease
637842|NCT00157794|Pacemaker
637843|NCT00157794|Dual Chamber Pacemaker
637844|NCT00157781|Atrial Fibrillation
637845|NCT00157781|Atrial Tachyarrhythmia
637846|NCT00157781|Pacing
637847|NCT00157781|Electrophysiology
637848|NCT00157768|Acute myocardial infarction
637849|NCT00157768|Non-sustained ventricular tachycardia
637850|NCT00157768|Left ventricular dysfunction
637851|NCT00157768|Implantable cardioverter defibrillator
637852|NCT00157768|ICD
637853|NCT00157768|Risk-stratification
637854|NCT00157755|Nausea and Vomiting
637855|NCT00157742|Angina Pectoris
637856|NCT00157742|Spinal Cord Stimulation (SCS)
637857|NCT00157742|Percutaneous Myocardial Revascularisation (PMR)
637858|NCT00157742|Refractory Angina Pectoris
637859|NCT00157729|Hypertension
637860|NCT00157729|antihypertensive agents
637861|NCT00157729|diabetes mellitus type 2
637862|NCT00157729|metabolic syndrome
637863|NCT00157716|Coronary
637864|NCT00157716|surgery
637865|NCT00157716|ischemia
637866|NCT00157716|reperfusion injury
637867|NCT00157716|cardiac
637868|NCT00157716|heart
637869|NCT00157716|neurological
637870|NCT00157716|cardiopulmonary bypass
637871|NCT00157716|cardioprotection
637872|NCT00157703|Malignant glioma
637873|NCT00157703|Glioblastoma multiforme
637874|NCT00157703|GBM
637875|NCT00157703|Gliosarcoma
637876|NCT00157703|Anaplastic astrocytoma
637877|NCT00157703|Brain cancer
637878|NCT00157703|Brain tumor
637879|NCT00157703|Glioma
637880|NCT00157703|recurrent/progressive malignant glioma
637881|NCT00157690|Alendronate
637882|NCT00157690|Bisphosphonates
637883|NCT00157690|Cystic Fibrosis
637884|NCT00157690|Osteoporosis
637885|NCT00157677|deep vein thrombosis
637886|NCT00157677|pulmonary embolism
637887|NCT00157677|D-dimer testing
637888|NCT00157651|end stage renal disease
637889|NCT00157651|thrombosis
637890|NCT00157651|bleeding
637891|NCT00157638|pharmacist
637892|NCT00157638|physician
637893|NCT00157638|primary care
637894|NCT00157638|collaboration
637895|NCT00157638|therapeutics
637896|NCT00157625|urinary infections, catheters, bacteriuria, trial
637897|NCT00157612|pneumonia
637898|NCT00157612|lower respiratory tract infection
637899|NCT00157612|clinical pathway
637900|NCT00157612|nursing home
637901|NCT00157612|long-term care
637902|NCT00157612|randomized control trial
637903|NCT00157599|deep vein thrombosis
637904|NCT00157599|DVT
637905|NCT00157573|Asymptomatic
637906|NCT00157573|Clinical trial
637907|NCT00157573|Phase II
637908|NCT00157573|GM-CSF
637909|NCT00157573|Immunotherapy
637910|NCT00157547|Depression
637911|NCT00157547|Quantitative EEG (QEEG)
637912|NCT00157547|Antidepressants
637913|NCT00157534|Hepatitis C
637914|NCT00157534|Celgosivir
637915|NCT00157534|HCV
637916|NCT00157534|Genotype 1
637917|NCT00157378|first episode,
637918|NCT00157378|schizophrenia,
637919|NCT00157378|atypical neuroleptics,
637920|NCT00157378|negative symptoms
637921|NCT00157326|High Blood Pressure
637922|NCT00157313|Schizophrenia
637923|NCT00157313|First episode psychosis
637924|NCT00157313|Psychosocial intervention
637925|NCT00157300|erythropoietin
637926|NCT00157300|kidney transplantation
637927|NCT00157300|delayed graft function
637928|NCT00157274|Alemtuzumab
637929|NCT00157274|Mycosis fungoides
637930|NCT00157274|Sezary
637931|NCT00157222|Charcot
637932|NCT00157222|Diabetic
637933|NCT00157222|osteoporosis
637934|NCT00157196|Carcinoma, Non-Small-Cell Lung, L-BLP25, Tecemotide
637935|NCT00157183|cystic fibrosis
637936|NCT00157183|hypoxia
637937|NCT00157183|oxygen
637938|NCT00157183|noninvasive ventilation
637939|NCT00157183|quality of life
637940|NCT00157170|exercise
637941|NCT00157170|self efficacy
637942|NCT00157170|quality of life
637943|NCT00157170|HIV
637944|NCT00157157|Factor VIII Deficiency
637945|NCT00157144|Lung Transplantation
637946|NCT00157144|Heart Transplantation
637947|NCT00157131|autologous sheet skin grafts
637948|NCT00157131|FS 4IU VH S/D
637949|NCT00157131|skin grafts
637950|NCT00157131|burn
637951|NCT00157118|Severe congenital protein C deficiency
637952|NCT00157079|PID
637953|NCT00157079|Immune Thrombocytopenic Purpura (ITP)
637954|NCT00157079|Kawasaki syndrome
637955|NCT00157079|Immunodeficiency
637956|NCT00157066|Latent tuberculosis infection
637957|NCT00157066|Active tuberculosis infection
637958|NCT00157053|Factor VIII Deficiency
637959|NCT00157040|Factor VIII Deficiency
637960|NCT00157027|Treatment Experienced
637961|NCT00157027|HIV-1 Positive by ELISA Assay
637962|NCT00157027|Confirmed by Western Blot
637963|NCT00157027|Refractory or intolerant to HAART
637964|NCT00157014|Treatment Outcome
637965|NCT00157014|Treatment Effectiveness
637966|NCT00157014|Anti-rejection therapy
637967|NCT00157014|Immunosuppression
637968|NCT00157014|Antirejection
637969|NCT00156988|burns
637970|NCT00156988|partial thickness
637971|NCT00156988|cerium flamazine
637972|NCT00156988|randomised clinical trial
637973|NCT00156975|Oxaliplatin
637974|NCT00156975|Capecitabine
637975|NCT00156975|Chemotherapy
637976|NCT00156975|Resection
637977|NCT00156975|Liver metastases
637978|NCT00156975|Liver resection
637979|NCT00156975|Adjuvant
637980|NCT00156962|Epogen
637981|NCT00156962|Procrit
637982|NCT00156962|Chronic Kidney Disease
637983|NCT00156962|Anemia Treatment
637984|NCT00156949|Epogen
637985|NCT00156949|Procrit
637986|NCT00156949|Chronic Kidney Disease
637987|NCT00156949|Anemia Treatment for Dialysis Patients
637988|NCT00156923|Alcohol dependence
637989|NCT00156897|Non-insulin-dependent diabetes mellitus
637990|NCT00156897|NIDDM
637991|NCT00156897|Type II diabetes
637992|NCT00156897|Obesity
637993|NCT00156897|Lipase inhibitor
637994|NCT00156884|prostate cancer
637995|NCT00156884|cisplatin
637996|NCT00156884|strontium-89
637997|NCT00156884|phase II
637998|NCT00156871|transplant
637999|NCT00156871|fatigue
638000|NCT00156871|exercise
638001|NCT00156871|Malignant disease
638002|NCT00156858|pharmacokinetics
638003|NCT00156858|transplantation
638004|NCT00156858|busulfan
638005|NCT00156845|coronary artery disease
638006|NCT00156845|ischemia
638007|NCT00156845|echocardiography
638008|NCT00156845|cardiac imaging
638009|NCT00156845|heart disease
638010|NCT00156845|myocardial contrast enhancement
638011|NCT00156845|myocardial perfusion
638012|NCT00156845|wall motion
638013|NCT00156845|ultrasound contrast agent
638014|NCT00156819|Asthma
638015|NCT00156819|Asthma Control
638016|NCT00156806|aloe
638017|NCT00156806|radiation dermatitis
638018|NCT00156806|radiation therapy
638019|NCT00156793|coronary artery disease
638020|NCT00156793|ischemia
638021|NCT00156793|echocardiography
638022|NCT00156793|cardiac imaging
638023|NCT00156793|heart disease
638024|NCT00156793|myocardial contrast enhancement
638025|NCT00156793|myocardial perfusion
638026|NCT00156793|wall motion
638027|NCT00156793|ultrasound contrast agent
638028|NCT00156780|ultrasound contrast agent
638029|NCT00156780|pharmacokinetics
638030|NCT00156780|congestive heart failure
638031|NCT00156780|chronic obstructive pulmonary disease
638032|NCT00156780|safety
638033|NCT00156767|Critical Care
638034|NCT00156767|Adrenal Insufficiency
638035|NCT00156767|Septic Shock
638036|NCT00156767|Cortrosyn
638037|NCT00156767|Steroids
638038|NCT00156767|Cortisol
638039|NCT00156767|Critical Care Unit
638040|NCT00156767|Adrenal Gland Function
638041|NCT00156741|Refined ventricular pacing
638042|NCT00156728|Pacemaker artificial, congestive heart failure and atrial fibrillation
638043|NCT00156715|Quetiapine
638044|NCT00156715|Seroquel
638045|NCT00156715|Schizophrenia
638046|NCT00156715|Dual Diagnosis
638047|NCT00156715|Substance Abuse
638048|NCT00156715|Alcohol Abuse
638049|NCT00156702|Smoking
638050|NCT00156702|Adolescents
638051|NCT00156702|Motivational Interviewing
638052|NCT00156689|polyneuropathy
638053|NCT00156676|Disability
638054|NCT00156676|Gait
638055|NCT00156676|Multiple Sclerosis
638056|NCT00156676|Rehabilitation
638057|NCT00156676|Robot
638058|NCT00156663|Women
638059|NCT00156663|Veterans
638060|NCT00156663|Delivery of Healthcare
638061|NCT00156663|Intervention Studies
638062|NCT00156663|United States Department of Veterans Affairs
638063|NCT00156663|Women's Health
638064|NCT00156650|Male contraception
638065|NCT00156650|Testosterone
638066|NCT00156637|schizophrenia
638067|NCT00156637|quality of health care
638068|NCT00156637|quality indicators
638069|NCT00156637|intervention studies
638070|NCT00156624|Intervention
638071|NCT00156624|Peripheral Vascular Disease
638072|NCT00156624|Drug
638073|NCT00156624|Restenosis
638074|NCT00156624|18 years and above
638075|NCT00156611|peripheral vascular disease
638076|NCT00156611|intervention
638077|NCT00156611|restenosis
638078|NCT00156611|Age above 18 years
638079|NCT00156598|metal ion concentration
638080|NCT00156585|cerebral metastases
638081|NCT00156585|dynamic contrast enhanced magnetic resonance imaging
638082|NCT00156585|DCE-MRI
638083|NCT00156585|gamma knife
638084|NCT00156559|immunization
638085|NCT00156559|vaccine
638086|NCT00156559|low birth weight infant
638087|NCT00156559|premature infant
638088|NCT00156546|Urinary tract infections
638089|NCT00156546|Children
638090|NCT00156546|Antibiotic prophylaxis
638091|NCT00156546|Renal scintigraphy
638092|NCT00156546|Vesico ureteral reflux
638093|NCT00156533|Insomnia
638094|NCT00156533|Sleep
638095|NCT00156533|zolpidem
638096|NCT00156533|Ambien
638097|NCT00156533|Hypnotics
638098|NCT00156455|Children
638099|NCT00156455|Hypoplastic left heart syndrome
638100|NCT00156455|Obstructive Sleep Apnea Syndrome
638101|NCT00156455|Single Ventricle Physiology
638102|NCT00156442|Obstructive Sleep Apnea Syndrome
638103|NCT00156442|Cleft lip/palate
638104|NCT00156442|Children
638105|NCT00156429|genetic testing
638106|NCT00156416|menopause
638107|NCT00156416|hot flash
638108|NCT00156416|night sweat
638109|NCT00156416|meditation
638110|NCT00156416|breast cancer
638111|NCT00156403|pancreatitis, hereditary
638112|NCT00156403|trypsinogen, cationic
638113|NCT00156403|pilot study
638114|NCT00156377|Mupirocin
638115|NCT00156377|Staphylococcus aureus
638116|NCT00156377|Nasal Cavity
638117|NCT00156377|Preventive measures
638118|NCT00156364|Diabetic Nephropathy
638119|NCT00156364|Kidney Transplant
638120|NCT00156364|Pancreas Transplant
638121|NCT00156364|Renal Interstitium
638122|NCT00156364|Diabetes Mellitus
638123|NCT00156364|Cyclosporine
638124|NCT00156364|Tacrolimus
638125|NCT00156351|African Americans
638126|NCT00156351|Women
638127|NCT00156351|Internet
638128|NCT00156351|Telephone Counseling
638129|NCT00156338|Fluid therapy
638130|NCT00156325|Bipolar Disorder
638131|NCT00156325|Depression
638132|NCT00156325|Hypomania
638133|NCT00156325|Mood Stabilizer
638134|NCT00156299|adult acute megakaryoblastic leukemia (M7)
638135|NCT00156299|adult acute minimally differentiated myeloid leukemia (M0)
638136|NCT00156299|adult acute monoblastic leukemia (M5a)
638137|NCT00156299|adult acute monocytic leukemia (M5b)
638138|NCT00156299|adult acute myeloblastic leukemia with maturation (M2)
638139|NCT00156299|adult acute myeloblastic leukemia without maturation (M1)
638140|NCT00156299|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
638141|NCT00156299|adult acute myeloid leukemia with inv(16)(p13;q22)
638142|NCT00156299|adult acute myeloid leukemia with t(16;16)(p13;q22)
638143|NCT00156299|adult acute myeloid leukemia with t(8;21)(q22;q22)
638144|NCT00156299|adult acute myelomonocytic leukemia (M4)
638145|NCT00156299|adult erythroleukemia (M6a)
638146|NCT00156299|adult pure erythroid leukemia (M6b)
638147|NCT00156299|untreated adult acute myeloid leukemia
638148|NCT00156247|psoriasis
638149|NCT00156247|etanercept
638150|NCT00156247|acitretin
638151|NCT00156221|Autism
638152|NCT00156221|MRI
638153|NCT00156221|Developmental Disorders
638154|NCT00156208|Symptomatic Uterine Fibroids
638155|NCT00156208|Excessive Uterine Bleeding
638156|NCT00156208|Uterine Hemorrhage
638157|NCT00156208|asoprisnil
638158|NCT00156195|Symptomatic Uterine Fibroids
638159|NCT00156195|Excessive Uterine Bleeding
638160|NCT00156195|Uterine Hemorrhage
638161|NCT00156195|asoprisnil
638162|NCT00156182|Fibroid Uterus
638163|NCT00156182|Leiomyoma
638164|NCT00156182|Uterine Fibroids
638165|NCT00156182|asoprisnil
638166|NCT00156156|Symptomatic Uterine Fibroids
638167|NCT00156156|Excessive Uterine Bleeding
638168|NCT00156156|Uterine Hemorrhage
638169|NCT00156130|Breast Cancer
638170|NCT00156130|Lumpectomy
638171|NCT00156130|Radiotherapy
638172|NCT00156130|Hypofractionated Radiotherapy
638173|NCT00156130|Long Term Outcomes
638174|NCT00156052|Breast Cancer
638175|NCT00156052|Hypofractionated Radiotherapy
638176|NCT00156052|Lumpectomy
638177|NCT00156039|Breast Cancer
638178|NCT00156039|Follow-up Strategy
638179|NCT00156039|Follow-up Care
638180|NCT00156039|Family Physician
638181|NCT00156039|Oncologist
638182|NCT00156026|CIN 1
638183|NCT00156026|cervical intraepithelial neoplasia
638184|NCT00156026|cervix
638185|NCT00156026|cancer
638186|NCT00156026|loop electrosurgical excision procedure
638187|NCT00156026|LEEP
638188|NCT00156026|expectant management
638189|NCT00156026|human papilloma virus
638190|NCT00156026|HPV
638191|NCT00156026|colposcopy
638192|NCT00156013|B-Cell NHL
638193|NCT00156000|Preterm Delivery
638194|NCT00156000|Multifetal pregnancy
638195|NCT00156000|Preterm Birth
638196|NCT00156000|17-alpha Hydroxyprogesterone Caproate
638197|NCT00156000|Markers of Preterm Birth
638198|NCT00155987|Severe diffuse TBI refractory intracranial hypertension.
638199|NCT00155974|Influenza
638200|NCT00155974|Vaccination
638201|NCT00155974|Hard-to-Reach Populations
638202|NCT00155974|Urban
638203|NCT00155974|Disadvantaged
638204|NCT00155961|Androgens
638205|NCT00155961|Metabolic syndrome
638206|NCT00155961|Bone mineral density
638207|NCT00155961|Body composition
638208|NCT00155961|Questionnaire
638209|NCT00155948|Ultrasonography
638210|NCT00155948|Cervical Multifidus
638211|NCT00155935|ovarian cancer
638212|NCT00155935|immunotherapy
638213|NCT00155935|folate receptor
638214|NCT00155935|Chemotherapy
638215|NCT00155922|Diabetes mellitus
638216|NCT00155922|Monocyte
638217|NCT00155922|Gene expression
638218|NCT00155922|Monocyte gene expression
638219|NCT00155909|Radiation Pneumonitis
638220|NCT00155909|Radiotherapy Planning, Computer-Assisted
638221|NCT00155896|BRCA1 gene, BRCA2 gene, DHPLC, genetic diagnosis
638222|NCT00155870|laparoscopic assisted vaginal hysterectomy leiomyoma
638223|NCT00155870|adenomyosis
638224|NCT00155870|quality of life
638225|NCT00155857|glaucoma, genetic
638226|NCT00155831|Premature infants
638227|NCT00155831|Kicking
638228|NCT00155831|Stepping
638229|NCT00155831|Walking
638230|NCT00155831|Motor development
638231|NCT00155831|Kinematics
638232|NCT00155818|DISC1
638233|NCT00155818|Schizophrenia
638234|NCT00155818|Chromosome 1q
638235|NCT00155818|Polymorphism detection
638236|NCT00155818|Association study
638237|NCT00155818|Balanced translocation
638238|NCT00155818|DHPLC
638239|NCT00155805|Gastroesophageal reflux disease
638240|NCT00155805|reflux esophagitis
638241|NCT00155805|nonerosive reflux disease
638242|NCT00155805|Barrett’s esophagus
638243|NCT00155805|hiatus hernia
638244|NCT00155805|lower esophageal sphincter pressure
638245|NCT00155805|24 hours esophageal pH monitor
638246|NCT00155805|Helicobacter pylori
638247|NCT00155792|ervical cancer, human papillomavirus, immunotherapy
638248|NCT00155779|adult respiratory distress syndrome
638249|NCT00155779|angiotensin-converting enzyme
638250|NCT00155779|polymorphism
638251|NCT00155766|cervical cancer, immunotherapy, DC
638252|NCT00155753|pathological myopia, genomic
638253|NCT00155740|ovarian cancer
638254|NCT00155740|tumor marker
638255|NCT00155740|mesothelin
638256|NCT00155727|colorectal cancer, laparoscopic colectomy
638257|NCT00155714|pulmonary arterial hypertension
638258|NCT00155714|type-5 phosphodiesterase Inhibitors
638259|NCT00155714|Sildenafil
638260|NCT00155701|DISC1
638261|NCT00155701|Schizophrenia
638262|NCT00155701|Chromosome 1q
638263|NCT00155701|Polymorphism detection
638264|NCT00155701|Association study
638265|NCT00155701|Balanced translocation
638266|NCT00155701|DHPLC
638267|NCT00155688|Schizophrenia
638268|NCT00155688|linkage
638269|NCT00155688|Taiwan
638270|NCT00155688|Han Chinese population
638271|NCT00155662|work hardening
638272|NCT00155662|chronic low back pain over 3 months
638273|NCT00155649|schizophrenia
638274|NCT00155649|vulnerability gene
638275|NCT00155649|positional cloning
638276|NCT00155649|subtype definition
638277|NCT00155649|endophenotype
638278|NCT00155649|genetic marker
638279|NCT00155649|genetic linkage
638280|NCT00155649|candidate genes
638281|NCT00155636|Schizophrenia
638282|NCT00155623|H. pylori, 13C-urea breath test, serology, epidemiology
638283|NCT00155610|diabetic cystopathy
638284|NCT00155610|bladder
638285|NCT00155610|voiding dysfunction
638286|NCT00155610|current perception test
638287|NCT00155597|physical therapy
638288|NCT00155597|post surgery
638289|NCT00155584|warts
638290|NCT00155584|photodynamic therapy
638291|NCT00155584|5-ALA
638292|NCT00155571|betel nut
638293|NCT00155571|periodontitis
638294|NCT00155571|periodontal microbiology
638295|NCT00155558|Colorectal Cancer, Maximum tolerated dose
638296|NCT00155545|functional scoliosis
638297|NCT00155545|idiopathic scoliosis
638298|NCT00155545|leg length discrepancy
638299|NCT00155545|motion analysis
638300|NCT00155545|biomechanics
638301|NCT00155532|Peripheral neuropathy;systemic lupus erythematosus
638302|NCT00155519|Schizophrenia
638303|NCT00155519|Latent Schizophrenia
638304|NCT00155519|Schizotypal Disorder
638305|NCT00155519|Psychopathology
638306|NCT00155519|Neuropsychological Function
638307|NCT00155519|Family History
638308|NCT00155519|Nosology
638309|NCT00155519|basic symptoms
638310|NCT00155506|Schizophrenia
638311|NCT00155506|Niacin
638312|NCT00155506|Genotyping
638313|NCT00155506|candidate gene
638314|NCT00155506|one proband, normal parents and one normal sibling
638315|NCT00155480|thoracic aorta
638316|NCT00155480|finite element mesh
638317|NCT00155467|CT
638318|NCT00155467|children
638319|NCT00155467|congenital
638320|NCT00155454|Diabetic retinopathy
638321|NCT00155454|Vitrectomy
638322|NCT00155454|Postoperative vitreous hemorrahge
638323|NCT00155454|Intravitreal gas injection
638324|NCT00155441|sleep disorder
638325|NCT00155441|peritoneal dialysis
638326|NCT00155441|cognitive-behavioral therapy
638327|NCT00155441|sleep disorder:C23.888.592.796
638328|NCT00155441|peritoneal dialysis: F03.870.664
638329|NCT00155025|Prostatic neoplasms
638330|NCT00155025|Family history
638331|NCT00154999|hyperbilirubinemia
638332|NCT00154999|free radicals
638333|NCT00154999|Health neonate
638334|NCT00154986|invasion
638335|NCT00154986|migration
638336|NCT00154986|metastasis
638337|NCT00154986|IGFBP-3
638338|NCT00154986|transfection
638339|NCT00154986|signal transduction.
638340|NCT00153972|Parkinson's disease
638341|NCT00153972|Fluoro-Dopa-PET
638342|NCT00153972|Dopamine agonists
638343|NCT00153972|Cabergoline
638344|NCT00153972|Surrogate marker
638345|NCT00153972|Dopamine turnover
638346|NCT00153946|Free Radical Scavenger
638347|NCT00153946|Selective Thrombin Inhibitor
638348|NCT00153946|Acute ischemic stroke (nonlacunar and noncardioembolic)
638349|NCT00153933|Multiple Myeloma
638350|NCT00153933|bortezomib
638351|NCT00153933|Revlimid
638352|NCT00153933|CC-5013
638353|NCT00153920|multiple myeloma
638354|NCT00153920|Velcade
638355|NCT00153920|bortezomib
638356|NCT00153907|Xeloda
638357|NCT00153907|Navelbine
638358|NCT00153907|capecitabine
638359|NCT00153907|metastatic breast cancer
638360|NCT00153894|Breast cancer survivor
638361|NCT00153894|Insulin levels
638362|NCT00153894|exercise regimen
638363|NCT00153894|endurance training
638364|NCT00153894|strength training
638365|NCT00153881|Esophageal Cancer
638366|NCT00153881|Trimodality
638367|NCT00153881|Capecitabine
638368|NCT00153881|Xeloda
638369|NCT00153881|Gastro-esophageal Neoplasm
638370|NCT00153881|Carcinoma of the Esophagus
638371|NCT00153868|Anemia
638372|NCT00153868|Cancer
638373|NCT00153868|Quality of life
638374|NCT00153868|Web-based
638375|NCT00153868|Aranesp
638376|NCT00153868|Darbepoetin alfa
638377|NCT00153855|etiology
638378|NCT00153855|pathology
638379|NCT00153842|NSCLC
638380|NCT00153842|Bexarotene
638381|NCT00153842|Targretin
638382|NCT00153829|Chronic Disease
638383|NCT00153829|Quality of Life
638384|NCT00153816|Colorectal neoplasms
638385|NCT00153816|Adenomatous polyps
638386|NCT00153803|Erlotinib
638387|NCT00153803|Tarceva
638388|NCT00153803|Web based
638389|NCT00153803|Stage III NSCLC
638390|NCT00153790|green tea
638391|NCT00153790|weight
638392|NCT00153790|women
638393|NCT00153777|HIV prevention
638394|NCT00153777|Randomized controlled trial
638395|NCT00153777|Women
638396|NCT00153777|Sexually transmitted infections
638397|NCT00153777|HIV Seronegativity
638398|NCT00153764|supplement
638399|NCT00153764|omega-3 fatty acid
638400|NCT00153764|Homocysteine
638401|NCT00153764|LDL cholesterol
638402|NCT00153751|Traditional Chinese Medicine
638403|NCT00153738|LDL-C, phytosterol
638404|NCT00155428|biomodel
638405|NCT00155428|rapid prototyping
638406|NCT00155428|computed tomograpgy
638407|NCT00155415|Colonoscopy
638408|NCT00155415|Polyethylene glycol(PEG)
638409|NCT00155415|Colon neoplasm
638410|NCT00155415|Colon cleansing
638411|NCT00155415|Timing
638412|NCT00155402|fibrin glue
638413|NCT00155402|corneal perforation
638414|NCT00155402|pterygium
638415|NCT00155402|conjunctiva
638416|NCT00155402|corneal ulcer
638417|NCT00155389|Helicobacter pylori
638418|NCT00155389|Gastric cancer
638419|NCT00155389|single nucleotide polymorphism
638420|NCT00155350|atherosclerosis
638421|NCT00155350|calcification
638422|NCT00155350|coronary
638423|NCT00155350|inflammation
638424|NCT00155350|insulin
638425|NCT00155350|plaque
638426|NCT00155350|Coronary calcification
638427|NCT00155350|Plaque vulnerability
638428|NCT00155337|leukoplakia
638429|NCT00155337|erythroleukoplakia
638430|NCT00155337|photodynamic therapy
638431|NCT00155324|plantar fasciitis
638432|NCT00155324|ultrasonographic examination
638433|NCT00155311|orthodontic tooth movement
638434|NCT00155311|OPG
638435|NCT00155311|RANKL
638436|NCT00155285|heart diseases
638437|NCT00155285|congenital
638438|NCT00155272|Hepatocellular Carcinoma
638439|NCT00155272|Radiotherapy
638440|NCT00155272|Thalidomide
638441|NCT00155272|Dynamic contrast enhanced MRI
638442|NCT00155259|Breast Cancer , Neoadjuvant Chemotherapy
638443|NCT00155246|CKD, pentoxifylline
638444|NCT00155233|analgeisa
638445|NCT00155233|postoperatve
638446|NCT00155233|side effects
638447|NCT00155207|Schizophrenia
638448|NCT00155207|endophenotype
638449|NCT00155207|risk genetic mutation
638450|NCT00155207|vulnerability genes
638451|NCT00155207|affected sib-pairs
638452|NCT00155207|case-control design
638453|NCT00155207|animal model
638454|NCT00155207|functional validity
638455|NCT00155207|genetic epidemiological analysis
638456|NCT00155181|Epstein-Barr virus
638457|NCT00155181|Nasopharyngeal carcinoma
638458|NCT00155181|Carcinogenesis
638459|NCT00155168|Spinal muscular atrophy (SMA)
638460|NCT00155168|SMN1/SMN2 gene
638461|NCT00155168|denaturing high-performance liquid chromatography (DHPLC)
638462|NCT00155168|multiplex PCR
638463|NCT00155168|gene dose
638464|NCT00155168|carrier test
638465|NCT00155129|migraine
638466|NCT00155129|CGRP
638467|NCT00155129|nociceptin
638468|NCT00155103|Hepatitis B
638469|NCT00155103|Carcinoma, Hepatocellular
638470|NCT00155103|Polymorphism, Genetic
638471|NCT00155090|Magnetic resonance imaging,
638472|NCT00155090|breast disease
638473|NCT00155077|cervical cancer, chemoradiotherapy, angiogenesis
638474|NCT00155064|Primary aldosteronism
638475|NCT00155064|kallikrein
638476|NCT00155064|aldosterone
638477|NCT00155064|captopril
638478|NCT00155038|Breast neoplasms
638479|NCT00155038|breast radiography
638480|NCT00155038|young women.
638481|NCT00154973|oral precancers
638482|NCT00154973|oral cancer
638483|NCT00154973|hypoxia-inducible factor
638484|NCT00154960|Spinal muscular atrophy (SMA)
638485|NCT00154960|SMN1/SMN2 gene
638486|NCT00154960|denaturing high-performance liquid chromatography (DHPLC)
638487|NCT00154960|multiplex PCR
638488|NCT00154960|gene dose
638489|NCT00154960|carrier test
638490|NCT00154960|screen
638491|NCT00154960|stool
638492|NCT00154960|microsatellite
638493|NCT00154895|minocycline
638494|NCT00154895|pleurodesis
638495|NCT00154895|thoracoscopy
638496|NCT00154895|primary spontaneous pneumothorax
638497|NCT00154895|clinical trial
638498|NCT00154882|Breast Cancer
638499|NCT00154882|First-line
638500|NCT00154869|Patients with dual chronic hepatitis B and C
638501|NCT00154856|osteogenesis
638502|NCT00154856|Ilizarov fixator
638503|NCT00154856|motion analysis
638504|NCT00154856|FEM
638505|NCT00154856|bone stress
638506|NCT00154843|Lycopene
638507|NCT00154843|BPH
638508|NCT00154843|PSA
638509|NCT00154843|IPSS
638510|NCT00154817|radiotherapy
638511|NCT00154817|dynamic contrast enhanced MRI
638512|NCT00154817|hepatocellular carcinoma
638513|NCT00154804|Concurrent Chemoradiotherapy
638514|NCT00154804|Esophageal Cancer
638515|NCT00154791|Pancreatic adenocarcinoma
638516|NCT00154791|Oxaliplatin
638517|NCT00154791|Gemcitabine
638518|NCT00154791|5-FU
638519|NCT00154778|Combination,Chemotherapy,Advanced Gastric Cancer
638520|NCT00154752|Rectal cancer, CCRT, Pelvic lymphadenoectomy.
638521|NCT00154739|Combination, Chemotherapy,non-small cell lung cancer
638522|NCT00154726|Paclitaxel-HDFL,Locally Advanced and Recurrent/Metastatic Gastric Cancer
638523|NCT00154713|colorectal cancer
638524|NCT00154713|dendritic cell
638525|NCT00154713|CEA
638526|NCT00154713|IL-2
638527|NCT00154700|Combination,Chemotherapy,Esophageal Cancer
638528|NCT00154687|Combination, Chemotherapy,transitional cell carcinoma
638529|NCT00154661|glomerulonephritis
638530|NCT00154648|MRA
638531|NCT00154648|DSA
638532|NCT00154648|gadovist
638533|NCT00154648|angiography
638534|NCT00154635|Alzheimer's disease
638535|NCT00154635|Fo-ti
638536|NCT00154635|Chinese herbs
638537|NCT00154622|musculoskeletal disorder, work hardening, return to work
638538|NCT00154596|etiology
638539|NCT00154596|transmission
638540|NCT00154596|vasculitis
638541|NCT00154596|household
638542|NCT00154596|etiology of disease
638543|NCT00154583|cervical cancer
638544|NCT00154583|human papillomavirus
638545|NCT00154583|cancer vaccine
638546|NCT00154583|normal volunteer
638547|NCT00154570|reflux esophagitis
638548|NCT00154570|24 hour esophageal pH
638549|NCT00154570|electrogastrography (EGG)
638550|NCT00154570|Running Spectral Analysis (RSA)
638551|NCT00154557|Judo, Performance, Injury
638552|NCT00154518|orthodontic tooth movement
638553|NCT00154518|matrix metalloproteinase
638554|NCT00154518|Orthodontics
638555|NCT00154505|Scoliosis
638556|NCT00154505|Spinal Cord Injury
638557|NCT00154505|Lateral Trunk Support
638558|NCT00154505|Radiography
638559|NCT00154492|Active variceal bleeding in patients with advanced cirrhosis
638560|NCT00154479|Cervical cancer
638561|NCT00154479|Human papillomavirus
638562|NCT00154479|Human leukocyte antigen
638563|NCT00154479|immunologic response
638564|NCT00154479|healthy volunteers
638565|NCT00154466|Myocardial infarction, stem cell, cardiac rehabilitation
638566|NCT00154453|Aging
638567|NCT00154453|Orbicularis oculi
638568|NCT00154453|Blepharoplasty
638569|NCT00154453|Myosin heavy chain (MHC)
638570|NCT00154440|primary gastric MALT lymphoma
638571|NCT00154440|Helicobacter pylori
638572|NCT00154440|eradication therapy
638573|NCT00154440|radiation
638574|NCT00154440|marginal zone B-cell lymphoma
638575|NCT00154440|Mucosa-associated Lymphoid Tissue
638576|NCT00154440|B-cell Non-Hodgkin's Lymphoma of the stomach
638577|NCT00154440|primary gastric lymphoma
638578|NCT00154388|adenocarcinoma
638579|NCT00154388|leiomyosarcoma
638580|NCT00154388|angiosarcoma
638581|NCT00154388|synovial sarcoma
638582|NCT00154388|myelodysplastic syndrome/HES
638583|NCT00154388|CMML
638584|NCT00154388|multiple myeloma
638585|NCT00154388|embryonal rhabdomyosarcoma
638586|NCT00154388|endometrial sarcoma
638587|NCT00154388|adenoid cystic carcinoma
638588|NCT00154388|fibromatosis
638589|NCT00154388|ductal invasive breast carcinoma
638590|NCT00154388|chondrosarcoma
638591|NCT00154388|pleural tumor
638592|NCT00154388|brenner tumor
638593|NCT00154388|ewing sarcoma
638594|NCT00154388|round cell tumor
638595|NCT00154388|seminoma
638596|NCT00154388|thymic carcinoma
638597|NCT00154388|malignant melanoma
638598|NCT00154388|fibrosarcoma breast
638599|NCT00154388|dermatofibrosarcoma protuberans
638600|NCT00154388|DFSP
638601|NCT00154388|ovarian stromal tumor
638602|NCT00154388|osteosarcoma
638603|NCT00154388|chorioideal melanoma
638604|NCT00154388|hemangiopericytoma
638605|NCT00154388|myelofibrosis
638606|NCT00154388|liposarcoma
638607|NCT00154388|SCLC
638608|NCT00154388|small cell lung carcinoma
638609|NCT00154388|hypereosinophilic syndrome
638610|NCT00154388|chronic myelo-monocytic leukemia
638611|NCT00154388|neurofibrosarcoma
638612|NCT00154388|mesothelioma
638613|NCT00154388|malignant mesenchymoma
638614|NCT00154388|malignant schwannoma
638615|NCT00154388|mast cell leukemia / mastocytosis
638616|NCT00154388|renal cell carcinoma
638617|NCT00154388|malignant histocytoma
638618|NCT00154388|chordoma
638619|NCT00154375|Open label
638620|NCT00154375|Imatinib mesylate
638621|NCT00154375|hydroxyurea
638622|NCT00154375|temozolomide
638623|NCT00154375|resistant
638624|NCT00154375|protein tyrosine kinases
638625|NCT00154375|adenocarcinoma
638626|NCT00154375|glioblastoma multiforme
638627|NCT00154375|astrocytoma
638628|NCT00154375|brain tumor
638629|NCT00154375|brain cancer
638630|NCT00154362|Oxcarbazepine, conduct disorder, adolescents
638631|NCT00154349|Ph+ALL
638632|NCT00154349|imatinib mesylate
638633|NCT00154336|Rheumatoid arthritis, imatinib, methotrexate
638634|NCT00154323|Oxcarbazepine, bipolar disorder
638635|NCT00154310|Renal transplantation, everolimus, immunosuppressants, CNI-free
638636|NCT00154297|Renal transplantation
638637|NCT00154297|everolimus
638638|NCT00154297|immunosuppressants
638639|NCT00154297|wound-healing
638640|NCT00154284|Renal transplantation,
638641|NCT00154284|everolimus,
638642|NCT00154284|immunosuppressants,
638643|NCT00154284|basiliximab,
638644|NCT00154284|cyclosporine microemulsion discontinuation, cyclosporine microemulsion minimization
638645|NCT00154271|Hypertension (HTN)
638646|NCT00154271|High Sensitivity C-Reactive Protein
638647|NCT00154258|Schizophrenia, treatment-resistant, clozapine
638648|NCT00154245|Enteric-coated mycophenolate sodium, transplantation, de novo, cyclosporine
638649|NCT00154232|Renal transplantation, DGF, basiliximab, EC-MPS, cyclosporine
638650|NCT00154219|Osteoarthritis, Hip, Lumiracoxib, Efficacy, Safety
638651|NCT00154206|Enteric-coated mycophenolate sodium,
638652|NCT00154206|de novo,
638653|NCT00154206|renal transplantation,
638654|NCT00154206|pediatric
638655|NCT00154206|De novo pediatric renal transplantation
638656|NCT00154193|Heart transplant, lung transplant, renal function, cyclosporine C2 Levels
638657|NCT00154180|Perimenopause
638658|NCT00154180|Coronary Disease
638659|NCT00154180|Estrogen Replacement Therapy
638660|NCT00154180|Hormone Replacement Therapy
638661|NCT00154154|borderline personality disorder
638662|NCT00154154|BPD
638663|NCT00154154|treatment
638664|NCT00154154|dialectical behavior therapy
638665|NCT00154154|DBT
638666|NCT00154154|general Psychiatric management
638667|NCT00154154|GPM
638668|NCT00154154|suicide
638669|NCT00154154|parasuicide
638670|NCT00154154|randomized control trials
638671|NCT00154128|temporomandibular disorder
638672|NCT00154128|craniomandibular disorder
638673|NCT00154128|occlusal appliance
638674|NCT00154128|clinical trial
638675|NCT00154115|heart failure
638676|NCT00154115|levosimendan
638677|NCT00154115|cardiac surgery
638678|NCT00154102|Metastatic colorectal cancer
638679|NCT00154102|EGFR
638680|NCT00154102|Irinotecan
638681|NCT00154102|cetuximab
638682|NCT00154102|first-line treatment
638683|NCT00154089|cervical intraepithelial neoplasia
638684|NCT00154089|CIN
638685|NCT00154089|HPV
638686|NCT00154050|restenosis
638687|NCT00154050|intima hyperproliferation
638688|NCT00154050|stent angioplasty
638689|NCT00154050|pain-free walking distance
638690|NCT00154037|vascular reactivity
638691|NCT00154037|venodilation
638692|NCT00154037|pulse wave velocity
638693|NCT00154024|venoconstriction
638694|NCT00154024|venodilation
638695|NCT00154024|pleiotropic effects
638696|NCT00154011|vascular reactivity, venodilation
638697|NCT00153998|Cetuximab
638698|NCT00153998|Oxaliplatin
638699|NCT00153998|Irinotecan
638700|NCT00153998|5-FU
638701|NCT00153998|Chemotherapy
638702|NCT00153998|Resection
638703|NCT00153998|Liver resection
638704|NCT00153998|Neoadjuvant
638705|NCT00153985|Hemoglobinopathies
638706|NCT00153985|Sickle cell anemia
638707|NCT00153985|sickle cell-hemoglobin C disease
638708|NCT00153985|sickle cell-B-thalassemia
638709|NCT00153985|transfusion-dependant thalassemia
638710|NCT00153985|allogeneic transplant
638711|NCT00153985|nonmyeloablative transplant
638712|NCT00153985|Stem cell transfusion
638713|NCT00153985|graft vs. host disease
638714|NCT00153712|Non-NSAID
638715|NCT00153712|Non-Hp Bleeding Peptic Ulcer
638716|NCT00153699|Side effects
638717|NCT00153699|Topiramate
638718|NCT00153686|Capsule Endoscopy
638719|NCT00153686|Mesenteric angiogram
638720|NCT00153673|celecoxib
638721|NCT00153673|arthritis
638722|NCT00153673|ulcer healing
638723|NCT00153634|Cystic fibrosis
638724|NCT00153634|Antibiotic susceptibility testing
638725|NCT00153634|Pseudomonas aeruginosa
638726|NCT00153634|Chronic bronchitis
638727|NCT00153634|Biofilms
638728|NCT00153621|Pediatrics
638729|NCT00153621|Chronic Kidney Failure
638730|NCT00153621|HIV
638731|NCT00153621|Acquired Immunodeficiency Syndrome
638732|NCT00153621|AIDS-Associated Nephropathy
638733|NCT00153595|Allergic rhinitis
638734|NCT00153595|EWO1
638735|NCT00153556|Haemophilus influenza type B
638736|NCT00153556|Carrier state
638737|NCT00153556|Bacterial Vaccines
638738|NCT00153556|Anti-PRP antibody
638739|NCT00153556|Antibody avidity
638740|NCT00153556|Serum bacteriocidal antibody
638741|NCT00153556|American Indians/Alaska Natives
638742|NCT00153556|Case control study
638743|NCT00153556|Adult vaccines
638744|NCT00153530|primary central nervous system lymphoma
638745|NCT00153517|Bacterial Vaginosis
638746|NCT00153517|Metronidazole
638747|NCT00153504|HIV
638748|NCT00153504|AIDS
638749|NCT00153504|Homeless
638750|NCT00153504|Homelessness
638751|NCT00153504|Housing
638752|NCT00153504|HIV seropositive
638753|NCT00153504|HIV risk behavior
638754|NCT00153491|malaria
638755|NCT00153491|artemether-lumefantrine
638756|NCT00153491|co-artem
638757|NCT00153491|Tanzania
638758|NCT00153491|adherence
638759|NCT00153478|Alcohol-Exposed Pregnancy
638760|NCT00153478|Binge drinking
638761|NCT00153478|Frequent drinking
638762|NCT00153478|Unintended pregnancy
638763|NCT00153478|Fetal Alcohol Syndrome
638764|NCT00153465|Parent training
638765|NCT00153465|Child maltreatment
638766|NCT00153465|Motivation
638767|NCT00153465|Program attrition
638768|NCT00153439|parenting
638769|NCT00153439|motivation
638770|NCT00153439|child maltreatment
638771|NCT00153439|program attrition
638772|NCT00153400|CVD risk
638773|NCT00152620|Inflammatory Bowel Disease (IBD)
638774|NCT00152607|Liver Transplantation
638775|NCT00152607|Living Donors
638776|NCT00152607|End Stage Liver Disease
638777|NCT00152581|HCV, genotype 1, treatment, HCV kinetics, T-cells
638778|NCT00152568|Car Seat Check
638779|NCT00152555|SLE,
638780|NCT00152555|exercize,
638781|NCT00152555|physical therapy,
638782|NCT00152555|Systemic lupus erythematosus
638783|NCT00152555|relaxation therapy
638784|NCT00152542|Inhaled nitric oxide,
638785|NCT00152542|Lung recruitment,
638786|NCT00152542|Ventilatory approach,
638787|NCT00152542|Neurodevelopmental outcomes,
638788|NCT00152542|School age children
638789|NCT00152529|Depression, educational site for depression
638790|NCT00152516|Partial Onset Seizures
638791|NCT00152516|levetiracetam
638792|NCT00152516|Epilepsy
638793|NCT00152516|Keppra
638794|NCT00152503|Epilepsy, Partial Onset Seizures, Seletracetam
638795|NCT00152490|Crohn's disease, CDP870, CDAI, clinical response, remission,
638796|NCT00152490|Certolizumab Pegol, Cimzia
638797|NCT00153361|HIV Seronegativity
638798|NCT00153361|HIV
638799|NCT00153335|Health Risk Assessment
638800|NCT00153335|Behavior Change
638801|NCT00153335|Patient-Provider Interaction
638802|NCT00153335|Employee Health
638803|NCT00153335|Absenteeism
638804|NCT00153335|Tobacco Use
638805|NCT00153335|Substance Use
638806|NCT00153335|Diet
638807|NCT00153335|Exercise
638808|NCT00153335|Medication Adherence
638809|NCT00153322|Childhood Obesity
638810|NCT00153322|Community-based Participatory Research
638811|NCT00153322|School intervention
638812|NCT00153322|Parental Involvement
638813|NCT00153309|arthritis
638814|NCT00153309|exercise
638815|NCT00153309|physical activity
638816|NCT00153309|physical function
638817|NCT00153309|pain
638818|NCT00153296|Bronchial asthma
638819|NCT00153296|Carbamazepine
638820|NCT00153296|Antiepileptic drugs
638821|NCT00153296|Efficacy
638822|NCT00153283|Bronchial asthma
638823|NCT00153283|Gabapentin
638824|NCT00153283|Antiepileptic drug
638825|NCT00153283|Efficacy
638826|NCT00153270|Bronchial asthma
638827|NCT00153270|Sodium valproate
638828|NCT00153270|Antiepileptic drug
638829|NCT00153270|Efficacy
638830|NCT00153244|Bronchial asthma
638831|NCT00153244|Lamotrigine
638832|NCT00153244|Antiepileptic drug
638833|NCT00153244|Efficacy
638834|NCT00153218|Metastatic Breast Cancer
638835|NCT00153218|Her2neu
638836|NCT00153218|trastuzumab
638837|NCT00153205|medication errors
638838|NCT00153205|medical records systems, computerized
638839|NCT00153205|patient safety
638840|NCT00153192|Marinol
638841|NCT00153192|Dronabinol
638842|NCT00153192|Cannabinoid
638843|NCT00153192|Chronic Pain
638844|NCT00153179|insulin resistance
638845|NCT00153179|insulin signaling
638846|NCT00153179|endothelium-dependent vasodilation
638847|NCT00153166|peripheral arterial disease
638848|NCT00153166|intermittent claudication
638849|NCT00152945|intestinal lipoprotein
638850|NCT00152945|very low density lipoprotein
638851|NCT00152945|free fatty acids
638852|NCT00152945|Apo B48 and Apo B100
638853|NCT00152945|triglycerides
638854|NCT00152945|Intestinal lipoprotein production
638855|NCT00152932|Glaucoma
638856|NCT00152932|Intraocular pressure
638857|NCT00152932|Ocular blood flow
638858|NCT00152932|Laser-Doppler Flowmetry
638859|NCT00152893|HIV
638860|NCT00152893|blood sugar > 6.1 mmol/l
638861|NCT00152893|triglycerides > 2 mmol/l
638862|NCT00152893|total cholesterol > 5.5 mmol/l or HDL < 0.9 mmol/l
638863|NCT00152880|Hepatitis B, apoptosis
638864|NCT00152867|quality of life
638865|NCT00152867|dexamethasone
638866|NCT00152867|emesis
638867|NCT00152854|cancer pain
638868|NCT00152854|acetaminophen
638869|NCT00152854|opioids
638870|NCT00152815|HIV
638871|NCT00152815|non-alcoholic fatty liver disease
638872|NCT00152802|liver transplant
638873|NCT00152802|antibody response
638874|NCT00152802|opsonophagocytic assay
638875|NCT00152802|pneumococcal conjugate vaccine
638876|NCT00152802|pneumococcal polysaccharide vaccine
638877|NCT00152776|menopausal symptoms
638878|NCT00152776|complementary medicine
638879|NCT00152763|health anxiety
638880|NCT00152750|Tourette's Syndrome
638881|NCT00152750|Attention Deficit Hyperactivity Disorder
638882|NCT00152750|Children
638883|NCT00152750|Sleep disorders
638884|NCT00152750|Aggression
638885|NCT00152737|Intermittent Claudication
638886|NCT00152737|Peripheral Vascular Diseases
638887|NCT00152737|Blood Gas Monitoring, Transcutaneous
638888|NCT00152737|Surgery
638889|NCT00152724|Physiology
638890|NCT00152724|Microcirculation
638891|NCT00152724|Laser-Doppler Flowmetry
638892|NCT00152659|Epilepsy
638893|NCT00152659|Tumor
638894|NCT00152659|Surgery
638895|NCT00152659|Brain
638896|NCT00152633|endothelium, hypertension, retina, AT1
638897|NCT00152477|Non-small-cell-lung cancer
638898|NCT00152477|carboplatin
638899|NCT00152477|paclitaxel
638900|NCT00152477|VEGF
638901|NCT00152477|monoclonal antibody
638902|NCT00152464|EPAAC , atopic Children, asthma, XYZAL, levocetirizine
638903|NCT00152451|Epilepsy: partial onset seizures, seletracetam
638904|NCT00152438|Vasomotor symptoms
638905|NCT00152438|Menopause
638906|NCT00152425|Crohn's disease, CDP870, CDAI, clinical response, remission, Certolizumab Pegol, Cimzia
638907|NCT00152412|Allergic Rhinitis, safety, levocetirizine, children
638908|NCT00152412|Xyzal
638909|NCT00152399|Peptic ulcer bleeding, upper intestinal bleeding, endoscopy, somatostatin
638910|NCT00152386|Rheumatoid Arthritis, CDP870
638911|NCT00152386|Certolizumab pegol, Cimzia
638912|NCT00152373|Epilepsy, Partial Onset Seizures; Keppra; Levetiracetam
638913|NCT00152360|Obesity
638914|NCT00152360|weight loss
638915|NCT00152360|cardiovascular risk factors
638916|NCT00152360|Obesity and obesity related pathology
638917|NCT00152334|Efficacy study
638918|NCT00152334|assessment of patient outcomes following treatment
638919|NCT00152321|osteoporosis
638920|NCT00152321|wrist fractures
638921|NCT00152321|quality improvement
638922|NCT00152321|knowledge translation
638923|NCT00152295|Postmenopausal
638924|NCT00152295|Amenorrhea
638925|NCT00152295|Hormone replacement therapy
638926|NCT00152295|HRT
638927|NCT00152295|asoprisnil
638928|NCT00152295|Estrogen Replacement Therapy, postmenopause
638929|NCT00152282|Postmenopausal
638930|NCT00152282|Amenorrhea
638931|NCT00152282|Hormone replacement therapy
638932|NCT00152282|HRT
638933|NCT00152282|asoprisnil
638934|NCT00152269|Symptomatic Uterine Fibroids
638935|NCT00152269|Excessive Uterine Bleeding
638936|NCT00152269|Uterine Hemorrhage
638937|NCT00152269|asoprisnil
638938|NCT00152256|Symptomatic Uterine Fibroids
638939|NCT00152256|Excessive Uterine Bleeding
638940|NCT00152256|Uterine Hemorrhage
638941|NCT00152243|Stomach Cancer
638942|NCT00152230|Colorectal Cancer
638943|NCT00152217|Stomach cancer
638944|NCT00152204|Use-Effectiveness
638945|NCT00152204|Cost Effectiveness
638946|NCT00152204|Patient Acceptance of Health Care
638947|NCT00152204|Drug Resistance
638948|NCT00152204|Delivery of Health Care
638949|NCT00152191|Breast Cancer
638950|NCT00152178|Breast Cancer
638951|NCT00152165|spinal motion
638952|NCT00152165|tantalum beads
638953|NCT00152165|DYNESYS Stabilization system
638954|NCT00152165|spinal fusion
639076|NCT00151346|labor pain
638955|NCT00152165|Radiostereometric Analysis following spinal fusion
638956|NCT00152165|Radiostereometric Analysis following surgery with DYNESYS Stabilization System
638957|NCT00152152|spinal motion
638958|NCT00152152|tantalum beads
638959|NCT00152139|High risk hematologic malignancies
638960|NCT00152139|Allogeneic stem cell transplant
638961|NCT00152139|Matched unrelated donor transplantation
638962|NCT00152139|Unmanipulated stem cell graft
638963|NCT00152139|Bone marrow transplantation
638964|NCT00152126|Autologous stem cell transplantation
638965|NCT00152126|CD133 cell selection
638966|NCT00152126|CliniMACS device
638967|NCT00152126|Tumor marker
638968|NCT00152126|Tumor purging
638969|NCT00152113|Sickle Cell Anemia
638970|NCT00152113|Stem Cell Transplantation
638971|NCT00152113|Haploidentical stem cell transplant
638972|NCT00152113|T cell depletion
638973|NCT00152113|CliniMACS device
638974|NCT00152100|Severe combined immunodeficiency
638975|NCT00152100|Transplantation
638976|NCT00152100|Haploidentical
638977|NCT00152087|Liver cancer
638978|NCT00152087|Brachytherapy
638979|NCT00152074|Blood pressure
638980|NCT00152074|Sodium
638981|NCT00152074|Dietary
638982|NCT00152074|Hypertension or prehypertension
638983|NCT00152061|HIV
638984|NCT00152061|Antiretroviral Drug Resistance
638985|NCT00152061|Treatment Experienced
638986|NCT00151905|bronchiolitis
638987|NCT00151905|hypertonic saline
638988|NCT00151879|partial seizures with or without secondary generalization
638989|NCT00151866|Thrombopenia
638990|NCT00151866|Platelet transfusion
638991|NCT00151866|Increment
638992|NCT00151866|Transfusion reactions
638993|NCT00151866|Bleeding complication
638994|NCT00151853|CPB
638995|NCT00151853|oral anticoagulant therapy
638996|NCT00151853|plasma
638997|NCT00151853|PCC
638998|NCT00151840|Purpura, Thrombocytopenic, Idiopathic
638999|NCT00151840|ITP
639000|NCT00151840|Immunoglobulin, Intravenous
639001|NCT00151814|Olmesartan PK in children
639002|NCT00151801|multiple sclerosis
639003|NCT00151801|estroprogestins
639004|NCT00151801|interferon-beta
639005|NCT00151801|sex hormones
639006|NCT00151801|MRI
639007|NCT00151775|Treatment of hypertension or high blood pressure in children ages 1-16 years.
639008|NCT00151762|Open label, Diabetes Mellitus
639009|NCT00151762|Long term safety study, extension study
639010|NCT00151749|Diabetes mellitus
639011|NCT00151736|Chronic Lymphocytic Leukemia
639012|NCT00151736|CLL
639013|NCT00151736|Leukemia
639014|NCT00151723|endogenous subclinical hyperthyroidism
639015|NCT00151697|diabetes
639016|NCT00151697|failing oral treatment
639017|NCT00151697|weight gain
639018|NCT00151684|Obesity
639019|NCT00151684|Hyperinsulinism
639020|NCT00151684|Diazoxide
639021|NCT00151671|Surgery
639022|NCT00151671|Liver Cancer
639023|NCT00151671|Cirrhosis
639024|NCT00151671|Nutrition
639025|NCT00151658|Coronary complex lesions
639026|NCT00151658|Restenosis
639027|NCT00151658|Drug eluting stents
639028|NCT00151645|Immunotherapy
639029|NCT00151645|Renal cell carcinoma
639030|NCT00151645|Metastasis
639031|NCT00151645|Lymphokine activated killers
639032|NCT00151645|Cell therapy
639033|NCT00151632|Immunosuppression
639034|NCT00151632|Liver transplantation
639035|NCT00151632|Acute graft rejection
639036|NCT00151632|Treatment combination
639037|NCT00151619|Calcium channel blockers
639038|NCT00151619|Heart failure
639039|NCT00151619|Hemodynamics
639040|NCT00151606|Infection prevention
639041|NCT00151606|Isolation
639042|NCT00151606|Resistant bacteria
639043|NCT00151606|MRSA colonization
639044|NCT00151593|Cold storage
639045|NCT00151593|Liver transplantation
639046|NCT00151593|Preservation solution
639047|NCT00151580|Hepatitis C
639048|NCT00151580|Viral recurrence
639049|NCT00151580|Ribavirin / Interferon
639050|NCT00151567|Ureterolithiasis
639051|NCT00151567|Alpha1-blocker
639052|NCT00151567|Lower ureteral stone
639053|NCT00151554|Anxiety
639054|NCT00151554|Intensive Care Unit (ICU)
639055|NCT00151554|Preoperative Information
639056|NCT00151554|Randomized Controlled Trial (RCT)
639057|NCT00151554|Chronic heart disease
639058|NCT00151541|Acne Vulgaris
639059|NCT00151541|Acne
639060|NCT00151541|Dermatology
639061|NCT00151541|Dapsone
639062|NCT00151541|Dapsone Topical Gel
639063|NCT00151515|Alopecia, Balding
639064|NCT00151476|Familial adenomatous polyposis
639065|NCT00151476|celecoxib
639066|NCT00151476|IRA
639067|NCT00151476|IPAA
639068|NCT00151411|Polycystic Ovary Syndrome (PCOS)
639069|NCT00151411|Anovulation
639070|NCT00151411|Elevated Testosterone
639071|NCT00151346|Epidural
639072|NCT00151346|Labour pain
639073|NCT00151346|Pregnant women
639074|NCT00151346|Epidural anesthesia
639075|NCT00151346|Labour, Obstetric
639077|NCT00151346|labor, obstetric
639078|NCT00151346|labor analgesia
639079|NCT00151320|diffuse large B cell
639080|NCT00151320|mantle cell lymphoma
639081|NCT00151307|Heart surgery
639082|NCT00151307|Cerebral oxygen saturation
639083|NCT00151307|Neuropsychological function
639084|NCT00151294|Depression (mild to moderate)
639085|NCT00151294|Affective symptoms
639086|NCT00151294|Emotional lability
639087|NCT00151294|Multiple Sclerosis
639088|NCT00151281|relapsed mantle cell lymphoma
639089|NCT00151268|Batten Disease
639090|NCT00151268|Late Infantile Neuronal Lipofuscinosis
639091|NCT00151268|LINCL
639092|NCT00151255|age > 60 years
639093|NCT00151229|isolated systolic hypertension
639094|NCT00151229|valsartan
639095|NCT00151229|target blood pressure
639096|NCT00151216|Batten Disease
639097|NCT00151216|Late Infantile Neuronal Ceroid Lipofuscinosis
639098|NCT00151216|LINCL
639099|NCT00151203|newly diagnosed multiple myeloma
639100|NCT00151177|ischemic stroke
639101|NCT00151177|CPAP ventilation
639102|NCT00151164|transplantation tolerance
639103|NCT00151164|thymus
639104|NCT00151164|bone marrow
639105|NCT00151164|pediatric heart transplantation
639106|NCT00151151|pregnancy prevention
639107|NCT00151151|STD prevention
639108|NCT00151151|adolescents
639109|NCT00151151|motivational interviewing
639110|NCT00151151|abstinence
639111|NCT00151151|contraception
639112|NCT00151151|transtheoretical model
639113|NCT00151151|sexual behavior
639114|NCT00151138|cerebral blood flow, positron emission tomography, magnetic resonance imaging, neuropsychology
639115|NCT00151125|Von Willebrand Disease
639116|NCT00151125|Bleeding
639117|NCT00151125|Coagulation
639118|NCT00151125|Hemostatic agent
639119|NCT00151112|nerve block
639120|NCT00151112|regional anesthesia
639121|NCT00151112|injuries
639122|NCT00151112|diverse malformations
639123|NCT00151099|preoperative nutrition
639124|NCT00151099|postoperative nausea and vomiting
639125|NCT00151099|Dysgnathia
639126|NCT00151099|anesthesia
639127|NCT00151073|Zometa
639128|NCT00151073|Prostate Cancer
639129|NCT00151073|Metastatic Prostate Cancer
639130|NCT00151034|Urothelial Cancer
639131|NCT00151034|Herceptin
639132|NCT00151034|Advanced Urothelial Cancer
639133|NCT00151021|Diabetes
639134|NCT00151021|Pedometer
639135|NCT00151021|Behavioral
639136|NCT00151008|psoriasis
639137|NCT00151008|bexarotene
639138|NCT00151008|narrow band
639139|NCT00151008|UVB
639140|NCT00150982|psoriasis
639141|NCT00150982|alefacept
639142|NCT00150969|vitamin K
639143|NCT00150969|bone mineral density
639144|NCT00150969|post-menopausal women
639145|NCT00150969|randomized double blind placebo controlled trial
639146|NCT00150969|osteoporosis
639147|NCT00150969|women's health
639148|NCT00150943|Renal artery stenosis
639149|NCT00150943|Stent
639150|NCT00150943|Renal failure
639151|NCT00150943|Atorvastatin
639152|NCT00150943|Hypertension
639153|NCT00150943|Atherosclerosis
639154|NCT00150930|psoriasis
639155|NCT00150930|ultraviolet
639156|NCT00150930|UVB
639157|NCT00150930|phototherapy
639158|NCT00150930|home care
639159|NCT00150930|narrowband
639160|NCT00150917|Breast cancer
639161|NCT00150917|Genetics
639162|NCT00150917|Psychotherapy
639163|NCT00150917|Group counselling
639164|NCT00150917|Randomized control trial
639165|NCT00150917|Risk counselling
639166|NCT00150917|Women's mental health
639167|NCT00150917|Familial breast cancer
639168|NCT00150904|HIV
639169|NCT00150904|hepatitis C
639170|NCT00150904|virologic
639171|NCT00150904|immunologic
639172|NCT00150904|HIV / Hepatitis C coinfection
639173|NCT00150891|Th1
639174|NCT00150891|Th2
639175|NCT00150891|B cell
639176|NCT00150891|monokines
639177|NCT00150891|kidney transplantation
639178|NCT00150891|acute rejection
639179|NCT00150891|chronic rejection
639180|NCT00150878|Reduced-intensity conditioning
639181|NCT00150878|Fludarabine
639182|NCT00150878|Acute myeloid Leukemia
639183|NCT00150878|Treatment-related mortality
639184|NCT00150865|ropivacaine
639185|NCT00150865|posterior lumbar plexus block
639186|NCT00150865|hip arthroplasy
639187|NCT00150865|analgesia
639188|NCT00150865|postoperative
639189|NCT00150852|Gastrostomy
639190|NCT00150852|Wound infection
639191|NCT00150852|Antibiotic prophylaxis
639192|NCT00150839|Depressive Disorder, Major
639193|NCT00150839|Venlafaxine
639194|NCT00150839|Mirtazapine
639195|NCT00150839|Double-blind RCT
639196|NCT00150839|Magnetic resonance imaging
639197|NCT00150839|Hippocampal volume
639198|NCT00150826|microvascular disease
639199|NCT00150826|women
639200|NCT00150826|renin angiotensin system
639201|NCT00150826|WISE
639202|NCT00150826|ischemic heart disease
639203|NCT00150813|Monotherapy, epilepsy
639204|NCT00150813|Keppra, levetiracetam
639205|NCT00150800|Brivaracetam
639206|NCT00150800|Epilepsy
639207|NCT00150800|Partial Onset Seizures
639208|NCT00150800|open label
639209|NCT00150787|Monotherapy, epilepsy
639210|NCT00150787|Levetiracetam
639211|NCT00150787|Keppra
639212|NCT00150774|Idiopathic Generalized Epilepsy, Myoclonic seizures
639213|NCT00150774|Keppra - Levetiracetam
639214|NCT00150761|Nasal histamine provocation, facial thermography, levocetirizine, cetirizine,
639215|NCT00150761|Xyzal, Zyrtec
639216|NCT00150748|Generalized Epilepsy, Primary Generalized Seizures
639217|NCT00150748|Keppra, Levetiracetam
639218|NCT00150735|Monotherapy, epilepsy, Levetiracetam, Keppra.
639219|NCT00150722|atherosclerosis
639220|NCT00150722|endothelial function
639221|NCT00150722|HDL
639222|NCT00150722|Niacin
639223|NCT00150722|statins
639224|NCT00150722|Stable Atherosclerotic Vascular Disease
639225|NCT00150709|Epilepsy, Pediatric , partial onset epilepsy,
639226|NCT00150709|Levetiracetam (Keppra®)
639227|NCT00150696|Osteoporosis
639228|NCT00150696|Spinal Cord Injury
639229|NCT00150683|Spinal Cord Injury.
639230|NCT00150683|Osteoporosis.
639231|NCT00150683|Standing.
639232|NCT00150683|Vibration.
639233|NCT00150670|Stomach cancer
639234|NCT00150644|Fibroid Uterus
639235|NCT00150644|Leiomyoma
639236|NCT00150644|Uterine Fibroids
639237|NCT00150644|Hysterectomy
639238|NCT00150644|Asoprisnil
639239|NCT00150631|Hypertension
639240|NCT00150631|Prevention
639241|NCT00150631|Offspring
639242|NCT00150631|Prevent or delay development of hypertension
639243|NCT00150527|antidepressive agents
639244|NCT00150514|nasal biopsy grasspollen sublingual immunotherapy
639245|NCT00150488|PBS
639246|NCT00150488|Painful Bladder Syndrome
639247|NCT00150488|Interstitial Cystitis
639248|NCT00150488|chrondroitin sulfate
639249|NCT00150475|Severe Acute Respiratory Syndrome
639250|NCT00150462|Hematological
639251|NCT00150462|Proteasome
639252|NCT00150462|Myeloma
639253|NCT00150462|Lymphoma
639254|NCT00150371|(D006937)
639255|NCT00150345|Neutropenia
639256|NCT00150345|Fever of unknown origin
639257|NCT00150345|Empirical treatment
639258|NCT00150345|Voriconazole
639259|NCT00150189|Pain
639260|NCT00150189|Procedural Pain
639261|NCT00150189|Sucrose
639262|NCT00150189|Infant
639263|NCT00150189|Newborn
639264|NCT00150163|Androgens
639265|NCT00150163|Bone
639266|NCT00150163|Muscle
639267|NCT00150163|Estrogens
639268|NCT00150163|Fat
639269|NCT00150163|Lipid and glucose metabolism
639270|NCT00150150|Interventional ultrasound
639271|NCT00150150|interstitial laser theraphy
639272|NCT00150150|tumor ablation
639273|NCT00150150|nodule reduction
639274|NCT00150150|adverse effects
639275|NCT00150150|patient satesfaction
639276|NCT00150137|Radioiodine therapy
639277|NCT00150137|Graves’ disease
639278|NCT00150137|toxic nodular goiter
639279|NCT00150137|antithyroid drugs
639280|NCT00150137|radioprotection
639281|NCT00150124|Radioiodine therapy
639282|NCT00150124|Graves' disease
639283|NCT00150124|toxic nodular goiter
639284|NCT00150124|antithyroid drugs
639285|NCT00150124|levothyroxine
639286|NCT00150124|radioprotection
639287|NCT00150111|Graves disease
639288|NCT00150111|thyroid
639289|NCT00150111|ophthalmopathy
639290|NCT00150111|autoimmunity
639291|NCT00150111|B lymphocyte depletion
639292|NCT00150111|rituximab
639293|NCT00150111|immunization
639294|NCT00150098|HIV
639295|NCT00150098|vaccines
639296|NCT00150098|women
639297|NCT00150098|substance use
639298|NCT00150085|diabetes, glucose, tacrolimus, cyclosporine micro-emulsion, liver, kidney, renal
639299|NCT00150072|chordoma
639300|NCT00150072|imatinib
639301|NCT00150072|PDGFR
639302|NCT00150059|atopic dermatitis, eczema, mild to moderate, children, IGA
639303|NCT00150046|Heart transplantation
639304|NCT00150046|Everolimus
639305|NCT00150046|Heart transplant recipient
639306|NCT00150033|thyroid disease
639307|NCT00150033|Quality of Life
639308|NCT00150033|Patient reported outcome
639309|NCT00150033|questionnaire
639310|NCT00150033|Quality of Life measurement
639311|NCT00150020|Renal/Kidney
639312|NCT00150020|Transplantation
639313|NCT00150020|MPA
639314|NCT00150020|EC-MPS
639315|NCT00150020|Renal Transplantation Patients with GI Intolerance with MMF
639316|NCT00150007|Kidney, maintenance transplant, GI complaints, patient reported outcome
639317|NCT00149994|Liver transplant, adults, C2 monitoring
639318|NCT00149981|Kidney, heart, lung, liver, pancreas
639319|NCT00149968|Renal transplantation
639320|NCT00149968|MMF
639321|NCT00149968|EC-MPS
639322|NCT00149968|GI problems
639323|NCT00149942|Enteric coated mycophenolate sodium
639324|NCT00149942|transplantation
639325|NCT00149942|gastrointestinal adverse events
639450|NCT00149370|HUI
639326|NCT00149942|Kidney and liver transplantation patients experiencing GI AEs with current MMF treatment
639327|NCT00149929|Renal Transplant, adults, immunosuppressant
639328|NCT00149916|Renal Transplant, adults, immunosuppressants
639329|NCT00149890|pediatric
639330|NCT00149890|liver transplantation
639331|NCT00149890|Simulect
639332|NCT00149890|Basiliximab
639333|NCT00149890|ciclosporin microemulsion
639334|NCT00149890|steroid reduction
639335|NCT00149890|pediatric liver transplantation
639336|NCT00149877|Chronic constipation, tegaserod
639337|NCT00149864|Renal Transplant, adults, immunosuppressant
639338|NCT00149851|GERD, heartburn, regurgitation, reflux disease
639339|NCT00149838|Electric Stimulation
639340|NCT00149838|Magnetic Stimulation
639341|NCT00149838|Prefrontal Cortex
639342|NCT00149838|Brain
639343|NCT00149825|Major Depressive Disorder
639344|NCT00149825|Insomnia
639345|NCT00149825|Sleep
639346|NCT00149825|Mental Health
639347|NCT00149812|Depression
639348|NCT00149812|Child disruptive behavior
639349|NCT00149812|Family functioning
639350|NCT00149799|Body Dysmorphic Disorder
639351|NCT00149799|Escitalopram
639352|NCT00149799|Lexapro
639353|NCT00149799|BDD
639354|NCT00149799|Body Image
639355|NCT00149786|Anorexia Nervosa
639356|NCT00149786|Adolescents
639357|NCT00149786|Family therapy
639358|NCT00149786|Individual therapy
639359|NCT00149773|Cognitive therapy
639360|NCT00149773|Suicide
639361|NCT00149773|Older men
639362|NCT00149773|Death ideation
639363|NCT00149773|Primary care
639364|NCT00149760|Cognitive Behavior Therapy
639365|NCT00149760|Treatment Outcome
639366|NCT00149760|Health Care Utilization
639367|NCT00149760|Somatization Disorder
639368|NCT00149760|Somatoform Disorder
639369|NCT00149747|Sleep
639370|NCT00149747|Exercise
639371|NCT00149747|Older Adults
639372|NCT00149734|Schizophrenia
639373|NCT00149734|Ondansetron
639374|NCT00149734|P50 sensory gating
639375|NCT00149734|Evoked potentials
639376|NCT00149734|5-HT3 receptors
639377|NCT00149734|Atypical antipsychotics
639378|NCT00149721|hydrocephalus
639379|NCT00149721|pituitary function
639380|NCT00149721|shunting
639381|NCT00149708|Growth hormone
639382|NCT00149708|Deficiency
639383|NCT00149708|Cardiovascular risk
639384|NCT00149708|Body composition
639385|NCT00149695|Obesity, beverages, weight loss, body mass index, diet
639386|NCT00149682|Obesity
639387|NCT00149656|Treatment Naive
639388|NCT00149656|Multivitamins
639389|NCT00149656|Selenium
639390|NCT00149656|Supplementation
639391|NCT00149656|HIV Disease Progression
639392|NCT00149643|Cannabis
639393|NCT00149643|MDD
639394|NCT00149630|Opioid Dependence
639395|NCT00149630|Substance Related Disorders
639396|NCT00149617|Marijuana
639397|NCT00149617|Mood Disorder
639398|NCT00149604|metabolic syndrome
639399|NCT00149604|hormone therapy
639400|NCT00149604|abdominal adiposity
639401|NCT00149604|lipolysis
639402|NCT00149591|Myocardial infarction
639403|NCT00149591|Viability
639404|NCT00149591|Coronary angioplasty
639405|NCT00149591|Prevention
639406|NCT00149591|Prognosis
639407|NCT00149578|pancreatic cancer
639408|NCT00149578|gemcitabine
639409|NCT00149578|oxaliplatin
639410|NCT00149578|5-Fluorouracil
639411|NCT00149578|radiation
639412|NCT00149552|Treatment Naive
639413|NCT00149552|Treatment Experienced
639414|NCT00149461|Asthma Action Plans
639415|NCT00149461|African Americans
639416|NCT00149461|Latinos
639417|NCT00149461|Health Literacy
639418|NCT00149461|Asthma Education
639419|NCT00149422|NT-proBNP
639420|NCT00149396|Colorectal cancer metastases to liver
639421|NCT00149396|Colorectal Cancer
639422|NCT00149396|Colorectal Carcinoma
639423|NCT00149396|Colorectal Tumors
639424|NCT00149396|Colorectal Neoplasms
639425|NCT00149396|Rectum Cancer
639426|NCT00149396|Rectum tumors
639427|NCT00149396|Rectum carcinoma
639428|NCT00149396|Colon cancer
639429|NCT00149396|Colon tumors
639430|NCT00149396|Colon carcinoma
639431|NCT00149396|Rectum Neoplasms
639432|NCT00149396|Colon Neoplasms
639433|NCT00149396|Liver Neoplasms
639434|NCT00149396|Hepatic Neoplasms
639435|NCT00149396|Liver Tumors
639436|NCT00149396|Liver cancer
639437|NCT00149396|Hepatic Cancer
639438|NCT00149396|Hepatic tumors
639439|NCT00149396|metastatic to the liver
639440|NCT00149383|randomized controlled trial
639441|NCT00149383|malaria
639442|NCT00149383|Plasmodium falciparum
639443|NCT00149383|thiazolidinediones
639444|NCT00149383|rosiglitazone
639445|NCT00149383|atovaquone-proguanil
639446|NCT00149370|breast hypertrophy
639447|NCT00149370|breast reduction surgery
639448|NCT00149370|health-related quality of life
639449|NCT00149370|Health Utilities Index
639451|NCT00149370|prospective
639452|NCT00149370|SF-36
639453|NCT00149370|quality-adjusted life years
639454|NCT00149370|QALY
639455|NCT00149357|venous thromboembolism
639456|NCT00149357|VTE
639457|NCT00149357|thrombophilia
639458|NCT00149357|fetal loss
639459|NCT00149344|cost-utility analysis;
639460|NCT00149344|breast reduction;
639461|NCT00149344|vertical scar mammoplasty;
639462|NCT00149344|pedicle reduction mammoplasty
639463|NCT00149331|Diabetes, Insulin, Education
639464|NCT00149305|Gouty diathesis
639465|NCT00149305|Acid uric nephrolithiasis
639466|NCT00149279|stomach neoplasms
639467|NCT00149279|lymph node excision
639468|NCT00149279|abdominal aorta
639469|NCT00149266|stomach neoplasms
639470|NCT00149266|lymph node resection
639471|NCT00149266|cardia
639472|NCT00149266|thoracotomy
639473|NCT00149253|Abdominal hysterectomy,
639474|NCT00149253|Etoricoxib,
639475|NCT00149253|morphine consumption,
639476|NCT00149253|pre-emptive analgesia
639477|NCT00149240|DYSPORT
639478|NCT00149240|botulinum toxin A
639479|NCT00149240|myofascial pain syndrome
639480|NCT00149227|High risk hypertension
639481|NCT00149227|Ischemic heart disease
639482|NCT00149227|Angiotensin receptor blockers
639483|NCT00149227|Cardiovascular mortality- morbidity
639484|NCT00149227|KYOTO HEART Study
639485|NCT00149201|gastric cancer
639486|NCT00149201|peritoneal metastasis
639487|NCT00149201|randomized trial
639488|NCT00149201|5-FU
639489|NCT00149201|MTX
639490|NCT00149188|Growth Hormone
639491|NCT00149175|Alzheimer's disease
639492|NCT00149175|Dementia
639493|NCT00149175|Phenotype-genotype correlations
639494|NCT00149175|Candidate genes
639495|NCT00149175|Related disorders
639496|NCT00149162|Controlled
639497|NCT00149162|Multicenter
639498|NCT00149162|International
639499|NCT00149162|Randomized study
639500|NCT00149162|Direct individual benefit
639501|NCT00149162|complete remission after chemotherapy
639502|NCT00149162|non allogeneic transplanted
639503|NCT00149149|Reduction in NSAID related gut damage
639504|NCT00149136|Acute Lymphocytic Leukemia,
639505|NCT00149136|Ph+,
639506|NCT00149136|elderly patients,
639507|NCT00149136|Imatinib
639508|NCT00149123|Burn
639509|NCT00149123|adrenal insufficiency
639510|NCT00149123|hydrocortisone
639511|NCT00149123|short corticotropin test
639512|NCT00149110|Sleep deprivation
639513|NCT00149110|Exercise
639514|NCT00149110|Light therapy
639515|NCT00149110|Major depression
639516|NCT00149110|Bipolar depression
639517|NCT00149110|Sleep-wake cycle
639518|NCT00149084|The tailored H. pylori eradication therapy
639519|NCT00149084|CYP2C19 genotype
639520|NCT00149084|23S rRNA
639521|NCT00149084|clarithromycin
639522|NCT00149084|Lansoprazole
639523|NCT00149084|Amoxicillin
639524|NCT00149084|H. pylori infection
639525|NCT00149071|Transcranial magnetic stimulation (TMS)
639526|NCT00149071|Major depression
639527|NCT00149071|treatment resistant major depression
639528|NCT00149058|acute myocardial infarction
639529|NCT00149058|primary angioplasty
639530|NCT00148343|hemiplegia
639531|NCT00148343|hemiparesis
639532|NCT00148343|stroke
639533|NCT00148343|foot-drop
639534|NCT00148343|electrical stimulation
639535|NCT00148343|ankle-foot-orthosis
639536|NCT00148330|Diabetic macular oedema
639537|NCT00148330|Triamcinolone acetate
639538|NCT00148330|Intravitreal injection
639539|NCT00148330|Clinical trial
639540|NCT00148330|Laser treatment
639541|NCT00148304|Decision-making
639542|NCT00148304|Insulin
639543|NCT00148304|Preference
639544|NCT00148304|Treatment Variation
639545|NCT00148304|Provider
639546|NCT00148304|Patient
639547|NCT00148278|Catecholamines
639548|NCT00148278|Septic shock
639549|NCT00148265|Diabetic macular oedema
639550|NCT00148265|Triamcinolone acetate
639551|NCT00148265|Intravitreal injection
639552|NCT00148265|Clinical trial
639553|NCT00148265|Laser treatment
639554|NCT00149045|familial peripheral Neuropathy Anticipation
639555|NCT00149032|Metastatic solid tumor
639556|NCT00149006|Metastatic solid tumor
639557|NCT00149006|Mismatch allogeneic cell mediated immunotherapy
639558|NCT00148993|Tumor cell vaccine
639559|NCT00148980|Myelodysplastic syndrome (MDS)
639560|NCT00148980|Allogeneic stem cell transplantation
639561|NCT00148980|Demineralized bone matrix (DBM)
639562|NCT00148980|Bone marrow microenvironment
639563|NCT00148967|right ventricular pacing
639564|NCT00148967|implantable cardioverter defibrillator
639565|NCT00148915|Osteoporosis
639566|NCT00148915|bisphosphonates
639567|NCT00148915|bone
639568|NCT00148902|tumor
639569|NCT00148889|cervical dystonia
639570|NCT00148889|torticollis
639571|NCT00148889|deep brain stimulation
639572|NCT00148889|pallidal stimulation
639699|NCT00148382|Obesity
639573|NCT00148889|globus pallidus internus
639574|NCT00148876|Progression after treatment with Trastuzumab
639575|NCT00148876|Metastatic Breast Cancer
639576|NCT00148876|Palliative Study
639577|NCT00148863|Hepatitis C, Chronic
639578|NCT00148863|Interferon Alfa-2a
639579|NCT00148863|Ribavirin
639580|NCT00148863|Interferon-gamma, Recombinant
639581|NCT00148850|HIV-Associated Lipodystrophy Syndrome
639582|NCT00148850|pioglitazone
639583|NCT00148850|HIV infections
639584|NCT00148850|Treatment Experienced
639585|NCT00148837|Hepatitis C, Chronic
639586|NCT00148837|Fibrosis
639587|NCT00148837|Interferon Alfa-2b
639588|NCT00148837|Ribavirin
639589|NCT00148837|Prazosin
639590|NCT00148824|HIV infections
639591|NCT00148824|Pneumococcal vaccines
639592|NCT00148824|Treatment Experienced
639593|NCT00148824|Treatment Naive
639594|NCT00148798|Cetuximab
639595|NCT00148798|Non small cell lung cancer
639596|NCT00148798|Lung cancer
639597|NCT00148798|Cisplatin/vinorelbine
639598|NCT00148798|Monoclonal antibody
639599|NCT00148798|Erbitux
639600|NCT00148785|Antiretroviral drugs
639601|NCT00148785|Pharmacokinetic
639602|NCT00148785|Indinavir
639603|NCT00148785|Ritonavir
639604|NCT00148785|Fosamprenavir
639605|NCT00148772|Prostate Cancer
639606|NCT00148772|Rising PSA
639607|NCT00148772|Erlotinib
639608|NCT00148772|Tarceva
639609|NCT00148772|Androgen Deprivation Therapy
639610|NCT00148772|Hormone Therapy
639611|NCT00148772|Rising Prostate Specific Antigen (PSA)
639612|NCT00148772|Non-Metastatic Prostate Cancer
639613|NCT00148759|Sex differences
639614|NCT00148759|Pharmacokinetic
639615|NCT00148759|Lopinavir/ritonavir
639616|NCT00148759|Treatment Experienced
639617|NCT00148759|HIV-infection
639618|NCT00148746|atopic dermatitis, atopy
639619|NCT00148733|Child
639620|NCT00148733|pneumonia
639621|NCT00148733|Zinc
639622|NCT00148733|clinical trial
639623|NCT00148733|Nepal
639624|NCT00148733|nutrition
639625|NCT00148733|therapeutic
639626|NCT00148720|Invasive Breast Cancer
639627|NCT00148720|Operable Breast Cancer
639628|NCT00148720|Capecitabine
639629|NCT00148707|Metastatic Breast Cancer
639630|NCT00148707|HER2-negative Breast Cancer
639631|NCT00148707|CT-2103
639632|NCT00148707|Xyotax
639633|NCT00148694|Cisplatin
639634|NCT00148694|Early Stage Breast Cancer
639635|NCT00148694|ER Negative Breast Cancer
639636|NCT00148694|PR Negative Breast Cancer
639637|NCT00148694|HER-2 Negative Breast Cancer
639638|NCT00148681|HER-2 Positive breast cancer
639639|NCT00148681|herceptin
639640|NCT00148681|navelbine
639641|NCT00148668|HER-2 Positive Breast Cancer
639642|NCT00148668|herceptin
639643|NCT00148668|navelbine
639644|NCT00148668|taxotere
639645|NCT00148668|carboplatin
639646|NCT00148668|Early stage Breast Cancer
639647|NCT00148655|educational intervention
639648|NCT00148655|decision board
639649|NCT00148655|DCIS
639650|NCT00148642|ventilator-associated pneumonia
639651|NCT00148642|nosocomial pneumonia
639652|NCT00148629|Anemia
639653|NCT00148629|Birth weight
639654|NCT00148629|Neonatal Mortality
639655|NCT00148629|Tanzania
639656|NCT00148629|Pregnancy
639657|NCT00148616|Memantine
639658|NCT00148616|Negative Syndrome
639659|NCT00148616|Schizophrenia
639660|NCT00148616|Cognitive impairment
639661|NCT00148603|dyspepsia
639662|NCT00148603|eosinophilic gastroenteritis
639663|NCT00148603|montelukast
639664|NCT00148590|Memantine
639665|NCT00148590|Negative syndrome
639666|NCT00148590|Schizophrenia
639667|NCT00148590|Cognitive impairment
639668|NCT00148590|Glutamate
639669|NCT00148577|Pain Relief, TENS, Acupuncture Points
639670|NCT00148564|weight gain
639671|NCT00148564|schizophrenia
639672|NCT00148564|atypical antipsychotics
639673|NCT00148551|AMD
639674|NCT00148551|Triamcinolone
639675|NCT00148551|Macular Degeneration
639676|NCT00148538|Type 1 Diabetes
639677|NCT00148538|Resistance Exercise
639678|NCT00148538|Aerobic Exercise
639679|NCT00148538|Exercise & Disease
639680|NCT00148538|Exercise
639681|NCT00148538|Diabetes
639682|NCT00148525|automated telephony, cancer prevention, healthy diet
639683|NCT00148473|Cervical ripening.
639684|NCT00148473|Induction of labor.
639685|NCT00148473|Misoprostol.
639686|NCT00148447|negative symptoms
639687|NCT00148447|depression
639688|NCT00148447|ssri
639689|NCT00148447|schizophrenia
639690|NCT00148434|hypertension
639691|NCT00148434|guidelines
639692|NCT00148434|patient empowerment
639693|NCT00148434|anxiety
639694|NCT00148421|Non-myeloid malignancy
639695|NCT00148421|Chemotherapy-induced anemia
639696|NCT00148408|Asthma
639697|NCT00148408|Placebo
639698|NCT00148408|Education
639700|NCT00148382|Pharmacokinetics
639701|NCT00148382|Pharmacodynamics
639702|NCT00148356|drug eluting stents
639703|NCT00148356|stents
639704|NCT00148356|angioplasty
639705|NCT00148356|coronary artery disease
639706|NCT00148356|total coronary occlusion
639707|NCT00148356|coronary artery restenosis
639708|NCT00148356|stent thrombosis
639709|NCT00148356|vascular disease
639710|NCT00148356|myocardial ischemia
639711|NCT00148356|coronary artery stenosis
639712|NCT00148252|Calcineurin
639713|NCT00148252|reduction
639714|NCT00148252|immunosuppression
639715|NCT00148252|cyclosporine A
639716|NCT00148252|mycophenolate mofetil
639717|NCT00148239|SCI
639718|NCT00148239|Caregiving
639719|NCT00148239|Aging
639720|NCT00148239|Disability
639721|NCT00148239|Paralysis
639722|NCT00148226|Decision Aid
639723|NCT00148226|Faecal Occult Blood Test
639724|NCT00148226|Colorectal Cancer Screening
639725|NCT00148226|Informed Decision-making
639726|NCT00148213|differentiated thyroid carcinoma
639727|NCT00148213|thyroglobulin
639728|NCT00148213|immunoassay
639729|NCT00148213|thyroidectomy
639730|NCT00148213|radioiodine therapy
639731|NCT00148200|female sexual dysfunction
639732|NCT00148200|desire
639733|NCT00148200|arousal
639734|NCT00148200|lubrification
639735|NCT00148200|orgasm
639736|NCT00148200|satisfaction
639737|NCT00148200|pain
639738|NCT00148187|Medication adherence
639739|NCT00148187|Patient compliance
639740|NCT00148187|Kidney transplant
639741|NCT00148187|Organ rejection
639742|NCT00148187|Allograft loss
639743|NCT00148187|Drug monitoring
639744|NCT00148174|Medication adherence
639745|NCT00148174|Patient compliance
639746|NCT00148174|Kidney transplant
639747|NCT00148174|Organ rejection
639748|NCT00148174|Allograft loss
639749|NCT00148174|Drug monitoring
639750|NCT00148161|Magnetoencephalography
639751|NCT00148161|Auditory cortex
639752|NCT00148161|Stuttering
639753|NCT00148161|Non stuttering
639754|NCT00148148|Hematopoietic Stem Cell Transplantation
639755|NCT00148148|Caspofungin
639756|NCT00148148|Liposomal Amphotericin B
639757|NCT00148135|Carcinoma of Unknown Primary Site (CUP)
639758|NCT00148122|Squamous cell cancer of the oral cavity and pharynx
639759|NCT00148109|Unresectable/metastatic high grade soft tissue bony sarcoma
639760|NCT00148096|asthma
639761|NCT00148096|house dust mite
639762|NCT00148096|allergy
639763|NCT00148096|housing
639764|NCT00148096|avoidance
639765|NCT00148096|humidity
639766|NCT00148083|Schizophrenia
639767|NCT00148083|Cognition
639768|NCT00148083|Clinical Trial
639769|NCT00148057|Diet
639770|NCT00148057|Dietary fat
639771|NCT00148057|Breast cancer
639772|NCT00148057|Prevention
639773|NCT00148031|behavior modification
639774|NCT00148031|health care service utilization
639775|NCT00148031|hepatitis C,
639776|NCT00148031|injection drug use
639777|NCT00148031|therapy compliance
639778|NCT00148031|alcoholism
639779|NCT00148031|alcohol abuse
639780|NCT00148031|prevention
639781|NCT00148031|drug abuse
639782|NCT00148031|liver disorder
639783|NCT00148031|HCV
639784|NCT00148031|methadone
639785|NCT00148018|Hodgkin disease
639786|NCT00148018|Bortezomib
639787|NCT00148018|Relapse
639788|NCT00148018|Lymphoma
639789|NCT00147966|active disease despite concomitant methotrexate
639790|NCT00147953|NHL
639791|NCT00147953|Lymphoma
639792|NCT00147953|Radiotherapy
639793|NCT00147953|Rituximab
639794|NCT00147953|Palliative treatment
639795|NCT00147940|Allergy
639796|NCT00147927|email
639797|NCT00147927|internet
639798|NCT00147927|health promotion
639799|NCT00147927|behavior change
639800|NCT00147927|health status
639801|NCT00147927|work productivity
639802|NCT00147927|healthcare cost
639803|NCT00147927|employee
639804|NCT00147914|Acute bacterial sinusitis
639805|NCT00147901|CLL
639806|NCT00147901|Immunochemotherapy
639807|NCT00147888|Mucosal congestion
639808|NCT00147888|Acoustic rhinometry
639809|NCT00147888|Physiology
639810|NCT00147875|Lymphoma
639811|NCT00147875|Gemcitabine
639812|NCT00147875|Advanced stages Hodgkin's lymphoma
639813|NCT00147875|Elderly
639814|NCT00147862|Tranexamic Acid
639815|NCT00147862|Antifibrinolytic Agents
639816|NCT00147862|Head and Neck Neoplasms
639817|NCT00147862|Thromboelastography
639818|NCT00147849|knowledge translation
639819|NCT00147849|health care utilization
639820|NCT00147849|economic analysis
639821|NCT00147836|type 2 diabetes mellitus
639822|NCT00147836|therapy
639823|NCT00147836|sulfonylureas
639824|NCT00147836|metformin
639825|NCT00147836|insulin
639826|NCT00147823|Bone formation
639827|NCT00147823|Bone lesions
639828|NCT00147823|Benign bone lesion
639829|NCT00147810|telephone outreach
639830|NCT00147810|asthma care
639831|NCT00147797|Atherosclerosis
639832|NCT00147797|intima media thickness
639833|NCT00147797|aortic stiffness
639834|NCT00147797|HIV infection
639835|NCT00147797|Dyslipidemia
639836|NCT00147797|Treatment Experienced
639837|NCT00147784|Chronical Hepatitis C treatment
639838|NCT00147784|Methadone Maintenance Treatment
639839|NCT00147784|Pegylated Interferon and Ribavirin
639840|NCT00147784|14 weeks treatment
639841|NCT00147784|Genotype 2 and 3
639842|NCT00147771|localized scleroderma
639843|NCT00147771|morphea
639844|NCT00147771|imiquimod
639845|NCT00147771|pediatrics
639846|NCT00147758|Diabetes Mellitus
639847|NCT00147745|Mechanism of action insulin sensitivity
639848|NCT00147732|larynx carcinoma
639849|NCT00147732|radiotherapy
639850|NCT00147732|carbogen
639851|NCT00147732|nicotinamide
639852|NCT00147719|Diabetes Mellitus
639853|NCT00147706|Electronic Health Record
639854|NCT00147706|Patient Portal
639855|NCT00147706|Chronic Diseases
639856|NCT00147693|Dementia
639857|NCT00147693|Alzheimer Disease
639858|NCT00147693|Lewy-Body
639859|NCT00147693|Cost*
639860|NCT00147693|Community (dwelling)
639861|NCT00147693|Caregiver(s)
639862|NCT00147693|Institutionalization
639863|NCT00147693|Quality of life
639864|NCT00147693|Randomized Control Trail
639865|NCT00147693|Vascular dementia
639866|NCT00147680|Uterine Papillary Serous Carcinoma (UPSC)
639867|NCT00147667|COPD
639868|NCT00147667|EXACERBATIONS
639869|NCT00147667|AIRWAY INFLAMMATION
639870|NCT00147537|non-small cell lung cancer
639871|NCT00147537|chemotherapy
639872|NCT00147537|figitumumab
639873|NCT00147537|insulin-like growth 1 factor receptor
639874|NCT00147537|IGF-IR
639875|NCT00147537|monoclonal antibody
639876|NCT00146471|alcohol withdrawal
639877|NCT00146471|detoxification
639878|NCT00146471|Inpatients
639879|NCT00146471|alcohol dependence according to DSM-IV/ICD-10
639880|NCT00146471|withdrawal symptoms
639881|NCT00146458|Cervical cancer
639882|NCT00146458|FDG-PET
639883|NCT00146458|Lymph node metastasis
639884|NCT00146458|Radiotherapy
639885|NCT00146458|Chemotherapy
639886|NCT00146445|IV drug users
639887|NCT00146419|Treatment Experienced
639888|NCT00146419|Treatment Naive
639889|NCT00146406|Adolescent Health
639890|NCT00146406|Sexually Transmitted Disease
639891|NCT00146406|Sexual Behavior
639892|NCT00146393|exercise
639893|NCT00146393|physical activity
639894|NCT00146393|physical conditioning
639895|NCT00146393|pain
639896|NCT00146393|physical function
639897|NCT00146380|Prevention Mother-to-Child HIV transmission
639898|NCT00146380|HIV Seronegativity
639899|NCT00146367|arthritis
639900|NCT00146367|osteoarthritis
639901|NCT00146367|rheumatoid arthritis
639902|NCT00146367|rheumatic disease
639903|NCT00146367|exercise
639904|NCT00146367|physical activity
639905|NCT00146367|physical function
639906|NCT00146367|disability
639907|NCT00146354|Electronic Medical Record
639908|NCT00146354|Electronic Results Tracking
639909|NCT00146354|Patient Safety
639910|NCT00146354|Post-Discharge Test Results
639911|NCT00146315|Primary Health Care
639912|NCT00146315|Family Practice
639913|NCT00146315|Family Physician
639914|NCT00146315|Exercise
639915|NCT00146315|Coronary Heart Disease
639916|NCT00146315|Randomized Controlled Trials
639917|NCT00146315|Multicenter Studies
639918|NCT00146302|Non-specific effects of vaccines
639919|NCT00146302|Infant mortality
639920|NCT00146302|Morbidity
639921|NCT00146302|Low income country
639922|NCT00146302|BCG
639923|NCT00146302|Vaccine policy
639924|NCT00146302|immunisation
639925|NCT00146302|Low birth weight
639926|NCT00146302|Tuberculin
639927|NCT00146302|Mortality
639928|NCT00146276|bladder cancer
639929|NCT00146276|cystectomy
639930|NCT00146276|gemcitabine
639931|NCT00146276|adjuvant chemotherapy
639932|NCT00146276|locally advanced bladder cancer
639933|NCT00146263|mild cognitive impairment
639934|NCT00146263|dementia
639935|NCT00146263|Alzheimer's Disease
639936|NCT00146263|cognitive training
639937|NCT00147498|oral JAK inhibitor
639938|NCT00147498|clinical trial
639939|NCT00147498|joint diseases
639940|NCT00147498|anti-Inflammatory agents
639941|NCT00147498|rheumatic diseases
639942|NCT00147498|DMARD
639943|NCT00147498|Antirheumatic Agents
639944|NCT00147498|Autoimmune Diseases
639945|NCT00147498|Immune System Diseases
639946|NCT00147472|Head and neck
639947|NCT00147472|Cancer
639948|NCT00147472|Diagnosis
639949|NCT00147472|Fluorodeoxyglucose
639950|NCT00147472|Positron-Emission Tomography
639951|NCT00147472|PET
639952|NCT00147472|Oncology
639953|NCT00147459|hepatitis B virus
639954|NCT00147459|vaccine
639955|NCT00147459|booster
639956|NCT00147459|liver transplantation
639957|NCT00147446|Stress
639958|NCT00147446|Stress Management
639959|NCT00147446|Behavioral Medicine
639960|NCT00147446|Multiple Sclerosis
639961|NCT00147446|Psychoneuroimmunology
639962|NCT00147433|free thyroxine
639963|NCT00147433|pregnancy
639964|NCT00147433|fetal brain development
639965|NCT00147433|thyroid stimulating hormone
639966|NCT00147433|IQ
639967|NCT00147420|Tibet
639968|NCT00147420|Third Stage Labor
639969|NCT00147420|Post Partum Hemorrhage
639970|NCT00147420|Misoprostol
639971|NCT00147420|Zhi Byed 11
639972|NCT00147420|Global Network
639973|NCT00147394|Risperidone
639974|NCT00147394|Autism
639975|NCT00147394|PDD
639976|NCT00147394|Pervasive Developmental Disorder
639977|NCT00147381|Campath-1H
639978|NCT00147381|Alemtuzumab
639979|NCT00147381|Tacrolimus
639980|NCT00147381|renal transplantation
639981|NCT00147381|immunosuppression
639982|NCT00147381|prevention of acute rejection
639983|NCT00147368|falciparum
639984|NCT00147368|malaria
639985|NCT00147368|arginine
639986|NCT00147355|rIL-2-toxicity
639987|NCT00147355|interleukin-2 therapy
639988|NCT00147355|HIV
639989|NCT00147355|Toxicity substudy of ESPRIT
639990|NCT00147342|exercise
639991|NCT00147342|hypoglycemia
639992|NCT00147342|Diabetes Mellitus, Type I
639993|NCT00147342|glucose monitoring
639994|NCT00147316|acute stroke
639995|NCT00147316|thrombolytic therapy
639996|NCT00147316|tissue plasminogen activator
639997|NCT00147290|ATP
639998|NCT00147290|Tachycardia
639999|NCT00147290|CRT-D
640000|NCT00147277|ATP
640001|NCT00147277|Thachy
640002|NCT00147277|FVT
640003|NCT00147264|insulin resistance, myocellular lipids, adipose tissue
640004|NCT00147251|lowering LDL and BP below current targets
640005|NCT00147251|LDL cholesterol treatment
640006|NCT00147251|blood pressure treatment
640007|NCT00147251|carotid intimal medial thickness
640008|NCT00147251|prevent progression of CVD
640009|NCT00147238|Bladder Cancer
640010|NCT00147238|Genitourinary Cancer
640011|NCT00147238|Prostate Cancer
640012|NCT00147238|MR Lymphangiography
640013|NCT00147238|Ferumoxtran-10
640014|NCT00147238|SPIO
640015|NCT00147238|Ultra-small superparamagnetic agent iron oxide
640016|NCT00147225|Advanced Cancer
640017|NCT00147225|Advanced Malignancy
640018|NCT00147225|Solid Tumors
640019|NCT00147225|Thrombocytopenia
640020|NCT00147225|AMG 531
640021|NCT00147225|Romiplostim
640022|NCT00147225|Carboplatin
640023|NCT00147225|Paraplatin
640024|NCT00147225|Platelets
640025|NCT00147225|Adriamycin
640026|NCT00147225|Doxorubicin
640027|NCT00147225|Rubex
640028|NCT00147225|Ifosfamide
640029|NCT00147225|Ifex
640030|NCT00147212|Advanced Prostate Cancer
640031|NCT00147212|Prostate Cancer
640032|NCT00147212|Trabectedin
640033|NCT00147212|ET 743
640034|NCT00147212|Yondelis
640035|NCT00147199|Pulmonary Arterial Hypertension
640036|NCT00147147|gastric neoplasm
640037|NCT00147147|gastrectomy
640038|NCT00147147|adjuvant chemotherapy
640039|NCT00147147|randomized trial
640040|NCT00147147|T3 and T4 carcinoma of the stomach/Gastric Neoplasm
640041|NCT00147134|colorectal cancer
640042|NCT00147134|laparoscopic surgery
640043|NCT00147134|randomized controlled trial
640044|NCT00147134|oncological outcome
640045|NCT00147121|Rituximab
640046|NCT00147121|CHOP
640047|NCT00147121|Bi-weekly
640048|NCT00147121|low-grade B-cell lymphoma
640049|NCT00147121|advanced stage
640050|NCT00147121|follicular lymphoma
640051|NCT00147121|G-CSF
640052|NCT00147121|Untreated stage III/IV low-grade B-cell lymphoma
640053|NCT00147108|Breast Cancer
640054|NCT00147095|macrophages
640055|NCT00147095|neutrophils
640056|NCT00147095|lymphocytes
640057|NCT00147082|chemokine
640058|NCT00147082|chemokine receptor
640059|NCT00147082|neutrophil
640060|NCT00147082|lymphocyte
640061|NCT00147082|monocyte
640062|NCT00147069|sputum
640063|NCT00147069|macrophage
640064|NCT00147069|neutrophil
640065|NCT00147056|Brain tumor
640066|NCT00147056|Brain Lesions
640067|NCT00147056|Brain Cancer
640068|NCT00147056|ExAblate
640069|NCT00147043|Adult stem cells
640070|NCT00147043|Liver disease
640071|NCT00147043|CD34 positive cells
640072|NCT00147030|Hypoxia
640073|NCT00147030|Ischaemia
640074|NCT00147030|Encephalopathy
640075|NCT00147030|Neonatal
640076|NCT00147030|Hypothermia
640077|NCT00147030|Perinatal
640078|NCT00147030|Cooling
640079|NCT00147030|Whole/Total Body
640080|NCT00147017|macrophage
640081|NCT00147017|inflammation
640082|NCT00147017|COPD
640083|NCT00147004|Septic shock
640084|NCT00147004|Steroids
640085|NCT00147004|Hydrocortisone
640086|NCT00147004|Mortality
640087|NCT00147004|Reversal of shock
640088|NCT00147004|Adrenal insufficiency
640089|NCT00146952|Hemineglects
640090|NCT00146926|Propofol
640091|NCT00146926|pain
640092|NCT00146926|general anesthesia
640093|NCT00146926|prevention
640094|NCT00146913|Chronic myeloid leukaemia
640095|NCT00146913|resistant
640096|NCT00146913|refractory
640097|NCT00146913|Imatinib mesylate
640098|NCT00146900|Traumatic Events
640099|NCT00146900|Post-traumatic Stress Disorder
640100|NCT00146900|Treatment (psychological)
640101|NCT00146900|Treatment (pharmacological)
640102|NCT00146900|Prevention
640103|NCT00146900|SSRIs
640104|NCT00146887|Coronary CT
640105|NCT00146887|sensitivity
640106|NCT00146887|specificity
640107|NCT00146809|Multi-System-Atrophy
640108|NCT00146809|Minocycline
640109|NCT00146796|Malaria
640110|NCT00146796|Diagnosis
640111|NCT00146796|RDT
640112|NCT00146796|Africa
640113|NCT00146796|Tanzania
640114|NCT00146783|intermittent preventive treatment
640115|NCT00146783|malaria
640116|NCT00146783|pregnancy
640117|NCT00146783|efficacy
640118|NCT00146783|safety
640119|NCT00146731|malaria
640120|NCT00146731|pregnancy
640121|NCT00146731|treatment
640122|NCT00146731|Africa
640123|NCT00146731|Tanzania
640124|NCT00146718|malaria
640125|NCT00146718|drug resistance
640126|NCT00146718|antimalarials
640127|NCT00146705|chronic HBV
640128|NCT00146705|Peginterferon
640129|NCT00146705|long term follow-up
640130|NCT00146692|Malaria
640131|NCT00146692|Cost
640132|NCT00146692|Treatment
640133|NCT00146692|Diagnosis
640134|NCT00146692|Africa
640135|NCT00146692|Ghana
640136|NCT00146679|Heart failure
640137|NCT00146679|Ventricular arrhythmias
640138|NCT00146679|ICD
640139|NCT00146679|Psychoeducational intervention
640140|NCT00146666|Peak walking time
640141|NCT00146666|Absolute claudication distance
640142|NCT00146666|Claudication onset time
640143|NCT00146666|Initial claudication distance
640144|NCT00146666|Intermittent compression
640145|NCT00146653|pediatrics
640146|NCT00146653|cardiopulmonary bypass
640147|NCT00146653|surgery
640148|NCT00146640|active disease
640149|NCT00146640|morning stiffness of joints
640150|NCT00146640|nighttime application of prednisone
640151|NCT00146640|modified releae prednisone
640152|NCT00146627|Human African Trypanosomiasis
640153|NCT00146627|Combination
640154|NCT00146627|Trypanosoma brucei gambiense Human African Trypanosomiasis
640155|NCT00146614|Graft versus Host Disease
640156|NCT00146614|GVHD
640157|NCT00146614|Stem Cell Transplantation
640158|NCT00146614|Tacrolimus
640159|NCT00146614|Sirolimus
640160|NCT00146614|Methotrexate
640161|NCT00146614|allogeneic stem cell transplantation
640162|NCT00146601|Fulvestrant
640163|NCT00146601|Advanced breast cancer
640164|NCT00146601|Invasive breast cancer
640165|NCT00146601|Stage IV Breast Cancer
640166|NCT00146601|Hormone Receptor-Positive Breast Cancer
640167|NCT00146588|Breast cancer
640168|NCT00146588|cytoxan
640169|NCT00146588|epirubicin
640170|NCT00146588|capecitabine
640171|NCT00146562|adjuvant chemotherapy
640172|NCT00146562|G-CSF
640173|NCT00146562|pegfilgrastim
640174|NCT00146562|darbepoetin alfa
640175|NCT00146549|HER2-positive Breast cancer
640176|NCT00146549|HER2 overexpressing
640177|NCT00146549|trastuzumab
640178|NCT00146549|Herceptin
640179|NCT00146549|vinorelbine
640180|NCT00146549|Navelbine
640181|NCT00146549|Taxotere
640182|NCT00146549|taxol
640183|NCT00146536|ALH
640184|NCT00146536|LCIS
640185|NCT00146536|DCIS
640186|NCT00146536|adjacent ipsilateral infiltrating carcinoma
640187|NCT00146536|core needle biopsy
640188|NCT00146536|Lobular neoplasia of the breast
640189|NCT00146523|Psychotic Major Depression
640190|NCT00146523|PMD
640191|NCT00146523|Depression
640192|NCT00146523|Major Depression
640193|NCT00146523|Psychosis
640194|NCT00146510|weight control
640195|NCT00146510|compliance
640196|NCT00146510|physical activity
640197|NCT00146510|nutrition
640198|NCT00146510|Health Behavior
640199|NCT00146510|Patient Compliance
640200|NCT00146497|Respiratory distress syndrome (RDS)
640201|NCT00146497|Premature infants
640202|NCT00146497|Chronic lung disease (CLD)
640203|NCT00146497|Bronchoalveolar lavage fluid (BALF)
640204|NCT00146497|Cytokines
640205|NCT00146484|Diabetes Mellitus, Type 1
640206|NCT00146484|Child
640207|NCT00146484|Adolescent
640208|NCT00146484|Disease Management
640209|NCT00146484|Newly Diagnosed
640210|NCT00146484|Hemoglobin A, Glycosylated
640211|NCT00146237|phenytoin
640212|NCT00146237|SSRI failure
640213|NCT00146237|depression
640214|NCT00146224|anemia
640215|NCT00146224|chronic kidney disease, CKD
640216|NCT00146224|hemodialysis
640217|NCT00146224|epoetin
640218|NCT00146224|Epogen®
640219|NCT00146211|Trial
640220|NCT00146211|ethyl-EPA
640221|NCT00146211|Miraxion™
640222|NCT00146211|treating
640223|NCT00146211|mild
640224|NCT00146211|moderate
640225|NCT00146211|Huntington's
640226|NCT00146198|Postoperative pain
640227|NCT00146198|Inguinal Hernia Repair
640228|NCT00146198|Capsaicin
640229|NCT00146185|Needlestick pain
640230|NCT00146185|Venipuncture pain
640231|NCT00146185|Procedural pain
640232|NCT00146172|Tumors
640233|NCT00146159|Multiple Sclerosis
640234|NCT00146146|transsexualism
640235|NCT00146146|testosterone
640236|NCT00146146|dihydrotestosterone
640237|NCT00146146|estradiol
640238|NCT00146133|Obesity, Aging, Frailty, exercise, weight loss
640239|NCT00146107|obesity
640240|NCT00146107|aging
640241|NCT00146107|exercise
640242|NCT00146107|diet
640243|NCT00146107|weight loss
640244|NCT00146107|physical function
640245|NCT00146107|Obesity in the Elderly
640246|NCT00146094|Osteopenia
640247|NCT00146094|osteoporosis
640248|NCT00146094|bone mineral density
640249|NCT00146094|HIV infection
640250|NCT00146094|bone metabolism
640251|NCT00146094|Treatment Naive
640252|NCT00146081|African Americans
640253|NCT00146081|weight control
640254|NCT00146081|social support
640255|NCT00146068|Clinically Isolated Syndrome
640256|NCT00146029|Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)
640257|NCT00146016|Chronic Hepatitis C
640258|NCT00146016|Amantadine
640259|NCT00146016|Triple therapy
640260|NCT00146003|eczema
640261|NCT00146003|atopic dermatitis
640262|NCT00146003|efalizumab
640263|NCT00145990|methacholine PC20
640264|NCT00145990|dosimeter
640265|NCT00145990|asthma
640266|NCT00145977|osteoporosis
640267|NCT00145977|bone density
640268|NCT00145977|women
640269|NCT00145977|endocrine
640270|NCT00145977|musculoskeletal
640271|NCT00145977|metabolic
640272|NCT00145964|Biliary Cirrhosis, Primary
640273|NCT00145964|genes
640274|NCT00145964|autoimmune disease
640275|NCT00145938|Portopulmonary hypertension
640276|NCT00145938|PTPH
640277|NCT00145938|pulmonary hypertension
640278|NCT00145938|high blood pressure in the pulmonary arteries
640279|NCT00145925|Diabetes Mellitus, Type 2
640280|NCT00145925|Blood Pressure
640281|NCT00145925|Stroke
640282|NCT00145925|MI
640283|NCT00145912|Depression in adolescents and young adults, depression web-base activity
640284|NCT00145886|low bone turnover; sclerosing bone disorders,
640285|NCT00145886|osteopetrosis
640286|NCT00145873|heart failure
640287|NCT00145873|nesiritide
640288|NCT00145873|heart disease
640289|NCT00145873|cardiovascular disease
640290|NCT00145860|Colorectal Cancer
640291|NCT00145847|alcohol
640292|NCT00145847|schizophrenia
640293|NCT00145847|naltrexone
640294|NCT00145834|psychosocial factors
640295|NCT00145834|breastfeeding
640296|NCT00145834|postnatal intervention
640297|NCT00145834|health visitor
640298|NCT00145808|Ulcerative colitis
640299|NCT00145795|HIV
640300|NCT00145795|HAART (Highly Active Anti-Retroviral Therapy) partial immune response
640301|NCT00145795|no immune response
640302|NCT00145795|Treatment Experienced
640303|NCT00145782|multiphasic screening
640304|NCT00145782|primary health care
640305|NCT00145782|randomized controlled trial
640306|NCT00145782|Risk factors
640307|NCT00145769|rectal cancer
640308|NCT00145769|radiotherapy
640309|NCT00145769|chemotherapy
640310|NCT00145769|chemoradiation
640311|NCT00145769|adjuvant therapy
640312|NCT00145756|Sodium Chloride
640313|NCT00145756|Blood Pressure
640314|NCT00145756|Cardiovascular Diseases
640315|NCT00145756|Clinical Trial
640316|NCT00145743|Quality of Life
640317|NCT00145743|Breast Cancer
640318|NCT00145743|Referee's Report
640319|NCT00145743|Diagnostics
640320|NCT00145743|Therapy
640321|NCT00145730|osteoarthritis hip
640322|NCT00145730|arthroplasty
640323|NCT00145730|ectopic bone formation
640324|NCT00145730|non-steroidal anti-inflammatory drugs
640325|NCT00145730|disability
640326|NCT00145717|Phytosterols
640327|NCT00145717|Cholesterol
640328|NCT00145717|China
640329|NCT00145717|Randomized controlled trial
640330|NCT00145704|osteopenia
640331|NCT00145704|growth hormone deficiency
640332|NCT00145704|pediatric malignancy
640333|NCT00145678|borderline
640334|NCT00145678|alcohol
640335|NCT00145678|substance
640336|NCT00145678|psychodynamic
640337|NCT00145678|psychotherapy
640338|NCT00145678|psychoanalytic
640339|NCT00145665|FLT-PET
640340|NCT00145665|colorectal liver metastases
640341|NCT00145665|proliferation
640342|NCT00145665|proliferation markers
640343|NCT00145665|recurrence
640344|NCT00145652|erythropoetin
640345|NCT00145652|adjuvant iron therapy
640346|NCT00145652|anemia
640347|NCT00145652|cancer
640348|NCT00145639|Osteosarcoma
640349|NCT00145639|Treatment, Carboplatin
640350|NCT00145626|Stem cell transplantation
640351|NCT00145626|Stem cell transplant
640352|NCT00145626|Haploidentical transplant
640353|NCT00145613|Haploidentical stem cell transplant
640354|NCT00145613|High risk hematologic malignancies
640355|NCT00145613|Allogeneic stem cell transplant
640356|NCT00145613|Mismatched family member stem cell donor
640357|NCT00145600|Lymphoma
640358|NCT00145600|Hodgkin Disease
640359|NCT00145587|Osteopetrosis
640360|NCT00145587|Autosomal recessive bone disease
640361|NCT00145587|Haploidentical stem cell transplantation
640362|NCT00145587|Allogeneic stem cell transplantation
640363|NCT00145587|T-cell depletion methodology
640364|NCT00145587|Miltenyi Biotec CliniMACS stem cell selection device
640365|NCT00145574|Pediatric
640366|NCT00145574|hypercholesterolemia
640367|NCT00145574|colesevelam
640368|NCT00145561|HIV
640369|NCT00145548|COPD
640370|NCT00145535|Glaucoma
640371|NCT00145535|Glaucoma, open angle
640372|NCT00145535|Intraocular Pressure
640373|NCT00145535|Trabeculoplasty
640374|NCT00145535|laser
640375|NCT00145535|laser, surgery
640376|NCT00145522|Menopause, IGF-1, HRT
640377|NCT00145418|Non small Cell Lung Cancer Stage IIIb and IV
640378|NCT00145405|Acromegaly
640379|NCT00145405|somatostatin analogues
640380|NCT00145405|lanreotide
640381|NCT00145405|octreotide
640382|NCT00145405|GH
640383|NCT00145405|IGF-I
640384|NCT00145405|injection site
640385|NCT00145392|Polycystic ovary syndrome
640386|NCT00145392|growth hormone
640387|NCT00145392|insulin resistance
640388|NCT00145392|overweight
640389|NCT00145392|glucose metabolism
640390|NCT00145379|type 1 diabetes mellitus
640391|NCT00145379|insulin resistance
640392|NCT00145379|metformin
640393|NCT00145379|randomized, controlled study
640394|NCT00145366|Benign nontoxic and toxic goiter
640395|NCT00145366|rhTSH
640396|NCT00145366|131I
640397|NCT00145366|goiter reduction
640398|NCT00145366|131I kinetic
640399|NCT00145366|thyroid size
640400|NCT00145366|patient satisfaction
640401|NCT00145366|adverse effects
640402|NCT00145366|BRT
640403|NCT00145366|Graves' disease
640404|NCT00145353|type 1 diabetes mellitus
640405|NCT00145353|hypoglycaemia
640406|NCT00145353|insulin profiles
640407|NCT00145353|growth hormone
640408|NCT00145353|cortisol
640409|NCT00145353|glucagon
640410|NCT00145340|polycystic ovary syndrome (PCOS)
640411|NCT00145340|PPARgamma
640412|NCT00145340|growth hormone
640413|NCT00145340|insulin resistance
640414|NCT00145340|pioglitazone
640415|NCT00145340|glucose metabolism
640416|NCT00145340|microarray
640417|NCT00145327|Osteoporosis, Zoledronic Acid
640418|NCT00145314|Metastatic colorectal cancer
640419|NCT00145314|FLOX
640420|NCT00145314|Cetuximab
640421|NCT00145301|Osteoarthritis, lumiracoxib, retention on treatment, efficacy, safety
640422|NCT00145288|hirsutism
640423|NCT00145288|type 2 diabetes
640424|NCT00145288|polycystic ovary syndrome
640425|NCT00145288|metabolism
640426|NCT00145275|zoledronic acid
640427|NCT00145275|bisphosphonate
640428|NCT00145275|Low bone mass
640429|NCT00145262|critical limb ischemia
640430|NCT00145262|bone marrow mononuclear cells
640431|NCT00145262|angiogenesis
640432|NCT00145262|vasculogenesis
640433|NCT00145262|Arteriosclerosis Obliterans (ASO)
640434|NCT00145262|Ischemic ulcers
640435|NCT00145249|Bacterial infections, HIV infection, cryptococcal meningitis
640436|NCT00145236|Nebivolol
640437|NCT00145236|Beta-Blocker
640438|NCT00145223|Wuchereria bancrofti, filariasis, Egypt
640439|NCT00145210|Nebivolol
640440|NCT00145197|breast cancer
640441|NCT00145197|adjuvant treatment
640442|NCT00145197|racial disparities
640443|NCT00145197|Early-Stage Breast Cancer
640444|NCT00145184|multivitamin, supplements, tuberculosis, Tanzania
640445|NCT00145158|Melanoma
640446|NCT00145158|Vaccine
640447|NCT00145158|Peptide
640448|NCT00145158|Montanide
640449|NCT00145145|Melanoma
640450|NCT00145145|Vaccine
640451|NCT00145145|Peptide
640452|NCT00145145|MAGE
640453|NCT00145145|CpG
640454|NCT00145132|depression
640455|NCT00145132|β-CIT-SPECT
640456|NCT00145132|SERT
640457|NCT00145132|DAT
640458|NCT00145132|neurophysiology
640459|NCT00145132|LDAEP
640460|NCT00145132|escitalopram
640461|NCT00145132|SSRI
640462|NCT00145119|Acute myocardial infarction
640463|NCT00145119|Cardiac arrhythmias
640464|NCT00145119|Left ventricular dysfunction
640465|NCT00145119|Implantable loop recorder
640466|NCT00145119|Risk stratifiers
640467|NCT00145106|acne, tazarotene, minocycline, maintenance, retinoid, efficacy, combination
640468|NCT00145093|Diabetes Mellitus, Type 2
640469|NCT00145093|Chromium
640470|NCT00145093|Saccharomyces cerevisiae
640471|NCT00145028|Neoplasms
640472|NCT00145028|Carboplatin
640473|NCT00145028|optimal exposure
640474|NCT00145028|AUC
640475|NCT00145015|Intervention
640476|NCT00145015|Adults
640477|NCT00145015|Colorectal cancer
640478|NCT00145015|Nutrition
640479|NCT00145015|Fish
640480|NCT00145015|n-3 fatty acids
640481|NCT00145015|Apoptosis
640482|NCT00145015|Ulcerative colitis
640483|NCT00145015|Polyps
640484|NCT00145015|Gastro-intestinal tract
640485|NCT00145002|ATLL
640486|NCT00145002|chemotherapy
640487|NCT00145002|phase III study
640488|NCT00145002|VCAP-AMP-VECP
640489|NCT00145002|biweekly-CHOP
640490|NCT00144989|Small-cell lung cancer
640491|NCT00144989|Limited-Stage Small-Cell Lung Cancer
640492|NCT00144989|Combined modality therapy
640493|NCT00144989|chemotherapy
640494|NCT00144989|radiotherapy
640495|NCT00144989|Irinotecan
640496|NCT00144989|Cisplatin
640497|NCT00144976|Head and Neck Neoplasms
640498|NCT00144976|Tarceva
640499|NCT00144976|ENT
640500|NCT00144911|exacerbations
640501|NCT00144911|breathing
640502|NCT00144911|chronic obstructive pulmonary disease
640503|NCT00144898|Breast cancer
640504|NCT00144898|sentinel node resection
640505|NCT00144898|survival
640506|NCT00144898|Breast cancer unifocal N0
640507|NCT00144885|Endocarditis
640508|NCT00144885|RMI
640509|NCT00144885|Impact measure
640510|NCT00144872|Absence Seizures
640511|NCT00144872|EEG
640512|NCT00144872|LTG
640513|NCT00144872|Typical Absence Epilepsy
640514|NCT00144872|Epilepsy
640515|NCT00144872|LAMICTAL
640516|NCT00144859|P38 map kinase
640517|NCT00144859|CRP
640518|NCT00144859|COPD
640519|NCT00144859|safety
640520|NCT00144846|wheezing
640521|NCT00144846|bronchospasm
640522|NCT00144846|albuterol sulfate HFA
640523|NCT00144833|Protease inhibitors-experienced HIV-1 infected patients
640524|NCT00144833|Highly-resistant HIV-1
640525|NCT00144833|Dual boosted Pis
640526|NCT00144833|fosamprenavir
640527|NCT00144833|lopinavir
640528|NCT00144820|Hyaluronan
640529|NCT00144820|Gonarthrosis
640530|NCT00144820|Osteoarthritis,knee
640531|NCT00144820|Double-blinded
640532|NCT00144820|Placebo controlled
640533|NCT00144820|Randomised
640534|NCT00144807|lymphoma, diffuse large B-cell
640535|NCT00144807|rituximab
640536|NCT00144807|chemotherapy
640537|NCT00144807|autologous stem cell transplant
640538|NCT00144794|Hurler's Syndrome
640539|NCT00144794|Hurler-Scheie Syndrome
640540|NCT00144794|Scheie Syndrome
640541|NCT00144755|lymphoma, diffuse large B-cell
640542|NCT00144755|rituximab
640543|NCT00144755|chemotherapy
640544|NCT00144755|erythropoetin
640545|NCT00144755|darbepoetin alfa
640546|NCT00144716|Vector Control
640547|NCT00144716|repellent
640548|NCT00144716|ITN's
640549|NCT00144716|malaria
640550|NCT00144716|Amazon
640551|NCT00144703|Graft versus host disease
640552|NCT00144703|GVHD
640553|NCT00144703|Stem cell transplantation
640554|NCT00144703|sirolimus
640555|NCT00144703|tacrolimus
640556|NCT00144690|Epilepsy refractory partial seizures
640557|NCT00144677|Graft versus Host Disease
640558|NCT00144677|GVHD
640559|NCT00144677|sirolimus
640560|NCT00144677|tacrolimus
640561|NCT00144677|Stem cell transplant
640562|NCT00144443|Aerobiology
640563|NCT00144443|Asthma
640564|NCT00144443|Indoor Fungi
640565|NCT00144443|Allergen
640566|NCT00144443|Home Remediation
640567|NCT00144430|chronic graft versus host disease
640568|NCT00144430|graft
640569|NCT00144430|host
640570|NCT00144430|transplant
640571|NCT00144430|stem cell
640572|NCT00144430|pediatric
640573|NCT00144430|GVH0313
640574|NCT00144430|leukemia
640575|NCT00144417|tuberculosis
640576|NCT00144417|TB
640577|NCT00144417|treatment
640578|NCT00144417|efficacy
640579|NCT00144417|safety
640580|NCT00144378|gastric cancer
640581|NCT00144378|metastatic
640582|NCT00144378|irinotecan
640583|NCT00144365|HIV
640584|NCT00144365|Africa
640585|NCT00144365|Adherence
640586|NCT00144365|HIV viral load
640587|NCT00144365|Sexual behavior
640588|NCT00144365|Voluntary counseling and testing
640589|NCT00144352|Malaria
640590|NCT00144352|HIV
640591|NCT00144352|AIDS
640592|NCT00144352|drug efficacy
640593|NCT00144352|Kenya
640594|NCT00144352|Africa
640595|NCT00144352|Sulfadoxine pyirmethamine
640596|NCT00144352|fansidar
640597|NCT00144313|vaccine
640598|NCT00144313|hepatitis B
640599|NCT00144313|immune memory
640600|NCT00144144|Hypertension
640601|NCT00144144|Diabetes Mellitus, Type 2
640602|NCT00144144|Calcium Channel Blocker
640603|NCT00144144|Angiotensin II type 1 Receptor Blocker
640604|NCT00144131|Chemotherapy, Anemia
640605|NCT00144131|Aranesp®, rHuEPO
640606|NCT00144131|Chemotherapy Induced Anemia
640607|NCT00144131|non-myeloid malignancy
640608|NCT00144131|Non-Myeloid Malignancies
640609|NCT00144131|Chemotherapy
640610|NCT00144092|autologous and allogeneic stem cell transplantation
640611|NCT00144092|low grade lymphoma
640612|NCT00144092|mantle cell
640613|NCT00144079|Differentiated thyroid carcinoma
640614|NCT00144079|radiotherapy
640615|NCT00144079|radioiodine therapy
640616|NCT00144079|thyroidectomy
640617|NCT00144040|Antibiotics
640618|NCT00144040|Respiratory Infections
640619|NCT00144040|Quality Assurance, Healthcare
640620|NCT00144040|Professional Education
640621|NCT00144040|Emergency Services, Medical
640622|NCT00144040|Education, Patient
640623|NCT00144027|patient non-adherence
640624|NCT00144027|intervention studies
640625|NCT00144014|Acute
640626|NCT00144014|Ischaemic
640627|NCT00144014|Stroke
640628|NCT00144001|Epilepsy
640629|NCT00144001|Pharmacoepidemiology
640630|NCT00144001|Quality of Care
640631|NCT00144001|Outcomes
640632|NCT00143988|Blood Pressure
640633|NCT00143988|Heart Rate
640634|NCT00143988|Sexual Activity
640635|NCT00143975|Acute myeloid leukemia
640636|NCT00143975|gemtuzumab ozogamicin
640637|NCT00143975|refractory disease
640638|NCT00143962|Weight Loss
640639|NCT00143949|diabetes
640640|NCT00143949|nephropathy
640641|NCT00143949|kidney
640642|NCT00143949|retinopathy
640643|NCT00143936|Weight Loss
640644|NCT00143923|Cardiovascular Diseases
640645|NCT00143923|Ethnic Groups
640646|NCT00143923|Risk Factors
640647|NCT00143910|Medication adherence
640648|NCT00143910|Patient compliance
640649|NCT00143910|Kidney transplant
640650|NCT00143910|Organ rejection
640651|NCT00143910|Allograft loss
640652|NCT00143910|Drug monitoring
640653|NCT00143858|Peripheral Pulse Volume
640654|NCT00143832|fMRI
640655|NCT00143819|psoriasis
640656|NCT00143819|dry skin
640657|NCT00143819|eczema
640658|NCT00143819|atopic dermatitis
640659|NCT00143806|psoriasis
640660|NCT00143806|cyclosporine
640661|NCT00143806|transition
640662|NCT00143806|alefacept
640663|NCT00143793|natruretic peptides
640664|NCT00143793|NT-proBNP
640665|NCT00143793|new biomarkers
640666|NCT00143793|congestive heart failure
640667|NCT00143793|atrial fibrillation
640668|NCT00143793|acute myocardial infarction
640669|NCT00143793|lung embolism
640670|NCT00143780|Bone Marrow Transplant
640671|NCT00143780|Pneumonia
640672|NCT00143780|Vaccine
640673|NCT00143780|Conjugate Vaccine
640674|NCT00143780|Polysaccharide Vaccine
640675|NCT00143767|Magnetic Resonance Imaging
640676|NCT00143078|Obesity
640677|NCT00143078|Reproduction
640678|NCT00143078|Weight Loss
640679|NCT00143078|Reproductive System
640680|NCT00143065|Antigens, CD5
640681|NCT00143065|Antigens, CD19
640682|NCT00143065|Antigens, CD20
640683|NCT00143052|Hirsutism
640684|NCT00143052|Bone status
640685|NCT00143052|Androgens
640686|NCT00143052|insulin
640687|NCT00143039|NIH
640688|NCT00143039|Severe Symmetrical IUGR
640689|NCT00143039|Tandem Mass Spectrometry
640690|NCT00143039|Nonimmune Hydrops
640691|NCT00143039|Severe Symmetrical Intrauterine Growth Restriction
640692|NCT00143026|Parkinson's disease, levodopa, motor fluctuations
640693|NCT00143013|type 2 diabetes
640694|NCT00143013|microarray
640695|NCT00143013|skeletal muscle
640696|NCT00143013|bioinformatics
640697|NCT00143000|Hepatitis C Virus
640698|NCT00143000|Genotype 2
640699|NCT00143000|Genotype 3
640700|NCT00142987|Tegaserod, IBS-C, women, mixed bowel habit
640701|NCT00142974|Diabetes, tegaserod, gastropathy
640702|NCT00142961|cannabis abuse
640703|NCT00142961|atomoxetine
640704|NCT00142961|ADHD
640705|NCT00142948|Heroin Abuse
640706|NCT00142948|Heroin Addiction
640707|NCT00142935|HIV Prevention
640708|NCT00142935|Opioid-Related Disorders
640709|NCT00142935|Medication Assisted Treatment
640710|NCT00142935|Methadone
640711|NCT00142922|Adherence
640712|NCT00142922|self-care
640713|NCT00142922|Behavioral intervention
640714|NCT00142922|Diabetes
640715|NCT00142909|Opioid dependence
640716|NCT00142896|Opiate Addiction
640717|NCT00142896|Opiate Dependence
640718|NCT00143741|Kidney Disease, Lipitor, Atorvastatin, Allosensitization
640719|NCT00143728|HIV
640720|NCT00143728|Treatment Experienced
640721|NCT00143715|Vitamin K1 (phytonadione)
640722|NCT00143715|Randomized controlled trial
640723|NCT00143715|Warfarin
640724|NCT00143715|Coagulopathy
640725|NCT00143715|Bleeding
640726|NCT00143715|Thrombosis
640727|NCT00143715|Warfarin associated coagulopathy defined as an INR of 4.5 and 10.0 (for entry into randomized tria) or greater than 10.0 (for entry into parallel cohort study
640728|NCT00143715|Warfarin associated coagulopathy
640729|NCT00143702|Elevated Lactic Acid
640730|NCT00143676|Hyperlipidemia
640731|NCT00143676|Dyslipidemia
640732|NCT00143676|Drug Therapy
640733|NCT00143663|Hypercholesterolemia
640734|NCT00143663|Hyperlipidemia
640735|NCT00143663|Drug Therapy
640736|NCT00143650|Upper airway, irritation inflammation, discomfort, house dust, damp buildings, climate chamber, humans
640737|NCT00143637|Office dust
640738|NCT00143637|Glucan
640739|NCT00143637|dose-response
640740|NCT00143637|lung function
640741|NCT00143637|peak expiratory flow
640742|NCT00143637|inflammation
640743|NCT00143637|perception
640744|NCT00143624|Treatment Experienced
640745|NCT00143624|HIV Metabolic Syndrome
640746|NCT00143624|Atherosclerosis in HIV
640747|NCT00143611|Shock, Septic
640748|NCT00143611|Sepsis Syndrome
640749|NCT00143611|Respiratory Insufficiency
640750|NCT00143611|SIRS (Systemic Inflammatory Response Syndrome)
640751|NCT00143611|Respiratory Failure
640752|NCT00143611|Drug Therapy
640753|NCT00143598|Postphlebitic Syndrome
640754|NCT00143598|Post-Thrombotic Syndrome
640755|NCT00143598|Elastic Stockings
640756|NCT00143598|Stockings, Compression
640757|NCT00143598|Randomized Controlled Trials
640758|NCT00143598|Quality of Life
640759|NCT00143585|angiogenesis
640760|NCT00143585|VEGF
640761|NCT00143572|Hematologic Diseases
640762|NCT00143572|Anemia, Sickle Cell
640763|NCT00143559|Allogeneic stem cell transplantation
640764|NCT00143559|Haploidentical stem cell transplant
640765|NCT00143559|Mismatched family member stem cell donor transplant
640766|NCT00143559|Bone marrow transplant
640767|NCT00143559|High risk hematological malignancies
640768|NCT00143559|T-cell depletion methodology
640769|NCT00143559|Miltenyi Biotec CliniMACS stem cell selection device
640770|NCT00143546|Hepatic Veno-occlusive Disease
640771|NCT00143533|Solid Tumors
640772|NCT00143520|Placebo and active control dose response study of rivoglitazone in type 2 diabetics
640773|NCT00143468|gas exchange
640774|NCT00143468|respiratory mechanics
640775|NCT00143429|Primary Open Angle Glaucoma
640776|NCT00143312|Invasive Fungal Infection, Allogenic Stem Cell Transplant, prophylaxis, leukemia, voriconazole
640777|NCT00143130|phase 4, open label, seizures, epilepsy, add-on therapy, pregabalin, lyrica
640778|NCT00143091|Major Depressive Disorder, Recurrent
640779|NCT00142883|addiction, crack, cocaine
640780|NCT00142870|marijuana
640781|NCT00142870|treatment
640782|NCT00142844|cocaine
640783|NCT00142831|nicotine dependence
640784|NCT00142818|Alcohol Abuse
640785|NCT00142818|Cocaine Abuse
640786|NCT00142805|ketones
640787|NCT00142805|Apolipoprotein E
640788|NCT00142805|ApoE genotype
640789|NCT00142805|cognitive function
640790|NCT00142805|glucose metabolism
640791|NCT00142792|stroke
640792|NCT00142792|recovery of function
640793|NCT00142792|functional electrical stimulation (FES)
640794|NCT00142779|Cocaine Addiction
640795|NCT00142779|Cocaine Dependence
640796|NCT00142779|Opiate Addiction
640797|NCT00142779|Opiate Dependence
640798|NCT00142766|Sedation
640799|NCT00142766|Mechanical ventilation
640800|NCT00142766|Critical illness
640801|NCT00142766|Analgesic
640802|NCT00142766|Opioid Withdrawal
640803|NCT00142766|Benzodiazepine Withdrawal
640804|NCT00142766|Nurse
640805|NCT00142753|Hepatitis B vaccines
640806|NCT00142753|HIV-infected adolescents
640807|NCT00142753|Hepatitis B infection
640808|NCT00142740|Hepatitis B vaccines
640809|NCT00142740|HIV-infected adolescents
640810|NCT00142740|Hepatitis B infection (negative)
640811|NCT00142740|HIV vaccine trial
640812|NCT00142714|sexual response
640813|NCT00142714|sexual dysfunction in females
640814|NCT00142714|spinal cord injury
640815|NCT00142636|Chronic Kideny Disease
640816|NCT00142636|Hypertension
640817|NCT00142610|alpha tocopherol
640818|NCT00142610|vitamin E
640819|NCT00142610|ascorbate
640820|NCT00142610|vitamin C
640821|NCT00142610|antioxidant
640822|NCT00142610|allergic
640823|NCT00142610|asthma
640824|NCT00142597|acupuncture
640825|NCT00142597|analgesia
640826|NCT00142597|pain
640827|NCT00142597|fibromyalgia
640828|NCT00142597|fMRI
640829|NCT00142597|PET
640830|NCT00142584|safety and tolerability study
640831|NCT00142584|hypertension
640832|NCT00142584|beta-blockers
640833|NCT00142571|Sarcoma, Soft Tissue
640834|NCT00142571|Gemcitabine
640835|NCT00142571|Docetaxel
640836|NCT00142558|Arcoxia
640837|NCT00142532|Acupuncture
640838|NCT00142532|Pain
640839|NCT00142532|Lung Cancer
640840|NCT00142532|Thoracotomy
640841|NCT00142532|Surgery
640842|NCT00142519|Pain
640843|NCT00142519|Analgesics
640844|NCT00142519|Retroperitoneal lymph node dissection
640845|NCT00142506|Prostate Cancer
640846|NCT00142506|Cancer of the Prostate
640847|NCT00142506|Prostate Neoplasms
640848|NCT00142506|Prostatic Cancer
640849|NCT00142506|Viagra
640850|NCT00142506|05-007
640851|NCT00142493|Episodic Memory
640852|NCT00142493|Amnesia
640853|NCT00142493|Amnesia, Temporary
640854|NCT00142480|locally advanced biliary adenocarcinoma
640855|NCT00142480|unresectable biliary adenocarcinoma
640856|NCT00142480|gallbladder adenocarcinoma
640857|NCT00142480|capecitabine
640858|NCT00142480|oxaliplatin
640859|NCT00142480|bevacizumab
640860|NCT00142480|Biliary tract adenocarcinoma
640861|NCT00142467|Unresectable hepatocellular carcinoma
640862|NCT00142467|Metastatic hepatocellular carcinoma
640863|NCT00142467|gemcitabine
640864|NCT00142467|oxaliplatin
640865|NCT00142467|bevacizumab
640866|NCT00142467|Avastin
640867|NCT00142454|Malignant melanoma
640868|NCT00142454|Stages IIB-III
640869|NCT00142441|Pulsed dye laser
640870|NCT00142441|Keloids
640871|NCT00142441|Hypertrophic scars
640872|NCT00142441|Pulse width
640873|NCT00142441|Pulse duration
640874|NCT00142428|Hepatocellular carcinoma
640875|NCT00142428|cetuximab
640876|NCT00142428|Unresectable hepatocellular carcinoma
640877|NCT00142428|Metastatic hepatocellular carcinoma
640878|NCT00142415|Advanced Renal Cell Carcinoma
640879|NCT00142415|Clear Cell Renal Cell Carcinoma (CCRCC)
640880|NCT00142415|Lutetium-177
640881|NCT00142415|177-Lu
640882|NCT00142415|cG250
640883|NCT00142415|DOTA-cG250
640884|NCT00142415|Monoclonal Antibody
640885|NCT00142402|Multiple Sclerosis
640886|NCT00142402|Memory
640887|NCT00142402|New Learning
640888|NCT00142402|Fatigue
640889|NCT00142389|gestational immunization,
640890|NCT00142389|infant antibody,
640891|NCT00142389|cord antibody
640892|NCT00142363|Parkinson's disease
640893|NCT00142363|Parkin
640894|NCT00142363|Epilepsy
640895|NCT00142363|Phenotype-genotype correlations
640896|NCT00142363|Ionic channels
640897|NCT00142350|gastric cancer
640898|NCT00142350|5-fluorouracil
640899|NCT00142350|irinotecan
640900|NCT00142350|cisplatin
640901|NCT00142350|S-1
640902|NCT00142350|advanced or recurrent gastric cancer
640903|NCT00142337|zidovudine
640904|NCT00142337|didanosine
640905|NCT00142337|Prevention of mother to child transmission of HIV
640906|NCT00142337|nevirapine
640907|NCT00142337|Thailand
640908|NCT00142337|Resistance
640909|NCT00142337|HIV
640910|NCT00142337|Postpartum period
640911|NCT00142324|Dementia
640912|NCT00142311|Parkinson's disease
640913|NCT00142311|Parkin mutations
640914|NCT00142311|Metabolic explorations
640915|NCT00142311|Clinics
640916|NCT00142311|Genetics
640917|NCT00142285|pneumonia
640918|NCT00142285|zinc
640919|NCT00142285|treatment
640920|NCT00142285|efficacy
640921|NCT00142285|children
640922|NCT00142272|Ciprofloxacin
640923|NCT00142272|children
640924|NCT00142272|V.cholerae O1 and O139
640925|NCT00142272|drug resistance
640926|NCT00142272|Bangladesh
640927|NCT00142259|deep brain stimulation
640928|NCT00142259|internal globus pallidus
640929|NCT00142259|dystonia
640930|NCT00142246|malaria
640931|NCT00142246|anaemia
640932|NCT00142246|school performance
640933|NCT00142246|education
640934|NCT00142246|intermittent preventive treatment
640935|NCT00142246|schools
640936|NCT00142233|EUROPAC 2, ANTOX (vers)1.2, MGCT (Magnesiocard) Hereditary Pancreatitis, Idiopathic chronic pancreatitis.
640937|NCT00142233|Hereditary Pancreatitis
640938|NCT00142233|idiopathic chronic pancreatitis
640939|NCT00142207|malaria
640940|NCT00142207|pregnancy
640941|NCT00142207|intermittent preventive treatment
640942|NCT00142207|insecticide-treated nets
640943|NCT00142194|Atrial Fibrillation
640944|NCT00142194|Oxidative stress
640945|NCT00142194|Cardiology
640946|NCT00142181|Lymphoplasmacytic lymphoma
640947|NCT00142181|Waldenstrom's Macroglobulinemia
640948|NCT00142181|Antibody
640949|NCT00142181|Campath-1H
640950|NCT00142168|CC-5103 (lenalidomide)
640951|NCT00142168|rituximab
640952|NCT00142168|Waldenstrom's macroglobulinemia
640953|NCT00142155|monoclonal antibody
640954|NCT00142155|Fc gamma RIII receptor expression
640955|NCT00142155|rituximab
640956|NCT00142129|bortezomib
640957|NCT00142129|Velcade
640958|NCT00142129|Waldenstrom's macroglobulinemia
640959|NCT00142116|thalidomide
640960|NCT00142116|rituximab
640961|NCT00142116|Waldenstrom's
640962|NCT00142103|Hepatitis c virus
640963|NCT00142103|HCV
640964|NCT00142103|Liver
640965|NCT00142090|Brain Concussion
640966|NCT00142090|Post-Concussion Syndrome
640967|NCT00142090|Closed Head Injury
640968|NCT00142090|Traumatic Brain Injury
640969|NCT00142090|Hypertonic Saline Solution
640970|NCT00142077|Influenza
640971|NCT00142077|Electronic health record
640972|NCT00142077|Behavior modification
640973|NCT00142064|Topical analgesia
640974|NCT00142064|Urinary catheterization
640975|NCT00142064|FlACC Pain Scale
640976|NCT00142064|Lidocaine jelly
640977|NCT00142051|sickle cell disease
640978|NCT00142051|pain crisis
640979|NCT00142051|vaso-occlusive crisis
640980|NCT00142051|nitric oxide
640981|NCT00142038|gastric cancer
640982|NCT00142038|metastatic
640983|NCT00142038|locally advanced
640984|NCT00142038|docetaxel
640985|NCT00142038|capecitabine
640986|NCT00142025|Bronchial asthma
640987|NCT00142025|Oxcarbazepine
640988|NCT00142025|Antiepileptic drug
640989|NCT00142025|Efficacy
640990|NCT00142012|School-based
640991|NCT00142012|Obesity
640992|NCT00142012|Prevention
640993|NCT00141999|vaccine
640994|NCT00141999|hepatitis
640995|NCT00141986|vitamin D
640996|NCT00141986|type 1 diabetes
640997|NCT00141986|prevention trial
640998|NCT00141973|Procalcitonin
640999|NCT00141973|Sepsis
641000|NCT00141973|Corticosteroids
641001|NCT00141960|Treatment efficacy
641002|NCT00141960|Treatment effectiveness
641003|NCT00141960|Gastrointestinal Diseases
641004|NCT00141960|Reflux, Gastroesophageal
641005|NCT00141960|GERD
641006|NCT00141947|bexarotene
641007|NCT00141947|schizophrenia
641008|NCT00141947|psychopathology
641009|NCT00141947|cognitive impairment
641010|NCT00141947|quality of life
641011|NCT00141947|open lable trial
641012|NCT00141934|Rheumatoid Arthritis
641013|NCT00141934|RA
641014|NCT00141934|ACR20 endpoint
641015|NCT00141934|Tender/swollen joints
641016|NCT00141934|Improvement in pain
641017|NCT00141934|Health assessment questionnaire
641018|NCT00141934|Profile of mood states
641019|NCT00141921|Immunex
641020|NCT00141921|Amgen
641021|NCT00141921|Pediatric,
641022|NCT00141921|plaque psoriasis
641023|NCT00141921|clinical trial
641024|NCT00141908|Hydroxyprogesterone Caproate, twins, preterm delivery
641025|NCT00141895|Intrauterine fetal death, 2nd trimester, induction
641026|NCT00141869|Sensory Processing
641027|NCT00141869|Magnetoencephalogram
641028|NCT00141869|Tourete Syndrome
641029|NCT00141869|Trigeminal Nerve
641030|NCT00141869|Tics
641031|NCT00141869|TS
641032|NCT00141869|Healthy Volunteer
641033|NCT00141869|HV
641034|NCT00141856|Dis Management
641035|NCT00141856|Heart Decompensation
641036|NCT00141856|Hearts
641037|NCT00141856|Veteran (M01.930)
641038|NCT00141843|Hemophilia A
641039|NCT00141830|Rheumatoid Arthritis
641040|NCT00141817|Gastrointestinal Reflux Disease
641041|NCT00141804|renal transplantation
641042|NCT00141804|immunosuppression
641043|NCT00141804|prevention of acute rejection
641044|NCT00141791|Asthma
641045|NCT00141791|Anti-Asthmatic Agents
641046|NCT00141791|Receptors
641047|NCT00141791|Tumor Necrosis Factor
641048|NCT00141778|atrial fibrillation
641049|NCT00141778|cardiac surgery
641050|NCT00141752|Cerebrovascular Accident
641051|NCT00141752|Deglutition Disorders
641052|NCT00141752|stroke
641053|NCT00141752|dysphagia
641054|NCT00141752|screening
641055|NCT00141739|Stem Cell Transplantation
641056|NCT00141739|Graft-Versus-Host Disease
641057|NCT00141739|prophylaxis
641058|NCT00141726|Enbrel
641059|NCT00141726|Stem Cell Transplantation
641060|NCT00141726|Lung Injury
641061|NCT00141687|External cephalic version
641062|NCT00141687|Cesarean section
641063|NCT00141687|pregnancy
641064|NCT00141687|labour
641065|NCT00141687|Breech pregnancy
641066|NCT00141674|Blood transfusion
641067|NCT00141674|Age of blood
641068|NCT00141674|Traumatic Brain Injury
641069|NCT00141674|Cerebral Oxygen Extraction Ratio
641070|NCT00141674|Age of transfused blood in traumatic brain injury
641071|NCT00141661|Interventional, Alzheimer, Safety and Tolerability
641072|NCT00141648|Osteolymphoma
641073|NCT00141648|Chemotherapy
641074|NCT00141648|Radiotherapy
641075|NCT00141648|Lymphoma
641076|NCT00141635|Quality of Life
641077|NCT00141635|Breast Cancer
641078|NCT00141635|Referee's Report
641079|NCT00141635|Diagnostics
641080|NCT00141635|Therapy
641081|NCT00141622|Endothelial dysfunction
641082|NCT00141622|ADMA
641083|NCT00141622|DDAH
641084|NCT00141622|Sodium
641085|NCT00141609|End-stage renal failure
641086|NCT00141609|Haemodialysis
641087|NCT00141609|Sodium
641088|NCT00141609|Blood Pressure
641089|NCT00141596|Resistant Hypertension
641090|NCT00141596|Extracellular Fluid Volume
641091|NCT00141583|Renin-angiotensin system
641092|NCT00141583|ACE Inhibitor
641093|NCT00141583|Angiotensin Receptor Blocker
641094|NCT00141570|Menopause; Postmenopause; Estrogen; Hormone Therapy
641095|NCT00141557|Menopause; Postmenopause; Estrogen; Hormone Therapy
641096|NCT00141544|Menopause; Postmenopause; Estrogen; Hormone Therapy
641097|NCT00141531|Bladder cancer
641098|NCT00141531|Superficial
641099|NCT00141531|Carcinoma in situ
641100|NCT00141531|Intravesical instillation
641101|NCT00141531|Chemotherapy
641102|NCT00141531|Adjuvant
641103|NCT00141518|Health economics,Quality of life
641104|NCT00141505|drug interaction
641105|NCT00141505|pharmacokinetics
641106|NCT00141505|valproate
641107|NCT00141505|bipolar
641108|NCT00141492|Type 2 diabetes
641109|NCT00141492|hypogonadism
641110|NCT00141492|testosterone
641111|NCT00141492|glycosylated hemoglobin A1C
641112|NCT00141479|Treatment interruption on reinitiation
641113|NCT00141479|Schizophrenia
641114|NCT00141479|Schizoaffective disorder
641115|NCT00141466|Hereditary colorectal cancer
641116|NCT00141466|Microsatellite instability
641117|NCT00141466|Physician roles
641118|NCT00141466|Health care implementation
641119|NCT00141466|Intervention
641120|NCT00141453|angiotensin II type I receptor blockers
641121|NCT00141453|diabetic nephropathy
641122|NCT00141453|end-stage renal disease
641123|NCT00141453|renal failure
641124|NCT00141453|type 2 diabetes
641125|NCT00141453|olmesartan medoxomil
641126|NCT00141440|gas exchange
641127|NCT00141440|pressure support ventilation
641128|NCT00141440|respiratory mechanics
641129|NCT00141440|COPD patients
641130|NCT00141297|Advanced cancer
641131|NCT00141271|Bipolar I Disorder
641132|NCT00141115|Substance-induced anxiety disorder
641133|NCT00141102|GI events in high risk GI arthritis patients
641134|NCT00141089|Male patients, chronic constipation, tegaserod
641135|NCT00141076|obesity
641136|NCT00141076|glycemic index
641137|NCT00141076|insulin resistance
641138|NCT00141076|cardiovascular disease
641139|NCT00141076|diabetes
641140|NCT00141063|ADHD, children
641141|NCT00141050|ADHD, children
641142|NCT00141037|Organ Rejection
641143|NCT00141037|Corticosteroids
641144|NCT00141037|Child
641145|NCT00141037|Adolescent
641146|NCT00141037|Immunosuppression
641147|NCT00141037|Steroids
641148|NCT00141024|HIV Seronegativity
641149|NCT00141024|HIV Preventive Vaccine
641150|NCT00141011|Stroke
641151|NCT00141011|Fibrinogen
641152|NCT00141011|Reperfusion
641153|NCT00141011|Thrombolysis
641154|NCT00140998|Turner syndrome
641155|NCT00140998|Hypogonadism
641156|NCT00140998|GH
641157|NCT00140998|Estrogen
641158|NCT00140998|Estrogen Patches
641159|NCT00140998|IGF-I
641160|NCT00140998|Body Composition
641161|NCT00140998|Protein Metabolism
641162|NCT00140998|Lipolysis
641163|NCT00140972|Arcoxia
641164|NCT00140894|Osteoarthritis
641165|NCT00140894|Cancer Pain
641166|NCT00140868|Colonic Pseudo-Obstruction
641167|NCT00140868|Large bowel obstruction
641168|NCT00140868|Stents
641169|NCT00140868|Laparotomy
641170|NCT00140868|Palliative Surgery
641171|NCT00140868|Surgery, Palliative
641172|NCT00140868|Palliative Therapy
641173|NCT00140855|synovial sarcoma
641174|NCT00140855|immunotherapy
641175|NCT00140855|cancer-testis antigen
641176|NCT00140855|cancer-germ cell antigen
641177|NCT00140855|soft tissue sarcoma
641178|NCT00140855|SYT-SSX chromosomal translocation
641179|NCT00140842|Obesity, adolescent, ghrelin, growth hormone, cortisol
641180|NCT00140829|Cerebellar ataxias
641181|NCT00140829|Spastic paraplegias
641182|NCT00140829|Mutations spectrum
641183|NCT00140829|Linkage studies
641184|NCT00140829|Genetic counselling
641185|NCT00140790|Cardiorenal syndrome
641186|NCT00140790|Renal dysfunction
641187|NCT00140790|Cardiovascular events
641188|NCT00140790|Valsartan
641189|NCT00140764|Genitourinary symptoms
641190|NCT00140751|HIV-1
641191|NCT00140751|Treatment simplification
641192|NCT00140751|Lopinavir/ritonavir
641193|NCT00140751|Treatment Experienced
641194|NCT00140751|HIV Seropositivity
641195|NCT00140725|HBeAg-positive
641196|NCT00140725|chronic
641197|NCT00140725|Hepatitis B
641198|NCT00140725|lamivudine
641199|NCT00140725|seroconversion
641200|NCT00140725|Chronic Hepatitis B
641201|NCT00140712|Adolescent
641202|NCT00140712|RLS
641203|NCT00140712|Periodic Limb Movements of Sleep
641204|NCT00140712|PLMS
641205|NCT00140712|Ropinirole
641206|NCT00140699|Children, Hearing loss, Balance control, Sensory inputs
641207|NCT00140660|lymphoma, diffuse large B-cell
641208|NCT00140660|rituximab
641209|NCT00140660|chemotherapy
641210|NCT00140647|atherosclerosis
641211|NCT00140647|carotid artery
641212|NCT00140647|ramipril
641213|NCT00140647|rosiglitazone
641214|NCT00140647|impaired glucose tolerance
641215|NCT00140647|impaired fasting glucose
641216|NCT00140647|diabetes prevention
641217|NCT00140621|cardiac fabry disease
641218|NCT00140608|sinus
641219|NCT00140595|Lymphoma, diffuse large B-cell
641220|NCT00140595|rituximab
641221|NCT00140595|chemotherapy
641222|NCT00140582|lymphoma
641223|NCT00140582|follicular
641224|NCT00140582|maintenance
641225|NCT00140569|follicular lymphoma
641226|NCT00140569|CHVP + interferon
641227|NCT00140569|fludarabine
641228|NCT00140569|autotransplant
641229|NCT00140556|head and neck cancer
641230|NCT00140556|targeted therapy
641231|NCT00140556|bevacizumab
641232|NCT00140556|erlotinib
641233|NCT00140556|Tarceva
641234|NCT00140556|radiotherapy
641235|NCT00140556|concurrent chemotherapy
641236|NCT00140556|pharynx cancer
641237|NCT00140556|tonsil cancer
641238|NCT00140556|hyperfractionation
641239|NCT00140556|angiogenesis
641240|NCT00140556|epidermal growth factor
641241|NCT00140556|vascular endothelial growth factor
641242|NCT00140556|magnetic resonance spectroscopy
641243|NCT00140556|cancer of the head and neck
641244|NCT00140556|upper aerodigestive tract neoplasms
641245|NCT00140556|pharynx neoplasms
641246|NCT00140543|simultaneous pancreas/kidney transplantation
641247|NCT00140543|Immunosuppression
641248|NCT00140517|Plasmodium falciparum
641249|NCT00140517|malaria
641250|NCT00140517|pregnancy
641251|NCT00140517|resistance
641252|NCT00140504|Adverse drug event
641253|NCT00140504|Patient safety
641254|NCT00140504|Internet portal
641255|NCT00140504|PatientSite
641256|NCT00140504|Preventive health
641257|NCT00140504|Primary care
641258|NCT00140491|Non-Arteritic Anterior Ischemic Optic Neuropathy
641259|NCT00140491|Visual Field Defect
641260|NCT00140491|Neuroplasticity
641261|NCT00140491|Rehabilitation
641262|NCT00140478|Androgen Independent Prostate Cancer
641263|NCT00140478|Prostate Cancer
641264|NCT00140478|Mifepristone
641265|NCT00140478|RU-486
641266|NCT00140452|ALS
641267|NCT00140439|asthma
641268|NCT00140439|emergency department
641269|NCT00140439|compliance
641270|NCT00140439|randomized clinical trial
641271|NCT00140426|Anorexia Nervosa
641272|NCT00140426|Risperidone
641273|NCT00140426|Atypical Neuroleptics
641274|NCT00140426|Dopamine
641275|NCT00140426|Leptin
641276|NCT00140426|Body Image
641277|NCT00140426|Adolescents
641278|NCT00140413|Optic Nerve Hypoplasia
641279|NCT00140400|Prostate
641280|NCT00140400|Cancer
641281|NCT00140400|Advanced prostate cancer
641282|NCT00140400|Metastatic
641283|NCT00140400|Hormone-refractory
641284|NCT00140400|GVAX
641285|NCT00140400|Vaccine
641286|NCT00140400|Allogeneic cells
641287|NCT00140387|Prostate
641288|NCT00140387|Cancer
641289|NCT00140387|GVAX
641290|NCT00140387|Metastatic
641291|NCT00140387|Vaccine
641292|NCT00140387|Allogeneic cells
641293|NCT00140374|Prostate
641294|NCT00140374|Cancer
641295|NCT00140374|Vaccine
641296|NCT00140374|GVAX
641297|NCT00140374|Allogeneic cells
641298|NCT00140361|malaria
641299|NCT00140361|sulfadoxine-pyrimethamine
641300|NCT00140361|sulfadoxine-pyrimethamine plus artsunate
641301|NCT00140361|lumefantrine plus artemether
641302|NCT00140361|combination therapy
641303|NCT00140348|Prostate
641304|NCT00140348|Cancer
641305|NCT00140348|Advanced Prostate Cancer
641306|NCT00140348|Metastatic
641307|NCT00140348|Hormone-refractory
641308|NCT00140348|GVAX
641309|NCT00140348|Vaccine
641310|NCT00140348|Allogeneic cells
641311|NCT00140335|handwashing
641312|NCT00140335|communicable diseases
641313|NCT00140335|health education
641314|NCT00140322|falls
641315|NCT00140322|injury
641316|NCT00140322|elderly
641317|NCT00140309|TB
641318|NCT00140309|Pulmonary Tuberculosis
641319|NCT00140309|Tuberculosis
641320|NCT00140309|Pulmonary TB
641321|NCT00140283|Effectiveness
641322|NCT00140283|Educational intervention
641323|NCT00140283|Primary health care
641324|NCT00140257|Myocardial Infarction
641325|NCT00140244|leptin
641326|NCT00140244|lipodystrophy
641327|NCT00140244|insulin resistance
641328|NCT00140244|hyperlipidemia
641329|NCT00140244|metabolic syndrome
641330|NCT00140231|leptin
641331|NCT00140231|fasting
641332|NCT00140231|reproductive
641333|NCT00140231|neuroendocrine
641334|NCT00140231|immune function
641335|NCT00140231|energy deficiency associated with short-term fasting
641336|NCT00140218|amyotrophic lateral sclerosis
641337|NCT00140218|pramipexole
641338|NCT00140218|oxidative stress
641339|NCT00140218|neuroprotection
641340|NCT00140205|leptin
641341|NCT00140205|fasting
641342|NCT00140205|pharmacokinetics
641343|NCT00140192|creatine metabolism
641344|NCT00140192|schizophrenia
641345|NCT00140192|energy metabolism
641346|NCT00140179|valnoctamide
641347|NCT00140179|teratogenicity
641348|NCT00140179|double-blind
641349|NCT00140179|mania
641350|NCT00140166|schizophrenia
641351|NCT00140166|niacinamide
641352|NCT00140153|androgel
641353|NCT00140153|female sexuale dysfunction
641354|NCT00140153|controlled double-blind
641355|NCT00140153|testosterone
641356|NCT00140140|Breast cancer
641357|NCT00140114|Vaginal, sublingual, misoprostol, cervical ripening
641358|NCT00140101|drug eluting stents
641359|NCT00140101|stents
641360|NCT00140101|angioplasty
641361|NCT00140101|coronary artery disease
641362|NCT00140101|total coronary occlusion
641363|NCT00140101|coronary artery restenosis
641364|NCT00140101|stent thrombosis
641365|NCT00140101|vascular disease
641366|NCT00140101|myocardial ischemia
641367|NCT00140101|coronary artery stenosis
641368|NCT00140088|Needlestick pain
641369|NCT00140088|Venipuncture pain
641370|NCT00140010|aneurysm
641371|NCT00140010|autoregulation
641372|NCT00140010|erythropoietion
641373|NCT00140010|stroke
641374|NCT00140010|subarachnoid hemorrhage
641375|NCT00140010|vasospasm
641376|NCT00139997|Major Depression
641377|NCT00139997|Seasonal Affective Disorder (SAD)
641378|NCT00139984|Hypertension
641379|NCT00139984|Ambulatory blood pressure monitoring
641380|NCT00139984|Blood pressure
641381|NCT00139984|Risk assessment
641382|NCT00139958|Acute coronary syndrome
641383|NCT00139958|HIV infection
641384|NCT00139958|Prognosis
641385|NCT00139958|Coronary heart disease
641386|NCT00139958|Revascularization
641387|NCT00139919|Decreasing Titration Study
641388|NCT00139919|Schizophrenia
641389|NCT00139919|Bipolar
641390|NCT00139919|Pharmacokinetic
641391|NCT00139906|Titration Study
641392|NCT00139906|Schizophrenia
641393|NCT00139906|BID dosing
641394|NCT00139906|Pharmacokinetic
641395|NCT00139841|Lymphoma, Non-Hodgkin
641396|NCT00139841|Rituximab Refractory
641397|NCT00139841|Rituximab Failure
641398|NCT00139841|Indolent Non-Hodgkins Lymphoma
641399|NCT00139828|haemophilia B
641400|NCT00139828|factor IX
641401|NCT00139828|Product Surveillance, Postmarketing
641402|NCT00139828|plasma products
641403|NCT00139815|unstable angina
641404|NCT00139815|acute coronary syndrome
641405|NCT00139815|fondaparinux sodium
641406|NCT00139815|non ST segment elevation myocardial infarction
641407|NCT00139815|myocardial infarction
641408|NCT00139776|Chronic treatment osteoarthritis, Celecoxib, Continuous Use, Intermittent Use
641409|NCT00139737|Open-label extension Ziprasidone study in Schizophrenia
641410|NCT00139633|esophageal cancer, chemotherapy, radiation
641411|NCT00139620|advanced cancer, solid tumor
641412|NCT00139594|Bipolar disorder, manic episode/treatment/licarbazepine
641413|NCT00139581|Atopic dermatitis, children, infants, pimecrolimus, bid, od
641414|NCT00139568|Chronic constipation
641415|NCT00139568|5-HT,5-HT4,
641416|NCT00139568|functional GI
641417|NCT00139568|China
641418|NCT00139568|tegaserod
641419|NCT00139555|Hypertension
641420|NCT00139555|Left ventricular hypertrophy
641421|NCT00139542|human
641422|NCT00139542|ventricular fibrillation
641423|NCT00139542|out-of-hospital
641424|NCT00139542|cardiac arrest
641425|NCT00139542|automated external defibrillators (AED)
641426|NCT00139542|defibrillators
641427|NCT00139542|electrick countershock
641428|NCT00139542|cardiopulmonary resuscitation
641429|NCT00139490|Blood Pressure, High
641430|NCT00139451|GH
641431|NCT00139451|Delayed Growth
641432|NCT00139451|Energy Expenditure
641433|NCT00139451|Puberty
641434|NCT00139451|Nutrition
641435|NCT00139451|Short Stature
641436|NCT00139399|Coronary artery bypass
641437|NCT00139399|Coronary arteries
641438|NCT00139399|Atherosclerosis
641439|NCT00139399|Angiography
641440|NCT00139399|Blood flow
641441|NCT00139386|Drug-eluting stent
641442|NCT00139386|Candesartan
641443|NCT00139386|Randomized control study
641444|NCT00139386|Coronary Angioplasty
641445|NCT00139373|Progressive supranuclear palsy
641446|NCT00139373|Frontal lobe
641447|NCT00139373|Oculomotor testing
641448|NCT00139373|Neuropsychological scores
641449|NCT00139373|Motor disability (UPDRS)
641450|NCT00139373|Distractibility
641451|NCT00139321|Gait disorders
641452|NCT00139321|Postural instability
641453|NCT00139321|parkinsonian syndrome
641454|NCT00139321|Gait initiation
641455|NCT00139321|Parkinson's disease
641456|NCT00139321|Adults
641457|NCT00139308|Tourette's syndrome
641458|NCT00139308|High frequency stimulation
641459|NCT00139308|Globus pallidus
641460|NCT00139308|Thalamus
641461|NCT00139295|musculoskeletal
641462|NCT00139295|osteoarthritis of the knee
641463|NCT00139282|wet AMD
641464|NCT00139282|macular degeneration
641465|NCT00139269|Advanced Squamous Cell Carcinoma
641466|NCT00139269|Squamous cell Carcinoma of Head and Neck
641467|NCT00139269|SSCHN
641468|NCT00139269|Docetaxel
641469|NCT00139256|Glucocorticoid
641470|NCT00139256|Antepartum Betamethasone Treatment
641471|NCT00139256|Elective Cesarean Section
641472|NCT00139256|Respiratory Distress in Infants
641473|NCT00139243|squamous cell carcinoma
641474|NCT00139243|Taxotere
641475|NCT00139243|carcinoma of head/neck
641476|NCT00139243|Cisplatin
641477|NCT00139243|5-Fluorouracil
641478|NCT00139243|Leucovorin
641479|NCT00139230|Squamous Cell Carcinoma of Head and Neck
641480|NCT00139230|Compressed TPFL
641481|NCT00139230|Taxotere
641482|NCT00139230|Growth Factor Support
641483|NCT00139217|Persistent pulmonary hypertension
641484|NCT00139217|Non-invasive inhaled nitric oxide
641485|NCT00139217|iNO
641486|NCT00139204|Prostate cancer
641487|NCT00139204|Hormone-refractory prostate cancer
641488|NCT00139204|PET scan
641489|NCT00139204|C11-methionine
641490|NCT00139204|positron emission tomography
641491|NCT00139191|Prostate Cancer
641492|NCT00139191|positron emission tomography
641493|NCT00139191|carbon 11 acetate
641494|NCT00139191|PET
641495|NCT00139191|fatty acid synthase
641496|NCT00139191|FAS
641497|NCT00139165|Collagenous colitis
641498|NCT00139165|Budesonide treatment
641499|NCT00139165|Diarrhea
641500|NCT00139152|moderate to severe allergic asthma
641501|NCT00139139|hepatitis A
641502|NCT00139139|hepatitis A vaccine
641503|NCT00139139|immune globulin
641504|NCT00139113|hepatitis A
641505|NCT00139113|hepatitis A vaccine
641506|NCT00139074|Bipolar I Disorder (DSM-IV 296.01, DSM-IV 296.4, DSM-IV 296.61)
641507|NCT00139048|informed choice
641508|NCT00139048|shared decision making
641509|NCT00139048|decision aid
641510|NCT00139048|mammography screening
641511|NCT00139048|decision support
641512|NCT00139035|glucose intolerance
641513|NCT00139035|insulin
641514|NCT00139035|microvascular function
641515|NCT00139035|genotyping
641516|NCT00139035|CYP3A5
641517|NCT00139035|pharmacokinetics
641518|NCT00139035|renal transplantation
641519|NCT00139022|sleep apnea, home monitoring, CPAP
641520|NCT00139009|intracellular concentration
641521|NCT00139009|cyclosporine A
641522|NCT00139009|renal biopsies
641523|NCT00139009|heart biopsies
641524|NCT00139009|Renal transplant recipients
641525|NCT00138996|cardiac arrest
641526|NCT00138996|resuscitation
641527|NCT00138996|quality
641528|NCT00138996|feedback
641529|NCT00138996|training
641530|NCT00138983|glucocorticoid-induced osteoporosis
641531|NCT00138983|rheumatic diseases
641532|NCT00138983|prevention
641533|NCT00138983|randomized double-blind, double placebo controlled trial
641534|NCT00138983|alendronate versus alfacalcidol
641535|NCT00138970|Cadaveric donor
641536|NCT00138970|Calcineurine free
641537|NCT00138957|Laparoscopic parastomal hernia repair
641538|NCT00138957|Intraperitoneally
641539|NCT00138957|Mesh
641540|NCT00138957|Quality of life
641541|NCT00138957|Postoperative pain
641542|NCT00138957|Recurrence
641543|NCT00138944|Essential hypertension
641544|NCT00138931|Cardiomyopathy
641545|NCT00138931|Arrhythmia
641546|NCT00138931|Muscular Dystrophy
641547|NCT00138918|Prostate Cancer
641548|NCT00138918|Clusterin
641549|NCT00138918|Neoadjuvant
641550|NCT00138918|Phase II
641551|NCT00138905|Base station, EMF, human exposure study,Well-being,cognitive
641552|NCT00138892|Quality of life
641553|NCT00138892|waiting time
641554|NCT00138892|total joint replacement
641555|NCT00138879|Citrulline
641556|NCT00138879|Parenteral Nutrition
641557|NCT00138879|functioning intestinal mass
641558|NCT00138879|small bowel permeability and absorption
641559|NCT00138879|Granulomatous Enteritis
641560|NCT00138866|Spinal cord injury
641561|NCT00138853|RSA
641562|NCT00138853|Genoarthrosis
641563|NCT00138853|Knee arthroplasty
641564|NCT00138853|Micromotion of polyethylene liner
641565|NCT00138840|Crohn's disease
641566|NCT00138840|Gastroenterology
641567|NCT00138827|Radiotherapy
641568|NCT00138827|Mucositis
641569|NCT00138827|Xerostomia
641570|NCT00138814|Neoplasm recurrence, local
641571|NCT00138814|Radiotherapy dosage
641572|NCT00138814|Cosmesis
641573|NCT00138814|Mastectomy, segmental
641574|NCT00138801|Neuroborreliosis
641575|NCT00138788|Radiotherapy
641576|NCT00138788|Qualify of life
641577|NCT00138788|Neoplasm metastasis of the brain
641578|NCT00138775|D-serine
641579|NCT00138775|Negative symptoms
641580|NCT00138775|Cognition
641581|NCT00138775|Schizophrenia
641582|NCT00138775|Amino acid
641583|NCT00138736|MBL-deficient
641584|NCT00138736|chemotherapy
641585|NCT00138736|neutropenia
641586|NCT00138736|chemotherapy-induced neutropenia
641587|NCT00138710|obesity
641588|NCT00138710|Hypogonadotrophic hypogonadism
641589|NCT00138710|aromatase inhibition
641590|NCT00138697|Agammaglobulinemia
641591|NCT00138697|Hypogammaglobulinemia
641592|NCT00138697|Immunoglobulins, Intravenous
641593|NCT00138684|insulin resistance
641594|NCT00138684|iron overload
641595|NCT00138684|phlebotomy
641596|NCT00138684|hepatic iron overload
641597|NCT00138658|NSCLC
641598|NCT00138658|custirsen sodium
641599|NCT00138658|OGX-011
641600|NCT00138658|Stage IIIB or IV advanced non-small cell lung cancer
641601|NCT00138632|Wet Age-related macular degeneration
641602|NCT00138632|PTK787
641603|NCT00138619|Type 2 diabetes
641604|NCT00138619|vildagliptin
641605|NCT00138606|Type 2 diabetes
641606|NCT00138606|vildagliptin
641607|NCT00138593|Type 2 diabetes
641608|NCT00138593|vildagliptin
641609|NCT00138580|Type 2 diabetes
641610|NCT00138580|vildagliptin
641611|NCT00138567|Type 2 diabetes
641612|NCT00138567|vildagliptin
641613|NCT00138554|Type 2 diabetes
641614|NCT00138554|vildagliptin
641615|NCT00138541|type 2 diabetes
641616|NCT00138541|vildagliptin
641617|NCT00138528|Metabolic Syndrome, fluvastatin
641618|NCT00138515|Type 2 diabetes
641619|NCT00138515|vildagliptin
641620|NCT00138502|Candidiasis, Funguria
641621|NCT00138489|Malaria, Papua New Guinea, infants, children
641622|NCT00138476|Norovirus, calicivirus, gastroenteritis, Norwalk virus, challenge
641623|NCT00138463|West Nile Virus, Neuroinvasive Disease
641624|NCT00138450|Schistosomiasis, S. haematobium, morbidity, Kenya
641625|NCT00138437|leprosy
641626|NCT00138437|Colombia
641627|NCT00138424|Vistide®, Cidofovir, renal transplant, BK Virus Nephropathy
641628|NCT00138411|anthrax, Bacillus anthracis, monoclonal antibody, ETI-204
641629|NCT00138398|Influenza, T cell, vaccine, Congestive heart failure
641630|NCT00138385|inactivated, attenuated, influenza vaccine, FluMist, Fluzone
641631|NCT00138372|malaria
641632|NCT00138372|immunity
641633|NCT00138372|MSP-1
641634|NCT00138372|Kenya
641635|NCT00138372|infants
641636|NCT00138359|T solium, cysticercus, pig triquina, solitaria, intestinal parasites, Niclosamide, tapeworms, Taeniasis
641637|NCT00138346|hydatid disease, Echinococcus granulosus, tapeworm
641638|NCT00138333|Thimerosal, mercury levels, low birth weight, Argentina
641639|NCT00138320|Herpes Simplex, vaccine, antibodies, mother
641640|NCT00138307|malaria, children, naturally acquired immunity, Ghana
641641|NCT00138294|influenza vaccine
641642|NCT00138294|live attenuated influenza vaccine (LAIV or FluMist)
641643|NCT00138294|inactivated influenza vaccine (IIV)
641644|NCT00138294|School-based influenza vaccination program
641645|NCT00138294|children
641646|NCT00138294|herd protection
641647|NCT00138281|influenza, vaccine, respiratory virus, Fluzone, FluMist
641648|NCT00138268|umbilical cord blood, vaccine, pregnant women
641649|NCT00138242|stage I ovarian epithelial cancer
641650|NCT00138242|stage II ovarian epithelial cancer
641651|NCT00138242|stage III ovarian epithelial cancer
641652|NCT00138242|stage IV ovarian epithelial cancer
641653|NCT00138242|fallopian tube cancer
641654|NCT00138242|primary peritoneal cavity cancer
641655|NCT00138229|recurrent melanoma
641656|NCT00138229|stage IV melanoma
641657|NCT00138216|unspecified childhood solid tumor, protocol specific
641658|NCT00138216|recurrent childhood cerebellar astrocytoma
641659|NCT00138216|recurrent childhood cerebral astrocytoma
641660|NCT00138216|recurrent childhood brain stem glioma
641661|NCT00138216|recurrent childhood brain tumor
641662|NCT00138216|recurrent childhood ependymoma
641663|NCT00138216|recurrent childhood medulloblastoma
641664|NCT00138216|recurrent childhood supratentorial primitive neuroectodermal tumor
641665|NCT00138216|recurrent childhood visual pathway and hypothalamic glioma
641666|NCT00138216|childhood oligodendroglioma
641667|NCT00138216|childhood craniopharyngioma
641668|NCT00138216|childhood choroid plexus tumor
641669|NCT00138216|childhood infratentorial ependymoma
641670|NCT00138216|childhood supratentorial ependymoma
641671|NCT00138216|childhood high-grade cerebral astrocytoma
641672|NCT00138216|childhood low-grade cerebral astrocytoma
641673|NCT00138216|childhood central nervous system germ cell tumor
641674|NCT00138216|childhood grade I meningioma
641675|NCT00138216|childhood grade II meningioma
641676|NCT00138216|childhood grade III meningioma
641677|NCT00138216|recurrent childhood subependymal giant cell astrocytoma
641678|NCT00138216|childhood atypical teratoid/rhabdoid tumor
641679|NCT00138164|recurrent adult diffuse large cell lymphoma
641680|NCT00138164|recurrent grade 1 follicular lymphoma
641681|NCT00138164|recurrent grade 2 follicular lymphoma
641682|NCT00138164|recurrent grade 3 follicular lymphoma
641683|NCT00138164|recurrent small lymphocytic lymphoma
641684|NCT00138151|recurrent cervical cancer
641685|NCT00138151|stage IVB cervical cancer
641686|NCT00138125|stage IV breast cancer
641687|NCT00138125|recurrent breast cancer
641688|NCT00138112|Streptococcal Sepsis
641689|NCT00138112|Hematopoietic Stem Cell Transplantation
641690|NCT00138112|Hematologic Malignancies
641691|NCT00138112|Streptococci
641692|NCT00138112|Transplant
641693|NCT00138099|Critically ill patients (ICU)
641694|NCT00138099|Deep Venous Thromboembolism prevention
641695|NCT00138099|Renal Failure
641696|NCT00138099|Critically ill
641697|NCT00138086|lymphoma
641698|NCT00138086|chemotherapy
641699|NCT00138086|Zevalin ( Yttrium-90 Ibritumomab Tiuxetan)
641700|NCT00138073|pulmonary artery catheter
641701|NCT00138073|waveform interpretation
641702|NCT00138073|computer-based learning
641703|NCT00138073|medical education
641704|NCT00138060|genotypic profile
641705|NCT00138060|metastatic colorectal cancer
641706|NCT00138047|zinc
641707|NCT00138047|HIV
641708|NCT00138047|children
641709|NCT00138034|Open infarct-related artery within 72 hours of thrombolysis
641710|NCT00138021|Serious mental illness
641711|NCT00138021|Supported Employment
641712|NCT00138021|Cognitive remediation
641713|NCT00138021|Cognitive impairments
641714|NCT00138008|prostate cancer
641715|NCT00138008|radical prostatectomy
641716|NCT00138008|PSA failure
641717|NCT00138008|RCT
641718|NCT00138008|radiation
641719|NCT00138008|endocrinotherapy
641720|NCT00137995|Lymphoma
641721|NCT00137995|Chemotherapy
641722|NCT00137995|rituximab
641723|NCT00137982|Ectopic pregnancy
641724|NCT00137982|Surgical treatment
641725|NCT00137982|Medical treatment
641726|NCT00137982|Fertility
641727|NCT00137969|Rituxan
641728|NCT00137969|SLE
641729|NCT00137969|Lupus
641730|NCT00137956|Endobronchial Valve
641731|NCT00137956|Endobronchial Valve ProcedureEBV
641732|NCT00137956|EBV Procedure
641733|NCT00137956|Endobronchial Lung Volume Reduction
641734|NCT00137956|Lung Volume Reduction
641735|NCT00137943|Parent-child communication
641736|NCT00137943|Primary prevention
641737|NCT00137943|sexual risk prevention
641738|NCT00137943|HIV
641739|NCT00137930|Prophylaxis of rotavirus gastroenteritis
641740|NCT00137917|Prophylaxis meningococcal serogroup B disease
641741|NCT00137904|multiple sclerosis
641742|NCT00137904|fatigue
641743|NCT00137904|sleep disorders
641744|NCT00137891|Multinodular goiter
641745|NCT00137852|Esophageal Cancer
641746|NCT00137852|Resectable Esophageal Cancer
641747|NCT00137852|Radiation Therapy
641748|NCT00137852|Celecoxib
641749|NCT00137852|Irinotecan
641750|NCT00137852|Cisplatin
641751|NCT00137839|Tarceva
641752|NCT00137839|Erlotinib
641753|NCT00137839|OSI-774
641754|NCT00137839|Adenocarcinoma
641755|NCT00137839|Advanced Lung Cancer
641756|NCT00137826|Mesothelioma
641757|NCT00137826|Avastin
641758|NCT00137826|Bevacizumab
641759|NCT00137826|Tarceva
641760|NCT00137826|OSI-774
641761|NCT00137826|Erlotinib
641762|NCT00137813|Bevacizumab
641763|NCT00137813|Docetaxel
641764|NCT00137813|AvaTax
641765|NCT00137813|Metastatic Esophagogastric Cancer
641766|NCT00137800|Non-Small Cell Lung Cancer
641767|NCT00137800|Elderly Cancer Patients
641768|NCT00137800|Tarceva
641769|NCT00137800|Erlotinib
641770|NCT00137800|OSI-774
641771|NCT00137800|Stage IIIB or IV Non-Small Cell Lung Cancer
641772|NCT00137787|febrile neutropenia
641773|NCT00137787|hematologic disease
641774|NCT00137774|Metastatic Neuroendocrine Tumor
641775|NCT00137774|Advanced Neuroendocrine tumor
641776|NCT00137774|Bevacizumab
641777|NCT00137774|Temozolomide
641778|NCT00137761|Pancreatic Carcinoma
641779|NCT00137761|Iressa
641780|NCT00137761|Docetaxel
641781|NCT00137748|Lung transplantation
641782|NCT00137735|carpal tunnel syndrome
641783|NCT00137735|gabapentin
641784|NCT00137722|Asthma
641785|NCT00137722|Disease Management
641786|NCT00137722|Outcomes
641787|NCT00137722|Utilization
641788|NCT00137709|epilepsy
641789|NCT00137709|hormone
641790|NCT00137696|polio
641791|NCT00137696|vaccine
641792|NCT00137696|immunogenicity
641793|NCT00137683|screening
641794|NCT00137683|prevention
641795|NCT00137683|community health education
641796|NCT00137670|Intervention studies
641797|NCT00137670|HIV
641798|NCT00137657|HIV
641799|NCT00137657|malaria
641800|NCT00137657|E. Coli
641801|NCT00137657|S. pneumoniae
641802|NCT00137657|drug resistance
641803|NCT00137657|antifolate
641804|NCT00137657|opportunistic infections
641805|NCT00137657|Africa
641806|NCT00137657|Kenya
641807|NCT00137657|East Africa
641808|NCT00137644|Adolescent
641809|NCT00137644|*HIV Infections/ pc [Prevention & Control]
641810|NCT00137644|Male
641811|NCT00137644|Humans
641812|NCT00137644|Risk-Taking
641813|NCT00137644|Safe Sex
641814|NCT00137644|Sexual Behavior
641815|NCT00137644|HIV
641816|NCT00137644|HIV Seronegativity
641817|NCT00137631|Adult
641818|NCT00137631|HIV Infections / pc [Prevention & Control]
641819|NCT00137631|Homosexuality, Male
641820|NCT00137631|Humans
641821|NCT00137631|Male
641822|NCT00137631|Risk-Taking
641823|NCT00137631|Safe Sex
641824|NCT00137631|Sexual Behavior
641825|NCT00137631|HIV
641826|NCT00137618|Prostatic neoplasm
641827|NCT00137618|Prostate cancer
641828|NCT00137618|Informed decision making
641829|NCT00137618|Prostate cancer screening
641830|NCT00137618|Prostate specific antigen
641831|NCT00137605|HIV
641832|NCT00137605|HIV Infections
641833|NCT00137592|screening
641834|NCT00137592|community health education
641835|NCT00137579|Influenza Vaccines
641836|NCT00137579|Acenocoumarol
641837|NCT00137579|Drug Administration Routes
641838|NCT00137579|Anticoagulants
641839|NCT00137566|malaria
641840|NCT00137566|treatment
641841|NCT00137566|paracetamol
641842|NCT00137566|chloroquine
641843|NCT00137566|Guinea-Bissau
641844|NCT00137566|children
641845|NCT00137566|P.falciparum
641846|NCT00137553|Children
641847|NCT00137553|malaria
641848|NCT00137553|sulfadoxine-pyrimethamine
641849|NCT00137553|Guinea-Bissau
641850|NCT00137553|treatment
641851|NCT00137540|First line ablation therapy
641852|NCT00137527|Cardiac Surgery
641853|NCT00137527|Cardiopulmonary Bypass
641854|NCT00137527|Cerebral Oxygenation
641855|NCT00137527|Neurologic Dysfunction
641856|NCT00137527|Neurocognitive Dysfunction
641857|NCT00137527|Neurological manifestations
641858|NCT00137527|Memory loss
641859|NCT00137527|Delirium
641860|NCT00137527|Coronary Artery Bypass
641861|NCT00137514|malaria
641862|NCT00137514|Plasmodium falciparum
641863|NCT00137514|chloroquine
641864|NCT00137514|amodiaquine
641865|NCT00137514|treatment
641866|NCT00137514|Guinea-Bissau
641867|NCT00137514|children
641868|NCT00137488|non-enhancing lesion
641869|NCT00137488|low grade glioma
641870|NCT00137488|high risk group selection
641871|NCT00137475|IMRT
641872|NCT00137475|head and neck cancer
641873|NCT00137475|parotid sparing
641874|NCT00137436|First-line treatment of metastatic hormone-refractory prostate cancer SUTENT in combination with docetaxel and prednisone
641875|NCT00137384|Magnetoencephalogram
641876|NCT00137384|Functional Connectivity
641877|NCT00137384|Electroencephalogram (EEG)
641878|NCT00137384|Focal Hand Dystonia
641879|NCT00137384|Spectral Analysis
641880|NCT00137384|Healthy Volunteer
641881|NCT00137384|HV
641882|NCT00137371|Postmenopause
641883|NCT00137371|Vaginitis
641884|NCT00137358|Cervical
641885|NCT00137358|Uterine
641886|NCT00137358|Para-aortic
641887|NCT00137358|Nodes
641888|NCT00137358|IMRT
641889|NCT00137358|Cancer
641890|NCT00137345|Randomized controlled trial
641891|NCT00137345|Clinical Trial Phase III
641892|NCT00137345|Drug therapy
641893|NCT00137345|Immunosuppression
641894|NCT00137345|Treatment outcome
641895|NCT00137345|Kidney transplantation
641896|NCT00137345|Kidney function tests
641897|NCT00137332|Arrhythmia
641898|NCT00137332|antiarrhythmic
641899|NCT00137332|programmed electrical stimulation
641900|NCT00137319|inspiratory impedance threshold device
641901|NCT00137319|blood pressure regulation
641902|NCT00137319|head-up tilt test
641903|NCT00137319|tilt table testing
641904|NCT00137319|burn injury
641905|NCT00137319|Burns
641906|NCT00137306|Guideline Adherence
641907|NCT00137306|Quality Assurance, Health Care
641908|NCT00137293|Arrhythmia, syncope, antiarrhythmic
641909|NCT00137280|Randomized Controlled Trial
641910|NCT00137280|Quality of Health Care
641911|NCT00137280|Health Services Research
641912|NCT00137280|Guidelines
641913|NCT00137280|Medical Informatics Computing
641914|NCT00137280|Services, Mental Health
641915|NCT00137280|Medicine, Evidenced-Based
641916|NCT00137280|Quality Assurance, Healthcare
641917|NCT00137280|Quality Indicators, Health Care
641918|NCT00137280|Veterans
641919|NCT00137280|Unemployment
641920|NCT00137280|Obesity
641921|NCT00137280|Quality Improvement
641922|NCT00137267|Schizophrenia / disorders w psychotic features
641923|NCT00137267|Substance-related disorders
641924|NCT00137267|Community Mental Health Services
641925|NCT00137267|Case Management
641926|NCT00137267|Health Education
641927|NCT00137254|Severe burns
641928|NCT00137254|Hyperinsulinemia
641929|NCT00137254|Insulin
641930|NCT00137254|Muscle protein kinetics
641931|NCT00137254|Immune function
641932|NCT00137254|Exercise
641933|NCT00137241|health literacy
641934|NCT00137241|screening
641935|NCT00137241|cancer
641936|NCT00137241|health disparities
641937|NCT00137228|Hand Edema
641938|NCT00137228|Figure of eight method
641939|NCT00137228|Measuring edema in burn patients
641940|NCT00137215|burns
641941|NCT00137215|donor site care
641942|NCT00137215|Silverlon dressing
641943|NCT00137202|pruritus
641944|NCT00137202|burn wound
641945|NCT00137189|Motivation
641946|NCT00137189|Music Therapy
641947|NCT00137189|Psychotherapy
641948|NCT00137176|Clinically Isolated Syndrome
641949|NCT00137163|burns
641950|NCT00137163|donor site care
641951|NCT00137163|Dermafill dressing
641952|NCT00137124|Essential hypertension
641953|NCT00137111|Leukemia
641954|NCT00137085|procedural sedation
641955|NCT00136955|Weekly Irinotecan(60mg/sqm, D1, 8, 15) in combination with Cisplatin (60mg/sqm, D1), Squamous Cell Carcinoma Of The Uterine Cervix
641956|NCT00136929|AMI
641957|NCT00136929|MI
641958|NCT00136929|Acute myocardial infarction (AMI), (MI)
641959|NCT00136903|Graft vs Host Disease
641960|NCT00136903|GVHD
641961|NCT00136903|Graft Versus Host Disease
641962|NCT00136903|Bone marrow transplant
641963|NCT00136903|Stem cells
641964|NCT00136903|Mesenchymal stem cells
641965|NCT00136903|Adult stem cells
641966|NCT00136903|Leukemia
641967|NCT00136903|Lymphoma
641968|NCT00136890|Positron-Emission Tomography
641969|NCT00136890|PET Scan
641970|NCT00136890|Lung Cancer
641971|NCT00136890|Thoracic Surgery
641972|NCT00136890|Diagnostic
641973|NCT00136890|Randomized Controlled Trial
641974|NCT00136890|Oncology
641975|NCT00136877|recurrent tonsillitis
641976|NCT00136877|streptococcus
641977|NCT00136877|tonsillectomy
641978|NCT00136877|prevention
641979|NCT00136864|Positron-Emission Tomography
641980|NCT00136864|PET Scan
641981|NCT00136864|Non-Small-Cell Lung Carcinoma
641982|NCT00136864|Diagnosis
641983|NCT00136864|Radiation Oncology
641984|NCT00136864|Lung Cancer
641985|NCT00136864|Randomized Controlled Trial
641986|NCT00136864|Oncology
641987|NCT00136864|Radiation Planning
641988|NCT00136851|Hypertension
641989|NCT00136838|tobacco use
641990|NCT00136825|cocaine
641991|NCT00136825|treatment
641992|NCT00136812|tobacco
641993|NCT00136799|Mixed Dyslipidemia
641994|NCT00136799|high cholesterol
641995|NCT00136799|adults
641996|NCT00136799|fluvastatin
641997|NCT00136786|tobacco use
641998|NCT00136773|Albuminuria
641999|NCT00136773|Type 2 diabetes mellitus
642000|NCT00136773|Hypertension
642001|NCT00136760|tobacco
642002|NCT00136747|tobacco use
642003|NCT00136734|ADHD
642004|NCT00136734|Cocaine dependence
642005|NCT00136734|treatment
642006|NCT00136734|methylphenidate
642007|NCT00136721|Parkinson's disease
642008|NCT00136721|phenotype-genotype correlations
642009|NCT00136721|mutations spectrum
642010|NCT00136721|candidate genes
642011|NCT00136708|Global Network
642012|NCT00136708|Neonatal mortality
642013|NCT00136708|Asphyxia
642014|NCT00136708|Maternal and child health
642015|NCT00136708|International
642016|NCT00136708|Zambia
642017|NCT00136708|Pakistan
642018|NCT00136708|India
642019|NCT00136708|Democratic Republic of Congo
642020|NCT00136708|Uruguay
642021|NCT00136708|Guatemala
642022|NCT00136708|Argentina
642023|NCT00136708|Neonatal resuscitation
642024|NCT00136695|Aging
642025|NCT00136682|Major abdominal or pelvic surgery
642026|NCT00136682|Patient-Controlled Epidural Analgesia (PCEA)
642027|NCT00136682|Length of hospital stay after surgery
642028|NCT00136669|Acupuncture
642029|NCT00136669|Pain
642030|NCT00136669|Pancreatic Neoplasms
642031|NCT00136656|infant
642032|NCT00136656|children
642033|NCT00136656|pyelonephritis
642034|NCT00136656|Renal scars
642035|NCT00136656|DMSA scan
642036|NCT00136643|microbicide
642037|NCT00136643|Women
642038|NCT00136643|Prevention
642039|NCT00136643|HIV
642040|NCT00136643|STIs
642041|NCT00136643|HIV Seronegativity
642042|NCT00136643|prevention of sexually transmitted infections including HIV.
642043|NCT00136630|dominant spinocerebellar degenerations
642044|NCT00136630|new rate scales
642045|NCT00136630|natural history
642046|NCT00136630|molecular biology
642047|NCT00136630|candidate genes
642048|NCT00136617|Short Alcohol Withdrawal Scale
642049|NCT00136617|Documentation
642050|NCT00136604|Prophylaxis diphtheria
642051|NCT00136604|Hib & meningococcal serogroup A & C disease
642052|NCT00136591|follicular lymphoma
642053|NCT00136591|bortezomib
642054|NCT00136591|relapse
642055|NCT00136578|Safety
642056|NCT00136578|tolerability
642057|NCT00136578|dose limiting toxicity
642058|NCT00136578|solid tumors
642059|NCT00136578|carboplatin
642060|NCT00136565|peripheral T-cell lymphomas
642061|NCT00136565|bortezomib
642062|NCT00136565|ACVBP regimen
642063|NCT00136552|lymphoma
642064|NCT00136552|follicular
642065|NCT00136552|B-cell
642066|NCT00136552|rituximab
642067|NCT00136552|interferon
642068|NCT00136539|Breast Cancer
642069|NCT00136539|Early Stage Breast Cancer
642070|NCT00136539|HER2-positive
642071|NCT00136539|HER2-positive breast cancer
642072|NCT00136539|Herceptin
642073|NCT00136539|Taxol
642074|NCT00136539|Stage II Breast Cancer
642075|NCT00136539|Stage III Breast Cancer
642076|NCT00136526|Prostate Cancer
642077|NCT00136526|Hormone refractory prostate cancer
642078|NCT00136526|Metastatic prostate cancer
642079|NCT00136513|Safety
642080|NCT00136513|tolerability
642081|NCT00136513|dose limiting toxicity
642082|NCT00136513|solid tumors
642083|NCT00136500|genetics
642084|NCT00136500|biomarkers
642085|NCT00136500|pre-symptomatic
642086|NCT00136500|natural history
642087|NCT00136487|Prostate Cancer
642088|NCT00136487|Cancer of Prostate
642089|NCT00136487|Cancer of the Prostate
642090|NCT00136487|Prostate-Specific Antigen
642091|NCT00136474|Lymphoma
642092|NCT00136474|Radiation therapy
642093|NCT00136474|Amifostine
642094|NCT00136461|AML
642095|NCT00136461|acute myelogenous leukemia
642096|NCT00136461|MDS
642097|NCT00136461|myelodysplastic syndrome
642098|NCT00136461|bryostatin 1
642099|NCT00136461|all-trans retinoic acid
642100|NCT00136461|ATRA
642101|NCT00136448|AML
642102|NCT00136448|acute myelogenous leukemia
642103|NCT00136448|cytarabine
642104|NCT00136448|interleukin-2
642105|NCT00136435|ALL
642106|NCT00136435|acute lymphoblastic leukemia
642107|NCT00136435|chemotherapy
642108|NCT00136435|asparaginase
642109|NCT00136422|AML
642110|NCT00136422|acute myelogenous leukemia
642111|NCT00136422|MDS
642112|NCT00136422|myelodysplasia
642113|NCT00136422|vaccine
642114|NCT00136409|myelofibrosis
642115|NCT00136409|agnogenic myeloid metaplasia with myelofibrosis
642116|NCT00136409|CMML
642117|NCT00136409|chronic myelomonocytic leukemia
642118|NCT00136409|imatinib mesylate
642119|NCT00136409|Gleevec
642120|NCT00136396|Steroid-refractory Chronic Graft vs. Host Disease
642121|NCT00136396|Chronic Graft vs. Host Disease
642122|NCT00136396|GVHD
642123|NCT00136396|steroid-refractory
642124|NCT00136396|rituximab
642125|NCT00136370|Chlorhexidine
642126|NCT00136370|Prevention
642127|NCT00136370|Neonatal sepsis
642128|NCT00136370|Peripartum infections
642129|NCT00136357|posttraumatic stress
642130|NCT00136357|mind-body techniques
642131|NCT00136357|war
642132|NCT00136357|adolescents
642133|NCT00136344|cataract surgery
642134|NCT00136344|phacoemulsification
642135|NCT00136344|post-operative endophthalmitis
642136|NCT00136331|Pandemic
642137|NCT00136331|Influenza
642138|NCT00136331|Prevention
642139|NCT00136331|Vaccine
642140|NCT00136331|Prevention of Pandemic Influenza
642141|NCT00136318|Pegasys-Induced depression
642142|NCT00136305|pediatric asthma
642143|NCT00136305|asthma action plans
642144|NCT00136305|patient education
642145|NCT00136305|medication adherence
642146|NCT00136292|Gram-Positive Infection
642147|NCT00136279|adolescent behavior
642148|NCT00136279|sexual behavior
642149|NCT00136279|smoking
642150|NCT00136279|parents
642151|NCT00136279|communication
642152|NCT00136279|health education
642153|NCT00136279|schools
642154|NCT00136279|Sexual initiation
642155|NCT00136266|Adherence
642156|NCT00136266|Supplements
642157|NCT00136266|Iron
642158|NCT00136266|Iron deficiency
642159|NCT00136266|Anemia
642160|NCT00136266|Vitamins
642161|NCT00136266|Minerals
642162|NCT00136227|screening,
642163|NCT00136227|community health education,
642164|NCT00136227|decision making,
642165|NCT00136227|computer-assisted decision making
642166|NCT00136201|Peritonitis
642167|NCT00136201|Community-Acquired Infections
642168|NCT00136201|Cross Infection
642169|NCT00136188|Prediabetes
642170|NCT00136188|Metabolic Syndrome
642171|NCT00136188|Healthy Controls
642172|NCT00136188|Endothelial function
642173|NCT00136175|Neoadjuvant chemotherapy
642174|NCT00136110|ALS
642175|NCT00136110|Sodium Valproate
642176|NCT00136110|randomised trial
642177|NCT00136110|Amyotrophic Lateral Sclerosis (ALS)
642178|NCT00136097|colonisation of the catheter
642179|NCT00136084|Leukemia,Erythroblastic, Acute
642180|NCT00136084|Erythroblastic Leukemia, Acute
642181|NCT00136084|Leukemia, Myeloid, Acute
642182|NCT00136084|Myeloid Leukemia, Acute
642183|NCT00136071|Stress Urinary Incontinence,
642184|NCT00136071|TOT,
642185|NCT00136071|TVT-O
642186|NCT00136058|osteoporosis
642187|NCT00136058|hip fracture
642188|NCT00136045|Idiopathic RLS
642189|NCT00136032|Growth Hormone
642190|NCT00136032|Cardiovascular risk
642191|NCT00136032|Pituitary
642192|NCT00136032|Hypothalamic
642193|NCT00136032|GH Deficiency
642194|NCT00136032|Pituitary Tumor
642195|NCT00136032|Pituitary Disease
642196|NCT00136019|Epilepsy with partial seizures
642197|NCT00136006|Epidemiology
642198|NCT00136006|Lung health
642199|NCT00136006|lung function
642200|NCT00136006|COPD
642201|NCT00135993|Idiopathic Restless Leg syndrome
642202|NCT00135967|membranous nephropathy
642203|NCT00135967|mycophenolate mofetil
642204|NCT00135967|cyclophosphamide
642205|NCT00135967|prednisone
642206|NCT00135954|membranous nephropathy
642207|NCT00135954|cyclophosphamide
642208|NCT00135954|prednisone
642209|NCT00135941|Diabetes Mellitus, Type 2
642210|NCT00135928|ST-elevation myocardial infarction
642211|NCT00135928|granulocyte-colony stimulating factor angiogenesis
642212|NCT00135928|stem cells
642213|NCT00135902|Preterm birth
642214|NCT00135902|Progesterone
642215|NCT00135902|Omega-3 fatty acid
642216|NCT00135902|Pregnancy
642217|NCT00135889|Total Knee Arthroplasty secondary to osteoarthritis
642218|NCT00135876|deep vein thrombosis
642219|NCT00135876|pulmonary embolism
642220|NCT00135876|glioma
642221|NCT00135876|fragmin
642222|NCT00135876|anticoagulant
642223|NCT00135876|prophylaxis
642224|NCT00135876|dalteparin
642225|NCT00135850|Gene therapy
642226|NCT00135850|VEGF
642227|NCT00135850|Stem cells
642228|NCT00135850|myocardial ischemia
642229|NCT00135850|angiogenesis
642230|NCT00135837|Age related Macula Degeneration,
642231|NCT00135837|AMD,
642232|NCT00135837|choroidal neovascularisation (CNV),
642233|NCT00135837|occult CNV lesion,
642234|NCT00135837|verteporfin for injection,
642235|NCT00135837|photodynamic therapy (PDT)
642236|NCT00135824|Artificial eye drops
642237|NCT00135824|tolerability
642238|NCT00135824|healthy volunteers
642239|NCT00135824|povidone
642240|NCT00135824|healthy subjects
642241|NCT00135811|Focal Segmental Glomerulosclerosis
642242|NCT00135798|Hepatitis C
642243|NCT00135798|Ribavirin
642244|NCT00135798|PegInterferon alfa2b
642245|NCT00135772|nicotine dependence
642246|NCT00135759|opiate dependence
642247|NCT00135746|tobacco
642248|NCT00135733|Lichen Planus
642249|NCT00135733|Mucosal lichen planus
642250|NCT00135733|Alefacept
642251|NCT00135733|T-cell mediated
642252|NCT00135733|subcutaneous medication
642253|NCT00135733|Autoimmune disease
642254|NCT00135720|Pemphigus Vulgaris
642255|NCT00135720|Chronic Pemphigus
642256|NCT00135720|Etanercept
642257|NCT00135720|Enbrel
642258|NCT00135720|anti-TNF-alpha
642259|NCT00135720|TNF-alpha antagonist
642260|NCT00135720|biologic
642261|NCT00135720|immunomodulator
642262|NCT00135720|subcutaneous medication
642263|NCT00135707|Antioxidants
642264|NCT00135707|Preeclampsia
642265|NCT00135707|Pregnancy
642266|NCT00135707|Hypertension
642267|NCT00135694|hepatitis
642268|NCT00135694|hepatitis C
642269|NCT00135694|HCV
642270|NCT00135694|liver
642271|NCT00135694|liver disease
642272|NCT00135694|liver transplant
642273|NCT00135694|liver transplantation
642274|NCT00135694|transplant
642275|NCT00135694|hepatic
642276|NCT00135694|hepatic transplantation
642277|NCT00135694|immunosuppression
642278|NCT00135694|rejection
642279|NCT00135668|children
642280|NCT00135668|sodium nitroprusside
642281|NCT00135668|controlled hypotension
642282|NCT00135668|dose-response
642283|NCT00135668|pharmacokinetics
642284|NCT00135668|pharmacodynamics
642285|NCT00135668|safety
642286|NCT00135668|efficacy
642287|NCT00135655|macular edema
642288|NCT00135655|post cataract extraction
642289|NCT00135655|cystoid macular edema
642290|NCT00135655|post cataract extraction macular edema
642291|NCT00135642|Hayfever
642292|NCT00135642|Subcutaneous Immunotherapy
642293|NCT00135642|Grass pollen immunotherapy
642294|NCT00135642|Seasonal Allergic Rhinoconjunctivitis
642295|NCT00135629|Hayfever
642296|NCT00135629|Sublingual Immunotherapy
642297|NCT00135629|Grass pollen immunotherapy
642298|NCT00135629|Late cutaneous response
642299|NCT00135629|Intradermal allergen challenge
642300|NCT00135629|Seasonal Allergic Rhinoconjunctivitis
642301|NCT00135616|urinary incontinence
642302|NCT00135616|stress incontinence
642303|NCT00135616|urethra
642304|NCT00135616|gynaecologic surgical procedures
642305|NCT00135616|suburethral sling
642306|NCT00135603|appendicitis.
642307|NCT00135603|adult.
642308|NCT00135603|treatment.
642309|NCT00135603|antibiotic therapy.
642310|NCT00135603|CT scanning.
642311|NCT00135603|randomized trial
642312|NCT00135603|safety
642313|NCT00135590|Protein pulse-feeding
642314|NCT00135590|Nutritional supplementation
642315|NCT00135590|Protein-energy malnutrition
642316|NCT00135590|Elderly subjects
642317|NCT00135590|Body composition
642318|NCT00135577|opioids
642319|NCT00135577|constipation
642320|NCT00135577|opioid-induced bowel dysfunction
642321|NCT00135564|Haemophilus Influenzae type b/Meningococcal (vaccine)
642322|NCT00135564|Prophylaxis meningococcal serogroup C disease, Hib diseases
642323|NCT00135551|Hypertension
642324|NCT00135551|Multicenter clinical trial
642325|NCT00135551|PROBE
642326|NCT00135551|Combination therapy
642327|NCT00135551|Benidipine
642328|NCT00135551|Essential Hypertension
642329|NCT00135538|Pulmonary Disease, Chronic Obstructive
642330|NCT00135538|Intermittent Positive-Pressure Ventilation
642331|NCT00135538|Rehabilitation
642332|NCT00135525|Generalized Anxiety Disorder
642333|NCT00135512|MDD
642334|NCT00135499|Lymphoma
642335|NCT00135499|chemotherapy
642336|NCT00135499|rituximab
642337|NCT00135486|Haemophilus Influenzae type b/Meningococcal vaccine
642338|NCT00135486|Prophylaxis meningococcal serogroup C disease, Hib diseases
642339|NCT00135473|Severe sepsis
642340|NCT00135473|septic shock
642341|NCT00135473|volume substitution
642342|NCT00135473|intensive insulin therapy
642343|NCT00135473|colloids
642344|NCT00135473|crystalloids
642345|NCT00135473|outcome
642346|NCT00135473|safety
642347|NCT00135460|HIV
642348|NCT00135460|Lipoatrophy
642349|NCT00135460|Lipodystrophy
642350|NCT00135460|Treatment Naive
642351|NCT00135460|HIV Infections
642352|NCT00135460|Hypercholesterolemia
642353|NCT00135447|HIV/AIDS
642354|NCT00135447|Treatment Experienced
642355|NCT00135408|Unresectable Stage III or IV Malignant Melanoma
642356|NCT00135395|HIV/AIDS
642357|NCT00135395|Treatment Experienced
642358|NCT00135382|HIV/AIDS
642359|NCT00135369|HIV-AIDS
642360|NCT00135356|HIV infections
642361|NCT00135343|HIV/AIDS
642362|NCT00135330|diabetes
642363|NCT00135330|exenatide
642364|NCT00135330|rosiglitazone
642365|NCT00135330|Amylin
642366|NCT00135330|Lilly
642367|NCT00135317|oncology
642368|NCT00135317|darbepoetin alfa
642369|NCT00135317|Aranesp®
642370|NCT00135317|Amgen
642371|NCT00135317|Non-myeloid malignancy
642372|NCT00135304|Vitamin D
642373|NCT00135304|Sensipar®
642374|NCT00135304|Cinacalcet HCl
642375|NCT00135304|Chronic Kidney Disease
642376|NCT00135291|transfusion-induced immunomodulation
642377|NCT00135291|leukoreduction
642378|NCT00135291|surgical site infections
642379|NCT00135291|nosocomial infections
642380|NCT00135291|transfusion
642381|NCT00135291|Infection
642382|NCT00135291|Sepsis
642383|NCT00135291|Hemorrhage
642384|NCT00135278|Neuroprotection
642385|NCT00135278|inflammation
642386|NCT00135278|cytokines
642387|NCT00135278|CSF
642388|NCT00135265|smoking cessation
642389|NCT00135265|adolescents
642390|NCT00135252|developing chronic lung disease
642391|NCT00135239|back
642392|NCT00135239|Lower Mechanical Back Pain
642393|NCT00135239|Rehabilitation
642394|NCT00135226|Diabetes Mellitus
642395|NCT00135226|Cardiovascular Disease
642396|NCT00135226|Aspirin
642397|NCT00135226|Omega-3 fatty acids
642398|NCT00135226|Primary prevention
642399|NCT00135226|Randomized Controlled Trial
642400|NCT00135226|Type 1 Diabetes Mellitus
642401|NCT00135226|Type 2 Diabetes Mellitus
642402|NCT00135213|passive smoking
642403|NCT00135213|pediatric practice
642404|NCT00135213|smoking cessation
642405|NCT00135174|Pacemaker
642406|NCT00135174|routine
642407|NCT00135174|follow-up
642408|NCT00135174|complications
642409|NCT00135174|Quality of Life
642410|NCT00135161|neoplasms (squamous cell carcinoma of the head and neck region)
642411|NCT00135135|Cancer
642412|NCT00135135|Childhood Tumor
642413|NCT00135135|Neoplasms
642414|NCT00135122|migraine
642415|NCT00135122|analgesics
642416|NCT00135122|tension type headache
642417|NCT00135070|Diabetes Mellitus
642418|NCT00135044|taurine
642419|NCT00135044|intestinal failure
642420|NCT00135044|HPN
642421|NCT00135044|hepatobiliary complications
642422|NCT00135044|chronic intestinal failure (CIF)
642423|NCT00135005|GIST
642424|NCT00135005|AMN107
642425|NCT00135005|Gastrointestinal Stromal Tumors
642426|NCT00134992|Prednisolone acetate
642427|NCT00134992|eye drops
642428|NCT00134992|tolerability
642429|NCT00134992|Healthy volunteers
642430|NCT00134979|COPD, formoterol,
642431|NCT00134966|Parkinson's disease, levodopa, dyskinesia
642432|NCT00134953|Mild cognitive impairment
642433|NCT00134953|Alzheimer's disease
642434|NCT00134953|Dementia
642435|NCT00134953|Mild Cognitive Impairment (MCI)
642436|NCT00134940|Transplantation, heart
642437|NCT00134940|Organ transplant
642438|NCT00134914|opiate dependence
642439|NCT00134901|Cocaine dependence
642440|NCT00134901|treatment
642441|NCT00134901|memantine
642442|NCT00134888|Opioid Dependence
642443|NCT00134875|opioid dependence
642444|NCT00134849|hypertension
642445|NCT00134823|Parent Experience of Care
642446|NCT00134823|Quality Improvement
642447|NCT00134823|Medication Errors
642448|NCT00134823|Abnormal Lab Values
642449|NCT00134823|Guideline Adherence
642450|NCT00134810|Myofascial pain syndrome
642451|NCT00134797|GFR
642452|NCT00134797|serum creatinine
642453|NCT00134784|parkinson
642454|NCT00134784|brain imaging
642455|NCT00134771|Infants whose birthweight is less than the 20th centile for gestational age (UK standards)
642456|NCT00134771|Infants who are formula fed from birth
642457|NCT00134771|Singletons
642458|NCT00134771|Infants free from major congenital disease
642459|NCT00134758|Treatment of adenomas of the duodenum in FAP patients.
642460|NCT00134758|Adenoma
642461|NCT00134745|Turner Syndrome
642462|NCT00134745|Hormonal replacement therapy
642463|NCT00134745|Bone mineralization
642464|NCT00134745|Uterine size
642465|NCT00134745|aortic root dilatation
642466|NCT00134732|Prophylaxis of Rotavirus Gastroenteritis
642467|NCT00134719|Invasive Hib & N. meningitidis diseases
642468|NCT00134706|Prostate Cancer
642469|NCT00134706|Cancer of the prostate
642470|NCT00134706|Cancer of prostate
642471|NCT00134706|Docetaxel
642472|NCT00134706|Carboplatin
642473|NCT00134693|SB-681323 rheumatoid arthritis CRP biomarkers
642474|NCT00134680|estrogen receptor positive
642475|NCT00134680|progesterone receptor positive
642476|NCT00134680|ErbB2 positive
642477|NCT00134680|metastatic breast cancer
642478|NCT00134667|AMD
642479|NCT00134667|Age-Related Macular Degeneration
642480|NCT00134667|Macular Degeneration
642481|NCT00134667|Macugen
642482|NCT00134667|Photodynamic Therapy
642483|NCT00134667|PDT
642484|NCT00134667|Visudyne
642485|NCT00134667|pegaptanib sodium
642486|NCT00134667|verteporfin
642487|NCT00134667|Predominantly Classic
642488|NCT00134667|Age-Related Macular Degeneration (AMD)
642489|NCT00134654|Androgen-independent prostate cancer
642490|NCT00134654|Premarin
642491|NCT00134654|conjugated estrogen
642492|NCT00134641|soft tissue sarcoma
642493|NCT00134641|metastatic soft tissue sarcoma
642494|NCT00134641|gemcitabine
642495|NCT00134641|vinorelbine
642496|NCT00134628|Hyperbaric Oxygenation
642497|NCT00134628|Radiation injuries
642498|NCT00134628|Prophylaxis
642499|NCT00134628|Proctitis
642500|NCT00134628|Cystitis
642501|NCT00134628|Enteritis
642502|NCT00134628|Osteoradionecrosis
642503|NCT00134615|decision-making
642504|NCT00134615|patient activation
642505|NCT00134615|empowerment
642506|NCT00134615|mental health
642507|NCT00134615|Depression
642508|NCT00134615|Anxiety
642509|NCT00134615|Other Psychiatric Disorder
642510|NCT00134602|HIV infection, antiretroviral therapy, adherence, pediatric
642511|NCT00134589|Academic Detailing
642512|NCT00134589|Decision Aid
642513|NCT00134589|Colorectal Cancer Screening
642514|NCT00134589|RECTAL NEOPLASMS
642515|NCT00134589|COLONIC POLYPS
642516|NCT00134563|Multiple Sclerosis
642517|NCT00134563|Relapsing Remitting
642518|NCT00134563|Secondary Progressive
642519|NCT00134563|Progressive Relapsing
642520|NCT00134550|Diabetes Mellitus
642521|NCT00134550|Foot ulcers
642522|NCT00134550|Complication
642523|NCT00134550|Foot Ulcer, Diabetic
642524|NCT00134537|Degenerative Disc Disease of the lumbar spine
642525|NCT00134524|Magnetics
642526|NCT00134524|Electromagnetics
642527|NCT00134524|Diabetic neuropathy
642528|NCT00134524|Pain
642529|NCT00134472|Hypothermia, induced
642530|NCT00134472|Traumatic Brain injuries
642531|NCT00134472|Anesthesia
642532|NCT00134472|Neuro-intensive care
642533|NCT00134472|neurochemistry
642534|NCT00134459|Depression
642535|NCT00134459|Bipolar Disorder
642536|NCT00134446|post traumatic stress disorder
642537|NCT00134446|PTSD
642538|NCT00134446|trauma
642539|NCT00134446|transcranial magnetic stimulation
642540|NCT00134446|randomized clinical trial
642541|NCT00134433|Coronary Artery Disease, Diffuse
642542|NCT00134433|Coronary Artery Disease, Deemed Inoperable
642543|NCT00134420|Growth Hormone
642544|NCT00134420|Chromosomes, Human, Pair 18
642545|NCT00134420|Child
642546|NCT00134407|Nutrition
642547|NCT00134407|Postoperative
642548|NCT00134407|oral
642549|NCT00134407|jejunal
642550|NCT00134407|feeding
642551|NCT00134407|Surgery
642552|NCT00134407|major
642553|NCT00134407|abdominal
642554|NCT00134407|adult
642555|NCT00134394|psoriasis
642556|NCT00134394|tacrolimus
642557|NCT00134394|etanercept
642558|NCT00134381|Normal volunteer study
642559|NCT00134368|vitiligo
642560|NCT00134368|etanercept
642561|NCT00134355|antiangiogenesis therapy
642562|NCT00134355|vatalanib
642563|NCT00134342|tuberculosis
642564|NCT00134342|tuberculin test
642565|NCT00134342|immunologic tests
642566|NCT00134342|Latent tuberculosis
642567|NCT00134342|end stage renal disease
642568|NCT00134342|solid organ transplantation
642569|NCT00134342|bone marrow transplantation
642570|NCT00134342|rheumatologic disease
642571|NCT00134316|sexual dysfunction
642572|NCT00134251|Parkinson's disease
642573|NCT00134251|adjunctive to L-dopa therapy
642574|NCT00134251|Advanced stage Parkinson's disease
642575|NCT00134225|Musculoskeletal abnormality
642576|NCT00134225|Musculoskeletal physiology
642577|NCT00134225|Musculoskeletal disease
642578|NCT00134225|Musculoskeletal dysfunction
642579|NCT00134212|Splanchnic perfusion, hepatic damage, oxidative stress.
642580|NCT00134186|Kidney cancer
642581|NCT00134186|Renal cell carcinoma
642582|NCT00134186|Motexafin gadolinium
642583|NCT00134160|Aged
642584|NCT00134160|Hypertension
642585|NCT00134160|Cardiovascular Diseases
642586|NCT00134160|Angiotensin II Type 1 Receptor Blockers
642587|NCT00134160|Calcium Channel Blockers
642588|NCT00134160|Combination Drug Therapy
642589|NCT00134160|Diabetes Mellitus Type 2
642590|NCT00134134|hidradenitis suppurativa
642591|NCT00134134|efalizumab
642592|NCT00134134|biologic
642593|NCT00134134|Raptiva
642594|NCT00134095|adenocarcinoma of the stomach
642595|NCT00134095|stage II gastric cancer
642596|NCT00134095|stage III gastric cancer
642597|NCT00134095|stage IV gastric cancer
642598|NCT00134082|recurrent adult Hodgkin lymphoma
642599|NCT00134056|adenocarcinoma of the prostate
642600|NCT00134056|stage IV prostate cancer
642601|NCT00134056|recurrent prostate cancer
642602|NCT00134056|bone metastases
642603|NCT00134017|adult acute myeloid leukemia in remission
642604|NCT00134017|refractory anemia with excess blasts
642605|NCT00134017|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
642606|NCT00134017|adult acute myeloid leukemia with inv(16)(p13;q22)
642607|NCT00134017|adult acute myeloid leukemia with t(15;17)(q22;q12)
642608|NCT00134017|adult acute myeloid leukemia with t(16;16)(p13;q22)
642609|NCT00134017|adult acute myeloid leukemia with t(8;21)(q22;q22)
642610|NCT00134017|childhood acute myeloid leukemia in remission
642611|NCT00134017|recurrent adult acute myeloid leukemia
642612|NCT00134017|recurrent childhood acute myeloid leukemia
642613|NCT00134017|secondary acute myeloid leukemia
642614|NCT00134017|de novo myelodysplastic syndromes
642615|NCT00134017|adult acute lymphoblastic leukemia in remission
642616|NCT00134017|childhood acute lymphoblastic leukemia in remission
642617|NCT00134017|recurrent adult acute lymphoblastic leukemia
642618|NCT00134017|recurrent childhood acute lymphoblastic leukemia
642619|NCT00134017|accelerated phase chronic myelogenous leukemia
642620|NCT00134017|blastic phase chronic myelogenous leukemia
642621|NCT00134017|childhood chronic myelogenous leukemia
642622|NCT00134017|chronic phase chronic myelogenous leukemia
642623|NCT00134017|relapsing chronic myelogenous leukemia
642624|NCT00134017|stage III chronic lymphocytic leukemia
642625|NCT00134017|stage IV chronic lymphocytic leukemia
642626|NCT00134017|chronic eosinophilic leukemia
642627|NCT00134017|chronic idiopathic myelofibrosis
642628|NCT00134017|chronic neutrophilic leukemia
642629|NCT00134017|stage III adult Hodgkin lymphoma
642630|NCT00134017|stage IV adult Hodgkin lymphoma
642631|NCT00134017|stage II multiple myeloma
642632|NCT00134017|stage III multiple myeloma
642633|NCT00134017|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
642634|NCT00134017|nodal marginal zone B-cell lymphoma
642635|NCT00134017|splenic marginal zone lymphoma
642636|NCT00134017|noncontiguous stage II adult Burkitt lymphoma
642637|NCT00134017|noncontiguous stage II adult diffuse large cell lymphoma
642638|NCT00134017|noncontiguous stage II adult diffuse mixed cell lymphoma
642639|NCT00134017|noncontiguous stage II adult diffuse small cleaved cell lymphoma
642640|NCT00134017|noncontiguous stage II adult immunoblastic large cell lymphoma
642641|NCT00134017|noncontiguous stage II adult lymphoblastic lymphoma
642642|NCT00134017|noncontiguous stage II grade 1 follicular lymphoma
642643|NCT00134017|noncontiguous stage II grade 2 follicular lymphoma
642644|NCT00134017|noncontiguous stage II grade 3 follicular lymphoma
642645|NCT00134017|noncontiguous stage II mantle cell lymphoma
642646|NCT00134017|noncontiguous stage II marginal zone lymphoma
642647|NCT00134017|noncontiguous stage II small lymphocytic lymphoma
642648|NCT00134017|previously treated myelodysplastic syndromes
642649|NCT00134017|recurrent adult Burkitt lymphoma
642650|NCT00134017|recurrent adult diffuse large cell lymphoma
642651|NCT00134017|recurrent adult diffuse mixed cell lymphoma
642652|NCT00134017|recurrent adult diffuse small cleaved cell lymphoma
642653|NCT00134017|recurrent adult immunoblastic large cell lymphoma
642654|NCT00134017|recurrent adult lymphoblastic lymphoma
642655|NCT00134017|recurrent childhood large cell lymphoma
642656|NCT00134017|recurrent childhood lymphoblastic lymphoma
642657|NCT00134017|recurrent grade 1 follicular lymphoma
642658|NCT00134017|recurrent grade 2 follicular lymphoma
642659|NCT00134017|recurrent grade 3 follicular lymphoma
642660|NCT00134017|recurrent mantle cell lymphoma
642661|NCT00134017|recurrent childhood small noncleaved cell lymphoma
642662|NCT00134017|recurrent/refractory childhood Hodgkin lymphoma
642663|NCT00134017|recurrent adult Hodgkin lymphoma
642664|NCT00134017|recurrent small lymphocytic lymphoma
642665|NCT00134017|recurrent marginal zone lymphoma
642666|NCT00134017|stage III adult Burkitt lymphoma
642667|NCT00134017|stage III adult diffuse large cell lymphoma
642668|NCT00134017|stage III adult diffuse mixed cell lymphoma
642669|NCT00134017|stage III adult diffuse small cleaved cell lymphoma
642670|NCT00134017|stage III adult immunoblastic large cell lymphoma
642671|NCT00134017|stage III adult lymphoblastic lymphoma
642672|NCT00134017|stage IV adult Burkitt lymphoma
642673|NCT00134017|stage IV adult diffuse large cell lymphoma
642674|NCT00134017|stage IV adult diffuse mixed cell lymphoma
642675|NCT00134017|stage IV adult diffuse small cleaved cell lymphoma
642676|NCT00134017|stage IV adult immunoblastic large cell lymphoma
642677|NCT00134017|stage III grade 1 follicular lymphoma
642678|NCT00134017|stage III grade 2 follicular lymphoma
642679|NCT00134017|stage III grade 3 follicular lymphoma
642680|NCT00134017|stage IV grade 1 follicular lymphoma
642681|NCT00134017|stage IV grade 2 follicular lymphoma
642682|NCT00134017|stage IV grade 3 follicular lymphoma
642683|NCT00134017|stage III mantle cell lymphoma
642684|NCT00134017|stage III marginal zone lymphoma
642685|NCT00134017|stage IV mantle cell lymphoma
642686|NCT00134017|stage IV marginal zone lymphoma
642687|NCT00134017|stage III small lymphocytic lymphoma
642688|NCT00134017|stage IV small lymphocytic lymphoma
642689|NCT00134017|chronic myelomonocytic leukemia
642690|NCT00134017|refractory chronic lymphocytic leukemia
642691|NCT00134017|refractory multiple myeloma
642692|NCT00134017|secondary myelodysplastic syndromes
642693|NCT00134017|stage IV adult lymphoblastic lymphoma
642694|NCT00134017|childhood myelodysplastic syndromes
642695|NCT00134004|adult acute lymphoblastic leukemia in remission
642696|NCT00134004|adult acute myeloid leukemia in remission
642697|NCT00134004|childhood acute lymphoblastic leukemia in remission
642698|NCT00134004|childhood acute myeloid leukemia in remission
642699|NCT00134004|childhood chronic myelogenous leukemia
642700|NCT00134004|chronic phase chronic myelogenous leukemia
642701|NCT00134004|refractory chronic lymphocytic leukemia
642702|NCT00134004|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
642703|NCT00134004|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
642704|NCT00134004|adult acute myeloid leukemia with inv(16)(p13;q22)
642705|NCT00134004|adult acute myeloid leukemia with t(15;17)(q22;q12)
642706|NCT00134004|adult acute myeloid leukemia with t(16;16)(p13;q22)
642707|NCT00134004|adult acute myeloid leukemia with t(8;21)(q22;q22)
642708|NCT00134004|chronic idiopathic myelofibrosis
642709|NCT00134004|chronic myelomonocytic leukemia
642710|NCT00134004|de novo myelodysplastic syndromes
642711|NCT00134004|previously treated myelodysplastic syndromes
642712|NCT00134004|noncontiguous stage II adult Burkitt lymphoma
642713|NCT00134004|noncontiguous stage II adult diffuse large cell lymphoma
642714|NCT00134004|noncontiguous stage II adult diffuse mixed cell lymphoma
642715|NCT00134004|noncontiguous stage II adult diffuse small cleaved cell lymphoma
642716|NCT00134004|noncontiguous stage II adult immunoblastic large cell lymphoma
642717|NCT00134004|noncontiguous stage II adult lymphoblastic lymphoma
642718|NCT00134004|noncontiguous stage II grade 1 follicular lymphoma
642719|NCT00134004|noncontiguous stage II grade 2 follicular lymphoma
642720|NCT00134004|noncontiguous stage II grade 3 follicular lymphoma
642721|NCT00134004|noncontiguous stage II mantle cell lymphoma
642722|NCT00134004|noncontiguous stage II marginal zone lymphoma
642723|NCT00134004|noncontiguous stage II small lymphocytic lymphoma
642724|NCT00134004|recurrent adult Burkitt lymphoma
642725|NCT00134004|recurrent adult diffuse large cell lymphoma
642726|NCT00134004|recurrent adult diffuse mixed cell lymphoma
642727|NCT00134004|recurrent adult diffuse small cleaved cell lymphoma
642728|NCT00134004|recurrent adult Hodgkin lymphoma
642729|NCT00134004|recurrent adult immunoblastic large cell lymphoma
642730|NCT00134004|recurrent adult lymphoblastic lymphoma
642731|NCT00134004|recurrent/refractory childhood Hodgkin lymphoma
642732|NCT00134004|recurrent childhood large cell lymphoma
642733|NCT00134004|recurrent childhood lymphoblastic lymphoma
642734|NCT00134004|recurrent childhood small noncleaved cell lymphoma
642735|NCT00134004|nodal marginal zone B-cell lymphoma
642736|NCT00134004|recurrent grade 1 follicular lymphoma
642737|NCT00134004|recurrent grade 2 follicular lymphoma
642738|NCT00134004|recurrent grade 3 follicular lymphoma
642739|NCT00134004|recurrent mantle cell lymphoma
642740|NCT00134004|recurrent marginal zone lymphoma
642741|NCT00134004|recurrent small lymphocytic lymphoma
642742|NCT00134004|refractory multiple myeloma
642855|NCT00133744|micronutrients
642743|NCT00134004|relapsing chronic myelogenous leukemia
642744|NCT00134004|secondary myelodysplastic syndromes
642745|NCT00134004|splenic marginal zone lymphoma
642746|NCT00134004|stage I multiple myeloma
642747|NCT00134004|stage II multiple myeloma
642748|NCT00134004|stage III multiple myeloma
642749|NCT00134004|stage III adult Burkitt lymphoma
642750|NCT00134004|stage III adult diffuse large cell lymphoma
642751|NCT00134004|stage III adult diffuse mixed cell lymphoma
642752|NCT00134004|stage III adult diffuse small cleaved cell lymphoma
642753|NCT00134004|stage III adult Hodgkin lymphoma
642754|NCT00134004|stage III adult immunoblastic large cell lymphoma
642755|NCT00134004|stage III adult lymphoblastic lymphoma
642756|NCT00134004|stage III grade 1 follicular lymphoma
642757|NCT00134004|stage III grade 2 follicular lymphoma
642758|NCT00134004|stage III grade 3 follicular lymphoma
642759|NCT00134004|stage III mantle cell lymphoma
642760|NCT00134004|stage III marginal zone lymphoma
642761|NCT00134004|polycythemia vera
642762|NCT00134004|essential thrombocythemia
642763|NCT00134004|stage III small lymphocytic lymphoma
642764|NCT00134004|stage IV mantle cell lymphoma
642765|NCT00134004|stage IV marginal zone lymphoma
642766|NCT00134004|stage IV grade 1 follicular lymphoma
642767|NCT00134004|stage IV grade 2 follicular lymphoma
642768|NCT00134004|stage IV grade 3 follicular lymphoma
642769|NCT00134004|stage IV adult Burkitt lymphoma
642770|NCT00134004|stage IV adult diffuse large cell lymphoma
642771|NCT00134004|stage IV adult diffuse mixed cell lymphoma
642772|NCT00134004|stage IV adult diffuse small cleaved cell lymphoma
642773|NCT00134004|stage IV adult immunoblastic large cell lymphoma
642774|NCT00134004|stage IV adult lymphoblastic lymphoma
642775|NCT00134004|stage IV small lymphocytic lymphoma
642776|NCT00134004|stage IV adult Hodgkin lymphoma
642777|NCT00134004|childhood myelodysplastic syndromes
642778|NCT00133991|untreated adult acute lymphoblastic leukemia
642779|NCT00133991|L3 adult acute lymphoblastic leukemia
642780|NCT00133991|contiguous stage II adult Burkitt lymphoma
642781|NCT00133991|noncontiguous stage II adult Burkitt lymphoma
642782|NCT00133991|stage I adult Burkitt lymphoma
642783|NCT00133991|stage III adult Burkitt lymphoma
642784|NCT00133991|stage IV adult Burkitt lymphoma
642785|NCT00133978|randomized trial
642786|NCT00133978|antioxidants
642787|NCT00133978|glutamine
642788|NCT00133978|organ failure
642789|NCT00133965|Advanced Cancer
642790|NCT00133965|Dignity Care
642791|NCT00133965|Supportive Care
642792|NCT00133965|Quality of Life
642793|NCT00133965|Psychotherapy
642794|NCT00133965|Palliative Care
642795|NCT00133939|Proportional assisted ventilation
642796|NCT00133939|Pressure support ventilation
642797|NCT00133939|Synchronism during mechanical ventilation
642798|NCT00133939|Patients undergoing partial mechanical ventilation
642799|NCT00133926|Periodontal disease
642800|NCT00133926|Pregnancy
642801|NCT00133926|Pre-term birth
642802|NCT00133926|Fetal growth
642803|NCT00133926|Pre-eclampsia
642804|NCT00133926|Infant, Low Birth Weight
642805|NCT00133913|metastatic colorectal cancer
642806|NCT00133900|hormone refractory prostate cancer
642807|NCT00133887|Squamous cell carcinoma
642808|NCT00133887|kidney transplant recipients
642809|NCT00133887|rapamycin
642810|NCT00133887|Skin cancers in kidney transplant recipients
642811|NCT00133874|topical antibacterial
642812|NCT00133874|topical antibiotic
642813|NCT00133874|impetigo
642814|NCT00133861|cerebral palsy children
642815|NCT00133861|Botulinum toxin
642816|NCT00133848|impetigo
642817|NCT00133848|topical antibacterial
642818|NCT00133848|topical antibiotic
642819|NCT00133835|Randomized controlled trial
642820|NCT00133835|Lithotripsy
642821|NCT00133835|Cholangiopancreatography, Endoscopic Retrograde
642822|NCT00133835|Abdominal pain
642823|NCT00133822|Post-Traumatic Stress Disorder
642824|NCT00133822|Sertraline
642825|NCT00133822|Risperidone
642826|NCT00133809|Type 1 Diabetes
642827|NCT00133809|Islet Transplantation
642828|NCT00133809|Immunology
642829|NCT00133796|Breast Cancer
642830|NCT00133796|Advanced Breast Cancer
642831|NCT00133783|Intermedin
642832|NCT00133783|estradiol
642833|NCT00133783|female hypertension
642834|NCT00133783|Premenopausal and postmenopausal women
642835|NCT00133783|Surgically-induced menopause women
642836|NCT00133783|IVF treatment patients
642837|NCT00133770|IV pantoprazole
642838|NCT00133770|Esophagitis
642839|NCT00133757|Tobacco
642840|NCT00133757|Nicotine
642841|NCT00133757|Bupropion
642842|NCT00133757|Cue-reactivity
642843|NCT00133757|Craving
642844|NCT00133744|pregnancy
642845|NCT00133744|vitamins
642846|NCT00133744|minerals
642847|NCT00133744|supplements
642848|NCT00133744|mortality
642849|NCT00133744|prenatal
642850|NCT00133744|perinatal
642851|NCT00133744|anemia
642852|NCT00133744|birthweight
642853|NCT00133744|preterm
642854|NCT00133744|iron
642856|NCT00133744|Stillbirths
642857|NCT00133744|Early neonatal deaths
642858|NCT00133718|Type 2 diabetes mellitus
642859|NCT00133718|Cardiovascular
642860|NCT00133718|Coronary artery disease
642861|NCT00133718|Glycemic control
642862|NCT00133718|Treatment
642863|NCT00133718|Diabetes Mellitus
642864|NCT00133705|A benign tumor derived from smooth uterine muscle tissue.
642865|NCT00133692|Hypertension
642866|NCT00133692|Coronary Artery Disease
642867|NCT00133692|INVEST
642868|NCT00133692|Diabetes
642869|NCT00133692|Verapamil SR
642870|NCT00133692|Trandolapril
642871|NCT00133692|Atenolol
642872|NCT00133692|HCTZ
642873|NCT00133679|Chronic lung disease
642874|NCT00133679|Nitric oxide
642875|NCT00133679|cyclic guanosine monophosphate
642876|NCT00133679|phosphodiesterase inhibitor
642877|NCT00133653|Hypertension; Job Strain; Marital Strain; Blood Pressure
642878|NCT00133640|Vitamin D
642879|NCT00133640|Elderly
642880|NCT00133640|Hip fracture
642881|NCT00133640|Falls
642882|NCT00133640|Physical Therapy
642883|NCT00133640|Disability
642884|NCT00133627|Allergic
642885|NCT00133627|Conjunctivitis
642886|NCT00133627|Ketotifen
642887|NCT00133627|Histamine
642888|NCT00133588|influenza, vaccine, proteomic profiling, elderly
642889|NCT00133575|MVA, smallpox, Acambis
642890|NCT00133562|Malnutrition, pediatric, Brazil, alanyl-glutamine
642891|NCT00133549|pneumococcal vaccine, 23-valent polysaccharide vaccine, elderly
642892|NCT00133536|H5N1, Influenza, children
642893|NCT00133523|FLU-VACS, influenza, vaccine
642894|NCT00133510|children, immunocompromised, influenza, liver transplant
642895|NCT00133497|cytomegalovirus, vaccine, women, children, parent protocol
642896|NCT00133484|Anthrax, rPA
642897|NCT00133471|Influenza, vaccine, A/H9N2, MF59, adjuvant
642898|NCT00133458|Albenza, Subarachnoid cysticercosis
642899|NCT00133445|Pentavalent vaccine, Pediarix, DTaP-Hep B-IPV vaccine
642900|NCT00133432|Pneumonia, acute respiratory infections, zinc, Tanzania, children, infants, hospitalization
642901|NCT00133419|micronutrient, supplementation, Africa, children, HIV
642902|NCT00133406|Brazil, Child Nutrition Disorders, Deficiency Diseases
642903|NCT00133367|Hematologic malignancy
642904|NCT00133367|Cord blood transfusion
642905|NCT00133367|Graft versus host disease
642906|NCT00133367|tacrolimus
642907|NCT00133367|sirolimus
642908|NCT00133354|Puberty
642909|NCT00133354|Growth hormone deficiency
642910|NCT00133354|aromatase inhibitors
642911|NCT00133354|estrogen
642912|NCT00133354|bone mineral density
642913|NCT00133354|short stature
642914|NCT00133341|Allergic contact dermatitis,patch testing, dilution series
642915|NCT00133328|stroke
642916|NCT00133328|myocardial infarction
642917|NCT00133328|angina
642918|NCT00133328|renal damage
642919|NCT00133302|Non-Hodgkin's lymphoma
642920|NCT00133302|intermediate-grade lymphoma
642921|NCT00133302|high-grade lymphoma
642922|NCT00133302|CHOP protocol
642923|NCT00133302|granulocyte-colony stimulating factor
642924|NCT00133276|Hepatitis C
642925|NCT00133276|Peg-interferon
642926|NCT00133276|Psychiatric side-effects
642927|NCT00133263|Randomized controlled trial
642928|NCT00133263|Primary Care
642929|NCT00133224|Advanced Prostate Cancer
642930|NCT00133224|HRPC
642931|NCT00133224|Prostate
642932|NCT00133224|Cancer
642933|NCT00133224|Metastatic
642934|NCT00133224|Hormone-refractory
642935|NCT00133224|GVAX
642936|NCT00133224|Chemotherapy
642937|NCT00133224|Taxotere
642938|NCT00133224|Docetaxel
642939|NCT00133224|Prednisone
642940|NCT00133224|Vaccine
642941|NCT00133224|Allogeneic cells
642942|NCT00133211|Paroxysmal atrial fibrillation
642943|NCT00133211|Heart arrhythmia
642944|NCT00133211|Ablation
642945|NCT00133211|Drug treatment
642946|NCT00133172|Treatment Efficacy
642947|NCT00133172|Treatment Effectiveness
642948|NCT00133172|Anti-rejection therapy
642949|NCT00133172|Immunosuppression
642950|NCT00133172|Antirejection
642951|NCT00133172|Renal Transplantation
642952|NCT00133172|Transplantation, Renal
642953|NCT00133172|Transplantation, Kidney
642954|NCT00133172|Grafting, Kidney
642955|NCT00133159|Allergy
642956|NCT00133159|Specific Immunotherapy
642957|NCT00133146|Allergy
642958|NCT00133146|Specific Immunotherapy
642959|NCT00133133|Postoperative pain
642960|NCT00133133|Open cholecystectomy
642961|NCT00133133|Capsaicin
642962|NCT00133094|Hypercholesterolemia
642963|NCT00133094|Decision Support Systems, Clinical
642964|NCT00133081|epilepsy
642965|NCT00133081|antiepileptic drugs
642966|NCT00133081|side effects
642967|NCT00133081|quality of life
642968|NCT00133068|High Blood Pressure
642969|NCT00133068|Health Behaviors
642970|NCT00133068|Patient Compliance
642971|NCT00133055|parenting
642972|NCT00133055|sleep problems
642973|NCT00133055|behavior problems
642974|NCT00133055|brief intervention
642975|NCT00133055|self-help
642976|NCT00133055|preschool-age children
642977|NCT00133055|psychosocial
642978|NCT00133042|anti-IgE, omalizumab
642979|NCT00133016|Induction of labor
642980|NCT00132990|Cervical dystonia
642981|NCT00132990|Deep brain stimulation
642982|NCT00132977|Cardiac Resynchronization Therapy
642983|NCT00132977|Heart Failure
642984|NCT00132977|Mechanical Dyssynchrony
642985|NCT00132964|pediatric
642986|NCT00132964|ankle fractures
642987|NCT00132964|randomized controlled trial
642988|NCT00132964|management
642989|NCT00132925|allergic rhinitis
642990|NCT00132912|Platelets
642991|NCT00132912|Platelet Aggregation Inhibitors
642992|NCT00132912|Protease-Activated Receptor 1
642993|NCT00132912|Hemorrhage
642994|NCT00132899|Crohn's Disease
642995|NCT00132899|multi-centre randomized placebo-controlled
642996|NCT00132899|infliximab
642997|NCT00132899|methotrexate
642998|NCT00132899|inflammatory bowel disease
642999|NCT00132873|Narcolepsy
643000|NCT00132873|Cataplexy
643001|NCT00132847|Child
643002|NCT00132847|Adolescent
643003|NCT00132847|Urban Health
643004|NCT00132821|Nicotine dependence
643005|NCT00132821|Sleep disorders
643006|NCT00132821|smoking cessation
643007|NCT00132821|Relapse
643008|NCT00132808|Postmenopausal osteoporosis
643009|NCT00132808|osteopenia
643010|NCT00132808|zoledronic acid
643011|NCT00132808|Osteopenia (osteoporosis prevention)
643012|NCT00132795|Cognitive Therapy
643013|NCT00132795|Recurrence
643014|NCT00132795|Prevention
643015|NCT00132795|Educational Technology
643016|NCT00132756|Hormone Refractory
643017|NCT00132756|Taxane Refractory
643018|NCT00132704|Lung cancer metastases to the CNS (adenocarcinomas)
643019|NCT00132704|Melanoma metastases to the CNS
643020|NCT00132704|Breast cancer metastases to the CNS (ductal carcinomas)
643021|NCT00132704|Central nervous system gliomas
643022|NCT00132704|Colorectal cancers (adenocarcinomas)
643023|NCT00132704|Ovarian cancers (papillary serous carcinomas)
643024|NCT00132704|Endometrial cancers (endometrioid carcinomas)
643025|NCT00132704|Cervical cancers (squamous cell carcinomas)
643026|NCT00132704|Sarcomas (liposarcomas and leiomyosarcomas)
643027|NCT00132704|Thoracic mesotheliomas
643028|NCT00132704|Colorectal cancers metastatic to the liver
643029|NCT00132704|Primary adenocarcinomas of the lung
643030|NCT00132704|Primary squamous cell carcinomas of the lung
643031|NCT00132704|Pancreatic Cancers-adenocarcinoma
643032|NCT00132691|uveitis
643033|NCT00132691|non-infectious intermediate uveitis
643034|NCT00132691|non-infectious posterior uveitis
643035|NCT00132691|non-infectious panuveitis
643036|NCT00132678|Mood episodes
643037|NCT00132678|Bipolar 1 disorder
643038|NCT00132678|Intramuscular Injectable
643039|NCT00132678|risperidone
643040|NCT00132678|safety and efficacy
643041|NCT00132665|non-small cell lung cancer
643042|NCT00132665|elderly patients
643043|NCT00132665|carboplatin
643044|NCT00132665|chemoradiotherapy
643045|NCT00132639|pulmonary neoplasm
643046|NCT00132639|preoperative chemotherapy
643047|NCT00132639|cisplatin, docetaxel
643048|NCT00132639|randomized trial
643049|NCT00132639|clinical stage IB or II nonsmall cell lung cancer
643050|NCT00132626|parkinson
643051|NCT00132626|diagnosis
643052|NCT00132613|pulmonary neoplasm
643053|NCT00132613|malignant pericardial effusion
643054|NCT00132613|pericardial drainage
643055|NCT00132613|randomized trial
643056|NCT00132613|bleomycin
643057|NCT00132613|intrapericardial instillation
643058|NCT00132600|Allergic contact dermatitis
643059|NCT00132600|Patch testing
643060|NCT00132600|bacitracin
643061|NCT00132587|Knee arthroplasty
643062|NCT00132587|Femoral loosening
643063|NCT00132587|Total Knee Arthroplasty
643064|NCT00132574|acne, dairy
643065|NCT00132548|Malaria
643066|NCT00132548|Children
643067|NCT00132548|Intermittent preventive treatment
643068|NCT00132548|Senegal
643069|NCT00132535|Malaria in pregnancy
643070|NCT00132535|IPT
643071|NCT00132535|Sulphadoxine-pyrimethamine
643072|NCT00132535|Chloroquine
643073|NCT00132535|HIV
643074|NCT00132535|Viral load
643075|NCT00132535|birth weight
643076|NCT00132535|anaemia
643077|NCT00132522|EpCAM
643078|NCT00132522|monoclonal-antibody
643079|NCT00132522|targeted therapy
643080|NCT00132522|colorectal
643081|NCT00132522|prostate
643082|NCT00132522|non-small cell lung cancer
643083|NCT00132522|ovarian
643084|NCT00132522|solid tumor
643085|NCT00132509|rt-PA
643086|NCT00132509|thrombolysis
643087|NCT00132509|Acute ischemic stroke
643088|NCT00132496|GERD
643089|NCT00132483|Physical activity
643090|NCT00132483|cerebral infarct
643091|NCT00132457|Chlamydia
643092|NCT00132457|screening
643093|NCT00132457|Sexually transmitted disease
643094|NCT00132444|HIV
643095|NCT00132444|topical microbicides
643096|NCT00132431|calcimimetic
643097|NCT00132431|cinacalcet
643098|NCT00132431|hemodialysis
643099|NCT00132431|secondary hyperparathyroidism
643100|NCT00132431|chronic kidney disease
643101|NCT00132418|rheumatoid arthritis and at least 1 qualifying comorbid condition (diabetes, chronic pulmonary disease, recent infection)
643102|NCT00132418|RA
643103|NCT00132418|rheumatoid arthritis
643104|NCT00132405|Needlestick pain
643105|NCT00132405|Venipuncture pain
643106|NCT00132405|Procedural pain
643107|NCT00132392|Arthroplasty
643108|NCT00132392|Total knee arthroplasty
643109|NCT00132392|Capsaicin
643110|NCT00132392|Pain
643111|NCT00132392|Analgesia
643112|NCT00132366|Neurotransmission
643113|NCT00132366|Cortical Excitability
643114|NCT00132366|GABA
643115|NCT00132366|Seizures
643116|NCT00132366|Succinic Semialdehyde Dehydrogenase Deficiency
643117|NCT00132366|SSADH
643118|NCT00132366|Healthy Volunteer
643119|NCT00132366|HV
643120|NCT00132353|Magnetic Stimulation
643121|NCT00132353|Single Fiber EMG
643122|NCT00132353|Ultrasonography
643123|NCT00132353|Quantitative Sensory Testing
643124|NCT00132353|Near-nerve recording
643125|NCT00132353|Neurological Disorders
643126|NCT00132353|Neuromuscular Transmission Disorders
643127|NCT00132353|Central Demyelinating Disorders
643128|NCT00132353|Myelopathy
643129|NCT00132353|Motor Neuron Disease
643130|NCT00132353|Movement Disorders
643131|NCT00132353|Healthy Volunteer
643132|NCT00132340|Spasmodic Torticollis
643133|NCT00132340|Treatment
643134|NCT00132340|Physiology
643135|NCT00132340|Surgery
643136|NCT00132340|Cervical Dystonia
643137|NCT00132327|Lyme Disease
643138|NCT00132327|Borrelia Burgdorferi
643139|NCT00132327|Inflammation
643140|NCT00132327|Skin
643141|NCT00132327|Host Response
643142|NCT00132327|Erythema Migrans Rash
643143|NCT00132327|Healthy Volunteer
643144|NCT00132327|HV
643145|NCT00132301|multi-site clinical trial
643146|NCT00132301|prostate
643147|NCT00132301|radical prostatectomy
643148|NCT00132301|randomized
643149|NCT00132288|Aging
643150|NCT00132288|Frailty
643151|NCT00132288|Sedentary
643152|NCT00132288|Falls
643153|NCT00132288|Physical Activity
643154|NCT00132275|bacterial
643155|NCT00132275|sinusitis
643156|NCT00132275|treatment
643157|NCT00132275|diagnosis
643158|NCT00132275|guideline
643159|NCT00132275|acute bacterial sinusitis
643160|NCT00132262|Screening and Brief Intervention
643161|NCT00132262|Ethnic Differences
643162|NCT00132262|Trauma Center
643163|NCT00132249|Traumatic Brain Injury
643164|NCT00132249|Penetrating head wound
643165|NCT00132249|Closed head trauma
643166|NCT00132249|Vietnam Veteran
643167|NCT00132236|smoking cessation
643168|NCT00132236|nicotine sublingual tablets
643169|NCT00132236|behaviour support
643170|NCT00132236|smoking reduction
643171|NCT00132236|quality of life
643172|NCT00132236|COPD
643173|NCT00132236|weight
643174|NCT00132223|magnetic imaging
643175|NCT00132223|angiography
643176|NCT00132223|contrast agent
643177|NCT00132223|signal/noise ratio
643178|NCT00132223|contrast/noise ratio
643179|NCT00132223|vessel
643180|NCT00132210|acute hepatitis C
643181|NCT00132210|HIV
643182|NCT00132210|pegylated interferon
643183|NCT00132197|Functional somatic symptoms
643184|NCT00132197|Cognitive behavioral therapy
643185|NCT00132197|somatization disorder
643186|NCT00132197|SF-36
643187|NCT00132197|cost-effectiveness
643188|NCT00132197|Medically unexplained symptoms
643189|NCT00132184|Vitamin D
643190|NCT00132184|Crohns Disease
643191|NCT00132171|Helicobacter pylori
643192|NCT00132171|Eradication
643193|NCT00132171|Sequential therapy
643194|NCT00132171|Standard therapy
643195|NCT00132145|Vascular diseases
643196|NCT00132145|Computerized decision support systems
643197|NCT00132145|Shared care
643198|NCT00132145|Patient motivation
643199|NCT00132145|Quality of care
643200|NCT00132132|BMI
643201|NCT00132132|obesity
643202|NCT00132132|behavioral intervention
643203|NCT00132132|longterm randomized controlled trial
643204|NCT00132132|exercise
643205|NCT00132132|empowerment
643206|NCT00132132|nutrition
643207|NCT00132093|Left ventricular remodelling
643208|NCT00132093|Acute myocardial infarction
643209|NCT00132093|Left ventricular dysfunction
643210|NCT00132093|Eplerenone
643211|NCT00132093|Cardiac Magnetic Resonance Imaging
643212|NCT00132054|extensive stage small cell lung cancer
643213|NCT00132054|recurrent small cell lung cancer
643214|NCT00132041|adult primary hepatocellular carcinoma
643215|NCT00132041|localized unresectable adult primary liver cancer
643216|NCT00132015|Waldenström macroglobulinemia
643217|NCT00132015|multicentric Castleman disease
643218|NCT00132015|unicentric Castleman disease
643219|NCT00132015|adult grade III lymphomatoid granulomatosis
643220|NCT00132015|polycythemia vera
643221|NCT00132015|essential thrombocythemia
643222|NCT00132015|hairy cell leukemia
643223|NCT00132015|monoclonal gammopathy of undetermined significance
643224|NCT00132015|adult Burkitt lymphoma
643225|NCT00132015|adult diffuse large cell lymphoma
643226|NCT00132015|adult diffuse mixed cell lymphoma
643227|NCT00132015|adult diffuse small cleaved cell lymphoma
643228|NCT00132015|adult immunoblastic large cell lymphoma
643229|NCT00132015|adult lymphoblastic lymphoma
643230|NCT00132015|grade 1 follicular lymphoma
643231|NCT00132015|grade 2 follicular lymphoma
643232|NCT00132015|grade 3 follicular lymphoma
643233|NCT00132015|mantle cell lymphoma
643234|NCT00132015|marginal zone lymphoma
643235|NCT00132015|small lymphocytic lymphoma
643236|NCT00132015|precancerous condition
643237|NCT00131963|stage One A (IA) breast cancer
643238|NCT00131963|stage Two (II) breast cancer
643239|NCT00131963|stage Three A (IIIA) breast cancer
643240|NCT00131963|stage Three B(IIIB) breast cancer
643241|NCT00131963|stage Three C(IIIC) breast cancer
643242|NCT00131963|stage One B (IB) breast cancer
643243|NCT00131950|breast cancer
643244|NCT00131924|recurrent breast cancer
643245|NCT00131924|stage IV breast cancer
643246|NCT00131898|IMRT+Surgery versus Surgery For Sarcoma
643247|NCT00131885|Menstruation
643248|NCT00131885|Complementary Therapies
643249|NCT00131885|Pharmacokinetics
643250|NCT00131885|Hypericum
643251|NCT00131885|St. John's wort
643252|NCT00131885|Levonorgestrel
643253|NCT00131885|Women
643254|NCT00131872|vascular access graft
643255|NCT00131872|hemodialysis
643256|NCT00131872|dialysis
643257|NCT00131872|end stage renal disease
643258|NCT00131859|Perinatal brain injury
643259|NCT00131859|Diffusion-tensor imaging
643260|NCT00131846|Thiazide diuretics
643261|NCT00131846|Essential hypertension
643262|NCT00131846|Type 2 diabetes
643263|NCT00131846|Randomized clinical trial
643264|NCT00131846|Cost-effectiveness
643265|NCT00131833|salmonella
643266|NCT00131833|typhoid vaccine
643267|NCT00131833|enteric fever
643268|NCT00131820|Salmonella
643269|NCT00131820|typhoid vaccine
643270|NCT00131820|enteric fever
643271|NCT00131820|socioeconomic costs
643272|NCT00131807|Blood Pressure
643273|NCT00131807|HIV
643274|NCT00131807|Antiretroviral therapy
643275|NCT00131794|Malaria
643276|NCT00131794|BCG vaccine
643277|NCT00131794|Guinea Bissau
643278|NCT00131781|Borderline personality disorder
643279|NCT00131781|Controlled trials
643280|NCT00131781|Cognitive Therapy
643281|NCT00131781|Supportive Therapy
643282|NCT00131781|suicide
643283|NCT00131781|impulsivity
643284|NCT00131768|osteoarthritis of the ankle
643285|NCT00131768|musculoskeletal
643286|NCT00131755|type 1 diabetes
643287|NCT00131755|beta cell rest
643288|NCT00131755|diazoxide
643289|NCT00131755|insulin secretion
643290|NCT00131729|Amblyopia
643291|NCT00131729|Occlusion therapy
643292|NCT00131729|Compliance
643293|NCT00131729|Risk factors
643294|NCT00131716|prevention
643295|NCT00131716|recurrence
643296|NCT00131716|severe
643297|NCT00131716|anaemia
643298|NCT00131703|Screening
643299|NCT00131703|Treatment
643300|NCT00131703|Amodiaquine
643301|NCT00131703|Sulphadoxine-pyrimethamine
643302|NCT00131703|Malaria in pregnancy
643303|NCT00131690|Caffeine
643304|NCT00131690|Coffee
643305|NCT00131690|Randomized
643306|NCT00131690|Birth weight
643307|NCT00131651|renal
643308|NCT00131651|cancer
643309|NCT00131651|advanced
643310|NCT00131651|unresectable
643311|NCT00131651|metastatic
643312|NCT00131651|recurrent
643313|NCT00131651|anti-angiogenic
643314|NCT00131651|targeted
643315|NCT00131651|ATN-161
643316|NCT00131651|Recurrent renal cell cancer
643317|NCT00131651|Renal clear cell carcinoma
643318|NCT00131651|Advanced Renal Cell Cancer
643319|NCT00131638|Oncology
643320|NCT00131638|KGF
643321|NCT00131638|Palifermin
643322|NCT00131638|Oral mucositis
643323|NCT00131638|Clinical Trial
643324|NCT00131638|Amgen
643325|NCT00131638|head and neck
643326|NCT00131625|Exclusive breast-feeding
643327|NCT00131625|Mortality
643328|NCT00131625|Morbidity
643329|NCT00131625|Nutrition
643330|NCT00131625|Low income country
643331|NCT00131612|adjuvant therapy
643332|NCT00131612|epirubicin
643333|NCT00131612|uridine glucuronosyl/transferase 2B7
643334|NCT00131612|pharmacogenetics
643335|NCT00131599|5-fluorouracil
643336|NCT00131599|thymidylate synthase
643337|NCT00131599|pharmacogenetics
643338|NCT00131586|platinum analogues
643339|NCT00131586|cisplatin, carboplatin, oxaliplatin
643340|NCT00131586|proteomics
643341|NCT00131586|hemoglobin
643342|NCT00131573|Urgency-Frequency
643343|NCT00131573|Syndrome
643344|NCT00131573|Urinary
643345|NCT00131573|Refractory
643346|NCT00131573|Stimulation
643347|NCT00131573|Nerve
643348|NCT00131573|Neuromodulation
643349|NCT00131573|Microstimulator
643350|NCT00131573|bion
643351|NCT00131573|Pudendal
643352|NCT00131573|Overactive bladder
643353|NCT00131560|HIV, gene therapy, leukapheresis, autologous CD4 T cell, lentivector
643354|NCT00131547|Obesity
643355|NCT00131547|Obstructive Sleep Apnea
643356|NCT00131534|Complex trauma
643357|NCT00131534|Trauma recovery
643358|NCT00131534|Resiliency
643359|NCT00131534|Posttraumatic stress
643360|NCT00131534|Individual psychotherapy
643361|NCT00131534|Group psychotherapy
643362|NCT00131521|mucus obstruction, ventilator management
643363|NCT00131508|Hemoglobin S Disease
643364|NCT00131508|Sickle Cell Anemia
643365|NCT00131495|Low Libido
643366|NCT00131495|Low Desire
643367|NCT00131495|Distress
643368|NCT00131482|Chrysalin
643369|NCT00131482|TP508
643370|NCT00131482|Fracture
643371|NCT00131482|Wrist
643372|NCT00131482|Healing
643373|NCT00131469|Osteogenesis Imperfecta
643374|NCT00131469|Brittle Bone Disease
643375|NCT00131469|Fragility Fractures
643376|NCT00131456|cannabis dependence
643377|NCT00131456|depression
643378|NCT00131456|treatment
643379|NCT00131456|venlafaxine
643380|NCT00131443|Basilar/Hemiplegic Migraine
643381|NCT00131443|Prophylaxis
643382|NCT00131417|severe
643383|NCT00131417|malnutrition
643384|NCT00131417|ready-to-use-therapeutic-food
643385|NCT00131417|children
643386|NCT00131417|Uganda
643387|NCT00131378|Visceral obesity
643388|NCT00131378|Growth hormone
643389|NCT00131378|Cardiovascular risk
643390|NCT00131378|Insulin resistance
643391|NCT00131365|fibroids
643392|NCT00131365|Uterine Fibroids
643393|NCT00131365|ExAblate
643394|NCT00131365|MrgFUS
643395|NCT00131352|Osteoarthritis of the knee
643396|NCT00131352|Musculoskeletal
643397|NCT00131339|panic disorder
643398|NCT00131339|cognitive behavioral therapy
643399|NCT00131339|D-cycloserine
643400|NCT00131339|medication
643401|NCT00131339|treatment trial
643402|NCT00131339|placebo-controlled
643403|NCT00131339|double-blind
643404|NCT00131339|randomized
643405|NCT00131326|osteoarthritis of the hip
643406|NCT00131326|Musculoskeletal Diseases
643407|NCT00131313|Leukemia
643408|NCT00131313|Cancer
643409|NCT00131313|Nipent
643410|NCT00131313|Rituxan
643411|NCT00131313|Cytoxan
643412|NCT00131300|Osteoarthritis of the shoulder
643413|NCT00131300|Musculoskeletal
643414|NCT00131287|Agaricus Blazei Murill
643415|NCT00131287|type II DM
643416|NCT00131287|insulin index
643417|NCT00131274|Pulmonary Fibrosis
643418|NCT00131274|Respiratory Diseases
643419|NCT00131274|Interstitial Lung Disease
643420|NCT00131274|Usual Interstitial Pneumonia
643421|NCT00131261|Multiple Myeloma
643422|NCT00131261|Neoplasms
643423|NCT00131235|Malaria
643424|NCT00131235|STI
643425|NCT00131235|Pregnancy
643426|NCT00131235|Prevention
643427|NCT00131235|Preterm birth
643428|NCT00131235|Low birth weight
643429|NCT00131235|Sub-Saharan Africa
643430|NCT00131222|Infant
643431|NCT00131222|Malnutrition
643432|NCT00131222|Sub-Saharan Africa
643433|NCT00131222|Treatment
643434|NCT00131222|Growth
643435|NCT00131222|Haemoglobin
643436|NCT00131222|Fortified spread
643437|NCT00131222|Food supplement
643438|NCT00131209|Infant
643439|NCT00131209|Sub-Saharan Africa
643440|NCT00131209|Complementary feeding
643441|NCT00131209|Malnutrition
643442|NCT00131209|Growth
643443|NCT00131209|Fortified spread
643444|NCT00131209|Haemoglobin
643445|NCT00131196|pneumonia
643446|NCT00131196|peritonitis
643447|NCT00131196|sepsis
643448|NCT00131196|outcome
643449|NCT00131196|genomics
643450|NCT00131183|Angina Pectoris
643451|NCT00131183|Arteriosclerosis
643452|NCT00131183|Testosterone
643453|NCT00131157|Pulmonary Disease, Chronic Obstructive
643454|NCT00131157|Family Practice
643455|NCT00131157|Spirometry
643456|NCT00131157|Decision Support Systems
643457|NCT00131157|Feedback
643458|NCT00131144|Diabetic retinopathy,Octreotide Acetate in Microspheres
643459|NCT00131131|physical activity
643460|NCT00131131|cholelithiasis
643461|NCT00131131|pregnancy complication
643462|NCT00131118|Osteogenesis Imperfecta, Brittle bone disease, bisphosphonate, children
643463|NCT00131105|Healthy
643464|NCT00131105|Caregivers
643465|NCT00131105|Aging
643466|NCT00131092|exercise
643467|NCT00131092|aging
643468|NCT00131092|physical activity
643469|NCT00131079|Primary Health Care
643470|NCT00131079|Physicians, Family
643471|NCT00131079|Family Practice
643472|NCT00131079|Health Promotion
643473|NCT00131079|Randomized Controlled Trials
643474|NCT00131079|Multicenter Studies
643475|NCT00131079|Physical Fitness
643476|NCT00131079|Quality of Life
643477|NCT00131066|Previously enrolled on a MEDI-507 for psoriasis
643478|NCT00131053|acute lymphoblastic leukemia
643479|NCT00131053|newly diagnosed
643480|NCT00131053|BCR-ABL-negative
643481|NCT00131040|Cardiopulmonary
643482|NCT00131040|Surgery
643483|NCT00131040|leukocyte
643484|NCT00131040|inflammation
643485|NCT00131040|Coronary Artery Bypass Grafting
643486|NCT00131027|acute lymphoblastic leukemia
643487|NCT00131027|newly diagnosed
643488|NCT00131027|BCR-ABL-negative
643489|NCT00131014|Non-Hodgkin's Lymphoma
643490|NCT00131014|Hodgkin's disease
643491|NCT00131014|Chronic Lymphocytic Leukemia
643492|NCT00131014|Lymphoproliferative disorder
643493|NCT00131014|Genetics
643494|NCT00131001|Carotid artery stenosis
643495|NCT00131001|cost effectiveness
643496|NCT00131001|magnetic resonance angiography
643497|NCT00131001|computed tomography angiography
643498|NCT00131001|digital subtraction angiography
643499|NCT00130988|Somatoform Disorders
643500|NCT00130988|Medically unexplained symptoms
643501|NCT00130988|Physician-Patient Relations
643502|NCT00130988|Primary Health Care
643503|NCT00130988|Family Physician
643504|NCT00130988|psychosocial therapy
643505|NCT00130988|re-attribution of symptoms
643506|NCT00130988|cluster randomised controlled trial
643507|NCT00130975|Atrial fibrillation.
643508|NCT00130975|Cardioversion.
643509|NCT00130975|Recurrence.
643510|NCT00130975|Candesartan.
643511|NCT00130962|Intermetatarsal neuroma
643512|NCT00130962|Morton's neuroma
643513|NCT00130962|ALGRX 4975
643514|NCT00130962|capsaicin
643515|NCT00130949|Acute lateral epicondylitis
643516|NCT00130949|Tennis elbow
643517|NCT00130949|Capsaicin
643518|NCT00130936|phase I
643519|NCT00130936|epirubicin
643520|NCT00130936|solid tumors
643521|NCT00130923|Risperidone
643522|NCT00130923|Schizophrenia
643523|NCT00130923|Substance Use Disorder
643524|NCT00130923|Alcohol Use Disorder
643525|NCT00130923|Treatment
643526|NCT00130923|Schizoaffective Disorder
643527|NCT00130910|HIV
643528|NCT00130910|Helminthiasis
643529|NCT00130910|Co-infection
643530|NCT00130910|Intestinal immune activation
643531|NCT00130910|Treatment Naive
643532|NCT00130884|levosimendan
643533|NCT00130884|chronic heart failure
643534|NCT00130884|oral administration
643535|NCT00130871|levosimendan
643536|NCT00130871|weaning
643537|NCT00130871|cardio-pulmonary bypass
643538|NCT00130858|Sarcoma, Soft Tissue
643539|NCT00130845|Diabetic retinopathy, Octreotide Acetate in Microspheres
643540|NCT00130819|Drug Dependence
643541|NCT00130819|Opiate Dependence
643542|NCT00130819|Human Immunodeficiency Viruses
643543|NCT00130819|Buprenorphine
643544|NCT00130780|Multi-modality treatment for lung cancer
643545|NCT00130780|Carcinoma, Squamous Cell
643546|NCT00130780|Bevacizumab
643547|NCT00130780|BEACON
643548|NCT00130780|05-052
643549|NCT00130767|Prostate
643550|NCT00130767|apoptosis
643551|NCT00130767|finasteride kinetics
643552|NCT00130728|NSCLC
643553|NCT00130728|Avastin
643554|NCT00130728|Tarceva
643555|NCT00130728|Lung Cancer
643556|NCT00130715|Patients undergoing a variety of abdominal surgical procedures
643557|NCT00130702|AML
643558|NCT00130702|acute myelogenous leukemia
643559|NCT00130702|gefitinib
643560|NCT00130702|Iressa
643561|NCT00130689|Esophageal Cancer
643562|NCT00130689|Gastric Cancer
643563|NCT00130689|Metastatic Esophageal Cancer
643564|NCT00130689|Metastatic Gastric Cancer
643565|NCT00130689|Cetuximab
643566|NCT00130689|Metastatic Esophageal and Gastric Cancer
643567|NCT00130676|PMD
643568|NCT00130676|Psychotic Major Depression
643569|NCT00130676|Depression
643570|NCT00130676|Major Depression
643571|NCT00130676|Psychosis
643572|NCT00130650|IV
643573|NCT00130650|cannulation
643574|NCT00130650|Injections, Intravenous
643575|NCT00130637|Anterior Uveitis
643576|NCT00130637|Arthritis, Juvenile Idiopathic
643577|NCT00130637|Daclizumab
643578|NCT00130637|Iritis
643579|NCT00130637|Immunosuppression
643580|NCT00130637|Chronic Inflammatory Eye-Disease
643581|NCT00130637|Juvenile Idiopathic Arthritis
643582|NCT00130624|Falls
643583|NCT00130624|Elderly
643584|NCT00130624|multidisciplinary assessment
643585|NCT00130611|heart failure
643586|NCT00130611|cost effectiveness
643587|NCT00130611|BNP
643588|NCT00130611|private practice
643589|NCT00130611|Acute dyspnoea
643590|NCT00130598|contrast nephropathy
643591|NCT00130598|contrast media
643592|NCT00130598|renal dysfunction
643593|NCT00130585|Folate
643594|NCT00130585|Bioavailability
643595|NCT00130585|Stable isotopes
643596|NCT00130559|Respiratory failure
643597|NCT00130559|BNP
643598|NCT00130546|coronary artery disease
643599|NCT00130546|coronary intervention
643600|NCT00130546|drug eluting stent implantation
643601|NCT00130546|Cypher - Stent
643602|NCT00130546|Sirolimus
643603|NCT00130546|Taxus - Stent
643604|NCT00130546|Paclitaxel
643605|NCT00130533|TNBC Triple-Negative Early Breast Cancer
643606|NCT00130533|Maintenance Adjuvant Chemotherapy
643607|NCT00130533|Capecitabine
643608|NCT00130533|Basal-like genotype
643609|NCT00130520|advanced ovarian cancer
643610|NCT00130520|refractory ovarian cancer
643611|NCT00130520|primary peritoneal cancer
643612|NCT00130507|HER2 positive breast cancer.
643613|NCT00130507|Progression to trastuzumab and taxanes.
643614|NCT00130494|Non-symptomatic bone metastases.
643615|NCT00130481|Diabetes
643616|NCT00130481|Children
643617|NCT00130481|Adolescents
643618|NCT00130481|Arterial Compliance
643619|NCT00130481|Physiology Cardiovascular Endothelium
643620|NCT00130442|phase II
643621|NCT00130442|metastatic melanoma
643622|NCT00130442|dacarbazine
643623|NCT00130442|combination
643624|NCT00130442|PI-88
643625|NCT00130429|dementia
643626|NCT00130429|memory
643627|NCT00130429|Hopkins verbal learning test
643628|NCT00130429|paired associated learning
643629|NCT00130416|behavior
643630|NCT00130416|randomized trial
643631|NCT00130416|communication
643632|NCT00130416|patient
643633|NCT00130416|internet
643634|NCT00130416|coaching
643635|NCT00130416|self-efficacy
643636|NCT00130416|nurse
643637|NCT00130416|primary care
643638|NCT00130416|physician
643639|NCT00130416|screening
643640|NCT00130416|survey
643641|NCT00130416|pain
643642|NCT00130416|mobility
643643|NCT00130416|disability
643644|NCT00130416|depression
643645|NCT00130390|Crohn's Disease
643646|NCT00130377|Stem Cell
643647|NCT00130377|Heart
643648|NCT00130377|Lung
643649|NCT00130377|Vascular
643650|NCT00130377|cell therapy registry
643651|NCT00130364|Atopic dermatitis
643652|NCT00130364|T-cell
643653|NCT00130364|pimecrolimus
643654|NCT00130364|children
643655|NCT00130364|facial
643656|NCT00130364|Facial atopic dermatitis
643657|NCT00130351|asthma, formoterol multi-dose dry powder inhaler (MDDPI)
643658|NCT00130338|Dementia
643659|NCT00130338|Vascular
643660|NCT00130338|Rivastigmine
643661|NCT00130338|Stroke
643662|NCT00130338|Memory loss
643663|NCT00130325|ELISPOT,
643664|NCT00130325|tuberculosis,
643665|NCT00130325|Mycobacterium tuberculosis
643666|NCT00130325|Isoniazid
643667|NCT00130325|Clinical trial
643668|NCT00130312|Diabetes
643669|NCT00130312|Diabetic Nephropathy
643670|NCT00130312|Proteinuria
643671|NCT00130286|Lipodystrophy
643672|NCT00130286|HIV
643673|NCT00130286|Growth hormone
643674|NCT00130286|Rosiglitazone
643675|NCT00130286|Visceral fat
643676|NCT00130286|Metabolic syndrome
643677|NCT00130286|Treatment Experienced
643678|NCT00130286|Visceral fat accumulation
643679|NCT00130286|fat accumulation
643680|NCT00130286|HIV-Associated Metabolic Syndrome
643681|NCT00130273|HIV
643682|NCT00130273|AIDS
643683|NCT00130273|Problem Solving
643684|NCT00130273|Antiretroviral Therapy, Highly Active
643685|NCT00130273|Patient Compliance
643686|NCT00130260|Staphylococcus aureus
643687|NCT00130260|Vaccine
643688|NCT00130260|Randomized Controlled Trial
643689|NCT00130247|Tuberculosis, Uganda, Brazil, Philippines
643690|NCT00130234|urticaria
643691|NCT00130234|hives
643692|NCT00130234|Xolair
643693|NCT00130221|Chlorhexidine
643694|NCT00130221|Blood stream infections
643695|NCT00130221|central venous catheter associated
643696|NCT00130221|Nosocomial infection
643697|NCT00130221|Bacteremia
643698|NCT00130221|sepsis
643699|NCT00130221|Pneumonia
643700|NCT00130221|Urinary tract infection
643701|NCT00130221|Clostridium Difficile
643702|NCT00130221|intensive care unit
643703|NCT00130221|catheter
643704|NCT00130221|nosocomial pneumonia
643705|NCT00130221|Infection control
643706|NCT00130208|Diabetes
643707|NCT00130208|Diabetes Mellitus, Type 2
643708|NCT00130208|Albuminuria
643709|NCT00130208|Diabetic Nephropathy
643710|NCT00130195|acute lymphoblastic leukemia
643711|NCT00130195|BCR-ABL
643712|NCT00130195|Philadelphia-chromosome
643713|NCT00130195|newly diagnosed
643714|NCT00130182|lung disease
643715|NCT00130169|Cancer
643716|NCT00130169|malignant tumors
643717|NCT00130156|Blood pressure
643718|NCT00130156|SBP
643719|NCT00130156|DBP
643720|NCT00130117|leptin
643721|NCT00130117|hypothalamic amenorrhea
643722|NCT00130117|exercise-induced amenorrhea
643723|NCT00130117|neuroendocrine function
643724|NCT00130117|bone metabolism
643725|NCT00130104|digital block
643726|NCT00130104|regional anesthesia
643727|NCT00130104|finger repair
643728|NCT00130104|Fingers
643729|NCT00130104|Anesthesia, Conduction
643730|NCT00130091|unilateral
643731|NCT00130091|hernia
643732|NCT00130091|hydrocele
643733|NCT00130091|pediatric
643734|NCT00130091|clonidine
643735|NCT00130091|nerve block
643736|NCT00130078|HIV Seronegativity
643737|NCT00130078|HIV transmission
643738|NCT00130065|Malaria
643739|NCT00130065|Pregnancy
643740|NCT00130065|Sulfadoxine-pyrimethamine
643741|NCT00130065|Folic acid
643742|NCT00130065|Folate
643743|NCT00130039|Infarction, Cerebral
643744|NCT00130039|cilostazol
643745|NCT00130039|stenosis
643746|NCT00130039|atherosclerosis
643747|NCT00130039|clopidogrel
643748|NCT00130013|Children
643749|NCT00130013|Non-severe pneumonia
643750|NCT00130013|Oral amoxicillin
643751|NCT00130000|h5g.1
643752|NCT00130000|Paroxysmal Nocturnal Hemoglobinuria
643753|NCT00130000|SHEPHERD
643754|NCT00130000|PNH
643755|NCT00129987|Asthma
643756|NCT00129974|Lung cancer
643757|NCT00129974|Phase II
643758|NCT00129974|Drug Therapy
643759|NCT00129961|Kidney
643760|NCT00129961|Transplant
643761|NCT00129961|Skin Cancer
643762|NCT00129948|Acute myeloid leukemia
643763|NCT00129948|AML
643764|NCT00129948|refractory
643765|NCT00129948|relapsed
643766|NCT00129935|HER2 negative breast cancer
643767|NCT00129935|Node positive breast cancer
643768|NCT00129935|Adjuvant treatment
643769|NCT00129935|Oral chemotherapy
643770|NCT00129922|Axillary node positive breast cancer.
643771|NCT00129922|Sequential drug administration.
643772|NCT00129922|Weekly paclitaxel.
643773|NCT00129909|hypertension
643774|NCT00129909|family physicians
643775|NCT00129909|fixed dose combination therapy
643776|NCT00129909|cluster randomized controlled trial
643777|NCT00129896|Her2neu positive breast cancer.
643778|NCT00129896|Neoadjuvant treatment.
643779|NCT00129883|quality of care
643780|NCT00129883|antibiotic use
643781|NCT00129883|intervention
643782|NCT00129883|lower respiratory tract infections
643783|NCT00129883|Community acquired Pneumonia
643784|NCT00129883|Acute Exacerbation of Chronic Bronchitis or COPD
643785|NCT00129844|Motexafin Gadolinium
643786|NCT00129844|non-small cell, lung cancer
643787|NCT00129844|Lung cancer
643788|NCT00129844|cancer of the lung
643789|NCT00129844|Carcinoma, Non-Small-Cell Lung
643790|NCT00129831|COPD, indacaterol, PK
643791|NCT00129818|Genital herpes
643792|NCT00129818|viral shedding
643793|NCT00129818|famciclovir
643794|NCT00129818|Symptomatic genital herpes
643795|NCT00129818|Asymptomatic genital herpes
643796|NCT00129792|Blood Glucose
643797|NCT00129792|Cholesterol
643798|NCT00129792|Weight Loss
643799|NCT00129792|Insulin
643800|NCT00129792|Complementary Therapies
643801|NCT00129779|COPD
643802|NCT00129766|Respiratory Syncytial Virus (RSV)
643803|NCT00129766|motavizumab
643804|NCT00129766|palivizumab
643805|NCT00129766|Synagis
643806|NCT00129753|Campath-1H Monoclonal Antibody
643807|NCT00129753|Alemtuzumab
643808|NCT00129753|Campath
643809|NCT00129753|Campath-1H
643810|NCT00129753|Relapsed and Resistant Classical Hodgkin's Disease
643811|NCT00129753|Lymphoma
643812|NCT00129740|Chronic phase CML
643813|NCT00129740|Newly diagnosed chronic phase CML
643814|NCT00129740|AMN107
643815|NCT00129727|Carboplatin
643816|NCT00129727|Paclitaxel
643817|NCT00129727|Bevacizumab
643818|NCT00129727|Ovarian
643819|NCT00129727|Cancer
643820|NCT00129714|cervical radiculopathy conservative treatment
643821|NCT00129688|febrile neutropenia
643822|NCT00129688|once-daily
643823|NCT00129688|amikacin
643824|NCT00129688|cloxacillin
643825|NCT00129688|children
643826|NCT00129675|parkinson
643827|NCT00129675|diagnosis
643828|NCT00129610|Agoraphobia
643829|NCT00129610|panic disorder
643830|NCT00129610|Virtual Reality Therapy
643831|NCT00129610|Cognitive Behavior Therapy
643832|NCT00129610|cognition
643833|NCT00129610|spatial cognition
643834|NCT00129610|PANIC DISORDER WITH AGORAPHOBIA
643835|NCT00129597|Ketalar
643836|NCT00129597|NMDA
643837|NCT00129597|mastectomy
643838|NCT00129597|postoperative chronic pain
643839|NCT00129597|Chronic pain after mastectomy for breast cancer
643840|NCT00129584|Endobronchial Valve (EBV) Procedure
643841|NCT00129584|Bronchoscopic Lung Volume Reduction
643842|NCT00129545|Atrial Fibrillation
643843|NCT00129545|AF
643844|NCT00129545|A Fib
643845|NCT00129545|Stroke
643846|NCT00129545|Coumadin
643847|NCT00129545|Warfarin
643848|NCT00129545|Blood thinning medication
643849|NCT00129545|transient ischemic attack (TIA)
643850|NCT00129545|WATCHMAN
643851|NCT00129545|Left atrial appendage
643852|NCT00129545|LAA isolation
643853|NCT00129545|LAA occlusion
643854|NCT00129532|HIV transmission
643855|NCT00129519|BCC curettage
643856|NCT00129506|medical abortion
643857|NCT00129506|methotrexate
643858|NCT00129506|misoprostol
643859|NCT00129493|Practice guidelines
643860|NCT00129493|Hypertension
643861|NCT00129493|Primary health care
643862|NCT00129493|Patient-centered care
643863|NCT00129493|Healthcare quality
643864|NCT00129493|Office visits
643865|NCT00129493|Self-efficacy
643866|NCT00129493|Self care
643867|NCT00129493|Guideline adherence
643868|NCT00129493|Patient noncompliance
643869|NCT00129480|veterans
643870|NCT00129480|pain and chronic disease
643871|NCT00129480|disease management
643872|NCT00129480|depression
643873|NCT00129480|primary health care
643874|NCT00129480|practice guidelines
643875|NCT00129480|guideline adherence
643876|NCT00129480|narcotics
643877|NCT00129480|patient compliance
643878|NCT00129480|randomized controlled trial
643879|NCT00129467|Depression
643880|NCT00129467|Hospice Care
643881|NCT00129467|Antidepressive Agents
643882|NCT00129467|Methylphenidate
643883|NCT00129467|Central Nervous System Stimulant
643884|NCT00129467|Pain
643885|NCT00129467|Caregiver Burden
643886|NCT00129467|Cancer
643887|NCT00129454|Telemedicine
643888|NCT00129454|Cognitive Behavior Therapy
643889|NCT00129454|Utilization
643890|NCT00129454|Randomized Control Trial
643891|NCT00129454|Gulf War Illness
643892|NCT00129454|Symptom-Based Illness
643893|NCT00129454|Multisymptom Illness
643894|NCT00129454|High utilization
643895|NCT00129441|schizophrenia
643896|NCT00129428|UVB
643897|NCT00129428|keloid
643898|NCT00129428|scleroderma
643899|NCT00129428|acne keloidalis nuchae
643900|NCT00129428|scars
643901|NCT00129428|granuloma annulare
643902|NCT00129415|UVA1
643903|NCT00129415|UVB
643904|NCT00129415|atopic dermatitis
643905|NCT00129415|psoriasis
643906|NCT00129415|alopecia
643907|NCT00129415|mycosis fungoides (CTCL)
643908|NCT00129415|urticaria
643909|NCT00129415|inflammatory dermatoses
643910|NCT00129415|stretch marks
643911|NCT00129402|cholesterol
643912|NCT00129402|drugs
643913|NCT00129402|hypercholesterolemia
643914|NCT00129402|adolescent
643915|NCT00129402|randomized controlled trials
643916|NCT00129389|Node negative, high risk breast cancer.
643917|NCT00129389|Prognostic gene profile.
643918|NCT00129389|Saint Gallen high risk criteria.
643919|NCT00129389|Weekly paclitaxel.
643920|NCT00129376|Stage II and IIIA breast Cancer.
643921|NCT00129376|Neoadjuvant chemotherapy.
643922|NCT00129376|Weekly docetaxel.
643923|NCT00129363|Adolescent
643924|NCT00129363|Adrenergic alpha-Antagonists/therapeutic use
643925|NCT00129363|Adrenergic alpha-Antagonists/pharmacokinetics
643926|NCT00129363|Adrenergic alpha-Antagonists/administration & dosage
643927|NCT00129363|Adrenergic beta-Antagonists/therapeutic use
643928|NCT00129363|Adrenergic beta-Antagonists/pharmacokinetics
643929|NCT00129363|Adrenergic beta-Antagonists/administration & dosage
643930|NCT00129363|Age Factors
643931|NCT00129363|Carbazoles/therapeutic use
643932|NCT00129363|Carbazoles/administration & dosage
643933|NCT00129363|Child
643934|NCT00129363|Child, Preschool
643935|NCT00129363|Drug Administration Schedule
643936|NCT00129363|Female
643937|NCT00129363|Heart Failure, Congestive/etiology
643938|NCT00129363|Heart Failure, Congestive/drug therapy
643939|NCT00129363|Heart Failure, Congestive/blood
643940|NCT00129363|Human
643941|NCT00129363|Infant
643942|NCT00129363|Infant, Newborn
643943|NCT00129363|Male
643944|NCT00129363|Natriuretic Peptide, Brain/blood
643945|NCT00129363|Placebos
643946|NCT00129363|Propanolamines/therapeutic use
643947|NCT00129363|Propanolamines/administration & dosage
643948|NCT00129363|Prospective Studies
643949|NCT00129363|Support, Non-U.S. Gov't
643950|NCT00129363|Treatment Outcome
643951|NCT00129363|Ventricular Dysfunction/drug therapy
643952|NCT00129363|Ventricular Dysfunction/complications
643953|NCT00129363|Ventricular Dysfunction/blood
643954|NCT00129363|Ventricular Function/drug effects
643955|NCT00129363|Ventricular Remodeling/drug effects
643956|NCT00129350|End Stage Fibrotic Lung Disease
643957|NCT00129337|monoclonal antibody
643958|NCT00129337|phase 1
643959|NCT00129337|solid tumor
643960|NCT00129337|anti-angiogenesis
643961|NCT00129337|refractory advanced solid tumor malignancy
643962|NCT00129324|HOME
643963|NCT00129324|Environmental Exposure
643964|NCT00129324|Neurobehavior
643965|NCT00129324|Child Development
643966|NCT00129324|Lead Exposure
643967|NCT00129324|Child Injury
643968|NCT00129324|Adolescence
643969|NCT00129324|Adiposity
643970|NCT00129324|Neuroimaging
643971|NCT00129311|Tobacco
643972|NCT00129298|cocaine abuse
643973|NCT00129298|opiate dependent
643974|NCT00129298|tiagabine
643975|NCT00129298|methadone
643976|NCT00129285|cocaine
643977|NCT00129259|T1D
643978|NCT00129259|type 1 diabetes
643979|NCT00129259|type 1 diabetes mellitus
643980|NCT00129259|juvenile diabetes
643981|NCT00129259|autoimmune diabetes
643982|NCT00129259|autoimmune
643983|NCT00129259|anti-CD3 mAb
643984|NCT00129259|mAb hOKT3g1(Ala-Ala)
643985|NCT00129259|teplizumab
643986|NCT00129246|Tobacco
643987|NCT00129246|Smoking
643988|NCT00129246|Weight
643989|NCT00129246|Weight perception
643990|NCT00129246|Naltrexone
643991|NCT00129246|Bupropion
643992|NCT00129233|cardiovascular disease
643993|NCT00129233|rennin-angiotensin system
643994|NCT00129233|calcium channel blocker
643995|NCT00129233|impaired glucose tolerance
643996|NCT00129220|Manic or mixed episode associated with bipolar I disorder
643997|NCT00129207|pharmacokinetic
643998|NCT00129207|pharmacodynamics
643999|NCT00129207|VELCADE
644000|NCT00129207|Ketoconazole
644001|NCT00129207|CYP 3A4
644002|NCT00129207|Solid Tumor
644003|NCT00129207|Advanced Solid Tumors
644004|NCT00129194|HIV
644005|NCT00129194|Treatment Experienced
644006|NCT00129181|parkinson
644007|NCT00129181|brain imaging
644008|NCT00129181|diagnosis
644009|NCT00129168|Leukemia, Myeloid
644010|NCT00129168|Relapse
644011|NCT00129168|Chemotherapy
644012|NCT00129168|Zosuquidar
644013|NCT00129168|Daunorubicin
644014|NCT00129168|Cytarabine
644015|NCT00129168|Acute
644016|NCT00129168|AML
644017|NCT00129168|Adult AML
644018|NCT00129155|Allogenic stem cell transplantation
644019|NCT00129155|Treosulfan
644020|NCT00129155|Haematological malignancies
644021|NCT00129155|allogeneic stem cell transplantation in patients with hematological malignancies
644022|NCT00129142|Prostate cancer
644023|NCT00129142|Bone Loss
644024|NCT00129142|Osteoporosis
644025|NCT00129142|Fractures
644026|NCT00129142|Androgen Deprivation Therapy
644027|NCT00129129|Immunogenicity
644028|NCT00129129|Primary & booster vaccination
644029|NCT00129129|Infants
644030|NCT00129129|Meningococcal vaccine
644031|NCT00129129|Safety
644032|NCT00129129|Children
644033|NCT00129129|Hib disease
644034|NCT00129129|Meningococcal disease
644035|NCT00129116|Invasive bacterial disease caused by Hib
644036|NCT00129116|Neisseria meningitidis serogroups C & Y
644037|NCT00129077|Pediatric critical care
644038|NCT00129077|neuromuscular blocking agents
644039|NCT00129077|corneal abrasions
644040|NCT00129064|Referrals
644041|NCT00129064|Quality of care
644042|NCT00129064|Ambulatory care
644043|NCT00129064|Electronic medical record
644044|NCT00129064|Referral communication
644045|NCT00129051|tomotherapy
644046|NCT00129051|metastatic carcinoma
644047|NCT00129025|conformal hypofractionated radiotherapy
644048|NCT00129025|localized prostate cancer
644049|NCT00129012|radiation therapy
644050|NCT00129012|carcinoma
644051|NCT00129012|non-small cell lung
644052|NCT00128999|radiation therapy
644053|NCT00128986|radiotherapy
644054|NCT00128986|brain
644055|NCT00128973|CGD
644056|NCT00128973|LAD
644057|NCT00128973|XSCID
644058|NCT00128973|cGVHD
644059|NCT00128973|Infection
644060|NCT00128973|Abnormal Immune Function
644061|NCT00128973|Recurrent Infection
644062|NCT00128973|Chronic Granulomatous Disease
644063|NCT00128973|X-Linked Severe Combined Immune Deficiency (XSCID)
644064|NCT00128973|Leukocyte Adhesion Deficiency 1
644065|NCT00128973|Healthy Volunteer
644066|NCT00128973|HV
644067|NCT00128960|Allogeneic Hematopoietic Stem Cell Transplant
644068|NCT00128960|Health Related Quality of Life
644069|NCT00128960|Symptom Experience
644070|NCT00128960|Fatigue
644071|NCT00128960|Functional Status
644072|NCT00128960|Survey
644073|NCT00128960|Allogeneic Stem Cell Transplant
644074|NCT00128947|Immunosuppresant
644075|NCT00128947|Pharmacogenetics
644076|NCT00128947|Glucuronidation
644077|NCT00128947|Metabolism
644078|NCT00128947|UGT
644079|NCT00128934|Premenstrual Syndrome (PMS)
644080|NCT00128934|Hormone Therapy
644081|NCT00128921|Multiple Myeloma
644082|NCT00128908|HIV-1
644083|NCT00128908|HAART
644084|NCT00128908|sequential HAART
644085|NCT00128908|resistance
644086|NCT00128908|salvage therapy
644087|NCT00128908|Treatment Experienced
644088|NCT00128895|Wegener's granulomatosis, ANCA, vasculitis, proteinase 3
644089|NCT00128895|ANCA-associated vasculitis
644090|NCT00128895|ANCA
644091|NCT00128882|Idiopathic Thrombocytopenic Purpura
644092|NCT00128882|Treatment
644093|NCT00128882|Anti-D
644094|NCT00128882|Subcutaneous
644095|NCT00128882|Clinical evaluation
644096|NCT00128882|Platelet count
644097|NCT00128882|IVIG
644098|NCT00128869|Manipulation
644099|NCT00128869|Mobilization
644100|NCT00128869|Neck Pain
644101|NCT00128869|Physical Therapy
644102|NCT00128856|Neoadjuvant chemotherapy.
644103|NCT00128856|Stage III disease.
644104|NCT00128843|Metastatic breast cancer
644105|NCT00128843|First line of hormone treatment
644106|NCT00128843|Postmenopausal women
644107|NCT00128843|Positive hormone receptor tumours
644108|NCT00128830|Human Immunodeficiency Virus Type 1
644109|NCT00128830|HIV-1 infection
644110|NCT00128830|TMC125
644111|NCT00128830|Etravirine
644112|NCT00128830|Enfuvirtide
644113|NCT00128830|Antiretroviral therapy
644114|NCT00128817|neoplasm
644115|NCT00128817|larynx
644116|NCT00128817|surgery
644117|NCT00128817|radiotherapy
644118|NCT00128817|chemotherapy
644119|NCT00128804|vitamin A
644120|NCT00128804|beta Carotene
644121|NCT00128804|diet
644122|NCT00128804|nutrition
644123|NCT00128804|nutritional requirements
644124|NCT00128791|myocardial infarction
644125|NCT00128791|angioplasty
644126|NCT00128791|nitric oxide
644127|NCT00128791|prevention
644128|NCT00128791|acute myocardial infarction
644129|NCT00128778|Breast cancer
644130|NCT00128778|Metastases
644131|NCT00128778|Maintenance treatment
644132|NCT00128765|chronic obstructive pulmonary disease (COPD)
644133|NCT00128765|self-management
644134|NCT00128765|practice nurse
644135|NCT00128765|cost-effectiveness
644136|NCT00128765|randomized controlled trial
644137|NCT00128752|vitamin A
644138|NCT00128752|beta Carotene
644139|NCT00128752|diet
644140|NCT00128752|nutrition
644141|NCT00128752|nutritional requirements
644142|NCT00128726|continuous combined oral contraceptive
644143|NCT00128726|endometrial and ovarian suppression
644144|NCT00128713|Blood Transfusion
644145|NCT00128713|Blood Platelets
644146|NCT00128700|adult glioblastoma
644147|NCT00128700|adult giant cell glioblastoma
644148|NCT00128700|adult gliosarcoma
644149|NCT00128661|cervical intraepithelial neoplasia grade 2
644150|NCT00128661|cervical cancer
644151|NCT00128661|cervical intraepithelial neoplasia grade 3
644152|NCT00128635|adult glioblastoma
644153|NCT00128635|adult gliosarcoma
644154|NCT00128635|adult giant cell glioblastoma
644155|NCT00128635|recurrent adult brain tumor
644156|NCT00128622|male breast cancer
644157|NCT00128622|recurrent breast cancer
644158|NCT00128622|stage IV breast cancer
644159|NCT00128622|recurrent colon cancer
644160|NCT00128622|stage IV colon cancer
644161|NCT00128622|recurrent rectal cancer
644162|NCT00128622|stage IV rectal cancer
644163|NCT00128622|recurrent pancreatic cancer
644164|NCT00128622|extensive stage small cell lung cancer
644165|NCT00128622|recurrent non-small cell lung cancer
644166|NCT00128622|recurrent small cell lung cancer
644167|NCT00128622|stage IV non-small cell lung cancer
644168|NCT00128622|unspecified adult solid tumor, protocol specific
644169|NCT00128622|stage IV pancreatic cancer
644170|NCT00128596|adult primary hepatocellular carcinoma
644171|NCT00128596|advanced adult primary liver cancer
644172|NCT00128596|recurrent adult primary liver cancer
644173|NCT00128583|stage III melanoma
644174|NCT00128570|unspecified adult solid tumor, protocol specific
644175|NCT00128557|Vitamin A
644176|NCT00128557|Newborn health
644177|NCT00128557|Infant Mortality
644178|NCT00128557|Supplementation
644179|NCT00128557|Micronutrients
644180|NCT00128557|Bangladesh
644181|NCT00128531|Phase III
644182|NCT00128531|open label
644183|NCT00128531|multiple dose
644184|NCT00128531|safety study
644185|NCT00128531|pharmacokinetic study
644186|NCT00128531|efficacy study
644187|NCT00128518|Hypertension - Drugs - Blood pressure response - Responders - pharmacogenetics
644188|NCT00128505|PMD
644189|NCT00128505|Depression
644190|NCT00128505|Psychosis
644191|NCT00128505|Psychotic Major Depression
644192|NCT00128505|Major Depression
644193|NCT00128492|cystic fibrosis
644194|NCT00128492|Pseudomonas aeruginosa
644195|NCT00128479|PMD
644196|NCT00128479|Psychotic Depression
644197|NCT00128479|Psychosis
644198|NCT00128479|Major Depression
644199|NCT00128479|Depression
644200|NCT00128479|Psychotic Major Depression
644201|NCT00128466|bubonic plague
644202|NCT00128466|pneumonic plague
644203|NCT00128466|septicemic plague
644204|NCT00128466|Yersinia pestis
644205|NCT00128466|Pasteurella pestis
644206|NCT00128453|Pericarditis
644207|NCT00128453|Recurrence
644208|NCT00128453|Therapeutics
644209|NCT00128453|Prevention
644210|NCT00128453|Colchicine
644211|NCT00128427|Postpericardiotomy Syndrome
644212|NCT00128427|Pericarditis
644213|NCT00128427|Prevention
644214|NCT00128427|Colchicine
644215|NCT00128427|Recurrence
644216|NCT00128414|Pericarditis
644217|NCT00128414|Recurrence
644218|NCT00128414|Therapeutics
644219|NCT00128414|Prevention
644220|NCT00128414|Colchicine
644221|NCT00128401|Cognitive
644222|NCT00128401|Behavioral
644223|NCT00128401|Adolescent
644224|NCT00128401|Therapy
644225|NCT00128401|Extinction
644226|NCT00128401|Social Phobia
644227|NCT00128388|panic disorder,
644228|NCT00128388|psychodynamic psychotherapy,
644229|NCT00128388|efficacy trial
644230|NCT00128375|Smoking Cessation
644231|NCT00128375|Work-site
644232|NCT00128375|Incentives
644233|NCT00128375|Cost Effectiveness
644234|NCT00128375|Health Behavior
644235|NCT00128375|Smoking
644236|NCT00128362|Sentinel node
644237|NCT00128362|Axillary sampling
644238|NCT00128362|Operable breast cancer
644239|NCT00128336|Weight
644240|NCT00128336|Diet
644241|NCT00128336|exercise
644242|NCT00128336|maintenance
644243|NCT00128323|Children
644244|NCT00128323|oropharyngeal candidiasis
644245|NCT00128323|GV solution
644246|NCT00128323|nystatin drops
644247|NCT00128310|Drug-resistant metastatic breast cancer
644248|NCT00128297|Breast cancer patients with symptomatic bone metastases
644249|NCT00128284|gastroparesis
644250|NCT00128284|Digestive
644251|NCT00128284|Gastrointestinal
644252|NCT00128284|Stomach
644253|NCT00128284|Motility
644254|NCT00128284|Non-Invasive
644255|NCT00128284|Capsule
644256|NCT00128284|GI
644257|NCT00128284|Device
644258|NCT00128284|Digestive System Diseases
644259|NCT00128271|HCV
644260|NCT00128271|monoclonal antibody
644261|NCT00128271|phase 1
644262|NCT00128258|Stem Cell
644263|NCT00128258|Heart Failure
644264|NCT00128258|Bone Marrow
644265|NCT00128245|KCS
644266|NCT00128245|dry eye
644267|NCT00128245|pimecrolimus
644268|NCT00128245|Keratoconjunctivitis sicca (dry eye syndrome)
644269|NCT00128232|Acromegaly
644270|NCT00128232|untreated
644271|NCT00128232|newly diagnosed
644272|NCT00128232|octreotide LAR
644273|NCT00128219|Group B Streptococcus, women, vaccine
644274|NCT00128206|LTBI, tuberculosis, rifampin, isoniazid, prisoners
644275|NCT00128193|leprosy, Mycobacterium leprae, Hansen's Disease, skin test, Nepal
644276|NCT00128180|hantaviruses, methylprednisolone, cardiopulmonary syndrome
644277|NCT00128154|Chromium
644278|NCT00128154|Chromium picolinate
644279|NCT00128154|Blood Glucose
644280|NCT00128154|Cholesterol
644281|NCT00128154|Complementary Therapies
644282|NCT00128128|Vaccinium macrocarpon
644283|NCT00128128|Cranberry
644284|NCT00128128|Complementary Therapies
644285|NCT00128102|Advanced malignant pleural mesothelioma
644286|NCT00128089|Obesity
644287|NCT00128089|Dietary treatment
644288|NCT00128089|Fasting as medical therapy
644289|NCT00128076|shoulder surgery
644290|NCT00128076|rotator cuff
644291|NCT00128076|arthroscopic repair
644292|NCT00128076|mini-open repair
644293|NCT00128063|HIV-1
644294|NCT00128063|succinylated human serum albumin
644295|NCT00128063|Treatment Naive
644296|NCT00128050|Spontaneous intracerebral hemorrhage
644297|NCT00128050|ICH
644298|NCT00128050|intracerebral rebleeding
644299|NCT00128050|cerebral hematoma evacuation
644300|NCT00128050|cerebral hematoma volume
644301|NCT00128037|pulmonary neoplasm
644302|NCT00128037|preoperative chemoradiotherapy
644303|NCT00128037|surgical resection
644304|NCT00128037|superior sulcus tumor
644305|NCT00128037|chest wall invasion
644306|NCT00128037|mytomicin C
644307|NCT00128037|vindesine
644308|NCT00128037|cisplatin
644309|NCT00128024|randomized prospective study
644310|NCT00128024|lipid-lowering therapy with any available statins
644311|NCT00128024|multicenter study
644312|NCT00128024|Japanese
644313|NCT00128024|acute myocardial infarction
644314|NCT00128024|primary percutaneous coronary intervention
644315|NCT00128011|watery diarrhea
644316|NCT00128011|cholera vaccine
644317|NCT00127998|malaria
644318|NCT00127998|Plasmodium falciparum
644319|NCT00127998|drug resistance
644320|NCT00127998|antimalarials
644321|NCT00127998|genotype
644322|NCT00127998|treatment outcome
644323|NCT00127985|multiple organ dysfunction syndrome
644324|NCT00127985|corticosteroids
644325|NCT00127985|mortality
644326|NCT00127972|nevirapine
644327|NCT00127972|efavirenz
644328|NCT00127972|hiv-1
644329|NCT00127972|Treatment Experienced
644330|NCT00127959|HIV-1
644331|NCT00127959|HBV
644332|NCT00127959|treatment
644333|NCT00127959|tenofovir
644334|NCT00127959|emtricitabine
644335|NCT00127959|Treatment Naive
644336|NCT00127959|HIV-1 infection
644337|NCT00127959|Hepatitis B virus infection
644338|NCT00127907|Out-of-hospital cardiac arrest - Vasopressin - Epinephrine
644339|NCT00127881|Refractory or intolerant to Mycosis Fungoides and sezary syndrome
644340|NCT00127881|Cutaneous T-cell Lymphoma
644341|NCT00127881|To evaluate the efficacy and safety of zanolimumab in Mycosis Fungoides and sezary syndrome
644342|NCT00127868|Tinea Capitis
644343|NCT00127868|Children
644344|NCT00127868|Pediatric
644345|NCT00127868|Treatment
644346|NCT00127868|Therapy
644347|NCT00127868|Adjunctive
644348|NCT00127868|Selenium Sulfide
644349|NCT00127868|Ciclopirox
644350|NCT00127868|Shampoo
644351|NCT00127855|Invasive bacterial disease caused by Hib
644352|NCT00127855|Neisseria meningitidis serogroups C & Y
644353|NCT00127842|Psoriatic Arthritis
644354|NCT00127842|PsA
644355|NCT00127842|Commercial product
644356|NCT00127842|American College of Rheumatology
644357|NCT00127842|ACR/PASI
644358|NCT00127829|Solid Tumors
644359|NCT00127816|brachytherapy
644360|NCT00127816|implant radiotherapy
644361|NCT00127803|Clostridium difficile
644362|NCT00127790|Insomnia
644363|NCT00127790|Sleep
644364|NCT00127790|Pain
644365|NCT00127790|Pain, Chronic
644366|NCT00127790|Behavior Therapy
644367|NCT00127790|CBT
644368|NCT00127790|CBT-I
644369|NCT00127790|cognitive-behavioral
644370|NCT00127777|HCV genotype 1
644371|NCT00127777|peginterferon alfa-2a
644372|NCT00127777|ribavirin
644373|NCT00127777|amantadine
644374|NCT00127777|treatment-naive
644375|NCT00127764|pemphigus
644376|NCT00127764|dexamethasone
644377|NCT00127764|glucocorticoids
644378|NCT00127764|pulse
644379|NCT00127764|therapy
644380|NCT00127764|randomised
644381|NCT00127764|placebo-controlled
644382|NCT00127751|Risk factor reduction
644383|NCT00127751|cardiovascular disease prevention
644384|NCT00127738|Hypertension
644385|NCT00127738|Renal artery stenosis
644386|NCT00127738|Kidney disease
644387|NCT00127738|Renal vascular disease
644388|NCT00127738|Atherosclerosis
644389|NCT00127725|tibia
644390|NCT00127725|fracture
644391|NCT00127725|PEMF
644392|NCT00127725|electromagnetic
644393|NCT00127725|non-union
644394|NCT00127725|revision
644395|NCT00127725|Diaphyseal fractures of the tibia
644396|NCT00127712|amiodarone
644397|NCT00127712|atrial fibrillation
644398|NCT00127712|surgical procedures, thoracic
644399|NCT00127699|Umbilical cord
644400|NCT00127699|Triple dye
644401|NCT00127699|Infant care
644402|NCT00127686|cough
644403|NCT00127686|nocturnal cough
644404|NCT00127686|upper respiratory tract infection
644405|NCT00127686|sleep quality
644406|NCT00127686|childhood cough
644407|NCT00127686|Dextromethorphan
644408|NCT00127686|Honey
644409|NCT00127673|Antidepressants
644410|NCT00127673|Cognitive behavior therapy
644411|NCT00127660|Behavior
644412|NCT00127621|ICU patients needing prolonged ventilatory support
644413|NCT00127595|carcinoma of the urothelial tract
644414|NCT00127582|Myotonic dystrophy type 1
644415|NCT00127582|Sudden cardiac death
644416|NCT00127582|Ventricular tachyarrhythmias
644417|NCT00127582|Bradyarrhythmias
644418|NCT00127569|HIV infections
644419|NCT00127569|Giant Lymph Node Hyperplasia
644420|NCT00127569|Herpesvirus 8, Human
644421|NCT00127569|Rituximab (Mabthera)
644422|NCT00127569|Antibodies, Monoclonal
644423|NCT00127556|Transfusion
644424|NCT00127556|Safety
644425|NCT00127543|Medication Education
644426|NCT00127543|Pediatric
644427|NCT00127530|Walking Ability
644428|NCT00127517|Oncology
644429|NCT00127517|Palliative Care
644430|NCT00127517|Advanced Cancer
644431|NCT00127517|Palliative Cancer Care
644432|NCT00127504|Onchocerciasis
644433|NCT00127504|Wolbachia
644434|NCT00127504|Therapy
644435|NCT00127491|Acute Lung Injury
644436|NCT00127491|Acute Respiratory Distress Syndrome
644437|NCT00127491|Mechanical Ventilation
644438|NCT00127491|Esophageal Pressures
644439|NCT00127491|Randomized Controlled Trial
644440|NCT00127478|Hormone Refractory Prostate Cancer
644441|NCT00127478|Adenocarcinoma of the Prostate
644442|NCT00127465|Medical Informatics
644443|NCT00127465|Patient education
644444|NCT00127465|Social support
644445|NCT00127465|Cancer
644446|NCT00127465|Anxiety
644447|NCT00127452|alpha-linolenic acid
644448|NCT00127452|cardiovascular diseases
644449|NCT00127452|coronary heart disease
644450|NCT00127452|coronary patients
644451|NCT00127452|DHA
644452|NCT00127452|dietary intervention
644453|NCT00127452|dietary supplementation
644454|NCT00127452|docosahexaenoic acid
644455|NCT00127452|eicosapentaenoic acid
644456|NCT00127452|EPA
644457|NCT00127452|fish oil
644458|NCT00127452|fish fatty acids
644459|NCT00127452|human subjects
644460|NCT00127452|ischaemic heart disease
644461|NCT00127452|margarine
644462|NCT00127452|marine fatty acids
644463|NCT00127452|mortality
644464|NCT00127452|myocardial infarction
644465|NCT00127452|n-3 fatty acids
644466|NCT00127452|n-3 polyunsaturated fatty acids
644467|NCT00127452|n-3 PUFA
644468|NCT00127452|omega-3 fatty acids
644469|NCT00127452|omega-3 polyunsaturated fatty acids
644470|NCT00127452|prevention
644471|NCT00127452|randomized controlled trial
644472|NCT00127452|secondary prevention
644473|NCT00127439|Ambulatory Disability
644474|NCT00127439|Disability Ambulation
644475|NCT00127439|Locomotion Disorders
644476|NCT00127439|Motor Activity
644477|NCT00127439|Rehabilitation
644478|NCT00127439|Spinal Cord Injury
644479|NCT00127413|Chronic pain
644480|NCT00127413|Co-morbid
644481|NCT00127413|Intervention
644482|NCT00127413|Posttraumatic Stress Disorder
644483|NCT00127413|Treatment
644484|NCT00127400|anger
644485|NCT00127400|intermittent
644486|NCT00127400|explosive
644487|NCT00127387|Bone metastasis
644488|NCT00127387|Radiation therapy
644489|NCT00127387|Lung cancer
644490|NCT00127387|Prostate cancer
644491|NCT00127387|Advanced lung cancer receiving radiation therapy
644492|NCT00127387|Advanced prostate cancer receiving radiation therapy
644493|NCT00127387|Any cancer with bone mets receiving radiation therapy
644494|NCT00127374|Overweight; self-esteem; depression
644495|NCT00127361|doula
644496|NCT00127361|caregivers
644497|NCT00127361|labor support
644498|NCT00127361|being with woman
644499|NCT00127361|continuous labor support
644500|NCT00127361|maternal outcomes
644501|NCT00127361|Parturition
644502|NCT00127335|rhabdomyolysis,
644503|NCT00127335|myositis,
644504|NCT00127335|myopathy,
644505|NCT00127335|statin side effects,
644506|NCT00127335|fatty acid oxidation
644507|NCT00127335|Statin induced Muscle toxicity
644508|NCT00127322|Heart Failure, Congestive
644509|NCT00127322|survival
644510|NCT00127322|patient admission
644511|NCT00127309|hangover
644512|NCT00127309|hangover symptoms
644513|NCT00127270|OAB
644514|NCT00127270|Overactive Bladder
644515|NCT00127270|Bladder hyperactivity
644516|NCT00127270|Urge Incontinence
644517|NCT00127270|Incontinence
644518|NCT00127270|Bladder
644519|NCT00127257|Constipation
644520|NCT00127257|Biofeedback
644521|NCT00127257|Dyssynergia
644522|NCT00127257|Pelvic floor dyssynergia
644523|NCT00127257|Outlet dysfunction
644524|NCT00127231|Controlled Clinical Trials, Randomized
644525|NCT00127231|Alcohol Consumption
644526|NCT00127231|Behavioral Research
644527|NCT00127231|HIV
644528|NCT00127231|Alcohol Abuse
644529|NCT00127218|atherosclerotic plaque
644530|NCT00127218|MRI
644531|NCT00127218|inflammatory markers
644532|NCT00127218|statins
644533|NCT00127205|stage I breast cancer
644534|NCT00127205|stage II breast cancer
644535|NCT00127205|stage IIIA breast cancer
644536|NCT00127205|stage IIIB breast cancer
644537|NCT00127205|stage IIIC breast cancer
644538|NCT00127127|Solid tumors
644539|NCT00127114|Behavioral disturbance
644540|NCT00127114|Frontotemporal dementia
644541|NCT00127114|Dementia
644542|NCT00127114|Amantadine
644543|NCT00127114|Behavioral disturbance due to frontotemporal dementia
644544|NCT00127088|Patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate
644545|NCT00127075|Multiple sclerosis. Relapses. Post partum. Pregnancy. Delivery. Hormones. Progesterone. Estradiol. Clinical trial. Prevention.
644546|NCT00127062|Exposure to Oxford Street
644547|NCT00127062|Exposure to Hyde Park
644548|NCT00127049|Patients with relapsed non-seminomatous germ-cell tumors (NSGCT)
644549|NCT00127036|colon
644550|NCT00127036|adenocarcinoma
644551|NCT00127036|adenocarcinoma-colon
644552|NCT00127036|adenocarcinoma-rectum
644553|NCT00127023|Prophylaxis measles, mumps, rubella and chickenpox
644554|NCT00127010|Prophylaxis measles, mumps, rubella and chickenpox
644555|NCT00126997|Prophylaxis measles, mumps, rubella and chickenpox
644556|NCT00126984|Safety
644557|NCT00126984|Reactogenicity
644558|NCT00126984|Immunogenicity
644559|NCT00126984|Meningococcal vaccine
644560|NCT00126984|Dose selection
644561|NCT00126984|Conjugate vaccine
644562|NCT00126971|malaria
644563|NCT00126971|pregnancy
644564|NCT00126971|Plasmodium falciparum
644565|NCT00126971|antimalarials
644566|NCT00126971|pharmacokinetics
644567|NCT00126971|treatment outcome
644568|NCT00126971|safety
644569|NCT00126958|superficial urothelial cell carcinoma
644570|NCT00126958|urinary analysis
644571|NCT00126958|Loss of heterozygosity
644572|NCT00126958|FGFR3 mutation
644573|NCT00126958|follow-up
644813|NCT00126087|dopamine
644574|NCT00126945|Meningococcal serogroups A, C, W-135, Y disease
644575|NCT00126906|Malaria
644576|NCT00126906|Pregnancy
644577|NCT00126906|HIV
644578|NCT00126893|Leukemia
644579|NCT00126893|AML
644580|NCT00126893|CC401
644581|NCT00126893|CC-401
644582|NCT00126893|Celgene
644583|NCT00126893|High Risk Myeloid Leukemia
644584|NCT00126893|Myeloid Leukemia
644585|NCT00126880|Human Immunodeficiency Virus
644586|NCT00126880|anti-retroviral therapy
644587|NCT00126880|nucleoside analogue
644588|NCT00126880|reverse transcriptase
644589|NCT00126880|lamivudine
644590|NCT00126880|resistance mutation
644591|NCT00126880|Treatment Experienced
644592|NCT00126867|thymidylate synthase polymers
644593|NCT00126867|rapecitabine
644594|NCT00126867|adjuvant
644595|NCT00126867|colon cancer
644596|NCT00126867|toxicity
644597|NCT00126867|Stage II colon cancer
644598|NCT00126867|Stage III colon cancer
644599|NCT00126867|adenocarcinoma of the colon
644600|NCT00126854|brachytherapy
644601|NCT00126854|magnetic resonance spectroscopy
644602|NCT00126841|radiotherapy planning CT/MR fusion
644603|NCT00126828|radiotherapy, conformal
644604|NCT00126828|lung neoplasm
644605|NCT00126828|radiotherapy dosage
644606|NCT00126815|prostate cancer
644607|NCT00126815|prostate specific antigen
644608|NCT00126815|radiotherapy
644609|NCT00126815|mathematical modeling
644610|NCT00126802|tomotherapy
644611|NCT00126802|MRSZ
644612|NCT00126802|high risk prostate cancer
644613|NCT00126789|Pain Cancer
644614|NCT00126789|Chronic Pain
644615|NCT00126776|chronic obstructive pulmonary disease
644616|NCT00126776|case management
644617|NCT00126776|self management
644618|NCT00126763|Chronic Pain
644619|NCT00126763|Pain
644620|NCT00126750|Myocardial Infarction
644621|NCT00126750|Comorbidities
644622|NCT00126750|Guidelines
644623|NCT00126750|Computer Assisted Instruction
644624|NCT00126750|Physician Practice Instruction
644625|NCT00126750|Online Systems
644626|NCT00126737|Elderly
644627|NCT00126737|Exercise
644628|NCT00126737|lean body mass
644629|NCT00126737|muscle strength
644630|NCT00126737|Nutrition program
644631|NCT00126737|Pain control
644632|NCT00126737|stair climb
644633|NCT00126737|walking distance
644634|NCT00126737|weight loss
644635|NCT00126724|tgAAC94
644636|NCT00126724|Rheumatoid arthritis
644637|NCT00126724|Inflammatory arthritis
644638|NCT00126724|Arthritis
644639|NCT00126724|Gene therapy
644640|NCT00126724|AAV
644641|NCT00126698|Bacteriuria
644642|NCT00126698|Urinary Catheter
644643|NCT00126698|Urinary tract infection
644644|NCT00126698|Prophylaxis
644645|NCT00126698|Urinary catheter removal
644646|NCT00126685|stage IV melanoma
644647|NCT00126685|recurrent melanoma
644648|NCT00126672|angiomyolipoma
644649|NCT00126646|B-cell chronic lymphocytic leukemia
644650|NCT00126646|refractory chronic lymphocytic leukemia
644651|NCT00126646|recurrent grade 1 follicular lymphoma
644652|NCT00126646|recurrent grade 2 follicular lymphoma
644653|NCT00126646|stage III grade 1 follicular lymphoma
644654|NCT00126646|stage III grade 2 follicular lymphoma
644655|NCT00126646|stage IV grade 1 follicular lymphoma
644656|NCT00126646|stage IV grade 2 follicular lymphoma
644657|NCT00126646|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
644658|NCT00126646|nodal marginal zone B-cell lymphoma
644659|NCT00126646|recurrent marginal zone lymphoma
644660|NCT00126646|splenic marginal zone lymphoma
644661|NCT00126646|stage III marginal zone lymphoma
644662|NCT00126646|stage IV marginal zone lymphoma
644663|NCT00126646|recurrent mantle cell lymphoma
644664|NCT00126646|stage III mantle cell lymphoma
644665|NCT00126646|stage IV mantle cell lymphoma
644666|NCT00126646|recurrent small lymphocytic lymphoma
644667|NCT00126646|stage III small lymphocytic lymphoma
644668|NCT00126646|stage IV small lymphocytic lymphoma
644669|NCT00126646|recurrent adult diffuse small cleaved cell lymphoma
644670|NCT00126646|stage III adult diffuse small cleaved cell lymphoma
644671|NCT00126646|stage IV adult diffuse small cleaved cell lymphoma
644672|NCT00126646|Waldenstrom macroglobulinemia
644673|NCT00126646|prolymphocytic leukemia
644674|NCT00126633|adenocarcinoma of the pancreas
644675|NCT00126633|stage IV pancreatic cancer
644676|NCT00126620|unspecified adult solid tumor, protocol specific
644677|NCT00126581|A Phase II Randomized Study of OSI-774
644678|NCT00126555|squamous cell carcinoma of the skin
644679|NCT00126555|recurrent skin cancer
644680|NCT00126555|non-melanomatous skin cancer
644681|NCT00126555|Radiation
644682|NCT00126555|ZD1839
644683|NCT00126555|Iressa
644684|NCT00126555|Gefitinib
644685|NCT00126516|silent brain infarction
644686|NCT00126516|cognitive decline
644687|NCT00126516|Angiotensin II Type 1 Receptor Blockers
644688|NCT00126516|Angiotensin-Converting Enzyme Inhibitors
644689|NCT00126516|hypertension
644690|NCT00126477|quality of life
644691|NCT00126477|de novo myelodysplastic syndromes
644692|NCT00126477|previously treated myelodysplastic syndromes
644693|NCT00126477|secondary myelodysplastic syndromes
644694|NCT00126477|juvenile myelomonocytic leukemia
644695|NCT00126477|childhood Hodgkin lymphoma
644696|NCT00126477|childhood lymphoblastic lymphoma
644697|NCT00126477|childhood large cell lymphoma
644698|NCT00126477|childhood small noncleaved cell lymphoma
644699|NCT00126477|childhood acute lymphoblastic leukemia in remission
644700|NCT00126477|childhood acute myeloid leukemia in remission
644701|NCT00126477|childhood chronic myelogenous leukemia
644702|NCT00126464|ductal breast carcinoma in situ
644703|NCT00126464|breast cancer in situ
644704|NCT00126438|Heart Failure
644705|NCT00126438|nuclear cardiology
644706|NCT00126438|sympathetic innervation
644707|NCT00126438|123I-mIBG
644708|NCT00126425|Heart Failure
644709|NCT00126425|nuclear cardiology
644710|NCT00126425|sympathetic innervation
644711|NCT00126425|123I-mIBG
644712|NCT00126412|Phaeochromocytoma
644713|NCT00126412|Neuroblastoma
644714|NCT00126412|diagnosis
644715|NCT00126412|123I-mIBG
644716|NCT00126399|rosacea
644717|NCT00126399|acne rosacea
644718|NCT00126386|tumor induced hypercalcemia
644719|NCT00126386|malignant bone pain
644720|NCT00126386|bisphosphonates
644721|NCT00126386|cancer
644722|NCT00126386|palliative
644723|NCT00126386|Zometa
644724|NCT00126386|palliative patient
644725|NCT00126386|treatment in community
644726|NCT00126373|Crohn disease
644727|NCT00126373|TNF-alpha
644728|NCT00126360|Breast Cancer
644729|NCT00126360|Timing of Radiotherapy
644730|NCT00126360|Local Control
644731|NCT00126347|betaine
644732|NCT00126347|serine
644733|NCT00126347|folic acid
644734|NCT00126347|methionine load
644735|NCT00126347|homocysteine
644736|NCT00126347|cardiovascular health
644737|NCT00126347|vascular function
644738|NCT00126347|human
644739|NCT00126334|Myocardial Infarction
644740|NCT00126334|Anemia
644741|NCT00126334|Erythrocyte Transfusion
644742|NCT00126321|AML, relapsed
644743|NCT00126321|cladribine
644744|NCT00126321|chemotherapy
644745|NCT00126308|HIV
644746|NCT00126308|Lipodystrophy
644747|NCT00126308|Intervention
644748|NCT00126308|Poly-L-lactic acid
644749|NCT00126308|HIV facial lipoatrophy
644750|NCT00126308|Treatment Experienced
644751|NCT00126282|obsessive-compulsive disorder
644752|NCT00126282|behavior therapy
644753|NCT00126282|D-Cycloserine
644754|NCT00126282|medication
644755|NCT00126282|treatment trial
644756|NCT00126282|placebo-controlled
644757|NCT00126282|double-blind
644758|NCT00126282|randomized
644759|NCT00126269|Patients with Carcinoma of Unknown Primary and a Predicted Favorable Prognosis
644760|NCT00126256|Colorectal cancer
644761|NCT00126256|metastatic
644762|NCT00126256|chemotherapy
644763|NCT00126256|randomized trial
644764|NCT00126243|AIDS related Lymphoma
644765|NCT00126243|chemotherapy
644766|NCT00126243|rituximab
644767|NCT00126230|hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine
644768|NCT00126217|Non-specific effects of vaccines
644769|NCT00126217|Infant mortality
644770|NCT00126217|Morbidity
644771|NCT00126217|Low income country
644772|NCT00126217|Malaria
644773|NCT00126217|BCG
644774|NCT00126217|immunisation
644775|NCT00126217|BCG revaccination
644776|NCT00126217|Tuberculin
644777|NCT00126217|Mortality
644778|NCT00126204|endoleak
644779|NCT00126204|doxycycline
644780|NCT00126204|matrix metalloproteinase
644781|NCT00126204|inflammation
644782|NCT00126204|endograft
644783|NCT00126204|circulating markers
644784|NCT00126191|Burkitt Lymphoma
644785|NCT00126191|atypical Burkitt lymphoma
644786|NCT00126191|Non-Hodgkin's Lymphoma
644787|NCT00126191|rituximab
644788|NCT00126178|Kidney Cancer
644789|NCT00126178|Renal
644790|NCT00126178|Immunotherapy
644791|NCT00126178|Vaccine
644792|NCT00126165|prostate cancer
644793|NCT00126165|radiotherapy
644794|NCT00126165|hypofraction
644795|NCT00126165|radiosensitivity
644796|NCT00126165|image-guidance
644797|NCT00126152|Falls
644798|NCT00126152|Exercise
644799|NCT00126152|Fall Risk Factors
644800|NCT00126152|Older Adults
644801|NCT00126139|stroke, ischemic
644802|NCT00126139|stenosis, internal carotid artery
644803|NCT00126139|Acute ischemic stroke
644804|NCT00126139|Stenosis of extracranial internal carotid artery
644805|NCT00126126|Artificial Limbs
644806|NCT00126126|Evidence based medicine
644807|NCT00126126|Exercise
644808|NCT00126126|Outcomes research
644809|NCT00126126|Physical therapy
644810|NCT00126113|Audiologic rehabilitation
644811|NCT00126113|Counseling
644812|NCT00126100|Stem Cells
644814|NCT00126087|NMDA receptor
644815|NCT00126087|brain imaging
644816|NCT00126087|neuroplasticity
644817|NCT00126087|learning
644818|NCT00126087|transcranial direct current stimulation
644819|NCT00126087|rehabilitation
644820|NCT00126087|aging
644821|NCT00126074|Atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
644822|NCT00126061|Atrial fibrillation
644823|NCT00126061|atrial flutter
644824|NCT00126061|anti-arrhythmic agents
644825|NCT00126061|conversion to normal sinus rhythm
644826|NCT00126048|Atopy
644827|NCT00126048|Statin
644828|NCT00126048|Asthma
644829|NCT00126048|methacholine
644830|NCT00126048|FEV1
644831|NCT00126035|Acute Migraine
644832|NCT00126035|Device
644833|NCT00126035|Migraid
644834|NCT00126035|Treatment
644835|NCT00126035|Aura
644836|NCT00126022|Atrial fibrillation
644837|NCT00126022|atrial flutter
644838|NCT00126022|anti-arrhythmic agents
644839|NCT00126022|conversion to normal sinus rhythm
644840|NCT00125996|ANAEMIA
644841|NCT00125996|Iron Deficiency
644842|NCT00125983|Birth Control Pills
644843|NCT00125983|Oral Contraceptives
644844|NCT00125983|Contraceptive Patch
644845|NCT00125983|Pharmacokinetics
644846|NCT00125983|Antiretroviral Therapy, Highly Active
644847|NCT00125983|Protease Inhibitor
644848|NCT00125983|Treatment Experienced
644849|NCT00125983|Treatment Naive
644850|NCT00125983|Contraception
644851|NCT00125970|HIV Seronegativity
644852|NCT00125970|HIV Preventive Vaccine
644853|NCT00125957|depression
644854|NCT00125957|serotonin
644855|NCT00125957|norepinephrine
644856|NCT00125957|SSRI
644857|NCT00125957|Wellbutrin
644858|NCT00125957|bupropion
644859|NCT00125957|executive function
644860|NCT00125957|residual symptoms
644861|NCT00125931|bipolar disorder
644862|NCT00125931|mania
644863|NCT00125931|manic state
644864|NCT00125931|opiate
644865|NCT00125931|kappa
644866|NCT00125918|Hypertension, Pulmonary; Pulmonary Heart Disease
644867|NCT00125905|Primary Care
644868|NCT00125905|Smoking Cessation
644869|NCT00125905|Stages of Change Model
644870|NCT00125905|Health Education
644871|NCT00125905|Clinical Practice guideline
644872|NCT00125879|Glycogen Storage Disease Type II
644873|NCT00125879|GSD-II
644874|NCT00125879|Pompe Disease
644875|NCT00125879|Pompe Disease (Late-onset)
644876|NCT00125879|Acid Maltase Deficiency Disease
644877|NCT00125879|Glycogenosis 2
644878|NCT00125879|Glycogen Storage Disease Type II (GSD-II)
644879|NCT00125866|randomised double blind trial
644880|NCT00125866|blood pressure
644881|NCT00125866|cocoa flavonoids
644882|NCT00125853|blood pressure
644883|NCT00125853|insulin sensitivity
644884|NCT00125853|beta blockers
644885|NCT00125853|randomised double blind crossover trial
644886|NCT00125840|CLO151
644887|NCT00125840|Clolar
644888|NCT00125840|Pediatric ALL and AML
644889|NCT00125840|Adult ALL and AML and MDS
644890|NCT00125827|CLO152
644891|NCT00125827|Clolar
644892|NCT00125814|Interferon Alfa-2b
644893|NCT00125814|HIV infections
644894|NCT00125788|sickle cell disease
644895|NCT00125788|sickle cell anemia
644896|NCT00125788|L-glutamine
644897|NCT00125788|Sickle Cell Anemia (homozygous)
644898|NCT00125788|Sickle ß0-Thalassemia
644899|NCT00125749|Dendritic
644900|NCT00125749|Vaccine
644901|NCT00125749|Melanoma
644902|NCT00125749|Stage IV metastatic melanoma
644903|NCT00125723|Phase 4 Clinical Trial
644904|NCT00125723|Chemotherapy
644905|NCT00125723|Neulasta®
644906|NCT00125723|Oncology
644907|NCT00125723|Malignancy
644908|NCT00125710|cryogenic analysis
644909|NCT00125710|oncogenes
644910|NCT00125697|malignant glioma
644911|NCT00125697|spectroscopy
644912|NCT00125697|magnetic resonance
644913|NCT00125684|transdermal morphine
644914|NCT00125684|cancer
644915|NCT00125684|pain
644916|NCT00125684|bioavailability
644917|NCT00125684|pharmacokinetics
644918|NCT00125684|cancer related pain
644919|NCT00125684|stable baseline pain
644920|NCT00125684|currently taking opioids
644921|NCT00125671|Warfarin and Antiplatelet Vascular Evaluation
644922|NCT00125671|Peripheral vascular disease
644923|NCT00125671|Atherosclerosis
644924|NCT00125671|cardiovascular events
644925|NCT00125671|Ischemia
644926|NCT00125671|oral anticoagulants
644927|NCT00125671|low ankle-brachial index
644928|NCT00125671|moderate intensity warfarin
644929|NCT00125671|International normalized ratio [INR]
644930|NCT00125658|biomechanics
644931|NCT00125658|Cerebrovascular Accident
644932|NCT00125658|electromyography
644933|NCT00125658|muscular weakness
644934|NCT00125658|recovery of function
644935|NCT00125658|reflex variability stroke
644936|NCT00125658|upper-extremity kinematics
644937|NCT00125645|AMI
644938|NCT00125645|Left ventricular function
644939|NCT00125645|Myocardial performance index
644940|NCT00125645|Acute myocardial infarction (AMI)
644941|NCT00125632|Reading
644942|NCT00125632|Rehabilitation
644943|NCT00125632|Treatment Outcomes
644944|NCT00125632|Low vision
644945|NCT00125619|biomechanics
644946|NCT00125619|stroke
644947|NCT00125619|electromyography
644948|NCT00125619|Gait disability stroke
644949|NCT00125619|locomotor therapy
644950|NCT00125619|muscular weakness
644951|NCT00125619|reflex variability stroke
644952|NCT00125606|AML
644953|NCT00125606|allogeneic HSCT
644954|NCT00125606|reduced intensity conditioning
644955|NCT00125606|randomized trail
644956|NCT00125593|Kidney Disease, Chronic
644957|NCT00125593|LDL cholesterol
644958|NCT00125593|simvastatin
644959|NCT00125593|ezetimibe
644960|NCT00125593|cardiovascular disease
644961|NCT00125593|atherosclerosis
644962|NCT00125580|Obesity
644963|NCT00125580|Childhood Obesity
644964|NCT00125580|Infant Sleep
644965|NCT00125580|Infant growth
644966|NCT00125580|Infant feeding
644967|NCT00125554|Clinical trial
644968|NCT00125554|double-blind
644969|NCT00125554|randomized placebo-controlled trial
644970|NCT00125554|metyrapone
644971|NCT00125554|Major Depression
644972|NCT00125541|MeSH: angioneurotic edema, complement 1 inactivators
644973|NCT00125541|Hereditary Angioedema Type I or II, Acquired Angioedema
644974|NCT00125528|chronic pain
644975|NCT00125528|low back pain
644976|NCT00125528|D-cycloserine
644977|NCT00125515|Heroin
644978|NCT00125515|Opiates
644979|NCT00125515|naltrexone
644980|NCT00125515|memantine
644981|NCT00125502|CMV, Cytomegalovirus, vaccine, women, postpartum
644982|NCT00125489|chloroquine, malaria, sulfadoxine/pyrimethamine, Malawi
644983|NCT00125476|Postmenopause
644984|NCT00125463|Hypertension
644985|NCT00125463|clinical trial
644986|NCT00125463|Candesartan Antihypertensive Survival Evaluation in Japan trial
644987|NCT00125463|candesartan cilexetil
644988|NCT00125463|amlodipine besilate
644989|NCT00125450|Acute Bronchiolitis
644990|NCT00125450|Chest Physiotherapy
644991|NCT00125450|Forced Expiratory Techniques
644992|NCT00125450|Double Blind Trial
644993|NCT00125450|Children
644994|NCT00125450|Pediatric
644995|NCT00125450|RESPIRATORY SYNCYTIAL VIRUS
644996|NCT00125437|aldosterone antagonists
644997|NCT00125437|spironolactone
644998|NCT00125437|left ventricular remodeling
644999|NCT00125424|Colonoscopy
645000|NCT00125424|Sedation
645001|NCT00125424|AQUAVAN
645002|NCT00125424|(fospropofol disodium)
645003|NCT00125424|Endoscopic sedation
645004|NCT00125424|Endoscopic outcomes
645005|NCT00125424|Endoscopy
645006|NCT00125411|satraplatin
645007|NCT00125411|docetaxel
645008|NCT00125411|cancer
645009|NCT00125411|Phase I
645010|NCT00125411|advanced solid tumors
645011|NCT00125398|AQUAVAN
645012|NCT00125398|GPI 15715
645013|NCT00125398|ICU
645014|NCT00125398|Sedation
645015|NCT00125385|IPF
645016|NCT00125385|Idiopathic
645017|NCT00125385|Pulmonary
645018|NCT00125385|Fibrosis
645019|NCT00125372|tarceva
645020|NCT00125372|targretin
645021|NCT00125372|non-small cell lung cancer
645022|NCT00125372|carcinoma, non-small cell lung cancer
645023|NCT00125372|nsclc
645024|NCT00125359|tarceva
645025|NCT00125359|targretin
645026|NCT00125359|non-small cell lung cancer
645027|NCT00125359|Carcinoma, non-small cell lung cancer
645028|NCT00125359|NSCLC
645029|NCT00125346|Tobramycin Inhalation Powder
645030|NCT00125333|atopic dermatitis, eczema
645031|NCT00125320|Treatment
645032|NCT00125307|SLE
645033|NCT00125307|glomerulonephritis
645034|NCT00125307|immunosuppressive therapy
645035|NCT00125307|type V (membranous) lupus nephritis
645036|NCT00125294|cancer pain
645037|NCT00125294|breakthrough pain
645038|NCT00125294|methadone
645039|NCT00125294|dose titration
645040|NCT00125294|sublingual route of administration
645041|NCT00125294|Cancer related pain
645042|NCT00125294|currently taking narcotics
645043|NCT00125281|Fatigue
645044|NCT00125281|Cirrhosis
645045|NCT00125281|S-Adenosyl Methionine
645046|NCT00125281|Primary Biliary Cirrhosis
645047|NCT00125281|Pruritus
645048|NCT00125281|Symptomatic Releif
645049|NCT00125281|Serum Liver-Related Enzymes
645050|NCT00125281|PBC
645051|NCT00125281|Liver Disease
645052|NCT00125268|painful
645053|NCT00125268|peripheral
645054|NCT00125268|neuropathy
645055|NCT00125268|light
645056|NCT00125268|therapy
645057|NCT00125242|Aphasia
645058|NCT00125242|Language therapy
645059|NCT00125242|Rehabilitation of speech and language disorders
645303|NCT00124176|Children
645060|NCT00125242|Speech-language pathology
645061|NCT00125229|Hypertonic Saline
645062|NCT00125229|Mannitol
645063|NCT00125229|Intracranial hypertension
645064|NCT00125229|Cerebral blood flow
645065|NCT00125229|Traumatic brain injury
645066|NCT00125216|Aphasia
645067|NCT00125216|Language Therapy
645068|NCT00125216|Rehabilitation of speech and language disorders
645069|NCT00125216|Speech-language pathology
645070|NCT00125203|ALS
645071|NCT00125203|Lou Gehrig's Disease
645072|NCT00125203|Motor Neuron Disease
645073|NCT00125203|Amyotrophic Lateral Sclerosis
645074|NCT00125203|Sialorrhea
645075|NCT00125203|Hypersalivation
645076|NCT00125203|Excessive Drooling
645077|NCT00125203|Myobloc
645078|NCT00125203|botulinum toxin type B
645079|NCT00125203|Clostridium botulinum B toxin
645080|NCT00125203|botulinum B toxin
645081|NCT00125203|botulinum neurotoxin B
645082|NCT00125203|NeuroBloc
645083|NCT00125190|Primary IGF-1 Deficiency
645084|NCT00125190|IGF-1
645085|NCT00125177|pelvic muscle therapy
645086|NCT00125177|urinary incontinence therapy
645087|NCT00125177|stress incontinence intervention
645088|NCT00125177|incontinence intervention
645089|NCT00125177|Incontinence
645090|NCT00125177|SUI
645091|NCT00125177|Stress Incontinence
645092|NCT00125164|Primary IGF-1 Deficiency
645093|NCT00125151|MeSH: angioneurotic edema, complement 1 inactivators
645094|NCT00125151|Hereditary angioedema type I or II, Acquired angioedema
645095|NCT00125125|Dyslipidemia, adults, fluvastatin
645096|NCT00125112|binge eating
645097|NCT00125112|weight loss
645098|NCT00125112|obesity
645099|NCT00125099|Acute Infection
645100|NCT00125099|Treatment Experienced
645101|NCT00125099|Treatment Interruption
645102|NCT00125099|HIV Therapeutic Vaccine
645103|NCT00125086|wounds
645104|NCT00125086|healing
645105|NCT00125086|Acute wounds healing by secondary intention
645106|NCT00125073|Standard Care
645107|NCT00125073|Nutritional Counseling
645108|NCT00125060|Aorta
645109|NCT00125060|Atherosclerosis
645110|NCT00125060|MRI
645111|NCT00125060|statin
645112|NCT00125060|inflammatory markers
645113|NCT00125047|Salmonellosis
645114|NCT00125047|typhoid vaccine
645115|NCT00125047|enteric fever
645116|NCT00125034|FOLFOX-4
645117|NCT00125034|Cetuximab
645118|NCT00125034|First-line mCRC
645119|NCT00125034|EGFR positive
645120|NCT00125034|metastatic CRC
645121|NCT00125021|Second Line Therapy
645122|NCT00125021|Gemcitabine Refractory
645123|NCT00125021|Pancreatic Cancer
645124|NCT00125021|Capecitabine
645125|NCT00125021|Tarceva
645126|NCT00125021|OSI-774
645127|NCT00125021|Metastatic Pancreatic Cancer
645128|NCT00125008|Salmonella
645129|NCT00125008|Typhoid vaccine
645130|NCT00125008|enteric fever
645131|NCT00124969|End-stage renal disease, hemodialysis
645132|NCT00124943|Prevention of Instent Restenosis
645133|NCT00124930|olanzapine
645134|NCT00124930|haldol
645135|NCT00124930|cancer
645136|NCT00124930|nausea
645137|NCT00124930|second line treatment
645138|NCT00124930|refractory nausea
645139|NCT00124917|Prostate Cancer
645140|NCT00124917|MRI
645141|NCT00124917|Fiducial Marker
645142|NCT00124917|IMRT
645143|NCT00124904|Biofeedback
645144|NCT00124904|Incontinence
645145|NCT00124891|Arrhythmias
645146|NCT00124878|HIV
645147|NCT00124878|STDs
645148|NCT00124878|Male circumcision
645149|NCT00124878|HIV+ males
645150|NCT00124878|HIV-negative males
645151|NCT00124878|Female partners
645152|NCT00124878|STDs such as the following:
645153|NCT00124878|HPV
645154|NCT00124878|HSV-2
645155|NCT00124878|HIV Seronegativity
645156|NCT00124865|Campylobacter
645157|NCT00124865|Bacterial enteritis
645158|NCT00124852|cognition
645159|NCT00124852|depression
645160|NCT00124852|elderly
645161|NCT00124839|Dissociation
645162|NCT00124839|Flashbacks
645163|NCT00124839|Self-injurious behavior
645164|NCT00124826|stroke
645165|NCT00124826|cerebrovascular disease
645166|NCT00124826|hyperglycemia
645167|NCT00124826|magnetic resonance imaging
645168|NCT00124826|acute ischemic stroke
645169|NCT00124800|tinnitus
645170|NCT00124774|hernia
645171|NCT00124774|nucleoplasty
645172|NCT00124774|radicular pain
645173|NCT00124774|Contained lumbar herniated disc
645174|NCT00124761|Radiosurgery
645175|NCT00124761|Brain metastases
645176|NCT00124761|Whole Brain Radiotherapy
645177|NCT00124761|Neurosurgery
645178|NCT00124761|Solitary Brain Metastases
645179|NCT00124761|Adult Tumours Metastatic to Brain
645180|NCT00124748|CML
645181|NCT00124748|Philadelphia positive
645182|NCT00124748|Bcr-abl
645183|NCT00124748|imatinib mesylate
645184|NCT00124748|Chronic myeloid leukemia (CML) in chronic phase
645304|NCT00124163|CT Virtual Colonoscopy
645185|NCT00124709|Atopic, dermatitis, asthma, children, modification
645186|NCT00124709|Atopic dermatitis/atopy
645187|NCT00124696|cocaine dependence
645188|NCT00124683|nicotine dependence
645189|NCT00124657|adult anaplastic astrocytoma
645190|NCT00124657|adult anaplastic oligodendroglioma
645191|NCT00124657|adult glioblastoma
645192|NCT00124657|adult giant cell glioblastoma
645193|NCT00124657|adult gliosarcoma
645194|NCT00124657|adult mixed glioma
645195|NCT00124657|childhood mixed glioma
645196|NCT00124657|untreated childhood cerebellar astrocytoma
645197|NCT00124657|childhood high-grade cerebral astrocytoma
645198|NCT00124657|childhood low-grade cerebral astrocytoma
645199|NCT00124657|childhood oligodendroglioma
645200|NCT00124657|childhood spinal cord neoplasm
645201|NCT00124644|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
645202|NCT00124644|adult acute myeloid leukemia with t(16;16)(p13;q22)
645203|NCT00124644|untreated adult acute myeloid leukemia
645204|NCT00124644|secondary acute myeloid leukemia
645205|NCT00124618|stage IIIA non-small cell lung cancer
645206|NCT00124618|stage IIIB non-small cell lung cancer
645207|NCT00124579|stage I multiple myeloma
645208|NCT00124579|stage II multiple myeloma
645209|NCT00124579|stage III multiple myeloma
645210|NCT00124579|refractory multiple myeloma
645211|NCT00124566|Irofulven
645212|NCT00124566|Docetaxel
645213|NCT00124566|Taxotere
645214|NCT00124553|Type 2 diabetes
645215|NCT00124553|cardiovascular risk
645216|NCT00124553|glycaemic control
645217|NCT00124553|dietary modification
645218|NCT00124540|Misoprostol
645219|NCT00124540|Active management
645220|NCT00124540|Postpartum hemorrhage
645221|NCT00124540|Maternal morbidity
645222|NCT00124540|Anemia
645223|NCT00124540|Developing countries
645224|NCT00124527|Irofulven, Thyroid Cancer
645225|NCT00124514|SLE
645226|NCT00124514|Lupus
645227|NCT00124514|Ovarian damage
645228|NCT00124514|Menopause
645229|NCT00124501|Biofeedback
645230|NCT00124488|radiotherapy planning
645231|NCT00124488|computer assisted radiotherapy
645232|NCT00124488|conformal
645233|NCT00124475|Chronic Hand Dermatitis
645234|NCT00124436|Patients who have been enrolled in study protocol BAP089, and whose severe chronic hand dermatitis responded with mild or moderate disease, or who relapsed
645235|NCT00124423|brachytherapy megavoltage CT imaging
645236|NCT00124410|prostate cancer
645237|NCT00124410|androgen suppression therapy (hormone therapy)
645238|NCT00124410|osteoporosis
645239|NCT00124384|primary insomnia, stimulants, cognitive behavioral therapy
645240|NCT00124371|coronary artery bypass surgery
645241|NCT00124371|risk factors
645242|NCT00124371|nurse-led secondary prevention
645243|NCT00124371|prehabilitation
645244|NCT00124371|waiting period
645245|NCT00124358|Drug Abuse
645246|NCT00124358|Drug Addiction
645247|NCT00124358|Drug Dependence
645248|NCT00124358|Drug Use Disorders
645249|NCT00124358|Drug Use Disorder
645250|NCT00124358|Substance Abuse
645251|NCT00124358|Substance Use Disorder
645252|NCT00124358|Buprenorphine
645253|NCT00124358|Opiate Addiction
645254|NCT00124358|Substance-related disorders
645255|NCT00124358|HIV
645256|NCT00124345|temperature
645257|NCT00124345|humidity
645258|NCT00124345|non invasive mechanical ventilation
645259|NCT00124319|Biomechanics
645260|NCT00124319|Neuromuscular
645261|NCT00124319|Lower limb
645262|NCT00124319|Injury
645263|NCT00124319|ACL
645264|NCT00124319|Anterior Cruciate Ligament injury
645265|NCT00124306|painful bladder syndrome
645266|NCT00124306|interstitial cystitis
645267|NCT00124306|newly diagnosed
645268|NCT00124280|Lung cancer
645269|NCT00124280|non-small cell
645270|NCT00124280|everolimus
645271|NCT00124280|Non-small cell lung cancer (NSCLC)
645272|NCT00124267|Cerebral
645273|NCT00124267|malaria
645274|NCT00124267|intra-rectal
645275|NCT00124267|quinine
645276|NCT00124267|children
645277|NCT00124267|Uganda
645278|NCT00124267|efficacy
645279|NCT00124267|safety
645280|NCT00124254|Metacarpophalangeal Joint
645281|NCT00124254|Arthroplasty
645282|NCT00124254|Outcomes
645283|NCT00124254|Michigan Hand Outcomes Questionnaire
645284|NCT00124254|Joint Replacement
645285|NCT00124228|Cirrhosis
645286|NCT00124228|Infection
645287|NCT00124228|Sepsis
645288|NCT00124228|Renal failure
645289|NCT00124215|Hepatitis
645290|NCT00124215|HCV
645291|NCT00124215|vaccine
645292|NCT00124215|Hepatitis C Infection
645293|NCT00124202|a fatty meal
645294|NCT00124202|ERCP
645295|NCT00124189|Chronic lymphocytic leukemia
645296|NCT00124189|T-cell prolymphocytic leukemia
645297|NCT00124189|Chronic lymphoproliferative diseases
645298|NCT00124189|Telomerase
645299|NCT00124189|Telomerase Inhibition
645300|NCT00124176|Asthma
645301|NCT00124176|Levalbuterol
645302|NCT00124176|Albuterol
645305|NCT00124163|Optical Colonoscopy
645306|NCT00124163|Stool Tagging
645307|NCT00124163|Patient Preparation
645308|NCT00124150|subarachnoid hemorrhage
645309|NCT00124150|magnesium sulfate
645310|NCT00124137|Ultrafiltration
645311|NCT00124137|acute decompensated heart failure
645312|NCT00124137|fluid overload
645313|NCT00124137|pulmonary congestion
645314|NCT00124111|clinical trial
645315|NCT00124111|pegfilgrastim
645316|NCT00124111|haematopoietic growth factor
645317|NCT00124111|neutropenia
645318|NCT00124111|CMF
645319|NCT00124111|Cancer
645320|NCT00124098|Chronic Kidney Disease (CKD)
645321|NCT00124098|anemia, clinical trial
645322|NCT00124098|darbepoetin alfa
645323|NCT00124098|Aranesp®
645324|NCT00124098|Amgen
645325|NCT00124072|Myocardial infarction
645326|NCT00124072|Coronary heart disease
645327|NCT00124072|Cholesterol
645328|NCT00124072|Stroke
645329|NCT00124059|alcohol dependence
645330|NCT00124046|Urinary Incontinence in Children
645331|NCT00124046|Surgical Section of the Filum Terminale
645332|NCT00124046|Occult Tethered Cord Syndrome
645333|NCT00124046|Urodynamic Scale
645334|NCT00124046|Enuresis-Specific Quality of Life Scale
645335|NCT00124033|Cholecystectomy
645336|NCT00124033|Cholangiopancreatography, Endoscopic Retrograde
645337|NCT00124007|HIV Seronegativity
645338|NCT00124007|HIV Preventive Vaccine
645339|NCT00123994|TaiChi
645340|NCT00123994|Hydrotherapy
645341|NCT00123994|Exercise
645342|NCT00123994|Joint pain
645343|NCT00123994|Disability
645344|NCT00123981|Off-pump Coronary Artery By-pass Grafting
645345|NCT00123981|Randomization
645346|NCT00123981|stroke
645347|NCT00123981|myocardial infarction
645348|NCT00123981|mortality
645349|NCT00123981|graft patency
645350|NCT00123981|quality of life
645351|NCT00123968|HIV Seronegativity
645352|NCT00123968|HIV Preventive Vaccine
645353|NCT00123942|CD2+ Lymphoproliferative disorder
645354|NCT00123929|breast cancer
645355|NCT00123929|neoadjuvant chemotherapy
645356|NCT00123929|genetic signature
645357|NCT00123929|doxorubicin
645358|NCT00123929|docetaxel
645359|NCT00123916|Chagas Disease
645360|NCT00123916|Trypanosomiasis
645361|NCT00123916|Benznidazole
645362|NCT00123916|Chronic Heart disease
645363|NCT00123916|Trypanosoma Cruzi
645364|NCT00123903|hypertension
645365|NCT00123903|urine albumin:creatinine ratio
645366|NCT00123903|microalbuminuria
645367|NCT00123890|HIV-1 GW873140 CCR5 antagonist experienced
645368|NCT00123877|Breast
645369|NCT00123877|Cancer
645370|NCT00123877|Metastasis
645371|NCT00123864|intensity modulated radiation therapy
645372|NCT00123864|parotid
645373|NCT00123864|nasopharyngeal carcinoma
645374|NCT00123851|Colorectal
645375|NCT00123851|Metastatic Colorectal Cancer
645376|NCT00123851|Oxaliplatin
645377|NCT00123851|Tarceva
645378|NCT00123851|Capecitabine
645379|NCT00123851|Xeloda
645380|NCT00123838|Prostate
645381|NCT00123838|Cancer
645382|NCT00123838|Radiotherapy
645383|NCT00123838|Neoplasm
645384|NCT00123838|Localization
645385|NCT00123838|Tracking
645386|NCT00123838|Cancer of Prostate
645387|NCT00123838|Neoplasms, Prostate
645388|NCT00123825|Gallbladder
645389|NCT00123825|Biliary Tract
645390|NCT00123825|Cholangiocarcinoma
645391|NCT00123812|quality assurance
645392|NCT00123812|frequency of port films
645393|NCT00123799|positron emission tomography
645394|NCT00123799|fluorodeoxyglucose F18
645395|NCT00123799|sentinel lymph node biopsy
645396|NCT00123786|positron emission tomography
645397|NCT00123786|fluorodeoxyglucose F18
645398|NCT00123786|tomography scanners, x-ray computed
645399|NCT00123773|positron emission tomography
645400|NCT00123773|fluorodeoxyglucose F18
645401|NCT00123773|Tomography scanners, x-ray computed
645402|NCT00123760|Positron-Emission Tomography
645403|NCT00123760|Fluorodeoxyglucose F18
645404|NCT00123760|Tomography scanners, X-Ray computed
645405|NCT00123747|Positron Emission Tomography
645406|NCT00123747|Fluorodeoxyglucose F18
645407|NCT00123747|Tomography scanners, X-Ray Computed
645408|NCT00123708|Spasticity
645409|NCT00123708|Dystonia
645410|NCT00123708|Movement Disorders
645411|NCT00123708|Walking
645412|NCT00123708|Muscle Weakness
645413|NCT00123708|Resistance
645414|NCT00123708|Gait
645415|NCT00123708|Cerebral Palsy
645416|NCT00123708|CP
645417|NCT00123695|Subarachnoid hemorrhage
645418|NCT00123695|Takotsubo cardiomyopathy
645419|NCT00123695|Cardiac abnormalities
645420|NCT00123695|outcome
645421|NCT00123682|Smoking Cessation
645422|NCT00123682|Care Management
645423|NCT00123682|Substance Use Disorder QUERI
645424|NCT00123682|Primary Care
645425|NCT00123682|Regional Expansion
645426|NCT00123682|Telephone
645427|NCT00123669|Cancer of the Breast
645428|NCT00123669|Neoplasm
645429|NCT00123656|Eosinophilic esophagitis
645430|NCT00123656|esomeprazole
645431|NCT00123656|fluticasone
645432|NCT00123643|thiazolidinedione
645433|NCT00123643|sulfonylurea
645434|NCT00123643|endothelial function
645435|NCT00123630|eosinophilic esophagitis
645436|NCT00123630|omalizumab
645437|NCT00123617|Chest pain
645438|NCT00123617|Women
645439|NCT00123617|Syndrome X
645440|NCT00123617|Cardiac rehabilitation
645441|NCT00123617|Psychological morbidity
645442|NCT00123617|Cardiovascular risk factors
645443|NCT00123604|beta-blockers
645444|NCT00123604|endothelial function
645445|NCT00123565|Coronary Disease
645446|NCT00123552|Uganda, malaria, combination antimalarial therapy
645447|NCT00123487|Accelerated Phase Chronic Myeloid Leukemia
645448|NCT00123487|Lymphoid Blast Phase Chronic Myeloid Leukemia
645449|NCT00123487|Myeloid Blast Phase Chronic Myeloid Leukemia
645450|NCT00123487|Philadelphia Positive Acute Lymphoblastic Leukemia
645451|NCT00123474|Chronic Phase Chronic Myelogenous Leukemia
645452|NCT00123448|Mirror Neurons
645453|NCT00123448|fMRI
645454|NCT00123448|Premotor Cortex
645455|NCT00123448|gesture
645456|NCT00123448|Healthy Volunteer
645457|NCT00123448|HV
645458|NCT00123435|Behavioral Research
645459|NCT00123435|Nutritional management
645460|NCT00123435|Physical activity
645461|NCT00123435|Prevention
645462|NCT00123435|Randomized control trial
645463|NCT00123435|walking program
645464|NCT00123435|Weight loss
645465|NCT00123435|World wide web
645466|NCT00123422|Breathing exercise
645467|NCT00123422|Exercise Therapy
645468|NCT00123422|Helium
645469|NCT00123422|Oxygen inhalation therapy
645470|NCT00123422|Pulmonary emphysema
645471|NCT00123422|Pulmonary ventilation
645472|NCT00123422|Rehabilitation
645473|NCT00123409|Primary Care
645474|NCT00123409|Telephone
645475|NCT00123409|Quality of Life
645476|NCT00123396|Bioterrorism
645477|NCT00123396|Education, Medical, Continuing
645478|NCT00123396|Internet
645479|NCT00123383|Modafinil
645480|NCT00123383|Cocaine Dependence
645481|NCT00123383|Randomised placebo-controlled trial
645482|NCT00123370|Modafinil
645483|NCT00123370|Amphetamine Dependence
645484|NCT00123370|Randomised placebo-controlled trial
645485|NCT00123344|symptomatic bradycardia
645486|NCT00123344|paroxysmal atrial fibrillation
645487|NCT00123344|antitachycardia pacing therapies
645488|NCT00123344|prevention algorithms
645489|NCT00123331|Heart transplantation
645490|NCT00123331|Renal failure
645491|NCT00123331|Cyclosporine
645492|NCT00123331|Rapamycin
645493|NCT00123318|Gastric cancer
645494|NCT00123318|Radiotherapy
645495|NCT00123318|Chemotherapy
645496|NCT00123318|Chemoradiation
645497|NCT00123305|Stroke
645498|NCT00123305|Acute Ischemic Stroke
645499|NCT00123292|arterial occlusion
645500|NCT00123292|thromboembolism
645501|NCT00123292|Acute Peripheral Arterial Occlusion
645502|NCT00123279|diabetic macular edema
645503|NCT00123279|macular hole
645504|NCT00123279|vitreomacular traction syndrome
645505|NCT00123266|stroke
645506|NCT00123266|vertebrobasilar
645507|NCT00123266|basilar
645508|NCT00123266|Acute vertebrobasilar artery occlusion
645509|NCT00123253|HIV
645510|NCT00123253|Lipodystrophy
645511|NCT00123253|Abdominal fat accumulation
645512|NCT00123253|Growth hormone releasing factor/Growth hormone releasing hormone
645513|NCT00123253|Treatment Experienced
645514|NCT00123240|overweight
645515|NCT00123240|obese
645516|NCT00123240|diet
645517|NCT00123227|Randomised controlled trial
645518|NCT00123227|Rosiglitazone
645519|NCT00123227|Cardiovascular magnetic resonance
645520|NCT00123227|Diabetes Mellitus
645521|NCT00123227|Vascular Diseases
645522|NCT00123227|Hypertension
645523|NCT00123214|Diet
645524|NCT00123214|Chronic sleep deprivation
645525|NCT00123214|Weight
645526|NCT00123214|Cognitive impairment
645527|NCT00123214|Lipids
645528|NCT00123214|Inflammation
645529|NCT00123214|Resting metabolic rate
645530|NCT00123214|Weight Gain
645531|NCT00123214|Percent Body Fat
645532|NCT00123214|Hyperlipidemia
645533|NCT00123201|efficacy & safety, migraine headache, placebo-controlled
645534|NCT00123201|migraine headache with or without aura
645535|NCT00123175|Endometrial Hyperplasia without atypia
645536|NCT00123162|Sildenafil
645537|NCT00123149|Anemia
645538|NCT00123149|Rheumatoid arthritis
645539|NCT00123149|Hemoglobin level
645540|NCT00123136|pulsed magnetic field therapy
645541|NCT00123136|diabetic peripheral neuropathy
645542|NCT00123136|neuromodulation
645543|NCT00123136|diabetic peripheral neuropathic pain
645544|NCT00123136|sleep benefit
645545|NCT00123136|diabetic peripheral neuropathic functioning
645546|NCT00123123|Ventilator-associated pneumonia
645547|NCT00123097|Facial Neoplasms
645548|NCT00123097|Head and Neck Neoplasms
645549|NCT00123097|Head Injuries, Penetrating
645550|NCT00123097|Birth Injuries
645551|NCT00123084|Parkinson's disease
645552|NCT00123084|Swallowing difficulties
645553|NCT00123084|speech
645554|NCT00123084|voice
645555|NCT00123058|Hypertension
645556|NCT00123058|Cariovascular Diseases
645557|NCT00123058|Health Illiteracy
645558|NCT00122980|Blood Diseases
645559|NCT00122954|Fatty Acids, Omega-3
645560|NCT00122954|Fish Oils
645561|NCT00122954|Complementary Therapies
645562|NCT00122941|multiple
645563|NCT00122941|micronutrients
645564|NCT00122941|supplementation
645565|NCT00122941|HIV
645566|NCT00122941|children
645567|NCT00122941|randomised
645568|NCT00122941|trial
645569|NCT00122941|mortality
645570|NCT00122941|morbidity
645571|NCT00122941|growth
645572|NCT00122941|Uganda
645573|NCT00122928|Worksite
645574|NCT00122928|Workplace
645575|NCT00122928|Return on Investment
645576|NCT00122928|Financial Impact
645577|NCT00122915|Motor Cortex Stimulation
645578|NCT00122915|Pain treatment
645579|NCT00122915|Central post-stroke pain (CPSP)
645580|NCT00122915|Trigeminal neuropathic pain (TGN)
645581|NCT00122915|Facial pain
645582|NCT00122915|Neurostimuation
645583|NCT00122915|Cortical lead
645584|NCT00122915|Neuropathic pain
645585|NCT00122902|HIV
645586|NCT00122902|AIDS
645587|NCT00122902|Spirituality
645588|NCT00122889|Drug Interactions
645589|NCT00122889|Pharmacokinetics
645590|NCT00122889|Garlic
645591|NCT00122889|Complementary Therapies
645592|NCT00122889|Complementary and Alternative Medicine
645593|NCT00122876|Hepatocellular Carcinoma
645594|NCT00122876|HCC
645595|NCT00122876|Photodynamic therapy
645596|NCT00122876|Talaporfin Sodium (LS11)
645597|NCT00122876|Light emitting diodes (LEDs)
645598|NCT00122876|Litx
645599|NCT00122876|Light Infusion Technology
645600|NCT00122811|Aged
645601|NCT00122811|Hypertension
645602|NCT00122811|Stroke
645603|NCT00122798|Stroke, stroke treatment, atrial fibrillation, medication, rehabilitation
645604|NCT00122785|bronchiolitis
645605|NCT00122785|wheezing
645606|NCT00122785|dexamethasone
645607|NCT00122785|young children
645608|NCT00122759|Mechanical ventilation
645609|NCT00122759|Agitation
645610|NCT00122746|Cervical Cancer
645611|NCT00122746|AIDS
645612|NCT00122746|External Beam Radiotherapy
645613|NCT00122746|Brachytherapy
645614|NCT00122746|Cisplatin
645615|NCT00122733|Mechanical ventilation
645616|NCT00122733|Agitation
645617|NCT00122733|Difficult weaning
645618|NCT00122720|colorectal cancer
645619|NCT00122720|erythropoietin
645620|NCT00122720|rehabilitation
645621|NCT00122720|physical capacity
645622|NCT00122707|catheter-related infection
645623|NCT00122707|mechanical complications of catheters
645624|NCT00122694|carbon monoxide
645625|NCT00122694|COPD
645626|NCT00122694|inflammation
645627|NCT00122694|sputum induction
645628|NCT00122694|stable COPD
645629|NCT00122668|HIV Protease Inhibitors
645630|NCT00122668|HIV-Associated Lipodystrophy Syndrome
645631|NCT00122668|HIV infections
645632|NCT00122655|HIV infections
645633|NCT00122655|HIV Lipodystrophy Syndrome
645634|NCT00122642|catheterization
645635|NCT00122642|Catheters, Indwelling
645636|NCT00122629|Hepatitis C, Chronic
645637|NCT00122629|peginterferon alfa-2b
645638|NCT00122629|ribavirin
645639|NCT00122629|Amantadine
645640|NCT00122616|HIV infections
645641|NCT00122616|peginterferon alfa-2a
645642|NCT00122616|Treatment Failure
645643|NCT00122616|Hepatitis C, Chronic
645644|NCT00122616|Treatment Experienced
645645|NCT00122603|HIV Protease Inhibitors
645646|NCT00122603|HIV infections
645647|NCT00122603|Atazanavir
645648|NCT00122603|Saquinavir
645649|NCT00122603|Fosamprenavir
645650|NCT00122603|ritonavir
645651|NCT00122603|Treatment Naive
645652|NCT00122590|protease inhibitors
645653|NCT00122590|nelfinavir
645654|NCT00122590|lopinavir
645655|NCT00122590|indinavir
645656|NCT00122590|Pharmacokinetics
645657|NCT00122577|HIV infections
645658|NCT00122577|Treatment Failure
645659|NCT00122577|tenofovir
645660|NCT00122577|atazanavir
645661|NCT00122564|HIV Vaccines
645662|NCT00122564|HIV Seronegativity
645663|NCT00122551|HIV infections
645664|NCT00122538|HAART
645665|NCT00122538|once-daily
645666|NCT00122538|child
645667|NCT00122538|africa
645668|NCT00122538|HIV
645669|NCT00122538|AIDS
645670|NCT00122538|Treatment Naive
645671|NCT00122525|HIV
645672|NCT00122525|Male circumcision
645673|NCT00122525|Prevention
645674|NCT00122525|HSV-2
645675|NCT00122525|Africa
645676|NCT00122525|Sexual behavior
645677|NCT00122512|AE adverse event
645678|NCT00122512|AIDS acquired immunodeficiency syndrome
645679|NCT00122512|ALT (SGPT) alanine aminotransferase
645680|NCT00122512|ART antiretroviral therapy
645681|NCT00122512|AST (SGOT) aspartate aminotransferase
645682|NCT00122512|DCF data collection forms
645683|NCT00122512|DMC Data Monitoring Committee
645684|NCT00122512|FDA (U.S.) Food and Drug Administration
645685|NCT00122512|GCP Good Clinical Practice guidelines
645686|NCT00122512|HB sAg Hepatitis B surface antigen
645687|NCT00122512|ICH International Conference of Harmonisation
645688|NCT00122512|IND Investigational New Drug Application
645689|NCT00122512|IRB Institutional Review Board
645690|NCT00122512|IU international units
645691|NCT00122512|mg milligram(s)
645692|NCT00122512|mm3 cubic millimeter(s)
645693|NCT00122512|PCR polymerase chain reaction
645694|NCT00122512|SAE serious adverse event
645695|NCT00122512|TDF tenofovir disoproxil fumarate, GS-4331-05, PMPA prodrug
645696|NCT00122512|µg microgram
645697|NCT00122512|ULN upper limit of the normal range
645698|NCT00122512|WB Western Blot
645699|NCT00122512|Human Immunodeficiency Virus
645700|NCT00122512|HIV Seronegativity
645701|NCT00122499|Prostate cancer
645702|NCT00122499|Radiotherapy
645703|NCT00122499|Erectile dysfunction
645704|NCT00122499|Tadalafil
645705|NCT00122486|AE adverse event
645706|NCT00122486|AIDS acquired immunodeficiency syndrome
645707|NCT00122486|ALT (SGPT) alanine aminotransferase
645708|NCT00122486|ART antiretroviral therapy
645709|NCT00122486|AST (SGOT) aspartate aminotransferase
645710|NCT00122486|DCF data collection forms
645711|NCT00122486|DMC Data Monitoring Committee
645712|NCT00122486|FDA (U.S.) Food and Drug Administration
645713|NCT00122486|GCP Good Clinical Practice guidelines
645714|NCT00122486|HB sAg Hepatitis B surface antigen
645715|NCT00122486|ICH International Conference of Harmonisation
645716|NCT00122486|IND Investigational New Drug Application
645717|NCT00122486|IRB Institutional Review Board
645718|NCT00122486|IU international units
645719|NCT00122486|mg milligram(s)
645720|NCT00122486|mm3 cubic millimeter(s)
645721|NCT00122486|PCR polymerase chain reaction
645722|NCT00122486|SAE serious adverse event
645723|NCT00122486|µg microgram
645724|NCT00122486|ULN upper limit of the normal range
645725|NCT00122486|WB Western Blot
645726|NCT00122486|Human Immunodeficiency Virus
645727|NCT00122473|Dermatofibrosarcoma
645728|NCT00122473|Imatinib
645729|NCT00122473|Tyrosine Kinase Inhibitor
645730|NCT00122460|Head and Neck Cancer
645731|NCT00122447|Prediabetic state
645732|NCT00122447|Cardiovascular disease
645733|NCT00122447|Diabetes
645734|NCT00122447|Glucose intolerance
645735|NCT00122421|diabetes
645736|NCT00122421|quality of care
645737|NCT00122421|pharmacist recommendations
645738|NCT00122408|ventilator-associated pneumonia
645739|NCT00122408|probiotic
645740|NCT00122408|mechanical ventilation
645741|NCT00122408|intensive care
645742|NCT00122395|Domestic violence
645743|NCT00122395|Screening
645744|NCT00122395|Emergency department
645745|NCT00122382|abatacept, methotrexate, erosive RA
645746|NCT00122369|Breast
645747|NCT00122369|Biopsy
645748|NCT00122369|Hypnosis
645749|NCT00122369|Relaxation
645750|NCT00122369|Anxiety
645751|NCT00122369|Pain
645752|NCT00122369|Medical and Surgical Procedures
645753|NCT00122343|Endometrial
645754|NCT00122343|Cancer
645755|NCT00122317|Transfusion dependent, hemolytic paroxysmal nocturnal hemoglobinuria
645756|NCT00122291|preoperative
645757|NCT00122291|chemotherapy
645758|NCT00122291|radiation therapy
645759|NCT00122291|rectal cancer
645760|NCT00122291|transmural rectal wall invasion
645761|NCT00122291|nodal metastasis
645762|NCT00122278|migraine, emergency department, dexamethasone
645763|NCT00122278|Migraine with or without aura or probable migraine without aura as defined by ICHD, 2nd edition
645764|NCT00122265|prostate cancer
645765|NCT00122265|radiotherapy
645766|NCT00122265|radiation toxicity
645767|NCT00122265|single nucleotide polymorphism
645768|NCT00122252|prostate cancer
645769|NCT00122252|radiotherapy
645770|NCT00122252|biological imaging
645771|NCT00122239|radiotherapy
645772|NCT00122239|radiation toxicity
645773|NCT00122239|single nucleotide polymorphism
645774|NCT00122239|breast carcinoma
645775|NCT00122239|prostate carcinoma
645776|NCT00122239|squamous cell carcinoma of the head and neck
645777|NCT00122239|lung carcinoma (non-small cell)
645778|NCT00122226|HIV
645779|NCT00122226|HIV-associated lipodystrophy syndrome
645780|NCT00122213|Prevention
645781|NCT00122213|Retirement
645782|NCT00122213|Physical activity
645783|NCT00122213|Diet
645784|NCT00122213|Weight gain
645785|NCT00122213|Body composition
645786|NCT00122187|cancer
645787|NCT00122187|colonoscopy
645788|NCT00122187|mass screening
645789|NCT00122187|colorectal cancer
645790|NCT00122187|colorectal carcinoma
645791|NCT00122187|reminder systems
645792|NCT00122187|rectal cancers
645793|NCT00122187|colorectal tumor
645794|NCT00122187|guidelines
645795|NCT00122187|CRC secondary prevention
645796|NCT00122187|colorectal neoplasms
645797|NCT00122187|colonic neoplasms
645798|NCT00122187|colonic diseases
645799|NCT00122187|hemoccult testing
645800|NCT00122174|Caregivers
645801|NCT00122174|Stress
645802|NCT00122174|Coping
645803|NCT00122174|Immune
645804|NCT00122174|Relaxation
645805|NCT00122174|Biofeedback
645806|NCT00122174|Bioinstrumentation
645807|NCT00122174|Homecare
645808|NCT00122161|Drug therapy
645809|NCT00122161|Practice guidelines
645810|NCT00122161|Reminder systems
645811|NCT00122161|Ambulatory care
645812|NCT00122161|Hypertension
645813|NCT00122161|Clinical protocols
645814|NCT00122161|Quality Assurance, Health Care
645815|NCT00122148|Quality of health care
645816|NCT00122148|Feedback
645817|NCT00122135|end-of-life care
645818|NCT00122135|clinical decision-making
645819|NCT00122135|values inventory
645820|NCT00122135|racial disparities
645821|NCT00122109|Posttraumatic Stress Disorder
645822|NCT00122109|Anger Management
645823|NCT00122109|Telemedicine modality
645824|NCT00122096|neurosurgery
645825|NCT00122096|COX-2
645826|NCT00122096|inflammation
645827|NCT00122096|pain
645828|NCT00122083|Depression
645829|NCT00122083|Students
645830|NCT00122083|Health education
645831|NCT00122070|Borderline Personality Disorder
645832|NCT00122070|Personality Disorder
645833|NCT00122070|Quetiapine
645834|NCT00122070|Atypical Antipsychotics
645835|NCT00122070|Seroquel
645836|NCT00122070|Antipsychotics
645837|NCT00122057|ventilator-associated tracheobronchitis
645838|NCT00122057|nosocomial tracheobronchitis
645839|NCT00122044|childhood
645840|NCT00122044|cerebral palsy
645841|NCT00122044|dystonia
645842|NCT00122044|secondary
645843|NCT00122044|trihexyphenidyl
645844|NCT00122044|pediatric dystonia
645845|NCT00122031|Major Depression
645846|NCT00122031|Treatment Refractory Major Depression
645847|NCT00122018|Kidney failure
645848|NCT00122018|Cardiac Surgery
645849|NCT00122018|Fenoldopam
645850|NCT00122018|N-acetylcysteine
645851|NCT00122005|Metastatic
645852|NCT00122005|Prostate
645853|NCT00122005|Advanced
645854|NCT00122005|Cancer
645855|NCT00122005|GVAX
645856|NCT00122005|Vaccine
645857|NCT00121992|High risk node negative breast cancer
645858|NCT00121992|Disease-Free survival
645859|NCT00121992|Quality of life
645860|NCT00121979|HIV
645861|NCT00121979|treatment-experienced
645862|NCT00121979|lamivudine
645863|NCT00121979|3TC
645864|NCT00121966|Type 2 diabetes
645865|NCT00121966|Insulin Aspart
645866|NCT00121966|Insulin NPH
645867|NCT00121966|Metformin
645868|NCT00121966|Rosiglitazone
645869|NCT00121953|Endometriosis
645870|NCT00121953|Peritoneal fluid
645871|NCT00121953|Cytokines
645872|NCT00121953|Peroxisome Proliferator-Activated Receptors
645873|NCT00121940|Chronic Disease
645874|NCT00121940|Nurses
645875|NCT00121940|Caregivers
645876|NCT00121940|Support Groups
645877|NCT00121927|intractable
645878|NCT00121927|ketogenic
645879|NCT00121927|ketosis
645880|NCT00121927|Atkins
645881|NCT00121914|Carcinoma, Hepatocellular,
645882|NCT00121914|percutaneous ethanol instillation
645883|NCT00121914|long-acting somatostatin
645884|NCT00121901|Pancreatitis
645885|NCT00121901|Cholangiopancreatograpy, Endoscopic Retrograde/adverse
645886|NCT00121901|Nitroglycerin
645887|NCT00121901|Randomized Controlled Trial,
645888|NCT00121888|post traumatic stress disorder
645889|NCT00121888|Prolonged Exposure Therapy
645890|NCT00121888|pharmacotherapy
645891|NCT00121888|double-blind
645892|NCT00121888|Anxiety Disorder
645893|NCT00121875|short stature
645894|NCT00121875|insulin resistance
645895|NCT00121875|body composition
645896|NCT00121875|Turner syndrome
645897|NCT00121875|intramyocellular lipid
645898|NCT00121875|glucose tolerance
645899|NCT00121862|Leishmaniasis
645900|NCT00121862|Subunit Vaccine
645901|NCT00121862|Prevention
645902|NCT00121862|T cell
645903|NCT00121849|Leishmaniasis,
645904|NCT00121849|Subunit Vaccine,
645905|NCT00121849|Prevention,
645906|NCT00121849|T cell
645907|NCT00121823|Malaria
645908|NCT00121823|PCR
645909|NCT00121823|Vaccines
645910|NCT00121823|Acceptability
645911|NCT00121797|Postpartum Period
645912|NCT00121771|Malaria
645913|NCT00121771|Vaccines
645914|NCT00121771|Safety
645915|NCT00121771|Immunogenicity
645916|NCT00121758|HIV Vaccines
645917|NCT00121758|HIV Seronegativity
645918|NCT00121745|gene transfer
645919|NCT00121745|cell cycle control
645920|NCT00121745|cancer gene therapy
645921|NCT00121745|pathotropic targeting
645922|NCT00121745|tumor targeted retroviral vector
645923|NCT00121719|Resistant and refractory solid tumors
645924|NCT00121719|lymphomas
645925|NCT00121719|hodgkins disease
645926|NCT00121719|non-hodgkins lymphoma
645927|NCT00121719|neoplasms
645928|NCT00121693|Fall prevention
645929|NCT00121693|posturography
645930|NCT00121693|music therapy
645931|NCT00121680|cancer
645932|NCT00121654|Angina pectoris
645933|NCT00121654|Spinal cord stimulation
645934|NCT00121654|Refractory angina pectoris
645935|NCT00121628|Thyroid cancer
645936|NCT00121628|Advanced thyroid cancer
645937|NCT00121628|Metastatic thyroid cancer
645938|NCT00121628|Medullary thyroid cancer
645939|NCT00121628|Follicular thyroid cancer
645940|NCT00121628|Papillary thyroid cancer
645941|NCT00121628|Hurthle cell thyroid cancer
645942|NCT00121628|Thyroid cancer treatments
645943|NCT00121628|Differentiated thyroid cancer and medullary thyroid cancer
645944|NCT00121615|Clinical Trials
645945|NCT00121602|Hemodialysis
645946|NCT00121602|Darbepoetin Alfa
645947|NCT00121602|Clinical Trials
645948|NCT00121602|Nephrology
645949|NCT00121602|Amgen
645950|NCT00121602|Chronic Kidney Disease (CKD)
645951|NCT00121589|AMD
645952|NCT00121589|Macular Pigment
645953|NCT00121589|Serum Lutein Levels
645954|NCT00121589|Vitamin Supplementation
645955|NCT00121589|Carotenoids
645956|NCT00121589|Lutein
645957|NCT00121589|Zeaxanthin
645958|NCT00121589|DHA
645959|NCT00121589|Age Related Macular Degeneration
645960|NCT00121563|Cytokines
645961|NCT00121563|Inflammation
645962|NCT00121563|Pain
645963|NCT00121563|Injury
645964|NCT00121563|Peripheral
645965|NCT00121563|Wisdom Teeth
645966|NCT00121563|Third Molar Extraction
645967|NCT00121550|Coronary heart disease
645968|NCT00121550|Clarithromycin
645969|NCT00121550|Macrolides
645970|NCT00121550|Cardiovascular mortality
645971|NCT00121550|Chlamydia pneumoniae
645972|NCT00121537|wounds-open
645973|NCT00121524|cardiac arrest
645974|NCT00121524|resuscitation
645975|NCT00121524|epinephrine
645976|NCT00121524|intravenous
645977|NCT00121524|survival
645978|NCT00121511|photoaging
645979|NCT00121511|Actinic Keratoses
645980|NCT00121511|Efudex
645981|NCT00121511|5 fluorouracil
645982|NCT00121498|Pain
645983|NCT00121498|Hysterectomy
645984|NCT00121498|Preemptive
645985|NCT00121498|Lidocaine
645986|NCT00121485|Heart-assist devices
645987|NCT00121472|Heart-assist devices
645988|NCT00121459|Diaphragm
645989|NCT00121459|HIV prevention
645990|NCT00121459|Southern/South Africa, Zimbabwe
645991|NCT00121459|female-controlled methods
645992|NCT00121459|Replens
645993|NCT00121459|STI prevention
645994|NCT00121459|HIV Seronegativity
645995|NCT00121446|Heart Attack
645996|NCT00121446|ST Elevation Myocardial Infarction
645997|NCT00121446|fibrinolytic therapy
645998|NCT00121446|percutaneous coronary intervention
645999|NCT00121446|Acute Myocardial Infarction
646000|NCT00121420|Brain Neoplasms/secondary
646001|NCT00121420|Brain neoplasms/radiotherapy
646002|NCT00121420|Brain metastasis
646003|NCT00121420|Neoplasm metastasis
646004|NCT00121420|Cranial irradiation
646005|NCT00121420|Radiosurgery
646006|NCT00121420|Lung Neoplasms
646007|NCT00121420|Breast Neoplasms
646008|NCT00121420|Kidney Neoplasms
646009|NCT00121420|Melanoma
646010|NCT00121420|Radiotherapy
646011|NCT00121420|Carcinoma, non-small cell lung
646012|NCT00121407|Age Related Macular Degeneration (AMD)
646013|NCT00121407|Photodynamic Therapy (PDT)
646014|NCT00121407|Visudyne
646015|NCT00121394|Chlorhexidine
646016|NCT00121394|Vaginal wash
646017|NCT00121394|Neonatal mortality
646018|NCT00121394|Sepsis
646019|NCT00121394|Global Network
646020|NCT00121394|Maternal and child health
646021|NCT00121394|Women's Health
646022|NCT00121394|International
646023|NCT00121394|Pakistan
646024|NCT00121381|Atopic dermatitis
646025|NCT00121381|T-cell
646026|NCT00121381|pimecrolimus
646027|NCT00121381|children
646028|NCT00121381|topical corticosteroids
646029|NCT00121368|Global Network
646030|NCT00121368|Maternal and child health
646031|NCT00121368|International
646032|NCT00121368|Women's health
646033|NCT00121368|Tobacco
646034|NCT00121368|Smoking
646035|NCT00121368|Africa
646036|NCT00121368|Latin America
646037|NCT00121368|South America
646038|NCT00121368|Guatemala
646039|NCT00121368|Zambia
646040|NCT00121368|India
646041|NCT00121368|Argentina
646042|NCT00121368|Democratic Republic of the Congo
646043|NCT00121329|Pain with procedures
646044|NCT00121316|Atopic dermatitis
646045|NCT00121316|pimecrolimus
646046|NCT00121303|adult acute monocytic leukemia (M5b)
646047|NCT00121303|adult erythroleukemia (M6a)
646048|NCT00121303|adult pure erythroid leukemia (M6b)
646049|NCT00121303|adult acute megakaryoblastic leukemia (M7)
646050|NCT00121303|adult acute myeloblastic leukemia with maturation (M2)
646051|NCT00121303|adult acute myeloblastic leukemia without maturation (M1)
646052|NCT00121303|adult acute myelomonocytic leukemia (M4)
646053|NCT00121303|adult acute monoblastic leukemia (M5a)
646054|NCT00121303|refractory anemia with excess blasts in transformation
646055|NCT00121303|refractory anemia with excess blasts
646056|NCT00121303|secondary acute myeloid leukemia
646057|NCT00121303|untreated adult acute myeloid leukemia
646058|NCT00121303|de novo myelodysplastic syndromes
646059|NCT00121303|adult acute minimally differentiated myeloid leukemia (M0)
646060|NCT00121303|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
646061|NCT00121303|adult acute myeloid leukemia with inv(16)(p13;q22)
646062|NCT00121303|adult acute myeloid leukemia with t(16;16)(p13;q22)
646063|NCT00121303|adult acute myeloid leukemia with t(8;21)(q22;q22)
646064|NCT00121303|secondary myelodysplastic syndromes
646065|NCT00121277|unspecified adult solid tumor, protocol specific
646066|NCT00121212|stage I prostate cancer
646067|NCT00121212|stage IIB prostate cancer
646068|NCT00121212|stage IIA prostate cancer
646069|NCT00121212|stage III prostate cancer
646070|NCT00121186|recurrent adult Hodgkin lymphoma
646071|NCT00121186|recurrent small lymphocytic lymphoma
646072|NCT00121186|recurrent mantle cell lymphoma
646073|NCT00121186|recurrent grade 1 follicular lymphoma
646074|NCT00121186|recurrent grade 2 follicular lymphoma
646075|NCT00121186|recurrent grade 3 follicular lymphoma
646076|NCT00121186|recurrent adult diffuse large cell lymphoma
646077|NCT00121173|cervical cancer
646078|NCT00121173|cervical intraepithelial neoplasia grade 2
646079|NCT00121173|cervical intraepithelial neoplasia grade 3
646080|NCT00121160|immune response to vaccines
646081|NCT00121160|stress management
646082|NCT00121160|breast cancer
646083|NCT00121147|glaucoma
646084|NCT00121147|pseudoexfoliation
646085|NCT00121134|Bevacizumab
646086|NCT00121134|Metronomic Chemotherapy
646087|NCT00121134|Breast Cancer Stages II-III
646088|NCT00121134|Invasive breast cancer stages II-III
646089|NCT00121121|HIV Vaccines
646090|NCT00121121|HIV Seronegativity
646091|NCT00121095|prostate cancer
646092|NCT00121069|specific phobia
646093|NCT00121069|anxiety
646094|NCT00121069|SSRI
646095|NCT00121069|clinical trial
646096|NCT00121069|escitalopram
646097|NCT00121043|Rheumatoid Arthritis, Inflammation
646098|NCT00121043|Interleukin-1 (IL-1), r-metHuIL-1ra
646099|NCT00121043|Autoimmune, Kineret®
646100|NCT00121043|Anakinra, Immunex
646101|NCT00121043|Amgen, Clinical Trials
646102|NCT00121030|uterine cancer
646103|NCT00121030|ovarian cancer
646104|NCT00121030|darbepoetin alfa
646105|NCT00121030|Amgen
646106|NCT00121030|Gynecological Malignancies
646107|NCT00121017|HCV Infection
646108|NCT00121017|Treatment Naive
646109|NCT00121004|Advance Directive
646110|NCT00121004|Living Will
646111|NCT00121004|Terminal Illness
646112|NCT00120991|Coronary artery bypass grafting
646113|NCT00120991|OPCAB
646114|NCT00120978|Clinical Trial; C-reactive protein; fluticasone; salmeterol
646115|NCT00120965|Cardiac arrest
646116|NCT00120965|OOH-cardiac arrest
646117|NCT00120965|CPR
646118|NCT00120965|Chest compressions
646119|NCT00120965|Chest compression device
646120|NCT00120952|RSA
646121|NCT00120952|Osteoarthritis
646122|NCT00120952|Hip arthroplasty
646123|NCT00120952|DEXA
646124|NCT00120952|Titanium
646125|NCT00120952|Cobalt chromium
646126|NCT00120952|Bone cement
646127|NCT00120939|Lung Cancer
646128|NCT00120939|Breast Cancer
646129|NCT00120939|Prostate Cancer
646130|NCT00120939|Ovarian Cancer
646131|NCT00120939|Head and Neck Cancer
646132|NCT00120939|Gastrointestinal Cancer
646133|NCT00120939|Metastatic Cancer
646134|NCT00120939|Advanced Cancer
646135|NCT00120939|Genitourinary Cancer
646136|NCT00120939|Glioblastoma Multiforme
646137|NCT00120939|Recurrent Cancer
646138|NCT00120939|Colon Cancer
646139|NCT00120939|Gastric Cancer
646140|NCT00120939|Stomach Cancer
646141|NCT00120939|Pancreatic Cancer
646142|NCT00120939|Esophageal Cancer
646143|NCT00120939|Throat Cancer
646144|NCT00120939|Bladder Cancer
646145|NCT00120939|Kidney Cancer
646146|NCT00120939|Renal Cancer
646147|NCT00120939|Cervical Cancer
646148|NCT00120939|Endometrial Cancer
646149|NCT00120939|Colorectal Cancer
646150|NCT00120926|Premature neonate
646151|NCT00120926|Parenteral nutrition
646152|NCT00120926|Growth
646153|NCT00120926|Amino Acids
646154|NCT00120926|Nutrition
646155|NCT00120913|Breakthrough bleeding while taking continuously dosed oral contraceptives
646156|NCT00120900|COX-2 inhibitor
646157|NCT00120900|Knee osteoarthritis
646158|NCT00120887|Atherosclerosis, SLE, statins
646159|NCT00120874|Alzheimer's disease
646160|NCT00120874|caregiver training
646161|NCT00120874|caregiver counseling
646162|NCT00120874|individualized management
646163|NCT00120874|memantine
646164|NCT00120874|dementia
646165|NCT00120861|Genotype-1
646166|NCT00120861|Previously failed treatment
646167|NCT00120848|HPV vaccine efficacy
646168|NCT00120848|Prophylaxis HPV 16/18 infections
646169|NCT00120835|Genotype-1
646170|NCT00120835|Treatment-Naive
646171|NCT00120822|Malaria
646172|NCT00120822|Pregnancy
646173|NCT00120822|Folic acid
646174|NCT00120822|Sulfadoxine-pyrimethamine
646175|NCT00120809|Malaria
646176|NCT00120809|Pregnancy
646177|NCT00120809|Multigravidae
646178|NCT00120809|Intermittent preventative treatment
646179|NCT00120809|Sulfadoxine-pyrimethamine
646180|NCT00120796|Hepatitis B
646181|NCT00120796|Hepatitis B Vaccines
646182|NCT00120796|Lamivudine
646183|NCT00120783|Treatment Failure
646184|NCT00120783|HIV infections
646185|NCT00120770|AE adverse event
646186|NCT00120770|AIDS acquired immunodeficiency syndrome
646187|NCT00120770|ALT (SGPT) alanine aminotransferase
646188|NCT00120770|ART antiretroviral therapy
646189|NCT00120770|AST (SGOT) aspartate aminotransferase
646190|NCT00120770|DCF data collection forms
646191|NCT00120770|DMC Data Monitoring Committee
646192|NCT00120770|FDA (U.S.) Food and Drug Administration
646193|NCT00120770|GCP Good Clinical Practice guidelines
646194|NCT00120770|HB sAg Hepatitis B surface antigen
646195|NCT00120770|ICH International Conference of Harmonisation
646196|NCT00120770|IND Investigational New Drug Application
646197|NCT00120770|IRB Institutional Review Board
646198|NCT00120770|IU international units
646199|NCT00120770|mg milligram(s)
646200|NCT00120770|mm3 cubic millimeter(s)
646201|NCT00120770|PCR polymerase chain reaction
646202|NCT00120770|SAE serious adverse event
646203|NCT00120770|µg microgram
646204|NCT00120770|ULN upper limit of the normal range
646205|NCT00120770|WB Western Blot
646206|NCT00120770|Human Immunodeficiency Virus
646207|NCT00120770|Neisseria gonorrhoeae
646208|NCT00120770|Chlamydia trachomatis
646209|NCT00120770|HIV Seronegativity
646210|NCT00120757|Osteoporosis
646211|NCT00120731|Recurrent nephrolithiasis
646212|NCT00120731|Potassium Citrate
646213|NCT00120731|Hypercalciuria
646214|NCT00120731|Distal Renal Tubular Acidosis
646215|NCT00120731|Nephrolithiasis in children
646216|NCT00120705|anemia
646217|NCT00120705|darbepoetin alfa
646218|NCT00120705|Amgen
646219|NCT00120705|Non-myeloid Malignancies
646220|NCT00120692|breast cancer
646221|NCT00120692|darbepoetin alfa
646222|NCT00120692|Amgen
646223|NCT00120679|non-small cell lung cancer
646224|NCT00120679|darbepoetin alfa
646225|NCT00120679|Amgen
646226|NCT00120666|Exercise
646227|NCT00120666|Stimulation
646228|NCT00120666|Nerve
646229|NCT00120666|Electrical
646230|NCT00120666|Muscle
646231|NCT00120666|Healthy Volunteer
646232|NCT00120666|HV
646233|NCT00120653|Reglan
646234|NCT00120653|Prolactin
646235|NCT00120653|MDS
646236|NCT00120653|Metoclopramide
646237|NCT00120653|Myelodysplastic Syndrome
646238|NCT00120640|Premature birth
646239|NCT00120640|Premature labor
646240|NCT00120640|Progesterone
646241|NCT00120627|Randomized Controlled Trial
646242|NCT00120627|Intervention Study
646243|NCT00120627|Mindfulness
646244|NCT00120627|Complementary Therapy
646245|NCT00120627|Mind-Body Relations (Metaphysics)
646246|NCT00120627|Spiritual Therapy
646247|NCT00120627|Meditation
646248|NCT00120627|Qualitative Analysis
646249|NCT00120614|Premature Infant
646250|NCT00120614|Premature Birth
646251|NCT00120614|Parenting Interventions
646252|NCT00120614|NICU Interventional studies
646253|NCT00120614|Parental coping
646254|NCT00120614|Low birthweight infant
646255|NCT00120614|Coping Behavior
646256|NCT00120614|Infant, Premature
646257|NCT00120601|treatment
646258|NCT00120601|alcohol
646259|NCT00120601|dependence
646260|NCT00120601|medication
646261|NCT00120588|brain protection
646262|NCT00120588|white matter injury
646263|NCT00120588|neurodevelopmental sequelae
646264|NCT00120588|magnesium sulfate
646265|NCT00120588|intraventricular hemorrhage
646266|NCT00120575|Hemofiltration
646267|NCT00120575|Pediatrics
646268|NCT00120562|weight loss surgery
646269|NCT00120562|gastric bypass surgery
646270|NCT00120549|Assisted Hatching
646271|NCT00120549|Cleavage Stage, Ovum
646272|NCT00120549|Embryo Transfer
646273|NCT00120549|Pregnancy
646274|NCT00120549|Embryo Implantation
646275|NCT00120536|Type 2 diabetes
646276|NCT00120536|vildagliptin
646277|NCT00120523|Atopic dermatitis, children, infants, pimecrolimus
646278|NCT00120510|Treatment Naive
646279|NCT00120510|TB
646280|NCT00120497|short stature
646281|NCT00120497|intrauterine growth restriction
646282|NCT00120497|insulin resistance
646283|NCT00120497|intramyocellular lipid
646284|NCT00120497|small for gestational age
646285|NCT00120497|glucose tolerance
646286|NCT00120484|Circadian Rhythm
646287|NCT00120484|Biological Clock
646288|NCT00120484|Complementary and Alternative Medicine
646289|NCT00120471|Perinatal Transmission
646290|NCT00120471|MTCT
646291|NCT00120471|HIV Seronegativity
646292|NCT00120458|Black Cohosh
646293|NCT00120458|Cimicifuga
646294|NCT00120458|Anxiety
646295|NCT00120458|Women
646296|NCT00120458|Complementary and Alternative Medicine
646297|NCT00120445|retinal detachment
646298|NCT00120445|pneumatic retinopexy
646299|NCT00120432|single dose
646300|NCT00120432|mydriatic drug
646301|NCT00120432|pupillary dilation
646302|NCT00120419|HIV-1 infection
646303|NCT00120419|immunomodulatory therapy
646304|NCT00120419|Treatment Naive
646305|NCT00120406|Peripheral Arterial Disease (PAD)
646306|NCT00120406|Peripheral Vascular Disease
646307|NCT00120406|Drug-Eluting Stent
646308|NCT00120406|Drug-Coated Stent
646309|NCT00120393|Treatment Experienced
646310|NCT00120380|Idiopathic pulmonary arterial hypertension
646311|NCT00120367|Leukoencephalopathy, Progressive Multifocal
646312|NCT00120367|HIV infections
646313|NCT00120367|HIV Fusion Inhibitors
646314|NCT00120354|Hepatitis B Virus
646315|NCT00120354|Antiviral Resistance
646316|NCT00120354|Drug Withdrawal
646317|NCT00120354|Immune Response
646318|NCT00120354|Hepatitis B Surface Antigen
646319|NCT00120354|Liver Biopsy
646320|NCT00120354|Hepatitis B
646321|NCT00120328|serum creatinine
646322|NCT00120328|end stage renal disease
646323|NCT00120328|cardiovascular mortality
646324|NCT00120328|cardiovascular morbidity
646325|NCT00120328|non-cardiovascular mortality
646326|NCT00120328|non-cardiovascular morbidity
646327|NCT00120315|dyspepsia
646328|NCT00120315|discontinuation
646329|NCT00120315|Primary health care
646330|NCT00120315|Helicobacter pylori
646331|NCT00120315|Proton Pump Inhibitor
646332|NCT00120315|Histamine-2-receptor-antagonist
646333|NCT00120302|Randomised
646334|NCT00120302|Placebo-controlled
646335|NCT00120302|Elidel
646336|NCT00120302|Quality of Life
646337|NCT00120302|Atopic Eczema
646338|NCT00120276|Functional Mitral Regurgitation (FMR)
646339|NCT00120276|Ischemic Mitral Regurgitation
646340|NCT00120276|Less invasive repair
646341|NCT00120276|Surgical MV repair
646342|NCT00120276|Mitral Valve Repair
646343|NCT00120276|Heart Failure
646344|NCT00120276|Left Ventricular Dysfunction
646345|NCT00120263|Plasma Exchange
646346|NCT00120263|Myeloma
646347|NCT00120263|Acute renal failure
646348|NCT00120263|Light Chains
646349|NCT00120263|Bence Jones Proteins
646350|NCT00120263|Kidney Function
646351|NCT00120250|PTSD
646352|NCT00120250|Sleep disturbance
646353|NCT00120250|Eszopiclone
646354|NCT00120250|Double-blind
646355|NCT00120250|Crossover
646356|NCT00120237|Postpartum hemorrhage
646357|NCT00120237|Misoprostol
646358|NCT00120237|Maternal morbidity
646359|NCT00120237|Developing countries
646360|NCT00120237|Traditional birth attendants
646361|NCT00120224|Mifepristone
646362|NCT00120224|Medical abortion
646363|NCT00120224|Ultrasound
646364|NCT00120198|NHL
646365|NCT00120198|elderly
646366|NCT00120185|HIV Infections
646367|NCT00120185|Interleukin-2
646368|NCT00120172|colorectal
646369|NCT00120172|metastatic
646370|NCT00120172|elderly
646371|NCT00120172|metastatic colorectal cancer
646372|NCT00120159|Necrotizing Enterocolitis
646373|NCT00120133|Osteoporosis
646374|NCT00120133|Bisphosphonates
646375|NCT00120133|Atorvastatin
646376|NCT00120120|Radiculopathy
646377|NCT00120120|Back Pain
646378|NCT00120120|Lumbar Pain
646379|NCT00120120|CC-5013
646380|NCT00120120|Revlimid
646381|NCT00120120|Lenalidomide
646382|NCT00120094|Syncope
646383|NCT00120094|Electrocardiographic monitoring
646384|NCT00120081|Vaccine
646385|NCT00120081|Hookworm
646386|NCT00120081|Phase 1
646387|NCT00120081|Human Hookworm Infection
646388|NCT00120081|Na-ASP-2
646389|NCT00120042|Abortion
646390|NCT00120042|Retained placenta
646391|NCT00120042|Hemorrhage
646392|NCT00120042|Postpartum ultrasound
646393|NCT00120029|weight loss
646394|NCT00120029|survivorship
646395|NCT00120029|breast ductal lavage
646396|NCT00120029|exercise
646397|NCT00120029|diet
646398|NCT00120016|cancer prevention
646399|NCT00120016|diet
646400|NCT00120016|nutrition
646401|NCT00120016|polyunsaturated fat
646402|NCT00120016|olive oil
646403|NCT00120003|Acute stroke
646404|NCT00120003|Elevated blood pressure
646405|NCT00120003|Blood pressure lowering treatment
646406|NCT00119990|vasopressin
646407|NCT00119990|icodextrin
646408|NCT00119990|cardiac output
646409|NCT00119977|cartilage thickness
646410|NCT00119977|RSA
646411|NCT00119977|DEXA
646412|NCT00119977|ultra sound
646413|NCT00119977|MRI
646414|NCT00119977|osteoarthritis
646415|NCT00119977|periacetabular osteotomy
646416|NCT00119951|Behavioral
646417|NCT00119938|Disease management
646418|NCT00119938|Patient access to records
646419|NCT00119938|Medical records systems, computerized
646420|NCT00119938|Questionnaires
646421|NCT00119938|Physician-patient relations
646422|NCT00119938|Medical records
646423|NCT00119925|infertility
646424|NCT00119925|guideline
646425|NCT00119925|health care implementation
646426|NCT00119925|intervention
646427|NCT00119925|gynecology
646428|NCT00119912|screening
646429|NCT00119912|flexible sigmoidoscopy
646430|NCT00119912|fecal occult blood
646431|NCT00119912|cancer
646432|NCT00119912|colon
646433|NCT00119912|rectum
646434|NCT00119899|Colorectal Cancer;
646435|NCT00119899|Liver;
646436|NCT00119899|Metastases;
646437|NCT00119899|Resection;
646438|NCT00119899|Fluorodeoxyglucose;
646439|NCT00119899|Tomography;
646440|NCT00119899|Positron-Emission
646441|NCT00119873|HIV Preventive Vaccine
646442|NCT00119873|AIDS Vaccines
646443|NCT00119873|Adenoviridae
646444|NCT00119834|Heart Failure
646445|NCT00119834|Intermacs
646446|NCT00119834|Pedimacs
646447|NCT00119834|Mechanical Circulatory Support
646448|NCT00119834|Ventricular Assist Device
646449|NCT00119769|HIV
646450|NCT00119769|immune stimulation
646451|NCT00119769|lipodystrophy
646452|NCT00119769|growth hormone
646453|NCT00119769|recombinant growth hormone
646454|NCT00119769|Treatment Experienced
646455|NCT00119756|Schizophrenia
646456|NCT00119756|Intramuscular injection
646457|NCT00119756|Deltoid muscle
646458|NCT00119756|Gluteus muscle
646459|NCT00119756|Paliperidone palmitate
646460|NCT00119743|Prophylaxis pneumococcal vaccine
646461|NCT00119730|Fludarabine
646462|NCT00119730|Mitoxantrone
646463|NCT00119730|Rituximab
646464|NCT00119730|Zevalin
646465|NCT00119730|Mantle Cell Lymphoma
646466|NCT00119730|Relapsed Mantle Cell Lymphoma
646467|NCT00119717|acute
646468|NCT00119717|ischemic
646469|NCT00119717|stroke
646470|NCT00119717|randomized
646471|NCT00119717|device
646472|NCT00119717|treatment
646473|NCT00119678|SLE
646474|NCT00119665|Postmenopausal symptoms
646475|NCT00119665|Hot Flashes
646476|NCT00119665|Postmenopausal Hot Flashes
646477|NCT00119652|Bipolar disorder
646478|NCT00119652|bipolar depression
646479|NCT00119652|depression
646480|NCT00119626|Stroke, Acute
646481|NCT00119626|Cerebrovascular Stroke
646482|NCT00119613|Oncology
646483|NCT00119613|Clinical Trial
646484|NCT00119613|Hemoglobin
646485|NCT00119613|Darbepoetin alfa
646486|NCT00119613|Survival
646487|NCT00119613|Carboplatin
646488|NCT00119613|Cisplatin
646489|NCT00119613|Etoposide
646490|NCT00119613|Extensive Stage Small Cell Lung Cancer
646491|NCT00119600|Non-myeloid malignancy
646492|NCT00119600|Clinical Trial
646493|NCT00119587|Hemodialysis
646494|NCT00119587|darbepoetin alfa
646495|NCT00119587|Clinical Trial
646496|NCT00119587|Amgen
646497|NCT00119574|Randomized Controlled Trial
646498|NCT00119574|Quality of Health Care
646499|NCT00119574|Health Services Research
646500|NCT00119574|Guidelines
646501|NCT00119574|Medical Informatics Computing
646502|NCT00119574|Services, Mental Health
646503|NCT00119574|Medicine, Evidence-Based
646504|NCT00119574|Quality Assurance, Healthcare
646505|NCT00119574|Quality Indicators, Health Care
646506|NCT00119574|Veterans
646507|NCT00119561|Caregiver
646508|NCT00119561|Dementia
646509|NCT00119561|Alzheimer Disease
646510|NCT00119561|Telephone
646511|NCT00119561|Randomized Controlled Trials
646512|NCT00119548|HIV Rapid Testing
646513|NCT00119548|Cost-effectiveness
646514|NCT00119548|HIV Seronegativity
646515|NCT00119535|Diabetes mellitus
646516|NCT00119535|Diabetic retinopathy
646517|NCT00119535|Organizational change
646518|NCT00119535|Quality improvement
646519|NCT00119535|Quasi-experimental
646520|NCT00119522|wheelchairs
646521|NCT00119522|falls
646522|NCT00119522|spinal cord injury
646523|NCT00119522|accidental falls
646524|NCT00119522|safety
646525|NCT00119509|Cervix Neoplasms
646526|NCT00119509|Vaginal smears
646527|NCT00119509|Papillomavirus - Human
646528|NCT00119496|Corticosteroid
646529|NCT00119496|Rosiglitazone
646530|NCT00119496|Theophylline
646531|NCT00119496|Beclomethasone
646532|NCT00119496|Inflammation
646533|NCT00119496|Asthma
646534|NCT00119496|Smoking
646535|NCT00119496|Pulmonary
646536|NCT00119483|Men
646537|NCT00119483|testosterone
646538|NCT00119483|hypogonadal
646539|NCT00119483|aging
646540|NCT00119483|body composition
646541|NCT00119483|quality og life
646542|NCT00119483|Muscle strength
646543|NCT00119483|Aging male
646544|NCT00119457|antithrombotic agents
646545|NCT00119457|anticoagulants
646546|NCT00119457|prophylaxis
646547|NCT00119457|embolism
646548|NCT00119457|deep vein thrombosis
646549|NCT00119457|hip fracture
646550|NCT00119444|PET
646551|NCT00119444|Periacetabular osteotomy
646552|NCT00119431|Hereditary angioedema type I (MeSH: angioneurotic edema, complement 1 inactivators)
646553|NCT00119418|hot flash
646554|NCT00119418|menopause
646555|NCT00119418|herbal medicine
646556|NCT00119418|kampo
646557|NCT00119418|alternative medicine
646558|NCT00119405|Lipoatrophy
646559|NCT00119405|Mitochondria
646560|NCT00119405|Treatment Naive
646561|NCT00119379|lipoatrophy
646562|NCT00119379|mitochondria
646563|NCT00119379|HIV
646564|NCT00119379|treatment experienced
646565|NCT00119340|accelerated phase chronic myelogenous leukemia
646566|NCT00119340|Philadelphia chromosome positive chronic myelogenous leukemia
646567|NCT00119340|relapsing chronic myelogenous leukemia
646568|NCT00119340|chronic phase chronic myelogenous leukemia
646569|NCT00119314|newly diagnosed carcinoma of unknown primary
646570|NCT00119314|recurrent carcinoma of unknown primary
646571|NCT00119301|recurrent osteosarcoma
646572|NCT00119210|Tobacco use cessation
646573|NCT00119210|Bupropion
646574|NCT00119210|Zyban
646575|NCT00119210|Puerperium
646576|NCT00119197|watery diarrhea
646577|NCT00119197|cholera vaccine
646578|NCT00119184|anesthesia
646579|NCT00119184|breech
646580|NCT00119184|external cephalic version
646581|NCT00119184|spinal
646582|NCT00119184|success
646583|NCT00119184|anesthesia,spinal
646584|NCT00119171|Safety
646585|NCT00119171|tolerability
646586|NCT00119171|dose limiting toxicity
646587|NCT00119171|solid tumors
646588|NCT00119171|capecitabine
646589|NCT00119158|THerapy for acute moderate to severe flares
646590|NCT00119145|antimalarial drugs
646591|NCT00119145|efficacy
646592|NCT00119145|safety
646593|NCT00119145|trial
646594|NCT00119132|intermittent preventive treatment
646595|NCT00119132|effectiveness
646596|NCT00119132|malaria
646597|NCT00119119|Hepatitis C
646598|NCT00119119|Liver Cirrhosis
646599|NCT00119119|Tocopherols
646600|NCT00119106|HIV
646601|NCT00119106|Prevention
646602|NCT00119106|Tenofovir
646603|NCT00119106|HIV Seronegativity
646604|NCT00119093|Antiretroviral therapy
646605|NCT00119093|HIV
646606|NCT00119093|Adherence
646607|NCT00119093|Viral Load
646608|NCT00119093|Opportunistic illness
646609|NCT00119080|Meningococcal carriage
646610|NCT00119080|Conjugate vaccine
646611|NCT00119067|Anthrax
646612|NCT00119067|Vaccine
646613|NCT00119067|Immunogenicity
646614|NCT00119067|Reactogenicity
646615|NCT00119054|Hypertension
646616|NCT00119054|Diabetes Mellitus
646617|NCT00119054|Telemedicine
646618|NCT00119054|Nursing Care
646619|NCT00119041|Diabetes Mellitus
646620|NCT00119041|Telemedicine
646621|NCT00119041|Referral
646622|NCT00119041|Consultation
646623|NCT00119028|Quality Improvement
646624|NCT00119028|Cluster Randomized Trial
646625|NCT00119028|Care Model
646626|NCT00119015|perennial allergic rhinitis
646627|NCT00119002|randomized clinical trial
646628|NCT00119002|placebo-controlled
646629|NCT00119002|double-blind
646630|NCT00119002|double-masked
646631|NCT00119002|infant
646632|NCT00119002|dexamethasone
646633|NCT00119002|wheezing
646634|NCT00118989|Curcumin
646635|NCT00118989|chemoprevention
646636|NCT00118989|adenomatous polyps
646637|NCT00118989|colorectal cancer
646638|NCT00118976|diabetic nephropathy
646639|NCT00118976|type 1 diabetes
646640|NCT00118976|albuminuria
646641|NCT00118976|hypertension
646642|NCT00118924|Dengue Vaccine
646643|NCT00118924|Tick-Borne Illnesses
646644|NCT00118924|Flavivirus
646645|NCT00118911|Adult
646646|NCT00118911|ADHD
646647|NCT00118911|ADD
646648|NCT00118911|CBT
646649|NCT00118911|Relaxation Techniques
646650|NCT00118911|Education
646651|NCT00118898|Treatment Naive
646652|NCT00118885|Shingles
646653|NCT00118885|depression
646654|NCT00118885|varicella zoster virus
646655|NCT00118885|alternative medicine
646656|NCT00118885|psychoneuroimmunology
646657|NCT00118872|Growth and Development
646658|NCT00118872|Pakistan
646659|NCT00118872|Weaning
646660|NCT00118872|Probiotics
646661|NCT00118872|Infant
646662|NCT00118872|Lactobacillus GG
646663|NCT00118859|Back Pain
646664|NCT00118859|Integrative Care
646665|NCT00118859|Acupuncture
646666|NCT00118859|Chiropractic
646667|NCT00118859|Exercise
646668|NCT00118859|Massage Therapy
646669|NCT00118859|Mind-Body Therapy
646670|NCT00118859|Nutritional Counseling
646671|NCT00118859|Complementary Therapies
646672|NCT00118859|Complementary and Alternative Medicine
646673|NCT00118846|Women
646674|NCT00118846|Complementary and Alternative Medicine
646675|NCT00118846|CAM
646676|NCT00118833|Social Anxiety Disorder
646677|NCT00118833|Social Phobia
646678|NCT00118833|Generalized Anxiety Disorder
646679|NCT00118833|Hypericum
646680|NCT00118833|St. John's wort
646681|NCT00118833|Medicine, Herbal
646682|NCT00118833|Complementary Therapies
646683|NCT00118820|Dry socket
646684|NCT00118820|Third molar
646685|NCT00118820|Infection
646686|NCT00118820|postop-infection
646687|NCT00118820|Antibiotic efficacy
646688|NCT00118820|Infection characterized by pus,erythema,edema and pain
646689|NCT00118807|malaria treatment
646690|NCT00118807|artemisinin based combination therapy
646691|NCT00118807|Plasmodium falciparum
646692|NCT00118807|pragmatic trial
646693|NCT00118807|effectiveness
646694|NCT00118794|uncomplicated malaria
646695|NCT00118794|G6PD deficiency
646696|NCT00118794|haemolytic anaemia
646697|NCT00118794|Lapdap
646698|NCT00118794|Artemsinin based combination treatment
646699|NCT00118794|compliance
646700|NCT00118794|pragmatic trials
646701|NCT00118781|ventilator-associated pneumonia
646702|NCT00118781|VAP
646703|NCT00118781|pneumonia
646704|NCT00118781|ICU infection
646705|NCT00118768|Genotype-1, Chronic Hepatitis C
646706|NCT00118729|Ragweed
646707|NCT00118729|GW685698X
646708|NCT00118729|seasonal allergic rhinitis
646709|NCT00118729|onset
646710|NCT00118716|asthma
646711|NCT00118716|bronchospasm
646712|NCT00118703|nonallergic rhinitis
646713|NCT00118703|GW685698X
646714|NCT00118703|VMR
646715|NCT00118703|vasomotor rhinitis
646716|NCT00118690|bronchospasm
646717|NCT00118690|asthma
646718|NCT00118677|HIV Infections
646719|NCT00118664|Septic Shock
646720|NCT00118664|Thrombocytopenia
646721|NCT00118664|Multiple Organ Failure
646722|NCT00118664|Pediatric
646723|NCT00118651|pneumonia
646724|NCT00118651|chest x-ray
646725|NCT00118651|diagnosis
646726|NCT00118638|Non-myeloid malignancy
646727|NCT00118638|Darbepoetin alfa
646728|NCT00118638|Clinical Trial
646729|NCT00118625|Allergy
646730|NCT00118625|Specific Immunotherapy
646731|NCT00118625|Adjuvant
646732|NCT00118625|Allergy Vaccination
646733|NCT00118625|Allergenicity
646734|NCT00118612|Allergy
646735|NCT00118612|Specific Immunotherapy
646736|NCT00118612|Allergy Vaccination
646737|NCT00118612|Allergenicity
646738|NCT00118586|Neuroanatomy
646739|NCT00118586|Brain Damage
646740|NCT00118586|Dystonia
646741|NCT00118586|Pathology
646742|NCT00118586|Brain Imaging
646743|NCT00118586|Spasmodic Dysphonia
646744|NCT00118586|SD
646745|NCT00118586|Focal Dystonia
646746|NCT00118586|Healthy Volunteer
646747|NCT00118586|HV
646748|NCT00118573|abdominal aortic aneurysm
646749|NCT00118573|randomized controlled trial
646750|NCT00118573|endovascular aneurysm repair
646751|NCT00118560|Collateral Circulation
646752|NCT00118560|Exercise Therapy
646753|NCT00118560|Microcirculation
646754|NCT00118560|Oxygen
646755|NCT00118560|Positron-emission tomography
646756|NCT00118560|Walking
646757|NCT00118547|Adherence
646758|NCT00118547|Medication
646759|NCT00118547|Multiple Sclerosis
646760|NCT00118534|addictive disorders
646761|NCT00118534|clinical trial
646762|NCT00118534|cost effectiveness
646763|NCT00118534|mental health
646764|NCT00118534|military or environmental exposure
646765|NCT00118534|multi-site trial
646766|NCT00118534|nicotine
646767|NCT00118534|nicotine replacement
646768|NCT00118534|post traumatic stress
646769|NCT00118534|post traumatic stress disorder
646770|NCT00118534|psychiatric
646771|NCT00118534|psychological
646772|NCT00118534|PTSD
646773|NCT00118534|smoking cessation
646774|NCT00118534|smoking cessation medications
646775|NCT00118534|substance abuse
646776|NCT00118521|Anterior Knee Pain
646777|NCT00118495|female sexual dysfunction
646778|NCT00118495|FSD
646779|NCT00118495|arousal
646780|NCT00118495|orgasm
646781|NCT00118495|desire
646782|NCT00118495|Zestra
646783|NCT00118495|Mixed FSD
646784|NCT00118495|Hypoactive sexual desire disorder
646785|NCT00118495|Sexual arousal disorder
646786|NCT00118495|Orgasmic disorder
646787|NCT00118482|vasovagal syncope
646788|NCT00118482|randomized clinical trial
646789|NCT00118482|quality of life
646790|NCT00118469|Adolescent
646791|NCT00118469|CBT
646792|NCT00118469|Parents
646793|NCT00118456|Advanced cancers
646794|NCT00118456|EGFR
646795|NCT00118456|Her2
646796|NCT00118456|VEGFR
646797|NCT00118443|Suicide Prevention
646798|NCT00118443|Depression
646799|NCT00118443|Adolescent
646800|NCT00118443|Students
646801|NCT00118443|School Teachers
646802|NCT00118430|Back Pain
646803|NCT00118430|Knee Pain
646804|NCT00118430|Hip Pain
646805|NCT00118430|Stepped Care
646806|NCT00118430|Antidepressant
646807|NCT00118430|Relaxation Techniques
646808|NCT00118430|Exercise
646809|NCT00118417|Selective serotonin reuptake inhibitor
646810|NCT00118417|Anxiety
646811|NCT00118417|Pharmacotherapy
646812|NCT00118417|Cognitive behavioral therapy
646813|NCT00118417|CBT
646814|NCT00118404|Cognitive therapy
646815|NCT00118404|Antidepressants
646816|NCT00118404|Psychotherapy
646817|NCT00118391|Pathological Gambling
646818|NCT00118391|CBT
646819|NCT00118391|CM
646820|NCT00118378|HIV
646821|NCT00118378|AIDS
646822|NCT00118378|Modafinil
646823|NCT00118378|Depression
646824|NCT00118339|oral complications
646825|NCT00118339|drug/agent toxicity by tissue/organ
646826|NCT00118339|stage I multiple myeloma
646827|NCT00118339|stage II multiple myeloma
646828|NCT00118339|stage III multiple myeloma
646829|NCT00118326|de novo myelodysplastic syndromes
646830|NCT00118326|disseminated neuroblastoma
646831|NCT00118326|previously treated myelodysplastic syndromes
646832|NCT00118326|recurrent neuroblastoma
646833|NCT00118326|secondary myelodysplastic syndromes
646834|NCT00118326|childhood acute myeloid leukemia in remission
646835|NCT00118326|childhood acute lymphoblastic leukemia in remission
646836|NCT00118326|childhood chronic myelogenous leukemia
646837|NCT00118326|juvenile myelomonocytic leukemia
646838|NCT00118326|previously treated childhood rhabdomyosarcoma
646839|NCT00118326|recurrent Wilms tumor and other childhood kidney tumors
646840|NCT00118326|recurrent/refractory childhood Hodgkin lymphoma
646841|NCT00118326|recurrent childhood acute lymphoblastic leukemia
646842|NCT00118326|recurrent childhood acute myeloid leukemia
646843|NCT00118326|recurrent childhood large cell lymphoma
646844|NCT00118326|recurrent childhood lymphoblastic lymphoma
646845|NCT00118326|recurrent childhood rhabdomyosarcoma
646846|NCT00118326|recurrent childhood small noncleaved cell lymphoma
646847|NCT00118326|untreated childhood acute lymphoblastic leukemia
646848|NCT00118326|untreated childhood acute myeloid leukemia and other myeloid malignancies
646849|NCT00118313|stage II melanoma
646850|NCT00118313|stage III melanoma
646851|NCT00118313|stage IV melanoma
646852|NCT00118300|stage III cervical cancer
646853|NCT00118300|stage IVA cervical cancer
646854|NCT00118300|recurrent cervical cancer
646855|NCT00118300|stage III endometrial carcinoma
646856|NCT00118300|recurrent endometrial carcinoma
646857|NCT00118300|stage III ovarian epithelial cancer
646858|NCT00118300|recurrent ovarian epithelial cancer
646859|NCT00118300|stage III ovarian germ cell tumor
646860|NCT00118300|recurrent ovarian germ cell tumor
646861|NCT00118300|stage III vaginal cancer
646862|NCT00118300|stage IVA vaginal cancer
646863|NCT00118300|recurrent vaginal cancer
646864|NCT00118300|ovarian sarcoma
646865|NCT00118300|ovarian stromal cancer
646866|NCT00118300|stage IV endometrial carcinoma
646867|NCT00118300|stage IB cervical cancer
646868|NCT00118300|stage IIA cervical cancer
646869|NCT00118300|stage IIB cervical cancer
646870|NCT00118300|stage II vaginal cancer
646871|NCT00118300|stage I vaginal cancer
646872|NCT00118274|stage II melanoma
646873|NCT00118274|stage III melanoma
646874|NCT00118274|stage IV melanoma
646875|NCT00118261|stage IV rectal cancer
646876|NCT00118261|stage IV colon cancer
646877|NCT00118261|recurrent rectal cancer
646878|NCT00118261|recurrent colon cancer
646879|NCT00118222|adult mixed glioma
646880|NCT00118222|adult anaplastic astrocytoma
646881|NCT00118222|recurrent adult brain tumor
646882|NCT00118222|adult giant cell glioblastoma
646883|NCT00118222|adult gliosarcoma
646884|NCT00118196|de novo myelodysplastic syndromes
646885|NCT00118196|previously treated myelodysplastic syndromes
646886|NCT00118196|secondary myelodysplastic syndromes
646887|NCT00118196|chronic myelomonocytic leukemia
646888|NCT00118131|stage IIIB non-small cell lung cancer
646889|NCT00118131|stage IV non-small cell lung cancer
646890|NCT00118131|recurrent non-small cell lung cancer
646891|NCT00118105|recurrent colon cancer
646892|NCT00118105|stage IV colon cancer
646893|NCT00118105|recurrent rectal cancer
646894|NCT00118105|stage IV rectal cancer
646895|NCT00118105|liver metastases
646896|NCT00118066|prostate cancer
646897|NCT00118066|high grade prostatic intraepithelial neoplasia
646898|NCT00118053|inflammatory breast cancer
646899|NCT00118053|stage II breast cancer
646900|NCT00118053|stage IIIA breast cancer
646901|NCT00118053|stage IIIB breast cancer
646902|NCT00118053|stage IIIC breast cancer
646903|NCT00118027|Malaria in pregnancy
646904|NCT00118027|Anaemia
646905|NCT00118027|Low birth weight
646906|NCT00118014|Trichotillomania
646907|NCT00118014|Habit Reversal Training
646908|NCT00118014|Sertraline
646909|NCT00118014|Zoloft
646910|NCT00118001|Psychotherapy
646911|NCT00118001|Generalized Anxiety Disorder
646912|NCT00118001|randomized-controlled trial
646913|NCT00118001|worry exposure
646914|NCT00118001|applied relaxation
646915|NCT00117975|contiguous stage II grade 1 follicular lymphoma
646916|NCT00117975|contiguous stage II grade 2 follicular lymphoma
646917|NCT00117975|noncontiguous stage II grade 1 follicular lymphoma
646918|NCT00117975|noncontiguous stage II grade 2 follicular lymphoma
646919|NCT00117975|noncontiguous stage II grade 3 follicular lymphoma
646920|NCT00117975|stage III grade 1 follicular lymphoma
646921|NCT00117975|stage III grade 2 follicular lymphoma
646922|NCT00117975|stage III grade 3 follicular lymphoma
646923|NCT00117975|stage IV grade 1 follicular lymphoma
646924|NCT00117975|stage IV grade 2 follicular lymphoma
646925|NCT00117975|stage IV grade 3 follicular lymphoma
646926|NCT00117975|contiguous stage II grade 3 follicular lymphoma
646927|NCT00117962|stage IIIA non-small cell lung cancer
646928|NCT00117962|stage IIIB non-small cell lung cancer
646929|NCT00117962|squamous cell lung cancer
646930|NCT00117962|large cell lung cancer
646931|NCT00117962|adenocarcinoma of the lung
646932|NCT00117962|bronchoalveolar cell lung cancer
646933|NCT00117949|Prostate Cancer
646934|NCT00117949|Androgen ablation therapy
646935|NCT00117936|Angiogenesis
646936|NCT00117936|No-option heart patients
646937|NCT00117936|Blocked coronary artery
646938|NCT00117936|Revascularization
646939|NCT00117936|FGF-1
646940|NCT00117936|growth factor
646941|NCT00117923|Warts
646942|NCT00117923|Adults
646943|NCT00117923|Common Warts
646944|NCT00117923|Resiquimod
646945|NCT00117910|Aged, Granulocyte Colony-Stimulating Factor
646946|NCT00117910|Combined Modality Therapy, Neutropenia
646947|NCT00117910|pegfilgrastim, Neulasta®
646948|NCT00117910|FEC-100, Antineoplastic Agents
646949|NCT00117910|Breast Cancer, Female
646950|NCT00117897|non-Hodgkin's lymphoma
646951|NCT00117897|R-CHOP-14
646952|NCT00117897|pegfilgrastim
646953|NCT00117897|neutropenia, clinical trial
646954|NCT00117897|haematopoietic growth factor
646955|NCT00117884|Papillomavirus infections;
646956|NCT00117884|Cervix Dysplasia
646957|NCT00117871|Warts
646958|NCT00117871|Adults
646959|NCT00117871|Common Warts
646960|NCT00117871|Resiquimod
646961|NCT00117858|Frontal Lobe
646962|NCT00117858|Language
646963|NCT00117858|Behavior
646964|NCT00117858|Degenerative Diseases
646965|NCT00117858|Pick's Disease
646966|NCT00117858|Frontotemporal Dementia
646967|NCT00117858|FTP
646968|NCT00117845|Denileukin Diftitox (Ontak)
646969|NCT00117845|Recombinant Immunotoxin
646970|NCT00117845|Human T-Cell Lymphotropic Virus (HTLV1)
646971|NCT00117845|CD25 Positive
646972|NCT00117845|IL-2R
646973|NCT00117845|ATL
646974|NCT00117845|Ontak
646975|NCT00117845|Adult T-Cell Leukemia
646976|NCT00117845|Lymphoproliferative Disorders
646977|NCT00117832|allergic rhinitis
646978|NCT00117819|parkinson
646979|NCT00117819|family history
646980|NCT00117819|diagnosis
646981|NCT00117806|Adult
646982|NCT00117806|Depression
646983|NCT00117806|Employment, supported
646984|NCT00117806|Health Service/ut
646985|NCT00117806|Humans
646986|NCT00117806|Outcomes
646987|NCT00117806|Quality of life
646988|NCT00117806|Veterans/rh (rehabilitation)
646989|NCT00117806|Workplace
646990|NCT00117806|Spinal Cord Injuries
646991|NCT00117793|Amputee
646992|NCT00117793|Artificial limbs
646993|NCT00117793|Gait
646994|NCT00117793|Walking
646995|NCT00117767|Terbinafine, Tinea capitis, pediatric, antifungal
646996|NCT00117754|Terbinafine, Tinea capitis, pediatric, antifungal
646997|NCT00117741|Opiate Dependence
646998|NCT00117741|DBT
646999|NCT00117741|Dialectical Behavior Therapy
647000|NCT00117741|Drug Counseling
647001|NCT00117741|Therapy, Cognitive Behavior
647002|NCT00117728|Non-nucleoside reverse transcriptase inhibitor
647003|NCT00117728|Drug Resistance
647004|NCT00117728|HIV Seronegativity
647005|NCT00117728|Treatment Naive
647006|NCT00117715|Developmental regulation of CYPs 1A2, 2D6, 3A4
647007|NCT00117715|Ontogeny
647008|NCT00117715|pharmacokinetics
647009|NCT00117715|drug biotransformation
647010|NCT00117715|enzymatic biotransformation of drugs
647011|NCT00117702|GvHD
647012|NCT00117702|Tacrolimus
647013|NCT00117702|Everolimus
647014|NCT00117702|Stem cell transplantation
647015|NCT00117689|Anti-T cell antibodies
647016|NCT00117689|Primary Liver Transplantation and Renal Dysfunction
647017|NCT00117689|Liver Transplant Rejection
647018|NCT00117689|Induction Therapy with reduction of Calcineurin inhibitors
647019|NCT00117689|Primary Liver Transplantation
647020|NCT00117689|Primary Transplant Rejection
647021|NCT00117689|Transplantation, Liver
647022|NCT00117689|Rejection, Transplant
647023|NCT00117676|tenofovir
647024|NCT00117676|adefovir
647025|NCT00117676|hepatitis B virus
647026|NCT00117676|HBeAg Negative
647027|NCT00117663|Randomized controlled trial
647028|NCT00117663|Mammography
647029|NCT00117663|health care setting
647030|NCT00117663|hormone replacement therapy
647031|NCT00117663|breast density
647032|NCT00117663|mammography performance
647033|NCT00117663|Breast Carcinoma
647034|NCT00117650|leg pain
647035|NCT00117650|gene transfer
647036|NCT00117650|angiogenesis
647037|NCT00117650|Phase 2
647038|NCT00117650|Genzyme
647039|NCT00117650|peripheral arterial disease
647040|NCT00117637|Renal Cell Cancer
647041|NCT00117637|RCC
647042|NCT00117637|Cancer
647043|NCT00117624|Non-myeloid malignancy
647044|NCT00117624|Darbepoetin alfa
647045|NCT00117624|Clinical Trial
647046|NCT00117611|chronic sinusitis
647047|NCT00117598|Lymphoma
647048|NCT00117585|Aging
647049|NCT00117585|Blood pressure
647050|NCT00117585|Hypotension
647051|NCT00117585|Orthostatic
647052|NCT00117585|Rehabilitation
647053|NCT00117572|Cancer of the Pharynx (Nasopharynx, Oropharynx, Hypopharynx)
647054|NCT00117572|Cancer of the Nasal Cavity and Paranasal Sinuses
647055|NCT00117559|Psychotherapy,group
647056|NCT00117559|Rehabilitation
647057|NCT00117559|Telecommunications
647058|NCT00117546|CAPACITY trial
647059|NCT00117546|preeclampsia
647060|NCT00117546|plasma volume
647061|NCT00117546|sympathetic activity
647062|NCT00117546|hypertension
647063|NCT00117546|cardiovascular system
647064|NCT00117533|chronic hepatitis B;
647065|NCT00117533|chronic hepatitis delta;
647066|NCT00117533|treatment;
647067|NCT00117533|pegylated interferon alfa-2b;
647068|NCT00117533|ribavirin
647069|NCT00117520|caffeine, endurance, postural stability, elderly
647070|NCT00117507|MDS
647071|NCT00117507|Myelodysplastic Syndrome
647072|NCT00117507|ICL-670
647073|NCT00117507|ICL-670 and Myelodysplastic Syndrome
647074|NCT00117494|Hyperlipidemia
647075|NCT00117494|HIV infections
647076|NCT00117494|STATINS, HMG-COA
647077|NCT00117494|Protease Inhibitor
647078|NCT00117494|Treatment Experienced
647079|NCT00117481|endometriosis
647080|NCT00117481|pelvic pain
647081|NCT00117481|hormonal treatment
647082|NCT00117468|luteal phase replacement
647083|NCT00117468|oocyte donation
647084|NCT00117468|infertility
647085|NCT00117468|progesterone
647086|NCT00117455|ICE
647087|NCT00117455|BEAM
647088|NCT00117455|PBPC transplant
647089|NCT00117442|solid tumour
647090|NCT00117442|unknown primary tumour
647091|NCT00117442|carboplatin
647092|NCT00117442|paclitaxel
647093|NCT00117429|HIV-1
647094|NCT00117429|therapeutic vaccination
647095|NCT00117429|cellular immunity
647096|NCT00117429|humoral immunity
647097|NCT00117429|HAART
647098|NCT00117429|chronic HIV-1 infection
647099|NCT00117429|Treatment Experienced
647100|NCT00117429|HIV Therapeutic Vaccine
647101|NCT00117403|dementia
647102|NCT00117403|anti-oxidant
647103|NCT00117403|biomarkers
647104|NCT00117403|alpha-tocopherol
647105|NCT00117403|CoQ
647106|NCT00117377|Atopic dermatitis, pimecrolimus, cellular, molecular
647107|NCT00117364|chronic ulcer
647108|NCT00117364|poor healing
647109|NCT00117364|The patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study
647110|NCT00117351|Adenocarcinoma
647111|NCT00117351|Bronchiolo-Alveolar
647112|NCT00117351|Carcinoma, Bronchioloalveolar
647113|NCT00117351|Carcinoma, Non-Small-Cell Lung
647114|NCT00117351|Carcinoma, Bronchiolo-Alveolar
647115|NCT00117325|Vasomotor Rhinitis
647116|NCT00117325|VMR
647117|NCT00117325|nonallergic rhinitis
647118|NCT00117325|GW685698X
647119|NCT00117312|Prostate Cancer
647120|NCT00117312|Androgen ablation therapy
647121|NCT00117299|Gastrointestinal stromal tumor
647122|NCT00117299|GIST
647123|NCT00117299|Sarcoma
647124|NCT00117299|PTK787
647125|NCT00117299|ZK 222584
647126|NCT00117299|Tyrosine kinase inhibitor
647127|NCT00117299|Tyrosine kinase
647128|NCT00117299|VEGF
647129|NCT00117299|Vascular endothelial growth factor
647130|NCT00117299|VEGFR
647131|NCT00117299|Vascular endothelial growth factor receptor
647132|NCT00117299|KDR
647133|NCT00117299|KIT
647134|NCT00117299|c-KIT
647135|NCT00117299|Platelet derived growth factor receptor
647136|NCT00117299|PDGFR
647137|NCT00117286|Prostate Cancer
647138|NCT00117286|Androgen ablation therapy
647139|NCT00117260|osteopenia
647140|NCT00117260|bone mineral density
647141|NCT00117260|amenorrhea
647142|NCT00117260|adolescents
647143|NCT00117247|Heart Failure
647144|NCT00117234|chronic heart failure
647145|NCT00117234|congestive heart failure
647146|NCT00117234|low hemoglobin
647147|NCT00117234|anemia
647148|NCT00117234|CHF
647149|NCT00117234|Symptomatic Congestive Heart Failure (CHF)
647150|NCT00117221|Magnetic Resonance Imaging
647151|NCT00117221|Functional Imaging
647152|NCT00117221|Cerebral Blood Flow
647153|NCT00117221|BOLD Effect
647154|NCT00117221|Sleep
647155|NCT00117208|cystic fibrosis
647156|NCT00117195|parkinson
647157|NCT00117195|diagnosis
647158|NCT00117195|screening
647159|NCT00117169|Pulmonary embolism
647160|NCT00117169|multi-detector helical computed tomography clinical probability
647161|NCT00117169|clinical score
647162|NCT00117156|Fludarabine
647163|NCT00117156|Rituximab
647164|NCT00117156|Marginal Zone Lymphoma
647165|NCT00117156|MALT lymphoma
647166|NCT00117143|Immune Thrombocytopenic Purpura
647167|NCT00117143|Idiopathic Thrombocytopenic Purpura
647168|NCT00117143|ITP
647169|NCT00117143|Thrombocytopenia
647170|NCT00117130|Kidney disease, Renal, CKD (Chronic Kidney Disease)
647171|NCT00117130|CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen
647172|NCT00117130|Aranesp®, Darbepoetin alfa, QW dosing
647173|NCT00117130|Q2W dosing, Q4W dosing
647174|NCT00117130|Patient preference, Subject preference
647175|NCT00117117|Chemotherapy induced anemia
647176|NCT00117117|Amgen
647177|NCT00117117|Aranesp®
647178|NCT00117117|darbepoetin alfa
647179|NCT00117104|End Stage Renal Disease (ESRD)
647180|NCT00117104|Kidney Disease, Dialysis
647181|NCT00117104|Aranesp®, rHuEPO
647182|NCT00117104|Anemia, Hemoglobin
647183|NCT00117104|Dosing, Amgen
647184|NCT00117091|Rheumatoid Arthritis
647185|NCT00117091|RA
647186|NCT00117091|Anakinra (Kineret®)
647187|NCT00117078|Kidney disease, Renal, CKD (Chronic Kidney Disease)
647188|NCT00117078|CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen
647189|NCT00117078|Aranesp®, Darbepoetin alfa, QW dosing
647190|NCT00117078|Q2W dosing, Q4W dosing
647191|NCT00117078|Patient preference, Subject preference
647192|NCT00117065|Kidney transplant, Renal transplant
647193|NCT00117065|Aranesp®, Darbepoetin alfa
647194|NCT00117065|Amgen, Q2W dosing, Q4W dosing
647195|NCT00117052|Clinical trial
647196|NCT00117052|Amgen
647197|NCT00117052|Secondary HyperParaThyroidism (SHPT)
647198|NCT00117052|Dialysis
647199|NCT00117052|End Stage Renal Disease (ESRD)
647200|NCT00117052|KDOQI
647201|NCT00117052|Cinacalcet
647202|NCT00117039|anemia
647203|NCT00117039|fatigue
647204|NCT00117039|Aranesp®
647205|NCT00117039|clinical trial
647206|NCT00117026|Diabetes Complications
647207|NCT00117026|benfotiamine
647208|NCT00117026|type 1 diabetes
647209|NCT00117026|elevated urinary albumin excretion
647210|NCT00117026|nerve function
647211|NCT00117026|advanced glycation end products
647212|NCT00117013|Phase I
647213|NCT00117013|Antiangiogenesis
647214|NCT00117013|Targeted Therapy
647215|NCT00117013|Chronic Schedule
647216|NCT00117013|VEGF
647217|NCT00117013|Cancer
647218|NCT00117013|Metastatic Solid Tumor
647219|NCT00117000|testosterone
647220|NCT00117000|food, formulated
647221|NCT00117000|malnutrition
647222|NCT00117000|undernutrition
647223|NCT00117000|aging
647224|NCT00117000|aged
647225|NCT00117000|aged, 80 and over
647226|NCT00117000|frail elderly
647227|NCT00116987|physiologic pacing
647228|NCT00116987|ventricular pacing
647229|NCT00116987|hospitalizations
647230|NCT00116974|Dental scaling
647231|NCT00116948|Osteoarthrosis
647232|NCT00116948|RSA
647233|NCT00116948|DEXA
647234|NCT00116948|Hip arthroplasty
647235|NCT00116948|Metal ion
647236|NCT00116948|Inflammatory response
647237|NCT00116948|Gait analysis
647238|NCT00116935|Gastrointestinal stromal tumor
647239|NCT00116935|GIST
647240|NCT00116935|Sarcoma
647241|NCT00116935|Imatinib
647242|NCT00116935|Adjuvant therapy
647243|NCT00116935|KIT
647244|NCT00116935|PDGFRA
647245|NCT00116935|Receptor tyrosine kinase
647246|NCT00116935|Tyrosine kinase inhibitor
647247|NCT00116922|Diabetes
647248|NCT00116922|Prevention.
647249|NCT00116922|Rosiglitazone
647250|NCT00116922|Metformin
647251|NCT00116922|Lifestyle
647252|NCT00116922|Impaired glucose Tolerance
647253|NCT00116883|GW685698X
647254|NCT00116883|perennial allergic rhinitis
647255|NCT00116883|pediatric
647256|NCT00116883|intranasal corticosteroid
647257|NCT00116883|HPA axis function
647258|NCT00116870|CAD
647259|NCT00116870|familial hypercholesterolemia
647260|NCT00116844|viral shedding
647261|NCT00116844|Recurrent
647262|NCT00116844|herpes
647263|NCT00116844|genital herpes
647264|NCT00116831|atheroma
647265|NCT00116831|IVUS
647266|NCT00116831|Intravascular ultrasound
647267|NCT00116831|atherosclerosis
647268|NCT00116818|perennial allergic rhinitis
647269|NCT00116818|intranasal corticosteroid
647270|NCT00116818|HPA axis function
647271|NCT00116818|GW685698X
647272|NCT00116805|tenofovir
647273|NCT00116805|adefovir
647274|NCT00116805|hepatitis B
647275|NCT00116805|HBeAg Positive
647276|NCT00116792|CAD
647277|NCT00116792|Diabetes Mellitus
647278|NCT00116792|Restenosis
647279|NCT00116792|ppar gamma
647280|NCT00116792|glitazone
647281|NCT00116779|Prostate Cancer
647282|NCT00116779|Androgen ablation therapy
647283|NCT00116766|mosquitoes
647284|NCT00116766|malaria
647285|NCT00116766|vector control
647286|NCT00116766|plant-based
647287|NCT00116753|Prostate Cancer
647288|NCT00116753|Androgen ablation therapy
647289|NCT00116740|Serotonin
647290|NCT00116740|5-HT2c
647291|NCT00116740|Satiety
647292|NCT00116740|Obesity
647293|NCT00116740|Appetite suppressant
647294|NCT00116740|Weight Loss
647295|NCT00116740|Overweight
647296|NCT00116727|Rheumatoid Arthritis
647297|NCT00116727|DMARD
647298|NCT00116714|rheumatoid arthritis
647299|NCT00116714|RA
647300|NCT00116714|DMARD
647301|NCT00116701|Chronic Kidney Disease (CKD)
647302|NCT00116701|Haemoglobin (Hb)
647303|NCT00116701|Erthropoetin (EPO)
647304|NCT00116701|End Stage Renal Disease (ESRD)
647305|NCT00116701|Recombinant Human Erthropoetic (rHuEPO)
647306|NCT00116701|Anaemia
647307|NCT00116701|Darbepoetin Alfa, Aranesp®
647308|NCT00116701|Haemodialysis
647309|NCT00116701|Clinical Trial
647310|NCT00116688|Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
647311|NCT00116688|Thrombocytopenic
647312|NCT00116675|Common Wart(s)
647313|NCT00116675|Pediatric
647314|NCT00116675|Wart(s)
647315|NCT00116675|Children
647316|NCT00116675|3M Pharmaceuticals
647317|NCT00116675|Resiquimod
647318|NCT00116662|Wart(s)
647319|NCT00116662|Common Wart(s)
647320|NCT00116662|Children
647321|NCT00116662|Pediatric
647322|NCT00116662|3M Pharmaceuticals
647323|NCT00116662|Resiquimod
647324|NCT00116649|actinic keratosis lesions large head torso extremities
647325|NCT00116649|actinic keratosis
647326|NCT00116636|HIV
647327|NCT00116636|Treatment Naive
647328|NCT00116610|small cell lung cancer
647329|NCT00116610|resistant
647330|NCT00116610|refractory
647331|NCT00116610|platinum
647332|NCT00116610|chemotherapy
647333|NCT00116610|second-line
647334|NCT00116610|relapse
647335|NCT00116610|sensitive
647336|NCT00116597|Active Specific Immunotherapy
647337|NCT00116597|Intranodal
647338|NCT00116597|Cancer
647339|NCT00116597|Melanoma stages IIb to IV
647340|NCT00116597|Gene Therapy
647341|NCT00116597|Recombinant Vaccinia virus
647342|NCT00116597|HLA-A2
647343|NCT00116597|Mart-1/Melan-A, Gp-100, tyrosinase
647344|NCT00116597|Clinical Trial
647345|NCT00116597|Phase I/II
647346|NCT00116584|heliox
647347|NCT00116584|bronchiolitis
647348|NCT00116584|racemic epinephrine
647349|NCT00116571|Benign Prostatic Hyperplasia (BPH)
647350|NCT00116571|Photodynamic Therapy (PDT)
647351|NCT00116571|Lower Urinary Tract Symptoms (LUTS)
647352|NCT00116558|amyotrophic lateral sclerosis
647353|NCT00116558|ALS
647354|NCT00116558|Lou Gehrig's disease
647355|NCT00116558|nutrition
647356|NCT00116558|NIPPV
647357|NCT00116558|non-invasive positive pressure ventilation
647358|NCT00116558|percutaneous endoscopic gastrostomy
647359|NCT00116558|PEG
647360|NCT00116545|IDDM
647361|NCT00116545|Insulin
647362|NCT00116545|cardiovascular disease
647363|NCT00116532|Obsessive Compulsive Disorder
647364|NCT00116532|Escitalopram
647365|NCT00116532|SSRI
647366|NCT00116532|Open Label
647367|NCT00116506|Metastatic Colorectal Cancer
647368|NCT00116506|Bevacizumab
647369|NCT00116506|Erlotinib
647370|NCT00116506|FOLFOX
647371|NCT00116493|severe anemia
647372|NCT00116493|anthelminthic
647373|NCT00116493|multivitamins
647374|NCT00116493|pregnancy
647375|NCT00116493|children
647376|NCT00116493|Pakistan
647377|NCT00116480|Postpartum Haemorrhage
647378|NCT00116480|Misoprostol
647379|NCT00116467|AML
647380|NCT00116467|Acute Myelogenous Leukemia
647381|NCT00116467|GVAX
647382|NCT00116467|Vaccine
647383|NCT00116467|Stem Cell Transplant
647384|NCT00116467|Autologous
647385|NCT00116454|Carcinoma, Hepatocellular
647386|NCT00116454|Viral Hepatitis, Alcoholic Hepatitis
647387|NCT00116441|Multiple Myeloma
647388|NCT00116441|Cancer
647389|NCT00116441|PSCT
647390|NCT00116441|Peripheral Stem Cell Transplant
647391|NCT00116441|Chemotherapy
647392|NCT00116441|GVAX
647393|NCT00116428|Atrial Fibrillation
647394|NCT00116428|Paroxysmal Atrial Fibrillation
647395|NCT00116415|HIV/AIDS
647396|NCT00116402|COPD
647397|NCT00116402|Chronic Obstructive
647398|NCT00116402|Pulmonary Disease
647399|NCT00116402|Inhaled Corticosteroids
647400|NCT00116402|Airway Inflammation
647401|NCT00116402|Bronchoscopy
647402|NCT00116389|pancreatic cancer
647403|NCT00116389|cancer of the pancreas
647404|NCT00116389|adenocarcinoma of the pancreas
647405|NCT00116389|pancreatic neoplasms
647406|NCT00116389|Metastatic pancreatic cancer (Stage IV)
647407|NCT00116389|Stage IV Adenocarcinoma of the Pancreas
647408|NCT00116376|GBM
647409|NCT00116376|recurrent/relapse
647410|NCT00116376|EGFR
647411|NCT00116376|VEGFR
647412|NCT00116363|gene therapy
647413|NCT00116363|melanoma
647414|NCT00116363|adenovirus
647415|NCT00116363|in-transit melanoma
647416|NCT00116363|metastatic melanoma
647417|NCT00116350|Postpartum hemorrhage
647418|NCT00116350|Misoprostol
647419|NCT00116350|Developing countries
647420|NCT00116350|Maternal morbidity
647421|NCT00116350|Randomized controlled trial
647422|NCT00116337|spinal cord injury
647423|NCT00116337|paralysis
647424|NCT00116337|cough
647425|NCT00116337|cervical spinal cord injury
647426|NCT00116337|thoracic spinal cord injury
647427|NCT00116324|Asthma
647428|NCT00116324|Leukotriene receptor antagonist
647429|NCT00116324|Hypertonic saline challenge
647430|NCT00116311|Adenosine receptors
647431|NCT00116311|asthma
647432|NCT00116311|sputum
647433|NCT00116311|peripheral blood
647434|NCT00116311|healthy
647435|NCT00116298|Antivirals
647436|NCT00116298|HIV
647437|NCT00116285|allergy
647438|NCT00116285|skin prick test
647439|NCT00116285|allergoid
647440|NCT00116285|allergenicity
647441|NCT00116285|specific immunotherapy
647442|NCT00116272|pregnancy
647443|NCT00116272|Autoimmune Disease
647444|NCT00116259|clinical trial
647445|NCT00116259|aripiprazole
647446|NCT00116259|Bipolar Disorder
647447|NCT00116259|Attention-Deficit Hyperactivity Disorder
647448|NCT00116259|ADHD
647449|NCT00116246|Labour
647450|NCT00116246|vaginal delivery
647451|NCT00116246|primigravida
647452|NCT00116246|McRobert's Manoeuvre
647453|NCT00116246|operative delivery
647454|NCT00116233|post operative adhesions
647455|NCT00116220|Prostate Cancer
647456|NCT00116220|Total Androgen Suppression
647457|NCT00116220|endorectal coil MRI
647458|NCT00116220|External Beam Radiation Therapy
647459|NCT00116220|Prostate Cancer- High Risk, clinically Organ-Confined
647460|NCT00116207|Type 1 Diabetes
647461|NCT00116207|Oxidative Stress
647462|NCT00116207|Diabetic Complications
647463|NCT00116207|Neuropathy
647464|NCT00116194|exercise
647465|NCT00116194|activities of daily living
647466|NCT00116194|ADL
647467|NCT00116194|loss of mobility
647468|NCT00116194|risk of disability
647469|NCT00116194|physical activity
647470|NCT00116194|mobility disability
647471|NCT00115466|ASCs (adult stem cells derived from adipose tissue)
647472|NCT00115466|Fistula
647473|NCT00115466|Cell Therapy
647474|NCT00115466|Complex perianal fistula
647475|NCT00115453|glioblastoma
647476|NCT00115453|boron neutron capture therapy
647477|NCT00115453|boronophenylalanine
647478|NCT00115453|brain tumor
647479|NCT00115440|glioblastoma
647480|NCT00115440|anaplastic astrocytoma
647481|NCT00115440|boron neutron capture therapy
647482|NCT00115440|radiation therapy
647483|NCT00115440|boronophenylalanine
647484|NCT00115427|Bilateral, Idiopathic Parkinson's Disease
647485|NCT00115414|Neulasta®
647486|NCT00115414|Chemotherapy
647487|NCT00115414|TAC
647488|NCT00115414|Amgen
647489|NCT00115401|Walking
647490|NCT00115401|Compensation
647491|NCT00115401|Leg Weakness
647492|NCT00115401|Orthotics
647493|NCT00115401|Joint Impairment
647494|NCT00115401|Healthy Volunteer
647495|NCT00115401|HV
647496|NCT00115401|Joint Inmpairment
647497|NCT00115388|Pelvic inflammatory disease
647498|NCT00115388|Chlamydia trachomatis
647499|NCT00115388|Screening
647500|NCT00115375|THROMBOSIS
647501|NCT00115375|PLATELET AGGREGATION
647502|NCT00115375|Pediatrics
647503|NCT00115362|functional dyspepsia;
647504|NCT00115362|Serotonin Uptake Inhibitors;
647505|NCT00115362|Antidepressive Agents.
647506|NCT00115336|Blood Diseases
647507|NCT00115336|Sickle Cell Anemia
647508|NCT00115310|dermal assessment
647509|NCT00115310|pain measurement
647510|NCT00115310|diary
647511|NCT00115310|PHN
647512|NCT00115310|shingles
647513|NCT00115310|neuropathy
647514|NCT00115310|analgesics
647515|NCT00115310|capsaicin
647516|NCT00115310|postherpetic neuralgia
647517|NCT00115284|Asthma
647518|NCT00115284|Education, Medical, Continuing
647519|NCT00115284|American Board of Internal Medicine
647520|NCT00115284|Recertification
647521|NCT00115284|Continuous Professional Development
647522|NCT00115284|Practice improvement
647523|NCT00115271|Micronutrients
647524|NCT00115271|Supplementation
647525|NCT00115271|Pregnancy
647526|NCT00115271|Birth weight
647527|NCT00115271|Infant mortality
647528|NCT00115258|Nutrition, Parenteral
647529|NCT00115258|Body Composition
647530|NCT00115258|Energy Expenditure
647531|NCT00115232|cardiovascular disease
647532|NCT00115232|metabolic syndrome
647533|NCT00115232|hypercholesterolemia
647534|NCT00115232|child
647535|NCT00115232|family history
647536|NCT00115232|inflammation
647537|NCT00116155|Hormone Refractory Metastatic Prostate Cancer
647538|NCT00116142|Prostate Cancer
647539|NCT00116142|Hormone Refractory
647540|NCT00116142|Metastatic
647541|NCT00116142|Localized
647542|NCT00116142|Locally Advanced
647543|NCT00116142|Prostate Cancer - High Risk Localized or Locally Advanced
647544|NCT00116129|Fibromyalgia
647545|NCT00116129|Treatment
647546|NCT00116129|Growth hormone
647547|NCT00116129|IGF-1
647548|NCT00116129|MK-0677
647549|NCT00116129|Oral growth hormone secretagogue
647550|NCT00116116|HIV/AIDS
647551|NCT00116103|Treatment Effectiveness
647552|NCT00116103|Treatment Efficacy
647553|NCT00116103|Investigational, Therapies
647554|NCT00116103|Asthma
647555|NCT00116103|Antiasthmatics
647556|NCT00116103|Antiasthmatic agents
647557|NCT00116090|Uveitis
647558|NCT00116090|Immunosuppression
647559|NCT00116090|Cancer
647560|NCT00116090|Infections
647561|NCT00116090|Mortality
647562|NCT00116090|Ocular Inflammatory Disease
647563|NCT00116090|Scleritis
647564|NCT00116090|Mucous Membranes Pemphigoid
647565|NCT00116077|PET
647566|NCT00116077|[C-11] NNC-112
647567|NCT00116077|[F-18] Fallypride
647568|NCT00116077|Dopamine Receptors
647569|NCT00116077|Mood Disorders
647570|NCT00116077|DA Receptors
647571|NCT00116077|Major Depressive Disorder
647572|NCT00116077|Bipolar Disorder
647573|NCT00116077|MDD
647574|NCT00116077|Bipolar Depression
647575|NCT00116077|Healthy Volunteer
647576|NCT00116077|HV
647577|NCT00116064|intranasal
647578|NCT00116064|lorazepam
647579|NCT00116064|paediatric
647580|NCT00116064|convulsions
647581|NCT00116051|RSA
647582|NCT00116051|DEXA
647583|NCT00116051|Osteoarthritis
647584|NCT00116051|Hip arthroplasty
647585|NCT00116038|RSA
647586|NCT00116038|Osteoarthritis
647587|NCT00116038|Hip arthroplasty
647588|NCT00116038|DEXA
647589|NCT00116012|acute coronary syndrome
647590|NCT00116012|rNAPc2
647591|NCT00116012|unstable angina
647592|NCT00116012|Non-STE myocardial infarction
647593|NCT00116012|ST elevation
647594|NCT00116012|cardiac enzymes
647595|NCT00116012|acute coronary syndromes
647596|NCT00116012|factor VIIa
647597|NCT00116012|tissue factor
647598|NCT00116012|nematode anticoagulant protein c2
647599|NCT00116012|anticoagulants
647600|NCT00116012|thrombin inhibitors
647601|NCT00116012|thrombosis
647602|NCT00115999|PAO
647603|NCT00115999|acute peripheral arterial occlusion
647604|NCT00115999|thrombolysis
647605|NCT00115999|blood clot
647606|NCT00115999|leg attack
647607|NCT00115999|alfimeprase
647608|NCT00115999|thrombus
647609|NCT00115999|embolism
647610|NCT00115999|thromboembolism
647611|NCT00115999|claudication
647612|NCT00115999|thrombolytic
647613|NCT00115999|thrombosis
647614|NCT00115999|plasminogen activator
647615|NCT00115999|arterial flow
647616|NCT00115986|A/H5N1, Influenza, Vaccine, parent protocol
647617|NCT00115973|Pump
647618|NCT00115973|Diabetes
647619|NCT00115960|IL-12
647620|NCT00115960|IL-15
647621|NCT00115960|HIV Seronegativity
647622|NCT00115960|HIV Preventive Vaccine
647623|NCT00115921|Home-based care
647624|NCT00115921|Malaria
647625|NCT00115921|Africa
647626|NCT00115908|Hepatitis C
647627|NCT00115895|radioiodine
647628|NCT00115895|serum thyroglobulin
647629|NCT00115895|whole body radioiodine scanning
647630|NCT00115882|Adolescent
647631|NCT00115882|smoking
647632|NCT00115882|smoking cessation
647633|NCT00115882|counseling
647634|NCT00115869|smoking prevention
647635|NCT00115869|tobacco use prevention
647636|NCT00115869|adolescent tobacco use
647637|NCT00115869|prevention intervention
647638|NCT00115856|Arterial Disease
647639|NCT00115843|Atrial fibrillation
647640|NCT00115843|Arrhythmia
647641|NCT00115843|Tachycardia
647642|NCT00115804|Fibromyalgia
647643|NCT00115804|Juvenile
647644|NCT00115791|Atrial Flutters
647645|NCT00115791|Atrial Fibrillations
647646|NCT00115791|RSD1235
647647|NCT00115778|Hypogammaglobulinemia
647648|NCT00115778|Lung Transplantation
647649|NCT00115765|Panitumumab Advanced Colorectal Cancer Evaluation Study (PACCE Study)
647650|NCT00115765|Colorectal, Colon, Rectal Cancer, Metastatic Colorectal
647651|NCT00115765|Cancer
647652|NCT00115765|EGFr, Clinical Trial
647653|NCT00115765|Panitumumab, ABX-EGF
647654|NCT00115765|Immunex, Abgenix, Amgen
647655|NCT00115765|Metastatic Colorectal Cancer
647656|NCT00115765|Oncology
647657|NCT00115752|Single Nucleotide Polymorphism
647658|NCT00115752|Analgesic Efficacy
647659|NCT00115752|Oral Surgery Model
647660|NCT00115752|Cyclooxygenase Inhibitor
647661|NCT00115752|Gene Expression Profile
647662|NCT00115752|Wisdom Teeth
647663|NCT00115752|Third Molar Extraction
647664|NCT00115739|Anaplastic Thyroid Cancer
647665|NCT00115726|anesthesia
647666|NCT00115726|hypotension
647667|NCT00115726|furosemide
647668|NCT00115726|blood pressure
647669|NCT00115726|peripheral edema
647670|NCT00115726|diuretic
647671|NCT00115726|surgery
647672|NCT00115726|congestive heart failure
647673|NCT00115713|Aerobic Exercise
647674|NCT00115713|Weight Lifting
647675|NCT00115713|Breast Cancer
647676|NCT00115713|Quality of Life
647677|NCT00115700|Radiotherapy
647678|NCT00115700|Chemotherapy
647679|NCT00115700|Rituximab
647680|NCT00115700|Randomised Trial
647681|NCT00115700|Stage I-II low grade follicular lymphoma
647682|NCT00115687|nicotine addiction
647683|NCT00115661|Peroxisome Proliferator-Activated Receptors
647684|NCT00115661|treatment of endometriosis
647685|NCT00115648|HIV
647686|NCT00115648|MTCT
647687|NCT00115648|Infants
647688|NCT00115648|africa
647689|NCT00115648|HIV Seronegativity
647690|NCT00115635|Hormonal refractory, chemotherapy, docetaxel, gemcitabine
647691|NCT00115622|GW685698X
647692|NCT00115622|once daily
647693|NCT00115622|mountain cedar
647694|NCT00115622|allergic rhinitis
647695|NCT00115622|fluticasone furoate
647696|NCT00115609|HIV infections
647697|NCT00115609|tuberculosis
647698|NCT00115609|tuberculosis agents
647699|NCT00115609|Anti HIV agents
647700|NCT00115609|Treatment Naive
647701|NCT00115596|Procedure
647702|NCT00115596|Training
647703|NCT00115596|Simulation
647704|NCT00115596|Pediatrics
647705|NCT00115596|Curriculum
647706|NCT00115596|Evaluation
647707|NCT00115570|Diabetes,Insulin-Dependent, pediatric,rapid acting injection
647708|NCT00115557|translational research
647709|NCT00115557|prevention
647710|NCT00115557|primary care
647711|NCT00115557|practice-based research network
647712|NCT00115544|neonatal
647713|NCT00115544|jaundice
647714|NCT00115544|hyperbilirubinemia
647715|NCT00115531|Elderly, influenza, vaccine, parent protocol
647716|NCT00115505|stage IA breast cancer
647717|NCT00115505|stage II breast cancer
647718|NCT00115505|stage IB breast cancer
647719|NCT00115505|estrogen receptor-negative breast cancer
647720|NCT00115505|estrogen receptor-positive breast cancer
647721|NCT00115505|progesterone receptor-negative breast cancer
647722|NCT00115505|progesterone receptor-positive breast cancer
647723|NCT00115492|Breathing
647724|NCT00115492|Exacerbation
647725|NCT00115492|Chronic Obstructive Pulmonary Disease
647726|NCT00115479|critical illness
647727|NCT00115479|intensive care
647728|NCT00115479|outcome
647729|NCT00115479|insulin
647730|NCT00115479|blood glucose
647731|NCT00115219|Rheumatoid Arthritis, RA
647732|NCT00115219|Enbrel® (etanercept)
647733|NCT00115219|Clinical Trials, Amgen
647734|NCT00115219|Immunex, Methotrexate (MTX)
647735|NCT00115219|Rheumatoid Arthritis (RA)
647736|NCT00115206|Non Small Cell Lung Cancer
647737|NCT00115206|NSCLC
647738|NCT00115206|Fever
647739|NCT00115206|Neutropenia
647740|NCT00115206|Neulasta®
647741|NCT00115206|Quality of Life
647742|NCT00115206|Chemotherapy
647743|NCT00115206|Amgen
647744|NCT00115193|Oncology
647745|NCT00115193|NHL
647746|NCT00115193|Mantle cell
647747|NCT00115193|Diffuse large B-cell
647748|NCT00115193|Chemotherapy
647749|NCT00115193|RCHOP
647750|NCT00115193|Neulasta®
647751|NCT00115193|Neutropenia
647752|NCT00115193|Pegfilgrastim
647753|NCT00115193|Amgen
647754|NCT00115180|analgesia
647755|NCT00115180|adult
647756|NCT00115180|opioid
647757|NCT00115180|Long Bone Fractures
647758|NCT00115167|Oncology
647759|NCT00115167|Cancer-related anemia
647760|NCT00115154|Actinic Keratosis
647761|NCT00115154|AK
647762|NCT00115154|3M Pharmaceuticals
647763|NCT00115154|Aldara
647764|NCT00115154|Imiquimod
647765|NCT00115154|Actinic Keratosis (AK)
647766|NCT00115141|Wart(s)
647767|NCT00115141|Adults
647768|NCT00115141|Common Wart(s)
647769|NCT00115128|normal PBPC donors
647770|NCT00115115|Donor dopamine
647771|NCT00115115|Immediate graft function
647772|NCT00115115|Kidney transplantation
647773|NCT00115102|Atypical odontalgia
647774|NCT00115102|capsaicin
647775|NCT00115102|pain
647776|NCT00115102|neuropathic pain
647777|NCT00115089|Allergic Rhinitis
647778|NCT00115089|Nasal Spray
647779|NCT00115089|Seasonal Allergic Rhinitis
647780|NCT00115076|skin
647781|NCT00115076|psoriasis
647782|NCT00115063|obesity
647783|NCT00115063|Low Calorie Diet
647784|NCT00115063|Obesity Pharmacotherapy
647785|NCT00115063|Pragmatic Clinical Trial
647786|NCT00115050|HIV infections
647787|NCT00115050|Antiretroviral
647788|NCT00115050|TMC114
647789|NCT00115050|Ritonavir
647790|NCT00115050|Safety, TMC114-C209
647791|NCT00115037|Alcoholism
647792|NCT00115037|alcohol abuse
647793|NCT00115037|therapy
647794|NCT00115037|drug resistance
647795|NCT00115037|naltrexone
647796|NCT00115037|patient care management
647797|NCT00115037|human subject
647798|NCT00115024|cardiovascular disease
647799|NCT00115024|CVD
647800|NCT00115024|estrogen
647801|NCT00115024|cholesterol
647802|NCT00115024|LDL
647803|NCT00115024|lipids
647804|NCT00115024|postmenopausal
647805|NCT00115011|Skin Picking
647806|NCT00115011|Escitalopram
647807|NCT00115011|Lexapro
647808|NCT00115011|Body Focused Repetitive Behaviors
647809|NCT00115011|Obsessive Compulsive Spectrum Disorders
647810|NCT00114985|Total Androgen Suppression
647811|NCT00114985|Simulation
647812|NCT00114985|3-D Conformal External Beam Radiation Therapy
647813|NCT00114985|Intra-rectal immobilization device
647814|NCT00114985|Quality of Life Assessment Questionnaire
647815|NCT00114985|Rectal Bleeding
647816|NCT00114985|Late effects
647817|NCT00114972|Three-vessel coronary artery disease
647818|NCT00114972|Left main coronary artery disease
647819|NCT00114959|ChemGenex Pharmaceuticals, Ltd
647820|NCT00114959|ChemGenex Pharmaceuticals
647821|NCT00114959|ChemGenex
647822|NCT00114959|Chronic Myeloid Leukemia
647823|NCT00114959|Myeloid Leukemia, Chronic
647824|NCT00114959|Leukemia
647825|NCT00114959|Myeloid Leukemia
647826|NCT00114959|Chronic Phase
647827|NCT00114959|Accelerated Phase
647828|NCT00114959|Blast Phase
647829|NCT00114959|Myeloid, Leukemia, Chronic, Accelerated Phase
647830|NCT00114959|Myeloid, Leukemia, Chronic
647831|NCT00114959|Leukemia, Myeloid, Chronic
647832|NCT00114959|Leukemia, Myeloid, Chronic-Phase
647833|NCT00114959|Leukemia, Myeloid, Chronic Phase
647834|NCT00114959|Leukemia, Myeloid, Accelerated-Phase
647835|NCT00114959|Myeloid, Leukemia, Chronic, Chronic Phase
647836|NCT00114959|Leukemia, Myeloid, Accelerated Phase
647837|NCT00114959|Homoharringtonine
647838|NCT00114959|Omacetaxine
647839|NCT00114946|Metastatic Colorectal Cancer OASIS
647840|NCT00114933|HIV
647841|NCT00114933|AIDS
647842|NCT00114933|Treatment Experienced
647843|NCT00114920|Wart(s)
647844|NCT00114920|Adults
647845|NCT00114920|Common Wart(s)
647846|NCT00114907|Tea
647847|NCT00114907|Oxidative stress markers
647848|NCT00114907|cardiovascular disease
647849|NCT00114907|polyphenolics
647850|NCT00114907|double blind
647851|NCT00114907|Ischaemic cardiac disease
647852|NCT00114894|Jellyfish
647853|NCT00114894|Stings
647854|NCT00114894|Marine
647855|NCT00114894|Envenomation
647856|NCT00114894|Jellyfish stings
647857|NCT00114881|Children
647858|NCT00114881|Urban Health
647859|NCT00114881|Pregnancy
647860|NCT00114881|Asthma
647861|NCT00114868|vitamin A
647862|NCT00114868|mortality
647863|NCT00114868|newborn
647864|NCT00114868|liveborn infants
647865|NCT00114855|Hypocol
647866|NCT00114855|Red yeast rice
647867|NCT00114855|Patients with mild Type IIa, Type IIb or IV hyperlipidaemia (LDL-cholesterol >3.0 mmol/L< 6.0 mmol/L.
647868|NCT00114855|Mildly elevated blood glucose
647869|NCT00114842|colorectal polyps
647870|NCT00114842|colorectal cancer
647871|NCT00114842|Virtual colonoscopy
647872|NCT00114842|Fecal tagging
647873|NCT00114842|MR colonography
647874|NCT00114829|Colorectal cancer
647875|NCT00114829|Colorectal tumor
647876|NCT00114829|Dynamic contrast uptake
647877|NCT00114829|MR colonography
647878|NCT00114816|breast cancer
647879|NCT00114816|chemotherapy
647880|NCT00114816|adjuvant
647881|NCT00114816|capecitabine
647882|NCT00114816|docetaxel
647883|NCT00114803|bone mineral density
647884|NCT00114803|osteoporosis
647885|NCT00114803|osteopenia
647886|NCT00114803|children
647887|NCT00114803|adolescents
647888|NCT00114803|DXA
647889|NCT00114790|head and neck cancer
647890|NCT00114790|boron neutron capture therapy
647891|NCT00114790|radiation therapy
647892|NCT00114790|boronophenylalanine
647893|NCT00114764|Acute myeloid leukaemia
647894|NCT00114764|Pegfilgrastim
647895|NCT00114764|Neulasta®
647896|NCT00114764|Neutropenia
647897|NCT00114764|Induction chemotherapy
647898|NCT00114764|Consolidation
647899|NCT00114738|Proteasome Inhibition
647900|NCT00114738|NF-Kappa-B
647901|NCT00114738|Gene Expression Signature
647902|NCT00114738|Cyclin D1
647903|NCT00114738|Translational Studies
647904|NCT00114738|Lymphoma
647905|NCT00114738|Mantle Cell Lymphoma
647906|NCT00114738|MCL
647907|NCT00114725|In Vitro Fertilization
647908|NCT00114725|Intracytoplasmic Sperm Injection
647909|NCT00114725|Oocytes
647910|NCT00114725|Zona Pellucida
647911|NCT00114725|Oolemma
647912|NCT00114725|Fertilization
647913|NCT00114725|Preimplantation Embryo Development
647914|NCT00114712|Birth Defects
647915|NCT00114712|Pregnancy
647916|NCT00114712|Ribavirin
647917|NCT00114712|Hepatitis C
647918|NCT00114699|HIV
647919|NCT00114699|Treatment Naive
647920|NCT00114686|Bipolar I Disorder
647921|NCT00114686|Alcohol Dependency
647922|NCT00114673|Uneven skin color
647923|NCT00114673|Wrinkles
647924|NCT00114673|Wrinkles and uneven skin color in the area around the eyes
647925|NCT00114660|striae gravidarum
647926|NCT00114660|stretch marks
647927|NCT00114660|cocoa butter
647928|NCT00114660|prevention
647929|NCT00114647|Plasmapheresis
647930|NCT00114647|Leukapheresis
647931|NCT00114647|Lymphocytes
647932|NCT00114647|Apheresis
647933|NCT00114634|SLOS
647934|NCT00114634|RSH syndrome
647935|NCT00114634|ABC Checklist
647936|NCT00114634|Cholesterol supplementation
647937|NCT00114634|Egg yolk
647938|NCT00114634|Smith-Lemli-Opitz Syndrome
647939|NCT00114621|PA
647940|NCT00114621|Phase I
647941|NCT00114621|Phase 2
647942|NCT00114621|Safety
647943|NCT00114621|Immunogenicity
647944|NCT00114608|Electrical foot stimulation
647945|NCT00114608|Intermittent pneumatic compression
647946|NCT00114608|Venous thromboembolism
647947|NCT00114608|Immobilization
647948|NCT00114608|Total hip replacement
647949|NCT00114608|Prolonged travel
647950|NCT00114608|Venous thromboembolic disease (VTE)
647951|NCT00114608|Deep vein thrombosis (DVT)
647952|NCT00114608|Pulmonary embolism (PE)
647953|NCT00114595|eicosapentaenoic acid
647954|NCT00114595|tardive dyskinesia
647955|NCT00114595|omega-3
647956|NCT00114595|schizophrenia
647957|NCT00114582|family style dinner
647958|NCT00114582|quality of life
647959|NCT00114582|nutritional status
647960|NCT00114582|nursing home residents
647961|NCT00114569|children
647962|NCT00114569|status epilepticus
647963|NCT00114569|lorazepam
647964|NCT00114569|safety
647965|NCT00114569|pharmacokinetics
647966|NCT00114569|status epilepticus in children
647967|NCT00114556|osteoporosis
647968|NCT00114556|liver transplantation
647969|NCT00114543|NICHD Neonatal Research Network
647970|NCT00114543|Bilirubin
647971|NCT00114543|Phototherapy
647972|NCT00114543|Very Low Birth Weight (VLBW)
647973|NCT00114543|Extremely Low Birth Weight (ELBW)
647974|NCT00114543|Prematurity
647975|NCT00114543|Neurodevelopmental outcome
647976|NCT00114530|autoimmune disease
647977|NCT00114517|atherosclerosis
647978|NCT00114517|CAD
647979|NCT00114517|cardiac computed tomography
647980|NCT00114517|cardiovascular disease
647981|NCT00114517|carotid artery intima-media thickness
647982|NCT00114517|cognitive function
647983|NCT00114517|computed tomography
647984|NCT00114517|coronary artery calcium
647985|NCT00114517|coronary artery disease
647986|NCT00114517|coronary artery lesions
647987|NCT00114517|CVD
647988|NCT00114517|estrogen
647989|NCT00114517|estrogen therapy
647990|NCT00114517|hormone therapy
647991|NCT00114517|postmenopausal
647992|NCT00114517|subclinical vascular disease
647993|NCT00114517|timing hypothesis
647994|NCT00114517|ultrasonography
647995|NCT00114504|atherosclerosis
647996|NCT00114504|inflammation
647997|NCT00114504|statins
647998|NCT00114504|PET
647999|NCT00114504|carotid ultrasonography
648000|NCT00114491|Aortic Stenosis
648001|NCT00114491|Statins
648002|NCT00114491|Hypercholesterolemia
648003|NCT00114478|Bronchiolitis
648004|NCT00114478|disposition
648005|NCT00114478|pediatric
648006|NCT00114478|epinephrine
648007|NCT00114478|albuterol
648008|NCT00114465|Randomized
648009|NCT00114465|Double-Blind
648010|NCT00114465|Probiotic
648011|NCT00114465|Remission
648012|NCT00114465|Crohn's Disease
648013|NCT00114452|Acute Myocardial Infarction
648014|NCT00114452|Heart Attack
648015|NCT00114452|Cardiovascular Disease
648016|NCT00114452|Stem cells
648017|NCT00114452|Congestive Heart Failure
648018|NCT00114452|Heart Attack Repair
648019|NCT00114439|cannabis withdrawal
648020|NCT00114439|lithium
648021|NCT00114439|Cannabis withdrawal syndrome
648022|NCT00114426|randomized controlled trial; COPD
648023|NCT00114413|Exhaled Nitric Oxide
648024|NCT00114413|Lung
648025|NCT00114413|Urban Health
648026|NCT00114413|Child
648027|NCT00114413|Adolescent
648028|NCT00114400|cardiovascular disease
648029|NCT00114400|CVD
648030|NCT00114387|vitamin E
648031|NCT00114374|Acute Stress Disorder
648032|NCT00114374|Posttraumatic Stress Disorder
648033|NCT00114374|Escitalopram
648034|NCT00114374|Double-Blind
648035|NCT00114361|HBeAg-negative
648036|NCT00114361|chronic
648037|NCT00114361|hepatitis B
648038|NCT00114361|viral
648039|NCT00114348|non-B ALL
648040|NCT00114348|relapse
648041|NCT00114348|treatment
648042|NCT00114348|Relapsed non-B ALL or non-B non-Hodgkin lymphoma
648043|NCT00114335|low molecular weight heparin
648044|NCT00114335|unfractionated heparin
648045|NCT00114309|High grade recurrent glioma
648046|NCT00114309|Phase II
648047|NCT00114309|Multi-Center
648048|NCT00114309|Open label
648049|NCT00114309|Multiple dose
648050|NCT00114309|Brain Cancer
648051|NCT00114309|Brain Tumor
648052|NCT00114309|GBM
648053|NCT00114309|glioma
648054|NCT00114296|breast cancer
648055|NCT00114270|breast cancer
648056|NCT00114270|osteoporosis
648057|NCT00114257|recurrent adult acute lymphoblastic leukemia
648058|NCT00114257|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
648059|NCT00114257|adult acute myeloid leukemia with inv(16)(p13;q22)
648060|NCT00114257|adult acute myeloid leukemia with t(15;17)(q22;q12)
648061|NCT00114257|adult acute myeloid leukemia with t(16;16)(p13;q22)
648062|NCT00114257|adult acute myeloid leukemia with t(8;21)(q22;q22)
648063|NCT00114257|recurrent adult acute myeloid leukemia
648064|NCT00114257|secondary acute myeloid leukemia
648065|NCT00114257|untreated adult acute myeloid leukemia
648066|NCT00114257|adult acute promyelocytic leukemia (M3)
648067|NCT00114257|relapsing chronic myelogenous leukemia
648068|NCT00114257|refractory chronic lymphocytic leukemia
648069|NCT00114257|de novo myelodysplastic syndromes
648070|NCT00114257|myelodysplastic/myeloproliferative neoplasm, unclassifiable
648071|NCT00114257|previously treated myelodysplastic syndromes
648072|NCT00114257|secondary myelodysplastic syndromes
648073|NCT00114257|atypical chronic myeloid leukemia, BCR-ABL1 negative
648074|NCT00114257|chronic myelomonocytic leukemia
648075|NCT00114257|chronic eosinophilic leukemia
648076|NCT00114257|primary myelofibrosis
648077|NCT00114257|chronic neutrophilic leukemia
648078|NCT00114257|essential thrombocythemia
648079|NCT00114257|polycythemia vera
648080|NCT00114257|Philadelphia chromosome negative chronic myelogenous leukemia
648081|NCT00114257|chronic myelogenous leukemia, BCR-ABL1 positive
648082|NCT00114257|adult acute minimally differentiated myeloid leukemia (M0)
648083|NCT00114257|adult acute myeloblastic leukemia without maturation (M1)
648084|NCT00114257|adult acute myeloblastic leukemia with maturation (M2)
648085|NCT00114257|adult acute myelomonocytic leukemia (M4)
648086|NCT00114257|adult acute monoblastic leukemia (M5a)
648087|NCT00114257|adult acute monocytic leukemia (M5b)
648088|NCT00114257|adult erythroleukemia (M6a)
648089|NCT00114257|adult pure erythroid leukemia (M6b)
648090|NCT00114257|adult acute megakaryoblastic leukemia (M7)
648091|NCT00114257|adult acute basophilic leukemia
648092|NCT00114257|adult acute eosinophilic leukemia
648093|NCT00114231|adenocarcinoma of the rectum
648094|NCT00114231|stage I rectal cancer
648095|NCT00114205|malignant pleural effusion
648096|NCT00114192|recurrent non-small cell lung cancer
648097|NCT00114192|stage IIIA non-small cell lung cancer
648098|NCT00114192|stage IIIB non-small cell lung cancer
648099|NCT00114192|stage IV non-small cell lung cancer
648100|NCT00114166|recurrent ovarian epithelial cancer
648101|NCT00114166|fallopian tube cancer
648102|NCT00114166|primary peritoneal cavity cancer
648103|NCT00114153|stage III squamous cell carcinoma of the hypopharynx
648104|NCT00114153|stage III squamous cell carcinoma of the lip and oral cavity
648105|NCT00114153|stage III squamous cell carcinoma of the oropharynx
648106|NCT00114153|stage IV squamous cell carcinoma of the hypopharynx
648107|NCT00114153|stage IV squamous cell carcinoma of the lip and oral cavity
648108|NCT00114153|stage IV squamous cell carcinoma of the oropharynx
648109|NCT00114140|adult diffuse astrocytoma
648110|NCT00114140|adult oligodendroglioma
648111|NCT00114140|adult mixed glioma
648112|NCT00114127|social anxiety disorder
648113|NCT00114127|social phobia
648114|NCT00114127|duloxetine
648115|NCT00114127|serotonin norepinephrine reuptake inhibitor
648116|NCT00114127|SNRI
648117|NCT00114127|double blind
648118|NCT00114114|Testosterone
648119|NCT00114114|Bone turnover
648120|NCT00114114|Aging
648121|NCT00114114|Body composition
648122|NCT00114114|Hypogonadism
648123|NCT00114114|Sexual function
648124|NCT00114088|Hysterectomy,
648125|NCT00114088|Endometrial ablation,
648126|NCT00114088|Ovulatory dysfunctional uterine bleeding,
648127|NCT00114088|Anovulatory dysfucntional uterine bleeding,
648128|NCT00114088|DUB
648129|NCT00114088|Dysfunctional uterine bleeding
648130|NCT00114075|gait
648131|NCT00114075|walking
648132|NCT00114075|orthopedic surgery
648133|NCT00114075|orthopaedic surgery
648134|NCT00114062|uveitis
648135|NCT00114062|macular edema
648136|NCT00114062|uveitis associated macular edema
648137|NCT00114049|Dental Pain
648138|NCT00114049|Dental Surgery
648139|NCT00114049|Cox-2 inhibitor
648140|NCT00114036|Antibiotic prophylaxis
648141|NCT00114036|Surgical wound infections
648142|NCT00113061|Coronary Heart Disease Risk Reduction
648143|NCT00113048|CD52 Expressing Hematologic Malignancies
648144|NCT00113035|Glycogen Storage Disease Type II
648145|NCT00113035|GSD-II
648146|NCT00113035|Pompe Disease
648147|NCT00113035|Pompe Disease (Late-Onset)
648148|NCT00113035|Glycogen Storage Disease Type II (GSD-II)
648149|NCT00113035|Acid Maltase Deficiency
648150|NCT00113035|Glycogenosis 2
648151|NCT00113022|Depression
648152|NCT00113022|Glutamate
648153|NCT00113022|Ampakine
648154|NCT00113022|Treatment
648155|NCT00113022|Memory
648156|NCT00113022|Major Depressive Disorder
648157|NCT00113022|AMPA Receptor Activation
648158|NCT00113022|BDNF
648159|NCT00113009|Peripheral arterial disease
648160|NCT00112996|neurotoxicity
648161|NCT00112996|unspecified adult solid tumor, protocol specific
648162|NCT00112996|unspecified childhood solid tumor, protocol specific
648163|NCT00114023|AK
648164|NCT00114023|Imiquimod 5% cream
648165|NCT00114023|3M Pharmaceuticals
648166|NCT00114023|Aldara
648167|NCT00114023|Actinic Keratosis
648168|NCT00114010|B Cells
648169|NCT00114010|T Cells
648170|NCT00114010|Erythrocyte Stage
648171|NCT00114010|Antibody
648172|NCT00114010|Immunogenicity
648173|NCT00114010|Healthy Volunteer
648174|NCT00113997|Anticoagulant
648175|NCT00113997|Antidote
648176|NCT00113997|Pharmacokinetics
648177|NCT00113997|Pharmacodynamics
648178|NCT00113997|Healthy Volunteer
648179|NCT00113997|HV
648180|NCT00113984|Monoclonal Antibody
648181|NCT00113984|Vaccine
648182|NCT00113984|Cytokines
648183|NCT00113984|Immunotherapy
648184|NCT00113984|Elispot Assay
648185|NCT00113984|Prostate Cancer
648186|NCT00113984|Metastatic Prostate Cancer
648187|NCT00113971|study of epratuzumab in systemic lupus erythematosus
648188|NCT00113971|systemic lupus erythematosus
648189|NCT00113971|SLE
648190|NCT00113958|End Stage Renal Disease (ESRD)
648191|NCT00113958|secondary hyperparathyroidism (SHPT)
648192|NCT00113958|hemodialysis
648193|NCT00113958|biPTH
648194|NCT00113958|AMG 073, Amgen
648195|NCT00113945|End Stage Renal Disease (ESRD)
648196|NCT00113945|secondary hyperparathyroidism
648197|NCT00113945|hemodialysis, biPTH
648198|NCT00113945|AMG 073, Amgen
648199|NCT00113932|Myeloma
648200|NCT00113919|Myeloma, MM
648201|NCT00113906|melatonin,
648202|NCT00113906|fatigue,
648203|NCT00113906|sleep quality,
648204|NCT00113906|circadian,
648205|NCT00113906|postoperative
648206|NCT00113906|Postoperative fatigue
648207|NCT00113906|postoperative sleep disturbance
648208|NCT00113906|general wellbeing
648209|NCT00113893|Myelodysplastic syndromes
648210|NCT00113893|p38 MAP kinase
648211|NCT00113893|Bone marrow diseases
648212|NCT00113893|SCIO-469
648213|NCT00113867|IVF
648214|NCT00113867|in vitro fertilization
648215|NCT00113867|hormones
648216|NCT00113867|stress
648217|NCT00113867|memory
648218|NCT00113867|Cognitive Function
648219|NCT00113867|adoption
648220|NCT00113854|cerebral
648221|NCT00113854|malaria
648222|NCT00113854|children
648223|NCT00113854|mannitol
648224|NCT00113854|adjunct
648225|NCT00113854|therapy
648226|NCT00113854|Uganda
648227|NCT00113841|Multiple Myeloma
648228|NCT00113841|Diferuloylmethane Derivative
648229|NCT00113841|Curcumin
648230|NCT00113841|Bioperine
648231|NCT00113828|Non-Myeloablative
648232|NCT00113828|Stem Cell Transplantation
648233|NCT00113828|T-cell Depletion
648234|NCT00113828|HLA-Matched
648235|NCT00113815|Partial seizure disorder
648236|NCT00113815|Topiramate
648237|NCT00113815|Epilepsy
648238|NCT00113815|Infants
648239|NCT00113802|Epratuzumab (hLL2- anti-CD22 humanized antibody)
648240|NCT00113802|Waldenstrom's Macroglobulinemia
648241|NCT00113802|Waldenstrom Macroglobulinemia
648242|NCT00113802|Hematologic Disease
648243|NCT00113802|Hematologic Diseases
648244|NCT00113802|Paraproteinemias
648245|NCT00113802|Vascular Hemostatic Disorders
648246|NCT00113802|Lymphoproliferative Disorders
648247|NCT00113789|ovarian cancer
648248|NCT00113789|topotecan
648249|NCT00113789|neutropenia
648250|NCT00113789|Neulasta®
648251|NCT00113776|Metastatic Colorectal Cancer, Colon
648252|NCT00113776|Colorectal, Rectal Cancer, EGFr
648253|NCT00113776|Metastatic, Cancer, ABX-EGF
648254|NCT00113776|Panitumumab, Clinical Trial
648255|NCT00113776|Immunex, Abgenix, Amgen
648256|NCT00113763|Metastatic Colorectal Cancer, Colon
648257|NCT00113763|Colorectal, Rectal Cancer, Cancer
648258|NCT00113763|Metastatic, EGFr, Clinical Trial
648259|NCT00113763|Panitumumab, ABX-EGF
648260|NCT00113763|Immunex, Abgenix, Amgen
648261|NCT00113750|Allergy
648262|NCT00113750|Allergoid
648263|NCT00113750|Specific Immunotherapy
648264|NCT00113724|taxane
648265|NCT00113724|multi-drug resistance
648266|NCT00113724|mutant tubulin binding
648267|NCT00113724|Advanced malignancies
648268|NCT00113724|Hodgkin's or Non-Hodgkin's Lymphoma
648269|NCT00113659|Asthma
648270|NCT00113659|Probiotics
648271|NCT00113659|Prevention
648272|NCT00113659|Eczema
648273|NCT00113646|Non-Myeloablative
648274|NCT00113646|T-cell Depleted
648275|NCT00113646|Mismatched
648276|NCT00113646|Stem Cell Transplantation
648277|NCT00113633|Asthma
648278|NCT00113633|Emergency
648279|NCT00113633|Primary Care
648280|NCT00113633|Children
648281|NCT00113620|distal symmetrical
648282|NCT00113620|pain
648283|NCT00113620|lower extremities
648284|NCT00113620|dextromethorphan
648285|NCT00113607|Ovarian cancer
648286|NCT00113607|Trabectedin
648287|NCT00113607|Yondelis
648288|NCT00113607|Advanced Relapsed Ovarian Cancer
648289|NCT00113607|DOXIL
648290|NCT00113607|CAELYX
648291|NCT00113581|EMD 72000
648292|NCT00113581|matuzumab
648293|NCT00113581|Esophageal adenocarcinoma
648294|NCT00113581|Gastric adenocarcinoma
648295|NCT00113568|Menorrhagia
648296|NCT00113568|Heavy Menstrual Bleeding
648297|NCT00113555|urinary incontinence
648298|NCT00113542|Psoriasis
648299|NCT00113542|Tetrathiomolybdate
648300|NCT00113516|Lung Neoplasms
648301|NCT00113503|Inflammatory Bowel Disease, Crohn's disease, Crohn's Colitis
648302|NCT00113490|motavizumab, palivizumab, synagis
648303|NCT00113490|Rezield, MEDI-524
648304|NCT00113477|Q10
648305|NCT00113477|CoQ10
648306|NCT00113477|Coenzyme Q10
648307|NCT00113477|selen
648308|NCT00113477|selenoprotein
648309|NCT00113477|selenoproteins
648310|NCT00113477|adverse events
648311|NCT00113477|adverse effects
648312|NCT00113477|AE
648313|NCT00113477|myalgia
648314|NCT00113477|muscle
648315|NCT00113477|statin therapy
648316|NCT00113477|Indication for statin therapy
648317|NCT00113464|SCID (Severe Combined Immunodeficiency)
648318|NCT00113464|TREC (T cell Receptor Excision Circle)
648319|NCT00113464|Bone Marrow Transplant
648320|NCT00113464|Dried Blood Spots
648321|NCT00113464|Early Detection
648322|NCT00113464|T Cell Immunodeficiency Diseases
648323|NCT00113464|Immunodeficiency Diseases
648324|NCT00113464|Primary Immunodeficiency
648325|NCT00113464|T Cell Immunodeficiency Disease
648326|NCT00113464|Severe Combined Immunodeficiency
648327|NCT00113464|SCID
648328|NCT00113451|radial artery
648329|NCT00113451|angina pectoris
648330|NCT00113451|infarction
648331|NCT00113451|bypass
648332|NCT00113451|angiography
648333|NCT00113438|cancer
648334|NCT00113438|tumor
648335|NCT00113438|imageable
648336|NCT00113438|CA4P
648337|NCT00113438|Combretastatin
648338|NCT00113438|Combretastatin A4 Phosphate
648339|NCT00113438|Combretastatin A-4 Phosphate
648340|NCT00113438|Carboplatin
648341|NCT00113438|Paclitaxel
648342|NCT00113438|carbo
648343|NCT00113438|taxol
648344|NCT00113425|non-ablative laser
648345|NCT00113425|acne
648346|NCT00113425|photosensitizer
648347|NCT00113425|photodynamic therapy
648348|NCT00113412|HIV
648349|NCT00113412|Treatment Experienced
648350|NCT00113399|recurrent squamous cell carcinoma of the hypopharynx
648351|NCT00113399|recurrent squamous cell carcinoma of the larynx
648352|NCT00113399|recurrent squamous cell carcinoma of the lip and oral cavity
648353|NCT00113399|recurrent squamous cell carcinoma of the oropharynx
648354|NCT00113399|recurrent metastatic squamous neck cancer with occult primary
648355|NCT00113399|recurrent lymphoepithelioma of the oropharynx
648356|NCT00113386|stage IIIA non-small cell lung cancer
648357|NCT00113386|adenocarcinoma of the lung
648358|NCT00113386|large cell lung cancer
648359|NCT00113386|squamous cell lung cancer
648360|NCT00113386|bronchoalveolar cell lung cancer
648361|NCT00113360|Neuroendocrine Carcinoma
648362|NCT00113360|Low Grade Neuroendocrine Carcinoma
648363|NCT00113360|Neuroendocrine Carcinoid
648364|NCT00113360|Islet Cell Carcinoma
648365|NCT00113360|RAD001
648366|NCT00113360|Everolimus
648367|NCT00113360|Octreotide Depot
648368|NCT00113360|Sandostatin LAR
648369|NCT00113360|Octreotide long-acting release (LAR)
648370|NCT00113360|Octreotide LAR
648371|NCT00113347|Head and Neck Cancer
648372|NCT00113347|Squamous Cell Carcinoma
648373|NCT00113347|Erlotinib
648374|NCT00113347|Docetaxel
648375|NCT00113347|Radiation
648376|NCT00113347|Radiotherapy
648377|NCT00113347|Concomitant Boost Radiation
648378|NCT00113334|Head and Neck Cancer
648379|NCT00113334|Thrombospondin Analogue
648380|NCT00113334|ABT-510
648381|NCT00113334|Antiangiogenic agent
648382|NCT00113334|Lung
648383|NCT00113334|Skin
648384|NCT00113334|Thyroid
648385|NCT00113321|Myelodysplastic Syndrome
648386|NCT00113321|Chronic Myelomonocytic Leukemia
648387|NCT00113321|Azacytidine Failure
648388|NCT00113321|Decitabine
648389|NCT00113308|Rheumatoid Arthritis
648390|NCT00113308|COX-2 Inhibitor
648391|NCT00113295|generalized anxiety disorder
648392|NCT00113295|pharmacotherapy
648393|NCT00113295|treatment refractory
648394|NCT00113295|double-blind
648395|NCT00113282|Treatment failure
648396|NCT00113282|Acquired Immunodeficiency Syndrome
648397|NCT00113282|Interleukin-2
648398|NCT00113282|Treatment Experienced
648399|NCT00113269|Treatment Effectiveness
648400|NCT00113269|Treatment Efficacy
648401|NCT00113269|Anti-rejection therapy
648402|NCT00113269|Immunosuppression
648403|NCT00113269|Therapy, antirejection
648404|NCT00113269|Renal Transplantation
648405|NCT00113269|Transplantation, Kidney
648406|NCT00113269|Transplantation, Renal
648407|NCT00113269|Grafting, Kidney
648408|NCT00113256|rubitecan
648409|NCT00113256|Orathecin
648410|NCT00113256|9-nitrocamptothecin
648411|NCT00113256|gemcitabine
648412|NCT00113256|Gemzar
648413|NCT00113256|pancreatic cancer
648414|NCT00113256|adenocarcinoma
648415|NCT00113256|RFS 2000
648416|NCT00113230|Rectal Cancer
648417|NCT00113230|Bevacizumab
648418|NCT00113230|RHUMAB VEGF
648419|NCT00113230|Avastin
648420|NCT00113230|Capecitabine
648421|NCT00113230|Neoadjuvant Concurrent Capecitabine
648422|NCT00113230|Xeloda
648423|NCT00113230|Radiation
648424|NCT00113230|Radiotherapy
648425|NCT00113230|Radiation Therapy
648426|NCT00113230|XRT
648427|NCT00113217|Renal Cell Carcinoma
648428|NCT00113217|Kidney Cancer
648429|NCT00113217|Bevacizumab
648430|NCT00113217|Avastin
648431|NCT00113217|RCC
648432|NCT00113204|Multiple myeloma
648433|NCT00113204|Relapsed
648434|NCT00113204|Relapsed refractory
648435|NCT00113204|Hematologic cancer
648436|NCT00113204|hematologic disease
648437|NCT00113204|plasma cells
648438|NCT00113191|late onset sepsis
648439|NCT00113191|premature infants
648440|NCT00113191|staphylococcus
648441|NCT00113191|candida
648442|NCT00113191|prevention
648443|NCT00113178|atrial flutter
648444|NCT00113178|cryoablation
648445|NCT00113165|partial seizures
648446|NCT00113165|Epilepsy
648447|NCT00113165|antiepileptic drugs
648448|NCT00113165|anticonvulsants
648449|NCT00113165|LAMICTAL
648450|NCT00113165|seizures
648451|NCT00113165|lamotrigine
648452|NCT00113152|Cardiac Arrhythmias
648453|NCT00113152|Diastolic Dysfunction
648454|NCT00113152|Pulmonary Hypertension
648455|NCT00113152|Sickle Cell Anemia
648456|NCT00113152|Sudden Death
648457|NCT00113152|Thalassemia
648458|NCT00113126|Scheduled treatment interruptions
648459|NCT00113126|STI
648460|NCT00113113|rubitecan
648461|NCT00113113|Orathecin
648462|NCT00113113|9-nitrocamptothecin
648463|NCT00113113|solid tumors
648464|NCT00113113|organ dysfunction
648465|NCT00113113|renal dysfunction
648466|NCT00113113|hepatic dysfunction
648467|NCT00113113|RFS 2000
648468|NCT00113100|skin
648469|NCT00113100|estrogen
648470|NCT00113100|sun damage
648471|NCT00113100|Photodamaged Skin
648472|NCT00112983|adult acute lymphoblastic leukemia
648473|NCT00112983|adult acute myeloid leukemia
648474|NCT00112957|fallopian tube cancer
648475|NCT00112957|stage II ovarian epithelial cancer
648476|NCT00112957|stage III ovarian epithelial cancer
648477|NCT00112957|stage IV ovarian epithelial cancer
648478|NCT00112957|peritoneal cavity cancer
648479|NCT00112931|stage III grade 1 follicular lymphoma
648480|NCT00112931|stage III grade 2 follicular lymphoma
648481|NCT00112931|stage III grade 3 follicular lymphoma
648482|NCT00112931|stage IV grade 1 follicular lymphoma
648483|NCT00112931|stage IV grade 2 follicular lymphoma
648484|NCT00112931|stage IV grade 3 follicular lymphoma
648485|NCT00112931|noncontiguous stage II grade 1 follicular lymphoma
648486|NCT00112931|noncontiguous stage II grade 2 follicular lymphoma
648487|NCT00112931|noncontiguous stage II grade 3 follicular lymphoma
648488|NCT00112931|contiguous stage II grade 1 follicular lymphoma
648489|NCT00112931|contiguous stage II grade 2 follicular lymphoma
648490|NCT00112931|contiguous stage II grade 3 follicular lymphoma
648491|NCT00112918|stage II colon cancer
648492|NCT00112918|stage III colon cancer
648493|NCT00112892|unspecified adult solid tumor, protocol specific
648494|NCT00112775|chronic phase chronic myelogenous leukemia
648495|NCT00112775|chronic myelogenous leukemia, BCR-ABL1 positive
648496|NCT00112775|relapsing chronic myelogenous leukemia
648497|NCT00112749|stage I breast cancer
648498|NCT00112749|stage II breast cancer
648499|NCT00112749|breast cancer in situ
648500|NCT00112749|fatigue
648501|NCT00112710|stage IIIB non-small cell lung cancer
648502|NCT00112710|stage IV non-small cell lung cancer
648503|NCT00112697|adenocarcinoma of the pancreas
648504|NCT00112697|stage IV pancreatic cancer
648505|NCT00112658|adenocarcinoma of the pancreas
648506|NCT00112658|stage IV pancreatic cancer
648507|NCT00112645|unspecified childhood solid tumor, protocol specific
648508|NCT00112645|recurrent neuroblastoma
648509|NCT00112645|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
648510|NCT00112645|recurrent childhood rhabdomyosarcoma
648511|NCT00112632|gastrointestinal stromal tumor
648512|NCT00112619|AIDS-related diffuse large cell lymphoma
648513|NCT00112619|AIDS-related diffuse mixed cell lymphoma
648514|NCT00112619|AIDS-related diffuse small cleaved cell lymphoma
648515|NCT00112619|AIDS-related immunoblastic large cell lymphoma
648516|NCT00112619|AIDS-related lymphoblastic lymphoma
648517|NCT00112619|AIDS-related peripheral/systemic lymphoma
648518|NCT00112619|AIDS-related primary CNS lymphoma
648519|NCT00112619|AIDS-related small noncleaved cell lymphoma
648520|NCT00112619|HIV-associated Hodgkin lymphoma
648521|NCT00112619|stage IV childhood Hodgkin lymphoma
648522|NCT00112619|stage IV childhood large cell lymphoma
648523|NCT00112619|stage IV childhood lymphoblastic lymphoma
648524|NCT00112619|stage IV childhood small noncleaved cell lymphoma
648525|NCT00112619|primary central nervous system non-Hodgkin lymphoma
648526|NCT00112619|primary central nervous system Hodgkin lymphoma
648527|NCT00112619|recurrent childhood acute lymphoblastic leukemia
648528|NCT00112619|recurrent childhood acute myeloid leukemia
648529|NCT00112619|unspecified childhood solid tumor, protocol specific
648530|NCT00112619|childhood grade I meningioma
648531|NCT00112619|childhood grade II meningioma
648532|NCT00112619|childhood grade III meningioma
648533|NCT00112619|recurrent childhood cerebellar astrocytoma
648534|NCT00112619|recurrent childhood cerebral astrocytoma
648535|NCT00112619|childhood high-grade cerebral astrocytoma
648536|NCT00112619|childhood low-grade cerebral astrocytoma
648537|NCT00112619|childhood choroid plexus tumor
648538|NCT00112619|childhood craniopharyngioma
648539|NCT00112619|childhood infratentorial ependymoma
648540|NCT00112619|childhood supratentorial ependymoma
648541|NCT00112619|recurrent childhood ependymoma
648542|NCT00112619|recurrent childhood medulloblastoma
648543|NCT00112619|childhood oligodendroglioma
648544|NCT00112619|recurrent childhood supratentorial primitive neuroectodermal tumor
648545|NCT00112619|leptomeningeal metastases
648546|NCT00112619|recurrent carcinoma of unknown primary
648547|NCT00112619|childhood central nervous system germ cell tumor
648548|NCT00112619|childhood chronic myelogenous leukemia
648549|NCT00112619|juvenile myelomonocytic leukemia
648550|NCT00112619|recurrent/refractory childhood Hodgkin lymphoma
648551|NCT00112619|recurrent childhood grade III lymphomatoid granulomatosis
648552|NCT00112619|recurrent childhood visual pathway and hypothalamic glioma
648553|NCT00112619|childhood atypical teratoid/rhabdoid tumor
648554|NCT00112619|recurrent childhood large cell lymphoma
648555|NCT00112619|recurrent childhood lymphoblastic lymphoma
648556|NCT00112619|recurrent childhood small noncleaved cell lymphoma
648557|NCT00112619|relapsing chronic myelogenous leukemia
648558|NCT00112619|recurrent childhood pineoblastoma
648559|NCT00112619|recurrent childhood subependymal giant cell astrocytoma
648560|NCT00112619|meningeal leukemia
648561|NCT00112619|secondary central nervous system Hodgkin lymphoma
648562|NCT00112619|secondary central nervous system non-Hodgkin lymphoma
648563|NCT00112593|HIV
648564|NCT00112593|Lymphoma
648565|NCT00112593|Leukemia
648566|NCT00112580|recurrent pancreatic cancer
648567|NCT00112580|adenocarcinoma of the pancreas
648568|NCT00112580|stage IV pancreatic cancer
648569|NCT00112567|recurrent childhood acute lymphoblastic leukemia
648570|NCT00112567|childhood myelodysplastic syndromes
648571|NCT00112567|childhood acute lymphoblastic leukemia in remission
648572|NCT00112567|recurrent childhood acute myeloid leukemia
648573|NCT00112567|childhood acute myeloid leukemia in remission
648574|NCT00112567|secondary acute myeloid leukemia
648575|NCT00112567|accelerated phase chronic myelogenous leukemia
648576|NCT00112567|blastic phase chronic myelogenous leukemia
648577|NCT00112567|childhood chronic myelogenous leukemia
648578|NCT00112567|relapsing chronic myelogenous leukemia
648579|NCT00112567|de novo myelodysplastic syndromes
648580|NCT00112567|secondary myelodysplastic syndromes
648581|NCT00112567|previously treated myelodysplastic syndromes
648582|NCT00112554|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
648583|NCT00112554|adult acute myeloid leukemia with inv(16)(p13;q22)
648584|NCT00112554|adult acute myeloid leukemia with t(16;16)(p13;q22)
648585|NCT00112554|adult acute myeloid leukemia with t(8;21)(q22;q22)
648586|NCT00112554|recurrent adult acute myeloid leukemia
648587|NCT00112554|adult acute basophilic leukemia
648588|NCT00112554|adult acute eosinophilic leukemia
648589|NCT00112554|adult erythroleukemia (M6a)
648590|NCT00112554|adult pure erythroid leukemia (M6b)
648591|NCT00112554|adult acute megakaryoblastic leukemia (M7)
648592|NCT00112554|adult acute minimally differentiated myeloid leukemia (M0)
648593|NCT00112554|adult acute monoblastic leukemia (M5a)
648594|NCT00112554|adult acute monocytic leukemia (M5b)
648595|NCT00112554|adult acute myeloblastic leukemia with maturation (M2)
648596|NCT00112554|adult acute myeloblastic leukemia without maturation (M1)
648597|NCT00112554|adult acute myelomonocytic leukemia (M4)
648598|NCT00112528|duct cell adenocarcinoma of the pancreas
648599|NCT00112528|recurrent pancreatic cancer
648600|NCT00112528|stage IV pancreatic cancer
648601|NCT00112515|depression
648602|NCT00112515|cognitive/functional effects
648603|NCT00112515|fatigue
648604|NCT00112515|unspecified adult solid tumor, protocol specific
648605|NCT00112502|adult giant cell glioblastoma
648606|NCT00112502|adult gliosarcoma
648607|NCT00112502|adult glioblastoma
648608|NCT00112489|recurrent uterine sarcoma
648609|NCT00112489|stage III uterine sarcoma
648610|NCT00112489|stage IV uterine sarcoma
648611|NCT00112489|uterine carcinosarcoma
648612|NCT00112424|Superior cavo-pulmonary anastomosis
648613|NCT00112424|Glenn operation
648614|NCT00112424|Congenital heart defects
648615|NCT00112424|Cardiac magnetic resonance imaging
648616|NCT00112398|Head injuries
648617|NCT00112398|Prehospital
648618|NCT00112398|Advanced Interventions
648619|NCT00112385|dermatomyositis
648620|NCT00112385|etanercept
648621|NCT00112385|tumor necrosis factor alpha
648622|NCT00112372|unresectable
648623|NCT00112372|metastatic
648624|NCT00112372|cancer
648625|NCT00112372|recurrent
648626|NCT00112372|malignancies
648627|NCT00112372|progressive
648628|NCT00112359|Cystic Fibrosis
648629|NCT00112359|Pseudomonas aeruginosa
648630|NCT00112359|Pulmonary Cystic Fibrosis
648631|NCT00112346|Non-Small Lung Cancer
648632|NCT00112333|Dyspepsia, fMRI
648633|NCT00112320|Pulmonary Valve Regurgitation
648634|NCT00112320|Right Ventricular Dysfunction
648635|NCT00112320|Heart Diseases
648636|NCT00112307|MRI
648637|NCT00112307|Brachytherapy
648638|NCT00112307|Carcinoma
648639|NCT00112307|Cervix
648640|NCT00112307|Uterus
648641|NCT00112307|Vagina
648642|NCT00112307|Vulva
648643|NCT00112307|Carcinoma of the cervix
648644|NCT00112307|Carcinoma of the uterus
648645|NCT00112307|Carcinoma of the vagina
648646|NCT00112307|Carcinoma of the vulva
648647|NCT00112294|Non-Small Cell Lung Cancer
648648|NCT00112281|"shock, cardiogenic, myocardial infarction"
648649|NCT00112268|randomized controlled trial
648650|NCT00112268|primary health care
648651|NCT00112268|smoking cessation
648652|NCT00112255|Chlamydia trachomatis
648653|NCT00112255|Chlamydia infections
648654|NCT00112255|Randomized controlled trials
648655|NCT00112255|Contact tracing
648656|NCT00112255|Family practice
648657|NCT00112242|Immunotherapy
648658|NCT00112242|Vaccination
648659|NCT00112242|Melanoma
648660|NCT00112242|Melan-A/Mart-1 peptide
648661|NCT00112242|MAGE-A10 peptide
648662|NCT00112242|NY-ESO-1 peptide
648663|NCT00112242|Montanide
648664|NCT00112229|Immunotherapy
648665|NCT00112229|Vaccination
648666|NCT00112229|Melanoma
648667|NCT00112229|Melan-A/Mart-1 peptide
648668|NCT00112229|Tyrosinase peptide
648669|NCT00112229|CpG
648670|NCT00112229|Montanide
648671|NCT00112216|Immunotherapy
648672|NCT00112216|Vaccination
648673|NCT00112216|Melanoma
648674|NCT00112216|Melan-A/Mart-1 peptide
648675|NCT00112216|Flu peptide
648676|NCT00112216|Mage-A10 peptide
648677|NCT00112216|SB AS-2 adjuvant
648678|NCT00112216|Montanide adjuvant
648679|NCT00112203|Abdominal Symptom Relief
648680|NCT00112203|Fullness
648681|NCT00112203|Bloating
648682|NCT00112203|Indigestion
648683|NCT00112203|Functional dyspepsia
648684|NCT00112190|Functional dyspepsia
648685|NCT00112190|Abdominal Symptom relief
648686|NCT00112190|Fullness
648687|NCT00112190|Bloating
648688|NCT00112190|Indigestion
648689|NCT00112177|Functional dyspepsia
648690|NCT00112177|Abdominal Symptom relief
648691|NCT00112177|Fullness
648692|NCT00112177|Bloating
648693|NCT00112177|Indigestion
648694|NCT00112164|Acute Respiratory Distress Syndrome
648695|NCT00112151|andropause
648696|NCT00112151|hypogonadism
648697|NCT00112151|AndroGel
648698|NCT00112151|exercise
648699|NCT00112151|PRT
648700|NCT00112151|Testosterone
648701|NCT00112151|T supplementation
648702|NCT00112138|gabapentin
648703|NCT00112138|hot flashes or flushes
648704|NCT00112138|menopause
648705|NCT00112125|cardiac contractility modulation
648706|NCT00112125|heart failure
648707|NCT00112125|cardiopulmonary exercise test
648708|NCT00112125|chronic heart disease
648709|NCT00112112|cancer, pediatric, influenza, vaccine
648710|NCT00112099|gastric neoplasm
648711|NCT00112099|gastrectomy
648712|NCT00112099|splenectomy
648713|NCT00112099|randomized trial
648714|NCT00112099|T2, T3 and T4 carcinoma in the proximal third of the stomach
648715|NCT00112086|ovarian neoplasms
648716|NCT00112086|laparoscopy
648717|NCT00112086|neoadjuvant therapy
648718|NCT00112086|interval cytoreductive surgery
648719|NCT00112073|Alzheimer's disease
648720|NCT00112073|immunotherapy
648721|NCT00112073|beta amyloid
648722|NCT00112060|Talotrexin
648723|NCT00112060|PT-523
648724|NCT00112060|Non-Small Cell Lung Carcinoma (NSCLC)
648725|NCT00112047|Human Immunodeficiency Virus
648726|NCT00112034|Multiple Sclerosis
648727|NCT00112034|Relapsing-Remitting
648728|NCT00112034|AVONEX
648729|NCT00112034|Combination
648730|NCT00112034|Methotrexate
648731|NCT00112034|IV Methylprednisolone
648732|NCT00112034|IVMP
648733|NCT00112034|ACT
648734|NCT00112034|MTX
648735|NCT00112021|obesity
648736|NCT00112021|weight loss
648737|NCT00112021|Amylin
648738|NCT00112021|pramlintide
648739|NCT00112021|Symlin
648740|NCT00112008|Anemia
648741|NCT00111995|Chronic Renal Failure (CRF)
648742|NCT00111995|Anemia
648743|NCT00111982|bilateral, idiopathic Parkinson's Disease
648744|NCT00111969|Heart failure
648745|NCT00111969|Immune modulation therapy
648746|NCT00111969|Inflammation
648747|NCT00111969|Chronic systolic heart failure
648748|NCT00111956|TNF
648749|NCT00111956|metabolic syndrome
648750|NCT00111956|inflammation
648751|NCT00111956|CRP
648752|NCT00111956|adiponectin
648753|NCT00111943|Anti-Infective Agents, Local
648754|NCT00111943|HIV Seronegativity
648755|NCT00111943|Tenofovir
648756|NCT00111943|Vaginal gel
648757|NCT00111943|Microbicide
648758|NCT00111943|Vaginal Microbicide
648759|NCT00111943|PMPA
648760|NCT00111930|dehydroepiandrosterone
648761|NCT00111930|DHEAS
648762|NCT00111930|bone mineral density
648763|NCT00111930|body composition
648764|NCT00111930|lean mass
648765|NCT00111930|fat mass
648766|NCT00111930|bone mass
648767|NCT00111930|decreased DHEAS levels
648768|NCT00111917|Chronic Beryllium Disease
648769|NCT00111917|Berylliosis
648770|NCT00111917|Beryllium Disease
648771|NCT00111917|CBD
648772|NCT00111917|Infliximab
648773|NCT00111904|stage III pancreatic cancer
648774|NCT00111904|recurrent pancreatic cancer
648775|NCT00111904|stage IV pancreatic cancer
648776|NCT00111878|Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)
648777|NCT00111865|physical exercise
648778|NCT00111865|quality of life
648779|NCT00111865|lymphoma
648780|NCT00111852|Desmoteplase
648781|NCT00111852|Acute Ischemic Stroke
648782|NCT00111852|Stroke, Acute
648783|NCT00111839|Lung cancer
648784|NCT00111826|Intermittent Claudication
648785|NCT00111826|Peripheral Arterial Disease
648786|NCT00111826|Immune modulation therapy
648787|NCT00111826|Inflammation
648788|NCT00111800|NIDDM
648789|NCT00111787|breast cancer
648790|NCT00111774|Colon Cancer, Rectal Cancer
648791|NCT00111774|Colorectal Carcinoma, EGFr
648792|NCT00111774|Metastatic Cancer, ABX-EGF
648793|NCT00111774|Panitumumab, Abgenix
648794|NCT00111774|Clinical Trial, Immunex, Amgen
648795|NCT00111774|Metastatic Colorectal
648796|NCT00111761|Immunex
648797|NCT00111761|Panitumumab
648798|NCT00111761|ABX-EGF
648799|NCT00111761|Abgenix
648800|NCT00111748|Myeloma
648801|NCT00111683|Myelodysplastic Syndrome[Refractory Anemia with
648802|NCT00111683|Excess Blasts-1 or 2 (WHO Classification)]
648803|NCT00111683|Chronic Myelogenous Leukemia in blast crisis
648804|NCT00111657|Gout
648805|NCT00111657|Tophi
648806|NCT00111657|Tophaceous gout
648807|NCT00111657|Allergy to allopurinol
648808|NCT00111657|Post-transplant gout
648809|NCT00111618|vascular disrupting agent
648810|NCT00111618|safety
648811|NCT00111618|tolerability
648812|NCT00111618|efficacy
648813|NCT00111618|hormone refractory prostate cancer
648814|NCT00111605|AIDS Vaccines
648815|NCT00111605|HIV Vaccines
648816|NCT00111605|HIV Preventive Vaccine
648817|NCT00111605|HIV Seronegativity
648818|NCT00111592|BPH
648819|NCT00111592|benign prostatic hyperplasia
648820|NCT00111566|Percutaneous Coronary Intervention (PCI)
648821|NCT00111566|Glycoprotein IIb/IIIa blockade
648822|NCT00111566|Ischemic complications following PCI
648823|NCT00111553|Leishmaniasis
648824|NCT00111553|Subunit vaccine
648825|NCT00111553|Therapeutic
648826|NCT00111553|T cell
648827|NCT00111553|Antimony
648828|NCT00111540|exenatide
648829|NCT00111540|diabetes
648830|NCT00111540|Amylin
648831|NCT00111540|exendin-4
648832|NCT00111527|Heart failure
648833|NCT00111527|Atrial fibrillation
648834|NCT00111527|Cardiac resynchronization
648835|NCT00111527|Cardiac pacing
648836|NCT00111527|Catheter ablation
648837|NCT00111527|Quality of life
648838|NCT00111527|Echocardiography
648839|NCT00111514|Leishmaniasis
648840|NCT00111514|Subunit vaccine
648841|NCT00111514|therapeutic
648842|NCT00111514|T-cell
648843|NCT00111514|pentavalent antimony
648844|NCT00111501|smoking
648845|NCT00111501|tobacco
648846|NCT00111488|atrial fibrillation
648847|NCT00111475|Immune Thrombocytopenic Purpura
648848|NCT00111475|Idiopathic Thrombocytopenic Purpura
648849|NCT00111475|Thrombocytopenic
648850|NCT00111475|Thrombocytopenia
648851|NCT00111475|ITP
648852|NCT00111462|non-myeloid malignancy
648853|NCT00111462|chemotherapy-induced anemia
648854|NCT00111449|Psoriasis, adults
648855|NCT00111449|skin, Phase 3
648856|NCT00111449|clinical trial, Amgen
648857|NCT00111449|etanercept, Enbrel®
648858|NCT00111449|moderate, severe
648859|NCT00111436|Psoriasis, adults, skin
648860|NCT00111436|Phase 3, clinical trial
648861|NCT00111436|Amgen, etanercept
648862|NCT00111436|Enbrel®, moderate
648863|NCT00111436|severe, extension
648864|NCT00111423|Rheumatoid Arthritis, Inflammation
648865|NCT00111423|Pegsunercept, PEG sTNF-RI
648866|NCT00111423|Autoimmune, Amgen
648867|NCT00111423|Clinical Trials
648868|NCT00111410|Rheumatoid Arthritis, Inflammation
648869|NCT00111410|Interleukin-1 (IL-1), r-metHuIL-1ra
648870|NCT00111410|Autoimmune, Kineret®
648871|NCT00111410|Anakinra, Immunex
648872|NCT00111410|Amgen, Clinical Trials
648873|NCT00111397|Mycobacterial
648874|NCT00111397|Interferon
648875|NCT00111397|GM-CSF
648876|NCT00111397|Microarray
648877|NCT00111397|Proteomics
648878|NCT00111397|Mycobacterium Avium Complex Infection
648879|NCT00111397|MAC
648880|NCT00111384|Phenotype
648881|NCT00111384|NF1-associated tumors
648882|NCT00111384|NF1
648883|NCT00111384|EQTL
648884|NCT00111384|Modifier Genes
648885|NCT00111384|Neurofibroma
648886|NCT00111384|Neurofibromatosis Type 1
648887|NCT00111371|artificial grammar learning
648888|NCT00111371|dyslexia
648889|NCT00111371|healthy subjects
648890|NCT00111371|levodopa
648891|NCT00111371|drug
648892|NCT00111371|treatment
648893|NCT00111371|intervention
648894|NCT00111358|HIV, AIDS, metabolic syndrome
648895|NCT00111345|Acute
648896|NCT00111345|myeloid
648897|NCT00111345|leukemia
648898|NCT00111345|Acute myeloid leukemia
648899|NCT00111319|Front Line
648900|NCT00111319|Multiple Myeloma
648901|NCT00111319|Untreated
648902|NCT00111306|Lupus
648903|NCT00111306|Antibody
648904|NCT00111306|B-cell immunotherapy
648905|NCT00111293|Attention
648906|NCT00111293|Executive Function
648907|NCT00111293|Vision
648908|NCT00111293|fMRI
648909|NCT00111293|Top-Down
648910|NCT00111293|Visual Processing
648911|NCT00111293|Lesion
648912|NCT00111293|Prefrontal
648913|NCT00111293|Parietal
648914|NCT00111293|Focal Brain Lesion
648915|NCT00111293|Healthy Volunteer
648916|NCT00111280|HIV infection
648917|NCT00111280|TMC125
648918|NCT00111280|Nucleoside reverse transcriptase inhibitors (NRTIs)
648919|NCT00111280|roll-over trial
648920|NCT00111280|antiretrovirals (ARVs)
648921|NCT00111267|vitamin B12
648922|NCT00111267|cognitive function
648923|NCT00111267|oral supplementation
648924|NCT00111267|elderly
648925|NCT00111254|microdermabrasion
648926|NCT00111254|skin
648927|NCT00111254|wrinkles
648928|NCT00111254|collagen
648929|NCT00111254|photoaging
648930|NCT00111254|wrinkled skin
648931|NCT00111241|bone fracture
648932|NCT00111241|cartilage
648933|NCT00111241|osteoporosis
648934|NCT00111241|breast cancer
648935|NCT00111241|aromatase inhibitors
648936|NCT00111241|knee articular cartilage volume
648937|NCT00111228|Diabetes
648938|NCT00111215|Menorrhagia
648939|NCT00111215|Von Willebrand's Disease
648940|NCT00111215|Platelet Disorder
648941|NCT00111202|Genetic counseling
648942|NCT00111202|Genetic counselling
648943|NCT00111202|Genetics
648944|NCT00111202|Schizophrenia
648945|NCT00111189|Schizophrenia
648946|NCT00111189|Paliperidone palmitate
648947|NCT00111189|R092670
648948|NCT00111189|antipsychotic
648949|NCT00111189|recurrence prevention
648950|NCT00111176|Thoracic Aortic Aneurysm
648951|NCT00111176|Descending
648952|NCT00111176|minimally invasive
648953|NCT00111176|endovascular
648954|NCT00111176|rupture
648955|NCT00111176|back pain
648956|NCT00111176|stent graft
648957|NCT00111176|endovascular aneurysm repair
648958|NCT00111176|aortic aneurysm
648959|NCT00111176|thoracic
648960|NCT00111163|malaria
648961|NCT00111163|anemia
648962|NCT00111163|Plasmodium falciparum
648963|NCT00111163|infants
648964|NCT00111163|prevention
648965|NCT00111163|safety
648966|NCT00111163|efficacy
648967|NCT00111163|antimalarials
648968|NCT00111150|HIV incidence
648969|NCT00111150|HIV prevention
648970|NCT00111137|darbepoetin alfa
648971|NCT00111137|anemia
648972|NCT00111137|Amgen
648973|NCT00111137|Chemotherapy
648974|NCT00111124|psoriasis
648975|NCT00111124|arthritis
648976|NCT00111124|Enbrel®
648977|NCT00111124|etanercept
648978|NCT00111111|Psoriasis
648979|NCT00111098|Anemia
648980|NCT00111098|Chronic Kidney Disease (CKD)
648981|NCT00111085|aneurysmal subarachnoid hemorrhage (aSAH)
648982|NCT00111085|vasospasm
648983|NCT00111085|delayed ischemic neurological deficits (DIND)
648984|NCT00111085|computer tomography scan (CT scan)
648985|NCT00111085|digital subtraction angiography (DSA)
648986|NCT00111085|endothelin A receptor
648987|NCT00111085|clazosentan
648988|NCT00111072|Mucosal Disease
648989|NCT00111072|Topical Steroids
648990|NCT00111072|Salivary Diagnostics
648991|NCT00111072|Oral Pain
648992|NCT00111072|Quality of Life Indicators
648993|NCT00111072|Oral Lichen Planus
648994|NCT00111059|obesity
648995|NCT00111059|cardiovascular disease
648996|NCT00111059|depression
648997|NCT00111059|stress
648998|NCT00111046|Pain Relief
648999|NCT00111046|Choroidal melanoma
649000|NCT00111046|plaque radiotherapy
649001|NCT00110981|psoriasis
649002|NCT00110981|dermatology
649003|NCT00110981|plaque psoriasis
649004|NCT00110981|skin
649005|NCT00110981|etanercept
649006|NCT00110981|ENBREL
649007|NCT00110981|NB-UVB, narrow-band UVB, phototherapy
649008|NCT00110981|combination therapy, 50 mg prefilled syringes
649009|NCT00110968|Abdominal Symptom relief
649010|NCT00110968|Fullness
649011|NCT00110968|Bloating
649012|NCT00110968|Indigestion
649013|NCT00110968|Functional dyspepsia
649014|NCT00110955|Non-myeloid malignancy
649015|NCT00110955|Chemotherapy-induced anemia
649016|NCT00110942|Intra-articular
649017|NCT00110942|Osteoarthritis
649018|NCT00110942|OA
649019|NCT00110942|anakinra
649020|NCT00110942|Amgen
649021|NCT00110929|Sensipar®
649022|NCT00110929|Secondary HPT
649023|NCT00110929|Mimpara®
649024|NCT00110929|Cinacalcet
649025|NCT00110929|calcimimetic
649026|NCT00110929|End-Stage Renal Disease (ESRD)
649027|NCT00110916|Intra-articular
649028|NCT00110916|Osteoarthritis
649029|NCT00110916|OA
649030|NCT00110916|anakinra
649031|NCT00110916|Amgen
649032|NCT00110903|Rheumatoid arthritis
649033|NCT00110903|RA
649034|NCT00110903|etanercept
649035|NCT00110903|Immunex
649036|NCT00110903|Amgen
649037|NCT00110890|Secondary HyperParaThyroidism (SHPT)
649038|NCT00110890|Dialysis, End Stage Renal Disease (ESRD)
649039|NCT00110890|KDOQI, Cinacalcet
649040|NCT00110890|Clinical Trial, Amgen
649041|NCT00110877|Human Immunodeficiency Virus
649042|NCT00110877|Treatment Experienced
649043|NCT00110877|TMC114-C214
649044|NCT00110864|diabetes, type 2
649045|NCT00110851|diabetes, type 2
649046|NCT00110838|fish oil
649047|NCT00110838|n-3 fatty acids
649048|NCT00110838|n-3 PUFA
649049|NCT00110838|omega-3 fatty acids
649050|NCT00110838|arrhythmia
649051|NCT00110838|ICD
649052|NCT00110838|human
649053|NCT00110838|Patients with an implantable cardioverter defibrillator
649054|NCT00110812|Treatment Naive
649055|NCT00110812|IL-2
649056|NCT00110812|rIL-2
649057|NCT00110799|thrombopoietin
649058|NCT00110799|platelets
649059|NCT00110799|Hepatitis C-related thrombocytopenia
649060|NCT00110799|Hepatitis C
649061|NCT00110786|Allergy
649062|NCT00110786|Specific Immunotherapy
649063|NCT00110786|Ragweed
649064|NCT00110786|Environmental Exposure Chamber
649065|NCT00110721|colorectal cancer
649066|NCT00110721|DAVANAT
649067|NCT00110721|5-fluorouracil
649068|NCT00110708|autism
649069|NCT00110708|gastrointestinal dysfunction
649070|NCT00110708|autistic disorder
649071|NCT00110708|diarrhea
649072|NCT00110708|constipation
649073|NCT00110708|abdominal pain
649074|NCT00110708|gastrointestinal problems associated with autism
649075|NCT00110708|immune globulin
649076|NCT00110708|immunoglobulin
649077|NCT00110708|Immunoglobulins, Intravenous
649078|NCT00110708|Intestinal Mucosa/immunology/pathology
649079|NCT00110708|Administration, Oral
649080|NCT00110708|Autistic Disorder/*drug therapy
649081|NCT00110708|Child Behavior/*drug effects
649082|NCT00110708|Constipation/drug therapy
649083|NCT00110708|Diarrhea/drug therapy
649084|NCT00110708|Gastrointestinal Agents/*therapeutic use
649085|NCT00110695|NSABP
649086|NCT00110695|Abraxis
649087|NCT00110695|Abraxane
649088|NCT00110695|Locally advanced breast cancer
649089|NCT00110695|Fluorouracil
649090|NCT00110695|Epirubicin
649091|NCT00110695|Cyclophosphamide
649092|NCT00110695|FEC
649093|NCT00110682|Actinic Keratosis
649094|NCT00110682|Cryotherapy
649095|NCT00110682|Imiquimod
649096|NCT00110669|Muscular dystrophy, Duchenne and Beckers
649097|NCT00110669|Beckers Muscular dystrophy
649098|NCT00110656|Kidney transplant
649099|NCT00110643|Acne
649100|NCT00110643|laser
649101|NCT00110630|nicotine dependence
649102|NCT00110617|Sickle Cell Disease
649103|NCT00110617|Iron Overload from Repeated Blood Transfusions
649104|NCT00110617|Iron Overload
649105|NCT00110617|Blood Transfusions
649106|NCT00110604|Folic acid
649107|NCT00110604|Atherosclerosis
649108|NCT00110604|Cognitive function
649109|NCT00110604|Hearing
649110|NCT00110604|Inflammation
649111|NCT00110604|Hemostasis
649112|NCT00110604|Arterial stiffness
649113|NCT00110578|Treatment Naive
649114|NCT00110578|Treatment Experienced
649115|NCT00110565|Magnetics
649116|NCT00110565|Pulsed Magnetic Pad
649117|NCT00110565|Magnetic Field
649118|NCT00110565|Electromagnetic Field
649119|NCT00110565|Women
649120|NCT00110565|Pulsed Magnetic Field
649121|NCT00110539|Medicine, Herbal
649122|NCT00110539|Dietary Supplements
649123|NCT00110539|Complementary and Alternative Medicine
649124|NCT00110539|Physicians
649125|NCT00110526|Prostate Cancer
649126|NCT00110526|Radiation Therapy
649127|NCT00110526|Local recurrence
649128|NCT00110526|Gene Therapy
649129|NCT00110513|Antithrombin Deficiency, Congenital or Hereditary
649130|NCT00110513|Antithrombin III Deficiency
649131|NCT00110513|ATIII
649132|NCT00110513|Hereditary Antithrombin Deficiency (HD)
649133|NCT00110500|Diabetes
649134|NCT00110500|Neuropathy
649135|NCT00110487|Endometriosis
649136|NCT00110474|Glucosamine sulfate
649137|NCT00110474|Osteoarthritis
649138|NCT00110474|Acetaminophen
649139|NCT00110474|Paracetamol
649140|NCT00110474|Clinical trial
649141|NCT00110461|Aripiprazole
649142|NCT00110461|Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features
649143|NCT00110448|type 2 diabetes
649144|NCT00110448|coronary heart diseases
649145|NCT00110448|primary prevention
649146|NCT00110448|atherosclerosis
649147|NCT00110448|aspirin
649148|NCT00110422|Metabolic Syndrome
649149|NCT00110396|Multiple Sclerosis
649150|NCT00110396|Relapsing forms of multiple sclerosis
649151|NCT00110344|Cancer
649152|NCT00110331|Encephalopathy
649153|NCT00110331|Neuroimaging
649154|NCT00110331|Cognition
649155|NCT00110331|Neuroinflammation
649156|NCT00110331|Opportunistic Infections
649157|NCT00110331|HIV
649158|NCT00110331|Central Nervous System Disease
649159|NCT00110331|Bipolar Disorder
649160|NCT00110331|Attention Deficit Hyperactivity Disorder
649161|NCT00110331|ADHD
649162|NCT00110331|Major Depression
649163|NCT00110331|Psychosis
649164|NCT00110318|Tennis Elbow
649165|NCT00110318|Physical Therapy Techniques
649166|NCT00110318|Evidence-Based Medicine
649167|NCT00110318|Primary Health Care
649168|NCT00110305|Human Immunodeficiency Virus Type 1
649169|NCT00110305|Human immunodeficiency virus (HIV)
649170|NCT00110305|Antiretroviral
649171|NCT00110305|Antiviral
649172|NCT00110305|ARV
649173|NCT00110305|TMC278
649174|NCT00110305|Efavirenz
649175|NCT00110305|Combivir
649176|NCT00110305|Truvada
649177|NCT00110305|Zidovudine
649178|NCT00110305|Lamivudine
649179|NCT00110305|Tenofovir disoproxil fumarate
649180|NCT00110305|Emtricitabine
649181|NCT00110292|Public health
649182|NCT00110292|Primary care
649183|NCT00110292|Parenting education
649184|NCT00110292|Child rearing
649185|NCT00110292|Parenting newsletters
649186|NCT00110292|Child development
649187|NCT00110292|Language delay
649188|NCT00110279|Bird Flu
649189|NCT00110266|ICL670
649190|NCT00110266|Deferasirox
649191|NCT00110266|Iron chelation
649192|NCT00110266|Chelator
649193|NCT00110266|Desferal
649194|NCT00110240|Type 2 diabetes
649195|NCT00110240|vildagliptin
649196|NCT00110227|Complementary Therapies
649197|NCT00110227|Tai Chi
649198|NCT00110201|Acute renal failure
649199|NCT00110201|Nesiritide
649200|NCT00110201|Cardiovascular surgery
649201|NCT00110188|prostate
649202|NCT00110188|cancer
649203|NCT00110175|Cortical Reorganization
649204|NCT00110175|Motor Function
649205|NCT00110175|Somatosensory Stimulation
649206|NCT00110175|Rehabilitation
649207|NCT00110175|Transcranial Direct Current Stimulation (tDCS)
649208|NCT00110175|Direct Current Stimulation
649209|NCT00110175|Stroke
649210|NCT00110175|Healthy Volunteer
649211|NCT00110162|adenocarcinoma of the prostate
649212|NCT00110162|stage I prostate cancer
649213|NCT00110162|stage IIB prostate cancer
649214|NCT00110162|stage IIA prostate cancer
649215|NCT00110162|stage III prostate cancer
649216|NCT00110162|stage IV prostate cancer
649217|NCT00110162|recurrent prostate cancer
649218|NCT00110149|contiguous stage II grade 1 follicular lymphoma
649219|NCT00110149|noncontiguous stage II grade 1 follicular lymphoma
649220|NCT00110149|stage I grade 1 follicular lymphoma
649221|NCT00110149|stage III grade 1 follicular lymphoma
649222|NCT00110149|stage IV grade 1 follicular lymphoma
649223|NCT00110149|contiguous stage II grade 2 follicular lymphoma
649224|NCT00110149|noncontiguous stage II grade 2 follicular lymphoma
649225|NCT00110149|stage I grade 2 follicular lymphoma
649226|NCT00110149|stage III grade 2 follicular lymphoma
649227|NCT00110149|stage IV grade 2 follicular lymphoma
649228|NCT00110149|contiguous stage II marginal zone lymphoma
649229|NCT00110149|noncontiguous stage II marginal zone lymphoma
649230|NCT00110149|splenic marginal zone lymphoma
649231|NCT00110149|stage I marginal zone lymphoma
649232|NCT00110149|stage III marginal zone lymphoma
649233|NCT00110149|stage IV marginal zone lymphoma
649234|NCT00110149|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
649235|NCT00110149|nodal marginal zone B-cell lymphoma
649236|NCT00110149|contiguous stage II small lymphocytic lymphoma
649237|NCT00110149|noncontiguous stage II small lymphocytic lymphoma
649238|NCT00110149|stage I small lymphocytic lymphoma
649239|NCT00110149|stage III small lymphocytic lymphoma
649240|NCT00110149|stage IV small lymphocytic lymphoma
649241|NCT00110136|recurrent breast cancer
649242|NCT00110136|stage I breast cancer
649243|NCT00110136|stage II breast cancer
649244|NCT00110136|stage IIIA breast cancer
649245|NCT00110136|stage IIIB breast cancer
649246|NCT00110136|breast cancer in situ
649247|NCT00110136|ductal breast carcinoma in situ
649248|NCT00110136|hot flashes
649249|NCT00110123|liver metastases
649250|NCT00110123|ciliary body and choroid melanoma, medium/large size
649251|NCT00110123|iris melanoma
649252|NCT00110123|extraocular extension melanoma
649253|NCT00110123|recurrent intraocular melanoma
649254|NCT00110123|metastatic intraocular melanoma
649255|NCT00110110|intraocular retinoblastoma
649256|NCT00110084|recurrent breast cancer
649257|NCT00110084|stage IV breast cancer
649258|NCT00110058|accelerated phase chronic myelogenous leukemia
649259|NCT00110058|childhood chronic myelogenous leukemia
649260|NCT00110058|chronic phase chronic myelogenous leukemia
649261|NCT00110058|Philadelphia chromosome positive chronic myelogenous leukemia
649262|NCT00110058|relapsing chronic myelogenous leukemia
649263|NCT00110045|infection
649264|NCT00110045|ataxia-telangiectasia
649265|NCT00110045|accelerated phase chronic myelogenous leukemia
649266|NCT00110045|acute undifferentiated leukemia
649267|NCT00110045|blastic phase chronic myelogenous leukemia
649268|NCT00110045|meningeal chronic myelogenous leukemia
649269|NCT00110045|relapsing chronic myelogenous leukemia
649270|NCT00110045|chronic eosinophilic leukemia
649271|NCT00110045|primary myelofibrosis
649272|NCT00110045|chronic neutrophilic leukemia
649273|NCT00110045|essential thrombocythemia
649274|NCT00110045|polycythemia vera
649275|NCT00110045|adult acute lymphoblastic leukemia in remission
649276|NCT00110045|recurrent adult acute lymphoblastic leukemia
649277|NCT00110045|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
649278|NCT00110045|adult acute myeloid leukemia with inv(16)(p13;q22)
649279|NCT00110045|adult acute myeloid leukemia with t(15;17)(q22;q12)
649280|NCT00110045|adult acute myeloid leukemia with t(16;16)(p13;q22)
649281|NCT00110045|adult acute myeloid leukemia with t(8;21)(q22;q22)
649282|NCT00110045|adult acute myeloid leukemia in remission
649283|NCT00110045|recurrent adult T-cell leukemia/lymphoma
649284|NCT00110045|stage I adult T-cell leukemia/lymphoma
649285|NCT00110045|stage II adult T-cell leukemia/lymphoma
649286|NCT00110045|stage III adult T-cell leukemia/lymphoma
649287|NCT00110045|stage IV adult T-cell leukemia/lymphoma
649288|NCT00110045|refractory chronic lymphocytic leukemia
649289|NCT00110045|stage 0 chronic lymphocytic leukemia
649290|NCT00110045|stage I chronic lymphocytic leukemia
649291|NCT00110045|stage II chronic lymphocytic leukemia
649292|NCT00110045|stage III chronic lymphocytic leukemia
649293|NCT00110045|stage IV chronic lymphocytic leukemia
649294|NCT00110045|progressive hairy cell leukemia, initial treatment
649295|NCT00110045|refractory hairy cell leukemia
649296|NCT00110045|prolymphocytic leukemia
649297|NCT00110045|recurrent adult Hodgkin lymphoma
649298|NCT00110045|stage I adult Hodgkin lymphoma
649299|NCT00110045|stage II adult Hodgkin lymphoma
649300|NCT00110045|stage III adult Hodgkin lymphoma
649301|NCT00110045|stage IV adult Hodgkin lymphoma
649302|NCT00110045|anaplastic large cell lymphoma
649303|NCT00110045|angioimmunoblastic T-cell lymphoma
649304|NCT00110045|recurrent mycosis fungoides/Sezary syndrome
649305|NCT00110045|stage I mycosis fungoides/Sezary syndrome
649306|NCT00110045|stage II mycosis fungoides/Sezary syndrome
649586|NCT00109772|Lenalidomide
649589|NCT00109759|allergy
649307|NCT00110045|stage III mycosis fungoides/Sezary syndrome
649308|NCT00110045|stage IV mycosis fungoides/Sezary syndrome
649309|NCT00110045|recurrent cutaneous T-cell non-Hodgkin lymphoma
649310|NCT00110045|stage I cutaneous T-cell non-Hodgkin lymphoma
649311|NCT00110045|stage II cutaneous T-cell non-Hodgkin lymphoma
649312|NCT00110045|stage III cutaneous T-cell non-Hodgkin lymphoma
649313|NCT00110045|stage IV cutaneous T-cell non-Hodgkin lymphoma
649314|NCT00110045|adult grade III lymphomatoid granulomatosis
649315|NCT00110045|recurrent adult grade III lymphomatoid granulomatosis
649316|NCT00110045|Waldenstrom macroglobulinemia
649317|NCT00110045|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
649318|NCT00110045|nodal marginal zone B-cell lymphoma
649319|NCT00110045|recurrent adult Burkitt lymphoma
649320|NCT00110045|recurrent adult diffuse large cell lymphoma
649321|NCT00110045|recurrent adult diffuse mixed cell lymphoma
649322|NCT00110045|recurrent adult diffuse small cleaved cell lymphoma
649323|NCT00110045|recurrent adult immunoblastic large cell lymphoma
649324|NCT00110045|recurrent adult lymphoblastic lymphoma
649325|NCT00110045|recurrent grade 3 follicular lymphoma
649326|NCT00110045|recurrent mantle cell lymphoma
649327|NCT00110045|recurrent grade 1 follicular lymphoma
649328|NCT00110045|recurrent grade 2 follicular lymphoma
649329|NCT00110045|recurrent marginal zone lymphoma
649330|NCT00110045|recurrent small lymphocytic lymphoma
649331|NCT00110045|contiguous stage II adult Burkitt lymphoma
649332|NCT00110045|noncontiguous stage II adult Burkitt lymphoma
649333|NCT00110045|stage I adult Burkitt lymphoma
649334|NCT00110045|stage III adult Burkitt lymphoma
649335|NCT00110045|stage IV adult Burkitt lymphoma
649336|NCT00110045|contiguous stage II adult diffuse large cell lymphoma
649337|NCT00110045|noncontiguous stage II adult diffuse large cell lymphoma
649338|NCT00110045|stage I adult diffuse large cell lymphoma
649339|NCT00110045|stage III adult diffuse large cell lymphoma
649340|NCT00110045|stage IV adult diffuse large cell lymphoma
649341|NCT00110045|contiguous stage II adult diffuse mixed cell lymphoma
649342|NCT00110045|noncontiguous stage II adult diffuse mixed cell lymphoma
649343|NCT00110045|stage I adult diffuse mixed cell lymphoma
649344|NCT00110045|stage III adult diffuse mixed cell lymphoma
649345|NCT00110045|stage IV adult diffuse mixed cell lymphoma
649346|NCT00110045|contiguous stage II adult immunoblastic large cell lymphoma
649347|NCT00110045|noncontiguous stage II adult immunoblastic large cell lymphoma
649348|NCT00110045|stage I adult immunoblastic large cell lymphoma
649349|NCT00110045|stage III adult immunoblastic large cell lymphoma
649350|NCT00110045|stage IV adult immunoblastic large cell lymphoma
649351|NCT00110045|contiguous stage II adult lymphoblastic lymphoma
649352|NCT00110045|noncontiguous stage II adult lymphoblastic lymphoma
649353|NCT00110045|stage I adult lymphoblastic lymphoma
649354|NCT00110045|stage III adult lymphoblastic lymphoma
649355|NCT00110045|stage IV adult lymphoblastic lymphoma
649356|NCT00110045|contiguous stage II grade 1 follicular lymphoma
649357|NCT00110045|noncontiguous stage II grade 1 follicular lymphoma
649358|NCT00110045|stage I grade 1 follicular lymphoma
649359|NCT00110045|stage III grade 1 follicular lymphoma
649360|NCT00110045|stage IV grade 1 follicular lymphoma
649361|NCT00110045|contiguous stage II grade 2 follicular lymphoma
649362|NCT00110045|noncontiguous stage II grade 2 follicular lymphoma
649363|NCT00110045|stage I grade 2 follicular lymphoma
649364|NCT00110045|stage III grade 2 follicular lymphoma
649365|NCT00110045|stage IV grade 2 follicular lymphoma
649366|NCT00110045|contiguous stage II grade 3 follicular lymphoma
649367|NCT00110045|noncontiguous stage II grade 3 follicular lymphoma
649368|NCT00110045|stage I grade 3 follicular lymphoma
649369|NCT00110045|stage III grade 3 follicular lymphoma
649370|NCT00110045|stage IV grade 3 follicular lymphoma
649371|NCT00110045|contiguous stage II mantle cell lymphoma
649372|NCT00110045|noncontiguous stage II mantle cell lymphoma
649373|NCT00110045|stage I mantle cell lymphoma
649374|NCT00110045|stage III mantle cell lymphoma
649375|NCT00110045|stage IV mantle cell lymphoma
649376|NCT00110045|contiguous stage II marginal zone lymphoma
649377|NCT00110045|noncontiguous stage II marginal zone lymphoma
649378|NCT00110045|stage I marginal zone lymphoma
649379|NCT00110045|stage III marginal zone lymphoma
649380|NCT00110045|stage IV marginal zone lymphoma
649381|NCT00110045|splenic marginal zone lymphoma
649382|NCT00110045|contiguous stage II small lymphocytic lymphoma
649383|NCT00110045|noncontiguous stage II small lymphocytic lymphoma
649384|NCT00110045|stage I small lymphocytic lymphoma
649385|NCT00110045|stage III small lymphocytic lymphoma
649386|NCT00110045|stage IV small lymphocytic lymphoma
649387|NCT00110045|intraocular lymphoma
649388|NCT00110045|primary central nervous system non-Hodgkin lymphoma
649389|NCT00110045|post-transplant lymphoproliferative disorder
649390|NCT00110045|extramedullary plasmacytoma
649391|NCT00110045|isolated plasmacytoma of bone
649392|NCT00110045|monoclonal gammopathy of undetermined significance
649393|NCT00110045|stage I multiple myeloma
649394|NCT00110045|stage II multiple myeloma
649395|NCT00110045|stage III multiple myeloma
649396|NCT00110045|primary systemic amyloidosis
649397|NCT00110045|refractory multiple myeloma
649587|NCT00109772|CRPS Type I
649398|NCT00110045|de novo myelodysplastic syndromes
649399|NCT00110045|myelodysplastic/myeloproliferative neoplasm, unclassifiable
649400|NCT00110045|previously treated myelodysplastic syndromes
649401|NCT00110045|secondary myelodysplastic syndromes
649402|NCT00110045|atypical chronic myeloid leukemia, BCR-ABL1 negative
649403|NCT00110045|chronic myelomonocytic leukemia
649404|NCT00110045|disseminated neuroblastoma
649405|NCT00110045|high risk metastatic gestational trophoblastic tumor
649406|NCT00110045|recurrent neuroblastoma
649407|NCT00110045|recurrent ovarian epithelial cancer
649408|NCT00110045|stage II ovarian epithelial cancer
649409|NCT00110045|stage III ovarian epithelial cancer
649410|NCT00110045|stage IV ovarian epithelial cancer
649411|NCT00110045|recurrent ovarian germ cell tumor
649412|NCT00110045|recurrent malignant testicular germ cell tumor
649413|NCT00110045|stage III malignant testicular germ cell tumor
649414|NCT00110045|secondary acute myeloid leukemia
649415|NCT00110045|stage IIIA breast cancer
649416|NCT00110045|stage IIIB breast cancer
649417|NCT00110045|stage IIIC breast cancer
649418|NCT00110045|stage IV breast cancer
649419|NCT00110045|chronic phase chronic myelogenous leukemia
649420|NCT00110045|contiguous stage II adult diffuse small cleaved cell lymphoma
649421|NCT00110045|noncontiguous stage II adult diffuse small cleaved cell lymphoma
649422|NCT00110045|recurrent adult acute myeloid leukemia
649423|NCT00110045|stage I adult diffuse small cleaved cell lymphoma
649424|NCT00110045|stage III adult diffuse small cleaved cell lymphoma
649425|NCT00110045|stage IV adult diffuse small cleaved cell lymphoma
649426|NCT00110045|T-cell large granular lymphocyte leukemia
649427|NCT00110006|contiguous stage II grade 3 follicular lymphoma
649428|NCT00110006|noncontiguous stage II grade 3 follicular lymphoma
649429|NCT00110006|stage I grade 3 follicular lymphoma
649430|NCT00110006|stage III grade 3 follicular lymphoma
649431|NCT00110006|stage IV grade 3 follicular lymphoma
649432|NCT00110006|contiguous stage II adult diffuse large cell lymphoma
649433|NCT00110006|noncontiguous stage II adult diffuse large cell lymphoma
649434|NCT00110006|stage I adult diffuse large cell lymphoma
649435|NCT00110006|stage III adult diffuse large cell lymphoma
649436|NCT00110006|stage IV adult diffuse large cell lymphoma
649437|NCT00110006|contiguous stage II mantle cell lymphoma
649438|NCT00110006|noncontiguous stage II mantle cell lymphoma
649439|NCT00110006|stage I mantle cell lymphoma
649440|NCT00110006|stage III mantle cell lymphoma
649441|NCT00110006|stage IV mantle cell lymphoma
649442|NCT00110006|anaplastic large cell lymphoma
649443|NCT00109993|graft versus host disease
649444|NCT00109993|accelerated phase chronic myelogenous leukemia
649445|NCT00109993|adult acute lymphoblastic leukemia in remission
649446|NCT00109993|adult acute myeloid leukemia in remission
649447|NCT00109993|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
649448|NCT00109993|adult acute myeloid leukemia with inv(16)(p13;q22)
649449|NCT00109993|adult acute myeloid leukemia with t(15;17)(q22;q12)
649450|NCT00109993|adult acute myeloid leukemia with t(16;16)(p13;q22)
649451|NCT00109993|adult acute myeloid leukemia with t(8;21)(q22;q22)
649452|NCT00109993|atypical chronic myeloid leukemia
649453|NCT00109993|blastic phase chronic myelogenous leukemia
649454|NCT00109993|chronic eosinophilic leukemia
649455|NCT00109993|chronic idiopathic myelofibrosis
649456|NCT00109993|chronic myelomonocytic leukemia
649457|NCT00109993|chronic neutrophilic leukemia
649458|NCT00109993|chronic phase chronic myelogenous leukemia
649459|NCT00109993|de novo myelodysplastic syndromes
649460|NCT00109993|disseminated neuroblastoma
649461|NCT00109993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
649462|NCT00109993|myelodysplastic/myeloproliferative disease, unclassifiable
649463|NCT00109993|nodal marginal zone B-cell lymphoma
649464|NCT00109993|noncontiguous stage II adult Burkitt lymphoma
649465|NCT00109993|noncontiguous stage II adult diffuse large cell lymphoma
649466|NCT00109993|noncontiguous stage II adult diffuse mixed cell lymphoma
649467|NCT00109993|noncontiguous stage II adult diffuse small cleaved cell lymphoma
649468|NCT00109993|noncontiguous stage II adult immunoblastic large cell lymphoma
649469|NCT00109993|noncontiguous stage II adult lymphoblastic lymphoma
649470|NCT00109993|noncontiguous stage II grade 1 follicular lymphoma
649471|NCT00109993|noncontiguous stage II grade 2 follicular lymphoma
649472|NCT00109993|noncontiguous stage II grade 3 follicular lymphoma
649473|NCT00109993|noncontiguous stage II mantle cell lymphoma
649474|NCT00109993|noncontiguous stage II marginal zone lymphoma
649475|NCT00109993|noncontiguous stage II small lymphocytic lymphoma
649476|NCT00109993|poor prognosis metastatic gestational trophoblastic tumor
649477|NCT00109993|previously treated myelodysplastic syndromes
649478|NCT00109993|recurrent adult acute lymphoblastic leukemia
649479|NCT00109993|recurrent adult acute myeloid leukemia
649480|NCT00109993|recurrent adult Burkitt lymphoma
649481|NCT00109993|recurrent adult diffuse large cell lymphoma
649482|NCT00109993|recurrent adult diffuse mixed cell lymphoma
649483|NCT00109993|recurrent adult diffuse small cleaved cell lymphoma
649484|NCT00109993|recurrent adult Hodgkin lymphoma
649485|NCT00109993|recurrent adult immunoblastic large cell lymphoma
649486|NCT00109993|recurrent adult lymphoblastic lymphoma
649487|NCT00109993|recurrent grade 1 follicular lymphoma
649488|NCT00109993|recurrent grade 2 follicular lymphoma
649489|NCT00109993|recurrent grade 3 follicular lymphoma
649490|NCT00109993|recurrent cutaneous T-cell non-Hodgkin lymphoma
649491|NCT00109993|recurrent mantle cell lymphoma
649492|NCT00109993|recurrent mycosis fungoides/Sezary syndrome
649493|NCT00109993|recurrent marginal zone lymphoma
649494|NCT00109993|recurrent neuroblastoma
649495|NCT00109993|recurrent ovarian epithelial cancer
649496|NCT00109993|recurrent ovarian germ cell tumor
649497|NCT00109993|recurrent small lymphocytic lymphoma
649498|NCT00109993|recurrent malignant testicular germ cell tumor
649499|NCT00109993|refractory chronic lymphocytic leukemia
649500|NCT00109993|refractory multiple myeloma
649501|NCT00109993|refractory hairy cell leukemia
649502|NCT00109993|relapsing chronic myelogenous leukemia
649503|NCT00109993|secondary acute myeloid leukemia
649504|NCT00109993|secondary myelodysplastic syndromes
649505|NCT00109993|splenic marginal zone lymphoma
649506|NCT00109993|stage I multiple myeloma
649507|NCT00109993|stage III adult Burkitt lymphoma
649508|NCT00109993|stage III adult diffuse large cell lymphoma
649509|NCT00109993|stage III adult diffuse mixed cell lymphoma
649510|NCT00109993|stage III adult diffuse small cleaved cell lymphoma
649511|NCT00109993|stage III adult immunoblastic large cell lymphoma
649512|NCT00109993|stage III adult lymphoblastic lymphoma
649513|NCT00109993|stage II ovarian epithelial cancer
649514|NCT00109993|stage III chronic lymphocytic leukemia
649515|NCT00109993|stage III grade 1 follicular lymphoma
649516|NCT00109993|stage III grade 2 follicular lymphoma
649517|NCT00109993|stage III grade 3 follicular lymphoma
649518|NCT00109993|stage III mantle cell lymphoma
649519|NCT00109993|stage III marginal zone lymphoma
649520|NCT00109993|stage III multiple myeloma
649521|NCT00109993|stage III ovarian epithelial cancer
649522|NCT00109993|stage III small lymphocytic lymphoma
649523|NCT00109993|stage III malignant testicular germ cell tumor
649524|NCT00109993|stage IIIA breast cancer
649525|NCT00109993|stage IIIB breast cancer
649526|NCT00109993|stage IIIC breast cancer
649527|NCT00109993|stage IV adult Burkitt lymphoma
649528|NCT00109993|stage IV adult diffuse large cell lymphoma
649529|NCT00109993|stage IV adult diffuse mixed cell lymphoma
649530|NCT00109993|stage IV adult diffuse small cleaved cell lymphoma
649531|NCT00109993|stage IV adult immunoblastic large cell lymphoma
649532|NCT00109993|stage IV adult lymphoblastic lymphoma
649533|NCT00109993|stage IV breast cancer
649534|NCT00109993|stage IV chronic lymphocytic leukemia
649535|NCT00109993|stage IV grade 1 follicular lymphoma
649536|NCT00109993|stage IV grade 2 follicular lymphoma
649537|NCT00109993|stage IV grade 3 follicular lymphoma
649538|NCT00109993|stage IV mantle cell lymphoma
649539|NCT00109993|stage IV marginal zone lymphoma
649540|NCT00109993|stage IV ovarian epithelial cancer
649541|NCT00109993|stage IV small lymphocytic lymphoma
649542|NCT00109980|Complementary Therapies
649543|NCT00109980|Plants, Medicinal
649544|NCT00109980|Dominican Republic
649545|NCT00109980|Hispanic Americans
649546|NCT00109954|adult primary hepatocellular carcinoma
649547|NCT00109954|advanced adult primary liver cancer
649548|NCT00109954|localized unresectable adult primary liver cancer
649549|NCT00109954|recurrent adult primary liver cancer
649550|NCT00109941|recurrent pancreatic cancer
649551|NCT00109941|stage III pancreatic cancer
649552|NCT00109941|stage IV pancreatic cancer
649553|NCT00109928|stage III adult diffuse mixed cell lymphoma
649554|NCT00109928|stage IV adult diffuse mixed cell lymphoma
649555|NCT00109928|contiguous stage II adult diffuse mixed cell lymphoma
649556|NCT00109928|noncontiguous stage II adult diffuse mixed cell lymphoma
649557|NCT00109928|contiguous stage II adult diffuse large cell lymphoma
649558|NCT00109928|noncontiguous stage II adult diffuse large cell lymphoma
649559|NCT00109928|stage III adult diffuse large cell lymphoma
649560|NCT00109928|stage IV adult diffuse large cell lymphoma
649561|NCT00109928|anaplastic large cell lymphoma
649562|NCT00109889|extramedullary plasmacytoma
649563|NCT00109889|isolated plasmacytoma of bone
649564|NCT00109876|stage I non-small cell lung cancer
649565|NCT00109863|recurrent melanoma
649566|NCT00109863|stage IV melanoma
649567|NCT00109850|adenocarcinoma of the esophagus
649568|NCT00109850|squamous cell carcinoma of the esophagus
649569|NCT00109850|stage III esophageal cancer
649570|NCT00109837|L1 adult acute lymphoblastic leukemia
649571|NCT00109837|L2 adult acute lymphoblastic leukemia
649572|NCT00109837|untreated adult acute lymphoblastic leukemia
649573|NCT00109798|primary central nervous system non-Hodgkin lymphoma
649574|NCT00109798|primary central nervous system Hodgkin lymphoma
649575|NCT00109785|stage IIIA breast cancer
649576|NCT00109785|stage IIIB breast cancer
649577|NCT00109785|stage IIIC breast cancer
649578|NCT00109785|male breast cancer
649579|NCT00109772|CRPS
649580|NCT00109772|RSDS
649581|NCT00109772|Pain
649582|NCT00109772|CC-5013
649583|NCT00109772|Revlimid
649584|NCT00109772|Complex Regional Pain Syndrome
649585|NCT00109772|Reflex Sympathy Dystrophy Syndrome
649588|NCT00109772|Celgene
649590|NCT00109759|allergoid
649591|NCT00109759|specific immunotherapy
649592|NCT00109759|ragweed
649593|NCT00109746|HIV
649594|NCT00109746|Treatment Experienced
649595|NCT00109746|Anti-Retroviral Agents
649596|NCT00109746|Antiretroviral Therapy, Highly Active
649597|NCT00109746|Picolinic acid
649598|NCT00109746|Dietary Supplements
649599|NCT00109733|Childhood-onset growth hormone deficiency (COGHD)
649600|NCT00109733|Saizen®
649601|NCT00109720|Diabetes
649602|NCT00109720|Self Management
649603|NCT00109720|Type 2 diabetes
649604|NCT00109707|CML in blast crisis
649605|NCT00109707|CML in chronic phase
649606|NCT00109707|CML in accelerated phase
649607|NCT00109707|Gleevec resistance
649608|NCT00109707|Gleevec intolerant
649609|NCT00109707|Gleevec and CML
649610|NCT00109707|imatinib resistance
649611|NCT00109707|imatinib intolerant
649612|NCT00109707|Hypereosinophilic Syndrome
649613|NCT00109707|Systemic Mastocytosis
649614|NCT00109707|Chronic eosinophilic syndrome
649615|NCT00109707|Philadelphia chromosome positive acute lymphoblastic leukemia
649616|NCT00109707|HES
649617|NCT00109707|CEL
649618|NCT00109707|CML
649619|NCT00109707|SM
649620|NCT00109707|Ph+ ALL refractory to standard therapy
649621|NCT00109707|Ph+ALL relapsed
649622|NCT00109707|AMN107A
649623|NCT00109681|ACTIVE
649624|NCT00109681|iloprost
649625|NCT00109681|idiopathic pulmonary fibrosis
649626|NCT00109681|pulmonary arterial hypertension
649627|NCT00109655|Superficial Transitional Cell Carcinoma
649628|NCT00109655|Bacillus Calmette-Guerin (BCG)
649629|NCT00109655|Superficial Bladder Cancer
649630|NCT00109655|Gene Therapy
649631|NCT00109655|Vaccine
649632|NCT00109655|Adenovirus
649633|NCT00109655|Carcinoma in situ
649634|NCT00109642|Amygdala
649635|NCT00109642|Orbitofrontal Cortex
649636|NCT00109642|Yohimbine
649637|NCT00109642|Emotion
649638|NCT00109642|Guanfacine
649639|NCT00109642|Norepinephrine
649640|NCT00109642|Healthy Volunteer
649641|NCT00109629|HIV-Negative
649642|NCT00109629|Healthy
649643|NCT00109629|Immunity
649644|NCT00109629|Preventive
649645|NCT00109629|Virus
649646|NCT00109629|Healthy Volunteer
649647|NCT00109616|neonatal mortality
649648|NCT00109616|chlorhexidine
649649|NCT00109616|newborn cleansing
649650|NCT00109616|umbilical cord care
649651|NCT00109616|community-based trial
649652|NCT00109616|prevention trial
649653|NCT00109616|omphalitis
649654|NCT00109603|Treatment Experienced
649655|NCT00109603|TDF
649656|NCT00109590|HIV Seronegativity
649657|NCT00109590|Treatment Naive
649658|NCT00109590|Pregnancy
649659|NCT00109590|Perinatal Transmission
649660|NCT00109590|Vertical Transmission
649661|NCT00109590|Mother-To-Child Transmission
649662|NCT00109590|MTCT
649663|NCT00109577|bipolar disorder
649664|NCT00109577|mood disorders
649665|NCT00109577|manic depression
649666|NCT00109577|nutrition
649667|NCT00109564|AAMI
649668|NCT00109564|Memory Impairment
649669|NCT00109564|Decline in Cognitive Function
649670|NCT00109564|Age Associated Memory Impairment
649671|NCT00109551|zinc
649672|NCT00109551|child mortality
649673|NCT00109551|child morbidity
649674|NCT00109551|community trial
649675|NCT00109551|prevention trial
649676|NCT00109551|dietary supplement
649677|NCT00109538|Lonafarnib
649678|NCT00109525|NICHD Neonatal Research Network
649679|NCT00109525|Fungal Infection
649680|NCT00109525|Mycosis
649681|NCT00109525|Extremely Low Birth Weight (ELBW)
649682|NCT00109525|Prematurity
649683|NCT00109525|Clinical Judgement
649684|NCT00109525|Polymerase chain reaction (PCR) testing
649685|NCT00109525|Beta-glucan assay
649686|NCT00109525|Mass Spectrometry
649687|NCT00109525|Lumbar puncture
649688|NCT00109512|endometriosis
649689|NCT00109512|pelvic pain
649690|NCT00109512|painful periods
649691|NCT00109512|dysmenorrhea
649692|NCT00109512|painful menstruation
649693|NCT00109512|GnRH
649694|NCT00109512|agonist
649695|NCT00109512|antagonist
649696|NCT00109512|menstrual pain
649697|NCT00109499|Wet Age-Related Macular Degeneration
649698|NCT00109499|Age-Related Maculopathies
649699|NCT00109486|GW685698X
649700|NCT00109486|seasonal allergic rhinitis
649701|NCT00109486|perennial allergic rhinitis
649702|NCT00109486|knemometry
649703|NCT00109486|children
649704|NCT00109473|Pediatric Crohn's disease
649705|NCT00109473|Pediatric
649706|NCT00109473|Crohn's Disease
649707|NCT00109460|Tobacco
649708|NCT00109434|exercise
649709|NCT00109434|hypoglycemia
649710|NCT00109434|Diabetes Mellitus, Type I
649711|NCT00109434|glucose monitoring
649712|NCT00109421|adolescent
649713|NCT00109421|female
649714|NCT00109421|community-based
649715|NCT00109421|social network
649716|NCT00109421|HIV/STI intervention
649717|NCT00109421|High HIV-risk African American adolescent females
649718|NCT00109395|Lorazepam
649719|NCT00109395|Midazolam
649720|NCT00109395|Best Pharmaceuticals for Children Act
649721|NCT00109395|Critically ill
649722|NCT00109395|pediatrics
649723|NCT00109395|mechanical ventilation
649724|NCT00109395|sedation
649725|NCT00109382|Transient Ischemic Attack
649726|NCT00109382|Stroke
649727|NCT00109382|Stroke Prevention
649728|NCT00109382|Recurrence
649729|NCT00109382|Neuroprotection
649730|NCT00109382|Antiplatelet Therapy
649731|NCT00109382|Statins
649732|NCT00109369|Chronic Disease
649733|NCT00109369|Multi-Hospital Information Systems
649734|NCT00109369|Clinical Decision Support Systems
649735|NCT00109369|Reminder Systems
649736|NCT00109369|Registries
649737|NCT00109369|Quality of Healthcare
649738|NCT00109369|Guideline Adherence
649739|NCT00109369|Outcome and Process Assessment (Health Care)
649740|NCT00109369|Technology Assessment, Biomedical
649741|NCT00109369|Primary Health Care
649742|NCT00109369|Hypercholesterolemia
649743|NCT00109369|Hypertension
649744|NCT00109369|Hyperglycemia
649745|NCT00109356|Non-Hodgkin's Lymphoma
649746|NCT00109356|Chronic Lymphocytic Leukemia
649747|NCT00109356|Small Lymphocytic Leukemia
649748|NCT00109330|Prevention of Diphtheria, Tetanus, Pertussis
649749|NCT00109317|Moderate Plaque Psoriasis
649750|NCT00109317|Severe Plaque Psoriasis
649751|NCT00109317|Topical
649752|NCT00109304|Venezuelan Equine Encephalitis
649753|NCT00109304|VEE
649754|NCT00109304|Vaccine
649755|NCT00109304|Provide protective immunity against VEE subtypes IA/B
649756|NCT00109291|anemia
649757|NCT00109291|chronic kidney disease
649758|NCT00109291|CKD
649759|NCT00109291|chronic renal failure
649760|NCT00109291|CRF
649761|NCT00109291|dialysis
649762|NCT00109291|erythropoietin
649763|NCT00109291|EPO
649764|NCT00109291|erythropoiesis stimulating agent
649765|NCT00109291|ESA
649766|NCT00109291|Hematide™
649767|NCT00109291|hemoglobin
649768|NCT00109291|Hb
649769|NCT00109291|Hgb
649770|NCT00109291|Omontys
649771|NCT00109291|peginesatide
649772|NCT00109291|red blood cell
649773|NCT00109291|red blood cell production
649774|NCT00109278|Prevention of Measles
649775|NCT00109265|Advanced Breast Cancer
649776|NCT00109265|Metastatic Breast Cancer
649777|NCT00109265|Cancer
649778|NCT00109252|Plaque Psoriasis
649779|NCT00109252|Topical
649780|NCT00109239|Metastatic Breast Cancer
649781|NCT00109239|Metastatic
649782|NCT00109239|Cancer
649783|NCT00109226|Metastatic Colorectal Cancer
649784|NCT00109226|Cancer
649785|NCT00109213|Spinal Stenosis
649786|NCT00109213|Lumbar Spine
649787|NCT00109213|Decompression
649788|NCT00109213|Fusion
649789|NCT00109213|Spondylolisthesis
649790|NCT00109213|Prospective, randomized clinical trial
649791|NCT00109200|Allergic Asthma
649792|NCT00109200|Severe Allergic Asthma
649793|NCT00109187|Moderate Persistent Asthma
649794|NCT00109187|Severe Persistent Asthma
649795|NCT00109174|Glutamate
649796|NCT00109174|Excitatory Amino Acid
649797|NCT00109174|Neurochemistry
649798|NCT00109174|GABA
649799|NCT00109174|Magnetic Resonance Spectroscopy
649800|NCT00109161|Multiple Sclerosis, MS, CNS, Daclizumab
649801|NCT00107939|bipolar disorder
649802|NCT00107939|manic episode
649803|NCT00107939|treatment
649804|NCT00107939|licarbazepine
649805|NCT00107926|bipolar disorder
649806|NCT00107926|manic episode
649807|NCT00107926|treatment
649808|NCT00107926|licarbazepine
649809|NCT00107913|Immune Thrombocytopenic Purpura
649810|NCT00107900|Deep Vein Thrombosis,
649811|NCT00107900|Anticoagulant,
649812|NCT00107900|Venous thromboembolic
649813|NCT00107887|TST
649814|NCT00107887|isoniazid
649815|NCT00107887|HAART
649816|NCT00107887|Brazil
649817|NCT00107887|HIV
649818|NCT00107874|Maternal
649819|NCT00107874|morbidity
649820|NCT00107874|mortality
649821|NCT00107874|pregnancy
649822|NCT00107874|postpartum hemorrhage
649823|NCT00107874|Cesarean Section
649824|NCT00107848|Pediatric Narcolepsy
649825|NCT00107848|Pediatric OSA
649826|NCT00107848|CPAP
649827|NCT00107848|Pediatric Narcolepsy or OSAHS
649828|NCT00107835|Pain
649829|NCT00107822|Pain
649830|NCT00107809|Pediatric Obstructive sleep Apnea
649831|NCT00107809|Excessive sleepiness
649832|NCT00107809|CPAP
649833|NCT00107809|Pediatric OSAHS
649834|NCT00109148|Obesity and obesity-related medical conditions
649835|NCT00109083|Migraine
649836|NCT00109083|Headaches
649837|NCT00109083|Migraine headaches
649838|NCT00109083|Head pain
649839|NCT00109070|Metastatic
649840|NCT00109057|Cancer
649841|NCT00109057|Advanced malignancies
649842|NCT00109044|Depression
649843|NCT00109044|Major Depressive Disorder
649844|NCT00109044|Escitalopram
649845|NCT00109031|Cancer
649846|NCT00109031|Oncology
649847|NCT00109018|Risk Assessment
649848|NCT00109018|Coronary Heart Disease
649849|NCT00109018|Vascular Function
649850|NCT00109018|Nitric Oxide Metabolites
649851|NCT00109018|Blood Tests
649852|NCT00109018|Nitrite
649853|NCT00109018|Flow-Mediated Dilation
649854|NCT00109018|Biomarker
649855|NCT00109018|Endothelial Dysfunction
649856|NCT00109018|Coronary Artery Disease
649857|NCT00109018|CAD
649858|NCT00109018|Coronary Artery Disease At Risk
649859|NCT00109018|Healthy Volunteer
649860|NCT00109005|Response Rate
649861|NCT00109005|Toxicity
649862|NCT00109005|Progression-Free Survival
649863|NCT00109005|Overall Survival
649864|NCT00109005|Pharmacokinetic
649865|NCT00109005|Ocular Melanoma
649866|NCT00108992|topical NSAID
649867|NCT00108992|topical diclofenac
649868|NCT00108979|Depression
649869|NCT00108979|Major Depressive Disorder
649870|NCT00108979|Escitalopram
649871|NCT00108953|Cancer
649872|NCT00108953|Liver Cancer
649873|NCT00108953|Hepatocellular carcinoma
649874|NCT00108953|HCC
649875|NCT00108940|stroke
649876|NCT00108940|ischemic stroke
649877|NCT00108940|siblings
649878|NCT00108927|Clinical trial
649879|NCT00108927|Diabetes
649880|NCT00108927|Quality Improvement
649881|NCT00108914|Perennial allergic rhinitis
649882|NCT00108914|pediatric
649883|NCT00108901|prevention
649884|NCT00108901|children
649885|NCT00108901|diabetes
649886|NCT00108901|overweight
649887|NCT00108901|obesity
649888|NCT00108901|metabolic syndrome
649889|NCT00108901|exercise
649890|NCT00108901|insulin resistance
649891|NCT00108901|female
649892|NCT00108901|male
649893|NCT00108901|black, African-American
649894|NCT00108901|white, Caucasian
649895|NCT00108901|cognition
649896|NCT00108901|executive function
649897|NCT00108875|Peptide vaccine therapy
649898|NCT00108875|Survivin
649899|NCT00108862|Treatment Naive
649900|NCT00108862|TB
649901|NCT00108862|HIV
649902|NCT00108862|Antiretroviral Agents
649903|NCT00108862|Strategy Study
649904|NCT00108836|GAD
649905|NCT00108836|Anxiety
649906|NCT00108836|XBD173
649907|NCT00108836|Generalized Anxiety Disorder
649908|NCT00108810|Pain
649909|NCT00108810|Osteoarthritis
649910|NCT00108810|OA
649911|NCT00108810|Mild to Moderate Osteoarthritis (OA) Pain of the Knee
649912|NCT00108784|reduced-energy-density diet
649913|NCT00108784|fat-restricted diet
649914|NCT00108784|fruit
649915|NCT00108784|vegetables
649916|NCT00108784|ad libitum intake
649917|NCT00108784|weight loss
649918|NCT00108784|obesity
649919|NCT00108771|Pain
649920|NCT00108771|Chronic Pain
649921|NCT00108771|Osteoarthritis Pain
649922|NCT00108771|Osteoarthritis
649923|NCT00108706|Acute Stroke
649924|NCT00108706|Cerebrovascular Accident
649925|NCT00108706|Ischaemic Stroke
649926|NCT00108706|Candesartan
649927|NCT00108706|Angiotensin Receptor Blocker
649928|NCT00108680|Hemiparesis
649929|NCT00108680|Rehabilitation
649930|NCT00108680|Reaching
649931|NCT00108680|Interlimb Coupling
649932|NCT00108680|Cortical Excitability
649933|NCT00108680|Stroke
649934|NCT00108667|Parkinson's Disease
649935|NCT00108667|AMPA Antagonist
649936|NCT00108667|Dyskinesias
649937|NCT00108667|Glutamate Antagonist
649938|NCT00108667|Parkinson Disease
649939|NCT00108667|PD
649940|NCT00108654|HIV-Negative
649941|NCT00108654|Healthy
649942|NCT00108654|Immunity
649943|NCT00108654|Preventive
649944|NCT00108654|Virus
649945|NCT00108654|Healthy Volunteer
649946|NCT00108628|Imagery
649947|NCT00108628|Nightmares
649948|NCT00108628|Post-Traumatic Stress Disorder
649949|NCT00108628|Psychotherapy
649950|NCT00108602|sleep apnea
649951|NCT00108602|stroke
649952|NCT00108602|ventilatory control
649953|NCT00108589|s-adenosylmethionine
649954|NCT00108589|fatty liver
649955|NCT00108589|obesity
649956|NCT00108589|Non-alcoholic steatohepatitis
649957|NCT00108576|anticonvulsant
649958|NCT00108576|anxiety
649959|NCT00108576|divalproex
649960|NCT00108576|PTSD
649961|NCT00108563|Hepatitis C
649962|NCT00108563|Depression
649963|NCT00108563|Interferon-alpha
649964|NCT00108563|Citalopram
649965|NCT00108563|ribavirin
649966|NCT00108563|antidepressive agents
649967|NCT00108550|analgesia
649968|NCT00108550|antidepressant agents
649969|NCT00108550|back pain
649970|NCT00108550|pain
649971|NCT00108537|smoking
649972|NCT00108537|nicotine
649973|NCT00108537|drug therapy
649974|NCT00108537|smoking cessation
649975|NCT00108524|anti-obesity agents
649976|NCT00108524|diet therapy
649977|NCT00108524|diet, reducing
649978|NCT00108524|obesity
649979|NCT00108524|overweight
649980|NCT00108524|risk factors
649981|NCT00108524|weight loss
649982|NCT00108511|hypertriglyceridemia
649983|NCT00108511|lipoproteins
649984|NCT00108511|triglycerides
649985|NCT00108511|serum GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D)
649986|NCT00108498|sleep apnea
649987|NCT00108498|mirtazapine
649988|NCT00108498|sleep
649989|NCT00108485|Diabetes Mellitus, Type 2
649990|NCT00108485|Kidney Failure, Chronic
649991|NCT00108485|Hyperlipidemia
649992|NCT00108485|Randomized Controlled Trials
649993|NCT00108459|Obesity
649994|NCT00108459|Type 2 Diabetes
649995|NCT00108459|Hyperlipidemia
649996|NCT00108459|Insulin resistance
649997|NCT00108446|Irritable Bowel Syndrome
649998|NCT00108446|visceral hypersensitivity
649999|NCT00108446|cutaneous hypersensitivity
650000|NCT00108446|lidocaine
650001|NCT00108420|Prazosin
650002|NCT00108420|Stress Disorders, Post-traumatic
650003|NCT00108407|Alcohol Abuse/Dependence
650004|NCT00108407|Alcohol Use Disorders
650005|NCT00108407|Cannabis Abuse/Dependence
650006|NCT00108407|Depression
650007|NCT00108407|Dual diagnosis
650008|NCT00108407|Dysthymia
650009|NCT00108407|Stimulant Abuse/Dependence
650010|NCT00108407|Substance Use Disorders
650011|NCT00108394|Uremia
650012|NCT00108394|Dialysis
650013|NCT00108394|Clinical Trials
650014|NCT00108394|Bone Diseases, Metabolic
650015|NCT00108394|adynamic bone disease
650016|NCT00108394|low bone turnover
650017|NCT00108381|chronic back pain
650018|NCT00108381|cognitive-behavioral
650019|NCT00108381|pain
650020|NCT00108381|stages of change
650021|NCT00108368|schizophrenia
650022|NCT00108368|cognition
650023|NCT00108368|antipsychotic medication
650024|NCT00108368|information processing
650025|NCT00108368|social cognition
650026|NCT00108368|Psychotic
650027|NCT00108355|albumin
650028|NCT00108355|ascites
650029|NCT00108355|paracentesis
650030|NCT00108342|nicotine
650031|NCT00108342|drug therapy
650032|NCT00108342|Smoking Cessation
650033|NCT00107796|Pediatric Narcolepsy
650034|NCT00107796|Excessive sleepiness
650035|NCT00107783|Arthritis
650036|NCT00107783|Homogentisic Acid
650037|NCT00107783|Corneal Damage
650038|NCT00107783|Tyrosine
650039|NCT00107783|Alkaptonuria
650040|NCT00107783|Photophobia
650041|NCT00107783|Nitisinone
650042|NCT00107770|ALS
650043|NCT00107770|histone deacetylase inhibition
650044|NCT00107770|open label
650045|NCT00107770|safety study
650046|NCT00107770|sodium phenylbutyrate
650047|NCT00107757|pediatric
650048|NCT00107757|Seasonal allergic rhinitis
650049|NCT00107744|Blood Pressure; Lipids; Dietary Protein
650050|NCT00107731|Bipolar I Disorder
650051|NCT00107731|Manic Depressive Disorder
650052|NCT00107731|Manic Depression
650053|NCT00107718|IL-18
650054|NCT00107718|Phase 2
650055|NCT00107718|melanoma
650056|NCT00107718|treatment naive
650057|NCT00107705|allergy
650058|NCT00107705|skin prick test
650059|NCT00107705|allergoid
650060|NCT00107705|allergenicity
650061|NCT00107705|specific immunotherapy
650062|NCT00107692|Child Obesity
650063|NCT00107692|Physical activity
650064|NCT00107692|community intervention study
650065|NCT00107692|competence
650066|NCT00107692|diet and nutrition
650067|NCT00107692|Nutrition
650068|NCT00107679|Treatment Experienced
650069|NCT00107679|HIV
650070|NCT00107679|HPV
650071|NCT00107679|Antiretroviral Therapy, Highly Active
650072|NCT00107679|Papillomavirus, Human
650073|NCT00107666|Coronary artery bypass grafting
650074|NCT00107666|Heart valve prosthesis implantation
650075|NCT00107666|Cardiopulmonary bypass
650076|NCT00107666|Oxidative stress
650077|NCT00107666|Inflammation
650078|NCT00107666|Endotoxemia
650079|NCT00107640|At-risk drinking
650080|NCT00107640|Alcohol education
650081|NCT00107640|Effectiveness
650082|NCT00107640|Cost-effectiveness
650083|NCT00107627|Gynaecological Cancer
650084|NCT00107627|Surgical Staples
650085|NCT00107627|Subcuticular Sutures
650086|NCT00107614|Waldenstrom
650087|NCT00107601|Glucose
650088|NCT00107601|Glucose Control
650089|NCT00107601|Insulin
650090|NCT00107601|Insulin therapy
650091|NCT00107601|Critically ill
650092|NCT00107601|Intensive Care
650093|NCT00107588|marijuana dependence
650094|NCT00107588|self-efficacy
650095|NCT00107588|coping skills
650096|NCT00107588|attendance
650097|NCT00107588|marijuana abstinence
650098|NCT00107575|tobacco
650099|NCT00107575|alcohol
650100|NCT00108329|aging
650101|NCT00108329|exercise
650102|NCT00108329|metabolic syndrome
650103|NCT00108329|insulin resistance
650104|NCT00108316|Depressive Disorder
650105|NCT00108316|DNA
650106|NCT00108316|Serotonin
650107|NCT00108303|schizophrenia
650108|NCT00108290|Prostate cancer
650109|NCT00108290|chemotherapy
650110|NCT00108290|hormone therapy
650111|NCT00108290|surgery
650112|NCT00108290|PSA
650113|NCT00108290|Gleason score
650114|NCT00108277|Anxiety
650115|NCT00108277|Breathing Training
650116|NCT00108277|Respiratory Dysregulation
650117|NCT00108264|Prostatic Neoplasms
650118|NCT00108264|Neoplasm Metastasis
650119|NCT00108264|Immunotherapy
650120|NCT00108264|Active
650121|NCT00108264|Dendritic Cells
650122|NCT00108251|controlled clinical trial
650123|NCT00108251|Diastole
650124|NCT00108251|Echocardiography
650125|NCT00108251|exercise tolerance
650126|NCT00108251|Heart Failure, Congestive
650127|NCT00108251|Receptors, Aldosterone
650128|NCT00108238|endothelial function
650129|NCT00108238|hormone replacement therapy
650130|NCT00108238|coronary flow reserve
650131|NCT00108238|posmenopausal women
650132|NCT00108238|women's cardiovascular heatlh
650133|NCT00108225|Cholesterol
650134|NCT00108225|Creatinine Clearance
650135|NCT00108225|Diabetes
650136|NCT00108225|Glycohemoglobin
650137|NCT00108225|High Protein Diet
650138|NCT00108212|Diet
650139|NCT00108212|triglyceride
650140|NCT00108212|inflammation
650141|NCT00108212|Genetic polymorphism
650142|NCT00108199|Schizophrenia
650143|NCT00108199|vocational rehabilitation
650144|NCT00108199|neuropsychology
650145|NCT00108186|cyclooxygenase 2
650146|NCT00108186|lung cancer
650147|NCT00108186|lymphocytes
650148|NCT00108186|non small cell
650149|NCT00108186|therapeutics
650150|NCT00108173|Position Emission Tomography (PET)
650151|NCT00108173|Nicotine dependence
650152|NCT00108173|functional magnetic resonance imaging
650153|NCT00108173|cigarette cues
650154|NCT00108160|mupirocin
650155|NCT00108160|prevention and control
650156|NCT00108160|s. aureus
650157|NCT00108147|Aged
650158|NCT00108147|Congestive Heart Failure
650159|NCT00108147|Exercise
650160|NCT00108134|Superficial basal cell carcinoma
650161|NCT00108134|basal cell carcinoma
650162|NCT00108134|sBCC
650163|NCT00108134|BCC
650164|NCT00108134|PEP005
650165|NCT00108134|Topical
650166|NCT00108134|Dermatology
650167|NCT00108121|Nodular basal cell carcinoma
650168|NCT00108121|basal cell carcinoma
650169|NCT00108121|nBCC
650170|NCT00108121|BCC
650171|NCT00108121|PEP005
650172|NCT00108121|Topical
650173|NCT00108121|Dermatology
650174|NCT00108108|Lymphocytic Leukemia
650175|NCT00108095|emesis
650176|NCT00108095|nausea
650177|NCT00108095|post operative nausea and vomiting
650178|NCT00108095|vomiting
650179|NCT00108095|PONV
650180|NCT00108082|left ventricular hypertrophy (LVH)
650181|NCT00108082|echocardiogram
650182|NCT00108082|left ventricular mass regression
650183|NCT00108082|cardiac MRI
650184|NCT00108082|left ventricular mass index (LVMI)hypertension
650185|NCT00108069|Brain
650186|NCT00108069|Tumor
650187|NCT00108069|Malignant
650188|NCT00108069|Therapy
650189|NCT00108069|Progression
650190|NCT00108069|Chemotherapy
650191|NCT00108069|Antiangiogenesis
650192|NCT00108069|Radiation
650193|NCT00108069|Malignant Brain Tumor
650194|NCT00108069|Malignant Glioma
650195|NCT00108069|Glioma
650196|NCT00108056|Brain
650197|NCT00108056|Tumor
650198|NCT00108056|Malignant
650199|NCT00108056|Therapy
650200|NCT00108056|Progression
650201|NCT00108056|Malignant Brain Tumor
650202|NCT00108056|Malignant Glioma
650203|NCT00108056|Glioma
650204|NCT00108043|Functional Electrical Stimulation
650205|NCT00108043|Gait
650206|NCT00108043|Blood pressure
650207|NCT00108043|Orthostatic Hypotension
650208|NCT00108043|Cardiovascular responses
650209|NCT00108043|Near-infra red spectroscopy
650210|NCT00108030|PBWST training
650211|NCT00108030|Strength training
650212|NCT00108030|6-min walking endurance
650213|NCT00108030|Cardiovascular fitness
650214|NCT00108030|Psychosocial attributes
650215|NCT00108017|Ocular hypertension (excessive pressure in the eye)
650216|NCT00108004|Diabetes
650217|NCT00108004|Amylin
650218|NCT00108004|Symlin
650219|NCT00108004|pramlintide acetate
650220|NCT00107991|clinical trial; efficacy; etanercept; hidradenitis suppurativa; quality of life; safety; tnf
650221|NCT00107978|cSSSI (complicated Skin and Skin Structure Infections)
650222|NCT00107978|Staph (Staphylococcus)
650450|NCT00106795|HV
650223|NCT00107978|MRSA (Methicillin-resistant Staphylococcus Aureus)
650224|NCT00107965|Actinic Keratosis
650225|NCT00107965|Solar Keratosis
650226|NCT00107965|AK
650227|NCT00107965|Sun spots
650228|NCT00107965|PEP005
650229|NCT00107965|Topical
650230|NCT00107965|Dermatology
650231|NCT00107952|Nosocomial pneumonia
650232|NCT00107952|MRSA
650233|NCT00107562|risk behavior
650234|NCT00107562|social networks
650235|NCT00107562|behavior
650236|NCT00107549|Treatment Experienced
650237|NCT00107549|HIV Therapeutic Vaccine
650238|NCT00107523|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
650239|NCT00107523|adult acute myeloid leukemia with inv(16)(p13;q22)
650240|NCT00107523|adult acute myeloid leukemia with t(15;17)(q22;q12)
650241|NCT00107523|adult acute myeloid leukemia with t(16;16)(p13;q22)
650242|NCT00107523|adult acute myeloid leukemia with t(8;21)(q22;q22)
650243|NCT00107523|recurrent adult acute myeloid leukemia
650244|NCT00107523|untreated adult acute myeloid leukemia
650245|NCT00107510|stage II breast cancer
650246|NCT00107510|stage IIIA breast cancer
650247|NCT00107510|stage IIIB breast cancer
650248|NCT00107510|stage IIIC breast cancer
650249|NCT00107510|male breast cancer
650250|NCT00107497|stage I breast cancer
650251|NCT00107497|stage II breast cancer
650252|NCT00107484|stage IV breast cancer
650253|NCT00107484|stage I breast cancer
650254|NCT00107484|stage II breast cancer
650255|NCT00107484|stage IIIA breast cancer
650256|NCT00107484|stage IIIB breast cancer
650257|NCT00107484|stage IIIC breast cancer
650258|NCT00107484|male breast cancer
650259|NCT00107471|untreated childhood brain stem glioma
650260|NCT00107458|recurrent childhood brain stem glioma
650261|NCT00107458|recurrent childhood brain tumor
650262|NCT00107458|recurrent childhood cerebellar astrocytoma
650263|NCT00107458|recurrent childhood cerebral astrocytoma
650264|NCT00107458|recurrent childhood ependymoma
650265|NCT00107458|recurrent childhood medulloblastoma
650266|NCT00107458|recurrent childhood supratentorial primitive neuroectodermal tumor
650267|NCT00107458|unspecified childhood solid tumor, protocol specific
650268|NCT00107458|recurrent childhood visual pathway and hypothalamic glioma
650269|NCT00107458|childhood high-grade cerebral astrocytoma
650270|NCT00107458|childhood low-grade cerebral astrocytoma
650271|NCT00107458|childhood infratentorial ependymoma
650272|NCT00107458|childhood supratentorial ependymoma
650273|NCT00107458|childhood spinal cord neoplasm
650274|NCT00107458|childhood grade I meningioma
650275|NCT00107458|childhood grade II meningioma
650276|NCT00107458|childhood grade III meningioma
650277|NCT00107458|childhood craniopharyngioma
650278|NCT00107458|childhood central nervous system germ cell tumor
650279|NCT00107419|chondrosarcoma
650280|NCT00107393|recurrent breast cancer
650281|NCT00107393|stage IV breast cancer
650282|NCT00107380|contiguous stage II adult diffuse large cell lymphoma
650283|NCT00107380|noncontiguous stage II adult diffuse large cell lymphoma
650284|NCT00107380|stage III adult diffuse large cell lymphoma
650285|NCT00107380|stage IV adult diffuse large cell lymphoma
650286|NCT00107367|tumors metastatic to brain
650287|NCT00107354|recurrent adult acute lymphoblastic leukemia
650288|NCT00107354|recurrent adult acute myeloid leukemia
650289|NCT00107354|recurrent childhood acute lymphoblastic leukemia
650290|NCT00107354|recurrent childhood acute myeloid leukemia
650291|NCT00107354|secondary acute myeloid leukemia
650292|NCT00107354|refractory anemia with excess blasts in transformation
650293|NCT00107354|refractory anemia with excess blasts
650294|NCT00107354|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
650295|NCT00107354|adult acute myeloid leukemia with inv(16)(p13;q22)
650296|NCT00107354|adult acute myeloid leukemia with t(15;17)(q22;q12)
650297|NCT00107354|adult acute myeloid leukemia with t(16;16)(p13;q22)
650298|NCT00107354|adult acute myeloid leukemia with t(8;21)(q22;q22)
650299|NCT00107354|de novo myelodysplastic syndromes
650300|NCT00107354|previously treated myelodysplastic syndromes
650301|NCT00107354|secondary myelodysplastic syndromes
650302|NCT00107354|T-cell adult acute lymphoblastic leukemia
650303|NCT00107354|T-cell childhood acute lymphoblastic leukemia
650304|NCT00107354|B-cell adult acute lymphoblastic leukemia
650305|NCT00107354|B-cell childhood acute lymphoblastic leukemia
650306|NCT00107354|childhood myelodysplastic syndromes
650307|NCT00107341|adenocarcinoma of the esophagus
650308|NCT00107341|stage IV esophageal cancer
650309|NCT00107341|recurrent esophageal cancer
650310|NCT00107315|recurrent colon cancer
650311|NCT00107315|stage IV colon cancer
650312|NCT00107315|recurrent rectal cancer
650313|NCT00107315|stage IV rectal cancer
650314|NCT00107289|metastatic pheochromocytoma
650315|NCT00107289|recurrent pheochromocytoma
650316|NCT00107289|regional pheochromocytoma
650317|NCT00107289|recurrent neuroblastoma
650318|NCT00107289|04-148
650319|NCT00107276|stage IV breast cancer
650320|NCT00107276|recurrent breast cancer
650321|NCT00107263|osteoporosis
650322|NCT00107263|stage I breast cancer
650323|NCT00107263|stage II breast cancer
650324|NCT00107263|stage IIIA breast cancer
650325|NCT00107250|recurrent non-small cell lung cancer
650326|NCT00107250|stage IIIB non-small cell lung cancer
650327|NCT00107250|stage IV non-small cell lung cancer
650328|NCT00107250|stage IV colon cancer
650329|NCT00107250|stage IV rectal cancer
650330|NCT00107250|unspecified adult solid tumor, protocol specific
650331|NCT00107237|adult glioblastoma
650332|NCT00107237|recurrent adult brain tumor
650333|NCT00107237|adult giant cell glioblastoma
650334|NCT00107237|adult gliosarcoma
650335|NCT00107211|ductal breast carcinoma in situ
650336|NCT00107211|breast cancer in situ
650337|NCT00107185|childhood high-grade cerebral astrocytoma
650338|NCT00107185|recurrent childhood cerebral astrocytoma
650339|NCT00107185|childhood oligodendroglioma
650340|NCT00107172|stage I non-small cell lung cancer
650341|NCT00107159|recurrent melanoma
650342|NCT00107159|stage III melanoma
650343|NCT00107159|stage IV melanoma
650344|NCT00107120|Major Depressive Disorder
650345|NCT00107120|Depression
650346|NCT00107120|Adolescents
650347|NCT00107120|Escitalopram
650348|NCT00107120|Pediatrics
650349|NCT00107107|Diabetes
650350|NCT00107107|Amylin
650351|NCT00107107|pramlintide
650352|NCT00107107|Symlin
650353|NCT00107094|Breast Cancer
650354|NCT00107094|Adriamycin
650355|NCT00107094|Cyclophosphamide
650356|NCT00107094|Abraxane
650357|NCT00107081|children
650358|NCT00107081|oral antibiotics
650359|NCT00107081|outpatient treatment
650360|NCT00107081|fever and neutropenia
650361|NCT00107068|Stroke
650362|NCT00107068|Exercise
650363|NCT00107068|Aerobic
650364|NCT00107068|PRT
650365|NCT00107068|Walking ability
650366|NCT00107055|Herniated nucleus pulposus
650367|NCT00107055|Lumbosacral radiculopathy
650368|NCT00107055|Anti-TNF alpha
650369|NCT00107055|Tumor necrosis factor alpha
650370|NCT00107042|Hepatitis B
650371|NCT00107042|HIV vaccine trial
650372|NCT00107029|HIV infection
650373|NCT00107029|CD8+ T-cells
650374|NCT00107029|HIV-1 genotype
650375|NCT00107016|Breast Cancer
650376|NCT00107016|Cancer of the Breast
650377|NCT00107016|Neo-adjuvant
650378|NCT00107016|Primary breast cancer
650379|NCT00107016|postmenopausal
650380|NCT00107016|pre-operative
650381|NCT00107003|Brain
650382|NCT00107003|Tumor
650383|NCT00107003|Surgery
650384|NCT00107003|Therapy
650385|NCT00107003|Trial
650386|NCT00107003|Brain Tumor
650387|NCT00107003|Glioblastoma Multiforme
650388|NCT00107003|GBM
650389|NCT00107003|Gliosarcoma
650390|NCT00107003|GS
650391|NCT00106977|Craniosynostosis
650392|NCT00106977|Hearing Loss
650393|NCT00106977|Genectic Disorders
650394|NCT00106977|Muenke Syndrome
650395|NCT00106964|Hepatitis B vaccines
650396|NCT00106964|HIV-infected adolescents
650397|NCT00106964|Hepatitis B infection (negative)
650398|NCT00106951|Surveillance
650399|NCT00106951|coronary heart disease
650400|NCT00106951|neighborhood SES
650401|NCT00106938|Carotid stenting
650402|NCT00106938|Carotid endarterectomy
650403|NCT00106938|Carotid artery disease with severe narrowing of the artery
650404|NCT00106938|Stroke prevention
650405|NCT00106925|Peripheral Blood Stem Cells
650406|NCT00106925|Graft-Versus Leukemia/Myeloma
650407|NCT00106925|Graft-Versus-Host Disease
650408|NCT00106925|Whole Body Irradiation
650409|NCT00106925|Leukemic Relapse
650410|NCT00106925|Allogeneic Stem Cell Transplantation Recipient
650411|NCT00106912|Genetic
650412|NCT00106912|Stroke
650413|NCT00106912|Heart
650414|NCT00106912|Lysosomal
650415|NCT00106912|Glycolipid
650416|NCT00106912|Fabry Disease
650417|NCT00106899|neuroimaging
650418|NCT00106899|brain metabolism
650419|NCT00106899|biomarkers
650420|NCT00106899|cognition disorder
650421|NCT00106899|Mild Cognitive Impairment
650422|NCT00106886|homocysteine
650423|NCT00106886|folic acid
650424|NCT00106886|micronutrients
650425|NCT00106886|multivitamins
650426|NCT00106886|vitamin supplements
650427|NCT00106860|Anxiety
650428|NCT00106860|Generalized Anxiety Disorder
650429|NCT00106847|plaque-type psoriasis
650430|NCT00106847|psoriasis
650431|NCT00106847|drug safety
650432|NCT00106847|drug efficacy
650433|NCT00106847|maintenance therapy
650434|NCT00106847|induction therapy
650435|NCT00106847|remicade
650436|NCT00106834|Psoriasis
650437|NCT00106834|Infliximab
650438|NCT00106834|Remicade
650439|NCT00106808|Type 2 Diabetes
650440|NCT00106795|Antiretrovirals
650441|NCT00106795|Adipocytes
650442|NCT00106795|Skeletal Muscle
650443|NCT00106795|Fatigue
650444|NCT00106795|HIV
650445|NCT00106795|AIDS
650446|NCT00106795|Lymphocytes
650447|NCT00106795|Lipodystrophy
650448|NCT00106795|HIV Positive
650449|NCT00106795|Healthy Volunteer
650451|NCT00106782|Electrical
650452|NCT00106782|Stimulation
650453|NCT00106782|Dystonia
650454|NCT00106782|Brain
650455|NCT00106782|Focal Hand Dystonia
650456|NCT00106782|FHD
650457|NCT00106769|Flavivirus
650458|NCT00106769|Mosquito
650459|NCT00106769|Immunity
650460|NCT00106769|Preventive
650461|NCT00106769|Virus
650462|NCT00106769|West Nile Fever
650463|NCT00106769|Healthy Volunteer
650464|NCT00106769|HV
650465|NCT00106756|Exudation
650466|NCT00106756|Avascular Retina
650467|NCT00106756|Retina Fold
650468|NCT00106743|Usher Syndrome
650469|NCT00106743|Retinitis Pigmentosa
650470|NCT00106743|Congenital Deafness
650471|NCT00106717|Cancer pain
650472|NCT00106717|Quality of life
650473|NCT00106717|Narrative medicine
650474|NCT00106717|Pain relief
650475|NCT00106691|neoplasia
650476|NCT00106691|chemoprevention
650477|NCT00106691|cancer
650478|NCT00106691|premalignant
650479|NCT00106691|precancerous
650480|NCT00106691|Chemoprophylaxis
650481|NCT00106691|Intraepithelial Prostatic Neoplasia
650482|NCT00106691|Neoplasia, Prostatic Intraepithelial
650483|NCT00106678|HIV
650484|NCT00106678|Antiretroviral therapy (ART)
650485|NCT00106678|HAART
650486|NCT00106678|Adherence
650487|NCT00106678|Barriers
650488|NCT00106665|ICU acquired weakness
650489|NCT00106665|Critical care polyneuropathy
650490|NCT00106665|Critical care myopathy
650491|NCT00106652|autism
650492|NCT00106652|neurodevelopment
650493|NCT00106652|neurotoxicology
650494|NCT00106652|perinatology
650495|NCT00106652|teratology
650496|NCT00106639|tofacitinib
650497|NCT00106639|CP-690550
650498|NCT00106639|kidney transplant
650499|NCT00106626|Advanced solid tumors including MPM and NSCLC
650500|NCT00106613|Renal Cell Carcinoma
650501|NCT00106613|Metastatic Cancer
650502|NCT00106613|Metastatic Renal Cell Carcinoma
650503|NCT00106600|Relapsed
650504|NCT00106600|Refractory
650505|NCT00106587|in stent restenosis
650506|NCT00106587|paclitaxel coated balloon catheter
650507|NCT00106587|paccocath
650508|NCT00106587|drug eluting balloon
650509|NCT00106561|spironolactone
650510|NCT00106561|proteinuria
650511|NCT00106561|angiotensin converting enzyme inhibitor
650512|NCT00106561|angiotensin receptor blocker
650513|NCT00106561|renin angiotensin aldosterone system
650514|NCT00106561|aldosterone
650515|NCT00106509|Clostridium Enterocolitis
650516|NCT00106509|Pseudomembranous Colitis
650517|NCT00106509|Clostridium difficile-associated diarrhea
650518|NCT00106509|C. difficile
650519|NCT00106509|CDAD
650520|NCT00106496|Treatment Effectiveness
650521|NCT00106496|Treatment Efficacy
650522|NCT00106496|Immunomodulator, Topical
650523|NCT00106496|Tacrolimus, Topical
650524|NCT00106496|Dermatitis, Atopic
650525|NCT00106496|Eczema, Atopic
650526|NCT00106496|Atopic Dermatitis
650527|NCT00106483|Cardiovascular Diseases
650528|NCT00106483|Coronary Disease
650529|NCT00106483|Heart Diseases
650530|NCT00106470|Chronic Obstructive Pulmonary Disease
650531|NCT00106431|romidepsin
650532|NCT00106418|Prostate Cancer
650533|NCT00106418|Androgen independent metastatic prostate cancer patients with rising PSA
650534|NCT00106418|romidepsin
650535|NCT00106405|Bipolar I Disorder
650536|NCT00106405|Mania
650537|NCT00106405|Memantine HCl
650538|NCT00106392|Treatment effectiveness
650539|NCT00106392|Treatment efficacy
650540|NCT00106392|Investigational, Therapies
650541|NCT00106392|Immunosuppressant
650542|NCT00106392|Erectile dysfunction
650543|NCT00106392|Prostatectomy
650544|NCT00106379|HIV-1
650545|NCT00106379|Treatment Naive
650546|NCT00106379|Treatment Experienced
650547|NCT00106366|Diabetes, Type 2
650548|NCT00106353|Pediatric Tumors
650549|NCT00106340|type 2 diabetes
650550|NCT00106340|vildagliptin
650551|NCT00106314|Dehydroepiandrosterone
650552|NCT00106314|DHEA
650553|NCT00106314|Crohn's disease
650554|NCT00106314|C-reactive protein
650555|NCT00106314|CRP
650556|NCT00106314|Crohn's Disease Activity Index
650557|NCT00106314|CDAI
650558|NCT00106314|Inflammatory Bowel Disease Questionnaire
650559|NCT00106314|IBDQ
650560|NCT00106301|FK228
650561|NCT00106301|Hormone Refractory Prostate Cancer
650562|NCT00106288|Candidaemia
650563|NCT00106288|Micafungin
650564|NCT00106275|Fibromyalgia
650565|NCT00106275|Meditation
650566|NCT00106275|Stress, Psychological
650567|NCT00106275|Monitoring, Ambulatory
650568|NCT00106275|Electrocardiographie, Ambulatory
650569|NCT00106275|Psychophysiology
650570|NCT00106262|advanced cervical cancer
650571|NCT00106262|metastatic cervical cancer
650572|NCT00106249|TMS, Supplementary Motor Area, Obsessive-Compulsive Disorder
650573|NCT00106236|Exercise
650574|NCT00106236|Fitness Club
650575|NCT00106236|Randomized Controlled Trial
650576|NCT00106236|Cardiovascular Risk Factor
650577|NCT00106236|Overweight
650578|NCT00106236|Inactivity
650579|NCT00106223|Cognitive Behavioral Therapy
650580|NCT00106223|CBT
650581|NCT00106223|BDD
650582|NCT00106223|Body dysmorphic disorder
650583|NCT00106210|Child
650584|NCT00106197|Sleep, REM
650585|NCT00106197|Antidepressant
650586|NCT00106197|Adolescent
650587|NCT00106197|Cortisol
650588|NCT00106184|rituximab
650589|NCT00106184|myositis
650590|NCT00106184|dermatomyositis
650591|NCT00106184|polymyositis
650592|NCT00106184|refractory
650593|NCT00106184|Juvenile Dermatomyositis
650594|NCT00106171|HIV
650595|NCT00106171|Acute/Early Seroconverters
650596|NCT00106171|Acute Infection
650597|NCT00106171|Treatment Naive
650598|NCT00106171|Primary HIV Infection
650599|NCT00106158|cancer/testis antigen
650600|NCT00106158|cancer vaccine
650601|NCT00106158|recombinant protein
650602|NCT00106145|Advanced Breast Cancer
650603|NCT00106145|Solid Tumors
650604|NCT00106145|Advanced Solid Tumors
650605|NCT00106132|Macular Edema
650606|NCT00106132|Steroid
650607|NCT00106132|Fluorescein Angiogram
650608|NCT00106132|Ocular Coherence Tomography
650609|NCT00106132|Laser
650610|NCT00106132|Retinal Vein Occlusion
650611|NCT00106119|Levothyroxine
650612|NCT00106119|Liothyronine
650613|NCT00106119|Lipid Metabolism
650614|NCT00106119|Gluconeogensis
650615|NCT00106119|Thyrotropin Releasing Hormone
650616|NCT00106119|Deiodinase
650617|NCT00106119|Replacement Thyroid Hormone Therapy
650618|NCT00106119|Thyroidectomy
650619|NCT00106119|Near Total Thyroidectomy
650620|NCT00106106|Alcoholism
650621|NCT00106106|Acamprosate
650622|NCT00106106|Withdrawal
650623|NCT00106106|Glutamate
650624|NCT00106106|Magnetic Resonance Spectroscopy
650625|NCT00106106|Alcohol Dependence
650626|NCT00106106|Healthy Volunteer
650627|NCT00106106|HV
650628|NCT00106093|Alcohol
650629|NCT00106093|Alcohol Treatment
650630|NCT00106093|DNA
650631|NCT00106093|Treatment
650632|NCT00106093|Alcohol Dependence
650633|NCT00106093|Alcoholism
650634|NCT00106093|Alcohol Drinking Related Problems
650635|NCT00106080|Communication
650636|NCT00106080|Palliative Care
650637|NCT00106067|aging
650638|NCT00106067|behavioral research
650639|NCT00106067|quality of life
650640|NCT00106067|end of life
650641|NCT00106067|family relations
650642|NCT00106067|supportive care
650643|NCT00106067|advanced care
650644|NCT00106067|bereavement
650645|NCT00106041|end of life care
650646|NCT00106041|evaluation studies
650647|NCT00106041|quality of death and dying
650648|NCT00106041|palliative care
650649|NCT00106041|coordination of care
650650|NCT00106041|satisfaction with care
650651|NCT00106041|healthcare cost
650652|NCT00106041|utilization of healthcare resources
650653|NCT00106041|caregivers
650654|NCT00106041|veterans
650655|NCT00106028|Primary disease: Osteogenesis Imperfecta
650656|NCT00106015|inherited pure red cell aplasia
650657|NCT00105963|abuse
650658|NCT00105950|ErbB2 overexpressing
650659|NCT00105950|ErbB1 expressing
650660|NCT00105950|relapsed breast cancer
650661|NCT00105950|refractory inflammatory breast cancer
650662|NCT00105937|Cancer
650663|NCT00105937|Pain
650664|NCT00105911|Cognitive Behavioral Therapy
650665|NCT00105898|Diabetes mellitus
650666|NCT00105898|Hypertension
650667|NCT00105898|Telemedicine
650668|NCT00105898|Case management
650669|NCT00105885|Telephone
650670|NCT00105885|Telemedicine
650671|NCT00105885|Psychopharmacology
650672|NCT00105872|insomnia
650673|NCT00105872|cognitive behavior therapy
650674|NCT00105820|Evaluation
650675|NCT00105820|Quality improvement
650676|NCT00105820|Cluster randomized trial
650677|NCT00105820|Care model
650678|NCT00105820|Collaborative care
650679|NCT00105820|Informatics
650680|NCT00105794|advance directives
650681|NCT00105794|advance directive adherence
650682|NCT00105794|patient-centered care
650683|NCT00105794|patient satisfaction
650684|NCT00105794|coercion
650685|NCT00105794|informed consent
650686|NCT00105794|commitment of mentally ill
650687|NCT00105794|physician-patient relations
650688|NCT00105781|Nurses
650689|NCT00105781|Telephone
650690|NCT00105781|Counseling
650691|NCT00105781|Exercise
650692|NCT00105755|Activity Cycles
650693|NCT00105755|Amputation
650694|NCT00105755|Prevention
650695|NCT00105755|Temperature
650696|NCT00105729|Self-help groups
650697|NCT00105729|Referral and consultation
650698|NCT00105716|hypertension
650699|NCT00105716|adherence
650700|NCT00105716|cardiovascular diseases
650701|NCT00105703|Nurse practitioners
650702|NCT00105703|Case management
650703|NCT00105677|Racial/ethnic health disparities
650704|NCT00105677|Attitudes
650705|NCT00105677|Osteoarthritis Management
650706|NCT00105677|Patient Perceptions
650707|NCT00105664|Outcomes Assessment
650708|NCT00105664|Primary Health Care
650709|NCT00105664|Group Process
650710|NCT00105638|Intervention studies
650711|NCT00105638|Health Care Costs
650712|NCT00105638|Telephone
650713|NCT00105638|Caregivers
650714|NCT00105625|Geriatrics
650715|NCT00105625|Nutrition
650716|NCT00105625|Immune function
650717|NCT00105625|Infection
650718|NCT00105625|Rehabilitation
650719|NCT00105625|Inpatient
650720|NCT00105612|Informed Consent
650721|NCT00105612|Memory Aid
650722|NCT00105586|Anxiety
650723|NCT00105586|Elderly
650724|NCT00105586|Aged
650725|NCT00105586|Serotonin Reuptake Inhibitors
650726|NCT00105586|SSRI
650727|NCT00105586|SERT
650728|NCT00105573|Mother-Child Relations
650729|NCT00105573|Infant
650730|NCT00105573|Child Development
650731|NCT00105573|Poverty
650732|NCT00105560|long-term effects secondary to cancer therapy in children
650733|NCT00105560|untreated childhood medulloblastoma
650734|NCT00105560|untreated childhood pineoblastoma
650735|NCT00105547|Alzheimer's
650736|NCT00105547|Dementia
650737|NCT00105547|Dementia of Alzheimer Type
650738|NCT00105534|Bacterial Conjunctivitis
650739|NCT00105534|Pink Eye
650740|NCT00105534|Conjunctivitis
650741|NCT00105534|Eye Infection
650742|NCT00105534|Eye Discharge
650743|NCT00105521|Parkinson's Disease
650744|NCT00105521|Dyskinesia
650745|NCT00105521|Dyskinesia associated with dopaminergic treatment
650746|NCT00105508|Parkinson's Disease
650747|NCT00105508|Dyskinesia
650748|NCT00105508|Dyskinesia associated with dopaminergic treatment
650749|NCT00105495|Iron Overload
650750|NCT00105495|Thalassemia
650751|NCT00105495|Haemosiderosis
650752|NCT00105495|Cardiac
650753|NCT00105495|Deferiprone
650754|NCT00105495|Chelation
650755|NCT00105482|Tobacco
650756|NCT00105482|Smoking
650757|NCT00105482|Weight
650758|NCT00105482|Weight perception
650759|NCT00105482|Naltrexone
650760|NCT00105469|Bacterial Conjunctivitis
650761|NCT00105469|Pink Eye
650762|NCT00105469|Conjunctivitis
650763|NCT00105469|Eye Infection
650764|NCT00105456|HER2-Positive Metastatic Breast Cancer
650765|NCT00105456|HER2
650766|NCT00105443|Liver Cancer
650767|NCT00105443|Cancer
650768|NCT00105430|Surgery
650769|NCT00105430|Treatment
650770|NCT00105430|Physiology
650771|NCT00105430|Pediatric
650772|NCT00105430|Neurosurgery
650773|NCT00105430|Generalized Primary Dystonia
650774|NCT00105417|Immune Reconstitution
650775|NCT00105417|Thymus
650776|NCT00105417|Cytokines
650777|NCT00105417|HIV
650778|NCT00105404|Steroid
650779|NCT00105404|Diabetic Macular Edema
650780|NCT00105404|DME
650781|NCT00105378|health care services research
650782|NCT00105378|frail elderly
650783|NCT00105378|intermediate care
650784|NCT00105378|patient centered care
650785|NCT00105378|comprehensive health care
650786|NCT00105378|geriatric nursing
650787|NCT00105378|Behavioral symptoms
650788|NCT00105365|lateral wedge inserts
650789|NCT00105365|shoe inserts
650790|NCT00105352|Type 1 Diabetes Study Group
650791|NCT00105352|TrialNet
650792|NCT00105352|type 1 diabetes
650793|NCT00105352|juvenile onset diabetes
650794|NCT00105339|consent form, vaccine trial
650795|NCT00105339|Simplified consent form
650796|NCT00105326|Schizophrenia
650797|NCT00105326|Schizophrenia-related insomnia
650798|NCT00105326|insomnia
650799|NCT00105326|paliperidone
650800|NCT00105326|placebo
650801|NCT00105326|polysomnography
650802|NCT00105287|cancer
650803|NCT00105287|pain
650804|NCT00105287|Breakthrough Pain in cancer patients
650805|NCT00105274|Velocardiofacial Syndrome
650806|NCT00105274|Susceptibility Genes
650807|NCT00105274|Neuroimaging
650808|NCT00105274|22q11.2
650809|NCT00105274|Psychosis
650810|NCT00105274|Mircodeletion
650811|NCT00105274|DiGeorge Syndrome
650812|NCT00105274|22q11.2 Syndrome
650813|NCT00105248|acute repiratory infections
650814|NCT00105248|antibiotic therapy
650815|NCT00105248|patient-centred communication
650816|NCT00105248|randomized controlled trial
650817|NCT00105235|transplantation
650818|NCT00105235|liver transplant
650819|NCT00105235|rejection
650820|NCT00105235|tolerance
650821|NCT00105235|antibody induction
650822|NCT00105222|Cycle Ergometer
650823|NCT00105222|Exercise Physiology
650824|NCT00105222|Nitric Oxide
650825|NCT00105222|Sodium Nitrite
650826|NCT00105222|Healthy Volunteers
650827|NCT00105222|Normal Volunteer
650828|NCT00105222|Healthy Volunteer
650829|NCT00105222|HV
650830|NCT00105209|Platelets
650831|NCT00105196|Single or recurrent
650832|NCT00105196|non-psychotic episode of Major Depressive Disorder
650833|NCT00105183|pulmonary transplantation
650834|NCT00105183|Pulmonary Allograft Rejection
650835|NCT00105170|Monoclonal antibody
650836|NCT00105170|Advanced solid tumors
650837|NCT00105170|Tumors
650838|NCT00105170|hCBE-11
650839|NCT00105144|Treatment Effectiveness
650840|NCT00105144|Treatment Efficacy
650841|NCT00105144|Investigational, Therapies
650842|NCT00105144|Antifungal, Systemic
650843|NCT00105144|Antibiotics, Antifungal
650844|NCT00105144|Micafungin
650845|NCT00105131|Parkinson's Disease
650846|NCT00105131|Movement Disorders
650847|NCT00105131|Tremor
650848|NCT00105131|Alpha-Synuclein
650849|NCT00105131|Lewy Bodies
650850|NCT00105131|Parkinson Disease
650851|NCT00105131|PD
650852|NCT00105131|Movement Disorder
650853|NCT00105131|Healthy Volunteer
650854|NCT00105131|HV
650855|NCT00105118|Cognition
650856|NCT00105118|Alpha
650857|NCT00105118|Schizophrenia
650858|NCT00105118|Functional Connectivity
650859|NCT00105118|Oscillatory Potential
650860|NCT00105105|Alzheimers
650861|NCT00105105|cognition
650862|NCT00105105|acetyl cholinesterase inhibitor
650863|NCT00105105|GR-II antagonist
650864|NCT00105066|Metabolic Syndrome
650865|NCT00105066|triglycerides
650866|NCT00105066|HDL
650867|NCT00105066|LDL
650868|NCT00105066|High Blood Pressure
650869|NCT00105066|High Cholesterol
650870|NCT00105066|High Blood Sugar
650871|NCT00105040|Partial onset seizures
650872|NCT00105040|epilepsy
650873|NCT00105040|levetiracetam
650874|NCT00105040|Keppra
650875|NCT00105040|cognition
650876|NCT00105040|behavior
650877|NCT00105040|pediatry
650878|NCT00105027|macular edema
650879|NCT00105027|central retinal vein occlusion (CRVO)
650880|NCT00105027|branch retinal vein occlusion (BRVO)
650881|NCT00104988|stage IV melanoma
650882|NCT00104975|accelerated phase chronic myelogenous leukemia
650883|NCT00104975|recurrent adult Burkitt lymphoma
650884|NCT00104975|stage IV adult Burkitt lymphoma
650885|NCT00104975|recurrent adult lymphoblastic lymphoma
650886|NCT00104975|stage IV adult lymphoblastic lymphoma
650887|NCT00104975|recurrent adult immunoblastic large cell lymphoma
650888|NCT00104975|stage IV adult immunoblastic large cell lymphoma
650889|NCT00104975|refractory anemia with excess blasts in transformation
650890|NCT00104975|refractory anemia with excess blasts
650891|NCT00104975|secondary myelodysplastic syndromes
650892|NCT00104975|chronic myelomonocytic leukemia
650893|NCT00104975|blastic phase chronic myelogenous leukemia
650894|NCT00104975|chronic eosinophilic leukemia
650895|NCT00104975|primary myelofibrosis
650896|NCT00104975|chronic neutrophilic leukemia
650897|NCT00104975|essential thrombocythemia
650898|NCT00104975|polycythemia vera
650899|NCT00104975|adult acute myeloid leukemia in remission
650900|NCT00104975|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
650901|NCT00104975|adult acute myeloid leukemia with inv(16)(p13;q22)
650902|NCT00104975|adult acute myeloid leukemia with t(15;17)(q22;q12)
650903|NCT00104975|adult acute myeloid leukemia with t(16;16)(p13;q22)
650904|NCT00104975|adult acute myeloid leukemia with t(8;21)(q22;q22)
650905|NCT00104975|recurrent adult acute myeloid leukemia
650906|NCT00104975|refractory chronic lymphocytic leukemia
650907|NCT00104975|stage III chronic lymphocytic leukemia
650908|NCT00104975|stage IV chronic lymphocytic leukemia
650909|NCT00104975|stage III adult Burkitt lymphoma
650910|NCT00104975|stage III adult immunoblastic large cell lymphoma
650911|NCT00104975|stage III adult lymphoblastic lymphoma
650912|NCT00104975|myelodysplastic/myeloproliferative neoplasm, unclassifiable
650913|NCT00104975|de novo myelodysplastic syndromes
650914|NCT00104975|previously treated myelodysplastic syndromes
650915|NCT00104975|atypical chronic myeloid leukemia, BCR-ABL1 negative
650916|NCT00104949|adult synovial sarcoma
650917|NCT00104949|recurrent adult soft tissue sarcoma
650918|NCT00104949|stage III adult soft tissue sarcoma
650919|NCT00104949|stage IV adult soft tissue sarcoma
650920|NCT00104936|adult grade I meningioma
650921|NCT00104923|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
650922|NCT00104923|adult acute myeloid leukemia with inv(16)(p13;q22)
650923|NCT00104923|adult acute myeloid leukemia with t(15;17)(q22;q12)
650924|NCT00104923|adult acute myeloid leukemia with t(16;16)(p13;q22)
650925|NCT00104923|adult acute myeloid leukemia with t(8;21)(q22;q22)
650926|NCT00104923|recurrent grade 1 follicular lymphoma
650927|NCT00104923|recurrent grade 2 follicular lymphoma
650928|NCT00104923|recurrent grade 3 follicular lymphoma
650929|NCT00104923|recurrent small lymphocytic lymphoma
650930|NCT00104923|recurrent mantle cell lymphoma
650931|NCT00104923|Waldenstrom macroglobulinemia
650932|NCT00104923|adult grade III lymphomatoid granulomatosis
650933|NCT00104923|recurrent adult grade III lymphomatoid granulomatosis
650934|NCT00104923|secondary acute myeloid leukemia
650935|NCT00104923|recurrent adult Burkitt lymphoma
650936|NCT00104923|recurrent adult immunoblastic large cell lymphoma
650937|NCT00104923|refractory chronic lymphocytic leukemia
650938|NCT00104923|recurrent adult lymphoblastic lymphoma
650939|NCT00104923|recurrent adult Hodgkin lymphoma
650940|NCT00104923|refractory multiple myeloma
650941|NCT00104923|recurrent adult acute lymphoblastic leukemia
650942|NCT00104923|relapsing chronic myelogenous leukemia
650943|NCT00104923|chronic eosinophilic leukemia
650944|NCT00104923|primary myelofibrosis
650945|NCT00104923|chronic neutrophilic leukemia
650946|NCT00104923|essential thrombocythemia
650947|NCT00104923|polycythemia vera
650948|NCT00104923|stage II multiple myeloma
650949|NCT00104923|stage III multiple myeloma
650950|NCT00104923|recurrent adult diffuse large cell lymphoma
650951|NCT00104923|recurrent adult diffuse mixed cell lymphoma
650952|NCT00104923|recurrent adult diffuse small cleaved cell lymphoma
650953|NCT00104923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
650954|NCT00104923|nodal marginal zone B-cell lymphoma
650955|NCT00104923|recurrent marginal zone lymphoma
650956|NCT00104923|splenic marginal zone lymphoma
650957|NCT00104923|recurrent adult acute myeloid leukemia
650958|NCT00104897|recurrent melanoma
650959|NCT00104897|stage IV melanoma
650960|NCT00104884|stage III melanoma
650961|NCT00104884|stage IV melanoma
650962|NCT00104884|Depsipeptide
650963|NCT00104871|National Thyroid Cancer Treatment Cooperative Study Group
650964|NCT00104871|NTCTCSG
650965|NCT00104871|bortezomib
650966|NCT00104871|velcade
650967|NCT00104871|metastatic differentiated thyroid carcinoma
650968|NCT00104871|Differentiated thyroid carcinoma
650969|NCT00104871|follicular epithelial thyroid cells
650970|NCT00104871|papillary
650971|NCT00104871|oxyphilic cell
650972|NCT00104871|Hurthle cell
650973|NCT00104871|insular cell
650974|NCT00104871|columnar cell
650975|NCT00104871|tall cell
650976|NCT00104845|stage II melanoma
650977|NCT00104845|stage III melanoma
650978|NCT00104845|stage IV melanoma
650979|NCT00104845|recurrent melanoma
650980|NCT00104819|recurrent grade 1 follicular lymphoma
650981|NCT00104819|recurrent grade 2 follicular lymphoma
650982|NCT00104819|recurrent grade 3 follicular lymphoma
650983|NCT00104806|de novo myelodysplastic syndromes
650984|NCT00104806|myelodysplastic/myeloproliferative neoplasm, unclassifiable
650985|NCT00104806|previously treated myelodysplastic syndromes
650986|NCT00104806|secondary myelodysplastic syndromes
650987|NCT00104806|refractory anemia with excess blasts in transformation
650988|NCT00104806|refractory anemia with excess blasts
650989|NCT00104806|refractory anemia
650990|NCT00104806|refractory anemia with ringed sideroblasts
650991|NCT00104806|refractory cytopenia with multilineage dysplasia
650992|NCT00104806|chronic myelomonocytic leukemia
650993|NCT00104806|childhood myelodysplastic syndromes
650994|NCT00104793|extensive stage small cell lung cancer
650995|NCT00104780|recurrent non-small cell lung cancer
650996|NCT00104780|stage IIIB non-small cell lung cancer
650997|NCT00104780|stage IV non-small cell lung cancer
650998|NCT00104767|stage IIIB non-small cell lung cancer
650999|NCT00104767|stage IV non-small cell lung cancer
651000|NCT00104767|recurrent non-small cell lung cancer
651001|NCT00104754|extensive stage small cell lung cancer
651002|NCT00104754|limited stage small cell lung cancer
651003|NCT00104754|recurrent small cell lung cancer
651004|NCT00104741|stage IIB prostate cancer
651005|NCT00104741|stage IIA prostate cancer
651006|NCT00104741|stage III prostate cancer
651007|NCT00104728|stage II non-small cell lung cancer
651008|NCT00104728|stage IIIA non-small cell lung cancer
651009|NCT00104728|stage IA non-small cell lung cancer
651010|NCT00104728|stage IB non-small cell lung cancer
651011|NCT00104715|adenocarcinoma of the prostate
651012|NCT00104715|recurrent prostate cancer
651013|NCT00104715|stage IV prostate cancer
651014|NCT00104702|stage I breast cancer
651015|NCT00104702|stage II breast cancer
651016|NCT00104689|stage IV colon cancer
651017|NCT00104689|stage IV rectal cancer
651018|NCT00104689|adenocarcinoma of the colon
651019|NCT00104689|adenocarcinoma of the rectum
651020|NCT00104676|stage II malignant testicular germ cell tumor
651021|NCT00104676|stage III malignant testicular germ cell tumor
651022|NCT00104676|testicular choriocarcinoma and embryonal carcinoma
651023|NCT00104676|testicular choriocarcinoma and teratoma
651024|NCT00104676|testicular choriocarcinoma and yolk sac tumor
651025|NCT00104676|testicular choriocarcinoma
651026|NCT00104676|testicular embryonal carcinoma and teratoma
651027|NCT00104676|testicular embryonal carcinoma and yolk sac tumor
651028|NCT00104676|testicular embryonal carcinoma
651029|NCT00104676|testicular yolk sac tumor and teratoma
651030|NCT00104676|testicular yolk sac tumor
651031|NCT00104676|stage II extragonadal non-seminomatous germ cell tumor
651032|NCT00104676|stage III extragonadal non-seminomatous germ cell tumor
651033|NCT00104676|testicular immature teratoma
651034|NCT00104676|testicular mature teratoma
651035|NCT00104676|adult teratoma
651036|NCT00104663|Creutzfeldt-Jakob disease
651037|NCT00104663|inherited
651038|NCT00104663|sporadic
651039|NCT00104663|acquired
651040|NCT00104663|new variant CJD
651041|NCT00104650|Bone Metastases
651042|NCT00104650|AMG 162
651043|NCT00104650|Bisphosphonates
651044|NCT00104650|Solid Tumor Carcinomas
651045|NCT00104650|Advanced
651046|NCT00104637|Chronic Obstructive Pulmonary Disease
651047|NCT00104637|Emphysema
651048|NCT00104637|Phosphodiesterase inhibitors
651049|NCT00104637|Sildenafil
651050|NCT00104637|Exercise testing
651051|NCT00104637|Quality of life
651052|NCT00104624|stage IV breast cancer
651053|NCT00104624|recurrent breast cancer
651054|NCT00104611|Major Depressive Disorder
651055|NCT00104611|Repetitive Transcranial Magnetic Stimulation
651056|NCT00104611|rTMS
651057|NCT00104611|Non-invasive Neuromodulation
651058|NCT00104611|Antidepressant
651059|NCT00104585|Parkinson's disease
651060|NCT00104585|PD
651061|NCT00104585|gene
651062|NCT00104585|environment
651063|NCT00104585|early-onset Parkinson's disease
651064|NCT00104572|Estrogen
651065|NCT00104572|Glucose Tolerance
651066|NCT00104572|Bone Density
651067|NCT00104572|Quality-of-Life
651068|NCT00104572|Sarcopenia
651069|NCT00104559|HIV
651070|NCT00104559|Informed Consent
651071|NCT00104546|Dysmenorrhea
651072|NCT00104546|Acupuncture
651073|NCT00104546|Vitamin K
651074|NCT00104546|Medicine, Chinese Traditional
651075|NCT00104546|Women
651076|NCT00104546|Menstruation
651077|NCT00104546|Pain, Menstrual
651078|NCT00104546|China
651079|NCT00104533|Static magnetic therapy
651080|NCT00104533|Pain
651081|NCT00104533|Analgesia
651082|NCT00104533|Opioids
651083|NCT00104520|Cystic Fibrosis
651084|NCT00104520|Pseudomonas aeruginosa
651085|NCT00104520|Pulmonary Cystic Fibrosis
651086|NCT00104507|Serotonin
651087|NCT00104507|5-HT2c
651088|NCT00104507|Satiety
651089|NCT00104507|Obesity
651090|NCT00104507|Appetite suppressant
651091|NCT00104507|Weight Loss
651092|NCT00104507|Overweight
651093|NCT00104494|Cystic Fibrosis
651094|NCT00104494|Zinc supplementation
651095|NCT00104494|Nutrition
651096|NCT00104494|Zinc absorption
651097|NCT00104494|Zinc excretion
651098|NCT00104494|Zinc status
651099|NCT00104481|cognitive behavior therapy
651100|NCT00104481|coping
651101|NCT00104481|smoking cessation
651102|NCT00104481|acceptance
651103|NCT00104481|expectancies
651104|NCT00104481|quit smoking
651105|NCT00104481|quitting smoking
651106|NCT00104468|Single-arm, open-label, multi-center, dose escalation, continuous infusion, multi-dose, acute myeloid leukemia
651107|NCT00104468|Acute myelogenous leukemia (AML) that has been refractory to prior therapy and/or is unlikely to benefit from known therapies
651108|NCT00104455|rFVIIa
651109|NCT00104455|Punch Biopsy
651110|NCT00104455|Dose Response
651111|NCT00104455|Healthy People Programs
651112|NCT00104442|Alzheimer's disease
651113|NCT00104442|memory loss
651114|NCT00104442|dementia
651115|NCT00104442|senility
651116|NCT00104442|forgetful
651117|NCT00104442|geriatric
651118|NCT00104442|behavior
651119|NCT00104442|mood swings
651120|NCT00104429|HIV infections
651121|NCT00104429|therapy naive
651122|NCT00104416|antiepileptic drugs
651123|NCT00104416|seizures
651124|NCT00104416|primary generalized tonic-clonic seizures
651125|NCT00104416|Epilepsy
651126|NCT00104416|lamotrigine
651127|NCT00104416|anticonvulsants
651128|NCT00104416|LAMICTAL
651129|NCT00104403|Vomiting
651130|NCT00104403|CINV
651131|NCT00104403|Emesis
651132|NCT00104403|Nausea
651133|NCT00104403|Chemotherapy-Induced Nausea and Vomiting
651134|NCT00104390|allergy
651135|NCT00104390|skin prick test
651136|NCT00104390|allergoid
651137|NCT00104390|allergenicity
651138|NCT00104390|specific immunotherapy
651139|NCT00104377|Allergy
651140|NCT00104377|Allergoid
651141|NCT00104377|Specific Immunotherapy
651142|NCT00104338|Investigational Therapies
651143|NCT00104338|Treatment Effectiveness
651144|NCT00104338|Treatment Efficacy
651145|NCT00104338|Immunosuppressant
651146|NCT00104338|BK Nephropathy
651147|NCT00104338|Polyomavirus, BK
651148|NCT00104338|Human Polyomavirus BK
651149|NCT00104338|Polyomavirus hominis 1
651150|NCT00104325|Cytapheresis
651151|NCT00104325|Blood Collection
651152|NCT00104325|Volunteer Donor
651153|NCT00104325|White Blood Cells
651154|NCT00104312|Knee Osteoarthritis
651155|NCT00104312|Muscle
651156|NCT00104312|Cytokine
651157|NCT00104312|Mobility
651158|NCT00104312|Function
651159|NCT00104299|ANCA
651160|NCT00104299|Vasculitis
651161|NCT00104299|Wegener's Granulomatosis
651162|NCT00104299|microscopic polyangiitis
651163|NCT00104299|ANCA-positive
651164|NCT00104299|ANCA-associated
651165|NCT00104299|ANCA-associated vasculitis
651166|NCT00104299|MPA
651167|NCT00104273|Dementia, Alzheimer's Disease
651168|NCT00104247|Phenylalanine Hydroxylase
651169|NCT00104195|Anxiety
651170|NCT00104195|Adolescence
651171|NCT00104195|Generalized Anxiety Disorder
651172|NCT00104169|Anemia
651173|NCT00104169|Frailty
651174|NCT00104169|Epoetin
651175|NCT00104169|Erythropoietin
651176|NCT00104169|EPO
651177|NCT00104156|Knee pain
651178|NCT00104156|Arthritis
651179|NCT00104156|Qigong
651180|NCT00104156|Qi
651181|NCT00104156|Meditation
651182|NCT00104156|Breathing Exercises
651183|NCT00104130|prostate
651184|NCT00104104|Z-MAX, multiple myeloma, zoledronic acid, bone metastases
651185|NCT00104091|Gross Total Resection
651186|NCT00104091|Convection Enhanced Delivery
651187|NCT00104091|Recurrent Glioblastoma Multiforme
651188|NCT00104065|oral mucositis
651189|NCT00104065|oncology - supportive care
651190|NCT00104065|mouth diseases
651191|NCT00104039|Amygdala
651192|NCT00104039|Orbital Frontal Cortex
651193|NCT00104039|Serotonin
651194|NCT00104039|Orbitofrontal Cortex
651195|NCT00104039|Attention Deficit Hyperactivity Disorder
651196|NCT00104039|ADHD
651197|NCT00104039|Anti-Social Behavior
651198|NCT00104039|Healthy Volunteer
651199|NCT00104039|HV
651200|NCT00104026|Periodontal Disease
651201|NCT00104026|Dilantin
651202|NCT00104026|Cyclosporin
651203|NCT00104026|Calcium-Channel Blockers
651204|NCT00104026|Genetics
651205|NCT00104026|Hereditary Gingival Fibromatosis
651206|NCT00104026|HGF
651207|NCT00104026|Gingival Overgrowth
651208|NCT00104026|Gum Overgrowth
651209|NCT00104000|Neuromuscular
651210|NCT00104000|Elevation
651211|NCT00104000|Current
651212|NCT00104000|Videofluoroscopy
651213|NCT00104000|Nasoendoscopy
651214|NCT00104000|Healthy Volunteer
651215|NCT00104000|HV
651216|NCT00103987|Panic Disorder
651217|NCT00103987|Norepinephrine
651218|NCT00103987|Yohimbine
651219|NCT00103987|Genes
651220|NCT00103987|Pathophysiology
651221|NCT00103987|Noradrenergic Mechanisms
651222|NCT00103987|PET Imaging
651223|NCT00103987|PD
651224|NCT00103987|Healthy Volunteer
651225|NCT00103987|HV
651226|NCT00103974|multiple sclerosis
651227|NCT00103974|relapsing-remitting
651228|NCT00103974|secondary progressive
651229|NCT00103961|Acute Infection
651230|NCT00103961|HIV
651231|NCT00103961|AIDS
651232|NCT00103961|Acute HIV
651233|NCT00103961|Early HIV
651234|NCT00103935|diabetes
651235|NCT00103935|exenatide
651236|NCT00103935|long acting release
651237|NCT00103935|Amylin
651238|NCT00103935|Lilly
651239|NCT00103922|smokers cough
651240|NCT00103896|High-risk youth
651241|NCT00103896|HIV infected youth
651242|NCT00103896|Community mobilization
651243|NCT00103896|HIV serosurveys
651244|NCT00103883|HIV
651245|NCT00103883|Detuned Assay
651246|NCT00103883|Enzyme Immunoassay (EIA)
651247|NCT00103883|HIV Incidence
651248|NCT00103883|Laboratory assay
651249|NCT00103883|Sensitive/Less sensitive Assay
651250|NCT00103883|Acute Infection
651251|NCT00103870|Music Therapy
651252|NCT00103870|Electric Stimulation
651253|NCT00103870|Electric Shock
651254|NCT00103870|Analgesics
651255|NCT00103870|Distraction
651256|NCT00103844|Chronic Phase Philadelphia chromosome Positive (Ph+) chronic myeloid leukemia
651257|NCT00103831|NSCLC - non-small cell lung cancer
651258|NCT00103805|language acquisition
651259|NCT00103805|plasticity
651260|NCT00103805|stroke recovery
651261|NCT00103805|associative learning
651262|NCT00103792|Induction therapy
651263|NCT00103792|ANCA-associated vasculitis
651264|NCT00103792|Wegener's granulomatosis
651265|NCT00103792|microscopic polyangiitis
651266|NCT00103792|mycophenolate mofetil
651267|NCT00103792|cyclophosphamide
651268|NCT00103779|Antigens, CD40
651269|NCT00103779|Antibody, Monoclonal
651270|NCT00103779|Lymphoma, Non-Hodgkin
651271|NCT00103779|Lymphoma, B-Cell
651272|NCT00103779|Hematologic Diseases
651273|NCT00103779|Immunoproliferative Disorders
651274|NCT00103779|Lymphatic Diseases
651275|NCT00103779|Lymphoproliferative Disorders
651276|NCT00103779|Lymphoma
651277|NCT00103766|Alteplase
651278|NCT00103766|Empyema
651279|NCT00103766|Complicated Parapneumonic Effusion
651280|NCT00103753|Randomized Controlled Trial
651281|NCT00103753|Deferiprone
651282|NCT00103753|Deferoxamine
651283|NCT00103753|Iron chelation
651284|NCT00103753|Beta Thalassemia Major
651285|NCT00103740|Zoledronic acid, risedronate, Paget's disease of bone
651286|NCT00103727|paranoid
651287|NCT00103727|catatonic
651288|NCT00103727|undifferentiated types
651289|NCT00103727|disorganized
651290|NCT00103714|lung disease
651291|NCT00103701|Chronic myelogenous leukemia (CML) chronic, accelerated, blast phase
651292|NCT00103701|Philadelphia chromosome positive acute (Ph+ALL)
651293|NCT00103675|Acupuncture
651294|NCT00103636|Phlebitis/etiology
651295|NCT00103636|Infusions
651296|NCT00103636|Intravenous/adverse effects
651297|NCT00103636|Randomised controlled trial
651298|NCT00103636|Phlebitis/prevention
651299|NCT00103636|Adult
651300|NCT00103636|Time factors
651301|NCT00103623|Advanced
651302|NCT00103623|Symptomatic
651303|NCT00103623|Prostate
651304|NCT00103623|Cancer
651305|NCT00103623|Advanced Symptomatic Prostate Cancer
651306|NCT00103610|Non-Hodgkin's lymphoma
651307|NCT00103610|Stem cell mobilization
651308|NCT00103597|Orthostatic hypotension
651309|NCT00103597|Parkinson's Disease
651310|NCT00103545|Ovarian Cancer
651311|NCT00103545|ACA 125
651312|NCT00103545|6 or 9 vaccinations
651313|NCT00103545|immune response
651314|NCT00103545|Fallopian tube cancer
651315|NCT00103545|Peritoneal cancer
651316|NCT00103532|motivational enhancement
651317|NCT00103532|health behaviors
651318|NCT00103532|risk behaviors
651319|NCT00103519|Heart Failure, DITPA
651320|NCT00103506|Multiple Myeloma
651321|NCT00103506|Doxil
651322|NCT00103506|Caelyx
651323|NCT00103506|Doxorubicin
651324|NCT00103506|Velcade
651325|NCT00103506|Bortezomib
651326|NCT00103454|allergic rhinitis
651327|NCT00103454|GW685698X
651328|NCT00103454|Perennial Allergic Rhinitis
651329|NCT00103428|chemotherapy
651330|NCT00103428|prostate cancer
651331|NCT00103428|cancer
651332|NCT00103428|metastatic
651333|NCT00103428|hormone refractory
651334|NCT00103428|chemotherapy naive
651335|NCT00103428|dose escalation
651336|NCT00103415|Depression
651337|NCT00103415|Exercise
651338|NCT00103415|Job
651339|NCT00103402|Prostatitis
651340|NCT00103402|Non-bacterial Prostatitis
651341|NCT00103402|Prostatodynia
651342|NCT00103402|Alfuzosin
651343|NCT00103402|Alpha-adrenergic blocker
651344|NCT00103389|recurrent non-small cell lung cancer
651345|NCT00103389|stage IIIB non-small cell lung cancer
651346|NCT00103389|stage IV non-small cell lung cancer
651347|NCT00103376|adenocarcinoma of the prostate
651348|NCT00103376|recurrent prostate cancer
651349|NCT00103363|non-small cell lung cancer
651350|NCT00103363|small cell lung cancer
651351|NCT00103350|myocardial infarction
651352|NCT00103350|infarct size
651353|NCT00103350|angioplasty
651354|NCT00103350|percutaneous coronary intervention
651355|NCT00103350|Acute Myocardial Infarction
651356|NCT00103298|recurrent colon cancer
651357|NCT00103298|stage IV colon cancer
651358|NCT00103298|recurrent rectal cancer
651359|NCT00103298|stage IV rectal cancer
651360|NCT00103298|liver metastases
651361|NCT00103246|skin cancer
651362|NCT00103246|squamous cell carcinoma of the skin
651363|NCT00103246|basal cell carcinoma of the skin
651364|NCT00103246|recurrent skin cancer
651365|NCT00103246|recurrent mycosis fungoides/Sezary syndrome
651366|NCT00103246|stage I mycosis fungoides/Sezary syndrome
651367|NCT00103246|stage II mycosis fungoides/Sezary syndrome
651368|NCT00103246|actinic keratosis
651369|NCT00103246|recurrent cutaneous T-cell non-Hodgkin lymphoma
651370|NCT00103246|stage I cutaneous T-cell non-Hodgkin lymphoma
651371|NCT00103246|stage II cutaneous T-cell non-Hodgkin lymphoma
651372|NCT00103233|stage IV breast cancer
651373|NCT00103233|recurrent breast cancer
651374|NCT00103207|bronchioalveolar carcinoma (BAC)
651375|NCT00103207|adenocarcinoma with BAC features
651376|NCT00103207|stage IIIB non-small cell lung cancer
651377|NCT00103207|stage IV non-small cell lung cancer
651378|NCT00103207|recurrent non-small cell lung cancer
651379|NCT00103207|cetuximab
651380|NCT00103181|stage II breast cancer
651381|NCT00103181|ductal breast carcinoma in situ
651382|NCT00103181|breast cancer in situ
651383|NCT00103181|stage IA breast cancer
651384|NCT00103181|stage IB breast cancer
651385|NCT00103168|gastrointestinal stromal tumor
651386|NCT00103155|stage I papillary thyroid cancer
651387|NCT00103142|liver metastases
651388|NCT00103142|adenocarcinoma of the colon
651389|NCT00103142|recurrent colon cancer
651390|NCT00103142|stage IV colon cancer
651391|NCT00103142|adenocarcinoma of the rectum
651392|NCT00103142|recurrent rectal cancer
651393|NCT00103142|stage IV rectal cancer
651394|NCT00103142|lung metastases
651395|NCT00103116|stage I non-small cell lung cancer
651396|NCT00103116|stage II non-small cell lung cancer
651397|NCT00103116|stage IIIA non-small cell lung cancer
651398|NCT00103116|stage IIIB non-small cell lung cancer
651399|NCT00103116|bronchoalveolar cell lung cancer
651400|NCT00103103|recurrent gastric cancer
651401|NCT00103103|stage IV gastric cancer
651402|NCT00103103|adenocarcinoma of the stomach
651403|NCT00103090|recurrent squamous cell carcinoma of the hypopharynx
651404|NCT00103090|stage III squamous cell carcinoma of the hypopharynx
651405|NCT00103090|stage IV squamous cell carcinoma of the hypopharynx
651406|NCT00103090|recurrent squamous cell carcinoma of the larynx
651407|NCT00103090|stage III squamous cell carcinoma of the larynx
651408|NCT00103090|stage IV squamous cell carcinoma of the larynx
651409|NCT00103090|recurrent squamous cell carcinoma of the lip and oral cavity
651410|NCT00103090|stage III squamous cell carcinoma of the lip and oral cavity
651411|NCT00103090|stage IV squamous cell carcinoma of the lip and oral cavity
651412|NCT00103090|recurrent squamous cell carcinoma of the nasopharynx
651413|NCT00103090|stage III squamous cell carcinoma of the nasopharynx
651414|NCT00103090|stage IV squamous cell carcinoma of the nasopharynx
651415|NCT00103090|recurrent squamous cell carcinoma of the oropharynx
651416|NCT00103090|stage III squamous cell carcinoma of the oropharynx
651417|NCT00103090|stage IV squamous cell carcinoma of the oropharynx
651418|NCT00103090|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
651419|NCT00103090|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
651420|NCT00103090|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
651421|NCT00103090|recurrent salivary gland cancer
651422|NCT00103090|salivary gland squamous cell carcinoma
651423|NCT00103090|stage III salivary gland cancer
651424|NCT00103090|stage IV salivary gland cancer
651425|NCT00103090|recurrent metastatic squamous neck cancer with occult primary
651426|NCT00103090|metastatic squamous neck cancer with occult primary squamous cell carcinoma
651427|NCT00103051|stage IIIA non-small cell lung cancer
651428|NCT00103025|Vasodilation
651429|NCT00103025|Hypotension
651430|NCT00103025|Hypertension
651431|NCT00103025|EDRF
651432|NCT00103025|Methemoglobinemia
651433|NCT00103025|Healthy Volunteer
651434|NCT00103025|HV
651435|NCT00103012|Antiretrovirals
651436|NCT00103012|Protease Inhibitors
651437|NCT00103012|Herbal Supplements
651438|NCT00103012|Drug Interactions
651439|NCT00103012|Metabolism
651440|NCT00103012|Healthy Volunteer
651441|NCT00103012|HV
651442|NCT00102999|Learning
651443|NCT00102999|PAS
651444|NCT00102999|Upper Limb
651445|NCT00102999|TMS
651446|NCT00102999|Somatosensory
651447|NCT00102999|Dystonia
651448|NCT00102999|Upper Limb Dystonia
651449|NCT00102999|Healthy Volunteer
651450|NCT00102999|HV
651451|NCT00102986|Kaletra
651452|NCT00102986|Treatment Experienced
651453|NCT00102973|Ovary
651454|NCT00102960|Infant
651455|NCT00102960|Perinatal
651456|NCT00102960|HIV
651457|NCT00102960|Disease Transmission, Vertical
651458|NCT00102960|Anti-Retroviral Agents
651459|NCT00102960|Treatment Interruption
651460|NCT00102960|Treatment Naive
651461|NCT00102960|Acute Infection
651462|NCT00102960|Mother-to-Child Transmission
651463|NCT00102947|renal impairment
651464|NCT00102947|daptomycin
651465|NCT00102947|Cubist
651466|NCT00102947|complicated skin and skin structure infections
651467|NCT00102934|HIV
651468|NCT00102934|Drug Resistance
651469|NCT00102934|Viral Fitness
651470|NCT00102934|HIV Specific Immunity
651471|NCT00102934|T Cell Activation
651472|NCT00102934|Drug Resistant Viremia
651473|NCT00102934|Treatment Experienced
651474|NCT00102921|Crohn Disease
651475|NCT00102921|oral medication
651476|NCT00102908|Bone Metabolism
651477|NCT00102908|Osteopenia
651478|NCT00102908|Osteoporosis
651479|NCT00102908|Treatment Experienced
651480|NCT00102882|genotype
651481|NCT00102882|Salmeterol
651482|NCT00102882|ADVAIR
651483|NCT00102869|language acquisition
651484|NCT00102869|plasticity
651485|NCT00102869|stroke recovery
651486|NCT00102869|aphasia treatment
651487|NCT00102869|naming
651488|NCT00102869|levodopa
651489|NCT00102869|stroke
651490|NCT00102856|language acquisition
651491|NCT00102856|plasticity
651492|NCT00102856|stroke recovery
651493|NCT00102856|associative learning
651494|NCT00102843|folic acid
651495|NCT00102843|betaine
651496|NCT00102843|homocysteine
651497|NCT00102843|cardiovascular disease prevention
651498|NCT00102843|human
651499|NCT00102843|Cardiovascular health
651500|NCT00102830|Solid Tumor
651501|NCT00102830|Metastatic Cancer
651502|NCT00102830|Advanced Solid Tumors
651503|NCT00102817|Growth Hormone Disorder
651504|NCT00102791|Sickle Cell Anemia
651505|NCT00102778|HIV infected
651506|NCT00102778|therapy-naive subjects
651507|NCT00102765|asthma exacerbation
651508|NCT00102765|asthma
651509|NCT00102752|Pancreas
651510|NCT00102752|Cancer
651511|NCT00102752|Metastatic
651512|NCT00102752|Glufosfamide
651513|NCT00102752|Advanced
651514|NCT00102752|Solid
651515|NCT00102752|Tumor
651516|NCT00102752|Advanced Solid Tumors
651517|NCT00102752|Pancreatic Adenocarcinoma
651518|NCT00102739|thrombopoietin
651519|NCT00102739|immune thrombocytopenic purpura
651520|NCT00102739|platelets
651521|NCT00102739|chronic thrombocytopenia
651522|NCT00102726|chemotherapy
651523|NCT00102726|thrombopoietin
651524|NCT00102726|platelets
651525|NCT00102726|chemotherapy induced
651526|NCT00102713|Partial Seizures
651527|NCT00102700|cancer
651528|NCT00102700|solid tumor
651529|NCT00102700|advanced solid tumor
651530|NCT00102700|pancreas
651531|NCT00102700|pancreatic cancer
651532|NCT00102700|cancer of the pancreas
651533|NCT00102674|cangrelor
651534|NCT00102674|clopidogrel
651535|NCT00102648|Glioblastoma Multiforme
651536|NCT00102648|Gliosarcoma
651537|NCT00102648|Brain Tumors
651538|NCT00102648|Sarasar
651539|NCT00102648|Temodar
651540|NCT00102648|Temozolomide
651541|NCT00102648|Lonafarnib
651542|NCT00102648|SCH 66336
651543|NCT00102635|apoptotic activity
651544|NCT00102635|4-HPR
651545|NCT00102635|FTI
651546|NCT00102635|Fenretinide
651547|NCT00102635|SCH66336
651548|NCT00102635|Farnesyl Transferase Inhibitor
651549|NCT00102635|HNC
651550|NCT00102622|Ovary
651551|NCT00102622|ovarian cancer
651552|NCT00102622|biologic therapy
651553|NCT00102622|platinum-resistant
651554|NCT00102622|platinum-refractory ovarian cancer
651555|NCT00102622|platinum-resistant ovarian cancer
651556|NCT00102622|paclitaxel
651557|NCT00102622|tgDCC-E1A
651558|NCT00102622|E1A
651559|NCT00102622|Taxol
651560|NCT00102609|Doxorubicin
651561|NCT00102609|Adriamycin
651562|NCT00102609|Trabectedin
651563|NCT00102609|Yondelis
651564|NCT00102609|Ecteinascidin 743
651565|NCT00102609|Filgrastim, Antineoplastic
651566|NCT00102609|Antineoplastic Agents
651567|NCT00102609|Pharmacologic Actions
651568|NCT00102609|Alkylating Agents
651569|NCT00102596|Ethanol
651570|NCT00102596|Alcohol Responsive
651571|NCT00102596|Movement Disorder
651572|NCT00102596|Gas Chromatography
651573|NCT00102596|Bioavailability
651574|NCT00102596|Pharmacokinetics
651575|NCT00102596|Essential Tremor
651576|NCT00102583|Dry Eye
651577|NCT00102583|Lacrimal Gland
651578|NCT00102583|Tear Deficiency
651579|NCT00102583|Keratitis Sicca
651580|NCT00102583|GVHD
651581|NCT00102583|Ocular GVHD
651582|NCT00102583|Ocular Graft Vs Host Disease
651583|NCT00102570|Pediatric
651584|NCT00102570|Atopic
651585|NCT00102570|Asthma
651586|NCT00102570|Rhinitis
651587|NCT00102570|Outpatient
651588|NCT00102570|Allergy
651589|NCT00102570|Pediatric Allergy
651590|NCT00102570|Food Allergy
651591|NCT00102570|Stinging Insect Allergy
651592|NCT00102570|Atopic Dermatitis
651593|NCT00102570|Insect Sting
651594|NCT00102557|Vesiculobullous
651595|NCT00102557|Mucosal Lesions
651596|NCT00102557|Oral Health
651597|NCT00102557|Dermatology
651598|NCT00102557|Plaquenil
651599|NCT00102557|Oral Lichen Planus
651600|NCT00102557|Mouth Lesions
651601|NCT00102557|Oral Lesions
651602|NCT00102544|CT-Guided
651603|NCT00102544|Electromagnetic Tracking
651604|NCT00102544|Ultrasound-Guided Biopsy
651605|NCT00102544|Ablation
651606|NCT00102544|Surgical Navigation
651607|NCT00102531|Osteosarcoma
651608|NCT00102531|relapsed
651609|NCT00102531|progressive
651610|NCT00102531|metastatic
651611|NCT00102531|lung
651612|NCT00102518|Open Label
651613|NCT00102518|Aripiprazole
651614|NCT00102518|Bipolar I Disorder, Manic or Mixed Episode
651615|NCT00102505|Non-Small Cell Lung Cancer
651616|NCT00102505|Lung Cancer
651617|NCT00102505|Metastatic lung cancer
651618|NCT00102505|Inoperable lung cancer
651619|NCT00102505|Advanced lung cancer
651620|NCT00102505|Large-cell lung cancer
651621|NCT00102505|Adenocarcinoma, lung
651622|NCT00102505|Squamous cell carcinoma, lung
651623|NCT00102505|Squamous cell lung cancer
651624|NCT00102505|Large cell carcinoma, lung
651625|NCT00102505|Bronchogenic
651626|NCT00102492|Major Depressive Disorder
651627|NCT00102492|Major Depression
651628|NCT00102492|Mood Disorders
651629|NCT00102492|Major Depressive Episode
651630|NCT00101816|Myeloid blast phase Chronic Myeloid Leukemia (CML)
651631|NCT00101803|type 2 diabetes
651632|NCT00101803|vildagliptin
651633|NCT00101790|low back pain
651634|NCT00101790|pamidronate
651635|NCT00101777|Anxiety
651636|NCT00101777|Ventilation
651637|NCT00101777|Panic Disorder
651638|NCT00101777|Children
651639|NCT00101777|Healthy Volunteer
651640|NCT00101777|HV
651641|NCT00101777|Normal Control
651642|NCT00101764|AMD
651643|NCT00101764|CRVO
651644|NCT00101764|BRVO
651645|NCT00101764|Uveitis
651646|NCT00101764|Choroidal Neovascularization
651772|NCT00102245|Hemoglobin
651647|NCT00101764|Age-Related Macular Degeneration (AMD)
651648|NCT00101764|Macular Edema
651649|NCT00101764|Central Retinal Vein Occlusion
651650|NCT00101764|Branch Retinal Vein Occlusion
651651|NCT00101764|Inflammation
651652|NCT00101764|Age Related Macular Degeneration
651653|NCT00101764|Retinal Disorder
651654|NCT00101738|MPA
651655|NCT00101738|Kidney Transplantation
651656|NCT00101738|Acute rejection
651657|NCT00101738|Kidney function
651658|NCT00101725|Diarrhea
651659|NCT00101725|IBS
651660|NCT00101725|Irritable Bowel Syndrome
651661|NCT00101725|Abdominal pain
651662|NCT00101712|type 2 diabetes
651663|NCT00101712|vildagliptin
651664|NCT00101699|Women
651665|NCT00101699|Soy Foods
651666|NCT00101699|Middle Aged
651667|NCT00101673|type 2 diabetes
651668|NCT00101673|vildagliptin
651669|NCT00101660|Chronic phase Philadelphia chromosome chronic myeloid leukemia (Ph+CML)
651670|NCT00101647|Chronic myelogenous leukemia (CML): Accelerated phase
651671|NCT00101634|Schizophrenia
651672|NCT00101634|Paliperidone palmitate
651673|NCT00101634|R092670
651674|NCT00101634|antipsychotic
651675|NCT00101621|cancer
651676|NCT00101621|pain
651677|NCT00101621|Cancers, Pain
651678|NCT00101608|urothelium
651679|NCT00101595|Lymphoid blast phase chronic myeloid leukemia
651680|NCT00101595|Philadelphia chromosome positive acute lymphoblastic leukemia
651681|NCT00101582|SCCHN
651682|NCT00101582|Palifermin
651683|NCT00101582|Mucositis
651684|NCT00101582|Oral Cavity
651685|NCT00101582|Oropharynx
651686|NCT00101582|Nasopharynx
651687|NCT00101582|Hypopharynx
651688|NCT00101582|Larynx
651689|NCT00101582|Mouth Pain
651690|NCT00101582|Mouth Sores
651691|NCT00101582|Radiation Therapy
651692|NCT00101582|Radiotherapy
651693|NCT00101582|Radiochemotherapy
651694|NCT00101582|Concurrent Chemotherapy
651695|NCT00101582|Xerostomia
651696|NCT00101582|Stomatitis
651697|NCT00101582|Mucosa
651698|NCT00101582|KGF
651699|NCT00101582|rHuKGF
651700|NCT00101582|Keratinocyte Growth Factor
651701|NCT00101582|HNC
651702|NCT00101582|Head and Neck Cancer
651703|NCT00101582|Oral Mucositis
651704|NCT00101543|Gait Training
651705|NCT00101543|Motor learning
651706|NCT00101543|Electrical stimulation
651707|NCT00101543|Body Weight supported Treadmill Training
651708|NCT00101543|Cerebrovascular Accident
651709|NCT00102479|Pharmacokinetics,
651710|NCT00102479|Aripiprazole
651711|NCT00102479|acute mania in pediatric populations
651712|NCT00102466|type 2 diabetes
651713|NCT00102466|vildagliptin
651714|NCT00102453|Duchenne
651715|NCT00102453|Genetics
651716|NCT00102440|uric Acid
651717|NCT00102440|xanthine oxidase
651718|NCT00102440|tophi
651719|NCT00102440|Drug Therapy
651720|NCT00102427|Anxiety
651721|NCT00102427|Panic
651722|NCT00102427|Generalized Anxiety Disorder
651723|NCT00102414|Ovarian cancer
651724|NCT00102414|Recurrence or progression
651725|NCT00102414|Gemcitabine plus Carboplatin vs Carboplatin
651726|NCT00102401|Chronic obstructive pulmonary disease
651727|NCT00102401|Pulmonary Disease, chronic obstructive
651728|NCT00102401|Lung disease, obstructive
651729|NCT00102401|Self-care
651730|NCT00102401|Self-management
651731|NCT00102401|Patient education
651732|NCT00102388|type 2 diabetes
651733|NCT00102388|vildagliptin
651734|NCT00102375|Ovarian Cancer
651735|NCT00102375|first-line
651736|NCT00102375|Topotecan
651737|NCT00102362|behavioral intervention
651738|NCT00102349|behavioral intervention
651739|NCT00102336|immune (idiopathic) thrombocytopenic purpura
651740|NCT00102336|pre-splenectomy
651741|NCT00102336|ITP
651742|NCT00102336|Thrombopenia
651743|NCT00102323|immune (idiopathic) thrombocytopenic purpura
651744|NCT00102323|post-splenectomy
651745|NCT00102323|ITP
651746|NCT00102323|Thrombopenia
651747|NCT00102310|Nausea
651748|NCT00102310|Indigestion
651749|NCT00102310|Bloating
651750|NCT00102310|Functional Dyspepsia
651751|NCT00102310|Fullness after Meals
651752|NCT00102297|Incipient Nephropathy
651753|NCT00102297|Type 1 or Type 2 Diabetes
651754|NCT00102284|language acquisition
651755|NCT00102284|plasticity
651756|NCT00102284|stroke recovery
651757|NCT00102284|associative learning
651758|NCT00102271|Sodium Nitrite
651759|NCT00102271|Oxypurinol
651760|NCT00102271|Ascorbic Acid
651761|NCT00102271|Hypoxic Gas
651762|NCT00102271|Forearm Blood Flow
651763|NCT00102271|Healthy Volunteer
651764|NCT00102271|HV
651765|NCT00102258|Short Stature
651766|NCT00102258|Constitutional Delay of Growth and Development
651767|NCT00102258|Body Composition
651768|NCT00102258|Energy Expenditure
651769|NCT00102258|Dietary Supplements
651770|NCT00102258|Constitutional Delay of Growth
651771|NCT00102258|CDGM
651773|NCT00102245|Hemoglobinapathies
651774|NCT00102245|Human Genome
651775|NCT00102245|Recombinant DNA Technology
651776|NCT00102245|Sequencing
651777|NCT00102245|Erythrocyte
651778|NCT00102232|phosphatidylcholine
651779|NCT00102232|choline
651780|NCT00102232|homocysteine
651781|NCT00102232|cardiovascular disease prevention
651782|NCT00102232|human
651783|NCT00102232|cardiovascular health
651784|NCT00102206|Treatment Experienced
651785|NCT00102206|Child
651786|NCT00102193|Ulcerative Colitis, Apheresis
651787|NCT00102141|Postmenopausal
651788|NCT00102141|vasomotor symptoms
651789|NCT00102141|essential hypertension
651790|NCT00102115|Macular disease
651791|NCT00102115|Wet AMD
651792|NCT00102115|AMD
651793|NCT00102115|Age-Related Macular Disease
651794|NCT00102115|PDT
651795|NCT00102115|Photodynamic Therapy
651796|NCT00102102|Substance P
651797|NCT00102102|Neurokinin
651798|NCT00102102|Tachykinin
651799|NCT00102102|Anxiety
651800|NCT00102102|Neuroreceptor Imaging
651801|NCT00102102|Post-Traumatic Stress Disorder
651802|NCT00102102|PTSD
651803|NCT00102102|Healthy Volunteer
651804|NCT00102102|HV
651805|NCT00102089|HIV-Negative
651806|NCT00102089|Healthy
651807|NCT00102089|Immunity
651808|NCT00102089|Preventive
651809|NCT00102089|Virus
651810|NCT00102089|Healthy Volunteer
651811|NCT00102089|HV
651812|NCT00102076|Minimal
651813|NCT00102076|Risk
651814|NCT00102076|Regulations
651815|NCT00102076|Parents
651816|NCT00102076|IRB
651817|NCT00102076|Surgery
651818|NCT00102076|Assent Requirement
651819|NCT00102063|Schizophrenia
651820|NCT00102063|Aripiprazole
651821|NCT00102050|NM-702 tablets
651822|NCT00102050|intermittent claudication
651823|NCT00102050|peripheral
651824|NCT00102050|arterial
651825|NCT00102050|vascular
651826|NCT00102050|peripheral arterial disease
651827|NCT00102024|Metastatic Colorectal Adenocarcinoma
651828|NCT00102024|Anti TAG-72
651829|NCT00102024|Monoclonal Antibody
651830|NCT00102011|colon cancer
651831|NCT00102011|rectal cancer
651832|NCT00101998|OBD (Induced Bowel Dysfunction)
651833|NCT00101998|cancer pain
651834|NCT00101998|pain medication
651835|NCT00101998|constipation
651836|NCT00101998|bowel
651837|NCT00101998|bowel dysfunction
651838|NCT00101985|Quality of Life
651839|NCT00101985|Irritable bowel syndrome
651840|NCT00101985|IBS
651841|NCT00101985|SB223412
651842|NCT00101985|Qol
651843|NCT00101972|adenocarcinoma of the bladder
651844|NCT00101972|adenocarcinoma of the colon
651845|NCT00101972|adenocarcinoma of the esophagus
651846|NCT00101972|adenocarcinoma of the extrahepatic bile duct
651847|NCT00101972|adenocarcinoma of the gallbladder
651848|NCT00101972|adenocarcinoma of the lung
651849|NCT00101972|adenocarcinoma of the pancreas
651850|NCT00101972|adenocarcinoma of the prostate
651851|NCT00101972|adenocarcinoma of the rectum
651852|NCT00101972|adenocarcinoma of the stomach
651853|NCT00101972|adenocarcinoma with squamous metaplasia of the gallbladder
651854|NCT00101972|cervical adenocarcinoma
651855|NCT00101972|endometrial adenocarcinoma
651856|NCT00101972|ovarian endometrioid adenocarcinoma
651857|NCT00101972|ovarian undifferentiated adenocarcinoma
651858|NCT00101972|salivary gland adenocarcinoma
651859|NCT00101972|small intestine adenocarcinoma
651860|NCT00101972|vaginal adenocarcinoma
651861|NCT00101972|vaginal clear cell adenocarcinoma
651862|NCT00101972|ovarian clear cell cystadenocarcinoma
651863|NCT00101972|ovarian mucinous cystadenocarcinoma
651864|NCT00101972|ovarian serous cystadenocarcinoma
651865|NCT00101972|stage IV bladder cancer
651866|NCT00101972|stage IV breast cancer
651867|NCT00101972|stage IV colon cancer
651868|NCT00101972|stage IV endometrial carcinoma
651869|NCT00101972|stage IV esophageal cancer
651870|NCT00101972|stage IV gastric cancer
651871|NCT00101972|stage IV non-small cell lung cancer
651872|NCT00101972|stage IV ovarian epithelial cancer
651873|NCT00101972|stage IV prostate cancer
651874|NCT00101972|stage IV rectal cancer
651875|NCT00101972|stage IV renal cell cancer
651876|NCT00101972|stage IV salivary gland cancer
651877|NCT00101972|stage IVA cervical cancer
651878|NCT00101972|stage IVA vaginal cancer
651879|NCT00101972|stage IVB cervical cancer
651880|NCT00101972|stage IVB vaginal cancer
651881|NCT00101972|recurrent bladder cancer
651882|NCT00101972|recurrent breast cancer
651883|NCT00101972|recurrent cervical cancer
651884|NCT00101972|recurrent colon cancer
651885|NCT00101972|recurrent endometrial carcinoma
651886|NCT00101972|recurrent esophageal cancer
651887|NCT00101972|recurrent extrahepatic bile duct cancer
651888|NCT00101972|recurrent gallbladder cancer
651889|NCT00101972|recurrent gastric cancer
651890|NCT00101972|recurrent non-small cell lung cancer
651891|NCT00101972|recurrent ovarian epithelial cancer
651892|NCT00101972|recurrent pancreatic cancer
651893|NCT00101972|recurrent prostate cancer
651894|NCT00101972|recurrent rectal cancer
651895|NCT00101972|recurrent renal cell cancer
651896|NCT00101972|recurrent salivary gland cancer
651897|NCT00101972|recurrent small intestine cancer
651898|NCT00101972|recurrent vaginal cancer
651899|NCT00101972|unresectable extrahepatic bile duct cancer
651900|NCT00101972|unresectable gallbladder cancer
651901|NCT00101972|stage IV pancreatic cancer
651902|NCT00101946|CD
651903|NCT00101946|Crohn's Disease
651904|NCT00101933|Direct brain stimulation, SANTE
651905|NCT00101907|Advanced Cancer
651906|NCT00101907|AMG 706
651907|NCT00101907|Panitumumab
651908|NCT00101907|Gemcitabine-Cisplatin
651909|NCT00101894|AMG 706
651910|NCT00101894|Panitumumab
651911|NCT00101881|Cardiac arrest
651912|NCT00101881|Defibrillation
651913|NCT00101881|Biphasic defibrillation
651914|NCT00101881|Monophasic defibrillation
651915|NCT00101881|Ventricular fibrillation
651916|NCT00101868|Aged
651917|NCT00101868|Hospitalists
651918|NCT00101868|Outcome and process assessment (health care)
651919|NCT00101868|Human
651920|NCT00101868|Hospitals, teaching
651921|NCT00101868|Physicians, family
651922|NCT00101868|Medical records
651923|NCT00101868|Quality assurance, health care
651924|NCT00101868|Medical errors
651925|NCT00101855|prevention
651926|NCT00101855|internet
651927|NCT00101855|quality of care
651928|NCT00101829|Autoimmune Diseases
651929|NCT00101465|Heart Failure
651930|NCT00101452|Depression
651931|NCT00101452|Antidepressive Agents
651932|NCT00101452|Complementary Therapies
651933|NCT00101439|Primary Hypercholesterolemia
651934|NCT00101426|Diabetic sensorimotor polyneuropathy
651935|NCT00101426|Diabetic Neuropathy
651936|NCT00101413|NSCLC
651937|NCT00101400|Cancer
651938|NCT00101387|Aged
651939|NCT00101387|Acupuncture
651940|NCT00101374|Immunomodulatory Drug
651941|NCT00101374|Antiviral
651942|NCT00101374|Ki67+
651943|NCT00101374|Immune Activation
651944|NCT00101374|T Cell Proliferation
651945|NCT00101374|HIV
651946|NCT00101374|Activated CD4+T-cell
651947|NCT00101374|Proliferation
651948|NCT00101361|dermatologic
651949|NCT00101361|skin
651950|NCT00101361|clinical trial
651951|NCT00101361|androgen/anabolic
651952|NCT00101335|hypopharyngeal cancer
651953|NCT00101335|lip and oral cavity cancer
651954|NCT00101335|nasopharyngeal cancer
651955|NCT00101335|oropharyngeal cancer
651956|NCT00101335|tongue cancer
651957|NCT00101335|oral leukoplakia
651958|NCT00101309|recurrent neuroblastoma
651959|NCT00101309|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
651960|NCT00101283|advanced malignant mesothelioma
651961|NCT00101283|recurrent malignant mesothelioma
651962|NCT00101257|recurrent ovarian epithelial cancer
651963|NCT00101257|stage III ovarian epithelial cancer
651964|NCT00101257|stage IV ovarian epithelial cancer
651965|NCT00101257|peritoneal cavity cancer
651966|NCT00101192|recurrent cervical cancer
651967|NCT00101192|cervical adenocarcinoma
651968|NCT00101192|cervical adenosquamous cell carcinoma
651969|NCT00101192|cervical small cell carcinoma
651970|NCT00101192|cervical squamous cell carcinoma
651971|NCT00101192|stage III cervical cancer
651972|NCT00101192|stage IVA cervical cancer
651973|NCT00101192|stage IVB cervical cancer
651974|NCT00101166|recurrent melanoma
651975|NCT00101166|stage III melanoma
651976|NCT00101166|stage IV melanoma
651977|NCT00101153|adult acute basophilic leukemia
651978|NCT00101153|adult acute eosinophilic leukemia
651979|NCT00101153|adult acute megakaryoblastic leukemia (M7)
651980|NCT00101153|adult acute minimally differentiated myeloid leukemia (M0)
651981|NCT00101153|adult acute monoblastic leukemia (M5a)
651982|NCT00101153|adult acute monocytic leukemia (M5b)
651983|NCT00101153|adult acute myeloblastic leukemia with maturation (M2)
651984|NCT00101153|adult acute myeloblastic leukemia without maturation (M1)
651985|NCT00101153|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
651986|NCT00101153|adult acute myeloid leukemia with inv(16)(p13;q22)
651987|NCT00101153|adult acute myeloid leukemia with t(16;16)(p13;q22)
651988|NCT00101153|adult acute myeloid leukemia with t(8;21)(q22;q22)
651989|NCT00101153|adult acute myelomonocytic leukemia (M4)
651990|NCT00101153|adult erythroleukemia (M6a)
651991|NCT00101153|adult pure erythroid leukemia (M6b)
651992|NCT00101153|untreated adult acute myeloid leukemia
651993|NCT00101140|adult erythroleukemia (M6a)
651994|NCT00101140|adult acute megakaryoblastic leukemia (M7)
651995|NCT00101140|adult acute minimally differentiated myeloid leukemia (M0)
651996|NCT00101140|adult acute monocytic leukemia (M5b)
651997|NCT00101140|adult acute myeloblastic leukemia with maturation (M2)
651998|NCT00101140|adult acute myeloblastic leukemia without maturation (M1)
651999|NCT00101140|adult acute myeloid leukemia in remission
652000|NCT00101140|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
652240|NCT00099528|Neuropathic pain
652001|NCT00101140|adult acute myeloid leukemia with inv(16)(p13;q22)
652002|NCT00101140|adult acute myeloid leukemia with t(16;16)(p13;q22)
652003|NCT00101140|adult acute myeloid leukemia with t(8;21)(q22;q22)
652004|NCT00101140|adult acute myelomonocytic leukemia (M4)
652005|NCT00101127|recurrent uterine sarcoma
652006|NCT00101127|stage III uterine sarcoma
652007|NCT00101127|stage IV uterine sarcoma
652008|NCT00101127|uterine leiomyosarcoma
652009|NCT00101101|recurrent mantle cell lymphoma
652010|NCT00101101|contiguous stage II mantle cell lymphoma
652011|NCT00101101|noncontiguous stage II mantle cell lymphoma
652012|NCT00101101|stage III mantle cell lymphoma
652013|NCT00101101|stage IV mantle cell lymphoma
652014|NCT00101075|high-grade salivary gland mucoepidermoid carcinoma
652015|NCT00101075|low-grade salivary gland mucoepidermoid carcinoma
652016|NCT00101075|salivary gland acinic cell tumor
652017|NCT00101075|salivary gland adenocarcinoma
652018|NCT00101075|salivary gland adenoid cystic carcinoma
652019|NCT00101075|salivary gland malignant mixed cell type tumor
652020|NCT00101075|salivary gland poorly differentiated carcinoma
652021|NCT00101075|salivary gland squamous cell carcinoma
652022|NCT00101075|recurrent salivary gland cancer
652023|NCT00101075|stage III salivary gland cancer
652024|NCT00101075|stage IV salivary gland cancer
652025|NCT00101062|stage IIIA breast cancer
652026|NCT00101062|stage IIIB breast cancer
652027|NCT00101062|stage IIIC breast cancer
652028|NCT00101062|stage IV breast cancer
652029|NCT00101062|recurrent breast cancer
652030|NCT00101010|contiguous stage II adult diffuse large cell lymphoma
652031|NCT00101010|noncontiguous stage II adult diffuse large cell lymphoma
652032|NCT00101010|stage III adult diffuse large cell lymphoma
652033|NCT00101010|stage IV adult diffuse large cell lymphoma
652034|NCT00100997|chronic myelogenous leukemia, BCR-ABL1 positive
652035|NCT00100997|chronic phase chronic myelogenous leukemia
652036|NCT00100997|relapsing chronic myelogenous leukemia
652037|NCT00100971|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
652038|NCT00100971|adult acute myeloid leukemia with inv(16)(p13;q22)
652039|NCT00100971|adult acute myeloid leukemia with t(15;17)(q22;q12)
652040|NCT00100971|adult acute myeloid leukemia with t(16;16)(p13;q22)
652041|NCT00100971|adult acute myeloid leukemia with t(8;21)(q22;q22)
652042|NCT00100971|secondary acute myeloid leukemia
652043|NCT00100958|unspecified adult solid tumor, protocol specific
652044|NCT00100945|adenocarcinoma of the esophagus
652045|NCT00100945|stage II esophageal cancer
652046|NCT00100919|Kinesithesia
652047|NCT00100919|Sensorimotor Function
652048|NCT00100919|Somatosensory
652049|NCT00100919|Muscle Spindles
652050|NCT00100919|Sensory Feedback
652051|NCT00100919|Healthy Volunteer
652052|NCT00100919|HV
652053|NCT00100906|stage IV renal cell cancer
652054|NCT00100906|recurrent renal cell cancer
652055|NCT00100906|clear cell renal cell carcinoma
652056|NCT00100893|breast cancer
652057|NCT00100867|Perinatal Transmission
652058|NCT00100867|Mother-to-Child Transmission
652059|NCT00100854|stage IIIB non-small cell lung cancer
652060|NCT00100854|stage IV non-small cell lung cancer
652061|NCT00100854|recurrent non-small cell lung cancer
652062|NCT00100828|thyroid gland medullary carcinoma
652063|NCT00100828|recurrent thyroid cancer
652064|NCT00100815|adenocarcinoma of the pancreas
652065|NCT00100815|recurrent pancreatic cancer
652066|NCT00100815|stage IV pancreatic cancer
652067|NCT00100802|childhood high-grade cerebral astrocytoma
652068|NCT00100802|childhood spinal cord neoplasm
652069|NCT00100789|Recurrent
652070|NCT00100789|stage IV
652071|NCT00100789|squamous cell carcinoma
652072|NCT00100789|hypopharynx
652073|NCT00100789|larynx
652074|NCT00100789|lip
652075|NCT00100789|oral cavity
652076|NCT00100789|nasopharynx
652077|NCT00100789|oropharynx
652078|NCT00100789|paranasal
652079|NCT00100789|nasal cavity
652080|NCT00100789|metastatic
652081|NCT00100789|neck cancer
652082|NCT00100737|non-hodgkins lymphoma
652083|NCT00100737|interleukin-2
652084|NCT00100737|rituximab
652085|NCT00100737|CD20+ follicular B-cell non-hodgkins lymphoma (grade I, II,III)
652086|NCT00100724|Anthrax
652087|NCT00100724|rPA102
652088|NCT00100724|vaccine
652089|NCT00100711|Chronic Lymphocytic Leukemia
652090|NCT00100711|Small Lymphocytic Lymphoma
652091|NCT00100711|Leukemia
652092|NCT00100711|Lymphoma
652093|NCT00100711|Motexafin Gadolinium
652094|NCT00100711|Relapsed Chronic Lymphocytic Leukemia
652095|NCT00100711|Relapsed Chronic Lymphocycic Lymphoma
652096|NCT00100711|Refractory Chronic Lymphocytic Leukemia
652097|NCT00100711|Refractory Small Lymphocytic Lymphoma
652098|NCT00100698|HIV
652099|NCT00100698|lipodystrophy
652100|NCT00100698|growth hormone
652101|NCT00100698|visceral fat
652102|NCT00100698|IGF-I
652103|NCT00100698|Treatment Experienced
652104|NCT00100685|Kidney
652105|NCT00100685|renal
652106|NCT00100685|cancer
652107|NCT00100685|carcinoma
652108|NCT00100685|cell
652109|NCT00100685|metastatic
652110|NCT00100685|metastatic renal cell carcinoma
652111|NCT00100685|RCC
652112|NCT00100672|LErafAON-ETU
652113|NCT00100672|Signal transduction
652114|NCT00100672|Neoplasm
652115|NCT00100672|Cancer
652116|NCT00100672|NeoPharm
652117|NCT00100672|Liposomes
652118|NCT00100672|Antisense
652119|NCT00100672|Anti-cancer
652120|NCT00100672|Advanced neoplasm
652121|NCT00100672|Advanced cancer
652122|NCT00100672|Chemotherapy
652123|NCT00100672|Refractory cancer
652124|NCT00100672|Metastatic cancer
652125|NCT00100659|pediatric
652126|NCT00100659|hepatitis
652127|NCT00100659|children
652128|NCT00100659|HCV
652129|NCT00100659|PEG
652130|NCT00100659|PEG-2a
652131|NCT00100659|peginterferon alfa-2a
652132|NCT00100659|Pegylated Interferon
652133|NCT00100659|RV
652134|NCT00100659|ribavirin
652135|NCT00100659|Pegasys
652136|NCT00100659|CHC
652137|NCT00100659|chronic hepatitis C
652138|NCT00100659|chronic hepatitis C virus
652139|NCT00100659|hepatitis c
652140|NCT00100659|pediatric hepatitis
652141|NCT00100659|pediatric HCV
652142|NCT00100646|Treatment Interruption
652143|NCT00100646|Treatment Naive
652144|NCT00100633|Hepatitis B Vaccine
652145|NCT00100633|Treatment Experienced
652146|NCT00100633|Treatment Naive
652147|NCT00100620|Corticosteroid induced osteoporosis
652148|NCT00100620|prevention
652149|NCT00100620|treatment
652150|NCT00100620|zoledronic acid
652151|NCT00100607|osteoporosis/osteopenia, BMD, postmenopausal
652152|NCT00100594|Treatment Naive
652153|NCT00100581|Treatment Naive
652154|NCT00100568|Treatment Naive
652155|NCT00100555|Osteoporosis, osteopenia, post-menopausal, zoledronic acid
652156|NCT00100542|Treatment Experienced
652157|NCT00100542|Treatment Naive
652158|NCT00100542|Psychopathology
652159|NCT00100542|Anti-Retroviral Agents
652160|NCT00100542|Child
652161|NCT00100542|Adolescent
652162|NCT00100529|Facial Imaging
652163|NCT00100529|Genetics
652164|NCT00100529|Growth
652165|NCT00100529|Development
652166|NCT00100529|Diagnostics
652167|NCT00100529|Craniofacial Dysmorphologies
652168|NCT00100529|Facial Features
652169|NCT00100516|Renal
652170|NCT00100516|Allografts
652171|NCT00100516|Nephrectomy
652172|NCT00100516|Pneumoperitoneum
652173|NCT00100516|LaparoscopIC
652174|NCT00100516|Kidney Donation
652175|NCT00100503|Rehabilitation
652176|NCT00100503|Forced Use
652177|NCT00100503|Hemiplegia
652178|NCT00100503|Magnetic Resonance Imaging
652179|NCT00100503|TMS
652180|NCT00100503|Cerebral Palsy
652181|NCT00100503|Spastic Hemiplegia
652182|NCT00100503|Healthy Volunteer
652183|NCT00100503|HV
652184|NCT00100477|Multiple Myeloma
652185|NCT00100477|Lymphoma
652186|NCT00100477|Leukemia
652187|NCT00100477|Etoposide
652188|NCT00100477|Drug Therapy
652189|NCT00100477|Clinical Trials
652190|NCT00100464|Serotonin
652191|NCT00100464|Sleep Apnea Syndrome
652192|NCT00100464|Pharyngeal Muscles
652193|NCT00100451|Adipose tissue
652194|NCT00100451|Aging
652195|NCT00100451|Exercise
652196|NCT00100451|Lipolysis
652197|NCT00100451|Estrogens
652198|NCT00099697|abdominal fat
652199|NCT00099697|dehydroepiandrosterone
652200|NCT00099697|Insulin sensitivity
652201|NCT00099684|Treatment Experienced
652202|NCT00099671|Treatment Experienced
652203|NCT00099658|MTCT
652204|NCT00099645|Mifepristone
652205|NCT00099645|Mifeprex
652206|NCT00099645|RU486
652207|NCT00099645|VGX-410
652208|NCT00099645|Abortion Pill
652209|NCT00099645|Investigational Drug
652210|NCT00099632|Treatment Naive
652211|NCT00099619|exenatide
652212|NCT00099619|exendin-4
652213|NCT00099619|diabetes
652214|NCT00099619|Amylin
652215|NCT00099619|Lilly
652216|NCT00099593|Cutaneous T-cell lymphoma (CTCL)
652217|NCT00099593|Sezary Syndrome
652218|NCT00099593|Mycosis Fungoides
652219|NCT00099593|Vaccine
652220|NCT00099580|Congestive Heart Failure
652221|NCT00099580|AC2592
652222|NCT00099580|GLP-1
652223|NCT00099580|Amylin
652224|NCT00099580|metabolic abnormality
652225|NCT00099567|Metabolic Syndrome
652226|NCT00099567|Alzheimer's Disease
652227|NCT00099567|Cognitive Impairment
652228|NCT00099567|Inflammation
652229|NCT00099541|Lung Cancer
652230|NCT00099541|Bone Metastases
652231|NCT00099541|Bone Markers
652232|NCT00099541|NTX
652233|NCT00099541|zoledronic acid
652234|NCT00099541|Registry
652235|NCT00099541|Unresectable Stage IV Non Small-cell Lung Cancer (NSCLC)
652236|NCT00099541|Unresectable Stage IIIB NSCLC with Pleural Effusion
652237|NCT00099528|Post-herpetic neuralgia
652238|NCT00099528|Shingles
652239|NCT00099528|Herpes Zoster
652241|NCT00099528|Neuralgia
652242|NCT00099528|Anti-TNF agents
652243|NCT00099528|Inflammatory cytokines
652244|NCT00099528|Hyperalgesia
652245|NCT00099528|Allodynia
652246|NCT00099528|Irritable nociceptor
652247|NCT00099502|Relapsing multiple sclerosis
652248|NCT00099502|interferon beta 1b
652249|NCT00099502|Betaferon
652250|NCT00099502|Betaseron
652251|NCT00099489|Chronic Inflammatory Demyelinating Polyradiculoneuropathy
652252|NCT00099489|CIDP
652253|NCT00099489|IVIg
652254|NCT00099489|AVONEX
652255|NCT00099476|Epicatechin
652256|NCT00099476|Polyphenols
652257|NCT00099476|Chocolate
652258|NCT00099476|Insulin Resistance
652259|NCT00099476|Endothelial Dysfunction
652260|NCT00099476|Hypertension
652261|NCT00099463|Coronavirus
652262|NCT00099463|Healthy
652263|NCT00099463|Immunity
652264|NCT00099463|Preventive
652265|NCT00099463|Virus
652266|NCT00099463|Healthy Volunteer
652267|NCT00099463|HV
652268|NCT00100425|Irritable Bowel Syndrome
652269|NCT00100425|Visceral Hypersensitivity
652270|NCT00100425|Visceral Pain
652271|NCT00100399|influenza, flu, Fluarix, vaccine, GSK, immunogenicity
652272|NCT00100386|Hand hygiene, antibiotic resistance, contact precautions
652273|NCT00100373|Respiratory Syncytial Virus Infections
652274|NCT00100360|Gonadal Steroids
652275|NCT00100360|GnRH Agonist
652276|NCT00100360|Depression
652277|NCT00100360|Menstrual Cycle
652278|NCT00100360|Menstrually Related Mood Disorder
652279|NCT00100360|MRMD
652280|NCT00100360|Healthy Volunteer
652281|NCT00100360|HV
652282|NCT00100347|non-Hodgkin lymphoma
652283|NCT00100347|non-Hodgkin’s lymphoma
652284|NCT00100347|NHL
652285|NCT00100347|MetAP2
652286|NCT00100347|Solid Tumors
652287|NCT00100334|Alzheimer's Disease
652288|NCT00100321|Tumor Antigen Identification
652289|NCT00100321|Standard Treatment
652290|NCT00100321|Tissue Acquisition
652291|NCT00100321|Surgery
652292|NCT00100321|Adjuvant Chemotherapy
652293|NCT00100321|Pancreatic Cancer
652294|NCT00100321|Pancreatic Tumor
652295|NCT00100308|sepsis
652296|NCT00100308|Randomized clinical trial
652297|NCT00100308|Heparin
652298|NCT00100308|Therapy
652299|NCT00100295|Adolescent
652300|NCT00100295|Child
652301|NCT00100295|Phytotherapy
652302|NCT00100282|Mild-moderate Alzheimer's disease
652303|NCT00100269|Male infertility
652304|NCT00100269|sperm
652305|NCT00100269|pregnancy
652306|NCT00100269|IVF (in vitro fertilisation)
652307|NCT00100269|oxidative stress
652308|NCT00100269|free radicals
652309|NCT00100269|DNA damage
652310|NCT00100256|Advanced or recurrent stage IIIb or IV non small cell lung cancer
652311|NCT00100256|Disseminated or recurrent small cell lung cancer
652312|NCT00100243|androgen-independent
652313|NCT00100243|prostate cancer
652314|NCT00100230|retina
652315|NCT00100230|electroretinography
652316|NCT00100230|clinical trial
652317|NCT00100230|docosahexaenoic acid
652318|NCT00100230|omega-3 fatty acid
652319|NCT00100230|x-linked inheritance
652320|NCT00100217|Training
652321|NCT00100217|Critical Care
652322|NCT00100217|Heart Failure
652323|NCT00100217|Pulmonary Hypertension
652324|NCT00100217|Infectious Diseases
652325|NCT00100204|Head and Neck Radiation
652326|NCT00100204|Diabetes
652327|NCT00100204|Sarcoidosis
652328|NCT00100204|Sjogren's Syndrome
652329|NCT00100204|Caries
652330|NCT00100204|Healthy Volunteer
652331|NCT00100204|HV
652332|NCT00100204|Saliva Sample
652333|NCT00100191|hysterectomy
652334|NCT00100191|fibroids
652335|NCT00100191|uterine artery embolization
652336|NCT00100191|therapeutic embolization
652337|NCT00100191|uterus
652338|NCT00100191|menorrhagia
652339|NCT00100178|immunosuppressive therapy
652340|NCT00100178|Type 1 Diabetes TrialNet
652341|NCT00100178|TrialNet
652342|NCT00100178|POPPII
652343|NCT00100178|POPPII-1
652344|NCT00100165|Schizophrenia
652345|NCT00100152|Relapsed or refractory T-cell ALL acute lymphoblastic/leukemia
652346|NCT00100152|Relapsed/refractory T-cell acute Lymphoblastic/leukemia
652347|NCT00100152|Acute/chronic myelogenous leukemia
652348|NCT00100152|Poor-risk myelodysplasia
652349|NCT00100139|Neoplasm
652350|NCT00100139|Cancer
652351|NCT00100139|NeoPharm
652352|NCT00100139|Liposomes
652353|NCT00100139|Taxol
652354|NCT00100139|Paclitaxel
652355|NCT00100139|Anti-cancer
652356|NCT00100139|Advanced neoplasm
652357|NCT00100139|Advanced cancer
652358|NCT00100139|Chemotherapy
652359|NCT00100139|Refractory cancer
652360|NCT00100139|Metastatic cancer
652361|NCT00100126|Pharyngitis
652362|NCT00100126|Strep throat
652363|NCT00100113|cocaine dependence
652364|NCT00100100|cocaine dependence
652365|NCT00100087|macular degeneration
652366|NCT00100087|brachytherapy
652367|NCT00100087|choroidal neovascularization
652368|NCT00100087|retinal degeneration
652369|NCT00100087|retinal diseases
652370|NCT00100061|Cranberry
652371|NCT00100061|Vaccinium macrocarpon
652372|NCT00100035|Caregivers
652373|NCT00100035|Complementary Therapies
652374|NCT00100009|Steroid
652375|NCT00100009|Inflammation
652376|NCT00100009|Choroidal Neovascularization
652377|NCT00100009|Intravitreal Injection
652378|NCT00100009|Verteporfin
652379|NCT00100009|Age-Related Macular Degeneration
652380|NCT00100009|Photodynamic Therapy
652381|NCT00100009|Age Related Macular Degeneration
652382|NCT00100009|AMD
652383|NCT00099996|Sitosterolemia
652384|NCT00099996|Sitosterol
652385|NCT00099996|Ezetimibe
652386|NCT00099996|Absorption
652387|NCT00099996|Intestine
652388|NCT00099996|Cholesterol
652389|NCT00099996|Atherosclerosis
652390|NCT00099996|Homozygous Sitosterolemia
652391|NCT00099983|PTSD
652392|NCT00099970|Solid tumors
652393|NCT00099970|Metastatic melanoma
652394|NCT00099957|type 2 diabetes
652395|NCT00099957|vildagliptin
652396|NCT00099944|type 2 diabetes
652397|NCT00099944|vildagliptin
652398|NCT00099931|type 2 diabetes
652399|NCT00099931|vildagliptin
652400|NCT00099918|type 2 diabetes
652401|NCT00099918|vildagliptin
652402|NCT00099905|type 2 diabetes
652403|NCT00099905|vildagliptin
652404|NCT00099892|type 2 diabetes
652405|NCT00099892|vildagliptin
652406|NCT00099866|type 2 diabetes
652407|NCT00099866|vildagliptin
652408|NCT00099853|type 2 diabetes
652409|NCT00099853|vildagliptin
652410|NCT00099840|common cold
652411|NCT00099840|pharyngitis
652412|NCT00099840|tonsillitis
652413|NCT00099840|rhinosinusitis
652414|NCT00099840|tracheo-bronchitis
652415|NCT00099840|otitis media
652416|NCT00099840|acute exacerbations of asthma
652417|NCT00099840|acute exacerbations of chronic pulmonary disease
652418|NCT00099840|community acquired pneumonia
652419|NCT00099827|Depression
652420|NCT00099814|tooth movement
652421|NCT00099814|orthodontics
652422|NCT00099814|force
652423|NCT00099814|humans
652424|NCT00099814|clinical trial
652425|NCT00099801|Kidney, Transplantation, Rejection, Immunosuppression
652426|NCT00099788|Acute Coronary Syndrome
652427|NCT00099788|Myocardial Infarction
652428|NCT00099788|Heart Attack
652429|NCT00099788|Angina
652430|NCT00099788|Chest pain
652431|NCT00099788|Ischemia
652432|NCT00099788|Non-ST Elevation Acute Coronary Syndrome
652433|NCT00099775|Mycoses
652434|NCT00099775|Candida
652435|NCT00099775|Echinocandin
652436|NCT00099775|Immunocompromised Host
652437|NCT00099775|Invasive Fungal Infection
652438|NCT00099775|Fungal Infection
652439|NCT00099762|Tumor Induced Osteomalacia
652440|NCT00099762|FGF-23
652441|NCT00099762|Phosphatonin
652442|NCT00099762|Hypophosphatemia
652443|NCT00099762|Oncogenic Osteomalacia
652444|NCT00099762|Phosphaturic Mesenchymal Tumor
652445|NCT00099762|TIO
652446|NCT00099762|Osteogenic Osteomalacia
652447|NCT00099762|OOM
652448|NCT00099749|Kidney, immunosuppression, transplant, rejection
652449|NCT00099736|Kidney, transplantation, rejection, immunosuppression
652450|NCT00099723|Hepatic steatosis
652451|NCT00099723|adult-onset diabetes
652452|NCT00099723|Non-alcoholic fatty liver disease
652453|NCT00099710|Curcumin
652454|NCT00099710|Turmeric
652455|NCT00099710|Curry
652456|NCT00099710|NSAID
652457|NCT00099710|anti-inflammatory
652458|NCT00099710|Cholesterol
652459|NCT00099710|anti-oxidant
652460|NCT00099450|bleeding
652461|NCT00099450|blood transfusion
652462|NCT00099450|surgeries
652463|NCT00099437|Advanced Breast Cancer
652464|NCT00099437|Metastatic Breast Cancer
652465|NCT00099424|exercise training
652466|NCT00099424|resistance training
652467|NCT00099424|endurance training
652468|NCT00099424|Boeck's Sarcoid
652469|NCT00099424|Besnier-Boeck Disease
652470|NCT00099385|social development
652471|NCT00099385|risk behaviors
652472|NCT00099385|social emotional education
652473|NCT00099385|classroom instruction
652474|NCT00099372|sacrocolpopexy
652475|NCT00099372|abdominal sacrocolpopexy
652476|NCT00099372|surgical procedure, prolapse
652477|NCT00099372|pelvic organ prolapse
652478|NCT00099372|urinary incontinence
652479|NCT00099372|stress urinary incontinence
652480|NCT00099359|HIV
652481|NCT00099359|Perinatal
652482|NCT00099359|Prevention
652483|NCT00099359|Transmission
652484|NCT00099359|Nevirapine
652485|NCT00099359|Epivir
652486|NCT00099359|Zidovudine
652487|NCT00099359|Nelfinavir
652488|NCT00099359|ZDV
652489|NCT00099359|NVP
652490|NCT00099359|3TC
652491|NCT00099359|NFV
652492|NCT00099359|Viracept
652493|NCT00099359|Viramune
652494|NCT00099359|HIV Seronegativity
652495|NCT00099359|Treatment Naive
652496|NCT00099333|exenatide
652497|NCT00099333|exendin-4
652498|NCT00099333|Amylin
652499|NCT00099333|Eli Lilly
652500|NCT00099333|diabetes
652501|NCT00099320|exenatide
652502|NCT00099320|exendin-4
652503|NCT00099320|diabetes
652504|NCT00099320|Amylin
652505|NCT00099320|Lilly
652506|NCT00099307|White Matter
652507|NCT00099307|Grey Matter
652508|NCT00099307|Brain
652509|NCT00099307|Disability
652510|NCT00099307|Lesions
652511|NCT00099307|Multiple Sclerosis
652512|NCT00099307|MS
652513|NCT00099307|Healthy Volunteer
652514|NCT00099307|HV
652515|NCT00099294|Pancreas
652516|NCT00099294|Cancer
652517|NCT00099294|Pancreatic Adenocarcinoma
652518|NCT00099294|Metastatic
652519|NCT00099294|Glufosfamide
652520|NCT00099281|Metastatic breast cancer
652521|NCT00099268|Parkinson's disease, levodopa therapy, dyskinesia
652522|NCT00099255|Keyword?
652523|NCT00099255|Primary Cutaneous Anaplastic Large Cell Lymphoma
652524|NCT00099255|Large Cell Transformation of Mycosis Fungoides
652525|NCT00099255|Lymphomatoid Papulosis
652526|NCT00099242|Alzheimer's Disease
652527|NCT00099242|Dementia
652528|NCT00099229|bipolar disorder
652529|NCT00099229|manic episode
652530|NCT00099229|treatment
652531|NCT00099229|licarbazepine
652532|NCT00099216|Dementia,vascular,rivastigmine,stroke,memory loss
652533|NCT00099190|cancer
652534|NCT00099190|solid tumor
652535|NCT00099190|advanced solid tumor
652536|NCT00099164|preterm birth
652537|NCT00099164|pregnancy
652538|NCT00099164|multifetal
652539|NCT00099164|Progesterone
652540|NCT00099151|Longevity
652541|NCT00099151|Dietary restriction
652542|NCT00099151|Physical activity
652543|NCT00099151|Weight Loss
652544|NCT00099151|Diabetes
652545|NCT00099138|Diet
652546|NCT00099138|Caloric Restriction
652547|NCT00099138|Exercise
652548|NCT00099138|Energy Metabolism
652549|NCT00099138|Primary Aging
652550|NCT00099138|Secondary Aging
652551|NCT00099125|adult giant cell glioblastoma
652552|NCT00099125|adult gliosarcoma
652553|NCT00099125|adult glioblastoma
652554|NCT00099112|basal cell carcinoma of the skin
652555|NCT00099112|squamous cell carcinoma of the skin
652556|NCT00099112|actinic keratosis
652557|NCT00099099|Longevity
652558|NCT00099099|Calorie restriction
652559|NCT00099099|Physical activity
652560|NCT00099099|Weight loss
652561|NCT00099086|adenocarcinoma of the prostate
652562|NCT00099086|stage IIB prostate cancer
652563|NCT00099086|stage IIA prostate cancer
652564|NCT00099086|stage III prostate cancer
652565|NCT00099086|stage IV prostate cancer
652566|NCT00099060|adult giant cell glioblastoma
652567|NCT00099060|adult gliosarcoma
652568|NCT00099060|recurrent adult brain tumor
652569|NCT00099008|breast cancer
652570|NCT00099008|endometrial cancer
652571|NCT00098995|stage IB cervical cancer
652572|NCT00098995|stage IIA cervical cancer
652573|NCT00098995|stage IIB cervical cancer
652574|NCT00098995|stage III cervical cancer
652575|NCT00098995|stage IVA cervical cancer
652576|NCT00098995|cervical adenocarcinoma
652577|NCT00098995|cervical adenosquamous cell carcinoma
652578|NCT00098995|cervical squamous cell carcinoma
652579|NCT00098982|stage III colon cancer
652580|NCT00098982|stage IV colon cancer
652581|NCT00098982|stage III rectal cancer
652582|NCT00098982|stage IV rectal cancer
652583|NCT00098982|recurrent colon cancer
652584|NCT00098982|recurrent rectal cancer
652585|NCT00098969|unspecified adult solid tumor, protocol specific
652586|NCT00098943|unspecified adult solid tumor, protocol specific
652587|NCT00098943|stage IV renal cell cancer
652588|NCT00098943|recurrent renal cell cancer
652589|NCT00098943|stage IV colon cancer
652590|NCT00098943|recurrent colon cancer
652591|NCT00098943|anaplastic thyroid cancer
652592|NCT00098943|insular thyroid cancer
652593|NCT00098943|thyroid gland medullary carcinoma
652594|NCT00098943|stage IV follicular thyroid cancer
652595|NCT00098943|stage IV papillary thyroid cancer
652596|NCT00098943|recurrent thyroid cancer
652597|NCT00098943|recurrent squamous cell carcinoma of the hypopharynx
652598|NCT00098943|recurrent squamous cell carcinoma of the larynx
652599|NCT00098943|recurrent squamous cell carcinoma of the lip and oral cavity
652600|NCT00098943|recurrent squamous cell carcinoma of the nasopharynx
652601|NCT00098943|recurrent squamous cell carcinoma of the oropharynx
652602|NCT00098943|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
652603|NCT00098943|stage IV squamous cell carcinoma of the hypopharynx
652604|NCT00098943|stage IV squamous cell carcinoma of the larynx
652605|NCT00098943|stage IV squamous cell carcinoma of the lip and oral cavity
652606|NCT00098943|stage IV squamous cell carcinoma of the nasopharynx
652607|NCT00098943|stage IV squamous cell carcinoma of the oropharynx
652818|NCT00097318|Brain
652608|NCT00098943|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
652609|NCT00098943|recurrent verrucous carcinoma of the larynx
652610|NCT00098943|recurrent verrucous carcinoma of the oral cavity
652611|NCT00098943|stage IV verrucous carcinoma of the oral cavity
652612|NCT00098943|stage IV verrucous carcinoma of the larynx
652613|NCT00098943|recurrent adenoid cystic carcinoma of the oral cavity
652614|NCT00098943|stage IV adenoid cystic carcinoma of the oral cavity
652615|NCT00098943|recurrent basal cell carcinoma of the lip
652616|NCT00098943|stage IV basal cell carcinoma of the lip
652617|NCT00098943|recurrent mucoepidermoid carcinoma of the oral cavity
652618|NCT00098943|stage IV mucoepidermoid carcinoma of the oral cavity
652619|NCT00098943|recurrent lymphoepithelioma of the nasopharynx
652620|NCT00098943|recurrent lymphoepithelioma of the oropharynx
652621|NCT00098943|stage IV lymphoepithelioma of the nasopharynx
652622|NCT00098943|stage IV lymphoepithelioma of the oropharynx
652623|NCT00098943|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
652624|NCT00098943|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
652625|NCT00098943|recurrent inverted papilloma of the paranasal sinus and nasal cavity
652626|NCT00098943|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
652627|NCT00098943|stage IV inverted papilloma of the paranasal sinus and nasal cavity
652628|NCT00098943|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
652629|NCT00098943|metastatic parathyroid cancer
652630|NCT00098943|recurrent parathyroid cancer
652631|NCT00098943|recurrent salivary gland cancer
652632|NCT00098943|stage IV salivary gland cancer
652633|NCT00098917|stage I non-small cell lung cancer
652634|NCT00098917|stage II non-small cell lung cancer
652635|NCT00098917|stage IIIA non-small cell lung cancer
652636|NCT00098878|stage I ovarian epithelial cancer
652637|NCT00098878|stage II ovarian epithelial cancer
652638|NCT00098878|stage III ovarian epithelial cancer
652639|NCT00098878|stage IV ovarian epithelial cancer
652640|NCT00098878|fallopian tube cancer
652641|NCT00098878|primary peritoneal cavity cancer
652642|NCT00098852|recurrent thyroid cancer
652643|NCT00098852|stage II follicular thyroid cancer
652644|NCT00098852|stage IV follicular thyroid cancer
652645|NCT00098852|stage II papillary thyroid cancer
652646|NCT00098852|stage IV papillary thyroid cancer
652647|NCT00098800|ovarian epithelial cancer
652648|NCT00098800|BRCA1 mutation carrier
652649|NCT00098800|BRCA2 mutation carrier
652650|NCT00098787|recurrent colon cancer
652651|NCT00098787|stage IV colon cancer
652652|NCT00098787|recurrent rectal cancer
652653|NCT00098787|stage IV rectal cancer
652654|NCT00098787|adenocarcinoma of the colon
652655|NCT00098787|adenocarcinoma of the rectum
652656|NCT00098774|primary central nervous system non-Hodgkin lymphoma
652657|NCT00098761|recurrent childhood brain stem glioma
652658|NCT00098761|recurrent childhood visual pathway and hypothalamic glioma
652659|NCT00098761|recurrent childhood cerebellar astrocytoma
652660|NCT00098761|recurrent childhood cerebral astrocytoma
652661|NCT00098761|recurrent childhood ependymoma
652662|NCT00098761|recurrent childhood medulloblastoma
652663|NCT00098761|recurrent childhood supratentorial primitive neuroectodermal tumor
652664|NCT00098761|childhood central nervous system germ cell tumor
652665|NCT00098761|childhood choroid plexus tumor
652666|NCT00098761|childhood craniopharyngioma
652667|NCT00098761|childhood infratentorial ependymoma
652668|NCT00098761|childhood grade I meningioma
652669|NCT00098761|childhood grade II meningioma
652670|NCT00098761|childhood grade III meningioma
652671|NCT00098761|childhood high-grade cerebral astrocytoma
652672|NCT00098761|childhood low-grade cerebral astrocytoma
652673|NCT00098735|Kidney,Transplantation, rejection, immunosuppression
652674|NCT00098709|pregnancy
652675|NCT00098709|labor, obstetric
652676|NCT00098709|fetal monitoring
652677|NCT00098709|oximetry
652678|NCT00098709|fetal heart rate
652679|NCT00098709|cardiotocography
652680|NCT00098683|refractory anemia with excess blasts
652681|NCT00098683|refractory anemia
652682|NCT00098683|refractory anemia with ringed sideroblasts
652683|NCT00098683|de novo myelodysplastic syndromes
652684|NCT00098683|myelodysplastic/myeloproliferative neoplasm, unclassifiable
652685|NCT00098683|refractory cytopenia with multilineage dysplasia
652686|NCT00098566|quality of life
652687|NCT00098566|recurrent adult Burkitt lymphoma
652688|NCT00098566|recurrent adult diffuse large cell lymphoma
652689|NCT00098566|recurrent adult diffuse mixed cell lymphoma
652690|NCT00098566|recurrent adult diffuse small cleaved cell lymphoma
652691|NCT00098566|recurrent adult immunoblastic large cell lymphoma
652692|NCT00098566|recurrent adult lymphoblastic lymphoma
652693|NCT00098566|recurrent grade 1 follicular lymphoma
652694|NCT00098566|recurrent grade 2 follicular lymphoma
652695|NCT00098566|recurrent grade 3 follicular lymphoma
652696|NCT00098566|recurrent small lymphocytic lymphoma
652697|NCT00098566|recurrent mantle cell lymphoma
652698|NCT00098566|recurrent marginal zone lymphoma
652699|NCT00098566|Waldenstrom macroglobulinemia
652700|NCT00098566|recurrent adult grade III lymphomatoid granulomatosis
652701|NCT00098566|splenic marginal zone lymphoma
652702|NCT00098566|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
652703|NCT00098566|nodal marginal zone B-cell lymphoma
652704|NCT00098553|stage IV melanoma
652705|NCT00098553|recurrent melanoma
652706|NCT00098514|unspecified adult solid tumor, protocol specific
652707|NCT00098462|recurrent non-small cell lung cancer
652708|NCT00098462|stage IIIB non-small cell lung cancer
652709|NCT00098462|stage IV non-small cell lung cancer
652710|NCT00098436|recurrent adult acute myeloid leukemia
652711|NCT00098436|recurrent adult acute lymphoblastic leukemia
652712|NCT00098436|blastic phase chronic myelogenous leukemia
652713|NCT00098436|relapsing chronic myelogenous leukemia
652714|NCT00098436|secondary acute myeloid leukemia
652715|NCT00098436|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
652716|NCT00098436|adult acute myeloid leukemia with inv(16)(p13;q22)
652717|NCT00098436|adult acute myeloid leukemia with t(15;17)(q22;q12)
652718|NCT00098436|adult acute myeloid leukemia with t(16;16)(p13;q22)
652719|NCT00098436|adult acute myeloid leukemia with t(8;21)(q22;q22)
652720|NCT00098384|Travelers’ diarrhea
652721|NCT00098384|rifaximin
652722|NCT00098384|prophylaxis
652723|NCT00098384|enterotoxigenic E. coli
652724|NCT00098358|Leukotrienes
652725|NCT00098358|inflammation
652726|NCT00098345|Caprelsa (vandetanib)
652727|NCT00098345|ZD6474
652728|NCT00098332|recurrent cutaneous T-cell non-Hodgkin lymphoma
652729|NCT00098332|stage II cutaneous T-cell non-Hodgkin lymphoma
652730|NCT00098332|stage III cutaneous T-cell non-Hodgkin lymphoma
652731|NCT00098332|stage IV cutaneous T-cell non-Hodgkin lymphoma
652732|NCT00098332|recurrent mycosis fungoides/Sezary syndrome
652733|NCT00098332|stage II mycosis fungoides/Sezary syndrome
652734|NCT00098332|stage III mycosis fungoides/Sezary syndrome
652735|NCT00098332|stage IV mycosis fungoides/Sezary syndrome
652736|NCT00098319|Cleft palate
652737|NCT00098319|Cleft lip
652738|NCT00098319|Folic acid
652739|NCT00098319|Global Network
652740|NCT00098319|Maternal and child health
652741|NCT00098319|International
652742|NCT00098319|Women's health
652743|NCT00098319|Brazil
652744|NCT00098319|Brasil
652745|NCT00098319|Latin America
652746|NCT00098319|ECLAMC
652747|NCT00098319|Congenital defects
652748|NCT00098319|Pregnancy
652749|NCT00098293|Aids
652750|NCT00098293|HIV
652751|NCT00098280|H5g1
652752|NCT00098280|PNH
652753|NCT00098280|TRIUMPH
652754|NCT00098280|Paroxysmal Nocturnal Hemoglobinuria
652755|NCT00098267|Bacteria
652756|NCT00098267|Biofilm Formation
652757|NCT00098267|Secretory Antibodies
652758|NCT00098267|Teeth
652759|NCT00098267|Health and Disease
652760|NCT00098254|Non-Small Cell
652761|NCT00098254|Molecular
652762|NCT00098254|Targeted
652763|NCT00098254|Therapies
652764|NCT00098254|Cancer
652765|NCT00098254|Non-Small Cell Lung Cancer
652766|NCT00098254|NSCLC
652767|NCT00098241|pediatric
652768|NCT00098241|renal
652769|NCT00098241|transplant recipients
652770|NCT00098241|de novo
652771|NCT00098241|De novo renal pediatric transplant
652772|NCT00098228|COPD, adults, QAB149
652773|NCT00098215|Residency training
652774|NCT00098202|Global Network
652775|NCT00098202|Micronutrients
652776|NCT00098202|Zinc
652777|NCT00098202|Maternal and child health
652778|NCT00098202|Women's health
652779|NCT00098202|International
652780|NCT00098202|Guatemala
652781|NCT00098202|Nutrition
652782|NCT00098202|Corn
652783|NCT00098202|Maize
652784|NCT00097370|Mepolizumab
652785|NCT00097370|Open-label
652786|NCT00097370|Anti-IL-5
652787|NCT00097370|Hypereosinophilic Syndrome
652788|NCT00097370|Hypereosinophilia
652789|NCT00097357|Prevention of deep vein thrombosis and pulmonary embolism
652790|NCT00097357|Preventive therapy
652791|NCT00097344|Aromatase inhibitor
652792|NCT00097344|Atamestane
652793|NCT00097344|Breast neoplasms
652794|NCT00097344|Combined hormonal therapy
652795|NCT00097344|Complete estrogen blockade
652796|NCT00097344|Ductal breast carcinoma
652797|NCT00097344|Estrogen blocker
652798|NCT00097344|Fareston®
652799|NCT00097344|Femara®
652800|NCT00097344|First line therapy
652801|NCT00097344|Letrozole
652802|NCT00097344|Lobular breast carcinoma
652803|NCT00097344|Locally advanced breast cancer
652804|NCT00097344|Locally recurrent breast cancer
652805|NCT00097344|Maximal estrogen inhibition
652806|NCT00097344|Metastatic breast cancer
652807|NCT00097344|Neoplasms, Hormone-dependent
652808|NCT00097344|Receptor-positive
652809|NCT00097344|Stage IIIA breast cancer
652810|NCT00097344|Stage IIIB breast cancer
652811|NCT00097344|Stage IV breast cancer
652812|NCT00097344|Toremifene
652813|NCT00097331|multiple sclerosis
652814|NCT00097331|relapsing
652815|NCT00097331|remitting
652816|NCT00097331|Relapsing-Remitting MS (RRMS)
652817|NCT00097318|Ischemic
652819|NCT00097318|Inflammation
652820|NCT00097318|Clinical Trial
652821|NCT00097318|Stroke
652822|NCT00097305|Mental Health
652823|NCT00097305|Psychotherapy
652824|NCT00097292|"at risk for developing type 1 diabetes"
652825|NCT00097292|T1DM
652826|NCT00097292|T1D
652827|NCT00097292|juvenile diabetes
652828|NCT00097292|Type 1 Diabetes TrialNet
652829|NCT00097292|TrialNet
652830|NCT00097266|Bipolar Mania
652831|NCT00097253|Aromatherapy
652832|NCT00097253|Smell
652833|NCT00098189|Safety, psoriasis, adverse event, SAE, extension
652834|NCT00098163|HIV Seronegativity
652835|NCT00098163|HIV Preventive Vaccine
652836|NCT00098150|Safety, atopic dermatitis, adverse event, SAE, extension
652837|NCT00098137|atrial fibrillation
652838|NCT00098137|angiotensin II
652839|NCT00098137|angiotensin receptor antagonist
652840|NCT00098137|drug
652841|NCT00098137|controlled clinical trial
652842|NCT00098124|NSRI
652843|NCT00098124|milnacipran
652844|NCT00098124|fibromyalgia
652845|NCT00098111|Crohn's disease
652846|NCT00098111|inflammatory bowel disease
652847|NCT00098111|IMURAN
652848|NCT00098111|azathioprine
652849|NCT00098098|Botulinum
652850|NCT00098098|Recombinant Botulinum Vaccine
652851|NCT00098098|botulinum neurotoxins
652852|NCT00098085|Lung cancer
652853|NCT00098085|Non-small cell lung cancer
652854|NCT00098085|Pulmonary
652855|NCT00098085|Immunotherapy
652856|NCT00098085|Vaccine
652857|NCT00098072|Cytometry
652858|NCT00098072|Genes
652859|NCT00098072|Hypertension
652860|NCT00098072|Lung
652861|NCT00098072|Proteomics
652862|NCT00098072|Primary Pulmonary Hypertenion
652863|NCT00098072|PPH
652864|NCT00098072|Healthy Volunteers
652865|NCT00098072|HV
652866|NCT00098059|herpes simplex
652867|NCT00098059|cold sores
652868|NCT00098059|fever blisters
652869|NCT00098059|children
652870|NCT00098059|Famvir
652871|NCT00098059|famciclovir
652872|NCT00098046|chickenpox
652873|NCT00098046|herpes zoster
652874|NCT00098046|children
652875|NCT00098046|Famvir
652876|NCT00098046|varicella zoster virus
652877|NCT00098033|clinical
652878|NCT00098033|pharmacodynamics
652879|NCT00098033|investigational drug clofarabine
652880|NCT00098033|AML, ALL, CML-accelerated phase, CML-blastic phase
652881|NCT00098033|Chronic Myelogenous Leukemia - accelerated phase
652882|NCT00098033|Chronic Myelogenous Leukemia - blastic phase
652883|NCT00098020|Glomerulosclerosis
652884|NCT00098020|Proteinuria
652885|NCT00098020|Fibrosis
652886|NCT00098020|Chronic Kidney Disease
652887|NCT00098020|Nephrotic Syndrome
652888|NCT00098007|Heart transplantation
652889|NCT00098007|Everolimus
652890|NCT00098007|De novo heart transplant patients
652891|NCT00097994|Menopause
652892|NCT00097994|Quality of Life
652893|NCT00097994|Health Services
652894|NCT00097994|Complementary Therapies
652895|NCT00097981|Multiple myeloma
652896|NCT00097981|Newly diagnosed multiple myeloma
652897|NCT00097981|Thalidomide
652898|NCT00097981|Dexamethasone
652899|NCT00097981|DOXIL
652900|NCT00097981|Pegylated liposomal hydrochloride doxorubicin injection
652901|NCT00097968|transplant, heart, adult, everolimus
652902|NCT00097968|allograft rejection
652903|NCT00097955|diabetes
652904|NCT00097955|nephropathy
652905|NCT00097955|hypertension
652906|NCT00097955|aliskiren
652907|NCT00097955|losartan
652908|NCT00097942|memantine
652909|NCT00097942|adjunctive therapy
652910|NCT00097942|schizophrenia
652911|NCT00097929|Relapsed Diffuse Large B-cell Lymphoma
652912|NCT00097916|memantine HCl
652913|NCT00097916|Dementia
652914|NCT00097916|Agitation
652915|NCT00097916|Alzheimer Disease
652916|NCT00097903|Carcinoma, Non-Small-Cell Lung
652917|NCT00097903|Solid Tumors
652918|NCT00097903|Oral
652919|NCT00097890|Lysosomes
652920|NCT00097890|Storage
652921|NCT00097890|Glycolipid
652922|NCT00097890|Fabry Disease
652923|NCT00097890|Stroke
652924|NCT00097877|Type 2 Diabetes
652925|NCT00097851|second-line
652926|NCT00097851|combination
652927|NCT00097851|chemotherapy
652928|NCT00097851|anti-angiogenic
652929|NCT00097838|HIV Seronegativity
652930|NCT00097838|HIV Preventive Vaccine
652931|NCT00097825|Male Osteoporosis
652932|NCT00097812|osteoporosis, osteopenia, post-menopausal, zoledronic acid
652933|NCT00097786|Prevention
652934|NCT00097786|Diabetes type 2
652935|NCT00097786|valsartan
652936|NCT00097786|nateglinide
652937|NCT00097773|Lung Diseases
652938|NCT00097773|Chronic Obstructive Pulmonary Disease
652939|NCT00097760|Multiple Sclerosis
652940|NCT00097760|MS
652941|NCT00097747|anemia
652942|NCT00097747|chronic kidney disease
652943|NCT00097747|CKD
652944|NCT00097747|chronic renal failure
652945|NCT00097747|CRF
652946|NCT00097747|erythropoietin
652947|NCT00097747|EPO
652948|NCT00097747|erythropoiesis stimulating agent
652949|NCT00097747|ESA
652950|NCT00097747|Hematide™
652951|NCT00097747|hemoglobin
652952|NCT00097747|Hb
652953|NCT00097747|Hgb
652954|NCT00097747|Omontys
652955|NCT00097747|peginesatide
652956|NCT00097747|red blood cell
652957|NCT00097747|red blood cell production
652958|NCT00097734|diverticulitis
652959|NCT00097734|Invanz
652960|NCT00097734|Ertapenem
652961|NCT00097734|acute attacks
652962|NCT00097734|sigmoid diverticulitis
652963|NCT00097734|Acute attacks of sigmoid diverticulitis
652964|NCT00097721|breast neoplasm
652965|NCT00097721|breast cancer
652966|NCT00097721|breast tumor
652967|NCT00097708|Double Blind, Placebo controlled, Safety and Efficacy
652968|NCT00097708|Generalized Anxiety Disorder
652969|NCT00097695|Hereditary Angioedema
652970|NCT00097695|C1 inhibitor deficiency
652971|NCT00097695|HAE
652972|NCT00097695|Icatibant
652973|NCT00097695|Bradykinin antagonist
652974|NCT00097695|acute attack
652975|NCT00097695|subcutaneous
652976|NCT00097682|Financial Ties
652977|NCT00097682|Institution
652978|NCT00097682|Research Doctor
652979|NCT00097682|Oncology
652980|NCT00097682|Attitudes
652981|NCT00097682|Cancer
652982|NCT00097682|Survey
652983|NCT00097669|VITATOPS
652984|NCT00097669|stroke
652985|NCT00097669|prevention
652986|NCT00097669|multivitamins
652987|NCT00097669|homocysteine
652988|NCT00097643|exercise
652989|NCT00097643|health promotion
652990|NCT00097643|independent living
652991|NCT00097643|affective aspects
652992|NCT00097630|mechanical ventilation
652993|NCT00097630|delirium
652994|NCT00097630|sedation scoring
652995|NCT00097630|cognitive impairment
652996|NCT00097630|ventilation weaning
652997|NCT00097604|Sleep
652998|NCT00097604|Aged
652999|NCT00097604|Valerian
653000|NCT00097604|Complementary Therapies
653001|NCT00097604|Medicine, Herbal
653002|NCT00097565|Follicular Non-Hodgkin's Lymphoma
653003|NCT00097539|Pediatric growth disorders
653004|NCT00097526|Growth Hormone Deficiency
653005|NCT00097513|Pubertal Growth Hormone Deficiency
653006|NCT00097500|diabetes
653007|NCT00097500|exenatide
653008|NCT00097500|exendin-4
653009|NCT00097500|Amylin
653010|NCT00097500|Lilly
653011|NCT00097487|Metastatic Breast Cancer
653012|NCT00097474|Cortisol
653013|NCT00097474|Travel
653014|NCT00097474|Saliva
653015|NCT00097474|Body Clock
653016|NCT00097474|Sleep
653017|NCT00097474|Healthy Volunteer
653018|NCT00097474|HV
653019|NCT00097474|Jet Lag
653020|NCT00097461|Employee Health
653021|NCT00097461|Insurance Benefit
653022|NCT00097461|Fringe Benefit
653023|NCT00097461|Health Status
653024|NCT00097461|Socioeconomic Factors
653025|NCT00097448|sudden hearing loss
653026|NCT00097448|unilateral sudden sensorineural hearing loss
653027|NCT00097448|sudden sensorineural hearing loss
653028|NCT00097448|sudden unilateral hearing loss
653029|NCT00097422|CDAD, diarrhea
653030|NCT00097422|Clostridium difficile-Associated Diarrhea
653031|NCT00097409|ovarian cancer
653032|NCT00097409|platinum/taxane-refractory chemotherapy
653033|NCT00097409|Persistent
653034|NCT00097409|Recurrent
653035|NCT00097396|plague
653036|NCT00097396|recombinant plague vaccine
653037|NCT00097396|vaccine
653038|NCT00097396|plague vaccine
653039|NCT00097396|Protection against pneumonic plague
653040|NCT00097240|FOLLOW
653041|NCT00097240|Psoriasis
653042|NCT00097240|Pregnancy
653043|NCT00097227|NSCLC
653044|NCT00097227|non-small
653045|NCT00097227|lung
653046|NCT00097227|IIIb
653047|NCT00097227|IV
653048|NCT00097227|Carboplatin
653049|NCT00097227|Paclitaxel
653050|NCT00097227|Cetuximab
653051|NCT00097227|Stage IIIB Non-Small Cell Lung Cancer
653052|NCT00097227|Stage IV Non-Small Cell Lung Cancer
653053|NCT00097214|NSCLC
653054|NCT00097214|Non-small
653055|NCT00097214|Lung
653056|NCT00097214|IIIB
653057|NCT00097214|IV
653058|NCT00097214|Carboplatin
653059|NCT00097214|Cetuximab
653060|NCT00097214|Stage IIIB non-small cell lung cancer
653061|NCT00097214|Stage IV non-small cell lung cancer
653062|NCT00097188|Relapsing remitting multiple sclerosis
653063|NCT00097175|Major Depressive Disorder
653064|NCT00097175|Serotonin
653065|NCT00097175|Functional MRI
653066|NCT00097175|Genotype
653067|NCT00097175|Negative Affect
653068|NCT00097175|MDD
653069|NCT00097175|Healthy Volunteer
653070|NCT00097175|HV
653071|NCT00097162|Anisometropia
653072|NCT00097162|Strabismus
653073|NCT00097162|Cortical Suppression
653074|NCT00097162|Impaired Vision
653075|NCT00097162|Cortical Plasticity
653076|NCT00097162|Amblyopia
653077|NCT00097162|Adult Amblyopia
653078|NCT00097149|Congenital birth defects
653079|NCT00097149|Cleft lip
653080|NCT00097149|Cleft palate
653081|NCT00097149|Global Network
653082|NCT00097149|Neurodevelopmental outcome
653083|NCT00097149|Maternal and child health
653084|NCT00097149|International
653085|NCT00097149|Women's health
653086|NCT00097149|Brazil
653087|NCT00097149|Brasil
653088|NCT00097149|Latin America
653089|NCT00097149|ECLAMC
653090|NCT00097149|Argentina
653091|NCT00097149|Bolivia
653092|NCT00097149|Chile
653093|NCT00097149|Colombia
653094|NCT00097149|Ecuador
653095|NCT00097149|Venezuela
653096|NCT00097123|Acute postpartum hemorrhage
653097|NCT00097123|PPH
653098|NCT00097123|Misoprostol
653099|NCT00097123|Global Network
653100|NCT00097123|Uterotonics
653101|NCT00097123|India
653102|NCT00097123|Maternal and child health
653103|NCT00097123|International
653104|NCT00097123|Women's health
653105|NCT00097110|Vitamin C
653106|NCT00097110|Vitamin E
653107|NCT00097110|Preeclampsia
653108|NCT00097110|Antioxidants
653109|NCT00097110|Global Network
653110|NCT00097110|Preterm birth
653111|NCT00097110|Low birth weight infants
653112|NCT00097110|Brazil
653113|NCT00097110|Brasil
653114|NCT00097110|Maternal and child health
653115|NCT00097110|International
653116|NCT00097110|Women's health
653117|NCT00097097|Asphyxia
653118|NCT00097097|Neonatal mortality
653119|NCT00097097|Neonatal morbidity
653120|NCT00097097|Hypoxic ischemic encephalopathy
653121|NCT00097097|Neurodevelopmental impairment
653122|NCT00097097|Neonatal resuscitation
653123|NCT00097097|Global Network
653124|NCT00097097|Zambia
653125|NCT00097097|Africa
653126|NCT00097097|Cerebral palsy
653127|NCT00097097|Child health
653128|NCT00097097|International
653129|NCT00097071|Diabetes, Type 1
653130|NCT00097058|Aging
653131|NCT00097058|Menopause
653132|NCT00097058|Estrogen Replacement Therapy
653133|NCT00097058|Cognitive Decline
653134|NCT00097045|Hepatitis C
653135|NCT00097045|HCV
653136|NCT00097045|Omega Interferon
653137|NCT00097045|Interferon
653138|NCT00097045|HCV genotype 1
653139|NCT00097032|Bipolar I Disorder
653140|NCT00097032|risperidone
653141|NCT00097032|quetiapine
653142|NCT00097032|sedation
653143|NCT00097032|cognition
653144|NCT00097019|Recurrent ovarian cancer
653145|NCT00097019|Refractory ovarian cancer
653146|NCT00096993|Omnitarg
653147|NCT00096993|Cancer
653148|NCT00096993|Platinum-Resistant
653149|NCT00096967|Metastatic breast cancer
653150|NCT00096967|Metastatic colorectal cancer
653151|NCT00096954|Omalizumab (Xolair)
653152|NCT00096954|Atopic Asthma
653153|NCT00096941|Advanced solid cancers
653154|NCT00096941|HER2
653155|NCT00096941|EGFR
653156|NCT00096928|Plaque Psoriasis
653157|NCT00096928|RESPONSE
653158|NCT00096928|Raptiva
653159|NCT00096928|efalizumab
653160|NCT00096915|chronic kidney disease, CKD
653161|NCT00096915|renal failure
653162|NCT00096915|anemia
653163|NCT00096915|hemodialysis
653164|NCT00096915|peritoneal dialysis
653165|NCT00096915|Aranesp®, Darbepoetin Alfa
653166|NCT00096902|Orthostatic Intolerance
653167|NCT00096902|Hypnosis
653168|NCT00096902|Cold Pressor
653169|NCT00096902|Isometric Exercise
653170|NCT00096902|Behavior
653171|NCT00096902|Neurocardiogenic Syncope
653172|NCT00096876|Parkinsonian syndrome
653173|NCT00096863|Delirium
653174|NCT00096863|Cognition Disorders
653175|NCT00096863|Antipsychotics
653176|NCT00096863|Mechanical Ventilation
653177|NCT00096863|Critical Illness
653178|NCT00096850|HIV Seronegativity
653179|NCT00096850|Antitubercular agents
653180|NCT00096837|Myeloma
653181|NCT00096837|Multiple Myeloma
653182|NCT00096837|Relapsed Multiple Myeloma
653183|NCT00096837|Refractory Multiple Myeloma
653184|NCT00096824|Acute Infection
653185|NCT00096824|Treatment Naive
653186|NCT00096798|Fatty Acids, Omega-3
653187|NCT00096798|Antidepressive Agents
653188|NCT00096798|Eicosapentanoic Acid
653189|NCT00096785|chronic hepatitis B infection
653190|NCT00096772|Genetic Testing
653191|NCT00096772|Genomics
653192|NCT00096772|Human Genetic Factors
653193|NCT00096759|Arthritis
653194|NCT00096759|Tai Chi
653195|NCT00096759|Meditation
653196|NCT00096759|Relaxation Techniques
653197|NCT00096746|Treatment Experienced
653198|NCT00096733|Living donors
653199|NCT00096733|Organ procurement
653200|NCT00096733|Liver transplantation
653201|NCT00096733|Hepatitis C
653202|NCT00096733|Hepatocellular carcinoma
653203|NCT00096733|Hepatectomy
653204|NCT00096733|Liver regeneration
653205|NCT00096733|Graft rejection
653206|NCT00096733|Quality of life
653207|NCT00096733|Informed consent
653208|NCT00096720|parkinson
653209|NCT00096720|brain imaging
653210|NCT00096720|diagnosis
653211|NCT00096707|advanced solid tumors
653212|NCT00096707|cancer
653213|NCT00096707|docetaxel
653214|NCT00096707|2-deoxy-D-glucose (2DG)
653215|NCT00096707|phase 1
653216|NCT00096694|Intrauterine Device
653217|NCT00096694|IUD
653218|NCT00096694|Contraceptive
653219|NCT00096694|Levonorgestrel
653220|NCT00096668|Breast cancer
653221|NCT00096668|TOCOSOL Paclitaxel
653222|NCT00096655|Ulcerative colitis
653223|NCT00096655|Infliximab
653224|NCT00096655|Remicade
653225|NCT00096642|cognitive behavioral therapy
653226|NCT00096642|depression
653227|NCT00096642|group therapy
653228|NCT00096642|parenting
653229|NCT00096642|children and adolescents
653230|NCT00096629|recurrent renal cell cancer
653231|NCT00096629|stage I renal cell cancer
653232|NCT00096629|stage II renal cell cancer
653233|NCT00096629|stage III renal cell cancer
653234|NCT00096629|stage IV renal cell cancer
653235|NCT00096603|Moderate to severe plaque psoriasis
653236|NCT00096590|thromboembolism
653237|NCT00096590|unspecified adult solid tumor, protocol specific
653238|NCT00096564|Mirror Neuron
653239|NCT00096564|Urge
653240|NCT00096564|Statistical Parametric Mapping
653241|NCT00096564|Healthy Volunteer
653242|NCT00096564|HV
653243|NCT00096551|Biochemical Failure
653244|NCT00096551|Immunotherapy
653245|NCT00096551|TRICOM
653246|NCT00096551|Pox-virus
653247|NCT00096551|Fowlpox
653248|NCT00096551|Prostate Cancer
653249|NCT00096538|classic Kaposi sarcoma
653250|NCT00096538|recurrent Kaposi sarcoma
653251|NCT00096525|recurrent renal cell cancer
653252|NCT00096525|stage III renal cell cancer
653253|NCT00096525|stage IV renal cell cancer
653254|NCT00096486|recurrent non-small cell lung cancer
653255|NCT00096486|stage IIIB non-small cell lung cancer
653256|NCT00096486|stage IV non-small cell lung cancer
653257|NCT00096473|Alzheimer's Disease
653258|NCT00096473|dementia
653259|NCT00096473|acetylcholinesterase
653260|NCT00096473|donepezil
653261|NCT00096473|Aricept
653262|NCT00096473|memory loss
653263|NCT00096473|Severe dementia of the Alzheimer's type
653264|NCT00096421|Critical illness
653265|NCT00096421|Critical care
653266|NCT00096421|Hyperglycemia
653267|NCT00096421|Intensive care
653268|NCT00096421|Intensive Care Units
653269|NCT00096421|Insulin resistance
653270|NCT00096421|Intensive insulin therapy
653271|NCT00096421|Conventional insulin therapy
653272|NCT00096408|Endometrial
653273|NCT00096408|Endometrium
653274|NCT00096408|Uterus
653275|NCT00096408|Cancer
653276|NCT00096408|Carcinoma
653277|NCT00096408|Adenocarcinoma
653278|NCT00096408|Stage 1
653279|NCT00096408|Hysterectomy
653280|NCT00096408|Laparoscopy
653281|NCT00096408|Abdominal
653282|NCT00096408|Total
653283|NCT00096408|Surgery
653284|NCT00096408|Quality of Life
653285|NCT00096408|Disease-free survival
653286|NCT00096382|stage IV melanoma
653287|NCT00096382|recurrent melanoma
653288|NCT00096369|breast cancer
653289|NCT00096369|lobular breast carcinoma in situ
653290|NCT00096369|breast cancer in situ
653291|NCT00096356|fatigue
653292|NCT00096356|stage I breast cancer
653293|NCT00096356|stage II breast cancer
653294|NCT00096356|stage IIIA breast cancer
653295|NCT00096356|stage IIIB breast cancer
653296|NCT00096356|stage IIIC breast cancer
653297|NCT00096356|stage IV breast cancer
653298|NCT00096343|invasive ductal breast carcinoma
653299|NCT00096343|invasive lobular breast carcinoma
653300|NCT00096343|stage II breast cancer
653301|NCT00096343|stage IIIA breast cancer
653302|NCT00096343|stage IIIB breast cancer
653303|NCT00096343|inflammatory breast cancer
653304|NCT00096330|colon cancer
653305|NCT00096330|rectal cancer
653306|NCT00096317|unspecified adult solid tumor, protocol specific
653307|NCT00096304|adenocarcinoma of the prostate
653308|NCT00096304|recurrent prostate cancer
653309|NCT00096304|stage IV prostate cancer
653310|NCT00096291|stage II breast cancer
653311|NCT00096291|stage IIIA breast cancer
653312|NCT00096291|stage IIIB breast cancer
653313|NCT00096291|stage IIIC breast cancer
653314|NCT00096239|recurrent ovarian epithelial cancer
653315|NCT00096239|primary peritoneal cavity cancer
653316|NCT00096239|fallopian tube cancer
653317|NCT00096226|stage IIIA non-small cell lung cancer
653318|NCT00096226|stage IIIB non-small cell lung cancer
653319|NCT00096213|chondrosarcoma
653320|NCT00096187|low risk metastatic gestational trophoblastic tumor
653321|NCT00096187|recurrent gestational trophoblastic tumor
653745|NCT00094822|pegfilgrastim
653322|NCT00096187|nonmetastatic gestational trophoblastic tumor
653323|NCT00096174|stage IV squamous cell carcinoma of the hypopharynx
653324|NCT00096174|stage IV squamous cell carcinoma of the larynx
653325|NCT00096174|stage IV squamous cell carcinoma of the lip and oral cavity
653326|NCT00096174|stage IV squamous cell carcinoma of the oropharynx
653327|NCT00096135|recurrent childhood acute lymphoblastic leukemia
653328|NCT00096135|B-cell childhood acute lymphoblastic leukemia
653329|NCT00096135|T-cell childhood acute lymphoblastic leukemia
653330|NCT00096135|TdT positive childhood acute lymphoblastic leukemia
653331|NCT00096096|graft versus host disease
653332|NCT00096096|accelerated phase chronic myelogenous leukemia
653333|NCT00096096|relapsing chronic myelogenous leukemia
653334|NCT00096096|recurrent adult Hodgkin lymphoma
653335|NCT00096096|refractory multiple myeloma
653336|NCT00096096|recurrent adult Burkitt lymphoma
653337|NCT00096096|chronic idiopathic myelofibrosis
653338|NCT00096096|recurrent adult diffuse large cell lymphoma
653339|NCT00096096|recurrent adult diffuse mixed cell lymphoma
653340|NCT00096096|recurrent adult diffuse small cleaved cell lymphoma
653341|NCT00096096|recurrent adult immunoblastic large cell lymphoma
653342|NCT00096096|recurrent mantle cell lymphoma
653343|NCT00096096|recurrent grade 1 follicular lymphoma
653344|NCT00096096|recurrent grade 2 follicular lymphoma
653345|NCT00096096|recurrent grade 3 follicular lymphoma
653346|NCT00096096|recurrent adult lymphoblastic lymphoma
653347|NCT00096096|secondary acute myeloid leukemia
653348|NCT00096096|secondary myelodysplastic syndromes
653349|NCT00096096|adult acute lymphoblastic leukemia in remission
653350|NCT00096096|de novo myelodysplastic syndromes
653351|NCT00096096|previously treated myelodysplastic syndromes
653352|NCT00096096|chronic myelomonocytic leukemia
653353|NCT00096096|refractory anemia with excess blasts in transformation
653354|NCT00096096|refractory anemia with excess blasts
653355|NCT00096096|refractory anemia with ringed sideroblasts
653356|NCT00096096|refractory hairy cell leukemia
653357|NCT00096096|juvenile myelomonocytic leukemia
653358|NCT00096096|chronic eosinophilic leukemia
653359|NCT00096096|chronic neutrophilic leukemia
653360|NCT00096096|chronic phase chronic myelogenous leukemia
653361|NCT00096096|recurrent adult acute lymphoblastic leukemia
653362|NCT00096096|recurrent adult acute myeloid leukemia
653363|NCT00096096|recurrent childhood acute lymphoblastic leukemia
653364|NCT00096096|recurrent childhood acute myeloid leukemia
653365|NCT00096096|recurrent childhood large cell lymphoma
653366|NCT00096096|recurrent childhood lymphoblastic lymphoma
653367|NCT00096096|recurrent childhood small noncleaved cell lymphoma
653368|NCT00096096|recurrent cutaneous T-cell non-Hodgkin lymphoma
653369|NCT00096096|recurrent marginal zone lymphoma
653370|NCT00096096|recurrent small lymphocytic lymphoma
653371|NCT00096096|recurrent/refractory childhood Hodgkin lymphoma
653372|NCT00096096|recurrent mycosis fungoides/Sezary syndrome
653373|NCT00096096|refractory chronic lymphocytic leukemia
653374|NCT00096096|refractory cytopenia with multilineage dysplasia
653375|NCT00096096|stage III adult Hodgkin lymphoma
653376|NCT00096096|stage IV adult Hodgkin lymphoma
653377|NCT00096096|adult acute myeloid leukemia in remission
653378|NCT00096096|childhood acute myeloid leukemia in remission
653379|NCT00096096|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
653380|NCT00096096|adult acute myeloid leukemia with inv(16)(p13;q22)
653381|NCT00096096|adult acute myeloid leukemia with t(15;17)(q22;q12)
653382|NCT00096096|adult acute myeloid leukemia with t(16;16)(p13;q22)
653383|NCT00096096|adult acute myeloid leukemia with t(8;21)(q22;q22)
653384|NCT00096096|childhood acute lymphoblastic leukemia in remission
653385|NCT00096096|childhood chronic myelogenous leukemia
653386|NCT00096096|blastic phase chronic myelogenous leukemia
653387|NCT00096096|stage I multiple myeloma
653388|NCT00096096|stage II multiple myeloma
653389|NCT00096096|stage III multiple myeloma
653390|NCT00096096|myelodysplastic/myeloproliferative disease, unclassifiable
653391|NCT00096096|nodal marginal zone B-cell lymphoma
653392|NCT00096096|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
653393|NCT00096096|splenic marginal zone lymphoma
653394|NCT00096096|atypical chronic myeloid leukemia
653395|NCT00096096|stage III childhood large cell lymphoma
653396|NCT00096096|stage IV childhood large cell lymphoma
653397|NCT00096096|stage III childhood lymphoblastic lymphoma
653398|NCT00096096|stage IV childhood lymphoblastic lymphoma
653399|NCT00096096|stage III childhood small noncleaved cell lymphoma
653400|NCT00096096|stage IV childhood small noncleaved cell lymphoma
653401|NCT00096096|stage III chronic lymphocytic leukemia
653402|NCT00096096|stage IV chronic lymphocytic leukemia
653403|NCT00096096|stage III adult Burkitt lymphoma
653404|NCT00096096|stage III adult diffuse large cell lymphoma
653405|NCT00096096|stage III adult diffuse mixed cell lymphoma
653406|NCT00096096|stage III adult diffuse small cleaved cell lymphoma
653407|NCT00096096|stage III adult immunoblastic large cell lymphoma
653408|NCT00096096|stage III adult lymphoblastic lymphoma
653409|NCT00096096|stage III grade 1 follicular lymphoma
653410|NCT00096096|stage III grade 2 follicular lymphoma
653411|NCT00096096|stage III grade 3 follicular lymphoma
653412|NCT00096096|stage IV adult Burkitt lymphoma
653413|NCT00096096|stage IV adult diffuse large cell lymphoma
653414|NCT00096096|stage IV adult diffuse mixed cell lymphoma
653415|NCT00096096|stage IV adult diffuse small cleaved cell lymphoma
653416|NCT00096096|stage IV adult immunoblastic large cell lymphoma
653417|NCT00096096|stage IV adult lymphoblastic lymphoma
653418|NCT00096096|stage IV grade 1 follicular lymphoma
653419|NCT00096096|stage IV grade 2 follicular lymphoma
653420|NCT00096096|stage IV grade 3 follicular lymphoma
653421|NCT00096096|stage III marginal zone lymphoma
653422|NCT00096096|stage IV marginal zone lymphoma
653423|NCT00096096|stage III small lymphocytic lymphoma
653424|NCT00096096|stage IV small lymphocytic lymphoma
653425|NCT00096096|childhood myelodysplastic syndromes
653426|NCT00096083|advanced adult primary liver cancer
653427|NCT00096083|localized unresectable adult primary liver cancer
653428|NCT00096083|recurrent adult primary liver cancer
653429|NCT00096083|liver metastases
653430|NCT00096083|adenocarcinoma of the colon
653431|NCT00096083|adenocarcinoma of the esophagus
653432|NCT00096083|adenocarcinoma of the extrahepatic bile duct
653433|NCT00096083|adenocarcinoma of the gallbladder
653434|NCT00096083|adenocarcinoma of the pancreas
653435|NCT00096083|adenocarcinoma of the rectum
653436|NCT00096083|adenocarcinoma of the stomach
653437|NCT00096083|carcinoma of the appendix
653438|NCT00096083|recurrent gallbladder cancer
653439|NCT00096083|unresectable gallbladder cancer
653440|NCT00096083|recurrent colon cancer
653441|NCT00096083|stage IV colon cancer
653442|NCT00096083|recurrent esophageal cancer
653443|NCT00096083|stage IV esophageal cancer
653444|NCT00096083|recurrent extrahepatic bile duct cancer
653445|NCT00096083|unresectable extrahepatic bile duct cancer
653446|NCT00096083|recurrent gastric cancer
653447|NCT00096083|stage IV gastric cancer
653448|NCT00096083|recurrent rectal cancer
653449|NCT00096083|stage IV rectal cancer
653450|NCT00096083|small intestine adenocarcinoma
653451|NCT00096083|recurrent small intestine cancer
653452|NCT00096083|recurrent islet cell carcinoma
653453|NCT00096083|recurrent pheochromocytoma
653454|NCT00096083|metastatic pheochromocytoma
653455|NCT00096083|pulmonary carcinoid tumor
653456|NCT00096083|thyroid gland medullary carcinoma
653457|NCT00096083|metastatic gastrointestinal carcinoid tumor
653458|NCT00096083|recurrent gastrointestinal carcinoid tumor
653459|NCT00096083|recurrent pancreatic cancer
653460|NCT00096083|insulinoma
653461|NCT00096083|WDHA syndrome
653462|NCT00096083|glucagonoma
653463|NCT00096083|pancreatic polypeptide tumor
653464|NCT00096083|somatostatinoma
653465|NCT00096083|stage IV pancreatic cancer
653466|NCT00096083|intraocular melanoma
653467|NCT00096083|conjunctival melanoma
653468|NCT00096083|iris melanoma
653469|NCT00096083|recurrent melanoma
653470|NCT00096083|stage IV melanoma
653471|NCT00096057|recurrent breast cancer
653472|NCT00096057|stage IIIA breast cancer
653473|NCT00096057|stage IIIB breast cancer
653474|NCT00096057|stage IIIC breast cancer
653475|NCT00096057|stage IV breast cancer
653476|NCT00096044|refractory chronic lymphocytic leukemia
653477|NCT00096031|adenocarcinoma of the esophagus
653478|NCT00096031|recurrent esophageal cancer
653479|NCT00096031|stage IV esophageal cancer
653480|NCT00096018|stage I chronic lymphocytic leukemia
653481|NCT00096018|stage II chronic lymphocytic leukemia
653482|NCT00096018|stage III chronic lymphocytic leukemia
653483|NCT00096018|stage IV chronic lymphocytic leukemia
653484|NCT00096018|B-cell chronic lymphocytic leukemia
653485|NCT00095992|adult primary hepatocellular carcinoma
653486|NCT00095992|advanced adult primary liver cancer
653487|NCT00095992|localized unresectable adult primary liver cancer
653488|NCT00095992|recurrent adult primary liver cancer
653489|NCT00095953|recurrent melanoma
653490|NCT00095953|stage IV melanoma
653491|NCT00095927|radiation toxicity
653492|NCT00095927|chemotherapeutic agent toxicity
653493|NCT00095927|mucositis
653494|NCT00095927|xerostomia
653495|NCT00095927|stage II squamous cell carcinoma of the lip and oral cavity
653496|NCT00095927|stage III squamous cell carcinoma of the lip and oral cavity
653497|NCT00095927|stage IV squamous cell carcinoma of the lip and oral cavity
653498|NCT00095927|stage II squamous cell carcinoma of the oropharynx
653499|NCT00095927|stage III squamous cell carcinoma of the oropharynx
653500|NCT00095927|stage IV squamous cell carcinoma of the oropharynx
653501|NCT00095927|stage II squamous cell carcinoma of the hypopharynx
653502|NCT00095927|stage III squamous cell carcinoma of the hypopharynx
653503|NCT00095927|stage IV squamous cell carcinoma of the hypopharynx
653504|NCT00095927|stage II squamous cell carcinoma of the larynx
653505|NCT00095927|stage III squamous cell carcinoma of the larynx
653506|NCT00095927|stage IV squamous cell carcinoma of the larynx
653507|NCT00095927|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
653508|NCT00095927|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
653621|NCT00095355|Lithium
653509|NCT00095927|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
653510|NCT00095927|untreated metastatic squamous neck cancer with occult primary
653511|NCT00095927|metastatic squamous neck cancer with occult primary squamous cell carcinoma
653512|NCT00095914|unspecified adult solid tumor, protocol specific
653513|NCT00095901|recurrent squamous cell carcinoma of the nasopharynx
653514|NCT00095901|stage IV squamous cell carcinoma of the nasopharynx
653515|NCT00095901|stage III squamous cell carcinoma of the nasopharynx
653516|NCT00095901|stage II squamous cell carcinoma of the nasopharynx
653517|NCT00095875|stage III squamous cell carcinoma of the hypopharynx
653518|NCT00095875|stage III squamous cell carcinoma of the larynx
653519|NCT00095875|stage III squamous cell carcinoma of the lip and oral cavity
653520|NCT00095875|stage III squamous cell carcinoma of the oropharynx
653521|NCT00095875|stage IV squamous cell carcinoma of the hypopharynx
653522|NCT00095875|stage IV squamous cell carcinoma of the larynx
653523|NCT00095875|stage IV squamous cell carcinoma of the lip and oral cavity
653524|NCT00095875|stage IV squamous cell carcinoma of the oropharynx
653525|NCT00095862|recurrent breast cancer
653526|NCT00095862|stage IV breast cancer
653527|NCT00095862|male breast cancer
653528|NCT00095862|unspecified adult solid tumor, protocol specific
653529|NCT00095836|recurrent thyroid cancer
653530|NCT00095836|stage III follicular thyroid cancer
653531|NCT00095836|stage III papillary thyroid cancer
653532|NCT00095836|stage IV follicular thyroid cancer
653533|NCT00095836|stage IV papillary thyroid cancer
653534|NCT00095836|anaplastic thyroid cancer
653535|NCT00095836|thyroid gland medullary carcinoma
653536|NCT00095810|Psychosis, Parkinson's Disease
653537|NCT00095771|untreated childhood brain stem glioma
653538|NCT00095771|childhood high-grade cerebral astrocytoma
653539|NCT00095732|Pancreatic Insufficiency
653540|NCT00095732|Cystic Fibrosis
653541|NCT00095732|Enzymes
653542|NCT00095719|Acute agitation in patients diagnosed with Dementia
653543|NCT00095706|Metastatic breast cancer
653544|NCT00095706|HER2
653545|NCT00095706|Trastuzumab
653546|NCT00095706|Herceptin
653547|NCT00095706|VEGF
653548|NCT00095706|Bevacizumab
653549|NCT00095706|Avastin
653550|NCT00095680|Multiple Myeloma
653551|NCT00095680|SCIO-469
653552|NCT00095680|Bortezomib
653553|NCT00095680|p38 MAP kinase
653554|NCT00095654|diabetes prevention
653555|NCT00095654|ramipril
653556|NCT00095654|rosiglitazone
653557|NCT00095654|impaired glucose tolerance
653558|NCT00095654|isolated impaired fasting glucose
653559|NCT00095654|Isolated Impaired Glucose Tolerance
653560|NCT00095589|bladder cancer
653561|NCT00095589|stage 0 bladder cancer
653562|NCT00095589|stage I bladder cancer
653563|NCT00095589|transitional cell carcinoma of the bladder
653564|NCT00095550|Moderate Hypertension
653565|NCT00095537|Solid tumors
653566|NCT00095537|cancer
653567|NCT00095537|HER-2-expressing tumors
653568|NCT00095524|Patient weight change
653569|NCT00095524|changes in metabolic status
653570|NCT00095511|Bipolar Mania
653571|NCT00095498|arthritis
653572|NCT00095498|joint pain
653573|NCT00095498|Methotrexate
653574|NCT00095485|Activity Level
653575|NCT00095485|Musculoskeletal
653576|NCT00095485|Healthy Volunteer
653577|NCT00095485|Physical Activity
653578|NCT00095472|Blood Flow
653579|NCT00095472|Nitric Oxide
653580|NCT00095472|Vascular Function
653581|NCT00095472|Vasodilation
653582|NCT00095472|Vaso-Occlusive Pain Crisis
653583|NCT00095472|Sickle Cell Disease
653584|NCT00095459|Raf-Kinase Inhibitor
653585|NCT00095459|Combinatorial Therapy
653586|NCT00095459|Pathway Profiling
653587|NCT00095459|VEGFR
653588|NCT00095459|Bevacizumab
653589|NCT00095459|Sorafenib
653590|NCT00095459|Advanced Solid Tumors
653591|NCT00095459|Angiogenesis
653592|NCT00095459|Targeted Therapy
653593|NCT00095459|VEGF
653594|NCT00095459|Cancer
653595|NCT00095459|Solid Tumor
653596|NCT00095459|Metastatic Uresectable Solid Tumors
653597|NCT00095446|Diabetes Mellitus
653598|NCT00095446|Diabetes
653599|NCT00095433|AMD
653600|NCT00095433|Neovascular age-related macular degeneration
653601|NCT00095420|Interpersonal Relationships
653602|NCT00095420|Child
653603|NCT00095407|Social Cognition
653604|NCT00095407|Semantic Memory
653605|NCT00095407|Prefrontal Cortex
653606|NCT00095407|Temporal Cortex
653607|NCT00095407|Conceptual Self
653608|NCT00095394|Severe Hypertension
653609|NCT00095381|Leukemia, Lymphocytic, T-Cell
653610|NCT00095381|Entry Term Lymphocytic Leukemia, T-Cell
653611|NCT00095381|T-Cell Leukemia
653612|NCT00095381|T-Lymphocytic Leukemia
653613|NCT00095381|Leukemia, Lymphocytic, T Cell
653614|NCT00095381|T Lymphocytic Leukemia
653615|NCT00095381|BCX-1777
653616|NCT00095381|forodesine hydrochloride
653617|NCT00095381|BioCryst
653618|NCT00095368|Pharyngitis
653619|NCT00095368|Tonsillitis
653620|NCT00095355|BDNF
653622|NCT00095355|Divalproex
653623|NCT00095355|Huntington Disease
653624|NCT00095355|HD
653625|NCT00095329|relapsing-remitting MS
653626|NCT00095329|nonresponsive to standard of care MS
653627|NCT00095329|sirolimus
653628|NCT00095316|candidiasis, caspofungin, fungal infection, prophylaxis
653629|NCT00095303|BSFT
653630|NCT00095303|Family Therapy
653631|NCT00095303|Adolescents
653632|NCT00095303|Substance Abuse
653633|NCT00095290|Albuminuria
653634|NCT00095290|Hypertension
653635|NCT00095290|Elevated Cardiovascular Risk
653636|NCT00095290|Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk
653637|NCT00095277|non-myeloid malignancies
653638|NCT00095277|myeloma
653639|NCT00095277|Anemia of Cancer
653640|NCT00095264|Myelodysplastic Syndrome
653641|NCT00095251|Delirium
653642|NCT00095251|Hypnotics and Sedatives
653643|NCT00095251|Adrenergic alpha-Agonists
653644|NCT00095251|efficacy of sedation
653645|NCT00095251|cognitive impairment
653646|NCT00095225|Recurrent or refractory non-small cell lung cancer
653647|NCT00095212|HIV
653648|NCT00095212|women
653649|NCT00095212|androgen
653650|NCT00095212|Treatment Experienced
653651|NCT00095199|Recurrent or Progressive Non-Small Cell Lung Cancer
653652|NCT00095199|Second-line therapy
653653|NCT00095199|Docetaxel
653654|NCT00095199|Pemetrexed
653655|NCT00095199|Cetuximab
653656|NCT00095199|Failed platinum-based therapy
653657|NCT00095199|NSCLC
653658|NCT00095186|Cancer
653659|NCT00095186|Metastatic
653660|NCT00095186|Kidney
653661|NCT00095186|Refractive
653662|NCT00095186|Lactoferrin
653663|NCT00095186|Oral
653664|NCT00095173|Juvenile Idiopathic Arthritis
653665|NCT00095160|Solid Organ Tumors
653666|NCT00095121|Hepatitis B
653667|NCT00095121|Children
653668|NCT00095121|Pediatric
653669|NCT00095121|Adefovir Dipivoxil
653670|NCT00095108|Metastatic Melanoma
653671|NCT00095108|Metastatic Renal Cell Carcinoma
653672|NCT00095095|Spine
653673|NCT00095095|Lumbar spine
653674|NCT00095095|Spinal fusion
653675|NCT00095095|Low back pain
653676|NCT00095095|Fusion cage
653677|NCT00095095|Posterior lumbar interbody fusion
653678|NCT00095095|Bioresorbable
653679|NCT00095095|Peek
653680|NCT00095082|Diabetes Mellitus, Type I
653681|NCT00095056|Type 2 Diabetes Mellitus and Chronic Renal Insufficiency
653682|NCT00095030|Diabetes
653683|NCT00095017|Arcoxia
653684|NCT00094991|Type 2 diabetes
653685|NCT00094978|Apoptosis
653686|NCT00094978|Toxicity
653687|NCT00094978|Pharmacokinetic
653688|NCT00094978|Gene Induction
653689|NCT00094978|Maximally Tolerated Dose
653690|NCT00094978|Small Cell Lung Cancer
653691|NCT00094978|SCLC
653692|NCT00094978|Non-Small Cell Lung Cancer
653693|NCT00094978|NSCLC
653694|NCT00094978|Esophageal Cancer
653695|NCT00094978|Pleural Mesothelioma
653696|NCT00094965|Advanced Gastrointestinal tumors and normal to severely abnormal renal function
653697|NCT00094952|Mild Cognitive Impairment
653698|NCT00094952|Alzheimer's disease
653699|NCT00094952|magnetic resonance imaging
653700|NCT00094952|cerebrospinal fluid (CSF) biomarkers
653701|NCT00094939|mild cognitive impairment
653702|NCT00094939|Alzheimer disease
653703|NCT00094939|magnetic resonance imaging
653704|NCT00094939|CSF tau protein
653705|NCT00094939|Hippocampus
653706|NCT00094926|Risperidal CONSTA
653707|NCT00094926|Bipolar disorder
653708|NCT00094926|mood episodes
653709|NCT00094926|Safety and efficacy, adjuvant therapy
653710|NCT00094913|Aging
653711|NCT00094913|Mild Cognitive Impairment
653712|NCT00094913|Alzheimer disease, preclinical
653713|NCT00094913|Hippocampal formation
653714|NCT00094913|Glucose metabolism
653715|NCT00094900|Muckle Wells Syndrome
653716|NCT00094900|NOMID
653717|NCT00094900|Adult Stills Disease
653718|NCT00094900|Familial Mediterranean
653719|NCT00094900|Treatment Trial/Fever
653720|NCT00094900|Autoinflammatory Disease
653721|NCT00094887|Blood Flow
653722|NCT00094887|Nitric Oxide
653723|NCT00094887|Pain Crisis
653724|NCT00094887|Sickle Cell Anemia
653725|NCT00094887|Vaso-Occlusive Crisis
653726|NCT00094887|Sickle Cell Disease
653727|NCT00094887|SCD
653728|NCT00094874|pelvic pain, bladder pain, urgency, frequency, nocturia
653729|NCT00094861|dysphagia
653730|NCT00094861|palifermin, KGF
653731|NCT00094861|chemoradiotherapy
653732|NCT00094861|NSCLC, non-small cell lung cancer
653733|NCT00094861|lung cancer
653734|NCT00094861|supportive care
653735|NCT00094861|clinical trial
653736|NCT00094861|consolidation chemotherapy
653737|NCT00094861|radiotherapy
653738|NCT00094835|Lung cancer, Non-small cell lung cancer, NSCLC
653739|NCT00094835|Clinical Trial, Panitumumab, AMG 706
653740|NCT00094835|Anti-angiogenesis
653741|NCT00094835|Immunex, Abgenix, Amgen
654312|NCT00091936|DOT
653742|NCT00094835|Stage IIIB, Stage IV, Unresectable
653743|NCT00094822|Metastatic Cancer
653744|NCT00094822|Neulasta®
653746|NCT00094809|Neulasta®
653747|NCT00094809|pegfilgrastim
653748|NCT00094809|Advanced
653749|NCT00094809|Chemotherapy
653750|NCT00094796|Insulin Resistance
653751|NCT00094796|Brachial Artery Reactivity
653752|NCT00094796|Endothelial Progenitor Cells
653753|NCT00094796|Metabolic Stress Test
653754|NCT00094796|Mitochondrial Function
653755|NCT00094796|Type 2 Diabetes
653756|NCT00094796|T2DM
653757|NCT00094796|Pre-Diabetes
653758|NCT00094783|Magnetic Resonance Imaging
653759|NCT00094783|Interventional MRI
653760|NCT00094783|Arterial Stenosis
653761|NCT00094783|Revascularization
653762|NCT00094783|Lllac Artery Stenosis
653763|NCT00094783|Peripheral Arterial Disease
653764|NCT00094783|Cardiovascular Disease
653765|NCT00094731|Aging
653766|NCT00094731|Memory
653767|NCT00094731|Mental Recall
653768|NCT00094731|Mental Processes
653769|NCT00094718|Chimeric Virus Vaccine
653770|NCT00094718|West Nile Virus
653771|NCT00094718|Dengue Virus
653772|NCT00094705|Dengue Vaccine
653773|NCT00094705|Dengue Virus
653774|NCT00094705|Dengue Hemorrhagic Fever
653775|NCT00094705|Dengue Shock Syndrome
653776|NCT00094692|Amblyopia
653777|NCT00094692|Patching
653778|NCT00094692|Spectacles
653779|NCT00094653|melanoma
653780|NCT00094653|metastatic melanoma
653781|NCT00094653|skin cancer
653782|NCT00094601|Positron Emission Tomograhy
653783|NCT00094601|[18F] FDOPA
653784|NCT00094601|[11C] NNC-112
653785|NCT00094601|Dopamine
653786|NCT00094601|Molecular Imaging
653787|NCT00094601|Dopamine D1 Receptor
653788|NCT00094601|PET
653789|NCT00094601|Parkinson's Disease
653790|NCT00094601|Cognition
653791|NCT00094601|Parkinson Disease
653792|NCT00094601|PD
653793|NCT00094601|Healthy Volunteer
653794|NCT00094601|HV
653795|NCT00094575|Abdominal
653796|NCT00094575|Aortic Aneurysm
653797|NCT00094575|cost of AAA repair
653798|NCT00094575|Endovascular Repair
653799|NCT00094575|Grafts
653800|NCT00094575|Long-term survival
653801|NCT00094575|secondary outcomes
653802|NCT00094562|Cancer
653803|NCT00094562|Cancer Cachexia
653804|NCT00094562|Weight Loss
653805|NCT00094562|Chronic Obstructive Pulmonary Disease
653806|NCT00094562|Chronic Heart Failure
653807|NCT00094562|Rheumatoid Arthritis
653808|NCT00094536|Menorrhagia
653809|NCT00094536|Excessive Uterine Bleeding
653810|NCT00094536|Cryoablation
653811|NCT00094536|Menstrual disorder
653812|NCT00094536|Endometrial ablation
653813|NCT00094536|Abnormal uterine bleeding
653814|NCT00094536|Dysfunctional uterine bleeding
653815|NCT00094523|fosamprenavir LEXIVA non-inferiority safety tolerability
653816|NCT00094510|Prefrontal GABA
653817|NCT00094510|Stress
653818|NCT00094510|Emotion Recognition
653819|NCT00094510|Differential Reward
653820|NCT00094510|Gabapentin
653821|NCT00094510|GABA
653822|NCT00094510|Prefrontal Cortex
653823|NCT00094510|Emotional Processing
653824|NCT00094510|Healthy Humans
653825|NCT00094510|Healthy Volunteer
653826|NCT00094510|HV
653827|NCT00094484|Sensipar®
653828|NCT00094484|Mimpara®
653829|NCT00094484|Cinacalcet
653830|NCT00094484|Calcimimetic
653831|NCT00094484|Chronic Kidney Disease
653832|NCT00094458|Crohn's Disease
653833|NCT00094458|infliximab
653834|NCT00094458|azathioprine
653835|NCT00094458|Remicade
653836|NCT00094458|SONIC
653837|NCT00094445|Pancreatic Cancer
653838|NCT00094445|Adenocarcinoma of the pancreas
653839|NCT00094445|Alternative therapy
653840|NCT00094445|Pancreas
653841|NCT00094445|Pancreatic Neoplasm
653842|NCT00094445|Cancer of the pancreas
653843|NCT00094432|depressed
653844|NCT00094419|Complementary Therapies
653845|NCT00094406|Lung Permeability
653846|NCT00094406|Endotoxin Tolerance
653847|NCT00094406|Bronchoscopy
653848|NCT00094406|Carbon Monoxide Inhalation
653849|NCT00094393|Ageing
653850|NCT00094393|Atherosclerosis
653851|NCT00094393|Lamin A
653852|NCT00094393|Lipodystrophy
653853|NCT00094393|Growth Impairment
653854|NCT00094393|Premature Aging
653855|NCT00094393|Hutchinson-Gilford Progeria Syndrome
653856|NCT00094393|HGPS
653857|NCT00094380|SLE
653858|NCT00094380|Lupus
653859|NCT00094380|Systemic Lupus Erythematosus
653860|NCT00094380|Lupus Nephritis
653861|NCT00094367|1592U89
653862|NCT00094367|GR109714
653863|NCT00094367|abacavir
653864|NCT00094367|lamivudine
653865|NCT00094367|fixed-dose combination
653866|NCT00094367|once-daily
653867|NCT00094367|twice-daily
653868|NCT00094367|HIV infection
653869|NCT00094367|naive
653870|NCT00094354|HIV infected former Plasma Donors
653871|NCT00094354|Needs assessment
653872|NCT00094354|HIV-related stigma and discrimination
653873|NCT00094354|In-depth interview
653874|NCT00094354|Focus Groups
653875|NCT00094341|Arthritis
653876|NCT00094341|Rheumatology
653877|NCT00094328|Testotoxicosis
653878|NCT00094328|Familial Male-limited Precocious Puberty (FMPP)
653879|NCT00094302|Heart Failure
653880|NCT00094302|Diastolic Heart Failure
653881|NCT00094302|Preserved Ejection Fraction
653882|NCT00094172|Early Multiple Sclerosis
653883|NCT00094172|MS
653884|NCT00094172|Clinically Isolated Syndrome
653885|NCT00094146|Primary Insulin Hypersecretion
653886|NCT00094146|PIH
653887|NCT00094146|Obesity
653888|NCT00094133|cancer survivor
653889|NCT00094133|stage IA breast cancer
653890|NCT00094133|stage IB breast cancer
653891|NCT00094133|stage II breast cancer
653892|NCT00094133|stage IIIA breast cancer
653893|NCT00094133|stage IIIB breast cancer
653894|NCT00094133|stage IIIC breast cancer
653895|NCT00094133|stage IV breast cancer
653896|NCT00094133|breast cancer in situ
653897|NCT00094133|inflammatory breast cancer
653898|NCT00094133|hot flashes
653899|NCT00094120|Age-Related Macular Degeneration - Wet Type
653900|NCT00094107|melanoma
653901|NCT00094107|antiangiogenesis
653902|NCT00094081|squamous cell carcinoma
653903|NCT00094081|oropharynx
653904|NCT00094081|oral cavity
653905|NCT00094081|larynx
653906|NCT00094081|hypopharynx
653907|NCT00094068|Gray Matter
653908|NCT00094068|White Matter
653909|NCT00094068|Cerebral Blood Flow
653910|NCT00094068|Cerebral Blood Volume
653911|NCT00094068|Lesion
653912|NCT00094068|MRI
653913|NCT00094068|Multiple Sclerosis
653914|NCT00094068|Perfusion
653915|NCT00094068|Imaging
653916|NCT00094068|Sildenafil
653917|NCT00094068|MS
653918|NCT00094068|Healthy Volunteer
653919|NCT00094068|HV
653920|NCT00094042|Socioeconomic Factors
653921|NCT00094042|Dietary Supplementation
653922|NCT00094003|Liver metastases
653923|NCT00094003|Colorectal cancer
653924|NCT00094003|Gastric cancer
653925|NCT00094003|Esophagus cancer
653926|NCT00094003|Breast cancer
653927|NCT00094003|Lung cancer
653928|NCT00094003|Skin cancer
653929|NCT00094003|Renal Cancer
653930|NCT00094003|Liver metastasis
653931|NCT00093990|Myeloid leukemia acute disease
653932|NCT00093990|Tipifarnib
653933|NCT00093990|Bone marrow aspirate
653934|NCT00093977|Chronic Kidney Disease
653935|NCT00093977|Dialysis
653936|NCT00093977|Anemia
653937|NCT00093977|Nephrology
653938|NCT00093964|brain cancer
653939|NCT00093964|brain tumor
653940|NCT00093951|Alzheimer disease
653941|NCT00093951|memory
653942|NCT00093951|cognition
653943|NCT00093951|GABA(B)receptor antagonist
653944|NCT00093938|Vaccinium macrocarpon
653945|NCT00093938|Asymptomatic Bacteriuria
653946|NCT00093925|Postoperative hypertension
653947|NCT00093912|Perioperative Hypertension
653948|NCT00093899|Mixed Hyperlipidemia
653949|NCT00093886|Preoperative hypertension
653950|NCT00093873|Cancer
653951|NCT00093873|antiangiogenesis
653952|NCT00093873|Solid Tumors
653953|NCT00093860|Adrenaline
653954|NCT00093860|Norepinephrine
653955|NCT00093860|Sympathetic Nervous System
653956|NCT00093860|Fainting
653957|NCT00093860|Hypotension
653958|NCT00093860|Beta-Adrenoceptors
653959|NCT00093860|Neurocardiogenic Syncope
653960|NCT00093860|Chronic Orthostatic Intolerance
653961|NCT00093860|Sympathoadrenal Imbalance
653962|NCT00093860|SAI
653963|NCT00093860|Children
653964|NCT00093847|Selective Serotonin Reuptake Inhibitors
653965|NCT00093847|S-adenosyl Methionine
653966|NCT00093847|SSRI
653967|NCT00093847|SAMe
653968|NCT00093834|stage IV breast cancer
653969|NCT00093834|recurrent breast cancer
653970|NCT00093808|recurrent breast cancer
653971|NCT00093808|stage IV breast cancer
653972|NCT00093808|male breast cancer
653973|NCT00093795|stage II breast cancer
653974|NCT00093795|stage IIIA breast cancer
653975|NCT00093795|stage IIIC breast cancer
653976|NCT00093769|recurrent grade 1 follicular lymphoma
653977|NCT00093769|recurrent grade 2 follicular lymphoma
653978|NCT00093769|recurrent grade 3 follicular lymphoma
653979|NCT00093769|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
653980|NCT00093769|nodal marginal zone B-cell lymphoma
653981|NCT00093769|recurrent marginal zone lymphoma
653982|NCT00093769|splenic marginal zone lymphoma
653983|NCT00093730|unspecified adult solid tumor, protocol specific
653984|NCT00093704|recurrent adult Hodgkin lymphoma
653985|NCT00093704|recurrent adult Burkitt lymphoma
653986|NCT00093704|post-transplant lymphoproliferative disorder
653987|NCT00093704|recurrent adult grade III lymphomatoid granulomatosis
653988|NCT00093704|angioimmunoblastic T-cell lymphoma
653989|NCT00093704|adult grade III lymphomatoid granulomatosis
653990|NCT00093678|pain
653991|NCT00093678|cachexia
654191|NCT00093093|Ribavirin
653992|NCT00093678|unspecified adult solid tumor, protocol specific
653993|NCT00093678|recurrent uterine sarcoma
653994|NCT00093678|stage III uterine sarcoma
653995|NCT00093678|stage IV uterine sarcoma
653996|NCT00093678|ovarian sarcoma
653997|NCT00093678|recurrent adult soft tissue sarcoma
653998|NCT00093678|stage III adult soft tissue sarcoma
653999|NCT00093678|stage IV adult soft tissue sarcoma
654000|NCT00093678|recurrent melanoma
654001|NCT00093678|stage III melanoma
654002|NCT00093678|stage IV melanoma
654003|NCT00093678|chondrosarcoma
654004|NCT00093678|metastatic osteosarcoma
654005|NCT00093678|recurrent osteosarcoma
654006|NCT00093678|classic Kaposi sarcoma
654007|NCT00093678|AIDS-related Kaposi sarcoma
654008|NCT00093678|recurrent Kaposi sarcoma
654009|NCT00093678|stage III adult Burkitt lymphoma
654010|NCT00093678|stage III adult diffuse large cell lymphoma
654011|NCT00093678|stage III adult diffuse mixed cell lymphoma
654012|NCT00093678|stage III adult diffuse small cleaved cell lymphoma
654013|NCT00093678|stage III adult immunoblastic large cell lymphoma
654014|NCT00093678|stage III adult lymphoblastic lymphoma
654015|NCT00093678|stage III grade 1 follicular lymphoma
654016|NCT00093678|stage III grade 2 follicular lymphoma
654017|NCT00093678|stage III grade 3 follicular lymphoma
654018|NCT00093678|stage III mantle cell lymphoma
654019|NCT00093678|stage III marginal zone lymphoma
654020|NCT00093678|stage III small lymphocytic lymphoma
654021|NCT00093678|stage IV adult Burkitt lymphoma
654022|NCT00093678|stage IV adult diffuse large cell lymphoma
654023|NCT00093678|stage IV adult diffuse mixed cell lymphoma
654024|NCT00093678|stage IV adult diffuse small cleaved cell lymphoma
654025|NCT00093678|stage IV adult immunoblastic large cell lymphoma
654026|NCT00093678|stage IV adult lymphoblastic lymphoma
654027|NCT00093678|stage IV grade 1 follicular lymphoma
654028|NCT00093678|stage IV grade 2 follicular lymphoma
654029|NCT00093678|stage IV grade 3 follicular lymphoma
654030|NCT00093678|stage IV mantle cell lymphoma
654031|NCT00093678|stage IV marginal zone lymphoma
654032|NCT00093678|stage IV small lymphocytic lymphoma
654033|NCT00093678|intraocular lymphoma
654034|NCT00093678|recurrent adult Burkitt lymphoma
654035|NCT00093678|recurrent adult diffuse large cell lymphoma
654036|NCT00093678|recurrent adult diffuse mixed cell lymphoma
654037|NCT00093678|recurrent adult diffuse small cleaved cell lymphoma
654038|NCT00093678|recurrent adult immunoblastic large cell lymphoma
654039|NCT00093678|recurrent adult lymphoblastic lymphoma
654040|NCT00093678|recurrent grade 1 follicular lymphoma
654041|NCT00093678|recurrent grade 2 follicular lymphoma
654042|NCT00093678|recurrent grade 3 follicular lymphoma
654043|NCT00093678|recurrent mantle cell lymphoma
654044|NCT00093678|recurrent marginal zone lymphoma
654045|NCT00093678|recurrent small lymphocytic lymphoma
654046|NCT00093678|primary central nervous system lymphoma
654047|NCT00093678|recurrent adult Hodgkin lymphoma
654048|NCT00093678|stage III adult Hodgkin lymphoma
654049|NCT00093678|stage IV adult Hodgkin lymphoma
654050|NCT00093678|recurrent cutaneous T-cell non-Hodgkin lymphoma
654051|NCT00093678|stage III cutaneous T-cell non-Hodgkin lymphoma
654052|NCT00093678|stage IV cutaneous T-cell non-Hodgkin lymphoma
654053|NCT00093678|anaplastic large cell lymphoma
654054|NCT00093678|angioimmunoblastic T-cell lymphoma
654055|NCT00093678|Waldenstrom macroglobulinemia
654056|NCT00093678|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
654057|NCT00093678|nodal marginal zone B-cell lymphoma
654058|NCT00093678|splenic marginal zone lymphoma
654059|NCT00093678|adult grade III lymphomatoid granulomatosis
654060|NCT00093678|recurrent adult grade III lymphomatoid granulomatosis
654061|NCT00093678|recurrent mycosis fungoides/Sezary syndrome
654062|NCT00093678|stage III mycosis fungoides/Sezary syndrome
654063|NCT00093678|stage IV mycosis fungoides/Sezary syndrome
654064|NCT00093678|recurrent adult T-cell leukemia/lymphoma
654065|NCT00093678|stage III adult T-cell leukemia/lymphoma
654066|NCT00093678|stage IV adult T-cell leukemia/lymphoma
654067|NCT00093678|AIDS-related peripheral/systemic lymphoma
654068|NCT00093678|AIDS-related primary CNS lymphoma
654069|NCT00093678|immunosuppressive treatment related Kaposi sarcoma
654070|NCT00093665|stage II lymphoepithelioma of the nasopharynx
654071|NCT00093665|stage III lymphoepithelioma of the nasopharynx
654072|NCT00093665|stage IV lymphoepithelioma of the nasopharynx
654073|NCT00093665|stage II squamous cell carcinoma of the nasopharynx
654074|NCT00093665|stage III squamous cell carcinoma of the nasopharynx
654075|NCT00093665|stage IV squamous cell carcinoma of the nasopharynx
654076|NCT00093652|adenocarcinoma of the esophagus
654077|NCT00093652|recurrent esophageal cancer
654078|NCT00093652|stage II esophageal cancer
654079|NCT00093652|stage III esophageal cancer
654080|NCT00093652|stage IV esophageal cancer
654081|NCT00093652|squamous cell carcinoma of the esophagus
654082|NCT00093639|chronic phase chronic myelogenous leukemia
654083|NCT00093639|chronic myelogenous leukemia, BCR-ABL1 positive
654084|NCT00093600|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
654085|NCT00093600|adult acute myeloid leukemia with inv(16)(p13;q22)
654086|NCT00093600|adult acute myeloid leukemia with t(15;17)(q22;q12)
654087|NCT00093600|adult acute myeloid leukemia with t(16;16)(p13;q22)
654088|NCT00093600|adult acute myeloid leukemia with t(8;21)(q22;q22)
654089|NCT00093600|untreated adult acute myeloid leukemia
654090|NCT00093587|graft versus host disease
654091|NCT00093587|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
654092|NCT00093587|adult acute myeloid leukemia with inv(16)(p13;q22)
654093|NCT00093587|adult acute myeloid leukemia with t(15;17)(q22;q12)
654094|NCT00093587|adult acute myeloid leukemia with t(16;16)(p13;q22)
654095|NCT00093587|adult acute myeloid leukemia with t(8;21)(q22;q22)
654096|NCT00093587|secondary acute myeloid leukemia
654097|NCT00093587|adult acute lymphoblastic leukemia in remission
654098|NCT00093587|adult acute myeloid leukemia in remission
654099|NCT00093561|prostate cancer
654100|NCT00093548|adult primary hepatocellular carcinoma
654101|NCT00093548|advanced adult primary liver cancer
654102|NCT00093548|localized resectable adult primary liver cancer
654103|NCT00093548|localized unresectable adult primary liver cancer
654104|NCT00093522|recurrent renal cell cancer
654105|NCT00093522|stage IV renal cell cancer
654106|NCT00093509|stage I adult soft tissue sarcoma
654107|NCT00093509|stage II adult soft tissue sarcoma
654108|NCT00093509|stage III adult soft tissue sarcoma
654109|NCT00093509|stage IV adult soft tissue sarcoma
654110|NCT00093483|adult acute basophilic leukemia
654111|NCT00093483|adult acute eosinophilic leukemia
654112|NCT00093483|adult erythroleukemia (M6a)
654113|NCT00093483|adult pure erythroid leukemia (M6b)
654114|NCT00093483|adult acute megakaryoblastic leukemia (M7)
654115|NCT00093483|adult acute minimally differentiated myeloid leukemia (M0)
654116|NCT00093483|adult acute monoblastic leukemia (M5a)
654117|NCT00093483|adult acute monocytic leukemia (M5b)
654118|NCT00093483|adult acute myeloblastic leukemia with maturation (M2)
654119|NCT00093483|adult acute myeloblastic leukemia without maturation (M1)
654120|NCT00093483|adult acute myelomonocytic leukemia (M4)
654121|NCT00093483|adult acute myeloid leukemia with t(8;21)(q22;q22)
654122|NCT00093483|adult acute myeloid leukemia with t(16;16)(p13;q22)
654123|NCT00093483|adult acute myeloid leukemia with inv(16)(p13;q22)
654124|NCT00093483|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
654125|NCT00093483|untreated adult acute myeloid leukemia
654126|NCT00093483|secondary acute myeloid leukemia
654127|NCT00093470|Leukemia
654128|NCT00093470|Acute Myeloid Leukemia
654129|NCT00093470|AML
654130|NCT00093470|Farnesyl Transferase Inhibitor
654131|NCT00093470|R115777
654132|NCT00093457|recurrent prostate cancer
654133|NCT00093457|stage IV prostate cancer
654134|NCT00093457|adenocarcinoma of the prostate
654135|NCT00093444|advanced adult primary liver cancer
654136|NCT00093444|liver metastases
654137|NCT00093444|localized unresectable adult primary liver cancer
654138|NCT00093444|recurrent adult primary liver cancer
654139|NCT00093405|recurrent renal cell cancer
654140|NCT00093405|stage IV renal cell cancer
654141|NCT00093405|clear cell renal cell carcinoma
654142|NCT00093379|stage II anal cancer
654143|NCT00093379|stage IIIA anal cancer
654144|NCT00093379|stage IIIB anal cancer
654145|NCT00093379|squamous cell carcinoma of the anus
654146|NCT00093379|Capecitabine
654147|NCT00093379|Xeloda
654148|NCT00093379|Oxaliplatin
654149|NCT00093379|Eloxatin
654150|NCT00093379|Radiotherapy
654151|NCT00093379|XRT
654152|NCT00093366|de novo myelodysplastic syndromes
654153|NCT00093366|previously treated myelodysplastic syndromes
654154|NCT00093366|secondary myelodysplastic syndromes
654155|NCT00093366|myelodysplastic/myeloproliferative disease, unclassifiable
654156|NCT00093366|atypical chronic myeloid leukemia
654157|NCT00093366|chronic myelomonocytic leukemia
654158|NCT00093353|diarrhea
654159|NCT00093353|drug/agent toxicity by tissue/organ
654160|NCT00093353|disseminated neuroblastoma
654161|NCT00093353|recurrent neuroblastoma
654162|NCT00093314|Chronic Lymphocytic Leukemia
654163|NCT00093314|B-cell Lymphoma
654164|NCT00093301|Shock
654165|NCT00093301|Levosimendan
654166|NCT00093301|Inotropes
654167|NCT00093301|Dobutamine
654168|NCT00093301|Heart failure
654169|NCT00093301|Sepsis
654170|NCT00093288|MDD
654171|NCT00093288|bupropion
654172|NCT00093288|Depression
654173|NCT00093262|Postoperative Hypertension
654174|NCT00093249|Pre-operative hypertension
654175|NCT00093223|In-Stent Restenosis
654176|NCT00093184|ST-Segment Elevation
654177|NCT00093184|Acute Myocardial Infarction
654178|NCT00093184|PCI
654179|NCT00093184|Percutaneous Coronary Intervention
654180|NCT00093158|Acute Coronary Syndromes
654181|NCT00093145|Advanced Breast Cancer
654182|NCT00093132|Non-Small Cell Lung Cancer (stage II or III)
654183|NCT00093132|NSCLC
654184|NCT00093132|Squamous Cell Lung Cancer
654185|NCT00093132|adenocarcinoma of the lung
654186|NCT00093132|adenosquamous cell lung cancer
654187|NCT00093132|bronchoalveolar cell lung cancer
654188|NCT00093132|carcinoma, non-small cell lung
654189|NCT00093119|Metastatic Melanoma
654190|NCT00093093|Viramidine
654192|NCT00093093|Valeant
654193|NCT00093093|Hepatitis C
654194|NCT00093093|Pegylated interferon alfa-2a
654195|NCT00093080|Metastatic and/or unresectable soft tissue or
654196|NCT00093067|Gram-positive bacterial infections
654197|NCT00093067|Staph Aureus
654198|NCT00093067|endocarditis
654199|NCT00093067|bacteremia
654200|NCT00093067|Cubist
654201|NCT00093054|Vaccinium macrocarpon
654202|NCT00093041|Head and neck cancer
654203|NCT00093041|squamous cell carcinoma of the head and neck
654204|NCT00093028|Myeloma
654205|NCT00093028|Revlimid
654206|NCT00093028|bortezomib
654207|NCT00093028|CC-5013
654208|NCT00093028|Dexamethasone
654209|NCT00093002|Early Breast Cancer
654210|NCT00093002|neoadjuvant therapy
654211|NCT00093002|hormonal treatment
654212|NCT00093002|newly diagnosed breast cancer
654213|NCT00093002|Estrogen Receptor Positive Breast Cancer
654214|NCT00093002|treatment naïve
654215|NCT00093002|neoadjuvant treatment
654216|NCT00093002|neoadjuvant setting
654217|NCT00093002|invasive breast cancer
654218|NCT00092976|Hemophilia A
654219|NCT00092950|Exercise
654220|NCT00092950|Pedometer
654221|NCT00092950|Physician Prescription
654222|NCT00092950|Biomarkers
654223|NCT00092950|Compliance
654224|NCT00092950|Breast Cancer Survivor
654225|NCT00092950|Breast Cancer Risk
654226|NCT00092937|Chronic Granulomatous Disease
654227|NCT00092937|Nonmyeloablative
654228|NCT00092937|CD34 Positive Cells
654229|NCT00092937|Donor Engraftment
654230|NCT00092937|Myeloid Chimerism
654231|NCT00092898|Sitosterolemia
654232|NCT00092846|High Blood Cholesterol Levels
654233|NCT00092820|Homozygous Sitosterolemia
654234|NCT00092807|Homozygous Sitosterolemia
654235|NCT00092781|Arcoxia
654236|NCT00092768|Arcoxia
654237|NCT00092755|Arcoxia
654238|NCT00092742|Arcoxia
654239|NCT00092703|Arcoxia
654240|NCT00092664|Primary hypercholesterolemia
654241|NCT00092651|Primary hypercholesterolemia
654242|NCT00092638|Elevated Cholesterol
654243|NCT00092625|Elevated Cholesterol
654244|NCT00092612|Elevated Cholesterol
654245|NCT00092599|Elevated Cholesterol
654246|NCT00092573|Mixed hyperlipidemia (high cholesterol and high triglycerides)
654247|NCT00092560|mixed hyperlipidemia
654248|NCT00092560|high cholesterol
654249|NCT00092560|high triglycerides
654250|NCT00092508|Ulcerative Colitis Remission
654251|NCT00092508|ulcerative
654252|NCT00092508|colitis
654253|NCT00092508|remission
654254|NCT00092508|relapse
654255|NCT00092508|Asacol®
654256|NCT00092508|maintain
654257|NCT00092508|maintenance
654258|NCT00092508|flare
654259|NCT00092508|rectal
654260|NCT00092508|bleeding
654261|NCT00092508|bowel
654262|NCT00092378|Bunionectomy
654263|NCT00092339|dental surgery
654264|NCT00092339|molar removal
654265|NCT00092326|dental surgery
654266|NCT00092326|molar removal
654267|NCT00092313|dental surgery
654268|NCT00092313|molar removal
654269|NCT00092300|dental surgery
654270|NCT00092300|molar removal
654271|NCT00092287|Carcinoid Syndrome
654272|NCT00092287|Neuroendocrine Tumuors
654273|NCT00092274|Follicular Lymphoma
654274|NCT00092274|Non Hodgkin´s Lymphoma
654275|NCT00092235|cGVHD-associated graft-versus-tumor effects (GVT)
654276|NCT00092235|Allo-HSCT controls
654277|NCT00092235|Leukapheresis
654278|NCT00092235|Chronic Graft-Versus-Host Disease
654279|NCT00092235|cGVHD
654280|NCT00092222|HHV-8
654281|NCT00092222|HIV
654282|NCT00092222|Malignancy
654283|NCT00092222|Lymphoproliferation
654284|NCT00092222|Lymph Node Hyperplasia
654285|NCT00092222|Multicentric Castleman DIsease
654286|NCT00092222|MCD
654287|NCT00092222|KSHV-MCD
654288|NCT00092222|KSHV Associated MCD
654289|NCT00092222|HIV Infections
654290|NCT00092222|Herpes Viruses
654291|NCT00092196|Chemotherapy-Induced Nausea and Vomiting
654292|NCT00092183|Chemotherapy-Induced Nausea and Vomiting
654293|NCT00092170|Intra-abdominal infections
654294|NCT00092170|Acute pelvic infections
654295|NCT00092157|High cholesterol
654296|NCT00092105|Rhinitis, Allergic
654297|NCT00092053|Postmenopausal
654298|NCT00092053|Osteoporosis
654299|NCT00092001|Non-small cell lung cancer, carcinoma, sunitinib, Phase 2
654300|NCT00091988|Urinary Incontinence
654301|NCT00091988|Weight Loss
654302|NCT00091988|Obesity
654303|NCT00091988|Motivation
654304|NCT00091975|Chronic Kidney Disease
654305|NCT00091949|stroke
654306|NCT00091949|heart attack
654307|NCT00091949|diabetes
654308|NCT00091949|pioglitazone
654309|NCT00091949|insulin resistance
654310|NCT00091936|Treatment Naive
654311|NCT00091936|Directly Observed Therapy
654313|NCT00091936|TB
654314|NCT00091910|Anemia
654315|NCT00091910|Epoetin alfa
654316|NCT00091910|Erythropoietin
654317|NCT00091910|Blood transfusion
654318|NCT00091910|Intensive care units
654319|NCT00091897|RITUXAN
654320|NCT00091897|GABA
654321|NCT00091897|B Cells
654322|NCT00091897|Humanized Monoclonal Antibodies
654323|NCT00091897|GAD
654324|NCT00091897|Stiff Person Syndrome
654325|NCT00091897|SPS
654326|NCT00091884|HIV
654327|NCT00091884|Immune Recovery
654328|NCT00091884|Reactivation
654329|NCT00091884|Anti-Viral Medication
654330|NCT00091884|HAART
654331|NCT00091884|CMV Retinitis
654332|NCT00091884|Retinal Disease
654333|NCT00091871|Genetic
654334|NCT00091871|Eosinophils
654335|NCT00091871|Familial Hypereosinophilia
654336|NCT00091871|Hypereosinophilia
654337|NCT00091871|FE
654338|NCT00091858|Cancer-related anemia
654339|NCT00091845|West Nile Fever Myelitis
654340|NCT00091845|West Nile Fever Encephalitis
654341|NCT00091845|West Nile Fever Meningitis
654342|NCT00091845|West Nile Fever Meningoencephalitis
654343|NCT00091832|Breast Cancer
654344|NCT00091832|Cancer
654345|NCT00091819|staph
654346|NCT00091819|MRSA
654347|NCT00091819|cSSSI
654348|NCT00091806|Targeted Therapy
654349|NCT00091806|Solid tumors
654350|NCT00091806|ABX-EGF, panitumumab
654351|NCT00091806|EGFr
654352|NCT00091806|Immunex, Abgenix, Amgen
654353|NCT00091806|Monoclonal Antibody
654354|NCT00091793|Osteoporosis
654355|NCT00091793|Postmenopausal
654356|NCT00091741|HIV
654357|NCT00091741|Treatment Experienced
654358|NCT00091741|Complementary Therapies
654359|NCT00091728|epidemiology
654360|NCT00091728|relative risk
654361|NCT00091728|cervical ectopy
654362|NCT00091728|hormonal contraceptives
654363|NCT00091728|sexually transmitted infections
654364|NCT00091715|Pulmonary arterial hypertension
654365|NCT00091715|PAH
654366|NCT00091715|PPH
654367|NCT00091715|bosentan
654368|NCT00091715|early
654369|NCT00091702|FluMist
654370|NCT00091702|Influenza Vaccine
654371|NCT00091702|Adolescent
654372|NCT00091702|Treatment Experienced
654373|NCT00091689|Advanced Metastatic Melanoma
654374|NCT00091676|follicular
654375|NCT00091676|lymphoma
654376|NCT00091676|Non-Hodgkins
654377|NCT00091676|idiotype
654378|NCT00091676|vaccine
654379|NCT00091676|indolent follicular Non-Hodgkins Lymphoma
654380|NCT00091676|tumor-derived
654381|NCT00091676|B-cell
654382|NCT00091676|cancer
654383|NCT00091663|Advanced non-small cell lung cancer
654384|NCT00091624|CC-5013
654385|NCT00091624|CC5013
654386|NCT00091624|Revlimid
654387|NCT00091624|Lenalidomide
654388|NCT00091624|Multiple myeloma
654389|NCT00091611|Clinical Response
654390|NCT00091611|Intravenous
654391|NCT00091611|Intra-Arterial
654392|NCT00091611|Lymphodepletion
654393|NCT00091611|Traffic of Cells
654394|NCT00091611|T-Cell Transfer
654395|NCT00091611|Renal Cell Carcinoma
654396|NCT00091611|Metastatic Renal Cell Cancer
654397|NCT00091598|Pulmonary Arterial Hypertension
654398|NCT00091572|Metastatic Melanoma
654399|NCT00091559|CTCL
654400|NCT00091533|fMRI
654401|NCT00091533|Mirror Neuron System
654402|NCT00091533|Bimodal Neurons
654403|NCT00091533|Somatosensory Cortex
654404|NCT00091533|Rehabilitation
654405|NCT00091533|Healthy Volunteer
654406|NCT00091533|HV
654407|NCT00091520|Congestive heart failure
654408|NCT00091520|Nesiritide
654409|NCT00091507|Acute Coronary Syndrome
654410|NCT00091481|Stage V Chronic Kidney Disease
654411|NCT00091468|Age-Related Memory Loss
654412|NCT00091468|Nicotine
654413|NCT00091468|Mild Cognitive Impairment (MCI)
654414|NCT00091442|Breast Cancer
654415|NCT00091442|Advanced breast cancer
654416|NCT00091442|Breast Tumors
654417|NCT00091442|Cancer of Breast
654418|NCT00091442|Human Mammary Carcinoma
654419|NCT00091442|Mammary Neoplasms, Human
654420|NCT00091442|DOXIL
654421|NCT00091442|Docetaxel
654422|NCT00091429|Angina
654423|NCT00091429|Chest Pain
654424|NCT00091429|Coronary Artery Disease
654425|NCT00091429|Heart Disease
654426|NCT00091416|HIV Seronegativity
654427|NCT00091416|HIV Preventive Vaccine
654428|NCT00091390|adenocarcinoma of the prostate
654429|NCT00091390|stage IIB prostate cancer
654430|NCT00091390|stage IIA prostate cancer
654431|NCT00091390|stage III prostate cancer
654432|NCT00091377|recurrent ovarian epithelial cancer
654433|NCT00091377|fallopian tube cancer
654434|NCT00091377|primary peritoneal cavity cancer
654435|NCT00091351|adult alveolar soft-part sarcoma
654436|NCT00091351|adult angiosarcoma
654437|NCT00091351|adult epithelioid sarcoma
654438|NCT00091351|adult fibrosarcoma
654439|NCT00091351|adult leiomyosarcoma
654440|NCT00091351|adult liposarcoma
654441|NCT00091351|adult neurofibrosarcoma
654442|NCT00091351|adult synovial sarcoma
654443|NCT00091351|adult malignant fibrous histiocytoma
654444|NCT00091351|stage I adult soft tissue sarcoma
654445|NCT00091351|stage II adult soft tissue sarcoma
654446|NCT00091351|stage III adult soft tissue sarcoma
654447|NCT00091338|recurrent melanoma
654448|NCT00091338|stage IV melanoma
654449|NCT00091325|unspecified adult solid tumor, protocol specific
654450|NCT00091312|stage II colon cancer
654451|NCT00091312|adenocarcinoma of the colon
654452|NCT00091299|unspecified adult solid tumor, protocol specific
654453|NCT00091286|recurrent colon cancer
654454|NCT00091286|stage IIB colon cancer
654455|NCT00091286|stage IIIA colon cancer
654456|NCT00091286|stage IIIB colon cancer
654457|NCT00091286|stage IIIC colon cancer
654458|NCT00091286|stage IVA colon cancer
654459|NCT00091286|stage IVB colon cancer
654460|NCT00091286|recurrent rectal cancer
654461|NCT00091286|stage IIB rectal cancer
654462|NCT00091286|stage IIIA rectal cancer
654463|NCT00091286|stage IIIB rectal cancer
654464|NCT00091286|stage IIIC rectal cancer
654465|NCT00091286|stage IVA rectal cancer
654466|NCT00091286|stage IVB rectal cancer
654467|NCT00091273|stage I ovarian epithelial cancer
654468|NCT00091273|stage II ovarian epithelial cancer
654469|NCT00091273|stage III ovarian epithelial cancer
654470|NCT00091273|stage IV ovarian epithelial cancer
654471|NCT00091273|primary peritoneal cavity cancer
654472|NCT00091260|primary systemic amyloidosis
654473|NCT00091247|unspecified adult solid tumor, protocol specific
654474|NCT00091234|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
654475|NCT00091234|adult acute myeloid leukemia with inv(16)(p13;q22)
654476|NCT00091234|adult acute myeloid leukemia with t(16;16)(p13;q22)
654477|NCT00091234|adult acute myeloid leukemia with t(8;21)(q22;q22)
654478|NCT00091234|untreated adult acute myeloid leukemia
654479|NCT00091234|secondary acute myeloid leukemia
654480|NCT00091234|adult acute basophilic leukemia
654481|NCT00091234|adult acute eosinophilic leukemia
654482|NCT00091234|adult erythroleukemia (M6a)
654483|NCT00091234|adult pure erythroid leukemia (M6b)
654484|NCT00091234|adult acute megakaryoblastic leukemia (M7)
654485|NCT00091234|adult acute minimally differentiated myeloid leukemia (M0)
654486|NCT00091234|adult acute monoblastic leukemia (M5a)
654487|NCT00091234|adult acute monocytic leukemia (M5b)
654488|NCT00091234|adult acute myeloblastic leukemia with maturation (M2)
654489|NCT00091234|adult acute myeloblastic leukemia without maturation (M1)
654490|NCT00091234|adult acute myelomonocytic leukemia (M4)
654491|NCT00091169|fatigue
654492|NCT00091169|unspecified adult solid tumor, protocol specific
654493|NCT00091169|levocarnitine
654494|NCT00091169|depression
654495|NCT00091169|pain
654496|NCT00091169|carnitine deficiency
654497|NCT00091156|stage IIIB non-small cell lung cancer
654498|NCT00091156|stage IV non-small cell lung cancer
654499|NCT00091143|recurrent melanoma
654500|NCT00091143|stage III melanoma
654501|NCT00091143|stage IV melanoma
654502|NCT00091104|stage IV melanoma
654503|NCT00091104|recurrent melanoma
654504|NCT00091091|long-term effects secondary to cancer therapy in children
654505|NCT00091091|stage I childhood Hodgkin lymphoma
654506|NCT00091091|stage II childhood Hodgkin lymphoma
654507|NCT00091091|stage III childhood Hodgkin lymphoma
654508|NCT00091091|stage IV childhood Hodgkin lymphoma
654509|NCT00091052|unspecified adult solid tumor, protocol specific
654510|NCT00091039|stage IIIA non-small cell lung cancer
654511|NCT00091039|stage IIIB non-small cell lung cancer
654512|NCT00090987|AIDS-related Kaposi sarcoma
654513|NCT00090987|recurrent Kaposi sarcoma
654514|NCT00090974|stage I breast cancer
654515|NCT00090974|stage II breast cancer
654516|NCT00090974|stage IIIA breast cancer
654517|NCT00090961|pulmonary complications
654518|NCT00090961|stage IIIA non-small cell lung cancer
654519|NCT00090961|stage IIIB non-small cell lung cancer
654520|NCT00090961|squamous cell lung cancer
654521|NCT00090961|large cell lung cancer
654522|NCT00090961|adenocarcinoma of the lung
654523|NCT00090961|bronchoalveolar cell lung cancer
654524|NCT00090961|limited stage small cell lung cancer
654525|NCT00090909|recurrent adult Hodgkin lymphoma
654526|NCT00090896|recurrent melanoma
654527|NCT00090896|stage III melanoma
654528|NCT00090896|stage IV melanoma
654529|NCT00090870|stage IV renal cell cancer
654530|NCT00090857|breast cancer
654531|NCT00090857|stage I breast cancer
654532|NCT00090857|stage II breast cancer
654533|NCT00090857|stage IIIA breast cancer
654534|NCT00090857|stage IIIB breast cancer
654535|NCT00090857|stage IIIC breast cancer
654536|NCT00090857|stage IV breast cancer
654537|NCT00090857|breast cancer in situ
654538|NCT00090857|ductal breast carcinoma in situ
654539|NCT00090844|drug/agent toxicity by tissue/organ
654540|NCT00090844|hormone changes
654541|NCT00090844|stage I breast cancer
654542|NCT00090844|stage II breast cancer
654543|NCT00090831|Emotional Learning
654544|NCT00090831|Neurotransmitter
654545|NCT00090831|Neural Systems
654546|NCT00090831|Response Control
654547|NCT00090831|Orbitofrontal Cortex
654548|NCT00090831|Amygdala
654549|NCT00090831|Serotonin
654550|NCT00090831|Healthy Volunteer
654551|NCT00090831|HV
654552|NCT00090818|Dental Abnormalities
654553|NCT00090818|Lichen Planus
654554|NCT00090818|Oral Mucosal Disease
654555|NCT00090818|Genetic Disease
654556|NCT00090818|Amelogensis Imperfecta
654557|NCT00090818|Maxillofacial Abnormalities
654558|NCT00090818|Craniofacial Abnormalities
654559|NCT00090818|Craniofacial Genetic Abnormalities
654560|NCT00090779|Acute Infection
654561|NCT00090779|Treatment Naive
654562|NCT00090727|diffuse
654563|NCT00090727|follicular
654564|NCT00090727|chronic lymphocytic leukemia
654565|NCT00090727|colorectal cancer
654566|NCT00090727|pancreatic cancer
654567|NCT00090727|acute myelogenous leukemia
654568|NCT00090727|head and neck cancer
654569|NCT00090727|breast cancer
654570|NCT00090727|prostate cancer
654571|NCT00090727|ovarian cancer
654572|NCT00090727|bladder cancer
654573|NCT00090727|hypoxia
654574|NCT00090727|refractory
654575|NCT00090727|metastatic
654576|NCT00090714|DNA
654577|NCT00090714|Circular
654578|NCT00090714|Gene Therapy
654579|NCT00090688|diarrhea
654580|NCT00090662|Normal Volunteer
654581|NCT00090662|Eosinophilopoiesis
654582|NCT00090662|Healthy Volunteer
654583|NCT00090662|HV
654584|NCT00090623|Subfoveal neovascular
654585|NCT00090623|Age-related macular degeneration
654586|NCT00090623|AMD
654587|NCT00090623|Wet AMD
654588|NCT00090610|Relapsed ovarian cancer
654589|NCT00090584|Urge urinary incontinence (UUI)
654590|NCT00090584|Drug/Behavior treatment
654591|NCT00090571|JRA ASPs
654592|NCT00090571|Genomics
654593|NCT00090558|Atherosclerosis
654594|NCT00090558|Bone Marrow
654595|NCT00090558|Exercise
654596|NCT00090558|Endothelium
654597|NCT00090558|Nitroglycerin
654598|NCT00090558|Coronary Artery Disease
654599|NCT00090558|CAD
654600|NCT00090545|Hormone-Refractory
654601|NCT00090545|Proteomics
654602|NCT00090545|Angiogenesis
654603|NCT00090545|VEGFR
654604|NCT00090545|Prostate Cancer
654605|NCT00090545|Metastatic Prostate Cancer
654606|NCT00090506|Yoga
654607|NCT00090506|Meditation
654608|NCT00090493|Myeloma
654609|NCT00090493|Mage-A3
654610|NCT00090493|Transplant
654611|NCT00090493|Peptide
654612|NCT00090493|DTPACE
654613|NCT00090493|vaccines
654614|NCT00090493|Immunotherapy
654615|NCT00090493|NY-ESO-1
654616|NCT00090480|Cancer
654617|NCT00090428|Autism
654618|NCT00090428|Applied Behavioral Analysis
654619|NCT00090428|Gluten
654620|NCT00090428|Casein
654621|NCT00090415|Autism
654622|NCT00090415|Developmental Delay Disorders
654623|NCT00090402|Fish Oils
654624|NCT00090402|Thioctic Acid
654625|NCT00090402|Antioxidants
654626|NCT00090402|Dietary Supplements
654627|NCT00090389|Acupuncture
654628|NCT00090389|Medicine, Chinese Traditional
654629|NCT00090376|Erectile Dysfunction
654630|NCT00090376|Impotence
654631|NCT00090376|Prostate Cancer
654632|NCT00090376|Prostatectomy
654633|NCT00090363|rising PSA
654634|NCT00090363|bone metastases
654635|NCT00090363|Clinical study
654636|NCT00090363|pain-free or mildly symptomatic
654637|NCT00090337|pain
654638|NCT00090337|recurrent squamous cell carcinoma of the hypopharynx
654639|NCT00090337|stage I squamous cell carcinoma of the hypopharynx
654640|NCT00090337|stage II squamous cell carcinoma of the hypopharynx
654641|NCT00090337|stage III squamous cell carcinoma of the hypopharynx
654642|NCT00090337|stage IV squamous cell carcinoma of the hypopharynx
654643|NCT00090337|recurrent squamous cell carcinoma of the larynx
654644|NCT00090337|recurrent verrucous carcinoma of the larynx
654645|NCT00090337|stage I squamous cell carcinoma of the larynx
654646|NCT00090337|stage I verrucous carcinoma of the larynx
654647|NCT00090337|stage II squamous cell carcinoma of the larynx
654648|NCT00090337|stage II verrucous carcinoma of the larynx
654649|NCT00090337|stage III squamous cell carcinoma of the larynx
654650|NCT00090337|stage III verrucous carcinoma of the larynx
654651|NCT00090337|stage IV squamous cell carcinoma of the larynx
654652|NCT00090337|stage IV verrucous carcinoma of the larynx
654653|NCT00090337|recurrent squamous cell carcinoma of the lip and oral cavity
654654|NCT00090337|stage I squamous cell carcinoma of the lip and oral cavity
654655|NCT00090337|stage II squamous cell carcinoma of the lip and oral cavity
654656|NCT00090337|stage III squamous cell carcinoma of the lip and oral cavity
654657|NCT00090337|stage IV squamous cell carcinoma of the lip and oral cavity
654658|NCT00090337|recurrent basal cell carcinoma of the lip
654659|NCT00090337|stage I basal cell carcinoma of the lip
654660|NCT00090337|stage II basal cell carcinoma of the lip
654661|NCT00090337|stage III basal cell carcinoma of the lip
654662|NCT00090337|stage IV basal cell carcinoma of the lip
654663|NCT00090337|recurrent adenoid cystic carcinoma of the oral cavity
654664|NCT00090337|recurrent mucoepidermoid carcinoma of the oral cavity
654665|NCT00090337|recurrent verrucous carcinoma of the oral cavity
654666|NCT00090337|stage I adenoid cystic carcinoma of the oral cavity
654667|NCT00090337|stage I mucoepidermoid carcinoma of the oral cavity
654668|NCT00090337|stage I verrucous carcinoma of the oral cavity
654669|NCT00090337|stage II adenoid cystic carcinoma of the oral cavity
654670|NCT00090337|stage II mucoepidermoid carcinoma of the oral cavity
654671|NCT00090337|stage II verrucous carcinoma of the oral cavity
654672|NCT00090337|stage III adenoid cystic carcinoma of the oral cavity
654673|NCT00090337|stage III mucoepidermoid carcinoma of the oral cavity
654674|NCT00090337|stage III verrucous carcinoma of the oral cavity
654675|NCT00090337|stage IV adenoid cystic carcinoma of the oral cavity
654676|NCT00090337|stage IV mucoepidermoid carcinoma of the oral cavity
654677|NCT00090337|stage IV verrucous carcinoma of the oral cavity
654678|NCT00090337|metastatic squamous neck cancer with occult primary squamous cell carcinoma
654679|NCT00090337|recurrent metastatic squamous neck cancer with occult primary
654680|NCT00090337|recurrent lymphoepithelioma of the nasopharynx
654681|NCT00090337|recurrent squamous cell carcinoma of the nasopharynx
654682|NCT00090337|stage I lymphoepithelioma of the nasopharynx
654683|NCT00090337|stage I squamous cell carcinoma of the nasopharynx
654684|NCT00090337|stage II lymphoepithelioma of the nasopharynx
654685|NCT00090337|stage II squamous cell carcinoma of the nasopharynx
654686|NCT00090337|stage III lymphoepithelioma of the nasopharynx
654687|NCT00090337|stage III squamous cell carcinoma of the nasopharynx
654688|NCT00090337|stage IV lymphoepithelioma of the nasopharynx
654689|NCT00090337|stage IV squamous cell carcinoma of the nasopharynx
654690|NCT00090337|recurrent lymphoepithelioma of the oropharynx
654691|NCT00090337|recurrent squamous cell carcinoma of the oropharynx
654692|NCT00090337|stage I lymphoepithelioma of the oropharynx
654693|NCT00090337|stage I squamous cell carcinoma of the oropharynx
654694|NCT00090337|stage II lymphoepithelioma of the oropharynx
654695|NCT00090337|stage II squamous cell carcinoma of the oropharynx
654696|NCT00090337|stage III lymphoepithelioma of the oropharynx
654697|NCT00090337|stage III squamous cell carcinoma of the oropharynx
654698|NCT00090337|stage IV lymphoepithelioma of the oropharynx
654699|NCT00090337|stage IV squamous cell carcinoma of the oropharynx
654700|NCT00090337|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
654701|NCT00090337|recurrent inverted papilloma of the paranasal sinus and nasal cavity
654702|NCT00090337|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
654703|NCT00090337|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
654704|NCT00090337|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
654705|NCT00090337|stage I inverted papilloma of the paranasal sinus and nasal cavity
654706|NCT00090337|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
654707|NCT00090337|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
654708|NCT00090337|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
654709|NCT00090337|stage II inverted papilloma of the paranasal sinus and nasal cavity
654710|NCT00090337|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
654711|NCT00090337|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
654712|NCT00090337|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
654713|NCT00090337|stage III inverted papilloma of the paranasal sinus and nasal cavity
654714|NCT00090337|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
654715|NCT00090337|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
654716|NCT00090337|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
654717|NCT00090337|stage IV inverted papilloma of the paranasal sinus and nasal cavity
654718|NCT00090337|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
654719|NCT00090337|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
654720|NCT00090337|recurrent salivary gland cancer
654721|NCT00090337|stage I salivary gland cancer
654722|NCT00090337|stage II salivary gland cancer
654723|NCT00090337|stage III salivary gland cancer
654724|NCT00090337|stage IV salivary gland cancer
654725|NCT00090324|Schizophrenia
654726|NCT00090311|Bipolar I Mania
654727|NCT00090285|anogenital warts
654728|NCT00090194|Kidney Transplantation
654729|NCT00090194|Transplantation, Homologous
654730|NCT00090194|HLA Antigens
654731|NCT00090194|Autoantibodies
654732|NCT00090194|Immunoglobulins, Intravenous
654733|NCT00090194|Living Donors
654734|NCT00090194|Dose-Response Relationship, Immunologic
654735|NCT00090181|Arcoxia
654736|NCT00090129|Psoriatic Arthritis
654737|NCT00090129|Moderate plaque psoriasis
654738|NCT00090129|severe plaque psoriasis
654739|NCT00090129|Onercept
654740|NCT00090129|Placebo
654741|NCT00090116|Neramexane
654742|NCT00090116|NMDA receptor antagonist
654743|NCT00090116|Memory Loss
654744|NCT00090116|Alzheimer Disease
654745|NCT00090103|Combination Therapy
654746|NCT00090103|dutasteride
654747|NCT00090103|BPH
654748|NCT00090077|GW695634G
654749|NCT00090077|GW695634X
654750|NCT00090077|GW678248X
654751|NCT00090077|pharmacokinetics
654752|NCT00090077|NNRTI
654753|NCT00090077|HIV
654754|NCT00090064|MDMA
654877|NCT00089609|Hormones
654755|NCT00090064|Methylenedioxymethamphetamine
654756|NCT00090064|PTSD
654757|NCT00090064|psychotherapy
654758|NCT00090025|Advanced Biliary Cancer
654759|NCT00090025|Cholangiocarcinoma
654760|NCT00090025|Gall bladder tumor
654761|NCT00090025|Gall bladder cancer
654762|NCT00090025|Bile duct tumor
654763|NCT00090025|Tumor of biliary tree
654764|NCT00089999|lapatinib
654765|NCT00089999|advanced
654766|NCT00089999|metastatic breast cancer
654767|NCT00089999|GW572016
654768|NCT00089999|ErbB2
654769|NCT00089986|septic shock
654770|NCT00089986|phospholipid emulsion
654771|NCT00089986|Gram-negative infection
654772|NCT00089986|severe sepsis
654773|NCT00089973|breast cancer
654774|NCT00089960|GIST
654775|NCT00089947|Anti-T cell antibodies
654776|NCT00089947|Living Donor Renal Transplantation
654777|NCT00089947|Acute Renal Allograft Rejection
654778|NCT00089947|Induction Therapy with Reduction of Calcineurin inhibitors
654779|NCT00089921|Rheumatoid Arthritis
654780|NCT00089921|DMARDs
654781|NCT00089921|Methotrexate
654782|NCT00089921|p38 kinase
654783|NCT00089908|Dengue Vaccine
654784|NCT00089908|Dengue Virus
654785|NCT00089908|Dengue Hemorrhagic Fever
654786|NCT00089908|Dengue Shock Syndrome
654787|NCT00089895|myocardial infarction
654788|NCT00089895|acute coronary syndrome
654789|NCT00089895|non-ST-segment elevation
654790|NCT00089895|eptifibatide
654791|NCT00089895|Integrilin
654792|NCT00089895|glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa)
654793|NCT00089895|percutaneous coronary intervention (PCI)
654794|NCT00089895|coronary artery bypass graph surgery (CABG)
654795|NCT00089895|catheterization
654796|NCT00089895|angina
654797|NCT00089895|ischemia
654798|NCT00089895|cardiac ischemia
654799|NCT00089895|cardiovascular disease
654800|NCT00089882|Alzheimer disease
654801|NCT00089882|Apolipoproteins E (APOE)
654802|NCT00089882|Genetic susceptibility testing
654803|NCT00089856|Prostate
654804|NCT00089856|Cancer
654805|NCT00089856|Metastatic
654806|NCT00089856|Hormone-refractory
654807|NCT00089856|GVAX
654808|NCT00089856|Chemotherapy
654809|NCT00089856|Taxotere
654810|NCT00089856|Docetaxel
654811|NCT00089856|Prednisone
654812|NCT00089856|Vaccine
654813|NCT00089856|Allogeneic cells
654814|NCT00089856|Advanced Prostate Cancer
654815|NCT00089843|Eating Disorders
654816|NCT00089843|Osteopenia
654817|NCT00089830|Subfoveal Choroidal Neovascularization
654818|NCT00089830|Squalamine Lactate
654819|NCT00089804|Lupus
654820|NCT00089804|Nephritis
654821|NCT00089804|Kidney
654822|NCT00089804|SLE
654823|NCT00089804|Systemic Lupus Erythematosus
654824|NCT00089804|Nephritis, Lupus
654825|NCT00089791|Postmenopausal Osteoporosis
654826|NCT00089778|Clinical Response
654827|NCT00089778|Toxicity
654828|NCT00089778|Immunologic Response
654829|NCT00089778|Adjuvant
654830|NCT00089778|IL-2
654831|NCT00089778|Renal Cancer
654832|NCT00089765|Retinal Angioma
654833|NCT00089765|Tumor
654834|NCT00089765|Anti-VEGF
654835|NCT00089765|Monoclonal Antibody
654836|NCT00089765|Macular Edema
654837|NCT00089765|Von Hippel-Lindau Disease
654838|NCT00089765|VEGF
654839|NCT00089765|Ranibizumab
654840|NCT00089765|VHL
654841|NCT00089739|Uveitis
654842|NCT00089739|Suppressor of Cytokine Secretion
654843|NCT00089739|GITR
654844|NCT00089739|Immunosuppression
654845|NCT00089739|GITR Ligand
654846|NCT00089739|Intraocular Inflammation
654847|NCT00089726|cancer vaccine
654848|NCT00089726|NSCLC
654849|NCT00089726|immunotherapy
654850|NCT00089713|antihypertensive agents/therapeutic use
654851|NCT00089713|hypertension/drug therapy
654852|NCT00089713|blood pressure
654853|NCT00089700|HIV
654854|NCT00089700|AIDS
654855|NCT00089700|Treatment Experienced
654856|NCT00089700|Optimized Background Therapy
654857|NCT00089700|HIV-1
654858|NCT00089674|Prostate Cancer
654859|NCT00089674|Bone Loss with Prostate Cancer
654860|NCT00089674|Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).
654861|NCT00089661|Breast Cancer
654862|NCT00089661|Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC
654863|NCT00089661|osteopenia
654864|NCT00089661|Low bone density
654865|NCT00089635|Colon, Rectal Cancer
654866|NCT00089635|ABX-EGF, Panitumumab, EGFr
654867|NCT00089635|Immunex, Abgenix, Amgen
654868|NCT00089635|Metastatic Colorectal Cancer
654869|NCT00089635|Vectibix
654870|NCT00089622|Parkinson's Disease
654871|NCT00089622|Motor Fluctuations
654872|NCT00089622|Intravenous Levodopa
654873|NCT00089622|Antiparkinsonian Response
654874|NCT00089622|Lisuride Patch
654875|NCT00089622|Parkinson Disease
654876|NCT00089622|PD
654878|NCT00089609|Angiogenesis
654879|NCT00089609|Markers
654880|NCT00089609|Tumor
654881|NCT00089609|Prostate Cancer
654882|NCT00089596|umbilical cord blood
654883|NCT00089596|transplant
654884|NCT00089596|ALL
654885|NCT00089596|AML
654886|NCT00089596|MDS
654887|NCT00089596|NHL
654888|NCT00089596|CML
654889|NCT00089583|antiretroviral therapy
654890|NCT00089583|pediatrics
654891|NCT00089583|AGENERASE
654892|NCT00089583|amprenavir
654893|NCT00089583|fosamprenavir
654894|NCT00089583|HIV Infection
654895|NCT00089583|ritonavir
654896|NCT00089583|protease inhibitor
654897|NCT00089583|LEXIVA
654898|NCT00089570|hepatorenal syndrome
654899|NCT00089570|terlipressin
654900|NCT00089557|Dermal assessment
654901|NCT00089557|Pain assessment
654902|NCT00089557|Diary
654903|NCT00089557|Analgesics
654904|NCT00089557|Capsaicin
654905|NCT00089557|Herpes zoster
654906|NCT00089557|Neuralgia
654907|NCT00089557|Pain
654908|NCT00089557|HIV Infections
654909|NCT00089557|Peripheral Nervous System Diseases
654910|NCT00089557|Diabetic Neuropathies
654911|NCT00089557|Diabetes Mellitus
654912|NCT00089557|Polyneuropathies
654913|NCT00089557|Complementary Therapies
654914|NCT00089531|Healthy
654915|NCT00089531|Virus
654916|NCT00089531|T-Cells
654917|NCT00089531|HIV-Negative
654918|NCT00089531|Immunity
654919|NCT00089531|Healthy Volunteer
654920|NCT00089531|HV
654921|NCT00089531|HIV Preventive Vaccine
654922|NCT00089531|HIV Seronegativity
654923|NCT00089518|Treatment Experienced
654924|NCT00089505|Treatment Experienced
654925|NCT00089505|Treatment Naive
654926|NCT00089505|MTCT
654927|NCT00089505|HIV Seronegativity
654928|NCT00089466|Entry Inhibitors
654929|NCT00089466|CXCR4 Entry Inhibitors
654930|NCT00089466|Treatment Experienced
654931|NCT00089466|Treatment Naive
654932|NCT00089453|Myeloma
654933|NCT00089453|Transplant
654934|NCT00089453|Relapsed
654935|NCT00089453|Donor
654936|NCT00089453|Stem Cell
654937|NCT00089453|Thalidomide
654938|NCT00089453|Dexamethasone
654939|NCT00089453|Cisplatin
654940|NCT00089453|Adriamycin
654941|NCT00089453|Cyclophosphamide
654942|NCT00089453|Etoposide
654943|NCT00089453|Melphalan
654944|NCT00089427|brain tumor
654945|NCT00089427|malignant glioma
654946|NCT00089427|brain neoplasm
654947|NCT00089427|central nervous system
654948|NCT00089427|surgery
654949|NCT00089427|resection
654950|NCT00089427|temozolomide
654951|NCT00089427|infusion
654952|NCT00089427|glioblastoma multiforme
654953|NCT00089427|anaplastic astrocytoma
654954|NCT00089427|oligoastrocytoma
654955|NCT00089427|Temodar
654956|NCT00089427|radiation
654957|NCT00089427|convection-enhanced delivery
654958|NCT00089427|GBM
654959|NCT00089414|Depression
654960|NCT00089414|Menstrual Cycle
654961|NCT00089414|Gonadal Steroids
654962|NCT00089414|Ethinyl Estradiol
654963|NCT00089414|Drospirenone
654964|NCT00089414|Menstrually Related Mood Disorder
654965|NCT00089414|MRMD
654966|NCT00089401|recurrent colon cancer
654967|NCT00089401|stage IV colon cancer
654968|NCT00089401|recurrent rectal cancer
654969|NCT00089401|stage IV rectal cancer
654970|NCT00089401|liver metastases
654971|NCT00089323|stage IA breast cancer
654972|NCT00089323|stage II breast cancer
654973|NCT00089323|stage IIIA breast cancer
654974|NCT00089323|male breast cancer
654975|NCT00089323|stage IB breast cancer
654976|NCT00089310|stage I non-small cell lung cancer
654977|NCT00089297|Stage III head and neck cancer
654978|NCT00089297|Stage IV head and neck cancer
654979|NCT00089297|Cetuximab
654980|NCT00089297|Paclitaxel
654981|NCT00089297|Carboplatin
654982|NCT00089258|localized unresectable neuroblastoma
654983|NCT00089258|disseminated neuroblastoma
654984|NCT00089258|regional neuroblastoma
654985|NCT00089258|stage 4S neuroblastoma
654986|NCT00089258|recurrent neuroblastoma
654987|NCT00089245|leptomeningeal metastases
654988|NCT00089245|recurrent neuroblastoma
654989|NCT00089245|disseminated neuroblastoma
654990|NCT00089245|recurrent adult brain tumor
654991|NCT00089245|recurrent childhood medulloblastoma
654992|NCT00089245|recurrent childhood rhabdomyosarcoma
654993|NCT00089245|recurrent childhood soft tissue sarcoma
654994|NCT00089245|recurrent osteosarcoma
654995|NCT00089245|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
654996|NCT00089245|childhood atypical teratoid/rhabdoid tumor
654997|NCT00089245|adult medulloblastoma
654998|NCT00089245|previously treated childhood rhabdomyosarcoma
655397|NCT00088569|Treatment
654999|NCT00089245|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
655000|NCT00089245|metastatic osteosarcoma
655401|NCT00088569|HV
655001|NCT00089245|childhood desmoplastic small round cell tumor
655002|NCT00089245|metastatic childhood soft tissue sarcoma
655003|NCT00089245|adult rhabdomyosarcoma
655004|NCT00089245|recurrent adult soft tissue sarcoma
655005|NCT00089245|stage IV adult soft tissue sarcoma
655006|NCT00089219|stage III melanoma
655007|NCT00089219|stage IV melanoma
655008|NCT00089219|recurrent melanoma
655009|NCT00089219|ciliary body and choroid melanoma, medium/large size
655010|NCT00089219|extraocular extension melanoma
655011|NCT00089219|iris melanoma
655012|NCT00089219|recurrent intraocular melanoma
655013|NCT00089206|stage III melanoma
655014|NCT00089206|stage IV melanoma
655015|NCT00089206|recurrent melanoma
655016|NCT00089206|recurrent intraocular melanoma
655017|NCT00089206|iris melanoma
655018|NCT00089206|extraocular extension melanoma
655019|NCT00089206|ciliary body and choroid melanoma, medium/large size
655020|NCT00089193|stage II melanoma
655021|NCT00089193|stage III melanoma
655022|NCT00089193|stage IV melanoma
655023|NCT00089193|recurrent melanoma
655024|NCT00089167|primary systemic amyloidosis
655025|NCT00089141|graft versus host disease
655026|NCT00089141|accelerated phase chronic myelogenous leukemia
655027|NCT00089141|adult acute lymphoblastic leukemia in remission
655028|NCT00089141|adult acute myeloid leukemia in remission
655029|NCT00089141|childhood acute lymphoblastic leukemia in remission
655030|NCT00089141|childhood acute myeloid leukemia in remission
655031|NCT00089141|atypical chronic myeloid leukemia
655032|NCT00089141|blastic phase chronic myelogenous leukemia
655033|NCT00089141|childhood chronic myelogenous leukemia
655034|NCT00089141|chronic eosinophilic leukemia
655035|NCT00089141|chronic idiopathic myelofibrosis
655036|NCT00089141|chronic myelomonocytic leukemia
655037|NCT00089141|chronic neutrophilic leukemia
655038|NCT00089141|chronic phase chronic myelogenous leukemia
655039|NCT00089141|de novo myelodysplastic syndromes
655040|NCT00089141|disseminated neuroblastoma
655041|NCT00089141|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
655042|NCT00089141|juvenile myelomonocytic leukemia
655043|NCT00089141|myelodysplastic/myeloproliferative disease, unclassifiable
655044|NCT00089141|nodal marginal zone B-cell lymphoma
655045|NCT00089141|noncontiguous stage II adult Burkitt lymphoma
655046|NCT00089141|noncontiguous stage II adult diffuse large cell lymphoma
655047|NCT00089141|noncontiguous stage II adult diffuse mixed cell lymphoma
655048|NCT00089141|noncontiguous stage II adult diffuse small cleaved cell lymphoma
655049|NCT00089141|noncontiguous stage II adult immunoblastic large cell lymphoma
655050|NCT00089141|noncontiguous stage II adult lymphoblastic lymphoma
655051|NCT00089141|noncontiguous stage II grade 1 follicular lymphoma
655052|NCT00089141|noncontiguous stage II grade 2 follicular lymphoma
655053|NCT00089141|noncontiguous stage II grade 3 follicular lymphoma
655054|NCT00089141|noncontiguous stage II mantle cell lymphoma
655055|NCT00089141|noncontiguous stage II marginal zone lymphoma
655056|NCT00089141|noncontiguous stage II small lymphocytic lymphoma
655057|NCT00089141|poor prognosis metastatic gestational trophoblastic tumor
655058|NCT00089141|previously treated childhood rhabdomyosarcoma
655059|NCT00089141|previously treated myelodysplastic syndromes
655060|NCT00089141|secondary acute myeloid leukemia
655061|NCT00089141|secondary myelodysplastic syndromes
655062|NCT00089141|splenic marginal zone lymphoma
655063|NCT00089141|stage I multiple myeloma
655064|NCT00089141|stage II multiple myeloma
655065|NCT00089141|stage II ovarian epithelial cancer
655066|NCT00089141|stage III adult Burkitt lymphoma
655067|NCT00089141|stage III adult diffuse large cell lymphoma
655068|NCT00089141|stage III adult diffuse mixed cell lymphoma
655069|NCT00089141|stage III adult diffuse small cleaved cell lymphoma
655070|NCT00089141|stage III adult immunoblastic large cell lymphoma
655071|NCT00089141|stage III adult lymphoblastic lymphoma
655072|NCT00089141|stage III chronic lymphocytic leukemia
655073|NCT00089141|stage III grade 1 follicular lymphoma
655074|NCT00089141|stage III grade 2 follicular lymphoma
655075|NCT00089141|stage III grade 3 follicular lymphoma
655076|NCT00089141|stage III mantle cell lymphoma
655077|NCT00089141|stage III marginal zone lymphoma
655078|NCT00089141|stage III multiple myeloma
655079|NCT00089141|stage III ovarian epithelial cancer
655080|NCT00089141|stage III small lymphocytic lymphoma
655081|NCT00089141|stage III malignant testicular germ cell tumor
655082|NCT00089141|stage IIIA breast cancer
655083|NCT00089141|stage IIIB breast cancer
655084|NCT00089141|stage IIIC breast cancer
655085|NCT00089141|stage IV adult Burkitt lymphoma
655086|NCT00089141|stage IV adult diffuse large cell lymphoma
655087|NCT00089141|stage IV adult diffuse mixed cell lymphoma
655088|NCT00089141|stage IV adult diffuse small cleaved cell lymphoma
655089|NCT00089141|stage IV adult immunoblastic large cell lymphoma
655090|NCT00089141|stage IV adult lymphoblastic lymphoma
655091|NCT00089141|stage IV breast cancer
655092|NCT00089141|stage IV chronic lymphocytic leukemia
655093|NCT00089141|stage IV grade 1 follicular lymphoma
655094|NCT00089141|stage IV grade 2 follicular lymphoma
655095|NCT00089141|stage IV grade 3 follicular lymphoma
655096|NCT00089141|stage IV mantle cell lymphoma
655097|NCT00089141|stage IV marginal zone lymphoma
655098|NCT00089141|stage IV ovarian epithelial cancer
655099|NCT00089141|stage IV small lymphocytic lymphoma
655100|NCT00089141|childhood myelodysplastic syndromes
655101|NCT00089128|transitional cell carcinoma of the bladder
655102|NCT00089128|recurrent bladder cancer
655103|NCT00089128|stage III bladder cancer
655104|NCT00089128|stage IV bladder cancer
655105|NCT00089115|contiguous stage II grade 1 follicular lymphoma
655106|NCT00089115|contiguous stage II grade 2 follicular lymphoma
655107|NCT00089115|contiguous stage II grade 3 follicular lymphoma
655108|NCT00089115|noncontiguous stage II grade 1 follicular lymphoma
655109|NCT00089115|noncontiguous stage II grade 2 follicular lymphoma
655110|NCT00089115|noncontiguous stage II grade 3 follicular lymphoma
655111|NCT00089115|stage I grade 1 follicular lymphoma
655112|NCT00089115|stage I grade 2 follicular lymphoma
655113|NCT00089115|stage I grade 3 follicular lymphoma
655114|NCT00089115|stage III grade 1 follicular lymphoma
655115|NCT00089115|stage III grade 2 follicular lymphoma
655116|NCT00089115|stage III grade 3 follicular lymphoma
655117|NCT00089115|stage IV grade 1 follicular lymphoma
655118|NCT00089115|stage IV grade 2 follicular lymphoma
655119|NCT00089115|stage IV grade 3 follicular lymphoma
655120|NCT00089115|recurrent grade 1 follicular lymphoma
655121|NCT00089115|recurrent grade 2 follicular lymphoma
655122|NCT00089115|recurrent grade 3 follicular lymphoma
655123|NCT00089102|recurrent renal cell cancer
655124|NCT00089102|stage III renal cell cancer
655125|NCT00089102|stage IV renal cell cancer
655126|NCT00089050|recurrent adult acute myeloid leukemia
655127|NCT00089050|adult acute minimally differentiated myeloid leukemia (M0)
655128|NCT00089050|adult acute myeloblastic leukemia without maturation (M1)
655129|NCT00089050|adult acute myeloblastic leukemia with maturation (M2)
655130|NCT00089050|adult acute myelomonocytic leukemia (M4)
655131|NCT00089050|adult acute monoblastic leukemia (M5a)
655132|NCT00089050|adult acute monocytic leukemia (M5b)
655133|NCT00089050|adult erythroleukemia (M6a)
655134|NCT00089050|adult pure erythroid leukemia (M6b)
655135|NCT00089050|adult acute megakaryoblastic leukemia (M7)
655136|NCT00089050|adult acute basophilic leukemia
655137|NCT00089050|adult acute eosinophilic leukemia
655138|NCT00089050|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
655139|NCT00089050|adult acute myeloid leukemia with inv(16)(p13;q22)
655140|NCT00089050|adult acute myeloid leukemia with t(16;16)(p13;q22)
655141|NCT00089050|adult acute myeloid leukemia with t(8;21)(q22;q22)
655142|NCT00089037|graft versus host disease
655143|NCT00089037|accelerated phase chronic myelogenous leukemia
655144|NCT00089037|atypical chronic myeloid leukemia
655145|NCT00089037|blastic phase chronic myelogenous leukemia
655146|NCT00089037|chronic eosinophilic leukemia
655147|NCT00089037|chronic idiopathic myelofibrosis
655148|NCT00089037|chronic myelomonocytic leukemia
655149|NCT00089037|chronic neutrophilic leukemia
655150|NCT00089037|myelodysplastic/myeloproliferative disease, unclassifiable
655151|NCT00089037|previously treated myelodysplastic syndromes
655152|NCT00089037|recurrent adult acute lymphoblastic leukemia
655153|NCT00089037|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
655154|NCT00089037|nodal marginal zone B-cell lymphoma
655155|NCT00089037|de novo myelodysplastic syndromes
655156|NCT00089037|adult acute lymphoblastic leukemia in remission
655157|NCT00089037|adult acute myeloid leukemia in remission
655158|NCT00089037|childhood acute lymphoblastic leukemia in remission
655159|NCT00089037|childhood acute myeloid leukemia in remission
655160|NCT00089037|recurrent adult acute myeloid leukemia
655161|NCT00089037|recurrent adult Burkitt lymphoma
655162|NCT00089037|recurrent adult diffuse large cell lymphoma
655163|NCT00089037|recurrent adult diffuse mixed cell lymphoma
655164|NCT00089037|recurrent adult diffuse small cleaved cell lymphoma
655165|NCT00089037|recurrent adult Hodgkin lymphoma
655166|NCT00089037|recurrent adult immunoblastic large cell lymphoma
655167|NCT00089037|recurrent adult lymphoblastic lymphoma
655168|NCT00089037|recurrent grade 1 follicular lymphoma
655169|NCT00089037|recurrent grade 2 follicular lymphoma
655170|NCT00089037|recurrent grade 3 follicular lymphoma
655171|NCT00089037|recurrent mantle cell lymphoma
655172|NCT00089037|recurrent mycosis fungoides/Sezary syndrome
655173|NCT00089037|recurrent small lymphocytic lymphoma
655174|NCT00089037|refractory chronic lymphocytic leukemia
655175|NCT00089037|refractory hairy cell leukemia
655176|NCT00089037|refractory multiple myeloma
655177|NCT00089037|relapsing chronic myelogenous leukemia
655178|NCT00089037|secondary acute myeloid leukemia
655179|NCT00089037|secondary myelodysplastic syndromes
655180|NCT00089037|noncontiguous stage II adult Burkitt lymphoma
655181|NCT00089037|stage III adult Burkitt lymphoma
655182|NCT00089037|stage IV adult Burkitt lymphoma
655183|NCT00089037|noncontiguous stage II adult diffuse large cell lymphoma
655184|NCT00089037|noncontiguous stage II adult diffuse mixed cell lymphoma
655185|NCT00089037|noncontiguous stage II adult diffuse small cleaved cell lymphoma
655398|NCT00088569|Transcranial
655186|NCT00089037|noncontiguous stage II adult immunoblastic large cell lymphoma
655642|NCT00087347|recurrent breast cancer
655187|NCT00089037|noncontiguous stage II adult lymphoblastic lymphoma
655188|NCT00089037|noncontiguous stage II grade 1 follicular lymphoma
655189|NCT00089037|noncontiguous stage II grade 2 follicular lymphoma
655190|NCT00089037|noncontiguous stage II grade 3 follicular lymphoma
655191|NCT00089037|noncontiguous stage II mantle cell lymphoma
655192|NCT00089037|noncontiguous stage II marginal zone lymphoma
655193|NCT00089037|noncontiguous stage II small lymphocytic lymphoma
655194|NCT00089037|stage III adult diffuse large cell lymphoma
655195|NCT00089037|stage III adult diffuse mixed cell lymphoma
655196|NCT00089037|stage III adult diffuse small cleaved cell lymphoma
655197|NCT00089037|stage IV adult diffuse large cell lymphoma
655198|NCT00089037|stage IV adult diffuse mixed cell lymphoma
655199|NCT00089037|stage IV adult diffuse small cleaved cell lymphoma
655200|NCT00089037|stage III adult immunoblastic large cell lymphoma
655201|NCT00089037|stage IV adult immunoblastic large cell lymphoma
655202|NCT00089037|stage III grade 1 follicular lymphoma
655203|NCT00089037|stage III grade 2 follicular lymphoma
655204|NCT00089037|stage III grade 3 follicular lymphoma
655205|NCT00089037|stage IV grade 1 follicular lymphoma
655206|NCT00089037|stage IV grade 2 follicular lymphoma
655207|NCT00089037|stage IV grade 3 follicular lymphoma
655208|NCT00089037|stage III mantle cell lymphoma
655209|NCT00089037|stage IV mantle cell lymphoma
655210|NCT00089037|stage III small lymphocytic lymphoma
655211|NCT00089037|stage IV small lymphocytic lymphoma
655212|NCT00089037|stage III marginal zone lymphoma
655213|NCT00089037|stage IV marginal zone lymphoma
655214|NCT00089037|childhood chronic myelogenous leukemia
655215|NCT00089037|recurrent childhood acute lymphoblastic leukemia
655216|NCT00089037|recurrent childhood acute myeloid leukemia
655217|NCT00089037|recurrent childhood large cell lymphoma
655218|NCT00089037|recurrent childhood lymphoblastic lymphoma
655219|NCT00089037|recurrent childhood small noncleaved cell lymphoma
655220|NCT00089037|untreated childhood acute lymphoblastic leukemia
655221|NCT00089037|untreated childhood acute myeloid leukemia and other myeloid malignancies
655222|NCT00089037|recurrent/refractory childhood Hodgkin lymphoma
655223|NCT00089037|juvenile myelomonocytic leukemia
655224|NCT00089037|splenic marginal zone lymphoma
655225|NCT00089037|untreated adult acute lymphoblastic leukemia
655226|NCT00089037|untreated adult acute myeloid leukemia
655227|NCT00089037|stage III chronic lymphocytic leukemia
655228|NCT00089037|stage IV chronic lymphocytic leukemia
655229|NCT00089037|stage I multiple myeloma
655230|NCT00089037|stage II multiple myeloma
655231|NCT00089037|stage III multiple myeloma
655232|NCT00089037|refractory cytopenia with multilineage dysplasia
655233|NCT00089037|recurrent cutaneous T-cell non-Hodgkin lymphoma
655234|NCT00089037|recurrent marginal zone lymphoma
655235|NCT00089024|adenocarcinoma of the pancreas
655236|NCT00089024|stage II pancreatic cancer
655237|NCT00089024|stage III pancreatic cancer
655238|NCT00088998|male breast cancer
655239|NCT00088998|recurrent breast cancer
655240|NCT00088998|stage IV breast cancer
655241|NCT00088985|recurrent breast cancer
655242|NCT00088985|stage IIIB breast cancer
655243|NCT00088985|stage IIIC breast cancer
655244|NCT00088985|stage IV breast cancer
655245|NCT00088972|breast cancer
655246|NCT00088972|breast cancer in situ
655247|NCT00088972|lobular breast carcinoma in situ
655248|NCT00088972|ductal breast carcinoma
655249|NCT00088946|transitional cell carcinoma of the bladder
655250|NCT00088946|stage 0 bladder cancer
655251|NCT00088946|stage I bladder cancer
655252|NCT00088907|docetaxel
655253|NCT00088907|gefitinib
655254|NCT00088907|head and neck cancer
655255|NCT00088868|unspecified adult solid tumor, protocol specific
655256|NCT00088868|anaplastic large cell lymphoma
655257|NCT00088868|intraocular lymphoma
655258|NCT00088868|recurrent grade 1 follicular lymphoma
655259|NCT00088868|recurrent grade 2 follicular lymphoma
655260|NCT00088868|recurrent grade 3 follicular lymphoma
655261|NCT00088868|recurrent mantle cell lymphoma
655262|NCT00088868|recurrent marginal zone lymphoma
655263|NCT00088868|recurrent small lymphocytic lymphoma
655264|NCT00088868|stage III adult Burkitt lymphoma
655265|NCT00088868|stage III adult diffuse large cell lymphoma
655266|NCT00088868|stage III adult diffuse mixed cell lymphoma
655267|NCT00088868|stage III adult diffuse small cleaved cell lymphoma
655268|NCT00088868|stage III adult Hodgkin lymphoma
655269|NCT00088868|stage III adult immunoblastic large cell lymphoma
655270|NCT00088868|stage III adult lymphoblastic lymphoma
655271|NCT00088868|stage III grade 1 follicular lymphoma
655272|NCT00088868|stage III grade 2 follicular lymphoma
655273|NCT00088868|stage III grade 3 follicular lymphoma
655274|NCT00088868|stage III mantle cell lymphoma
655275|NCT00088868|stage III marginal zone lymphoma
655276|NCT00088868|stage III small lymphocytic lymphoma
655277|NCT00088868|stage IV adult Burkitt lymphoma
655278|NCT00088868|stage IV adult diffuse large cell lymphoma
655279|NCT00088868|stage IV adult diffuse mixed cell lymphoma
655280|NCT00088868|stage IV adult diffuse small cleaved cell lymphoma
655281|NCT00088868|stage IV adult Hodgkin lymphoma
655282|NCT00088868|stage IV adult immunoblastic large cell lymphoma
655283|NCT00088868|stage IV adult lymphoblastic lymphoma
655284|NCT00088868|stage IV grade 1 follicular lymphoma
655285|NCT00088868|stage IV grade 2 follicular lymphoma
655286|NCT00088868|stage IV grade 3 follicular lymphoma
655287|NCT00088868|stage IV mantle cell lymphoma
655288|NCT00088868|stage IV marginal zone lymphoma
655289|NCT00088868|stage IV small lymphocytic lymphoma
655290|NCT00088868|recurrent mycosis fungoides/Sezary syndrome
655291|NCT00088868|stage III mycosis fungoides/Sezary syndrome
655292|NCT00088868|stage IV mycosis fungoides/Sezary syndrome
655293|NCT00088868|recurrent adult Burkitt lymphoma
655294|NCT00088868|recurrent adult diffuse large cell lymphoma
655295|NCT00088868|recurrent adult diffuse mixed cell lymphoma
655296|NCT00088868|recurrent adult diffuse small cleaved cell lymphoma
655297|NCT00088868|recurrent adult Hodgkin lymphoma
655298|NCT00088868|recurrent adult immunoblastic large cell lymphoma
655299|NCT00088868|recurrent adult lymphoblastic lymphoma
655300|NCT00088868|angioimmunoblastic T-cell lymphoma
655301|NCT00088868|small intestine lymphoma
655302|NCT00088868|Waldenström macroglobulinemia
655303|NCT00088868|recurrent cutaneous T-cell non-Hodgkin lymphoma
655304|NCT00088868|stage III cutaneous T-cell non-Hodgkin lymphoma
655305|NCT00088868|stage IV cutaneous T-cell non-Hodgkin lymphoma
655306|NCT00088868|recurrent adult T-cell leukemia/lymphoma
655307|NCT00088868|stage III adult T-cell leukemia/lymphoma
655308|NCT00088868|stage IV adult T-cell leukemia/lymphoma
655309|NCT00088868|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
655310|NCT00088868|nodal marginal zone B-cell lymphoma
655311|NCT00088868|splenic marginal zone lymphoma
655312|NCT00088829|stage II breast cancer
655313|NCT00088829|stage IIIA breast cancer
655314|NCT00088829|stage IIIB breast cancer
655315|NCT00088829|stage IIIC breast cancer
655316|NCT00088829|stage IV breast cancer
655317|NCT00088829|stage IA breast cancer
655318|NCT00088829|stage IB breast cancer
655319|NCT00088829|HER2-negative breast cancer
655320|NCT00088829|HER2-positive breast cancer
655321|NCT00088816|stage IV gastric cancer
655322|NCT00088816|adenocarcinoma of the stomach
655323|NCT00088803|recurrent Wilms tumor and other childhood kidney tumors
655324|NCT00088803|stage I Wilms tumor
655325|NCT00088803|stage II Wilms tumor
655326|NCT00088803|stage III Wilms tumor
655327|NCT00088803|stage IV Wilms tumor
655328|NCT00088803|stage V Wilms tumor
655329|NCT00088790|advanced, solid, malignancies
655330|NCT00088764|Stress
655331|NCT00088764|Coping
655332|NCT00088764|Expressive Writing
655333|NCT00088764|Self-Efficacy
655334|NCT00088764|Disclosure
655335|NCT00088751|Frontotemporal Dementia
655336|NCT00088751|Alzheimer's Disease
655337|NCT00088751|Atypical Antipsychotic
655338|NCT00088751|Stimulant
655339|NCT00088751|Apathy
655340|NCT00088751|Disinhibition
655341|NCT00088751|Antipsychotic
655342|NCT00088751|Biomarkers
655343|NCT00088751|Dementia
655344|NCT00088751|FTD
655345|NCT00088738|Tachykinin
655346|NCT00088738|Anxiety
655347|NCT00088738|Neuroreceptor
655348|NCT00088738|Internalization
655349|NCT00088738|Carbon Dioxide
655350|NCT00088738|Healthy Volunteer
655351|NCT00088738|HV
655352|NCT00088738|Panic Disorder
655353|NCT00088712|Behavior and Neurocognition
655354|NCT00088712|Functional Brian Activity
655355|NCT00088712|Visual Perception
655356|NCT00088712|Selective Attention
655357|NCT00088712|Information Processing
655358|NCT00088712|Age Differences
655359|NCT00088712|Childhood Growth and Development
655360|NCT00088712|Cognitive Development
655361|NCT00088712|Brain Connectivity
655362|NCT00088712|Healthy Volunteer
655363|NCT00088712|HV
655364|NCT00088699|Depression
655365|NCT00088699|NMDA Antagonist
655366|NCT00088699|Treatment Resistant
655367|NCT00088699|Glutamatergic System
655368|NCT00088699|Bipolar Disorder
655369|NCT00088699|Major Depression
655370|NCT00088686|Preemptive Analgesia
655371|NCT00088686|Vanilloid
655372|NCT00088686|Capsaicin
655373|NCT00088686|Acute Pain
655374|NCT00088686|Orofacial
655375|NCT00088686|Vanilloid Receptor (VR)
655376|NCT00088686|Visual Analog Scale (VAS)
655377|NCT00088686|Wisdom Teeth
655378|NCT00088686|Third Molar Extraction
655379|NCT00088673|Alzheimer Disease
655380|NCT00088660|Metastatic
655381|NCT00088647|advanced malignant solid tumors
655382|NCT00088647|breast cancer
655383|NCT00088634|Schizophrenia
655384|NCT00088634|Latuda
655385|NCT00088634|Lurasidone
655386|NCT00088621|Schizophrenia
655387|NCT00088621|Latuda
655388|NCT00088621|Lurasidone
655389|NCT00088595|SOM230
655390|NCT00088595|Sandostatin
655391|NCT00088595|Carcinoid syndrome
655392|NCT00088582|Acromegaly
655393|NCT00088582|SOM230
655394|NCT00088582|Sandostatin
655395|NCT00088569|Frontal Lobe
655396|NCT00088569|Working Memory
655399|NCT00088569|Electrical
655400|NCT00088569|Healthy Volunteer
655402|NCT00088556|Non-small cell lung cancer
655403|NCT00088543|Acute myelogenous leukemia (AML)
655404|NCT00088543|Acute lymphocytic leukemia (ALL)
655405|NCT00088543|Anti-T cell antibodies
655406|NCT00088543|Allogenic stem cell transplant
655407|NCT00088543|Graft vs. Host Disease (GvHD)
655408|NCT00088530|Pixantrone
655409|NCT00088530|Non-Hodgkins lymphoma
655410|NCT00088517|Biodistribution
655411|NCT00088517|MIRD
655412|NCT00088517|Radiation Absorbed Dose
655413|NCT00088517|Healthy
655414|NCT00088517|Prefrontal Cortex
655415|NCT00088517|Radiation Exposure
655416|NCT00088517|PET
655417|NCT00088517|Dopamine D1 Receptor
655418|NCT00088517|(11C)NNC-112
655419|NCT00088517|Healthy Volunteer
655420|NCT00088517|HV
655421|NCT00088504|Hepatitis
655422|NCT00088452|childhood absence epilepsy
655423|NCT00088452|CAE
655424|NCT00088452|petit mal epilepsy
655425|NCT00088452|epilepsy
655426|NCT00088452|seizures
655427|NCT00088452|ethosuximide
655428|NCT00088452|lamotrigine
655429|NCT00088452|valproic acid
655430|NCT00088426|Holoprosencephaly
655431|NCT00088426|HPE
655432|NCT00088413|CEA
655433|NCT00088413|Vaccine
655434|NCT00088413|Immunotherapy
655435|NCT00088413|MUC-1
655436|NCT00088413|Cancer
655437|NCT00088413|Adenocarcinoma
655438|NCT00088413|Metastatic Adenocarcinoma
655439|NCT00088400|Transferrin
655440|NCT00088400|Brain Tumor
655441|NCT00088400|Convection
655442|NCT00088400|Immunotherapy
655443|NCT00088400|Targeted Protein Toxin
655444|NCT00088400|Glioblastoma Multiforme
655445|NCT00088400|GBM
655446|NCT00088387|Tau
655447|NCT00088387|T181
655448|NCT00088387|T231
655449|NCT00088387|Amyloid Beta
655450|NCT00088387|Beta-Catenin
655451|NCT00088387|Alzheimer Disease
655452|NCT00088387|AD
655453|NCT00088374|Kidney Cancer
655454|NCT00088374|VHL
655455|NCT00088374|17 AAG
655456|NCT00088374|Chemotherapy
655457|NCT00088374|Von Hippel Lindau Disease
655458|NCT00088374|Renal Tumor
655459|NCT00088361|Reconstruction
655460|NCT00088361|PET Artifacts
655461|NCT00088361|PET/CT Motion Artifacts
655462|NCT00088361|Liver
655463|NCT00088361|Heart
655464|NCT00088361|Respiratory Motion
655465|NCT00088348|Cornea
655466|NCT00088348|Conjunctiva
655467|NCT00088348|Keratitis
655468|NCT00088348|Ocular Surface
655469|NCT00088348|Inflammation
655470|NCT00088348|Evaluation
655471|NCT00088348|Screening
655472|NCT00088348|Ocular Surface Disease
655473|NCT00088348|Eye
655474|NCT00088348|Ocular Disease
655475|NCT00088348|Anterior Segment Disease
655476|NCT00088335|Parkinsonism
655477|NCT00088335|Biomarker
655478|NCT00088335|Proteomics
655479|NCT00088335|Parkinson's Disease
655480|NCT00088335|Neurodegenerative Disorders
655481|NCT00088335|Parkinson Disease
655482|NCT00088335|PD
655483|NCT00088309|Drug Resistance
655484|NCT00088309|HAART
655485|NCT00088309|Pamidronate
655486|NCT00088309|Osteopenia
655487|NCT00088309|Pediatric
655488|NCT00088309|HIV
655489|NCT00088309|Pediatrics
655490|NCT00088309|Treatment Experienced
655491|NCT00088296|Osteoarthritis
655492|NCT00088296|MS Contin
655493|NCT00088296|Placebo
655494|NCT00088296|Cortisol
655495|NCT00088296|Testosterone
655496|NCT00088296|Degenerative Joint Disease
655497|NCT00088296|OA
655498|NCT00088296|Arthritis
655499|NCT00088296|Joint Pain
655500|NCT00088296|Arthritic Pain
655501|NCT00088296|Opioid
655502|NCT00088283|CRVO
655503|NCT00088283|Central Retinal Vein Occlusion
655504|NCT00088283|RVO
655505|NCT00088283|Retinal Vein Occlusion
655506|NCT00088231|Acute Myelogenous Leukemia (AML)
655507|NCT00088231|Agnogenic Myeloid Metaplasia (AMM)
655508|NCT00088231|Chronic Myelogenous Leukemia-Blastic Phase (CML-BP)
655509|NCT00088218|Acute Myeloid Leukemia
655510|NCT00088218|AML
655511|NCT00088218|High-Risk Myelodysplastic Syndrome
655512|NCT00088218|MDS
655513|NCT00088218|Clofarabine
655514|NCT00088218|Cytarabine
655515|NCT00088218|ara-C
655516|NCT00088192|AMD
655517|NCT00088192|Age-Related Macular Degeneration
655518|NCT00088192|Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization
655519|NCT00088179|CABG
655520|NCT00088179|CPB
655521|NCT00088166|peritumoral brain edema
655522|NCT00088166|edema
655523|NCT00088166|malignant brain tumor
655524|NCT00088166|astrocytoma
655525|NCT00088166|brain tumor
655526|NCT00088166|dexamethasone
655527|NCT00088166|Decadron
655528|NCT00088153|Anorexia Nervosa
655529|NCT00088153|Amenorrhea
655530|NCT00088153|Bone Mass
655531|NCT00088153|Growth hormone
655532|NCT00088101|Hematological Malignancies
655533|NCT00088101|Leukemia
655534|NCT00088101|Lymphoma
655535|NCT00088101|Metastatic
655536|NCT00088101|Unresectable solid tumors
655537|NCT00088075|Schizophrenia
655538|NCT00088075|Risperidone
655539|NCT00088075|Adolescents
655540|NCT00088062|Crohn's Disease
655541|NCT00088023|Solid tumors
655542|NCT00087997|sarcoma
655543|NCT00087984|Kidney cancer
655544|NCT00087984|Renal cancer
655545|NCT00087958|Metastatic breast cancer
655546|NCT00087945|Treatment Experienced
655547|NCT00087932|Complementary Therapies
655548|NCT00087880|smoking cessation
655549|NCT00087867|Multiple Myeloma
655550|NCT00087867|SCIO-469
655551|NCT00087867|p38 MAP kinase
655552|NCT00087867|myeloma
655553|NCT00087867|bone marrow
655554|NCT00087841|Hypnosis
655555|NCT00087841|Analgesia
655556|NCT00087841|Embolization, Therapeutic
655557|NCT00087841|Chemoembolization, Therapeutic
655558|NCT00087828|Vaccinium macrocarpon
655559|NCT00087815|cognitive/functional effects
655560|NCT00087815|radiation toxicity
655561|NCT00087815|adult brain tumor
655562|NCT00087815|childhood brain tumor
655563|NCT00087789|Alzheimer's Disease
655564|NCT00087789|Gene Transfer
655565|NCT00087763|AMD
655566|NCT00087763|Age Related Macular Degeneration
655567|NCT00087763|Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization
655568|NCT00087685|Recurrent Endometrial Cancer
655569|NCT00087685|Endometrial
655570|NCT00087685|Endometrioid
655571|NCT00087685|RAD001
655572|NCT00087685|Uterine Cancer
655573|NCT00087672|Myelofibrosis
655574|NCT00087672|Philadelphia negative myeloproliferative disorder
655575|NCT00087672|CC-5013
655576|NCT00087672|Lenalidomide
655577|NCT00087672|Revlimid
655578|NCT00087672|Antiangiogenesis
655579|NCT00087659|ADT, BMD, US63, H014
655580|NCT00087555|Fibromyalgia
655581|NCT00087555|Pain
655582|NCT00087542|Hallucinosis/Psychosis
655583|NCT00087529|PPMS
655584|NCT00087529|Primary progressive MS
655585|NCT00087529|Primary progressive multiple sclerosis
655586|NCT00087529|Rituxan
655587|NCT00087529|MS
655588|NCT00087477|Malignant Melanoma, Pivanex, Histone deacetylases inhibitor
655589|NCT00087464|Acute Infection
655590|NCT00087464|Treatment Naive
655591|NCT00087464|Treatment Interruption
655592|NCT00087451|Progressive or recurrent malignant glioma
655593|NCT00087438|stage I non-small cell lung cancer
655594|NCT00087438|stage II non-small cell lung cancer
655595|NCT00087438|squamous cell lung cancer
655596|NCT00087438|large cell lung cancer
655597|NCT00087438|adenocarcinoma of the lung
655598|NCT00087438|bronchoalveolar cell lung cancer
655599|NCT00087425|contiguous stage II adult diffuse small cleaved cell lymphoma
655600|NCT00087425|noncontiguous stage II adult diffuse small cleaved cell lymphoma
655601|NCT00087425|recurrent adult diffuse small cleaved cell lymphoma
655602|NCT00087425|stage III adult diffuse small cleaved cell lymphoma
655603|NCT00087425|stage IV adult diffuse small cleaved cell lymphoma
655604|NCT00087425|contiguous stage II grade 1 follicular lymphoma
655605|NCT00087425|noncontiguous stage II grade 1 follicular lymphoma
655606|NCT00087425|recurrent grade 1 follicular lymphoma
655607|NCT00087425|stage III grade 1 follicular lymphoma
655608|NCT00087425|stage IV grade 1 follicular lymphoma
655609|NCT00087425|contiguous stage II grade 2 follicular lymphoma
655610|NCT00087425|noncontiguous stage II grade 2 follicular lymphoma
655611|NCT00087425|recurrent grade 2 follicular lymphoma
655612|NCT00087425|stage III grade 2 follicular lymphoma
655613|NCT00087425|stage IV grade 2 follicular lymphoma
655614|NCT00087425|contiguous stage II marginal zone lymphoma
655615|NCT00087425|noncontiguous stage II marginal zone lymphoma
655616|NCT00087425|recurrent marginal zone lymphoma
655617|NCT00087425|stage III marginal zone lymphoma
655618|NCT00087425|stage IV marginal zone lymphoma
655619|NCT00087425|refractory chronic lymphocytic leukemia
655620|NCT00087425|Waldenström macroglobulinemia
655621|NCT00087425|contiguous stage II small lymphocytic lymphoma
655622|NCT00087425|noncontiguous stage II small lymphocytic lymphoma
655623|NCT00087425|recurrent small lymphocytic lymphoma
655624|NCT00087425|stage III small lymphocytic lymphoma
655625|NCT00087425|stage IV small lymphocytic lymphoma
655626|NCT00087399|breast cancer
655627|NCT00087399|hot flashes
655628|NCT00087360|colon cancer
655629|NCT00087360|rectal cancer
655630|NCT00087347|recurrent prostate cancer
655631|NCT00087347|stage I prostate cancer
655632|NCT00087347|stage IIB prostate cancer
655633|NCT00087347|stage IIA prostate cancer
655634|NCT00087347|stage III prostate cancer
655635|NCT00087347|stage IV prostate cancer
655636|NCT00087347|stage I breast cancer
655637|NCT00087347|stage II breast cancer
655638|NCT00087347|stage IIIA breast cancer
655639|NCT00087347|stage IIIB breast cancer
655640|NCT00087347|stage IIIC breast cancer
655641|NCT00087347|stage IV breast cancer
655643|NCT00087334|recurrent colon cancer
655644|NCT00087334|stage IV colon cancer
655645|NCT00087334|recurrent rectal cancer
655646|NCT00087334|stage IV rectal cancer
655647|NCT00087295|recurrent bladder cancer
655648|NCT00087295|stage IV bladder cancer
655649|NCT00087295|transitional cell carcinoma of the bladder
655650|NCT00087295|metastatic transitional cell cancer of the renal pelvis and ureter
655651|NCT00087295|recurrent transitional cell cancer of the renal pelvis and ureter
655652|NCT00087295|anterior urethral cancer
655653|NCT00087295|posterior urethral cancer
655654|NCT00087295|recurrent urethral cancer
655655|NCT00087295|urethral cancer associated with invasive bladder cancer
655656|NCT00087282|adult primary hepatocellular carcinoma
655657|NCT00087282|advanced adult primary liver cancer
655658|NCT00087282|recurrent adult primary liver cancer
655659|NCT00087256|stage I colon cancer
655660|NCT00087256|adenocarcinoma of the colon
655661|NCT00087178|stage I breast cancer
655662|NCT00087178|stage II breast cancer
655663|NCT00087165|adenocarcinoma of the prostate
655664|NCT00087165|recurrent prostate cancer
655665|NCT00087152|stage IV breast cancer
655666|NCT00087152|recurrent breast cancer
655667|NCT00087126|recurrent cervical cancer
655668|NCT00087126|cervical squamous cell carcinoma
655669|NCT00087113|cervical squamous cell carcinoma
655670|NCT00087113|recurrent cervical cancer
655671|NCT00087113|stage III cervical cancer
655672|NCT00087113|stage IVA cervical cancer
655673|NCT00087113|stage IVB cervical cancer
655674|NCT00087100|recurrent endometrial carcinoma
655675|NCT00087100|endometrial adenocarcinoma
655676|NCT00087100|stage III endometrial carcinoma
655677|NCT00087100|stage IV endometrial carcinoma
655678|NCT00087087|recurrent ovarian epithelial cancer
655679|NCT00087087|primary peritoneal cavity cancer
655680|NCT00087061|adult anaplastic oligodendroglioma
655681|NCT00087061|recurrent adult brain tumor
655682|NCT00087061|adult glioblastoma
655683|NCT00087061|adult anaplastic astrocytoma
655684|NCT00087061|adult giant cell glioblastoma
655685|NCT00087061|adult gliosarcoma
655686|NCT00087048|extensive stage small cell lung cancer
655687|NCT00087048|recurrent small cell lung cancer
655688|NCT00087035|adenocarcinoma of the prostate
655689|NCT00087035|recurrent prostate cancer
655690|NCT00087022|clear cell renal cell carcinoma
655691|NCT00087022|stage I renal cell cancer
655692|NCT00087022|stage II renal cell cancer
655693|NCT00087022|stage III renal cell cancer
655694|NCT00087022|stage IV renal cell cancer
655695|NCT00087009|post-transplant lymphoproliferative disorder
655696|NCT00087009|recurrent childhood acute lymphoblastic leukemia
655697|NCT00087009|recurrent childhood large cell lymphoma
655698|NCT00087009|recurrent childhood lymphoblastic lymphoma
655699|NCT00087009|recurrent childhood small noncleaved cell lymphoma
655700|NCT00087009|recurrent/refractory childhood Hodgkin lymphoma
655701|NCT00087009|AIDS-related peripheral/systemic lymphoma
655702|NCT00087009|AIDS-related primary CNS lymphoma
655703|NCT00086996|adenocarcinoma of the esophagus
655704|NCT00086996|stage II esophageal cancer
655705|NCT00086996|stage III esophageal cancer
655706|NCT00086957|stage IV breast cancer
655707|NCT00086957|male breast cancer
655708|NCT00086957|recurrent breast cancer
655709|NCT00086931|adenocarcinoma of the rectum
655710|NCT00086931|stage III rectal cancer
655711|NCT00086931|stage II rectal cancer
655712|NCT00086892|recurrent ovarian epithelial cancer
655713|NCT00086892|primary peritoneal cavity cancer
655714|NCT00086879|adult glioblastoma
655715|NCT00086879|recurrent adult brain tumor
655716|NCT00086879|adult giant cell glioblastoma
655717|NCT00086879|adult gliosarcoma
655718|NCT00086866|stage III melanoma
655719|NCT00086866|stage IV melanoma
655720|NCT00086866|recurrent melanoma
655721|NCT00086801|stage I adult Hodgkin lymphoma
655722|NCT00086801|stage II adult Hodgkin lymphoma
655723|NCT00086775|refractory chronic lymphocytic leukemia
655724|NCT00086775|B-cell chronic lymphocytic leukemia
655725|NCT00086762|nausea and vomiting
655726|NCT00086762|unspecified adult solid tumor, protocol specific
655727|NCT00086762|mindfulness relaxation
655728|NCT00086749|breast cancer
655729|NCT00086749|stage I breast cancer
655730|NCT00086749|stage II breast cancer
655731|NCT00086749|stage IIIA breast cancer
655732|NCT00086749|stage IIIB breast cancer
655733|NCT00086749|stage IIIC breast cancer
655734|NCT00086736|stage I prostate cancer
655735|NCT00086736|stage IIB prostate cancer
655736|NCT00086736|stage IIA prostate cancer
655737|NCT00086736|stage III prostate cancer
655738|NCT00086723|unspecified adult solid tumor, protocol specific
655739|NCT00086684|Interstitial Cystitis
655740|NCT00086684|Urinary Bladder Pain
655741|NCT00086658|Hypereosinophilic Syndrome Hypereosinophilia
655742|NCT00086658|mepolizumab
655743|NCT00086658|anti IL-5
655744|NCT00086645|Autism
655745|NCT00086645|Asperger Syndrome
655746|NCT00086645|Pervasive Developmental Disorder
655747|NCT00086645|PDD
655748|NCT00086645|Rituals
655749|NCT00086645|Compulsions
655750|NCT00086645|Stereotypy
655751|NCT00086645|Routines
655752|NCT00086645|Repetitive behavior
655753|NCT00086645|SSRI
655754|NCT00086645|Serotonin
655755|NCT00086632|oregovomab
655756|NCT00086632|ovarex
655757|NCT00086632|ovarian cancer
655758|NCT00086632|ovary
655759|NCT00086632|ovarian carcinoma
655760|NCT00086632|front-line
655761|NCT00086619|Osteoporosis
655762|NCT00086619|Parathyroid hormone
655763|NCT00086619|Teriparatide
655764|NCT00086619|Bone formation
655765|NCT00086619|Bone resorption
655766|NCT00086606|Peanut
655767|NCT00086593|adjunctive
655768|NCT00086593|atypical antipsychotics
655769|NCT00086593|add-on
655770|NCT00086593|Schizophrenia
655771|NCT00086593|psychosis
655772|NCT00086567|Blood
655773|NCT00086567|Testing
655774|NCT00086567|Gynecologic
655775|NCT00086567|Urine
655776|NCT00086567|CA125
655777|NCT00086567|Epithelial Ovarian Cancer
655778|NCT00086567|Peritoneal Cancer
655779|NCT00086567|Fallopian Tube Cancer
655780|NCT00086554|Surgery
655781|NCT00086554|Intestinal Resection
655782|NCT00086554|Blood Sample
655783|NCT00086541|Chronic Hepatitis C
655784|NCT00086541|Liver
655785|NCT00086541|Pegylated
655786|NCT00086541|Interferon
655787|NCT00086541|Alpha
655788|NCT00086541|Ribavirin
655789|NCT00086541|Combination
655790|NCT00086541|Nonresponder
655791|NCT00086541|HCV
655792|NCT00086541|Infergen
655793|NCT00086541|SVR
655794|NCT00086528|Solid Tumors
655795|NCT00086515|Type 2 Diabetes Mellitus
655796|NCT00086489|metastatic melanoma
655797|NCT00086489|multiple dose
655798|NCT00086476|Gray Platelet Syndrome
655799|NCT00086476|Hermansky-Pudlak Syndrome
655800|NCT00086476|Storage Pool Deficiency
655801|NCT00086476|Organelle Formation
655802|NCT00086476|Megakaryocyte Development
655803|NCT00086476|Megakaryocytes
655804|NCT00086476|Platelets
655805|NCT00086476|Dense Granules
655806|NCT00086476|Alpha Granules
655807|NCT00086476|Lysosome-related Organelles
655808|NCT00086476|GPS
655809|NCT00086476|HPS
655810|NCT00086476|Griscelli Disease
655811|NCT00086476|Chediak Higashi Syndrome
655812|NCT00086476|Wiskott Aldrich Syndrome
655813|NCT00086476|Platelet
655814|NCT00086476|Congenital Bleeding Disorders
655815|NCT00086476|SAC
655816|NCT00086476|Vesicle
655817|NCT00086463|STEP
655818|NCT00086463|PAH
655819|NCT00086463|iloprost
655820|NCT00086463|inhalation
655821|NCT00086463|prostacyclin
655822|NCT00086411|light smokers, smoking cessation treatment programs
655823|NCT00086385|Smoking cessation
655824|NCT00086385|Tobacco
655825|NCT00086372|Acute Infection
655826|NCT00086372|Treatment Experienced
655827|NCT00086372|Treatment Naive
655828|NCT00086359|Treatment Naive
655829|NCT00086359|Perinatal Transmission
655830|NCT00086359|Mother-to-Child Transmission
655831|NCT00086359|MTCT
655832|NCT00086359|Treatment Experienced
655833|NCT00086346|Liver
655834|NCT00086346|Transplant
655835|NCT00086333|Carcinoma, Non-Small-Cell Lung
655836|NCT00086333|Taxotere
655837|NCT00086333|docetaxel
655838|NCT00086333|taxanes
655839|NCT00086320|Schizophrenia
655840|NCT00086320|paliperidone
655841|NCT00086320|Risperidone
655842|NCT00086307|Pramipexole
655843|NCT00086307|Escitalopran
655844|NCT00086307|Antidepressant
655845|NCT00086307|Dopaminergic Receptor Agonist
655846|NCT00086307|Depression
655847|NCT00086307|Major Depression
655848|NCT00086294|Non-Dopaminergic
655849|NCT00086294|Dyskinesias
655850|NCT00086294|Fluctuations
655851|NCT00086294|Inverse Agonist
655852|NCT00086294|ACP-103
655853|NCT00086294|Parkinson Disease
655854|NCT00086294|PD
655855|NCT00086281|Sleep-disordered breathing
655856|NCT00086281|Obstructive sleep apnea syndrome
655857|NCT00086268|lung cancer
655858|NCT00086268|ZPACT
655859|NCT00086268|US75
655860|NCT00086268|Bone Metastases
655861|NCT00086255|cocaine dependence
655862|NCT00086242|psychosocial effects of cancer and its treatment
655863|NCT00086242|stage IA cervical cancer
655864|NCT00086242|stage IB cervical cancer
655865|NCT00086242|stage IIA cervical cancer
655866|NCT00086242|stage IIB cervical cancer
655867|NCT00086242|stage III cervical cancer
655868|NCT00086229|Complementary Therapies
655869|NCT00086216|Multiple myeloma
655870|NCT00086190|Parkinson disease
655871|NCT00086190|depression
655872|NCT00086190|Parkinson's disease
655873|NCT00086190|paroxetine
655874|NCT00086190|venlafaxine
655875|NCT00086190|antidepressant
655876|NCT00086177|Pregnancy,
655877|NCT00086177|prevention of preterm birth,
655878|NCT00086177|prevention of preterm labor,
655879|NCT00086164|edifoligide
655880|NCT00086164|E2F Decoy
655881|NCT00086164|Chronic Renal failure
655882|NCT00086164|hemodialysis
655883|NCT00086164|AV Graft
655884|NCT00086164|neointimal hyperplasia
655885|NCT00086138|Alzheimer's disease
655886|NCT00086138|Depression
655887|NCT00086125|Relapsed or refractory hematologic malignancies
655888|NCT00086112|Anxiety
655889|NCT00086112|antipsychotic
655890|NCT00086086|Symptomatic Congestive Heart Failure
655891|NCT00086086|CHF
655892|NCT00086086|Anaemia
655893|NCT00086086|Anemia
655894|NCT00086073|Parkinson disease
655895|NCT00086073|Parkinson's disease
655896|NCT00086073|PD
655897|NCT00086073|genetics
655898|NCT00086073|genes
655899|NCT00086073|siblings
655900|NCT00086073|family
655901|NCT00086060|Internal-External Control
655902|NCT00086060|Magnetic Resonance Imaging
655903|NCT00086060|fMRI
655904|NCT00086060|Exercise
655905|NCT00086060|Relaxation
655906|NCT00086047|Juvenile Fibromyalgia Syndrome
655907|NCT00086047|JPFS
655908|NCT00086047|Fibromyalgia
655909|NCT00086047|Chronic Pain
655910|NCT00086047|Pediatric Pain
655911|NCT00086047|Juvenile Fibromyalgia
655912|NCT00086034|Lymphoma
655913|NCT00086034|Non-Hodgkin's Lymphoma
655914|NCT00086034|Indolent lymphoma
655915|NCT00086034|Relapsed lymphoma
655916|NCT00086034|Refractory lymphoma
655917|NCT00086034|Motexafin gadolinium
655918|NCT00086021|Headache
655919|NCT00086021|Acupuncture
655920|NCT00085995|Syndesmophyte
655921|NCT00085995|Ankylosing Spondylitis
655922|NCT00085995|AS
655923|NCT00085995|Spondyloarthropathy
655924|NCT00085995|Spondyloarthritis
655925|NCT00085982|Rabson Mendenhall
655926|NCT00085982|Type B Insulin Resistance
655927|NCT00085982|Type A Insulin Resistance
655928|NCT00085982|Diabetes
655929|NCT00085969|diabetes
655930|NCT00085969|exenatide
655931|NCT00085969|Amylin
655932|NCT00085969|Lilly
655933|NCT00085943|ritonavir
655934|NCT00085943|abacavir
655935|NCT00085943|HIV
655936|NCT00085943|lopinavir
655937|NCT00085943|lamivudine
655938|NCT00085943|fosamprenavir
655939|NCT00085943|Epzicom
655940|NCT00085930|Neuroblastoma
655941|NCT00085917|Pegasys
655942|NCT00085917|Ribavirin
655943|NCT00085917|Early Virological Response
655944|NCT00085917|Hepatitis C
655945|NCT00085917|HIV
655946|NCT00085904|Advanced cancer
655947|NCT00085904|IL-18
655948|NCT00085904|repeat dosing
655949|NCT00085904|Phase 1
655950|NCT00085904|pharmacokinetics
655951|NCT00085904|oncology
655952|NCT00085891|Schizophrenia
655953|NCT00085891|Schizophrenic disorder
655954|NCT00085878|IL-18
655955|NCT00085878|subcutaneous
655956|NCT00085878|pharmacokinetics
655957|NCT00085878|Phase 1
655958|NCT00085865|5 HT
655959|NCT00085865|Neuroreceptors
655960|NCT00085865|Radiotracer
655961|NCT00085865|Neuroimaging
655962|NCT00085865|Serotonin Transporter
655963|NCT00085865|Alcoholism
655964|NCT00085865|PET
655965|NCT00085865|Healthy Volunteer
655966|NCT00085865|HV
655967|NCT00085852|emphysema
655968|NCT00085852|chronic obstructive pulmonary disease
655969|NCT00085852|lung volume reduction
655970|NCT00085852|bronchoscopic
655971|NCT00085852|bronchoscopy
655972|NCT00085852|bronchoscope
655973|NCT00085839|Tarceva
655974|NCT00085839|NSCLC
655975|NCT00085839|EGFR
655976|NCT00085839|ECOG Performance Status 2
655977|NCT00085839|erlotinib
655978|NCT00085839|Non-Small Cell Lung Cancer
655979|NCT00085839|OSI-774
655980|NCT00085826|Lung Cancer
655981|NCT00085826|NSCLC
655982|NCT00085826|Non-small Cell Lung Cancer
655983|NCT00085813|Platinum-Refractory
655984|NCT00085813|Platinum-Relapsed
655985|NCT00085813|Non-Small Cell Lung Cancer
655986|NCT00085774|albuterol
655987|NCT00085774|aerosol inhaler
655988|NCT00085774|metered-dose inhaler
655989|NCT00085774|breath-actuated inhaler
655990|NCT00085774|exercise-induced bronchospasm
655991|NCT00085761|Dermal assessment
655992|NCT00085761|Pain measurement
655993|NCT00085761|Diary
655994|NCT00085761|Neuropathy
655995|NCT00085761|Analgesics/*therapeutic use
655996|NCT00085761|Capsaicin/*administration & dosage/adverse effects
655997|NCT00085761|HIV Infections/*complications/*drug therapy
655998|NCT00085761|Pain
655999|NCT00085761|Complementary Therapies
656000|NCT00085748|schizophrenia
656001|NCT00085748|geriatric
656002|NCT00085748|elderly
656003|NCT00085722|Injection Therapy
656004|NCT00085709|untreated adult acute myeloid leukemia
656005|NCT00085709|adult acute eosinophilic leukemia
656006|NCT00085709|adult acute basophilic leukemia
656007|NCT00085709|adult acute monocytic leukemia (M5b)
656008|NCT00085709|adult acute erythroid leukemia (M6)
656009|NCT00085709|adult acute megakaryoblastic leukemia (M7)
656010|NCT00085709|adult acute minimally differentiated myeloid leukemia (M0)
656011|NCT00085709|adult acute myeloblastic leukemia with maturation (M2)
656012|NCT00085709|adult acute myeloblastic leukemia without maturation (M1)
656013|NCT00085709|adult acute myelomonocytic leukemia (M4)
656014|NCT00085709|adult acute monoblastic leukemia (M5a)
656015|NCT00085709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
656016|NCT00085709|adult acute myeloid leukemia with inv(16)(p13;q22)
656017|NCT00085709|adult acute myeloid leukemia with t(16;16)(p13;q22)
656018|NCT00085709|adult acute myeloid leukemia with t(8;21)(q22;q22)
656019|NCT00085696|Lymphoma
656020|NCT00085696|Non-Hodgkin's
656021|NCT00085696|NHL
656022|NCT00085696|B-Cell
656023|NCT00085696|Indolent
656024|NCT00085683|Magnetic Resonance Spectroscopy
656025|NCT00085683|Lumbar Puncture
656026|NCT00085683|Healthy Control Subjects
656027|NCT00085683|Mesial Temporal Sclerosis
656028|NCT00085683|Neuroexcitotoxicity
656029|NCT00085683|Seizure Disorder
656030|NCT00085683|Epilepsy
656031|NCT00085683|Healthy Volunteer
656032|NCT00085683|HV
656033|NCT00085670|Tumor Necrosis Factor Alpha (TNF-Alpha)
656034|NCT00085670|Interferon-Gamma (IFN-Gamma)
656035|NCT00085670|Transforming Growth Factor Beta 1 (TGF-B1)
656036|NCT00085670|Interleukin-10 (IL-10)
656037|NCT00085670|Interleukin-1 Receptor Antagonist (IL-1 Ra)
656038|NCT00085670|Vitamin D Receptor (VitD R)
656039|NCT00085670|Interleukin-6 (IL-6)
656040|NCT00085670|Bone Marrow Failure
656041|NCT00085670|Aplastic Anemia
656042|NCT00085670|Myelodysplastic Syndrome
656043|NCT00085670|MDS
656044|NCT00085670|Pure Red Cell Aplasia
656045|NCT00085670|PRCA
656046|NCT00085657|Direct Current Stimulation
656047|NCT00085657|Cortical Reorganization
656048|NCT00085657|Rehabilitation
656049|NCT00085657|Acute Stroke
656050|NCT00085657|Stroke
656051|NCT00085631|stage IA cervical cancer
656052|NCT00085631|stage IB cervical cancer
656053|NCT00085631|stage IIA cervical cancer
656054|NCT00085631|stage IIB cervical cancer
656055|NCT00085631|stage III cervical cancer
656056|NCT00085631|stage IVA cervical cancer
656057|NCT00085631|cervical adenocarcinoma
656058|NCT00085631|cervical adenosquamous cell carcinoma
656059|NCT00085631|cervical squamous cell carcinoma
656060|NCT00085579|stage III melanoma
656061|NCT00085579|stage IV melanoma
656062|NCT00085566|adult glioblastoma
656063|NCT00085566|recurrent prostate cancer
656064|NCT00085566|recurrent adult brain tumor
656065|NCT00085566|stage IV prostate cancer
656066|NCT00085566|adult giant cell glioblastoma
656067|NCT00085566|adult gliosarcoma
656068|NCT00085527|recurrent ovarian epithelial cancer
656069|NCT00085527|stage III ovarian epithelial cancer
656070|NCT00085527|stage IV ovarian epithelial cancer
656071|NCT00085501|recurrent non-small cell lung cancer
656072|NCT00085501|stage IIIB non-small cell lung cancer
656073|NCT00085501|stage IV non-small cell lung cancer
656074|NCT00085501|adenocarcinoma of the lung
656075|NCT00085501|squamous cell lung cancer
656076|NCT00085501|large cell lung cancer
656077|NCT00085488|recurrent melanoma
656078|NCT00085488|stage III melanoma
656079|NCT00085488|stage IV melanoma
656080|NCT00085475|recurrent adult soft tissue sarcoma
656081|NCT00085475|stage III adult soft tissue sarcoma
656082|NCT00085475|stage IV adult soft tissue sarcoma
656083|NCT00085475|adult fibrosarcoma
656084|NCT00085475|adult malignant fibrous histiocytoma
656085|NCT00085462|recurrent melanoma
656086|NCT00085462|stage IV melanoma
656087|NCT00085449|recurrent adult acute myeloid leukemia
656088|NCT00085449|adult acute myeloid leukemia in remission
656089|NCT00085449|recurrent adult acute lymphoblastic leukemia
656090|NCT00085449|adult acute lymphoblastic leukemia in remission
656091|NCT00085449|myelodysplastic/myeloproliferative neoplasm, unclassifiable
656092|NCT00085449|previously treated myelodysplastic syndromes
656093|NCT00085449|atypical chronic myeloid leukemia, BCR-ABL1 negative
656094|NCT00085449|chronic myelomonocytic leukemia
656095|NCT00085449|recurrent adult Burkitt lymphoma
656096|NCT00085449|recurrent grade 1 follicular lymphoma
656097|NCT00085449|recurrent grade 2 follicular lymphoma
656098|NCT00085449|recurrent grade 3 follicular lymphoma
656099|NCT00085449|recurrent adult diffuse small cleaved cell lymphoma
656100|NCT00085449|recurrent adult immunoblastic large cell lymphoma
656101|NCT00085449|recurrent small lymphocytic lymphoma
656102|NCT00085449|recurrent marginal zone lymphoma
656103|NCT00085449|recurrent mantle cell lymphoma
656104|NCT00085449|recurrent adult lymphoblastic lymphoma
656105|NCT00085449|accelerated phase chronic myelogenous leukemia
656106|NCT00085449|chronic phase chronic myelogenous leukemia
656107|NCT00085449|recurrent adult diffuse mixed cell lymphoma
656108|NCT00085449|recurrent adult diffuse large cell lymphoma
656109|NCT00085449|refractory chronic lymphocytic leukemia
656110|NCT00085449|stage III chronic lymphocytic leukemia
656111|NCT00085449|stage IV chronic lymphocytic leukemia
656112|NCT00085449|refractory multiple myeloma
656113|NCT00085449|secondary myelodysplastic syndromes
656114|NCT00085449|de novo myelodysplastic syndromes
656115|NCT00085449|adult acute myeloid leukemia with t(8;21)(q22;q22)
656116|NCT00085449|adult acute myeloid leukemia with t(16;16)(p13;q22)
656117|NCT00085449|adult acute myeloid leukemia with inv(16)(p13;q22)
656118|NCT00085449|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
656119|NCT00085449|adult acute myeloid leukemia with t(15;17)(q22;q12)
656120|NCT00085436|recurrent renal cell cancer
656121|NCT00085436|stage IV renal cell cancer
656122|NCT00085423|recurrent melanoma
656123|NCT00085423|stage IV melanoma
656124|NCT00085397|recurrent melanoma
656125|NCT00085397|stage III melanoma
656126|NCT00085397|stage IV melanoma
656127|NCT00085384|recurrent ovarian epithelial cancer
656128|NCT00085384|peritoneal cavity cancer
656129|NCT00085384|fallopian tube cancer
656130|NCT00085332|recurrent endometrial carcinoma
656131|NCT00085332|stage III endometrial carcinoma
656132|NCT00085332|stage IV endometrial carcinoma
656133|NCT00085306|recurrent melanoma
656134|NCT00085306|stage IV melanoma
656135|NCT00085306|iris melanoma
656136|NCT00085306|ciliary body and choroid melanoma, medium/large size
656137|NCT00085306|extraocular extension melanoma
656138|NCT00085306|recurrent intraocular melanoma
656139|NCT00085228|adenocarcinoma of the prostate
656140|NCT00085228|recurrent prostate cancer
656141|NCT00085228|stage IV prostate cancer
656142|NCT00085202|untreated childhood medulloblastoma
656143|NCT00085202|untreated childhood supratentorial primitive neuroectodermal tumor
656144|NCT00085202|childhood atypical teratoid/rhabdoid tumor
656145|NCT00085202|untreated childhood pineoblastoma
656146|NCT00085176|long-term effects secondary to cancer therapy in children
656147|NCT00085176|neurotoxicity
656148|NCT00085176|psychosocial effects of cancer and its treatment
656149|NCT00085176|childhood acute lymphoblastic leukemia in remission
656150|NCT00085163|adenocarcinoma of the colon
656151|NCT00085163|stage III colon cancer
656152|NCT00085150|recurrent adult T-cell leukemia/lymphoma
656153|NCT00085150|recurrent childhood acute lymphoblastic leukemia
656154|NCT00085150|childhood Burkitt lymphoma
656155|NCT00085150|recurrent childhood acute myeloid leukemia
656156|NCT00085150|recurrent childhood large cell lymphoma
656157|NCT00085150|recurrent childhood lymphoblastic lymphoma
656158|NCT00085150|recurrent mycosis fungoides/Sezary syndrome
656159|NCT00085150|recurrent cutaneous T-cell non-Hodgkin lymphoma
656160|NCT00085150|recurrent/refractory childhood Hodgkin lymphoma
656161|NCT00085150|relapsing chronic myelogenous leukemia
656162|NCT00085150|acute undifferentiated leukemia
656163|NCT00085098|childhood central nervous system germ cell tumor
656164|NCT00085059|stage IV melanoma
656165|NCT00085059|recurrent melanoma
656166|NCT00085020|stage IV breast cancer
656167|NCT00085020|male breast cancer
656168|NCT00085020|recurrent breast cancer
656169|NCT00084942|cholangiocarcinoma of the gallbladder
656170|NCT00084942|recurrent gallbladder cancer
656171|NCT00084942|unresectable gallbladder cancer
656172|NCT00084942|cholangiocarcinoma of the extrahepatic bile duct
656173|NCT00084942|recurrent extrahepatic bile duct cancer
656174|NCT00084942|unresectable extrahepatic bile duct cancer
656175|NCT00084929|colon cancer
656176|NCT00084929|rectal cancer
656177|NCT00084903|cervical cancer
656178|NCT00084903|cervical intraepithelial neoplasia
656179|NCT00084890|stage IVB cervical cancer
656180|NCT00084890|recurrent cervical cancer
656181|NCT00084890|cervical squamous cell carcinoma
656182|NCT00084864|adenocarcinoma of the prostate
656183|NCT00084864|stage II prostate cancer
656184|NCT00084864|stage III prostate cancer
656185|NCT00084838|childhood atypical teratoid/rhabdoid tumor
656186|NCT00084825|adenocarcinoma of the prostate
656187|NCT00084825|recurrent prostate cancer
656188|NCT00084825|stage IV prostate cancer
656189|NCT00084825|bone metastases
656190|NCT00084812|unspecified adult solid tumor, protocol specific
656191|NCT00084799|recurrent small cell lung cancer
656192|NCT00084786|unspecified adult solid tumor, protocol specific
656193|NCT00084773|recurrent rectal cancer
656194|NCT00084773|stage II rectal cancer
656195|NCT00084773|stage III rectal cancer
656196|NCT00084773|adenocarcinoma of the rectum
656197|NCT00084747|stage II multiple myeloma
656198|NCT00084747|stage III multiple myeloma
656199|NCT00084734|unspecified adult solid tumor, protocol specific
656200|NCT00084721|diarrhea
656201|NCT00084721|recurrent colon cancer
656202|NCT00084721|stage IV colon cancer
656203|NCT00084721|recurrent rectal cancer
656204|NCT00084721|stage IV rectal cancer
656205|NCT00084721|stage III colon cancer
656206|NCT00084721|stage III rectal cancer
656207|NCT00084708|unspecified adult solid tumor, protocol specific
656208|NCT00084695|childhood myelodysplastic syndromes
656209|NCT00084695|recurrent childhood rhabdomyosarcoma
656433|NCT00083915|Dexamethasone
656210|NCT00084695|unspecified childhood solid tumor, protocol specific
656436|NCT00083915|Sargramostim
656211|NCT00084695|previously treated childhood rhabdomyosarcoma
656212|NCT00084695|previously untreated childhood rhabdomyosarcoma
656213|NCT00084695|disseminated neuroblastoma
656214|NCT00084695|regional neuroblastoma
656215|NCT00084695|recurrent neuroblastoma
656216|NCT00084695|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
656217|NCT00084695|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
656218|NCT00084695|recurrent childhood acute lymphoblastic leukemia
656219|NCT00084695|juvenile myelomonocytic leukemia
656220|NCT00084695|childhood acute lymphoblastic leukemia in remission
656221|NCT00084695|childhood Burkitt lymphoma
656222|NCT00084695|recurrent childhood lymphoblastic lymphoma
656223|NCT00084695|stage III childhood lymphoblastic lymphoma
656224|NCT00084695|stage IV childhood lymphoblastic lymphoma
656225|NCT00084695|recurrent childhood small noncleaved cell lymphoma
656226|NCT00084695|stage III childhood small noncleaved cell lymphoma
656227|NCT00084695|stage IV childhood small noncleaved cell lymphoma
656228|NCT00084695|recurrent childhood large cell lymphoma
656229|NCT00084695|stage III childhood large cell lymphoma
656230|NCT00084695|stage IV childhood large cell lymphoma
656231|NCT00084695|stage III childhood Hodgkin lymphoma
656232|NCT00084695|stage IV childhood Hodgkin lymphoma
656233|NCT00084695|previously treated myelodysplastic syndromes
656234|NCT00084695|Fanconi anemia
656235|NCT00084695|de novo myelodysplastic syndromes
656236|NCT00084695|secondary myelodysplastic syndromes
656237|NCT00084695|childhood chronic myelogenous leukemia
656238|NCT00084695|chronic phase chronic myelogenous leukemia
656239|NCT00084695|relapsing chronic myelogenous leukemia
656240|NCT00084695|childhood Langerhans cell histiocytosis
656241|NCT00084695|recurrent childhood acute myeloid leukemia
656242|NCT00084695|recurrent/refractory childhood Hodgkin lymphoma
656243|NCT00084669|hot flashes
656244|NCT00084669|sleep disorders
656245|NCT00084669|ductal breast carcinoma in situ
656246|NCT00084669|breast cancer in situ
656247|NCT00084669|lobular breast carcinoma in situ
656248|NCT00084669|lobular breast carcinoma
656249|NCT00084669|recurrent breast cancer
656250|NCT00084669|stage I breast cancer
656251|NCT00084669|stage II breast cancer
656252|NCT00084669|stage IIIA breast cancer
656253|NCT00084669|stage IIIB breast cancer
656254|NCT00084669|stage IIIC breast cancer
656255|NCT00084669|stage IV breast cancer
656256|NCT00084656|stage III melanoma
656257|NCT00084656|stage IV melanoma
656258|NCT00084656|ciliary body and choroid melanoma, medium/large size
656259|NCT00084656|extraocular extension melanoma
656260|NCT00084656|iris melanoma
656261|NCT00084656|recurrent melanoma
656262|NCT00084656|recurrent intraocular melanoma
656263|NCT00084656|metastatic intraocular melanoma
656264|NCT00084591|stage II rectal cancer
656265|NCT00084591|stage III rectal cancer
656266|NCT00084591|adenocarcinoma of the rectum
656267|NCT00084578|stage 0 bladder cancer
656268|NCT00084578|stage I bladder cancer
656269|NCT00084578|stage II bladder cancer
656270|NCT00084578|stage III bladder cancer
656271|NCT00084578|stage IV bladder cancer
656272|NCT00084578|transitional cell carcinoma of the bladder
656273|NCT00084565|stage IV prostate cancer
656274|NCT00084565|adenocarcinoma of the prostate
656275|NCT00084552|sexual dysfunction
656276|NCT00084552|sexuality and reproductive issues
656277|NCT00084552|adenocarcinoma of the prostate
656278|NCT00084552|stage IIB prostate cancer
656279|NCT00084552|stage IIA prostate cancer
656280|NCT00084539|stage I breast cancer
656281|NCT00084539|stage II breast cancer
656282|NCT00084539|breast cancer in situ
656283|NCT00084526|recurrent prostate cancer
656284|NCT00084526|stage I prostate cancer
656285|NCT00084526|stage II prostate cancer
656286|NCT00084526|stage III prostate cancer
656287|NCT00084526|stage IV prostate cancer
656288|NCT00084513|unspecified adult solid tumor, protocol specific
656289|NCT00084448|recurrent ovarian epithelial cancer
656290|NCT00084448|primary peritoneal cavity cancer
656291|NCT00084435|stage III squamous cell carcinoma of the lip and oral cavity
656292|NCT00084435|stage IV squamous cell carcinoma of the lip and oral cavity
656293|NCT00084435|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
656294|NCT00084435|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
656295|NCT00084435|stage III salivary gland cancer
656296|NCT00084435|stage IV salivary gland cancer
656297|NCT00084435|stage III squamous cell carcinoma of the hypopharynx
656298|NCT00084435|stage IV squamous cell carcinoma of the hypopharynx
656299|NCT00084435|stage III squamous cell carcinoma of the larynx
656300|NCT00084435|stage IV squamous cell carcinoma of the larynx
656301|NCT00084435|stage III squamous cell carcinoma of the oropharynx
656302|NCT00084435|stage IV squamous cell carcinoma of the oropharynx
656303|NCT00084435|salivary gland squamous cell carcinoma
656304|NCT00084422|recurrent neuroblastoma
656305|NCT00084409|non-small cell lung cancer
656306|NCT00084409|squamous lung dysplasia
656307|NCT00084396|stage II breast cancer
656308|NCT00084396|stage IIIA breast cancer
656309|NCT00084396|stage IIIB breast cancer
656310|NCT00084383|stage I pancreatic cancer
656311|NCT00084383|stage II pancreatic cancer
656312|NCT00084383|duct cell adenocarcinoma of the pancreas
656313|NCT00084370|ovarian epithelial cancer
656314|NCT00084370|BRCA1 mutation carrier
656315|NCT00084370|BRCA2 mutation carrier
656316|NCT00084344|breast cancer
656317|NCT00084318|stage III squamous cell carcinoma of the hypopharynx
656318|NCT00084318|stage IV squamous cell carcinoma of the hypopharynx
656319|NCT00084318|stage III squamous cell carcinoma of the oropharynx
656320|NCT00084318|stage IV squamous cell carcinoma of the oropharynx
656321|NCT00084318|stage III squamous cell carcinoma of the larynx
656322|NCT00084318|stage IV squamous cell carcinoma of the larynx
656323|NCT00084318|stage III lymphoepithelioma of the oropharynx
656324|NCT00084318|stage IV lymphoepithelioma of the oropharynx
656325|NCT00084305|Bronchoscopy
656326|NCT00084305|Pulmonary Fibrosis
656327|NCT00084305|Lung Biopsy (Clinically-Indicated)
656328|NCT00084305|Hereditary Pulmonary Fibrosis
656329|NCT00084305|Healthy Volunteer
656330|NCT00084305|HV
656331|NCT00084292|Ischemia
656332|NCT00084292|Pediatric
656333|NCT00084292|Etiology
656334|NCT00084292|Treatment
656335|NCT00084292|Outcome
656336|NCT00084292|Childhood Stroke
656337|NCT00084292|Pediatric Stroke
656338|NCT00084292|Ischemic Stroke
656339|NCT00084292|Spastic Hemiplegia
656340|NCT00084292|Hemiplegic cerebral palsy
656341|NCT00084279|Chronic Hepatitis C
656342|NCT00084279|Liver
656343|NCT00084279|Pegylated
656344|NCT00084279|Interferon
656345|NCT00084279|Alpha
656346|NCT00084279|Gamma
656347|NCT00084279|Ribavirin
656348|NCT00084279|Combination
656349|NCT00084279|Nonresponder
656350|NCT00084279|Pegasys
656351|NCT00084279|PegIntron
656352|NCT00084266|Staphylococcal pneumonia
656353|NCT00084266|Methicillin-resistant staphylococcal pneumonia
656354|NCT00084266|healthcare-associated pneumonia
656355|NCT00084253|HIV
656356|NCT00084253|Treatment Naive
656357|NCT00084214|metastatic
656358|NCT00084214|increased antitumor effect
656359|NCT00084201|Vaccinium macrocarpon
656360|NCT00084188|behavioral intervention
656361|NCT00084175|behavioral intervention
656362|NCT00084162|PET
656363|NCT00084162|Heart Rate Variability
656364|NCT00084162|N-Back Task
656365|NCT00084162|Isometric Handgrip
656366|NCT00084162|MRI
656367|NCT00084162|Depression
656368|NCT00084162|MDD
656369|NCT00084162|Heart
656370|NCT00084149|Acute Infection
656371|NCT00084149|Treatment Naive
656372|NCT00084136|Treatment Naive
656373|NCT00084136|Adherence
656374|NCT00084136|Drug Resistance
656375|NCT00084136|Treatment Failure
656376|NCT00084123|Relaxation Techniques
656377|NCT00084123|Radiation
656378|NCT00084123|Drug Therapy
656379|NCT00084123|Healing Touch
656380|NCT00084110|Aged
656381|NCT00084110|Mexican Americans
656382|NCT00084110|Complementary Therapies
656383|NCT00084097|Allergy
656384|NCT00084097|IgE
656385|NCT00084097|Eosinophil
656386|NCT00084097|Monoclonal Antibody
656387|NCT00084097|Eosinophilic Gastroenteritis
656388|NCT00084097|EG
656389|NCT00084084|Lysosomes
656390|NCT00084084|Storage
656391|NCT00084084|Glycolipid
656392|NCT00084084|Fabry disease
656393|NCT00084084|Stroke
656394|NCT00084084|Children
656395|NCT00084084|Pediatrics
656396|NCT00084058|Dose Intensification
656397|NCT00084058|Pharmacokinetic Sampling
656398|NCT00084058|Treatment Experienced
656399|NCT00084058|Child
656400|NCT00084045|HIV Seronegativity
656401|NCT00084045|Treatment Naive
656402|NCT00084045|Pediatric HIV
656403|NCT00084045|Perinatal Transmission
656404|NCT00084032|Acute Infection
656405|NCT00084032|Treatment Interruption
656406|NCT00084032|Treatment Naive
656407|NCT00084032|Primary HIV Infection
656408|NCT00084032|PHI
656409|NCT00084019|Treatment Experienced
656410|NCT00083993|Breast Cancer
656411|NCT00083980|Kava
656412|NCT00083980|Complementary Therapies
656413|NCT00083980|Medicine, Herbal
656414|NCT00083967|rhegmatogenous retinal detachment
656415|NCT00083967|detached retina
656416|NCT00083967|retinal tear
656417|NCT00083967|retinal break
656418|NCT00083954|Bipolar I Disorder
656419|NCT00083941|Renal Cell Cancer
656420|NCT00083941|Requiring IL-2 treatment
656421|NCT00083941|Stage IV Renal Cell Cancer
656422|NCT00083928|Asymptomatic
656423|NCT00083928|subcutaneous
656424|NCT00083928|CA125 Progression
656425|NCT00083928|Angstrom
656426|NCT00083928|Ångstrom
656427|NCT00083928|ovarian cancer
656428|NCT00083915|Multiple Myeloma
656429|NCT00083915|DTPACE
656430|NCT00083915|Tandem Transplant
656431|NCT00083915|Cisplatin
656432|NCT00083915|Cyclophosphamide
656434|NCT00083915|Doxorubicin
656435|NCT00083915|Etoposide
656437|NCT00083915|Thalidomide
656438|NCT00083915|Melphalan
656439|NCT00083902|Myeloma
656440|NCT00083902|Thalidomide
656441|NCT00083902|Dexamethasone
656442|NCT00083876|Multiple Myeloma
656443|NCT00083876|D.T. PACE
656444|NCT00083876|Melphalan
656445|NCT00083876|Transplant
656446|NCT00083876|Thalidomide
656447|NCT00083876|Dexamethasone
656448|NCT00083876|Cisplatin
656449|NCT00083876|Cyclophosphamide
656450|NCT00083876|Doxorubicin
656451|NCT00083876|Etoposide
656452|NCT00083876|Filgrastim
656453|NCT00083876|Interferon-alpha 2b
656454|NCT00083876|Sargramostim
656455|NCT00083772|Heart failure
656456|NCT00083772|Diastolic heart failure
656457|NCT00083772|Congestive heart failure
656458|NCT00083772|Nesiritide
656459|NCT00083772|Natrecor
656460|NCT00083772|Left ventricular (LV) diastolic function
656461|NCT00083772|Fatigue
656462|NCT00083772|Shortness of breath
656463|NCT00083772|Edema
656464|NCT00083772|Heart disease
656465|NCT00083733|Gene Expression
656466|NCT00083733|Microarray
656467|NCT00083733|Stem Cell
656468|NCT00083733|Proteomics
656469|NCT00083733|Metastases
656470|NCT00083733|Breast Tissue
656471|NCT00083733|Normal Breast Tissue
656472|NCT00083733|Breast Cancer
656473|NCT00083720|EGFR-undetectable
656474|NCT00083720|Metastatic Colorectal Cancer
656475|NCT00083707|Macroglobulinemia
656476|NCT00083707|Waldenstrom
656477|NCT00083707|Thalidomide
656478|NCT00083694|Leukemia
656479|NCT00083694|Thalidomide
656480|NCT00083694|relapsed
656481|NCT00083681|Multiple Myeloma
656482|NCT00083681|Thalidomide
656483|NCT00083681|G-CSF
656484|NCT00083681|Cisplatin
656485|NCT00083681|Etoposide
656486|NCT00083681|Dexamethasone
656487|NCT00083681|Cytoxan
656488|NCT00083681|DCEP
656489|NCT00083681|Relapse
656490|NCT00083668|Schizophrenia
656491|NCT00083668|Paliperidone
656492|NCT00083668|Olanzapine
656493|NCT00083668|PANSS
656494|NCT00083668|Extended release
656495|NCT00083668|Atypical neuroleptic
656496|NCT00083642|Brain Plasticity
656497|NCT00083642|Functional MRI
656498|NCT00083642|Finger Movement
656499|NCT00083642|Rehabilitation
656500|NCT00083642|Improvement
656501|NCT00083642|Stroke
656502|NCT00083642|Motor Recovery
656503|NCT00083642|Observation
656504|NCT00083642|fMRI
656505|NCT00083642|Healthy Volunteer
656506|NCT00083642|HV
656507|NCT00083629|[18F]FECNT
656508|NCT00083629|Biodistribution
656509|NCT00083629|Dosimetry
656510|NCT00083629|Dopamine Transporter
656511|NCT00083629|MIRD
656512|NCT00083629|Kinetic Analysis
656513|NCT00083629|Compartment Analysis
656514|NCT00083629|Healthy Volunteer
656515|NCT00083629|HV
656516|NCT00083616|EGFr
656517|NCT00083616|Clinical Trial
656518|NCT00083616|Panitumumab
656519|NCT00083616|ABX-EGF
656520|NCT00083616|Immunex
656521|NCT00083616|Metastatic Cancer
656522|NCT00083616|Vectibix
656523|NCT00083616|Abgenix
656524|NCT00083616|Amgen
656525|NCT00083603|HIV Seronegativity
656526|NCT00083603|HIV Preventive Vaccine
656527|NCT00083603|Vaccinia vector
656528|NCT00083603|Pox vector
656529|NCT00083590|Alzheimer disease
656530|NCT00083590|Cholinesterase inhibitor
656531|NCT00083577|Multiple Myeloma
656532|NCT00083577|Thalidomide
656533|NCT00083577|Anti-Angiogenesis
656534|NCT00083564|Multiple myeloma
656535|NCT00083564|Primary refractory multiple myeloma
656536|NCT00083564|STR
656537|NCT00083564|Skeletal Targeted Radiotherapy
656538|NCT00083564|Holmium-166
656539|NCT00083564|166-Ho-DOTMP
656540|NCT00083551|Multiple Myeloma
656541|NCT00083551|Cancer
656542|NCT00083551|Therapy
656543|NCT00083551|Thalidomide
656544|NCT00083551|DTPACE
656545|NCT00083551|Transplant
656546|NCT00083551|VAD
656547|NCT00083551|DCEP
656548|NCT00083551|CAD
656549|NCT00083551|Consolidation
656550|NCT00083551|Melphalan
656551|NCT00083538|Multiple Myeloma
656552|NCT00083538|DTPACE
656553|NCT00083538|Dexamethasone
656554|NCT00083538|Thalidomide
656555|NCT00083538|Cisplatin
656556|NCT00083538|Cytoxan
656557|NCT00083538|Doxorubicin
656558|NCT00083538|Etoposide
656559|NCT00083538|Dendritic Cell Vaccination
656560|NCT00083538|Leukapheresis
656561|NCT00083512|Blood
656562|NCT00083512|Urine
656563|NCT00083512|GBM
656564|NCT00083512|Radiation
656565|NCT00083512|Glioblastoma Multiforme
656566|NCT00083499|Pental of Cantrell
656567|NCT00083499|TAS Syndrome
656568|NCT00083499|Midline Defects
656569|NCT00083499|Contractile Proteins
656570|NCT00083499|Herniation
656571|NCT00083499|Nonmuscle Myosin IIC
656572|NCT00083499|Pentalogy of Cantrell
656573|NCT00083499|Non-muscle Myosin Heavy Chain Genes
656574|NCT00083473|Leukemia Lymphocytic Chronic,
656575|NCT00083473|Pivanex,
656576|NCT00083473|Histone deacetylase inhibitor
656577|NCT00083460|Multiple Myeloma
656578|NCT00083460|Thalidomide
656579|NCT00083460|Velcade
656580|NCT00083460|PS-341
656581|NCT00083460|Refractory
656582|NCT00083460|Bortezomid
656583|NCT00083447|brain tumor
656584|NCT00083447|GBM
656585|NCT00083447|glioblastoma
656586|NCT00083447|glioblastoma multiforme
656587|NCT00083447|brain cancer
656588|NCT00083447|treatment
656589|NCT00083434|Anemia
656590|NCT00083434|Cancer
656591|NCT00083408|Multiple Myeloma
656592|NCT00083408|Pamidronate
656593|NCT00083408|Thalidomide
656594|NCT00083408|refractory myeloma
656595|NCT00083408|bisphosphonates
656596|NCT00083408|Aredia
656597|NCT00083395|ARVC/ARVD
656598|NCT00083395|Genetics
656599|NCT00083395|Sudden Death
656600|NCT00083395|Heart
656601|NCT00083395|MRI
656602|NCT00083395|Cardiomyopathy
656603|NCT00083395|Arrhythmogenic Right Ventricular
656604|NCT00083395|ARVC
656605|NCT00083395|Healthy Volunteer
656606|NCT00083395|HV
656607|NCT00083382|Myeloma
656608|NCT00083382|Thalidomide
656609|NCT00083382|Pamidronate
656610|NCT00083382|Aredia
656611|NCT00083382|Bisphosphonate
656612|NCT00083382|Anti-Angiogenesis
656613|NCT00083382|Smoldering/Indolent Myeloma
656614|NCT00083382|Zometa
656615|NCT00083356|Pain
656616|NCT00083356|Kinins
656617|NCT00083356|Inflammation
656618|NCT00083356|Gene Expression
656619|NCT00083356|Oral Surgey
656620|NCT00083356|Bradykinin B1 Receptors
656621|NCT00083356|Acute Peripheral Inflammation
656622|NCT00083356|Inflammatory Gene Expression
656623|NCT00083356|Wisdom Teeth
656624|NCT00083356|Third Molar Extraction
656625|NCT00083330|Healthy
656626|NCT00083330|T Cells
656627|NCT00083330|Immunity
656628|NCT00083330|Healthy Volunteer
656629|NCT00083330|HV
656630|NCT00083317|PFC
656631|NCT00083317|Competition
656632|NCT00083317|Bargaining Games
656633|NCT00083317|Hyper-Brain Scanning
656634|NCT00083317|fMRI
656635|NCT00083317|Healthy Volunteer
656636|NCT00083317|HV
656637|NCT00083304|Breast
656638|NCT00083304|Brain
656639|NCT00083304|RSR13
656640|NCT00083304|efaproxiral
656641|NCT00083304|Whole Brain Radiation Therapy
656642|NCT00083304|Brain metastases
656643|NCT00083304|Metastatic breast cancer
656644|NCT00083291|Dry Eyes
656645|NCT00083291|Conjunctiva
656646|NCT00083291|Infection
656647|NCT00083291|Antibodies
656648|NCT00083291|Inflammation
656649|NCT00083291|Ocular Surface Disease
656650|NCT00083291|Helicobacter Pylori
656651|NCT00083278|Breast Cancer
656652|NCT00083278|Stage IV adenocarcinoma of the breast
656653|NCT00083265|Adenosine Receptor
656654|NCT00083265|Panic Disorder
656655|NCT00083265|Polymorphism
656656|NCT00083265|Challenge Study
656657|NCT00083265|Caffeine
656658|NCT00083265|Healthy Volunteer
656659|NCT00083265|HV
656660|NCT00083226|doxorubicin
656661|NCT00083226|doxorubicin hydrochloride
656662|NCT00083226|bortezomib
656663|NCT00083226|hepatocellular carcinoma
656664|NCT00083213|recurrent grade 1 follicular lymphoma
656665|NCT00083213|stage IV grade 1 follicular lymphoma
656666|NCT00083213|recurrent grade 2 follicular lymphoma
656667|NCT00083213|stage IV grade 2 follicular lymphoma
656668|NCT00083213|recurrent grade 3 follicular lymphoma
656669|NCT00083213|stage IV grade 3 follicular lymphoma
656670|NCT00083213|recurrent adult diffuse small cleaved cell lymphoma
656671|NCT00083213|stage IV adult diffuse small cleaved cell lymphoma
656672|NCT00083213|recurrent adult diffuse large cell lymphoma
656673|NCT00083213|stage IV adult diffuse large cell lymphoma
656674|NCT00083213|stage IV adult diffuse mixed cell lymphoma
656675|NCT00083213|recurrent adult diffuse mixed cell lymphoma
656676|NCT00083213|recurrent adult immunoblastic large cell lymphoma
656677|NCT00083213|stage IV adult immunoblastic large cell lymphoma
656678|NCT00083213|recurrent adult Burkitt lymphoma
656679|NCT00083213|stage IV adult Burkitt lymphoma
656680|NCT00083213|recurrent mantle cell lymphoma
656681|NCT00083213|stage IV mantle cell lymphoma
656682|NCT00083213|recurrent adult lymphoblastic lymphoma
656683|NCT00083213|stage IV adult lymphoblastic lymphoma
656684|NCT00083213|unspecified adult solid tumor, protocol specific
656685|NCT00083213|recurrent adult soft tissue sarcoma
656686|NCT00083213|recurrent adult primary liver cancer
656687|NCT00083213|advanced adult primary liver cancer
656688|NCT00083213|recurrent cervical cancer
656689|NCT00083213|stage IVA cervical cancer
656690|NCT00083213|stage IVB cervical cancer
656691|NCT00083213|fallopian tube cancer
656692|NCT00083213|ovarian sarcoma
656693|NCT00083213|recurrent ovarian epithelial cancer
656694|NCT00083213|stage IV ovarian epithelial cancer
656695|NCT00083213|recurrent endometrial carcinoma
656696|NCT00083213|stage IV endometrial carcinoma
656697|NCT00083213|recurrent uterine sarcoma
656698|NCT00083213|stage IV uterine sarcoma
656699|NCT00083213|recurrent ovarian germ cell tumor
656700|NCT00083213|stage IV ovarian germ cell tumor
656701|NCT00083213|ovarian stromal cancer
656702|NCT00083213|recurrent vaginal cancer
656703|NCT00083213|stage IVA vaginal cancer
656704|NCT00083213|stage IVB vaginal cancer
656705|NCT00083213|recurrent prostate cancer
656706|NCT00083213|stage IV prostate cancer
656707|NCT00083213|recurrent penile cancer
656708|NCT00083213|stage IV penile cancer
656709|NCT00083213|recurrent malignant testicular germ cell tumor
656710|NCT00083213|stage III malignant testicular germ cell tumor
656711|NCT00083213|recurrent bladder cancer
656712|NCT00083213|stage IV bladder cancer
656713|NCT00083213|recurrent vulvar cancer
656714|NCT00083213|stage IVB vulvar cancer
656715|NCT00083213|distal urethral cancer
656716|NCT00083213|proximal urethral cancer
656717|NCT00083213|recurrent urethral cancer
656718|NCT00083213|urethral cancer associated with invasive bladder cancer
656719|NCT00083213|primary peritoneal cavity cancer
656720|NCT00083213|recurrent marginal zone lymphoma
656721|NCT00083213|recurrent small lymphocytic lymphoma
656722|NCT00083213|stage IV small lymphocytic lymphoma
656723|NCT00083213|stage IV marginal zone lymphoma
656724|NCT00083213|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
656725|NCT00083213|nodal marginal zone B-cell lymphoma
656726|NCT00083213|splenic marginal zone lymphoma
656727|NCT00083213|stage IV adult soft tissue sarcoma
656728|NCT00083187|recurrent adult acute myeloid leukemia
656729|NCT00083187|untreated adult acute myeloid leukemia
656730|NCT00083187|atypical chronic myeloid leukemia, BCR-ABL1 negative
656731|NCT00083187|chronic myelomonocytic leukemia
656732|NCT00083187|myelodysplastic/myeloproliferative neoplasm, unclassifiable
656733|NCT00083187|secondary myelodysplastic syndromes
656734|NCT00083187|de novo myelodysplastic syndromes
656735|NCT00083187|adult acute myeloid leukemia with t(8;21)(q22;q22)
656736|NCT00083187|adult acute myeloid leukemia with t(16;16)(p13;q22)
656737|NCT00083187|adult acute myeloid leukemia with inv(16)(p13;q22)
656738|NCT00083187|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
656739|NCT00083187|adult acute myeloid leukemia with t(15;17)(q22;q12)
656740|NCT00083174|breast cancer
656741|NCT00083161|extensive stage small cell lung cancer
656742|NCT00083161|recurrent small cell lung cancer
656743|NCT00083148|recurrent breast cancer
656744|NCT00083148|stage IV breast cancer
656745|NCT00083135|recurrent neuroblastoma
656746|NCT00083096|recurrent adult brain tumor
656747|NCT00083096|adult mixed glioma
656748|NCT00083096|adult anaplastic astrocytoma
656749|NCT00083096|adult anaplastic oligodendroglioma
656750|NCT00083096|adult glioblastoma
656751|NCT00083096|adult pilocytic astrocytoma
656752|NCT00083096|adult anaplastic ependymoma
656753|NCT00083096|adult subependymoma
656754|NCT00083096|adult myxopapillary ependymoma
656755|NCT00083096|adult oligodendroglioma
656756|NCT00083096|adult giant cell glioblastoma
656757|NCT00083096|adult gliosarcoma
656758|NCT00083096|adult diffuse astrocytoma
656759|NCT00083096|adult subependymal giant cell astrocytoma
656760|NCT00083096|adult pineal gland astrocytoma
656761|NCT00083083|stage II non-small cell lung cancer
656762|NCT00083083|stage IIIA non-small cell lung cancer
656763|NCT00083083|stage IIIB non-small cell lung cancer
656764|NCT00083070|recurrent childhood acute lymphoblastic leukemia
656765|NCT00083070|recurrent childhood acute myeloid leukemia
656766|NCT00083070|relapsing chronic myelogenous leukemia
656767|NCT00083070|childhood acute promyelocytic leukemia (M3)
656768|NCT00083070|blastic phase chronic myelogenous leukemia
656769|NCT00083057|stage III squamous cell carcinoma of the lip and oral cavity
656770|NCT00083057|stage IV squamous cell carcinoma of the lip and oral cavity
656771|NCT00083057|recurrent squamous cell carcinoma of the lip and oral cavity
656772|NCT00083057|stage III squamous cell carcinoma of the hypopharynx
656773|NCT00083057|stage IV squamous cell carcinoma of the hypopharynx
656774|NCT00083057|recurrent squamous cell carcinoma of the hypopharynx
656775|NCT00083057|stage III squamous cell carcinoma of the oropharynx
656776|NCT00083057|stage IV squamous cell carcinoma of the oropharynx
656777|NCT00083057|recurrent squamous cell carcinoma of the oropharynx
656778|NCT00083057|recurrent squamous cell carcinoma of the nasopharynx
656779|NCT00083057|stage III squamous cell carcinoma of the nasopharynx
656780|NCT00083057|stage IV squamous cell carcinoma of the nasopharynx
656781|NCT00083057|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
656782|NCT00083057|recurrent squamous cell carcinoma of the larynx
656783|NCT00083057|stage III squamous cell carcinoma of the larynx
656784|NCT00083057|stage IV squamous cell carcinoma of the larynx
656785|NCT00083044|breast cancer
656786|NCT00083044|breast cancer in situ
656787|NCT00083044|stage I breast cancer
656788|NCT00083044|lobular breast carcinoma in situ
656789|NCT00083044|ductal breast carcinoma in situ
656790|NCT00083031|recurrent breast cancer
656791|NCT00083031|stage IV breast cancer
656792|NCT00083018|stage II breast cancer
656793|NCT00083018|stage IIIA breast cancer
656794|NCT00083018|stage IIIB breast cancer
656795|NCT00083018|stage IIIC breast cancer
656796|NCT00083018|stage IA breast cancer
656797|NCT00083018|stage IB breast cancer
656798|NCT00083005|adenocarcinoma of the prostate
656799|NCT00083005|recurrent prostate cancer
656800|NCT00083005|stage IV prostate cancer
656801|NCT00082979|breast cancer
656802|NCT00082940|B-cell chronic lymphocytic leukemia
656803|NCT00082940|refractory chronic lymphocytic leukemia
656804|NCT00082927|stage IV prostate cancer
656805|NCT00082927|bone metastases
656806|NCT00082927|pain
656807|NCT00082927|recurrent prostate cancer
656808|NCT00082914|recurrent renal cell cancer
656809|NCT00082914|stage IV renal cell cancer
656810|NCT00082914|recurrent melanoma
656811|NCT00082914|stage IV melanoma
656812|NCT00082862|stage II pancreatic cancer
656813|NCT00082862|stage III pancreatic cancer
656814|NCT00082862|recurrent pancreatic cancer
656815|NCT00082862|stage IV pancreatic cancer
656816|NCT00082836|primary central nervous system non-Hodgkin lymphoma
656817|NCT00082823|recurrent grade 1 follicular lymphoma
656818|NCT00082823|stage IV grade 1 follicular lymphoma
656819|NCT00082823|recurrent grade 2 follicular lymphoma
656820|NCT00082823|stage IV grade 2 follicular lymphoma
656821|NCT00082823|recurrent grade 3 follicular lymphoma
656822|NCT00082823|stage IV grade 3 follicular lymphoma
656823|NCT00082823|recurrent adult diffuse small cleaved cell lymphoma
656824|NCT00082823|stage IV adult diffuse small cleaved cell lymphoma
656825|NCT00082823|recurrent adult diffuse large cell lymphoma
656826|NCT00082823|stage IV adult diffuse large cell lymphoma
656827|NCT00082823|recurrent adult diffuse mixed cell lymphoma
656828|NCT00082823|stage IV adult diffuse mixed cell lymphoma
656829|NCT00082823|recurrent adult immunoblastic large cell lymphoma
656830|NCT00082823|stage IV adult immunoblastic large cell lymphoma
656831|NCT00082823|recurrent adult Burkitt lymphoma
656832|NCT00082823|stage IV adult Burkitt lymphoma
656833|NCT00082823|recurrent mantle cell lymphoma
656834|NCT00082823|stage IV mantle cell lymphoma
656835|NCT00082823|recurrent adult lymphoblastic lymphoma
656836|NCT00082823|stage IV adult lymphoblastic lymphoma
656837|NCT00082823|unspecified adult solid tumor, protocol specific
656838|NCT00082823|recurrent adult soft tissue sarcoma
656839|NCT00082823|advanced adult primary liver cancer
656840|NCT00082823|recurrent adult primary liver cancer
656841|NCT00082823|recurrent cervical cancer
656842|NCT00082823|stage IVA cervical cancer
656843|NCT00082823|stage IVB cervical cancer
656844|NCT00082823|fallopian tube cancer
656845|NCT00082823|ovarian sarcoma
656846|NCT00082823|recurrent ovarian epithelial cancer
656847|NCT00082823|stage IV ovarian epithelial cancer
656848|NCT00082823|recurrent endometrial carcinoma
656849|NCT00082823|stage IV endometrial carcinoma
656850|NCT00082823|recurrent uterine sarcoma
656851|NCT00082823|stage IV uterine sarcoma
656852|NCT00082823|recurrent ovarian germ cell tumor
656853|NCT00082823|stage IV ovarian germ cell tumor
656854|NCT00082823|ovarian stromal cancer
656855|NCT00082823|recurrent vaginal cancer
656856|NCT00082823|stage IVA vaginal cancer
656857|NCT00082823|stage IVB vaginal cancer
656858|NCT00082823|recurrent prostate cancer
656859|NCT00082823|stage IV prostate cancer
656860|NCT00082823|recurrent penile cancer
656861|NCT00082823|stage IV penile cancer
656862|NCT00082823|recurrent malignant testicular germ cell tumor
656863|NCT00082823|stage III malignant testicular germ cell tumor
656864|NCT00082823|recurrent bladder cancer
656865|NCT00082823|stage IV bladder cancer
656866|NCT00082823|recurrent vulvar cancer
656867|NCT00082823|stage IVB vulvar cancer
656868|NCT00082823|distal urethral cancer
656869|NCT00082823|proximal urethral cancer
656870|NCT00082823|recurrent urethral cancer
656871|NCT00082823|urethral cancer associated with invasive bladder cancer
656872|NCT00082823|primary peritoneal cavity cancer
656873|NCT00082823|recurrent marginal zone lymphoma
656874|NCT00082823|recurrent small lymphocytic lymphoma
656875|NCT00082823|stage IV small lymphocytic lymphoma
656876|NCT00082823|stage IV marginal zone lymphoma
656877|NCT00082823|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
656878|NCT00082823|nodal marginal zone B-cell lymphoma
656879|NCT00082823|splenic marginal zone lymphoma
656880|NCT00082823|stage IV adult soft tissue sarcoma
656881|NCT00082797|adult glioblastoma
656882|NCT00082797|adult giant cell glioblastoma
656883|NCT00082797|adult gliosarcoma
656884|NCT00082758|recurrent neuroblastoma
656885|NCT00082732|stage I prostate cancer
656886|NCT00082732|stage II prostate cancer
656887|NCT00082732|adenocarcinoma of the prostate
656888|NCT00082719|stage II bladder cancer
656889|NCT00082719|stage III bladder cancer
656890|NCT00082719|stage IV bladder cancer
656891|NCT00082719|localized transitional cell cancer of the renal pelvis and ureter
656892|NCT00082719|regional transitional cell cancer of the renal pelvis and ureter
656893|NCT00082719|metastatic transitional cell cancer of the renal pelvis and ureter
656894|NCT00082719|anterior urethral cancer
656895|NCT00082719|posterior urethral cancer
656896|NCT00082719|urethral cancer associated with invasive bladder cancer
656897|NCT00082706|adenocarcinoma of the bladder
656898|NCT00082706|recurrent bladder cancer
656899|NCT00082706|stage IV bladder cancer
656900|NCT00082706|recurrent urethral cancer
656901|NCT00082706|anterior urethral cancer
656902|NCT00082706|posterior urethral cancer
656903|NCT00082706|urethral cancer associated with invasive bladder cancer
656904|NCT00082706|stage III bladder cancer
656905|NCT00082667|breast cancer in situ
656906|NCT00082667|ductal breast carcinoma in situ
656907|NCT00082654|psychosocial effects of cancer and its treatment
656908|NCT00082654|accelerated phase chronic myelogenous leukemia
656909|NCT00082654|adult acute lymphoblastic leukemia in remission
656910|NCT00082654|adult acute myeloid leukemia in remission
656911|NCT00082654|atypical chronic myeloid leukemia
656912|NCT00082654|blastic phase chronic myelogenous leukemia
656913|NCT00082654|chronic eosinophilic leukemia
656914|NCT00082654|chronic idiopathic myelofibrosis
656915|NCT00082654|chronic myelomonocytic leukemia
656916|NCT00082654|chronic neutrophilic leukemia
656917|NCT00082654|chronic phase chronic myelogenous leukemia
656918|NCT00082654|de novo myelodysplastic syndromes
656919|NCT00082654|disseminated neuroblastoma
656920|NCT00082654|myelodysplastic/myeloproliferative disease, unclassifiable
656921|NCT00082654|noncontiguous stage II adult Burkitt lymphoma
656922|NCT00082654|noncontiguous stage II adult diffuse large cell lymphoma
656923|NCT00082654|noncontiguous stage II adult diffuse mixed cell lymphoma
656924|NCT00082654|noncontiguous stage II adult diffuse small cleaved cell lymphoma
656925|NCT00082654|noncontiguous stage II adult immunoblastic large cell lymphoma
656926|NCT00082654|noncontiguous stage II adult lymphoblastic lymphoma
656927|NCT00082654|noncontiguous stage II grade 1 follicular lymphoma
656928|NCT00082654|noncontiguous stage II grade 2 follicular lymphoma
656929|NCT00082654|noncontiguous stage II grade 3 follicular lymphoma
656930|NCT00082654|noncontiguous stage II mantle cell lymphoma
656931|NCT00082654|poor prognosis metastatic gestational trophoblastic tumor
656932|NCT00082654|previously treated myelodysplastic syndromes
656933|NCT00082654|recurrent adult acute lymphoblastic leukemia
656934|NCT00082654|recurrent adult acute myeloid leukemia
656935|NCT00082654|recurrent adult Burkitt lymphoma
656936|NCT00082654|recurrent adult diffuse large cell lymphoma
656937|NCT00082654|recurrent adult diffuse mixed cell lymphoma
656938|NCT00082654|recurrent adult diffuse small cleaved cell lymphoma
656939|NCT00082654|recurrent adult Hodgkin lymphoma
656940|NCT00082654|recurrent adult immunoblastic large cell lymphoma
656941|NCT00082654|recurrent adult lymphoblastic lymphoma
656942|NCT00082654|recurrent cutaneous T-cell non-Hodgkin lymphoma
656943|NCT00082654|recurrent grade 1 follicular lymphoma
656944|NCT00082654|recurrent grade 2 follicular lymphoma
656945|NCT00082654|recurrent grade 3 follicular lymphoma
656946|NCT00082654|recurrent mantle cell lymphoma
656947|NCT00082654|recurrent mycosis fungoides/Sezary syndrome
656948|NCT00082654|recurrent neuroblastoma
656949|NCT00082654|recurrent ovarian epithelial cancer
656950|NCT00082654|recurrent ovarian germ cell tumor
656951|NCT00082654|recurrent malignant testicular germ cell tumor
656952|NCT00082654|refractory chronic lymphocytic leukemia
656953|NCT00082654|refractory hairy cell leukemia
656954|NCT00082654|refractory multiple myeloma
656955|NCT00082654|relapsing chronic myelogenous leukemia
656956|NCT00082654|secondary acute myeloid leukemia
656957|NCT00082654|secondary myelodysplastic syndromes
656958|NCT00082654|stage I multiple myeloma
656959|NCT00082654|stage II multiple myeloma
656960|NCT00082654|stage II ovarian epithelial cancer
656961|NCT00082654|stage III adult Burkitt lymphoma
656962|NCT00082654|stage III adult diffuse large cell lymphoma
656963|NCT00082654|stage III adult diffuse mixed cell lymphoma
656964|NCT00082654|stage III adult diffuse small cleaved cell lymphoma
656965|NCT00082654|stage III adult immunoblastic large cell lymphoma
656966|NCT00082654|stage III adult lymphoblastic lymphoma
656967|NCT00082654|stage III chronic lymphocytic leukemia
656968|NCT00082654|stage III grade 1 follicular lymphoma
656969|NCT00082654|stage III grade 2 follicular lymphoma
656970|NCT00082654|stage III grade 3 follicular lymphoma
656971|NCT00082654|stage III mantle cell lymphoma
656972|NCT00082654|stage III multiple myeloma
656973|NCT00082654|stage III ovarian epithelial cancer
656974|NCT00082654|stage III malignant testicular germ cell tumor
656975|NCT00082654|stage IIIA breast cancer
656976|NCT00082654|stage IIIB breast cancer
656977|NCT00082654|stage IIIC breast cancer
656978|NCT00082654|stage IV adult Burkitt lymphoma
656979|NCT00082654|stage IV adult diffuse large cell lymphoma
656980|NCT00082654|stage IV adult diffuse mixed cell lymphoma
656981|NCT00082654|stage IV adult diffuse small cleaved cell lymphoma
656982|NCT00082654|stage IV adult immunoblastic large cell lymphoma
656983|NCT00082654|stage IV adult lymphoblastic lymphoma
656984|NCT00082654|stage IV breast cancer
656985|NCT00082654|stage IV chronic lymphocytic leukemia
656986|NCT00082654|stage IV grade 1 follicular lymphoma
656987|NCT00082654|stage IV grade 2 follicular lymphoma
656988|NCT00082654|stage IV grade 3 follicular lymphoma
656989|NCT00082654|stage IV mantle cell lymphoma
656990|NCT00082654|stage IV ovarian epithelial cancer
656991|NCT00082654|untreated adult acute lymphoblastic leukemia
656992|NCT00082654|untreated adult acute myeloid leukemia
656993|NCT00082654|noncontiguous stage II small lymphocytic lymphoma
656994|NCT00082654|noncontiguous stage II marginal zone lymphoma
656995|NCT00082654|recurrent marginal zone lymphoma
656996|NCT00082654|recurrent small lymphocytic lymphoma
656997|NCT00082654|stage III small lymphocytic lymphoma
656998|NCT00082654|stage III marginal zone lymphoma
656999|NCT00082654|stage IV small lymphocytic lymphoma
657000|NCT00082654|stage IV marginal zone lymphoma
657001|NCT00082654|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
657002|NCT00082654|nodal marginal zone B-cell lymphoma
657003|NCT00082654|splenic marginal zone lymphoma
657004|NCT00082654|adult acute myeloid leukemia with t(8;21)(q22;q22)
657005|NCT00082654|adult acute myeloid leukemia with t(16;16)(p13;q22)
657006|NCT00082654|adult acute myeloid leukemia with inv(16)(p13;q22)
657007|NCT00082654|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
657008|NCT00082654|adult acute myeloid leukemia with t(15;17)(q22;q12)
657009|NCT00082641|stage IIIA breast cancer
657010|NCT00082641|stage IIIB breast cancer
657011|NCT00082628|growth hormone
657012|NCT00082628|Serostim®
657013|NCT00082628|Human Adipose Redistribution Syndrome
657014|NCT00082628|Human Immunodeficiency Virus lipodystrophy
657015|NCT00082628|Treatment Experienced
657016|NCT00082615|Movement Disorders
657017|NCT00082615|Recovery Cycle
657018|NCT00082615|Blink Reflex
657019|NCT00082615|Cervical Dystonia
657020|NCT00082615|Blepharospasm
657021|NCT00082615|Dystonia
657022|NCT00082615|Craniofacial Dystonia
657023|NCT00082615|Healthy Volunteer
657024|NCT00082615|HV
657025|NCT00082602|galantamine
657026|NCT00082602|Alzheimer's disease
657027|NCT00082550|Genetics
657028|NCT00082550|Serotonin Transporter
657029|NCT00082550|Brain Imaging
657030|NCT00082550|Neurotransmitter
657031|NCT00082550|OCD
657032|NCT00082550|Obsessive-Compulsive Disorder
657033|NCT00082550|PET
657034|NCT00082550|Obsessive Compulsive Disorder
657035|NCT00082550|Healthy Volunteer
657036|NCT00082550|HV
657037|NCT00082511|Lupus
657038|NCT00082511|Systemic Lupus Erythematosus
657039|NCT00082511|SLE
657040|NCT00082511|Bone Loss
657041|NCT00082511|DHEA
657042|NCT00082498|SCH-D
657043|NCT00082498|Schering D
657044|NCT00082498|Treatment Experienced
657045|NCT00082498|Entry Inhibitors
657046|NCT00082498|Fusion Inhibitors
657047|NCT00082498|Vicriviroc
657048|NCT00082485|Cocaine Dependence
657049|NCT00082472|NSCLC
657050|NCT00082472|Metastatic
657051|NCT00082472|Unresectable
657052|NCT00082472|No Prior Chemotherapy
657053|NCT00082459|Kidney Cancer
657054|NCT00082459|Renal
657055|NCT00082459|Tumor
657056|NCT00082459|Immunotherapy
657057|NCT00082446|Smallpox, vaccine
657058|NCT00082420|Vitamin A malnutrition
657059|NCT00082420|low vitamin A status
657060|NCT00082407|diabetes
657061|NCT00082407|exendin
657062|NCT00082407|Amylin
657063|NCT00082407|Lilly
657064|NCT00082407|insulin aspart
657065|NCT00082394|TRIZIVIR
657066|NCT00082394|COMBIVIR
657067|NCT00082394|atazanavir
657068|NCT00082394|HIV
657069|NCT00082394|drug efficacy
657070|NCT00082394|safety
657071|NCT00082394|tolerability
657072|NCT00082381|Diabetes
657073|NCT00082381|Insulin glargine
657074|NCT00082381|comparator
657075|NCT00082381|Amylin
657076|NCT00082381|Lilly
657077|NCT00082368|Tariquidar
657078|NCT00082368|PET
657079|NCT00082368|Sestamibi
657080|NCT00082368|Cancer
657081|NCT00082355|r-tPA
657082|NCT00082355|Thrombolysis
657083|NCT00082355|Clot
657084|NCT00082355|Anticoagulation
657085|NCT00082355|Fibrinolysis
657086|NCT00082355|Deep Vein Thrombosis
657087|NCT00082355|DVT
657088|NCT00082342|Human Brain
657089|NCT00082342|Electrical Stimulation
657090|NCT00082342|Parkinson Disease
657091|NCT00082342|PD
657092|NCT00082329|Hematopoietic Stem Cells
657093|NCT00082329|PBSC's
657094|NCT00082329|Mobilization
657095|NCT00082329|Alloreactivity
657096|NCT00082329|T Cell Polarization
657097|NCT00082329|Dendritic Cells
657098|NCT00082329|CXCR4
657099|NCT00082329|Plerixafor
657100|NCT00082329|Healthy Volunteer (HV)
657101|NCT00082316|Dermal assessment
657102|NCT00082316|Pain assessment
657103|NCT00082316|Diary
657104|NCT00082316|Analgesics
657105|NCT00082316|Capsaicin
657106|NCT00082316|Herpes zoster
657107|NCT00082316|Neuralgia
657108|NCT00082316|HIV Infections
657109|NCT00082316|Peripheral Nervous System Diseases
657110|NCT00082316|Diabetic Neuropathies
657111|NCT00082316|Diabetes Mellitus
657112|NCT00082316|Polyneuropathies
657113|NCT00082316|Complementary Therapies
657114|NCT00082303|Music Therapy
657115|NCT00082303|Anxiety
657116|NCT00082303|Depression
657117|NCT00082290|unspecified adult solid tumor, protocol specific
657118|NCT00082290|pain
657119|NCT00082277|hormone-receptor positive, breast cancer
657120|NCT00082277|Osteopenia
657121|NCT00082277|Osteoporosis
657122|NCT00082277|risk of fracture
657123|NCT00082277|bone loss
657124|NCT00082251|Dyslipidemia
657125|NCT00082251|High Blood Cholesterol
657126|NCT00082251|Coronary Heart Disease
657127|NCT00082251|Hypertension
657128|NCT00082251|National Cholesterol Education Program
657129|NCT00082251|Adult Treatment Panel III
657130|NCT00082251|Niacin
657131|NCT00082251|Simvastatin
657132|NCT00082251|Diabetes
657133|NCT00082251|Peripheral Vascular Disease
657134|NCT00082251|Cerebrovascular disease
657135|NCT00082251|Stroke
657136|NCT00082251|High-Density Lipoprotein Cholesterol
657137|NCT00082251|Hydroxymethyl Glutaryl Coenzyme A
657138|NCT00082251|High-Sensitivity C-Reactive Protein
657139|NCT00082251|Low-Density Lipoprotein Cholesterol
657140|NCT00082251|Lipoprotein (a)
657141|NCT00082251|Lipoprotein A-I
657142|NCT00082251|Total Cholesterol
657143|NCT00082251|Triglycerides
657144|NCT00082225|Hodgkins
657145|NCT00082225|Non-Hodgkins
657146|NCT00082225|Lymphoma
657147|NCT00082212|ovarian
657148|NCT00082212|primary peritoneal cancer
657149|NCT00082212|Persistent or Recurrent Ovarian Cancer
657150|NCT00082212|Primary Peritoneal Carcinoma
657151|NCT00082160|Meditation
657152|NCT00082160|Relaxation
657153|NCT00082147|MRI
657154|NCT00082147|Biopsy
657155|NCT00082147|Fiducial Marker
657156|NCT00082147|Prostate Cancer
657157|NCT00082134|Prostate cancer
657158|NCT00082134|Hormone-refractory prostate cancer
657159|NCT00082134|HRPC
657160|NCT00082134|Prostate
657161|NCT00082134|Docetaxel
657162|NCT00082134|PSA progression
657163|NCT00082134|PSA progressed
657164|NCT00082121|cardiac bypass
657165|NCT00082121|CABG
657166|NCT00082121|complement activation
657167|NCT00082108|Registry
657168|NCT00082108|FSHD
657169|NCT00082108|DM
657170|NCT00082108|Muscular Dystrophy
657171|NCT00082108|Facioscapulohumeral Myotonic Dystrophy
657172|NCT00082108|Myotonic Dystrophy
657173|NCT00082108|DM1
657174|NCT00082108|DM2
657175|NCT00082108|FSH
657176|NCT00082108|MMD
657177|NCT00082095|Metastatic breast cancer
657178|NCT00082095|Breast Cancer
657179|NCT00082095|Pegylated Liposomal Doxorubicin
657180|NCT00082095|Capecitabine
657181|NCT00082095|DOXIL
657182|NCT00082095|Xeloda
657183|NCT00082069|Shigella
657184|NCT00082069|diarrhea
657185|NCT00082043|Neurosteroids
657186|NCT00082043|5 Alpha-Reductase Inhibitor
657187|NCT00082043|Depression
657188|NCT00082043|Menstrual Cycle
657189|NCT00082043|Gonadal Steroids
657190|NCT00082043|Menstrual Cycle Related Mood Disorder
657191|NCT00082043|MRMD
657192|NCT00082043|Healthy Volunteer
657193|NCT00082030|Depression
657194|NCT00082030|PET
657195|NCT00082030|fMRI
657196|NCT00082030|Dopamine
657197|NCT00082030|Norepinephrine Depletion
657198|NCT00082030|Emotional Stimuli
657199|NCT00082030|Anhedonia
657200|NCT00082030|Norepinephrine
657201|NCT00082030|Dopamine Depletion
657202|NCT00082030|Major Depressive Disorder
657203|NCT00082030|MDD
657204|NCT00082030|Healthy Volunteer
657205|NCT00082030|HV
657206|NCT00082017|Protein Kinase Inhibition
657207|NCT00082017|Soluble Tac
657208|NCT00082017|Gene Expression Profiling
657209|NCT00082017|ALK Expression
657210|NCT00082017|Apoptosis
657211|NCT00082017|Lymphoma
657212|NCT00082017|Anaplastic Large Cell Lymphoma
657213|NCT00082017|ALCL
657214|NCT00082017|T-Cell Lymphoma
657215|NCT00081991|Cataract
657216|NCT00081991|Blindness
657217|NCT00081991|Clinical
657218|NCT00081991|Human Aging
657219|NCT00081991|Dynamic Light Scattering (DLS)
657220|NCT00081991|Aging-Related Lens Changes
657221|NCT00081991|Early Cataract
657222|NCT00081991|Lens
657223|NCT00081991|AREDS Grading
657224|NCT00081991|In Vivo
657225|NCT00081991|Healthy Volunteer
657226|NCT00081978|HIV infection
657227|NCT00081978|TMC125
657228|NCT00081978|Non-nucleoside reverse transcriptase inhibitor, TMC125-C223
657229|NCT00081965|breast cancer in situ
657230|NCT00081965|stage I breast cancer
657231|NCT00081965|stage II breast cancer
657232|NCT00081965|stage IIIA breast cancer
657233|NCT00081965|stage IIIB breast cancer
657234|NCT00081965|stage IV breast cancer
657235|NCT00081965|recurrent breast cancer
657236|NCT00081965|stage IIIC breast cancer
657237|NCT00081965|hot flashes
657238|NCT00081952|Postmenopause
657239|NCT00081926|CML
657240|NCT00081926|Chronic Myelogenous Leukemia
657241|NCT00081926|RIGHT Trial
657242|NCT00081926|US177
657243|NCT00081926|CSTI571
657244|NCT00081913|Apheresis
657245|NCT00081913|Cell Transfer
657246|NCT00081913|Chest Pain
657247|NCT00081913|Adult Stem Cell Therapy
657248|NCT00081900|Carcinoma, Hepatocellular
657249|NCT00081887|Chronic Lymphocytic Leukemia
657250|NCT00081887|CLL
657251|NCT00081887|Leukemia
657252|NCT00081887|Clofarabine
657253|NCT00081887|Clofarex
657254|NCT00081887|Clolar
657255|NCT00081874|Leukemia
657256|NCT00081874|Mantle cell lymphoma
657257|NCT00081874|Myelofibrosis
657258|NCT00081874|Relapsed or Refractory Acute Myeloid Leukemia
657259|NCT00081874|Acute Lymphocytic Leukemia
657260|NCT00081874|Chronic Myeloid Leukemia in Blastic-Phase
657261|NCT00081874|Agnogenic Myeloid Metaplasia
657262|NCT00081874|Chronic Lymphocytic Leukemia
657263|NCT00081874|T-Cell Leukemia
657264|NCT00081874|RAD001
657265|NCT00081874|Everolimus
657266|NCT00081874|Afinitor
657267|NCT00081861|Non-Hodgkin's Lymphoma
657268|NCT00081861|B-Cell Lymphoma
657269|NCT00081861|Lymphoma
657270|NCT00081861|Avastin
657271|NCT00081861|Bevacizumab
657272|NCT00081861|Rituximab
657273|NCT00081861|Rituxan
657274|NCT00081848|Colon Cancer
657275|NCT00081848|Gastrointestinal Cancer
657276|NCT00081848|Cytokines
657277|NCT00081848|Immunotherapy
657278|NCT00081848|Cancer
657279|NCT00081848|Solid Tumor
657280|NCT00081848|Liver Metastasis
657281|NCT00081835|Smallpox
657282|NCT00081835|Cowpox
657283|NCT00081835|Corneal Ulcer
657284|NCT00081835|Keratitis
657285|NCT00081835|Immune Response, Vaccine
657286|NCT00081835|Cornea
657287|NCT00081835|Vaccinia
657288|NCT00081835|Vaccinia Immune Globulin (VIG)
657289|NCT00081835|Conjunctivitis
657290|NCT00081835|Vaccinia Vaccination
657291|NCT00081835|Smallpox Vaccination
657292|NCT00081822|Foran
657293|NCT00081822|clofarabine
657294|NCT00081822|cytosine arabinoside
657295|NCT00081822|acute myeloid leukemia
657296|NCT00081809|non-Hodgkin's lymphoma
657297|NCT00081809|Brill-Symmers Disease
657298|NCT00081809|Follicular Lymphoma
657299|NCT00081809|Lymphoma, Giant Follicular
657300|NCT00081809|Lymphoma, Nodular
657301|NCT00081809|Follicular Lymphoma, Giant
657302|NCT00081809|Giant Follicular Lymphoma
657303|NCT00081809|Lymphocytic Lymphoma, Diffuse, Well-Differentiated
657304|NCT00081809|Lymphocytic Lymphoma, Well-Differentiated
657305|NCT00081809|Lymphoma, Lymphocytic, Diffuse, Well-Differentiated
657306|NCT00081809|Lymphoma, Lymphocytic, Well-Differentiated
657307|NCT00081809|Lymphoma, Lymphoplasmacytoid, CLL
657308|NCT00081809|Lymphoma, Small Lymphocytic, Plasmacytoid
657309|NCT00081809|Lymphoplasmacytoid Lymphoma, CLL
657310|NCT00081809|Diffuse Well-Differentiated Lymphocytic Lymphoma
657311|NCT00081809|Lymphocytic Lymphoma, Diffuse, Well Differentiated
657312|NCT00081809|Lymphocytic Lymphoma, Well Differentiated
657313|NCT00081809|Lymphoma, Lymphocytic, Diffuse, Well Differentiated
657314|NCT00081809|Lymphoma, Lymphocytic, Well Differentiated
657315|NCT00081809|Lymphoma, Mucosa-Associated Lymphoid Tissue
657316|NCT00081809|MALT Lymphoma
657317|NCT00081809|Lymphoma of Mucosa-Associated Lymphoid Tissue
657318|NCT00081809|Mucosa-Associated Lymphoid Tissue Lymphoma
657319|NCT00081809|Monocytoid B-cell lymphoma
657320|NCT00081809|Waldenstrom's macroglobulinemia
657321|NCT00081809|Marginal zone lymphoma
657322|NCT00081796|Metastatic Breast Cancer
657323|NCT00081783|T Cells
657324|NCT00081783|Immunotherapy
657325|NCT00081783|NHL
657326|NCT00081783|Xcellerated T Cells
657327|NCT00081757|Advanced
657328|NCT00081757|Refractory
657329|NCT00081757|Plasmacytoma
657330|NCT00081757|Myeloma Proteins
657331|NCT00081744|Bacterial Infections
657332|NCT00081640|HIV Seronegativity
657333|NCT00081640|Vaginal Microbicide
657334|NCT00081614|Metastatic renal cell carcinoma
657335|NCT00081601|prostate cancer
657336|NCT00081601|prostate specific antigen
657337|NCT00081601|PSA
657338|NCT00081588|TMC114-C215
657339|NCT00081588|Ritonavir
657340|NCT00081588|HIV infections
657341|NCT00081588|TMC114-C202
657342|NCT00081588|TMC114-C213
657343|NCT00081575|Bacterial Pneumonia
657344|NCT00081549|Pancreatic Cancer
657345|NCT00081549|Neoplasms Pancreatic
657346|NCT00081549|Pancreas Cancer
657347|NCT00081549|Pancreas Neoplasms
657348|NCT00081549|Pancreatic Tumor
657349|NCT00081549|Pancreas Tumor
657350|NCT00081549|Unresectable
657351|NCT00081549|Metastatic
657352|NCT00081549|Refractory
657353|NCT00081536|Colorectal Neoplasms
657354|NCT00081536|Colorectal Cancer
657355|NCT00081536|Colorectal Carcinoma
657356|NCT00081536|Colorectal Tumor
657357|NCT00081536|Neoplasms, Colorectal
657358|NCT00081536|Unresectable
657359|NCT00081536|Metastatic
657360|NCT00081536|Refractory
657361|NCT00081523|Hemoglobin
657362|NCT00081523|Pain Crisis
657363|NCT00081523|Treatment Options
657364|NCT00081523|Sickle Cell Disease
657365|NCT00081523|Sickle Cell Trait
657366|NCT00081523|Red Blood Cell Disorder
657367|NCT00081523|Thalassemia
657368|NCT00081523|Paroxysmal Nocturnal Hemoglobinuria
657369|NCT00081523|Hemolytic Disorders
657370|NCT00081497|alpha-galactosidase A
657371|NCT00081497|a-GAL
657372|NCT00081497|r-haGAL
657373|NCT00081497|Fabry
657374|NCT00081497|GL-3
657375|NCT00081497|Fabrazyme
657376|NCT00081458|Short Bowel Syndrome
657377|NCT00081458|Parenteral Nutrition
657378|NCT00081458|SBS
657379|NCT00081432|Seizures
657380|NCT00081432|Language
657381|NCT00081432|Memory
657382|NCT00081432|Brain
657383|NCT00081432|Imaging
657384|NCT00081432|Epilepsy
657385|NCT00081432|Temporal Lobe Epilepsy
657386|NCT00081419|Bereitschaftspotential
657387|NCT00081419|Timing of Volition
657388|NCT00081419|Urge
657389|NCT00081419|Conscious Will
657390|NCT00081419|Libet's Clock
657391|NCT00081419|Tourette Syndrome
657392|NCT00081419|Tic Disorder
657393|NCT00081419|Healthy Volunteer
657394|NCT00081419|HV
657395|NCT00081380|Bipolar I Disorder
657396|NCT00081380|Manic Depressive Disorder
657397|NCT00081380|Manic Depression, Mixed
657398|NCT00081367|Minority Groups
657399|NCT00081354|Esophageal Adenocarcinoma
657400|NCT00081354|Dysplasia
657401|NCT00081354|Surveillance
657402|NCT00081354|Proteomics
657403|NCT00081354|SNP's
657404|NCT00081354|Barrett Esophagus
657405|NCT00081354|Gastroesophageal Reflux Disease
657406|NCT00081354|GERD
657407|NCT00081354|Dysphagia
657408|NCT00081354|Swallowing Difficulty
657409|NCT00081315|- Non-Small cell lung cancer
657410|NCT00081302|stage IIIA non-small cell lung cancer
657411|NCT00081302|stage IIIB non-small cell lung cancer
657412|NCT00081302|squamous cell lung cancer
657413|NCT00081302|large cell lung cancer
657414|NCT00081302|adenocarcinoma of the lung
657415|NCT00081302|bronchoalveolar cell lung cancer
657416|NCT00081289|stage III rectal cancer
657417|NCT00081289|adenocarcinoma of the rectum
657418|NCT00081289|stage II rectal cancer
657419|NCT00081250|unspecified adult solid tumor, protocol specific
657420|NCT00081250|cachexia
657421|NCT00081250|anorexia
657422|NCT00081250|weight changes
657423|NCT00081237|recurrent colon cancer
657424|NCT00081237|stage III colon cancer
657425|NCT00081237|stage IV colon cancer
657426|NCT00081237|recurrent rectal cancer
657427|NCT00081237|stage III rectal cancer
657428|NCT00081237|stage IV rectal cancer
657429|NCT00081224|adenocarcinoma of the rectum
657430|NCT00081224|stage II rectal cancer
657431|NCT00081224|stage III rectal cancer
657432|NCT00081172|adenocarcinoma of the prostate
657433|NCT00081172|recurrent prostate cancer
657434|NCT00081172|stage IV prostate cancer
657435|NCT00081159|recurrent prostate cancer
657436|NCT00081159|stage IV prostate cancer
657437|NCT00081159|bone metastases
657438|NCT00081133|accelerated phase chronic myelogenous leukemia
657439|NCT00081133|blastic phase chronic myelogenous leukemia
657440|NCT00081133|recurrent adult acute lymphoblastic leukemia
657441|NCT00081133|untreated adult acute lymphoblastic leukemia
657442|NCT00081107|recurrent non-small cell lung cancer
657443|NCT00081107|stage IIIB non-small cell lung cancer
657444|NCT00081107|stage IV non-small cell lung cancer
657445|NCT00081094|adult primary hepatocellular carcinoma
657446|NCT00081094|recurrent adult primary liver cancer
657447|NCT00081094|localized resectable adult primary liver cancer
657448|NCT00081068|Waldenström macroglobulinemia
657449|NCT00081055|graft versus host disease
657450|NCT00081055|adult acute lymphoblastic leukemia in remission
657451|NCT00081055|recurrent adult acute lymphoblastic leukemia
657452|NCT00081055|adult acute myeloid leukemia in remission
657453|NCT00081055|recurrent adult acute myeloid leukemia
657454|NCT00081055|accelerated phase chronic myelogenous leukemia
657455|NCT00081055|chronic phase chronic myelogenous leukemia
657456|NCT00081055|refractory anemia
657457|NCT00081055|refractory anemia with excess blasts
657458|NCT00081055|refractory anemia with ringed sideroblasts
657459|NCT00081055|de novo myelodysplastic syndromes
657460|NCT00081055|previously treated myelodysplastic syndromes
657461|NCT00081055|secondary myelodysplastic syndromes
657462|NCT00081055|adult acute myeloid leukemia with t(8;21)(q22;q22)
657463|NCT00081055|adult acute myeloid leukemia with t(16;16)(p13;q22)
657464|NCT00081055|adult acute myeloid leukemia with inv(16)(p13;q22)
657465|NCT00081055|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
657676|NCT00080522|Treatment Naive
657466|NCT00081055|adult acute myeloid leukemia with t(15;17)(q22;q12)
657467|NCT00081042|recurrent melanoma
657468|NCT00081042|stage III melanoma
657469|NCT00081042|stage IV melanoma
657470|NCT00081029|xerostomia
657471|NCT00081029|radiation toxicity
657472|NCT00081029|stage I squamous cell carcinoma of the hypopharynx
657473|NCT00081029|stage I squamous cell carcinoma of the oropharynx
657474|NCT00081029|stage II squamous cell carcinoma of the hypopharynx
657475|NCT00081029|stage II squamous cell carcinoma of the oropharynx
657476|NCT00081029|stage III squamous cell carcinoma of the hypopharynx
657477|NCT00081029|stage III squamous cell carcinoma of the oropharynx
657478|NCT00081029|stage IV squamous cell carcinoma of the hypopharynx
657479|NCT00081029|stage IV squamous cell carcinoma of the oropharynx
657480|NCT00081003|breast cancer
657481|NCT00080977|recurrent renal cell cancer
657482|NCT00080977|stage IV renal cell cancer
657483|NCT00080951|stage IV colon cancer
657484|NCT00080951|stage IV rectal cancer
657485|NCT00080951|adenocarcinoma of the colon
657486|NCT00080951|adenocarcinoma of the rectum
657487|NCT00080938|recurrent non-small cell lung cancer
657488|NCT00080938|stage IV non-small cell lung cancer
657489|NCT00080938|squamous cell lung cancer
657490|NCT00080938|adenocarcinoma of the lung
657491|NCT00080938|large cell lung cancer
657492|NCT00080938|bronchoalveolar cell lung cancer
657493|NCT00080938|adenosquamous cell lung cancer
657494|NCT00080938|tumors metastatic to brain
657495|NCT00080925|prolymphocytic leukemia
657496|NCT00080925|accelerated phase chronic myelogenous leukemia
657497|NCT00080925|chronic phase chronic myelogenous leukemia
657498|NCT00080925|relapsing chronic myelogenous leukemia
657499|NCT00080925|refractory chronic lymphocytic leukemia
657500|NCT00080925|de novo myelodysplastic syndromes
657501|NCT00080925|myelodysplastic/myeloproliferative neoplasm, unclassifiable
657502|NCT00080925|previously treated myelodysplastic syndromes
657503|NCT00080925|secondary myelodysplastic syndromes
657504|NCT00080925|secondary acute myeloid leukemia
657505|NCT00080925|recurrent adult Hodgkin lymphoma
657506|NCT00080925|refractory anemia with excess blasts
657507|NCT00080925|refractory multiple myeloma
657508|NCT00080925|primary myelofibrosis
657509|NCT00080925|recurrent adult diffuse large cell lymphoma
657510|NCT00080925|recurrent adult diffuse mixed cell lymphoma
657511|NCT00080925|recurrent adult diffuse small cleaved cell lymphoma
657512|NCT00080925|recurrent adult immunoblastic large cell lymphoma
657513|NCT00080925|recurrent adult lymphoblastic lymphoma
657514|NCT00080925|recurrent grade 1 follicular lymphoma
657515|NCT00080925|recurrent grade 2 follicular lymphoma
657516|NCT00080925|recurrent grade 3 follicular lymphoma
657517|NCT00080925|recurrent adult Burkitt lymphoma
657518|NCT00080925|recurrent mantle cell lymphoma
657519|NCT00080925|adult acute lymphoblastic leukemia in remission
657520|NCT00080925|adult acute myeloid leukemia in remission
657521|NCT00080925|chronic myelomonocytic leukemia
657522|NCT00080925|polycythemia vera
657523|NCT00080925|essential thrombocythemia
657524|NCT00080925|stage II multiple myeloma
657525|NCT00080925|stage III multiple myeloma
657526|NCT00080925|recurrent marginal zone lymphoma
657527|NCT00080925|recurrent small lymphocytic lymphoma
657528|NCT00080925|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
657529|NCT00080925|nodal marginal zone B-cell lymphoma
657530|NCT00080925|splenic marginal zone lymphoma
657531|NCT00080925|adult acute myeloid leukemia with t(8;21)(q22;q22)
657532|NCT00080925|adult acute myeloid leukemia with t(16;16)(p13;q22)
657533|NCT00080925|adult acute myeloid leukemia with inv(16)(p13;q22)
657534|NCT00080925|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
657535|NCT00080925|adult acute myeloid leukemia with t(15;17)(q22;q12)
657536|NCT00080912|bone metastases
657537|NCT00080912|pain
657538|NCT00080886|recurrent adult Burkitt lymphoma
657539|NCT00080886|recurrent adult diffuse large cell lymphoma
657540|NCT00080886|recurrent adult diffuse mixed cell lymphoma
657541|NCT00080886|recurrent adult diffuse small cleaved cell lymphoma
657542|NCT00080886|recurrent adult immunoblastic large cell lymphoma
657543|NCT00080886|recurrent adult lymphoblastic lymphoma
657544|NCT00080886|recurrent grade 1 follicular lymphoma
657545|NCT00080886|recurrent grade 2 follicular lymphoma
657546|NCT00080886|recurrent grade 3 follicular lymphoma
657547|NCT00080886|recurrent mantle cell lymphoma
657548|NCT00080886|recurrent marginal zone lymphoma
657549|NCT00080886|recurrent small lymphocytic lymphoma
657550|NCT00080886|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
657551|NCT00080886|nodal marginal zone B-cell lymphoma
657552|NCT00080886|splenic marginal zone lymphoma
657553|NCT00080873|oral complications
657554|NCT00080873|disseminated neuroblastoma
657555|NCT00080873|previously treated childhood rhabdomyosarcoma
657556|NCT00080873|recurrent Wilms tumor and other childhood kidney tumors
657557|NCT00080873|recurrent/refractory childhood Hodgkin lymphoma
657558|NCT00080873|recurrent childhood acute lymphoblastic leukemia
657559|NCT00080873|recurrent childhood acute myeloid leukemia
657560|NCT00080873|recurrent childhood large cell lymphoma
657677|NCT00080522|Resource Poor Setting
657561|NCT00080873|recurrent childhood lymphoblastic lymphoma
657562|NCT00080873|recurrent childhood rhabdomyosarcoma
657563|NCT00080873|recurrent childhood small noncleaved cell lymphoma
657564|NCT00080873|untreated childhood acute lymphoblastic leukemia
657565|NCT00080873|untreated childhood acute myeloid leukemia and other myeloid malignancies
657566|NCT00080873|childhood acute lymphoblastic leukemia in remission
657567|NCT00080873|childhood acute myeloid leukemia in remission
657568|NCT00080873|childhood chronic myelogenous leukemia
657569|NCT00080873|juvenile myelomonocytic leukemia
657570|NCT00080873|recurrent neuroblastoma
657571|NCT00080860|stage II breast cancer
657572|NCT00080860|stage IIIA breast cancer
657573|NCT00080860|stage IIIB breast cancer
657574|NCT00080860|stage IIIC breast cancer
657575|NCT00080860|stage IV breast cancer
657576|NCT00080834|adenocarcinoma of the colon
657577|NCT00080834|adenocarcinoma of the rectum
657578|NCT00080834|recurrent colon cancer
657579|NCT00080834|recurrent rectal cancer
657580|NCT00080834|stage III colon cancer
657581|NCT00080834|stage IV colon cancer
657582|NCT00080834|stage III rectal cancer
657583|NCT00080834|stage IV rectal cancer
657584|NCT00080808|perioperative/postoperative complications
657585|NCT00080808|sexual dysfunction and infertility
657586|NCT00080808|sexuality and reproductive issues
657587|NCT00080808|adenocarcinoma of the prostate
657588|NCT00080808|stage I prostate cancer
657589|NCT00080808|stage II prostate cancer
657590|NCT00080808|prostaglandin E1
657591|NCT00080808|papaverine
657592|NCT00080808|phentolamine
657593|NCT00080808|Nerve-sparing radical prostatectomy
657594|NCT00080808|nerve grafting
657595|NCT00080795|stage III bladder cancer
657596|NCT00080795|regional transitional cell cancer of the renal pelvis and ureter
657597|NCT00080795|anterior urethral cancer
657598|NCT00080795|posterior urethral cancer
657599|NCT00080795|urethral cancer associated with invasive bladder cancer
657600|NCT00080782|recurrent prostate cancer
657601|NCT00080782|stage IV prostate cancer
657602|NCT00080782|bone metastases
657603|NCT00080782|Progressive Androgen-Independent Prostate Cancer
657604|NCT00080782|Metastron
657605|NCT00080782|Sr-89
657606|NCT00080782|Strontium-89
657607|NCT00080782|strontium chloride Sr 89
657608|NCT00080782|Celecoxib
657609|NCT00080782|Celebrex
657610|NCT00080782|Doxorubicin
657611|NCT00080782|Rubex
657612|NCT00080782|Adriamycin
657613|NCT00080756|breast cancer
657614|NCT00080756|BRCA1 mutation carrier
657615|NCT00080756|BRCA2 mutation carrier
657616|NCT00080743|recurrent breast cancer
657617|NCT00080743|stage IV breast cancer
657618|NCT00080678|adenocarcinoma of the prostate
657619|NCT00080678|recurrent prostate cancer
657620|NCT00080678|stage IV prostate cancer
657621|NCT00080678|bone metastases
657622|NCT00080665|male breast cancer
657623|NCT00080665|stage IIIB breast cancer
657624|NCT00080665|stage IIIC breast cancer
657625|NCT00080665|stage IV breast cancer
657626|NCT00080665|recurrent breast cancer
657627|NCT00080639|ovarian epithelial cancer
657628|NCT00080626|stage I breast cancer
657629|NCT00080626|stage II breast cancer
657630|NCT00080626|stage IIIA breast cancer
657631|NCT00080626|stage IIIB breast cancer
657632|NCT00080626|stage IIIC breast cancer
657633|NCT00080626|stage IV breast cancer
657634|NCT00080600|Post Polio Syndrome
657635|NCT00080600|Magnetic Stimulation
657636|NCT00080600|Fatigue
657637|NCT00080600|Exercise
657638|NCT00080600|Weakness
657639|NCT00080600|Transcranial Magnetic Stimulation
657640|NCT00080600|Post-Exercise Fatigue
657641|NCT00080600|Motor Neuron Disease
657642|NCT00080600|Cortical Reorganization
657643|NCT00080600|Intracortical Facilitation
657644|NCT00080600|Polio
657645|NCT00080600|Healthy Volunteer
657646|NCT00080600|HV
657647|NCT00080587|Intravascular Ultrasound
657648|NCT00080587|Magnetic Resonance Imaging
657649|NCT00080587|Hyperlipidemia
657650|NCT00080587|Cholesterol
657651|NCT00080587|Coronary Artery Disease
657652|NCT00080574|Pharmacokinetics
657653|NCT00080574|Drug Metabolism
657654|NCT00080574|Levothyroxine
657655|NCT00080574|Hypothyroidism
657656|NCT00080574|Hyperthyroidism
657657|NCT00080574|Drug Interactions
657658|NCT00080574|Cytochrome P450
657659|NCT00080574|P-Glycoprotein
657660|NCT00080574|Drug Transport Proteins
657661|NCT00080574|Thyroid Hormone
657662|NCT00080574|Thyroid Cancer
657663|NCT00080548|Bereitschafts Potential
657664|NCT00080548|Timing of Volition
657665|NCT00080548|Somatic Passivity Phenomenon
657666|NCT00080548|Conscious Will
657667|NCT00080548|Libet's Clock
657668|NCT00080548|Schizophrenia
657669|NCT00080548|Healthy Volunteer
657670|NCT00080548|HV
657671|NCT00080535|LMB-2
657672|NCT00080535|Cutaneous T Cell Lymphoma
657673|NCT00080535|CTCL
657674|NCT00080535|Immunotoxin
657675|NCT00080535|Oncology
657678|NCT00080522|Drug Delivery
657679|NCT00080522|Household
657680|NCT00080522|South Africa
657681|NCT00080496|Pneumonia
657682|NCT00080470|Incontinence
657683|NCT00080470|Refractory
657684|NCT00080470|Urinary
657685|NCT00080470|Urge
657686|NCT00080470|Stimulation
657687|NCT00080470|Nerve
657688|NCT00080470|Microstimulator
657689|NCT00080470|Neuromodulation
657690|NCT00080457|Primary or secondary pulmonary arterial hypertension
657691|NCT00080457|Scleroderma
657692|NCT00080457|Connective tissue disease
657693|NCT00080457|Congenital heart defects
657694|NCT00080457|Lupus
657695|NCT00080457|Pulmonary Arterial Hypertension
657696|NCT00080431|Reservoir
657697|NCT00080431|Viral Load
657698|NCT00080431|Immunosuppression
657699|NCT00080431|Activation
657700|NCT00080431|Latency
657701|NCT00080431|HIV
657702|NCT00080431|HAART
657703|NCT00080431|Immunosuppressive Drug
657704|NCT00080431|Viral Reservoirs
657705|NCT00080418|neoplasm
657706|NCT00080418|cancer
657707|NCT00080418|NeoPharm
657708|NCT00080418|liposomes
657709|NCT00080418|Taxol
657710|NCT00080418|paclitaxel
657711|NCT00080418|anti-cancer
657712|NCT00080418|advanced neoplasm
657713|NCT00080418|advanced cancer
657714|NCT00080418|chemotherapy
657715|NCT00080418|refractory cancer
657716|NCT00080418|metastatic cancer
657717|NCT00080405|Relapsed
657718|NCT00080405|Multiple Myeloma
657719|NCT00080405|Pharmacokinetic
657720|NCT00080405|Pharmacodynamic
657721|NCT00080392|Gene Transfer
657722|NCT00080392|Therapeutic Angiogenesis
657723|NCT00080392|Peripheral Arterial Disease
657724|NCT00080392|Perfusion
657725|NCT00080392|Magnetic Resonance Imaging
657726|NCT00080392|Peripheral Vascular Disease
657727|NCT00080392|Claudication
657728|NCT00080392|PAD
657729|NCT00080392|Leg Claudication
657730|NCT00080392|Intermittent Claudication
657731|NCT00080366|Essential Tremor
657732|NCT00080366|Cross over Design
657733|NCT00080366|Accelerometry
657734|NCT00080366|Placebo
657735|NCT00080366|Alcohol Responsive
657736|NCT00080366|Double Blind
657737|NCT00080366|1-Octanol
657738|NCT00080353|Complete Tumor Regression
657739|NCT00080353|Cell Survival
657740|NCT00080353|Chemotherapy Preparative Regimen
657741|NCT00080353|IL-2
657742|NCT00080353|Toxicity
657743|NCT00080353|Metastatic Melanoma
657744|NCT00080314|Bipolar 1 Disorder, depressed
657745|NCT00080301|Metastatic Breast Cancer
657746|NCT00080288|Excessive Sleepiness
657747|NCT00080288|Chronic Shift Work Sleep Disorder
657748|NCT00080288|Chronic SWSD
657749|NCT00080288|Circadian Rhythm Disorder
657750|NCT00080288|Shift Worker
657751|NCT00080288|Cephalon
657752|NCT00080288|Cephalon, Inc
657753|NCT00080288|Nuvigil
657754|NCT00080275|Niacin
657755|NCT00080275|Statin
657756|NCT00080275|Zocor
657757|NCT00080275|Simvastatin
657758|NCT00080275|Coronary Heart Disease
657759|NCT00080275|Dyslipidemia
657760|NCT00080275|Atherosclerosis
657761|NCT00080275|Hypercholesterolemia
657762|NCT00080275|Stroke
657763|NCT00080275|High-Density Lipoprotein Cholesterol
657764|NCT00080275|Low-Density Lipoprotein Cholesterol
657765|NCT00080275|Lipoprotein
657766|NCT00080275|Lipid
657767|NCT00080275|Niacin ER/simvastatin
657768|NCT00080275|Total Cholesterol
657769|NCT00080275|Triglycerides
657770|NCT00080262|Metastatic Breast Cancer
657771|NCT00080236|Liver Transplantation
657772|NCT00080223|pulmonary fibrosis
657773|NCT00080223|respiratory diseases
657774|NCT00080210|elevated uric acid
657775|NCT00080210|Elevated serum uric acid level
657776|NCT00080210|Symptomatic gout
657777|NCT00080197|Breast Cancer
657778|NCT00080197|Cancer of the Breast
657779|NCT00080184|Fibromyalgia
657780|NCT00080184|Electroencephalograph (EEG) biofeedback
657781|NCT00080184|Electromagnetic stimulation
657782|NCT00080184|Neurofeedback
657783|NCT00080184|Neurotherapy
657784|NCT00080184|Complementary and Alternative Medicine
657785|NCT00080171|Osteoarthritis
657786|NCT00080171|Knee Pain
657787|NCT00080171|Knee Health
657788|NCT00080158|Dysthymic Disorder
657789|NCT00080158|Adolescent
657790|NCT00080145|Autistic Disorder
657791|NCT00080145|Asperger Syndrome
657792|NCT00080132|HTG
657793|NCT00080132|Hypertriglyceridemia, Fredrickson Type I
657794|NCT00080132|Hypertriglyceridemia, Fredrickson Type V
657795|NCT00080119|Treatment Naive
657796|NCT00080119|INH Prophylaxis
657797|NCT00080119|HIV Seronegativity
657798|NCT00080106|HIV Therapeutic Vaccine
657799|NCT00080106|Treatment Experienced
657800|NCT00080106|Treatment Interruption
657801|NCT00080106|Adenovirus Vector
657802|NCT00080093|Condom
657803|NCT00080093|HIV Seronegativity
657804|NCT00080093|HIV Prevention
657805|NCT00080093|Behavioral Intervention
657806|NCT00080067|Movement
657807|NCT00080067|Anticipation
657808|NCT00080067|Stimulation
657809|NCT00080067|Timing
657810|NCT00080067|Execution
657811|NCT00080067|Perception
657812|NCT00080067|Rhythm
657813|NCT00080067|Healthy Volunteer
657814|NCT00080067|HV
657815|NCT00080054|Malignant Glioma
657816|NCT00080054|Glioblastoma multiforme
657817|NCT00080054|GBM
657818|NCT00080054|Anaplastic astrocytoma
657819|NCT00080054|AA
657820|NCT00080054|Anaplastic oligodendroglioma
657821|NCT00080054|Anaplastic mixed glioma
657822|NCT00080054|Brain tumor
657823|NCT00080054|Brain neoplasm
657824|NCT00080054|Glioma
657825|NCT00080041|Antineoplastic Combined Chemotherapy Protocols
657826|NCT00080028|Head and Neck Cancer
657827|NCT00080028|SCCHN
657828|NCT00080028|Oropharynx Cancer
657829|NCT00080028|Hypopharynx Cancer
657830|NCT00080028|Larynx Cancer
657831|NCT00080028|Soft palate Cancer
657832|NCT00080028|Tonsil Cancer
657833|NCT00080028|Base of tongue Cancer
657834|NCT00080028|Supraglottic Cancer
657835|NCT00080028|Glottic Cancer
657836|NCT00080028|Pyriform Sinus Cancer
657837|NCT00080028|Pharyngeal wall Cancer
657838|NCT00080028|Throat cancer
657839|NCT00080002|cancer
657840|NCT00080002|gastric
657841|NCT00080002|gastroesophageal junction
657842|NCT00080002|neoplasms
657843|NCT00080002|gastric cancer
657844|NCT00080002|gastric neoplasms
657845|NCT00079989|Bacterial Infections
657846|NCT00079976|Staphylococcus aureus
657847|NCT00079976|Bacterial Infections
657848|NCT00079950|soft
657849|NCT00079950|sarcoma
657850|NCT00079950|metastatic
657851|NCT00079937|allergic
657852|NCT00079937|asthma
657853|NCT00079937|atopic
657854|NCT00079937|omalizumab
657855|NCT00079937|immunoglobulin E
657856|NCT00079937|IgE
657857|NCT00079937|anti-IgE
657858|NCT00079911|Herpes
657859|NCT00079911|HIV
657860|NCT00079911|HSV
657861|NCT00079911|Genital Herpes
657862|NCT00079885|Bacterial Pneumonia
657863|NCT00079859|Heterozygous Familial Hypercholesterolemia (HeFH)
657864|NCT00079846|Homozygous Familial Hypercholesterolemia (HoFH)
657865|NCT00079833|gastric acid hypersecretory conditions
657866|NCT00079833|Idiopathic Hypersecretion
657867|NCT00079833|Excessive Gastric Acid secretion
657868|NCT00079820|Smallpox
657869|NCT00079820|Smallpox Vaccine
657870|NCT00079820|Variola virus
657871|NCT00079820|Smallpox Virus
657872|NCT00079820|MODIFIED VACCINIA ANKARA
657873|NCT00079820|MVA
657874|NCT00079820|Dryvax
657875|NCT00079820|Dryvax vaccine
657876|NCT00079820|Protection against smallpox
657877|NCT00079807|HIV
657878|NCT00079807|Peripheral neuropathy
657879|NCT00079807|Alpha-Lipoic Acid
657880|NCT00079807|ALA
657881|NCT00079807|Complementary Therapies
657882|NCT00079794|lung cancer
657883|NCT00079794|herbal medicine
657884|NCT00079794|non-small cell cancer
657885|NCT00079794|Iscar
657886|NCT00079794|mistletoe
657887|NCT00079781|Responsive Stimulation
657888|NCT00079781|Brain Stimulator
657889|NCT00079781|Epilepsy
657890|NCT00079781|Seizures
657891|NCT00079768|Inflammation
657892|NCT00079768|Myositis
657893|NCT00079768|Humanized Monoclonal Antibody
657894|NCT00079768|Cytotoxic T Cells
657895|NCT00079768|Endomysial T Cells
657896|NCT00079768|Alemtuzumab
657897|NCT00079768|Monoclonal Antibodies
657898|NCT00079768|IBM
657899|NCT00079768|Anti-CD 52
657900|NCT00079768|Inclusion Body Myositis
657901|NCT00079755|Anaplastic Large-Cell Lymphoma
657902|NCT00079755|Lymphoma
657903|NCT00079755|antigens, CD30
657904|NCT00079755|Monoclonal Antibody
657905|NCT00079742|Growth restriction in children with cystic fibrosis
657906|NCT00079729|Treatment Experienced
657907|NCT00079716|Antigens, CD40
657908|NCT00079716|Antibody, Monoclonal
657909|NCT00079716|Blood Coagulation Disorders
657910|NCT00079716|Hematologic Diseases
657911|NCT00079716|Hemorrhagic Disorders
657912|NCT00079716|Hemostatic Disorders
657913|NCT00079716|Immunoproliferative Disorders
657914|NCT00079716|Lymphoproliferative Disorders
657915|NCT00079716|Paraproteinemias
657916|NCT00079716|Vascular Diseases
657917|NCT00079716|Antibody-Dependent Cell Cytotoxicity
657918|NCT00079677|Excessive Sleepiness
657919|NCT00079677|Obstructive Sleep Apnea
657920|NCT00079677|Obstructive Sleep Hypopnea
657921|NCT00079677|nCPAP
657922|NCT00079677|Cephalon
657923|NCT00079677|Cephalon, Inc
657924|NCT00079677|Nuvigil
657925|NCT00079664|Tai Ji
657926|NCT00079651|Aged
657927|NCT00079651|Nursing Homes
657928|NCT00079651|Assisted Living Facilities
657929|NCT00079638|Niaspan
657930|NCT00079638|Niacin
657931|NCT00079638|Statin
657932|NCT00079638|Cholesterol
657933|NCT00079638|Triglycerides
657934|NCT00079638|Lipid-Modifying Therapies
657935|NCT00079638|Dyslipidemia
657936|NCT00079638|Coronary Heart Disease
657937|NCT00079638|Atherosclerosis
657938|NCT00079638|Stroke
657939|NCT00079638|VA-HIT
657940|NCT00079638|Niacin Statin Combination Threrapy
657941|NCT00079638|High Density Lipoprotein
657942|NCT00079638|Low Density Lipoprotein
657943|NCT00079638|Hypertension
657944|NCT00079638|Diabetes
657945|NCT00079638|Adult Treatment Panel III
657946|NCT00079625|Engraftment
657947|NCT00079625|Graft-Versus-Host Disease
657948|NCT00079625|Metastatic Breast Cancer
657949|NCT00079625|MBC
657950|NCT00079612|Renal Cell Cancer
657951|NCT00079612|RCC
657952|NCT00079612|Cancer
657953|NCT00079599|Carnitine Deficiency
657954|NCT00079599|Fatigue
657955|NCT00079599|Complementary Therapies
657956|NCT00079573|Weight Loss
657957|NCT00079573|Obesity
657958|NCT00079573|Overweight
657959|NCT00079573|Premenopausal women
657960|NCT00079573|Diet
657961|NCT00079560|HIV
657962|NCT00079560|Marijuana
657963|NCT00079560|Marinol
657964|NCT00079560|Oral THC
657965|NCT00079560|Appetite
657966|NCT00079560|Complementary Therapies
657967|NCT00079547|Weight Loss
657968|NCT00079534|AIDS
657969|NCT00079534|HIV
657970|NCT00079534|Prayer
657971|NCT00079534|Healing
657972|NCT00079534|Complementary Therapies
657973|NCT00079521|Bone Metabolism
657974|NCT00079521|Therapeutic Touch
657975|NCT00079508|Heparin-induced Thrombocytopenia
657976|NCT00079508|Heparin-induced Thrombocytopenia/Thrombosis Syndrome
657977|NCT00079508|HIT/HITTS
657978|NCT00079508|Heparin anti-body positive
657979|NCT00079495|MS
657980|NCT00079495|Autoimmune disease
657981|NCT00079495|relapsing
657982|NCT00079495|progressive
657983|NCT00079495|Myelin
657984|NCT00079495|Myelin Basic Protein
657985|NCT00079495|MBP
657986|NCT00079495|acute fulminating
657987|NCT00079495|chronic progressive
657988|NCT00079495|Altered Peptide Ligand
657989|NCT00079495|APL
657990|NCT00079495|Neurocrine
657991|NCT00079495|NBI-5788
657992|NCT00079495|Relapse
657993|NCT00079482|AML
657994|NCT00079469|cancer survivor
657995|NCT00079469|unspecified adult solid tumor, protocol specific
657996|NCT00079391|Chronic Myelogenous Leukemia (CML)
657997|NCT00079391|Acute Lymphoblastic Leukemia (ALL)
657998|NCT00079391|Acute Myelogenous Leukemia (AML)
657999|NCT00079391|Chronic Lymphocytic Leukemia (CLL)
658000|NCT00079391|Myelodysplastic Syndromes (MDS)
658001|NCT00079391|Peripheral Blood Stem Cells
658002|NCT00079391|Graft-Versus Leukemia/Myeloma
658003|NCT00079391|Graft-Versus-Host Disease (GVHD)
658004|NCT00079391|Cyclosporine
658005|NCT00079391|Fludarabine
658006|NCT00079391|Leukemia
658007|NCT00079391|Myelodysplastic Syndrome
658008|NCT00079391|Myeloproliferative Syndrome
658009|NCT00079391|Non-Hodgkin Lymphoma
658010|NCT00079365|adenocarcinoma of the pancreas
658011|NCT00079365|stage II pancreatic cancer
658012|NCT00079365|stage III pancreatic cancer
658013|NCT00079365|stage IV pancreatic cancer
658014|NCT00079313|CMML
658015|NCT00079313|CML
658016|NCT00079313|Gleevec
658017|NCT00079313|Glivec
658018|NCT00079313|STI-571
658019|NCT00079313|Tyrosine Kinase Inhibitor
658020|NCT00079313|Chronic Myelogenous Leukemia
658021|NCT00079313|Atypical Chronic Myelogenous Leukemia
658022|NCT00079313|Chronic Myelomoncytic Leukemia
658023|NCT00079313|Leukemia
658024|NCT00079300|basal cell carcinoma of the skin
658025|NCT00079287|adenocarcinoma of the lung
658026|NCT00079287|large cell lung cancer
658027|NCT00079287|recurrent non-small cell lung cancer
658028|NCT00079287|squamous cell lung cancer
658029|NCT00079287|stage IIIB non-small cell lung cancer
658030|NCT00079287|stage IV non-small cell lung cancer
658031|NCT00079261|contiguous stage II grade 3 follicular lymphoma
658032|NCT00079261|noncontiguous stage II grade 3 follicular lymphoma
658033|NCT00079261|stage III grade 3 follicular lymphoma
658034|NCT00079261|stage IV grade 3 follicular lymphoma
658035|NCT00079261|contiguous stage II adult diffuse large cell lymphoma
658036|NCT00079261|noncontiguous stage II adult diffuse large cell lymphoma
658037|NCT00079261|stage III adult diffuse large cell lymphoma
658038|NCT00079261|stage IV adult diffuse large cell lymphoma
658039|NCT00079261|anaplastic large cell lymphoma
658040|NCT00079261|angioimmunoblastic T-cell lymphoma
658041|NCT00079261|adult grade III lymphomatoid granulomatosis
658042|NCT00079261|small intestine lymphoma
658043|NCT00079248|osteoporosis
658044|NCT00079248|stage I breast cancer
658045|NCT00079248|stage II breast cancer
658046|NCT00079248|menopausal symptoms
658047|NCT00079248|hot flashes
658048|NCT00079222|infection
658049|NCT00079222|adult acute lymphoblastic leukemia in remission
658050|NCT00079222|adult acute myeloid leukemia in remission
658051|NCT00079222|childhood acute lymphoblastic leukemia in remission
658052|NCT00079222|childhood acute myeloid leukemia in remission
658053|NCT00079222|recurrent adult acute lymphoblastic leukemia
658054|NCT00079222|recurrent adult acute myeloid leukemia
658055|NCT00079222|recurrent childhood acute lymphoblastic leukemia
658056|NCT00079222|recurrent childhood acute myeloid leukemia
658057|NCT00079222|untreated adult acute lymphoblastic leukemia
658058|NCT00079222|untreated adult acute myeloid leukemia
658059|NCT00079222|untreated childhood acute lymphoblastic leukemia
658060|NCT00079222|untreated childhood acute myeloid leukemia and other myeloid malignancies
658061|NCT00079222|refractory chronic lymphocytic leukemia
658062|NCT00079222|stage III chronic lymphocytic leukemia
658063|NCT00079222|stage IV chronic lymphocytic leukemia
658064|NCT00079222|accelerated phase chronic myelogenous leukemia
658065|NCT00079222|atypical chronic myeloid leukemia
658066|NCT00079222|blastic phase chronic myelogenous leukemia
658067|NCT00079222|childhood chronic myelogenous leukemia
658068|NCT00079222|chronic myelomonocytic leukemia
658069|NCT00079222|chronic phase chronic myelogenous leukemia
658070|NCT00079222|relapsing chronic myelogenous leukemia
658071|NCT00079222|secondary acute myeloid leukemia
658072|NCT00079222|secondary myelodysplastic syndromes
658073|NCT00079222|de novo myelodysplastic syndromes
658074|NCT00079222|myelodysplastic/myeloproliferative disease, unclassifiable
658075|NCT00079222|previously treated myelodysplastic syndromes
658076|NCT00079222|chronic eosinophilic leukemia
658077|NCT00079222|primary myelofibrosis
658078|NCT00079222|chronic neutrophilic leukemia
658079|NCT00079222|stage I multiple myeloma
658080|NCT00079222|stage II multiple myeloma
658081|NCT00079222|stage III multiple myeloma
658082|NCT00079222|refractory hairy cell leukemia
658083|NCT00079222|refractory multiple myeloma
658084|NCT00079222|recurrent adult Burkitt lymphoma
658085|NCT00079222|recurrent adult diffuse large cell lymphoma
658086|NCT00079222|recurrent adult diffuse mixed cell lymphoma
658087|NCT00079222|recurrent adult diffuse small cleaved cell lymphoma
658088|NCT00079222|recurrent adult Hodgkin lymphoma
658089|NCT00079222|recurrent adult immunoblastic large cell lymphoma
658090|NCT00079222|recurrent adult lymphoblastic lymphoma
658091|NCT00079222|recurrent childhood large cell lymphoma
658092|NCT00079222|recurrent childhood lymphoblastic lymphoma
658093|NCT00079222|recurrent childhood small noncleaved cell lymphoma
658094|NCT00079222|recurrent cutaneous T-cell non-Hodgkin lymphoma
658095|NCT00079222|recurrent grade 1 follicular lymphoma
658096|NCT00079222|recurrent grade 2 follicular lymphoma
658097|NCT00079222|recurrent grade 3 follicular lymphoma
658098|NCT00079222|recurrent mantle cell lymphoma
658099|NCT00079222|recurrent/refractory childhood Hodgkin lymphoma
658100|NCT00079222|noncontiguous stage II adult Burkitt lymphoma
658101|NCT00079222|noncontiguous stage II adult diffuse large cell lymphoma
658102|NCT00079222|noncontiguous stage II adult diffuse mixed cell lymphoma
658103|NCT00079222|noncontiguous stage II adult diffuse small cleaved cell lymphoma
658104|NCT00079222|noncontiguous stage II adult immunoblastic large cell lymphoma
658105|NCT00079222|noncontiguous stage II adult lymphoblastic lymphoma
658106|NCT00079222|noncontiguous stage II grade 1 follicular lymphoma
658107|NCT00079222|noncontiguous stage II grade 2 follicular lymphoma
658108|NCT00079222|noncontiguous stage II grade 3 follicular lymphoma
658109|NCT00079222|noncontiguous stage II mantle cell lymphoma
658110|NCT00079222|stage III adult Burkitt lymphoma
658111|NCT00079222|stage III adult diffuse large cell lymphoma
658112|NCT00079222|stage III adult diffuse mixed cell lymphoma
658113|NCT00079222|stage III adult diffuse small cleaved cell lymphoma
658114|NCT00079222|stage III adult immunoblastic large cell lymphoma
658115|NCT00079222|stage III adult lymphoblastic lymphoma
658116|NCT00079222|stage III grade 1 follicular lymphoma
658117|NCT00079222|stage III grade 2 follicular lymphoma
658118|NCT00079222|stage III grade 3 follicular lymphoma
658119|NCT00079222|stage III mantle cell lymphoma
658120|NCT00079222|stage IV adult Burkitt lymphoma
658121|NCT00079222|stage IV adult diffuse large cell lymphoma
658122|NCT00079222|stage IV adult diffuse mixed cell lymphoma
658123|NCT00079222|stage IV adult diffuse small cleaved cell lymphoma
658124|NCT00079222|stage IV adult immunoblastic large cell lymphoma
658125|NCT00079222|stage IV adult lymphoblastic lymphoma
658126|NCT00079222|stage IV grade 1 follicular lymphoma
658127|NCT00079222|stage IV grade 2 follicular lymphoma
658128|NCT00079222|stage IV grade 3 follicular lymphoma
658129|NCT00079222|stage IV mantle cell lymphoma
658130|NCT00079222|recurrent mycosis fungoides/Sezary syndrome
658131|NCT00079222|recurrent malignant testicular germ cell tumor
658132|NCT00079222|stage III malignant testicular germ cell tumor
658133|NCT00079222|recurrent ovarian epithelial cancer
658134|NCT00079222|stage II ovarian epithelial cancer
658135|NCT00079222|stage III ovarian epithelial cancer
658136|NCT00079222|stage IV ovarian epithelial cancer
658137|NCT00079222|poor prognosis metastatic gestational trophoblastic tumor
658138|NCT00079222|disseminated neuroblastoma
658139|NCT00079222|recurrent neuroblastoma
658140|NCT00079222|recurrent ovarian germ cell tumor
658141|NCT00079222|previously treated childhood rhabdomyosarcoma
658142|NCT00079222|recurrent childhood rhabdomyosarcoma
658143|NCT00079222|recurrent Wilms tumor and other childhood kidney tumors
658144|NCT00079222|stage IIIA breast cancer
658145|NCT00079222|stage IIIB breast cancer
658146|NCT00079222|stage IIIC breast cancer
658147|NCT00079222|stage IV breast cancer
658148|NCT00079222|juvenile myelomonocytic leukemia
658149|NCT00079222|noncontiguous stage II small lymphocytic lymphoma
658150|NCT00079222|noncontiguous stage II marginal zone lymphoma
658151|NCT00079222|recurrent marginal zone lymphoma
658152|NCT00079222|recurrent small lymphocytic lymphoma
658153|NCT00079222|stage III small lymphocytic lymphoma
658154|NCT00079222|stage III marginal zone lymphoma
658155|NCT00079222|stage IV small lymphocytic lymphoma
658156|NCT00079222|stage IV marginal zone lymphoma
658157|NCT00079222|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
658158|NCT00079222|nodal marginal zone B-cell lymphoma
658159|NCT00079222|splenic marginal zone lymphoma
658160|NCT00079222|adult acute myeloid leukemia with t(8;21)(q22;q22)
658161|NCT00079222|adult acute myeloid leukemia with t(16;16)(p13;q22)
658162|NCT00079222|adult acute myeloid leukemia with inv(16)(p13;q22)
658163|NCT00079222|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
658164|NCT00079222|adult acute myeloid leukemia with t(15;17)(q22;q12)
658165|NCT00079222|childhood myelodysplastic syndromes
658166|NCT00079170|male breast cancer
658167|NCT00079170|recurrent breast cancer
658168|NCT00079170|stage IIIA breast cancer
658169|NCT00079170|stage IIIB breast cancer
658170|NCT00079170|stage IIIC breast cancer
658171|NCT00079170|stage IV breast cancer
658172|NCT00079157|recurrent breast cancer
658173|NCT00079157|stage IV breast cancer
658174|NCT00079144|recurrent melanoma
658175|NCT00079144|stage IV melanoma
658176|NCT00079118|stage IV breast cancer
658177|NCT00079118|recurrent breast cancer
658178|NCT00079118|male breast cancer
658179|NCT00079105|stage I adult Hodgkin lymphoma
658180|NCT00079105|stage II adult Hodgkin lymphoma
658181|NCT00079105|stage III adult Hodgkin lymphoma
658182|NCT00079105|stage IV adult Hodgkin lymphoma
658183|NCT00079092|recurrent adult brain tumor
658184|NCT00079092|adult anaplastic astrocytoma
658185|NCT00079092|adult anaplastic oligodendroglioma
658186|NCT00079092|adult glioblastoma
658187|NCT00079092|adult mixed glioma
658188|NCT00079092|adult giant cell glioblastoma
658189|NCT00079092|adult gliosarcoma
658190|NCT00079079|stage II salivary gland cancer
658191|NCT00079079|stage III salivary gland cancer
658192|NCT00079079|stage IV salivary gland cancer
658193|NCT00079079|recurrent salivary gland cancer
658194|NCT00079079|salivary gland acinic cell tumor
658195|NCT00079079|salivary gland adenoid cystic carcinoma
658196|NCT00079079|salivary gland poorly differentiated carcinoma
658197|NCT00079079|high-grade salivary gland mucoepidermoid carcinoma
658198|NCT00079079|low-grade salivary gland mucoepidermoid carcinoma
658199|NCT00079079|salivary gland malignant mixed cell type tumor
658200|NCT00079079|salivary gland adenocarcinoma
658201|NCT00079079|salivary gland anaplastic carcinoma
658202|NCT00079079|salivary gland squamous cell carcinoma
658203|NCT00079066|quality of life
658204|NCT00079066|stage IV colon cancer
658205|NCT00079066|recurrent colon cancer
658206|NCT00079066|recurrent rectal cancer
658207|NCT00079066|stage IV rectal cancer
658208|NCT00079053|stage III squamous cell carcinoma of the hypopharynx
658209|NCT00079053|stage III squamous cell carcinoma of the larynx
658210|NCT00079053|stage III squamous cell carcinoma of the lip and oral cavity
658211|NCT00079053|stage III squamous cell carcinoma of the nasopharynx
658212|NCT00079053|stage III squamous cell carcinoma of the oropharynx
658213|NCT00079053|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
658214|NCT00079053|stage IV squamous cell carcinoma of the hypopharynx
658215|NCT00079053|stage IV squamous cell carcinoma of the larynx
658216|NCT00079053|stage IV squamous cell carcinoma of the lip and oral cavity
658217|NCT00079053|stage IV squamous cell carcinoma of the nasopharynx
658218|NCT00079053|stage IV squamous cell carcinoma of the oropharynx
658219|NCT00079053|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
658220|NCT00079053|salivary gland squamous cell carcinoma
658221|NCT00079053|stage III salivary gland cancer
658222|NCT00079053|stage IV salivary gland cancer
658223|NCT00079027|advanced adult primary liver cancer
658224|NCT00079027|adult primary hepatocellular carcinoma
658225|NCT00079001|adenocarcinoma of the prostate
658226|NCT00079001|recurrent prostate cancer
658227|NCT00079001|stage IV prostate cancer
658228|NCT00079001|bone metastases
658229|NCT00078988|childhood high-grade cerebral astrocytoma
658230|NCT00078988|recurrent childhood cerebellar astrocytoma
658231|NCT00078988|recurrent childhood cerebral astrocytoma
658232|NCT00078975|adenocarcinoma of the pancreas
658233|NCT00078975|recurrent pancreatic cancer
658234|NCT00078975|stage II pancreatic cancer
658235|NCT00078975|stage III pancreatic cancer
658236|NCT00078975|stage IV pancreatic cancer
658237|NCT00078949|anaplastic large cell lymphoma
658238|NCT00078949|recurrent adult Burkitt lymphoma
658239|NCT00078949|recurrent adult diffuse large cell lymphoma
658240|NCT00078949|angioimmunoblastic T-cell lymphoma
658241|NCT00078923|stage I prostate cancer
658242|NCT00078923|stage II prostate cancer
658243|NCT00078923|adenocarcinoma of the prostate
658244|NCT00078910|adenocarcinoma of the prostate
658245|NCT00078910|stage IIB prostate cancer
658246|NCT00078910|stage IIA prostate cancer
658247|NCT00078910|stage III prostate cancer
658248|NCT00078897|colon cancer
658249|NCT00078897|rectal cancer
658250|NCT00078897|colorectal cancer
658251|NCT00078897|adenomatous polyp
658252|NCT00078845|neurotoxicity
658253|NCT00078845|unspecified adult solid tumor, protocol specific
658254|NCT00078845|recurrent prostate cancer
658255|NCT00078845|stage I prostate cancer
658256|NCT00078845|stage IIB prostate cancer
658257|NCT00078845|stage IIA prostate cancer
658258|NCT00078845|stage III prostate cancer
658259|NCT00078845|stage IV prostate cancer
658260|NCT00078845|recurrent non-small cell lung cancer
658261|NCT00078845|stage I non-small cell lung cancer
658262|NCT00078845|stage II non-small cell lung cancer
658263|NCT00078845|stage IIIA non-small cell lung cancer
658264|NCT00078845|stage IIIB non-small cell lung cancer
658265|NCT00078845|stage IV non-small cell lung cancer
658266|NCT00078845|limited stage small cell lung cancer
658267|NCT00078845|extensive stage small cell lung cancer
658268|NCT00078845|recurrent small cell lung cancer
658269|NCT00078845|recurrent breast cancer
658270|NCT00078845|stage I breast cancer
658271|NCT00078845|stage II breast cancer
658272|NCT00078845|stage IIIA breast cancer
658273|NCT00078845|stage IIIB breast cancer
658274|NCT00078845|stage IIIC breast cancer
658275|NCT00078845|stage IV breast cancer
658276|NCT00078845|recurrent ovarian epithelial cancer
658277|NCT00078845|stage I ovarian epithelial cancer
658278|NCT00078845|stage II ovarian epithelial cancer
658279|NCT00078845|stage III ovarian epithelial cancer
658280|NCT00078845|stage IV ovarian epithelial cancer
658281|NCT00078832|breast cancer, chemoprevention
658282|NCT00078819|Pediatric Psoriasis
658283|NCT00078806|Systemic Onset Juvenile Rheumatoid Arthiritis
658284|NCT00078806|SOJRA
658285|NCT00078806|Fever
658286|NCT00078806|Rash
658287|NCT00078806|Joint Pain
658288|NCT00078793|JRA
658289|NCT00078793|Registry
658290|NCT00078767|PTSD
658291|NCT00078767|Depression
658292|NCT00078767|Anxiety
658293|NCT00078741|Psychotic Disorders
658294|NCT00078728|Anxiety
658295|NCT00078715|Yohimbine
658296|NCT00078715|Sleep Deprivation
658297|NCT00078715|Depression
658298|NCT00078715|Mood Disorder
658299|NCT00078715|Fast
658300|NCT00078715|Affective Disorder
658301|NCT00078715|Rapid Onset
658302|NCT00078715|Major Depression
658303|NCT00078715|MDD
658304|NCT00078689|Sirolimus
658305|NCT00078689|Daclizumab
658306|NCT00078689|Inflammation
658307|NCT00078689|Induce Tolerance
658308|NCT00078689|Uveitis
658309|NCT00078689|Immune Tolerance
658310|NCT00078689|T Cell
658311|NCT00078663|Oral Care
658312|NCT00078663|ICU
658313|NCT00078663|Pneumonia
658314|NCT00078663|Pathogens
658315|NCT00078663|Intubation
658316|NCT00078663|Intubated
658317|NCT00078663|Oral Hygiene
658318|NCT00078663|Intensive Care
658319|NCT00078624|Osteoarthritis
658320|NCT00078624|Knee Joint
658321|NCT00078624|Joint Stability
658322|NCT00078624|Motor Control
658323|NCT00078624|Exercise Therapy
658324|NCT00078611|Crohn's disease
658325|NCT00078611|Inflammatory Bowel Disease
658326|NCT00078611|IBD
658327|NCT00078611|Gastroenterology
658328|NCT00078611|Regional Enteritis
658329|NCT00078611|Colitis
658330|NCT00078598|Relapsed
658331|NCT00078598|Follicular
658332|NCT00078572|XELODA
658333|NCT00078572|Metastatic
658334|NCT00078572|Breast Cancer
658335|NCT00078572|Advanced
658336|NCT00078572|HERCEPTIN
658337|NCT00078559|Immunosuppression
658338|NCT00078559|Renal Failure
658339|NCT00078546|EBV
658340|NCT00078546|NASOPHARYNGEAL
658341|NCT00078546|CARCINOMA
658342|NCT00078546|EBV POSITIVE NASOPHARYNGEAL CARCINOMA
658343|NCT00078533|Allogeneic
658344|NCT00078533|Transplant
658345|NCT00078533|CMV
658346|NCT00078533|Stem Cell
658347|NCT00078533|Donor
658348|NCT00078533|Allogeneic stem cell recipients at risk for CMV reactivation
658349|NCT00078520|Leukemia
658350|NCT00078507|Outcome and Process Assessment (Health Care)
658351|NCT00078507|Behavior Control
658352|NCT00078507|Sensation
658353|NCT00078507|Randomized Controlled Trials
658354|NCT00078507|Adolescent
658355|NCT00078507|Adult
658356|NCT00078494|Immunization
658357|NCT00078494|Vaccine
658358|NCT00078494|Nasopharyngeal Cancer
658359|NCT00078494|Immunotherapy
658360|NCT00078494|Cancer
658361|NCT00078494|NPC
658362|NCT00078481|Neurodegeneration
658363|NCT00078481|Anti-Oxidant
658364|NCT00078481|Neuropathy
658365|NCT00078481|Hereditary
658366|NCT00078481|Spinocerebellar
658367|NCT00078481|Friedreich Ataxia
658368|NCT00078481|FRDA
658369|NCT00078455|NSCLC
658370|NCT00078455|Non-small Cell Lung Cancer
658371|NCT00078455|Non-small Cell Lung Carcinoma
658372|NCT00078455|Locally Advanced NSCLC
658373|NCT00078455|Metastatic NSCLC
658374|NCT00078442|Treatment Experienced
658375|NCT00078442|Treatment Interruption
658376|NCT00078442|Treatment Naive
658377|NCT00078403|Treatment Experienced
658378|NCT00078390|Lung cancer
658379|NCT00078390|Lung carcinoma
658380|NCT00078390|Non small cell lung cancer
658381|NCT00078390|Stage IIIA non small cell lung cancer
658382|NCT00078390|Stage IIIB non small cell lung cancer
658383|NCT00078390|NSCLC
658384|NCT00078390|Stage III
658385|NCT00078390|chemotherapy
658386|NCT00078390|radiation
658387|NCT00078390|chemoradiation
658388|NCT00078390|matrix metalloproteinases
658389|NCT00078390|neovascularization
658390|NCT00078390|antiangiogenesis
658391|NCT00078390|type IV collagenases
658392|NCT00078390|Unresectable locally advanced non-small cell lung cancer
658393|NCT00078377|Narcolepsy
658394|NCT00078377|Excessive Sleepiness
658395|NCT00078377|Cataplexy
658396|NCT00078377|Sleep Attacks
658397|NCT00078377|Excessive Sleepiness associated with Narcolepsy
658398|NCT00078377|Cephalon
658399|NCT00078377|Cephalon, Inc
658400|NCT00078377|Nuvigil
658401|NCT00078364|MRI
658402|NCT00078364|NSAID Analgesia
658403|NCT00078364|Pain Mechanisms
658404|NCT00078364|SNP's
658405|NCT00078364|Acute Pain
658406|NCT00078364|Wisdom Teeth
658407|NCT00078364|Third Molar Extraction
658408|NCT00078364|Third Molar Impaction
658409|NCT00078351|Chronic Pain
658410|NCT00078351|Synvisc
658411|NCT00078351|Temporomandibular Joint
658412|NCT00078351|Osteoarthritis
658413|NCT00078351|TMD
658414|NCT00078351|Temporomandibular Joint Osteoarthritis
658415|NCT00078351|TMJ OA
658416|NCT00078351|Temporomandibular Joint Disease
658417|NCT00078351|TMJ
658418|NCT00078325|Excessive Sleepiness
658419|NCT00078325|Obstructive Sleep Apnea
658420|NCT00078325|Obstructive Sleep Hypopnea
658421|NCT00078325|nCPAP
658422|NCT00078325|Cephalon
658423|NCT00078325|Cephalon, Inc
658424|NCT00078325|NUVIGIL
658425|NCT00078312|Excessive Sleepiness
658426|NCT00078312|Narcolepsy
658427|NCT00078312|Cataplexy
658428|NCT00078312|Sleep Attacks
658429|NCT00078312|Obstructive Sleep Apnea
658430|NCT00078312|Obstructive Sleep Hypopnea
658431|NCT00078312|nCPAP
658432|NCT00078312|Chronic Shift Work Sleep Disorder
658433|NCT00078312|Chronic SWSD
658434|NCT00078312|Circadian Rhythm Disorder
658435|NCT00078312|Shift Worker
658436|NCT00078312|Cepahlon
658437|NCT00078312|Cephalon, Inc
658438|NCT00078312|Nuvigil
658439|NCT00078299|Cortical
658440|NCT00078299|Nuclear Sclerosis
658441|NCT00078299|Posterior Subcapsular
658442|NCT00078299|Photographic Methods
658443|NCT00078299|Reproducibility (intra and interobserver)
658444|NCT00078299|Cataract
658445|NCT00078299|Agreement
658446|NCT00078299|Grading System
658447|NCT00078286|Antidepressive Agents
658448|NCT00078273|Gambling
658449|NCT00078273|Pathological Gambling
658450|NCT00078273|Problem Gambling
658451|NCT00078273|College Students
658452|NCT00078273|Prevention
658453|NCT00078247|Antiretroviral Therapy
658454|NCT00078247|Africa
658455|NCT00078234|CLL
658456|NCT00078234|Leukemia
658457|NCT00078234|Chronic
658458|NCT00078234|Cancer
658459|NCT00078234|Adult
658460|NCT00078234|Lymphocytic
658461|NCT00078234|Genasense
658462|NCT00078234|G3139
658463|NCT00078234|Genta
658464|NCT00078234|Bcl-2
658465|NCT00078234|Antisense
658466|NCT00078234|Oligonucleotide
658467|NCT00078234|oblimersen
658468|NCT00078221|Dry AMD
658469|NCT00078221|Age-related Macular Degeneration
658470|NCT00078221|Rheopheresis
658471|NCT00078208|Pediatric
658472|NCT00078208|Non-Invasive
658473|NCT00078208|Anti-Inflammatory
658474|NCT00078208|pH
658475|NCT00078208|Mediators
658476|NCT00078208|Asthma
658477|NCT00078208|Childhood Asthma
658478|NCT00078208|Healthy Volunteer
658479|NCT00078208|HV
658480|NCT00078195|Ragweed
658481|NCT00078195|Immunotherapy
658482|NCT00078195|Rush Immunotherapy
658483|NCT00078195|RIT
658484|NCT00078195|Hayfever
658485|NCT00078195|Seasonal Allergic Rhinitis
658486|NCT00078182|HIV Prevention
658487|NCT00078169|behavioral intervention
658488|NCT00078156|behavioral intervention
658489|NCT00078143|behavioral intervention
658490|NCT00078130|opioid dependence
658491|NCT00078130|behavioral intervention
658492|NCT00078117|opiate dependence
658493|NCT00078104|Prostanoid
658494|NCT00078104|Cyclooxygenase (COX)
658495|NCT00078104|Selective Cox Inhibitor
658496|NCT00078104|Acute Peripheral Inflammation
658497|NCT00078104|Neuronal Expression of COX
658498|NCT00078104|Pain
658499|NCT00078104|Coxibs
658500|NCT00078104|Wisdom Teeth
658501|NCT00078104|Third Molar Extraction
658502|NCT00078104|Third Molar Impaction
658503|NCT00078091|Obesity
658504|NCT00078091|Retinopathy
658505|NCT00078091|Dyslipidemia
658506|NCT00078091|Insulin Resistance
658507|NCT00078091|Hypogonadism
658508|NCT00078091|Polydactyly
658509|NCT00078091|Bardet-Biedl Syndrome
658510|NCT00078091|BBS
658511|NCT00078078|Vitamin B12
658512|NCT00078078|Methylmalonic Acidemia
658513|NCT00078078|Hyperhomocysteinemia
658514|NCT00078078|MMA
658515|NCT00078078|Metabolic Disease
658516|NCT00078065|multiple myeloma
658517|NCT00078065|fludarabine
658518|NCT00078065|Xcellerated T Cells
658519|NCT00078039|Schizophrenia, paliperidone
658520|NCT00078026|Apomine
658521|NCT00078026|Osteoporosis
658522|NCT00078026|Bone Mass
658523|NCT00078026|Postmenopausal
658524|NCT00078013|AMI
658525|NCT00078013|STEMI
658526|NCT00078013|Infarct
658527|NCT00078013|acute myocardial infarction with ST segment elevation
658528|NCT00077961|Non-Hodgkin's Lymphoma
658529|NCT00077961|NHL
658530|NCT00077961|CAMPATH
658531|NCT00077961|alemtuzumab
658532|NCT00077948|positive inotrope
658533|NCT00077948|enoximone
658534|NCT00077948|beta-blocker
658535|NCT00077948|intolerant
658536|NCT00077922|LMB-2
658537|NCT00077922|Chronic Lymphocytic Leukemia
658538|NCT00077922|CLL
658539|NCT00077922|Immunotoxin
658540|NCT00077922|Oncology
658541|NCT00077922|Lymphocytes
658542|NCT00077922|Hematological Disease
658543|NCT00077922|Monoclonal Antibody
658544|NCT00077922|Neutralizing Antibodies
658545|NCT00077909|Proteomics
658546|NCT00077909|Infection
658547|NCT00077909|Pneumonia
658548|NCT00077909|Mass Spectrometry
658549|NCT00077909|BAL
658550|NCT00077909|Lung
658551|NCT00077909|Pulmonary Disease
658552|NCT00077909|Lung Infiltrates
658553|NCT00077896|Treatment
658554|NCT00077896|Transcranial Stimulation
658555|NCT00077896|Frontal Lobe
658556|NCT00077896|Pick's Disease
658557|NCT00077896|Cognitive Impairment
658558|NCT00077896|Dementia
658559|NCT00077896|Frontotemporal Dementia
658560|NCT00077896|FTD
658561|NCT00077870|Moderate to severe rheumatoid arthritis
658562|NCT00077792|Receiving fibrinolytic therapy
658563|NCT00077727|Schizophrenia
658564|NCT00077727|cognitive impairment
658565|NCT00077727|galantamine
658566|NCT00077727|acetylcholinesterase inhibitors
658567|NCT00077727|antipsychotic drugs
658568|NCT00077727|BACS
658569|NCT00077714|Schizophrenia
658570|NCT00077714|Paliperidone
658571|NCT00077675|Abscess
658572|NCT00077675|Burns
658573|NCT00077675|Cellulitis
658574|NCT00077675|Ulcer
658575|NCT00077675|Wound infections
658576|NCT00077662|Pompe Disease
658577|NCT00077662|Glycogen Storage Disease Type II
658578|NCT00077662|GSD-II
658579|NCT00077662|Acid Maltase Deficiency Disease
658580|NCT00077662|Glycogenosis 2
658581|NCT00077584|Scleroderma
658582|NCT00077584|Finger Ulcers
658583|NCT00077584|Digital Ulcers
658584|NCT00077584|Systemic Sclerosis
658585|NCT00077558|accelerated phase chronic myelogenous leukemia
658586|NCT00077558|blastic phase chronic myelogenous leukemia
658587|NCT00077558|relapsing chronic myelogenous leukemia
658588|NCT00077558|previously treated myelodysplastic syndromes
658589|NCT00077558|secondary myelodysplastic syndromes
658590|NCT00077558|refractory chronic lymphocytic leukemia
658591|NCT00077558|recurrent adult acute lymphoblastic leukemia
658592|NCT00077558|prolymphocytic leukemia
658593|NCT00077558|refractory anemia with excess blasts
658594|NCT00077558|chronic myelomonocytic leukemia
658595|NCT00077558|recurrent adult acute myeloid leukemia
658596|NCT00077558|secondary acute myeloid leukemia
658597|NCT00077558|adult acute minimally differentiated myeloid leukemia (M0)
658598|NCT00077558|adult acute monocytic leukemia (M5b)
658599|NCT00077558|adult acute erythroid leukemia (M6)
658600|NCT00077558|adult acute megakaryoblastic leukemia (M7)
658601|NCT00077558|adult acute myeloblastic leukemia with maturation (M2)
658602|NCT00077558|adult acute myeloblastic leukemia without maturation (M1)
658603|NCT00077558|adult acute myelomonocytic leukemia (M4)
658604|NCT00077558|adult acute monoblastic leukemia (M5a)
658605|NCT00077558|adult acute promyelocytic leukemia (M3)
658606|NCT00077558|adult acute eosinophilic leukemia
658607|NCT00077558|adult acute basophilic leukemia
658608|NCT00077558|atypical chronic myeloid leukemia
658711|NCT00077116|secondary myelodysplastic syndromes
658609|NCT00077558|myelodysplastic/myeloproliferative disease, unclassifiable
658610|NCT00077558|adult acute myeloid leukemia with t(8;21)(q22;q22)
658611|NCT00077558|adult acute myeloid leukemia with t(16;16)(p13;q22)
658612|NCT00077558|adult acute myeloid leukemia with inv(16)(p13;q22)
658613|NCT00077558|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
658614|NCT00077558|adult acute myeloid leukemia with t(15;17)(q22;q12)
658615|NCT00077532|stage IV melanoma
658616|NCT00077532|recurrent melanoma
658617|NCT00077519|stage II pancreatic cancer
658618|NCT00077519|stage III pancreatic cancer
658619|NCT00077519|recurrent pancreatic cancer
658620|NCT00077493|recurrent childhood acute lymphoblastic leukemia
658621|NCT00077493|Burkitt lymphoma
658622|NCT00077493|recurrent childhood large cell lymphoma
658623|NCT00077493|recurrent childhood lymphoblastic lymphoma
658624|NCT00077493|childhood non-Hodgkin lymphoma
658625|NCT00077415|recurrent non-small cell lung cancer
658626|NCT00077415|stage IIIA non-small cell lung cancer
658627|NCT00077415|stage IIIB non-small cell lung cancer
658628|NCT00077415|stage IV non-small cell lung cancer
658629|NCT00077415|adenocarcinoma of the lung
658630|NCT00077415|bronchoalveolar cell lung cancer
658631|NCT00077415|large cell lung cancer
658632|NCT00077415|squamous cell lung cancer
658633|NCT00077402|recurrent prostate cancer
658634|NCT00077402|stage III prostate cancer
658635|NCT00077402|stage IV prostate cancer
658636|NCT00077402|adenocarcinoma of the prostate
658637|NCT00077389|childhood hepatoblastoma
658638|NCT00077389|stage IV childhood liver cancer
658639|NCT00077337|recurrent colon cancer
658640|NCT00077337|stage III colon cancer
658641|NCT00077337|stage IV colon cancer
658642|NCT00077337|recurrent rectal cancer
658643|NCT00077337|stage III rectal cancer
658644|NCT00077337|stage IV rectal cancer
658645|NCT00077324|stage I non-small cell lung cancer
658646|NCT00077311|drug/agent toxicity by tissue/organ
658647|NCT00077311|anemia
658648|NCT00077311|neutropenia
658649|NCT00077311|stage IV non-small cell lung cancer
658650|NCT00077311|stage IIIB non-small cell lung cancer
658651|NCT00077311|recurrent non-small cell lung cancer
658652|NCT00077311|squamous cell lung cancer
658653|NCT00077311|large cell lung cancer
658654|NCT00077311|adenocarcinoma of the lung
658655|NCT00077311|bronchoalveolar cell lung cancer
658656|NCT00077311|adenosquamous cell lung cancer
658657|NCT00077285|previously untreated childhood rhabdomyosarcoma
658658|NCT00077285|embryonal childhood rhabdomyosarcoma
658659|NCT00077285|alveolar childhood rhabdomyosarcoma
658660|NCT00077285|adult rhabdomyosarcoma
658661|NCT00077285|stage IV adult soft tissue sarcoma
658662|NCT00077285|metastatic childhood soft tissue sarcoma
658663|NCT00077285|nonmetastatic childhood soft tissue sarcoma
658664|NCT00077285|childhood malignant mesenchymoma
658665|NCT00077285|adult malignant mesenchymoma
658666|NCT00077285|stage III adult soft tissue sarcoma
658667|NCT00077285|stage II adult soft tissue sarcoma
658668|NCT00077285|stage I adult soft tissue sarcoma
658669|NCT00077259|recurrent colon cancer
658670|NCT00077259|recurrent rectal cancer
658671|NCT00077259|stage III colon cancer
658672|NCT00077259|stage III rectal cancer
658673|NCT00077259|stage IV colon cancer
658674|NCT00077259|stage IV rectal cancer
658675|NCT00077259|adenocarcinoma of the colon
658676|NCT00077259|adenocarcinoma of the rectum
658677|NCT00077246|stage IV non-small cell lung cancer
658678|NCT00077246|recurrent non-small cell lung cancer
658679|NCT00077233|adenocarcinoma of the colon
658680|NCT00077233|adenocarcinoma of the rectum
658681|NCT00077233|recurrent colon cancer
658682|NCT00077233|recurrent rectal cancer
658683|NCT00077233|stage IV colon cancer
658684|NCT00077233|stage IV rectal cancer
658685|NCT00077220|stage II non-small cell lung cancer
658686|NCT00077220|stage IIIA non-small cell lung cancer
658687|NCT00077220|stage IIIB non-small cell lung cancer
658688|NCT00077207|untreated childhood cerebellar astrocytoma
658689|NCT00077207|untreated childhood visual pathway and hypothalamic glioma
658690|NCT00077207|childhood spinal cord neoplasm
658691|NCT00077207|childhood oligodendroglioma
658692|NCT00077207|childhood low-grade cerebral astrocytoma
658693|NCT00077194|recurrent adult diffuse large cell lymphoma
658694|NCT00077194|recurrent mantle cell lymphoma
658695|NCT00077194|recurrent adult Burkitt lymphoma
658696|NCT00077168|ductal breast carcinoma in situ
658697|NCT00077168|breast cancer in situ
658698|NCT00077142|advanced adult primary liver cancer
658699|NCT00077142|recurrent adult primary liver cancer
658700|NCT00077142|adult primary hepatocellular carcinoma
658701|NCT00077142|localized unresectable adult primary liver cancer
658702|NCT00077142|Oral TAC-101
658703|NCT00077129|stage III renal cell cancer
658704|NCT00077129|stage IV renal cell cancer
658705|NCT00077129|recurrent renal cell cancer
658706|NCT00077116|untreated adult acute myeloid leukemia
658707|NCT00077116|refractory anemia with excess blasts
658708|NCT00077116|refractory anemia with excess blasts in transformation
658709|NCT00077116|chronic myelomonocytic leukemia
658710|NCT00077116|de novo myelodysplastic syndromes
658712|NCT00077116|adult acute myeloid leukemia with t(8;21)(q22;q22)
658713|NCT00077116|adult acute myeloid leukemia with t(16;16)(p13;q22)
658714|NCT00077116|adult acute myeloid leukemia with inv(16)(p13;q22)
658715|NCT00077116|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
658716|NCT00077116|adult acute myeloid leukemia with t(15;17)(q22;q12)
658717|NCT00077116|childhood myelodysplastic syndromes
658718|NCT00077103|anaplastic thyroid cancer
658719|NCT00077090|lymphedema
658720|NCT00077090|radiation fibrosis
658721|NCT00077090|perioperative/postoperative complications
658722|NCT00077090|stage I breast cancer
658723|NCT00077090|stage II breast cancer
658724|NCT00077090|stage IIIA breast cancer
658725|NCT00077077|unspecified adult solid tumor, protocol specific
658726|NCT00077064|radiation fibrosis
658727|NCT00077064|pulmonary complications
658728|NCT00077064|limited stage small cell lung cancer
658729|NCT00077064|stage II non-small cell lung cancer
658730|NCT00077064|stage IIIA non-small cell lung cancer
658731|NCT00077064|stage IIIB non-small cell lung cancer
658732|NCT00077064|stage I non-small cell lung cancer
658733|NCT00077051|stage III squamous cell carcinoma of the lip and oral cavity
658734|NCT00077051|stage III squamous cell carcinoma of the oropharynx
658735|NCT00077051|stage IV squamous cell carcinoma of the lip and oral cavity
658736|NCT00077051|stage IV squamous cell carcinoma of the oropharynx
658737|NCT00077038|Visual Feedback
658738|NCT00077038|Cortical Connectivity
658739|NCT00077038|Magnetoencephalography
658740|NCT00077038|Eye Tracking
658741|NCT00077038|Healthy Volunteer
658742|NCT00077038|HV
658743|NCT00077025|metastatic breast cancer
658744|NCT00077012|BPH
658745|NCT00076986|brain tumor
658746|NCT00076986|recurrent malignant glioma
658747|NCT00076986|brain neoplasm
658748|NCT00076986|central nervous system
658749|NCT00076986|surgery
658750|NCT00076986|resection
658751|NCT00076986|GLIADEL
658752|NCT00076986|infusion
658753|NCT00076986|glioblastoma multiforme
658754|NCT00076986|convection-enhanced delivery
658755|NCT00076986|first recurrence
658756|NCT00076986|recurrent GBM
658757|NCT00076986|GBM
658758|NCT00076986|supratentorial GBM
658759|NCT00076973|RSV Bronchiolitis
658760|NCT00076960|hyperbilirubinemia
658761|NCT00076960|jaundice
658762|NCT00076960|tin-mesoporphyrin
658763|NCT00076960|stannsoporfin
658764|NCT00076960|exchange transfusion
658765|NCT00076960|neonatal hyperbilirubinemia
658766|NCT00076947|HIV Preventive Vaccine
658767|NCT00076947|HIV Seronegativity
658768|NCT00076947|Protein
658769|NCT00076934|Ataxia
658770|NCT00076934|MRI
658771|NCT00076934|MS
658772|NCT00076934|CTLA4-IgG4m
658773|NCT00076934|Costimulatory Signals
658774|NCT00076934|Autoimmune Disorders
658775|NCT00076869|Definite or probable Invasive Aspergillosis either refractory or intolerant to prior antifungal treatment.
658776|NCT00076843|Interleukin-15
658777|NCT00076843|CD8+ T-cells
658778|NCT00076843|HAM/TSP
658779|NCT00076843|HTLV-1
658780|NCT00076843|HTLV-1 Associated Myelopathy
658781|NCT00076843|Tropical Spastic Paraparesis
658782|NCT00076830|Errors of Bone Matrix and Metabolism
658783|NCT00076830|Connective Tissue Disorders
658784|NCT00076817|HIV Preventive Vaccine
658785|NCT00076817|ALVAC Vaccine
658786|NCT00076817|Immunization Site
658787|NCT00076817|Deltoid
658788|NCT00076817|Groin
658789|NCT00076817|Targeted Inguinal Lymph Node
658790|NCT00076817|TILN
658791|NCT00076804|Directly Observed Therapy
658792|NCT00076804|DOT
658793|NCT00076791|HIV Seronegativity
658794|NCT00076752|Refractory SLE
658795|NCT00076752|Immunoablation
658796|NCT00076752|Immunological Recovery
658797|NCT00076752|Efficacy
658798|NCT00076752|Mechanism of Disease
658799|NCT00076752|Lupus
658800|NCT00076752|Systemic Lupus Erythematosus
658801|NCT00076752|SLE
658802|NCT00076739|Prefrontal Cortex
658803|NCT00076739|Semantic Memory
658804|NCT00076739|Semantic Relations
658805|NCT00076739|Priming Paradigm
658806|NCT00076739|fMRI
658807|NCT00076739|Healthy Volunteer
658808|NCT00076739|HV
658809|NCT00076726|Giant Cell Arteritis
658810|NCT00076726|infliximab
658811|NCT00076713|Antiphospholipid
658812|NCT00076700|Cross-Modal Plasticity
658813|NCT00076700|Functional MRI
658814|NCT00076700|Behavior
658815|NCT00076700|Memory
658816|NCT00076700|Blind
658817|NCT00076700|Blindness
658818|NCT00076700|Healthy Volunteer
658819|NCT00076700|HV
658820|NCT00076674|Parkinson's Disease
658821|NCT00076674|Keppra
658822|NCT00076674|Motor Fluctuations
658823|NCT00076674|Intravenous Levodopa
658824|NCT00076674|Antiparkinsonian Response
658825|NCT00076674|Parkinson Disease
658826|NCT00076674|PD
658827|NCT00076635|Idiopathic
658828|NCT00076635|Pulmonary
658829|NCT00076635|Fibrosis
658830|NCT00076635|IPF
658831|NCT00076635|Lung
658832|NCT00076635|Actimmune
658833|NCT00076635|Interferon
658834|NCT00076635|Gamma
658835|NCT00076635|InterMune
658836|NCT00076622|Antidepressant drugs
658837|NCT00076622|Nursing Homes
658838|NCT00076609|hepatocellular carcinoma
658839|NCT00076609|advanced
658840|NCT00076609|unresectable
658841|NCT00076609|liver cancer
658842|NCT00076609|systemic chemotherapy
658843|NCT00076609|botanical
658844|NCT00076609|herbal
658845|NCT00076609|alternative and complementary medicine
658846|NCT00076609|capecitabine
658847|NCT00076609|PHY906
658848|NCT00076609|oral
658849|NCT00076609|HCC
658850|NCT00076609|traditional chinese medicine
658851|NCT00076609|tcm
658852|NCT00076609|QOL
658853|NCT00076609|quality of life
658854|NCT00076596|Corticospinal Tracts
658855|NCT00076596|Spastic Hemiplegia
658856|NCT00076596|Spastic Diplegia
658857|NCT00076596|Cortical Re-Organization
658858|NCT00076596|Functional Outcome
658859|NCT00076596|Cerebral Palsy
658860|NCT00076583|Motor Learning
658861|NCT00076583|Co-contraction
658862|NCT00076583|Reciprocal Inhibition
658863|NCT00076583|Spinal Plasticity
658864|NCT00076583|Rhythmic Movement
658865|NCT00076583|Healthy Volunteer
658866|NCT00076583|HV
658867|NCT00076570|Tolerance
658868|NCT00076570|Kidney
658869|NCT00076570|Transplant
658870|NCT00076570|Polyclonal
658871|NCT00076570|Antibody
658872|NCT00076570|Kidney Transplant
658873|NCT00076557|Hemophilia B
658874|NCT00076557|Factor IX
658875|NCT00076557|Gene Transfer
658876|NCT00076557|Adeno-Associated Virus (AAV)
658877|NCT00076544|Intrathecal
658878|NCT00075426|stage IIIA non-small cell lung cancer
658879|NCT00075426|stage IIIB non-small cell lung cancer
658880|NCT00075426|stage IV non-small cell lung cancer
658881|NCT00075426|recurrent non-small cell lung cancer
658882|NCT00075413|stage IIIB breast cancer
658883|NCT00075413|stage IIIC breast cancer
658884|NCT00075413|stage IV breast cancer
658885|NCT00075413|recurrent breast cancer
658886|NCT00075413|stage IIIA breast cancer
658887|NCT00075374|stage IIIB non-small cell lung cancer
658888|NCT00075374|stage IV non-small cell lung cancer
658889|NCT00075374|recurrent non-small cell lung cancer
658890|NCT00075348|renal cell carcinoma
658891|NCT00075348|von Hippel-Lindau syndrome
658892|NCT00075335|Hematopoietic Stem Cells
658893|NCT00075335|Mobilization
658894|NCT00075335|Alloreactivity
658895|NCT00075335|T Cell Polarization
658896|NCT00075335|Dendritic Cells
658897|NCT00075335|Plerixafor
658898|NCT00075335|Mozobil
658899|NCT00075335|Healthy Volunteer
658900|NCT00075335|HV
658901|NCT00075296|Major Depressive Disorder
658902|NCT00075296|Bipolar Disorder
658903|NCT00075296|Negative Feedback
658904|NCT00075296|Cognitive Performance
658905|NCT00075296|Negative Affect
658906|NCT00075296|Depression
658907|NCT00075296|Major Depression
658908|NCT00075296|MDD
658909|NCT00075296|Healthy Volunteer
658910|NCT00075296|HV
658911|NCT00075283|Physical Therapy
658912|NCT00075283|Locomotion therapy
658913|NCT00075283|Gait training
658914|NCT00075283|Stroke
658915|NCT00075283|Robotics
658916|NCT00075283|Rehabilitation
658917|NCT00075283|Treadmill
658918|NCT00075283|Hemiparetic stroke
658919|NCT00075283|Unilateral brain lesion
658920|NCT00075270|metastatic breast cancer
658921|NCT00075270|ErbB1
658922|NCT00075270|kinase inhibitor
658923|NCT00075270|ErbB2
658924|NCT00075270|EGFR
658925|NCT00075270|lapatinib
658926|NCT00075270|Her2-neu
658927|NCT00075244|Lysosomes
658928|NCT00075244|Storage
658929|NCT00075244|Glycolipid
658930|NCT00075244|Fabry Disease
658931|NCT00075244|Stroke
658932|NCT00076531|Prostate
658933|NCT00076531|Cancer
658934|NCT00076531|PSA
658935|NCT00076531|Leuprolide
658936|NCT00076518|Treatment Experienced
658937|NCT00076505|Mitochondria
658938|NCT00076505|Proteasome
658939|NCT00076505|Lipid
658940|NCT00076505|Polymorphism
658941|NCT00076505|Genetic
658942|NCT00076505|Parkinson's Disease
658943|NCT00076505|Parkinson Disease
658944|NCT00076505|PD
658945|NCT00076505|Heredity
658946|NCT00076505|Parkinson Disease At Risk
658947|NCT00076505|Healthy Volunteer
658948|NCT00076505|HV
658949|NCT00076492|Parkinson's disease
658950|NCT00076492|Parkinson disease
658951|NCT00076492|CoQ10
658952|NCT00076492|GPI 1485
658953|NCT00076479|Aphasia
658954|NCT00076479|Rehabilitation
658955|NCT00076479|Neuroplasticity
658956|NCT00076479|Picture Naming
658957|NCT00076479|Transcranial Magnetic
658958|NCT00076479|Stroke
658959|NCT00076479|Healthy Volunteer
658960|NCT00076479|HV
658961|NCT00076466|Brain Excitability
658962|NCT00076466|Reaction Time
658963|NCT00076466|Plasticity
658964|NCT00076466|Motor Evoked Potential
658965|NCT00076466|Transcranial Magnetic Stimulation
658966|NCT00076466|Healthy Volunteer
658967|NCT00076466|HV
658968|NCT00076453|Knee Pain
658969|NCT00076453|Degenerative Arthritis
658970|NCT00076453|Cartilage Disease
658971|NCT00076453|Non-drug Therapy
658972|NCT00076440|Alzheimer disease
658973|NCT00076427|Immunity
658974|NCT00076427|Liver
658975|NCT00076427|Apheresis
658976|NCT00076427|Cytokine
658977|NCT00076427|Virology
658978|NCT00076427|Hepatitis C
658979|NCT00076427|HCV
658980|NCT00076427|Hepatitis C co-infection
658981|NCT00076414|Endothelial Function
658982|NCT00076414|Lopinavir/Ritonavir
658983|NCT00076414|HIV
658984|NCT00076414|Blood Flow Studies
658985|NCT00076414|Flow-Mediated Vasodilatation
658986|NCT00076414|Healthy Volunteer
658987|NCT00076414|HV
658988|NCT00076401|CLL
658989|NCT00076401|chronic lymphocytic leukemia
658990|NCT00076401|relapsed chronic lymphocytic leukemia
658991|NCT00076401|refractory chronic lymphocytic leukemia
658992|NCT00076401|Leukemia
658993|NCT00076401|Motexafin gadolinium
658994|NCT00076401|Chronic leukemia
658995|NCT00076401|Lymphocytic leukemia, chronic
658996|NCT00076388|Non-Small-Cell Lung Cancer
658997|NCT00076375|Atopic Dermatitis
658998|NCT00076375|Eczema
658999|NCT00076349|Non-Hodgkin's Lymphoma
659000|NCT00076349|NHL
659001|NCT00076349|Rituxan
659002|NCT00076349|Mantle Cell
659003|NCT00076349|mabs
659004|NCT00076323|G6PD
659005|NCT00076323|Favism
659006|NCT00076323|G6PD Deficiency
659007|NCT00076323|hemolysis
659008|NCT00076323|drug reaction
659009|NCT00076323|drug-induced hemolysis
659010|NCT00076310|Head and Neck Cancer
659011|NCT00076310|Squamous Cell Cancer
659012|NCT00076310|OSI-774
659013|NCT00076310|Cisplatin
659014|NCT00076310|Platinol®-AQ
659015|NCT00076310|Platinol®
659016|NCT00076310|CDDP
659017|NCT00076310|Docetaxel
659018|NCT00076310|Taxotere
659019|NCT00076310|Tarceva
659020|NCT00076310|HNSCC
659021|NCT00076310|Erlotinib Hydrochloride
659022|NCT00076284|CCR5 Antagonist
659023|NCT00076284|Coreceptor Inhibitor
659024|NCT00076284|Fusion Inhibitor
659025|NCT00076284|Entry Inhibitor
659026|NCT00076284|Antiretroviral
659027|NCT00076284|HIV
659028|NCT00076271|Strabismus
659029|NCT00076271|Cataract, Pediatric
659030|NCT00076271|Optic Nerve Anomaly
659031|NCT00076271|Coloboma
659032|NCT00076271|Evaluation and Treatment
659033|NCT00076271|Pediatric Ophthalmology
659034|NCT00076271|Genetic Eye Disease
659035|NCT00076271|Nystagmus
659036|NCT00076271|Pediatric Eye Disease
659037|NCT00076271|Developmental Eye Condition
659038|NCT00076271|Cataract
659039|NCT00076271|Juvenile Glaucoma
659040|NCT00076271|Eye Movement Disorder
659041|NCT00076258|Exercise therapy
659042|NCT00076258|Complementary Therapies
659043|NCT00076245|Phototherapy
659044|NCT00076232|HIV Seronegativity
659045|NCT00076219|Acute Renal Failure
659046|NCT00076219|Renal Replacement Therapy
659047|NCT00076219|multi-site randomization trial
659048|NCT00076219|Hemodialysis
659049|NCT00076219|Hemofiltration
659050|NCT00076219|Critical Illness
659051|NCT00076219|Hemodiafiltration
659052|NCT00076180|cytotoxic activity against T-LGL cells
659053|NCT00076180|chronic lymphoproliferative disorder
659054|NCT00076180|T-LGL Leukemia
659055|NCT00076180|Natural Killer Cells
659056|NCT00076180|Leukemia
659057|NCT00076180|Lymphocytic Leukemia
659058|NCT00076180|T-LGL
659059|NCT00076154|ALS
659060|NCT00076141|relatively healthy male
659061|NCT00076115|Bipolar
659062|NCT00076115|Mania
659063|NCT00076115|Manic
659064|NCT00076115|Depressive
659065|NCT00076115|Manic Depressive
659066|NCT00076115|Bipolar mania
659067|NCT00076115|risperidone
659068|NCT00076115|adolescents
659069|NCT00076115|children
659070|NCT00076102|Side Effect
659071|NCT00076102|Oral Administration
659072|NCT00076102|Nerve Sheath Tumor
659073|NCT00076102|Antifibrotic Agent
659074|NCT00076102|Volumetric Tumor Measurement
659075|NCT00076102|Plexiform Neurofibroma
659076|NCT00076102|Neurofibromatosis Type 1
659077|NCT00076102|Volumetric MRI Analysis
659078|NCT00076102|Time to Progression
659079|NCT00076102|NF1
659080|NCT00076089|Roflumilast
659081|NCT00076089|Chronic obstructive pulmonary disease
659082|NCT00076089|COPD
659083|NCT00076076|Roflumilast
659084|NCT00076076|Asthma
659085|NCT00076063|HIV Seronegativity
659086|NCT00076063|ALVAC-HIV vCP1452
659087|NCT00076063|ALVAC Vaccine
659088|NCT00076063|HIV-1
659089|NCT00076063|Normal Values
659090|NCT00076063|HIV Preventive Vaccine
659091|NCT00076037|HIV Preventive Vaccine
659092|NCT00076037|Granulocyte-Macrophage Colony-Stimulating Factor
659093|NCT00076037|AIDS Vaccines
659094|NCT00076037|HIV-1
659095|NCT00076037|HIV Seronegativity
659096|NCT00076037|Injections, Intramuscular
659097|NCT00076037|RC529
659098|NCT00076037|Epitopes
659099|NCT00076037|T-Lymphocytes, Cytotoxic
659100|NCT00076024|metastatic breast cancer
659101|NCT00075998|Idiopathic
659102|NCT00075998|Pulmonary
659103|NCT00075998|Fibrosis
659104|NCT00075998|IPF
659105|NCT00075998|Lung
659106|NCT00075998|Interferon
659107|NCT00075998|Gamma
659108|NCT00075998|Actimmune
659109|NCT00075998|INSPIRE
659110|NCT00075998|InterMune
659111|NCT00075959|Stroke
659112|NCT00075959|cerebral vascular accident
659113|NCT00075959|CVA
659114|NCT00075959|Hemorrhage
659115|NCT00075959|Intracerebral Hemorrhage (ICH)
659116|NCT00075959|Brain Attack
659117|NCT00075959|Cataplexy
659118|NCT00075946|stage III grade 1 follicular lymphoma
659119|NCT00075946|stage III grade 2 follicular lymphoma
659120|NCT00075946|stage IV grade 1 follicular lymphoma
659121|NCT00075946|stage IV grade 2 follicular lymphoma
659122|NCT00075946|stage III small lymphocytic lymphoma
659123|NCT00075946|stage III marginal zone lymphoma
659124|NCT00075946|stage IV small lymphocytic lymphoma
659125|NCT00075946|stage IV marginal zone lymphoma
659126|NCT00075946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
659127|NCT00075946|nodal marginal zone B-cell lymphoma
659128|NCT00075946|splenic marginal zone lymphoma
659129|NCT00075920|Heart
659130|NCT00075920|Function
659131|NCT00075920|Ultrasound
659132|NCT00075920|MRI
659133|NCT00075920|Left Ventricle
659134|NCT00075920|Healthy Volunteer
659135|NCT00075920|HV
659136|NCT00075920|Heart Disease
659137|NCT00075907|Acute Infection
659138|NCT00075907|Treatment Experienced
659139|NCT00075907|Treatment Naive
659140|NCT00075894|adult anaplastic oligodendroglioma
659141|NCT00075894|adult anaplastic astrocytoma
659142|NCT00075894|adult glioblastoma
659143|NCT00075894|recurrent adult brain tumor
659144|NCT00075894|adult giant cell glioblastoma
659145|NCT00075894|adult gliosarcoma
659146|NCT00075868|radiation enteritis
659147|NCT00075868|drug/agent toxicity by tissue/organ
659148|NCT00075868|stage I rectal cancer
659149|NCT00075868|stage II rectal cancer
659150|NCT00075868|stage III rectal cancer
659151|NCT00075868|stage IIIA anal cancer
659152|NCT00075868|stage IIIB anal cancer
659153|NCT00075868|recurrent anal cancer
659154|NCT00075868|stage I anal cancer
659155|NCT00075868|stage II anal cancer
659156|NCT00075868|recurrent rectal cancer
659157|NCT00075855|sexual dysfunction
659158|NCT00075855|unspecified adult solid tumor, protocol specific
659159|NCT00075855|sexuality and reproductive issues
659160|NCT00075855|cancer survivor
659161|NCT00075842|sleep disorders
659162|NCT00075842|unspecified adult solid tumor, protocol specific
659163|NCT00075842|fatigue
659164|NCT00075829|Stage II Multiple Myeloma
659165|NCT00075829|Stage III Multiple Myeloma
659166|NCT00075829|Refractory Plasma Cell Neoplasm
659167|NCT00075803|Myelodysplastic and Myeloproliferative Diseases
659168|NCT00075777|recurrent Kaposi sarcoma
659169|NCT00075777|AIDS-related Kaposi sarcoma
659170|NCT00075764|stage IV breast cancer
659171|NCT00075764|recurrent breast cancer
659172|NCT00075738|stage IV esophageal cancer
659173|NCT00075738|recurrent esophageal cancer
659174|NCT00075725|untreated childhood acute lymphoblastic leukemia
659175|NCT00075725|B-cell childhood acute lymphoblastic leukemia
659176|NCT00075725|untreated adult acute lymphoblastic leukemia
659177|NCT00075725|B-cell adult acute lymphoblastic leukemia
659178|NCT00075712|stage IV ovarian epithelial cancer
659179|NCT00075712|stage IIIA fallopian tube cancer
659180|NCT00075712|stage IIIB fallopian tube cancer
659181|NCT00075712|stage IIIC fallopian tube cancer
659182|NCT00075712|stage IV fallopian tube cancer
659183|NCT00075712|stage IIIA primary peritoneal cavity cancer
659184|NCT00075712|stage IIIB primary peritoneal cavity cancer
659185|NCT00075712|stage IIIC primary peritoneal cavity cancer
659186|NCT00075712|stage IV primary peritoneal cavity cancer
659187|NCT00075712|stage IIIA ovarian epithelial cancer
659188|NCT00075712|stage IIIB ovarian epithelial cancer
659189|NCT00075712|stage IIIC ovarian epithelial cancer
659190|NCT00075699|epithelial mesothelioma
659191|NCT00075699|localized malignant mesothelioma
659192|NCT00075699|advanced malignant mesothelioma
659193|NCT00075686|adenocarcinoma of the pancreas
659194|NCT00075686|stage III pancreatic cancer
659195|NCT00075686|stage IV pancreatic cancer
659196|NCT00075673|recurrent breast cancer
659197|NCT00075673|stage IV breast cancer
659198|NCT00075660|recurrent renal cell cancer
659199|NCT00075660|stage III renal cell cancer
659200|NCT00075660|stage IV renal cell cancer
659201|NCT00075621|primary systemic amyloidosis
659202|NCT00075608|primary systemic amyloidosis
659203|NCT00075595|stage IV colon cancer
659204|NCT00075595|stage IV rectal cancer
659205|NCT00075595|recurrent colon cancer
659206|NCT00075595|recurrent rectal cancer
659207|NCT00075595|adenocarcinoma of the colon
659208|NCT00075595|adenocarcinoma of the rectum
659209|NCT00075569|cervical cancer
659210|NCT00075569|cervical intraepithelial neoplasia grade 3
659211|NCT00075556|stage III colon cancer
659212|NCT00075556|stage IV colon cancer
659213|NCT00075556|stage III rectal cancer
659214|NCT00075556|stage IV rectal cancer
659215|NCT00075556|adenocarcinoma of the rectum
659216|NCT00075556|adenocarcinoma of the colon
659217|NCT00075543|recurrent ovarian epithelial cancer
659218|NCT00075543|stage III ovarian epithelial cancer
659219|NCT00075543|stage IV ovarian epithelial cancer
659220|NCT00075517|stage IIIB non-small cell lung cancer
659221|NCT00075517|stage IV non-small cell lung cancer
659222|NCT00075517|adenocarcinoma of the lung
659223|NCT00075517|large cell lung cancer
659224|NCT00075517|squamous cell lung cancer
659225|NCT00075465|adenocarcinoma of the stomach
659226|NCT00075465|stage III gastric cancer
659227|NCT00075465|stage IV gastric cancer
659228|NCT00075452|adenocarcinoma of the pancreas
659229|NCT00075452|stage II pancreatic cancer
659230|NCT00075452|stage III pancreatic cancer
659231|NCT00075452|stage IV pancreatic cancer
659232|NCT00075231|Treatment Naive
659233|NCT00075205|Alcohol Consumption
659234|NCT00075205|Alcohol Treatment
659235|NCT00075205|Medication Trial
659236|NCT00075205|Craving
659237|NCT00075205|Cannabinoids
659238|NCT00075205|CB 1 Receptor Antagonist
659239|NCT00075205|SR141716
659240|NCT00075205|Alcoholism
659241|NCT00075179|Pulmonary hypertension
659242|NCT00075179|cancer
659243|NCT00075179|lung cancer
659244|NCT00075179|lung disease
659245|NCT00075179|cardiothoracic surgery
659246|NCT00075179|Nesiritide
659247|NCT00075179|Natrecor
659248|NCT00075179|CV Surgery
659249|NCT00075179|Lung Tumor
659250|NCT00075166|Stereotactic
659251|NCT00075166|Carcinoma
659252|NCT00075166|Melanoma
659253|NCT00075166|Surgical Resection
659254|NCT00075166|Metastases
659255|NCT00075166|Metastatic Brain Tumor
659256|NCT00075166|Surgery
659257|NCT00075166|Radiosurgery
659258|NCT00075166|Treatment
659259|NCT00075153|ADOLESCENCE
659260|NCT00075153|HIV INFECTION
659261|NCT00075153|PEDIATRIC AIDS
659262|NCT00075153|QUALITY OF LIFE
659263|NCT00075153|HIV
659264|NCT00075140|Patient Care Management
659265|NCT00075140|Family
659266|NCT00075140|Huntington's Disease
659267|NCT00075114|Self Care
659268|NCT00075114|Behavior Modification
659269|NCT00075101|Drug Adverse Effect
659270|NCT00075101|Pediatric Cancer
659271|NCT00075088|Telemedicine
659272|NCT00075088|Emergency Care
659273|NCT00075088|Cardiac
659274|NCT00075075|Infliximab
659275|NCT00075075|Scleritis
659276|NCT00075075|Intraocular Inflammatory Disease
659277|NCT00075075|Corticosteroids
659278|NCT00075075|Immunosuppressives
659279|NCT00075049|malaria
659280|NCT00075036|Health Disparities
659281|NCT00075036|Transplantation
659282|NCT00075036|Trust
659283|NCT00075036|Interview
659284|NCT00075036|Ethnic Bias
659285|NCT00075023|Stomatitis
659286|NCT00075023|Oropharyngeal pain
659287|NCT00075023|TNF-alpha
659288|NCT00075023|Allogeneic hematopoietic stem cell transplant
659289|NCT00075023|Inflammation
659290|NCT00075023|Thalidomide
659291|NCT00075023|Oral chronic graft-versus-host disease
659292|NCT00075010|Relapsed/Refractory Leukemia
659293|NCT00075010|Myelodysplastic Syndromes
659294|NCT00074997|Gene Therapy
659295|NCT00074997|Anti-HIV-1 Ribozyme
659296|NCT00074997|OZ1
659297|NCT00074997|HIV-1 Infections
659298|NCT00074984|a-Galactosidase A
659299|NCT00074984|aGAL
659300|NCT00074984|r-haGAL
659301|NCT00074984|Fabry
659302|NCT00074984|GL-3
659303|NCT00074984|Fabrazyme
659304|NCT00074971|a-Galactosidase A
659305|NCT00074971|aGAL
659306|NCT00074971|r-haGAL
659307|NCT00074971|Fabry
659308|NCT00074971|GL-3
659309|NCT00074971|Fabrazyme
659310|NCT00074958|a-Galactosidase A
659311|NCT00074958|aGal
659312|NCT00074958|r-haGAL
659313|NCT00074958|Fabry
659314|NCT00074958|GL-3
659315|NCT00074958|Fabrazyme
659316|NCT00074945|Obesity
659317|NCT00074945|Resting Energy Expenditure
659318|NCT00074945|Metabolic Rate
659319|NCT00074945|Visceral Fat
659320|NCT00074945|Body Fat Distribution
659321|NCT00074932|Glycogen Storage Disease Type II
659322|NCT00074932|GSD-II
659323|NCT00074932|Pompe Disease
659324|NCT00074932|Acid Maltase Deficiency Disease
659325|NCT00074919|Glycogen Storage Disease Type II
659326|NCT00074919|GSD-II
659327|NCT00074919|Pompe Disease
659328|NCT00074919|Acid Maltase Deficiency Disease
659329|NCT00074906|Aspiration of gastric contents
659330|NCT00074893|Repetitive Strain Injuries
659331|NCT00074893|Vibration Damping
659332|NCT00074893|Protective Brace
659333|NCT00074893|Piezoelectric
659334|NCT00074893|SmartWear
659335|NCT00074880|Cardiac Hypertrophy
659336|NCT00074880|Diastolic Dysfunction
659337|NCT00074880|Cardiac Glycosides
659338|NCT00074880|Cardiac Fibrosis
659339|NCT00074880|Atrial Systole
659340|NCT00074841|MALARIA
659341|NCT00074841|INDIA
659342|NCT00074841|CHLOROQUINE
659343|NCT00074841|PLASMODIUM FALCIPARUM
659344|NCT00074841|SULFADOXINE-PYRIMETHAMINE
659345|NCT00074828|elective
659346|NCT00074828|primary unilateral
659347|NCT00074815|Child
659348|NCT00074815|Adolescent
659349|NCT00074802|Social Phobia
659350|NCT00074789|Early Head Start Program
659351|NCT00074776|Bipolar Depression
659352|NCT00074763|Leukemia
659353|NCT00074763|Lymphoma
659354|NCT00074763|ALL
659355|NCT00074763|CLL
659356|NCT00074763|AML
659357|NCT00074763|CML
659358|NCT00074763|MDS
659359|NCT00074763|Remission
659360|NCT00074763|Hematologic Disorder
659361|NCT00074763|Transfusion
659362|NCT00074763|Thrombosol
659363|NCT00074763|Autologous Platelet Transfusion
659364|NCT00074763|Platelet Transfusion
659365|NCT00074763|Single donor platelet apheresis
659366|NCT00074763|Cryopreservation
659367|NCT00074763|Thrombocytopenia
659368|NCT00074750|AML
659369|NCT00074750|CMML
659370|NCT00074737|Refractory or Relapsed Acute Myelogenous Leukemia (AML)
659371|NCT00074737|Antisense
659372|NCT00074711|Bone Mineral Density
659373|NCT00074711|Calcium
659374|NCT00074698|Idiopathic pulmonary fibrosis
659375|NCT00074698|IPF
659376|NCT00074698|Pulmonary fibrosis
659377|NCT00074698|Respiratory disease
659378|NCT00074685|Congenital
659379|NCT00074685|Epidermal nevus
659380|NCT00074685|Erythroderma
659381|NCT00074685|Darier
659382|NCT00074685|Hailey-Hailey
659383|NCT00074685|Harlequin
659384|NCT00074685|Ichthyosiform
659385|NCT00074685|Ichthyosiform erythroderma
659386|NCT00074685|Keratoderma
659387|NCT00074685|Keratosis
659388|NCT00074685|Pachyonychia
659389|NCT00074685|Sjogren-Larsson
659390|NCT00074672|Prepulse Inhibition
659391|NCT00074672|PPI
659392|NCT00074672|Dopamine
659393|NCT00074672|Sensorimotor Integration
659394|NCT00074672|Dopaminergic
659395|NCT00074646|CC-8490
659396|NCT00074646|CC8490
659397|NCT00074646|Glio
659398|NCT00074646|Glioblastoma
659399|NCT00074646|Malignant Gliomas
659400|NCT00074633|Type 2 Diabetes
659401|NCT00074633|Self-Esteem
659402|NCT00074620|Haemodialysis
659403|NCT00074620|PEG-Hirudin
659404|NCT00074620|Vascular graft occlusion
659405|NCT00074620|Renal replacement therapy
659406|NCT00074620|Hemodialysis
659407|NCT00074607|Neoplastic meningitis
659408|NCT00074581|HIV Infections
659409|NCT00074581|HIV Seronegativity
659410|NCT00074568|Genetic Study
659411|NCT00074568|Transmission Dysequilibrium Testing
659412|NCT00074568|Genome Wide Scan
659413|NCT00074568|Family Study
659414|NCT00074555|African American, Rheumatoid Arthritis
659415|NCT00074542|Crohn's
659416|NCT00074542|colon
659417|NCT00074542|small bowel
659418|NCT00074542|inflammation
659419|NCT00074542|steroid therapy
659420|NCT00074542|free fatty acids
659421|NCT00074516|Immunosuppression
659422|NCT00074516|Kidney
659423|NCT00074516|Cysteamine
659424|NCT00074516|Steroid-Free
659425|NCT00074516|Outcomes
659426|NCT00074503|Positron Emission Tomography
659427|NCT00074503|Phospholipids
659428|NCT00074503|Alcoholism
659429|NCT00074503|[11C]Docosahexaenoate
659430|NCT00074503|[150]Water
659431|NCT00074503|Brain
659432|NCT00074503|Fatty Acids
659433|NCT00074503|Blood Flow
659434|NCT00074503|Healthy
659435|NCT00074490|Leukemia
659436|NCT00074490|Lymphoma
659437|NCT00074490|Multiple Myeloma
659438|NCT00074490|Bone Marrow Transplantation
659439|NCT00074490|Immune Therapy
659440|NCT00074477|Schizophrenia
659441|NCT00074477|Paliperidone palmitate
659442|NCT00074477|R092670
659443|NCT00074477|antipsychotic
659444|NCT00074438|Rituxan
659445|NCT00074438|RA
659446|NCT00074425|HIV Seronegativity
659447|NCT00074425|Anti-Infective Agents, Local
659448|NCT00074425|BufferGel
659449|NCT00074425|PRO 2000
659450|NCT00074425|Vagina
659451|NCT00074425|Risk Factors
659452|NCT00074412|HIV Seronegativity
659453|NCT00074412|Treatment Experienced
659454|NCT00074412|Treatment Naive
659455|NCT00074399|Maternal/Infant Transmisson
659456|NCT00074399|Vertical Transmission
659457|NCT00074399|Pregnancy
659458|NCT00074399|HIV Seronegativity
659459|NCT00074386|HIV
659460|NCT00074386|Transplant
659461|NCT00074386|Liver
659462|NCT00074386|Kidney
659463|NCT00074386|Organ
659464|NCT00074386|Treatment Experienced
659465|NCT00074386|Kidney Transplant
659466|NCT00074386|Liver Transplant
659467|NCT00074373|Anti-SSA/Ro Antibodies
659468|NCT00074373|Anti-SSB/La Antibodies
659469|NCT00074360|Ethanol
659470|NCT00074360|fMRI
659471|NCT00074360|Blood Flow
659472|NCT00074360|Conditioning
659473|NCT00074360|Reinforcement
659474|NCT00074334|childhood high-grade cerebral astrocytoma
659475|NCT00074334|recurrent childhood cerebral astrocytoma
659476|NCT00074334|childhood oligodendroglioma
659477|NCT00074334|childhood supratentorial ependymoma
659478|NCT00074334|recurrent childhood ependymoma
659479|NCT00074334|recurrent childhood brain tumor
659480|NCT00074295|bronchoalveolar cell lung cancer
659481|NCT00074295|stage IIIB non-small cell lung cancer
659482|NCT00074295|stage IV non-small cell lung cancer
659483|NCT00074295|recurrent non-small cell lung cancer
659484|NCT00074282|refractory chronic lymphocytic leukemia
659485|NCT00074282|B-cell chronic lymphocytic leukemia
659486|NCT00074269|recurrent breast cancer
659487|NCT00074269|stage IV breast cancer
659488|NCT00074243|adult anaplastic astrocytoma
659489|NCT00074243|adult anaplastic oligodendroglioma
659490|NCT00074243|adult glioblastoma
659491|NCT00074243|adult mixed glioma
659492|NCT00074243|adult brain stem glioma
659493|NCT00074243|recurrent adult brain tumor
659494|NCT00074243|adult giant cell glioblastoma
659495|NCT00074243|adult gliosarcoma
659496|NCT00074230|stage IV melanoma
659497|NCT00074230|recurrent melanoma
659498|NCT00074204|stage IIIB non-small cell lung cancer
659499|NCT00074204|stage IV non-small cell lung cancer
659500|NCT00074204|recurrent non-small cell lung cancer
659501|NCT00074191|intraocular lymphoma
659502|NCT00074191|primary central nervous system lymphoma
659503|NCT00074178|primary central nervous system lymphoma
659504|NCT00074178|intraocular lymphoma
659505|NCT00074165|drug/agent toxicity by tissue/organ
659506|NCT00074165|thrombocytopenia
659507|NCT00074165|intraocular lymphoma
659508|NCT00074165|primary central nervous system non-Hodgkin lymphoma
659509|NCT00074165|primary central nervous system Hodgkin lymphoma
659510|NCT00074152|recurrent breast cancer
659511|NCT00074152|stage I breast cancer
659512|NCT00074152|stage II breast cancer
659513|NCT00074152|stage IIIA breast cancer
659514|NCT00074152|stage IIIB breast cancer
659515|NCT00074152|stage IIIC breast cancer
659516|NCT00074139|stage IIIA breast cancer
659517|NCT00074139|recurrent breast cancer
659518|NCT00074139|stage IIIB breast cancer
659519|NCT00074139|stage IIIC breast cancer
659520|NCT00074139|stage IV breast cancer
659521|NCT00074100|stage IV breast cancer
659522|NCT00074100|recurrent breast cancer
659523|NCT00074087|stage II mycosis fungoides/Sezary syndrome
659524|NCT00074087|stage IV mycosis fungoides/Sezary syndrome
659525|NCT00074087|recurrent mycosis fungoides/Sezary syndrome
659526|NCT00074087|stage IV cutaneous T-cell non-Hodgkin lymphoma
659527|NCT00074087|stage II cutaneous T-cell non-Hodgkin lymphoma
659528|NCT00074087|recurrent cutaneous T-cell non-Hodgkin lymphoma
659529|NCT00074074|refractory anemia with excess blasts
659530|NCT00074074|refractory anemia with ringed sideroblasts
659531|NCT00074074|refractory anemia
659532|NCT00074074|de novo myelodysplastic syndromes
659533|NCT00074074|secondary myelodysplastic syndromes
659534|NCT00074074|previously treated myelodysplastic syndromes
659535|NCT00074048|refractory hairy cell leukemia
659536|NCT00074009|recurrent gastric cancer
659537|NCT00074009|stage III gastric cancer
659538|NCT00074009|stage IV gastric cancer
659539|NCT00074009|adenocarcinoma of the stomach
659540|NCT00073983|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
659541|NCT00073983|chondrosarcoma
659542|NCT00073983|recurrent osteosarcoma
659543|NCT00073970|recurrent prostate cancer
659544|NCT00073970|stage I prostate cancer
659545|NCT00073970|stage II prostate cancer
659546|NCT00073970|adenocarcinoma of the prostate
659547|NCT00073957|recurrent adult diffuse large cell lymphoma
659548|NCT00073957|recurrent adult immunoblastic large cell lymphoma
659549|NCT00073957|anaplastic large cell lymphoma
659550|NCT00073944|acute undifferentiated leukemia
659551|NCT00073944|anaplastic large cell lymphoma
659552|NCT00073944|angioimmunoblastic T-cell lymphoma
659553|NCT00073944|atypical chronic myeloid leukemia, BCR-ABL1 negative
659554|NCT00073944|chronic eosinophilic leukemia
659555|NCT00073944|primary myelofibrosis
659556|NCT00073944|chronic myelomonocytic leukemia
659557|NCT00073944|chronic neutrophilic leukemia
659657|NCT00073840|levalbuterol
659558|NCT00073944|essential thrombocythemia
659559|NCT00073944|intraocular lymphoma
659560|NCT00073944|myelodysplastic/myeloproliferative neoplasm, unclassifiable
659561|NCT00073944|polycythemia vera
659562|NCT00073944|previously treated myelodysplastic syndromes
659563|NCT00073944|primary central nervous system non-Hodgkin lymphoma
659564|NCT00073944|prolymphocytic leukemia
659565|NCT00073944|recurrent adult acute lymphoblastic leukemia
659566|NCT00073944|recurrent adult acute myeloid leukemia
659567|NCT00073944|recurrent adult T-cell leukemia/lymphoma
659568|NCT00073944|recurrent adult diffuse large cell lymphoma
659569|NCT00073944|recurrent adult diffuse mixed cell lymphoma
659570|NCT00073944|recurrent adult diffuse small cleaved cell lymphoma
659571|NCT00073944|recurrent adult Burkitt lymphoma
659572|NCT00073944|recurrent adult Hodgkin lymphoma
659573|NCT00073944|recurrent adult immunoblastic large cell lymphoma
659574|NCT00073944|recurrent adult lymphoblastic lymphoma
659575|NCT00073944|recurrent grade 1 follicular lymphoma
659576|NCT00073944|recurrent grade 2 follicular lymphoma
659577|NCT00073944|recurrent grade 3 follicular lymphoma
659578|NCT00073944|recurrent mantle cell lymphoma
659579|NCT00073944|recurrent mycosis fungoides/Sezary syndrome
659580|NCT00073944|refractory chronic lymphocytic leukemia
659581|NCT00073944|refractory hairy cell leukemia
659582|NCT00073944|refractory multiple myeloma
659583|NCT00073944|relapsing chronic myelogenous leukemia
659584|NCT00073944|secondary acute myeloid leukemia
659585|NCT00073944|secondary myelodysplastic syndromes
659586|NCT00073944|Waldenström macroglobulinemia
659587|NCT00073944|adenocarcinoma of the colon
659588|NCT00073944|adenocarcinoma of the esophagus
659589|NCT00073944|adenocarcinoma of the pancreas
659590|NCT00073944|adenocarcinoma of the rectum
659591|NCT00073944|recurrent adult brain tumor
659592|NCT00073944|recurrent adult primary liver cancer
659593|NCT00073944|recurrent colon cancer
659594|NCT00073944|recurrent esophageal cancer
659595|NCT00073944|recurrent gastric cancer
659596|NCT00073944|recurrent melanoma
659597|NCT00073944|recurrent ovarian epithelial cancer
659598|NCT00073944|recurrent pancreatic cancer
659599|NCT00073944|recurrent rectal cancer
659600|NCT00073944|adenocarcinoma of the stomach
659601|NCT00073944|adult anaplastic astrocytoma
659602|NCT00073944|adult glioblastoma
659603|NCT00073944|adult pilocytic astrocytoma
659604|NCT00073944|adult subependymoma
659605|NCT00073944|adenocarcinoma of the extrahepatic bile duct
659606|NCT00073944|recurrent extrahepatic bile duct cancer
659607|NCT00073944|recurrent cutaneous T-cell non-Hodgkin lymphoma
659608|NCT00073944|de novo myelodysplastic syndromes
659609|NCT00073944|recurrent marginal zone lymphoma
659610|NCT00073944|recurrent small lymphocytic lymphoma
659611|NCT00073944|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
659612|NCT00073944|nodal marginal zone B-cell lymphoma
659613|NCT00073944|splenic marginal zone lymphoma
659614|NCT00073944|adult acute myeloid leukemia with t(8;21)(q22;q22)
659615|NCT00073944|adult acute myeloid leukemia with t(16;16)(p13;q22)
659616|NCT00073944|adult acute myeloid leukemia with inv(16)(p13;q22)
659617|NCT00073944|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
659618|NCT00073944|adult acute myeloid leukemia with t(15;17)(q22;q12)
659619|NCT00073944|adult diffuse astrocytoma
659620|NCT00073944|adult giant cell glioblastoma
659621|NCT00073944|adult gliosarcoma
659622|NCT00073944|T-cell large granular lymphocyte leukemia
659623|NCT00073931|recurrent adult diffuse large cell lymphoma
659624|NCT00073931|recurrent adult diffuse mixed cell lymphoma
659625|NCT00073931|recurrent adult diffuse small cleaved cell lymphoma
659626|NCT00073931|recurrent adult Burkitt lymphoma
659627|NCT00073931|recurrent adult immunoblastic large cell lymphoma
659628|NCT00073931|recurrent adult lymphoblastic lymphoma
659629|NCT00073931|recurrent grade 1 follicular lymphoma
659630|NCT00073931|recurrent grade 2 follicular lymphoma
659631|NCT00073931|recurrent grade 3 follicular lymphoma
659632|NCT00073931|recurrent mantle cell lymphoma
659633|NCT00073905|unresectable gallbladder cancer
659634|NCT00073905|adenocarcinoma of the gallbladder
659635|NCT00073905|adenocarcinoma of the extrahepatic bile duct
659636|NCT00073905|unresectable extrahepatic bile duct cancer
659637|NCT00073905|pain
659638|NCT00073905|recurrent gallbladder cancer
659639|NCT00073905|recurrent extrahepatic bile duct cancer
659640|NCT00073905|localized unresectable adult primary liver cancer
659641|NCT00073905|advanced adult primary liver cancer
659642|NCT00073905|recurrent adult primary liver cancer
659643|NCT00073892|unspecified adult solid tumor, protocol specific
659644|NCT00073892|stage IV melanoma
659645|NCT00073892|recurrent melanoma
659646|NCT00073879|stage IV renal cell cancer
659647|NCT00073879|recurrent renal cell cancer
659648|NCT00073866|recurrent non-small cell lung cancer
659649|NCT00073866|stage IIIB non-small cell lung cancer
659650|NCT00073866|stage IV non-small cell lung cancer
659651|NCT00073853|paraplegia
659652|NCT00073853|quadraplegia
659653|NCT00073853|tetraplegia
659654|NCT00073853|paralysis
659655|NCT00073853|nerve regeneration
659656|NCT00073853|Acute, Complete SCI
659658|NCT00073840|asthma
659659|NCT00073840|bronchoconstriction
659660|NCT00073840|adolescent
659661|NCT00073840|adult
659662|NCT00073827|adolescent
659663|NCT00073827|adult
659664|NCT00073827|asthma
659665|NCT00073827|levalbuterol
659666|NCT00073827|bronchoconstriction
659667|NCT00073814|levalbuterol
659668|NCT00073814|pediatric
659669|NCT00073814|asthma
659670|NCT00073801|Neuromusculoskeletal Pain
659671|NCT00073801|Laparoscopy
659672|NCT00073801|Cytokines
659673|NCT00073801|HPA Axis
659674|NCT00073801|Neuroimmune
659675|NCT00073801|Endometriosis
659676|NCT00073801|Surgical Excision
659677|NCT00073801|Inflammatory Cytokines
659678|NCT00073749|B-Cell
659679|NCT00073749|Non-Hodgkin's
659680|NCT00073749|Lymphoma
659681|NCT00073736|Hepatocellular
659682|NCT00073736|Carcinoma
659683|NCT00073736|Liver
659684|NCT00073736|Cancer
659685|NCT00073723|Non-Small Cell Lung Cancer
659686|NCT00073723|Taxol
659687|NCT00073723|Advanced Non-Small Cell Lung Cancer
659688|NCT00073710|secondary hyperparathyroidism
659689|NCT00073697|Psychotherapy
659690|NCT00073697|Depressive disorder
659691|NCT00073697|Antidepressive agents
659692|NCT00073697|Citalopram
659693|NCT00073684|Stress Disorders, Post-Traumatic
659694|NCT00073684|Depression
659695|NCT00073684|Anxiety
659696|NCT00073671|Adolescent
659697|NCT00073658|Alzheimer disease
659698|NCT00073658|Aggression
659699|NCT00073658|Delusions
659700|NCT00073658|Paranoid behavior
659701|NCT00073619|Violence
659702|NCT00073619|School based
659703|NCT00073619|Urban Youth
659704|NCT00073619|Prevention
659705|NCT00073619|Community
659706|NCT00073606|Spinal Reflexes
659707|NCT00073606|Locomotion
659708|NCT00073606|Motor Practice
659709|NCT00073606|Healthy Volunteer
659710|NCT00073606|HV
659711|NCT00073593|Off-Pump Coronary Artery Bypass Graft Surgery
659712|NCT00073593|CABG
659713|NCT00073593|OPCAB
659714|NCT00073593|Heparin
659715|NCT00073593|Patients requiring off-pump CABG
659716|NCT00073580|HIT
659717|NCT00073580|HITTS
659718|NCT00073580|Heparin-antibodies
659719|NCT00073580|Coronary artery bypass surgery
659720|NCT00073580|CABG
659721|NCT00073580|Heparin-induced thrombocytopenia
659722|NCT00073580|Heparin-induced thrombocytopenia and thrombosis syndrome
659723|NCT00073541|EGFR; HER-1; monoclonal antibody; targeted therapy
659724|NCT00073528|metastatic
659725|NCT00073528|advanced breast cancer
659726|NCT00073528|breast cancer
659727|NCT00073515|central venous access device
659728|NCT00073515|thrombosis
659729|NCT00073515|central venous catheter
659730|NCT00073515|thrombolysis
659731|NCT00073515|fibrinolysis
659732|NCT00073489|chronic leukemia
659733|NCT00073489|leukemia
659734|NCT00073489|CLL
659735|NCT00073463|Gene Transfer
659736|NCT00073463|Pulmonary function
659737|NCT00073450|Squamous Cell Carcinoma of the Head & Neck
659738|NCT00073437|Sarcoidosis
659739|NCT00073437|Infliximab
659740|NCT00073437|Pulmonary involvement
659741|NCT00073437|Remicade
659742|NCT00073424|Treatment Experienced
659743|NCT00073398|Anti-tumor Vaccination
659744|NCT00073398|Alpha (1,3) Galactosyltransferase
659745|NCT00073398|Allogeneic Tumor Cells
659746|NCT00073398|Hyperacute Lung
659747|NCT00073398|NSCLC
659748|NCT00073398|Lung Cancer
659749|NCT00073398|Non-Small Cell Lung Cancer
659750|NCT00073385|Lung cancer, Docetaxel, Histone deacetylase inhibitor
659751|NCT00073372|Acute ischemic stroke
659752|NCT00073372|abciximab
659753|NCT00073372|ReoPro
659754|NCT00073372|drug safety
659755|NCT00073372|drug efficacy
659756|NCT00073372|intracranial hemorrhage
659757|NCT00073372|stroke
659758|NCT00073359|Adolescent
659759|NCT00073346|Compulsive Hoarding
659760|NCT00073333|Phobic Disorders
659761|NCT00073320|Schizophrenia
659762|NCT00073320|Paliperidone palmitate
659763|NCT00073320|R092670
659764|NCT00073320|antipsychotic
659765|NCT00073307|Renal Cell Cancer (RCC)
659766|NCT00073307|Cancer
659767|NCT00073294|diabetes
659768|NCT00073281|diabetes
659769|NCT00073281|autoimmunity
659770|NCT00073268|diabetes
659771|NCT00073268|adolescent
659772|NCT00073242|leptin
659773|NCT00073242|obesity
659774|NCT00073229|AIDS
659775|NCT00073229|Vertical Transmission
659776|NCT00073229|Acute Infection
659777|NCT00073216|HIV Seronegativity
659778|NCT00073216|HIV Preventive Vaccine
659779|NCT00073190|Patient Education
659780|NCT00073190|Physician Education
659781|NCT00073125|Advanced histologically documented renal cell carcinoma
659782|NCT00073099|Dry Eye
659783|NCT00073099|Lissamine Green
659784|NCT00073099|Fluorescein
659785|NCT00073099|Conjunctiva
659786|NCT00073099|Cornea
659787|NCT00073099|Digital Photography
659788|NCT00073099|Corneal and Conjunctival Staining
659789|NCT00073086|Coronavirus
659790|NCT00073086|Pneumonia
659791|NCT00073086|Asia
659792|NCT00073086|China
659793|NCT00073086|Severe Acut Respiratory Syndrome
659794|NCT00073086|SARS
659795|NCT00073086|Suspected SARS
659796|NCT00073073|Chemoprevention
659797|NCT00073073|Mammographic Density
659798|NCT00073073|Bone Mineral Density
659799|NCT00073073|Biomarkers
659800|NCT00073073|Safety
659801|NCT00073073|Breast Cancer
659802|NCT00073073|Postmenopausal
659803|NCT00073060|Plateletpheresis
659804|NCT00073060|Lymphocytapheresis
659805|NCT00073060|Apheresis
659806|NCT00073060|Citrate
659807|NCT00073060|Bone Density
659808|NCT00073060|Healthy Volunteer
659809|NCT00073060|HV
659810|NCT00073047|Ulcerative Colitis
659811|NCT00073047|Inflammatory Bowel Disease
659812|NCT00073047|Gastrointestinal
659813|NCT00073047|Humanized Monoclonal antibody
659814|NCT00073034|Neuropathic Pain
659815|NCT00073034|Diabetic Neuropathy
659816|NCT00073008|EGFR
659817|NCT00073008|ErbB1
659818|NCT00073008|ErbB2
659819|NCT00073008|metastatic
659820|NCT00073008|lapatinib
659821|NCT00073008|Her-2/neu
659822|NCT00073008|protein kinase inhibitor
659823|NCT00073008|BAC
659824|NCT00073008|GW572016
659825|NCT00073008|Advanced
659826|NCT00073008|NSCLC
659827|NCT00072982|Fish oil
659828|NCT00072982|Borage oil
659829|NCT00072969|Immunosuppression
659830|NCT00072969|Myelodysplastic Syndrome
659831|NCT00072969|MDS
659832|NCT00072956|Transcranial Magnetic Stimulation
659833|NCT00072956|Torticollis
659834|NCT00072956|Cervical Dystonia
659835|NCT00072956|Surround Inhibition
659836|NCT00072956|Sensory Tricks
659837|NCT00072943|Crohn's Disease
659838|NCT00072943|Colitis
659839|NCT00072943|Monoclonal antibody therapy
659840|NCT00072943|anti-interferon gamma
659841|NCT00072917|obesity
659842|NCT00072917|thinness
659843|NCT00072917|weight gain
659844|NCT00072917|physical activity
659845|NCT00072917|diet
659846|NCT00072917|fat oxidation
659847|NCT00072917|hunger
659848|NCT00072917|feeding behavior
659849|NCT00072917|overfeeding
659850|NCT00072904|Cystic Fibrosis Related Diabetes
659851|NCT00072904|Diabetes without Fasting Hyperglycemia
659852|NCT00072891|Diabetes
659853|NCT00072826|3-hydroxy-3-methlglutaryl (HMG)
659854|NCT00072826|Inhibitors
659855|NCT00072826|Endothelial Function
659856|NCT00072826|Leukocyte Gene Expression
659857|NCT00072826|Statins
659858|NCT00072826|Atorvastatin
659859|NCT00072826|Sickle Cell Disease
659860|NCT00072813|Genetics
659861|NCT00072813|Seizures
659862|NCT00072813|Brain Imaging
659863|NCT00072813|Diffusion
659864|NCT00072813|Temporal Lobe
659865|NCT00072800|Reliability
659866|NCT00072800|Muscle Tone Abnormality
659867|NCT00072800|Spasticity
659868|NCT00072800|Dystonia
659869|NCT00072800|Rigidity
659870|NCT00072800|Cerebral Palsy
659871|NCT00072800|CP
659872|NCT00072800|Children
659873|NCT00072787|gastric cancer
659874|NCT00072787|phase 2 clinical trial
659875|NCT00072774|Depressive Disorder, Major
659876|NCT00072774|Melancholia, Involutional
659877|NCT00072774|Depression, Involutional
659878|NCT00072761|silent cerebral infarct
659879|NCT00072761|silent stroke
659880|NCT00072761|sickle cell anemia
659881|NCT00072761|stroke
659882|NCT00072761|transfusion therapy
659883|NCT00072748|Advanced Colorectal Cancer
659884|NCT00072748|Colorectal Carcinoma
659885|NCT00072748|Colorectal Tumors
659886|NCT00072748|Neoplasms, Colorectal
659887|NCT00072735|Use Dependent Plasticity
659888|NCT00072735|Cortical Reorganization
659889|NCT00072735|Rehabilitation
659890|NCT00072735|Somatosensory Nerve
659891|NCT00072735|Amphetamine
659892|NCT00072735|Stroke
659893|NCT00072735|Healthy Volunteer
659894|NCT00072735|HV
659895|NCT00072722|Prostate Cancer
659896|NCT00072722|Metastatic Hormone Refractory Prostate Cancer
659897|NCT00072722|CC4047
659898|NCT00072722|CC-4047
659899|NCT00072722|Prostate Carcinoma
659900|NCT00072722|Celgene
659901|NCT00072709|ALS
659902|NCT00072709|Lou Gehrig's disease
659903|NCT00072683|Sodium
659904|NCT00072683|SIADH
659905|NCT00072683|Vasopressin
659906|NCT00072683|CHF
659907|NCT00072683|Cirrhosis
659908|NCT00072683|salt
659909|NCT00072683|water
659910|NCT00072683|electrolyte
659911|NCT00072670|Prostate cancer
659912|NCT00072670|Advanced prostate cancer
659913|NCT00072670|Metastatic prostate cancer
659914|NCT00072670|Trabectedin
659915|NCT00072670|Yondelis
659916|NCT00072670|ET-743
659917|NCT00072657|Arthritis
659918|NCT00072657|Pain
659919|NCT00072657|Meditation
659920|NCT00072657|Tai Chi
659921|NCT00072657|Chronic Illness
659922|NCT00072657|Depression
659923|NCT00072644|HIV
659924|NCT00072644|Osteonecrosis
659925|NCT00072644|Drug Interaction
659926|NCT00072644|P-Glycoprotein
659927|NCT00072644|Cytochrome P 450
659928|NCT00072644|Healthy Volunteer
659929|NCT00072644|HV
659930|NCT00072631|Tarceva
659931|NCT00072631|erlotinib
659932|NCT00072631|NSCLC
659933|NCT00072631|Non-Small Cell Lung Cancer
659934|NCT00072631|EGFR
659935|NCT00072631|OSI-774
659936|NCT00072605|Healthy
659937|NCT00072605|T Cells
659938|NCT00072605|Immunity
659939|NCT00072605|Hemorrhagic Fever
659940|NCT00072605|Healthy Volunteer
659941|NCT00072605|HV
659942|NCT00072592|ANCA
659943|NCT00072592|B Lymphocyte
659944|NCT00072592|Vasculitis
659945|NCT00072592|Treatment
659946|NCT00072592|Remission
659947|NCT00072592|Wegener Granulomatosis
659948|NCT00072592|WG
659949|NCT00072579|chronic phase chronic myelogenous leukemia
659950|NCT00072579|chronic myelogenous leukemia, BCR-ABL1 positive
659951|NCT00072553|stage IV rectal cancer
659952|NCT00072553|stage IV colon cancer
659953|NCT00072553|adenocarcinoma of the colon
659954|NCT00072553|adenocarcinoma of the rectum
659955|NCT00072553|recurrent rectal cancer
659956|NCT00072553|recurrent colon cancer
659957|NCT00072527|limited stage small cell lung cancer
659958|NCT00072501|breast cancer
659959|NCT00072488|disseminated neuroblastoma
659960|NCT00072488|localized resectable neuroblastoma
659961|NCT00072488|localized unresectable neuroblastoma
659962|NCT00072488|regional neuroblastoma
659963|NCT00072488|stage 4S neuroblastoma
659964|NCT00072488|previously untreated childhood rhabdomyosarcoma
659965|NCT00072488|stage I childhood Hodgkin lymphoma
659966|NCT00072488|stage I childhood large cell lymphoma
659967|NCT00072488|stage I childhood lymphoblastic lymphoma
659968|NCT00072488|stage I childhood small noncleaved cell lymphoma
659969|NCT00072488|stage II childhood Hodgkin lymphoma
659970|NCT00072488|stage II childhood large cell lymphoma
659971|NCT00072488|stage II childhood lymphoblastic lymphoma
659972|NCT00072488|stage II childhood small noncleaved cell lymphoma
659973|NCT00072488|stage III childhood Hodgkin lymphoma
659974|NCT00072488|stage III childhood large cell lymphoma
659975|NCT00072488|stage III childhood lymphoblastic lymphoma
659976|NCT00072488|stage III childhood small noncleaved cell lymphoma
659977|NCT00072488|stage IV childhood Hodgkin lymphoma
659978|NCT00072488|stage IV childhood large cell lymphoma
659979|NCT00072488|stage IV childhood lymphoblastic lymphoma
659980|NCT00072488|stage IV childhood small noncleaved cell lymphoma
659981|NCT00072488|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
659982|NCT00072488|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
659983|NCT00072488|previously treated childhood rhabdomyosarcoma
659984|NCT00072475|refractory anemia with excess blasts
659985|NCT00072475|refractory anemia with ringed sideroblasts
659986|NCT00072475|refractory cytopenia with multilineage dysplasia
659987|NCT00072475|chronic myelomonocytic leukemia
659988|NCT00072475|de novo myelodysplastic syndromes
659989|NCT00072475|secondary myelodysplastic syndromes
659990|NCT00072475|myelodysplastic/myeloproliferative neoplasm, unclassifiable
659991|NCT00072475|refractory anemia
659992|NCT00072475|previously treated myelodysplastic syndromes
659993|NCT00072462|ductal breast carcinoma in situ
659994|NCT00072462|breast cancer in situ
659995|NCT00072449|primary central nervous system non-Hodgkin lymphoma
659996|NCT00072410|recurrent ovarian epithelial cancer
659997|NCT00072410|stage III ovarian epithelial cancer
659998|NCT00072358|disseminated neuroblastoma
659999|NCT00072358|localized unresectable neuroblastoma
660000|NCT00072358|recurrent neuroblastoma
660001|NCT00072358|regional neuroblastoma
660002|NCT00072358|stage 4S neuroblastoma
660003|NCT00072345|stage III melanoma
660004|NCT00072345|stage IV melanoma
660005|NCT00072345|recurrent melanoma
660006|NCT00072345|iris melanoma
660007|NCT00072345|ciliary body and choroid melanoma, medium/large size
660008|NCT00072345|ciliary body and choroid melanoma, small size
660009|NCT00072345|extraocular extension melanoma
660010|NCT00072345|recurrent intraocular melanoma
660011|NCT00072332|unspecified adult solid tumor, protocol specific
660012|NCT00072332|stage IV esophageal cancer
660013|NCT00072332|stage IV gastric cancer
660014|NCT00072319|stage I breast cancer
660015|NCT00072319|stage II breast cancer
660016|NCT00072319|stage IIIA breast cancer
660017|NCT00072319|stage IIIB breast cancer
660018|NCT00072319|stage IIIC breast cancer
660019|NCT00072319|inflammatory breast cancer
660020|NCT00072293|stage IA breast cancer
660021|NCT00072293|stage IB breast cancer
660022|NCT00072293|stage II breast cancer
660023|NCT00072293|estrogen receptor-negative breast cancer
660024|NCT00072293|estrogen receptor-positive breast cancer
660025|NCT00072293|progesterone receptor-negative breast cancer
660026|NCT00072293|progesterone receptor-positive breast cancer
660027|NCT00072280|childhood fibrosarcoma
660028|NCT00072280|nonmetastatic childhood soft tissue sarcoma
660029|NCT00072267|stage IV ovarian epithelial cancer
660030|NCT00072267|recurrent ovarian epithelial cancer
660031|NCT00072267|primary peritoneal cavity cancer
660032|NCT00072267|fallopian tube cancer
660033|NCT00072267|stage III ovarian epithelial cancer
660034|NCT00072215|recurrent malignant testicular germ cell tumor
660035|NCT00072215|stage III malignant testicular germ cell tumor
660036|NCT00072215|testicular choriocarcinoma and embryonal carcinoma
660037|NCT00072215|testicular choriocarcinoma and seminoma
660038|NCT00072215|testicular choriocarcinoma and teratoma
660039|NCT00072215|testicular choriocarcinoma and yolk sac tumor
660040|NCT00072215|testicular choriocarcinoma
660041|NCT00072215|testicular embryonal carcinoma and seminoma
660042|NCT00072215|testicular embryonal carcinoma and teratoma with seminoma
660043|NCT00072215|testicular embryonal carcinoma and teratoma
660044|NCT00072215|testicular embryonal carcinoma and yolk sac tumor with seminoma
660045|NCT00072215|testicular embryonal carcinoma and yolk sac tumor
660046|NCT00072215|testicular embryonal carcinoma
660047|NCT00072215|testicular seminoma
660048|NCT00072215|testicular yolk sac tumor and teratoma with seminoma
660049|NCT00072215|testicular yolk sac tumor and teratoma
660050|NCT00072215|testicular yolk sac tumor
660051|NCT00072215|recurrent extragonadal non-seminomatous germ cell tumor
660052|NCT00072215|recurrent extragonadal seminoma
660053|NCT00072215|stage IV extragonadal non-seminomatous germ cell tumor
660054|NCT00072215|stage IV extragonadal seminoma
660055|NCT00072215|testicular immature teratoma
660056|NCT00072215|testicular mature teratoma
660057|NCT00072215|recurrent extragonadal germ cell tumor
660058|NCT00072124|stage IV melanoma
660059|NCT00072124|recurrent melanoma
660060|NCT00072111|unspecified adult solid tumor, protocol specific
660061|NCT00072098|stage IV colon cancer
660062|NCT00072098|stage IV rectal cancer
660063|NCT00072098|liver metastases
660064|NCT00072098|recurrent rectal cancer
660065|NCT00072098|recurrent colon cancer
660066|NCT00072085|stage IV melanoma
660067|NCT00072085|recurrent melanoma
660068|NCT00072072|recurrent non-small cell lung cancer
660069|NCT00072072|stage IIIB non-small cell lung cancer
660070|NCT00072072|stage IV non-small cell lung cancer
660071|NCT00072059|anemia
660072|NCT00072059|stage IIIB non-small cell lung cancer
660073|NCT00072059|stage IV non-small cell lung cancer
660074|NCT00072059|recurrent non-small cell lung cancer
660075|NCT00072046|stage IV renal cell cancer
660076|NCT00072046|clear cell renal cell carcinoma
660077|NCT00072046|recurrent renal cell cancer
660078|NCT00072033|stage II esophageal cancer
660079|NCT00072033|stage III esophageal cancer
660080|NCT00072033|adenocarcinoma of the esophagus
660081|NCT00072033|squamous cell carcinoma of the esophagus
660082|NCT00072020|bone metastases
660083|NCT00072020|stage II breast cancer
660084|NCT00072020|stage IIIA breast cancer
660085|NCT00072020|stage IIIB breast cancer
660086|NCT00072020|stage IIIC breast cancer
660087|NCT00072007|B-cell chronic lymphocytic leukemia
660088|NCT00072007|refractory chronic lymphocytic leukemia
660089|NCT00072007|stage II chronic lymphocytic leukemia
660090|NCT00072007|stage III chronic lymphocytic leukemia
660091|NCT00072007|stage I chronic lymphocytic leukemia
660092|NCT00072007|stage IV chronic lymphocytic leukemia
660093|NCT00071981|stage IV melanoma
660094|NCT00071981|recurrent melanoma
660095|NCT00071968|adenocarcinoma of the prostate
660096|NCT00071968|stage IIB prostate cancer
660097|NCT00071968|stage IIA prostate cancer
660098|NCT00071968|stage I prostate cancer
660099|NCT00071955|recurrent grade 1 follicular lymphoma
660100|NCT00071955|recurrent grade 2 follicular lymphoma
660101|NCT00071955|recurrent grade 3 follicular lymphoma
660102|NCT00071955|stage III grade 1 follicular lymphoma
660103|NCT00071955|stage III grade 2 follicular lymphoma
660104|NCT00071955|stage III grade 3 follicular lymphoma
660105|NCT00071955|stage IV grade 1 follicular lymphoma
660106|NCT00071955|stage IV grade 2 follicular lymphoma
660107|NCT00071955|stage IV grade 3 follicular lymphoma
660108|NCT00071929|recurrent endometrial carcinoma
660109|NCT00071916|Hepatitis C, African Americans, ribavirin
660110|NCT00071903|Thrombophilia
660111|NCT00071903|Idiopathic Intracranial Hypertension
660112|NCT00071903|Kidney Involvement
660113|NCT00071903|Lysosomal Storage Disorder
660114|NCT00071903|Cystine
660115|NCT00071903|Pseudotumor Cerebri
660116|NCT00071903|Susceptibility to Thrombosis
660117|NCT00071903|Nephropathic Cystinosis
660118|NCT00071903|PTC
660119|NCT00071903|Intracranial Hypertension
660120|NCT00071890|Interleukin 2
660121|NCT00071890|Treatment Interruption
660122|NCT00071890|HIV
660123|NCT00071877|Lysosomal Disease
660124|NCT00071877|Hypohidrosis
660125|NCT00071877|Pain
660126|NCT00071877|Neuropathy
660127|NCT00071877|X-Linked
660128|NCT00071877|Fabry Disease
660129|NCT00071877|Children
660130|NCT00071851|HIV Seronegativity
660131|NCT00071851|HIV Preventive Vaccine
660132|NCT00071838|Neuroimmunology
660133|NCT00071838|Therapy
660134|NCT00071838|Demyelinating Disease
660135|NCT00071838|Immunological Mechanism
660136|NCT00071838|MRI
660137|NCT00071838|Multiple Sclerosis
660138|NCT00071838|MS
660139|NCT00071812|RA
660140|NCT00071786|Bipolar Mood Disorder
660141|NCT00071786|Migraine
660142|NCT00071786|Behavior Genetics
660143|NCT00071786|Genetic Epidemiology
660144|NCT00071786|Family Study
660145|NCT00071773|diabetic macular edema
660146|NCT00071773|laser photocoagulation
660147|NCT00071773|etdrs
660148|NCT00071773|macular grid photocoagulation
660149|NCT00071773|DME
660150|NCT00071760|pediatrics
660151|NCT00071760|ritonavir
660152|NCT00071760|amprenavir
660153|NCT00071760|AGENERASE
660154|NCT00071760|HIV
660155|NCT00071760|Lexiva
660156|NCT00071760|protease inhibitors
660157|NCT00071760|HIV Infection
660158|NCT00071760|fosamprenavir
660159|NCT00071747|schizophrenia
660160|NCT00071747|lamotrigine
660161|NCT00071734|fMRI
660162|NCT00071734|Auditory Feedback
660163|NCT00071734|Motor Control
660164|NCT00071734|Adult
660165|NCT00071734|BOLD
660166|NCT00071734|Healthy Volunteer
660167|NCT00071734|HV
660168|NCT00071721|Alzheimer disease
660169|NCT00071721|Agitation
660170|NCT00071721|Psychosis
660171|NCT00071682|herbal medicine
660172|NCT00071682|alternative medicines
660173|NCT00071682|anticoagulation
660174|NCT00071682|side effects
660175|NCT00071682|bleeding
660176|NCT00071682|clotting
660177|NCT00071669|Mood Disorder
660178|NCT00071669|Acupuncture
660179|NCT00071643|Stroke
660180|NCT00071630|Adolescent
660181|NCT00071617|Suicide
660182|NCT00071617|Adolescence
660183|NCT00071578|Psychotherapy
660184|NCT00071578|Treatment
660185|NCT00071565|familial intracranial aneurysm
660186|NCT00071565|intracranial aneurysm
660187|NCT00071565|brain aneurysm
660188|NCT00071565|aneurysm
660189|NCT00071565|subarachnoid hemorrhage
660190|NCT00071565|stroke
660191|NCT00071552|Poorly Controlled Asthma
660192|NCT00071539|gross total resection
660193|NCT00071526|Vitamin C
660194|NCT00071526|Diabetes Mellitus
660195|NCT00071526|Proteinuria
660196|NCT00071526|Renal Threshold
660197|NCT00071526|Healthy Volunteer
660198|NCT00071513|Adolescent
660199|NCT00071513|Substance Abuse
660200|NCT00071513|At-risk
660201|NCT00071500|Compliance
660202|NCT00071500|Adherence
660203|NCT00071500|Computerized
660204|NCT00071500|Electronic Pillbox
660205|NCT00071500|Treatment Experienced
660206|NCT00071487|SLE
660207|NCT00071474|temporomandibular disroders
660208|NCT00071474|shamanism
660209|NCT00071474|chronic pain
660210|NCT00071461|Idiopathic pulmonary fibrosis
660211|NCT00071461|Interstitial lung disease
660212|NCT00071461|Bosentan
660213|NCT00071461|BUILD
660214|NCT00071435|EEG
660215|NCT00071435|Voluntary Movement
660216|NCT00071435|Motor Cortex
660217|NCT00071435|Reaction Time
660218|NCT00071435|Corticospinal
660219|NCT00071435|Primary Lateral Sclerosis
660220|NCT00071435|PLS
660221|NCT00071435|Healthy Volunteer
660222|NCT00071435|HV
660223|NCT00071422|Type 2 diabetes
660224|NCT00071409|Type 1 diabetes
660225|NCT00071396|Chronic Lymphocytic Leukemia
660226|NCT00071396|CD-52 and CD-20 Positive
660227|NCT00071396|Refractory
660228|NCT00071396|Relapsed
660229|NCT00071383|Herceptin
660230|NCT00071383|Trastuzumab
660231|NCT00071383|Microdissection
660232|NCT00071383|Proteomics
660233|NCT00071383|Microarrays
660234|NCT00071383|Metastatic Brain Tumor
660235|NCT00071383|Breast Cancer
660236|NCT00071383|Brain
660237|NCT00071383|Carcinoma
660238|NCT00071383|Genomics
660239|NCT00071383|Metastatic Breast Cancer
660240|NCT00071383|Metastatic Breast Tumor
660241|NCT00071370|Magnetoencephalography
660242|NCT00071370|Electroencephalogram (EEG)
660243|NCT00071370|Interictal Epileptiform Discharges
660244|NCT00071370|Epilepsy
660245|NCT00071370|Sleep Deprivation
660246|NCT00071370|Seizure
660247|NCT00071357|Microarray
660248|NCT00071357|Herceptin
660249|NCT00071357|Trastuzumab
660250|NCT00071357|Carcinoma
660251|NCT00071357|Proteomics
660252|NCT00071357|Breast Cancer
660253|NCT00071357|Metastatic Breast Cancer
660254|NCT00071357|Metastatic Breast Tumor
660255|NCT00071344|Microarray
660256|NCT00071344|Genomics
660257|NCT00071344|Trastuzumab
660258|NCT00071344|Carcinoma
660259|NCT00071344|Non-Small Cell Lung Cancer
660260|NCT00071344|Metastatic Brain Tumor
660261|NCT00071344|Brain
660262|NCT00071344|Microarrays
660263|NCT00071344|Microdissection
660264|NCT00071344|Lung Cancer
660265|NCT00071344|NSCLC
660266|NCT00071331|chronic heart failure
660267|NCT00071331|heart failure
660268|NCT00071305|Magnetoencephalography
660269|NCT00071305|Electroencephalography
660270|NCT00071305|Epilepsy
660271|NCT00071305|Dipole Modeling
660272|NCT00071305|Surgery
660273|NCT00071292|rheumatoid arthritis
660274|NCT00071292|stress reduction
660275|NCT00071292|meditation
660276|NCT00071292|mindfulness
660277|NCT00071292|MBSR
660278|NCT00071292|mindfulness-based stress reduction
660279|NCT00071292|mind-body skills
660280|NCT00071266|Intermittent Claudication
660281|NCT00071266|Peripheral Arterial Disease
660282|NCT00071266|Atherosclerosis
660283|NCT00071266|Niacin
660284|NCT00071266|Lovastatin
660285|NCT00071266|PAD
660286|NCT00071266|IC
660287|NCT00071253|Bipolar Disorder - Mania
660288|NCT00071240|Growth Hormone
660289|NCT00071240|HIV
660290|NCT00071240|AIDS
660291|NCT00071240|Thymus
660292|NCT00071240|CD4 Cell
660293|NCT00071240|Immune System
660294|NCT00071240|Treatment Experienced
660295|NCT00071227|Age Related Macular Degeneration
660296|NCT00071227|Macular Edema
660297|NCT00071227|Inflammation
660298|NCT00071227|Choroidal Neovascularization
660299|NCT00071227|CRVO
660300|NCT00071227|Diabetic Retinopathy
660301|NCT00071227|Age Related Macular Edema
660302|NCT00071227|AMD
660303|NCT00071214|Staphylococcal infection
660304|NCT00071214|Gram positive bacteria
660305|NCT00071214|Staphylococcus
660306|NCT00071214|Staphylococcus aureus
660307|NCT00071214|Staphylococcus aureus infection
660308|NCT00071188|Non-Small-Cell Lung Carcinoma
660309|NCT00071175|Lupus
660310|NCT00071175|Genetics
660311|NCT00071162|Pain
660312|NCT00071162|Fatigue
660313|NCT00071162|Sleep
660314|NCT00071162|Depression
660315|NCT00071162|Irritable Bowel Syndrome
660316|NCT00071162|Chronic Fatigue Syndrome
660317|NCT00071149|Rheumatoid Arthritis
660318|NCT00071149|TCM
660319|NCT00071149|Diagnosis
660320|NCT00071149|Traditional Chinese Medicine
660321|NCT00071149|Complementary Therapies
660322|NCT00071123|fMRI
660323|NCT00071123|Habituation
660324|NCT00071123|Extinction
660325|NCT00071123|Amygdala
660326|NCT00071123|Emotion
660327|NCT00071123|Major Depressive Disorder
660328|NCT00071123|Medial Prefrontal Cortex
660329|NCT00071123|Backward Masking
660330|NCT00071123|Depression
660331|NCT00071123|MDD
660332|NCT00071123|Healthy Volunteer
660333|NCT00071123|HV
660334|NCT00071110|Acupuncture
660335|NCT00071110|Electroacupuncture
660336|NCT00071110|Alternative therapy
660337|NCT00071097|HIV
660338|NCT00071097|TMC114
660339|NCT00071097|Ritonavir
660340|NCT00071097|Tolerability
660341|NCT00071097|Safety and efficacy
660342|NCT00071097|TMC114-C211
660343|NCT00071084|Skin cancer
660344|NCT00071084|Lymphoma
660345|NCT00071084|Mycosis fungoides
660346|NCT00071084|Sezary syndrome
660347|NCT00071071|Skin cancer
660348|NCT00071071|Lymphoma
660349|NCT00071071|Mycosis fungoides
660350|NCT00071071|Sezary syndrome
660351|NCT00071058|P-glycoprotein Inhibition
660352|NCT00071058|Drug Resistance Reversal
660353|NCT00071058|Pharmacodynamics
660354|NCT00071058|Molecular Target
660355|NCT00071058|Endocrine Cancer
660356|NCT00071058|Adrenocortical Cancer
660357|NCT00071058|ACC
660358|NCT00071058|Adrenocortical Tumor
660359|NCT00071045|Tissue Procurement
660360|NCT00071045|Sample Collection
660361|NCT00071045|Laboratory Research
660362|NCT00071045|Tissue Sample
660363|NCT00071045|Solid Tumor
660364|NCT00071045|Blood Disorder
660365|NCT00071045|HLA Donor
660366|NCT00071032|Blood Disease
660367|NCT00071032|blood transfusion
660368|NCT00070993|ALS
660369|NCT00070993|Creatine
660370|NCT00070980|Complementary Therapies
660371|NCT00070967|Acupuncture
660372|NCT00070967|Quality of Life
660373|NCT00070967|Complementary Therapies
660374|NCT00070967|TCM
660375|NCT00070967|Traditional Chinese Medicine
660376|NCT00070954|ECT
660377|NCT00070954|Memory
660378|NCT00070954|Ginkgo biloba
660379|NCT00070941|Parkinsons Disease
660380|NCT00070941|Depression
660381|NCT00070941|SAM-e
660382|NCT00070928|Sleep
660383|NCT00070902|Spinal Manipulation
660384|NCT00070902|Chiropractic
660385|NCT00070902|Zygapophysial Joints
660386|NCT00070889|Complementary Therapies
660387|NCT00070876|Child
660388|NCT00070876|Adolescent
660389|NCT00070850|Screening
660390|NCT00070850|Prenatal
660391|NCT00070850|Amniocentesis
660392|NCT00070824|Acupuncture
660393|NCT00070824|SPECT
660394|NCT00070824|f-MRI
660395|NCT00070824|Functional brain imaging
660396|NCT00070824|RCT
660397|NCT00070811|Facial form
660398|NCT00070811|Facial animation
660399|NCT00070811|Lip muscle reconstruction
660400|NCT00070811|Lip form
660401|NCT00070811|Lip function
660402|NCT00070785|Nasopharyngeal Cancer
660403|NCT00070785|EBV Virus
660404|NCT00070785|Epitope Mapping
660405|NCT00070785|Epstein-Barr Virus
660406|NCT00070785|Latent Protein-2
660407|NCT00070785|Healthy Volunteer
660408|NCT00070785|HV
660409|NCT00070759|Daclizumab
660410|NCT00070759|Uveitis
660411|NCT00070759|Active
660412|NCT00070759|Acute
660413|NCT00070746|Perinatal mortality [PNM]
660414|NCT00070746|Neonatal mortality
660415|NCT00070746|Low birth weight [LBW]
660416|NCT00070746|Spontaneous preterm delivery [SPTD]
660417|NCT00070746|Premature rupture of membranes [PROM]
660418|NCT00070746|Histological chorioamnionitis
660419|NCT00070746|Global Network
660420|NCT00070746|Pakistan
660421|NCT00070746|Maternal and child health
660422|NCT00070746|International
660423|NCT00070746|Women's health
660424|NCT00070733|Testosterone
660425|NCT00070733|5-alpha Reductase
660426|NCT00070733|Muscle Strength
660427|NCT00070733|Libido
660428|NCT00070733|Sexual Function
660429|NCT00070733|Muscle Mass
660430|NCT00070733|Testosterone 5-alpha-Reductase
660431|NCT00070720|Behavior change
660432|NCT00070720|Change in practitioner behavior
660433|NCT00070720|Episiotomy
660434|NCT00070720|Active management of third stage of labor
660435|NCT00070720|Global Network
660436|NCT00070720|Latin America
660437|NCT00070720|Uruguay
660438|NCT00070720|Argentina
660439|NCT00070720|Maternal and child health
660440|NCT00070720|International
660441|NCT00070720|Women's health
660442|NCT00070707|Seasonal Allergic Rhinitis
660443|NCT00070707|Concomitant Asthma
660444|NCT00070694|Affective Disorders
660445|NCT00070694|Refractory
660446|NCT00070694|Augmentation
660447|NCT00070694|Polysomogram
660448|NCT00070694|Combination Therapy
660449|NCT00070694|Affective Disorder
660450|NCT00070694|Depression
660451|NCT00070694|Major Depression
660452|NCT00070642|Immunotherapy, skin cancer
660453|NCT00070629|Immunotherapy
660454|NCT00070629|lung cancer
660455|NCT00070616|mucositis
660456|NCT00070616|chemotherapy
660457|NCT00070616|radiation therapy
660458|NCT00070590|Scleroderma
660459|NCT00070590|Fibrosing alveolitis
660460|NCT00070590|Build
660461|NCT00070590|bosentan
660462|NCT00070577|Alcohol Clamp
660463|NCT00070577|Pharmacokinetics
660464|NCT00070577|Pharmacodynamics
660465|NCT00070577|Alcohol
660466|NCT00070577|Metabolism
660467|NCT00070577|Response
660468|NCT00070577|Age
660469|NCT00070577|Sex
660470|NCT00070577|Healthy Volunteer
660471|NCT00070577|HV
660472|NCT00070564|stage II breast cancer
660473|NCT00070564|stage IA breast cancer
660474|NCT00070564|stage IB breast cancer
660475|NCT00070564|stage IIIC breast cancer
660476|NCT00070564|male breast cancer
660477|NCT00070564|HER2-positive breast cancer
660478|NCT00070564|estrogen receptor-negative breast cancer
660479|NCT00070564|estrogen receptor-positive breast cancer
660480|NCT00070564|progesterone receptor-negative breast cancer
660481|NCT00070564|progesterone receptor-positive breast cancer
660482|NCT00070538|recurrent adult acute lymphoblastic leukemia
660483|NCT00070538|blastic phase chronic myelogenous leukemia
660484|NCT00070538|relapsing chronic myelogenous leukemia
660485|NCT00070538|chronic myelomonocytic leukemia
660486|NCT00070538|refractory anemia with excess blasts in transformation
660487|NCT00070538|refractory anemia with excess blasts
660488|NCT00070538|recurrent adult acute myeloid leukemia
660489|NCT00070538|untreated adult acute myeloid leukemia
660490|NCT00070538|untreated adult acute lymphoblastic leukemia
660491|NCT00070538|de novo myelodysplastic syndromes
660492|NCT00070538|previously treated myelodysplastic syndromes
660493|NCT00070538|secondary myelodysplastic syndromes
660494|NCT00070538|adult acute myeloid leukemia with t(8;21)(q22;q22)
660495|NCT00070538|adult acute myeloid leukemia with t(16;16)(p13;q22)
660496|NCT00070538|adult acute myeloid leukemia with inv(16)(p13;q22)
660497|NCT00070538|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
660498|NCT00070538|adult acute myeloid leukemia with t(15;17)(q22;q12)
660499|NCT00070486|stage IV non-small cell lung cancer
660500|NCT00070486|adenocarcinoma of the lung
660501|NCT00070486|squamous cell lung cancer
660502|NCT00070486|large cell lung cancer
660503|NCT00070486|stage IIIB non-small cell lung cancer
660504|NCT00070473|unspecified childhood solid tumor, protocol specific
661034|NCT00069082|Cluster
660505|NCT00070447|contiguous stage II mantle cell lymphoma
660506|NCT00070447|noncontiguous stage II mantle cell lymphoma
660507|NCT00070447|stage III mantle cell lymphoma
660508|NCT00070447|stage IV mantle cell lymphoma
660509|NCT00070434|stage II rectal cancer
660510|NCT00070434|stage III rectal cancer
660511|NCT00070434|adenocarcinoma of the rectum
660512|NCT00070421|psychosocial effects of cancer and its treatment
660513|NCT00070421|unspecified childhood solid tumor, protocol specific
660514|NCT00070421|childhood acute lymphoblastic leukemia in remission
660515|NCT00070421|childhood acute myeloid leukemia in remission
660516|NCT00070421|recurrent childhood acute lymphoblastic leukemia
660517|NCT00070421|recurrent childhood acute myeloid leukemia
660518|NCT00070421|recurrent childhood large cell lymphoma
660519|NCT00070421|recurrent childhood lymphoblastic lymphoma
660520|NCT00070421|recurrent childhood small noncleaved cell lymphoma
660521|NCT00070421|stage I childhood Hodgkin lymphoma
660522|NCT00070421|stage I childhood large cell lymphoma
660523|NCT00070421|stage I childhood lymphoblastic lymphoma
660524|NCT00070421|stage I childhood small noncleaved cell lymphoma
660525|NCT00070421|stage II childhood Hodgkin lymphoma
660526|NCT00070421|stage II childhood large cell lymphoma
660527|NCT00070421|stage II childhood lymphoblastic lymphoma
660528|NCT00070421|stage II childhood small noncleaved cell lymphoma
660529|NCT00070421|stage III childhood Hodgkin lymphoma
660530|NCT00070421|stage III childhood large cell lymphoma
660531|NCT00070421|stage III childhood lymphoblastic lymphoma
660532|NCT00070421|stage III childhood small noncleaved cell lymphoma
660533|NCT00070421|stage IV childhood Hodgkin lymphoma
660534|NCT00070421|stage IV childhood large cell lymphoma
660535|NCT00070421|stage IV childhood lymphoblastic lymphoma
660536|NCT00070421|stage IV childhood small noncleaved cell lymphoma
660537|NCT00070421|recurrent/refractory childhood Hodgkin lymphoma
660538|NCT00070382|anemia
660539|NCT00070382|unspecified adult solid tumor, protocol specific
660540|NCT00070382|Waldenstrom macroglobulinemia
660541|NCT00070382|monoclonal gammopathy of undetermined significance
660542|NCT00070382|extramedullary plasmacytoma
660543|NCT00070382|isolated plasmacytoma of bone
660544|NCT00070382|refractory multiple myeloma
660545|NCT00070382|primary systemic amyloidosis
660546|NCT00070382|stage I multiple myeloma
660547|NCT00070382|stage II multiple myeloma
660548|NCT00070382|stage III multiple myeloma
660549|NCT00070382|post-transplant lymphoproliferative disorder
660550|NCT00070382|angioimmunoblastic T-cell lymphoma
660551|NCT00070382|anaplastic large cell lymphoma
660552|NCT00070382|stage I cutaneous T-cell non-Hodgkin lymphoma
660553|NCT00070382|stage II cutaneous T-cell non-Hodgkin lymphoma
660554|NCT00070382|stage III cutaneous T-cell non-Hodgkin lymphoma
660555|NCT00070382|stage IV cutaneous T-cell non-Hodgkin lymphoma
660556|NCT00070382|recurrent adult T-cell leukemia/lymphoma
660557|NCT00070382|stage I adult T-cell leukemia/lymphoma
660558|NCT00070382|stage II adult T-cell leukemia/lymphoma
660559|NCT00070382|stage III adult T-cell leukemia/lymphoma
660560|NCT00070382|stage IV adult T-cell leukemia/lymphoma
660561|NCT00070382|recurrent cutaneous T-cell non-Hodgkin lymphoma
660562|NCT00070382|recurrent mycosis fungoides/Sezary syndrome
660563|NCT00070382|stage I mycosis fungoides/Sezary syndrome
660564|NCT00070382|stage II mycosis fungoides/Sezary syndrome
660565|NCT00070382|stage III mycosis fungoides/Sezary syndrome
660566|NCT00070382|stage IV mycosis fungoides/Sezary syndrome
660567|NCT00070382|recurrent adult Hodgkin lymphoma
660568|NCT00070382|stage I adult Hodgkin lymphoma
660569|NCT00070382|stage II adult Hodgkin lymphoma
660570|NCT00070382|stage III adult Hodgkin lymphoma
660571|NCT00070382|stage IV adult Hodgkin lymphoma
660572|NCT00070382|T-cell large granular lymphocyte leukemia
660573|NCT00070382|refractory chronic lymphocytic leukemia
660574|NCT00070382|stage 0 chronic lymphocytic leukemia
660575|NCT00070382|stage I chronic lymphocytic leukemia
660576|NCT00070382|stage II chronic lymphocytic leukemia
660577|NCT00070382|stage III chronic lymphocytic leukemia
660578|NCT00070382|stage IV chronic lymphocytic leukemia
660579|NCT00070382|prolymphocytic leukemia
660580|NCT00070382|recurrent grade 1 follicular lymphoma
660581|NCT00070382|recurrent grade 2 follicular lymphoma
660582|NCT00070382|recurrent grade 3 follicular lymphoma
660583|NCT00070382|stage I grade 1 follicular lymphoma
660584|NCT00070382|stage I grade 2 follicular lymphoma
660585|NCT00070382|stage I grade 3 follicular lymphoma
660586|NCT00070382|stage III grade 1 follicular lymphoma
660587|NCT00070382|stage III grade 2 follicular lymphoma
660588|NCT00070382|stage III grade 3 follicular lymphoma
660589|NCT00070382|stage IV grade 1 follicular lymphoma
660590|NCT00070382|stage IV grade 2 follicular lymphoma
660591|NCT00070382|stage IV grade 3 follicular lymphoma
660592|NCT00070382|contiguous stage II adult diffuse large cell lymphoma
660593|NCT00070382|contiguous stage II adult diffuse mixed cell lymphoma
660594|NCT00070382|contiguous stage II adult diffuse small cleaved cell lymphoma
660595|NCT00070382|noncontiguous stage II adult diffuse large cell lymphoma
660596|NCT00070382|noncontiguous stage II adult diffuse mixed cell lymphoma
660597|NCT00070382|noncontiguous stage II adult diffuse small cleaved cell lymphoma
660598|NCT00070382|recurrent adult diffuse large cell lymphoma
660599|NCT00070382|recurrent adult diffuse mixed cell lymphoma
660600|NCT00070382|recurrent adult diffuse small cleaved cell lymphoma
660601|NCT00070382|stage I adult diffuse large cell lymphoma
660602|NCT00070382|stage I adult diffuse mixed cell lymphoma
660603|NCT00070382|stage I adult diffuse small cleaved cell lymphoma
660604|NCT00070382|stage III adult diffuse large cell lymphoma
660605|NCT00070382|stage III adult diffuse mixed cell lymphoma
660606|NCT00070382|stage III adult diffuse small cleaved cell lymphoma
660607|NCT00070382|stage IV adult diffuse large cell lymphoma
660608|NCT00070382|stage IV adult diffuse mixed cell lymphoma
660609|NCT00070382|stage IV adult diffuse small cleaved cell lymphoma
660610|NCT00070382|contiguous stage II adult immunoblastic large cell lymphoma
660611|NCT00070382|noncontiguous stage II adult immunoblastic large cell lymphoma
660612|NCT00070382|recurrent adult immunoblastic large cell lymphoma
660613|NCT00070382|stage I adult immunoblastic large cell lymphoma
660614|NCT00070382|stage III adult immunoblastic large cell lymphoma
660615|NCT00070382|stage IV adult immunoblastic large cell lymphoma
660616|NCT00070382|contiguous stage II mantle cell lymphoma
660617|NCT00070382|noncontiguous stage II mantle cell lymphoma
660618|NCT00070382|recurrent mantle cell lymphoma
660619|NCT00070382|stage I mantle cell lymphoma
660620|NCT00070382|stage III mantle cell lymphoma
660621|NCT00070382|stage IV mantle cell lymphoma
660622|NCT00070382|contiguous stage II grade 1 follicular lymphoma
660623|NCT00070382|contiguous stage II grade 2 follicular lymphoma
660624|NCT00070382|contiguous stage II grade 3 follicular lymphoma
660625|NCT00070382|noncontiguous stage II grade 1 follicular lymphoma
660626|NCT00070382|noncontiguous stage II grade 2 follicular lymphoma
660627|NCT00070382|noncontiguous stage II grade 3 follicular lymphoma
660628|NCT00070343|stage IV melanoma
660629|NCT00070343|stage III melanoma
660630|NCT00070304|recurrent/refractory childhood Hodgkin lymphoma
660631|NCT00070304|childhood lymphocyte predominant Hodgkin lymphoma
660632|NCT00070304|childhood lymphocyte depletion Hodgkin lymphoma
660633|NCT00070304|childhood nodular sclerosis Hodgkin lymphoma
660634|NCT00070304|childhood mixed cellularity Hodgkin lymphoma
660635|NCT00070291|angioimmunoblastic T-cell lymphoma
660636|NCT00070278|stage II breast cancer
660637|NCT00070278|stage IIIA breast cancer
660638|NCT00070278|stage IIIB breast cancer
660639|NCT00070278|stage IIIC breast cancer
660640|NCT00070213|adenocarcinoma of the colon
660641|NCT00070213|adenocarcinoma of the rectum
660642|NCT00070213|stage IV rectal cancer
660643|NCT00070213|stage IV colon cancer
660644|NCT00070213|recurrent rectal cancer
660645|NCT00070213|recurrent colon cancer
660646|NCT00070200|recurrent neuroblastoma
660647|NCT00070200|stage 4S neuroblastoma
660648|NCT00070200|localized unresectable neuroblastoma
660649|NCT00070200|localized resectable neuroblastoma
660650|NCT00070200|regional neuroblastoma
660651|NCT00070200|disseminated neuroblastoma
660652|NCT00070187|recurrent adult Hodgkin lymphoma
660653|NCT00070187|recurrent/refractory childhood Hodgkin lymphoma
660654|NCT00070174|untreated childhood acute myeloid leukemia and other myeloid malignancies
660655|NCT00070174|childhood acute monocytic leukemia (M5b)
660656|NCT00070174|childhood acute megakaryocytic leukemia (M7)
660657|NCT00070174|childhood acute minimally differentiated myeloid leukemia (M0)
660658|NCT00070174|childhood acute myeloblastic leukemia with maturation (M2)
660659|NCT00070174|childhood acute myeloblastic leukemia without maturation (M1)
660660|NCT00070174|childhood acute myelomonocytic leukemia (M4)
660661|NCT00070174|childhood acute monoblastic leukemia (M5a)
660662|NCT00070174|childhood acute erythroleukemia (M6)
660663|NCT00070161|radiation toxicity
660664|NCT00070161|adult mixed glioma
660665|NCT00070161|adult central nervous system germ cell tumor
660666|NCT00070161|adult brain stem glioma
660667|NCT00070161|adult craniopharyngioma
660668|NCT00070161|adult medulloblastoma
660669|NCT00070161|adult meningioma
660670|NCT00070161|adult choroid plexus tumor
660671|NCT00070161|adult tumors metastatic to brain
660672|NCT00070161|adult anaplastic oligodendroglioma
660673|NCT00070161|adult anaplastic astrocytoma
660674|NCT00070161|adult pilocytic astrocytoma
660675|NCT00070161|adult subependymoma
660676|NCT00070161|adult meningeal hemangiopericytoma
660677|NCT00070161|adult ependymoblastoma
660678|NCT00070161|adult anaplastic ependymoma
660679|NCT00070161|adult pineoblastoma
660680|NCT00070161|adult pineocytoma
660681|NCT00070161|adult myxopapillary ependymoma
660682|NCT00070161|adult glioblastoma
660683|NCT00070161|adult grade III meningioma
660684|NCT00070161|adult oligodendroglioma
660685|NCT00070161|adult giant cell glioblastoma
660686|NCT00070161|adult gliosarcoma
660687|NCT00070161|adult ependymoma
660688|NCT00070148|weight changes
660689|NCT00070148|unspecified adult solid tumor, protocol specific
660690|NCT00070135|adult acute myeloid leukemia in remission
660691|NCT00070135|secondary acute myeloid leukemia
660692|NCT00070135|adult acute monocytic leukemia (M5b)
660693|NCT00070135|adult acute erythroid leukemia (M6)
660694|NCT00070135|adult acute megakaryoblastic leukemia (M7)
660695|NCT00070135|adult acute minimally differentiated myeloid leukemia (M0)
660696|NCT00070135|adult acute myeloblastic leukemia with maturation (M2)
661039|NCT00069056|Grid Laser
660697|NCT00070135|adult acute myeloblastic leukemia without maturation (M1)
660698|NCT00070135|adult acute myelomonocytic leukemia (M4)
660699|NCT00070135|adult acute monoblastic leukemia (M5a)
660700|NCT00070135|adult acute myeloid leukemia with t(8;21)(q22;q22)
660701|NCT00070135|adult acute myeloid leukemia with t(16;16)(p13;q22)
660702|NCT00070135|adult acute myeloid leukemia with inv(16)(p13;q22)
660703|NCT00070135|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
660704|NCT00070096|stage IV ovarian germ cell tumor
660705|NCT00070096|recurrent ovarian germ cell tumor
660706|NCT00070096|adult central nervous system germ cell tumor
660707|NCT00070096|recurrent malignant testicular germ cell tumor
660708|NCT00070096|stage III malignant testicular germ cell tumor
660709|NCT00070096|testicular seminoma
660710|NCT00070096|testicular choriocarcinoma and embryonal carcinoma
660711|NCT00070096|testicular choriocarcinoma and seminoma
660712|NCT00070096|testicular choriocarcinoma and teratoma
660713|NCT00070096|testicular choriocarcinoma and yolk sac tumor
660714|NCT00070096|testicular choriocarcinoma
660715|NCT00070096|testicular embryonal carcinoma and seminoma
660716|NCT00070096|testicular embryonal carcinoma and teratoma with seminoma
660717|NCT00070096|testicular embryonal carcinoma and teratoma
660718|NCT00070096|testicular embryonal carcinoma and yolk sac tumor with seminoma
660719|NCT00070096|testicular embryonal carcinoma and yolk sac tumor
660720|NCT00070096|testicular embryonal carcinoma
660721|NCT00070096|testicular yolk sac tumor and teratoma with seminoma
660722|NCT00070096|testicular yolk sac tumor and teratoma
660723|NCT00070096|testicular yolk sac tumor
660724|NCT00070096|recurrent extragonadal non-seminomatous germ cell tumor
660725|NCT00070096|recurrent extragonadal seminoma
660726|NCT00070096|stage IV extragonadal non-seminomatous germ cell tumor
660727|NCT00070096|stage IV extragonadal seminoma
660728|NCT00070096|recurrent extragonadal germ cell tumor
660729|NCT00070096|testicular immature teratoma
660730|NCT00070096|testicular mature teratoma
660731|NCT00070083|contiguous stage II adult diffuse large cell lymphoma
660732|NCT00070083|noncontiguous stage II adult diffuse large cell lymphoma
660733|NCT00070083|stage III adult diffuse large cell lymphoma
660734|NCT00070083|stage IV adult diffuse large cell lymphoma
660735|NCT00070070|transitional cell carcinoma of the bladder
660736|NCT00070070|stage I bladder cancer
660737|NCT00070031|recurrent breast cancer
660738|NCT00070031|stage IIIA breast cancer
660739|NCT00070031|stage IIIB breast cancer
660740|NCT00070031|stage IIIC breast cancer
660741|NCT00070031|stage IV breast cancer
660742|NCT00070018|stage I mantle cell lymphoma
660743|NCT00070018|stage I adult diffuse large cell lymphoma
660744|NCT00070018|stage I adult Burkitt lymphoma
660745|NCT00070018|anaplastic large cell lymphoma
660746|NCT00070018|contiguous stage II adult diffuse large cell lymphoma
660747|NCT00070018|contiguous stage II adult Burkitt lymphoma
660748|NCT00070018|contiguous stage II mantle cell lymphoma
660749|NCT00070018|noncontiguous stage II adult diffuse large cell lymphoma
660750|NCT00070018|noncontiguous stage II adult Burkitt lymphoma
660751|NCT00070018|noncontiguous stage II mantle cell lymphoma
660752|NCT00070005|perioperative/postoperative complications
660753|NCT00070005|stage I rectal cancer
660754|NCT00070005|stage II rectal cancer
660755|NCT00070005|stage III rectal cancer
660756|NCT00070005|adenocarcinoma of the rectum
660757|NCT00069992|polycythemia vera
660758|NCT00069992|essential thrombocythemia
660759|NCT00069992|de novo myelodysplastic syndromes
660760|NCT00069992|previously treated myelodysplastic syndromes
660761|NCT00069992|secondary myelodysplastic syndromes
660762|NCT00069992|primary myelofibrosis
660763|NCT00069992|chronic myelogenous leukemia
660764|NCT00069992|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
660765|NCT00069992|adult acute myeloid leukemia with inv(16)(p13;q22)
660766|NCT00069992|adult acute myeloid leukemia with t(15;17)(q22;q12)
660767|NCT00069992|adult acute myeloid leukemia with t(16;16)(p13;q22)
660768|NCT00069992|adult acute myeloid leukemia with t(8;21)(q22;q22)
660769|NCT00069992|childhood myelodysplastic syndromes
660770|NCT00069966|recurrent adult diffuse large cell lymphoma
660771|NCT00069966|anaplastic large cell lymphoma
660772|NCT00069966|recurrent adult diffuse mixed cell lymphoma
660773|NCT00069966|recurrent adult immunoblastic large cell lymphoma
660774|NCT00069966|recurrent grade 3 follicular lymphoma
660775|NCT00069966|recurrent adult Burkitt lymphoma
660776|NCT00069953|adenocarcinoma of the esophagus
660777|NCT00069953|squamous cell carcinoma of the esophagus
660778|NCT00069953|stage II esophageal cancer
660779|NCT00069953|stage III esophageal cancer
660780|NCT00069940|adult glioblastoma
660781|NCT00069940|stage III adult soft tissue sarcoma
660782|NCT00069940|stage IV adult soft tissue sarcoma
660783|NCT00069940|adult synovial sarcoma
660784|NCT00069940|childhood synovial sarcoma
660785|NCT00069940|childhood leiomyosarcoma
660786|NCT00069940|adult leiomyosarcoma
660787|NCT00069940|adult liposarcoma
660788|NCT00069940|childhood liposarcoma
660789|NCT00069940|gastrointestinal stromal tumor
660790|NCT00069940|recurrent childhood brain tumor
660791|NCT00069940|recurrent adult brain tumor
660792|NCT00069940|metastatic childhood soft tissue sarcoma
660793|NCT00069940|recurrent childhood soft tissue sarcoma
660794|NCT00069940|recurrent adult soft tissue sarcoma
660795|NCT00069940|adult giant cell glioblastoma
660796|NCT00069940|adult gliosarcoma
660797|NCT00069940|adult anaplastic astrocytoma
660798|NCT00069940|adult oligodendroglioma
660799|NCT00069940|adult anaplastic oligodendroglioma
660800|NCT00069940|adult diffuse astrocytoma
660801|NCT00069940|adult mixed glioma
660802|NCT00069940|adult myxopapillary ependymoma
660803|NCT00069940|adult anaplastic ependymoma
660804|NCT00069940|childhood high-grade cerebral astrocytoma
660805|NCT00069940|recurrent childhood cerebral astrocytoma
660806|NCT00069940|untreated childhood cerebellar astrocytoma
660807|NCT00069940|recurrent childhood cerebellar astrocytoma
660808|NCT00069940|childhood infratentorial ependymoma
660809|NCT00069940|newly diagnosed childhood ependymoma
660810|NCT00069940|recurrent childhood ependymoma
660811|NCT00069940|childhood oligodendroglioma
660812|NCT00069927|unspecified childhood solid tumor, protocol specific
660813|NCT00069927|depression
660814|NCT00069927|neurotoxicity
660815|NCT00069914|Immunization
660816|NCT00069914|Immune Activation
660817|NCT00069914|Flu
660818|NCT00069914|Antibodies
660819|NCT00069914|Titers
660820|NCT00069914|HIV
660821|NCT00069914|Healthy Volunteer
660822|NCT00069914|HV
660823|NCT00069901|ovarian cancer
660824|NCT00069901|paclitaxel
660825|NCT00069901|carboplatin
660826|NCT00069862|Beta Thalassemia
660827|NCT00069836|AVANDAMET insulin type 2 diabetes
660828|NCT00069784|Impaired Fasting Glucose (IFG)
660829|NCT00069784|Impaired Glucose Tolerance (IGT)
660830|NCT00069758|NHL, indolent NHL, non-Hodgkin's lymphoma, lymphoma
660831|NCT00069745|Prostatic Neoplasms
660832|NCT00069745|Cancer Treatment Protocols
660833|NCT00069745|Antineoplastic protocols
660834|NCT00069745|One Prior Cytotoxic Chemotherapy Regimen
660835|NCT00069732|Overweight
660836|NCT00069732|Weight loss maintenance
660837|NCT00069732|CAM therapy
660838|NCT00069732|Qigong
660839|NCT00069732|Acupressure
660840|NCT00069732|Traditional Chinese Medicine
660841|NCT00069719|open-angle
660842|NCT00069719|glaucoma
660843|NCT00069719|ocular
660844|NCT00069719|hypertension
660845|NCT00069719|POAG
660846|NCT00069706|open-angle
660847|NCT00069706|glaucoma
660848|NCT00069706|ocular
660849|NCT00069706|hypertension
660850|NCT00069706|POAG
660851|NCT00069693|Dysautonomia
660852|NCT00069693|Sympathetic Nervous System
660853|NCT00069693|Autonomic Nervous System
660854|NCT00069693|Syncope
660855|NCT00069693|Post Tachycardia Syndrome
660856|NCT00069693|POTS
660857|NCT00069693|Neurocardiogenic Syncope
660858|NCT00069693|Baroreflex
660859|NCT00069693|Norepinephrine
660860|NCT00069693|Epinephrine
660861|NCT00069693|Neurocardiology
660862|NCT00069693|Chronic Orthostatic Intolerance
660863|NCT00069693|COI
660864|NCT00069693|Healthy Volunteer
660865|NCT00069693|HV
660866|NCT00069680|Gene Identification
660867|NCT00069680|Linkage Analysis
660868|NCT00069680|Homozygosity Mapping
660869|NCT00069680|Gray Platelet Syndrome
660870|NCT00069680|GPS
660871|NCT00069680|Platelet Function Defect
660872|NCT00069680|Bleeding Disorder
660873|NCT00069654|Endothelium
660874|NCT00069654|Atherosclerosis
660875|NCT00069654|Vasodilation
660876|NCT00069654|Ischemia
660877|NCT00069654|Exercise
660878|NCT00069654|Coronary Artery Disease
660879|NCT00069654|CAD
660880|NCT00069641|Mucopolysaccharidosis II
660881|NCT00069641|MPS II
660882|NCT00069641|Hunter Syndrome
660883|NCT00069641|iduronate-2-sulfatase
660884|NCT00069641|I2S
660885|NCT00069641|Iduronate-2-sulfatase deficiency
660886|NCT00069628|Diabetes Mellitus, Insulin-Dependent
660887|NCT00069628|Type 1 Diabetes
660888|NCT00069628|Diabetes in Children
660889|NCT00069628|Continuous Glucose Monitoring Devices
660890|NCT00069615|Diabetes Mellitus, Insulin-Dependent
660891|NCT00069615|Type 1 Diabetes
660892|NCT00069615|Continuous Glucose Monitoring Devices
660893|NCT00069615|Electronic Data Collection
660894|NCT00069602|Continuous Glucose Monitoring Devices
660895|NCT00069602|Blood glucose profiles in normal children
660896|NCT00069602|Blood glucose profiles in non-diabetic children
660897|NCT00069589|Baldness
660898|NCT00069589|Autoimmunity
660899|NCT00069589|Hair
660900|NCT00069589|Alopecia Areata
660901|NCT00069589|Alopecia Partialis
660902|NCT00069589|Alopecia Totalis
660903|NCT00069589|Alopecia Universalis
660904|NCT00069589|Autoimmune Hair Loss
660905|NCT00069576|Mild gestational diabetes mellitus
660906|NCT00069576|Maternal Fetal Medicine Units Network
660907|NCT00069563|Internalizing psychopathology
660908|NCT00069563|Externalizing psychopathology
660909|NCT00069550|Glutamate/NMDA receptors
660910|NCT00069550|Cholinergic upregulation
660911|NCT00069550|Dextromethorphan
660912|NCT00069550|Donepezil hydrochloride
660913|NCT00069550|Aricept
660914|NCT00069537|Diabetes Mellitus, Insulin-Dependent
660915|NCT00069537|Type 1 Diabetes
660916|NCT00069537|Diabetes in Children
660917|NCT00069537|Continuous Glucose Monitoring Devices
660918|NCT00069524|Highly active antiretroviral therapy (HAART)
660919|NCT00069524|Ritonavir
660920|NCT00069524|Oyster mushrooms
660921|NCT00069524|Non-HDL cholesterol
660922|NCT00069524|Complementary Therapies
660923|NCT00069524|Treatment Experienced
660924|NCT00069511|Hepatitis C
660925|NCT00069498|Mucosa
660926|NCT00069498|Inflammation
660927|NCT00069498|Tissue Viral Load
660928|NCT00069498|Anti-inflammatory
660929|NCT00069498|HIV-related diarrhea
660930|NCT00069498|Mucosal Inflammation
660931|NCT00069498|Treatment Experienced
660932|NCT00069485|HIV Seronegativity
660933|NCT00069472|Genetics
660934|NCT00069459|Winter depression, winter blues, depression, seasonal depression, seasonal affective disorder
660935|NCT00069446|Diabetes
660936|NCT00069446|Diabetic
660937|NCT00069446|Diabetic Foot Ulcer
660938|NCT00069433|Psychotic Disorders
660939|NCT00069407|Bipolar Disorder
660940|NCT00069368|Healthy
660941|NCT00069355|PTSD
660942|NCT00069355|Catecholamines
660943|NCT00069355|Conditioning
660944|NCT00069355|Memory
660945|NCT00069355|Psychophysiology
660946|NCT00069355|Acute Stress Disorder
660947|NCT00069355|Post-Traumatic Stress Disorder
660948|NCT00069342|Chronic Pain
660949|NCT00069342|Pain
660950|NCT00069342|Rheumatoid Arthritis
660951|NCT00069342|Depression
660952|NCT00069342|Function
660953|NCT00069342|Rheumatic Disease
660954|NCT00069329|Central Nervous System
660955|NCT00069329|Abnormalities
660956|NCT00069329|Arthropathy
660957|NCT00069329|Urticaria
660958|NCT00069329|Papilledema
660959|NCT00069329|Auto-Inflammation
660960|NCT00069329|Inflammatory Disease
660961|NCT00069329|Neonatal Onset Multisystem Inflammatory Disease
660962|NCT00069329|NOMID
660963|NCT00069329|CINCA Syndrome
660964|NCT00069316|West Nile Virus
660965|NCT00069316|Encephalitis
660966|NCT00069316|Virus
660967|NCT00069316|Mosquito
660968|NCT00069316|Fever
660969|NCT00069316|WNV
660970|NCT00069316|Myelitis
660971|NCT00069303|West Nile Virus
660972|NCT00069303|Encephalitis
660973|NCT00069303|Virus
660974|NCT00069303|Mosquito
660975|NCT00069303|Fever
660976|NCT00069303|WNV
660977|NCT00069303|Myelitis
660978|NCT00069277|Cancer, tumors
660979|NCT00069264|Metastatic Tumors
660980|NCT00069264|Advanced Solid Tumors
660981|NCT00069264|Stage IV Tumors
660982|NCT00069264|Solid Tumors
660983|NCT00069264|Recurrent Solid Tumors
660984|NCT00069251|amphetamine dependence
660985|NCT00069238|Lymphoma
660986|NCT00069238|T-Cell Lymphoma
660987|NCT00069238|NK -Cell Lymphoma
660988|NCT00069225|fMRI
660989|NCT00069225|Prolonged Exposure
660990|NCT00069225|Brain Activation
660991|NCT00069225|Conditioning
660992|NCT00069225|Paroxetine
660993|NCT00069225|PTSD
660994|NCT00069225|Differential Fear Conditioning
660995|NCT00069225|Masked Faces
660996|NCT00069225|Amygdala
660997|NCT00069225|Hippocampus
660998|NCT00069225|Post-Traumatic Stress Disorder
660999|NCT00069212|Post-Traumatic Stress Disorder
661000|NCT00069212|Neural Circuits
661001|NCT00069212|Fear
661002|NCT00069212|Emotional Regulation
661003|NCT00069212|Reward
661004|NCT00069212|PTSD
661005|NCT00069199|Reproducibility
661006|NCT00069199|Macular Edema
661007|NCT00069199|OCT2
661008|NCT00069199|OCT3
661009|NCT00069199|Retina
661010|NCT00069186|Amyotrophic Lateral Sclerosis
661011|NCT00069186|ALS
661012|NCT00069186|Creatine
661013|NCT00069186|Creatine Monohydrate
661014|NCT00069186|Muscle Strength
661015|NCT00069173|Females
661016|NCT00069173|Sedentary
661017|NCT00069173|School-based
661018|NCT00069160|Pharmacokinetics
661019|NCT00069160|Pharmacodynamics
661020|NCT00069160|Multidrug Resistance Reversal
661021|NCT00069160|Molecular Target
661022|NCT00069160|P-Glycoprotein Inhibition
661023|NCT00069160|Lung Cancer
661024|NCT00069160|Ovarian Cancer
661025|NCT00069160|Cervical Cancer
661026|NCT00069160|Renal Cancer
661027|NCT00069134|glutathione kinetics
661028|NCT00069134|oxidant damage
661029|NCT00069134|anti-oxidant capacity
661030|NCT00069134|oxidative stress
661031|NCT00069134|cysteine kinetics
661032|NCT00069134|severe childhood malnutrition
661033|NCT00069082|Headache
661035|NCT00069082|EC
661036|NCT00069082|Episodic Cluster
661037|NCT00069069|Stroke
661038|NCT00069069|TIA
661040|NCT00069056|Focal Laser
661041|NCT00069056|Glycemic Control
661042|NCT00069056|Diabetes
661043|NCT00069056|Diabetic Macular Edema
661044|NCT00069056|Macular Edema
661045|NCT00069030|HIV Seronegativity
661046|NCT00069030|HIV Preventive Vaccine
661047|NCT00069030|HIV-1
661048|NCT00069030|AIDS Vaccines
661049|NCT00069030|Vaccines, DNA
661050|NCT00069030|Dose-Response Relationship, Immunologic
661051|NCT00069030|Cytokines
661052|NCT00069030|Plasmids
661053|NCT00069030|Adjuvants, Immunologic
661054|NCT00069030|Drug Administration Schedule
661055|NCT00069030|Interleukin
661056|NCT00069030|IL2
661057|NCT00069030|Ig
661058|NCT00069030|IL@/Ig
661059|NCT00069004|HIV-Associated Lipodystrophy Syndrome
661060|NCT00069004|HIV Lipodystrophy Syndrome
661061|NCT00069004|Treatment Experienced
661062|NCT00069004|Lipodystrophy
661063|NCT00069004|Dyslipidemia
661064|NCT00069004|Osteoporosis
661065|NCT00069004|Osteopenia
661066|NCT00068991|Behavioral Intervention Study
661067|NCT00068991|Randomized Prevention Trial
661068|NCT00068991|China
661069|NCT00068991|Condom Use
661070|NCT00068991|STDs
661071|NCT00068991|Sexual Partners
661072|NCT00068991|HIV Seronegativity
661073|NCT00068978|HIV Seronegativity
661074|NCT00068978|HIV Preventive Vaccine
661075|NCT00068978|HIV Therapeutic Vaccine
661076|NCT00068926|Biodefense
661077|NCT00068926|Prevention
661078|NCT00068926|Emergent
661079|NCT00068926|Virus
661080|NCT00068926|Immune Response
661081|NCT00068926|Healthy Volunteer
661082|NCT00068926|HV
661083|NCT00068913|Lactic Acidosis
661084|NCT00068913|Mitochondrial Disorder
661085|NCT00068913|Stroke
661086|NCT00068913|Seizure
661087|NCT00068887|type 2 diabetes
661088|NCT00068887|some studies - family history of type 2 diabetes
661089|NCT00068874|African American
661090|NCT00068874|Adolescent
661091|NCT00068874|Coping
661092|NCT00068874|Adjustment
661093|NCT00068874|Quality of Life
661094|NCT00068848|Oral Contraceptives
661095|NCT00068848|Initiation
661096|NCT00068848|Continuation
661097|NCT00068835|Reading
661098|NCT00068835|Brain imaging
661099|NCT00068822|Vertebroplasty
661100|NCT00068822|Crushed Vertebrae
661101|NCT00068822|Back Pain
661102|NCT00068822|Structurally Unstable Vertebrae
661103|NCT00068822|polymethylmethacrylate
661104|NCT00068822|INVEST
661105|NCT00068822|PMMA
661106|NCT00068822|RDQ
661107|NCT00068809|Treatment experienced
661108|NCT00068809|Treatment interruption
661109|NCT00068770|adult glioblastoma
661110|NCT00068770|adult giant cell glioblastoma
661111|NCT00068770|adult gliosarcoma
661112|NCT00068757|recurrent breast cancer
661113|NCT00068757|stage IIIB breast cancer
661114|NCT00068757|stage IIIC breast cancer
661115|NCT00068757|stage IV breast cancer
661116|NCT00068757|male breast cancer
661117|NCT00068757|HER2-positive breast cancer
661118|NCT00068744|squamous cell carcinoma of the anus
661119|NCT00068744|stage II anal cancer
661120|NCT00068744|stage IIIA anal cancer
661121|NCT00068744|stage IIIB anal cancer
661122|NCT00068731|stage IV prostate cancer
661123|NCT00068731|recurrent prostate cancer
661124|NCT00068666|stage IV melanoma
661125|NCT00068666|recurrent melanoma
661126|NCT00068666|tumors metastatic to brain
661127|NCT00068653|recurrent non-small cell lung cancer
661128|NCT00068614|stage IV breast cancer
661129|NCT00068614|stage II breast cancer
661130|NCT00068614|stage IIIA breast cancer
661131|NCT00068614|stage IIIB breast cancer
661132|NCT00068614|stage IIIC breast cancer
661133|NCT00068601|infertility
661134|NCT00068601|menopausal symptoms
661135|NCT00068601|stage II breast cancer
661136|NCT00068601|stage IIIA breast cancer
661137|NCT00068601|stage IA breast cancer
661138|NCT00068601|stage IB breast cancer
661139|NCT00068601|estrogen receptor-negative breast cancer
661140|NCT00068601|progesterone receptor-negative breast cancer
661141|NCT00068575|stage I pancreatic cancer
661142|NCT00068575|stage II pancreatic cancer
661143|NCT00068575|stage III pancreatic cancer
661144|NCT00068575|adenocarcinoma of the pancreas
661145|NCT00068523|refractory multiple myeloma
661146|NCT00068523|accelerated phase chronic myelogenous leukemia
661147|NCT00068523|adult acute lymphoblastic leukemia in remission
661148|NCT00068523|adult acute myeloid leukemia in remission
661149|NCT00068523|blastic phase chronic myelogenous leukemia
661150|NCT00068523|recurrent adult acute lymphoblastic leukemia
661151|NCT00068523|recurrent adult acute myeloid leukemia
661152|NCT00068523|refractory chronic lymphocytic leukemia
661153|NCT00068523|relapsing chronic myelogenous leukemia
661154|NCT00068523|de novo myelodysplastic syndromes
661155|NCT00068523|previously treated myelodysplastic syndromes
661156|NCT00068523|recurrent adult diffuse large cell lymphoma
661157|NCT00068523|recurrent adult diffuse mixed cell lymphoma
661158|NCT00068523|recurrent adult diffuse small cleaved cell lymphoma
661159|NCT00068523|recurrent adult Burkitt lymphoma
661160|NCT00068523|recurrent adult immunoblastic large cell lymphoma
661161|NCT00068523|recurrent adult lymphoblastic lymphoma
661162|NCT00068523|recurrent grade 1 follicular lymphoma
661163|NCT00068523|recurrent grade 2 follicular lymphoma
661164|NCT00068523|recurrent grade 3 follicular lymphoma
661165|NCT00068523|recurrent mantle cell lymphoma
661166|NCT00068523|refractory anemia with excess blasts in transformation
661167|NCT00068523|refractory anemia with excess blasts
661168|NCT00068523|secondary myelodysplastic syndromes
661169|NCT00068523|Philadelphia chromosome negative chronic myelogenous leukemia
661170|NCT00068523|chronic idiopathic myelofibrosis
661171|NCT00068523|B-cell chronic lymphocytic leukemia
661172|NCT00068523|T-cell large granular lymphocyte leukemia
661173|NCT00068523|chronic phase chronic myelogenous leukemia
661174|NCT00068523|recurrent adult Hodgkin lymphoma
661175|NCT00068523|recurrent adult T-cell leukemia/lymphoma
661176|NCT00068523|stage III chronic lymphocytic leukemia
661177|NCT00068523|stage IV chronic lymphocytic leukemia
661178|NCT00068523|recurrent cutaneous T-cell non-Hodgkin lymphoma
661179|NCT00068523|recurrent mycosis fungoides/Sezary syndrome
661180|NCT00068523|secondary acute myeloid leukemia
661181|NCT00068523|atypical chronic myeloid leukemia
661182|NCT00068523|myelodysplastic/myeloproliferative disease, unclassifiable
661183|NCT00068523|recurrent marginal zone lymphoma
661184|NCT00068523|recurrent small lymphocytic lymphoma
661185|NCT00068523|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
661186|NCT00068523|nodal marginal zone B-cell lymphoma
661187|NCT00068523|splenic marginal zone lymphoma
661188|NCT00068523|adult acute myeloid leukemia with t(8;21)(q22;q22)
661189|NCT00068523|adult acute myeloid leukemia with t(16;16)(p13;q22)
661190|NCT00068523|adult acute myeloid leukemia with inv(16)(p13;q22)
661191|NCT00068523|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
661192|NCT00068523|adult acute myeloid leukemia with t(15;17)(q22;q12)
661193|NCT00068510|adult glioblastoma
661194|NCT00068510|adult anaplastic astrocytoma
661195|NCT00068510|adult brain tumor
661196|NCT00068510|adult giant cell glioblastoma
661197|NCT00068510|adult gliosarcoma
661198|NCT00068510|adult anaplastic oligodendroglioma
661199|NCT00068471|infection
661200|NCT00068471|neutropenia
661201|NCT00068471|unspecified childhood solid tumor, protocol specific
661202|NCT00068458|weight changes
661203|NCT00068458|depression
661204|NCT00068458|stage I breast cancer
661205|NCT00068458|stage II breast cancer
661206|NCT00068458|stage IIIA breast cancer
661207|NCT00068445|neurotoxicity
661208|NCT00068445|pain
661209|NCT00068445|unspecified adult solid tumor, protocol specific
661210|NCT00068432|recurrent pancreatic cancer
661211|NCT00068432|stage IV pancreatic cancer
661212|NCT00068406|squamous cell carcinoma of the vulva
661213|NCT00068406|stage III vulvar cancer
661214|NCT00068406|stage IVB vulvar cancer
661215|NCT00068393|Sarcomatoid
661216|NCT00068393|Gemcitabine
661217|NCT00068393|Doxorubicin
661218|NCT00068393|Renal cell cancer
661219|NCT00068393|Kidney cancer
661220|NCT00068367|adult neurofibrosarcoma
661221|NCT00068367|stage III adult soft tissue sarcoma
661222|NCT00068367|recurrent adult soft tissue sarcoma
661223|NCT00068367|stage II adult soft tissue sarcoma
661224|NCT00068367|stage IV adult soft tissue sarcoma
661225|NCT00068341|stage IIIA breast cancer
661226|NCT00068341|stage IIIB breast cancer
661227|NCT00068341|stage IIIC breast cancer
661228|NCT00068341|stage II breast cancer
661229|NCT00068328|psychosocial effects of cancer and its treatment
661230|NCT00068328|stage II breast cancer
661231|NCT00068328|stage IIIA breast cancer
661232|NCT00068328|stage IIIB breast cancer
661233|NCT00068328|stage IIIC breast cancer
661234|NCT00068328|stage IA breast cancer
661235|NCT00068328|stage IB breast cancer
661236|NCT00068328|estrogen receptor-negative breast cancer
661237|NCT00068328|estrogen receptor-positive breast cancer
661238|NCT00068302|recurrent childhood lymphoblastic lymphoma
661239|NCT00068302|recurrent childhood small noncleaved cell lymphoma
661240|NCT00068302|recurrent childhood large cell lymphoma
661241|NCT00068302|recurrent childhood acute myeloid leukemia
661242|NCT00068302|recurrent childhood acute lymphoblastic leukemia
661243|NCT00068289|extensive stage small cell lung cancer
661244|NCT00068289|recurrent small cell lung cancer
661245|NCT00068276|previously treated myelodysplastic syndromes
661246|NCT00068276|de novo myelodysplastic syndromes
661247|NCT00068276|secondary myelodysplastic syndromes
661248|NCT00068276|atypical chronic myeloid leukemia, BCR-ABL1 negative
661249|NCT00068276|myelodysplastic/myeloproliferative neoplasm, unclassifiable
661250|NCT00068276|childhood myelodysplastic syndromes
661251|NCT00068263|stage I breast cancer
661252|NCT00068263|stage II breast cancer
661627|NCT00066976|Prenatal
661253|NCT00068250|primary central nervous system non-Hodgkin lymphoma
661254|NCT00068250|primary central nervous system Hodgkin lymphoma
661255|NCT00068237|xerostomia
661256|NCT00068237|radiation toxicity
661257|NCT00068237|stage II squamous cell carcinoma of the oropharynx
661258|NCT00068237|stage III squamous cell carcinoma of the oropharynx
661259|NCT00068237|stage I squamous cell carcinoma of the hypopharynx
661260|NCT00068237|stage II squamous cell carcinoma of the hypopharynx
661261|NCT00068237|stage III squamous cell carcinoma of the hypopharynx
661262|NCT00068237|stage III squamous cell carcinoma of the larynx
661263|NCT00068237|untreated metastatic squamous neck cancer with occult primary
661264|NCT00068237|stage IV squamous cell carcinoma of the larynx
661265|NCT00068237|stage IV squamous cell carcinoma of the hypopharynx
661266|NCT00068237|stage IV squamous cell carcinoma of the oropharynx
661267|NCT00068224|Caroli's Syndrome
661268|NCT00068224|Congenital Hepatic Fibrosis
661269|NCT00068224|Ductal Plate Malformation
661270|NCT00068224|Ciliopathy
661271|NCT00068224|Polycystic Kidney
661272|NCT00068224|Polycystic Liver
661273|NCT00068224|Nephronophthisis
661274|NCT00068224|Molar Tooth Sign
661275|NCT00068224|Dandy-Walker Malformation
661276|NCT00068224|Retinopathy
661277|NCT00068224|Situs Inversus
661278|NCT00068224|Heterotaxia
661279|NCT00068224|Cerebellar Vermis Hypoplasia
661280|NCT00068224|Autosomal Recessive Polycystic Kidney Disease
661281|NCT00068224|ARPKD
661282|NCT00068224|Kidney
661283|NCT00068224|Liver
661284|NCT00068211|Metastatic Melanoma
661285|NCT00068211|Melanoma
661286|NCT00068211|Inoperable Locally Advanced Melanoma
661287|NCT00068185|Black cohosh
661288|NCT00068185|Pharmacokinetics
661289|NCT00068185|Alternative therapies
661290|NCT00068185|Natural product
661291|NCT00068159|Hereditary Disease
661292|NCT00068159|Diastolic Dysfunction
661293|NCT00068159|Exercise Tolerance
661294|NCT00068159|Exercise Stress Echocardiography
661295|NCT00068159|MRI
661296|NCT00068159|Hereditary Hemochromatosis
661297|NCT00068159|HH
661298|NCT00068159|Iron Overload
661299|NCT00068146|Adenopathy
661300|NCT00068146|Genetic Disorder
661301|NCT00068146|Apoptosis
661302|NCT00068146|Diagnostic Imaging
661303|NCT00068146|Hodgkins
661304|NCT00068146|Autoimmune Lymphoproliferative
661305|NCT00068146|Syndrome
661306|NCT00068146|ALPS
661307|NCT00068146|ALPS-Associated Lymphoma
661308|NCT00068120|Urinary tract infection
661309|NCT00068107|Lysosomal Storage
661310|NCT00068107|Renal Insufficiency
661311|NCT00068107|Stroke
661312|NCT00068107|Hypohidrosis
661313|NCT00068107|Peripheral Neuropathy
661314|NCT00068107|Fabry Disease
661315|NCT00068094|Probiotics
661316|NCT00068094|Bacteria
661317|NCT00068081|Dermal assessment
661318|NCT00068081|Pain measurement
661319|NCT00068081|Diary
661320|NCT00068081|Analgesics/*therapeutic use
661321|NCT00068081|Capsaicin/*administration & dosage/adverse effects
661322|NCT00068081|Herpes zoster/*complication/drug therapy
661323|NCT00068081|Neuralgia/*drug therapy/etiology
661324|NCT00068081|Pain
661325|NCT00068081|Peripheral nervous system diseases/*complications
661326|NCT00068068|Photodynamic therapy
661327|NCT00068068|Liver metastases
661328|NCT00068068|Colorectal cancer
661329|NCT00068068|Litx™
661330|NCT00068068|Light Infusion Technology™
661331|NCT00068068|Talaporfin sodium
661332|NCT00068068|LS11
661333|NCT00068068|Liver mets
661334|NCT00068068|Metastatic colorectal cancer
661335|NCT00068068|Light emittting diodes (LED)
661336|NCT00068068|Tumor ablation
661337|NCT00068068|Combination therapy
661338|NCT00068055|West Nile Virus, encephalitis, myelitis, immunoglobulin G
661339|NCT00068003|Adoptive Cell Therapy
661340|NCT00068003|Screening
661341|NCT00068003|Cell Harvest
661342|NCT00068003|Blood
661343|NCT00068003|Tumor Tissue
661344|NCT00067990|chronic allograft nephropathy
661345|NCT00067990|post transplant proteinuria
661346|NCT00067977|PKD
661347|NCT00067977|ADPKD
661348|NCT00067977|polycystic kidney disease
661349|NCT00067977|autosomal dominant polycystic kidney disease
661350|NCT00067951|Hyperglycemia
661351|NCT00067951|HbA1c
661352|NCT00067951|Hemoglobin A1c
661353|NCT00067951|Type 2 diabetes mellitus
661354|NCT00067938|bipolar disorder
661355|NCT00067938|lamotrigine
661356|NCT00067925|Weight-bearing physical activity
661357|NCT00067925|Calcium intake
661358|NCT00067925|School-based health education
661359|NCT00067925|Adolescent girls
661360|NCT00067925|Child nutrition
661361|NCT00067925|Diet
661362|NCT00067899|cigarette smoking
661363|NCT00067899|tocopherol
661364|NCT00067899|bioavailability
661365|NCT00067899|metabolism
661366|NCT00067899|oxidative stress
661367|NCT00067847|obesity
661368|NCT00067847|food policy
661369|NCT00067847|physical fitness (Respiratory Burst)
661370|NCT00067847|academic achievement
661371|NCT00067834|Electromagnetic Fields
661372|NCT00067834|Bone
661373|NCT00067834|Forelimb
661374|NCT00067834|Radius
661375|NCT00067821|Brain Tumor
661376|NCT00067821|Children
661377|NCT00067821|Metabolic
661378|NCT00067821|Spectroscopy
661379|NCT00067821|PET
661380|NCT00067808|Myelodysplastic Syndrome
661381|NCT00067808|Chronic Myelomonocytic Leukemia
661382|NCT00067808|MDS
661383|NCT00067808|Decitabine
661384|NCT00067808|Dacogen
661385|NCT00067808|Methylation
661386|NCT00067795|Treatment Experienced
661387|NCT00067795|Antiretroviral Therapy, Highly Active
661388|NCT00067795|HIV Antigens
661389|NCT00067795|Cohort Studies
661390|NCT00067795|Immunity, Cellular
661391|NCT00067795|T-Lymphocytes
661392|NCT00067782|HIV
661393|NCT00067782|Treatment Experienced
661394|NCT00067769|Encopresis
661395|NCT00067769|Internet
661396|NCT00067769|Web
661397|NCT00067769|Treatment
661398|NCT00067769|Intervention
661399|NCT00067756|Pulmonary Disease
661400|NCT00067756|Liver Disease
661401|NCT00067743|Pain
661402|NCT00067743|Pain syndrome
661403|NCT00067743|Reflex sympathetic dystrophy
661404|NCT00067743|CC-5013
661405|NCT00067743|CC5013
661406|NCT00067743|Revlimid
661407|NCT00067743|Celgene
661408|NCT00067743|CRPS
661409|NCT00067717|breast reconstruction surgery
661410|NCT00067717|prayer
661411|NCT00067717|distance healing
661412|NCT00067717|wound healing
661413|NCT00067704|Complementary Therapies
661414|NCT00067691|Lung cancer
661415|NCT00067691|Breast cancer
661416|NCT00067691|Shortness of breath
661417|NCT00067691|Dyspnea
661418|NCT00067691|Metastasis
661419|NCT00067691|Breathlessness
661420|NCT00067691|Acupuncture
661421|NCT00067678|diabetic nephropathy
661422|NCT00067678|nephropathy
661423|NCT00067678|diabetes
661424|NCT00067678|diabetes mellitus
661425|NCT00067678|type I diabetes
661426|NCT00067678|soy protein
661427|NCT00067665|hemodialysis
661428|NCT00067639|Multiple Myeloma
661429|NCT00067639|PBSC mobilization
661430|NCT00067639|Pegfilgrastim
661431|NCT00067639|Neulasta
661432|NCT00067639|PEG-G-CSF
661433|NCT00067626|glucose tolerance test
661434|NCT00067626|minerals
661435|NCT00067626|chromium
661436|NCT00067626|complementary and alternative medicine
661437|NCT00067613|NICHD Neonatal Research Network
661438|NCT00067613|Extremely Low Birth Weight (ELBW)
661439|NCT00067613|Very Low Birth Weight (VLBW)
661440|NCT00067613|Prematurity
661441|NCT00067613|Mechanical ventilation
661442|NCT00067613|Benchmarking
661443|NCT00067613|Chronic Lung Disease (CLD)
661444|NCT00067587|Treatment experienced
661445|NCT00067587|Treatment naive
661446|NCT00067574|Structured treatment interruption
661447|NCT00067574|Treatment experienced
661448|NCT00067561|Dose-ranging
661449|NCT00067561|Diarrhea-Predominant Irritable Bowel Syndrome
661450|NCT00067561|d-IBS
661451|NCT00067561|IBS
661452|NCT00067561|Irritable Bowel Syndrome
661453|NCT00067548|Advanced Non-Small Cell Lung Cancer
661454|NCT00067535|cocaine dependence
661455|NCT00067522|Family Planning
661456|NCT00067522|Sexually Transmitted Diseases
661457|NCT00067522|HIV
661458|NCT00067522|Africa
661459|NCT00067522|Zambia
661460|NCT00067522|AIDS
661461|NCT00067522|Contraception
661462|NCT00067522|HIV Prevention
661463|NCT00067509|Female
661464|NCT00067496|Pain
661465|NCT00067496|Weakness
661466|NCT00067496|Depression
661467|NCT00067496|Poliomyelitis
661468|NCT00067496|Sleep Apnea
661469|NCT00067496|Post-Polio Syndrome
661470|NCT00067496|PPS
661471|NCT00067483|Cataract
661472|NCT00067483|Pre-Senile
661473|NCT00067483|Dynamic Light Scattering (DLS)
661474|NCT00067483|Light Scattering
661475|NCT00067483|Lens
661476|NCT00067483|Cataracts
661477|NCT00067457|PRN
661478|NCT00067457|Diarrhea-Predominant Irritable Bowel Syndrome
661479|NCT00067457|Irritable Bowel Syndrome (IBS)
661480|NCT00067444|Elderly
661481|NCT00067444|Major Depressive Disorder
661482|NCT00067444|MDD
661483|NCT00067431|Partial Seizures
661484|NCT00067418|Glioma
661485|NCT00067418|Brain Tumor
661486|NCT00067418|Spectroscopy
661487|NCT00067405|Fibromyalgia
661488|NCT00067405|Intravenous micronutrient therapy
661489|NCT00067405|IVMT
661490|NCT00067405|alternative medicine
661491|NCT00067405|complementary medicine
661492|NCT00067405|vitamins
661493|NCT00067405|vitamin supplements
661494|NCT00067392|Partial edentulism
661495|NCT00067392|Bone atrophy
661496|NCT00067392|Bone healing
661497|NCT00067353|Early Childhood Caries
661498|NCT00067327|Relapsing remitting multiple sclerosis
661499|NCT00067327|Multiple sclerosis
661500|NCT00067327|Peroxynitrite
661501|NCT00067327|Uric acid
661502|NCT00067327|Inosine
661503|NCT00067301|depression
661504|NCT00067301|citalopram
661505|NCT00067301|Celexa
661506|NCT00067301|Polyunsaturated Fatty Acids
661507|NCT00067301|omega-3
661508|NCT00067301|EPA
661509|NCT00067301|antidepressants
661510|NCT00067288|Stage 3 cancer;
661511|NCT00067288|Stage 4 cancer;
661512|NCT00067288|solid tumor cancer;
661513|NCT00067288|Non-Hodgkin's Lymphoma;
661514|NCT00067288|solid tumors;
661515|NCT00067288|end-stage cancer;
661516|NCT00067288|group psychotherapy;
661517|NCT00067288|psychotherapy;
661518|NCT00067288|emotional support;
661519|NCT00067288|support groups
661520|NCT00067275|Stroke
661521|NCT00067275|Motor Training
661522|NCT00067275|Positron Emission Tomograhy
661523|NCT00067275|Plasticity
661524|NCT00067275|Transcranial Magnetic Stimulation
661525|NCT00067275|Healthy Volunteer
661526|NCT00067275|HV
661527|NCT00067262|Bipolar Disorder Type 1 (manic or mixed type)
661528|NCT00067249|Race
661529|NCT00067249|Ethnicity
661530|NCT00067249|Complementary and Alternative Medicine
661531|NCT00067249|Women's health
661532|NCT00067249|Social determinants of Health
661533|NCT00067223|Transcranial Magnetic Stimulation (TMS)
661534|NCT00067223|Unilateral Finger Movement
661535|NCT00067223|Interhemispheric Inhibition
661536|NCT00067223|Motor Training
661537|NCT00067223|Plasticity
661538|NCT00067223|Healthy Volunteer
661539|NCT00067223|HV
661540|NCT00067210|Brain
661541|NCT00067210|Epilepsy
661542|NCT00067210|Core
661543|NCT00067210|Temperature
661544|NCT00067197|Transcranial Direct Current Stimulation (tDCS)
661545|NCT00067197|Cortical Reorganization
661546|NCT00067197|Rehabilitation
661547|NCT00067197|Motor Learning
661548|NCT00067197|Activity of Daily Living (ADL)
661549|NCT00067197|Stroke
661550|NCT00067197|Healthy Volunteer
661551|NCT00067197|HV
661552|NCT00067184|methadone
661553|NCT00067184|fetus
661554|NCT00067171|behavioral intervention
661555|NCT00067158|nicotine dependence
661556|NCT00067119|Graft Failure
661557|NCT00067119|Access Blood Flow Monitoring
661558|NCT00067119|Clinical Trial Vascular Access
661559|NCT00067119|Fistula Failure
661560|NCT00067119|Hemodialysis
661561|NCT00067119|Vascular Access
661562|NCT00067106|HIV
661563|NCT00067106|Women
661564|NCT00067106|Genital tract
661565|NCT00067106|Treatment experienced
661566|NCT00067106|Drug resistance
661567|NCT00067080|Sickle cell disease
661568|NCT00067080|iron overload
661569|NCT00067080|deferoxamine
661570|NCT00067080|hemosiderosis
661571|NCT00067067|Glioma
661572|NCT00067067|Brain Tumor
661573|NCT00067067|Endothelial Progenitor Cells
661574|NCT00067054|Volunteer
661575|NCT00067054|Plasmapheresis
661576|NCT00067054|Leukapheresis
661577|NCT00067054|Immunology
661578|NCT00067054|Leukocyte
661579|NCT00067054|Healthy Volunteer
661580|NCT00067054|HV
661581|NCT00067041|Critical Limb Ischemia
661582|NCT00067041|Autogenous Bypass Graft
661583|NCT00067041|CLI
661584|NCT00067028|Chronic Myeloid Leukemia
661585|NCT00067028|CML Myeloid Blast Phase
661586|NCT00067028|Acute Myeloid Leukemia
661587|NCT00067028|Myelodysplastic Syndrome
661588|NCT00067028|Clofarabine
661589|NCT00067028|Clofarex
661590|NCT00067028|Clolar
661591|NCT00067028|Ara-C
661592|NCT00067028|Cytarabine
661593|NCT00067028|Cytosar
661594|NCT00067028|DepoCyt
661595|NCT00067028|Cytosine arabinosine hydrochloride
661596|NCT00067028|Idarubicin
661597|NCT00067028|Idamycin
661598|NCT00067015|adenocarcinoma of the prostate
661599|NCT00067015|stage III prostate cancer
661600|NCT00067002|ALL
661601|NCT00067002|Leukemia, Lymphocytic, Acute
661602|NCT00067002|AML
661603|NCT00067002|Leukemia, Myelocytic, Acute
661604|NCT00067002|CML
661605|NCT00067002|Leukemia, Myeloid, Chronic
661606|NCT00067002|NHL
661607|NCT00067002|Lymphoma, Non-Hodgkin
661608|NCT00067002|double cord blood transplant
661609|NCT00067002|expanded cord blood transplant
661610|NCT00067002|Rituxan
661611|NCT00067002|Rituximab
661612|NCT00067002|Melphalan
661613|NCT00067002|Alkeran
661614|NCT00067002|Thiotepa
661615|NCT00067002|Fludarabine
661616|NCT00067002|Fludarabine phosphate
661617|NCT00067002|Fludara
661618|NCT00067002|Cyclophosphamide
661619|NCT00067002|Cytoxan
661620|NCT00067002|Neosar
661621|NCT00067002|Mesna
661622|NCT00067002|Mesnex
661623|NCT00066989|Staphylococcal infection
661624|NCT00066989|Gram positive bacteria
661625|NCT00066989|Staphylococcus
661626|NCT00066989|Staphylococcus aureus
661628|NCT00066976|Respiration
661629|NCT00066976|Ultrasound
661630|NCT00066976|Prematurity
661631|NCT00066976|Diagnoses
661632|NCT00066976|Fetal Breathing-Movement
661633|NCT00066976|Doppler Sonography
661634|NCT00066976|Amniotic Fluid
661635|NCT00066976|Oligohydraminos
661636|NCT00066976|Polyhydraminos
661637|NCT00066976|Pregnancy
661638|NCT00066963|Early Childhood Caries
661639|NCT00066950|Early childhood caries
661640|NCT00066924|spirituality
661641|NCT00066924|religiosity
661642|NCT00066924|immune functioning
661643|NCT00066924|psychoneuroimmunology
661644|NCT00066924|cytokines
661645|NCT00066924|cancer
661646|NCT00066924|death
661647|NCT00066924|depression
661648|NCT00066911|Functional Magnetic Resonance Imaging
661649|NCT00066911|Vocalization
661650|NCT00066911|Spasmodic Dysphonia
661651|NCT00066911|Muscular Tension Dysphonia
661652|NCT00066911|Topical Lidocaine
661653|NCT00066911|Voice Disorders
661654|NCT00066911|Vocal Tremor
661655|NCT00066911|Healthy Volunteer
661656|NCT00066911|HV
661657|NCT00066898|succinobucol
661658|NCT00066898|AGI-1067
661659|NCT00066898|coronary artery disease
661660|NCT00066885|DN101
661661|NCT00066885|Calcitriol
661662|NCT00066885|Lung Cancer
661663|NCT00066885|NSCLC
661664|NCT00066885|Taxotere
661665|NCT00066872|basal cell carcinoma of the skin
661666|NCT00066859|depression
661667|NCT00066859|unspecified adult solid tumor, protocol specific
661668|NCT00066846|adenocarcinoma of the colon
661669|NCT00066846|adenocarcinoma of the rectum
661670|NCT00066846|stage IV rectal cancer
661671|NCT00066846|recurrent rectal cancer
661672|NCT00066846|stage IV colon cancer
661673|NCT00066846|recurrent colon cancer
661674|NCT00066807|stage IIIA breast cancer
661675|NCT00066807|stage I breast cancer
661676|NCT00066807|stage II breast cancer
661677|NCT00066794|adult acute monocytic leukemia (M5b)
661678|NCT00066794|adult acute megakaryoblastic leukemia (M7)
661679|NCT00066794|adult acute minimally differentiated myeloid leukemia (M0)
661680|NCT00066794|adult acute myeloblastic leukemia with maturation (M2)
661681|NCT00066794|adult acute myeloblastic leukemia without maturation (M1)
661682|NCT00066794|adult acute myelomonocytic leukemia (M4)
661683|NCT00066794|adult acute monoblastic leukemia (M5a)
661684|NCT00066794|untreated adult acute myeloid leukemia
661685|NCT00066794|adult acute myeloid leukemia with t(8;21)(q22;q22)
661686|NCT00066794|adult acute myeloid leukemia with t(16;16)(p13;q22)
661687|NCT00066794|adult acute myeloid leukemia with inv(16)(p13;q22)
661688|NCT00066794|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
661689|NCT00066794|adult pure erythroid leukemia (M6b)
661690|NCT00066794|adult erythroleukemia (M6a)
661691|NCT00066781|adenocarcinoma of unknown primary
661692|NCT00066781|newly diagnosed carcinoma of unknown primary
661693|NCT00066781|squamous cell carcinoma of unknown primary
661694|NCT00066781|undifferentiated carcinoma of unknown primary
661695|NCT00066729|stage II ovarian epithelial cancer
661696|NCT00066729|stage III ovarian epithelial cancer
661697|NCT00066729|stage IV ovarian epithelial cancer
661698|NCT00066729|primary peritoneal cavity cancer
661699|NCT00066729|fallopian tube cancer
661700|NCT00066716|adenocarcinoma of the esophagus
661701|NCT00066716|squamous cell carcinoma of the esophagus
661702|NCT00066716|stage I esophageal cancer
661703|NCT00066716|stage II esophageal cancer
661704|NCT00066716|stage III esophageal cancer
661705|NCT00066716|stage IV esophageal cancer (lymph node metastasis only)
661706|NCT00066703|stage II breast cancer
661707|NCT00066703|stage IIIA breast cancer
661708|NCT00066703|estrogen receptor-positive breast cancer
661709|NCT00066703|progesterone receptor-positive breast cancer
661710|NCT00066703|stage IA breast cancer
661711|NCT00066703|stage IB breast cancer
661712|NCT00066690|tamoxifen
661713|NCT00066690|ovarian function suppression + tamoxifen
661714|NCT00066690|ovarian function suppression + exemestane
661715|NCT00066677|adenocarcinoma of the pancreas
661716|NCT00066677|recurrent pancreatic cancer
661717|NCT00066677|stage IV pancreatic cancer
661718|NCT00066664|recurrent cutaneous T-cell non-Hodgkin lymphoma
661719|NCT00066664|stage I cutaneous T-cell non-Hodgkin lymphoma
661720|NCT00066664|stage II cutaneous T-cell non-Hodgkin lymphoma
661721|NCT00066664|stage III cutaneous T-cell non-Hodgkin lymphoma
661722|NCT00066664|stage IV cutaneous T-cell non-Hodgkin lymphoma
661723|NCT00066664|recurrent mycosis fungoides/Sezary syndrome
661724|NCT00066664|stage I mycosis fungoides/Sezary syndrome
661725|NCT00066664|stage II mycosis fungoides/Sezary syndrome
661726|NCT00066664|stage III mycosis fungoides/Sezary syndrome
661727|NCT00066664|stage IV mycosis fungoides/Sezary syndrome
661728|NCT00066651|ovarian carcinosarcoma
661729|NCT00066651|ovarian clear cell cystadenocarcinoma
661730|NCT00066651|ovarian endometrioid adenocarcinoma
661731|NCT00066651|ovarian mixed epithelial carcinoma
661732|NCT00066651|ovarian serous cystadenocarcinoma
661733|NCT00066651|ovarian undifferentiated adenocarcinoma
661734|NCT00066651|recurrent ovarian epithelial cancer
661735|NCT00066651|Brenner tumor
661736|NCT00066651|primary peritoneal cavity cancer
661737|NCT00066651|fallopian tube cancer
661738|NCT00066651|epithelial mesothelioma
661739|NCT00066651|recurrent malignant mesothelioma
661740|NCT00066651|recurrent pancreatic cancer
661741|NCT00066651|cervical squamous cell carcinoma
661742|NCT00066651|recurrent cervical cancer
661743|NCT00066651|recurrent non-small cell lung cancer
661744|NCT00066651|squamous cell lung cancer
661745|NCT00066651|recurrent squamous cell carcinoma of the lip and oral cavity
661746|NCT00066651|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
661747|NCT00066651|recurrent metastatic squamous neck cancer with occult primary
661748|NCT00066651|recurrent salivary gland cancer
661749|NCT00066651|salivary gland squamous cell carcinoma
661750|NCT00066651|recurrent squamous cell carcinoma of the hypopharynx
661751|NCT00066651|recurrent squamous cell carcinoma of the larynx
661752|NCT00066651|recurrent squamous cell carcinoma of the oropharynx
661753|NCT00066651|recurrent squamous cell carcinoma of the nasopharynx
661754|NCT00066612|recurrent bladder cancer
661755|NCT00066612|stage IV bladder cancer
661756|NCT00066612|metastatic transitional cell cancer of the renal pelvis and ureter
661757|NCT00066612|recurrent transitional cell cancer of the renal pelvis and ureter
661758|NCT00066612|regional transitional cell cancer of the renal pelvis and ureter
661759|NCT00066612|transitional cell carcinoma of the bladder
661760|NCT00066612|anterior urethral cancer
661761|NCT00066612|posterior urethral cancer
661762|NCT00066612|recurrent urethral cancer
661763|NCT00066612|urethral cancer associated with invasive bladder cancer
661764|NCT00066599|neutropenia
661765|NCT00066599|recurrent childhood lymphoblastic lymphoma
661766|NCT00066599|stage I childhood lymphoblastic lymphoma
661767|NCT00066599|stage II childhood lymphoblastic lymphoma
661768|NCT00066599|stage III childhood lymphoblastic lymphoma
661769|NCT00066599|stage IV childhood lymphoblastic lymphoma
661770|NCT00066599|recurrent childhood small noncleaved cell lymphoma
661771|NCT00066599|stage I childhood small noncleaved cell lymphoma
661772|NCT00066599|stage II childhood small noncleaved cell lymphoma
661773|NCT00066599|stage III childhood small noncleaved cell lymphoma
661774|NCT00066599|stage IV childhood small noncleaved cell lymphoma
661775|NCT00066599|recurrent childhood large cell lymphoma
661776|NCT00066599|stage I childhood large cell lymphoma
661777|NCT00066599|stage II childhood large cell lymphoma
661778|NCT00066599|stage III childhood large cell lymphoma
661779|NCT00066599|stage IV childhood large cell lymphoma
661780|NCT00066599|childhood acute myeloid leukemia in remission
661781|NCT00066599|recurrent childhood acute myeloid leukemia
661782|NCT00066599|untreated childhood acute myeloid leukemia and other myeloid malignancies
661783|NCT00066599|recurrent/refractory childhood Hodgkin lymphoma
661784|NCT00066599|stage I childhood Hodgkin lymphoma
661785|NCT00066599|stage II childhood Hodgkin lymphoma
661786|NCT00066599|stage III childhood Hodgkin lymphoma
661787|NCT00066599|stage IV childhood Hodgkin lymphoma
661788|NCT00066599|childhood acute promyelocytic leukemia (M3)
661789|NCT00066599|previously treated childhood rhabdomyosarcoma
661790|NCT00066599|recurrent Wilms tumor and other childhood kidney tumors
661791|NCT00066599|recurrent childhood rhabdomyosarcoma
661792|NCT00066599|childhood chronic myelogenous leukemia
661793|NCT00066599|accelerated phase chronic myelogenous leukemia
661794|NCT00066599|blastic phase chronic myelogenous leukemia
661795|NCT00066599|chronic phase chronic myelogenous leukemia
661796|NCT00066599|meningeal chronic myelogenous leukemia
661797|NCT00066599|relapsing chronic myelogenous leukemia
661798|NCT00066599|anaplastic large cell lymphoma
661799|NCT00066599|angioimmunoblastic T-cell lymphoma
661800|NCT00066599|intraocular lymphoma
661801|NCT00066599|primary central nervous system non-Hodgkin lymphoma
661802|NCT00066599|recurrent adult T-cell leukemia/lymphoma
661803|NCT00066599|acute undifferentiated leukemia
661804|NCT00066599|childhood acute lymphoblastic leukemia in remission
661805|NCT00066599|recurrent childhood acute lymphoblastic leukemia
661806|NCT00066599|secondary acute myeloid leukemia
661807|NCT00066599|untreated childhood acute lymphoblastic leukemia
661808|NCT00066599|disseminated neuroblastoma
661809|NCT00066599|de novo myelodysplastic syndromes
661810|NCT00066599|previously treated myelodysplastic syndromes
661811|NCT00066599|secondary myelodysplastic syndromes
661812|NCT00066599|stage I multiple myeloma
661813|NCT00066599|stage II multiple myeloma
661814|NCT00066599|stage III multiple myeloma
661815|NCT00066599|refractory multiple myeloma
661816|NCT00066599|stage I cutaneous T-cell non-Hodgkin lymphoma
661817|NCT00066599|stage II cutaneous T-cell non-Hodgkin lymphoma
661818|NCT00066599|stage III cutaneous T-cell non-Hodgkin lymphoma
661819|NCT00066599|stage IV cutaneous T-cell non-Hodgkin lymphoma
661820|NCT00066599|recurrent neuroblastoma
661821|NCT00066599|atypical chronic myeloid leukemia, BCR-ABL1 negative
661822|NCT00066599|myelodysplastic/myeloproliferative neoplasm, unclassifiable
661823|NCT00066586|breast cancer
661824|NCT00066573|stage IIIA breast cancer
661825|NCT00066573|stage I breast cancer
661826|NCT00066573|stage II breast cancer
661827|NCT00066547|recurrent breast cancer
661828|NCT00066547|stage IIIA breast cancer
661829|NCT00066547|stage IIIB breast cancer
661830|NCT00066547|stage IIIC breast cancer
661831|NCT00066547|stage IV breast cancer
661832|NCT00066508|recurrent adult diffuse large cell lymphoma
661833|NCT00066482|childhood teratoma
661834|NCT00066482|childhood extragonadal germ cell tumor
661835|NCT00066469|post-transplant lymphoproliferative disorder
661836|NCT00066443|stage IIIA breast cancer
661837|NCT00066443|stage IIIB breast cancer
661838|NCT00066443|stage IIIC breast cancer
661839|NCT00066443|inflammatory breast cancer
661840|NCT00066430|anal cancer
661841|NCT00066430|high-grade squamous intraepithelial lesion
661842|NCT00066417|essential thrombocythemia
661843|NCT00066417|polycythemia vera
661844|NCT00066417|blastic phase chronic myelogenous leukemia
661845|NCT00066417|secondary myelodysplastic syndromes
661846|NCT00066417|previously treated myelodysplastic syndromes
661847|NCT00066417|adult acute myeloid leukemia in remission
661848|NCT00066417|childhood acute myeloid leukemia in remission
661849|NCT00066417|de novo myelodysplastic syndromes
661850|NCT00066417|secondary acute myeloid leukemia
661851|NCT00066417|accelerated phase chronic myelogenous leukemia
661852|NCT00066417|childhood chronic myelogenous leukemia
661853|NCT00066417|adult acute lymphoblastic leukemia in remission
661854|NCT00066417|childhood acute lymphoblastic leukemia in remission
661855|NCT00066417|recurrent adult acute myeloid leukemia
661856|NCT00066417|relapsing chronic myelogenous leukemia
661857|NCT00066417|recurrent childhood acute myeloid leukemia
661858|NCT00066417|chronic idiopathic myelofibrosis
661859|NCT00066417|atypical chronic myeloid leukemia
661860|NCT00066417|myelodysplastic/myeloproliferative disease, unclassifiable
661861|NCT00066417|adult acute myeloid leukemia with t(8;21)(q22;q22)
661862|NCT00066417|adult acute myeloid leukemia with t(16;16)(p13;q22)
661863|NCT00066417|adult acute myeloid leukemia with inv(16)(p13;q22)
661864|NCT00066417|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
661865|NCT00066417|adult acute myeloid leukemia with t(15;17)(q22;q12)
661866|NCT00066404|advanced malignant mesothelioma
661867|NCT00066404|male breast cancer
661868|NCT00066404|localized malignant mesothelioma
661869|NCT00066404|recurrent bladder cancer
661870|NCT00066404|recurrent renal cell cancer
661871|NCT00066404|recurrent urethral cancer
661872|NCT00066404|recurrent breast cancer
661873|NCT00066404|recurrent penile cancer
661874|NCT00066404|recurrent prostate cancer
661875|NCT00066404|recurrent anal cancer
661876|NCT00066404|recurrent colon cancer
661877|NCT00066404|recurrent esophageal cancer
661878|NCT00066404|recurrent gastric cancer
661879|NCT00066404|recurrent pancreatic cancer
661880|NCT00066404|recurrent rectal cancer
661881|NCT00066404|recurrent gastrointestinal carcinoid tumor
661882|NCT00066404|recurrent small intestine cancer
661883|NCT00066404|recurrent gallbladder cancer
661884|NCT00066404|recurrent extrahepatic bile duct cancer
661885|NCT00066404|recurrent adult primary liver cancer
661886|NCT00066404|recurrent non-small cell lung cancer
661887|NCT00066404|recurrent small cell lung cancer
661888|NCT00066404|recurrent thymoma and thymic carcinoma
661889|NCT00066404|recurrent melanoma
661890|NCT00066404|recurrent malignant mesothelioma
661891|NCT00066404|recurrent malignant testicular germ cell tumor
661892|NCT00066404|recurrent cervical cancer
661893|NCT00066404|recurrent ovarian epithelial cancer
661894|NCT00066404|fallopian tube cancer
661895|NCT00066404|recurrent vulvar cancer
661896|NCT00066404|recurrent vaginal cancer
661897|NCT00066404|recurrent gestational trophoblastic tumor
661898|NCT00066404|recurrent endometrial carcinoma
661899|NCT00066404|recurrent ovarian germ cell tumor
661900|NCT00066404|malignant pleural effusion
661901|NCT00066391|penile squamous cell carcinoma
661902|NCT00066391|stage III penile cancer
661903|NCT00066391|stage IV penile cancer
661904|NCT00066378|recurrent breast cancer
661905|NCT00066378|stage IIIA breast cancer
661906|NCT00066378|stage IIIB breast cancer
661907|NCT00066378|stage IIIC breast cancer
661908|NCT00066378|stage IV breast cancer
661909|NCT00066365|metastatic osteosarcoma
661910|NCT00066365|recurrent osteosarcoma
661911|NCT00066365|lung metastases
661912|NCT00066352|recurrent bladder cancer
661913|NCT00066352|stage IV bladder cancer
661914|NCT00066352|metastatic transitional cell cancer of the renal pelvis and ureter
661915|NCT00066352|recurrent transitional cell cancer of the renal pelvis and ureter
661916|NCT00066352|regional transitional cell cancer of the renal pelvis and ureter
661917|NCT00066352|transitional cell carcinoma of the bladder
661918|NCT00066339|stage IV breast cancer
661919|NCT00066339|recurrent breast cancer
661920|NCT00066326|blastic phase chronic myelogenous leukemia
661921|NCT00066326|Philadelphia chromosome positive chronic myelogenous leukemia
661922|NCT00066326|chronic phase chronic myelogenous leukemia
661923|NCT00066326|accelerated phase chronic myelogenous leukemia
661924|NCT00066326|relapsing chronic myelogenous leukemia
661925|NCT00066313|extensive stage small cell lung cancer
662025|NCT00066157|Postmenopausal women
661926|NCT00066313|limited stage small cell lung cancer
661927|NCT00066274|stage IV colon cancer
661928|NCT00066274|stage IV rectal cancer
661929|NCT00066248|cachexia
661930|NCT00066248|unspecified childhood solid tumor
661931|NCT00066248|childhood spinal cord neoplasm
661932|NCT00066248|recurrent childhood medulloblastoma
661933|NCT00066248|untreated childhood medulloblastoma
661934|NCT00066248|childhood high-grade cerebral astrocytoma
661935|NCT00066248|childhood low-grade cerebral astrocytoma
661936|NCT00066248|recurrent childhood cerebellar astrocytoma
661937|NCT00066248|recurrent childhood cerebral astrocytoma
661938|NCT00066248|untreated childhood cerebellar astrocytoma
661939|NCT00066248|childhood oligodendroglioma
661940|NCT00066248|recurrent childhood brain stem glioma
661941|NCT00066248|recurrent childhood visual pathway glioma
661942|NCT00066248|hypothalamic glioma
661943|NCT00066248|untreated childhood brain stem glioma
661944|NCT00066248|untreated childhood visual pathway
661945|NCT00066248|childhood supratentorial primitive neuroectodermal tumor
661946|NCT00066248|childhood craniopharyngioma
661947|NCT00066248|childhood infratentorial ependymoma
661948|NCT00066248|childhood supratentorial ependymoma
661949|NCT00066248|newly diagnosed childhood ependymoma
661950|NCT00066248|recurrent childhood ependymoma
661951|NCT00066248|childhood choroid plexus tumor
661952|NCT00066248|childhood central nervous system germ cell tumor
661953|NCT00066248|childhood acute lymphoblastic leukemia in remission
661954|NCT00066248|recurrent childhood acute lymphoblastic leukemia
661955|NCT00066248|untreated childhood acute lymphoblastic leukemia
661956|NCT00066248|childhood acute myeloid leukemia in remission
661957|NCT00066248|recurrent childhood acute myeloid leukemia
661958|NCT00066248|untreated childhood acute myeloid leukemia
661959|NCT00066248|other myeloid malignancies
661960|NCT00066248|refractory chronic lymphocytic leukemia
661961|NCT00066248|stage I chronic lymphocytic leukemia
661962|NCT00066248|stage II chronic lymphocytic leukemia
661963|NCT00066248|stage III chronic lymphocytic leukemia
661964|NCT00066248|stage IV chronic lymphocytic leukemia
661965|NCT00066248|accelerated phase chronic myelogenous leukemia
661966|NCT00066248|blastic phase chronic myelogenous leukemia
661967|NCT00066248|chronic phase chronic myelogenous leukemia
661968|NCT00066248|meningeal chronic myelogenous leukemia
661969|NCT00066248|relapsing chronic myelogenous leukemia
661970|NCT00066248|juvenile myelomonocytic leukemia
661971|NCT00066248|recurrent/refractory childhood Hodgkin lymphoma
661972|NCT00066248|stage I childhood Hodgkin lymphoma
661973|NCT00066248|stage II childhood Hodgkin lymphoma
661974|NCT00066248|stage III childhood Hodgkin lymphoma
661975|NCT00066248|stage IV childhood Hodgkin lymphoma
661976|NCT00066248|AIDS-related peripheral/systemic lymphoma
661977|NCT00066248|AIDS-related primary CNS lymphoma
661978|NCT00066248|progressive hairy cell leukemia, initial treatment
661979|NCT00066248|refractory hairy cell leukemia
661980|NCT00066248|untreated hairy cell leukemia
661981|NCT00066248|recurrent childhood lymphoblastic lymphoma
661982|NCT00066248|stage I childhood lymphoblastic lymphoma
661983|NCT00066248|stage II childhood lymphoblastic lymphoma
661984|NCT00066248|stage III childhood lymphoblastic lymphoma
661985|NCT00066248|stage IV childhood lymphoblastic lymphoma
661986|NCT00066248|recurrent childhood small noncleaved cell lymphoma
661987|NCT00066248|stage I childhood small noncleaved cell lymphoma
661988|NCT00066248|stage II childhood small noncleaved cell lymphoma
661989|NCT00066248|stage III childhood small noncleaved cell lymphoma
661990|NCT00066248|stage IV childhood small noncleaved cell lymphoma
661991|NCT00066248|recurrent childhood large cell lymphoma
661992|NCT00066248|stage I childhood large cell lymphoma
661993|NCT00066248|stage II childhood large cell lymphoma
661994|NCT00066248|stage III childhood large cell lymphoma
661995|NCT00066248|stage IV childhood large cell lymphoma
661996|NCT00066248|recurrent childhood brain tumor
661997|NCT00066248|atypical chronic myeloid leukemia
661998|NCT00066248|myelodysplastic/myeloproliferative disease
661999|NCT00066248|childhood chronic myelogenous leukemia
662000|NCT00066248|de novo myelodysplastic syndromes
662001|NCT00066248|previously treated myelodysplastic syndromes
662002|NCT00066248|secondary myelodysplastic syndromes
662003|NCT00066248|chronic myelomonocytic leukemia
662004|NCT00066222|limited stage small cell lung cancer
662005|NCT00066209|Inflammation
662006|NCT00066209|Coronavirus
662007|NCT00066209|Immunity
662008|NCT00066209|Interferon
662009|NCT00066209|Cytokine
662010|NCT00066209|Severe Acute Respiratory Syndrome
662011|NCT00066209|SARS
662012|NCT00066209|Healthy Volunteer
662013|NCT00066209|HV
662014|NCT00066183|Fibroblast Growth Factor 23
662015|NCT00066183|FGF-23
662016|NCT00066183|Hypophosphatemia
662017|NCT00066183|Phosphaturia
662018|NCT00066183|Phosphorus
662019|NCT00066183|Phosphorus Metabolism
662020|NCT00066170|Narcolepsy
662021|NCT00066170|Daytime Sleepiness
662022|NCT00066170|Daytime sleepiness in narcolepsy
662023|NCT00066157|Alzheimer disease
662024|NCT00066157|Hormone replacement therapy
662026|NCT00066144|menopause
662027|NCT00066144|hot flashes
662028|NCT00066144|red clover
662029|NCT00066144|black cohosh
662030|NCT00066144|sexual dysfunction
662031|NCT00066118|neurologic
662032|NCT00066118|nerve conduction
662033|NCT00066118|neurobehavioral
662034|NCT00066118|renal disease
662035|NCT00066092|PBPC transplant
662036|NCT00066092|Hodgkin's Disease
662037|NCT00066092|Non-Hodgkin's Lymphoma
662038|NCT00066092|NHL
662039|NCT00066092|mobilization
662040|NCT00066079|Sickle Cell Pain
662041|NCT00066079|Sickle Cell Disease
662042|NCT00066079|Chronic Pain
662043|NCT00066079|Alternative Medicine/Therapy
662044|NCT00066079|Complementary Medicine
662045|NCT00066079|Massage Therapy
662046|NCT00066079|Relaxation Technique
662047|NCT00066079|Home-based Therapy
662048|NCT00066053|Heart attacks
662049|NCT00066053|Stroke
662050|NCT00066053|Angina
662051|NCT00066040|mutans streptococci infections
662052|NCT00066027|periodontitis, metabolic bone diseases, doxycycline
662053|NCT00066014|Dental Implantation-Osseointegrated
662054|NCT00066014|Dentures
662055|NCT00066014|Dental Prostheses
662056|NCT00066014|Denture, Implant-Supported
662057|NCT00065975|chronic low back pain
662058|NCT00065975|acupuncture
662059|NCT00065975|chiropractic
662060|NCT00065975|massage therapy
662061|NCT00065975|CAM therapies
662062|NCT00065962|Pervasive Developmental Disorders
662063|NCT00065962|Secretin, synthetic porcine
662064|NCT00065962|Secretin, biological porcine
662065|NCT00065962|Autism Diagnostic Observation Schedule - Generic (ADOS-G)
662066|NCT00065962|Rimland Questionnaire
662067|NCT00065962|Expressive Vocabulary Test
662068|NCT00065962|MacArthur Communication Inventory
662069|NCT00065962|Aberrant Behavior Checklist
662070|NCT00065949|Low birthweight infants
662071|NCT00065949|Magnesium supplementation
662072|NCT00065949|Intracranial hemorrhage
662073|NCT00065949|Cystic periventricular leukomalacia
662074|NCT00065949|Mental retardation
662075|NCT00065936|Intractable self-injurious behavior
662076|NCT00065936|Naltrexone
662077|NCT00065936|Transcutaneous electrical nerve stimulation
662078|NCT00065936|Substance P
662079|NCT00065936|Met-enkephalin
662080|NCT00065936|Cortisol
662081|NCT00065923|Prader-Willi Syndrome
662082|NCT00065923|Self-Injurious Behavior
662083|NCT00065910|Joint attention
662084|NCT00065910|Developmental delay
662085|NCT00065910|Caregiver interaction
662086|NCT00065897|Amniocentesis
662087|NCT00065897|Transabdominal chorionic villus sampling
662088|NCT00065897|Fluorescence in situ hybridization
662089|NCT00065897|Alpha fetoprotein
662090|NCT00065897|Acetylcholinesterase
662091|NCT00065897|Prenatal testing
662092|NCT00065897|Prenatal diagnosis
662093|NCT00065884|Adolescents
662094|NCT00065871|Pharmacist prescribers
662095|NCT00065871|Increased access
662096|NCT00065871|Hormonal contraception
662097|NCT00065871|Birth control pills
662098|NCT00065871|Birth control patch
662099|NCT00065871|Vaginal contraceptive ring
662100|NCT00065858|Contraception
662101|NCT00065858|Nonoxynol 9
662102|NCT00065858|Microbicide
662103|NCT00065858|Spermicide
662104|NCT00065845|Urinary incontinence
662105|NCT00065845|Pelvic organ prolapse
662106|NCT00065845|Stress incontinence
662107|NCT00065845|Sacrocolpopexy
662108|NCT00065845|Burch urethropexy
662109|NCT00065845|Surgical Trials
662110|NCT00065832|Reading disabilities
662111|NCT00065832|Inner-city
662112|NCT00065832|Urban
662113|NCT00065819|HIV
662114|NCT00065819|African American
662115|NCT00065819|Symptom Management
662116|NCT00065806|Pediatric lupus
662117|NCT00065806|Atherosclerosis
662118|NCT00065806|SLE
662119|NCT00065806|HMG CoA reductase inhibitor
662120|NCT00065767|Alzheimer disease
662121|NCT00065767|Postmenopausal women
662122|NCT00065767|Hormone therapy
662123|NCT00065754|Placebo
662124|NCT00065754|Analgesia
662125|NCT00065754|Pain
662126|NCT00065754|Brain mechanism
662127|NCT00065754|Expectation
662128|NCT00065741|Milk thistle
662129|NCT00065741|silymarin
662130|NCT00065741|piperine
662131|NCT00065741|glucarate
662132|NCT00065741|zidovudine
662133|NCT00065741|abacavir
662134|NCT00065741|mycophenolate mofetil
662135|NCT00065741|HIV
662136|NCT00065741|pharmacokinetics
662137|NCT00065741|interaction
662138|NCT00065741|glucuronidation
662139|NCT00065741|Healthy
662140|NCT00065741|Complementary Therapies
662141|NCT00065728|AMD
662142|NCT00065728|age-related macular degeneration
662143|NCT00065728|Anecortave
662144|NCT00065728|Acetate
662145|NCT00065728|Wet form of age-related macular degeneration
662146|NCT00065728|CNV
662147|NCT00065728|Anecortave Acetate
662148|NCT00065715|head cold
662149|NCT00065715|common cold
662150|NCT00065715|echinacea
662151|NCT00065715|placebo
662152|NCT00065702|fibromyalgia
662153|NCT00065702|homeopathy
662154|NCT00065702|EEG
662155|NCT00065702|EKG
662156|NCT00065702|chronic pain
662157|NCT00065689|Alzheimer's disease
662158|NCT00065689|light therapy
662159|NCT00065689|long-term care
662160|NCT00065689|depression
662161|NCT00065689|sleep
662162|NCT00065689|agitation
662163|NCT00065676|Hyperglycemia
662164|NCT00065676|Hyperinsulinemia
662165|NCT00065676|OGTT
662166|NCT00065676|GLUT2
662167|NCT00065676|Post-Prandial
662168|NCT00065676|Type 2 Diabetes
662169|NCT00065676|Obesity
662170|NCT00065663|gene transfer
662171|NCT00065663|adenovirus
662172|NCT00065663|platelet-derived growth factor-B
662173|NCT00065663|collagen
662174|NCT00065663|diabetic ulcer
662175|NCT00065663|foot
662176|NCT00065663|wounds
662177|NCT00065663|diabetic
662178|NCT00065663|ulcers
662179|NCT00065650|Diabetes Mellitus Type 2
662180|NCT00065650|Vedic medicine
662181|NCT00065650|Ayurveda
662182|NCT00065650|Transcendental Meditation
662183|NCT00065624|Lipoic acid
662184|NCT00065624|F2-isoprostanes
662185|NCT00065624|endothelial dysfunction
662186|NCT00065624|natural product
662187|NCT00065611|Steroids
662188|NCT00065611|Osteoporosis
662189|NCT00065611|Proteinuria
662190|NCT00065611|Minimal Change Disease
662191|NCT00065611|Focal Segmental Glomerulosclerosis
662192|NCT00065611|FSGS
662193|NCT00065611|MCD
662194|NCT00065611|Kidney Disease
662195|NCT00065585|low back pain
662196|NCT00065585|acupuncture
662197|NCT00065572|Kidney Cancer
662198|NCT00065572|Metastatic
662199|NCT00065572|Newly diagnosed renal cell carcinoma
662200|NCT00065507|hepatic decompensation
662201|NCT00065468|Advanced Renal Cell Carcinoma
662202|NCT00065468|Kidney Cancer
662203|NCT00065455|Retinitis Pigmentosa
662204|NCT00065455|Vitamin A
662205|NCT00065455|ERG
662206|NCT00065455|RP
662207|NCT00065442|prostate cancer
662208|NCT00065442|prostate
662209|NCT00065442|AIPC
662210|NCT00065442|androgen-independent
662211|NCT00065442|androgen independent
662212|NCT00065442|hormone insensitive
662213|NCT00065442|hormone-insensitive
662214|NCT00065442|PSA
662215|NCT00065442|prostatic adenocarcinoma
662216|NCT00065442|hormone-refractory
662217|NCT00065442|hormone refractory
662218|NCT00065442|HRPC
662219|NCT00065442|LHRH
662220|NCT00065442|immune therapy
662221|NCT00065442|immunotherapy
662222|NCT00065442|vaccine
662223|NCT00065442|dendritic cells
662224|NCT00065442|antigen-presenting cells
662225|NCT00065442|antigen presenting cells
662226|NCT00065442|cancer vaccine
662227|NCT00065442|therapeutic vaccine
662228|NCT00065442|therapeutic cancer vaccine
662229|NCT00065442|recombinant
662230|NCT00065442|biological
662231|NCT00065442|biopharmaceutical
662232|NCT00065442|biotechnology
662233|NCT00065442|biotech
662234|NCT00065416|neck pain
662235|NCT00065416|cervicalgia
662236|NCT00065416|massage
662237|NCT00065403|Irritable Bowel Syndrome
662238|NCT00065403|Acupuncture
662239|NCT00065390|ALPS
662240|NCT00065390|Pyrimethamine
662241|NCT00065390|Folinic Acid
662242|NCT00065390|Lymphadenopathy
662243|NCT00065390|Splenomegaly
662244|NCT00065390|Autoimmune Lymphoproliferative Syndrome
662245|NCT00065377|Diabetes
662246|NCT00065377|Insulin Resistance
662247|NCT00065377|Capillary Blood Flow
662248|NCT00065377|Osteoarthritis
662249|NCT00065377|Endothelial Dysfunction
662250|NCT00065377|Obesity
662251|NCT00065377|Healthy Volunteer
662252|NCT00065377|HV
662253|NCT00065364|Preterm infant
662254|NCT00065364|Premature infant
662255|NCT00065364|Developmental care
662256|NCT00065364|MRI
662257|NCT00065364|qEEG
662258|NCT00065364|Neurodevelopment
662259|NCT00065364|Behavior
662260|NCT00065364|Infants
662261|NCT00065364|NICU
662262|NCT00065351|Multiple Myeloma
662263|NCT00065351|CC-5013
662264|NCT00065351|Revlimid
662265|NCT00065351|MM
662266|NCT00065351|CC5013
662267|NCT00065351|relapsed and refractory multiple myeloma
662268|NCT00065338|Physical activity
662269|NCT00065325|Locally advanced breast cancer
662270|NCT00065325|metastatic breast cancer
662271|NCT00065325|Breast Cancer
662272|NCT00065325|Cancer of Breast
662273|NCT00065325|Cancer of the Breast
662274|NCT00065312|Type 2 diabetes
662275|NCT00065299|Hyperphenylalaninemia
662276|NCT00065299|PKU
662277|NCT00065299|Maternal PKU
662278|NCT00065299|Pregnancy outcome
662279|NCT00065299|Phenylalanine restricted diet
662280|NCT00065299|Tyrosine supplementation
662281|NCT00065299|Maternal hyperphenylalanemia during pregnancy
662282|NCT00065286|Akathisia
662283|NCT00065286|Mental retardation
662284|NCT00065286|Schizophrenia
662285|NCT00065286|Neuroleptic medication
662286|NCT00065286|Tardive dyskinesia
662287|NCT00065286|Brief Psychiatric Rating Scale
662288|NCT00065286|Barnes test
662289|NCT00065286|Stereotypy Checklist Test
662290|NCT00065286|DISCUS Tardive Dyskinesia test
662291|NCT00065273|Severe aberrant behavior
662292|NCT00065273|Risperidone
662293|NCT00065273|Clozapine
662294|NCT00065273|Haloperidol
662295|NCT00065273|Laboratory operant tasks
662296|NCT00065273|Simple acquisition procedures
662297|NCT00065273|Matching to sample task
662298|NCT00065273|Lag sequential analysis
662299|NCT00065260|Alemtuzumab (Campath-1H)
662300|NCT00065260|Rabbit ATG
662301|NCT00065260|Severe Aplastic Anemia
662302|NCT00065260|Cyclosporine
662303|NCT00065260|Thrombocytopenia
662304|NCT00065260|Leukopenia
662305|NCT00065260|Neutropenia
662306|NCT00065260|Autoimmunity
662307|NCT00065260|Relapse
662308|NCT00065260|Anemia
662309|NCT00065247|Bone
662310|NCT00065247|Children
662311|NCT00065247|After-school program
662312|NCT00065247|Osteoporosis
662313|NCT00065247|Calcium
662314|NCT00065247|Physical activity
662315|NCT00065234|Colostomy
662316|NCT00065234|Ileostomy
662317|NCT00065221|Ginger
662318|NCT00065221|Plant preparation
662319|NCT00065221|Herbal medicine
662320|NCT00065221|Chemotherapy
662321|NCT00065221|Nausea
662322|NCT00065208|Prostate cancer
662323|NCT00065208|Reiki
662324|NCT00065208|Energy Healing
662325|NCT00065195|Massage
662326|NCT00065195|Palliative Care
662327|NCT00065195|Hospices
662328|NCT00065195|Cancer
662329|NCT00065182|Stage IIIB/IV
662330|NCT00065182|topotecan
662331|NCT00065182|docetaxel
662332|NCT00065182|TAXOTERE
662333|NCT00065182|HYCAMTIN
662334|NCT00065182|non-small cell lung cancer
662335|NCT00065182|Advanced
662336|NCT00065182|NSCLC
662337|NCT00065156|MDS
662338|NCT00065156|CC-5013
662339|NCT00065156|Revlimid
662340|NCT00065156|Celgene
662341|NCT00065143|Newly diagnosed and previously untreated acute myeloid leukemia (AML)
662342|NCT00065143|High-risk myelodysplastic syndrome (MDS) (>/= 10% bone marrow blasts)
662343|NCT00065143|Acute Myeloid Leukemia (AML)
662344|NCT00065143|Myelodysplastic Syndrome (MDS)
662345|NCT00065117|metastatic
662346|NCT00065117|colorectal
662347|NCT00065117|first-line
662348|NCT00065117|adjuvant
662349|NCT00065117|cancer
662350|NCT00065117|Colorectal Cancer
662351|NCT00065117|Colorectal Carcinoma
662352|NCT00065117|Colorectal Tumors
662353|NCT00065117|Neoplasms, Colorectal
662354|NCT00065104|HIV
662355|NCT00065104|DHEA
662356|NCT00065104|immune system
662357|NCT00065104|hormones
662358|NCT00065104|body composition
662359|NCT00065104|quality of life
662360|NCT00065078|Home-visits
662361|NCT00065078|Community nurse
662362|NCT00065078|Unintended pregnancy
662363|NCT00065065|Rosiglitazone
662364|NCT00065065|Ulcerative
662365|NCT00065065|Colitis
662366|NCT00065052|physical activity
662367|NCT00065052|television
662368|NCT00065052|child obesity
662369|NCT00065052|Reduce TV
662370|NCT00065052|Usual control
662371|NCT00065013|obesity
662372|NCT00065013|gastric bypass
662373|NCT00065013|obesity surgery
662374|NCT00065013|bariatric surgery
662375|NCT00065013|exercise
662376|NCT00064987|Male reproduction hormones
662377|NCT00064987|Hypogonadotropic hypogonadism
662378|NCT00064987|FSH
662379|NCT00064987|LH
662380|NCT00064987|GnRH
662381|NCT00064974|MDS
662382|NCT00064974|CC-5013
662383|NCT00064974|Revlimid
662384|NCT00064974|Celgene
662385|NCT00064961|Smoking Cessation
662386|NCT00064935|Endometrium
662387|NCT00064935|Luteal phase
662388|NCT00064935|Endometrial biopsy
662389|NCT00064922|nicotine dependence
662390|NCT00064909|Multiple Sclerosis
662391|NCT00064909|MRI
662392|NCT00064909|Perfusion
662393|NCT00064909|Imaging
662394|NCT00064909|Cerebral Blood Flow
662395|NCT00064909|Cerebral Blood Volume
662396|NCT00064909|CO2 Inhalation
662397|NCT00064909|Contrast Agent
662398|NCT00064909|Healthy Volunteer
662399|NCT00064909|HV
662400|NCT00064896|Blood Flow
662401|NCT00064896|Revascularization
662402|NCT00064896|Image Fusion
662403|NCT00064896|Fluoroscopy
662404|NCT00064896|MRI
662405|NCT00064896|Chronic Total Occlusion of Arteries
662406|NCT00064896|Claudication
662407|NCT00064896|Safety
662408|NCT00064896|Atherosclerosis
662409|NCT00064896|Cardiovascular Disease
662410|NCT00064883|Radiation Therapy
662411|NCT00064883|Children
662412|NCT00064883|Cancer
662413|NCT00064883|Late Effects
662414|NCT00064883|Natural History
662415|NCT00064883|Radiation
662416|NCT00064870|Alzheimer disease
662417|NCT00064870|Late Onset Alzheimer disease risk factor genes
662418|NCT00064870|Genetics
662419|NCT00064870|Initiative
662420|NCT00064870|Dementia
662421|NCT00064857|lymphedema
662422|NCT00064857|breast
662423|NCT00064857|cancer
662424|NCT00064857|plant preparation
662425|NCT00064857|herbal preparation
662426|NCT00064857|pine bark extract
662427|NCT00064844|Smoking
662428|NCT00064844|Alcoholism
662429|NCT00064831|estrogen stimulation
662430|NCT00064831|relief of hot flashes
662431|NCT00064831|nipple aspirate fluid
662432|NCT00064831|body fluid levels of black cohosh
662433|NCT00063778|HIV Seronegativity
662434|NCT00063778|HIV Preventive Vaccine
662435|NCT00063778|AIDS Vaccines
662436|NCT00063778|Gene Products, gag
662437|NCT00063778|HIV-1
662438|NCT00063778|Dose-Response Relationship, Immunologic
662439|NCT00063778|Injections, Subcutaneous
662440|NCT00063765|NT-501
662441|NCT00063765|CNTF
662442|NCT00063765|Retinitis Pigmentosa
662443|NCT00063765|RP
662444|NCT00063726|Relapsed Multiple Myeloma
662445|NCT00063726|Refractory Multiple Myeloma
662446|NCT00062894|Iodine I 131 Tositumomab
662447|NCT00062894|BEXXAR
662448|NCT00062894|non-Hodgkin's lymphoma
662449|NCT00062881|Cancer
662450|NCT00062881|Leukemia
662451|NCT00062881|Lymphoma
662452|NCT00062881|Solid Tumor
662453|NCT00062868|Lymphoma
662454|NCT00062868|EBV-T/NK lymphoproliferative disease
662455|NCT00062868|Severe Chronic EBV
662456|NCT00062868|LMP1/2
662457|NCT00062868|CTL
662458|NCT00062868|EBV
662459|NCT00062868|Relapse
662460|NCT00064818|connective tissue
662461|NCT00064818|ultrasound
662462|NCT00064818|acupuncture
662463|NCT00064805|Cognitive therapy
662464|NCT00064805|Aphasia therapy
662465|NCT00064805|Alexia
662466|NCT00064805|Acquired dyslexia
662467|NCT00064805|Phonological deficits
662468|NCT00064805|Orthographic deficits
662469|NCT00064805|Brain disorders
662470|NCT00064805|Brain injury
662471|NCT00064805|Stroke
662472|NCT00064792|Cholesterol
662473|NCT00064792|SLOS
662474|NCT00064792|HMG-COA Reductase Inhibitor
662475|NCT00064792|Malformation Syndrome
662476|NCT00064792|Mental Retardation
662477|NCT00064792|Smith-Lemli-Opitz Syndrome
662478|NCT00064779|CNS neoplasms
662479|NCT00064779|Brain neoplasms
662480|NCT00064779|neurosurgery
662481|NCT00064779|intralesional infusion
662482|NCT00064779|recombinant proteins
662483|NCT00064779|immunotoxins
662484|NCT00064766|Norplant
662485|NCT00064766|Periodontal disease
662486|NCT00064766|Endometrial bleeding
662487|NCT00064766|Progestin-induced endometrial bleeding
662488|NCT00064753|homocysteine
662489|NCT00064753|multi-vitamin
662490|NCT00064753|cardiovascular disease
662491|NCT00064753|renal transplant recipients
662492|NCT00064740|Human Immunodeficiency Viruses
662493|NCT00064740|Relaxation
662494|NCT00064740|Acupuncture
662495|NCT00064740|Complementary therapies
662496|NCT00064727|Ventricular Contractile Function
662497|NCT00064727|Diastolic Dysfunction
662498|NCT00064727|PPAR gamma
662499|NCT00064727|Gene Expression Patterns
662500|NCT00064727|Insulin Sensitization
662501|NCT00064727|Glucose Intolerance
662502|NCT00064727|Intolerance
662503|NCT00064714|Type 1 Diabetes Mellitus (T1DM)
662504|NCT00064714|Beta-Cell
662505|NCT00064714|C-Peptide
662506|NCT00064714|Immunosuppression
662507|NCT00064714|Insulin
662508|NCT00064714|Islet
662509|NCT00064714|Function
662510|NCT00064714|AC2993 (Synthetic Exendin-4)
662511|NCT00064714|Diabetes Mellitus
662512|NCT00064714|Type I Diabetes Mellitus
662513|NCT00064714|T1DM
662514|NCT00064701|De Novo Kidney Transplant
662515|NCT00064701|cyclosporine
662516|NCT00064701|Prograf®
662517|NCT00064701|mycophenolate mofetil
662518|NCT00064701|tacrolimus
662519|NCT00064662|Stress urinary incontinence
662520|NCT00064662|Surgery
662521|NCT00064649|prostate
662522|NCT00064649|benign disease
662523|NCT00064649|TUNA
662524|NCT00064649|TUMT
662525|NCT00064649|medical therapy
662526|NCT00064623|Dermal assessment
662527|NCT00064623|Pain measurement
662528|NCT00064623|Diary
662529|NCT00064623|Analgesics/*therapeutic use
662530|NCT00064623|Capsaicin/*administration & dosage/adverse effects
662531|NCT00064623|HIV Infections/*complications/*drug therapy
662532|NCT00064623|Peripheral Nervous System Diseases/*complications/diagnosis/*therapy
662533|NCT00064623|Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology
662534|NCT00064610|Advanced androgen-independent prostate cancer
662535|NCT00064597|Fetal cells
662536|NCT00064597|Prenatal diagnosis
662537|NCT00064597|Cytogenetic disorders
662538|NCT00064597|Chromosomal disorders
662539|NCT00064597|Single gene mutation detection
662540|NCT00064597|Abnormal serum marker profile
662541|NCT00064597|Fluorescence activated cell sorting (FACS)
662542|NCT00064597|Magnetic activated cell sorting (MACS)
662543|NCT00064597|Fluorescence in situ hybridization (FISH)
662544|NCT00064597|Chromosomal disorders of the fetus
662545|NCT00064597|Single gene defects of the fetus
662546|NCT00064571|unilateral vocal fold paralysis
662547|NCT00064467|lethargic
662548|NCT00064467|decreased interest
662549|NCT00064467|decreased motivation
662550|NCT00064467|depression
662551|NCT00064454|Ulcerative Colitis
662552|NCT00064441|Ulcerative Colitis
662553|NCT00064428|ST-segment elevation myocardial infarction
662554|NCT00064428|fondaparinux
662555|NCT00064428|Acute Myocardial Infarction
662556|NCT00064428|acute coronary syndrome
662557|NCT00064376|de novo myelodysplastic syndromes
662558|NCT00064376|previously treated myelodysplastic syndromes
662559|NCT00064376|secondary myelodysplastic syndromes
662560|NCT00064376|refractory anemia with excess blasts in transformation
662561|NCT00064376|refractory anemia with excess blasts
662562|NCT00064376|refractory anemia with ringed sideroblasts
662563|NCT00064376|refractory anemia
662564|NCT00064376|chronic myelomonocytic leukemia
662565|NCT00064363|recurrent adult brain tumor
662566|NCT00064363|adult anaplastic astrocytoma
662567|NCT00064363|adult glioblastoma
662568|NCT00064363|adult anaplastic oligodendroglioma
662569|NCT00064363|adult mixed glioma
662570|NCT00064363|adult giant cell glioblastoma
662571|NCT00064363|adult gliosarcoma
662572|NCT00064363|adult brain stem glioma
662573|NCT00064350|recurrent non-small cell lung cancer
662574|NCT00064350|stage IIIB non-small cell lung cancer
662575|NCT00064350|stage IV non-small cell lung cancer
662576|NCT00064350|sorafenib
662577|NCT00064337|primary systemic amyloidosis
662578|NCT00064337|stage II multiple myeloma
662579|NCT00064337|stage III multiple myeloma
662580|NCT00064311|infection
662581|NCT00064311|recurrent cutaneous T-cell non-Hodgkin lymphoma
662582|NCT00064311|recurrent adult diffuse large cell lymphoma
662583|NCT00064311|recurrent adult diffuse mixed cell lymphoma
662584|NCT00064311|recurrent adult diffuse small cleaved cell lymphoma
662585|NCT00064311|recurrent adult Burkitt lymphoma
662586|NCT00064311|recurrent adult Hodgkin lymphoma
662587|NCT00064311|recurrent adult immunoblastic large cell lymphoma
662588|NCT00064311|recurrent adult lymphoblastic lymphoma
662589|NCT00064311|recurrent grade 1 follicular lymphoma
662590|NCT00064311|recurrent grade 2 follicular lymphoma
662591|NCT00064311|recurrent grade 3 follicular lymphoma
662592|NCT00064311|recurrent mantle cell lymphoma
662593|NCT00064311|noncontiguous stage II adult diffuse large cell lymphoma
662594|NCT00064311|noncontiguous stage II adult diffuse mixed cell lymphoma
662595|NCT00064311|noncontiguous stage II adult Burkitt lymphoma
662596|NCT00064311|noncontiguous stage II adult immunoblastic large cell lymphoma
662597|NCT00064311|noncontiguous stage II adult lymphoblastic lymphoma
662598|NCT00064311|noncontiguous stage II grade 3 follicular lymphoma
662599|NCT00064311|noncontiguous stage II mantle cell lymphoma
662600|NCT00064311|stage III adult diffuse large cell lymphoma
662601|NCT00064311|stage III adult diffuse mixed cell lymphoma
662602|NCT00064311|stage III adult Burkitt lymphoma
662603|NCT00064311|stage III adult immunoblastic large cell lymphoma
662604|NCT00064311|stage III adult lymphoblastic lymphoma
662605|NCT00064311|stage III grade 3 follicular lymphoma
662606|NCT00064311|stage III mantle cell lymphoma
662607|NCT00064311|stage IV grade 3 follicular lymphoma
662608|NCT00064311|stage IV adult diffuse large cell lymphoma
662609|NCT00064311|stage IV adult diffuse mixed cell lymphoma
662610|NCT00064311|stage IV adult Burkitt lymphoma
662611|NCT00064311|stage IV adult immunoblastic large cell lymphoma
662612|NCT00064311|stage IV adult lymphoblastic lymphoma
662613|NCT00064311|stage IV mantle cell lymphoma
662614|NCT00064311|refractory chronic lymphocytic leukemia
662615|NCT00064311|stage III chronic lymphocytic leukemia
662616|NCT00064311|stage IV chronic lymphocytic leukemia
662617|NCT00064311|accelerated phase chronic myelogenous leukemia
662618|NCT00064311|blastic phase chronic myelogenous leukemia
662619|NCT00064311|chronic phase chronic myelogenous leukemia
662620|NCT00064311|meningeal chronic myelogenous leukemia
662621|NCT00064311|relapsing chronic myelogenous leukemia
662622|NCT00064311|refractory hairy cell leukemia
662623|NCT00064311|de novo myelodysplastic syndromes
662624|NCT00064311|previously treated myelodysplastic syndromes
662625|NCT00064311|secondary myelodysplastic syndromes
662626|NCT00064311|stage I multiple myeloma
662627|NCT00064311|stage II multiple myeloma
662628|NCT00064311|stage III multiple myeloma
662629|NCT00064311|recurrent malignant testicular germ cell tumor
662630|NCT00064311|stage III malignant testicular germ cell tumor
662631|NCT00064311|disseminated neuroblastoma
662632|NCT00064311|recurrent neuroblastoma
662633|NCT00064311|stage II ovarian epithelial cancer
662634|NCT00064311|recurrent ovarian epithelial cancer
662635|NCT00064311|stage III ovarian epithelial cancer
662636|NCT00064311|stage IV ovarian epithelial cancer
662637|NCT00064311|recurrent ovarian germ cell tumor
662638|NCT00064311|stage IIIA breast cancer
662639|NCT00064311|stage IIIB breast cancer
662640|NCT00064311|stage IV breast cancer
662641|NCT00064311|high risk metastatic gestational trophoblastic tumor
662642|NCT00064311|primary myelofibrosis
662643|NCT00064311|recurrent adult acute lymphoblastic leukemia
662644|NCT00064311|adult acute lymphoblastic leukemia in remission
662645|NCT00064311|recurrent adult acute myeloid leukemia
662646|NCT00064311|adult acute myeloid leukemia in remission
662647|NCT00064311|secondary acute myeloid leukemia
662648|NCT00064311|atypical chronic myeloid leukemia, BCR-ABL1 negative
662649|NCT00064311|myelodysplastic/myeloproliferative neoplasm, unclassifiable
662650|NCT00064311|stage IIIC breast cancer
662651|NCT00064311|recurrent marginal zone lymphoma
662652|NCT00064311|recurrent small lymphocytic lymphoma
662653|NCT00064311|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
662654|NCT00064311|nodal marginal zone B-cell lymphoma
662655|NCT00064311|splenic marginal zone lymphoma
662656|NCT00064311|adult acute myeloid leukemia with t(8;21)(q22;q22)
662657|NCT00064311|adult acute myeloid leukemia with t(16;16)(p13;q22)
662658|NCT00064311|adult acute myeloid leukemia with inv(16)(p13;q22)
662659|NCT00064311|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
662660|NCT00064311|adult acute myeloid leukemia with t(15;17)(q22;q12)
662661|NCT00064298|stage I squamous cell carcinoma of the hypopharynx
662662|NCT00064298|stage I squamous cell carcinoma of the larynx
662663|NCT00064298|stage I squamous cell carcinoma of the lip and oral cavity
662664|NCT00064298|stage I squamous cell carcinoma of the oropharynx
662665|NCT00064298|stage II squamous cell carcinoma of the hypopharynx
662666|NCT00064298|stage II squamous cell carcinoma of the larynx
662667|NCT00064298|stage II squamous cell carcinoma of the lip and oral cavity
662668|NCT00064298|stage II squamous cell carcinoma of the oropharynx
662669|NCT00064298|stage III squamous cell carcinoma of the hypopharynx
662670|NCT00064298|stage III squamous cell carcinoma of the larynx
662671|NCT00064298|stage III squamous cell carcinoma of the lip and oral cavity
662672|NCT00064298|stage III squamous cell carcinoma of the oropharynx
662673|NCT00064298|stage IV squamous cell carcinoma of the hypopharynx
662674|NCT00064298|stage IV squamous cell carcinoma of the larynx
662675|NCT00064298|stage IV squamous cell carcinoma of the lip and oral cavity
662676|NCT00064298|stage IV squamous cell carcinoma of the oropharynx
662677|NCT00064285|chronic phase chronic myelogenous leukemia
662678|NCT00064285|blastic phase chronic myelogenous leukemia
662679|NCT00064285|accelerated phase chronic myelogenous leukemia
662680|NCT00064285|recurrent adult acute myeloid leukemia
662681|NCT00064285|untreated adult acute myeloid leukemia
662682|NCT00064285|adult acute myeloid leukemia in remission
662683|NCT00064285|adult acute lymphoblastic leukemia in remission
662684|NCT00064285|recurrent adult acute lymphoblastic leukemia
662685|NCT00064285|untreated adult acute lymphoblastic leukemia
662686|NCT00064285|relapsing chronic myelogenous leukemia
662687|NCT00064285|adult acute myeloid leukemia with t(8;21)(q22;q22)
662688|NCT00064285|adult acute myeloid leukemia with t(16;16)(p13;q22)
662689|NCT00064285|adult acute myeloid leukemia with inv(16)(p13;q22)
662690|NCT00064285|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
662691|NCT00064285|adult acute myeloid leukemia with t(15;17)(q22;q12)
662692|NCT00064272|nausea and vomiting
662693|NCT00064272|unspecified adult solid tumor, protocol specific
662694|NCT00064233|chronic phase chronic myelogenous leukemia
662695|NCT00064233|relapsing chronic myelogenous leukemia
662696|NCT00064233|Philadelphia chromosome positive chronic myelogenous leukemia
662697|NCT00064220|adult leiomyosarcoma
662698|NCT00064220|adult malignant fibrous histiocytoma
662699|NCT00064220|adult liposarcoma
662700|NCT00064220|adult rhabdomyosarcoma
662701|NCT00064220|adult synovial sarcoma
662702|NCT00064220|adult fibrosarcoma
662703|NCT00064220|adult angiosarcoma
662704|NCT00064220|adult malignant hemangiopericytoma
662705|NCT00064220|stage IV adult soft tissue sarcoma
662706|NCT00064220|recurrent adult soft tissue sarcoma
662707|NCT00064207|adenocarcinoma of the pancreas
662708|NCT00064207|stage I pancreatic cancer
662709|NCT00064207|stage II pancreatic cancer
662710|NCT00064207|stage III pancreatic cancer
662711|NCT00064194|prostate cancer
662712|NCT00064194|high grade prostatic intraepithelial neoplasia
662713|NCT00064181|adenocarcinoma of the colon
662714|NCT00064181|adenocarcinoma of the rectum
662715|NCT00064181|stage IV colon cancer
662716|NCT00064181|stage IV rectal cancer
662717|NCT00064116|stage I adult diffuse large cell lymphoma
662718|NCT00064116|contiguous stage II adult diffuse large cell lymphoma
662719|NCT00064116|noncontiguous stage II adult diffuse large cell lymphoma
662720|NCT00064116|stage III adult diffuse large cell lymphoma
662721|NCT00064116|stage IV adult diffuse large cell lymphoma
662722|NCT00064090|recurrent adult acute lymphoblastic leukemia
662723|NCT00064090|recurrent adult acute myeloid leukemia
662840|NCT00063323|Nicotine replacement
662724|NCT00064090|blastic phase chronic myelogenous leukemia
662725|NCT00064090|refractory chronic lymphocytic leukemia
662726|NCT00064090|relapsing chronic myelogenous leukemia
662727|NCT00064090|chronic myelomonocytic leukemia
662728|NCT00064090|refractory anemia with excess blasts in transformation
662729|NCT00064090|refractory anemia with excess blasts
662730|NCT00064090|previously treated myelodysplastic syndromes
662731|NCT00064090|atypical chronic myeloid leukemia, BCR-ABL1 negative
662732|NCT00064090|myelodysplastic/myeloproliferative neoplasm, unclassifiable
662733|NCT00064090|adult acute myeloid leukemia with t(8;21)(q22;q22)
662734|NCT00064090|adult acute myeloid leukemia with t(16;16)(p13;q22)
662735|NCT00064090|adult acute myeloid leukemia with inv(16)(p13;q22)
662736|NCT00064090|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
662737|NCT00064090|adult acute myeloid leukemia with t(15;17)(q22;q12)
662738|NCT00064064|recurrent non-small cell lung cancer
662739|NCT00064064|stage IV non-small cell lung cancer
662740|NCT00064051|stage II pancreatic cancer
662741|NCT00064051|stage III pancreatic cancer
662742|NCT00064051|recurrent pancreatic cancer
662743|NCT00064051|stage IV pancreatic cancer
662744|NCT00064038|stage I multiple myeloma
662745|NCT00064038|stage II multiple myeloma
662746|NCT00064038|stage III multiple myeloma
662747|NCT00064012|stage IIIB non-small cell lung cancer
662748|NCT00064012|stage IV non-small cell lung cancer
662749|NCT00064012|recurrent non-small cell lung cancer
662750|NCT00063986|esophageal cancer
662751|NCT00063986|minimally invasive esophagectomy (MIE)
662752|NCT00063960|stage IV colon cancer
662753|NCT00063960|adenocarcinoma of the colon
662754|NCT00063960|adenocarcinoma of the rectum
662755|NCT00063960|stage IV rectal cancer
662756|NCT00063960|liver metastases
662757|NCT00063882|stage IIB prostate cancer
662758|NCT00063882|stage IIA prostate cancer
662759|NCT00063882|adenocarcinoma of the prostate
662760|NCT00063869|Idiopathic Pulmonary Fibrosis
662761|NCT00063869|Fibrosis, Pulmonary
662762|NCT00063869|Pulmonary Fibroses
662763|NCT00063869|Fibroses, Pulmonary
662764|NCT00063856|Smallpox, wetvax
662765|NCT00063843|Bacillus anthracis (anthrax)
662766|NCT00063830|Ulcerative Colitis
662767|NCT00063817|Renal Disease
662768|NCT00063817|End-stage renal disease
662769|NCT00063817|Renal Transplant
662770|NCT00063817|Bone Marrow Transplant
662771|NCT00063817|Tolerance, Chimerism
662772|NCT00063817|Immune Tolerance
662773|NCT00063817|ESRD
662774|NCT00063804|HIV Seronegativity
662775|NCT00063804|CXCR4
662776|NCT00063804|AMD11070
662777|NCT00063791|Relapsed or Refractory
662778|NCT00063700|obesity in school aged children
662779|NCT00063674|exercise
662780|NCT00063674|eating
662781|NCT00063674|dance
662782|NCT00063674|health education
662783|NCT00063674|obesity prevention
662784|NCT00063674|diabetes prevention
662785|NCT00063674|children
662786|NCT00063661|fMRI
662787|NCT00063661|Brain Activity
662788|NCT00063661|Overlearned
662789|NCT00063661|Dual-Task
662790|NCT00063661|Mechanism
662791|NCT00063661|Parkinson Disease
662792|NCT00063661|PD
662793|NCT00063648|PTLD
662794|NCT00063648|CTL Therapy
662795|NCT00063648|Post-transplant lymphoproliferative disorder
662796|NCT00063635|Non alcoholic fatty liver disease
662797|NCT00063622|Non alcoholic steatohepatitis
662798|NCT00063622|Steatohepatitis
662799|NCT00063609|Prostate Cancer
662800|NCT00063609|Bone Loss
662801|NCT00063609|Osteoporosis
662802|NCT00063609|Bone Mineral Density
662803|NCT00063609|Androgen Deprivation Therapy
662804|NCT00063596|Vitamin A
662805|NCT00063596|Hepatitis B vaccine
662806|NCT00063596|Immune responses
662807|NCT00063596|T-cell subsets
662808|NCT00063596|Chronic lung disease
662809|NCT00063596|Cytokines, intracytoplasmic
662810|NCT00063596|Antibodies, hepatitis B and tetanus toxoid
662811|NCT00063583|Kidney disease
662812|NCT00063570|Cancer of Breast
662813|NCT00063570|Cancer of the Breast
662814|NCT00063479|Osteogenesis Imperfecta
662815|NCT00063479|OI
662816|NCT00063479|bone markers
662817|NCT00063479|fracture
662818|NCT00063479|bone loss
662819|NCT00063479|pediatric
662820|NCT00063479|bisphosphonate
662821|NCT00063479|brittle bone disease
662822|NCT00063479|pamidronate
662823|NCT00063427|Colorectal Cancer
662824|NCT00063427|Colorectal Carcinoma
662825|NCT00063427|Colorectal Tumors
662826|NCT00063427|Neoplasms, Colorectal
662827|NCT00063427|Colorectal Neoplasms
662828|NCT00063401|ovarian
662829|NCT00063401|primary peritoneal cancer
662830|NCT00063401|fallopian tube cancer
662831|NCT00063388|Non
662832|NCT00063388|Small
662833|NCT00063388|Cell
662834|NCT00063388|Lung
662835|NCT00063388|Cancer
662836|NCT00063362|Depression
662837|NCT00063323|Maintenance treatment
662838|NCT00063323|Smoking relapse
662839|NCT00063323|Bupropion
662841|NCT00063310|Alzheimer disease
662842|NCT00063310|Aging Women
662843|NCT00063310|Hormone therapy
662844|NCT00063297|schizophrenia with negative symptoms
662845|NCT00063284|Electrical Stimulation
662846|NCT00063284|Human Brain
662847|NCT00063284|Parkinson Disease
662848|NCT00063284|PD
662849|NCT00063258|Non-Small Cell Lung Cancer
662850|NCT00063258|Lung Cancer
662851|NCT00063258|OSI-774
662852|NCT00063258|Tarceva
662853|NCT00063258|Carboplatin
662854|NCT00063258|Paclitaxel
662855|NCT00063258|NSCLC
662856|NCT00063245|Motor Cortex
662857|NCT00063245|Mood
662858|NCT00063245|Reward
662859|NCT00063245|Transcranial Magnetic Stimulation
662860|NCT00063245|Magnetic Coil
662861|NCT00063245|Healthy Volunteer
662862|NCT00063245|HV
662863|NCT00063232|Insulin
662864|NCT00063232|Obesity
662865|NCT00063232|Fatty Liver
662866|NCT00063232|Diabetes
662867|NCT00063232|Cirrhosis
662868|NCT00063232|Metformin
662869|NCT00063232|Insulin Resistance
662870|NCT00063232|Nonalcoholic Steatohepatitis
662871|NCT00063232|Hepatitis
662872|NCT00063232|NASH
662873|NCT00063219|Non-Small-Cell Lung Carcinoma
662874|NCT00063219|Lung Cancer
662875|NCT00063219|Cancer of Lung
662876|NCT00063206|Depressive Disorder, Major
662877|NCT00063206|Depression, Involutional
662878|NCT00063193|Parkinson's disease
662879|NCT00063193|minocycline
662880|NCT00063193|creatine
662881|NCT00063193|neuroprotection
662882|NCT00063180|Diaschisis
662883|NCT00063180|Glucose
662884|NCT00063180|GABA
662885|NCT00063180|N-Acetylaspartate
662886|NCT00063180|Glutamate
662887|NCT00063180|Stroke
662888|NCT00063180|Healthy Volunteer
662889|NCT00063180|HV
662890|NCT00063154|Lung cancer
662891|NCT00063115|Praxis Movements
662892|NCT00063115|Pantomime
662893|NCT00063115|Statistical Parametric Mapping
662894|NCT00063115|Functional Connectivity
662895|NCT00063115|Path Analysis
662896|NCT00063115|Ideomotor Apraxia
662897|NCT00063115|Healthy Volunteer
662898|NCT00063115|HV
662899|NCT00063089|Staphylococcal infection
662900|NCT00063089|Gram positive bacteria
662901|NCT00063089|Staphylococcus
662902|NCT00063089|Staphylococcus aureus
662903|NCT00063076|Alopecia Areata
662904|NCT00063076|Alopecia Totalis
662905|NCT00063076|Alopecia Universalis
662906|NCT00063076|Targretin Gel
662907|NCT00063063|NICHD Neonatal Research Network
662908|NCT00063063|Extremely Low Birth Weight (ELBW)
662909|NCT00063063|Prematurity
662910|NCT00063050|Bone density
662911|NCT00063050|Children
662912|NCT00063050|Adolescents
662913|NCT00063050|Behavior
662914|NCT00063050|Health education
662915|NCT00063050|Health promotion
662916|NCT00063050|Physical fitness
662917|NCT00063050|Diet
662918|NCT00063050|Parent training
662919|NCT00063050|Injury control
662920|NCT00063037|Bone mass
662921|NCT00063037|Calcium intake
662922|NCT00063037|Prevention of osteoporosis
662923|NCT00063037|Optimizing peak bone mass
662924|NCT00063037|Bone mineral density
662925|NCT00063024|Bone health
662926|NCT00063024|Weight-bearing physical activity
662927|NCT00063024|Calcium
662928|NCT00063011|Weight-bearing exercise
662929|NCT00063011|Calcium-rich diet
662930|NCT00063011|Adolescents
662931|NCT00063011|Females
662932|NCT00063011|Bone mass
662933|NCT00063011|Osteopenia
662934|NCT00062985|obesity treatment
662935|NCT00062985|weight management
662936|NCT00062985|managed care
662937|NCT00062972|Multiple Sclerosis
662938|NCT00062972|Cognitive Dysfunction
662939|NCT00062972|Treatment Interventions
662940|NCT00062972|Verbal memory deficits
662941|NCT00062959|Adolescence
662942|NCT00062959|Parenting
662943|NCT00062959|School
662944|NCT00062959|Primary Prevention
662945|NCT00062959|School-based intervention
662946|NCT00062946|Thalamus
662947|NCT00062946|Cerebral Cortices
662948|NCT00062946|Quantification
662949|NCT00062946|Reproducibility
662950|NCT00062946|Dopamine Release
662951|NCT00062946|(18F) Fallypride
662952|NCT00062946|D-Amphetamine
662953|NCT00062946|Alpha-Methyl-Para-Tyrosine (AMPT)
662954|NCT00062946|PET
662955|NCT00062946|Dopamine D2 Receptor
662956|NCT00062946|Healthy Volunteer
662957|NCT00062946|HV
662958|NCT00062933|Clinical Response
662959|NCT00062933|Duration of Response
662960|NCT00062933|Quality of Life
662961|NCT00062933|Hyperthermia
662962|NCT00062933|Survival
662963|NCT00062933|Melanoma
662964|NCT00062933|Ocular Melanoma
662965|NCT00062933|Eye Cancer
662966|NCT00062855|GENE MODIFIED AUTOLOGOUS NEUROBLASTOMA CELLS
662967|NCT00062855|Gene Therapy
662968|NCT00062829|Teen driving
662969|NCT00062829|Adolescent risk behavior
662970|NCT00062829|Parenting
662971|NCT00062829|Checkpoints Program
662972|NCT00062829|Health Education
662973|NCT00062816|Hepatitis
662974|NCT00062816|Chronic
662975|NCT00062790|Testosterone
662976|NCT00062790|DHT
662977|NCT00062790|TURP
662978|NCT00062777|Genetics
662979|NCT00062777|Populations
662980|NCT00062777|CVD Risk
662981|NCT00062777|Gene Mapping
662982|NCT00062777|Epidemiology
662983|NCT00062777|Framingham Study
662984|NCT00062777|Vascular Diseases
662985|NCT00062764|Insulin Resistance
662986|NCT00062764|Obesity
662987|NCT00062764|Fatty Liver
662988|NCT00062764|Cirrhosis
662989|NCT00062764|Diabetes
662990|NCT00062764|Pioglitazone
662991|NCT00062764|Thiazolidinediones
662992|NCT00062764|Peroxisome Proliferator-Advanced Receptor Gamma
662993|NCT00062764|PPAR Gama
662994|NCT00062764|Nonalcoholic Steatohepatitis
662995|NCT00062764|Hepatitis
662996|NCT00062764|Non-Alcoholic Steatohepatitis
662997|NCT00062764|NASH
662998|NCT00062751|breast
662999|NCT00062751|neoplasms
663000|NCT00062738|Parkinson's disease
663001|NCT00062738|Parkinson disease
663002|NCT00062738|depression
663003|NCT00062738|antidepressants
663004|NCT00062738|nortriptyline
663005|NCT00062738|paroxetine
663006|NCT00062712|Immunosuppression
663007|NCT00062712|Transplant
663008|NCT00062712|Kidney Transplant
663009|NCT00062686|Lapatinib
663010|NCT00062686|Metastatic Breast Cancer
663011|NCT00062686|HERCEPTIN refractory
663012|NCT00062634|Female condom use
663013|NCT00062634|Male condom use
663014|NCT00062634|AIDS education
663015|NCT00062634|AIDS prevention
663016|NCT00062634|HIV Seronegativity
663017|NCT00062621|Immune tolerance
663018|NCT00062621|Graft vs host disease
663019|NCT00062621|Kidney Failure
663020|NCT00062621|Kidney diseases
663021|NCT00062621|End Stage Renal Disease
663022|NCT00062621|Multiple Myeloma
663023|NCT00062621|Bone Marrow Transplant
663024|NCT00062621|Kidney Transplant
663025|NCT00062621|Renal Transplant
663026|NCT00062621|Tolerance
663027|NCT00062621|Chimerism
663028|NCT00062621|ESRD
663029|NCT00062608|Abdominal
663030|NCT00062595|Menopause
663031|NCT00062595|Vitamin K
663032|NCT00062595|Bone turnover
663033|NCT00062595|Bone Density
663034|NCT00062582|Roflumilast
663035|NCT00062582|Chronic Obstructive Pulmonary Disease
663036|NCT00062582|COPD
663037|NCT00062569|Alzheimer disease
663038|NCT00062569|Resistiveness to baths
663039|NCT00062569|Caregiver stress
663040|NCT00062569|Bathing support intervention
663041|NCT00062569|Reminiscence
663042|NCT00062569|Agitated behavior
663043|NCT00062569|Resistiveness to care
663044|NCT00062556|Intermittent Claudication
663045|NCT00062556|Peripheral Arterial Disease
663046|NCT00062556|Atherosclerosis
663047|NCT00062556|Niacin
663048|NCT00062556|Lovastatin
663049|NCT00062556|PAD
663050|NCT00062556|IC
663051|NCT00062543|Severe hepatic dysfunction post stem cell transplantation
663052|NCT00062543|Stem Cell Transplantation
663053|NCT00062543|Hepatic Artery Infusion
663054|NCT00062543|Liver Diseases
663055|NCT00062543|CD34+ Cells
663056|NCT00062543|SCT
663057|NCT00062530|AIDS
663058|NCT00062530|HIV seronegativity
663059|NCT00062530|HIV preventive vaccine
663060|NCT00062517|Amygdala
663061|NCT00062517|Generalized Anxiety Disorder
663062|NCT00062517|Anxiety Disorder
663063|NCT00062517|GAD
663064|NCT00062517|Social Anxiety Disorder
663065|NCT00062517|SAD
663066|NCT00062465|DMARD
663067|NCT00062465|Clinical Trial
663068|NCT00062465|Thunder God Vine
663069|NCT00062465|Chinese Herb
663070|NCT00062465|Rheumatoid Arthritis
663071|NCT00062465|RA
663072|NCT00062452|Esophageal
663073|NCT00062452|Airway
663074|NCT00062439|stage II non-small cell lung cancer
663075|NCT00062439|stage IIIA non-small cell lung cancer
663076|NCT00062439|stage IIIB non-small cell lung cancer
663077|NCT00062426|adenocarcinoma of the colon
663078|NCT00062426|adenocarcinoma of the rectum
663079|NCT00062426|recurrent colon cancer
663080|NCT00062426|stage IV colon cancer
663081|NCT00062426|recurrent rectal cancer
663082|NCT00062426|stage IV rectal cancer
663083|NCT00062400|sexual dysfunction and infertility
663084|NCT00062400|sexuality and reproductive issues
663085|NCT00062400|psychosocial effects of cancer and its treatment
663086|NCT00062400|stage II breast cancer
663087|NCT00062400|stage IA breast cancer
663088|NCT00062400|stage IB breast cancer
663089|NCT00062387|stage IV squamous cell carcinoma of the hypopharynx
663090|NCT00062387|stage IV squamous cell carcinoma of the larynx
663091|NCT00062387|stage IV squamous cell carcinoma of the lip and oral cavity
663092|NCT00062387|stage IV squamous cell carcinoma of the nasopharynx
663093|NCT00062387|stage IV squamous cell carcinoma of the oropharynx
663094|NCT00062387|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
663581|NCT00061139|Limb restraint
663095|NCT00062387|recurrent squamous cell carcinoma of the hypopharynx
663096|NCT00062387|recurrent squamous cell carcinoma of the larynx
663097|NCT00062387|recurrent squamous cell carcinoma of the lip and oral cavity
663098|NCT00062387|recurrent squamous cell carcinoma of the nasopharynx
663099|NCT00062387|recurrent squamous cell carcinoma of the oropharynx
663100|NCT00062387|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
663101|NCT00062387|metastatic squamous neck cancer with occult primary squamous cell carcinoma
663102|NCT00062387|recurrent metastatic squamous neck cancer with occult primary
663103|NCT00062387|recurrent salivary gland cancer
663104|NCT00062387|salivary gland squamous cell carcinoma
663105|NCT00062387|stage IV salivary gland cancer
663106|NCT00062348|recurrent squamous cell carcinoma of the hypopharynx
663107|NCT00062348|recurrent squamous cell carcinoma of the larynx
663108|NCT00062348|recurrent squamous cell carcinoma of the lip and oral cavity
663109|NCT00062348|recurrent squamous cell carcinoma of the nasopharynx
663110|NCT00062348|recurrent squamous cell carcinoma of the oropharynx
663111|NCT00062348|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
663112|NCT00062348|stage IV squamous cell carcinoma of the hypopharynx
663113|NCT00062348|stage IV squamous cell carcinoma of the larynx
663114|NCT00062348|stage IV squamous cell carcinoma of the lip and oral cavity
663115|NCT00062348|stage IV squamous cell carcinoma of the nasopharynx
663116|NCT00062348|stage IV squamous cell carcinoma of the oropharynx
663117|NCT00062348|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
663118|NCT00062348|untreated metastatic squamous neck cancer with occult primary
663119|NCT00062348|recurrent thyroid cancer
663120|NCT00062348|stage IV follicular thyroid cancer
663121|NCT00062348|stage IV papillary thyroid cancer
663122|NCT00062348|stage IVA colon cancer
663123|NCT00062348|stage IVB colon cancer
663124|NCT00062348|recurrent colon cancer
663125|NCT00062348|adenocarcinoma of the colon
663126|NCT00062348|recurrent rectal cancer
663127|NCT00062348|stage IVA rectal cancer
663128|NCT00062348|stage IVB rectal cancer
663129|NCT00062348|adenocarcinoma of the rectum
663130|NCT00062348|anaplastic thyroid cancer
663131|NCT00062348|insular thyroid cancer
663132|NCT00062348|thyroid gland medullary carcinoma
663133|NCT00062348|liver metastases
663134|NCT00062348|stage I squamous cell carcinoma of the hypopharynx
663135|NCT00062348|stage I squamous cell carcinoma of the larynx
663136|NCT00062348|stage I squamous cell carcinoma of the lip and oral cavity
663137|NCT00062348|stage I squamous cell carcinoma of the nasopharynx
663138|NCT00062348|stage I squamous cell carcinoma of the oropharynx
663139|NCT00062348|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
663140|NCT00062348|stage II squamous cell carcinoma of the hypopharynx
663141|NCT00062348|stage II squamous cell carcinoma of the larynx
663142|NCT00062348|stage II squamous cell carcinoma of the lip and oral cavity
663143|NCT00062348|stage II squamous cell carcinoma of the nasopharynx
663144|NCT00062348|stage II squamous cell carcinoma of the oropharynx
663145|NCT00062348|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
663146|NCT00062348|stage III squamous cell carcinoma of the hypopharynx
663147|NCT00062348|stage III squamous cell carcinoma of the larynx
663148|NCT00062348|stage III squamous cell carcinoma of the lip and oral cavity
663149|NCT00062348|stage III squamous cell carcinoma of the nasopharynx
663150|NCT00062348|stage III squamous cell carcinoma of the oropharynx
663151|NCT00062348|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
663152|NCT00062348|stage I papillary thyroid cancer
663153|NCT00062348|stage II papillary thyroid cancer
663154|NCT00062348|stage III papillary thyroid cancer
663155|NCT00062348|stage I follicular thyroid cancer
663156|NCT00062348|stage II follicular thyroid cancer
663157|NCT00062348|stage III follicular thyroid cancer
663158|NCT00062348|recurrent metastatic squamous neck cancer with occult primary
663159|NCT00062348|recurrent salivary gland cancer
663160|NCT00062348|salivary gland squamous cell carcinoma
663161|NCT00062348|stage I salivary gland cancer
663162|NCT00062348|stage II salivary gland cancer
663163|NCT00062348|stage III salivary gland cancer
663164|NCT00062348|stage IV salivary gland cancer
663165|NCT00062348|tongue cancer
663166|NCT00062335|stage I non-small cell lung cancer
663167|NCT00062335|stage II non-small cell lung cancer
663168|NCT00062335|stage IIIA non-small cell lung cancer
663169|NCT00062322|limited stage small cell lung cancer
663170|NCT00062309|stage II prostate cancer
663171|NCT00062309|stage III prostate cancer
663172|NCT00062309|adenocarcinoma of the prostate
663173|NCT00062296|B-cell chronic lymphocytic leukemia
663174|NCT00062296|refractory chronic lymphocytic leukemia
663175|NCT00062296|recurrent adult diffuse large cell lymphoma
663176|NCT00062296|recurrent adult diffuse mixed cell lymphoma
663177|NCT00062296|recurrent adult diffuse small cleaved cell lymphoma
663178|NCT00062296|recurrent adult Burkitt lymphoma
663179|NCT00062296|recurrent adult immunoblastic large cell lymphoma
663180|NCT00062296|recurrent grade 1 follicular lymphoma
663181|NCT00062296|recurrent grade 2 follicular lymphoma
663182|NCT00062296|recurrent grade 3 follicular lymphoma
663183|NCT00062296|recurrent mantle cell lymphoma
663184|NCT00062296|recurrent adult lymphoblastic lymphoma
663185|NCT00062296|recurrent marginal zone lymphoma
663186|NCT00062296|recurrent small lymphocytic lymphoma
663187|NCT00062296|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
663188|NCT00062296|nodal marginal zone B-cell lymphoma
663189|NCT00062296|splenic marginal zone lymphoma
663190|NCT00062283|advanced malignant mesothelioma
663191|NCT00062283|recurrent malignant mesothelioma
663192|NCT00062283|metastatic osteosarcoma
663193|NCT00062283|recurrent osteosarcoma
663194|NCT00062283|recurrent adult soft tissue sarcoma
663195|NCT00062283|stage IV adult soft tissue sarcoma
663196|NCT00062283|chondrosarcoma
663197|NCT00062283|recurrent non-small cell lung cancer
663198|NCT00062283|stage IIIB non-small cell lung cancer
663199|NCT00062283|stage IV non-small cell lung cancer
663200|NCT00062283|adenocarcinoma of the pancreas
663201|NCT00062283|recurrent pancreatic cancer
663202|NCT00062283|stage III adult soft tissue sarcoma
663203|NCT00062283|stage II adult soft tissue sarcoma
663204|NCT00062283|stage IV pancreatic cancer
663205|NCT00062270|stage IIIA non-small cell lung cancer
663206|NCT00062270|stage IIIB non-small cell lung cancer
663207|NCT00062257|recurrent gastric cancer
663208|NCT00062257|stage IV gastric cancer
663209|NCT00062257|adenocarcinoma of the stomach
663210|NCT00062231|infection
663211|NCT00062231|neutropenia
663212|NCT00062231|fever, sweats, and hot flashes
663213|NCT00062231|unspecified adult solid tumor, protocol specific
663214|NCT00062231|stage I adult Hodgkin lymphoma
663215|NCT00062231|stage II adult Hodgkin lymphoma
663216|NCT00062231|stage III adult Hodgkin lymphoma
663217|NCT00062231|stage IV adult Hodgkin lymphoma
663218|NCT00062231|monoclonal gammopathy of undetermined significance
663219|NCT00062231|recurrent adult Hodgkin lymphoma
663220|NCT00062231|stage I cutaneous T-cell non-Hodgkin lymphoma
663221|NCT00062231|stage II cutaneous T-cell non-Hodgkin lymphoma
663222|NCT00062231|stage III cutaneous T-cell non-Hodgkin lymphoma
663223|NCT00062231|stage IV cutaneous T-cell non-Hodgkin lymphoma
663224|NCT00062231|recurrent cutaneous T-cell non-Hodgkin lymphoma
663225|NCT00062231|isolated plasmacytoma of bone
663226|NCT00062231|extramedullary plasmacytoma
663227|NCT00062231|refractory multiple myeloma
663228|NCT00062231|stage 0 chronic lymphocytic leukemia
663229|NCT00062231|Waldenstrom macroglobulinemia
663230|NCT00062231|stage I multiple myeloma
663231|NCT00062231|stage II multiple myeloma
663232|NCT00062231|stage III multiple myeloma
663233|NCT00062231|stage I chronic lymphocytic leukemia
663234|NCT00062231|stage II chronic lymphocytic leukemia
663235|NCT00062231|stage III chronic lymphocytic leukemia
663236|NCT00062231|stage IV chronic lymphocytic leukemia
663237|NCT00062231|recurrent adult acute lymphoblastic leukemia
663238|NCT00062231|relapsing chronic myelogenous leukemia
663239|NCT00062231|refractory chronic lymphocytic leukemia
663240|NCT00062231|accelerated phase chronic myelogenous leukemia
663241|NCT00062231|blastic phase chronic myelogenous leukemia
663242|NCT00062231|chronic phase chronic myelogenous leukemia
663243|NCT00062231|meningeal chronic myelogenous leukemia
663244|NCT00062231|adult acute myeloid leukemia in remission
663245|NCT00062231|polycythemia vera
663246|NCT00062231|primary myelofibrosis
663247|NCT00062231|essential thrombocythemia
663248|NCT00062231|progressive hairy cell leukemia, initial treatment
663249|NCT00062231|refractory hairy cell leukemia
663250|NCT00062231|contiguous stage II grade 1 follicular lymphoma
663251|NCT00062231|contiguous stage II grade 2 follicular lymphoma
663252|NCT00062231|contiguous stage II grade 3 follicular lymphoma
663253|NCT00062231|noncontiguous stage II grade 1 follicular lymphoma
663254|NCT00062231|noncontiguous stage II grade 2 follicular lymphoma
663255|NCT00062231|noncontiguous stage II grade 3 follicular lymphoma
663256|NCT00062231|recurrent grade 1 follicular lymphoma
663257|NCT00062231|recurrent grade 2 follicular lymphoma
663258|NCT00062231|recurrent grade 3 follicular lymphoma
663259|NCT00062231|stage I grade 1 follicular lymphoma
663260|NCT00062231|stage I grade 2 follicular lymphoma
663261|NCT00062231|stage I grade 3 follicular lymphoma
663262|NCT00062231|stage III grade 1 follicular lymphoma
663263|NCT00062231|stage III grade 2 follicular lymphoma
663264|NCT00062231|stage III grade 3 follicular lymphoma
663265|NCT00062231|stage IV grade 1 follicular lymphoma
663266|NCT00062231|stage IV grade 2 follicular lymphoma
663267|NCT00062231|stage IV grade 3 follicular lymphoma
663268|NCT00062231|contiguous stage II adult diffuse large cell lymphoma
663269|NCT00062231|contiguous stage II adult diffuse mixed cell lymphoma
663270|NCT00062231|contiguous stage II adult diffuse small cleaved cell lymphoma
663271|NCT00062231|contiguous stage II adult Burkitt lymphoma
663272|NCT00062231|noncontiguous stage II adult diffuse large cell lymphoma
663273|NCT00062231|noncontiguous stage II adult diffuse mixed cell lymphoma
663274|NCT00062231|noncontiguous stage II adult diffuse small cleaved cell lymphoma
663275|NCT00062231|noncontiguous stage II adult Burkitt lymphoma
663276|NCT00062231|recurrent adult diffuse large cell lymphoma
663277|NCT00062231|recurrent adult diffuse mixed cell lymphoma
663278|NCT00062231|recurrent adult diffuse small cleaved cell lymphoma
663279|NCT00062231|recurrent adult Burkitt lymphoma
663582|NCT00061126|Prostate Cancer
663280|NCT00062231|stage I adult diffuse large cell lymphoma
663281|NCT00062231|stage I adult diffuse mixed cell lymphoma
663282|NCT00062231|stage I adult diffuse small cleaved cell lymphoma
663283|NCT00062231|stage I adult Burkitt lymphoma
663284|NCT00062231|stage III adult diffuse large cell lymphoma
663285|NCT00062231|stage III adult diffuse mixed cell lymphoma
663286|NCT00062231|stage III adult diffuse small cleaved cell lymphoma
663287|NCT00062231|stage III adult Burkitt lymphoma
663288|NCT00062231|stage IV adult diffuse large cell lymphoma
663289|NCT00062231|stage IV adult diffuse mixed cell lymphoma
663290|NCT00062231|stage IV adult diffuse small cleaved cell lymphoma
663291|NCT00062231|stage IV adult Burkitt lymphoma
663292|NCT00062231|stage I adult immunoblastic large cell lymphoma
663293|NCT00062231|stage I adult lymphoblastic lymphoma
663294|NCT00062231|chronic myelomonocytic leukemia
663295|NCT00062231|T-cell large granular lymphocyte leukemia
663296|NCT00062231|acute undifferentiated leukemia
663297|NCT00062231|stage III adult immunoblastic large cell lymphoma
663298|NCT00062231|stage IV adult immunoblastic large cell lymphoma
663299|NCT00062231|recurrent adult immunoblastic large cell lymphoma
663300|NCT00062231|stage III adult lymphoblastic lymphoma
663301|NCT00062231|stage IV adult lymphoblastic lymphoma
663302|NCT00062231|recurrent adult lymphoblastic lymphoma
663303|NCT00062231|recurrent adult T-cell leukemia/lymphoma
663304|NCT00062231|stage I adult T-cell leukemia/lymphoma
663305|NCT00062231|stage II adult T-cell leukemia/lymphoma
663306|NCT00062231|stage III adult T-cell leukemia/lymphoma
663307|NCT00062231|stage IV adult T-cell leukemia/lymphoma
663308|NCT00062231|de novo myelodysplastic syndromes
663309|NCT00062231|previously treated myelodysplastic syndromes
663310|NCT00062231|secondary myelodysplastic syndromes
663311|NCT00062231|prolymphocytic leukemia
663312|NCT00062231|primary systemic amyloidosis
663313|NCT00062231|intraocular lymphoma
663314|NCT00062231|stage I mantle cell lymphoma
663315|NCT00062231|stage III mantle cell lymphoma
663316|NCT00062231|stage IV mantle cell lymphoma
663317|NCT00062231|contiguous stage II mantle cell lymphoma
663318|NCT00062231|noncontiguous stage II mantle cell lymphoma
663319|NCT00062231|recurrent mantle cell lymphoma
663320|NCT00062231|anaplastic large cell lymphoma
663321|NCT00062231|angioimmunoblastic T-cell lymphoma
663322|NCT00062231|recurrent mycosis fungoides/Sezary syndrome
663323|NCT00062231|stage I mycosis fungoides/Sezary syndrome
663324|NCT00062231|stage II mycosis fungoides/Sezary syndrome
663325|NCT00062231|stage III mycosis fungoides/Sezary syndrome
663326|NCT00062231|stage IV mycosis fungoides/Sezary syndrome
663327|NCT00062231|chronic eosinophilic leukemia
663328|NCT00062231|chronic neutrophilic leukemia
663329|NCT00062231|recurrent adult acute myeloid leukemia
663330|NCT00062231|adult acute lymphoblastic leukemia in remission
663331|NCT00062231|contiguous stage II adult lymphoblastic lymphoma
663332|NCT00062231|noncontiguous stage II adult lymphoblastic lymphoma
663333|NCT00062231|contiguous stage II adult immunoblastic large cell lymphoma
663334|NCT00062231|noncontiguous stage II adult immunoblastic large cell lymphoma
663335|NCT00062231|atypical chronic myeloid leukemia, BCR-ABL1 negative
663336|NCT00062231|myelodysplastic/myeloproliferative neoplasm, unclassifiable
663337|NCT00062231|contiguous stage II small lymphocytic lymphoma
663338|NCT00062231|contiguous stage II marginal zone lymphoma
663339|NCT00062231|noncontiguous stage II small lymphocytic lymphoma
663340|NCT00062231|noncontiguous stage II marginal zone lymphoma
663341|NCT00062231|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
663342|NCT00062231|nodal marginal zone B-cell lymphoma
663343|NCT00062231|splenic marginal zone lymphoma
663344|NCT00062231|recurrent marginal zone lymphoma
663345|NCT00062231|recurrent small lymphocytic lymphoma
663346|NCT00062231|stage I marginal zone lymphoma
663347|NCT00062231|stage I small lymphocytic lymphoma
663348|NCT00062231|stage III small lymphocytic lymphoma
663349|NCT00062231|stage III marginal zone lymphoma
663350|NCT00062231|stage IV small lymphocytic lymphoma
663351|NCT00062231|stage IV marginal zone lymphoma
663352|NCT00062231|adult acute myeloid leukemia with t(8;21)(q22;q22)
663353|NCT00062231|adult acute myeloid leukemia with t(16;16)(p13;q22)
663354|NCT00062231|adult acute myeloid leukemia with inv(16)(p13;q22)
663355|NCT00062231|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
663356|NCT00062231|adult acute myeloid leukemia with t(15;17)(q22;q12)
663357|NCT00062205|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
663358|NCT00062179|stage IIIA non-small cell lung cancer
663359|NCT00062166|Imaging Studies
663360|NCT00062166|Rate of Tumor Growth
663361|NCT00062166|Familial Cancer Syndrome
663362|NCT00062166|Surgical Resection
663363|NCT00062140|recurrent adult diffuse large cell lymphoma
663364|NCT00062140|recurrent adult diffuse mixed cell lymphoma
663365|NCT00062140|recurrent adult diffuse small cleaved cell lymphoma
663366|NCT00062140|recurrent adult Burkitt lymphoma
663367|NCT00062140|recurrent adult Hodgkin lymphoma
663368|NCT00062140|recurrent adult immunoblastic large cell lymphoma
663369|NCT00062140|recurrent adult lymphoblastic lymphoma
663370|NCT00062140|recurrent cutaneous T-cell non-Hodgkin lymphoma
663371|NCT00062140|recurrent grade 1 follicular lymphoma
663372|NCT00062140|recurrent grade 2 follicular lymphoma
663373|NCT00062140|recurrent grade 3 follicular lymphoma
663374|NCT00062140|recurrent mantle cell lymphoma
663375|NCT00062140|noncontiguous stage II adult diffuse large cell lymphoma
663376|NCT00062140|noncontiguous stage II adult diffuse mixed cell lymphoma
663377|NCT00062140|noncontiguous stage II adult Burkitt lymphoma
663378|NCT00062140|noncontiguous stage II adult immunoblastic large cell lymphoma
663379|NCT00062140|noncontiguous stage II adult lymphoblastic lymphoma
663380|NCT00062140|noncontiguous stage II grade 3 follicular lymphoma
663381|NCT00062140|noncontiguous stage II mantle cell lymphoma
663382|NCT00062140|stage III adult lymphoblastic lymphoma
663383|NCT00062140|stage IV adult lymphoblastic lymphoma
663384|NCT00062140|stage III adult Burkitt lymphoma
663385|NCT00062140|stage IV adult Burkitt lymphoma
663386|NCT00062140|recurrent adult acute myeloid leukemia
663387|NCT00062140|untreated adult acute myeloid leukemia
663388|NCT00062140|accelerated phase chronic myelogenous leukemia
663389|NCT00062140|blastic phase chronic myelogenous leukemia
663390|NCT00062140|chronic phase chronic myelogenous leukemia
663391|NCT00062140|meningeal chronic myelogenous leukemia
663392|NCT00062140|relapsing chronic myelogenous leukemia
663393|NCT00062140|de novo myelodysplastic syndromes
663394|NCT00062140|previously treated myelodysplastic syndromes
663395|NCT00062140|secondary myelodysplastic syndromes
663396|NCT00062140|noncontiguous stage II adult diffuse small cleaved cell lymphoma
663397|NCT00062140|noncontiguous stage II grade 1 follicular lymphoma
663398|NCT00062140|noncontiguous stage II grade 2 follicular lymphoma
663399|NCT00062140|recurrent mycosis fungoides/Sezary syndrome
663400|NCT00062140|secondary acute myeloid leukemia
663401|NCT00062140|stage III grade 1 follicular lymphoma
663402|NCT00062140|stage III grade 2 follicular lymphoma
663403|NCT00062140|stage III adult diffuse small cleaved cell lymphoma
663404|NCT00062140|stage III grade 3 follicular lymphoma
663405|NCT00062140|stage III adult diffuse large cell lymphoma
663406|NCT00062140|stage III adult diffuse mixed cell lymphoma
663407|NCT00062140|stage III adult immunoblastic large cell lymphoma
663408|NCT00062140|stage III mantle cell lymphoma
663409|NCT00062140|stage IV grade 3 follicular lymphoma
663410|NCT00062140|stage IV adult diffuse large cell lymphoma
663411|NCT00062140|stage IV adult diffuse mixed cell lymphoma
663412|NCT00062140|stage IV adult immunoblastic large cell lymphoma
663413|NCT00062140|stage IV mantle cell lymphoma
663414|NCT00062140|stage IV adult diffuse small cleaved cell lymphoma
663415|NCT00062140|stage IV grade 1 follicular lymphoma
663416|NCT00062140|stage IV grade 2 follicular lymphoma
663417|NCT00062140|recurrent adult acute lymphoblastic leukemia
663418|NCT00062140|untreated adult acute lymphoblastic leukemia
663419|NCT00062140|atypical chronic myeloid leukemia
663420|NCT00062140|myelodysplastic/myeloproliferative disease, unclassifiable
663421|NCT00062140|noncontiguous stage II small lymphocytic lymphoma
663422|NCT00062140|noncontiguous stage II marginal zone lymphoma
663423|NCT00062140|recurrent marginal zone lymphoma
663424|NCT00062140|recurrent small lymphocytic lymphoma
663425|NCT00062140|stage III small lymphocytic lymphoma
663426|NCT00062140|stage III marginal zone lymphoma
663427|NCT00062140|stage IV small lymphocytic lymphoma
663428|NCT00062140|stage IV marginal zone lymphoma
663429|NCT00062140|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
663430|NCT00062140|nodal marginal zone B-cell lymphoma
663431|NCT00062140|splenic marginal zone lymphoma
663432|NCT00062140|adult acute myeloid leukemia with t(8;21)(q22;q22)
663433|NCT00062140|adult acute myeloid leukemia with t(16;16)(p13;q22)
663434|NCT00062140|adult acute myeloid leukemia with inv(16)(p13;q22)
663435|NCT00062140|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
663436|NCT00062140|adult acute myeloid leukemia with t(15;17)(q22;q12)
663437|NCT00062114|recurrent adult diffuse large cell lymphoma
663438|NCT00062114|recurrent adult diffuse mixed cell lymphoma
663439|NCT00062114|recurrent adult immunoblastic large cell lymphoma
663440|NCT00062062|stage IV non-small cell lung cancer
663441|NCT00062062|stage IIIB non-small cell lung cancer
663442|NCT00062049|unspecified adult solid tumor, protocol specific
663443|NCT00062036|stage IV melanoma
663444|NCT00062036|recurrent melanoma
663445|NCT00062023|colorectal cancer
663446|NCT00062023|stage I colon cancer
663447|NCT00062023|stage II colon cancer
663448|NCT00062023|stage III colon cancer
663449|NCT00062023|stage IV colon cancer
663450|NCT00062010|recurrent small cell lung cancer
663451|NCT00061997|non-small cell lung cancer
663452|NCT00061997|small cell lung cancer
663453|NCT00061997|precancerous condition
663454|NCT00061984|adult angiosarcoma
663455|NCT00061984|adult epithelioid sarcoma
663456|NCT00061984|adult fibrosarcoma
663457|NCT00061984|adult leiomyosarcoma
663458|NCT00061984|adult liposarcoma
663459|NCT00061984|adult rhabdomyosarcoma
663460|NCT00061984|adult synovial sarcoma
663461|NCT00061984|stage III adult soft tissue sarcoma
663462|NCT00061984|adult malignant fibrous histiocytoma
663463|NCT00061984|adult neurofibrosarcoma
663464|NCT00061984|stage II adult soft tissue sarcoma
663465|NCT00061984|stage IV adult soft tissue sarcoma
663466|NCT00061919|extensive stage small cell lung cancer
663467|NCT00061919|limited stage small cell lung cancer
663468|NCT00061906|insular thyroid cancer
663469|NCT00061906|recurrent thyroid cancer
663470|NCT00061906|stage II follicular thyroid cancer
663471|NCT00061906|stage II papillary thyroid cancer
663472|NCT00061906|stage IV follicular thyroid cancer
663473|NCT00061906|stage IV papillary thyroid cancer
663474|NCT00061893|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
663475|NCT00061880|recurrent cutaneous T-cell non-Hodgkin lymphoma
663476|NCT00061880|stage I cutaneous T-cell non-Hodgkin lymphoma
663477|NCT00061880|stage II cutaneous T-cell non-Hodgkin lymphoma
663478|NCT00061880|stage III cutaneous T-cell non-Hodgkin lymphoma
663479|NCT00061880|stage IV cutaneous T-cell non-Hodgkin lymphoma
663480|NCT00061880|recurrent mycosis fungoides/Sezary syndrome
663481|NCT00061880|stage I mycosis fungoides/Sezary syndrome
663482|NCT00061880|stage II mycosis fungoides/Sezary syndrome
663483|NCT00061880|stage III mycosis fungoides/Sezary syndrome
663484|NCT00061880|stage IV mycosis fungoides/Sezary syndrome
663485|NCT00061867|adenocarcinoma of the prostate
663486|NCT00061867|stage III prostate cancer
663487|NCT00061867|stage IV prostate cancer
663488|NCT00061854|stage IIIA non-small cell lung cancer
663489|NCT00061854|stage IIIB non-small cell lung cancer
663490|NCT00061854|stage IV non-small cell lung cancer
663491|NCT00061854|recurrent non-small cell lung cancer
663492|NCT00061789|Schizophrenia
663493|NCT00061789|SPECT
663494|NCT00061789|Nicotinic Acetylcholine Receptors
663495|NCT00061789|Cigarette Smoking
663496|NCT00061789|Cognitive Dysfunction
663497|NCT00061789|Reproducibility
663498|NCT00061789|Quantification
663499|NCT00061789|Healthy Volunteer
663500|NCT00061789|HV
663501|NCT00061776|Dermal assessment
663502|NCT00061776|Pain measurement
663503|NCT00061776|Diary
663504|NCT00061776|Shingles
663505|NCT00061776|Neuropathy
663506|NCT00061776|Analgesics/*therapeutic use
663507|NCT00061776|Capsaicin/*administration & dosage/adverse effects
663508|NCT00061776|Herpes Zoster/*complications/drug therapy
663509|NCT00061776|Neuralgia/*drug therapy/etiology
663510|NCT00061776|Pain
663511|NCT00061776|Peripheral Nervous System Diseases/*complications
663512|NCT00061763|beta-thalassemia
663513|NCT00061763|iron overload
663514|NCT00061763|deferoxamine
663515|NCT00061763|Myelodysplastic Syndromes
663516|NCT00061763|Fanconi Syndrome
663517|NCT00061763|Anemia, Diamond-Blackfan
663518|NCT00061763|Anemia, Aplastic
663519|NCT00061750|Thalassemia, iron overload, deferoxamine, hemosiderosis
663520|NCT00061737|Pediatric IBD
663521|NCT00061737|Inflammatory
663522|NCT00061737|Bowel
663523|NCT00061308|Ovarian cancer
663524|NCT00061308|peritoneal cancer
663525|NCT00061308|cancer
663526|NCT00061308|Fallopian cancer
663527|NCT00061295|Locomotion
663528|NCT00061295|Spinal Cord Injury
663529|NCT00061295|Body Weight Supported Walking
663530|NCT00061282|Pouchitis
663531|NCT00061282|Colitis
663532|NCT00061282|Ileitis
663533|NCT00061269|Infected pancreatic necrosis
663534|NCT00061256|Bone Mineral Density
663535|NCT00061256|Lumbar Vertebrae
663536|NCT00061256|Treatment Experienced
663537|NCT00061243|HIV
663538|NCT00061243|Vaccine
663539|NCT00061243|DNA prime
663540|NCT00061243|Protein boost
663541|NCT00061243|HIV Seronegativity
663542|NCT00061243|HIV preventive vaccine
663543|NCT00061230|Relaxation training
663544|NCT00061217|Transtibial amputees
663545|NCT00061217|Rectified sockets
663546|NCT00061217|Unrectified sockets
663547|NCT00061217|Gait
663548|NCT00061217|Energy expenditure
663549|NCT00061217|Prosthetic evaluation questionnaire
663550|NCT00061204|fMRI
663551|NCT00061204|Susceptibility Artifacts
663552|NCT00061204|Prefrontal Cortex
663553|NCT00061204|Temporal Lobes
663554|NCT00061204|Methodology
663555|NCT00061204|Healthy Volunteer
663556|NCT00061204|HV
663557|NCT00061165|obesity
663558|NCT00061165|overweight
663559|NCT00061165|children
663560|NCT00061165|adolescents
663561|NCT00061165|African American
663562|NCT00061165|diet
663563|NCT00061165|nutrition
663564|NCT00061165|physical activity
663565|NCT00061165|Chicago
663566|NCT00061152|Pain Measurement
663567|NCT00061152|Diary
663568|NCT00061152|Painful HIV Neuropathy
663569|NCT00061152|HIV Neuropathy
663570|NCT00061152|Capsaicin
663571|NCT00061152|Analgesics/*therapeutic use
663572|NCT00061152|Capsaicin/*administration & dosage/adverse effects
663573|NCT00061152|Peripheral Nervous System Diseases/*complications/diagnosis/*therapy
663574|NCT00061152|Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology
663575|NCT00061152|Pain
663576|NCT00061139|Cerebral palsy
663577|NCT00061139|Hemiparesis
663578|NCT00061139|Pediatric CI therapy
663579|NCT00061139|Upper extremity
663580|NCT00061139|Training
663583|NCT00061126|PSA
663584|NCT00061126|Hormone refractory
663585|NCT00061126|Rising PSA
663586|NCT00061113|alcohol dependence
663587|NCT00061113|marijuana dependence
663588|NCT00061100|HIV
663589|NCT00061100|methadone maintenance
663590|NCT00061087|ADHD
663591|NCT00061087|Cocaine
663592|NCT00061087|Treatment
663593|NCT00061087|Methadone
663594|NCT00061074|Smoking
663595|NCT00061724|Esophageal
663596|NCT00061724|Reflux
663597|NCT00061672|Non-Hodgkin's Lymphoma (NHL)
663598|NCT00061672|Hodgkin's Lymphoma (HL)
663599|NCT00061659|high grade locally advanced/metastatic soft tissue sarcoma
663600|NCT00061646|Stage IIIb with pleural effusion or IV NSCLC
663601|NCT00061620|Investigational
663602|NCT00061620|Chemotherapy
663603|NCT00061620|Hematologic Malignancies
663604|NCT00061620|Nucleoside analogue
663605|NCT00061607|Motor Neuron Disease
663606|NCT00061607|Neuromuscular Disease
663607|NCT00061607|Histone Deacytelase Inhibitors
663608|NCT00061607|Spinal Muscular Atrophy
663609|NCT00061607|SMA
663610|NCT00061594|Neovascular age-related macular degeneration
663611|NCT00061581|Chronic Myelogenous Leukemia
663612|NCT00061581|Acute Lymphoblastic Leukemia
663613|NCT00061581|Acute Myelogenous Leukemia (AML)
663614|NCT00061581|Chronic Lymphocytic Leukemia
663615|NCT00061581|Myelodysplastic Syndrome
663616|NCT00061581|Non-Hodgkin's Lymphoma
663617|NCT00061581|Graft-Versus Leukemia/Myeloma
663618|NCT00061581|Graft-Versus-Host Disease
663619|NCT00061581|Cyclosporine
663620|NCT00061581|Fludarabine
663621|NCT00061581|Myelodysplasia Syndrome
663622|NCT00061568|Stem Cell Transplant
663623|NCT00061568|Low Dose Radiation
663624|NCT00061568|Alemtuzumab (Campath)
663625|NCT00061568|Sirolimus (Rapamune)
663626|NCT00061568|Donor Apheresis
663627|NCT00061568|Graft-Versus-Host Disease
663628|NCT00061568|Graft-Versus-Marrow
663629|NCT00061568|Host-Donor Chimerism
663630|NCT00061568|Peripheral Blood Stem Cells
663631|NCT00061568|Low Dose Irradiation
663632|NCT00061568|Sickle Cell Anemia
663633|NCT00061568|SCA
663634|NCT00061568|Thalassemia
663635|NCT00061568|Diamond-Blackfan Anemia
663636|NCT00061568|DBA
663637|NCT00061542|Glaucoma
663638|NCT00061542|Ocular Hypertension
663639|NCT00061529|Open-Angle Glaucoma
663640|NCT00061529|Ocular Hypertension
663641|NCT00061516|Glaucoma
663642|NCT00061516|Ocular Hypertension
663643|NCT00061503|Glaucoma
663644|NCT00061503|Ocular Hypertension
663645|NCT00061490|Osteoarthritis
663646|NCT00061490|Arthritis
663647|NCT00061490|Weight Loss
663648|NCT00061438|non-infected necrotizing pancreatitis
663649|NCT00061438|pancreatic infection
663650|NCT00061438|peripancreatic infection
663651|NCT00061425|NHL
663652|NCT00061425|recurrent B-cell lymphoma
663653|NCT00061412|Low reading and writing achievement
663654|NCT00061412|At-risk students
663655|NCT00061412|Reading Disability
663656|NCT00061412|Writing Disability
663657|NCT00061399|TBI
663658|NCT00061399|Prospective memory
663659|NCT00061386|Postpartum
663660|NCT00061386|Low income
663661|NCT00061386|Diet
663662|NCT00061386|Physical activity
663663|NCT00061373|Alteplase
663664|NCT00061373|Recombinant tissue plasminogen activator
663665|NCT00061373|Reperfusion therapy
663666|NCT00061373|Magnetic Resonance Imaging
663667|NCT00061373|Clinical Trial
663668|NCT00061373|Tinzaparin
663669|NCT00061373|Eptifibatide
663670|NCT00061373|Ischemic Stroke
663671|NCT00061360|Bone Marrow Failure
663672|NCT00061360|Cyclosporine
663673|NCT00061360|Anti Thymocyte Globulin
663674|NCT00061360|Severe Aplastic Anemia
663675|NCT00061347|Fiducial Marker
663676|NCT00061347|MRI
663677|NCT00061347|Prostate Cancer
663678|NCT00061347|Radiation
663679|NCT00061334|Attitudes
663680|NCT00061334|fMRI
663681|NCT00061334|Development
663682|NCT00061334|Stereotypes
663683|NCT00061334|Memory
663684|NCT00061334|Healthy Volunteer
663685|NCT00061334|HV
663686|NCT00061321|Nevirapine
663687|NCT00061321|Pregnancy
663688|NCT00061321|Maternal to Infant transmission
663689|NCT00061321|Infant
663690|NCT00061321|Breastfeeding
663691|NCT00061321|HIV Seronegativity
663692|NCT00061061|Tobacco Cessation
663693|NCT00061061|Postmenopausal Women
663694|NCT00061048|Monoclonal Antibody
663695|NCT00061048|HTLV-1
663696|NCT00061048|CD52
663697|NCT00061048|Flow Cytometry
663698|NCT00061048|Antibody Saturation
663699|NCT00061048|Adult T-Cell Leukemia (ATL)
663700|NCT00061048|ATL
663701|NCT00061035|Prostate Cancer; Immunotherapy
663702|NCT00061022|Stroke
663703|NCT00061022|cerebral vascular accident
663704|NCT00061022|CVA
663705|NCT00061022|Ischemia
663706|NCT00061022|Hemorrhage
663707|NCT00061022|TIA
663708|NCT00061022|Transient Ischemic Attack
663709|NCT00061022|Brain Attack
663710|NCT00061022|Cataplexy
663711|NCT00061009|Chronic Orthostatic Intolerance
663712|NCT00061009|Dysautonomia
663713|NCT00061009|Postural Tachycardia Syndrome
663714|NCT00061009|Neurocardiogenic
663715|NCT00061009|Syncope
663716|NCT00061009|Neurocardiogenic Syncope
663717|NCT00061009|COI
663718|NCT00061009|POTS
663719|NCT00061009|Neurocardogenic Syncope
663720|NCT00061009|NCS
663721|NCT00061009|Healthy Volunteer
663722|NCT00061009|HV
663723|NCT00060996|Critical Limb Ischemia
663724|NCT00060996|Peripheral Vascular Disease
663725|NCT00060996|UT-15
663726|NCT00060996|Remodulin
663727|NCT00060996|treprostinil
663728|NCT00060983|Locomotion
663729|NCT00060983|Spinal Cord Injury, ASIA C
663730|NCT00060983|Body weight support (BWS)
663731|NCT00060983|Functional electrical stimulation (FES)
663732|NCT00060983|Gait
663733|NCT00060983|Treadmill training
663734|NCT00060983|Physical Therapy
663735|NCT00060970|Disuse atrophy
663736|NCT00060970|Ankle fracture
663737|NCT00060970|Exercise, therapy
663738|NCT00060970|Cast immobilization
663739|NCT00060970|Deconditioning
663740|NCT00060970|Sarcopenia
663741|NCT00060957|Cerebral Palsy
663742|NCT00060957|Spasticity
663743|NCT00060957|Botulinum toxin
663744|NCT00060957|BOTOX
663745|NCT00060944|Trabectedin
663746|NCT00060944|Yondelis
663747|NCT00060944|ET-743
663748|NCT00060944|Ecteinascidin
663749|NCT00060944|Anthracycline
663750|NCT00060944|Ifosfamide
663751|NCT00060944|Dexamethasone
663752|NCT00060944|Intravenous
663753|NCT00060944|Cancer
663754|NCT00060944|Malignant
663755|NCT00060944|Metastatic
663756|NCT00060931|hypertension
663757|NCT00060931|beta-blockers
663758|NCT00060931|Type 2 diabetes
663759|NCT00060918|Type 2 diabetes
663760|NCT00060918|hypertension
663761|NCT00060918|beta-blockers
663762|NCT00060905|Bipolar Disorder (manic or mixed type)
663763|NCT00060892|Critical Limb Ischemia
663764|NCT00060866|Beta-Adrenoceptors
663765|NCT00060866|Beta-Adrenoceptor Blocker
663766|NCT00060866|Neurocardiogenic Syncope
663767|NCT00060866|Chronic Orthostatic Intolerance
663768|NCT00060866|Neurocardiogenic
663769|NCT00060866|Dysautonomia
663770|NCT00060866|Autonomic Nervous System
663771|NCT00060866|Nurocardiogenic Syncope
663772|NCT00060866|NCS
663773|NCT00060866|Sympathoadrenal Imbalance
663774|NCT00060866|SAI
663775|NCT00060866|Orthostatic Intolerance
663776|NCT00060853|Amygdala
663777|NCT00060853|Orbitofrontal Cortex
663778|NCT00060853|Emotion
663779|NCT00060853|Cognition
663780|NCT00060853|Theory of Mind
663781|NCT00060853|Healthy Volunteer
663782|NCT00060853|HV
663783|NCT00060840|Left Ventricular Assist Device Implantation
663784|NCT00060840|Progressive Left Ventricular Failure
663785|NCT00060827|Mild traumatic brain injury
663786|NCT00060801|Cystic Fibrosis
663787|NCT00060801|BIIL 284
663788|NCT00060801|Boehringer Ingelheim
663789|NCT00060788|Antisocial behavior
663790|NCT00060788|Mauritius Child Health Project
663791|NCT00060788|Intergenerational transmission
663792|NCT00060775|Magnetic Resonance Imaging
663793|NCT00060775|fMRI
663794|NCT00060775|Emotion
663795|NCT00060775|Children
663796|NCT00060775|Adolescence
663797|NCT00060775|Affective Neuroscience
663798|NCT00060775|Neuroimaging
663799|NCT00060775|Behavioral Inhibition
663800|NCT00060775|Depression
663801|NCT00060775|Anxiety
663802|NCT00060775|Normal Volunteers
663803|NCT00060775|Healthy Volunteer
663804|NCT00060775|HV
663805|NCT00060762|Weight Loss
663806|NCT00060749|Stargardt
663807|NCT00060749|Macular Dystrophy
663808|NCT00060749|ELOVL4
663809|NCT00060749|DHA
663810|NCT00060749|Stargardt's Disease
663811|NCT00060749|Autosomal Dominant Macular Dystrophy
663812|NCT00060749|Autosomal Recessive Macular Dystrophy
663813|NCT00060736|Hormone Replacement
663814|NCT00060736|Gonadal Steroids
663815|NCT00060736|Estrogen
663816|NCT00060736|Major Depression
663817|NCT00060736|Minor Depression
663818|NCT00060736|Perimenopause
663819|NCT00060736|Estradiol
663820|NCT00060736|Depression
663821|NCT00060736|Perimenopausal Depression
663822|NCT00060723|Polysomnography
663823|NCT00060723|Sleep-disordered breathing
663824|NCT00060723|Sleep apnea, obstructive
663825|NCT00060723|Hyperactivity
663826|NCT00060723|Sleep
663827|NCT00060723|Child
663828|NCT00060710|melanoma
663829|NCT00060697|Sexual risk taking
663830|NCT00060697|Mother-child communication
663831|NCT00060697|Problem behaviors
663832|NCT00060684|Pixantrone
663833|NCT00060684|BBR 2778
663834|NCT00060684|chemotherapy
663835|NCT00060684|DNA Intercalator
663836|NCT00060684|mitoxantrone
663837|NCT00060684|fludarabine
663838|NCT00060684|dexamethasone
663839|NCT00060684|Rituximab
663840|NCT00060684|Rituxan
663841|NCT00060684|Mabthera
663842|NCT00060684|monoclonal antibody
663843|NCT00060684|antibody
663844|NCT00060684|NHL
663845|NCT00060684|Non-Hodgkin's lymphoma
663846|NCT00060684|indolent
663847|NCT00060684|low grade
663848|NCT00060684|Novuspharma
663849|NCT00060671|Pixantrone
663850|NCT00060671|BBR 2778
663851|NCT00060671|chemotherapy
663852|NCT00060671|DNA Intercalator
663853|NCT00060671|Anthracycline
663854|NCT00060671|Rituximab
663855|NCT00060671|Rituxan
663856|NCT00060671|Mabthera
663857|NCT00060671|monoclonal antibody
663858|NCT00060671|antibody
663859|NCT00060671|NHL
663860|NCT00060671|Non-Hodgkin's lymphoma
663861|NCT00060671|indolent
663862|NCT00060671|low grade
663863|NCT00060671|Novuspharma
663864|NCT00060658|Prefrontal Cortex
663865|NCT00060658|Calculation
663866|NCT00060658|Mathematician
663867|NCT00060658|Cognition
663868|NCT00060658|Brain Mapping
663869|NCT00060658|Healthy Volunteer
663870|NCT00060658|HV
663871|NCT00060645|Advanced, refractory or recurrent solid tumors
663872|NCT00060632|Advanced, refractory or recurrent solid tumors
663873|NCT00060619|Migraine
663874|NCT00060619|Functional abdominal pain
663875|NCT00060619|Biofeedback
663876|NCT00060619|Psychological assessment
663877|NCT00060606|Maternal fetal surgery
663878|NCT00060606|Fetal diagnosis
663879|NCT00060606|Myelomeningocele
663880|NCT00060606|Meningomyelocele
663881|NCT00060606|Open neural tube defect
663882|NCT00060606|ONTD
663883|NCT00060606|Spina bifida
663884|NCT00060593|Balance
663885|NCT00060593|Functional Connectivity
663886|NCT00060593|Healthy Volunteer
663887|NCT00060593|HV
663888|NCT00060580|Retinal Measurements
663889|NCT00060580|Lutein in Vivo
663890|NCT00060580|Raman Spectroscopy
663891|NCT00060580|Retinal Measurements of Lutein in Vivo in the Human Eye
663892|NCT00060580|Healthy Volunteer
663893|NCT00060580|HV
663894|NCT00060567|E7070
663895|NCT00060567|Irinotecan
663896|NCT00060567|hydrochloride
663897|NCT00060567|gastrointestinal
663898|NCT00060567|cancer
663899|NCT00060554|Elective PCI
663900|NCT00060554|Heart catherization
663901|NCT00060554|Acute coronary syndromes
663902|NCT00060541|Brain Tumor
663903|NCT00060541|Epilepsy
663904|NCT00060541|Pituitary Adenoma
663905|NCT00060541|Parkinson's Disease
663906|NCT00060541|Vascular Malformation
663907|NCT00060541|Neurosurgery
663908|NCT00060541|Glioblastoma
663909|NCT00060541|Astrocytoma
663910|NCT00060541|Oligodendroglioma
663911|NCT00060541|Spinal Arteriovenous Malformation
663912|NCT00060541|Oncogenes
663913|NCT00060541|Proteomics
663914|NCT00060528|Immunotherapy
663915|NCT00060528|Cytokines
663916|NCT00060528|Immune Assays
663917|NCT00060528|Prostate Cancer
663918|NCT00060502|cachexia
663919|NCT00060502|pancreatic cancer
663920|NCT00060502|infliximab
663921|NCT00060502|anorexia
663922|NCT00060502|anemia
663923|NCT00060502|Remicade.
663924|NCT00060489|Bipolar Depression
663925|NCT00060463|Emergency contraceptive pills
663926|NCT00060463|Pregnancy
663927|NCT00060463|Sexually transmitted infection
663928|NCT00060463|Chlamydia
663929|NCT00060463|Gonorrhea
663930|NCT00060463|Trichomonas
663931|NCT00060463|Contraception
663932|NCT00060450|Ischemia-reperfusion lung injury
663933|NCT00060450|IRLI
663934|NCT00060437|stage IV prostate cancer
663935|NCT00060437|recurrent prostate cancer
663936|NCT00060437|adenocarcinoma of the prostate
663937|NCT00060398|recurrent prostate cancer
663938|NCT00060398|anemia
663939|NCT00060398|fatigue
663940|NCT00060385|stage I adult T-cell leukemia/lymphoma
663941|NCT00060385|stage I cutaneous T-cell non-Hodgkin lymphoma
663942|NCT00060385|stage II adult T-cell leukemia/lymphoma
663943|NCT00060385|stage II cutaneous T-cell non-Hodgkin lymphoma
663944|NCT00060385|stage III adult T-cell leukemia/lymphoma
663945|NCT00060385|stage III cutaneous T-cell non-Hodgkin lymphoma
663946|NCT00060385|stage IV adult T-cell leukemia/lymphoma
663947|NCT00060385|stage IV cutaneous T-cell non-Hodgkin lymphoma
663948|NCT00060385|stage I mycosis fungoides/Sezary syndrome
663949|NCT00060385|stage II mycosis fungoides/Sezary syndrome
663950|NCT00060385|stage III mycosis fungoides/Sezary syndrome
663951|NCT00060385|stage IV mycosis fungoides/Sezary syndrome
663952|NCT00060385|contiguous stage II adult diffuse large cell lymphoma
663953|NCT00060385|noncontiguous stage II adult diffuse large cell lymphoma
663954|NCT00060385|stage I adult diffuse large cell lymphoma
663955|NCT00060385|stage III adult diffuse large cell lymphoma
663956|NCT00060385|stage IV adult diffuse large cell lymphoma
663957|NCT00060346|Waldenstrom macroglobulinemia
663958|NCT00060346|Rituximab
663959|NCT00060346|CHOP
663960|NCT00060333|recurrent melanoma
663961|NCT00060333|stage I melanoma
663962|NCT00060333|stage II melanoma
663963|NCT00060333|stage III melanoma
663964|NCT00060320|stage IV breast cancer
663965|NCT00060320|stage I breast cancer
663966|NCT00060320|stage II breast cancer
663967|NCT00060320|stage IIIA breast cancer
663968|NCT00060320|stage IIIB breast cancer
663969|NCT00060320|stage IIIC breast cancer
663970|NCT00060320|hot flashes
663971|NCT00060294|Waldenström macroglobulinemia
663972|NCT00060268|recurrent esophageal cancer
663973|NCT00060268|stage I esophageal cancer
663974|NCT00060268|stage II esophageal cancer
663975|NCT00060268|stage III esophageal cancer
663976|NCT00060268|stage IV esophageal cancer
663977|NCT00060255|stage IV breast cancer
663978|NCT00060255|male breast cancer
663979|NCT00060255|recurrent malignant testicular germ cell tumor
663980|NCT00060255|Waldenstrom macroglobulinemia
663981|NCT00060255|childhood acute lymphoblastic leukemia in remission
663982|NCT00060255|adult acute lymphoblastic leukemia in remission
663983|NCT00060255|recurrent adult acute myeloid leukemia
663984|NCT00060255|adult acute myeloid leukemia in remission
663985|NCT00060255|recurrent childhood acute myeloid leukemia
663986|NCT00060255|childhood acute myeloid leukemia in remission
663987|NCT00060255|chronic phase chronic myelogenous leukemia
663988|NCT00060255|accelerated phase chronic myelogenous leukemia
663989|NCT00060255|blastic phase chronic myelogenous leukemia
663990|NCT00060255|refractory chronic lymphocytic leukemia
663991|NCT00060255|recurrent adult diffuse large cell lymphoma
663992|NCT00060255|recurrent adult diffuse mixed cell lymphoma
663993|NCT00060255|recurrent adult diffuse small cleaved cell lymphoma
663994|NCT00060255|recurrent adult Burkitt lymphoma
663995|NCT00060255|recurrent adult Hodgkin lymphoma
663996|NCT00060255|recurrent adult immunoblastic large cell lymphoma
663997|NCT00060255|recurrent childhood large cell lymphoma
663998|NCT00060255|recurrent childhood lymphoblastic lymphoma
663999|NCT00060255|recurrent childhood small noncleaved cell lymphoma
664000|NCT00060255|recurrent grade 1 follicular lymphoma
664001|NCT00060255|recurrent grade 2 follicular lymphoma
664002|NCT00060255|recurrent grade 3 follicular lymphoma
664003|NCT00060255|recurrent mantle cell lymphoma
664004|NCT00060255|recurrent/refractory childhood Hodgkin lymphoma
664005|NCT00060255|unspecified adult solid tumor, protocol specific
664006|NCT00060255|unspecified childhood solid tumor, protocol specific
664007|NCT00060255|stage IIIA breast cancer
664008|NCT00060255|stage IIIB breast cancer
664009|NCT00060255|stage IIIC breast cancer
664010|NCT00060255|recurrent breast cancer
664011|NCT00060255|primary systemic amyloidosis
664012|NCT00060255|refractory multiple myeloma
664013|NCT00060255|childhood chronic myelogenous leukemia
664014|NCT00060255|atypical chronic myeloid leukemia
664015|NCT00060255|recurrent marginal zone lymphoma
664016|NCT00060255|recurrent small lymphocytic lymphoma
664017|NCT00060255|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
664018|NCT00060255|nodal marginal zone B-cell lymphoma
664019|NCT00060255|splenic marginal zone lymphoma
664020|NCT00060255|adult acute myeloid leukemia with t(8;21)(q22;q22)
664021|NCT00060255|adult acute myeloid leukemia with t(16;16)(p13;q22)
664022|NCT00060255|adult acute myeloid leukemia with inv(16)(p13;q22)
664023|NCT00060255|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
664024|NCT00060255|adult acute myeloid leukemia with t(15;17)(q22;q12)
664025|NCT00060242|anaplastic thyroid cancer
664026|NCT00060242|recurrent thyroid cancer
664027|NCT00060203|stage III multiple myeloma
664028|NCT00060203|refractory multiple myeloma
664029|NCT00060151|unspecified adult solid tumor, protocol specific
664030|NCT00060138|hypercalcemia of malignancy
664031|NCT00060138|stage IV breast cancer
664032|NCT00060138|recurrent breast cancer
664033|NCT00060138|bone metastases
664034|NCT00060138|pain
664035|NCT00060099|cervical intraepithelial neoplasia grade 2
664036|NCT00060099|cervical intraepithelial neoplasia grade 3
664037|NCT00060099|human papilloma virus infection
664038|NCT00060086|adenocarcinoma of the prostate
664039|NCT00060086|recurrent prostate cancer
664040|NCT00060021|oral complications
664041|NCT00060021|pain
664042|NCT00060021|accelerated phase chronic myelogenous leukemia
664043|NCT00060021|blastic phase chronic myelogenous leukemia
664044|NCT00060021|chronic eosinophilic leukemia
664045|NCT00060021|primary myelofibrosis
664046|NCT00060021|chronic neutrophilic leukemia
664047|NCT00060021|chronic phase chronic myelogenous leukemia
664048|NCT00060021|de novo myelodysplastic syndromes
664049|NCT00060021|disseminated neuroblastoma
664050|NCT00060021|meningeal chronic myelogenous leukemia
664051|NCT00060021|noncontiguous stage II adult diffuse large cell lymphoma
664052|NCT00060021|noncontiguous stage II adult diffuse mixed cell lymphoma
664053|NCT00060021|noncontiguous stage II adult diffuse small cleaved cell lymphoma
664054|NCT00060021|noncontiguous stage II adult Burkitt lymphoma
664055|NCT00060021|noncontiguous stage II adult immunoblastic large cell lymphoma
664056|NCT00060021|noncontiguous stage II adult lymphoblastic lymphoma
664057|NCT00060021|noncontiguous stage II grade 1 follicular lymphoma
664058|NCT00060021|noncontiguous stage II grade 2 follicular lymphoma
664059|NCT00060021|noncontiguous stage II grade 3 follicular lymphoma
664060|NCT00060021|noncontiguous stage II mantle cell lymphoma
664061|NCT00060021|ovarian choriocarcinoma
664062|NCT00060021|ovarian embryonal carcinoma
664063|NCT00060021|ovarian yolk sac tumor
664064|NCT00060021|ovarian immature teratoma
664065|NCT00060021|ovarian mature teratoma
664066|NCT00060021|ovarian monodermal and highly specialized teratoma
664067|NCT00060021|ovarian polyembryoma
664068|NCT00060021|ovarian mixed germ cell tumor
664069|NCT00060021|high risk metastatic gestational trophoblastic tumor
664070|NCT00060021|previously treated myelodysplastic syndromes
664071|NCT00060021|recurrent adult acute lymphoblastic leukemia
664072|NCT00060021|recurrent adult diffuse large cell lymphoma
664073|NCT00060021|recurrent adult diffuse mixed cell lymphoma
664074|NCT00060021|recurrent adult diffuse small cleaved cell lymphoma
664075|NCT00060021|recurrent adult Burkitt lymphoma
664076|NCT00060021|recurrent adult Hodgkin lymphoma
664077|NCT00060021|recurrent adult immunoblastic large cell lymphoma
664078|NCT00060021|recurrent adult lymphoblastic lymphoma
664079|NCT00060021|recurrent cutaneous T-cell non-Hodgkin lymphoma
664080|NCT00060021|recurrent grade 1 follicular lymphoma
664081|NCT00060021|recurrent grade 2 follicular lymphoma
664082|NCT00060021|recurrent grade 3 follicular lymphoma
664083|NCT00060021|recurrent mantle cell lymphoma
664084|NCT00060021|recurrent mycosis fungoides/Sezary syndrome
664085|NCT00060021|recurrent neuroblastoma
664086|NCT00060021|recurrent ovarian epithelial cancer
664087|NCT00060021|recurrent ovarian germ cell tumor
664088|NCT00060021|recurrent malignant testicular germ cell tumor
664089|NCT00060021|refractory chronic lymphocytic leukemia
664090|NCT00060021|relapsing chronic myelogenous leukemia
664091|NCT00060021|refractory hairy cell leukemia
664092|NCT00060021|refractory multiple myeloma
664093|NCT00060021|secondary acute myeloid leukemia
664094|NCT00060021|secondary myelodysplastic syndromes
664095|NCT00060021|stage I multiple myeloma
664096|NCT00060021|stage II multiple myeloma
664097|NCT00060021|stage III multiple myeloma
664098|NCT00060021|stage II ovarian epithelial cancer
664099|NCT00060021|stage III adult diffuse large cell lymphoma
664100|NCT00060021|stage III adult diffuse mixed cell lymphoma
664101|NCT00060021|stage III adult diffuse small cleaved cell lymphoma
664102|NCT00060021|stage III adult Burkitt lymphoma
664103|NCT00060021|stage III adult immunoblastic large cell lymphoma
664104|NCT00060021|stage III adult lymphoblastic lymphoma
664105|NCT00060021|stage III chronic lymphocytic leukemia
664106|NCT00060021|stage III grade 1 follicular lymphoma
664107|NCT00060021|stage III grade 2 follicular lymphoma
664108|NCT00060021|stage III grade 3 follicular lymphoma
664109|NCT00060021|stage III mantle cell lymphoma
664110|NCT00060021|stage III ovarian epithelial cancer
664111|NCT00060021|stage III malignant testicular germ cell tumor
664112|NCT00060021|stage IIIA breast cancer
664113|NCT00060021|stage IIIB breast cancer
664114|NCT00060021|stage IIIC breast cancer
664115|NCT00060021|stage IV adult diffuse large cell lymphoma
664116|NCT00060021|stage IV adult diffuse mixed cell lymphoma
664117|NCT00060021|stage IV adult diffuse small cleaved cell lymphoma
664118|NCT00060021|stage IV adult Burkitt lymphoma
664119|NCT00060021|stage IV adult immunoblastic large cell lymphoma
664120|NCT00060021|stage IV adult lymphoblastic lymphoma
664121|NCT00060021|stage IV breast cancer
664122|NCT00060021|stage IV chronic lymphocytic leukemia
664123|NCT00060021|stage IV grade 1 follicular lymphoma
664124|NCT00060021|stage IV grade 2 follicular lymphoma
664125|NCT00060021|stage IV grade 3 follicular lymphoma
664126|NCT00060021|stage IV mantle cell lymphoma
664127|NCT00060021|stage IV ovarian epithelial cancer
664128|NCT00060021|testicular choriocarcinoma and embryonal carcinoma
664129|NCT00060021|testicular choriocarcinoma and seminoma
664130|NCT00060021|testicular choriocarcinoma and teratoma
664131|NCT00060021|testicular choriocarcinoma and yolk sac tumor
664132|NCT00060021|testicular embryonal carcinoma and seminoma
664133|NCT00060021|testicular embryonal carcinoma and teratoma with seminoma
664134|NCT00060021|testicular embryonal carcinoma and teratoma
664135|NCT00060021|testicular embryonal carcinoma and yolk sac tumor with seminoma
664136|NCT00060021|testicular embryonal carcinoma and yolk sac tumor
664137|NCT00060021|testicular embryonal carcinoma
664138|NCT00060021|testicular teratoma
664139|NCT00060021|testicular yolk sac tumor and teratoma with seminoma
664140|NCT00060021|testicular yolk sac tumor and teratoma
664141|NCT00060021|testicular yolk sac tumor
664142|NCT00060021|recurrent adult acute myeloid leukemia
664143|NCT00060021|testicular choriocarcinoma
664254|NCT00059644|peripheral
664144|NCT00060021|atypical chronic myeloid leukemia, BCR-ABL1 negative
664145|NCT00060021|myelodysplastic/myeloproliferative neoplasm, unclassifiable
664146|NCT00060021|noncontiguous stage II small lymphocytic lymphoma
664147|NCT00060021|noncontiguous stage II marginal zone lymphoma
664148|NCT00060021|recurrent marginal zone lymphoma
664149|NCT00060021|recurrent small lymphocytic lymphoma
664150|NCT00060021|stage III small lymphocytic lymphoma
664151|NCT00060021|stage III marginal zone lymphoma
664152|NCT00060021|stage IV small lymphocytic lymphoma
664153|NCT00060021|stage IV marginal zone lymphoma
664154|NCT00060021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
664155|NCT00060021|nodal marginal zone B-cell lymphoma
664156|NCT00060021|splenic marginal zone lymphoma
664157|NCT00060008|neurofibromatosis type 1
664158|NCT00060008|plexiform neurofibroma
664159|NCT00059995|recurrent adult Hodgkin lymphoma
664160|NCT00059995|recurrent/refractory childhood Hodgkin lymphoma
664161|NCT00059995|anaplastic large cell lymphoma
664162|NCT00059995|recurrent adult diffuse large cell lymphoma
664163|NCT00059995|recurrent childhood large cell lymphoma
664164|NCT00059995|recurrent cutaneous T-cell non-Hodgkin lymphoma
664165|NCT00059982|adenocarcinoma of the pancreas
664166|NCT00059982|stage II pancreatic cancer
664167|NCT00059982|stage III pancreatic cancer
664168|NCT00059982|stage IV pancreatic cancer
664169|NCT00059943|stage IV breast cancer
664170|NCT00059943|stage IV non-small cell lung cancer
664171|NCT00059943|recurrent non-small cell lung cancer
664172|NCT00059943|recurrent breast cancer
664173|NCT00059943|stage IV prostate cancer
664174|NCT00059943|recurrent prostate cancer
664175|NCT00059930|liver metastases
664176|NCT00059930|stage IV colon cancer
664177|NCT00059930|stage IV rectal cancer
664178|NCT00059930|adenocarcinoma of the colon
664179|NCT00059930|adenocarcinoma of the rectum
664180|NCT00059930|recurrent colon cancer
664181|NCT00059930|recurrent rectal cancer
664182|NCT00059917|unspecified adult solid tumor, protocol specific
664183|NCT00059904|recurrent adult diffuse large cell lymphoma
664184|NCT00059904|recurrent adult diffuse mixed cell lymphoma
664185|NCT00059904|recurrent adult immunoblastic large cell lymphoma
664186|NCT00059891|perioperative/postoperative complications
664187|NCT00059891|stage II anal cancer
664188|NCT00059891|stage I anal cancer
664189|NCT00059891|stage III anal cancer
664190|NCT00059891|stage I rectal cancer
664191|NCT00059891|stage II rectal cancer
664192|NCT00059891|stage III rectal cancer
664193|NCT00059878|infection
664194|NCT00059878|unspecified adult solid tumor, protocol specific
664195|NCT00059865|advanced adult primary liver cancer
664196|NCT00059865|unresectable gallbladder cancer
664197|NCT00059865|unresectable extrahepatic bile duct cancer
664198|NCT00059865|adult primary cholangiocellular carcinoma
664199|NCT00059852|male breast cancer
664200|NCT00059852|recurrent breast cancer
664201|NCT00059852|stage IV breast cancer
664202|NCT00059839|anaplastic large cell lymphoma
664203|NCT00059826|stage I pancreatic cancer
664204|NCT00059826|stage II pancreatic cancer
664205|NCT00059826|stage III pancreatic cancer
664206|NCT00059826|adenocarcinoma of the pancreas
664207|NCT00059800|recurrent melanoma
664208|NCT00059800|stage 0 melanoma
664209|NCT00059800|stage I melanoma
664210|NCT00059800|stage II melanoma
664211|NCT00059800|stage III melanoma
664212|NCT00059800|stage IV melanoma
664213|NCT00059761|limited stage small cell lung cancer
664214|NCT00059748|Central Nervous System Abnormalities
664215|NCT00059748|Arthropathy
664216|NCT00059748|Urticaria
664217|NCT00059748|Papilledema
664218|NCT00059748|Autoinflammation
664219|NCT00059748|Neonatal Onset Multisystem Imflammatory
664220|NCT00059748|Disease
664221|NCT00059748|NOMID
664222|NCT00059735|kidney cancer
664223|NCT00059735|kidney neoplasms
664224|NCT00059735|renal cell cancer
664225|NCT00059722|NSCLC
664226|NCT00059722|locally advanced or metastatic
664227|NCT00059722|second-line
664228|NCT00059709|Conflict Resolution training
664229|NCT00059709|Children
664230|NCT00059696|Constraint-Induced Movement Therapy
664231|NCT00059696|CI therapy
664232|NCT00059696|Rehabilitation
664233|NCT00059696|Cerebrovascular accident
664234|NCT00059696|Upper extremity
664235|NCT00059696|Concentrated, extended practice
664236|NCT00059696|Limb restraint
664237|NCT00059696|Motor Deficits
664238|NCT00059683|Preterm Birth
664239|NCT00059683|Premature Birth
664240|NCT00059683|Cervical cerclage
664241|NCT00059683|Vaginal ultrasound
664242|NCT00059683|Cervical length
664243|NCT00059670|UES
664244|NCT00059670|Dysphagia
664245|NCT00059657|Ecraprost in lipid emulsion
664246|NCT00059657|CLI
664247|NCT00059657|peripheral, vascular
664248|NCT00059657|amputation
664249|NCT00059657|Angioplasty
664250|NCT00059657|by-pass
664251|NCT00059657|Critical Limb Ischemia due to peripheral arterial disease
664252|NCT00059644|Ecraprost in lipid emulsion
664253|NCT00059644|CLI
664255|NCT00059644|vascular
664256|NCT00059644|amputation
664257|NCT00059644|Critical Limb Ischemia due to peripheral arterial disease
664258|NCT00059631|Prostate Cancer
664259|NCT00059631|Advanced Androgen-Independent Prostate Cancer
664260|NCT00059631|AI-PCa
664261|NCT00059631|Advanced Prostate Cancer
664262|NCT00059631|Novantrone
664263|NCT00059631|Mitoxantrone
664264|NCT00059631|PS-341
664265|NCT00059631|Bortezomib
664266|NCT00059631|Velcade
664267|NCT00059631|LDP-341
664268|NCT00059631|MLN341
664269|NCT00059631|20S proteasome
664270|NCT00059618|Platinum Resistant
664271|NCT00059618|Taxane Resistant
664272|NCT00059618|Ovarian Cancer
664273|NCT00059618|Primary Peritoneal Cancer
664274|NCT00059618|Fallopian Tube Cancer
664275|NCT00059618|Bortezomib
664276|NCT00059618|PS-341
664277|NCT00059618|Velcade
664278|NCT00059618|LDP-341
664279|NCT00059618|MLN341
664280|NCT00059618|Carboplatin
664281|NCT00059618|Paraplatin
664282|NCT00059605|Non-Small Cell Lung Cancer
664283|NCT00059605|Small Cell Lung Cancer
664284|NCT00059605|Lung Cancer
664285|NCT00059605|NSCLC
664286|NCT00059605|SCLC
664287|NCT00059605|DOTAP:Chol-fus1
664288|NCT00059605|gene
664289|NCT00059605|gene transfer
664290|NCT00059579|Reward
664291|NCT00059579|Cortex
664292|NCT00059579|Dopamine
664293|NCT00059579|Neuroimaging
664294|NCT00059579|Strirtum
664295|NCT00059579|Major Depressive Disorder (MDD)
664296|NCT00059579|Melancholic Features
664297|NCT00059579|Brain Imaging
664298|NCT00059579|Functional Magnetic Resonance Imaging (fMRI)
664299|NCT00059579|Dopaminergic Mechanisms
664300|NCT00059579|Anhedonia
664301|NCT00059579|Depression
664302|NCT00059579|Major Depressive Disorder
664303|NCT00059579|MDD
664304|NCT00059579|Healthy Volunteer
664305|NCT00059579|HV
664306|NCT00059553|spinal cord injury
664307|NCT00059553|walking
664308|NCT00059553|training
664309|NCT00059553|treadmill
664310|NCT00059553|incomplete spinal cord injury
664311|NCT00059540|NICHD Neonatal Research Network
664312|NCT00059540|Maternal Lifestyle Study
664313|NCT00059540|Cocaine abuse
664314|NCT00059540|Cocaine dependence
664315|NCT00059540|Opiate abuse
664316|NCT00059540|Opiate dependence
664317|NCT00059540|Follow-up
664318|NCT00059540|Neurodevelopmental outcome
664319|NCT00059540|Substance-related disorders
664320|NCT00059527|Physical Activity
664321|NCT00059527|Nutrition
664322|NCT00059527|Self Efficacy
664323|NCT00059527|Middle School
664324|NCT00059527|Intervention
664325|NCT00059514|Youth
664326|NCT00059514|Adolescents
664327|NCT00059514|Smoking cessation
664328|NCT00059514|Smoking prevention
664329|NCT00059514|Risk factors
664330|NCT00059514|Arab Americans
664331|NCT00059501|Postural Stability
664332|NCT00059501|EEG
664333|NCT00059501|Aging
664334|NCT00059501|Falls
664335|NCT00059501|Healthy Volunteer
664336|NCT00059501|HV
664337|NCT00059475|Adjuvant Therapy
664338|NCT00059475|MART-1 Peptides
664339|NCT00059475|GP100 Peptide
664340|NCT00059475|Immunologic Response
664341|NCT00059475|Melanoma
664342|NCT00059462|Treatment experienced
664343|NCT00059449|Enterocolitis
664344|NCT00059436|Muscle strengthening
664345|NCT00059436|Skeletal muscle Contractions
664346|NCT00059436|Rehabilitative exercise
664347|NCT00059423|Leukapheresis
664348|NCT00059423|G-CSF
664349|NCT00059423|Dexamethasone
664350|NCT00059423|mRNA
664351|NCT00059423|Benign Ethnic Neutropenia
664352|NCT00059423|BEN
664353|NCT00059423|Healthy Volunteer
664354|NCT00059423|HV
664355|NCT00059410|Alzheimer disease
664356|NCT00059410|Caregivers
664357|NCT00059410|African Americans
664358|NCT00059410|Perceptions
664359|NCT00059410|Cultural Competency
664360|NCT00059397|Hepatitis C
664361|NCT00059384|Treatment experienced
664362|NCT00059384|Therapeutic Drug Monitoring
664363|NCT00059371|Male circumcision
664364|NCT00059371|HIV acquisition
664365|NCT00059371|Sexually transmitted infection
664366|NCT00059371|HIV Seronegativity
664367|NCT00059358|HIV
664368|NCT00059358|HCV
664369|NCT00059358|Ribavirin
664370|NCT00059358|Interferon
664371|NCT00059358|Co-infection
664372|NCT00059358|Treatment experienced
664373|NCT00059345|Acupuncture
664374|NCT00059345|Arthritis
664375|NCT00059332|stroke
664376|NCT00059332|brain attack
664377|NCT00059332|magnesium sulfate
664378|NCT00059332|neuroprotection
664379|NCT00059332|prehospital care
664380|NCT00059332|emergency medical services
664381|NCT00059319|coronary artery bypass graft surgery
664382|NCT00059319|CABG surgery
664383|NCT00059319|neurobehavioral impairment
664384|NCT00059319|aorta clamping
664385|NCT00059319|aorta manipulation
664386|NCT00059319|microemboli
664387|NCT00059306|stroke
664388|NCT00059306|hypertension
664389|NCT00059306|high blood pressure
664390|NCT00059306|lacunar stroke
664391|NCT00059306|subcortical stroke
664392|NCT00059306|aspirin
664393|NCT00059306|clopidogrel
664394|NCT00059280|Pompe disease
664395|NCT00059280|Glycogen storage disease type II
664396|NCT00059280|GSD-II
664397|NCT00059280|Acid maltase deficiency disease
664398|NCT00059280|Glycogenosis 2
664399|NCT00059254|fatty acids
664400|NCT00059254|oleic acid
664401|NCT00059254|palmitic acid
664402|NCT00059254|fat oxidation
664403|NCT00059254|energy expenditure
664404|NCT00059254|body composition
664405|NCT00059254|monounsaturated fat
664406|NCT00059254|human
664407|NCT00059241|Early sexual initiation
664408|NCT00059241|Prevention of early sexual activity
664409|NCT00059241|Middle childhood
664410|NCT00059228|Pregnancy
664411|NCT00059228|Gonadal Steroids
664412|NCT00059228|Antidepressants
664413|NCT00059228|Puerperium
664414|NCT00059228|Depression
664415|NCT00059228|Postpartum
664416|NCT00059228|Estradiol
664417|NCT00059228|Estrogen Response Element
664418|NCT00059228|Postpartum Depression
664419|NCT00059202|Urso
664420|NCT00059202|PSC
664421|NCT00059189|Occipital Cortex
664422|NCT00059189|Prefrontal Cortex
664423|NCT00059189|Transcranial Magnetic Stimulation
664424|NCT00059189|Inhibition
664425|NCT00059189|Cortical Excitability
664426|NCT00059189|Blindness
664427|NCT00059189|Healthy Volunteer
664428|NCT00059189|HV
664429|NCT00059137|Gating
664430|NCT00059137|Respiratory Misregistration
664431|NCT00059137|Abdominal Belt
664432|NCT00059137|Percutaneous
664433|NCT00059137|CT Guided Biopsy
664434|NCT00059137|Respiratory Cycle
664435|NCT00059137|Needle Biopsy
664436|NCT00059046|Neuroreceptors
664437|NCT00059046|PET Measurements
664438|NCT00059046|Kinetic Analysis
664439|NCT00059046|Test/Retest
664440|NCT00059046|Healthy Volunteer
664441|NCT00059046|HV
664442|NCT00059033|6-[18F]Fluorodopamine
664443|NCT00059033|Autonomic Failure
664444|NCT00059033|Parkinson's Disease
664445|NCT00059033|Multiple System Atrophy
664446|NCT00059033|Pure Autonomic Failure
664447|NCT00059033|Primary Chronic Autonomic Failure
664448|NCT00059033|CAF
664449|NCT00059020|Glioma
664450|NCT00059020|Brain Tumor
664451|NCT00059020|Epidermal Growth Factor
664452|NCT00059020|Polymorphisms
664453|NCT00058994|AMD
664454|NCT00058994|anecortave acetate
664455|NCT00058994|wet AMD
664456|NCT00058994|age-related macular degeneration
664457|NCT00058994|Macular Degeneration
664458|NCT00058994|Maculopathy, Age-Related
664459|NCT00058994|Age-Related Maculopathies
664460|NCT00058994|Age-Related Maculopathy
664461|NCT00058994|Maculopathies, Age-Related
664462|NCT00058981|Diabetes
664463|NCT00058981|LADA
664464|NCT00058981|latent autoimmune diabetes in adults
664465|NCT00058968|neuropathy
664466|NCT00058968|pain
664467|NCT00058968|diabetes
664468|NCT00058968|chronic pain
664469|NCT00058968|persistent pain
664470|NCT00058968|leg pain
664471|NCT00058968|peripheral neuropathy
664472|NCT00058968|foot pain
664473|NCT00058968|painful neuropathy
664474|NCT00058968|diabetic neuropathy
664475|NCT00058955|ghb
664476|NCT00058955|Xyrem
664477|NCT00058955|triazolam
664478|NCT00058955|pentobarbital
664479|NCT00058955|sedative
664480|NCT00058955|abuse
664481|NCT00058942|Drinking Water
664482|NCT00058903|Cholestatic
664483|NCT00058903|Pruritus
664484|NCT00058903|Sertraline
664485|NCT00058903|primary biliary cirrhosis
664486|NCT00058903|hepatitis C
664487|NCT00058890|itching
664488|NCT00058890|pruritus
664489|NCT00058890|cholestasis
664490|NCT00058890|liver disease
664491|NCT00058890|hepatitis
664492|NCT00058890|cirrhosis
664493|NCT00058877|Barrett's
664494|NCT00058877|Esophagus
664495|NCT00058851|Manual lymph drainage
664496|NCT00058851|Combined physiotherapy
664497|NCT00058825|Campath
664498|NCT00058825|stem cell transplant
664499|NCT00058812|Cytotoxic T Lymphocytes
664500|NCT00058812|bone marrow transplant
664501|NCT00058812|EBV+ lymphoproliferative disease
664502|NCT00058773|Hodgkin disease
664503|NCT00058773|non-Hodgkins Lymphoma
664504|NCT00058773|bone marrow transplant
664505|NCT00058760|Prevention of early sexual behavior
664506|NCT00058760|NIA intervention
664507|NCT00058747|Granulocytic Leukemia, Chronic
664508|NCT00058747|Leukemia, Granulocytic, Chronic
664509|NCT00058747|Leukemia, Myelocytic, Chronic
664510|NCT00058747|Leukemia, Myelogenous, Chronic
664511|NCT00058747|Myelocytic Leukemia, Chronic
664512|NCT00058747|Myelogenous Leukemia, Chronic
664513|NCT00058747|Myeloid Leukemia, Chronic
664514|NCT00058734|Dendritic Cell
664515|NCT00058734|Immunotherapy
664516|NCT00058734|Acute HIV
664517|NCT00058734|Human Immunodeficiency Virus
664518|NCT00058734|AIDS
664519|NCT00058734|HIV Therapeutic Vaccine
664520|NCT00058734|Treatment Experienced
664521|NCT00058734|Treatment Interruption
664522|NCT00058721|Dementia
664523|NCT00058721|Feasibility
664524|NCT00058721|Dopamine
664525|NCT00058721|Lewy Body
664526|NCT00058721|Parkinson Disease
664527|NCT00058721|PD
664528|NCT00058721|Healthy Volunteer
664529|NCT00058721|HV
664530|NCT00058695|Macualar Degeneration
664531|NCT00058695|AMD
664532|NCT00058695|Healthy Volunteer
664533|NCT00058695|HV
664534|NCT00058682|Fungal Infection
664535|NCT00058682|Mycoses
664536|NCT00058682|Candida Species
664537|NCT00058682|Candidiasis
664538|NCT00058656|Immunotherapy
664539|NCT00058656|T Cell Therapy
664540|NCT00058656|Adoptive immunotherapy
664541|NCT00058656|Xcellerate
664542|NCT00058656|Xcellerated
664543|NCT00058617|EBV Positive Hodgkin's Lymphoma
664544|NCT00058617|EBV Positive Non-Hodgkin's Lymphoma
664545|NCT00058617|EBV Specific Cytotoxic T-Lymphocytes
664546|NCT00058552|Advanced, refractory, or recurrent ovarian cancer
664547|NCT00058526|dHER2-AS15 ASCI
664548|NCT00058526|Immunotherapeutic
664549|NCT00058526|Dose escalation
664550|NCT00058526|Breast cancer
664551|NCT00058487|adult primary hepatocellular carcinoma
664552|NCT00058487|advanced adult primary liver cancer
664553|NCT00058487|localized unresectable adult primary liver cancer
664554|NCT00058487|recurrent adult primary liver cancer
664555|NCT00058474|stage II rectal cancer
664556|NCT00058474|stage III rectal cancer
664557|NCT00058474|adenocarcinoma of the rectum
664558|NCT00058448|stage II penile cancer
664559|NCT00058448|stage III penile cancer
664560|NCT00058448|stage IV penile cancer
664561|NCT00058435|stage II ovarian epithelial cancer
664562|NCT00058435|stage III ovarian epithelial cancer
664563|NCT00058435|stage IV ovarian epithelial cancer
664564|NCT00058435|recurrent ovarian epithelial cancer
664565|NCT00058435|fallopian tube cancer
664566|NCT00058435|primary peritoneal cavity cancer
664567|NCT00058422|noncontiguous stage II adult diffuse large cell lymphoma
664568|NCT00058422|stage III adult diffuse large cell lymphoma
664569|NCT00058422|stage IV adult diffuse large cell lymphoma
664570|NCT00058396|refractory chronic lymphocytic leukemia
664571|NCT00058396|stage I chronic lymphocytic leukemia
664572|NCT00058396|stage II chronic lymphocytic leukemia
664573|NCT00058396|stage III chronic lymphocytic leukemia
664574|NCT00058396|stage IV chronic lymphocytic leukemia
664575|NCT00058396|noncontiguous stage II small lymphocytic lymphoma
664576|NCT00058396|recurrent small lymphocytic lymphoma
664577|NCT00058396|stage I small lymphocytic lymphoma
664578|NCT00058396|stage III small lymphocytic lymphoma
664579|NCT00058396|stage IV small lymphocytic lymphoma
664580|NCT00058396|contiguous stage II small lymphocytic lymphoma
664581|NCT00058370|adult medulloblastoma
664582|NCT00058370|untreated childhood medulloblastoma
664583|NCT00058357|unspecified adult solid tumor, protocol specific
664584|NCT00058357|pain
664585|NCT00058318|stage IV renal cell cancer
664586|NCT00058318|stage III renal cell cancer
664587|NCT00058292|recurrent grade 1 follicular lymphoma
664588|NCT00058292|recurrent grade 2 follicular lymphoma
664589|NCT00058292|recurrent grade 3 follicular lymphoma
664590|NCT00058292|recurrent adult diffuse large cell lymphoma
664591|NCT00058292|recurrent adult diffuse mixed cell lymphoma
664592|NCT00058292|recurrent adult Burkitt lymphoma
664593|NCT00058292|recurrent adult immunoblastic large cell lymphoma
664594|NCT00058292|recurrent mantle cell lymphoma
664595|NCT00058292|recurrent adult lymphoblastic lymphoma
664596|NCT00058292|recurrent adult diffuse small cleaved cell lymphoma
664597|NCT00058292|recurrent marginal zone lymphoma
664598|NCT00058292|recurrent small lymphocytic lymphoma
664599|NCT00058292|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
664600|NCT00058292|nodal marginal zone B-cell lymphoma
664601|NCT00058292|splenic marginal zone lymphoma
664602|NCT00058279|stage IV melanoma
664603|NCT00058279|extraocular extension melanoma
664604|NCT00058279|recurrent melanoma
664605|NCT00058279|iris melanoma
664606|NCT00058279|ciliary body and choroid melanoma, medium/large size
664607|NCT00058279|ciliary body and choroid melanoma, small size
664608|NCT00058279|recurrent intraocular melanoma
664609|NCT00058266|stage I prostate cancer
664610|NCT00058266|stage II prostate cancer
664611|NCT00058201|acinar cell adenocarcinoma of the pancreas
664612|NCT00058201|duct cell adenocarcinoma of the pancreas
664613|NCT00058201|stage I pancreatic cancer
664614|NCT00058201|stage II pancreatic cancer
664615|NCT00058201|stage III pancreatic cancer
664616|NCT00058201|stage IV pancreatic cancer
664617|NCT00058188|osteoporosis
664618|NCT00058188|stage III prostate cancer
664619|NCT00058188|stage IV prostate cancer
664620|NCT00058149|stage II pancreatic cancer
664621|NCT00058149|stage III pancreatic cancer
664622|NCT00058149|adenocarcinoma of the pancreas
664623|NCT00058149|stage IV pancreatic cancer
664624|NCT00058123|adult anaplastic astrocytoma
664625|NCT00058123|adult mixed glioma
664626|NCT00058123|adult anaplastic oligodendroglioma
664627|NCT00058123|recurrent adult brain tumor
664628|NCT00058123|adult anaplastic ependymoma
664629|NCT00058071|peripheral neuropathy
664630|NCT00058071|neurotoxicity
664631|NCT00058071|hydatidiform mole
664632|NCT00058071|unspecified adult solid tumor, protocol specific
664633|NCT00058058|ductal breast carcinoma in situ
664634|NCT00058058|invasive ductal breast carcinoma
664635|NCT00058058|invasive lobular breast carcinoma
664636|NCT00058058|breast cancer in situ
664637|NCT00058058|stage I breast cancer
664638|NCT00058058|stage II breast cancer
664639|NCT00058058|stage IIIA breast cancer
664640|NCT00058058|stage IIIB breast cancer
664641|NCT00058058|stage IIIC breast cancer
664642|NCT00058058|stage IV breast cancer
664643|NCT00058045|AIDS-related peripheral/systemic lymphoma
664644|NCT00058032|ovarian epithelial cancer
664645|NCT00058006|stage I non-small cell lung cancer
664646|NCT00058006|stage I squamous cell carcinoma of the hypopharynx
664647|NCT00058006|stage I squamous cell carcinoma of the larynx
664648|NCT00058006|stage I squamous cell carcinoma of the lip and oral cavity
664649|NCT00058006|stage I squamous cell carcinoma of the nasopharynx
664650|NCT00058006|stage I squamous cell carcinoma of the oropharynx
664651|NCT00058006|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
664652|NCT00058006|stage II squamous cell carcinoma of the hypopharynx
664653|NCT00058006|stage II squamous cell carcinoma of the larynx
664654|NCT00058006|stage II squamous cell carcinoma of the lip and oral cavity
664655|NCT00058006|stage II squamous cell carcinoma of the nasopharynx
664656|NCT00058006|stage II squamous cell carcinoma of the oropharynx
664657|NCT00058006|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
664658|NCT00058006|salivary gland squamous cell carcinoma
664659|NCT00058006|stage I salivary gland cancer
664660|NCT00058006|stage II salivary gland cancer
664661|NCT00057993|stage IV breast cancer
664662|NCT00057993|stage IIIA breast cancer
664663|NCT00057993|stage IIIB breast cancer
664664|NCT00057993|stage IIIC breast cancer
664665|NCT00057980|advanced adult primary liver cancer
664666|NCT00057980|localized unresectable adult primary liver cancer
664667|NCT00057980|adult primary hepatocellular carcinoma
664668|NCT00057967|recurrent mycosis fungoides/Sezary syndrome
664669|NCT00057967|stage I mycosis fungoides/Sezary syndrome
664670|NCT00057967|stage II mycosis fungoides/Sezary syndrome
664671|NCT00057967|stage III mycosis fungoides/Sezary syndrome
664672|NCT00057967|stage IV mycosis fungoides/Sezary syndrome
664673|NCT00057967|recurrent cutaneous T-cell non-Hodgkin lymphoma
664674|NCT00057967|stage I cutaneous T-cell non-Hodgkin lymphoma
664675|NCT00057967|stage II cutaneous T-cell non-Hodgkin lymphoma
664676|NCT00057967|stage III cutaneous T-cell non-Hodgkin lymphoma
664677|NCT00057967|stage IV cutaneous T-cell non-Hodgkin lymphoma
664678|NCT00057954|recurrent adult Hodgkin lymphoma
664679|NCT00057954|recurrent adult diffuse large cell lymphoma
664680|NCT00057954|recurrent adult diffuse mixed cell lymphoma
664681|NCT00057954|recurrent adult diffuse small cleaved cell lymphoma
664682|NCT00057954|recurrent adult Burkitt lymphoma
664683|NCT00057954|recurrent adult immunoblastic large cell lymphoma
664684|NCT00057954|recurrent adult lymphoblastic lymphoma
664685|NCT00057954|recurrent grade 1 follicular lymphoma
664686|NCT00057954|recurrent grade 2 follicular lymphoma
664687|NCT00057954|recurrent grade 3 follicular lymphoma
664688|NCT00057954|recurrent mantle cell lymphoma
664689|NCT00057954|recurrent mycosis fungoides/Sezary syndrome
664690|NCT00057954|recurrent adult T-cell leukemia/lymphoma
664691|NCT00057954|anaplastic large cell lymphoma
664692|NCT00057954|recurrent marginal zone lymphoma
664693|NCT00057954|recurrent small lymphocytic lymphoma
664694|NCT00057954|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
664695|NCT00057954|nodal marginal zone B-cell lymphoma
664696|NCT00057954|splenic marginal zone lymphoma
664697|NCT00057928|recurrent cervical cancer
664698|NCT00057928|stage IVB cervical cancer
664699|NCT00057915|unspecified adult solid tumor, protocol specific
664700|NCT00057889|clear cell renal cell carcinoma
664701|NCT00057889|stage IV renal cell cancer
664702|NCT00057889|recurrent renal cell cancer
664703|NCT00057876|stage III pancreatic cancer
664704|NCT00057876|adenocarcinoma of the pancreas
664705|NCT00057850|recurrent squamous cell carcinoma of the hypopharynx
664706|NCT00057850|recurrent squamous cell carcinoma of the larynx
664707|NCT00057850|recurrent squamous cell carcinoma of the lip and oral cavity
664708|NCT00057850|recurrent squamous cell carcinoma of the oropharynx
664709|NCT00057850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
664710|NCT00057850|stage IV squamous cell carcinoma of the hypopharynx
664711|NCT00057850|stage IV squamous cell carcinoma of the larynx
664712|NCT00057850|stage IV squamous cell carcinoma of the lip and oral cavity
664713|NCT00057850|stage IV squamous cell carcinoma of the oropharynx
664714|NCT00057850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
664715|NCT00057850|recurrent salivary gland cancer
664716|NCT00057850|salivary gland squamous cell carcinoma
664717|NCT00057850|stage IV salivary gland cancer
664718|NCT00057837|extensive stage small cell lung cancer
664719|NCT00057837|Topotecan
664720|NCT00057837|Etoposide
664721|NCT00057837|Cisplatin
664722|NCT00057837|Irinotecan
664723|NCT00057798|stage I non-small cell lung cancer
664724|NCT00057798|stage II non-small cell lung cancer
664725|NCT00057798|stage IIIA non-small cell lung cancer
664726|NCT00057798|stage IIIB non-small cell lung cancer
664727|NCT00057785|oral complications of radiation therapy
664728|NCT00057785|radiation toxicity
664729|NCT00057785|stage I squamous cell carcinoma of the nasopharynx
664730|NCT00057785|stage II squamous cell carcinoma of the nasopharynx
664731|NCT00057785|stage III squamous cell carcinoma of the nasopharynx
664732|NCT00057785|stage IV squamous cell carcinoma of the nasopharynx
664733|NCT00057759|sexual dysfunction
664734|NCT00057759|sexuality and reproductive issues
664735|NCT00057759|radiation toxicity
664736|NCT00057759|stage IIB prostate cancer
664737|NCT00057759|stage IIA prostate cancer
664738|NCT00057759|stage III prostate cancer
664739|NCT00057759|psychosocial effects of cancer and its treatment
664740|NCT00057746|limited stage small cell lung cancer
664741|NCT00057733|anxiety disorder
664742|NCT00057733|depression
664743|NCT00057733|unspecified adult solid tumor, protocol specific
664744|NCT00057720|ovary
664745|NCT00057707|Catecholamines
664746|NCT00057707|Dopamine
664747|NCT00057707|fMRI
664748|NCT00057707|Working Memory
664749|NCT00057707|Clinical Trial
664750|NCT00057707|Stabilization
664751|NCT00057707|Inpatients
664752|NCT00057707|Placebo
664753|NCT00057707|Modafinil
664754|NCT00057707|Normal Volunteers
664755|NCT00057707|Schizophrenia
664756|NCT00057707|Schizoaffective Disorder
664757|NCT00057707|Healthy Volunteer
664758|NCT00057707|HV
664759|NCT00057694|Qualitative
664760|NCT00057694|Telephone Interviews
664761|NCT00057694|Genetic Counseling
664762|NCT00057694|Family History
664763|NCT00057694|Health Information
664764|NCT00057694|Adult Adoptees
664765|NCT00057694|Adult Adoptee
664766|NCT00057694|Interview
664767|NCT00057681|Mania
664768|NCT00057655|Social Welfare
664769|NCT00057655|Mentally Ill Persons
664770|NCT00057655|Mental Health Services
664771|NCT00057642|Hispanic Americans
664772|NCT00057629|Rape
664773|NCT00057629|Sex Offenses
664774|NCT00057616|Metastatic Melanoma
664775|NCT00057616|Melanoma
664776|NCT00057616|Revimid
664777|NCT00057616|CC5013
664778|NCT00057564|Newly Diagnosed Multiple Myeloma
664779|NCT00057564|Multiple Myeloma
664780|NCT00057538|HIV
664781|NCT00057538|Randomized Trial
664782|NCT00057538|Stress
664783|NCT00057538|Spirituality
664784|NCT00057538|Quality of Life
664785|NCT00057538|Complementary Therapies
664786|NCT00057525|Anthrax
664787|NCT00057499|Juvenile diabetes
664788|NCT00057499|Diabetes
664789|NCT00057499|Insulin
664790|NCT00057499|Vaccine
664791|NCT00057499|Type 1 Diabetes
664792|NCT00057499|Diabetes Mellitus
664793|NCT00057486|Chronic Diarrhea
664794|NCT00057486|Interleukin 12
664795|NCT00057473|unspecified childhood solid tumor, protocol specific
664796|NCT00057460|Antiepileptic Drug
664797|NCT00057460|Neuroprotection
664798|NCT00057460|Seizure Disorder
664799|NCT00057460|TMS Stimulation
664800|NCT00057460|EEG
664801|NCT00057460|AMPA Antagonist
664802|NCT00057460|Dosing
664803|NCT00057460|Transcranial Magnetic Stimulation
664804|NCT00057460|Healthy Volunteer
664805|NCT00057460|HV
664806|NCT00057447|lymphoma
664807|NCT00057434|Vitamin A
664808|NCT00057421|Tuberculosis
664809|NCT00057421|HIV infection
664810|NCT00057421|Prednisolone
664811|NCT00057421|Safety
664812|NCT00057421|Immune activation
664813|NCT00057408|Autism
664814|NCT00057408|Pervasive Developmental Disorder
664815|NCT00057408|Treatment
664816|NCT00057408|Olanzapine
664817|NCT00057408|Antipsychotic
664818|NCT00057395|Esophageal Neoplasms
664819|NCT00057395|Esophagus Neoplasm
664820|NCT00057395|Esophagus Cancer
664821|NCT00057395|Esophageal Cancer
664822|NCT00057395|Esophageal Tumors
664823|NCT00057395|Esophagus Tumors
664824|NCT00057395|Neoplasms, Esophageal
664825|NCT00057395|Hepatocellular Carcinoma
664826|NCT00057395|Carcinoma, Hepatocellular
664827|NCT00057395|Hepatoma
664828|NCT00057395|Colorectal Neoplasms
664829|NCT00057395|Colorectal Cancer
664830|NCT00057395|Colorectal Carcinoma
664831|NCT00057395|Colorectal Tumor
664832|NCT00057395|Neoplasms, Colorectal
664833|NCT00057395|Ovarian Neoplasms
664834|NCT00057395|Ovary Neoplasms
664835|NCT00057395|Ovary Cancer
664836|NCT00057395|Ovary Carcinoma
664837|NCT00057395|Ovarian Cancer
664838|NCT00057395|Ovarian Carcinoma
664839|NCT00057395|Neoplasms, Ovarian
664840|NCT00057395|Pancreatic Neoplasms
664841|NCT00057395|Pancreatic Cancer
664842|NCT00057395|Pancreas Neoplasms
664843|NCT00057395|Pancreas Cancer
664844|NCT00057395|Neoplasms, Pancreatic
664845|NCT00057395|Neoplasms, Pancreas
664846|NCT00057395|and other solid tumors
664847|NCT00057382|liver cancer
664848|NCT00057356|Chronic Heart Failure
664849|NCT00057356|YM078
664850|NCT00057291|Orphanage
664851|NCT00057291|Caregiving
664852|NCT00057291|Training
664853|NCT00057291|Child development
664854|NCT00057278|Gabapentin
664855|NCT00057252|Diagnostic Radiology
664856|NCT00057252|Imaging
664857|NCT00057252|Algorithms
664858|NCT00057252|Healthy Volunteer
664859|NCT00057252|HV
664860|NCT00057239|GW353162
664861|NCT00057239|Major Depressive Disorder
664862|NCT00057239|MDD
664863|NCT00057226|GW353162,
664864|NCT00057226|Major depressive disorder,
664865|NCT00057226|flexible
664866|NCT00057213|Major Depressive Disorder (MDD),
664867|NCT00057213|Flexible
664868|NCT00057213|GW353162,
664869|NCT00057200|Home Care
664870|NCT00057174|Proton pump inhibitor
664871|NCT00057148|massage therapy
664872|NCT00057148|pain management
664873|NCT00057148|post-surgical
664874|NCT00057148|complementary therapy
664875|NCT00057135|Schizophrenia
664876|NCT00057135|Treatment Refusal
664877|NCT00057135|Drug Packaging
664878|NCT00057135|Reminder Systems
664879|NCT00057135|Antipsychotic Agents
664880|NCT00057122|Preventive therapy
664881|NCT00057083|Telemedicine
664882|NCT00057083|Remote consultation
664883|NCT00057083|Patient Satisfaction
664884|NCT00057083|Physician patient relations
664885|NCT00057083|Provider satisfaction
664886|NCT00057083|Doctor-patient relations
664887|NCT00057031|myelodysplastic syndrome
664888|NCT00057031|MDS
664889|NCT00057018|stroke
664890|NCT00057018|cerebrovascular accident
664891|NCT00057018|upper extremity
664892|NCT00057018|physical therapy
664893|NCT00057018|constraint-induced therapy
664894|NCT00057005|LEUKEMIA
664895|NCT00056979|Metabolic diseases
664896|NCT00056966|Acute myeloid leukemia
664897|NCT00056966|Acute lymphoblastic leukemia
664898|NCT00056966|Chronic myeloid leukemia
664899|NCT00056966|Non-Hodgkin's lymphoma
664900|NCT00056966|Hodgkin's disease
664901|NCT00056966|Myelodysplastic syndrome
664902|NCT00056966|Myeloproliferative disorders
664903|NCT00056966|Multiple myeloma
664904|NCT00056966|Severe aplastic anemia
664905|NCT00056953|health behavior
664906|NCT00056953|adolescent behavior
664907|NCT00056953|peer mentoring
664908|NCT00056940|Prevention
664909|NCT00056940|Parenting strategies
664910|NCT00056940|Media use
664911|NCT00056940|Discipline
664912|NCT00056940|Firearm storage
664913|NCT00056927|Smoking
664914|NCT00056927|Primary Prevention
664915|NCT00056927|Health Education
664916|NCT00056927|Child
664917|NCT00056927|Parents
664918|NCT00056927|Parenting Education
664919|NCT00056927|Communication
664920|NCT00056914|Magnetic Resonance Imaging
664921|NCT00056914|Functional Imaging
664922|NCT00056914|Cerebral Blood Flow
664923|NCT00056914|Parallel Imaging
664924|NCT00056914|BOLD Effect
664925|NCT00056914|Spectroscopic Imaging
664926|NCT00056914|Healthy Volunteer
664927|NCT00056914|HV
664928|NCT00056901|Puerperium
664929|NCT00056901|Pregnancy
664930|NCT00056901|Mood Disorders
664931|NCT00056901|Estradiol
664932|NCT00056901|Progesterone
664933|NCT00056901|Mood
664934|NCT00056901|Behavior
664935|NCT00056901|Cognition
664936|NCT00056901|Perimenopause
664937|NCT00056901|Menopause
664938|NCT00056901|Post Partum Depression
664939|NCT00056901|PPD
664940|NCT00056901|Healthy Volunteer
664941|NCT00056901|HV
664942|NCT00056888|Electroencephalogram
664943|NCT00056888|Functional (BOLD) MRI
664944|NCT00056888|Startle Reflex
664945|NCT00056888|Electromyogram
664946|NCT00056888|Psychogenic
664947|NCT00056888|Paroxysmal
664948|NCT00056888|Dyskinesia
664949|NCT00056888|Kinesiogenic
664950|NCT00056888|EEG
664951|NCT00056888|Movement-Related Potential
664952|NCT00056888|Movement Disorder
664953|NCT00056888|Paroxysmal Hyperkinetic Movement
664954|NCT00056888|Disorder
664955|NCT00056888|Paroxysmal Dyskinesia
664956|NCT00056875|graft versus host disease
664957|NCT00056875|bone marrow transplant
664958|NCT00056875|alternative donor
664959|NCT00056862|Hepatitis C Virus
664960|NCT00056862|Antiviral Agents
664961|NCT00056862|Hemolysis
664962|NCT00056862|Neutropenia
664963|NCT00056862|Cirrhosis
664964|NCT00056862|Hemolytic Anemia
664965|NCT00056862|Viral Hepatitis
664966|NCT00056862|Ribavirin
664967|NCT00056862|Alfa Interferon
664968|NCT00056862|Pegylated Interferon
664969|NCT00056862|Hepatitis C
664970|NCT00056862|HCV
664971|NCT00056849|Arthritis
664972|NCT00056849|Spondyloarthropathy
664973|NCT00056849|Spine
664974|NCT00056849|Hereditary
664975|NCT00056849|Disability
664976|NCT00056849|Ankylosing Spondylitis
664977|NCT00056849|AS
664978|NCT00056849|Spondyloarthritis
664979|NCT00056836|AMD
664980|NCT00056836|Neovascular age-related macular degeneration
664981|NCT00056823|AMD
664982|NCT00056810|Guillain Barre Syndrome
664983|NCT00056810|4-aminopyridine
664984|NCT00056797|HIV Therapeutic vaccine
664985|NCT00056797|IL-2
664986|NCT00056797|Structured Treatment Interruption
664987|NCT00056797|Treatment Experienced
664988|NCT00056784|TGF-Beta
664989|NCT00056784|Kidney
664990|NCT00056784|Transplantation
664991|NCT00056784|Rejection
664992|NCT00056784|Immunosuppression
664993|NCT00056784|Kidney Transplant
664994|NCT00056784|Chronic Allograft Nephropathy
664995|NCT00056784|CAN
664996|NCT00056771|Cataract
664997|NCT00056771|Congenital Cataracts
664998|NCT00056771|Hereditary Cataracts
664999|NCT00056758|HIV-1
665000|NCT00056758|HAART
665001|NCT00056758|Therapeutic immunization
665002|NCT00056758|HIV Therapeutic Vaccine
665003|NCT00056758|Treatment Experienced
665004|NCT00056745|HIV seronegativity
665005|NCT00056745|HIV preventive vaccine
665006|NCT00056719|Arthritis
665007|NCT00056719|Spondylarthropathy
665008|NCT00056719|Spine
665009|NCT00056719|Hereditary
665010|NCT00056719|Disability
665011|NCT00056719|Ankylosing Spondylitis
665012|NCT00056719|Spondyloarthropathy
665013|NCT00056719|Spondyloarthritis
665014|NCT00056719|AS
665015|NCT00056706|Motor Deficit
665016|NCT00056706|Somatosensory Deficit
665017|NCT00056706|Cortical Reorganization
665018|NCT00056706|Disinhibition
665019|NCT00056706|Rehabilitation
665020|NCT00056706|Plasticity
665021|NCT00056706|Stroke
665022|NCT00056693|Neuroendocrine tumor, advanced disease, sunitinib, Phase 2
665023|NCT00056680|Prematurity
665024|NCT00056680|low birthweight
665025|NCT00056680|parenting
665026|NCT00056680|intervention
665027|NCT00056667|Treatment
665028|NCT00056667|Pain
665029|NCT00056667|Relaxation Response
665030|NCT00056667|Cognitive Behavioral Therapy
665031|NCT00056654|Leuprolide
665032|NCT00056654|Prostatic Neoplasms
665033|NCT00056654|Testosterone
665034|NCT00056654|Prostate-specific Antigen
665035|NCT00056654|Pharmacokinetics
665036|NCT00056654|luprolide acetate
665037|NCT00056628|Alzheimer disease
665038|NCT00056628|Dementia
665039|NCT00056628|Ventriculoperitoneal shunt
665040|NCT00056628|Tau
665041|NCT00056628|ABeta
665042|NCT00056602|Utility
665043|NCT00056602|Health Status
665044|NCT00056602|Preferences
665045|NCT00056602|Response Criteria
665046|NCT00056602|Treatment
665047|NCT00056602|Rheumatoid Arthritis
665048|NCT00056602|RA
665049|NCT00056576|Monotherapy
665050|NCT00056576|Complex Partial Seizures
665051|NCT00056576|Epilepsy
665052|NCT00056576|anti-epilepsy drug
665053|NCT00056576|AED
665054|NCT00056563|Parkinson's disease
665055|NCT00056563|levo-dopa
665056|NCT00056563|tremor
665057|NCT00056563|dyskinesia
665058|NCT00056563|subthalamic nucleus
665059|NCT00056563|globus pallidus
665060|NCT00056550|Antithrombin Deficiency, Congenital
665061|NCT00056550|Antithrombin III Deficiency
665062|NCT00056524|ALS
665063|NCT00056524|MS
665064|NCT00056524|CNS
665065|NCT00056524|AD
665066|NCT00056524|TBI
665067|NCT00056524|Dextromethorphan
665068|NCT00056524|IEED
665069|NCT00056524|Emotional
665070|NCT00056511|Garlic
665071|NCT00056511|Supplements
665072|NCT00056511|Adults
665073|NCT00056511|Hypercholesterolemics
665074|NCT00056511|Randomized Clinical Trial
665075|NCT00056485|Nursing homes
665076|NCT00056485|Aging
665077|NCT00056472|Major depressive disorder with psychotic features
665078|NCT00056472|Delusional Depression
665079|NCT00056472|Randomized Trial
665080|NCT00056472|Combination Treatment
665081|NCT00056472|SSRI
665082|NCT00056472|Atypical Antipsychotic
665083|NCT00056459|Colorectal Cancer
665084|NCT00056459|PTK787
665085|NCT00056459|Vatalanib
665086|NCT00056459|VEGF inhibitor
665087|NCT00056459|Oxaliplatin
665088|NCT00056459|Angiogenesis
665089|NCT00056459|Rectal Cancer
665090|NCT00056459|Colon Cancer
665091|NCT00056459|Colorectal Carcinoma
665092|NCT00056459|Colorectal Tumor
665093|NCT00056446|Colorectal Cancer
665094|NCT00056446|Oxaliplatin
665095|NCT00056446|VEGF inhibitor
665096|NCT00056446|Vatalanib
665097|NCT00056446|PTK787
665098|NCT00056446|Colon Cancer
665099|NCT00056446|Colorectal Carcinoma
665100|NCT00056446|Rectal Cancer
665101|NCT00056446|Colorectal Tumor
665102|NCT00056433|Fetal Hemoglobin Induction
665103|NCT00056433|L-Arginine
665104|NCT00056433|Nitric Oxide Therapy
665105|NCT00056433|Sickle Cell Disease
665106|NCT00056433|Sildenafil (Viagra)
665107|NCT00056433|Sickle Cell Anemia
665108|NCT00056420|Tourette's Syndrome
665109|NCT00056420|Tic Disorder
665110|NCT00056420|(EEG) Electroencephalography
665111|NCT00056420|Event-Related Desynchronization/Synchronization
665112|NCT00056420|Coherence
665113|NCT00056420|Tourette's
665114|NCT00056420|Tourette Syndrome
665115|NCT00056420|Healthy Volunteer
665116|NCT00056420|HV
665117|NCT00056407|Prostate cancer prevention
665118|NCT00056407|prostate
665119|NCT00056407|BPH
665120|NCT00056407|enlarged prostate
665121|NCT00056407|PSA
665122|NCT00056407|prostate cancer
665123|NCT00056394|Early Rheumatoid Arthritis
665124|NCT00056394|Coping Skills Training
665125|NCT00056394|Pain
665126|NCT00056394|Physical Disability
665127|NCT00056394|Psychological Disability
665128|NCT00056394|Daily Diary Measures
665129|NCT00056381|neutropenia
665130|NCT00056381|fever
665131|NCT00056381|febrile neutropenia
665132|NCT00056368|Candida blood stream infections
665133|NCT00056368|Candida infections
665134|NCT00056368|Candidemia
665135|NCT00056368|Invasive Candidiasis
665136|NCT00056355|Pheresis
665137|NCT00056355|Cytokine
665138|NCT00056355|Lymphocyte
665139|NCT00056355|Remission
665140|NCT00056355|Ultraviolet A Light
665141|NCT00056355|Crohn's Disease
665142|NCT00056355|Crohn Disease
665143|NCT00056329|Aging Persons
665144|NCT00056329|Down Syndrome
665145|NCT00056329|Vitamin E
665146|NCT00056329|Alzheimer disease
665147|NCT00056316|Caregiving
665148|NCT00056316|Dementia
665149|NCT00056316|Alzheimer's
665150|NCT00056316|Depression
665151|NCT00056316|Technology
665152|NCT00056316|Treatment
665153|NCT00056303|Attachment
665154|NCT00056303|Intervention
665155|NCT00056303|Prevention
665156|NCT00056290|Diabetes Mellitus
665157|NCT00056290|Neuropathy
665158|NCT00056290|Peripheral Artery Disease
665159|NCT00056264|Chronic obstructive pulmonary disease
665160|NCT00056264|COPD
665161|NCT00056264|Infliximab
665162|NCT00056264|Remicade
665163|NCT00056251|Interstitial Cystitis
665164|NCT00056251|Bladder
665165|NCT00056238|Neurologic Diseases (General)
665166|NCT00056238|Hemorrhagic Stroke
665167|NCT00056238|Cerebral Amyloid Angiopathy
665168|NCT00056238|Cerebrovascular Accident
665169|NCT00056225|homocysteine
665170|NCT00056199|Vision Loss
665171|NCT00056199|Optic Nerve Tumors
665172|NCT00056199|Macular Edema
665173|NCT00056199|Von Hippel-Lindau Disease
665174|NCT00056199|VEGF
665175|NCT00056199|EYE001
665176|NCT00056199|VHL
665177|NCT00056186|Adaptation
665178|NCT00056186|Neurodegenerative
665179|NCT00056186|Health Care Provider
665180|NCT00056186|Psychosocial
665181|NCT00056186|Chronic Illness/Disability
665182|NCT00056186|Friedreich's Ataxia
665183|NCT00056186|Friedreich Ataxia
665184|NCT00056186|FA
665185|NCT00056173|Metastatic Renal Cell Carcinoma
665186|NCT00056160|Multiple Myeloma
665187|NCT00056160|Refractory and Relapsed
665188|NCT00056160|Revlimid
665189|NCT00056160|CC5013
665190|NCT00056147|cystic fibrosis
665191|NCT00056134|recurrent melanoma
665192|NCT00056134|stage IV melanoma
665193|NCT00056134|stage IIIA melanoma
665194|NCT00056134|stage IIIB melanoma
665195|NCT00056134|stage IIIC melanoma
665196|NCT00056095|recurrent renal cell cancer
665197|NCT00056095|stage IV renal cell cancer
665198|NCT00056082|breast cancer
665199|NCT00056069|psychosocial effects of cancer and its treatment
665200|NCT00056069|childhood acute lymphoblastic leukemia
665201|NCT00056056|stage I mycosis fungoides/Sezary syndrome
665202|NCT00056056|stage II mycosis fungoides/Sezary syndrome
665203|NCT00056056|recurrent mycosis fungoides/Sezary syndrome
665204|NCT00056030|liver metastases
665205|NCT00056030|stage IV colon cancer
665206|NCT00056030|stage IV rectal cancer
665207|NCT00056030|adenocarcinoma of the colon
665208|NCT00056030|adenocarcinoma of the rectum
665209|NCT00056004|non-small cell lung cancer
665210|NCT00056004|small cell lung cancer
665211|NCT00056004|stage I non-small cell lung cancer
665212|NCT00056004|stage I squamous cell carcinoma of the hypopharynx
665213|NCT00056004|stage I squamous cell carcinoma of the larynx
665214|NCT00056004|stage I squamous cell carcinoma of the lip and oral cavity
665215|NCT00056004|stage I squamous cell carcinoma of the nasopharynx
665216|NCT00056004|stage I squamous cell carcinoma of the oropharynx
665217|NCT00056004|stage II squamous cell carcinoma of the hypopharynx
665218|NCT00056004|stage II squamous cell carcinoma of the larynx
665219|NCT00056004|stage II squamous cell carcinoma of the lip and oral cavity
665220|NCT00056004|stage II squamous cell carcinoma of the nasopharynx
665221|NCT00056004|stage II squamous cell carcinoma of the oropharynx
665222|NCT00055991|breast cancer
665223|NCT00055978|non-small cell lung cancer
665224|NCT00055978|stage I non-small cell lung cancer
665225|NCT00055965|stage IIIA non-small cell lung cancer
665226|NCT00055965|stage IIIB non-small cell lung cancer
665227|NCT00055965|stage IV non-small cell lung cancer
665228|NCT00055952|childhood desmoplastic small round cell tumor
665229|NCT00055952|metastatic childhood soft tissue sarcoma
665230|NCT00055952|nonmetastatic childhood soft tissue sarcoma
665231|NCT00055952|recurrent childhood soft tissue sarcoma
665232|NCT00055952|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
665233|NCT00055952|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
665234|NCT00055952|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
665235|NCT00055939|previously treated childhood rhabdomyosarcoma
665236|NCT00055939|recurrent childhood rhabdomyosarcoma
665237|NCT00055926|recurrent breast cancer
665238|NCT00055926|stage IV breast cancer
665239|NCT00055926|male breast cancer
665240|NCT00055887|stage IIIB non-small cell lung cancer
665241|NCT00055887|stage IIIA non-small cell lung cancer
665242|NCT00055887|adenocarcinoma of the lung
665243|NCT00055887|squamous cell lung cancer
665244|NCT00055887|large cell lung cancer
665245|NCT00055874|chronic phase chronic myelogenous leukemia
665246|NCT00055874|childhood chronic myelogenous leukemia
665247|NCT00055874|chronic myelogenous leukemia, BCR-ABL1 positive
665248|NCT00055848|adenocarcinoma of the colon
665249|NCT00055848|stage I colon cancer
665250|NCT00055848|stage II colon cancer
665251|NCT00055848|stage III colon cancer
665252|NCT00055848|stage IV colon cancer
665253|NCT00055835|recurrent bladder cancer
665254|NCT00055835|stage III bladder cancer
665255|NCT00055835|squamous cell carcinoma of the bladder
665256|NCT00055835|stage II bladder cancer
665257|NCT00055835|recurrent urethral cancer
665258|NCT00055835|urethral cancer associated with invasive bladder cancer
665259|NCT00055835|distal urethral cancer
665260|NCT00055835|proximal urethral cancer
665261|NCT00055835|stage IV bladder cancer
665262|NCT00055835|transitional cell carcinoma of the bladder
665263|NCT00055822|adenocarcinoma of the colon
665264|NCT00055822|recurrent colon cancer
665265|NCT00055822|stage III colon cancer
665266|NCT00055822|stage IV colon cancer
665267|NCT00055822|adenocarcinoma of the rectum
665268|NCT00055822|recurrent rectal cancer
665269|NCT00055822|stage III rectal cancer
665270|NCT00055822|stage IV rectal cancer
665271|NCT00055783|recurrent adult Hodgkin lymphoma
665272|NCT00055731|stage III prostate cancer
665273|NCT00055731|stage IIB prostate cancer
665274|NCT00055731|stage IIA prostate cancer
665275|NCT00055718|drug/agent toxicity by tissue/organ
665276|NCT00055718|childhood acute lymphoblastic leukemia
665277|NCT00055705|recurrent ovarian epithelial cancer
665278|NCT00055705|stage IV ovarian epithelial cancer
665279|NCT00055705|fallopian tube cancer
665280|NCT00055705|primary peritoneal cavity cancer
665281|NCT00055705|recurrent colon cancer
665282|NCT00055705|stage IV colon cancer
665283|NCT00055705|ovarian sarcoma
665284|NCT00055705|recurrent ovarian germ cell tumor
665285|NCT00055705|stage IV ovarian germ cell tumor
665286|NCT00055705|recurrent endometrial carcinoma
665287|NCT00055705|stage IV endometrial carcinoma
665288|NCT00055705|recurrent uterine sarcoma
665289|NCT00055705|stage IV uterine sarcoma
665290|NCT00055705|ovarian stromal cancer
665291|NCT00055705|recurrent rectal cancer
665292|NCT00055705|stage IV rectal cancer
665293|NCT00055705|metastatic gastrointestinal carcinoid tumor
665294|NCT00055705|recurrent gastrointestinal carcinoid tumor
665295|NCT00055705|gastrointestinal stromal tumor
665296|NCT00055705|advanced malignant mesothelioma
665297|NCT00055705|recurrent malignant mesothelioma
665298|NCT00055705|recurrent gastric cancer
665299|NCT00055705|stage IV gastric cancer
665300|NCT00055705|carcinoma of the appendix
665301|NCT00055705|small intestine adenocarcinoma
665302|NCT00055705|small intestine leiomyosarcoma
665303|NCT00055705|small intestine lymphoma
665304|NCT00055705|recurrent small intestine cancer
665305|NCT00055705|recurrent gallbladder cancer
665306|NCT00055705|unresectable gallbladder cancer
665307|NCT00055705|advanced adult primary liver cancer
665308|NCT00055705|localized unresectable adult primary liver cancer
665309|NCT00055705|recurrent adult primary liver cancer
665310|NCT00055679|stage I breast cancer
665311|NCT00055666|graft versus host disease
665312|NCT00055653|refractory anemia with excess blasts in transformation
665313|NCT00055653|refractory anemia with excess blasts
665314|NCT00055653|refractory anemia with ringed sideroblasts
665315|NCT00055653|refractory anemia
665316|NCT00055653|chronic myelomonocytic leukemia
665317|NCT00055653|childhood acute myeloid leukemia in remission
665318|NCT00055653|recurrent childhood acute myeloid leukemia
665319|NCT00055653|secondary acute myeloid leukemia
665320|NCT00055653|childhood acute lymphoblastic leukemia in remission
665321|NCT00055653|recurrent childhood acute lymphoblastic leukemia
665322|NCT00055653|accelerated phase chronic myelogenous leukemia
665323|NCT00055653|blastic phase chronic myelogenous leukemia
665324|NCT00055653|chronic phase chronic myelogenous leukemia
665325|NCT00055653|acute undifferentiated leukemia
665326|NCT00055653|recurrent/refractory childhood Hodgkin lymphoma
665327|NCT00055653|recurrent childhood large cell lymphoma
665328|NCT00055653|recurrent childhood lymphoblastic lymphoma
665329|NCT00055653|recurrent childhood small noncleaved cell lymphoma
665330|NCT00055653|untreated childhood acute lymphoblastic leukemia
665331|NCT00055653|untreated childhood acute myeloid leukemia and other myeloid malignancies
665332|NCT00055653|de novo myelodysplastic syndromes
665333|NCT00055653|previously treated myelodysplastic syndromes
665334|NCT00055653|secondary myelodysplastic syndromes
665335|NCT00055653|atypical chronic myeloid leukemia
665336|NCT00055653|myelodysplastic/myeloproliferative disease, unclassifiable
665337|NCT00055640|stage I adult diffuse large cell lymphoma
665338|NCT00055640|contiguous stage II adult diffuse large cell lymphoma
665339|NCT00055640|stage III adult diffuse large cell lymphoma
665340|NCT00055640|noncontiguous stage II adult diffuse large cell lymphoma
665341|NCT00055640|stage IV adult diffuse large cell lymphoma
665342|NCT00055614|stage III ovarian epithelial cancer
665343|NCT00055614|stage IV ovarian epithelial cancer
665344|NCT00055614|fallopian tube cancer
665345|NCT00055614|primary peritoneal cavity cancer
665346|NCT00055601|stage II bladder cancer
665347|NCT00055601|stage III bladder cancer
665348|NCT00055588|Spinal Reflexes
665349|NCT00055588|Motor Practice
665350|NCT00055588|Spinal Cord Injury
665351|NCT00055588|Locomotion
665352|NCT00055588|Healthy Volunteer
665353|NCT00055588|HV
665354|NCT00055575|Scopolamine
665355|NCT00055575|Depression
665356|NCT00055575|fMRI
665357|NCT00055575|Cognition
665358|NCT00055575|Emotion
665359|NCT00055575|Brain
665360|NCT00055575|Bipolar Disorder
665361|NCT00055575|Major Depressive Disorder
665362|NCT00055575|MDD
665363|NCT00055575|Healthy Volunteer
665364|NCT00055575|HV
665365|NCT00055562|Metastatic Melanoma
665366|NCT00055562|Metastatic Malignant Melanoma
665367|NCT00055562|Revimid
665368|NCT00055562|CC5013
665369|NCT00055549|Dextromethorphan
665370|NCT00055549|Sensorimotor Modulation
665371|NCT00055549|Spasmodic Dysphonia
665372|NCT00055549|Muscular Tension Dysphonia
665373|NCT00055549|Voice Tremor
665374|NCT00055549|Lorazepam
665375|NCT00055549|Dysphonia
665376|NCT00055549|Macular Tension Dysphonia
665377|NCT00055510|BO-653
665378|NCT00055510|Coronary restenosis
665379|NCT00055510|Stent restenosis
665380|NCT00055510|LDL oxidative inhibitor
665381|NCT00055510|Antioxidant
665382|NCT00055484|Migraine Headache
665383|NCT00055484|prophylaxis
665384|NCT00055484|AED
665385|NCT00055484|migraine prophylaxis
665386|NCT00055471|prostate cancer
665387|NCT00055471|Metastatic prostate cancer
665388|NCT00055471|bone metastases
665389|NCT00055445|Complementary Therapies
665390|NCT00055445|IdB 1016
665391|NCT00055445|Silybin
665392|NCT00055445|Antioxidant
665393|NCT00055445|Hepatitis C Virus
665394|NCT00055445|Phosphatidylcholine
665395|NCT00055432|recurrent ovarian cancer
665396|NCT00055432|platinum-resistant
665397|NCT00055432|platinum-sensitive
665398|NCT00055432|folate receptor antagonist
665399|NCT00055419|Stage IV colorectal cancer
665400|NCT00055380|Molecular Targets
665401|NCT00055380|Keratinocytes
665402|NCT00055380|Cell Cycle
665403|NCT00055380|Small Molecule
665404|NCT00055380|Gene Expression
665405|NCT00055380|Pharmacodynamics
665406|NCT00055380|Surrogate Markers
665407|NCT00055380|Targeted Therapy
665408|NCT00055380|Buccal Mucosa
665409|NCT00055380|Pharmacogenomics
665410|NCT00055380|Oral Mucosa
665411|NCT00055354|Acupuncture
665412|NCT00055354|Medicine, Chinese Traditional
665413|NCT00055302|vaginal bleeding
665414|NCT00055302|advanced bone age
665415|NCT00055302|fibrous dysplasia
665416|NCT00055302|MAS
665417|NCT00055302|McCune-Albright Syndrome
665418|NCT00055289|Transcranial Magnetic Stimulation
665419|NCT00055289|Counting
665420|NCT00055289|Sensorimotor Integration
665421|NCT00055289|Superior Temporal Cortex
665422|NCT00055289|Dorsal Premotor Cortex
665423|NCT00055289|Healthy Volunteer
665424|NCT00055289|HV
665425|NCT00055263|advanced solid tumor malignancies
665426|NCT00055237|Angiogenesis
665427|NCT00055237|Cancer
665428|NCT00055237|HHV-8
665429|NCT00055237|KSHV
665430|NCT00055237|Skin
665431|NCT00055237|Kaposi Sarcoma
665432|NCT00055237|KS
665433|NCT00055224|Anxiety Disorder
665434|NCT00055224|Fear
665435|NCT00055224|Aversive Conditioning
665436|NCT00055224|Psychophysiology
665437|NCT00055224|Predictability
665438|NCT00055224|Startle
665439|NCT00055224|Context Conditioning
665440|NCT00055224|Fear Conditioning
665441|NCT00055224|Agoraphobia
665442|NCT00055224|Panic Disorder
665443|NCT00055224|Generalized Anxiety Disorder
665444|NCT00055224|GAD
665445|NCT00055224|Healthy Volunteer
665446|NCT00055224|HV
665447|NCT00055198|Gram positive bacterial infections
665448|NCT00055198|expanded access program
665449|NCT00055198|resistant infections
665450|NCT00055198|bacteremia
665451|NCT00055198|Bacterial and fungal infections
665452|NCT00055198|bacterial infections
665453|NCT00055185|Treatment Experienced
665454|NCT00055172|Cytokines
665455|NCT00055172|Mutation
665456|NCT00055172|DNA
665457|NCT00055172|Phenotype
665458|NCT00055172|T Cell
665459|NCT00055172|Immunodeficiency
665460|NCT00055172|Inherited Immunodeficiency
665461|NCT00055159|RT PA
665462|NCT00055159|Blood Clots
665463|NCT00055159|Catheter Directed Thrombolytic Therapy
665464|NCT00055159|Alteplase
665465|NCT00055159|Deep Vein Thrombosis
665466|NCT00055159|DVT
665467|NCT00055133|rheumatoid arthritis
665468|NCT00055133|Paxceed
665469|NCT00055133|Micellar Paclitaxel
665470|NCT00055120|Anti-HIV Agents
665471|NCT00055120|Disease Progression
665472|NCT00055120|Drug Administration Schedule
665473|NCT00055120|Viral Load
665474|NCT00055120|HIV-1
665475|NCT00055120|Treatment Outcome
665476|NCT00055120|Survival Analysis
665477|NCT00055120|Treatment Naive
665478|NCT00055107|Nitazoxanide
665479|NCT00055107|Antiprotozoal Agents
665480|NCT00055107|Cryptosporidiosis
665481|NCT00055107|Cryptosporidium parvum
665482|NCT00055107|AIDS-Related Opportunistic Infections
665483|NCT00055107|Pharmacokinetics
665484|NCT00055107|Drug Adminstration Schedule
665485|NCT00055094|Immune system
665486|NCT00055094|Helper T-Cells
665487|NCT00055094|Acute Infection
665488|NCT00055094|Treatment naive
665489|NCT00055081|Homeless Persons
665490|NCT00055055|Autoimmunity Pathogenesis
665491|NCT00055055|Microarray Analyses
665492|NCT00055055|Microchimerism
665493|NCT00055055|Genetic and Environmental Risk Factors
665494|NCT00055055|Adult and Pediatric Disease
665495|NCT00055055|Rheumatoid Arthritis
665496|NCT00055055|Systemic Lupus Erythematosus
665497|NCT00055055|Systemic Sclerosis
665498|NCT00055055|Idiopathic Inflammatory Myopathies
665499|NCT00055055|Inflammatory Myopathies
665500|NCT00055055|Dermatomyositis
665501|NCT00055055|Scleroderma
665502|NCT00055055|SLE
665503|NCT00055055|Lupus
665504|NCT00055055|Rheumatic Disease
665505|NCT00055055|RA
665506|NCT00055055|Healthy Volunteer
665507|NCT00055055|HV
665508|NCT00055042|Types 1 and 2 Diabetes
665509|NCT00055042|Diode Laser Photocoagulation
665510|NCT00055042|Vitamin E
665511|NCT00055042|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
665512|NCT00055042|Diabetes Type I
665513|NCT00055042|Diabetes Type II
665514|NCT00055042|Diabetic Macular Edema
665515|NCT00055029|Retinoschisis
665516|NCT00055029|Genomic DNA
665517|NCT00055029|Pedigree Analysis
665518|NCT00055029|Genetic Analysis
665519|NCT00055029|Macular Degeneration
665520|NCT00055029|Juvenile Retinoschisis
665521|NCT00055029|X-Linked Juvenile Retinoschisis
665522|NCT00055029|XLRS
665523|NCT00055016|Lysosomal Disease
665524|NCT00055016|Renal Function
665525|NCT00055016|Stroke
665526|NCT00055016|Cardiac Disease
665527|NCT00055016|Natural History
665528|NCT00055016|Fabry Disease
665529|NCT00055003|Amygdala
665530|NCT00055003|Medial Prefrontal Cortex
665531|NCT00055003|Orbitofrontal Cortex
665532|NCT00055003|Cortisol
665533|NCT00055003|Memory
665534|NCT00055003|Glucocorticoid
665535|NCT00055003|Hydrocortisone
665536|NCT00055003|Stress
665537|NCT00055003|Perception
665538|NCT00055003|Affect
665539|NCT00055003|Healthy Volunteer
665540|NCT00055003|HV
665541|NCT00054990|Antiepileptic Drugs
665542|NCT00054990|Cortical Excitability
665543|NCT00054990|Transcranial Magnetic Stimulation
665544|NCT00054990|Epilepsy
665545|NCT00054990|TMS
665546|NCT00054990|Healthy Volunteer
665547|NCT00054990|HV
665548|NCT00054977|cancer
665549|NCT00054977|tumor
665550|NCT00054951|Hepatoma
665551|NCT00054951|Liver Cancer
665552|NCT00054938|SLE
665553|NCT00054938|Accelerated Atherosclerosis
665554|NCT00054938|Cholesterol
665555|NCT00054912|vaccine
665556|NCT00054912|colon
665557|NCT00054912|cancer
665558|NCT00054912|colorectal
665559|NCT00054912|neoplasm
665560|NCT00054912|Colonic Cancer
665561|NCT00054912|Colon Cancer
665562|NCT00054912|Cancer of the Colon
665563|NCT00054899|vaccine
665564|NCT00054899|lung
665565|NCT00054899|cancer
665566|NCT00054899|Carcinoma, Large Cell
665567|NCT00054899|Non-Small-Cell Lung Carcinoma
665568|NCT00054873|Adenocarcinoma of the esophagus or stomach
665569|NCT00054860|HIV Preventive Vaccine
665570|NCT00054860|HIV Seronegativity
665571|NCT00054860|HIV-1
665572|NCT00054860|AIDS Vaccines
665573|NCT00054860|Vaccines, DNA
665574|NCT00054860|Dose-Response Relationship, Immunologic
665575|NCT00054860|CD4-Positive T-Lymphocytes
665576|NCT00054860|CD8-Positive T-Lymphocytes
665577|NCT00054860|Epitopes
665578|NCT00054847|CABG
665579|NCT00054847|cardiovascular
665580|NCT00054847|chronic diseases
665581|NCT00054847|clinical trial
665582|NCT00054847|heart
665583|NCT00054847|multi-site trial
665584|NCT00054847|prospective
665585|NCT00054821|Osteoarthritis, Ankle
665586|NCT00054821|Ankle Distraction
665587|NCT00054808|Gallium Nitrate
665588|NCT00054808|Ganite
665589|NCT00054808|NHL
665590|NCT00054808|Relapsed
665591|NCT00054795|Brain Neoplasms/radiotherapy
665592|NCT00054795|Neoplasms/complications/prevention & control,
665593|NCT00054795|Neuropsychological Tests,
665594|NCT00054795|Metalloporphyrins/therapeutic use,
665595|NCT00054795|Combined Modality Therapy,
665596|NCT00054795|Drug therapy,
665597|NCT00054795|Quality of Life,
665598|NCT00054795|Cranial Irradiation,
665599|NCT00054795|Radiotherapy/Targeted,
665600|NCT00054795|Prospective Studies,
665601|NCT00054795|Neoplasm Recurrence/Local,
665602|NCT00054795|Treatment Outcome
665603|NCT00054795|Brain metastases
665604|NCT00054795|Brain Neoplasms/secondary
665605|NCT00054795|Non-small cell lung cancer
665606|NCT00054769|Pediatrics
665607|NCT00054769|Polymerase Chain Reaction
665608|NCT00054756|Hypothalamic Releasing Factor
665609|NCT00054756|Neuropeptide
665610|NCT00054756|Diagnostic Testing
665611|NCT00054756|Pituitary Tumors
665612|NCT00054756|Central Hypothyroidism
665613|NCT00054756|Pituitary Disorder
665614|NCT00054756|Thyroid Disorder
665615|NCT00054756|Healthy Volunteer
665616|NCT00054756|HV
665617|NCT00054743|Race
665618|NCT00054743|Ethnicity
665619|NCT00054743|Pharmacogenetics
665620|NCT00054743|Cytochrome P450
665621|NCT00054743|Population Pharmacokinetics
665622|NCT00054743|HIV
665623|NCT00054730|Fragile X Syndrome
665624|NCT00054730|Autism
665625|NCT00054704|Riluzole
665626|NCT00054704|Neuroprotective
665627|NCT00054704|Open-Label Study
665628|NCT00054704|Glutamate Dysfunction
665629|NCT00054704|Bipolar Mood Disorder
665630|NCT00054704|Bipolar Disorder
665631|NCT00054704|Mood Disorder
665632|NCT00054691|Skin Cancer
665633|NCT00054691|Squamous Cell Carcinoma of the Skin
665634|NCT00054691|Gefitinib
665635|NCT00054691|ZD1839
665636|NCT00054691|Iressa
665637|NCT00054691|Epidermal Growth Factor Receptor
665638|NCT00054691|EGFR
665639|NCT00054678|Myocardial infarction
665640|NCT00054678|Heart disease
665641|NCT00054678|Endoventricular
665642|NCT00054678|Cardiovascular
665643|NCT00054678|Interventional
665644|NCT00054678|ICD
665645|NCT00054678|Heart failure
665646|NCT00054678|Implantable Cardioverter Defibrillator
665647|NCT00054665|BCL-2
665648|NCT00054665|NFK-B
665649|NCT00054665|Drug Resistance
665650|NCT00054665|Translational
665651|NCT00054665|Lymphoma
665652|NCT00054665|Large B-Cell Lymphoma
665653|NCT00054652|Geste Antagoniste
665654|NCT00054652|TMS
665655|NCT00054652|Sensorimotor Integration
665656|NCT00054652|Writer's Cramp
665657|NCT00054652|Sensory Input
665658|NCT00054652|Focal Dystonia
665659|NCT00054626|stage II bladder cancer
665660|NCT00054626|stage III bladder cancer
665661|NCT00054626|stage IV bladder cancer
665662|NCT00054626|transitional cell carcinoma of the bladder
665663|NCT00054613|Graft-versus-Host Disease
665664|NCT00054613|Extracorporeal Photopheresis
665665|NCT00054600|Extracorporeal Photopheresis
665666|NCT00054600|Graft-versus-Host Disease
665667|NCT00054587|stage II breast cancer
665668|NCT00054587|stage IIIA breast cancer
665669|NCT00054574|recurrent prostate cancer
665670|NCT00054574|stage I prostate cancer
665671|NCT00054574|stage II prostate cancer
665672|NCT00054574|stage III prostate cancer
665673|NCT00054561|stage III squamous cell carcinoma of the lip and oral cavity
665961|NCT00053846|pulmonary complications
665674|NCT00054561|stage IV squamous cell carcinoma of the lip and oral cavity
665675|NCT00054561|stage III squamous cell carcinoma of the oropharynx
665676|NCT00054561|stage IV squamous cell carcinoma of the oropharynx
665677|NCT00054561|stage III squamous cell carcinoma of the larynx
665678|NCT00054561|stage IV squamous cell carcinoma of the larynx
665679|NCT00054561|stage III squamous cell carcinoma of the hypopharynx
665680|NCT00054561|stage IV squamous cell carcinoma of the hypopharynx
665681|NCT00054535|stage IV melanoma
665682|NCT00054535|recurrent melanoma
665683|NCT00054522|adenocarcinoma of the prostate
665684|NCT00054522|recurrent prostate cancer
665685|NCT00054496|adult glioblastoma
665686|NCT00054496|recurrent adult brain tumor
665687|NCT00054496|adult giant cell glioblastoma
665688|NCT00054496|adult gliosarcoma
665689|NCT00054470|stage IV breast cancer
665690|NCT00054470|recurrent breast cancer
665691|NCT00054470|male breast cancer
665692|NCT00054457|adenocarcinoma of the stomach
665693|NCT00054457|adenocarcinoma of the esophagus
665694|NCT00054457|stage IV gastric cancer
665695|NCT00054457|recurrent gastric cancer
665696|NCT00054457|stage IV esophageal cancer
665697|NCT00054457|recurrent esophageal cancer
665698|NCT00054418|osteoporosis
665699|NCT00054418|stage I breast cancer
665700|NCT00054418|stage II breast cancer
665701|NCT00054418|stage IIIA breast cancer
665702|NCT00054418|stage IIIB breast cancer
665703|NCT00054392|adenosquamous cell lung cancer
665704|NCT00054392|bronchoalveolar cell lung cancer
665705|NCT00054392|large cell lung cancer
665706|NCT00054392|recurrent non-small cell lung cancer
665707|NCT00054392|squamous cell lung cancer
665708|NCT00054392|stage IIIB non-small cell lung cancer
665709|NCT00054392|stage IV non-small cell lung cancer
665710|NCT00054392|adenocarcinoma of the lung
665711|NCT00054340|graft versus host disease
665712|NCT00054340|polycythemia vera
665713|NCT00054340|chronic idiopathic myelofibrosis
665714|NCT00054340|essential thrombocythemia
665715|NCT00054340|untreated adult acute myeloid leukemia
665716|NCT00054340|recurrent adult acute myeloid leukemia
665717|NCT00054340|recurrent childhood acute myeloid leukemia
665718|NCT00054340|untreated childhood acute myeloid leukemia and other myeloid malignancies
665719|NCT00054340|de novo myelodysplastic syndromes
665720|NCT00054340|previously treated myelodysplastic syndromes
665721|NCT00054340|secondary myelodysplastic syndromes
665722|NCT00054340|chronic eosinophilic leukemia
665723|NCT00054340|chronic neutrophilic leukemia
665724|NCT00054340|myelodysplastic/myeloproliferative disease, unclassifiable
665725|NCT00054340|adult acute myeloid leukemia with t(8;21)(q22;q22)
665726|NCT00054340|adult acute myeloid leukemia with t(16;16)(p13;q22)
665727|NCT00054340|adult acute myeloid leukemia with inv(16)(p13;q22)
665728|NCT00054340|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
665729|NCT00054340|adult acute myeloid leukemia with t(15;17)(q22;q12)
665730|NCT00054340|childhood myelodysplastic syndromes
665731|NCT00054327|adult acute myeloid leukemia in remission
665732|NCT00054327|childhood acute myeloid leukemia in remission
665733|NCT00054327|recurrent adult acute myeloid leukemia
665734|NCT00054327|recurrent childhood acute myeloid leukemia
665735|NCT00054327|adult acute lymphoblastic leukemia in remission
665736|NCT00054327|childhood acute lymphoblastic leukemia in remission
665737|NCT00054327|refractory anemia with excess blasts in transformation
665738|NCT00054327|refractory anemia with excess blasts
665739|NCT00054327|recurrent adult diffuse large cell lymphoma
665740|NCT00054327|recurrent adult diffuse mixed cell lymphoma
665741|NCT00054327|recurrent adult diffuse small cleaved cell lymphoma
665742|NCT00054327|recurrent adult Burkitt lymphoma
665743|NCT00054327|recurrent adult immunoblastic large cell lymphoma
665744|NCT00054327|recurrent adult lymphoblastic lymphoma
665745|NCT00054327|recurrent grade 3 follicular lymphoma
665746|NCT00054327|secondary acute myeloid leukemia
665747|NCT00054327|accelerated phase chronic myelogenous leukemia
665748|NCT00054327|blastic phase chronic myelogenous leukemia
665749|NCT00054327|chronic phase chronic myelogenous leukemia
665750|NCT00054327|recurrent childhood large cell lymphoma
665751|NCT00054327|recurrent childhood lymphoblastic lymphoma
665752|NCT00054327|recurrent childhood small noncleaved cell lymphoma
665753|NCT00054327|recurrent mantle cell lymphoma
665754|NCT00054327|refractory anemia with ringed sideroblasts
665755|NCT00054327|refractory anemia
665756|NCT00054327|chronic myelomonocytic leukemia
665757|NCT00054327|refractory cytopenia with multilineage dysplasia
665758|NCT00054327|previously treated myelodysplastic syndromes
665759|NCT00054327|de novo myelodysplastic syndromes
665760|NCT00054327|secondary myelodysplastic syndromes
665761|NCT00054327|relapsing chronic myelogenous leukemia
665762|NCT00054327|childhood chronic myelogenous leukemia
665763|NCT00054327|atypical chronic myeloid leukemia
665764|NCT00054327|myelodysplastic/myeloproliferative disease, unclassifiable
665765|NCT00054327|juvenile myelomonocytic leukemia
665766|NCT00054327|adult acute myeloid leukemia with t(8;21)(q22;q22)
665767|NCT00054327|adult acute myeloid leukemia with t(16;16)(p13;q22)
665768|NCT00054327|adult acute myeloid leukemia with inv(16)(p13;q22)
665769|NCT00054327|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
665770|NCT00054327|adult acute myeloid leukemia with t(15;17)(q22;q12)
665771|NCT00054327|childhood myelodysplastic syndromes
665772|NCT00054314|recurrent non-small cell lung cancer
665773|NCT00054301|stage I breast cancer
665774|NCT00054301|stage II breast cancer
665775|NCT00054301|stage IIIA breast cancer
665776|NCT00054301|ductal breast carcinoma in situ
665777|NCT00054301|breast cancer in situ
665778|NCT00054288|unspecified adult solid tumor, protocol specific
665779|NCT00054275|recurrent breast cancer
665780|NCT00054275|stage IV breast cancer
665781|NCT00054275|male breast cancer
665782|NCT00054262|localized unresectable adult primary liver cancer
665783|NCT00054262|advanced adult primary liver cancer
665784|NCT00054262|adult primary hepatocellular carcinoma
665785|NCT00054249|recurrent gastric cancer
665786|NCT00054236|refractory anemia with excess blasts in transformation
665787|NCT00054236|refractory anemia with excess blasts
665788|NCT00054236|adult acute myeloid leukemia in remission
665789|NCT00054236|childhood acute myeloid leukemia in remission
665790|NCT00054236|recurrent adult acute myeloid leukemia
665791|NCT00054236|recurrent childhood acute myeloid leukemia
665792|NCT00054236|adult erythroleukemia (M6a)
665793|NCT00054236|childhood acute erythroleukemia (M6)
665794|NCT00054236|adult acute minimally differentiated myeloid leukemia (M0)
665795|NCT00054236|childhood acute minimally differentiated myeloid leukemia (M0)
665796|NCT00054236|adult acute megakaryoblastic leukemia (M7)
665797|NCT00054236|childhood acute megakaryocytic leukemia (M7)
665798|NCT00054236|adult acute lymphoblastic leukemia in remission
665799|NCT00054236|childhood acute lymphoblastic leukemia in remission
665800|NCT00054236|recurrent adult acute lymphoblastic leukemia
665801|NCT00054236|recurrent childhood acute lymphoblastic leukemia
665802|NCT00054236|accelerated phase chronic myelogenous leukemia
665803|NCT00054236|chronic phase chronic myelogenous leukemia
665804|NCT00054236|previously treated myelodysplastic syndromes
665805|NCT00054236|refractory chronic lymphocytic leukemia
665806|NCT00054236|stage I multiple myeloma
665807|NCT00054236|stage II multiple myeloma
665808|NCT00054236|stage III multiple myeloma
665809|NCT00054236|recurrent/refractory childhood Hodgkin lymphoma
665810|NCT00054236|polycythemia vera
665811|NCT00054236|primary myelofibrosis
665812|NCT00054236|essential thrombocythemia
665813|NCT00054236|refractory multiple myeloma
665814|NCT00054236|recurrent grade 1 follicular lymphoma
665815|NCT00054236|recurrent grade 2 follicular lymphoma
665816|NCT00054236|recurrent grade 3 follicular lymphoma
665817|NCT00054236|recurrent adult diffuse large cell lymphoma
665818|NCT00054236|recurrent adult diffuse mixed cell lymphoma
665819|NCT00054236|recurrent adult diffuse small cleaved cell lymphoma
665820|NCT00054236|recurrent adult Burkitt lymphoma
665821|NCT00054236|recurrent adult immunoblastic large cell lymphoma
665822|NCT00054236|recurrent adult lymphoblastic lymphoma
665823|NCT00054236|recurrent mantle cell lymphoma
665824|NCT00054236|recurrent childhood large cell lymphoma
665825|NCT00054236|recurrent childhood lymphoblastic lymphoma
665826|NCT00054236|recurrent childhood small noncleaved cell lymphoma
665827|NCT00054236|childhood diffuse large cell lymphoma
665828|NCT00054236|childhood immunoblastic large cell lymphoma
665829|NCT00054236|Burkitt lymphoma
665830|NCT00054236|anaplastic large cell lymphoma
665831|NCT00054236|recurrent adult Hodgkin lymphoma
665832|NCT00054236|childhood chronic myelogenous leukemia
665833|NCT00054236|chronic eosinophilic leukemia
665834|NCT00054236|chronic neutrophilic leukemia
665835|NCT00054236|myelodysplastic/myeloproliferative disease, unclassifiable
665836|NCT00054236|atypical chronic myeloid leukemia
665837|NCT00054236|recurrent marginal zone lymphoma
665838|NCT00054236|recurrent small lymphocytic lymphoma
665839|NCT00054236|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
665840|NCT00054236|nodal marginal zone B-cell lymphoma
665841|NCT00054236|splenic marginal zone lymphoma
665842|NCT00054236|adult acute myeloid leukemia with t(8;21)(q22;q22)
665843|NCT00054236|adult acute myeloid leukemia with t(16;16)(p13;q22)
665844|NCT00054236|adult acute myeloid leukemia with inv(16)(p13;q22)
665845|NCT00054236|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
665846|NCT00054236|adult acute myeloid leukemia with t(15;17)(q22;q12)
665847|NCT00054236|childhood myelodysplastic syndromes
665848|NCT00054223|psychosocial effects of cancer and its treatment
665849|NCT00054223|unspecified adult solid tumor, protocol specific
665850|NCT00054210|recurrent non-small cell lung cancer
665851|NCT00054210|stage IIIB non-small cell lung cancer
665852|NCT00054210|stage IV non-small cell lung cancer
665853|NCT00054197|recurrent non-small cell lung cancer
665854|NCT00054197|stage IIIB non-small cell lung cancer
665855|NCT00054197|stage IV non-small cell lung cancer
665856|NCT00054184|recurrent non-small cell lung cancer
665857|NCT00054184|stage IV non-small cell lung cancer
665858|NCT00054184|stage IIIB non-small cell lung cancer
665859|NCT00054171|B-cell chronic lymphocytic leukemia
665860|NCT00054171|stage I cutaneous T-cell non-Hodgkin lymphoma
665861|NCT00054171|stage I mycosis fungoides/Sezary syndrome
666069|NCT00053469|Categorization
665862|NCT00054171|stage 0 chronic lymphocytic leukemia
665863|NCT00054171|stage I chronic lymphocytic leukemia
665864|NCT00054158|stage I multiple myeloma
665865|NCT00054158|stage II multiple myeloma
665866|NCT00054158|stage III multiple myeloma
665867|NCT00054145|male breast cancer
665868|NCT00054145|recurrent breast cancer
665869|NCT00054145|stage IV breast cancer
665870|NCT00054145|stage IIIA breast cancer
665871|NCT00054145|stage IIIB breast cancer
665872|NCT00054145|stage IIIC breast cancer
665873|NCT00054106|adenocarcinoma of the prostate
665874|NCT00054106|stage III prostate cancer
665875|NCT00054106|stage II prostate cancer
665876|NCT00054067|cervical adenocarcinoma
665877|NCT00054067|cervical adenosquamous cell carcinoma
665878|NCT00054067|cervical squamous cell carcinoma
665879|NCT00054067|stage IB cervical cancer
665880|NCT00054054|stage III squamous cell carcinoma of the hypopharynx
665881|NCT00054054|stage III squamous cell carcinoma of the larynx
665882|NCT00054054|stage III squamous cell carcinoma of the oropharynx
665883|NCT00054054|stage IV squamous cell carcinoma of the hypopharynx
665884|NCT00054054|stage IV squamous cell carcinoma of the larynx
665885|NCT00054054|stage IV squamous cell carcinoma of the oropharynx
665886|NCT00054015|recurrent prostate cancer
665887|NCT00054015|stage IV prostate cancer
665888|NCT00054002|localized malignant mesothelioma
665889|NCT00054002|recurrent malignant mesothelioma
665890|NCT00054002|epithelial mesothelioma
665891|NCT00054002|sarcomatous mesothelioma
665892|NCT00053989|accelerated phase chronic myelogenous leukemia
665893|NCT00053989|chronic myelomonocytic leukemia
665894|NCT00053989|primary myelofibrosis
665895|NCT00053989|de novo myelodysplastic syndromes
665896|NCT00053989|chronic phase chronic myelogenous leukemia
665897|NCT00053989|relapsing chronic myelogenous leukemia
665898|NCT00053989|refractory anemia with excess blasts
665899|NCT00053989|stage I multiple myeloma
665900|NCT00053989|stage II multiple myeloma
665901|NCT00053989|stage III multiple myeloma
665902|NCT00053989|Waldenstrom macroglobulinemia
665903|NCT00053989|stage III adult lymphoblastic lymphoma
665904|NCT00053989|stage IV adult lymphoblastic lymphoma
665905|NCT00053989|noncontiguous stage II adult Burkitt lymphoma
665906|NCT00053989|stage III adult Burkitt lymphoma
665907|NCT00053989|stage IV adult Burkitt lymphoma
665908|NCT00053989|recurrent adult Hodgkin lymphoma
665909|NCT00053989|adult acute myeloid leukemia in remission
665910|NCT00053989|secondary acute myeloid leukemia
665911|NCT00053989|recurrent childhood acute lymphoblastic leukemia
665912|NCT00053989|recurrent adult acute myeloid leukemia
665913|NCT00053989|childhood acute lymphoblastic leukemia in remission
665914|NCT00053989|adult acute lymphoblastic leukemia in remission
665915|NCT00053989|noncontiguous stage II adult lymphoblastic lymphoma
665916|NCT00053989|refractory multiple myeloma
665917|NCT00053989|refractory anemia
665918|NCT00053989|refractory chronic lymphocytic leukemia
665919|NCT00053989|previously treated myelodysplastic syndromes
665920|NCT00053989|secondary myelodysplastic syndromes
665921|NCT00053989|grade 1 follicular lymphoma
665922|NCT00053989|grade 2 follicular lymphoma
665923|NCT00053989|recurrent/refractory childhood Hodgkin lymphoma
665924|NCT00053989|recurrent adult acute lymphoblastic leukemia
665925|NCT00053989|recurrent childhood acute myeloid leukemia
665926|NCT00053989|childhood acute myeloid leukemia in remission
665927|NCT00053989|childhood chronic myelogenous leukemia
665928|NCT00053989|atypical chronic myeloid leukemia
665929|NCT00053989|myelodysplastic/myeloproliferative disease, unclassifiable
665930|NCT00053989|recurrent marginal zone lymphoma
665931|NCT00053989|recurrent small lymphocytic lymphoma
665932|NCT00053989|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
665933|NCT00053989|nodal marginal zone B-cell lymphoma
665934|NCT00053989|splenic marginal zone lymphoma
665935|NCT00053989|adult acute myeloid leukemia with t(8;21)(q22;q22)
665936|NCT00053989|adult acute myeloid leukemia with t(16;16)(p13;q22)
665937|NCT00053989|adult acute myeloid leukemia with inv(16)(p13;q22)
665938|NCT00053989|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
665939|NCT00053989|adult acute myeloid leukemia with t(15;17)(q22;q12)
665940|NCT00053989|childhood myelodysplastic syndromes
665941|NCT00053976|graft versus host disease
665942|NCT00053937|plexiform neurofibroma
665943|NCT00053937|neurofibromatosis type 1
665944|NCT00053924|recurrent pancreatic cancer
665945|NCT00053924|stage II pancreatic cancer
665946|NCT00053924|adenocarcinoma of the pancreas
665947|NCT00053924|stage III pancreatic cancer
665948|NCT00053924|stage IV pancreatic cancer
665949|NCT00053911|recurrent breast cancer
665950|NCT00053911|stage I breast cancer
665951|NCT00053911|stage II breast cancer
665952|NCT00053911|stage IIIA breast cancer
665953|NCT00053898|breast cancer in situ
665954|NCT00053898|ductal breast carcinoma in situ
665955|NCT00053885|advanced malignant mesothelioma
665956|NCT00053885|epithelial mesothelioma
665957|NCT00053885|recurrent malignant mesothelioma
665958|NCT00053885|sarcomatous mesothelioma
665959|NCT00053872|untreated childhood medulloblastoma
665960|NCT00053846|dyspnea
665962|NCT00053846|unspecified adult solid tumor, protocol specific
665963|NCT00053833|recurrent ovarian epithelial cancer
665964|NCT00053833|fallopian tube cancer
665965|NCT00053833|primary peritoneal cavity cancer
665966|NCT00053833|stage III ovarian epithelial cancer
665967|NCT00053833|stage IV ovarian epithelial cancer
665968|NCT00053820|stage IV renal cell cancer
665969|NCT00053807|stage III renal cell cancer
665970|NCT00053807|stage IV renal cell cancer
665971|NCT00053794|adult alveolar soft-part sarcoma
665972|NCT00053794|adult angiosarcoma
665973|NCT00053794|adult fibrosarcoma
665974|NCT00053794|adult leiomyosarcoma
665975|NCT00053794|adult liposarcoma
665976|NCT00053794|adult synovial sarcoma
665977|NCT00053794|endometrial stromal sarcoma
665978|NCT00053794|uterine leiomyosarcoma
665979|NCT00053794|adult malignant hemangiopericytoma
665980|NCT00053794|stage III adult soft tissue sarcoma
665981|NCT00053794|stage III uterine sarcoma
665982|NCT00053794|stage IV uterine sarcoma
665983|NCT00053794|recurrent adult soft tissue sarcoma
665984|NCT00053794|recurrent uterine sarcoma
665985|NCT00053794|adult malignant fibrous histiocytoma
665986|NCT00053794|adult neurofibrosarcoma
665987|NCT00053794|adult rhabdomyosarcoma
665988|NCT00053794|stage IV adult soft tissue sarcoma
665989|NCT00053781|recurrent melanoma
665990|NCT00053781|stage IV melanoma
665991|NCT00053768|contiguous stage II grade 3 follicular lymphoma
665992|NCT00053768|noncontiguous stage II grade 3 follicular lymphoma
665993|NCT00053768|stage I grade 3 follicular lymphoma
665994|NCT00053768|stage III grade 3 follicular lymphoma
665995|NCT00053768|stage IV grade 3 follicular lymphoma
665996|NCT00053768|contiguous stage II adult diffuse mixed cell lymphoma
665997|NCT00053768|noncontiguous stage II adult diffuse mixed cell lymphoma
665998|NCT00053768|stage I adult diffuse mixed cell lymphoma
665999|NCT00053768|stage III adult diffuse mixed cell lymphoma
666000|NCT00053768|stage IV adult diffuse mixed cell lymphoma
666001|NCT00053768|contiguous stage II adult diffuse large cell lymphoma
666002|NCT00053768|contiguous stage II adult Burkitt lymphoma
666003|NCT00053768|noncontiguous stage II adult diffuse large cell lymphoma
666004|NCT00053768|noncontiguous stage II adult Burkitt lymphoma
666005|NCT00053768|stage I adult diffuse large cell lymphoma
666006|NCT00053768|stage I adult Burkitt lymphoma
666007|NCT00053768|stage III adult diffuse large cell lymphoma
666008|NCT00053768|stage III adult Burkitt lymphoma
666009|NCT00053768|stage IV adult diffuse large cell lymphoma
666010|NCT00053768|stage IV adult Burkitt lymphoma
666011|NCT00053768|contiguous stage II adult immunoblastic large cell lymphoma
666012|NCT00053768|noncontiguous stage II adult immunoblastic large cell lymphoma
666013|NCT00053768|stage I adult immunoblastic large cell lymphoma
666014|NCT00053768|stage III adult immunoblastic large cell lymphoma
666015|NCT00053768|stage IV adult immunoblastic large cell lymphoma
666016|NCT00053768|contiguous stage II adult lymphoblastic lymphoma
666017|NCT00053768|noncontiguous stage II adult lymphoblastic lymphoma
666018|NCT00053768|stage I adult lymphoblastic lymphoma
666019|NCT00053768|stage III adult lymphoblastic lymphoma
666020|NCT00053768|stage IV adult lymphoblastic lymphoma
666021|NCT00053768|contiguous stage II mantle cell lymphoma
666022|NCT00053768|noncontiguous stage II mantle cell lymphoma
666023|NCT00053768|stage I mantle cell lymphoma
666024|NCT00053768|stage III mantle cell lymphoma
666025|NCT00053768|stage IV mantle cell lymphoma
666026|NCT00053742|Smallpox
666027|NCT00053742|Vaccine
666028|NCT00053742|Vaccination
666029|NCT00053742|Variola
666030|NCT00053742|Adults
666031|NCT00053742|Healthy Volunteer
666032|NCT00053742|HV
666033|NCT00053742|Smallpox Vaccine
666034|NCT00053716|Angioplasty & PGE1 Treatment of Peripheral Vascular Disease
666035|NCT00053703|Psychotic Disorders
666036|NCT00053703|Schizophreniform Disorder
666037|NCT00053690|Comorbidity
666038|NCT00053690|Schizophrenia
666039|NCT00053690|Bipolar Disorder
666040|NCT00053690|Depression
666041|NCT00053677|Impulse Control Disorders
666042|NCT00053638|HIV-1 Efavirenz Tenofovir
666043|NCT00053625|Parkinson's disease
666044|NCT00053625|PD
666045|NCT00053625|deep brain stimulation
666046|NCT00053625|DBS
666047|NCT00053612|HIV-1
666048|NCT00053612|Women
666049|NCT00053612|Vitamin A
666050|NCT00053612|Shedding
666051|NCT00053599|Cholesterol-lowering drug
666052|NCT00053599|Mild to Moderate Alzheimer disease
666053|NCT00053573|Glycogen Storage Disease Type II
666054|NCT00053573|GSD-II
666055|NCT00053573|Pompe Disease
666056|NCT00053560|lupus
666057|NCT00053560|systemic lupus erythematosus
666058|NCT00053560|SLE
666059|NCT00053560|bone loss
666060|NCT00053560|DHEA
666061|NCT00053495|Smallpox
666062|NCT00053482|Smallpox vaccines
666063|NCT00053482|Dryvax®
666064|NCT00053482|Orthopoxvirus
666065|NCT00053482|Vaccinia virus
666066|NCT00053482|ACAM2000
666067|NCT00053469|Cognitive Development
666068|NCT00053469|Motor Planning
666070|NCT00053469|Perception
666071|NCT00053469|Adaptation
666072|NCT00053456|Endothelium
666073|NCT00053456|Nitric Oxide
666074|NCT00053456|Myocardial Ischemia
666075|NCT00053456|Exercise
666076|NCT00053456|Endothelial Progenitor Cells
666077|NCT00053443|Adherence
666078|NCT00053443|Treatment Experienced
666079|NCT00053430|Immune Modulation
666080|NCT00053430|Thalidomide
666081|NCT00053430|Immune reconstitution
666082|NCT00053430|Treatment Experienced
666083|NCT00053417|Walking Ability
666084|NCT00053417|Muscle strength
666085|NCT00053417|Spasticity
666086|NCT00053404|Treatment Experienced
666087|NCT00053404|Drug Resistance
666088|NCT00053391|stage III melanoma
666089|NCT00053391|stage IV melanoma
666090|NCT00053391|recurrent melanoma
666091|NCT00053378|hypocalcemia, ionized calcium, intensive care
666092|NCT00053300|extensive stage small cell lung cancer
666093|NCT00053287|adult acute promyelocytic leukemia (M3)
666094|NCT00053287|refractory anemia with excess blasts in transformation
666095|NCT00053287|refractory anemia with excess blasts
666096|NCT00053287|de novo myelodysplastic syndromes
666097|NCT00053287|recurrent adult acute myeloid leukemia
666098|NCT00053287|secondary acute myeloid leukemia
666099|NCT00053287|untreated adult acute myeloid leukemia
666100|NCT00053287|blastic phase chronic myelogenous leukemia
666101|NCT00053287|relapsing chronic myelogenous leukemia
666102|NCT00053287|previously treated myelodysplastic syndromes
666103|NCT00053287|secondary myelodysplastic syndromes
666104|NCT00053287|atypical chronic myeloid leukemia
666105|NCT00053287|myelodysplastic/myeloproliferative disease, unclassifiable
666106|NCT00053287|adult acute myeloid leukemia with t(8;21)(q22;q22)
666107|NCT00053287|adult acute myeloid leukemia with t(16;16)(p13;q22)
666108|NCT00053287|adult acute myeloid leukemia with inv(16)(p13;q22)
666109|NCT00053287|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
666110|NCT00053287|adult acute myeloid leukemia with t(15;17)(q22;q12)
666111|NCT00053261|sexuality and reproductive issues
666112|NCT00053261|stage IB cervical cancer
666113|NCT00053248|chronic phase chronic myelogenous leukemia
666114|NCT00053248|Philadelphia chromosome positive chronic myelogenous leukemia
666115|NCT00053222|recurrent pancreatic cancer
666116|NCT00053222|stage II pancreatic cancer
666117|NCT00053222|stage III pancreatic cancer
666118|NCT00053222|adenocarcinoma of the pancreas
666119|NCT00053222|stage IV pancreatic cancer
666120|NCT00053209|metastatic transitional cell cancer of the renal pelvis and ureter
666121|NCT00053209|recurrent transitional cell cancer of the renal pelvis and ureter
666122|NCT00053209|regional transitional cell cancer of the renal pelvis and ureter
666123|NCT00053209|transitional cell carcinoma of the bladder
666124|NCT00053209|recurrent bladder cancer
666125|NCT00053209|stage III bladder cancer
666126|NCT00053209|stage IV bladder cancer
666127|NCT00053209|anterior urethral cancer
666128|NCT00053209|posterior urethral cancer
666129|NCT00053209|recurrent urethral cancer
666130|NCT00053209|urethral cancer associated with invasive bladder cancer
666131|NCT00053196|refractory chronic lymphocytic leukemia
666132|NCT00053196|prolymphocytic leukemia
666133|NCT00053196|recurrent adult Hodgkin lymphoma
666134|NCT00053196|stage I multiple myeloma
666135|NCT00053196|stage II multiple myeloma
666136|NCT00053196|stage III multiple myeloma
666137|NCT00053196|refractory multiple myeloma
666138|NCT00053196|previously treated myelodysplastic syndromes
666139|NCT00053196|recurrent adult diffuse large cell lymphoma
666140|NCT00053196|recurrent adult diffuse mixed cell lymphoma
666141|NCT00053196|recurrent adult diffuse small cleaved cell lymphoma
666142|NCT00053196|recurrent adult Burkitt lymphoma
666143|NCT00053196|recurrent adult immunoblastic large cell lymphoma
666144|NCT00053196|recurrent grade 1 follicular lymphoma
666145|NCT00053196|recurrent grade 2 follicular lymphoma
666146|NCT00053196|recurrent grade 3 follicular lymphoma
666147|NCT00053196|secondary myelodysplastic syndromes
666148|NCT00053196|de novo myelodysplastic syndromes
666149|NCT00053196|recurrent adult acute myeloid leukemia
666150|NCT00053196|recurrent childhood acute myeloid leukemia
666151|NCT00053196|recurrent childhood large cell lymphoma
666152|NCT00053196|recurrent childhood lymphoblastic lymphoma
666153|NCT00053196|recurrent childhood small noncleaved cell lymphoma
666154|NCT00053196|recurrent/refractory childhood Hodgkin lymphoma
666155|NCT00053196|atypical chronic myeloid leukemia, BCR-ABL negative
666156|NCT00053196|myelodysplastic/myeloproliferative neoplasm, unclassifiable
666157|NCT00053196|recurrent marginal zone lymphoma
666158|NCT00053196|recurrent small lymphocytic lymphoma
666159|NCT00053196|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666160|NCT00053196|nodal marginal zone B-cell lymphoma
666161|NCT00053196|splenic marginal zone lymphoma
666162|NCT00053196|adult acute myeloid leukemia with t(8;21)(q22;q22)
666163|NCT00053196|adult acute myeloid leukemia with t(16;16)(p13;q22)
666164|NCT00053196|adult acute myeloid leukemia with inv(16)(p13;q22)
666165|NCT00053196|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
666166|NCT00053196|adult acute myeloid leukemia with t(15;17)(q22;q12)
666167|NCT00053196|childhood myelodysplastic syndromes
666168|NCT00053183|adult glioblastoma
666169|NCT00053183|adult giant cell glioblastoma
666170|NCT00053183|adult gliosarcoma
666171|NCT00053157|graft versus host disease
666172|NCT00053157|accelerated phase chronic myelogenous leukemia
666173|NCT00053157|chronic phase chronic myelogenous leukemia
666174|NCT00053157|primary myelofibrosis
666175|NCT00053157|childhood acute myeloid leukemia/other myeloid malignancies
666176|NCT00053157|childhood acute promyelocytic leukemia (M3)
666177|NCT00053157|recurrent childhood acute lymphoblastic leukemia
666178|NCT00053157|recurrent childhood acute myeloid leukemia
666179|NCT00053157|recurrent childhood large cell lymphoma
666180|NCT00053157|recurrent childhood lymphoblastic lymphoma
666181|NCT00053157|recurrent childhood small noncleaved cell lymphoma
666182|NCT00053157|recurrent/refractory childhood Hodgkin lymphoma
666183|NCT00053157|de novo myelodysplastic syndromes
666184|NCT00053157|previously treated myelodysplastic syndromes
666185|NCT00053157|secondary myelodysplastic syndromes
666186|NCT00053157|meningeal chronic myelogenous leukemia
666187|NCT00053157|noncontiguous stage II adult diffuse large cell lymphoma
666188|NCT00053157|noncontiguous stage II adult diffuse mixed cell lymphoma
666189|NCT00053157|noncontiguous stage II adult diffuse small cleaved cell lymphoma
666190|NCT00053157|noncontiguous stage II adult Burkitt lymphoma
666191|NCT00053157|noncontiguous stage II adult immunoblastic large cell lymphoma
666192|NCT00053157|noncontiguous stage II adult lymphoblastic lymphoma
666193|NCT00053157|noncontiguous stage II grade 1 follicular lymphoma
666194|NCT00053157|noncontiguous stage II grade 2 follicular lymphoma
666195|NCT00053157|noncontiguous stage II grade 3 follicular lymphoma
666196|NCT00053157|noncontiguous stage II mantle cell lymphoma
666197|NCT00053157|recurrent adult diffuse large cell lymphoma
666198|NCT00053157|recurrent adult diffuse mixed cell lymphoma
666199|NCT00053157|recurrent adult diffuse small cleaved cell lymphoma
666200|NCT00053157|recurrent adult Burkitt lymphoma
666201|NCT00053157|recurrent adult immunoblastic large cell lymphoma
666202|NCT00053157|recurrent adult lymphoblastic lymphoma
666203|NCT00053157|recurrent adult acute lymphoblastic leukemia
666204|NCT00053157|recurrent adult acute myeloid leukemia
666205|NCT00053157|recurrent adult Hodgkin lymphoma
666206|NCT00053157|recurrent cutaneous T-cell non-Hodgkin lymphoma
666207|NCT00053157|recurrent grade 1 follicular lymphoma
666208|NCT00053157|recurrent grade 2 follicular lymphoma
666209|NCT00053157|recurrent grade 3 follicular lymphoma
666210|NCT00053157|recurrent mantle cell lymphoma
666211|NCT00053157|relapsing chronic myelogenous leukemia
666212|NCT00053157|secondary acute myeloid leukemia
666213|NCT00053157|refractory chronic lymphocytic leukemia
666214|NCT00053157|stage III adult diffuse large cell lymphoma
666215|NCT00053157|stage III adult diffuse mixed cell lymphoma
666216|NCT00053157|stage III adult diffuse small cleaved cell lymphoma
666217|NCT00053157|stage III adult Burkitt lymphoma
666218|NCT00053157|stage III adult immunoblastic large cell lymphoma
666219|NCT00053157|stage III adult lymphoblastic lymphoma
666220|NCT00053157|stage III grade 1 follicular lymphoma
666221|NCT00053157|stage III grade 2 follicular lymphoma
666222|NCT00053157|stage III grade 3 follicular lymphoma
666223|NCT00053157|stage III mantle cell lymphoma
666224|NCT00053157|stage III chronic lymphocytic leukemia
666225|NCT00053157|stage IV adult diffuse large cell lymphoma
666226|NCT00053157|stage IV adult diffuse mixed cell lymphoma
666227|NCT00053157|stage IV adult diffuse small cleaved cell lymphoma
666228|NCT00053157|stage IV adult Burkitt lymphoma
666229|NCT00053157|stage IV adult immunoblastic large cell lymphoma
666230|NCT00053157|stage IV adult lymphoblastic lymphoma
666231|NCT00053157|stage IV grade 1 follicular lymphoma
666232|NCT00053157|stage IV grade 2 follicular lymphoma
666233|NCT00053157|stage IV grade 3 follicular lymphoma
666234|NCT00053157|stage IV mantle cell lymphoma
666235|NCT00053157|stage IV chronic lymphocytic leukemia
666236|NCT00053157|untreated adult acute lymphoblastic leukemia
666237|NCT00053157|untreated adult acute myeloid leukemia
666238|NCT00053157|untreated childhood acute lymphoblastic leukemia
666239|NCT00053157|untreated childhood acute myeloid leukemia and other myeloid malignancies
666240|NCT00053157|childhood chronic myelogenous leukemia
666241|NCT00053157|chronic eosinophilic leukemia
666242|NCT00053157|chronic neutrophilic leukemia
666243|NCT00053157|atypical chronic myeloid leukemia, BCR-ABL1 negative
666244|NCT00053157|myelodysplastic/myeloproliferative neoplasm, unclassifiable
666245|NCT00053157|noncontiguous stage II small lymphocytic lymphoma
666246|NCT00053157|noncontiguous stage II marginal zone lymphoma
666247|NCT00053157|recurrent marginal zone lymphoma
666248|NCT00053157|recurrent small lymphocytic lymphoma
666249|NCT00053157|stage III small lymphocytic lymphoma
666250|NCT00053157|stage III marginal zone lymphoma
666251|NCT00053157|stage IV small lymphocytic lymphoma
666252|NCT00053157|stage IV marginal zone lymphoma
666253|NCT00053157|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666254|NCT00053157|nodal marginal zone B-cell lymphoma
666255|NCT00053157|splenic marginal zone lymphoma
666256|NCT00053157|adult acute myeloid leukemia with t(8;21)(q22;q22)
666447|NCT00052676|stage II breast cancer
666257|NCT00053157|adult acute myeloid leukemia with t(16;16)(p13;q22)
666258|NCT00053157|adult acute myeloid leukemia with inv(16)(p13;q22)
666259|NCT00053157|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
666260|NCT00053157|adult acute myeloid leukemia with t(15;17)(q22;q12)
666261|NCT00053157|childhood myelodysplastic syndromes
666262|NCT00053144|recurrent adult acute myeloid leukemia
666263|NCT00053144|Philadelphia chromosome positive chronic myelogenous leukemia
666264|NCT00053144|secondary acute myeloid leukemia
666265|NCT00053144|blastic phase chronic myelogenous leukemia
666266|NCT00053144|relapsing chronic myelogenous leukemia
666267|NCT00053144|adult acute monocytic leukemia (M5b)
666268|NCT00053144|adult acute erythroid leukemia (M6)
666269|NCT00053144|adult acute megakaryoblastic leukemia (M7)
666270|NCT00053144|adult acute minimally differentiated myeloid leukemia (M0)
666271|NCT00053144|adult acute myeloblastic leukemia with maturation (M2)
666272|NCT00053144|adult acute myeloblastic leukemia without maturation (M1)
666273|NCT00053144|adult acute myelomonocytic leukemia (M4)
666274|NCT00053144|adult acute monoblastic leukemia (M5a)
666275|NCT00053144|adult acute promyelocytic leukemia (M3)
666276|NCT00053131|recurrent adult acute myeloid leukemia
666277|NCT00053131|recurrent childhood acute myeloid leukemia
666278|NCT00053131|recurrent adult acute lymphoblastic leukemia
666279|NCT00053131|recurrent childhood acute lymphoblastic leukemia
666280|NCT00053118|childhood central nervous system germ cell tumor
666281|NCT00053118|childhood choroid plexus tumor
666282|NCT00053118|childhood craniopharyngioma
666283|NCT00053118|childhood grade I meningioma
666284|NCT00053118|childhood grade II meningioma
666285|NCT00053118|childhood grade III meningioma
666286|NCT00053118|recurrent childhood brain stem glioma
666287|NCT00053118|recurrent childhood cerebellar astrocytoma
666288|NCT00053118|recurrent childhood cerebral astrocytoma
666289|NCT00053118|recurrent childhood ependymoma
666290|NCT00053118|recurrent childhood medulloblastoma
666291|NCT00053118|recurrent childhood supratentorial primitive neuroectodermal tumor
666292|NCT00053118|recurrent neuroblastoma
666293|NCT00053118|recurrent retinoblastoma
666294|NCT00053118|childhood visual pathway and hypothalamic glioma
666295|NCT00053118|childhood atypical teratoid/rhabdoid tumor
666296|NCT00053118|primary central nervous system non-Hodgkin lymphoma
666297|NCT00053105|recurrent adult diffuse large cell lymphoma
666298|NCT00053105|recurrent grade 3 follicular lymphoma
666299|NCT00053105|recurrent cutaneous T-cell non-Hodgkin lymphoma
666300|NCT00053105|recurrent adult immunoblastic large cell lymphoma
666301|NCT00053092|contiguous stage II mantle cell lymphoma
666302|NCT00053092|noncontiguous stage II mantle cell lymphoma
666303|NCT00053092|stage I mantle cell lymphoma
666304|NCT00053092|stage III mantle cell lymphoma
666305|NCT00053092|stage IV mantle cell lymphoma
666306|NCT00053053|unspecified adult solid tumor, protocol specific
666307|NCT00053053|cachexia
666308|NCT00053053|recurrent adult diffuse large cell lymphoma
666309|NCT00053053|recurrent adult diffuse mixed cell lymphoma
666310|NCT00053053|recurrent adult diffuse small cleaved cell lymphoma
666311|NCT00053053|recurrent adult Hodgkin lymphoma
666312|NCT00053053|recurrent adult immunoblastic large cell lymphoma
666313|NCT00053053|recurrent adult lymphoblastic lymphoma
666314|NCT00053053|recurrent cutaneous T-cell non-Hodgkin lymphoma
666315|NCT00053053|recurrent grade 1 follicular lymphoma
666316|NCT00053053|recurrent grade 2 follicular lymphoma
666317|NCT00053053|recurrent grade 3 follicular lymphoma
666318|NCT00053053|recurrent mantle cell lymphoma
666319|NCT00053053|stage III adult diffuse large cell lymphoma
666320|NCT00053053|stage III adult diffuse mixed cell lymphoma
666321|NCT00053053|stage III adult diffuse small cleaved cell lymphoma
666322|NCT00053053|stage III adult Burkitt lymphoma
666323|NCT00053053|stage III adult Hodgkin lymphoma
666324|NCT00053053|stage III adult immunoblastic large cell lymphoma
666325|NCT00053053|stage III adult lymphoblastic lymphoma
666326|NCT00053053|stage III cutaneous T-cell non-Hodgkin lymphoma
666327|NCT00053053|stage III grade 1 follicular lymphoma
666328|NCT00053053|stage III grade 2 follicular lymphoma
666329|NCT00053053|stage III grade 3 follicular lymphoma
666330|NCT00053053|stage III mantle cell lymphoma
666331|NCT00053053|stage IV adult diffuse large cell lymphoma
666332|NCT00053053|stage IV adult diffuse mixed cell lymphoma
666333|NCT00053053|stage IV adult diffuse small cleaved cell lymphoma
666334|NCT00053053|stage IV adult Burkitt lymphoma
666335|NCT00053053|stage IV adult Hodgkin lymphoma
666336|NCT00053053|stage IV adult immunoblastic large cell lymphoma
666337|NCT00053053|stage IV adult lymphoblastic lymphoma
666338|NCT00053053|stage IV cutaneous T-cell non-Hodgkin lymphoma
666339|NCT00053053|stage IV grade 1 follicular lymphoma
666340|NCT00053053|stage IV grade 2 follicular lymphoma
666341|NCT00053053|stage IV grade 3 follicular lymphoma
666342|NCT00053053|stage IV mantle cell lymphoma
666343|NCT00053053|intraocular lymphoma
666344|NCT00053053|AIDS-related peripheral/systemic lymphoma
666345|NCT00053053|recurrent adult Burkitt lymphoma
666346|NCT00053053|anaplastic large cell lymphoma
666347|NCT00053053|post-transplant lymphoproliferative disorder
666348|NCT00053053|recurrent marginal zone lymphoma
666349|NCT00053053|recurrent small lymphocytic lymphoma
666350|NCT00053053|stage III small lymphocytic lymphoma
666351|NCT00053053|stage III marginal zone lymphoma
666352|NCT00053053|stage IV small lymphocytic lymphoma
666353|NCT00053053|stage IV marginal zone lymphoma
666354|NCT00053053|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666355|NCT00053053|nodal marginal zone B-cell lymphoma
666356|NCT00053053|splenic marginal zone lymphoma
666357|NCT00053040|recurrent childhood brain tumor
666358|NCT00053027|contiguous stage II mantle cell lymphoma
666359|NCT00053027|noncontiguous stage II mantle cell lymphoma
666360|NCT00053027|stage I mantle cell lymphoma
666361|NCT00053027|stage III mantle cell lymphoma
666362|NCT00053027|stage IV mantle cell lymphoma
666363|NCT00053014|adult acute myeloid leukemia in remission
666364|NCT00053014|adult acute myeloid leukemia with t(8;21)(q22;q22)
666365|NCT00053014|adult acute myeloid leukemia with t(16;16)(p13;q22)
666366|NCT00053014|adult acute myeloid leukemia with inv(16)(p13;q22)
666367|NCT00053014|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
666368|NCT00053001|de novo myelodysplastic syndromes
666369|NCT00053001|secondary myelodysplastic syndromes
666370|NCT00053001|previously treated myelodysplastic syndromes
666371|NCT00053001|anemia
666372|NCT00053001|atypical chronic myeloid leukemia, BCR-ABL1 negative
666373|NCT00053001|myelodysplastic/myeloproliferative neoplasm, unclassifiable
666374|NCT00053001|childhood myelodysplastic syndromes
666375|NCT00052962|Appendiceal Cancer
666376|NCT00052962|Regional Therapy
666377|NCT00052962|Carcinomatosis
666378|NCT00052962|Hyperthermia
666379|NCT00052936|anaplastic large cell lymphoma
666380|NCT00052936|angioimmunoblastic T-cell lymphoma
666381|NCT00052936|stage III grade 1 follicular lymphoma
666382|NCT00052936|stage III grade 3 follicular lymphoma
666383|NCT00052936|stage III grade 2 follicular lymphoma
666384|NCT00052936|stage I adult T-cell leukemia/lymphoma
666385|NCT00052936|stage II adult T-cell leukemia/lymphoma
666386|NCT00052936|stage III adult T-cell leukemia/lymphoma
666387|NCT00052936|stage IV adult T-cell leukemia/lymphoma
666388|NCT00052936|contiguous stage II adult lymphoblastic lymphoma
666389|NCT00052936|noncontiguous stage II adult lymphoblastic lymphoma
666390|NCT00052936|stage I adult lymphoblastic lymphoma
666391|NCT00052936|stage III adult lymphoblastic lymphoma
666392|NCT00052936|stage IV adult lymphoblastic lymphoma
666393|NCT00052936|contiguous stage II adult diffuse large cell lymphoma
666394|NCT00052936|noncontiguous stage II adult diffuse large cell lymphoma
666395|NCT00052936|stage I adult diffuse large cell lymphoma
666396|NCT00052936|stage III adult diffuse large cell lymphoma
666397|NCT00052936|stage IV adult diffuse large cell lymphoma
666398|NCT00052936|contiguous stage II mantle cell lymphoma
666399|NCT00052936|noncontiguous stage II mantle cell lymphoma
666400|NCT00052936|stage I mantle cell lymphoma
666401|NCT00052936|stage III mantle cell lymphoma
666402|NCT00052936|stage IV mantle cell lymphoma
666403|NCT00052936|contiguous stage II adult Burkitt lymphoma
666404|NCT00052936|noncontiguous stage II adult Burkitt lymphoma
666405|NCT00052936|stage I adult Burkitt lymphoma
666406|NCT00052936|stage III adult Burkitt lymphoma
666407|NCT00052936|stage IV adult Burkitt lymphoma
666408|NCT00052936|contiguous stage II marginal zone lymphoma
666409|NCT00052936|noncontiguous stage II marginal zone lymphoma
666410|NCT00052936|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666411|NCT00052936|nodal marginal zone B-cell lymphoma
666412|NCT00052936|splenic marginal zone lymphoma
666413|NCT00052936|stage I marginal zone lymphoma
666414|NCT00052936|stage III marginal zone lymphoma
666415|NCT00052936|stage IV marginal zone lymphoma
666416|NCT00052923|recurrent adult diffuse large cell lymphoma
666417|NCT00052910|stage I gastric cancer
666418|NCT00052910|stage II gastric cancer
666419|NCT00052910|stage III gastric cancer
666420|NCT00052910|adenocarcinoma of the stomach
666421|NCT00052910|adenocarcinoma of the esophagus
666422|NCT00052910|stage I esophageal cancer
666423|NCT00052910|stage II esophageal cancer
666424|NCT00052910|stage III esophageal cancer
666425|NCT00052897|anal cancer
666426|NCT00052884|drug/agent toxicity by tissue/organ
666427|NCT00052884|primary systemic amyloidosis
666428|NCT00052845|adenocarcinoma of the prostate
666429|NCT00052845|recurrent prostate cancer
666430|NCT00052845|stage IV prostate cancer
666431|NCT00052832|chronic myelomonocytic leukemia
666432|NCT00052832|previously treated myelodysplastic syndromes
666433|NCT00052832|secondary myelodysplastic syndromes
666434|NCT00052832|de novo myelodysplastic syndromes
666435|NCT00052832|atypical chronic myeloid leukemia
666436|NCT00052832|myelodysplastic/myeloproliferative disease, unclassifiable
666437|NCT00052754|adult synovial sarcoma
666438|NCT00052754|stage III adult soft tissue sarcoma
666439|NCT00052754|recurrent adult soft tissue sarcoma
666440|NCT00052754|stage IV adult soft tissue sarcoma
666441|NCT00052728|stage IV breast cancer
666442|NCT00052728|recurrent breast cancer
666443|NCT00052715|adult glioblastoma
666444|NCT00052715|adult giant cell glioblastoma
666445|NCT00052715|adult gliosarcoma
666446|NCT00052676|stage I breast cancer
666448|NCT00052637|bladder cancer
666449|NCT00052637|recurrent bladder cancer
666450|NCT00052637|stage 0 bladder cancer
666451|NCT00052624|recurrent childhood cerebral astrocytoma
666452|NCT00052611|lip and oral cavity cancer
666453|NCT00052611|paranasal sinus and nasal cavity cancer
666454|NCT00052611|hypopharyngeal cancer
666455|NCT00052611|laryngeal cancer
666456|NCT00052611|oropharyngeal cancer
666457|NCT00052611|nasopharyngeal cancer
666458|NCT00052611|salivary gland cancer
666459|NCT00052572|refractory chronic lymphocytic leukemia
666460|NCT00052572|B-cell chronic lymphocytic leukemia
666461|NCT00052572|recurrent grade 1 follicular lymphoma
666462|NCT00052572|recurrent grade 2 follicular lymphoma
666463|NCT00052572|recurrent grade 3 follicular lymphoma
666464|NCT00052572|Waldenström macroglobulinemia
666465|NCT00052572|recurrent marginal zone lymphoma
666466|NCT00052572|recurrent small lymphocytic lymphoma
666467|NCT00052572|recurrent mantle cell lymphoma
666468|NCT00052572|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666469|NCT00052572|nodal marginal zone B-cell lymphoma
666470|NCT00052572|splenic marginal zone lymphoma
666471|NCT00052507|stage IV colon cancer
666472|NCT00052507|stage IV rectal cancer
666473|NCT00052507|adenocarcinoma of the colon
666474|NCT00052507|adenocarcinoma of the rectum
666475|NCT00052507|recurrent colon cancer
666476|NCT00052507|recurrent rectal cancer
666477|NCT00052494|extensive stage small cell lung cancer
666478|NCT00052494|recurrent small cell lung cancer
666479|NCT00052481|stage IIB prostate cancer
666480|NCT00052481|stage IIA prostate cancer
666481|NCT00052481|adenocarcinoma of the prostate
666482|NCT00052468|stage I ovarian epithelial cancer
666483|NCT00052468|stage II ovarian epithelial cancer
666484|NCT00052468|stage III ovarian epithelial cancer
666485|NCT00052468|stage IV ovarian epithelial cancer
666486|NCT00052468|fallopian tube cancer
666487|NCT00052455|adult glioblastoma
666488|NCT00052455|adult anaplastic astrocytoma
666489|NCT00052455|recurrent adult brain tumor
666490|NCT00052455|adult giant cell glioblastoma
666491|NCT00052455|adult gliosarcoma
666492|NCT00052442|recurrent adult diffuse large cell lymphoma
666493|NCT00052442|recurrent adult diffuse mixed cell lymphoma
666494|NCT00052442|recurrent adult Burkitt lymphoma
666495|NCT00052442|recurrent adult immunoblastic large cell lymphoma
666496|NCT00052442|recurrent adult lymphoblastic lymphoma
666497|NCT00052442|recurrent mantle cell lymphoma
666498|NCT00052442|recurrent adult Hodgkin lymphoma
666499|NCT00052442|recurrent grade 3 follicular lymphoma
666500|NCT00052429|stage II lymphoepithelioma of the nasopharynx
666501|NCT00052429|stage II squamous cell carcinoma of the nasopharynx
666502|NCT00052429|stage III lymphoepithelioma of the nasopharynx
666503|NCT00052429|stage III squamous cell carcinoma of the nasopharynx
666504|NCT00052429|stage IV lymphoepithelioma of the nasopharynx
666505|NCT00052429|stage IV squamous cell carcinoma of the nasopharynx
666506|NCT00052416|B-cell chronic lymphocytic leukemia
666507|NCT00052416|stage 0 chronic lymphocytic leukemia
666508|NCT00052416|stage I chronic lymphocytic leukemia
666509|NCT00052416|stage II chronic lymphocytic leukemia
666510|NCT00052416|stage III chronic lymphocytic leukemia
666511|NCT00052416|stage IV chronic lymphocytic leukemia
666512|NCT00052416|stage I grade 1 follicular lymphoma
666513|NCT00052416|stage III grade 1 follicular lymphoma
666514|NCT00052416|stage IV grade 1 follicular lymphoma
666515|NCT00052416|contiguous stage II grade 1 follicular lymphoma
666516|NCT00052416|noncontiguous stage II grade 1 follicular lymphoma
666517|NCT00052416|contiguous stage II grade 2 follicular lymphoma
666518|NCT00052416|noncontiguous stage II grade 2 follicular lymphoma
666519|NCT00052416|stage I grade 2 follicular lymphoma
666520|NCT00052416|stage III grade 2 follicular lymphoma
666521|NCT00052416|stage IV grade 2 follicular lymphoma
666522|NCT00052416|Waldenström macroglobulinemia
666523|NCT00052416|contiguous stage II marginal zone lymphoma
666524|NCT00052416|contiguous stage II small lymphocytic lymphoma
666525|NCT00052416|noncontiguous stage II small lymphocytic lymphoma
666526|NCT00052416|noncontiguous stage II marginal zone lymphoma
666527|NCT00052416|stage I marginal zone lymphoma
666528|NCT00052416|stage I small lymphocytic lymphoma
666529|NCT00052416|stage III small lymphocytic lymphoma
666530|NCT00052416|stage III marginal zone lymphoma
666531|NCT00052416|stage IV small lymphocytic lymphoma
666532|NCT00052416|stage IV marginal zone lymphoma
666533|NCT00052416|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
666534|NCT00052416|nodal marginal zone B-cell lymphoma
666535|NCT00052416|splenic marginal zone lymphoma
666536|NCT00052390|recurrent adult soft tissue sarcoma
666537|NCT00052390|stage III adult soft tissue sarcoma
666538|NCT00052390|stage IV adult soft tissue sarcoma
666539|NCT00052351|stage II breast cancer
666540|NCT00052351|stage IIIA breast cancer
666541|NCT00052351|stage IIIB breast cancer
666542|NCT00052325|stage IV non-small cell lung cancer
666543|NCT00052325|stage IIIB non-small cell lung cancer
666544|NCT00052312|recurrent endometrial carcinoma
666545|NCT00052312|stage III endometrial carcinoma
666546|NCT00052312|stage IV endometrial carcinoma
666547|NCT00052312|endometrial papillary serous carcinoma
666548|NCT00052299|adult acute monocytic leukemia (M5b)
666549|NCT00052299|adult acute erythroid leukemia (M6)
666550|NCT00052299|adult acute megakaryoblastic leukemia (M7)
666551|NCT00052299|adult acute minimally differentiated myeloid leukemia (M0)
666552|NCT00052299|adult acute myeloblastic leukemia with maturation (M2)
666553|NCT00052299|adult acute myeloblastic leukemia without maturation (M1)
666554|NCT00052299|adult acute myelomonocytic leukemia (M4)
666555|NCT00052299|adult acute monoblastic leukemia (M5a)
666556|NCT00052299|untreated adult acute myeloid leukemia
666557|NCT00052299|secondary acute myeloid leukemia
666558|NCT00052299|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
666559|NCT00052299|adult acute myeloid leukemia with inv(16)(p13;q22)
666560|NCT00052299|adult acute myeloid leukemia with t(16;16)(p13;q22)
666561|NCT00052299|adult acute myeloid leukemia with t(8;21)(q22;q22)
666562|NCT00052286|adult brain tumor
666563|NCT00052286|fatigue
666564|NCT00052286|cognitive/functional effects
666565|NCT00052273|unspecified adult solid tumor
666566|NCT00052273|protocol specific
666567|NCT00052221|unspecified adult solid tumor, protocol specific
666568|NCT00052221|fatigue
666569|NCT00052195|Mycobacterium vaccae
666570|NCT00052195|BCG
666571|NCT00052195|Disseminated tuberculosis
666572|NCT00052195|SRL-172
666573|NCT00052195|DAR-901
666574|NCT00052182|HIV Therapeutic Vaccine
666575|NCT00052182|CTL Epitope
666576|NCT00052182|Treatment Experienced
666577|NCT00052169|metastatic breast cancer
666578|NCT00052169|docetaxel
666579|NCT00052169|Taxotere
666580|NCT00052169|ZD 1839
666581|NCT00052169|gefitinib
666582|NCT00052169|NSABP
666583|NCT00052169|advanced breast cancer
666584|NCT00052169|AstraZeneca
666585|NCT00052143|Huntington's disease
666586|NCT00052143|HD
666587|NCT00052143|Huntington disease
666588|NCT00052091|Geriatrics
666589|NCT00052078|Phobic Disorders
666590|NCT00052078|Anxiety, Separation
666591|NCT00052052|idiopathic pulmonary fibrosis
666592|NCT00052052|IPF
666593|NCT00052039|idiopathic pulmonary fibrosis
666594|NCT00052026|Adolescent
666595|NCT00052026|Adrenergic alpha-Antagonists/therapeutic use
666596|NCT00052026|Adrenergic alpha-Antagonists/pharmacokinetics
666597|NCT00052026|Adrenergic alpha-Antagonists/administration & dosage
666598|NCT00052026|Adrenergic beta-Antagonists/therapeutic use
666599|NCT00052026|Adrenergic beta-Antagonists/pharmacokinetics
666600|NCT00052026|Adrenergic beta-Antagonists/administration & dosage
666601|NCT00052026|Age Factors
666602|NCT00052026|Carbazoles/therapeutic use
666603|NCT00052026|Carbazoles/administration & dosage
666604|NCT00052026|Child
666605|NCT00052026|Child, Preschool
666606|NCT00052026|Drug Administration Schedule
666607|NCT00052026|Female
666608|NCT00052026|Heart Failure, Congestive/etiology
666609|NCT00052026|Heart Failure, Congestive/drug therapy
666610|NCT00052026|Heart Failure, Congestive/blood
666611|NCT00052026|Human
666612|NCT00052026|Infant
666613|NCT00052026|Infant, Newborn
666614|NCT00052026|Male
666615|NCT00052026|Natriuretic Peptide, Brain/blood
666616|NCT00052026|Placebos
666617|NCT00052026|Propanolamines/therapeutic use
666618|NCT00052026|Propanolamines/administration & dosage
666619|NCT00052026|Prospective Studies
666620|NCT00052026|Support, Non-U.S. Gov't
666621|NCT00052026|Treatment Outcome
666622|NCT00052026|Ventricular Dysfunction/drug therapy
666623|NCT00052026|Ventricular Dysfunction/complications
666624|NCT00052026|Ventricular Dysfunction/blood
666625|NCT00052026|Ventricular Function/drug effects
666626|NCT00052026|Ventricular Remodeling/drug effects
666627|NCT00052013|von Hippel-Lindau disease,
666628|NCT00052013|CNS,
666629|NCT00052013|hemangioblastoma,
666630|NCT00052013|retinal
666631|NCT00051961|Dopamine
666632|NCT00051961|Spinal Physiology
666633|NCT00051961|Flexor Reflex
666634|NCT00051961|Ropinirole
666635|NCT00051961|Motor Control
666636|NCT00051961|Dopaminergic
666637|NCT00051961|Restless Legs
666638|NCT00051935|Glycogen Storage Disease Type II
666639|NCT00051935|GSD-II
666640|NCT00051935|Pompe Disease
666641|NCT00051922|HIV Preventive Vaccine
666642|NCT00051922|HIV Seronegativity
666643|NCT00051909|Alzheimer's Disease
666644|NCT00051870|Verbal Memory
666645|NCT00051870|Inhibition
666646|NCT00051870|Transcranial Magnetic Stimulation
666647|NCT00051870|Cortical Excitability
666648|NCT00051870|Nonverbal Memory
666649|NCT00051857|Magnetic Resonance Imaging
666650|NCT00051857|Muscle
666651|NCT00051857|Bone
666652|NCT00051857|Dynamics
666653|NCT00051857|Visualization
666654|NCT00051844|HIV
666655|NCT00051844|NNRTI Failure
666656|NCT00051844|HIV Infections
666657|NCT00051831|Treatment Naive
666658|NCT00051831|HIV-1
666659|NCT00051831|Virus Replication
666660|NCT00051831|CD4-Positive T-Lymphocytes
666661|NCT00051831|Immunologic Memory
666662|NCT00051831|Pentafuside
666663|NCT00051831|Anti-HIV Agents
666664|NCT00051831|Drug Therapy, Combination
666665|NCT00051831|Saquinavir
666666|NCT00051831|Ritonavir
666667|NCT00051831|Tenofovir Disoproxil Fumarate
666668|NCT00051831|RNA, Viral
666669|NCT00051831|Viral Load
666670|NCT00051831|Fusion Inhibitors
666671|NCT00051831|Entry Inhibitors
666672|NCT00051818|chronic HIV infection
666673|NCT00051818|treatment interruption
666674|NCT00051818|HIV-specific immune response
666675|NCT00051818|immune response
666676|NCT00051818|virological response
666677|NCT00051818|treatment experienced
666678|NCT00051805|Patient Compliance
666679|NCT00051805|Adherence
666680|NCT00051805|Treatment Experienced
666681|NCT00051779|CAL
666682|NCT00051779|Parathyroid hormone-related protein (PTHrP)
666683|NCT00051779|Breast Cancer
666684|NCT00051779|Bone Metastasis
666685|NCT00051779|Hypercalcemia
666686|NCT00051766|compliance
666687|NCT00051766|medication
666688|NCT00051766|antiretroviral
666689|NCT00051766|adherence
666690|NCT00051766|intervention
666691|NCT00051766|treatment experienced
666692|NCT00051753|Otitis Media
666693|NCT00051753|Acute Otitis Media
666694|NCT00051753|ear infection
666695|NCT00051753|levofloxacin
666696|NCT00051753|amoxicillin
666697|NCT00051753|clavulanate
666698|NCT00051714|Social Behavior Disorders
666699|NCT00051701|Non-Hodgkins lymphoma
666700|NCT00051701|NHL
666701|NCT00051701|Campath
666702|NCT00051701|alemtuzumab
666703|NCT00051675|adenocarcinoma
666704|NCT00051675|monoclonal antibody
666705|NCT00051636|Bisphosphonate
666706|NCT00051636|SAP
666707|NCT00051636|SAP excess
666708|NCT00051636|non-inferiority
666709|NCT00051636|therapeutic response
666710|NCT00051636|extended observation period
666711|NCT00051623|Psoriatic arthritis
666712|NCT00051623|Infliximab
666713|NCT00051623|Remicade
666714|NCT00051571|Carcinoma, Non-Small-Cell Lung
666715|NCT00051545|liver
666716|NCT00051545|cancer
666717|NCT00051545|hepatocellular
666718|NCT00051545|carcinoma
666719|NCT00051532|hepatocellular
666720|NCT00051532|carcinoma
666721|NCT00051532|liver
666722|NCT00051532|cancer
666723|NCT00051519|HIV
666724|NCT00051519|AIDS
666725|NCT00051519|Vaccine
666726|NCT00051519|HIV-positive
666727|NCT00051519|Therapy
666728|NCT00051493|Non-Small Cell Lung Cancer
666729|NCT00051493|Lung Cancer
666730|NCT00051493|NSCLC
666731|NCT00051493|Advanced Non-Small Cell Lung Cancer
666732|NCT00051454|HIV Seronegativity
666733|NCT00051454|HIV Preventive Vaccine
666734|NCT00051441|stomatitis
666735|NCT00051441|radiation effects
666736|NCT00051428|Fibromyalgia, Reiki, Energy Medicine
666737|NCT00051415|Flaxseed
666738|NCT00051415|Cholesterol
666739|NCT00051402|Postmenopausal
666740|NCT00051402|Memory Loss
666741|NCT00051402|Cognition
666742|NCT00051402|Phytoestrogens
666743|NCT00051363|Obstructive Sleep Apnea
666744|NCT00051337|Kinesiogenic
666745|NCT00051337|Psychogenic
666746|NCT00051337|Channelopathy
666747|NCT00051337|Ictal
666748|NCT00051337|Paroxysmal Dyskinesia
666749|NCT00051337|Psychogenic Movement Disorders
666750|NCT00051337|Single Photon Emission
666751|NCT00051337|Computed Tomography (SPECT)
666752|NCT00051324|Huntington's disease
666753|NCT00051324|Huntington disease
666754|NCT00051324|HD
666755|NCT00051311|Lymphoma
666756|NCT00051311|Leukemia
666757|NCT00051311|Hodgkin's Disease
666758|NCT00051311|Multiple Myeloma
666759|NCT00051311|Immunotherapy
666760|NCT00051285|CHF
666761|NCT00051285|heart
666762|NCT00051285|failure
666763|NCT00051285|congestive
666764|NCT00051285|enoximone
666765|NCT00051285|phosphodiesterase
666766|NCT00051285|inhibitor
666767|NCT00051272|depression, sexual dysfunction, orgasm disorder, MDD
666768|NCT00051259|depression
666769|NCT00051259|MDD
666770|NCT00051259|sexual dysfunction
666771|NCT00051259|orgasm disorder
666772|NCT00051207|Mood Disorders
666773|NCT00051207|Psychotherapy
666774|NCT00051207|Comorbidity
666775|NCT00051194|Glaucoma
666776|NCT00051194|POAG
666777|NCT00051194|OAG
666778|NCT00051194|OHT
666779|NCT00051181|Glaucoma
666780|NCT00051181|POAG
666781|NCT00051181|OAG
666782|NCT00051181|OHT
666783|NCT00051168|Glaucoma
666784|NCT00051168|POAG
666785|NCT00051168|OAG
666786|NCT00051168|OHT
666787|NCT00050440|Endometrial
666788|NCT00050440|Cancer
666789|NCT00050440|Carcinoma
666790|NCT00050440|Trabectedin
666791|NCT00050440|Ecteinascidin 743
666792|NCT00050440|ET743
666793|NCT00050440|Antineoplastic Agents
666794|NCT00050440|Alkylating Agents
666795|NCT00050440|Molecular Mechanisms of Pharmacological Action
666796|NCT00050427|Trabectedin
666797|NCT00050427|Yondelis
666798|NCT00050427|ET743
666799|NCT00050427|Advanced breast cancer
666800|NCT00050427|Breast
666801|NCT00050427|Cancer
666802|NCT00050427|Antineoplastic Agents, Alkylating Agents
666803|NCT00050427|Molecular Mechanisms of Pharmacological Action
666804|NCT00050414|Ovarian cancer
666805|NCT00050414|Ovary
666806|NCT00050414|Cancer
666807|NCT00050414|Trabectedin
666808|NCT00050414|Yondelis
666809|NCT00050414|ET743
666810|NCT00050414|Ecteinascidin 743
666811|NCT00050414|Antineoplastic Agents, Alkylating
666812|NCT00050414|Alkylating Agents
666813|NCT00050401|ventilator-associated
666814|NCT00050401|nosocomial
666815|NCT00050388|Cancer
666816|NCT00050388|Carcinoma
666817|NCT00050388|Neoplasm
666818|NCT00050388|Head cancer
666819|NCT00050388|Neck cancer
666820|NCT00050388|Tongue cancer
666821|NCT00050388|Lip cancer
666822|NCT00050388|Oral Cavity
666823|NCT00050388|Oropharynx
666824|NCT00050388|Pharynx
666825|NCT00050388|Larynx
666826|NCT00050388|Squamous Cell
666827|NCT00050388|Salivary Glands
666828|NCT00050388|Tumor
666829|NCT00050388|Lesion
666830|NCT00050388|Cancer treatment
666831|NCT00050388|Clinical trial
666832|NCT00050388|Allovectin-7®
666833|NCT00050388|Otorhinolaryngologic Neoplasm
666834|NCT00050388|Otolaryngologic Cancer
666835|NCT00050388|Gene therapy
666836|NCT00050388|Immunotherapy
666837|NCT00050388|Cancer research
666838|NCT00050388|Cancer vaccine
666839|NCT00050388|Cancer cells
666840|NCT00050375|OvaRex
666841|NCT00050375|ovarian
666842|NCT00050375|CA125
666843|NCT00050375|murine
666844|NCT00050375|antibody
666845|NCT00050375|immunotherapy
666846|NCT00050362|Pain
666847|NCT00050362|NSAID
666848|NCT00050362|Oral Surgery
666849|NCT00050362|Hyperalgesia
666850|NCT00050362|Preemptive Analgesia
666851|NCT00050349|cancer
666852|NCT00050349|tumor
666853|NCT00050349|tumour
666854|NCT00050349|neoplasm
666855|NCT00050349|carcinoma
666856|NCT00050349|carcinoid
666857|NCT00050349|neuroendocrine
666858|NCT00050349|Islet cell
666859|NCT00050349|Gastrinoma
666860|NCT00050349|VIPoma
666861|NCT00050349|metastatic
666862|NCT00050349|intravenous
666863|NCT00050349|epothilone
666864|NCT00050336|Stage 3b or 4 (metastatic) non-small cell lung cancer
666865|NCT00050323|Stage IV Renal Cell Carcinoma
666866|NCT00050323|Kidney Cancer
666867|NCT00050323|Cancer (General)
666868|NCT00050310|Confirmed
666869|NCT00050310|Suspected
666870|NCT00050310|Pathogenesis
666871|NCT00050310|Bronchoscopy
666872|NCT00050310|Cultures
666873|NCT00050310|Anthrax
666874|NCT00050310|Natural History
666875|NCT00050310|Vaccinated Healthy Volunteer
666876|NCT00050284|Treatment Experienced
666877|NCT00050284|Disease Progression
666878|NCT00050284|Anti-HIV Agents
666879|NCT00050284|Treatment Interruption
666880|NCT00050271|Acetylcarnitine
666881|NCT00050271|Dideoxynucleosides
666882|NCT00050271|Epidermis
666883|NCT00050271|Biopsy
666884|NCT00050271|Immunohistochemistry
666885|NCT00050271|Nerve Fibers
666886|NCT00050271|Treatment Experienced
666887|NCT00050245|Neuropathy
666888|NCT00050245|B Cells
666889|NCT00050245|Anti-MAG
666890|NCT00050245|Demyelination
666891|NCT00050245|MAG
666892|NCT00050245|RITUXAN
666893|NCT00050245|Monoclonal Antibodies
666894|NCT00050245|Retuximab
666895|NCT00050245|Demyelinating Neuropathy
666896|NCT00050232|Pseudobulbar Affect
666897|NCT00050232|Uncontrolled
666898|NCT00050232|Laughing
666899|NCT00050232|Crying
666900|NCT00050219|Raclopride
666901|NCT00050219|D2 Receptors
666902|NCT00050219|Striatum
666903|NCT00050219|Low-Response
666904|NCT00050219|Alcoholism
666905|NCT00050219|Alcohol
666906|NCT00050219|Dopamine
666907|NCT00050219|Response
666908|NCT00050193|Children
666909|NCT00050193|Mast Cells
666910|NCT00050193|Urticaria Pigmentosa
666911|NCT00050193|Bone Marrow
666912|NCT00050193|Severe
666913|NCT00050193|Mastocytosis
666914|NCT00050193|Pediatric Mastocytosis
666915|NCT00050180|P-Glycoprotein
666916|NCT00050180|Protease Inhibitor
666917|NCT00050180|Antiretrovirals
666918|NCT00050180|Cytochrome P450
666919|NCT00050180|Drug Transporters
666920|NCT00050180|Healthy Volunteer
666921|NCT00050180|HV
666922|NCT00050167|Breast Cancer
666923|NCT00050167|Capecitabine
666924|NCT00050167|Docetaxel
666925|NCT00050167|Paclitaxel
666926|NCT00050167|Taxotere
666927|NCT00050167|Taxol
666928|NCT00050167|Xeloda
666929|NCT00050167|Taxanes
666930|NCT00050167|Operable Breast Cancer
666931|NCT00050154|R115777
666932|NCT00050154|Myelodysplastic syndromes
666933|NCT00050154|Tipifarnib
666934|NCT00050154|Zarnestra
666935|NCT00051155|Glaucoma
666936|NCT00051155|POAG
666937|NCT00051155|OAG
666938|NCT00051155|OHT
666939|NCT00051142|Glaucoma
666940|NCT00051142|POAG
666941|NCT00051142|OAG
666942|NCT00051142|OHT
666943|NCT00051129|AMD
666944|NCT00051129|anecortave acetate
666945|NCT00051129|wet AMD
666946|NCT00051129|age-related macular degeneration
666947|NCT00051129|Macular Degeneration
666948|NCT00051129|Maculopathy, Age-Related
666949|NCT00051129|Age-Related Maculopathies
666950|NCT00051129|Age-Related Maculopathy
666951|NCT00051129|Maculopathies, Age-Related
666952|NCT00051116|Multiple Myeloma
666953|NCT00051116|Revimid
666954|NCT00051116|CC5013
666955|NCT00051116|CC-5013
666956|NCT00051103|Refractory
666957|NCT00051090|Hepatitis B
666958|NCT00051090|Antiretroviral Therapy, Highly-Active
666959|NCT00051090|HIV Infections
666960|NCT00051090|Lamivudine
666961|NCT00051090|Reverse Transcriptase Inhibitors
666962|NCT00051090|Antiviral Agents
666963|NCT00051090|Drug Therapy, Combination
666964|NCT00051090|Treatment Naive
666965|NCT00051077|HIV Infections
666966|NCT00051077|Hepatitis B
666967|NCT00051077|Hepatitis C
666968|NCT00051077|Interferon Alfa-2a
666969|NCT00051077|Adefovir dipivoxil
666970|NCT00051077|Ribavirin
666971|NCT00051077|Antiviral Agents
666972|NCT00051077|Drug Resistance, Viral
666973|NCT00051077|Treatment Experienced
666974|NCT00050986|Brain Neoplasms
666975|NCT00050986|CNS Diseases
666976|NCT00050986|Glioblastoma Multiforme
666977|NCT00050986|Temozolomide
666978|NCT00050986|Temodar
666979|NCT00050986|R115777
666980|NCT00050986|Zarnestra
666981|NCT00050973|NSCLC
666982|NCT00050973|Targretin
666983|NCT00050973|Retinoid
666984|NCT00050973|Bexarotene
666985|NCT00050960|NSCLC
666986|NCT00050960|Targretin
666987|NCT00050960|Retinoid
666988|NCT00050960|Bexarotene
666989|NCT00050947|partial seizures
666990|NCT00050934|partial seizures
666991|NCT00050921|HIV Infections
666992|NCT00050921|CD4 Lymphocyte Count
666993|NCT00050921|Antiretroviral Therapy, Highly Active
666994|NCT00050921|Growth Hormone
666995|NCT00050921|Cell Division
666996|NCT00050921|CD4-Positive T-Lymphocytes
666997|NCT00050921|Treatment Experienced
666998|NCT00050908|Brachial Artery
666999|NCT00050908|Endothelium, Vascular
667000|NCT00050908|Vasodilation
667001|NCT00050908|Nitroglycerin
667002|NCT00050908|Reverse Transcriptase Inhibitors
667003|NCT00050908|HIV Protease Inhibitors
667004|NCT00050908|Drug Therapy, Combination
667005|NCT00050908|Ritonavir
667006|NCT00050908|efavirenz
667007|NCT00050908|lopinavir
667008|NCT00050908|stavudine
667009|NCT00050908|lamivudine
667010|NCT00050908|zidovudine
667011|NCT00050908|Treatment Naive
667012|NCT00050895|Reverse Transcriptase Inhibitors
667013|NCT00050895|HIV Protease Inhibitors
667014|NCT00050895|Drug Therapy, Combination
667015|NCT00050895|Delayed Action Preparations
667016|NCT00050895|Treatment Naive
667017|NCT00050895|HIV-1
667018|NCT00050882|GM-611
667019|NCT00050882|Diabetic gastroparesis
667020|NCT00050882|Bloating
667021|NCT00050882|Delayed gastric emptying
667022|NCT00050882|Mitemcinal
667023|NCT00050869|Mirror Neurons
667024|NCT00050869|Performance
667025|NCT00050869|Use-Dependent Plasticity
667026|NCT00050869|Attention
667027|NCT00050869|Premotor Cortex
667028|NCT00050856|Antiretrovial Therapy
667029|NCT00050856|Salvage
667030|NCT00050856|CD4+Lymphocyte Count
667031|NCT00050856|HIV-1 RNA Level
667032|NCT00050856|Subcutaneous Injection
667033|NCT00050817|Embolism
667034|NCT00050804|Acute Stress Disorder
667035|NCT00050804|PTSD
667036|NCT00050804|Treatment
667037|NCT00050804|SSRI
667038|NCT00050804|Startle
667039|NCT00050804|Psychophysiology
667040|NCT00050804|Trauma
667041|NCT00050804|Anxiety
667042|NCT00050804|Emotion
667043|NCT00050791|Obesity
667044|NCT00050791|Weightloss
667045|NCT00050791|Leptin
667046|NCT00050791|Diet
667047|NCT00050791|Reducing
667048|NCT00050791|Overweight
667049|NCT00050791|Fat
667050|NCT00050778|Multiple Sclerosis
667051|NCT00050778|Active Relapsing-Remitting Multiple Sclerosis
667052|NCT00050765|Myocardial Infarction
667053|NCT00050765|Heart disease
667054|NCT00050765|Coronary bypass graft (CABG) surgery
667055|NCT00050765|Implantable Cardioverter Defibrillator (ICD)
667056|NCT00050765|CABG
667057|NCT00050765|ICD
667058|NCT00050765|Heart failure
667059|NCT00050752|Renal Cancer
667060|NCT00050752|Hereditary Leiomyomatosis
667061|NCT00050752|Uterine Fibroid
667062|NCT00050752|Cutaneous Leiomyoma
667063|NCT00050726|Interleukin-2
667064|NCT00050726|Immunotherapy
667065|NCT00050726|HIV
667066|NCT00050726|IL-2
667067|NCT00050713|Kidney Disease
667068|NCT00050713|Glomerulonephritis
667069|NCT00050713|Lupus Nephritis
667070|NCT00050713|Nephrotic Syndrome
667071|NCT00050713|Hyperlipidemia
667072|NCT00050700|PET
667073|NCT00050700|[18F]FP-TZTP
667074|NCT00050700|Bipolar Disorder
667075|NCT00050700|Major Depressive Disorder
667076|NCT00050700|Muscarinic 2 Receptors
667077|NCT00050674|lung cancer, oncology, neutropenia, chemotherapy, filgrastim
667078|NCT00050661|psoriasis
667079|NCT00050661|Cyclosporine
667080|NCT00050661|Daclizamub
667081|NCT00050661|anti-TAC
667082|NCT00050661|dermatology
667083|NCT00050661|skin
667084|NCT00050661|lesions
667085|NCT00050648|psoriasis
667086|NCT00050648|Daclizumab
667087|NCT00050648|Cyclosporin
667088|NCT00050648|anti-TAC
667089|NCT00050648|dermatology
667090|NCT00050648|skin
667091|NCT00050635|chemotherapy induced diarrhea
667092|NCT00050635|diarrhea
667093|NCT00050635|CTID
667094|NCT00050635|colorectal cancer
667095|NCT00050635|Sandostatin LAR Depot
667096|NCT00050635|Sandostatin
667097|NCT00050635|adverse events
667098|NCT00050635|side effects
667099|NCT00050531|Chronic Myelogenous Leukemia
667100|NCT00050531|CML
667101|NCT00050531|Early Chronic Phase Chronic Myelogenous Leukemia
667102|NCT00050531|Imatinib Mesylate
667103|NCT00050531|Gleevec
667104|NCT00050531|Peg-Alpha Interferon
667105|NCT00050531|Peg-Intron
667106|NCT00050531|Sargramostim
667107|NCT00050531|GM-CSF
667108|NCT00050518|Smallpox
667109|NCT00050518|Aventis Pasteur
667110|NCT00050518|Vaccine
667111|NCT00050505|smallpox, Dryvax, vaccine, dilution
667112|NCT00050492|Ocular
667113|NCT00050492|Cytokine
667114|NCT00050492|Chemokine
667115|NCT00050492|Viruses
667116|NCT00050492|Autoantibody
667117|NCT00050492|Retina
667118|NCT00050492|Vasculitis
667119|NCT00050492|Adhesion Molecules
667120|NCT00050479|Types 1 and 2 diabetes
667121|NCT00050479|Diode Laser Photocoagulation
667122|NCT00050479|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
667123|NCT00050466|Normal Volunteers
667124|NCT00050466|Dynamic Light Scattering (DLS)
667125|NCT00050466|Corneal Opacities
667126|NCT00050466|Cornea
667127|NCT00050466|Transparency
667128|NCT00050466|Vision
667129|NCT00050141|Breast cancer
667130|NCT00050141|ZARNESTRA
667131|NCT00050141|tipifarnib
667132|NCT00050141|R115777
667133|NCT00050141|Estrogen receptor positive
667134|NCT00050141|Progesterone receptor positive
667135|NCT00050141|Anti-estrogen therapy
667136|NCT00050128|Rehabilitation
667137|NCT00050128|Plasticity
667138|NCT00050128|Frequency
667139|NCT00050128|Inhibition
667140|NCT00050128|Pinch
667141|NCT00050128|Stroke
667142|NCT00050115|Bone Marrow Failure
667143|NCT00050115|Seronegative Hepatitis
667144|NCT00050115|Fulminate Hepatitis
667145|NCT00050115|Hepatitis
667146|NCT00050115|Aplastic Anemia
667147|NCT00050115|Hepatitis Associated Aplastic Anemia
667148|NCT00050089|AIDS
667149|NCT00050089|antiretrovirals
667150|NCT00050089|ART
667151|NCT00050089|drug-free period
667152|NCT00050089|HAART
667153|NCT00050089|HIV
667154|NCT00050089|human immunodeficiency virus
667155|NCT00050089|randomized
667156|NCT00050089|structured treatment interruptions
667157|NCT00050076|Congestive Heart Failure
667158|NCT00050076|Cardiac Failure
667159|NCT00050076|Heart Decompensation
667160|NCT00050076|Drug Therapy
667161|NCT00050063|HIV Therapeutic Vaccine
667162|NCT00050063|Treatment Experienced
667163|NCT00050063|AIDS Vaccines
667164|NCT00050063|Treatment Interruption
667165|NCT00050063|Viral Load
667166|NCT00050063|T-Lymphocytes, Cytotoxic
667167|NCT00050063|T-Lymphocytes, Helper-Inducer
667168|NCT00050050|Adult
667169|NCT00050050|ADHD
667170|NCT00050050|ADD
667171|NCT00050024|TMS
667172|NCT00050024|Afferent Stimulation
667173|NCT00050024|Motor Cortex
667174|NCT00050024|Writer's Cramp
667175|NCT00050024|Surround Inhibition
667176|NCT00050024|Heterotopic Inhibition
667177|NCT00050024|Focal Dystonia
667178|NCT00050024|Writer Cramp
667179|NCT00050011|cancer-treatment related bone loss
667180|NCT00050011|postmenopausal women
667181|NCT00050011|breast cancer
667182|NCT00050011|hormone receptor positive breast cancer
667183|NCT00050011|adjuvant therapy
667184|NCT00050011|hormonal therapy
667185|NCT00050011|bone loss
667186|NCT00050011|bisphosphonates
667187|NCT00050011|ZFAST
667188|NCT00050011|Letrozole
667189|NCT00050011|Zoledronic Acid
667190|NCT00050011|US32
667191|NCT00049998|Nonsmall Cell Lung cancer
667192|NCT00049998|advanced
667193|NCT00049998|Second-line
667194|NCT00049998|topotecan
667195|NCT00049998|Hycamtin
667196|NCT00049998|oral
667197|NCT00049998|docetaxel
667198|NCT00049972|Major Depressive Disorder Open-label discontinued
667199|NCT00049959|Verteporfin PDT
667200|NCT00049959|multiple basal cell carcinoma
667201|NCT00049959|nevoid basal cell carcinoma syndrome
667202|NCT00049946|Talnetant
667203|NCT00049946|schizophrenia
667204|NCT00049946|NK3 receptor antagonist
667205|NCT00049946|psychosis
667206|NCT00049829|Bisphosphonate,BMD,Height loss, Hip protectors,HRT,
667207|NCT00049829|Osteoporosis
667208|NCT00049816|knee
667209|NCT00049816|aerobic exercise
667210|NCT00049816|walking
667211|NCT00049816|cycling
667212|NCT00049816|gait
667213|NCT00049816|MRI
667214|NCT00049803|Narcolepsy
667215|NCT00049803|Sodium Oxybate
667216|NCT00049803|Cataplexy
667217|NCT00049803|Excessive Daytime Sleepiness
667218|NCT00049803|GHB
667219|NCT00049803|Gamma Hydroxybutyric Acid
667220|NCT00049803|Orphan Medical
667221|NCT00049803|Orphan Drug
667222|NCT00049790|Advanced non-small cell lung cancer
667223|NCT00049738|Psychosis
667224|NCT00049738|Childhood Onset Schizophrenia
667225|NCT00049738|Schizophrenia
667226|NCT00049738|Schizoaffective
667227|NCT00049738|Psychotic Disorder
667228|NCT00049738|Multidimensionally Impaired Syndrome
667229|NCT00049725|Autoimmune Disease
667230|NCT00049725|Monoclonal Antibody Therapy
667231|NCT00049725|Anti-IL2 Receptor
667232|NCT00049725|Platelets
667233|NCT00049725|Monoclonal Antibody
667234|NCT00049725|Immune Thrombocytopenia
667235|NCT00049725|ITP
667236|NCT00049712|anaplastic large cell lymphoma
667237|NCT00049712|angioimmunoblastic T-cell lymphoma
667238|NCT00049712|intraocular lymphoma
667239|NCT00049712|primary central nervous system lymphoma
667240|NCT00049712|recurrent adult diffuse large cell lymphoma
667241|NCT00049712|recurrent adult diffuse mixed cell lymphoma
667242|NCT00049712|recurrent adult diffuse small cleaved cell lymphoma
667243|NCT00049712|recurrent adult Burkitt lymphoma
667244|NCT00049712|recurrent adult Hodgkin lymphoma
667245|NCT00049712|recurrent adult immunoblastic large cell lymphoma
667246|NCT00049712|recurrent adult lymphoblastic lymphoma
667247|NCT00049712|recurrent adult T-cell leukemia/lymphoma
667248|NCT00049712|recurrent cutaneous T-cell non-Hodgkin lymphoma
667249|NCT00049712|recurrent grade 1 follicular lymphoma
667250|NCT00049712|recurrent grade 2 follicular lymphoma
667251|NCT00049712|recurrent grade 3 follicular lymphoma
667252|NCT00049712|recurrent mantle cell lymphoma
667253|NCT00049712|recurrent mycosis fungoides/Sezary syndrome
667254|NCT00049712|small intestine lymphoma
667255|NCT00049712|stage IV adult diffuse large cell lymphoma
667256|NCT00049712|stage IV adult diffuse mixed cell lymphoma
667257|NCT00049712|stage IV adult diffuse small cleaved cell lymphoma
667258|NCT00049712|stage IV adult Burkitt lymphoma
667259|NCT00049712|stage IV adult Hodgkin lymphoma
667260|NCT00049712|stage IV adult immunoblastic large cell lymphoma
667261|NCT00049712|stage IV adult T-cell leukemia/lymphoma
667262|NCT00049712|stage IV cutaneous T-cell non-Hodgkin lymphoma
667263|NCT00049712|stage IV grade 1 follicular lymphoma
667264|NCT00049712|stage IV grade 2 follicular lymphoma
667265|NCT00049712|stage IV grade 3 follicular lymphoma
667266|NCT00049712|stage IV mantle cell lymphoma
667267|NCT00049712|stage IV mycosis fungoides/Sezary syndrome
667268|NCT00049712|unspecified adult solid tumor, protocol specific
667269|NCT00049712|stage IV adult lymphoblastic lymphoma
667270|NCT00049712|stage III adult diffuse large cell lymphoma
667271|NCT00049712|stage III adult diffuse mixed cell lymphoma
667272|NCT00049712|stage III adult diffuse small cleaved cell lymphoma
667273|NCT00049712|stage III adult Burkitt lymphoma
667274|NCT00049712|stage III adult Hodgkin lymphoma
667275|NCT00049712|stage III adult immunoblastic large cell lymphoma
667276|NCT00049712|stage III adult lymphoblastic lymphoma
667277|NCT00049712|stage III cutaneous T-cell non-Hodgkin lymphoma
667278|NCT00049712|stage III grade 1 follicular lymphoma
667279|NCT00049712|stage III grade 2 follicular lymphoma
667280|NCT00049712|stage III grade 3 follicular lymphoma
667281|NCT00049712|stage III mantle cell lymphoma
667282|NCT00049712|stage III mycosis fungoides/Sezary syndrome
667283|NCT00049712|stage III adult T-cell leukemia/lymphoma
667284|NCT00049712|recurrent marginal zone lymphoma
667285|NCT00049712|recurrent small lymphocytic lymphoma
667286|NCT00049712|stage III small lymphocytic lymphoma
667287|NCT00049712|stage III marginal zone lymphoma
667288|NCT00049712|stage IV small lymphocytic lymphoma
667289|NCT00049712|stage IV marginal zone lymphoma
667290|NCT00049712|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
667875|NCT00048789|Stem Cell
667291|NCT00049712|nodal marginal zone B-cell lymphoma
667292|NCT00049712|splenic marginal zone lymphoma
667293|NCT00049699|anaplastic large cell lymphoma
667294|NCT00049699|angioimmunoblastic T-cell lymphoma
667295|NCT00049699|intraocular lymphoma
667296|NCT00049699|primary central nervous system non-Hodgkin lymphoma
667297|NCT00049699|recurrent adult diffuse large cell lymphoma
667298|NCT00049699|recurrent adult diffuse mixed cell lymphoma
667299|NCT00049699|recurrent adult diffuse small cleaved cell lymphoma
667300|NCT00049699|recurrent adult Burkitt lymphoma
667301|NCT00049699|recurrent adult Hodgkin lymphoma
667302|NCT00049699|recurrent adult immunoblastic large cell lymphoma
667303|NCT00049699|recurrent adult lymphoblastic lymphoma
667304|NCT00049699|recurrent adult T-cell leukemia/lymphoma
667305|NCT00049699|recurrent cutaneous T-cell non-Hodgkin lymphoma
667306|NCT00049699|recurrent grade 1 follicular lymphoma
667307|NCT00049699|recurrent grade 2 follicular lymphoma
667308|NCT00049699|recurrent grade 3 follicular lymphoma
667309|NCT00049699|recurrent mantle cell lymphoma
667310|NCT00049699|recurrent mycosis fungoides/Sezary syndrome
667311|NCT00049699|small intestine lymphoma
667312|NCT00049699|stage IV adult diffuse large cell lymphoma
667313|NCT00049699|stage IV adult diffuse mixed cell lymphoma
667314|NCT00049699|stage IV adult diffuse small cleaved cell lymphoma
667315|NCT00049699|stage IV adult Burkitt lymphoma
667316|NCT00049699|stage IV adult Hodgkin lymphoma
667317|NCT00049699|stage IV adult immunoblastic large cell lymphoma
667318|NCT00049699|stage IV adult lymphoblastic lymphoma
667319|NCT00049699|stage IV adult T-cell leukemia/lymphoma
667320|NCT00049699|stage IV cutaneous T-cell non-Hodgkin lymphoma
667321|NCT00049699|stage IV grade 1 follicular lymphoma
667322|NCT00049699|stage IV grade 2 follicular lymphoma
667323|NCT00049699|stage IV grade 3 follicular lymphoma
667324|NCT00049699|stage IV mantle cell lymphoma
667325|NCT00049699|stage IV mycosis fungoides/Sezary syndrome
667326|NCT00049699|unspecified adult solid tumor, protocol specific
667327|NCT00049699|recurrent marginal zone lymphoma
667328|NCT00049699|recurrent small lymphocytic lymphoma
667329|NCT00049699|stage IV small lymphocytic lymphoma
667330|NCT00049699|stage IV marginal zone lymphoma
667331|NCT00049699|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
667332|NCT00049699|nodal marginal zone B-cell lymphoma
667333|NCT00049699|splenic marginal zone lymphoma
667334|NCT00049686|acute undifferentiated leukemia
667335|NCT00049686|chronic myelomonocytic leukemia
667336|NCT00049686|previously treated myelodysplastic syndromes
667337|NCT00049686|prolymphocytic leukemia
667338|NCT00049686|recurrent adult acute lymphoblastic leukemia
667339|NCT00049686|recurrent adult acute myeloid leukemia
667340|NCT00049686|refractory chronic lymphocytic leukemia
667341|NCT00049686|refractory anemia with excess blasts
667342|NCT00049686|refractory cytopenia with multilineage dysplasia
667343|NCT00049686|refractory hairy cell leukemia
667344|NCT00049686|relapsing chronic myelogenous leukemia
667345|NCT00049686|secondary acute myeloid leukemia
667346|NCT00049686|secondary myelodysplastic syndromes
667347|NCT00049686|atypical chronic myeloid leukemia, BCR-ABL1 negative
667348|NCT00049686|myelodysplastic/myeloproliferative neoplasm, unclassifiable
667349|NCT00049673|stage I multiple myeloma
667350|NCT00049673|stage II multiple myeloma
667351|NCT00049673|stage III multiple myeloma
667352|NCT00049660|stage IV breast cancer
667353|NCT00049634|chronic myelomonocytic leukemia
667354|NCT00049634|de novo myelodysplastic syndromes
667355|NCT00049634|essential thrombocythemia
667356|NCT00049634|polycythemia vera
667357|NCT00049634|previously treated myelodysplastic syndromes
667358|NCT00049634|refractory anemia with excess blasts
667359|NCT00049634|refractory anemia with excess blasts in transformation
667360|NCT00049634|secondary acute myeloid leukemia
667361|NCT00049634|secondary myelodysplastic syndromes
667362|NCT00049634|chronic eosinophilic leukemia
667363|NCT00049634|chronic neutrophilic leukemia
667364|NCT00049634|atypical chronic myeloid leukemia
667365|NCT00049634|myelodysplastic/myeloproliferative disease, unclassifiable
667366|NCT00049608|male breast cancer
667367|NCT00049608|recurrent breast cancer
667368|NCT00049608|recurrent colon cancer
667369|NCT00049608|recurrent non-small cell lung cancer
667370|NCT00049608|recurrent pancreatic cancer
667371|NCT00049608|recurrent rectal cancer
667372|NCT00049608|stage III colon cancer
667373|NCT00049608|stage III pancreatic cancer
667374|NCT00049608|stage III rectal cancer
667375|NCT00049608|stage IIIA breast cancer
667376|NCT00049608|stage IIIB breast cancer
667377|NCT00049608|stage IIIC breast cancer
667378|NCT00049608|stage IV breast cancer
667379|NCT00049608|stage IV colon cancer
667380|NCT00049608|stage IV non-small cell lung cancer
667381|NCT00049608|stage IV rectal cancer
667382|NCT00049608|stage IIIA non-small cell lung cancer
667383|NCT00049608|stage IIIB non-small cell lung cancer
667384|NCT00049608|stage IV pancreatic cancer
667385|NCT00049595|adult lymphocyte depletion Hodgkin lymphoma
667386|NCT00049595|adult mixed cellularity Hodgkin lymphoma
667387|NCT00049595|adult nodular sclerosis Hodgkin lymphoma
667876|NCT00048789|UVA
667388|NCT00049595|stage III adult Hodgkin lymphoma
667389|NCT00049595|stage IV adult Hodgkin lymphoma
667390|NCT00049556|fallopian tube cancer
667391|NCT00049556|borderline ovarian surface epithelial-stromal tumor
667392|NCT00049556|primary peritoneal cavity cancer
667393|NCT00049556|recurrent cervical cancer
667394|NCT00049556|recurrent ovarian epithelial cancer
667395|NCT00049530|recurrent melanoma
667396|NCT00049530|stage IV melanoma
667397|NCT00049517|acute myeloid leukemia
667398|NCT00049517|autologous transplantation
667399|NCT00049517|gemtuzumab ozogamicin
667400|NCT00049465|depression
667401|NCT00049465|fatigue
667402|NCT00049465|menopausal symptoms
667403|NCT00049465|transitional care planning
667404|NCT00049465|psychosocial effects of cancer and its treatment
667405|NCT00049465|accelerated phase chronic myelogenous leukemia
667406|NCT00049465|chronic idiopathic myelofibrosis
667407|NCT00049465|blastic phase chronic myelogenous leukemia
667408|NCT00049465|chronic phase chronic myelogenous leukemia
667409|NCT00049465|de novo myelodysplastic syndromes
667410|NCT00049465|disseminated neuroblastoma
667411|NCT00049465|meningeal chronic myelogenous leukemia
667412|NCT00049465|noncontiguous stage II adult diffuse large cell lymphoma
667413|NCT00049465|noncontiguous stage II adult diffuse mixed cell lymphoma
667414|NCT00049465|noncontiguous stage II adult diffuse small cleaved cell lymphoma
667415|NCT00049465|noncontiguous stage II adult Burkitt lymphoma
667416|NCT00049465|noncontiguous stage II adult immunoblastic large cell lymphoma
667417|NCT00049465|noncontiguous stage II adult lymphoblastic lymphoma
667418|NCT00049465|noncontiguous stage II grade 1 follicular lymphoma
667419|NCT00049465|noncontiguous stage II grade 2 follicular lymphoma
667420|NCT00049465|noncontiguous stage II grade 3 follicular lymphoma
667421|NCT00049465|noncontiguous stage II mantle cell lymphoma
667422|NCT00049465|ovarian choriocarcinoma
667423|NCT00049465|ovarian embryonal carcinoma
667424|NCT00049465|ovarian yolk sac tumor
667425|NCT00049465|ovarian immature teratoma
667426|NCT00049465|ovarian mature teratoma
667427|NCT00049465|ovarian monodermal and highly specialized teratoma
667428|NCT00049465|ovarian polyembryoma
667429|NCT00049465|ovarian mixed germ cell tumor
667430|NCT00049465|poor prognosis metastatic gestational trophoblastic tumor
667431|NCT00049465|previously treated myelodysplastic syndromes
667432|NCT00049465|recurrent adult acute lymphoblastic leukemia
667433|NCT00049465|recurrent adult acute myeloid leukemia
667434|NCT00049465|recurrent adult diffuse large cell lymphoma
667435|NCT00049465|recurrent adult diffuse mixed cell lymphoma
667436|NCT00049465|recurrent adult diffuse small cleaved cell lymphoma
667437|NCT00049465|recurrent adult Burkitt lymphoma
667438|NCT00049465|recurrent adult Hodgkin lymphoma
667439|NCT00049465|recurrent adult immunoblastic large cell lymphoma
667440|NCT00049465|recurrent adult lymphoblastic lymphoma
667441|NCT00049465|recurrent cutaneous T-cell non-Hodgkin lymphoma
667442|NCT00049465|recurrent grade 1 follicular lymphoma
667443|NCT00049465|recurrent grade 2 follicular lymphoma
667444|NCT00049465|recurrent grade 3 follicular lymphoma
667445|NCT00049465|recurrent mantle cell lymphoma
667446|NCT00049465|recurrent mycosis fungoides/Sezary syndrome
667447|NCT00049465|recurrent neuroblastoma
667448|NCT00049465|recurrent ovarian epithelial cancer
667449|NCT00049465|recurrent ovarian germ cell tumor
667450|NCT00049465|recurrent malignant testicular germ cell tumor
667451|NCT00049465|refractory chronic lymphocytic leukemia
667452|NCT00049465|refractory hairy cell leukemia
667453|NCT00049465|refractory multiple myeloma
667454|NCT00049465|relapsing chronic myelogenous leukemia
667455|NCT00049465|secondary acute myeloid leukemia
667456|NCT00049465|secondary myelodysplastic syndromes
667457|NCT00049465|stage I multiple myeloma
667458|NCT00049465|stage II multiple myeloma
667459|NCT00049465|stage II ovarian epithelial cancer
667460|NCT00049465|stage III adult diffuse large cell lymphoma
667461|NCT00049465|stage III adult diffuse mixed cell lymphoma
667462|NCT00049465|stage III adult diffuse small cleaved cell lymphoma
667463|NCT00049465|stage III adult Burkitt lymphoma
667464|NCT00049465|stage III adult immunoblastic large cell lymphoma
667465|NCT00049465|stage III adult lymphoblastic lymphoma
667466|NCT00049465|stage III chronic lymphocytic leukemia
667467|NCT00049465|stage III grade 1 follicular lymphoma
667468|NCT00049465|stage III grade 2 follicular lymphoma
667469|NCT00049465|stage III grade 3 follicular lymphoma
667470|NCT00049465|stage III mantle cell lymphoma
667471|NCT00049465|stage III ovarian epithelial cancer
667472|NCT00049465|stage III malignant testicular germ cell tumor
667473|NCT00049465|stage IIIA breast cancer
667474|NCT00049465|stage IIIB breast cancer
667475|NCT00049465|stage IIIC breast cancer
667476|NCT00049465|stage IV adult diffuse large cell lymphoma
667477|NCT00049465|stage IV adult diffuse mixed cell lymphoma
667478|NCT00049465|stage IV adult diffuse small cleaved cell lymphoma
667479|NCT00049465|stage IV adult Burkitt lymphoma
667480|NCT00049465|stage IV adult immunoblastic large cell lymphoma
667481|NCT00049465|stage IV adult lymphoblastic lymphoma
667482|NCT00049465|stage IV breast cancer
667483|NCT00049465|stage IV chronic lymphocytic leukemia
667484|NCT00049465|stage IV grade 1 follicular lymphoma
667485|NCT00049465|stage IV grade 2 follicular lymphoma
667486|NCT00049465|stage IV grade 3 follicular lymphoma
667487|NCT00049465|stage IV mantle cell lymphoma
667488|NCT00049465|stage IV ovarian epithelial cancer
667489|NCT00049465|testicular choriocarcinoma and embryonal carcinoma
667490|NCT00049465|testicular choriocarcinoma and seminoma
667491|NCT00049465|testicular choriocarcinoma and teratoma
667492|NCT00049465|testicular choriocarcinoma and yolk sac tumor
667493|NCT00049465|testicular choriocarcinoma
667494|NCT00049465|testicular embryonal carcinoma and seminoma
667495|NCT00049465|testicular embryonal carcinoma and teratoma with seminoma
667496|NCT00049465|testicular embryonal carcinoma and teratoma
667497|NCT00049465|testicular embryonal carcinoma and yolk sac tumor with seminoma
667498|NCT00049465|testicular embryonal carcinoma and yolk sac tumor
667499|NCT00049465|testicular embryonal carcinoma
667500|NCT00049465|testicular teratoma
667501|NCT00049465|testicular yolk sac tumor and teratoma with seminoma
667502|NCT00049465|testicular yolk sac tumor and teratoma
667503|NCT00049465|testicular yolk sac tumor
667504|NCT00049465|stage III multiple myeloma
667505|NCT00049465|chronic eosinophilic leukemia
667506|NCT00049465|chronic neutrophilic leukemia
667507|NCT00049465|atypical chronic myeloid leukemia
667508|NCT00049465|myelodysplastic/myeloproliferative disease, unclassifiable
667509|NCT00049465|noncontiguous stage II small lymphocytic lymphoma
667510|NCT00049465|noncontiguous stage II marginal zone lymphoma
667511|NCT00049465|recurrent marginal zone lymphoma
667512|NCT00049465|recurrent small lymphocytic lymphoma
667513|NCT00049465|stage III small lymphocytic lymphoma
667514|NCT00049465|stage III marginal zone lymphoma
667515|NCT00049465|stage IV small lymphocytic lymphoma
667516|NCT00049465|stage IV marginal zone lymphoma
667517|NCT00049465|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
667518|NCT00049465|nodal marginal zone B-cell lymphoma
667519|NCT00049465|splenic marginal zone lymphoma
667520|NCT00049452|osteoporosis
667521|NCT00049452|stage I breast cancer
667522|NCT00049452|stage II breast cancer
667523|NCT00049439|AIDS-related diffuse large cell lymphoma
667524|NCT00049439|AIDS-related diffuse mixed cell lymphoma
667525|NCT00049439|AIDS-related diffuse small cleaved cell lymphoma
667526|NCT00049439|AIDS-related immunoblastic large cell lymphoma
667527|NCT00049439|AIDS-related lymphoblastic lymphoma
667528|NCT00049439|AIDS-related small noncleaved cell lymphoma
667529|NCT00049413|B-cell chronic lymphocytic leukemia
667530|NCT00049413|refractory chronic lymphocytic leukemia
667531|NCT00049413|stage I chronic lymphocytic leukemia
667532|NCT00049413|stage II chronic lymphocytic leukemia
667533|NCT00049413|stage III chronic lymphocytic leukemia
667534|NCT00049413|stage IV chronic lymphocytic leukemia
667535|NCT00049413|contiguous stage II small lymphocytic lymphoma
667536|NCT00049413|noncontiguous stage II small lymphocytic lymphoma
667537|NCT00049413|recurrent small lymphocytic lymphoma
667538|NCT00049413|stage I small lymphocytic lymphoma
667539|NCT00049413|stage III small lymphocytic lymphoma
667540|NCT00049413|stage IV small lymphocytic lymphoma
667541|NCT00049400|unspecified adult solid tumor, protocol specific
667542|NCT00049400|anaplastic large cell lymphoma
667543|NCT00049400|angioimmunoblastic T-cell lymphoma
667544|NCT00049400|intraocular lymphoma
667545|NCT00049400|primary central nervous system lymphoma
667546|NCT00049400|recurrent adult diffuse large cell lymphoma
667547|NCT00049400|recurrent adult Hodgkin lymphoma
667548|NCT00049400|recurrent adult immunoblastic large cell lymphoma
667549|NCT00049400|recurrent adult T-cell leukemia/lymphoma
667550|NCT00049400|recurrent cutaneous T-cell non-Hodgkin lymphoma
667551|NCT00049400|recurrent grade 1, 2, or 3 follicular lymphoma
667552|NCT00049400|recurrent mantle cell lymphoma
667553|NCT00049400|small intestine lymphoma
667554|NCT00049400|stage IV adult diffuse large cell or mixed cell lymphoma
667555|NCT00049400|stage IV adult diffuse small cleaved cell lymphoma
667556|NCT00049400|stage IV adult Burkitt lymphoma or Hodgkin lymphoma
667557|NCT00049400|stage IV adult immunoblastic large cell lymphoma
667558|NCT00049400|stage IV adult lymphoblastic lymphoma
667559|NCT00049400|stage IV adult T-cell leukemia/lymphoma
667560|NCT00049400|stage IV cutaneous T-cell non-Hodgkin lymphoma
667561|NCT00049400|stage IV grade 1, 2, or 3 follicular lymphoma
667562|NCT00049400|stage IV mantle cell lymphoma
667563|NCT00049400|recurrent marginal zone lymphoma
667564|NCT00049400|recurrent small lymphocytic lymphoma
667565|NCT00049400|stage IV small lymphocytic lymphoma
667566|NCT00049400|stage IV marginal zone lymphoma
667567|NCT00049400|extranodal marginal zone B-cell lymphoma of MALT
667568|NCT00049400|nodal marginal zone B-cell lymphoma
667569|NCT00049400|splenic marginal zone lymphoma
667570|NCT00049400|recurrent adult Burkitt lymphoma
667571|NCT00049400|recurrent adult lymphoblastic lymphoma
667572|NCT00049400|recurrent adult diffuse small cleaved cell lymphoma
667573|NCT00049400|recurrent adult diffuse mixed cell lymphoma
667574|NCT00049374|refractory multiple myeloma
667575|NCT00049361|adult tumors metastatic to brain
667576|NCT00049361|unspecified adult solid tumor, protocol specific
667577|NCT00049348|adenocarcinoma of the pancreas
667578|NCT00049348|stage II pancreatic cancer
667579|NCT00049348|stage III pancreatic cancer
667580|NCT00049335|recurrent colon cancer
667581|NCT00049335|stage IV colon cancer
667582|NCT00049335|recurrent rectal cancer
667583|NCT00049335|stage IV rectal cancer
667584|NCT00049322|localized unresectable adult primary liver cancer
667585|NCT00049322|recurrent adult primary liver cancer
667586|NCT00049322|adult primary hepatocellular carcinoma
667587|NCT00049309|stage I prostate cancer
667588|NCT00049309|stage IIB prostate cancer
667589|NCT00049309|stage IIA prostate cancer
667590|NCT00049309|stage III prostate cancer
667591|NCT00049296|adult anaplastic astrocytoma
667592|NCT00049296|male breast cancer
667593|NCT00049296|adult anaplastic oligodendroglioma
667594|NCT00049296|adult meningeal hemangiopericytoma
667595|NCT00049296|adult brain stem glioma
667596|NCT00049296|adult central nervous system germ cell tumor
667597|NCT00049296|adult choroid plexus tumor
667598|NCT00049296|adult craniopharyngioma
667599|NCT00049296|adult ependymoblastoma
667600|NCT00049296|adult glioblastoma
667601|NCT00049296|adult pilocytic astrocytoma
667602|NCT00049296|adult anaplastic ependymoma
667603|NCT00049296|adult medulloblastoma
667604|NCT00049296|adult meningioma
667605|NCT00049296|adult pineoblastoma
667606|NCT00049296|adult pineocytoma
667607|NCT00049296|adult subependymoma
667608|NCT00049296|adult myxopapillary ependymoma
667609|NCT00049296|advanced adult primary liver cancer
667610|NCT00049296|anterior urethral cancer
667611|NCT00049296|carcinoma of the appendix
667612|NCT00049296|chondrosarcoma
667613|NCT00049296|classic Kaposi sarcoma
667614|NCT00049296|AIDS-related Kaposi sarcoma
667615|NCT00049296|immunosuppressive treatment related Kaposi sarcoma
667616|NCT00049296|recurrent Kaposi sarcoma
667617|NCT00049296|clear cell sarcoma of the kidney
667618|NCT00049296|disseminated neuroblastoma
667619|NCT00049296|extensive stage small cell lung cancer
667620|NCT00049296|gastrointestinal stromal tumor
667621|NCT00049296|metastatic gastrointestinal carcinoid tumor
667622|NCT00049296|metastatic osteosarcoma
667623|NCT00049296|metastatic transitional cell cancer of the renal pelvis and ureter
667624|NCT00049296|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
667625|NCT00049296|adult mixed glioma
667626|NCT00049296|ovarian sarcoma
667627|NCT00049296|posterior urethral cancer
667628|NCT00049296|primary central nervous system lymphoma
667629|NCT00049296|pulmonary carcinoid tumor
667630|NCT00049296|recurrent adenoid cystic carcinoma of the oral cavity
667631|NCT00049296|recurrent adult brain tumor
667632|NCT00049296|recurrent adult diffuse large cell lymphoma
667633|NCT00049296|recurrent adult diffuse mixed cell lymphoma
667634|NCT00049296|recurrent adult diffuse small cleaved cell lymphoma
667635|NCT00049296|recurrent adult Burkitt lymphoma
667636|NCT00049296|recurrent adult immunoblastic large cell lymphoma
667637|NCT00049296|recurrent adult lymphoblastic lymphoma
667638|NCT00049296|recurrent adult primary liver cancer
667639|NCT00049296|recurrent adult soft tissue sarcoma
667640|NCT00049296|recurrent anal cancer
667641|NCT00049296|recurrent basal cell carcinoma of the lip
667642|NCT00049296|recurrent bladder cancer
667643|NCT00049296|recurrent breast cancer
667644|NCT00049296|recurrent colon cancer
667645|NCT00049296|recurrent esophageal cancer
667646|NCT00049296|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
667647|NCT00049296|recurrent extrahepatic bile duct cancer
667648|NCT00049296|recurrent gallbladder cancer
667649|NCT00049296|recurrent gastric cancer
667650|NCT00049296|recurrent gastrointestinal carcinoid tumor
667651|NCT00049296|recurrent grade 1 follicular lymphoma
667652|NCT00049296|recurrent grade 2 follicular lymphoma
667653|NCT00049296|recurrent grade 3 follicular lymphoma
667654|NCT00049296|recurrent inverted papilloma of the paranasal sinus and nasal cavity
667655|NCT00049296|recurrent lymphoepithelioma of the nasopharynx
667656|NCT00049296|recurrent lymphoepithelioma of the oropharynx
667657|NCT00049296|recurrent mantle cell lymphoma
667658|NCT00049296|recurrent melanoma
667659|NCT00049296|recurrent metastatic squamous neck cancer with occult primary
667660|NCT00049296|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
667661|NCT00049296|recurrent mucoepidermoid carcinoma of the oral cavity
667662|NCT00049296|recurrent neuroblastoma
667663|NCT00049296|recurrent non-small cell lung cancer
667664|NCT00049296|recurrent osteosarcoma
667665|NCT00049296|recurrent pancreatic cancer
667666|NCT00049296|recurrent rectal cancer
667667|NCT00049296|recurrent renal cell cancer
667668|NCT00049296|recurrent small cell lung cancer
667669|NCT00049296|recurrent small intestine cancer
667670|NCT00049296|recurrent squamous cell carcinoma of the hypopharynx
667671|NCT00049296|recurrent squamous cell carcinoma of the larynx
667672|NCT00049296|recurrent squamous cell carcinoma of the lip and oral cavity
667673|NCT00049296|recurrent squamous cell carcinoma of the nasopharynx
667674|NCT00049296|recurrent squamous cell carcinoma of the oropharynx
667675|NCT00049296|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
667676|NCT00049296|recurrent transitional cell cancer of the renal pelvis and ureter
667677|NCT00049296|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
667678|NCT00049296|recurrent urethral cancer
667679|NCT00049296|recurrent uterine sarcoma
667680|NCT00049296|recurrent verrucous carcinoma of the larynx
667681|NCT00049296|recurrent verrucous carcinoma of the oral cavity
667682|NCT00049296|refractory multiple myeloma
667683|NCT00049296|rhabdoid tumor of the kidney
667684|NCT00049296|small intestine adenocarcinoma
667685|NCT00049296|small intestine leiomyosarcoma
667686|NCT00049296|small intestine lymphoma
667687|NCT00049296|stage II esophageal cancer
667688|NCT00049296|stage II pancreatic cancer
667689|NCT00049296|stage III esophageal cancer
667690|NCT00049296|stage III multiple myeloma
667691|NCT00049296|stage III pancreatic cancer
667692|NCT00049296|stage IV adenoid cystic carcinoma of the oral cavity
667693|NCT00049296|stage IV adult diffuse large cell lymphoma
667694|NCT00049296|stage IV adult diffuse mixed cell lymphoma
667695|NCT00049296|stage IV adult diffuse small cleaved cell lymphoma
667696|NCT00049296|stage IV adult Burkitt lymphoma
667697|NCT00049296|stage IV adult immunoblastic large cell lymphoma
667698|NCT00049296|stage IV adult lymphoblastic lymphoma
667699|NCT00049296|stage IV anal cancer
667700|NCT00049296|stage IV basal cell carcinoma of the lip
667701|NCT00049296|stage IV bladder cancer
667702|NCT00049296|stage IV breast cancer
667703|NCT00049296|stage IV colon cancer
667704|NCT00049296|stage IV esophageal cancer
667705|NCT00049296|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
667706|NCT00049296|stage IV gastric cancer
667707|NCT00049296|stage IV grade 1 follicular lymphoma
667708|NCT00049296|stage IV grade 2 follicular lymphoma
667709|NCT00049296|stage IV grade 3 follicular lymphoma
667710|NCT00049296|stage IV inverted papilloma of the paranasal sinus and nasal cavity
667711|NCT00049296|stage IV lymphoepithelioma of the nasopharynx
667712|NCT00049296|stage IV lymphoepithelioma of the oropharynx
667713|NCT00049296|stage IV mantle cell lymphoma
667714|NCT00049296|stage IV melanoma
667715|NCT00049296|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
667716|NCT00049296|stage IV mucoepidermoid carcinoma of the oral cavity
667717|NCT00049296|stage IV non-small cell lung cancer
667718|NCT00049296|stage IV rectal cancer
667719|NCT00049296|stage IV renal cell cancer
667720|NCT00049296|stage IV squamous cell carcinoma of the hypopharynx
667721|NCT00049296|stage IV squamous cell carcinoma of the larynx
667722|NCT00049296|stage IV squamous cell carcinoma of the lip and oral cavity
667723|NCT00049296|stage IV squamous cell carcinoma of the nasopharynx
667724|NCT00049296|stage IV squamous cell carcinoma of the oropharynx
667725|NCT00049296|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
667726|NCT00049296|stage IV uterine sarcoma
667727|NCT00049296|stage IV verrucous carcinoma of the larynx
667728|NCT00049296|stage IV verrucous carcinoma of the oral cavity
667729|NCT00049296|unresectable extrahepatic bile duct cancer
667730|NCT00049296|unresectable gallbladder cancer
667731|NCT00049296|unspecified adult solid tumor, protocol specific
667732|NCT00049296|urethral cancer associated with invasive bladder cancer
667733|NCT00049296|recurrent salivary gland cancer
667734|NCT00049296|stage IV salivary gland cancer
667735|NCT00049296|recurrent marginal zone lymphoma
667736|NCT00049296|recurrent small lymphocytic lymphoma
667737|NCT00049296|stage IV small lymphocytic lymphoma
667738|NCT00049296|stage IV marginal zone lymphoma
667739|NCT00049296|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
667740|NCT00049296|nodal marginal zone B-cell lymphoma
667741|NCT00049296|splenic marginal zone lymphoma
667742|NCT00049296|stage IV adult soft tissue sarcoma
667743|NCT00049296|adult grade III meningioma
667744|NCT00049296|adult oligodendroglioma
667745|NCT00049296|adult giant cell glioblastoma
667746|NCT00049296|adult gliosarcoma
667747|NCT00049296|stage IV pancreatic cancer
667748|NCT00049257|adenocarcinoma of the prostate
667749|NCT00049257|recurrent prostate cancer
667750|NCT00049257|stage IV prostate cancer
667751|NCT00049244|recurrent breast cancer
667752|NCT00049244|stage IV breast cancer
667753|NCT00049231|cervical adenocarcinoma
667754|NCT00049231|cervical adenosquamous cell carcinoma
667755|NCT00049231|cervical squamous cell carcinoma
667756|NCT00049231|stage IIB cervical cancer
667757|NCT00049231|stage III cervical cancer
667758|NCT00049231|stage IVA cervical cancer
667759|NCT00049218|extensive stage small cell lung cancer
667760|NCT00049179|adult acute monocytic leukemia (M5b)
667761|NCT00049179|adult acute erythroid leukemia (M6)
667762|NCT00049179|adult acute megakaryoblastic leukemia (M7)
667763|NCT00049179|adult acute myeloblastic leukemia with maturation (M2)
667764|NCT00049179|adult acute myeloblastic leukemia without maturation (M1)
667765|NCT00049179|adult acute myelomonocytic leukemia (M4)
667766|NCT00049179|adult acute monoblastic leukemia (M5a)
667767|NCT00049179|recurrent adult acute myeloid leukemia
667768|NCT00049179|secondary acute myeloid leukemia
667769|NCT00049179|adult acute myeloid leukemia with t(8;21)(q22;q22)
667770|NCT00049179|adult acute myeloid leukemia with t(16;16)(p13;q22)
667771|NCT00049179|adult acute myeloid leukemia with inv(16)(p13;q22)
667772|NCT00049179|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
667773|NCT00049140|stage I squamous cell carcinoma of the hypopharynx
667774|NCT00049140|stage I squamous cell carcinoma of the larynx
667775|NCT00049140|stage I squamous cell carcinoma of the lip and oral cavity
667776|NCT00049140|stage I squamous cell carcinoma of the nasopharynx
667777|NCT00049140|stage I squamous cell carcinoma of the oropharynx
667778|NCT00049140|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
667779|NCT00049140|stage II squamous cell carcinoma of the hypopharynx
667780|NCT00049140|stage II squamous cell carcinoma of the larynx
667781|NCT00049140|stage II squamous cell carcinoma of the lip and oral cavity
667782|NCT00049140|stage II squamous cell carcinoma of the nasopharynx
667783|NCT00049140|stage II squamous cell carcinoma of the oropharynx
667784|NCT00049140|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
667785|NCT00049140|stage III squamous cell carcinoma of the hypopharynx
667786|NCT00049140|stage III squamous cell carcinoma of the larynx
667787|NCT00049140|stage III squamous cell carcinoma of the lip and oral cavity
667788|NCT00049140|stage III squamous cell carcinoma of the nasopharynx
667789|NCT00049140|stage III squamous cell carcinoma of the oropharynx
667790|NCT00049140|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
667791|NCT00049140|stage IV squamous cell carcinoma of the hypopharynx
667792|NCT00049140|stage IV squamous cell carcinoma of the larynx
667793|NCT00049140|stage IV squamous cell carcinoma of the lip and oral cavity
667794|NCT00049140|stage IV squamous cell carcinoma of the nasopharynx
667795|NCT00049140|stage IV squamous cell carcinoma of the oropharynx
667796|NCT00049140|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
667797|NCT00049140|stage I salivary gland cancer
667798|NCT00049140|stage II salivary gland cancer
667799|NCT00049140|stage III salivary gland cancer
667800|NCT00049140|stage IV salivary gland cancer
667801|NCT00049140|salivary gland squamous cell carcinoma
667802|NCT00049101|recurrent colon cancer
667803|NCT00049101|stage IV colon cancer
667804|NCT00049101|recurrent rectal cancer
667805|NCT00049101|stage IV rectal cancer
667806|NCT00049075|B-cell chronic lymphocytic leukemia
667807|NCT00049075|stage I chronic lymphocytic leukemia
667808|NCT00049075|stage II chronic lymphocytic leukemia
667809|NCT00049075|stage III chronic lymphocytic leukemia
667810|NCT00049075|stage IV chronic lymphocytic leukemia
667811|NCT00049062|recurrent breast cancer
667812|NCT00049062|stage IIIB breast cancer
667813|NCT00049062|stage IIIC breast cancer
667814|NCT00049062|stage IV breast cancer
667815|NCT00049023|childhood grade III meningioma
667816|NCT00049023|disseminated neuroblastoma
667817|NCT00049023|localized unresectable neuroblastoma
667818|NCT00049023|metastatic pheochromocytoma
667819|NCT00049023|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
667820|NCT00049023|recurrent childhood brain tumor
667821|NCT00049023|recurrent childhood medulloblastoma
667822|NCT00049023|recurrent neuroblastoma
667823|NCT00049023|recurrent pheochromocytoma
667824|NCT00049023|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
667825|NCT00049023|regional neuroblastoma
667826|NCT00049023|regional pheochromocytoma
667827|NCT00049023|unspecified childhood solid tumor, protocol specific
667828|NCT00049023|recurrent childhood ependymoma
667829|NCT00049023|childhood infratentorial ependymoma
667830|NCT00049023|childhood supratentorial ependymoma
667831|NCT00049023|recurrent islet cell carcinoma
667832|NCT00049023|gastrinoma
667833|NCT00049023|insulinoma
667834|NCT00049023|metastatic gastrointestinal carcinoid tumor
667835|NCT00049023|recurrent gastrointestinal carcinoid tumor
667836|NCT00049023|regional gastrointestinal carcinoid tumor
667837|NCT00049010|stage I melanoma
667838|NCT00049010|stage II melanoma
667839|NCT00048997|stage IIIA non-small cell lung cancer
667840|NCT00048997|stage IIIB non-small cell lung cancer
667841|NCT00048971|adenocarcinoma of the colon
667842|NCT00048971|stage III colon cancer
667843|NCT00048971|diarrhea
667844|NCT00048971|neutropenia
667845|NCT00048906|Pharmacokinetics
667846|NCT00048906|Enzyme
667847|NCT00048906|Lysosomal
667848|NCT00048906|Kidney
667849|NCT00048906|Stroke
667850|NCT00048906|Fabry Disease
667851|NCT00048906|Fabrys
667852|NCT00048906|Fabry's
667853|NCT00048893|CEA vaccine
667854|NCT00048893|Metastatic Breast Cancer
667855|NCT00048893|T- Cell Repertoire
667856|NCT00048893|High-dose Chemotherapy
667857|NCT00048893|Breast Cancer
667858|NCT00048880|Anaplastic Large Cell Lymphoma
667859|NCT00048880|Monoclonal Antibody
667860|NCT00048880|CD30
667861|NCT00048880|Antibody Saturation
667862|NCT00048880|Apoptosis
667863|NCT00048880|Flow Cytometry
667864|NCT00048880|Cancer
667865|NCT00048841|Male
667866|NCT00048841|Osteoporosis
667867|NCT00048841|Prostate cancer
667868|NCT00048841|Hypogonadism
667869|NCT00048841|Bisphosphonates
667870|NCT00048841|Bone mineral density
667871|NCT00048802|Adolescence
667872|NCT00048789|Psoralen
667873|NCT00048789|Refractory
667874|NCT00048789|Transplantation
667877|NCT00048789|Graft-versus-host Disease
667878|NCT00048789|GVHD
667879|NCT00048776|Secondary Raynaud's
667880|NCT00048776|circulatory
667881|NCT00048776|vascular
667882|NCT00048776|scleroderma
667883|NCT00048776|lupus
667884|NCT00048776|mixed connective tissue disease
667885|NCT00048763|circulatory
667886|NCT00048763|vascular
667887|NCT00048763|idiopathic
667888|NCT00048750|Anti-Fungal Therapy
667889|NCT00048750|Preemptive Anti-Fungal Therapy
667890|NCT00048750|Invasive Fungal Infection
667891|NCT00048750|Micafungin
667892|NCT00048750|ICU
667893|NCT00048737|Leukemia
667894|NCT00048737|Lymphoma
667895|NCT00048737|Lymphoid Malignancy
667896|NCT00048737|Cyclophosphamide
667897|NCT00048737|Cytoxan
667898|NCT00048737|Neosar
667899|NCT00048737|Fludarabine
667900|NCT00048737|Fludarabine Phosphate
667901|NCT00048737|Fludara
667902|NCT00048737|Rituximab
667903|NCT00048737|Rituxan
667904|NCT00048737|Zevalin
667905|NCT00048737|Indium Zevalin
667906|NCT00048737|90Y Zevalin
667907|NCT00048737|CD-20-positive
667908|NCT00048737|B-cell Lymphoma
667909|NCT00048737|CD-20-positive B-cell Lymphoma
667910|NCT00048737|NHL
667911|NCT00048737|CLL
667912|NCT00048737|Chronic Lymphocytic Leukemia
667913|NCT00048737|Allogeneic Stem Cell Transplantation
667914|NCT00048737|ASCT
667915|NCT00048724|Hepatitis C; Cirrhosis
667916|NCT00048698|Frontal Lobe
667917|NCT00048698|Motor Cortex
667918|NCT00048698|Dementia
667919|NCT00048698|Cognition
667920|NCT00048698|Healthy Volunteer
667921|NCT00048698|HV
667922|NCT00048685|Caries
667923|NCT00048685|Bacteria
667924|NCT00048685|Saliva
667925|NCT00048685|Teeth
667926|NCT00048685|Autoimmune
667927|NCT00048685|Dry Mouth
667928|NCT00048685|Salivary Gland Dysfunction
667929|NCT00048685|Sjogren's Syndrome
667930|NCT00048672|Early Chronic Phase Chronic Myelogenous Leukemia
667931|NCT00048672|Leukemia
667932|NCT00048672|Gleevec
667933|NCT00048672|STI571
667934|NCT00048672|Imatinib mesylate
667935|NCT00048659|Androgen-independent prostate cancer
667936|NCT00048646|TBI
667937|NCT00048646|ProTECT
667938|NCT00048633|Chemotherapy resistance advanced breast cancer
667939|NCT00048542|Polyarticular Juvenile Idiopathic Arthritis
667940|NCT00048529|adenocarcinoma of the esophagus
667941|NCT00048503|Zarnestra
667942|NCT00048503|Acute myeloid leukemia
667943|NCT00048503|Tipifarnib
667944|NCT00048490|Seizures
667945|NCT00048490|Magnetism
667946|NCT00048490|Brain
667947|NCT00048490|Stimulation
667948|NCT00048490|Therapy
667949|NCT00048490|Epilepsy
667950|NCT00048477|Endothelium
667951|NCT00048477|Vasodilation
667952|NCT00048477|Exercise
667953|NCT00048477|Hemoglobin
667954|NCT00048477|Blood Flow
667955|NCT00048477|Healthy Volunteer
667956|NCT00048477|HV
667957|NCT00048464|Immunotherapy
667958|NCT00048464|T Cell Therapy
667959|NCT00048464|Peripheral Blood Stem Cell Transplant
667960|NCT00048464|Bone marrow transplant
667961|NCT00048464|Adoptive immunotherapy
667962|NCT00048464|Xcellerate
667963|NCT00048425|Decompensated chronic heart failure
667964|NCT00048373|LANGERHANS
667965|NCT00048373|HISTIOCYTOSIS
667966|NCT00048360|ADD
667967|NCT00048360|ADHD
667968|NCT00048360|attention deficit
667969|NCT00048360|hyperactivity
667970|NCT00048347|Lymphocyte
667971|NCT00048347|Monocyte
667972|NCT00048347|Inflammation
667973|NCT00048347|Th2
667974|NCT00048347|Colonoscopy
667975|NCT00048347|Ulcerative Colitis
667976|NCT00048334|Histone Acetylation
667977|NCT00048334|Cancer
667978|NCT00048308|CABG
667979|NCT00048282|Incidence
667980|NCT00048282|HIV Seroprevalence
667981|NCT00048282|Vagina
667982|NCT00048282|Anti-Infective Agents
667983|NCT00048282|Administration, Topical
667984|NCT00048282|Gels
667985|NCT00048282|HIV Seronegativity
667986|NCT00048256|Cancer
667987|NCT00048256|Personality Assessment
667988|NCT00048256|Coping Styles
667989|NCT00048256|Psychological Distress
667990|NCT00048256|Bone Marrow Transplants
667991|NCT00048256|Bone Marrow Transplant
667992|NCT00048230|Relapsed Multiple Myeloma
667993|NCT00048230|Refractory Multiple Myeloma
667994|NCT00048217|Treatment Experienced
667995|NCT00048204|Depression
667996|NCT00048204|Psychiatry
667997|NCT00048204|Major Depressive Disorder
667998|NCT00048113|Crohn's
667999|NCT00048100|Dendritic cells
668000|NCT00048100|Lymphocytes
668001|NCT00048100|AML
668002|NCT00048087|Non-small cell lung cancer
668003|NCT00047983|Kidney Transplantation
668004|NCT00047983|Fatty Acids, Omega-3
668005|NCT00047983|Erythrocyte Membrane
668006|NCT00047983|Graft Survival
668007|NCT00047970|Breast Cancer
668008|NCT00047970|Sisters
668009|NCT00047957|Transcranial
668010|NCT00047957|Magnetic
668011|NCT00047957|Stimulation
668012|NCT00047957|Motor
668013|NCT00047957|Cortex
668014|NCT00047957|Motor Cortex
668015|NCT00047957|Afferent Stimulation
668016|NCT00047957|Transcranial Magnetic Stimulation
668017|NCT00047957|Healthy Volunteer
668018|NCT00047957|HV
668019|NCT00047944|Attention
668020|NCT00047944|Emotion
668021|NCT00047944|Amygdala
668022|NCT00047944|Prefrontal Cortex
668023|NCT00047944|Facial Expression
668024|NCT00047944|Magnetic Resonance Imaging
668025|NCT00047944|fMRI
668026|NCT00047944|Depression
668027|NCT00047944|Anxiety
668028|NCT00047944|Adolescence
668029|NCT00047944|Children
668030|NCT00047931|Healthy
668031|NCT00047931|HIV-Negative
668032|NCT00047931|Placebo-Controlled
668033|NCT00047931|Volunteer
668034|NCT00047931|Dose-Escalation
668035|NCT00047931|HIV Seronegativity
668036|NCT00047931|Healthy Volunteer
668037|NCT00047931|HV
668038|NCT00047918|Mast Cells
668039|NCT00047918|Bone Marrow
668040|NCT00047918|Flushing
668041|NCT00047918|Mutations
668042|NCT00047918|Mastocytosis
668043|NCT00047918|Anaphylaxis
668044|NCT00047905|Qualitative
668045|NCT00047905|Communication Analysis
668046|NCT00047905|RIAS
668047|NCT00047905|Counseling Models
668048|NCT00047905|Videotaping
668049|NCT00047905|Prenatal Genetic Counselors
668050|NCT00047905|Counseling Process
668051|NCT00047905|Video Tape Study
668052|NCT00047905|Simulated Clients
668053|NCT00047905|Prenatal Genetic Counseling
668054|NCT00047879|Brain Tumors
668055|NCT00047879|Experimental
668056|NCT00047879|Toxicities
668057|NCT00047879|Efficacy
668058|NCT00047879|Progression-Free
668059|NCT00047879|Brain Tumor
668060|NCT00047879|Glioma
668061|NCT00047866|Limbic System
668062|NCT00047866|Amphetamine
668063|NCT00047866|Dopamine
668064|NCT00047866|Brain Imaging
668065|NCT00047866|Cerebral Blood Flow
668066|NCT00047866|Cerebral Blood Volume
668067|NCT00047866|Alcoholism
668068|NCT00047866|Tyrosine Depletion
668069|NCT00047866|Amino Acids
668070|NCT00047866|Affect
668071|NCT00047866|Healthy Volunteer
668072|NCT00047866|HV
668073|NCT00047853|Anxiety
668074|NCT00047853|Neuroimaging
668075|NCT00047853|Affective Neuroscience
668076|NCT00047853|Healthy Volunteer
668077|NCT00047853|HV
668078|NCT00047827|Aspergillus
668079|NCT00047827|Aspergillosis
668080|NCT00047827|Anti-Fungal
668081|NCT00047827|AmBisome
668082|NCT00047827|Micafungin
668083|NCT00047814|HCV
668084|NCT00047788|Relapsed Multiple Myeloma
668085|NCT00047749|pain
668086|NCT00047749|ziconotide
668087|NCT00047749|Prialt
668088|NCT00047749|intrathecal
668089|NCT00047749|Synchromed
668090|NCT00047736|Non-small cell lung cancer
668091|NCT00047723|ALS
668092|NCT00047723|amyotrophic lateral sclerosis
668093|NCT00047723|minocycline
668094|NCT00047710|pancreatic cancer
668095|NCT00047710|pancreas cancer
668096|NCT00047710|pancreas
668097|NCT00047684|Child Abuse, Sexual
668098|NCT00047671|Depressive Disorder
668099|NCT00047645|lung
668100|NCT00047645|IPF
668101|NCT00047632|ovarian
668102|NCT00047632|carcinoma
668103|NCT00047632|peritoneal
668104|NCT00047632|cancer
668105|NCT00047632|ovary
668106|NCT00047632|interferon gamma
668107|NCT00047619|Decubitus Ulcers
668108|NCT00047619|Pulsatile Lavage
668109|NCT00047619|SCI
668110|NCT00047619|Spinal Cord Injury
668111|NCT00047619|Wound healing
668112|NCT00047619|pressure ulcer
668113|NCT00047606|open-angle
668114|NCT00047606|glaucoma
668115|NCT00047606|ocular
668116|NCT00047606|hypertension
668117|NCT00047606|POAG
668118|NCT00047606|Iris
668119|NCT00047606|Pigmentation
668120|NCT00047606|Japanese
668121|NCT00047593|open-angle
668122|NCT00047593|glaucoma
668123|NCT00047593|ocular
668124|NCT00047593|hypertension
668125|NCT00047593|POAG
668126|NCT00047593|Iris
668127|NCT00047593|Pigmentation
668128|NCT00047593|Japanese
668129|NCT00047580|Spasticity
668130|NCT00047580|spasticity secondary to Multiple Sclerosis
668131|NCT00047580|Spinal Cord Injury
668132|NCT00047580|Stroke
668133|NCT00047567|ZONISAMIDE
668134|NCT00047567|BIPOLAR
668135|NCT00047554|open-angle
668136|NCT00047554|glaucoma
668137|NCT00047554|ocular
668138|NCT00047554|hypertension
668139|NCT00047554|primary open-angle glaucoma
668140|NCT00047554|iris
668141|NCT00047554|pigmentation
668142|NCT00047541|open-angle
668143|NCT00047541|glaucoma
668144|NCT00047541|ocular
668145|NCT00047541|hypertension
668146|NCT00047541|POAG
668147|NCT00047528|open-angle
668148|NCT00047528|glaucoma
668149|NCT00047528|ocular
668150|NCT00047528|hypertension
668151|NCT00047528|POAG
668152|NCT00047515|open-angle
668153|NCT00047515|glaucoma
668154|NCT00047515|ocular
668155|NCT00047515|hypertension
668156|NCT00047515|POAG
668157|NCT00047476|neurobehavioral function
668158|NCT00047476|chemobrain
668159|NCT00047476|chemo brain
668160|NCT00047476|fatigue
668161|NCT00047476|memory loss
668162|NCT00047476|exhausted
668163|NCT00047476|trouble concentrating
668164|NCT00047463|epilepsy
668165|NCT00047463|sleep apnea
668166|NCT00047463|obstructive sleep apnea
668167|NCT00047463|continuous positive airway pressure
668168|NCT00047463|CPAP
668169|NCT00047450|Psychotic Disorders
668170|NCT00047411|CPR, AED
668171|NCT00047385|small cell lung cancer
668172|NCT00047385|non-small cell lung cancer
668173|NCT00047320|childhood central nervous system germ cell tumor
668174|NCT00047320|childhood teratoma
668175|NCT00047320|recurrent childhood malignant germ cell tumor
668176|NCT00047320|childhood central nervous system choriocarcinoma
668177|NCT00047320|childhood central nervous system embryonal tumor
668178|NCT00047320|childhood central nervous system germinoma
668179|NCT00047320|childhood central nervous system mixed germ cell tumor
668180|NCT00047320|childhood central nervous system teratoma
668181|NCT00047320|childhood central nervous system yolk sac tumor
668182|NCT00047320|recurrent childhood central nervous system embryonal tumor
668183|NCT00047294|adult mixed glioma
668184|NCT00047294|adult glioblastoma
668185|NCT00047294|adult giant cell glioblastoma
668186|NCT00047294|adult gliosarcoma
668187|NCT00047281|adult anaplastic astrocytoma
668188|NCT00047281|adult anaplastic oligodendroglioma
668189|NCT00047281|adult glioblastoma
668190|NCT00047281|adult mixed glioma
668191|NCT00047281|recurrent adult brain tumor
668192|NCT00047281|adult giant cell glioblastoma
668193|NCT00047281|adult gliosarcoma
668194|NCT00047268|juvenile myelomonocytic leukemia
668195|NCT00047268|childhood myelodysplastic syndromes
668196|NCT00047268|atypical chronic myeloid leukemia, BCR-ABL1 negative
668197|NCT00047268|myelodysplastic/myeloproliferative neoplasm, unclassifiable
668198|NCT00047268|chronic myelomonocytic leukemia
668199|NCT00047255|stage IIIB breast cancer
668200|NCT00047255|stage IIIC breast cancer
668201|NCT00047255|stage IV breast cancer
668202|NCT00047255|recurrent breast cancer
668203|NCT00047242|unspecified adult solid tumor, protocol specific
668204|NCT00047229|adult primary hepatocellular carcinoma
668205|NCT00047229|advanced adult primary liver cancer
668206|NCT00047229|localized unresectable adult primary liver cancer
668207|NCT00047229|recurrent adult primary liver cancer
668208|NCT00047216|recurrent bladder cancer
668209|NCT00047216|stage 0 bladder cancer
668210|NCT00047216|stage I bladder cancer
668211|NCT00047216|transitional cell carcinoma of the bladder
668212|NCT00047177|recurrent childhood medulloblastoma
668213|NCT00047177|recurrent childhood supratentorial primitive neuroectodermal tumor
668214|NCT00047177|recurrent childhood ependymoma
668215|NCT00047177|childhood atypical teratoid/rhabdoid tumor
668216|NCT00047164|recurrent grade 1 follicular lymphoma
668217|NCT00047164|recurrent grade 2 follicular lymphoma
668218|NCT00047164|contiguous stage II adult lymphoblastic lymphoma
668219|NCT00047164|noncontiguous stage II adult lymphoblastic lymphoma
668220|NCT00047164|recurrent adult lymphoblastic lymphoma
668221|NCT00047164|stage I adult lymphoblastic lymphoma
668222|NCT00047164|stage III adult lymphoblastic lymphoma
668223|NCT00047164|stage IV adult lymphoblastic lymphoma
668224|NCT00047164|noncontiguous stage II grade 3 follicular lymphoma
668225|NCT00047164|recurrent grade 3 follicular lymphoma
668226|NCT00047164|stage I grade 3 follicular lymphoma
668227|NCT00047164|stage III grade 3 follicular lymphoma
668228|NCT00047164|stage IV grade 3 follicular lymphoma
668229|NCT00047164|contiguous stage II grade 3 follicular lymphoma
668230|NCT00047164|contiguous stage II grade 2 follicular lymphoma
668231|NCT00047164|contiguous stage II grade 1 follicular lymphoma
668232|NCT00047164|contiguous stage II adult diffuse mixed cell lymphoma
668233|NCT00047164|noncontiguous stage II adult diffuse mixed cell lymphoma
668234|NCT00047164|recurrent adult diffuse mixed cell lymphoma
668235|NCT00047164|stage I adult diffuse mixed cell lymphoma
668236|NCT00047164|stage III adult diffuse mixed cell lymphoma
668237|NCT00047164|stage IV adult diffuse mixed cell lymphoma
668238|NCT00047164|contiguous stage II adult diffuse large cell lymphoma
668239|NCT00047164|noncontiguous stage II adult diffuse large cell lymphoma
668240|NCT00047164|recurrent adult diffuse large cell lymphoma
668241|NCT00047164|stage I adult diffuse large cell lymphoma
668242|NCT00047164|stage III adult diffuse large cell lymphoma
668243|NCT00047164|stage IV adult diffuse large cell lymphoma
668244|NCT00047164|contiguous stage II adult immunoblastic large cell lymphoma
668245|NCT00047164|noncontiguous stage II adult immunoblastic large cell lymphoma
668246|NCT00047164|recurrent adult immunoblastic large cell lymphoma
668247|NCT00047164|stage I adult immunoblastic large cell lymphoma
668248|NCT00047164|stage III adult immunoblastic large cell lymphoma
668249|NCT00047164|stage IV adult immunoblastic large cell lymphoma
668250|NCT00047164|contiguous stage II adult Burkitt lymphoma
668251|NCT00047164|noncontiguous stage II adult Burkitt lymphoma
668252|NCT00047164|recurrent adult Burkitt lymphoma
668253|NCT00047164|stage I adult Burkitt lymphoma
668254|NCT00047164|stage III adult Burkitt lymphoma
668255|NCT00047164|stage IV adult Burkitt lymphoma
668256|NCT00047164|contiguous stage II mantle cell lymphoma
668257|NCT00047164|noncontiguous stage II mantle cell lymphoma
668258|NCT00047164|recurrent mantle cell lymphoma
668259|NCT00047164|stage I mantle cell lymphoma
668260|NCT00047164|stage III mantle cell lymphoma
668261|NCT00047164|stage IV mantle cell lymphoma
668262|NCT00047164|recurrent adult Hodgkin lymphoma
668263|NCT00047164|stage I adult Hodgkin lymphoma
668264|NCT00047164|stage II adult Hodgkin lymphoma
668265|NCT00047164|stage III adult Hodgkin lymphoma
668266|NCT00047164|stage IV adult Hodgkin lymphoma
668267|NCT00047164|recurrent adult diffuse small cleaved cell lymphoma
668268|NCT00047164|stage I adult diffuse small cleaved cell lymphoma
668269|NCT00047164|stage II adult diffuse small cleaved cell lymphoma
668270|NCT00047164|stage III adult diffuse small cleaved cell lymphoma
668271|NCT00047164|stage IV adult diffuse small cleaved cell lymphoma
668272|NCT00047164|contiguous stage II marginal zone lymphoma
668273|NCT00047164|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
668274|NCT00047164|nodal marginal zone B-cell lymphoma
668275|NCT00047164|noncontiguous stage II marginal zone lymphoma
668276|NCT00047164|recurrent marginal zone lymphoma
668277|NCT00047164|splenic marginal zone lymphoma
668278|NCT00047164|stage I marginal zone lymphoma
668279|NCT00047164|stage III marginal zone lymphoma
668280|NCT00047164|stage IV marginal zone lymphoma
668281|NCT00047164|contiguous stage II small lymphocytic lymphoma
668282|NCT00047164|noncontiguous stage II small lymphocytic lymphoma
668283|NCT00047164|recurrent small lymphocytic lymphoma
668284|NCT00047164|stage I small lymphocytic lymphoma
668285|NCT00047164|stage III small lymphocytic lymphoma
668286|NCT00047164|stage IV small lymphocytic lymphoma
668287|NCT00047164|recurrent adult T-cell leukemia/lymphoma
668288|NCT00047164|recurrent cutaneous T-cell non-Hodgkin lymphoma
668289|NCT00047164|stage I adult T-cell leukemia/lymphoma
668290|NCT00047164|stage I cutaneous T-cell non-Hodgkin lymphoma
668291|NCT00047164|stage II adult T-cell leukemia/lymphoma
668292|NCT00047164|stage II cutaneous T-cell non-Hodgkin lymphoma
668293|NCT00047164|stage III adult T-cell leukemia/lymphoma
668294|NCT00047164|stage III cutaneous T-cell non-Hodgkin lymphoma
668295|NCT00047164|stage IV adult T-cell leukemia/lymphoma
668296|NCT00047164|stage IV cutaneous T-cell non-Hodgkin lymphoma
668297|NCT00047138|blastema predominant Wilms tumor
668298|NCT00047138|epithelial predominant Wilms tumor
668299|NCT00047138|mixed cell type Wilms tumor
668300|NCT00047138|stage I Wilms tumor
668301|NCT00047138|stage II Wilms tumor
668302|NCT00047138|stage III Wilms tumor
668303|NCT00047138|stage IV Wilms tumor
668304|NCT00047138|stage V Wilms tumor
668305|NCT00047138|stromal predominant Wilms tumor
668306|NCT00047125|newly diagnosed carcinoma of unknown primary
668307|NCT00047125|squamous cell carcinoma of unknown primary
668308|NCT00047112|adenocarcinoma of the esophagus
668309|NCT00047112|squamous cell carcinoma of the esophagus
668310|NCT00047112|stage I esophageal cancer
668311|NCT00047112|stage II esophageal cancer
668312|NCT00047099|stage II breast cancer
668313|NCT00047099|stage IIIA breast cancer
668314|NCT00047099|stage IIIB breast cancer
668315|NCT00047073|recurrent adult brain tumor
668316|NCT00047073|adult glioblastoma
668317|NCT00047073|adult giant cell glioblastoma
668318|NCT00047073|adult gliosarcoma
668319|NCT00047060|Cutaneous T Cell Lymphoma
668320|NCT00047060|Allogeneic PBSCT
668321|NCT00047060|Low Intensity Regimen
668322|NCT00047060|Mycosis Fungoides
668323|NCT00047060|Sezary Syndrome
668324|NCT00047060|CTCL
668325|NCT00047021|accelerated phase chronic myelogenous leukemia
668326|NCT00047021|blastic phase chronic myelogenous leukemia
668327|NCT00047021|recurrent adult acute lymphoblastic leukemia
668328|NCT00047021|recurrent adult acute myeloid leukemia
668329|NCT00047021|recurrent adult diffuse large cell lymphoma
668330|NCT00047021|recurrent adult diffuse mixed cell lymphoma
668331|NCT00047021|recurrent adult diffuse small cleaved cell lymphoma
668332|NCT00047021|recurrent adult Burkitt lymphoma
668333|NCT00047021|recurrent adult Hodgkin lymphoma
668334|NCT00047021|recurrent adult immunoblastic large cell lymphoma
668335|NCT00047021|recurrent adult lymphoblastic lymphoma
668336|NCT00047021|recurrent childhood acute lymphoblastic leukemia
668337|NCT00047021|recurrent childhood acute myeloid leukemia
668338|NCT00047021|recurrent childhood large cell lymphoma
668339|NCT00047021|recurrent childhood lymphoblastic lymphoma
668340|NCT00047021|recurrent childhood small noncleaved cell lymphoma
668341|NCT00047021|recurrent grade 1 follicular lymphoma
668342|NCT00047021|recurrent grade 2 follicular lymphoma
668343|NCT00047021|recurrent grade 3 follicular lymphoma
668344|NCT00047021|recurrent mantle cell lymphoma
668345|NCT00047021|recurrent/refractory childhood Hodgkin lymphoma
668346|NCT00047021|relapsing chronic myelogenous leukemia
668347|NCT00047021|secondary acute myeloid leukemia
668348|NCT00047021|childhood chronic myelogenous leukemia
668349|NCT00047021|atypical chronic myeloid leukemia
668350|NCT00047021|recurrent marginal zone lymphoma
668351|NCT00047021|recurrent small lymphocytic lymphoma
668352|NCT00047021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
668353|NCT00047021|nodal marginal zone B-cell lymphoma
668354|NCT00047021|splenic marginal zone lymphoma
668355|NCT00047021|adult acute myeloid leukemia with t(8;21)(q22;q22)
668356|NCT00047021|adult acute myeloid leukemia with t(16;16)(p13;q22)
668357|NCT00047021|adult acute myeloid leukemia with inv(16)(p13;q22)
668358|NCT00047021|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
668359|NCT00047021|adult acute myeloid leukemia with t(15;17)(q22;q12)
668360|NCT00047008|stage III squamous cell carcinoma of the hypopharynx
668361|NCT00047008|stage III squamous cell carcinoma of the larynx
668362|NCT00047008|stage III squamous cell carcinoma of the lip and oral cavity
668363|NCT00047008|stage III squamous cell carcinoma of the oropharynx
668364|NCT00047008|stage IV squamous cell carcinoma of the hypopharynx
668365|NCT00047008|stage IV squamous cell carcinoma of the larynx
668366|NCT00047008|stage IV squamous cell carcinoma of the lip and oral cavity
668367|NCT00047008|stage IV squamous cell carcinoma of the oropharynx
668368|NCT00046995|adenocarcinoma of the colon
668369|NCT00046995|stage IIB colon cancer
668370|NCT00046995|stage IIIA colon cancer
668371|NCT00046995|stage IIIB colon cancer
668372|NCT00046995|stage IIIC colon cancer
668373|NCT00046969|anemia
668374|NCT00046969|stage IIB cervical cancer
668375|NCT00046969|stage III cervical cancer
668376|NCT00046969|stage IVA cervical cancer
668377|NCT00046969|cervical adenosquamous cell carcinoma
668378|NCT00046969|cervical squamous cell carcinoma
668379|NCT00046969|cervical adenocarcinoma
668380|NCT00046943|adenocarcinoma of the prostate
668381|NCT00046943|recurrent prostate cancer
668382|NCT00046943|stage IIB prostate cancer
668383|NCT00046943|stage IIA prostate cancer
668384|NCT00046943|stage III prostate cancer
668385|NCT00046943|stage IV prostate cancer
668386|NCT00046930|adult acute monocytic leukemia (M5b)
668387|NCT00046930|adult acute erythroid leukemia (M6)
668388|NCT00046930|adult acute megakaryoblastic leukemia (M7)
668389|NCT00046930|adult acute myeloblastic leukemia with maturation (M2)
668390|NCT00046930|adult acute myeloblastic leukemia without maturation (M1)
668391|NCT00046930|adult acute myelomonocytic leukemia (M4)
668392|NCT00046930|adult acute monoblastic leukemia (M5a)
668393|NCT00046930|refractory anemia with excess blasts in transformation
668394|NCT00046930|refractory anemia with excess blasts
668395|NCT00046930|secondary acute myeloid leukemia
668396|NCT00046930|untreated adult acute myeloid leukemia
668397|NCT00046930|de novo myelodysplastic syndromes
668398|NCT00046930|adult acute minimally differentiated myeloid leukemia (M0)
668399|NCT00046930|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
668400|NCT00046930|adult acute myeloid leukemia with inv(16)(p13;q22)
668401|NCT00046930|adult acute myeloid leukemia with t(16;16)(p13;q22)
668402|NCT00046930|adult acute myeloid leukemia with t(8;21)(q22;q22)
668403|NCT00046904|unspecified adult solid tumor, protocol specific
668404|NCT00046904|anorexia
668405|NCT00046904|cachexia
668406|NCT00046891|neurotoxicity
668407|NCT00046891|stage I breast cancer
668408|NCT00046891|stage II breast cancer
668409|NCT00046891|stage IIIA breast cancer
668410|NCT00046891|stage IIIB breast cancer
668411|NCT00046891|stage IIIC breast cancer
668412|NCT00046878|adult glioblastoma
668413|NCT00046878|adult giant cell glioblastoma
668414|NCT00046878|adult gliosarcoma
668415|NCT00046865|nausea and vomiting
668416|NCT00046865|stage I breast cancer
668417|NCT00046865|stage II breast cancer
668418|NCT00046865|stage IIIA breast cancer
668419|NCT00046865|stage IIIB breast cancer
668420|NCT00046865|stage IIIC breast cancer
668421|NCT00046865|stage IV breast cancer
668422|NCT00046852|infection
668423|NCT00046852|refractory multiple myeloma
668424|NCT00046852|stage I multiple myeloma
668425|NCT00046852|stage II multiple myeloma
668426|NCT00046852|stage III multiple myeloma
668427|NCT00046839|stage II non-small cell lung cancer
668428|NCT00046839|stage IIIA non-small cell lung cancer
668429|NCT00046839|stage IIIB non-small cell lung cancer
668430|NCT00046826|adenocarcinoma of the prostate
668431|NCT00046826|stage IV prostate cancer
668432|NCT00046826|recurrent prostate cancer
668433|NCT00046800|Ovarian Cancer
668434|NCT00046787|Small Cell Lung Cancer
668435|NCT00046774|Safety
668436|NCT00046774|Nephritis
668437|NCT00046774|Biologic Therapy
668438|NCT00046774|Lymphocytes
668439|NCT00046774|Response
668440|NCT00046774|Lupus
668441|NCT00046774|Systemic Lupus Erythematosus
668442|NCT00046774|SLE
668443|NCT00046761|Acute Ischemic Stroke
668444|NCT00046735|solid tumors
668445|NCT00046735|Revimid
668446|NCT00046735|CC5013
668447|NCT00046735|CC-5013
668448|NCT00046722|treatment experienced
668449|NCT00046722|complementary therapies
668450|NCT00046722|Neuropathy
668451|NCT00046722|Peripheral Neuropathy
668452|NCT00046722|HIV-Related Peripheral Neuropathy
668453|NCT00046722|HIV
668454|NCT00046709|Cancer pain
668455|NCT00046709|All types of cancer except lung cancer
668456|NCT00046696|Cancer
668457|NCT00046696|Cancer Alternative Therapies
668458|NCT00046696|Living with Cancer
668459|NCT00046683|Adult acute leukemia
668460|NCT00046683|Adult chronic leukemia
668461|NCT00046683|Childhood leukemia
668462|NCT00046683|Campath
668463|NCT00046683|Alemtuzumab
668464|NCT00046631|built environment
668465|NCT00046631|parks
668466|NCT00046631|retail outlets
668467|NCT00046631|adolescent girls
668468|NCT00046631|physical activity
668469|NCT00046553|Cortisol
668470|NCT00046553|CRH
668471|NCT00046553|HPA Axis
668472|NCT00046553|Hypothalamus
668473|NCT00046553|Hippocampus
668474|NCT00046553|Post-Traumatic Stress Disorder
668475|NCT00046553|PTSD
668476|NCT00046553|Healthy Volunteer
668477|NCT00046540|Liposome-Encapsulated SN38
668478|NCT00046540|Irinotecan
668479|NCT00046540|CPT-11
668480|NCT00046540|Malignant Tumors
668481|NCT00046527|Metastatic breast cancer
668482|NCT00046527|Taxol
668483|NCT00046527|Taxane
668484|NCT00046514|Metastatic Breast Cancer
668485|NCT00046514|Taxol
668486|NCT00046488|Chronic Lymphoblastic Leukemia
668487|NCT00046488|Leukemia, Lymphoblastic, Chronic
668488|NCT00046488|Chronic Lymphocytic Leukemia
668489|NCT00046488|CLL
668490|NCT00046436|AIDS Serodiagnosis
668491|NCT00046436|Pregnancy Complications, Infectious
668492|NCT00046436|Anti-HIV Agents
668493|NCT00046436|Disease Transmission, Vertical
668494|NCT00046423|Cancer
668495|NCT00046423|solid tumor
668496|NCT00046423|Advanced malignancy
668497|NCT00046423|Taxane therapy
668498|NCT00046423|Biopsy-proven diagnosis of advanced malignancy
668499|NCT00046423|Various solid tumors which are refractory
668500|NCT00046410|MRI
668501|NCT00046410|Diffusion
668502|NCT00046410|Cognitive
668503|NCT00046410|Stroke
668504|NCT00046410|Heart
668505|NCT00046410|Coronary Artery Disease
668506|NCT00046410|Heart Disease
668507|NCT00046397|Smallpox
668508|NCT00046397|Vaccine
668509|NCT00046397|Vaccination
668510|NCT00046397|Variola
668511|NCT00046397|Adults
668512|NCT00046397|Smallpox Vaccine
668513|NCT00046397|Healthy Volunteer
668514|NCT00046397|Small Pox
668515|NCT00046371|Cancer Vaccines
668516|NCT00046371|Aromatase
668517|NCT00046371|Receptors, Estrogen
668518|NCT00046371|Receptors, Progesterone
668519|NCT00046358|Cerebrospinal Fluid
668520|NCT00046358|Cholesterol
668521|NCT00046358|Statin
668522|NCT00046358|NSAID
668523|NCT00046358|Antiinflammatory
668524|NCT00046358|Dementia
668525|NCT00046358|Alzheimer's Disease
668526|NCT00046358|Nonsteroidal Antiinflammatory
668527|NCT00046358|Healthy Volunteer
668528|NCT00046345|treatment experienced
668529|NCT00046332|Integrase inhibitors
668530|NCT00046332|Monotherapy
668531|NCT00046332|HIV-1 infection
668532|NCT00046319|Pulmonary Arterial Hypertension
668533|NCT00046319|Primary Pulmonary Hypertension
668534|NCT00046306|Oxidative Stress
668535|NCT00046306|Cardiovascular Disease
668536|NCT00046306|Cancer
668537|NCT00046293|Stroke
668538|NCT00046293|Abciximab
668539|NCT00046293|Retavase
668540|NCT00046293|MRI
668541|NCT00046293|Cerebral Blood Flow
668542|NCT00046267|Delayed-Action Preparations
668543|NCT00046267|Blood Glucose
668544|NCT00046267|Insulin
668545|NCT00046267|Alanine Transaminase
668546|NCT00046267|Aspartate Aminotransferases
668547|NCT00046267|Fructosamine
668548|NCT00046267|Glucose Tolerance Test
668549|NCT00046267|Treatment Experienced
668550|NCT00046254|hip fracture
668551|NCT00046254|recurrent fracture
668552|NCT00046254|fracture
668553|NCT00046254|bone loss
668554|NCT00046254|bisphosphonate
668555|NCT00046254|bone mineral density
668556|NCT00046254|osteoporosis
668557|NCT00046254|zoledronic acid
668558|NCT00046254|geriatrics
668559|NCT00046254|rehabilitation
668560|NCT00046254|elderly
668561|NCT00046254|nursing home
668562|NCT00046254|orthopedic
668563|NCT00046241|seasonal depression winter blues winter depression
668564|NCT00046228|Myocardial infarction
668565|NCT00046228|percutaneous coronary intervention
668566|NCT00046228|abciximab
668567|NCT00046228|reteplase
668568|NCT00046228|safety and efficacy
668569|NCT00046215|Virtual Lesion Study
668570|NCT00046215|Motor Imagery
668571|NCT00046215|Primary Motor Cortex
668572|NCT00046215|Motor Inhibition
668573|NCT00046215|Motor Execution
668574|NCT00046215|Healthy Volunteer
668575|NCT00046202|Smith-Lemli-Opitz Syndrome
668576|NCT00046202|Sterol
668577|NCT00046202|Mutations
668578|NCT00046202|Dysmorphology
668579|NCT00046202|Mental Retardation
668580|NCT00046202|Inborn Errors of Cholesterol Synthesis
668581|NCT00046202|Smith-Lemli-Optiz Syndrome
668582|NCT00046202|Lathosterolosis
668583|NCT00046202|Desmosterols
668584|NCT00046202|CHILD Syndrome
668585|NCT00046202|Greenberg Dysplasia
668586|NCT00046202|X Linked Dominant Chrondrodysplasia
668587|NCT00046189|Sun Exposure
668588|NCT00046189|Xeroderma Pigmentosum
668589|NCT00046189|Skin Cancer
668590|NCT00046189|Family History
668591|NCT00046189|HETEROZYGOTE
668592|NCT00046189|XP
668593|NCT00046176|HIV-1 Abacavir Lamivudine Antiretroviral-experienced
668594|NCT00046163|Neurology
668595|NCT00046163|Cardiology
668596|NCT00046111|oral
668597|NCT00046111|Bioequivalence
668598|NCT00046111|Hycamtin
668599|NCT00046111|Topotecan
668600|NCT00046085|Schizophrenia
668601|NCT00046085|Family
668602|NCT00046085|Psychoeducation
668603|NCT00046085|Internet
668604|NCT00046072|Sepsis
668605|NCT00046072|Shock
668606|NCT00046072|Septic
668607|NCT00046072|Sepsis Syndrome
668608|NCT00046072|Septicemia
668609|NCT00046072|Endotoxins
668610|NCT00046072|Endotoxemia
668611|NCT00046072|Infection
668612|NCT00046059|Linkage
668613|NCT00046059|Gene Identification
668614|NCT00046059|ADHD
668615|NCT00046059|Hyperactivity
668616|NCT00046059|Attention Deficit Hyperactivity Disorder
668617|NCT00046033|Dose-Relationship, Drug
668618|NCT00046033|HIV Protease Inhibitors
668619|NCT00046033|Salvage Therapy
668620|NCT00046033|Viral Load
668621|NCT00046033|RNA, Viral
668622|NCT00046033|Drug Therapy, Combination
668623|NCT00046020|Depression
668624|NCT00045994|cardiovascular
668625|NCT00045994|aged
668626|NCT00045994|antihypertensive agents/therapeutic use
668627|NCT00045994|hypertension/*drug therapy
668628|NCT00045994|blood pressure
668629|NCT00045981|cardiovascular
668630|NCT00045981|aged
668631|NCT00045981|antihypertensive agents/therapeutic use
668632|NCT00045981|hypertension/*drug therapy
668633|NCT00045981|blood pressure
668634|NCT00045968|oncology
668635|NCT00045968|neurology
668636|NCT00045968|glioma
668637|NCT00045968|brain tumor
668638|NCT00045968|brain cancer
668639|NCT00045968|glioblastoma multiforme
668640|NCT00045968|glioblastoma
668641|NCT00045968|newly diagnosed glioblastoma
668642|NCT00045968|immunotherapy
668643|NCT00045968|dendritic cells
668644|NCT00045968|immune therapy
668645|NCT00045968|GBM
668646|NCT00045968|Brain cancer, primary
668647|NCT00045968|tumor vaccine
668648|NCT00045968|grade IV astrocytoma
668649|NCT00045968|DCVax
668650|NCT00045968|Grade IV brain cancer
668651|NCT00045942|AML
668652|NCT00045942|MDS
668653|NCT00045942|high risk myelodysplastic syndrome
668654|NCT00045916|Electroconvulsive therapy
668655|NCT00045916|Antidepressive Agents
668656|NCT00045903|Cognitive Behavioral Therapy
668657|NCT00045877|Low-Grade or Follicular Non-Hodgkin's Lymphoma
668658|NCT00045864|Intermediate and High-Grade Non-Hodgkin's Lymphoma
668659|NCT00045838|Healthy
668660|NCT00045838|HIV-Negative
668661|NCT00045838|Placebo Controlled
668662|NCT00045838|Volunteer
668663|NCT00045838|Dose-Escalation
668664|NCT00045838|Healthy Volunteers
668665|NCT00045838|HV
668666|NCT00045838|HIV Seronegativity
668667|NCT00045838|HIV Preventive Vaccine
668668|NCT00045812|Cholesterol
668669|NCT00045812|Sitosterol
668670|NCT00045812|Atherosclerosis
668671|NCT00045812|Intestine
668672|NCT00045812|Absorption
668673|NCT00045812|Homozygous Sitosterolemia
668674|NCT00045812|Sterol Metabolism
668675|NCT00045786|myelodysplastic syndrome
668676|NCT00045747|adenocarcinoma of the pancreas
668677|NCT00045747|recurrent pancreatic cancer
668678|NCT00045747|stage IV pancreatic cancer
668679|NCT00045721|recurrent childhood cerebral astrocytoma
668680|NCT00045695|Waldenstrom macroglobulinemia
668681|NCT00045669|recurrent salivary gland cancer
668682|NCT00045669|salivary gland adenoid cystic carcinoma
668683|NCT00045669|stage III salivary gland cancer
668684|NCT00045669|stage IV salivary gland cancer
668685|NCT00045630|anterior urethral cancer
668686|NCT00045630|localized transitional cell cancer of the renal pelvis and ureter
668687|NCT00045630|posterior urethral cancer
668688|NCT00045630|stage II bladder cancer
668689|NCT00045630|stage III bladder cancer
668690|NCT00045630|transitional cell carcinoma of the bladder
668691|NCT00045630|urethral cancer associated with invasive bladder cancer
668692|NCT00045630|regional transitional cell cancer of the renal pelvis and ureter
668693|NCT00045617|limited stage small cell lung cancer
668694|NCT00045604|extensive stage small cell lung cancer
668695|NCT00045591|recurrent breast cancer
668696|NCT00045591|stage IV breast cancer
668697|NCT00045539|primary central nervous system non-Hodgkin lymphoma
668698|NCT00045513|refractory chronic lymphocytic leukemia
668699|NCT00045513|recurrent small lymphocytic lymphoma
668700|NCT00045500|anaplastic large cell lymphoma
668701|NCT00045500|angioimmunoblastic T-cell lymphoma
668702|NCT00045500|intraocular lymphoma
668703|NCT00045500|primary central nervous system non-Hodgkin lymphoma
668704|NCT00045500|recurrent adult Hodgkin lymphoma
668705|NCT00045500|recurrent adult T-cell leukemia/lymphoma
668706|NCT00045500|recurrent adult diffuse large cell lymphoma
668707|NCT00045500|recurrent adult diffuse mixed cell lymphoma
668708|NCT00045500|recurrent adult diffuse small cleaved cell lymphoma
668709|NCT00045500|recurrent adult immunoblastic large cell lymphoma
668710|NCT00045500|recurrent adult lymphoblastic lymphoma
668711|NCT00045500|recurrent cutaneous T-cell non-Hodgkin lymphoma
668712|NCT00045500|recurrent grade 1 follicular lymphoma
668713|NCT00045500|recurrent grade 2 follicular lymphoma
668714|NCT00045500|recurrent mantle cell lymphoma
668715|NCT00045500|unspecified adult solid tumor, protocol specific
668716|NCT00045500|recurrent adult Burkitt lymphoma
668717|NCT00045500|recurrent grade 3 follicular lymphoma
668718|NCT00045500|recurrent marginal zone lymphoma
668719|NCT00045500|recurrent small lymphocytic lymphoma
668720|NCT00045500|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
668721|NCT00045500|nodal marginal zone B-cell lymphoma
668722|NCT00045500|splenic marginal zone lymphoma
668723|NCT00045487|recurrent renal cell cancer
668724|NCT00045487|stage III renal cell cancer
668725|NCT00045487|stage IV renal cell cancer
668726|NCT00045474|adult anaplastic astrocytoma
668727|NCT00045474|adult anaplastic oligodendroglioma
668728|NCT00045474|adult glioblastoma
668729|NCT00045474|recurrent adult brain tumor
668730|NCT00045474|adult giant cell glioblastoma
668731|NCT00045474|adult gliosarcoma
668732|NCT00045461|recurrent ovarian epithelial cancer
668733|NCT00045461|recurrent fallopian tube cancer
668734|NCT00045461|stage IIIA fallopian tube cancer
668735|NCT00045461|stage IIIB fallopian tube cancer
668736|NCT00045461|stage IIIC fallopian tube cancer
668737|NCT00045461|stage IV fallopian tube cancer
668738|NCT00045461|recurrent primary peritoneal cavity cancer
668739|NCT00045461|stage IIIA primary peritoneal cavity cancer
668740|NCT00045461|stage IIIB primary peritoneal cavity cancer
668741|NCT00045461|stage IIIC primary peritoneal cavity cancer
668742|NCT00045461|stage IV primary peritoneal cavity cancer
668743|NCT00045461|stage IIIA ovarian epithelial cancer
668744|NCT00045461|stage IIIB ovarian epithelial cancer
668745|NCT00045461|stage IIIC ovarian epithelial cancer
668746|NCT00045461|stage IV ovarian epithelial cancer
668747|NCT00045448|unspecified adult solid tumor, protocol specific
668748|NCT00045422|chronic myelogenous leukemia, BCR-ABL1 positive
668749|NCT00045422|chronic phase chronic myelogenous leukemia
668750|NCT00045422|childhood chronic myelogenous leukemia
668751|NCT00045370|recurrent renal cell cancer
668752|NCT00045370|stage III renal cell cancer
668753|NCT00045370|stage IV renal cell cancer
668754|NCT00045357|recurrent melanoma
668755|NCT00045357|stage IV melanoma
668756|NCT00045331|recurrent prostate cancer
668757|NCT00045331|stage I prostate cancer
668758|NCT00045331|stage IIB prostate cancer
668759|NCT00045331|stage IIA prostate cancer
668760|NCT00045331|stage III prostate cancer
668761|NCT00045331|stage IV prostate cancer
668762|NCT00045318|unspecified adult solid tumor, protocol specific
668763|NCT00045305|chronic myelomonocytic leukemia
668764|NCT00045305|de novo myelodysplastic syndromes
668765|NCT00045305|previously treated myelodysplastic syndromes
668766|NCT00045305|refractory anemia
668767|NCT00045305|refractory anemia with excess blasts
668768|NCT00045305|refractory anemia with ringed sideroblasts
668769|NCT00045305|secondary myelodysplastic syndromes
668770|NCT00045305|atypical chronic myeloid leukemia, BCR-ABL1 negative
668771|NCT00045305|myelodysplastic/myeloproliferative neoplasm, unclassifiable
668772|NCT00045292|infection
668773|NCT00045292|accelerated phase chronic myelogenous leukemia
668774|NCT00045292|blastic phase chronic myelogenous leukemia
668775|NCT00045292|childhood chronic myelogenous leukemia
668776|NCT00045292|chronic phase chronic myelogenous leukemia
668777|NCT00045292|relapsing chronic myelogenous leukemia
668778|NCT00045292|adult acute lymphoblastic leukemia in remission
668779|NCT00045292|childhood acute lymphoblastic leukemia in remission
668780|NCT00045292|recurrent adult acute lymphoblastic leukemia
668781|NCT00045292|recurrent childhood acute lymphoblastic leukemia
668782|NCT00045292|untreated adult acute lymphoblastic leukemia
668783|NCT00045292|untreated childhood acute lymphoblastic leukemia
668784|NCT00045292|adult acute myeloid leukemia in remission
668785|NCT00045292|childhood acute myeloid leukemia in remission
668786|NCT00045292|recurrent adult acute myeloid leukemia
668787|NCT00045292|recurrent childhood acute myeloid leukemia
668788|NCT00045292|secondary acute myeloid leukemia
668789|NCT00045292|untreated adult acute myeloid leukemia
668790|NCT00045292|untreated childhood acute myeloid leukemia and other myeloid malignancies
668791|NCT00045292|atypical chronic myeloid leukemia
668792|NCT00045292|chronic eosinophilic leukemia
668793|NCT00045292|chronic idiopathic myelofibrosis
668794|NCT00045292|chronic neutrophilic leukemia
668795|NCT00045292|chronic myelomonocytic leukemia
668796|NCT00045292|juvenile myelomonocytic leukemia
668797|NCT00045292|de novo myelodysplastic syndromes
668798|NCT00045292|myelodysplastic/myeloproliferative disease, unclassifiable
668799|NCT00045292|previously treated myelodysplastic syndromes
668800|NCT00045292|secondary myelodysplastic syndromes
668801|NCT00045292|disseminated neuroblastoma
668802|NCT00045292|recurrent neuroblastoma
668803|NCT00045292|noncontiguous stage II adult diffuse large cell lymphoma
668804|NCT00045292|recurrent adult diffuse large cell lymphoma
668805|NCT00045292|stage III adult diffuse large cell lymphoma
668806|NCT00045292|stage IV adult diffuse large cell lymphoma
668807|NCT00045292|noncontiguous stage II adult Burkitt lymphoma
668808|NCT00045292|recurrent adult Burkitt lymphoma
668809|NCT00045292|stage III adult Burkitt lymphoma
668810|NCT00045292|stage IV adult Burkitt lymphoma
668811|NCT00045292|noncontiguous stage II adult diffuse mixed cell lymphoma
668812|NCT00045292|recurrent adult diffuse mixed cell lymphoma
668813|NCT00045292|stage III adult diffuse mixed cell lymphoma
668814|NCT00045292|stage IV adult diffuse mixed cell lymphoma
668815|NCT00045292|noncontiguous stage II adult diffuse small cleaved cell lymphoma
668816|NCT00045292|recurrent adult diffuse small cleaved cell lymphoma
668817|NCT00045292|stage III adult diffuse small cleaved cell lymphoma
668818|NCT00045292|stage IV adult diffuse small cleaved cell lymphoma
668819|NCT00045292|noncontiguous stage II adult immunoblastic large cell lymphoma
668820|NCT00045292|recurrent adult immunoblastic large cell lymphoma
668821|NCT00045292|stage III adult immunoblastic large cell lymphoma
668822|NCT00045292|stage IV adult immunoblastic large cell lymphoma
668823|NCT00045292|noncontiguous stage II adult lymphoblastic lymphoma
668824|NCT00045292|recurrent adult lymphoblastic lymphoma
668825|NCT00045292|recurrent childhood lymphoblastic lymphoma
668826|NCT00045292|stage III adult lymphoblastic lymphoma
668827|NCT00045292|stage IV adult lymphoblastic lymphoma
668828|NCT00045292|noncontiguous stage II grade 1 follicular lymphoma
668829|NCT00045292|noncontiguous stage II grade 2 follicular lymphoma
668830|NCT00045292|noncontiguous stage II grade 3 follicular lymphoma
668831|NCT00045292|recurrent grade 1 follicular lymphoma
668832|NCT00045292|recurrent grade 2 follicular lymphoma
668833|NCT00045292|recurrent grade 3 follicular lymphoma
668834|NCT00045292|stage III grade 1 follicular lymphoma
668835|NCT00045292|stage III grade 2 follicular lymphoma
668836|NCT00045292|stage III grade 3 follicular lymphoma
668837|NCT00045292|stage IV grade 1 follicular lymphoma
668838|NCT00045292|stage IV grade 2 follicular lymphoma
668839|NCT00045292|stage IV grade 3 follicular lymphoma
668840|NCT00045292|noncontiguous stage II mantle cell lymphoma
668841|NCT00045292|recurrent mantle cell lymphoma
668842|NCT00045292|stage III mantle cell lymphoma
668843|NCT00045292|stage IV mantle cell lymphoma
668844|NCT00045292|poor prognosis metastatic gestational trophoblastic tumor
668845|NCT00045292|previously treated childhood rhabdomyosarcoma
668846|NCT00045292|recurrent Wilms tumor and other childhood kidney tumors
668847|NCT00045292|recurrent adult Hodgkin lymphoma
668848|NCT00045292|recurrent/refractory childhood Hodgkin lymphoma
668849|NCT00045292|recurrent childhood rhabdomyosarcoma
668850|NCT00045292|recurrent childhood large cell lymphoma
668851|NCT00045292|recurrent childhood small noncleaved cell lymphoma
668852|NCT00045292|recurrent cutaneous T-cell non-Hodgkin lymphoma
668853|NCT00045292|recurrent mycosis fungoides/Sezary syndrome
668854|NCT00045292|recurrent ovarian epithelial cancer
668855|NCT00045292|recurrent ovarian germ cell tumor
668856|NCT00045292|stage II ovarian epithelial cancer
668857|NCT00045292|stage III ovarian epithelial cancer
668858|NCT00045292|stage IV ovarian epithelial cancer
668859|NCT00045292|recurrent malignant testicular germ cell tumor
668860|NCT00045292|stage III malignant testicular germ cell tumor
668861|NCT00045292|refractory chronic lymphocytic leukemia
668862|NCT00045292|stage III chronic lymphocytic leukemia
668863|NCT00045292|stage IV chronic lymphocytic leukemia
668864|NCT00045292|refractory hairy cell leukemia
668865|NCT00045292|refractory multiple myeloma
668866|NCT00045292|stage I multiple myeloma
668867|NCT00045292|stage II multiple myeloma
668868|NCT00045292|stage III multiple myeloma
668869|NCT00045292|stage IIIA breast cancer
668870|NCT00045292|stage IIIB breast cancer
668871|NCT00045292|stage IIIC breast cancer
668872|NCT00045292|stage IV breast cancer
668873|NCT00045292|noncontiguous stage II small lymphocytic lymphoma
668874|NCT00045292|noncontiguous stage II marginal zone lymphoma
668875|NCT00045292|recurrent marginal zone lymphoma
668876|NCT00045292|recurrent small lymphocytic lymphoma
668877|NCT00045292|stage III small lymphocytic lymphoma
668878|NCT00045292|stage III marginal zone lymphoma
668879|NCT00045292|stage IV small lymphocytic lymphoma
668880|NCT00045292|stage IV marginal zone lymphoma
668881|NCT00045292|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
668882|NCT00045292|nodal marginal zone B-cell lymphoma
668883|NCT00045292|splenic marginal zone lymphoma
668884|NCT00045292|childhood myelodysplastic syndromes
668885|NCT00045279|stage IV renal cell cancer
668886|NCT00045266|recurrent adult diffuse large cell lymphoma
668887|NCT00045266|recurrent adult diffuse mixed cell lymphoma
668888|NCT00045266|recurrent adult diffuse small cleaved cell lymphoma
668889|NCT00045266|recurrent adult Burkitt lymphoma
668890|NCT00045266|recurrent adult immunoblastic large cell lymphoma
668891|NCT00045266|recurrent adult lymphoblastic lymphoma
668892|NCT00045266|recurrent grade 1 follicular lymphoma
668893|NCT00045266|recurrent grade 2 follicular lymphoma
668894|NCT00045266|recurrent grade 3 follicular lymphoma
668895|NCT00045266|recurrent mantle cell lymphoma
668896|NCT00045266|stage IV adult diffuse large cell lymphoma
668897|NCT00045266|stage IV adult diffuse mixed cell lymphoma
668898|NCT00045266|stage IV adult diffuse small cleaved cell lymphoma
668899|NCT00045266|stage IV adult Burkitt lymphoma
668900|NCT00045266|stage IV adult immunoblastic large cell lymphoma
668901|NCT00045266|stage IV adult lymphoblastic lymphoma
668902|NCT00045266|stage IV grade 1 follicular lymphoma
668903|NCT00045266|stage IV grade 2 follicular lymphoma
668904|NCT00045266|stage IV grade 3 follicular lymphoma
668905|NCT00045266|stage IV mantle cell lymphoma
668906|NCT00045266|unspecified adult solid tumor, protocol specific
668907|NCT00045266|recurrent marginal zone lymphoma
668908|NCT00045266|recurrent small lymphocytic lymphoma
668909|NCT00045266|stage IV small lymphocytic lymphoma
668910|NCT00045266|stage IV marginal zone lymphoma
668911|NCT00045266|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
668912|NCT00045266|nodal marginal zone B-cell lymphoma
668913|NCT00045266|splenic marginal zone lymphoma
668914|NCT00045227|adenocarcinoma of the prostate
668915|NCT00045227|recurrent prostate cancer
668916|NCT00045227|stage IV prostate cancer
668917|NCT00045175|primary peritoneal cavity cancer
668918|NCT00045175|recurrent ovarian epithelial cancer
668919|NCT00045175|fallopian tube cancer
668920|NCT00045162|extensive stage small cell lung cancer
668921|NCT00045149|recurrent melanoma
668922|NCT00045149|stage IV melanoma
668923|NCT00045136|refractory multiple myeloma
668924|NCT00045136|stage I multiple myeloma
668925|NCT00045136|stage II multiple myeloma
668926|NCT00045136|stage III multiple myeloma
668927|NCT00045123|adenocarcinoma of the prostate
668928|NCT00045123|recurrent prostate cancer
668929|NCT00045097|male breast cancer
668930|NCT00045097|recurrent breast cancer
668931|NCT00045097|stage IIIB breast cancer
668932|NCT00045097|stage IIIC breast cancer
668933|NCT00045097|stage IV breast cancer
668934|NCT00045045|stage I malignant testicular germ cell tumor
668935|NCT00045045|testicular choriocarcinoma
668936|NCT00045045|testicular choriocarcinoma and embryonal carcinoma
668937|NCT00045045|testicular choriocarcinoma and seminoma
668938|NCT00045045|testicular choriocarcinoma and teratoma
668939|NCT00045045|testicular choriocarcinoma and yolk sac tumor
668940|NCT00045045|testicular embryonal carcinoma and seminoma
668941|NCT00045045|testicular embryonal carcinoma and teratoma with seminoma
668942|NCT00045045|testicular embryonal carcinoma and teratoma
668943|NCT00045045|testicular embryonal carcinoma and yolk sac tumor with seminoma
668944|NCT00045045|testicular embryonal carcinoma and yolk sac tumor
668945|NCT00045045|testicular embryonal carcinoma
668946|NCT00045045|testicular teratoma
668947|NCT00045045|testicular yolk sac tumor and teratoma with seminoma
668948|NCT00045045|testicular yolk sac tumor and teratoma
668949|NCT00045045|testicular yolk sac tumor
668950|NCT00045032|stage I breast cancer
668951|NCT00045032|stage II breast cancer
668952|NCT00045032|stage IIIA breast cancer
668953|NCT00045019|unspecified adult solid tumor, protocol specific
668954|NCT00045006|acute undifferentiated leukemia
668955|NCT00045006|de novo myelodysplastic syndromes
668956|NCT00045006|borderline ovarian surface epithelial-stromal tumor
668957|NCT00045006|ovarian sarcoma
668958|NCT00045006|ovarian stromal cancer
668959|NCT00045006|previously treated myelodysplastic syndromes
668960|NCT00045006|prolymphocytic leukemia
668961|NCT00045006|recurrent adult Hodgkin lymphoma
668962|NCT00045006|recurrent adult T-cell leukemia/lymphoma
668963|NCT00045006|recurrent adult acute lymphoblastic leukemia
668964|NCT00045006|recurrent adult acute myeloid leukemia
668965|NCT00045006|recurrent adult diffuse large cell lymphoma
668966|NCT00045006|recurrent adult diffuse small cleaved cell lymphoma
668967|NCT00045006|recurrent adult diffuse mixed cell lymphoma
668968|NCT00045006|recurrent bladder cancer
668969|NCT00045006|recurrent breast cancer
668970|NCT00045006|recurrent cutaneous T-cell non-Hodgkin lymphoma
668971|NCT00045006|recurrent grade 1 follicular lymphoma
668972|NCT00045006|recurrent grade 2 follicular lymphoma
668973|NCT00045006|recurrent grade 3 follicular lymphoma
669168|NCT00044681|melancholia
668974|NCT00045006|recurrent metastatic squamous neck cancer with occult primary
668975|NCT00045006|recurrent mycosis fungoides/Sezary syndrome
668976|NCT00045006|recurrent non-small cell lung cancer
668977|NCT00045006|recurrent ovarian epithelial cancer
668978|NCT00045006|recurrent ovarian germ cell tumor
668979|NCT00045006|recurrent prostate cancer
668980|NCT00045006|recurrent renal cell cancer
668981|NCT00045006|refractory chronic lymphocytic leukemia
668982|NCT00045006|refractory hairy cell leukemia
668983|NCT00045006|refractory multiple myeloma
668984|NCT00045006|relapsing chronic myelogenous leukemia
668985|NCT00045006|secondary acute myeloid leukemia
668986|NCT00045006|secondary myelodysplastic syndromes
668987|NCT00045006|stage III multiple myeloma
668988|NCT00045006|stage III mycosis fungoides/Sezary syndrome
668989|NCT00045006|stage III ovarian germ cell tumor
668990|NCT00045006|stage IV mycosis fungoides/Sezary syndrome
668991|NCT00045006|stage IV ovarian germ cell tumor
668992|NCT00045006|unspecified adult solid tumor, protocol specific
668993|NCT00045006|stage III adult Hodgkin lymphoma
668994|NCT00045006|stage IV adult Hodgkin lymphoma
668995|NCT00045006|stage III adult T-cell leukemia/lymphoma
668996|NCT00045006|stage IV adult T-cell leukemia/lymphoma
668997|NCT00045006|stage III adult diffuse large cell lymphoma
668998|NCT00045006|stage III adult diffuse mixed cell lymphoma
668999|NCT00045006|stage III adult diffuse small cleaved cell lymphoma
669000|NCT00045006|stage IV adult diffuse large cell lymphoma
669001|NCT00045006|stage IV adult diffuse mixed cell lymphoma
669002|NCT00045006|stage IV adult diffuse small cleaved cell lymphoma
669003|NCT00045006|stage III bladder cancer
669004|NCT00045006|stage IV bladder cancer
669005|NCT00045006|stage IIIA breast cancer
669006|NCT00045006|stage IIIB breast cancer
669007|NCT00045006|stage IIIC breast cancer
669008|NCT00045006|stage IV breast cancer
669009|NCT00045006|stage III cutaneous T-cell non-Hodgkin lymphoma
669010|NCT00045006|stage IV cutaneous T-cell non-Hodgkin lymphoma
669011|NCT00045006|stage III grade 1 follicular lymphoma
669012|NCT00045006|stage III grade 2 follicular lymphoma
669013|NCT00045006|stage III grade 3 follicular lymphoma
669014|NCT00045006|stage IV grade 1 follicular lymphoma
669015|NCT00045006|stage IV grade 2 follicular lymphoma
669016|NCT00045006|stage IV grade 3 follicular lymphoma
669017|NCT00045006|stage IIIA non-small cell lung cancer
669018|NCT00045006|stage IIIB non-small cell lung cancer
669019|NCT00045006|stage IV non-small cell lung cancer
669020|NCT00045006|stage III oropharyngeal cancer
669021|NCT00045006|stage IV oropharyngeal cancer
669022|NCT00045006|stage III ovarian epithelial cancer
669023|NCT00045006|stage IV ovarian epithelial cancer
669024|NCT00045006|stage III prostate cancer
669025|NCT00045006|stage IV prostate cancer
669026|NCT00045006|stage III renal cell cancer
669027|NCT00045006|stage IV renal cell cancer
669028|NCT00045006|stage III chronic lymphocytic leukemia
669029|NCT00045006|stage IV chronic lymphocytic leukemia
669030|NCT00045006|recurrent salivary gland cancer
669031|NCT00045006|stage IV salivary gland cancer
669032|NCT00045006|stage III salivary gland cancer
669033|NCT00045006|recurrent squamous cell carcinoma of the hypopharynx
669034|NCT00045006|stage III squamous cell carcinoma of the hypopharynx
669035|NCT00045006|stage IV squamous cell carcinoma of the hypopharynx
669036|NCT00045006|recurrent squamous cell carcinoma of the larynx
669037|NCT00045006|recurrent verrucous carcinoma of the larynx
669038|NCT00045006|stage III squamous cell carcinoma of the larynx
669039|NCT00045006|stage III verrucous carcinoma of the larynx
669040|NCT00045006|stage IV squamous cell carcinoma of the larynx
669041|NCT00045006|stage IV verrucous carcinoma of the larynx
669042|NCT00045006|recurrent squamous cell carcinoma of the lip and oral cavity
669043|NCT00045006|stage III squamous cell carcinoma of the lip and oral cavity
669044|NCT00045006|stage IV squamous cell carcinoma of the lip and oral cavity
669045|NCT00045006|recurrent lymphoepithelioma of the nasopharynx
669046|NCT00045006|recurrent squamous cell carcinoma of the nasopharynx
669047|NCT00045006|stage III lymphoepithelioma of the nasopharynx
669048|NCT00045006|stage III squamous cell carcinoma of the nasopharynx
669049|NCT00045006|stage IV lymphoepithelioma of the nasopharynx
669050|NCT00045006|stage IV squamous cell carcinoma of the nasopharynx
669051|NCT00045006|recurrent lymphoepithelioma of the oropharynx
669052|NCT00045006|recurrent squamous cell carcinoma of the oropharynx
669053|NCT00045006|stage III lymphoepithelioma of the oropharynx
669054|NCT00045006|stage III squamous cell carcinoma of the oropharynx
669055|NCT00045006|stage IV lymphoepithelioma of the oropharynx
669056|NCT00045006|stage IV squamous cell carcinoma of the oropharynx
669057|NCT00045006|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
669058|NCT00045006|recurrent inverted papilloma of the paranasal sinus and nasal cavity
669059|NCT00045006|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
669060|NCT00045006|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
669061|NCT00045006|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
669062|NCT00045006|stage III inverted papilloma of the paranasal sinus and nasal cavity
669063|NCT00045006|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
669169|NCT00044681|depressive disorder
669064|NCT00045006|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
669065|NCT00045006|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
669066|NCT00045006|stage IV inverted papilloma of the paranasal sinus and nasal cavity
669067|NCT00045006|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
669068|NCT00045006|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
669069|NCT00045006|recurrent basal cell carcinoma of the lip
669070|NCT00045006|stage III basal cell carcinoma of the lip
669071|NCT00045006|stage IV basal cell carcinoma of the lip
669072|NCT00045006|recurrent mucoepidermoid carcinoma of the oral cavity
669073|NCT00045006|stage III mucoepidermoid carcinoma of the oral cavity
669074|NCT00045006|stage IV mucoepidermoid carcinoma of the oral cavity
669075|NCT00045006|recurrent adenoid cystic carcinoma of the oral cavity
669076|NCT00045006|stage III adenoid cystic carcinoma of the oral cavity
669077|NCT00045006|stage IV adenoid cystic carcinoma of the oral cavity
669078|NCT00045006|recurrent verrucous carcinoma of the oral cavity
669079|NCT00045006|stage III verrucous carcinoma of the oral cavity
669080|NCT00045006|stage IV verrucous carcinoma of the oral cavity
669081|NCT00045006|atypical chronic myeloid leukemia, BCR-ABL1 negative
669082|NCT00045006|myelodysplastic/myeloproliferative neoplasm, unclassifiable
669083|NCT00045006|male breast cancer
669084|NCT00044993|male breast cancer
669085|NCT00044993|stage IIIA breast cancer
669086|NCT00044993|stage IIIB breast cancer
669087|NCT00044993|stage IIIC breast cancer
669088|NCT00044993|stage IV breast cancer
669089|NCT00044980|malnutrition
669090|NCT00044980|stage I prostate cancer
669091|NCT00044980|stage II B prostate cancer
669092|NCT00044980|stage II A prostate cancer
669093|NCT00044967|stage I colon cancer
669094|NCT00044967|stage II colon cancer
669095|NCT00044967|stage III colon cancer
669096|NCT00044967|stage I rectal cancer
669097|NCT00044967|stage II rectal cancer
669098|NCT00044967|stage III rectal cancer
669099|NCT00044967|adenocarcinoma of the colon
669100|NCT00044967|adenocarcinoma of the rectum
669101|NCT00044954|recurrent adult Hodgkin lymphoma
669102|NCT00044954|stage I multiple myeloma
669103|NCT00044954|stage II multiple myeloma
669104|NCT00044954|stage III multiple myeloma
669105|NCT00044954|chronic phase chronic myelogenous leukemia
669106|NCT00044954|accelerated phase chronic myelogenous leukemia
669107|NCT00044954|adult acute myeloid leukemia in remission
669108|NCT00044954|recurrent grade 3 follicular lymphoma
669109|NCT00044954|recurrent adult diffuse large cell lymphoma
669110|NCT00044954|de novo myelodysplastic syndromes
669111|NCT00044954|previously treated myelodysplastic syndromes
669112|NCT00044954|secondary myelodysplastic syndromes
669113|NCT00044954|recurrent mantle cell lymphoma
669114|NCT00044954|stage III mantle cell lymphoma
669115|NCT00044954|stage IV mantle cell lymphoma
669116|NCT00044954|refractory multiple myeloma
669117|NCT00044954|stage I mantle cell lymphoma
669118|NCT00044954|contiguous stage II mantle cell lymphoma
669119|NCT00044954|noncontiguous stage II mantle cell lymphoma
669120|NCT00044954|atypical chronic myeloid leukemia
669121|NCT00044954|myelodysplastic/myeloproliferative disease, unclassifiable
669122|NCT00044954|refractory chronic lymphocytic leukemia
669123|NCT00044954|adult acute myeloid leukemia with t(8;21)(q22;q22)
669124|NCT00044954|adult acute myeloid leukemia with t(16;16)(p13;q22)
669125|NCT00044954|adult acute myeloid leukemia with inv(16)(p13;q22)
669126|NCT00044954|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
669127|NCT00044954|adult acute myeloid leukemia with t(15;17)(q22;q12)
669128|NCT00044928|Abdominal Infections
669129|NCT00044915|Acute Ischemic Stroke Without Hemorrhage
669130|NCT00044889|CLO221
669131|NCT00044889|clolar
669132|NCT00044876|Endometrium
669133|NCT00044876|Progesterone
669134|NCT00044876|Estrogen
669135|NCT00044876|Leiomyoma
669136|NCT00044876|Uterine Leiomyoma
669137|NCT00044876|Uterine Fibroids
669138|NCT00044876|Fibroids
669139|NCT00044863|EGFr
669140|NCT00044863|Metastatic Colorectal Carcinoma
669141|NCT00044837|Lopinavir
669142|NCT00044837|HIV-1
669143|NCT00044837|HIV Protease Inhibitors
669144|NCT00044837|Ritonavir
669145|NCT00044837|Postmenopause
669146|NCT00044837|Reverse Transcriptase Inhibitors
669147|NCT00044837|Pharmacokinetics
669148|NCT00044837|Area Under Curve
669149|NCT00044837|Hormone Replacement Therapy
669150|NCT00044837|efavirenz
669151|NCT00044837|estradiol
669152|NCT00044798|Aged
669153|NCT00044785|colorectal cancer
669154|NCT00044785|gastric cancer
669155|NCT00044785|breast cancer
669156|NCT00044772|Panic
669157|NCT00044772|Disorder
669158|NCT00044759|Hematologic
669159|NCT00044759|Neoplasms
669160|NCT00044746|Diabetes
669161|NCT00044733|Leukemia
669162|NCT00044733|Stem Cell Transplant
669163|NCT00044720|Kidney Transplant
669164|NCT00044707|Diabetes Mellitus, Type 2
669165|NCT00044694|Diabetes Mellitus, Type 2
669166|NCT00044681|Risperidone
669167|NCT00044681|depression
669170|NCT00044681|antipsychotic agents
669171|NCT00044668|exenatide
669172|NCT00044668|exendin-4
669173|NCT00044668|diabetes
669174|NCT00044668|Amylin
669175|NCT00044668|Lilly
669176|NCT00044642|Anxiety
669177|NCT00044629|Sleep Deprivation
669178|NCT00044629|Insomnia
669179|NCT00044629|Sleep Disorders
669180|NCT00044603|Pregnancy
669181|NCT00044590|Parkinson's disease
669182|NCT00044590|Pesticides
669183|NCT00044590|Genetic susceptibility
669184|NCT00044590|Polymorphisms
669185|NCT00044577|HIV-1 Abacavir Lamivudine Tenofovir
669186|NCT00044564|Taxane
669187|NCT00044564|Renal Cell Carcinoma
669188|NCT00044564|Advanced Renal Cell Carcinoma
669189|NCT00044551|Taxane
669190|NCT00044551|Lymphoma
669191|NCT00044551|Non-Hodgkin's Lymphoma
669192|NCT00044538|Taxane
669193|NCT00044538|Lung cancer, non-small cell
669194|NCT00044538|NSCLC
669195|NCT00044525|Taxane
669196|NCT00044525|Breast Cancer
669197|NCT00044525|Metastasis
669198|NCT00044512|Cancer
669199|NCT00044512|Liver Cancer
669200|NCT00044512|Hepatocellular carcinoma (HCC)
669201|NCT00044486|Prophylaxis
669202|NCT00044486|neutropenia
669203|NCT00044486|AML
669204|NCT00044486|MDS
669205|NCT00044486|fungal infections
669206|NCT00044486|Acute Myelogenous Leukemia
669207|NCT00044486|Anticipated prolonged profound neutropenia
669208|NCT00044473|Otitis Media
669209|NCT00044473|Ear Diaeases
669210|NCT00044473|Levofloxacin
669211|NCT00044473|Quinolones
669212|NCT00044460|Type 2 diabetes drug-naive
669213|NCT00044382|Revimid
669214|NCT00044382|CC5013
669215|NCT00044382|CC-5013
669216|NCT00044369|Varicocele
669217|NCT00044369|environmental toxins
669218|NCT00044369|male infertility
669219|NCT00044369|cadmium
669220|NCT00044356|Melanoma
669221|NCT00044356|Metastatic Melanoma
669222|NCT00044356|Malignant Melanoma
669223|NCT00044356|Skin Cancer
669224|NCT00044356|Tumor
669225|NCT00044356|Experimental Treatment
669226|NCT00044356|Clinical Trial
669227|NCT00044356|Gene Therapy
669228|NCT00044356|Gene Delivery
669229|NCT00044356|Gene Transfer
669230|NCT00044356|Immunotherapy
669231|NCT00044356|Cancer
669232|NCT00044356|Neoplasm
669233|NCT00044356|Lesion
669234|NCT00044356|Metastasis
669235|NCT00044356|Cancerous mole
669236|NCT00044356|Melanoma vaccine
669237|NCT00044356|Cancer research
669238|NCT00044356|Cancer cells
669239|NCT00044356|Allovectin-7®
669240|NCT00044343|colorectal cancer
669241|NCT00044343|EGFR inhibitor
669242|NCT00044343|lapatinib
669243|NCT00044343|metastatic
669244|NCT00044317|FEV
669245|NCT00044317|Smoking
669246|NCT00044317|antioxidents
669247|NCT00044317|lung growth
669248|NCT00044304|Treatment
669249|NCT00044304|Eosinophil
669250|NCT00044304|Tyrosine Kinase Inhibitor
669251|NCT00044304|Hypereosinophilia
669252|NCT00044304|Biologicals
669253|NCT00044304|Chemotherapy
669254|NCT00044304|Gleevec
669255|NCT00044304|Eosinophils
669256|NCT00044304|Hypereosinophilic Syndrome
669257|NCT00044304|HES
669258|NCT00044291|Atamestane
669259|NCT00044291|Toremifene
669260|NCT00044291|Letrozole
669261|NCT00044291|Aromatase inhibitor
669262|NCT00044291|Receptor-positive
669263|NCT00044291|First line therapy
669264|NCT00044291|Estrogen blocker
669265|NCT00044291|Metastatic breast cancer
669266|NCT00044291|Locally advanced breast cancer
669267|NCT00044291|Locally recurrent breast cancer
669268|NCT00044291|stage IV breast cancer
669269|NCT00044291|ductal breast carcinoma
669270|NCT00044291|lobular breast carcinoma
669271|NCT00044291|stage IIIA breast cancer
669272|NCT00044291|stage IIIB breast cancer
669273|NCT00044291|recurrent breast cancer
669274|NCT00044278|epilepsy
669275|NCT00044278|pediatric
669276|NCT00044278|partial seizures
669277|NCT00044265|ACE inhibitor
669278|NCT00044265|high blood pressure
669279|NCT00044265|pediatric
669280|NCT00044252|Neurosteroids
669281|NCT00044252|Complex Partial Seizure
669282|NCT00044252|Menstrual Cycle
669283|NCT00044252|Allopregnanolone
669284|NCT00044252|Catamenial Epilepsy
669285|NCT00044252|Seizures
669286|NCT00044252|Epilepsy
669287|NCT00044252|Healthy Volunteer
669288|NCT00044252|HV
669289|NCT00044252|Normal Control
669290|NCT00044239|Tic Disorders
669291|NCT00044239|Neurophyschological
669292|NCT00044239|Immunology
669293|NCT00044239|Magnetic Resonance Imaging
669294|NCT00044239|Basal Ganglia
669295|NCT00044239|Obsessive-Compulsive Disorder
669296|NCT00044239|Children
669297|NCT00044239|Adolescents
669298|NCT00044239|Magnetic Resonance Spectroscopy
669431|NCT00043862|limited stage
669299|NCT00044239|PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated d
669300|NCT00044239|Obsessive Compulsive Disorder
669301|NCT00044239|OCD
669302|NCT00044239|Healthy Volunteers
669303|NCT00044239|HV
669304|NCT00044226|BPH
669305|NCT00044226|Benign Prostatic Hyperplasia
669306|NCT00044226|Benign Prostatic Hypertrophy
669307|NCT00044226|Enlarged Prostate
669308|NCT00044200|Phospholipase A2
669309|NCT00044200|Arachidonic Acid
669310|NCT00044200|Blood Flow
669311|NCT00044200|Coupling
669312|NCT00044200|Neurotransmission
669313|NCT00044200|PET
669314|NCT00044200|Signal Transduction
669315|NCT00044200|Activation
669316|NCT00044200|Brain
669317|NCT00044200|[15O]H20
669318|NCT00044187|schizoaffective disorder
669319|NCT00044187|schizophreniform disorder
669320|NCT00044187|bipolar I disorder
669321|NCT00044174|Depression
669322|NCT00044174|Mother-Infant Interaction
669323|NCT00044174|Still-face
669324|NCT00044174|Socioemotional Development
669325|NCT00044174|Cognitive Development
669326|NCT00044174|Healthy
669327|NCT00044174|Mothers
669328|NCT00044174|Postpartum
669329|NCT00044174|Postpartum Depression
669330|NCT00044148|Persistent Albuminuria
669331|NCT00044135|clevudine
669332|NCT00044135|hepatitis B
669333|NCT00044122|Mastocytosis
669334|NCT00044122|Urticaria Pigmentosa
669335|NCT00044122|Classification
669336|NCT00044122|Tryptase
669337|NCT00044122|Mutations
669338|NCT00044109|Pain
669339|NCT00044109|Low Back
669340|NCT00044109|Radiculopathy
669341|NCT00044109|Electromagnetic Treatment
669342|NCT00044109|Back Device
669343|NCT00044109|Sciatica
669344|NCT00044109|Low Back Pain
669345|NCT00044096|SSRI
669346|NCT00044096|Anxiety
669347|NCT00044096|Stress
669348|NCT00044096|Citalopram
669349|NCT00044096|Benadryl
669350|NCT00044096|Diphenhydramine
669351|NCT00044096|Startle
669352|NCT00044096|Fear-Potentiated Startle
669353|NCT00044096|Fear
669354|NCT00044096|Normal Volunteers
669355|NCT00044096|Healthy Volunteers
669356|NCT00044096|HV
669357|NCT00044083|Catecholamines
669358|NCT00044083|Dopamine
669359|NCT00044083|Clinical Trial
669360|NCT00044083|fMRI
669361|NCT00044083|PFC
669362|NCT00044083|Vitamin B2
669363|NCT00044083|Riboflavin
669364|NCT00044083|Tolcapone
669365|NCT00044083|Placebo
669366|NCT00044083|Normal Volunteers
669367|NCT00044083|Schizophrenia
669368|NCT00044083|Healthy Volunteers
669369|NCT00044083|HV
669370|NCT00044070|ARTIST
669371|NCT00044070|Acute ischemic stroke
669372|NCT00044057|ARTIST
669373|NCT00044044|Schizophrenia
669374|NCT00044044|Latuda
669375|NCT00044044|Lurasidone
669376|NCT00044031|pancreatic cancer
669377|NCT00044031|G17DT
669378|NCT00044031|gemcitabine
669379|NCT00044018|Revimid
669380|NCT00044018|CC5013
669381|NCT00044005|Schizophrenia
669382|NCT00044005|Latuda
669383|NCT00044005|Lurasidone
669384|NCT00043992|Asthma
669385|NCT00043992|Allergens
669386|NCT00043979|Ewing's Sarcoma
669387|NCT00043979|Rhabdomyosarcoma
669388|NCT00043979|Desmoplastic Small Round Cell Tumor
669389|NCT00043979|Sarcoma
669390|NCT00043979|Ewing Sarcoma
669391|NCT00043966|treatment naive
669392|NCT00043953|treatment naive
669393|NCT00043940|thrombosis
669394|NCT00043940|bivalirudin
669395|NCT00043940|direct thrombin inhibitor
669396|NCT00043940|HIT
669397|NCT00043940|HITTS
669398|NCT00043940|HIT/HITTS
669399|NCT00043927|Chemotherapy-naive
669400|NCT00043927|Small Cell Lung Cancer
669401|NCT00043927|SCLC
669402|NCT00043927|Extensive disease
669403|NCT00043927|ED
669404|NCT00043927|topotecan
669405|NCT00043927|Hycamtin
669406|NCT00043927|oral
669407|NCT00043914|epilepsy
669408|NCT00043914|monotherapy conversion
669409|NCT00043901|PGTC
669410|NCT00043901|Lamotrigine
669411|NCT00043901|epilepsy
669412|NCT00043901|seizures
669413|NCT00043901|primary generalized tonic-clonic
669414|NCT00043888|fosamprenavir
669415|NCT00043888|ritonavir
669416|NCT00043888|COMBIVIR
669417|NCT00043888|TRIZIVIR
669418|NCT00043888|abacavir
669419|NCT00043888|lamivudine
669420|NCT00043888|zidovudine
669421|NCT00043888|HIV
669422|NCT00043888|protease inhibitors
669423|NCT00043875|partial seizures
669424|NCT00043875|pediatric
669425|NCT00043875|epilepsy
669426|NCT00043862|Hycamtin
669427|NCT00043862|oral
669428|NCT00043862|Radiation Sensitization
669429|NCT00043862|Small Cell Lung Cancer
669430|NCT00043862|newly diagnosed
669432|NCT00043862|topotecan
669433|NCT00043849|Psychosis
669434|NCT00043849|Agitation, Psychomotor
669435|NCT00043836|ejection fraction
669436|NCT00043836|exercise tolerance
669437|NCT00043836|heart failure, congestive
669438|NCT00043836|quality of life
669439|NCT00043823|Non-Small Cell Lung Cancer
669440|NCT00043823|NSCLC
669441|NCT00043823|Lung Cancer
669442|NCT00043823|Avastin
669443|NCT00043823|Bevacizumab
669444|NCT00043823|rhuMAb VEGF
669445|NCT00043823|Anti-VEGF monoclonal antibody
669446|NCT00043823|Tarceva
669447|NCT00043823|OSI-774
669448|NCT00043823|Erlotinib Hydrocholoride
669449|NCT00043810|AML
669450|NCT00043810|MDS
669451|NCT00043810|Gelonin
669452|NCT00043810|Purging
669453|NCT00043810|Transplant
669454|NCT00043810|Peripheral Stem Cell
669455|NCT00043797|ARI
669456|NCT00043797|Diabetic polyneuropathy
669457|NCT00043797|Diabetic complications
669458|NCT00043784|Acute coronary syndromes
669459|NCT00043784|non-ST-segment elevation
669460|NCT00043771|CHF
669461|NCT00043758|CHF
669462|NCT00043745|soy
669463|NCT00043745|isoflavones
669464|NCT00043745|alternative hormone therapy
669465|NCT00043745|bone loss
669466|NCT00043732|Rheumatoid arthritis
669467|NCT00043732|Scio-469
669468|NCT00043719|Human Female
669469|NCT00043719|Osteoporosis
669470|NCT00043719|Postmenopausal
669471|NCT00043719|Nitric Oxide
669472|NCT00043719|Nitroglycerin
669473|NCT00043719|Calcium
669474|NCT00043719|Vitamin D
669475|NCT00043693|Psychotic Disorders
669476|NCT00043693|Schizoaffective Disorder
669477|NCT00043693|Substance Abuse
669478|NCT00043680|Classic
669479|NCT00043680|Occult
669480|NCT00043680|Neovascular
669481|NCT00043680|Celecoxib
669482|NCT00043680|Age-Related Macular Degeneration
669483|NCT00043680|Photodynamic Therapy
669484|NCT00043680|Choroidal Neovascularization
669485|NCT00043680|Cyclooxygenase 2
669486|NCT00043680|Macular Degeneration
669487|NCT00043680|AMD
669488|NCT00043680|Age Related Macular Degeneration
669489|NCT00043667|Interleukin 2
669490|NCT00043667|IL-2 Receptor
669491|NCT00043667|Anti-CD25
669492|NCT00043667|Anti-Tac
669493|NCT00043667|Anti-IL-2R
669494|NCT00043667|Uveitis
669495|NCT00043667|Daclizumab
669496|NCT00043667|Inflammatory Eye DIsease
669497|NCT00043654|Antidepressant
669498|NCT00043654|Manic-Depressive Disorder
669499|NCT00043654|Cortisol
669500|NCT00043654|Neuroendocrine
669501|NCT00043654|Cognition
669502|NCT00043654|Bipolar
669503|NCT00043654|Bipolar Disorder
669504|NCT00043654|BPD
669505|NCT00043654|HV
669506|NCT00043641|RT PCR
669507|NCT00043641|Antiretrovial Therapy
669508|NCT00043641|Drug Intensification
669509|NCT00043641|Ultra-low
669510|NCT00043641|Sequence
669511|NCT00043641|HIV
669512|NCT00043641|Treatment Experienced
669513|NCT00043628|Progenitor Cells
669514|NCT00043628|MRI
669515|NCT00043628|Coronary Blood Flow
669516|NCT00043628|Hematopoiesis
669517|NCT00043628|Myocardial Contractility
669518|NCT00043628|Coronary Artery Disease
669519|NCT00043628|CAD
669520|NCT00043628|Heart Disease
669521|NCT00043615|Angiogenesis
669522|NCT00043615|Drug Resistance
669523|NCT00043615|Signal Transduction
669524|NCT00043615|EGFR
669525|NCT00043615|Survival Factors
669526|NCT00043615|Malignancy
669527|NCT00043615|Pre-Cancer Condition
669528|NCT00043615|Cancer Risk
669529|NCT00043589|Memory
669530|NCT00043576|Prostate Cancer
669531|NCT00043576|Androgen Independent Prostate Cancer
669532|NCT00043563|Cognitive-behavior Therapy
669533|NCT00043563|Minimal Attention Control
669534|NCT00043550|Major Depressive Disorder
669535|NCT00043537|Phobic Disorders
669536|NCT00043537|Mutism
669537|NCT00043511|Injections, Intramuscular
669538|NCT00043511|HIV Seronegativity
669539|NCT00043511|Plasmids
669540|NCT00043511|Vaccines, DNA
669541|NCT00043511|HIV Preventive Vaccine
669542|NCT00043498|Pollutants
669543|NCT00043472|Screening
669544|NCT00043472|Oophorectomy
669545|NCT00043472|Hereditary
669546|NCT00043472|Genetics
669547|NCT00043472|Cancer
669548|NCT00043472|Ovarian Cancer
669549|NCT00043472|Ovarian Cancer Risk
669550|NCT00043459|NHL
669551|NCT00043433|HCC
669552|NCT00043420|immunotherapy, lymphoma
669553|NCT00043407|Renal Cell Carcinoma, Phase I, Phase II, Immunotherapy
669554|NCT00043394|CpG 7909 subcutaneous injection combination with Herceptin® metastatic breast cancer.
669555|NCT00043381|myelodysplastic syndrome
669556|NCT00043381|MDS
669557|NCT00043381|chronic myelomonocytic leukemia
669558|NCT00043381|CMML
669559|NCT00043381|decitabine
669560|NCT00043381|5-aza-2'deoxycytidine
669561|NCT00043368|CPG 7909 continuation study
669562|NCT00043355|pulmonary
669563|NCT00043355|mycobacterium avium complex infection
669564|NCT00043355|MAC
669565|NCT00043355|nontuberculous
669566|NCT00043355|mycobacteria
669567|NCT00043355|lung
669568|NCT00043342|cystic fibrosis
669569|NCT00043342|pulmonary impairment
669570|NCT00043329|Registry
669571|NCT00043329|Actimmune
669572|NCT00043329|osteopetrosis
669573|NCT00043316|cystic fibrosis
669574|NCT00043316|pulmonary impairment
669575|NCT00043303|hepatitis C
669576|NCT00043303|liver fibrosis
669577|NCT00043303|liver cirrhosis
669578|NCT00043277|neonates
669579|NCT00043277|thrombosis
669580|NCT00043277|bivalirudin
669581|NCT00043277|direct thrombin inhibitor
669582|NCT00043238|PCBs
669583|NCT00043238|Thyroid
669584|NCT00043238|Hyperactivity
669585|NCT00043238|School Performance
669586|NCT00043238|Mohawk Tribe
669587|NCT00043225|Type III Secretion Pathways
669588|NCT00043225|Exotoxin A Polymorphisms
669589|NCT00043225|Cystic Fibrosis and Pseudomonas Aeruginosa
669590|NCT00043225|Adenosine Deaminase Deficiency
669591|NCT00043225|Severe Combined Immune Deficiency
669592|NCT00043225|SCID
669593|NCT00043225|ADA-SCID
669594|NCT00043225|Immune Deficiency
669595|NCT00043212|prostate cancer
669596|NCT00043212|oncology
669597|NCT00043212|urology
669598|NCT00043212|hormone refractory prostate cancer
669599|NCT00043199|Colorectal Neoplasms
669600|NCT00043199|Colorectal Cancer
669601|NCT00043199|Colorectal Carcinoma
669602|NCT00043199|Colorectal Tumor
669603|NCT00043199|Neoplasms, Colorectal
669604|NCT00043199|Unresectable
669605|NCT00043199|Metastatic
669606|NCT00043199|Refractory
669607|NCT00043186|bone loss
669608|NCT00043186|osteoporosis
669609|NCT00043147|graft versus host disease
669610|NCT00043134|chronic myelomonocytic leukemia
669611|NCT00043134|de novo myelodysplastic syndromes
669612|NCT00043134|previously treated myelodysplastic syndromes
669613|NCT00043134|refractory anemia
669614|NCT00043134|refractory anemia with excess blasts
669615|NCT00043134|refractory anemia with excess blasts in transformation
669616|NCT00043134|refractory anemia with ringed sideroblasts
669617|NCT00043134|refractory cytopenia with multilineage dysplasia
669618|NCT00043134|secondary myelodysplastic syndromes
669619|NCT00043134|atypical chronic myeloid leukemia, BCR-ABL negative
669620|NCT00043134|myelodysplastic/myeloproliferative neoplasm, unclassifiable
669621|NCT00043108|stage II non-small cell lung cancer
669622|NCT00043108|stage IIIA non-small cell lung cancer
669623|NCT00043108|stage IIIB non-small cell lung cancer
669624|NCT00043095|unspecified adult solid tumor, protocol specific
669625|NCT00043082|peritoneal cavity cancer
669626|NCT00043082|recurrent ovarian epithelial cancer
669627|NCT00043082|stage III ovarian epithelial cancer
669628|NCT00043082|stage IV ovarian epithelial cancer
669629|NCT00043069|osteoporosis
669630|NCT00043069|stage I prostate cancer
669631|NCT00043069|stage IIB prostate cancer
669632|NCT00043069|stage IIA prostate cancer
669633|NCT00043069|stage III prostate cancer
669634|NCT00043043|colorectal cancer
669635|NCT00043030|psychosocial effects of cancer and its treatment
669636|NCT00043030|unspecified adult solid tumor, protocol specific
669637|NCT00043017|stage IIIA breast cancer
669638|NCT00043017|stage IIIB breast cancer
669639|NCT00043017|stage IIIC breast cancer
669640|NCT00043004|liver metastases
669641|NCT00043004|stage IV colon cancer
669642|NCT00043004|stage IV rectal cancer
669643|NCT00042965|recurrent renal cell cancer
669644|NCT00042965|stage IV renal cell cancer
669645|NCT00042939|pancreatic cancer
669646|NCT00042939|metastatic pancreatic cancer
669647|NCT00042939|EGF-r
669648|NCT00042939|irinotecan
669649|NCT00042939|docetaxel
669650|NCT00042939|cetuximab
669651|NCT00042926|stage I squamous cell carcinoma of the lip and oral cavity
669652|NCT00042926|stage II squamous cell carcinoma of the lip and oral cavity
669653|NCT00042913|recurrent adult diffuse large cell lymphoma
669654|NCT00042900|AIDS-related peripheral/systemic lymphoma
669655|NCT00042900|AIDS-related primary CNS lymphoma
669656|NCT00042900|T-cell large granular lymphocyte leukemia
669657|NCT00042900|Waldenström macroglobulinemia
669658|NCT00042900|accelerated phase chronic myelogenous leukemia
669659|NCT00042900|acute undifferentiated leukemia
669660|NCT00042900|adult acute lymphoblastic leukemia in remission
669661|NCT00042900|adult acute myeloid leukemia in remission
669662|NCT00042900|primary myelofibrosis
669663|NCT00042900|anaplastic large cell lymphoma
669664|NCT00042900|angioimmunoblastic T-cell lymphoma
669665|NCT00042900|blastic phase chronic myelogenous leukemia
669666|NCT00042900|chronic myelomonocytic leukemia
669667|NCT00042900|chronic phase chronic myelogenous leukemia
669668|NCT00042900|de novo myelodysplastic syndromes
669669|NCT00042900|essential thrombocythemia
669670|NCT00042900|extramedullary plasmacytoma
669671|NCT00042900|intraocular lymphoma
669672|NCT00042900|isolated plasmacytoma of bone
669673|NCT00042900|meningeal chronic myelogenous leukemia
669674|NCT00042900|monoclonal gammopathy of undetermined significance
669675|NCT00042900|polycythemia vera
669676|NCT00042900|previously treated myelodysplastic syndromes
669677|NCT00042900|primary central nervous system non-Hodgkin lymphoma
669678|NCT00042900|primary systemic amyloidosis
669679|NCT00042900|progressive hairy cell leukemia, initial treatment
669680|NCT00042900|prolymphocytic leukemia
669681|NCT00042900|recurrent adult Hodgkin lymphoma
669682|NCT00042900|recurrent adult T-cell leukemia/lymphoma
669683|NCT00042900|recurrent adult acute lymphoblastic leukemia
669684|NCT00042900|recurrent adult acute myeloid leukemia
669685|NCT00042900|recurrent adult diffuse large cell lymphoma
669686|NCT00042900|recurrent adult diffuse mixed cell lymphoma
669687|NCT00042900|recurrent adult diffuse small cleaved cell lymphoma
669688|NCT00042900|recurrent adult Burkitt lymphoma
669689|NCT00042900|recurrent adult immunoblastic large cell lymphoma
669690|NCT00042900|recurrent adult lymphoblastic lymphoma
669691|NCT00042900|recurrent cutaneous T-cell non-Hodgkin lymphoma
669692|NCT00042900|recurrent grade 1 follicular lymphoma
669693|NCT00042900|recurrent grade 2 follicular lymphoma
669694|NCT00042900|recurrent grade 3 follicular lymphoma
669695|NCT00042900|recurrent mantle cell lymphoma
669696|NCT00042900|recurrent mycosis fungoides/Sezary syndrome
669697|NCT00042900|refractory chronic lymphocytic leukemia
669698|NCT00042900|refractory hairy cell leukemia
669699|NCT00042900|refractory multiple myeloma
669700|NCT00042900|relapsing chronic myelogenous leukemia
669701|NCT00042900|secondary acute myeloid leukemia
669702|NCT00042900|secondary myelodysplastic syndromes
669703|NCT00042900|small intestine lymphoma
669704|NCT00042900|stage III adult Hodgkin lymphoma
669705|NCT00042900|stage III adult T-cell leukemia/lymphoma
669706|NCT00042900|stage III adult diffuse mixed cell lymphoma
669707|NCT00042900|stage III adult diffuse large cell lymphoma
669708|NCT00042900|stage III adult diffuse small cleaved cell lymphoma
669709|NCT00042900|stage III adult Burkitt lymphoma
669710|NCT00042900|stage III adult immunoblastic large cell lymphoma
669711|NCT00042900|stage III adult lymphoblastic lymphoma
669712|NCT00042900|stage III chronic lymphocytic leukemia
669713|NCT00042900|stage III cutaneous T-cell non-Hodgkin lymphoma
669714|NCT00042900|stage III grade 1 follicular lymphoma
669715|NCT00042900|stage III grade 2 follicular lymphoma
669716|NCT00042900|stage III grade 3 follicular lymphoma
669717|NCT00042900|stage III mantle cell lymphoma
669718|NCT00042900|stage III multiple myeloma
669719|NCT00042900|stage III mycosis fungoides/Sezary syndrome
669720|NCT00042900|stage IV adult diffuse large cell lymphoma
669721|NCT00042900|stage IV adult diffuse mixed cell lymphoma
669722|NCT00042900|stage IV adult diffuse small cleaved cell lymphoma
669723|NCT00042900|stage IV adult Burkitt lymphoma
669724|NCT00042900|stage IV adult immunoblastic large cell lymphoma
669725|NCT00042900|stage IV adult lymphoblastic lymphoma
669726|NCT00042900|stage IV chronic lymphocytic leukemia
669727|NCT00042900|stage IV cutaneous T-cell non-Hodgkin lymphoma
669728|NCT00042900|stage IV grade 1 follicular lymphoma
669729|NCT00042900|stage IV grade 2 follicular lymphoma
669730|NCT00042900|stage IV grade 3 follicular lymphoma
669731|NCT00042900|stage IV mantle cell lymphoma
669732|NCT00042900|stage IV mycosis fungoides/Sezary syndrome
669733|NCT00042900|untreated adult acute lymphoblastic leukemia
669734|NCT00042900|untreated adult acute myeloid leukemia
669735|NCT00042900|untreated hairy cell leukemia
669736|NCT00042900|stage IV adult Hodgkin lymphoma
669737|NCT00042900|stage IV adult T-cell leukemia/lymphoma
669738|NCT00042900|unspecified adult solid tumor, protocol specific
669739|NCT00042900|recurrent marginal zone lymphoma
669740|NCT00042900|recurrent small lymphocytic lymphoma
669741|NCT00042900|stage III small lymphocytic lymphoma
669742|NCT00042900|stage III marginal zone lymphoma
669743|NCT00042900|stage IV small lymphocytic lymphoma
669744|NCT00042900|stage IV marginal zone lymphoma
669745|NCT00042900|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
669746|NCT00042900|nodal marginal zone B-cell lymphoma
669747|NCT00042900|splenic marginal zone lymphoma
669748|NCT00042887|stage 0 bladder cancer
669749|NCT00042887|stage I bladder cancer
669750|NCT00042887|recurrent bladder cancer
669751|NCT00042887|transitional cell carcinoma of the bladder
669752|NCT00042861|unspecified adult solid tumor, protocol specific
669753|NCT00042848|fatigue
669754|NCT00042848|unspecified adult solid tumor, protocol specific
669755|NCT00042822|recurrent adult acute myeloid leukemia
669756|NCT00042822|refractory anemia with excess blasts
669757|NCT00042822|refractory anemia with excess blasts in transformation
669758|NCT00042822|chronic myelomonocytic leukemia
669759|NCT00042822|recurrent grade 3 follicular lymphoma
669760|NCT00042822|previously treated myelodysplastic syndromes
669761|NCT00042822|secondary myelodysplastic syndromes
669762|NCT00042822|untreated adult acute myeloid leukemia
669763|NCT00042822|recurrent grade 1 follicular lymphoma
669764|NCT00042822|recurrent grade 2 follicular lymphoma
669765|NCT00042822|recurrent adult diffuse large cell lymphoma
669766|NCT00042822|recurrent adult diffuse mixed cell lymphoma
669767|NCT00042822|recurrent adult diffuse small cleaved cell lymphoma
669768|NCT00042822|atypical chronic myeloid leukemia, BCR-ABL1 negative
669769|NCT00042822|myelodysplastic/myeloproliferative neoplasm, unclassifiable
669770|NCT00042822|adult acute myeloid leukemia with t(8;21)(q22;q22)
669771|NCT00042822|adult acute myeloid leukemia with t(16;16)(p13;q22)
669772|NCT00042822|adult acute myeloid leukemia with inv(16)(p13;q22)
669773|NCT00042822|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
669774|NCT00042822|adult acute myeloid leukemia with t(15;17)(q22;q12)
669775|NCT00042783|stage IV melanoma
669776|NCT00042783|recurrent melanoma
669777|NCT00042770|malignant pleural effusion
669778|NCT00042770|pulmonary complications
669779|NCT00042731|stage I prostate cancer
669780|NCT00042731|stage IIB prostate cancer
669781|NCT00042731|stage IIA prostate cancer
669782|NCT00042718|Chronic Bronchitis
669783|NCT00042718|Acute Bacterial Exacerbation of Chronic Bronchitis
669784|NCT00042705|asthma
669785|NCT00042705|indoor allergens
669786|NCT00042120|Parkinson's disease
669787|NCT00042120|Movement Disorders
669788|NCT00042120|Epidemiological Study
669789|NCT00042107|Parkinson Disease
669790|NCT00042107|Neurodegenerative
669791|NCT00042094|Smallpox
669792|NCT00042094|Smallpox Vaccine
669793|NCT00042094|Vaccinia
669794|NCT00042081|CABG
669795|NCT00042081|coronary artery bypass surgery
669796|NCT00042081|coronary artery disease
669797|NCT00042081|coronary arteriosclerosis
669798|NCT00042081|coronary stenosis
669799|NCT00042081|coronary occlusion
669800|NCT00042055|Crohn's Disease
669801|NCT00042055|Inflammatory Bowel Disease
669802|NCT00042016|Chronic myelogenous leukemia
669803|NCT00042016|CML
669804|NCT00042016|CML-CP
669805|NCT00042016|Chronic phase
669806|NCT00042016|Decitabine
669807|NCT00042016|5-aza-2'deoxycytidine
669808|NCT00042016|Methylation
669809|NCT00042016|STI 571
669810|NCT00042016|Imatinib mesylate
669811|NCT00042016|Gleevec
669812|NCT00042016|BCR/ABL
669813|NCT00042003|Chronic myelogenous leukemia
669814|NCT00042003|CML
669815|NCT00042003|CML-BP
669816|NCT00042003|Blast phase
669817|NCT00042003|Decitabine
669818|NCT00042003|5-aza-2'deoxycytidine
669819|NCT00042003|Methylation
669820|NCT00042003|STI 571
669821|NCT00042003|Imatinib mesylate
669822|NCT00042003|Gleevec
669823|NCT00042003|BCR/ABL
669824|NCT00041990|Chronic myelogenous leukemia
669825|NCT00041990|CML
669826|NCT00041990|CML-AP
669827|NCT00041990|Accelerated phase
669828|NCT00041990|Decitabine
669829|NCT00041990|5-aza-2'deoxycytidine
669830|NCT00041990|Methylation
669831|NCT00041990|STI 571
669832|NCT00041990|Imatinib mesylate
669833|NCT00041990|Gleevec
669834|NCT00041990|BCR/ABL
669835|NCT00041977|Rosacea
669836|NCT00041964|Lopinavir
669837|NCT00041964|Pregnancy Trimester, Third
669838|NCT00041964|Pregnancy Complications, Infectious
669839|NCT00041964|HIV Protease Inhibitors
669840|NCT00041964|Ritonavir
669841|NCT00041964|Nelfinavir
669842|NCT00041964|Viral Load
669843|NCT00041964|puerperium
669844|NCT00042692|catechol thioethers
669845|NCT00042692|Parkinson's disease
669846|NCT00042692|neurodegenerative disease
669847|NCT00042679|Non-Small-Cell Lung Cancer
669848|NCT00042679|Adenocarcinoma
669849|NCT00042679|Carcinoma Squamous
669850|NCT00042679|Adult Lung Cancer
669851|NCT00042627|Cataracts
669852|NCT00042627|Granulocytapheresis
669853|NCT00042627|Granulocyte Donors
669854|NCT00042614|Genes
669855|NCT00042614|Heart
669856|NCT00042614|Lymphocytes
669857|NCT00042614|Proteomics
669858|NCT00042614|Transplant
669859|NCT00042614|Heart Transplant
669860|NCT00042614|Healthy Volunteer
669861|NCT00042614|HV
669862|NCT00042614|Normal Control
669863|NCT00042588|Safety and Efficacy
669864|NCT00042588|Community-Acquired Pneumonia, Sepsis
669865|NCT00042575|Sad, blue, lack of energy, depressed, hopelessness, guilt
669866|NCT00042562|Depressed
669867|NCT00042562|blues
669868|NCT00042562|sadness
669869|NCT00042562|feelings of guilt
669870|NCT00042562|hopelessness
669871|NCT00042562|lack of energy
669872|NCT00042549|Gallstones
669873|NCT00042549|Gallstone
669874|NCT00042549|Biliary stones
669875|NCT00042549|Gallbladder stones
669876|NCT00042549|Gallbladder
669877|NCT00042549|Lithotripsy
669878|NCT00042549|Cholelithiasis
669879|NCT00042549|ESWL
669880|NCT00042549|Shock wave
669881|NCT00042549|Shock waves
669882|NCT00042549|shockwaves
669883|NCT00042549|shockwave
669884|NCT00042536|Yohimbine
669885|NCT00042536|Naltrexone
669886|NCT00042536|Sexual Function
669887|NCT00042536|Erectile Dysfunction
669888|NCT00042536|Alpha-2 Adrenoreceptor
669889|NCT00042536|Opiate Receptor
669890|NCT00042536|Male Impotence
669891|NCT00042536|ED
669892|NCT00042536|Healthy Volunteer
669893|NCT00042536|HV
669894|NCT00042536|Normal Control
669895|NCT00042523|Autoantibody
669896|NCT00042523|Anti-DNA Antibody
669897|NCT00042523|Cross-Reactivity
669898|NCT00042523|Neuron Loss
669899|NCT00042523|Imaging
669900|NCT00042523|Lupus
669901|NCT00042523|SLE
669902|NCT00042523|Systemic Lupus Erythematosus
669903|NCT00042510|Gastroesophageal cancer
669904|NCT00042510|Gastric cancer
669905|NCT00041951|Childhood Absence Epilepsy
669906|NCT00041951|CAE
669907|NCT00041951|Petit Mal
669908|NCT00041951|Epilepsy
669909|NCT00041951|Seizures
669910|NCT00041951|Genes
669911|NCT00041951|Inheritance
669912|NCT00041951|Genetics
669913|NCT00041951|Genetic Linkage
669914|NCT00041938|heart disease
669915|NCT00041938|stroke
669916|NCT00041938|ischemic heart disease
669917|NCT00041938|myocardial infarction
669918|NCT00041938|atrial fibrillation
669919|NCT00041938|low ejection fraction
669920|NCT00041938|cardiac failure
669921|NCT00041938|aspirin
669922|NCT00041938|Warfarin
669923|NCT00041938|anticoagulant
669924|NCT00041925|atherosclerotic vascular disease
669925|NCT00041925|chronic critical limb ischemia
669926|NCT00041925|neointimal hyperplasia
669927|NCT00041925|peripheral vein bypass
669928|NCT00041925|infra-inguinal bypass grafting surgery
669929|NCT00041925|graft stenosis
669930|NCT00041925|occluded grafts
669931|NCT00041899|Progesterone
669932|NCT00041899|Cortisol
669933|NCT00041899|Menstrual Cycle
669934|NCT00041899|Formulation
669935|NCT00041899|Endometrium
669936|NCT00041899|Estrogen
669937|NCT00041886|Minimally Invasive Surgery
669938|NCT00041886|Percutaneous
669939|NCT00041886|Radiofrequency Ablation
669940|NCT00041886|Soft Tissue Metastases
669941|NCT00041886|Thermal Ablation
669942|NCT00041886|Soft Tissue Neoplasm
669943|NCT00041886|Tumor
669944|NCT00041860|Benzene
669945|NCT00041860|Air pollution
669946|NCT00041067|stage IV breast cancer
669947|NCT00041067|recurrent breast cancer
669948|NCT00041054|extensive stage small cell lung cancer
669949|NCT00041028|stage I non-small cell lung cancer
669950|NCT00041028|stage II non-small cell lung cancer
669951|NCT00041028|stage IIIA non-small cell lung cancer
669952|NCT00041028|stage IIIB non-small cell lung cancer
669953|NCT00041015|extensive stage small cell lung cancer
669954|NCT00041015|recurrent small cell lung cancer
669955|NCT00040950|recurrent grade 1 follicular lymphoma
669956|NCT00040950|recurrent grade 2 follicular lymphoma
669957|NCT00040950|recurrent grade 3 follicular lymphoma
669958|NCT00040950|recurrent adult diffuse small cleaved cell lymphoma
669959|NCT00040950|recurrent adult diffuse mixed cell lymphoma
669960|NCT00040950|recurrent adult diffuse large cell lymphoma
669961|NCT00040950|recurrent adult immunoblastic large cell lymphoma
669962|NCT00040950|recurrent adult lymphoblastic lymphoma
669963|NCT00040950|recurrent adult Burkitt lymphoma
669964|NCT00040950|recurrent mantle cell lymphoma
669965|NCT00040950|recurrent marginal zone lymphoma
669966|NCT00040950|recurrent small lymphocytic lymphoma
669967|NCT00040950|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
669968|NCT00040950|nodal marginal zone B-cell lymphoma
669969|NCT00040950|splenic marginal zone lymphoma
669970|NCT00040937|stage I multiple myeloma
669971|NCT00040937|stage II multiple myeloma
669972|NCT00040937|stage III multiple myeloma
669973|NCT00040911|nausea and vomiting
669974|NCT00040911|localized osteosarcoma
669975|NCT00040911|metastatic osteosarcoma
669976|NCT00040911|nonmetastatic childhood soft tissue sarcoma
669977|NCT00040911|metastatic childhood soft tissue sarcoma
669978|NCT00040911|previously untreated childhood rhabdomyosarcoma
669979|NCT00040911|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
669980|NCT00040911|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
669981|NCT00040911|childhood teratoma
669982|NCT00040911|childhood extragonadal germ cell tumor
669983|NCT00040911|childhood malignant testicular germ cell tumor
669984|NCT00040911|childhood malignant ovarian germ cell tumor
669985|NCT00040911|childhood central nervous system germ cell tumor
669986|NCT00040911|localized resectable neuroblastoma
669987|NCT00040911|localized unresectable neuroblastoma
669988|NCT00040911|disseminated neuroblastoma
669989|NCT00040911|regional neuroblastoma
669990|NCT00040911|stage 4S neuroblastoma
669991|NCT00040911|stage I lymphoepithelioma of the nasopharynx
669992|NCT00040911|stage I squamous cell carcinoma of the nasopharynx
669993|NCT00040911|stage II lymphoepithelioma of the nasopharynx
669994|NCT00040911|stage II squamous cell carcinoma of the nasopharynx
669995|NCT00040911|stage III lymphoepithelioma of the nasopharynx
669996|NCT00040911|stage III squamous cell carcinoma of the nasopharynx
670119|NCT00041808|gastric cancer
669997|NCT00040911|stage IV lymphoepithelioma of the nasopharynx
669998|NCT00040911|stage IV squamous cell carcinoma of the nasopharynx
669999|NCT00040911|stage I adult Hodgkin lymphoma
670000|NCT00040911|stage I childhood Hodgkin lymphoma
670001|NCT00040911|stage II adult Hodgkin lymphoma
670002|NCT00040911|stage II childhood Hodgkin lymphoma
670003|NCT00040911|stage III adult Hodgkin lymphoma
670004|NCT00040911|stage III childhood Hodgkin lymphoma
670005|NCT00040911|stage IV adult Hodgkin lymphoma
670006|NCT00040911|stage IV childhood Hodgkin lymphoma
670007|NCT00040898|localized unresectable adult primary liver cancer
670008|NCT00040898|advanced adult primary liver cancer
670009|NCT00040898|recurrent adult primary liver cancer
670010|NCT00040898|adult primary hepatocellular carcinoma
670011|NCT00040885|recurrent non-small cell lung cancer
670012|NCT00040885|stage IIIA non-small cell lung cancer
670013|NCT00040885|stage IIIB non-small cell lung cancer
670014|NCT00040885|stage IV non-small cell lung cancer
670015|NCT00040885|fatigue
670016|NCT00040885|anorexia
670017|NCT00040885|cachexia
670018|NCT00040872|regional neuroblastoma
670019|NCT00040872|disseminated neuroblastoma
670020|NCT00040872|recurrent neuroblastoma
670021|NCT00040872|localized unresectable neuroblastoma
670022|NCT00040859|stage IV gastric cancer
670023|NCT00040859|recurrent gastric cancer
670024|NCT00040859|stage III esophageal cancer
670025|NCT00040859|stage IV esophageal cancer
670026|NCT00040859|recurrent esophageal cancer
670027|NCT00040859|adenocarcinoma of the stomach
670028|NCT00040859|adenocarcinoma of the esophagus
670029|NCT00042484|Asthma
670030|NCT00042484|Children's Health
670031|NCT00042484|Community Based Research
670032|NCT00042445|Neoplasm
670033|NCT00042445|Petrochemical
670034|NCT00042445|Leukemia
670035|NCT00042445|Taiwan
670036|NCT00042419|Industrial Injuries
670037|NCT00042419|Tendonitis
670038|NCT00042419|Assembly Line
670039|NCT00042393|Hepatitis B, Chronic
670040|NCT00042380|Antidepressant
670041|NCT00042380|Anxiety
670042|NCT00042380|Dopamine
670043|NCT00042380|Tyrosine Kinase Inhibitor
670044|NCT00042380|Affective Disorder
670045|NCT00042380|Phytoestrogen
670046|NCT00042380|Genistein
670047|NCT00042380|Major Depression
670048|NCT00042380|Depression
670049|NCT00042354|CLO222
670050|NCT00042354|clolar
670051|NCT00042354|Pediatric Acute Myelogenous Leukemia
670052|NCT00042341|CLO212
670053|NCT00042341|clolar
670054|NCT00042341|pediatric ALL
670055|NCT00042341|Leukemia, Lymphoblastic, Acute - pediatric
670056|NCT00042328|Cancer
670057|NCT00042289|Pregnancy
670058|NCT00042289|Pharmacokinetics
670059|NCT00042289|Treatment Experienced
670060|NCT00042276|Pressure Pain Threshold
670061|NCT00042276|MTrP
670062|NCT00042276|Musculoskeletal Pain
670063|NCT00042276|Soft Tissue Pain
670064|NCT00042276|Pathophysiology
670065|NCT00042276|Myofascial Pain
670066|NCT00042276|Microdialysis
670067|NCT00042276|Myofascial Trigger Points
670068|NCT00042276|Rehabilitation
670069|NCT00042276|Muscle Pain
670070|NCT00042276|Neck Pain
670071|NCT00042276|Healthy Volunteer
670072|NCT00042276|HV
670073|NCT00042276|Normal Control
670074|NCT00042263|health disparities
670075|NCT00042263|social environment
670076|NCT00042263|physical environment
670077|NCT00042263|racial health disparities
670078|NCT00042250|Cell Cycle Interphase
670079|NCT00042250|G0
670080|NCT00042250|G1
670081|NCT00042250|G2
670082|NCT00042250|S Phase
670083|NCT00042237|Child Abuse, Sexual
670084|NCT00042224|Electroconvulsive Therapy
670085|NCT00042211|Depressive Disorder
670086|NCT00042211|Blindness
670087|NCT00042211|Aged
670088|NCT00042198|Cognitive therapy
670089|NCT00042198|Relaxation techniques
670090|NCT00042185|Adolescence
670091|NCT00042185|Prevention and Control
670092|NCT00042185|Bulimia
670093|NCT00042172|Cognition
670094|NCT00042172|Memory
670095|NCT00042159|Auditory hallucinations (voices)
670096|NCT00042146|Insomnia
670097|NCT00042146|Sleep Disorders
670098|NCT00042146|Sleep Deprivation
670099|NCT00042133|aging
670100|NCT00042133|disability
670101|NCT00042133|longitudinal studies
670102|NCT00042133|neighborhood factors
670103|NCT00042133|socio-economic status
670104|NCT00042133|race
670105|NCT00041847|gene
670106|NCT00041847|environment
670107|NCT00041847|occupation
670108|NCT00041847|diet
670109|NCT00041847|interaction
670110|NCT00041834|childhood asthma
670111|NCT00041834|traffic
670112|NCT00041821|rhinitis
670113|NCT00041821|irritation
670114|NCT00041821|trigeminal
670115|NCT00041808|Metastatic liver cancer
670116|NCT00041808|Cholangiocarcinoma
670117|NCT00041808|colorectal cancer
670118|NCT00041808|esophageal cancer
670120|NCT00041808|pancreatic cancer
670121|NCT00041808|breast cancer
670122|NCT00041808|malignant melanoma
670123|NCT00041808|sarcoma
670124|NCT00041808|GIST
670125|NCT00041808|gastrointestinal stromal tumor
670126|NCT00041808|lung cancer
670127|NCT00041808|liver cancer
670128|NCT00041782|Deep Vein Thrombosis
670129|NCT00041769|Drug Therapy, Combination
670130|NCT00041769|HIV Protease Inhibitors
670131|NCT00041769|Salvage Therapy
670132|NCT00041769|Viral Load
670133|NCT00041769|Treatment Experienced
670134|NCT00041756|Primary Disease: Knee Primary Osteoarthritis
670135|NCT00041730|lymphoma
670136|NCT00041730|vaccine
670137|NCT00041730|idiotype
670138|NCT00041730|KLH
670139|NCT00041730|GM-CSF
670140|NCT00041730|FavId
670141|NCT00041717|spinal cord injury
670142|NCT00041717|muscle spasticity
670143|NCT00041704|Azole-Refractory Mucosal Candidiasis
670144|NCT00041704|Mucosal Candidiasis
670145|NCT00041691|Colorectal Cancer
670146|NCT00041691|Colon Cancer
670147|NCT00041691|Rectal Cancer
670148|NCT00041691|Colorectal Neoplasms
670149|NCT00041691|Colorectal Carcinoma
670150|NCT00041691|Colorectal Tumor
670151|NCT00041678|Psychosis Associated with Dementia of the Alzheimer's Type
670152|NCT00041652|Colorectal Cancer
670153|NCT00041652|Colon Cancer
670154|NCT00041652|Rectal Cancer
670155|NCT00041652|Colorectal Neoplasms
670156|NCT00041652|Colorectal Carcinoma
670157|NCT00041652|Breast Cancer
670158|NCT00041652|Breast Neoplasms
670159|NCT00041639|Pancreatic Cancer
670160|NCT00041639|Pancreatic Carcinoma
670161|NCT00041639|Pancreatic Neoplasms
670162|NCT00041639|Pancreas Cancer
670163|NCT00041639|Pancreatic Tumor
670164|NCT00041626|Recurrent Squamous Cell Carcinoma of the Head and Neck
670165|NCT00041613|Refractory Squamous Cell Carcinoma of the Head and Neck
670166|NCT00041600|epilepsy
670167|NCT00041600|seizures
670168|NCT00041600|disorders of human cognition
670169|NCT00041600|neuronal migration
670170|NCT00041600|neuronal migration disorders
670171|NCT00041600|lissencephaly
670172|NCT00041600|schizencephaly
670173|NCT00041600|polymicrogyria
670174|NCT00041600|agenesis of the corpus callosum
670175|NCT00041600|heterotopia
670176|NCT00041587|Cancer
670177|NCT00041587|Recurrent resectable supratentorial malignant glioma
670178|NCT00041561|Acute hypoxemic respiratory failure
670179|NCT00041535|Eye Movements
670180|NCT00041535|Saccades
670181|NCT00041535|Metabolic
670182|NCT00041535|Lysosomal
670183|NCT00041535|Myoclonus
670184|NCT00041535|Gaucher Disease
670185|NCT00041535|Neuronopathic Gaucher Disease
670186|NCT00041509|venous thromboembolism
670187|NCT00041509|thromboembolism
670188|NCT00041509|pulmonary embolism
670189|NCT00041509|deep vein thrombosis
670190|NCT00041496|symptomatic atrial fibrillation
670191|NCT00041496|persistent atrial fibrillation
670192|NCT00041483|AMD
670193|NCT00041483|age-related macular degeneration
670194|NCT00041483|Anecortave
670195|NCT00041483|Acetate
670196|NCT00041483|Wet form of age-related macular degeneration
670197|NCT00041379|Waldenström macroglobulinemia
670198|NCT00041353|ductal breast carcinoma in situ
670199|NCT00041353|lobular breast carcinoma in situ
670200|NCT00041327|stage I adult T-cell leukemia/lymphoma
670201|NCT00041327|stage II adult T-cell leukemia/lymphoma
670202|NCT00041327|stage III adult T-cell leukemia/lymphoma
670203|NCT00041327|stage IV adult T-cell leukemia/lymphoma
670204|NCT00041314|recurrent non-small cell lung cancer
670205|NCT00041314|stage IIIB non-small cell lung cancer
670206|NCT00041314|stage IV non-small cell lung cancer
670207|NCT00041301|stage I prostate cancer
670208|NCT00041301|stage IIB prostate cancer
670209|NCT00041301|stage IIA prostate cancer
670210|NCT00041301|stage III prostate cancer
670211|NCT00041301|stage IV prostate cancer
670212|NCT00041288|Waldenstrom macroglobulinemia
670213|NCT00041288|refractory chronic lymphocytic leukemia
670214|NCT00041288|recurrent grade 1 follicular lymphoma
670215|NCT00041288|recurrent grade 2 follicular lymphoma
670216|NCT00041288|recurrent adult diffuse small cleaved cell lymphoma
670217|NCT00041288|recurrent small lymphocytic lymphoma
670218|NCT00041275|localized unresectable adult primary liver cancer
670219|NCT00041275|advanced adult primary liver cancer
670220|NCT00041275|adult primary hepatocellular carcinoma
670221|NCT00041262|stage IIB esophageal cancer
670222|NCT00041262|stage IIIA esophageal cancer
670223|NCT00041262|stage IIIB esophageal cancer
670224|NCT00041262|adenocarcinoma of the esophagus
670225|NCT00041249|adult angiosarcoma
670226|NCT00041249|adult fibrosarcoma
670227|NCT00041249|adult leiomyosarcoma
670228|NCT00041249|adult liposarcoma
670229|NCT00041249|adult neurofibrosarcoma
670230|NCT00041249|adult synovial sarcoma
670231|NCT00041249|stage III adult soft tissue sarcoma
670232|NCT00041249|recurrent adult soft tissue sarcoma
670233|NCT00041249|adult malignant fibrous histiocytoma
670234|NCT00041249|adult malignant hemangiopericytoma
670235|NCT00041249|adult rhabdomyosarcoma
670236|NCT00041249|gastrointestinal stromal tumor
670237|NCT00041249|stage IV adult soft tissue sarcoma
670238|NCT00041236|adult angiosarcoma
670239|NCT00041236|adult fibrosarcoma
670240|NCT00041236|adult leiomyosarcoma
670241|NCT00041236|adult liposarcoma
670242|NCT00041236|adult neurofibrosarcoma
670243|NCT00041236|adult synovial sarcoma
670244|NCT00041236|stage IV adult soft tissue sarcoma
670245|NCT00041236|recurrent adult soft tissue sarcoma
670246|NCT00041236|adult malignant fibrous histiocytoma
670247|NCT00041236|adult malignant hemangiopericytoma
670248|NCT00041236|adult rhabdomyosarcoma
670249|NCT00041236|stage IV uterine sarcoma
670250|NCT00041236|recurrent uterine sarcoma
670251|NCT00041236|uterine leiomyosarcoma
670252|NCT00041223|radiation fibrosis
670253|NCT00041223|stage I breast cancer
670254|NCT00041223|stage II breast cancer
670255|NCT00041223|stage IIIA breast cancer
670256|NCT00041210|stage I adult Hodgkin lymphoma
670257|NCT00041210|stage II adult Hodgkin lymphoma
670258|NCT00041210|stage III adult Hodgkin lymphoma
670259|NCT00041210|stage IV adult Hodgkin lymphoma
670260|NCT00041210|adult lymphocyte predominant Hodgkin lymphoma
670261|NCT00041210|adult lymphocyte depletion Hodgkin lymphoma
670262|NCT00041210|adult nodular sclerosis Hodgkin lymphoma
670263|NCT00041210|adult mixed cellularity Hodgkin lymphoma
670264|NCT00041171|stage IV breast cancer
670265|NCT00041171|stage IIIA breast cancer
670266|NCT00041171|recurrent breast cancer
670267|NCT00041171|stage IIIB breast cancer
670268|NCT00041171|recurrent non-small cell lung cancer
670269|NCT00041171|extensive stage small cell lung cancer
670270|NCT00041171|recurrent small cell lung cancer
670271|NCT00041171|stage III bladder cancer
670272|NCT00041171|recurrent bladder cancer
670273|NCT00041171|stage IV bladder cancer
670274|NCT00041171|stage III prostate cancer
670275|NCT00041171|stage IV prostate cancer
670276|NCT00041171|recurrent prostate cancer
670277|NCT00041171|stage IIIA non-small cell lung cancer
670278|NCT00041171|stage IIIB non-small cell lung cancer
670279|NCT00041171|stage IV non-small cell lung cancer
670280|NCT00041171|unspecified adult solid tumor, protocol specific
670281|NCT00041171|untreated metastatic squamous neck cancer with occult primary
670282|NCT00041171|recurrent metastatic squamous neck cancer with occult primary
670283|NCT00041171|metastatic squamous neck cancer with occult primary squamous cell carcinoma
670284|NCT00041171|stage III squamous cell carcinoma of the lip and oral cavity
670285|NCT00041171|stage III basal cell carcinoma of the lip
670286|NCT00041171|stage III verrucous carcinoma of the oral cavity
670287|NCT00041171|stage III mucoepidermoid carcinoma of the oral cavity
670288|NCT00041171|stage III adenoid cystic carcinoma of the oral cavity
670289|NCT00041171|stage IV squamous cell carcinoma of the lip and oral cavity
670290|NCT00041171|stage IV basal cell carcinoma of the lip
670291|NCT00041171|stage IV verrucous carcinoma of the oral cavity
670292|NCT00041171|stage IV mucoepidermoid carcinoma of the oral cavity
670293|NCT00041171|stage IV adenoid cystic carcinoma of the oral cavity
670294|NCT00041171|recurrent squamous cell carcinoma of the lip and oral cavity
670295|NCT00041171|recurrent basal cell carcinoma of the lip
670296|NCT00041171|recurrent verrucous carcinoma of the oral cavity
670297|NCT00041171|recurrent mucoepidermoid carcinoma of the oral cavity
670298|NCT00041171|recurrent adenoid cystic carcinoma of the oral cavity
670299|NCT00041171|stage III squamous cell carcinoma of the oropharynx
670300|NCT00041171|stage III lymphoepithelioma of the oropharynx
670301|NCT00041171|stage IV squamous cell carcinoma of the oropharynx
670302|NCT00041171|stage IV lymphoepithelioma of the oropharynx
670303|NCT00041171|recurrent squamous cell carcinoma of the oropharynx
670304|NCT00041171|recurrent lymphoepithelioma of the oropharynx
670305|NCT00041171|stage III squamous cell carcinoma of the nasopharynx
670306|NCT00041171|stage III lymphoepithelioma of the nasopharynx
670307|NCT00041171|stage IV squamous cell carcinoma of the nasopharynx
670308|NCT00041171|stage IV lymphoepithelioma of the nasopharynx
670309|NCT00041171|recurrent squamous cell carcinoma of the nasopharynx
670310|NCT00041171|recurrent lymphoepithelioma of the nasopharynx
670311|NCT00041171|stage III squamous cell carcinoma of the hypopharynx
670312|NCT00041171|stage IV squamous cell carcinoma of the hypopharynx
670313|NCT00041171|recurrent squamous cell carcinoma of the hypopharynx
670314|NCT00041171|stage III squamous cell carcinoma of the larynx
670315|NCT00041171|stage III verrucous carcinoma of the larynx
670316|NCT00041171|stage IV squamous cell carcinoma of the larynx
670317|NCT00041171|stage IV verrucous carcinoma of the larynx
670318|NCT00041171|recurrent squamous cell carcinoma of the larynx
670319|NCT00041171|recurrent verrucous carcinoma of the larynx
670320|NCT00041171|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
670321|NCT00041171|stage III inverting papilloma of the paranasal sinus and nasal cavity
670322|NCT00041171|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
670323|NCT00041171|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
670324|NCT00041171|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
670432|NCT00040443|Brain Aging
670325|NCT00041171|stage IV inverting papilloma of the paranasal sinus and nasal cavity
670326|NCT00041171|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
670327|NCT00041171|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
670328|NCT00041171|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
670329|NCT00041171|recurrent inverting papilloma of the paranasal sinus and nasal cavity
670330|NCT00041171|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
670331|NCT00041171|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
670332|NCT00041171|recurrent salivary gland cancer
670333|NCT00041171|stage III salivary gland cancer
670334|NCT00041171|stage IV salivary gland cancer
670335|NCT00041132|stage III mantle cell lymphoma
670336|NCT00041132|stage IV mantle cell lymphoma
670337|NCT00041132|contiguous stage II mantle cell lymphoma
670338|NCT00041132|noncontiguous stage II mantle cell lymphoma
670339|NCT00041119|stage IB breast cancer
670340|NCT00041119|stage II breast cancer
670341|NCT00040833|stage III pancreatic cancer
670342|NCT00040833|recurrent pancreatic cancer
670343|NCT00040833|pain
670344|NCT00040833|stage IV pancreatic cancer
670345|NCT00040820|stage III colon cancer
670346|NCT00040820|stage IV colon cancer
670347|NCT00040820|stage III rectal cancer
670348|NCT00040820|stage IV rectal cancer
670349|NCT00040820|recurrent colon cancer
670350|NCT00040820|recurrent rectal cancer
670351|NCT00040820|adenocarcinoma of the colon
670352|NCT00040820|adenocarcinoma of the rectum
670353|NCT00040807|recurrent metastatic squamous neck cancer with occult primary
670354|NCT00040807|metastatic squamous neck cancer with occult primary squamous cell carcinoma
670355|NCT00040807|stage IV squamous cell carcinoma of the lip and oral cavity
670356|NCT00040807|recurrent squamous cell carcinoma of the lip and oral cavity
670357|NCT00040807|stage IV squamous cell carcinoma of the oropharynx
670358|NCT00040807|recurrent squamous cell carcinoma of the oropharynx
670359|NCT00040807|stage IV squamous cell carcinoma of the nasopharynx
670360|NCT00040807|recurrent squamous cell carcinoma of the nasopharynx
670361|NCT00040807|stage IV squamous cell carcinoma of the hypopharynx
670362|NCT00040807|recurrent squamous cell carcinoma of the hypopharynx
670363|NCT00040807|stage IV squamous cell carcinoma of the larynx
670364|NCT00040807|recurrent squamous cell carcinoma of the larynx
670365|NCT00040807|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
670366|NCT00040807|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
670367|NCT00040807|recurrent salivary gland cancer
670368|NCT00040807|salivary gland squamous cell carcinoma
670369|NCT00040807|stage IV salivary gland cancer
670370|NCT00040742|nausea
670371|NCT00040742|vomiting
670372|NCT00040729|unspecified adult solid tumor, protocol specific
670373|NCT00040690|untreated adult acute lymphoblastic leukemia
670374|NCT00040690|L3 adult acute lymphoblastic leukemia
670375|NCT00040690|stage I adult Burkitt lymphoma
670376|NCT00040690|stage III adult Burkitt lymphoma
670377|NCT00040690|stage IV adult Burkitt lymphoma
670378|NCT00040690|contiguous stage II adult Burkitt lymphoma
670379|NCT00040690|noncontiguous stage II adult Burkitt lymphoma
670380|NCT00040677|sickle cell anemia
670381|NCT00040677|sickle cell disease
670382|NCT00040677|anemia
670383|NCT00040677|ICA-17043
670384|NCT00040677|senicapoc
670385|NCT00040664|pediatrics
670386|NCT00040664|HIV
670387|NCT00040664|protease inhibitors
670388|NCT00040664|ritonavir
670389|NCT00040664|fosamprenavir
670390|NCT00040664|LEXIVA
670391|NCT00040664|AGENERASE
670392|NCT00040664|amprenavir
670393|NCT00040651|Systemic Sclerosis
670394|NCT00040651|Chemotherapy
670395|NCT00040651|Cyclophosphamide
670396|NCT00040651|Fludarabine
670397|NCT00040651|Leukapheresis
670398|NCT00040651|Mesna
670399|NCT00040651|Stem Cell
670400|NCT00040651|T-Cell
670401|NCT00040651|Thymoglobulin
670402|NCT00040651|Scleroderma
670403|NCT00040599|Colon Cancer
670404|NCT00040599|Rectal Cancer
670405|NCT00040599|Colorectal Neoplasms
670406|NCT00040599|Colorectal Carcinoma
670407|NCT00040599|Colorectal Tumor
670408|NCT00040586|hormone-refractory
670409|NCT00040573|Brain neoplasm
670410|NCT00040573|Clinical trial, phase I/II
670411|NCT00040560|Lung Cancer
670412|NCT00040560|Metastatic Brain Cancer
670413|NCT00040547|Cancer-Advanced Solid Tumors
670414|NCT00040534|Advanced Cancer
670415|NCT00040521|Crohn's Disease
670416|NCT00040521|Active Crohns Disease
670417|NCT00040508|Proteinuria
670418|NCT00040508|Renal Failure
670419|NCT00040508|Fibrosis
670420|NCT00040508|Rapamycin
670421|NCT00040508|Immunosuppression
670422|NCT00040508|Focal Segmental Glomerulosclerosis
670423|NCT00040508|FSGS
670424|NCT00040495|Peptic
670425|NCT00040495|Ulcer
670426|NCT00040495|Hemorrhage
670427|NCT00040456|Hemoglobin SC disease
670428|NCT00040456|sickle cell-hemoglobin
670429|NCT00040443|Mild Cognitive Impairment
670430|NCT00040443|Memory Loss
670431|NCT00040443|Alzheimer's Disease
670433|NCT00040443|Ampalex®
670434|NCT00040443|CX516
670435|NCT00040404|Parkinson's disease
670436|NCT00040404|Idiopathic Parkinson's disease
670437|NCT00040404|Idiopathic Parkinson disease
670438|NCT00040404|Parkinson's disease, idiopathic
670439|NCT00040391|Pharmacia
670440|NCT00040378|Alzheimer Disease
670441|NCT00040378|Vitamin E
670442|NCT00040378|Selenium
670443|NCT00040365|Prostate Cancer
670444|NCT00040365|Radiation Therapy
670445|NCT00040365|Rectal Toxicity
670446|NCT00040365|Amifostine
670447|NCT00040365|Radioprotector
670448|NCT00040352|Genetics
670449|NCT00040352|Risk Factors
670450|NCT00040352|Natural History
670451|NCT00040352|Melanoma Precursors
670452|NCT00040352|Skin Cancer
670453|NCT00040352|Melanoma
670454|NCT00040339|brain injury
670455|NCT00040339|hypothermia
670456|NCT00040339|body cooling
670457|NCT00040339|body temperature
670458|NCT00040326|epilepsy
670459|NCT00040326|mesial temporal lobe epilepsy
670460|NCT00040326|temporal lobe epilepsy
670461|NCT00040326|MTLE
670462|NCT00040326|seizures
670463|NCT00040326|anteromesial temporal resection
670464|NCT00040326|surgery
670465|NCT00040326|antiepileptic drugs
670466|NCT00040326|hippocampal sclerosis
670467|NCT00040300|treatment experienced
670468|NCT00040300|HIV
670469|NCT00040300|Phase I
670470|NCT00040300|Combination Therapy
670471|NCT00040287|smoking
670472|NCT00040287|obesity
670473|NCT00040287|weight loss
670474|NCT00040287|smoking cessation
670475|NCT00040287|weight control
670476|NCT00040274|HIV
670477|NCT00040274|Phase I
670478|NCT00040261|Antiglutamatergic
670479|NCT00040261|Neuroprotective
670480|NCT00040261|Unipolar Depression
670481|NCT00040261|Treatment
670482|NCT00040261|Antidepressant
670483|NCT00040261|Depression
670484|NCT00040261|Glutamate
670485|NCT00040261|Memantine
670486|NCT00040261|Pathophysiology
670487|NCT00040261|Positron Emission Tomography
670488|NCT00040261|Major Depression
670489|NCT00040248|Relapse
670490|NCT00040248|Monoclonal Antibody
670491|NCT00040248|Biologic Agent
670492|NCT00040248|Anti-CD25
670493|NCT00040248|Activated Lymphocyte
670494|NCT00040248|Wegener Granulomatosis
670495|NCT00040248|Wegener's Granulomatosis
670496|NCT00040248|WG
670497|NCT00040235|Leukapheresis
670498|NCT00040235|Hypomagnesemia
670499|NCT00040235|Plateletpheresis
670500|NCT00040235|Hypocalcemia
670501|NCT00040235|Citrate
670502|NCT00040235|Healthy Volunteer
670503|NCT00040235|HV
670504|NCT00040235|Normal Control
670505|NCT00040222|Counseling/behavioral/psychosocial
670506|NCT00040222|Gene discovery
670507|NCT00040222|Cancer prevention
670508|NCT00040222|Risk-reduction
670509|NCT00040222|Hereditary
670510|NCT00040222|Breast Cancer
670511|NCT00040222|Ovarian Cancer
670512|NCT00040222|Cowden Syndrome
670513|NCT00040222|Peutz-Jegher Syndrome
670514|NCT00040222|Li-Fraumeni Syndrome
670515|NCT00040209|JP 1730
670516|NCT00040209|Dyskinesias
670517|NCT00040209|Levodopa Infusion
670518|NCT00040209|Apomorphine Infusion
670519|NCT00040209|Clinical Trial
670520|NCT00040209|Parkinson Disease
670521|NCT00040209|PD
670522|NCT00040196|Parkinson's Disease
670523|NCT00040196|Levodopa
670524|NCT00040196|Perfusion fMRI
670525|NCT00040196|Aging
670526|NCT00040196|Motor Control
670527|NCT00040196|PD
670528|NCT00040196|Healthy Volunteer
670529|NCT00040196|HV
670530|NCT00040196|Normal Control
670531|NCT00040183|Tarceva, EGFR, erlotinib, OSI-774
670532|NCT00040170|Adenocarcinoma of the prostate
670533|NCT00040157|treatment experienced,
670534|NCT00040157|Stable triple anti-retroviral combination therapy in HIV-infected,
670535|NCT00040157|Achillion
670536|NCT00040144|E-Antigen positive,
670537|NCT00040144|Lamivudine-Resistant Chronic Hepatitis B,
670538|NCT00040144|Achillion
670539|NCT00040105|Chronic Myelogenous Leukemia, Chronic Phase
670540|NCT00040105|R115777
670541|NCT00040105|Zarnestra
670542|NCT00040105|Tipifarnib
670543|NCT00040105|Imatinib Mesylate
670544|NCT00040105|Gleevec
670545|NCT00040105|Imatinib
670546|NCT00040105|STI571
670547|NCT00040105|NSC-716051
670548|NCT00040092|Virulizin
670549|NCT00040092|Immunotherapy
670550|NCT00040092|Pancreas
670551|NCT00040092|Pancreatic Cancer
670552|NCT00040092|clinical trial
670553|NCT00040053|amphetamine dependence
670554|NCT00040027|hepatitis C
670555|NCT00040027|hepatitis C, chronic
670556|NCT00039195|stage I adult diffuse large cell lymphoma
670557|NCT00039195|stage III adult diffuse large cell lymphoma
670558|NCT00039195|stage IV adult diffuse large cell lymphoma
670559|NCT00039195|contiguous stage II adult diffuse large cell lymphoma
670560|NCT00039195|noncontiguous stage II adult diffuse large cell lymphoma
670561|NCT00039169|stage III renal cell cancer
670562|NCT00039169|stage IV renal cell cancer
670563|NCT00039169|recurrent renal cell cancer
670564|NCT00039156|recurrent grade 3 follicular lymphoma
670565|NCT00039156|recurrent adult diffuse mixed cell lymphoma
670566|NCT00039156|recurrent adult diffuse large cell lymphoma
670567|NCT00039156|recurrent adult immunoblastic large cell lymphoma
670568|NCT00039156|recurrent adult lymphoblastic lymphoma
670569|NCT00039156|recurrent adult Burkitt lymphoma
670570|NCT00039156|recurrent mantle cell lymphoma
670571|NCT00039130|untreated adult acute lymphoblastic leukemia
670572|NCT00039130|L3 adult acute lymphoblastic leukemia
670573|NCT00039130|stage I adult Burkitt lymphoma
670574|NCT00039130|stage III adult Burkitt lymphoma
670575|NCT00039130|stage IV adult Burkitt lymphoma
670576|NCT00039130|contiguous stage II adult Burkitt lymphoma
670577|NCT00039130|noncontiguous stage II adult Burkitt lymphoma
670578|NCT00039078|localized unresectable adult primary liver cancer
670579|NCT00039078|recurrent adult primary liver cancer
670580|NCT00039078|adult primary hepatocellular carcinoma
670581|NCT00039052|stage IV breast cancer
670582|NCT00039052|recurrent breast cancer
670583|NCT00039052|recurrent non-small cell lung cancer
670584|NCT00039052|stage IV renal cell cancer
670585|NCT00039052|recurrent renal cell cancer
670586|NCT00039052|stage IV non-small cell lung cancer
670587|NCT00039052|male breast cancer
670588|NCT00039039|recurrent non-small cell lung cancer
670589|NCT00039039|stage IIIA non-small cell lung cancer
670590|NCT00039039|stage IIIB non-small cell lung cancer
670591|NCT00039026|Type 2 Diabetes Mellitis
670592|NCT00039000|Immunotherapy, Cancer, Melanoma, Skin Cancer, tumor
670593|NCT00039988|Treatment Outcome
670594|NCT00039988|Multiple Sclerosis
670595|NCT00039988|Albuterol
670596|NCT00039988|Copolymer 1
670597|NCT00039975|Drug Interactions
670598|NCT00039975|HIV Protease Inhibitors
670599|NCT00039975|Ritonavir
670600|NCT00039975|Indinavir
670601|NCT00039975|Calcium Channel Blockers
670602|NCT00039975|Pharmacokinetics
670603|NCT00039975|Diltiazem
670604|NCT00039975|Amlodipine
670605|NCT00039962|hepatitis C
670606|NCT00039962|hepatitis C, chronic
670607|NCT00039962|cirrhosis, liver
670608|NCT00039936|Binge Eating
670609|NCT00039936|Obesity
670610|NCT00039936|Cognitive
670611|NCT00039936|Behavior
670612|NCT00039923|Hemolysis
670613|NCT00039923|CD55
670614|NCT00039923|CD59
670615|NCT00039923|Transfusion
670616|NCT00039923|Paroxysmal Nocturnal Hemoglobinuria
670617|NCT00039923|PNH
670618|NCT00039884|Cervical cancer
670619|NCT00039858|heparin-induced thrombocytopenia
670620|NCT00039858|heparin-induced thrombocytopenia and thrombosis
670621|NCT00039858|HIT
670622|NCT00039858|HITTS
670623|NCT00039858|anticoagulation
670624|NCT00039845|Brain
670625|NCT00039845|Imaging
670626|NCT00039845|Pediatrics
670627|NCT00039845|Mapping
670628|NCT00039845|Development
670629|NCT00039845|fMRI
670630|NCT00039845|Children
670631|NCT00039845|Language
670632|NCT00039845|Healthy Volunteer
670633|NCT00039845|HV
670634|NCT00039845|Normal Control
670635|NCT00039832|Stroke
670636|NCT00039832|Abciximab
670637|NCT00039832|Reteplase
670638|NCT00039832|MRI
670639|NCT00039832|Cerebral Blood Flow
670640|NCT00039819|Spinal Cord
670641|NCT00039819|Sensory Stimulation
670642|NCT00039819|Locomotion
670643|NCT00039819|Magnetic Stimulation
670644|NCT00039819|Reflexes
670645|NCT00039819|Healthy Volunteer
670646|NCT00039819|HV
670647|NCT00039819|Normal Control
670648|NCT00039793|Cancer-related fatigue
670649|NCT00039793|alternative medicine
670650|NCT00039793|cancer rehabilitation /care
670651|NCT00039793|fatigue
670652|NCT00039793|human therapy evaluation
670653|NCT00039793|physical therapy
670654|NCT00039793|neoplasm /cancer chemotherapy
670655|NCT00039793|neoplasm /cancer palliative treatment
670656|NCT00039780|Breast
670657|NCT00039780|Cancer
670658|NCT00039780|Metastatic
670659|NCT00039780|Paclitaxel
670660|NCT00039780|Peripheral
670661|NCT00039780|Taxol
670662|NCT00039780|Neuropathy
670663|NCT00039780|Neurotoxicity
670664|NCT00039780|Paresthesias
670665|NCT00039780|Weekly
670666|NCT00039780|BNP7787
670667|NCT00039780|7787
670668|NCT00039780|Tavocept
670669|NCT00039780|Prevention
670670|NCT00039767|Fibrin Sleeves
670671|NCT00039767|Anticoagulants
670672|NCT00039767|Catheters
670673|NCT00039767|Thrombosis
670674|NCT00039767|Hirudin
670675|NCT00039767|Lepirudin
670676|NCT00039754|Multiple myeloma
670677|NCT00039754|Transplant
670678|NCT00039754|Skeletal Targeted Radiotherapy
670679|NCT00039754|Holmium
670680|NCT00039741|Drug Therapy, Combination
670681|NCT00039741|HIV Protease Inhibitors
670682|NCT00039741|Reverse Transcriptase Inhibitors
670683|NCT00039741|Viral Load
670684|NCT00039741|Treatment Naive
670685|NCT00039715|Glucocorticoid Receptor
670686|NCT00039715|Traumatic Reminders
670687|NCT00039715|Stress
670688|NCT00039715|Hippocampus
670689|NCT00039715|Flashbacks
670690|NCT00039715|PTSD
670691|NCT00039715|Type II GR Receptor
670692|NCT00039715|Hydrocortisone
670693|NCT00039715|Memory
670694|NCT00039715|Major Depression
670695|NCT00039715|Post-Traumatic Stress Disorder
670696|NCT00039715|Healthy Volunteer
670697|NCT00039715|HV
670698|NCT00039715|Normal Control
670699|NCT00039702|Nicotinic Acetylcholine Receptors
670700|NCT00039702|Alzheimer's Disease
670701|NCT00039702|SPECT
670702|NCT00039702|AD
670703|NCT00039702|Healthy Volunteer
670704|NCT00039702|HV
670705|NCT00039702|Normal Control
670706|NCT00039689|Primary HIV Infection
670707|NCT00039689|Chronic HIV Infection
670708|NCT00039689|Antiretroviral Therapy
670709|NCT00039689|Innate Immunity
670710|NCT00039689|B Cell
670711|NCT00039689|HIV Infection
670712|NCT00039689|Acute Infection
670713|NCT00039689|Treatment Naive
670714|NCT00039676|Genetics
670715|NCT00039676|Risk Factors
670716|NCT00039676|Natural History
670717|NCT00039676|Lymphoma
670718|NCT00039676|Leukemia
670719|NCT00039676|Lymph Node Cancer
670720|NCT00039663|Hyperlipidemia
670721|NCT00039663|Insulin Resistance
670722|NCT00039663|Coronary Artery Disease
670723|NCT00039663|Lipodystrophy
670724|NCT00039663|Antiretroviral Therapy
670725|NCT00039663|HIV Infection
670726|NCT00039663|Treatment Experienced
670727|NCT00039650|Granulocyte Colony-Stimulating Factor
670728|NCT00039650|T Cells
670729|NCT00039650|Peripheral Blood Stem Cells
670730|NCT00039650|Apheresis
670731|NCT00039650|Hematopoietic Progenitor Cell Transplantation
670732|NCT00039650|Healthy Volunteer
670733|NCT00039650|HV
670734|NCT00039650|Normal Control
670735|NCT00039624|Radiation Therapy
670736|NCT00039624|Prostate
670737|NCT00039624|MRI
670738|NCT00039624|Brachytherapy
670739|NCT00039624|Phase II
670740|NCT00039624|Prostate Cancer
670741|NCT00039611|stage III colon cancer
670742|NCT00039611|stage IV colon cancer
670743|NCT00039611|stage III rectal cancer
670744|NCT00039611|stage IV rectal cancer
670745|NCT00039611|recurrent colon cancer
670746|NCT00039611|recurrent rectal cancer
670747|NCT00039585|recurrent ovarian epithelial cancer
670748|NCT00039585|fallopian tube cancer
670749|NCT00039585|primary peritoneal cavity cancer
670750|NCT00039585|borderline ovarian surface epithelial-stromal tumor
670751|NCT00039572|adult glioblastoma
670752|NCT00039572|stage IV melanoma
670753|NCT00039572|tumors metastatic to brain
670754|NCT00039572|adult giant cell glioblastoma
670755|NCT00039572|adult gliosarcoma
670756|NCT00039559|ovarian epithelial cancer
670757|NCT00039546|stage I breast cancer
670758|NCT00039546|stage II breast cancer
670759|NCT00039520|stage IV breast cancer
670760|NCT00039520|recurrent breast cancer
670761|NCT00039507|stage I non-small cell lung cancer
670762|NCT00039507|stage II non-small cell lung cancer
670763|NCT00039468|adult glioblastoma
670764|NCT00039468|recurrent adult brain tumor
670765|NCT00039468|adult giant cell glioblastoma
670766|NCT00039468|adult gliosarcoma
670767|NCT00039429|stage IV renal cell cancer
670768|NCT00039429|recurrent renal cell cancer
670769|NCT00039364|recurrent adult brain tumor
670770|NCT00039364|adult glioblastoma
670771|NCT00039364|adult anaplastic astrocytoma
670772|NCT00039364|adult anaplastic oligodendroglioma
670773|NCT00039364|adult mixed glioma
670774|NCT00039364|adult pilocytic astrocytoma
670775|NCT00039364|adult subependymoma
670776|NCT00039364|adult giant cell glioblastoma
670777|NCT00039364|adult gliosarcoma
670778|NCT00039364|adult diffuse astrocytoma
670779|NCT00039351|stage I adult diffuse large cell lymphoma
670780|NCT00039351|stage III adult diffuse large cell lymphoma
670781|NCT00039351|stage IV adult diffuse large cell lymphoma
670782|NCT00039351|contiguous stage II adult diffuse large cell lymphoma
670783|NCT00039351|noncontiguous stage II adult diffuse large cell lymphoma
670784|NCT00039351|angioimmunoblastic T-cell lymphoma
670785|NCT00039338|stage IB cervical cancer
670786|NCT00039338|stage IIB cervical cancer
670787|NCT00039338|stage IIA cervical cancer
670788|NCT00039338|cervical squamous cell carcinoma
670789|NCT00039338|cervical adenocarcinoma
670790|NCT00039338|cervical adenosquamous cell carcinoma
670791|NCT00039325|stage IV melanoma
670792|NCT00039325|recurrent melanoma
670793|NCT00039312|cervical cancer
670794|NCT00039299|adenocarcinoma of the prostate
670795|NCT00039299|recurrent prostate cancer
670796|NCT00039286|stage II breast cancer
670797|NCT00039286|stage IIIA breast cancer
670798|NCT00039286|recurrent breast cancer
670799|NCT00039273|stage IV colon cancer
670800|NCT00039273|stage IV rectal cancer
670801|NCT00039273|recurrent colon cancer
670802|NCT00039273|recurrent rectal cancer
670803|NCT00039234|stage IV melanoma
670804|NCT00039234|recurrent melanoma
670805|NCT00039234|liver metastases
670806|NCT00039208|stage III colon cancer
670807|NCT00039208|stage IV colon cancer
670808|NCT00039208|stage III rectal cancer
670809|NCT00039208|stage IV rectal cancer
670810|NCT00039208|recurrent colon cancer
670811|NCT00039208|recurrent rectal cancer
670812|NCT00038987|Smallpox
670813|NCT00038987|APSV
670814|NCT00038987|Aventis Pasteur Smallpox Vaccine
670815|NCT00038987|vaccinia-naive
670816|NCT00038974|Hepatitis C
670817|NCT00038974|Interferon
670818|NCT00038974|Ribavirin
670819|NCT00038974|Efficacy
670820|NCT00038974|Viral load
670821|NCT00038974|Genetics
670822|NCT00038974|Cytokines
670823|NCT00038974|Immunology
670824|NCT00038961|fondaparinux sodium
670825|NCT00038961|DVT Prevention
670826|NCT00038961|abdominal surgery
670827|NCT00038961|VTE prevention
670828|NCT00038961|venous thromboembolism
670829|NCT00038961|pulmonary embolism
670830|NCT00038948|Renal
670831|NCT00038948|Allograft
670832|NCT00038948|Recipients
670833|NCT00038935|Hemophilia
670834|NCT00038922|Left-Sided
670835|NCT00038922|Ulcerative
670836|NCT00038922|Colitis
670837|NCT00038896|Panic
670838|NCT00038896|Disorder
670839|NCT00038883|Lymphoid Malignancies
670840|NCT00038883|Chronic Lymphocytic Leukemia
670841|NCT00038883|Acute Lymphoblastic Leukemia
670842|NCT00038883|Low grade Lymphoma
670843|NCT00038883|B and T cell Lymphoma of the intermediate and high grade
670844|NCT00038870|AML
670845|NCT00038870|CML
670846|NCT00038870|Dendritic Cells
670847|NCT00038857|Acute Myelogenous Leukemia
670848|NCT00038857|Acute Lymphocytic Leukemia
670849|NCT00038857|Myelodysplastic Syndrome
670850|NCT00038857|Chronic Lymphocytic Leukemia
670851|NCT00038857|Leukemia
670852|NCT00038857|Lymphoma
670853|NCT00038857|Non Hodgkin's Lymphoma
670854|NCT00038857|T cell depletion
670855|NCT00038857|CD34 selected progenitors cell
670856|NCT00038857|GVHD
670857|NCT00038844|Lymphoma
670858|NCT00038844|Leukemia
670859|NCT00038844|Campath-1 H
670860|NCT00038844|Campath
670861|NCT00038844|Alemtuzumab
670862|NCT00038844|Fludarabine
670863|NCT00038844|Fludarabine Phosphate
670864|NCT00038844|Fludara
670865|NCT00038844|Cyclophosphamide
670866|NCT00038844|Cytoxan
670867|NCT00038844|Neosar
670868|NCT00038844|Rituxan
670869|NCT00038844|Rituximab
670870|NCT00038831|Acute Myelogenous leukemia
670871|NCT00038831|AML
670872|NCT00038831|Myelodysplastic Syndrome
670873|NCT00038831|MDS
670874|NCT00038831|Chronic Lymphocytic Leukemia
670875|NCT00038831|CML
670876|NCT00038831|Mylotarg
670877|NCT00038831|Gemtuzumab
670878|NCT00038831|Gemtuzumab ozogamicin
670879|NCT00038831|Melphalan
670880|NCT00038831|Alkeran
670881|NCT00038831|Fludarabine Phosphate
670882|NCT00038831|Fludarabine
670883|NCT00038831|Fludara
670884|NCT00038831|Anti-thymocyte globulin
670885|NCT00038831|ATG
670886|NCT00038831|Allogeneic Bone Marrow
670887|NCT00038831|Peripheral Blood Stem Cell Transplantation
670888|NCT00038831|Allo PBSCT
670889|NCT00038831|Allogeneic transplantation
670890|NCT00038818|CML
670891|NCT00038818|MM
670892|NCT00038818|NHL
670893|NCT00038818|HD
670894|NCT00038818|CLL
670895|NCT00038818|CD8 Depleted
670896|NCT00038818|Donor Lymphocyte
670897|NCT00038805|High Risk Acute Myeloid Leukemia
670898|NCT00038805|Acute Lymphocytic Leukemia
670899|NCT00038805|Chronic Myeloid Leukemia
670900|NCT00038805|Myelodysplastic Syndrome
670901|NCT00038805|ALL
670902|NCT00038805|AML
670903|NCT00038805|MDS
670904|NCT00038805|CML
670905|NCT00038805|CMML
670906|NCT00038805|Nonmyeloablative Preparative Regimen
670907|NCT00038805|Mylotarg
670908|NCT00038805|CMA-676
670909|NCT00038792|Acute Graft Versus Host Disease
670910|NCT00038792|Refractory
670911|NCT00038779|Lymphoma
670912|NCT00038779|CML
670913|NCT00038779|CLL
670914|NCT00038779|AML
670915|NCT00038779|ALL
670916|NCT00038779|MDS
670917|NCT00038779|AA
670918|NCT00038766|Inflammatory Bowel Disease
670919|NCT00038753|vision screening
670920|NCT00038727|DPP
670921|NCT00038727|IGT
670922|NCT00038727|Prediabetes
670923|NCT00038727|Type 2 diabetes
670924|NCT00038727|Macrovascular disease
670925|NCT00038727|Microvascular disease
670926|NCT00038714|HPV
670927|NCT00038714|Papilloma
670928|NCT00038701|Metastatic Pancreas Cancer
670929|NCT00038688|Health Education
670930|NCT00038688|Substance Abuse, Intravenous
670931|NCT00038688|Program Evaluation
670932|NCT00038688|Peer Group
670933|NCT00038688|Risk-Taking
670934|NCT00038688|HIV Seronegativity
670935|NCT00038688|Substance-related Disorders
670936|NCT00038675|Leukemia
670937|NCT00038675|Chronic Myelomonocytic Leukemia
670938|NCT00038675|Chronic Myeloid Leukemia
670939|NCT00038675|Polycythemia Vera
670940|NCT00038675|Hypereosinophilic Syndrome
670941|NCT00038675|Mastocytosis
670942|NCT00038675|Imatinib Mesylate
670943|NCT00038675|Gleevec
670944|NCT00038649|Philadelphia chromosome positive
670945|NCT00038649|early chronic phase (diagnosis < 12 months)
670946|NCT00038649|Chronic Myelogenous Leukemia, Chronic Phase
670947|NCT00038649|Chronic Myelogenous Leukemia
670948|NCT00038649|CML
670949|NCT00038649|Gleevec
670950|NCT00038649|STI571
670951|NCT00038636|HIV
670952|NCT00038623|Relapsed/Refractory Mantle Cell Lymphoma
670953|NCT00038623|Yttrium-Ibritumomab
670954|NCT00038623|Zevalin
670955|NCT00038610|Leukemia
670956|NCT00038610|Lymphoblastic
670957|NCT00038610|Acute
670958|NCT00038610|Philadelphia-Positive
670959|NCT00038610|Imatinib Mesylate
670960|NCT00038610|Gleevec
670961|NCT00038610|Glivec
670962|NCT00038610|Imatinib
670963|NCT00038610|STI571
670964|NCT00038610|STI-571
670965|NCT00038610|CGP-57148B
670966|NCT00038610|NSC-716051
670967|NCT00038610|Cyclophosphamide
670968|NCT00038610|Cytoxan®,
670969|NCT00038610|Neosar®
670970|NCT00038610|Doxorubicin
670971|NCT00038610|Adriamycin ®
670972|NCT00038610|Rubex ®
670973|NCT00038610|Adriamycin PFS
670974|NCT00038610|Adriamycin RDF
670975|NCT00038610|Vincristine
670976|NCT00038610|Dexamethasone
670977|NCT00038610|Decadron
670978|NCT00038610|Methotrexate
670979|NCT00038610|Cytarabine
670980|NCT00038610|Ara-C
670981|NCT00038610|Cytosar
670982|NCT00038610|DepoCyt
670983|NCT00038610|Cytosine Arabinosine Hydrochloride
670984|NCT00038610|Mesna
670985|NCT00038610|Mesnex
670986|NCT00038610|G-CSF
670987|NCT00038610|Filgrastim
670988|NCT00038610|Neupogen
670989|NCT00038597|Philadelphia chromosome positive CML
670990|NCT00038597|Myelogenous Leukemia, Chronic, Chronic Phase
670991|NCT00038597|Myelogenous Leukemia, Chronic, Accelerated Phase
670992|NCT00038571|Cancer
670993|NCT00038571|Relapsed
670994|NCT00038571|Refractory
670995|NCT00038571|B cell lymphoma
670996|NCT00038571|Proteasome Inhibitor
670997|NCT00038571|PS-341
670998|NCT00038558|Hodgkin's lymphoma
670999|NCT00038558|Dacarbazine
671000|NCT00038558|DTIC
671001|NCT00038558|DTIC-Dome
671002|NCT00038558|Vinblastine
671003|NCT00038558|Velban
671004|NCT00038558|Bleomycin sulfate
671005|NCT00038558|Blenoxane
671006|NCT00038558|BLM
671007|NCT00038558|Doxorubicin Hydrochloride
671008|NCT00038558|Adriamycin
671009|NCT00038558|Filgrastim
671010|NCT00038558|G-CSF
671011|NCT00038558|Neupogen
671012|NCT00038558|Pegfilgrastim
671013|NCT00038558|granulocyte colony-stimulating factor
671014|NCT00038545|LYMPHOMA
671015|NCT00038545|NON-HODGKINS
671016|NCT00038545|AGGRESSIVE
671017|NCT00038545|RELAPSED AND REFRACTORY
671018|NCT00038532|treatment experienced
671019|NCT00038532|HIV
671020|NCT00038519|treatment experienced
671021|NCT00038519|HIV
671022|NCT00038506|HIV-1 TRIZIVIR Tenofovir
671023|NCT00038493|GBM
671024|NCT00038493|Glioma
671025|NCT00038493|Brain Tumor
671026|NCT00038480|Lopinavir
671027|NCT00038480|HIV-1
671028|NCT00038480|Drug Therapy, Combination
671029|NCT00038480|HIV Protease Inhibitors
671030|NCT00038480|Ritonavir
671031|NCT00038480|Reverse Transcriptase Inhibitors
671032|NCT00038454|Oxygen Therapeutics
671033|NCT00038454|CABG
671034|NCT00038454|Transfusion
671035|NCT00038441|Malignant Glioma
671036|NCT00038415|Chronic Lymphocytic Leukemia
671037|NCT00038415|CLL
671038|NCT00038415|Binet Stage A
671039|NCT00038415|Vaccination
671040|NCT00038415|Idiotypic
671041|NCT00038415|Genetic
671042|NCT00038415|Deoxyribonucleic acid
671043|NCT00038415|DNA
671044|NCT00038402|Breast Cancer
671045|NCT00038402|Non-Inflammatory Breast Cancer
671046|NCT00038402|Operable Breast Cancer
671047|NCT00038402|Herceptin
671048|NCT00038402|Taxol
671049|NCT00038402|FEC
671050|NCT00038402|Fluorouracil
671051|NCT00038402|Cyclophosphamide
671052|NCT00038402|Epirubicin
671053|NCT00038402|Trastuzumab
671054|NCT00038402|Paclitaxel
671055|NCT00038402|Neosar
671056|NCT00038389|Brain Stem Tumor
671057|NCT00038376|T-cell lymphoma
671058|NCT00038376|accutane
671059|NCT00038376|isotretinoin
671060|NCT00038376|mycosis fungoides
671061|NCT00038376|T-cell malignancies
671062|NCT00038363|Frail
671063|NCT00038363|Disable
671064|NCT00038363|Disabled Persons
671065|NCT00038363|Physically disabled
671066|NCT00038363|Elderly
671067|NCT00038363|Rehabilitation
671068|NCT00038363|Subacute care
671069|NCT00038350|Age
671070|NCT00038350|Dysphagia
671071|NCT00038350|Swallowing
671072|NCT00038337|Health Literacy
671073|NCT00038337|Visual
671074|NCT00038337|Cognitive
671075|NCT00038285|Amputation
671076|NCT00038285|Cardiovascular Disease
671077|NCT00038285|PVD
671078|NCT00038272|Placebos
671079|NCT00038272|Drug Therapy, Combination
671080|NCT00038272|Anti-HIV Agents
671081|NCT00038272|Mycophenolate Mofetil
671082|NCT00038272|2,6-diaminopurine dioxolane
671083|NCT00038272|Treatment Experienced
671084|NCT00038272|DAPD
671085|NCT00038272|MMF
671086|NCT00038259|Interleukin-2
671087|NCT00038259|Drug Administration Schedule
671088|NCT00038259|CD4 Lymphocyte Count
671089|NCT00038259|Anti-HIV Agents
671090|NCT00038259|Viral Load
671091|NCT00038259|Treatment Interruption
671092|NCT00038259|Treatment Experienced
671093|NCT00038259|STI
671094|NCT00038246|Prostate Cancer
671095|NCT00038233|myeloma
671096|NCT00038220|HIV
671097|NCT00038207|soft tissue sarcoma
671098|NCT00038207|Bone sarcomas
671099|NCT00038194|Prostate Cancer
671100|NCT00038194|bone metastasis
671101|NCT00038181|Prostate Cancer
671102|NCT00038168|Prostate Cancer
671103|NCT00038155|Ambulation
671104|NCT00038155|Difficulties in ambulation
671105|NCT00038155|Geriatric
671106|NCT00038155|Rehabilitation
671107|NCT00038142|Ewing's Sarcoma
671108|NCT00038142|Vincristine
671109|NCT00038142|Doxorubicin
671110|NCT00038142|Adriamycin
671111|NCT00038142|Rubex
671112|NCT00038142|Cyclophosphamide
671113|NCT00038142|Dexrazoxane
671114|NCT00038142|Zinecard
671115|NCT00038142|VACdxr
671116|NCT00038142|ImmTher
671117|NCT00038116|Parkinson's disease
671118|NCT00038116|PD
671119|NCT00038116|dopamine
671120|NCT00038116|embryonic dopamine cell implant surgery
671121|NCT00038116|tissue implants
671122|NCT00038090|Myeloma
671123|NCT00038090|Thalidomide
671124|NCT00038090|Thalomid
671125|NCT00038090|Dexamethasone
671126|NCT00038090|Decadron
671127|NCT00038064|anemia of cancer/chemotherapy
671128|NCT00038064|non-myeloid malignancies
671129|NCT00038064|Drug Therapy
671130|NCT00038051|Acute Myeloid Leukemia
671131|NCT00038051|AML
671132|NCT00038051|Chronic Myelomonocytic Leukemia
671133|NCT00038051|CMML
671134|NCT00038051|Myeloproliferative Disorders
671135|NCT00038051|Refractory Anemia with Excess of Blasts
671136|NCT00038051|RAEB-t
671137|NCT00038051|RAEB
671138|NCT00038051|Hum-195/rGel
671139|NCT00038038|Squamous cell carcinoma of head and neck
671140|NCT00038025|Mycosis Fungoides
671141|NCT00038025|Lymphoma
671142|NCT00038025|Chronic lymphocytic leukemia
671143|NCT00038025|Deoxycoformycin
671144|NCT00038025|Pentostatin
671145|NCT00038025|All other lymphomas
671146|NCT00038025|Nucleoside analogue
671147|NCT00038025|Adenosine deaminase inhibitor
671148|NCT00038025|T-cells
671149|NCT00038012|Dose-intensified carboplatin
671150|NCT00038012|autologous cryopreserved platelets
671151|NCT00038012|thrombopoietin
671152|NCT00038012|Gynecologic malignancy
671153|NCT00037999|Muscle strength
671154|NCT00037999|Testosterone
671155|NCT00037999|Rehabilitation
671156|NCT00037999|Impaired muscle strength
671157|NCT00037986|Audiology
671158|NCT00037986|Hearing
671159|NCT00037986|Hearing Aids
671160|NCT00037986|Quality of Life
671161|NCT00037973|COPD
671162|NCT00037973|Ventilation
671163|NCT00037960|Constrained Induced
671164|NCT00037960|CI therapy
671165|NCT00037960|CVA
671166|NCT00037960|Strokes
671167|NCT00037947|Multiple Sclerosis
671168|NCT00037947|MS
671169|NCT00037947|Hearing
671170|NCT00037934|Robot
671171|NCT00037934|Stroke
671172|NCT00037934|Upper Extremity
671173|NCT00037921|SCI
671174|NCT00037921|UTI
671175|NCT00037908|Stroke
671176|NCT00037908|Hemiparesis
671177|NCT00037908|Upper limb function
671178|NCT00037908|Strength training
671179|NCT00037895|Stroke
671180|NCT00037895|Ambulation Training
671181|NCT00037895|Rehabilitation
671182|NCT00037895|Treadmill
671183|NCT00037882|Chronic Myelogenous Leukemia
671184|NCT00037882|Interferon alpha
671185|NCT00037882|Roferon
671186|NCT00037882|Intron
671413|NCT00036894|adult meningioma
671187|NCT00037882|Chronic Myelogenous Leukemia-Philadelphia positive
671188|NCT00037869|Metastatic neuroendocrine tumors
671189|NCT00037843|adrenal diseases
671190|NCT00037830|Parkinson's disease
671191|NCT00037830|PD
671192|NCT00037830|GM1 Ganglioside
671193|NCT00037830|Sygen
671194|NCT00037817|Toxicity Evaluation
671195|NCT00037817|Pharmacokinetics
671196|NCT00037817|Apoptosis
671197|NCT00037817|Gene Induction
671198|NCT00037817|Gene Expression
671199|NCT00037817|Lung Cancer
671200|NCT00037817|Small Cell Lung Cancer
671201|NCT00037817|Non-Small Cell Lung Cancer
671202|NCT00037817|Pleural Mesothelioma
671203|NCT00037804|Pharmacia
671204|NCT00037713|LD Small Cell Lung Cancer
671205|NCT00037713|BEC2, vaccine
671206|NCT00037713|adjuvant, monoclonal antibody
671207|NCT00037713|LD Small Cell Lung Cancer (VA Classification, Zelen, 1973)
671208|NCT00037687|Severe sepsis
671209|NCT00037687|Platelet-activating factor acetylhydrolase
671210|NCT00037674|Bipolar Disorder
671211|NCT00037674|Bipolar
671212|NCT00037674|Mania
671213|NCT00037674|Topiramate
671214|NCT00037674|Lithium
671215|NCT00037661|dry eye
671216|NCT00037622|E-antigen positive, treatment naïve chronic HBV infected, lamivudine resistant chronic Hepatitis B, Achillion
671217|NCT00037609|Metastatic breast cancer
671218|NCT00037583|Acute
671219|NCT00037583|Myeloid
671220|NCT00037583|Leukemia
671221|NCT00037570|Peptic
671222|NCT00037570|Ulcer
671223|NCT00037570|Hemorrhage
671224|NCT00037557|Hemophilia B
671225|NCT00037544|Severe
671226|NCT00037544|Hemophilia
671227|NCT00037544|A
671228|NCT00037531|Transplant
671229|NCT00037531|Kidney
671230|NCT00037518|Severe primary hyperparathyroidism
671231|NCT00037518|Parathyroid carcinoma
671232|NCT00037492|stroke
671233|NCT00037492|recovery
671234|NCT00037479|neurologic Lyme disease
671235|NCT00037479|Lyme disease
671236|NCT00037479|ceftriaxone
671237|NCT00037479|Rocephin
671238|NCT00037479|PET scans
671239|NCT00037479|Lyme encephalopathy
671240|NCT00037479|neuroborreliosis
671241|NCT00037479|borreliosis
671242|NCT00037219|Anidulafungin
671243|NCT00037219|Candidemia
671244|NCT00037219|Invasive Candidiasis
671245|NCT00037206|Invasive Aspergillosis
671246|NCT00037167|Fall-Prevention
671247|NCT00037167|Balance
671248|NCT00037167|Musculoskeletal Systems
671249|NCT00037167|Protective Devices
671250|NCT00037167|Gait
671251|NCT00037167|Equilibrium
671252|NCT00037167|Accidental Falls
671253|NCT00037167|Frail Elderly
671254|NCT00037154|Benign Prostatic Hyperplasia
671255|NCT00037154|Herbal Therapies
671256|NCT00037154|Complementary and Alternative Medicine
671257|NCT00037154|Men's Health
671258|NCT00037141|Prostate
671259|NCT00037141|BPH
671260|NCT00037141|Prostatitis
671261|NCT00037128|Lupus
671262|NCT00037128|SLE
671263|NCT00037128|DHEA
671264|NCT00037128|GL701
671265|NCT00037115|Demyelinating
671266|NCT00037115|Multiple Sclerosis
671267|NCT00037115|Myelitis
671268|NCT00037115|Neuritis
671269|NCT00037115|Optic Neuritis
671270|NCT00037115|AVONEX
671271|NCT00037115|methotrexate
671272|NCT00037115|methylprednisolone
671273|NCT00037115|interferon beta 1a
671274|NCT00037115|demyelination
671275|NCT00037115|central nervous system
671276|NCT00037115|brain
671277|NCT00037115|nerve
671278|NCT00037115|lesions
671279|NCT00037115|enhancement
671280|NCT00037115|enhancing
671281|NCT00037102|Multiple Sclerosis
671282|NCT00037102|Relapsing
671283|NCT00037102|Methotrexate
671284|NCT00037102|AVONEX
671285|NCT00037102|interferon beta 1a
671286|NCT00037102|demyelinating
671287|NCT00037102|autoimmune
671288|NCT00037076|HIV Seropositivity
671289|NCT00037076|Hepatitis C
671290|NCT00037076|Polymerase Chain Reaction
671291|NCT00037076|RNA, Viral
671292|NCT00037076|Prevalence
671293|NCT00037076|Disease Transmission, Vertical
671294|NCT00037076|Hepacivirus
671295|NCT00037076|Enzyme Immunoassay
671296|NCT00037076|GB virus C
671297|NCT00037063|Pilot Projects
671298|NCT00037063|Recurrence
671299|NCT00037063|Antioxidants
671300|NCT00037063|Reverse Transcriptase Inhibitors
671301|NCT00037063|Anti-HIV Agents
671302|NCT00037063|Ascorbic Acid
671303|NCT00037063|Alpha-Tocopherol
671304|NCT00037063|Riboflavin
671305|NCT00037063|Thiamine
671306|NCT00037063|Lactic Acid
671307|NCT00037037|stage III melanoma
671308|NCT00037037|stage IV melanoma
671309|NCT00037037|recurrent melanoma
671310|NCT00037024|stage I breast cancer
671311|NCT00037024|stage II breast cancer
671312|NCT00037024|stage I prostate cancer
671313|NCT00037024|stage II B prostate cancer
671314|NCT00037024|stage II A prostate cancer
671315|NCT00037024|male breast cancer
671316|NCT00037024|fatigue
671317|NCT00037024|malnutrition
671318|NCT00037024|psychosocial effects of cancer and its treatment
671319|NCT00037024|depression
671320|NCT00037011|disseminated neuroblastoma
671321|NCT00037011|recurrent neuroblastoma
671322|NCT00036998|stage I breast cancer
671323|NCT00036998|stage II breast cancer
671324|NCT00036985|stage IIIA breast cancer
671325|NCT00036972|recurrent adult brain tumor
671326|NCT00036972|adult glioblastoma
671327|NCT00036972|adult anaplastic astrocytoma
671328|NCT00036972|adult mixed glioma
671329|NCT00036972|adult giant cell glioblastoma
671330|NCT00036972|adult gliosarcoma
671331|NCT00036959|metastatic osteosarcoma
671332|NCT00036959|childhood infratentorial ependymoma
671333|NCT00036959|recurrent childhood rhabdomyosarcoma
671334|NCT00036959|childhood supratentorial ependymoma
671335|NCT00036959|childhood craniopharyngioma
671336|NCT00036959|disseminated neuroblastoma
671337|NCT00036959|recurrent neuroblastoma
671338|NCT00036959|recurrent childhood liver cancer
671339|NCT00036959|stage IV childhood liver cancer
671340|NCT00036959|recurrent Wilms tumor and other childhood kidney tumors
671341|NCT00036959|stage IV Wilms tumor
671342|NCT00036959|childhood central nervous system germ cell tumor
671343|NCT00036959|recurrent osteosarcoma
671344|NCT00036959|unspecified childhood solid tumor, protocol specific
671345|NCT00036959|childhood germ cell tumor
671346|NCT00036959|metastatic childhood soft tissue sarcoma
671347|NCT00036959|recurrent childhood soft tissue sarcoma
671348|NCT00036959|childhood high-grade cerebral astrocytoma
671349|NCT00036959|childhood oligodendroglioma
671350|NCT00036959|childhood choroid plexus tumor
671351|NCT00036959|childhood grade I meningioma
671352|NCT00036959|childhood grade II meningioma
671353|NCT00036959|childhood grade III meningioma
671354|NCT00036959|recurrent childhood cerebellar astrocytoma
671355|NCT00036959|recurrent childhood cerebral astrocytoma
671356|NCT00036959|recurrent childhood medulloblastoma
671357|NCT00036959|recurrent childhood visual pathway and hypothalamic glioma
671358|NCT00036959|previously treated childhood rhabdomyosarcoma
671359|NCT00036959|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
671360|NCT00036959|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
671361|NCT00036959|recurrent childhood ependymoma
671362|NCT00036959|childhood teratoma
671363|NCT00036959|childhood malignant testicular germ cell tumor
671364|NCT00036959|childhood malignant ovarian germ cell tumor
671365|NCT00036959|childhood extragonadal germ cell tumor
671366|NCT00036959|recurrent childhood malignant germ cell tumor
671367|NCT00036946|unspecified adult solid tumor, protocol specific
671368|NCT00036946|stage IV grade 1 follicular lymphoma
671369|NCT00036946|stage IV grade 2 follicular lymphoma
671370|NCT00036946|stage IV grade 3 follicular lymphoma
671371|NCT00036946|stage IV adult diffuse small cleaved cell lymphoma
671372|NCT00036946|stage IV adult diffuse mixed cell lymphoma
671373|NCT00036946|stage IV adult diffuse large cell lymphoma
671374|NCT00036946|stage IV adult immunoblastic large cell lymphoma
671375|NCT00036946|stage IV adult lymphoblastic lymphoma
671376|NCT00036946|stage IV adult Burkitt lymphoma
671377|NCT00036946|recurrent grade 1 follicular lymphoma
671378|NCT00036946|recurrent grade 2 follicular lymphoma
671379|NCT00036946|recurrent grade 3 follicular lymphoma
671380|NCT00036946|recurrent adult diffuse small cleaved cell lymphoma
671381|NCT00036946|recurrent adult diffuse mixed cell lymphoma
671382|NCT00036946|recurrent adult diffuse large cell lymphoma
671383|NCT00036946|recurrent adult immunoblastic large cell lymphoma
671384|NCT00036946|recurrent adult lymphoblastic lymphoma
671385|NCT00036946|recurrent adult Burkitt lymphoma
671386|NCT00036946|stage IV mantle cell lymphoma
671387|NCT00036946|recurrent mantle cell lymphoma
671388|NCT00036946|recurrent marginal zone lymphoma
671389|NCT00036946|recurrent small lymphocytic lymphoma
671390|NCT00036946|stage IV small lymphocytic lymphoma
671391|NCT00036946|stage IV marginal zone lymphoma
671392|NCT00036946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
671393|NCT00036946|nodal marginal zone B-cell lymphoma
671394|NCT00036946|splenic marginal zone lymphoma
671395|NCT00036933|stage III prostate cancer
671396|NCT00036933|recurrent prostate cancer
671397|NCT00036920|recurrent non-small cell lung cancer
671398|NCT00036920|squamous cell lung cancer
671399|NCT00036920|large cell lung cancer
671400|NCT00036920|stage IIIB non-small cell lung cancer
671401|NCT00036920|stage IV non-small cell lung cancer
671402|NCT00036920|adenocarcinoma of the lung
671403|NCT00036920|adenosquamous cell lung cancer
671404|NCT00036920|bronchoalveolar cell lung cancer
671405|NCT00036894|recurrent adult brain tumor
671406|NCT00036894|adult glioblastoma
671407|NCT00036894|adult anaplastic astrocytoma
671408|NCT00036894|adult anaplastic oligodendroglioma
671409|NCT00036894|adult mixed glioma
671410|NCT00036894|adult ependymoblastoma
671411|NCT00036894|adult anaplastic ependymoma
671412|NCT00036894|adult myxopapillary ependymoma
671414|NCT00036894|adult meningeal hemangiopericytoma
671415|NCT00036894|adult brain stem glioma
671416|NCT00036894|adult grade III meningioma
671417|NCT00036894|adult giant cell glioblastoma
671418|NCT00036894|adult gliosarcoma
671419|NCT00036868|stage IV breast cancer
671420|NCT00036868|recurrent breast cancer
671421|NCT00036842|recurrent malignant testicular germ cell tumor
671422|NCT00036842|extragonadal germ cell tumor
671423|NCT00036829|unspecified adult solid tumor, protocol specific
671424|NCT00036829|pain
671425|NCT00036816|ciliary body and choroid melanoma, medium/large size
671426|NCT00036790|stage III adult Hodgkin lymphoma
671427|NCT00036790|stage IV adult Hodgkin lymphoma
671428|NCT00036790|recurrent adult Hodgkin lymphoma
671429|NCT00036790|stage III cutaneous T-cell non-Hodgkin lymphoma
671430|NCT00036790|stage IV cutaneous T-cell non-Hodgkin lymphoma
671431|NCT00036790|recurrent cutaneous T-cell non-Hodgkin lymphoma
671432|NCT00036790|isolated plasmacytoma of bone
671433|NCT00036790|extramedullary plasmacytoma
671434|NCT00036790|refractory multiple myeloma
671435|NCT00036790|Waldenstrom macroglobulinemia
671436|NCT00036790|stage III multiple myeloma
671437|NCT00036790|stage III chronic lymphocytic leukemia
671438|NCT00036790|stage IV chronic lymphocytic leukemia
671439|NCT00036790|recurrent adult acute myeloid leukemia
671440|NCT00036790|recurrent adult acute lymphoblastic leukemia
671441|NCT00036790|relapsing chronic myelogenous leukemia
671442|NCT00036790|refractory chronic lymphocytic leukemia
671443|NCT00036790|small intestine lymphoma
671444|NCT00036790|unspecified adult solid tumor, protocol specific
671445|NCT00036790|chronic phase chronic myelogenous leukemia
671446|NCT00036790|accelerated phase chronic myelogenous leukemia
671447|NCT00036790|blastic phase chronic myelogenous leukemia
671448|NCT00036790|meningeal chronic myelogenous leukemia
671449|NCT00036790|untreated adult acute lymphoblastic leukemia
671450|NCT00036790|untreated adult acute myeloid leukemia
671451|NCT00036790|refractory hairy cell leukemia
671452|NCT00036790|chronic myelomonocytic leukemia
671453|NCT00036790|T-cell large granular lymphocyte leukemia
671454|NCT00036790|acute undifferentiated leukemia
671455|NCT00036790|stage III grade 1 follicular lymphoma
671456|NCT00036790|stage III grade 2 follicular lymphoma
671457|NCT00036790|stage III grade 3 follicular lymphoma
671458|NCT00036790|stage III adult diffuse small cleaved cell lymphoma
671459|NCT00036790|stage III adult diffuse mixed cell lymphoma
671460|NCT00036790|stage III adult diffuse large cell lymphoma
671461|NCT00036790|stage III adult immunoblastic large cell lymphoma
671462|NCT00036790|stage III adult lymphoblastic lymphoma
671463|NCT00036790|stage III adult Burkitt lymphoma
671464|NCT00036790|stage IV grade 1 follicular lymphoma
671465|NCT00036790|stage IV grade 2 follicular lymphoma
671466|NCT00036790|stage IV grade 3 follicular lymphoma
671467|NCT00036790|stage IV adult diffuse small cleaved cell lymphoma
671468|NCT00036790|stage IV adult diffuse mixed cell lymphoma
671469|NCT00036790|stage IV adult diffuse large cell lymphoma
671470|NCT00036790|stage IV adult immunoblastic large cell lymphoma
671471|NCT00036790|stage IV adult lymphoblastic lymphoma
671472|NCT00036790|stage IV adult Burkitt lymphoma
671473|NCT00036790|recurrent grade 1 follicular lymphoma
671474|NCT00036790|recurrent grade 2 follicular lymphoma
671475|NCT00036790|recurrent grade 3 follicular lymphoma
671476|NCT00036790|recurrent adult diffuse small cleaved cell lymphoma
671477|NCT00036790|recurrent adult diffuse mixed cell lymphoma
671478|NCT00036790|recurrent adult diffuse large cell lymphoma
671479|NCT00036790|recurrent adult immunoblastic large cell lymphoma
671480|NCT00036790|recurrent adult lymphoblastic lymphoma
671481|NCT00036790|recurrent adult Burkitt lymphoma
671482|NCT00036790|stage III adult T-cell leukemia/lymphoma
671483|NCT00036790|stage IV adult T-cell leukemia/lymphoma
671484|NCT00036790|recurrent adult T-cell leukemia/lymphoma
671485|NCT00036790|secondary acute myeloid leukemia
671486|NCT00036790|prolymphocytic leukemia
671487|NCT00036790|stage III mantle cell lymphoma
671488|NCT00036790|stage IV mantle cell lymphoma
671489|NCT00036790|recurrent mantle cell lymphoma
671490|NCT00036790|angioimmunoblastic T-cell lymphoma
671491|NCT00036790|anaplastic large cell lymphoma
671492|NCT00036790|stage III mycosis fungoides/Sezary syndrome
671493|NCT00036790|stage IV mycosis fungoides/Sezary syndrome
671494|NCT00036790|recurrent mycosis fungoides/Sezary syndrome
671495|NCT00036790|chronic eosinophilic leukemia
671496|NCT00036790|chronic neutrophilic leukemia
671497|NCT00036790|recurrent non-small cell lung cancer
671498|NCT00036790|recurrent small cell lung cancer
671499|NCT00036790|stage IIIA non-small cell lung cancer
671500|NCT00036790|stage IIIB non-small cell lung cancer
671501|NCT00036790|stage IV non-small cell lung cancer
671502|NCT00036790|extensive stage small cell lung cancer
671503|NCT00036790|limited stage small cell lung cancer
671504|NCT00036790|recurrent breast cancer
671505|NCT00036790|stage IIIA breast cancer
671506|NCT00036790|stage IIIB breast cancer
671507|NCT00036790|stage IIIC breast cancer
671508|NCT00036790|stage IV breast cancer
671509|NCT00036790|recurrent colon cancer
671510|NCT00036790|stage III colon cancer
671511|NCT00036790|stage IV colon cancer
671512|NCT00036790|recurrent prostate cancer
671513|NCT00036790|stage III prostate cancer
671514|NCT00036790|stage IV prostate cancer
671515|NCT00036790|recurrent lip and oral cavity cancer
671516|NCT00036790|stage III lip and oral cavity cancer
671517|NCT00036790|stage IV lip and oral cavity cancer
671518|NCT00036790|recurrent paranasal sinus and nasal cavity cancer
671519|NCT00036790|stage III paranasal sinus and nasal cavity cancer
671520|NCT00036790|stage IV paranasal sinus and nasal cavity cancer
671521|NCT00036790|recurrent metastatic squamous neck cancer with occult primary
671522|NCT00036790|recurrent hypopharyngeal cancer
671523|NCT00036790|stage III hypopharyngeal cancer
671524|NCT00036790|stage IV hypopharyngeal cancer
671525|NCT00036790|recurrent laryngeal cancer
671526|NCT00036790|stage III laryngeal cancer
671527|NCT00036790|stage IV laryngeal cancer
671528|NCT00036790|recurrent oropharyngeal cancer
671529|NCT00036790|stage III oropharyngeal cancer
671530|NCT00036790|stage IV oropharyngeal cancer
671531|NCT00036790|recurrent nasopharyngeal cancer
671532|NCT00036790|stage III nasopharyngeal cancer
671533|NCT00036790|stage IV nasopharyngeal cancer
671534|NCT00036790|atypical chronic myeloid leukemia
671535|NCT00036790|myelodysplastic/myeloproliferative disease, unclassifiable
671536|NCT00036790|recurrent marginal zone lymphoma
671537|NCT00036790|recurrent small lymphocytic lymphoma
671538|NCT00036790|stage III small lymphocytic lymphoma
671539|NCT00036790|stage III marginal zone lymphoma
671540|NCT00036790|stage IV small lymphocytic lymphoma
671541|NCT00036790|stage IV marginal zone lymphoma
671542|NCT00036790|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
671543|NCT00036790|nodal marginal zone B-cell lymphoma
671544|NCT00036790|splenic marginal zone lymphoma
671545|NCT00036790|adult acute myeloid leukemia with t(8;21)(q22;q22)
671546|NCT00036790|adult acute myeloid leukemia with t(16;16)(p13;q22)
671547|NCT00036790|adult acute myeloid leukemia with inv(16)(p13;q22)
671548|NCT00036790|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
671549|NCT00036790|adult acute myeloid leukemia with t(15;17)(q22;q12)
671550|NCT00036712|recurrent childhood acute lymphoblastic leukemia
671551|NCT00036712|refractory multiple myeloma
671552|NCT00036712|recurrent childhood rhabdomyosarcoma
671553|NCT00036712|disseminated neuroblastoma
671554|NCT00036712|recurrent neuroblastoma
671555|NCT00036712|recurrent Wilms tumor and other childhood kidney tumors
671556|NCT00036712|recurrent childhood lymphoblastic lymphoma
671557|NCT00036712|stage III chronic lymphocytic leukemia
671558|NCT00036712|stage IV chronic lymphocytic leukemia
671559|NCT00036712|recurrent childhood acute myeloid leukemia
671560|NCT00036712|relapsing chronic myelogenous leukemia
671561|NCT00036712|refractory chronic lymphocytic leukemia
671562|NCT00036712|chronic phase chronic myelogenous leukemia
671563|NCT00036712|accelerated phase chronic myelogenous leukemia
671564|NCT00036712|blastic phase chronic myelogenous leukemia
671565|NCT00036712|primary myelofibrosis
671566|NCT00036712|childhood acute promyelocytic leukemia (M3)
671567|NCT00036712|refractory hairy cell leukemia
671568|NCT00036712|oral complications
671569|NCT00036712|recurrent/refractory childhood Hodgkin lymphoma
671570|NCT00036712|de novo myelodysplastic syndromes
671571|NCT00036712|previously treated myelodysplastic syndromes
671572|NCT00036712|secondary myelodysplastic syndromes
671573|NCT00036712|pain
671574|NCT00036712|recurrent childhood small noncleaved cell lymphoma
671575|NCT00036712|recurrent childhood large cell lymphoma
671576|NCT00036712|previously treated childhood rhabdomyosarcoma
671577|NCT00036712|childhood malignant ovarian germ cell tumor
671578|NCT00036712|childhood chronic myelogenous leukemia
671579|NCT00036712|atypical chronic myeloid leukemia, BCR-ABL1 negative
671580|NCT00036712|myelodysplastic/myeloproliferative neoplasm, unclassifiable
671581|NCT00036712|childhood myelodysplastic syndromes
671582|NCT00036686|stage I breast cancer
671583|NCT00036686|stage II breast cancer
671584|NCT00036686|stage IIIA breast cancer
671585|NCT00036686|stage IIIB breast cancer
671586|NCT00036686|stage IIIC breast cancer
671587|NCT00036686|recurrent breast cancer
671588|NCT00036686|stage IV breast cancer
671589|NCT00036660|recurrent adult brain tumor
671590|NCT00036660|adult glioblastoma
671591|NCT00036660|adult anaplastic astrocytoma
671592|NCT00036660|adult giant cell glioblastoma
671593|NCT00036660|adult gliosarcoma
671594|NCT00036647|Non-Small Cell Lung Cancer
671595|NCT00036647|Tarceva
671596|NCT00036647|EGFR
671597|NCT00036647|erlotinib
671598|NCT00036634|treatment naive
671599|NCT00036595|Subdural
671600|NCT00036595|Epilepsy
671601|NCT00036595|Motor Function
671602|NCT00036595|Desynchronization
671603|NCT00036595|Coherence
671604|NCT00036595|Motor Control
671605|NCT00036582|Psychophysiology
671606|NCT00036582|Structural MRI
671607|NCT00036582|Genetics
671608|NCT00036582|Bipolar Disorder
671609|NCT00036582|Children and Adolescents
671610|NCT00036582|Clozapine
671611|NCT00036582|Placebo
671612|NCT00036582|Treatment-Refractory
671613|NCT00036582|Bipolar
671614|NCT00036582|Healthy Volunteer
671615|NCT00036582|HV
671616|NCT00036582|BPD
671617|NCT00036582|Normal Control
671618|NCT00036569|Brainstem Glioma
671619|NCT00036569|Pediatric
671620|NCT00036569|Interferon
671621|NCT00036569|MR Imaging
671622|NCT00036569|Angiogenesis
671623|NCT00036569|Brain Tumor
671624|NCT00036569|Glioma
671625|NCT00036569|Pediatric Brain Tumor
671626|NCT00036556|Hormone-Refractory Prostate Cancer
671627|NCT00036543|Hormone-Refractory, Prostate Cancer
671628|NCT00036517|Stage III and Stage IV colorectal cancer
671629|NCT00036517|diarrhea
671630|NCT00036517|reduce
671631|NCT00036517|alleviate
671632|NCT00036517|modulate
671633|NCT00036517|Saltz regimen
671634|NCT00036517|CPT-11
671635|NCT00036517|irinotecan
671636|NCT00036517|camptosar
671637|NCT00036517|5-fluorouracil
671638|NCT00036517|leucovorin
671639|NCT00036517|5-FU
671640|NCT00036517|LV
671641|NCT00036517|chemotherapy
671642|NCT00036517|side effect
671643|NCT00036517|toxicity
671644|NCT00036517|botanical drug
671645|NCT00036517|herbal medicine
671646|NCT00036517|chinese herbal medicine
671647|NCT00036517|traditional chinese medicine
671648|NCT00036517|TCM
671649|NCT00036517|oral dose
671650|NCT00036517|oral administration
671651|NCT00036517|concomitant use
671652|NCT00036504|Diabetes mellitus, insulin deficiency, hyperglycemia
671653|NCT00036491|Systemic Lupus Erythematosus
671654|NCT00036491|SLE
671655|NCT00036491|B-Lymphocytes
671656|NCT00036491|anti-CD20
671657|NCT00036491|rituximab
671658|NCT00036478|Pilot Projects
671659|NCT00036478|Exercise
671660|NCT00036478|Phosphorus Isotopes
671661|NCT00036478|Mitochondria
671662|NCT00036478|Lactates
671663|NCT00036478|Magnetic Resonance Spectroscopy
671664|NCT00036465|Pilot Projects
671665|NCT00036465|HIV-1
671666|NCT00036465|RNA, Viral
671667|NCT00036465|Genotype
671668|NCT00036465|Viral Load
671669|NCT00036465|Antiretroviral Therapy, Highly Active
671670|NCT00036465|Treatment Experienced
671671|NCT00036452|Lopinavir
671672|NCT00036452|HIV-1
671673|NCT00036452|Drug Administration Schedule
671674|NCT00036452|Stavudine
671675|NCT00036452|HIV Protease Inhibitors
671676|NCT00036452|Ritonavir
671677|NCT00036452|Reverse Transcriptase Inhibitors
671678|NCT00036452|Self Care
671679|NCT00036452|Viral Load
671680|NCT00036452|Emtricitabine
671681|NCT00036452|Directly Observed Therapy
671682|NCT00036452|Tenofovir Disoproxil Fumarate
671683|NCT00036452|Treatment Naive
671684|NCT00036439|ulcerative colitis
671685|NCT00036439|infliximab
671686|NCT00036439|Remicade
671687|NCT00036439|infusion
671688|NCT00036426|lymphoma
671689|NCT00036426|vaccine
671690|NCT00036426|idiotype
671691|NCT00036426|KLH
671692|NCT00036426|GM-CSF
671693|NCT00036413|(ALS)
671694|NCT00036400|Anemia
671695|NCT00036400|Gastric Cancer
671696|NCT00036400|Rectal Cancer
671697|NCT00036400|Epoetin Alfa
671698|NCT00036387|Rheumatoid arthritis
671699|NCT00036387|infliximab
671700|NCT00036387|anti-TNF
671701|NCT00036387|methotrexate
671702|NCT00036387|safety and efficacy
671703|NCT00036387|Remicade
671704|NCT00036374|Juvenile rheumatoid arthritis
671705|NCT00036374|Infliximab
671706|NCT00036374|Methotrexate
671707|NCT00036374|remicade
671708|NCT00036348|Bipolar I disorder
671709|NCT00036335|depression
671710|NCT00036335|pain
671711|NCT00036335|blues
671712|NCT00036335|sadness
671713|NCT00036335|aches
671714|NCT00036309|Major Depressive Disorder
671715|NCT00036309|Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features
671716|NCT00036296|Involuntary Movements
671717|NCT00036296|Abnormal Movements
671718|NCT00036296|Advanced Parkinson's disease
671719|NCT00036296|Levodopa induced dyskinesia
671720|NCT00036257|Chronic Lymphocytic Leukemia
671721|NCT00036257|Leukemia
671722|NCT00036257|CLL
671723|NCT00036179|Candidemia
671724|NCT00036179|Anti-Fungal
671725|NCT00036166|Aspergillus
671726|NCT00036166|Anti-Fungal
671727|NCT00036153|Tacrolimus, Prograf®, FK506
671728|NCT00036140|Pharmacia
671729|NCT00036127|agitated schizophrenic patients
671730|NCT00036114|Psychosis associated with dementia of the Alzheimer's type
671731|NCT00036101|Bipolar I Disorder
671732|NCT00036075|prostate cancer
671733|NCT00036075|prostate
671734|NCT00036062|Sivelestat
671735|NCT00036062|acute lung injury
671736|NCT00036036|renal
671737|NCT00036036|renal cell cancer
671738|NCT00036036|renal cell carcinoma
671739|NCT00036036|kidney cancer
671740|NCT00035997|Hormone-sensitive Prostate Cancer
671741|NCT00035997|Prostate Cancer
671742|NCT00035997|Bone Metastasis
671743|NCT00035984|Type 2 Diabetes Mellitis
671744|NCT00035958|Juvenile Dermatomyositis
671745|NCT00035958|Pediatric
671746|NCT00035958|Randomized Clinical Trial
671747|NCT00035958|Pediatric Rheumatology
671748|NCT00035919|Colon cancer
671749|NCT00035919|Targeted Injectable Vector
671750|NCT00035919|Gene Transfer
671751|NCT00035919|Gene Therapy
671752|NCT00035919|Retroviral vector
671753|NCT00035906|Diabetes
671754|NCT00035906|Macular Edema
671755|NCT00035906|Diabetic Macular Edema
671756|NCT00035906|Diabetic Retinopathy
671757|NCT00035906|Cystoid Macular Edema
671758|NCT00035906|Uveitis
671759|NCT00035906|Vision
671760|NCT00035906|Eye
671761|NCT00035906|Retina
671762|NCT00035906|Retinal Vein Occlusion
671763|NCT00035906|Irvine-Gass Syndrome
671764|NCT00035893|treatment interruption
671765|NCT00035893|HIV Infections
671766|NCT00035880|Acute graft versus host disease
671767|NCT00035880|Stem Cell Transplantation
671768|NCT00035854|Pharmacia
671769|NCT00035854|Drug Resistance, Microbial
671770|NCT00035828|COPD
671771|NCT00035828|Chronic bronchitis
671772|NCT00035828|Chronic obstructive pulmonary disease
671773|NCT00035828|Shortness of breath
671774|NCT00035828|Dyspnea
671775|NCT00035828|Bronchitis
671776|NCT00035815|amyotrophic lateral sclerosis
671777|NCT00035815|ALS
671778|NCT00035815|progressive weakness
671779|NCT00035815|insulin-like growth factor-1
671780|NCT00035815|IGF-I
671781|NCT00035815|Myotrophin
671782|NCT00035802|Bipolar
671783|NCT00035802|Mania
671784|NCT00035802|Pediatric
671785|NCT00035802|Children
671786|NCT00035802|Adolescent
671787|NCT00035802|Topiramate
671788|NCT00035802|Anticonvulsants
671789|NCT00035802|Central Nervous System Agents
671790|NCT00035802|Protective Agents
671791|NCT00035802|Neuroprotectiive Agents
671792|NCT00035620|Bone cancer
671793|NCT00035620|Sarcoma
671794|NCT00035620|Neutropenia
671795|NCT00035620|Chemotherapy
671796|NCT00035594|Breast cancer
671797|NCT00035594|Neutropenia
671798|NCT00035594|Chemotherapy
671799|NCT00035581|treatment experienced
671800|NCT00035581|HIV Infections
671801|NCT00035581|HIV
671802|NCT00035581|HAART
671803|NCT00035581|early virologic failure
671804|NCT00035568|Type 2 Diabetes Mellitus
671805|NCT00035555|kidney
671806|NCT00035555|transplant
671807|NCT00035555|rejection
671808|NCT00035542|Diabetes Mellitus, Type II
671809|NCT00035529|MS
671810|NCT00035438|obsessive compulsive disorder
671811|NCT00035438|ocd
671812|NCT00035438|Anxiety
671813|NCT00035438|St. John’s Wort
671814|NCT00035438|Wisconsin
671815|NCT00035438|Psychiatric
671816|NCT00035438|Mental health
671817|NCT00035412|Social phobia
671818|NCT00035412|Social anxiety
671819|NCT00035412|Anxiety
671820|NCT00035412|St. John’ Wort
671821|NCT00035412|Wisconsin
671822|NCT00035412|Psychiatric
671823|NCT00035412|Mental health
671824|NCT00035399|acupressure /acupuncture
671825|NCT00035399|alternative medicine
671826|NCT00035399|arthritis therapy
671827|NCT00035399|combination therapy
671828|NCT00035399|human therapy evaluation
671829|NCT00035399|knee
671830|NCT00035399|osteoarthritis
671831|NCT00035399|physical therapy
671832|NCT00035399|chronic pain
671833|NCT00035399|clinical trial
671834|NCT00035399|functional ability
671835|NCT00035386|Outflow Obstruction
671836|NCT00035386|ICE
671837|NCT00035386|HCM
671838|NCT00035386|Hypertrophic Cardiomyopathy
671839|NCT00035386|OHC
671840|NCT00035386|Obstructive HCM
671841|NCT00035386|Cardiomyopathy
671842|NCT00035373|Tumor
671843|NCT00035373|Brain
671844|NCT00035373|Chemotherapy
671845|NCT00035373|Anti-Angiogenesis
671846|NCT00035373|Radiation Therapy
671847|NCT00035373|CNS Tumor
671848|NCT00035360|PEG-Intron
671849|NCT00035360|treatment experienced
671850|NCT00035334|Familial Mediterranean Fever
671851|NCT00035334|Amyloidosis
671852|NCT00035334|Secondary (AA) Amyloidosis
671853|NCT00035334|Nephrotic Syndrome
671854|NCT00035308|Immunologic Diseases
671855|NCT00035308|Autoimmune Diseases
671856|NCT00035308|Systemic Lupus Erythematosus
671857|NCT00035308|SLE
671858|NCT00035308|Lupus Nephritis
671859|NCT00035308|Lupus Glomerulonephritis
671860|NCT00035269|Pharmacia
671861|NCT00035243|kidney cancer
671862|NCT00035243|renal cancer
671863|NCT00035243|cancer
671864|NCT00035243|tumor
671865|NCT00035243|tumour
671866|NCT00035243|neoplasm
671867|NCT00035243|carcinoma
671868|NCT00035243|clear cell
671869|NCT00035243|sarcomatoid
671870|NCT00035243|papillary
671871|NCT00035243|medullary
671872|NCT00035243|collecting duct
671873|NCT00035243|chromophobe
671874|NCT00035243|intravenous
671875|NCT00035243|epothilone
671876|NCT00035230|Bipolar disorders
671877|NCT00035230|Bipolar
671878|NCT00035230|mania
671879|NCT00035230|Topiramate
671880|NCT00035230|Lithium
671881|NCT00035204|Donepezil
671882|NCT00035204|Alzheimer's
671883|NCT00035204|Dementia
671884|NCT00035204|Cognitive impairment
671885|NCT00035204|Aricept
671886|NCT00035204|Alzheimer's disease
671887|NCT00035204|Razadyne
671888|NCT00035204|Galantamine
671889|NCT00035191|Dementia
671890|NCT00035191|vascular dementia
671891|NCT00035191|cerebral vascular disease
671892|NCT00035178|ESRD
671893|NCT00035178|End-stage renal disease
671894|NCT00035178|Hemodialysis
671895|NCT00035165|melanoma
671896|NCT00035165|cancer
671897|NCT00035165|tumor
671898|NCT00035165|tumour
671899|NCT00035165|malignant
671900|NCT00035165|metastatic
671901|NCT00035165|intravenous
671902|NCT00035165|epothilone
671903|NCT00035139|pediatric traumatic brain injury
671904|NCT00035126|breast
671905|NCT00035126|cancer
671906|NCT00035126|tumor
671907|NCT00035126|tumour
671908|NCT00035126|intravenous
671909|NCT00035126|epothilone
671910|NCT00035126|taxane
671911|NCT00035126|anthracycline
671912|NCT00035113|prostate cancer
671913|NCT00035113|prostate
671914|NCT00035113|androgen independent
671915|NCT00035113|cancer
671916|NCT00035113|tumor
671917|NCT00035113|tumour
671918|NCT00035113|neoplasm
671919|NCT00035113|carcinoma
671920|NCT00035113|intravenous
671921|NCT00035113|epothilone
671922|NCT00035100|ovarian
671923|NCT00035100|ovary
671924|NCT00035100|peritoneal cancer
671925|NCT00035100|fallopian cancer
671926|NCT00035100|cancer
671927|NCT00035100|tumor
671928|NCT00035100|tumour
671929|NCT00035100|neoplasm
671930|NCT00035100|carcinoma
671931|NCT00035100|intravenous
671932|NCT00035100|epothilone
671933|NCT00035087|colon
671934|NCT00035087|rectum
671935|NCT00035087|colorectal
671936|NCT00035087|rectal
671937|NCT00035087|cancer
671938|NCT00035087|tumor
671939|NCT00035087|tumour
671940|NCT00035087|neoplasm
671941|NCT00035087|carcinoma
671942|NCT00035087|intravenous
671943|NCT00035087|epothilone
671944|NCT00035061|Bladder Cancer
671945|NCT00035061|Metastatic
671946|NCT00035061|Recurrent
671947|NCT00035061|Transitional cell carcinoma of the urothelium
671948|NCT00035035|Pancreas
671949|NCT00035035|Cancer
671950|NCT00035035|Unresectable or Metastatic Cancer of the Pancreas
671951|NCT00035035|Alimta
671952|NCT00035022|Leukemia, Lymphoma, T-Cell
671953|NCT00034970|alternative medicine
671954|NCT00034970|art
671955|NCT00034970|cancer
671956|NCT00034970|combination cancer therapy
671957|NCT00034970|creative-expression
671958|NCT00034970|group therapy
671959|NCT00034970|holistic
671960|NCT00034970|human therapy evaluation
671961|NCT00034970|meditation
671962|NCT00034970|neoplasm /cancer chemotherapy
671963|NCT00034970|coping
671964|NCT00034970|gender difference
671965|NCT00034970|outcomes research
671966|NCT00034970|psychological aspect of cancer
671967|NCT00034970|psychological stressor
671968|NCT00034970|quality of life
671969|NCT00034970|racial /ethnic difference
671970|NCT00034970|stress management
671971|NCT00034970|support
671972|NCT00034970|behavioral /social science research
671973|NCT00034970|patient oriented research
671974|NCT00034957|Pharmacia
671975|NCT00034918|Metastatic breast cancer
671976|NCT00034879|Locally advanced and/or metastatic non-operable
671977|NCT00034879|non-small cell lung cancer (stage III or IV)
671978|NCT00034879|patients who have failed standard therapy.
671979|NCT00034866|HIV
671980|NCT00034866|treatment experienced
671981|NCT00034866|Boehringer
671982|NCT00034866|tipranavir
671983|NCT00034866|ritonavir
671984|NCT00034840|hypertension
671985|NCT00034840|telmisartan
671986|NCT00034840|valsartan
671987|NCT00034840|boehringer
671988|NCT00034801|Depression
671989|NCT00034801|Comorbid Depression
671990|NCT00034801|Schizophrenia
671991|NCT00034801|Schizoaffective Disorder
671992|NCT00034788|Regranex
671993|NCT00034788|Foot ulcers
671994|NCT00034788|Diabetes
671995|NCT00034788|Diabetes mellitus
671996|NCT00034788|Diabetic foot
671997|NCT00034775|Schizophrenia
671998|NCT00034775|intramuscular injection
671999|NCT00034775|antipsychotic agents
672000|NCT00034775|risperidone
672001|NCT00034762|Alzheimer's disease
672002|NCT00034762|psychosis
672003|NCT00034762|elderly
672004|NCT00034762|dementia
672005|NCT00034762|risperidone
672006|NCT00034762|antipsychotic agents
672007|NCT00034749|Adolescents
672008|NCT00034749|Schizophrenia
672009|NCT00034749|risperidone
672010|NCT00034736|Pneumonia
672011|NCT00034736|Bacterial pneumonia
672012|NCT00034736|Community acquired pneumonia
672013|NCT00034736|Lung Inflammation
672014|NCT00034736|Quinolones
672015|NCT00034736|Levofloxacin
672016|NCT00034736|Ceftriaxone
672017|NCT00034736|Erythromycin
672018|NCT00034736|Clarithromycin
672019|NCT00034723|DTI
672020|NCT00034723|MRSI
672021|NCT00034723|MTR
672022|NCT00034723|NAWN
672023|NCT00034723|Fiber-Tract
672024|NCT00034723|Normal Control
672025|NCT00034723|Healthy Volunteer
672026|NCT00034723|HV
672027|NCT00034723|HTLV-1 Associated Myelopathy
672028|NCT00034723|Tropical Spastic Paraparesis
672029|NCT00034723|HAM/TSP
672030|NCT00034710|Analgesics/*therapeutic use
672031|NCT00034710|Capsaicin/*administration & dosage/adverse effects
672032|NCT00034710|Herpes Zoster/*complications/drug therapy
672033|NCT00034710|Neuralgia/*drug therapy/etiology
672034|NCT00034710|Pain
672035|NCT00034710|Capsicum
672036|NCT00034710|Pepper
672037|NCT00034710|Dermal assessment
672038|NCT00034710|Pain measurement
672039|NCT00034710|Diary
672040|NCT00034710|PHN
672041|NCT00034710|Postherpetic Neuralgia
672042|NCT00034710|allodynia
672043|NCT00034710|hyperalgesia
672044|NCT00034710|shingles
672045|NCT00034710|varicella
672046|NCT00034697|Brain mets
672047|NCT00034697|non-small cell lung cancer
672048|NCT00034684|Leukemia
672049|NCT00034684|Myelodysplastic Syndromes
672050|NCT00034684|Leukemia, Myeloid
672051|NCT00034684|Leukemia, Lymphocytic
672052|NCT00034671|Aspergillosis, Candidiasis, Mucormycosis, Cryptococcosis
672053|NCT00034671|Invasive Fungal Infections
672054|NCT00034658|Aspergillosis, Candidiasis, Cryptococcosis,
672055|NCT00034645|Allogenic Stem cell transplantation
672056|NCT00034645|Fungal infections
672057|NCT00034632|Aspergillosis, Candidiasis, Cryptococcosis, Phaeohyphomycosis
672058|NCT00034632|Invasive Fungal Infections
672059|NCT00034606|Lung cancer
672060|NCT00034606|cancer
672061|NCT00034606|neoplasm
672062|NCT00034606|non-small
672063|NCT00034606|chemotherapy
672064|NCT00034593|Bladder cancer
672065|NCT00034593|metastatic
672066|NCT00034593|transitional cell carcinoma of the urothelium
672067|NCT00034580|Bipolar I Disorder
672068|NCT00034567|Prevention
672069|NCT00034554|AJCC stage III or stage IV malignant melanoma
672070|NCT00034554|melanoma
672071|NCT00034554|gp75
672072|NCT00034554|DNA vaccine
672073|NCT00034541|cetuximab
672074|NCT00034541|epidermal growth factor receptor
672075|NCT00034541|antibody
672076|NCT00034541|non-small cell lung cancer
672077|NCT00034541|carboplatin
672078|NCT00034541|paclitaxel
672079|NCT00034489|metastatic breast cancer
672080|NCT00034489|combination therapy
672081|NCT00034489|Alimta
672082|NCT00034476|Sepsis, sPLA2 Inhibitor
672083|NCT00034463|metastatic cancer
672084|NCT00034463|chemotherapy
672085|NCT00034450|Terminal Cancer
672086|NCT00034437|Normal Volunteer
672087|NCT00034437|Phlebotomy
672088|NCT00034437|Cytomegalovirus
672089|NCT00034437|CMV
672090|NCT00034437|CMV Seropositve
672091|NCT00034424|Genetics
672092|NCT00034424|Hereditary
672093|NCT00034424|Screening
672094|NCT00034424|Behavioral
672095|NCT00034424|Familial Testicular Germ Cell Tumor
672096|NCT00034424|Testicular Cancer
672097|NCT00034398|Basal Ganglia
672098|NCT00034398|Neuroimaging
672099|NCT00034398|Inhibitory Neurons
672100|NCT00034398|Disinhibition
672101|NCT00034398|Tics
672102|NCT00034398|Tourette's Syndrome
672103|NCT00034398|Tourette Syndrome
672104|NCT00034398|Healthy Volunteer
672105|NCT00034398|HV
672106|NCT00034398|Normal Control
672107|NCT00034385|Cytomegalovirus
672108|NCT00034385|Prophylaxis
672109|NCT00034385|Renal Transplant
672110|NCT00034385|Valcyte
672111|NCT00034385|Kidney Transplant
672112|NCT00034372|immunotherapy
672113|NCT00034372|monoclonal
672114|NCT00034372|antibody
672115|NCT00034372|Stage III ovarian epithelial cancer
672116|NCT00034372|Stage IV ovarian epithelial cancer
672117|NCT00034359|E-antigen positive
672118|NCT00034359|Treatment Naive Chronic Hepatitis B, Achillion
672119|NCT00034346|Advanced
672120|NCT00034346|Non-Small-Cell
672121|NCT00034346|Lung
672122|NCT00034346|Cancer
672123|NCT00034346|NSCLC
672124|NCT00034346|Carcinoma
672125|NCT00034346|Advanced Non-Small-Cell Lung Cancer (NSCLC)
672126|NCT00034333|Hepatoma
672127|NCT00034333|Unresectable adult primary liver cancer
672128|NCT00034333|liver cancer
672129|NCT00034333|HCC
672130|NCT00034333|Hepatocellular Carcinoma
672131|NCT00034294|C. difficile-associated diarrhea
672132|NCT00034294|CDAD
672133|NCT00034294|Clostridium difficile-Associated Diarrhea
672134|NCT00034294|Clostridium enterocolitis
672135|NCT00034294|antibiotic-associated diarrhea
672136|NCT00034294|clostridium difficile colitis
672137|NCT00034294|infectious diarrhea
672138|NCT00034294|chronic diarrhea
672139|NCT00034294|antibiotic-associated colitis
672140|NCT00034281|Gene, HER2
672141|NCT00034281|Clinical Trial, Phase I
672142|NCT00034281|Breast neoplasm
672143|NCT00034281|Pancreatic neoplasm
672144|NCT00034281|Ovarian neoplasm
672145|NCT00034281|Colorectal neoplasm
672146|NCT00034281|Renal neoplasm
672147|NCT00034281|Prostate neoplasm
672148|NCT00034281|Cancer
672149|NCT00034268|non-small cell lung cancer
672150|NCT00034268|Stage IIIB or IV non-small cell lung cancer (NSCLC)
672151|NCT00034242|Ataxia
672152|NCT00034242|Treatment
672153|NCT00034242|IVIG
672154|NCT00034242|SCA
672155|NCT00034242|Cerebellar Degeneration
672156|NCT00034242|Cerebellar Ataxia
672157|NCT00034242|Cerebellum
672158|NCT00034229|Antidepressant
672159|NCT00034229|Anti-Glutamatergic
672160|NCT00034229|Bipolar Disorder
672161|NCT00034229|Depression
672162|NCT00034229|Treatment Refractory
672163|NCT00034229|Felbamate
672164|NCT00034229|Glutamate
672165|NCT00034229|Treatment-Resistant
672166|NCT00034229|Bipolar
672167|NCT00034229|BPD
672168|NCT00034229|Bipolar Depression
672169|NCT00034216|Suppressor Cells
672170|NCT00034216|T-cells
672171|NCT00034216|CD4+/CD25+ Cells
672172|NCT00034216|Cancer
672173|NCT00034216|Malignancy
672174|NCT00034216|Blood Sample
672175|NCT00034177|Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium
672176|NCT00034138|immunotherapy
672177|NCT00034138|monoclonal
672178|NCT00034138|antibody
672179|NCT00034138|Stage III ovarian epithelial cancer
672180|NCT00034138|Stage IV ovarian epithelial cancer
672181|NCT00034125|cancer
672182|NCT00034125|metastatic breast cancer
672183|NCT00034125|hormonal therapy
672184|NCT00034112|chronic obstructive pulmonary disease
672185|NCT00034112|combination therapy,
672186|NCT00034112|emphysema
672187|NCT00034112|exercise
672188|NCT00034112|human therapy evaluation
672189|NCT00034112|rehabilitation
672190|NCT00034112|respiratory disease /disorder therapy
672191|NCT00034112|respiratory function
672192|NCT00034112|biomechanics
672193|NCT00034112|body movement
672194|NCT00034112|diaphragm
672195|NCT00034112|dyspnea
672196|NCT00034112|muscle tension
672197|NCT00034112|musculoskeletal system
672198|NCT00034112|outcomes research
672199|NCT00034112|quality of life
672200|NCT00034112|somatic reflex
672201|NCT00034086|Lopinavir
672202|NCT00034086|OspA Protein
672203|NCT00034086|HIV-1
672204|NCT00034086|HIV Protease Inhibitors
672205|NCT00034086|CD4 Lymphocyte Count
672206|NCT00034086|Ritonavir
672207|NCT00034086|Haemophilus Vaccines
672208|NCT00034086|HAART
672209|NCT00034086|Pneumococcal Vaccines
672210|NCT00034086|tenofovir disoproxil
672211|NCT00034073|Imaging
672212|NCT00034073|Pediatrics
672213|NCT00034073|Brain
672214|NCT00034073|Mapping
672215|NCT00034073|Development
672216|NCT00034073|Healthy Volunteer
672217|NCT00034073|HV
672218|NCT00034073|Normal Control
672219|NCT00034060|Cytokines
672220|NCT00034060|Exanercept
672221|NCT00034060|Cachexia
672222|NCT00034060|Body Composition
672223|NCT00034060|Vascular Endothelial System
672224|NCT00034060|Rheumatoid Arthritis
672225|NCT00034060|RA
672226|NCT00034060|Women
672227|NCT00034060|Healthy Volunteer
672228|NCT00034060|HV
672229|NCT00034060|Normal Control
672230|NCT00034047|Endometriosis
672231|NCT00034047|Pelvic pain
672232|NCT00034047|Acupuncture
672233|NCT00034047|Chinese herbs
672234|NCT00034047|Hormone therapy
672235|NCT00034047|Nafarelin
672236|NCT00034034|Advanced colorectal cancer
672237|NCT00034034|acupressure /acupuncture
672238|NCT00034034|anxiety
672239|NCT00034034|colorectal neoplasm
672240|NCT00034034|human therapy evaluation
672241|NCT00034034|neoplasm /cancer palliative treatment
672242|NCT00034034|quality of life
672243|NCT00034034|terminal patient care
672244|NCT00034034|hypothalamic pituitary adrenal axis
672245|NCT00034034|pain
672246|NCT00034034|psychological aspect of cancer
672247|NCT00034034|stress management
672248|NCT00034034|alternative medicine
672249|NCT00034034|behavioral /social science research tag
672250|NCT00034034|human subject
672251|NCT00034034|patient oriented research
672252|NCT00034021|Female Sexual Arousal Disorder
672253|NCT00034021|Female Orgasmic Disorder
672254|NCT00034021|ginkgo biloba
672255|NCT00034021|human therapy evaluation
672256|NCT00034021|sex behavior
672257|NCT00034021|antidepressant
672258|NCT00034021|blood flow
672259|NCT00034021|clinical trial
672260|NCT00034021|drug adverse effect
672261|NCT00034021|mental disorder chemotherapy
672262|NCT00034021|relaxation
672263|NCT00034021|smooth muscle
672264|NCT00034021|alternative medicine
672265|NCT00034021|blood flow measurement
672266|NCT00034021|female
672267|NCT00034021|placebo
672268|NCT00034021|women's health
672269|NCT00034021|Secondary to either to fluoxetine, sertraline, or paroxetine use.
672270|NCT00034008|Energy Medicine
672271|NCT00034008|Healing Touch
672272|NCT00034008|CAM Research
672273|NCT00034008|Neonates
672274|NCT00034008|Stress
672275|NCT00034008|Conditions resulting from stress
672276|NCT00034008|Neonatal intensive care
672277|NCT00034008|Healing of stress and prevention of negative
672278|NCT00034008|Developmental outcomes – physical and behavioral
672279|NCT00034008|Therapeutic Touch
672280|NCT00034008|Touch therapies
672281|NCT00034008|Energy therapies
672282|NCT00034008|Infant touch
672283|NCT00034008|Infant stimulation
672284|NCT00033995|Tics
672285|NCT00033995|Basal Ganglia
672286|NCT00033995|Neuroimaging
672287|NCT00033995|Sleep
672288|NCT00033995|Suppression of Tics
672289|NCT00033995|Tourette Syndrome
672290|NCT00033995|Tourette's Syndrome
672291|NCT00033995|Tic Disorder
672292|NCT00033995|Healthy Volunteer
672293|NCT00033995|HV
672294|NCT00033995|Normal Control
672295|NCT00033982|Triazole
672296|NCT00033982|Refractory
672297|NCT00033982|Antifungal
672298|NCT00033982|Fungal Infection
672299|NCT00033969|CRPS
672300|NCT00033969|RSD
672301|NCT00033969|Causalgia
672302|NCT00033969|Chronic Pain
672303|NCT00033969|Neuropathic Pain
672304|NCT00033969|Normal Control
672305|NCT00033969|Complex Regional Pain Syndrome
672306|NCT00033969|Healthy Volunteer
672307|NCT00033969|HV
672308|NCT00033956|Metastatic Melanoma
672309|NCT00033956|Renal Cell Carcinoma
672310|NCT00033956|IL-2
672311|NCT00033956|Interleukin-2
672312|NCT00033956|Hypotension
672313|NCT00033917|intraventricular hemorrhage (IVH)
672314|NCT00033917|bleeding in the brain
672315|NCT00033917|indomethacin
672316|NCT00033917|prematurity
672317|NCT00033917|very low birth weight infants
672318|NCT00033904|Kidney Cancer, renal, immunotherapy, tumor,
672319|NCT00033891|Muscle Weakness
672320|NCT00033891|Muscle Biopsy
672321|NCT00033891|Gene Expression Profiling
672322|NCT00033891|MRI
672323|NCT00033891|Inflammation
672324|NCT00033891|Polymyositis
672325|NCT00033891|Dermatomyositis
672326|NCT00033878|Advanced Cancer
672327|NCT00033865|Insomnia
672328|NCT00033865|Yoga
672329|NCT00033865|Meditation
672330|NCT00033865|Behavioral treatment
672331|NCT00033852|complementary therapies
672332|NCT00033852|Depression
672333|NCT00033852|HIV
672334|NCT00033852|Massage Therapy
672335|NCT00033852|Alternative Treatments
672336|NCT00033839|Headache
672337|NCT00033839|Cluster
672338|NCT00033839|EC
672339|NCT00033839|Episodic Cluster
672340|NCT00033826|Vitamin D
672341|NCT00033826|Adipose tissue
672342|NCT00033826|Metabolism
672343|NCT00033813|Duchenne
672344|NCT00033813|muscular
672345|NCT00033813|dystrophy
672346|NCT00033813|controlled clinical trial
672347|NCT00033813|CINRG
672348|NCT00033787|Depression
672349|NCT00033787|Tryptophan Depletion
672350|NCT00033787|PET
672351|NCT00033787|Serotonin
672352|NCT00033787|Pathophysiology
672353|NCT00033787|Emotional Stimuli
672354|NCT00033787|GABA MRS
672355|NCT00033787|MDD
672356|NCT00033787|Healthy Volunteer
672357|NCT00033787|HV
672358|NCT00033787|Normal Control
672359|NCT00033774|Leukapheresis
672360|NCT00033774|G-CSF
672361|NCT00033774|Mobilization
672362|NCT00033774|Stem Cells
672363|NCT00033774|Adult
672364|NCT00033774|Healthy Volunteer
672365|NCT00033774|HV
672366|NCT00033774|Normal Control
672367|NCT00033748|stage IV colon cancer
672368|NCT00033748|stage IV rectal cancer
672369|NCT00033748|recurrent colon cancer
672370|NCT00033748|recurrent rectal cancer
672371|NCT00033748|liver metastases
672372|NCT00033735|recurrent pancreatic cancer
672373|NCT00033735|duct cell adenocarcinoma of the pancreas
672374|NCT00033722|recurrent non-small cell lung cancer
672375|NCT00033722|squamous cell lung cancer
672376|NCT00033722|large cell lung cancer
672377|NCT00033722|stage IIIB non-small cell lung cancer
672378|NCT00033722|stage IV non-small cell lung cancer
672379|NCT00033722|adenocarcinoma of the lung
672380|NCT00033722|adenosquamous cell lung cancer
672381|NCT00033709|adult leiomyosarcoma
672382|NCT00033709|stage III adult soft tissue sarcoma
672383|NCT00033709|recurrent adult soft tissue sarcoma
672384|NCT00033709|stage III uterine sarcoma
672385|NCT00033709|stage IV uterine sarcoma
672386|NCT00033709|recurrent uterine sarcoma
672387|NCT00033709|uterine leiomyosarcoma
672388|NCT00033709|stage IV adult soft tissue sarcoma
672389|NCT00033696|limited stage small cell lung cancer
672390|NCT00033683|stage I breast cancer
672391|NCT00033683|stage II breast cancer
672392|NCT00033657|stage I gastric cancer
672393|NCT00033657|stage II gastric cancer
672394|NCT00033657|stage III gastric cancer
672395|NCT00033657|stage IV gastric cancer
672396|NCT00033657|stage I esophageal cancer
672397|NCT00033657|stage II esophageal cancer
672398|NCT00033657|stage III esophageal cancer
672399|NCT00033657|stage IV esophageal cancer
672400|NCT00033657|adenocarcinoma of the stomach
672401|NCT00033657|adenocarcinoma of the esophagus
672402|NCT00033644|stage IV uterine sarcoma
672403|NCT00033644|recurrent uterine sarcoma
672404|NCT00033644|uterine leiomyosarcoma
672405|NCT00033631|adenocarcinoma of the prostate
672406|NCT00033631|stage IIB prostate cancer
672407|NCT00033631|stage IIA prostate cancer
672408|NCT00033592|non-small cell lung cancer
672409|NCT00033592|small cell lung cancer
672410|NCT00033566|unspecified adult solid tumor, protocol specific
672411|NCT00033553|squamous cell lung cancer
672412|NCT00033553|large cell lung cancer
672413|NCT00033553|stage IIIA non-small cell lung cancer
672414|NCT00033553|stage IIIB non-small cell lung cancer
672415|NCT00033553|adenocarcinoma of the lung
672416|NCT00033553|bronchoalveolar cell lung cancer
672417|NCT00033540|unresectable gallbladder cancer
672418|NCT00033540|recurrent gallbladder cancer
672419|NCT00033540|unresectable extrahepatic bile duct cancer
672420|NCT00033540|recurrent extrahepatic bile duct cancer
672421|NCT00033540|adenocarcinoma of the gallbladder
672422|NCT00033540|adenocarcinoma with squamous metaplasia of the gallbladder
672423|NCT00033540|squamous cell carcinoma of the gallbladder
672424|NCT00033540|adenocarcinoma of the extrahepatic bile duct
672425|NCT00033540|cholangiocarcinoma of the gallbladder
672426|NCT00033540|cholangiocarcinoma of the extrahepatic bile duct
672427|NCT00033527|non-small cell lung cancer
672428|NCT00033527|small cell lung cancer
672429|NCT00033514|stage IV breast cancer
672430|NCT00033514|recurrent breast cancer
672431|NCT00033488|ovarian epithelial cancer
672432|NCT00033475|post-transplant lymphoproliferative disorder
672433|NCT00033436|stage I bladder cancer
672434|NCT00033436|stage II bladder cancer
672435|NCT00033436|stage III bladder cancer
672436|NCT00033436|transitional cell carcinoma of the bladder
672437|NCT00033423|recurrent grade 1 follicular lymphoma
672438|NCT00033423|recurrent grade 2 follicular lymphoma
672439|NCT00033423|recurrent grade 3 follicular lymphoma
672440|NCT00033423|recurrent marginal zone lymphoma
672441|NCT00033423|recurrent small lymphocytic lymphoma
672442|NCT00033423|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
672443|NCT00033423|nodal marginal zone B-cell lymphoma
672444|NCT00033423|splenic marginal zone lymphoma
672445|NCT00033410|stage II non-small cell lung cancer
672446|NCT00033410|squamous cell lung cancer
672447|NCT00033410|large cell lung cancer
672448|NCT00033410|stage IIIA non-small cell lung cancer
672449|NCT00033410|stage IIIB non-small cell lung cancer
672450|NCT00033410|adenocarcinoma of the lung
672451|NCT00033397|stage II breast cancer
672452|NCT00033397|stage IV breast cancer
672453|NCT00033397|stage IIIA breast cancer
672454|NCT00033397|stage IIIB breast cancer
672455|NCT00033397|stage IIIC breast cancer
672456|NCT00033397|inflammatory breast cancer
672457|NCT00033384|stage III colon cancer
672458|NCT00033384|stage IV colon cancer
672459|NCT00033384|stage IV breast cancer
672460|NCT00033384|stage IIIA breast cancer
672461|NCT00033384|recurrent breast cancer
672462|NCT00033384|stage IIIB breast cancer
672463|NCT00033384|recurrent non-small cell lung cancer
672464|NCT00033384|stage II pancreatic cancer
672465|NCT00033384|stage III pancreatic cancer
672466|NCT00033384|recurrent pancreatic cancer
672467|NCT00033384|recurrent colon cancer
672468|NCT00033384|stage IIIA non-small cell lung cancer
672469|NCT00033384|stage IIIB non-small cell lung cancer
672470|NCT00033384|stage IV non-small cell lung cancer
672471|NCT00033384|duct cell adenocarcinoma of the pancreas
672472|NCT00033384|stage IV pancreatic cancer
672473|NCT00033345|breast cancer
672474|NCT00033332|stage I multiple myeloma
672475|NCT00033332|stage II multiple myeloma
672476|NCT00033332|stage III multiple myeloma
672477|NCT00033319|colon cancer
672478|NCT00033319|rectal cancer
672479|NCT00033306|stage IV colon cancer
672480|NCT00033306|stage IV rectal cancer
672481|NCT00033306|recurrent colon cancer
672482|NCT00033306|recurrent rectal cancer
672483|NCT00033306|adenocarcinoma of the colon
672484|NCT00033306|adenocarcinoma of the rectum
672485|NCT00033280|adult anaplastic oligodendroglioma
672486|NCT00033280|adult mixed glioma
672487|NCT00033241|stage II pancreatic cancer
672488|NCT00033241|stage III pancreatic cancer
672489|NCT00033241|recurrent pancreatic cancer
672490|NCT00033241|unspecified adult solid tumor, protocol specific
672491|NCT00033241|stage IV pancreatic cancer
672492|NCT00033228|stage IV melanoma
672493|NCT00033228|recurrent melanoma
672494|NCT00033215|neovascularization
672495|NCT00033215|matrix metalloproteinases
672496|NCT00033215|antiangiogenesis
672497|NCT00033215|type IV collagenases
672498|NCT00033202|Solid Tumor
672499|NCT00033202|Camptothecin
672500|NCT00033202|Pharmacokinetics
672501|NCT00033189|duchenne
672502|NCT00033189|dystrophy
672503|NCT00033189|DMD
672504|NCT00033189|clinical trial
672505|NCT00033189|CINRG
672506|NCT00033176|complementary therapies
672507|NCT00033176|Immune restoration
672508|NCT00033176|HIV infection
672509|NCT00033176|AIDS
672510|NCT00033176|HAART non-responsiveness
672511|NCT00033176|glutathione restoration
672512|NCT00033176|lipoic acid
672513|NCT00033176|dithiol
672514|NCT00033163|Antiviral Agents
672515|NCT00033163|Hepatitis B
672516|NCT00033163|Drug Resistance, Microbial
672517|NCT00033163|Lamivudine
672518|NCT00033163|DNA, Viral
672519|NCT00033163|Hepatitis B Virus
672520|NCT00033163|Adefovir dipivoxil
672521|NCT00033163|Tenofovir disoproxil fumarate
672522|NCT00033163|Treatment Experienced
672523|NCT00033150|Specific Language Impairment
672524|NCT00033150|Fast ForWord
672525|NCT00033150|Language therapy
672526|NCT00033150|Auditory processing
672527|NCT00033137|Pneumothorax
672528|NCT00033137|Kidney
672529|NCT00033137|Fibrofolliculoma
672530|NCT00033137|BHD
672531|NCT00033137|Neoplasms
672532|NCT00033137|Kidney Cancer
672533|NCT00033137|Birt Hogg Dube Syndrome
672534|NCT00033137|Skin Papules
672535|NCT00033085|cocaine dependence
672536|NCT00033033|cocaine dependence
672537|NCT00033020|substance use disorders
672538|NCT00033007|substance use disorders
672539|NCT00032994|substance use disorders
672540|NCT00032981|substance use disorder
672541|NCT00032968|opiate dependence
672542|NCT00032955|opiate addiction
672543|NCT00032955|morphine addiction
672544|NCT00032942|opiate dependence
672545|NCT00032929|Cocaine Dependence
672546|NCT00032903|Malignant Glioma, Camptothecin, Pharmacokinetics
672547|NCT00032890|osteoarthritis
672548|NCT00032890|knee pain
672549|NCT00032877|Linkage Study
672550|NCT00032877|Gene Identification Study
672551|NCT00032877|Diaphragmatic Hernia
672552|NCT00032877|Fraser Syndrome
672553|NCT00032877|Cryptophthalmos
672554|NCT00032877|Fryns Syndrome
672555|NCT00032877|Hydrolethalus Syndrome
672556|NCT00032877|Positional Cloning
672557|NCT00032864|amputations, diabetes,
672558|NCT00032838|Hydrocortisone
672559|NCT00032838|Yohimbine
672560|NCT00032838|Cognition
672561|NCT00032838|Norepinephrine
672562|NCT00032838|Cortisol
672563|NCT00032838|Emotion
672564|NCT00032838|Healthy Volunteer
672565|NCT00032838|HV
672566|NCT00032838|Normal Control
672567|NCT00032825|Combination
672568|NCT00032825|Microtubule
672569|NCT00032825|Hormonal
672570|NCT00032825|Chemotherapy
672571|NCT00032825|Pharmacokinetics
672572|NCT00032825|Prostate Cancer
672573|NCT00032825|Prostate
672574|NCT00032812|Motor Learning
672575|NCT00032812|Sequencing
672576|NCT00032812|Functional Imaging
672577|NCT00032812|Raclopride
672578|NCT00032812|Connectivity
672579|NCT00032812|Parkinson Disease
672580|NCT00032812|Parkinson's Disease
672581|NCT00032812|PD
672582|NCT00032812|Healthy Volunteer
672583|NCT00032812|HV
672584|NCT00032812|Normal Control
672585|NCT00032773|acute graft versus host disease
672586|NCT00032773|aGVHD
672587|NCT00032773|allogeneic hematopoietic stem cell transplantation
672588|NCT00032773|peripheral blood stem cell transplantation
672589|NCT00032773|cord blood transplant
672590|NCT00032773|pentostatin
672591|NCT00032773|Nipent
672592|NCT00032773|deoxycoformycin
672593|NCT00032760|binge eating disorder
672594|NCT00032760|human therapy evaluation
672595|NCT00032760|meditation
672596|NCT00032760|obesity
672597|NCT00032760|nutrition education
672598|NCT00032760|psychotherapy
672599|NCT00032760|racial /ethnic difference
672600|NCT00032760|adult human
672601|NCT00032760|alternative medicine
672602|NCT00032760|patient oriented research
672603|NCT00032747|Chronic Heart Failure
672604|NCT00032747|Heart Disease
672605|NCT00032734|Low Blood Sodium (Hyponatremia)
672606|NCT00032734|SIADH
672607|NCT00032734|Inappropriate ADH Syndrome
672608|NCT00032721|complementary therapies
672609|NCT00032721|Alternative medicine
672610|NCT00032721|Complementary and alternative medicine
672611|NCT00032721|Subtle energy therapy
672612|NCT00032721|Reiki
672613|NCT00032721|HIV/AIDS
672614|NCT00032695|myelopathy
672615|NCT00032695|AIDS-myelopathy
672616|NCT00032695|AIDS vacuolar myelopathy
672617|NCT00032695|methionine
672618|NCT00032682|Bowel Movement
672619|NCT00032682|Children
672620|NCT00032682|Stool
672621|NCT00032682|Symptom Management
672622|NCT00032682|Cancer
672623|NCT00032682|Constipation
672624|NCT00032669|Antiretrovirals
672625|NCT00032669|Adherence
672626|NCT00032669|Dose Adjustments
672627|NCT00032669|Genotypic Resistance
672628|NCT00032669|Phenotypic Resistance
672629|NCT00032656|Adolescents
672630|NCT00032656|Alternative and complimentary medication use
672631|NCT00032656|Health services utilization
672632|NCT00032656|Communication
672633|NCT00032656|Quality of care
672634|NCT00032617|PTSD
672635|NCT00032617|Stress Disorder
672636|NCT00032617|Trauma
672637|NCT00032591|AF
672638|NCT00032591|Mechanical heart valve (MHV)
672639|NCT00032539|Informed Consent
672640|NCT00032513|Herpesvirus
672641|NCT00032513|Hemophagocytosis
672642|NCT00032513|Lymphoproliferative
672643|NCT00032513|Epstein-Barr
672644|NCT00032513|Mononucleosis
672645|NCT00032513|EBV
672646|NCT00032513|CAEBV
672647|NCT00032513|Chronic Active Epstein-Barr Virus
672648|NCT00032513|Virus
672649|NCT00032500|common cold
672650|NCT00032500|Echinacea
672651|NCT00032487|DM
672652|NCT00032487|glycemic control
672653|NCT00032487|insulin
672654|NCT00032487|type 2 diabetes mellitus
672655|NCT00032474|Ginkgo biloba
672656|NCT00032474|type 2 diabetes
672657|NCT00032474|platelet function
672658|NCT00032474|antioxidant
672659|NCT00032461|chronic fatigue syndrome
672660|NCT00032461|fibromyalgia
672661|NCT00032461|post-traumatic stress disorder
672662|NCT00032461|neurologic abnormalities
672663|NCT00032448|Hernia
672664|NCT00032448|laparoscopic herniorrhaphy
672665|NCT00032448|tension-free herniorrhaphy
672666|NCT00032435|folate
672667|NCT00032435|pyridoxine
672668|NCT00032435|vitamin B6
672669|NCT00032435|cyanocobalamin
672670|NCT00032435|homoc
672671|NCT00032422|Acupuncture
672672|NCT00032422|Heart Failure
672673|NCT00032422|Autonomic nervous system
672674|NCT00032409|Music Therapy
672675|NCT00032409|Relaxation Therapy
672676|NCT00032409|Stress Reduction
672677|NCT00032409|Bone Marrow Transplantation
672678|NCT00032409|Stem Cell Transplantation
672679|NCT00031278|Metastatic
672680|NCT00031278|Breast
672681|NCT00031278|Cancer
672682|NCT00031278|immunotherapy
672683|NCT00031278|CPG 7909
672684|NCT00031265|stroke
672685|NCT00031265|telephone
672686|NCT00031265|intervention
672687|NCT00031187|Prostate
672688|NCT00031187|Lewis Blood-Group System
672689|NCT00031187|Antibodies, Monoclonal
672690|NCT00031187|Antigens, Neoplasm
672691|NCT00031187|Antineoplastic Agents
672692|NCT00031174|Apheresis
672693|NCT00031174|Healthy Volunteer
672694|NCT00031174|Rheumatoid Disease
672695|NCT00031174|Rheumatic Disease
672696|NCT00031174|Lupus
672697|NCT00031174|Rheumatoid Arthritis
672698|NCT00031174|Myositis
672699|NCT00031174|HV
672700|NCT00031174|Normal Control
672701|NCT00031161|Tyrosine
672702|NCT00031161|Diet
672703|NCT00031161|2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
672704|NCT00031161|4-Hydroxyphenylpyruvate Dioxygenase
672705|NCT00031161|Enzyme Inhibitors
672706|NCT00031148|Keratinocyte growth factor
672707|NCT00031148|Bone Marrow Transplantation
672708|NCT00031148|Hematopoietic Stem Cell Transplantation
672709|NCT00031148|HLA Antigens
672710|NCT00031148|Transplantation, Homologous
672711|NCT00031148|Recombinant Proteins
672712|NCT00031135|Parenteral Nutrition, Total
672713|NCT00031135|Lipotropic Agents
672714|NCT00031135|Choline
672715|NCT00032396|AMD
672716|NCT00032396|ARMD
672717|NCT00032396|Age-Related Macular Degeneration
672718|NCT00032396|Subfoveal Choroidal Neovascularization
672719|NCT00032396|CNV
672720|NCT00032383|Rehabilitation
672721|NCT00032383|Tai Chi
672722|NCT00032370|myocardial infarction
672723|NCT00032370|Prophylactic coronary artery revascularization
672724|NCT00032357|Ferritin reduction
672725|NCT00032357|Peripheral Vascular Disease (PVD)
672726|NCT00032357|phlebotomy
672727|NCT00032357|Reduction of Total Body Iron Storage(TBIS)
672728|NCT00032357|Total Body Iron Storage(TBIS)
672729|NCT00032344|large (>1 cm) adenomas
672730|NCT00032331|PET imaging, benign and malignant solitary pulmonary nodules
672731|NCT00032305|Colitis
672732|NCT00032305|Gastrointestinal Disease
672733|NCT00032305|Digestive System Disease
672734|NCT00032305|Intestinal Disease
672735|NCT00032305|Colonic Disease
672736|NCT00032240|Biomechanics
672737|NCT00032227|Carpal Tunnel Release
672738|NCT00032227|MR Nerve Imaging
672739|NCT00032227|Wrist MRI
672740|NCT00032201|Surgery
672741|NCT00032201|Tissue Sample
672742|NCT00032201|Gene Expression Profiling
672743|NCT00032201|Tissue Array Gene Expression
672744|NCT00032201|Comparative Genomic Hybridization
672745|NCT00032201|Breast Cancer
672746|NCT00032201|Breast Cancer Risk
672747|NCT00032201|Breast
672748|NCT00032175|stage III pancreatic cancer
672749|NCT00032175|duct cell adenocarcinoma of the pancreas
672750|NCT00032175|stage IV pancreatic cancer
672751|NCT00032162|stage III cervical cancer
672752|NCT00032162|recurrent cervical cancer
672753|NCT00032162|stage IB cervical cancer
672754|NCT00032162|stage IIB cervical cancer
672755|NCT00032162|stage IVB cervical cancer
672756|NCT00032162|stage IA cervical cancer
672757|NCT00032162|stage IIA cervical cancer
672758|NCT00032162|stage IVA cervical cancer
672759|NCT00032162|stage I endometrial carcinoma
672760|NCT00032162|stage II endometrial carcinoma
672761|NCT00032162|stage III endometrial carcinoma
672762|NCT00032162|stage IV endometrial carcinoma
672763|NCT00032162|recurrent endometrial carcinoma
672764|NCT00032162|fallopian tube cancer
672765|NCT00032162|stage I uterine sarcoma
672766|NCT00032162|stage II uterine sarcoma
672767|NCT00032162|stage III uterine sarcoma
672768|NCT00032162|stage IV uterine sarcoma
672769|NCT00032162|recurrent uterine sarcoma
672770|NCT00032162|ovarian sarcoma
672771|NCT00032162|ovarian carcinosarcoma
672772|NCT00032149|AIDS-related peripheral/systemic lymphoma
672773|NCT00032149|AIDS-related primary CNS lymphoma
672774|NCT00032149|AIDS-related diffuse large cell lymphoma
672775|NCT00032149|AIDS-related immunoblastic large cell lymphoma
672776|NCT00032149|AIDS-related small noncleaved cell lymphoma
672777|NCT00032149|AIDS-related diffuse mixed cell lymphoma
672778|NCT00032149|AIDS-related diffuse small cleaved cell lymphoma
672779|NCT00032149|AIDS-related lymphoblastic lymphoma
672780|NCT00032136|stage I breast cancer
672781|NCT00032136|stage II breast cancer
672782|NCT00032123|stage IV gastric cancer
672783|NCT00032123|stage IV esophageal cancer
672784|NCT00032123|adenocarcinoma of the stomach
672785|NCT00032123|adenocarcinoma of the esophagus
672786|NCT00032123|recurrent esophageal cancer
672787|NCT00032123|recurrent gastric cancer
672788|NCT00032097|adult glioblastoma
672789|NCT00032097|adult giant cell glioblastoma
672790|NCT00032097|adult gliosarcoma
672791|NCT00032084|non-small cell lung cancer
672792|NCT00032084|stage I non-small cell lung cancer
672793|NCT00032084|stage II non-small cell lung cancer
672794|NCT00032058|adenocarcinoma of the prostate
672795|NCT00032058|stage I prostate cancer
672796|NCT00032058|stage IIB prostate cancer
672797|NCT00032058|stage IIA prostate cancer
672798|NCT00032045|iris melanoma
672799|NCT00032045|ciliary body and choroid melanoma, small size
672800|NCT00032045|ciliary body and choroid melanoma, medium/large size
672801|NCT00032045|extraocular extension melanoma
672802|NCT00032045|recurrent intraocular melanoma
672803|NCT00032045|stage IV melanoma
672804|NCT00032045|recurrent melanoma
672805|NCT00032032|stage I non-small cell lung cancer
672806|NCT00032032|stage II non-small cell lung cancer
672807|NCT00032032|stage IIIA non-small cell lung cancer
672808|NCT00032032|stage IIIB non-small cell lung cancer
672809|NCT00032019|stage III adult diffuse large cell lymphoma
672810|NCT00032019|stage III adult immunoblastic large cell lymphoma
672811|NCT00032019|stage IV adult diffuse large cell lymphoma
672812|NCT00032019|stage IV adult immunoblastic large cell lymphoma
672813|NCT00032019|contiguous stage II adult immunoblastic large cell lymphoma
672814|NCT00032019|contiguous stage II adult diffuse large cell lymphoma
672815|NCT00032019|noncontiguous stage II adult immunoblastic large cell lymphoma
672816|NCT00032019|noncontiguous stage II adult diffuse large cell lymphoma
672817|NCT00032006|adenocarcinoma of the prostate
672818|NCT00032006|stage I prostate cancer
672819|NCT00032006|stage IIB prostate cancer
672820|NCT00032006|stage IIA prostate cancer
672821|NCT00032006|recurrent prostate cancer
672822|NCT00031980|stage I chronic lymphocytic leukemia
672823|NCT00031980|stage II chronic lymphocytic leukemia
672824|NCT00031980|stage III chronic lymphocytic leukemia
672825|NCT00031980|stage IV chronic lymphocytic leukemia
672826|NCT00031980|T-cell large granular lymphocyte leukemia
672827|NCT00031980|anemia
672828|NCT00031980|neutropenia
672829|NCT00031980|thrombocytopenia
672830|NCT00031967|unspecified adult solid tumor, protocol specific
672831|NCT00031967|tumors metastatic to brain
672832|NCT00031967|radiation toxicity
672833|NCT00031954|stage II ovarian epithelial cancer
672834|NCT00031954|stage I ovarian epithelial cancer
672835|NCT00031954|stage III ovarian epithelial cancer
672836|NCT00031954|stage IV ovarian epithelial cancer
672837|NCT00031954|fallopian tube cancer
672838|NCT00031954|primary peritoneal cavity cancer
672839|NCT00031941|stage IV adult Hodgkin lymphoma
672840|NCT00031941|recurrent adult Hodgkin lymphoma
672841|NCT00031941|stage IV cutaneous T-cell non-Hodgkin lymphoma
672842|NCT00031941|recurrent cutaneous T-cell non-Hodgkin lymphoma
672843|NCT00031941|unspecified adult solid tumor, protocol specific
672844|NCT00031941|stage IV grade 1 follicular lymphoma
672845|NCT00031941|stage IV grade 2 follicular lymphoma
672846|NCT00031941|stage IV grade 3 follicular lymphoma
672847|NCT00031941|stage IV adult diffuse small cleaved cell lymphoma
672848|NCT00031941|stage IV adult diffuse mixed cell lymphoma
672849|NCT00031941|stage IV adult diffuse large cell lymphoma
672850|NCT00031941|stage IV adult immunoblastic large cell lymphoma
672851|NCT00031941|stage IV adult lymphoblastic lymphoma
672852|NCT00031941|stage IV adult Burkitt lymphoma
672853|NCT00031941|recurrent grade 1 follicular lymphoma
672854|NCT00031941|recurrent grade 2 follicular lymphoma
672855|NCT00031941|recurrent grade 3 follicular lymphoma
672856|NCT00031941|recurrent adult diffuse small cleaved cell lymphoma
672857|NCT00031941|recurrent adult diffuse mixed cell lymphoma
672858|NCT00031941|recurrent adult diffuse large cell lymphoma
672859|NCT00031941|recurrent adult immunoblastic large cell lymphoma
672860|NCT00031941|recurrent adult lymphoblastic lymphoma
672861|NCT00031941|recurrent adult Burkitt lymphoma
672862|NCT00031941|stage IV adult T-cell leukemia/lymphoma
672863|NCT00031941|recurrent adult T-cell leukemia/lymphoma
672864|NCT00031941|stage IV mantle cell lymphoma
672865|NCT00031941|recurrent mantle cell lymphoma
672866|NCT00031941|angioimmunoblastic T-cell lymphoma
672867|NCT00031941|anaplastic large cell lymphoma
672868|NCT00031941|recurrent mycosis fungoides/Sezary syndrome
672869|NCT00031941|stage IV mycosis fungoides/Sezary syndrome
672870|NCT00031941|small intestine lymphoma
672871|NCT00031941|recurrent marginal zone lymphoma
672872|NCT00031941|recurrent small lymphocytic lymphoma
672873|NCT00031941|stage IV small lymphocytic lymphoma
672874|NCT00031941|stage IV marginal zone lymphoma
672875|NCT00031941|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
672876|NCT00031941|nodal marginal zone B-cell lymphoma
672877|NCT00031941|splenic marginal zone lymphoma
672878|NCT00031928|leptomeningeal metastases
672879|NCT00031915|metastatic osteosarcoma
672880|NCT00031915|recurrent childhood rhabdomyosarcoma
672881|NCT00031915|recurrent osteosarcoma
672882|NCT00031915|embryonal childhood rhabdomyosarcoma
672883|NCT00031915|alveolar childhood rhabdomyosarcoma
672884|NCT00031915|pleomorphic childhood rhabdomyosarcoma
672885|NCT00031915|metastatic childhood soft tissue sarcoma
672886|NCT00031915|recurrent childhood soft tissue sarcoma
672887|NCT00031915|childhood fibrosarcoma
672888|NCT00031915|childhood synovial sarcoma
672889|NCT00031915|childhood liposarcoma
672890|NCT00031915|childhood alveolar soft-part sarcoma
672891|NCT00031915|childhood neurofibrosarcoma
672892|NCT00031915|childhood angiosarcoma
672893|NCT00031915|childhood malignant fibrous histiocytoma of bone
672894|NCT00031915|previously treated childhood rhabdomyosarcoma
672895|NCT00031915|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
672896|NCT00031915|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
672897|NCT00031915|fibrosarcomatous osteosarcoma
672898|NCT00031902|AIDS-related peripheral/systemic lymphoma
672899|NCT00031902|AIDS-related diffuse large cell lymphoma
672900|NCT00031902|AIDS-related immunoblastic large cell lymphoma
672901|NCT00031902|AIDS-related small noncleaved cell lymphoma
672902|NCT00031902|AIDS-related diffuse mixed cell lymphoma
672903|NCT00031902|AIDS-related diffuse small cleaved cell lymphoma
672904|NCT00031902|AIDS-related lymphoblastic lymphoma
672905|NCT00031889|adenocarcinoma of the prostate
672906|NCT00031889|stage IV prostate cancer
672907|NCT00031889|recurrent prostate cancer
672908|NCT00031876|stage IV breast cancer
672909|NCT00031876|recurrent breast cancer
672910|NCT00031863|stage II colon cancer
672911|NCT00031863|stage III colon cancer
672912|NCT00031863|stage II rectal cancer
672913|NCT00031863|stage III rectal cancer
672914|NCT00031850|breast cancer
672915|NCT00031837|thromboembolism
672916|NCT00031837|stage III pancreatic cancer
672917|NCT00031837|recurrent pancreatic cancer
672918|NCT00031837|adenocarcinoma of the pancreas
672919|NCT00031837|stage IV pancreatic cancer
672920|NCT00031824|graft versus host disease
672921|NCT00031811|stage I breast cancer
672922|NCT00031811|stage II breast cancer
672923|NCT00031811|stage IIIA breast cancer
672924|NCT00031811|stage IIIB breast cancer
672925|NCT00031811|osteoporosis
672926|NCT00031811|menopausal symptoms
672927|NCT00031798|fatigue
672928|NCT00031798|depression
672929|NCT00031798|quality of life
672930|NCT00031798|cognitive/functional effects
672931|NCT00031798|recurrent adult brain tumor
672932|NCT00031798|adult brain stem glioma
672933|NCT00031798|adult glioblastoma
672934|NCT00031798|adult tumors metastatic to brain
672935|NCT00031798|adult anaplastic astrocytoma
672936|NCT00031798|adult anaplastic oligodendroglioma
672937|NCT00031798|adult mixed glioma
672938|NCT00031798|adult meningioma
672939|NCT00031798|adult anaplastic ependymoma
672940|NCT00031798|adult myxopapillary ependymoma
672941|NCT00031798|adult ependymoblastoma
672942|NCT00031798|adult pilocytic astrocytoma
672943|NCT00031798|adult subependymoma
672944|NCT00031798|adult grade III meningioma
672945|NCT00031798|adult giant cell glioblastoma
672946|NCT00031798|adult gliosarcoma
672947|NCT00031798|adult grade II meningioma
672948|NCT00031785|stage I non-small cell lung cancer
672949|NCT00031785|stage II non-small cell lung cancer
672950|NCT00031785|limited stage small cell lung cancer
672951|NCT00031785|stage IIIA non-small cell lung cancer
672952|NCT00031785|stage IIIB non-small cell lung cancer
672953|NCT00031785|anorexia
672954|NCT00031785|cachexia
672955|NCT00031772|recurrent breast cancer
672956|NCT00031772|psychosocial effects of cancer and its treatment
672957|NCT00031759|cervical cancer
672958|NCT00031759|cervical intraepithelial neoplasia grade 1
672959|NCT00031759|cervical intraepithelial neoplasia grade 2
672960|NCT00031759|cervical intraepithelial neoplasia grade 3
672961|NCT00031746|prostate cancer
672962|NCT00031733|iris melanoma
672963|NCT00031733|ciliary body and choroid melanoma, small size
672964|NCT00031733|ciliary body and choroid melanoma, medium/large size
672965|NCT00031733|extraocular extension melanoma
672966|NCT00031733|recurrent intraocular melanoma
672967|NCT00031733|stage II melanoma
672968|NCT00031733|stage III melanoma
672969|NCT00031733|stage IV melanoma
672970|NCT00031733|recurrent melanoma
672971|NCT00031720|lobular breast carcinoma in situ
672972|NCT00031720|stage I breast cancer
672973|NCT00031720|stage II breast cancer
672974|NCT00031720|stage IIIA breast cancer
672975|NCT00031720|recurrent breast cancer
672976|NCT00031720|ductal breast carcinoma in situ
672977|NCT00031720|hot flashes
672978|NCT00031707|anorexia
672979|NCT00031707|cachexia
672980|NCT00031668|Waldenstrom macroglobulinemia
672981|NCT00031668|recurrent adult diffuse large cell lymphoma
672982|NCT00031668|recurrent adult Burkitt lymphoma
672983|NCT00031668|recurrent adult T-cell leukemia/lymphoma
672984|NCT00031668|anaplastic large cell lymphoma
672985|NCT00031642|recurrent grade 1 follicular lymphoma
672986|NCT00031642|recurrent grade 2 follicular lymphoma
672987|NCT00031642|recurrent grade 3 follicular lymphoma
672988|NCT00031642|recurrent adult diffuse small cleaved cell lymphoma
672989|NCT00031642|recurrent adult diffuse mixed cell lymphoma
672990|NCT00031642|recurrent adult diffuse large cell lymphoma
672991|NCT00031642|recurrent adult immunoblastic large cell lymphoma
672992|NCT00031642|recurrent adult Burkitt lymphoma
672993|NCT00031642|recurrent mantle cell lymphoma
672994|NCT00031642|recurrent marginal zone lymphoma
672995|NCT00031642|recurrent small lymphocytic lymphoma
672996|NCT00031642|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
672997|NCT00031642|nodal marginal zone B-cell lymphoma
672998|NCT00031642|splenic marginal zone lymphoma
672999|NCT00031616|stage IV colon cancer
673000|NCT00031616|stage IV rectal cancer
673001|NCT00031616|recurrent colon cancer
673002|NCT00031616|recurrent rectal cancer
673003|NCT00031616|adenocarcinoma of the colon
673004|NCT00031616|adenocarcinoma of the rectum
673005|NCT00031590|untreated childhood medulloblastoma
673006|NCT00031590|PNET
673007|NCT00031590|craniospinal radiotherapy
673008|NCT00031577|untreated childhood brain stem glioma
673009|NCT00031564|stage IV
673010|NCT00031564|renal cell carcinoma
673011|NCT00031551|Stomatitis
673012|NCT00031551|Oropharyngeal pain
673013|NCT00031551|TNF
673014|NCT00031551|Etanercept
673015|NCT00031551|Bone marrow transplantation
673016|NCT00031551|Chemotherapy
673017|NCT00031551|Cancer
673018|NCT00031551|Oral cavity
673019|NCT00031551|Oral mucous membranes
673020|NCT00031551|Randomized controlled clinical trial
673021|NCT00031551|Inflammation
673022|NCT00031538|Brain Tumor
673023|NCT00031538|Surgery
673024|NCT00031538|Molecular
673025|NCT00031538|Glioma
673026|NCT00031538|Intraoperative
673027|NCT00031538|Gliomas
673028|NCT00031512|enterovirus, enteroviral sepsis, Pleconaril, infants
673029|NCT00031499|Azithromycin, Syphilis, Penicillin
673030|NCT00031486|encephalitis, herpes simplex, valacyclovir
673031|NCT00031473|Ribavirin
673032|NCT00031473|RSV
673033|NCT00031460|acyclovir, central nervous system, Herpes Simplex Virus
673034|NCT00031447|Herpes Simplex, Acyclovir, Infants
673035|NCT00031434|Valganciclovir, congenital cytomegalovirus, ganciclovir
673036|NCT00031421|CMV, cytomegalovirus, children, ganciclovir
673037|NCT00031408|Specimen Handling
673038|NCT00031408|Blood
673039|NCT00031408|Informed Consent
673040|NCT00031408|Genetic Screening
673041|NCT00031395|Attention Deficit Hyperactivity Disorder
673042|NCT00031395|ADHD
673043|NCT00031395|clonidine
673044|NCT00031395|methylphenidate
673045|NCT00031395|MPH
673046|NCT00031382|Functional MRI
673047|NCT00031382|Dual Task
673048|NCT00031382|Neural Activation
673049|NCT00031382|Basal Ganglia
673050|NCT00031382|Cerebellum
673051|NCT00031382|Healthy Volunteer
673052|NCT00031382|HV
673053|NCT00031382|Normal Control
673054|NCT00031369|MRI
673055|NCT00031369|Writer's Cramp
673056|NCT00031369|Movement Disorder
673057|NCT00031369|Gray Matter
673058|NCT00031369|Brain Morphology
673059|NCT00031369|Dystonia
673060|NCT00031369|Focal Hand Dystonia
673061|NCT00031369|Healthy Volunteer
673062|NCT00031369|HV
673063|NCT00031369|Normal Control
673064|NCT00031343|Liver Disease
673065|NCT00031343|Virologic Response
673066|NCT00031343|Immune Mechanisms
673067|NCT00031343|Eradication
673068|NCT00031343|Antiviral Therapy
673069|NCT00031343|HIV
673070|NCT00031343|Hepatitis C
673071|NCT00031343|HCV
673072|NCT00031343|Coinfection
673073|NCT00031317|Depression
673074|NCT00031317|Treatment
673075|NCT00031317|Antidepressant
673076|NCT00031317|Benzodiazepine (clonazepam)
673077|NCT00031317|SSRI (paroxetine)
673078|NCT00031317|Combined Treatment
673079|NCT00031317|Panic Disorder (PD)
673080|NCT00031317|Panic Disorder
673081|NCT00031317|PD
673082|NCT00031304|HIV
673083|NCT00031304|AIDS
673084|NCT00031304|Vaccine
673085|NCT00031304|Screening
673086|NCT00031304|Prevention
673087|NCT00031304|HV
673088|NCT00031304|Healthy Volunteer
673089|NCT00031304|Volunteer
673090|NCT00031304|HIV Seronegativity
673091|NCT00031304|HIV Preventive Vaccine
673092|NCT00031291|Anthrax
673093|NCT00031291|Immune Globulin
673094|NCT00031291|Plasmapheresis
673095|NCT00031291|Vaccine
673096|NCT00031122|Genetic Predisposition to Disease
673097|NCT00031122|Environmental Exposure
673098|NCT00031122|Chromosome Mapping
673099|NCT00031122|Data Collection
673100|NCT00031109|HIV Antibodies
673101|NCT00031109|HIV-1
673102|NCT00031109|HIV Envelope Protein gp160
673103|NCT00031109|Adjuvants, Immunologic
673104|NCT00031109|AIDS Vaccines
673105|NCT00031109|CD4 Lymphocyte Count
673106|NCT00031109|Disease Models, Animal
673107|NCT00031109|Antibody Formation
673108|NCT00031109|Macaca
673109|NCT00031109|Neutralization Tests
673110|NCT00031109|Viral Load
673111|NCT00031109|aluminum hydroxide
673112|NCT00031109|HIV Preventive Vaccine
673113|NCT00031096|Acne Vulgaris
673114|NCT00031096|Propionibacterium acnes
673115|NCT00031083|Glioma
673116|NCT00031083|Brain Tumor
673117|NCT00031083|Adenovirus
673118|NCT00031083|Gene Therapy
673119|NCT00031083|Biogen
673120|NCT00031070|Zidovudine
673121|NCT00031070|CD4 Lymphocyte Count
673122|NCT00031070|Lamivudine
673123|NCT00031070|Cyclosporine
673124|NCT00031070|Hepatitis A Vaccine
673125|NCT00031070|Rabies Vaccine
673126|NCT00031070|abacavir
673127|NCT00031070|Antiretroviral Therapy, Highly Active
673128|NCT00031070|efavirenz
673129|NCT00031070|Treatment Naive
673130|NCT00031057|Administration, Oral
673131|NCT00031057|Blood
673132|NCT00031057|Reverse Transcriptase Inhibitors
673133|NCT00031057|Riboflavin
673134|NCT00031057|Thiamine
673135|NCT00031057|Vitamin B Complex
673136|NCT00031057|Lactic Acid
673137|NCT00031044|HIV-1
673138|NCT00031044|Drug Therapy, Combination
673139|NCT00031044|RNA, Viral
673140|NCT00031044|Salvage Therapy
673141|NCT00031044|Anti-HIV Agents
673142|NCT00031044|Viral Load
673143|NCT00031044|Purines
673144|NCT00031044|T-20 Peptide
673145|NCT00031044|ABT 378
673146|NCT00031044|Treatment Experienced
673147|NCT00031031|MTD
673148|NCT00031031|Safety
673149|NCT00031031|Pharmacokinetics
673150|NCT00031031|Efficacy
673151|NCT00031018|Inflammation
673152|NCT00031018|immunosenescence
673153|NCT00031018|autoimmunity
673154|NCT00031018|atherosclerosis
673155|NCT00031018|pro-inflammatory cytokines
673156|NCT00031018|Hayflick phenomenon
673157|NCT00031005|Non-Myeloablative
673158|NCT00031005|Campath 1-H
673159|NCT00031005|Fludarabine
673160|NCT00031005|Immunodeficiency
673161|NCT00031005|Infection
673162|NCT00031005|Leukocyte Adhesion Deficiency
673163|NCT00031005|LAD
673164|NCT00030992|Epothilone B
673165|NCT00030992|Ixabepilone
673166|NCT00030992|Renal Cell Carcinoma
673167|NCT00030992|Kidney Cancer
673168|NCT00030979|Mild Dementia
673169|NCT00030979|Acetylcholine
673170|NCT00030979|Memory
673171|NCT00030979|Hallucinations
673172|NCT00030979|Washout
673173|NCT00030979|Parkinson Disease
673174|NCT00030979|Parkinson's Disease
673175|NCT00030979|PD
673176|NCT00030979|Dementia
673177|NCT00030966|Multiple Sclerosis
673178|NCT00030966|MS
673179|NCT00030953|Tourette's Syndrome
673180|NCT00030953|GABA
673181|NCT00030953|NAA
673182|NCT00030953|Choline
673183|NCT00030953|Creatine
673184|NCT00030953|Tourette Syndrome
673185|NCT00030953|Healthy Volunteer
673186|NCT00030953|HV
673187|NCT00030953|Normal Control
673188|NCT00030940|Antigenic Epitopes
673189|NCT00030940|Glutamic Acid Decarboxylase (GAD)
673190|NCT00030940|Auto-antibodies
673191|NCT00030940|Stiffness Index
673192|NCT00030940|SPS
673193|NCT00030940|Anti-GAD
673194|NCT00030940|MR Spectroscopy
673195|NCT00030940|GAD
673196|NCT00030940|Stiff Person Syndrome
673197|NCT00030914|hot flashes
673198|NCT00030901|prostate cancer
673199|NCT00030901|high grade prostatic intraepithelial neoplasia
673200|NCT00030888|stage III renal cell cancer
673201|NCT00030888|stage IV renal cell cancer
673202|NCT00030888|recurrent renal cell cancer
673203|NCT00030875|stage I mantle cell lymphoma
673204|NCT00030875|contiguous stage II mantle cell lymphoma
673205|NCT00030875|noncontiguous stage II mantle cell lymphoma
673206|NCT00030875|stage III mantle cell lymphoma
673207|NCT00030875|stage IV mantle cell lymphoma
673208|NCT00030875|recurrent mantle cell lymphoma
673209|NCT00030862|stage II esophageal cancer
673210|NCT00030862|stage III esophageal cancer
673211|NCT00030862|stage IV esophageal cancer
673212|NCT00030862|squamous cell carcinoma of the esophagus
673213|NCT00030862|adenocarcinoma of the esophagus
673214|NCT00030849|stage I cutaneous T-cell non-Hodgkin lymphoma
673215|NCT00030849|stage II cutaneous T-cell non-Hodgkin lymphoma
673216|NCT00030849|stage III cutaneous T-cell non-Hodgkin lymphoma
673217|NCT00030849|stage IV cutaneous T-cell non-Hodgkin lymphoma
673218|NCT00030849|recurrent cutaneous T-cell non-Hodgkin lymphoma
673219|NCT00030823|stage I breast cancer
673220|NCT00030823|stage II breast cancer
673221|NCT00030823|stage IV breast cancer
673222|NCT00030823|stage IIIA breast cancer
673223|NCT00030823|recurrent breast cancer
673224|NCT00030823|stage IIIB breast cancer
673225|NCT00030823|stage IIIC breast cancer
673226|NCT00030823|male breast cancer
673227|NCT00030810|squamous cell lung cancer
673228|NCT00030810|large cell lung cancer
673229|NCT00030810|stage IIIB non-small cell lung cancer
673230|NCT00030810|adenosquamous cell lung cancer
673231|NCT00030797|stage III colon cancer
673232|NCT00030797|stage IV colon cancer
673233|NCT00030797|stage III rectal cancer
673234|NCT00030797|stage IV rectal cancer
673235|NCT00030784|adult angiosarcoma
673236|NCT00030784|adult fibrosarcoma
673237|NCT00030784|adult leiomyosarcoma
673238|NCT00030784|adult liposarcoma
673239|NCT00030784|adult neurofibrosarcoma
673240|NCT00030784|adult synovial sarcoma
673241|NCT00030784|stage III adult soft tissue sarcoma
673242|NCT00030784|adult alveolar soft-part sarcoma
673243|NCT00030784|adult epithelioid sarcoma
673244|NCT00030784|adult malignant fibrous histiocytoma
673245|NCT00030784|adult malignant hemangiopericytoma
673246|NCT00030784|adult malignant mesenchymoma
673247|NCT00030784|adult rhabdomyosarcoma
673248|NCT00030784|stage IV adult soft tissue sarcoma
673249|NCT00030771|squamous cell lung cancer
673250|NCT00030771|large cell lung cancer
673251|NCT00030771|stage IIIA non-small cell lung cancer
673252|NCT00030771|adenosquamous cell lung cancer
673253|NCT00030758|neutropenia
673254|NCT00030758|stage I breast cancer
673255|NCT00030758|stage II breast cancer
673256|NCT00030745|stage IA malignant mesothelioma
673257|NCT00030745|stage IB malignant mesothelioma
673258|NCT00030745|stage II malignant mesothelioma
673259|NCT00030745|stage III malignant mesothelioma
673260|NCT00030732|stage III pancreatic cancer
673261|NCT00030732|recurrent pancreatic cancer
673262|NCT00030732|adenocarcinoma of the pancreas
673263|NCT00030732|stage IV pancreatic cancer
673264|NCT00030719|regional neuroblastoma
673265|NCT00030719|disseminated neuroblastoma
673266|NCT00030719|stage 4S neuroblastoma
673267|NCT00030719|localized unresectable neuroblastoma
673268|NCT00030706|stage III ovarian epithelial cancer
673269|NCT00030706|stage IV ovarian epithelial cancer
673270|NCT00030706|recurrent ovarian epithelial cancer
673271|NCT00030706|peritoneal cavity cancer
673272|NCT00030680|desmoid tumor
673273|NCT00030654|adenocarcinoma of the prostate
673274|NCT00030654|stage IIB prostate cancer
673275|NCT00030654|stage IIA prostate cancer
673276|NCT00030654|stage III prostate cancer
673277|NCT00030654|stage IV prostate cancer
673278|NCT00030654|recurrent prostate cancer
673279|NCT00030641|recurrent non-small cell lung cancer
673280|NCT00030641|stage IIIB non-small cell lung cancer
673281|NCT00030641|stage IV non-small cell lung cancer
673282|NCT00030628|tumors metastatic to brain
673283|NCT00030602|adenocarcinoma of the prostate
673284|NCT00030602|recurrent prostate cancer
673285|NCT00030589|stage I cutaneous T-cell non-Hodgkin lymphoma
673286|NCT00030589|stage II cutaneous T-cell non-Hodgkin lymphoma
673287|NCT00030589|recurrent cutaneous T-cell non-Hodgkin lymphoma
673288|NCT00030589|stage I mycosis fungoides/Sezary syndrome
673289|NCT00030589|stage II mycosis fungoides/Sezary syndrome
673290|NCT00030589|recurrent mycosis fungoides/Sezary syndrome
673291|NCT00030576|recurrent metastatic squamous neck cancer occult primary
673292|NCT00030576|neck cancer with occult primary squamous carcinoma
673293|NCT00030576|stage IV squamous cell carcinoma of the lip and oral cavity
673294|NCT00030576|recurrent squamous cell carcinoma of the lip and oral cavity
673295|NCT00030576|stage IV squamous cell carcinoma of the oropharynx
673296|NCT00030576|recurrent squamous cell carcinoma of the oropharynx
673297|NCT00030576|stage IV squamous cell carcinoma of the nasopharynx
673298|NCT00030576|recurrent squamous cell carcinoma of the nasopharynx
673299|NCT00030576|stage IV squamous cell carcinoma of the hypopharynx
673300|NCT00030576|recurrent squamous cell carcinoma of the hypopharynx
673301|NCT00030576|stage IV squamous cell carcinoma of the larynx
673302|NCT00030576|recurrent squamous cell carcinoma of the larynx
673303|NCT00030576|squamous cell carcinoma of paranasal sinus and nasal cavity
673304|NCT00030576|recurrent squamous cell carcinoma of sinus and nasal cavity
673305|NCT00030563|liver metastases
673306|NCT00030563|stage IV colon cancer
673307|NCT00030563|stage IV rectal cancer
673308|NCT00030563|adenocarcinoma of the colon
673309|NCT00030563|adenocarcinoma of the rectum
673310|NCT00030563|recurrent colon cancer
673311|NCT00030563|recurrent rectal cancer
673312|NCT00030550|refractory anemia
673313|NCT00030550|refractory anemia with ringed sideroblasts
673314|NCT00030550|refractory anemia with excess blasts
673315|NCT00030550|de novo myelodysplastic syndromes
673316|NCT00030550|chronic myelomonocytic leukemia
673317|NCT00030550|previously treated myelodysplastic syndromes
673318|NCT00030550|myelodysplastic/myeloproliferative neoplasm, unclassifiable
673319|NCT00030550|atypical chronic myeloid leukemia, BCR-ABL1 negative
673320|NCT00030537|stage IV breast cancer
673321|NCT00030537|recurrent breast cancer
673322|NCT00030537|stage IIIB breast cancer
673323|NCT00030537|male breast cancer
673324|NCT00030524|stage III colon cancer
673325|NCT00030524|stage IV colon cancer
673326|NCT00030524|stage III rectal cancer
673327|NCT00030524|stage IV rectal cancer
673328|NCT00030524|recurrent colon cancer
673329|NCT00030524|recurrent rectal cancer
673330|NCT00030524|adenocarcinoma of the colon
673331|NCT00030524|adenocarcinoma of the rectum
673332|NCT00030511|localized resectable adult primary liver cancer
673333|NCT00030511|recurrent adult primary liver cancer
673334|NCT00030511|localized extrahepatic bile duct cancer
673335|NCT00030511|recurrent extrahepatic bile duct cancer
673336|NCT00030485|stage IV endometrial carcinoma
673337|NCT00030485|recurrent endometrial carcinoma
673338|NCT00030485|endometrial adenocarcinoma
673339|NCT00030485|endometrial adenosquamous cell carcinoma
673340|NCT00030472|recurrent cervical cancer
673341|NCT00030472|stage IVB cervical cancer
673342|NCT00030472|cervical squamous cell carcinoma
673343|NCT00030459|localized malignant mesothelioma
673344|NCT00030459|advanced malignant mesothelioma
673345|NCT00030459|recurrent malignant mesothelioma
673346|NCT00030446|recurrent ovarian epithelial cancer
673347|NCT00030446|fallopian tube cancer
673348|NCT00030446|peritoneal cavity cancer
673349|NCT00030433|extensive stage small cell lung cancer
673350|NCT00030420|recurrent non-small cell lung cancer
673351|NCT00030420|stage IIIA non-small cell lung cancer
673352|NCT00030420|stage IIIB non-small cell lung cancer
673353|NCT00030420|stage IV non-small cell lung cancer
673354|NCT00030407|stage IIIB non-small cell lung cancer
673355|NCT00030407|stage IV non-small cell lung cancer
673356|NCT00030355|recurrent childhood acute myeloid leukemia
673357|NCT00030355|recurrent adult acute myeloid leukemia
673358|NCT00030355|adult acute promyelocytic leukemia (M3)
673359|NCT00030355|childhood acute promyelocytic leukemia (M3)
673360|NCT00030355|adult acute myeloid leukemia with t(15;17)(q22;q12)
673361|NCT00030342|stage IV colon cancer
673362|NCT00030342|stage IV rectal cancer
673363|NCT00030342|recurrent colon cancer
673364|NCT00030342|recurrent rectal cancer
673365|NCT00030342|stage IV renal cell cancer
673366|NCT00030342|recurrent renal cell cancer
673367|NCT00030303|chronic phase chronic myelogenous leukemia
673368|NCT00030303|chronic myelogenous leukemia, BCR-ABL1 positive
673369|NCT00030290|stage I prostate cancer
673370|NCT00030290|stage IIB prostate cancer
673371|NCT00030290|stage IIA prostate cancer
673372|NCT00030277|stage I prostate cancer
673373|NCT00030277|stage IIB prostate cancer
673374|NCT00030277|stage IIA prostate cancer
673375|NCT00030277|recurrent prostate cancer
673376|NCT00030264|plexiform neurofibroma
673377|NCT00030264|neurofibromatosis type 1
673378|NCT00030238|Body Fat
673379|NCT00030238|Weight Gain
673380|NCT00030238|Adult
673381|NCT00030238|Hypertension
673382|NCT00030238|Dietary Supplements
673383|NCT00030238|Healthy Volunteer
673384|NCT00030238|HIV
673385|NCT00030238|Body Weight
673386|NCT00030225|Fulminant Hepatic Failure
673387|NCT00030212|T Cell
673388|NCT00030212|IBM
673389|NCT00030212|Inflammatory Myopathies
673390|NCT00030212|Antigenic Epitopes
673391|NCT00030212|Endomysial T Lymphocytes
673392|NCT00030212|Myositis
673393|NCT00030212|Inclusion Body Myositis
673394|NCT00030212|Inflammatory Myopathy
673395|NCT00030199|Transcranial Magnetic Stimuli
673396|NCT00030199|Eletromyography
673397|NCT00030199|Needle Electrode
673398|NCT00030199|Facial Muscles
673399|NCT00030199|Blink Reflex
673400|NCT00030199|Motor Cortex
673401|NCT00030199|Transcranial Magnetic Stimulation
673402|NCT00030199|Healthy Volunteer
673403|NCT00030199|HV
673404|NCT00030199|Normal Control
673405|NCT00030186|AML
673406|NCT00030186|FLT-3 mutation
673407|NCT00030173|Epothilone D
673408|NCT00030173|tubulin polymerization
673409|NCT00030160|Obesity
673410|NCT00030160|Prevention
673411|NCT00030160|Exercise
673412|NCT00030147|Gonadal Steroids
673413|NCT00030147|Estrogen Receptor
673414|NCT00030147|Mood Disorders
673415|NCT00030147|Perimenopause
673416|NCT00030147|Estradiol
673417|NCT00030147|Depression
673418|NCT00030147|Estrogen Response Element
673419|NCT00030147|Perimenopausal
673420|NCT00030147|Perimenopausal Depression
673421|NCT00030134|Natural History
673422|NCT00030134|Female Carrier
673423|NCT00030134|Alpha-Galactosidase
673424|NCT00030134|Lysosomal Disease
673425|NCT00030134|X-Linked
673426|NCT00030134|Fabry
673427|NCT00030134|Fabry Disease
673428|NCT00030121|Acute Respiratory Distress
673429|NCT00030121|Acute Lung Injury
673430|NCT00030108|recurrent childhood rhabdomyosarcoma
673431|NCT00030108|childhood craniopharyngioma
673432|NCT00030108|recurrent neuroblastoma
673433|NCT00030108|recurrent childhood liver cancer
673434|NCT00030108|recurrent Wilms tumor and other childhood kidney tumors
673435|NCT00030108|childhood central nervous system germ cell tumor
673436|NCT00030108|recurrent osteosarcoma
673437|NCT00030108|unspecified childhood solid tumor, protocol specific
673438|NCT00030108|childhood germ cell tumor
673439|NCT00030108|recurrent childhood soft tissue sarcoma
673440|NCT00030108|childhood oligodendroglioma
673441|NCT00030108|childhood choroid plexus tumor
673442|NCT00030108|childhood grade I meningioma
673443|NCT00030108|childhood grade II meningioma
673444|NCT00030108|childhood grade III meningioma
673445|NCT00030108|recurrent childhood cerebellar astrocytoma
673446|NCT00030108|recurrent childhood cerebral astrocytoma
673447|NCT00030108|recurrent childhood medulloblastoma
673448|NCT00030108|recurrent childhood visual pathway and hypothalamic glioma
673449|NCT00030108|previously treated childhood rhabdomyosarcoma
673450|NCT00030108|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
673451|NCT00030108|recurrent childhood ependymoma
673452|NCT00030108|childhood teratoma
673453|NCT00030108|childhood malignant testicular germ cell tumor
673454|NCT00030108|childhood malignant ovarian germ cell tumor
673455|NCT00030108|childhood extragonadal germ cell tumor
673456|NCT00030108|recurrent childhood malignant germ cell tumor
673457|NCT00030108|B-cell childhood acute lymphoblastic leukemia
673458|NCT00030108|childhood acute basophilic leukemia
673459|NCT00030108|childhood acute eosinophilic leukemia
673460|NCT00030108|childhood acute lymphoblastic leukemia
673461|NCT00030108|childhood acute myeloid leukemia in remission
673462|NCT00030108|childhood acute promyelocytic leukemia (M3)
673463|NCT00030108|L1 childhood acute lymphoblastic leukemia
673464|NCT00030108|L2 childhood acute lymphoblastic leukemia
673465|NCT00030108|L3 childhood acute lymphoblastic leukemia
673466|NCT00030108|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
673467|NCT00030108|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
673468|NCT00030108|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
673469|NCT00030108|recurrent childhood acute lymphoblastic leukemia
673470|NCT00030108|recurrent childhood acute myeloid leukemia
673471|NCT00030108|TdT negative childhood acute lymphoblastic leukemia
673472|NCT00030108|TdT positive childhood acute lymphoblastic leukemia
673473|NCT00030108|chronic myelogenous leukemia, BCR-ABL1 positive
673474|NCT00030108|childhood chronic myelogenous leukemia
673475|NCT00030095|unspecified adult solid tumor, protocol specific
673476|NCT00030082|localized unresectable adult primary liver cancer
673477|NCT00030082|advanced adult primary liver cancer
673478|NCT00030082|recurrent adult primary liver cancer
673479|NCT00030082|liver metastases
673480|NCT00030069|Hematopoiesis
673481|NCT00030069|Apoptosis
673482|NCT00030069|Cell Differentiation
673483|NCT00030069|Bone Marrow Cells
673484|NCT00030056|Sargramostim
673485|NCT00030056|Injections, Subcutaneous
673486|NCT00030043|Electric Stimulation
673487|NCT00030043|Implants, Artificial
673488|NCT00030043|Brainstem
673489|NCT00030043|Electrodes
673490|NCT00030043|Speech Perception
673491|NCT00029991|Leg pain
673492|NCT00029991|Peripheral angiopathies
673493|NCT00029991|Vascular Diseases, peripheral
673494|NCT00029965|Tay-Sachs
673495|NCT00029965|Lysosomal Storage Disease
673496|NCT00029965|Sandhoff
673497|NCT00029965|GM1 Gangliosidosis
673498|NCT00029965|GM2 Gangliosidosis
673499|NCT00029965|Lysosomal Storage Disorder
673500|NCT00029965|Gaucher
673501|NCT00029952|Cortisol
673502|NCT00029952|Bone Density
673503|NCT00029952|Cushing Syndrome
673504|NCT00029952|Postoperative
673505|NCT00029939|Preparation
673506|NCT00029939|Subconscious
673507|NCT00029939|Healthy Volunteer
673508|NCT00029939|HV
673509|NCT00029939|Normal Control
673510|NCT00029926|Imaging
673511|NCT00029926|Immune System
673512|NCT00029926|Autoimmune Disease
673513|NCT00029926|Lymphonodes
673514|NCT00029926|Spleen
673515|NCT00029926|Systemic Lupus Erythematosus
673516|NCT00029926|Lupus
673517|NCT00029926|SLE
673518|NCT00029913|Placebos
673519|NCT00029913|AIDS Vaccines
673520|NCT00029913|CD4 Lymphocyte Count
673521|NCT00029913|Disease Progression
673522|NCT00029913|Viral Load
673523|NCT00029913|HIV Preventive Vaccine
673524|NCT00029900|Dose-Response Relationship, Drug
673525|NCT00029900|Polyethylene Glycol
673526|NCT00029900|Arginine Deiminase
673527|NCT00029874|Tetracyclines
673528|NCT00029874|Dose-Response Relationship, Drug
673529|NCT00029861|Weight Loss
673530|NCT00029861|Obesity
673531|NCT00029861|Weight Reduction
673532|NCT00029861|Overweight
673533|NCT00029848|Diabetes
673534|NCT00029848|Obesity
673535|NCT00029835|Obesity
673536|NCT00029822|Acute Urinary Retention
673537|NCT00029822|AUR
673538|NCT00029822|Benign Prostatic Hyperplasia
673539|NCT00029822|Benign Prostatic Hypertrophy
673540|NCT00029822|BPH
673541|NCT00029822|Enlarged Prostate
673542|NCT00029809|Parkinsons Disease
673543|NCT00029809|Chinese exercise
673544|NCT00029783|Glioblastoma
673545|NCT00029783|Brain tumor
673546|NCT00029783|Distant healing
673547|NCT00029783|Distance healing
673548|NCT00029757|Surgical menopause
673549|NCT00029744|AIDS Vaccines
673550|NCT00029744|Clinical Protocols
673551|NCT00029744|HIV Seronegativity
673552|NCT00029744|Patient Selection
673553|NCT00029744|Patient Acceptance of Health Care
673554|NCT00029744|Demography
673555|NCT00029744|HIV Preventive Vaccine
673556|NCT00029731|Nitric Oxide
673557|NCT00029731|Administration, Oral
673558|NCT00029718|Chronic Stroke
673559|NCT00029718|Transcallosal Inhibition
673560|NCT00029718|Motor Cortex
673561|NCT00029718|Motor Control
673562|NCT00029718|Motor Recovery
673563|NCT00029718|Healthy Volunteer
673564|NCT00029718|HV
673565|NCT00029718|Normal Control
673566|NCT00029666|Motor Cortex
673567|NCT00029666|Sham Stimulation
673568|NCT00029666|Prefrontal Cortex
673569|NCT00029666|Brain Stimulation
673570|NCT00029666|Gait
673571|NCT00029666|Parkinson
673572|NCT00029666|Parkinson's
673573|NCT00029666|PD
673574|NCT00029653|Frontal Lobe
673575|NCT00029653|Reaction Time
673576|NCT00029653|Movement Preparation
673577|NCT00029653|Motor Threshold
673578|NCT00029653|Transcranial Magnetic Stimulation
673579|NCT00029653|Motor Cortex
673580|NCT00029653|Healthy Volunteer
673581|NCT00029653|Normal Control
673582|NCT00029653|HV
673583|NCT00029640|MRI
673584|NCT00029640|MRS
673585|NCT00029640|SSRI
673586|NCT00029640|Children
673587|NCT00029640|Depression
673588|NCT00029640|Augmentation
673589|NCT00029640|Magnetic Resonance Imaging
673590|NCT00029640|Major Depression
673591|NCT00029640|MDD
673592|NCT00029627|Alpha2-Adrenoreceptors
673593|NCT00029627|Polymorphisms
673594|NCT00029627|Challenge Study
673595|NCT00029627|Yohimbine
673596|NCT00029627|Clonidine
673597|NCT00029627|Subtypes
673598|NCT00029627|Normal Control
673599|NCT00029627|HV
673600|NCT00029627|Healthy Volunteer
673601|NCT00029614|ADHD
673602|NCT00029614|Substance Use
673603|NCT00029601|Magnetic Stimulation
673604|NCT00029601|Intracortical Inhibition
673605|NCT00029601|Intracortical Facilitation
673606|NCT00029601|Motor Evoked Potential
673607|NCT00029601|Reaction Time
673608|NCT00029601|Transcranial Magnetic Stimulation
673609|NCT00029601|Dystonia
673610|NCT00029601|Focal Dystonia
673611|NCT00029601|Healthy Volunteer
673612|NCT00029601|HV
673613|NCT00029601|Normal Control
673614|NCT00029588|fMRI
673615|NCT00029588|Adolescents and Adults
673616|NCT00029588|Depression
673617|NCT00029588|Anxiety
673618|NCT00029588|Anxiety Disorder
673619|NCT00029588|GAD
673620|NCT00029588|Adolescents
673621|NCT00029588|Healthy Volunteer
673622|NCT00029588|HV
673623|NCT00029588|Normal Control
673624|NCT00029575|Atherosclerotic
673625|NCT00029575|Plaque
673626|NCT00029575|Resolution
673627|NCT00029575|Adventitia
673628|NCT00029575|Ultrasound
673629|NCT00029575|Cardiac Catheterization
673630|NCT00029575|Arteriosclerosis
673631|NCT00029575|Coronary Artery Disease
673632|NCT00029536|Epilepsy
673633|NCT00029536|Seizure
673634|NCT00029536|Hormone
673635|NCT00029536|Progesterone
673636|NCT00029536|Catamenial
673637|NCT00029523|neoplastic
673638|NCT00029523|meningitis
673639|NCT00029523|cerebrospinal fluid
673640|NCT00029523|CSF
673641|NCT00029523|meningeal
673642|NCT00029523|meninges
673643|NCT00029523|CNS
673644|NCT00029523|Leptomeningeal Neoplasms
673645|NCT00029458|Placebo Controlled
673646|NCT00029458|Atypical Anti-Psychotic
673647|NCT00029458|Bipolar Mood Disorder
673648|NCT00029458|Positron Emission Tomography
673649|NCT00029458|Dopamine Receptor Blockade
673650|NCT00029458|Antimanic
673651|NCT00029458|Mania
673652|NCT00029458|Pathophysiology
673653|NCT00029458|Treatment-Resistant
673654|NCT00029458|Mood Disorder
673655|NCT00029458|BPD
673656|NCT00029458|Bipolar
673657|NCT00029445|HLA B5701
673658|NCT00029445|LTNP
673659|NCT00029445|Neutralizing Antibodies
673660|NCT00029445|CTL
673661|NCT00029445|Virus Restriction
673662|NCT00029445|HIV
673663|NCT00029445|HIV-Infected Long Term Nonprogressors
673664|NCT00029341|Drug Therapy, Combination
673665|NCT00029341|Drug Administration Schedule
673666|NCT00029341|Drug Resistance, Microbial
673667|NCT00029341|Genotype
673668|NCT00029341|Reverse Transcriptase Inhibitors
673669|NCT00029341|Anti-HIV Agents
673670|NCT00029341|Viral Load
673671|NCT00029341|Pharmacokinetics
673672|NCT00029341|Efavirenz
673673|NCT00029341|Treatment Interruption
673674|NCT00029328|TNFR-Fc fusion protein
673675|NCT00029328|Stem Cell Transplantation
673676|NCT00029328|Transplantation, Homologous
673677|NCT00029328|Respiratory Function Tests
673678|NCT00029315|Intraventricular hemorrhage
673679|NCT00029315|Subarachnoid hemorrhage
673680|NCT00029315|Intracerebral hemorrhage
673681|NCT00029315|Pharmacokinetics
673682|NCT00029315|Recombinant Proteins
673683|NCT00029315|Anticoagulants
673684|NCT00029315|Tissue Plasminogen Activator
673685|NCT00029315|Pharmacology
673686|NCT00029315|Catheters, Indwelling
673687|NCT00029315|Cerebral Ventricles
673688|NCT00029302|fMRI
673689|NCT00029302|Voluntary Movement
673690|NCT00029302|Healthy Volunteer
673691|NCT00029302|HV
673692|NCT00029302|Normal Control
673693|NCT00029276|Parkinson's
673694|NCT00029276|Depression
673695|NCT00029276|Magnetic Stimulation
673696|NCT00029250|complementary therapies
673697|NCT00029250|garlic
673698|NCT00029250|Allium sativum
673699|NCT00029250|metabolic diseases
673700|NCT00029250|HAART
673701|NCT00029250|Protease inhibitors
673702|NCT00029237|Behavioral intervention
673703|NCT00029237|Psychoneuroimmunology
673704|NCT00029237|Complementary therapy
673705|NCT00029237|Stress and coping
673706|NCT00029237|complementary therapies
673707|NCT00029224|bone lesions
673708|NCT00029224|breast cancer
673709|NCT00029224|multiple myeloma
673710|NCT00029224|prostate cancer
673711|NCT00029224|bone metastases
673712|NCT00029224|pain
673713|NCT00029198|Massage Therapy
673714|NCT00029198|Preterm Infants
673715|NCT00029198|Weight Gain
673716|NCT00029198|Vagal Tone
673717|NCT00029198|IGF-1
673718|NCT00029198|Oxytocin
673719|NCT00029198|Brazelton
673720|NCT00029185|Corneal Erosion
673721|NCT00029185|Dextrans
673722|NCT00029185|Administration, Topical
673723|NCT00029185|Ophthalmic Solutions
673724|NCT00029185|Thimerosal
673725|NCT00029172|stroke
673726|NCT00029172|depression
673727|NCT00029159|Turner syndrome
673728|NCT00029159|estrogen
673729|NCT00029159|androgen
673730|NCT00029159|growth hormone
673731|NCT00029146|stroke
673732|NCT00029146|transient ischemic attack (TIA)
673733|NCT00029146|carotid arteries
673734|NCT00029146|cerebral infarction
673735|NCT00029133|aneurysm
673736|NCT00029133|hypothermia
673737|NCT00029133|subarachnoid intracranial hemorrhage
673738|NCT00029120|Alzheimer's Disease
673739|NCT00029120|Spectroscopy
673740|NCT00029120|Longitudinal
673741|NCT00029120|Perfusion
673742|NCT00029120|Hippocampus
673743|NCT00029120|N-acetylaspartic Acid
673744|NCT00029120|Cerebral Blood Flow
673745|NCT00029120|Aging
673746|NCT00029120|Dementia
673747|NCT00029120|Alzheimer's
673748|NCT00029120|Memory Disorder
673749|NCT00029120|Memory
673750|NCT00029120|Healthy Volunteer
673751|NCT00029120|HV
673752|NCT00029120|Normal Control
673753|NCT00029107|Hepatitis
673754|NCT00029107|Vasculitis
673755|NCT00029107|Rituximab
673756|NCT00029107|Cryoglobulinemia
673757|NCT00029107|Hepatitis C
673758|NCT00029107|HcV-cV
673759|NCT00029107|Cryoglobulinemic Vasculitis
673760|NCT00029068|Neurophysiology
673761|NCT00029068|Tourette Syndrome
673762|NCT00029068|Anorexia
673763|NCT00029068|SRIs
673764|NCT00029068|Personality
673765|NCT00029068|Obsessive-Compulsive Disorder (OCD)
673766|NCT00029068|Cortical Excitability
673767|NCT00029068|Motor Cortex
673768|NCT00029068|Transcranial Magnetic Stimulation
673769|NCT00029068|OCD Spectrum Disorders
673770|NCT00029068|Obsessive Compulsive
673771|NCT00029068|OCD
673772|NCT00029068|Healthy Volunteer
673773|NCT00029068|Normal Control
673774|NCT00029068|HV
673775|NCT00029042|MRI
673776|NCT00029042|Inflammation
673777|NCT00029042|Joint Disability
673778|NCT00029042|Imaging
673779|NCT00029042|Biologic Therapy
673780|NCT00029042|Rheumatoid Arthritis
673781|NCT00029042|Juvenile Rheumatoid Arthritis
673782|NCT00029042|JRA
673783|NCT00029042|Children
673784|NCT00029042|Joints
673785|NCT00029042|Joint Inflammation
673786|NCT00029029|bone metastases
673787|NCT00029029|pain
673788|NCT00028990|stage IV breast cancer
673789|NCT00028990|recurrent breast cancer
673790|NCT00028990|male breast cancer
673791|NCT00028977|stage IV breast cancer
673792|NCT00028977|recurrent breast cancer
673793|NCT00028964|stage I breast cancer
673794|NCT00028964|stage II breast cancer
673795|NCT00028964|stage IIIA breast cancer
673796|NCT00028964|recurrent breast cancer
673797|NCT00028964|drug/agent toxicity by tissue/organ
673798|NCT00028951|lymphedema
673799|NCT00028951|perioperative/postoperative complications
673800|NCT00028951|stage I vulvar cancer
673801|NCT00028951|stage II vulvar cancer
673802|NCT00028951|stage III vulvar cancer
673803|NCT00028951|stage IVB vulvar cancer
673804|NCT00028938|squamous cell lung cancer
673805|NCT00028938|large cell lung cancer
673806|NCT00028938|stage IIIA non-small cell lung cancer
673807|NCT00028938|stage IIIB non-small cell lung cancer
673808|NCT00028938|adenocarcinoma of the lung
673809|NCT00028938|bronchoalveolar cell lung cancer
673810|NCT00028925|extensive stage small cell lung cancer
673811|NCT00028912|recurrent ovarian epithelial cancer
673812|NCT00028912|primary peritoneal cavity cancer
673813|NCT00028912|fallopian tube cancer
673814|NCT00028899|recurrent childhood acute myeloid leukemia
673815|NCT00028899|secondary acute myeloid leukemia
673816|NCT00028899|previously treated myelodysplastic syndromes
673817|NCT00028886|stage II multiple myeloma
673818|NCT00028886|stage III multiple myeloma
673819|NCT00028873|stage IV breast cancer
673820|NCT00028873|recurrent breast cancer
673821|NCT00028860|stage III bladder cancer
673822|NCT00028860|stage IV bladder cancer
673823|NCT00028860|transitional cell carcinoma of the bladder
673824|NCT00028860|localized transitional cell cancer of the renal pelvis and ureter
673825|NCT00028860|regional transitional cell cancer of the renal pelvis and ureter
673826|NCT00028847|chronic phase chronic myelogenous leukemia
673827|NCT00028847|chronic myelogenous leukemia, BCR-ABL1 positive
673828|NCT00028795|childhood brain stem glioma
673829|NCT00028795|childhood high-grade cerebral astrocytoma
673830|NCT00028795|childhood spinal cord neoplasm
673831|NCT00028795|untreated childhood brain stem glioma
673832|NCT00028769|adenocarcinoma of the prostate
673833|NCT00028769|stage IV prostate cancer
673834|NCT00028769|recurrent prostate cancer
673835|NCT00028743|stage II ovarian epithelial cancer
673836|NCT00028743|stage III ovarian epithelial cancer
673837|NCT00028743|stage IV ovarian epithelial cancer
673838|NCT00028743|fallopian tube cancer
673839|NCT00028743|peritoneal cavity cancer
673840|NCT00028730|recurrent childhood lymphoblastic lymphoma
673841|NCT00028730|chronic phase chronic myelogenous leukemia
673842|NCT00028730|childhood acute myeloid leukemia in remission
673843|NCT00028730|childhood acute lymphoblastic leukemia in remission
673844|NCT00028730|secondary acute myeloid leukemia
673845|NCT00028730|de novo myelodysplastic syndromes
673846|NCT00028730|previously treated myelodysplastic syndromes
673847|NCT00028730|secondary myelodysplastic syndromes
673848|NCT00028730|recurrent childhood small noncleaved cell lymphoma
673849|NCT00028730|recurrent childhood large cell lymphoma
673850|NCT00028730|myelodysplastic/myeloproliferative neoplasm, unclassifiable
673851|NCT00028717|stage I grade 3 follicular lymphoma
673852|NCT00028717|stage I adult diffuse large cell lymphoma
673853|NCT00028717|stage III grade 3 follicular lymphoma
673854|NCT00028717|stage III adult diffuse large cell lymphoma
673855|NCT00028717|stage IV grade 3 follicular lymphoma
673856|NCT00028717|stage IV adult diffuse large cell lymphoma
673857|NCT00028717|stage I mantle cell lymphoma
673858|NCT00028717|contiguous stage II grade 3 follicular lymphoma
673859|NCT00028717|contiguous stage II mantle cell lymphoma
673860|NCT00028717|contiguous stage II adult diffuse large cell lymphoma
673861|NCT00028717|noncontiguous stage II grade 3 follicular lymphoma
673862|NCT00028717|noncontiguous stage II mantle cell lymphoma
673863|NCT00028717|noncontiguous stage II adult diffuse large cell lymphoma
673864|NCT00028717|stage III mantle cell lymphoma
673865|NCT00028717|stage IV mantle cell lymphoma
673866|NCT00028704|stage II breast cancer
673867|NCT00028704|stage IIIA breast cancer
673868|NCT00028704|stage IIIB breast cancer
673869|NCT00028704|inflammatory breast cancer
673870|NCT00028691|stage III grade 1 follicular lymphoma
673871|NCT00028691|stage III grade 2 follicular lymphoma
673872|NCT00028691|stage III grade 3 follicular lymphoma
673873|NCT00028691|stage IV grade 1 follicular lymphoma
673874|NCT00028691|stage IV grade 2 follicular lymphoma
673875|NCT00028691|stage IV grade 3 follicular lymphoma
673876|NCT00028678|adult glioblastoma
673877|NCT00028678|adult giant cell glioblastoma
673878|NCT00028678|adult gliosarcoma
673879|NCT00028665|stage III grade 1 follicular lymphoma
673880|NCT00028665|stage III grade 2 follicular lymphoma
673881|NCT00028665|stage III grade 3 follicular lymphoma
673882|NCT00028665|stage III adult diffuse small cleaved cell lymphoma
673883|NCT00028665|stage III adult diffuse mixed cell lymphoma
673884|NCT00028665|stage III adult diffuse large cell lymphoma
673885|NCT00028665|stage III adult immunoblastic large cell lymphoma
673886|NCT00028665|stage III adult lymphoblastic lymphoma
673887|NCT00028665|stage IV grade 1 follicular lymphoma
673888|NCT00028665|stage IV grade 2 follicular lymphoma
673889|NCT00028665|stage IV grade 3 follicular lymphoma
673890|NCT00028665|stage IV adult diffuse small cleaved cell lymphoma
673891|NCT00028665|stage IV adult diffuse mixed cell lymphoma
673892|NCT00028665|stage IV adult diffuse large cell lymphoma
673893|NCT00028665|stage IV adult immunoblastic large cell lymphoma
673894|NCT00028665|stage IV adult lymphoblastic lymphoma
673895|NCT00028665|recurrent grade 1 follicular lymphoma
673896|NCT00028665|recurrent grade 2 follicular lymphoma
673897|NCT00028665|recurrent grade 3 follicular lymphoma
673898|NCT00028665|recurrent adult diffuse small cleaved cell lymphoma
673899|NCT00028665|recurrent adult diffuse mixed cell lymphoma
673900|NCT00028665|recurrent adult diffuse large cell lymphoma
673901|NCT00028665|recurrent adult immunoblastic large cell lymphoma
673902|NCT00028665|stage III mantle cell lymphoma
673903|NCT00028665|stage IV mantle cell lymphoma
673904|NCT00028665|recurrent mantle cell lymphoma
673905|NCT00028652|skin metastases
673906|NCT00028639|stage IV breast cancer
673907|NCT00028639|recurrent breast cancer
673908|NCT00028626|liver metastases
673909|NCT00028626|adenocarcinoma of the colon
673910|NCT00028626|recurrent colon cancer
673911|NCT00028626|stage IV colon cancer
673912|NCT00028626|adenocarcinoma of the rectum
673913|NCT00028626|recurrent rectal cancer
673914|NCT00028626|stage IV rectal cancer
673915|NCT00028613|recurrent adult diffuse large cell lymphoma
673916|NCT00028600|refractory multiple myeloma
673917|NCT00028600|stage I multiple myeloma
673918|NCT00028600|stage II multiple myeloma
673919|NCT00028600|stage III multiple myeloma
673920|NCT00028574|stage I prostate cancer
673921|NCT00028574|stage IIB prostate cancer
673922|NCT00028574|stage IIA prostate cancer
673923|NCT00028574|stage III prostate cancer
673924|NCT00028574|stage IV prostate cancer
673925|NCT00028574|recurrent prostate cancer
673926|NCT00028574|hot flashes
673927|NCT00028548|unspecified adult solid tumor, protocol specific
673928|NCT00028509|neurotoxicity
673929|NCT00028509|long-term effects secondary to cancer therapy in children
673930|NCT00028483|stage IV breast cancer
673931|NCT00028483|recurrent breast cancer
673932|NCT00028431|Stage III melanoma
673933|NCT00028431|Stage IV melanoma
673934|NCT00028431|Interleukin-12
673935|NCT00028431|Cancer Vaccines
673936|NCT00028431|Antineoplastic Agents, Combined
673937|NCT00028431|Incomplete Freund's adjuvant
673938|NCT00028431|Monophenol Monooxygenase
673939|NCT00028431|Mannitol
673940|NCT00028431|Adjuvants, Immunologic
673941|NCT00028431|Melan-A Protein
673942|NCT00028431|Antigens, Neoplasm
673943|NCT00028431|Antibodies
673944|NCT00028431|Melanocyte lineage-specific antigen gp100
673945|NCT00028431|CTLA-4
673946|NCT00028418|Acute Leukemia
673947|NCT00028418|Chronic Lymphocytic Leukemia
673948|NCT00028418|Antineoplastic Agents
673949|NCT00028418|Nucleosides
673950|NCT00028418|Dose-Response Relationship, Drug
673951|NCT00028418|Cladribine
673952|NCT00028418|Fludarabine
673953|NCT00028405|Photodynamic Therapy
673954|NCT00028405|Bulky Tumor
673955|NCT00028405|Refractory Tumor
673956|NCT00028405|Head and Neck Cancer
673957|NCT00028405|Breast Cancer
673958|NCT00028405|Pelvic Tumors
673959|NCT00028405|Liver Metastasis
673960|NCT00028405|Colorectal Cancer
673961|NCT00028405|Sarcoma
673962|NCT00028405|Anal Cancer
673963|NCT00028405|Oral Cancer
673964|NCT00028405|Recurrent
673965|NCT00028405|Lymphadenopathy
673966|NCT00028405|Ovarian Cancer
673967|NCT00028405|Cervical Cancer
673968|NCT00028379|Plasticity
673969|NCT00028379|Motor Cortex
673970|NCT00028379|Stroke
673971|NCT00028379|Somatosensory
673972|NCT00028379|Hemiparesis
673973|NCT00028366|HIV-1
673974|NCT00028366|Drug Therapy, Combination
673975|NCT00028366|HIV Protease Inhibitors
673976|NCT00028366|Ritonavir
673977|NCT00028366|RNA, Viral
673978|NCT00028366|Reverse Transcriptase Inhibitors
673979|NCT00028366|Viral Load
673980|NCT00028366|ABT 378
673981|NCT00028366|tenofovir disoproxil
673982|NCT00028366|VX-175
673983|NCT00028366|Treatment Experienced
673984|NCT00028353|PIN
673985|NCT00028353|High Grade Prostate Intraepithelial Neoplasia (PIN)
673986|NCT00028340|Breast Cancer
673987|NCT00028340|Post Menopausal
673988|NCT00028340|Breast Duct
673989|NCT00028340|Healthy Volunteer
673990|NCT00028340|HV
673991|NCT00028340|Normal Control
673992|NCT00028327|AIDS-Related Opportunistic Infections
673993|NCT00028327|Zidovudine
673994|NCT00028327|HIV Protease Inhibitors
673995|NCT00028327|CD4 Lymphocyte Count
673996|NCT00028327|Lamivudine
673997|NCT00028327|Pneumonia
673998|NCT00028327|Nelfinavir
673999|NCT00028327|Reverse Transcriptase Inhibitors
674000|NCT00028327|Antiretroviral Therapy, Highly Active
674001|NCT00028327|Efavirenz
674002|NCT00028327|Intensive Care Units
674003|NCT00028327|Sepsis
674004|NCT00028314|HIV-1
674005|NCT00028314|Abacavir
674006|NCT00028314|Nevirapine
674007|NCT00028314|Ritonavir
674008|NCT00028314|RNA, Viral
674009|NCT00028314|HIV Protease Inhibitors
674010|NCT00028314|Reverse Transcriptase Inhibitors
674011|NCT00028314|Anti-HIV Agents
674012|NCT00028314|Viral Load
674013|NCT00028314|HIV Wasting Syndrome
674014|NCT00028314|ABT 378
674015|NCT00028314|Treatment Experienced
674016|NCT00028301|HIV Protease Inhibitors
674017|NCT00028301|RNA, Viral
674018|NCT00028301|Reverse Transcriptase Inhibitors
674019|NCT00028301|Anti-HIV Agents
674020|NCT00028301|Viral Load
674021|NCT00028301|Lipids
674022|NCT00028301|ABT 378
674023|NCT00028301|Antiretroviral Therapy, Highly Active
674024|NCT00028301|Lipoproteins, LDL Cholesterol
674025|NCT00028288|Asthma
674026|NCT00028288|Daclizumab
674027|NCT00028288|anti-Tac monoclonal antibody
674028|NCT00028288|anti-IL-2
674029|NCT00028288|Zenapax
674030|NCT00028275|Hepatitis C Virus
674031|NCT00028275|Cirrhosis
674032|NCT00028275|Antiviral Agents
674033|NCT00028275|Viral Resistance
674034|NCT00028275|Alpha Interferon
674035|NCT00028275|Hepatitis C
674036|NCT00028275|Hepatitis
674037|NCT00028262|Palmitoyl-Protein Thioesterase
674038|NCT00028262|Lysosomes
674039|NCT00028262|Batten Disease
674040|NCT00028262|Encephalopathy
674041|NCT00028262|Progressive Neurodegeneration
674042|NCT00028262|CLN 1
674043|NCT00028262|Infantile Neuronal Ceroid Lipofuscinosis
674044|NCT00028262|Cystagon
674045|NCT00028249|Patient Satisfaction
674046|NCT00028249|Self Efficacy
674047|NCT00028249|Social Support
674048|NCT00028249|Symptom Management
674049|NCT00028249|Advanced Malignancies
674050|NCT00028249|Pain Intervention
674051|NCT00028236|Peripheral Blood Stem Cells
674052|NCT00028236|Common Gamma Chain (GC)
674053|NCT00028236|Immune Reconstitution
674054|NCT00028236|T Lymphocytes
674055|NCT00028236|B Lymphocytes
674056|NCT00028236|X-Linked Severe Combined Immune Deficiency (XSCID)
674057|NCT00028236|Gene Therapy
674058|NCT00028236|NK Cell
674059|NCT00028236|Bone Marrow Transplantation
674060|NCT00028236|Engraftment
674061|NCT00028236|XSCID
674062|NCT00028236|Immune Deficiency
674063|NCT00028236|Immune System
674064|NCT00028210|Amputee
674065|NCT00028210|Plasticity
674066|NCT00028210|Somatosensory
674067|NCT00028210|Upper Limb Amputation
674068|NCT00028210|Tactile Performance
674069|NCT00028210|Cortical Reorganization
674070|NCT00028210|Healthy Volunteer
674071|NCT00028210|HV
674072|NCT00028210|Normal Control
674073|NCT00028197|Voluntary Movement
674074|NCT00028197|Functional MRI
674075|NCT00028197|Sensorimotor Integration
674076|NCT00028197|Superior Parietal Lobe
674077|NCT00028197|Supplementary Motor Area
674078|NCT00028197|Normal Control
674079|NCT00028197|HV
674080|NCT00028197|Healthy Volunteer
674081|NCT00028184|Chronic Stroke
674082|NCT00028184|Ipsilateral Motor Cortex
674083|NCT00028184|Motor Control
674084|NCT00028184|Motor Recovery
674085|NCT00028184|Stroke
674086|NCT00028184|Healthy Volunteer
674087|NCT00028184|HV
674088|NCT00028184|Healthy Control
674089|NCT00028158|Antineoplastic agents
674090|NCT00028158|Herpes virus
674091|NCT00028158|Brain tumor
674092|NCT00028158|Oncolytic virs
674093|NCT00028145|Women's Health
674094|NCT00028145|Disease Transmission, Vertical
674095|NCT00028145|Preventive Medicine
674096|NCT00028145|Treatment Experienced
674097|NCT00028132|Risk Factors
674098|NCT00028132|Mucous Membrane
674099|NCT00028132|Anti-Infective Agents
674100|NCT00028132|Cervix Uteri
674101|NCT00028132|Vagina
674102|NCT00028132|Anti-HIV Agents
674103|NCT00028132|Pharmacokinetics
674104|NCT00028132|Vulva
674105|NCT00028132|9-(2-phosphonylmethoxypropyl)adenine
674106|NCT00028132|HIV Seronegativity
674107|NCT00028119|Clinical Trials
674108|NCT00028119|Sexual Partners
674109|NCT00028119|Risk Factors
674110|NCT00028119|Incidence
674111|NCT00028119|HIV Seronegativity
674112|NCT00028119|India
674113|NCT00028119|Patient Compliance
674114|NCT00028119|Preventive Health Services
674115|NCT00028106|Cancer
674116|NCT00028106|Metastasis
674117|NCT00028106|Fluorodopamine
674118|NCT00028106|PET
674119|NCT00028106|Methylprednisolone
674120|NCT00028106|Catecholamines
674121|NCT00028106|Metanephrines
674122|NCT00028106|Alpha-Methyl-Para-Tyrosine
674123|NCT00028106|Retinoic Acid
674124|NCT00028106|Carbidopa
674125|NCT00028093|Chronic Hepatitis
674126|NCT00028093|Cirrhosis
674127|NCT00028093|Hepatitis C Virus
674128|NCT00028093|Hemolysis
674129|NCT00028093|Ribavirin
674130|NCT00028093|Alpha Interferon
674131|NCT00028093|Peginterferon
674132|NCT00028093|Antiviral Agents
674133|NCT00028093|Viral Hepatitis
674134|NCT00028093|Hemolytic Anemia
674135|NCT00028093|Renal Failure
674136|NCT00028093|Renal Dialysis
674137|NCT00028093|Hepatitis
674138|NCT00028093|Hepatitis C
674139|NCT00028080|Borrelia Burgdorferi
674140|NCT00028080|Lyme Disease
674141|NCT00028080|Infection
674142|NCT00028080|Therapy
674143|NCT00028080|Lyme
674144|NCT00028067|Drug Therapy, Combination
674145|NCT00028067|HIV Protease Inhibitors
674146|NCT00028067|RNA, Viral
674147|NCT00028067|Reverse Transcriptase Inhibitors
674148|NCT00028067|Viral Load
674149|NCT00028067|BMS 232632
674150|NCT00028015|stage IV colon cancer
674151|NCT00028015|stage IV rectal cancer
674152|NCT00028015|recurrent colon cancer
674153|NCT00028015|recurrent rectal cancer
674154|NCT00027989|stage IV breast cancer
674155|NCT00027976|actinic keratosis
674156|NCT00027963|neurotoxicity
674157|NCT00027963|pain
674158|NCT00027937|stage I adult Hodgkin lymphoma
674159|NCT00027937|stage II adult Hodgkin lymphoma
674160|NCT00027937|stage III adult Hodgkin lymphoma
674161|NCT00027937|stage IV adult Hodgkin lymphoma
674162|NCT00027937|recurrent adult Hodgkin lymphoma
674163|NCT00027937|unspecified childhood solid tumor, protocol specific
674164|NCT00027937|unspecified adult solid tumor, protocol specific
674165|NCT00027937|stage II childhood Hodgkin lymphoma
674166|NCT00027937|stage I childhood Hodgkin lymphoma
674167|NCT00027937|stage III childhood Hodgkin lymphoma
674168|NCT00027937|stage IV childhood Hodgkin lymphoma
674169|NCT00027937|recurrent/refractory childhood Hodgkin lymphoma
674170|NCT00027937|stage I grade 1 follicular lymphoma
674171|NCT00027937|stage I grade 2 follicular lymphoma
674172|NCT00027937|stage I grade 3 follicular lymphoma
674173|NCT00027937|stage I adult diffuse small cleaved cell lymphoma
674174|NCT00027937|stage I adult diffuse mixed cell lymphoma
674175|NCT00027937|stage I adult diffuse large cell lymphoma
674176|NCT00027937|stage I adult immunoblastic large cell lymphoma
674177|NCT00027937|stage I adult lymphoblastic lymphoma
674178|NCT00027937|stage I adult Burkitt lymphoma
674179|NCT00027937|stage III grade 1 follicular lymphoma
674180|NCT00027937|stage III grade 2 follicular lymphoma
674181|NCT00027937|stage III grade 3 follicular lymphoma
674182|NCT00027937|stage III adult diffuse small cleaved cell lymphoma
674183|NCT00027937|stage III adult diffuse mixed cell lymphoma
674184|NCT00027937|stage III adult diffuse large cell lymphoma
674185|NCT00027937|stage III adult immunoblastic large cell lymphoma
674186|NCT00027937|stage III adult lymphoblastic lymphoma
674187|NCT00027937|stage III adult Burkitt lymphoma
674188|NCT00027937|stage IV grade 1 follicular lymphoma
674189|NCT00027937|stage IV grade 2 follicular lymphoma
674190|NCT00027937|stage IV grade 3 follicular lymphoma
674191|NCT00027937|stage IV adult diffuse small cleaved cell lymphoma
674192|NCT00027937|stage IV adult diffuse mixed cell lymphoma
674193|NCT00027937|stage IV adult diffuse large cell lymphoma
674194|NCT00027937|stage IV adult immunoblastic large cell lymphoma
674195|NCT00027937|stage IV adult lymphoblastic lymphoma
674196|NCT00027937|stage IV adult Burkitt lymphoma
674197|NCT00027937|recurrent grade 1 follicular lymphoma
674198|NCT00027937|recurrent grade 2 follicular lymphoma
674199|NCT00027937|recurrent grade 3 follicular lymphoma
674200|NCT00027937|recurrent adult diffuse small cleaved cell lymphoma
674201|NCT00027937|recurrent adult diffuse mixed cell lymphoma
674202|NCT00027937|recurrent adult diffuse large cell lymphoma
674203|NCT00027937|recurrent adult immunoblastic large cell lymphoma
674204|NCT00027937|recurrent adult lymphoblastic lymphoma
674205|NCT00027937|recurrent adult Burkitt lymphoma
674206|NCT00027937|stage I childhood small noncleaved cell lymphoma
674207|NCT00027937|stage I childhood large cell lymphoma
674208|NCT00027937|stage II childhood small noncleaved cell lymphoma
674209|NCT00027937|stage II childhood large cell lymphoma
674210|NCT00027937|stage III childhood small noncleaved cell lymphoma
674211|NCT00027937|stage III childhood large cell lymphoma
674212|NCT00027937|stage IV childhood small noncleaved cell lymphoma
674213|NCT00027937|stage IV childhood large cell lymphoma
674214|NCT00027937|recurrent childhood small noncleaved cell lymphoma
674215|NCT00027937|recurrent childhood large cell lymphoma
674216|NCT00027937|stage I mantle cell lymphoma
674217|NCT00027937|contiguous stage II grade 1 follicular lymphoma
674218|NCT00027937|contiguous stage II grade 2 follicular lymphoma
674219|NCT00027937|contiguous stage II grade 3 follicular lymphoma
674220|NCT00027937|contiguous stage II adult diffuse small cleaved cell lymphoma
674221|NCT00027937|contiguous stage II mantle cell lymphoma
674222|NCT00027937|contiguous stage II adult diffuse mixed cell lymphoma
674223|NCT00027937|contiguous stage II adult immunoblastic large cell lymphoma
674224|NCT00027937|contiguous stage II adult diffuse large cell lymphoma
674225|NCT00027937|contiguous stage II adult Burkitt lymphoma
674226|NCT00027937|contiguous stage II adult lymphoblastic lymphoma
674227|NCT00027937|noncontiguous stage II grade 1 follicular lymphoma
674228|NCT00027937|noncontiguous stage II grade 2 follicular lymphoma
674229|NCT00027937|noncontiguous stage II grade 3 follicular lymphoma
674230|NCT00027937|noncontiguous stage II adult diffuse small cleaved cell lymphoma
674231|NCT00027937|noncontiguous stage II mantle cell lymphoma
674232|NCT00027937|noncontiguous stage II adult diffuse mixed cell lymphoma
674233|NCT00027937|noncontiguous stage II adult immunoblastic large cell lymphoma
674234|NCT00027937|noncontiguous stage II adult diffuse large cell lymphoma
674235|NCT00027937|noncontiguous stage II adult Burkitt lymphoma
674236|NCT00027937|noncontiguous stage II adult lymphoblastic lymphoma
674237|NCT00027937|stage III mantle cell lymphoma
674238|NCT00027937|stage IV mantle cell lymphoma
674239|NCT00027937|recurrent mantle cell lymphoma
674240|NCT00027937|noncontiguous stage II small lymphocytic lymphoma
674241|NCT00027937|noncontiguous stage II marginal zone lymphoma
674242|NCT00027937|recurrent marginal zone lymphoma
674243|NCT00027937|recurrent small lymphocytic lymphoma
674244|NCT00027937|stage I marginal zone lymphoma
674245|NCT00027937|stage I small lymphocytic lymphoma
674246|NCT00027937|stage III small lymphocytic lymphoma
674247|NCT00027937|stage III marginal zone lymphoma
674248|NCT00027937|stage IV small lymphocytic lymphoma
674249|NCT00027937|stage IV marginal zone lymphoma
674250|NCT00027937|contiguous stage II marginal zone lymphoma
674251|NCT00027937|contiguous stage II small lymphocytic lymphoma
674252|NCT00027937|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
674253|NCT00027937|nodal marginal zone B-cell lymphoma
674254|NCT00027937|splenic marginal zone lymphoma
674255|NCT00027924|relapsing chronic myelogenous leukemia
674256|NCT00027924|chronic phase chronic myelogenous leukemia
674257|NCT00027924|accelerated phase chronic myelogenous leukemia
674258|NCT00027924|blastic phase chronic myelogenous leukemia
674259|NCT00027924|meningeal chronic myelogenous leukemia
674260|NCT00027924|Philadelphia chromosome positive chronic myelogenous leukemia
674261|NCT00027924|refractory anemia
674262|NCT00027924|refractory anemia with ringed sideroblasts
674263|NCT00027924|refractory anemia with excess blasts
674264|NCT00027924|refractory anemia with excess blasts in transformation
674265|NCT00027924|chronic myelomonocytic leukemia
674266|NCT00027924|secondary acute myeloid leukemia
674267|NCT00027924|de novo myelodysplastic syndromes
674268|NCT00027924|previously treated myelodysplastic syndromes
674269|NCT00027924|secondary myelodysplastic syndromes
674270|NCT00027924|childhood myelodysplastic syndromes
674271|NCT00027911|adult synovial sarcoma
674272|NCT00027911|stage III adult soft tissue sarcoma
674273|NCT00027911|recurrent adult soft tissue sarcoma
674274|NCT00027911|stage IV adult soft tissue sarcoma
674275|NCT00027911|stage II adult soft tissue sarcoma
674276|NCT00027885|stage IV breast cancer
674277|NCT00027885|stage IIIA breast cancer
674278|NCT00027885|stage IIIB breast cancer
674279|NCT00027885|stage IIIC breast cancer
674280|NCT00027885|male breast cancer
674281|NCT00027859|adenocarcinoma of the prostate
674282|NCT00027859|stage III prostate cancer
674283|NCT00027846|childhood supratentorial ependymoma
674284|NCT00027846|newly diagnosed childhood ependymoma
674285|NCT00027846|childhood infratentorial ependymoma
674286|NCT00027833|stage IV colon cancer
674287|NCT00027833|stage IV rectal cancer
674288|NCT00027833|adenocarcinoma of the colon
674289|NCT00027833|adenocarcinoma of the rectum
674290|NCT00027807|stage IV breast cancer
674291|NCT00027807|recurrent breast cancer
674292|NCT00027807|ductal breast carcinoma
674293|NCT00027794|adenocarcinoma of the prostate
674294|NCT00027794|stage III prostate cancer
674295|NCT00027781|adenocarcinoma of the prostate
674296|NCT00027781|recurrent prostate cancer
674297|NCT00027768|localized resectable adult primary liver cancer
674298|NCT00027768|adult primary hepatocellular carcinoma
674299|NCT00027742|iris melanoma
674300|NCT00027742|extraocular extension melanoma
674301|NCT00027742|recurrent intraocular melanoma
674302|NCT00027742|stage III melanoma
674303|NCT00027742|stage IV melanoma
674304|NCT00027742|recurrent melanoma
674305|NCT00027729|recurrent colon cancer
674306|NCT00027729|recurrent rectal cancer
674307|NCT00027716|metastatic osteosarcoma
674308|NCT00027716|recurrent adult soft tissue sarcoma
674309|NCT00027716|recurrent osteosarcoma
674310|NCT00027716|adult rhabdomyosarcoma
674311|NCT00027716|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
674312|NCT00027716|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
674313|NCT00027716|stage IV adult soft tissue sarcoma
674314|NCT00027677|unspecified adult solid tumor, protocol specific
674315|NCT00027664|stage IV renal cell cancer
674316|NCT00027638|metastatic gastrointestinal carcinoid tumor
674317|NCT00027638|recurrent gastrointestinal carcinoid tumor
674318|NCT00027638|gastrinoma
674319|NCT00027638|insulinoma
674320|NCT00027638|recurrent islet cell carcinoma
674321|NCT00027638|WDHA syndrome
674322|NCT00027638|somatostatinoma
674323|NCT00027638|pancreatic polypeptide tumor
674324|NCT00027638|glucagonoma
674325|NCT00027638|pulmonary carcinoid tumor
674326|NCT00027625|recurrent adult brain tumor
674327|NCT00027625|adult glioblastoma
674328|NCT00027625|adult anaplastic astrocytoma
674329|NCT00027625|adult anaplastic oligodendroglioma
674330|NCT00027625|adult mixed glioma
674331|NCT00027625|adult giant cell glioblastoma
674332|NCT00027625|adult gliosarcoma
674333|NCT00027612|adult glioblastoma
674334|NCT00027612|adult giant cell glioblastoma
674335|NCT00027612|adult gliosarcoma
674336|NCT00027599|adenocarcinoma of the prostate
674337|NCT00027599|stage I prostate cancer
674338|NCT00027599|stage IIB prostate cancer
674339|NCT00027599|stage IIA prostate cancer
674340|NCT00027599|stage III prostate cancer
674341|NCT00027599|stage IV prostate cancer
674342|NCT00027599|recurrent prostate cancer
674343|NCT00027586|stage IV melanoma
674344|NCT00027586|recurrent melanoma
674345|NCT00027586|Imatinib Mesylate
674346|NCT00027586|Gleevec
674347|NCT00027586|protein tyrosine kinases
674348|NCT00027586|PTK
674349|NCT00027586|Gleevec targets
674350|NCT00027586|metastatic melanoma
674351|NCT00027573|stage IV renal cell cancer
674352|NCT00027573|recurrent renal cell cancer
674353|NCT00027573|clear cell renal cell carcinoma
674354|NCT00027573|papillary renal cell carcinoma
674355|NCT00027560|recurrent childhood acute lymphoblastic leukemia
674356|NCT00027560|recurrent adult Hodgkin lymphoma
674357|NCT00027560|refractory multiple myeloma
674358|NCT00027560|stage II multiple myeloma
674359|NCT00027560|stage III multiple myeloma
674360|NCT00027560|recurrent childhood lymphoblastic lymphoma
674361|NCT00027560|recurrent childhood acute myeloid leukemia
674362|NCT00027560|recurrent adult acute myeloid leukemia
674363|NCT00027560|recurrent adult acute lymphoblastic leukemia
674364|NCT00027560|relapsing chronic myelogenous leukemia
674365|NCT00027560|refractory chronic lymphocytic leukemia
674366|NCT00027560|recurrent/refractory childhood Hodgkin lymphoma
674367|NCT00027560|recurrent grade 1 follicular lymphoma
674368|NCT00027560|recurrent grade 2 follicular lymphoma
674369|NCT00027560|recurrent grade 3 follicular lymphoma
674370|NCT00027560|recurrent adult diffuse small cleaved cell lymphoma
674371|NCT00027560|recurrent adult diffuse mixed cell lymphoma
674372|NCT00027560|recurrent adult diffuse large cell lymphoma
674373|NCT00027560|recurrent adult immunoblastic large cell lymphoma
674374|NCT00027560|recurrent adult lymphoblastic lymphoma
674375|NCT00027560|recurrent adult Burkitt lymphoma
674376|NCT00027560|previously treated myelodysplastic syndromes
674377|NCT00027560|recurrent childhood small noncleaved cell lymphoma
674378|NCT00027560|recurrent childhood large cell lymphoma
674379|NCT00027560|recurrent mantle cell lymphoma
674380|NCT00027560|Waldenström macroglobulinemia
674381|NCT00027560|childhood chronic myelogenous leukemia
674382|NCT00027560|atypical chronic myeloid leukemia, BCR-ABL1 negative
674383|NCT00027560|myelodysplastic/myeloproliferative neoplasm, unclassifiable
674384|NCT00027560|recurrent marginal zone lymphoma
674385|NCT00027560|recurrent small lymphocytic lymphoma
674386|NCT00027560|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
674387|NCT00027560|nodal marginal zone B-cell lymphoma
674388|NCT00027560|splenic marginal zone lymphoma
674389|NCT00027560|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
674390|NCT00027560|childhood myelodysplastic syndromes
674391|NCT00027547|adult acute lymphoblastic leukemia in remission
674392|NCT00027547|childhood acute lymphoblastic leukemia in remission
674393|NCT00027534|recurrent colon cancer
674394|NCT00027534|stage III colon cancer
674395|NCT00027534|stage IV colon cancer
674396|NCT00027534|recurrent breast cancer
674397|NCT00027534|stage IIIA breast cancer
674398|NCT00027534|stage IIIB breast cancer
674399|NCT00027534|stage IIIC breast cancer
674400|NCT00027534|stage IV breast cancer
674401|NCT00027534|recurrent gastric cancer
674402|NCT00027534|stage III gastric cancer
674403|NCT00027534|stage IV gastric cancer
674404|NCT00027534|recurrent pancreatic cancer
674405|NCT00027534|stage II pancreatic cancer
674406|NCT00027534|stage III pancreatic cancer
674407|NCT00027534|recurrent rectal cancer
674408|NCT00027534|stage III rectal cancer
674409|NCT00027534|stage IV rectal cancer
674410|NCT00027534|advanced adult primary liver cancer
674411|NCT00027534|recurrent adult primary liver cancer
674412|NCT00027534|recurrent gallbladder cancer
674413|NCT00027534|unresectable gallbladder cancer
674414|NCT00027534|thyroid gland medullary carcinoma
674415|NCT00027534|recurrent salivary gland cancer
674416|NCT00027534|stage III salivary gland cancer
674417|NCT00027534|stage IV salivary gland cancer
674418|NCT00027534|Paget disease of the breast with intraductal carcinoma
674419|NCT00027534|Paget disease of the breast with invasive ductal carcinoma
674420|NCT00027534|adult primary hepatocellular carcinoma
674421|NCT00027534|diffuse adenocarcinoma of the stomach
674422|NCT00027534|intestinal adenocarcinoma of the stomach
674423|NCT00027534|mixed adenocarcinoma of the stomach
674424|NCT00027534|adenocarcinoma of the colon
674425|NCT00027534|adenocarcinoma of the gallbladder
674426|NCT00027534|adenocarcinoma of the rectum
674427|NCT00027534|recurrent malignant testicular germ cell tumor
674428|NCT00027534|stage II malignant testicular germ cell tumor
674429|NCT00027534|stage III malignant testicular germ cell tumor
674430|NCT00027534|male breast cancer
674431|NCT00027534|adenocarcinoma of the pancreas
674432|NCT00027534|cholangiocarcinoma of the gallbladder
674433|NCT00027534|salivary gland adenocarcinoma
674434|NCT00027534|ovarian endometrioid adenocarcinoma
674435|NCT00027534|stage IV pancreatic cancer
674436|NCT00027521|stage III pancreatic cancer
674437|NCT00027521|adenocarcinoma of the pancreas
674438|NCT00027508|advanced malignant mesothelioma
674439|NCT00027508|recurrent malignant mesothelioma
674440|NCT00027495|colon cancer
674441|NCT00027482|T Cell
674442|NCT00027482|B Cell
674443|NCT00027482|Flow Cytometry
674444|NCT00027482|Cell-Mediated Immunity
674445|NCT00027482|Thymus
674446|NCT00027482|HIV
674447|NCT00027482|Immunity
674448|NCT00027482|Lymphocytes
674449|NCT00027482|Monocytes
674450|NCT00027482|Healthy Volunteer
674451|NCT00027482|HV
674452|NCT00027482|Normal Control
674453|NCT00027469|Atheroembolism
674454|NCT00027469|Atherosclerosis
674455|NCT00027469|MRI
674456|NCT00027469|Renal Artery Stenosis
674457|NCT00027469|Renovascular Hypertension
674458|NCT00027469|ARAS
674459|NCT00027469|Renovascular Disease
674460|NCT00027469|Renal Artery Stenting
674461|NCT00027469|PTRAS
674462|NCT00027456|Insulin Resistance
674463|NCT00027456|Diabetes Mellitus
674464|NCT00027456|Adipocytes
674465|NCT00027456|Rabson Mendenhall Syndrome
674466|NCT00027456|Leprechaunism
674467|NCT00027456|Leptin
674468|NCT00027443|Giant Cell Myocarditis
674469|NCT00027417|Congenital heart defects
674470|NCT00027417|Hypoplastic left heart syndrome
674471|NCT00027417|Complete atrioventricular canal defect
674472|NCT00027417|Triostat
674473|NCT00027417|Cardiac surgery
674474|NCT00027404|Adult, Autism
674475|NCT00027391|Muscle Weakness, Muscular Dystrophy
674476|NCT00027378|fluoxetine,
674477|NCT00027378|adolescents,
674478|NCT00027378|alcohol dependence,
674479|NCT00027378|major depression
674480|NCT00027378|Alcoholism
674481|NCT00027365|HIV Seronegativity
674482|NCT00027365|HIV Preventive Vaccine
674483|NCT00027365|Injections, Intramuscular
674484|NCT00027365|HIV Antibodies
674485|NCT00027365|HIV-1
674486|NCT00027365|HIV Envelope Protein gp120
674487|NCT00027365|Gene Products, tat
674488|NCT00027365|AIDS Vaccines
674489|NCT00027365|Neutralization Tests
674490|NCT00027365|Vaccines, Combined
674491|NCT00027365|AIDS Seronegativity
674492|NCT00027365|Gene Products, nef
674493|NCT00027352|Physician's Practice Patterns
674494|NCT00027352|Anti-HIV Agents
674495|NCT00027339|HIV-1
674496|NCT00027339|HIV Protease Inhibitors
674497|NCT00027339|RNA, Viral
674498|NCT00027339|Phenotype
674499|NCT00027339|Viral Load
674500|NCT00027339|Pharmacokinetics
674501|NCT00027339|Treatment Experienced
674502|NCT00027326|Blood
674503|NCT00027326|Samples
674504|NCT00027326|Radiation
674505|NCT00027326|Urine
674506|NCT00027326|Cancer
674507|NCT00027326|Radiation Therapy
674508|NCT00027300|Relapsing Remitting Multiple Sclerosis
674509|NCT00027287|Type I Diabetes
674510|NCT00027287|Type 2 Diabetes
674511|NCT00027287|Diode Laser Photocoagulation
674512|NCT00027287|Vitamin E
674513|NCT00027287|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
674514|NCT00027287|Diabetic Retinopathy
674515|NCT00027287|Macular Edema
674516|NCT00027287|Type II Diabetes
674517|NCT00027274|Fanconi's Anemia
674518|NCT00027274|Diamond Blackfan Anemia
674519|NCT00027274|Dyskeratosis Congenita
674649|NCT00026871|Radiation Therapy
674520|NCT00027274|Shwachman-Diamond Syndrome
674521|NCT00027274|Hereditary
674522|NCT00027274|Bone Marrow
674523|NCT00027274|Inherited Bone Marrow Failure Syndromes
674524|NCT00027274|IBMFS
674525|NCT00027274|Familial Cancer
674526|NCT00027261|Vaccines, Synthetic
674527|NCT00027261|HIV-1
674528|NCT00027261|AIDS Vaccines
674529|NCT00027261|CD8-Positive T-Lymphocytes
674530|NCT00027261|HIV Seronegativity
674531|NCT00027261|Avipoxvirus
674532|NCT00027261|Dose-Response Relationship, Immunologic
674533|NCT00027261|HIV Preventive Vaccine
674534|NCT00027248|central venous catheter
674535|NCT00027248|bloodstream infection
674536|NCT00027248|CVC
674537|NCT00027248|catheter colonization
674538|NCT00027248|local catheter site infection
674539|NCT00027209|seizures
674540|NCT00027209|epilepsy
674541|NCT00027209|menopause
674542|NCT00027196|Genetics
674543|NCT00027196|Cardiac Diseases
674544|NCT00027196|Cardiac Hypertrophy
674545|NCT00027196|Sudden Death
674546|NCT00027196|Arrhythmias
674547|NCT00027183|Cystic Fibrosis
674548|NCT00027183|Effector Proteins
674549|NCT00027183|Cytotoxin
674550|NCT00027183|Lung Injury
674551|NCT00027183|Genetic Screen
674552|NCT00027170|Myocardial Infarction
674553|NCT00027170|Myocardial Viability
674554|NCT00027170|Myocardial Perfusion
674555|NCT00027170|Myocardial Ischemia
674556|NCT00027170|Atherosclerosis
674557|NCT00027170|Cardiovascular Disease
674558|NCT00027170|Coronary Artery Disease
674559|NCT00027157|Coronary Spasm
674560|NCT00027157|Endothelial-Derived-Relaxation Factor
674561|NCT00027157|Nitric Oxide Synthase
674562|NCT00027157|Susceptibility Genes
674563|NCT00027157|Tetrahydrobiopterin
674564|NCT00027144|Leukemia
674565|NCT00027144|Vaccine
674566|NCT00027131|vaccine
674567|NCT00027131|immunotherapy
674568|NCT00027118|Shoulder
674569|NCT00027118|Breast Cancer
674570|NCT00027118|Physical Therapy
674571|NCT00027118|Lymphedema
674572|NCT00027118|Quality of Life
674573|NCT00027118|Breast Cancer Surgery
674574|NCT00027118|Healthy Volunteer
674575|NCT00027118|HV
674576|NCT00027118|Normal Control
674577|NCT00027105|Fatigue
674578|NCT00027105|Shoulder function
674579|NCT00027105|Lymphedema
674580|NCT00027105|Breast Cancer
674581|NCT00027105|Breast Cancer Surgery
674582|NCT00027105|Quality of Life
674583|NCT00027092|Infusions, Intravenous
674584|NCT00027092|Testosterone
674585|NCT00027092|Insulin Resistance
674586|NCT00027092|Hormone Replacement Therapy
674587|NCT00027092|Glucose Tolerance Test
674588|NCT00027066|stroke
674589|NCT00027066|aspirin
674590|NCT00027066|warfarin
674591|NCT00027053|alcoholism
674592|NCT00027053|alcohol dependence
674593|NCT00027053|trazadone
674594|NCT00027053|sleep
674595|NCT00027040|AIDS Dementia Complex
674596|NCT00027040|Selegiline
674597|NCT00027040|Oxidative Stress
674598|NCT00027040|Cognition
674599|NCT00027040|Neuroprotective Agents
674600|NCT00027040|Brain Injuries
674601|NCT00027040|Magnetic Resonance Spectroscopy
674602|NCT00027040|Protons
674603|NCT00027014|opioid
674604|NCT00027014|St. John's wort
674605|NCT00027014|analgesia
674606|NCT00027014|metabolism
674607|NCT00027014|transporter
674608|NCT00027001|Qigong, exercise, circulatory assist devices
674609|NCT00026988|Huntington's disease
674610|NCT00026988|creatine
674611|NCT00026988|energy depletion
674612|NCT00026975|Laryngeal Cancer
674613|NCT00026975|Laryngectomy
674614|NCT00026975|Tissue Oxygenation
674615|NCT00026975|Irradiated Tissue
674616|NCT00026975|Hyperbaric Oxygen
674617|NCT00026975|Angiogenesis
674618|NCT00026975|EF5
674619|NCT00026962|Breast
674620|NCT00026962|Hormones
674621|NCT00026962|Prevention
674622|NCT00026962|Saliva
674623|NCT00026962|Serum
674624|NCT00026949|Etoposide
674625|NCT00026949|Breast Cancer
674626|NCT00026949|Pharmacokinetics
674627|NCT00026936|External Beam Radiotherapy
674628|NCT00026936|TCP
674629|NCT00026936|DVH
674630|NCT00026936|NTCP
674631|NCT00026936|3-D Programming
674632|NCT00026923|Laparoscopy
674633|NCT00026923|Telemedicine
674634|NCT00026923|Surgery
674635|NCT00026923|Endoscopy
674636|NCT00026910|Cell-Cycle
674637|NCT00026910|Apoptosis
674638|NCT00026910|Molecular Prognosis
674639|NCT00026897|Adoptive Immunotherapy
674640|NCT00026897|Cellular Therapy
674641|NCT00026897|Lymphocyte Migration
674642|NCT00026897|Tumor Imaging
674643|NCT00026884|Serum
674644|NCT00026884|Collection of Tissue
674645|NCT00026884|Malignant Disease
674646|NCT00026884|Molecular Basis
674647|NCT00026884|Genome Sequencing
674648|NCT00026871|Non-Therapeutic
674650|NCT00026871|Dosimetry
674651|NCT00026871|Dose-Rate
674652|NCT00026871|Fiberoptic
674653|NCT00026858|Bone Marrow Transplantation
674654|NCT00026858|Leukemia
674655|NCT00026858|Breast Cancer
674656|NCT00026858|Multiple Myeloma
674657|NCT00026858|Total Body Irradiation
674658|NCT00026832|PET
674659|NCT00026832|Major Depression
674660|NCT00026832|MRI
674661|NCT00026832|Cerebral Blood Flow
674662|NCT00026832|Neuroendocrine
674663|NCT00026832|Bipolar Disorder
674664|NCT00026832|Serotonin1A
674665|NCT00026832|Mood Disorder
674666|NCT00026832|Major Depressive Disorder
674667|NCT00026832|MDD
674668|NCT00026832|Depression
674669|NCT00026832|Healthy Volunteer
674670|NCT00026832|HV
674671|NCT00026832|Normal Control
674672|NCT00026819|NSAID
674673|NCT00026819|Acute Pain Model
674674|NCT00026819|Hyperalgesia
674675|NCT00026819|Central Sensitization
674676|NCT00026819|Wisdom Teeth
674677|NCT00026819|Wisdom Teeth Extraction
674678|NCT00026819|Third Molar
674679|NCT00026806|HIV Infection
674680|NCT00026806|Mental Health
674681|NCT00026806|Risk Behaviors
674682|NCT00026806|Post-Traumatic Stress Disorder
674683|NCT00026806|Youth
674684|NCT00026806|HIV
674685|NCT00026806|Long Term Survivor
674686|NCT00026793|Kaposi Sarcoma
674687|NCT00026793|Doppler
674688|NCT00026793|Infrared
674689|NCT00026793|HIV
674690|NCT00026793|Imaging
674691|NCT00026793|Kaposi's Sarcoma
674692|NCT00026793|Laser Imaging
674693|NCT00026793|Infrared Imaging
674694|NCT00026780|CT Scan
674695|NCT00026780|MRI Scan
674696|NCT00026780|Childhood Cancer
674697|NCT00026780|Eligibility Screening
674698|NCT00026780|Tissue Procurement
674699|NCT00026780|Pediatric
674700|NCT00026780|Children
674701|NCT00026780|Screening
674702|NCT00026767|Risk Factors
674703|NCT00026767|Epidemiology
674704|NCT00026767|BMT/SCT
674705|NCT00026767|Fungal Infection
674706|NCT00026767|Bone Marrow Stem Cell Transplant
674707|NCT00026767|Organ Transplant
674708|NCT00026754|Screening
674709|NCT00026754|Cancer
674710|NCT00026754|HIV Infection
674711|NCT00026754|Scans
674712|NCT00026754|Laboratory Tests
674713|NCT00026754|HIV
674714|NCT00026754|Skin Disorders
674715|NCT00026741|Cytokine
674716|NCT00026741|Inflammation
674717|NCT00026741|Lymphocyte
674718|NCT00026741|T Cell
674719|NCT00026741|Migration
674720|NCT00026741|Healthy Volunteer
674721|NCT00026741|Skin Biopsy
674722|NCT00026728|Human Herpesvirus B
674723|NCT00026728|NHANES
674724|NCT00026728|Epidemiology
674725|NCT00026728|Population-Based Study
674726|NCT00026728|Kaposi's Sarcoma Herpes Virus
674727|NCT00026715|Renal Function
674728|NCT00026715|Iothalamate
674729|NCT00026702|Acute Renal Failure
674730|NCT00026702|Biomarkers
674731|NCT00026689|Evaluation
674732|NCT00026689|Screening
674733|NCT00026689|Cancer
674734|NCT00026689|Radiation
674735|NCT00026689|Eligibility
674736|NCT00026676|Surrogate Markers
674737|NCT00026676|Genotypic Resistance
674738|NCT00026676|Phenotypic Resistance
674739|NCT00026676|Selenium
674740|NCT00026663|Assays
674741|NCT00026663|Resistance
674742|NCT00026663|Biopsy Samples
674743|NCT00026663|Specimen Acquisition
674744|NCT00026663|Cancer Cells
674745|NCT00026650|Late Effects
674746|NCT00026650|Radiation Therapy
674747|NCT00026650|Cancer
674748|NCT00026637|depression
674749|NCT00026637|epilepsy
674750|NCT00026637|seizures
674751|NCT00026624|Virus Replication
674752|NCT00026624|Injections, Subcutaneous
674753|NCT00026624|HIV-1
674754|NCT00026624|AIDS Vaccines
674755|NCT00026624|Dendritic Cells
674756|NCT00026624|Adoptive Transfer
674757|NCT00026624|Keyhole-Limpet Hemocyanin
674758|NCT00026624|HIV Therapeutic Vaccine
674759|NCT00026611|Vaccine prophylaxis
674760|NCT00026598|Basal Ganglia
674761|NCT00026598|Cerebral Cortex
674762|NCT00026598|Functional Neuroanatomy
674763|NCT00026598|Bradykinesia
674764|NCT00026598|Bradyphrenia
674765|NCT00026598|Parkinson's Disease
674766|NCT00026598|Parkinson Disease
674767|NCT00026598|PD
674768|NCT00026598|Healthy Volunteer
674769|NCT00026598|HV
674770|NCT00026598|Normal Control
674771|NCT00026585|Bipolar Disorder
674772|NCT00026585|Antimanic
674773|NCT00026585|Placebo Controlled
674774|NCT00026585|Randomized
674775|NCT00026585|Cytochrome P450
674776|NCT00026585|Mania
674777|NCT00026585|PKC Inhibitor
674778|NCT00026585|Tamoxifen
674779|NCT00026585|Bipolar
674780|NCT00026585|Manic
674781|NCT00026585|BPD
674782|NCT00026559|Classical Conditioning
674783|NCT00026559|Fear Conditioning
674784|NCT00026559|Stress
674785|NCT00026559|Anxiety
674786|NCT00026559|Learning
674787|NCT00026559|Normal Volunteers
674788|NCT00026559|Adults
674789|NCT00026559|Healthy Volunteer
674790|NCT00026559|Normal Control
674791|NCT00026546|Stop Task
674792|NCT00026546|Functional (BOLD) MRI
674793|NCT00026546|Developmental
674794|NCT00026546|Inhibitory Control
674795|NCT00026546|Attention Deficit Hyperactivity Disorder
674796|NCT00026546|ADHD
674797|NCT00026546|Impulsivity
674798|NCT00026546|Healthy Volunteer
674799|NCT00026546|Normal Volunteer
674800|NCT00026546|HV
674801|NCT00026533|stage IV papillary thyroid cancer
674802|NCT00026533|stage IV follicular thyroid cancer
674803|NCT00026533|thyroid gland medullary carcinoma
674804|NCT00026533|recurrent thyroid cancer
674805|NCT00026533|insular thyroid cancer
674806|NCT00026520|stage IV melanoma
674807|NCT00026520|recurrent melanoma
674808|NCT00026494|tumors metastatic to brain
674809|NCT00026468|colon cancer
674810|NCT00026468|rectal cancer
674811|NCT00026468|small intestine cancer
674812|NCT00026442|stage IV breast cancer
674813|NCT00026442|stage IIIA breast cancer
674814|NCT00026442|stage IIIB breast cancer
674815|NCT00026442|stage IIIC breast cancer
674816|NCT00026429|stage I chronic lymphocytic leukemia
674817|NCT00026429|stage II chronic lymphocytic leukemia
674818|NCT00026429|stage III chronic lymphocytic leukemia
674819|NCT00026429|stage IV chronic lymphocytic leukemia
674820|NCT00026429|refractory chronic lymphocytic leukemia
674821|NCT00026429|B-cell chronic lymphocytic leukemia
674822|NCT00026429|stage I grade 1 follicular lymphoma
674823|NCT00026429|stage I grade 2 follicular lymphoma
674824|NCT00026429|stage I grade 3 follicular lymphoma
674825|NCT00026429|stage I adult diffuse small cleaved cell lymphoma
674826|NCT00026429|stage I adult diffuse mixed cell lymphoma
674827|NCT00026429|stage I adult diffuse large cell lymphoma
674828|NCT00026429|stage III grade 1 follicular lymphoma
674829|NCT00026429|stage III grade 2 follicular lymphoma
674830|NCT00026429|stage III grade 3 follicular lymphoma
674831|NCT00026429|stage III adult diffuse small cleaved cell lymphoma
674832|NCT00026429|stage III adult diffuse mixed cell lymphoma
674833|NCT00026429|stage III adult diffuse large cell lymphoma
674834|NCT00026429|stage IV grade 1 follicular lymphoma
674835|NCT00026429|stage IV grade 2 follicular lymphoma
674836|NCT00026429|stage IV grade 3 follicular lymphoma
674837|NCT00026429|stage IV adult diffuse small cleaved cell lymphoma
674838|NCT00026429|stage IV adult diffuse mixed cell lymphoma
674839|NCT00026429|stage IV adult diffuse large cell lymphoma
674840|NCT00026429|recurrent grade 1 follicular lymphoma
674841|NCT00026429|recurrent grade 2 follicular lymphoma
674842|NCT00026429|recurrent grade 3 follicular lymphoma
674843|NCT00026429|recurrent adult diffuse small cleaved cell lymphoma
674844|NCT00026429|recurrent adult diffuse mixed cell lymphoma
674845|NCT00026429|recurrent adult diffuse large cell lymphoma
674846|NCT00026429|stage I mantle cell lymphoma
674847|NCT00026429|contiguous stage II grade 1 follicular lymphoma
674848|NCT00026429|contiguous stage II grade 2 follicular lymphoma
674849|NCT00026429|contiguous stage II grade 3 follicular lymphoma
674850|NCT00026429|contiguous stage II adult diffuse small cleaved cell lymphoma
674851|NCT00026429|contiguous stage II mantle cell lymphoma
674852|NCT00026429|contiguous stage II adult diffuse mixed cell lymphoma
674853|NCT00026429|contiguous stage II adult diffuse large cell lymphoma
674854|NCT00026429|noncontiguous stage II grade 1 follicular lymphoma
674855|NCT00026429|noncontiguous stage II grade 2 follicular lymphoma
674856|NCT00026429|noncontiguous stage II grade 3 follicular lymphoma
674857|NCT00026429|noncontiguous stage II adult diffuse small cleaved cell lymphoma
674858|NCT00026429|noncontiguous stage II mantle cell lymphoma
674859|NCT00026429|noncontiguous stage II adult diffuse mixed cell lymphoma
674860|NCT00026429|noncontiguous stage II adult diffuse large cell lymphoma
674861|NCT00026429|stage III mantle cell lymphoma
674862|NCT00026429|stage IV mantle cell lymphoma
674863|NCT00026429|recurrent mantle cell lymphoma
674864|NCT00026429|noncontiguous stage II small lymphocytic lymphoma
674865|NCT00026429|noncontiguous stage II marginal zone lymphoma
674866|NCT00026429|recurrent marginal zone lymphoma
674867|NCT00026429|recurrent small lymphocytic lymphoma
674868|NCT00026429|stage I marginal zone lymphoma
674869|NCT00026429|stage I small lymphocytic lymphoma
674870|NCT00026429|stage III small lymphocytic lymphoma
674871|NCT00026429|stage III marginal zone lymphoma
674872|NCT00026429|stage IV small lymphocytic lymphoma
674873|NCT00026429|stage IV marginal zone lymphoma
674874|NCT00026429|contiguous stage II marginal zone lymphoma
674875|NCT00026429|contiguous stage II small lymphocytic lymphoma
674876|NCT00026429|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
674877|NCT00026416|stage III adult soft tissue sarcoma
674878|NCT00026416|localized osteosarcoma
674879|NCT00026416|metastatic osteosarcoma
674880|NCT00026416|stage II adult soft tissue sarcoma
674986|NCT00026052|Antidepressant
674881|NCT00026416|stage IV adult soft tissue sarcoma
674882|NCT00026403|stage III pancreatic cancer
674883|NCT00026403|adenocarcinoma of the pancreas
674884|NCT00026403|stage IV pancreatic cancer
674885|NCT00026377|adenocarcinoma of the prostate
674886|NCT00026377|stage IIB prostate cancer
674887|NCT00026377|stage IIA prostate cancer
674888|NCT00026377|stage III prostate cancer
674889|NCT00026377|stage IV prostate cancer
674890|NCT00026364|stage IV colon cancer
674891|NCT00026364|stage IV rectal cancer
674892|NCT00026364|recurrent colon cancer
674893|NCT00026364|recurrent rectal cancer
674894|NCT00026364|adenocarcinoma of the colon
674895|NCT00026364|adenocarcinoma of the rectum
674896|NCT00026351|stage I chronic lymphocytic leukemia
674897|NCT00026351|stage II chronic lymphocytic leukemia
674898|NCT00026351|stage III chronic lymphocytic leukemia
674899|NCT00026351|stage IV chronic lymphocytic leukemia
674900|NCT00026351|refractory chronic lymphocytic leukemia
674901|NCT00026351|B-cell chronic lymphocytic leukemia
674902|NCT00026351|stage I grade 1 follicular lymphoma
674903|NCT00026351|stage I grade 2 follicular lymphoma
674904|NCT00026351|stage I grade 3 follicular lymphoma
674905|NCT00026351|stage III grade 1 follicular lymphoma
674906|NCT00026351|stage III grade 2 follicular lymphoma
674907|NCT00026351|stage III grade 3 follicular lymphoma
674908|NCT00026351|stage IV grade 1 follicular lymphoma
674909|NCT00026351|stage IV grade 2 follicular lymphoma
674910|NCT00026351|stage IV grade 3 follicular lymphoma
674911|NCT00026351|recurrent grade 1 follicular lymphoma
674912|NCT00026351|recurrent grade 2 follicular lymphoma
674913|NCT00026351|recurrent grade 3 follicular lymphoma
674914|NCT00026351|prolymphocytic leukemia
674915|NCT00026351|contiguous stage II grade 1 follicular lymphoma
674916|NCT00026351|contiguous stage II grade 2 follicular lymphoma
674917|NCT00026351|contiguous stage II grade 3 follicular lymphoma
674918|NCT00026351|noncontiguous stage II grade 1 follicular lymphoma
674919|NCT00026351|noncontiguous stage II grade 2 follicular lymphoma
674920|NCT00026351|noncontiguous stage II grade 3 follicular lymphoma
674921|NCT00026351|noncontiguous stage II small lymphocytic lymphoma
674922|NCT00026351|noncontiguous stage II marginal zone lymphoma
674923|NCT00026351|recurrent marginal zone lymphoma
674924|NCT00026351|recurrent small lymphocytic lymphoma
674925|NCT00026351|stage I marginal zone lymphoma
674926|NCT00026351|stage I small lymphocytic lymphoma
674927|NCT00026351|stage III small lymphocytic lymphoma
674928|NCT00026351|stage III marginal zone lymphoma
674929|NCT00026351|stage IV small lymphocytic lymphoma
674930|NCT00026351|stage IV marginal zone lymphoma
674931|NCT00026351|contiguous stage II marginal zone lymphoma
674932|NCT00026351|contiguous stage II small lymphocytic lymphoma
674933|NCT00026351|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
674934|NCT00026338|stage III pancreatic cancer
674935|NCT00026338|adenocarcinoma of the pancreas
674936|NCT00026338|stage IV pancreatic cancer
674937|NCT00026299|stage IV colon cancer
674938|NCT00026299|stage IV rectal cancer
674939|NCT00026299|recurrent colon cancer
674940|NCT00026299|recurrent rectal cancer
674941|NCT00026299|adenocarcinoma of the colon
674942|NCT00026299|adenocarcinoma of the rectum
674943|NCT00026286|stage I breast cancer
674944|NCT00026286|stage II breast cancer
674945|NCT00026286|breast cancer in situ
674946|NCT00026286|ductal breast carcinoma
674947|NCT00026286|hot flashes
674948|NCT00026286|menopausal symptoms
674949|NCT00026273|stage III colon cancer
674950|NCT00026273|stage III rectal cancer
674951|NCT00026273|adenocarcinoma of the colon
674952|NCT00026273|adenocarcinoma of the rectum
674953|NCT00026260|recurrent cervical cancer
674954|NCT00026260|cervical squamous cell carcinoma
674955|NCT00026247|bone metastases
674956|NCT00026247|pain
674957|NCT00026247|unspecified adult solid tumor, protocol specific
674958|NCT00026195|unspecified adult solid tumor, protocol specific
674959|NCT00026156|recurrent non-small cell lung cancer
674960|NCT00026156|squamous cell lung cancer
674961|NCT00026156|large cell lung cancer
674962|NCT00026156|stage IIIB non-small cell lung cancer
674963|NCT00026156|stage IV non-small cell lung cancer
674964|NCT00026156|adenocarcinoma of the lung
674965|NCT00026130|stage II pancreatic cancer
674966|NCT00026130|stage III pancreatic cancer
674967|NCT00026130|adenocarcinoma of the pancreas
674968|NCT00026117|stage IV colon cancer
674969|NCT00026117|stage IV breast cancer
674970|NCT00026117|recurrent breast cancer
674971|NCT00026117|stage IV rectal cancer
674972|NCT00026117|recurrent colon cancer
674973|NCT00026117|recurrent rectal cancer
674974|NCT00026117|male breast cancer
674975|NCT00026078|stage IV breast cancer
674976|NCT00026078|recurrent breast cancer
674977|NCT00026065|Hypertension
674978|NCT00026065|BIofeedback
674979|NCT00026065|Non-pharmacological treatment
674980|NCT00026065|Prediction
674981|NCT00026052|Riluzole
674982|NCT00026052|Neuroprotective
674983|NCT00026052|Open-Label Study
674984|NCT00026052|Glutamate Dysfunction
674985|NCT00026052|Unipolar Depression
674987|NCT00026052|Depression
674988|NCT00026052|Major Depression
674989|NCT00026039|stroke
674990|NCT00026039|estrogen
674991|NCT00026026|Human tooth agenesis
674992|NCT00026013|contraception
674993|NCT00026013|hormonal contraception
674994|NCT00026013|herbal remedies
674995|NCT00026013|hypericum perforatum
674996|NCT00026013|contraceptive effectiveness
674997|NCT00026000|Voluntary Movement
674998|NCT00026000|Basal Ganglia
674999|NCT00026000|Frontal Lobe
675000|NCT00026000|Motor Cortex
675001|NCT00026000|Motor Tic Disorder
675002|NCT00026000|Tourette's Syndrome
675003|NCT00026000|Vocal Tic Disorder
675004|NCT00026000|Tic
675005|NCT00026000|Healthy Volunteer
675006|NCT00026000|HV
675007|NCT00026000|Normal Control
675008|NCT00025987|Brain
675009|NCT00025987|Temperature
675010|NCT00025987|Lower
675011|NCT00025987|Tympanic
675012|NCT00025987|Rectal
675013|NCT00025987|Cooling of the Head and Neck
675014|NCT00025987|Control
675015|NCT00025987|Epilepsy
675016|NCT00025987|Healthy Volunteer
675017|NCT00025987|HV
675018|NCT00025974|PET
675019|NCT00025974|5-HT1A Receptors
675020|NCT00025974|Benzodiazepine Receptors
675021|NCT00025974|Panic Disorder
675022|NCT00025974|PTSD
675023|NCT00025974|Serotonin Type 1A Receptors
675024|NCT00025974|Post-Traumatic Stress Disorder
675025|NCT00025974|Major Depression
675026|NCT00025974|Anxiety
675027|NCT00025974|Depression
675028|NCT00025974|Healthy Volunteer
675029|NCT00025974|HV
675030|NCT00025974|Normal Control
675031|NCT00025935|Mood Disorders
675032|NCT00025935|Bipolar Disorder
675033|NCT00025935|Neuroimaging
675034|NCT00025935|Psychophysiology
675035|NCT00025935|Frustration
675036|NCT00025935|Emotional Dysregulation
675037|NCT00025935|Lithium
675038|NCT00025935|Conduct Disorder
675039|NCT00025935|Children and Adolescents
675040|NCT00025935|Affective Neuroscience
675041|NCT00025935|Behavioral Dysregulation
675042|NCT00025935|Mood Disorder
675043|NCT00025935|Behavior
675044|NCT00025935|Children
675045|NCT00025935|Adolescent
675046|NCT00025935|Healthy Volunteer
675047|NCT00025935|HV
675048|NCT00025935|Normal Control
675049|NCT00025922|Immunization
675050|NCT00025922|Titers
675051|NCT00025922|Immune Activation
675052|NCT00025922|Antibody
675053|NCT00025922|CD4 Cell Count
675054|NCT00025922|HIV
675055|NCT00025909|Therapy
675056|NCT00025909|Antiretrovirals
675057|NCT00025909|Interruption
675058|NCT00025909|CD4+ T Cell
675059|NCT00025909|Plasma Viremia
675060|NCT00025909|HIV
675061|NCT00025909|Treatment Experienced
675062|NCT00025909|Treatment Interuption
675063|NCT00025883|Lipoatrophic Diabetes
675064|NCT00025883|Diabetes Mellitus
675065|NCT00025883|Hypertriglyceridemia
675066|NCT00025883|NASH
675067|NCT00025883|Lipodystrophy
675068|NCT00025883|Leptin
675069|NCT00025883|Diabetes
675070|NCT00025870|Genetics
675071|NCT00025870|Metabolic
675072|NCT00025870|Dysmorphology
675073|NCT00025870|Training
675074|NCT00025870|DNA
675075|NCT00025870|DNA Testing
675076|NCT00025870|Dysmorphic Syndromes
675077|NCT00025870|Developmental Delay
675078|NCT00025870|Genetic Counseling
675079|NCT00025870|Molecular Genetics
675080|NCT00025857|fMRI
675081|NCT00025857|Depression
675082|NCT00025857|PTSD
675083|NCT00025857|Emotion
675084|NCT00025857|Magnetic Resonance Imaging
675085|NCT00025857|Anxiety
675086|NCT00025857|Normal Volunteers
675087|NCT00025857|Adolescence
675088|NCT00025857|Memory
675089|NCT00025857|Physical/Sexual Abuse History
675090|NCT00025857|Post-Traumatic Stress Disorder
675091|NCT00025857|Adolescent
675092|NCT00025857|Healthy Volunteer
675093|NCT00025857|HV
675094|NCT00025857|Normal Control
675095|NCT00025844|Stress
675096|NCT00025844|Anxiety
675097|NCT00025844|Adults
675098|NCT00025844|Fear Conditioning
675099|NCT00025844|Normal Volunteers
675100|NCT00025844|Associative Learning
675101|NCT00025844|Virtual Reality
675102|NCT00025844|Context Conditioning
675103|NCT00025844|Healthy Volunteer
675104|NCT00025844|HV
675105|NCT00025844|Normal Control
675106|NCT00025831|Buccal
675107|NCT00025831|DNA
675108|NCT00025831|Pooling
675109|NCT00025831|Genotyping
675110|NCT00025831|Mouthwash
675111|NCT00025831|Healthy Volunteer
675112|NCT00025831|HV
675113|NCT00025831|Normal Control
675114|NCT00025818|dry eyes
675115|NCT00025818|rheumatoid arthritis
675116|NCT00025818|Lupus
675117|NCT00025818|Sjogren's syndrome
675118|NCT00025818|myositis
675119|NCT00025818|scleroderma
675120|NCT00025818|autoimmune disorder
675121|NCT00025805|Cytokines
675122|NCT00025805|Th1 Th2 Response
675123|NCT00025805|Inflammatory Bowel Dx
675124|NCT00025805|Lymphocyte
675125|NCT00025805|Colonoscopy
675126|NCT00025805|Crohn's Disease
675127|NCT00025805|Crohn's
675128|NCT00025792|Pramipexole
675129|NCT00025792|Neuroprotective
675130|NCT00025792|Placebo Controlled
675131|NCT00025792|Depression
675132|NCT00025792|Brain Imaging
675133|NCT00025792|Antidepressant
675134|NCT00025792|Bipolar Disorder
675135|NCT00025792|Bipolar
675136|NCT00025792|BPD
675137|NCT00025792|Bipolar Depression
675138|NCT00025779|Hyperactivity
675139|NCT00025779|Distractibility
675140|NCT00025779|Impulsiveness
675141|NCT00025779|Pervasive Development Disorders
675142|NCT00025740|SSRI (paroxetine)
675143|NCT00025740|Benzodiazepine (clonazepam)
675144|NCT00025740|Post-Traumatic Stress Disorder (PTSD)
675145|NCT00025740|Combined Treatment
675146|NCT00025740|Rapid Treatment
675147|NCT00025740|Post-Traumatic Stress Disorder
675148|NCT00025740|PTSD
675149|NCT00025727|HIV-1
675150|NCT00025727|HIV Protease Inhibitors
675151|NCT00025727|Ritonavir
675152|NCT00025727|RNA, Viral
675153|NCT00025727|Anti-HIV Agents
675154|NCT00025727|Viral Load
675155|NCT00025727|ABT 378
675156|NCT00025727|VX-175
675157|NCT00025714|Serotonin Receptor
675158|NCT00025714|Cell Culture
675159|NCT00025714|Temporal Lobe
675160|NCT00025714|Endothelial Cells
675161|NCT00025714|Superficial Temporal Artery
675162|NCT00025714|Magnetic Resonance Imaging (MRI)
675163|NCT00025714|Epilepsy
675164|NCT00025714|Intractable Epilepsy
675165|NCT00025701|Cortex
675166|NCT00025701|Inhibition
675167|NCT00025701|Motor Control
675168|NCT00025701|Event-Related Synchronization
675169|NCT00025701|Event-Related Desynchronization
675170|NCT00025701|Focal Hand Dystonia
675171|NCT00025701|Focal Dystonia
675172|NCT00025701|Dystonia
675173|NCT00025701|Hand
675174|NCT00025701|Healthy Volunteer
675175|NCT00025701|HV
675176|NCT00025688|stage IV breast cancer
675177|NCT00025688|recurrent breast cancer
675178|NCT00025675|recurrent adult brain tumor
675179|NCT00025675|adult meningioma
675180|NCT00025675|adult glioblastoma
675181|NCT00025675|adult anaplastic astrocytoma
675182|NCT00025675|adult anaplastic oligodendroglioma
675183|NCT00025675|adult pilocytic astrocytoma
675184|NCT00025675|adult subependymoma
675185|NCT00025675|adult mixed glioma
675186|NCT00025675|adult meningeal hemangiopericytoma
675187|NCT00025675|adult grade III meningioma
675188|NCT00025675|adult giant cell glioblastoma
675189|NCT00025675|adult gliosarcoma
675190|NCT00025675|adult grade I meningioma
675191|NCT00025675|adult grade II meningioma
675192|NCT00025662|Peripheral Blood Stem Cell
675193|NCT00025662|Melphalan
675194|NCT00025662|Fludarabine
675195|NCT00025662|Donor Apheresis
675196|NCT00025662|Non-Myeloablative
675197|NCT00025662|MDS
675198|NCT00025662|Chronic Myeloid Leukemia
675199|NCT00025662|CML
675200|NCT00025662|Chronic Lymphocytic Leukemia
675201|NCT00025662|CLL
675202|NCT00025662|Lymphoma
675203|NCT00025662|Non-Hodgkin's Lymphoma
675204|NCT00025662|Hodgkin's Disease
675205|NCT00025662|Mantle Cell Lymphoma
675206|NCT00025662|Acute Myelogenous Leukemia (AML)
675207|NCT00025662|Chronic Myeloid Leukemia (CML)
675208|NCT00025662|Chronic Lymphocytic Leukemia (CLL)
675209|NCT00025662|Myelodysplasia (MDS)
675210|NCT00025662|Acute Lymphoblastic Leukemia (ALL)
675211|NCT00025662|Bone Marrow Transplant
675212|NCT00025649|localized resectable neuroblastoma
675213|NCT00025649|regional neuroblastoma
675214|NCT00025649|disseminated neuroblastoma
675215|NCT00025649|stage 4S neuroblastoma
675216|NCT00025649|localized unresectable neuroblastoma
675217|NCT00025636|recurrent adult Hodgkin lymphoma
675218|NCT00025623|disseminated neuroblastoma
675219|NCT00025610|disseminated neuroblastoma
675220|NCT00025610|stage 4S neuroblastoma
675221|NCT00025597|localized unresectable neuroblastoma
675222|NCT00025571|squamous cell lung cancer
675223|NCT00025571|large cell lung cancer
675224|NCT00025571|adenocarcinoma of the lung
675225|NCT00025571|stage I non-small cell lung cancer
675226|NCT00025571|stage II non-small cell lung cancer
675227|NCT00025558|childhood central nervous system germ cell tumor
675228|NCT00025558|recurrent adult brain tumor
675229|NCT00025558|adult medulloblastoma
675230|NCT00025558|adult glioblastoma
675231|NCT00025558|adult anaplastic astrocytoma
675232|NCT00025558|adult anaplastic oligodendroglioma
675233|NCT00025558|adult mixed glioma
675234|NCT00025558|adult central nervous system germ cell tumor
675235|NCT00025558|adult pineoblastoma
675236|NCT00025558|recurrent childhood supratentorial primitive neuroectodermal tumor
675237|NCT00025558|recurrent childhood medulloblastoma
675238|NCT00025558|recurrent childhood ependymoma
675239|NCT00025558|adult giant cell glioblastoma
675240|NCT00025558|adult gliosarcoma
675241|NCT00025558|adult anaplastic ependymoma
675242|NCT00025558|adult supratentorial primitive neuroectodermal tumor (PNET)
675243|NCT00025545|recurrent childhood acute lymphoblastic leukemia
675244|NCT00025545|recurrent childhood acute myeloid leukemia
675245|NCT00025545|recurrent adult acute myeloid leukemia
675246|NCT00025545|recurrent adult acute lymphoblastic leukemia
675247|NCT00025545|adult acute lymphoblastic leukemia in remission
675248|NCT00025545|childhood acute lymphoblastic leukemia in remission
675249|NCT00025545|acute undifferentiated leukemia
675250|NCT00025545|secondary acute myeloid leukemia
675251|NCT00025532|stage III colon cancer
675252|NCT00025532|stage IV colon cancer
675253|NCT00025532|stage III gastric cancer
675254|NCT00025532|stage IV gastric cancer
675255|NCT00025532|recurrent gastric cancer
675256|NCT00025532|stage III pancreatic cancer
675257|NCT00025532|recurrent pancreatic cancer
675258|NCT00025532|stage III rectal cancer
675259|NCT00025532|stage IV rectal cancer
675260|NCT00025532|recurrent colon cancer
675261|NCT00025532|recurrent rectal cancer
675262|NCT00025532|stage III esophageal cancer
675263|NCT00025532|stage IV esophageal cancer
675264|NCT00025532|recurrent esophageal cancer
675265|NCT00025532|adenocarcinoma of the stomach
675266|NCT00025532|adenocarcinoma of the esophagus
675267|NCT00025532|adenocarcinoma of the colon
675268|NCT00025532|adenocarcinoma of the rectum
675269|NCT00025532|adenocarcinoma of the pancreas
675270|NCT00025532|stage IV pancreatic cancer
675271|NCT00025519|stage IV renal cell cancer
675272|NCT00025519|recurrent renal cell cancer
675273|NCT00025519|clear cell renal cell carcinoma
675274|NCT00025493|stage IV breast cancer
675275|NCT00025493|recurrent breast cancer
675276|NCT00025480|stage IIIA non-small cell lung cancer
675277|NCT00025480|stage IIIB non-small cell lung cancer
675278|NCT00025454|unspecified adult solid tumor, protocol specific
675279|NCT00025441|chondrosarcoma
675280|NCT00025441|small intestine leiomyosarcoma
675281|NCT00025441|fibrosarcomatous osteosarcoma
675282|NCT00025441|embryonal childhood rhabdomyosarcoma
675283|NCT00025441|alveolar childhood rhabdomyosarcoma
675284|NCT00025441|pleomorphic childhood rhabdomyosarcoma
675285|NCT00025441|mixed childhood rhabdomyosarcoma
675286|NCT00025441|embryonal-botryoid childhood rhabdomyosarcoma
675287|NCT00025441|metastatic childhood soft tissue sarcoma
675288|NCT00025441|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
675289|NCT00025441|childhood fibrosarcoma
675290|NCT00025441|childhood synovial sarcoma
675291|NCT00025441|childhood malignant hemangiopericytoma
675292|NCT00025441|childhood liposarcoma
675293|NCT00025441|childhood alveolar soft-part sarcoma
675294|NCT00025441|childhood leiomyosarcoma
675295|NCT00025441|childhood angiosarcoma
675296|NCT00025441|childhood epithelioid sarcoma
675297|NCT00025441|childhood malignant mesenchymoma
675298|NCT00025441|stage IV uterine sarcoma
675299|NCT00025441|uterine leiomyosarcoma
675300|NCT00025441|ovarian sarcoma
675301|NCT00025441|previously untreated childhood rhabdomyosarcoma
675302|NCT00025441|childhood desmoplastic small round cell tumor
675303|NCT00025428|localized unresectable neuroblastoma
675304|NCT00025402|chronic phase chronic myelogenous leukemia
675305|NCT00025402|chronic myelogenous leukemia, BCR-ABL1 positive
675306|NCT00025402|Philadelphia chromosome negative chronic myelogenous leukemia
675307|NCT00025402|childhood chronic myelogenous leukemia
675308|NCT00025402|atypical chronic myeloid leukemia, BCR-ABL1 negative
675309|NCT00025389|stage I non-small cell lung cancer
675310|NCT00025389|stage II non-small cell lung cancer
675311|NCT00025389|stage IIIA non-small cell lung cancer
675312|NCT00025376|stage IV renal cell cancer
675313|NCT00025376|recurrent renal cell cancer
675314|NCT00025350|stage IV colon cancer
675315|NCT00025350|stage IV rectal cancer
675316|NCT00025350|recurrent colon cancer
675317|NCT00025350|recurrent rectal cancer
675318|NCT00025350|adenocarcinoma of the colon
675319|NCT00025350|adenocarcinoma of the rectum
675320|NCT00025324|childhood central nervous system germ cell tumor
675321|NCT00025324|adult central nervous system germ cell tumor
675322|NCT00025311|leptomeningeal metastases
675323|NCT00025298|stage II nasopharyngeal cancer
675324|NCT00025298|stage III nasopharyngeal cancer
675325|NCT00025298|stage IV nasopharyngeal cancer
675326|NCT00025298|oral complications
675327|NCT00025298|drug/agent toxicity by tissue/organ
675328|NCT00025298|radiation toxicity
675329|NCT00025285|squamous cell lung cancer
675330|NCT00025285|large cell lung cancer
675331|NCT00025285|stage IIIB non-small cell lung cancer
675332|NCT00025285|stage IV non-small cell lung cancer
675333|NCT00025285|adenocarcinoma of the lung
675334|NCT00025285|adenosquamous cell lung cancer
675335|NCT00025285|bronchoalveolar cell lung cancer
675336|NCT00025272|extensive stage small cell lung cancer
675337|NCT00025194|adenocarcinoma of the prostate
675338|NCT00025194|stage IV prostate cancer
675339|NCT00025194|recurrent prostate cancer
675340|NCT00025181|iris melanoma
675341|NCT00025181|ciliary body and choroid melanoma, small size
675342|NCT00025181|ciliary body and choroid melanoma, medium/large size
675343|NCT00025181|extraocular extension melanoma
675344|NCT00025181|recurrent intraocular melanoma
675345|NCT00025181|stage III melanoma
675346|NCT00025181|stage IV melanoma
675347|NCT00025181|recurrent melanoma
675348|NCT00025168|stage III pancreatic cancer
675349|NCT00025142|stage IV colon cancer
675350|NCT00025142|stage IV rectal cancer
675351|NCT00025142|recurrent colon cancer
675352|NCT00025142|recurrent rectal cancer
675353|NCT00025142|adenocarcinoma of the colon
675354|NCT00025142|adenocarcinoma of the rectum
675355|NCT00025129|stage IV adult Hodgkin lymphoma
675356|NCT00025129|recurrent adult Hodgkin lymphoma
675357|NCT00025129|stage IV cutaneous T-cell non-Hodgkin lymphoma
675358|NCT00025129|recurrent cutaneous T-cell non-Hodgkin lymphoma
675359|NCT00025129|small intestine lymphoma
675360|NCT00025129|unspecified adult solid tumor, protocol specific
675361|NCT00025129|stage IV grade 1 follicular lymphoma
675362|NCT00025129|stage IV grade 2 follicular lymphoma
675363|NCT00025129|stage IV grade 3 follicular lymphoma
675364|NCT00025129|stage IV adult diffuse small cleaved cell lymphoma
675365|NCT00025129|stage IV adult diffuse mixed cell lymphoma
675366|NCT00025129|stage IV adult diffuse large cell lymphoma
675367|NCT00025129|stage IV adult immunoblastic large cell lymphoma
675368|NCT00025129|stage IV adult lymphoblastic lymphoma
675369|NCT00025129|stage IV adult Burkitt lymphoma
675370|NCT00025129|recurrent grade 1 follicular lymphoma
675371|NCT00025129|recurrent grade 2 follicular lymphoma
675372|NCT00025129|recurrent grade 3 follicular lymphoma
675373|NCT00025129|recurrent adult diffuse small cleaved cell lymphoma
675374|NCT00025129|recurrent adult diffuse mixed cell lymphoma
675375|NCT00025129|recurrent adult diffuse large cell lymphoma
675376|NCT00025129|recurrent adult immunoblastic large cell lymphoma
675377|NCT00025129|recurrent adult lymphoblastic lymphoma
675378|NCT00025129|recurrent adult Burkitt lymphoma
675379|NCT00025129|stage IV adult T-cell leukemia/lymphoma
675380|NCT00025129|recurrent adult T-cell leukemia/lymphoma
675381|NCT00025129|primary central nervous system non-Hodgkin lymphoma
675382|NCT00025129|intraocular lymphoma
675383|NCT00025129|stage IV mantle cell lymphoma
675384|NCT00025129|recurrent mantle cell lymphoma
675385|NCT00025129|angioimmunoblastic T-cell lymphoma
675386|NCT00025129|anaplastic large cell lymphoma
675387|NCT00025129|stage IV mycosis fungoides/Sezary syndrome
675388|NCT00025129|recurrent mycosis fungoides/Sezary syndrome
675389|NCT00025129|recurrent marginal zone lymphoma
675390|NCT00025129|recurrent small lymphocytic lymphoma
675391|NCT00025129|stage IV small lymphocytic lymphoma
675392|NCT00025129|stage IV marginal zone lymphoma
675393|NCT00025129|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
675394|NCT00025129|nodal marginal zone B-cell lymphoma
675395|NCT00025129|splenic marginal zone lymphoma
675396|NCT00025116|adenocarcinoma of the prostate
675397|NCT00025116|recurrent prostate cancer
675398|NCT00025103|recurrent Wilms tumor and other childhood kidney tumors
675399|NCT00025103|clear cell sarcoma of the kidney
675400|NCT00025090|stage I anal cancer
675401|NCT00025090|stage II anal cancer
675402|NCT00025090|stage IIIA anal cancer
675403|NCT00025090|stage IIIB anal cancer
675404|NCT00025090|squamous cell carcinoma of the anus
675405|NCT00025090|cloacogenic carcinoma of the anus
675406|NCT00025090|basaloid carcinoma of the anus
675407|NCT00025077|recurrent childhood supratentorial primitive neuroectodermal tumor
675408|NCT00025077|recurrent childhood medulloblastoma
675409|NCT00025064|stage II childhood Hodgkin lymphoma
675410|NCT00025064|stage I childhood Hodgkin lymphoma
675411|NCT00025064|stage III childhood Hodgkin lymphoma
675412|NCT00025064|stage IV childhood Hodgkin lymphoma
675413|NCT00025064|recurrent/refractory childhood Hodgkin lymphoma
675414|NCT00025051|basal cell carcinoma of the skin
675415|NCT00025051|squamous cell carcinoma of the skin
675416|NCT00025025|colon cancer
675417|NCT00025025|rectal cancer
675418|NCT00025012|basal cell carcinoma of the skin
675419|NCT00025012|squamous cell carcinoma of the skin
675420|NCT00025012|melanoma
675421|NCT00024999|Movement
675422|NCT00024999|Coordination
675423|NCT00024999|Correlation
675424|NCT00024999|Coherence
675425|NCT00024999|Parietofrontal Circuitry
675426|NCT00024999|Apraxia
675427|NCT00024999|Ideomotor Apraxia
675428|NCT00024999|Healthy Volunteer
675429|NCT00024999|HV
675430|NCT00024999|Normal Control
675431|NCT00024986|HAART
675432|NCT00024986|Genotypic Resistance
675433|NCT00024986|Phenotypic Resistance
675434|NCT00024986|Immune Reconstitution
675435|NCT00024986|Bone Density
675436|NCT00024986|HIV
675437|NCT00024986|Children
675438|NCT00024986|Pediatric HIV Infection
675439|NCT00024960|Speech
675440|NCT00024960|Motor Control
675441|NCT00024960|Phenotype
675442|NCT00024960|Dysfluency
675443|NCT00024960|Fluency
675444|NCT00024960|Stuttering
675445|NCT00024960|Healthy Volunteer
675446|NCT00024960|HV
675447|NCT00024960|Normal Control
675448|NCT00024934|Immunodeficiency
675449|NCT00024934|Primary
675450|NCT00024934|Cancer
675451|NCT00024934|Genetics
675452|NCT00024934|IGA Deficiency
675453|NCT00024934|Immune Deficiency
675454|NCT00024908|Cognition
675455|NCT00024908|Frontal Lobes
675456|NCT00024908|Frontotemporal Dementia
675457|NCT00024908|Focal Lesions
675458|NCT00024908|Executive Functions
675459|NCT00024908|Frontotemporal Lobe Dementia
675460|NCT00024908|Frontal Lobe
675461|NCT00024908|Frontal Lobe Dementia
675462|NCT00024908|Healthy Volunteer
675463|NCT00024908|HV
675464|NCT00024908|Normal Control
675465|NCT00024804|SKELETAL DISEASE
675466|NCT00024804|Osteoporosis
675467|NCT00024804|Dysplasia
675468|NCT00024804|Osteomalacia
675469|NCT00024804|Bone Diseases
675470|NCT00024791|Cerebral Palsy
675471|NCT00024791|Pediatric
675472|NCT00024791|Cognition
675473|NCT00024791|Motor Learning
675474|NCT00024791|Visuomotor Integration
675475|NCT00024791|Corticospinal Tracts
675476|NCT00024791|Cortical Re-Organization
675477|NCT00024791|Spastic Hemiplegia
675478|NCT00024791|Spastic Diplegia
675479|NCT00024791|Functional Outcome
675480|NCT00024791|Children
675481|NCT00024791|Healthy Volunteer
675482|NCT00024791|HV
675483|NCT00024791|Normal Control
675484|NCT00024687|SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin
675485|NCT00024687|advanced malignancy
675486|NCT00024674|SS1(dsFv)-PE38
675487|NCT00024674|SS1P
675488|NCT00024674|anti-mesothelin immunotoxin
675489|NCT00024674|advanced malignancy
675490|NCT00024661|recurrent solid tumors
675491|NCT00024661|liposomes containing AON to c-raf protein (LErafAON)
675492|NCT00024648|advanced malignancy
675493|NCT00024648|liposomes containing AON to c-raf messenger RNA
675494|NCT00024648|antisense oligodeoxynucleotide (AON)
675495|NCT00024648|LErafAON
675496|NCT00024635|Screening
675497|NCT00024635|Psychiatric History
675498|NCT00024635|Medical History
675499|NCT00024635|Diagnostic Evaluation
675500|NCT00024635|Natural History
675501|NCT00024635|Anxiety
675502|NCT00024635|HV
675503|NCT00024635|Healthy Volunteer
675504|NCT00024635|Normal Control
675505|NCT00024635|Mood Disorder
675506|NCT00024635|PTSD
675507|NCT00024635|Post-Traumatic Stress Disorder
675508|NCT00024622|Familial
675509|NCT00024622|Genetic
675510|NCT00024622|Symptomatic
675511|NCT00024622|Equivocally Affected
675512|NCT00024622|18F-Fluoro-L-dopa
675513|NCT00024622|O-15 Labelled Water
675514|NCT00024622|Carbidopa
675515|NCT00024622|Adult
675516|NCT00024622|Schizophrenia
675517|NCT00024622|Parkinson's Disease
675518|NCT00024622|PD
675519|NCT00024622|Parkinson
675520|NCT00024622|Healthy Control
675521|NCT00024622|HV
675522|NCT00024622|Normal Control
675523|NCT00024570|neurosurgery, craniotomy
675524|NCT00024570|convection-enhanced delivery
675525|NCT00024570|CNS interstitial infusion
675526|NCT00024570|recombinant toxins
675527|NCT00024570|malignant glioma, recurrent
675528|NCT00024570|catheter, stereotaxic
675529|NCT00024570|intratumoral therapy
675530|NCT00024570|positive pressure microinfusion
675531|NCT00024557|neurosurgery, craniotomy
675532|NCT00024557|convection-enhanced delivery
675533|NCT00024557|CNS interstitial infusion
675534|NCT00024557|recombinant toxins
675535|NCT00024557|malignant glioma, recurrent
675536|NCT00024557|intratumoral therapy
675537|NCT00024557|positive pressure microinfusion
675538|NCT00024544|asthma
675539|NCT00024544|anti-IL-4 monoclonal antibody
675540|NCT00024544|pascolizumab
675541|NCT00024531|Alzheimer disease
675542|NCT00024531|Cholesterol-lowering drugs
675543|NCT00024518|Diabetes
675544|NCT00024518|Immunotherapy
675545|NCT00024518|Study Drug
675546|NCT00024518|Insulin Dependent Diabetes
675547|NCT00024518|Diabetes Mellitus
675548|NCT00024518|TIBM
675549|NCT00024492|Liposome Encapsulated Mitoxantrone (LEM)
675550|NCT00024492|solid tumors
675551|NCT00024479|Minorities
675552|NCT00024479|Rheumatic Disease
675553|NCT00024479|Community Based
675554|NCT00024479|Ethnicity
675555|NCT00024479|Health Disparities
675556|NCT00024466|stage I multiple myeloma
675557|NCT00024466|stage II multiple myeloma
675558|NCT00024466|stage III multiple myeloma
675559|NCT00024453|infection
675560|NCT00024440|refractory chronic lymphocytic leukemia
675561|NCT00024440|B-cell chronic lymphocytic leukemia
675562|NCT00024427|drug/agent toxicity by tissue/organ
675563|NCT00024427|stage II pancreatic cancer
675564|NCT00024427|stage III pancreatic cancer
675565|NCT00024427|recurrent pancreatic cancer
675566|NCT00024427|adenocarcinoma of the pancreas
675567|NCT00024427|stage IV pancreatic cancer
675760|NCT00023868|stage IV colon cancer
675568|NCT00024414|adenocarcinoma of the prostate
675569|NCT00024414|stage IV prostate cancer
675570|NCT00024414|recurrent prostate cancer
675571|NCT00024401|stage IV colon cancer
675572|NCT00024401|stage IV rectal cancer
675573|NCT00024401|recurrent colon cancer
675574|NCT00024401|recurrent rectal cancer
675575|NCT00024388|stage III renal cell cancer
675576|NCT00024388|stage IV renal cell cancer
675577|NCT00024388|recurrent renal cell cancer
675578|NCT00024375|recurrent pancreatic cancer
675579|NCT00024375|stage IV pancreatic cancer
675580|NCT00024362|stage III pancreatic cancer
675581|NCT00024362|adenocarcinoma of the pancreas
675582|NCT00024362|stage IV pancreatic cancer
675583|NCT00024349|stage II bladder cancer
675584|NCT00024349|stage III bladder cancer
675585|NCT00024349|transitional cell carcinoma of the bladder
675586|NCT00024349|squamous cell carcinoma of the bladder
675587|NCT00024349|adenocarcinoma of the bladder
675588|NCT00024336|untreated childhood brain stem glioma
675589|NCT00024323|unspecified adult solid tumor, protocol specific
675590|NCT00024310|unspecified adult solid tumor, protocol specific
675591|NCT00024310|drug/agent toxicity by tissue/organ
675592|NCT00024297|thromboembolism
675593|NCT00024284|unspecified childhood solid tumor, protocol specific
675594|NCT00024271|localized malignant mesothelioma
675595|NCT00024271|advanced malignant mesothelioma
675596|NCT00024271|recurrent malignant mesothelioma
675597|NCT00024258|metastatic osteosarcoma
675598|NCT00024258|recurrent childhood rhabdomyosarcoma
675599|NCT00024258|regional neuroblastoma
675600|NCT00024258|disseminated neuroblastoma
675601|NCT00024258|stage 4S neuroblastoma
675602|NCT00024258|recurrent neuroblastoma
675603|NCT00024258|stage III childhood liver cancer
675604|NCT00024258|stage IV childhood liver cancer
675605|NCT00024258|recurrent childhood liver cancer
675606|NCT00024258|childhood hepatoblastoma
675607|NCT00024258|stage III Wilms tumor
675608|NCT00024258|stage IV Wilms tumor
675609|NCT00024258|stage V Wilms tumor
675610|NCT00024258|recurrent Wilms tumor and other childhood kidney tumors
675611|NCT00024258|intraocular retinoblastoma
675612|NCT00024258|extraocular retinoblastoma
675613|NCT00024258|recurrent retinoblastoma
675614|NCT00024258|recurrent osteosarcoma
675615|NCT00024258|childhood germ cell tumor
675616|NCT00024258|metastatic childhood soft tissue sarcoma
675617|NCT00024258|recurrent childhood soft tissue sarcoma
675618|NCT00024258|localized unresectable neuroblastoma
675619|NCT00024258|previously untreated childhood rhabdomyosarcoma
675620|NCT00024258|childhood desmoplastic small round cell tumor
675621|NCT00024258|untreated childhood medulloblastoma
675622|NCT00024258|recurrent childhood medulloblastoma
675623|NCT00024258|previously treated childhood rhabdomyosarcoma
675624|NCT00024258|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
675625|NCT00024258|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
675626|NCT00024258|childhood teratoma
675627|NCT00024258|childhood malignant testicular germ cell tumor
675628|NCT00024258|childhood malignant ovarian germ cell tumor
675629|NCT00024258|childhood extragonadal germ cell tumor
675630|NCT00024258|recurrent childhood malignant germ cell tumor
675631|NCT00024245|unspecified adult solid tumor, protocol specific
675632|NCT00024232|stage IV prostate cancer
675633|NCT00024232|recurrent prostate cancer
675634|NCT00024193|stage 4S neuroblastoma
675635|NCT00024180|Waldenström macroglobulinemia
675636|NCT00024180|recurrent adult acute myeloid leukemia
675637|NCT00024180|recurrent adult acute lymphoblastic leukemia
675638|NCT00024180|refractory chronic lymphocytic leukemia
675639|NCT00024180|untreated adult acute lymphoblastic leukemia
675640|NCT00024180|untreated adult acute myeloid leukemia
675641|NCT00024180|recurrent small lymphocytic lymphoma
675642|NCT00024167|adenocarcinoma of the prostate
675643|NCT00024167|stage IV prostate cancer
675644|NCT00024167|recurrent prostate cancer
675645|NCT00024167|Strontium-89
675646|NCT00024167|Induction Chemotherapy
675647|NCT00024167|Androgen-Independent Prostate Cancer
675648|NCT00024141|unspecified adult solid tumor, protocol specific
675649|NCT00024128|AIDS-related peripheral/systemic lymphoma
675650|NCT00024128|HIV-associated Hodgkin lymphoma
675651|NCT00024115|refractory chronic lymphocytic leukemia
675652|NCT00024115|B-cell chronic lymphocytic leukemia
675653|NCT00024115|stage III grade I follicular small cleaved cell lymphoma
675654|NCT00024115|stage III grade II follicular mixed cell lymphoma
675655|NCT00024115|stage III adult diffuse small cleaved cell lymphoma
675656|NCT00024115|stage IV grade I follicular small cleaved cell lymphoma
675657|NCT00024115|stage IV grade II follicular mixed cell lymphoma
675658|NCT00024115|stage IV adult diffuse small cleaved cell lymphoma
675659|NCT00024115|recurrent grade I follicular small cleaved cell lymphoma
675660|NCT00024115|recurrent grade II follicular mixed cell lymphoma
675661|NCT00024115|recurrent grade III follicular large cell lymphoma
675662|NCT00024115|recurrent adult diffuse small cleaved cell lymphoma
675663|NCT00024115|recurrent adult diffuse mixed cell lymphoma
675664|NCT00024115|recurrent adult diffuse large cell lymphoma
675665|NCT00024115|recurrent adult immunoblastic large cell lymphoma
675666|NCT00024115|recurrent adult lymphoblastic lymphoma
675667|NCT00024115|recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma
675668|NCT00024115|prolymphocytic leukemia
675669|NCT00024115|contiguous stage II grade I follicular small cleaved cell lymphoma
675670|NCT00024115|contiguous stage II grade II follicular mixed cell lymphoma
675671|NCT00024115|contiguous stage II adult diffuse small cleaved cell lymphoma
675672|NCT00024115|noncontiguous stage II grade I follicular small cleaved cell lymphoma
675673|NCT00024115|noncontiguous stage II grade II follicular mixed cell lymphoma
675674|NCT00024115|noncontiguous stage II adult diffuse small cleaved cell lymphoma
675675|NCT00024115|stage III diffuse small lymphocytic/marginal zone lymphoma
675676|NCT00024115|contiguous stage II diffuse small lymphocytic/marginal zone lymphoma
675677|NCT00024115|noncontiguous stage II diffuse small lymphocytic/marginal zone lymphoma
675678|NCT00024115|stage IV diffuse small lymphocytic/marginal zone lymphoma
675679|NCT00024115|recurrent diffuse small lymphocytic/marginal zone lymphoma
675680|NCT00024115|recurrent mantle cell lymphoma
675681|NCT00024102|stage I breast cancer
675682|NCT00024102|stage II breast cancer
675683|NCT00024102|stage IIIA breast cancer
675684|NCT00024102|stage IIIB breast cancer
675685|NCT00024102|stage IIIC breast cancer
675686|NCT00024089|recurrent metastatic squamous neck cancer with occult primary
675687|NCT00024089|metastatic squamous neck cancer with occult primary squamous cell carcinoma
675688|NCT00024089|stage IV squamous cell carcinoma of the lip and oral cavity
675689|NCT00024089|recurrent squamous cell carcinoma of the lip and oral cavity
675690|NCT00024089|stage IV squamous cell carcinoma of the oropharynx
675691|NCT00024089|recurrent squamous cell carcinoma of the oropharynx
675692|NCT00024089|stage IV squamous cell carcinoma of the nasopharynx
675693|NCT00024089|recurrent squamous cell carcinoma of the nasopharynx
675694|NCT00024089|stage IV squamous cell carcinoma of the hypopharynx
675695|NCT00024089|recurrent squamous cell carcinoma of the hypopharynx
675696|NCT00024089|stage IV squamous cell carcinoma of the larynx
675697|NCT00024089|recurrent squamous cell carcinoma of the larynx
675698|NCT00024089|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
675699|NCT00024089|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
675700|NCT00024089|salivary gland squamous cell carcinoma
675701|NCT00024076|recurrent non-small cell lung cancer
675702|NCT00024076|recurrent small cell lung cancer
675703|NCT00024076|recurrent malignant mesothelioma
675704|NCT00024076|recurrent thymoma and thymic carcinoma
675705|NCT00024076|stage IIIB non-small cell lung cancer
675706|NCT00024076|stage IV non-small cell lung cancer
675707|NCT00024076|pulmonary carcinoid tumor
675708|NCT00024076|lung metastases
675709|NCT00024063|stage III colon cancer
675710|NCT00024063|stage IV colon cancer
675711|NCT00024063|stage IV breast cancer
675712|NCT00024063|stage IIIA breast cancer
675713|NCT00024063|recurrent breast cancer
675714|NCT00024063|stage III gastric cancer
675715|NCT00024063|stage IV gastric cancer
675716|NCT00024063|recurrent gastric cancer
675717|NCT00024063|stage IIIB breast cancer
675718|NCT00024063|recurrent non-small cell lung cancer
675719|NCT00024063|stage II pancreatic cancer
675720|NCT00024063|stage III pancreatic cancer
675721|NCT00024063|recurrent pancreatic cancer
675722|NCT00024063|stage III rectal cancer
675723|NCT00024063|stage IV rectal cancer
675724|NCT00024063|recurrent colon cancer
675725|NCT00024063|recurrent rectal cancer
675726|NCT00024063|refractory multiple myeloma
675727|NCT00024063|stage III renal cell cancer
675728|NCT00024063|stage IV renal cell cancer
675729|NCT00024063|recurrent renal cell cancer
675730|NCT00024063|stage III multiple myeloma
675731|NCT00024063|stage III prostate cancer
675732|NCT00024063|stage IV prostate cancer
675733|NCT00024063|recurrent prostate cancer
675734|NCT00024063|stage IIIA non-small cell lung cancer
675735|NCT00024063|stage IIIB non-small cell lung cancer
675736|NCT00024063|stage IV non-small cell lung cancer
675737|NCT00024063|male breast cancer
675738|NCT00024063|stage IV pancreatic cancer
675739|NCT00024050|refractory anemia
675740|NCT00024050|refractory anemia with ringed sideroblasts
675741|NCT00024050|de novo myelodysplastic syndromes
675742|NCT00024050|previously treated myelodysplastic syndromes
675743|NCT00024050|secondary myelodysplastic syndromes
675744|NCT00024050|childhood myelodysplastic syndromes
675745|NCT00024037|oral complications
675746|NCT00024024|AIDS-related Kaposi sarcoma
675747|NCT00024024|recurrent Kaposi sarcoma
675748|NCT00023985|stage I non-small cell lung cancer
675749|NCT00023985|stage II non-small cell lung cancer
675750|NCT00023985|stage IIIA non-small cell lung cancer
675751|NCT00023972|stage III pancreatic cancer
675752|NCT00023972|stage IV pancreatic cancer
675753|NCT00023907|recurrent ovarian epithelial cancer
675754|NCT00023907|primary peritoneal cavity cancer
675755|NCT00023894|recurrent endometrial carcinoma
675756|NCT00023881|relapsing chronic myelogenous leukemia
675757|NCT00023881|chronic phase chronic myelogenous leukemia
675758|NCT00023881|accelerated phase chronic myelogenous leukemia
675759|NCT00023881|chronic myelogenous leukemia, BCR-ABL1 positive
675761|NCT00023868|stage IV rectal cancer
675762|NCT00023868|recurrent colon cancer
675763|NCT00023868|recurrent rectal cancer
675764|NCT00023868|adenocarcinoma of the colon
675765|NCT00023868|adenocarcinoma of the rectum
675766|NCT00023868|liver metastases
675767|NCT00023855|unspecified adult solid tumor, protocol specific
675768|NCT00023842|stage 0 bladder cancer
675769|NCT00023842|recurrent bladder cancer
675770|NCT00023842|transitional cell carcinoma of the bladder
675771|NCT00023829|stage III prostate cancer
675772|NCT00023829|stage IIB prostate cancer
675773|NCT00023829|stage IIA prostate cancer
675774|NCT00023816|stage IV adult Hodgkin lymphoma
675775|NCT00023816|recurrent adult Hodgkin lymphoma
675776|NCT00023816|stage IV cutaneous T-cell non-Hodgkin lymphoma
675777|NCT00023816|recurrent cutaneous T-cell non-Hodgkin lymphoma
675778|NCT00023816|unspecified adult solid tumor, protocol specific
675779|NCT00023816|stage IV grade 1 follicular lymphoma
675780|NCT00023816|stage IV grade 2 follicular lymphoma
675781|NCT00023816|stage IV grade 3 follicular lymphoma
675782|NCT00023816|stage IV adult diffuse small cleaved cell lymphoma
675783|NCT00023816|stage IV adult diffuse mixed cell lymphoma
675784|NCT00023816|stage IV adult diffuse large cell lymphoma
675785|NCT00023816|stage IV adult immunoblastic large cell lymphoma
675786|NCT00023816|stage IV adult lymphoblastic lymphoma
675787|NCT00023816|stage IV adult Burkitt lymphoma
675788|NCT00023816|recurrent grade 1 follicular lymphoma
675789|NCT00023816|recurrent grade 2 follicular lymphoma
675790|NCT00023816|recurrent grade 3 follicular lymphoma
675791|NCT00023816|recurrent adult diffuse small cleaved cell lymphoma
675792|NCT00023816|recurrent adult diffuse mixed cell lymphoma
675793|NCT00023816|recurrent adult diffuse large cell lymphoma
675794|NCT00023816|recurrent adult immunoblastic large cell lymphoma
675795|NCT00023816|recurrent adult lymphoblastic lymphoma
675796|NCT00023816|recurrent adult Burkitt lymphoma
675797|NCT00023816|stage IV adult T-cell leukemia/lymphoma
675798|NCT00023816|recurrent adult T-cell leukemia/lymphoma
675799|NCT00023816|primary central nervous system non-Hodgkin lymphoma
675800|NCT00023816|AIDS-related peripheral/systemic lymphoma
675801|NCT00023816|AIDS-related primary CNS lymphoma
675802|NCT00023816|intraocular lymphoma
675803|NCT00023816|stage IV mantle cell lymphoma
675804|NCT00023816|recurrent mantle cell lymphoma
675805|NCT00023816|anaplastic large cell lymphoma
675806|NCT00023816|stage IV mycosis fungoides/Sezary syndrome
675807|NCT00023816|recurrent mycosis fungoides/Sezary syndrome
675808|NCT00023816|recurrent marginal zone lymphoma
675809|NCT00023816|recurrent small lymphocytic lymphoma
675810|NCT00023816|stage IV small lymphocytic lymphoma
675811|NCT00023816|stage IV marginal zone lymphoma
675812|NCT00023816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
675813|NCT00023816|nodal marginal zone B-cell lymphoma
675814|NCT00023816|splenic marginal zone lymphoma
675815|NCT00023790|stage IV breast cancer
675816|NCT00023790|recurrent breast cancer
675817|NCT00023790|stage I cutaneous T-cell non-Hodgkin lymphoma
675818|NCT00023790|stage II cutaneous T-cell non-Hodgkin lymphoma
675819|NCT00023790|stage IV cutaneous T-cell non-Hodgkin lymphoma
675820|NCT00023790|recurrent cutaneous T-cell non-Hodgkin lymphoma
675821|NCT00023790|basal cell carcinoma of the skin
675822|NCT00023790|squamous cell carcinoma of the skin
675823|NCT00023790|recurrent skin cancer
675824|NCT00023790|classic Kaposi sarcoma
675825|NCT00023790|immunosuppressive treatment related Kaposi sarcoma
675826|NCT00023790|AIDS-related Kaposi sarcoma
675827|NCT00023790|recurrent Kaposi sarcoma
675828|NCT00023790|stage IV squamous cell carcinoma of the lip and oral cavity
675829|NCT00023790|stage IV basal cell carcinoma of the lip
675830|NCT00023790|stage IV verrucous carcinoma of the oral cavity
675831|NCT00023790|stage IV mucoepidermoid carcinoma of the oral cavity
675832|NCT00023790|stage IV adenoid cystic carcinoma of the oral cavity
675833|NCT00023790|recurrent squamous cell carcinoma of the lip and oral cavity
675834|NCT00023790|recurrent basal cell carcinoma of the lip
675835|NCT00023790|recurrent verrucous carcinoma of the oral cavity
675836|NCT00023790|recurrent mucoepidermoid carcinoma of the oral cavity
675837|NCT00023790|recurrent adenoid cystic carcinoma of the oral cavity
675838|NCT00023790|stage IV squamous cell carcinoma of the oropharynx
675839|NCT00023790|stage IV lymphoepithelioma of the oropharynx
675840|NCT00023790|recurrent squamous cell carcinoma of the oropharynx
675841|NCT00023790|recurrent lymphoepithelioma of the oropharynx
675842|NCT00023790|stage IV squamous cell carcinoma of the nasopharynx
675843|NCT00023790|stage IV lymphoepithelioma of the nasopharynx
675844|NCT00023790|recurrent squamous cell carcinoma of the nasopharynx
675845|NCT00023790|recurrent lymphoepithelioma of the nasopharynx
675846|NCT00023790|stage IV squamous cell carcinoma of the hypopharynx
675847|NCT00023790|recurrent squamous cell carcinoma of the hypopharynx
675848|NCT00023790|stage IV squamous cell carcinoma of the larynx
675849|NCT00023790|stage IV verrucous carcinoma of the larynx
675850|NCT00023790|recurrent squamous cell carcinoma of the larynx
675851|NCT00023790|recurrent verrucous carcinoma of the larynx
675852|NCT00023790|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
675961|NCT00023374|isoniazid resistance
675853|NCT00023790|stage IV inverted papilloma of the paranasal sinus and nasal cavity
675854|NCT00023790|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
675855|NCT00023790|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
675856|NCT00023790|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
675857|NCT00023790|recurrent inverted papilloma of the paranasal sinus and nasal cavity
675858|NCT00023790|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
675859|NCT00023790|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
675860|NCT00023790|skin metastases
675861|NCT00023790|stage I mycosis fungoides/Sezary syndrome
675862|NCT00023790|stage II mycosis fungoides/Sezary syndrome
675863|NCT00023790|stage IV mycosis fungoides/Sezary syndrome
675864|NCT00023790|recurrent mycosis fungoides/Sezary syndrome
675865|NCT00023790|male breast cancer
675866|NCT00023777|untreated adult acute myeloid leukemia
675867|NCT00023777|adult acute erythroid leukemia (M6)
675868|NCT00023777|adult acute myeloblastic leukemia without maturation (M1)
675869|NCT00023777|adult acute myeloblastic leukemia with maturation (M2)
675870|NCT00023777|adult acute myelomonocytic leukemia (M4)
675871|NCT00023777|adult acute monoblastic leukemia (M5a)
675872|NCT00023777|adult acute eosinophilic leukemia
675873|NCT00023777|adult acute basophilic leukemia
675874|NCT00023777|adult acute megakaryoblastic leukemia (M7)
675875|NCT00023777|adult acute monocytic leukemia (M5b)
675876|NCT00023777|adult acute minimally differentiated myeloid leukemia (M0)
675877|NCT00023751|stage I rectal cancer
675878|NCT00023751|adenocarcinoma of the rectum
675879|NCT00023738|stage III adult soft tissue sarcoma
675880|NCT00023738|recurrent adult soft tissue sarcoma
675881|NCT00023738|stage II adult soft tissue sarcoma
675882|NCT00023725|stage I adult soft tissue sarcoma
675883|NCT00023699|recurrent ovarian epithelial cancer
675884|NCT00023699|primary peritoneal cavity cancer
675885|NCT00023686|adenocarcinoma of the prostate
675886|NCT00023686|stage IIB prostate cancer
675887|NCT00023686|stage IIA prostate cancer
675888|NCT00023673|squamous cell lung cancer
675889|NCT00023673|large cell lung cancer
675890|NCT00023673|stage IIIA non-small cell lung cancer
675891|NCT00023673|stage IIIB non-small cell lung cancer
675892|NCT00023673|adenocarcinoma of the lung
675893|NCT00023673|adenosquamous cell lung cancer
675894|NCT00023660|stage III cervical cancer
675895|NCT00023660|stage IB cervical cancer
675896|NCT00023660|stage IIB cervical cancer
675897|NCT00023660|stage IIA cervical cancer
675898|NCT00023660|stage IVA cervical cancer
675899|NCT00023660|cervical squamous cell carcinoma
675900|NCT00023660|cervical adenocarcinoma
675901|NCT00023660|cervical adenosquamous cell carcinoma
675902|NCT00023647|stage IV melanoma
675903|NCT00023647|recurrent melanoma
675904|NCT00023634|stage II gastric cancer
675905|NCT00023634|stage III gastric cancer
675906|NCT00023634|stage IV gastric cancer
675907|NCT00023634|recurrent gastric cancer
675908|NCT00023634|adenocarcinoma of the prostate
675909|NCT00023634|stage II ovarian epithelial cancer
675910|NCT00023634|stage III ovarian epithelial cancer
675911|NCT00023634|stage IV ovarian epithelial cancer
675912|NCT00023634|recurrent adult brain tumor
675913|NCT00023634|stage IV prostate cancer
675914|NCT00023634|recurrent prostate cancer
675915|NCT00023634|adult anaplastic astrocytoma
675916|NCT00023621|basal cell carcinoma of the skin
675917|NCT00023582|Syphilis
675918|NCT00023582|Herpes Genitalis
675919|NCT00023582|Risk Factors
675920|NCT00023582|Incidence
675921|NCT00023582|Prevalence
675922|NCT00023582|Homosexuality, Male
675923|NCT00023582|Informed Consent
675924|NCT00023582|Peru
675925|NCT00023582|HIV Seronegativity
675926|NCT00023569|TMS
675927|NCT00023569|Conjoint Movement
675928|NCT00023569|Chronic Hemiplegia
675929|NCT00023569|Brain Plasticity
675930|NCT00023569|Electrical Stimulation
675931|NCT00023569|Stroke
675932|NCT00023569|CVA
675933|NCT00023504|Immunization
675934|NCT00023504|Antibody
675935|NCT00023504|Immunodeficiency
675936|NCT00023504|Pneumococcal Vaccines
675937|NCT00023504|Phi-X 174
675938|NCT00023504|Primary Immune Disorders
675939|NCT00023491|Sjogren's Syndrome
675940|NCT00023491|Peripheral Blood Stem Cell
675941|NCT00023491|Tissue Regeneration
675942|NCT00023491|Graft-versus-host Disease
675943|NCT00023491|Head and Neck Cancer
675944|NCT00023491|Salivary Gland
675945|NCT00023491|Saliva Gland
675946|NCT00023491|Salivary Gland Dysfunction
675947|NCT00023452|Latent TB infection
675948|NCT00023439|tuberculosis
675949|NCT00023439|TB
675950|NCT00023426|tuberculosis
675951|NCT00023426|tb
675952|NCT00023426|rifapentine
675953|NCT00023426|safety
675954|NCT00023426|dose
675955|NCT00023413|tuberculosis
675956|NCT00023413|TB
675957|NCT00023400|tuberculosis
675958|NCT00023400|TB
675959|NCT00023374|tuberculosis
675960|NCT00023374|TB
675962|NCT00023374|isoniazid intolerance
675963|NCT00023374|treatment
675964|NCT00023374|efficacy
675965|NCT00023374|toxicity
675966|NCT00023361|tuberculosis
675967|NCT00023361|TB
675968|NCT00023348|Tuberculosis
675969|NCT00023348|TB
675970|NCT00023322|Cirrhosis
675971|NCT00023322|Chronic Hepatitis
675972|NCT00023322|Alpha Interferon
675973|NCT00023322|Hepatitis D Virus
675974|NCT00023322|Delta Hepatitis
675975|NCT00023322|Viral Hepatitis
675976|NCT00023322|Antiviral Agents
675977|NCT00023322|Hepatitis D
675978|NCT00023322|HDV
675979|NCT00023322|Liver
675980|NCT00023322|Hepatitis
675981|NCT00023309|Adefovir Dipivoxil
675982|NCT00023309|Lamivudine
675983|NCT00023309|Nucleoside/Nucleotide Analogue
675984|NCT00023309|Chronic Hepatitis B
675985|NCT00023309|Hepatitis B Mutants
675986|NCT00023309|Liver Biopsy
675987|NCT00023309|Hepatitis B
675988|NCT00023309|Hepatitis
675989|NCT00023309|HBV
675990|NCT00023309|Liver
675991|NCT00023296|Acute Chest Syndrome
675992|NCT00023296|Blood Flow
675993|NCT00023296|Nitric Oxide
675994|NCT00023296|NO Therapy
675995|NCT00023296|Vaso-Occlusive Crisis
675996|NCT00023296|Sickle Cell Anemia
675997|NCT00023296|Sickle Cell
675998|NCT00023296|ACS
675999|NCT00023296|Pulmonary Hypertension
676000|NCT00023218|Liver
676001|NCT00023218|HIV-1
676002|NCT00023218|HIV Protease Inhibitors
676003|NCT00023218|Ritonavir
676004|NCT00023218|Biopsy
676005|NCT00023218|Reverse Transcriptase Inhibitors
676006|NCT00023218|Anti-HIV Agents
676007|NCT00023218|ABT 378
676008|NCT00023218|Acidosis, Lactic
676009|NCT00023218|efavirenz
676010|NCT00023218|Alanine Transaminase
676011|NCT00023205|Arthritis
676012|NCT00023205|Health literacy
676013|NCT00023205|Patient education
676014|NCT00023205|Self-efficacy
676015|NCT00023192|Campath 1-H
676016|NCT00023192|T-Cell Depletion
676017|NCT00023192|Therapy
676018|NCT00023192|Stem Cell Transplantation
676019|NCT00023192|Chronic Granulomatous Disease
676020|NCT00023192|CGD
676021|NCT00023166|Phase I
676022|NCT00023166|Open label
676023|NCT00023166|Safety/efficacy
676024|NCT00023166|Lymphomas
676025|NCT00023166|Advanced primary and/or metastatic solid tumors
676026|NCT00023166|Neoplasms
676027|NCT00023166|Neoplasm metastasis
676028|NCT00023153|Drug Resistance
676029|NCT00023153|Viral Load
676030|NCT00023153|Liver
676031|NCT00023153|Immunology
676032|NCT00023153|Liver Histology
676033|NCT00023153|Hepatitis B
676034|NCT00023153|HBV
676035|NCT00023153|HIV
676036|NCT00023140|biomarkers
676037|NCT00023140|exposure
676038|NCT00023140|adducts
676039|NCT00023140|metabolites
676040|NCT00023140|butadiene
676041|NCT00022087|osteoporosis
676042|NCT00022087|stage I breast cancer
676043|NCT00022087|stage II breast cancer
676044|NCT00022087|stage IV breast cancer
676045|NCT00022087|stage IIIA breast cancer
676046|NCT00022087|stage IIIB breast cancer
676047|NCT00022087|stage IIIC breast cancer
676048|NCT00022074|stage I breast cancer
676049|NCT00022074|stage II breast cancer
676050|NCT00022074|stage IV breast cancer
676051|NCT00022074|stage IIIA breast cancer
676052|NCT00022074|recurrent breast cancer
676053|NCT00022074|stage IIIB breast cancer
676054|NCT00022074|stage IIIC breast cancer
676055|NCT00022074|anxiety disorder
676056|NCT00022074|depression
676057|NCT00022074|hot flashes
676058|NCT00022048|refractory anemia
676059|NCT00022048|refractory anemia with ringed sideroblasts
676060|NCT00022048|refractory anemia with excess blasts
676061|NCT00022048|refractory anemia with excess blasts in transformation
676062|NCT00022048|chronic myelomonocytic leukemia
676063|NCT00022048|de novo myelodysplastic syndromes
676064|NCT00022048|previously treated myelodysplastic syndromes
676065|NCT00022048|myelodysplastic/myeloproliferative neoplasm, unclassifiable
676066|NCT00022048|atypical chronic myeloid leukemia, BCR-ABL1 negative
676067|NCT00022035|childhood acute lymphoblastic leukemia in remission
676068|NCT00022035|infection
676069|NCT00022022|recurrent non-small cell lung cancer
676070|NCT00022022|stage IIIB non-small cell lung cancer
676071|NCT00022022|stage IV non-small cell lung cancer
676072|NCT00022009|stage IIIA non-small cell lung cancer
676073|NCT00022009|stage IIIB non-small cell lung cancer
676074|NCT00022009|stage IV non-small cell lung cancer
676075|NCT00021996|unspecified adult solid tumor, protocol specific
676076|NCT00021996|pain
676077|NCT00021983|refractory hairy cell leukemia
676078|NCT00023127|Asthma
676079|NCT00023127|Allergen
676080|NCT00023127|Cockroach
676081|NCT00023114|lung function
676082|NCT00023114|smoking
676083|NCT00023114|metabolism
676084|NCT00023101|lead
676085|NCT00023101|endocrine dysfunction
676086|NCT00023088|Rehabilitation
676087|NCT00023088|Functional Level
676088|NCT00023088|Activity of Daily Living
676089|NCT00023088|Mobility
676090|NCT00023088|Normal Volunteer
676091|NCT00023075|MRI
676092|NCT00023075|Neuromuscular Disease
676093|NCT00023075|N-Acetyl Aspartate
676094|NCT00023075|Choline
676095|NCT00023075|Creatine
676096|NCT00023075|Spasms
676097|NCT00023075|Spasticity
676098|NCT00023075|Primary Lateral Sclerosis
676099|NCT00023075|Hereditary Spastic Paraplegia
676100|NCT00023075|Spastic Paraparesis
676101|NCT00023075|Healthy Volunteer
676102|NCT00023075|HV
676103|NCT00023075|Normal Control
676104|NCT00023062|Natural History
676105|NCT00023062|Motor Cortex
676106|NCT00023062|Behavior
676107|NCT00023062|Healthy Volunteers
676108|NCT00023062|Motor Control
676109|NCT00023062|Parkinson Disease
676110|NCT00023062|Parkinson's
676111|NCT00023062|Healthy Volunteer
676112|NCT00023062|HV
676113|NCT00023062|Normal Control
676114|NCT00023049|Deafness
676115|NCT00023049|Genes
676116|NCT00023049|Impairment
676117|NCT00023049|Auditory
676118|NCT00023049|Vestibular
676119|NCT00023049|Hereditary Hearing Disorder
676120|NCT00023049|Hearing Impairment
676121|NCT00023049|Sensorineural Hearing Loss
676122|NCT00023049|Vestibular Dysfunction
676123|NCT00023049|SNHL
676124|NCT00023036|Genetics
676125|NCT00023036|Deafness
676126|NCT00023036|EVA
676127|NCT00023036|Pendred
676128|NCT00023036|Hearing
676129|NCT00023036|Hearing Impairment
676130|NCT00023036|Nonsyndromic Hereditary Hearing Impairment
676131|NCT00023036|SNHL
676132|NCT00023036|Inner Ear
676133|NCT00023036|Enlarged Vestibular Aqueducts
676134|NCT00023023|Hepatitis
676135|NCT00023023|Blood Bank
676136|NCT00023023|Viruses
676137|NCT00023023|Blood Donors
676138|NCT00023023|Blood Recipients
676139|NCT00023010|CD18
676140|NCT00023010|Retrovirus
676141|NCT00023010|RCR
676142|NCT00023010|Stem Cell
676143|NCT00023010|Gene Transfer
676144|NCT00023010|Leukocyte Adhesion Deficiency
676145|NCT00023010|LAD
676146|NCT00022997|Phenylthiocarbamide
676147|NCT00022997|Phlebotomy
676148|NCT00022997|Chemoreceptors
676149|NCT00022997|Population Associations
676150|NCT00022997|Non-Tasters
676151|NCT00022997|Taste
676152|NCT00022997|Healthy Volunteer
676153|NCT00022997|HV
676154|NCT00022997|Normal Control
676155|NCT00022984|Attitudes Towards Technology
676156|NCT00022984|Cardiovascular Disease
676157|NCT00022984|Illness Representation
676158|NCT00022984|Implantable Cardioverter Defibrillator
676159|NCT00022984|Symptom Distress
676160|NCT00022984|Heart Disease
676161|NCT00022984|ICD
676162|NCT00022971|Monoclonal Antibody
676163|NCT00022971|Lymphoma
676164|NCT00022971|Rituximab
676165|NCT00022971|Hu1D10
676166|NCT00022971|Non-Hodgkin's Lymphoma
676167|NCT00022971|NHL
676168|NCT00022971|Chronic Lymphocytic Leukemia
676169|NCT00022971|CLL
676170|NCT00022971|Leukemia
676171|NCT00022958|Non-Hodgkin's Lymphoma
676172|NCT00022958|Radioimmunotherapy
676173|NCT00022958|Monoclonal Antibody
676174|NCT00022958|Corixa
676175|NCT00022958|Bexxar
676176|NCT00022958|Anti-B1 Antibody
676177|NCT00022958|Tositumomab
676178|NCT00022958|Iodine -131 Anti-B1 Antibody
676179|NCT00022958|Iodine I 131 Tositumomab
676180|NCT00022945|Mantle Cell Lymphoma
676181|NCT00022945|Radioimmunotherapy
676182|NCT00022945|Monoclonal Antibody
676183|NCT00022945|Corixa
676184|NCT00022945|Bexxar
676185|NCT00022945|Anti-B1 Antibody
676186|NCT00022945|Tositumomab
676187|NCT00022945|Iodine -131 Anti-B1 Antibody
676188|NCT00022945|Iodine I 131 Tositumomab
676189|NCT00022932|Non-Hodgkin's Lymphoma
676190|NCT00022932|Radioimmunotherapy
676191|NCT00022932|Monoclonal Antibody
676192|NCT00022932|Corixa
676193|NCT00022932|Bexxar
676194|NCT00022932|Anti-B1 Antibody
676195|NCT00022932|Tositumomab
676196|NCT00022932|Iodine -131 Anti-B1 Antibody
676197|NCT00022932|Iodine I 131 Tositumomab
676198|NCT00022919|Microdissection
676199|NCT00022919|Chromosome
676200|NCT00022919|Karyotype
676201|NCT00022919|Tumor
676202|NCT00022919|Malignancy
676203|NCT00022919|Prostate Adenocarcinoma
676204|NCT00022919|Prostate Intraepithelial Neoplasia
676205|NCT00022919|Prostate Cancer
676206|NCT00022919|Prostate
676207|NCT00022906|Non-Hodgkin's Lymphoma
676208|NCT00022906|Radioimmunotherapy
676209|NCT00022906|Monoclonal Antibody
676210|NCT00022906|Corixa
676211|NCT00022906|Bexxar
676212|NCT00022906|Anti-B1 Antibody
676213|NCT00022906|Tositumomab
676214|NCT00022906|Iodine -131 Anti-B1 Antibody
676215|NCT00022906|Iodine I 131 Tositumomab
676216|NCT00022893|Non-Hodgkin's Lymphoma
676217|NCT00022893|Radioimmunotherapy
676218|NCT00022893|Monoclonal Antibody
676219|NCT00022893|Corixa
676220|NCT00022893|Bexxar
676221|NCT00022893|Anti-B1 Antibody
676222|NCT00022893|Tositumomab
676223|NCT00022893|Iodine -131 Anti-B1 Antibody
676224|NCT00022893|Iodine I 131 Tositumomab
676225|NCT00022880|Chronic Lymphocytic Leukemia
676226|NCT00022880|Dose-Escalation
676227|NCT00022880|Radioimmunotherapy
676228|NCT00022880|Monoclonal Antibody
676229|NCT00022880|Corixa
676230|NCT00022880|Bexxar
676231|NCT00022880|Anti-B1 Antibody
676232|NCT00022880|Tositumomab
676233|NCT00022880|Iodine -131 Anti-B1 Antibody
676234|NCT00022880|Iodine I 131 Tositumomab
676235|NCT00022867|Bone growth
676236|NCT00022867|Calcium
676237|NCT00022867|Children
676238|NCT00022867|Diet
676239|NCT00022867|Puberty
676240|NCT00022854|ACL
676241|NCT00022854|Nerve block
676242|NCT00022854|Knee
676243|NCT00022854|Outcome survey
676244|NCT00022854|Anesthesia
676245|NCT00022854|Analgesia
676246|NCT00022854|Pain
676247|NCT00022841|Bone mineral density (BMD)
676248|NCT00022841|Children
676249|NCT00022841|Glucocorticoids
676250|NCT00022841|Osteoporosis
676251|NCT00022841|Pediatric
676252|NCT00022841|Pamidronate
676253|NCT00022841|Steroids
676254|NCT00022828|Laser
676255|NCT00022828|Cervical
676256|NCT00022828|Spinal
676257|NCT00022828|Spine
676258|NCT00022828|Neck
676259|NCT00022828|Illinois
676260|NCT00022815|Compartment syndrome
676261|NCT00022815|Tissue ultrafiltration
676262|NCT00022815|Reperfusion injury
676263|NCT00022815|Ischemia
676264|NCT00022802|Biomedical equipment development
676265|NCT00022802|Computer assisted patient care
676266|NCT00022802|Digital imaging
676267|NCT00022802|Hip surgery
676268|NCT00022802|Orthopedics
676269|NCT00022802|Trauma
676270|NCT00022802|Radiography
676271|NCT00022802|Biomedical imaging
676272|NCT00022789|Sleep-Disordered Breathing
676273|NCT00022776|Human therapy evaluation
676274|NCT00022776|Orthopedics
676275|NCT00022776|Physical therapy
676276|NCT00022776|Nonsurgical treatment
676277|NCT00022776|Surgical decompression
676278|NCT00022776|Surgery
676279|NCT00022776|Lumbar
676280|NCT00022776|Spine disorder
676281|NCT00022776|Spinal stenosis
676282|NCT00022776|Gender difference
676283|NCT00022776|Medical rehabilitation
676284|NCT00022763|Anti-HIV Agents
676285|NCT00022763|pentafuside
676286|NCT00022750|Type 2 Diabetes Mellitus
676287|NCT00022750|Nurse Case Manager
676288|NCT00022750|Community Health Worker
676289|NCT00022750|Behavioral Interventions
676290|NCT00022750|Cost-effectiveness
676291|NCT00022750|Randomized trial
676292|NCT00022724|recurrent adult brain tumor
676293|NCT00022724|adult glioblastoma
676294|NCT00022724|adult anaplastic astrocytoma
676295|NCT00022724|adult anaplastic oligodendroglioma
676296|NCT00022724|adult mixed glioma
676297|NCT00022724|adult giant cell glioblastoma
676298|NCT00022724|adult gliosarcoma
676299|NCT00022711|recurrent small cell lung cancer
676300|NCT00022711|intermediate type small cell lung cancer
676301|NCT00022698|stage III colon cancer
676302|NCT00022698|stage IV colon cancer
676303|NCT00022698|stage III rectal cancer
676304|NCT00022698|stage IV rectal cancer
676305|NCT00022698|recurrent colon cancer
676306|NCT00022698|recurrent rectal cancer
676307|NCT00022698|adenocarcinoma of the colon
676308|NCT00022698|adenocarcinoma of the rectum
676309|NCT00022685|recurrent grade 1 follicular lymphoma
676310|NCT00022685|recurrent grade 2 follicular lymphoma
676311|NCT00022646|stage IIIB non-small cell lung cancer
676312|NCT00022646|stage IV non-small cell lung cancer
676313|NCT00022633|recurrent bladder cancer
676314|NCT00022633|stage IV bladder cancer
676315|NCT00022633|transitional cell carcinoma of the bladder
676316|NCT00022633|squamous cell carcinoma of the bladder
676317|NCT00022633|adenocarcinoma of the bladder
676318|NCT00022633|recurrent urethral cancer
676319|NCT00022633|anterior urethral cancer
676320|NCT00022633|posterior urethral cancer
676321|NCT00022633|urethral cancer associated with invasive bladder cancer
676322|NCT00022633|metastatic transitional cell cancer of the renal pelvis and ureter
676323|NCT00022633|regional transitional cell cancer of the renal pelvis and ureter
676324|NCT00022633|recurrent transitional cell cancer of the renal pelvis and ureter
676325|NCT00022620|recurrent endometrial carcinoma
676326|NCT00022620|endometrial papillary serous carcinoma
676327|NCT00022607|refractory multiple myeloma
676328|NCT00022607|stage I multiple myeloma
676329|NCT00022607|stage II multiple myeloma
676330|NCT00022607|stage III multiple myeloma
676331|NCT00022594|recurrent metastatic squamous neck cancer with occult primary
676332|NCT00022594|metastatic squamous neck cancer with occult primary squamous cell carcinoma
676333|NCT00022594|stage III squamous cell carcinoma of the lip and oral cavity
676334|NCT00022594|stage IV squamous cell carcinoma of the lip and oral cavity
676335|NCT00022594|recurrent squamous cell carcinoma of the lip and oral cavity
676336|NCT00022594|stage III squamous cell carcinoma of the oropharynx
676337|NCT00022594|stage IV squamous cell carcinoma of the oropharynx
676338|NCT00022594|recurrent squamous cell carcinoma of the oropharynx
676339|NCT00022594|stage III squamous cell carcinoma of the hypopharynx
676340|NCT00022594|stage IV squamous cell carcinoma of the hypopharynx
676341|NCT00022594|recurrent squamous cell carcinoma of the hypopharynx
676342|NCT00022594|stage III squamous cell carcinoma of the larynx
676343|NCT00022594|stage IV squamous cell carcinoma of the larynx
676344|NCT00022594|recurrent squamous cell carcinoma of the larynx
676345|NCT00022568|stage IV melanoma
676346|NCT00022568|recurrent melanoma
676347|NCT00022516|stage IA breast cancer
676348|NCT00022516|stage II breast cancer
676349|NCT00022516|stage IIIA breast cancer
676350|NCT00022516|stage IIIB breast cancer
676351|NCT00022516|stage IB breast cancer
676352|NCT00022516|estrogen receptor-negative breast cancer
676353|NCT00022516|progesterone receptor-negative breast cancer
676354|NCT00022516|triple-negative breast cancer
676355|NCT00022516|low-dose maintenance chemotherapy
676356|NCT00022516|stroma
676357|NCT00022516|angiogenesis
676358|NCT00022490|chronic phase chronic myelogenous leukemia
676359|NCT00022490|Philadelphia chromosome positive chronic myelogenous leukemia
676360|NCT00022477|stage IV colon cancer
676361|NCT00022477|stage IV rectal cancer
676362|NCT00022477|recurrent colon cancer
676363|NCT00022477|recurrent rectal cancer
676364|NCT00022477|adenocarcinoma of the colon
676365|NCT00022477|adenocarcinoma of the rectum
676366|NCT00022464|stage IV melanoma
676367|NCT00022464|recurrent melanoma
676368|NCT00022451|recurrent childhood acute lymphoblastic leukemia
676369|NCT00022451|recurrent childhood acute myeloid leukemia
676370|NCT00022451|relapsing chronic myelogenous leukemia
676371|NCT00022451|blastic phase chronic myelogenous leukemia
676372|NCT00022451|chronic myelogenous leukemia, BCR-ABL1 positive
676373|NCT00022451|childhood acute promyelocytic leukemia (M3)
676374|NCT00022451|acute undifferentiated leukemia
676375|NCT00022451|juvenile myelomonocytic leukemia
676376|NCT00022451|childhood chronic myelogenous leukemia
676377|NCT00022438|stage IV melanoma
676378|NCT00022438|recurrent melanoma
676379|NCT00022425|recurrent breast cancer
676380|NCT00022412|adenocarcinoma of the prostate
676381|NCT00022412|stage I prostate cancer
676382|NCT00022412|stage II prostate cancer
676383|NCT00022399|stage I prostate cancer
676384|NCT00022399|stage IIB prostate cancer
676385|NCT00022399|stage IIA prostate cancer
676386|NCT00022399|adenocarcinoma of the prostate
676387|NCT00022386|stage I breast cancer
676388|NCT00022386|stage II breast cancer
676389|NCT00022386|stage IIIA breast cancer
676390|NCT00022386|stage IIIB breast cancer
676391|NCT00022386|anemia
676392|NCT00022386|fatigue
676393|NCT00022373|stage I nasopharyngeal cancer
676394|NCT00022373|stage II nasopharyngeal cancer
676395|NCT00022373|stage III nasopharyngeal cancer
676396|NCT00022373|stage IV nasopharyngeal cancer
676397|NCT00022373|stage I salivary gland cancer
676398|NCT00022373|stage II salivary gland cancer
676399|NCT00022373|stage III salivary gland cancer
676400|NCT00022373|stage IV salivary gland cancer
676401|NCT00022373|recurrent salivary gland cancer
676402|NCT00022373|untreated metastatic squamous neck cancer with occult primary
676403|NCT00022373|recurrent metastatic squamous neck cancer with occult primary
676404|NCT00022373|stage I lip and oral cavity cancer
676405|NCT00022373|stage II lip and oral cavity cancer
676406|NCT00022373|stage III lip and oral cavity cancer
676407|NCT00022373|stage IV lip and oral cavity cancer
676408|NCT00022373|stage I hypopharyngeal cancer
676409|NCT00022373|stage II hypopharyngeal cancer
676410|NCT00022373|stage III hypopharyngeal cancer
676411|NCT00022373|stage IV hypopharyngeal cancer
676412|NCT00022373|stage I oropharyngeal cancer
676413|NCT00022373|stage II oropharyngeal cancer
676414|NCT00022373|stage III oropharyngeal cancer
676415|NCT00022373|stage IV oropharyngeal cancer
676416|NCT00022373|radiation toxicity
676417|NCT00022373|oral complications of radiation therapy
676418|NCT00022360|recurrent adult brain tumor
676419|NCT00022360|adult glioblastoma
676420|NCT00022360|adult anaplastic astrocytoma
676421|NCT00022360|adult giant cell glioblastoma
676422|NCT00022360|adult gliosarcoma
676423|NCT00022347|stage IV ovarian epithelial cancer
676424|NCT00022347|recurrent ovarian epithelial cancer
676425|NCT00022347|ovarian undifferentiated adenocarcinoma
676426|NCT00022347|ovarian mixed epithelial carcinoma
676427|NCT00022347|ovarian serous cystadenocarcinoma
676428|NCT00022347|ovarian mucinous cystadenocarcinoma
676429|NCT00022347|ovarian endometrioid adenocarcinoma
676430|NCT00022347|ovarian clear cell cystadenocarcinoma
676431|NCT00022347|fallopian tube cancer
676432|NCT00022347|primary peritoneal cavity cancer
676433|NCT00022334|localized resectable adult primary liver cancer
676434|NCT00022334|localized unresectable adult primary liver cancer
676435|NCT00022334|advanced adult primary liver cancer
676436|NCT00022334|recurrent adult primary liver cancer
676437|NCT00022334|adult primary hepatocellular carcinoma
676438|NCT00022321|refractory anemia
676439|NCT00022321|refractory anemia with ringed sideroblasts
676440|NCT00022321|refractory anemia with excess blasts
676441|NCT00022321|refractory anemia with excess blasts in transformation
676442|NCT00022321|de novo myelodysplastic syndromes
676443|NCT00022308|stage II non-small cell lung cancer
676444|NCT00022308|recurrent non-small cell lung cancer
676445|NCT00022308|stage IIIA non-small cell lung cancer
676446|NCT00022308|stage IIIB non-small cell lung cancer
676447|NCT00022295|unspecified adult solid tumor, protocol specific
676448|NCT00022282|refractory multiple myeloma
676449|NCT00022256|adult glioblastoma
676450|NCT00022256|adult giant cell glioblastoma
676451|NCT00022256|adult gliosarcoma
676452|NCT00022243|recurrent non-small cell lung cancer
676453|NCT00022243|stage IIIA non-small cell lung cancer
676454|NCT00022243|stage IIIB non-small cell lung cancer
676455|NCT00022243|stage IV non-small cell lung cancer
676456|NCT00022230|stage II breast cancer
676457|NCT00022230|stage IIIA breast cancer
676458|NCT00022230|stage IIIB breast cancer
676459|NCT00022230|stage IIIC breast cancer
676460|NCT00022217|recurrent salivary gland cancer
676461|NCT00022217|salivary gland squamous cell carcinoma
676462|NCT00022217|salivary gland anaplastic carcinoma
676463|NCT00022217|recurrent squamous cell carcinoma of the lip and oral cavity
676464|NCT00022217|recurrent verrucous carcinoma of the oral cavity
676465|NCT00022217|recurrent squamous cell carcinoma of the oropharynx
676466|NCT00022217|recurrent lymphoepithelioma of the oropharynx
676467|NCT00022217|recurrent squamous cell carcinoma of the nasopharynx
676468|NCT00022217|recurrent lymphoepithelioma of the nasopharynx
676469|NCT00022217|recurrent squamous cell carcinoma of the hypopharynx
676470|NCT00022217|recurrent squamous cell carcinoma of the larynx
676471|NCT00022217|recurrent verrucous carcinoma of the larynx
676472|NCT00022217|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
676473|NCT00022204|stage I breast cancer
676474|NCT00022204|stage II breast cancer
676475|NCT00022204|stage IIIA breast cancer
676476|NCT00022204|lymphedema
676477|NCT00022204|male breast cancer
676478|NCT00022191|stage IV bladder cancer
676479|NCT00022191|transitional cell carcinoma of the bladder
676480|NCT00022191|urethral cancer associated with invasive bladder cancer
676481|NCT00022191|metastatic transitional cell cancer of the renal pelvis and ureter
676482|NCT00022191|regional transitional cell cancer of the renal pelvis and ureter
676483|NCT00022178|adenocarcinoma of unknown primary
676484|NCT00022178|squamous cell carcinoma of unknown primary
676485|NCT00022178|undifferentiated carcinoma of unknown primary
676486|NCT00022178|newly diagnosed carcinoma of unknown primary
676487|NCT00022165|unspecified adult solid tumor, protocol specific
676488|NCT00022152|stage IV breast cancer
676489|NCT00022152|recurrent breast cancer
676490|NCT00022139|stage III gastric cancer
676491|NCT00022139|stage II esophageal cancer
676492|NCT00022139|stage III esophageal cancer
676493|NCT00022139|adenocarcinoma of the stomach
676494|NCT00022139|squamous cell carcinoma of the esophagus
676495|NCT00022139|adenocarcinoma of the esophagus
676496|NCT00022126|untreated childhood acute lymphoblastic leukemia
676497|NCT00022126|L1 childhood acute lymphoblastic leukemia
676498|NCT00022126|L2 childhood acute lymphoblastic leukemia
676499|NCT00022126|acute undifferentiated leukemia
676500|NCT00021866|epilepsy
676501|NCT00021866|seizure
676502|NCT00021866|pregnancy
676503|NCT00021866|antiepileptic
676504|NCT00021866|AED
676505|NCT00021866|carbamazepine
676506|NCT00021866|phenytoin
676507|NCT00021866|valproate
676508|NCT00021866|lamotrigine
676509|NCT00021866|child
676510|NCT00021866|behavior
676511|NCT00021853|Individualized
676512|NCT00021853|Finger
676513|NCT00021853|Training
676514|NCT00021853|Splinting
676515|NCT00021853|TMS
676516|NCT00021853|Dystonia
676517|NCT00021853|Focal Dystonia
676518|NCT00021853|Movement Disorder
676519|NCT00021853|Focal Hand Dystonia
676520|NCT00021853|Writer's Cramp
676521|NCT00021827|parathyroid hormone-related protein
676522|NCT00021827|parathyroid hormone
676523|NCT00021827|anabolic skeletal therapy
676524|NCT00021827|postmenopausal women
676525|NCT00021814|BPH progression
676526|NCT00021814|Medical Therapy
676527|NCT00021814|Finasteride
676528|NCT00021814|Doxazosin
676529|NCT00021814|Randomized
676530|NCT00021814|Multi-center
676531|NCT00021814|Clinical Trial
676532|NCT00021814|Proscar
676533|NCT00021814|Cardura
676534|NCT00021801|Type I Diabetes Mellitus
676535|NCT00021801|Immunosuppression
676536|NCT00021801|Islet Cell Transplant
676537|NCT00021801|Percutaneous Transhepatic Portal
676538|NCT00021788|Type I Diabetes Mellitus
676539|NCT00021788|Immunosuppression
676540|NCT00021788|Islet Cell Transplantation
676541|NCT00021788|PercutaneousTranshepaticPortalVein Catheterization
676542|NCT00021775|Risk Factors
676543|NCT00021775|Incidence
676544|NCT00021775|Patient Selection
676545|NCT00021775|HIV Seronegativity
676546|NCT00021762|Virus Replication
676547|NCT00021762|HIV-1
676548|NCT00021762|Drug Administration Schedule
676549|NCT00021762|AIDS Vaccines
676550|NCT00021762|RNA, Viral
676551|NCT00021762|Viral Load
676552|NCT00021762|HIV-1 immunogen, incomplete Freund's adjuvant
676553|NCT00021762|Treatment Interruption
676554|NCT00021762|HIV Therapeutic Vaccine
676555|NCT00021749|CLL
676556|NCT00021749|Leukemia
676557|NCT00021749|Chronic
676558|NCT00021749|Cancer
676559|NCT00021749|Adult
676560|NCT00021749|Lymphocytic
676561|NCT00021749|Genasense
676562|NCT00021749|G3139
676563|NCT00021749|Genta
676564|NCT00021749|Bcl-2
676565|NCT00021749|Antisense
676566|NCT00021749|Oligonucleotide
676567|NCT00021749|oblimerson
676568|NCT00021736|choroidal neovascularization (CNV)
676569|NCT00021736|subretinal neovascularization
676570|NCT00021723|Alzheimer's
676571|NCT00021723|AN-1792
676572|NCT00021723|AIP-001
676573|NCT00021710|Stroke
676574|NCT00021710|Learning
676575|NCT00021710|Plasticity
676576|NCT00021710|Motor
676577|NCT00021710|Rehabilitation
676578|NCT00021710|Premotor
676579|NCT00021710|Normal Control
676580|NCT00021710|Healthy Volunteer
676581|NCT00021710|HV
676582|NCT00021710|Motor Learning
676583|NCT00021697|AVP-923
676584|NCT00021697|Dextromethorphan
676585|NCT00021697|Quinidine
676586|NCT00021697|Pseudobulbar Affect
676587|NCT00021671|Drug Therapy, Combination
676588|NCT00021671|Ampicillin
676589|NCT00021671|Nevirapine
676590|NCT00021671|Disease Transmission, Vertical
676591|NCT00021671|Anti-Infective Agents
676592|NCT00021671|Erythromycin
676593|NCT00021671|Reverse Transcriptase Inhibitors
676594|NCT00021671|Metronidazole
676595|NCT00021671|Anti-HIV Agents
676596|NCT00021671|Chorioamnionitis
676597|NCT00021671|HIV Seronegativity
676598|NCT00021658|Epidemiology
676599|NCT00021658|pesticide
676600|NCT00021658|asthma
676601|NCT00021658|children
676602|NCT00021658|exposure
676603|NCT00021645|Corticosteroids
676604|NCT00021645|Immunosuppressives
676605|NCT00021645|Intraocular Inflammatory Disease
676606|NCT00021645|Uveitis
676607|NCT00021645|Macular Edema
676608|NCT00021632|Ribavirin
676609|NCT00021632|Drug Interactions
676610|NCT00021632|Drug Therapy, Combination
676611|NCT00021632|Zidovudine
676612|NCT00021632|Stavudine
676613|NCT00021632|Reverse Transcriptase Inhibitors
676614|NCT00021632|Anti-HIV Agents
676615|NCT00021632|Pharmacokinetics
676616|NCT00021632|Area Under Curve
676617|NCT00021567|Pneumonia
676618|NCT00021567|Cytokine
676619|NCT00021567|Aerosol
676620|NCT00021567|Therapy
676621|NCT00021567|Mycobacteria
676622|NCT00021567|Mycobacterium Avium Complex
676623|NCT00021567|MAC
676624|NCT00021567|Pulmonary Infection
676625|NCT00021567|Lung Infection
676626|NCT00021554|HIV-1
676627|NCT00021554|Drug Therapy, Combination
676628|NCT00021554|HIV Protease Inhibitors
676629|NCT00021554|RNA, Viral
676630|NCT00021554|Reverse Transcriptase Inhibitors
676631|NCT00021554|Anti-HIV Agents
676632|NCT00021554|Viral Load
676633|NCT00021554|pentafuside
676634|NCT00021541|Surrogate Markers
676635|NCT00021541|3-Dimensional Magnetic Resonance Imaging (MRI)
676636|NCT00021541|Natural History of Neurofibromatosis Type 1 (NF1)
676637|NCT00021541|Tumor Tissue Bank
676638|NCT00021541|Neurofibromatosis
676639|NCT00021541|NF1
676640|NCT00021541|Neurofibromatosis Type 1
676641|NCT00021541|Plexiform Neurofibroma
676642|NCT00021541|Neurofibroma
676643|NCT00021528|Sequential Treatment
676644|NCT00021528|Major Depression
676645|NCT00021528|Treatment Resistant Depression
676646|NCT00021502|Pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)
676647|NCT00021502|Systemic Inflammatory Response Syndrome (SIRS)
676648|NCT00021502|Nitric oxide (NO)
676649|NCT00021502|Shock
676650|NCT00021489|Placebos
676651|NCT00021489|Drug Therapy, Combination
676652|NCT00021489|Reverse Transcriptase Inhibitors
676653|NCT00021489|Anti-HIV Agents
676654|NCT00021489|abacavir
676655|NCT00021489|mycophenolate mofetil
676656|NCT00021476|Whiplash
676657|NCT00021476|Chronic pain
676658|NCT00021476|Motor vehicle accidents
676659|NCT00021463|Nevirapine
676660|NCT00021463|Reverse Transcriptase Inhibitors
676661|NCT00021463|Anti-HIV Agents
676662|NCT00021463|Triglycerides
676663|NCT00021463|abacavir
676664|NCT00021463|efavirenz
676665|NCT00021463|Lipoproteins, LDL Cholesterol
676666|NCT00021450|stage IIB prostate cancer
676667|NCT00021450|stage IIA prostate cancer
676668|NCT00021437|Bloom syndrome protein
676669|NCT00021424|stage IV squamous cell carcinoma of the lip and oral cavity
676670|NCT00021424|recurrent squamous cell carcinoma of the lip and oral cavity
676671|NCT00021424|stage IV squamous cell carcinoma of the oropharynx
676672|NCT00021424|recurrent squamous cell carcinoma of the oropharynx
676673|NCT00021424|skin metastases
676674|NCT00021398|stage II rectal cancer
676675|NCT00021398|stage III rectal cancer
676676|NCT00021398|adenocarcinoma of the rectum
676677|NCT00021385|stage III ovarian epithelial cancer
676678|NCT00021385|stage IV ovarian epithelial cancer
676679|NCT00021385|recurrent ovarian epithelial cancer
676680|NCT00021385|ovarian stromal cancer
676681|NCT00021385|stage III ovarian germ cell tumor
676682|NCT00021385|stage IV ovarian germ cell tumor
676683|NCT00021385|recurrent ovarian germ cell tumor
676684|NCT00021385|borderline ovarian surface epithelial-stromal tumor
676685|NCT00021385|ovarian sarcoma
676686|NCT00021372|recurrent grade 1 follicular lymphoma
676687|NCT00021372|recurrent grade 2 follicular lymphoma
676688|NCT00021372|recurrent grade 3 follicular lymphoma
676689|NCT00021372|recurrent adult diffuse small cleaved cell lymphoma
676690|NCT00021372|recurrent adult diffuse mixed cell lymphoma
676691|NCT00021372|recurrent adult diffuse large cell lymphoma
676692|NCT00021372|recurrent adult immunoblastic large cell lymphoma
676693|NCT00021372|recurrent adult lymphoblastic lymphoma
676694|NCT00021372|recurrent adult Burkitt lymphoma
676695|NCT00021372|recurrent mantle cell lymphoma
676696|NCT00021372|recurrent marginal zone lymphoma
676697|NCT00021372|recurrent small lymphocytic lymphoma
676698|NCT00021372|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
676699|NCT00021372|nodal marginal zone B-cell lymphoma
676700|NCT00021372|splenic marginal zone lymphoma
676701|NCT00021359|stage I multiple myeloma
676702|NCT00021359|stage II multiple myeloma
676703|NCT00021359|stage III multiple myeloma
676704|NCT00021346|unspecified adult solid tumor, protocol specific
676705|NCT00021333|recurrent non-small cell lung cancer
676706|NCT00021333|recurrent small cell lung cancer
676707|NCT00021333|recurrent thyroid cancer
676708|NCT00021333|recurrent salivary gland cancer
676709|NCT00021333|recurrent squamous cell carcinoma of the lip and oral cavity
676710|NCT00021333|recurrent basal cell carcinoma of the lip
676711|NCT00021333|recurrent verrucous carcinoma of the oral cavity
676712|NCT00021333|recurrent mucoepidermoid carcinoma of the oral cavity
676713|NCT00021333|recurrent adenoid cystic carcinoma of the oral cavity
676714|NCT00021333|recurrent squamous cell carcinoma of the oropharynx
676715|NCT00021333|recurrent lymphoepithelioma of the oropharynx
676716|NCT00021333|recurrent squamous cell carcinoma of the nasopharynx
676717|NCT00021333|recurrent lymphoepithelioma of the nasopharynx
676718|NCT00021333|recurrent squamous cell carcinoma of the hypopharynx
676719|NCT00021333|recurrent squamous cell carcinoma of the larynx
676720|NCT00021333|recurrent verrucous carcinoma of the larynx
676721|NCT00021333|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
676722|NCT00021333|recurrent inverted papilloma of the paranasal sinus and nasal cavity
676723|NCT00021333|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
676724|NCT00021333|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
676725|NCT00021320|stage 0 esophageal cancer
676726|NCT00021320|stage I esophageal cancer
676727|NCT00021320|stage II esophageal cancer
676728|NCT00021320|stage III esophageal cancer
676729|NCT00021320|squamous cell carcinoma of the esophagus
676730|NCT00021320|adenocarcinoma of the esophagus
676731|NCT00021307|recurrent adult brain tumor
676732|NCT00021307|adult glioblastoma
676733|NCT00021307|adult giant cell glioblastoma
676734|NCT00021307|adult gliosarcoma
676735|NCT00021294|basal cell carcinoma of the skin
676736|NCT00021294|squamous cell carcinoma of the skin
676737|NCT00021294|actinic keratosis
676738|NCT00021281|stage IV colon cancer
676739|NCT00021281|stage IV rectal cancer
676740|NCT00021281|recurrent colon cancer
676741|NCT00021281|recurrent rectal cancer
676742|NCT00021281|adenocarcinoma of the colon
676743|NCT00021281|adenocarcinoma of the rectum
676744|NCT00021268|stage IV colon cancer
676745|NCT00021268|stage IV rectal cancer
676746|NCT00021268|recurrent colon cancer
676747|NCT00021268|recurrent rectal cancer
676748|NCT00021242|recurrent childhood acute lymphoblastic leukemia
676749|NCT00021242|recurrent childhood acute myeloid leukemia
676750|NCT00021242|childhood acute promyelocytic leukemia (M3)
676751|NCT00021229|childhood central nervous system germ cell tumor
676752|NCT00021229|childhood high-grade cerebral astrocytoma
676753|NCT00021229|untreated childhood brain stem glioma
676754|NCT00021229|recurrent childhood brain stem glioma
676755|NCT00021229|recurrent childhood cerebral astrocytoma
676756|NCT00021164|stage IV melanoma
676757|NCT00021164|recurrent melanoma
676758|NCT00021164|unspecified adult solid tumor, protocol specific
676759|NCT00021151|refractory chronic lymphocytic leukemia
676760|NCT00021151|prolymphocytic leukemia
676761|NCT00021138|non-small cell lung cancer
676762|NCT00021138|small cell lung cancer
676763|NCT00021138|esophageal cancer
676764|NCT00021138|hypopharyngeal cancer
676765|NCT00021138|laryngeal cancer
676766|NCT00021138|nasopharyngeal cancer
676767|NCT00021138|oropharyngeal cancer
676768|NCT00021138|lip and oral cavity cancer
676769|NCT00021138|paranasal sinus and nasal cavity cancer
676770|NCT00021138|tongue cancer
676771|NCT00021125|squamous cell carcinoma of the skin
676772|NCT00021125|stage I squamous cell carcinoma of the lip and oral cavity
676773|NCT00021125|stage II squamous cell carcinoma of the lip and oral cavity
676774|NCT00021125|stage III squamous cell carcinoma of the lip and oral cavity
676775|NCT00021125|stage IV squamous cell carcinoma of the lip and oral cavity
676776|NCT00021125|stage I squamous cell carcinoma of the oropharynx
676777|NCT00021125|stage II squamous cell carcinoma of the oropharynx
676778|NCT00021125|stage III squamous cell carcinoma of the oropharynx
676779|NCT00021125|stage IV squamous cell carcinoma of the oropharynx
676780|NCT00021125|stage I squamous cell carcinoma of the hypopharynx
676781|NCT00021125|stage II squamous cell carcinoma of the hypopharynx
676782|NCT00021125|stage III squamous cell carcinoma of the hypopharynx
676783|NCT00021125|stage IV squamous cell carcinoma of the hypopharynx
676784|NCT00021125|stage I squamous cell carcinoma of the larynx
676785|NCT00021125|stage II squamous cell carcinoma of the larynx
676786|NCT00021125|stage III squamous cell carcinoma of the larynx
676787|NCT00021125|stage IV squamous cell carcinoma of the larynx
676788|NCT00021125|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
676789|NCT00021125|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
676790|NCT00021125|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
676791|NCT00021125|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
676792|NCT00021125|salivary gland squamous cell carcinoma
676793|NCT00021125|stage I salivary gland cancer
676794|NCT00021125|stage II salivary gland cancer
676795|NCT00021125|stage III salivary gland cancer
676796|NCT00021125|stage IV salivary gland cancer
676797|NCT00021112|stage IIIB non-small cell lung cancer
676798|NCT00021047|stage IV gastric cancer
676799|NCT00021047|recurrent gastric cancer
676800|NCT00021047|stage II esophageal cancer
676801|NCT00021047|stage III esophageal cancer
676802|NCT00021047|stage IV esophageal cancer
676803|NCT00021047|recurrent esophageal cancer
676804|NCT00021047|advanced adult primary liver cancer
676805|NCT00021047|recurrent adult primary liver cancer
676806|NCT00021047|unresectable extrahepatic bile duct cancer
676807|NCT00021047|recurrent extrahepatic bile duct cancer
676808|NCT00021047|unspecified adult solid tumor, protocol specific
676809|NCT00021047|untreated metastatic squamous neck cancer with occult primary
676810|NCT00021047|recurrent metastatic squamous neck cancer with occult primary
676811|NCT00021047|stage IV squamous cell carcinoma of the lip and oral cavity
676812|NCT00021047|stage IV basal cell carcinoma of the lip
676813|NCT00021047|stage IV verrucous carcinoma of the oral cavity
676814|NCT00021047|stage IV mucoepidermoid carcinoma of the oral cavity
676815|NCT00021047|stage IV adenoid cystic carcinoma of the oral cavity
676816|NCT00021047|recurrent squamous cell carcinoma of the lip and oral cavity
676817|NCT00021047|recurrent basal cell carcinoma of the lip
676818|NCT00021047|recurrent verrucous carcinoma of the oral cavity
676819|NCT00021047|recurrent mucoepidermoid carcinoma of the oral cavity
676820|NCT00021047|recurrent adenoid cystic carcinoma of the oral cavity
676821|NCT00021047|stage IV squamous cell carcinoma of the oropharynx
676822|NCT00021047|stage IV lymphoepithelioma of the oropharynx
676823|NCT00021047|recurrent squamous cell carcinoma of the oropharynx
676824|NCT00021047|recurrent lymphoepithelioma of the oropharynx
676825|NCT00021047|stage IV squamous cell carcinoma of the nasopharynx
676826|NCT00021047|stage IV lymphoepithelioma of the nasopharynx
676827|NCT00021047|recurrent squamous cell carcinoma of the nasopharynx
676828|NCT00021047|recurrent lymphoepithelioma of the nasopharynx
676829|NCT00021047|stage IV squamous cell carcinoma of the hypopharynx
676830|NCT00021047|recurrent squamous cell carcinoma of the hypopharynx
676831|NCT00021047|stage IV squamous cell carcinoma of the larynx
676832|NCT00021047|stage IV verrucous carcinoma of the larynx
676833|NCT00021047|recurrent squamous cell carcinoma of the larynx
676834|NCT00021047|recurrent verrucous carcinoma of the larynx
676835|NCT00021047|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
676836|NCT00021047|stage IV inverted papilloma of the paranasal sinus and nasal cavity
676837|NCT00021047|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
676838|NCT00021047|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
676839|NCT00021047|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
676840|NCT00021047|recurrent inverted papilloma of the paranasal sinus and nasal cavity
676841|NCT00021047|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
676842|NCT00021047|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
676843|NCT00021047|recurrent salivary gland cancer
676844|NCT00021047|stage IV salivary gland cancer
676845|NCT00021034|stage II ovarian epithelial cancer
676846|NCT00021034|stage III ovarian epithelial cancer
676847|NCT00021034|stage IV ovarian epithelial cancer
676848|NCT00021034|recurrent ovarian epithelial cancer
676849|NCT00021034|fallopian tube cancer
676850|NCT00021034|primary peritoneal cavity cancer
676851|NCT00021021|stage IV renal cell cancer
676852|NCT00021021|clear cell renal cell carcinoma
676853|NCT00021008|recurrent non-small cell lung cancer
676854|NCT00021008|stage IIIB non-small cell lung cancer
676855|NCT00021008|stage IV non-small cell lung cancer
676856|NCT00020995|adenocarcinoma of the prostate
676857|NCT00020995|stage I prostate cancer
676858|NCT00020995|stage IIB prostate cancer
676859|NCT00020995|stage IIA prostate cancer
676860|NCT00020995|stage III prostate cancer
676861|NCT00020995|stage IV prostate cancer
676862|NCT00020969|refractory anemia
676863|NCT00020969|refractory anemia with ringed sideroblasts
676864|NCT00020969|refractory anemia with excess blasts
676865|NCT00020969|refractory anemia with excess blasts in transformation
676866|NCT00020969|chronic myelomonocytic leukemia
676867|NCT00020969|de novo myelodysplastic syndromes
676868|NCT00020969|previously treated myelodysplastic syndromes
676869|NCT00020969|secondary myelodysplastic syndromes
676870|NCT00020969|atypical chronic myeloid leukemia, BCR-ABL1 negative
676871|NCT00020969|myelodysplastic/myeloproliferative neoplasm, unclassifiable
676872|NCT00020943|stage I mantle cell lymphoma
676873|NCT00020943|contiguous stage II mantle cell lymphoma
676874|NCT00020943|noncontiguous stage II mantle cell lymphoma
676875|NCT00020943|stage III mantle cell lymphoma
676876|NCT00020943|stage IV mantle cell lymphoma
676877|NCT00020930|stage IV colon cancer
676878|NCT00020930|stage IV rectal cancer
676879|NCT00020930|recurrent colon cancer
676880|NCT00020930|recurrent rectal cancer
676881|NCT00020917|stage IV colon cancer
676882|NCT00020917|stage IV rectal cancer
676883|NCT00020904|stage IV breast cancer
676884|NCT00020904|recurrent breast cancer
676885|NCT00020891|stage I prostate cancer
676886|NCT00020891|stage IIB prostate cancer
676887|NCT00020891|stage IIA prostate cancer
676888|NCT00020891|stage III prostate cancer
676889|NCT00020891|stage IV prostate cancer
676890|NCT00020891|recurrent prostate cancer
676891|NCT00020878|non-small cell lung cancer
676892|NCT00020865|stage I adult Hodgkin lymphoma
676893|NCT00020865|stage II adult Hodgkin lymphoma
676894|NCT00020865|stage III adult Hodgkin lymphoma
676895|NCT00020865|stage IV adult Hodgkin lymphoma
676896|NCT00020865|recurrent adult Hodgkin lymphoma
676897|NCT00020865|stage I cutaneous T-cell non-Hodgkin lymphoma
676898|NCT00020865|stage II cutaneous T-cell non-Hodgkin lymphoma
676899|NCT00020865|stage III cutaneous T-cell non-Hodgkin lymphoma
676900|NCT00020865|stage IV cutaneous T-cell non-Hodgkin lymphoma
676901|NCT00020865|recurrent cutaneous T-cell non-Hodgkin lymphoma
676902|NCT00020865|stage 0 chronic lymphocytic leukemia
676903|NCT00020865|stage I chronic lymphocytic leukemia
676904|NCT00020865|stage II chronic lymphocytic leukemia
676905|NCT00020865|stage III chronic lymphocytic leukemia
676906|NCT00020865|stage IV chronic lymphocytic leukemia
676907|NCT00020865|recurrent adult acute myeloid leukemia
676908|NCT00020865|recurrent adult acute lymphoblastic leukemia
676909|NCT00020865|relapsing chronic myelogenous leukemia
676910|NCT00020865|refractory chronic lymphocytic leukemia
676911|NCT00020865|unspecified adult solid tumor, protocol specific
676912|NCT00020865|chronic phase chronic myelogenous leukemia
676913|NCT00020865|accelerated phase chronic myelogenous leukemia
676914|NCT00020865|blastic phase chronic myelogenous leukemia
676915|NCT00020865|meningeal chronic myelogenous leukemia
676916|NCT00020865|adult acute myeloid leukemia in remission
676917|NCT00020865|adult acute lymphoblastic leukemia in remission
676918|NCT00020865|fever, sweats, and hot flashes
676919|NCT00020865|progressive hairy cell leukemia, initial treatment
676920|NCT00020865|refractory hairy cell leukemia
676921|NCT00020865|stage I grade 1 follicular lymphoma
676922|NCT00020865|stage I grade 2 follicular lymphoma
676923|NCT00020865|stage I grade 3 follicular lymphoma
676924|NCT00020865|stage I adult diffuse small cleaved cell lymphoma
676925|NCT00020865|stage I adult diffuse mixed cell lymphoma
676926|NCT00020865|stage I adult diffuse large cell lymphoma
676927|NCT00020865|stage I adult immunoblastic large cell lymphoma
676928|NCT00020865|stage I adult lymphoblastic lymphoma
676929|NCT00020865|stage I adult Burkitt lymphoma
676930|NCT00020865|chronic myelomonocytic leukemia
676931|NCT00020865|T-cell large granular lymphocyte leukemia
676932|NCT00020865|acute undifferentiated leukemia
676933|NCT00020865|stage III grade 1 follicular lymphoma
676934|NCT00020865|stage III grade 2 follicular lymphoma
676935|NCT00020865|stage III grade 3 follicular lymphoma
676936|NCT00020865|stage III adult diffuse small cleaved cell lymphoma
676937|NCT00020865|stage III adult diffuse mixed cell lymphoma
676938|NCT00020865|stage III adult diffuse large cell lymphoma
676939|NCT00020865|stage III adult immunoblastic large cell lymphoma
676940|NCT00020865|stage III adult lymphoblastic lymphoma
676941|NCT00020865|stage III adult Burkitt lymphoma
676942|NCT00020865|stage IV grade 1 follicular lymphoma
676943|NCT00020865|stage IV grade 2 follicular lymphoma
676944|NCT00020865|stage IV grade 3 follicular lymphoma
676945|NCT00020865|stage IV adult diffuse small cleaved cell lymphoma
676946|NCT00020865|stage IV adult diffuse mixed cell lymphoma
676947|NCT00020865|stage IV adult diffuse large cell lymphoma
676948|NCT00020865|stage IV adult immunoblastic large cell lymphoma
676949|NCT00020865|stage IV adult lymphoblastic lymphoma
676950|NCT00020865|stage IV adult Burkitt lymphoma
676951|NCT00020865|recurrent grade 1 follicular lymphoma
676952|NCT00020865|recurrent grade 2 follicular lymphoma
676953|NCT00020865|recurrent grade 3 follicular lymphoma
676954|NCT00020865|recurrent adult diffuse small cleaved cell lymphoma
676955|NCT00020865|recurrent adult diffuse mixed cell lymphoma
676956|NCT00020865|recurrent adult diffuse large cell lymphoma
676957|NCT00020865|recurrent adult immunoblastic large cell lymphoma
676958|NCT00020865|recurrent adult lymphoblastic lymphoma
676959|NCT00020865|recurrent adult Burkitt lymphoma
676960|NCT00020865|stage I adult T-cell leukemia/lymphoma
676961|NCT00020865|stage II adult T-cell leukemia/lymphoma
676962|NCT00020865|stage III adult T-cell leukemia/lymphoma
676963|NCT00020865|stage IV adult T-cell leukemia/lymphoma
676964|NCT00020865|recurrent adult T-cell leukemia/lymphoma
676965|NCT00020865|secondary acute myeloid leukemia
676966|NCT00020865|primary central nervous system non-Hodgkin lymphoma
676967|NCT00020865|neutropenia
676968|NCT00020865|infection
676969|NCT00020865|prolymphocytic leukemia
676970|NCT00020865|AIDS-related peripheral/systemic lymphoma
676971|NCT00020865|AIDS-related primary CNS lymphoma
676972|NCT00020865|intraocular lymphoma
676973|NCT00020865|stage I mantle cell lymphoma
676974|NCT00020865|contiguous stage II grade 1 follicular lymphoma
676975|NCT00020865|contiguous stage II grade 2 follicular lymphoma
676976|NCT00020865|contiguous stage II grade 3 follicular lymphoma
676977|NCT00020865|contiguous stage II adult diffuse small cleaved cell lymphoma
676978|NCT00020865|contiguous stage II mantle cell lymphoma
676979|NCT00020865|contiguous stage II adult diffuse mixed cell lymphoma
676980|NCT00020865|contiguous stage II adult immunoblastic large cell lymphoma
676981|NCT00020865|contiguous stage II adult diffuse large cell lymphoma
676982|NCT00020865|contiguous stage II adult Burkitt lymphoma
676983|NCT00020865|contiguous stage II adult lymphoblastic lymphoma
676984|NCT00020865|noncontiguous stage II grade 1 follicular lymphoma
676985|NCT00020865|noncontiguous stage II grade 2 follicular lymphoma
676986|NCT00020865|noncontiguous stage II grade 3 follicular lymphoma
676987|NCT00020865|noncontiguous stage II adult diffuse small cleaved cell lymphoma
676988|NCT00020865|noncontiguous stage II mantle cell lymphoma
676989|NCT00020865|noncontiguous stage II adult diffuse mixed cell lymphoma
676990|NCT00020865|noncontiguous stage II adult immunoblastic large cell lymphoma
676991|NCT00020865|noncontiguous stage II adult diffuse large cell lymphoma
676992|NCT00020865|noncontiguous stage II adult Burkitt lymphoma
676993|NCT00020865|noncontiguous stage II adult lymphoblastic lymphoma
676994|NCT00020865|stage III mantle cell lymphoma
676995|NCT00020865|stage IV mantle cell lymphoma
676996|NCT00020865|recurrent mantle cell lymphoma
676997|NCT00020865|angioimmunoblastic T-cell lymphoma
676998|NCT00020865|anaplastic large cell lymphoma
676999|NCT00020865|stage I mycosis fungoides/Sezary syndrome
677000|NCT00020865|stage II mycosis fungoides/Sezary syndrome
677001|NCT00020865|stage III mycosis fungoides/Sezary syndrome
677002|NCT00020865|stage IV mycosis fungoides/Sezary syndrome
677003|NCT00020865|recurrent mycosis fungoides/Sezary syndrome
677004|NCT00020865|noncontiguous stage II small lymphocytic lymphoma
677005|NCT00020865|noncontiguous stage II marginal zone lymphoma
677006|NCT00020865|recurrent marginal zone lymphoma
677007|NCT00020865|recurrent small lymphocytic lymphoma
677008|NCT00020865|stage I marginal zone lymphoma
677009|NCT00020865|stage I small lymphocytic lymphoma
677010|NCT00020865|stage III small lymphocytic lymphoma
677011|NCT00020865|stage III marginal zone lymphoma
677012|NCT00020865|stage IV small lymphocytic lymphoma
677013|NCT00020865|stage IV marginal zone lymphoma
677014|NCT00020865|contiguous stage II marginal zone lymphoma
677015|NCT00020865|contiguous stage II small lymphocytic lymphoma
677016|NCT00020865|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
677017|NCT00020865|nodal marginal zone B-cell lymphoma
677018|NCT00020865|splenic marginal zone lymphoma
677019|NCT00020852|stage I breast cancer
677020|NCT00020852|stage II breast cancer
677021|NCT00020839|stage IV melanoma
677022|NCT00020839|recurrent melanoma
677023|NCT00020839|tumors metastatic to brain
677024|NCT00020826|adenocarcinoma of the stomach
677025|NCT00020800|Waldenström macroglobulinemia
677026|NCT00020787|stage IV gastric cancer
677027|NCT00020787|recurrent gastric cancer
677028|NCT00020787|stage IV esophageal cancer
677029|NCT00020787|recurrent esophageal cancer
677030|NCT00020787|adenocarcinoma of the stomach
677031|NCT00020787|adenocarcinoma of the esophagus
677032|NCT00020774|localized resectable adult primary liver cancer
677033|NCT00020774|recurrent adult primary liver cancer
677034|NCT00020774|adult primary hepatocellular carcinoma
677035|NCT00020774|adult primary cholangiocellular carcinoma
677036|NCT00020761|stage IV gastric cancer
677037|NCT00020761|recurrent gastric cancer
677038|NCT00020761|stage IV esophageal cancer
677039|NCT00020761|recurrent esophageal cancer
677040|NCT00020761|adenocarcinoma of the stomach
677041|NCT00020761|adenocarcinoma of the esophagus
677042|NCT00020748|unspecified adult solid tumor, protocol specific
677043|NCT00020735|adenocarcinoma of the prostate
677044|NCT00020735|stage I prostate cancer
677045|NCT00020735|stage II prostate cancer
677046|NCT00020722|stage IV breast cancer
677047|NCT00020722|recurrent breast cancer
677048|NCT00020696|recurrent ovarian epithelial cancer
677049|NCT00020696|primary peritoneal cavity cancer
677050|NCT00020670|recurrent childhood acute lymphoblastic leukemia
677051|NCT00020670|recurrent adult acute lymphoblastic leukemia
677052|NCT00020670|B-cell childhood acute lymphoblastic leukemia
677053|NCT00020670|B-cell adult acute lymphoblastic leukemia
677054|NCT00020657|nausea and vomiting
677055|NCT00020657|unspecified adult solid tumor, protocol specific
677056|NCT00020644|unspecified adult solid tumor, protocol specific
677057|NCT00020631|radiation fibrosis
677058|NCT00020618|unspecified adult solid tumor, protocol specific
677059|NCT00020618|pain
677060|NCT00020605|unspecified adult solid tumor, protocol specific
677061|NCT00020605|constipation, impaction, and bowel obstruction
677062|NCT00020579|stage IV cutaneous T-cell non-Hodgkin lymphoma
677063|NCT00020579|recurrent cutaneous T-cell non-Hodgkin lymphoma
677064|NCT00020579|small intestine lymphoma
677065|NCT00020579|stage IV grade 1 follicular lymphoma
677066|NCT00020579|stage IV grade 2 follicular lymphoma
677067|NCT00020579|stage IV grade 3 follicular lymphoma
677068|NCT00020579|stage IV adult diffuse small cleaved cell lymphoma
677069|NCT00020579|stage IV adult diffuse mixed cell lymphoma
677070|NCT00020579|stage IV adult diffuse large cell lymphoma
677071|NCT00020579|stage IV adult immunoblastic large cell lymphoma
677072|NCT00020579|stage IV adult lymphoblastic lymphoma
677073|NCT00020579|stage IV adult Burkitt lymphoma
677074|NCT00020579|recurrent grade 1 follicular lymphoma
677075|NCT00020579|recurrent grade 2 follicular lymphoma
677076|NCT00020579|recurrent grade 3 follicular lymphoma
677077|NCT00020579|recurrent adult diffuse small cleaved cell lymphoma
677078|NCT00020579|recurrent adult diffuse mixed cell lymphoma
677079|NCT00020579|recurrent adult diffuse large cell lymphoma
677080|NCT00020579|recurrent adult immunoblastic large cell lymphoma
677081|NCT00020579|recurrent adult lymphoblastic lymphoma
677082|NCT00020579|recurrent adult Burkitt lymphoma
677083|NCT00020579|stage IV adult T-cell leukemia/lymphoma
677084|NCT00020579|recurrent adult T-cell leukemia/lymphoma
677085|NCT00020579|primary central nervous system non-Hodgkin lymphoma
677086|NCT00020579|intraocular lymphoma
677087|NCT00020579|stage IV mantle cell lymphoma
677088|NCT00020579|recurrent mantle cell lymphoma
677089|NCT00020579|angioimmunoblastic T-cell lymphoma
677090|NCT00020579|anaplastic large cell lymphoma
677091|NCT00020579|stage IV mycosis fungoides/Sezary syndrome
677092|NCT00020579|recurrent mycosis fungoides/Sezary syndrome
677093|NCT00020579|recurrent marginal zone lymphoma
677094|NCT00020579|recurrent small lymphocytic lymphoma
677095|NCT00020579|stage IV small lymphocytic lymphoma
677096|NCT00020579|stage IV marginal zone lymphoma
677097|NCT00020579|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
677098|NCT00020579|nodal marginal zone B-cell lymphoma
677099|NCT00020579|splenic marginal zone lymphoma
677100|NCT00020579|male breast cancer
677101|NCT00020579|stage IIIA breast cancer
677102|NCT00020579|stage IIIB breast cancer
677103|NCT00020579|stage IIIC breast cancer
677104|NCT00020579|stage IV breast cancer
677105|NCT00020579|recurrent pancreatic cancer
677106|NCT00020579|stage III pancreatic cancer
677107|NCT00020579|recurrent colon cancer
677108|NCT00020579|stage III colon cancer
677109|NCT00020579|stage IV colon cancer
677110|NCT00020579|recurrent rectal cancer
677111|NCT00020579|stage III rectal cancer
677112|NCT00020579|stage IV rectal cancer
677113|NCT00020579|recurrent ovarian epithelial cancer
677114|NCT00020579|recurrent ovarian germ cell tumor
677115|NCT00020579|stage III ovarian epithelial cancer
677116|NCT00020579|stage III ovarian germ cell tumor
677117|NCT00020579|stage IV ovarian epithelial cancer
677118|NCT00020579|stage IV ovarian germ cell tumor
677119|NCT00020579|recurrent malignant testicular germ cell tumor
677120|NCT00020579|stage III malignant testicular germ cell tumor
677121|NCT00020579|recurrent cervical cancer
677122|NCT00020579|stage III cervical cancer
677123|NCT00020579|stage IVA cervical cancer
677124|NCT00020579|stage IVB cervical cancer
677125|NCT00020579|recurrent endometrial carcinoma
677126|NCT00020579|stage III endometrial carcinoma
677127|NCT00020579|stage IV endometrial carcinoma
677128|NCT00020579|fallopian tube cancer
677129|NCT00020579|primary peritoneal cavity cancer
677130|NCT00020579|recurrent uterine sarcoma
677131|NCT00020579|stage III uterine sarcoma
677132|NCT00020579|stage IV uterine sarcoma
677133|NCT00020579|recurrent vaginal cancer
677134|NCT00020579|stage III vaginal cancer
677135|NCT00020579|stage IVA vaginal cancer
677136|NCT00020579|stage IVB vaginal cancer
677137|NCT00020579|recurrent vulvar cancer
677138|NCT00020579|stage III vulvar cancer
677139|NCT00020579|stage IV vulvar cancer
677140|NCT00020579|recurrent anal cancer
677141|NCT00020579|stage IIIA anal cancer
677142|NCT00020579|stage IIIB anal cancer
677143|NCT00020579|stage IV anal cancer
677144|NCT00020579|recurrent esophageal cancer
677145|NCT00020579|stage III esophageal cancer
677146|NCT00020579|stage IV esophageal cancer
677147|NCT00020579|recurrent gastric cancer
677148|NCT00020579|stage III gastric cancer
677149|NCT00020579|stage IV gastric cancer
677150|NCT00020579|recurrent extrahepatic bile duct cancer
677151|NCT00020579|unresectable extrahepatic bile duct cancer
677152|NCT00020579|advanced adult primary liver cancer
677153|NCT00020579|localized unresectable adult primary liver cancer
677154|NCT00020579|recurrent adult primary liver cancer
677155|NCT00020579|recurrent squamous cell carcinoma of the larynx
677156|NCT00020579|recurrent verrucous carcinoma of the larynx
677157|NCT00020579|stage III squamous cell carcinoma of the larynx
677158|NCT00020579|stage III verrucous carcinoma of the larynx
677159|NCT00020579|stage IV squamous cell carcinoma of the larynx
677160|NCT00020579|stage IV verrucous carcinoma of the larynx
677161|NCT00020579|recurrent basal cell carcinoma of the lip
677162|NCT00020579|recurrent squamous cell carcinoma of the lip and oral cavity
677163|NCT00020579|stage III basal cell carcinoma of the lip
677164|NCT00020579|stage III squamous cell carcinoma of the lip and oral cavity
677165|NCT00020579|stage IV basal cell carcinoma of the lip
677166|NCT00020579|stage IV squamous cell carcinoma of the lip and oral cavity
677167|NCT00020579|recurrent lymphoepithelioma of the oropharynx
677168|NCT00020579|recurrent squamous cell carcinoma of the oropharynx
677169|NCT00020579|stage III lymphoepithelioma of the oropharynx
677170|NCT00020579|stage III squamous cell carcinoma of the oropharynx
677171|NCT00020579|stage IV lymphoepithelioma of the oropharynx
677172|NCT00020579|stage IV squamous cell carcinoma of the oropharynx
677173|NCT00020579|recurrent lymphoepithelioma of the nasopharynx
677174|NCT00020579|recurrent squamous cell carcinoma of the nasopharynx
677175|NCT00020579|stage III lymphoepithelioma of the nasopharynx
677176|NCT00020579|stage III squamous cell carcinoma of the nasopharynx
677177|NCT00020579|stage IV lymphoepithelioma of the nasopharynx
677178|NCT00020579|stage IV squamous cell carcinoma of the nasopharynx
677179|NCT00020579|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
677180|NCT00020579|recurrent inverted papilloma of the paranasal sinus and nasal cavity
677181|NCT00020579|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
677182|NCT00020579|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
677183|NCT00020579|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
677184|NCT00020579|stage III inverted papilloma of the paranasal sinus and nasal cavity
677185|NCT00020579|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
677186|NCT00020579|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
677187|NCT00020579|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
677188|NCT00020579|stage IV inverted papilloma of the paranasal sinus and nasal cavity
677189|NCT00020579|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
677190|NCT00020579|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
677191|NCT00020579|metastatic parathyroid cancer
677192|NCT00020579|recurrent parathyroid cancer
677193|NCT00020579|recurrent salivary gland cancer
677194|NCT00020579|stage III salivary gland cancer
677195|NCT00020579|stage IV salivary gland cancer
677196|NCT00020579|recurrent bladder cancer
677197|NCT00020579|recurrent gallbladder cancer
677198|NCT00020579|stage III bladder cancer
677199|NCT00020579|stage IV bladder cancer
677200|NCT00020579|unresectable gallbladder cancer
677201|NCT00020579|recurrent renal cell cancer
677202|NCT00020579|stage III renal cell cancer
677203|NCT00020579|stage IV renal cell cancer
677204|NCT00020579|stage III Wilms tumor
677205|NCT00020579|stage IV Wilms tumor
677206|NCT00020579|stage V Wilms tumor
677207|NCT00020579|metastatic transitional cell cancer of the renal pelvis and ureter
677208|NCT00020579|recurrent transitional cell cancer of the renal pelvis and ureter
677209|NCT00020579|regional transitional cell cancer of the renal pelvis and ureter
677210|NCT00020579|anterior urethral cancer
677211|NCT00020579|posterior urethral cancer
677212|NCT00020579|recurrent urethral cancer
677213|NCT00020579|recurrent penile cancer
677214|NCT00020579|stage III penile cancer
677215|NCT00020579|stage IV penile cancer
677216|NCT00020579|recurrent prostate cancer
677217|NCT00020579|stage III prostate cancer
677218|NCT00020579|stage IV prostate cancer
677219|NCT00020579|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
677220|NCT00020579|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
677221|NCT00020579|metastatic osteosarcoma
677222|NCT00020579|recurrent osteosarcoma
677223|NCT00020579|recurrent adult soft tissue sarcoma
677224|NCT00020579|stage III adult soft tissue sarcoma
677225|NCT00020579|stage IV adult soft tissue sarcoma
677226|NCT00020579|classic Kaposi sarcoma
677227|NCT00020579|AIDS-related Kaposi sarcoma
677228|NCT00020579|recurrent Kaposi sarcoma
677229|NCT00020579|stage III cutaneous T-cell non-Hodgkin lymphoma
677758|NCT00019630|brain tumor
677230|NCT00020579|ciliary body and choroid melanoma, medium/large size
677231|NCT00020579|ciliary body and choroid melanoma, small size
677232|NCT00020579|extraocular extension melanoma
677233|NCT00020579|iris melanoma
677234|NCT00020579|recurrent intraocular melanoma
677235|NCT00020579|recurrent melanoma
677236|NCT00020579|stage III melanoma
677237|NCT00020579|stage IV melanoma
677238|NCT00020579|extensive stage small cell lung cancer
677239|NCT00020579|recurrent non-small cell lung cancer
677240|NCT00020579|recurrent small cell lung cancer
677241|NCT00020579|stage IIIA non-small cell lung cancer
677242|NCT00020579|stage IIIB non-small cell lung cancer
677243|NCT00020579|stage IV non-small cell lung cancer
677244|NCT00020579|recurrent thymoma and thymic carcinoma
677245|NCT00020579|advanced malignant mesothelioma
677246|NCT00020579|recurrent malignant mesothelioma
677247|NCT00020579|recurrent adrenocortical carcinoma
677248|NCT00020579|stage III adrenocortical carcinoma
677249|NCT00020579|stage IV adrenocortical carcinoma
677250|NCT00020579|metastatic gastrointestinal carcinoid tumor
677251|NCT00020579|recurrent gastrointestinal carcinoid tumor
677252|NCT00020579|regional gastrointestinal carcinoid tumor
677253|NCT00020579|desmoid tumor
677254|NCT00020579|newly diagnosed carcinoma of unknown primary
677255|NCT00020579|recurrent carcinoma of unknown primary
677256|NCT00020579|undifferentiated carcinoma of unknown primary
677257|NCT00020579|carcinoma of the appendix
677258|NCT00020579|recurrent metastatic squamous neck cancer with occult primary
677259|NCT00020579|untreated metastatic squamous neck cancer with occult primary
677260|NCT00020579|recurrent pituitary tumor
677261|NCT00020579|adult anaplastic astrocytoma
677262|NCT00020579|adult astrocytic tumors
677263|NCT00020579|adult diffuse astrocytoma
677264|NCT00020579|adult pilocytic astrocytoma
677265|NCT00020579|adult anaplastic oligodendroglioma
677266|NCT00020579|adult brain stem glioma
677267|NCT00020579|adult oligodendroglioma
677268|NCT00020579|adult mixed glioma
677269|NCT00020579|adult central nervous system germ cell tumor
677270|NCT00020579|adult choroid plexus tumor
677271|NCT00020579|adult craniopharyngioma
677272|NCT00020579|adult anaplastic ependymoma
677273|NCT00020579|adult subependymoma
677274|NCT00020579|adult medulloblastoma
677275|NCT00020579|adult supratentorial primitive neuroectodermal tumor (PNET)
677276|NCT00020579|adult ependymoblastoma
677277|NCT00020579|adult ependymoma
677278|NCT00020579|adult myxopapillary ependymoma
677279|NCT00020579|adult anaplastic meningioma
677280|NCT00020579|adult meningeal hemangiopericytoma
677281|NCT00020579|adult meningioma
677282|NCT00020579|adult papillary meningioma
677283|NCT00020579|adult grade I meningioma
677284|NCT00020579|adult grade II meningioma
677285|NCT00020579|adult grade III meningioma
677286|NCT00020579|adult pineal parenchymal tumor
677287|NCT00020579|recurrent adult brain tumor
677288|NCT00020579|stage IV pancreatic cancer
677289|NCT00020579|stage III thymoma
677290|NCT00020579|stage IVA thymoma
677291|NCT00020579|stage IVB thymoma
677292|NCT00020566|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
677293|NCT00020566|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
677294|NCT00020553|psychosocial effects of cancer and its treatment
677295|NCT00020540|stage IV renal cell cancer
677296|NCT00020540|recurrent renal cell cancer
677297|NCT00020540|stage IV melanoma
677298|NCT00020540|recurrent melanoma
677299|NCT00020527|recurrent childhood acute lymphoblastic leukemia
677300|NCT00020527|recurrent childhood rhabdomyosarcoma
677301|NCT00020527|disseminated neuroblastoma
677302|NCT00020527|recurrent neuroblastoma
677303|NCT00020527|recurrent Wilms tumor and other childhood kidney tumors
677304|NCT00020527|recurrent childhood lymphoblastic lymphoma
677305|NCT00020527|recurrent childhood acute myeloid leukemia
677306|NCT00020527|fever, sweats, and hot flashes
677307|NCT00020527|childhood acute promyelocytic leukemia (M3)
677308|NCT00020527|recurrent/refractory childhood Hodgkin lymphoma
677309|NCT00020527|neutropenia
677310|NCT00020527|infection
677311|NCT00020527|recurrent childhood small noncleaved cell lymphoma
677312|NCT00020527|recurrent childhood large cell lymphoma
677313|NCT00020527|previously treated childhood rhabdomyosarcoma
677314|NCT00020501|stage IV colon cancer
677315|NCT00020501|stage IV rectal cancer
677316|NCT00020501|recurrent colon cancer
677317|NCT00020501|recurrent rectal cancer
677318|NCT00020501|liver metastases
677319|NCT00020488|unspecified adult solid tumor, protocol specific
677320|NCT00020475|adult solid tumor
677321|NCT00020475|body system/site cancer
677322|NCT00020475|cancer
677323|NCT00020475|extraocular extension melanoma
677324|NCT00020475|eye cancer
677325|NCT00020475|intraocular melanoma
677326|NCT00020475|recurrent intraocular melanoma
677327|NCT00020475|solid tumor
677328|NCT00020475|stage, intraocular melanoma
677329|NCT00020462|stage III grade 1 follicular lymphoma
677330|NCT00020462|stage III grade 2 follicular lymphoma
677331|NCT00020462|stage III grade 3 follicular lymphoma
677332|NCT00020462|stage IV grade 1 follicular lymphoma
677333|NCT00020462|stage IV grade 2 follicular lymphoma
677334|NCT00020462|stage IV grade 3 follicular lymphoma
677335|NCT00020462|recurrent grade 1 follicular lymphoma
677336|NCT00020462|recurrent grade 2 follicular lymphoma
677337|NCT00020462|recurrent grade 3 follicular lymphoma
677338|NCT00020449|AIDS-related Kaposi sarcoma
677339|NCT00020449|recurrent Kaposi sarcoma
677340|NCT00020410|stage IV breast cancer
677341|NCT00020410|recurrent breast cancer
677342|NCT00020410|male breast cancer
677343|NCT00020397|recurrent melanoma
677344|NCT00020397|stage IV melanoma
677345|NCT00020371|adult solid tumor
677346|NCT00020371|bone marrow suppression
677347|NCT00020371|cancer
677348|NCT00020371|cancer-related problem/condition
677349|NCT00020371|neutropenia
677350|NCT00020371|solid tumor
677351|NCT00020371|unspecified adult solid tumor, protocol specific
677352|NCT00020358|stage I melanoma
677353|NCT00020358|stage II melanoma
677354|NCT00020358|stage III melanoma
677355|NCT00020358|stage IV melanoma
677356|NCT00020358|recurrent melanoma
677357|NCT00020345|adenocarcinoma of the pancreas
677358|NCT00020345|adult solid tumor
677359|NCT00020345|body system/site cancer
677360|NCT00020345|cancer
677361|NCT00020345|cellular diagnosis, pancreatic cancer
677362|NCT00020345|gastrointestinal cancer
677363|NCT00020345|pancreatic cancer
677364|NCT00020345|solid tumor
677365|NCT00020345|stage III pancreatic cancer
677366|NCT00020345|stage IV pancreatic cancer
677367|NCT00020345|stage IVA pancreatic cancer
677368|NCT00020345|stage, pancreatic cancer
677369|NCT00020332|stage IV breast cancer
677370|NCT00020332|stage IIIA breast cancer
677371|NCT00020332|recurrent breast cancer
677372|NCT00020332|stage IIIB breast cancer
677373|NCT00020332|male breast cancer
677374|NCT00020267|Ewing's family of tumors
677375|NCT00020267|adult soft tissue sarcoma
677376|NCT00020267|adult solid tumor
677377|NCT00020267|body system/site cancer
677378|NCT00020267|bone cancer
677379|NCT00020267|breast cancer
677380|NCT00020267|cancer
677381|NCT00020267|childhood cancer
677382|NCT00020267|childhood solid tumor
677383|NCT00020267|ciliary body and choroid melanoma, medium/large size
677384|NCT00020267|colon cancer
677385|NCT00020267|colorectal cancer
677386|NCT00020267|extraocular extension melanoma
677387|NCT00020267|eye cancer
677388|NCT00020267|female reproductive cancer
677389|NCT00020267|gastrointestinal cancer
677390|NCT00020267|genetic condition
677391|NCT00020267|intraocular melanoma
677392|NCT00020267|lung cancer
677393|NCT00020267|male breast cancer
677394|NCT00020267|melanoma
677395|NCT00020267|metastatic osteosarcoma
677396|NCT00020267|metastatic tumors of the Ewing's family
677397|NCT00020267|muscle cancer
677398|NCT00020267|musculoskeletal cancer
677399|NCT00020267|non-small cell lung cancer
677400|NCT00020267|osteosarcoma
677401|NCT00020267|osteosarcoma/malignant fibrous histiocytoma of bone
677402|NCT00020267|ovarian sarcoma
677403|NCT00020267|rectal cancer
677404|NCT00020267|recurrent adult soft tissue sarcoma
677405|NCT00020267|recurrent breast cancer
677406|NCT00020267|recurrent colon cancer
677407|NCT00020267|recurrent intraocular melanoma
677408|NCT00020267|recurrent melanoma
677409|NCT00020267|recurrent non-small cell lung cancer
677410|NCT00020267|recurrent osteosarcoma
677411|NCT00020267|recurrent rectal cancer
677412|NCT00020267|recurrent tumors of the Ewing's family
677413|NCT00020267|recurrent uterine sarcoma
677414|NCT00020267|skin tumor
677415|NCT00020267|solid tumor
677416|NCT00020267|stage IIIB, IV, recurrent, and metastatic breast cancer
677417|NCT00020267|stage IV adult soft tissue sarcoma
677418|NCT00020267|stage IV breast cancer
677419|NCT00020267|stage IV colon cancer
677420|NCT00020267|stage IV melanoma
677421|NCT00020267|stage IV non-small cell lung cancer
677422|NCT00020267|stage IV rectal cancer
677423|NCT00020267|stage IV uterine sarcoma
677424|NCT00020267|stage IVA adult soft tissue sarcoma
677425|NCT00020267|stage IVB adult soft tissue sarcoma
677426|NCT00020267|stage, Ewing's family of tumors
677427|NCT00020267|stage, adult soft tissue sarcoma
677428|NCT00020267|stage, breast cancer
677429|NCT00020267|stage, colon cancer
677430|NCT00020267|stage, intraocular melanoma
677431|NCT00020267|stage, melanoma
677432|NCT00020267|stage, non-small cell lung cancer
677433|NCT00020267|stage, osteosarcoma
677434|NCT00020267|stage, rectal cancer
677435|NCT00020267|stage, uterine sarcoma
677436|NCT00020267|thorax/respiratory cancer
677437|NCT00020267|uterine sarcoma
677438|NCT00020254|adenocarcinoma of the prostate
677439|NCT00020254|recurrent prostate cancer
677440|NCT00020202|adult solid tumor
677441|NCT00020202|body system/site cancer
677442|NCT00020202|cancer
677443|NCT00020202|extensive stage small cell lung cancer
677444|NCT00020202|genetic condition
677445|NCT00020202|lung cancer
677446|NCT00020202|non-small cell lung cancer
677447|NCT00020202|recurrent non-small cell lung cancer
677448|NCT00020202|recurrent small cell lung cancer
677449|NCT00020202|small cell lung cancer
677450|NCT00020202|solid tumor
677451|NCT00020202|stage III non-small cell lung cancer
677452|NCT00020202|stage IIIA non-small cell lung cancer
677453|NCT00020202|stage IIIB non-small cell lung cancer
677454|NCT00020202|stage IV non-small cell lung cancer
677455|NCT00020202|stage, non-small cell lung cancer
677456|NCT00020202|stage, small cell lung cancer
677457|NCT00020202|thorax/respiratory cancer
677458|NCT00020189|thromboembolism
677459|NCT00020189|untreated metastatic squamous neck cancer with occult primary
677460|NCT00020189|recurrent metastatic squamous neck cancer with occult primary
677461|NCT00020189|metastatic squamous neck cancer with occult primary squamous cell carcinoma
677462|NCT00020189|stage IV squamous cell carcinoma of the lip and oral cavity
677463|NCT00020189|recurrent squamous cell carcinoma of the lip and oral cavity
677464|NCT00020189|stage IV squamous cell carcinoma of the oropharynx
677465|NCT00020189|recurrent squamous cell carcinoma of the oropharynx
677466|NCT00020189|stage IV squamous cell carcinoma of the hypopharynx
677467|NCT00020189|recurrent squamous cell carcinoma of the hypopharynx
677468|NCT00020189|stage IV squamous cell carcinoma of the larynx
677469|NCT00020189|recurrent squamous cell carcinoma of the larynx
677470|NCT00020189|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
677471|NCT00020189|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
677472|NCT00020189|recurrent salivary gland cancer
677473|NCT00020189|salivary gland squamous cell carcinoma
677474|NCT00020189|stage IV salivary gland cancer
677475|NCT00020176|stage IV breast cancer
677476|NCT00020176|recurrent breast cancer
677477|NCT00020176|male breast cancer
677478|NCT00020150|recurrent childhood rhabdomyosarcoma
677479|NCT00020150|childhood craniopharyngioma
677480|NCT00020150|recurrent childhood brain tumor
677481|NCT00020150|recurrent neuroblastoma
677482|NCT00020150|recurrent childhood liver cancer
677483|NCT00020150|recurrent Wilms tumor and other childhood kidney tumors
677484|NCT00020150|childhood central nervous system germ cell tumor
677485|NCT00020150|recurrent osteosarcoma
677486|NCT00020150|unspecified childhood solid tumor, protocol specific
677487|NCT00020150|childhood germ cell tumor
677488|NCT00020150|recurrent childhood soft tissue sarcoma
677489|NCT00020150|childhood oligodendroglioma
677490|NCT00020150|childhood choroid plexus tumor
677491|NCT00020150|childhood grade I meningioma
677492|NCT00020150|childhood grade II meningioma
677493|NCT00020150|childhood grade III meningioma
677494|NCT00020150|recurrent childhood cerebellar astrocytoma
677495|NCT00020150|recurrent childhood cerebral astrocytoma
677496|NCT00020150|recurrent childhood medulloblastoma
677497|NCT00020150|recurrent childhood visual pathway and hypothalamic glioma
677498|NCT00020150|previously treated childhood rhabdomyosarcoma
677499|NCT00020150|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
677500|NCT00020150|recurrent childhood ependymoma
677501|NCT00020150|childhood teratoma
677502|NCT00020150|childhood malignant testicular germ cell tumor
677503|NCT00020150|childhood extragonadal germ cell tumor
677504|NCT00020150|childhood malignant ovarian germ cell tumor
677505|NCT00020150|recurrent childhood malignant germ cell tumor
677506|NCT00020124|recurrent non-small cell lung cancer
677507|NCT00020124|extensive stage small cell lung cancer
677508|NCT00020124|recurrent small cell lung cancer
677509|NCT00020124|advanced malignant mesothelioma
677510|NCT00020124|recurrent malignant mesothelioma
677511|NCT00020124|stage IIIB non-small cell lung cancer
677512|NCT00020124|stage IV non-small cell lung cancer
677513|NCT00020124|pulmonary carcinoid tumor
677514|NCT00020124|lung metastases
677515|NCT00020111|recurrent childhood acute myeloid leukemia
677516|NCT00020111|childhood acute promyelocytic leukemia (M3)
677517|NCT00020111|recurrent childhood acute lymphoblastic leukemia
677518|NCT00020111|recurrent childhood large cell lymphoma
677519|NCT00020111|recurrent childhood lymphoblastic lymphoma
677520|NCT00020111|recurrent childhood small noncleaved cell lymphoma
677521|NCT00020111|recurrent/refractory childhood Hodgkin lymphoma
677522|NCT00020111|childhood chronic myelogenous leukemia
677523|NCT00020111|atypical chronic myeloid leukemia, BCR-ABL1 negative
677524|NCT00020098|breast cancer
677525|NCT00020072|cutaneous T-cell non-Hodgkin lymphoma
677526|NCT00020072|mycosis fungoides/Sezary syndrome
677527|NCT00020046|adenocarcinoma of the prostate
677528|NCT00020046|adult solid tumor
677529|NCT00020046|body system/site cancer
677530|NCT00020046|cancer
677531|NCT00020046|cellular diagnosis, prostate cancer
677532|NCT00020046|genetic condition
677533|NCT00020046|male reproductive cancer
677534|NCT00020046|prostate cancer
677535|NCT00020046|recurrent prostate cancer
677536|NCT00020046|solid tumor
677537|NCT00020046|stage IV prostate cancer
677538|NCT00020046|stage, prostate cancer
677539|NCT00020007|recurrent non-small cell lung cancer
677540|NCT00020007|limited stage small cell lung cancer
677541|NCT00020007|extensive stage small cell lung cancer
677542|NCT00020007|recurrent small cell lung cancer
677759|NCT00019630|cancer
677543|NCT00020007|stage IIIA non-small cell lung cancer
677544|NCT00020007|stage IIIB non-small cell lung cancer
677545|NCT00020007|stage IV non-small cell lung cancer
677546|NCT00020007|lung metastases
677547|NCT00020007|bronchoalveolar cell lung cancer
677548|NCT00020007|pulmonary carcinoid tumor
677549|NCT00019994|stage IV melanoma
677550|NCT00019994|recurrent melanoma
677551|NCT00019968|adult soft tissue sarcoma
677552|NCT00019968|adult solid tumor
677553|NCT00019968|body system/site cancer
677554|NCT00019968|cancer
677555|NCT00019968|muscle cancer
677556|NCT00019968|musculoskeletal cancer
677557|NCT00019968|recurrent adult soft tissue sarcoma
677558|NCT00019968|solid tumor
677559|NCT00019968|stage IA, IB, and IIA adult soft tissue sarcoma
677560|NCT00019968|stage II adult soft tissue sarcoma
677561|NCT00019968|stage IIB adult soft tissue sarcoma
677562|NCT00019968|stage IIB, IIC, and III adult soft tissue sarcoma
677563|NCT00019968|stage IIC adult soft tissue sarcoma
677564|NCT00019968|stage III adult soft tissue sarcoma
677565|NCT00019968|stage IV adult soft tissue sarcoma
677566|NCT00019968|stage IVA adult soft tissue sarcoma
677567|NCT00019968|stage IVB adult soft tissue sarcoma
677568|NCT00019968|stage, adult soft tissue sarcoma
677569|NCT00019955|stage I renal cell cancer
677570|NCT00019955|stage II renal cell cancer
677571|NCT00019929|stage IIIA non-small cell lung cancer
677572|NCT00019929|stage IIIB non-small cell lung cancer
677573|NCT00019916|stage IV breast cancer
677574|NCT00019916|recurrent breast cancer
677575|NCT00019916|recurrent ovarian epithelial cancer
677576|NCT00019916|stage IV ovarian epithelial cancer
677577|NCT00019890|adult solid tumor
677578|NCT00019890|body system/site cancer
677579|NCT00019890|cancer
677580|NCT00019890|melanoma
677581|NCT00019890|recurrent melanoma
677582|NCT00019890|skin tumor
677583|NCT00019890|solid tumor
677584|NCT00019890|stage III melanoma
677585|NCT00019890|stage IV melanoma
677586|NCT00019890|stage, melanoma
677587|NCT00019864|cardiac toxicity
677588|NCT00019864|localized osteosarcoma
677589|NCT00019864|metastatic osteosarcoma
677590|NCT00019864|recurrent osteosarcoma
677591|NCT00019838|Waldenström macroglobulinemia
677592|NCT00019838|refractory chronic lymphocytic leukemia
677593|NCT00019838|refractory hairy cell leukemia
677594|NCT00019838|recurrent grade 1 follicular lymphoma
677595|NCT00019838|recurrent grade 2 follicular lymphoma
677596|NCT00019838|recurrent mantle cell lymphoma
677597|NCT00019838|recurrent marginal zone lymphoma
677598|NCT00019838|recurrent small lymphocytic lymphoma
677599|NCT00019838|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
677600|NCT00019838|nodal marginal zone B-cell lymphoma
677601|NCT00019838|splenic marginal zone lymphoma
677602|NCT00019825|recurrent non-small cell lung cancer
677603|NCT00019825|stage II esophageal cancer
677604|NCT00019825|stage III esophageal cancer
677605|NCT00019825|stage IV esophageal cancer
677606|NCT00019825|recurrent esophageal cancer
677607|NCT00019825|extensive stage small cell lung cancer
677608|NCT00019825|recurrent small cell lung cancer
677609|NCT00019825|advanced malignant mesothelioma
677610|NCT00019825|recurrent malignant mesothelioma
677611|NCT00019825|stage IIIB non-small cell lung cancer
677612|NCT00019825|stage IV non-small cell lung cancer
677613|NCT00019825|malignant pleural effusion
677614|NCT00019812|stage IV breast cancer
677615|NCT00019812|male breast cancer
677616|NCT00019786|stage IV colon cancer
677617|NCT00019786|stage IV rectal cancer
677618|NCT00019786|recurrent colon cancer
677619|NCT00019786|recurrent rectal cancer
677620|NCT00019786|localized unresectable adult primary liver cancer
677621|NCT00019786|recurrent adult primary liver cancer
677622|NCT00019786|recurrent islet cell carcinoma
677623|NCT00019786|adult primary hepatocellular carcinoma
677624|NCT00019786|adenocarcinoma of the colon
677625|NCT00019786|adenocarcinoma of the rectum
677626|NCT00019786|liver metastases
677627|NCT00019786|adult primary cholangiocellular carcinoma
677628|NCT00019786|advanced adult primary liver cancer
677629|NCT00019786|recurrent childhood liver cancer
677630|NCT00019786|childhood hepatocellular carcinoma
677631|NCT00019786|stage III childhood liver cancer
677632|NCT00019786|stage IV childhood liver cancer
677633|NCT00019786|neuroendocrine carcinoma
677634|NCT00019773|stage I colon cancer
677635|NCT00019773|stage II colon cancer
677636|NCT00019773|stage III colon cancer
677637|NCT00019773|stage IV colon cancer
677638|NCT00019773|stage 0 colon cancer
677639|NCT00019773|stage 0 rectal cancer
677640|NCT00019773|stage I rectal cancer
677641|NCT00019773|stage II rectal cancer
677642|NCT00019773|stage III rectal cancer
677643|NCT00019773|stage IV rectal cancer
677644|NCT00019773|recurrent colon cancer
677645|NCT00019773|recurrent rectal cancer
677646|NCT00019773|small intestine adenocarcinoma
677647|NCT00019773|small intestine lymphoma
677648|NCT00019773|small intestine leiomyosarcoma
677649|NCT00019773|recurrent small intestine cancer
677650|NCT00019773|carcinoma of the appendix
677651|NCT00019760|adult solid tumor
677652|NCT00019760|body system/site cancer
677653|NCT00019760|cancer
677654|NCT00019760|colon cancer
677655|NCT00019760|colorectal cancer
677656|NCT00019760|gastrointestinal cancer
677657|NCT00019760|genetic condition
677658|NCT00019760|liver and intrahepatic biliary tract cancer
677659|NCT00019760|liver metastases
677660|NCT00019760|metastatic cancer
677661|NCT00019760|rectal cancer
677662|NCT00019760|recurrent colon cancer
677663|NCT00019760|recurrent rectal cancer
677664|NCT00019760|site, metastatic cancer
677665|NCT00019760|solid tumor
677666|NCT00019760|stage IV colon cancer
677667|NCT00019760|stage IV rectal cancer
677668|NCT00019760|stage, colon cancer
677669|NCT00019760|stage, rectal cancer
677670|NCT00019760|unclassified/other cancer
677671|NCT00019747|stage IV colon cancer
677672|NCT00019747|stage IV rectal cancer
677673|NCT00019747|recurrent colon cancer
677674|NCT00019747|recurrent rectal cancer
677675|NCT00019734|stage IV melanoma
677676|NCT00019734|recurrent melanoma
677677|NCT00019721|stage IV melanoma
677678|NCT00019721|recurrent melanoma
677679|NCT00019695|adenocarcinoma of the prostate
677680|NCT00019695|adult solid tumor
677681|NCT00019695|body system/site cancer
677682|NCT00019695|bone metastases
677683|NCT00019695|cancer
677684|NCT00019695|cellular diagnosis, prostate cancer
677685|NCT00019695|genetic condition
677686|NCT00019695|male reproductive cancer
677687|NCT00019695|metastatic cancer
677688|NCT00019695|prostate cancer
677689|NCT00019695|recurrent prostate cancer
677690|NCT00019695|site, metastatic cancer
677691|NCT00019695|solid tumor
677692|NCT00019695|stage IV prostate cancer
677693|NCT00019695|stage, prostate cancer
677694|NCT00019695|unclassified/other cancer
677695|NCT00019669|stage IV melanoma
677696|NCT00019669|recurrent melanoma
677697|NCT00019656|stage IV chronic lymphocytic leukemia
677698|NCT00019656|refractory chronic lymphocytic leukemia
677699|NCT00019656|unspecified adult solid tumor, protocol specific
677700|NCT00019656|previously treated myelodysplastic syndromes
677701|NCT00019656|de novo myelodysplastic syndromes
677702|NCT00019656|recurrent adult diffuse large cell lymphoma
677703|NCT00019656|recurrent adult diffuse mixed cell lymphoma
677704|NCT00019656|recurrent adult diffuse small cleaved cell lymphoma
677705|NCT00019656|recurrent adult Burkitt lymphoma
677706|NCT00019656|recurrent adult Hodgkin lymphoma
677707|NCT00019656|recurrent adult immunoblastic large cell lymphoma
677708|NCT00019656|recurrent adult lymphoblastic lymphoma
677709|NCT00019656|recurrent grade 1 follicular lymphoma
677710|NCT00019656|recurrent grade 2 follicular lymphoma
677711|NCT00019656|recurrent grade 3 follicular lymphoma
677712|NCT00019656|recurrent mantle cell lymphoma
677713|NCT00019656|secondary myelodysplastic syndromes
677714|NCT00019656|stage IV adult diffuse large cell lymphoma
677715|NCT00019656|stage IV adult diffuse mixed cell lymphoma
677716|NCT00019656|stage IV adult diffuse small cleaved cell lymphoma
677717|NCT00019656|stage IV adult Burkitt lymphoma
677718|NCT00019656|stage IV adult Hodgkin lymphoma
677719|NCT00019656|stage IV adult immunoblastic large cell lymphoma
677720|NCT00019656|stage IV adult lymphoblastic lymphoma
677721|NCT00019656|stage IV grade 1 follicular lymphoma
677722|NCT00019656|stage IV grade 2 follicular lymphoma
677723|NCT00019656|stage IV grade 3 follicular lymphoma
677724|NCT00019656|stage IV mantle cell lymphoma
677725|NCT00019656|chronic myelomonocytic leukemia
677726|NCT00019656|atypical chronic myeloid leukemia, BCR-ABL1 negative
677727|NCT00019656|myelodysplastic/myeloproliferative neoplasm, unclassifiable
677728|NCT00019656|recurrent marginal zone lymphoma
677729|NCT00019656|recurrent small lymphocytic lymphoma
677730|NCT00019656|stage IV small lymphocytic lymphoma
677731|NCT00019656|stage IV marginal zone lymphoma
677732|NCT00019656|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
677733|NCT00019656|nodal marginal zone B-cell lymphoma
677734|NCT00019656|splenic marginal zone lymphoma
677735|NCT00019643|adult solid tumor
677736|NCT00019643|body system/site cancer
677737|NCT00019643|breast cancer
677738|NCT00019643|cancer
677739|NCT00019643|cancer-related problem/condition
677740|NCT00019643|depression
677741|NCT00019643|depression and suicide
677742|NCT00019643|nutrition
677743|NCT00019643|psychosocial effects/treatment
677744|NCT00019643|quality of life
677745|NCT00019643|solid tumor
677746|NCT00019643|stage I breast cancer
677747|NCT00019643|stage I, II, and IIIA breast cancer
677748|NCT00019643|stage II breast cancer
677749|NCT00019643|stage III breast cancer
677750|NCT00019643|stage IIIA breast cancer
677751|NCT00019643|stage IIIB, IV, recurrent, and metastatic breast cancer
677752|NCT00019643|stage, breast cancer
677753|NCT00019630|Ewing's family of tumors
677754|NCT00019630|Wilms' tumor
677755|NCT00019630|adult solid tumor
677756|NCT00019630|body system/site cancer
677757|NCT00019630|bone cancer
677760|NCT00019630|central nervous system cancer
677761|NCT00019630|childhood brain stem glioma
677762|NCT00019630|childhood brain tumor
677763|NCT00019630|childhood cancer
677764|NCT00019630|childhood central nervous system germ cell tumor
677765|NCT00019630|childhood cerebellar astrocytoma
677766|NCT00019630|childhood cerebral astrocytoma
677767|NCT00019630|childhood choroid plexus tumor
677768|NCT00019630|childhood craniopharyngioma
677769|NCT00019630|childhood ependymoma
677770|NCT00019630|childhood extracranial germ cell tumor
677771|NCT00019630|childhood extragonadal malignant germ cell tumor
677772|NCT00019630|childhood liver cancer
677773|NCT00019630|childhood malignant ovarian germ cell tumor
677774|NCT00019630|childhood malignant testicular germ cell tumor
677775|NCT00019630|childhood mature and immature teratomas
677776|NCT00019630|childhood medulloblastoma
677777|NCT00019630|childhood meningioma
677778|NCT00019630|childhood oligodendroglioma
677779|NCT00019630|childhood rhabdomyosarcoma
677780|NCT00019630|childhood soft tissue sarcoma
677781|NCT00019630|childhood solid tumor
677782|NCT00019630|childhood supratentorial primitive neuroectodermal and pineal tumors
677783|NCT00019630|childhood visual pathway and hypothalamic glioma
677784|NCT00019630|endocrine cancer
677785|NCT00019630|gastrointestinal cancer
677786|NCT00019630|genetic condition
677787|NCT00019630|kidney tumor
677788|NCT00019630|kidney/urinary cancer
677789|NCT00019630|liver and intrahepatic biliary tract cancer
677790|NCT00019630|muscle cancer
677791|NCT00019630|musculoskeletal cancer
677792|NCT00019630|neuroblastoma
677793|NCT00019630|osteosarcoma
677794|NCT00019630|osteosarcoma/malignant fibrous histiocytoma of bone
677795|NCT00019630|pediatric germ cell tumor
677796|NCT00019630|previously treated childhood rhabdomyosarcoma
677797|NCT00019630|recurrent Wilms' tumor
677798|NCT00019630|recurrent childhood brain stem glioma
677799|NCT00019630|recurrent childhood brain tumor
677800|NCT00019630|recurrent childhood cerebellar astrocytoma
677801|NCT00019630|recurrent childhood cerebral astrocytoma
677802|NCT00019630|recurrent childhood ependymoma
677803|NCT00019630|recurrent childhood liver cancer
677804|NCT00019630|recurrent childhood malignant germ cell tumor
677805|NCT00019630|recurrent childhood medulloblastoma
677806|NCT00019630|recurrent childhood rhabdomyosarcoma
677807|NCT00019630|recurrent childhood soft tissue sarcoma
677808|NCT00019630|recurrent childhood supratentorial primitive neuroectodermal and pineal tumors
677809|NCT00019630|recurrent childhood visual pathway and hypothalamic glioma
677810|NCT00019630|recurrent neuroblastoma
677811|NCT00019630|recurrent osteosarcoma
677812|NCT00019630|recurrent tumors of the Ewing's family
677813|NCT00019630|solid tumor
677814|NCT00019630|stage, Ewing's family of tumors
677815|NCT00019630|stage, Wilms' tumor
677816|NCT00019630|stage, childhood extracranial germ cell tumor
677817|NCT00019630|stage, childhood liver cancer
677818|NCT00019630|stage, childhood medulloblastoma
677819|NCT00019630|stage, childhood rhabdomyosarcoma
677820|NCT00019630|stage, childhood soft tissue sarcoma
677821|NCT00019630|stage, neuroblastoma
677822|NCT00019630|stage, osteosarcoma
677823|NCT00019630|stage/type, childhood brain tumor
677824|NCT00019630|unspecified childhood solid tumor, protocol specific
677825|NCT00019604|localized unresectable adult primary liver cancer
677826|NCT00019604|recurrent adult primary liver cancer
677827|NCT00019604|liver metastases
677828|NCT00019604|unspecified adult solid tumor, protocol specific
677829|NCT00019591|stage III colon cancer
677830|NCT00019591|stage IV colon cancer
677831|NCT00019591|stage III rectal cancer
677832|NCT00019591|stage IV rectal cancer
677833|NCT00019591|recurrent colon cancer
677834|NCT00019591|recurrent rectal cancer
677835|NCT00019578|adult brain stem glioma
677836|NCT00019578|adult brain tumor
677837|NCT00019578|adult central nervous system germ cell tumor
677838|NCT00019578|adult craniopharyngioma
677839|NCT00019578|adult ependymoma
677840|NCT00019578|adult infiltrating astrocytoma
677841|NCT00019578|adult malignant meningioma
677842|NCT00019578|adult medulloblastoma
677843|NCT00019578|adult meningioma
677844|NCT00019578|adult noninfiltrating astrocytoma
677845|NCT00019578|adult oligodendroglioma
677846|NCT00019578|adult pineal parenchymal tumor
677847|NCT00019578|adult solid tumor
677848|NCT00019578|body system/site cancer
677849|NCT00019578|brain metastases
677850|NCT00019578|brain tumor
677851|NCT00019578|cancer
677852|NCT00019578|central nervous system cancer
677853|NCT00019578|genetic condition
677854|NCT00019578|metastatic cancer
677855|NCT00019578|mixed gliomas
677856|NCT00019578|site, metastatic cancer
677857|NCT00019578|solid tumor
677858|NCT00019578|stage IV peripheral primitive neuroectodermal tumor
677859|NCT00019578|stage/type, adult brain tumor
677860|NCT00019578|unclassified/other cancer
677861|NCT00019565|unspecified adult solid tumor, protocol specific
677862|NCT00019552|recurrent ovarian epithelial cancer
677863|NCT00019552|fallopian tube cancer
677864|NCT00019552|primary peritoneal cavity cancer
677865|NCT00019539|adult solid tumor
677866|NCT00019539|body system/site cancer
677867|NCT00019539|cancer
677868|NCT00019539|kidney tumor
677869|NCT00019539|kidney/urinary cancer
677870|NCT00019539|recurrent renal cell cancer
677871|NCT00019539|renal cell cancer
677872|NCT00019539|solid tumor
677873|NCT00019539|stage IV renal cell cancer
677874|NCT00019539|stage, renal cell cancer
677875|NCT00019513|stage IV adult Hodgkin lymphoma
677876|NCT00019513|recurrent adult Hodgkin lymphoma
677877|NCT00019513|stage IV cutaneous T-cell non-Hodgkin lymphoma
677878|NCT00019513|recurrent cutaneous T-cell non-Hodgkin lymphoma
677879|NCT00019513|small intestine lymphoma
677880|NCT00019513|unspecified adult solid tumor, protocol specific
677881|NCT00019513|stage IV grade 1 follicular lymphoma
677882|NCT00019513|stage IV grade 2 follicular lymphoma
677883|NCT00019513|stage IV grade 3 follicular lymphoma
677884|NCT00019513|stage IV adult diffuse small cleaved cell lymphoma
677885|NCT00019513|stage IV adult diffuse mixed cell lymphoma
677886|NCT00019513|stage IV adult diffuse large cell lymphoma
677887|NCT00019513|stage IV adult immunoblastic large cell lymphoma
677888|NCT00019513|stage IV adult lymphoblastic lymphoma
677889|NCT00019513|stage IV adult Burkitt lymphoma
677890|NCT00019513|recurrent grade 1 follicular lymphoma
677891|NCT00019513|recurrent grade 2 follicular lymphoma
677892|NCT00019513|recurrent grade 3 follicular lymphoma
677893|NCT00019513|recurrent adult diffuse small cleaved cell lymphoma
677894|NCT00019513|recurrent adult diffuse mixed cell lymphoma
677895|NCT00019513|recurrent adult diffuse large cell lymphoma
677896|NCT00019513|recurrent adult immunoblastic large cell lymphoma
677897|NCT00019513|recurrent adult lymphoblastic lymphoma
677898|NCT00019513|recurrent adult Burkitt lymphoma
677899|NCT00019513|stage IV adult T-cell leukemia/lymphoma
677900|NCT00019513|recurrent adult T-cell leukemia/lymphoma
677901|NCT00019513|stage IV mantle cell lymphoma
677902|NCT00019513|recurrent mantle cell lymphoma
677903|NCT00019513|anaplastic large cell lymphoma
677904|NCT00019513|stage IV mycosis fungoides/Sezary syndrome
677905|NCT00019513|recurrent mycosis fungoides/Sezary syndrome
677906|NCT00019513|recurrent adult primary liver cancer
677907|NCT00019513|advanced adult primary liver cancer
677908|NCT00019513|adult primary cholangiocellular carcinoma
677909|NCT00019513|stage IV non-small cell lung cancer
677910|NCT00019513|recurrent non-small cell lung cancer
677911|NCT00019513|extensive stage small cell lung cancer
677912|NCT00019513|recurrent small cell lung cancer
677913|NCT00019513|recurrent pancreatic cancer
677914|NCT00019513|stage IV esophageal cancer
677915|NCT00019513|recurrent esophageal cancer
677916|NCT00019513|recurrent colon cancer
677917|NCT00019513|stage IV colon cancer
677918|NCT00019513|recurrent gallbladder cancer
677919|NCT00019513|unresectable gallbladder cancer
677920|NCT00019513|cholangiocarcinoma of the gallbladder
677921|NCT00019513|unresectable extrahepatic bile duct cancer
677922|NCT00019513|recurrent extrahepatic bile duct cancer
677923|NCT00019513|cholangiocarcinoma of the extrahepatic bile duct
677924|NCT00019513|recurrent marginal zone lymphoma
677925|NCT00019513|recurrent small lymphocytic lymphoma
677926|NCT00019513|stage IV small lymphocytic lymphoma
677927|NCT00019513|stage IV marginal zone lymphoma
677928|NCT00019513|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
677929|NCT00019513|nodal marginal zone B-cell lymphoma
677930|NCT00019513|splenic marginal zone lymphoma
677931|NCT00019513|stage IV pancreatic cancer
677932|NCT00019500|breast cancer
677933|NCT00019487|stage IV melanoma
677934|NCT00019487|recurrent melanoma
677935|NCT00019474|stage III gastric cancer
677936|NCT00019474|stage IV gastric cancer
677937|NCT00019474|recurrent gastric cancer
677938|NCT00019474|stage II pancreatic cancer
677939|NCT00019474|stage III pancreatic cancer
677940|NCT00019474|recurrent pancreatic cancer
677941|NCT00019474|regional gastrointestinal carcinoid tumor
677942|NCT00019474|metastatic gastrointestinal carcinoid tumor
677943|NCT00019474|recurrent gastrointestinal carcinoid tumor
677944|NCT00019474|localized unresectable adult primary liver cancer
677945|NCT00019474|advanced adult primary liver cancer
677946|NCT00019474|recurrent adult primary liver cancer
677947|NCT00019474|small intestine adenocarcinoma
677948|NCT00019474|unresectable extrahepatic bile duct cancer
677949|NCT00019474|recurrent extrahepatic bile duct cancer
677950|NCT00019474|recurrent small intestine cancer
677951|NCT00019474|adult primary hepatocellular carcinoma
677952|NCT00019474|stage IV pancreatic cancer
677953|NCT00019461|recurrent ovarian epithelial cancer
677954|NCT00019461|fallopian tube cancer
677955|NCT00019461|primary peritoneal cavity cancer
677956|NCT00019448|adult solid tumor
677957|NCT00019448|body system/site cancer
677958|NCT00019448|cancer
677959|NCT00019448|melanoma
677960|NCT00019448|recurrent melanoma
677961|NCT00019448|skin tumor
677962|NCT00019448|solid tumor
677963|NCT00019448|stage IV melanoma
677964|NCT00019448|stage, melanoma
677965|NCT00019435|stage IV colon cancer
677966|NCT00019435|stage IV breast cancer
677967|NCT00019435|recurrent breast cancer
677968|NCT00019435|stage IV gastric cancer
677969|NCT00019435|recurrent gastric cancer
677970|NCT00019435|recurrent non-small cell lung cancer
677971|NCT00019435|recurrent pancreatic cancer
677972|NCT00019435|recurrent colon cancer
677973|NCT00019435|stage IV esophageal cancer
677974|NCT00019435|recurrent esophageal cancer
677975|NCT00019435|recurrent bladder cancer
677976|NCT00019435|stage IV bladder cancer
677977|NCT00019435|stage IV non-small cell lung cancer
677978|NCT00019435|stage IV pancreatic cancer
677979|NCT00019422|childhood low-grade cerebral astrocytoma
677980|NCT00019422|recurrent childhood supratentorial primitive neuroectodermal tumor
677981|NCT00019422|recurrent childhood cerebellar astrocytoma
677982|NCT00019422|recurrent childhood cerebral astrocytoma
677983|NCT00019422|recurrent childhood medulloblastoma
677984|NCT00019422|untreated childhood visual pathway and hypothalamic glioma
677985|NCT00019422|recurrent childhood visual pathway and hypothalamic glioma
677986|NCT00019422|recurrent childhood ependymoma
677987|NCT00019409|untreated childhood acute lymphoblastic leukemia
677988|NCT00019409|childhood acute lymphoblastic leukemia in remission
677989|NCT00019409|L1 childhood acute lymphoblastic leukemia
677990|NCT00019409|L2 childhood acute lymphoblastic leukemia
677991|NCT00019396|adult solid tumor
677992|NCT00019396|body system/site cancer
677993|NCT00019396|cancer
677994|NCT00019396|kidney tumor
677995|NCT00019396|kidney/urinary cancer
677996|NCT00019396|melanoma
677997|NCT00019396|recurrent melanoma
677998|NCT00019396|recurrent renal cell cancer
677999|NCT00019396|renal cell cancer
678000|NCT00019396|skin tumor
678001|NCT00019396|solid tumor
678002|NCT00019396|stage IV melanoma
678003|NCT00019396|stage IV renal cell cancer
678004|NCT00019396|stage, melanoma
678005|NCT00019396|stage, renal cell cancer
678006|NCT00019383|recurrent melanoma
678007|NCT00019357|unspecified adult solid tumor, protocol specific
678008|NCT00019344|stage IV adult Hodgkin lymphoma
678009|NCT00019344|recurrent adult Hodgkin lymphoma
678010|NCT00019344|stage IV cutaneous T-cell non-Hodgkin lymphoma
678011|NCT00019344|recurrent cutaneous T-cell non-Hodgkin lymphoma
678012|NCT00019344|small intestine lymphoma
678013|NCT00019344|stage IV prostate cancer
678014|NCT00019344|recurrent prostate cancer
678015|NCT00019344|unspecified adult solid tumor, protocol specific
678016|NCT00019344|stage IV grade 1 follicular lymphoma
678017|NCT00019344|stage IV grade 2 follicular lymphoma
678018|NCT00019344|stage IV grade 3 follicular lymphoma
678019|NCT00019344|stage IV adult diffuse small cleaved cell lymphoma
678020|NCT00019344|stage IV adult diffuse mixed cell lymphoma
678021|NCT00019344|stage IV adult diffuse large cell lymphoma
678022|NCT00019344|stage IV adult immunoblastic large cell lymphoma
678023|NCT00019344|stage IV adult lymphoblastic lymphoma
678024|NCT00019344|stage IV adult Burkitt lymphoma
678025|NCT00019344|recurrent grade 1 follicular lymphoma
678026|NCT00019344|recurrent grade 2 follicular lymphoma
678027|NCT00019344|recurrent grade 3 follicular lymphoma
678028|NCT00019344|recurrent adult diffuse small cleaved cell lymphoma
678029|NCT00019344|recurrent adult diffuse mixed cell lymphoma
678030|NCT00019344|recurrent adult diffuse large cell lymphoma
678031|NCT00019344|recurrent adult immunoblastic large cell lymphoma
678032|NCT00019344|recurrent adult lymphoblastic lymphoma
678033|NCT00019344|recurrent adult Burkitt lymphoma
678034|NCT00019344|stage IV adult T-cell leukemia/lymphoma
678035|NCT00019344|recurrent adult T-cell leukemia/lymphoma
678036|NCT00019344|intraocular lymphoma
678037|NCT00019344|stage IV mantle cell lymphoma
678038|NCT00019344|recurrent mantle cell lymphoma
678039|NCT00019344|angioimmunoblastic T-cell lymphoma
678040|NCT00019344|anaplastic large cell lymphoma
678041|NCT00019344|stage IV mycosis fungoides/Sezary syndrome
678042|NCT00019344|recurrent mycosis fungoides/Sezary syndrome
678043|NCT00019344|recurrent marginal zone lymphoma
678044|NCT00019344|recurrent small lymphocytic lymphoma
678045|NCT00019344|stage IV small lymphocytic lymphoma
678046|NCT00019344|stage IV marginal zone lymphoma
678047|NCT00019344|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
678048|NCT00019344|nodal marginal zone B-cell lymphoma
678049|NCT00019344|splenic marginal zone lymphoma
678050|NCT00019331|stage IV colon cancer
678051|NCT00019331|recurrent non-small cell lung cancer
678052|NCT00019331|stage II pancreatic cancer
678053|NCT00019331|stage III pancreatic cancer
678054|NCT00019331|recurrent pancreatic cancer
678055|NCT00019331|recurrent colon cancer
678056|NCT00019331|extensive stage small cell lung cancer
678057|NCT00019331|recurrent small cell lung cancer
678058|NCT00019331|advanced adult primary liver cancer
678059|NCT00019331|recurrent adult primary liver cancer
678060|NCT00019331|stage IV endometrial carcinoma
678061|NCT00019331|recurrent endometrial carcinoma
678062|NCT00019331|stage III malignant testicular germ cell tumor
678063|NCT00019331|recurrent malignant testicular germ cell tumor
678064|NCT00019331|stage IV papillary thyroid cancer
678065|NCT00019331|stage IV follicular thyroid cancer
678066|NCT00019331|thyroid gland medullary carcinoma
678067|NCT00019331|anaplastic thyroid cancer
678068|NCT00019331|recurrent thyroid cancer
678069|NCT00019331|stage IV melanoma
678070|NCT00019331|recurrent melanoma
678071|NCT00019331|stage IV non-small cell lung cancer
678072|NCT00019331|unspecified adult solid tumor, protocol specific
678073|NCT00019331|untreated metastatic squamous neck cancer with occult primary
678074|NCT00019331|recurrent metastatic squamous neck cancer with occult primary
678075|NCT00019331|adult primary hepatocellular carcinoma
678076|NCT00019331|pulmonary carcinoid tumor
678077|NCT00019331|stage IV squamous cell carcinoma of the lip and oral cavity
678078|NCT00019331|stage IV basal cell carcinoma of the lip
678079|NCT00019331|stage IV verrucous carcinoma of the oral cavity
678080|NCT00019331|stage IV mucoepidermoid carcinoma of the oral cavity
678081|NCT00019331|stage IV adenoid cystic carcinoma of the oral cavity
678082|NCT00019331|recurrent squamous cell carcinoma of the lip and oral cavity
678083|NCT00019331|recurrent basal cell carcinoma of the lip
678084|NCT00019331|recurrent verrucous carcinoma of the oral cavity
678085|NCT00019331|recurrent mucoepidermoid carcinoma of the oral cavity
678086|NCT00019331|recurrent adenoid cystic carcinoma of the oral cavity
678087|NCT00019331|stage IV squamous cell carcinoma of the oropharynx
678088|NCT00019331|stage IV lymphoepithelioma of the oropharynx
678089|NCT00019331|recurrent squamous cell carcinoma of the oropharynx
678090|NCT00019331|recurrent lymphoepithelioma of the oropharynx
678091|NCT00019331|stage IV squamous cell carcinoma of the nasopharynx
678092|NCT00019331|stage IV lymphoepithelioma of the nasopharynx
678093|NCT00019331|recurrent squamous cell carcinoma of the nasopharynx
678094|NCT00019331|recurrent lymphoepithelioma of the nasopharynx
678095|NCT00019331|stage IV squamous cell carcinoma of the hypopharynx
678096|NCT00019331|recurrent squamous cell carcinoma of the hypopharynx
678097|NCT00019331|stage IV squamous cell carcinoma of the larynx
678098|NCT00019331|stage IV verrucous carcinoma of the larynx
678099|NCT00019331|recurrent squamous cell carcinoma of the larynx
678100|NCT00019331|recurrent verrucous carcinoma of the larynx
678101|NCT00019331|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
678102|NCT00019331|stage IV inverted papilloma of the paranasal sinus and nasal cavity
678103|NCT00019331|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
678104|NCT00019331|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
678105|NCT00019331|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
678106|NCT00019331|recurrent inverted papilloma of the paranasal sinus and nasal cavity
678107|NCT00019331|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
678108|NCT00019331|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
678109|NCT00019331|insular thyroid cancer
678110|NCT00019331|recurrent salivary gland cancer
678111|NCT00019331|stage IV salivary gland cancer
678112|NCT00019331|stage IV pancreatic cancer
678113|NCT00019318|stage III cutaneous T-cell non-Hodgkin lymphoma
678114|NCT00019318|stage IV cutaneous T-cell non-Hodgkin lymphoma
678115|NCT00019318|recurrent cutaneous T-cell non-Hodgkin lymphoma
678116|NCT00019318|stage III mycosis fungoides/Sezary syndrome
678117|NCT00019318|stage IV mycosis fungoides/Sezary syndrome
678118|NCT00019318|recurrent mycosis fungoides/Sezary syndrome
678119|NCT00019240|classic Kaposi sarcoma
678120|NCT00019240|AIDS-related Kaposi sarcoma
678121|NCT00019240|recurrent Kaposi sarcoma
678122|NCT00019227|stage I adult T-cell leukemia/lymphoma
678123|NCT00019227|stage II adult T-cell leukemia/lymphoma
678124|NCT00019227|stage III adult T-cell leukemia/lymphoma
678125|NCT00019227|stage IV adult T-cell leukemia/lymphoma
678126|NCT00019227|recurrent adult T-cell leukemia/lymphoma
678127|NCT00019227|radiation toxicity
678128|NCT00019214|recurrent melanoma
678129|NCT00019201|stage I non-small cell lung cancer
678130|NCT00019201|stage II non-small cell lung cancer
678131|NCT00019201|stage III non-small cell lung cancer
678132|NCT00019201|limited stage small cell lung cancer
678133|NCT00019201|stage I nasopharyngeal cancer
678134|NCT00019201|stage II nasopharyngeal cancer
678135|NCT00019201|stage III nasopharyngeal cancer
678136|NCT00019201|stage I lip and oral cavity cancer
678137|NCT00019201|stage II lip and oral cavity cancer
678138|NCT00019201|stage III lip and oral cavity cancer
678139|NCT00019201|stage I hypopharyngeal cancer
678140|NCT00019201|stage II hypopharyngeal cancer
678141|NCT00019201|stage III hypopharyngeal cancer
678142|NCT00019201|stage I laryngeal cancer
678143|NCT00019201|stage II laryngeal cancer
678144|NCT00019201|stage III laryngeal cancer
678145|NCT00019201|stage I paranasal sinus and nasal cavity cancer
678146|NCT00019201|stage II paranasal sinus and nasal cavity cancer
678147|NCT00019201|stage III paranasal sinus and nasal cavity cancer
678148|NCT00019201|stage I oropharyngeal cancer
678149|NCT00019201|stage II oropharyngeal cancer
678150|NCT00019201|stage III oropharyngeal cancer
678151|NCT00019188|AIDS-related malignancies
678152|NCT00019188|Kaposi's sarcoma
678153|NCT00019188|adult solid tumor
678154|NCT00019188|body system/site cancer
678155|NCT00019188|cancer
678156|NCT00019188|epidemic Kaposi's sarcoma
678157|NCT00019188|recurrent Kaposi's sarcoma
678158|NCT00019188|skin tumor
678159|NCT00019188|solid tumor
678160|NCT00019188|stage, Kaposi's sarcoma
678161|NCT00019175|stage IV melanoma
678162|NCT00019175|recurrent melanoma
678163|NCT00019136|recurrent ovarian epithelial cancer
678164|NCT00019123|AIDS-related Kaposi sarcoma
678165|NCT00019110|stage IV anal cancer
678166|NCT00019110|recurrent anal cancer
678167|NCT00019110|stage II esophageal cancer
678168|NCT00019110|stage III esophageal cancer
678169|NCT00019110|stage IV esophageal cancer
678170|NCT00019110|stage IIIA anal cancer
678171|NCT00019110|stage IIIB anal cancer
678172|NCT00019110|recurrent esophageal cancer
678173|NCT00019110|stage III cervical cancer
678174|NCT00019110|stage IV cervical cancer
678175|NCT00019110|recurrent cervical cancer
678176|NCT00019110|stage III vulvar cancer
678177|NCT00019110|stage IVB vulvar cancer
678178|NCT00019110|recurrent vulvar cancer
678179|NCT00019110|stage III penile cancer
678180|NCT00019110|stage IV penile cancer
678181|NCT00019110|recurrent penile cancer
678182|NCT00019110|recurrent metastatic squamous neck cancer with occult primary
678183|NCT00019110|metastatic squamous neck cancer with occult primary squamous cell carcinoma
678184|NCT00019110|stage III squamous cell carcinoma of the lip and oral cavity
678185|NCT00019110|stage III basal cell carcinoma of the lip
678186|NCT00019110|stage III verrucous carcinoma of the oral cavity
678187|NCT00019110|stage III mucoepidermoid carcinoma of the oral cavity
678188|NCT00019110|stage III adenoid cystic carcinoma of the oral cavity
678189|NCT00019110|stage IV squamous cell carcinoma of the lip and oral cavity
678190|NCT00019110|stage IV basal cell carcinoma of the lip
678191|NCT00019110|stage IV verrucous carcinoma of the oral cavity
678192|NCT00019110|stage IV mucoepidermoid carcinoma of the oral cavity
678193|NCT00019110|recurrent squamous cell carcinoma of the lip and oral cavity
678194|NCT00019110|recurrent basal cell carcinoma of the lip
678195|NCT00019110|recurrent verrucous carcinoma of the oral cavity
678196|NCT00019110|recurrent mucoepidermoid carcinoma of the oral cavity
678197|NCT00019110|recurrent adenoid cystic carcinoma of the oral cavity
678198|NCT00019110|stage III squamous cell carcinoma of the oropharynx
678199|NCT00019110|stage III lymphoepithelioma of the oropharynx
678200|NCT00019110|stage IV squamous cell carcinoma of the oropharynx
678201|NCT00019110|stage IV lymphoepithelioma of the oropharynx
678202|NCT00019110|recurrent squamous cell carcinoma of the oropharynx
678203|NCT00019110|recurrent lymphoepithelioma of the oropharynx
678204|NCT00019110|stage III squamous cell carcinoma of the nasopharynx
678205|NCT00019110|stage III lymphoepithelioma of the nasopharynx
678206|NCT00019110|stage IV squamous cell carcinoma of the nasopharynx
678207|NCT00019110|stage IV lymphoepithelioma of the nasopharynx
678208|NCT00019110|recurrent squamous cell carcinoma of the nasopharynx
678209|NCT00019110|recurrent lymphoepithelioma of the nasopharynx
678210|NCT00019110|stage III squamous cell carcinoma of the hypopharynx
678211|NCT00019110|stage IV squamous cell carcinoma of the hypopharynx
678212|NCT00019110|recurrent squamous cell carcinoma of the hypopharynx
678213|NCT00019110|stage III squamous cell carcinoma of the larynx
678214|NCT00019110|stage III verrucous carcinoma of the larynx
678215|NCT00019110|stage IV squamous cell carcinoma of the larynx
678216|NCT00019110|stage IV verrucous carcinoma of the larynx
678217|NCT00019110|recurrent squamous cell carcinoma of the larynx
678218|NCT00019110|recurrent verrucous carcinoma of the larynx
678219|NCT00019110|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
678220|NCT00019110|stage III inverted papilloma of the paranasal sinus and nasal cavity
678221|NCT00019110|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
678222|NCT00019110|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
678223|NCT00019110|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
678224|NCT00019110|stage IV inverted papilloma of the paranasal sinus and nasal cavity
678225|NCT00019110|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
678226|NCT00019110|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
678227|NCT00019110|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
678228|NCT00019110|recurrent inverted papilloma of the paranasal sinus and nasal cavity
678229|NCT00019110|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
678230|NCT00019110|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
678231|NCT00019110|recurrent salivary gland cancer
678232|NCT00019110|stage IV salivary gland cancer
678233|NCT00019110|stage III salivary gland cancer
678234|NCT00019097|body system/site cancer
678235|NCT00019097|cancer
678236|NCT00019097|genetic condition
678237|NCT00019097|hematopoietic/lymphoid cancer
678238|NCT00019097|multiple myeloma
678239|NCT00019097|multiple myeloma and other plasma cell neoplasms
678240|NCT00019097|plasma cell neoplasm
678241|NCT00019097|refractory plasma cell neoplasm
678242|NCT00019097|stage II multiple myeloma
678243|NCT00019097|stage III multiple myeloma
678244|NCT00019097|stage, plasma cell neoplasm
678245|NCT00019084|stage IV colon cancer
678246|NCT00019084|stage IV breast cancer
678247|NCT00019084|recurrent breast cancer
678248|NCT00019084|recurrent non-small cell lung cancer
678249|NCT00019084|stage II pancreatic cancer
678250|NCT00019084|stage III pancreatic cancer
678251|NCT00019084|recurrent pancreatic cancer
678252|NCT00019084|recurrent colon cancer
678253|NCT00019084|recurrent cervical cancer
678254|NCT00019084|stage IVB cervical cancer
678255|NCT00019084|stage IV ovarian epithelial cancer
678256|NCT00019084|recurrent ovarian epithelial cancer
678257|NCT00019084|extensive stage small cell lung cancer
678258|NCT00019084|recurrent small cell lung cancer
678259|NCT00019084|stage IV non-small cell lung cancer
678260|NCT00019084|stage IV pancreatic cancer
678261|NCT00019071|adult glioblastoma
678262|NCT00019071|adult anaplastic astrocytoma
678263|NCT00019071|adult giant cell glioblastoma
678264|NCT00019071|adult gliosarcoma
678265|NCT00019058|adult glioblastoma
678266|NCT00019058|adult giant cell glioblastoma
678267|NCT00019058|adult gliosarcoma
678268|NCT00019032|refractory chronic lymphocytic leukemia
678269|NCT00019032|T-cell large granular lymphocyte leukemia
678270|NCT00019019|stage III adult Hodgkin lymphoma
678271|NCT00019019|stage IV adult Hodgkin lymphoma
678272|NCT00019019|stage IV breast cancer
678273|NCT00019019|stage IIIA breast cancer
678274|NCT00019019|recurrent breast cancer
678275|NCT00019019|stage IIIB breast cancer
678276|NCT00019019|recurrent non-small cell lung cancer
678277|NCT00019019|recurrent adult Hodgkin lymphoma
678278|NCT00019019|stage III cutaneous T-cell non-Hodgkin lymphoma
678279|NCT00019019|stage IV cutaneous T-cell non-Hodgkin lymphoma
678280|NCT00019019|recurrent cutaneous T-cell non-Hodgkin lymphoma
678281|NCT00019019|stage III renal cell cancer
678282|NCT00019019|stage IV renal cell cancer
678283|NCT00019019|recurrent renal cell cancer
678284|NCT00019019|stage III ovarian epithelial cancer
678285|NCT00019019|stage IV ovarian epithelial cancer
678286|NCT00019019|recurrent ovarian epithelial cancer
678287|NCT00019019|recurrent adult brain tumor
678288|NCT00019019|small intestine lymphoma
678289|NCT00019019|adult brain stem glioma
678290|NCT00019019|adult craniopharyngioma
678291|NCT00019019|adult medulloblastoma
678292|NCT00019019|adult meningioma
678293|NCT00019019|adult glioblastoma
678294|NCT00019019|stage III melanoma
678295|NCT00019019|stage IV melanoma
678296|NCT00019019|recurrent melanoma
678297|NCT00019019|stage IIIA non-small cell lung cancer
678298|NCT00019019|stage IIIB non-small cell lung cancer
678299|NCT00019019|stage IIIC breast cancer
678300|NCT00019019|stage IV non-small cell lung cancer
678301|NCT00019019|unspecified adult solid tumor, protocol specific
678302|NCT00019019|stage III grade 1 follicular lymphoma
678303|NCT00019019|stage III grade 2 follicular lymphoma
678304|NCT00019019|stage III grade 3 follicular lymphoma
678305|NCT00019019|stage III adult diffuse small cleaved cell lymphoma
678306|NCT00019019|stage III adult diffuse mixed cell lymphoma
678307|NCT00019019|stage III adult diffuse large cell lymphoma
678308|NCT00019019|stage III adult immunoblastic large cell lymphoma
678309|NCT00019019|stage III adult lymphoblastic lymphoma
678310|NCT00019019|stage III adult Burkitt lymphoma
678311|NCT00019019|stage IV grade 1 follicular lymphoma
678312|NCT00019019|stage IV grade 2 follicular lymphoma
678313|NCT00019019|stage IV grade 3 follicular lymphoma
678314|NCT00019019|stage IV adult diffuse small cleaved cell lymphoma
678315|NCT00019019|stage IV adult diffuse mixed cell lymphoma
678316|NCT00019019|stage IV adult diffuse large cell lymphoma
678317|NCT00019019|stage IV adult immunoblastic large cell lymphoma
678318|NCT00019019|stage IV adult lymphoblastic lymphoma
678319|NCT00019019|stage IV adult Burkitt lymphoma
678320|NCT00019019|recurrent grade 1 follicular lymphoma
678321|NCT00019019|recurrent grade 2 follicular lymphoma
678322|NCT00019019|recurrent grade 3 follicular lymphoma
678323|NCT00019019|recurrent adult diffuse small cleaved cell lymphoma
678324|NCT00019019|recurrent adult diffuse mixed cell lymphoma
678325|NCT00019019|recurrent adult diffuse large cell lymphoma
678326|NCT00019019|recurrent adult immunoblastic large cell lymphoma
678327|NCT00019019|recurrent adult lymphoblastic lymphoma
678328|NCT00019019|recurrent adult Burkitt lymphoma
678329|NCT00019019|stage III adult T-cell leukemia/lymphoma
678330|NCT00019019|stage IV adult T-cell leukemia/lymphoma
678331|NCT00019019|recurrent adult T-cell leukemia/lymphoma
678332|NCT00019019|adult anaplastic astrocytoma
678333|NCT00019019|adult myxopapillary ependymoma
678334|NCT00019019|adult anaplastic ependymoma
678335|NCT00019019|adult anaplastic oligodendroglioma
678336|NCT00019019|adult mixed glioma
678337|NCT00019019|adult central nervous system germ cell tumor
678338|NCT00019019|primary central nervous system non-Hodgkin lymphoma
678339|NCT00019019|adult pilocytic astrocytoma
678340|NCT00019019|adult subependymoma
678341|NCT00019019|adult ependymoblastoma
678342|NCT00019019|adult pineocytoma
678343|NCT00019019|adult pineoblastoma
678344|NCT00019019|adult meningeal hemangiopericytoma
678345|NCT00019019|intraocular lymphoma
678346|NCT00019019|stage III mantle cell lymphoma
678347|NCT00019019|stage IV mantle cell lymphoma
678348|NCT00019019|recurrent mantle cell lymphoma
678349|NCT00019019|angioimmunoblastic T-cell lymphoma
678565|NCT00017121|lung metastases
678350|NCT00019019|anaplastic large cell lymphoma
678351|NCT00019019|adult choroid plexus tumor
678352|NCT00019019|stage III mycosis fungoides/Sezary syndrome
678353|NCT00019019|stage IV mycosis fungoides/Sezary syndrome
678354|NCT00019019|recurrent mycosis fungoides/Sezary syndrome
678355|NCT00019019|recurrent marginal zone lymphoma
678356|NCT00019019|recurrent small lymphocytic lymphoma
678357|NCT00019019|stage III small lymphocytic lymphoma
678358|NCT00019019|stage III marginal zone lymphoma
678359|NCT00019019|stage IV small lymphocytic lymphoma
678360|NCT00019019|stage IV marginal zone lymphoma
678361|NCT00019019|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
678362|NCT00019019|nodal marginal zone B-cell lymphoma
678363|NCT00019019|splenic marginal zone lymphoma
678364|NCT00019019|adult grade III meningioma
678365|NCT00019019|adult oligodendroglioma
678366|NCT00019019|adult giant cell glioblastoma
678367|NCT00019019|adult gliosarcoma
678368|NCT00019006|adult solid tumor
678369|NCT00019006|body system/site cancer
678370|NCT00019006|cancer
678371|NCT00019006|colon cancer
678372|NCT00019006|colorectal cancer
678373|NCT00019006|extensive stage small cell lung cancer
678374|NCT00019006|gastrointestinal cancer
678375|NCT00019006|genetic condition
678376|NCT00019006|limited stage small cell lung cancer
678377|NCT00019006|lung cancer
678378|NCT00019006|non-small cell lung cancer
678379|NCT00019006|pancreatic cancer
678380|NCT00019006|rectal cancer
678381|NCT00019006|recurrent colon cancer
678382|NCT00019006|recurrent pancreatic cancer
678383|NCT00019006|recurrent rectal cancer
678384|NCT00019006|small cell lung cancer
678385|NCT00019006|solid tumor
678386|NCT00019006|stage I pancreatic cancer
678387|NCT00019006|stage II non-small cell lung cancer
678388|NCT00019006|stage II pancreatic cancer
678389|NCT00019006|stage III colon cancer
678390|NCT00019006|stage III non-small cell lung cancer
678391|NCT00019006|stage III pancreatic cancer
678392|NCT00019006|stage III rectal cancer
678393|NCT00019006|stage IV pancreatic cancer
678394|NCT00019006|stage IVA pancreatic cancer
678395|NCT00019006|stage IVB pancreatic cancer
678396|NCT00019006|stage, colon cancer
678397|NCT00019006|stage, non-small cell lung cancer
678398|NCT00019006|stage, pancreatic cancer
678399|NCT00019006|stage, rectal cancer
678400|NCT00019006|stage, small cell lung cancer
678401|NCT00019006|thorax/respiratory cancer
678402|NCT00018967|unspecified childhood solid tumor, protocol specific
678403|NCT00018967|unspecified adult solid tumor, protocol specific
678404|NCT00018967|neurotoxicity
678405|NCT00018954|stage I childhood lymphoblastic lymphoma
678406|NCT00018954|stage II childhood lymphoblastic lymphoma
678407|NCT00018954|stage III childhood lymphoblastic lymphoma
678408|NCT00018954|stage IV childhood lymphoblastic lymphoma
678409|NCT00018954|untreated adult acute lymphoblastic leukemia
678410|NCT00018954|untreated childhood acute lymphoblastic leukemia
678411|NCT00018954|stage I adult diffuse small cleaved cell lymphoma
678412|NCT00018954|stage I adult diffuse mixed cell lymphoma
678413|NCT00018954|stage I adult diffuse large cell lymphoma
678414|NCT00018954|stage I adult immunoblastic large cell lymphoma
678415|NCT00018954|stage I adult lymphoblastic lymphoma
678416|NCT00018954|stage I adult Burkitt lymphoma
678417|NCT00018954|stage III adult diffuse small cleaved cell lymphoma
678418|NCT00018954|stage III adult diffuse mixed cell lymphoma
678419|NCT00018954|stage III adult diffuse large cell lymphoma
678420|NCT00018954|stage III adult immunoblastic large cell lymphoma
678421|NCT00018954|stage III adult lymphoblastic lymphoma
678422|NCT00018954|stage III adult Burkitt lymphoma
678423|NCT00018954|stage IV adult diffuse small cleaved cell lymphoma
678424|NCT00018954|stage IV adult diffuse mixed cell lymphoma
678425|NCT00018954|stage IV adult diffuse large cell lymphoma
678426|NCT00018954|stage IV adult immunoblastic large cell lymphoma
678427|NCT00018954|stage IV adult lymphoblastic lymphoma
678428|NCT00018954|stage IV adult Burkitt lymphoma
678429|NCT00018954|stage I childhood small noncleaved cell lymphoma
678430|NCT00018954|stage I childhood large cell lymphoma
678431|NCT00018954|stage II childhood small noncleaved cell lymphoma
678432|NCT00018954|stage II childhood large cell lymphoma
678433|NCT00018954|stage III childhood small noncleaved cell lymphoma
678434|NCT00018954|stage III childhood large cell lymphoma
678435|NCT00018954|stage IV childhood small noncleaved cell lymphoma
678436|NCT00018954|stage IV childhood large cell lymphoma
678437|NCT00018954|stage I mantle cell lymphoma
678438|NCT00018954|contiguous stage II adult diffuse small cleaved cell lymphoma
678439|NCT00018954|contiguous stage II mantle cell lymphoma
678440|NCT00018954|contiguous stage II adult diffuse mixed cell lymphoma
678441|NCT00018954|contiguous stage II adult immunoblastic large cell lymphoma
678442|NCT00018954|contiguous stage II adult diffuse large cell lymphoma
678443|NCT00018954|contiguous stage II adult Burkitt lymphoma
678444|NCT00018954|contiguous stage II adult lymphoblastic lymphoma
678445|NCT00018954|noncontiguous stage II adult diffuse small cleaved cell lymphoma
678446|NCT00018954|noncontiguous stage II mantle cell lymphoma
678809|NCT00017953|Heart Attack
678447|NCT00018954|noncontiguous stage II adult diffuse mixed cell lymphoma
678448|NCT00018954|noncontiguous stage II adult immunoblastic large cell lymphoma
678449|NCT00018954|noncontiguous stage II adult diffuse large cell lymphoma
678450|NCT00018954|noncontiguous stage II adult Burkitt lymphoma
678451|NCT00018954|noncontiguous stage II adult lymphoblastic lymphoma
678452|NCT00018954|stage III mantle cell lymphoma
678453|NCT00018954|stage IV mantle cell lymphoma
678454|NCT00018954|noncontiguous stage II small lymphocytic lymphoma
678455|NCT00018954|noncontiguous stage II marginal zone lymphoma
678456|NCT00018954|stage I marginal zone lymphoma
678457|NCT00018954|stage I small lymphocytic lymphoma
678458|NCT00018954|stage III small lymphocytic lymphoma
678459|NCT00018954|stage III marginal zone lymphoma
678460|NCT00018954|stage IV small lymphocytic lymphoma
678461|NCT00018954|stage IV marginal zone lymphoma
678462|NCT00018954|contiguous stage II marginal zone lymphoma
678463|NCT00018954|contiguous stage II small lymphocytic lymphoma
678464|NCT00018954|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
678465|NCT00018954|nodal marginal zone B-cell lymphoma
678466|NCT00018954|splenic marginal zone lymphoma
678467|NCT00018941|stage IV renal cell cancer
678468|NCT00018941|recurrent renal cell cancer
678469|NCT00018902|Depressive Disorder
678470|NCT00018902|Adolescents
678471|NCT00018902|Teenagers
678472|NCT00018902|Teens
678473|NCT00018902|Cognitive Behavior Therapy
678474|NCT00018889|Clinical Evaluation
678475|NCT00018889|Genetic Study
678476|NCT00018889|Essential Tremor
678477|NCT00018889|Familial Myoclonus
678478|NCT00018889|Hereditary Ataxia
678479|NCT00018889|Movement Disorder
678480|NCT00018889|Inherited Movement Disorder
678481|NCT00018876|Epidural fibrosis
678482|NCT00018876|Failed back surgery syndrome
678483|NCT00018876|Postlaminectomy syndrome
678484|NCT00018876|Lumbar laminectomy
678485|NCT00018876|Radiotherapy
678486|NCT00018876|Radiation
678487|NCT00018876|Perineural scar formation
678488|NCT00018876|Peridural fibrosis
678489|NCT00018876|Back surgery
678490|NCT00018863|ADHD
678491|NCT00018850|schizophrenia
678492|NCT00018850|ondansetron
678493|NCT00018850|nicotine
678494|NCT00018850|haloperidol
678495|NCT00018811|Relaxation Techniques
678496|NCT00018811|Behavior Therapy Feedback
678497|NCT00018811|Psychophysiology
678498|NCT00018798|Combat-Related PTSD, Vietnam Veterans
678499|NCT00018785|kidney transplantation
678500|NCT00018785|immunosuppression
678501|NCT00018785|bone marrow
678502|NCT00018772|coagulation
678503|NCT00018772|thrombosis genetic markers
678504|NCT00018759|Serotonin, Hypertension, Depression
678505|NCT00018733|Depression
678506|NCT00018720|triglyceride
678507|NCT00018720|bile acids
678508|NCT00018720|cholelithias
678509|NCT00018694|bile acid synthesis
678510|NCT00018694|chenodeoxycholic acid
678511|NCT00018694|sterol 27-hydroxylase
678512|NCT00018668|Antipsychotics
678513|NCT00018668|schizophrenia
678514|NCT00018668|motor retardation
678515|NCT00018668|bradykinesia
678516|NCT00018655|Mood Disorders
678517|NCT00018655|Substance-Related Disorders
678518|NCT00018642|quetiapine
678519|NCT00018642|haloperidol decanoate
678520|NCT00018629|Aging
678521|NCT00018629|Neuropsychology
678522|NCT00018629|Psychotherapy
678523|NCT00018629|Rehabilitation
678524|NCT00018629|Schizophrenia
678525|NCT00018616|compliance
678526|NCT00018616|MEMS
678527|NCT00018616|metformin
678528|NCT00018603|PTSD
678529|NCT00018395|Calcium Metabolism
678530|NCT00016679|Pharmacokinetics
678531|NCT00016679|Metabolism
678532|NCT00016679|Toxicity
678533|NCT00016679|Side Effects
678534|NCT00016679|Essential Tremor
678535|NCT00016679|Tremor
678536|NCT00016679|Movement Disorder
678537|NCT00018590|Vascular Diseases
678538|NCT00018538|vitamin D
678539|NCT00018538|prostatic neoplasms
678540|NCT00018538|neoplasm recurrence
678541|NCT00018512|dental implant
678542|NCT00018499|Traumatic Brain Injury
678543|NCT00018473|Risk Factors
678544|NCT00018473|Genes
678545|NCT00018473|Epidemiology
678546|NCT00018473|Apolipoproteins E
678547|NCT00018473|Alzheimer's Disease
678548|NCT00018460|geriatrics
678549|NCT00018460|vitamin B complex
678550|NCT00018460|thrombomodulin
678551|NCT00018460|anticoagulants
678552|NCT00018447|osteoporosis
678553|NCT00018434|Infection
678554|NCT00018421|Cerebrovascular Disorders
678555|NCT00018421|Exercise
678556|NCT00018421|Rehabilitation
678557|NCT00018408|COPD
678558|NCT00018408|Smoking
678559|NCT00017147|adult glioblastoma
678560|NCT00017147|adult giant cell glioblastoma
678561|NCT00017147|adult gliosarcoma
678562|NCT00017134|ovarian epithelial cancer
678563|NCT00017121|stage IV melanoma
678564|NCT00017121|recurrent melanoma
678566|NCT00017108|stage III chronic lymphocytic leukemia
678567|NCT00017108|stage IV chronic lymphocytic leukemia
678568|NCT00017108|B-cell chronic lymphocytic leukemia
678569|NCT00017095|stage II breast cancer
678570|NCT00017095|stage IIIA breast cancer
678571|NCT00017095|stage IIIB breast cancer
678572|NCT00017095|stage IIIC breast cancer
678573|NCT00017095|inflammatory breast cancer
678574|NCT00017082|stage IV colon cancer
678575|NCT00017082|stage IV rectal cancer
678576|NCT00017082|recurrent colon cancer
678577|NCT00017082|recurrent rectal cancer
678578|NCT00017082|adenocarcinoma of the colon
678579|NCT00017082|adenocarcinoma of the rectum
678580|NCT00017069|refractory multiple myeloma
678581|NCT00017069|stage II multiple myeloma
678582|NCT00017069|stage III multiple myeloma
678583|NCT00017056|stage IV gastric cancer
678584|NCT00017056|recurrent gastric cancer
678585|NCT00017056|stage IV esophageal cancer
678586|NCT00017056|recurrent esophageal cancer
678587|NCT00017056|adenocarcinoma of the stomach
678588|NCT00017056|adenocarcinoma of the esophagus
678589|NCT00017043|stage IV gastric cancer
678590|NCT00017043|recurrent gastric cancer
678591|NCT00017043|stage IV esophageal cancer
678592|NCT00017043|recurrent esophageal cancer
678593|NCT00017043|adenocarcinoma of the stomach
678594|NCT00017043|adenocarcinoma of the esophagus
678595|NCT00017030|stage III adult soft tissue sarcoma
678596|NCT00017030|recurrent adult soft tissue sarcoma
678597|NCT00017030|stage IV adult soft tissue sarcoma
678598|NCT00017017|recurrent ovarian epithelial cancer
678599|NCT00017017|fallopian tube cancer
678600|NCT00017017|primary peritoneal cavity cancer
678601|NCT00016991|recurrent adult brain tumor
678602|NCT00016991|adult glioblastoma
678603|NCT00016991|adult giant cell glioblastoma
678604|NCT00016991|adult gliosarcoma
678605|NCT00016978|stage IV colon cancer
678606|NCT00016978|stage IV rectal cancer
678607|NCT00016978|recurrent colon cancer
678608|NCT00016978|recurrent rectal cancer
678609|NCT00016978|adenocarcinoma of the colon
678610|NCT00016978|adenocarcinoma of the rectum
678611|NCT00016965|stage II pancreatic cancer
678612|NCT00016965|stage III pancreatic cancer
678613|NCT00016965|recurrent pancreatic cancer
678614|NCT00016965|adenocarcinoma of the pancreas
678615|NCT00016965|stage IV pancreatic cancer
678616|NCT00018369|Aging
678617|NCT00018369|Hydrocortisone Corticotropin Feedback
678618|NCT00018356|Aging
678619|NCT00018356|nutrition
678620|NCT00018356|rehabilitation
678621|NCT00018330|Behavioral
678622|NCT00018330|Weight Loss
678623|NCT00018330|Genetics
678624|NCT00018330|Lipoprotein lipase
678625|NCT00018330|Visceral fat
678626|NCT00018330|Lipoprotein
678627|NCT00018317|Diet
678628|NCT00018317|exercise
678629|NCT00018304|blood pressure
678630|NCT00018304|insulin sensitivity
678631|NCT00018304|blood flow
678632|NCT00018291|Dementia
678633|NCT00018291|Agitated Behavior
678634|NCT00018291|Behavioral disturbance
678635|NCT00018265|Rehabilitation
678636|NCT00018265|exercise test
678637|NCT00018265|aging
678638|NCT00018213|Naltrexone
678639|NCT00018213|Nicotine patch
678640|NCT00018213|Tobacco dependence
678641|NCT00018200|analgesia
678642|NCT00018200|Back pain
678643|NCT00018200|sciatica
678644|NCT00016952|stage IV colon cancer
678645|NCT00016952|stage IV rectal cancer
678646|NCT00016952|recurrent colon cancer
678647|NCT00016952|recurrent rectal cancer
678648|NCT00016952|adenocarcinoma of the colon
678649|NCT00016952|adenocarcinoma of the rectum
678650|NCT00016939|stage III renal cell cancer
678651|NCT00016939|stage IV renal cell cancer
678652|NCT00016939|recurrent renal cell cancer
678653|NCT00016926|stage III cervical cancer
678654|NCT00016926|recurrent cervical cancer
678655|NCT00016926|stage IVB cervical cancer
678656|NCT00016926|stage IVA cervical cancer
678657|NCT00016926|cervical squamous cell carcinoma
678658|NCT00016913|adenocarcinoma of the prostate
678659|NCT00016913|stage III prostate cancer
678660|NCT00016900|stage III esophageal cancer
678661|NCT00016900|stage IV esophageal cancer
678662|NCT00016900|recurrent esophageal cancer
678663|NCT00016900|squamous cell carcinoma of the esophagus
678664|NCT00016900|adenocarcinoma of the esophagus
678665|NCT00016887|stage III mantle cell lymphoma
678666|NCT00016887|stage IV mantle cell lymphoma
678667|NCT00016874|unspecified adult solid tumor, protocol specific
678668|NCT00016861|unspecified childhood solid tumor, protocol specific
678669|NCT00016848|Obesity
678670|NCT00016848|Endocrine
678671|NCT00016848|Diet
678672|NCT00016848|Metabolism
678673|NCT00016848|Macronutrients
678674|NCT00016835|Type 2 diabetes mellitus
678675|NCT00016796|Reading
678676|NCT00016796|Naming
678677|NCT00016783|Drug Therapy, Combination
678678|NCT00016783|Drug Administration Schedule
678679|NCT00016783|HIV Protease Inhibitors
678680|NCT00016783|CD4 Lymphocyte Count
678681|NCT00016783|CD8-Positive T-Lymphocytes
678682|NCT00016783|Reverse Transcriptase Inhibitors
678683|NCT00016783|Anti-HIV Agents
678684|NCT00016783|Viral Load
678685|NCT00016783|Antiretroviral Therapy, Highly Active
678686|NCT00016783|Treatment Experienced
678687|NCT00016783|Treatment Interruption
678688|NCT00016731|Depression
678689|NCT00016731|Anxiety
678690|NCT00016731|CAH
678691|NCT00016731|Adults
678692|NCT00016731|FMPP
678693|NCT00016731|Emotion
678694|NCT00016731|Cushing's Syndrome
678695|NCT00016731|Adolescence
678696|NCT00016731|Magnetic Resonance Imaging
678697|NCT00016731|fMRI
678698|NCT00016731|Healthy Volunteer
678699|NCT00016731|HV
678700|NCT00016731|MRI
678701|NCT00016718|Didanosine
678702|NCT00016718|Drug Therapy, Combination
678703|NCT00016718|Drug Administration Schedule
678704|NCT00016718|Reverse Transcriptase Inhibitors
678705|NCT00016718|Anti-HIV Agents
678706|NCT00016718|Pharmacokinetics
678707|NCT00016718|Deoxycytidine
678708|NCT00016718|Efavirenz
678709|NCT00016718|Treatment Naive
678710|NCT00016692|Drug tolerance
678711|NCT00016692|Acute Infection
678712|NCT00018187|smoking cessation
678713|NCT00018187|bupropion
678714|NCT00018187|mecamylamine
678715|NCT00018187|nicotine
678716|NCT00018174|Depression
678717|NCT00018174|Fluoxetine
678718|NCT00018174|Nicotine dependence
678719|NCT00018161|Nicotine
678720|NCT00018161|addiction
678721|NCT00018161|cigarette smoking
678722|NCT00018148|smoking cessation
678723|NCT00018135|high iPTH levels
678724|NCT00018122|Islet cell transplant
678725|NCT00018096|Genetics
678726|NCT00018096|Lipopolysaccharide
678727|NCT00018070|Age-Related Macular Degeneration
678728|NCT00018070|Choroid
678729|NCT00018070|Blood Vessels
678730|NCT00018070|Choroidal Neovascularization
678731|NCT00018070|Laser
678732|NCT00018070|Macular Degeneration
678733|NCT00018070|AMD
678734|NCT00018057|fMRI
678735|NCT00018057|SSRI
678736|NCT00018057|Neuropsychological
678737|NCT00018057|Evaluative Learning
678738|NCT00018057|Adolescent
678739|NCT00018057|Normal Volunteers
678740|NCT00018057|Magnetic Resonance Imaging
678741|NCT00018057|CBT
678742|NCT00018057|IPT
678743|NCT00018057|Anxiety
678744|NCT00018057|Anxiety Disorder
678745|NCT00018057|Mood Disorder
678746|NCT00018057|Depression
678747|NCT00018057|Healthy Volunteer
678748|NCT00018057|Normal Control
678749|NCT00018044|Morphotype
678750|NCT00018044|Pulmonary
678751|NCT00018044|Infection
678752|NCT00018044|Mycobacterium
678753|NCT00018044|Nontuberculous
678754|NCT00018044|Mycobacterial Infection
678755|NCT00018044|Nontuberculous Mycobacterial Infection
678756|NCT00018044|NTM
678757|NCT00018044|Job's Syndrome
678758|NCT00018044|Job Syndrome
678759|NCT00018044|Cystic Fibrosis
678760|NCT00018044|CF
678761|NCT00018031|Liver Disease
678762|NCT00018031|Virologic Response
678763|NCT00018031|Immune Mechanisms
678764|NCT00018031|Cirrhosis
678765|NCT00018031|Eradication
678766|NCT00018031|HIV
678767|NCT00018031|Hepatitis C
678768|NCT00018018|Gene Therapy
678769|NCT00018018|ADA-SCID
678770|NCT00018018|Stem Cells
678771|NCT00018018|Retroviruses
678772|NCT00018018|Immune Deficiency Disease
678773|NCT00018018|Adenosine Deaminase Deficiency
678774|NCT00018018|ADA-Deficiency
678775|NCT00018018|Retroviral Vectors
678776|NCT00018018|Hematopoietic Progenitors
678777|NCT00018018|Severe Combined Immunodeficiency
678778|NCT00018018|SCID
678779|NCT00018018|Immune Deficiency
678780|NCT00018005|Heart Failure
678781|NCT00018005|Self-Management
678782|NCT00018005|Behavioral Clinical Trial
678783|NCT00017992|HIV-1
678784|NCT00017992|Drug Administration Schedule
678785|NCT00017992|Stavudine
678786|NCT00017992|HIV Protease Inhibitors
678787|NCT00017992|Ritonavir
678788|NCT00017992|Reverse Transcriptase Inhibitors
678789|NCT00017992|Anti-HIV Agents
678790|NCT00017992|Pharmacokinetics
678791|NCT00017992|ABT 378
678792|NCT00017992|emtricitabine
678793|NCT00017979|Transcranial Magnetic Stimulation
678794|NCT00017979|Motor Cortex
678795|NCT00017979|Motor Imagery
678796|NCT00017979|Reaction Time
678797|NCT00017979|Cerebral Inhibition
678798|NCT00017979|Healthy Volunteer
678799|NCT00017979|Normal Control
678800|NCT00017966|Transcranial Magnetic Stimulation
678801|NCT00017966|Motor Cortex
678802|NCT00017966|Cerebral Inhibition
678803|NCT00017966|Corpus Callosum
678804|NCT00017966|Evoked Potential
678805|NCT00017966|Healthy Volunteer
678806|NCT00017966|Normal Control
678807|NCT00017953|Diabetes
678808|NCT00017953|Weight loss
678810|NCT00017953|Heart disease
678811|NCT00017953|Lifestyle Intervention
678812|NCT00017953|Physical Fitness/Physical Activity
678813|NCT00017953|Psychosocial outcomes (e.g., depression, eating disorders)
678814|NCT00017953|Bone Density
678815|NCT00017940|Gene Therapy
678816|NCT00017927|Acromegaly
678817|NCT00017927|McCune-Albright Syndrome
678818|NCT00017927|IGF-1
678819|NCT00017927|Adenoma
678820|NCT00017927|Hyperplasia
678821|NCT00017927|MAS
678822|NCT00017927|Polyostotic Fibrous Dysplasia
678823|NCT00017927|PFD
678824|NCT00017914|Adult and Pediatric Disease
678825|NCT00017914|Idiopathic Inflammatory Myopathies
678826|NCT00017914|Autoimmunity Pathogenesis
678827|NCT00017914|Disease Assessment
678828|NCT00017914|Genetic and Environmental Risk Factors
678829|NCT00017914|Idiopathic Inflammatory Myopathy
678830|NCT00017875|Transcranial Magnetic Stimulation
678831|NCT00017875|Intracortical Inhibition
678832|NCT00017875|Dystonia
678833|NCT00017875|Focal Dystonia
678834|NCT00017875|Dystonic Disorder
678835|NCT00017875|DYTI Dystonia
678836|NCT00017875|Movement Disorder
678837|NCT00017875|Generalized Dystonia
678838|NCT00017875|Healthy Control
678839|NCT00017875|Normal Volunteer
678840|NCT00017862|Eosinophils
678841|NCT00017862|Monoclonal Antibody
678842|NCT00017862|Hypereosinophilia
678843|NCT00017862|Biologicals
678844|NCT00017862|Hypereosinophilic Syndrome
678845|NCT00017823|complementary therapies
678846|NCT00017823|Acupressure
678847|NCT00017823|HIV Infections
678848|NCT00017823|Nausea
678849|NCT00017823|Vomiting
678850|NCT00017810|complementary therapies
678851|NCT00017810|Behavior Therapy
678852|NCT00017810|Diarrhea
678853|NCT00017810|Diet Therapy
678854|NCT00017810|Food
678855|NCT00017810|HIV Seropositivity
678856|NCT00017797|Pregnancy Complications, Infectious
678857|NCT00017797|HIV-1
678858|NCT00017797|HIV Protease Inhibitors
678859|NCT00017797|Reverse Transcriptase Inhibitors
678860|NCT00017797|Anti-HIV Agents
678861|NCT00017797|Glucose Intolerance
678862|NCT00017784|AIDS-Related Opportunistic Infections
678863|NCT00017784|Infusions, Intravenous
678864|NCT00017784|Antiviral Agents
678865|NCT00017784|Cytomegalovirus Retinitis
678866|NCT00017784|valganciclovir
678867|NCT00017771|HIV-1
678868|NCT00017771|CD4 Lymphocyte Count
678869|NCT00017771|Risk Factors
678870|NCT00017771|Hydroxyurea
678871|NCT00017771|Disease Progression
678872|NCT00017771|Alcohol Drinking
678873|NCT00017771|Reverse Transcriptase Inhibitors
678874|NCT00017771|Anti-HIV Agents
678875|NCT00017771|Viral Load
678876|NCT00017771|Polyneuropathies
678877|NCT00017771|Treatment Experienced
678878|NCT00017758|Drug Interactions
678879|NCT00017758|Nelfinavir
678880|NCT00017758|Reverse Transcriptase Inhibitors
678881|NCT00017758|Anti-HIV Agents
678882|NCT00017758|Pharmacokinetics
678883|NCT00017758|Pravastatin
678884|NCT00017758|efavirenz
678885|NCT00017758|Simvastatin
678886|NCT00017758|atorvastatin
678887|NCT00017758|Hydroxymethylglutaryl-CoA Reductase Inhibitors
678888|NCT00017745|DNA
678889|NCT00017745|Hereditary Myopathies
678890|NCT00017745|Intermediate Filaments
678891|NCT00017745|Cardiomyopathies
678892|NCT00017745|Genetic Testing
678893|NCT00017745|Myopathy
678894|NCT00017745|Inherited Neuromuscular Disorder
678895|NCT00017732|Malformations
678896|NCT00017732|Ethnicity
678897|NCT00017732|Mutations
678898|NCT00017732|Cholesterol
678899|NCT00017732|Metabolism
678900|NCT00017732|Smith-Lemli-Opitz Syndrome
678901|NCT00017732|SLOS
678902|NCT00017732|Cholesterol Metabolism
678903|NCT00017719|Pregnancy Complications, Infectious
678904|NCT00017719|HIV Protease Inhibitors
678905|NCT00017719|Reverse Transcriptase Inhibitors
678906|NCT00017719|Anti-HIV Agents
678907|NCT00017719|Viral Load
678908|NCT00017719|Combivir
678909|NCT00017719|Treatment Naive
678910|NCT00017706|physician education
678911|NCT00017706|behavioral weight control
678912|NCT00017706|physician intervention
678913|NCT00017706|obesity counseling
678914|NCT00017693|Recombinant Proteins
678915|NCT00017693|Aerosols
678916|NCT00017693|Asthma
678917|NCT00017693|Receptors, Interleukin-4
678918|NCT00017693|Forced Expiratory Volume
678919|NCT00017680|amyloidosis
678920|NCT00017680|arthritis & connective tissue diseases
678921|NCT00017680|genetic diseases and dysmorphic syndromes
678922|NCT00017680|hematopoietic/lymphoid cancer
678923|NCT00017680|oncologic disorders
678924|NCT00017680|plasma cell neoplasm
678925|NCT00017680|primary systemic amyloidosis
678926|NCT00017680|rare disease
678927|NCT00017654|aplastic anemia
678928|NCT00017654|disease-related problem/condition
678929|NCT00017654|graft versus host disease
678930|NCT00017654|hematologic disorders
678931|NCT00017654|rare disease
678932|NCT00017641|arthritis & connective tissue diseases
678933|NCT00017641|immunologic disorders and infectious disorders
678934|NCT00017641|rare disease
678935|NCT00017641|systemic lupus erythematosus
678936|NCT00017628|multiple sclerosis
678937|NCT00017628|neurologic and psychiatric disorders
678938|NCT00017628|rare disease
678939|NCT00017602|refractory multiple myeloma
678940|NCT00017602|stage I multiple myeloma
678941|NCT00017602|stage II multiple myeloma
678942|NCT00017602|stage III multiple myeloma
678943|NCT00017589|recurrent adult acute myeloid leukemia
678944|NCT00017576|adenocarcinoma of the prostate
678945|NCT00017576|stage IV prostate cancer
678946|NCT00017576|recurrent prostate cancer
678947|NCT00017563|adenocarcinoma of the prostate
678948|NCT00017563|stage II prostate cancer
678949|NCT00017563|stage III prostate cancer
678950|NCT00017550|refractory anemia
678951|NCT00017550|refractory anemia with excess blasts
678952|NCT00017550|de novo myelodysplastic syndromes
678953|NCT00017550|previously treated myelodysplastic syndromes
678954|NCT00017537|stage IV breast cancer
678955|NCT00017537|recurrent breast cancer
678956|NCT00017537|stage IV gastric cancer
678957|NCT00017537|recurrent gastric cancer
678958|NCT00017537|recurrent non-small cell lung cancer
678959|NCT00017537|stage IV ovarian epithelial cancer
678960|NCT00017537|recurrent ovarian epithelial cancer
678961|NCT00017537|adenocarcinoma of the stomach
678962|NCT00017537|stage IV non-small cell lung cancer
678963|NCT00017537|unspecified adult solid tumor, protocol specific
678964|NCT00017524|unspecified adult solid tumor, protocol specific
678965|NCT00017511|stage I salivary gland cancer
678966|NCT00017511|stage II salivary gland cancer
678967|NCT00017511|stage III salivary gland cancer
678968|NCT00017511|stage IV salivary gland cancer
678969|NCT00017511|recurrent salivary gland cancer
678970|NCT00017511|untreated metastatic squamous neck cancer with occult primary
678971|NCT00017511|recurrent metastatic squamous neck cancer with occult primary
678972|NCT00017511|metastatic squamous neck cancer with occult primary squamous cell carcinoma
678973|NCT00017511|oral complications
678974|NCT00017511|stage I squamous cell carcinoma of the lip and oral cavity
678975|NCT00017511|stage I basal cell carcinoma of the lip
678976|NCT00017511|stage I verrucous carcinoma of the oral cavity
678977|NCT00017511|stage I mucoepidermoid carcinoma of the oral cavity
678978|NCT00017511|stage I adenoid cystic carcinoma of the oral cavity
678979|NCT00017511|stage II squamous cell carcinoma of the lip and oral cavity
678980|NCT00017511|stage II basal cell carcinoma of the lip
678981|NCT00017511|stage II verrucous carcinoma of the oral cavity
678982|NCT00017511|stage II mucoepidermoid carcinoma of the oral cavity
678983|NCT00017511|stage II adenoid cystic carcinoma of the oral cavity
678984|NCT00017511|stage III squamous cell carcinoma of the lip and oral cavity
678985|NCT00017511|stage III basal cell carcinoma of the lip
678986|NCT00017511|stage III verrucous carcinoma of the oral cavity
678987|NCT00017511|stage III mucoepidermoid carcinoma of the oral cavity
678988|NCT00017511|stage III adenoid cystic carcinoma of the oral cavity
678989|NCT00017511|stage IV squamous cell carcinoma of the lip and oral cavity
678990|NCT00017511|stage IV basal cell carcinoma of the lip
678991|NCT00017511|stage IV verrucous carcinoma of the oral cavity
678992|NCT00017511|stage IV mucoepidermoid carcinoma of the oral cavity
678993|NCT00017511|stage IV adenoid cystic carcinoma of the oral cavity
678994|NCT00017511|recurrent squamous cell carcinoma of the lip and oral cavity
678995|NCT00017511|recurrent basal cell carcinoma of the lip
678996|NCT00017511|recurrent verrucous carcinoma of the oral cavity
678997|NCT00017511|recurrent mucoepidermoid carcinoma of the oral cavity
678998|NCT00017511|recurrent adenoid cystic carcinoma of the oral cavity
678999|NCT00017511|stage I squamous cell carcinoma of the oropharynx
679000|NCT00017511|stage I lymphoepithelioma of the oropharynx
679001|NCT00017511|stage II squamous cell carcinoma of the oropharynx
679002|NCT00017511|stage II lymphoepithelioma of the oropharynx
679003|NCT00017511|stage III squamous cell carcinoma of the oropharynx
679004|NCT00017511|stage III lymphoepithelioma of the oropharynx
679005|NCT00017511|stage IV squamous cell carcinoma of the oropharynx
679006|NCT00017511|stage IV lymphoepithelioma of the oropharynx
679007|NCT00017511|recurrent squamous cell carcinoma of the oropharynx
679008|NCT00017511|recurrent lymphoepithelioma of the oropharynx
679009|NCT00017511|stage I squamous cell carcinoma of the nasopharynx
679010|NCT00017511|stage I lymphoepithelioma of the nasopharynx
679011|NCT00017511|stage II squamous cell carcinoma of the nasopharynx
679012|NCT00017511|stage II lymphoepithelioma of the nasopharynx
679013|NCT00017511|stage III squamous cell carcinoma of the nasopharynx
679014|NCT00017511|stage III lymphoepithelioma of the nasopharynx
679015|NCT00017511|stage IV squamous cell carcinoma of the nasopharynx
679016|NCT00017511|stage IV lymphoepithelioma of the nasopharynx
679017|NCT00017511|recurrent squamous cell carcinoma of the nasopharynx
679018|NCT00017511|recurrent lymphoepithelioma of the nasopharynx
679019|NCT00017511|stage I squamous cell carcinoma of the hypopharynx
679020|NCT00017511|stage II squamous cell carcinoma of the hypopharynx
679021|NCT00017511|stage III squamous cell carcinoma of the hypopharynx
679022|NCT00017511|stage IV squamous cell carcinoma of the hypopharynx
679023|NCT00017511|recurrent squamous cell carcinoma of the hypopharynx
679024|NCT00017511|stage I squamous cell carcinoma of the larynx
679025|NCT00017511|stage I verrucous carcinoma of the larynx
679026|NCT00017511|stage II squamous cell carcinoma of the larynx
679027|NCT00017511|stage II verrucous carcinoma of the larynx
679028|NCT00017511|stage III squamous cell carcinoma of the larynx
679029|NCT00017511|stage III verrucous carcinoma of the larynx
679030|NCT00017511|stage IV squamous cell carcinoma of the larynx
679031|NCT00017511|stage IV verrucous carcinoma of the larynx
679032|NCT00017511|recurrent squamous cell carcinoma of the larynx
679033|NCT00017511|recurrent verrucous carcinoma of the larynx
679034|NCT00017511|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
679035|NCT00017511|stage I inverted papilloma of the paranasal sinus and nasal cavity
679036|NCT00017511|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
679037|NCT00017511|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
679038|NCT00017511|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
679039|NCT00017511|stage II inverted papilloma of the paranasal sinus and nasal cavity
679040|NCT00017511|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
679041|NCT00017511|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
679042|NCT00017511|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
679043|NCT00017511|stage III inverted papilloma of the paranasal sinus and nasal cavity
679044|NCT00017511|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
679045|NCT00017511|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
679046|NCT00017511|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
679047|NCT00017511|stage IV inverted papilloma of the paranasal sinus and nasal cavity
679048|NCT00017511|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
679049|NCT00017511|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
679050|NCT00017511|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
679051|NCT00017511|recurrent inverted papilloma of the paranasal sinus and nasal cavity
679052|NCT00017511|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
679053|NCT00017511|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
679054|NCT00017511|radiation toxicity
679055|NCT00017498|stage IV salivary gland cancer
679056|NCT00017498|recurrent salivary gland cancer
679057|NCT00017498|salivary gland adenoid cystic carcinoma
679058|NCT00017498|stage IV adenoid cystic carcinoma of the oral cavity
679059|NCT00017498|recurrent adenoid cystic carcinoma of the oral cavity
679060|NCT00017485|basal cell carcinoma of the skin
679061|NCT00017485|recurrent skin cancer
679062|NCT00017459|recurrent non-small cell lung cancer
679063|NCT00017459|stage IIIB non-small cell lung cancer
679064|NCT00017459|stage IV non-small cell lung cancer
679065|NCT00017446|stage III adult soft tissue sarcoma
679066|NCT00017446|recurrent adult soft tissue sarcoma
679067|NCT00017446|stage IV adult soft tissue sarcoma
679068|NCT00017433|refractory multiple myeloma
679069|NCT00017433|stage II multiple myeloma
679070|NCT00017433|stage III multiple myeloma
679071|NCT00017407|recurrent non-small cell lung cancer
679072|NCT00017407|stage IIIB non-small cell lung cancer
679073|NCT00017407|stage IV non-small cell lung cancer
679074|NCT00017368|regional neuroblastoma
679075|NCT00017368|disseminated neuroblastoma
679076|NCT00017368|localized unresectable neuroblastoma
679077|NCT00017368|stage 4S neuroblastoma
679078|NCT00017355|stage IV melanoma
679079|NCT00017355|recurrent melanoma
679080|NCT00017342|recurrent adult acute myeloid leukemia
679081|NCT00017342|adult acute myeloid leukemia with t(8;21)(q22;q22)
679082|NCT00017342|adult acute myeloid leukemia with t(16;16)(p13;q22)
679083|NCT00017342|adult acute myeloid leukemia with inv(16)(p13;q22)
679084|NCT00017342|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
679085|NCT00017342|adult acute myeloid leukemia with t(15;17)(q22;q12)
679086|NCT00017329|stage IV renal cell cancer
679087|NCT00017316|stage IV melanoma
679088|NCT00017316|recurrent melanoma
679089|NCT00017303|stage III ovarian epithelial cancer
679090|NCT00017303|ovarian undifferentiated adenocarcinoma
679091|NCT00017303|ovarian mixed epithelial carcinoma
679092|NCT00017303|ovarian serous cystadenocarcinoma
679093|NCT00017303|ovarian mucinous cystadenocarcinoma
679094|NCT00017303|ovarian endometrioid adenocarcinoma
679095|NCT00017303|ovarian clear cell cystadenocarcinoma
679096|NCT00017303|primary peritoneal cavity cancer
679097|NCT00017303|Brenner tumor
679098|NCT00017290|stage III grade 1 follicular lymphoma
679099|NCT00017290|stage III grade 2 follicular lymphoma
679100|NCT00017290|stage III grade 3 follicular lymphoma
679101|NCT00017290|stage IV grade 1 follicular lymphoma
679102|NCT00017290|stage IV grade 2 follicular lymphoma
679103|NCT00017290|stage IV grade 3 follicular lymphoma
679104|NCT00017277|stage I squamous cell carcinoma of the lip and oral cavity
679105|NCT00017277|stage II squamous cell carcinoma of the lip and oral cavity
679106|NCT00017277|stage III squamous cell carcinoma of the lip and oral cavity
679107|NCT00017277|stage IV squamous cell carcinoma of the lip and oral cavity
679108|NCT00017277|stage I squamous cell carcinoma of the oropharynx
679109|NCT00017277|stage II squamous cell carcinoma of the oropharynx
679110|NCT00017277|stage III squamous cell carcinoma of the oropharynx
679111|NCT00017277|stage IV squamous cell carcinoma of the oropharynx
679112|NCT00017277|stage I squamous cell carcinoma of the hypopharynx
679113|NCT00017277|stage II squamous cell carcinoma of the hypopharynx
679114|NCT00017277|stage III squamous cell carcinoma of the hypopharynx
679115|NCT00017277|stage IV squamous cell carcinoma of the hypopharynx
679116|NCT00017277|stage I squamous cell carcinoma of the larynx
679117|NCT00017277|stage II squamous cell carcinoma of the larynx
679118|NCT00017277|stage III squamous cell carcinoma of the larynx
679119|NCT00017277|stage IV squamous cell carcinoma of the larynx
679120|NCT00017264|recurrent adult brain tumor
679121|NCT00017264|adult glioblastoma
679122|NCT00017264|adult anaplastic astrocytoma
679123|NCT00017264|adult anaplastic oligodendroglioma
679124|NCT00017264|adult giant cell glioblastoma
679125|NCT00017264|adult gliosarcoma
679126|NCT00017225|localized resectable neuroblastoma
679127|NCT00017225|regional neuroblastoma
679128|NCT00017225|disseminated neuroblastoma
679129|NCT00017225|stage 4S neuroblastoma
679130|NCT00017225|recurrent neuroblastoma
679131|NCT00017225|localized unresectable neuroblastoma
679132|NCT00017212|stage III gastric cancer
679133|NCT00017212|stage IV gastric cancer
679134|NCT00017212|recurrent gastric cancer
679135|NCT00017212|stage III esophageal cancer
679136|NCT00017212|stage IV esophageal cancer
679137|NCT00017212|recurrent esophageal cancer
679138|NCT00017212|adenocarcinoma of the stomach
679139|NCT00017212|adenocarcinoma of the esophagus
679140|NCT00017199|metastatic gastrointestinal carcinoid tumor
679141|NCT00017199|gastrinoma
679142|NCT00017199|insulinoma
679143|NCT00017199|somatostatinoma
679144|NCT00017199|glucagonoma
679145|NCT00017186|localized malignant mesothelioma
679146|NCT00017186|advanced malignant mesothelioma
679147|NCT00017186|recurrent malignant mesothelioma
679148|NCT00017173|stage III squamous cell carcinoma of the lip and oral cavity
679149|NCT00017173|stage IV squamous cell carcinoma of the lip and oral cavity
679150|NCT00017173|stage III squamous cell carcinoma of the oropharynx
679151|NCT00017173|stage IV squamous cell carcinoma of the oropharynx
679152|NCT00017173|stage III squamous cell carcinoma of the hypopharynx
679153|NCT00017173|stage III squamous cell carcinoma of the larynx
679154|NCT00017173|stage IV squamous cell carcinoma of the hypopharynx
679155|NCT00017173|stage IV verrucous carcinoma of the larynx
679156|NCT00016666|Season
679157|NCT00016666|Light
679158|NCT00016666|Propranolol
679159|NCT00016666|Photoperiod
679160|NCT00016666|Pharmacokinetics
679161|NCT00016666|Circadian Rhythm
679162|NCT00016666|Seasonal Rhythm
679163|NCT00016666|Seasonal Affective Disorder
679164|NCT00016666|Pineal Gland
679165|NCT00016666|Suprachiasmatic Nucleus
679166|NCT00016666|Healthy Volunteer
679167|NCT00016666|HV
679168|NCT00016666|Winter Depression
679169|NCT00016666|SAD
679170|NCT00016653|Duchenne
679171|NCT00016653|muscular
679172|NCT00016653|dystrophy
679173|NCT00016653|treatment
679174|NCT00016601|Delayed-Action Preparations
679175|NCT00016601|Drug Interactions
679176|NCT00016601|Drug Therapy, Combination
679177|NCT00016601|Nevirapine
679178|NCT00016601|HIV Protease Inhibitors
679179|NCT00016601|Ritonavir
679180|NCT00016601|Indinavir
679181|NCT00016601|Nelfinavir
679182|NCT00016601|Reverse Transcriptase Inhibitors
679183|NCT00016601|Anti-HIV Agents
679184|NCT00016601|Pharmacokinetics
679185|NCT00016601|Medroxyprogesterone 17-Acetate
679186|NCT00016601|efavirenz
679187|NCT00016588|HIV-1
679188|NCT00016588|Adenine
679189|NCT00016588|Anti-HIV Agents
679190|NCT00016588|Viral Load
679191|NCT00016588|Organophosphorus Compounds
679192|NCT00016562|Genetic
679193|NCT00016562|Degenerative
679194|NCT00016562|Lysosomal
679195|NCT00016562|Brain
679196|NCT00016562|Mental Retardation
679197|NCT00016562|Neurodegenerative Disorder
679198|NCT00016562|Neurometabolic
679199|NCT00016562|Metabolic Neurological Disorder
679200|NCT00016562|Abnormal Metabolism
679201|NCT00016549|Endothelial Proliferation
679202|NCT00016549|Endothelial Apoptosis
679203|NCT00016549|VEGF
679204|NCT00016549|Magnetic Resonance Imaging
679205|NCT00016549|Molecular Targets
679206|NCT00016549|Breast Cancer
679207|NCT00016549|Inflammatory Breast Cancer
679208|NCT00016549|IBC
679209|NCT00016536|Antiviral Agents
679210|NCT00016536|Mucous Membrane
679211|NCT00016536|Spermatocidal Agents
679212|NCT00016536|Penis
679213|NCT00016536|Epithelium
679214|NCT00016536|PRO 2000
679215|NCT00016536|Urethra
679216|NCT00016536|HIV Seronegativity
679217|NCT00016523|NICHD Neonatal Research Network
679218|NCT00016523|Extremely Low Birth Weight (ELBW)
679219|NCT00016523|Very Low Birth Weight (VLBW)
679220|NCT00016523|Prematurity
679221|NCT00016523|Inhaled nitric oxide
679222|NCT00016523|Aspiration syndrome
679223|NCT00016523|Idiopathic pulmonary hypertension
679224|NCT00016523|Pulmonary hypoplasia
679225|NCT00016510|Bilingualism
679226|NCT00016510|Fluency
679227|NCT00016510|Age at Acquisition
679228|NCT00016510|Words and Sentences
679229|NCT00016510|Cortical Area
679230|NCT00016510|Healthy Volunteer
679231|NCT00016510|HV
679232|NCT00016510|Bilingual
679233|NCT00016510|Second Language
679234|NCT00016497|otitis media with effusion
679235|NCT00016497|children
679236|NCT00016497|tympanostomy tubes
679237|NCT00016497|adenoidectomy
679238|NCT00016458|arthritis & connective tissue diseases
679239|NCT00016458|rare disease
679240|NCT00016458|systemic sclerosis
679241|NCT00016445|cardiovascular and respiratory diseases
679242|NCT00016445|cystic fibrosis
679243|NCT00016445|disease-related problem/condition
679244|NCT00016445|genetic diseases and dysmorphic syndromes
679245|NCT00016445|quality of life
679246|NCT00016445|rare disease
679247|NCT00016432|stage I breast cancer
679248|NCT00016432|stage II breast cancer
679249|NCT00016432|stage IIIA breast cancer
679250|NCT00016419|refractory anemia
679251|NCT00016419|refractory anemia with ringed sideroblasts
679252|NCT00016419|refractory anemia with excess blasts
679253|NCT00016419|de novo myelodysplastic syndromes
679254|NCT00016419|secondary myelodysplastic syndromes
679255|NCT00016419|childhood myelodysplastic syndromes
679256|NCT00016406|stage II breast cancer
679257|NCT00016406|stage IIIA breast cancer
679258|NCT00016406|stage IIIB breast cancer
679259|NCT00016406|stage IIIC breast cancer
679260|NCT00016406|inflammatory breast cancer
679261|NCT00016393|adenocarcinoma of the prostate
679262|NCT00016393|stage IV prostate cancer
679263|NCT00016393|recurrent prostate cancer
679264|NCT00016380|nausea and vomiting
679265|NCT00016380|stage I colon cancer
679266|NCT00016380|stage II colon cancer
679267|NCT00016380|stage III colon cancer
679268|NCT00016380|stage IV colon cancer
679269|NCT00016380|stage I gastric cancer
679270|NCT00016380|stage II gastric cancer
679271|NCT00016380|stage III gastric cancer
679272|NCT00016380|stage IV gastric cancer
679273|NCT00016380|recurrent gastric cancer
679274|NCT00016380|stage I pancreatic cancer
679275|NCT00016380|stage II pancreatic cancer
679276|NCT00016380|stage III pancreatic cancer
679277|NCT00016380|recurrent pancreatic cancer
679278|NCT00016380|recurrent colon cancer
679279|NCT00016380|recurrent cervical cancer
679280|NCT00016380|stage IB cervical cancer
679281|NCT00016380|stage IIB cervical cancer
679282|NCT00016380|stage IVB cervical cancer
679283|NCT00016380|stage IA cervical cancer
679284|NCT00016380|stage IIA cervical cancer
679285|NCT00016380|stage IVA cervical cancer
679286|NCT00016380|stage I ovarian epithelial cancer
679287|NCT00016380|stage II ovarian epithelial cancer
679288|NCT00016380|stage III ovarian epithelial cancer
679289|NCT00016380|stage IV ovarian epithelial cancer
679290|NCT00016380|recurrent ovarian epithelial cancer
679291|NCT00016380|localized gastrointestinal carcinoid tumor
679292|NCT00016380|regional gastrointestinal carcinoid tumor
679293|NCT00016380|metastatic gastrointestinal carcinoid tumor
679294|NCT00016380|recurrent gastrointestinal carcinoid tumor
679295|NCT00016380|localized resectable adult primary liver cancer
679296|NCT00016380|localized unresectable adult primary liver cancer
679297|NCT00016380|advanced adult primary liver cancer
679298|NCT00016380|recurrent adult primary liver cancer
679299|NCT00016380|small intestine adenocarcinoma
679300|NCT00016380|small intestine lymphoma
679301|NCT00016380|small intestine leiomyosarcoma
679302|NCT00016380|localized gallbladder cancer
679303|NCT00016380|unresectable gallbladder cancer
679304|NCT00016380|recurrent gallbladder cancer
679305|NCT00016380|localized extrahepatic bile duct cancer
679306|NCT00016380|unresectable extrahepatic bile duct cancer
679307|NCT00016380|recurrent extrahepatic bile duct cancer
679308|NCT00016380|recurrent small intestine cancer
679309|NCT00016380|testicular seminoma
679310|NCT00016380|carcinoma of the appendix
679311|NCT00016380|quality of life
679312|NCT00016380|stage IV pancreatic cancer
679313|NCT00016367|stage IIIB non-small cell lung cancer
679314|NCT00016367|stage IV non-small cell lung cancer
679315|NCT00016354|unspecified adult solid tumor, protocol specific
679316|NCT00016341|stage III endometrial carcinoma
679317|NCT00016341|stage IV endometrial carcinoma
679318|NCT00016341|recurrent endometrial carcinoma
679319|NCT00016315|stage IIIA non-small cell lung cancer
679320|NCT00016315|stage IIIB non-small cell lung cancer
679321|NCT00016263|stage III melanoma
679322|NCT00016263|stage IV melanoma
679323|NCT00016263|recurrent melanoma
679324|NCT00016250|stage IV colon cancer
679325|NCT00016250|stage IV rectal cancer
679326|NCT00016250|recurrent colon cancer
679327|NCT00016250|recurrent rectal cancer
679328|NCT00016250|adenocarcinoma of the colon
679329|NCT00016250|adenocarcinoma of the rectum
679330|NCT00016237|recurrent non-small cell lung cancer
679331|NCT00016237|squamous cell lung cancer
679332|NCT00016237|stage IV renal cell cancer
679333|NCT00016237|recurrent renal cell cancer
679334|NCT00016237|extensive stage small cell lung cancer
679335|NCT00016237|recurrent small cell lung cancer
679336|NCT00016237|recurrent bladder cancer
679337|NCT00016237|stage IV bladder cancer
679338|NCT00016237|stage IV non-small cell lung cancer
679339|NCT00016237|transitional cell carcinoma of the bladder
679340|NCT00016237|squamous cell carcinoma of the bladder
679341|NCT00016224|recurrent ovarian epithelial cancer
679342|NCT00016211|extensive stage small cell lung cancer
679343|NCT00016198|stage IV colon cancer
679344|NCT00016198|stage IV rectal cancer
679345|NCT00016198|recurrent colon cancer
679346|NCT00016198|recurrent rectal cancer
679347|NCT00016198|adenocarcinoma of the colon
679348|NCT00016198|adenocarcinoma of the rectum
679349|NCT00016185|unspecified adult solid tumor, protocol specific
679350|NCT00016172|stage III adult Hodgkin lymphoma
679351|NCT00016172|stage IV adult Hodgkin lymphoma
679352|NCT00016172|recurrent adult Hodgkin lymphoma
679353|NCT00016172|stage III cutaneous T-cell non-Hodgkin lymphoma
679354|NCT00016172|stage IV cutaneous T-cell non-Hodgkin lymphoma
679355|NCT00016172|recurrent cutaneous T-cell non-Hodgkin lymphoma
679356|NCT00016172|small intestine lymphoma
679357|NCT00016172|unspecified adult solid tumor, protocol specific
679358|NCT00016172|stage III grade 1 follicular lymphoma
679359|NCT00016172|stage III grade 2 follicular lymphoma
679360|NCT00016172|stage III grade 3 follicular lymphoma
679361|NCT00016172|stage III adult diffuse small cleaved cell lymphoma
679362|NCT00016172|stage III adult diffuse mixed cell lymphoma
679363|NCT00016172|stage III adult diffuse large cell lymphoma
679364|NCT00016172|stage III adult immunoblastic large cell lymphoma
679365|NCT00016172|stage III adult lymphoblastic lymphoma
679366|NCT00016172|stage III adult Burkitt lymphoma
679367|NCT00016172|stage IV grade 1 follicular lymphoma
679368|NCT00016172|stage IV grade 2 follicular lymphoma
679369|NCT00016172|stage IV grade 3 follicular lymphoma
679370|NCT00016172|stage IV adult diffuse small cleaved cell lymphoma
679371|NCT00016172|stage IV adult diffuse mixed cell lymphoma
679372|NCT00016172|stage IV adult diffuse large cell lymphoma
679373|NCT00016172|stage IV adult immunoblastic large cell lymphoma
679374|NCT00016172|stage IV adult lymphoblastic lymphoma
679375|NCT00016172|stage IV adult Burkitt lymphoma
679376|NCT00016172|recurrent grade 1 follicular lymphoma
679377|NCT00016172|recurrent grade 2 follicular lymphoma
679378|NCT00016172|recurrent grade 3 follicular lymphoma
679379|NCT00016172|recurrent adult diffuse small cleaved cell lymphoma
679380|NCT00016172|recurrent adult diffuse mixed cell lymphoma
679381|NCT00016172|recurrent adult diffuse large cell lymphoma
679382|NCT00016172|recurrent adult immunoblastic large cell lymphoma
679383|NCT00016172|recurrent adult lymphoblastic lymphoma
679384|NCT00016172|recurrent adult Burkitt lymphoma
679385|NCT00016172|stage III adult T-cell leukemia/lymphoma
679386|NCT00016172|stage IV adult T-cell leukemia/lymphoma
679387|NCT00016172|recurrent adult T-cell leukemia/lymphoma
679388|NCT00016172|primary central nervous system non-Hodgkin lymphoma
679389|NCT00016172|AIDS-related peripheral/systemic lymphoma
679390|NCT00016172|AIDS-related primary CNS lymphoma
679391|NCT00016172|intraocular lymphoma
679392|NCT00016172|stage III mantle cell lymphoma
679393|NCT00016172|stage IV mantle cell lymphoma
679394|NCT00016172|recurrent mantle cell lymphoma
679395|NCT00016172|angioimmunoblastic T-cell lymphoma
679396|NCT00016172|anaplastic large cell lymphoma
679397|NCT00016172|stage III mycosis fungoides/Sezary syndrome
679398|NCT00016172|stage IV mycosis fungoides/Sezary syndrome
679399|NCT00016172|recurrent mycosis fungoides/Sezary syndrome
679400|NCT00016172|recurrent marginal zone lymphoma
679401|NCT00016172|recurrent small lymphocytic lymphoma
679402|NCT00016172|stage III small lymphocytic lymphoma
679403|NCT00016172|stage III marginal zone lymphoma
679404|NCT00016172|stage IV small lymphocytic lymphoma
679405|NCT00016172|stage IV marginal zone lymphoma
679406|NCT00016172|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
679407|NCT00016172|nodal marginal zone B-cell lymphoma
679408|NCT00016172|splenic marginal zone lymphoma
679409|NCT00016159|adult acute myeloid leukemia in remission
679410|NCT00016159|childhood acute myeloid leukemia in remission
679411|NCT00016159|adult acute promyelocytic leukemia (M3)
679412|NCT00016159|childhood acute promyelocytic leukemia (M3)
679413|NCT00016159|adult acute myeloid leukemia with t(15;17)(q22;q12)
679414|NCT00016146|recurrent prostate cancer
679415|NCT00016133|stage II colon cancer
679416|NCT00016133|stage III colon cancer
679417|NCT00016133|adenocarcinoma of the colon
679418|NCT00016081|infection
679419|NCT00016068|infection
679420|NCT00016055|stage IV melanoma
679421|NCT00016055|recurrent melanoma
679422|NCT00016042|stage IV colon cancer
679423|NCT00016042|stage IV rectal cancer
679424|NCT00016042|recurrent colon cancer
679425|NCT00016042|recurrent rectal cancer
679426|NCT00016042|stage IV renal cell cancer
679427|NCT00016042|recurrent renal cell cancer
679428|NCT00016029|colon cancer
679429|NCT00016029|rectal cancer
679430|NCT00015977|adenocarcinoma of the prostate
679431|NCT00015977|stage IV prostate cancer
679432|NCT00015977|recurrent prostate cancer
679433|NCT00015964|recurrent metastatic squamous neck cancer with occult primary
679434|NCT00015964|metastatic squamous neck cancer with occult primary squamous cell carcinoma
679435|NCT00015964|stage IV squamous cell carcinoma of the lip and oral cavity
679436|NCT00015964|recurrent squamous cell carcinoma of the lip and oral cavity
679437|NCT00015964|stage IV squamous cell carcinoma of the oropharynx
679438|NCT00015964|recurrent squamous cell carcinoma of the oropharynx
679439|NCT00015964|stage IV squamous cell carcinoma of the nasopharynx
679440|NCT00015964|recurrent squamous cell carcinoma of the nasopharynx
679441|NCT00015964|stage IV squamous cell carcinoma of the hypopharynx
679442|NCT00015964|recurrent squamous cell carcinoma of the hypopharynx
679443|NCT00015964|stage IV squamous cell carcinoma of the larynx
679444|NCT00015964|recurrent squamous cell carcinoma of the larynx
679445|NCT00015964|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
679446|NCT00015964|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
679447|NCT00015951|recurrent adult acute myeloid leukemia
679448|NCT00015951|relapsing chronic myelogenous leukemia
679449|NCT00015951|blastic phase chronic myelogenous leukemia
679450|NCT00015951|refractory anemia with excess blasts
679451|NCT00015951|refractory anemia with excess blasts in transformation
679452|NCT00015951|chronic myelomonocytic leukemia
679453|NCT00015951|secondary acute myeloid leukemia
679454|NCT00015951|previously treated myelodysplastic syndromes
679455|NCT00015951|childhood myelodysplastic syndromes
679456|NCT00015938|stage IV breast cancer
679457|NCT00015938|recurrent breast cancer
679458|NCT00015925|refractory multiple myeloma
679459|NCT00015925|recurrent adult acute myeloid leukemia
679460|NCT00015925|recurrent adult acute lymphoblastic leukemia
679461|NCT00015925|relapsing chronic myelogenous leukemia
679462|NCT00015925|chronic phase chronic myelogenous leukemia
679463|NCT00015925|accelerated phase chronic myelogenous leukemia
679464|NCT00015925|blastic phase chronic myelogenous leukemia
679465|NCT00015925|untreated adult acute lymphoblastic leukemia
679466|NCT00015925|untreated adult acute myeloid leukemia
679467|NCT00015925|adult acute promyelocytic leukemia (M3)
679468|NCT00015925|refractory anemia with excess blasts
679469|NCT00015925|refractory anemia with excess blasts in transformation
679470|NCT00015925|chronic myelomonocytic leukemia
679471|NCT00015925|secondary acute myeloid leukemia
679472|NCT00015925|de novo myelodysplastic syndromes
679473|NCT00015925|previously treated myelodysplastic syndromes
679474|NCT00015925|atypical chronic myeloid leukemia
679475|NCT00015925|myelodysplastic/myeloproliferative disease, unclassifiable
679476|NCT00015925|adult acute myeloid leukemia with t(8;21)(q22;q22)
679477|NCT00015925|adult acute myeloid leukemia with t(16;16)(p13;q22)
679478|NCT00015925|adult acute myeloid leukemia with inv(16)(p13;q22)
679479|NCT00015925|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
679480|NCT00015925|adult acute myeloid leukemia with t(15;17)(q22;q12)
679481|NCT00015899|childhood craniopharyngioma
679482|NCT00015899|childhood central nervous system germ cell tumor
679483|NCT00015899|childhood oligodendroglioma
679484|NCT00015899|childhood choroid plexus tumor
679485|NCT00015899|childhood grade I meningioma
679486|NCT00015899|childhood grade II meningioma
679487|NCT00015899|childhood grade III meningioma
679488|NCT00015899|recurrent childhood cerebellar astrocytoma
679489|NCT00015899|recurrent childhood cerebral astrocytoma
679490|NCT00015899|recurrent childhood medulloblastoma
679491|NCT00015899|recurrent childhood visual pathway and hypothalamic glioma
679492|NCT00015899|recurrent childhood ependymoma
679493|NCT00015899|childhood atypical teratoid/rhabdoid tumor
679494|NCT00015899|childhood spinal cord neoplasm
679495|NCT00015886|stage IV breast cancer
679496|NCT00015886|recurrent breast cancer
679497|NCT00015886|stage IIIB breast cancer
679498|NCT00015873|untreated childhood acute lymphoblastic leukemia
679499|NCT00015860|recurrent adult acute lymphoblastic leukemia
679500|NCT00015860|relapsing chronic myelogenous leukemia
679501|NCT00015860|blastic phase chronic myelogenous leukemia
679502|NCT00015847|relapsing chronic myelogenous leukemia
679503|NCT00015847|chronic phase chronic myelogenous leukemia
679504|NCT00015847|Philadelphia chromosome positive chronic myelogenous leukemia
679505|NCT00015808|Neurodegeneration
679506|NCT00015808|Anti-Oxidant
679507|NCT00015808|Neuropathy
679508|NCT00015808|Hereditary
679509|NCT00015808|Spinocerebellar
679510|NCT00015808|Friedreich's Ataxia
679511|NCT00015808|Friedreich Ataxia
679512|NCT00015808|FRDA
679513|NCT00015795|Pressure
679514|NCT00015795|Botulinum Toxin
679515|NCT00015795|Voice
679516|NCT00015795|Dystonia
679517|NCT00015795|Pathophysiology
679518|NCT00015795|Healthy Volunteer
679519|NCT00015795|HV
679520|NCT00015795|ABSD
679521|NCT00015795|Spasmodic Dysphonia
679522|NCT00015795|Abductor Spasmodic Dysphonia
679523|NCT00015782|Metabolic
679524|NCT00015782|Genetic
679525|NCT00015782|Storage
679526|NCT00015782|Retinal Disease
679527|NCT00015782|Degenerative
679528|NCT00015782|Mucolipidosis Type IV
679529|NCT00015782|ML-IV
679530|NCT00015769|Mania
679531|NCT00015769|Depression
679532|NCT00015769|Anticonvulsants
679533|NCT00015769|Mood Stabilizers
679534|NCT00015769|Bipolar
679535|NCT00015769|Mood Stabilizer
679536|NCT00015756|Apheresis
679537|NCT00015756|Transplantation
679538|NCT00015756|Type III Secretion Pathway
679539|NCT00015756|Exotoxins
679540|NCT00015756|Pseudomonas Aeruginosa
679541|NCT00015756|Cystic Fibrosis
679542|NCT00015756|CF
679543|NCT00015717|Imaging
679544|NCT00015717|Complications
679545|NCT00015717|Stenosis
679546|NCT00015717|Treatment
679547|NCT00015717|Strokes
679548|NCT00015717|Cerebral Ischemia
679549|NCT00015717|Cranial Cervical Angioplasty
679550|NCT00015704|Treatment Experienced
679551|NCT00015704|Treatment Interruption
679552|NCT00015704|Drug Administration Schedule
679553|NCT00015704|CD4 Lymphocyte Count
679554|NCT00015704|Anti-HIV Agents
679555|NCT00015704|Tetanus Toxoid
679556|NCT00015704|Aldesleukin
679557|NCT00015704|Diphtheria Toxoid
679558|NCT00015691|Drug Therapy, Combination
679559|NCT00015691|Adipose Tissue
679560|NCT00015691|Area Under Curve
679561|NCT00015691|Hypoglycemic Agents
679562|NCT00015691|Anthropometry
679563|NCT00015691|Hyperinsulinemia
679564|NCT00015691|Metformin
679565|NCT00015691|BRL 49653
679566|NCT00015691|Insulin
679567|NCT00015691|Glucose Tolerance Test
679568|NCT00015678|Motor Cortex
679569|NCT00015678|Drug
679570|NCT00015678|GABA
679571|NCT00015678|Cortical Modulation
679572|NCT00015678|Magnetic Stimulation
679573|NCT00015678|Healthy Volunteer
679574|NCT00015665|Fungal
679575|NCT00015665|Immunodeficiency
679576|NCT00015665|Infection
679577|NCT00015665|Refractory
679578|NCT00015665|Severe
679579|NCT00015665|Fungal Infections
679580|NCT00015652|Ribavirin
679581|NCT00015652|Polyethylene Glycols
679582|NCT00015652|Interferon Alfa-2b
679583|NCT00015652|Dose-Response Relationship, Drug
679584|NCT00015652|Drug Therapy, Combination
679585|NCT00015652|Antiviral Agents
679586|NCT00015652|Hepatitis C
679587|NCT00015652|Aldesleukin
679588|NCT00015652|Peginterferon
679589|NCT00015639|Blood Donors
679590|NCT00015639|Employees
679591|NCT00015639|Heparin
679592|NCT00015639|Histidine-Rich Glycoprotein
679593|NCT00015639|Membrane
679594|NCT00015639|Healthy Volunteer
679595|NCT00015613|Hispanics
679596|NCT00015613|Acculturation
679597|NCT00015613|Maternal Exposure
679598|NCT00015613|Infant, Low Birth Weight
679599|NCT00015613|Infant, Premature
679600|NCT00015613|Organophosphates
679601|NCT00015613|Pesticides
679602|NCT00015613|Stress
679603|NCT00015613|Nutrition
679604|NCT00015600|Pesticide
679605|NCT00015600|Farmworker
679606|NCT00015600|Occupational health
679607|NCT00015587|Molecular Epidemiology
679608|NCT00015587|Case Control
679609|NCT00015574|arrhythmia
679610|NCT00015574|cardiac
679611|NCT00015574|air pollution
679612|NCT00015574|time series
679613|NCT00015561|population studies
679614|NCT00015561|laboratory evaluation
679615|NCT00015561|hormone analysis
679616|NCT00015561|semen analysis
679617|NCT00015561|chromosome studies
679618|NCT00015548|antipsychotic treatment
679619|NCT00015548|Alzheimer's disease
679620|NCT00015548|agitation
679621|NCT00015548|dementia
679622|NCT00015548|psychosis
679623|NCT00015548|behavioral symptoms
679624|NCT00015548|hallucinations
679625|NCT00015548|delusions
679626|NCT00014547|extensive stage small cell lung cancer
679627|NCT00014547|recurrent small cell lung cancer
679628|NCT00014534|stage III bladder cancer
679629|NCT00014534|stage IV bladder cancer
679630|NCT00014534|transitional cell carcinoma of the bladder
679631|NCT00014521|recurrent adult brain tumor
679632|NCT00014521|adult glioblastoma
679633|NCT00014521|adult anaplastic astrocytoma
679634|NCT00014521|adult anaplastic oligodendroglioma
679635|NCT00014521|adult giant cell glioblastoma
679636|NCT00014521|adult gliosarcoma
679637|NCT00014508|refractory multiple myeloma
679638|NCT00014508|stage I multiple myeloma
679639|NCT00014508|stage II multiple myeloma
679640|NCT00014508|stage III multiple myeloma
679641|NCT00014495|recurrent childhood acute myeloid leukemia
679642|NCT00014495|recurrent adult acute myeloid leukemia
679643|NCT00014495|accelerated phase chronic myelogenous leukemia
679644|NCT00014495|blastic phase chronic myelogenous leukemia
679645|NCT00014495|untreated adult acute myeloid leukemia
679646|NCT00014495|untreated childhood acute myeloid leukemia and other myeloid malignancies
679647|NCT00014495|refractory anemia with excess blasts
679648|NCT00014495|refractory anemia with excess blasts in transformation
679649|NCT00014495|chronic myelomonocytic leukemia
679650|NCT00014495|previously treated myelodysplastic syndromes
679651|NCT00014495|secondary myelodysplastic syndromes
679652|NCT00014495|childhood chronic myelogenous leukemia
679653|NCT00014495|atypical chronic myeloid leukemia, BCR-ABL1 negative
679654|NCT00014495|myelodysplastic/myeloproliferative neoplasm, unclassifiable
679655|NCT00014495|adult acute myeloid leukemia with t(8;21)(q22;q22)
679656|NCT00014495|adult acute myeloid leukemia with t(16;16)(p13;q22)
679657|NCT00014495|adult acute myeloid leukemia with inv(16)(p13;q22)
679658|NCT00014495|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
679659|NCT00014495|adult acute myeloid leukemia with t(15;17)(q22;q12)
679660|NCT00014495|childhood myelodysplastic syndromes
679661|NCT00014482|anxiety disorder
679662|NCT00014482|depression
679663|NCT00014482|pain
679664|NCT00014482|recurrent adult Hodgkin lymphoma
679665|NCT00014482|recurrent cutaneous T-cell non-Hodgkin lymphoma
679666|NCT00014482|refractory multiple myeloma
679667|NCT00014482|stage I multiple myeloma
679668|NCT00014482|stage II multiple myeloma
679669|NCT00014482|stage III multiple myeloma
679670|NCT00014482|primary myelofibrosis
679671|NCT00014482|stage III grade 1 follicular lymphoma
679672|NCT00014482|stage III grade 2 follicular lymphoma
679673|NCT00014482|stage III grade 3 follicular lymphoma
679674|NCT00014482|stage III adult diffuse small cleaved cell lymphoma
679675|NCT00014482|stage III adult diffuse mixed cell lymphoma
679676|NCT00014482|stage III adult diffuse large cell lymphoma
679677|NCT00014482|stage III adult immunoblastic large cell lymphoma
679678|NCT00014482|stage III adult lymphoblastic lymphoma
679679|NCT00014482|stage III adult Burkitt lymphoma
679680|NCT00014482|stage IV grade 1 follicular lymphoma
679681|NCT00014482|stage IV grade 2 follicular lymphoma
679682|NCT00014482|stage IV grade 3 follicular lymphoma
679683|NCT00014482|stage IV adult diffuse small cleaved cell lymphoma
679684|NCT00014482|stage IV adult diffuse mixed cell lymphoma
679685|NCT00014482|stage IV adult diffuse large cell lymphoma
679686|NCT00014482|stage IV adult immunoblastic large cell lymphoma
679687|NCT00014482|stage IV adult lymphoblastic lymphoma
679688|NCT00014482|stage IV adult Burkitt lymphoma
679689|NCT00014482|recurrent grade 1 follicular lymphoma
679690|NCT00014482|recurrent grade 2 follicular lymphoma
679691|NCT00014482|recurrent grade 3 follicular lymphoma
679692|NCT00014482|recurrent adult diffuse small cleaved cell lymphoma
679693|NCT00014482|recurrent adult diffuse mixed cell lymphoma
679694|NCT00014482|recurrent adult diffuse large cell lymphoma
679695|NCT00014482|recurrent adult immunoblastic large cell lymphoma
679696|NCT00014482|recurrent adult lymphoblastic lymphoma
679697|NCT00014482|recurrent adult Burkitt lymphoma
679698|NCT00014482|de novo myelodysplastic syndromes
679699|NCT00014482|previously treated myelodysplastic syndromes
679700|NCT00014482|secondary myelodysplastic syndromes
679701|NCT00014482|noncontiguous stage II grade 1 follicular lymphoma
679702|NCT00014482|noncontiguous stage II grade 2 follicular lymphoma
679703|NCT00014482|noncontiguous stage II grade 3 follicular lymphoma
679704|NCT00014482|noncontiguous stage II adult diffuse small cleaved cell lymphoma
679705|NCT00014482|noncontiguous stage II mantle cell lymphoma
679706|NCT00014482|noncontiguous stage II adult diffuse mixed cell lymphoma
679707|NCT00014482|noncontiguous stage II adult immunoblastic large cell lymphoma
679708|NCT00014482|noncontiguous stage II adult diffuse large cell lymphoma
679709|NCT00014482|noncontiguous stage II adult Burkitt lymphoma
679710|NCT00014482|noncontiguous stage II adult lymphoblastic lymphoma
679711|NCT00014482|stage III mantle cell lymphoma
679712|NCT00014482|stage IV mantle cell lymphoma
679713|NCT00014482|recurrent mantle cell lymphoma
679714|NCT00014482|recurrent mycosis fungoides/Sezary syndrome
679715|NCT00014482|noncontiguous stage II small lymphocytic lymphoma
679716|NCT00014482|noncontiguous stage II marginal zone lymphoma
679717|NCT00014482|recurrent marginal zone lymphoma
679718|NCT00014482|recurrent small lymphocytic lymphoma
679719|NCT00014482|stage III small lymphocytic lymphoma
679720|NCT00014482|stage III marginal zone lymphoma
679721|NCT00014482|stage IV small lymphocytic lymphoma
679722|NCT00014482|stage IV marginal zone lymphoma
679723|NCT00014482|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
679724|NCT00014482|nodal marginal zone B-cell lymphoma
679725|NCT00014482|splenic marginal zone lymphoma
679726|NCT00014469|recurrent childhood acute lymphoblastic leukemia
679727|NCT00014469|recurrent childhood acute myeloid leukemia
679728|NCT00014469|recurrent adult acute myeloid leukemia
679729|NCT00014469|recurrent adult acute lymphoblastic leukemia
679730|NCT00014469|relapsing chronic myelogenous leukemia
679731|NCT00014469|refractory chronic lymphocytic leukemia
679732|NCT00014469|chronic phase chronic myelogenous leukemia
679733|NCT00014469|accelerated phase chronic myelogenous leukemia
679734|NCT00014469|blastic phase chronic myelogenous leukemia
679735|NCT00014469|adult acute myeloid leukemia in remission
679736|NCT00014469|adult acute lymphoblastic leukemia in remission
679737|NCT00014469|childhood acute myeloid leukemia in remission
679738|NCT00014469|childhood acute lymphoblastic leukemia in remission
679739|NCT00014469|refractory anemia with excess blasts
679740|NCT00014469|refractory anemia with excess blasts in transformation
679741|NCT00014469|chronic myelomonocytic leukemia
679742|NCT00014469|acute undifferentiated leukemia
679743|NCT00014469|secondary acute myeloid leukemia
679744|NCT00014469|de novo myelodysplastic syndromes
679745|NCT00014469|previously treated myelodysplastic syndromes
679746|NCT00014469|secondary myelodysplastic syndromes
679747|NCT00014469|graft versus host disease
679748|NCT00014469|refractory cytopenia with multilineage dysplasia
679749|NCT00014469|juvenile myelomonocytic leukemia
679750|NCT00014469|childhood chronic myelogenous leukemia
679751|NCT00014469|atypical chronic myeloid leukemia, BCR-ABL1 negative
679752|NCT00014469|myelodysplastic/myeloproliferative neoplasm, unclassifiable
679753|NCT00014469|adult acute myeloid leukemia with t(8;21)(q22;q22)
679754|NCT00014469|adult acute myeloid leukemia with t(16;16)(p13;q22)
679755|NCT00014469|adult acute myeloid leukemia with inv(16)(p13;q22)
679756|NCT00014469|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
679757|NCT00014469|adult acute myeloid leukemia with t(15;17)(q22;q12)
679758|NCT00014456|stage IV breast cancer
679759|NCT00014456|recurrent breast cancer
679760|NCT00014456|stage IV gastric cancer
679761|NCT00014456|recurrent gastric cancer
679762|NCT00014456|metastatic osteosarcoma
679763|NCT00014456|recurrent non-small cell lung cancer
679764|NCT00014456|stage II pancreatic cancer
679765|NCT00014456|stage III pancreatic cancer
679766|NCT00014456|recurrent pancreatic cancer
679767|NCT00014456|stage II esophageal cancer
679768|NCT00014456|stage III esophageal cancer
679769|NCT00014456|stage IV esophageal cancer
679770|NCT00014456|recurrent esophageal cancer
679771|NCT00014456|chondrosarcoma
679772|NCT00014456|recurrent adult soft tissue sarcoma
679773|NCT00014456|stage IV ovarian epithelial cancer
679774|NCT00014456|recurrent ovarian epithelial cancer
679775|NCT00014456|extensive stage small cell lung cancer
679776|NCT00014456|recurrent small cell lung cancer
679777|NCT00014456|recurrent osteosarcoma
679778|NCT00014456|recurrent bladder cancer
679779|NCT00014456|stage IV bladder cancer
679780|NCT00014456|stage IV prostate cancer
679781|NCT00014456|recurrent prostate cancer
679782|NCT00014456|stage IV melanoma
679783|NCT00014456|recurrent melanoma
679784|NCT00014456|stage IV non-small cell lung cancer
679785|NCT00014456|stage IV salivary gland cancer
679786|NCT00014456|recurrent salivary gland cancer
679787|NCT00014456|classic Kaposi sarcoma
679788|NCT00014456|AIDS-related Kaposi sarcoma
679789|NCT00014456|recurrent Kaposi sarcoma
679790|NCT00014456|recurrent metastatic squamous neck cancer with occult primary
679791|NCT00014456|stage IV ovarian germ cell tumor
679792|NCT00014456|recurrent ovarian germ cell tumor
679793|NCT00014456|stage IV uterine sarcoma
679794|NCT00014456|recurrent uterine sarcoma
679795|NCT00014456|borderline ovarian surface epithelial-stromal tumor
679796|NCT00014456|recurrent carcinoma of unknown primary
679797|NCT00014456|ovarian sarcoma
679798|NCT00014456|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
679799|NCT00014456|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
679800|NCT00014456|recurrent squamous cell carcinoma of the hypopharynx
679801|NCT00014456|stage IV squamous cell carcinoma of the hypopharynx
679802|NCT00014456|recurrent squamous cell carcinoma of the larynx
679803|NCT00014456|recurrent verrucous carcinoma of the larynx
679804|NCT00014456|stage IV squamous cell carcinoma of the larynx
679805|NCT00014456|stage IV verrucous carcinoma of the larynx
679806|NCT00014456|recurrent squamous cell carcinoma of the lip and oral cavity
679807|NCT00014456|stage IV squamous cell carcinoma of the lip and oral cavity
679808|NCT00014456|recurrent lymphoepithelioma of the nasopharynx
679809|NCT00014456|recurrent squamous cell carcinoma of the nasopharynx
679810|NCT00014456|stage IV lymphoepithelioma of the nasopharynx
679811|NCT00014456|stage IV squamous cell carcinoma of the nasopharynx
679812|NCT00014456|recurrent lymphoepithelioma of the oropharynx
679813|NCT00014456|recurrent squamous cell carcinoma of the oropharynx
679814|NCT00014456|stage IV lymphoepithelioma of the oropharynx
679815|NCT00014456|stage IV squamous cell carcinoma of the oropharynx
679816|NCT00014456|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
679817|NCT00014456|recurrent inverted papilloma of the paranasal sinus and nasal cavity
679818|NCT00014456|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
679819|NCT00014456|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
679820|NCT00014456|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
679821|NCT00014456|stage IV inverted papilloma of the paranasal sinus and nasal cavity
679822|NCT00014456|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
679823|NCT00014456|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
679824|NCT00014456|recurrent verrucous carcinoma of the oral cavity
679825|NCT00014456|stage IV verrucous carcinoma of the oral cavity
679826|NCT00014456|recurrent basal cell carcinoma of the lip
679827|NCT00014456|stage IV basal cell carcinoma of the lip
679828|NCT00014456|recurrent mucoepidermoid carcinoma of the oral cavity
679829|NCT00014456|stage IV mucoepidermoid carcinoma of the oral cavity
679830|NCT00014456|recurrent adenoid cystic carcinoma of the oral cavity
679831|NCT00014456|stage IV adenoid cystic carcinoma of the oral cavity
679832|NCT00014456|stage IV adult soft tissue sarcoma
679833|NCT00014456|stage IV pancreatic cancer
679834|NCT00014443|recurrent adult brain tumor
679835|NCT00014443|adult glioblastoma
679836|NCT00014443|adult anaplastic astrocytoma
679837|NCT00014443|adult giant cell glioblastoma
679838|NCT00014443|adult gliosarcoma
679839|NCT00014430|stage IV breast cancer
679840|NCT00014430|stage IIIA breast cancer
679841|NCT00014430|recurrent breast cancer
679842|NCT00014430|stage IIIB breast cancer
679843|NCT00014404|lip and oral cavity cancer
679844|NCT00014391|stage IV breast cancer
679845|NCT00014391|stage IIIA breast cancer
679846|NCT00014391|stage IIIB breast cancer
679847|NCT00014391|recurrent childhood acute lymphoblastic leukemia
679848|NCT00014391|recurrent adult Hodgkin lymphoma
679849|NCT00014391|recurrent cutaneous T-cell non-Hodgkin lymphoma
679850|NCT00014391|refractory multiple myeloma
679851|NCT00014391|recurrent childhood rhabdomyosarcoma
679852|NCT00014391|stage II ovarian epithelial cancer
679853|NCT00014391|stage III ovarian epithelial cancer
679854|NCT00014391|stage IV ovarian epithelial cancer
679855|NCT00014391|recurrent ovarian epithelial cancer
679856|NCT00014391|disseminated neuroblastoma
679857|NCT00014391|recurrent neuroblastoma
679858|NCT00014391|recurrent Wilms tumor and other childhood kidney tumors
679859|NCT00014391|stage I multiple myeloma
679860|NCT00014391|stage II multiple myeloma
679861|NCT00014391|stage III multiple myeloma
679862|NCT00014391|recurrent childhood lymphoblastic lymphoma
679863|NCT00014391|stage III chronic lymphocytic leukemia
679864|NCT00014391|stage IV chronic lymphocytic leukemia
679865|NCT00014391|recurrent childhood acute myeloid leukemia
679866|NCT00014391|recurrent adult acute myeloid leukemia
679867|NCT00014391|recurrent adult acute lymphoblastic leukemia
679868|NCT00014391|relapsing chronic myelogenous leukemia
679869|NCT00014391|refractory chronic lymphocytic leukemia
679870|NCT00014391|stage III malignant testicular germ cell tumor
679871|NCT00014391|recurrent malignant testicular germ cell tumor
679872|NCT00014391|chronic phase chronic myelogenous leukemia
679873|NCT00014391|accelerated phase chronic myelogenous leukemia
679874|NCT00014391|blastic phase chronic myelogenous leukemia
679875|NCT00014391|meningeal chronic myelogenous leukemia
679876|NCT00014391|chronic idiopathic myelofibrosis
679877|NCT00014391|childhood acute promyelocytic leukemia (M3)
679878|NCT00014391|testicular embryonal carcinoma
679879|NCT00014391|testicular choriocarcinoma
679880|NCT00014391|testicular teratoma
679881|NCT00014391|testicular yolk sac tumor
679882|NCT00014391|testicular embryonal carcinoma and teratoma
679883|NCT00014391|testicular embryonal carcinoma and teratoma with seminoma
679884|NCT00014391|testicular embryonal carcinoma and yolk sac tumor
679885|NCT00014391|testicular embryonal carcinoma and yolk sac tumor with seminoma
679886|NCT00014391|testicular embryonal carcinoma and seminoma
679887|NCT00014391|testicular yolk sac tumor and teratoma
679888|NCT00014391|testicular yolk sac tumor and teratoma with seminoma
679889|NCT00014391|testicular choriocarcinoma and yolk sac tumor
679890|NCT00014391|testicular choriocarcinoma and embryonal carcinoma
679891|NCT00014391|testicular choriocarcinoma and teratoma
679892|NCT00014391|testicular choriocarcinoma and seminoma
679893|NCT00014391|refractory hairy cell leukemia
679894|NCT00014391|recurrent/refractory childhood Hodgkin lymphoma
679895|NCT00014391|recurrent ovarian germ cell tumor
679896|NCT00014391|ovarian yolk sac tumor
679897|NCT00014391|ovarian embryonal carcinoma
679898|NCT00014391|ovarian polyembryoma
679899|NCT00014391|ovarian choriocarcinoma
679900|NCT00014391|ovarian immature teratoma
679901|NCT00014391|ovarian mature teratoma
679902|NCT00014391|ovarian monodermal and highly specialized teratoma
679903|NCT00014391|ovarian mixed germ cell tumor
679904|NCT00014391|stage III grade 1 follicular lymphoma
679905|NCT00014391|stage III grade 2 follicular lymphoma
679906|NCT00014391|stage III grade 3 follicular lymphoma
679907|NCT00014391|stage III adult diffuse small cleaved cell lymphoma
679908|NCT00014391|stage III adult diffuse mixed cell lymphoma
679909|NCT00014391|stage III adult diffuse large cell lymphoma
679910|NCT00014391|stage III adult immunoblastic large cell lymphoma
679911|NCT00014391|stage III adult lymphoblastic lymphoma
679912|NCT00014391|stage III adult Burkitt lymphoma
679913|NCT00014391|stage IV grade 1 follicular lymphoma
679914|NCT00014391|stage IV grade 2 follicular lymphoma
679915|NCT00014391|stage IV grade 3 follicular lymphoma
679916|NCT00014391|stage IV adult diffuse small cleaved cell lymphoma
679917|NCT00014391|stage IV adult diffuse mixed cell lymphoma
679918|NCT00014391|stage IV adult diffuse large cell lymphoma
679919|NCT00014391|stage IV adult immunoblastic large cell lymphoma
679920|NCT00014391|stage IV adult lymphoblastic lymphoma
679921|NCT00014391|stage IV adult Burkitt lymphoma
679922|NCT00014391|recurrent grade 1 follicular lymphoma
679923|NCT00014391|recurrent grade 2 follicular lymphoma
679924|NCT00014391|recurrent grade 3 follicular lymphoma
679925|NCT00014391|recurrent adult diffuse small cleaved cell lymphoma
679926|NCT00014391|recurrent adult diffuse mixed cell lymphoma
679927|NCT00014391|recurrent adult diffuse large cell lymphoma
679928|NCT00014391|recurrent adult immunoblastic large cell lymphoma
679929|NCT00014391|recurrent adult lymphoblastic lymphoma
679930|NCT00014391|recurrent adult Burkitt lymphoma
679931|NCT00014391|secondary acute myeloid leukemia
679932|NCT00014391|de novo myelodysplastic syndromes
679933|NCT00014391|poor prognosis metastatic gestational trophoblastic tumor
679934|NCT00014391|previously treated myelodysplastic syndromes
679935|NCT00014391|secondary myelodysplastic syndromes
679936|NCT00014391|infection
679937|NCT00014391|pulmonary complications
679938|NCT00014391|recurrent childhood small noncleaved cell lymphoma
679939|NCT00014391|recurrent childhood large cell lymphoma
679940|NCT00014391|noncontiguous stage II grade 1 follicular lymphoma
679941|NCT00014391|noncontiguous stage II grade 2 follicular lymphoma
679942|NCT00014391|noncontiguous stage II grade 3 follicular lymphoma
679943|NCT00014391|noncontiguous stage II adult diffuse small cleaved cell lymphoma
679944|NCT00014391|noncontiguous stage II mantle cell lymphoma
679945|NCT00014391|noncontiguous stage II adult diffuse mixed cell lymphoma
679946|NCT00014391|noncontiguous stage II adult immunoblastic large cell lymphoma
679947|NCT00014391|noncontiguous stage II adult diffuse large cell lymphoma
679948|NCT00014391|noncontiguous stage II adult Burkitt lymphoma
679949|NCT00014391|noncontiguous stage II adult lymphoblastic lymphoma
679950|NCT00014391|stage III mantle cell lymphoma
679951|NCT00014391|stage IV mantle cell lymphoma
679952|NCT00014391|recurrent mantle cell lymphoma
679953|NCT00014391|previously treated childhood rhabdomyosarcoma
679954|NCT00014391|noncontiguous stage II small lymphocytic lymphoma
679955|NCT00014391|noncontiguous stage II marginal zone lymphoma
679956|NCT00014391|recurrent marginal zone lymphoma
679957|NCT00014391|recurrent small lymphocytic lymphoma
679958|NCT00014391|stage III small lymphocytic lymphoma
679959|NCT00014391|stage III marginal zone lymphoma
679960|NCT00014391|stage IV small lymphocytic lymphoma
679961|NCT00014391|stage IV marginal zone lymphoma
679962|NCT00014391|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
679963|NCT00014391|nodal marginal zone B-cell lymphoma
679964|NCT00014391|splenic marginal zone lymphoma
679965|NCT00014391|childhood myelodysplastic syndromes
679966|NCT00014378|unspecified adult solid tumor, protocol specific
679967|NCT00014365|unspecified adult solid tumor, protocol specific
679968|NCT00014352|stage III prostate cancer
679969|NCT00014352|stage IV prostate cancer
679970|NCT00014352|recurrent prostate cancer
679971|NCT00014352|thromboembolism
679972|NCT00014339|stage II multiple myeloma
679973|NCT00014339|stage III multiple myeloma
679974|NCT00014326|stage I grade 1 follicular lymphoma
679975|NCT00014326|stage I grade 2 follicular lymphoma
679976|NCT00014326|stage I grade 3 follicular lymphoma
679977|NCT00014326|contiguous stage II grade 1 follicular lymphoma
679978|NCT00014326|contiguous stage II grade 2 follicular lymphoma
679979|NCT00014326|contiguous stage II grade 3 follicular lymphoma
679980|NCT00014326|noncontiguous stage II grade 1 follicular lymphoma
679981|NCT00014326|noncontiguous stage II grade 2 follicular lymphoma
679982|NCT00014326|noncontiguous stage II grade 3 follicular lymphoma
679983|NCT00014326|contiguous stage II small lymphocytic lymphoma
679984|NCT00014326|contiguous stage II marginal zone lymphoma
679985|NCT00014326|noncontiguous stage II small lymphocytic lymphoma
679986|NCT00014326|noncontiguous stage II marginal zone lymphoma
679987|NCT00014326|nodal marginal zone B-cell lymphoma
679988|NCT00014326|stage I marginal zone lymphoma
679989|NCT00014326|stage I small lymphocytic lymphoma
679990|NCT00014313|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
679991|NCT00015483|Hematotoxicity
679992|NCT00015483|Benzene
679993|NCT00015483|Bone Marrow
679994|NCT00015470|Myopathy
679995|NCT00015470|Dystrophy
679996|NCT00015470|Neuropathy
679997|NCT00015470|Muscle Weakness
679998|NCT00015470|Muscle Cramps and Pains
679999|NCT00015470|Neuromuscular Disorders
680000|NCT00015457|Writer's Cramp
680001|NCT00015457|Calcium Channel Antagonists
680002|NCT00015457|Torticollis
680003|NCT00015457|Chemodenervation
680004|NCT00015444|Apparently Sporadic Spastic Paraplegia
680005|NCT00015444|Spasticity
680006|NCT00015444|Motor Neuron Disease
680007|NCT00015444|Amyotrophic Lateral Sclerosis
680008|NCT00015444|Primary Lateral Sclerosis
680009|NCT00015444|Muscle Stiffness
680010|NCT00015444|Involuntary Muscle Contraction
680011|NCT00015444|Isaacs Syndrome
680012|NCT00015431|Malabsorption
680013|NCT00015431|Endoscopy
680014|NCT00015431|Cytokine
680015|NCT00015431|Immunophenotype
680016|NCT00015431|Lymphocyte
680017|NCT00015431|Common Variable Immunodeficiency
680018|NCT00015431|Gastrointestinal
680019|NCT00015340|Opioid Dependence
680020|NCT00015249|cocaine dependence
680021|NCT00015210|Cocaine Use Disorders Dependence Depression
680022|NCT00015171|opioid dependence
680023|NCT00015132|cocaine dependence
680024|NCT00015106|cocaine dependence
680025|NCT00015080|cocaine dependence
680026|NCT00015054|cocaine dependence
680027|NCT00015041|opiate dependence
680028|NCT00015028|opioid dependence
680029|NCT00015015|Dichloroacetate
680030|NCT00015015|Chlorinated hydrocarbons
680031|NCT00015015|Genetic disease
680032|NCT00015015|Toxicology
680033|NCT00015015|Biotransformation
680034|NCT00015002|Antenatal corticosteroids
680035|NCT00015002|Preterm delivery
680036|NCT00014989|Preterm delivery
680037|NCT00014989|Cerebral palsy
680038|NCT00014989|Magnesium sulfate
680039|NCT00014976|Pyramidal Tract
680040|NCT00014976|Primary Lateral Sclerosis
680041|NCT00014976|Spastic Paraparesis
680042|NCT00014976|EMG
680043|NCT00014976|Magnetic Stimulation
680044|NCT00014976|Muscle Spasticity
680045|NCT00014976|Healthy Volunteer
680046|NCT00014963|benzene
680047|NCT00014963|biomarkers
680048|NCT00014963|air pollution
680049|NCT00014963|muconic acid
680050|NCT00014963|phenylmercapturic acid
680051|NCT00014950|Cystic Fibrosis
680052|NCT00014950|Immunoreactive trypsinogen
680053|NCT00014950|deltaF508- CFTR gene
680054|NCT00014950|newborn screening
680055|NCT00014950|Pseudomonas aeruginosa infection
680056|NCT00014950|nutrition
680057|NCT00014950|pulmonary status
680058|NCT00014950|meconium ileus
680059|NCT00014950|growth
680060|NCT00014950|Genetic counseling
680061|NCT00014950|risk communication
680062|NCT00014937|HIV-1
680063|NCT00014937|Didanosine
680064|NCT00014937|Drug Therapy, Combination
680065|NCT00014937|Zidovudine
680066|NCT00014937|Nevirapine
680067|NCT00014937|Stavudine
680068|NCT00014937|HIV Protease Inhibitors
680069|NCT00014937|Ritonavir
680070|NCT00014937|Lamivudine
680071|NCT00014937|RNA, Viral
680072|NCT00014937|Reverse Transcriptase Inhibitors
680073|NCT00014937|Anti-HIV Agents
680074|NCT00014937|Viral Load
680075|NCT00014937|ABT 378
680076|NCT00014937|Combivir
680077|NCT00014937|Efavirenz
680078|NCT00014937|Treatment Experienced
680079|NCT00014898|Lead exposure
680080|NCT00014898|Bone lead
680081|NCT00014898|Attention deficit
680082|NCT00014885|Lead exposure
680083|NCT00014885|Bone lead
680084|NCT00014885|Cognitive function
680085|NCT00014885|Academic achievement
680086|NCT00014885|Neurobehavior
680087|NCT00014859|Pulmonary surfactant
680088|NCT00014859|Surfactant protein B
680089|NCT00014859|Surfactant protein C
680090|NCT00014859|ABCA3
680091|NCT00014859|NKX2-1
680092|NCT00014807|Pesticide exposure
680093|NCT00014807|Organophosphate
680094|NCT00014807|Biomarkers of exposure
680095|NCT00014807|Poisoning
680096|NCT00014807|Occupational Health
680097|NCT00014794|Arthritis
680098|NCT00014794|Vascularity
680099|NCT00014794|Angiogenesis
680100|NCT00014794|Imaging
680101|NCT00014794|MRI
680102|NCT00014794|Rheumatoid Arthritis
680103|NCT00014794|PET Scan
680104|NCT00014794|Synovitis
680105|NCT00014781|cardiovascular and respiratory diseases
680106|NCT00014781|cystic fibrosis
680107|NCT00014781|genetic diseases and dysmorphic syndromes
680108|NCT00014781|rare disease
680109|NCT00014768|cardiovascular and respiratory diseases
680110|NCT00014768|cystic fibrosis
680111|NCT00014768|genetic diseases and dysmorphic syndromes
680112|NCT00014768|rare disease
680113|NCT00014755|multiple sclerosis
680114|NCT00014755|neurologic and psychiatric disorders
680115|NCT00014755|rare disease
680116|NCT00014742|Dupuytren's disease
680117|NCT00014742|arthritis & connective tissue diseases
680118|NCT00014742|rare disease
680119|NCT00014729|dermatologic disorders
680120|NCT00014729|epidermolysis bullosa
680121|NCT00014729|genetic diseases and dysmorphic syndromes
680122|NCT00014729|rare disease
680123|NCT00014690|recurrent ovarian epithelial cancer
680124|NCT00014690|fallopian tube cancer
680125|NCT00014690|primary peritoneal cavity cancer
680126|NCT00014677|recurrent adult brain tumor
680127|NCT00014677|adult glioblastoma
680128|NCT00014677|adult giant cell glioblastoma
680129|NCT00014677|adult gliosarcoma
680130|NCT00014664|recurrent grade 1 follicular lymphoma
680131|NCT00014664|recurrent grade 2 follicular lymphoma
680132|NCT00014664|recurrent grade 3 follicular lymphoma
680133|NCT00014664|recurrent marginal zone lymphoma
680134|NCT00014664|recurrent small lymphocytic lymphoma
680135|NCT00014664|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
680136|NCT00014651|perioperative/postoperative complications
680137|NCT00014651|stage I pancreatic cancer
680138|NCT00014638|stage IV breast cancer
680139|NCT00014638|recurrent breast cancer
680140|NCT00014625|stage IV melanoma
680141|NCT00014625|recurrent melanoma
680142|NCT00014612|stage IA breast cancer
680143|NCT00014612|stage IB breast cancer
680144|NCT00014612|stage II breast cancer
680145|NCT00014599|stage III vulvar cancer
680146|NCT00014599|stage IV vulvar cancer
680147|NCT00014599|recurrent vulvar cancer
680148|NCT00014599|squamous cell carcinoma of the vulva
680149|NCT00014586|stage I prostate cancer
680150|NCT00014586|stage IIB prostate cancer
680151|NCT00014586|stage IIA prostate cancer
680152|NCT00014586|stage III prostate cancer
680153|NCT00014573|childhood infratentorial ependymoma
680154|NCT00014573|childhood supratentorial ependymoma
680155|NCT00014573|childhood central nervous system germ cell tumor
680156|NCT00014573|recurrent adult brain tumor
680157|NCT00014573|adult brain stem glioma
680158|NCT00014573|adult medulloblastoma
680159|NCT00014573|adult glioblastoma
680160|NCT00014573|childhood high-grade cerebral astrocytoma
680161|NCT00014573|adult anaplastic astrocytoma
680162|NCT00014573|childhood choroid plexus tumor
680163|NCT00014573|childhood grade III meningioma
680164|NCT00014573|adult anaplastic ependymoma
680165|NCT00014573|adult mixed glioma
680166|NCT00014573|adult central nervous system germ cell tumor
680167|NCT00014573|adult ependymoblastoma
680168|NCT00014573|recurrent childhood brain stem glioma
680169|NCT00014573|recurrent childhood supratentorial primitive neuroectodermal tumor
680170|NCT00014573|recurrent childhood cerebral astrocytoma
680171|NCT00014573|recurrent childhood medulloblastoma
680172|NCT00014573|adult choroid plexus tumor
680173|NCT00014573|recurrent childhood ependymoma
680174|NCT00014573|adult grade III meningioma
680175|NCT00014573|adult giant cell glioblastoma
680176|NCT00014573|adult gliosarcoma
680177|NCT00014560|refractory chronic lymphocytic leukemia
680178|NCT00014560|recurrent grade 1 follicular lymphoma
680179|NCT00014560|recurrent grade 2 follicular lymphoma
680180|NCT00014560|recurrent grade 3 follicular lymphoma
680181|NCT00014560|recurrent adult diffuse small cleaved cell lymphoma
680182|NCT00014560|recurrent adult diffuse mixed cell lymphoma
680183|NCT00014560|recurrent adult diffuse large cell lymphoma
680184|NCT00014560|recurrent adult immunoblastic large cell lymphoma
680185|NCT00014560|recurrent adult lymphoblastic lymphoma
680186|NCT00014560|recurrent adult Burkitt lymphoma
680187|NCT00014560|recurrent mantle cell lymphoma
680188|NCT00014560|recurrent small lymphocytic lymphoma
680189|NCT00014300|recurrent adult brain tumor
680190|NCT00014300|adult glioblastoma
680191|NCT00014300|adult giant cell glioblastoma
680192|NCT00014300|adult gliosarcoma
680193|NCT00014287|stage 0 bladder cancer
680194|NCT00014287|stage I bladder cancer
680195|NCT00014287|recurrent bladder cancer
680196|NCT00014274|stage III bladder cancer
680197|NCT00014274|stage IV bladder cancer
680198|NCT00014274|transitional cell carcinoma of the bladder
680199|NCT00014274|anterior urethral cancer
680200|NCT00014274|posterior urethral cancer
680201|NCT00014274|urethral cancer associated with invasive bladder cancer
680202|NCT00014274|metastatic transitional cell cancer of the renal pelvis and ureter
680203|NCT00014274|regional transitional cell cancer of the renal pelvis and ureter
680204|NCT00014261|unspecified adult solid tumor, protocol specific
680205|NCT00014248|unspecified adult solid tumor, protocol specific
680206|NCT00014248|cachexia
680207|NCT00014222|stage I breast cancer
680208|NCT00014222|stage II breast cancer
680209|NCT00014222|stage IIIA breast cancer
680210|NCT00014222|stage IIIB breast cancer
680211|NCT00014209|recurrent adult Hodgkin lymphoma
680212|NCT00014209|recurrent adult diffuse mixed cell lymphoma
680213|NCT00014209|recurrent adult diffuse large cell lymphoma
680214|NCT00014209|recurrent adult immunoblastic large cell lymphoma
680215|NCT00014209|anaplastic large cell lymphoma
680216|NCT00014196|squamous cell lung cancer
680217|NCT00014196|large cell lung cancer
680218|NCT00014196|stage IIIB non-small cell lung cancer
680219|NCT00014196|adenocarcinoma of the lung
680220|NCT00014183|stage IV renal cell cancer
680221|NCT00014183|recurrent renal cell cancer
680222|NCT00014144|recurrent bladder cancer
680223|NCT00014144|stage IV bladder cancer
680224|NCT00014144|transitional cell carcinoma of the bladder
680225|NCT00014144|recurrent urethral cancer
680226|NCT00014144|urethral cancer associated with invasive bladder cancer
680227|NCT00014144|metastatic transitional cell cancer of the renal pelvis and ureter
680228|NCT00014144|recurrent transitional cell cancer of the renal pelvis and ureter
680229|NCT00014144|anterior urethral cancer
680230|NCT00014144|posterior urethral cancer
680231|NCT00014131|stage III renal cell cancer
680232|NCT00014131|stage IV renal cell cancer
680233|NCT00014131|recurrent renal cell cancer
680234|NCT00014118|stage III squamous cell carcinoma of the oropharynx
680235|NCT00014118|stage IV squamous cell carcinoma of the oropharynx
680236|NCT00014118|stage III squamous cell carcinoma of the larynx
680237|NCT00014118|stage IV squamous cell carcinoma of the larynx
680238|NCT00014105|recurrent adult brain tumor
680239|NCT00014105|adult glioblastoma
680240|NCT00014105|adult giant cell glioblastoma
680241|NCT00014105|adult gliosarcoma
680242|NCT00014092|stage IV melanoma
680243|NCT00014092|recurrent melanoma
680244|NCT00014079|colon cancer
680245|NCT00014079|rectal cancer
680246|NCT00014066|stage I non-small cell lung cancer
680247|NCT00014066|recurrent non-small cell lung cancer
680248|NCT00014066|limited stage small cell lung cancer
680249|NCT00014066|recurrent small cell lung cancer
680250|NCT00014066|stage 0 non-small cell lung cancer
680251|NCT00014053|Reference Values
680252|NCT00014053|HIV Seropositivity
680253|NCT00014053|Immune System
680254|NCT00014053|CD4-Positive T-Lymphocytes
680255|NCT00014053|HIV Seronegativity
680256|NCT00014053|Antigens, CD
680257|NCT00014040|Angina Pectoris
680258|NCT00014040|Endothelium
680259|NCT00014040|Platelets
680260|NCT00014040|Inflammation
680261|NCT00014040|Atherosclerosis
680262|NCT00014040|Coronary Artery Disease
680263|NCT00014040|Chest Pain
680264|NCT00014040|Nitrous Oxide Inhalation
680265|NCT00014040|Treadmill Exercise
680266|NCT00014027|Omega-3 Fatty Acids
680267|NCT00014027|Cerebrospinal Fluid
680268|NCT00014027|Neurotransmitters
680269|NCT00014027|Cardiovascular
680270|NCT00014027|Reactivity
680271|NCT00014027|Healthy Volunteer
680272|NCT00014027|Lumbar Puncture
680273|NCT00014027|MRI
680274|NCT00014014|Zidovudine
680275|NCT00014014|Phosphorylation
680276|NCT00014014|Drug Administration Schedule
680277|NCT00014014|Lamivudine
680278|NCT00014014|Reverse Transcriptase Inhibitors
680279|NCT00014014|Anti-HIV Agents
680280|NCT00014014|Pharmacokinetics
680281|NCT00014014|Combivir
680282|NCT00014001|Antipsychotic Treatment
680283|NCT00014001|Effectiveness
680284|NCT00013975|Framingham Risk Scoring
680285|NCT00013975|Brachial Artery Reactivity
680286|NCT00013975|EPC Colony Assay
680287|NCT00013975|Healthy Volunteer
680288|NCT00013975|Atherosclerosis Risk Factors
680289|NCT00013975|Cholesterol
680290|NCT00013975|Hypertension
680291|NCT00013975|Smoking
680292|NCT00013975|Diabetes
680293|NCT00013975|Postmenopausal
680294|NCT00013975|Heart Disease Risk Factors
680295|NCT00013975|Risk Factors
680296|NCT00013949|Holter monitoring
680297|NCT00013949|ECG
680298|NCT00013949|Cardiac
680299|NCT00013949|particulate exposure
680300|NCT00013936|Instrument Development
680301|NCT00013936|Psychophysical Methods
680302|NCT00013936|ETDRS
680303|NCT00013936|Computer-Based Methods
680304|NCT00013936|Validation Study
680305|NCT00013936|Visual Acuity
680306|NCT00013936|Vision Tests/Instrumentation
680307|NCT00013936|Psychophysics
680308|NCT00013936|Modified Binary Search
680309|NCT00013936|Visual Acuity Test
680310|NCT00013923|Nutritional Supplement
680311|NCT00013910|glucagon-like peptide 1
680312|NCT00013897|Placebos
680313|NCT00013897|Drug Therapy, Combination
680314|NCT00013897|Zidovudine
680315|NCT00013897|HIV Protease Inhibitors
680316|NCT00013897|Lamivudine
680317|NCT00013897|RNA, Viral
680318|NCT00013897|Reverse Transcriptase Inhibitors
680319|NCT00013897|Anti-HIV Agents
680320|NCT00013897|Viral Load
680321|NCT00013897|BMS 232632
680322|NCT00013897|efavirenz
680323|NCT00013884|HIV
680324|NCT00013884|T20
680325|NCT00013884|HAART
680326|NCT00013884|Interruption
680327|NCT00013884|Therapy
680328|NCT00013884|Fusion Inhibitor T20
680329|NCT00013884|Treatment Interuption
680330|NCT00013871|Measles-Mumps-Rubella Vaccine
680331|NCT00013871|Antibodies, Viral
680332|NCT00013871|Hepatitis B Vaccines
680333|NCT00013871|Immunization, Secondary
680334|NCT00013871|Pneumococcal Vaccines
680335|NCT00013871|Antiretroviral Therapy, Highly Active
680336|NCT00013871|Diphtheria-Tetanus-acellular Pertussis Vaccines
680337|NCT00013858|methylmercury
680338|NCT00013858|PCBs
680339|NCT00013858|lead
680340|NCT00013858|fish consumption
680341|NCT00013858|breast-feeding
680342|NCT00013845|Seizures
680343|NCT00013845|Anti-Epileptic Drugs
680344|NCT00013845|Pharmacotherapy
680345|NCT00013845|Neuropsychology
680346|NCT00013845|Temporal Lobe Epilepsy
680347|NCT00013845|Frontal Lobe Epilepsy
680348|NCT00013845|Complex Partial Seizures
680349|NCT00013845|Grand Mal Seizures
680350|NCT00013845|Generalized Seizures
680351|NCT00013845|Epilepsy
680352|NCT00013832|Pressure
680353|NCT00013832|Swallowing
680354|NCT00013832|Tongue
680355|NCT00013832|Healthy Volunteer
680356|NCT00013832|Dysphagia
680357|NCT00013819|lead poisoning
680358|NCT00013819|central nervous system
680359|NCT00013819|peripheral nervous system
680360|NCT00013819|occupational health
680361|NCT00013819|genetic susceptibility
680362|NCT00013806|Relapsed and refractory neuroblastoma
680363|NCT00013780|ozone uptake
680364|NCT00013780|inhalation toxicology
680365|NCT00013780|nasal cavities
680366|NCT00013780|antioxidants
680367|NCT00013767|Pesticide
680368|NCT00013767|Insecticide
680369|NCT00013767|Organophosphate
680370|NCT00013767|Child Health
680371|NCT00013767|Exposure Prevention
680372|NCT00013754|pesticide
680373|NCT00013754|insecticide
680374|NCT00013754|organophosphate
680375|NCT00013754|exposure
680376|NCT00013754|child health
680377|NCT00013741|Acute Myocardial Infarction
680378|NCT00013741|Diabetes Mellitus
680379|NCT00013741|Renal Dialysis
680380|NCT00013741|Heart Attack
680381|NCT00013741|Coronary Heart Disease
680382|NCT00013728|asthma
680383|NCT00013728|particulate matter
680384|NCT00013715|Asthma
680385|NCT00013715|Rhinovirus
680386|NCT00013715|Ozone
680387|NCT00013702|Immunology
680388|NCT00013702|Cirrhosis
680389|NCT00013702|Ascites
680390|NCT00013702|Open-Label
680391|NCT00013702|Chronic
680392|NCT00013702|HIV
680393|NCT00013702|Hepatitis B
680394|NCT00013689|Lymphadenopathy
680395|NCT00013689|Splenomegaly
680396|NCT00013689|Children
680397|NCT00013689|Tomography
680398|NCT00013689|Autoimmune Lymphoproliferative Syndrome (ALPS)
680399|NCT00013663|Virus Replication
680400|NCT00013663|HIV-1
680401|NCT00013663|AIDS Vaccines
680402|NCT00013663|RNA, Viral
680403|NCT00013663|Avipoxvirus
680404|NCT00013663|Genetic Vectors
680405|NCT00013663|Viral Load
680406|NCT00013663|aldesleukin
680407|NCT00013663|Antiretroviral Therapy, Highly Active
680408|NCT00013663|HIV Therapeutic Vaccine
680409|NCT00013663|Treatment Interruption
680410|NCT00013650|Alzheimer's Disease
680411|NCT00013650|Immunomodulatory
680412|NCT00013650|Antiinflammatory
680413|NCT00013650|Cyclophosphamide
680414|NCT00013650|Non-steroidal
680415|NCT00013650|Complement
680416|NCT00013650|Immune Function
680417|NCT00013650|Immunotherapy
680418|NCT00013637|Osteoporosis
680419|NCT00013637|Lead
680420|NCT00013624|Riluzole
680421|NCT00013624|Dyskinesias
680422|NCT00013624|L-Dopa Infusion
680423|NCT00013624|Parkinson's Disease
680424|NCT00013611|HIV
680425|NCT00013611|Proleukin
680426|NCT00013611|IL-2
680427|NCT00013611|Adult
680428|NCT00013611|HAART
680429|NCT00013611|Treatment Experienced
680430|NCT00013598|Insulin Resistance
680431|NCT00013598|Obesity
680432|NCT00013598|Diabetes
680433|NCT00013598|Fatty Liver
680434|NCT00013598|Cirrhosis
680435|NCT00013598|Thiazolidinediones
680436|NCT00013598|Peroxisome Proliferator-Activated Receptor Gamma
680437|NCT00013598|PPARgamma
680438|NCT00013598|Nonalcoholic Steatohepatitis
680439|NCT00013598|Pioglitazone
680440|NCT00013598|Non-Alcoholic Steatohepatitis
680441|NCT00013598|Liver Biopsy
680442|NCT00013598|Pharmacotherapy
680443|NCT00013585|Cognitive Disorders
680444|NCT00013585|AIDS Dementia Complex
680445|NCT00013585|Selegiline
680446|NCT00013585|Administration, Cutaneous
680447|NCT00013585|Neuroprotective Agents
680448|NCT00013572|Injections, Intramuscular
680449|NCT00013572|Injections, Intradermal
680450|NCT00013572|Injections, Subcutaneous
680451|NCT00013572|HIV-1
680452|NCT00013572|AIDS Vaccines
680453|NCT00013572|Dendritic Cells
680454|NCT00013572|HIV Seronegativity
680455|NCT00013572|Genes, env
680456|NCT00013572|Genes, pol
680457|NCT00013572|Genes, gag
680458|NCT00013572|Transfection
680459|NCT00013572|HIV Preventive Vaccine
680460|NCT00013559|Sleep Disturbance
680461|NCT00013559|Developmental Delay/ MR
680462|NCT00013559|Deletion 17p11.2
680463|NCT00013559|Chromosomal Abnormalities
680464|NCT00013559|Behavioral Phenotype
680465|NCT00013559|Smith-Magenis Syndrome
680466|NCT00013559|Genetics
680467|NCT00013546|Osteoporosis
680468|NCT00013546|Body Composition
680469|NCT00013546|Estrogen
680470|NCT00013546|Androgen
680471|NCT00013546|Ovarian Failure
680472|NCT00013546|Turner's Syndrome
680473|NCT00013546|Hormone Replacement
680474|NCT00013546|Turners
680475|NCT00013546|Turner's
680476|NCT00013546|TS
680477|NCT00013533|Leukemia
680478|NCT00013533|Myelodysplastic Syndrome
680479|NCT00013533|Bone Marrow Transplant
680480|NCT00013533|Pediatric Oncology
680481|NCT00013533|Lymphoma
680482|NCT00013533|Efficacy
680483|NCT00013533|Safety
680484|NCT00013533|Childhood Cancer
680485|NCT00013520|HIV-1
680486|NCT00013520|Didanosine
680487|NCT00013520|Drug Therapy, Combination
680488|NCT00013520|Zidovudine
680489|NCT00013520|Nevirapine
680490|NCT00013520|Stavudine
680491|NCT00013520|Lamivudine
680492|NCT00013520|RNA, Viral
680493|NCT00013520|Reverse Transcriptase Inhibitors
680494|NCT00013520|Anti-HIV Agents
680495|NCT00013520|Viral Load
680496|NCT00013520|Combivir
680497|NCT00013520|BMS 232632
680498|NCT00013520|Efavirenz
680499|NCT00013520|Treatment Naive
680500|NCT00013507|Frail
680501|NCT00013507|FIT
680502|NCT00013507|transfer
680503|NCT00013507|continence
680504|NCT00013507|ambulation
680505|NCT00013507|balance
680506|NCT00013507|fall risk
680507|NCT00013507|strength,endurance
680508|NCT00013494|Hemiplegia
680509|NCT00013494|elderly
680510|NCT00013494|Video
680511|NCT00013494|F-PAT,Functional Performance
680512|NCT00013494|digitized videoclips
680513|NCT00013481|stroke, hemiparesis, CNS, motor coordination
680514|NCT00013468|Hearing loss, ear, steroids, auditory
680515|NCT00013455|Hearing aid, hearing impaired
680516|NCT00013442|Aphasia, auditory evoked, aging
680517|NCT00013429|Vision, Opthalmology, blindness, aging
680518|NCT00013416|Hearing loss, hearing aid, amplification
680519|NCT00013403|Vision, quality of life
680520|NCT00013390|Auditory, tinnitus
680521|NCT00013377|Low vision, Driving rehabilitation
680522|NCT00013364|Hearing loss, speech recognition
680523|NCT00013351|Aging adult, attention, falls, vision
680524|NCT00013338|Spinal cord injury, ambulation, treadmill
680525|NCT00013325|Spinal cord injury, heart disease, electrocardiography
680526|NCT00013312|Spinal cord injury, gastrointestinal motility, gastrointestinal transit
680527|NCT00013299|Foot ulcers, amputation prevention, diabetes, footwear, insoles
680528|NCT00013286|Diabetes mellitus, foot ulcer, endothelium
680529|NCT00013273|Venous insufficiency, plethysmography, hypertension
680530|NCT00013260|Case management
680531|NCT00013260|Nurse intervention
680532|NCT00013195|Telephone
680533|NCT00013026|Congestive Heart Failure
680534|NCT00012844|Musculoskeletal Disorders
680535|NCT00012844|Patient Lifting
680536|NCT00012844|Occupational Accidents
680537|NCT00012779|Health Care Education
680538|NCT00012779|Health Care Cost
680539|NCT00012558|Psychotic Disorders
680540|NCT00012558|Mood Disorders
680541|NCT00012558|Manic-Depressive Illness
680542|NCT00012558|Hypomania
680543|NCT00012558|Mania
680544|NCT00012558|Mood Stabilizer
680545|NCT00012545|Stem Cells
680546|NCT00012545|Sickle Cell Disease
680547|NCT00012545|Umbilical Cord Blood
680548|NCT00012519|Dose-Response Relationship, Drug
680549|NCT00012519|Drug Therapy, Combination
680550|NCT00012519|HIV Protease Inhibitors
680551|NCT00012519|Ritonavir
680552|NCT00012519|Indinavir
680553|NCT00012519|Anti-HIV Agents
680554|NCT00012519|Viral Load
680555|NCT00012519|Pharmacokinetics
680556|NCT00012519|Treatment Experienced
680557|NCT00012493|Cardiac event
680558|NCT00012493|Heart disease
680559|NCT00012493|Particulate Matter
680560|NCT00012480|Lead
680561|NCT00012480|Male infertility
680562|NCT00012480|Gene expression
680563|NCT00012480|Economics, Medical
680564|NCT00012467|Interferon-gamma, Recombinant
680565|NCT00012467|Injections, Subcutaneous
680566|NCT00012467|Itraconazole
680567|NCT00012467|Dose-Response Relationship, Drug
680568|NCT00012467|Fluconazole
680569|NCT00012467|Flucytosine
680570|NCT00012467|Antifungal Agents
680571|NCT00012467|Amphotericin B
680572|NCT00012467|Meningitis, Cryptococcal
680573|NCT00012454|Transforming Growth Factor-Beta
680574|NCT00012454|Stroke
680575|NCT00012454|Prevention
680576|NCT00012454|Mucosal Tolerance
680577|NCT00012454|E-selectin
680578|NCT00012441|Renal Dialysis
680579|NCT00011583|Cerebrovascular
680580|NCT00011583|Hemiplegia
680581|NCT00011583|Robotics
680582|NCT00011570|defecation
680583|NCT00011570|electrical stimulation
680584|NCT00011570|penile erection
680585|NCT00011570|Spinal cord injury
680586|NCT00011570|urology
680587|NCT00011557|Bladder, electromagnetic fields, Spinal cord injury
680588|NCT00011544|wheelchair, biomechanics, aging, functional outcome, disability
680589|NCT00011531|Decubitus Ulcers
680590|NCT00011531|dehiscence
680591|NCT00011531|SCI
680592|NCT00011531|wound healing
680593|NCT00011518|Arsenic
680594|NCT00011518|Bladder Cancer
680595|NCT00011518|Drinking Water
680596|NCT00011505|G-CSF
680597|NCT00011505|Leukapheresis
680598|NCT00011505|Stem Cell Cryopreservation
680599|NCT00011505|Central Line Placement
680600|NCT00011505|G-CSF Administration
680601|NCT00011505|Stem Cell Preservation
680602|NCT00011505|Diamond Blackfan Anemia
680603|NCT00011505|Healthy Volunteer
680604|NCT00011492|Oral Cancer
680605|NCT00011492|Squamous Cell Cancer
680606|NCT00011492|Head and Neck Cancer
680607|NCT00011492|Laryngeal Cancer
680608|NCT00011492|Pharnygeal Cancer
680609|NCT00011492|Squamous Cell Carcinoma
680610|NCT00011479|Administration, Oral
680611|NCT00011479|Drug Administration Schedule
680612|NCT00011479|Reverse Transcriptase Inhibitors
680613|NCT00011479|Anti-HIV Agents
680614|NCT00011479|Pharmacokinetics
680615|NCT00011479|abacavir
680616|NCT00011466|ADHD
680617|NCT00011466|Attention Deficit Hyperactivity Disorder
680618|NCT00011466|Carbohydrate Craving
680619|NCT00010309|stage II melanoma
680620|NCT00010309|stage III melanoma
680621|NCT00010309|stage IV melanoma
680622|NCT00012428|Cognitive development
680623|NCT00012428|Prenatal exposure
680624|NCT00012428|PCBs
680625|NCT00012389|stage IV colon cancer
680626|NCT00012389|stage IV rectal cancer
680627|NCT00012389|recurrent colon cancer
680628|NCT00012389|recurrent rectal cancer
680629|NCT00012363|stage IV gastric cancer
680630|NCT00012363|recurrent gastric cancer
680631|NCT00012363|stage IV esophageal cancer
680632|NCT00012363|recurrent esophageal cancer
680633|NCT00012363|adenocarcinoma of the stomach
680634|NCT00012363|squamous cell carcinoma of the esophagus
680635|NCT00012363|adenocarcinoma of the esophagus
680636|NCT00012350|refractory multiple myeloma
680637|NCT00012350|stage II multiple myeloma
680638|NCT00012350|stage III multiple myeloma
680639|NCT00012350|plasma cell neoplasm
680640|NCT00012337|stage IV renal cell cancer
680641|NCT00012337|recurrent renal cell cancer
680642|NCT00012324|localized unresectable adult primary liver cancer
680643|NCT00012324|advanced adult primary liver cancer
680644|NCT00012324|recurrent adult primary liver cancer
680645|NCT00012324|adult primary hepatocellular carcinoma
680646|NCT00012311|stage IV breast cancer
680647|NCT00012311|recurrent breast cancer
680648|NCT00012259|relapsing chronic myelogenous leukemia
680649|NCT00012259|blastic phase chronic myelogenous leukemia
680650|NCT00012259|chronic myelogenous leukemia, BCR-ABL1 positive
680651|NCT00012246|stage II colon cancer
680652|NCT00012246|stage III colon cancer
680653|NCT00012246|stage IV colon cancer
680654|NCT00012246|stage II gastric cancer
680655|NCT00012246|stage III gastric cancer
680656|NCT00012246|stage IV gastric cancer
680657|NCT00012246|recurrent gastric cancer
680658|NCT00012246|stage II pancreatic cancer
680659|NCT00012246|stage III pancreatic cancer
680660|NCT00012246|recurrent pancreatic cancer
680661|NCT00012246|stage II rectal cancer
680662|NCT00012246|stage III rectal cancer
680663|NCT00012246|stage IV rectal cancer
680664|NCT00012246|recurrent colon cancer
680665|NCT00012246|recurrent rectal cancer
680666|NCT00012246|stage II esophageal cancer
680667|NCT00012246|stage III esophageal cancer
680668|NCT00012246|stage IV esophageal cancer
680669|NCT00012246|recurrent esophageal cancer
680670|NCT00012246|adenocarcinoma of the stomach
680671|NCT00012246|small intestine adenocarcinoma
680672|NCT00012246|localized gallbladder cancer
680673|NCT00012246|unresectable gallbladder cancer
680674|NCT00012246|recurrent gallbladder cancer
680675|NCT00012246|localized extrahepatic bile duct cancer
680676|NCT00012246|unresectable extrahepatic bile duct cancer
680677|NCT00012246|recurrent extrahepatic bile duct cancer
680678|NCT00012246|recurrent small intestine cancer
680679|NCT00012246|adenocarcinoma of the esophagus
680680|NCT00012246|adenocarcinoma of the colon
680681|NCT00012246|adenocarcinoma of the rectum
680682|NCT00012246|adenocarcinoma of the gallbladder
680683|NCT00012246|adenocarcinoma of the extrahepatic bile duct
680684|NCT00012246|adenocarcinoma of the pancreas
680685|NCT00012246|stage IV pancreatic cancer
680686|NCT00012220|adenocarcinoma of the pancreas
680687|NCT00012220|stage IV pancreatic cancer
680688|NCT00012207|recurrent grade 1 follicular lymphoma
680689|NCT00012207|recurrent grade 2 follicular lymphoma
680690|NCT00012207|recurrent grade 3 follicular lymphoma
680691|NCT00012207|recurrent mantle cell lymphoma
680692|NCT00012207|recurrent marginal zone lymphoma
680693|NCT00012207|recurrent small lymphocytic lymphoma
680694|NCT00012207|refractory chronic lymphocytic leukemia
680695|NCT00012168|stage 0 oropharyngeal cancer
680696|NCT00012168|stage 0 lip and oral cavity cancer
680697|NCT00012168|stage I squamous cell carcinoma of the lip and oral cavity
680698|NCT00012168|stage II squamous cell carcinoma of the lip and oral cavity
680699|NCT00012168|stage III squamous cell carcinoma of the lip and oral cavity
680700|NCT00012168|stage IV squamous cell carcinoma of the lip and oral cavity
680701|NCT00012168|stage I squamous cell carcinoma of the oropharynx
680702|NCT00012168|stage II squamous cell carcinoma of the oropharynx
680703|NCT00012168|stage III squamous cell carcinoma of the oropharynx
680704|NCT00012168|stage IV squamous cell carcinoma of the oropharynx
680705|NCT00012155|stage IV colon cancer
680706|NCT00012155|recurrent colon cancer
680707|NCT00012155|adenocarcinoma of the colon
680708|NCT00012155|liver metastases
680709|NCT00012142|stage IV prostate cancer
680710|NCT00012129|stage IV breast cancer
680711|NCT00012129|stage IIIA breast cancer
680712|NCT00012129|recurrent breast cancer
680713|NCT00012129|stage IIIB breast cancer
680714|NCT00012129|male breast cancer
680715|NCT00012116|tumors metastatic to brain
680716|NCT00012103|non-small cell lung cancer
680717|NCT00012103|small cell lung cancer
680718|NCT00012090|recurrent ovarian epithelial cancer
680719|NCT00012090|fallopian tube cancer
680720|NCT00012090|primary peritoneal cavity cancer
680721|NCT00012064|stage IV melanoma
680722|NCT00012064|recurrent melanoma
680723|NCT00012051|recurrent grade 3 follicular lymphoma
680965|NCT00011193|Sedentary
680724|NCT00012051|recurrent adult diffuse large cell lymphoma
680725|NCT00012038|recurrent adult brain tumor
680726|NCT00012038|adult glioblastoma
680727|NCT00012038|adult anaplastic astrocytoma
680728|NCT00012038|adult anaplastic oligodendroglioma
680729|NCT00012038|adult giant cell glioblastoma
680730|NCT00012038|adult gliosarcoma
680731|NCT00012025|stage IV breast cancer
680732|NCT00012025|recurrent breast cancer
680733|NCT00012025|stage IIIB breast cancer
680734|NCT00012025|stage IIIC breast cancer
680735|NCT00012012|radiation toxicity
680736|NCT00012012|stage III cervical cancer
680737|NCT00012012|stage IVA cervical cancer
680738|NCT00012012|cervical squamous cell carcinoma
680739|NCT00012012|cervical adenocarcinoma
680740|NCT00012012|cervical adenosquamous cell carcinoma
680741|NCT00011999|stage III squamous cell carcinoma of the lip and oral cavity
680742|NCT00011999|stage IV squamous cell carcinoma of the lip and oral cavity
680743|NCT00011999|stage III squamous cell carcinoma of the oropharynx
680744|NCT00011999|stage IV squamous cell carcinoma of the oropharynx
680745|NCT00011999|stage III squamous cell carcinoma of the hypopharynx
680746|NCT00011999|stage IV squamous cell carcinoma of the hypopharynx
680747|NCT00011999|stage III squamous cell carcinoma of the larynx
680748|NCT00011999|stage IV squamous cell carcinoma of the larynx
680749|NCT00011973|stage III renal cell cancer
680750|NCT00011973|stage IV renal cell cancer
680751|NCT00011973|recurrent renal cell cancer
680752|NCT00011960|stage I gastric cancer
680753|NCT00011960|stage II gastric cancer
680754|NCT00011960|stage III gastric cancer
680755|NCT00011960|stage I esophageal cancer
680756|NCT00011960|stage II esophageal cancer
680757|NCT00011960|stage III esophageal cancer
680758|NCT00011960|adenocarcinoma of the stomach
680759|NCT00011960|adenocarcinoma of the esophagus
680760|NCT00011934|relapsing chronic myelogenous leukemia
680761|NCT00011934|chronic phase chronic myelogenous leukemia
680762|NCT00011934|Philadelphia chromosome positive chronic myelogenous leukemia
680763|NCT00011934|Philadelphia chromosome negative chronic myelogenous leukemia
680764|NCT00011921|limited stage small cell lung cancer
680765|NCT00011921|extensive stage small cell lung cancer
680766|NCT00011908|Safety
680767|NCT00011908|B-Lymphocyte Depletion
680768|NCT00011908|Anti-CD22
680769|NCT00011908|Response
680770|NCT00011908|Efficacy
680771|NCT00011908|Lupus
680772|NCT00011908|Immunotherapy
680773|NCT00011895|HIV-1
680774|NCT00011895|Drug Therapy, Combination
680775|NCT00011895|Zidovudine
680776|NCT00011895|Lamivudine
680777|NCT00011895|Drug Combinations
680778|NCT00011895|RNA, Viral
680779|NCT00011895|Reverse Transcriptase Inhibitors
680780|NCT00011895|Anti-HIV Agents
680781|NCT00011895|Viral Load
680782|NCT00011895|abacavir
680783|NCT00011895|efavirenz
680784|NCT00011856|Intracranial Aneurysms
680785|NCT00011856|Cerebral
680786|NCT00011856|Loci
680787|NCT00011856|Susceptibility Genes
680788|NCT00011856|Cerebral Aneurysm
680789|NCT00011856|Familial Cerebral Aneurysm
680790|NCT00011856|Genetics
680791|NCT00011843|X-Linked
680792|NCT00011843|Heterogeneous
680793|NCT00011843|Embryologic Development
680794|NCT00011843|Mental Retardation
680795|NCT00011843|Brain Development
680796|NCT00011843|Microphthalmia
680797|NCT00011843|Anophthalmia
680798|NCT00011843|Malformations
680799|NCT00011843|Lenz Dysplasia
680800|NCT00011843|Microphthalmia/Anophthalmia
680801|NCT00011843|Mutation Screening
680802|NCT00011843|Gene Characterization
680803|NCT00011830|Stem Cell Cryopreservation
680804|NCT00011830|Leukapheresis
680805|NCT00011817|Evaluation and Treatment
680806|NCT00011817|Ophthalmic Genetic Diseases
680807|NCT00011817|Genetic Testing
680808|NCT00011817|Genetic Eye Diseases
680809|NCT00011817|Evaluation
680810|NCT00011804|Low Back Pain
680811|NCT00011804|Lumbar Radiculopathy
680812|NCT00011804|Anticonvulsants
680813|NCT00011804|Neuropathic Pain
680814|NCT00011804|Analgesia
680815|NCT00011804|Sciatica
680816|NCT00011791|CAH
680817|NCT00011791|Catecholamines
680818|NCT00011791|Adrenal Medulla
680819|NCT00011791|Endocrine
680820|NCT00011791|Congenital Adrenal Hyperplasia
680821|NCT00011791|Exercise
680822|NCT00011791|Healthy Volunteer
680823|NCT00011778|Cell Cycle
680824|NCT00011778|NFKB
680825|NCT00011778|Combined Modality
680826|NCT00011778|Radiosensitizer
680827|NCT00011778|Ubiquitin
680828|NCT00011778|Head and Neck Cancer
680829|NCT00011778|Squamous Cell Carcinoma
680830|NCT00011778|Radiation Therapy
680831|NCT00011778|Protease Inhibitor
680832|NCT00011765|Aggression
680833|NCT00011765|Serotonin Reuptake Inhibitors (SSRI)
680834|NCT00011765|Rage
680835|NCT00011765|Fear
680836|NCT00011765|Violence
680837|NCT00011765|Domestic Violence
680838|NCT00011765|Physical Aggression
680839|NCT00011765|Serotonin Reuptake Inhibitor
680840|NCT00011752|Serotonin Reuptake
680841|NCT00011752|Large Neutral Amino Acids
680842|NCT00011752|5-Hydroxyindoleacetic Acid
680843|NCT00011752|Alcoholism
680844|NCT00011752|PET
680845|NCT00011752|TRP
680846|NCT00011752|Tryptophan Depletion
680847|NCT00011752|Healthy Volunteer
680848|NCT00011739|Low back pain, Magnetic resonance imaging (MRI),
680849|NCT00011726|Pregnancy
680850|NCT00011726|Lead Exposure
680851|NCT00011726|Lactation
680852|NCT00011726|Bone Mineralization
680853|NCT00011726|Maternal-Fetal Exchange
680854|NCT00011713|Semen
680855|NCT00011713|Infertility
680856|NCT00011713|ART - Assisted Reproduction Technology
680857|NCT00011713|Phthalates
680858|NCT00011713|Bisphenol A
680859|NCT00011700|idiopathic pulmonary hemorrhage in infants,
680860|NCT00011700|toxigenic mold exposure
680861|NCT00011687|Fertility
680862|NCT00011687|Hormones
680863|NCT00011687|Semen
680864|NCT00011687|Reproductive Health
680865|NCT00011674|Lead
680866|NCT00011674|Prenatal
680867|NCT00011674|Development
680868|NCT00011674|Children
680869|NCT00011674|Psychology
680870|NCT00011674|Toxicology
680871|NCT00011674|Teratology
680872|NCT00011661|Lead poisoning
680873|NCT00011661|Native Americans
680874|NCT00011648|Echocardiogram
680875|NCT00011648|Morbidity
680876|NCT00011648|Mortality
680877|NCT00011648|Sickle Cell Anemia
680878|NCT00011648|Secondary Pulmonary Hypertension
680879|NCT00011635|Caffeine
680880|NCT00011635|Cytochrome P 450
680881|NCT00011635|Dextromethorphan
680882|NCT00011635|Drug Interaction
680883|NCT00011635|Metabolism
680884|NCT00011635|Drug Metabolism
680885|NCT00011635|Healthy Volunteer
680886|NCT00011635|Milk Thistle
680887|NCT00011609|Robotics; Activities of Daily Living; Spinal Cord Injuries
680888|NCT00011596|Hemiplegia, gait, electric stimulation
680889|NCT00011453|NQO1
680890|NCT00011453|DT-diaphorase
680891|NCT00011453|Benzene
680892|NCT00011453|Leukemia
680893|NCT00011453|Aplastic anemia
680894|NCT00011440|Allergy
680895|NCT00011440|Air pollution
680896|NCT00011440|Lung function
680897|NCT00011440|Inflammation
680898|NCT00011414|Drug Resistance
680899|NCT00011414|PEDIATRIC SOLID TUMORS
680900|NCT00011414|Chemotherapy
680901|NCT00011414|p-glycoprotien
680902|NCT00011414|Brain Tumors
680903|NCT00011414|Childhood Cancer
680904|NCT00011414|Brain Tumor
680905|NCT00011388|Organochlorine compounds
680906|NCT00011388|Endocrine disruptors
680907|NCT00011388|Sex Hormones
680908|NCT00011388|Reproductive function
680909|NCT00011388|Menstrual Disturbances
680910|NCT00011375|Phosphodiesterase Inhibitor
680911|NCT00011375|Immunology
680912|NCT00011375|Immunomodulation
680913|NCT00011375|Antidepressant
680914|NCT00011375|Therapy
680915|NCT00011375|Multiple Sclerosis
680916|NCT00011375|Immunotherapy
680917|NCT00011362|NICHD Neonatal Research Network
680918|NCT00011362|Extremely Low Birth Weight (ELBW)
680919|NCT00011362|Prematurity
680920|NCT00011362|Dexamethasone
680921|NCT00011362|Glucocorticoids
680922|NCT00011362|Respiratory Distress Syndrome
680923|NCT00011362|Respiratory insufficiency
680924|NCT00011362|Steroids
680925|NCT00011349|Prostate Cancer
680926|NCT00011336|SCI
680927|NCT00011336|chronic respiratory symptoms
680928|NCT00011336|measures of pulmonary function
680929|NCT00011336|respiratory illness
680930|NCT00011323|osteoporosis,smoking, alcohol, caffeine
680931|NCT00011310|Particulates
680932|NCT00011310|Air Pollution
680933|NCT00011310|Cardiopulmonary Disease
680934|NCT00011310|Lung
680935|NCT00011310|Inflammation
680936|NCT00011284|Liver
680937|NCT00011284|Inflammation
680938|NCT00011284|Endotoxin
680939|NCT00011284|Neutrophils
680940|NCT00011284|Hepatocytes
680941|NCT00011258|Atherosclerosis of the carotid arteries
680942|NCT00011258|stroke
680943|NCT00011258|lipoprotein metabolism
680944|NCT00011258|paraoxonase
680945|NCT00011245|Arachnoiditis
680946|NCT00011245|Myelography
680947|NCT00011245|Intraoperative Ultrasonography
680948|NCT00011245|Magnetic Resonance
680949|NCT00011245|CSF Pressure
680950|NCT00011245|Trauma
680951|NCT00011245|Meningitis
680952|NCT00011245|Paralysis
680953|NCT00011245|Spondylosis
680954|NCT00011245|Spinal Syringomyelia
680955|NCT00011245|Presyringomyelia
680956|NCT00011245|Spinal Cord Edema
680957|NCT00011245|Magnetic Resonance Imaging (MRI)
680958|NCT00011245|Intraoperative Radiation
680959|NCT00011245|Ultrasonography
680960|NCT00011193|Cardiovascular Diseases
680961|NCT00011193|Hypertension
680962|NCT00011193|Postmenopausal
680963|NCT00011193|Overweight or Obese
680964|NCT00011193|Women
680966|NCT00011180|Venous thromboembolism (VTE)
680967|NCT00011180|Deep vein thrombosis (DVT)
680968|NCT00011180|Pulmonary embolism (PE)
680969|NCT00011141|Immune-mediated diabetes mellitus
680970|NCT00011128|HIV-1
680971|NCT00011128|Drug Resistance, Microbial
680972|NCT00011128|Microbial Sensitivity Tests
680973|NCT00011128|Salvage Therapy
680974|NCT00011128|Anti-HIV Agents
680975|NCT00011128|Viral Load
680976|NCT00011128|Treatment Experienced
680977|NCT00011115|overweight
680978|NCT00011102|weight gain
680979|NCT00011089|HIV-1
680980|NCT00011089|Disease Progression
680981|NCT00011089|Reverse Transcriptase Inhibitors
680982|NCT00011089|Anti-HIV Agents
680983|NCT00011089|9-(2-phosphonylmethoxypropyl)adenine
680984|NCT00011076|Deskar
680985|NCT00011076|Fibrosis
680986|NCT00011076|Myocardium
680987|NCT00011076|Scarring
680988|NCT00011076|Arrhythmia
680989|NCT00011076|Hypertrophic Cardiomyopathy
680990|NCT00011076|Left Ventricular Diastolic Dysfunction
680991|NCT00011076|Myocardial Fibrosis
680992|NCT00011063|Anti-Epileptic
680993|NCT00011063|CYP2C9
680994|NCT00011063|Herbal
680995|NCT00011063|Interaction
680996|NCT00011063|Metabolism
680997|NCT00011063|Drug Interaction
680998|NCT00011063|Drug Metabolism
680999|NCT00011063|Ginko Biloba
681000|NCT00011063|Healthy Volunteer
681001|NCT00011050|Specimen Handling
681002|NCT00011050|Blood
681003|NCT00011050|Cryopreservation
681004|NCT00011050|Lactic Acid
681005|NCT00011050|Sodium Fluoride
681006|NCT00011050|Oxalates
681007|NCT00011037|HIV Antibodies
681008|NCT00011037|HIV Antigens
681009|NCT00011037|HIV Envelope Protein gp120
681010|NCT00011037|AIDS Vaccines
681011|NCT00011037|CD4-Positive T-Lymphocytes
681012|NCT00011037|CD8-Positive T-Lymphocytes
681013|NCT00011037|Neutralization Tests
681014|NCT00011037|Haiti
681015|NCT00011037|Brazil
681016|NCT00011037|Cytotoxicity, Immunologic
681017|NCT00011037|Epitopes
681018|NCT00011037|Viral Proteins
681019|NCT00011037|Trinidad and Tobago
681020|NCT00011037|Peru
681021|NCT00011037|HIV Preventive Vaccine
681022|NCT00011037|HIV Seronegativity
681023|NCT00011011|HIV-1
681024|NCT00011011|Drug Administration Schedule
681025|NCT00011011|AIDS Vaccines
681026|NCT00011011|CD4 Lymphocyte Count
681027|NCT00011011|RNA, Viral
681028|NCT00011011|Anti-HIV Agents
681029|NCT00011011|Viral Load
681030|NCT00011011|HIV Therapeutic Vaccine
681031|NCT00011011|Treatment Interruption
681032|NCT00010998|Multiple Sclerosis
681033|NCT00010998|Yoga
681034|NCT00010985|Backpain
681035|NCT00010985|Pain
681036|NCT00010985|Alternative Medicine
681037|NCT00010985|Acupuncture
681038|NCT00010985|Chiropractic
681039|NCT00010985|Massage Therapy
681040|NCT00010959|menopause
681041|NCT00010959|hot flashes
681042|NCT00010959|botanicals
681043|NCT00010946|acupuncture
681044|NCT00010946|osteoarthritis
681045|NCT00010946|elderly
681046|NCT00010868|bipolar disorder
681047|NCT00010868|omega-3 fatty acids
681048|NCT00010868|eicosapentaenoic acid
681049|NCT00010868|docosahexaenoic acid
681050|NCT00010855|hypnosis
681051|NCT00010855|relaxation
681052|NCT00010855|invasive medical procedures
681053|NCT00010855|interventional radiology
681054|NCT00010855|conscious sedation
681055|NCT00010855|anesthesia
681056|NCT00010855|complications
681057|NCT00010855|cost analysis
681058|NCT00010855|Interventional procedures, complications
681059|NCT00010855|Angiography
681060|NCT00010855|Nephrostomy
681061|NCT00010855|Hepatic chemoembolization
681062|NCT00010855|Fibroid Embolization
681063|NCT00010829|Cardiovascular Diseases
681064|NCT00010829|Osteoporosis
681065|NCT00010829|Breast Cancer
681066|NCT00010829|Endometrial Cancer
681067|NCT00010725|CVD
681068|NCT00010712|Menopause
681069|NCT00010712|Hot Flashes
681070|NCT00010712|Osteoporosis
681071|NCT00010712|Postmenopausal
681072|NCT00010699|cvd
681073|NCT00010608|CVD
681074|NCT00010530|CVD
681075|NCT00010504|acupuncture
681076|NCT00010504|fibromyalgia
681077|NCT00010504|pain
681078|NCT00010504|analgesia
681079|NCT00010491|Diarrhea
681080|NCT00010491|complementary therapies
681081|NCT00010452|cystic hygroma
681082|NCT00010452|lymphangiomas
681083|NCT00010452|lymphatic malformations
681084|NCT00010439|arthritis & connective tissue diseases
681085|NCT00010439|idiopathic juvenile osteoporosis
681086|NCT00010439|rare disease
681087|NCT00010426|cystinosis
681088|NCT00010426|rare disease
681089|NCT00010426|renal and genitourinary disorders
681090|NCT00010413|immunologic disorders and infectious disorders
681091|NCT00010413|pemphigus
681092|NCT00010413|rare disease
681093|NCT00010400|antiphospholipid antibody syndrome
681094|NCT00010400|arthritis & connective tissue diseases
681095|NCT00010400|immunologic disorders and infectious disorders
681096|NCT00010400|rare disease
681097|NCT00010400|systemic lupus erythematosus
681098|NCT00010387|Felty syndrome
681099|NCT00010387|autoimmune hemolytic anemia
681100|NCT00010387|autoimmune neutropenia
681101|NCT00010387|hematologic disorders
681102|NCT00010387|immune thrombocytopenic purpura
681103|NCT00010387|rare disease
681104|NCT00010374|Diaphragm for Ventilatory Assist
681105|NCT00010374|environmental/toxic disorders
681106|NCT00010374|neurologic and psychiatric disorders
681107|NCT00010374|rare disease
681108|NCT00010374|spinal cord injury
681109|NCT00010348|human immunodeficiency virus infection
681110|NCT00010348|immunologic disorders and infectious disorders
681111|NCT00010348|rare disease
681112|NCT00010348|viral infection
681113|NCT00010335|arthritis & connective tissue diseases
681114|NCT00010335|dermatomyositis
681115|NCT00010335|immunologic disorders and infectious disorders
681116|NCT00010335|juvenile rheumatoid arthritis
681117|NCT00010335|rare disease
681118|NCT00010335|systemic lupus erythematosus
681119|NCT00010335|systemic sclerosis
681120|NCT00010322|stage IV breast cancer
681121|NCT00010322|recurrent breast cancer
681122|NCT00010283|stage III breast cancer
681123|NCT00010283|stage IV breast cancer
681124|NCT00010283|stage IIIA breast cancer
681125|NCT00010283|stage IIIB breast cancer
681126|NCT00010283|recurrent childhood acute lymphoblastic leukemia
681127|NCT00010283|recurrent adult Hodgkin lymphoma
681128|NCT00010283|stage IV cutaneous T-cell non-Hodgkin lymphoma
681129|NCT00010283|recurrent cutaneous T-cell non-Hodgkin lymphoma
681130|NCT00010283|Burkitt lymphoma
681131|NCT00010283|extramedullary plasmacytoma
681132|NCT00010283|refractory multiple myeloma
681133|NCT00010283|stage II ovarian epithelial cancer
681134|NCT00010283|stage III ovarian epithelial cancer
681135|NCT00010283|stage IV ovarian epithelial cancer
681136|NCT00010283|recurrent ovarian epithelial cancer
681137|NCT00010283|disseminated neuroblastoma
681138|NCT00010283|recurrent neuroblastoma
681139|NCT00010283|recurrent Wilms tumor and other childhood kidney tumors
681140|NCT00010283|stage I multiple myeloma
681141|NCT00010283|stage II multiple myeloma
681142|NCT00010283|stage III multiple myeloma
681143|NCT00010283|recurrent childhood lymphoblastic lymphoma
681144|NCT00010283|stage III chronic lymphocytic leukemia
681145|NCT00010283|stage IV chronic lymphocytic leukemia
681146|NCT00010283|recurrent childhood acute myeloid leukemia
681147|NCT00010283|recurrent adult acute myeloid leukemia
681148|NCT00010283|recurrent adult acute lymphoblastic leukemia
681149|NCT00010283|relapsing chronic myelogenous leukemia
681150|NCT00010283|refractory chronic lymphocytic leukemia
681151|NCT00010283|stage III malignant testicular germ cell tumor
681152|NCT00010283|childhood diffuse large cell lymphoma
681153|NCT00010283|recurrent malignant testicular germ cell tumor
681154|NCT00010283|childhood immunoblastic large cell lymphoma
681155|NCT00010283|chronic phase chronic myelogenous leukemia
681156|NCT00010283|accelerated phase chronic myelogenous leukemia
681157|NCT00010283|blastic phase chronic myelogenous leukemia
681158|NCT00010283|meningeal chronic myelogenous leukemia
681159|NCT00010283|chronic idiopathic myelofibrosis
681160|NCT00010283|essential thrombocythemia
681161|NCT00010283|testicular embryonal carcinoma
681162|NCT00010283|testicular choriocarcinoma
681163|NCT00010283|testicular teratoma
681164|NCT00010283|testicular yolk sac tumor
681165|NCT00010283|testicular embryonal carcinoma and teratoma
681166|NCT00010283|testicular embryonal carcinoma and teratoma with seminoma
681167|NCT00010283|testicular embryonal carcinoma and yolk sac tumor
681168|NCT00010283|testicular embryonal carcinoma and yolk sac tumor with seminoma
681169|NCT00010283|testicular embryonal carcinoma and seminoma
681170|NCT00010283|testicular yolk sac tumor and teratoma
681171|NCT00010283|testicular yolk sac tumor and teratoma with seminoma
681172|NCT00010283|testicular choriocarcinoma and yolk sac tumor
681173|NCT00010283|testicular choriocarcinoma and embryonal carcinoma
681174|NCT00010283|testicular choriocarcinoma and teratoma
681175|NCT00010283|testicular choriocarcinoma and seminoma
681176|NCT00010283|refractory hairy cell leukemia
681177|NCT00010283|recurrent/refractory childhood Hodgkin lymphoma
681178|NCT00010283|recurrent ovarian germ cell tumor
681179|NCT00010283|chronic myelomonocytic leukemia
681180|NCT00010283|ovarian yolk sac tumor
681181|NCT00010283|ovarian embryonal carcinoma
681182|NCT00010283|ovarian polyembryoma
681183|NCT00010283|ovarian choriocarcinoma
681184|NCT00010283|ovarian immature teratoma
681185|NCT00010283|ovarian mature teratoma
681186|NCT00010283|ovarian monodermal and highly specialized teratoma
681187|NCT00010283|ovarian mixed germ cell tumor
681188|NCT00010283|acute undifferentiated leukemia
681189|NCT00010283|stage III grade 1 follicular lymphoma
681190|NCT00010283|stage III grade 2 follicular lymphoma
681191|NCT00010283|stage III grade 3 follicular lymphoma
681192|NCT00010283|stage III adult diffuse small cleaved cell lymphoma
681591|NCT00009243|Brain
681193|NCT00010283|stage III adult diffuse mixed cell lymphoma
681194|NCT00010283|stage III adult diffuse large cell lymphoma
681195|NCT00010283|stage III adult immunoblastic large cell lymphoma
681196|NCT00010283|stage III adult lymphoblastic lymphoma
681197|NCT00010283|stage III adult Burkitt lymphoma
681198|NCT00010283|stage IV grade 1 follicular lymphoma
681199|NCT00010283|stage IV grade 2 follicular lymphoma
681200|NCT00010283|stage IV grade 3 follicular lymphoma
681201|NCT00010283|stage IV adult diffuse small cleaved cell lymphoma
681202|NCT00010283|stage IV adult diffuse mixed cell lymphoma
681203|NCT00010283|stage IV adult diffuse large cell lymphoma
681204|NCT00010283|stage IV adult immunoblastic large cell lymphoma
681205|NCT00010283|stage IV adult lymphoblastic lymphoma
681206|NCT00010283|stage IV adult Burkitt lymphoma
681207|NCT00010283|recurrent grade 1 follicular lymphoma
681208|NCT00010283|recurrent grade 2 follicular lymphoma
681209|NCT00010283|recurrent grade 3 follicular lymphoma
681210|NCT00010283|recurrent adult diffuse small cleaved cell lymphoma
681211|NCT00010283|recurrent adult diffuse mixed cell lymphoma
681212|NCT00010283|recurrent adult diffuse large cell lymphoma
681213|NCT00010283|recurrent adult immunoblastic large cell lymphoma
681214|NCT00010283|recurrent adult lymphoblastic lymphoma
681215|NCT00010283|recurrent adult Burkitt lymphoma
681216|NCT00010283|recurrent adult T-cell leukemia/lymphoma
681217|NCT00010283|secondary acute myeloid leukemia
681218|NCT00010283|de novo myelodysplastic syndromes
681219|NCT00010283|poor prognosis metastatic gestational trophoblastic tumor
681220|NCT00010283|previously treated myelodysplastic syndromes
681221|NCT00010283|secondary myelodysplastic syndromes
681222|NCT00010283|graft versus host disease
681223|NCT00010283|prolymphocytic leukemia
681224|NCT00010283|primary systemic amyloidosis
681225|NCT00010283|recurrent childhood small noncleaved cell lymphoma
681226|NCT00010283|recurrent childhood large cell lymphoma
681227|NCT00010283|noncontiguous stage II grade 1 follicular lymphoma
681228|NCT00010283|noncontiguous stage II grade 2 follicular lymphoma
681229|NCT00010283|noncontiguous stage II grade 3 follicular lymphoma
681230|NCT00010283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
681231|NCT00010283|noncontiguous stage II mantle cell lymphoma
681232|NCT00010283|noncontiguous stage II adult diffuse mixed cell lymphoma
681233|NCT00010283|noncontiguous stage II adult immunoblastic large cell lymphoma
681234|NCT00010283|noncontiguous stage II adult diffuse large cell lymphoma
681235|NCT00010283|noncontiguous stage II adult Burkitt lymphoma
681236|NCT00010283|noncontiguous stage II adult lymphoblastic lymphoma
681237|NCT00010283|stage III mantle cell lymphoma
681238|NCT00010283|stage IV mantle cell lymphoma
681239|NCT00010283|recurrent mantle cell lymphoma
681240|NCT00010283|anaplastic large cell lymphoma
681241|NCT00010283|stage IV mycosis fungoides/Sezary syndrome
681242|NCT00010283|recurrent mycosis fungoides/Sezary syndrome
681243|NCT00010283|noncontiguous stage II small lymphocytic lymphoma
681244|NCT00010283|noncontiguous stage II marginal zone lymphoma
681245|NCT00010283|recurrent marginal zone lymphoma
681246|NCT00010283|recurrent small lymphocytic lymphoma
681247|NCT00010283|stage III small lymphocytic lymphoma
681248|NCT00010283|stage III marginal zone lymphoma
681249|NCT00010283|stage IV small lymphocytic lymphoma
681250|NCT00010283|stage IV marginal zone lymphoma
681251|NCT00010283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
681252|NCT00010283|nodal marginal zone B-cell lymphoma
681253|NCT00010283|splenic marginal zone lymphoma
681254|NCT00010283|childhood myelodysplastic syndromes
681255|NCT00010270|stage IV colon cancer
681256|NCT00010270|stage IV rectal cancer
681257|NCT00010270|recurrent colon cancer
681258|NCT00010270|recurrent rectal cancer
681259|NCT00010270|adenocarcinoma of the colon
681260|NCT00010270|stage III pancreatic cancer
681261|NCT00010270|stage II pancreatic cancer
681262|NCT00010270|recurrent pancreatic cancer
681263|NCT00010270|adenocarcinoma of the pancreas
681264|NCT00010270|stage IV gastric cancer
681265|NCT00010270|adenocarcinoma of the stomach
681266|NCT00010270|recurrent gastric cancer
681267|NCT00010270|adenocarcinoma of the esophagus
681268|NCT00010270|stage IV esophageal cancer
681269|NCT00010270|stage III esophageal cancer
681270|NCT00010270|recurrent esophageal cancer
681271|NCT00010270|stage II esophageal cancer
681272|NCT00010270|adenocarcinoma of the rectum
681273|NCT00010270|stage III colon cancer
681274|NCT00010270|stage III rectal cancer
681275|NCT00010270|stage III gastric cancer
681276|NCT00010270|stage IV pancreatic cancer
681277|NCT00010257|thymoma
681278|NCT00010257|thymic carcinoma
681279|NCT00010244|stage IIB prostate cancer
681280|NCT00010244|stage IIA prostate cancer
681281|NCT00010244|stage III prostate cancer
681282|NCT00010231|adenocarcinoma of the prostate
681283|NCT00010231|stage III prostate cancer
681284|NCT00010231|stage IV prostate cancer
681285|NCT00010231|recurrent prostate cancer
681286|NCT00010218|recurrent non-small cell lung cancer
681287|NCT00010218|squamous cell lung cancer
681288|NCT00010218|large cell lung cancer
681289|NCT00010218|adenocarcinoma of the lung
681290|NCT00010218|adenosquamous cell lung cancer
681291|NCT00010218|bronchoalveolar cell lung cancer
681292|NCT00010179|stage III ovarian epithelial cancer
681293|NCT00010179|stage IV ovarian epithelial cancer
681294|NCT00010179|recurrent ovarian epithelial cancer
681295|NCT00010179|fallopian tube cancer
681296|NCT00010179|peritoneal cavity cancer
681297|NCT00010166|stage I pancreatic cancer
681298|NCT00010166|adenocarcinoma of the pancreas
681299|NCT00010153|stage I breast cancer
681300|NCT00010153|stage II breast cancer
681301|NCT00010140|stage II breast cancer
681302|NCT00010140|stage IIIA breast cancer
681303|NCT00010140|stage IIIB breast cancer
681304|NCT00010140|stage IIIC breast cancer
681305|NCT00010127|adenocarcinoma of the prostate
681306|NCT00010127|stage IV prostate cancer
681307|NCT00010114|childhood central nervous system germ cell tumor
681308|NCT00010114|childhood choroid plexus tumor
681309|NCT00010114|untreated childhood supratentorial primitive neuroectodermal tumor
681310|NCT00010114|untreated childhood medulloblastoma
681311|NCT00010114|newly diagnosed childhood ependymoma
681312|NCT00010101|childhood choroid plexus tumor
681313|NCT00010101|untreated childhood supratentorial primitive neuroectodermal tumor
681314|NCT00010101|untreated childhood medulloblastoma
681315|NCT00010101|childhood atypical teratoid/rhabdoid tumor
681316|NCT00010088|stage II pancreatic cancer
681317|NCT00010088|stage III pancreatic cancer
681318|NCT00010088|unresectable extrahepatic bile duct cancer
681319|NCT00010088|adenocarcinoma of the extrahepatic bile duct
681320|NCT00010088|adenocarcinoma of the pancreas
681321|NCT00010088|stage IV pancreatic cancer
681322|NCT00010075|stage IV breast cancer
681323|NCT00010075|recurrent breast cancer
681324|NCT00010062|stage I pancreatic cancer
681325|NCT00010062|stage II pancreatic cancer
681326|NCT00010062|stage III pancreatic cancer
681327|NCT00010062|adenocarcinoma of the pancreas
681328|NCT00010062|stage IV pancreatic cancer
681329|NCT00010049|recurrent adult brain tumor
681330|NCT00010049|adult meningioma
681331|NCT00010049|adult glioblastoma
681332|NCT00010049|adult anaplastic astrocytoma
681333|NCT00010049|adult anaplastic oligodendroglioma
681334|NCT00010049|adult mixed glioma
681335|NCT00010049|adult pilocytic astrocytoma
681336|NCT00010049|adult subependymoma
681337|NCT00010049|adult grade III meningioma
681338|NCT00010049|adult giant cell glioblastoma
681339|NCT00010049|adult gliosarcoma
681340|NCT00010036|adult glioblastoma
681341|NCT00010036|adult giant cell glioblastoma
681342|NCT00010036|adult gliosarcoma
681343|NCT00010023|stage IV breast cancer
681344|NCT00010023|stage IIIA breast cancer
681345|NCT00010023|recurrent breast cancer
681346|NCT00010023|stage III gastric cancer
681347|NCT00010023|stage IV gastric cancer
681348|NCT00010023|recurrent gastric cancer
681349|NCT00010023|stage IIIB breast cancer
681350|NCT00010023|stage IIIC breast cancer
681351|NCT00010023|recurrent non-small cell lung cancer
681352|NCT00010023|stage III pancreatic cancer
681353|NCT00010023|recurrent pancreatic cancer
681354|NCT00010023|stage III esophageal cancer
681355|NCT00010023|stage IV esophageal cancer
681356|NCT00010023|recurrent esophageal cancer
681357|NCT00010023|extensive stage small cell lung cancer
681358|NCT00010023|recurrent small cell lung cancer
681359|NCT00010023|metastatic gastrointestinal carcinoid tumor
681360|NCT00010023|recurrent gastrointestinal carcinoid tumor
681361|NCT00010023|localized unresectable adult primary liver cancer
681362|NCT00010023|advanced adult primary liver cancer
681363|NCT00010023|recurrent adult primary liver cancer
681364|NCT00010023|small intestine adenocarcinoma
681365|NCT00010023|unresectable gallbladder cancer
681366|NCT00010023|recurrent gallbladder cancer
681367|NCT00010023|unresectable extrahepatic bile duct cancer
681368|NCT00010023|recurrent extrahepatic bile duct cancer
681369|NCT00010023|recurrent small intestine cancer
681370|NCT00010023|stage IIIA non-small cell lung cancer
681371|NCT00010023|stage IIIB non-small cell lung cancer
681372|NCT00010023|untreated metastatic squamous neck cancer with occult primary
681373|NCT00010023|recurrent metastatic squamous neck cancer with occult primary
681374|NCT00010023|pulmonary carcinoid tumor
681375|NCT00010023|stage III squamous cell carcinoma of the lip and oral cavity
681376|NCT00010023|stage III basal cell carcinoma of the lip
681377|NCT00010023|stage III verrucous carcinoma of the oral cavity
681378|NCT00010023|stage III mucoepidermoid carcinoma of the oral cavity
681379|NCT00010023|stage III adenoid cystic carcinoma of the oral cavity
681380|NCT00010023|stage IV squamous cell carcinoma of the lip and oral cavity
681381|NCT00010023|stage IV basal cell carcinoma of the lip
681382|NCT00010023|stage IV verrucous carcinoma of the oral cavity
681383|NCT00010023|stage IV mucoepidermoid carcinoma of the oral cavity
681384|NCT00010023|stage IV adenoid cystic carcinoma of the oral cavity
681385|NCT00010023|recurrent squamous cell carcinoma of the lip and oral cavity
681386|NCT00010023|recurrent basal cell carcinoma of the lip
681387|NCT00010023|recurrent verrucous carcinoma of the oral cavity
681388|NCT00010023|recurrent mucoepidermoid carcinoma of the oral cavity
681389|NCT00010023|recurrent adenoid cystic carcinoma of the oral cavity
681390|NCT00010023|stage III squamous cell carcinoma of the oropharynx
681391|NCT00010023|stage III lymphoepithelioma of the oropharynx
681392|NCT00010023|stage IV squamous cell carcinoma of the oropharynx
681393|NCT00010023|stage IV lymphoepithelioma of the oropharynx
681394|NCT00010023|recurrent squamous cell carcinoma of the oropharynx
681395|NCT00010023|recurrent lymphoepithelioma of the oropharynx
681396|NCT00010023|stage III squamous cell carcinoma of the nasopharynx
681397|NCT00010023|stage III lymphoepithelioma of the nasopharynx
681398|NCT00010023|stage IV squamous cell carcinoma of the nasopharynx
681399|NCT00010023|stage IV lymphoepithelioma of the nasopharynx
681400|NCT00010023|recurrent squamous cell carcinoma of the nasopharynx
681401|NCT00010023|recurrent lymphoepithelioma of the nasopharynx
681402|NCT00010023|stage III squamous cell carcinoma of the hypopharynx
681403|NCT00010023|stage IV squamous cell carcinoma of the hypopharynx
681404|NCT00010023|recurrent squamous cell carcinoma of the hypopharynx
681405|NCT00010023|stage III squamous cell carcinoma of the larynx
681406|NCT00010023|stage III verrucous carcinoma of the larynx
681407|NCT00010023|stage IV squamous cell carcinoma of the larynx
681408|NCT00010023|stage IV verrucous carcinoma of the larynx
681409|NCT00010023|recurrent squamous cell carcinoma of the larynx
681410|NCT00010023|recurrent verrucous carcinoma of the larynx
681411|NCT00010023|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
681412|NCT00010023|stage III inverted papilloma of the paranasal sinus and nasal cavity
681413|NCT00010023|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
681414|NCT00010023|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
681415|NCT00010023|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
681416|NCT00010023|stage IV inverted papilloma of the paranasal sinus and nasal cavity
681417|NCT00010023|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
681418|NCT00010023|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
681419|NCT00010023|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
681420|NCT00010023|recurrent inverted papilloma of the paranasal sinus and nasal cavity
681421|NCT00010023|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
681422|NCT00010023|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
681423|NCT00010023|newly diagnosed carcinoma of unknown primary
681424|NCT00010023|carcinoma of the appendix
681425|NCT00010023|recurrent carcinoma of unknown primary
681426|NCT00010023|gastrointestinal stromal tumor
681427|NCT00010023|recurrent salivary gland cancer
681428|NCT00010023|stage III salivary gland cancer
681429|NCT00010023|stage IV salivary gland cancer
681430|NCT00010023|stage IV pancreatic cancer
681431|NCT00010010|stage IV breast cancer
681432|NCT00010010|recurrent breast cancer
681433|NCT00009997|stage II breast cancer
681434|NCT00009997|stage IIIA breast cancer
681435|NCT00009997|stage IIIB breast cancer
681436|NCT00009971|limited stage small cell lung cancer
681437|NCT00009971|extensive stage small cell lung cancer
681438|NCT00009971|recurrent small cell lung cancer
681439|NCT00009945|stage I breast cancer
681440|NCT00009945|stage II breast cancer
681441|NCT00009932|unspecified adult solid tumor, protocol specific
681442|NCT00009893|localized unresectable adult primary liver cancer
681443|NCT00009893|advanced adult primary liver cancer
681444|NCT00009893|recurrent adult primary liver cancer
681445|NCT00009893|unresectable gallbladder cancer
681446|NCT00009893|recurrent gallbladder cancer
681447|NCT00009893|unresectable extrahepatic bile duct cancer
681448|NCT00009893|recurrent extrahepatic bile duct cancer
681449|NCT00009880|stage I gastric cancer
681450|NCT00009880|stage II gastric cancer
681451|NCT00009880|stage III gastric cancer
681452|NCT00009880|stage I esophageal cancer
681453|NCT00009880|stage II esophageal cancer
681454|NCT00009880|stage III esophageal cancer
681455|NCT00009880|adenocarcinoma of the stomach
681456|NCT00009880|squamous cell carcinoma of the esophagus
681457|NCT00009880|adenocarcinoma of the esophagus
681458|NCT00009854|adult glioblastoma
681459|NCT00009854|tumors metastatic to brain
681460|NCT00009854|adult anaplastic astrocytoma
681461|NCT00009854|adult anaplastic ependymoma
681462|NCT00009854|adult anaplastic oligodendroglioma
681463|NCT00009854|adult giant cell glioblastoma
681464|NCT00009854|adult gliosarcoma
681465|NCT00009841|untreated metastatic squamous neck cancer with occult primary
681466|NCT00009841|recurrent metastatic squamous neck cancer with occult primary
681467|NCT00009841|metastatic squamous neck cancer with occult primary squamous cell carcinoma
681468|NCT00009841|stage IV squamous cell carcinoma of the lip and oral cavity
681469|NCT00009841|recurrent squamous cell carcinoma of the lip and oral cavity
681470|NCT00009841|stage IV squamous cell carcinoma of the oropharynx
681471|NCT00009841|recurrent squamous cell carcinoma of the oropharynx
681472|NCT00009841|stage IV squamous cell carcinoma of the nasopharynx
681473|NCT00009841|recurrent squamous cell carcinoma of the nasopharynx
681474|NCT00009841|stage IV squamous cell carcinoma of the hypopharynx
681475|NCT00009841|recurrent squamous cell carcinoma of the hypopharynx
681476|NCT00009841|stage IV squamous cell carcinoma of the larynx
681477|NCT00009841|recurrent squamous cell carcinoma of the larynx
681478|NCT00009841|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
681479|NCT00009841|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
681480|NCT00009828|unspecified adult solid tumor, protocol specific
681481|NCT00009815|unspecified adult solid tumor, protocol specific
681482|NCT00009802|unspecified adult solid tumor, protocol specific
681483|NCT00009789|stage I non-small cell lung cancer
681484|NCT00009789|squamous cell lung cancer
681485|NCT00009789|large cell lung cancer
681486|NCT00009789|adenocarcinoma of the lung
681487|NCT00009789|adenosquamous cell lung cancer
681488|NCT00009789|bronchoalveolar cell lung cancer
681489|NCT00009776|recurrent grade 1 follicular lymphoma
681490|NCT00009776|recurrent grade 2 follicular lymphoma
681491|NCT00009776|recurrent grade 3 follicular lymphoma
681492|NCT00009776|recurrent adult diffuse small cleaved cell lymphoma
681493|NCT00009776|recurrent adult diffuse mixed cell lymphoma
681494|NCT00009776|recurrent adult diffuse large cell lymphoma
681495|NCT00009776|recurrent adult immunoblastic large cell lymphoma
681496|NCT00009776|recurrent adult lymphoblastic lymphoma
681497|NCT00009776|recurrent adult Burkitt lymphoma
681498|NCT00009776|recurrent mantle cell lymphoma
681499|NCT00009776|recurrent marginal zone lymphoma
681500|NCT00009776|recurrent small lymphocytic lymphoma
681501|NCT00009776|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
681502|NCT00009776|nodal marginal zone B-cell lymphoma
681503|NCT00009776|splenic marginal zone lymphoma
681504|NCT00009763|stage IV breast cancer
681505|NCT00009763|recurrent breast cancer
681506|NCT00009750|stage IV prostate cancer
681507|NCT00009750|recurrent prostate cancer
681508|NCT00009711|long-term effects secondary to cancer therapy in children
681509|NCT00009711|pulmonary complications
681510|NCT00009698|recurrent childhood acute myeloid leukemia
681511|NCT00009698|childhood acute myeloid leukemia in remission
681512|NCT00009698|childhood acute myeloblastic leukemia without maturation (M1)
681513|NCT00009698|childhood acute myeloblastic leukemia with maturation (M2)
681514|NCT00009685|Vaccine
681515|NCT00009685|HIV
681516|NCT00009685|Codon-Optimized
681517|NCT00009685|HIV Vaccine
681518|NCT00009685|Healthy Volunteer
681519|NCT00009685|HIV-1 DNA Vaccine
681520|NCT00009685|HIV Seronegativity
681521|NCT00009685|HIV Preventive Vaccine
681522|NCT00009672|Low Back Pain
681523|NCT00009672|Opioid
681524|NCT00009672|Antidepressant
681525|NCT00009672|Randomized Controlled Trial
681526|NCT00009672|Analgesic
681527|NCT00009672|Sciatica
681528|NCT00009659|Endometrium
681529|NCT00009659|Estrogen
681530|NCT00009659|Antihormone
681531|NCT00009659|Menopause
681532|NCT00009659|Progesterone
681533|NCT00009659|Postmenopausal Women
681534|NCT00009659|Hormone Replacement
681535|NCT00009646|Chronic lung disease
681536|NCT00009646|Indocin
681537|NCT00009646|Indomethacin
681538|NCT00009646|Infants, very low birth weight
681539|NCT00009646|Intraventricular hemorrhage
681540|NCT00009646|Necrotizing enterocolitis
681541|NCT00009646|Patent ductus arteriosus
681542|NCT00009646|Pulmonary hemorrhage
681543|NCT00009633|NICHD Neonatal Research Network
681544|NCT00009633|Extremely Low Birth Weight (ELBW)
681545|NCT00009633|Prematurity
681546|NCT00009633|Neurodevelopmental Outcome
681547|NCT00009633|Follow up studies
681548|NCT00009620|NICHD Neonatal Research Network
681549|NCT00009620|Extremely Low Birth Weight (ELBW)
681550|NCT00009620|Prematurity
681551|NCT00009620|Cerebral hemorrhage
681552|NCT00009620|Phenobarbital
681553|NCT00009620|Pregnancy
681554|NCT00009620|Prenatal care
681555|NCT00009620|Intraventricular hemorrhage
681556|NCT00009620|Periventricular leukomalacia
681557|NCT00009620|Brain injury
681558|NCT00009620|Brain hemorrhage
681559|NCT00009581|Endothelial Function
681560|NCT00009581|Hydroxyurea
681561|NCT00009581|Leukocyte Gene Expression
681562|NCT00009581|Nitrosylated Hemoglobin
681563|NCT00009581|Sickle Cell Anemia
681564|NCT00009581|Nitric Oxide
681565|NCT00009568|Antidepressants
681566|NCT00009568|Platelet Function
681567|NCT00009568|SSRI
681568|NCT00009568|Depression
681569|NCT00009568|Bleeding Time
681570|NCT00009555|Testosterone
681571|NCT00009555|Anthropometry
681572|NCT00009555|Obesity
681573|NCT00009555|Abdomen
681574|NCT00009542|Caffeine
681575|NCT00009542|Cytochrome P 450
681576|NCT00009542|Dextromethorphan
681577|NCT00009542|Herbal
681578|NCT00009542|Interactions
681579|NCT00009542|Alternative Therapy
681580|NCT00009542|Healthy Volunteer
681581|NCT00009542|Kava
681582|NCT00009256|Quasispecies Variation
681583|NCT00009256|Genotyping
681584|NCT00009256|Phenotyping
681585|NCT00009256|Antiretroviral Therapy
681586|NCT00009256|Drug Naive Patients
681587|NCT00009256|HIV
681588|NCT00009256|Treatment Naive
681589|NCT00009243|Brain Scans
681590|NCT00009243|Brain Imaging
681592|NCT00009243|Alteplase
681593|NCT00009243|Acute Stroke
681594|NCT00009243|Stroke
681595|NCT00009243|TIA
681596|NCT00009230|Age associated memory impairment
681597|NCT00009230|Mild cognitive impairment
681598|NCT00009217|Alzheimer's disease
681599|NCT00009217|psychosis
681600|NCT00009217|agitation
681601|NCT00009217|haloperidol
681602|NCT00009204|Behavioral problems
681603|NCT00009204|Agitation
681604|NCT00009178|Primary Care
681605|NCT00009178|Fluoxetine
681606|NCT00009061|HIV-1
681607|NCT00009061|Drug Therapy, Combination
681608|NCT00009061|HIV Protease Inhibitors
681609|NCT00009061|Ritonavir
681610|NCT00009061|Lamivudine
681611|NCT00009061|Nelfinavir
681612|NCT00009061|Reverse Transcriptase Inhibitors
681613|NCT00009061|Anti-HIV Agents
681614|NCT00009061|abacavir
681615|NCT00009048|Dyskinesias
681616|NCT00009048|L-Dopa Infusion
681617|NCT00009048|Clinical Trial
681618|NCT00009048|Motor Function
681619|NCT00009048|Psychosis
681620|NCT00009048|Parkinson's Disease
681621|NCT00009035|Brain
681622|NCT00009035|Tumor
681623|NCT00009035|Chemotherapy
681624|NCT00009035|Antiangiogenesis
681625|NCT00009035|Radiation
681626|NCT00009035|CNS Tumor
681627|NCT00009035|Glioma
681628|NCT00009035|Medulloblastoma
681629|NCT00009035|Astrocytoma
681630|NCT00009035|Glioblastoma
681631|NCT00009009|Immune System
681632|NCT00009009|Biopsy
681633|NCT00009009|AIDS
681634|NCT00009009|HIV
681635|NCT00009009|End Stage Renal Disease
681636|NCT00009009|Kidney Transplant
681637|NCT00008892|Magnetic Resonance Imaging
681638|NCT00008892|Diffusion Tensor Imaging
681639|NCT00008892|Twin Study
681640|NCT00008892|Attention Deficit Hyperactivity Disorder
681641|NCT00008892|Normal Volunteers
681642|NCT00008866|HIV-1
681643|NCT00008866|Didanosine
681644|NCT00008866|Drug Therapy, Combination
681645|NCT00008866|Drug Administration Schedule
681646|NCT00008866|CD4-Positive T-Lymphocytes
681647|NCT00008866|Hydroxyurea
681648|NCT00008866|RNA, Viral
681649|NCT00008866|Genotype
681650|NCT00008866|Reverse Transcriptase Inhibitors
681651|NCT00008866|Anti-HIV Agents
681652|NCT00008866|Viral Load
681653|NCT00008853|Clinical Evaluation
681654|NCT00008827|Obesity
681655|NCT00008827|Behavioral weight control
681656|NCT00008827|Internet
681657|NCT00008814|Cognition
681658|NCT00008814|Infant Development
681659|NCT00008814|MRI, Functional
681660|NCT00008736|Feeding intolerance
681661|NCT00008736|Infant, premature
681662|NCT00008697|recurrent childhood acute myeloid leukemia
681663|NCT00008697|recurrent adult acute myeloid leukemia
681664|NCT00008697|adult acute promyelocytic leukemia (M3)
681665|NCT00008697|childhood acute promyelocytic leukemia (M3)
681666|NCT00008554|HIV-1
681667|NCT00008554|Drug Therapy, Combination
681668|NCT00008554|HIV Protease Inhibitors
681669|NCT00008554|Lamivudine
681670|NCT00008554|Nelfinavir
681671|NCT00008554|Reverse Transcriptase Inhibitors
681672|NCT00008554|Anti-HIV Agents
681673|NCT00008554|abacavir
681674|NCT00008541|Keratitis
681675|NCT00008541|Conjunctivitis
681676|NCT00008541|Meibomitis
681677|NCT00008541|Corneal Infiltrates
681678|NCT00008541|Dacryocystitis
681679|NCT00008541|Blepharitis
681680|NCT00008541|Dacryoadenitis
681681|NCT00008541|Corneal Eye Disease
681682|NCT00008528|HIV-1
681683|NCT00008528|Drug Therapy, Combination
681684|NCT00008528|Drug Resistance, Microbial
681685|NCT00008528|RNA, Viral
681686|NCT00008528|Membrane Fusion
681687|NCT00008528|Anti-HIV Agents
681688|NCT00008528|Viral Load
681689|NCT00008515|Steroids
681690|NCT00008515|Age-Related Macular Degeneration
681691|NCT00008515|Implant
681692|NCT00008515|Choroidal Neovascularization
681693|NCT00008515|Sustained Release Implant
681694|NCT00008502|Genetics
681695|NCT00008502|African Americans
681696|NCT00008502|Skin
681697|NCT00008502|Keloids
681698|NCT00008502|Familial Disposition
681699|NCT00008489|Didanosine
681700|NCT00008489|Gastrointestinal System
681701|NCT00008489|Tablets
681702|NCT00008489|Reverse Transcriptase Inhibitors
681703|NCT00008489|Anti-HIV Agents
681704|NCT00008489|Capsules
681705|NCT00008476|Preemptive Analgesia
681706|NCT00008476|Vanilloid
681707|NCT00008476|Vanilloid Receptor (VR)
681708|NCT00008476|Capsaicin
681709|NCT00008476|Acute Pain
681710|NCT00008476|Orofacial
681711|NCT00008476|Visual Analog Scale (VAS)
681712|NCT00008476|Resiniferatoxin
681713|NCT00008476|Healthy Volunteer
681714|NCT00008476|Wisdom Teeth
681715|NCT00008476|Pain
681716|NCT00008463|Ribavirin
681717|NCT00008463|Polyethylene Glycols
681718|NCT00008463|Interferon Alfa-2a
681719|NCT00008463|HIV-1
681720|NCT00008463|Antiviral Agents
681721|NCT00008463|Hepatitis C, Chronic
681722|NCT00008437|stage I breast cancer
681723|NCT00008437|stage II breast cancer
681724|NCT00008437|stage IIIA breast cancer
681725|NCT00008424|unspecified childhood solid tumor, protocol specific
681726|NCT00008411|stage IV breast cancer
681727|NCT00008411|recurrent breast cancer
681728|NCT00008398|stage I nasopharyngeal cancer
681729|NCT00008398|stage II nasopharyngeal cancer
681730|NCT00008398|stage III nasopharyngeal cancer
681731|NCT00008398|stage IV nasopharyngeal cancer
681732|NCT00008398|recurrent nasopharyngeal cancer
681733|NCT00008398|stage 0 paranasal sinus and nasal cavity cancer
681734|NCT00008398|stage 0 nasopharyngeal cancer
681735|NCT00008398|stage 0 oropharyngeal cancer
681736|NCT00008398|stage 0 laryngeal cancer
681737|NCT00008398|stage 0 hypopharyngeal cancer
681738|NCT00008398|untreated metastatic squamous neck cancer with occult primary
681739|NCT00008398|recurrent metastatic squamous neck cancer with occult primary
681740|NCT00008398|stage 0 lip and oral cavity cancer
681741|NCT00008398|stage I lip and oral cavity cancer
681742|NCT00008398|stage II lip and oral cavity cancer
681743|NCT00008398|stage III lip and oral cavity cancer
681744|NCT00008398|stage IV lip and oral cavity cancer
681745|NCT00008398|recurrent lip and oral cavity cancer
681746|NCT00008398|stage I hypopharyngeal cancer
681747|NCT00008398|stage II hypopharyngeal cancer
681748|NCT00008398|stage III hypopharyngeal cancer
681749|NCT00008398|stage IV hypopharyngeal cancer
681750|NCT00008398|recurrent hypopharyngeal cancer
681751|NCT00008398|stage I paranasal sinus and nasal cavity cancer
681752|NCT00008398|stage II paranasal sinus and nasal cavity cancer
681753|NCT00008398|stage III paranasal sinus and nasal cavity cancer
681754|NCT00008398|stage IV paranasal sinus and nasal cavity cancer
681755|NCT00008398|recurrent paranasal sinus and nasal cavity cancer
681756|NCT00008398|stage I oropharyngeal cancer
681757|NCT00008398|stage II oropharyngeal cancer
681758|NCT00008398|stage III oropharyngeal cancer
681759|NCT00008398|stage IV oropharyngeal cancer
681760|NCT00008398|recurrent oropharyngeal cancer
681761|NCT00008398|oral complications
681762|NCT00008398|radiation toxicity
681763|NCT00008385|stage I non-small cell lung cancer
681764|NCT00008372|extensive stage small cell lung cancer
681765|NCT00008372|recurrent small cell lung cancer
681766|NCT00008359|stage I adult Hodgkin lymphoma
681767|NCT00008359|stage II adult Hodgkin lymphoma
681768|NCT00008359|stage III adult Hodgkin lymphoma
681769|NCT00008359|stage IV adult Hodgkin lymphoma
681770|NCT00008359|stage IV breast cancer
681771|NCT00008359|stage IIIA breast cancer
681772|NCT00008359|monoclonal gammopathy of undetermined significance
681773|NCT00008359|stage IIIB breast cancer
681774|NCT00008359|recurrent adult Hodgkin lymphoma
681775|NCT00008359|stage I cutaneous T-cell non-Hodgkin lymphoma
681776|NCT00008359|stage II cutaneous T-cell non-Hodgkin lymphoma
681777|NCT00008359|stage III cutaneous T-cell non-Hodgkin lymphoma
681778|NCT00008359|stage IV cutaneous T-cell non-Hodgkin lymphoma
681779|NCT00008359|recurrent cutaneous T-cell non-Hodgkin lymphoma
681780|NCT00008359|isolated plasmacytoma of bone
681781|NCT00008359|extramedullary plasmacytoma
681782|NCT00008359|refractory multiple myeloma
681783|NCT00008359|stage II ovarian epithelial cancer
681784|NCT00008359|stage III ovarian epithelial cancer
681785|NCT00008359|stage IV ovarian epithelial cancer
681786|NCT00008359|recurrent ovarian epithelial cancer
681787|NCT00008359|disseminated neuroblastoma
681788|NCT00008359|recurrent neuroblastoma
681789|NCT00008359|recurrent Wilms tumor and other childhood kidney tumors
681790|NCT00008359|stage 0 chronic lymphocytic leukemia
681791|NCT00008359|Waldenstrom macroglobulinemia
681792|NCT00008359|stage I multiple myeloma
681793|NCT00008359|stage II multiple myeloma
681794|NCT00008359|stage III multiple myeloma
681795|NCT00008359|stage I chronic lymphocytic leukemia
681796|NCT00008359|stage II chronic lymphocytic leukemia
681797|NCT00008359|stage III chronic lymphocytic leukemia
681798|NCT00008359|stage IV chronic lymphocytic leukemia
681799|NCT00008359|recurrent adult acute myeloid leukemia
681800|NCT00008359|recurrent adult acute lymphoblastic leukemia
681801|NCT00008359|relapsing chronic myelogenous leukemia
681802|NCT00008359|refractory chronic lymphocytic leukemia
681803|NCT00008359|small intestine lymphoma
681804|NCT00008359|stage III malignant testicular germ cell tumor
681805|NCT00008359|recurrent malignant testicular germ cell tumor
681806|NCT00008359|unspecified adult solid tumor, protocol specific
681807|NCT00008359|chronic phase chronic myelogenous leukemia
681808|NCT00008359|accelerated phase chronic myelogenous leukemia
681809|NCT00008359|blastic phase chronic myelogenous leukemia
681810|NCT00008359|meningeal chronic myelogenous leukemia
681811|NCT00008359|adult acute myeloid leukemia in remission
681812|NCT00008359|adult acute lymphoblastic leukemia in remission
681813|NCT00008359|polycythemia vera
681814|NCT00008359|primary myelofibrosis
681815|NCT00008359|essential thrombocythemia
681816|NCT00008359|fever, sweats, and hot flashes
681817|NCT00008359|testicular embryonal carcinoma
681818|NCT00008359|testicular choriocarcinoma
681819|NCT00008359|testicular teratoma
681820|NCT00008359|testicular yolk sac tumor
681821|NCT00008359|testicular embryonal carcinoma and teratoma
681822|NCT00008359|testicular embryonal carcinoma and teratoma with seminoma
681823|NCT00008359|testicular embryonal carcinoma and yolk sac tumor
681824|NCT00008359|testicular embryonal carcinoma and yolk sac tumor with seminoma
681825|NCT00008359|testicular embryonal carcinoma and seminoma
681826|NCT00008359|testicular yolk sac tumor and teratoma
681827|NCT00008359|testicular yolk sac tumor and teratoma with seminoma
681828|NCT00008359|testicular choriocarcinoma and yolk sac tumor
681829|NCT00008359|testicular choriocarcinoma and embryonal carcinoma
681830|NCT00008359|testicular choriocarcinoma and teratoma
681831|NCT00008359|testicular choriocarcinoma and seminoma
681832|NCT00008359|progressive hairy cell leukemia, initial treatment
681833|NCT00008359|refractory hairy cell leukemia
681834|NCT00008359|stage I grade 1 follicular lymphoma
681835|NCT00008359|stage I grade 2 follicular lymphoma
681836|NCT00008359|stage I grade 3 follicular lymphoma
681837|NCT00008359|stage I adult diffuse small cleaved cell lymphoma
681838|NCT00008359|stage I adult diffuse mixed cell lymphoma
681839|NCT00008359|stage I adult diffuse large cell lymphoma
681840|NCT00008359|stage I adult immunoblastic large cell lymphoma
681841|NCT00008359|stage I adult lymphoblastic lymphoma
681842|NCT00008359|stage I adult Burkitt lymphoma
681843|NCT00008359|recurrent ovarian germ cell tumor
681844|NCT00008359|chronic myelomonocytic leukemia
681845|NCT00008359|T-cell large granular lymphocyte leukemia
681846|NCT00008359|ovarian yolk sac tumor
681847|NCT00008359|ovarian embryonal carcinoma
681848|NCT00008359|ovarian polyembryoma
681849|NCT00008359|ovarian choriocarcinoma
681850|NCT00008359|ovarian immature teratoma
681851|NCT00008359|ovarian mature teratoma
681852|NCT00008359|ovarian monodermal and highly specialized teratoma
681853|NCT00008359|ovarian mixed germ cell tumor
681854|NCT00008359|acute undifferentiated leukemia
681855|NCT00008359|stage III grade 1 follicular lymphoma
681856|NCT00008359|stage III grade 2 follicular lymphoma
681857|NCT00008359|stage III grade 3 follicular lymphoma
681858|NCT00008359|stage III adult diffuse small cleaved cell lymphoma
681859|NCT00008359|stage III adult diffuse mixed cell lymphoma
681860|NCT00008359|stage III adult diffuse large cell lymphoma
681861|NCT00008359|stage III adult immunoblastic large cell lymphoma
681862|NCT00008359|stage III adult lymphoblastic lymphoma
681863|NCT00008359|stage III adult Burkitt lymphoma
681864|NCT00008359|stage IV grade 1 follicular lymphoma
681865|NCT00008359|stage IV grade 2 follicular lymphoma
681866|NCT00008359|stage IV grade 3 follicular lymphoma
681867|NCT00008359|stage IV adult diffuse small cleaved cell lymphoma
681868|NCT00008359|stage IV adult diffuse mixed cell lymphoma
681869|NCT00008359|stage IV adult diffuse large cell lymphoma
681870|NCT00008359|stage IV adult immunoblastic large cell lymphoma
681871|NCT00008359|stage IV adult lymphoblastic lymphoma
681872|NCT00008359|stage IV adult Burkitt lymphoma
681873|NCT00008359|recurrent grade 1 follicular lymphoma
681874|NCT00008359|recurrent grade 2 follicular lymphoma
681875|NCT00008359|recurrent grade 3 follicular lymphoma
681876|NCT00008359|recurrent adult diffuse small cleaved cell lymphoma
681877|NCT00008359|recurrent adult diffuse mixed cell lymphoma
681878|NCT00008359|recurrent adult diffuse large cell lymphoma
681879|NCT00008359|recurrent adult immunoblastic large cell lymphoma
681880|NCT00008359|recurrent adult lymphoblastic lymphoma
681881|NCT00008359|recurrent adult Burkitt lymphoma
681882|NCT00008359|stage I adult T-cell leukemia/lymphoma
681883|NCT00008359|stage II adult T-cell leukemia/lymphoma
681884|NCT00008359|stage III adult T-cell leukemia/lymphoma
681885|NCT00008359|stage IV adult T-cell leukemia/lymphoma
681886|NCT00008359|recurrent adult T-cell leukemia/lymphoma
681887|NCT00008359|secondary acute myeloid leukemia
681888|NCT00008359|de novo myelodysplastic syndromes
681889|NCT00008359|high risk metastatic gestational trophoblastic tumor
681890|NCT00008359|previously treated myelodysplastic syndromes
681891|NCT00008359|secondary myelodysplastic syndromes
681892|NCT00008359|primary central nervous system non-Hodgkin lymphoma
681893|NCT00008359|neutropenia
681894|NCT00008359|infection
681895|NCT00008359|prolymphocytic leukemia
681896|NCT00008359|AIDS-related peripheral/systemic lymphoma
681897|NCT00008359|AIDS-related primary CNS lymphoma
681898|NCT00008359|primary systemic amyloidosis
681899|NCT00008359|intraocular lymphoma
681900|NCT00008359|stage I mantle cell lymphoma
681901|NCT00008359|contiguous stage II grade 1 follicular lymphoma
681902|NCT00008359|contiguous stage II grade 2 follicular lymphoma
681903|NCT00008359|contiguous stage II grade 3 follicular lymphoma
681904|NCT00008359|contiguous stage II adult diffuse small cleaved cell lymphoma
681905|NCT00008359|contiguous stage II mantle cell lymphoma
681906|NCT00008359|contiguous stage II adult diffuse mixed cell lymphoma
681907|NCT00008359|contiguous stage II adult immunoblastic large cell lymphoma
681908|NCT00008359|contiguous stage II adult diffuse large cell lymphoma
681909|NCT00008359|contiguous stage II adult Burkitt lymphoma
681910|NCT00008359|contiguous stage II adult lymphoblastic lymphoma
682805|NCT00007137|Healthy Volunteer
681911|NCT00008359|noncontiguous stage II grade 1 follicular lymphoma
681912|NCT00008359|noncontiguous stage II grade 2 follicular lymphoma
681913|NCT00008359|noncontiguous stage II grade 3 follicular lymphoma
681914|NCT00008359|noncontiguous stage II adult diffuse small cleaved cell lymphoma
681915|NCT00008359|noncontiguous stage II mantle cell lymphoma
681916|NCT00008359|noncontiguous stage II adult diffuse mixed cell lymphoma
681917|NCT00008359|noncontiguous stage II adult immunoblastic large cell lymphoma
681918|NCT00008359|noncontiguous stage II adult diffuse large cell lymphoma
681919|NCT00008359|noncontiguous stage II adult Burkitt lymphoma
681920|NCT00008359|noncontiguous stage II adult lymphoblastic lymphoma
681921|NCT00008359|stage III mantle cell lymphoma
681922|NCT00008359|stage IV mantle cell lymphoma
681923|NCT00008359|recurrent mantle cell lymphoma
681924|NCT00008359|angioimmunoblastic T-cell lymphoma
681925|NCT00008359|anaplastic large cell lymphoma
681926|NCT00008359|stage I mycosis fungoides/Sezary syndrome
681927|NCT00008359|stage II mycosis fungoides/Sezary syndrome
681928|NCT00008359|stage III mycosis fungoides/Sezary syndrome
681929|NCT00008359|stage IV mycosis fungoides/Sezary syndrome
681930|NCT00008359|recurrent mycosis fungoides/Sezary syndrome
681931|NCT00008359|noncontiguous stage II small lymphocytic lymphoma
681932|NCT00008359|noncontiguous stage II marginal zone lymphoma
681933|NCT00008359|recurrent marginal zone lymphoma
681934|NCT00008359|recurrent small lymphocytic lymphoma
681935|NCT00008359|stage I marginal zone lymphoma
681936|NCT00008359|stage I small lymphocytic lymphoma
681937|NCT00008359|stage III small lymphocytic lymphoma
681938|NCT00008359|stage III marginal zone lymphoma
681939|NCT00008359|stage IV small lymphocytic lymphoma
681940|NCT00008359|stage IV marginal zone lymphoma
681941|NCT00008359|contiguous stage II marginal zone lymphoma
681942|NCT00008359|contiguous stage II small lymphocytic lymphoma
681943|NCT00008359|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
681944|NCT00008359|nodal marginal zone B-cell lymphoma
681945|NCT00008359|splenic marginal zone lymphoma
681946|NCT00008359|childhood myelodysplastic syndromes
681947|NCT00008346|breast cancer
681948|NCT00008333|stage IIIB non-small cell lung cancer
681949|NCT00008333|stage IV non-small cell lung cancer
681950|NCT00008320|stage IV breast cancer
681951|NCT00008320|recurrent breast cancer
681952|NCT00008307|stage I adult Hodgkin lymphoma
681953|NCT00008307|stage II adult Hodgkin lymphoma
681954|NCT00008307|stage III adult Hodgkin lymphoma
681955|NCT00008307|stage IV adult Hodgkin lymphoma
681956|NCT00008307|recurrent childhood acute lymphoblastic leukemia
681957|NCT00008307|recurrent adult Hodgkin lymphoma
681958|NCT00008307|stage I cutaneous T-cell non-Hodgkin lymphoma
681959|NCT00008307|stage II cutaneous T-cell non-Hodgkin lymphoma
681960|NCT00008307|stage III cutaneous T-cell non-Hodgkin lymphoma
681961|NCT00008307|stage IV cutaneous T-cell non-Hodgkin lymphoma
681962|NCT00008307|recurrent cutaneous T-cell non-Hodgkin lymphoma
681963|NCT00008307|refractory multiple myeloma
681964|NCT00008307|stage I multiple myeloma
681965|NCT00008307|stage II multiple myeloma
681966|NCT00008307|stage III multiple myeloma
681967|NCT00008307|stage I childhood lymphoblastic lymphoma
681968|NCT00008307|stage II childhood lymphoblastic lymphoma
681969|NCT00008307|stage III childhood lymphoblastic lymphoma
681970|NCT00008307|stage IV childhood lymphoblastic lymphoma
681971|NCT00008307|recurrent childhood lymphoblastic lymphoma
681972|NCT00008307|recurrent childhood acute myeloid leukemia
681973|NCT00008307|recurrent adult acute myeloid leukemia
681974|NCT00008307|recurrent adult acute lymphoblastic leukemia
681975|NCT00008307|relapsing chronic myelogenous leukemia
681976|NCT00008307|chronic phase chronic myelogenous leukemia
681977|NCT00008307|accelerated phase chronic myelogenous leukemia
681978|NCT00008307|blastic phase chronic myelogenous leukemia
681979|NCT00008307|meningeal chronic myelogenous leukemia
681980|NCT00008307|untreated adult acute lymphoblastic leukemia
681981|NCT00008307|untreated adult acute myeloid leukemia
681982|NCT00008307|untreated childhood acute myeloid leukemia and other myeloid malignancies
681983|NCT00008307|untreated childhood acute lymphoblastic leukemia
681984|NCT00008307|adult acute myeloid leukemia in remission
681985|NCT00008307|adult acute lymphoblastic leukemia in remission
681986|NCT00008307|childhood acute myeloid leukemia in remission
681987|NCT00008307|childhood acute lymphoblastic leukemia in remission
681988|NCT00008307|chronic myelogenous leukemia, BCR-ABL1 positive
681989|NCT00008307|Philadelphia chromosome negative chronic myelogenous leukemia
681990|NCT00008307|stage II childhood Hodgkin lymphoma
681991|NCT00008307|stage I childhood Hodgkin lymphoma
681992|NCT00008307|stage III childhood Hodgkin lymphoma
681993|NCT00008307|stage IV childhood Hodgkin lymphoma
681994|NCT00008307|recurrent/refractory childhood Hodgkin lymphoma
681995|NCT00008307|stage I grade 1 follicular lymphoma
681996|NCT00008307|stage I grade 2 follicular lymphoma
681997|NCT00008307|stage I grade 3 follicular lymphoma
681998|NCT00008307|stage I adult diffuse small cleaved cell lymphoma
681999|NCT00008307|stage I adult diffuse mixed cell lymphoma
682000|NCT00008307|stage I adult diffuse large cell lymphoma
682001|NCT00008307|stage I adult immunoblastic large cell lymphoma
682806|NCT00007137|Swallowing
682002|NCT00008307|stage I adult lymphoblastic lymphoma
682003|NCT00008307|stage I adult Burkitt lymphoma
682004|NCT00008307|stage III grade 1 follicular lymphoma
682005|NCT00008307|stage III grade 2 follicular lymphoma
682006|NCT00008307|stage III grade 3 follicular lymphoma
682007|NCT00008307|stage III adult diffuse small cleaved cell lymphoma
682008|NCT00008307|stage III adult diffuse mixed cell lymphoma
682009|NCT00008307|stage III adult diffuse large cell lymphoma
682010|NCT00008307|stage III adult immunoblastic large cell lymphoma
682011|NCT00008307|stage III adult lymphoblastic lymphoma
682012|NCT00008307|stage III adult Burkitt lymphoma
682013|NCT00008307|stage IV grade 1 follicular lymphoma
682014|NCT00008307|stage IV grade 2 follicular lymphoma
682015|NCT00008307|stage IV grade 3 follicular lymphoma
682016|NCT00008307|stage IV adult diffuse small cleaved cell lymphoma
682017|NCT00008307|stage IV adult diffuse mixed cell lymphoma
682018|NCT00008307|stage IV adult diffuse large cell lymphoma
682019|NCT00008307|stage IV adult immunoblastic large cell lymphoma
682020|NCT00008307|stage IV adult lymphoblastic lymphoma
682021|NCT00008307|stage IV adult Burkitt lymphoma
682022|NCT00008307|recurrent grade 1 follicular lymphoma
682023|NCT00008307|recurrent grade 2 follicular lymphoma
682024|NCT00008307|recurrent grade 3 follicular lymphoma
682025|NCT00008307|recurrent adult diffuse small cleaved cell lymphoma
682026|NCT00008307|recurrent adult diffuse mixed cell lymphoma
682027|NCT00008307|recurrent adult diffuse large cell lymphoma
682028|NCT00008307|recurrent adult immunoblastic large cell lymphoma
682029|NCT00008307|recurrent adult lymphoblastic lymphoma
682030|NCT00008307|recurrent adult Burkitt lymphoma
682031|NCT00008307|stage I adult T-cell leukemia/lymphoma
682032|NCT00008307|stage II adult T-cell leukemia/lymphoma
682033|NCT00008307|stage III adult T-cell leukemia/lymphoma
682034|NCT00008307|stage IV adult T-cell leukemia/lymphoma
682035|NCT00008307|recurrent adult T-cell leukemia/lymphoma
682036|NCT00008307|de novo myelodysplastic syndromes
682037|NCT00008307|previously treated myelodysplastic syndromes
682038|NCT00008307|secondary myelodysplastic syndromes
682039|NCT00008307|intraocular lymphoma
682040|NCT00008307|stage I childhood large cell lymphoma
682041|NCT00008307|stage II childhood large cell lymphoma
682042|NCT00008307|stage III childhood large cell lymphoma
682043|NCT00008307|stage IV childhood large cell lymphoma
682044|NCT00008307|recurrent childhood large cell lymphoma
682045|NCT00008307|stage I mantle cell lymphoma
682046|NCT00008307|contiguous stage II grade 1 follicular lymphoma
682047|NCT00008307|contiguous stage II grade 2 follicular lymphoma
682048|NCT00008307|contiguous stage II grade 3 follicular lymphoma
682049|NCT00008307|contiguous stage II adult diffuse small cleaved cell lymphoma
682050|NCT00008307|contiguous stage II mantle cell lymphoma
682051|NCT00008307|contiguous stage II adult diffuse mixed cell lymphoma
682052|NCT00008307|contiguous stage II adult immunoblastic large cell lymphoma
682053|NCT00008307|contiguous stage II adult diffuse large cell lymphoma
682054|NCT00008307|contiguous stage II adult Burkitt lymphoma
682055|NCT00008307|contiguous stage II adult lymphoblastic lymphoma
682056|NCT00008307|noncontiguous stage II grade 1 follicular lymphoma
682057|NCT00008307|noncontiguous stage II grade 2 follicular lymphoma
682058|NCT00008307|noncontiguous stage II grade 3 follicular lymphoma
682059|NCT00008307|noncontiguous stage II adult diffuse small cleaved cell lymphoma
682060|NCT00008307|noncontiguous stage II mantle cell lymphoma
682061|NCT00008307|noncontiguous stage II adult diffuse mixed cell lymphoma
682062|NCT00008307|noncontiguous stage II adult immunoblastic large cell lymphoma
682063|NCT00008307|noncontiguous stage II adult diffuse large cell lymphoma
682064|NCT00008307|noncontiguous stage II adult Burkitt lymphoma
682065|NCT00008307|noncontiguous stage II adult lymphoblastic lymphoma
682066|NCT00008307|stage III mantle cell lymphoma
682067|NCT00008307|stage IV mantle cell lymphoma
682068|NCT00008307|recurrent mantle cell lymphoma
682069|NCT00008307|angioimmunoblastic T-cell lymphoma
682070|NCT00008307|anaplastic large cell lymphoma
682071|NCT00008307|stage I mycosis fungoides/Sezary syndrome
682072|NCT00008307|stage II mycosis fungoides/Sezary syndrome
682073|NCT00008307|stage III mycosis fungoides/Sezary syndrome
682074|NCT00008307|stage IV mycosis fungoides/Sezary syndrome
682075|NCT00008307|recurrent mycosis fungoides/Sezary syndrome
682076|NCT00008307|childhood chronic myelogenous leukemia
682077|NCT00008307|contiguous stage II small lymphocytic lymphoma
682078|NCT00008307|contiguous stage II marginal zone lymphoma
682079|NCT00008307|noncontiguous stage II small lymphocytic lymphoma
682080|NCT00008307|noncontiguous stage II marginal zone lymphoma
682081|NCT00008307|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682082|NCT00008307|nodal marginal zone B-cell lymphoma
682083|NCT00008307|splenic marginal zone lymphoma
682084|NCT00008307|recurrent marginal zone lymphoma
682085|NCT00008307|recurrent small lymphocytic lymphoma
682086|NCT00008307|stage I marginal zone lymphoma
682087|NCT00008307|stage I small lymphocytic lymphoma
682088|NCT00008307|stage III small lymphocytic lymphoma
682089|NCT00008307|stage III marginal zone lymphoma
682090|NCT00008307|stage IV small lymphocytic lymphoma
682091|NCT00008307|stage IV marginal zone lymphoma
682807|NCT00007137|Tongue Weakness
682092|NCT00008307|adult acute myeloid leukemia with t(8;21)(q22;q22)
682093|NCT00008307|adult acute myeloid leukemia with t(16;16)(p13;q22)
682094|NCT00008307|adult acute myeloid leukemia with inv(16)(p13;q22)
682095|NCT00008307|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
682096|NCT00008307|adult acute myeloid leukemia with t(15;17)(q22;q12)
682097|NCT00008307|childhood myelodysplastic syndromes
682098|NCT00008294|stage IV colon cancer
682099|NCT00008294|stage IV rectal cancer
682100|NCT00008294|adenocarcinoma of the colon
682101|NCT00008294|adenocarcinoma of the rectum
682102|NCT00008294|liver metastases
682103|NCT00008294|recurrent colon cancer
682104|NCT00008294|recurrent rectal cancer
682105|NCT00008281|stage IV colon cancer
682106|NCT00008281|stage IV rectal cancer
682107|NCT00008281|recurrent colon cancer
682108|NCT00008281|recurrent rectal cancer
682109|NCT00008281|adenocarcinoma of the colon
682110|NCT00008281|adenocarcinoma of the rectum
682111|NCT00008268|stage I multiple myeloma
682112|NCT00008268|stage II multiple myeloma
682113|NCT00008268|stage III multiple myeloma
682114|NCT00008255|non-small cell lung cancer
682115|NCT00008255|small cell lung cancer
682116|NCT00008242|stage II multiple myeloma
682117|NCT00008242|stage III multiple myeloma
682118|NCT00008229|stage I multiple myeloma
682119|NCT00008229|stage II multiple myeloma
682120|NCT00008229|stage III multiple myeloma
682121|NCT00008216|stage IV adult Hodgkin lymphoma
682122|NCT00008216|recurrent childhood acute lymphoblastic leukemia
682123|NCT00008216|recurrent adult Hodgkin lymphoma
682124|NCT00008216|recurrent cutaneous T-cell non-Hodgkin lymphoma
682125|NCT00008216|refractory multiple myeloma
682126|NCT00008216|stage I multiple myeloma
682127|NCT00008216|stage II multiple myeloma
682128|NCT00008216|stage III multiple myeloma
682129|NCT00008216|stage II childhood lymphoblastic lymphoma
682130|NCT00008216|stage III childhood lymphoblastic lymphoma
682131|NCT00008216|stage IV childhood lymphoblastic lymphoma
682132|NCT00008216|recurrent childhood lymphoblastic lymphoma
682133|NCT00008216|recurrent childhood acute myeloid leukemia
682134|NCT00008216|recurrent adult acute myeloid leukemia
682135|NCT00008216|recurrent adult acute lymphoblastic leukemia
682136|NCT00008216|relapsing chronic myelogenous leukemia
682137|NCT00008216|childhood Langerhans cell histiocytosis
682138|NCT00008216|chronic phase chronic myelogenous leukemia
682139|NCT00008216|accelerated phase chronic myelogenous leukemia
682140|NCT00008216|blastic phase chronic myelogenous leukemia
682141|NCT00008216|meningeal chronic myelogenous leukemia
682142|NCT00008216|untreated adult acute lymphoblastic leukemia
682143|NCT00008216|untreated adult acute myeloid leukemia
682144|NCT00008216|untreated childhood acute myeloid leukemia and other myeloid malignancies
682145|NCT00008216|untreated childhood acute lymphoblastic leukemia
682146|NCT00008216|adult acute myeloid leukemia in remission
682147|NCT00008216|adult acute lymphoblastic leukemia in remission
682148|NCT00008216|childhood acute myeloid leukemia in remission
682149|NCT00008216|childhood acute lymphoblastic leukemia in remission
682150|NCT00008216|chronic myelogenous leukemia, BCR-ABL1 positive
682151|NCT00008216|Philadelphia chromosome negative chronic myelogenous leukemia
682152|NCT00008216|stage IV childhood Hodgkin lymphoma
682153|NCT00008216|recurrent/refractory childhood Hodgkin lymphoma
682154|NCT00008216|stage III grade 1 follicular lymphoma
682155|NCT00008216|stage III grade 2 follicular lymphoma
682156|NCT00008216|stage III grade 3 follicular lymphoma
682157|NCT00008216|stage III adult diffuse small cleaved cell lymphoma
682158|NCT00008216|stage III adult diffuse mixed cell lymphoma
682159|NCT00008216|stage III adult diffuse large cell lymphoma
682160|NCT00008216|stage III adult immunoblastic large cell lymphoma
682161|NCT00008216|stage III adult lymphoblastic lymphoma
682162|NCT00008216|stage III adult Burkitt lymphoma
682163|NCT00008216|stage IV grade 1 follicular lymphoma
682164|NCT00008216|stage IV grade 2 follicular lymphoma
682165|NCT00008216|stage IV grade 3 follicular lymphoma
682166|NCT00008216|stage IV adult diffuse small cleaved cell lymphoma
682167|NCT00008216|stage IV adult diffuse mixed cell lymphoma
682168|NCT00008216|stage IV adult diffuse large cell lymphoma
682169|NCT00008216|stage IV adult immunoblastic large cell lymphoma
682170|NCT00008216|stage IV adult lymphoblastic lymphoma
682171|NCT00008216|stage IV adult Burkitt lymphoma
682172|NCT00008216|recurrent grade 1 follicular lymphoma
682173|NCT00008216|recurrent grade 2 follicular lymphoma
682174|NCT00008216|recurrent grade 3 follicular lymphoma
682175|NCT00008216|recurrent adult diffuse small cleaved cell lymphoma
682176|NCT00008216|recurrent adult diffuse mixed cell lymphoma
682177|NCT00008216|recurrent adult diffuse large cell lymphoma
682178|NCT00008216|recurrent adult immunoblastic large cell lymphoma
682179|NCT00008216|recurrent adult lymphoblastic lymphoma
682180|NCT00008216|recurrent adult Burkitt lymphoma
682181|NCT00008216|stage II adult T-cell leukemia/lymphoma
682182|NCT00008216|stage III adult T-cell leukemia/lymphoma
682183|NCT00008216|stage IV adult T-cell leukemia/lymphoma
682184|NCT00008216|recurrent adult T-cell leukemia/lymphoma
682185|NCT00008216|secondary acute myeloid leukemia
682186|NCT00008216|de novo myelodysplastic syndromes
682187|NCT00008216|previously treated myelodysplastic syndromes
682188|NCT00008216|secondary myelodysplastic syndromes
682189|NCT00008216|intraocular lymphoma
682190|NCT00008216|stage II childhood small noncleaved cell lymphoma
682191|NCT00008216|stage II childhood large cell lymphoma
682192|NCT00008216|stage III childhood small noncleaved cell lymphoma
682193|NCT00008216|stage III childhood large cell lymphoma
682194|NCT00008216|stage IV childhood small noncleaved cell lymphoma
682195|NCT00008216|stage IV childhood large cell lymphoma
682196|NCT00008216|recurrent childhood small noncleaved cell lymphoma
682197|NCT00008216|recurrent childhood large cell lymphoma
682198|NCT00008216|contiguous stage II grade 1 follicular lymphoma
682199|NCT00008216|contiguous stage II grade 2 follicular lymphoma
682200|NCT00008216|contiguous stage II grade 3 follicular lymphoma
682201|NCT00008216|contiguous stage II adult diffuse small cleaved cell lymphoma
682202|NCT00008216|contiguous stage II mantle cell lymphoma
682203|NCT00008216|contiguous stage II adult diffuse mixed cell lymphoma
682204|NCT00008216|contiguous stage II adult immunoblastic large cell lymphoma
682205|NCT00008216|contiguous stage II adult diffuse large cell lymphoma
682206|NCT00008216|contiguous stage II adult Burkitt lymphoma
682207|NCT00008216|contiguous stage II adult lymphoblastic lymphoma
682208|NCT00008216|noncontiguous stage II grade 1 follicular lymphoma
682209|NCT00008216|noncontiguous stage II grade 2 follicular lymphoma
682210|NCT00008216|noncontiguous stage II grade 3 follicular lymphoma
682211|NCT00008216|noncontiguous stage II adult diffuse small cleaved cell lymphoma
682212|NCT00008216|noncontiguous stage II mantle cell lymphoma
682213|NCT00008216|noncontiguous stage II adult diffuse mixed cell lymphoma
682214|NCT00008216|noncontiguous stage II adult immunoblastic large cell lymphoma
682215|NCT00008216|noncontiguous stage II adult diffuse large cell lymphoma
682216|NCT00008216|noncontiguous stage II adult Burkitt lymphoma
682217|NCT00008216|noncontiguous stage II adult lymphoblastic lymphoma
682218|NCT00008216|stage III mantle cell lymphoma
682219|NCT00008216|stage IV mantle cell lymphoma
682220|NCT00008216|recurrent mantle cell lymphoma
682221|NCT00008216|angioimmunoblastic T-cell lymphoma
682222|NCT00008216|anaplastic large cell lymphoma
682223|NCT00008216|recurrent mycosis fungoides/Sezary syndrome
682224|NCT00008216|juvenile myelomonocytic leukemia
682225|NCT00008216|childhood chronic myelogenous leukemia
682226|NCT00008216|atypical chronic myeloid leukemia, BCR-ABL1 negative
682227|NCT00008216|myelodysplastic/myeloproliferative neoplasm, unclassifiable
682228|NCT00008216|chronic myelomonocytic leukemia
682229|NCT00008216|contiguous stage II small lymphocytic lymphoma
682230|NCT00008216|contiguous stage II marginal zone lymphoma
682231|NCT00008216|noncontiguous stage II small lymphocytic lymphoma
682232|NCT00008216|noncontiguous stage II marginal zone lymphoma
682233|NCT00008216|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682234|NCT00008216|nodal marginal zone B-cell lymphoma
682235|NCT00008216|splenic marginal zone lymphoma
682236|NCT00008216|recurrent marginal zone lymphoma
682237|NCT00008216|recurrent small lymphocytic lymphoma
682238|NCT00008216|stage III small lymphocytic lymphoma
682239|NCT00008216|stage III marginal zone lymphoma
682240|NCT00008216|stage IV small lymphocytic lymphoma
682241|NCT00008216|stage IV marginal zone lymphoma
682242|NCT00008216|adult acute myeloid leukemia with t(8;21)(q22;q22)
682243|NCT00008216|adult acute myeloid leukemia with t(16;16)(p13;q22)
682244|NCT00008216|adult acute myeloid leukemia with inv(16)(p13;q22)
682245|NCT00008216|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
682246|NCT00008216|adult acute myeloid leukemia with t(15;17)(q22;q12)
682247|NCT00008216|childhood myelodysplastic syndromes
682248|NCT00008216|adult Langerhans cell histiocytosis
682249|NCT00008203|stage II breast cancer
682250|NCT00008203|stage IIIA breast cancer
682251|NCT00008203|stage IIIB breast cancer
682252|NCT00008190|recurrent childhood acute lymphoblastic leukemia
682253|NCT00008190|recurrent childhood acute myeloid leukemia
682254|NCT00008190|recurrent adult acute myeloid leukemia
682255|NCT00008190|recurrent adult acute lymphoblastic leukemia
682256|NCT00008190|adult acute myeloid leukemia in remission
682257|NCT00008190|adult acute lymphoblastic leukemia in remission
682258|NCT00008190|childhood acute myeloid leukemia in remission
682259|NCT00008190|childhood acute lymphoblastic leukemia in remission
682260|NCT00008190|secondary acute myeloid leukemia
682261|NCT00008164|recurrent childhood acute lymphoblastic leukemia
682262|NCT00008164|recurrent adult Hodgkin lymphoma
682263|NCT00008164|recurrent cutaneous T-cell non-Hodgkin lymphoma
682264|NCT00008164|refractory multiple myeloma
682265|NCT00008164|stage I multiple myeloma
682266|NCT00008164|stage II multiple myeloma
682267|NCT00008164|stage III multiple myeloma
682268|NCT00008164|recurrent childhood lymphoblastic lymphoma
682269|NCT00008164|recurrent childhood acute myeloid leukemia
682270|NCT00008164|recurrent adult acute myeloid leukemia
682271|NCT00008164|recurrent adult acute lymphoblastic leukemia
682272|NCT00008164|relapsing chronic myelogenous leukemia
682273|NCT00008164|childhood Langerhans cell histiocytosis
682274|NCT00008164|chronic phase chronic myelogenous leukemia
682275|NCT00008164|accelerated phase chronic myelogenous leukemia
682905|NCT00006981|ovarian stromal cancer
682276|NCT00008164|blastic phase chronic myelogenous leukemia
682277|NCT00008164|meningeal chronic myelogenous leukemia
682278|NCT00008164|untreated adult acute lymphoblastic leukemia
682279|NCT00008164|untreated adult acute myeloid leukemia
682280|NCT00008164|untreated childhood acute myeloid leukemia and other myeloid malignancies
682281|NCT00008164|untreated childhood acute lymphoblastic leukemia
682282|NCT00008164|recurrent/refractory childhood Hodgkin lymphoma
682283|NCT00008164|stage I adult Burkitt lymphoma
682284|NCT00008164|stage III grade 1 follicular lymphoma
682285|NCT00008164|stage III grade 2 follicular lymphoma
682286|NCT00008164|stage III grade 3 follicular lymphoma
682287|NCT00008164|stage III adult diffuse small cleaved cell lymphoma
682288|NCT00008164|stage III adult diffuse mixed cell lymphoma
682289|NCT00008164|stage III adult diffuse large cell lymphoma
682290|NCT00008164|stage III adult immunoblastic large cell lymphoma
682291|NCT00008164|stage III adult lymphoblastic lymphoma
682292|NCT00008164|stage III adult Burkitt lymphoma
682293|NCT00008164|stage IV grade 1 follicular lymphoma
682294|NCT00008164|stage IV grade 2 follicular lymphoma
682295|NCT00008164|stage IV grade 3 follicular lymphoma
682296|NCT00008164|stage IV adult diffuse small cleaved cell lymphoma
682297|NCT00008164|stage IV adult diffuse mixed cell lymphoma
682298|NCT00008164|stage IV adult diffuse large cell lymphoma
682299|NCT00008164|stage IV adult immunoblastic large cell lymphoma
682300|NCT00008164|stage IV adult lymphoblastic lymphoma
682301|NCT00008164|stage IV adult Burkitt lymphoma
682302|NCT00008164|recurrent grade 1 follicular lymphoma
682303|NCT00008164|recurrent grade 2 follicular lymphoma
682304|NCT00008164|recurrent grade 3 follicular lymphoma
682305|NCT00008164|recurrent adult diffuse small cleaved cell lymphoma
682306|NCT00008164|recurrent adult diffuse mixed cell lymphoma
682307|NCT00008164|recurrent adult diffuse large cell lymphoma
682308|NCT00008164|recurrent adult immunoblastic large cell lymphoma
682309|NCT00008164|recurrent adult lymphoblastic lymphoma
682310|NCT00008164|recurrent adult Burkitt lymphoma
682311|NCT00008164|de novo myelodysplastic syndromes
682312|NCT00008164|previously treated myelodysplastic syndromes
682313|NCT00008164|secondary myelodysplastic syndromes
682314|NCT00008164|recurrent childhood small noncleaved cell lymphoma
682315|NCT00008164|recurrent childhood large cell lymphoma
682316|NCT00008164|contiguous stage II adult Burkitt lymphoma
682317|NCT00008164|contiguous stage II adult lymphoblastic lymphoma
682318|NCT00008164|noncontiguous stage II grade 1 follicular lymphoma
682319|NCT00008164|noncontiguous stage II grade 2 follicular lymphoma
682320|NCT00008164|noncontiguous stage II grade 3 follicular lymphoma
682321|NCT00008164|noncontiguous stage II adult diffuse small cleaved cell lymphoma
682322|NCT00008164|noncontiguous stage II mantle cell lymphoma
682323|NCT00008164|noncontiguous stage II adult diffuse mixed cell lymphoma
682324|NCT00008164|noncontiguous stage II adult immunoblastic large cell lymphoma
682325|NCT00008164|noncontiguous stage II adult diffuse large cell lymphoma
682326|NCT00008164|noncontiguous stage II adult Burkitt lymphoma
682327|NCT00008164|noncontiguous stage II adult lymphoblastic lymphoma
682328|NCT00008164|stage III mantle cell lymphoma
682329|NCT00008164|stage IV mantle cell lymphoma
682330|NCT00008164|recurrent mantle cell lymphoma
682331|NCT00008164|recurrent mycosis fungoides/Sezary syndrome
682332|NCT00008164|childhood chronic myelogenous leukemia
682333|NCT00008164|atypical chronic myeloid leukemia, BCR-ABL1 negative
682334|NCT00008164|myelodysplastic/myeloproliferative neoplasm, unclassifiable
682335|NCT00008164|noncontiguous stage II small lymphocytic lymphoma
682336|NCT00008164|noncontiguous stage II marginal zone lymphoma
682337|NCT00008164|recurrent marginal zone lymphoma
682338|NCT00008164|recurrent small lymphocytic lymphoma
682339|NCT00008164|stage III small lymphocytic lymphoma
682340|NCT00008164|stage III marginal zone lymphoma
682341|NCT00008164|stage IV small lymphocytic lymphoma
682342|NCT00008164|stage IV marginal zone lymphoma
682343|NCT00008164|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682344|NCT00008164|nodal marginal zone B-cell lymphoma
682345|NCT00008164|splenic marginal zone lymphoma
682346|NCT00008164|adult acute myeloid leukemia with t(8;21)(q22;q22)
682347|NCT00008164|adult acute myeloid leukemia with t(16;16)(p13;q22)
682348|NCT00008164|adult acute myeloid leukemia with inv(16)(p13;q22)
682349|NCT00008164|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
682350|NCT00008164|adult acute myeloid leukemia with t(15;17)(q22;q12)
682351|NCT00008164|childhood myelodysplastic syndromes
682352|NCT00008151|recurrent childhood acute myeloid leukemia
682353|NCT00008151|recurrent adult acute myeloid leukemia
682354|NCT00008151|refractory anemia with excess blasts
682355|NCT00008151|refractory anemia with excess blasts in transformation
682356|NCT00008151|de novo myelodysplastic syndromes
682357|NCT00008151|previously treated myelodysplastic syndromes
682358|NCT00008151|secondary myelodysplastic syndromes
682359|NCT00008151|childhood myelodysplastic syndromes
682360|NCT00008138|stage III ovarian epithelial cancer
682361|NCT00008138|stage IV ovarian epithelial cancer
682362|NCT00008138|ovarian undifferentiated adenocarcinoma
682363|NCT00008138|ovarian serous cystadenocarcinoma
682364|NCT00008138|ovarian mucinous cystadenocarcinoma
682365|NCT00008138|ovarian endometrioid adenocarcinoma
682366|NCT00008138|ovarian clear cell cystadenocarcinoma
682367|NCT00008138|fallopian tube cancer
682368|NCT00008138|peritoneal cavity cancer
682369|NCT00008125|unspecified adult solid tumor, protocol specific
682370|NCT00008112|stage III cervical cancer
682371|NCT00008112|stage IIB cervical cancer
682372|NCT00008112|stage IVA cervical cancer
682373|NCT00008112|cervical squamous cell carcinoma
682374|NCT00008112|cervical adenocarcinoma
682375|NCT00008112|cervical adenosquamous cell carcinoma
682376|NCT00008099|stage I pancreatic cancer
682377|NCT00008099|stage II pancreatic cancer
682378|NCT00008099|stage III pancreatic cancer
682379|NCT00008099|stage IV pancreatic cancer
682380|NCT00008086|recurrent adult brain tumor
682381|NCT00008086|adult brain stem glioma
682382|NCT00008086|adult craniopharyngioma
682383|NCT00008086|adult medulloblastoma
682384|NCT00008086|adult meningioma
682385|NCT00008086|adult glioblastoma
682386|NCT00008086|unspecified adult solid tumor, protocol specific
682387|NCT00008086|adult anaplastic astrocytoma
682388|NCT00008086|adult myxopapillary ependymoma
682389|NCT00008086|adult anaplastic ependymoma
682390|NCT00008086|adult anaplastic oligodendroglioma
682391|NCT00008086|adult mixed glioma
682392|NCT00008086|adult central nervous system germ cell tumor
682393|NCT00008086|adult pilocytic astrocytoma
682394|NCT00008086|adult subependymoma
682395|NCT00008086|adult ependymoblastoma
682396|NCT00008086|adult pineocytoma
682397|NCT00008086|adult pineoblastoma
682398|NCT00008086|adult meningeal hemangiopericytoma
682399|NCT00008086|adult choroid plexus tumor
682400|NCT00008086|adult grade III meningioma
682401|NCT00008086|adult oligodendroglioma
682402|NCT00008086|adult giant cell glioblastoma
682403|NCT00008086|adult gliosarcoma
682404|NCT00008073|unspecified adult solid tumor, protocol specific
682405|NCT00008060|stage IV colon cancer
682406|NCT00008060|stage IV rectal cancer
682407|NCT00008060|recurrent colon cancer
682408|NCT00008060|recurrent rectal cancer
682409|NCT00008060|adenocarcinoma of the colon
682410|NCT00008060|adenocarcinoma of the rectum
682411|NCT00008047|stage II esophageal cancer
682412|NCT00008047|stage III esophageal cancer
682413|NCT00008034|stage II breast cancer
682414|NCT00008034|stage IIIA breast cancer
682415|NCT00008034|stage IIIB breast cancer
682416|NCT00008034|inflammatory breast cancer
682417|NCT00008021|recurrent grade 1 follicular lymphoma
682418|NCT00008021|recurrent grade 2 follicular lymphoma
682419|NCT00008021|recurrent grade 3 follicular lymphoma
682420|NCT00008021|recurrent adult diffuse small cleaved cell lymphoma
682421|NCT00008021|recurrent adult diffuse mixed cell lymphoma
682422|NCT00008021|recurrent adult diffuse large cell lymphoma
682423|NCT00008021|recurrent adult immunoblastic large cell lymphoma
682424|NCT00008021|recurrent adult lymphoblastic lymphoma
682425|NCT00008021|recurrent adult Burkitt lymphoma
682426|NCT00008021|recurrent mantle cell lymphoma
682427|NCT00008021|recurrent marginal zone lymphoma
682428|NCT00008021|recurrent small lymphocytic lymphoma
682429|NCT00008021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682430|NCT00008021|nodal marginal zone B-cell lymphoma
682431|NCT00008021|splenic marginal zone lymphoma
682432|NCT00008008|childhood infratentorial ependymoma
682433|NCT00008008|childhood supratentorial ependymoma
682434|NCT00008008|recurrent adult brain tumor
682435|NCT00008008|adult medulloblastoma
682436|NCT00008008|adult glioblastoma
682437|NCT00008008|adult oligodendroglioma
682438|NCT00008008|childhood high-grade cerebral astrocytoma
682439|NCT00008008|childhood oligodendroglioma
682440|NCT00008008|adult anaplastic astrocytoma
682441|NCT00008008|adult anaplastic ependymoma
682442|NCT00008008|adult mixed glioma
682443|NCT00008008|recurrent childhood supratentorial primitive neuroectodermal tumor
682444|NCT00008008|recurrent childhood cerebellar astrocytoma
682445|NCT00008008|recurrent childhood cerebral astrocytoma
682446|NCT00008008|recurrent childhood ependymoma
682447|NCT00008008|adult giant cell glioblastoma
682448|NCT00008008|adult gliosarcoma
682449|NCT00008008|adult supratentorial primitive neuroectodermal tumor (PNET)
682450|NCT00007995|refractory multiple myeloma
682451|NCT00007995|stage I multiple myeloma
682452|NCT00007995|stage II multiple myeloma
682453|NCT00007995|stage III multiple myeloma
682454|NCT00007995|primary systemic amyloidosis
682455|NCT00007982|recurrent adult brain tumor
682456|NCT00007982|adult medulloblastoma
682457|NCT00007982|adult oligodendroglioma
682458|NCT00007982|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
682459|NCT00007982|adult anaplastic astrocytoma
682460|NCT00007982|adult central nervous system germ cell tumor
682461|NCT00007982|primary central nervous system non-Hodgkin lymphoma
682462|NCT00007982|adult anaplastic oligodendroglioma
682463|NCT00007969|stage III melanoma
682464|NCT00007969|stage IV melanoma
682465|NCT00007969|recurrent melanoma
682466|NCT00007956|recurrent grade 1 follicular lymphoma
682467|NCT00007956|recurrent grade 2 follicular lymphoma
682468|NCT00007956|recurrent grade 3 follicular lymphoma
682469|NCT00007956|recurrent adult diffuse small cleaved cell lymphoma
682470|NCT00007956|recurrent adult diffuse mixed cell lymphoma
682471|NCT00007956|recurrent adult diffuse large cell lymphoma
682472|NCT00007956|recurrent adult immunoblastic large cell lymphoma
682473|NCT00007956|recurrent adult Burkitt lymphoma
682474|NCT00007956|recurrent mantle cell lymphoma
682475|NCT00007956|recurrent small lymphocytic lymphoma
682476|NCT00007943|stage III colon cancer
682477|NCT00007943|stage IV colon cancer
682478|NCT00007943|stage III rectal cancer
682479|NCT00007943|stage IV rectal cancer
682480|NCT00007943|recurrent colon cancer
682481|NCT00007943|recurrent rectal cancer
682482|NCT00007930|stage I rectal cancer
682483|NCT00007930|stage II rectal cancer
682484|NCT00007930|stage III rectal cancer
682485|NCT00007917|unspecified adult solid tumor, protocol specific
682486|NCT00007904|stage II breast cancer
682487|NCT00007904|stage IIIA breast cancer
682488|NCT00007904|male breast cancer
682489|NCT00007891|stage IV breast cancer
682490|NCT00007891|recurrent breast cancer
682491|NCT00007891|male breast cancer
682492|NCT00007865|recurrent grade 1 follicular lymphoma
682493|NCT00007865|recurrent grade 2 follicular lymphoma
682494|NCT00007865|recurrent grade 3 follicular lymphoma
682495|NCT00007865|recurrent adult diffuse small cleaved cell lymphoma
682496|NCT00007865|recurrent adult diffuse mixed cell lymphoma
682497|NCT00007865|recurrent adult diffuse large cell lymphoma
682498|NCT00007865|recurrent adult immunoblastic large cell lymphoma
682499|NCT00007865|recurrent adult Burkitt lymphoma
682500|NCT00007865|recurrent mantle cell lymphoma
682501|NCT00007865|recurrent marginal zone lymphoma
682502|NCT00007865|recurrent small lymphocytic lymphoma
682503|NCT00007865|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682504|NCT00007865|nodal marginal zone B-cell lymphoma
682505|NCT00007865|splenic marginal zone lymphoma
682506|NCT00007852|recurrent grade 1 follicular lymphoma
682507|NCT00007852|recurrent grade 2 follicular lymphoma
682508|NCT00007852|recurrent grade 3 follicular lymphoma
682509|NCT00007852|recurrent adult diffuse small cleaved cell lymphoma
682510|NCT00007852|recurrent adult diffuse mixed cell lymphoma
682511|NCT00007852|recurrent adult diffuse large cell lymphoma
682512|NCT00007852|recurrent adult immunoblastic large cell lymphoma
682513|NCT00007852|recurrent adult Burkitt lymphoma
682514|NCT00007852|recurrent mantle cell lymphoma
682515|NCT00007852|recurrent marginal zone lymphoma
682516|NCT00007852|recurrent small lymphocytic lymphoma
682517|NCT00007852|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682518|NCT00007852|nodal marginal zone B-cell lymphoma
682519|NCT00007852|splenic marginal zone lymphoma
682520|NCT00007839|stage I grade 1 follicular lymphoma
682521|NCT00007839|stage I grade 2 follicular lymphoma
682522|NCT00007839|stage I adult diffuse small cleaved cell lymphoma
682523|NCT00007839|stage III grade 1 follicular lymphoma
682524|NCT00007839|stage III grade 2 follicular lymphoma
682525|NCT00007839|stage III adult diffuse small cleaved cell lymphoma
682526|NCT00007839|stage IV grade 1 follicular lymphoma
682527|NCT00007839|stage IV grade 2 follicular lymphoma
682528|NCT00007839|stage IV adult diffuse small cleaved cell lymphoma
682529|NCT00007839|recurrent grade 1 follicular lymphoma
682530|NCT00007839|recurrent grade 2 follicular lymphoma
682531|NCT00007839|recurrent adult diffuse small cleaved cell lymphoma
682532|NCT00007839|contiguous stage II grade 1 follicular lymphoma
682533|NCT00007839|contiguous stage II grade 2 follicular lymphoma
682534|NCT00007839|contiguous stage II adult diffuse small cleaved cell lymphoma
682535|NCT00007839|noncontiguous stage II grade 1 follicular lymphoma
682536|NCT00007839|noncontiguous stage II grade 2 follicular lymphoma
682537|NCT00007839|noncontiguous stage II adult diffuse small cleaved cell lymphoma
682538|NCT00007839|noncontiguous stage II small lymphocytic lymphoma
682539|NCT00007839|noncontiguous stage II marginal zone lymphoma
682540|NCT00007839|recurrent marginal zone lymphoma
682541|NCT00007839|recurrent small lymphocytic lymphoma
682542|NCT00007839|stage I marginal zone lymphoma
682543|NCT00007839|stage I small lymphocytic lymphoma
682544|NCT00007839|stage III small lymphocytic lymphoma
682545|NCT00007839|stage III marginal zone lymphoma
682546|NCT00007839|stage IV small lymphocytic lymphoma
682547|NCT00007839|stage IV marginal zone lymphoma
682548|NCT00007839|contiguous stage II marginal zone lymphoma
682549|NCT00007839|contiguous stage II small lymphocytic lymphoma
682550|NCT00007839|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
682551|NCT00007839|nodal marginal zone B-cell lymphoma
682552|NCT00007839|splenic marginal zone lymphoma
682553|NCT00007826|stage II colon cancer
682554|NCT00007826|stage III colon cancer
682555|NCT00007826|stage IV colon cancer
682556|NCT00007826|stage II rectal cancer
682557|NCT00007826|stage III rectal cancer
682558|NCT00007826|stage IV rectal cancer
682559|NCT00007826|adenocarcinoma of the colon
682560|NCT00007826|adenocarcinoma of the rectum
682561|NCT00007813|recurrent childhood rhabdomyosarcoma
682562|NCT00007813|childhood craniopharyngioma
682563|NCT00007813|recurrent childhood brain tumor
682564|NCT00007813|disseminated neuroblastoma
682565|NCT00007813|stage 4S neuroblastoma
682566|NCT00007813|recurrent neuroblastoma
682567|NCT00007813|stage IV childhood liver cancer
682568|NCT00007813|recurrent childhood liver cancer
682569|NCT00007813|childhood hepatoblastoma
682570|NCT00007813|childhood central nervous system germ cell tumor
682571|NCT00007813|stage III malignant testicular germ cell tumor
682572|NCT00007813|recurrent malignant testicular germ cell tumor
682573|NCT00007813|childhood germ cell tumor
682574|NCT00007813|stage IV ovarian germ cell tumor
682575|NCT00007813|recurrent ovarian germ cell tumor
682576|NCT00007813|extragonadal germ cell tumor
682577|NCT00007813|childhood oligodendroglioma
682578|NCT00007813|childhood choroid plexus tumor
682579|NCT00007813|childhood grade III meningioma
682580|NCT00007813|recurrent childhood cerebellar astrocytoma
682581|NCT00007813|recurrent childhood cerebral astrocytoma
682582|NCT00007813|recurrent childhood medulloblastoma
682583|NCT00007813|recurrent childhood visual pathway and hypothalamic glioma
682584|NCT00007813|previously treated childhood rhabdomyosarcoma
682585|NCT00007813|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
682586|NCT00007813|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
682587|NCT00007813|recurrent childhood ependymoma
682588|NCT00007813|childhood teratoma
682589|NCT00007813|childhood malignant testicular germ cell tumor
682590|NCT00007813|childhood malignant ovarian germ cell tumor
682591|NCT00007813|childhood extragonadal germ cell tumor
682592|NCT00007813|recurrent childhood malignant germ cell tumor
682593|NCT00007813|childhood atypical teratoid/rhabdoid tumor
682594|NCT00007800|obesity treatment
682595|NCT00007800|non insulin dependent diabetes
682596|NCT00007800|type 2 diabetes
682597|NCT00007800|behavioral weight control
682598|NCT00007800|motivational interviewing
682599|NCT00007800|motivational enhancement
682600|NCT00007774|Olanzapine, haloperidol, schizophrenia, schisoaffe
682601|NCT00007761|Bipolar Disease Program intervention
682602|NCT00007748|aerobic exercise
682603|NCT00007748|cognitive behavioral therapy
682604|NCT00007748|CBT
682605|NCT00007748|Gulf War Illnesses
682606|NCT00007748|GWI
682607|NCT00007735|antibiotic treatment
682608|NCT00007735|mycoplasma species
682609|NCT00007735|Gulf War Veterans' Illnesses (GWI)
682610|NCT00007735|mycoplasma positive
682611|NCT00007735|Gulf War Syndrome
682612|NCT00007722|ALS
682613|NCT00007722|amyotrophic lateral sclerosis
682614|NCT00007722|Gulf War Veterans
682615|NCT00007709|Hepatitis C
682616|NCT00007709|HIV
682617|NCT00007709|severe mental illness (SMI)
682618|NCT00007696|Diabetes Mellitus,DM,glycemic control
682619|NCT00007683|aspirin
682620|NCT00007683|clopidogrel
682621|NCT00007683|embolic events
682622|NCT00007683|Left ventricular ejection fraction less than or eq
682623|NCT00007683|NYHA Class II, III or IV CHF
682624|NCT00007683|symptomatic CHF
682625|NCT00007683|warfarin
682626|NCT00007670|gabapentin
682627|NCT00007670|lamotrigine
682628|NCT00007670|seizures in the elderly
682629|NCT00007670|Carbamazepine
682630|NCT00007657|PCI plus intensive medical therapy
682631|NCT00007644|cancer of the prostate (CAP)
682632|NCT00007644|cancer treatment
682633|NCT00007644|chronic diseases
682634|NCT00007644|expectant management
682635|NCT00007644|genitourinary
682636|NCT00007644|prostate
682637|NCT00007644|prostate specific cancer mortality
682638|NCT00007644|radical prostatectomy
682639|NCT00007631|NMSC
682640|NCT00007631|nonmelanoma skin cancer
682641|NCT00007631|topical tretinoin cream
682642|NCT00007618|colorectal cancer
682643|NCT00007605|amiodarone
682644|NCT00007605|atrial fibrillation converted to sinus rhythm
682645|NCT00007605|cardiac mortality
682646|NCT00007605|major and minor bleeds
682647|NCT00007605|sinus rhythm
682648|NCT00007605|sotalol
682649|NCT00007592|Hypertension
682650|NCT00007592|national data base on the treatment of hypertension
682651|NCT00007592|cost of different antihypertensive regimens
682652|NCT00007579|prostate cancer
682653|NCT00007540|Prostate cancer
682654|NCT00007540|CAG repeat sequence
682655|NCT00007527|buprenorphine and naloxone
682656|NCT00007527|opiate dependence
682657|NCT00007527|narcotic treatment
682658|NCT00007514|olfactory functioning
682659|NCT00007514|neurotoxic exposure
682660|NCT00007514|Gulf War-era veterans
682661|NCT00007501|varicella-zoster vaccine
682662|NCT00007488|HIV-1
682663|NCT00007488|Lymphoid Tissue
682664|NCT00007488|Viremia
682665|NCT00007488|RNA, Viral
682666|NCT00007488|Saliva
682667|NCT00007488|Anti-HIV Agents
682668|NCT00007488|Viral Load
682669|NCT00007488|Genitalia, Female
682670|NCT00007488|Genitalia, Male
682671|NCT00007475|Plasma Exchange
682672|NCT00007475|Cyclophosphamide
682673|NCT00007475|Proteinuria
682674|NCT00007475|Hemodialysis
682675|NCT00007475|Expression Profiling
682676|NCT00007449|HIV-1
682677|NCT00007449|Drug Therapy, Combination
682678|NCT00007449|RNA, Viral
682679|NCT00007449|Reverse Transcriptase Inhibitors
682680|NCT00007449|Anti-HIV Agents
682681|NCT00007449|Viral Load
682682|NCT00007436|HIV-1
682683|NCT00007436|Drug Therapy, Combination
682684|NCT00007436|Reverse Transcriptase Inhibitors
682685|NCT00007436|Anti-HIV Agents
682686|NCT00007436|9-(2-phosphonylmethoxypropyl)adenine
682687|NCT00007423|HIV Antibodies
682688|NCT00007423|HIV-1
682689|NCT00007423|AIDS Vaccines
682690|NCT00007423|HIV Seronegativity
682691|NCT00007423|Uganda
682692|NCT00007423|Cross Reactions
682693|NCT00007423|HIV Preventive Vaccine
682694|NCT00007358|Dexamethasone
682695|NCT00007358|Anti-SSA/Ro antibodies
682696|NCT00007358|Anti-SSB/La antibodies
682697|NCT00007358|Ultrasound
682698|NCT00007358|Atrioventricular (AV) nodal dysfunction
682699|NCT00007358|Echocardiograms
682700|NCT00007358|Mothers
682701|NCT00007345|Histone Acetylase
682702|NCT00007345|Differentiation
682703|NCT00007345|Sezary Syndrome
682704|NCT00007345|Mycosis Fungoides
682705|NCT00007345|CD 30 Lymphoma
682706|NCT00007332|Drug Therapy, Combination
682707|NCT00007332|HIV Envelope Protein gp120
682708|NCT00007332|AIDS Vaccines
682709|NCT00007332|CD8-Positive T-Lymphocytes
682710|NCT00007332|HIV Seronegativity
682711|NCT00007332|AIDSVAX
682712|NCT00007332|HIV Preventive Vaccine
682713|NCT00007319|HIV Protease Inhibitors
682714|NCT00007319|Risk Factors
682715|NCT00007319|HIV Seronegativity
682716|NCT00007319|Anti-HIV Agents
682717|NCT00007319|Carotid Artery
682718|NCT00007319|Tunica Intima
682719|NCT00007319|Atherosclerosis
682720|NCT00007306|Parathyroid hormone
682721|NCT00007306|Psoriasis
682722|NCT00007306|Lesions
682723|NCT00007306|Topical medications
682724|NCT00007306|Ointment
682725|NCT00007306|Calcium metabolism
682726|NCT00007306|Skin biopsy
682727|NCT00007293|Phototherapy
682728|NCT00007293|Psoriasis
682729|NCT00007293|Scalp psoriasis
682730|NCT00007293|Fiber optic
682731|NCT00007293|Light comb
682732|NCT00007293|UV source
682733|NCT00007280|Bioengineered skin
682734|NCT00007280|Venous leg ulcer
682735|NCT00007267|Scleroderma
682736|NCT00007267|Systemic sclerosis
682737|NCT00007267|Depression
682738|NCT00007267|Pain
682739|NCT00007267|Disfigurement
682740|NCT00007267|Body image dissatisfaction
682741|NCT00007267|Cognitive-behavioral therapy
682742|NCT00007267|Self-help
682743|NCT00007267|Psychological intervention
682744|NCT00007254|Analgesia
682745|NCT00007254|Bedsore
682746|NCT00007254|Morphine gel
682747|NCT00007254|Pressure ulcer
682748|NCT00007254|Pain
682749|NCT00007254|Ulcer
682750|NCT00007241|Osteoarthritis
682751|NCT00007241|Knee
682752|NCT00007241|OA
682753|NCT00007241|Isometric
682754|NCT00007241|Exercise
682755|NCT00007241|Strengthening
682756|NCT00007241|Joint-related pain
682757|NCT00007228|Chorea
682758|NCT00007228|DCM
682759|NCT00007228|Hypertrophic Cardiomyopathy
682760|NCT00007228|Sudden Death
682761|NCT00007228|Neuroacanthocytosis
682762|NCT00007215|Cataract
682763|NCT00007215|Early Lens Changes
682764|NCT00007215|Protein Aggregation
682765|NCT00007215|Blindness
682766|NCT00007215|Vision
682767|NCT00007215|Dynamic Laser Scattering (DLS)
682768|NCT00007215|Age-Related Changes
682769|NCT00007215|Test Re-test Reproducibility
682770|NCT00007215|Normal Volunteers
682771|NCT00007215|Lens
682772|NCT00007215|Healthy Volunteer
682773|NCT00007202|Virus Replication
682774|NCT00007202|HIV-1
682775|NCT00007202|Didanosine
682776|NCT00007202|Drug Therapy, Combination
682777|NCT00007202|Stavudine
682778|NCT00007202|HIV Protease Inhibitors
682779|NCT00007202|Sensitivity and Specificity
682780|NCT00007202|Reverse Transcriptase Inhibitors
682781|NCT00007202|Anti-HIV Agents
682782|NCT00007202|Viral Load
682783|NCT00007202|Reverse Transcriptase Polymerase Chain Reaction
682784|NCT00007202|Acute Infection
682785|NCT00007189|Alzheimer disease
682786|NCT00007189|Anti-inflammatory drugs
682787|NCT00007163|Immunosuppression
682788|NCT00007163|Recombinant IgG1
682789|NCT00007163|Apoptosis
682790|NCT00007163|Interferon Gamma
682791|NCT00007163|Colonoscopy
682792|NCT00007163|Crohn's Disease
682793|NCT00007163|Immunotherapy
682794|NCT00007163|IL-12
682795|NCT00007150|Phlebotomy Therapy
682796|NCT00007150|Hemochromatosis
682797|NCT00007150|Iron Overload
682798|NCT00007150|Hereditary Hemochromatosis
682799|NCT00007150|Blood Donation
682800|NCT00007137|3D MRI
682801|NCT00007137|Diffusion Tensor
682802|NCT00007137|Tongue
682803|NCT00007137|Ultrasound
682804|NCT00007137|Volume
682808|NCT00007137|Tongue Movement Coordination Problem
682809|NCT00007124|Myoclonus
682810|NCT00007124|Epilepsy
682811|NCT00007124|Dementia
682812|NCT00007124|Polyglucosan
682813|NCT00007124|Insulin
682814|NCT00007124|Lafora Disease
682815|NCT00007124|Restrictive Carbohydrate Diet
682816|NCT00007072|genetic diseases and dysmorphic syndromes
682817|NCT00007072|hematologic disorders
682818|NCT00007072|rare disease
682819|NCT00007072|thalassemia major
682820|NCT00007059|disease-related problem/condition
682821|NCT00007059|graft versus host disease
682822|NCT00007059|rare disease
682823|NCT00007046|arthritis & connective tissue diseases
682824|NCT00007046|bone cancer
682825|NCT00007046|diaphyseal medullary stenosis
682826|NCT00007046|genetic diseases and dysmorphic syndromes
682827|NCT00007046|malignant fibrous histiocytoma of bone
682828|NCT00007046|musculoskeletal/mesodermal cancer
682829|NCT00007046|oncologic disorders
682830|NCT00007046|rare disease
682831|NCT00007033|Alagille syndrome
682832|NCT00007033|biliary atresia
682833|NCT00007033|cholestasis
682834|NCT00007033|gastrointestinal disorders
682835|NCT00007033|rare disease
682836|NCT00007007|tumors metastatic to brain
682837|NCT00007007|radiation toxicity
682838|NCT00007007|cognitive/functional effects
682839|NCT00006994|oral complications of radiation therapy
682840|NCT00006994|pain
682841|NCT00006994|radiation toxicity
682842|NCT00006994|stage I squamous cell carcinoma of the lip and oral cavity
682843|NCT00006994|stage II squamous cell carcinoma of the lip and oral cavity
682844|NCT00006994|stage III squamous cell carcinoma of the lip and oral cavity
682845|NCT00006994|stage IV squamous cell carcinoma of the lip and oral cavity
682846|NCT00006994|stage I squamous cell carcinoma of the oropharynx
682847|NCT00006994|stage II squamous cell carcinoma of the oropharynx
682848|NCT00006994|stage III squamous cell carcinoma of the oropharynx
682849|NCT00006994|stage IV squamous cell carcinoma of the oropharynx
682850|NCT00006981|recurrent non-small cell lung cancer
682851|NCT00006981|stage III cervical cancer
682852|NCT00006981|recurrent cervical cancer
682853|NCT00006981|stage IVB cervical cancer
682854|NCT00006981|stage IVA cervical cancer
682855|NCT00006981|squamous cell lung cancer
682856|NCT00006981|stage III ovarian epithelial cancer
682857|NCT00006981|stage IV ovarian epithelial cancer
682858|NCT00006981|recurrent ovarian epithelial cancer
682859|NCT00006981|advanced malignant mesothelioma
682860|NCT00006981|recurrent malignant mesothelioma
682861|NCT00006981|stage IIIA non-small cell lung cancer
682862|NCT00006981|stage IIIB non-small cell lung cancer
682863|NCT00006981|stage IV non-small cell lung cancer
682864|NCT00006981|recurrent metastatic squamous neck cancer with occult primary
682865|NCT00006981|ovarian undifferentiated adenocarcinoma
682866|NCT00006981|ovarian mixed epithelial carcinoma
682867|NCT00006981|ovarian serous cystadenocarcinoma
682868|NCT00006981|ovarian endometrioid adenocarcinoma
682869|NCT00006981|ovarian clear cell cystadenocarcinoma
682870|NCT00006981|cervical squamous cell carcinoma
682871|NCT00006981|metastatic squamous neck cancer with occult primary squamous cell carcinoma
682872|NCT00006981|stage III squamous cell carcinoma of the lip and oral cavity
682873|NCT00006981|stage IV squamous cell carcinoma of the lip and oral cavity
682874|NCT00006981|recurrent squamous cell carcinoma of the lip and oral cavity
682875|NCT00006981|stage III squamous cell carcinoma of the oropharynx
682876|NCT00006981|stage IV squamous cell carcinoma of the oropharynx
682877|NCT00006981|recurrent squamous cell carcinoma of the oropharynx
682878|NCT00006981|stage III squamous cell carcinoma of the nasopharynx
682879|NCT00006981|stage IV squamous cell carcinoma of the nasopharynx
682880|NCT00006981|recurrent squamous cell carcinoma of the nasopharynx
682881|NCT00006981|stage III squamous cell carcinoma of the hypopharynx
682882|NCT00006981|stage IV squamous cell carcinoma of the hypopharynx
682883|NCT00006981|recurrent squamous cell carcinoma of the hypopharynx
682884|NCT00006981|stage III squamous cell carcinoma of the larynx
682885|NCT00006981|stage IV squamous cell carcinoma of the larynx
682886|NCT00006981|recurrent squamous cell carcinoma of the larynx
682887|NCT00006981|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
682888|NCT00006981|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
682889|NCT00006981|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
682890|NCT00006981|fallopian tube cancer
682891|NCT00006981|primary peritoneal cavity cancer
682892|NCT00006981|ovarian carcinosarcoma
682893|NCT00006981|Brenner tumor
682894|NCT00006981|untreated metastatic squamous neck cancer with occult primary
682895|NCT00006981|recurrent salivary gland cancer
682896|NCT00006981|salivary gland squamous cell carcinoma
682897|NCT00006981|stage III salivary gland cancer
682898|NCT00006981|stage IV salivary gland cancer
682899|NCT00006981|recurrent pancreatic cancer
682900|NCT00006981|stage II pancreatic cancer
682901|NCT00006981|stage III pancreatic cancer
682902|NCT00006981|ovarian mucinous cystadenocarcinoma
682903|NCT00006981|borderline ovarian surface epithelial-stromal tumor
682904|NCT00006981|ovarian sarcoma
682906|NCT00006981|stage IV pancreatic cancer
682907|NCT00006968|stage III renal cell cancer
682908|NCT00006968|stage IV renal cell cancer
682909|NCT00006968|recurrent renal cell cancer
682910|NCT00006916|adult glioblastoma
682911|NCT00006916|adult giant cell glioblastoma
682912|NCT00006916|adult gliosarcoma
682913|NCT00006903|stage IV endometrial carcinoma
682914|NCT00006903|recurrent endometrial carcinoma
682915|NCT00006903|stage III endometrial carcinoma
682916|NCT00006890|refractory multiple myeloma
682917|NCT00006890|stage I multiple myeloma
682918|NCT00006890|stage II multiple myeloma
682919|NCT00006890|stage III multiple myeloma
682920|NCT00006877|recurrent non-small cell lung cancer
682921|NCT00006877|squamous cell lung cancer
682922|NCT00006877|large cell lung cancer
682923|NCT00006877|stage IV non-small cell lung cancer
682924|NCT00006877|adenocarcinoma of the lung
682925|NCT00006864|stage IV renal cell cancer
682926|NCT00006864|recurrent renal cell cancer
682927|NCT00006864|clear cell renal cell carcinoma
682928|NCT00006825|stage IV breast cancer
682929|NCT00006825|recurrent breast cancer
682930|NCT00006812|recurrent ovarian epithelial cancer
682931|NCT00006812|primary peritoneal cavity cancer
682932|NCT00006799|untreated metastatic squamous neck cancer with occult primary
682933|NCT00006799|metastatic squamous neck cancer with occult primary squamous cell carcinoma
682934|NCT00006799|stage I squamous cell carcinoma of the lip and oral cavity
682935|NCT00006799|stage I basal cell carcinoma of the lip
682936|NCT00006799|stage I verrucous carcinoma of the oral cavity
682937|NCT00006799|stage I mucoepidermoid carcinoma of the oral cavity
682938|NCT00006799|stage I adenoid cystic carcinoma of the oral cavity
682939|NCT00006799|stage II squamous cell carcinoma of the lip and oral cavity
682940|NCT00006799|stage II basal cell carcinoma of the lip
682941|NCT00006799|stage II verrucous carcinoma of the oral cavity
682942|NCT00006799|stage II mucoepidermoid carcinoma of the oral cavity
682943|NCT00006799|stage II adenoid cystic carcinoma of the oral cavity
682944|NCT00006799|stage III squamous cell carcinoma of the lip and oral cavity
682945|NCT00006799|stage III basal cell carcinoma of the lip
682946|NCT00006799|stage III verrucous carcinoma of the oral cavity
682947|NCT00006799|stage III mucoepidermoid carcinoma of the oral cavity
682948|NCT00006799|stage III adenoid cystic carcinoma of the oral cavity
682949|NCT00006799|stage IV squamous cell carcinoma of the lip and oral cavity
682950|NCT00006799|stage IV basal cell carcinoma of the lip
682951|NCT00006799|stage IV verrucous carcinoma of the oral cavity
682952|NCT00006799|stage IV mucoepidermoid carcinoma of the oral cavity
682953|NCT00006799|stage IV adenoid cystic carcinoma of the oral cavity
682954|NCT00006799|stage I squamous cell carcinoma of the oropharynx
682955|NCT00006799|stage I lymphoepithelioma of the oropharynx
682956|NCT00006799|stage II squamous cell carcinoma of the oropharynx
682957|NCT00006799|stage II lymphoepithelioma of the oropharynx
682958|NCT00006799|stage III squamous cell carcinoma of the oropharynx
682959|NCT00006799|stage III lymphoepithelioma of the oropharynx
682960|NCT00006799|stage IV squamous cell carcinoma of the oropharynx
682961|NCT00006799|stage IV lymphoepithelioma of the oropharynx
682962|NCT00006799|stage I squamous cell carcinoma of the nasopharynx
682963|NCT00006799|stage I lymphoepithelioma of the nasopharynx
682964|NCT00006799|stage II squamous cell carcinoma of the nasopharynx
682965|NCT00006799|stage II lymphoepithelioma of the nasopharynx
682966|NCT00006799|stage III squamous cell carcinoma of the nasopharynx
682967|NCT00006799|stage III lymphoepithelioma of the nasopharynx
682968|NCT00006799|stage IV squamous cell carcinoma of the nasopharynx
682969|NCT00006799|stage IV lymphoepithelioma of the nasopharynx
682970|NCT00006799|stage I squamous cell carcinoma of the hypopharynx
682971|NCT00006799|stage II squamous cell carcinoma of the hypopharynx
682972|NCT00006799|stage III squamous cell carcinoma of the hypopharynx
682973|NCT00006799|stage IV squamous cell carcinoma of the hypopharynx
682974|NCT00006799|stage I squamous cell carcinoma of the larynx
682975|NCT00006799|stage I verrucous carcinoma of the larynx
682976|NCT00006799|stage II squamous cell carcinoma of the larynx
682977|NCT00006799|stage II verrucous carcinoma of the larynx
682978|NCT00006799|stage III squamous cell carcinoma of the larynx
682979|NCT00006799|stage III verrucous carcinoma of the larynx
682980|NCT00006799|stage IV squamous cell carcinoma of the larynx
682981|NCT00006799|stage IV verrucous carcinoma of the larynx
682982|NCT00006799|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
682983|NCT00006799|stage I inverted papilloma of the paranasal sinus and nasal cavity
682984|NCT00006799|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
682985|NCT00006799|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
682986|NCT00006799|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
682987|NCT00006799|stage II inverted papilloma of the paranasal sinus and nasal cavity
682988|NCT00006799|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
682989|NCT00006799|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
682990|NCT00006799|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
682991|NCT00006799|stage III inverted papilloma of the paranasal sinus and nasal cavity
682992|NCT00006799|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
682993|NCT00006799|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
682994|NCT00006799|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
682995|NCT00006799|stage IV inverted papilloma of the paranasal sinus and nasal cavity
682996|NCT00006799|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
682997|NCT00006799|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
682998|NCT00006799|anorexia
682999|NCT00006799|cachexia
683000|NCT00006799|quality of life
683001|NCT00006786|stage IV colon cancer
683002|NCT00006786|stage IV rectal cancer
683003|NCT00006786|recurrent colon cancer
683004|NCT00006786|recurrent rectal cancer
683005|NCT00006786|adenocarcinoma of the colon
683006|NCT00006786|adenocarcinoma of the rectum
683007|NCT00006760|recurrent/refractory childhood Hodgkin lymphoma
683008|NCT00006760|childhood lymphocyte predominant Hodgkin lymphoma
683009|NCT00006760|childhood lymphocyte depletion Hodgkin lymphoma
683010|NCT00006760|childhood nodular sclerosis Hodgkin lymphoma
683011|NCT00006760|childhood mixed cellularity Hodgkin lymphoma
683012|NCT00006747|graft versus host disease
683013|NCT00006747|stage I mantle cell lymphoma
683014|NCT00006747|contiguous stage II mantle cell lymphoma
683015|NCT00006747|noncontiguous stage II mantle cell lymphoma
683016|NCT00006747|stage III mantle cell lymphoma
683017|NCT00006747|stage IV mantle cell lymphoma
683018|NCT00006747|recurrent mantle cell lymphoma
683019|NCT00006734|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
683020|NCT00006721|stage III grade 1 follicular lymphoma
683021|NCT00006721|stage III grade 2 follicular lymphoma
683022|NCT00006721|stage III grade 3 follicular lymphoma
683023|NCT00006721|stage IV grade 1 follicular lymphoma
683024|NCT00006721|stage IV grade 2 follicular lymphoma
683025|NCT00006721|stage IV grade 3 follicular lymphoma
683026|NCT00006721|contiguous stage II grade 1 follicular lymphoma
683027|NCT00006721|contiguous stage II grade 2 follicular lymphoma
683028|NCT00006721|contiguous stage II grade 3 follicular lymphoma
683029|NCT00006721|noncontiguous stage II grade 1 follicular lymphoma
683030|NCT00006721|noncontiguous stage II grade 2 follicular lymphoma
683031|NCT00006721|noncontiguous stage II grade 3 follicular lymphoma
683032|NCT00006708|recurrent adult diffuse large cell lymphoma
683033|NCT00006708|recurrent adult Burkitt lymphoma
683034|NCT00006695|recurrent adult diffuse mixed cell lymphoma
683035|NCT00006695|recurrent adult diffuse large cell lymphoma
683036|NCT00006695|recurrent adult immunoblastic large cell lymphoma
683037|NCT00006682|stage IV breast cancer
683038|NCT00006682|recurrent breast cancer
683039|NCT00006669|recurrent grade 3 follicular lymphoma
683040|NCT00006669|recurrent adult diffuse small cleaved cell lymphoma
683041|NCT00006669|recurrent adult diffuse mixed cell lymphoma
683042|NCT00006669|recurrent adult diffuse large cell lymphoma
683043|NCT00006656|recurrent adult brain tumor
683044|NCT00006656|adult glioblastoma
683045|NCT00006656|adult giant cell glioblastoma
683046|NCT00006656|adult gliosarcoma
683047|NCT00006643|Liver
683048|NCT00006643|Hepatitis C
683049|NCT00006643|Biopsy
683050|NCT00006643|Tomography, Emission-Computed, Single-Photon
683051|NCT00006630|Smallpox Vaccine
683052|NCT00006630|Injections, Intramuscular
683053|NCT00006630|Immunoglobulins
683054|NCT00006630|Orthopoxvirus
683055|NCT00006617|HIV-1
683056|NCT00006617|Drug Therapy, Combination
683057|NCT00006617|Zidovudine
683058|NCT00006617|Lymphoid Tissue
683059|NCT00006617|Gastrointestinal System
683060|NCT00006617|HIV Protease Inhibitors
683061|NCT00006617|Lamivudine
683062|NCT00006617|Lymphocyte Subsets
683063|NCT00006617|VX 478
683064|NCT00006617|Reverse Transcriptase Inhibitors
683065|NCT00006617|Anti-HIV Agents
683066|NCT00006617|Viral Load
683067|NCT00006617|Cerebrospinal Fluid
683068|NCT00006617|abacavir
683069|NCT00006604|Dose-Response Relationship, Drug
683070|NCT00006604|Drug Therapy, Combination
683071|NCT00006604|Drug Administration Schedule
683072|NCT00006604|HIV Protease Inhibitors
683073|NCT00006604|Reverse Transcriptase Inhibitors
683074|NCT00006604|Anti-HIV Agents
683075|NCT00006604|Pharmacokinetics
683076|NCT00006604|Treatment Experienced
683077|NCT00006604|Treatment Naive
683078|NCT00006591|Drug Therapy, Combination
683079|NCT00006591|HIV Protease Inhibitors
683080|NCT00006591|Ritonavir
683081|NCT00006591|VX 478
683082|NCT00006591|Salvage Therapy
683083|NCT00006591|Anti-HIV Agents
683084|NCT00006591|Drug Monitoring
683085|NCT00006591|Nelfinavir
683086|NCT00006591|Treatment Experienced
683087|NCT00006578|Drug Therapy, Combination
683088|NCT00006578|Granulocyte Colony-Stimulating Factor
683089|NCT00006578|HIV Protease Inhibitors
683090|NCT00006578|Ritonavir
683091|NCT00006578|Lamivudine
683092|NCT00006578|Stem Cells
683093|NCT00006578|VX 478
683094|NCT00006578|Reverse Transcriptase Inhibitors
683095|NCT00006578|Anti-HIV Agents
683096|NCT00006578|Antigens, CD34
683097|NCT00006578|abacavir
683098|NCT00006578|Treatment Naive
683099|NCT00006565|asthma
683100|NCT00006565|HEPA
683101|NCT00006565|ETS
683102|NCT00006519|Pharmacokinetic
683103|NCT00006519|Pediatric AIDS
683104|NCT00006519|Resistance Testing
683105|NCT00006519|Combination Therapy
683106|NCT00006519|Viral Drug Dynamics
683107|NCT00006519|Treatment Experienced
683108|NCT00006518|Tumor
683109|NCT00006518|Viruses
683110|NCT00006518|HIV
683111|NCT00006518|KSHV
683112|NCT00006518|AIDS
683113|NCT00006517|Seasonal Affective Disorder (SAD)
683114|NCT00006517|Winter Depression
683115|NCT00006517|Mood disorders
683116|NCT00006517|Bipolar I and II disorders
683117|NCT00006517|Major Depressive Disorder, Recurrent
683118|NCT00006517|Light therapy
683119|NCT00006517|Phototherapy
683120|NCT00006517|Dawn Simulation therapy
683121|NCT00006517|Negative air ionization therapy
683122|NCT00006517|Chronobiology
683123|NCT00006517|Biological rhythms
683124|NCT00006516|Neonatal brain injury
683125|NCT00006516|Brain Hypoxia
683126|NCT00006516|Cerebral Hypoxia
683127|NCT00006516|Brain Hypoxia-Ischemia
683128|NCT00006516|Brain Ischemia-Hypoxia
683129|NCT00006516|Cerebral Hypoxia-Ischemia
683130|NCT00006516|Cerebral Ischemia-Hypoxia
683131|NCT00006516|Environmental enrichment
683132|NCT00006516|Cognitive/sensorimotor stimulation
683133|NCT00006516|Parent-infant interactions
683134|NCT00006516|Prenatal hypoxia
683135|NCT00006515|Pediatric
683136|NCT00006515|Sarcoma
683137|NCT00006515|Effects
683138|NCT00006515|Survivors
683139|NCT00006515|Pilot
683140|NCT00006509|Recombinant Proteins
683141|NCT00006509|HIV Envelope Protein gp160
683142|NCT00006509|AIDS Vaccines
683143|NCT00006509|Anti-HIV Agents
683144|NCT00006509|Treatment Experienced
683145|NCT00006509|HIV Therapeutic Vaccine
683146|NCT00006507|Sensory integration
683147|NCT00006507|Occupational therapy
683148|NCT00006507|Sensory Modulation Dysfunction (SMD)
683149|NCT00006506|Observational Studies
683150|NCT00006506|Clinical Trials
683151|NCT00006505|Islet Isolation
683152|NCT00006505|Diabetes
683153|NCT00006495|Placebos
683154|NCT00006495|T-Lymphocytes, Helper-Inducer
683155|NCT00006495|AIDS Vaccines
683156|NCT00006495|RNA, Viral
683157|NCT00006495|HIV Core Protein p24
683158|NCT00006495|T-Lymphocytes, Cytotoxic
683159|NCT00006495|Anti-HIV Agents
683160|NCT00006495|HIV Therapeutic Vaccine
683161|NCT00006494|AIDS
683162|NCT00006494|Antiretroviral Therapy
683163|NCT00006494|Drug Resistance
683164|NCT00006494|Phenotype
683165|NCT00006494|HIV
683166|NCT00006494|Genotype
683167|NCT00006494|Treatment Experienced
683168|NCT00006493|HIV-associated hyperlipidemia
683169|NCT00006492|Celiac Disease
683170|NCT00006492|Cerebellar Ataxia
683171|NCT00006492|Gluten-Free Diet
683172|NCT00006490|HIV-1
683173|NCT00006490|Drug Resistance, Microbial
683174|NCT00006490|Sequence Analysis, DNA
683175|NCT00006490|Microbial Sensitivity Tests
683176|NCT00006490|Genotype
683177|NCT00006490|Phenotype
683178|NCT00006490|Anti-HIV Agents
683179|NCT00006489|Alcoholism
683180|NCT00006489|Alcohol Dependence
683181|NCT00006489|Post-Traumatic Stress Disorder
683182|NCT00006489|Naltrexone
683183|NCT00006489|Cognitive Behavior Therapy
683184|NCT00006487|limited stage small cell lung cancer
683185|NCT00006485|unspecified adult solid tumor, protocol specific
683186|NCT00006484|recurrent non-small cell lung cancer
683187|NCT00006484|squamous cell lung cancer
683188|NCT00006484|large cell lung cancer
683189|NCT00006484|stage IIIB non-small cell lung cancer
683190|NCT00006484|stage IV non-small cell lung cancer
683191|NCT00006484|adenocarcinoma of the lung
683192|NCT00006483|stage IV renal cell cancer
683193|NCT00006483|recurrent renal cell cancer
683194|NCT00006483|lung metastases
683195|NCT00006482|recurrent cervical cancer
683196|NCT00006482|stage IVB cervical cancer
683197|NCT00006482|stage IVA cervical cancer
683198|NCT00006482|cervical squamous cell carcinoma
683199|NCT00006481|stage III squamous cell carcinoma of the lip and oral cavity
683200|NCT00006481|stage IV squamous cell carcinoma of the lip and oral cavity
683201|NCT00006481|stage III squamous cell carcinoma of the oropharynx
683202|NCT00006481|stage IV squamous cell carcinoma of the oropharynx
683203|NCT00006481|stage III squamous cell carcinoma of the hypopharynx
683204|NCT00006481|stage IV squamous cell carcinoma of the hypopharynx
683205|NCT00006481|stage III squamous cell carcinoma of the larynx
683206|NCT00006481|stage IV squamous cell carcinoma of the larynx
683207|NCT00006481|skin reactions secondary to radiation therapy
683208|NCT00006480|disseminated neuroblastoma
683209|NCT00006480|recurrent neuroblastoma
683210|NCT00006479|stage IV colon cancer
683211|NCT00006479|stage IV rectal cancer
683212|NCT00006479|recurrent colon cancer
683213|NCT00006479|recurrent rectal cancer
683214|NCT00006479|liver metastases
683215|NCT00006478|recurrent grade 1 follicular lymphoma
683216|NCT00006478|recurrent grade 2 follicular lymphoma
683217|NCT00006478|recurrent grade 3 follicular lymphoma
683218|NCT00006477|unspecified adult solid tumor, protocol specific
683219|NCT00006476|stage 0 bladder cancer
683220|NCT00006476|stage I bladder cancer
683221|NCT00006476|recurrent bladder cancer
683222|NCT00006475|relapsing chronic myelogenous leukemia
683223|NCT00006475|blastic phase chronic myelogenous leukemia
683224|NCT00006475|chronic myelogenous leukemia, BCR-ABL1 positive
683225|NCT00006475|Philadelphia chromosome negative chronic myelogenous leukemia
683226|NCT00006474|recurrent adult brain tumor
683227|NCT00006474|adult glioblastoma
683228|NCT00006474|adult anaplastic astrocytoma
683229|NCT00006474|adult anaplastic oligodendroglioma
683230|NCT00006474|adult mixed glioma
683231|NCT00006474|adult oligodendroglioma
683232|NCT00006474|adult giant cell glioblastoma
683233|NCT00006474|adult gliosarcoma
683234|NCT00006472|stage I esophageal cancer
683235|NCT00006472|stage II esophageal cancer
683236|NCT00006472|stage III esophageal cancer
683237|NCT00006472|squamous cell carcinoma of the esophagus
683238|NCT00006472|adenocarcinoma of the esophagus
683239|NCT00006471|untreated metastatic squamous neck cancer with occult primary
683240|NCT00006471|recurrent metastatic squamous neck cancer with occult primary
683241|NCT00006471|metastatic squamous neck cancer with occult primary squamous cell carcinoma
683242|NCT00006471|stage IV squamous cell carcinoma of the lip and oral cavity
683243|NCT00006471|recurrent squamous cell carcinoma of the lip and oral cavity
683244|NCT00006471|stage IV squamous cell carcinoma of the oropharynx
683245|NCT00006471|recurrent squamous cell carcinoma of the oropharynx
683246|NCT00006471|recurrent squamous cell carcinoma of the nasopharynx
683247|NCT00006471|stage IV squamous cell carcinoma of the hypopharynx
683248|NCT00006471|recurrent squamous cell carcinoma of the hypopharynx
683249|NCT00006471|stage IV squamous cell carcinoma of the larynx
683250|NCT00006471|recurrent squamous cell carcinoma of the larynx
683251|NCT00006471|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
683252|NCT00006471|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
683253|NCT00006471|stage IV squamous cell carcinoma of the nasopharynx
683254|NCT00006470|stage II non-small cell lung cancer
683255|NCT00006470|stage IIIA non-small cell lung cancer
683256|NCT00006469|stage II non-small cell lung cancer
683257|NCT00006469|stage IIIA non-small cell lung cancer
683258|NCT00006468|stage IV colon cancer
683259|NCT00006468|stage IV rectal cancer
683260|NCT00006468|recurrent colon cancer
683261|NCT00006468|recurrent rectal cancer
683262|NCT00006468|adenocarcinoma of the colon
683263|NCT00006468|adenocarcinoma of the rectum
683264|NCT00006467|stage III pancreatic cancer
683265|NCT00006467|recurrent pancreatic cancer
683266|NCT00006467|duct cell adenocarcinoma of the pancreas
683267|NCT00006467|adenocarcinoma of the pancreas
683268|NCT00006467|stage IV pancreatic cancer
683269|NCT00006466|monoclonal gammopathy of undetermined significance
683270|NCT00006466|isolated plasmacytoma of bone
683271|NCT00006466|extramedullary plasmacytoma
683272|NCT00006466|refractory multiple myeloma
683273|NCT00006466|stage I multiple myeloma
683274|NCT00006466|stage II multiple myeloma
683275|NCT00006466|stage III multiple myeloma
683276|NCT00006465|unspecified adult solid tumor, protocol specific
683277|NCT00006464|unspecified adult solid tumor, protocol specific
683278|NCT00006463|unspecified childhood solid tumor, protocol specific
683279|NCT00006462|recurrent childhood acute lymphoblastic leukemia
683280|NCT00006462|recurrent childhood acute myeloid leukemia
683281|NCT00006460|adult glioblastoma
683282|NCT00006460|adult giant cell glioblastoma
683283|NCT00006460|adult gliosarcoma
683284|NCT00006459|stage IV breast cancer
683285|NCT00006459|stage IIIA breast cancer
683286|NCT00006459|recurrent breast cancer
683287|NCT00006459|stage IIIB breast cancer
683288|NCT00006458|recurrent non-small cell lung cancer
683289|NCT00006458|squamous cell lung cancer
683290|NCT00006458|large cell lung cancer
683291|NCT00006458|adenocarcinoma of the lung
683292|NCT00006458|adenosquamous cell lung cancer
683293|NCT00006457|non-small cell lung cancer
683294|NCT00006457|small cell lung cancer
683295|NCT00006456|unspecified adult solid tumor, protocol specific
683296|NCT00006456|lung metastases
683297|NCT00006456|liver metastases
683298|NCT00006455|stage I childhood anaplastic large cell lymphoma
683299|NCT00006455|stage II childhood anaplastic large cell lymphoma
683300|NCT00006455|stage III childhood anaplastic large cell lymphoma
683301|NCT00006455|stage IV childhood anaplastic large cell lymphoma
683302|NCT00006455|recurrent childhood anaplastic large cell lymphoma
683303|NCT00006454|stage II ovarian epithelial cancer
683304|NCT00006454|stage III ovarian epithelial cancer
683305|NCT00006454|stage IV ovarian epithelial cancer
683306|NCT00006454|fallopian tube cancer
683307|NCT00006453|recurrent ovarian epithelial cancer
683308|NCT00006452|adult glioblastoma
683309|NCT00006452|adult giant cell glioblastoma
683310|NCT00006452|adult gliosarcoma
683311|NCT00006451|recurrent childhood acute lymphoblastic leukemia
683561|NCT00006393|rare disease
683312|NCT00006451|stage IV childhood lymphoblastic lymphoma
683313|NCT00006451|recurrent childhood acute myeloid leukemia
683314|NCT00006451|recurrent adult acute myeloid leukemia
683315|NCT00006451|recurrent adult acute lymphoblastic leukemia
683316|NCT00006451|chronic phase chronic myelogenous leukemia
683317|NCT00006451|accelerated phase chronic myelogenous leukemia
683318|NCT00006451|adult acute lymphoblastic leukemia in remission
683319|NCT00006451|childhood acute lymphoblastic leukemia in remission
683320|NCT00006451|acute undifferentiated leukemia
683321|NCT00006451|stage IV adult lymphoblastic lymphoma
683322|NCT00006451|graft versus host disease
683323|NCT00006450|Children
683324|NCT00006450|Brain
683325|NCT00006450|Maturation
683326|NCT00006450|Phenylacetate
683327|NCT00006450|Differentiation
683328|NCT00006448|Spinal cord injury
683329|NCT00006448|Amputation
683330|NCT00006448|Pain management
683331|NCT00006447|Brain Injuries
683332|NCT00006447|Trauma
683333|NCT00006447|Caregivers
683334|NCT00006447|Burden and Dependency
683335|NCT00006447|Rehabilitation
683336|NCT00006447|Support, social
683337|NCT00006447|Information System
683338|NCT00006447|Information Resources (PT)
683339|NCT00006447|Disability, persons with
683340|NCT00006446|Behavioral disorders
683341|NCT00006446|Parenting skills and communication
683342|NCT00006446|Parent-child interactions
683343|NCT00006446|At-risk preschooler
683344|NCT00006446|Head Start
683345|NCT00006445|Pregnancy
683346|NCT00006445|Ultrasound
683347|NCT00006445|Serum screen
683348|NCT00006445|Pregnancy associated plasma protein-A (PAPP-A)
683349|NCT00006445|Free-beta human chorionic gonadotropin (FbhCG)
683350|NCT00006445|Alpha fetoprotein
683351|NCT00006445|Unconjugated estriol
683352|NCT00006445|Inhibin-A
683353|NCT00006445|Down syndrome
683354|NCT00006445|Aneuploidy
683355|NCT00006444|Drug Therapy, Combination
683356|NCT00006444|Papillomavirus, Human
683357|NCT00006444|DNA, Viral
683358|NCT00006444|Anti-HIV Agent
683359|NCT00006444|Treatment Naive
683360|NCT00006443|T-Lymphocytes
683361|NCT00006443|HIV-1
683362|NCT00006443|Lymphoid Tissue
683363|NCT00006443|Stavudine
683364|NCT00006443|HIV Protease Inhibitors
683365|NCT00006443|Polymerase Chain Reaction
683366|NCT00006443|Biological Markers
683367|NCT00006443|Lamivudine
683368|NCT00006443|Indinavir
683369|NCT00006443|RNA, Viral
683370|NCT00006443|Genotype
683371|NCT00006443|Phenotype
683372|NCT00006443|Cytokines
683373|NCT00006443|Nelfinavir
683374|NCT00006443|Macrophages
683375|NCT00006443|Reverse Transcriptase Inhibitors
683376|NCT00006443|In Situ Hybridization
683377|NCT00006443|Anti-HIV Agents
683378|NCT00006443|Viral Load
683379|NCT00006443|Cell Membrane
683380|NCT00006443|Acute Infection
683381|NCT00006443|Treatment Naive
683382|NCT00006442|Lymphocytes
683383|NCT00006442|HIV-1
683384|NCT00006442|Lymphoid Tissue
683385|NCT00006442|Blood
683386|NCT00006442|Anti-HIV Agents
683387|NCT00006442|Viral Load
683388|NCT00006441|Virus Replication
683389|NCT00006441|HIV-1
683390|NCT00006441|Interleukin-2
683391|NCT00006441|Drug Therapy, Combination
683392|NCT00006441|Zidovudine
683393|NCT00006441|HIV Protease Inhibitors
683394|NCT00006441|CD4-Positive T-Lymphocytes
683395|NCT00006441|CD8-Positive T-Lymphocytes
683396|NCT00006441|Biological Markers
683397|NCT00006441|Lamivudine
683398|NCT00006441|Reverse Transcriptase Inhibitors
683399|NCT00006441|Anti-HIV Agents
683400|NCT00006441|Nelfinavir
683401|NCT00006441|Cytotoxicity, Immunologic
683402|NCT00006441|Acute Infection
683403|NCT00006440|Risk Factors
683404|NCT00006440|Behavior Therapy
683405|NCT00006440|Substance-Related Disorders
683406|NCT00006440|Feasibility Studies
683407|NCT00006439|HIV
683408|NCT00006438|Rocker sole
683409|NCT00006438|Plantar pressure
683410|NCT00006438|Diabetic feet
683411|NCT00006438|Insensate feet
683412|NCT00006438|gait analysis
683413|NCT00006438|Pedorthics
683414|NCT00006438|Gait abnormalities
683415|NCT00006437|MMP
683416|NCT00006437|Proteases
683417|NCT00006437|Adhesion
683418|NCT00006437|Migration
683419|NCT00006437|Extracellular Matrix
683420|NCT00006436|AIDS
683421|NCT00006436|Malignancy
683422|NCT00006436|Antiretroviral
683423|NCT00006436|Chemotherapy
683424|NCT00006436|Monoclonal
683425|NCT00006435|Tissue Repository
683426|NCT00006435|Growth Rate
683427|NCT00006435|Volumetric MRI
683428|NCT00006434|Dendritic cells
683429|NCT00006429|Spinal Cord Injury
683430|NCT00006429|Body Weight Supported Ambulation Training
683431|NCT00006429|Treadmill Training
683432|NCT00006429|Physical therapy
683433|NCT00006429|Gait
683434|NCT00006429|Assisted Ambulation
683435|NCT00006428|Spinal Cord injury (SCI)
683436|NCT00006428|Chronic Pain
683437|NCT00006428|Amitriptyline
683438|NCT00006427|Amputation
683439|NCT00006427|Chronic Pain
683440|NCT00006427|Amitriptyline
683441|NCT00006426|Foot ulcers
683442|NCT00006426|Diabetes
683443|NCT00006426|Peripheral neuropathy
683444|NCT00006426|Casting
683445|NCT00006426|Achilles Lengthening
683446|NCT00006426|Ambulatory surgery
683447|NCT00006426|Foot deformity
683448|NCT00006425|Breast MRI
683449|NCT00006425|Ductal lavage
683450|NCT00006425|Nipple Aspirate Fluid
683451|NCT00006425|Transvaginal ultrasound
683452|NCT00006425|Healthy Volunteer
683453|NCT00006424|Plasticity
683454|NCT00006424|Motor
683455|NCT00006424|Stroke
683456|NCT00006424|Amphetamine
683457|NCT00006424|fMRI
683458|NCT00006424|Cortical Reorganization
683459|NCT00006424|Spectroscopy
683460|NCT00006422|Lazy Eye
683461|NCT00006422|Amblyopia
683462|NCT00006422|Nystagmus
683463|NCT00006422|Eye Movements
683464|NCT00006422|Child Vision
683465|NCT00006421|Breast MRI
683466|NCT00006421|Nipple Aspirate Fluid
683467|NCT00006421|Transvaginal ultrasound
683468|NCT00006421|Ductal lavage
683469|NCT00006418|Schizophrenia
683470|NCT00006418|Genetics
683471|NCT00006417|Fludarabine
683472|NCT00006417|Non-Myeloablative BMT
683473|NCT00006417|Immunodeficiency
683474|NCT00006417|Neutrophils
683475|NCT00006417|Oxidase
683476|NCT00006417|Engraftment
683477|NCT00006417|Graft-versus-host Disease
683478|NCT00006417|Cyclophosphamide
683479|NCT00006417|Donor Apheresis
683480|NCT00006417|Peripheral Blood Stem Cells
683481|NCT00006417|Therapy
683482|NCT00006415|Virus Replication
683483|NCT00006415|HIV-1
683484|NCT00006415|Polymerase Chain Reaction
683485|NCT00006415|DNA, Viral
683486|NCT00006415|RNA, Viral
683487|NCT00006415|Sensitivity and Specificity
683488|NCT00006415|Anti-HIV Agents
683489|NCT00006415|Viral Load
683490|NCT00006415|Proviruses
683491|NCT00006415|Acute Infection
683492|NCT00006414|Anesthesia
683493|NCT00006414|Magnetic Stimulation
683494|NCT00006414|Motor
683495|NCT00006414|Neuroplasticity
683496|NCT00006414|Practice
683497|NCT00006414|Rehabilitation
683498|NCT00006414|Stroke
683499|NCT00006413|Peripheral Blood Stem Cells
683500|NCT00006413|Non-Myeloablative Bone Marrow Transplantation
683501|NCT00006413|Engraftment
683502|NCT00006413|Graft-versus-host Disease
683503|NCT00006413|Graft-Versus-Leukemia
683504|NCT00006413|Graft-Versus-Mast Cell
683505|NCT00006413|Cyclophosphamide
683506|NCT00006413|Fludarabine
683507|NCT00006413|Donor Apheresis
683508|NCT00006413|Mast Cells
683509|NCT00006412|Hyperlipidemia
683510|NCT00006412|Procetofen
683511|NCT00006412|Pravastatin
683512|NCT00006412|Antilipemic Agents
683513|NCT00006411|cornea transplant
683514|NCT00006411|corneal endothelial cell density
683515|NCT00006411|moderate risk corneal diseases requiring corneal transplantation
683516|NCT00006411|corneal transplantation
683517|NCT00006400|Blood Diseases
683518|NCT00006400|Sickle Cell Anemia
683519|NCT00006399|Alzheimer disease
683520|NCT00006399|Estrogen therapy
683521|NCT00006399|Post-menopausal women
683522|NCT00006398|cirrhosis
683523|NCT00006398|esophageal varices
683524|NCT00006398|variceal hemorrhage
683525|NCT00006398|beta-adrenergic blocker
683526|NCT00006397|Didanosine
683527|NCT00006397|Drug Therapy, Combination
683528|NCT00006397|Stavudine
683529|NCT00006397|HIV Protease Inhibitors
683530|NCT00006397|Sex Factors
683531|NCT00006397|Ritonavir
683532|NCT00006397|Indinavir
683533|NCT00006397|Dosage Forms
683534|NCT00006397|Reverse Transcriptase Inhibitors
683535|NCT00006397|Anti-HIV Agents
683536|NCT00006396|Pregnancy Complications, Infectious
683537|NCT00006396|HIV-1
683538|NCT00006396|Administration, Oral
683539|NCT00006396|Zidovudine
683540|NCT00006396|Nevirapine
683541|NCT00006396|RNA, Viral
683542|NCT00006396|Disease Transmission, Vertical
683543|NCT00006396|Enzyme-Linked Immunosorbent Assay
683544|NCT00006396|Blotting, Western
683545|NCT00006396|Reverse Transcriptase Inhibitors
683546|NCT00006396|Anti-HIV Agents
683547|NCT00006396|Viral Load
683548|NCT00006396|HIV Seronegativity
683549|NCT00006395|Antiepileptic
683550|NCT00006395|CYP3A4
683551|NCT00006395|Herbal
683552|NCT00006395|Induction
683553|NCT00006395|Interaction
683554|NCT00006394|disease-related problem/condition
683555|NCT00006394|endocrine disorders
683556|NCT00006394|growth hormone deficiency
683557|NCT00006394|osteoporosis
683558|NCT00006394|quality of life
683559|NCT00006394|rare disease
683560|NCT00006393|arthritis & connective tissue diseases
683562|NCT00006393|systemic sclerosis
683563|NCT00006392|prostate cancer
683564|NCT00006391|recurrent ovarian epithelial cancer
683565|NCT00006391|fallopian tube cancer
683566|NCT00006391|peritoneal cavity cancer
683567|NCT00006390|stage III chronic lymphocytic leukemia
683568|NCT00006390|stage IV chronic lymphocytic leukemia
683569|NCT00006390|B-cell chronic lymphocytic leukemia
683570|NCT00006390|stage I chronic lymphocytic leukemia
683571|NCT00006390|stage II chronic lymphocytic leukemia
683572|NCT00006388|adult glioblastoma
683573|NCT00006388|adult giant cell glioblastoma
683574|NCT00006388|adult gliosarcoma
683575|NCT00006387|stage IV colon cancer
683576|NCT00006387|recurrent pancreatic cancer
683577|NCT00006387|stage IV rectal cancer
683578|NCT00006387|recurrent colon cancer
683579|NCT00006387|recurrent rectal cancer
683580|NCT00006387|adenocarcinoma of the colon
683581|NCT00006387|adenocarcinoma of the rectum
683582|NCT00006387|adenocarcinoma of the pancreas
683583|NCT00006387|stage IV pancreatic cancer
683584|NCT00006386|adult glioblastoma
683585|NCT00006386|adult giant cell glioblastoma
683586|NCT00006386|adult gliosarcoma
683587|NCT00006385|stage IV melanoma
683588|NCT00006385|recurrent melanoma
683589|NCT00006384|stage IV renal cell cancer
683590|NCT00006384|recurrent renal cell cancer
683591|NCT00006383|recurrent adult diffuse large cell lymphoma
683592|NCT00006383|recurrent adult immunoblastic large cell lymphoma
683593|NCT00006383|recurrent adult T-cell leukemia/lymphoma
683594|NCT00006383|anaplastic large cell lymphoma
683595|NCT00006382|non-small cell lung cancer
683596|NCT00006382|small cell lung cancer
683597|NCT00006381|stage IV breast cancer
683598|NCT00006381|recurrent breast cancer
683599|NCT00006380|stage III prostate cancer
683600|NCT00006380|stage IV prostate cancer
683601|NCT00006380|recurrent prostate cancer
683602|NCT00006379|monoclonal gammopathy of undetermined significance
683603|NCT00006379|recurrent childhood acute lymphoblastic leukemia
683604|NCT00006379|recurrent adult Hodgkin lymphoma
683605|NCT00006379|recurrent cutaneous T-cell non-Hodgkin lymphoma
683606|NCT00006379|isolated plasmacytoma of bone
683607|NCT00006379|extramedullary plasmacytoma
683608|NCT00006379|refractory multiple myeloma
683609|NCT00006379|Waldenstrom macroglobulinemia
683610|NCT00006379|recurrent childhood lymphoblastic lymphoma
683611|NCT00006379|recurrent childhood acute myeloid leukemia
683612|NCT00006379|recurrent adult acute myeloid leukemia
683613|NCT00006379|recurrent adult acute lymphoblastic leukemia
683614|NCT00006379|relapsing chronic myelogenous leukemia
683615|NCT00006379|small intestine lymphoma
683616|NCT00006379|chronic phase chronic myelogenous leukemia
683617|NCT00006379|accelerated phase chronic myelogenous leukemia
683618|NCT00006379|blastic phase chronic myelogenous leukemia
683619|NCT00006379|adult acute myeloid leukemia in remission
683620|NCT00006379|adult acute lymphoblastic leukemia in remission
683621|NCT00006379|childhood acute myeloid leukemia in remission
683622|NCT00006379|childhood acute lymphoblastic leukemia in remission
683623|NCT00006379|polycythemia vera
683624|NCT00006379|chronic idiopathic myelofibrosis
683625|NCT00006379|essential thrombocythemia
683626|NCT00006379|adult acute erythroid leukemia (M6)
683627|NCT00006379|adult acute megakaryoblastic leukemia (M7)
683628|NCT00006379|childhood acute erythroleukemia (M6)
683629|NCT00006379|childhood acute megakaryocytic leukemia (M7)
683630|NCT00006379|recurrent/refractory childhood Hodgkin lymphoma
683631|NCT00006379|refractory anemia with excess blasts
683632|NCT00006379|refractory anemia with excess blasts in transformation
683633|NCT00006379|chronic myelomonocytic leukemia
683634|NCT00006379|acute undifferentiated leukemia
683635|NCT00006379|recurrent grade 1 follicular lymphoma
683636|NCT00006379|recurrent grade 2 follicular lymphoma
683637|NCT00006379|recurrent grade 3 follicular lymphoma
683638|NCT00006379|recurrent adult diffuse small cleaved cell lymphoma
683639|NCT00006379|recurrent adult diffuse mixed cell lymphoma
683640|NCT00006379|recurrent adult diffuse large cell lymphoma
683641|NCT00006379|recurrent adult immunoblastic large cell lymphoma
683642|NCT00006379|recurrent adult lymphoblastic lymphoma
683643|NCT00006379|recurrent adult Burkitt lymphoma
683644|NCT00006379|recurrent adult T-cell leukemia/lymphoma
683645|NCT00006379|secondary acute myeloid leukemia
683646|NCT00006379|de novo myelodysplastic syndromes
683647|NCT00006379|previously treated myelodysplastic syndromes
683648|NCT00006379|secondary myelodysplastic syndromes
683649|NCT00006379|prolymphocytic leukemia
683650|NCT00006379|primary systemic amyloidosis
683651|NCT00006379|adult acute minimally differentiated myeloid leukemia (M0)
683652|NCT00006379|childhood acute minimally differentiated myeloid leukemia (M0)
683653|NCT00006379|recurrent childhood small noncleaved cell lymphoma
683654|NCT00006379|recurrent childhood large cell lymphoma
683655|NCT00006379|recurrent mantle cell lymphoma
683656|NCT00006379|angioimmunoblastic T-cell lymphoma
683657|NCT00006379|anaplastic large cell lymphoma
683658|NCT00006379|recurrent mycosis fungoides/Sezary syndrome
683659|NCT00006379|childhood chronic myelogenous leukemia
683660|NCT00006379|chronic eosinophilic leukemia
683661|NCT00006379|chronic neutrophilic leukemia
683662|NCT00006379|atypical chronic myeloid leukemia
683663|NCT00006379|myelodysplastic/myeloproliferative disease, unclassifiable
683664|NCT00006379|juvenile myelomonocytic leukemia
683665|NCT00006379|recurrent marginal zone lymphoma
683666|NCT00006379|recurrent small lymphocytic lymphoma
683667|NCT00006379|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
683668|NCT00006379|nodal marginal zone B-cell lymphoma
683669|NCT00006379|splenic marginal zone lymphoma
683670|NCT00006379|adult acute myeloid leukemia with t(8;21)(q22;q22)
683671|NCT00006379|adult acute myeloid leukemia with t(16;16)(p13;q22)
683672|NCT00006379|adult acute myeloid leukemia with inv(16)(p13;q22)
683673|NCT00006379|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
683674|NCT00006379|adult acute myeloid leukemia with t(15;17)(q22;q12)
683675|NCT00006379|childhood myelodysplastic syndromes
683676|NCT00006378|squamous cell lung cancer
683677|NCT00006378|large cell lung cancer
683678|NCT00006378|stage IIIA non-small cell lung cancer
683679|NCT00006378|stage IIIB non-small cell lung cancer
683680|NCT00006378|adenocarcinoma of the lung
683681|NCT00006378|adenosquamous cell lung cancer
683682|NCT00006378|bronchoalveolar cell lung cancer
683683|NCT00006377|stage III endometrial carcinoma
683684|NCT00006377|stage IV endometrial carcinoma
683685|NCT00006377|recurrent endometrial carcinoma
683686|NCT00006376|stage II bladder cancer
683687|NCT00006376|stage III bladder cancer
683688|NCT00006376|recurrent bladder cancer
683689|NCT00006376|stage IV bladder cancer
683690|NCT00006376|transitional cell carcinoma of the bladder
683691|NCT00006376|metastatic transitional cell cancer of the renal pelvis and ureter
683692|NCT00006376|regional transitional cell cancer of the renal pelvis and ureter
683693|NCT00006376|recurrent transitional cell cancer of the renal pelvis and ureter
683694|NCT00006375|unspecified adult solid tumor, protocol specific
683695|NCT00006374|extensive stage small cell lung cancer
683696|NCT00006374|recurrent small cell lung cancer
683697|NCT00006373|stage III adult Hodgkin lymphoma
683698|NCT00006373|stage IV adult Hodgkin lymphoma
683699|NCT00006373|recurrent adult Hodgkin lymphoma
683700|NCT00006373|recurrent grade 1 follicular lymphoma
683701|NCT00006373|recurrent grade 2 follicular lymphoma
683702|NCT00006373|recurrent grade 3 follicular lymphoma
683703|NCT00006373|recurrent adult diffuse small cleaved cell lymphoma
683704|NCT00006373|recurrent adult diffuse mixed cell lymphoma
683705|NCT00006373|recurrent adult diffuse large cell lymphoma
683706|NCT00006373|recurrent adult immunoblastic large cell lymphoma
683707|NCT00006373|recurrent adult Burkitt lymphoma
683708|NCT00006373|recurrent mantle cell lymphoma
683709|NCT00006373|recurrent marginal zone lymphoma
683710|NCT00006373|recurrent small lymphocytic lymphoma
683711|NCT00006373|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
683712|NCT00006373|nodal marginal zone B-cell lymphoma
683713|NCT00006373|splenic marginal zone lymphoma
683714|NCT00006372|unspecified adult solid tumor, protocol specific
683715|NCT00006371|adenocarcinoma of the prostate
683716|NCT00006371|stage IV prostate cancer
683717|NCT00006371|recurrent prostate cancer
683718|NCT00006370|stage IV breast cancer
683719|NCT00006370|recurrent breast cancer
683720|NCT00006370|recurrent small cell lung cancer
683721|NCT00006370|male breast cancer
683722|NCT00006369|stage IV breast cancer
683723|NCT00006369|recurrent breast cancer
683724|NCT00006368|stage IV adult Hodgkin lymphoma
683725|NCT00006368|stage IV breast cancer
683726|NCT00006368|recurrent breast cancer
683727|NCT00006368|recurrent non-small cell lung cancer
683728|NCT00006368|recurrent adult Hodgkin lymphoma
683729|NCT00006368|extensive stage small cell lung cancer
683730|NCT00006368|recurrent small cell lung cancer
683731|NCT00006368|metastatic gastrointestinal carcinoid tumor
683732|NCT00006368|recurrent gastrointestinal carcinoid tumor
683733|NCT00006368|gastrinoma
683734|NCT00006368|recurrent adult brain tumor
683735|NCT00006368|insulinoma
683736|NCT00006368|recurrent islet cell carcinoma
683737|NCT00006368|ACTH-producing pituitary tumor
683738|NCT00006368|prolactin-producing pituitary tumor
683739|NCT00006368|growth hormone-producing pituitary tumor
683740|NCT00006368|recurrent pituitary tumor
683741|NCT00006368|TSH producing pituitary tumor
683742|NCT00006368|nonfunctioning pituitary tumor
683743|NCT00006368|adult brain stem glioma
683744|NCT00006368|adult craniopharyngioma
683745|NCT00006368|adult medulloblastoma
683746|NCT00006368|adult meningioma
683747|NCT00006368|adult glioblastoma
683748|NCT00006368|stage IV melanoma
683749|NCT00006368|recurrent melanoma
683750|NCT00006368|stage IV non-small cell lung cancer
683751|NCT00006368|WDHA syndrome
683752|NCT00006368|somatostatinoma
683753|NCT00006368|pancreatic polypeptide tumor
683754|NCT00006368|glucagonoma
683755|NCT00006368|pulmonary carcinoid tumor
683756|NCT00006368|stage IV grade 1 follicular lymphoma
683757|NCT00006368|stage IV grade 2 follicular lymphoma
683758|NCT00006368|stage IV grade 3 follicular lymphoma
683759|NCT00006368|stage IV adult diffuse small cleaved cell lymphoma
683760|NCT00006368|stage IV adult diffuse mixed cell lymphoma
683761|NCT00006368|stage IV adult diffuse large cell lymphoma
683762|NCT00006368|stage IV adult immunoblastic large cell lymphoma
683763|NCT00006368|stage IV adult lymphoblastic lymphoma
683764|NCT00006368|stage IV adult Burkitt lymphoma
683765|NCT00006368|recurrent grade 1 follicular lymphoma
683766|NCT00006368|recurrent grade 2 follicular lymphoma
683767|NCT00006368|recurrent grade 3 follicular lymphoma
683768|NCT00006368|recurrent adult diffuse small cleaved cell lymphoma
683769|NCT00006368|recurrent adult diffuse mixed cell lymphoma
683770|NCT00006368|recurrent adult diffuse large cell lymphoma
683771|NCT00006368|recurrent adult immunoblastic large cell lymphoma
683772|NCT00006368|recurrent adult lymphoblastic lymphoma
683773|NCT00006368|recurrent adult Burkitt lymphoma
683774|NCT00006368|adult anaplastic astrocytoma
683775|NCT00006368|adult myxopapillary ependymoma
683776|NCT00006368|adult anaplastic ependymoma
683777|NCT00006368|adult anaplastic oligodendroglioma
683778|NCT00006368|adult central nervous system germ cell tumor
683779|NCT00006368|adult pilocytic astrocytoma
683780|NCT00006368|adult subependymoma
683781|NCT00006368|adult ependymoblastoma
683782|NCT00006368|adult pineocytoma
683783|NCT00006368|adult pineoblastoma
683784|NCT00006368|adult meningeal hemangiopericytoma
683785|NCT00006368|stage IV mantle cell lymphoma
683786|NCT00006368|recurrent mantle cell lymphoma
683787|NCT00006368|adult choroid plexus tumor
683788|NCT00006368|recurrent marginal zone lymphoma
683789|NCT00006368|recurrent small lymphocytic lymphoma
683790|NCT00006368|stage IV small lymphocytic lymphoma
683791|NCT00006368|stage IV marginal zone lymphoma
683792|NCT00006368|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
683793|NCT00006368|nodal marginal zone B-cell lymphoma
683794|NCT00006368|splenic marginal zone lymphoma
683795|NCT00006368|adult grade III meningioma
683796|NCT00006368|adult giant cell glioblastoma
683797|NCT00006368|adult gliosarcoma
683798|NCT00006367|polycythemia vera
683799|NCT00006367|chronic idiopathic myelofibrosis
683800|NCT00006367|essential thrombocythemia
683801|NCT00006366|stage II rectal cancer
683802|NCT00006366|stage III rectal cancer
683803|NCT00006366|adenocarcinoma of the rectum
683804|NCT00006365|adenocarcinoma of the prostate
683805|NCT00006365|stage I prostate cancer
683806|NCT00006365|stage IIB prostate cancer
683807|NCT00006365|stage IIA prostate cancer
683808|NCT00006362|monoclonal gammopathy of undetermined significance
683809|NCT00006362|isolated plasmacytoma of bone
683810|NCT00006362|extramedullary plasmacytoma
683811|NCT00006362|refractory multiple myeloma
683812|NCT00006362|Waldenstrom macroglobulinemia
683813|NCT00006362|stage III multiple myeloma
683814|NCT00006362|stage IV chronic lymphocytic leukemia
683815|NCT00006362|refractory chronic lymphocytic leukemia
683816|NCT00006362|unspecified adult solid tumor, protocol specific
683817|NCT00006362|B-cell chronic lymphocytic leukemia
683818|NCT00006362|untreated hairy cell leukemia
683819|NCT00006362|progressive hairy cell leukemia, initial treatment
683820|NCT00006362|refractory hairy cell leukemia
683821|NCT00006362|stage IV grade 1 follicular lymphoma
683822|NCT00006362|stage IV grade 2 follicular lymphoma
683823|NCT00006362|stage IV grade 3 follicular lymphoma
683824|NCT00006362|stage IV adult diffuse small cleaved cell lymphoma
683825|NCT00006362|stage IV adult diffuse mixed cell lymphoma
683826|NCT00006362|stage IV adult diffuse large cell lymphoma
683827|NCT00006362|stage IV adult immunoblastic large cell lymphoma
683828|NCT00006362|stage IV adult lymphoblastic lymphoma
683829|NCT00006362|stage IV adult Burkitt lymphoma
683830|NCT00006362|recurrent grade 1 follicular lymphoma
683831|NCT00006362|recurrent grade 2 follicular lymphoma
683832|NCT00006362|recurrent grade 3 follicular lymphoma
683833|NCT00006362|recurrent adult diffuse small cleaved cell lymphoma
683834|NCT00006362|recurrent adult diffuse mixed cell lymphoma
683835|NCT00006362|recurrent adult diffuse large cell lymphoma
683836|NCT00006362|recurrent adult immunoblastic large cell lymphoma
683837|NCT00006362|recurrent adult lymphoblastic lymphoma
683838|NCT00006362|recurrent adult Burkitt lymphoma
683839|NCT00006362|primary systemic amyloidosis
683840|NCT00006362|stage IV mantle cell lymphoma
683841|NCT00006362|recurrent mantle cell lymphoma
683842|NCT00006362|recurrent marginal zone lymphoma
683843|NCT00006362|recurrent small lymphocytic lymphoma
683844|NCT00006362|stage IV small lymphocytic lymphoma
683845|NCT00006362|stage IV marginal zone lymphoma
683846|NCT00006362|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
683847|NCT00006362|nodal marginal zone B-cell lymphoma
683848|NCT00006362|splenic marginal zone lymphoma
683849|NCT00006361|squamous cell carcinoma of the skin
683850|NCT00006361|recurrent skin cancer
683851|NCT00006361|stage IV nasopharyngeal cancer
683852|NCT00006361|recurrent metastatic squamous neck cancer with occult primary
683853|NCT00006361|metastatic squamous neck cancer with occult primary squamous cell carcinoma
683854|NCT00006361|squamous cell carcinoma of unknown primary
683855|NCT00006361|stage IV squamous cell carcinoma of the lip and oral cavity
683953|NCT00006350|recurrent grade 2 follicular lymphoma
683856|NCT00006361|recurrent squamous cell carcinoma of the lip and oral cavity
683857|NCT00006361|stage IV squamous cell carcinoma of the oropharynx
683858|NCT00006361|recurrent squamous cell carcinoma of the oropharynx
683859|NCT00006361|stage IV squamous cell carcinoma of the nasopharynx
683860|NCT00006361|recurrent squamous cell carcinoma of the nasopharynx
683861|NCT00006361|stage IV squamous cell carcinoma of the hypopharynx
683862|NCT00006361|recurrent squamous cell carcinoma of the hypopharynx
683863|NCT00006361|stage IV squamous cell carcinoma of the larynx
683864|NCT00006361|recurrent squamous cell carcinoma of the larynx
683865|NCT00006361|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
683866|NCT00006361|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
683867|NCT00006361|recurrent carcinoma of unknown primary
683868|NCT00006360|stage II squamous cell carcinoma of the oropharynx
683869|NCT00006360|stage III squamous cell carcinoma of the oropharynx
683870|NCT00006360|radiation toxicity
683871|NCT00006359|adenocarcinoma of the prostate
683872|NCT00006359|stage I prostate cancer
683873|NCT00006359|stage II prostate cancer
683874|NCT00006359|stage III prostate cancer
683875|NCT00006358|recurrent adult brain tumor
683876|NCT00006358|adult glioblastoma
683877|NCT00006358|adult giant cell glioblastoma
683878|NCT00006358|adult gliosarcoma
683879|NCT00006357|adult angiosarcoma
683880|NCT00006357|adult fibrosarcoma
683881|NCT00006357|adult leiomyosarcoma
683882|NCT00006357|adult liposarcoma
683883|NCT00006357|adult neurofibrosarcoma
683884|NCT00006357|adult synovial sarcoma
683885|NCT00006357|recurrent adult soft tissue sarcoma
683886|NCT00006357|small intestine leiomyosarcoma
683887|NCT00006357|adult alveolar soft-part sarcoma
683888|NCT00006357|adult epithelioid sarcoma
683889|NCT00006357|adult malignant fibrous histiocytoma
683890|NCT00006357|adult malignant hemangiopericytoma
683891|NCT00006357|adult malignant mesenchymoma
683892|NCT00006357|adult rhabdomyosarcoma
683893|NCT00006357|ovarian stromal cancer
683894|NCT00006357|recurrent uterine sarcoma
683895|NCT00006357|uterine carcinosarcoma
683896|NCT00006357|uterine leiomyosarcoma
683897|NCT00006357|endometrial stromal sarcoma
683898|NCT00006357|ovarian sarcoma
683899|NCT00006357|gastrointestinal stromal tumor
683900|NCT00006356|recurrent ovarian epithelial cancer
683901|NCT00006355|adult glioblastoma
683902|NCT00006355|adult giant cell glioblastoma
683903|NCT00006355|adult gliosarcoma
683904|NCT00006354|unspecified adult solid tumor, protocol specific
683905|NCT00006353|adult glioblastoma
683906|NCT00006353|adult giant cell glioblastoma
683907|NCT00006353|adult gliosarcoma
683908|NCT00006352|limited stage small cell lung cancer
683909|NCT00006351|recurrent bladder cancer
683910|NCT00006351|stage IV bladder cancer
683911|NCT00006351|transitional cell carcinoma of the bladder
683912|NCT00006351|recurrent urethral cancer
683913|NCT00006351|anterior urethral cancer
683914|NCT00006351|posterior urethral cancer
683915|NCT00006351|urethral cancer associated with invasive bladder cancer
683916|NCT00006351|metastatic transitional cell cancer of the renal pelvis and ureter
683917|NCT00006351|recurrent transitional cell cancer of the renal pelvis and ureter
683918|NCT00006350|recurrent adult Hodgkin lymphoma
683919|NCT00006350|refractory multiple myeloma
683920|NCT00006350|stage I multiple myeloma
683921|NCT00006350|stage II multiple myeloma
683922|NCT00006350|stage III multiple myeloma
683923|NCT00006350|stage III chronic lymphocytic leukemia
683924|NCT00006350|stage IV chronic lymphocytic leukemia
683925|NCT00006350|recurrent adult acute myeloid leukemia
683926|NCT00006350|recurrent adult acute lymphoblastic leukemia
683927|NCT00006350|relapsing chronic myelogenous leukemia
683928|NCT00006350|refractory chronic lymphocytic leukemia
683929|NCT00006350|chronic phase chronic myelogenous leukemia
683930|NCT00006350|accelerated phase chronic myelogenous leukemia
683931|NCT00006350|blastic phase chronic myelogenous leukemia
683932|NCT00006350|meningeal chronic myelogenous leukemia
683933|NCT00006350|adult acute myeloid leukemia in remission
683934|NCT00006350|adult acute lymphoblastic leukemia in remission
683935|NCT00006350|stage III grade 1 follicular lymphoma
683936|NCT00006350|stage III grade 2 follicular lymphoma
683937|NCT00006350|stage III grade 3 follicular lymphoma
683938|NCT00006350|stage III adult diffuse small cleaved cell lymphoma
683939|NCT00006350|stage III adult diffuse mixed cell lymphoma
683940|NCT00006350|stage III adult diffuse large cell lymphoma
683941|NCT00006350|stage III adult immunoblastic large cell lymphoma
683942|NCT00006350|stage III adult lymphoblastic lymphoma
683943|NCT00006350|stage III adult Burkitt lymphoma
683944|NCT00006350|stage IV grade 1 follicular lymphoma
683945|NCT00006350|stage IV grade 2 follicular lymphoma
683946|NCT00006350|stage IV grade 3 follicular lymphoma
683947|NCT00006350|stage IV adult diffuse small cleaved cell lymphoma
683948|NCT00006350|stage IV adult diffuse mixed cell lymphoma
683949|NCT00006350|stage IV adult diffuse large cell lymphoma
683950|NCT00006350|stage IV adult lymphoblastic lymphoma
683951|NCT00006350|stage IV adult Burkitt lymphoma
683952|NCT00006350|recurrent grade 1 follicular lymphoma
683954|NCT00006350|recurrent grade 3 follicular lymphoma
683955|NCT00006350|recurrent adult diffuse small cleaved cell lymphoma
683956|NCT00006350|recurrent adult diffuse mixed cell lymphoma
683957|NCT00006350|recurrent adult diffuse large cell lymphoma
683958|NCT00006350|recurrent adult immunoblastic large cell lymphoma
683959|NCT00006350|recurrent adult lymphoblastic lymphoma
683960|NCT00006350|recurrent adult Burkitt lymphoma
683961|NCT00006350|de novo myelodysplastic syndromes
683962|NCT00006350|previously treated myelodysplastic syndromes
683963|NCT00006350|secondary myelodysplastic syndromes
683964|NCT00006350|contiguous stage II grade 1 follicular lymphoma
683965|NCT00006350|contiguous stage II grade 2 follicular lymphoma
683966|NCT00006350|contiguous stage II grade 3 follicular lymphoma
683967|NCT00006350|contiguous stage II adult diffuse small cleaved cell lymphoma
683968|NCT00006350|contiguous stage II adult diffuse mixed cell lymphoma
683969|NCT00006350|contiguous stage II adult immunoblastic large cell lymphoma
683970|NCT00006350|contiguous stage II adult diffuse large cell lymphoma
683971|NCT00006350|contiguous stage II adult Burkitt lymphoma
683972|NCT00006350|contiguous stage II adult lymphoblastic lymphoma
683973|NCT00006350|noncontiguous stage II grade 1 follicular lymphoma
683974|NCT00006350|noncontiguous stage II grade 2 follicular lymphoma
683975|NCT00006350|noncontiguous stage II grade 3 follicular lymphoma
683976|NCT00006350|noncontiguous stage II adult diffuse small cleaved cell lymphoma
683977|NCT00006350|noncontiguous stage II adult diffuse mixed cell lymphoma
683978|NCT00006350|noncontiguous stage II adult immunoblastic large cell lymphoma
683979|NCT00006350|noncontiguous stage II adult diffuse large cell lymphoma
683980|NCT00006350|noncontiguous stage II adult Burkitt lymphoma
683981|NCT00006350|noncontiguous stage II adult lymphoblastic lymphoma
683982|NCT00006350|recurrent mantle cell lymphoma
683983|NCT00006350|noncontiguous stage II small lymphocytic lymphoma
683984|NCT00006350|noncontiguous stage II marginal zone lymphoma
683985|NCT00006350|recurrent marginal zone lymphoma
683986|NCT00006350|recurrent small lymphocytic lymphoma
683987|NCT00006350|stage III small lymphocytic lymphoma
683988|NCT00006350|stage III marginal zone lymphoma
683989|NCT00006350|stage IV small lymphocytic lymphoma
683990|NCT00006350|stage IV marginal zone lymphoma
683991|NCT00006350|contiguous stage II marginal zone lymphoma
683992|NCT00006350|contiguous stage II small lymphocytic lymphoma
683993|NCT00006350|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
683994|NCT00006350|nodal marginal zone B-cell lymphoma
683995|NCT00006350|splenic marginal zone lymphoma
683996|NCT00006349|depression
683997|NCT00006349|delirium
683998|NCT00006349|cognitive/functional effects
683999|NCT00006349|radiation toxicity
684000|NCT00006349|limited stage small cell lung cancer
684001|NCT00006349|extensive stage small cell lung cancer
684002|NCT00006349|recurrent small cell lung cancer
684003|NCT00006348|stage IV adult Hodgkin lymphoma
684004|NCT00006348|monoclonal gammopathy of undetermined significance
684005|NCT00006348|recurrent childhood acute lymphoblastic leukemia
684006|NCT00006348|recurrent adult Hodgkin lymphoma
684007|NCT00006348|stage IV cutaneous T-cell non-Hodgkin lymphoma
684008|NCT00006348|recurrent cutaneous T-cell non-Hodgkin lymphoma
684009|NCT00006348|isolated plasmacytoma of bone
684010|NCT00006348|extramedullary plasmacytoma
684011|NCT00006348|refractory multiple myeloma
684012|NCT00006348|Waldenström macroglobulinemia
684013|NCT00006348|stage III multiple myeloma
684014|NCT00006348|stage IV childhood lymphoblastic lymphoma
684015|NCT00006348|recurrent childhood lymphoblastic lymphoma
684016|NCT00006348|stage IV chronic lymphocytic leukemia
684017|NCT00006348|recurrent childhood acute myeloid leukemia
684018|NCT00006348|recurrent adult acute myeloid leukemia
684019|NCT00006348|recurrent adult acute lymphoblastic leukemia
684020|NCT00006348|relapsing chronic myelogenous leukemia
684021|NCT00006348|refractory chronic lymphocytic leukemia
684022|NCT00006348|small intestine lymphoma
684023|NCT00006348|unspecified childhood solid tumor, protocol specific
684024|NCT00006348|unspecified adult solid tumor, protocol specific
684025|NCT00006348|chronic phase chronic myelogenous leukemia
684026|NCT00006348|accelerated phase chronic myelogenous leukemia
684027|NCT00006348|blastic phase chronic myelogenous leukemia
684028|NCT00006348|meningeal chronic myelogenous leukemia
684029|NCT00006348|untreated adult acute lymphoblastic leukemia
684030|NCT00006348|untreated adult acute myeloid leukemia
684031|NCT00006348|untreated childhood acute myeloid leukemia and other myeloid malignancies
684032|NCT00006348|untreated childhood acute lymphoblastic leukemia
684033|NCT00006348|polycythemia vera
684034|NCT00006348|primary myelofibrosis
684035|NCT00006348|essential thrombocythemia
684036|NCT00006348|untreated hairy cell leukemia
684037|NCT00006348|progressive hairy cell leukemia, initial treatment
684038|NCT00006348|refractory hairy cell leukemia
684039|NCT00006348|stage IV childhood Hodgkin lymphoma
684040|NCT00006348|recurrent/refractory childhood Hodgkin lymphoma
684041|NCT00006348|chronic myelomonocytic leukemia
684042|NCT00006348|T-cell large granular lymphocyte leukemia
684043|NCT00006348|acute undifferentiated leukemia
684044|NCT00006348|stage IV grade 1 follicular lymphoma
684963|NCT00006191|Healthy Volunteer
684045|NCT00006348|stage IV grade 2 follicular lymphoma
684046|NCT00006348|stage IV grade 3 follicular lymphoma
684047|NCT00006348|stage IV adult diffuse small cleaved cell lymphoma
684048|NCT00006348|stage IV adult diffuse mixed cell lymphoma
684049|NCT00006348|stage IV adult diffuse large cell lymphoma
684050|NCT00006348|stage IV adult immunoblastic large cell lymphoma
684051|NCT00006348|stage IV adult lymphoblastic lymphoma
684052|NCT00006348|stage IV adult Burkitt lymphoma
684053|NCT00006348|recurrent grade 1 follicular lymphoma
684054|NCT00006348|recurrent grade 2 follicular lymphoma
684055|NCT00006348|recurrent grade 3 follicular lymphoma
684056|NCT00006348|recurrent adult diffuse small cleaved cell lymphoma
684057|NCT00006348|recurrent adult diffuse mixed cell lymphoma
684058|NCT00006348|recurrent adult diffuse large cell lymphoma
684059|NCT00006348|recurrent adult immunoblastic large cell lymphoma
684060|NCT00006348|recurrent adult lymphoblastic lymphoma
684061|NCT00006348|recurrent adult Burkitt lymphoma
684062|NCT00006348|stage IV adult T-cell leukemia/lymphoma
684063|NCT00006348|recurrent adult T-cell leukemia/lymphoma
684064|NCT00006348|secondary acute myeloid leukemia
684065|NCT00006348|de novo myelodysplastic syndromes
684066|NCT00006348|previously treated myelodysplastic syndromes
684067|NCT00006348|secondary myelodysplastic syndromes
684068|NCT00006348|primary central nervous system non-Hodgkin lymphoma
684069|NCT00006348|nausea and vomiting
684070|NCT00006348|prolymphocytic leukemia
684071|NCT00006348|AIDS-related peripheral/systemic lymphoma
684072|NCT00006348|AIDS-related primary CNS lymphoma
684073|NCT00006348|primary systemic amyloidosis
684074|NCT00006348|intraocular lymphoma
684075|NCT00006348|stage IV childhood small noncleaved cell lymphoma
684076|NCT00006348|stage IV childhood large cell lymphoma
684077|NCT00006348|recurrent childhood small noncleaved cell lymphoma
684078|NCT00006348|recurrent childhood large cell lymphoma
684079|NCT00006348|stage IV mantle cell lymphoma
684080|NCT00006348|recurrent mantle cell lymphoma
684081|NCT00006348|angioimmunoblastic T-cell lymphoma
684082|NCT00006348|anaplastic large cell lymphoma
684083|NCT00006348|stage IV mycosis fungoides/Sezary syndrome
684084|NCT00006348|recurrent mycosis fungoides/Sezary syndrome
684085|NCT00006348|recurrent marginal zone lymphoma
684086|NCT00006348|recurrent small lymphocytic lymphoma
684087|NCT00006348|stage IV small lymphocytic lymphoma
684088|NCT00006348|stage IV marginal zone lymphoma
684089|NCT00006348|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684090|NCT00006348|nodal marginal zone B-cell lymphoma
684091|NCT00006348|splenic marginal zone lymphoma
684092|NCT00006348|childhood myelodysplastic syndromes
684093|NCT00006347|recurrent small cell lung cancer
684094|NCT00006346|stage II breast cancer
684095|NCT00006346|stage IV breast cancer
684096|NCT00006346|stage IIIA breast cancer
684097|NCT00006346|stage IIIB breast cancer
684098|NCT00006346|psychosocial effects of cancer and its treatment
684099|NCT00006345|recurrent cutaneous T-cell non-Hodgkin lymphoma
684100|NCT00006345|drug/agent toxicity by tissue/organ
684101|NCT00006345|recurrent mycosis fungoides/Sezary syndrome
684102|NCT00006344|limited stage small cell lung cancer
684103|NCT00006344|extensive stage small cell lung cancer
684104|NCT00006343|chronic phase chronic myelogenous leukemia
684105|NCT00006343|chronic myelogenous leukemia, BCR-ABL1 positive
684106|NCT00006342|stage I adult Hodgkin lymphoma
684107|NCT00006342|stage II adult Hodgkin lymphoma
684108|NCT00006342|stage III adult Hodgkin lymphoma
684109|NCT00006342|stage IV adult Hodgkin lymphoma
684110|NCT00006342|recurrent adult Hodgkin lymphoma
684111|NCT00006342|childhood infratentorial ependymoma
684112|NCT00006342|childhood low-grade cerebral astrocytoma
684113|NCT00006342|childhood supratentorial ependymoma
684114|NCT00006342|stage II childhood Hodgkin lymphoma
684115|NCT00006342|stage I childhood Hodgkin lymphoma
684116|NCT00006342|stage III childhood Hodgkin lymphoma
684117|NCT00006342|stage IV childhood Hodgkin lymphoma
684118|NCT00006342|recurrent/refractory childhood Hodgkin lymphoma
684119|NCT00006342|childhood high-grade cerebral astrocytoma
684120|NCT00006342|untreated childhood brain stem glioma
684121|NCT00006342|recurrent childhood brain stem glioma
684122|NCT00006342|untreated childhood supratentorial primitive neuroectodermal tumor
684123|NCT00006342|recurrent childhood supratentorial primitive neuroectodermal tumor
684124|NCT00006342|untreated childhood cerebellar astrocytoma
684125|NCT00006342|recurrent childhood cerebellar astrocytoma
684126|NCT00006342|recurrent childhood cerebral astrocytoma
684127|NCT00006342|untreated childhood medulloblastoma
684128|NCT00006342|recurrent childhood medulloblastoma
684129|NCT00006342|newly diagnosed childhood ependymoma
684130|NCT00006342|recurrent childhood ependymoma
684131|NCT00006341|stage I lip and oral cavity cancer
684132|NCT00006341|stage II lip and oral cavity cancer
684133|NCT00006341|stage III lip and oral cavity cancer
684134|NCT00006340|stage I adult Hodgkin lymphoma
684135|NCT00006340|stage II adult Hodgkin lymphoma
684136|NCT00006340|stage III adult Hodgkin lymphoma
684137|NCT00006340|stage IV adult Hodgkin lymphoma
684138|NCT00006340|recurrent adult Hodgkin lymphoma
684139|NCT00006340|stage I cutaneous T-cell non-Hodgkin lymphoma
684140|NCT00006340|stage II cutaneous T-cell non-Hodgkin lymphoma
684141|NCT00006340|stage III cutaneous T-cell non-Hodgkin lymphoma
684142|NCT00006340|stage IV cutaneous T-cell non-Hodgkin lymphoma
684143|NCT00006340|recurrent cutaneous T-cell non-Hodgkin lymphoma
684144|NCT00006340|stage I childhood lymphoblastic lymphoma
684145|NCT00006340|stage II childhood lymphoblastic lymphoma
684146|NCT00006340|stage III childhood lymphoblastic lymphoma
684147|NCT00006340|stage IV childhood lymphoblastic lymphoma
684148|NCT00006340|recurrent childhood lymphoblastic lymphoma
684149|NCT00006340|small intestine lymphoma
684150|NCT00006340|childhood immunoblastic large cell lymphoma
684151|NCT00006340|grade I lymphomatoid granulomatosis
684152|NCT00006340|grade II lymphomatoid granulomatosis
684153|NCT00006340|adult grade III lymphomatoid granulomatosis
684154|NCT00006340|recurrent adult grade III lymphomatoid granulomatosis
684155|NCT00006340|childhood grade III lymphomatoid granulomatosis
684156|NCT00006340|recurrent childhood grade III lymphomatoid granulomatosis
684157|NCT00006340|recurrent grade I lymphomatoid granulomatosis
684158|NCT00006340|recurrent grade II lymphomatoid granulomatosis
684159|NCT00006340|stage II childhood Hodgkin lymphoma
684160|NCT00006340|stage I childhood Hodgkin lymphoma
684161|NCT00006340|stage III childhood Hodgkin lymphoma
684162|NCT00006340|stage IV childhood Hodgkin lymphoma
684163|NCT00006340|recurrent/refractory childhood Hodgkin lymphoma
684164|NCT00006340|stage I grade 1 follicular lymphoma
684165|NCT00006340|stage I grade 2 follicular lymphoma
684166|NCT00006340|stage I grade 3 follicular lymphoma
684167|NCT00006340|stage I adult diffuse small cleaved cell lymphoma
684168|NCT00006340|stage I adult diffuse mixed cell lymphoma
684169|NCT00006340|stage I adult diffuse large cell lymphoma
684170|NCT00006340|stage I adult immunoblastic large cell lymphoma
684171|NCT00006340|stage I adult lymphoblastic lymphoma
684172|NCT00006340|stage I adult Burkitt lymphoma
684173|NCT00006340|T-cell large granular lymphocyte leukemia
684174|NCT00006340|stage II grade 1 follicular lymphoma
684175|NCT00006340|stage II grade 2 follicular lymphoma
684176|NCT00006340|stage II grade 3 follicular lymphoma
684177|NCT00006340|stage II adult diffuse small cleaved cell lymphoma
684178|NCT00006340|stage II adult diffuse mixed cell lymphoma
684179|NCT00006340|stage II adult diffuse large cell lymphoma
684180|NCT00006340|stage II adult immunoblastic large cell lymphoma
684181|NCT00006340|stage II adult lymphoblastic lymphoma
684182|NCT00006340|stage II adult Burkitt lymphoma
684183|NCT00006340|stage III grade 1 follicular lymphoma
684184|NCT00006340|stage III grade 2 follicular lymphoma
684185|NCT00006340|stage III grade 3 follicular lymphoma
684186|NCT00006340|stage III adult diffuse small cleaved cell lymphoma
684187|NCT00006340|stage III adult diffuse mixed cell lymphoma
684188|NCT00006340|stage III adult diffuse large cell lymphoma
684189|NCT00006340|stage III adult immunoblastic large cell lymphoma
684190|NCT00006340|stage III adult lymphoblastic lymphoma
684191|NCT00006340|stage III adult Burkitt lymphoma
684192|NCT00006340|stage IV grade 1 follicular lymphoma
684193|NCT00006340|stage IV grade 2 follicular lymphoma
684194|NCT00006340|stage IV grade 3 follicular lymphoma
684195|NCT00006340|stage IV adult diffuse small cleaved cell lymphoma
684196|NCT00006340|stage IV adult diffuse mixed cell lymphoma
684197|NCT00006340|stage IV adult diffuse large cell lymphoma
684198|NCT00006340|stage IV adult immunoblastic large cell lymphoma
684199|NCT00006340|stage IV adult lymphoblastic lymphoma
684200|NCT00006340|stage IV adult Burkitt lymphoma
684201|NCT00006340|recurrent grade 1 follicular lymphoma
684202|NCT00006340|recurrent grade 2 follicular lymphoma
684203|NCT00006340|recurrent grade 3 follicular lymphoma
684204|NCT00006340|recurrent adult diffuse small cleaved cell lymphoma
684205|NCT00006340|recurrent adult diffuse mixed cell lymphoma
684206|NCT00006340|recurrent adult diffuse large cell lymphoma
684207|NCT00006340|recurrent adult immunoblastic large cell lymphoma
684208|NCT00006340|recurrent adult lymphoblastic lymphoma
684209|NCT00006340|recurrent adult Burkitt lymphoma
684210|NCT00006340|stage I adult T-cell leukemia/lymphoma
684211|NCT00006340|stage II adult T-cell leukemia/lymphoma
684212|NCT00006340|stage III adult T-cell leukemia/lymphoma
684213|NCT00006340|stage IV adult T-cell leukemia/lymphoma
684214|NCT00006340|recurrent adult T-cell leukemia/lymphoma
684215|NCT00006340|AIDS-related peripheral/systemic lymphoma
684216|NCT00006340|AIDS-related primary CNS lymphoma
684217|NCT00006340|stage I childhood small noncleaved cell lymphoma
684218|NCT00006340|stage I childhood large cell lymphoma
684219|NCT00006340|stage II childhood small noncleaved cell lymphoma
684220|NCT00006340|stage II childhood large cell lymphoma
684221|NCT00006340|stage III childhood small noncleaved cell lymphoma
684222|NCT00006340|stage III childhood large cell lymphoma
684223|NCT00006340|stage IV childhood small noncleaved cell lymphoma
684224|NCT00006340|stage IV childhood large cell lymphoma
684225|NCT00006340|recurrent childhood small noncleaved cell lymphoma
684226|NCT00006340|recurrent childhood large cell lymphoma
684227|NCT00006340|stage I mantle cell lymphoma
684228|NCT00006340|stage III mantle cell lymphoma
684229|NCT00006340|stage IV mantle cell lymphoma
684230|NCT00006340|recurrent mantle cell lymphoma
684231|NCT00006340|angioimmunoblastic T-cell lymphoma
684232|NCT00006340|anaplastic large cell lymphoma
684233|NCT00006340|stage II mantle cell lymphoma
684234|NCT00006340|stage I mycosis fungoides/Sezary syndrome
684235|NCT00006340|stage II mycosis fungoides/Sezary syndrome
684236|NCT00006340|stage III mycosis fungoides/Sezary syndrome
684237|NCT00006340|stage IV mycosis fungoides/Sezary syndrome
684238|NCT00006340|recurrent mycosis fungoides/Sezary syndrome
684239|NCT00006340|recurrent marginal zone lymphoma
684240|NCT00006340|recurrent small lymphocytic lymphoma
684241|NCT00006340|stage I marginal zone lymphoma
684242|NCT00006340|stage I small lymphocytic lymphoma
684243|NCT00006340|stage II small lymphocytic lymphoma
684244|NCT00006340|stage II marginal zone lymphoma
684245|NCT00006340|stage III small lymphocytic lymphoma
684246|NCT00006340|stage III marginal zone lymphoma
684247|NCT00006340|stage IV small lymphocytic lymphoma
684248|NCT00006340|stage IV marginal zone lymphoma
684249|NCT00006340|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684250|NCT00006340|nodal marginal zone B-cell lymphoma
684251|NCT00006340|splenic marginal zone lymphoma
684252|NCT00006339|Prospective Studies
684253|NCT00006339|HIV-1
684254|NCT00006339|Didanosine
684255|NCT00006339|Drug Therapy, Combination
684256|NCT00006339|Stavudine
684257|NCT00006339|HIV Protease Inhibitors
684258|NCT00006339|Hydroxyurea
684259|NCT00006339|Ritonavir
684260|NCT00006339|Indinavir
684261|NCT00006339|Reverse Transcriptase Inhibitors
684262|NCT00006339|Anti-HIV Agents
684263|NCT00006339|Viral Load
684264|NCT00006339|Reverse Transcriptase Polymerase Chain Reaction
684265|NCT00006337|Clinical Trial
684266|NCT00006337|Dyskinesias
684267|NCT00006337|Levodopa Infusion
684268|NCT00006336|Gap Detection Test
684269|NCT00006336|Fahn-Scale
684270|NCT00006336|Visual Analog and Verbal Scale
684271|NCT00006336|Writing Standard Paragraph
684272|NCT00006336|Braille Reading Grade I
684273|NCT00006335|Genetic
684274|NCT00006335|Analysis
684275|NCT00006335|Immune
684276|NCT00006335|Teenage
684277|NCT00006335|Girls
684278|NCT00006335|Severe Combined Immune Deficiency (SCID)
684279|NCT00006335|XSCID
684280|NCT00006335|Carrier Testing
684281|NCT00006335|X-Linked Disease
684282|NCT00006335|Adolescent
684283|NCT00006334|Genes
684284|NCT00006334|X-Chromosome
684285|NCT00006334|Osteoporosis
684286|NCT00006334|Ovarian Failure
684287|NCT00006334|Imprinting
684288|NCT00006334|Turner's
684289|NCT00006334|Turner
684290|NCT00006334|TS
684291|NCT00006333|Rheumatoid Arthritis
684292|NCT00006333|Inflammation
684293|NCT00006333|Synovitis
684294|NCT00006333|Genetics
684295|NCT00006333|Synovial Biopsy
684296|NCT00006333|Arthritis
684297|NCT00006333|Juvenile Rheumatoid Arthritis
684298|NCT00006333|JRA
684299|NCT00006332|Molybdenum
684300|NCT00006331|Kidney transplantation
684301|NCT00006331|Immunology
684302|NCT00006330|Digoxin
684303|NCT00006330|Effect modifiers (Epidemiology)
684304|NCT00006330|Rosales
684305|NCT00006330|Drug Interaction
684306|NCT00006329|Radionuclide imaging
684307|NCT00006329|Surgery
684308|NCT00006328|Chronic Allograft Nephropathy (CAN)
684309|NCT00006328|Transplantation immunology
684310|NCT00006328|Genetics
684311|NCT00006328|Graft Rejection
684312|NCT00006327|Recombinant Proteins
684313|NCT00006327|HIV-1
684314|NCT00006327|AIDS Serodiagnosis
684315|NCT00006327|Substance Abuse, Intravenous
684316|NCT00006327|Enzyme-Linked Immunosorbent Assay
684317|NCT00006327|Blotting, Western
684318|NCT00006327|HIV Envelope Protein gp120
684319|NCT00006327|AIDSVAX
684320|NCT00006326|Drug Therapy, Combination
684321|NCT00006326|HIV Protease Inhibitors
684322|NCT00006326|Ritonavir
684323|NCT00006326|Indinavir
684324|NCT00006326|Delavirdine
684325|NCT00006326|Reverse Transcriptase Inhibitors
684326|NCT00006326|Salvage Therapy
684327|NCT00006326|Anti-HIV Agents
684328|NCT00006326|Viral Load
684329|NCT00006326|Nelfinavir
684330|NCT00006325|Polyethylene Glycols
684331|NCT00006325|Interferon Alfa-2b
684332|NCT00006325|HIV-1
684333|NCT00006325|Dose-Response Relationship, Drug
684334|NCT00006325|Drug Therapy, Combination
684335|NCT00006325|Virus Inhibitors
684336|NCT00006325|Anti-HIV Agents
684337|NCT00006325|Pharmacokinetics
684338|NCT00006324|HIV Seronegativity
684339|NCT00006324|Delayed-Action Preparations
684340|NCT00006324|Risk Factors
684341|NCT00006324|Prevalence
684342|NCT00006324|Contraceptive Agents, Female
684343|NCT00006324|Contraceptives, Oral, Combined
684344|NCT00006324|Medroxyprogesterone 17-Acetate
684345|NCT00006320|Reverse Transcriptase Inhibitor
684346|NCT00006320|Protease Inhibitor
684347|NCT00006319|X-Linked Agammagloblinemia
684348|NCT00006319|Wiskott-Aldrich Syndrome
684349|NCT00006319|Jak-3 SCID
684350|NCT00006319|X-Linked SCID
684351|NCT00006319|X-Linked Hyper-IgM Syndrome
684352|NCT00006319|Primary Immunodeficiencies
684353|NCT00006319|ADA-SCID
684354|NCT00006319|CVID
684355|NCT00006318|Cerebral Blood Flow
684356|NCT00006318|CO2 Inhalation
684357|NCT00006318|Imaging
684358|NCT00006318|MRI
684359|NCT00006318|Perfusion
684360|NCT00006318|Functional Activation
684361|NCT00006316|AIDS-Related Opportunistic Infections
684362|NCT00006316|Histoplasmosis
684363|NCT00006316|Antifungal Agents
684364|NCT00006316|Recurrence
684365|NCT00006316|Anti-HIV Agents
684366|NCT00006304|Acquired Immunodeficiency Syndrome
684367|NCT00006304|AIDS-Related Complex
684368|NCT00006301|Hepatitis C
684369|NCT00006301|Viral Sequence
684370|NCT00006301|PCR
684371|NCT00006301|T Cell
684372|NCT00006301|Seroconversion
684373|NCT00006301|Cytokines
684374|NCT00006300|Immunosuppression
684375|NCT00006300|Treatment Recommendations
684376|NCT00006300|Pancytopenia
684377|NCT00006300|Schizophrenia
684378|NCT00006300|Inpatient Population
684379|NCT00006299|Celecoxib
684380|NCT00006299|Thromboxane B2
684381|NCT00006299|Prostaglandin E2
684382|NCT00006299|Microdialysis
684383|NCT00006299|Ibuprofen
684384|NCT00006298|HIV Antibodies
684385|NCT00006298|HIV-1
684386|NCT00006298|CD4 Lymphocyte Count
684387|NCT00006298|T-Lymphocytes, Cytotoxic
684388|NCT00006298|Genotype
684389|NCT00006298|Species Specificity
684390|NCT00006298|Neutralization Tests
684391|NCT00006298|Viral Load
684392|NCT00006298|Alleles
684393|NCT00006298|HLA Antigens
684394|NCT00006298|Cross Reactions
684395|NCT00006298|Immunodominant Epitopes
684396|NCT00006298|Haplotypes
684397|NCT00006292|Biologic Therapy
684398|NCT00006292|Bone Erosion
684399|NCT00006292|CT
684400|NCT00006292|MRI
684401|NCT00006292|Rheumatoid Arthritis
684402|NCT00006292|RA
684403|NCT00006291|Virus Replication
684404|NCT00006291|T-Lymphocytes
684405|NCT00006291|Lymphocyte Transformation
684406|NCT00006291|AIDS Vaccines
684407|NCT00006291|Anti-HIV Agents
684408|NCT00006291|Viral Load
684409|NCT00006291|Aldesleukin
684410|NCT00006291|HIV Therapeutic Vaccine
684411|NCT00006290|Drug Therapy, Combination
684412|NCT00006290|Questionnaires
684413|NCT00006290|Quality of Life
684414|NCT00006290|Patient Compliance
684415|NCT00006290|Body Composition
684416|NCT00006290|Anti-HIV Agents
684417|NCT00006290|Adipose Tissue
684418|NCT00006290|Body Image
684419|NCT00006289|Analgesia
684420|NCT00006289|Causalgia
684421|NCT00006289|CRPS
684422|NCT00006289|Neuropathic Pain
684423|NCT00006289|Oral Surgery
684424|NCT00006289|Reflex Sympathetic Dystrophy
684425|NCT00006289|Sympathetic Nervous System
684426|NCT00006289|Chronic Regional Pain Syndrome
684427|NCT00006286|Depression
684428|NCT00006286|Major Depressive Disorder
684429|NCT00006286|Fluoxetine
684430|NCT00006286|Prozac
684431|NCT00006286|SSRI
684432|NCT00006286|Psychotherapy
684433|NCT00006286|CBT
684434|NCT00006286|Teenagers
684435|NCT00006286|Adolescents
684436|NCT00006286|Teens
684437|NCT00006285|Transcranial Magnetic Stimulation
684438|NCT00006285|Parietal Lobe
684439|NCT00006285|fMRI
684440|NCT00006285|Cognition
684441|NCT00006285|Perception
684442|NCT00006285|Cortical Stimulation
684443|NCT00006285|Spatial Attention
684444|NCT00006280|Cystic Fibrosis
684445|NCT00006279|Pregnancy Complications, Infectious
684446|NCT00006279|Dose-Response Relationship, Drug
684447|NCT00006279|Drug Administration Schedule
684448|NCT00006279|Nevirapine
684449|NCT00006279|Disease Transmission, Vertical
684450|NCT00006279|Reverse Transcriptase Inhibitors
684451|NCT00006279|Anti-HIV Agents
684452|NCT00006279|Breast Feeding
684453|NCT00006278|Cushing's Syndrome
684454|NCT00006278|Adrenal Glands
684455|NCT00006278|Proteomics
684456|NCT00006278|Cortisol
684457|NCT00006276|Angiogenesis Inhibition
684458|NCT00006276|Skin Disease
684459|NCT00006276|Blood Vessels
684460|NCT00006276|Cytokines
684461|NCT00006276|Autoimmune Disease
684462|NCT00006275|dermatologic disorders
684463|NCT00006275|psoriasis
684464|NCT00006275|rare disease
684465|NCT00006274|cardiovascular and respiratory diseases
684466|NCT00006274|neonatal disorders
684467|NCT00006274|rare disease
684468|NCT00006274|respiratory distress syndrome
684469|NCT00006273|cardiovascular and respiratory diseases
684470|NCT00006273|cystic fibrosis
684471|NCT00006273|genetic diseases and dysmorphic syndromes
684472|NCT00006273|rare disease
684473|NCT00006272|cardiovascular and respiratory diseases
684474|NCT00006272|heart defects
684475|NCT00006272|rare disease
684476|NCT00006271|brain injury
684964|NCT00006190|Lipoproteins
684477|NCT00006271|neurologic and psychiatric disorders
684478|NCT00006271|rare disease
684479|NCT00006270|brain injury
684480|NCT00006270|neurologic and psychiatric disorders
684481|NCT00006270|rare disease
684482|NCT00006269|stage IV colon cancer
684483|NCT00006269|stage IV rectal cancer
684484|NCT00006269|recurrent colon cancer
684485|NCT00006269|recurrent rectal cancer
684486|NCT00006269|diarrhea
684487|NCT00006268|recurrent adult brain tumor
684488|NCT00006268|adult glioblastoma
684489|NCT00006268|adult anaplastic astrocytoma
684490|NCT00006268|adult mixed glioma
684491|NCT00006268|adult giant cell glioblastoma
684492|NCT00006268|adult gliosarcoma
684493|NCT00006267|stage IV ovarian epithelial cancer
684494|NCT00006267|recurrent ovarian epithelial cancer
684495|NCT00006267|primary peritoneal cavity cancer
684496|NCT00006265|recurrent adult acute myeloid leukemia
684497|NCT00006264|AIDS-related primary CNS lymphoma
684498|NCT00006263|adult brain stem glioma
684499|NCT00006263|adult glioblastoma
684500|NCT00006263|childhood high-grade cerebral astrocytoma
684501|NCT00006263|adult anaplastic astrocytoma
684502|NCT00006263|adult anaplastic oligodendroglioma
684503|NCT00006263|adult giant cell glioblastoma
684504|NCT00006263|adult gliosarcoma
684505|NCT00006262|stage III ovarian epithelial cancer
684506|NCT00006262|stage IV ovarian epithelial cancer
684507|NCT00006262|recurrent ovarian epithelial cancer
684508|NCT00006261|stage IV breast cancer
684509|NCT00006261|recurrent breast cancer
684510|NCT00006260|stage IV breast cancer
684511|NCT00006260|recurrent breast cancer
684512|NCT00006259|tumors metastatic to brain
684513|NCT00006258|childhood infratentorial ependymoma
684514|NCT00006258|childhood supratentorial ependymoma
684515|NCT00006258|adult medulloblastoma
684516|NCT00006258|adult myxopapillary ependymoma
684517|NCT00006258|adult anaplastic ependymoma
684518|NCT00006258|adult ependymoblastoma
684519|NCT00006258|untreated childhood supratentorial primitive neuroectodermal tumor
684520|NCT00006258|untreated childhood medulloblastoma
684521|NCT00006258|newly diagnosed childhood ependymoma
684522|NCT00006258|adult supratentorial primitive neuroectodermal tumor (PNET)
684523|NCT00006257|unspecified adult solid tumor, protocol specific
684524|NCT00006256|stage II breast cancer
684525|NCT00006256|stage IIIA breast cancer
684526|NCT00006256|stage IIIB breast cancer
684527|NCT00006256|stage IIIC breast cancer
684528|NCT00006255|stage III renal cell cancer
684529|NCT00006255|stage IV renal cell cancer
684530|NCT00006255|recurrent renal cell cancer
684531|NCT00006255|unspecified adult solid tumor, protocol specific
684532|NCT00006255|liver metastases
684533|NCT00006254|unspecified adult solid tumor, protocol specific
684534|NCT00006253|symptom management
684535|NCT00006253|cancer
684536|NCT00006253|chemotherapy treatment
684537|NCT00006253|Behavioral Research
684538|NCT00006253|Physiological Effects of Drugs
684539|NCT00006253|Clinical Trial, Phase II
684540|NCT00006252|refractory chronic lymphocytic leukemia
684541|NCT00006252|stage I grade 1 follicular lymphoma
684542|NCT00006252|stage I grade 2 follicular lymphoma
684543|NCT00006252|stage I adult diffuse small cleaved cell lymphoma
684544|NCT00006252|stage III grade 1 follicular lymphoma
684545|NCT00006252|stage III grade 2 follicular lymphoma
684546|NCT00006252|stage III adult diffuse small cleaved cell lymphoma
684547|NCT00006252|stage IV grade 1 follicular lymphoma
684548|NCT00006252|stage IV grade 2 follicular lymphoma
684549|NCT00006252|stage IV adult diffuse small cleaved cell lymphoma
684550|NCT00006252|recurrent grade 1 follicular lymphoma
684551|NCT00006252|recurrent grade 2 follicular lymphoma
684552|NCT00006252|recurrent adult diffuse small cleaved cell lymphoma
684553|NCT00006252|prolymphocytic leukemia
684554|NCT00006252|stage I mantle cell lymphoma
684555|NCT00006252|contiguous stage II grade 1 follicular lymphoma
684556|NCT00006252|contiguous stage II grade 2 follicular lymphoma
684557|NCT00006252|contiguous stage II adult diffuse small cleaved cell lymphoma
684558|NCT00006252|contiguous stage II mantle cell lymphoma
684559|NCT00006252|noncontiguous stage II grade 1 follicular lymphoma
684560|NCT00006252|noncontiguous stage II grade 2 follicular lymphoma
684561|NCT00006252|noncontiguous stage II adult diffuse small cleaved cell lymphoma
684562|NCT00006252|noncontiguous stage II mantle cell lymphoma
684563|NCT00006252|stage III mantle cell lymphoma
684564|NCT00006252|stage IV mantle cell lymphoma
684565|NCT00006252|recurrent mantle cell lymphoma
684566|NCT00006252|contiguous stage II small lymphocytic lymphoma
684567|NCT00006252|contiguous stage II marginal zone lymphoma
684568|NCT00006252|noncontiguous stage II small lymphocytic lymphoma
684569|NCT00006252|noncontiguous stage II marginal zone lymphoma
684570|NCT00006252|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684571|NCT00006252|nodal marginal zone B-cell lymphoma
684572|NCT00006252|splenic marginal zone lymphoma
684573|NCT00006252|recurrent marginal zone lymphoma
684574|NCT00006252|recurrent small lymphocytic lymphoma
684575|NCT00006252|stage I marginal zone lymphoma
684576|NCT00006252|stage I small lymphocytic lymphoma
684577|NCT00006252|stage III small lymphocytic lymphoma
684578|NCT00006252|stage III marginal zone lymphoma
684579|NCT00006252|stage IV small lymphocytic lymphoma
684580|NCT00006252|stage IV marginal zone lymphoma
684581|NCT00006250|stage III grade 1 follicular lymphoma
684582|NCT00006250|stage III grade 2 follicular lymphoma
684583|NCT00006250|stage III grade 3 follicular lymphoma
684584|NCT00006250|stage IV grade 1 follicular lymphoma
684585|NCT00006250|stage IV grade 2 follicular lymphoma
684586|NCT00006250|stage IV grade 3 follicular lymphoma
684587|NCT00006249|stage III melanoma
684588|NCT00006248|stage IV squamous cell carcinoma of the lip and oral cavity
684589|NCT00006248|recurrent squamous cell carcinoma of the lip and oral cavity
684590|NCT00006248|stage IV squamous cell carcinoma of the oropharynx
684591|NCT00006248|recurrent squamous cell carcinoma of the oropharynx
684592|NCT00006248|stage IV squamous cell carcinoma of the nasopharynx
684593|NCT00006248|recurrent squamous cell carcinoma of the nasopharynx
684594|NCT00006248|stage IV squamous cell carcinoma of the hypopharynx
684595|NCT00006248|recurrent squamous cell carcinoma of the hypopharynx
684596|NCT00006248|stage IV squamous cell carcinoma of the larynx
684597|NCT00006248|recurrent squamous cell carcinoma of the larynx
684598|NCT00006248|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
684599|NCT00006248|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
684600|NCT00006247|childhood craniopharyngioma
684601|NCT00006247|childhood central nervous system germ cell tumor
684602|NCT00006247|childhood oligodendroglioma
684603|NCT00006247|childhood choroid plexus tumor
684604|NCT00006247|childhood grade I meningioma
684605|NCT00006247|childhood grade II meningioma
684606|NCT00006247|childhood grade III meningioma
684607|NCT00006247|recurrent childhood cerebellar astrocytoma
684608|NCT00006247|recurrent childhood cerebral astrocytoma
684609|NCT00006247|recurrent childhood medulloblastoma
684610|NCT00006247|recurrent childhood visual pathway and hypothalamic glioma
684611|NCT00006247|recurrent childhood ependymoma
684612|NCT00006246|recurrent childhood acute lymphoblastic leukemia
684613|NCT00006246|childhood infratentorial ependymoma
684614|NCT00006246|recurrent childhood rhabdomyosarcoma
684615|NCT00006246|recurrent childhood brain tumor
684616|NCT00006246|recurrent retinoblastoma
684617|NCT00006246|recurrent childhood lymphoblastic lymphoma
684618|NCT00006246|childhood central nervous system germ cell tumor
684619|NCT00006246|recurrent childhood acute myeloid leukemia
684620|NCT00006246|recurrent/refractory childhood Hodgkin lymphoma
684621|NCT00006246|leptomeningeal metastases
684622|NCT00006246|childhood high-grade cerebral astrocytoma
684623|NCT00006246|childhood oligodendroglioma
684624|NCT00006246|childhood choroid plexus tumor
684625|NCT00006246|childhood grade I meningioma
684626|NCT00006246|childhood grade II meningioma
684627|NCT00006246|childhood grade III meningioma
684628|NCT00006246|recurrent childhood large cell lymphoma
684629|NCT00006246|recurrent childhood brain stem glioma
684630|NCT00006246|recurrent childhood supratentorial primitive neuroectodermal tumor
684631|NCT00006246|recurrent childhood cerebellar astrocytoma
684632|NCT00006246|recurrent childhood cerebral astrocytoma
684633|NCT00006246|recurrent childhood medulloblastoma
684634|NCT00006246|recurrent childhood visual pathway and hypothalamic glioma
684635|NCT00006246|recurrent childhood ependymoma
684636|NCT00006246|recurrent childhood malignant germ cell tumor
684637|NCT00006245|stage III esophageal cancer
684638|NCT00006245|stage IV esophageal cancer
684639|NCT00006245|recurrent esophageal cancer
684640|NCT00006245|squamous cell carcinoma of the esophagus
684641|NCT00006245|adenocarcinoma of the esophagus
684642|NCT00006241|recurrent grade 1 follicular lymphoma
684643|NCT00006241|recurrent grade 2 follicular lymphoma
684644|NCT00006241|recurrent grade 3 follicular lymphoma
684645|NCT00006241|recurrent adult diffuse small cleaved cell lymphoma
684646|NCT00006241|recurrent adult diffuse mixed cell lymphoma
684647|NCT00006241|recurrent adult diffuse large cell lymphoma
684648|NCT00006241|recurrent mantle cell lymphoma
684649|NCT00006241|recurrent marginal zone lymphoma
684650|NCT00006241|recurrent small lymphocytic lymphoma
684651|NCT00006241|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684652|NCT00006241|nodal marginal zone B-cell lymphoma
684653|NCT00006241|splenic marginal zone lymphoma
684654|NCT00006240|recurrent adult acute myeloid leukemia
684655|NCT00006239|recurrent adult acute myeloid leukemia
684656|NCT00006239|untreated adult acute myeloid leukemia
684657|NCT00006239|refractory anemia
684658|NCT00006239|refractory anemia with ringed sideroblasts
684659|NCT00006239|refractory anemia with excess blasts
684660|NCT00006239|refractory anemia with excess blasts in transformation
684661|NCT00006239|chronic myelomonocytic leukemia
684662|NCT00006239|previously treated myelodysplastic syndromes
684663|NCT00006239|atypical chronic myeloid leukemia
684664|NCT00006239|myelodysplastic/myeloproliferative disease, unclassifiable
684665|NCT00006239|adult acute myeloid leukemia with t(8;21)(q22;q22)
684666|NCT00006239|adult acute myeloid leukemia with t(16;16)(p13;q22)
684667|NCT00006239|adult acute myeloid leukemia with inv(16)(p13;q22)
684668|NCT00006239|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
684669|NCT00006239|adult acute myeloid leukemia with t(15;17)(q22;q12)
684670|NCT00006237|stage III melanoma
684671|NCT00006237|recurrent melanoma
684672|NCT00006235|recurrent ovarian epithelial cancer
684673|NCT00006235|ovarian undifferentiated adenocarcinoma
684674|NCT00006235|ovarian mixed epithelial carcinoma
684675|NCT00006235|ovarian serous cystadenocarcinoma
684676|NCT00006235|ovarian mucinous cystadenocarcinoma
684677|NCT00006235|ovarian endometrioid adenocarcinoma
684678|NCT00006235|ovarian clear cell cystadenocarcinoma
684679|NCT00006235|fallopian tube cancer
684680|NCT00006235|primary peritoneal cavity cancer
684681|NCT00006235|Brenner tumor
684682|NCT00006234|recurrent childhood rhabdomyosarcoma
684683|NCT00006234|recurrent adult soft tissue sarcoma
684684|NCT00006234|adult rhabdomyosarcoma
684685|NCT00006234|bone metastases
684686|NCT00006234|previously treated childhood rhabdomyosarcoma
684687|NCT00006234|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
684688|NCT00006234|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
684689|NCT00006234|stage IV adult soft tissue sarcoma
684690|NCT00006233|stage IV melanoma
684691|NCT00006233|recurrent melanoma
684692|NCT00006232|stage II multiple myeloma
684693|NCT00006232|stage III multiple myeloma
684694|NCT00006231|localized malignant mesothelioma
684695|NCT00006231|advanced malignant mesothelioma
684696|NCT00006231|perioperative/postoperative complications
684697|NCT00006230|stage III ovarian epithelial cancer
684698|NCT00006230|stage IV ovarian epithelial cancer
684699|NCT00006230|recurrent ovarian epithelial cancer
684700|NCT00006229|stage IIIB non-small cell lung cancer
684701|NCT00006229|stage IV non-small cell lung cancer
684702|NCT00006225|stage IV adult Hodgkin lymphoma
684703|NCT00006225|stage IV breast cancer
684704|NCT00006225|stage IIIA breast cancer
684705|NCT00006225|recurrent breast cancer
684706|NCT00006225|stage IIIB breast cancer
684707|NCT00006225|stage IIIC breast cancer
684708|NCT00006225|recurrent adult Hodgkin lymphoma
684709|NCT00006225|stage II cutaneous T-cell non-Hodgkin lymphoma
684710|NCT00006225|stage III cutaneous T-cell non-Hodgkin lymphoma
684711|NCT00006225|stage IV cutaneous T-cell non-Hodgkin lymphoma
684712|NCT00006225|recurrent cutaneous T-cell non-Hodgkin lymphoma
684713|NCT00006225|isolated plasmacytoma of bone
684714|NCT00006225|extramedullary plasmacytoma
684715|NCT00006225|refractory multiple myeloma
684716|NCT00006225|Waldenstrom macroglobulinemia
684717|NCT00006225|stage I multiple myeloma
684718|NCT00006225|stage II multiple myeloma
684719|NCT00006225|stage III multiple myeloma
684720|NCT00006225|stage II chronic lymphocytic leukemia
684721|NCT00006225|stage IV chronic lymphocytic leukemia
684722|NCT00006225|recurrent adult acute lymphoblastic leukemia
684723|NCT00006225|adult acute myeloid leukemia in remission
684724|NCT00006225|adult acute lymphoblastic leukemia in remission
684725|NCT00006225|T-cell large granular lymphocyte leukemia
684726|NCT00006225|acute undifferentiated leukemia
684727|NCT00006225|stage III grade 1 follicular lymphoma
684728|NCT00006225|stage III grade 2 follicular lymphoma
684729|NCT00006225|stage III grade 3 follicular lymphoma
684730|NCT00006225|stage III adult diffuse small cleaved cell lymphoma
684731|NCT00006225|stage III adult diffuse mixed cell lymphoma
684732|NCT00006225|stage III adult diffuse large cell lymphoma
684733|NCT00006225|stage III adult immunoblastic large cell lymphoma
684734|NCT00006225|stage III adult lymphoblastic lymphoma
684735|NCT00006225|stage III adult Burkitt lymphoma
684736|NCT00006225|stage IV grade 1 follicular lymphoma
684737|NCT00006225|stage IV grade 2 follicular lymphoma
684738|NCT00006225|stage IV grade 3 follicular lymphoma
684739|NCT00006225|stage IV adult diffuse small cleaved cell lymphoma
684740|NCT00006225|stage IV adult diffuse mixed cell lymphoma
684741|NCT00006225|stage IV adult diffuse large cell lymphoma
684742|NCT00006225|stage IV adult immunoblastic large cell lymphoma
684743|NCT00006225|stage IV adult lymphoblastic lymphoma
684744|NCT00006225|stage IV adult Burkitt lymphoma
684745|NCT00006225|recurrent grade 1 follicular lymphoma
684746|NCT00006225|recurrent grade 2 follicular lymphoma
684747|NCT00006225|recurrent grade 3 follicular lymphoma
684748|NCT00006225|recurrent adult diffuse small cleaved cell lymphoma
684749|NCT00006225|recurrent adult diffuse mixed cell lymphoma
684750|NCT00006225|recurrent adult diffuse large cell lymphoma
684751|NCT00006225|recurrent adult immunoblastic large cell lymphoma
684752|NCT00006225|recurrent adult lymphoblastic lymphoma
684753|NCT00006225|recurrent adult Burkitt lymphoma
684754|NCT00006225|stage I adult T-cell leukemia/lymphoma
684755|NCT00006225|stage II adult T-cell leukemia/lymphoma
684756|NCT00006225|stage III adult T-cell leukemia/lymphoma
684757|NCT00006225|stage IV adult T-cell leukemia/lymphoma
684758|NCT00006225|recurrent adult T-cell leukemia/lymphoma
684759|NCT00006225|primary central nervous system lymphoma
684760|NCT00006225|male breast cancer
684761|NCT00006225|intraocular lymphoma
684762|NCT00006225|stage I mantle cell lymphoma
684763|NCT00006225|contiguous stage II grade 1 follicular lymphoma
684764|NCT00006225|contiguous stage II grade 2 follicular lymphoma
684765|NCT00006225|contiguous stage II grade 3 follicular lymphoma
684766|NCT00006225|contiguous stage II adult diffuse small cleaved cell lymphoma
684767|NCT00006225|contiguous stage II mantle cell lymphoma
684768|NCT00006225|contiguous stage II adult diffuse mixed cell lymphoma
684769|NCT00006225|contiguous stage II adult immunoblastic large cell lymphoma
684770|NCT00006225|contiguous stage II adult diffuse large cell lymphoma
684771|NCT00006225|contiguous stage II adult Burkitt lymphoma
684772|NCT00006225|contiguous stage II adult lymphoblastic lymphoma
684773|NCT00006225|noncontiguous stage II grade 1 follicular lymphoma
684774|NCT00006225|noncontiguous stage II grade 2 follicular lymphoma
684775|NCT00006225|noncontiguous stage II grade 3 follicular lymphoma
684776|NCT00006225|noncontiguous stage II adult diffuse small cleaved cell lymphoma
684777|NCT00006225|noncontiguous stage II mantle cell lymphoma
684778|NCT00006225|noncontiguous stage II adult diffuse mixed cell lymphoma
684779|NCT00006225|noncontiguous stage II adult immunoblastic large cell lymphoma
684780|NCT00006225|noncontiguous stage II adult diffuse large cell lymphoma
684781|NCT00006225|noncontiguous stage II adult Burkitt lymphoma
684782|NCT00006225|noncontiguous stage II adult lymphoblastic lymphoma
684783|NCT00006225|stage III mantle cell lymphoma
684784|NCT00006225|stage IV mantle cell lymphoma
684785|NCT00006225|recurrent mantle cell lymphoma
684786|NCT00006225|angioimmunoblastic T-cell lymphoma
684787|NCT00006225|anaplastic large cell lymphoma
684788|NCT00006225|stage I mycosis fungoides/Sezary syndrome
684789|NCT00006225|stage II mycosis fungoides/Sezary syndrome
684790|NCT00006225|stage III mycosis fungoides/Sezary syndrome
684791|NCT00006225|stage IV mycosis fungoides/Sezary syndrome
684792|NCT00006225|recurrent mycosis fungoides/Sezary syndrome
684793|NCT00006225|chronic myelomonocytic leukemia
684794|NCT00006225|atypical chronic myeloid leukemia
684795|NCT00006225|myelodysplastic/myeloproliferative disease, unclassifiable
684796|NCT00006225|noncontiguous stage II small lymphocytic lymphoma
684797|NCT00006225|noncontiguous stage II marginal zone lymphoma
684798|NCT00006225|recurrent marginal zone lymphoma
684799|NCT00006225|recurrent small lymphocytic lymphoma
684800|NCT00006225|stage III small lymphocytic lymphoma
684801|NCT00006225|stage III marginal zone lymphoma
684802|NCT00006225|stage IV small lymphocytic lymphoma
684803|NCT00006225|stage IV marginal zone lymphoma
684804|NCT00006225|contiguous stage II marginal zone lymphoma
684805|NCT00006225|contiguous stage II small lymphocytic lymphoma
684806|NCT00006225|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684807|NCT00006225|nodal marginal zone B-cell lymphoma
684808|NCT00006225|splenic marginal zone lymphoma
684809|NCT00006224|recurrent cervical cancer
684810|NCT00006224|cervical adenocarcinoma
684811|NCT00006224|cervical adenosquamous cell carcinoma
684812|NCT00006223|adult acute myeloid leukemia in remission
684813|NCT00006223|adult acute erythroid leukemia (M6)
684814|NCT00006223|adult acute myeloblastic leukemia without maturation (M1)
684815|NCT00006223|adult acute myeloblastic leukemia with maturation (M2)
684816|NCT00006223|adult acute promyelocytic leukemia (M3)
684817|NCT00006223|adult acute myelomonocytic leukemia (M4)
684818|NCT00006223|adult acute monoblastic leukemia (M5a)
684819|NCT00006223|adult acute megakaryoblastic leukemia (M7)
684820|NCT00006223|adult acute monocytic leukemia (M5b)
684821|NCT00006223|adult acute minimally differentiated myeloid leukemia (M0)
684822|NCT00006222|AIDS-related Kaposi sarcoma
684823|NCT00006222|recurrent Kaposi sarcoma
684824|NCT00006221|stage IV adult Hodgkin lymphoma
684825|NCT00006221|recurrent adult Hodgkin lymphoma
684826|NCT00006221|stage IV cutaneous T-cell non-Hodgkin lymphoma
684827|NCT00006221|recurrent cutaneous T-cell non-Hodgkin lymphoma
684828|NCT00006221|small intestine lymphoma
684829|NCT00006221|unspecified adult solid tumor, protocol specific
684830|NCT00006221|stage IV grade 1 follicular lymphoma
684831|NCT00006221|stage IV grade 2 follicular lymphoma
684832|NCT00006221|stage IV grade 3 follicular lymphoma
684833|NCT00006221|stage IV adult diffuse small cleaved cell lymphoma
684834|NCT00006221|stage IV adult diffuse mixed cell lymphoma
684835|NCT00006221|stage IV adult diffuse large cell lymphoma
684836|NCT00006221|stage IV adult immunoblastic large cell lymphoma
684837|NCT00006221|stage IV adult lymphoblastic lymphoma
684838|NCT00006221|stage IV adult Burkitt lymphoma
684839|NCT00006221|recurrent grade 1 follicular lymphoma
684840|NCT00006221|recurrent grade 2 follicular lymphoma
684841|NCT00006221|recurrent grade 3 follicular lymphoma
684842|NCT00006221|recurrent adult diffuse small cleaved cell lymphoma
684843|NCT00006221|recurrent adult diffuse mixed cell lymphoma
684844|NCT00006221|recurrent adult diffuse large cell lymphoma
684845|NCT00006221|recurrent adult immunoblastic large cell lymphoma
684846|NCT00006221|recurrent adult lymphoblastic lymphoma
684847|NCT00006221|recurrent adult Burkitt lymphoma
684848|NCT00006221|stage IV adult T-cell leukemia/lymphoma
684849|NCT00006221|recurrent adult T-cell leukemia/lymphoma
684850|NCT00006221|primary central nervous system non-Hodgkin lymphoma
684851|NCT00006221|AIDS-related peripheral/systemic lymphoma
684852|NCT00006221|AIDS-related primary CNS lymphoma
684853|NCT00006221|intraocular lymphoma
684854|NCT00006221|stage IV mantle cell lymphoma
684855|NCT00006221|recurrent mantle cell lymphoma
684965|NCT00006190|Insulin resistance
684856|NCT00006221|angioimmunoblastic T-cell lymphoma
684857|NCT00006221|anaplastic large cell lymphoma
684858|NCT00006221|stage IV mycosis fungoides/Sezary syndrome
684859|NCT00006221|recurrent mycosis fungoides/Sezary syndrome
684860|NCT00006221|recurrent marginal zone lymphoma
684861|NCT00006221|recurrent small lymphocytic lymphoma
684862|NCT00006221|stage IV small lymphocytic lymphoma
684863|NCT00006221|stage IV marginal zone lymphoma
684864|NCT00006221|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
684865|NCT00006221|nodal marginal zone B-cell lymphoma
684866|NCT00006221|splenic marginal zone lymphoma
684867|NCT00006220|stage III adult Hodgkin lymphoma
684868|NCT00006220|stage IV adult Hodgkin lymphoma
684869|NCT00006220|recurrent adult Hodgkin lymphoma
684870|NCT00006220|refractory multiple myeloma
684871|NCT00006220|recurrent adult acute myeloid leukemia
684872|NCT00006220|recurrent adult acute lymphoblastic leukemia
684873|NCT00006220|relapsing chronic myelogenous leukemia
684874|NCT00006220|blastic phase chronic myelogenous leukemia
684875|NCT00006220|refractory anemia with excess blasts
684876|NCT00006220|refractory anemia with excess blasts in transformation
684877|NCT00006220|stage III grade 3 follicular lymphoma
684878|NCT00006220|stage III adult diffuse small cleaved cell lymphoma
684879|NCT00006220|stage III adult diffuse mixed cell lymphoma
684880|NCT00006220|stage III adult diffuse large cell lymphoma
684881|NCT00006220|stage III adult immunoblastic large cell lymphoma
684882|NCT00006220|stage III adult lymphoblastic lymphoma
684883|NCT00006220|stage III adult Burkitt lymphoma
684884|NCT00006220|stage IV grade 3 follicular lymphoma
684885|NCT00006220|stage IV adult diffuse small cleaved cell lymphoma
684886|NCT00006220|stage IV adult diffuse mixed cell lymphoma
684887|NCT00006220|stage IV adult diffuse large cell lymphoma
684888|NCT00006220|stage IV adult immunoblastic large cell lymphoma
684889|NCT00006220|stage IV adult lymphoblastic lymphoma
684890|NCT00006220|stage IV adult Burkitt lymphoma
684891|NCT00006220|recurrent grade 3 follicular lymphoma
684892|NCT00006220|recurrent adult diffuse small cleaved cell lymphoma
684893|NCT00006220|recurrent adult diffuse mixed cell lymphoma
684894|NCT00006220|recurrent adult diffuse large cell lymphoma
684895|NCT00006220|recurrent adult immunoblastic large cell lymphoma
684896|NCT00006220|recurrent adult lymphoblastic lymphoma
684897|NCT00006220|recurrent adult Burkitt lymphoma
684898|NCT00006220|previously treated myelodysplastic syndromes
684899|NCT00006220|stage III mantle cell lymphoma
684900|NCT00006220|stage IV mantle cell lymphoma
684901|NCT00006220|recurrent mantle cell lymphoma
684902|NCT00006220|childhood myelodysplastic syndromes
684903|NCT00006219|multiple myeloma
684904|NCT00006218|unspecified adult solid tumor, protocol specific
684905|NCT00006216|stage IA malignant mesothelioma
684906|NCT00006216|stage IB malignant mesothelioma
684907|NCT00006216|stage II malignant mesothelioma
684908|NCT00006216|stage III malignant mesothelioma
684909|NCT00006215|stage IIIB non-small cell lung cancer
684910|NCT00006215|stage IV non-small cell lung cancer
684911|NCT00006214|prostate cancer
684912|NCT00006212|stage II non-small cell lung cancer
684913|NCT00006212|stage IIIA non-small cell lung cancer
684914|NCT00006212|stage IIIB non-small cell lung cancer
684915|NCT00006211|Drug Therapy, Combination
684916|NCT00006211|HIV Protease Inhibitors
684917|NCT00006211|Reverse Transcriptase Inhibitors
684918|NCT00006211|Anti-HIV Agents
684919|NCT00006211|Viral Load
684920|NCT00006211|Nelfinavir
684921|NCT00006209|HIV-1
684922|NCT00006209|Immunity, Cellular
684923|NCT00006209|Drug Therapy, Combination
684924|NCT00006209|CD4-Positive T-Lymphocytes
684925|NCT00006209|Antigens
684926|NCT00006209|Anti-HIV Agents
684927|NCT00006209|Viral Load
684928|NCT00006209|tucaresol
684929|NCT00006208|HIV-1
684930|NCT00006208|Didanosine
684931|NCT00006208|Drug Therapy, Combination
684932|NCT00006208|Reverse Transcriptase Inhibitors
684933|NCT00006208|Anti-HIV Agents
684934|NCT00006208|Deoxycytidine
684935|NCT00006208|efavirenz
684936|NCT00006207|HIV Seropositivity
684937|NCT00006207|Dose-Response Relationship, Drug
684938|NCT00006207|HIV Seronegativity
684939|NCT00006207|Mucous Membrane
684940|NCT00006207|Ulcer
684941|NCT00006207|Vagina
684942|NCT00006207|Anti-HIV Agents
684943|NCT00006207|Sexual Abstinence
684944|NCT00006207|Irritants
684945|NCT00006207|PRO 2000
684946|NCT00006205|alcoholism
684947|NCT00006205|alcohol addiction
684948|NCT00006204|Alcoholism
684949|NCT00006204|Alcohol Dependence
684950|NCT00006204|Depression
684951|NCT00006204|Naltrexone
684952|NCT00006204|Fluoxetine
684953|NCT00006202|Serum levels of Lutein
684954|NCT00006202|Age-Related Macular Degeneration
684955|NCT00006202|Safety
684956|NCT00006202|Toxicity
684957|NCT00006199|solid tumor
684958|NCT00006196|Vitamin D resistance
684959|NCT00006194|sarcopenia
684960|NCT00006191|Antiepileptic Drugs
684961|NCT00006191|Motor Cortex
684962|NCT00006191|Myoclonus
684966|NCT00006190|Adipose tissue
684967|NCT00006188|Behcet's Disease
684968|NCT00006188|Sarcoidosis
684969|NCT00006188|Iritis
684970|NCT00006188|Choroiditis
684971|NCT00006188|Iridocyclitis
684972|NCT00006188|Retinal Disease
684973|NCT00006188|Cystoid Macular Edema
684974|NCT00006188|Uveitis
684975|NCT00006188|Intraocular Inflammation
684976|NCT00006188|Inflammatory Eye DIsease
684977|NCT00006187|Investigational Drug
684978|NCT00006186|dilutional coagulopathy
684979|NCT00006185|peripheral fat wasting
684980|NCT00006185|truncal adiposity
684981|NCT00006185|fat biopsy
684982|NCT00006185|muscle biopsy
684983|NCT00006185|intravenous lines
684984|NCT00006185|blood draws
684985|NCT00006185|insulin administration
684986|NCT00006185|sugar water
684987|NCT00006185|screening
684988|NCT00006184|Immunoablative
684989|NCT00006184|Mobilization
684990|NCT00006184|Apheresis
684991|NCT00006184|Multiple Myeloma
684992|NCT00006184|IgG Multiple Myeloma
684993|NCT00006184|IgA Multiple Myeloma
684994|NCT00006181|Health behavior change
684995|NCT00006181|Motivational interviewing
684996|NCT00006181|Motivational enhancement
684997|NCT00006181|Health counseling
684998|NCT00006181|Team intervention
684999|NCT00006181|One-on-one intervention
685000|NCT00006181|Physical activity
685001|NCT00006181|Exercise
685002|NCT00006181|Nutrition
685003|NCT00006181|Health assessments
685004|NCT00006181|Strength
685005|NCT00006181|Flexibility
685006|NCT00006181|Percent body fat
685007|NCT00006181|Social-learning theory
685008|NCT00006181|PHLAME
685009|NCT00006181|Fire fighters
685010|NCT00006181|Fire stations
685011|NCT00006181|Cancer
685012|NCT00006181|Cardiovascular diseases
685013|NCT00006180|Preventive Medicine
685014|NCT00006180|Women's Health
685015|NCT00006180|Bone Formation
685016|NCT00006180|Mood Disorders
685017|NCT00006180|Bone Resorption
685018|NCT00006180|Major Depression
685019|NCT00006180|Osteopenia
685020|NCT00006180|Osteoporosis
685021|NCT00006180|Bone Fracture
685022|NCT00006180|Bisphosphonate
685023|NCT00006180|Depression
685024|NCT00006180|Bone Density
685025|NCT00006180|Healthy Volunteer
685026|NCT00006180|HV
685027|NCT00006180|Normal Control
685028|NCT00006178|Renal Failure
685029|NCT00006178|Anti-rejection
685030|NCT00006178|Apoptosis
685031|NCT00006178|Polyclonal Antibody
685032|NCT00006178|Kidney Transplant
685033|NCT00006177|Emotion
685034|NCT00006177|Children and Adolescents
685035|NCT00006177|Affective Neuroscience
685036|NCT00006177|Bipolar Disorder
685037|NCT00006177|Child
685038|NCT00006177|Child Bipolar
685039|NCT00006177|BPD
685040|NCT00006177|Adolescent Bipolar
685041|NCT00006176|FENIB
685042|NCT00006176|Presenile Dementia
685043|NCT00006176|Progressive Myoclonic Epilepsy
685044|NCT00006176|Dementia
685045|NCT00006176|Early Onset Progressive Dementia
685046|NCT00006176|Familial Presenile Dementia
685047|NCT00006176|FDNIB
685048|NCT00006176|familial encephalopathy with neuroserpin inclusion bodies
685049|NCT00006176|Heredodegenerative Disorders, Nervous System
685050|NCT00006175|Cyclooxygenase
685051|NCT00006175|COX-1
685052|NCT00006175|COX-2
685053|NCT00006175|Prostanoids
685054|NCT00006175|P.C.R.
685055|NCT00006175|Healthy Volunteer
685056|NCT00006174|Precocious Puberty
685057|NCT00006174|Polyostotic
685058|NCT00006174|Fibrous Dysplasia
685059|NCT00006174|PFD
685060|NCT00006174|McCune-Albright Syndrome (MAS)
685061|NCT00006173|Atherosclerosis
685062|NCT00006173|Hypertension
685063|NCT00006173|Magnetic Resonance Angiography
685064|NCT00006172|Antidepressive Agents
685065|NCT00006172|Chronobiology
685066|NCT00006172|Chronotherapy
685067|NCT00006172|Circadian rhythms
685068|NCT00006172|Depressive Disorder
685069|NCT00006172|Ions
685070|NCT00006172|Light
685071|NCT00006172|Lighting
685072|NCT00006172|Mood disorders
685073|NCT00006172|Phototherapy.
685074|NCT00006171|HHV-8
685075|NCT00006171|Pathophysiology
685076|NCT00006171|AIDS
685077|NCT00006171|Cancer
685078|NCT00006171|Anti-Retroviral
685079|NCT00006171|Kaposi's Sarcoma
685080|NCT00006171|HIV
685081|NCT00006170|smoking cessation
685082|NCT00006170|Women
685083|NCT00006170|bupropion
685084|NCT00006170|weight concerns
685085|NCT00006170|weight
685086|NCT00006169|Nutrition
685087|NCT00006169|Behavior Therapy
685088|NCT00006169|Cystic Fibrosis
685089|NCT00006168|primary biliary cirrhosis
685090|NCT00006168|Ursodeoxycholic acid
685091|NCT00006168|UDCA
685092|NCT00006168|MTX
685093|NCT00006168|Hepatology
685094|NCT00006168|methotrexate
685095|NCT00006168|liver
685096|NCT00006167|oxandrolone
685097|NCT00006167|AIDS wasting
685098|NCT00006167|strength training
685099|NCT00006167|progressive resistance training
685100|NCT00006167|exercise
685101|NCT00006167|dietary intervention
685102|NCT00006166|refractory ascites
685103|NCT00006166|paracenteses
685104|NCT00006165|Native Hawaiian
685105|NCT00006165|Diabetes Mellitus
685106|NCT00006165|Lifestyle Intervention
685107|NCT00006165|Family Support
685108|NCT00006165|Diabetes Mellitus, at-risk
685109|NCT00006164|liver disease
685110|NCT00006164|hepatitis c virus
685111|NCT00006164|antiviral agent
685112|NCT00006164|cirrhosis
685113|NCT00006163|diabetes
685114|NCT00006163|self-management
685115|NCT00006163|randomized trial
685116|NCT00006163|RE-AIM evaluation
685117|NCT00006163|participation
685118|NCT00006163|maintenance
685119|NCT00006163|community resources
685120|NCT00006163|dietary change
685121|NCT00006162|low fat diet
685122|NCT00006162|aerobic exercise
685123|NCT00006162|impaired glucose tolerance
685124|NCT00006162|Japanese Americans
685125|NCT00006162|metabolic risk factors
685126|NCT00006161|TIPS
685127|NCT00006161|DSRS
685128|NCT00006161|Varices
685129|NCT00006161|Variceal bleeding
685130|NCT00006161|Splenorenal Shunt
685131|NCT00006161|Transjugular Intrahepatic Portosystemic Shunt
685132|NCT00006161|Cirrhosis
685133|NCT00006161|Portal hypertension
685134|NCT00006161|Liver disease
685135|NCT00006159|diabetes
685136|NCT00006159|lifestyle intervention
685137|NCT00006159|Native American
685138|NCT00006159|community intervention
685139|NCT00006159|diet
685140|NCT00006159|exercise
685141|NCT00006158|AIDS
685142|NCT00006158|HIV
685143|NCT00006158|weight loss
685144|NCT00006158|Wasting Syndrome
685145|NCT00006158|testosterone
685146|NCT00006158|androgen levels
685147|NCT00006158|hormones
685148|NCT00006157|Functional bowel disorder
685149|NCT00006157|Irritable bowel syndrome
685150|NCT00006157|Painful constipation
685151|NCT00006157|Unspecified functional bowel disorder
685152|NCT00006157|Chronic functional abdominal pain
685153|NCT00006157|Cognitive-behavioral psychological treatment
685154|NCT00006157|IBS
685155|NCT00006157|CFAP
685156|NCT00006156|Ovarian Failure
685157|NCT00006156|Ovary
685158|NCT00006156|Aging
685159|NCT00006156|Healthy Volunteer
685160|NCT00006156|Primary Ovarian Insufficiency(POI)
685161|NCT00006156|Premature Menopause
685162|NCT00006156|Premature Ovarian Failure (POF)
685163|NCT00006155|DNA Damage
685164|NCT00006155|DNA Repair
685165|NCT00006155|FLK-1
685166|NCT00006155|Pharmacokinetics
685167|NCT00006155|VEGF
685168|NCT00006155|Fallopian Tube Cancer
685169|NCT00006155|Ovarian Cancer
685170|NCT00006155|Platinum-Refractory Disease
685171|NCT00006154|Interleukin-2
685172|NCT00006154|Didanosine
685173|NCT00006154|Drug Therapy, Combination
685174|NCT00006154|Stavudine
685175|NCT00006154|HIV Protease Inhibitors
685176|NCT00006154|Ritonavir
685177|NCT00006154|Indinavir
685178|NCT00006154|Virus Latency
685179|NCT00006154|Reverse Transcriptase Inhibitors
685180|NCT00006154|Anti-HIV Agents
685181|NCT00006154|abacavir
685182|NCT00006154|efavirenz
685183|NCT00006154|Acute Infection
685184|NCT00006153|HIV Antibodies
685185|NCT00006153|Immunity, Cellular
685186|NCT00006153|Drug Therapy, Combination
685187|NCT00006153|Anti-HIV Agents
685188|NCT00006153|remune
685189|NCT00006153|HIV Therapeutic Vaccine
685190|NCT00006152|Drug Therapy, Combination
685191|NCT00006152|HIV Protease Inhibitors
685192|NCT00006152|Ritonavir
685193|NCT00006152|VX 478
685194|NCT00006152|Reverse Transcriptase Inhibitors
685195|NCT00006152|Anti-HIV Agents
685196|NCT00006152|Viral Load
685197|NCT00006152|abacavir
685198|NCT00006151|nicotine fading
685199|NCT00006151|Accu Drop
685200|NCT00006151|cigarette tapering
685201|NCT00006151|smoking cessation
685202|NCT00006151|motivational interviewing
685203|NCT00006150|IgE
685204|NCT00006150|Fractures
685205|NCT00006150|Pneumonia
685206|NCT00006150|Scoliosis
685207|NCT00006150|Eczema
685208|NCT00006150|Job's Syndrome
685209|NCT00006150|Hyperimmunologobulin E Syndrome
685210|NCT00006150|HIE Syndrome
685211|NCT00006148|Granulocyte Colony - Stimulation Factor
685212|NCT00006148|Peripheral Blood Stem Cells
685213|NCT00006148|Splenomegaly
685214|NCT00006145|Ganciclovir
685215|NCT00006145|Cytomegalovirus
685216|NCT00006145|Cytomegalovirus Infections
685217|NCT00006145|Administration, Oral
685218|NCT00006145|Antiviral Agents
685219|NCT00006145|Polymerase Chain Reaction
685220|NCT00006145|Viremia
685221|NCT00006145|DNA, Viral
685222|NCT00006144|Drug Therapy, Combination
685223|NCT00006144|Stavudine
685224|NCT00006144|HIV Protease Inhibitors
685225|NCT00006144|Cohort Studies
685226|NCT00006144|Ritonavir
685227|NCT00006144|Disease Progression
685228|NCT00006144|Antigens, CD
685229|NCT00006144|Reverse Transcriptase Inhibitors
685230|NCT00006144|Anti-HIV Agents
685231|NCT00006144|Immunophenotyping
685232|NCT00006144|Deoxycytidine
685233|NCT00006143|Treatment Outcome
685234|NCT00006143|serostim
685235|NCT00006143|Developmental Disabilities
685236|NCT00006142|inborn errors of metabolism
685237|NCT00006142|phenylketonuria
685238|NCT00006142|rare disease
685239|NCT00006138|disease-related problem/condition
685240|NCT00006138|genetic diseases and dysmorphic syndromes
685241|NCT00006138|hematologic disorders
685242|NCT00006138|osteoporosis
685243|NCT00006138|rare disease
685244|NCT00006138|thalassemia major
685245|NCT00006137|IgA glomerulonephritis
685246|NCT00006137|rare disease
685247|NCT00006137|renal and genitourinary disorders
685248|NCT00006136|genetic diseases and dysmorphic syndromes
685249|NCT00006136|hematologic disorders
685250|NCT00006136|rare disease
685251|NCT00006136|thalassemia intermedia
685252|NCT00006135|herpes simplex virus infection
685253|NCT00006135|herpesvirus infection
685254|NCT00006135|immunologic disorders and infectious disorders
685255|NCT00006135|rare disease
685256|NCT00006135|viral infection
685257|NCT00006134|arthritis & connective tissue diseases
685258|NCT00006134|immunologic disorders and infectious disorders
685259|NCT00006134|rare disease
685260|NCT00006134|systemic lupus erythematosus
685261|NCT00006133|arthritis & connective tissue diseases
685262|NCT00006133|immunologic disorders and infectious disorders
685263|NCT00006133|rare disease
685264|NCT00006133|systemic lupus erythematosus
685265|NCT00006132|herpes simplex virus infection
685266|NCT00006132|herpes virus infection
685267|NCT00006132|immunologic disorders and infectious disorders
685268|NCT00006132|rare disease
685269|NCT00006132|viral infection
685270|NCT00006130|arthritis & connective tissue diseases
685271|NCT00006130|avascular necrosis
685272|NCT00006130|disease-related problem/condition
685273|NCT00006130|genetic diseases and dysmorphic syndromes
685274|NCT00006130|hematologic disorders
685275|NCT00006130|pain
685276|NCT00006130|rare disease
685277|NCT00006130|sickle cell anemia
685278|NCT00006129|burns
685279|NCT00006129|dermatologic disorders
685280|NCT00006129|rare disease
685281|NCT00006128|neurologic and psychiatric disorders
685282|NCT00006128|rare disease
685283|NCT00006127|Fanconi's anemia
685284|NCT00006127|aplastic anemia
685285|NCT00006127|hematologic disorders
685286|NCT00006127|rare disease
685287|NCT00006126|stage IV breast cancer
685288|NCT00006126|recurrent breast cancer
685289|NCT00006126|stage IV renal cell cancer
685290|NCT00006126|recurrent renal cell cancer
685291|NCT00006126|extensive stage small cell lung cancer
685292|NCT00006126|recurrent small cell lung cancer
685293|NCT00006126|stage II malignant testicular germ cell tumor
685294|NCT00006126|stage III malignant testicular germ cell tumor
685295|NCT00006126|recurrent malignant testicular germ cell tumor
685296|NCT00006126|stage IV melanoma
685297|NCT00006126|recurrent melanoma
685298|NCT00006125|recurrent grade 3 follicular lymphoma
685299|NCT00006125|recurrent adult diffuse large cell lymphoma
685300|NCT00006125|recurrent adult Burkitt lymphoma
685301|NCT00006125|anaplastic large cell lymphoma
685302|NCT00006123|stage IV breast cancer
685303|NCT00006122|untreated adult acute myeloid leukemia
685304|NCT00006122|adult acute erythroid leukemia (M6)
685305|NCT00006122|adult acute myeloblastic leukemia without maturation (M1)
685306|NCT00006122|adult acute myeloblastic leukemia with maturation (M2)
685307|NCT00006122|adult acute myelomonocytic leukemia (M4)
685308|NCT00006122|adult acute monoblastic leukemia (M5a)
685309|NCT00006122|adult acute megakaryoblastic leukemia (M7)
685310|NCT00006122|secondary acute myeloid leukemia
685311|NCT00006122|adult acute monocytic leukemia (M5b)
685312|NCT00006122|adult acute minimally differentiated myeloid leukemia (M0)
685313|NCT00006121|stage III breast cancer
685314|NCT00006121|stage IV breast cancer
685315|NCT00006121|recurrent breast cancer
685316|NCT00006120|stage IV breast cancer
685317|NCT00006120|stage IIIA breast cancer
685318|NCT00006120|recurrent breast cancer
685319|NCT00006120|stage IIIB breast cancer
685320|NCT00006119|recurrent adult brain tumor
685321|NCT00006119|adult grade III meningioma
685322|NCT00006119|adult grade I meningioma
685323|NCT00006119|adult grade II meningioma
685324|NCT00006118|stage III bladder cancer
685325|NCT00006118|stage IV bladder cancer
685326|NCT00006118|transitional cell carcinoma of the bladder
685327|NCT00006117|stage III pancreatic cancer
685328|NCT00006117|stage IV pancreatic cancer
685329|NCT00006117|adenocarcinoma of the pancreas
685330|NCT00006116|recurrent non-small cell lung cancer
685331|NCT00006116|squamous cell lung cancer
685332|NCT00006116|large cell lung cancer
685333|NCT00006116|stage IIIB non-small cell lung cancer
685334|NCT00006116|stage IV non-small cell lung cancer
685335|NCT00006116|adenocarcinoma of the lung
685336|NCT00006115|stage IV colon cancer
685337|NCT00006115|stage IV rectal cancer
685338|NCT00006115|recurrent colon cancer
685339|NCT00006115|recurrent rectal cancer
685340|NCT00006115|adenocarcinoma of the colon
685341|NCT00006115|adenocarcinoma of the rectum
685342|NCT00006114|adenocarcinoma of the prostate
685343|NCT00006114|stage IV prostate cancer
685344|NCT00006114|recurrent prostate cancer
685345|NCT00006113|stage III melanoma
685346|NCT00006113|stage IV melanoma
685347|NCT00006113|recurrent melanoma
685348|NCT00006112|stage IV colon cancer
685349|NCT00006112|stage IV rectal cancer
685350|NCT00006112|adenocarcinoma of the colon
685351|NCT00006112|adenocarcinoma of the rectum
685352|NCT00006112|carcinoma of the appendix
685353|NCT00006112|primary peritoneal cavity cancer
685354|NCT00006111|stage II bladder cancer
685355|NCT00006111|stage III bladder cancer
685356|NCT00006111|stage IV bladder cancer
685357|NCT00006111|anterior urethral cancer
685358|NCT00006111|posterior urethral cancer
685359|NCT00006111|urethral cancer associated with invasive bladder cancer
685360|NCT00006111|metastatic transitional cell cancer of the renal pelvis and ureter
685361|NCT00006111|regional transitional cell cancer of the renal pelvis and ureter
685362|NCT00006110|stage II breast cancer
685363|NCT00006110|stage IV breast cancer
685364|NCT00006110|stage IIIA breast cancer
685365|NCT00006110|stage IIIB breast cancer
685366|NCT00006110|stage IIIC breast cancer
685367|NCT00006110|inflammatory breast cancer
685368|NCT00006108|stage IV breast cancer
685369|NCT00006108|recurrent breast cancer
685370|NCT00006107|recurrent metastatic squamous neck cancer with occult primary
685371|NCT00006107|metastatic squamous neck cancer with occult primary squamous cell carcinoma
685372|NCT00006107|stage III squamous cell carcinoma of the lip and oral cavity
685373|NCT00006107|stage IV squamous cell carcinoma of the lip and oral cavity
685374|NCT00006107|recurrent squamous cell carcinoma of the lip and oral cavity
685375|NCT00006107|stage III squamous cell carcinoma of the oropharynx
685376|NCT00006107|stage IV squamous cell carcinoma of the oropharynx
685377|NCT00006107|recurrent squamous cell carcinoma of the oropharynx
685378|NCT00006107|stage III squamous cell carcinoma of the nasopharynx
685379|NCT00006107|stage IV squamous cell carcinoma of the nasopharynx
685380|NCT00006107|recurrent squamous cell carcinoma of the nasopharynx
685381|NCT00006107|stage III squamous cell carcinoma of the hypopharynx
685382|NCT00006107|stage IV squamous cell carcinoma of the hypopharynx
685383|NCT00006107|recurrent squamous cell carcinoma of the hypopharynx
685384|NCT00006107|stage III squamous cell carcinoma of the larynx
685385|NCT00006107|stage IV squamous cell carcinoma of the larynx
685386|NCT00006107|recurrent squamous cell carcinoma of the larynx
685387|NCT00006107|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
685388|NCT00006107|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
685389|NCT00006107|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
685390|NCT00006107|recurrent salivary gland cancer
685391|NCT00006107|stage III salivary gland cancer
685392|NCT00006107|stage IV salivary gland cancer
685393|NCT00006107|salivary gland squamous cell carcinoma
685394|NCT00006107|recurrent lymphoepithelioma of the nasopharynx
685395|NCT00006107|recurrent lymphoepithelioma of the oropharynx
685396|NCT00006107|stage III lymphoepithelioma of the nasopharynx
685397|NCT00006107|stage III lymphoepithelioma of the oropharynx
685398|NCT00006107|stage IV lymphoepithelioma of the nasopharynx
685399|NCT00006107|stage IV lymphoepithelioma of the oropharynx
685400|NCT00006106|adult solid tumor
685401|NCT00006106|body system/site cancer
685402|NCT00006106|cancer
685403|NCT00006106|cellular diagnosis, hypopharyngeal cancer
685404|NCT00006106|cellular diagnosis, laryngeal cancer
685405|NCT00006106|cellular diagnosis, lip and oral cavity cancer
685406|NCT00006106|cellular diagnosis, nasopharyngeal cancer
685407|NCT00006106|cellular diagnosis, oropharyngeal cancer
685408|NCT00006106|cellular diagnosis, paranasal sinus and nasal cavity cancer
685409|NCT00006106|head and neck cancer
685410|NCT00006106|hypopharyngeal cancer
685411|NCT00006106|hypopharyngeal squamous cell carcinoma
685412|NCT00006106|laryngeal cancer
685413|NCT00006106|laryngeal squamous cell carcinoma
685414|NCT00006106|lip and oral cavity cancer
685415|NCT00006106|lip and oral cavity squamous cell carcinoma
685416|NCT00006106|metastatic squamous neck cancer with occult primary
685417|NCT00006106|nasopharyngeal cancer
685418|NCT00006106|nasopharyngeal squamous cell carcinoma
685419|NCT00006106|oropharyngeal cancer
685420|NCT00006106|oropharyngeal squamous cell carcinoma
685421|NCT00006106|paranasal sinus and nasal cavity cancer
685422|NCT00006106|paranasal sinus and nasal cavity squamous cell carcinoma
685423|NCT00006106|recurrent hypopharyngeal cancer
685424|NCT00006106|recurrent laryngeal cancer
685425|NCT00006106|recurrent lip and oral cavity cancer
685426|NCT00006106|recurrent metastatic squamous neck cancer with occult primary
685427|NCT00006106|recurrent nasopharyngeal cancer
685428|NCT00006106|recurrent oropharyngeal cancer
685429|NCT00006106|recurrent paranasal sinus and nasal cavity cancer
685430|NCT00006106|recurrent squamous cell carcinoma of the hypopharynx
685431|NCT00006106|recurrent squamous cell carcinoma of the larynx
685432|NCT00006106|recurrent squamous cell carcinoma of the lip and oral cavity
685433|NCT00006106|recurrent squamous cell carcinoma of the nasopharynx
685434|NCT00006106|recurrent squamous cell carcinoma of the oropharynx
685435|NCT00006106|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
685436|NCT00006106|solid tumor
685437|NCT00006106|stage III hypopharyngeal cancer
685438|NCT00006106|stage III laryngeal cancer
685439|NCT00006106|stage III lip and oral cavity cancer
685440|NCT00006106|stage III nasopharyngeal cancer
685441|NCT00006106|stage III oropharyngeal cancer
685442|NCT00006106|stage III paranasal sinus and nasal cavity cancer
685443|NCT00006106|stage III squamous cell carcinoma of the hypopharynx
685444|NCT00006106|stage III squamous cell carcinoma of the larynx
685445|NCT00006106|stage III squamous cell carcinoma of the lip and oral cavity
685446|NCT00006106|stage III squamous cell carcinoma of the nasopharynx
685447|NCT00006106|stage III squamous cell carcinoma of the oropharynx
685448|NCT00006106|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
685449|NCT00006106|stage IV hypopharyngeal cancer
685450|NCT00006106|stage IV laryngeal cancer
685451|NCT00006106|stage IV lip and oral cavity cancer
685452|NCT00006106|stage IV nasopharyngeal cancer
685453|NCT00006106|stage IV oropharyngeal cancer
685454|NCT00006106|stage IV paranasal sinus and nasal cavity cancer
685455|NCT00006106|stage IV squamous cell carcinoma of the hypopharynx
685456|NCT00006106|stage IV squamous cell carcinoma of the larynx
685457|NCT00006106|stage IV squamous cell carcinoma of the lip and oral cavity
685458|NCT00006106|stage IV squamous cell carcinoma of the nasopharynx
685459|NCT00006106|stage IV squamous cell carcinoma of the oropharynx
685460|NCT00006106|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
685461|NCT00006106|stage, hypopharyngeal cancer
685462|NCT00006106|stage, laryngeal cancer
685463|NCT00006106|stage, lip and oral cavity cancer
685464|NCT00006106|stage, metastatic squamous neck cancer with occult primary
685465|NCT00006106|stage, nasopharyngeal cancer
685466|NCT00006106|stage, oropharyngeal cancer
685467|NCT00006106|stage, paranasal sinus and nasal cavity cancer
685468|NCT00006105|stage II bladder cancer
685469|NCT00006105|stage III bladder cancer
685470|NCT00006105|stage IV bladder cancer
685471|NCT00006105|drug/agent toxicity by tissue/organ
685472|NCT00006104|stage IV breast cancer
685473|NCT00006104|recurrent breast cancer
685474|NCT00006103|stage III colon cancer
685475|NCT00006103|stage IV colon cancer
685476|NCT00006103|stage III rectal cancer
685477|NCT00006103|stage IV rectal cancer
685478|NCT00006103|recurrent colon cancer
685479|NCT00006103|recurrent rectal cancer
685480|NCT00006103|adenocarcinoma of the colon
685481|NCT00006103|adenocarcinoma of the rectum
685482|NCT00006102|childhood infratentorial ependymoma
685483|NCT00006102|recurrent childhood rhabdomyosarcoma
685484|NCT00006102|childhood supratentorial ependymoma
685485|NCT00006102|childhood craniopharyngioma
685486|NCT00006102|disseminated neuroblastoma
685487|NCT00006102|recurrent neuroblastoma
685488|NCT00006102|intraocular retinoblastoma
685489|NCT00006102|extraocular retinoblastoma
685490|NCT00006102|stage III childhood lymphoblastic lymphoma
685491|NCT00006102|stage IV childhood lymphoblastic lymphoma
685492|NCT00006102|recurrent childhood lymphoblastic lymphoma
685493|NCT00006102|childhood central nervous system germ cell tumor
685494|NCT00006102|unspecified childhood solid tumor, protocol specific
685495|NCT00006102|childhood high-grade cerebral astrocytoma
685496|NCT00006102|childhood oligodendroglioma
685497|NCT00006102|childhood choroid plexus tumor
685498|NCT00006102|childhood grade I meningioma
685499|NCT00006102|childhood grade II meningioma
685500|NCT00006102|childhood grade III meningioma
685501|NCT00006102|stage III childhood large cell lymphoma
685502|NCT00006102|stage IV childhood small noncleaved cell lymphoma
685503|NCT00006102|stage IV childhood large cell lymphoma
685504|NCT00006102|recurrent childhood small noncleaved cell lymphoma
685505|NCT00006102|recurrent childhood large cell lymphoma
685506|NCT00006102|recurrent childhood brain stem glioma
685507|NCT00006102|recurrent childhood supratentorial primitive neuroectodermal tumor
685508|NCT00006102|recurrent childhood cerebellar astrocytoma
685509|NCT00006102|recurrent childhood cerebral astrocytoma
685510|NCT00006102|recurrent childhood medulloblastoma
685511|NCT00006102|recurrent childhood visual pathway and hypothalamic glioma
685512|NCT00006102|previously treated childhood rhabdomyosarcoma
685513|NCT00006102|recurrent childhood ependymoma
685514|NCT00006102|recurrent retinoblastoma
685515|NCT00006101|stage I prostate cancer
685516|NCT00006100|recurrent adult Hodgkin lymphoma
685517|NCT00006099|ovarian epithelial cancer
685518|NCT00006098|recurrent adult Hodgkin lymphoma
685519|NCT00006098|refractory multiple myeloma
685520|NCT00006098|recurrent adult acute myeloid leukemia
685521|NCT00006098|recurrent adult acute lymphoblastic leukemia
685522|NCT00006098|relapsing chronic myelogenous leukemia
685523|NCT00006098|refractory chronic lymphocytic leukemia
685524|NCT00006098|refractory anemia with excess blasts
685525|NCT00006098|refractory anemia with excess blasts in transformation
685526|NCT00006098|recurrent grade 1 follicular lymphoma
685527|NCT00006098|recurrent grade 2 follicular lymphoma
685528|NCT00006098|recurrent grade 3 follicular lymphoma
685529|NCT00006098|recurrent adult diffuse small cleaved cell lymphoma
685530|NCT00006098|recurrent adult diffuse mixed cell lymphoma
685531|NCT00006098|recurrent adult diffuse large cell lymphoma
685532|NCT00006098|recurrent adult immunoblastic large cell lymphoma
685533|NCT00006098|recurrent adult lymphoblastic lymphoma
685534|NCT00006098|recurrent adult Burkitt lymphoma
685535|NCT00006098|previously treated myelodysplastic syndromes
685536|NCT00006098|recurrent mantle cell lymphoma
685537|NCT00006098|recurrent marginal zone lymphoma
685538|NCT00006098|recurrent small lymphocytic lymphoma
685539|NCT00006098|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
685540|NCT00006098|nodal marginal zone B-cell lymphoma
685541|NCT00006098|splenic marginal zone lymphoma
685542|NCT00006097|refractory chronic lymphocytic leukemia
685543|NCT00006097|B-cell chronic lymphocytic leukemia
685544|NCT00006096|stage I vulvar cancer
685545|NCT00006096|stage II vulvar cancer
685546|NCT00006096|stage III vulvar cancer
685547|NCT00006096|stage IVB vulvar cancer
685548|NCT00006096|squamous cell carcinoma of the vulva
685549|NCT00006095|unspecified childhood solid tumor, protocol specific
685550|NCT00006093|recurrent adult brain tumor
685551|NCT00006093|adult glioblastoma
685552|NCT00006093|adult anaplastic astrocytoma
685553|NCT00006093|adult anaplastic oligodendroglioma
685554|NCT00006093|adult giant cell glioblastoma
685555|NCT00006093|adult gliosarcoma
685556|NCT00006092|recurrent adult acute lymphoblastic leukemia
685557|NCT00006092|relapsing chronic myelogenous leukemia
685558|NCT00006092|blastic phase chronic myelogenous leukemia
685559|NCT00006092|chronic myelogenous leukemia, BCR-ABL1 positive
685560|NCT00006092|lymphoid leukemia
685561|NCT00006092|myeloid and monocytic leukemia
685562|NCT00006091|relapsing chronic myelogenous leukemia
685563|NCT00006091|chronic phase chronic myelogenous leukemia
685564|NCT00006091|chronic myelogenous leukemia, BCR-ABL1 positive
685565|NCT00006090|refractory chronic lymphocytic leukemia
685566|NCT00006090|B-cell chronic lymphocytic leukemia
685567|NCT00006088|unspecified adult solid tumor, protocol specific
685568|NCT00006087|non-small cell lung cancer
685569|NCT00006087|small cell lung cancer
685570|NCT00006086|unspecified adult solid tumor, protocol specific
685571|NCT00006085|unspecified adult solid tumor, protocol specific
685572|NCT00006084|recurrent adult acute myeloid leukemia
685573|NCT00006084|adult acute erythroid leukemia (M6)
685574|NCT00006084|adult acute myeloblastic leukemia without maturation (M1)
685575|NCT00006084|adult acute myeloblastic leukemia with maturation (M2)
685576|NCT00006084|adult acute myelomonocytic leukemia (M4)
685577|NCT00006084|adult acute monoblastic leukemia (M5a)
685578|NCT00006084|adult acute megakaryoblastic leukemia (M7)
685579|NCT00006084|secondary acute myeloid leukemia
685580|NCT00006084|adult acute monocytic leukemia (M5b)
685581|NCT00006084|adult acute minimally differentiated myeloid leukemia (M0)
685582|NCT00006083|stage I adult Hodgkin lymphoma
685583|NCT00006083|stage II adult Hodgkin lymphoma
685584|NCT00006083|stage III adult Hodgkin lymphoma
685585|NCT00006083|stage IV adult Hodgkin lymphoma
685586|NCT00006083|monoclonal gammopathy of undetermined significance
685587|NCT00006083|recurrent adult Hodgkin lymphoma
685588|NCT00006083|stage I cutaneous T-cell non-Hodgkin lymphoma
685589|NCT00006083|stage II cutaneous T-cell non-Hodgkin lymphoma
685590|NCT00006083|stage III cutaneous T-cell non-Hodgkin lymphoma
685591|NCT00006083|stage IV cutaneous T-cell non-Hodgkin lymphoma
685592|NCT00006083|recurrent cutaneous T-cell non-Hodgkin lymphoma
685593|NCT00006083|stage IB cervical cancer
685594|NCT00006083|Burkitt lymphoma
685595|NCT00006083|isolated plasmacytoma of bone
685596|NCT00006083|extramedullary plasmacytoma
685597|NCT00006083|refractory multiple myeloma
685598|NCT00006083|stage 0 chronic lymphocytic leukemia
685599|NCT00006083|stage I multiple myeloma
685600|NCT00006083|stage II multiple myeloma
685601|NCT00006083|stage III multiple myeloma
685602|NCT00006083|stage I chronic lymphocytic leukemia
685603|NCT00006083|stage II chronic lymphocytic leukemia
685604|NCT00006083|stage IV chronic lymphocytic leukemia
685605|NCT00006083|recurrent adult acute myeloid leukemia
685606|NCT00006083|recurrent adult acute lymphoblastic leukemia
685607|NCT00006083|relapsing chronic myelogenous leukemia
685608|NCT00006083|refractory chronic lymphocytic leukemia
685609|NCT00006083|unspecified adult solid tumor, protocol specific
685610|NCT00006083|chronic phase chronic myelogenous leukemia
685611|NCT00006083|accelerated phase chronic myelogenous leukemia
685612|NCT00006083|blastic phase chronic myelogenous leukemia
685613|NCT00006083|meningeal chronic myelogenous leukemia
685614|NCT00006083|untreated adult acute lymphoblastic leukemia
685615|NCT00006083|untreated adult acute myeloid leukemia
685616|NCT00006083|adult acute myeloid leukemia in remission
685617|NCT00006083|adult acute lymphoblastic leukemia in remission
685618|NCT00006083|chronic idiopathic myelofibrosis
685619|NCT00006083|essential thrombocythemia
685620|NCT00006083|untreated hairy cell leukemia
685621|NCT00006083|progressive hairy cell leukemia, initial treatment
685622|NCT00006083|refractory hairy cell leukemia
685623|NCT00006083|stage I grade 1 follicular lymphoma
685624|NCT00006083|stage I grade 2 follicular lymphoma
685625|NCT00006083|stage I grade 3 follicular lymphoma
685626|NCT00006083|stage I adult diffuse small cleaved cell lymphoma
685627|NCT00006083|stage I adult diffuse mixed cell lymphoma
685628|NCT00006083|stage I adult diffuse large cell lymphoma
685629|NCT00006083|stage I adult immunoblastic large cell lymphoma
685630|NCT00006083|stage I adult lymphoblastic lymphoma
685631|NCT00006083|stage I adult Burkitt lymphoma
685632|NCT00006083|chronic myelomonocytic leukemia
685633|NCT00006083|T-cell large granular lymphocyte leukemia
685634|NCT00006083|acute undifferentiated leukemia
685635|NCT00006083|stage III grade 1 follicular lymphoma
685636|NCT00006083|stage III grade 2 follicular lymphoma
685637|NCT00006083|stage III grade 3 follicular lymphoma
685638|NCT00006083|stage III adult diffuse small cleaved cell lymphoma
685639|NCT00006083|stage III adult diffuse mixed cell lymphoma
685640|NCT00006083|stage III adult diffuse large cell lymphoma
685641|NCT00006083|stage III adult immunoblastic large cell lymphoma
685642|NCT00006083|stage III adult lymphoblastic lymphoma
685643|NCT00006083|stage III adult Burkitt lymphoma
685644|NCT00006083|stage IV grade 1 follicular lymphoma
685645|NCT00006083|stage IV grade 2 follicular lymphoma
685646|NCT00006083|stage IV grade 3 follicular lymphoma
685647|NCT00006083|stage IV adult diffuse small cleaved cell lymphoma
685648|NCT00006083|stage IV adult diffuse mixed cell lymphoma
685649|NCT00006083|stage IV adult diffuse large cell lymphoma
685650|NCT00006083|stage IV adult immunoblastic large cell lymphoma
685651|NCT00006083|stage IV adult lymphoblastic lymphoma
685652|NCT00006083|stage IV adult Burkitt lymphoma
685653|NCT00006083|recurrent grade 1 follicular lymphoma
685654|NCT00006083|recurrent grade 2 follicular lymphoma
685655|NCT00006083|recurrent grade 3 follicular lymphoma
685656|NCT00006083|recurrent adult diffuse small cleaved cell lymphoma
685657|NCT00006083|recurrent adult diffuse mixed cell lymphoma
685658|NCT00006083|recurrent adult diffuse large cell lymphoma
685659|NCT00006083|recurrent adult immunoblastic large cell lymphoma
685660|NCT00006083|recurrent adult lymphoblastic lymphoma
685661|NCT00006083|recurrent adult Burkitt lymphoma
685662|NCT00006083|stage I adult T-cell leukemia/lymphoma
685663|NCT00006083|stage II adult T-cell leukemia/lymphoma
685664|NCT00006083|stage III adult T-cell leukemia/lymphoma
685665|NCT00006083|stage IV adult T-cell leukemia/lymphoma
685666|NCT00006083|recurrent adult T-cell leukemia/lymphoma
685667|NCT00006083|secondary acute myeloid leukemia
685668|NCT00006083|de novo myelodysplastic syndromes
685669|NCT00006083|previously treated myelodysplastic syndromes
685670|NCT00006083|secondary myelodysplastic syndromes
685671|NCT00006083|primary central nervous system lymphoma
685672|NCT00006083|prolymphocytic leukemia
685673|NCT00006083|primary systemic amyloidosis
685674|NCT00006083|veno-occlusive disease
685675|NCT00006083|stage I mantle cell lymphoma
685676|NCT00006083|contiguous stage II grade 1 follicular lymphoma
685677|NCT00006083|contiguous stage II grade 2 follicular lymphoma
685678|NCT00006083|contiguous stage II grade 3 follicular lymphoma
685679|NCT00006083|contiguous stage II adult diffuse small cleaved cell lymphoma
685680|NCT00006083|contiguous stage II mantle cell lymphoma
685681|NCT00006083|contiguous stage II adult diffuse mixed cell lymphoma
685682|NCT00006083|contiguous stage II adult immunoblastic large cell lymphoma
685683|NCT00006083|contiguous stage II adult diffuse large cell lymphoma
685684|NCT00006083|contiguous stage II adult Burkitt lymphoma
685685|NCT00006083|contiguous stage II adult lymphoblastic lymphoma
685686|NCT00006083|noncontiguous stage II grade 1 follicular lymphoma
685687|NCT00006083|noncontiguous stage II grade 2 follicular lymphoma
685688|NCT00006083|noncontiguous stage II grade 3 follicular lymphoma
685689|NCT00006083|noncontiguous stage II adult diffuse small cleaved cell lymphoma
685690|NCT00006083|noncontiguous stage II mantle cell lymphoma
685691|NCT00006083|noncontiguous stage II adult diffuse mixed cell lymphoma
685692|NCT00006083|noncontiguous stage II adult immunoblastic large cell lymphoma
685693|NCT00006083|noncontiguous stage II adult diffuse large cell lymphoma
685694|NCT00006083|noncontiguous stage II adult Burkitt lymphoma
685695|NCT00006083|noncontiguous stage II adult lymphoblastic lymphoma
685696|NCT00006083|stage III mantle cell lymphoma
685697|NCT00006083|stage IV mantle cell lymphoma
685698|NCT00006083|recurrent mantle cell lymphoma
685699|NCT00006083|angioimmunoblastic T-cell lymphoma
685700|NCT00006083|anaplastic large cell lymphoma
685701|NCT00006083|noncontiguous stage II small lymphocytic lymphoma
685702|NCT00006083|noncontiguous stage II marginal zone lymphoma
685703|NCT00006083|recurrent marginal zone lymphoma
685704|NCT00006083|recurrent small lymphocytic lymphoma
685705|NCT00006083|stage I marginal zone lymphoma
685706|NCT00006083|stage I small lymphocytic lymphoma
685707|NCT00006083|stage III small lymphocytic lymphoma
685708|NCT00006083|stage III marginal zone lymphoma
685709|NCT00006083|stage IV small lymphocytic lymphoma
685710|NCT00006083|stage IV marginal zone lymphoma
685711|NCT00006083|contiguous stage II marginal zone lymphoma
685712|NCT00006083|contiguous stage II small lymphocytic lymphoma
685713|NCT00006083|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
685714|NCT00006083|nodal marginal zone B-cell lymphoma
685715|NCT00006083|splenic marginal zone lymphoma
685716|NCT00006082|extensive stage small cell lung cancer
685717|NCT00006082|recurrent small cell lung cancer
685718|NCT00006081|stage III gastric cancer
685719|NCT00006081|stage IV gastric cancer
685720|NCT00006081|stage III esophageal cancer
685721|NCT00006081|stage IV esophageal cancer
685722|NCT00006081|adenocarcinoma of the stomach
685723|NCT00006081|adenocarcinoma of the esophagus
685724|NCT00006080|recurrent adult brain tumor
685725|NCT00006080|adult anaplastic astrocytoma
685726|NCT00006080|adult anaplastic oligodendroglioma
685727|NCT00006080|adult mixed glioma
685728|NCT00006079|cervical cancer
685729|NCT00006079|cervical intraepithelial neoplasia grade 2
685730|NCT00006079|cervical intraepithelial neoplasia grade 3
685731|NCT00006079|Eflornithine
685732|NCT00006078|prostate cancer
685733|NCT00006077|Clinical Trial
685734|NCT00006077|Dyskinesias
685735|NCT00006077|Levodopa Infusion
685736|NCT00006077|Parkinson's Disease
685737|NCT00006076|Hearing
685738|NCT00006076|Auditory Processing
685739|NCT00006076|Pitch Recognition
685740|NCT00006076|Tone Deafness
685741|NCT00006076|Tune Deafness
685742|NCT00006076|HV
685743|NCT00006076|Deafness
685744|NCT00006076|Congenital Amusia
685745|NCT00006076|Healthy Volunteer
685746|NCT00006075|Pregnancy Complications, Infectious
685747|NCT00006075|Dose-Response Relationship, Drug
685748|NCT00006075|Polymerase Chain Reaction
685749|NCT00006075|Disease Transmission, Vertical
685750|NCT00006075|Labor
685751|NCT00006075|Disinfectants
685752|NCT00006075|Vagina
685753|NCT00006075|Chlorhexidine
685754|NCT00006075|Irrigation
685755|NCT00006073|Evaluation
685756|NCT00006073|Endocrinology
685757|NCT00006073|Hormones
685758|NCT00006073|Metabolism
685759|NCT00006073|Teaching
685760|NCT00006073|Endocrine Disorder
685761|NCT00006071|Brachial Reactivity
685762|NCT00006071|Endothelial Function
685763|NCT00006071|Endothelial Markers
685764|NCT00006071|Forearm Flow
685765|NCT00006071|Insulin Resistance
685766|NCT00006071|Elevated Cholesterol
685767|NCT00006071|Hypertension
685768|NCT00006070|Oral Surgery
685769|NCT00006070|Swelling
685770|NCT00006070|Pain
685771|NCT00006070|TNF
685772|NCT00006070|Etanercept
685773|NCT00006066|Injections, Subcutaneous
685774|NCT00006066|Interleukin-2
685775|NCT00006066|Dose-Response Relationship, Drug
685776|NCT00006066|Drug Therapy, Combination
685777|NCT00006066|Immunocompromised Host
685778|NCT00006066|CD4 Lymphocyte Count
685779|NCT00006066|Anti-HIV Agents
685780|NCT00006064|Tumor Necrosis Factor
685781|NCT00006064|CD4 Lymphocyte Count
685782|NCT00006064|Polymerase Chain Reaction
685783|NCT00006064|Enzyme-Linked Immunosorbent Assay
685784|NCT00006064|RNA, Messenger
685785|NCT00006064|Interleukin-1
685786|NCT00006064|Body Composition
685787|NCT00006064|Anti-HIV Agents
685788|NCT00006064|Viral Load
685789|NCT00006064|Age Factors
685790|NCT00006064|Anthropometry
685791|NCT00006063|cardiovascular and respiratory diseases
685792|NCT00006063|cystic fibrosis
685793|NCT00006063|genetic diseases and dysmorphic syndromes
685794|NCT00006063|rare disease
685795|NCT00006062|Liver Impairment
685796|NCT00006062|Pharmacokinetics
685797|NCT00006062|Platinum Analogues
685798|NCT00006061|genetic diseases and dysmorphic syndromes
685799|NCT00006061|inborn errors of metabolism
685800|NCT00006061|methionine adenosyltransferase deficiency
685801|NCT00006061|rare disease
685802|NCT00006060|multiple sclerosis
685803|NCT00006060|neurologic and psychiatric disorders
685804|NCT00006060|rare disease
685805|NCT00006059|epilepsy
685806|NCT00006059|neurologic and psychiatric disorders
685807|NCT00006059|rare disease
685808|NCT00006059|seizures
685809|NCT00006058|bronchopulmonary dysplasia
685810|NCT00006058|cardiovascular and respiratory diseases
685811|NCT00006058|neonatal disorders
685812|NCT00006058|rare disease
685813|NCT00006058|respiratory distress syndrome
685814|NCT00006056|Chediak-Higashi syndrome
685815|NCT00006056|X-linked lymphoproliferative syndrome
685816|NCT00006056|disease-related problem/condition
685817|NCT00006056|familial erythrophagocytic lymphohistiocytosis
685818|NCT00006056|genetic diseases and dysmorphic syndromes
685819|NCT00006056|graft versus host disease
685820|NCT00006056|hematologic disorders
685821|NCT00006056|hemophagocytic lymphohistiocytosis
685822|NCT00006056|histiocytosis
685823|NCT00006056|immunologic disorders and infectious disorders
685824|NCT00006056|primary immunodeficiency disease
685825|NCT00006056|rare disease
685826|NCT00006056|virus-associated hemophagocytic syndrome
685827|NCT00006055|Churg-Strauss syndrome
685828|NCT00006055|Schonlein-Henoch purpura
685829|NCT00006055|Takayasu arteritis
685830|NCT00006055|Wegener's granulomatosis
685831|NCT00006055|arthritis & connective tissue diseases
685832|NCT00006055|autoimmune hemolytic anemia
685833|NCT00006055|cardiovascular and respiratory diseases
685834|NCT00006055|disease-related problem/condition
685835|NCT00006055|giant cell arteritis
685836|NCT00006055|graft versus host disease
685837|NCT00006055|hematologic disorders
685838|NCT00006055|hypersensitivity vasculitis
685839|NCT00006055|immune thrombocytopenic purpura
685840|NCT00006055|immunologic disorders and infectious disorders
685841|NCT00006055|juvenile rheumatoid arthritis
685842|NCT00006055|polyarteritis nodosa
685843|NCT00006055|pure red cell aplasia
685844|NCT00006055|rare disease
685845|NCT00006055|rheumatoid arthritis
685846|NCT00006055|systemic lupus erythematosus
685847|NCT00006055|vasculitis
685848|NCT00006054|Chediak-Higashi syndrome
685849|NCT00006054|Langerhans cell histiocytosis
685850|NCT00006054|Wiskott-Aldrich syndrome
685851|NCT00006054|X-linked agammaglobulinemia
685852|NCT00006054|X-linked hyper IgM syndrome
685853|NCT00006054|X-linked lymphoproliferative syndrome
685854|NCT00006054|chronic granulomatous disease
685855|NCT00006054|common variable immunodeficiency
685856|NCT00006054|complement deficiency
685857|NCT00006054|disease-related problem/condition
685858|NCT00006054|familial erythrophagocytic lymphohistiocytosis
685859|NCT00006054|genetic diseases and dysmorphic syndromes
685860|NCT00006054|graft versus host disease
685861|NCT00006054|hematologic disorders
685862|NCT00006054|hemophagocytic lymphohistiocytosis
685863|NCT00006054|histiocytosis
685864|NCT00006054|immunologic disorders and infectious disorders
685865|NCT00006054|leukocyte adhesion deficiency syndrome
685866|NCT00006054|primary immunodeficiency disease
685867|NCT00006054|rare disease
685868|NCT00006054|severe combined immunodeficiency
685869|NCT00006054|virus-associated hemophagocytic syndrome
685870|NCT00006053|relapsing chronic myelogenous leukemia
685871|NCT00006053|chronic phase chronic myelogenous leukemia
685872|NCT00006053|chronic myelogenous leukemia, BCR-ABL1 positive
685873|NCT00006053|Philadelphia chromosome negative chronic myelogenous leukemia
685874|NCT00006052|accelerated phase chronic myelogenous leukemia
685875|NCT00006052|chronic myelogenous leukemia, BCR-ABL1 positive
685876|NCT00006052|Philadelphia chromosome negative chronic myelogenous leukemia
685877|NCT00006051|stage I squamous cell carcinoma of the lip and oral cavity
685878|NCT00006051|stage II squamous cell carcinoma of the lip and oral cavity
685879|NCT00006051|stage III squamous cell carcinoma of the lip and oral cavity
685880|NCT00006051|stage IV squamous cell carcinoma of the lip and oral cavity
685881|NCT00006051|stage I squamous cell carcinoma of the oropharynx
685882|NCT00006051|stage II squamous cell carcinoma of the oropharynx
685883|NCT00006051|stage III squamous cell carcinoma of the oropharynx
685884|NCT00006051|stage IV squamous cell carcinoma of the oropharynx
685885|NCT00006051|stage I squamous cell carcinoma of the hypopharynx
685886|NCT00006051|stage II squamous cell carcinoma of the hypopharynx
685887|NCT00006051|stage III squamous cell carcinoma of the hypopharynx
685888|NCT00006051|stage IV squamous cell carcinoma of the hypopharynx
685889|NCT00006051|stage I squamous cell carcinoma of the larynx
685890|NCT00006051|stage II squamous cell carcinoma of the larynx
685891|NCT00006051|stage III squamous cell carcinoma of the larynx
685892|NCT00006051|stage IV squamous cell carcinoma of the larynx
685893|NCT00006050|stage IV colon cancer
685894|NCT00006050|stage IV rectal cancer
685895|NCT00006050|liver metastases
685896|NCT00006049|recurrent non-small cell lung cancer
685897|NCT00006049|stage IIIB non-small cell lung cancer
685898|NCT00006049|stage IV non-small cell lung cancer
685899|NCT00006048|recurrent non-small cell lung cancer
685900|NCT00006048|stage IIIB non-small cell lung cancer
685901|NCT00006048|stage IV non-small cell lung cancer
685902|NCT00006047|unspecified adult solid tumor, protocol specific
685903|NCT00006046|stage IV colon cancer
685904|NCT00006046|stage IV rectal cancer
685905|NCT00006046|recurrent colon cancer
685906|NCT00006046|recurrent rectal cancer
685907|NCT00006045|recurrent adult acute myeloid leukemia
685908|NCT00006045|adult acute erythroid leukemia (M6)
685909|NCT00006045|adult acute myeloblastic leukemia without maturation (M1)
685910|NCT00006045|adult acute myeloblastic leukemia with maturation (M2)
685911|NCT00006045|adult acute myelomonocytic leukemia (M4)
685912|NCT00006045|adult acute monoblastic leukemia (M5a)
685913|NCT00006045|adult acute megakaryoblastic leukemia (M7)
685914|NCT00006045|secondary acute myeloid leukemia
685915|NCT00006045|adult acute monocytic leukemia (M5b)
685916|NCT00006045|adult acute minimally differentiated myeloid leukemia (M0)
685917|NCT00006044|stage IV prostate cancer
685918|NCT00006044|recurrent prostate cancer
685919|NCT00006043|stage III malignant testicular germ cell tumor
685920|NCT00006043|recurrent malignant testicular germ cell tumor
685921|NCT00006043|stage IV ovarian germ cell tumor
685922|NCT00006043|recurrent ovarian germ cell tumor
685923|NCT00006042|recurrent adult Hodgkin lymphoma
685924|NCT00006042|Burkitt lymphoma
685925|NCT00006042|refractory multiple myeloma
685926|NCT00006042|stage II multiple myeloma
685927|NCT00006042|stage III multiple myeloma
685928|NCT00006042|recurrent childhood lymphoblastic lymphoma
685929|NCT00006042|stage III chronic lymphocytic leukemia
685930|NCT00006042|stage IV chronic lymphocytic leukemia
685931|NCT00006042|relapsing chronic myelogenous leukemia
685932|NCT00006042|refractory chronic lymphocytic leukemia
685933|NCT00006042|chronic phase chronic myelogenous leukemia
685934|NCT00006042|adult acute myeloid leukemia in remission
685935|NCT00006042|adult acute lymphoblastic leukemia in remission
685936|NCT00006042|childhood acute myeloid leukemia in remission
685937|NCT00006042|childhood acute lymphoblastic leukemia in remission
685938|NCT00006042|recurrent/refractory childhood Hodgkin lymphoma
685939|NCT00006042|stage II adult lymphoblastic lymphoma
685940|NCT00006042|stage III grade 3 follicular lymphoma
685941|NCT00006042|stage III adult diffuse mixed cell lymphoma
685942|NCT00006042|stage III adult diffuse large cell lymphoma
685943|NCT00006042|stage III adult immunoblastic large cell lymphoma
685944|NCT00006042|stage III adult lymphoblastic lymphoma
685945|NCT00006042|stage III adult Burkitt lymphoma
685946|NCT00006042|stage IV grade 1 follicular lymphoma
685947|NCT00006042|stage IV grade 2 follicular lymphoma
685948|NCT00006042|stage IV grade 3 follicular lymphoma
685949|NCT00006042|stage IV adult diffuse mixed cell lymphoma
685950|NCT00006042|stage IV adult diffuse large cell lymphoma
685951|NCT00006042|stage IV adult immunoblastic large cell lymphoma
685952|NCT00006042|stage IV adult lymphoblastic lymphoma
685953|NCT00006042|stage IV adult Burkitt lymphoma
685954|NCT00006042|recurrent grade 1 follicular lymphoma
685955|NCT00006042|recurrent grade 2 follicular lymphoma
685956|NCT00006042|recurrent grade 3 follicular lymphoma
685957|NCT00006042|recurrent adult diffuse small cleaved cell lymphoma
685958|NCT00006042|recurrent adult diffuse mixed cell lymphoma
685959|NCT00006042|recurrent adult diffuse large cell lymphoma
685960|NCT00006042|recurrent adult immunoblastic large cell lymphoma
685961|NCT00006042|recurrent adult lymphoblastic lymphoma
685962|NCT00006042|recurrent adult Burkitt lymphoma
685963|NCT00006042|de novo myelodysplastic syndromes
685964|NCT00006042|previously treated myelodysplastic syndromes
685965|NCT00006042|secondary myelodysplastic syndromes
685966|NCT00006042|recurrent childhood small noncleaved cell lymphoma
685967|NCT00006042|recurrent childhood large cell lymphoma
685968|NCT00006042|noncontiguous stage II grade 3 follicular lymphoma
685969|NCT00006042|noncontiguous stage II mantle cell lymphoma
685970|NCT00006042|noncontiguous stage II adult diffuse mixed cell lymphoma
685971|NCT00006042|noncontiguous stage II adult immunoblastic large cell lymphoma
685972|NCT00006042|noncontiguous stage II adult diffuse large cell lymphoma
685973|NCT00006042|noncontiguous stage II adult Burkitt lymphoma
685974|NCT00006042|noncontiguous stage II adult lymphoblastic lymphoma
685975|NCT00006042|stage III mantle cell lymphoma
685976|NCT00006042|stage IV mantle cell lymphoma
685977|NCT00006042|recurrent mantle cell lymphoma
685978|NCT00006042|childhood chronic myelogenous leukemia
685979|NCT00006042|atypical chronic myeloid leukemia
685980|NCT00006042|myelodysplastic/myeloproliferative disease, unclassifiable
685981|NCT00006042|recurrent marginal zone lymphoma
685982|NCT00006042|recurrent small lymphocytic lymphoma
685983|NCT00006042|stage III small lymphocytic lymphoma
685984|NCT00006042|stage III marginal zone lymphoma
685985|NCT00006042|stage IV small lymphocytic lymphoma
685986|NCT00006042|stage IV marginal zone lymphoma
685987|NCT00006042|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
685988|NCT00006042|nodal marginal zone B-cell lymphoma
685989|NCT00006042|splenic marginal zone lymphoma
685990|NCT00006042|adult acute myeloid leukemia with t(8;21)(q22;q22)
685991|NCT00006042|adult acute myeloid leukemia with t(16;16)(p13;q22)
685992|NCT00006042|adult acute myeloid leukemia with inv(16)(p13;q22)
685993|NCT00006042|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
685994|NCT00006042|adult acute myeloid leukemia with t(15;17)(q22;q12)
685995|NCT00006042|childhood myelodysplastic syndromes
685996|NCT00006041|recurrent ovarian epithelial cancer
685997|NCT00006041|fallopian tube cancer
685998|NCT00006041|primary peritoneal cavity cancer
685999|NCT00006040|recurrent adult acute myeloid leukemia
686000|NCT00006040|recurrent adult acute lymphoblastic leukemia
686001|NCT00006040|relapsing chronic myelogenous leukemia
686002|NCT00006040|accelerated phase chronic myelogenous leukemia
686003|NCT00006040|blastic phase chronic myelogenous leukemia
686004|NCT00006040|previously treated myelodysplastic syndromes
686005|NCT00006040|atypical chronic myeloid leukemia, BCR-ABL1 negative
686006|NCT00006040|myelodysplastic/myeloproliferative neoplasm, unclassifiable
686007|NCT00006039|small intestine lymphoma
686008|NCT00006039|stage III grade 1 follicular lymphoma
686009|NCT00006039|stage III grade 2 follicular lymphoma
686010|NCT00006039|stage IV grade 1 follicular lymphoma
686011|NCT00006039|stage IV grade 2 follicular lymphoma
686012|NCT00006039|recurrent grade 1 follicular lymphoma
686013|NCT00006039|recurrent grade 2 follicular lymphoma
686014|NCT00006039|contiguous stage II grade 1 follicular lymphoma
686015|NCT00006039|contiguous stage II grade 2 follicular lymphoma
686016|NCT00006039|noncontiguous stage II grade 1 follicular lymphoma
686017|NCT00006039|noncontiguous stage II grade 2 follicular lymphoma
686018|NCT00006039|noncontiguous stage II small lymphocytic lymphoma
686019|NCT00006039|noncontiguous stage II marginal zone lymphoma
686020|NCT00006039|recurrent marginal zone lymphoma
686021|NCT00006039|recurrent small lymphocytic lymphoma
686022|NCT00006039|stage III small lymphocytic lymphoma
686023|NCT00006039|stage III marginal zone lymphoma
686024|NCT00006039|stage IV small lymphocytic lymphoma
686025|NCT00006039|stage IV marginal zone lymphoma
686026|NCT00006039|contiguous stage II marginal zone lymphoma
686027|NCT00006039|contiguous stage II small lymphocytic lymphoma
686028|NCT00006039|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686029|NCT00006039|nodal marginal zone B-cell lymphoma
686030|NCT00006039|splenic marginal zone lymphoma
686031|NCT00006038|stage II gastric cancer
686032|NCT00006038|stage III gastric cancer
686033|NCT00006038|stage IV gastric cancer
686034|NCT00006038|stage II esophageal cancer
686035|NCT00006038|stage III esophageal cancer
686036|NCT00006038|adenocarcinoma of the stomach
686037|NCT00006038|adenocarcinoma of the esophagus
686038|NCT00006037|stage IV colon cancer
686039|NCT00006037|stage IV rectal cancer
686040|NCT00006037|recurrent colon cancer
686041|NCT00006037|recurrent rectal cancer
686042|NCT00006037|adenocarcinoma of the colon
686043|NCT00006037|adenocarcinoma of the rectum
686044|NCT00006036|recurrent non-small cell lung cancer
686045|NCT00006036|stage III ovarian epithelial cancer
686046|NCT00006036|stage IV ovarian epithelial cancer
686047|NCT00006036|recurrent ovarian epithelial cancer
686048|NCT00006036|extensive stage small cell lung cancer
686049|NCT00006036|recurrent small cell lung cancer
686050|NCT00006036|stage IV nasopharyngeal cancer
686051|NCT00006036|stage IIIA non-small cell lung cancer
686052|NCT00006036|stage IIIB non-small cell lung cancer
686053|NCT00006036|stage IV non-small cell lung cancer
686054|NCT00006036|unspecified adult solid tumor, protocol specific
686055|NCT00006036|untreated metastatic squamous neck cancer with occult primary
686056|NCT00006036|recurrent metastatic squamous neck cancer with occult primary
686057|NCT00006036|ovarian stromal cancer
686058|NCT00006036|stage III ovarian germ cell tumor
686059|NCT00006036|stage IV ovarian germ cell tumor
686060|NCT00006036|recurrent ovarian germ cell tumor
686061|NCT00006036|stage III squamous cell carcinoma of the lip and oral cavity
686062|NCT00006036|stage III basal cell carcinoma of the lip
686063|NCT00006036|stage III verrucous carcinoma of the oral cavity
686064|NCT00006036|stage III mucoepidermoid carcinoma of the oral cavity
686065|NCT00006036|stage III adenoid cystic carcinoma of the oral cavity
686066|NCT00006036|stage IV squamous cell carcinoma of the lip and oral cavity
686067|NCT00006036|stage IV basal cell carcinoma of the lip
686068|NCT00006036|stage IV verrucous carcinoma of the oral cavity
686069|NCT00006036|stage IV mucoepidermoid carcinoma of the oral cavity
686070|NCT00006036|stage IV adenoid cystic carcinoma of the oral cavity
686071|NCT00006036|recurrent squamous cell carcinoma of the lip and oral cavity
686072|NCT00006036|recurrent basal cell carcinoma of the lip
686073|NCT00006036|recurrent verrucous carcinoma of the oral cavity
686074|NCT00006036|recurrent mucoepidermoid carcinoma of the oral cavity
686075|NCT00006036|recurrent adenoid cystic carcinoma of the oral cavity
686076|NCT00006036|stage III squamous cell carcinoma of the oropharynx
686077|NCT00006036|stage III lymphoepithelioma of the oropharynx
686078|NCT00006036|stage IV squamous cell carcinoma of the oropharynx
686079|NCT00006036|stage IV lymphoepithelioma of the oropharynx
686080|NCT00006036|recurrent squamous cell carcinoma of the oropharynx
686081|NCT00006036|recurrent lymphoepithelioma of the oropharynx
686082|NCT00006036|stage III squamous cell carcinoma of the nasopharynx
686083|NCT00006036|stage III lymphoepithelioma of the nasopharynx
686084|NCT00006036|stage IV squamous cell carcinoma of the nasopharynx
686085|NCT00006036|stage IV lymphoepithelioma of the nasopharynx
686086|NCT00006036|recurrent squamous cell carcinoma of the nasopharynx
686087|NCT00006036|recurrent lymphoepithelioma of the nasopharynx
686088|NCT00006036|stage III squamous cell carcinoma of the hypopharynx
686089|NCT00006036|stage IV squamous cell carcinoma of the hypopharynx
686090|NCT00006036|recurrent squamous cell carcinoma of the hypopharynx
686091|NCT00006036|stage III squamous cell carcinoma of the larynx
686092|NCT00006036|stage III verrucous carcinoma of the larynx
686093|NCT00006036|stage IV squamous cell carcinoma of the larynx
686094|NCT00006036|stage IV verrucous carcinoma of the larynx
686095|NCT00006036|recurrent squamous cell carcinoma of the larynx
686096|NCT00006036|recurrent verrucous carcinoma of the larynx
686097|NCT00006036|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
686098|NCT00006036|stage III inverted papilloma of the paranasal sinus and nasal cavity
686099|NCT00006036|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
686100|NCT00006036|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
686101|NCT00006036|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
686102|NCT00006036|stage IV inverted papilloma of the paranasal sinus and nasal cavity
686103|NCT00006036|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
686104|NCT00006036|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
686105|NCT00006036|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
686106|NCT00006036|recurrent inverted papilloma of the paranasal sinus and nasal cavity
686107|NCT00006036|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
686108|NCT00006036|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
686109|NCT00006036|borderline ovarian surface epithelial-stromal tumor
686110|NCT00006036|ovarian sarcoma
686111|NCT00006035|stage III melanoma
686112|NCT00006035|stage IV melanoma
686113|NCT00006035|recurrent melanoma
686114|NCT00006034|stage 0 bladder cancer
686115|NCT00006034|recurrent bladder cancer
686116|NCT00006033|recurrent metastatic squamous neck cancer with occult primary
686117|NCT00006033|stage III squamous cell carcinoma of the lip and oral cavity
686118|NCT00006033|stage IV squamous cell carcinoma of the lip and oral cavity
686119|NCT00006033|recurrent squamous cell carcinoma of the lip and oral cavity
686120|NCT00006033|stage III squamous cell carcinoma of the oropharynx
686121|NCT00006033|stage IV squamous cell carcinoma of the oropharynx
686122|NCT00006033|recurrent squamous cell carcinoma of the oropharynx
686123|NCT00006033|stage III squamous cell carcinoma of the nasopharynx
686124|NCT00006033|stage IV squamous cell carcinoma of the nasopharynx
686125|NCT00006033|recurrent squamous cell carcinoma of the nasopharynx
686126|NCT00006033|stage III squamous cell carcinoma of the hypopharynx
686127|NCT00006033|stage IV squamous cell carcinoma of the hypopharynx
686128|NCT00006033|recurrent squamous cell carcinoma of the hypopharynx
686129|NCT00006033|stage III squamous cell carcinoma of the larynx
686130|NCT00006033|stage IV squamous cell carcinoma of the larynx
686131|NCT00006033|recurrent squamous cell carcinoma of the larynx
686132|NCT00006033|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
686133|NCT00006033|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
686134|NCT00006033|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
686135|NCT00006032|stage IV breast cancer
686136|NCT00006032|recurrent breast cancer
686137|NCT00006031|biopsy
686138|NCT00006031|radioactive seed
686139|NCT00006031|nonpalpable lesions
686140|NCT00006030|stage I breast cancer
686141|NCT00006029|recurrent adult Hodgkin lymphoma
686142|NCT00006029|recurrent/refractory childhood Hodgkin lymphoma
686143|NCT00006028|recurrent ovarian epithelial cancer
686144|NCT00006028|primary peritoneal cavity cancer
686145|NCT00006027|stage I endometrial carcinoma
686146|NCT00006027|stage II endometrial carcinoma
686147|NCT00006027|endometrial adenocarcinoma
686148|NCT00006027|endometrial adenosquamous cell carcinoma
686149|NCT00006027|endometrial adenoacanthoma
686150|NCT00006027|endometrial clear cell carcinoma
686151|NCT00006027|endometrial papillary serous carcinoma
686152|NCT00006026|recurrent bladder cancer
686153|NCT00006026|stage IV bladder cancer
686154|NCT00006026|transitional cell carcinoma of the bladder
686155|NCT00006026|squamous cell carcinoma of the bladder
686156|NCT00006026|adenocarcinoma of the bladder
686157|NCT00006026|recurrent urethral cancer
686158|NCT00006026|anterior urethral cancer
686159|NCT00006026|posterior urethral cancer
686160|NCT00006026|urethral cancer associated with invasive bladder cancer
686161|NCT00006026|metastatic transitional cell cancer of the renal pelvis and ureter
686162|NCT00006026|regional transitional cell cancer of the renal pelvis and ureter
686163|NCT00006026|recurrent transitional cell cancer of the renal pelvis and ureter
686164|NCT00006025|recurrent adult brain tumor
686165|NCT00006025|adult glioblastoma
686166|NCT00006025|adult anaplastic astrocytoma
686167|NCT00006025|adult anaplastic oligodendroglioma
686168|NCT00006025|adult mixed glioma
686169|NCT00006025|adult giant cell glioblastoma
686170|NCT00006025|adult gliosarcoma
686171|NCT00006024|childhood high-grade cerebral astrocytoma
686172|NCT00006023|stage IV prostate cancer
686173|NCT00006023|recurrent prostate cancer
686174|NCT00006022|stage III renal cell cancer
686175|NCT00006022|stage IV renal cell cancer
686176|NCT00006022|recurrent renal cell cancer
686177|NCT00006022|stage III melanoma
686178|NCT00006022|stage IV melanoma
686179|NCT00006022|recurrent melanoma
686180|NCT00006021|refractory multiple myeloma
686181|NCT00006021|stage II multiple myeloma
686182|NCT00006021|stage III multiple myeloma
686183|NCT00006020|recurrent adult acute lymphoblastic leukemia
686184|NCT00006020|L1 adult acute lymphoblastic leukemia
686185|NCT00006020|L2 adult acute lymphoblastic leukemia
686186|NCT00006020|B-cell adult acute lymphoblastic leukemia
686187|NCT00006020|non-T, non-B adult acute lymphoblastic leukemia
686188|NCT00006019|recurrent non-small cell lung cancer
686189|NCT00006019|refractory multiple myeloma
686190|NCT00006019|recurrent adult acute myeloid leukemia
686191|NCT00006019|recurrent prostate cancer
686192|NCT00006019|adult acute myeloblastic leukemia without maturation (M1)
686193|NCT00006019|adult acute myeloblastic leukemia with maturation (M2)
686666|NCT00005960|stage I prostate cancer
686194|NCT00006019|adult acute promyelocytic leukemia (M3)
686195|NCT00006019|adult acute myelomonocytic leukemia (M4)
686196|NCT00006019|adult acute monoblastic leukemia (M5a)
686197|NCT00006019|recurrent grade 1 follicular lymphoma
686198|NCT00006019|recurrent grade 2 follicular lymphoma
686199|NCT00006019|recurrent grade 3 follicular lymphoma
686200|NCT00006019|recurrent adult diffuse small cleaved cell lymphoma
686201|NCT00006019|recurrent adult diffuse mixed cell lymphoma
686202|NCT00006019|recurrent adult diffuse large cell lymphoma
686203|NCT00006019|adult acute monocytic leukemia (M5b)
686204|NCT00006019|previously treated myelodysplastic syndromes
686205|NCT00006019|secondary myelodysplastic syndromes
686206|NCT00006019|recurrent marginal zone lymphoma
686207|NCT00006019|recurrent small lymphocytic lymphoma
686208|NCT00006019|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686209|NCT00006019|nodal marginal zone B-cell lymphoma
686210|NCT00006019|splenic marginal zone lymphoma
686211|NCT00006018|unspecified adult solid tumor, protocol specific
686212|NCT00006017|recurrent non-small cell lung cancer
686213|NCT00006017|stage IIIB non-small cell lung cancer
686214|NCT00006017|stage IV non-small cell lung cancer
686215|NCT00006015|stage IV colon cancer
686216|NCT00006015|stage IV rectal cancer
686217|NCT00006015|recurrent colon cancer
686218|NCT00006015|recurrent rectal cancer
686219|NCT00006015|adenocarcinoma of the colon
686220|NCT00006015|adenocarcinoma of the rectum
686221|NCT00006014|advanced malignant mesothelioma
686222|NCT00006014|recurrent malignant mesothelioma
686223|NCT00006014|epithelial mesothelioma
686224|NCT00006014|sarcomatous mesothelioma
686225|NCT00006013|refractory multiple myeloma
686226|NCT00006012|drug/agent toxicity by tissue/organ
686227|NCT00006012|radiation toxicity
686228|NCT00006012|limited stage small cell lung cancer
686229|NCT00006010|localized unresectable adult primary liver cancer
686230|NCT00006010|advanced adult primary liver cancer
686231|NCT00006010|recurrent adult primary liver cancer
686232|NCT00006010|adult primary hepatocellular carcinoma
686233|NCT00006009|stage I cutaneous T-cell non-Hodgkin lymphoma
686234|NCT00006009|stage II cutaneous T-cell non-Hodgkin lymphoma
686235|NCT00006009|stage III cutaneous T-cell non-Hodgkin lymphoma
686236|NCT00006009|stage IV cutaneous T-cell non-Hodgkin lymphoma
686237|NCT00006009|recurrent cutaneous T-cell non-Hodgkin lymphoma
686238|NCT00006009|small intestine lymphoma
686239|NCT00006009|stage III adult T-cell leukemia/lymphoma
686240|NCT00006009|stage IV adult T-cell leukemia/lymphoma
686241|NCT00006009|recurrent adult T-cell leukemia/lymphoma
686242|NCT00006009|angioimmunoblastic T-cell lymphoma
686243|NCT00006009|anaplastic large cell lymphoma
686244|NCT00006009|stage I mycosis fungoides/Sezary syndrome
686245|NCT00006009|stage II mycosis fungoides/Sezary syndrome
686246|NCT00006009|stage III mycosis fungoides/Sezary syndrome
686247|NCT00006009|stage IV mycosis fungoides/Sezary syndrome
686248|NCT00006009|recurrent mycosis fungoides/Sezary syndrome
686249|NCT00006008|recurrent adult acute lymphoblastic leukemia
686250|NCT00006008|L1 adult acute lymphoblastic leukemia
686251|NCT00006008|L2 adult acute lymphoblastic leukemia
686252|NCT00006008|L3 adult acute lymphoblastic leukemia
686253|NCT00006007|stage IV breast cancer
686254|NCT00006007|recurrent breast cancer
686255|NCT00006006|localized unresectable adult primary liver cancer
686256|NCT00006006|advanced adult primary liver cancer
686257|NCT00006006|recurrent adult primary liver cancer
686258|NCT00006006|adult primary hepatocellular carcinoma
686259|NCT00006005|stage I uterine sarcoma
686260|NCT00006005|stage II uterine sarcoma
686261|NCT00006005|stage III uterine sarcoma
686262|NCT00006005|stage IV uterine sarcoma
686263|NCT00006005|recurrent uterine sarcoma
686264|NCT00006005|uterine carcinosarcoma
686265|NCT00006005|uterine leiomyosarcoma
686266|NCT00006005|endometrial stromal sarcoma
686267|NCT00006004|recurrent non-small cell lung cancer
686268|NCT00006004|squamous cell lung cancer
686269|NCT00006004|large cell lung cancer
686270|NCT00006004|stage IIIB non-small cell lung cancer
686271|NCT00006004|stage IV non-small cell lung cancer
686272|NCT00006004|adenocarcinoma of the lung
686273|NCT00006004|adenosquamous cell lung cancer
686274|NCT00006004|bronchoalveolar cell lung cancer
686275|NCT00006002|stage IV prostate cancer
686276|NCT00006002|recurrent prostate cancer
686277|NCT00006001|stage III colon cancer
686278|NCT00006001|stage IV colon cancer
686279|NCT00006001|stage III rectal cancer
686280|NCT00006001|stage IV rectal cancer
686281|NCT00006001|recurrent colon cancer
686282|NCT00006001|recurrent rectal cancer
686283|NCT00006001|adenocarcinoma of the colon
686284|NCT00006001|adenocarcinoma of the rectum
686285|NCT00006000|unspecified adult solid tumor, protocol specific
686286|NCT00005999|recurrent cervical cancer
686287|NCT00005999|stage IVB cervical cancer
686288|NCT00005999|cervical squamous cell carcinoma
686289|NCT00005999|cervical adenocarcinoma
686290|NCT00005998|recurrent adult Hodgkin lymphoma
686291|NCT00005998|recurrent grade 1 follicular lymphoma
686292|NCT00005998|recurrent grade 2 follicular lymphoma
687310|NCT00005892|leukemia
686293|NCT00005998|recurrent grade 3 follicular lymphoma
686294|NCT00005998|recurrent adult diffuse small cleaved cell lymphoma
686295|NCT00005998|recurrent adult diffuse mixed cell lymphoma
686296|NCT00005998|recurrent adult diffuse large cell lymphoma
686297|NCT00005998|recurrent adult immunoblastic large cell lymphoma
686298|NCT00005998|recurrent adult lymphoblastic lymphoma
686299|NCT00005998|recurrent adult Burkitt lymphoma
686300|NCT00005998|recurrent mantle cell lymphoma
686301|NCT00005998|recurrent marginal zone lymphoma
686302|NCT00005998|recurrent small lymphocytic lymphoma
686303|NCT00005998|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686304|NCT00005998|nodal marginal zone B-cell lymphoma
686305|NCT00005998|splenic marginal zone lymphoma
686306|NCT00005997|localized unresectable adult primary liver cancer
686307|NCT00005997|advanced adult primary liver cancer
686308|NCT00005997|unresectable gallbladder cancer
686309|NCT00005997|unresectable extrahepatic bile duct cancer
686310|NCT00005997|adult primary hepatocellular carcinoma
686311|NCT00005997|cholangiocarcinoma of the gallbladder
686312|NCT00005997|cholangiocarcinoma of the extrahepatic bile duct
686313|NCT00005997|adult primary cholangiocellular carcinoma
686314|NCT00005996|unspecified adult solid tumor, protocol specific
686315|NCT00005995|stage IV renal cell cancer
686316|NCT00005995|recurrent renal cell cancer
686317|NCT00005994|nausea and vomiting
686318|NCT00005994|unspecified adult solid tumor, protocol specific
686319|NCT00005993|stage IV breast cancer
686320|NCT00005993|stage IIIA breast cancer
686321|NCT00005993|recurrent breast cancer
686322|NCT00005993|stage IIIB breast cancer
686323|NCT00005993|recurrent adult Hodgkin lymphoma
686324|NCT00005993|stage III grade 3 follicular lymphoma
686325|NCT00005993|stage III adult diffuse mixed cell lymphoma
686326|NCT00005993|stage III adult diffuse large cell lymphoma
686327|NCT00005993|stage III adult immunoblastic large cell lymphoma
686328|NCT00005993|stage III adult lymphoblastic lymphoma
686329|NCT00005993|stage III adult Burkitt lymphoma
686330|NCT00005993|stage IV grade 3 follicular lymphoma
686331|NCT00005993|stage IV adult diffuse mixed cell lymphoma
686332|NCT00005993|stage IV adult diffuse large cell lymphoma
686333|NCT00005993|stage IV adult immunoblastic large cell lymphoma
686334|NCT00005993|stage IV adult lymphoblastic lymphoma
686335|NCT00005993|stage IV adult Burkitt lymphoma
686336|NCT00005993|recurrent grade 1 follicular lymphoma
686337|NCT00005993|recurrent grade 2 follicular lymphoma
686338|NCT00005993|recurrent grade 3 follicular lymphoma
686339|NCT00005993|recurrent adult diffuse small cleaved cell lymphoma
686340|NCT00005993|recurrent adult diffuse mixed cell lymphoma
686341|NCT00005993|recurrent adult diffuse large cell lymphoma
686342|NCT00005993|recurrent adult immunoblastic large cell lymphoma
686343|NCT00005993|recurrent adult lymphoblastic lymphoma
686344|NCT00005993|recurrent adult Burkitt lymphoma
686345|NCT00005993|noncontiguous stage II grade 3 follicular lymphoma
686346|NCT00005993|noncontiguous stage II mantle cell lymphoma
686347|NCT00005993|noncontiguous stage II adult diffuse mixed cell lymphoma
686348|NCT00005993|noncontiguous stage II adult immunoblastic large cell lymphoma
686349|NCT00005993|noncontiguous stage II adult diffuse large cell lymphoma
686350|NCT00005993|noncontiguous stage II adult Burkitt lymphoma
686351|NCT00005993|noncontiguous stage II adult lymphoblastic lymphoma
686352|NCT00005993|stage III mantle cell lymphoma
686353|NCT00005993|stage IV mantle cell lymphoma
686354|NCT00005993|recurrent mantle cell lymphoma
686355|NCT00005993|recurrent marginal zone lymphoma
686356|NCT00005993|recurrent small lymphocytic lymphoma
686357|NCT00005993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686358|NCT00005993|nodal marginal zone B-cell lymphoma
686359|NCT00005993|splenic marginal zone lymphoma
686360|NCT00005992|stage IV prostate cancer
686361|NCT00005992|recurrent prostate cancer
686362|NCT00005991|stage IV breast cancer
686363|NCT00005991|recurrent breast cancer
686364|NCT00005990|unspecified adult solid tumor, protocol specific
686365|NCT00005989|recurrent non-small cell lung cancer
686366|NCT00005989|stage IV non-small cell lung cancer
686367|NCT00005988|recurrent childhood acute lymphoblastic leukemia
686368|NCT00005988|recurrent adult Hodgkin lymphoma
686369|NCT00005988|refractory multiple myeloma
686370|NCT00005988|stage I multiple myeloma
686371|NCT00005988|stage II multiple myeloma
686372|NCT00005988|stage III multiple myeloma
686373|NCT00005988|stage I childhood lymphoblastic lymphoma
686374|NCT00005988|stage II childhood lymphoblastic lymphoma
686375|NCT00005988|stage III childhood lymphoblastic lymphoma
686376|NCT00005988|stage IV childhood lymphoblastic lymphoma
686377|NCT00005988|recurrent childhood lymphoblastic lymphoma
686378|NCT00005988|recurrent childhood acute myeloid leukemia
686379|NCT00005988|recurrent adult acute myeloid leukemia
686380|NCT00005988|recurrent adult acute lymphoblastic leukemia
686381|NCT00005988|childhood diffuse large cell lymphoma
686382|NCT00005988|childhood immunoblastic large cell lymphoma
686383|NCT00005988|adult acute myeloid leukemia in remission
686384|NCT00005988|adult acute lymphoblastic leukemia in remission
686385|NCT00005988|childhood acute myeloid leukemia in remission
686386|NCT00005988|childhood acute lymphoblastic leukemia in remission
686387|NCT00005988|recurrent/refractory childhood Hodgkin lymphoma
686388|NCT00005988|stage I grade 3 follicular lymphoma
686389|NCT00005988|stage I adult diffuse small cleaved cell lymphoma
686390|NCT00005988|stage I adult diffuse mixed cell lymphoma
686391|NCT00005988|stage I adult diffuse large cell lymphoma
686392|NCT00005988|stage I adult immunoblastic large cell lymphoma
686393|NCT00005988|stage I adult lymphoblastic lymphoma
686394|NCT00005988|stage I adult Burkitt lymphoma
686395|NCT00005988|chronic myelomonocytic leukemia
686396|NCT00005988|stage III grade 3 follicular lymphoma
686397|NCT00005988|stage III adult diffuse small cleaved cell lymphoma
686398|NCT00005988|stage III adult diffuse mixed cell lymphoma
686399|NCT00005988|stage III adult diffuse large cell lymphoma
686400|NCT00005988|stage III adult immunoblastic large cell lymphoma
686401|NCT00005988|stage III adult lymphoblastic lymphoma
686402|NCT00005988|stage III adult Burkitt lymphoma
686403|NCT00005988|stage IV grade 3 follicular lymphoma
686404|NCT00005988|stage IV adult diffuse mixed cell lymphoma
686405|NCT00005988|stage IV adult diffuse large cell lymphoma
686406|NCT00005988|stage IV adult immunoblastic large cell lymphoma
686407|NCT00005988|stage IV adult lymphoblastic lymphoma
686408|NCT00005988|stage IV adult Burkitt lymphoma
686409|NCT00005988|recurrent grade 3 follicular lymphoma
686410|NCT00005988|recurrent adult diffuse small cleaved cell lymphoma
686411|NCT00005988|recurrent adult diffuse mixed cell lymphoma
686412|NCT00005988|recurrent adult diffuse large cell lymphoma
686413|NCT00005988|recurrent adult immunoblastic large cell lymphoma
686414|NCT00005988|recurrent adult lymphoblastic lymphoma
686415|NCT00005988|recurrent adult Burkitt lymphoma
686416|NCT00005988|de novo myelodysplastic syndromes
686417|NCT00005988|previously treated myelodysplastic syndromes
686418|NCT00005988|secondary myelodysplastic syndromes
686419|NCT00005988|graft versus host disease
686420|NCT00005988|stage I childhood small noncleaved cell lymphoma
686421|NCT00005988|stage I childhood large cell lymphoma
686422|NCT00005988|stage II childhood small noncleaved cell lymphoma
686423|NCT00005988|stage II childhood large cell lymphoma
686424|NCT00005988|stage III childhood small noncleaved cell lymphoma
686425|NCT00005988|stage III childhood large cell lymphoma
686426|NCT00005988|stage IV childhood small noncleaved cell lymphoma
686427|NCT00005988|stage IV childhood large cell lymphoma
686428|NCT00005988|recurrent childhood small noncleaved cell lymphoma
686429|NCT00005988|recurrent childhood large cell lymphoma
686430|NCT00005988|contiguous stage II grade 3 follicular lymphoma
686431|NCT00005988|contiguous stage II adult diffuse small cleaved cell lymphoma
686432|NCT00005988|contiguous stage II adult diffuse mixed cell lymphoma
686433|NCT00005988|contiguous stage II adult immunoblastic large cell lymphoma
686434|NCT00005988|contiguous stage II adult diffuse large cell lymphoma
686435|NCT00005988|contiguous stage II adult Burkitt lymphoma
686436|NCT00005988|contiguous stage II adult lymphoblastic lymphoma
686437|NCT00005988|noncontiguous stage II grade 3 follicular lymphoma
686438|NCT00005988|noncontiguous stage II adult diffuse small cleaved cell lymphoma
686439|NCT00005988|noncontiguous stage II adult diffuse mixed cell lymphoma
686440|NCT00005988|noncontiguous stage II adult immunoblastic large cell lymphoma
686441|NCT00005988|noncontiguous stage II adult diffuse large cell lymphoma
686442|NCT00005988|noncontiguous stage II adult Burkitt lymphoma
686443|NCT00005988|noncontiguous stage II adult lymphoblastic lymphoma
686444|NCT00005988|refractory cytopenia with multilineage dysplasia
686445|NCT00005988|childhood myelodysplastic syndromes
686446|NCT00005987|stage I multiple myeloma
686447|NCT00005987|stage II multiple myeloma
686448|NCT00005987|stage III multiple myeloma
686449|NCT00005986|chronic phase chronic myelogenous leukemia
686450|NCT00005986|accelerated phase chronic myelogenous leukemia
686451|NCT00005986|Philadelphia chromosome positive chronic myelogenous leukemia
686452|NCT00005985|stage I adult Hodgkin lymphoma
686453|NCT00005985|stage II adult Hodgkin lymphoma
686454|NCT00005985|stage III adult Hodgkin lymphoma
686455|NCT00005985|stage IV adult Hodgkin lymphoma
686456|NCT00005985|recurrent adult Hodgkin lymphoma
686457|NCT00005985|stage I grade 1 follicular lymphoma
686458|NCT00005985|stage I grade 2 follicular lymphoma
686459|NCT00005985|stage I grade 3 follicular lymphoma
686460|NCT00005985|stage I adult diffuse small cleaved cell lymphoma
686461|NCT00005985|stage I adult diffuse mixed cell lymphoma
686462|NCT00005985|stage I adult diffuse large cell lymphoma
686463|NCT00005985|stage I adult immunoblastic large cell lymphoma
686464|NCT00005985|stage I adult lymphoblastic lymphoma
686465|NCT00005985|stage I adult Burkitt lymphoma
686466|NCT00005985|stage III grade 1 follicular lymphoma
686467|NCT00005985|stage III grade 2 follicular lymphoma
686468|NCT00005985|stage III grade 3 follicular lymphoma
686469|NCT00005985|stage III adult diffuse small cleaved cell lymphoma
686470|NCT00005985|stage III adult diffuse mixed cell lymphoma
686471|NCT00005985|stage III adult diffuse large cell lymphoma
686472|NCT00005985|stage III adult immunoblastic large cell lymphoma
686473|NCT00005985|stage III adult lymphoblastic lymphoma
686474|NCT00005985|stage III adult Burkitt lymphoma
686475|NCT00005985|stage IV grade 1 follicular lymphoma
686476|NCT00005985|stage IV grade 2 follicular lymphoma
686477|NCT00005985|stage IV grade 3 follicular lymphoma
686478|NCT00005985|stage IV adult diffuse small cleaved cell lymphoma
686479|NCT00005985|stage IV adult diffuse mixed cell lymphoma
686480|NCT00005985|stage IV adult diffuse large cell lymphoma
686481|NCT00005985|stage IV adult immunoblastic large cell lymphoma
686482|NCT00005985|stage IV adult lymphoblastic lymphoma
686483|NCT00005985|stage IV adult Burkitt lymphoma
686484|NCT00005985|recurrent grade 1 follicular lymphoma
686485|NCT00005985|recurrent grade 2 follicular lymphoma
686486|NCT00005985|recurrent grade 3 follicular lymphoma
686487|NCT00005985|recurrent adult diffuse small cleaved cell lymphoma
686488|NCT00005985|recurrent adult diffuse mixed cell lymphoma
686489|NCT00005985|recurrent adult diffuse large cell lymphoma
686490|NCT00005985|recurrent adult immunoblastic large cell lymphoma
686491|NCT00005985|recurrent adult lymphoblastic lymphoma
686492|NCT00005985|recurrent adult Burkitt lymphoma
686493|NCT00005985|stage I adult T-cell leukemia/lymphoma
686494|NCT00005985|stage II adult T-cell leukemia/lymphoma
686495|NCT00005985|stage III adult T-cell leukemia/lymphoma
686496|NCT00005985|stage IV adult T-cell leukemia/lymphoma
686497|NCT00005985|recurrent adult T-cell leukemia/lymphoma
686498|NCT00005985|contiguous stage II grade 1 follicular lymphoma
686499|NCT00005985|contiguous stage II grade 2 follicular lymphoma
686500|NCT00005985|contiguous stage II grade 3 follicular lymphoma
686501|NCT00005985|contiguous stage II adult diffuse small cleaved cell lymphoma
686502|NCT00005985|contiguous stage II adult diffuse mixed cell lymphoma
686503|NCT00005985|contiguous stage II adult immunoblastic large cell lymphoma
686504|NCT00005985|contiguous stage II adult diffuse large cell lymphoma
686505|NCT00005985|contiguous stage II adult Burkitt lymphoma
686506|NCT00005985|contiguous stage II adult lymphoblastic lymphoma
686507|NCT00005985|noncontiguous stage II grade 1 follicular lymphoma
686508|NCT00005985|noncontiguous stage II grade 2 follicular lymphoma
686509|NCT00005985|noncontiguous stage II grade 3 follicular lymphoma
686510|NCT00005985|noncontiguous stage II adult diffuse small cleaved cell lymphoma
686511|NCT00005985|noncontiguous stage II adult diffuse mixed cell lymphoma
686512|NCT00005985|noncontiguous stage II adult immunoblastic large cell lymphoma
686513|NCT00005985|noncontiguous stage II adult diffuse large cell lymphoma
686514|NCT00005985|noncontiguous stage II adult Burkitt lymphoma
686515|NCT00005985|noncontiguous stage II adult lymphoblastic lymphoma
686516|NCT00005985|contiguous stage II small lymphocytic lymphoma
686517|NCT00005985|noncontiguous stage II small lymphocytic lymphoma
686518|NCT00005985|recurrent small lymphocytic lymphoma
686519|NCT00005985|stage I small lymphocytic lymphoma
686520|NCT00005985|stage III small lymphocytic lymphoma
686521|NCT00005985|stage IV small lymphocytic lymphoma
686522|NCT00005984|chronic phase myelogenous leukemia
686523|NCT00005984|accelerated phase myelogenous leukemia
686524|NCT00005983|stage II breast cancer
686525|NCT00005981|stage IV colon cancer
686526|NCT00005981|stage IV rectal cancer
686527|NCT00005981|recurrent colon cancer
686528|NCT00005981|recurrent rectal cancer
686529|NCT00005980|stage IV breast cancer
686530|NCT00005980|recurrent breast cancer
686531|NCT00005979|stage III colon cancer
686532|NCT00005979|adenocarcinoma of the colon
686533|NCT00005978|localized resectable neuroblastoma
686534|NCT00005978|regional neuroblastoma
686535|NCT00005978|disseminated neuroblastoma
686536|NCT00005978|stage 4S neuroblastoma
686537|NCT00005978|recurrent neuroblastoma
686538|NCT00005978|localized unresectable neuroblastoma
686539|NCT00005977|childhood Burkitt lymphoma
686540|NCT00005977|L3 childhood acute lymphoblastic leukemia
686541|NCT00005977|B-cell childhood acute lymphoblastic leukemia
686542|NCT00005977|L3 adult acute lymphoblastic leukemia
686543|NCT00005977|B-cell adult acute lymphoblastic leukemia
686544|NCT00005977|stage III adult Burkitt lymphoma
686545|NCT00005977|stage IV adult Burkitt lymphoma
686546|NCT00005977|stage III childhood small noncleaved cell lymphoma
686547|NCT00005977|stage IV childhood small noncleaved cell lymphoma
686548|NCT00005976|recurrent adult brain tumor
686549|NCT00005976|adult glioblastoma
686550|NCT00005976|adult anaplastic astrocytoma
686551|NCT00005976|adult anaplastic oligodendroglioma
686552|NCT00005976|adult mixed glioma
686553|NCT00005976|adult oligodendroglioma
686554|NCT00005976|adult giant cell glioblastoma
686555|NCT00005976|adult gliosarcoma
686556|NCT00005975|stage I breast cancer
686557|NCT00005975|stage II breast cancer
686558|NCT00005975|hot flashes
686559|NCT00005974|stage III adult soft tissue sarcoma
686560|NCT00005974|stage IV adult soft tissue sarcoma
686561|NCT00005972|recurrent small cell lung cancer
686562|NCT00005971|stage IV melanoma
686563|NCT00005969|recurrent adult Hodgkin lymphoma
686564|NCT00005969|recurrent/refractory childhood Hodgkin lymphoma
686565|NCT00005968|stage IV melanoma
686566|NCT00005967|stage III adult Hodgkin lymphoma
686567|NCT00005967|stage IV adult Hodgkin lymphoma
686568|NCT00005967|recurrent adult Hodgkin lymphoma
686569|NCT00005967|refractory multiple myeloma
686570|NCT00005967|stage III multiple myeloma
686571|NCT00005967|stage III chronic lymphocytic leukemia
686572|NCT00005967|stage IV chronic lymphocytic leukemia
686573|NCT00005967|recurrent adult acute myeloid leukemia
686574|NCT00005967|recurrent adult acute lymphoblastic leukemia
686575|NCT00005967|relapsing chronic myelogenous leukemia
686576|NCT00005967|refractory chronic lymphocytic leukemia
686577|NCT00005967|chronic phase chronic myelogenous leukemia
686578|NCT00005967|accelerated phase chronic myelogenous leukemia
686579|NCT00005967|blastic phase chronic myelogenous leukemia
686580|NCT00005967|refractory anemia with excess blasts
686581|NCT00005967|refractory anemia with excess blasts in transformation
686582|NCT00005967|chronic myelomonocytic leukemia
686583|NCT00005967|stage III grade 1 follicular lymphoma
686584|NCT00005967|stage III grade 2 follicular lymphoma
686585|NCT00005967|stage III grade 3 follicular lymphoma
686586|NCT00005967|stage III adult diffuse small cleaved cell lymphoma
686587|NCT00005967|stage III adult diffuse mixed cell lymphoma
686588|NCT00005967|stage III adult diffuse large cell lymphoma
686589|NCT00005967|stage III adult immunoblastic large cell lymphoma
686590|NCT00005967|stage III adult lymphoblastic lymphoma
686591|NCT00005967|stage III adult Burkitt lymphoma
686592|NCT00005967|stage IV grade 1 follicular lymphoma
686593|NCT00005967|stage IV grade 2 follicular lymphoma
686594|NCT00005967|stage IV grade 3 follicular lymphoma
686595|NCT00005967|stage IV adult diffuse small cleaved cell lymphoma
686596|NCT00005967|stage IV adult diffuse mixed cell lymphoma
686597|NCT00005967|stage IV adult diffuse large cell lymphoma
686598|NCT00005967|stage IV adult immunoblastic large cell lymphoma
686599|NCT00005967|stage IV adult lymphoblastic lymphoma
686600|NCT00005967|stage IV adult Burkitt lymphoma
686601|NCT00005967|recurrent grade 1 follicular lymphoma
686602|NCT00005967|recurrent grade 2 follicular lymphoma
686603|NCT00005967|recurrent grade 3 follicular lymphoma
686604|NCT00005967|recurrent adult diffuse small cleaved cell lymphoma
686605|NCT00005967|recurrent adult diffuse mixed cell lymphoma
686606|NCT00005967|recurrent adult diffuse large cell lymphoma
686607|NCT00005967|recurrent adult immunoblastic large cell lymphoma
686608|NCT00005967|recurrent adult lymphoblastic lymphoma
686609|NCT00005967|recurrent adult Burkitt lymphoma
686610|NCT00005967|previously treated myelodysplastic syndromes
686611|NCT00005967|secondary myelodysplastic syndromes
686612|NCT00005967|stage III mantle cell lymphoma
686613|NCT00005967|stage IV mantle cell lymphoma
686614|NCT00005967|recurrent mantle cell lymphoma
686615|NCT00005967|polycythemia vera
686616|NCT00005967|primary myelofibrosis
686617|NCT00005967|essential thrombocythemia
686618|NCT00005967|chronic eosinophilic leukemia
686619|NCT00005967|chronic neutrophilic leukemia
686620|NCT00005967|recurrent marginal zone lymphoma
686621|NCT00005967|recurrent small lymphocytic lymphoma
686622|NCT00005967|stage III small lymphocytic lymphoma
686623|NCT00005967|stage III marginal zone lymphoma
686624|NCT00005967|stage IV small lymphocytic lymphoma
686625|NCT00005967|stage IV marginal zone lymphoma
686626|NCT00005967|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686627|NCT00005967|nodal marginal zone B-cell lymphoma
686628|NCT00005967|splenic marginal zone lymphoma
686629|NCT00005966|stage III renal cell cancer
686630|NCT00005966|stage IV renal cell cancer
686631|NCT00005965|stage III cervical cancer
686632|NCT00005965|recurrent cervical cancer
686633|NCT00005965|stage IVB cervical cancer
686634|NCT00005965|stage IVA cervical cancer
686635|NCT00005965|cervical squamous cell carcinoma
686636|NCT00005965|cervical adenocarcinoma
686637|NCT00005965|cervical adenosquamous cell carcinoma
686638|NCT00005964|stage III adult diffuse large cell lymphoma
686639|NCT00005964|stage III adult immunoblastic large cell lymphoma
686640|NCT00005964|stage III adult lymphoblastic lymphoma
686641|NCT00005964|stage IV adult diffuse large cell lymphoma
686642|NCT00005964|stage IV adult immunoblastic large cell lymphoma
686643|NCT00005964|stage IV adult lymphoblastic lymphoma
686644|NCT00005964|contiguous stage II adult immunoblastic large cell lymphoma
686645|NCT00005964|contiguous stage II adult diffuse large cell lymphoma
686646|NCT00005964|contiguous stage II adult lymphoblastic lymphoma
686647|NCT00005964|noncontiguous stage II adult immunoblastic large cell lymphoma
686648|NCT00005964|noncontiguous stage II adult diffuse large cell lymphoma
686649|NCT00005964|noncontiguous stage II adult lymphoblastic lymphoma
686650|NCT00005963|stage IV breast cancer
686651|NCT00005963|recurrent breast cancer
686652|NCT00005962|recurrent adult acute myeloid leukemia
686653|NCT00005962|adult acute erythroid leukemia (M6)
686654|NCT00005962|adult acute myeloblastic leukemia without maturation (M1)
686655|NCT00005962|adult acute myeloblastic leukemia with maturation (M2)
686656|NCT00005962|adult acute promyelocytic leukemia (M3)
686657|NCT00005962|adult acute myelomonocytic leukemia (M4)
686658|NCT00005962|adult acute monoblastic leukemia (M5a)
686659|NCT00005962|adult acute megakaryoblastic leukemia (M7)
686660|NCT00005962|adult acute monocytic leukemia (M5b)
686661|NCT00005962|adult acute minimally differentiated myeloid leukemia (M0)
686662|NCT00005961|stage III melanoma
686663|NCT00005961|stage IV melanoma
686664|NCT00005961|recurrent melanoma
686665|NCT00005960|adenocarcinoma of the prostate
686667|NCT00005960|stage IIB prostate cancer
686668|NCT00005960|stage IIA prostate cancer
686669|NCT00005960|stage III prostate cancer
686670|NCT00005960|stage IV prostate cancer
686671|NCT00005960|recurrent prostate cancer
686672|NCT00005960|pain
686673|NCT00005959|stage III grade 3 follicular lymphoma
686674|NCT00005959|stage III adult diffuse small cleaved cell lymphoma
686675|NCT00005959|stage III adult diffuse mixed cell lymphoma
686676|NCT00005959|stage III adult diffuse large cell lymphoma
686677|NCT00005959|stage III adult immunoblastic large cell lymphoma
686678|NCT00005959|stage III adult Burkitt lymphoma
686679|NCT00005959|stage IV grade 3 follicular lymphoma
686680|NCT00005959|stage IV adult diffuse small cleaved cell lymphoma
686681|NCT00005959|stage IV adult diffuse mixed cell lymphoma
686682|NCT00005959|stage IV adult diffuse large cell lymphoma
686683|NCT00005959|stage IV adult immunoblastic large cell lymphoma
686684|NCT00005959|stage IV adult Burkitt lymphoma
686685|NCT00005959|contiguous stage II grade 3 follicular lymphoma
686686|NCT00005959|contiguous stage II adult diffuse small cleaved cell lymphoma
686687|NCT00005959|contiguous stage II adult diffuse mixed cell lymphoma
686688|NCT00005959|contiguous stage II adult immunoblastic large cell lymphoma
686689|NCT00005959|contiguous stage II adult diffuse large cell lymphoma
686690|NCT00005959|contiguous stage II adult Burkitt lymphoma
686691|NCT00005959|noncontiguous stage II grade 3 follicular lymphoma
686692|NCT00005959|noncontiguous stage II adult diffuse small cleaved cell lymphoma
686693|NCT00005959|noncontiguous stage II adult diffuse mixed cell lymphoma
686694|NCT00005959|noncontiguous stage II adult immunoblastic large cell lymphoma
686695|NCT00005959|noncontiguous stage II adult diffuse large cell lymphoma
686696|NCT00005959|noncontiguous stage II adult Burkitt lymphoma
686697|NCT00005958|stage III bladder cancer
686698|NCT00005958|recurrent bladder cancer
686699|NCT00005958|stage IV bladder cancer
686700|NCT00005958|transitional cell carcinoma of the bladder
686701|NCT00005958|metastatic transitional cell cancer of the renal pelvis and ureter
686702|NCT00005958|regional transitional cell cancer of the renal pelvis and ureter
686703|NCT00005958|recurrent transitional cell cancer of the renal pelvis and ureter
686704|NCT00005957|stage I breast cancer
686705|NCT00005957|stage II breast cancer
686706|NCT00005956|stage II breast cancer
686707|NCT00005956|stage IV breast cancer
686708|NCT00005956|stage IIIA breast cancer
686709|NCT00005956|stage II gastric cancer
686710|NCT00005956|stage III gastric cancer
686711|NCT00005956|stage IV gastric cancer
686712|NCT00005956|stage IIIB breast cancer
686713|NCT00005956|stage III ovarian epithelial cancer
686714|NCT00005956|stage IV ovarian epithelial cancer
686715|NCT00005955|childhood infratentorial ependymoma
686716|NCT00005955|childhood low-grade cerebral astrocytoma
686717|NCT00005955|childhood supratentorial ependymoma
686718|NCT00005955|childhood craniopharyngioma
686719|NCT00005955|localized resectable neuroblastoma
686720|NCT00005955|regional neuroblastoma
686721|NCT00005955|disseminated neuroblastoma
686722|NCT00005955|stage 4S neuroblastoma
686723|NCT00005955|childhood high-grade cerebral astrocytoma
686724|NCT00005955|childhood oligodendroglioma
686725|NCT00005955|childhood choroid plexus tumor
686726|NCT00005955|childhood grade I meningioma
686727|NCT00005955|childhood grade II meningioma
686728|NCT00005955|childhood grade III meningioma
686729|NCT00005955|untreated childhood supratentorial primitive neuroectodermal tumor
686730|NCT00005955|untreated childhood cerebellar astrocytoma
686731|NCT00005955|untreated childhood medulloblastoma
686732|NCT00005955|untreated childhood visual pathway and hypothalamic glioma
686733|NCT00005955|newly diagnosed childhood ependymoma
686734|NCT00005955|childhood central nervous system choriocarcinoma
686735|NCT00005955|childhood central nervous system embryonal tumor
686736|NCT00005955|childhood central nervous system mixed germ cell tumor
686737|NCT00005955|childhood central nervous system teratoma
686738|NCT00005955|childhood central nervous system yolk sac tumor
686739|NCT00005954|adult tumors metastatic to brain
686740|NCT00005952|childhood low-grade cerebral astrocytoma
686741|NCT00005952|recurrent childhood rhabdomyosarcoma
686742|NCT00005952|childhood craniopharyngioma
686743|NCT00005952|disseminated neuroblastoma
686744|NCT00005952|stage 4S neuroblastoma
686745|NCT00005952|recurrent neuroblastoma
686746|NCT00005952|stage IV Wilms tumor
686747|NCT00005952|stage V Wilms tumor
686748|NCT00005952|recurrent Wilms tumor and other childhood kidney tumors
686749|NCT00005952|childhood central nervous system germ cell tumor
686750|NCT00005952|stage III malignant testicular germ cell tumor
686751|NCT00005952|recurrent malignant testicular germ cell tumor
686752|NCT00005952|stage IV nasopharyngeal cancer
686753|NCT00005952|recurrent nasopharyngeal cancer
686754|NCT00005952|childhood germ cell tumor
686755|NCT00005952|metastatic childhood soft tissue sarcoma
686756|NCT00005952|recurrent childhood soft tissue sarcoma
686757|NCT00005952|stage IV ovarian germ cell tumor
686758|NCT00005952|recurrent ovarian germ cell tumor
686759|NCT00005952|childhood high-grade cerebral astrocytoma
686760|NCT00005952|childhood oligodendroglioma
686761|NCT00005952|childhood choroid plexus tumor
686762|NCT00005952|untreated childhood brain stem glioma
686763|NCT00005952|recurrent childhood brain stem glioma
686764|NCT00005952|untreated childhood supratentorial primitive neuroectodermal tumor
686765|NCT00005952|recurrent childhood supratentorial primitive neuroectodermal tumor
686766|NCT00005952|untreated childhood cerebellar astrocytoma
686767|NCT00005952|recurrent childhood cerebellar astrocytoma
686768|NCT00005952|recurrent childhood cerebral astrocytoma
686769|NCT00005952|untreated childhood medulloblastoma
686770|NCT00005952|recurrent childhood medulloblastoma
686771|NCT00005952|untreated childhood visual pathway and hypothalamic glioma
686772|NCT00005952|recurrent childhood visual pathway and hypothalamic glioma
686773|NCT00005952|previously treated childhood rhabdomyosarcoma
686774|NCT00005952|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
686775|NCT00005952|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
686776|NCT00005952|newly diagnosed childhood ependymoma
686777|NCT00005952|recurrent childhood ependymoma
686778|NCT00005951|recurrent adult brain tumor
686779|NCT00005951|adult glioblastoma
686780|NCT00005951|adult anaplastic astrocytoma
686781|NCT00005951|adult anaplastic oligodendroglioma
686782|NCT00005951|adult mixed glioma
686783|NCT00005951|adult giant cell glioblastoma
686784|NCT00005951|adult gliosarcoma
686785|NCT00005948|relapsing chronic myelogenous leukemia
686786|NCT00005948|chronic phase chronic myelogenous leukemia
686787|NCT00005948|accelerated phase chronic myelogenous leukemia
686788|NCT00005947|adenocarcinoma of the prostate
686789|NCT00005947|stage IV prostate cancer
686790|NCT00005947|recurrent prostate cancer
686791|NCT00005946|recurrent childhood acute lymphoblastic leukemia
686792|NCT00005946|recurrent adult Hodgkin lymphoma
686793|NCT00005946|refractory multiple myeloma
686794|NCT00005946|recurrent childhood lymphoblastic lymphoma
686795|NCT00005946|recurrent childhood acute myeloid leukemia
686796|NCT00005946|recurrent adult acute myeloid leukemia
686797|NCT00005946|recurrent adult acute lymphoblastic leukemia
686798|NCT00005946|relapsing chronic myelogenous leukemia
686799|NCT00005946|refractory chronic lymphocytic leukemia
686800|NCT00005946|chronic phase chronic myelogenous leukemia
686801|NCT00005946|accelerated phase chronic myelogenous leukemia
686802|NCT00005946|blastic phase chronic myelogenous leukemia
686803|NCT00005946|recurrent/refractory childhood Hodgkin lymphoma
686804|NCT00005946|recurrent grade 1 follicular lymphoma
686805|NCT00005946|recurrent grade 2 follicular lymphoma
686806|NCT00005946|recurrent grade 3 follicular lymphoma
686807|NCT00005946|recurrent adult diffuse small cleaved cell lymphoma
686808|NCT00005946|recurrent adult diffuse mixed cell lymphoma
686809|NCT00005946|recurrent adult diffuse large cell lymphoma
686810|NCT00005946|recurrent adult immunoblastic large cell lymphoma
686811|NCT00005946|recurrent adult lymphoblastic lymphoma
686812|NCT00005946|recurrent adult Burkitt lymphoma
686813|NCT00005946|previously treated myelodysplastic syndromes
686814|NCT00005946|secondary myelodysplastic syndromes
686815|NCT00005946|recurrent childhood small noncleaved cell lymphoma
686816|NCT00005946|recurrent childhood large cell lymphoma
686817|NCT00005946|recurrent mantle cell lymphoma
686818|NCT00005946|recurrent marginal zone lymphoma
686819|NCT00005946|recurrent small lymphocytic lymphoma
686820|NCT00005946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
686821|NCT00005946|nodal marginal zone B-cell lymphoma
686822|NCT00005946|splenic marginal zone lymphoma
686823|NCT00005946|childhood myelodysplastic syndromes
686824|NCT00005945|untreated childhood acute lymphoblastic leukemia
686825|NCT00005945|L1 childhood acute lymphoblastic leukemia
686826|NCT00005945|L2 childhood acute lymphoblastic leukemia
686827|NCT00005945|L3 childhood acute lymphoblastic leukemia
686828|NCT00005944|recurrent colon cancer
686829|NCT00005944|recurrent rectal cancer
686830|NCT00005944|adenocarcinoma of the colon
686831|NCT00005944|adenocarcinoma of the rectum
686832|NCT00005944|liver metastases
686833|NCT00005944|primary peritoneal cavity cancer
686834|NCT00005943|stage IV melanoma
686835|NCT00005943|recurrent melanoma
686836|NCT00005941|stage III cervical cancer
686837|NCT00005941|recurrent cervical cancer
686838|NCT00005941|stage IVB cervical cancer
686839|NCT00005941|stage IVA cervical cancer
686840|NCT00005941|stage III vaginal cancer
686841|NCT00005941|stage IVA vaginal cancer
686842|NCT00005941|stage IVB vaginal cancer
686843|NCT00005941|recurrent vaginal cancer
686844|NCT00005939|stage I prostate cancer
686845|NCT00005939|stage IIB prostate cancer
686846|NCT00005939|stage IIA prostate cancer
686847|NCT00005939|stage III prostate cancer
686848|NCT00005939|recurrent prostate cancer
686849|NCT00005938|localized gallbladder cancer
686850|NCT00005938|unresectable gallbladder cancer
686851|NCT00005938|recurrent gallbladder cancer
686852|NCT00005938|localized extrahepatic bile duct cancer
686853|NCT00005938|unresectable extrahepatic bile duct cancer
686854|NCT00005938|recurrent extrahepatic bile duct cancer
686855|NCT00005938|liver and intrahepatic biliary tract cancer
686856|NCT00005938|cholangiocarcinoma of the gallbladder
686857|NCT00005938|cholangiocarcinoma of the extrahepatic bile duct
686858|NCT00005938|adult primary cholangiocellular carcinoma
686859|NCT00005937|MDS
686860|NCT00005937|Immunosuppression
686861|NCT00005937|ATG
686862|NCT00005937|Cyclosporine
686863|NCT00005937|Myelodysplastic Syndrome
686864|NCT00005936|Fulminant Hepatitis
686865|NCT00005936|Parvovirus
686866|NCT00005936|Hepatitis
686867|NCT00005936|Biopsy
686868|NCT00005936|Control
686869|NCT00005936|Liver Biopsy
686870|NCT00005935|Immunosuppression
686871|NCT00005935|T Cells
686872|NCT00005935|Autoimmunity
686873|NCT00005935|Bone Marrow Failure
686874|NCT00005935|Hematopoiesis
686875|NCT00005935|Relapsing Aplastic Anemia
686876|NCT00005934|Fetal Hemoglobin
686877|NCT00005934|5-Azacytidine
686878|NCT00005934|Phenylbutyrate
686879|NCT00005934|Thalassemia
686880|NCT00005934|Hemoglobin
686881|NCT00005934|Anemia
686882|NCT00005934|Blood
686883|NCT00005934|Thalassemia Major
686884|NCT00005934|Beta Thalassemia
686885|NCT00005933|Chronic Disease
686886|NCT00005933|Pediatric
686887|NCT00005933|Pulmonary
686888|NCT00005933|Intelligence
686889|NCT00005933|Coping
686890|NCT00005933|Chronic Illness
686891|NCT00005933|Learning
686892|NCT00005931|Skin Neoplasms
686893|NCT00005931|Sarcoma, Kaposi
686894|NCT00005931|Acquired Immunodeficiency Syndrome
686895|NCT00005931|Antineoplastic Agents
686896|NCT00005931|Enzyme Inhibitors
686897|NCT00005931|SU 5416
686898|NCT00005931|Protein-Tyrosine Kinase
686899|NCT00005928|ACE Inhibitor
686900|NCT00005928|Vascular Inflammation
686901|NCT00005928|Vascular Compliance
686902|NCT00005928|Cell Adhesion Molecules
686903|NCT00005928|Coronary Artery Disease
686904|NCT00005927|Adrenal Adenoma
686905|NCT00005927|Adrenal Cancer
686906|NCT00005927|Macronodular Adrenals
686907|NCT00005927|Ectopic Receptors
686908|NCT00005927|Gene Profiling
686909|NCT00005927|Adrenocortical Carcinoma
686910|NCT00005927|Cushing Syndrome
686911|NCT00005927|Virilizing Adrenal Tumor
686912|NCT00005927|Feminizing Adrenal Tumor
686913|NCT00005927|Massive Macronodular Adrenocortical Disease
686914|NCT00005927|Adrenal Gland Tumor
686915|NCT00005926|Cancer
686916|NCT00005926|Gemzar
686917|NCT00005926|Her-2/Neu
686918|NCT00005926|Pancreatic
686919|NCT00005926|Radiotherapy
686920|NCT00005926|Pancreatic Cancer
686921|NCT00005925|Video-EEG
686922|NCT00005925|Muscimol
686923|NCT00005925|Depth Electrode
686924|NCT00005925|Brain Catheter
686925|NCT00005925|Pharmacology
686926|NCT00005925|Epilepsy
686927|NCT00005925|Infusion
686928|NCT00005925|Magnetic Resonance Imaging
686929|NCT00005924|B Cell
686930|NCT00005924|Epstein-Barr Virus
686931|NCT00005842|stage III colon cancer
686932|NCT00005842|stage IV colon cancer
686933|NCT00005842|stage IV breast cancer
686934|NCT00005842|stage IIIA breast cancer
686935|NCT00005842|recurrent breast cancer
686936|NCT00005842|stage III gastric cancer
686937|NCT00005842|stage IV gastric cancer
686938|NCT00005842|recurrent gastric cancer
686939|NCT00005842|occult non-small cell lung cancer
686940|NCT00005842|stage IIIB breast cancer
686941|NCT00005842|recurrent non-small cell lung cancer
686942|NCT00005842|stage III pancreatic cancer
686943|NCT00005842|recurrent pancreatic cancer
686944|NCT00005842|stage III rectal cancer
686945|NCT00005842|stage IV rectal cancer
686946|NCT00005842|recurrent colon cancer
686947|NCT00005842|recurrent rectal cancer
686948|NCT00005842|stage IV anal cancer
686949|NCT00005842|recurrent anal cancer
686950|NCT00005842|stage III esophageal cancer
686951|NCT00005842|stage IV esophageal cancer
686952|NCT00005842|stage IIIA anal cancer
686953|NCT00005842|stage IIIB anal cancer
686954|NCT00005842|recurrent esophageal cancer
686955|NCT00005842|stage III cervical cancer
686956|NCT00005842|recurrent cervical cancer
686957|NCT00005842|stage IVB cervical cancer
686958|NCT00005842|stage IVA cervical cancer
686959|NCT00005842|inflammatory breast cancer
686960|NCT00005842|stage III renal cell cancer
686961|NCT00005842|stage IV renal cell cancer
686962|NCT00005842|recurrent renal cell cancer
686963|NCT00005842|metastatic parathyroid cancer
686964|NCT00005842|recurrent parathyroid cancer
686965|NCT00005842|stage III vulvar cancer
686966|NCT00005842|stage IVB vulvar cancer
686967|NCT00005842|recurrent vulvar cancer
686968|NCT00005842|stage III vaginal cancer
686969|NCT00005842|stage IVA vaginal cancer
686970|NCT00005842|stage IVB vaginal cancer
686971|NCT00005842|recurrent vaginal cancer
686972|NCT00005842|metastatic gastrointestinal carcinoid tumor
686973|NCT00005842|recurrent gastrointestinal carcinoid tumor
686974|NCT00005842|localized unresectable adult primary liver cancer
686975|NCT00005842|advanced adult primary liver cancer
687510|NCT00005860|insulinoma
686976|NCT00005842|recurrent adult primary liver cancer
686977|NCT00005842|gastrinoma
686978|NCT00005842|stage III endometrial carcinoma
686979|NCT00005842|stage IV endometrial carcinoma
686980|NCT00005842|recurrent endometrial carcinoma
686981|NCT00005842|small intestine adenocarcinoma
686982|NCT00005842|unresectable gallbladder cancer
686983|NCT00005842|recurrent gallbladder cancer
686984|NCT00005842|unresectable extrahepatic bile duct cancer
686985|NCT00005842|recurrent extrahepatic bile duct cancer
686986|NCT00005842|recurrent small intestine cancer
686987|NCT00005842|stage III adrenocortical carcinoma
686988|NCT00005842|stage IV adrenocortical carcinoma
686989|NCT00005842|recurrent adrenocortical carcinoma
686990|NCT00005842|stage III bladder cancer
686991|NCT00005842|recurrent bladder cancer
686992|NCT00005842|stage IV bladder cancer
686993|NCT00005842|stage III malignant testicular germ cell tumor
686994|NCT00005842|stage III prostate cancer
686995|NCT00005842|stage IV prostate cancer
686996|NCT00005842|recurrent prostate cancer
686997|NCT00005842|recurrent malignant testicular germ cell tumor
686998|NCT00005842|insulinoma
686999|NCT00005842|recurrent islet cell carcinoma
687000|NCT00005842|stage IV papillary thyroid cancer
687001|NCT00005842|stage IV follicular thyroid cancer
687002|NCT00005842|thyroid gland medullary carcinoma
687003|NCT00005842|anaplastic thyroid cancer
687004|NCT00005842|recurrent thyroid cancer
687005|NCT00005842|stage IIIA non-small cell lung cancer
687006|NCT00005842|stage IIIB non-small cell lung cancer
687007|NCT00005842|stage IV non-small cell lung cancer
687008|NCT00005842|stage III salivary gland cancer
687009|NCT00005842|stage IV salivary gland cancer
687010|NCT00005842|recurrent salivary gland cancer
687011|NCT00005842|WDHA syndrome
687012|NCT00005842|somatostatinoma
687013|NCT00005842|pancreatic polypeptide tumor
687014|NCT00005842|glucagonoma
687015|NCT00005842|stage III follicular thyroid cancer
687016|NCT00005842|stage III papillary thyroid cancer
687017|NCT00005842|recurrent urethral cancer
687018|NCT00005842|distal urethral cancer
687019|NCT00005842|proximal urethral cancer
687020|NCT00005842|urethral cancer associated with invasive bladder cancer
687021|NCT00005842|metastatic transitional cell cancer of the renal pelvis and ureter
687022|NCT00005842|pulmonary carcinoid tumor
687023|NCT00005842|stage III mucoepidermoid carcinoma of the oral cavity
687024|NCT00005842|stage III adenoid cystic carcinoma of the oral cavity
687025|NCT00005842|stage IV mucoepidermoid carcinoma of the oral cavity
687026|NCT00005842|stage IV adenoid cystic carcinoma of the oral cavity
687027|NCT00005842|recurrent mucoepidermoid carcinoma of the oral cavity
687028|NCT00005842|recurrent adenoid cystic carcinoma of the oral cavity
687029|NCT00005842|tumors metastatic to brain
687030|NCT00005842|lung metastases
687031|NCT00005842|liver metastases
687032|NCT00005842|bone metastases
687033|NCT00005842|skin metastases
687034|NCT00005842|leptomeningeal metastases
687035|NCT00005842|malignant pericardial effusion
687036|NCT00005842|malignant pleural effusion
687037|NCT00005842|newly diagnosed carcinoma of unknown primary
687038|NCT00005842|recurrent transitional cell cancer of the renal pelvis and ureter
687039|NCT00005842|carcinoma of the appendix
687040|NCT00005842|primary peritoneal cavity cancer
687041|NCT00005842|recurrent carcinoma of unknown primary
687042|NCT00005842|male breast cancer
687043|NCT00005842|stage IV pancreatic cancer
687044|NCT00005841|iris melanoma
687045|NCT00005841|ciliary body and choroid melanoma, small size
687046|NCT00005841|ciliary body and choroid melanoma, medium/large size
687047|NCT00005841|extraocular extension melanoma
687048|NCT00005841|recurrent intraocular melanoma
687049|NCT00005841|stage III melanoma
687050|NCT00005841|stage IV melanoma
687051|NCT00005841|recurrent melanoma
687052|NCT00005839|unspecified adult solid tumor, protocol specific
687053|NCT00005837|recurrent cervical cancer
687054|NCT00005837|cervical squamous cell carcinoma
687055|NCT00005836|recurrent ovarian epithelial cancer
687056|NCT00005836|primary peritoneal cavity cancer
687057|NCT00005835|regional neuroblastoma
687058|NCT00005835|disseminated neuroblastoma
687059|NCT00005835|recurrent neuroblastoma
687060|NCT00005835|localized unresectable neuroblastoma
687061|NCT00005834|refractory multiple myeloma
687062|NCT00005834|stage I multiple myeloma
687063|NCT00005834|stage II multiple myeloma
687064|NCT00005834|stage III multiple myeloma
687065|NCT00005833|stage IV colon cancer
687066|NCT00005833|stage IV rectal cancer
687067|NCT00005833|recurrent colon cancer
687068|NCT00005833|recurrent rectal cancer
687069|NCT00005833|adenocarcinoma of the colon
687070|NCT00005833|adenocarcinoma of the rectum
687071|NCT00005832|stage II pancreatic cancer
687072|NCT00005832|stage III pancreatic cancer
687073|NCT00005832|duct cell adenocarcinoma of the pancreas
687074|NCT00005832|adenocarcinoma of the pancreas
687075|NCT00005832|stage IV pancreatic cancer
687076|NCT00005829|refractory chronic lymphocytic leukemia
687077|NCT00005829|B-cell chronic lymphocytic leukemia
687078|NCT00005828|stage IV prostate cancer
687079|NCT00005828|recurrent prostate cancer
687080|NCT00005827|adenocarcinoma of the prostate
687081|NCT00005827|stage II prostate cancer
687082|NCT00005827|stage III prostate cancer
687083|NCT00005827|stage IV prostate cancer
687084|NCT00005827|recurrent prostate cancer
687085|NCT00005826|adult glioblastoma
687086|NCT00005826|adult giant cell glioblastoma
687087|NCT00005826|adult gliosarcoma
687088|NCT00005825|stage IIIB non-small cell lung cancer
687089|NCT00005825|stage IV non-small cell lung cancer
687090|NCT00005824|AIDS-related peripheral/systemic lymphoma
687091|NCT00005824|AIDS-related diffuse large cell lymphoma
687092|NCT00005824|AIDS-related immunoblastic large cell lymphoma
687093|NCT00005824|AIDS-related small noncleaved cell lymphoma
687094|NCT00005824|HIV-associated Hodgkin lymphoma
687095|NCT00005824|AIDS-related diffuse mixed cell lymphoma
687096|NCT00005824|AIDS-related diffuse small cleaved cell lymphoma
687097|NCT00005824|AIDS-related lymphoblastic lymphoma
687098|NCT00005823|untreated adult acute myeloid leukemia
687099|NCT00005823|adult acute erythroid leukemia (M6)
687100|NCT00005823|adult acute myeloblastic leukemia without maturation (M1)
687101|NCT00005823|adult acute myeloblastic leukemia with maturation (M2)
687102|NCT00005823|adult acute myelomonocytic leukemia (M4)
687103|NCT00005823|adult acute monoblastic leukemia (M5a)
687104|NCT00005823|adult acute megakaryoblastic leukemia (M7)
687105|NCT00005823|refractory anemia with excess blasts
687106|NCT00005823|refractory anemia with excess blasts in transformation
687107|NCT00005823|chronic myelomonocytic leukemia
687108|NCT00005823|secondary acute myeloid leukemia
687109|NCT00005823|de novo myelodysplastic syndromes
687110|NCT00005823|adult acute monocytic leukemia (M5b)
687111|NCT00005823|secondary myelodysplastic syndromes
687112|NCT00005823|adult acute minimally differentiated myeloid leukemia (M0)
687113|NCT00005823|atypical chronic myeloid leukemia, BCR-ABL1 negative
687114|NCT00005823|myelodysplastic/myeloproliferative neoplasm, unclassifiable
687115|NCT00005823|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
687116|NCT00005823|adult acute myeloid leukemia with inv(16)(p13;q22)
687117|NCT00005823|adult acute myeloid leukemia with t(16;16)(p13;q22)
687118|NCT00005823|adult acute myeloid leukemia with t(8;21)(q22;q22)
687119|NCT00005822|stage IV breast cancer
687120|NCT00005822|recurrent breast cancer
687121|NCT00005822|stage IIIB breast cancer
687122|NCT00005822|inflammatory breast cancer
687123|NCT00005822|male breast cancer
687124|NCT00005821|stage I breast cancer
687125|NCT00005821|stage II breast cancer
687126|NCT00005923|Joint Instability
687127|NCT00005922|Conditioning
687128|NCT00005922|Corticosteroid
687129|NCT00005922|Lesions
687130|NCT00005922|Pharmacotherapy
687131|NCT00005922|Placebo effect
687132|NCT00005922|Psoriasis
687133|NCT00005922|Psychoneuroimmunology
687134|NCT00005921|Dose-Response Relationship, Drug
687135|NCT00005921|Antifungal Agents
687136|NCT00005921|Candidiasis
687137|NCT00005921|Esophageal Diseases
687138|NCT00005921|MK 0991
687139|NCT00005920|AIDS-Related Opportunistic Infections
687140|NCT00005920|Dose-Response Relationship, Drug
687141|NCT00005920|Fluconazole
687142|NCT00005920|Antifungal Agents
687143|NCT00005920|Candidiasis, Oral
687144|NCT00005920|Pharyngeal Diseases
687145|NCT00005920|MK 0991
687146|NCT00005919|Pigment Dispersion
687147|NCT00005919|Ocular Hypertension
687148|NCT00005919|Glaucoma
687149|NCT00005919|Pupil Reaction
687150|NCT00005919|Natural History
687151|NCT00005919|Pigment Dispersion Syndrome
687152|NCT00005919|Gene Mutation
687153|NCT00005918|Drug Therapy, Combination
687154|NCT00005918|Stavudine
687155|NCT00005918|Lamivudine
687156|NCT00005918|RNA, Viral
687157|NCT00005918|Dosage Forms
687158|NCT00005918|Reverse Transcriptase Inhibitors
687159|NCT00005918|Anti-HIV Agents
687160|NCT00005918|Viral Load
687161|NCT00005918|efavirenz
687162|NCT00005917|Albinism
687163|NCT00005917|Giant Granules
687164|NCT00005917|Infection
687165|NCT00005917|Melanosomes
687166|NCT00005917|Platelet Storage Pool Defect
687167|NCT00005916|Immunotherapy
687168|NCT00005916|Radiation
687169|NCT00005916|Immunology
687170|NCT00005916|Prostvac
687171|NCT00005916|Prostate Cancer
687172|NCT00005915|HIV-1
687173|NCT00005915|Drug Administration Schedule
687174|NCT00005915|Drug Resistance, Microbial
687175|NCT00005915|Disease Progression
687176|NCT00005915|Genotype
687177|NCT00005915|Phenotype
687178|NCT00005915|Drug Resistance, Multiple
687179|NCT00005915|Anti-HIV Agents
687180|NCT00005915|Treatment Experienced
687181|NCT00005914|Depression
687182|NCT00005914|Depressive Disorder
687183|NCT00005914|Family
687184|NCT00005914|Genes
687185|NCT00005914|Genetic Techniques
687186|NCT00005914|Genetics
687187|NCT00005914|Linkage (Genetics)
687188|NCT00005914|Nuclear Family
687189|NCT00005914|Recurrence
687190|NCT00005914|Severity of Illness Index
687191|NCT00005912|Aspergillosis
687192|NCT00005912|Candidiasis
687193|NCT00005912|Fungal Infections
687194|NCT00005912|Fungemia
687195|NCT00005912|Prophylactic Antifungal Therapy
687196|NCT00005912|Pediatric Fungal Infection
687197|NCT00005911|Magnetic Resonance Imaging
687198|NCT00005911|Human Eye
687199|NCT00005911|Lens
687200|NCT00005911|Normal Volunteers
687201|NCT00005911|Cataract
687202|NCT00005911|Human Lens
687203|NCT00005911|Healthy Volunteer
687204|NCT00005910|Islet Cell Tumors
687205|NCT00005910|Surgery
687206|NCT00005910|Ultrasound
687207|NCT00005910|Insulin
687208|NCT00005910|Rapid Assay
687209|NCT00005910|Arteriogram
687210|NCT00005910|Pancreas
687211|NCT00005910|Laparoscopy
687212|NCT00005910|Insulinoma
687213|NCT00005910|Localization
687214|NCT00005910|Hypoglycemia
687215|NCT00005909|Homogentisic Acid
687216|NCT00005909|Ochronosis
687217|NCT00005909|Inborn Error of Metabolism
687218|NCT00005909|Arthritis
687219|NCT00005909|Enzyme Defect
687220|NCT00005909|Alkaptonuria
687221|NCT00005909|Homogentisic Acid Oxidase
687222|NCT00005908|cDNA Microarray
687223|NCT00005908|Stage II and Stage III Breast Cancer
687224|NCT00005908|Biological Response
687225|NCT00005908|Molecular Profiling
687226|NCT00005908|Fine Needle Aspirate
687227|NCT00005908|Breast Cancer
687228|NCT00005907|B Cell
687229|NCT00005907|Reconstitution
687230|NCT00005907|T Cell
687231|NCT00005907|Transplant
687232|NCT00005907|Vaccine
687233|NCT00005906|Chylous Ascites
687234|NCT00005906|Chylous Pleural Effusion
687235|NCT00005906|Inhibitory Effects
687236|NCT00005906|Lymphangioleiomyoma
687237|NCT00005906|Somatostatin
687238|NCT00005906|Lymphangioleiomyomatosis (LAM)
687239|NCT00005905|Adipocyte - Development
687240|NCT00005905|Insulin Resistance
687241|NCT00005905|Dyslipidemia
687242|NCT00005905|Diabetes Mellitus
687243|NCT00005905|Non-Alcoholic Steatohepatitis
687244|NCT00005905|Leptin Replacement
687245|NCT00005903|Parkinsonism
687246|NCT00005903|Trophic Factor
687247|NCT00005903|Neurodegenerative Disorder
687248|NCT00005903|Progressive Supranuclear Palsy
687249|NCT00005902|Brain
687250|NCT00005902|Brainstem
687251|NCT00005902|Cyst
687252|NCT00005902|Magnetic Resonance Imaging
687253|NCT00005902|Spinal Cord
687254|NCT00005902|von Hippel-Lindau
687255|NCT00005901|Bisphosphonates
687256|NCT00005901|Growth Hormone
687257|NCT00005901|Bone Density
687258|NCT00005901|Osteogenesis Imperfecta
687259|NCT00005900|Gaucher's disease
687260|NCT00005900|I cell disease
687261|NCT00005900|Niemann-Pick disease
687262|NCT00005900|Wolman disease
687263|NCT00005900|adrenoleukodystrophy
687264|NCT00005900|disease-related problem/condition
687265|NCT00005900|fucosidosis
687266|NCT00005900|genetic diseases and dysmorphic syndromes
687267|NCT00005900|globoid cell leukodystrophy
687268|NCT00005900|inborn errors of metabolism
687269|NCT00005900|mannosidosis
687270|NCT00005900|metachromatic leukodystrophy
687271|NCT00005900|mucopolysaccharidosis
687272|NCT00005900|mucopolysaccharidosis I
687273|NCT00005900|mucopolysaccharidosis VI
687274|NCT00005900|oncologic disorders
687275|NCT00005900|pulmonary complications
687276|NCT00005900|rare disease
687277|NCT00005900|sphingolipidoses
687278|NCT00005896|Fanconi's anemia
687279|NCT00005896|aplastic anemia
687280|NCT00005896|hematologic disorders
687281|NCT00005896|rare disease
687282|NCT00005893|chronic congenital neutropenia
687283|NCT00005893|chronic neutropenia
687284|NCT00005893|congenital pure red cell aplasia
687285|NCT00005893|disease-related problem/condition
687286|NCT00005893|genetic diseases and dysmorphic syndromes
687287|NCT00005893|hematologic disorders
687288|NCT00005893|neutropenia
687289|NCT00005893|pure red cell aplasia
687290|NCT00005893|rare disease
687291|NCT00005893|sickle cell anemia
687292|NCT00005893|thalassemia major
687293|NCT00005892|Fanconi's anemia
687294|NCT00005892|acute leukemia
687295|NCT00005892|acute lymphocytic leukemia
687296|NCT00005892|acute myeloid leukemia
687297|NCT00005892|acute undifferentiated leukemia
687298|NCT00005892|adult acute lymphoblastic leukemia
687299|NCT00005892|adult acute lymphoblastic leukemia in remission
687300|NCT00005892|adult acute myeloid leukemia
687301|NCT00005892|adult acute myeloid leukemia in remission
687302|NCT00005892|aplastic anemia
687303|NCT00005892|childhood acute lymphoblastic leukemia
687304|NCT00005892|childhood acute lymphoblastic leukemia in remission
687305|NCT00005892|childhood acute myeloid leukemia
687306|NCT00005892|childhood acute myeloid leukemia in remission
687307|NCT00005892|de novo myelodysplastic syndrome
687308|NCT00005892|hematologic disorders
687309|NCT00005892|hematopoietic/lymphoid cancer
687311|NCT00005892|myelodysplastic syndrome
687312|NCT00005892|oncologic disorders
687313|NCT00005892|previously treated myelodysplastic syndrome
687314|NCT00005892|rare disease
687315|NCT00005892|secondary myelodysplastic syndrome
687316|NCT00005891|Fanconi's Anemia
687317|NCT00005891|aplastic anemia
687318|NCT00005891|hematologic disorders
687319|NCT00005891|rare disease
687320|NCT00005890|immunologic disorders and infectious disorders
687321|NCT00005890|rare disease
687322|NCT00005890|sepsis
687323|NCT00005890|septic shock
687324|NCT00005889|endocrine disorders
687325|NCT00005889|hyperglycemia
687326|NCT00005889|low birth weight
687327|NCT00005889|neonatal disorders
687328|NCT00005889|rare disease
687329|NCT00005888|gastrointestinal disorders
687330|NCT00005888|immunologic disorders and infectious disorders
687331|NCT00005888|low birth weight
687332|NCT00005888|necrotizing enterocolitis
687333|NCT00005888|neonatal disorders
687334|NCT00005888|rare disease
687335|NCT00005888|sepsis
687336|NCT00005887|tumors metastatic to brain
687337|NCT00005886|stage I breast cancer
687338|NCT00005886|stage II breast cancer
687339|NCT00005886|ductal breast carcinoma in situ
687340|NCT00005886|breast cancer in situ
687341|NCT00005884|basal cell carcinoma of the skin
687342|NCT00005884|squamous cell carcinoma of the skin
687343|NCT00005883|non-small cell lung cancer
687344|NCT00005883|small cell lung cancer
687345|NCT00005882|colon cancer
687346|NCT00005882|rectal cancer
687347|NCT00005881|recurrent childhood acute lymphoblastic leukemia
687348|NCT00005881|childhood Burkitt lymphoma
687349|NCT00005881|stage I childhood lymphoblastic lymphoma
687350|NCT00005881|stage II childhood lymphoblastic lymphoma
687351|NCT00005881|stage III childhood lymphoblastic lymphoma
687352|NCT00005881|stage IV childhood lymphoblastic lymphoma
687353|NCT00005881|recurrent childhood lymphoblastic lymphoma
687354|NCT00005881|recurrent childhood acute myeloid leukemia
687355|NCT00005881|childhood diffuse large cell lymphoma
687356|NCT00005881|childhood immunoblastic large cell lymphoma
687357|NCT00005881|unspecified childhood solid tumor, protocol specific
687358|NCT00005881|childhood acute myeloid leukemia in remission
687359|NCT00005881|stage II childhood Hodgkin lymphoma
687360|NCT00005881|stage I childhood Hodgkin lymphoma
687361|NCT00005881|stage III childhood Hodgkin lymphoma
687362|NCT00005881|stage IV childhood Hodgkin lymphoma
687363|NCT00005881|recurrent/refractory childhood Hodgkin lymphoma
687364|NCT00005881|stage I childhood small noncleaved cell lymphoma
687365|NCT00005881|stage I childhood large cell lymphoma
687366|NCT00005881|stage II childhood small noncleaved cell lymphoma
687367|NCT00005881|stage II childhood large cell lymphoma
687368|NCT00005881|stage III childhood small noncleaved cell lymphoma
687369|NCT00005881|stage III childhood large cell lymphoma
687370|NCT00005881|stage IV childhood small noncleaved cell lymphoma
687371|NCT00005881|stage IV childhood large cell lymphoma
687372|NCT00005881|recurrent childhood small noncleaved cell lymphoma
687373|NCT00005881|recurrent childhood large cell lymphoma
687374|NCT00005880|non-small cell lung cancer
687375|NCT00005880|small cell lung cancer
687376|NCT00005879|breast cancer
687377|NCT00005878|esophageal cancer
687378|NCT00005877|stage III colon cancer
687379|NCT00005877|stage IV colon cancer
687380|NCT00005877|stage III rectal cancer
687381|NCT00005877|stage IV rectal cancer
687382|NCT00005877|recurrent colon cancer
687383|NCT00005877|recurrent rectal cancer
687384|NCT00005876|stage III gastric cancer
687385|NCT00005876|stage IV gastric cancer
687386|NCT00005876|recurrent gastric cancer
687387|NCT00005876|stage III esophageal cancer
687388|NCT00005876|stage IV esophageal cancer
687389|NCT00005876|recurrent esophageal cancer
687390|NCT00005876|adenocarcinoma of the stomach
687391|NCT00005876|adenocarcinoma of the esophagus
687392|NCT00005875|stage IV melanoma
687393|NCT00005875|recurrent melanoma
687394|NCT00005874|adult leiomyosarcoma
687395|NCT00005874|stage III adult soft tissue sarcoma
687396|NCT00005874|recurrent adult soft tissue sarcoma
687397|NCT00005874|small intestine leiomyosarcoma
687398|NCT00005874|metastatic childhood soft tissue sarcoma
687399|NCT00005874|recurrent childhood soft tissue sarcoma
687400|NCT00005874|childhood leiomyosarcoma
687401|NCT00005874|gastrointestinal stromal tumor
687402|NCT00005874|stage IV adult soft tissue sarcoma
687403|NCT00005873|stage IV breast cancer
687404|NCT00005873|recurrent breast cancer
687405|NCT00005872|recurrent non-small cell lung cancer
687406|NCT00005871|recurrent pancreatic cancer
687407|NCT00005871|adenocarcinoma of the pancreas
687408|NCT00005870|recurrent pancreatic cancer
687409|NCT00005870|adenocarcinoma of the pancreas
687410|NCT00005869|stage II pancreatic cancer
687411|NCT00005869|stage III pancreatic cancer
687412|NCT00005869|recurrent pancreatic cancer
687413|NCT00005869|adenocarcinoma of the pancreas
687414|NCT00005869|stage IV pancreatic cancer
687415|NCT00005868|stage IIIA non-small cell lung cancer
687416|NCT00005867|stage I grade 3 follicular lymphoma
687417|NCT00005867|stage I adult diffuse mixed cell lymphoma
687418|NCT00005867|stage I adult diffuse large cell lymphoma
687419|NCT00005867|stage I adult immunoblastic large cell lymphoma
687420|NCT00005867|stage III grade 3 follicular lymphoma
687421|NCT00005867|stage III adult diffuse mixed cell lymphoma
687422|NCT00005867|stage III adult diffuse large cell lymphoma
687423|NCT00005867|stage III adult immunoblastic large cell lymphoma
687424|NCT00005867|stage IV grade 3 follicular lymphoma
687425|NCT00005867|stage IV adult diffuse mixed cell lymphoma
687426|NCT00005867|stage IV adult diffuse large cell lymphoma
687427|NCT00005867|stage IV adult immunoblastic large cell lymphoma
687428|NCT00005867|contiguous stage II grade 3 follicular lymphoma
687429|NCT00005867|contiguous stage II adult diffuse mixed cell lymphoma
687430|NCT00005867|contiguous stage II adult immunoblastic large cell lymphoma
687431|NCT00005867|contiguous stage II adult diffuse large cell lymphoma
687432|NCT00005867|noncontiguous stage II grade 3 follicular lymphoma
687433|NCT00005867|noncontiguous stage II adult diffuse mixed cell lymphoma
687434|NCT00005867|noncontiguous stage II adult immunoblastic large cell lymphoma
687435|NCT00005867|noncontiguous stage II adult diffuse large cell lymphoma
687436|NCT00005866|untreated adult acute myeloid leukemia
687437|NCT00005866|refractory anemia with excess blasts
687438|NCT00005866|refractory anemia with excess blasts in transformation
687439|NCT00005866|chronic myelomonocytic leukemia
687440|NCT00005866|secondary acute myeloid leukemia
687441|NCT00005866|de novo myelodysplastic syndromes
687442|NCT00005866|secondary myelodysplastic syndromes
687443|NCT00005866|childhood myelodysplastic syndromes
687444|NCT00005865|stage IIIB non-small cell lung cancer
687445|NCT00005865|stage IV non-small cell lung cancer
687446|NCT00005864|stage IV colon cancer
687447|NCT00005864|stage IV rectal cancer
687448|NCT00005864|recurrent colon cancer
687449|NCT00005864|recurrent rectal cancer
687450|NCT00005863|recurrent childhood acute myeloid leukemia
687451|NCT00005863|recurrent adult acute myeloid leukemia
687452|NCT00005863|adult acute myeloid leukemia in remission
687453|NCT00005863|childhood acute myeloid leukemia in remission
687454|NCT00005863|adult acute erythroid leukemia (M6)
687455|NCT00005863|adult acute myeloblastic leukemia without maturation (M1)
687456|NCT00005863|adult acute myeloblastic leukemia with maturation (M2)
687457|NCT00005863|adult acute myelomonocytic leukemia (M4)
687458|NCT00005863|adult acute monoblastic leukemia (M5a)
687459|NCT00005863|adult acute megakaryoblastic leukemia (M7)
687460|NCT00005863|childhood acute myeloblastic leukemia without maturation (M1)
687461|NCT00005863|childhood acute myeloblastic leukemia with maturation (M2)
687462|NCT00005863|childhood acute myelomonocytic leukemia (M4)
687463|NCT00005863|childhood acute monoblastic leukemia (M5a)
687464|NCT00005863|childhood acute monocytic leukemia (M5b)
687465|NCT00005863|childhood acute erythroleukemia (M6)
687466|NCT00005863|childhood acute megakaryocytic leukemia (M7)
687467|NCT00005863|secondary acute myeloid leukemia
687468|NCT00005863|de novo myelodysplastic syndromes
687469|NCT00005863|adult acute monocytic leukemia (M5b)
687470|NCT00005863|previously treated myelodysplastic syndromes
687471|NCT00005863|secondary myelodysplastic syndromes
687472|NCT00005863|adult acute minimally differentiated myeloid leukemia (M0)
687473|NCT00005863|childhood acute minimally differentiated myeloid leukemia (M0)
687474|NCT00005863|atypical chronic myeloid leukemia, BCR-ABL1 negative
687475|NCT00005863|myelodysplastic/myeloproliferative neoplasm, unclassifiable
687476|NCT00005863|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
687477|NCT00005863|adult acute myeloid leukemia with inv(16)(p13;q22)
687478|NCT00005863|adult acute myeloid leukemia with t(16;16)(p13;q22)
687479|NCT00005863|adult acute myeloid leukemia with t(8;21)(q22;q22)
687480|NCT00005863|childhood myelodysplastic syndromes
687481|NCT00005862|stage III adult soft tissue sarcoma
687482|NCT00005862|recurrent adult soft tissue sarcoma
687483|NCT00005862|gastrointestinal stromal tumor
687484|NCT00005862|stage IV adult soft tissue sarcoma
687485|NCT00005861|stage III endometrial carcinoma
687486|NCT00005861|stage IV endometrial carcinoma
687487|NCT00005861|recurrent endometrial carcinoma
687488|NCT00005860|stage IV colon cancer
687489|NCT00005860|stage IV gastric cancer
687490|NCT00005860|recurrent gastric cancer
687491|NCT00005860|recurrent pancreatic cancer
687492|NCT00005860|recurrent colon cancer
687493|NCT00005860|regional neuroblastoma
687494|NCT00005860|stage 4S neuroblastoma
687495|NCT00005860|recurrent neuroblastoma
687496|NCT00005860|regional gastrointestinal carcinoid tumor
687497|NCT00005860|metastatic gastrointestinal carcinoid tumor
687498|NCT00005860|recurrent gastrointestinal carcinoid tumor
687499|NCT00005860|advanced adult primary liver cancer
687500|NCT00005860|recurrent adult primary liver cancer
687501|NCT00005860|gastrinoma
687502|NCT00005860|small intestine adenocarcinoma
687503|NCT00005860|small intestine lymphoma
687504|NCT00005860|small intestine leiomyosarcoma
687505|NCT00005860|unresectable gallbladder cancer
687506|NCT00005860|recurrent gallbladder cancer
687507|NCT00005860|unresectable extrahepatic bile duct cancer
687508|NCT00005860|recurrent extrahepatic bile duct cancer
687509|NCT00005860|recurrent small intestine cancer
687511|NCT00005860|recurrent islet cell carcinoma
687512|NCT00005860|WDHA syndrome
687513|NCT00005860|somatostatinoma
687514|NCT00005860|pancreatic polypeptide tumor
687515|NCT00005860|glucagonoma
687516|NCT00005860|regional pheochromocytoma
687517|NCT00005860|metastatic pheochromocytoma
687518|NCT00005860|recurrent pheochromocytoma
687519|NCT00005860|extragonadal germ cell tumor
687520|NCT00005860|liver metastases
687521|NCT00005860|malignant ascites
687522|NCT00005860|newly diagnosed carcinoma of unknown primary
687523|NCT00005860|carcinoma of the appendix
687524|NCT00005860|pseudomyxoma peritonei
687525|NCT00005860|fallopian tube cancer
687526|NCT00005860|primary peritoneal cavity cancer
687527|NCT00005860|recurrent carcinoma of unknown primary
687528|NCT00005860|gastrointestinal stromal tumor
687529|NCT00005860|stage IV pancreatic cancer
687530|NCT00005859|recurrent adult brain tumor
687531|NCT00005859|adult glioblastoma
687532|NCT00005859|adult giant cell glioblastoma
687533|NCT00005859|adult gliosarcoma
687534|NCT00005858|stage III colon cancer
687535|NCT00005858|stage IV colon cancer
687536|NCT00005858|stage IV breast cancer
687537|NCT00005858|stage IIIA breast cancer
687538|NCT00005858|recurrent breast cancer
687539|NCT00005858|stage IIIB breast cancer
687540|NCT00005858|recurrent non-small cell lung cancer
687541|NCT00005858|stage II pancreatic cancer
687542|NCT00005858|stage III pancreatic cancer
687543|NCT00005858|recurrent pancreatic cancer
687544|NCT00005858|recurrent colon cancer
687545|NCT00005858|stage III ovarian epithelial cancer
687546|NCT00005858|stage IV ovarian epithelial cancer
687547|NCT00005858|recurrent ovarian epithelial cancer
687548|NCT00005858|stage III bladder cancer
687549|NCT00005858|recurrent bladder cancer
687550|NCT00005858|stage IV bladder cancer
687551|NCT00005858|stage IIIA non-small cell lung cancer
687552|NCT00005858|stage IIIB non-small cell lung cancer
687553|NCT00005858|stage IV non-small cell lung cancer
687554|NCT00005858|ovarian stromal cancer
687555|NCT00005858|stage III ovarian germ cell tumor
687556|NCT00005858|stage IV ovarian germ cell tumor
687557|NCT00005858|recurrent ovarian germ cell tumor
687558|NCT00005858|borderline ovarian surface epithelial-stromal tumor
687559|NCT00005858|ovarian sarcoma
687560|NCT00005858|male breast cancer
687561|NCT00005858|stage IV pancreatic cancer
687562|NCT00005857|stage IV prostate cancer
687563|NCT00005857|recurrent prostate cancer
687564|NCT00005855|adult glioblastoma
687565|NCT00005855|adult anaplastic astrocytoma
687566|NCT00005855|adult anaplastic oligodendroglioma
687567|NCT00005855|recurrent adult brain tumor
687568|NCT00005855|adult giant cell glioblastoma
687569|NCT00005855|adult gliosarcoma
687570|NCT00005854|recurrent childhood acute lymphoblastic leukemia
687571|NCT00005854|refractory multiple myeloma
687572|NCT00005854|stage I multiple myeloma
687573|NCT00005854|stage II multiple myeloma
687574|NCT00005854|stage III multiple myeloma
687575|NCT00005854|recurrent childhood lymphoblastic lymphoma
687576|NCT00005854|stage III chronic lymphocytic leukemia
687577|NCT00005854|stage IV chronic lymphocytic leukemia
687578|NCT00005854|recurrent childhood acute myeloid leukemia
687579|NCT00005854|recurrent adult acute myeloid leukemia
687580|NCT00005854|recurrent adult acute lymphoblastic leukemia
687581|NCT00005854|relapsing chronic myelogenous leukemia
687582|NCT00005854|refractory chronic lymphocytic leukemia
687583|NCT00005854|accelerated phase chronic myelogenous leukemia
687584|NCT00005854|blastic phase chronic myelogenous leukemia
687585|NCT00005854|meningeal chronic myelogenous leukemia
687586|NCT00005854|adult acute myeloid leukemia in remission
687587|NCT00005854|adult acute lymphoblastic leukemia in remission
687588|NCT00005854|childhood acute myeloid leukemia in remission
687589|NCT00005854|childhood acute lymphoblastic leukemia in remission
687590|NCT00005854|recurrent grade 1 follicular lymphoma
687591|NCT00005854|recurrent grade 2 follicular lymphoma
687592|NCT00005854|recurrent grade 3 follicular lymphoma
687593|NCT00005854|recurrent adult diffuse small cleaved cell lymphoma
687594|NCT00005854|recurrent adult diffuse mixed cell lymphoma
687595|NCT00005854|recurrent adult diffuse large cell lymphoma
687596|NCT00005854|recurrent adult immunoblastic large cell lymphoma
687597|NCT00005854|recurrent adult lymphoblastic lymphoma
687598|NCT00005854|recurrent adult Burkitt lymphoma
687599|NCT00005854|secondary acute myeloid leukemia
687600|NCT00005854|de novo myelodysplastic syndromes
687601|NCT00005854|previously treated myelodysplastic syndromes
687602|NCT00005854|secondary myelodysplastic syndromes
687603|NCT00005854|recurrent childhood small noncleaved cell lymphoma
687604|NCT00005854|recurrent childhood large cell lymphoma
687605|NCT00005854|recurrent mantle cell lymphoma
687606|NCT00005854|recurrent marginal zone lymphoma
687607|NCT00005854|recurrent small lymphocytic lymphoma
687608|NCT00005854|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
687609|NCT00005854|nodal marginal zone B-cell lymphoma
687610|NCT00005854|splenic marginal zone lymphoma
687611|NCT00005854|childhood myelodysplastic syndromes
687612|NCT00005853|refractory anemia
687613|NCT00005853|refractory anemia with ringed sideroblasts
687614|NCT00005853|refractory anemia with excess blasts
687615|NCT00005853|refractory anemia with excess blasts in transformation
687616|NCT00005853|de novo myelodysplastic syndromes
687617|NCT00005853|previously treated myelodysplastic syndromes
687618|NCT00005853|secondary myelodysplastic syndromes
687619|NCT00005853|refractory cytopenia with multilineage dysplasia
687620|NCT00005853|childhood myelodysplastic syndromes
687621|NCT00005852|recurrent childhood acute lymphoblastic leukemia
687622|NCT00005852|recurrent adult Hodgkin lymphoma
687623|NCT00005852|recurrent cutaneous T-cell non-Hodgkin lymphoma
687624|NCT00005852|refractory multiple myeloma
687625|NCT00005852|stage I multiple myeloma
687626|NCT00005852|stage II multiple myeloma
687627|NCT00005852|stage III multiple myeloma
687628|NCT00005852|recurrent childhood lymphoblastic lymphoma
687629|NCT00005852|recurrent childhood acute myeloid leukemia
687630|NCT00005852|recurrent adult acute myeloid leukemia
687631|NCT00005852|recurrent adult acute lymphoblastic leukemia
687632|NCT00005852|relapsing chronic myelogenous leukemia
687633|NCT00005852|refractory chronic lymphocytic leukemia
687634|NCT00005852|primary myelofibrosis
687635|NCT00005852|childhood acute promyelocytic leukemia (M3)
687636|NCT00005852|refractory hairy cell leukemia
687637|NCT00005852|recurrent/refractory childhood Hodgkin lymphoma
687638|NCT00005852|recurrent grade 1 follicular lymphoma
687639|NCT00005852|recurrent grade 2 follicular lymphoma
687640|NCT00005852|recurrent grade 3 follicular lymphoma
687641|NCT00005852|recurrent adult diffuse small cleaved cell lymphoma
687642|NCT00005852|recurrent adult diffuse mixed cell lymphoma
687643|NCT00005852|recurrent adult diffuse large cell lymphoma
687644|NCT00005852|recurrent adult immunoblastic large cell lymphoma
687645|NCT00005852|recurrent adult lymphoblastic lymphoma
687646|NCT00005852|recurrent adult Burkitt lymphoma
687647|NCT00005852|previously treated myelodysplastic syndromes
687648|NCT00005852|secondary myelodysplastic syndromes
687649|NCT00005852|graft versus host disease
687650|NCT00005852|recurrent childhood small noncleaved cell lymphoma
687651|NCT00005852|recurrent childhood large cell lymphoma
687652|NCT00005852|recurrent mantle cell lymphoma
687653|NCT00005852|recurrent marginal zone lymphoma
687654|NCT00005852|recurrent small lymphocytic lymphoma
687655|NCT00005852|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
687656|NCT00005852|nodal marginal zone B-cell lymphoma
687657|NCT00005852|splenic marginal zone lymphoma
687658|NCT00005852|childhood myelodysplastic syndromes
687659|NCT00005850|stage I non-small cell lung cancer
687660|NCT00005850|stage II non-small cell lung cancer
687661|NCT00005850|recurrent non-small cell lung cancer
687662|NCT00005850|squamous cell lung cancer
687663|NCT00005850|large cell lung cancer
687664|NCT00005850|stage IIIA non-small cell lung cancer
687665|NCT00005850|stage IIIB non-small cell lung cancer
687666|NCT00005850|stage IV non-small cell lung cancer
687667|NCT00005850|adenocarcinoma of the lung
687668|NCT00005850|adenosquamous cell lung cancer
687669|NCT00005850|fatigue
687670|NCT00005850|anxiety disorder
687671|NCT00005850|depression
687672|NCT00005849|recurrent non-small cell lung cancer
687673|NCT00005849|stage IIIB non-small cell lung cancer
687674|NCT00005849|stage IV non-small cell lung cancer
687675|NCT00005848|adenocarcinoma of the prostate
687676|NCT00005848|stage IV prostate cancer
687677|NCT00005848|recurrent prostate cancer
687678|NCT00005847|adenocarcinoma of the prostate
687679|NCT00005847|stage IV prostate cancer
687680|NCT00005847|recurrent prostate cancer
687681|NCT00005846|relapsing chronic myelogenous leukemia
687682|NCT00005846|chronic phase chronic myelogenous leukemia
687683|NCT00005846|accelerated phase chronic myelogenous leukemia
687684|NCT00005846|chronic myelogenous leukemia, BCR-ABL1 positive
687685|NCT00005846|Philadelphia chromosome negative chronic myelogenous leukemia
687686|NCT00005846|chronic myelomonocytic leukemia
687687|NCT00005846|atypical chronic myeloid leukemia, BCR-ABL1 negative
687688|NCT00005846|myelodysplastic/myeloproliferative neoplasm, unclassifiable
687689|NCT00005844|unspecified childhood solid tumor, protocol specific
687690|NCT00005843|recurrent pancreatic cancer
687691|NCT00005843|adenocarcinoma of the pancreas
687692|NCT00005843|stage IV pancreatic cancer
687693|NCT00005820|adenocarcinoma of the prostate
687694|NCT00005820|stage IV prostate cancer
687695|NCT00005820|recurrent prostate cancer
687696|NCT00005819|unspecified adult solid tumor, protocol specific
687697|NCT00005816|stage III renal cell cancer
687698|NCT00005816|stage IV renal cell cancer
687699|NCT00005815|iris melanoma
687700|NCT00005815|ciliary body and choroid melanoma, small size
687701|NCT00005815|ciliary body and choroid melanoma, medium/large size
687702|NCT00005815|extraocular extension melanoma
687703|NCT00005815|recurrent intraocular melanoma
687704|NCT00005815|stage III melanoma
687705|NCT00005815|stage IV melanoma
687706|NCT00005815|recurrent melanoma
687707|NCT00005814|stage III squamous cell carcinoma of the lip and oral cavity
687708|NCT00005814|stage IV squamous cell carcinoma of the lip and oral cavity
687709|NCT00005814|recurrent squamous cell carcinoma of the lip and oral cavity
687710|NCT00005814|stage III squamous cell carcinoma of the oropharynx
687711|NCT00005814|stage IV squamous cell carcinoma of the oropharynx
687712|NCT00005814|recurrent squamous cell carcinoma of the oropharynx
687713|NCT00005814|stage III squamous cell carcinoma of the hypopharynx
687714|NCT00005814|stage IV squamous cell carcinoma of the hypopharynx
687715|NCT00005814|recurrent squamous cell carcinoma of the hypopharynx
687716|NCT00005814|stage III squamous cell carcinoma of the larynx
687717|NCT00005814|stage IV squamous cell carcinoma of the larynx
687718|NCT00005814|recurrent squamous cell carcinoma of the larynx
687719|NCT00005814|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
687720|NCT00005814|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
687721|NCT00005814|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
687722|NCT00005813|adult glioblastoma
687723|NCT00005813|adult giant cell glioblastoma
687724|NCT00005813|adult gliosarcoma
687725|NCT00005812|leptomeningeal metastases
687726|NCT00005812|temozolomide
687727|NCT00005810|adenocarcinoma of the prostate
687728|NCT00005810|stage IV prostate cancer
687729|NCT00005810|recurrent prostate cancer
687730|NCT00005809|colon cancer
687731|NCT00005809|rectal cancer
687732|NCT00005807|stage IV breast cancer
687733|NCT00005807|stage IIIA breast cancer
687734|NCT00005807|recurrent breast cancer
687735|NCT00005807|stage IIIB breast cancer
687736|NCT00005807|stage III ovarian epithelial cancer
687737|NCT00005807|stage IV ovarian epithelial cancer
687738|NCT00005807|recurrent ovarian epithelial cancer
687739|NCT00005807|unspecified adult solid tumor, protocol specific
687740|NCT00005807|ovarian stromal cancer
687741|NCT00005807|stage III ovarian germ cell tumor
687742|NCT00005807|stage IV ovarian germ cell tumor
687743|NCT00005807|recurrent ovarian germ cell tumor
687744|NCT00005807|borderline ovarian surface epithelial-stromal tumor
687745|NCT00005807|ovarian sarcoma
687746|NCT00005807|male breast cancer
687747|NCT00005806|recurrent non-small cell lung cancer
687748|NCT00005806|stage IIIA non-small cell lung cancer
687749|NCT00005806|stage IIIB non-small cell lung cancer
687750|NCT00005806|stage IV non-small cell lung cancer
687751|NCT00005805|stage I adult Hodgkin lymphoma
687752|NCT00005805|stage II adult Hodgkin lymphoma
687753|NCT00005805|stage III adult Hodgkin lymphoma
687754|NCT00005805|stage IV adult Hodgkin lymphoma
687755|NCT00005805|monoclonal gammopathy of undetermined significance
687756|NCT00005805|recurrent adult Hodgkin lymphoma
687757|NCT00005805|stage I cutaneous T-cell non-Hodgkin lymphoma
687758|NCT00005805|stage II cutaneous T-cell non-Hodgkin lymphoma
687759|NCT00005805|stage III cutaneous T-cell non-Hodgkin lymphoma
687760|NCT00005805|stage IV cutaneous T-cell non-Hodgkin lymphoma
687761|NCT00005805|recurrent cutaneous T-cell non-Hodgkin lymphoma
687762|NCT00005805|childhood Burkitt lymphoma
687763|NCT00005805|isolated plasmacytoma of bone
687764|NCT00005805|extramedullary plasmacytoma
687765|NCT00005805|refractory multiple myeloma
687766|NCT00005805|stage 0 chronic lymphocytic leukemia
687767|NCT00005805|Waldenström macroglobulinemia
687768|NCT00005805|stage I multiple myeloma
687769|NCT00005805|stage II multiple myeloma
687770|NCT00005805|stage III multiple myeloma
687771|NCT00005805|stage I chronic lymphocytic leukemia
687772|NCT00005805|stage II chronic lymphocytic leukemia
687773|NCT00005805|stage III chronic lymphocytic leukemia
687774|NCT00005805|stage IV chronic lymphocytic leukemia
687775|NCT00005805|recurrent childhood acute myeloid leukemia
687776|NCT00005805|recurrent adult acute myeloid leukemia
687777|NCT00005805|recurrent adult acute lymphoblastic leukemia
687778|NCT00005805|relapsing chronic myelogenous leukemia
687779|NCT00005805|refractory chronic lymphocytic leukemia
687780|NCT00005805|unspecified adult solid tumor, protocol specific
687781|NCT00005805|chronic phase chronic myelogenous leukemia
687782|NCT00005805|accelerated phase chronic myelogenous leukemia
687783|NCT00005805|blastic phase chronic myelogenous leukemia
687784|NCT00005805|meningeal chronic myelogenous leukemia
687785|NCT00005805|untreated adult acute lymphoblastic leukemia
687786|NCT00005805|untreated adult acute myeloid leukemia
687787|NCT00005805|untreated childhood acute myeloid leukemia and other myeloid malignancies
687788|NCT00005805|adult acute lymphoblastic leukemia in remission
687789|NCT00005805|childhood acute myeloid leukemia in remission
687790|NCT00005805|polycythemia vera
687791|NCT00005805|primary myelofibrosis
687792|NCT00005805|essential thrombocythemia
687793|NCT00005805|untreated hairy cell leukemia
687794|NCT00005805|progressive hairy cell leukemia, initial treatment
687795|NCT00005805|refractory hairy cell leukemia
687796|NCT00005805|stage II childhood Hodgkin lymphoma
687797|NCT00005805|stage I childhood Hodgkin lymphoma
687798|NCT00005805|stage III childhood Hodgkin lymphoma
687799|NCT00005805|stage IV childhood Hodgkin lymphoma
687800|NCT00005805|recurrent/refractory childhood Hodgkin lymphoma
687801|NCT00005805|stage I small lymphocytic lymphoma
687802|NCT00005805|stage I grade 1 follicular lymphoma
687803|NCT00005805|stage I grade 2 follicular lymphoma
687804|NCT00005805|stage I grade 3 follicular lymphoma
687805|NCT00005805|stage I adult diffuse small cleaved cell lymphoma
687806|NCT00005805|stage I adult diffuse mixed cell lymphoma
687807|NCT00005805|stage I adult diffuse large cell lymphoma
687808|NCT00005805|stage I adult immunoblastic large cell lymphoma
687809|NCT00005805|stage I adult lymphoblastic lymphoma
687810|NCT00005805|stage I adult Burkitt lymphoma
687811|NCT00005805|stage I adult non-Hodgkin lymphoma
687812|NCT00005805|stage II adult non-Hodgkin lymphoma
687813|NCT00005805|stage II small lymphocytic lymphoma
687814|NCT00005805|stage II grade 1 follicular lymphoma
687815|NCT00005805|stage II grade 2 follicular lymphoma
687816|NCT00005805|stage II grade 3 follicular lymphoma
687817|NCT00005805|stage II adult diffuse small cleaved cell lymphoma
687818|NCT00005805|stage II adult diffuse mixed cell lymphoma
687819|NCT00005805|stage II adult diffuse large cell lymphoma
687820|NCT00005805|stage II adult immunoblastic large cell lymphoma
687821|NCT00005805|stage II adult lymphoblastic lymphoma
687822|NCT00005805|stage II adult Burkitt lymphoma
687823|NCT00005805|stage III small lymphocytic lymphoma
687824|NCT00005805|stage III grade 1 follicular lymphoma
687825|NCT00005805|stage III grade 2 follicular lymphoma
687826|NCT00005805|stage III grade 3 follicular lymphoma
687827|NCT00005805|stage III adult diffuse small cleaved cell lymphoma
687828|NCT00005805|stage III adult diffuse mixed cell lymphoma
687829|NCT00005805|stage III adult diffuse large cell lymphoma
687830|NCT00005805|stage III adult immunoblastic large cell lymphoma
687831|NCT00005805|stage III adult lymphoblastic lymphoma
687832|NCT00005805|stage III adult Burkitt lymphoma
687833|NCT00005805|stage IV small lymphocytic lymphoma
687834|NCT00005805|stage IV grade 1 follicular lymphoma
687835|NCT00005805|stage IV grade 2 follicular lymphoma
687836|NCT00005805|stage IV grade 3 follicular lymphoma
687837|NCT00005805|stage IV adult diffuse small cleaved cell lymphoma
687838|NCT00005805|stage IV adult diffuse mixed cell lymphoma
687839|NCT00005805|stage IV adult diffuse large cell lymphoma
687840|NCT00005805|stage IV adult immunoblastic large cell lymphoma
687841|NCT00005805|stage IV adult lymphoblastic lymphoma
687842|NCT00005805|stage IV adult Burkitt lymphoma
687843|NCT00005805|recurrent small lymphocytic lymphoma
687844|NCT00005805|recurrent grade 1 follicular lymphoma
687845|NCT00005805|recurrent grade 2 follicular lymphoma
687846|NCT00005805|recurrent grade 3 follicular lymphoma
687847|NCT00005805|recurrent adult diffuse small cleaved cell lymphoma
687848|NCT00005805|recurrent adult diffuse mixed cell lymphoma
687849|NCT00005805|recurrent adult diffuse large cell lymphoma
687850|NCT00005805|recurrent adult immunoblastic large cell lymphoma
687851|NCT00005805|recurrent adult lymphoblastic lymphoma
687852|NCT00005805|recurrent adult Burkitt lymphoma
687853|NCT00005805|stage I adult T-cell leukemia/lymphoma
687854|NCT00005805|stage II adult T-cell leukemia/lymphoma
687855|NCT00005805|stage III adult T-cell leukemia/lymphoma
687856|NCT00005805|stage IV adult T-cell leukemia/lymphoma
687857|NCT00005805|recurrent adult T-cell leukemia/lymphoma
687858|NCT00005805|de novo myelodysplastic syndromes
687859|NCT00005805|previously treated myelodysplastic syndromes
687860|NCT00005805|secondary myelodysplastic syndromes
687861|NCT00005805|primary central nervous system non-Hodgkin lymphoma
687862|NCT00005805|fatigue
687863|NCT00005805|AIDS-related peripheral/systemic lymphoma
687864|NCT00005805|AIDS-related primary CNS lymphoma
687865|NCT00005805|primary systemic amyloidosis
687866|NCT00005805|intraocular lymphoma
687867|NCT00005805|stage I mantle cell lymphoma
687868|NCT00005805|contiguous stage II adult non-Hodgkin lymphoma
687869|NCT00005805|contiguous stage II grade 1 follicular lymphoma
687870|NCT00005805|contiguous stage II grade 2 follicular lymphoma
687871|NCT00005805|contiguous stage II grade 3 follicular lymphoma
687872|NCT00005805|contiguous stage II adult diffuse small cleaved cell lymphoma
687873|NCT00005805|contiguous stage II mantle cell lymphoma
687874|NCT00005805|contiguous stage II adult diffuse mixed cell lymphoma
687875|NCT00005805|contiguous stage II adult immunoblastic large cell lymphoma
687876|NCT00005805|contiguous stage II adult diffuse large cell lymphoma
687877|NCT00005805|contiguous stage II adult Burkitt lymphoma
687878|NCT00005805|contiguous stage II adult lymphoblastic lymphoma
687879|NCT00005805|noncontiguous stage II adult non-Hodgkin lymphoma
687880|NCT00005805|noncontiguous stage II grade 1 follicular lymphoma
687881|NCT00005805|noncontiguous stage II grade 2 follicular lymphoma
687882|NCT00005805|noncontiguous stage II grade 3 follicular lymphoma
687883|NCT00005805|noncontiguous stage II adult diffuse small cleaved cell lymphoma
687884|NCT00005805|noncontiguous stage II mantle cell lymphoma
687885|NCT00005805|noncontiguous stage II adult diffuse mixed cell lymphoma
687886|NCT00005805|noncontiguous stage II adult immunoblastic large cell lymphoma
687887|NCT00005805|noncontiguous stage II adult diffuse large cell lymphoma
687888|NCT00005805|noncontiguous stage II adult Burkitt lymphoma
687889|NCT00005805|noncontiguous stage II adult lymphoblastic lymphoma
687890|NCT00005805|stage III mantle cell lymphoma
687891|NCT00005805|stage IV mantle cell lymphoma
687892|NCT00005805|recurrent mantle cell lymphoma
687893|NCT00005805|angioimmunoblastic T-cell lymphoma
687894|NCT00005805|anaplastic large cell lymphoma
687895|NCT00005805|stage II mantle cell lymphoma
687896|NCT00005805|multiple myeloma
687897|NCT00005805|noncontiguous stage II small lymphocytic lymphoma
687898|NCT00005805|noncontiguous stage II marginal zone lymphoma
687899|NCT00005805|recurrent marginal zone lymphoma
687900|NCT00005805|stage I marginal zone lymphoma
687901|NCT00005805|stage II marginal zone lymphoma
687902|NCT00005805|stage III marginal zone lymphoma
687903|NCT00005805|stage IV marginal zone lymphoma
687904|NCT00005805|contiguous stage II marginal zone lymphoma
687905|NCT00005805|contiguous stage II small lymphocytic lymphoma
687906|NCT00005805|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
687907|NCT00005805|nodal marginal zone B-cell lymphoma
687908|NCT00005805|splenic marginal zone lymphoma
687909|NCT00005804|monoclonal gammopathy of undetermined significance
687910|NCT00005804|recurrent childhood acute lymphoblastic leukemia
687911|NCT00005804|recurrent adult Hodgkin lymphoma
687912|NCT00005804|recurrent cutaneous T-cell non-Hodgkin lymphoma
687913|NCT00005804|Burkitt lymphoma
687914|NCT00005804|isolated plasmacytoma of bone
687915|NCT00005804|extramedullary plasmacytoma
687916|NCT00005804|refractory multiple myeloma
687917|NCT00005804|Waldenstrom macroglobulinemia
687918|NCT00005804|stage III multiple myeloma
687919|NCT00005804|stage II childhood lymphoblastic lymphoma
687920|NCT00005804|stage III childhood lymphoblastic lymphoma
687921|NCT00005804|stage IV childhood lymphoblastic lymphoma
687922|NCT00005804|recurrent childhood lymphoblastic lymphoma
687923|NCT00005804|recurrent childhood acute myeloid leukemia
687924|NCT00005804|recurrent adult acute myeloid leukemia
687925|NCT00005804|recurrent adult acute lymphoblastic leukemia
687926|NCT00005804|small intestine lymphoma
687927|NCT00005804|childhood immunoblastic large cell lymphoma
687928|NCT00005804|chronic phase chronic myelogenous leukemia
687929|NCT00005804|accelerated phase chronic myelogenous leukemia
687930|NCT00005804|blastic phase chronic myelogenous leukemia
687931|NCT00005804|untreated adult acute lymphoblastic leukemia
687932|NCT00005804|untreated adult acute myeloid leukemia
687933|NCT00005804|untreated childhood acute myeloid leukemia and other myeloid malignancies
687934|NCT00005804|untreated childhood acute lymphoblastic leukemia
687935|NCT00005804|adult acute myeloid leukemia in remission
687936|NCT00005804|adult acute lymphoblastic leukemia in remission
687937|NCT00005804|childhood acute myeloid leukemia in remission
687938|NCT00005804|childhood acute lymphoblastic leukemia in remission
687939|NCT00005804|polycythemia vera
687940|NCT00005804|chronic idiopathic myelofibrosis
687941|NCT00005804|essential thrombocythemia
687942|NCT00005804|progressive hairy cell leukemia, initial treatment
687943|NCT00005804|refractory hairy cell leukemia
687944|NCT00005804|recurrent/refractory childhood Hodgkin lymphoma
687945|NCT00005804|chronic myelomonocytic leukemia
687946|NCT00005804|T-cell large granular lymphocyte leukemia
687947|NCT00005804|acute undifferentiated leukemia
687948|NCT00005804|stage III adult lymphoblastic lymphoma
687949|NCT00005804|stage IV adult lymphoblastic lymphoma
687950|NCT00005804|recurrent grade 1 follicular lymphoma
687951|NCT00005804|recurrent grade 2 follicular lymphoma
687952|NCT00005804|recurrent grade 3 follicular lymphoma
687953|NCT00005804|recurrent adult diffuse small cleaved cell lymphoma
687954|NCT00005804|recurrent adult diffuse mixed cell lymphoma
687955|NCT00005804|recurrent adult diffuse large cell lymphoma
687956|NCT00005804|recurrent adult immunoblastic large cell lymphoma
687957|NCT00005804|recurrent adult lymphoblastic lymphoma
687958|NCT00005804|recurrent adult Burkitt lymphoma
687959|NCT00005804|recurrent adult T-cell leukemia/lymphoma
687960|NCT00005804|secondary acute myeloid leukemia
687961|NCT00005804|de novo myelodysplastic syndromes
687962|NCT00005804|previously treated myelodysplastic syndromes
687963|NCT00005804|secondary myelodysplastic syndromes
687964|NCT00005804|prolymphocytic leukemia
687965|NCT00005804|primary systemic amyloidosis
687966|NCT00005804|intraocular lymphoma
687967|NCT00005804|recurrent childhood small noncleaved cell lymphoma
687968|NCT00005804|recurrent childhood large cell lymphoma
687969|NCT00005804|contiguous stage II adult lymphoblastic lymphoma
687970|NCT00005804|noncontiguous stage II adult lymphoblastic lymphoma
687971|NCT00005804|recurrent mantle cell lymphoma
687972|NCT00005804|angioimmunoblastic T-cell lymphoma
687973|NCT00005804|anaplastic large cell lymphoma
687974|NCT00005804|recurrent mycosis fungoides/Sezary syndrome
687975|NCT00005804|recurrent marginal zone lymphoma
687976|NCT00005804|recurrent small lymphocytic lymphoma
687977|NCT00005804|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
687978|NCT00005804|nodal marginal zone B-cell lymphoma
687979|NCT00005804|splenic marginal zone lymphoma
687980|NCT00005804|childhood myelodysplastic syndromes
687981|NCT00005802|recurrent childhood acute lymphoblastic leukemia
687982|NCT00005802|recurrent childhood acute myeloid leukemia
687983|NCT00005802|recurrent adult acute myeloid leukemia
687984|NCT00005802|recurrent adult acute lymphoblastic leukemia
687985|NCT00005802|adult acute myeloid leukemia with t(8;21)(q22;q22)
687986|NCT00005802|adult acute myeloid leukemia with t(16;16)(p13;q22)
687987|NCT00005802|adult acute myeloid leukemia with inv(16)(p13;q22)
688189|NCT00005779|Interleukin-12
687988|NCT00005802|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
687989|NCT00005802|adult acute myeloid leukemia with t(15;17)(q22;q12)
687990|NCT00005801|adult acute myeloid leukemia in remission
687991|NCT00005801|adult acute erythroid leukemia (M6)
687992|NCT00005801|adult acute myeloblastic leukemia without maturation (M1)
687993|NCT00005801|adult acute myeloblastic leukemia with maturation (M2)
687994|NCT00005801|adult acute myelomonocytic leukemia (M4)
687995|NCT00005801|adult acute monoblastic leukemia (M5a)
687996|NCT00005801|adult acute megakaryoblastic leukemia (M7)
687997|NCT00005801|adult acute monocytic leukemia (M5b)
687998|NCT00005800|stage IIIA breast cancer
687999|NCT00005800|stage IIIB breast cancer
688000|NCT00005800|inflammatory breast cancer
688001|NCT00005798|stage II breast cancer
688002|NCT00005798|stage IV breast cancer
688003|NCT00005798|stage IIIA breast cancer
688004|NCT00005798|recurrent breast cancer
688005|NCT00005798|stage IIIB breast cancer
688006|NCT00005798|inflammatory breast cancer
688007|NCT00005797|refractory multiple myeloma
688008|NCT00005797|stage II multiple myeloma
688009|NCT00005797|stage III multiple myeloma
688010|NCT00005797|stage III chronic lymphocytic leukemia
688011|NCT00005797|stage IV chronic lymphocytic leukemia
688012|NCT00005797|recurrent adult acute myeloid leukemia
688013|NCT00005797|recurrent adult acute lymphoblastic leukemia
688014|NCT00005797|refractory chronic lymphocytic leukemia
688015|NCT00005797|chronic phase chronic myelogenous leukemia
688016|NCT00005797|accelerated phase chronic myelogenous leukemia
688017|NCT00005797|adult acute myeloid leukemia in remission
688018|NCT00005797|adult acute lymphoblastic leukemia in remission
688019|NCT00005797|polycythemia vera
688020|NCT00005797|primary myelofibrosis
688021|NCT00005797|essential thrombocythemia
688022|NCT00005797|refractory anemia
688023|NCT00005797|refractory anemia with ringed sideroblasts
688024|NCT00005797|refractory anemia with excess blasts
688025|NCT00005797|refractory anemia with excess blasts in transformation
688026|NCT00005797|chronic myelomonocytic leukemia
688027|NCT00005797|previously treated myelodysplastic syndromes
688028|NCT00005797|refractory cytopenia with multilineage dysplasia
688029|NCT00005797|chronic eosinophilic leukemia
688030|NCT00005797|chronic neutrophilic leukemia
688031|NCT00005797|atypical chronic myeloid leukemia, BCR-ABL1 negative
688032|NCT00005797|myelodysplastic/myeloproliferative neoplasm, unclassifiable
688033|NCT00005797|adult acute myeloid leukemia with t(8;21)(q22;q22)
688034|NCT00005797|adult acute myeloid leukemia with t(16;16)(p13;q22)
688035|NCT00005797|adult acute myeloid leukemia with inv(16)(p13;q22)
688036|NCT00005797|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
688037|NCT00005797|adult acute myeloid leukemia with t(15;17)(q22;q12)
688038|NCT00005797|childhood myelodysplastic syndromes
688039|NCT00005796|recurrent adult brain tumor
688040|NCT00005796|adult brain stem glioma
688041|NCT00005796|adult ependymoma
688042|NCT00005796|adult medulloblastoma
688043|NCT00005796|adult glioblastoma
688044|NCT00005796|childhood high-grade cerebral astrocytoma
688045|NCT00005796|childhood oligodendroglioma
688046|NCT00005796|adult anaplastic astrocytoma
688047|NCT00005796|adult anaplastic oligodendroglioma
688048|NCT00005796|adult mixed glioma
688049|NCT00005796|drug/agent toxicity by tissue/organ
688050|NCT00005796|bone marrow suppression
688051|NCT00005796|untreated childhood brain stem glioma
688052|NCT00005796|recurrent childhood brain stem glioma
688053|NCT00005796|untreated childhood cerebellar astrocytoma
688054|NCT00005796|recurrent childhood cerebellar astrocytoma
688055|NCT00005796|recurrent childhood cerebral astrocytoma
688056|NCT00005796|recurrent childhood medulloblastoma
688057|NCT00005796|newly diagnosed childhood ependymoma
688058|NCT00005796|recurrent childhood ependymoma
688059|NCT00005796|adult giant cell glioblastoma
688060|NCT00005796|adult gliosarcoma
688061|NCT00005795|recurrent adult acute myeloid leukemia
688062|NCT00005795|untreated adult acute myeloid leukemia
688063|NCT00005795|adult acute erythroid leukemia (M6)
688064|NCT00005795|adult acute myeloblastic leukemia without maturation (M1)
688065|NCT00005795|adult acute myeloblastic leukemia with maturation (M2)
688066|NCT00005795|adult acute myelomonocytic leukemia (M4)
688067|NCT00005795|adult acute monoblastic leukemia (M5a)
688068|NCT00005795|adult acute megakaryoblastic leukemia (M7)
688069|NCT00005795|secondary acute myeloid leukemia
688070|NCT00005795|adult acute monocytic leukemia (M5b)
688071|NCT00005795|adult acute minimally differentiated myeloid leukemia (M0)
688072|NCT00005794|unspecified adult solid tumor, protocol specific
688073|NCT00005793|untreated adult acute myeloid leukemia
688074|NCT00005793|adult acute erythroid leukemia (M6)
688075|NCT00005793|adult acute myeloblastic leukemia without maturation (M1)
688076|NCT00005793|adult acute myeloblastic leukemia with maturation (M2)
688077|NCT00005793|adult acute myelomonocytic leukemia (M4)
688078|NCT00005793|adult acute monoblastic leukemia (M5a)
688079|NCT00005793|adult acute megakaryoblastic leukemia (M7)
688080|NCT00005793|adult acute monocytic leukemia (M5b)
688081|NCT00005793|adult acute minimally differentiated myeloid leukemia (M0)
688190|NCT00005779|HIV Therapeutic Vaccine
688082|NCT00005793|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
688083|NCT00005793|adult acute myeloid leukemia with inv(16)(p13;q22)
688084|NCT00005793|adult acute myeloid leukemia with t(16;16)(p13;q22)
688085|NCT00005793|adult acute myeloid leukemia with t(8;21)(q22;q22)
688086|NCT00005792|refractory multiple myeloma
688087|NCT00005792|stage I multiple myeloma
688088|NCT00005792|stage II multiple myeloma
688089|NCT00005792|stage III multiple myeloma
688090|NCT00005791|unspecified adult solid tumor, protocol specific
688091|NCT00005790|adult brain stem glioma
688092|NCT00005790|adult ependymoma
688093|NCT00005790|adult craniopharyngioma
688094|NCT00005790|adult medulloblastoma
688095|NCT00005790|adult meningioma
688096|NCT00005790|adult glioblastoma
688097|NCT00005790|adult oligodendroglioma
688098|NCT00005790|adult anaplastic astrocytoma
688099|NCT00005790|adult myxopapillary ependymoma
688100|NCT00005790|adult anaplastic ependymoma
688101|NCT00005790|adult anaplastic oligodendroglioma
688102|NCT00005790|adult mixed glioma
688103|NCT00005790|adult pineal parenchymal tumor
688104|NCT00005790|adult central nervous system germ cell tumor
688105|NCT00005790|adult pilocytic astrocytoma
688106|NCT00005790|adult subependymoma
688107|NCT00005790|adult diffuse astrocytoma
688108|NCT00005790|adult ependymoblastoma
688109|NCT00005790|adult pineocytoma
688110|NCT00005790|adult pineoblastoma
688111|NCT00005790|adult meningeal hemangiopericytoma
688112|NCT00005790|adult choroid plexus tumor
688113|NCT00005790|adult grade III meningioma
688114|NCT00005790|adult giant cell glioblastoma
688115|NCT00005790|adult gliosarcoma
688116|NCT00005788|stage I cutaneous T-cell non-Hodgkin lymphoma
688117|NCT00005788|stage II cutaneous T-cell non-Hodgkin lymphoma
688118|NCT00005788|stage III cutaneous T-cell non-Hodgkin lymphoma
688119|NCT00005788|stage IV cutaneous T-cell non-Hodgkin lymphoma
688120|NCT00005788|recurrent cutaneous T-cell non-Hodgkin lymphoma
688121|NCT00005788|stage I mycosis fungoides/Sezary syndrome
688122|NCT00005788|stage II mycosis fungoides/Sezary syndrome
688123|NCT00005788|stage III mycosis fungoides/Sezary syndrome
688124|NCT00005788|stage IV mycosis fungoides/Sezary syndrome
688125|NCT00005788|recurrent mycosis fungoides/Sezary syndrome
688126|NCT00005787|neutropenia
688127|NCT00005787|recurrent grade 1 follicular lymphoma
688128|NCT00005787|recurrent grade 2 follicular lymphoma
688129|NCT00005787|recurrent grade 3 follicular lymphoma
688130|NCT00005787|recurrent adult diffuse small cleaved cell lymphoma
688131|NCT00005787|recurrent adult diffuse mixed cell lymphoma
688132|NCT00005787|recurrent adult diffuse large cell lymphoma
688133|NCT00005787|recurrent adult immunoblastic large cell lymphoma
688134|NCT00005787|recurrent adult lymphoblastic lymphoma
688135|NCT00005787|recurrent adult Burkitt lymphoma
688136|NCT00005787|recurrent mantle cell lymphoma
688137|NCT00005787|recurrent marginal zone lymphoma
688138|NCT00005787|recurrent small lymphocytic lymphoma
688139|NCT00005787|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688140|NCT00005787|nodal marginal zone B-cell lymphoma
688141|NCT00005787|splenic marginal zone lymphoma
688142|NCT00005785|Peripheral Blood Stem Cells
688143|NCT00005785|Engraftment
688144|NCT00005785|Graft vs. Host Disease
688145|NCT00005785|Graft-Versus-Leukemia
688146|NCT00005785|Donor Apheresis
688147|NCT00005785|Cyclophosphamide
688148|NCT00005785|Fludarabine
688149|NCT00005785|HIV
688150|NCT00005785|AIDS
688151|NCT00005785|Gene Therapy
688152|NCT00005785|Chronic Myelogenous Leukemia
688153|NCT00005785|Acute Lymphoblastic Leukemia
688154|NCT00005785|Acute Myelogenous Leukemia
688155|NCT00005785|Chronic Lymphocytic Leukemia
688156|NCT00005784|Macular Degeneration
688157|NCT00005784|Diabetic Retinopathy
688158|NCT00005784|Vascular Occlusive Disease
688159|NCT00005784|Central Serous Retinopathy
688160|NCT00005784|Rare/Unknown Retinal Disease
688161|NCT00005784|Retinal Disease
688162|NCT00005784|Age-Related Macular Degeneration
688163|NCT00005783|Fetal Hemoglobin
688164|NCT00005783|Hematopoietic Growth Factor
688165|NCT00005783|Peripheral Blood CD34 Cells
688166|NCT00005783|Vasoocclusive Crisis
688167|NCT00005783|Sickle Cell Anemia
688168|NCT00005783|Sickle Cell Disease
688169|NCT00005783|Sickle Cell Disorder
688170|NCT00005782|Donor Apheresis
688171|NCT00005782|Sickle Cell Trait
688172|NCT00005782|Red Cell Alloimmunization
688173|NCT00005781|Epidemiology
688174|NCT00005781|NHANES
688175|NCT00005781|Photography
688176|NCT00005781|Prevalence
688177|NCT00005781|Skin Disease
688178|NCT00005781|Healthy Volunteer
688179|NCT00005780|Lymphoma Vaccines
688180|NCT00005780|Immune Response Against Lymphoma
688181|NCT00005780|Molecular Complete Remissions
688182|NCT00005780|Novel Treatment Approach
688183|NCT00005780|Mantle Cell Lymphoma
688184|NCT00005779|Virus Replication
688185|NCT00005779|HIV-1
688186|NCT00005779|AIDS Vaccines
688187|NCT00005779|CD4 Lymphocyte Count
688188|NCT00005779|Cohort Studies
688191|NCT00005778|Systemic Lupus Erythematosus (SLE)
688192|NCT00005778|Cytoxan
688193|NCT00005778|Cyclophosphamide
688194|NCT00005778|High-dose immunoablative therapy
688195|NCT00005777|NICHD Neonatal Research Network
688196|NCT00005777|Extremely Low Birth Weight (ELBW)
688197|NCT00005777|Prematurity
688198|NCT00005777|Chronic Lung Disease (CLD)
688199|NCT00005777|Dexamethasone
688200|NCT00005777|Glucocorticoids
688201|NCT00005777|Respiration, Artificial
688202|NCT00005777|Mechanical ventilation
688203|NCT00005777|Respiratory Insufficiency
688204|NCT00005776|NICHD Neonatal Research Network
688205|NCT00005776|Hypertension, pulmonary
688206|NCT00005776|Hypoxic respiratory failure
688207|NCT00005776|Meconium aspiration
688208|NCT00005776|Methemoglobinemia
688209|NCT00005776|Nitric oxide
688210|NCT00005776|Oxygen inhalation therapy
688211|NCT00005776|Persistent Fetal Circulation Syndrome
688212|NCT00005776|Pneumonia, aspiration
688213|NCT00005776|Respiratory distress syndrome
688214|NCT00005776|Respiratory insufficiency
688215|NCT00005776|Severe respiratory failure
688216|NCT00005775|NICHD Neonatal Research Network
688217|NCT00005775|Extremely Low Birth Weight (ELBW) infants
688218|NCT00005775|Prematurity
688219|NCT00005775|Glutamine
688220|NCT00005775|Total parenteral nutrition
688221|NCT00005775|Nutrition
688222|NCT00005775|Very low birth weight (VLBW) infants
688223|NCT00005774|NICHD Neonatal Research Network
688224|NCT00005774|Pulmonary ventilation
688225|NCT00005774|Respiratory distress syndrome
688226|NCT00005774|Respiratory insufficiency
688227|NCT00005774|Surfactant, pulmonary
688228|NCT00005774|Mechanical Ventilation
688229|NCT00005774|Survanta
688230|NCT00005773|NICHD Neonatal Research Network
688231|NCT00005773|Hypertension, pulmonary
688232|NCT00005773|Hypoxic respiratory failure
688233|NCT00005773|Meconium aspiration
688234|NCT00005773|Methemoglobinemia
688235|NCT00005773|Nitric oxide
688236|NCT00005773|Oxygen inhalation therapy
688237|NCT00005773|Persistent Fetal Circulation Syndrome
688238|NCT00005773|Pneumonia, aspiration
688239|NCT00005773|Respiratory distress syndrome
688240|NCT00005773|Respiratory insufficiency
688241|NCT00005773|Severe respiratory failure
688242|NCT00005772|NICHD Neonatal Research Network
688243|NCT00005772|Hypoxic-ischemic encephalopathy (HIE)
688244|NCT00005772|Hypothermia
688245|NCT00005772|Neonatal depression
688246|NCT00005772|Perinatal asphyxia
688247|NCT00005771|Abdominal Hollowing Exercises
688248|NCT00005770|elastic property of skin
688249|NCT00005767|Amino Acid Metabolism
688250|NCT00005766|ALS
688251|NCT00005764|HIV-1
688252|NCT00005764|Zalcitabine
688253|NCT00005764|Didanosine
688254|NCT00005764|Drug Therapy, Combination
688255|NCT00005764|Zidovudine
688256|NCT00005764|Stavudine
688257|NCT00005764|Lamivudine
688258|NCT00005764|Blood
688259|NCT00005764|Reverse Transcriptase Inhibitors
688260|NCT00005764|Anti-HIV Agents
688261|NCT00005764|Lipodystrophy
688262|NCT00005764|Combivir
688263|NCT00005764|Lactic Acid
688264|NCT00005764|abacavir
688265|NCT00005762|Drug Interactions
688266|NCT00005762|Drug Therapy, Combination
688267|NCT00005762|HIV Protease Inhibitors
688268|NCT00005762|Ritonavir
688269|NCT00005762|Dosage Forms
688270|NCT00005762|Saquinavir
688271|NCT00005762|VX 478
688272|NCT00005762|Anti-HIV Agents
688273|NCT00005762|Nelfinavir
688274|NCT00005762|Pharmacokinetics
688275|NCT00005762|efavirenz
688276|NCT00005761|Types 1 & 2 Diabetes
688277|NCT00005761|Cell Adhesion Molecules
688278|NCT00005761|Chemokines
688279|NCT00005761|Vascular Endothelial Growth Factor
688280|NCT00005761|Cross-Sectional
688281|NCT00005761|Serum Levels
688282|NCT00005761|Diabetic Retinopathy
688283|NCT00005760|Dyslipidemia
688284|NCT00005760|Hypertension
688285|NCT00005760|Metabolic Syndrome X
688286|NCT00005760|Obesity
688287|NCT00005760|Subcutaneous Adipose Tissue
688288|NCT00005760|Visceral Abdominal Adipose Tissue
688289|NCT00005758|T-Lymphocytes, Helper-Inducer
688290|NCT00005758|Combined Modality Therapy
688291|NCT00005758|HIV Envelope Protein gp120
688292|NCT00005758|AIDS Vaccines
688293|NCT00005758|RNA, Viral
688294|NCT00005758|HIV Core Protein p24
688295|NCT00005758|T-Lymphocytes, Cytotoxic
688296|NCT00005758|Anti-HIV Agents
688297|NCT00005758|Viral Load
688298|NCT00005758|HIV Therapeutic Vaccine
688299|NCT00005675|Systemic Scleroderma (SSc)
688300|NCT00005675|Bovine Type I Collagen (CI)
688301|NCT00005675|Multicenter
688302|NCT00005673|HIV
688303|NCT00005673|Antiretroviral
688304|NCT00005673|NNRTI
688305|NCT00005671|Angina
688306|NCT00005671|Condition Specific
688307|NCT00005671|Heart Failure
688308|NCT00005671|Symptom Distress
688309|NCT00005671|Revascularization
688310|NCT00005671|Coronary Artery Disease
688311|NCT00005671|Ischemic Heart Disease
688312|NCT00005669|Child
688313|NCT00005669|Body Fat
688314|NCT00005669|Food Intake
688315|NCT00005669|Diabetes Mellitus
688316|NCT00005669|Dyslipidemia
688317|NCT00005669|Vitamin B12
688318|NCT00005669|Childhood Obesity
688319|NCT00005667|liver transplantation
688320|NCT00005667|vancomycin resistance
688321|NCT00005666|Diagnostic imaging
688322|NCT00005664|Healthy Volunteers
688323|NCT00005664|Endocrine Related Conditions
688324|NCT00005664|Endocrine Dysfunction
688325|NCT00005664|Early Pubertal Development
688326|NCT00005727|Nutrition
688327|NCT00005727|Education
688328|NCT00005663|Herpes Simplex
688329|NCT00005663|Antiviral Agents
688330|NCT00005663|Anus Diseases
688331|NCT00005663|Herpes Genitalis
688332|NCT00005663|Recurrence
688333|NCT00005663|valacyclovir
688334|NCT00005660|Hypertriglyceridemia
688335|NCT00005660|Teratogenicity
688336|NCT00005660|Ichthyosis
688337|NCT00005660|Darier's Disease
688338|NCT00005660|Retinoids
688339|NCT00005660|Skin
688340|NCT00005660|Psoriasis
688341|NCT00005660|Basal cell carcinoma
688342|NCT00005660|Skin Cancer
688343|NCT00005658|Biochemical
688344|NCT00005658|Schizophrenia
688345|NCT00005658|NMDA
688346|NCT00005658|Adolescence
688347|NCT00005658|Psychosis
688348|NCT00005658|Child Psychosis
688349|NCT00005658|Biochemical Correlates
688350|NCT00005658|Brain Imaging
688351|NCT00005658|Glycine
688352|NCT00005658|Adjunctive Glycine Therapy
688353|NCT00005657|Cytokines
688354|NCT00005657|Treatment
688355|NCT00005657|Genetic Polymorphism
688356|NCT00005657|Chronic Hepatitis C
688357|NCT00005657|Mononuclear Cells
688358|NCT00005655|Gene Expression
688359|NCT00005655|Neovascularization
688360|NCT00005655|antiangiogenic therapy
688361|NCT00005655|immunomodulatory therapy
688362|NCT00005655|Immunotherapy
688363|NCT00005655|Tumor
688364|NCT00005654|endocrine disorders
688365|NCT00005654|hyperinsulinism
688366|NCT00005654|polycystic ovarian syndrome
688367|NCT00005654|rare disease
688368|NCT00005652|hematologic disorders
688369|NCT00005652|immune thrombocytopenic purpura
688370|NCT00005652|rare disease
688371|NCT00005650|cardiovascular and respiratory diseases
688372|NCT00005650|genetic diseases and dysmorphic syndromes
688373|NCT00005650|primary ciliary dyskinesia
688374|NCT00005650|rare disease
688375|NCT00005649|stage IV breast cancer
688376|NCT00005649|recurrent breast cancer
688377|NCT00005648|Stage II pancreatic cancer
688378|NCT00005648|Stage III pancreatic cancer
688379|NCT00005648|Recurrent pancreatic cancer
688380|NCT00005648|Adenocarcinoma of the pancreas
688381|NCT00005648|Stage IV pancreatic cancer
688382|NCT00005647|thyroid gland medullary carcinoma
688383|NCT00005647|anaplastic thyroid cancer
688384|NCT00005647|recurrent thyroid cancer
688385|NCT00005647|recurrent salivary gland cancer
688386|NCT00005647|recurrent metastatic squamous neck cancer with occult primary
688387|NCT00005647|stage III follicular thyroid cancer
688388|NCT00005647|metastatic squamous neck cancer with occult primary squamous cell carcinoma
688389|NCT00005647|recurrent hypopharyngeal cancer
688390|NCT00005647|stage III adenoid cystic carcinoma of the oral cavity
688391|NCT00005647|recurrent squamous cell carcinoma of the lip and oral cavity
688392|NCT00005647|recurrent verrucous carcinoma of the oral cavity
688393|NCT00005647|recurrent mucoepidermoid carcinoma of the oral cavity
688394|NCT00005647|recurrent adenoid cystic carcinoma of the oral cavity
688395|NCT00005647|recurrent squamous cell carcinoma of the oropharynx
688396|NCT00005647|recurrent lymphoepithelioma of the oropharynx
688397|NCT00005647|recurrent squamous cell carcinoma of the nasopharynx
688398|NCT00005647|recurrent lymphoepithelioma of the nasopharynx
688399|NCT00005647|recurrent squamous cell carcinoma of the hypopharynx
688400|NCT00005647|recurrent squamous cell carcinoma of the larynx
688401|NCT00005647|recurrent verrucous carcinoma of the larynx
688402|NCT00005647|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
688403|NCT00005647|recurrent inverted papilloma of the paranasal sinus and nasal cavity
688404|NCT00005647|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
688405|NCT00005646|extensive stage small cell lung cancer
688406|NCT00005645|stage III ovarian epithelial cancer
688407|NCT00005645|stage IV ovarian epithelial cancer
688408|NCT00005645|recurrent ovarian epithelial cancer
688409|NCT00005645|liver metastases
688410|NCT00005645|malignant pericardial effusion
688411|NCT00005645|malignant pleural effusion
688412|NCT00005645|malignant ascites
688413|NCT00005645|fallopian tube cancer
688414|NCT00005645|primary peritoneal cavity cancer
688415|NCT00005644|stage III bladder cancer
688416|NCT00005644|recurrent bladder cancer
688417|NCT00005644|stage IV bladder cancer
688418|NCT00005644|transitional cell carcinoma of the bladder
688419|NCT00005644|recurrent urethral cancer
688420|NCT00005644|distal urethral cancer
688421|NCT00005644|proximal urethral cancer
688422|NCT00005644|urethral cancer associated with invasive bladder cancer
688423|NCT00005644|metastatic transitional cell cancer of the renal pelvis and ureter
688424|NCT00005644|regional transitional cell cancer of the renal pelvis and ureter
688425|NCT00005644|recurrent transitional cell cancer of the renal pelvis and ureter
688426|NCT00005643|stage IV uterine sarcoma
688427|NCT00005643|recurrent uterine sarcoma
688428|NCT00005643|uterine carcinosarcoma
688429|NCT00005643|uterine leiomyosarcoma
688430|NCT00005643|endometrial stromal sarcoma
688431|NCT00005642|unspecified adult solid tumor, protocol specific
688432|NCT00005641|recurrent childhood acute lymphoblastic leukemia
688433|NCT00005641|refractory multiple myeloma
688434|NCT00005641|stage 0 chronic lymphocytic leukemia
688435|NCT00005641|stage I multiple myeloma
688436|NCT00005641|stage II multiple myeloma
688437|NCT00005641|stage III multiple myeloma
688438|NCT00005641|stage I chronic lymphocytic leukemia
688439|NCT00005641|stage II chronic lymphocytic leukemia
688440|NCT00005641|stage III chronic lymphocytic leukemia
688441|NCT00005641|stage IV chronic lymphocytic leukemia
688442|NCT00005641|recurrent childhood acute myeloid leukemia
688443|NCT00005641|recurrent adult acute myeloid leukemia
688444|NCT00005641|recurrent adult acute lymphoblastic leukemia
688445|NCT00005641|relapsing chronic myelogenous leukemia
688446|NCT00005641|refractory chronic lymphocytic leukemia
688447|NCT00005641|chronic phase chronic myelogenous leukemia
688448|NCT00005641|accelerated phase chronic myelogenous leukemia
688449|NCT00005641|blastic phase chronic myelogenous leukemia
688450|NCT00005641|adult acute myeloid leukemia in remission
688451|NCT00005641|adult acute lymphoblastic leukemia in remission
688452|NCT00005641|polycythemia vera
688453|NCT00005641|primary myelofibrosis
688454|NCT00005641|essential thrombocythemia
688455|NCT00005641|refractory anemia
688456|NCT00005641|refractory anemia with ringed sideroblasts
688457|NCT00005641|refractory anemia with excess blasts
688458|NCT00005641|refractory anemia with excess blasts in transformation
688459|NCT00005641|chronic myelomonocytic leukemia
688460|NCT00005641|de novo myelodysplastic syndromes
688461|NCT00005641|previously treated myelodysplastic syndromes
688462|NCT00005641|secondary myelodysplastic syndromes
688463|NCT00005641|graft versus host disease
688464|NCT00005641|refractory cytopenia with multilineage dysplasia
688465|NCT00005641|childhood myelodysplastic syndromes
688466|NCT00005640|stage I colon cancer
688467|NCT00005640|stage II colon cancer
688468|NCT00005640|stage III colon cancer
688469|NCT00005640|stage I rectal cancer
688470|NCT00005640|stage II rectal cancer
688471|NCT00005640|stage III rectal cancer
688472|NCT00005639|stage III adult Hodgkin lymphoma
688473|NCT00005639|stage IV adult Hodgkin lymphoma
688474|NCT00005639|recurrent adult Hodgkin lymphoma
688475|NCT00005639|stage III cutaneous T-cell non-Hodgkin lymphoma
688476|NCT00005639|stage IV cutaneous T-cell non-Hodgkin lymphoma
688477|NCT00005639|recurrent cutaneous T-cell non-Hodgkin lymphoma
688478|NCT00005639|small intestine lymphoma
688479|NCT00005639|unspecified adult solid tumor, protocol specific
688480|NCT00005639|stage III grade 1 follicular lymphoma
688481|NCT00005639|stage III grade 2 follicular lymphoma
688482|NCT00005639|stage III grade 3 follicular lymphoma
688483|NCT00005639|stage III adult diffuse small cleaved cell lymphoma
688484|NCT00005639|stage III adult diffuse mixed cell lymphoma
688485|NCT00005639|stage III adult diffuse large cell lymphoma
688486|NCT00005639|stage III adult immunoblastic large cell lymphoma
688487|NCT00005639|stage III adult lymphoblastic lymphoma
688488|NCT00005639|stage III adult Burkitt lymphoma
688489|NCT00005639|stage IV grade 1 follicular lymphoma
688490|NCT00005639|stage IV grade 2 follicular lymphoma
688491|NCT00005639|stage IV grade 3 follicular lymphoma
688492|NCT00005639|stage IV adult diffuse small cleaved cell lymphoma
688493|NCT00005639|stage IV adult diffuse mixed cell lymphoma
688494|NCT00005639|stage IV adult diffuse large cell lymphoma
688495|NCT00005639|stage IV adult immunoblastic large cell lymphoma
688496|NCT00005639|stage IV adult lymphoblastic lymphoma
688497|NCT00005639|stage IV adult Burkitt lymphoma
688498|NCT00005639|recurrent grade 1 follicular lymphoma
688499|NCT00005639|recurrent grade 2 follicular lymphoma
688500|NCT00005639|recurrent grade 3 follicular lymphoma
688501|NCT00005639|recurrent adult diffuse small cleaved cell lymphoma
688502|NCT00005639|recurrent adult diffuse mixed cell lymphoma
688503|NCT00005639|recurrent adult diffuse large cell lymphoma
688504|NCT00005639|recurrent adult immunoblastic large cell lymphoma
688505|NCT00005639|recurrent adult lymphoblastic lymphoma
688506|NCT00005639|recurrent adult Burkitt lymphoma
688507|NCT00005639|stage III adult T-cell leukemia/lymphoma
688508|NCT00005639|stage IV adult T-cell leukemia/lymphoma
688509|NCT00005639|recurrent adult T-cell leukemia/lymphoma
688510|NCT00005639|primary central nervous system non-Hodgkin lymphoma
688511|NCT00005639|intraocular lymphoma
688512|NCT00005639|stage III mantle cell lymphoma
688513|NCT00005639|stage IV mantle cell lymphoma
688514|NCT00005639|recurrent mantle cell lymphoma
688515|NCT00005639|angioimmunoblastic T-cell lymphoma
688516|NCT00005639|anaplastic large cell lymphoma
688517|NCT00005639|stage III mycosis fungoides/Sezary syndrome
688518|NCT00005639|stage IV mycosis fungoides/Sezary syndrome
688519|NCT00005639|recurrent mycosis fungoides/Sezary syndrome
688520|NCT00005639|recurrent marginal zone lymphoma
688521|NCT00005639|recurrent small lymphocytic lymphoma
688522|NCT00005639|stage III small lymphocytic lymphoma
688523|NCT00005639|stage III marginal zone lymphoma
688524|NCT00005639|stage IV small lymphocytic lymphoma
688525|NCT00005639|stage IV marginal zone lymphoma
688526|NCT00005639|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688527|NCT00005639|nodal marginal zone B-cell lymphoma
688528|NCT00005639|splenic marginal zone lymphoma
688529|NCT00005638|stage II gastric cancer
688530|NCT00005638|stage III gastric cancer
688531|NCT00005638|stage II esophageal cancer
688532|NCT00005638|stage III esophageal cancer
688533|NCT00005638|adenocarcinoma of the stomach
688534|NCT00005638|squamous cell carcinoma of the esophagus
688535|NCT00005638|adenocarcinoma of the esophagus
688536|NCT00005637|adult glioblastoma
688537|NCT00005637|adult anaplastic astrocytoma
688538|NCT00005637|adult anaplastic oligodendroglioma
688539|NCT00005637|adult mixed glioma
688540|NCT00005637|adult giant cell glioblastoma
688541|NCT00005637|adult gliosarcoma
688542|NCT00005637|adult anaplastic ependymoma
688543|NCT00005636|localized malignant mesothelioma
688544|NCT00005636|advanced malignant mesothelioma
688545|NCT00005636|recurrent malignant mesothelioma
688546|NCT00005635|stage IV breast cancer
688547|NCT00005635|recurrent breast cancer
688548|NCT00005634|recurrent adult Hodgkin lymphoma
688549|NCT00005634|recurrent cutaneous T-cell non-Hodgkin lymphoma
688550|NCT00005634|isolated plasmacytoma of bone
688551|NCT00005634|extramedullary plasmacytoma
688552|NCT00005634|refractory multiple myeloma
688553|NCT00005634|recurrent adult acute myeloid leukemia
688554|NCT00005634|recurrent adult acute lymphoblastic leukemia
688555|NCT00005634|relapsing chronic myelogenous leukemia
688556|NCT00005634|refractory chronic lymphocytic leukemia
688557|NCT00005634|small intestine lymphoma
688558|NCT00005634|recurrent prostate cancer
688559|NCT00005634|unspecified adult solid tumor, protocol specific
688560|NCT00005634|chronic phase chronic myelogenous leukemia
688561|NCT00005634|refractory hairy cell leukemia
688562|NCT00005634|chronic myelomonocytic leukemia
688563|NCT00005634|recurrent grade 1 follicular lymphoma
688564|NCT00005634|recurrent grade 2 follicular lymphoma
688565|NCT00005634|recurrent grade 3 follicular lymphoma
688566|NCT00005634|recurrent adult diffuse small cleaved cell lymphoma
688567|NCT00005634|recurrent adult diffuse mixed cell lymphoma
688568|NCT00005634|recurrent adult diffuse large cell lymphoma
688569|NCT00005634|recurrent adult immunoblastic large cell lymphoma
688570|NCT00005634|recurrent adult lymphoblastic lymphoma
688571|NCT00005634|recurrent adult Burkitt lymphoma
688572|NCT00005634|recurrent adult T-cell leukemia/lymphoma
688573|NCT00005634|secondary acute myeloid leukemia
688574|NCT00005634|recurrent mantle cell lymphoma
688575|NCT00005634|recurrent mycosis fungoides/Sezary syndrome
688576|NCT00005634|recurrent marginal zone lymphoma
688577|NCT00005634|recurrent small lymphocytic lymphoma
688578|NCT00005634|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688579|NCT00005634|nodal marginal zone B-cell lymphoma
688580|NCT00005634|splenic marginal zone lymphoma
688581|NCT00005633|stage III melanoma
688582|NCT00005633|stage IV melanoma
688583|NCT00005633|recurrent melanoma
688584|NCT00005632|recurrent prostate cancer
688585|NCT00005631|recurrent adult diffuse large cell lymphoma
688586|NCT00005631|recurrent adult immunoblastic large cell lymphoma
688587|NCT00005631|anaplastic large cell lymphoma
688588|NCT00005630|stage I non-small cell lung cancer
688589|NCT00005630|stage II non-small cell lung cancer
688590|NCT00005630|large cell lung cancer
688591|NCT00005630|stage IIIA non-small cell lung cancer
688592|NCT00005630|stage IIIB non-small cell lung cancer
688593|NCT00005630|stage IV non-small cell lung cancer
688594|NCT00005630|adenocarcinoma of the lung
688595|NCT00005630|bronchoalveolar cell lung cancer
688596|NCT00005629|localized resectable adult primary liver cancer
688597|NCT00005629|localized unresectable adult primary liver cancer
688598|NCT00005629|advanced adult primary liver cancer
688599|NCT00005629|recurrent adult primary liver cancer
688600|NCT00005629|adult primary hepatocellular carcinoma
688601|NCT00005628|recurrent adult soft tissue sarcoma
688602|NCT00005628|stage IV adult soft tissue sarcoma
688603|NCT00005627|adenocarcinoma of the prostate
688604|NCT00005627|recurrent prostate cancer
688605|NCT00005626|stage III chronic lymphocytic leukemia
688606|NCT00005626|stage IV chronic lymphocytic leukemia
688607|NCT00005626|refractory chronic lymphocytic leukemia
688608|NCT00005626|stage I grade 1 follicular lymphoma
688609|NCT00005626|stage I grade 2 follicular lymphoma
688610|NCT00005626|stage III grade 1 follicular lymphoma
688611|NCT00005626|stage III grade 2 follicular lymphoma
688612|NCT00005626|stage IV grade 1 follicular lymphoma
688613|NCT00005626|stage IV grade 2 follicular lymphoma
688614|NCT00005626|recurrent grade 1 follicular lymphoma
688615|NCT00005626|recurrent grade 2 follicular lymphoma
688616|NCT00005626|prolymphocytic leukemia
688617|NCT00005626|stage I mantle cell lymphoma
688618|NCT00005626|contiguous stage II grade 1 follicular lymphoma
688619|NCT00005626|contiguous stage II grade 2 follicular lymphoma
688620|NCT00005626|contiguous stage II mantle cell lymphoma
688621|NCT00005626|noncontiguous stage II grade 1 follicular lymphoma
688622|NCT00005626|noncontiguous stage II grade 2 follicular lymphoma
688623|NCT00005626|noncontiguous stage II mantle cell lymphoma
688624|NCT00005626|stage III mantle cell lymphoma
688625|NCT00005626|stage IV mantle cell lymphoma
688626|NCT00005626|recurrent mantle cell lymphoma
688627|NCT00005626|noncontiguous stage II small lymphocytic lymphoma
688628|NCT00005626|noncontiguous stage II marginal zone lymphoma
688629|NCT00005626|recurrent marginal zone lymphoma
688630|NCT00005626|recurrent small lymphocytic lymphoma
688631|NCT00005626|stage I marginal zone lymphoma
688632|NCT00005626|stage I small lymphocytic lymphoma
688633|NCT00005626|stage III small lymphocytic lymphoma
688634|NCT00005626|stage III marginal zone lymphoma
688635|NCT00005626|stage IV small lymphocytic lymphoma
688636|NCT00005626|stage IV marginal zone lymphoma
688637|NCT00005626|contiguous stage II marginal zone lymphoma
688638|NCT00005626|contiguous stage II small lymphocytic lymphoma
688639|NCT00005626|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688640|NCT00005626|nodal marginal zone B-cell lymphoma
688641|NCT00005626|splenic marginal zone lymphoma
688642|NCT00005625|metastatic osteosarcoma
688643|NCT00005625|recurrent osteosarcoma
688644|NCT00005624|refractory multiple myeloma
688645|NCT00005624|stage II multiple myeloma
688646|NCT00005624|stage III multiple myeloma
688647|NCT00005624|plasma cell neoplasm
688648|NCT00005623|stage IV prostate cancer
688649|NCT00005623|recurrent prostate cancer
688650|NCT00005623|hot flashes
688651|NCT00005622|recurrent childhood acute lymphoblastic leukemia
688652|NCT00005622|refractory multiple myeloma
688653|NCT00005622|stage I multiple myeloma
688654|NCT00005622|stage II multiple myeloma
688655|NCT00005622|stage III multiple myeloma
688656|NCT00005622|stage I chronic lymphocytic leukemia
688657|NCT00005622|stage II chronic lymphocytic leukemia
688658|NCT00005622|stage III chronic lymphocytic leukemia
688659|NCT00005622|stage IV chronic lymphocytic leukemia
688660|NCT00005622|recurrent childhood acute myeloid leukemia
688661|NCT00005622|recurrent adult acute myeloid leukemia
688662|NCT00005622|recurrent adult acute lymphoblastic leukemia
688663|NCT00005622|refractory chronic lymphocytic leukemia
688664|NCT00005622|chronic phase chronic myelogenous leukemia
688665|NCT00005622|accelerated phase chronic myelogenous leukemia
688666|NCT00005622|blastic phase chronic myelogenous leukemia
688667|NCT00005622|adult acute myeloid leukemia in remission
688668|NCT00005622|adult acute lymphoblastic leukemia in remission
688669|NCT00005622|childhood acute myeloid leukemia in remission
688670|NCT00005622|childhood acute lymphoblastic leukemia in remission
688671|NCT00005622|polycythemia vera
688672|NCT00005622|primary myelofibrosis
688673|NCT00005622|essential thrombocythemia
688674|NCT00005622|refractory anemia
688675|NCT00005622|refractory anemia with ringed sideroblasts
688676|NCT00005622|refractory anemia with excess blasts
688677|NCT00005622|refractory anemia with excess blasts in transformation
688678|NCT00005622|chronic myelomonocytic leukemia
688679|NCT00005622|de novo myelodysplastic syndromes
688680|NCT00005622|previously treated myelodysplastic syndromes
688681|NCT00005622|secondary myelodysplastic syndromes
688682|NCT00005622|refractory cytopenia with multilineage dysplasia
688683|NCT00005622|chronic eosinophilic leukemia
688684|NCT00005622|chronic neutrophilic leukemia
688685|NCT00005622|atypical chronic myeloid leukemia, BCR-ABL1 negative
688686|NCT00005622|myelodysplastic/myeloproliferative neoplasm, unclassifiable
688687|NCT00005622|adult acute myeloid leukemia with t(8;21)(q22;q22)
688688|NCT00005622|adult acute myeloid leukemia with t(16;16)(p13;q22)
688689|NCT00005622|adult acute myeloid leukemia with inv(16)(p13;q22)
688690|NCT00005622|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
688691|NCT00005622|adult acute myeloid leukemia with t(15;17)(q22;q12)
688692|NCT00005622|childhood myelodysplastic syndromes
688693|NCT00005619|progressive hairy cell leukemia, initial treatment
688694|NCT00005619|refractory hairy cell leukemia
688695|NCT00005618|relapsing chronic myelogenous leukemia
688696|NCT00005618|chronic phase chronic myelogenous leukemia
688697|NCT00005618|accelerated phase chronic myelogenous leukemia
688698|NCT00005618|blastic phase chronic myelogenous leukemia
688699|NCT00005617|stage IV melanoma
688700|NCT00005617|recurrent melanoma
688701|NCT00005616|stage I colon cancer
688702|NCT00005616|stage II colon cancer
688703|NCT00005616|stage III colon cancer
688704|NCT00005616|stage IV colon cancer
688705|NCT00005616|stage I rectal cancer
688706|NCT00005616|stage II rectal cancer
688707|NCT00005616|stage III rectal cancer
688708|NCT00005616|stage IV rectal cancer
688709|NCT00005616|recurrent colon cancer
688710|NCT00005616|recurrent rectal cancer
688711|NCT00005616|liver metastases
688712|NCT00005615|stage III melanoma
688713|NCT00005615|recurrent melanoma
688714|NCT00005614|stage IV breast cancer
688715|NCT00005614|recurrent breast cancer
688716|NCT00005613|stage III adult Hodgkin lymphoma
688717|NCT00005613|stage IV adult Hodgkin lymphoma
688718|NCT00005613|recurrent adult Hodgkin lymphoma
688719|NCT00005613|recurrent grade 1 follicular lymphoma
688720|NCT00005613|recurrent grade 2 follicular lymphoma
688721|NCT00005613|recurrent grade 3 follicular lymphoma
688722|NCT00005613|recurrent adult diffuse small cleaved cell lymphoma
688723|NCT00005613|recurrent adult diffuse mixed cell lymphoma
688724|NCT00005613|recurrent adult diffuse large cell lymphoma
688725|NCT00005613|recurrent adult immunoblastic large cell lymphoma
688726|NCT00005613|recurrent adult Burkitt lymphoma
688727|NCT00005613|recurrent mantle cell lymphoma
688728|NCT00005613|recurrent marginal zone lymphoma
688729|NCT00005613|recurrent small lymphocytic lymphoma
688730|NCT00005613|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688731|NCT00005613|nodal marginal zone B-cell lymphoma
688732|NCT00005613|splenic marginal zone lymphoma
688733|NCT00005612|stage III ovarian epithelial cancer
688734|NCT00005612|stage IV ovarian epithelial cancer
688735|NCT00005612|recurrent ovarian epithelial cancer
688736|NCT00005611|unspecified adult solid tumor, protocol specific
688737|NCT00005610|stage IV melanoma
688738|NCT00005610|recurrent melanoma
688739|NCT00005610|lung metastases
688740|NCT00005609|Waldenström macroglobulinemia
688741|NCT00005608|stage IV breast cancer
688742|NCT00005608|recurrent breast cancer
688743|NCT00005607|stage IV gastric cancer
688744|NCT00005607|recurrent gastric cancer
688745|NCT00005607|stage IV esophageal cancer
688746|NCT00005607|recurrent esophageal cancer
688747|NCT00005607|adenocarcinoma of the stomach
688748|NCT00005607|adenocarcinoma of the esophagus
688749|NCT00005606|stage I adult Hodgkin lymphoma
688750|NCT00005606|stage II adult Hodgkin lymphoma
688751|NCT00005606|stage III adult Hodgkin lymphoma
688752|NCT00005606|stage IV adult Hodgkin lymphoma
688753|NCT00005606|recurrent childhood acute lymphoblastic leukemia
688754|NCT00005606|recurrent adult Hodgkin lymphoma
688755|NCT00005606|stage I cutaneous T-cell non-Hodgkin lymphoma
688756|NCT00005606|stage II cutaneous T-cell non-Hodgkin lymphoma
688757|NCT00005606|stage III cutaneous T-cell non-Hodgkin lymphoma
688758|NCT00005606|stage IV cutaneous T-cell non-Hodgkin lymphoma
688759|NCT00005606|recurrent cutaneous T-cell non-Hodgkin lymphoma
688760|NCT00005606|isolated plasmacytoma of bone
688761|NCT00005606|extramedullary plasmacytoma
688762|NCT00005606|stage 0 chronic lymphocytic leukemia
688763|NCT00005606|stage I multiple myeloma
688764|NCT00005606|stage II multiple myeloma
688765|NCT00005606|stage III multiple myeloma
688766|NCT00005606|stage I chronic lymphocytic leukemia
688767|NCT00005606|stage II chronic lymphocytic leukemia
688768|NCT00005606|stage III chronic lymphocytic leukemia
688769|NCT00005606|stage IV chronic lymphocytic leukemia
688770|NCT00005606|recurrent adult acute lymphoblastic leukemia
688771|NCT00005606|refractory chronic lymphocytic leukemia
688772|NCT00005606|untreated adult acute lymphoblastic leukemia
688773|NCT00005606|untreated childhood acute lymphoblastic leukemia
688774|NCT00005606|adult acute lymphoblastic leukemia in remission
688775|NCT00005606|childhood acute lymphoblastic leukemia in remission
688776|NCT00005606|untreated hairy cell leukemia
688777|NCT00005606|progressive hairy cell leukemia, initial treatment
688778|NCT00005606|refractory hairy cell leukemia
688779|NCT00005606|stage II childhood Hodgkin lymphoma
688780|NCT00005606|stage I childhood Hodgkin lymphoma
688781|NCT00005606|stage III childhood Hodgkin lymphoma
688782|NCT00005606|stage IV childhood Hodgkin lymphoma
688783|NCT00005606|recurrent/refractory childhood Hodgkin lymphoma
688784|NCT00005606|stage IV small lymphocytic lymphoma
688785|NCT00005606|stage I adult T-cell leukemia/lymphoma
688786|NCT00005606|stage II adult T-cell leukemia/lymphoma
688787|NCT00005606|stage III adult T-cell leukemia/lymphoma
688788|NCT00005606|stage IV adult T-cell leukemia/lymphoma
688789|NCT00005606|recurrent adult T-cell leukemia/lymphoma
688790|NCT00005606|stage I mycosis fungoides/Sezary syndrome
688791|NCT00005606|stage II mycosis fungoides/Sezary syndrome
688792|NCT00005606|stage III mycosis fungoides/Sezary syndrome
688793|NCT00005606|stage IV mycosis fungoides/Sezary syndrome
688794|NCT00005606|recurrent mycosis fungoides/Sezary syndrome
688795|NCT00005606|noncontiguous stage II small lymphocytic lymphoma
688796|NCT00005606|noncontiguous stage II marginal zone lymphoma
688797|NCT00005606|recurrent marginal zone lymphoma
688798|NCT00005606|recurrent small lymphocytic lymphoma
688799|NCT00005606|stage I marginal zone lymphoma
688800|NCT00005606|stage I small lymphocytic lymphoma
688801|NCT00005606|stage II small lymphocytic lymphoma
688802|NCT00005606|stage II marginal zone lymphoma
688803|NCT00005606|stage III small lymphocytic lymphoma
688804|NCT00005606|stage III marginal zone lymphoma
688805|NCT00005606|stage IV marginal zone lymphoma
688806|NCT00005606|contiguous stage II marginal zone lymphoma
688807|NCT00005606|contiguous stage II small lymphocytic lymphoma
688808|NCT00005606|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688809|NCT00005606|nodal marginal zone B-cell lymphoma
688810|NCT00005606|splenic marginal zone lymphoma
688811|NCT00005605|osteoporosis
688812|NCT00005605|stage I breast cancer
688813|NCT00005605|stage II breast cancer
688814|NCT00005603|childhood acute lymphoblastic leukemia in remission
688815|NCT00005603|B-cell childhood acute lymphoblastic leukemia
688816|NCT00005602|untreated childhood brain stem glioma
688817|NCT00005601|recurrent grade 1 follicular lymphoma
688818|NCT00005601|recurrent grade 2 follicular lymphoma
688819|NCT00005601|recurrent grade 3 follicular lymphoma
688820|NCT00005601|recurrent adult diffuse small cleaved cell lymphoma
688821|NCT00005601|recurrent adult diffuse mixed cell lymphoma
688822|NCT00005601|recurrent adult diffuse large cell lymphoma
688823|NCT00005601|recurrent adult immunoblastic large cell lymphoma
688824|NCT00005601|recurrent adult lymphoblastic lymphoma
688825|NCT00005601|recurrent adult Burkitt lymphoma
688826|NCT00005601|recurrent mantle cell lymphoma
688827|NCT00005601|recurrent marginal zone lymphoma
688828|NCT00005601|recurrent small lymphocytic lymphoma
688829|NCT00005601|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688830|NCT00005601|nodal marginal zone B-cell lymphoma
688831|NCT00005601|splenic marginal zone lymphoma
688832|NCT00005600|stage I breast cancer
688833|NCT00005600|stage II breast cancer
688834|NCT00005600|lymphedema
688835|NCT00005600|perioperative/postoperative complications
688836|NCT00005599|stage III gastric cancer
688837|NCT00005599|stage IV gastric cancer
688838|NCT00005599|recurrent gastric cancer
688839|NCT00005599|stage III esophageal cancer
688840|NCT00005599|stage IV esophageal cancer
688841|NCT00005599|recurrent esophageal cancer
688842|NCT00005599|squamous cell carcinoma of the esophagus
688843|NCT00005599|adenocarcinoma of the esophagus
688844|NCT00005598|refractory anemia
688845|NCT00005598|de novo myelodysplastic syndromes
688846|NCT00005598|previously treated myelodysplastic syndromes
688847|NCT00005598|secondary myelodysplastic syndromes
688848|NCT00005597|gastrointestinal stromal tumor
688849|NCT00005596|untreated childhood acute lymphoblastic leukemia
688850|NCT00005595|recurrent adult Hodgkin lymphoma
688851|NCT00005594|stage III pancreatic cancer
688852|NCT00005594|adenocarcinoma of the pancreas
688853|NCT00005594|stage IV pancreatic cancer
688854|NCT00005593|recurrent childhood acute lymphoblastic leukemia
688855|NCT00005593|recurrent childhood acute myeloid leukemia
688856|NCT00005593|recurrent adult acute myeloid leukemia
688857|NCT00005593|recurrent adult acute lymphoblastic leukemia
688858|NCT00005593|relapsing chronic myelogenous leukemia
688859|NCT00005593|blastic phase chronic myelogenous leukemia
688860|NCT00005593|L1 childhood acute lymphoblastic leukemia
688861|NCT00005593|L2 childhood acute lymphoblastic leukemia
688862|NCT00005593|L1 adult acute lymphoblastic leukemia
688863|NCT00005593|L2 adult acute lymphoblastic leukemia
688864|NCT00005593|adult acute erythroid leukemia (M6)
688865|NCT00005593|adult acute myeloblastic leukemia without maturation (M1)
688866|NCT00005593|adult acute myeloblastic leukemia with maturation (M2)
688867|NCT00005593|adult acute promyelocytic leukemia (M3)
688868|NCT00005593|adult acute myelomonocytic leukemia (M4)
688869|NCT00005593|adult acute monoblastic leukemia (M5a)
688870|NCT00005593|adult acute megakaryoblastic leukemia (M7)
688871|NCT00005593|childhood acute myeloblastic leukemia without maturation (M1)
688872|NCT00005593|childhood acute myeloblastic leukemia with maturation (M2)
688873|NCT00005593|childhood acute promyelocytic leukemia (M3)
688874|NCT00005593|childhood acute myelomonocytic leukemia (M4)
688875|NCT00005593|childhood acute monoblastic leukemia (M5a)
688876|NCT00005593|childhood acute monocytic leukemia (M5b)
688877|NCT00005593|childhood acute erythroleukemia (M6)
688878|NCT00005593|childhood acute megakaryocytic leukemia (M7)
688879|NCT00005593|refractory anemia with excess blasts
688880|NCT00005593|refractory anemia with excess blasts in transformation
688881|NCT00005593|chronic myelomonocytic leukemia
688882|NCT00005593|secondary acute myeloid leukemia
688883|NCT00005593|adult acute monocytic leukemia (M5b)
688884|NCT00005593|previously treated myelodysplastic syndromes
688885|NCT00005593|secondary myelodysplastic syndromes
688886|NCT00005593|adult acute minimally differentiated myeloid leukemia (M0)
688887|NCT00005593|childhood acute minimally differentiated myeloid leukemia (M0)
688888|NCT00005593|childhood myelodysplastic syndromes
688889|NCT00005592|recurrent grade 1 follicular lymphoma
688890|NCT00005592|recurrent grade 2 follicular lymphoma
688891|NCT00005592|recurrent grade 3 follicular lymphoma
688892|NCT00005592|recurrent adult diffuse small cleaved cell lymphoma
688893|NCT00005592|recurrent marginal zone lymphoma
688894|NCT00005592|recurrent small lymphocytic lymphoma
688895|NCT00005592|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
688896|NCT00005592|nodal marginal zone B-cell lymphoma
688897|NCT00005592|splenic marginal zone lymphoma
688898|NCT00005591|stage III pancreatic cancer
688899|NCT00005591|recurrent pancreatic cancer
688900|NCT00005591|adenocarcinoma of the pancreas
688901|NCT00005591|stage IV pancreatic cancer
688902|NCT00005590|stage I adult Hodgkin lymphoma
688903|NCT00005590|stage II adult Hodgkin lymphoma
688904|NCT00005590|stage III adult Hodgkin lymphoma
688905|NCT00005590|stage IV adult Hodgkin lymphoma
688906|NCT00005590|recurrent breast cancer
688907|NCT00005590|recurrent adult Hodgkin lymphoma
688908|NCT00005590|stage I cutaneous T-cell non-Hodgkin lymphoma
688909|NCT00005590|stage II cutaneous T-cell non-Hodgkin lymphoma
688910|NCT00005590|stage III cutaneous T-cell non-Hodgkin lymphoma
688911|NCT00005590|stage IV cutaneous T-cell non-Hodgkin lymphoma
688912|NCT00005590|recurrent cutaneous T-cell non-Hodgkin lymphoma
688913|NCT00005590|limited stage small cell lung cancer
688914|NCT00005590|extensive stage small cell lung cancer
688915|NCT00005590|recurrent small cell lung cancer
688916|NCT00005590|small intestine lymphoma
688917|NCT00005590|stage II malignant testicular germ cell tumor
688918|NCT00005590|stage III malignant testicular germ cell tumor
688919|NCT00005590|unspecified adult solid tumor, protocol specific
688920|NCT00005590|stage I grade 2 follicular lymphoma
688921|NCT00005590|stage I grade 3 follicular lymphoma
688922|NCT00005590|stage I adult diffuse small cleaved cell lymphoma
688923|NCT00005590|stage I adult diffuse mixed cell lymphoma
688924|NCT00005590|stage I adult diffuse large cell lymphoma
688925|NCT00005590|stage I adult immunoblastic large cell lymphoma
688926|NCT00005590|stage I adult lymphoblastic lymphoma
688927|NCT00005590|stage I adult Burkitt lymphoma
688928|NCT00005590|stage II ovarian germ cell tumor
688929|NCT00005590|stage III ovarian germ cell tumor
688930|NCT00005590|stage IV ovarian germ cell tumor
688931|NCT00005590|stage III grade 1 follicular lymphoma
688932|NCT00005590|stage III grade 2 follicular lymphoma
688933|NCT00005590|stage III grade 3 follicular lymphoma
688934|NCT00005590|stage III adult diffuse small cleaved cell lymphoma
688935|NCT00005590|stage III adult diffuse mixed cell lymphoma
688936|NCT00005590|stage III adult diffuse large cell lymphoma
688937|NCT00005590|stage III adult immunoblastic large cell lymphoma
688938|NCT00005590|stage III adult lymphoblastic lymphoma
688939|NCT00005590|stage III adult Burkitt lymphoma
688940|NCT00005590|stage IV grade 1 follicular lymphoma
688941|NCT00005590|stage IV grade 2 follicular lymphoma
688942|NCT00005590|stage IV grade 3 follicular lymphoma
688943|NCT00005590|stage IV adult diffuse small cleaved cell lymphoma
688944|NCT00005590|stage IV adult diffuse mixed cell lymphoma
688945|NCT00005590|stage IV adult diffuse large cell lymphoma
688946|NCT00005590|stage IV adult immunoblastic large cell lymphoma
688947|NCT00005590|stage IV adult lymphoblastic lymphoma
688948|NCT00005590|stage IV adult Burkitt lymphoma
688949|NCT00005590|recurrent grade 1 follicular lymphoma
688950|NCT00005590|recurrent grade 2 follicular lymphoma
688951|NCT00005590|recurrent grade 3 follicular lymphoma
688952|NCT00005590|recurrent adult diffuse small cleaved cell lymphoma
688953|NCT00005590|recurrent adult diffuse mixed cell lymphoma
688954|NCT00005590|recurrent adult diffuse large cell lymphoma
688955|NCT00005590|recurrent adult immunoblastic large cell lymphoma
688956|NCT00005590|recurrent adult lymphoblastic lymphoma
688957|NCT00005590|recurrent adult Burkitt lymphoma
688958|NCT00005590|stage I adult T-cell leukemia/lymphoma
688959|NCT00005590|stage II adult T-cell leukemia/lymphoma
688960|NCT00005590|stage III adult T-cell leukemia/lymphoma
688961|NCT00005590|stage IV adult T-cell leukemia/lymphoma
688962|NCT00005590|recurrent adult T-cell leukemia/lymphoma
688963|NCT00005590|extragonadal germ cell tumor
688964|NCT00005590|adult central nervous system germ cell tumor
688965|NCT00005590|primary central nervous system non-Hodgkin lymphoma
688966|NCT00005590|infection
688967|NCT00005590|intraocular lymphoma
688968|NCT00005590|stage I mantle cell lymphoma
688969|NCT00005590|contiguous stage II grade 1 follicular lymphoma
688970|NCT00005590|contiguous stage II grade 2 follicular lymphoma
688971|NCT00005590|contiguous stage II grade 3 follicular lymphoma
688972|NCT00005590|contiguous stage II adult diffuse small cleaved cell lymphoma
688973|NCT00005590|contiguous stage II mantle cell lymphoma
688974|NCT00005590|contiguous stage II adult diffuse mixed cell lymphoma
688975|NCT00005590|contiguous stage II adult immunoblastic large cell lymphoma
688976|NCT00005590|contiguous stage II adult diffuse large cell lymphoma
688977|NCT00005590|contiguous stage II adult Burkitt lymphoma
688978|NCT00005590|contiguous stage II adult lymphoblastic lymphoma
688979|NCT00005590|noncontiguous stage II grade 1 follicular lymphoma
688980|NCT00005590|noncontiguous stage II grade 2 follicular lymphoma
688981|NCT00005590|noncontiguous stage II grade 3 follicular lymphoma
688982|NCT00005590|noncontiguous stage II adult diffuse small cleaved cell lymphoma
688983|NCT00005590|noncontiguous stage II mantle cell lymphoma
688984|NCT00005590|noncontiguous stage II adult diffuse mixed cell lymphoma
688985|NCT00005590|noncontiguous stage II adult immunoblastic large cell lymphoma
688986|NCT00005590|noncontiguous stage II adult diffuse large cell lymphoma
688987|NCT00005590|noncontiguous stage II adult Burkitt lymphoma
688988|NCT00005590|noncontiguous stage II adult lymphoblastic lymphoma
688989|NCT00005590|stage III mantle cell lymphoma
688990|NCT00005590|stage IV mantle cell lymphoma
688991|NCT00005590|recurrent mantle cell lymphoma
688992|NCT00005590|angioimmunoblastic T-cell lymphoma
688993|NCT00005590|anaplastic large cell lymphoma
688994|NCT00005590|stage I mycosis fungoides/Sezary syndrome
688995|NCT00005590|stage II mycosis fungoides/Sezary syndrome
688996|NCT00005590|stage III mycosis fungoides/Sezary syndrome
688997|NCT00005590|stage IV mycosis fungoides/Sezary syndrome
688998|NCT00005590|recurrent mycosis fungoides/Sezary syndrome
688999|NCT00005590|contiguous stage II marginal zone lymphoma
689000|NCT00005590|contiguous stage II small lymphocytic lymphoma
689001|NCT00005590|noncontiguous stage II small lymphocytic lymphoma
689002|NCT00005590|noncontiguous stage II marginal zone lymphoma
689003|NCT00005590|recurrent marginal zone lymphoma
689004|NCT00005590|recurrent small lymphocytic lymphoma
689005|NCT00005590|stage I marginal zone lymphoma
689006|NCT00005590|stage I small lymphocytic lymphoma
689007|NCT00005590|stage II small lymphocytic lymphoma
689008|NCT00005590|stage II marginal zone lymphoma
689009|NCT00005590|stage III small lymphocytic lymphoma
689010|NCT00005590|stage III marginal zone lymphoma
689011|NCT00005590|stage IV small lymphocytic lymphoma
689012|NCT00005590|stage IV marginal zone lymphoma
689013|NCT00005590|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
689014|NCT00005590|nodal marginal zone B-cell lymphoma
689015|NCT00005590|splenic marginal zone lymphoma
689016|NCT00005589|recurrent grade 1 follicular lymphoma
689017|NCT00005589|recurrent grade 2 follicular lymphoma
689018|NCT00005589|recurrent grade 3 follicular lymphoma
689019|NCT00005588|stage I breast cancer
689020|NCT00005588|stage II breast cancer
689021|NCT00005588|stage IIIA breast cancer
689022|NCT00005587|stage I breast cancer
689023|NCT00005587|stage II breast cancer
689024|NCT00005587|stage IIIA breast cancer
689025|NCT00005586|stage II colon cancer
689026|NCT00005586|stage III colon cancer
689027|NCT00005586|stage II rectal cancer
689028|NCT00005586|stage III rectal cancer
689029|NCT00005585|childhood acute lymphoblastic leukemia in remission
689030|NCT00005585|B-cell childhood acute lymphoblastic leukemia
689031|NCT00005584|stage I adult Hodgkin lymphoma
689032|NCT00005584|stage II adult Hodgkin lymphoma
689033|NCT00005584|adult lymphocyte predominant Hodgkin lymphoma
689034|NCT00005583|stage I endometrial carcinoma
689035|NCT00005583|stage II endometrial carcinoma
689036|NCT00005583|endometrial adenocarcinoma
689037|NCT00005583|endometrial papillary serous carcinoma
689038|NCT00005583|endometrial clear cell carcinoma
689039|NCT00005581|stage II breast cancer
689040|NCT00005581|stage IIIA breast cancer
689041|NCT00005581|stage IIIB breast cancer
689042|NCT00005580|recurrent cutaneous T-cell non-Hodgkin lymphoma
689043|NCT00005580|Waldenstrom macroglobulinemia
689044|NCT00005580|stage I chronic lymphocytic leukemia
689045|NCT00005580|stage II chronic lymphocytic leukemia
689046|NCT00005580|stage III chronic lymphocytic leukemia
689047|NCT00005580|stage IV chronic lymphocytic leukemia
689048|NCT00005580|refractory chronic lymphocytic leukemia
689049|NCT00005580|T-cell large granular lymphocyte leukemia
689050|NCT00005580|B-cell chronic lymphocytic leukemia
689051|NCT00005580|refractory hairy cell leukemia
689052|NCT00005580|recurrent grade 1 follicular lymphoma
689053|NCT00005580|recurrent grade 2 follicular lymphoma
689054|NCT00005580|recurrent adult diffuse small cleaved cell lymphoma
689055|NCT00005580|recurrent adult T-cell leukemia/lymphoma
689056|NCT00005580|prolymphocytic leukemia
689057|NCT00005580|recurrent mantle cell lymphoma
689058|NCT00005580|recurrent mycosis fungoides/Sezary syndrome
689059|NCT00005580|recurrent marginal zone lymphoma
689060|NCT00005580|recurrent small lymphocytic lymphoma
689061|NCT00005580|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
689062|NCT00005580|nodal marginal zone B-cell lymphoma
689063|NCT00005580|splenic marginal zone lymphoma
689064|NCT00005579|Waldenström macroglobulinemia
689065|NCT00005579|stage I chronic lymphocytic leukemia
689066|NCT00005579|stage II chronic lymphocytic leukemia
689067|NCT00005579|stage III chronic lymphocytic leukemia
689068|NCT00005579|stage IV chronic lymphocytic leukemia
689069|NCT00005579|refractory chronic lymphocytic leukemia
689070|NCT00005579|stage III grade 1 follicular lymphoma
689071|NCT00005579|stage III grade 2 follicular lymphoma
689072|NCT00005579|stage III adult diffuse small cleaved cell lymphoma
689073|NCT00005579|stage IV grade 1 follicular lymphoma
689074|NCT00005579|stage IV grade 2 follicular lymphoma
689075|NCT00005579|stage IV adult diffuse small cleaved cell lymphoma
689076|NCT00005579|recurrent grade 1 follicular lymphoma
689077|NCT00005579|recurrent grade 2 follicular lymphoma
689078|NCT00005579|recurrent adult diffuse small cleaved cell lymphoma
689079|NCT00005579|recurrent small lymphocytic lymphoma
689080|NCT00005579|stage III small lymphocytic lymphoma
689081|NCT00005579|stage IV small lymphocytic lymphoma
689082|NCT00005578|stage II childhood Hodgkin lymphoma
689083|NCT00005578|stage I childhood Hodgkin lymphoma
689084|NCT00005578|stage III childhood Hodgkin lymphoma
689085|NCT00005578|stage IV childhood Hodgkin lymphoma
689086|NCT00005578|cardiac toxicity
689087|NCT00005577|unspecified childhood solid tumor, protocol specific
689088|NCT00005575|Imipramine
689089|NCT00005575|Cognitive-Behavioral Therapy
689090|NCT00005574|Becker Muscular Dystrophy
689091|NCT00005574|Duchenne Muscular Dystrophy
689092|NCT00005574|Muscle Disease
689093|NCT00005574|Myopathy
689094|NCT00005572|AIDS-Related Opportunistic Infections
689095|NCT00005572|Pneumonia, Pneumocystis carinii
689096|NCT00005572|Lymphocytes
689097|NCT00005572|Histoplasmosis
689098|NCT00005572|Recurrence
689099|NCT00005572|Cytomegalovirus Retinitis
689100|NCT00005572|Cell Division
689101|NCT00005572|Immunocompetence
689102|NCT00005572|Anti-HIV Agents
689103|NCT00005571|Skin
689104|NCT00005571|Humoral Immunity
689105|NCT00005571|Myositis
689106|NCT00005571|Complement
689107|NCT00005571|Antibody
689108|NCT00005571|Dermatomyositis
689109|NCT00005570|Bleeding
689110|NCT00005570|Cytokines
689111|NCT00005570|Immune Response
689112|NCT00005570|Pharmacogenomic
689113|NCT00005570|Serum Antibodies
689114|NCT00005570|ITP
689115|NCT00005570|Immune Thrombocytopenia Purpura
689116|NCT00005569|Elastase
689117|NCT00005569|Inflammation
689118|NCT00005569|Age
689119|NCT00005569|Gender
689120|NCT00005569|Cytokine
689121|NCT00005569|Healthy Volunteer
689122|NCT00005566|Suicide
689123|NCT00005520|Hypertension
689124|NCT00005520|Pharmacogenetics
689125|NCT00005520|Hydrochlorothiazide
689126|NCT00005520|Candesartan
689127|NCT00005487|Coronary Arteriosclerosis
689128|NCT00005487|Cerebrovascular Accident
689129|NCT00005487|Heart Failure, Congestive
689130|NCT00005487|Diabetes Mellitus, Non-Insulin Dependent
689131|NCT00005120|CD4 Lymphocyte Count
689132|NCT00005120|Biological Markers
689133|NCT00005120|Anti-HIV Agents
689134|NCT00005120|Viral Load
689135|NCT00005120|Pharmacokinetics
689136|NCT00005120|calanolide A
689137|NCT00005119|Premenstrual Dysphoric Disorder
689138|NCT00005119|Severe Premenstrual Syndrome
689139|NCT00005119|Calcium metabolism
689140|NCT00005119|Vitamin D
689141|NCT00005119|Bone Markers
689142|NCT00005119|Premenopausal
689143|NCT00005119|Menstrual Cycle
689144|NCT00005118|HIV-1
689145|NCT00005118|Drug Therapy, Combination
689146|NCT00005118|HIV Protease Inhibitors
689147|NCT00005118|Ritonavir
689148|NCT00005118|Indinavir
689149|NCT00005118|Reverse Transcriptase Inhibitors
689150|NCT00005118|Anti-HIV Agents
689151|NCT00005118|Viral Load
689152|NCT00005118|Nelfinavir
689153|NCT00005117|endothelial dysfunction
689154|NCT00005116|depression
689155|NCT00005111|Blood Flow
689156|NCT00005111|Glucose
689157|NCT00005111|Lysosomal Disease
689158|NCT00005111|Metabolic
689159|NCT00005111|Uptake
689160|NCT00005111|Fabry Disease
689161|NCT00005108|Menopause
689162|NCT00005108|Atherosclerosis
689163|NCT00005108|Estrogen
689164|NCT00005108|MRI
689165|NCT00005108|Ultrasound
689166|NCT00005106|Drug Therapy, Combination
689167|NCT00005106|Zidovudine
689168|NCT00005106|Stavudine
689169|NCT00005106|HIV Protease Inhibitors
689170|NCT00005106|Lamivudine
689171|NCT00005106|Nelfinavir
689172|NCT00005106|Reverse Transcriptase Inhibitors
689173|NCT00005106|Anti-HIV Agents
689174|NCT00005106|Adipose Tissue
689175|NCT00005106|Lipodystrophy
689176|NCT00005106|abacavir
689177|NCT00005105|endocrine disorders
689178|NCT00005105|intrauterine growth retardation
689179|NCT00005105|rare disease
689180|NCT00005104|endocrine disorders
689181|NCT00005104|hyperinsulinism
689182|NCT00005104|polycystic ovarian syndrome
689183|NCT00005104|rare disease
689184|NCT00005103|inborn errors of metabolism
689185|NCT00005103|porphyria
689186|NCT00005103|porphyria cutanea tarda
689187|NCT00005103|rare disease
689188|NCT00005102|DiGeorge syndrome
689189|NCT00005102|Shprintzen syndrome
689190|NCT00005102|cardiovascular and respiratory diseases
689191|NCT00005102|conotruncal cardiac defects
689192|NCT00005102|genetic diseases and dysmorphic syndromes
689193|NCT00005102|rare disease
689194|NCT00005101|disease-related problem/condition
689195|NCT00005101|osteoporosis
689196|NCT00005101|rare disease
689197|NCT00005100|acromegaly
689198|NCT00005100|endocrine disorders
689199|NCT00005100|rare disease
689200|NCT00005098|alpha 1-antitrypsin deficiency
689201|NCT00005098|genetic diseases and dysmorphic syndromes
689202|NCT00005098|rare disease
689203|NCT00005097|squamous cell carcinoma of the skin
689204|NCT00005096|adenocarcinoma of the prostate
689205|NCT00005096|stage II prostate cancer
689206|NCT00005096|stage III prostate cancer
689207|NCT00005095|ovarian epithelial cancer
689208|NCT00005095|hereditary breast/ovarian cancer (BRCA1, BRCA2)
689209|NCT00005095|fallopian tube cancer
689210|NCT00005095|ovarian germ cell tumor
689211|NCT00005095|ovarian sarcoma
689212|NCT00005095|ovarian stromal cancer
689213|NCT00005095|endometrial cancer
689214|NCT00005095|uterine sarcoma
689215|NCT00005095|vaginal cancer
689216|NCT00005095|cervical cancer
689217|NCT00005095|vulvar cancer
689218|NCT00005095|uterine leiomyomata
689219|NCT00005093|recurrent non-small cell lung cancer
689220|NCT00005093|stage IIIA non-small cell lung cancer
689221|NCT00005093|stage IIIB non-small cell lung cancer
689222|NCT00005093|stage IV non-small cell lung cancer
689223|NCT00005092|stage III adult Hodgkin lymphoma
689224|NCT00005092|stage IV adult Hodgkin lymphoma
689225|NCT00005092|recurrent childhood acute lymphoblastic leukemia
689226|NCT00005092|recurrent adult Hodgkin lymphoma
689227|NCT00005092|stage III cutaneous T-cell non-Hodgkin lymphoma
689228|NCT00005092|stage IV cutaneous T-cell non-Hodgkin lymphoma
689229|NCT00005092|recurrent cutaneous T-cell non-Hodgkin lymphoma
689230|NCT00005092|refractory multiple myeloma
689231|NCT00005092|stage III multiple myeloma
689232|NCT00005092|stage III childhood lymphoblastic lymphoma
689233|NCT00005092|stage IV childhood lymphoblastic lymphoma
689234|NCT00005092|recurrent childhood lymphoblastic lymphoma
689235|NCT00005092|stage III chronic lymphocytic leukemia
689236|NCT00005092|stage IV chronic lymphocytic leukemia
689237|NCT00005092|recurrent childhood acute myeloid leukemia
689238|NCT00005092|recurrent adult acute myeloid leukemia
689239|NCT00005092|recurrent adult acute lymphoblastic leukemia
689240|NCT00005092|relapsing chronic myelogenous leukemia
689241|NCT00005092|refractory chronic lymphocytic leukemia
689242|NCT00005092|childhood diffuse large cell lymphoma
689243|NCT00005092|childhood immunoblastic large cell lymphoma
689244|NCT00005092|chronic phase chronic myelogenous leukemia
689245|NCT00005092|accelerated phase chronic myelogenous leukemia
689246|NCT00005092|blastic phase chronic myelogenous leukemia
689247|NCT00005092|meningeal chronic myelogenous leukemia
689248|NCT00005092|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
689249|NCT00005092|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
689250|NCT00005092|T-cell large granular lymphocyte leukemia
689251|NCT00005092|B-cell chronic lymphocytic leukemia
689252|NCT00005092|Philadelphia chromosome positive chronic myelogenous leukemia
689253|NCT00005092|Philadelphia chromosome negative chronic myelogenous leukemia
689254|NCT00005092|L1 childhood acute lymphoblastic leukemia
689255|NCT00005092|L2 childhood acute lymphoblastic leukemia
689256|NCT00005092|L3 childhood acute lymphoblastic leukemia
689257|NCT00005092|T-cell childhood acute lymphoblastic leukemia
689258|NCT00005092|B-cell childhood acute lymphoblastic leukemia
689259|NCT00005092|non-T, non-B childhood acute lymphoblastic leukemia
689260|NCT00005092|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
689261|NCT00005092|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
689262|NCT00005092|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
689263|NCT00005092|L1 adult acute lymphoblastic leukemia
689264|NCT00005092|L2 adult acute lymphoblastic leukemia
689265|NCT00005092|L3 adult acute lymphoblastic leukemia
689266|NCT00005092|T-cell adult acute lymphoblastic leukemia
689267|NCT00005092|B-cell adult acute lymphoblastic leukemia
689268|NCT00005092|non-T, non-B adult acute lymphoblastic leukemia
689269|NCT00005092|non-T, non-B, cALLa positive adult acute lymphoblastic leukemia
689270|NCT00005092|non-T, non-B, cALLa positive, pre-B adult acute lymphoblastic leukemia
689271|NCT00005092|non-T, non-B, cALLa negative adult acute lymphoblastic leukemia
689272|NCT00005092|TdT positive adult acute lymphoblastic leukemia
689273|NCT00005092|TdT negative adult acute lymphoblastic leukemia
689274|NCT00005092|TdT negative childhood acute lymphoblastic leukemia
689275|NCT00005092|TdT positive childhood acute lymphoblastic leukemia
689276|NCT00005092|adult acute erythroid leukemia (M6)
689277|NCT00005092|adult acute myeloblastic leukemia without maturation (M1)
689278|NCT00005092|adult acute myeloblastic leukemia with maturation (M2)
689279|NCT00005092|adult acute promyelocytic leukemia (M3)
689280|NCT00005092|adult acute myelomonocytic leukemia (M4)
689281|NCT00005092|adult acute monoblastic leukemia (M5a)
689282|NCT00005092|adult acute eosinophilic leukemia
689283|NCT00005092|adult acute basophilic leukemia
689284|NCT00005092|adult acute megakaryoblastic leukemia (M7)
689285|NCT00005092|childhood acute myeloblastic leukemia without maturation (M1)
689286|NCT00005092|childhood acute myeloblastic leukemia with maturation (M2)
689287|NCT00005092|childhood acute promyelocytic leukemia (M3)
689288|NCT00005092|childhood acute myelomonocytic leukemia (M4)
689289|NCT00005092|childhood acute monoblastic leukemia (M5a)
689290|NCT00005092|childhood acute monocytic leukemia (M5b)
689291|NCT00005092|childhood acute erythroleukemia (M6)
689292|NCT00005092|childhood acute eosinophilic leukemia
689293|NCT00005092|childhood acute basophilic leukemia
689294|NCT00005092|childhood acute megakaryocytic leukemia (M7)
689295|NCT00005092|untreated hairy cell leukemia
689296|NCT00005092|chronic myelomonocytic leukemia
689297|NCT00005092|acute undifferentiated leukemia
689298|NCT00005092|stage III grade 2 follicular lymphoma
689299|NCT00005092|stage III grade 3 follicular lymphoma
689300|NCT00005092|stage III adult diffuse small cleaved cell lymphoma
689301|NCT00005092|stage III adult diffuse mixed cell lymphoma
689302|NCT00005092|stage III adult diffuse large cell lymphoma
689303|NCT00005092|stage III adult immunoblastic large cell lymphoma
689304|NCT00005092|stage III adult lymphoblastic lymphoma
689305|NCT00005092|stage III adult Burkitt lymphoma
689306|NCT00005092|stage IV grade 2 follicular lymphoma
689307|NCT00005092|stage IV grade 3 follicular lymphoma
689308|NCT00005092|stage IV adult diffuse small cleaved cell lymphoma
689309|NCT00005092|stage IV adult diffuse mixed cell lymphoma
689310|NCT00005092|stage IV adult diffuse large cell lymphoma
689311|NCT00005092|stage IV adult immunoblastic large cell lymphoma
689312|NCT00005092|stage IV adult lymphoblastic lymphoma
689313|NCT00005092|recurrent grade 2 follicular lymphoma
689314|NCT00005092|recurrent grade 3 follicular lymphoma
689315|NCT00005092|recurrent adult diffuse small cleaved cell lymphoma
689316|NCT00005092|recurrent adult diffuse mixed cell lymphoma
689317|NCT00005092|recurrent adult diffuse large cell lymphoma
689318|NCT00005092|recurrent adult immunoblastic large cell lymphoma
689319|NCT00005092|recurrent adult lymphoblastic lymphoma
689320|NCT00005092|stage III adult T-cell leukemia/lymphoma
689321|NCT00005092|stage IV adult T-cell leukemia/lymphoma
689322|NCT00005092|recurrent adult T-cell leukemia/lymphoma
689323|NCT00005092|secondary acute myeloid leukemia
689324|NCT00005092|de novo myelodysplastic syndromes
689325|NCT00005092|adult acute monocytic leukemia (M5b)
689326|NCT00005092|previously treated myelodysplastic syndromes
689327|NCT00005092|secondary myelodysplastic syndromes
689328|NCT00005092|prolymphocytic leukemia
689329|NCT00005092|adult acute minimally differentiated myeloid leukemia (M0)
689330|NCT00005092|childhood acute minimally differentiated myeloid leukemia (M0)
689331|NCT00005092|intraocular lymphoma
689332|NCT00005092|stage III childhood large cell lymphoma
689333|NCT00005092|stage IV childhood large cell lymphoma
689334|NCT00005092|recurrent childhood large cell lymphoma
689335|NCT00005092|childhood large cell lymphoma
689336|NCT00005092|stage III mantle cell lymphoma
689337|NCT00005092|stage IV mantle cell lymphoma
689338|NCT00005092|recurrent mantle cell lymphoma
689339|NCT00005092|angioimmunoblastic T-cell lymphoma
689340|NCT00005092|anaplastic large cell lymphoma
689341|NCT00005092|stage III mycosis fungoides/Sezary syndrome
689342|NCT00005092|stage IV mycosis fungoides/Sezary syndrome
689343|NCT00005092|recurrent mycosis fungoides/Sezary syndrome
689344|NCT00005092|childhood myelodysplastic syndromes
689345|NCT00005091|recurrent non-small cell lung cancer
689346|NCT00005091|stage IIIB non-small cell lung cancer
689347|NCT00005091|stage IV non-small cell lung cancer
689348|NCT00005090|stage III adult Hodgkin lymphoma
689349|NCT00005090|stage IV adult Hodgkin lymphoma
689350|NCT00005089|stage I adult diffuse large cell lymphoma
689351|NCT00005089|stage I adult Burkitt lymphoma
689352|NCT00005089|stage I mantle cell lymphoma
689353|NCT00005089|contiguous stage II mantle cell lymphoma
689354|NCT00005089|contiguous stage II adult diffuse large cell lymphoma
689355|NCT00005089|contiguous stage II adult Burkitt lymphoma
689356|NCT00005089|noncontiguous stage II mantle cell lymphoma
689357|NCT00005089|noncontiguous stage II adult diffuse large cell lymphoma
689358|NCT00005089|noncontiguous stage II adult Burkitt lymphoma
689359|NCT00005088|stage III squamous cell carcinoma of the lip and oral cavity
689360|NCT00005088|stage IV squamous cell carcinoma of the lip and oral cavity
689361|NCT00005088|stage III squamous cell carcinoma of the oropharynx
689362|NCT00005088|stage IV squamous cell carcinoma of the oropharynx
689363|NCT00005088|stage III squamous cell carcinoma of the hypopharynx
689364|NCT00005088|stage IV squamous cell carcinoma of the hypopharynx
689365|NCT00005088|stage III squamous cell carcinoma of the larynx
689366|NCT00005088|stage IV squamous cell carcinoma of the larynx
689367|NCT00005087|recurrent metastatic squamous neck cancer with occult primary
689368|NCT00005087|metastatic squamous neck cancer with occult primary squamous cell carcinoma
689369|NCT00005087|stage I squamous cell carcinoma of the lip and oral cavity
689370|NCT00005087|stage II squamous cell carcinoma of the lip and oral cavity
689371|NCT00005087|stage III squamous cell carcinoma of the lip and oral cavity
689372|NCT00005087|recurrent squamous cell carcinoma of the lip and oral cavity
689373|NCT00005087|stage I squamous cell carcinoma of the oropharynx
689374|NCT00005087|stage II squamous cell carcinoma of the oropharynx
689375|NCT00005087|stage III squamous cell carcinoma of the oropharynx
689376|NCT00005087|recurrent squamous cell carcinoma of the oropharynx
689377|NCT00005087|stage I squamous cell carcinoma of the hypopharynx
689378|NCT00005087|stage II squamous cell carcinoma of the hypopharynx
689379|NCT00005087|stage III squamous cell carcinoma of the hypopharynx
689380|NCT00005087|recurrent squamous cell carcinoma of the hypopharynx
689381|NCT00005087|stage I squamous cell carcinoma of the larynx
689382|NCT00005087|stage II squamous cell carcinoma of the larynx
689383|NCT00005087|stage III squamous cell carcinoma of the larynx
689384|NCT00005087|recurrent squamous cell carcinoma of the larynx
689385|NCT00005087|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
689386|NCT00005087|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
689387|NCT00005087|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
689388|NCT00005087|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
689389|NCT00005086|stage IV bladder cancer
689390|NCT00005086|transitional cell carcinoma of the bladder
689391|NCT00005085|stage IV colon cancer
689392|NCT00005085|stage IV rectal cancer
689393|NCT00005085|recurrent colon cancer
689394|NCT00005085|recurrent rectal cancer
689395|NCT00005085|adenocarcinoma of the colon
689396|NCT00005085|adenocarcinoma of the rectum
689397|NCT00005084|childhood low-grade cerebral astrocytoma
689398|NCT00005084|childhood low-grade cerebellar astrocytoma
689399|NCT00005084|recurrent childhood cerebral astrocytoma
689400|NCT00005083|adult glioblastoma
689401|NCT00005083|adult anaplastic astrocytoma
689402|NCT00005083|adult myxopapillary ependymoma
689403|NCT00005083|adult anaplastic ependymoma
689404|NCT00005083|adult anaplastic oligodendroglioma
689405|NCT00005083|adult mixed glioma
689406|NCT00005083|adult pilocytic astrocytoma
689407|NCT00005083|adult subependymoma
689408|NCT00005083|adult ependymoblastoma
689409|NCT00005083|adult oligodendroglioma
689410|NCT00005083|adult giant cell glioblastoma
689411|NCT00005083|adult gliosarcoma
689412|NCT00005082|adult medulloblastoma
689413|NCT00005082|adult glioblastoma
689414|NCT00005082|adult anaplastic astrocytoma
689415|NCT00005082|adult myxopapillary ependymoma
689416|NCT00005082|adult anaplastic ependymoma
689417|NCT00005082|adult anaplastic oligodendroglioma
689418|NCT00005082|adult mixed glioma
689419|NCT00005082|adult pilocytic astrocytoma
689420|NCT00005082|adult subependymoma
689421|NCT00005082|adult ependymoblastoma
689422|NCT00005082|adult oligodendroglioma
689423|NCT00005082|adult giant cell glioblastoma
689424|NCT00005082|adult gliosarcoma
689425|NCT00005081|recurrent adult brain tumor
689426|NCT00005081|adult glioblastoma
689427|NCT00005081|adult anaplastic astrocytoma
689428|NCT00005081|adult mixed glioma
689429|NCT00005081|adult giant cell glioblastoma
689430|NCT00005081|adult gliosarcoma
689431|NCT00005079|stage I breast cancer
689432|NCT00005079|stage II breast cancer
689433|NCT00005079|stage IIIA breast cancer
689434|NCT00005079|stage IIIB breast cancer
689435|NCT00005078|unspecified adult solid tumor, protocol specific
689436|NCT00005077|unspecified adult solid tumor, protocol specific
689437|NCT00005076|stage III colon cancer
689438|NCT00005076|stage IV colon cancer
689439|NCT00005076|stage III rectal cancer
689440|NCT00005076|stage IV rectal cancer
689441|NCT00005076|recurrent colon cancer
689442|NCT00005076|recurrent rectal cancer
689443|NCT00005075|stage I prostate cancer
689444|NCT00005075|stage II prostate cancer
689445|NCT00005075|recurrent prostate cancer
689446|NCT00005074|stage I mantle cell lymphoma
689447|NCT00005074|stage III mantle cell lymphoma
689448|NCT00005074|stage IV mantle cell lymphoma
689449|NCT00005074|recurrent mantle cell lymphoma
689450|NCT00005074|stage II mantle cell lymphoma
689451|NCT00005073|stage I prostate cancer
689452|NCT00005073|stage IIB prostate cancer
689453|NCT00005073|stage IIA prostate cancer
689454|NCT00005073|stage III prostate cancer
689455|NCT00005073|recurrent prostate cancer
689456|NCT00005072|stage I prostate cancer
689457|NCT00005072|stage IIB prostate cancer
689458|NCT00005072|stage IIA prostate cancer
689459|NCT00005072|recurrent prostate cancer
689460|NCT00005071|stage I non-small cell lung cancer
689461|NCT00005071|stage II non-small cell lung cancer
689462|NCT00005071|limited stage small cell lung cancer
689463|NCT00005070|recurrent cervical cancer
689464|NCT00005070|stage IVB cervical cancer
689465|NCT00005070|cervical squamous cell carcinoma
689466|NCT00005070|cervical adenocarcinoma
689467|NCT00005070|cervical adenosquamous cell carcinoma
689468|NCT00005069|stage IV renal cell cancer
689469|NCT00005069|recurrent renal cell cancer
689470|NCT00005068|unspecified adult solid tumor, protocol specific
689471|NCT00005066|recurrent adult soft tissue sarcoma
689472|NCT00005066|stage IV adult soft tissue sarcoma
689473|NCT00005062|limited stage small cell lung cancer
689474|NCT00005061|unspecified adult solid tumor, protocol specific
689475|NCT00005060|stage II gastric cancer
689476|NCT00005060|stage III gastric cancer
689477|NCT00005059|recurrent non-small cell lung cancer
689478|NCT00005059|stage IV non-small cell lung cancer
689479|NCT00005058|stage I breast cancer
689480|NCT00005058|stage II breast cancer
689481|NCT00005058|stage IIIA breast cancer
689482|NCT00005058|stage IIIB breast cancer
689483|NCT00005058|inflammatory breast cancer
689484|NCT00005057|stage IV melanoma
689485|NCT00005057|recurrent melanoma
689486|NCT00005057|lentigo maligna malignant melanoma
689487|NCT00005057|superficial spreading malignant melanoma
689488|NCT00005057|acral lentiginous malignant melanoma
689489|NCT00005057|nodular malignant melanoma
689490|NCT00005056|stage I renal cell cancer
689491|NCT00005056|stage II renal cell cancer
689492|NCT00005056|stage III renal cell cancer
689493|NCT00005056|stage IV renal cell cancer
689494|NCT00005056|recurrent renal cell cancer
689495|NCT00005055|recurrent non-small cell lung cancer
689496|NCT00005055|stage IIIA non-small cell lung cancer
689497|NCT00005055|stage IIIB non-small cell lung cancer
689498|NCT00005055|stage IV non-small cell lung cancer
689499|NCT00005054|stage IV breast cancer
689500|NCT00005054|stage IIIA breast cancer
689501|NCT00005054|recurrent breast cancer
689502|NCT00005054|stage IIIB breast cancer
689503|NCT00005053|stage III pancreatic cancer
689504|NCT00005053|recurrent pancreatic cancer
689505|NCT00005053|adenocarcinoma of the pancreas
689506|NCT00005053|stage IV pancreatic cancer
689507|NCT00005052|stage II melanoma
689508|NCT00005051|stage I ovarian epithelial cancer
689509|NCT00005051|stage II ovarian epithelial cancer
689510|NCT00005051|stage III ovarian epithelial cancer
689511|NCT00005051|stage IV ovarian epithelial cancer
689512|NCT00005050|stage III colon cancer
689513|NCT00005050|stage IV colon cancer
689514|NCT00005050|stage III rectal cancer
689515|NCT00005050|stage IV rectal cancer
689516|NCT00005050|recurrent colon cancer
689517|NCT00005050|recurrent rectal cancer
689518|NCT00005049|stage II colon cancer
689519|NCT00005049|stage III colon cancer
689520|NCT00005049|stage II gastric cancer
689521|NCT00005049|stage III gastric cancer
689522|NCT00005049|recurrent gastric cancer
689523|NCT00005049|stage II rectal cancer
689524|NCT00005049|stage III rectal cancer
689525|NCT00005049|recurrent colon cancer
689526|NCT00005049|stage III ovarian epithelial cancer
689527|NCT00005049|recurrent ovarian epithelial cancer
689528|NCT00005049|regional gastrointestinal carcinoid tumor
689529|NCT00005049|small intestine adenocarcinoma
689530|NCT00005049|small intestine lymphoma
689531|NCT00005049|small intestine leiomyosarcoma
689532|NCT00005049|recurrent small intestine cancer
689533|NCT00005049|peritoneal cavity cancer
689534|NCT00005049|gastrointestinal stromal tumor
689535|NCT00005048|adenocarcinoma of the prostate
689536|NCT00005048|recurrent prostate cancer
689537|NCT00005047|stage I bladder cancer
689538|NCT00005047|stage II bladder cancer
689539|NCT00005047|transitional cell carcinoma of the bladder
689540|NCT00005046|recurrent ovarian epithelial cancer
689541|NCT00005046|primary peritoneal cavity cancer
689542|NCT00005045|stage III renal cell cancer
689543|NCT00005045|stage IV renal cell cancer
689544|NCT00005045|recurrent renal cell cancer
689545|NCT00005044|adenocarcinoma of the prostate
689546|NCT00005044|stage IIB prostate cancer
689547|NCT00005044|stage IIA prostate cancer
689548|NCT00005044|stage III prostate cancer
689549|NCT00005042|AIDS-related Kaposi sarcoma
689550|NCT00005042|recurrent Kaposi sarcoma
689551|NCT00005041|extensive stage small cell lung cancer
689552|NCT00005041|recurrent small cell lung cancer
689553|NCT00005040|recurrent adult grade III lymphomatoid granulomatosis
689554|NCT00005040|recurrent grade 3 follicular lymphoma
689555|NCT00005040|recurrent adult diffuse small cleaved cell lymphoma
689556|NCT00005040|recurrent adult diffuse mixed cell lymphoma
689557|NCT00005040|recurrent adult diffuse large cell lymphoma
689558|NCT00005040|recurrent adult immunoblastic large cell lymphoma
689559|NCT00005040|recurrent adult lymphoblastic lymphoma
689560|NCT00005040|recurrent adult Burkitt lymphoma
689561|NCT00005040|recurrent adult T-cell leukemia/lymphoma
689562|NCT00005040|recurrent mantle cell lymphoma
689563|NCT00005040|angioimmunoblastic T-cell lymphoma
689564|NCT00005040|anaplastic large cell lymphoma
689565|NCT00005038|stage IV renal cell cancer
689566|NCT00005038|recurrent renal cell cancer
689567|NCT00005037|recurrent non-small cell lung cancer
689568|NCT00005037|stage IIIB non-small cell lung cancer
689569|NCT00005037|stage IV non-small cell lung cancer
689570|NCT00005035|metastatic squamous neck cancer with occult primary squamous cell carcinoma
689571|NCT00005035|stage III squamous cell carcinoma of the lip and oral cavity
689572|NCT00005035|stage IV squamous cell carcinoma of the lip and oral cavity
689573|NCT00005035|recurrent squamous cell carcinoma of the lip and oral cavity
689574|NCT00005035|stage III squamous cell carcinoma of the oropharynx
689575|NCT00005035|stage IV squamous cell carcinoma of the oropharynx
689576|NCT00005035|recurrent squamous cell carcinoma of the oropharynx
689577|NCT00005035|stage III squamous cell carcinoma of the nasopharynx
689578|NCT00005035|stage IV squamous cell carcinoma of the nasopharynx
689579|NCT00005035|recurrent squamous cell carcinoma of the nasopharynx
689580|NCT00005035|stage III squamous cell carcinoma of the hypopharynx
689581|NCT00005035|stage IV squamous cell carcinoma of the hypopharynx
689582|NCT00005035|recurrent squamous cell carcinoma of the hypopharynx
689583|NCT00005035|stage III squamous cell carcinoma of the larynx
689584|NCT00005035|stage IV squamous cell carcinoma of the larynx
689585|NCT00005035|recurrent squamous cell carcinoma of the larynx
689586|NCT00005035|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
689587|NCT00005035|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
689588|NCT00005035|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
689589|NCT00005033|recurrent osteosarcoma
689590|NCT00005032|recurrent small cell lung cancer
689591|NCT00005031|recurrent endometrial carcinoma
689592|NCT00005030|stage IV colon cancer
689593|NCT00005030|stage IV rectal cancer
689594|NCT00005030|recurrent colon cancer
689595|NCT00005030|recurrent rectal cancer
689596|NCT00005030|liver metastases
689597|NCT00005029|recurrent ovarian epithelial cancer
689598|NCT00005029|primary peritoneal cavity cancer
689599|NCT00005028|adenocarcinoma of the prostate
689600|NCT00005028|stage IV prostate cancer
689601|NCT00005028|recurrent prostate cancer
689602|NCT00005027|stage III renal cell cancer
689603|NCT00005027|stage IV renal cell cancer
689604|NCT00005027|recurrent renal cell cancer
689605|NCT00005026|stage III ovarian epithelial cancer
689606|NCT00005026|stage IV ovarian epithelial cancer
689607|NCT00005026|ovarian undifferentiated adenocarcinoma
689608|NCT00005026|ovarian mixed epithelial carcinoma
689609|NCT00005026|ovarian serous cystadenocarcinoma
689610|NCT00005026|ovarian mucinous cystadenocarcinoma
689611|NCT00005026|ovarian endometrioid adenocarcinoma
689612|NCT00005026|ovarian clear cell cystadenocarcinoma
689613|NCT00005026|primary peritoneal cavity cancer
689614|NCT00005026|Brenner tumor
689615|NCT00005025|recurrent ovarian epithelial cancer
689616|NCT00005025|fallopian tube cancer
689617|NCT00005025|primary peritoneal cavity cancer
689618|NCT00005024|unspecified adult solid tumor, protocol specific
689619|NCT00005023|stage IV breast cancer
689620|NCT00005023|stage IIIA breast cancer
689621|NCT00005023|stage III non-small cell lung cancer
689622|NCT00005023|stage IIIB breast cancer
689623|NCT00005023|stage III ovarian epithelial cancer
689624|NCT00005023|stage IV ovarian epithelial cancer
689625|NCT00005023|stage IV non-small cell lung cancer
689626|NCT00005023|adenocarcinoma of the lung
689627|NCT00005022|limited stage small cell lung cancer
689628|NCT00005021|stage III adult Hodgkin lymphoma
689629|NCT00005021|stage IV adult Hodgkin lymphoma
689630|NCT00005021|recurrent adult Hodgkin lymphoma
689631|NCT00005021|stage III cutaneous T-cell non-Hodgkin lymphoma
689632|NCT00005021|stage IV cutaneous T-cell non-Hodgkin lymphoma
689633|NCT00005021|recurrent cutaneous T-cell non-Hodgkin lymphoma
689634|NCT00005021|small intestine lymphoma
689635|NCT00005021|unspecified adult solid tumor, protocol specific
689636|NCT00005021|stage III grade 1 follicular lymphoma
689637|NCT00005021|stage III grade 2 follicular lymphoma
689638|NCT00005021|stage III grade 3 follicular lymphoma
689639|NCT00005021|stage III adult diffuse small cleaved cell lymphoma
689640|NCT00005021|stage III adult diffuse mixed cell lymphoma
689641|NCT00005021|stage III adult diffuse large cell lymphoma
689642|NCT00005021|stage III adult immunoblastic large cell lymphoma
689643|NCT00005021|stage III adult lymphoblastic lymphoma
689644|NCT00005021|stage III adult Burkitt lymphoma
689645|NCT00005021|stage IV grade 1 follicular lymphoma
689646|NCT00005021|stage IV grade 2 follicular lymphoma
689647|NCT00005021|stage IV grade 3 follicular lymphoma
689648|NCT00005021|stage IV adult diffuse small cleaved cell lymphoma
689649|NCT00005021|stage IV adult diffuse mixed cell lymphoma
689650|NCT00005021|stage IV adult diffuse large cell lymphoma
689651|NCT00005021|stage IV adult immunoblastic large cell lymphoma
689652|NCT00005021|stage IV adult lymphoblastic lymphoma
689653|NCT00005021|stage IV adult Burkitt lymphoma
689654|NCT00005021|recurrent grade 1 follicular lymphoma
689655|NCT00005021|recurrent grade 2 follicular lymphoma
689656|NCT00005021|recurrent grade 3 follicular lymphoma
689657|NCT00005021|recurrent adult diffuse small cleaved cell lymphoma
689658|NCT00005021|recurrent adult diffuse mixed cell lymphoma
689659|NCT00005021|recurrent adult diffuse large cell lymphoma
689660|NCT00005021|recurrent adult immunoblastic large cell lymphoma
689661|NCT00005021|recurrent adult lymphoblastic lymphoma
689662|NCT00005021|recurrent adult Burkitt lymphoma
689663|NCT00005021|stage III adult T-cell leukemia/lymphoma
689664|NCT00005021|stage IV adult T-cell leukemia/lymphoma
689665|NCT00005021|recurrent adult T-cell leukemia/lymphoma
689666|NCT00005021|primary central nervous system non-Hodgkin lymphoma
689667|NCT00005021|AIDS-related peripheral/systemic lymphoma
689668|NCT00005021|AIDS-related primary CNS lymphoma
689669|NCT00005021|intraocular lymphoma
689670|NCT00005021|stage III mantle cell lymphoma
689671|NCT00005021|stage IV mantle cell lymphoma
689672|NCT00005021|recurrent mantle cell lymphoma
689673|NCT00005021|angioimmunoblastic T-cell lymphoma
689674|NCT00005021|anaplastic large cell lymphoma
689675|NCT00005021|stage III mycosis fungoides/Sezary syndrome
689676|NCT00005021|stage IV mycosis fungoides/Sezary syndrome
689677|NCT00005021|recurrent mycosis fungoides/Sezary syndrome
689678|NCT00005021|recurrent marginal zone lymphoma
689679|NCT00005021|recurrent small lymphocytic lymphoma
689680|NCT00005021|stage III small lymphocytic lymphoma
689681|NCT00005021|stage III marginal zone lymphoma
689682|NCT00005021|stage IV small lymphocytic lymphoma
689683|NCT00005021|stage IV marginal zone lymphoma
689684|NCT00005021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
689685|NCT00005021|nodal marginal zone B-cell lymphoma
689686|NCT00005021|splenic marginal zone lymphoma
689687|NCT00005020|CD4 Lymphocyte Count
689688|NCT00005020|CD4-Positive T-Lymphocytes
689689|NCT00005020|Phenotype
689690|NCT00005020|Viral Load
689691|NCT00005020|Acute Infection
689692|NCT00005018|HIV-1
689693|NCT00005018|Didanosine
689694|NCT00005018|Drug Therapy, Combination
689695|NCT00005018|Zidovudine
689696|NCT00005018|Stavudine
689697|NCT00005018|HIV Protease Inhibitors
689698|NCT00005018|Hydroxyurea
689699|NCT00005018|RNA, Viral
689700|NCT00005018|Reverse Transcriptase Inhibitors
689701|NCT00005018|Anti-HIV Agents
689702|NCT00005018|Viral Load
689703|NCT00005018|abacavir
689704|NCT00005018|efavirenz
689705|NCT00005017|HIV-1
689706|NCT00005017|Drug Therapy, Combination
689707|NCT00005017|Stavudine
689708|NCT00005017|HIV Protease Inhibitors
689709|NCT00005017|Ritonavir
689710|NCT00005017|Lamivudine
689711|NCT00005017|VX 478
689712|NCT00005017|Reverse Transcriptase Inhibitors
689713|NCT00005017|Anti-HIV Agents
689714|NCT00005017|abacavir
689715|NCT00005017|efavirenz
689716|NCT00005016|Fetal Anomaly
689717|NCT00005016|Genetic Counseling
689718|NCT00005016|Prenatal Diagnosis
689719|NCT00005016|Psychosocial Issues
689720|NCT00005016|Qualitative
689721|NCT00005016|HPE
689722|NCT00005016|Holoprosencephaly
689723|NCT00005015|Bipolar Disorder
689724|NCT00005015|Depression
689725|NCT00005015|Fluoxetine
689726|NCT00005014|Autistic Disorder
689727|NCT00005014|Risperidone
689728|NCT00005013|Antidepressive Agents
689729|NCT00005013|Depression
689730|NCT00005013|Depressive Disorder
689731|NCT00005013|Herbs
689732|NCT00005013|Hypericum
689733|NCT00005013|Medicine, Herbal
689734|NCT00005013|Plant Extracts
689735|NCT00005013|Alternative Medicine
689736|NCT00005012|Interferon Alfa-2b
689737|NCT00005012|Lymphocyte Transformation
689738|NCT00005012|CD4 Lymphocyte Count
689739|NCT00005012|RNA, Viral
689740|NCT00005012|Virus Inhibitors
689741|NCT00005012|Anti-HIV Agents
689742|NCT00005012|Viral Load
689743|NCT00005011|Depression
689744|NCT00005011|Menstrual Cycle
689745|NCT00005011|Gonadal Steroids
689746|NCT00005011|GnRH Agonist
689747|NCT00005011|PMS
689748|NCT00005011|Estradiol
689749|NCT00005011|Progesterone
689750|NCT00005011|Mood
689751|NCT00005011|MRMD
689752|NCT00005011|PMDD
689753|NCT00005011|Menstrually Related Mood Disorders
689754|NCT00005009|pediatric renal transplant recipients
689755|NCT00005009|varicella zoster virus (VZV) vaccine
689756|NCT00005009|herpes zoster vaccine
689757|NCT00005009|VZV susceptible
689758|NCT00005009|safety
689759|NCT00005009|immunogenicity
689760|NCT00005007|Wegener's granulomatosis
689761|NCT00005007|Vasculitis
689762|NCT00005007|Etanercept
689763|NCT00005007|Tumor necrosis factor
689764|NCT00005006|Anabolic agent
689765|NCT00005006|hPTH
689766|NCT00005006|PTH
689767|NCT00005006|Parathyroid hormone
689768|NCT00005006|Bone mass
689769|NCT00005006|Bone turnover
689770|NCT00005006|Bone formation
689771|NCT00005006|Alendronate
689772|NCT00005006|Osteoporosis
689773|NCT00005006|Cyclical therapy
689774|NCT00005005|PTH
689775|NCT00005005|Alendronate
689776|NCT00005005|Parathyroid hormone
689777|NCT00005005|Osteoporosis
689778|NCT00005005|Postmenopausal
689779|NCT00005004|Cognitive Processes
689780|NCT00005004|Inferential Ambiguities
689781|NCT00005004|Language Processes
689782|NCT00005004|Lexical Ambiguities
689783|NCT00005004|Suppression Mechanism
689784|NCT00005004|Discourse Processes
689785|NCT00005004|Discourse Production Analysis
689786|NCT00005004|Magnetic Resonance Imaging
689787|NCT00005004|Prefrontal Cortex Function
689788|NCT00005004|Aging Effects
689789|NCT00005004|Garden Path Phenomena
689790|NCT00005004|Text Integration
689791|NCT00005003|Handedness
689792|NCT00005003|Laterality
689793|NCT00005003|Linkage
689794|NCT00005003|VNTR/Dinucleotide
689795|NCT00005003|Dinucleotide
689796|NCT00005003|High-Frequency-Trait Analysis
689797|NCT00005002|HIV-1
689798|NCT00005002|Drug Therapy, Combination
689799|NCT00005002|HIV Protease Inhibitors
689800|NCT00005002|CD4 Lymphocyte Count
689801|NCT00005002|Nelfinavir
689802|NCT00005002|Reverse Transcriptase Inhibitors
689803|NCT00005002|Anti-HIV Agents
689804|NCT00005002|Viral Load
689805|NCT00005002|remune
689806|NCT00005002|Combivir
689807|NCT00005001|HIV-1
689808|NCT00005001|Drug Therapy, Combination
689809|NCT00005001|RNA, Viral
689810|NCT00005001|Anti-HIV Agents
689811|NCT00005001|Viral Load
689812|NCT00005001|remune
689813|NCT00005000|HIV-1
689814|NCT00005000|Drug Therapy, Combination
689815|NCT00005000|Lymphoid Tissue
689816|NCT00005000|HIV Protease Inhibitors
689817|NCT00005000|Genotype
689818|NCT00005000|Phenotype
689819|NCT00005000|Nelfinavir
689820|NCT00005000|Reverse Transcriptase Inhibitors
689821|NCT00005000|Anti-HIV Agents
689822|NCT00005000|Viral Load
689823|NCT00005000|Adipose Tissue
689824|NCT00005000|Glucose
689825|NCT00005000|Lipids
689826|NCT00005000|Immunophenotyping
689827|NCT00005000|efavirenz
689828|NCT00004999|Drug Therapy, Combination
689829|NCT00004999|Zidovudine
689830|NCT00004999|HIV Protease Inhibitors
689831|NCT00004999|Lamivudine
689832|NCT00004999|Disease Progression
689833|NCT00004999|Reverse Transcriptase Inhibitors
689834|NCT00004999|Anti-HIV Agents
689835|NCT00004999|Viral Load
689836|NCT00004999|Nelfinavir
689837|NCT00004999|Combivir
689838|NCT00004998|Drug Therapy, Combination
689839|NCT00004998|Zidovudine
689840|NCT00004998|HIV Protease Inhibitors
689841|NCT00004998|Lamivudine
689842|NCT00004998|Reverse Transcriptase Inhibitors
689843|NCT00004998|Anti-HIV Agents
689844|NCT00004998|Nelfinavir
689845|NCT00004998|Combivir
689846|NCT00004997|Hematopoietic
689847|NCT00004997|DHFR Enzyme
689848|NCT00004997|Anemia
689849|NCT00004997|Folic Acid
689850|NCT00004997|MDS
689851|NCT00004997|Myelodysplasia
689852|NCT00004997|Myelodysplastic
689853|NCT00004996|Antigen Presentation
689854|NCT00004996|Cytokines
689855|NCT00004996|Helminth
689856|NCT00004996|Healthy Volunteer
689857|NCT00004996|Cross-Over Study
689858|NCT00004996|Helminth Infection
689859|NCT00004994|Allogeneic Transplant
689860|NCT00004994|Function
689861|NCT00004994|Mini-Transplant
689862|NCT00004994|Physical Symptoms
689863|NCT00004994|Symptom Distress
689864|NCT00004993|Parathyroid hormone (1-34)
689865|NCT00004993|Glucocorticoid-induced osteoporosis
689866|NCT00004993|Postmenopausal women
689867|NCT00004993|osteoporotic fractures
689868|NCT00004992|clinical trial
689869|NCT00004992|multi-center
689870|NCT00004992|NIDDM
689871|NCT00004992|NIDDK
689872|NCT00004992|DPP
689873|NCT00004992|diabetes risk factors
689874|NCT00004992|diabetes
689875|NCT00004992|glycemia
689876|NCT00004992|cardiovascular risk factors
689877|NCT00004992|quality of life
689878|NCT00004992|physical activity and nutrition
689879|NCT00004992|occurrence of adverse events
689880|NCT00004992|insulin secretion and sensitivity
689881|NCT00004992|prevention
689882|NCT00004992|abnormal glucose metabolism
689883|NCT00004992|lifestyle intervention
689884|NCT00004992|drug intervention
689885|NCT00004991|Functional Magnetic Resonance Imaging
689886|NCT00004991|Stuttering
689887|NCT00004991|Speech Perception
689888|NCT00004991|Speech Production
689889|NCT00004991|Phonology
689890|NCT00004991|Development
689891|NCT00004991|Motor Control
689892|NCT00004991|Neural Networks
689893|NCT00004991|Phonological Disorders
689894|NCT00004990|Nephrotic Syndrome
689895|NCT00004990|Steroids
689896|NCT00004990|Osteoporosis
689897|NCT00004990|Adrenal Suppression
689898|NCT00004990|Proteinuria
689899|NCT00004990|Focal Segmental Glomerulosclerosis
689900|NCT00004988|Anti-Tumor Effects
689901|NCT00004988|Maximum Tolerated Dose (MTD)
689902|NCT00004988|Metastatic Cancer
689903|NCT00004988|Pharmacokinetics
689904|NCT00004988|Solid Tumors
689905|NCT00004988|Tumor
689906|NCT00004987|Anti-HIV Agents
689907|NCT00004987|Viral Load
689908|NCT00004987|dextrin 2-sulfate
689909|NCT00004987|Infusions, Parenteral
689910|NCT00004986|AIDS-Related Opportunistic Infections
689911|NCT00004986|Cryptosporidiosis
689912|NCT00004986|Drug Evaluation
689913|NCT00004986|Antiprotozoal Agents
689914|NCT00004986|Treatment Failure
689915|NCT00004986|nitazoxanide
689916|NCT00004985|HIV-1
689917|NCT00004985|Drug Therapy, Combination
689918|NCT00004985|HIV Protease Inhibitors
689919|NCT00004985|RNA, Viral
689920|NCT00004985|Reverse Transcriptase Inhibitors
689921|NCT00004985|Anti-HIV Agents
689922|NCT00004985|Viral Load
689923|NCT00004985|Nelfinavir
689924|NCT00004984|diabetes
689925|NCT00004984|insulin
689926|NCT00004984|prediction
689927|NCT00004984|prevention
689928|NCT00004984|C-peptide levels
689929|NCT00004984|insulin autoantibodies
689930|NCT00004984|pancreatic beta cell autoantibodies
689931|NCT00004984|cellular immune responses
689932|NCT00004984|prediction of type 1 diabetes
689933|NCT00004983|diabetes mellitus, type 2
689934|NCT00004983|diabetes self-management education
689935|NCT00004983|diabetes self-care
689936|NCT00004983|blood glucose self-monitoring
689937|NCT00004983|health education
689938|NCT00004983|patient education
689939|NCT00004982|chelation therapy
689940|NCT00004982|combination chemotherapy
689941|NCT00004982|iron poisoning
689942|NCT00004982|thalassemia
689943|NCT00004982|chelating agent
689944|NCT00004982|deferoxamine
689945|NCT00004982|drug screening /evaluation
689946|NCT00004982|therapy evaluation
689947|NCT00004981|Drug Therapy, Combination
689948|NCT00004981|Zidovudine
689949|NCT00004981|Drug Administration Schedule
689950|NCT00004981|Lamivudine
689951|NCT00004981|RNA, Viral
689952|NCT00004981|Reverse Transcriptase Inhibitors
689953|NCT00004981|Anti-HIV Agents
689954|NCT00004981|Viral Load
689955|NCT00004981|Combivir
689956|NCT00004981|abacavir
689957|NCT00004980|neurologic and psychiatric disorders
689958|NCT00004980|rare disease
689959|NCT00004980|schizophrenia
689960|NCT00004979|unspecified adult solid tumor, protocol specific
689961|NCT00004978|Recombinant Proteins
689962|NCT00004978|Injections, Subcutaneous
689963|NCT00004978|HIV-1
689964|NCT00004978|Interleukin-2
689965|NCT00004978|Drug Therapy, Combination
689966|NCT00004978|CD4 Lymphocyte Count
689967|NCT00004978|Disease Progression
689968|NCT00004978|Follow-Up Studies
689969|NCT00004978|Anti-HIV Agents
689970|NCT00004941|Crohn's disease
689971|NCT00004941|gastrointestinal disorders
689972|NCT00004941|rare disease
689973|NCT00004940|erythropoietic protoporphyria
689974|NCT00004940|inborn errors of metabolism
689975|NCT00004940|porphyria
689976|NCT00004940|rare disease
689977|NCT00004939|demyelinating neuropathy
689978|NCT00004939|neurologic and psychiatric disorders
689979|NCT00004939|rare disease
689980|NCT00004938|fungal infection
689981|NCT00004938|rare disease
689982|NCT00004938|sporotrichosis
689983|NCT00004937|recurrent adult brain tumor
689984|NCT00004937|adult glioblastoma
689985|NCT00004937|adult giant cell glioblastoma
689986|NCT00004937|adult gliosarcoma
689987|NCT00004936|stage III cervical cancer
689988|NCT00004936|stage IB cervical cancer
689989|NCT00004936|stage IIB cervical cancer
689990|NCT00004936|stage IVB cervical cancer
689991|NCT00004936|stage IIA cervical cancer
689992|NCT00004936|stage IVA cervical cancer
689993|NCT00004936|cervical squamous cell carcinoma
689994|NCT00004936|cervical adenocarcinoma
689995|NCT00004936|cervical adenosquamous cell carcinoma
689996|NCT00004935|stage IV breast cancer
689997|NCT00004935|recurrent breast cancer
689998|NCT00004934|stage II ovarian epithelial cancer
689999|NCT00004934|stage III ovarian epithelial cancer
690000|NCT00004934|stage IV ovarian epithelial cancer
690001|NCT00004934|fallopian tube cancer
690002|NCT00004934|primary peritoneal cavity cancer
690003|NCT00004933|relapsing chronic myelogenous leukemia
690004|NCT00004933|chronic phase chronic myelogenous leukemia
690005|NCT00004933|Philadelphia chromosome positive chronic myelogenous leukemia
690006|NCT00004932|recurrent childhood acute lymphoblastic leukemia
690007|NCT00004932|recurrent childhood acute myeloid leukemia
690008|NCT00004932|relapsing chronic myelogenous leukemia
690009|NCT00004932|chronic myelogenous leukemia, BCR-ABL1 positive
690010|NCT00004932|childhood chronic myelogenous leukemia
690011|NCT00004930|recurrent non-small cell lung cancer
690012|NCT00004930|extensive stage small cell lung cancer
690013|NCT00004930|recurrent small cell lung cancer
690014|NCT00004930|stage IIIB non-small cell lung cancer
690015|NCT00004930|stage IV non-small cell lung cancer
690016|NCT00004930|lung metastases
690017|NCT00004930|bronchoalveolar cell lung cancer
690018|NCT00004929|recurrent prostate cancer
690019|NCT00004928|adenocarcinoma of the prostate
690020|NCT00004928|stage I prostate cancer
690021|NCT00004928|stage IIB prostate cancer
690022|NCT00004928|stage IIA prostate cancer
690023|NCT00004928|stage III prostate cancer
690024|NCT00004928|stage IV prostate cancer
690025|NCT00004928|recurrent prostate cancer
690026|NCT00004927|unspecified adult solid tumor, protocol specific
690027|NCT00004926|unspecified adult solid tumor, protocol specific
690028|NCT00004925|stage IV breast cancer
690029|NCT00004925|recurrent breast cancer
690030|NCT00004925|stage IIIB breast cancer
690031|NCT00004925|inflammatory breast cancer
690032|NCT00004924|stage IIIB non-small cell lung cancer
690033|NCT00004924|stage IV non-small cell lung cancer
690034|NCT00004923|unspecified adult solid tumor, protocol specific
690035|NCT00004922|newly diagnosed carcinoma of unknown primary
690036|NCT00004922|recurrent carcinoma of unknown primary
690037|NCT00004922|stage III neuroendocrine carcinoma of the skin
690038|NCT00004922|recurrent neuroendocrine carcinoma of the skin
690039|NCT00004922|neuroendocrine carcinoma
690040|NCT00004921|stage III ovarian epithelial cancer
690041|NCT00004921|stage IV ovarian epithelial cancer
690042|NCT00004920|localized malignant mesothelioma
690043|NCT00004920|advanced malignant mesothelioma
690044|NCT00004920|recurrent malignant mesothelioma
690045|NCT00004917|stage I squamous cell carcinoma of the lip and oral cavity
690046|NCT00004917|stage II squamous cell carcinoma of the lip and oral cavity
690047|NCT00004917|stage III squamous cell carcinoma of the lip and oral cavity
690048|NCT00004917|stage IV squamous cell carcinoma of the lip and oral cavity
690049|NCT00004917|stage I squamous cell carcinoma of the oropharynx
690050|NCT00004917|stage II squamous cell carcinoma of the oropharynx
690051|NCT00004917|stage III squamous cell carcinoma of the oropharynx
690052|NCT00004917|stage IV squamous cell carcinoma of the oropharynx
690053|NCT00004917|stage I squamous cell carcinoma of the hypopharynx
690054|NCT00004917|stage II squamous cell carcinoma of the hypopharynx
690055|NCT00004917|stage III squamous cell carcinoma of the hypopharynx
690056|NCT00004917|stage IV squamous cell carcinoma of the hypopharynx
690057|NCT00004917|stage I squamous cell carcinoma of the larynx
690058|NCT00004917|stage II squamous cell carcinoma of the larynx
690059|NCT00004917|stage III squamous cell carcinoma of the larynx
690060|NCT00004917|stage IV squamous cell carcinoma of the larynx
690061|NCT00004917|anemia
690062|NCT00004916|recurrent grade 3 follicular lymphoma
690063|NCT00004916|recurrent adult diffuse mixed cell lymphoma
690064|NCT00004916|recurrent adult diffuse large cell lymphoma
690065|NCT00004916|recurrent adult immunoblastic large cell lymphoma
690066|NCT00004916|recurrent adult Burkitt lymphoma
690067|NCT00004915|recurrent endometrial carcinoma
690068|NCT00004914|unspecified adult solid tumor, protocol specific
690069|NCT00004914|anemia
690070|NCT00004914|fatigue
690071|NCT00004913|unspecified adult solid tumor, protocol specific
690072|NCT00004912|unspecified adult solid tumor, protocol specific
690073|NCT00004912|fatigue
690074|NCT00004912|cachexia
690075|NCT00004911|stage I colon cancer
690076|NCT00004911|stage II colon cancer
690077|NCT00004911|stage III colon cancer
690078|NCT00004911|stage IV colon cancer
690079|NCT00004911|stage I gastric cancer
690080|NCT00004911|stage II gastric cancer
690081|NCT00004911|stage III gastric cancer
690082|NCT00004911|stage IV gastric cancer
690083|NCT00004911|recurrent gastric cancer
690084|NCT00004911|stage I rectal cancer
690085|NCT00004911|stage II rectal cancer
690086|NCT00004911|stage III rectal cancer
690087|NCT00004911|stage IV rectal cancer
690088|NCT00004911|recurrent colon cancer
690089|NCT00004911|recurrent rectal cancer
690090|NCT00004911|localized gastrointestinal carcinoid tumor
690091|NCT00004911|regional gastrointestinal carcinoid tumor
690092|NCT00004911|metastatic gastrointestinal carcinoid tumor
690093|NCT00004911|recurrent gastrointestinal carcinoid tumor
690094|NCT00004911|small intestine adenocarcinoma
690095|NCT00004911|small intestine lymphoma
690096|NCT00004911|small intestine leiomyosarcoma
690097|NCT00004911|recurrent small intestine cancer
690098|NCT00004911|constipation, impaction, and bowel obstruction
690099|NCT00004911|quality of life
690100|NCT00004911|gastrointestinal stromal tumor
690101|NCT00004910|stage I colon cancer
690102|NCT00004910|stage II colon cancer
690103|NCT00004910|stage III colon cancer
690104|NCT00004910|stage IV colon cancer
690105|NCT00004910|stage I gastric cancer
690106|NCT00004910|stage II gastric cancer
690107|NCT00004910|stage III gastric cancer
690108|NCT00004910|stage IV gastric cancer
690109|NCT00004910|recurrent gastric cancer
690110|NCT00004910|stage I pancreatic cancer
690111|NCT00004910|stage II pancreatic cancer
690112|NCT00004910|stage III pancreatic cancer
690113|NCT00004910|recurrent pancreatic cancer
690114|NCT00004910|recurrent colon cancer
690115|NCT00004910|localized gastrointestinal carcinoid tumor
690116|NCT00004910|regional gastrointestinal carcinoid tumor
690117|NCT00004910|metastatic gastrointestinal carcinoid tumor
690118|NCT00004910|recurrent gastrointestinal carcinoid tumor
690119|NCT00004910|small intestine adenocarcinoma
690120|NCT00004910|small intestine lymphoma
690121|NCT00004910|small intestine leiomyosarcoma
690122|NCT00004910|localized extrahepatic bile duct cancer
690123|NCT00004910|unresectable extrahepatic bile duct cancer
690124|NCT00004910|recurrent extrahepatic bile duct cancer
690125|NCT00004910|recurrent small intestine cancer
690126|NCT00004910|constipation, impaction, and bowel obstruction
690127|NCT00004910|quality of life
690128|NCT00004910|gastrointestinal stromal tumor
690129|NCT00004910|stage IV pancreatic cancer
690130|NCT00004909|recurrent ovarian epithelial cancer
690131|NCT00004909|peritoneal cavity cancer
690132|NCT00004909|quality of life
690133|NCT00004908|recurrent adult Hodgkin lymphoma
690134|NCT00004908|recurrent/refractory childhood Hodgkin lymphoma
690135|NCT00004908|recurrent grade 1 follicular lymphoma
690136|NCT00004908|recurrent grade 2 follicular lymphoma
690137|NCT00004908|recurrent grade 3 follicular lymphoma
690138|NCT00004908|recurrent adult diffuse small cleaved cell lymphoma
690139|NCT00004908|recurrent adult diffuse mixed cell lymphoma
690140|NCT00004908|recurrent adult diffuse large cell lymphoma
690141|NCT00004908|recurrent adult immunoblastic large cell lymphoma
690142|NCT00004908|recurrent childhood large cell lymphoma
690143|NCT00004908|recurrent marginal zone lymphoma
690144|NCT00004908|recurrent small lymphocytic lymphoma
690145|NCT00004908|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
690146|NCT00004908|nodal marginal zone B-cell lymphoma
690147|NCT00004908|splenic marginal zone lymphoma
690148|NCT00004907|recurrent adult Hodgkin lymphoma
690149|NCT00004907|recurrent cutaneous T-cell non-Hodgkin lymphoma
690150|NCT00004907|recurrent grade 1 follicular lymphoma
690151|NCT00004907|recurrent grade 2 follicular lymphoma
690152|NCT00004907|recurrent grade 3 follicular lymphoma
690153|NCT00004907|recurrent adult diffuse small cleaved cell lymphoma
690154|NCT00004907|recurrent adult diffuse mixed cell lymphoma
690155|NCT00004907|recurrent adult diffuse large cell lymphoma
690156|NCT00004907|recurrent adult immunoblastic large cell lymphoma
690157|NCT00004907|recurrent mycosis fungoides/Sezary syndrome
690158|NCT00004907|recurrent marginal zone lymphoma
690159|NCT00004907|recurrent small lymphocytic lymphoma
690160|NCT00004907|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
690161|NCT00004907|nodal marginal zone B-cell lymphoma
690162|NCT00004907|splenic marginal zone lymphoma
690163|NCT00004906|stage IV breast cancer
690164|NCT00004906|recurrent breast cancer
690165|NCT00004905|recurrent adult acute myeloid leukemia
690166|NCT00004905|recurrent adult acute lymphoblastic leukemia
690167|NCT00004905|relapsing chronic myelogenous leukemia
690168|NCT00004905|chronic phase chronic myelogenous leukemia
690169|NCT00004905|adult acute myeloid leukemia in remission
690170|NCT00004905|adult acute lymphoblastic leukemia in remission
690171|NCT00004904|monoclonal gammopathy of undetermined significance
690172|NCT00004904|stage III cutaneous T-cell non-Hodgkin lymphoma
690173|NCT00004904|stage IV cutaneous T-cell non-Hodgkin lymphoma
690174|NCT00004904|recurrent cutaneous T-cell non-Hodgkin lymphoma
690175|NCT00004904|isolated plasmacytoma of bone
690176|NCT00004904|extramedullary plasmacytoma
690177|NCT00004904|refractory multiple myeloma
690178|NCT00004904|Waldenstrom macroglobulinemia
690179|NCT00004904|stage III multiple myeloma
690180|NCT00004904|recurrent childhood lymphoblastic lymphoma
690181|NCT00004904|recurrent childhood acute myeloid leukemia
690182|NCT00004904|recurrent adult acute myeloid leukemia
690183|NCT00004904|recurrent adult acute lymphoblastic leukemia
690184|NCT00004904|small intestine lymphoma
690185|NCT00004904|chronic phase chronic myelogenous leukemia
690186|NCT00004904|accelerated phase chronic myelogenous leukemia
690187|NCT00004904|blastic phase chronic myelogenous leukemia
690188|NCT00004904|adult acute myeloid leukemia in remission
690189|NCT00004904|adult acute lymphoblastic leukemia in remission
690190|NCT00004904|childhood acute myeloid leukemia in remission
690191|NCT00004904|polycythemia vera
690192|NCT00004904|chronic idiopathic myelofibrosis
690193|NCT00004904|essential thrombocythemia
690194|NCT00004904|refractory hairy cell leukemia
690195|NCT00004904|T-cell large granular lymphocyte leukemia
690196|NCT00004904|acute undifferentiated leukemia
690197|NCT00004904|stage III grade 1 follicular lymphoma
690198|NCT00004904|stage III grade 2 follicular lymphoma
690199|NCT00004904|stage III grade 3 follicular lymphoma
690200|NCT00004904|stage III adult diffuse small cleaved cell lymphoma
690201|NCT00004904|stage III adult diffuse mixed cell lymphoma
690202|NCT00004904|stage III adult diffuse large cell lymphoma
690203|NCT00004904|stage III adult immunoblastic large cell lymphoma
690204|NCT00004904|stage III adult lymphoblastic lymphoma
690205|NCT00004904|stage III adult Burkitt lymphoma
690206|NCT00004904|stage IV grade 1 follicular lymphoma
690207|NCT00004904|stage IV grade 2 follicular lymphoma
690208|NCT00004904|stage IV grade 3 follicular lymphoma
690209|NCT00004904|stage IV adult diffuse small cleaved cell lymphoma
690210|NCT00004904|stage IV adult diffuse mixed cell lymphoma
690211|NCT00004904|stage IV adult diffuse large cell lymphoma
690212|NCT00004904|stage IV adult immunoblastic large cell lymphoma
690213|NCT00004904|stage IV adult lymphoblastic lymphoma
690214|NCT00004904|stage IV adult Burkitt lymphoma
690215|NCT00004904|recurrent grade 1 follicular lymphoma
690216|NCT00004904|recurrent grade 2 follicular lymphoma
690217|NCT00004904|recurrent grade 3 follicular lymphoma
690218|NCT00004904|recurrent adult diffuse small cleaved cell lymphoma
690219|NCT00004904|recurrent adult diffuse mixed cell lymphoma
690220|NCT00004904|recurrent adult diffuse large cell lymphoma
690221|NCT00004904|recurrent adult immunoblastic large cell lymphoma
690222|NCT00004904|recurrent adult lymphoblastic lymphoma
690223|NCT00004904|recurrent adult Burkitt lymphoma
690224|NCT00004904|stage III adult T-cell leukemia/lymphoma
690225|NCT00004904|stage IV adult T-cell leukemia/lymphoma
690226|NCT00004904|recurrent adult T-cell leukemia/lymphoma
690227|NCT00004904|secondary acute myeloid leukemia
690228|NCT00004904|de novo myelodysplastic syndromes
690229|NCT00004904|previously treated myelodysplastic syndromes
690230|NCT00004904|secondary myelodysplastic syndromes
690231|NCT00004904|graft versus host disease
690232|NCT00004904|primary systemic amyloidosis
690233|NCT00004904|intraocular lymphoma
690234|NCT00004904|recurrent childhood small noncleaved cell lymphoma
690235|NCT00004904|recurrent childhood large cell lymphoma
690236|NCT00004904|stage III mantle cell lymphoma
690237|NCT00004904|stage IV mantle cell lymphoma
690238|NCT00004904|recurrent mantle cell lymphoma
690239|NCT00004904|stage III mycosis fungoides/Sezary syndrome
690240|NCT00004904|stage IV mycosis fungoides/Sezary syndrome
690241|NCT00004904|recurrent mycosis fungoides/Sezary syndrome
690242|NCT00004904|recurrent marginal zone lymphoma
690243|NCT00004904|recurrent small lymphocytic lymphoma
690244|NCT00004904|stage III small lymphocytic lymphoma
690245|NCT00004904|stage III marginal zone lymphoma
690246|NCT00004904|stage IV small lymphocytic lymphoma
690247|NCT00004904|stage IV marginal zone lymphoma
690248|NCT00004904|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
690249|NCT00004904|nodal marginal zone B-cell lymphoma
690250|NCT00004904|splenic marginal zone lymphoma
690251|NCT00004904|childhood myelodysplastic syndromes
690252|NCT00004903|refractory multiple myeloma
690253|NCT00004903|stage I multiple myeloma
690254|NCT00004903|stage II multiple myeloma
690255|NCT00004903|stage III multiple myeloma
690256|NCT00004902|refractory multiple myeloma
690257|NCT00004902|stage I multiple myeloma
690258|NCT00004902|stage II multiple myeloma
690259|NCT00004902|stage III multiple myeloma
690260|NCT00004901|stage IV hypopharyngeal cancer
690261|NCT00004901|recurrent hypopharyngeal cancer
690262|NCT00004901|stage IV squamous cell carcinoma of the lip and oral cavity
690263|NCT00004901|stage IV verrucous carcinoma of the oral cavity
690264|NCT00004901|stage IV mucoepidermoid carcinoma of the oral cavity
690265|NCT00004901|stage IV adenoid cystic carcinoma of the oral cavity
690266|NCT00004901|recurrent squamous cell carcinoma of the lip and oral cavity
690267|NCT00004901|recurrent verrucous carcinoma of the oral cavity
690268|NCT00004901|recurrent mucoepidermoid carcinoma of the oral cavity
690269|NCT00004901|recurrent adenoid cystic carcinoma of the oral cavity
690270|NCT00004901|stage IV squamous cell carcinoma of the oropharynx
690271|NCT00004901|stage IV lymphoepithelioma of the oropharynx
690272|NCT00004901|recurrent squamous cell carcinoma of the oropharynx
690273|NCT00004901|recurrent lymphoepithelioma of the oropharynx
690274|NCT00004901|stage IV squamous cell carcinoma of the nasopharynx
690275|NCT00004901|stage IV lymphoepithelioma of the nasopharynx
690276|NCT00004901|recurrent squamous cell carcinoma of the nasopharynx
690277|NCT00004901|recurrent lymphoepithelioma of the nasopharynx
690278|NCT00004901|stage IV squamous cell carcinoma of the hypopharynx
690279|NCT00004901|recurrent squamous cell carcinoma of the hypopharynx
690280|NCT00004901|stage IV squamous cell carcinoma of the larynx
690281|NCT00004901|stage IV verrucous carcinoma of the larynx
690282|NCT00004901|recurrent squamous cell carcinoma of the larynx
690283|NCT00004901|recurrent verrucous carcinoma of the larynx
690284|NCT00004900|stage IV breast cancer
690285|NCT00004900|recurrent breast cancer
690286|NCT00004900|stage IIIB breast cancer
690287|NCT00004899|recurrent childhood acute myeloid leukemia
690288|NCT00004899|recurrent adult acute myeloid leukemia
690289|NCT00004899|adult acute myeloid leukemia in remission
690290|NCT00004899|childhood acute myeloid leukemia in remission
690291|NCT00004899|adult acute erythroid leukemia (M6)
690292|NCT00004899|adult acute myeloblastic leukemia without maturation (M1)
690293|NCT00004899|adult acute myeloblastic leukemia with maturation (M2)
690294|NCT00004899|adult acute promyelocytic leukemia (M3)
690295|NCT00004899|adult acute myelomonocytic leukemia (M4)
690296|NCT00004899|adult acute monoblastic leukemia (M5a)
690297|NCT00004899|childhood acute myeloblastic leukemia without maturation (M1)
690298|NCT00004899|childhood acute myeloblastic leukemia with maturation (M2)
690299|NCT00004899|childhood acute promyelocytic leukemia (M3)
690300|NCT00004899|childhood acute myelomonocytic leukemia (M4)
690301|NCT00004899|childhood acute monoblastic leukemia (M5a)
690302|NCT00004899|childhood acute monocytic leukemia (M5b)
690303|NCT00004899|childhood acute erythroleukemia (M6)
690304|NCT00004899|secondary acute myeloid leukemia
690305|NCT00004899|adult acute monocytic leukemia (M5b)
690306|NCT00004899|previously treated myelodysplastic syndromes
690307|NCT00004899|myelodysplastic/myeloproliferative disease, unclassifiable
690308|NCT00004899|atypical chronic myeloid leukemia
690309|NCT00004899|adult acute myeloid leukemia with t(8;21)(q22;q22)
690310|NCT00004899|adult acute myeloid leukemia with t(16;16)(p13;q22)
690311|NCT00004899|adult acute myeloid leukemia with inv(16)(p13;q22)
690312|NCT00004899|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
690313|NCT00004899|adult acute myeloid leukemia with t(15;17)(q22;q12)
690314|NCT00004899|childhood myelodysplastic syndromes
690315|NCT00004898|recurrent childhood acute lymphoblastic leukemia
690316|NCT00004898|stage I childhood lymphoblastic lymphoma
690317|NCT00004898|stage II childhood lymphoblastic lymphoma
690318|NCT00004898|stage III childhood lymphoblastic lymphoma
690319|NCT00004898|stage IV childhood lymphoblastic lymphoma
690320|NCT00004898|recurrent childhood lymphoblastic lymphoma
690321|NCT00004898|recurrent adult acute lymphoblastic leukemia
690322|NCT00004898|adult acute lymphoblastic leukemia in remission
690323|NCT00004898|childhood acute lymphoblastic leukemia in remission
690324|NCT00004898|stage I adult immunoblastic large cell lymphoma
690325|NCT00004898|stage I adult lymphoblastic lymphoma
690326|NCT00004898|stage I adult Burkitt lymphoma
690327|NCT00004898|stage II adult immunoblastic large cell lymphoma
690328|NCT00004898|stage II adult lymphoblastic lymphoma
690329|NCT00004898|stage II adult Burkitt lymphoma
690330|NCT00004898|stage III adult immunoblastic large cell lymphoma
690331|NCT00004898|stage III adult lymphoblastic lymphoma
690332|NCT00004898|stage III adult Burkitt lymphoma
690333|NCT00004898|stage IV adult immunoblastic large cell lymphoma
690334|NCT00004898|stage IV adult lymphoblastic lymphoma
690335|NCT00004898|stage IV adult Burkitt lymphoma
690336|NCT00004898|recurrent adult immunoblastic large cell lymphoma
690337|NCT00004898|recurrent adult lymphoblastic lymphoma
690338|NCT00004898|recurrent adult Burkitt lymphoma
690339|NCT00004898|stage I childhood small noncleaved cell lymphoma
690340|NCT00004898|stage I childhood large cell lymphoma
690341|NCT00004898|stage II childhood small noncleaved cell lymphoma
690342|NCT00004898|stage II childhood large cell lymphoma
690343|NCT00004898|stage III childhood small noncleaved cell lymphoma
690344|NCT00004898|stage III childhood large cell lymphoma
690345|NCT00004898|stage IV childhood small noncleaved cell lymphoma
690346|NCT00004898|stage IV childhood large cell lymphoma
690347|NCT00004898|recurrent childhood small noncleaved cell lymphoma
690348|NCT00004898|recurrent childhood large cell lymphoma
690349|NCT00004897|stage I esophageal cancer
690350|NCT00004897|stage II esophageal cancer
690351|NCT00004897|stage III esophageal cancer
690352|NCT00004897|squamous cell carcinoma of the esophagus
690353|NCT00004897|adenocarcinoma of the esophagus
690354|NCT00004896|recurrent adult acute myeloid leukemia
690355|NCT00004896|adult acute myeloid leukemia in remission
690356|NCT00004896|adult acute erythroid leukemia (M6)
690357|NCT00004896|adult acute myeloblastic leukemia without maturation (M1)
690358|NCT00004896|adult acute myeloblastic leukemia with maturation (M2)
690359|NCT00004896|adult acute promyelocytic leukemia (M3)
690360|NCT00004896|adult acute myelomonocytic leukemia (M4)
690361|NCT00004896|adult acute monoblastic leukemia (M5a)
690362|NCT00004896|adult acute megakaryoblastic leukemia (M7)
690363|NCT00004896|refractory anemia
690364|NCT00004896|refractory anemia with ringed sideroblasts
690365|NCT00004896|refractory anemia with excess blasts
690366|NCT00004896|refractory anemia with excess blasts in transformation
690367|NCT00004896|chronic myelomonocytic leukemia
690368|NCT00004896|adult acute monocytic leukemia (M5b)
690369|NCT00004896|previously treated myelodysplastic syndromes
690370|NCT00004896|myelodysplastic/myeloproliferative disease, unclassifiable
690371|NCT00004896|atypical chronic myeloid leukemia
690372|NCT00004896|adult acute myeloid leukemia with t(8;21)(q22;q22)
690373|NCT00004896|adult acute myeloid leukemia with t(16;16)(p13;q22)
690374|NCT00004896|adult acute myeloid leukemia with inv(16)(p13;q22)
690375|NCT00004896|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
690376|NCT00004896|adult acute myeloid leukemia with t(15;17)(q22;q12)
690377|NCT00004896|childhood myelodysplastic syndromes
690378|NCT00004895|stage I colon cancer
690379|NCT00004895|stage II colon cancer
690380|NCT00004895|stage III colon cancer
690381|NCT00004895|stage IV colon cancer
690382|NCT00004895|stage I gastric cancer
690383|NCT00004895|stage II gastric cancer
690384|NCT00004895|stage III gastric cancer
690385|NCT00004895|stage IV gastric cancer
690386|NCT00004895|recurrent gastric cancer
690387|NCT00004895|stage I pancreatic cancer
690388|NCT00004895|stage II pancreatic cancer
690389|NCT00004895|stage III pancreatic cancer
690390|NCT00004895|stage IV pancreatic cancer
690391|NCT00004895|recurrent pancreatic cancer
690392|NCT00004895|stage I rectal cancer
690393|NCT00004895|stage II rectal cancer
690394|NCT00004895|stage III rectal cancer
690395|NCT00004895|stage IV rectal cancer
690396|NCT00004895|recurrent colon cancer
690397|NCT00004895|recurrent rectal cancer
690398|NCT00004895|stage I ovarian epithelial cancer
690399|NCT00004895|stage II ovarian epithelial cancer
690400|NCT00004895|stage III ovarian epithelial cancer
690401|NCT00004895|stage IV ovarian epithelial cancer
690402|NCT00004895|recurrent ovarian epithelial cancer
690403|NCT00004895|small intestine adenocarcinoma
690404|NCT00004895|small intestine lymphoma
690405|NCT00004895|small intestine leiomyosarcoma
690406|NCT00004895|localized extrahepatic bile duct cancer
690407|NCT00004895|unresectable extrahepatic bile duct cancer
690408|NCT00004895|recurrent extrahepatic bile duct cancer
690409|NCT00004895|recurrent small intestine cancer
690410|NCT00004895|constipation, impaction, and bowel obstruction
690411|NCT00004895|peritoneal cavity cancer
690412|NCT00004895|nausea and vomiting
690413|NCT00004895|gastrointestinal stromal tumor
690414|NCT00004893|stage IV breast cancer
690415|NCT00004893|recurrent breast cancer
690416|NCT00004892|recurrent adult brain tumor
690417|NCT00004892|adult brain stem glioma
690418|NCT00004892|adult ependymoma
690419|NCT00004892|adult glioblastoma
690420|NCT00004892|adult oligodendroglioma
690421|NCT00004892|adult anaplastic astrocytoma
690422|NCT00004892|adult mixed glioma
690423|NCT00004892|adult giant cell glioblastoma
690424|NCT00004892|adult gliosarcoma
690425|NCT00004891|stage II rectal cancer
690426|NCT00004891|stage III rectal cancer
690427|NCT00004891|stage IV rectal cancer
690428|NCT00004890|stage I renal cell cancer
690429|NCT00004890|stage II renal cell cancer
690430|NCT00004890|stage III renal cell cancer
690431|NCT00004890|stage IV renal cell cancer
690432|NCT00004890|recurrent renal cell cancer
690433|NCT00004890|drug extravasation
690434|NCT00004889|Waldenstrom macroglobulinemia
690435|NCT00004887|stage IIIA non-small cell lung cancer
690436|NCT00004887|stage IIIB non-small cell lung cancer
690437|NCT00004887|stage IV non-small cell lung cancer
690438|NCT00004886|unspecified adult solid tumor, protocol specific
690439|NCT00004885|stage IV colon cancer
690440|NCT00004885|stage IV rectal cancer
690441|NCT00004885|recurrent colon cancer
690442|NCT00004885|recurrent rectal cancer
690443|NCT00004885|adenocarcinoma of the colon
690444|NCT00004885|adenocarcinoma of the rectum
690445|NCT00004884|stage III pancreatic cancer
690446|NCT00004884|recurrent pancreatic cancer
690447|NCT00004884|adenocarcinoma of the pancreas
690448|NCT00004884|stage IV pancreatic cancer
690449|NCT00004881|unspecified adult solid tumor, protocol specific
690450|NCT00004880|stage IV renal cell cancer
690451|NCT00004880|recurrent renal cell cancer
690452|NCT00004879|recurrent renal cell cancer
690453|NCT00004879|recurrent prostate cancer
690454|NCT00004879|recurrent colon cancer
690455|NCT00004879|recurrent rectal cancer
690456|NCT00004879|recurrent non-small cell lung cancer
690457|NCT00004879|recurrent pancreatic cancer
690458|NCT00004879|recurrent esophageal cancer
690459|NCT00004878|chronic phase chronic myelogenous leukemia
690460|NCT00004878|accelerated phase chronic myelogenous leukemia
690461|NCT00004878|Philadelphia chromosome positive chronic myelogenous leukemia
690462|NCT00004878|graft versus host disease
690463|NCT00004877|unspecified adult solid tumor, protocol specific
690464|NCT00004876|stage IV ovarian epithelial cancer
690465|NCT00004876|stage IC ovarian epithelial cancer
690466|NCT00004876|stage IIA ovarian epithelial cancer
690467|NCT00004876|stage IIB ovarian epithelial cancer
690468|NCT00004876|stage IIC ovarian epithelial cancer
690469|NCT00004876|stage IIIA ovarian epithelial cancer
690470|NCT00004876|stage IIIB ovarian epithelial cancer
690471|NCT00004876|stage IIIC ovarian epithelial cancer
690472|NCT00004875|stage I adult Hodgkin lymphoma
690473|NCT00004875|stage II adult Hodgkin lymphoma
690474|NCT00004875|stage III adult Hodgkin lymphoma
690475|NCT00004875|stage IV adult Hodgkin lymphoma
690476|NCT00004875|recurrent adult Hodgkin lymphoma
690477|NCT00004875|unspecified adult solid tumor, protocol specific
690478|NCT00004875|stage I grade 1 follicular lymphoma
690479|NCT00004875|stage I grade 2 follicular lymphoma
690480|NCT00004875|stage I grade 3 follicular lymphoma
690481|NCT00004875|stage I adult diffuse small cleaved cell lymphoma
690482|NCT00004875|stage I adult diffuse mixed cell lymphoma
690483|NCT00004875|stage I adult diffuse large cell lymphoma
690484|NCT00004875|stage I adult immunoblastic large cell lymphoma
690485|NCT00004875|stage I adult Burkitt lymphoma
690486|NCT00004875|stage III grade 1 follicular lymphoma
690487|NCT00004875|stage III grade 2 follicular lymphoma
690488|NCT00004875|stage III grade 3 follicular lymphoma
690489|NCT00004875|stage III adult diffuse small cleaved cell lymphoma
690490|NCT00004875|stage III adult diffuse mixed cell lymphoma
690491|NCT00004875|stage III adult diffuse large cell lymphoma
690492|NCT00004875|stage III adult immunoblastic large cell lymphoma
690493|NCT00004875|stage III adult Burkitt lymphoma
690494|NCT00004875|stage IV grade 1 follicular lymphoma
690495|NCT00004875|stage IV grade 2 follicular lymphoma
690496|NCT00004875|stage IV grade 3 follicular lymphoma
690497|NCT00004875|stage IV adult diffuse small cleaved cell lymphoma
690498|NCT00004875|stage IV adult diffuse mixed cell lymphoma
690499|NCT00004875|stage IV adult diffuse large cell lymphoma
690500|NCT00004875|stage IV adult immunoblastic large cell lymphoma
690501|NCT00004875|stage IV adult Burkitt lymphoma
690502|NCT00004875|recurrent grade 1 follicular lymphoma
690503|NCT00004875|recurrent grade 2 follicular lymphoma
690504|NCT00004875|recurrent grade 3 follicular lymphoma
690505|NCT00004875|recurrent adult diffuse small cleaved cell lymphoma
690506|NCT00004875|recurrent adult diffuse mixed cell lymphoma
690507|NCT00004875|recurrent adult diffuse large cell lymphoma
690508|NCT00004875|recurrent adult immunoblastic large cell lymphoma
690509|NCT00004875|recurrent adult Burkitt lymphoma
690510|NCT00004875|AIDS-related peripheral/systemic lymphoma
690511|NCT00004875|AIDS-related primary CNS lymphoma
690512|NCT00004875|stage I mantle cell lymphoma
690513|NCT00004875|contiguous stage II grade 1 follicular lymphoma
690514|NCT00004875|contiguous stage II grade 2 follicular lymphoma
690515|NCT00004875|contiguous stage II grade 3 follicular lymphoma
690516|NCT00004875|contiguous stage II adult diffuse small cleaved cell lymphoma
690517|NCT00004875|contiguous stage II mantle cell lymphoma
690518|NCT00004875|contiguous stage II adult diffuse mixed cell lymphoma
690519|NCT00004875|contiguous stage II adult immunoblastic large cell lymphoma
690520|NCT00004875|contiguous stage II adult diffuse large cell lymphoma
690521|NCT00004875|contiguous stage II adult Burkitt lymphoma
690522|NCT00004875|noncontiguous stage II grade 1 follicular lymphoma
690523|NCT00004875|noncontiguous stage II grade 2 follicular lymphoma
690524|NCT00004875|noncontiguous stage II grade 3 follicular lymphoma
690525|NCT00004875|noncontiguous stage II adult diffuse small cleaved cell lymphoma
690526|NCT00004875|noncontiguous stage II mantle cell lymphoma
690527|NCT00004875|noncontiguous stage II adult diffuse mixed cell lymphoma
690528|NCT00004875|noncontiguous stage II adult immunoblastic large cell lymphoma
690529|NCT00004875|noncontiguous stage II adult diffuse large cell lymphoma
690530|NCT00004875|noncontiguous stage II adult Burkitt lymphoma
690531|NCT00004875|stage III mantle cell lymphoma
690532|NCT00004875|stage IV mantle cell lymphoma
690533|NCT00004875|recurrent mantle cell lymphoma
690534|NCT00004875|angioimmunoblastic T-cell lymphoma
690535|NCT00004875|anaplastic large cell lymphoma
690536|NCT00004875|thromboembolism
690537|NCT00004875|noncontiguous stage II small lymphocytic lymphoma
690538|NCT00004875|noncontiguous stage II marginal zone lymphoma
690539|NCT00004875|recurrent marginal zone lymphoma
690540|NCT00004875|recurrent small lymphocytic lymphoma
690541|NCT00004875|stage I marginal zone lymphoma
690542|NCT00004875|stage I small lymphocytic lymphoma
690543|NCT00004875|stage III small lymphocytic lymphoma
690544|NCT00004875|stage III marginal zone lymphoma
690545|NCT00004875|stage IV small lymphocytic lymphoma
690546|NCT00004875|stage IV marginal zone lymphoma
690547|NCT00004875|contiguous stage II marginal zone lymphoma
690548|NCT00004875|contiguous stage II small lymphocytic lymphoma
690549|NCT00004875|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
690550|NCT00004875|nodal marginal zone B-cell lymphoma
690551|NCT00004875|splenic marginal zone lymphoma
690552|NCT00004874|recurrent grade 1 follicular lymphoma
690553|NCT00004874|recurrent grade 2 follicular lymphoma
690554|NCT00004874|recurrent small lymphocytic lymphoma
690555|NCT00004873|stage III gastric cancer
690556|NCT00004873|stage IV gastric cancer
690557|NCT00004873|recurrent gastric cancer
690558|NCT00004872|unspecified adult solid tumor, protocol specific
690559|NCT00004871|recurrent adult acute myeloid leukemia
690560|NCT00004871|untreated adult acute myeloid leukemia
690561|NCT00004871|refractory anemia
690562|NCT00004871|refractory anemia with ringed sideroblasts
690563|NCT00004871|refractory anemia with excess blasts
690564|NCT00004871|refractory anemia with excess blasts in transformation
690565|NCT00004871|chronic myelomonocytic leukemia
690566|NCT00004871|de novo myelodysplastic syndromes
690567|NCT00004871|previously treated myelodysplastic syndromes
690568|NCT00004871|secondary myelodysplastic syndromes
690569|NCT00004871|atypical chronic myeloid leukemia
690570|NCT00004871|myelodysplastic/myeloproliferative disease, unclassifiable
690571|NCT00004870|stage IV colon cancer
690572|NCT00004870|stage IV rectal cancer
690573|NCT00004870|recurrent colon cancer
690574|NCT00004870|recurrent rectal cancer
690575|NCT00004870|adenocarcinoma of the colon
690576|NCT00004870|adenocarcinoma of the rectum
690577|NCT00004868|recurrent adult brain tumor
690578|NCT00004868|adult meningioma
690579|NCT00004868|adult glioblastoma
690580|NCT00004868|adult anaplastic astrocytoma
690581|NCT00004868|adult anaplastic oligodendroglioma
690582|NCT00004868|adult mixed glioma
690583|NCT00004868|adult grade III meningioma
690584|NCT00004868|adult giant cell glioblastoma
690585|NCT00004868|adult gliosarcoma
690586|NCT00004867|stage I esophageal cancer
690587|NCT00004867|stage II esophageal cancer
690588|NCT00004867|stage III esophageal cancer
690589|NCT00004867|stage IV esophageal cancer
690590|NCT00004867|squamous cell carcinoma of the esophagus
690591|NCT00004867|adenocarcinoma of the esophagus
690592|NCT00004866|stage III cervical cancer
690593|NCT00004866|stage IV cervical cancer
690594|NCT00004866|recurrent cervical cancer
690595|NCT00004866|cervical squamous cell carcinoma
690596|NCT00004865|recurrent metastatic squamous neck cancer with occult primary
690597|NCT00004865|metastatic squamous neck cancer with occult primary squamous cell carcinoma
690598|NCT00004865|stage IV squamous cell carcinoma of the lip and oral cavity
690599|NCT00004865|recurrent squamous cell carcinoma of the lip and oral cavity
690600|NCT00004865|stage IV squamous cell carcinoma of the oropharynx
690601|NCT00004865|recurrent squamous cell carcinoma of the oropharynx
690602|NCT00004865|stage IV squamous cell carcinoma of the nasopharynx
690603|NCT00004865|recurrent squamous cell carcinoma of the nasopharynx
690604|NCT00004865|stage IV squamous cell carcinoma of the hypopharynx
690605|NCT00004865|recurrent squamous cell carcinoma of the hypopharynx
690606|NCT00004865|stage IV squamous cell carcinoma of the larynx
690607|NCT00004865|recurrent squamous cell carcinoma of the larynx
690608|NCT00004865|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
690609|NCT00004865|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
690610|NCT00004864|unspecified adult solid tumor, protocol specific
690611|NCT00004863|unspecified adult solid tumor, protocol specific
690612|NCT00004862|recurrent adult acute myeloid leukemia
690613|NCT00004862|recurrent adult acute lymphoblastic leukemia
690614|NCT00004861|stage II pancreatic cancer
690615|NCT00004861|stage III pancreatic cancer
690616|NCT00004861|adenocarcinoma of the pancreas
690617|NCT00004861|stage IV pancreatic cancer
690618|NCT00004860|stage III colon cancer
690619|NCT00004860|stage IV colon cancer
690620|NCT00004860|stage III rectal cancer
690621|NCT00004860|stage IV rectal cancer
690622|NCT00004860|recurrent colon cancer
690623|NCT00004860|recurrent rectal cancer
690624|NCT00004860|adenocarcinoma of the colon
690625|NCT00004860|adenocarcinoma of the rectum
690626|NCT00004859|squamous cell lung cancer
690627|NCT00004859|large cell lung cancer
690628|NCT00004859|stage IIIA non-small cell lung cancer
690629|NCT00004859|stage IIIB non-small cell lung cancer
690630|NCT00004859|adenocarcinoma of the lung
690631|NCT00004859|adenosquamous cell lung cancer
690632|NCT00004859|bronchoalveolar cell lung cancer
690633|NCT00004858|recurrent childhood acute lymphoblastic leukemia
690634|NCT00004858|recurrent childhood lymphoblastic lymphoma
690635|NCT00004858|recurrent adult acute lymphoblastic leukemia
690636|NCT00004858|recurrent grade 1 follicular lymphoma
690637|NCT00004858|recurrent grade 2 follicular lymphoma
690638|NCT00004858|recurrent grade 3 follicular lymphoma
690639|NCT00004858|recurrent adult diffuse small cleaved cell lymphoma
690640|NCT00004858|recurrent adult diffuse mixed cell lymphoma
690641|NCT00004858|recurrent adult diffuse large cell lymphoma
690642|NCT00004858|recurrent adult immunoblastic large cell lymphoma
690643|NCT00004858|recurrent adult lymphoblastic lymphoma
690644|NCT00004858|recurrent adult Burkitt lymphoma
690645|NCT00004858|recurrent childhood small noncleaved cell lymphoma
690646|NCT00004858|recurrent childhood large cell lymphoma
690647|NCT00004858|recurrent small lymphocytic lymphoma
690648|NCT00004857|stage I chronic lymphocytic leukemia
690649|NCT00004857|stage II chronic lymphocytic leukemia
690650|NCT00004857|stage III chronic lymphocytic leukemia
690651|NCT00004857|stage IV chronic lymphocytic leukemia
690652|NCT00004857|B-cell chronic lymphocytic leukemia
690653|NCT00004855|Drug Therapy, Combination
690654|NCT00004855|Nevirapine
690655|NCT00004855|Stavudine
690656|NCT00004855|HIV Protease Inhibitors
690657|NCT00004855|Ritonavir
690658|NCT00004855|Lamivudine
690659|NCT00004855|Reverse Transcriptase Inhibitors
690660|NCT00004855|Anti-HIV Agents
690661|NCT00004855|ABT 378
690662|NCT00004855|abacavir
690663|NCT00004854|moderate heart failure
690664|NCT00004853|AMGEN
690665|NCT00004853|Granulocyte Colony-Stimulating Factor
690666|NCT00004853|MPNST
690667|NCT00004853|Randomized
690668|NCT00004853|Sarcoma
690669|NCT00004853|Tumor
690670|NCT00004852|HIV-1
690671|NCT00004852|Drug Therapy, Combination
690672|NCT00004852|Zidovudine
690673|NCT00004852|Drug Administration Schedule
690674|NCT00004852|Lamivudine
690675|NCT00004852|Genotype
690676|NCT00004852|Phenotype
690677|NCT00004852|Reverse Transcriptase Inhibitors
690678|NCT00004852|Anti-HIV Agents
690679|NCT00004852|Viral Load
690680|NCT00004852|efavirenz
690681|NCT00004851|HCV Antibody Library
690682|NCT00004850|Hepatitis C Virus
690683|NCT00004850|Blood Donors
690684|NCT00004850|Liver Biopsy
690685|NCT00004850|ALT
690686|NCT00004850|Natural History
690687|NCT00004848|AIDS
690688|NCT00004848|Autologous Blood
690689|NCT00004848|Cardiac Surgery
690690|NCT00004848|HIV
690691|NCT00004848|Hepatocellular Inflammation
690692|NCT00004848|Liver Biopsy
690693|NCT00004848|Long Term Sera Storage
690694|NCT00004848|Non-A Hepatitis
690695|NCT00004848|Non-B Hepatitis
690696|NCT00004847|Neurofibromatosis
690697|NCT00004847|Multiple Endocrine Neoplasia (MEN)
690698|NCT00004847|Von Hippel-Lindau Disease
690699|NCT00004847|Norepinephrine
690700|NCT00004847|Epinephrine
690701|NCT00004847|Metanephrines
690702|NCT00004847|PET
690703|NCT00004847|Paraganglioma
690704|NCT00004847|Pheochromocytoma
690705|NCT00004846|Viral Gene Amplification
690706|NCT00004846|Blood Transmitted Infections
690707|NCT00004846|Transfusion Risks
690708|NCT00004846|Transcription Mediated Analysis
690709|NCT00004846|Viral Detection Assays
690710|NCT00004846|HIV Seronegativity
690711|NCT00004845|Anti-inflammatory
690712|NCT00004844|Parkinson Disease
690713|NCT00004844|neurologic and psychiatric disorders
690714|NCT00004844|rare disease
690715|NCT00004843|disease-related problem/condition
690716|NCT00004843|endocrine disorders
690717|NCT00004843|hyperparathyroidism
690718|NCT00004843|quality of life
690719|NCT00004843|rare disease
690720|NCT00004842|cirrhosis
690721|NCT00004842|gastrointestinal disorders
690722|NCT00004842|primary biliary cirrhosis
690723|NCT00004842|primary sclerosing cholangitis
690724|NCT00004842|rare disease
690725|NCT00004840|cardiovascular and respiratory diseases
690726|NCT00004840|neonatal disorders
690727|NCT00004840|rare disease
690728|NCT00004840|respiratory distress syndrome
690729|NCT00004838|environmental/toxic disorders
690730|NCT00004838|lead poisoning
690731|NCT00004838|rare disease
690732|NCT00004834|anxiety disorder
690733|NCT00004834|disease-related problem/condition
690734|NCT00004834|neurologic and psychiatric disorders
690735|NCT00004834|panic disorder
690736|NCT00004834|rare disease
690737|NCT00004833|Guillain-Barre syndrome
690738|NCT00004833|demyelinating neuropathy
690739|NCT00004833|neurologic and psychiatric disorders
690740|NCT00004833|rare disease
690741|NCT00004832|Lambert-Eaton myasthenic syndrome
690742|NCT00004832|neurologic and psychiatric disorders
690743|NCT00004832|rare disease
690744|NCT00004831|erythropoietic protoporphyria
690745|NCT00004831|inborn errors of metabolism
690746|NCT00004831|porphyria
690747|NCT00004831|rare disease
690748|NCT00004829|bacterial infection
690749|NCT00004829|cardiovascular and respiratory diseases
690750|NCT00004829|cystic fibrosis
690751|NCT00004829|genetic diseases and dysmorphic syndromes
690752|NCT00004829|immunologic disorders and infectious disorders
690753|NCT00004829|rare disease
690754|NCT00004828|cardiovascular and respiratory diseases
690755|NCT00004828|heart defects
690756|NCT00004828|rare disease
690757|NCT00004827|ophthalmologic disorders
690758|NCT00004827|rare disease
690759|NCT00004827|retinitis pigmentosa
690760|NCT00004826|Parkinson disease
690761|NCT00004826|neurologic and psychiatric disorders
690762|NCT00004826|rare disease
690763|NCT00004825|endocrine disorders
690764|NCT00004825|hyperinsulinism
690765|NCT00004825|rare disease
690766|NCT00004817|neurologic and psychiatric disorders
690767|NCT00004817|rare disease
690768|NCT00004817|seizures
690769|NCT00004816|multiple sclerosis
690770|NCT00004816|neurologic and psychiatric disorders
690771|NCT00004816|rare disease
690772|NCT00004815|Werner's syndrome
690773|NCT00004815|genetic diseases and dysmorphic syndromes
690774|NCT00004815|rare disease
690775|NCT00004814|multiple sclerosis
690776|NCT00004814|neurologic and psychiatric disorders
690777|NCT00004814|rare disease
690778|NCT00004812|environmental/toxic disorders
690779|NCT00004812|neurologic and psychiatric disorders
690780|NCT00004812|rare disease
690781|NCT00004812|spinal cord injury
690782|NCT00004811|blastomycosis
690783|NCT00004811|fungal infection
690784|NCT00004811|histoplasmosis
690785|NCT00004811|immunologic disorders and infectious disorders
690786|NCT00004811|rare disease
690787|NCT00004811|sporotrichosis
690788|NCT00004810|gastrointestinal disorders
690789|NCT00004810|rare disease
690790|NCT00004810|ulcerative colitis
690791|NCT00004809|familial hypercholesterolemia
690792|NCT00004809|inborn errors of metabolism
690793|NCT00004809|rare disease
690794|NCT00004808|blastomycosis
690795|NCT00004808|fungal infection
690796|NCT00004808|histoplasmosis
690797|NCT00004808|immunologic disorders and infectious disorders
690798|NCT00004808|rare disease
690799|NCT00004808|sporotrichosis
690800|NCT00004807|Rett syndrome
690801|NCT00004807|neurologic and psychiatric disorders
690802|NCT00004807|rare disease
690803|NCT00004806|cardiovascular and respiratory diseases
690804|NCT00004806|cystic fibrosis
690805|NCT00004806|genetic diseases and dysmorphic syndromes
690806|NCT00004806|rare disease
690807|NCT00004805|bronchopulmonary dysplasia
690808|NCT00004805|cardiovascular and respiratory diseases
690809|NCT00004805|disease-related problem/condition
690810|NCT00004805|educational needs
690811|NCT00004805|hypertensive disorder
690812|NCT00004805|neonatal disorders
690813|NCT00004805|primary pulmonary hypertension
690814|NCT00004805|rare disease
690815|NCT00004805|respiratory distress syndrome
690816|NCT00004804|hepatitis C
690817|NCT00004804|immunologic disorders and infectious disorders
690818|NCT00004804|rare disease
690819|NCT00004804|viral infection
690820|NCT00004802|neurologic and psychiatric disorders
690821|NCT00004802|periodic paralysis
690822|NCT00004802|rare disease
690823|NCT00004801|hematologic disorders
690824|NCT00004801|rare disease
690825|NCT00004800|bacterial infection
690826|NCT00004800|immunologic disorders and infectious disorders
690827|NCT00004800|pertussis
690828|NCT00004800|rare disease
690829|NCT00004799|bacterial infection
690830|NCT00004799|immunologic disorders and infectious disorders
690831|NCT00004799|pertussis
690832|NCT00004799|rare disease
690833|NCT00004797|disease-related problem/condition
690834|NCT00004797|genetic diseases and dysmorphic syndromes
690835|NCT00004797|hematologic disorders
690836|NCT00004797|pain
690837|NCT00004797|rare disease
690838|NCT00004797|sickle cell anemia
690839|NCT00004796|cardiovascular and respiratory diseases
690840|NCT00004796|cirrhosis
690841|NCT00004796|gastrointestinal disorders
690842|NCT00004796|hypertensive disorder
690843|NCT00004796|portal hypertension
690844|NCT00004796|rare disease
690845|NCT00004795|arthritis & connective tissue diseases
690846|NCT00004795|immunologic disorders and infectious disorders
690847|NCT00004795|rare disease
690848|NCT00004795|systemic lupus erythematosus
690849|NCT00004794|cytomegalovirus retinitis
690850|NCT00004794|ophthalmologic disorders
690851|NCT00004794|rare disease
690852|NCT00004793|constitutional growth delay
690853|NCT00004793|endocrine disorders
690854|NCT00004793|rare disease
690855|NCT00004791|dermatologic disorders
690856|NCT00004791|epidermolysis bullosa
690857|NCT00004791|genetic diseases and dysmorphic syndromes
690858|NCT00004791|rare disease
690859|NCT00004789|inborn errors of metabolism
690860|NCT00004789|acute porphyria
690861|NCT00004789|rare disease
690862|NCT00004788|inborn errors of metabolism
690863|NCT00004788|porphyria
690864|NCT00004788|rare disease
690865|NCT00004787|Fanconi's anemia
690866|NCT00004787|Shwachman syndrome
690867|NCT00004787|aplastic anemia
690868|NCT00004787|dermatologic disorders
690869|NCT00004787|dyskeratosis congenita
690870|NCT00004787|hematologic disorders
690871|NCT00004787|rare disease
690872|NCT00004787|thrombocytopenia
690873|NCT00004786|Raynaud's syndrome
690874|NCT00004786|arthritis & connective tissue diseases
690875|NCT00004786|cardiovascular and respiratory diseases
690876|NCT00004786|rare disease
690877|NCT00004786|systemic sclerosis
690878|NCT00004785|bronchopulmonary dysplasia
690879|NCT00004785|cardiovascular and respiratory diseases
690880|NCT00004785|neonatal disorders
690881|NCT00004785|rare disease
690882|NCT00004784|cirrhosis
690883|NCT00004784|gastrointestinal disorders
690884|NCT00004784|primary biliary cirrhosis
690885|NCT00004784|rare disease
690886|NCT00004781|HIV-associated candidiasis
690887|NCT00004781|candidiasis
690888|NCT00004781|disease-related problem/condition
690889|NCT00004781|fungal infection
690890|NCT00004781|immunologic disorders and infectious disorders
690891|NCT00004781|infection
690892|NCT00004781|rare disease
690893|NCT00004779|cardiovascular and respiratory diseases
690894|NCT00004779|cystic fibrosis
690895|NCT00004779|genetic diseases and dysmorphic syndromes
690896|NCT00004779|rare disease
690897|NCT00004778|cardiovascular and respiratory diseases
690898|NCT00004778|neonatal disorders
690899|NCT00004778|rare disease
690900|NCT00004778|respiratory distress syndrome
690901|NCT00004776|Lennox-Gastaut syndrome
690902|NCT00004776|epilepsy
690903|NCT00004776|neurologic and psychiatric disorders
690904|NCT00004776|rare disease
690905|NCT00004776|seizures
690906|NCT00004773|Rett syndrome
690907|NCT00004773|neurologic and psychiatric disorders
690908|NCT00004773|rare disease
690909|NCT00004772|demyelinating neuropathy
690910|NCT00004772|neurologic and psychiatric disorders
690911|NCT00004772|rare disease
690912|NCT00004771|amyotrophic lateral sclerosis
690913|NCT00004771|motor neuron disease
690914|NCT00004771|neurologic and psychiatric disorders
690915|NCT00004771|rare disease
690916|NCT00004771|spinal and bulbar muscular atrophy
690917|NCT00004771|spinal muscular atrophy
690918|NCT00004771|Kennedy's Syndrome
690919|NCT00004770|inborn errors of metabolism
690920|NCT00004770|mitochondrial myopathy
690921|NCT00004770|rare disease
690922|NCT00004769|Genetic diseases
690923|NCT00004769|Myotonic muscular dystrophy
690924|NCT00004769|Facioscapulohumeral muscular dystrophy
690925|NCT00004769|CMT
690926|NCT00004769|Rare disease
690927|NCT00004767|inborn errors of metabolism
690928|NCT00004767|rare disease
690929|NCT00004767|urea cycle disorder
690930|NCT00004763|endocrine disorders
690931|NCT00004763|hyperandrogenism
690932|NCT00004763|rare disease
690933|NCT00004762|gastrointestinal disorders
690934|NCT00004762|primary sclerosing cholangitis
690935|NCT00004762|rare disease
690936|NCT00004761|dermatologic disorders
690937|NCT00004761|epidermolysis bullosa
690938|NCT00004761|genetic diseases and dysmorphic syndromes
690939|NCT00004761|rare disease
690940|NCT00004760|Parkinson disease
690941|NCT00004760|Neurologic and psychiatric disorders
690942|NCT00004760|Rare disease
690943|NCT00004759|environmental/toxic disorders
690944|NCT00004759|neurologic and psychiatric disorders
690945|NCT00004759|rare disease
690946|NCT00004759|spinal cord injury
690947|NCT00004758|infantile spasms
690948|NCT00004758|epilepsy
690949|NCT00004758|neurologic and psychiatric disorders
690950|NCT00004758|rare disease
690951|NCT00004758|seizures
690952|NCT00004757|herpes simplex virus infection
690953|NCT00004757|herpesvirus infection
690954|NCT00004757|immunologic disorders and infectious disorders
690955|NCT00004757|rare disease
690956|NCT00004757|viral infection
690957|NCT00004756|arthritis & connective tissue diseases
690958|NCT00004756|disease-related problem/condition
690959|NCT00004756|educational needs
690960|NCT00004756|immunologic disorders and infectious disorders
690961|NCT00004756|rare disease
690962|NCT00004756|systemic lupus erythematosus
690963|NCT00004755|dermatologic disorders
690964|NCT00004755|environmental/toxic disorders
690965|NCT00004755|immunologic disorders and infectious disorders
690966|NCT00004755|leishmaniasis
690967|NCT00004755|rare disease
690968|NCT00004754|cardiovascular and respiratory diseases
690969|NCT00004754|hypertensive disorder
690970|NCT00004754|primary pulmonary hypertension
690971|NCT00004754|rare disease
690972|NCT00004753|Huntington's disease
690973|NCT00004753|neurologic and psychiatric disorders
690974|NCT00004753|rare disease
690975|NCT00004751|cerebral palsy
690976|NCT00004751|neurologic and psychiatric disorders
690977|NCT00004751|rare disease
690978|NCT00004751|spastic diplegia
690979|NCT00004748|cirrhosis
690980|NCT00004748|gastrointestinal disorders
690981|NCT00004748|primary biliary cirrhosis
690982|NCT00004748|rare disease
690983|NCT00004747|bacterial infections
690984|NCT00004747|cardiovascular and respiratory diseases
690985|NCT00004747|cystic fibrosis
690986|NCT00004747|genetic diseases and dysmorphic syndromes
690987|NCT00004747|immunologic disorders and infectious disorders
690988|NCT00004747|rare disease
690989|NCT00004744|multiple sclerosis
690990|NCT00004744|neurologic and psychiatric disorders
690991|NCT00004744|rare disease
690992|NCT00004740|cardiovascular and respiratory diseases
690993|NCT00004740|rare disease
690994|NCT00004740|tuberculosis
690995|NCT00004739|Pediatric HIV infection
690996|NCT00004738|Arnold Chiari Malformation
690997|NCT00004738|Skeletal Dysplasia
690998|NCT00004738|Syringomyelia
690999|NCT00004738|Genetics
691000|NCT00004738|Chiari I Malformation
691001|NCT00004736|Tuberculosis
691002|NCT00004736|Rifabutin
691003|NCT00004736|AIDS-Related Opportunistic Infections
691004|NCT00004736|Drug Therapy, Combination
691005|NCT00004736|Antitubercular Agents
691006|NCT00004736|Anti-HIV Agents
691007|NCT00004735|Viral Vaccines
691008|NCT00004735|Drug Therapy, Combination
691009|NCT00004735|CD4-Positive T-Lymphocytes
691010|NCT00004735|Immunologic Memory
691011|NCT00004735|Antibody Formation
691012|NCT00004735|Anti-HIV Agents
691013|NCT00004735|Tetanus Toxoid
691014|NCT00004735|Hepatitis A Virus, Human
691015|NCT00004735|Enfuvirtide
691016|NCT00004735|T-20
691017|NCT00004735|Treatment Naive
691018|NCT00004735|Treatment Experienced
691019|NCT00004734|stroke
691020|NCT00004734|cerebral infarction
691021|NCT00004734|homocysteine
691022|NCT00004734|vitamin
691023|NCT00004734|folic acid
691024|NCT00004734|pyridoxine
691025|NCT00004734|vitamin B6
691026|NCT00004734|cyanocobalamin
691027|NCT00004734|vitamin B12
691028|NCT00004734|multivitamin
691029|NCT00004733|Parkinson's
691030|NCT00004733|ELLDOPA
691031|NCT00004733|L-dopa
691032|NCT00004733|levodopa
691033|NCT00004733|Sinemet
691034|NCT00004733|tremor
691035|NCT00004732|angioplasty
691036|NCT00004732|asymptomatic
691037|NCT00004732|atherosclerosis
691038|NCT00004732|carotid endarterectomy
691039|NCT00004732|carotid stenting
691040|NCT00004732|CREST
691041|NCT00004732|Cerebral Infarction
691042|NCT00004732|device
691043|NCT00004732|intervention
691044|NCT00004732|restenosis
691045|NCT00004732|revascularization
691046|NCT00004732|stenosis
691047|NCT00004732|stent
691048|NCT00004732|stroke
691049|NCT00004732|symptomatic
691050|NCT00004732|surgery
691051|NCT00004732|transient ischemic attack
691052|NCT00004731|Parkinson's disease
691053|NCT00004731|coenzyme Q10
691054|NCT00004730|head injury
691055|NCT00004730|traumatic brain injury
691056|NCT00004730|concussion
691057|NCT00004730|magnesium sulfate
691058|NCT00004730|neuroprotection
691059|NCT00004729|child
691060|NCT00004729|children
691061|NCT00004729|epilepsy
691062|NCT00004729|seizure
691063|NCT00004729|ketogenic
691064|NCT00004729|diet
691065|NCT00004729|Lennox-Gastaut Syndrome
691066|NCT00004729|LGS
691067|NCT00004728|stroke
691068|NCT00004728|cerebral infarction
691069|NCT00004728|warfarin
691070|NCT00004728|coumadin
691071|NCT00004728|aspirin
691072|NCT00004728|ASA
691073|NCT00004728|acetysalicylic acid
691074|NCT00004728|atherosclerosis
691075|NCT00004728|stenosis
691076|NCT00004728|intracranial
691077|NCT00004728|artery
691078|NCT00004728|arteries
691079|NCT00004728|transient ischemic attack
691080|NCT00004728|TIA
691081|NCT00004728|minorities
691082|NCT00004727|African American
691083|NCT00004727|antiplatelet
691084|NCT00004727|aspirin
691085|NCT00004727|ASA
691086|NCT00004727|acetylsalicylic acid
691087|NCT00004727|ticlopidine
691088|NCT00004727|prevention
691089|NCT00004727|stroke
691090|NCT00004727|cerebral infarction
691091|NCT00004727|Chicago
691092|NCT00004727|non-cardioembolic ischemic stroke
691093|NCT00004705|cardiovascular and respiratory diseases
691094|NCT00004705|cystic fibrosis
691095|NCT00004705|genetic diseases and dysmorphic syndromes
691096|NCT00004705|rare disease
691097|NCT00004700|endocrine disorders
691098|NCT00004700|hyperinsulinism
691099|NCT00004700|rare disease
691100|NCT00004699|endocrine disorders
691101|NCT00004699|hyperinsulinism
691102|NCT00004699|rare disease
691216|NCT00004647|diabetic neuropathy
691103|NCT00004697|gastrointestinal disorders
691104|NCT00004697|hepatic steatosis
691105|NCT00004697|rare disease
691106|NCT00004696|disease-related problem/condition
691107|NCT00004696|pain
691108|NCT00004696|intraoperative/postoperative complications
691109|NCT00004696|rare disease
691110|NCT00004695|common variable immunodeficiency
691111|NCT00004695|immunologic disorders and infectious disorders
691112|NCT00004695|primary immunodeficiency disease
691113|NCT00004695|rare disease
691114|NCT00004694|genetic diseases and dysmorphic syndromes
691115|NCT00004694|hereditary angioedema
691116|NCT00004694|rare disease
691117|NCT00004690|dermatologic disorders
691118|NCT00004690|ichthyosis
691119|NCT00004690|rare disease
691120|NCT00004689|bacterial infection
691121|NCT00004689|immunologic disorders and infectious disorders
691122|NCT00004689|mycobacterium avium infection
691123|NCT00004689|mycobacterium infection
691124|NCT00004689|rare disease
691125|NCT00004688|adult anaplastic astrocytoma
691126|NCT00004688|adult anaplastic oligodendroglioma
691127|NCT00004688|adult brain stem glioma
691128|NCT00004688|adult brain tumor
691129|NCT00004688|adult glioblastoma multiforme
691130|NCT00004688|adult infiltrating astrocytoma
691131|NCT00004688|brain tumor
691132|NCT00004688|genetic condition
691133|NCT00004688|miscellaneous sites/terms
691134|NCT00004688|mixed gliomas
691135|NCT00004688|nervous tissue tumors
691136|NCT00004688|oncologic disorders
691137|NCT00004688|rare disease
691138|NCT00004688|recurrent adult brain tumor
691139|NCT00004686|cardiovascular and respiratory diseases
691140|NCT00004686|giant cell arteritis
691141|NCT00004686|rare disease
691142|NCT00004685|genetic diseases and dysmorphic syndromes
691143|NCT00004685|muscular dystrophy
691144|NCT00004685|neurologic and psychiatric disorders
691145|NCT00004685|rare disease
691146|NCT00004682|myasthenia gravis
691147|NCT00004682|neurologic and psychiatric disorders
691148|NCT00004682|rare disease
691149|NCT00004670|Parkinson disease
691150|NCT00004670|neurologic and psychiatric disorders
691151|NCT00004670|rare disease
691152|NCT00004669|bronchopulmonary dysplasia
691153|NCT00004669|cardiovascular and respiratory diseases
691154|NCT00004669|neonatal disorders
691155|NCT00004669|rare disease
691156|NCT00004667|hematologic disorders
691157|NCT00004667|rare disease
691158|NCT00004667|von Willebrand's disease
691159|NCT00004665|arthritis & connective tissue diseases
691160|NCT00004665|immunologic disorders and infectious disorders
691161|NCT00004665|rare disease
691162|NCT00004665|systemic lupus erythematosus
691163|NCT00004664|disease-related problem/condition
691164|NCT00004664|human immunodeficiency virus infection
691165|NCT00004664|immunologic disorders and infectious disorders
691166|NCT00004664|nutrition
691167|NCT00004664|rare disease
691168|NCT00004664|viral infection
691169|NCT00004663|arthritis & connective tissue diseases
691170|NCT00004663|immunologic disorders and infectious disorders
691171|NCT00004663|rare disease
691172|NCT00004663|systemic lupus erythematosus
691173|NCT00004662|arthritis & connective tissue diseases
691174|NCT00004662|immunologic disorders and infectious disorders
691175|NCT00004662|rare disease
691176|NCT00004662|systemic lupus erythematosus
691177|NCT00004661|endocrine disorders
691178|NCT00004661|pseudohypoparathyroidism
691179|NCT00004661|rare disease
691180|NCT00004660|Graves' disease
691181|NCT00004660|thyroid disease
691182|NCT00004660|endocrine disorders
691183|NCT00004660|rare disease
691184|NCT00004659|adult brain tumor
691185|NCT00004659|brain tumor
691186|NCT00004659|childhood brain tumor
691187|NCT00004659|genetic condition
691188|NCT00004659|nervous tissue tumors
691189|NCT00004659|oncologic disorders
691190|NCT00004659|rare disease
691191|NCT00004658|5'-nucleotidase syndrome
691192|NCT00004658|inborn errors of metabolism
691193|NCT00004658|rare disease
691194|NCT00004656|Rett syndrome
691195|NCT00004656|neurologic and psychiatric disorders
691196|NCT00004656|rare disease
691197|NCT00004654|genetic diseases and dysmorphic syndromes
691198|NCT00004654|hematologic disorders
691199|NCT00004654|hereditary hemorrhagic telangiectasia
691200|NCT00004654|rare disease
691201|NCT00004652|Tourette syndrome
691202|NCT00004652|neurologic and psychiatric disorders
691203|NCT00004652|rare disease
691204|NCT00004650|disease-related problem/condition
691205|NCT00004650|osteoporosis
691206|NCT00004650|rare disease
691207|NCT00004649|genetic diseases and dysmorphic syndromes
691208|NCT00004649|hematologic disorders
691209|NCT00004649|hereditary hemorrhagic telangiectasia
691210|NCT00004649|rare disease
691211|NCT00004648|genetic diseases and dysmorphic syndromes
691212|NCT00004648|hematologic disorders
691213|NCT00004648|hereditary hemorrhagic telangiectasia
691214|NCT00004648|rare disease
691215|NCT00004648|Osler-Rendu-Weber disease
691217|NCT00004647|disease-related problem/condition
691218|NCT00004647|neurologic and psychiatric disorders
691219|NCT00004647|pain
691220|NCT00004647|rare disease
691221|NCT00004646|Duchenne muscular dystrophy
691222|NCT00004646|genetic diseases and dysmorphic syndromes
691223|NCT00004646|muscular dystrophy
691224|NCT00004646|neurologic and psychiatric disorders
691225|NCT00004646|rare disease
691226|NCT00004645|Balo's concentric sclerosis
691227|NCT00004645|Devic's syndrome
691228|NCT00004645|Marburg's variant of multiple sclerosis
691229|NCT00004645|acute disseminated encephalomyelitis
691230|NCT00004645|acute transverse myelitis
691231|NCT00004645|multiple sclerosis
691232|NCT00004645|neurologic and psychiatric disorders
691233|NCT00004645|rare disease
691234|NCT00004644|herpes simplex virus infection
691235|NCT00004644|herpesvirus infection
691236|NCT00004644|immunologic disorders and infectious disorders
691237|NCT00004644|rare disease
691238|NCT00004644|viral infection
691239|NCT00004643|arthritis & connective tissue diseases
691240|NCT00004643|immunologic disorders and infectious disorders
691241|NCT00004643|rare disease
691242|NCT00004643|systemic lupus erythematosus
691243|NCT00004642|congenital cytomegalovirus infection
691244|NCT00004642|cytomegalovirus infection
691245|NCT00004642|herpesvirus infection
691246|NCT00004642|immunologic disorders and infectious disorders
691247|NCT00004642|neonatal disorders
691248|NCT00004642|rare disease
691249|NCT00004642|viral infection
691250|NCT00004641|Cruveilhier-Baumgarten Syndrome
691251|NCT00004641|Esophageal Varices
691252|NCT00004641|Gastric Varices
691253|NCT00004641|Esophageal Varix
691254|NCT00004641|Gastric Varix
691255|NCT00004641|Alcoholic Cirrhosis
691256|NCT00004640|Aging
691257|NCT00004640|Elderly
691258|NCT00004640|Periodontal Disease
691259|NCT00004640|Dental Caries
691260|NCT00004640|Fluoride
691261|NCT00004640|Antibacterial rinse
691262|NCT00004640|Chlorhexidine
691263|NCT00004640|Tooth Mortality
691264|NCT00004639|cleft lip and palate
691265|NCT00004639|children
691266|NCT00004639|speech
691267|NCT00004639|velopharyngeal function
691268|NCT00004639|congenital facial malformation
691269|NCT00004639|von Langenbeck procedure
691270|NCT00004639|Furlow procedure
691271|NCT00004639|cleft lip and palate repair
691272|NCT00004639|Unilateral cleft lip and palate
691273|NCT00004638|chronic sinusitis
691274|NCT00004635|Angiogenesis
691275|NCT00004635|Cancer
691276|NCT00004635|Hormonal Therapy
691277|NCT00004635|Prostate
691278|NCT00004635|Thalidomide
691279|NCT00004635|Prostate Cancer
691280|NCT00004604|stage IV colon cancer
691281|NCT00004604|stage IV breast cancer
691282|NCT00004604|recurrent breast cancer
691283|NCT00004604|stage IV gastric cancer
691284|NCT00004604|recurrent gastric cancer
691285|NCT00004604|recurrent non-small cell lung cancer
691286|NCT00004604|recurrent pancreatic cancer
691287|NCT00004604|stage IV rectal cancer
691288|NCT00004604|recurrent colon cancer
691289|NCT00004604|recurrent rectal cancer
691290|NCT00004604|inflammatory breast cancer
691291|NCT00004604|stage IV ovarian epithelial cancer
691292|NCT00004604|recurrent ovarian epithelial cancer
691293|NCT00004604|extensive stage small cell lung cancer
691294|NCT00004604|recurrent small cell lung cancer
691295|NCT00004604|unresectable gallbladder cancer
691296|NCT00004604|recurrent gallbladder cancer
691297|NCT00004604|unresectable extrahepatic bile duct cancer
691298|NCT00004604|recurrent extrahepatic bile duct cancer
691299|NCT00004604|stage III malignant testicular germ cell tumor
691300|NCT00004604|recurrent malignant testicular germ cell tumor
691301|NCT00004604|thyroid gland medullary carcinoma
691302|NCT00004604|stage IV non-small cell lung cancer
691303|NCT00004604|stage IV salivary gland cancer
691304|NCT00004604|recurrent salivary gland cancer
691305|NCT00004604|Paget disease of the breast with invasive ductal carcinoma
691306|NCT00004604|adult primary hepatocellular carcinoma
691307|NCT00004604|testicular yolk sac tumor
691308|NCT00004604|lung metastases
691309|NCT00004604|liver metastases
691310|NCT00004604|cholangiocarcinoma of the gallbladder
691311|NCT00004604|cholangiocarcinoma of the extrahepatic bile duct
691312|NCT00004604|male breast cancer
691313|NCT00004604|stage IV pancreatic cancer
691314|NCT00004585|Drug Therapy, Combination
691315|NCT00004585|Zidovudine
691316|NCT00004585|Lamivudine
691317|NCT00004585|RNA, Viral
691318|NCT00004585|Reverse Transcriptase Inhibitors
691319|NCT00004585|Anti-HIV Agents
691320|NCT00004585|Viral Load
691321|NCT00004585|abacavir
691322|NCT00004585|efavirenz
691323|NCT00004584|Dose-Response Relationship, Drug
691324|NCT00004584|Drug Therapy, Combination
691325|NCT00004584|HIV Protease Inhibitors
691326|NCT00004584|Ritonavir
691327|NCT00004584|Saquinavir
691328|NCT00004584|Reverse Transcriptase Inhibitors
691329|NCT00004584|Anti-HIV Agents
691330|NCT00004583|Drug Therapy, Combination
691331|NCT00004583|Administration, Oral
691332|NCT00004583|Stavudine
691333|NCT00004583|HIV Protease Inhibitors
691334|NCT00004583|Lamivudine
691335|NCT00004583|Reverse Transcriptase Inhibitors
691336|NCT00004583|Anti-HIV Agents
691337|NCT00004583|Nelfinavir
691338|NCT00004583|ABT 378
691339|NCT00004582|HIV Protease Inhibitors
691340|NCT00004582|Ritonavir
691341|NCT00004582|Reverse Transcriptase Inhibitors
691342|NCT00004582|Anti-HIV Agents
691343|NCT00004582|Viral Load
691344|NCT00004582|ABT 378
691345|NCT00004582|efavirenz
691346|NCT00004581|Drug Therapy, Combination
691347|NCT00004581|Nevirapine
691348|NCT00004581|HIV Protease Inhibitors
691349|NCT00004581|Ritonavir
691350|NCT00004581|Reverse Transcriptase Inhibitors
691351|NCT00004581|Anti-HIV Agents
691352|NCT00004581|ABT 378
691353|NCT00004580|Drug Therapy, Combination
691354|NCT00004580|Nevirapine
691355|NCT00004580|HIV Protease Inhibitors
691356|NCT00004580|Ritonavir
691357|NCT00004580|Reverse Transcriptase Inhibitors
691358|NCT00004579|Vaccines, Synthetic
691359|NCT00004579|Viral Vaccines
691360|NCT00004579|HIV-1
691361|NCT00004579|Dose-Response Relationship, Drug
691362|NCT00004579|HIV Envelope Protein gp160
691363|NCT00004579|AIDS Vaccines
691364|NCT00004579|HIV Seronegativity
691365|NCT00004579|Avipoxvirus
691366|NCT00004579|Immunization
691367|NCT00004579|HIV Envelope Protein gp120
691368|NCT00004579|Recombination, Genetic
691369|NCT00004578|Stavudine
691370|NCT00004578|HIV Protease Inhibitors
691371|NCT00004578|Ritonavir
691372|NCT00004578|Lamivudine
691373|NCT00004578|Reverse Transcriptase Inhibitors
691374|NCT00004577|BOLD Effect
691375|NCT00004577|Cerebral Blood Flow
691376|NCT00004577|Cerebral Blood Volume
691377|NCT00004577|Functional Imaging
691378|NCT00004577|Magnetic Resonance Imaging
691379|NCT00004577|Technical Developments
691380|NCT00004576|Dyskinesias
691381|NCT00004576|Glutamate
691382|NCT00004576|Levodopa
691383|NCT00004576|Parkinson's Disease
691384|NCT00004575|Endothelium
691385|NCT00004575|Vasodilation
691386|NCT00004575|Vascular Biology
691387|NCT00004575|Venous Occlusion Plethysmography
691388|NCT00004574|Abetalipoproteinemia
691389|NCT00004574|Ataxia
691390|NCT00004574|Retinitis Pigmentosa
691391|NCT00004574|Vitamin A
691392|NCT00004574|Vitamin E
691393|NCT00004573|cytomegalovirus viremia
691394|NCT00004572|Type 2 Diabetes
691395|NCT00004571|Magnetic Resonance Imaging
691396|NCT00004571|Brain Metabolism
691397|NCT00004571|Brain Physiology
691398|NCT00004571|Neuropsychiatric Disorders
691399|NCT00004571|Cognitition
691400|NCT00004570|Temporal Processing
691401|NCT00004570|Language Impairment
691402|NCT00004570|Linkage Analysis
691403|NCT00004570|Inheritance
691404|NCT00004570|Language Delay
691405|NCT00004570|Healthy
691406|NCT00004570|Auditory Temporal Processing Disorder
691407|NCT00004570|Speech Impediment
691408|NCT00004568|Peripheral Neuropathies
691409|NCT00004568|Myopathy
691410|NCT00004568|Muscular Dystrophy
691411|NCT00004568|Motor Neuron Disease
691412|NCT00004568|Spinocerebellar Degeneration
691413|NCT00004568|Neurological Disorders
691414|NCT00004567|Relapse
691415|NCT00004567|Immunosuppressive
691416|NCT00004567|Toxicity
691417|NCT00004567|Purineantimetabolite
691418|NCT00004567|Alternative Agents
691419|NCT00004567|Wegener's Granulomatosis
691420|NCT00004567|Wegener's Disease
691421|NCT00004567|Blood Vessel Disorder
691422|NCT00004567|Systemic Vasculitis
691423|NCT00004566|3D Imaging
691424|NCT00004566|Swallowing
691425|NCT00004566|Fetal Development
691426|NCT00004566|High-Risk Pregnancy
691427|NCT00004566|Ultrasound
691428|NCT00004565|Breast Cancer
691429|NCT00004565|Genetics
691430|NCT00004565|High Risk
691431|NCT00004565|Polymorphisms
691432|NCT00004565|Susceptibility
691433|NCT00004565|Biomarkers
691434|NCT00004565|Estrogen
691435|NCT00004565|Genes
691436|NCT00004564|Platelet Aggregation Inhibitors
691437|NCT00004564|Cerebrovascular accident
691438|NCT00004563|Lung Diseases
691439|NCT00004563|Pulmonary Fibrosis
691440|NCT00004563|Systemic Scleroderma
691441|NCT00004563|Scleroderma, systemic
691442|NCT00004557|Attention
691443|NCT00004557|Cognition
691444|NCT00004557|Dementia
691445|NCT00004557|Memory
691446|NCT00004557|Object Recognition
691447|NCT00004557|Spatial Processes
691448|NCT00004556|Stimulants
691449|NCT00004556|Affect
691450|NCT00004556|Cognition
691451|NCT00004556|Brain Physiology
691452|NCT00004556|Brain Metabolism
691453|NCT00004556|Catecholamines
691454|NCT00004556|Brain Imaging
691455|NCT00004556|Cognitive Efficiency
691456|NCT00004556|Dopamine Genes
691457|NCT00004553|Single Fiber EMG
691458|NCT00004553|Macro-EMG
691459|NCT00004553|Myasthenia
691460|NCT00004553|Post-Polio Syndrome
691461|NCT00004553|Neuromuscular Transmission
691462|NCT00004553|Motor Dysfunction
691463|NCT00004553|Neuromuscular Disorder
691464|NCT00004550|Screening
691465|NCT00004550|Longitudinal
691466|NCT00004550|Transition
691467|NCT00004550|Treatment
691468|NCT00004550|Comorbidity
691469|NCT00004550|Obsessive Compulsive Disorder
691470|NCT00004550|Evaluation
691471|NCT00004550|Follow-Up
691472|NCT00004550|OC Spectrum Disorders
691473|NCT00004550|OCD
691474|NCT00004549|Atherosclerosis
691475|NCT00004549|Endothelium
691476|NCT00004549|Peripheral Vascular Disease
691477|NCT00004549|Markers of Inflammation
691478|NCT00004549|Claudication
691479|NCT00004547|Surgery
691480|NCT00004547|Mesothelioma
691481|NCT00004547|Pseudomyxoma
691482|NCT00004547|Colon Cancer
691483|NCT00004547|Chemotherapy
691484|NCT00004533|cardiovascular and respiratory diseases
691485|NCT00004533|cystic fibrosis
691486|NCT00004533|genetic diseases and dysmorphic syndromes
691487|NCT00004533|rare disease
691488|NCT00004500|cardiovascular and respiratory diseases
691489|NCT00004500|meconium aspiration syndrome
691490|NCT00004500|rare disease
691491|NCT00004498|genetic diseases and dysmorphic syndromes
691492|NCT00004498|inborn errors of metabolism
691493|NCT00004498|ornithine transcarbamylase deficiency
691494|NCT00004498|rare disease
691495|NCT00004498|urea cycle disorder
691496|NCT00004497|cardiovascular and respiratory diseases
691497|NCT00004497|hypertensive disorder
691498|NCT00004497|primary pulmonary hypertension
691499|NCT00004497|rare disease
691500|NCT00004496|acute renal failure
691501|NCT00004496|rare disease
691502|NCT00004496|renal and genitourinary disorders
691503|NCT00004495|cardiovascular and respiratory diseases
691504|NCT00004495|end stage renal disease
691505|NCT00004495|hyperhomocysteinemia
691506|NCT00004495|rare disease
691507|NCT00004495|renal and genitourinary disorders
691508|NCT00004494|cardiovascular and respiratory diseases
691509|NCT00004494|immunologic disorders and infectious disorders
691510|NCT00004494|neonatal disorders
691511|NCT00004494|rare disease
691512|NCT00004494|respiratory distress syndrome
691513|NCT00004494|sepsis
691514|NCT00004493|inborn errors of metabolism
691515|NCT00004493|lactic acidosis
691516|NCT00004493|rare disease
691517|NCT00004492|genetic diseases and dysmorphic syndromes
691518|NCT00004492|hematologic disorders
691519|NCT00004492|rare disease
691520|NCT00004492|sickle cell anemia
691521|NCT00004490|disease-related problem/condition
691522|NCT00004490|inborn errors of metabolism
691523|NCT00004490|lactic acidosis
691524|NCT00004490|quality of life
691525|NCT00004490|rare disease
691526|NCT00004489|cardiovascular and respiratory diseases
691527|NCT00004489|cystic fibrosis
691528|NCT00004489|disease-related problem/condition
691529|NCT00004489|genetic diseases and dysmorphic syndromes
691530|NCT00004489|osteoporosis
691531|NCT00004489|rare disease
691532|NCT00004488|Gaucher's disease
691533|NCT00004488|inborn errors of metabolism
691534|NCT00004488|rare disease
691535|NCT00004488|sphingolipidoses
691536|NCT00004487|rare disease
691537|NCT00004487|renal and genitourinary disorders
691538|NCT00004487|vesicoureteral reflux
691539|NCT00004486|autism
691540|NCT00004486|neurologic and psychiatric disorders
691541|NCT00004486|rare disease
691542|NCT00004485|genetic diseases and dysmorphic syndromes
691543|NCT00004485|hematologic disorders
691544|NCT00004485|rare disease
691545|NCT00004485|sickle cell anemia
691546|NCT00004482|cardiovascular and respiratory diseases
691547|NCT00004482|giant cell myocarditis
691548|NCT00004482|rare disease
691549|NCT00004481|endocrine disorders
691550|NCT00004481|inborn errors of metabolism
691551|NCT00004481|rare disease
691552|NCT00004481|sitosterolemia
691553|NCT00004480|dermatologic disorders
691554|NCT00004480|hyperhidrosis
691555|NCT00004480|rare disease
691556|NCT00004479|neurologic and psychiatric disorders
691557|NCT00004479|rare disease
691558|NCT00004479|syncope
691559|NCT00004478|Shy-Drager Syndrome
691560|NCT00004478|cardiovascular and respiratory diseases
691561|NCT00004478|neurologic and psychiatric disorders
691562|NCT00004478|orthostatic hypotension
691563|NCT00004478|rare disease
691564|NCT00004474|Hematologic Disorders
691565|NCT00004474|Rare Disease
691566|NCT00004471|cardiovascular and respiratory diseases
691567|NCT00004471|cystic fibrosis
691568|NCT00004471|genetic diseases and dysmorphic syndromes
691569|NCT00004471|rare disease
691570|NCT00004468|dermatologic disorders
691571|NCT00004468|psoriasis
691572|NCT00004468|rare disease
691573|NCT00004467|acute liver failure
691574|NCT00004467|gastrointestinal disorders
691575|NCT00004467|rare disease
691576|NCT00004466|cardiovascular and respiratory diseases
691577|NCT00004466|hyperlipidemia
691578|NCT00004466|nephrotic syndrome
691579|NCT00004466|rare disease
691580|NCT00004466|renal and genitourinary disorders
691581|NCT00004465|E. coli infection
691582|NCT00004465|bacterial infection
691583|NCT00004465|hemolytic uremic syndrome
691584|NCT00004465|immunologic disorders and infectious disorders
691585|NCT00004465|rare disease
691586|NCT00004465|renal and genitourinary disorders
691587|NCT00004464|aplastic anemia
691588|NCT00004464|hematologic disorders
691589|NCT00004464|paroxysmal nocturnal hemoglobinuria
691590|NCT00004464|rare disease
691591|NCT00004458|autism
691592|NCT00004458|childhood disintegrative disorder
691593|NCT00004458|neurologic and psychiatric disorders
691594|NCT00004458|rare disease
691595|NCT00004457|amyotrophic lateral sclerosis
691596|NCT00004457|motor neuron disease
691597|NCT00004457|neurologic and psychiatric disorders
691598|NCT00004457|rare disease
691599|NCT00004454|inborn errors of metabolism
691600|NCT00004454|mucopolysaccharidosis
691601|NCT00004454|mucopolysaccharidosis II
691602|NCT00004454|rare disease
691603|NCT00004451|Parkinson disease
691604|NCT00004451|neurologic and psychiatric disorders
691605|NCT00004451|rare disease
691606|NCT00004450|adrenoleukodystrophy
691607|NCT00004450|inborn errors of metabolism
691608|NCT00004450|rare disease
691609|NCT00004450|sphingolipidoses
691610|NCT00004449|autism
691611|NCT00004449|neurologic and psychiatric disorders
691612|NCT00004449|rare disease
691613|NCT00004448|IgA glomerulonephritis
691614|NCT00004448|rare disease
691615|NCT00004448|renal and genitourinary disorders
691616|NCT00004446|depersonalization disorder
691617|NCT00004446|neurologic and psychiatric disorders
691618|NCT00004446|rare disease
691619|NCT00004445|environmental/toxic disorders
691620|NCT00004445|neurologic and psychiatric disorders
691621|NCT00004445|rare disease
691622|NCT00004445|spinal cord injury
691623|NCT00004444|bacterial infection
691624|NCT00004444|immunologic disorders and infectious disorders
691625|NCT00004444|mycobacterium infection
691626|NCT00004444|mycobacterium tuberculosis infection
691627|NCT00004444|rare disease
691628|NCT00004443|inborn errors of metabolism
691629|NCT00004443|rare disease
691630|NCT00004443|tyrosinemia I
691631|NCT00004442|Zellweger syndrome
691632|NCT00004442|adrenoleukodystrophy
691633|NCT00004442|bifunctional enzyme deficiency
691634|NCT00004442|inborn errors of metabolism
691635|NCT00004442|infantile Refsum's disease
691636|NCT00004442|peroxisomal disorders
691637|NCT00004442|pseudo-Zellweger syndrome
691638|NCT00004442|rare disease
691639|NCT00004442|sphingolipidoses
691640|NCT00004441|cardiovascular and respiratory diseases
691641|NCT00004441|cystic fibrosis
691642|NCT00004441|genetic diseases and dysmorphic syndromes
691643|NCT00004441|rare disease
691644|NCT00004440|cardiovascular and respiratory diseases
691645|NCT00004440|cystic fibrosis
691646|NCT00004440|genetic diseases and dysmorphic syndromes
691647|NCT00004440|rare disease
691648|NCT00004438|endocrine disorders
691649|NCT00004438|hypogonadism
691650|NCT00004438|rare disease
691651|NCT00004437|acoustic neuroma
691652|NCT00004437|genetic diseases and dysmorphic syndromes
691653|NCT00004437|hearing loss
691654|NCT00004437|neurofibromatosis
691655|NCT00004437|neurologic and psychiatric disorders
691656|NCT00004437|rare disease
691657|NCT00004436|cardiovascular and respiratory diseases
691658|NCT00004436|hemangioma
691659|NCT00004436|rare disease
691660|NCT00004433|Tourette syndrome
691661|NCT00004433|neurologic and psychiatric disorders
691662|NCT00004433|rare disease
691663|NCT00004431|neurologic and psychiatric disorders
691664|NCT00004431|rare disease
691665|NCT00004431|trigeminal neuralgia
691666|NCT00004430|cardiovascular and respiratory diseases
691667|NCT00004430|corneal neovascularization
691668|NCT00004430|rare disease
691669|NCT00004429|end stage renal disease
691670|NCT00004429|rare disease
691671|NCT00004429|renal and genitourinary disorders
691672|NCT00004428|cardiovascular and respiratory diseases
691673|NCT00004428|cystic fibrosis
691674|NCT00004428|genetic diseases and dysmorphic syndromes
691675|NCT00004428|rare disease
691676|NCT00004426|endocrine disorders
691677|NCT00004426|hypogonadism
691678|NCT00004426|rare disease
691679|NCT00004424|disease-related problem/condition
691680|NCT00004424|oncologic disorders
691681|NCT00004424|pulmonary complications
691682|NCT00004424|rare disease
691683|NCT00004424|Respiration, Artificial
691684|NCT00004423|Crohn's disease
691685|NCT00004423|gastrointestinal disorders
691686|NCT00004423|rare disease
691687|NCT00004422|bacterial infection
691688|NCT00004422|immunologic disorders and infectious disorders
691689|NCT00004422|pertussis
691690|NCT00004422|rare disease
691691|NCT00004421|dystonia
691692|NCT00004421|neurologic and psychiatric disorders
691693|NCT00004421|rare disease
691694|NCT00004420|arthritis & connective tissue diseases
691695|NCT00004420|juvenile rheumatoid arthritis
691696|NCT00004420|rare disease
691697|NCT00004419|endocrine disorders
691698|NCT00004419|insulin resistance
691699|NCT00004419|rare disease
691700|NCT00004418|adrenoleukodystrophy
691701|NCT00004418|inborn errors of metabolism
691702|NCT00004418|rare disease
691703|NCT00004418|sphingolipidoses
691704|NCT00004416|achalasia
691705|NCT00004416|gastrointestinal disorders
691706|NCT00004416|rare disease
691707|NCT00004415|environmental/toxic disorders
691708|NCT00004415|neurologic and psychiatric disorders
691709|NCT00004415|rare disease
691710|NCT00004415|spinal cord injury
691711|NCT00004414|cholestasis
691712|NCT00004414|gastrointestinal disorders
691713|NCT00004414|rare disease
691714|NCT00004412|dermatologic disorders
691715|NCT00004412|genetic diseases and dysmorphic syndromes
691716|NCT00004412|hematologic disorders
691717|NCT00004412|rare disease
691718|NCT00004412|sickle cell anemia
691719|NCT00004412|skin ulcers
691720|NCT00004412|thalassemia major
691721|NCT00004410|cholestasis
691722|NCT00004410|gastrointestinal disorders
691723|NCT00004410|rare disease
691724|NCT00004409|Dupuytren's disease
691725|NCT00004409|arthritis & connective tissue diseases
691726|NCT00004409|rare disease
691727|NCT00004408|disease-related problem/condition
691728|NCT00004408|genetic diseases and dysmorphic syndromes
691729|NCT00004408|hematologic disorders
691730|NCT00004408|pain
691731|NCT00004408|rare disease
691732|NCT00004408|sickle cell anemia
691733|NCT00004407|diabetic amyotrophy
691734|NCT00004407|diabetic lumbosacral radiculoplexus neuropathy
691735|NCT00004407|diabetic neuropathy
691736|NCT00004407|diabetic proximal neuropathy
691737|NCT00004407|neurologic and psychiatric disorders
691738|NCT00004407|rare disease
691739|NCT00004406|disease-related problem/condition
691740|NCT00004406|osteoporosis
691741|NCT00004406|rare disease
691742|NCT00004404|genetic diseases and dysmorphic syndromes
691743|NCT00004404|hematologic disorders
691744|NCT00004404|rare disease
691745|NCT00004404|sickle cell anemia
691746|NCT00004403|cysticercosis
691747|NCT00004403|epilepsy
691748|NCT00004403|immunologic disorders and infectious disorders
691749|NCT00004403|neurologic and psychiatric disorders
691750|NCT00004403|parasitic infection
691751|NCT00004403|rare disease
691752|NCT00004403|seizures
691753|NCT00004402|genetic diseases and dysmorphic syndromes
691754|NCT00004402|osteopetrosis
691755|NCT00004402|rare disease
691756|NCT00004401|bacterial infection
691757|NCT00004401|clostridium infection
691758|NCT00004401|immunologic disorders and infectious disorders
691759|NCT00004401|infant botulism
691760|NCT00004401|rare disease
691761|NCT00004400|cachexia
691762|NCT00004400|disease-related problem/condition
691763|NCT00004400|human immunodeficiency virus infection
691764|NCT00004400|immunologic disorders and infectious disorders
691765|NCT00004400|nutrition
691766|NCT00004400|quality of life
691767|NCT00004400|rare disease
691768|NCT00004400|viral infection
691769|NCT00004399|cardiovascular and respiratory diseases
691770|NCT00004399|hypertensive disorder
691771|NCT00004399|pre-eclampsia
691772|NCT00004399|rare disease
691773|NCT00004398|inborn errors of metabolism
691774|NCT00004398|porphyria
691775|NCT00004398|rare disease
691776|NCT00004397|inborn errors of metabolism
691777|NCT00004397|porphyria
691778|NCT00004397|rare disease
691779|NCT00004396|inborn errors of metabolism
691780|NCT00004396|porphyria
691781|NCT00004396|rare disease
691782|NCT00004393|Tourette syndrome
691783|NCT00004393|neurologic and psychiatric disorders
691784|NCT00004393|rare disease
691785|NCT00004392|apnea
691786|NCT00004392|cardiovascular and respiratory diseases
691787|NCT00004392|neurologic and psychiatric disorders
691788|NCT00004392|rare disease
691789|NCT00004392|sudden infant death syndrome
691790|NCT00004390|disease-related problem/condition
691791|NCT00004390|herpes zoster infection
691792|NCT00004390|herpesvirus infection
691793|NCT00004390|immunologic disorders and infectious disorders
691794|NCT00004390|pain
691795|NCT00004390|rare disease
691796|NCT00004390|viral infection
691797|NCT00004387|Parkinson disease
691798|NCT00004387|neurologic and psychiatric disorders
691799|NCT00004387|rare disease
691800|NCT00004386|inborn errors of metabolism
691801|NCT00004386|rare disease
691802|NCT00004386|urea cycle disorder
691803|NCT00004382|hematologic disorders
691804|NCT00004382|hyperbilirubinemia
691805|NCT00004382|rare disease
691806|NCT00004381|glucose-6-phosphate dehydrogenase deficiency
691807|NCT00004381|hematologic disorders
691808|NCT00004381|hemolytic disease
691809|NCT00004381|hyperbilirubinemia
691810|NCT00004381|neonatal disorders
691811|NCT00004381|rare disease
691812|NCT00004380|arthritis & connective tissue diseases
691813|NCT00004380|rare disease
691814|NCT00004380|systemic sclerosis
691815|NCT00004378|Fanconi's anemia
691816|NCT00004378|amegakaryocytic thrombocytopenia
691817|NCT00004378|aplastic anemia
691818|NCT00004378|congenital pure red cell aplasia
691819|NCT00004378|genetic diseases and dysmorphic syndromes
691820|NCT00004378|hematologic disorders
691821|NCT00004378|inborn errors of metabolism
691822|NCT00004378|metachromatic leukodystrophy
691823|NCT00004378|pure red cell aplasia
691824|NCT00004378|rare disease
691825|NCT00004378|sphingolipidoses
691826|NCT00004378|thalassemia major
691827|NCT00004376|Tourette syndrome
691828|NCT00004376|neurologic and psychiatric disorders
691829|NCT00004376|rare disease
691830|NCT00004375|arthritis & connective tissue diseases
691831|NCT00004375|immunologic disorders and infectious disorders
691832|NCT00004375|rare disease
691833|NCT00004375|systemic lupus erythematosus
691834|NCT00004374|amyloidosis
691835|NCT00004374|arthritis & connective tissue diseases
691836|NCT00004374|genetic diseases and dysmorphic syndromes
691837|NCT00004374|rare disease
691838|NCT00004373|anxiety disorder
691839|NCT00004373|disease-related problem/condition
691840|NCT00004373|neurologic and psychiatric disorders
691841|NCT00004373|panic disorder
691842|NCT00004373|rare disease
691843|NCT00004368|hepatic cirrhosis
691844|NCT00004368|gastrointestinal disorders
691845|NCT00004368|rare disease
691846|NCT00004367|anxiety disorder
691847|NCT00004367|disease-related problem/condition
691848|NCT00004367|neurologic and psychiatric disorders
691849|NCT00004367|panic disorder
691850|NCT00004367|rare disease
691851|NCT00004366|agoraphobia
691852|NCT00004366|anxiety disorder
691853|NCT00004366|disease-related problem/condition
691854|NCT00004366|neurologic and psychiatric disorders
691855|NCT00004366|panic disorder
691856|NCT00004366|rare disease
691857|NCT00004366|vestibular diseases
691858|NCT00004365|endocrine disorders
691859|NCT00004365|growth hormone deficiency
691860|NCT00004365|rare disease
691861|NCT00004364|diabetes insipidus
691862|NCT00004364|endocrine disorders
691863|NCT00004364|rare disease
691864|NCT00004363|diabetes insipidus
691865|NCT00004363|endocrine disorders
691866|NCT00004363|rare disease
691867|NCT00004361|DiGeorge syndrome
691868|NCT00004361|cardiovascular and respiratory diseases
691869|NCT00004361|conotruncal cardiac defects
691870|NCT00004361|endocrine disorders
691871|NCT00004361|genetic diseases and dysmorphic syndromes
691872|NCT00004361|hypoparathyroidism
691873|NCT00004361|pulmonary valve stenosis
691874|NCT00004361|rare disease
691875|NCT00004361|tetralogy of Fallot
691876|NCT00004360|diabetes insipidus
691877|NCT00004360|endocrine disorders
691878|NCT00004360|rare disease
691879|NCT00004359|dermatologic disorders
691880|NCT00004359|epidermolysis bullosa
691881|NCT00004359|genetic diseases and dysmorphic syndromes
691882|NCT00004359|rare disease
691883|NCT00004358|arthritis & connective tissue diseases
691884|NCT00004358|rare disease
691885|NCT00004358|tumoral calcinosis
691886|NCT00004357|Cardiovascular Disease
691887|NCT00004357|Respiratory Disease
691888|NCT00004357|Rare Diseases
691889|NCT00004357|Vasculitis
691890|NCT00004356|homocystinuria
691891|NCT00004356|inborn errors of metabolism
691892|NCT00004356|rare disease
691893|NCT00004354|endocrine disorders
691894|NCT00004354|genetic diseases and dysmorphic syndromes
691895|NCT00004354|hyperaldosteronism
691896|NCT00004354|rare disease
691897|NCT00004353|MELAS syndrome
691898|NCT00004353|inborn errors of metabolism
691899|NCT00004353|lactic acidosis
691900|NCT00004353|mitochondrial myopathy
691901|NCT00004353|rare disease
691902|NCT00004351|Angelman syndrome
691903|NCT00004351|DiGeorge syndrome
691904|NCT00004351|Prader-Willi syndrome
691905|NCT00004351|Shprintzen syndrome
691906|NCT00004351|Smith-Magenis syndrome
691907|NCT00004351|Williams syndrome
691908|NCT00004351|genetic diseases and dysmorphic syndromes
691909|NCT00004351|neurologic and psychiatric disorders
691910|NCT00004351|rare disease
691911|NCT00004350|Fanconi syndrome
691912|NCT00004350|cystinosis
691913|NCT00004350|rare disease
691914|NCT00004350|renal and genitourinary disorders
691915|NCT00004348|beta-oxidation disorder
691916|NCT00004348|inborn errors of metabolism
691917|NCT00004348|rare disease
691918|NCT00004347|Smith-Lemli-Opitz syndrome
691919|NCT00004347|genetic diseases and dysmorphic syndromes
691920|NCT00004347|rare disease
691921|NCT00004346|cerebrotendinous xanthomatosis
691922|NCT00004346|inborn errors of metabolism
691923|NCT00004346|rare disease
691924|NCT00004345|Usher syndrome
691925|NCT00004345|ophthalmologic disorders
691926|NCT00004345|rare disease
691927|NCT00004345|retinitis pigmentosa
691928|NCT00004344|endocrine disorders
691929|NCT00004344|precocious puberty
691930|NCT00004344|rare disease
691931|NCT00004343|Cushing's syndrome
691932|NCT00004343|endocrine disorders
691933|NCT00004343|rare disease
691934|NCT00004342|chronic neutropenia
691935|NCT00004342|disease-related problem/condition
691936|NCT00004342|hematologic disorders
691937|NCT00004342|neutropenia
691938|NCT00004342|rare disease
691939|NCT00004342|severe chronic neutropenia
691940|NCT00004341|Wiskott-Aldrich syndrome
691941|NCT00004341|X-linked agammaglobulinemia
691942|NCT00004341|X-linked hyper IgM syndrome
691943|NCT00004341|genetic diseases and dysmorphic syndromes
691944|NCT00004341|immunologic disorders and infectious disorders
691945|NCT00004341|leukocyte adhesion deficiency syndrome
691946|NCT00004341|primary immunodeficiency disease
691947|NCT00004341|rare disease
691948|NCT00004340|end stage renal disease
691949|NCT00004340|rare disease
691950|NCT00004340|renal and genitourinary disorders
691951|NCT00004340|renal osteodystrophy
691952|NCT00004339|Wilson disease
691953|NCT00004339|inborn errors of metabolism
691954|NCT00004339|rare disease
691955|NCT00004338|Wilson disease
691956|NCT00004338|inborn errors of metabolism
691957|NCT00004338|rare disease
691958|NCT00004336|Mondini dysplasia
691959|NCT00004336|genetic diseases and dysmorphic syndromes
691960|NCT00004336|rare disease
691961|NCT00004335|endocrine disorders
691962|NCT00004335|growth hormone deficiency
691963|NCT00004335|hypogonadism
691964|NCT00004335|precocious puberty
691965|NCT00004335|rare disease
691966|NCT00004334|Cushing's syndrome
691967|NCT00004334|endocrine disorders
691968|NCT00004334|rare disease
691969|NCT00004333|inborn errors of metabolism
691970|NCT00004333|rare disease
691971|NCT00004333|tyrosinemia I
691972|NCT00004332|acromegaly
691973|NCT00004332|endocrine disorders
691974|NCT00004332|rare disease
691975|NCT00004331|inborn errors of metabolism
691976|NCT00004331|porphyria
691977|NCT00004331|rare disease
691978|NCT00004330|inborn errors of metabolism
691979|NCT00004330|porphyria
691980|NCT00004330|rare disease
691981|NCT00004329|endocrine disorders
691982|NCT00004329|rare disease
691983|NCT00004328|endocrine disorders
691984|NCT00004328|pseudohypoaldosteronism
691985|NCT00004328|rare disease
691986|NCT00004327|genetic diseases and dysmorphic syndromes
691987|NCT00004327|hematologic disorders
691988|NCT00004327|hereditary hemorrhagic telangiectasia
691989|NCT00004327|rare disease
691990|NCT00004327|senile ectasia
691991|NCT00004326|Cushing's syndrome
691992|NCT00004326|endocrine disorders
691993|NCT00004326|rare disease
691994|NCT00004325|Tourette syndrome
691995|NCT00004325|anxiety disorder
691996|NCT00004325|disease-related problem/condition
691997|NCT00004325|neurologic and psychiatric disorders
691998|NCT00004325|obsessive compulsive disorder
691999|NCT00004325|oncologic disorders
692000|NCT00004325|rare disease
692001|NCT00004324|Tourette syndrome
692002|NCT00004324|anxiety disorder
692003|NCT00004324|disease-related problem/condition
692004|NCT00004324|neurologic and psychiatric disorders
692005|NCT00004324|obsessive compulsive disorder
692006|NCT00004324|oncologic disorders
692007|NCT00004324|rare disease
692008|NCT00004323|aplastic anemia
692009|NCT00004323|hematologic disorders
692010|NCT00004323|rare disease
692011|NCT00004317|immunologic disorders and infectious disorders
692012|NCT00004317|rare disease
692013|NCT00004317|toxoplasmosis
692014|NCT00004316|interstitial cystitis
692015|NCT00004316|rare disease
692016|NCT00004316|renal and genitourinary disorders
692017|NCT00004316|vulvar vestibulitis
692018|NCT00004315|cardiovascular and respiratory diseases
692019|NCT00004315|cholestasis
692020|NCT00004315|cystic fibrosis
692021|NCT00004315|gastrointestinal disorders
692022|NCT00004315|genetic diseases and dysmorphic syndromes
692023|NCT00004315|rare disease
692024|NCT00004314|Lesch-Nyhan syndrome
692025|NCT00004314|inborn errors of metabolism
692026|NCT00004314|neurologic and psychiatric disorders
692027|NCT00004314|rare disease
692028|NCT00004313|Addison's disease
692029|NCT00004313|endocrine disorders
692030|NCT00004313|rare disease
692031|NCT00004313|primary adrenal insufficiency
692032|NCT00004312|cystinosis
692033|NCT00004312|rare disease
692034|NCT00004312|renal and genitourinary disorders
692035|NCT00004311|acanthosis nigricans
692036|NCT00004311|dermatologic disorders
692037|NCT00004311|endocrine disorders
692038|NCT00004311|polycystic ovarian syndrome
692039|NCT00004311|rare disease
692040|NCT00004310|anxiety disorder
692041|NCT00004310|disease-related problem/condition
692042|NCT00004310|neurologic and psychiatric disorders
692043|NCT00004310|obsessive compulsive disorder
692044|NCT00004310|oncologic disorders
692045|NCT00004310|rare disease
692046|NCT00004307|inborn errors of metabolism
692047|NCT00004307|rare disease
692048|NCT00004307|urea cycle disorder
692049|NCT00004306|hereditary ataxia
692050|NCT00004306|neurologic and psychiatric disorders
692051|NCT00004306|rare disease
692052|NCT00004305|IgA glomerulonephritis
692053|NCT00004305|rare disease
692054|NCT00004305|renal and genitourinary disorders
692055|NCT00004300|mental retardation
692056|NCT00004300|neurologic and psychiatric disorders
692057|NCT00004300|rare disease
692058|NCT00004300|stereotyped behavior
692059|NCT00004297|epilepsy
692060|NCT00004297|neurologic and psychiatric disorders
692061|NCT00004297|rare disease
692062|NCT00004297|seizures
692063|NCT00004297|status epilepticus
692064|NCT00004296|atypical mycobacterium infection
692065|NCT00004296|bacterial infection
692066|NCT00004296|cardiovascular and respiratory diseases
692067|NCT00004296|cystic fibrosis
692068|NCT00004296|genetic diseases and dysmorphic syndromes
692069|NCT00004296|immunologic disorders and infectious disorders
692070|NCT00004296|mycobacterium infection
692071|NCT00004296|rare disease
692072|NCT00004294|Gaucher's disease
692073|NCT00004294|inborn errors of metabolism
692074|NCT00004294|rare disease
692075|NCT00004294|sphingolipidoses
692076|NCT00004293|Gaucher's disease
692077|NCT00004293|inborn errors of metabolism
692078|NCT00004293|rare disease
692079|NCT00004293|sphingolipidoses
692080|NCT00004288|ankylosing spondylitis
692081|NCT00004288|genetic diseases and dysmorphic syndromes
692082|NCT00004288|rare disease
692083|NCT00004287|cardiovascular and respiratory diseases
692084|NCT00004287|cystic fibrosis
692085|NCT00004287|genetic diseases and dysmorphic syndromes
692086|NCT00004287|rare disease
692087|NCT00004286|demyelinating neuropathy
692088|NCT00004286|neurologic and psychiatric disorders
692089|NCT00004286|rare disease
692090|NCT00004285|end stage renal disease
692091|NCT00004285|rare disease
692092|NCT00004285|renal and genitourinary disorders
692093|NCT00004284|hypercalciuria
692094|NCT00004284|nephrolithiasis
692095|NCT00004284|rare disease
692096|NCT00004284|renal and genitourinary disorders
692097|NCT00004278|congenital cytomegalovirus infection
692098|NCT00004278|cytomegalovirus infection
692099|NCT00004278|herpesvirus infection
692100|NCT00004278|immunologic disorders and infectious disorders
692101|NCT00004278|neonatal disorders
692102|NCT00004278|rare disease
692103|NCT00004278|viral infection
692104|NCT00004276|bacterial infection
692105|NCT00004276|human immunodeficiency virus infection
692106|NCT00004276|immunologic disorders and infectious disorders
692107|NCT00004276|mycobacterium infection
692108|NCT00004276|mycobacterium tuberculosis infection
692109|NCT00004276|rare disease
692110|NCT00004276|viral infection
692111|NCT00004275|Turner's syndrome
692112|NCT00004275|genetic diseases and dysmorphic syndromes
692113|NCT00004275|rare disease
692114|NCT00004274|Turner's syndrome
692115|NCT00004274|genetic diseases and dysmorphic syndromes
692116|NCT00004274|rare disease
692117|NCT00004268|cardiovascular and respiratory diseases
692118|NCT00004268|disease-related problem/condition
692119|NCT00004268|orthostatic hypotension
692120|NCT00004268|quality of life
692121|NCT00004268|rare disease
692122|NCT00004266|diabetic nephropathy
692123|NCT00004266|rare disease
692124|NCT00004266|renal and genitourinary disorders
692125|NCT00004265|recurrent non-small cell lung cancer
692126|NCT00004264|recurrent non-small cell lung cancer
692127|NCT00004264|stage IV non-small cell lung cancer
692128|NCT00004264|drug/agent toxicity by tissue/organ
692129|NCT00004263|recurrent adult acute myeloid leukemia
692130|NCT00004263|refractory anemia with excess blasts
692131|NCT00004263|refractory anemia with excess blasts in transformation
692132|NCT00004263|previously treated myelodysplastic syndromes
692133|NCT00004263|childhood myelodysplastic syndromes
692134|NCT00004263|Ara-C
692135|NCT00004263|Cytosar
692136|NCT00004263|DepoCyt
692137|NCT00004263|Cytosine arabinosine hydrochloride
692138|NCT00004263|cytarabine
692139|NCT00004263|7-hydroxystaurosporine
692140|NCT00004263|UCN-01
692141|NCT00004261|stage I breast cancer
692142|NCT00004261|stage II breast cancer
692143|NCT00004261|stage IV breast cancer
692144|NCT00004261|stage IIIA breast cancer
692145|NCT00004261|breast cancer in situ
692146|NCT00004261|recurrent breast cancer
692147|NCT00004261|stage IIIB breast cancer
692148|NCT00004261|stage 0 cervical cancer
692149|NCT00004261|stage III cervical cancer
692150|NCT00004261|recurrent cervical cancer
692151|NCT00004261|stage IB cervical cancer
692152|NCT00004261|stage IIB cervical cancer
692153|NCT00004261|stage IVB cervical cancer
692154|NCT00004261|stage IA cervical cancer
692155|NCT00004261|stage IIA cervical cancer
692156|NCT00004261|stage IVA cervical cancer
692157|NCT00004261|inflammatory breast cancer
692158|NCT00004261|stage III adult soft tissue sarcoma
692159|NCT00004261|recurrent adult soft tissue sarcoma
692160|NCT00004261|stage I prostate cancer
692161|NCT00004261|stage IIB prostate cancer
692162|NCT00004261|stage IIA prostate cancer
692163|NCT00004261|stage III prostate cancer
692164|NCT00004261|stage IV prostate cancer
692165|NCT00004261|recurrent prostate cancer
692166|NCT00004261|stage I nasopharyngeal cancer
692167|NCT00004261|stage II nasopharyngeal cancer
692168|NCT00004261|stage III nasopharyngeal cancer
692169|NCT00004261|stage IV nasopharyngeal cancer
692170|NCT00004261|recurrent nasopharyngeal cancer
692171|NCT00004261|stage 0 paranasal sinus and nasal cavity cancer
692172|NCT00004261|stage 0 nasopharyngeal cancer
692173|NCT00004261|stage 0 oropharyngeal cancer
692174|NCT00004261|stage 0 laryngeal cancer
692175|NCT00004261|stage 0 hypopharyngeal cancer
692176|NCT00004261|stage I salivary gland cancer
692177|NCT00004261|stage II salivary gland cancer
692178|NCT00004261|stage III salivary gland cancer
692179|NCT00004261|stage IV salivary gland cancer
692180|NCT00004261|recurrent salivary gland cancer
692181|NCT00004261|untreated metastatic squamous neck cancer with occult primary
692182|NCT00004261|recurrent metastatic squamous neck cancer with occult primary
692183|NCT00004261|stage 0 lip and oral cavity cancer
692184|NCT00004261|stage IV adult soft tissue sarcoma
692185|NCT00004261|stage I lip and oral cavity cancer
692186|NCT00004261|stage II lip and oral cavity cancer
692187|NCT00004261|stage III lip and oral cavity cancer
692188|NCT00004261|stage IV lip and oral cavity cancer
692189|NCT00004261|recurrent lip and oral cavity cancer
692190|NCT00004261|stage I hypopharyngeal cancer
692191|NCT00004261|stage II hypopharyngeal cancer
692192|NCT00004261|stage III hypopharyngeal cancer
692193|NCT00004261|stage IV hypopharyngeal cancer
692194|NCT00004261|recurrent hypopharyngeal cancer
692195|NCT00004261|stage I laryngeal cancer
692196|NCT00004261|stage II laryngeal cancer
692197|NCT00004261|stage III laryngeal cancer
692198|NCT00004261|stage IV laryngeal cancer
692199|NCT00004261|recurrent laryngeal cancer
692200|NCT00004261|stage I paranasal sinus and nasal cavity cancer
692201|NCT00004261|stage II paranasal sinus and nasal cavity cancer
692202|NCT00004261|stage III paranasal sinus and nasal cavity cancer
692203|NCT00004261|stage IV paranasal sinus and nasal cavity cancer
692204|NCT00004261|recurrent paranasal sinus and nasal cavity cancer
692205|NCT00004261|stage I oropharyngeal cancer
692206|NCT00004261|stage II oropharyngeal cancer
692207|NCT00004261|stage III oropharyngeal cancer
692208|NCT00004261|stage IV oropharyngeal cancer
692209|NCT00004261|recurrent oropharyngeal cancer
692210|NCT00004261|stage II adult soft tissue sarcoma
692211|NCT00004261|stage I adult soft tissue sarcoma
692212|NCT00004260|stage I grade 1 follicular lymphoma
692213|NCT00004260|stage I grade 2 follicular lymphoma
692214|NCT00004260|stage I grade 3 follicular lymphoma
692215|NCT00004260|stage I adult diffuse small cleaved cell lymphoma
692216|NCT00004260|stage I adult diffuse mixed cell lymphoma
692217|NCT00004260|stage I adult diffuse large cell lymphoma
692218|NCT00004260|stage I adult immunoblastic large cell lymphoma
692219|NCT00004260|stage I adult lymphoblastic lymphoma
692220|NCT00004260|stage I adult Burkitt lymphoma
692221|NCT00004260|stage III grade 1 follicular lymphoma
692222|NCT00004260|stage III grade 2 follicular lymphoma
692223|NCT00004260|stage III grade 3 follicular lymphoma
692224|NCT00004260|stage III adult diffuse small cleaved cell lymphoma
692225|NCT00004260|stage III adult diffuse mixed cell lymphoma
692226|NCT00004260|stage III adult diffuse large cell lymphoma
692227|NCT00004260|stage III adult immunoblastic large cell lymphoma
692228|NCT00004260|stage III adult lymphoblastic lymphoma
692229|NCT00004260|stage III adult Burkitt lymphoma
692230|NCT00004260|stage IV grade 1 follicular lymphoma
692231|NCT00004260|stage IV grade 2 follicular lymphoma
692232|NCT00004260|stage IV grade 3 follicular lymphoma
692233|NCT00004260|stage IV adult diffuse small cleaved cell lymphoma
692234|NCT00004260|stage IV adult diffuse mixed cell lymphoma
692235|NCT00004260|stage IV adult diffuse large cell lymphoma
692236|NCT00004260|stage IV adult immunoblastic large cell lymphoma
692237|NCT00004260|stage IV adult lymphoblastic lymphoma
692238|NCT00004260|stage IV adult Burkitt lymphoma
692239|NCT00004260|recurrent grade 1 follicular lymphoma
692240|NCT00004260|recurrent grade 2 follicular lymphoma
692241|NCT00004260|recurrent grade 3 follicular lymphoma
692242|NCT00004260|recurrent adult diffuse small cleaved cell lymphoma
692243|NCT00004260|recurrent adult diffuse mixed cell lymphoma
692244|NCT00004260|recurrent adult diffuse large cell lymphoma
692245|NCT00004260|recurrent adult immunoblastic large cell lymphoma
692246|NCT00004260|recurrent adult lymphoblastic lymphoma
692247|NCT00004260|recurrent adult Burkitt lymphoma
692248|NCT00004260|stage I mantle cell lymphoma
692249|NCT00004260|contiguous stage II grade 1 follicular lymphoma
692250|NCT00004260|contiguous stage II grade 2 follicular lymphoma
692251|NCT00004260|contiguous stage II grade 3 follicular lymphoma
692252|NCT00004260|contiguous stage II adult diffuse small cleaved cell lymphoma
692253|NCT00004260|contiguous stage II mantle cell lymphoma
692254|NCT00004260|contiguous stage II adult diffuse mixed cell lymphoma
692255|NCT00004260|contiguous stage II adult immunoblastic large cell lymphoma
692256|NCT00004260|contiguous stage II adult diffuse large cell lymphoma
692257|NCT00004260|contiguous stage II adult Burkitt lymphoma
692258|NCT00004260|contiguous stage II adult lymphoblastic lymphoma
692259|NCT00004260|noncontiguous stage II grade 1 follicular lymphoma
692260|NCT00004260|noncontiguous stage II grade 2 follicular lymphoma
692261|NCT00004260|noncontiguous stage II grade 3 follicular lymphoma
692262|NCT00004260|noncontiguous stage II adult diffuse small cleaved cell lymphoma
692263|NCT00004260|noncontiguous stage II mantle cell lymphoma
692264|NCT00004260|noncontiguous stage II adult diffuse mixed cell lymphoma
692265|NCT00004260|noncontiguous stage II adult immunoblastic large cell lymphoma
692266|NCT00004260|noncontiguous stage II adult diffuse large cell lymphoma
692267|NCT00004260|noncontiguous stage II adult Burkitt lymphoma
692268|NCT00004260|noncontiguous stage II adult lymphoblastic lymphoma
692269|NCT00004260|stage III mantle cell lymphoma
692270|NCT00004260|stage IV mantle cell lymphoma
692271|NCT00004260|recurrent mantle cell lymphoma
692272|NCT00004260|noncontiguous stage II small lymphocytic lymphoma
692273|NCT00004260|noncontiguous stage II marginal zone lymphoma
692274|NCT00004260|recurrent marginal zone lymphoma
692275|NCT00004260|recurrent small lymphocytic lymphoma
692276|NCT00004260|stage I marginal zone lymphoma
692277|NCT00004260|stage I small lymphocytic lymphoma
692278|NCT00004260|stage III small lymphocytic lymphoma
692279|NCT00004260|stage III marginal zone lymphoma
692280|NCT00004260|stage IV small lymphocytic lymphoma
692281|NCT00004260|stage IV marginal zone lymphoma
692282|NCT00004260|contiguous stage II marginal zone lymphoma
692283|NCT00004260|contiguous stage II small lymphocytic lymphoma
692284|NCT00004260|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
692285|NCT00004260|nodal marginal zone B-cell lymphoma
692286|NCT00004260|splenic marginal zone lymphoma
692287|NCT00004259|adult anaplastic astrocytoma
692288|NCT00004259|adult mixed glioma
692289|NCT00004258|stage III adult Hodgkin lymphoma
692290|NCT00004258|stage IV adult Hodgkin lymphoma
692291|NCT00004258|monoclonal gammopathy of undetermined significance
692292|NCT00004258|recurrent adult Hodgkin lymphoma
692293|NCT00004258|stage I cutaneous T-cell non-Hodgkin lymphoma
692294|NCT00004258|stage II cutaneous T-cell non-Hodgkin lymphoma
692295|NCT00004258|stage III cutaneous T-cell non-Hodgkin lymphoma
692296|NCT00004258|stage IV cutaneous T-cell non-Hodgkin lymphoma
692297|NCT00004258|recurrent cutaneous T-cell non-Hodgkin lymphoma
692298|NCT00004258|isolated plasmacytoma of bone
692299|NCT00004258|extramedullary plasmacytoma
692300|NCT00004258|refractory multiple myeloma
692301|NCT00004258|Waldenstrom macroglobulinemia
692302|NCT00004258|stage III multiple myeloma
692303|NCT00004258|stage III chronic lymphocytic leukemia
692304|NCT00004258|stage IV chronic lymphocytic leukemia
692305|NCT00004258|recurrent adult acute myeloid leukemia
692306|NCT00004258|recurrent adult acute lymphoblastic leukemia
692307|NCT00004258|relapsing chronic myelogenous leukemia
692308|NCT00004258|refractory chronic lymphocytic leukemia
692309|NCT00004258|small intestine lymphoma
692310|NCT00004258|unspecified adult solid tumor, protocol specific
692311|NCT00004258|chronic phase chronic myelogenous leukemia
692312|NCT00004258|blastic phase chronic myelogenous leukemia
692313|NCT00004258|meningeal chronic myelogenous leukemia
692314|NCT00004258|untreated adult acute lymphoblastic leukemia
692315|NCT00004258|untreated adult acute myeloid leukemia
692316|NCT00004258|polycythemia vera
692317|NCT00004258|essential thrombocythemia
692318|NCT00004258|untreated hairy cell leukemia
692319|NCT00004258|progressive hairy cell leukemia, initial treatment
692320|NCT00004258|refractory hairy cell leukemia
692321|NCT00004258|chronic myelomonocytic leukemia
692322|NCT00004258|T-cell large granular lymphocyte leukemia
692323|NCT00004258|stage III grade 1 follicular lymphoma
692324|NCT00004258|stage III grade 2 follicular lymphoma
692325|NCT00004258|stage III grade 3 follicular lymphoma
692326|NCT00004258|stage III adult diffuse small cleaved cell lymphoma
692327|NCT00004258|stage III adult diffuse mixed cell lymphoma
692328|NCT00004258|stage III adult diffuse large cell lymphoma
692329|NCT00004258|stage III adult immunoblastic large cell lymphoma
692330|NCT00004258|stage III adult lymphoblastic lymphoma
692331|NCT00004258|stage III adult Burkitt lymphoma
692332|NCT00004258|stage IV grade 1 follicular lymphoma
692333|NCT00004258|stage IV grade 2 follicular lymphoma
692334|NCT00004258|stage IV grade 3 follicular lymphoma
692335|NCT00004258|stage IV adult diffuse small cleaved cell lymphoma
692336|NCT00004258|stage IV adult diffuse mixed cell lymphoma
692337|NCT00004258|stage IV adult diffuse large cell lymphoma
692338|NCT00004258|stage IV adult immunoblastic large cell lymphoma
692339|NCT00004258|stage IV adult lymphoblastic lymphoma
692340|NCT00004258|stage IV adult Burkitt lymphoma
692341|NCT00004258|recurrent grade 1 follicular lymphoma
692342|NCT00004258|recurrent grade 2 follicular lymphoma
692343|NCT00004258|recurrent grade 3 follicular lymphoma
692344|NCT00004258|recurrent adult diffuse small cleaved cell lymphoma
692345|NCT00004258|recurrent adult diffuse mixed cell lymphoma
692346|NCT00004258|recurrent adult diffuse large cell lymphoma
692347|NCT00004258|recurrent adult immunoblastic large cell lymphoma
692348|NCT00004258|recurrent adult lymphoblastic lymphoma
692349|NCT00004258|recurrent adult Burkitt lymphoma
692350|NCT00004258|stage III adult T-cell leukemia/lymphoma
692351|NCT00004258|stage IV adult T-cell leukemia/lymphoma
692352|NCT00004258|recurrent adult T-cell leukemia/lymphoma
692353|NCT00004258|secondary acute myeloid leukemia
692354|NCT00004258|de novo myelodysplastic syndromes
692355|NCT00004258|previously treated myelodysplastic syndromes
692356|NCT00004258|secondary myelodysplastic syndromes
692357|NCT00004258|prolymphocytic leukemia
692358|NCT00004258|primary systemic amyloidosis
692359|NCT00004258|stage III mantle cell lymphoma
692360|NCT00004258|stage IV mantle cell lymphoma
692361|NCT00004258|recurrent mantle cell lymphoma
692362|NCT00004258|angioimmunoblastic T-cell lymphoma
692363|NCT00004258|chronic idiopathic myelofibrosis
692364|NCT00004258|recurrent marginal zone lymphoma
692365|NCT00004258|recurrent small lymphocytic lymphoma
692366|NCT00004258|stage III small lymphocytic lymphoma
692367|NCT00004258|stage III marginal zone lymphoma
692368|NCT00004258|stage IV small lymphocytic lymphoma
692369|NCT00004258|stage IV marginal zone lymphoma
692370|NCT00004258|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
692371|NCT00004258|nodal marginal zone B-cell lymphoma
692372|NCT00004258|splenic marginal zone lymphoma
692373|NCT00004257|stage I esophageal cancer
692374|NCT00004257|stage II esophageal cancer
692375|NCT00004257|stage III esophageal cancer
692376|NCT00004257|squamous cell carcinoma of the esophagus
692377|NCT00004257|adenocarcinoma of the esophagus
692378|NCT00004256|stage I laryngeal cancer
692379|NCT00004256|stage II laryngeal cancer
692380|NCT00004256|recurrent laryngeal cancer
692381|NCT00004256|oral complications
692382|NCT00004256|radiation toxicity
692383|NCT00004255|recurrent childhood acute lymphoblastic leukemia
692384|NCT00004255|recurrent childhood acute myeloid leukemia
692385|NCT00004255|recurrent adult acute myeloid leukemia
692386|NCT00004255|recurrent adult acute lymphoblastic leukemia
692387|NCT00004255|chronic phase chronic myelogenous leukemia
692388|NCT00004255|accelerated phase chronic myelogenous leukemia
692389|NCT00004255|adult acute myeloid leukemia in remission
692390|NCT00004255|adult acute lymphoblastic leukemia in remission
692391|NCT00004255|childhood acute myeloid leukemia in remission
692392|NCT00004255|childhood acute lymphoblastic leukemia in remission
692393|NCT00004255|refractory anemia with excess blasts
692394|NCT00004255|refractory anemia with excess blasts in transformation
692395|NCT00004255|secondary acute myeloid leukemia
692396|NCT00004255|de novo myelodysplastic syndromes
692397|NCT00004255|previously treated myelodysplastic syndromes
692398|NCT00004255|secondary myelodysplastic syndromes
692399|NCT00004255|graft versus host disease
692400|NCT00004255|childhood myelodysplastic syndromes
692401|NCT00004254|localized malignant mesothelioma
692402|NCT00004254|advanced malignant mesothelioma
692403|NCT00004254|recurrent malignant mesothelioma
692404|NCT00004253|stage II non-small cell lung cancer
692405|NCT00004253|stage IIIA non-small cell lung cancer
692406|NCT00004253|stage IIIB non-small cell lung cancer
692407|NCT00004252|stage IV colon cancer
692408|NCT00004252|stage IV rectal cancer
692409|NCT00004252|recurrent colon cancer
692410|NCT00004252|recurrent rectal cancer
692411|NCT00004252|adenocarcinoma of the colon
692412|NCT00004251|stage IV endometrial carcinoma
692413|NCT00004251|recurrent endometrial carcinoma
692414|NCT00004251|endometrial adenocarcinoma
692415|NCT00004251|endometrial adenosquamous cell carcinoma
692416|NCT00004250|stage III adult soft tissue sarcoma
692417|NCT00004250|recurrent adult soft tissue sarcoma
692418|NCT00004250|stage III melanoma
692419|NCT00004250|stage IV melanoma
692420|NCT00004250|recurrent melanoma
692421|NCT00004250|stage IV adult soft tissue sarcoma
692422|NCT00004249|limited stage small cell lung cancer
692423|NCT00004248|localized unresectable adult primary liver cancer
692424|NCT00004248|recurrent adult primary liver cancer
692425|NCT00004248|adult primary hepatocellular carcinoma
692426|NCT00004246|Radiation Therapy
692427|NCT00004246|RT
692428|NCT00004246|Radiotherapy
692429|NCT00004246|Fludarabine
692430|NCT00004246|Fludara
692431|NCT00004246|Fludarabine Phosphate
692432|NCT00004246|stage III squamous cell carcinoma of the lip and oral cavity
692433|NCT00004246|stage IV squamous cell carcinoma of the lip and oral cavity
692434|NCT00004246|stage III squamous cell carcinoma of the oropharynx
692435|NCT00004246|stage IV squamous cell carcinoma of the oropharynx
692436|NCT00004246|stage III squamous cell carcinoma of the nasopharynx
692437|NCT00004246|stage IV squamous cell carcinoma of the nasopharynx
692438|NCT00004246|stage III squamous cell carcinoma of the hypopharynx
692439|NCT00004246|stage IV squamous cell carcinoma of the hypopharynx
692901|NCT00004215|thrombocytopenia
692440|NCT00004246|stage III squamous cell carcinoma of the larynx
692441|NCT00004246|stage IV squamous cell carcinoma of the larynx
692442|NCT00004245|recurrent adult acute myeloid leukemia
692443|NCT00004245|refractory chronic lymphocytic leukemia
692444|NCT00004245|untreated adult acute myeloid leukemia
692445|NCT00004245|refractory anemia with excess blasts
692446|NCT00004245|refractory anemia with excess blasts in transformation
692447|NCT00004245|chronic myelomonocytic leukemia
692448|NCT00004245|previously treated myelodysplastic syndromes
692449|NCT00004245|atypical chronic myeloid leukemia, BCR-ABL1 negative
692450|NCT00004245|myelodysplastic/myeloproliferative neoplasm, unclassifiable
692451|NCT00004245|adult acute myeloid leukemia with t(8;21)(q22;q22)
692452|NCT00004245|adult acute myeloid leukemia with t(16;16)(p13;q22)
692453|NCT00004245|adult acute myeloid leukemia with inv(16)(p13;q22)
692454|NCT00004245|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
692455|NCT00004245|adult acute myeloid leukemia with t(15;17)(q22;q12)
692456|NCT00004244|stage IV renal cell cancer
692457|NCT00004244|recurrent renal cell cancer
692458|NCT00004244|stage IV melanoma
692459|NCT00004244|recurrent melanoma
692460|NCT00004243|unspecified adult solid tumor, protocol specific
692461|NCT00004242|unspecified adult solid tumor, protocol specific
692462|NCT00004239|recurrent adult Hodgkin lymphoma
692463|NCT00004239|recurrent cutaneous T-cell non-Hodgkin lymphoma
692464|NCT00004239|refractory multiple myeloma
692465|NCT00004239|Waldenstrom macroglobulinemia
692466|NCT00004239|stage III multiple myeloma
692467|NCT00004239|recurrent adult acute myeloid leukemia
692468|NCT00004239|recurrent adult acute lymphoblastic leukemia
692469|NCT00004239|relapsing chronic myelogenous leukemia
692470|NCT00004239|refractory chronic lymphocytic leukemia
692471|NCT00004239|polycythemia vera
692472|NCT00004239|primary myelofibrosis
692473|NCT00004239|essential thrombocythemia
692474|NCT00004239|refractory hairy cell leukemia
692475|NCT00004239|chronic myelomonocytic leukemia
692476|NCT00004239|recurrent grade 1 follicular lymphoma
692477|NCT00004239|recurrent grade 2 follicular lymphoma
692478|NCT00004239|recurrent grade 3 follicular lymphoma
692479|NCT00004239|recurrent adult diffuse small cleaved cell lymphoma
692480|NCT00004239|recurrent adult diffuse mixed cell lymphoma
692481|NCT00004239|recurrent adult diffuse large cell lymphoma
692482|NCT00004239|recurrent adult immunoblastic large cell lymphoma
692483|NCT00004239|recurrent adult lymphoblastic lymphoma
692484|NCT00004239|recurrent adult Burkitt lymphoma
692485|NCT00004239|recurrent adult T-cell leukemia/lymphoma
692486|NCT00004239|previously treated myelodysplastic syndromes
692487|NCT00004239|prolymphocytic leukemia
692488|NCT00004239|primary systemic amyloidosis
692489|NCT00004239|recurrent mantle cell lymphoma
692490|NCT00004239|anaplastic large cell lymphoma
692491|NCT00004239|recurrent mycosis fungoides/Sezary syndrome
692492|NCT00004239|recurrent marginal zone lymphoma
692493|NCT00004239|recurrent small lymphocytic lymphoma
692494|NCT00004239|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
692495|NCT00004239|nodal marginal zone B-cell lymphoma
692496|NCT00004239|splenic marginal zone lymphoma
692497|NCT00004238|recurrent non-small cell lung cancer
692498|NCT00004238|stage IIIB non-small cell lung cancer
692499|NCT00004238|stage IV non-small cell lung cancer
692500|NCT00004237|stage I breast cancer
692501|NCT00004237|stage II breast cancer
692502|NCT00004236|stage III gastric cancer
692503|NCT00004236|stage IV gastric cancer
692504|NCT00004236|recurrent gastric cancer
692505|NCT00004236|stage III esophageal cancer
692506|NCT00004236|stage IV esophageal cancer
692507|NCT00004236|recurrent esophageal cancer
692508|NCT00004236|adenocarcinoma of the stomach
692509|NCT00004236|adenocarcinoma of the esophagus
692510|NCT00004235|stage IV gastric cancer
692511|NCT00004235|recurrent gastric cancer
692512|NCT00004235|stage II esophageal cancer
692513|NCT00004235|stage III esophageal cancer
692514|NCT00004235|stage IV esophageal cancer
692515|NCT00004235|recurrent esophageal cancer
692516|NCT00004235|adenocarcinoma of the stomach
692517|NCT00004235|adenocarcinoma of the esophagus
692518|NCT00004234|oral complications
692519|NCT00004234|stage I squamous cell carcinoma of the lip and oral cavity
692520|NCT00004234|stage II squamous cell carcinoma of the lip and oral cavity
692521|NCT00004234|stage III squamous cell carcinoma of the lip and oral cavity
692522|NCT00004234|stage IV squamous cell carcinoma of the lip and oral cavity
692523|NCT00004234|recurrent squamous cell carcinoma of the lip and oral cavity
692524|NCT00004234|stage I squamous cell carcinoma of the oropharynx
692525|NCT00004234|stage II squamous cell carcinoma of the oropharynx
692526|NCT00004234|stage III squamous cell carcinoma of the oropharynx
692527|NCT00004234|stage IV squamous cell carcinoma of the oropharynx
692528|NCT00004234|recurrent squamous cell carcinoma of the oropharynx
692529|NCT00004234|stage I squamous cell carcinoma of the nasopharynx
692530|NCT00004234|stage II squamous cell carcinoma of the nasopharynx
692531|NCT00004234|stage III squamous cell carcinoma of the nasopharynx
692532|NCT00004234|stage IV squamous cell carcinoma of the nasopharynx
692533|NCT00004234|recurrent squamous cell carcinoma of the nasopharynx
692534|NCT00004234|stage I squamous cell carcinoma of the hypopharynx
692535|NCT00004234|stage II squamous cell carcinoma of the hypopharynx
692536|NCT00004234|stage III squamous cell carcinoma of the hypopharynx
692537|NCT00004234|stage IV squamous cell carcinoma of the hypopharynx
692538|NCT00004234|recurrent squamous cell carcinoma of the hypopharynx
692539|NCT00004234|stage I squamous cell carcinoma of the larynx
692540|NCT00004234|stage II squamous cell carcinoma of the larynx
692541|NCT00004234|stage III squamous cell carcinoma of the larynx
692542|NCT00004234|stage IV squamous cell carcinoma of the larynx
692543|NCT00004234|recurrent squamous cell carcinoma of the larynx
692544|NCT00004233|stage III gastric cancer
692545|NCT00004233|stage IV gastric cancer
692546|NCT00004233|recurrent gastric cancer
692547|NCT00004233|stage III esophageal cancer
692548|NCT00004233|stage IV esophageal cancer
692549|NCT00004233|recurrent esophageal cancer
692550|NCT00004233|adenocarcinoma of the stomach
692551|NCT00004233|adenocarcinoma of the esophagus
692552|NCT00004232|stage I adult Hodgkin lymphoma
692553|NCT00004232|stage II adult Hodgkin lymphoma
692554|NCT00004232|stage III adult Hodgkin lymphoma
692555|NCT00004232|stage IV adult Hodgkin lymphoma
692556|NCT00004232|monoclonal gammopathy of undetermined significance
692557|NCT00004232|recurrent childhood acute lymphoblastic leukemia
692558|NCT00004232|recurrent adult Hodgkin lymphoma
692559|NCT00004232|stage I cutaneous T-cell non-Hodgkin lymphoma
692560|NCT00004232|stage II cutaneous T-cell non-Hodgkin lymphoma
692561|NCT00004232|stage III cutaneous T-cell non-Hodgkin lymphoma
692562|NCT00004232|stage IV cutaneous T-cell non-Hodgkin lymphoma
692563|NCT00004232|recurrent cutaneous T-cell non-Hodgkin lymphoma
692564|NCT00004232|Burkitt lymphoma
692565|NCT00004232|isolated plasmacytoma of bone
692566|NCT00004232|extramedullary plasmacytoma
692567|NCT00004232|refractory multiple myeloma
692568|NCT00004232|stage 0 chronic lymphocytic leukemia
692569|NCT00004232|stage I multiple myeloma
692570|NCT00004232|stage II multiple myeloma
692571|NCT00004232|stage III multiple myeloma
692572|NCT00004232|stage I childhood lymphoblastic lymphoma
692573|NCT00004232|stage II childhood lymphoblastic lymphoma
692574|NCT00004232|stage III childhood lymphoblastic lymphoma
692575|NCT00004232|stage IV childhood lymphoblastic lymphoma
692576|NCT00004232|recurrent childhood lymphoblastic lymphoma
692577|NCT00004232|stage I chronic lymphocytic leukemia
692578|NCT00004232|stage II chronic lymphocytic leukemia
692579|NCT00004232|stage IV chronic lymphocytic leukemia
692580|NCT00004232|recurrent childhood acute myeloid leukemia
692581|NCT00004232|recurrent adult acute myeloid leukemia
692582|NCT00004232|recurrent adult acute lymphoblastic leukemia
692583|NCT00004232|relapsing chronic myelogenous leukemia
692584|NCT00004232|refractory chronic lymphocytic leukemia
692585|NCT00004232|childhood diffuse large cell lymphoma
692586|NCT00004232|childhood immunoblastic large cell lymphoma
692587|NCT00004232|chronic phase chronic myelogenous leukemia
692588|NCT00004232|accelerated phase chronic myelogenous leukemia
692589|NCT00004232|blastic phase chronic myelogenous leukemia
692590|NCT00004232|meningeal chronic myelogenous leukemia
692591|NCT00004232|untreated adult acute lymphoblastic leukemia
692592|NCT00004232|untreated adult acute myeloid leukemia
692593|NCT00004232|untreated childhood acute myeloid leukemia and other myeloid malignancies
692594|NCT00004232|untreated childhood acute lymphoblastic leukemia
692595|NCT00004232|adult acute myeloid leukemia in remission
692596|NCT00004232|adult acute lymphoblastic leukemia in remission
692597|NCT00004232|childhood acute myeloid leukemia in remission
692598|NCT00004232|childhood acute lymphoblastic leukemia in remission
692599|NCT00004232|chronic idiopathic myelofibrosis
692600|NCT00004232|essential thrombocythemia
692601|NCT00004232|untreated hairy cell leukemia
692602|NCT00004232|progressive hairy cell leukemia, initial treatment
692603|NCT00004232|refractory hairy cell leukemia
692604|NCT00004232|stage II childhood Hodgkin lymphoma
692605|NCT00004232|stage I childhood Hodgkin lymphoma
692606|NCT00004232|stage III childhood Hodgkin lymphoma
692607|NCT00004232|stage IV childhood Hodgkin lymphoma
692608|NCT00004232|recurrent/refractory childhood Hodgkin lymphoma
692609|NCT00004232|stage I grade 1 follicular lymphoma
692610|NCT00004232|stage I grade 2 follicular lymphoma
692611|NCT00004232|stage I grade 3 follicular lymphoma
692612|NCT00004232|stage I adult diffuse small cleaved cell lymphoma
692613|NCT00004232|stage I adult diffuse mixed cell lymphoma
692614|NCT00004232|stage I adult diffuse large cell lymphoma
692615|NCT00004232|stage I adult immunoblastic large cell lymphoma
692616|NCT00004232|stage I adult lymphoblastic lymphoma
692617|NCT00004232|stage I adult Burkitt lymphoma
692618|NCT00004232|chronic myelomonocytic leukemia
692619|NCT00004232|T-cell large granular lymphocyte leukemia
692620|NCT00004232|acute undifferentiated leukemia
692621|NCT00004232|stage III grade 1 follicular lymphoma
692622|NCT00004232|stage III grade 2 follicular lymphoma
692623|NCT00004232|stage III grade 3 follicular lymphoma
692624|NCT00004232|stage III adult diffuse small cleaved cell lymphoma
692625|NCT00004232|stage III adult diffuse mixed cell lymphoma
692626|NCT00004232|stage III adult diffuse large cell lymphoma
693869|NCT00004099|stage II gastric cancer
692627|NCT00004232|stage III adult immunoblastic large cell lymphoma
692628|NCT00004232|stage III adult lymphoblastic lymphoma
692629|NCT00004232|stage III adult Burkitt lymphoma
692630|NCT00004232|stage IV grade 1 follicular lymphoma
692631|NCT00004232|stage IV grade 2 follicular lymphoma
692632|NCT00004232|stage IV grade 3 follicular lymphoma
692633|NCT00004232|stage IV adult diffuse small cleaved cell lymphoma
692634|NCT00004232|stage IV adult diffuse mixed cell lymphoma
692635|NCT00004232|stage IV adult diffuse large cell lymphoma
692636|NCT00004232|stage IV adult immunoblastic large cell lymphoma
692637|NCT00004232|stage IV adult lymphoblastic lymphoma
692638|NCT00004232|stage IV adult Burkitt lymphoma
692639|NCT00004232|recurrent grade 1 follicular lymphoma
692640|NCT00004232|recurrent grade 2 follicular lymphoma
692641|NCT00004232|recurrent grade 3 follicular lymphoma
692642|NCT00004232|recurrent adult diffuse small cleaved cell lymphoma
692643|NCT00004232|recurrent adult diffuse mixed cell lymphoma
692644|NCT00004232|recurrent adult diffuse large cell lymphoma
692645|NCT00004232|recurrent adult immunoblastic large cell lymphoma
692646|NCT00004232|recurrent adult lymphoblastic lymphoma
692647|NCT00004232|recurrent adult Burkitt lymphoma
692648|NCT00004232|stage I adult T-cell leukemia/lymphoma
692649|NCT00004232|stage II adult T-cell leukemia/lymphoma
692650|NCT00004232|stage III adult T-cell leukemia/lymphoma
692651|NCT00004232|stage IV adult T-cell leukemia/lymphoma
692652|NCT00004232|recurrent adult T-cell leukemia/lymphoma
692653|NCT00004232|secondary acute myeloid leukemia
692654|NCT00004232|de novo myelodysplastic syndromes
692655|NCT00004232|previously treated myelodysplastic syndromes
692656|NCT00004232|secondary myelodysplastic syndromes
692657|NCT00004232|graft versus host disease
692658|NCT00004232|prolymphocytic leukemia
692659|NCT00004232|AIDS-related peripheral/systemic lymphoma
692660|NCT00004232|primary systemic amyloidosis
692661|NCT00004232|stage I childhood small noncleaved cell lymphoma
692662|NCT00004232|stage I childhood large cell lymphoma
692663|NCT00004232|stage II childhood small noncleaved cell lymphoma
692664|NCT00004232|stage II childhood large cell lymphoma
692665|NCT00004232|stage III childhood small noncleaved cell lymphoma
692666|NCT00004232|stage III childhood large cell lymphoma
692667|NCT00004232|stage IV childhood small noncleaved cell lymphoma
692668|NCT00004232|stage IV childhood large cell lymphoma
692669|NCT00004232|recurrent childhood small noncleaved cell lymphoma
692670|NCT00004232|recurrent childhood large cell lymphoma
692671|NCT00004232|stage I mantle cell lymphoma
692672|NCT00004232|contiguous stage II grade 1 follicular lymphoma
692673|NCT00004232|contiguous stage II grade 2 follicular lymphoma
692674|NCT00004232|contiguous stage II grade 3 follicular lymphoma
692675|NCT00004232|contiguous stage II adult diffuse small cleaved cell lymphoma
692676|NCT00004232|contiguous stage II mantle cell lymphoma
692677|NCT00004232|contiguous stage II adult diffuse mixed cell lymphoma
692678|NCT00004232|contiguous stage II adult immunoblastic large cell lymphoma
692679|NCT00004232|contiguous stage II adult diffuse large cell lymphoma
692680|NCT00004232|contiguous stage II adult Burkitt lymphoma
692681|NCT00004232|contiguous stage II adult lymphoblastic lymphoma
692682|NCT00004232|noncontiguous stage II grade 1 follicular lymphoma
692683|NCT00004232|noncontiguous stage II grade 2 follicular lymphoma
692684|NCT00004232|noncontiguous stage II grade 3 follicular lymphoma
692685|NCT00004232|noncontiguous stage II adult diffuse small cleaved cell lymphoma
692686|NCT00004232|noncontiguous stage II mantle cell lymphoma
692687|NCT00004232|noncontiguous stage II adult diffuse mixed cell lymphoma
692688|NCT00004232|noncontiguous stage II adult immunoblastic large cell lymphoma
692689|NCT00004232|noncontiguous stage II adult diffuse large cell lymphoma
692690|NCT00004232|noncontiguous stage II adult Burkitt lymphoma
692691|NCT00004232|noncontiguous stage II adult lymphoblastic lymphoma
692692|NCT00004232|stage III mantle cell lymphoma
692693|NCT00004232|stage IV mantle cell lymphoma
692694|NCT00004232|recurrent mantle cell lymphoma
692695|NCT00004232|angioimmunoblastic T-cell lymphoma
692696|NCT00004232|anaplastic large cell lymphoma
692697|NCT00004232|stage I mycosis fungoides/Sezary syndrome
692698|NCT00004232|stage II mycosis fungoides/Sezary syndrome
692699|NCT00004232|stage III mycosis fungoides/Sezary syndrome
692700|NCT00004232|stage IV mycosis fungoides/Sezary syndrome
692701|NCT00004232|recurrent mycosis fungoides/Sezary syndrome
692702|NCT00004232|noncontiguous stage II small lymphocytic lymphoma
692703|NCT00004232|noncontiguous stage II marginal zone lymphoma
692704|NCT00004232|recurrent marginal zone lymphoma
692705|NCT00004232|recurrent small lymphocytic lymphoma
692706|NCT00004232|stage I marginal zone lymphoma
692707|NCT00004232|stage I small lymphocytic lymphoma
692708|NCT00004232|stage III small lymphocytic lymphoma
692709|NCT00004232|stage III marginal zone lymphoma
692710|NCT00004232|stage IV small lymphocytic lymphoma
692711|NCT00004232|stage IV marginal zone lymphoma
692712|NCT00004232|contiguous stage II marginal zone lymphoma
692713|NCT00004232|contiguous stage II small lymphocytic lymphoma
692714|NCT00004232|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
692715|NCT00004232|nodal marginal zone B-cell lymphoma
692716|NCT00004232|splenic marginal zone lymphoma
692717|NCT00004232|childhood myelodysplastic syndromes
692718|NCT00004231|stage III mantle cell lymphoma
692719|NCT00004231|stage IV mantle cell lymphoma
692720|NCT00004231|recurrent mantle cell lymphoma
692721|NCT00004230|pulmonary complications
692722|NCT00004230|stage IV breast cancer
692723|NCT00004230|stage IIIA breast cancer
692724|NCT00004230|stage IIIB breast cancer
692725|NCT00004230|recurrent childhood acute lymphoblastic leukemia
692726|NCT00004230|recurrent adult Hodgkin lymphoma
692727|NCT00004230|recurrent cutaneous T-cell non-Hodgkin lymphoma
692728|NCT00004230|refractory multiple myeloma
692729|NCT00004230|recurrent childhood rhabdomyosarcoma
692730|NCT00004230|stage II ovarian epithelial cancer
692731|NCT00004230|stage III ovarian epithelial cancer
692732|NCT00004230|stage IV ovarian epithelial cancer
692733|NCT00004230|recurrent ovarian epithelial cancer
692734|NCT00004230|disseminated neuroblastoma
692735|NCT00004230|recurrent neuroblastoma
692736|NCT00004230|recurrent Wilms tumor and other childhood kidney tumors
692737|NCT00004230|stage I multiple myeloma
692738|NCT00004230|stage II multiple myeloma
692739|NCT00004230|stage III multiple myeloma
692740|NCT00004230|recurrent childhood lymphoblastic lymphoma
692741|NCT00004230|stage III chronic lymphocytic leukemia
692742|NCT00004230|stage IV chronic lymphocytic leukemia
692743|NCT00004230|recurrent childhood acute myeloid leukemia
692744|NCT00004230|recurrent adult acute myeloid leukemia
692745|NCT00004230|recurrent adult acute lymphoblastic leukemia
692746|NCT00004230|relapsing chronic myelogenous leukemia
692747|NCT00004230|refractory chronic lymphocytic leukemia
692748|NCT00004230|stage III malignant testicular germ cell tumor
692749|NCT00004230|recurrent malignant testicular germ cell tumor
692750|NCT00004230|chronic phase chronic myelogenous leukemia
692751|NCT00004230|accelerated phase chronic myelogenous leukemia
692752|NCT00004230|blastic phase chronic myelogenous leukemia
692753|NCT00004230|meningeal chronic myelogenous leukemia
692754|NCT00004230|chronic idiopathic myelofibrosis
692755|NCT00004230|childhood acute promyelocytic leukemia (M3)
692756|NCT00004230|testicular embryonal carcinoma
692757|NCT00004230|testicular choriocarcinoma
692758|NCT00004230|testicular teratoma
692759|NCT00004230|testicular yolk sac tumor
692760|NCT00004230|testicular embryonal carcinoma and teratoma
692761|NCT00004230|testicular embryonal carcinoma and teratoma with seminoma
692762|NCT00004230|testicular embryonal carcinoma and yolk sac tumor
692763|NCT00004230|testicular embryonal carcinoma and yolk sac tumor with seminoma
692764|NCT00004230|testicular embryonal carcinoma and seminoma
692765|NCT00004230|testicular yolk sac tumor and teratoma
692766|NCT00004230|testicular yolk sac tumor and teratoma with seminoma
692767|NCT00004230|testicular choriocarcinoma and yolk sac tumor
692768|NCT00004230|testicular choriocarcinoma and embryonal carcinoma
692769|NCT00004230|testicular choriocarcinoma and teratoma
692770|NCT00004230|testicular choriocarcinoma and seminoma
692771|NCT00004230|refractory hairy cell leukemia
692772|NCT00004230|recurrent/refractory childhood Hodgkin lymphoma
692773|NCT00004230|recurrent ovarian germ cell tumor
692774|NCT00004230|ovarian yolk sac tumor
692775|NCT00004230|ovarian embryonal carcinoma
692776|NCT00004230|ovarian polyembryoma
692777|NCT00004230|ovarian choriocarcinoma
692778|NCT00004230|ovarian immature teratoma
692779|NCT00004230|ovarian mature teratoma
692780|NCT00004230|ovarian monodermal and highly specialized teratoma
692781|NCT00004230|ovarian mixed germ cell tumor
692782|NCT00004230|stage III grade 1 follicular lymphoma
692783|NCT00004230|stage III grade 2 follicular lymphoma
692784|NCT00004230|stage III grade 3 follicular lymphoma
692785|NCT00004230|stage III adult diffuse small cleaved cell lymphoma
692786|NCT00004230|stage III adult diffuse mixed cell lymphoma
692787|NCT00004230|stage III adult diffuse large cell lymphoma
692788|NCT00004230|stage III adult immunoblastic large cell lymphoma
692789|NCT00004230|stage III adult lymphoblastic lymphoma
692790|NCT00004230|stage III adult Burkitt lymphoma
692791|NCT00004230|stage IV grade 1 follicular lymphoma
692792|NCT00004230|stage IV grade 2 follicular lymphoma
692793|NCT00004230|stage IV grade 3 follicular lymphoma
692794|NCT00004230|stage IV adult diffuse small cleaved cell lymphoma
692795|NCT00004230|stage IV adult diffuse mixed cell lymphoma
692796|NCT00004230|stage IV adult diffuse large cell lymphoma
692797|NCT00004230|stage IV adult immunoblastic large cell lymphoma
692798|NCT00004230|stage IV adult lymphoblastic lymphoma
692799|NCT00004230|stage IV adult Burkitt lymphoma
692800|NCT00004230|recurrent grade 1 follicular lymphoma
692801|NCT00004230|recurrent grade 2 follicular lymphoma
692802|NCT00004230|recurrent grade 3 follicular lymphoma
692803|NCT00004230|recurrent adult diffuse small cleaved cell lymphoma
692804|NCT00004230|recurrent adult diffuse mixed cell lymphoma
692805|NCT00004230|recurrent adult diffuse large cell lymphoma
692806|NCT00004230|recurrent adult immunoblastic large cell lymphoma
692807|NCT00004230|recurrent adult lymphoblastic lymphoma
692808|NCT00004230|recurrent adult Burkitt lymphoma
692809|NCT00004230|secondary acute myeloid leukemia
692810|NCT00004230|de novo myelodysplastic syndromes
692811|NCT00004230|poor prognosis metastatic gestational trophoblastic tumor
692812|NCT00004230|previously treated myelodysplastic syndromes
692813|NCT00004230|secondary myelodysplastic syndromes
692814|NCT00004230|recurrent childhood small noncleaved cell lymphoma
692815|NCT00004230|recurrent childhood large cell lymphoma
692816|NCT00004230|noncontiguous stage II grade 1 follicular lymphoma
692817|NCT00004230|noncontiguous stage II grade 2 follicular lymphoma
692818|NCT00004230|noncontiguous stage II grade 3 follicular lymphoma
692819|NCT00004230|noncontiguous stage II adult diffuse small cleaved cell lymphoma
692820|NCT00004230|noncontiguous stage II mantle cell lymphoma
692821|NCT00004230|noncontiguous stage II adult diffuse mixed cell lymphoma
692822|NCT00004230|noncontiguous stage II adult immunoblastic large cell lymphoma
692823|NCT00004230|noncontiguous stage II adult diffuse large cell lymphoma
692824|NCT00004230|noncontiguous stage II adult Burkitt lymphoma
692825|NCT00004230|noncontiguous stage II adult lymphoblastic lymphoma
692826|NCT00004230|stage III mantle cell lymphoma
692827|NCT00004230|stage IV mantle cell lymphoma
692828|NCT00004230|recurrent mantle cell lymphoma
692829|NCT00004230|previously treated childhood rhabdomyosarcoma
692830|NCT00004230|recurrent mycosis fungoides/Sezary syndrome
692831|NCT00004230|noncontiguous stage II small lymphocytic lymphoma
692832|NCT00004230|noncontiguous stage II marginal zone lymphoma
692833|NCT00004230|recurrent marginal zone lymphoma
692834|NCT00004230|recurrent small lymphocytic lymphoma
692835|NCT00004230|stage III small lymphocytic lymphoma
692836|NCT00004230|stage III marginal zone lymphoma
692837|NCT00004230|stage IV small lymphocytic lymphoma
692838|NCT00004230|stage IV marginal zone lymphoma
692839|NCT00004230|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
692840|NCT00004230|nodal marginal zone B-cell lymphoma
692841|NCT00004230|splenic marginal zone lymphoma
692842|NCT00004230|childhood myelodysplastic syndromes
692843|NCT00004229|unspecified adult solid tumor, protocol specific
692844|NCT00004228|stage III childhood lymphoblastic lymphoma
692845|NCT00004228|stage IV childhood lymphoblastic lymphoma
692846|NCT00004227|stage III squamous cell carcinoma of the oropharynx
692847|NCT00004227|stage IV squamous cell carcinoma of the oropharynx
692848|NCT00004227|recurrent squamous cell carcinoma of the oropharynx
692849|NCT00004227|stage III squamous cell carcinoma of the hypopharynx
692850|NCT00004227|stage IV squamous cell carcinoma of the hypopharynx
692851|NCT00004227|recurrent squamous cell carcinoma of the hypopharynx
692852|NCT00004227|stage III squamous cell carcinoma of the larynx
692853|NCT00004227|stage IV squamous cell carcinoma of the larynx
692854|NCT00004227|recurrent squamous cell carcinoma of the larynx
692855|NCT00004226|recurrent squamous cell carcinoma of the lip and oral cavity
692856|NCT00004226|recurrent squamous cell carcinoma of the hypopharynx
692857|NCT00004226|recurrent squamous cell carcinoma of the larynx
692858|NCT00004226|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
692859|NCT00004226|recurrent squamous cell carcinoma of the oropharynx
692860|NCT00004226|recurrent metastatic squamous neck cancer with occult primary
692861|NCT00004225|recurrent non-small cell lung cancer
692862|NCT00004224|childhood infratentorial ependymoma
692863|NCT00004224|childhood supratentorial ependymoma
692864|NCT00004224|newly diagnosed childhood ependymoma
692865|NCT00004223|stage III bladder cancer
692866|NCT00004223|recurrent bladder cancer
692867|NCT00004223|stage IV bladder cancer
692868|NCT00004223|transitional cell carcinoma of the bladder
692869|NCT00004223|posterior urethral cancer
692870|NCT00004223|metastatic transitional cell cancer of the renal pelvis and ureter
692871|NCT00004223|regional transitional cell cancer of the renal pelvis and ureter
692872|NCT00004220|unspecified adult solid tumor, protocol specific
692873|NCT00004219|nausea and vomiting
692874|NCT00004219|stage I malignant testicular germ cell tumor
692875|NCT00004219|testicular seminoma
692876|NCT00004218|stage I chronic lymphocytic leukemia
692877|NCT00004218|stage II chronic lymphocytic leukemia
692878|NCT00004218|stage III chronic lymphocytic leukemia
692879|NCT00004218|B-cell chronic lymphocytic leukemia
692880|NCT00004218|stage 0 chronic lymphocytic leukemia
692881|NCT00004217|untreated adult acute myeloid leukemia
692882|NCT00004217|adult acute erythroid leukemia (M6)
692883|NCT00004217|adult acute myeloblastic leukemia without maturation (M1)
692884|NCT00004217|adult acute myeloblastic leukemia with maturation (M2)
692885|NCT00004217|adult acute myelomonocytic leukemia (M4)
692886|NCT00004217|adult acute monoblastic leukemia (M5a)
692887|NCT00004217|adult acute megakaryoblastic leukemia (M7)
692888|NCT00004217|adult acute monocytic leukemia (M5b)
692889|NCT00004217|adult acute minimally differentiated myeloid leukemia (M0)
692890|NCT00004216|unspecified adult solid tumor, protocol specific
692891|NCT00004215|untreated adult acute myeloid leukemia
692892|NCT00004215|adult acute erythroid leukemia (M6)
692893|NCT00004215|adult acute myeloblastic leukemia without maturation (M1)
692894|NCT00004215|adult acute myeloblastic leukemia with maturation (M2)
692895|NCT00004215|adult acute myelomonocytic leukemia (M4)
692896|NCT00004215|adult acute monoblastic leukemia (M5a)
692897|NCT00004215|adult acute megakaryoblastic leukemia (M7)
692898|NCT00004215|adult acute monocytic leukemia (M5b)
692899|NCT00004215|anemia
692900|NCT00004215|neutropenia
692902|NCT00004215|adult acute minimally differentiated myeloid leukemia (M0)
692903|NCT00004213|unspecified adult solid tumor, protocol specific
692904|NCT00004212|childhood infratentorial ependymoma
692905|NCT00004212|childhood supratentorial ependymoma
692906|NCT00004212|childhood craniopharyngioma
692907|NCT00004212|stage III childhood lymphoblastic lymphoma
692908|NCT00004212|stage IV childhood lymphoblastic lymphoma
692909|NCT00004212|recurrent childhood lymphoblastic lymphoma
692910|NCT00004212|childhood central nervous system germ cell tumor
692911|NCT00004212|unspecified childhood solid tumor, protocol specific
692912|NCT00004212|stage III childhood Hodgkin lymphoma
692913|NCT00004212|stage IV childhood Hodgkin lymphoma
692914|NCT00004212|recurrent/refractory childhood Hodgkin lymphoma
692915|NCT00004212|childhood high-grade cerebral astrocytoma
692916|NCT00004212|childhood oligodendroglioma
692917|NCT00004212|childhood choroid plexus tumor
692918|NCT00004212|stage III childhood small noncleaved cell lymphoma
692919|NCT00004212|stage III childhood large cell lymphoma
692920|NCT00004212|stage IV childhood small noncleaved cell lymphoma
692921|NCT00004212|stage IV childhood large cell lymphoma
692922|NCT00004212|recurrent childhood small noncleaved cell lymphoma
692923|NCT00004212|recurrent childhood large cell lymphoma
692924|NCT00004212|untreated childhood brain stem glioma
692925|NCT00004212|recurrent childhood brain stem glioma
692926|NCT00004212|untreated childhood supratentorial primitive neuroectodermal tumor
692927|NCT00004212|recurrent childhood supratentorial primitive neuroectodermal tumor
692928|NCT00004212|untreated childhood cerebellar astrocytoma
692929|NCT00004212|recurrent childhood cerebellar astrocytoma
692930|NCT00004212|recurrent childhood cerebral astrocytoma
692931|NCT00004212|untreated childhood medulloblastoma
692932|NCT00004212|recurrent childhood medulloblastoma
692933|NCT00004212|untreated childhood visual pathway and hypothalamic glioma
692934|NCT00004212|recurrent childhood visual pathway and hypothalamic glioma
692935|NCT00004212|newly diagnosed childhood ependymoma
692936|NCT00004212|recurrent childhood ependymoma
692937|NCT00004211|stage IV prostate cancer
692938|NCT00004211|recurrent prostate cancer
692939|NCT00004210|colon cancer
692940|NCT00004210|rectal cancer
692941|NCT00004209|stage IIIB non-small cell lung cancer
692942|NCT00004209|stage IV non-small cell lung cancer
692943|NCT00004208|refractory anemia
692944|NCT00004208|refractory anemia with ringed sideroblasts
692945|NCT00004208|refractory anemia with excess blasts
692946|NCT00004208|de novo myelodysplastic syndromes
692947|NCT00004208|previously treated myelodysplastic syndromes
692948|NCT00004208|secondary myelodysplastic syndromes
692949|NCT00004207|stage IV breast cancer
692950|NCT00004207|recurrent breast cancer
692951|NCT00004206|recurrent ovarian epithelial cancer
692952|NCT00004205|stage I breast cancer
692953|NCT00004205|stage II breast cancer
692954|NCT00004205|stage IIIA breast cancer
692955|NCT00004205|breast cancer in situ
692956|NCT00004205|recurrent breast cancer
692957|NCT00004205|ductal breast carcinoma
692958|NCT00004205|lobular breast carcinoma in situ
692959|NCT00004204|recurrent adult brain tumor
692960|NCT00004204|adult anaplastic astrocytoma
692961|NCT00004204|adult anaplastic oligodendroglioma
692962|NCT00004203|recurrent bladder cancer
692963|NCT00004203|stage IV bladder cancer
692964|NCT00004203|transitional cell carcinoma of the bladder
692965|NCT00004203|metastatic transitional cell cancer of the renal pelvis and ureter
692966|NCT00004203|recurrent transitional cell cancer of the renal pelvis and ureter
692967|NCT00004202|recurrent non-small cell lung cancer
692968|NCT00004202|stage IIIA non-small cell lung cancer
692969|NCT00004202|stage IIIB non-small cell lung cancer
692970|NCT00004201|recurrent non-small cell lung cancer
692971|NCT00004201|stage IIIB non-small cell lung cancer
692972|NCT00004201|stage IV non-small cell lung cancer
692973|NCT00004200|adult glioblastoma
692974|NCT00004200|adult giant cell glioblastoma
692975|NCT00004200|adult gliosarcoma
692976|NCT00004199|recurrent non-small cell lung cancer
692977|NCT00004199|stage IV non-small cell lung cancer
692978|NCT00004198|stage III grade 1 follicular lymphoma
692979|NCT00004198|stage III grade 2 follicular lymphoma
692980|NCT00004198|stage IV grade 1 follicular lymphoma
692981|NCT00004198|stage IV grade 2 follicular lymphoma
692982|NCT00004197|stage I grade 3 follicular lymphoma
692983|NCT00004197|stage I adult diffuse mixed cell lymphoma
692984|NCT00004197|stage I adult diffuse large cell lymphoma
692985|NCT00004197|stage I adult immunoblastic large cell lymphoma
692986|NCT00004197|stage III grade 3 follicular lymphoma
692987|NCT00004197|stage III adult diffuse mixed cell lymphoma
692988|NCT00004197|stage III adult diffuse large cell lymphoma
692989|NCT00004197|stage III adult immunoblastic large cell lymphoma
692990|NCT00004197|stage IV grade 3 follicular lymphoma
692991|NCT00004197|stage IV adult diffuse mixed cell lymphoma
692992|NCT00004197|stage IV adult diffuse large cell lymphoma
692993|NCT00004197|stage IV adult immunoblastic large cell lymphoma
692994|NCT00004197|stage I mantle cell lymphoma
692995|NCT00004197|contiguous stage II grade 3 follicular lymphoma
692996|NCT00004197|contiguous stage II mantle cell lymphoma
692997|NCT00004197|contiguous stage II adult diffuse mixed cell lymphoma
692998|NCT00004197|contiguous stage II adult immunoblastic large cell lymphoma
692999|NCT00004197|contiguous stage II adult diffuse large cell lymphoma
693000|NCT00004197|noncontiguous stage II grade 3 follicular lymphoma
693001|NCT00004197|noncontiguous stage II mantle cell lymphoma
693002|NCT00004197|noncontiguous stage II adult diffuse mixed cell lymphoma
693003|NCT00004197|noncontiguous stage II adult immunoblastic large cell lymphoma
693004|NCT00004197|noncontiguous stage II adult diffuse large cell lymphoma
693005|NCT00004197|stage III mantle cell lymphoma
693006|NCT00004197|stage IV mantle cell lymphoma
693007|NCT00004196|stage I melanoma
693008|NCT00004196|stage II melanoma
693009|NCT00004196|stage III melanoma
693010|NCT00004195|stage I colon cancer
693011|NCT00004195|stage II colon cancer
693012|NCT00004195|stage III colon cancer
693013|NCT00004195|stage IV colon cancer
693014|NCT00004195|stage I rectal cancer
693015|NCT00004195|stage II rectal cancer
693016|NCT00004195|stage III rectal cancer
693017|NCT00004195|stage IV rectal cancer
693018|NCT00004195|recurrent colon cancer
693019|NCT00004195|recurrent rectal cancer
693020|NCT00004194|graft versus host disease
693021|NCT00004193|stage IV colon cancer
693022|NCT00004193|stage IV rectal cancer
693023|NCT00004193|recurrent colon cancer
693024|NCT00004193|recurrent rectal cancer
693025|NCT00004193|adenocarcinoma of the colon
693026|NCT00004193|adenocarcinoma of the rectum
693027|NCT00004192|neutropenia
693028|NCT00004192|Waldenstrom macroglobulinemia
693029|NCT00004192|recurrent grade 1 follicular lymphoma
693030|NCT00004192|recurrent grade 2 follicular lymphoma
693031|NCT00004192|recurrent grade 3 follicular lymphoma
693032|NCT00004192|recurrent adult diffuse small cleaved cell lymphoma
693033|NCT00004192|recurrent adult diffuse mixed cell lymphoma
693034|NCT00004192|recurrent adult diffuse large cell lymphoma
693035|NCT00004192|recurrent adult immunoblastic large cell lymphoma
693036|NCT00004192|recurrent adult lymphoblastic lymphoma
693037|NCT00004192|recurrent adult Burkitt lymphoma
693038|NCT00004192|recurrent mantle cell lymphoma
693039|NCT00004192|recurrent marginal zone lymphoma
693040|NCT00004192|recurrent small lymphocytic lymphoma
693041|NCT00004192|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693042|NCT00004192|nodal marginal zone B-cell lymphoma
693043|NCT00004192|splenic marginal zone lymphoma
693044|NCT00004190|stage III pancreatic cancer
693045|NCT00004190|recurrent pancreatic cancer
693046|NCT00004190|duct cell adenocarcinoma of the pancreas
693047|NCT00004190|stage IV pancreatic cancer
693048|NCT00004189|stage III adult Hodgkin lymphoma
693049|NCT00004189|stage IV adult Hodgkin lymphoma
693050|NCT00004189|recurrent adult Hodgkin lymphoma
693051|NCT00004189|stage III cutaneous T-cell non-Hodgkin lymphoma
693052|NCT00004189|stage IV cutaneous T-cell non-Hodgkin lymphoma
693053|NCT00004189|recurrent cutaneous T-cell non-Hodgkin lymphoma
693054|NCT00004189|small intestine lymphoma
693055|NCT00004189|unspecified adult solid tumor, protocol specific
693056|NCT00004189|stage III grade 1 follicular lymphoma
693057|NCT00004189|stage III grade 2 follicular lymphoma
693058|NCT00004189|stage III grade 3 follicular lymphoma
693059|NCT00004189|stage III adult diffuse small cleaved cell lymphoma
693060|NCT00004189|stage III adult diffuse mixed cell lymphoma
693061|NCT00004189|stage III adult diffuse large cell lymphoma
693062|NCT00004189|stage III adult immunoblastic large cell lymphoma
693063|NCT00004189|stage III adult lymphoblastic lymphoma
693064|NCT00004189|stage III adult Burkitt lymphoma
693065|NCT00004189|stage IV grade 1 follicular lymphoma
693066|NCT00004189|stage IV grade 2 follicular lymphoma
693067|NCT00004189|stage IV grade 3 follicular lymphoma
693068|NCT00004189|stage IV adult diffuse small cleaved cell lymphoma
693069|NCT00004189|stage IV adult diffuse mixed cell lymphoma
693070|NCT00004189|stage IV adult diffuse large cell lymphoma
693071|NCT00004189|stage IV adult immunoblastic large cell lymphoma
693072|NCT00004189|stage IV adult lymphoblastic lymphoma
693073|NCT00004189|stage IV adult Burkitt lymphoma
693074|NCT00004189|recurrent grade 1 follicular lymphoma
693075|NCT00004189|recurrent grade 2 follicular lymphoma
693076|NCT00004189|recurrent grade 3 follicular lymphoma
693077|NCT00004189|recurrent adult diffuse small cleaved cell lymphoma
693078|NCT00004189|recurrent adult diffuse mixed cell lymphoma
693079|NCT00004189|recurrent adult diffuse large cell lymphoma
693080|NCT00004189|recurrent adult immunoblastic large cell lymphoma
693081|NCT00004189|recurrent adult lymphoblastic lymphoma
693082|NCT00004189|recurrent adult Burkitt lymphoma
693083|NCT00004189|stage III adult T-cell leukemia/lymphoma
693084|NCT00004189|stage IV adult T-cell leukemia/lymphoma
693085|NCT00004189|recurrent adult T-cell leukemia/lymphoma
693086|NCT00004189|primary central nervous system non-Hodgkin lymphoma
693087|NCT00004189|AIDS-related peripheral/systemic lymphoma
693088|NCT00004189|AIDS-related primary CNS lymphoma
693089|NCT00004189|intraocular lymphoma
693090|NCT00004189|stage III mantle cell lymphoma
693091|NCT00004189|stage IV mantle cell lymphoma
693092|NCT00004189|recurrent mantle cell lymphoma
695764|NCT00003876|adult glioblastoma
693093|NCT00004189|angioimmunoblastic T-cell lymphoma
693094|NCT00004189|anaplastic large cell lymphoma
693095|NCT00004189|stage III mycosis fungoides/Sezary syndrome
693096|NCT00004189|stage IV mycosis fungoides/Sezary syndrome
693097|NCT00004189|recurrent mycosis fungoides/Sezary syndrome
693098|NCT00004189|recurrent marginal zone lymphoma
693099|NCT00004189|recurrent small lymphocytic lymphoma
693100|NCT00004189|stage III small lymphocytic lymphoma
693101|NCT00004189|stage III marginal zone lymphoma
693102|NCT00004189|stage IV small lymphocytic lymphoma
693103|NCT00004189|stage IV marginal zone lymphoma
693104|NCT00004189|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693105|NCT00004189|nodal marginal zone B-cell lymphoma
693106|NCT00004189|splenic marginal zone lymphoma
693107|NCT00004188|localized resectable neuroblastoma
693108|NCT00004188|regional neuroblastoma
693109|NCT00004188|disseminated neuroblastoma
693110|NCT00004188|stage 4S neuroblastoma
693111|NCT00004188|localized unresectable neuroblastoma
693112|NCT00004187|stage III colon cancer
693113|NCT00004187|stage IV colon cancer
693114|NCT00004187|stage III rectal cancer
693115|NCT00004187|stage IV rectal cancer
693116|NCT00004187|recurrent colon cancer
693117|NCT00004187|recurrent rectal cancer
693118|NCT00004186|limited stage small cell lung cancer
693119|NCT00004186|extensive stage small cell lung cancer
693120|NCT00004186|recurrent small cell lung cancer
693121|NCT00004184|stage III melanoma
693122|NCT00004184|stage IV melanoma
693123|NCT00004184|recurrent melanoma
693124|NCT00004183|localized malignant mesothelioma
693125|NCT00004183|advanced malignant mesothelioma
693126|NCT00004183|recurrent malignant mesothelioma
693127|NCT00004183|epithelial mesothelioma
693128|NCT00004183|sarcomatous mesothelioma
693129|NCT00004182|stage IV breast cancer
693130|NCT00004182|recurrent breast cancer
693131|NCT00004181|refractory multiple myeloma
693132|NCT00004181|stage I multiple myeloma
693133|NCT00004181|stage II multiple myeloma
693134|NCT00004181|stage III multiple myeloma
693135|NCT00004181|chronic phase chronic myelogenous leukemia
693136|NCT00004181|chronic idiopathic myelofibrosis
693137|NCT00004181|Philadelphia chromosome positive chronic myelogenous leukemia
693138|NCT00004180|adult liposarcoma
693139|NCT00004180|recurrent adult soft tissue sarcoma
693140|NCT00004179|stage III grade 1 follicular lymphoma
693141|NCT00004179|stage III grade 2 follicular lymphoma
693142|NCT00004179|stage III grade 3 follicular lymphoma
693143|NCT00004179|stage IV grade 1 follicular lymphoma
693144|NCT00004179|stage IV grade 2 follicular lymphoma
693145|NCT00004179|stage IV grade 3 follicular lymphoma
693146|NCT00004179|recurrent grade 1 follicular lymphoma
693147|NCT00004179|recurrent grade 2 follicular lymphoma
693148|NCT00004179|recurrent grade 3 follicular lymphoma
693149|NCT00004178|stage III colon cancer
693150|NCT00004178|stage IV colon cancer
693151|NCT00004178|stage III gastric cancer
693152|NCT00004178|stage IV gastric cancer
693153|NCT00004178|recurrent gastric cancer
693154|NCT00004178|recurrent non-small cell lung cancer
693155|NCT00004178|stage II pancreatic cancer
693156|NCT00004178|stage III pancreatic cancer
693157|NCT00004178|recurrent pancreatic cancer
693158|NCT00004178|stage III rectal cancer
693159|NCT00004178|stage IV rectal cancer
693160|NCT00004178|recurrent colon cancer
693161|NCT00004178|recurrent rectal cancer
693162|NCT00004178|stage II esophageal cancer
693163|NCT00004178|stage III esophageal cancer
693164|NCT00004178|stage IV esophageal cancer
693165|NCT00004178|recurrent esophageal cancer
693166|NCT00004178|stage III cervical cancer
693167|NCT00004178|recurrent cervical cancer
693168|NCT00004178|stage IVB cervical cancer
693169|NCT00004178|stage IVA cervical cancer
693170|NCT00004178|adenocarcinoma of the prostate
693171|NCT00004178|stage III renal cell cancer
693172|NCT00004178|stage IV renal cell cancer
693173|NCT00004178|recurrent renal cell cancer
693174|NCT00004178|stage III ovarian epithelial cancer
693175|NCT00004178|stage IV ovarian epithelial cancer
693176|NCT00004178|recurrent ovarian epithelial cancer
693177|NCT00004178|adenocarcinoma of the stomach
693178|NCT00004178|extensive stage small cell lung cancer
693179|NCT00004178|recurrent small cell lung cancer
693180|NCT00004178|stage III vaginal cancer
693181|NCT00004178|stage IVA vaginal cancer
693182|NCT00004178|stage IVB vaginal cancer
693183|NCT00004178|recurrent vaginal cancer
693184|NCT00004178|localized unresectable adult primary liver cancer
693185|NCT00004178|advanced adult primary liver cancer
693186|NCT00004178|recurrent adult primary liver cancer
693187|NCT00004178|stage III endometrial carcinoma
693188|NCT00004178|stage IV endometrial carcinoma
693189|NCT00004178|recurrent endometrial carcinoma
693190|NCT00004178|small intestine adenocarcinoma
693191|NCT00004178|unresectable gallbladder cancer
693192|NCT00004178|recurrent gallbladder cancer
693193|NCT00004178|unresectable extrahepatic bile duct cancer
693194|NCT00004178|recurrent extrahepatic bile duct cancer
693195|NCT00004178|recurrent small intestine cancer
693196|NCT00004178|stage III bladder cancer
693197|NCT00004178|recurrent bladder cancer
693198|NCT00004178|stage IV bladder cancer
693199|NCT00004178|stage III prostate cancer
693200|NCT00004178|stage IV prostate cancer
693201|NCT00004178|recurrent prostate cancer
693202|NCT00004178|stage IV non-small cell lung cancer
693203|NCT00004178|stage III salivary gland cancer
693204|NCT00004178|stage IV salivary gland cancer
693205|NCT00004178|recurrent salivary gland cancer
693206|NCT00004178|duct cell adenocarcinoma of the pancreas
693207|NCT00004178|ovarian undifferentiated adenocarcinoma
693208|NCT00004178|adenocarcinoma of the lung
693209|NCT00004178|adenocarcinoma of the esophagus
693210|NCT00004178|intestinal adenocarcinoma of the stomach
693211|NCT00004178|adenocarcinoma of the colon
693212|NCT00004178|diffuse adenocarcinoma of the stomach
693213|NCT00004178|mixed adenocarcinoma of the stomach
693214|NCT00004178|mucinous adenocarcinoma of the colon
693215|NCT00004178|signet ring adenocarcinoma of the colon
693216|NCT00004178|adenocarcinoma of the rectum
693217|NCT00004178|adenocarcinoma of the gallbladder
693218|NCT00004178|mucinous adenocarcinoma of the rectum
693219|NCT00004178|signet ring adenocarcinoma of the rectum
693220|NCT00004178|adenocarcinoma with squamous metaplasia of the gallbladder
693221|NCT00004178|adenocarcinoma of the extrahepatic bile duct
693222|NCT00004178|ovarian serous cystadenocarcinoma
693223|NCT00004178|ovarian mucinous cystadenocarcinoma
693224|NCT00004178|ovarian endometrioid adenocarcinoma
693225|NCT00004178|ovarian clear cell cystadenocarcinoma
693226|NCT00004178|vaginal adenocarcinoma
693227|NCT00004178|vaginal clear cell adenocarcinoma
693228|NCT00004178|endometrial adenocarcinoma
693229|NCT00004178|cervical adenocarcinoma
693230|NCT00004178|adenocarcinoma of the bladder
693231|NCT00004178|salivary gland adenocarcinoma
693232|NCT00004178|adenocarcinoma of unknown primary
693233|NCT00004178|adenocarcinoma of the pancreas
693234|NCT00004178|stage IV pancreatic cancer
693235|NCT00004177|recurrent ovarian epithelial cancer
693236|NCT00004176|limited stage small cell lung cancer
693237|NCT00004176|drug/agent toxicity by tissue/organ
693238|NCT00004176|radiation toxicity
693239|NCT00004175|stage IIIA breast cancer
693240|NCT00004175|stage IIIB breast cancer
693241|NCT00004174|stage IV breast cancer
693242|NCT00004174|stage IIIA breast cancer
693243|NCT00004174|recurrent breast cancer
693244|NCT00004174|stage IIIB breast cancer
693245|NCT00004173|unspecified adult solid tumor, protocol specific
693246|NCT00004172|stage IV breast cancer
693247|NCT00004172|stage IIIA breast cancer
693248|NCT00004172|recurrent breast cancer
693249|NCT00004172|stage IIIB breast cancer
693250|NCT00004171|recurrent adult Hodgkin lymphoma
693251|NCT00004171|childhood immunoblastic large cell lymphoma
693252|NCT00004171|recurrent/refractory childhood Hodgkin lymphoma
693253|NCT00004171|recurrent grade 3 follicular lymphoma
693254|NCT00004171|recurrent adult diffuse small cleaved cell lymphoma
693255|NCT00004171|recurrent adult diffuse mixed cell lymphoma
693256|NCT00004171|recurrent adult diffuse large cell lymphoma
693257|NCT00004171|recurrent adult immunoblastic large cell lymphoma
693258|NCT00004169|recurrent adult Hodgkin lymphoma
693259|NCT00004169|recurrent/refractory childhood Hodgkin lymphoma
693260|NCT00004166|stage I ovarian epithelial cancer
693261|NCT00004166|stage II ovarian epithelial cancer
693262|NCT00004166|stage III ovarian epithelial cancer
693263|NCT00004166|stage IV ovarian epithelial cancer
693264|NCT00004166|quality of life
693265|NCT00004165|refractory multiple myeloma
693266|NCT00004165|stage I multiple myeloma
693267|NCT00004165|stage II multiple myeloma
693268|NCT00004165|stage III multiple myeloma
693269|NCT00004165|primary systemic amyloidosis
693270|NCT00004164|stage II nasopharyngeal cancer
693271|NCT00004164|stage III nasopharyngeal cancer
693272|NCT00004164|stage IV nasopharyngeal cancer
693273|NCT00004163|stage III salivary gland cancer
693274|NCT00004163|stage IV salivary gland cancer
693275|NCT00004163|recurrent salivary gland cancer
693276|NCT00004163|salivary gland squamous cell carcinoma
693277|NCT00004163|salivary gland acinic cell tumor
693278|NCT00004163|low-grade salivary gland mucoepidermoid carcinoma
693279|NCT00004163|high-grade salivary gland mucoepidermoid carcinoma
693280|NCT00004163|salivary gland adenocarcinoma
693281|NCT00004163|salivary gland poorly differentiated carcinoma
693282|NCT00004163|salivary gland malignant mixed cell type tumor
693283|NCT00004163|salivary gland adenoid cystic carcinoma
693284|NCT00004162|AIDS-related diffuse large cell lymphoma
693285|NCT00004162|AIDS-related immunoblastic large cell lymphoma
693286|NCT00004162|AIDS-related small noncleaved cell lymphoma
693287|NCT00004162|AIDS-related diffuse mixed cell lymphoma
693288|NCT00004162|AIDS-related diffuse small cleaved cell lymphoma
693289|NCT00004162|AIDS-related lymphoblastic lymphoma
693290|NCT00004161|lip and oral cavity cancer
693291|NCT00004160|stage IIIA non-small cell lung cancer
693292|NCT00004160|stage IIIB non-small cell lung cancer
693293|NCT00004159|recurrent non-small cell lung cancer
693294|NCT00004159|stage IV non-small cell lung cancer
693295|NCT00004158|refractory multiple myeloma
693296|NCT00004158|stage I multiple myeloma
693297|NCT00004158|stage II multiple myeloma
693298|NCT00004158|stage III multiple myeloma
693299|NCT00004157|stage IV breast cancer
693300|NCT00004157|stage IIIA breast cancer
693301|NCT00004157|stage IIIB breast cancer
693302|NCT00004157|recurrent adult Hodgkin lymphoma
693303|NCT00004157|recurrent childhood rhabdomyosarcoma
693304|NCT00004157|stage II ovarian epithelial cancer
693305|NCT00004157|stage III ovarian epithelial cancer
693306|NCT00004157|stage IV ovarian epithelial cancer
693307|NCT00004157|recurrent ovarian epithelial cancer
693308|NCT00004157|disseminated neuroblastoma
693309|NCT00004157|recurrent neuroblastoma
693310|NCT00004157|recurrent Wilms tumor and other childhood kidney tumors
693311|NCT00004157|recurrent childhood lymphoblastic lymphoma
693312|NCT00004157|stage III malignant testicular germ cell tumor
693313|NCT00004157|recurrent malignant testicular germ cell tumor
693314|NCT00004157|testicular embryonal carcinoma
693315|NCT00004157|testicular choriocarcinoma
693316|NCT00004157|testicular teratoma
693317|NCT00004157|testicular yolk sac tumor
693318|NCT00004157|testicular embryonal carcinoma and teratoma
693319|NCT00004157|testicular embryonal carcinoma and teratoma with seminoma
693320|NCT00004157|testicular embryonal carcinoma and yolk sac tumor
693321|NCT00004157|testicular embryonal carcinoma and yolk sac tumor with seminoma
693322|NCT00004157|testicular embryonal carcinoma and seminoma
693323|NCT00004157|testicular yolk sac tumor and teratoma
693324|NCT00004157|testicular yolk sac tumor and teratoma with seminoma
693325|NCT00004157|testicular choriocarcinoma and yolk sac tumor
693326|NCT00004157|testicular choriocarcinoma and embryonal carcinoma
693327|NCT00004157|testicular choriocarcinoma and teratoma
693328|NCT00004157|testicular choriocarcinoma and seminoma
693329|NCT00004157|recurrent/refractory childhood Hodgkin lymphoma
693330|NCT00004157|recurrent ovarian germ cell tumor
693331|NCT00004157|ovarian yolk sac tumor
693332|NCT00004157|ovarian embryonal carcinoma
693333|NCT00004157|ovarian polyembryoma
693334|NCT00004157|ovarian choriocarcinoma
693335|NCT00004157|ovarian immature teratoma
693336|NCT00004157|ovarian mature teratoma
693337|NCT00004157|ovarian monodermal and highly specialized teratoma
693338|NCT00004157|ovarian mixed germ cell tumor
693339|NCT00004157|stage III grade 1 follicular lymphoma
693340|NCT00004157|stage III grade 2 follicular lymphoma
693341|NCT00004157|stage III grade 3 follicular lymphoma
693342|NCT00004157|stage III adult diffuse small cleaved cell lymphoma
693343|NCT00004157|stage III adult diffuse mixed cell lymphoma
693344|NCT00004157|stage III adult diffuse large cell lymphoma
693345|NCT00004157|stage III adult immunoblastic large cell lymphoma
693346|NCT00004157|stage III adult lymphoblastic lymphoma
693347|NCT00004157|stage III adult Burkitt lymphoma
693348|NCT00004157|stage IV grade 1 follicular lymphoma
693349|NCT00004157|stage IV grade 2 follicular lymphoma
693350|NCT00004157|stage IV grade 3 follicular lymphoma
693351|NCT00004157|stage IV adult diffuse small cleaved cell lymphoma
693352|NCT00004157|stage IV adult diffuse mixed cell lymphoma
693353|NCT00004157|stage IV adult diffuse large cell lymphoma
693354|NCT00004157|stage IV adult immunoblastic large cell lymphoma
693355|NCT00004157|stage IV adult lymphoblastic lymphoma
693356|NCT00004157|stage IV adult Burkitt lymphoma
693357|NCT00004157|recurrent grade 1 follicular lymphoma
693358|NCT00004157|recurrent grade 2 follicular lymphoma
693359|NCT00004157|recurrent grade 3 follicular lymphoma
693360|NCT00004157|recurrent adult diffuse small cleaved cell lymphoma
693361|NCT00004157|recurrent adult diffuse mixed cell lymphoma
693362|NCT00004157|recurrent adult diffuse large cell lymphoma
693363|NCT00004157|recurrent adult immunoblastic large cell lymphoma
693364|NCT00004157|recurrent adult lymphoblastic lymphoma
693365|NCT00004157|recurrent adult Burkitt lymphoma
693366|NCT00004157|poor prognosis metastatic gestational trophoblastic tumor
693367|NCT00004157|recurrent childhood small noncleaved cell lymphoma
693368|NCT00004157|recurrent childhood large cell lymphoma
693369|NCT00004157|noncontiguous stage II grade 1 follicular lymphoma
693370|NCT00004157|noncontiguous stage II grade 2 follicular lymphoma
693371|NCT00004157|noncontiguous stage II grade 3 follicular lymphoma
693372|NCT00004157|noncontiguous stage II adult diffuse small cleaved cell lymphoma
693373|NCT00004157|noncontiguous stage II mantle cell lymphoma
693374|NCT00004157|noncontiguous stage II adult diffuse mixed cell lymphoma
693375|NCT00004157|noncontiguous stage II adult immunoblastic large cell lymphoma
693376|NCT00004157|noncontiguous stage II adult diffuse large cell lymphoma
693377|NCT00004157|noncontiguous stage II adult Burkitt lymphoma
693378|NCT00004157|noncontiguous stage II adult lymphoblastic lymphoma
693379|NCT00004157|stage III mantle cell lymphoma
693380|NCT00004157|stage IV mantle cell lymphoma
693381|NCT00004157|recurrent mantle cell lymphoma
693382|NCT00004157|previously treated childhood rhabdomyosarcoma
693383|NCT00004157|noncontiguous stage II small lymphocytic lymphoma
693384|NCT00004157|noncontiguous stage II marginal zone lymphoma
693385|NCT00004157|recurrent marginal zone lymphoma
693386|NCT00004157|recurrent small lymphocytic lymphoma
693387|NCT00004157|stage III small lymphocytic lymphoma
693388|NCT00004157|stage III marginal zone lymphoma
693389|NCT00004157|stage IV small lymphocytic lymphoma
693390|NCT00004157|stage IV marginal zone lymphoma
693391|NCT00004157|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693392|NCT00004157|nodal marginal zone B-cell lymphoma
693393|NCT00004157|splenic marginal zone lymphoma
693394|NCT00004156|stage I breast cancer
693395|NCT00004156|stage II breast cancer
693396|NCT00004156|stage IV breast cancer
693397|NCT00004156|stage IIIA breast cancer
693398|NCT00004156|recurrent breast cancer
693399|NCT00004156|stage IIIB breast cancer
693400|NCT00004154|stage 0 bladder cancer
693401|NCT00004154|stage I bladder cancer
693402|NCT00004154|transitional cell carcinoma of the bladder
693403|NCT00004153|stage I melanoma
693404|NCT00004153|stage II melanoma
693405|NCT00004153|stage III melanoma
693406|NCT00004153|stage IV melanoma
693407|NCT00004152|stage III melanoma
693408|NCT00004152|stage IV melanoma
693409|NCT00004152|recurrent melanoma
693410|NCT00004151|recurrent non-small cell lung cancer
693411|NCT00004151|stage IIIA non-small cell lung cancer
693412|NCT00004151|stage IIIB non-small cell lung cancer
693413|NCT00004151|stage IV non-small cell lung cancer
693414|NCT00004150|stage III colon cancer
693415|NCT00004150|adenocarcinoma of the colon
693416|NCT00004150|mucinous adenocarcinoma of the colon
693417|NCT00004149|stage IV prostate cancer
693418|NCT00004149|recurrent prostate cancer
693419|NCT00004148|stage III melanoma
693420|NCT00004148|stage IV melanoma
693421|NCT00004148|recurrent melanoma
693422|NCT00004147|recurrent adult brain tumor
693423|NCT00004147|adult glioblastoma
693424|NCT00004147|adult anaplastic astrocytoma
693425|NCT00004147|adult anaplastic oligodendroglioma
693426|NCT00004147|adult giant cell glioblastoma
693427|NCT00004147|adult gliosarcoma
693428|NCT00004145|stage III adult Hodgkin lymphoma
693429|NCT00004145|stage IV adult Hodgkin lymphoma
693430|NCT00004145|recurrent adult Hodgkin lymphoma
693431|NCT00004145|refractory multiple myeloma
693432|NCT00004145|stage I multiple myeloma
693433|NCT00004145|stage II multiple myeloma
693434|NCT00004145|stage III multiple myeloma
693435|NCT00004145|stage II chronic lymphocytic leukemia
693436|NCT00004145|stage III chronic lymphocytic leukemia
693437|NCT00004145|stage IV chronic lymphocytic leukemia
693438|NCT00004145|recurrent adult acute myeloid leukemia
693439|NCT00004145|recurrent adult acute lymphoblastic leukemia
693440|NCT00004145|refractory chronic lymphocytic leukemia
693441|NCT00004145|chronic phase chronic myelogenous leukemia
693442|NCT00004145|accelerated phase chronic myelogenous leukemia
693443|NCT00004145|adult acute myeloid leukemia in remission
693444|NCT00004145|adult acute lymphoblastic leukemia in remission
693445|NCT00004145|refractory anemia
693446|NCT00004145|refractory anemia with ringed sideroblasts
693447|NCT00004145|refractory anemia with excess blasts
693448|NCT00004145|refractory anemia with excess blasts in transformation
693449|NCT00004145|chronic myelomonocytic leukemia
693450|NCT00004145|stage III grade 1 follicular lymphoma
693451|NCT00004145|stage III grade 2 follicular lymphoma
693452|NCT00004145|stage III grade 3 follicular lymphoma
693453|NCT00004145|stage III adult diffuse small cleaved cell lymphoma
693454|NCT00004145|stage III adult diffuse mixed cell lymphoma
693455|NCT00004145|stage III adult diffuse large cell lymphoma
693456|NCT00004145|stage III adult immunoblastic large cell lymphoma
693457|NCT00004145|stage III adult lymphoblastic lymphoma
693458|NCT00004145|stage III adult Burkitt lymphoma
693459|NCT00004145|stage IV grade 1 follicular lymphoma
693460|NCT00004145|stage IV grade 2 follicular lymphoma
693461|NCT00004145|stage IV grade 3 follicular lymphoma
693462|NCT00004145|stage IV adult diffuse small cleaved cell lymphoma
693463|NCT00004145|stage IV adult diffuse mixed cell lymphoma
693464|NCT00004145|stage IV adult diffuse large cell lymphoma
693465|NCT00004145|stage IV adult immunoblastic large cell lymphoma
693466|NCT00004145|stage IV adult lymphoblastic lymphoma
693467|NCT00004145|stage IV adult Burkitt lymphoma
693468|NCT00004145|recurrent grade 1 follicular lymphoma
693469|NCT00004145|recurrent grade 2 follicular lymphoma
693470|NCT00004145|recurrent grade 3 follicular lymphoma
693471|NCT00004145|recurrent adult diffuse small cleaved cell lymphoma
693472|NCT00004145|recurrent adult diffuse mixed cell lymphoma
693473|NCT00004145|recurrent adult diffuse large cell lymphoma
693474|NCT00004145|recurrent adult immunoblastic large cell lymphoma
693475|NCT00004145|recurrent adult lymphoblastic lymphoma
693476|NCT00004145|recurrent adult Burkitt lymphoma
693477|NCT00004145|secondary acute myeloid leukemia
693478|NCT00004145|de novo myelodysplastic syndromes
693479|NCT00004145|previously treated myelodysplastic syndromes
693480|NCT00004145|secondary myelodysplastic syndromes
693481|NCT00004145|stage III mantle cell lymphoma
693482|NCT00004145|stage IV mantle cell lymphoma
693483|NCT00004145|recurrent mantle cell lymphoma
693484|NCT00004145|recurrent marginal zone lymphoma
693485|NCT00004145|recurrent small lymphocytic lymphoma
693486|NCT00004145|stage III small lymphocytic lymphoma
696528|NCT00003751|adult gliosarcoma
693487|NCT00004145|stage III marginal zone lymphoma
693488|NCT00004145|stage IV small lymphocytic lymphoma
693489|NCT00004145|stage IV marginal zone lymphoma
693490|NCT00004145|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693491|NCT00004145|nodal marginal zone B-cell lymphoma
693492|NCT00004145|splenic marginal zone lymphoma
693493|NCT00004144|unspecified adult solid tumor, protocol specific
693494|NCT00004143|sickle cell anemia
693495|NCT00004143|severe aplastic anemia
693496|NCT00004142|stage IV colon cancer
693497|NCT00004142|stage IV rectal cancer
693498|NCT00004142|recurrent colon cancer
693499|NCT00004142|recurrent rectal cancer
693500|NCT00004142|liver metastases
693501|NCT00004141|stage III melanoma
693502|NCT00004141|stage IV melanoma
693503|NCT00004141|recurrent melanoma
693504|NCT00004139|recurrent non-small cell lung cancer
693505|NCT00004139|squamous cell lung cancer
693506|NCT00004139|large cell lung cancer
693507|NCT00004139|stage IIIB non-small cell lung cancer
693508|NCT00004139|stage IV non-small cell lung cancer
693509|NCT00004139|adenocarcinoma of the lung
693510|NCT00004139|bronchoalveolar cell lung cancer
693511|NCT00004138|stage I non-small cell lung cancer
693512|NCT00004138|stage II non-small cell lung cancer
693513|NCT00004138|squamous cell lung cancer
693514|NCT00004138|large cell lung cancer
693515|NCT00004138|stage IIIA non-small cell lung cancer
693516|NCT00004138|adenocarcinoma of the lung
693517|NCT00004138|bronchoalveolar cell lung cancer
693518|NCT00004137|extensive stage small cell lung cancer
693519|NCT00004136|stage III childhood liver cancer
693520|NCT00004136|stage IV childhood liver cancer
693521|NCT00004136|recurrent childhood liver cancer
693522|NCT00004136|localized unresectable adult primary liver cancer
693523|NCT00004136|advanced adult primary liver cancer
693524|NCT00004136|recurrent adult primary liver cancer
693525|NCT00004136|liver metastases
693526|NCT00004135|stage IV renal cell cancer
693527|NCT00004135|recurrent renal cell cancer
693528|NCT00004135|stage IV melanoma
693529|NCT00004135|recurrent melanoma
693530|NCT00004132|stage I adult Hodgkin lymphoma
693531|NCT00004132|stage II adult Hodgkin lymphoma
693532|NCT00004132|stage III adult Hodgkin lymphoma
693533|NCT00004132|stage IV adult Hodgkin lymphoma
693534|NCT00004132|recurrent adult Hodgkin lymphoma
693535|NCT00004132|childhood Burkitt lymphoma
693536|NCT00004132|refractory multiple myeloma
693537|NCT00004132|stage 0 chronic lymphocytic leukemia
693538|NCT00004132|stage I multiple myeloma
693539|NCT00004132|stage II multiple myeloma
693540|NCT00004132|stage III multiple myeloma
693541|NCT00004132|stage IV childhood lymphoblastic lymphoma
693542|NCT00004132|stage I chronic lymphocytic leukemia
693543|NCT00004132|stage II chronic lymphocytic leukemia
693544|NCT00004132|stage III chronic lymphocytic leukemia
693545|NCT00004132|stage IV chronic lymphocytic leukemia
693546|NCT00004132|recurrent adult acute myeloid leukemia
693547|NCT00004132|recurrent adult acute lymphoblastic leukemia
693548|NCT00004132|refractory chronic lymphocytic leukemia
693549|NCT00004132|blastic phase chronic myelogenous leukemia
693550|NCT00004132|untreated adult acute lymphoblastic leukemia
693551|NCT00004132|untreated adult acute myeloid leukemia
693552|NCT00004132|untreated childhood acute myeloid leukemia and other myeloid malignancies
693553|NCT00004132|untreated childhood acute lymphoblastic leukemia
693554|NCT00004132|oral complications
693555|NCT00004132|stage IV childhood Hodgkin lymphoma
693556|NCT00004132|stage I grade 1 follicular lymphoma
693557|NCT00004132|stage I grade 2 follicular lymphoma
693558|NCT00004132|stage I grade 3 follicular lymphoma
693559|NCT00004132|stage I adult diffuse small cleaved cell lymphoma
693560|NCT00004132|stage I adult diffuse mixed cell lymphoma
693561|NCT00004132|stage I adult diffuse large cell lymphoma
693562|NCT00004132|stage I adult immunoblastic large cell lymphoma
693563|NCT00004132|stage I adult lymphoblastic lymphoma
693564|NCT00004132|stage I adult Burkitt lymphoma
693565|NCT00004132|stage III grade 1 follicular lymphoma
693566|NCT00004132|stage III grade 2 follicular lymphoma
693567|NCT00004132|stage III grade 3 follicular lymphoma
693568|NCT00004132|stage III adult diffuse small cleaved cell lymphoma
693569|NCT00004132|stage III adult diffuse mixed cell lymphoma
693570|NCT00004132|stage III adult diffuse large cell lymphoma
693571|NCT00004132|stage III adult immunoblastic large cell lymphoma
693572|NCT00004132|stage III adult lymphoblastic lymphoma
693573|NCT00004132|stage III adult Burkitt lymphoma
693574|NCT00004132|stage IV grade 1 follicular lymphoma
693575|NCT00004132|stage IV grade 2 follicular lymphoma
693576|NCT00004132|stage IV grade 3 follicular lymphoma
693577|NCT00004132|stage IV adult diffuse small cleaved cell lymphoma
693578|NCT00004132|stage IV adult diffuse mixed cell lymphoma
693579|NCT00004132|stage IV adult diffuse large cell lymphoma
693580|NCT00004132|stage IV adult immunoblastic large cell lymphoma
693581|NCT00004132|stage IV adult lymphoblastic lymphoma
693582|NCT00004132|stage IV adult Burkitt lymphoma
693583|NCT00004132|recurrent grade 1 follicular lymphoma
693584|NCT00004132|recurrent grade 2 follicular lymphoma
693585|NCT00004132|recurrent grade 3 follicular lymphoma
693586|NCT00004132|recurrent adult diffuse small cleaved cell lymphoma
693587|NCT00004132|recurrent adult diffuse mixed cell lymphoma
693588|NCT00004132|recurrent adult diffuse large cell lymphoma
693589|NCT00004132|recurrent adult immunoblastic large cell lymphoma
693590|NCT00004132|recurrent adult lymphoblastic lymphoma
693591|NCT00004132|recurrent adult Burkitt lymphoma
693592|NCT00004132|primary central nervous system non-Hodgkin lymphoma
693593|NCT00004132|drug/agent toxicity by tissue/organ
693594|NCT00004132|radiation toxicity
693595|NCT00004132|stage IV childhood small noncleaved cell lymphoma
693596|NCT00004132|stage IV childhood large cell lymphoma
693597|NCT00004132|stage I mantle cell lymphoma
693598|NCT00004132|contiguous stage II grade 1 follicular lymphoma
693599|NCT00004132|contiguous stage II grade 2 follicular lymphoma
693600|NCT00004132|contiguous stage II grade 3 follicular lymphoma
693601|NCT00004132|contiguous stage II adult diffuse small cleaved cell lymphoma
693602|NCT00004132|contiguous stage II mantle cell lymphoma
693603|NCT00004132|contiguous stage II adult diffuse mixed cell lymphoma
693604|NCT00004132|contiguous stage II adult immunoblastic large cell lymphoma
693605|NCT00004132|contiguous stage II adult diffuse large cell lymphoma
693606|NCT00004132|contiguous stage II adult Burkitt lymphoma
693607|NCT00004132|contiguous stage II adult lymphoblastic lymphoma
693608|NCT00004132|noncontiguous stage II grade 1 follicular lymphoma
693609|NCT00004132|noncontiguous stage II grade 2 follicular lymphoma
693610|NCT00004132|noncontiguous stage II grade 3 follicular lymphoma
693611|NCT00004132|noncontiguous stage II adult diffuse small cleaved cell lymphoma
693612|NCT00004132|noncontiguous stage II mantle cell lymphoma
693613|NCT00004132|noncontiguous stage II adult diffuse mixed cell lymphoma
693614|NCT00004132|noncontiguous stage II adult immunoblastic large cell lymphoma
693615|NCT00004132|noncontiguous stage II adult diffuse large cell lymphoma
693616|NCT00004132|noncontiguous stage II adult Burkitt lymphoma
693617|NCT00004132|noncontiguous stage II adult lymphoblastic lymphoma
693618|NCT00004132|stage III mantle cell lymphoma
693619|NCT00004132|stage IV mantle cell lymphoma
693620|NCT00004132|recurrent mantle cell lymphoma
693621|NCT00004132|anaplastic large cell lymphoma
693622|NCT00004132|noncontiguous stage II small lymphocytic lymphoma
693623|NCT00004132|noncontiguous stage II marginal zone lymphoma
693624|NCT00004132|recurrent marginal zone lymphoma
693625|NCT00004132|recurrent small lymphocytic lymphoma
693626|NCT00004132|stage I marginal zone lymphoma
693627|NCT00004132|stage I small lymphocytic lymphoma
693628|NCT00004132|stage III small lymphocytic lymphoma
693629|NCT00004132|stage III marginal zone lymphoma
693630|NCT00004132|stage IV small lymphocytic lymphoma
693631|NCT00004132|stage IV marginal zone lymphoma
693632|NCT00004132|contiguous stage II marginal zone lymphoma
693633|NCT00004132|contiguous stage II small lymphocytic lymphoma
693634|NCT00004132|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693635|NCT00004132|nodal marginal zone B-cell lymphoma
693636|NCT00004132|splenic marginal zone lymphoma
693637|NCT00004129|recurrent adult brain tumor
693638|NCT00004129|adult glioblastoma
693639|NCT00004129|adult giant cell glioblastoma
693640|NCT00004129|adult gliosarcoma
693641|NCT00004128|untreated adult acute myeloid leukemia
693642|NCT00004128|adult acute erythroid leukemia (M6)
693643|NCT00004128|adult acute myeloblastic leukemia without maturation (M1)
693644|NCT00004128|adult acute myeloblastic leukemia with maturation (M2)
693645|NCT00004128|adult acute myelomonocytic leukemia (M4)
693646|NCT00004128|adult acute monoblastic leukemia (M5a)
693647|NCT00004128|adult acute megakaryoblastic leukemia (M7)
693648|NCT00004128|adult acute monocytic leukemia (M5b)
693649|NCT00004128|adult acute minimally differentiated myeloid leukemia (M0)
693650|NCT00004128|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
693651|NCT00004128|adult acute myeloid leukemia with inv(16)(p13;q22)
693652|NCT00004128|adult acute myeloid leukemia with t(16;16)(p13;q22)
693653|NCT00004128|adult acute myeloid leukemia with t(8;21)(q22;q22)
693654|NCT00004127|stage IV gastric cancer
693655|NCT00004127|recurrent gastric cancer
693656|NCT00004127|stage IV esophageal cancer
693657|NCT00004127|recurrent esophageal cancer
693658|NCT00004127|adenocarcinoma of the stomach
693659|NCT00004127|adenocarcinoma of the esophagus
693660|NCT00004126|recurrent non-small cell lung cancer
693661|NCT00004126|stage IIIB non-small cell lung cancer
693662|NCT00004126|stage IV non-small cell lung cancer
693663|NCT00004125|stage II breast cancer
693664|NCT00004125|stage IIIA breast cancer
693665|NCT00004124|adenocarcinoma of the prostate
693666|NCT00004124|stage I prostate cancer
693667|NCT00004124|stage II prostate cancer
693668|NCT00004124|stage III prostate cancer
693669|NCT00004123|adult leiomyosarcoma
693670|NCT00004123|adult liposarcoma
693671|NCT00004123|stage III adult soft tissue sarcoma
693672|NCT00004123|recurrent adult soft tissue sarcoma
693673|NCT00004123|stage II adult soft tissue sarcoma
693674|NCT00004122|stage I bladder cancer
693675|NCT00004122|recurrent bladder cancer
693676|NCT00004122|transitional cell carcinoma of the bladder
693677|NCT00004115|stage I ovarian epithelial cancer
693678|NCT00004115|stage II ovarian epithelial cancer
693679|NCT00004115|stage III ovarian epithelial cancer
693680|NCT00004115|stage IV ovarian epithelial cancer
693681|NCT00004115|primary peritoneal cavity cancer
693682|NCT00004114|recurrent adult Hodgkin lymphoma
693683|NCT00004114|recurrent cutaneous T-cell non-Hodgkin lymphoma
693684|NCT00004114|recurrent adult acute myeloid leukemia
693685|NCT00004114|recurrent adult acute lymphoblastic leukemia
693686|NCT00004114|relapsing chronic myelogenous leukemia
693687|NCT00004114|refractory chronic lymphocytic leukemia
693688|NCT00004114|chronic myelomonocytic leukemia
693689|NCT00004114|recurrent grade 1 follicular lymphoma
693690|NCT00004114|recurrent grade 2 follicular lymphoma
693691|NCT00004114|recurrent grade 3 follicular lymphoma
693692|NCT00004114|recurrent adult diffuse small cleaved cell lymphoma
693693|NCT00004114|recurrent adult diffuse mixed cell lymphoma
693694|NCT00004114|recurrent adult diffuse large cell lymphoma
693695|NCT00004114|recurrent adult immunoblastic large cell lymphoma
693696|NCT00004114|recurrent adult lymphoblastic lymphoma
693697|NCT00004114|recurrent adult Burkitt lymphoma
693698|NCT00004114|recurrent adult T-cell leukemia/lymphoma
693699|NCT00004114|previously treated myelodysplastic syndromes
693700|NCT00004114|AIDS-related peripheral/systemic lymphoma
693701|NCT00004114|recurrent mantle cell lymphoma
693702|NCT00004114|anaplastic large cell lymphoma
693703|NCT00004114|refractory cytopenia with multilineage dysplasia
693704|NCT00004114|recurrent mycosis fungoides/Sezary syndrome
693705|NCT00004114|recurrent marginal zone lymphoma
693706|NCT00004114|recurrent small lymphocytic lymphoma
693707|NCT00004114|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693708|NCT00004114|nodal marginal zone B-cell lymphoma
693709|NCT00004114|splenic marginal zone lymphoma
693710|NCT00004113|recurrent adult brain tumor
693711|NCT00004113|adult glioblastoma
693712|NCT00004113|adult anaplastic astrocytoma
693713|NCT00004113|adult anaplastic oligodendroglioma
693714|NCT00004113|adult mixed glioma
693715|NCT00004113|adult giant cell glioblastoma
693716|NCT00004113|adult gliosarcoma
693717|NCT00004112|stage II adult diffuse small cleaved cell lymphoma
693718|NCT00004112|stage II adult diffuse mixed cell lymphoma
693719|NCT00004112|stage II adult diffuse large cell lymphoma
693720|NCT00004112|stage III adult diffuse small cleaved cell lymphoma
693721|NCT00004112|stage III adult diffuse mixed cell lymphoma
693722|NCT00004112|stage III adult diffuse large cell lymphoma
693723|NCT00004112|stage IV adult diffuse small cleaved cell lymphoma
693724|NCT00004112|stage IV adult diffuse mixed cell lymphoma
693725|NCT00004112|stage IV adult diffuse large cell lymphoma
693726|NCT00004112|stage III mantle cell lymphoma
693727|NCT00004112|stage IV mantle cell lymphoma
693728|NCT00004112|anaplastic large cell lymphoma
693729|NCT00004112|stage II mantle cell lymphoma
693730|NCT00004112|stage II small lymphocytic lymphoma
693731|NCT00004112|stage II marginal zone lymphoma
693732|NCT00004112|stage III small lymphocytic lymphoma
693733|NCT00004112|stage III marginal zone lymphoma
693734|NCT00004112|stage IV small lymphocytic lymphoma
693735|NCT00004112|stage IV marginal zone lymphoma
693736|NCT00004112|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693737|NCT00004112|nodal marginal zone B-cell lymphoma
693738|NCT00004112|splenic marginal zone lymphoma
693739|NCT00004110|regional neuroblastoma
693740|NCT00004110|disseminated neuroblastoma
693741|NCT00004110|recurrent neuroblastoma
693742|NCT00004110|localized unresectable neuroblastoma
693743|NCT00004109|stage III adult soft tissue sarcoma
693744|NCT00004109|recurrent adult soft tissue sarcoma
693745|NCT00004109|Doxorubicin
693746|NCT00004109|External-Beam RT
693747|NCT00004109|XRT
693748|NCT00004109|cancer
693749|NCT00004109|PREOPERATIVE CONCURRENT CHEMORADIATION
693750|NCT00004109|EXTREMITY SOFT TISSUE SARCOMAS
693751|NCT00004109|TRUNK SOFT TISSUE SARCOMAS
693752|NCT00004109|Concurrent Chemoradiation
693753|NCT00004109|Surgical Resection
693754|NCT00004109|Localized Extremity Soft Tissue Sarcomas
693755|NCT00004109|Body Wall Soft Tissue Sarcomas
693756|NCT00004108|localized resectable adult primary liver cancer
693757|NCT00004108|localized unresectable adult primary liver cancer
693758|NCT00004108|advanced adult primary liver cancer
693759|NCT00004108|recurrent adult primary liver cancer
693760|NCT00004108|adult primary hepatocellular carcinoma
693761|NCT00004107|Waldenstrom macroglobulinemia
693762|NCT00004107|recurrent adult acute lymphoblastic leukemia
693763|NCT00004107|refractory chronic lymphocytic leukemia
693764|NCT00004107|B-cell chronic lymphocytic leukemia
693765|NCT00004107|B-cell adult acute lymphoblastic leukemia
693766|NCT00004107|recurrent grade 1 follicular lymphoma
693767|NCT00004107|recurrent grade 2 follicular lymphoma
693768|NCT00004107|recurrent grade 3 follicular lymphoma
693769|NCT00004107|recurrent adult diffuse small cleaved cell lymphoma
693770|NCT00004107|recurrent adult diffuse mixed cell lymphoma
693771|NCT00004107|recurrent adult diffuse large cell lymphoma
693772|NCT00004107|recurrent adult immunoblastic large cell lymphoma
693773|NCT00004107|recurrent adult lymphoblastic lymphoma
696529|NCT00003750|metastatic osteosarcoma
693774|NCT00004107|recurrent adult Burkitt lymphoma
693775|NCT00004107|recurrent mantle cell lymphoma
693776|NCT00004107|recurrent marginal zone lymphoma
693777|NCT00004107|recurrent small lymphocytic lymphoma
693778|NCT00004107|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693779|NCT00004107|nodal marginal zone B-cell lymphoma
693780|NCT00004107|splenic marginal zone lymphoma
693781|NCT00004106|stage I cutaneous T-cell non-Hodgkin lymphoma
693782|NCT00004106|stage II cutaneous T-cell non-Hodgkin lymphoma
693783|NCT00004106|stage III cutaneous T-cell non-Hodgkin lymphoma
693784|NCT00004106|stage IV cutaneous T-cell non-Hodgkin lymphoma
693785|NCT00004106|recurrent cutaneous T-cell non-Hodgkin lymphoma
693786|NCT00004106|stage I mycosis fungoides/Sezary syndrome
693787|NCT00004106|stage II mycosis fungoides/Sezary syndrome
693788|NCT00004106|stage III mycosis fungoides/Sezary syndrome
693789|NCT00004106|stage IV mycosis fungoides/Sezary syndrome
693790|NCT00004106|recurrent mycosis fungoides/Sezary syndrome
693791|NCT00004105|stage III adult Hodgkin lymphoma
693792|NCT00004105|stage IV adult Hodgkin lymphoma
693793|NCT00004105|recurrent adult Hodgkin lymphoma
693794|NCT00004105|stage III chronic lymphocytic leukemia
693795|NCT00004105|stage IV chronic lymphocytic leukemia
693796|NCT00004105|recurrent adult acute myeloid leukemia
693797|NCT00004105|unspecified adult solid tumor, protocol specific
693798|NCT00004105|childhood fibrosarcoma
693799|NCT00004105|stage III grade 1 follicular lymphoma
693800|NCT00004105|stage III grade 2 follicular lymphoma
693801|NCT00004105|stage III grade 3 follicular lymphoma
693802|NCT00004105|stage III adult diffuse small cleaved cell lymphoma
693803|NCT00004105|stage III adult diffuse mixed cell lymphoma
693804|NCT00004105|stage III adult diffuse large cell lymphoma
693805|NCT00004105|stage III adult immunoblastic large cell lymphoma
693806|NCT00004105|stage III adult lymphoblastic lymphoma
693807|NCT00004105|stage III adult Burkitt lymphoma
693808|NCT00004105|stage IV grade 1 follicular lymphoma
693809|NCT00004105|stage IV grade 2 follicular lymphoma
693810|NCT00004105|stage IV grade 3 follicular lymphoma
693811|NCT00004105|stage IV adult diffuse small cleaved cell lymphoma
693812|NCT00004105|stage IV adult diffuse mixed cell lymphoma
693813|NCT00004105|stage IV adult diffuse large cell lymphoma
693814|NCT00004105|stage IV adult immunoblastic large cell lymphoma
693815|NCT00004105|stage IV adult lymphoblastic lymphoma
693816|NCT00004105|stage IV adult Burkitt lymphoma
693817|NCT00004105|recurrent grade 1 follicular lymphoma
693818|NCT00004105|recurrent grade 2 follicular lymphoma
693819|NCT00004105|recurrent grade 3 follicular lymphoma
693820|NCT00004105|recurrent adult diffuse small cleaved cell lymphoma
693821|NCT00004105|recurrent adult diffuse mixed cell lymphoma
693822|NCT00004105|recurrent adult diffuse large cell lymphoma
693823|NCT00004105|recurrent adult immunoblastic large cell lymphoma
693824|NCT00004105|recurrent adult lymphoblastic lymphoma
693825|NCT00004105|recurrent adult Burkitt lymphoma
693826|NCT00004105|stage III adult T-cell leukemia/lymphoma
693827|NCT00004105|stage IV adult T-cell leukemia/lymphoma
693828|NCT00004105|recurrent adult T-cell leukemia/lymphoma
693829|NCT00004105|stage III mantle cell lymphoma
693830|NCT00004105|stage IV mantle cell lymphoma
693831|NCT00004105|recurrent mantle cell lymphoma
693832|NCT00004105|recurrent marginal zone lymphoma
693833|NCT00004105|recurrent small lymphocytic lymphoma
693834|NCT00004105|stage III small lymphocytic lymphoma
693835|NCT00004105|stage III marginal zone lymphoma
693836|NCT00004105|stage IV small lymphocytic lymphoma
693837|NCT00004105|stage IV marginal zone lymphoma
693838|NCT00004105|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693839|NCT00004105|nodal marginal zone B-cell lymphoma
693840|NCT00004105|splenic marginal zone lymphoma
693841|NCT00004104|stage III melanoma
693842|NCT00004103|stage I gastric cancer
693843|NCT00004103|stage II gastric cancer
693844|NCT00004103|stage III gastric cancer
693845|NCT00004103|stage IV gastric cancer
693846|NCT00004102|stage IV colon cancer
693847|NCT00004102|stage IV rectal cancer
693848|NCT00004102|recurrent colon cancer
693849|NCT00004102|recurrent rectal cancer
693850|NCT00004102|adenocarcinoma of the colon
693851|NCT00004102|adenocarcinoma of the rectum
693852|NCT00004101|recurrent grade 1 follicular lymphoma
693853|NCT00004101|recurrent grade 2 follicular lymphoma
693854|NCT00004101|recurrent grade 3 follicular lymphoma
693855|NCT00004101|recurrent adult diffuse small cleaved cell lymphoma
693856|NCT00004101|recurrent adult diffuse mixed cell lymphoma
693857|NCT00004101|recurrent adult diffuse large cell lymphoma
693858|NCT00004101|recurrent adult immunoblastic large cell lymphoma
693859|NCT00004101|recurrent adult lymphoblastic lymphoma
693860|NCT00004101|recurrent adult Burkitt lymphoma
693861|NCT00004101|recurrent mantle cell lymphoma
693862|NCT00004101|recurrent marginal zone lymphoma
693863|NCT00004101|recurrent small lymphocytic lymphoma
693864|NCT00004101|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693865|NCT00004101|nodal marginal zone B-cell lymphoma
693866|NCT00004101|splenic marginal zone lymphoma
693867|NCT00004100|stage IIIB non-small cell lung cancer
693868|NCT00004100|stage IV non-small cell lung cancer
693870|NCT00004099|stage III gastric cancer
693871|NCT00004099|stage IV gastric cancer
693872|NCT00004099|intestinal adenocarcinoma of the stomach
693873|NCT00004099|diffuse adenocarcinoma of the stomach
693874|NCT00004099|mixed adenocarcinoma of the stomach
693875|NCT00004097|stage III nasopharyngeal cancer
693876|NCT00004097|stage IV nasopharyngeal cancer
693877|NCT00004097|recurrent nasopharyngeal cancer
693878|NCT00004097|untreated metastatic squamous neck cancer with occult primary
693879|NCT00004097|recurrent metastatic squamous neck cancer with occult primary
693880|NCT00004097|stage III lip and oral cavity cancer
693881|NCT00004097|stage IV lip and oral cavity cancer
693882|NCT00004097|recurrent lip and oral cavity cancer
693883|NCT00004097|stage III hypopharyngeal cancer
693884|NCT00004097|stage IV hypopharyngeal cancer
693885|NCT00004097|recurrent hypopharyngeal cancer
693886|NCT00004097|stage III laryngeal cancer
693887|NCT00004097|stage IV laryngeal cancer
693888|NCT00004097|recurrent laryngeal cancer
693889|NCT00004097|stage III paranasal sinus and nasal cavity cancer
693890|NCT00004097|stage IV paranasal sinus and nasal cavity cancer
693891|NCT00004097|recurrent paranasal sinus and nasal cavity cancer
693892|NCT00004097|stage III oropharyngeal cancer
693893|NCT00004097|stage IV oropharyngeal cancer
693894|NCT00004097|recurrent oropharyngeal cancer
693895|NCT00004096|stage IIIB non-small cell lung cancer
693896|NCT00004096|stage IV non-small cell lung cancer
693897|NCT00004095|stage IV colon cancer
693898|NCT00004095|stage IV breast cancer
693899|NCT00004095|recurrent breast cancer
693900|NCT00004095|recurrent non-small cell lung cancer
693901|NCT00004095|recurrent pancreatic cancer
693902|NCT00004095|stage IV rectal cancer
693903|NCT00004095|recurrent colon cancer
693904|NCT00004095|recurrent rectal cancer
693905|NCT00004095|stage IV renal cell cancer
693906|NCT00004095|recurrent renal cell cancer
693907|NCT00004095|extensive stage small cell lung cancer
693908|NCT00004095|recurrent small cell lung cancer
693909|NCT00004095|recurrent bladder cancer
693910|NCT00004095|stage IV bladder cancer
693911|NCT00004095|stage IV non-small cell lung cancer
693912|NCT00004095|stage IV pancreatic cancer
693913|NCT00004094|stage III squamous cell carcinoma of the lip and oral cavity
693914|NCT00004094|stage IV squamous cell carcinoma of the lip and oral cavity
693915|NCT00004094|stage IV squamous cell carcinoma of the oropharynx
693916|NCT00004094|stage IV lymphoepithelioma of the oropharynx
693917|NCT00004094|stage IV squamous cell carcinoma of the nasopharynx
693918|NCT00004094|stage IV lymphoepithelioma of the nasopharynx
693919|NCT00004094|stage III squamous cell carcinoma of the hypopharynx
693920|NCT00004094|stage IV squamous cell carcinoma of the hypopharynx
693921|NCT00004094|stage IV squamous cell carcinoma of the larynx
693922|NCT00004093|stage IIIA non-small cell lung cancer
693923|NCT00004093|stage IIIB non-small cell lung cancer
693924|NCT00004092|stage II breast cancer
693925|NCT00004092|stage IIIA breast cancer
693926|NCT00004092|stage IIIB breast cancer
693927|NCT00004091|cervical cancer
693928|NCT00004090|unspecified adult solid tumor, protocol specific
693929|NCT00004089|anaplastic thyroid cancer
693930|NCT00004088|stage I multiple myeloma
693931|NCT00004088|stage II multiple myeloma
693932|NCT00004088|stage III multiple myeloma
693933|NCT00004087|stage IV colon cancer
693934|NCT00004087|stage IV pancreatic cancer
693935|NCT00004087|recurrent pancreatic cancer
693936|NCT00004087|stage IV rectal cancer
693937|NCT00004087|recurrent colon cancer
693938|NCT00004087|recurrent rectal cancer
693939|NCT00004086|Waldenstrom macroglobulinemia
693940|NCT00004086|refractory chronic lymphocytic leukemia
693941|NCT00004086|B-cell chronic lymphocytic leukemia
693942|NCT00004086|refractory hairy cell leukemia
693943|NCT00004086|recurrent grade 1 follicular lymphoma
693944|NCT00004086|recurrent grade 2 follicular lymphoma
693945|NCT00004086|recurrent grade 3 follicular lymphoma
693946|NCT00004086|recurrent adult diffuse small cleaved cell lymphoma
693947|NCT00004086|recurrent adult diffuse mixed cell lymphoma
693948|NCT00004086|recurrent adult diffuse large cell lymphoma
693949|NCT00004086|recurrent adult immunoblastic large cell lymphoma
693950|NCT00004086|recurrent adult lymphoblastic lymphoma
693951|NCT00004086|recurrent adult Burkitt lymphoma
693952|NCT00004086|recurrent mantle cell lymphoma
693953|NCT00004086|recurrent marginal zone lymphoma
693954|NCT00004086|recurrent small lymphocytic lymphoma
693955|NCT00004086|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
693956|NCT00004086|nodal marginal zone B-cell lymphoma
693957|NCT00004086|splenic marginal zone lymphoma
693958|NCT00004085|stage IV breast cancer
693959|NCT00004085|recurrent breast cancer
693960|NCT00004084|stage I chronic lymphocytic leukemia
693961|NCT00004084|stage II chronic lymphocytic leukemia
693962|NCT00004084|stage III chronic lymphocytic leukemia
693963|NCT00004084|stage IV chronic lymphocytic leukemia
693964|NCT00004084|refractory chronic lymphocytic leukemia
693965|NCT00004084|stage I grade 1 follicular lymphoma
693966|NCT00004084|stage I grade 2 follicular lymphoma
693967|NCT00004084|stage I grade 3 follicular lymphoma
693968|NCT00004084|stage I adult diffuse mixed cell lymphoma
693969|NCT00004084|stage I adult diffuse large cell lymphoma
693970|NCT00004084|stage I adult immunoblastic large cell lymphoma
693971|NCT00004084|stage I adult lymphoblastic lymphoma
693972|NCT00004084|stage I adult Burkitt lymphoma
693973|NCT00004084|stage III grade 1 follicular lymphoma
693974|NCT00004084|stage III grade 2 follicular lymphoma
693975|NCT00004084|stage III grade 3 follicular lymphoma
693976|NCT00004084|stage III adult diffuse small cleaved cell lymphoma
693977|NCT00004084|stage III adult diffuse mixed cell lymphoma
693978|NCT00004084|stage III adult diffuse large cell lymphoma
693979|NCT00004084|stage III adult immunoblastic large cell lymphoma
693980|NCT00004084|stage III adult lymphoblastic lymphoma
693981|NCT00004084|stage III adult Burkitt lymphoma
693982|NCT00004084|stage IV grade 1 follicular lymphoma
693983|NCT00004084|stage IV grade 2 follicular lymphoma
693984|NCT00004084|stage IV grade 3 follicular lymphoma
693985|NCT00004084|stage IV adult diffuse small cleaved cell lymphoma
693986|NCT00004084|stage IV adult diffuse mixed cell lymphoma
693987|NCT00004084|stage IV adult diffuse large cell lymphoma
693988|NCT00004084|stage IV adult immunoblastic large cell lymphoma
693989|NCT00004084|stage IV adult lymphoblastic lymphoma
693990|NCT00004084|stage IV adult Burkitt lymphoma
693991|NCT00004084|recurrent grade 1 follicular lymphoma
693992|NCT00004084|recurrent grade 2 follicular lymphoma
693993|NCT00004084|recurrent grade 3 follicular lymphoma
693994|NCT00004084|recurrent adult diffuse small cleaved cell lymphoma
693995|NCT00004084|recurrent adult diffuse mixed cell lymphoma
693996|NCT00004084|recurrent adult diffuse large cell lymphoma
693997|NCT00004084|recurrent adult immunoblastic large cell lymphoma
693998|NCT00004084|recurrent adult lymphoblastic lymphoma
693999|NCT00004084|recurrent adult Burkitt lymphoma
694000|NCT00004084|contiguous stage II grade 1 follicular lymphoma
694001|NCT00004084|contiguous stage II grade 2 follicular lymphoma
694002|NCT00004084|contiguous stage II grade 3 follicular lymphoma
694003|NCT00004084|contiguous stage II adult diffuse small cleaved cell lymphoma
694004|NCT00004084|contiguous stage II mantle cell lymphoma
694005|NCT00004084|contiguous stage II adult diffuse mixed cell lymphoma
694006|NCT00004084|contiguous stage II adult immunoblastic large cell lymphoma
694007|NCT00004084|contiguous stage II adult diffuse large cell lymphoma
694008|NCT00004084|contiguous stage II adult Burkitt lymphoma
694009|NCT00004084|contiguous stage II adult lymphoblastic lymphoma
694010|NCT00004084|noncontiguous stage II grade 1 follicular lymphoma
694011|NCT00004084|noncontiguous stage II grade 2 follicular lymphoma
694012|NCT00004084|noncontiguous stage II grade 3 follicular lymphoma
694013|NCT00004084|noncontiguous stage II adult diffuse small cleaved cell lymphoma
694014|NCT00004084|noncontiguous stage II mantle cell lymphoma
694015|NCT00004084|noncontiguous stage II adult diffuse mixed cell lymphoma
694016|NCT00004084|noncontiguous stage II adult immunoblastic large cell lymphoma
694017|NCT00004084|noncontiguous stage II adult diffuse large cell lymphoma
694018|NCT00004084|noncontiguous stage II adult Burkitt lymphoma
694019|NCT00004084|noncontiguous stage II adult lymphoblastic lymphoma
694020|NCT00004084|stage III mantle cell lymphoma
694021|NCT00004084|stage IV mantle cell lymphoma
694022|NCT00004084|recurrent mantle cell lymphoma
694023|NCT00004084|contiguous stage II marginal zone lymphoma
694024|NCT00004084|contiguous stage II small lymphocytic lymphoma
694025|NCT00004084|noncontiguous stage II small lymphocytic lymphoma
694026|NCT00004084|noncontiguous stage II marginal zone lymphoma
694027|NCT00004084|recurrent marginal zone lymphoma
694028|NCT00004084|recurrent small lymphocytic lymphoma
694029|NCT00004084|stage I marginal zone lymphoma
694030|NCT00004084|stage I small lymphocytic lymphoma
694031|NCT00004084|stage III small lymphocytic lymphoma
694032|NCT00004084|stage III marginal zone lymphoma
694033|NCT00004084|stage IV small lymphocytic lymphoma
694034|NCT00004084|stage IV marginal zone lymphoma
694035|NCT00004084|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694036|NCT00004084|nodal marginal zone B-cell lymphoma
694037|NCT00004084|splenic marginal zone lymphoma
694038|NCT00004083|stage IV ovarian epithelial cancer
694039|NCT00004083|recurrent ovarian epithelial cancer
694040|NCT00004082|stage III ovarian epithelial cancer
694041|NCT00004082|stage IV ovarian epithelial cancer
694042|NCT00004082|stage III endometrial carcinoma
694043|NCT00004082|stage IV endometrial carcinoma
694044|NCT00004082|endometrial adenocarcinoma
694045|NCT00004082|fallopian tube cancer
694046|NCT00004082|primary peritoneal cavity cancer
694047|NCT00004081|recurrent ovarian epithelial cancer
694048|NCT00004081|peritoneal cavity cancer
694049|NCT00004080|recurrent adult brain tumor
694050|NCT00004080|adult glioblastoma
694051|NCT00004080|adult anaplastic astrocytoma
694052|NCT00004080|adult mixed glioma
694053|NCT00004080|adult giant cell glioblastoma
694054|NCT00004080|adult gliosarcoma
694055|NCT00004077|stage III malignant testicular germ cell tumor
694056|NCT00004077|recurrent malignant testicular germ cell tumor
694057|NCT00004077|testicular embryonal carcinoma
694058|NCT00004077|testicular choriocarcinoma
694059|NCT00004077|testicular teratoma
694060|NCT00004077|testicular yolk sac tumor
696530|NCT00003750|recurrent neuroblastoma
694061|NCT00004077|testicular embryonal carcinoma and teratoma
694062|NCT00004077|testicular embryonal carcinoma and yolk sac tumor
694063|NCT00004077|testicular yolk sac tumor and teratoma
694064|NCT00004077|testicular choriocarcinoma and yolk sac tumor
694065|NCT00004077|testicular choriocarcinoma and embryonal carcinoma
694066|NCT00004077|testicular choriocarcinoma and teratoma
694067|NCT00004076|unspecified adult solid tumor, protocol specific
694068|NCT00004075|unspecified adult solid tumor, protocol specific
694069|NCT00004075|recurrent adult Burkitt lymphoma
694070|NCT00004075|recurrent adult diffuse large cell lymphoma
694071|NCT00004075|recurrent adult diffuse mixed cell lymphoma
694072|NCT00004075|recurrent adult diffuse small cleaved cell lymphoma
694073|NCT00004075|recurrent adult Hodgkin lymphoma
694074|NCT00004075|recurrent adult immunoblastic large cell lymphoma
694075|NCT00004075|recurrent adult lymphoblastic lymphoma
694076|NCT00004075|recurrent grade 1 follicular lymphoma
694077|NCT00004075|recurrent grade 2 follicular lymphoma
694078|NCT00004075|recurrent grade 3 follicular lymphoma
694079|NCT00004075|recurrent mantle cell lymphoma
694080|NCT00004075|recurrent adult T-cell leukemia/lymphoma
694081|NCT00004075|recurrent cutaneous T-cell non-Hodgkin lymphoma
694082|NCT00004075|recurrent mycosis fungoides/Sezary syndrome
694083|NCT00004075|recurrent adult grade III lymphomatoid granulomatosis
694084|NCT00004075|recurrent marginal zone lymphoma
694085|NCT00004075|recurrent small lymphocytic lymphoma
694086|NCT00004075|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694087|NCT00004075|nodal marginal zone B-cell lymphoma
694088|NCT00004075|splenic marginal zone lymphoma
694089|NCT00004073|adult glioblastoma
694090|NCT00004073|adult giant cell glioblastoma
694091|NCT00004073|adult gliosarcoma
694092|NCT00004072|refractory multiple myeloma
694093|NCT00004072|stage I multiple myeloma
694094|NCT00004072|stage II multiple myeloma
694095|NCT00004072|stage III multiple myeloma
694096|NCT00004071|stage IV prostate cancer
694097|NCT00004071|recurrent prostate cancer
694098|NCT00004070|recurrent metastatic squamous neck cancer with occult primary
694099|NCT00004070|metastatic squamous neck cancer with occult primary squamous cell carcinoma
694100|NCT00004070|stage III squamous cell carcinoma of the lip and oral cavity
694101|NCT00004070|stage IV squamous cell carcinoma of the lip and oral cavity
694102|NCT00004070|recurrent squamous cell carcinoma of the lip and oral cavity
694103|NCT00004070|stage III squamous cell carcinoma of the oropharynx
694104|NCT00004070|stage IV squamous cell carcinoma of the oropharynx
694105|NCT00004070|recurrent squamous cell carcinoma of the oropharynx
694106|NCT00004070|stage III squamous cell carcinoma of the nasopharynx
694107|NCT00004070|stage IV squamous cell carcinoma of the nasopharynx
694108|NCT00004070|recurrent squamous cell carcinoma of the nasopharynx
694109|NCT00004070|stage III squamous cell carcinoma of the hypopharynx
694110|NCT00004070|stage IV squamous cell carcinoma of the hypopharynx
694111|NCT00004070|recurrent squamous cell carcinoma of the hypopharynx
694112|NCT00004070|stage III squamous cell carcinoma of the larynx
694113|NCT00004070|stage IV squamous cell carcinoma of the larynx
694114|NCT00004070|recurrent squamous cell carcinoma of the larynx
694115|NCT00004070|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
694116|NCT00004070|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
694117|NCT00004070|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
694118|NCT00004068|childhood high-grade cerebral astrocytoma
694119|NCT00004068|childhood high-grade cerebellar astrocytoma
694120|NCT00004068|childhood oligodendroglioma
694121|NCT00004068|untreated childhood brain stem glioma
694122|NCT00004068|untreated childhood cerebellar astrocytoma
694123|NCT00004067|stage II breast cancer
694124|NCT00004067|stage IIIA breast cancer
694125|NCT00004066|adult leiomyosarcoma
694126|NCT00004066|recurrent adult soft tissue sarcoma
694127|NCT00004066|small intestine leiomyosarcoma
694128|NCT00004066|stage IV uterine sarcoma
694129|NCT00004066|recurrent uterine sarcoma
694130|NCT00004066|uterine leiomyosarcoma
694131|NCT00004066|ovarian sarcoma
694132|NCT00004066|recurrent small intestine cancer
694133|NCT00004066|stage IV adult soft tissue sarcoma
694134|NCT00004065|stage III colon cancer
694135|NCT00004065|stage IV colon cancer
694136|NCT00004065|stage IV breast cancer
694137|NCT00004065|stage IIIA breast cancer
694138|NCT00004065|recurrent breast cancer
694139|NCT00004065|stage III gastric cancer
694140|NCT00004065|stage IV gastric cancer
694141|NCT00004065|recurrent gastric cancer
694142|NCT00004065|stage IIIB breast cancer
694143|NCT00004065|stage IIIC breast cancer
694144|NCT00004065|recurrent non-small cell lung cancer
694145|NCT00004065|recurrent colon cancer
694146|NCT00004065|stage III renal cell cancer
694147|NCT00004065|stage IV renal cell cancer
694148|NCT00004065|recurrent renal cell cancer
694149|NCT00004065|stage III ovarian epithelial cancer
694150|NCT00004065|stage IV ovarian epithelial cancer
694151|NCT00004065|recurrent ovarian epithelial cancer
694152|NCT00004065|recurrent adult acute lymphoblastic leukemia
694153|NCT00004065|relapsing chronic myelogenous leukemia
696531|NCT00003750|recurrent osteosarcoma
694154|NCT00004065|stage III bladder cancer
694155|NCT00004065|recurrent bladder cancer
694156|NCT00004065|stage IV bladder cancer
694157|NCT00004065|stage III prostate cancer
694158|NCT00004065|stage IV prostate cancer
694159|NCT00004065|recurrent prostate cancer
694160|NCT00004065|stage III melanoma
694161|NCT00004065|stage IV melanoma
694162|NCT00004065|recurrent melanoma
694163|NCT00004065|stage IIIA non-small cell lung cancer
694164|NCT00004065|stage IIIB non-small cell lung cancer
694165|NCT00004065|stage IV non-small cell lung cancer
694166|NCT00004065|unspecified adult solid tumor, protocol specific
694167|NCT00004065|chronic phase chronic myelogenous leukemia
694168|NCT00004065|accelerated phase chronic myelogenous leukemia
694169|NCT00004065|blastic phase chronic myelogenous leukemia
694170|NCT00004065|untreated metastatic squamous neck cancer with occult primary
694171|NCT00004065|recurrent metastatic squamous neck cancer with occult primary
694172|NCT00004065|ovarian stromal cancer
694173|NCT00004065|stage III ovarian germ cell tumor
694174|NCT00004065|stage IV ovarian germ cell tumor
694175|NCT00004065|recurrent ovarian germ cell tumor
694176|NCT00004065|stage III squamous cell carcinoma of the lip and oral cavity
694177|NCT00004065|stage III basal cell carcinoma of the lip
694178|NCT00004065|stage III mucoepidermoid carcinoma of the oral cavity
694179|NCT00004065|stage III adenoid cystic carcinoma of the oral cavity
694180|NCT00004065|stage IV squamous cell carcinoma of the lip and oral cavity
694181|NCT00004065|stage IV basal cell carcinoma of the lip
694182|NCT00004065|stage IV verrucous carcinoma of the oral cavity
694183|NCT00004065|stage IV mucoepidermoid carcinoma of the oral cavity
694184|NCT00004065|stage IV adenoid cystic carcinoma of the oral cavity
694185|NCT00004065|recurrent squamous cell carcinoma of the lip and oral cavity
694186|NCT00004065|recurrent basal cell carcinoma of the lip
694187|NCT00004065|recurrent verrucous carcinoma of the oral cavity
694188|NCT00004065|recurrent mucoepidermoid carcinoma of the oral cavity
694189|NCT00004065|recurrent adenoid cystic carcinoma of the oral cavity
694190|NCT00004065|stage III squamous cell carcinoma of the oropharynx
694191|NCT00004065|stage III lymphoepithelioma of the oropharynx
694192|NCT00004065|stage IV squamous cell carcinoma of the oropharynx
694193|NCT00004065|stage IV lymphoepithelioma of the oropharynx
694194|NCT00004065|recurrent squamous cell carcinoma of the oropharynx
694195|NCT00004065|recurrent lymphoepithelioma of the oropharynx
694196|NCT00004065|stage III squamous cell carcinoma of the nasopharynx
694197|NCT00004065|stage III lymphoepithelioma of the nasopharynx
694198|NCT00004065|stage IV squamous cell carcinoma of the nasopharynx
694199|NCT00004065|stage IV lymphoepithelioma of the nasopharynx
694200|NCT00004065|recurrent squamous cell carcinoma of the nasopharynx
694201|NCT00004065|recurrent lymphoepithelioma of the nasopharynx
694202|NCT00004065|stage III squamous cell carcinoma of the hypopharynx
694203|NCT00004065|stage IV squamous cell carcinoma of the hypopharynx
694204|NCT00004065|recurrent squamous cell carcinoma of the hypopharynx
694205|NCT00004065|stage III squamous cell carcinoma of the larynx
694206|NCT00004065|stage III verrucous carcinoma of the larynx
694207|NCT00004065|stage IV squamous cell carcinoma of the larynx
694208|NCT00004065|stage IV verrucous carcinoma of the larynx
694209|NCT00004065|recurrent squamous cell carcinoma of the larynx
694210|NCT00004065|recurrent verrucous carcinoma of the larynx
694211|NCT00004065|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
694212|NCT00004065|stage III inverted papilloma of the paranasal sinus and nasal cavity
694213|NCT00004065|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
694214|NCT00004065|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
694215|NCT00004065|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
694216|NCT00004065|stage IV inverted papilloma of the paranasal sinus and nasal cavity
694217|NCT00004065|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
694218|NCT00004065|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
694219|NCT00004065|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
694220|NCT00004065|recurrent inverted papilloma of the paranasal sinus and nasal cavity
694221|NCT00004065|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
694222|NCT00004065|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
694223|NCT00004065|borderline ovarian surface epithelial-stromal tumor
694224|NCT00004065|ovarian sarcoma
694225|NCT00004065|stage III verrucous carcinoma of the oral cavity
694226|NCT00004065|recurrent salivary gland cancer
694227|NCT00004065|stage IV salivary gland cancer
694228|NCT00004065|stage III salivary gland cancer
694229|NCT00004064|stage I ovarian epithelial cancer
694230|NCT00004064|stage II ovarian epithelial cancer
694231|NCT00004064|stage III ovarian epithelial cancer
694232|NCT00004064|stage IV ovarian epithelial cancer
694233|NCT00004064|fallopian tube cancer
694234|NCT00004064|primary peritoneal cavity cancer
694235|NCT00004063|unspecified adult solid tumor, protocol specific
694236|NCT00004062|stage IV papillary thyroid cancer
694237|NCT00004062|stage IV follicular thyroid cancer
694238|NCT00004062|recurrent thyroid cancer
694239|NCT00004061|stage I adult Hodgkin lymphoma
694240|NCT00004061|stage II adult Hodgkin lymphoma
694241|NCT00004061|stage III adult Hodgkin lymphoma
694242|NCT00004061|stage IV adult Hodgkin lymphoma
694243|NCT00004061|recurrent adult Hodgkin lymphoma
694244|NCT00004061|stage 0 chronic lymphocytic leukemia
694245|NCT00004061|stage I chronic lymphocytic leukemia
694246|NCT00004061|stage II chronic lymphocytic leukemia
694247|NCT00004061|stage III chronic lymphocytic leukemia
694248|NCT00004061|stage IV chronic lymphocytic leukemia
694249|NCT00004061|recurrent adult acute myeloid leukemia
694250|NCT00004061|recurrent adult acute lymphoblastic leukemia
694251|NCT00004061|relapsing chronic myelogenous leukemia
694252|NCT00004061|refractory chronic lymphocytic leukemia
694253|NCT00004061|chronic phase chronic myelogenous leukemia
694254|NCT00004061|accelerated phase chronic myelogenous leukemia
694255|NCT00004061|blastic phase chronic myelogenous leukemia
694256|NCT00004061|meningeal chronic myelogenous leukemia
694257|NCT00004061|untreated adult acute lymphoblastic leukemia
694258|NCT00004061|untreated adult acute myeloid leukemia
694259|NCT00004061|adult acute myeloid leukemia in remission
694260|NCT00004061|adult acute lymphoblastic leukemia in remission
694261|NCT00004061|oral complications
694262|NCT00004061|stage I grade 1 follicular lymphoma
694263|NCT00004061|stage I grade 2 follicular lymphoma
694264|NCT00004061|stage I grade 3 follicular lymphoma
694265|NCT00004061|stage I adult diffuse small cleaved cell lymphoma
694266|NCT00004061|stage I adult diffuse mixed cell lymphoma
694267|NCT00004061|stage I adult diffuse large cell lymphoma
694268|NCT00004061|stage I adult immunoblastic large cell lymphoma
694269|NCT00004061|stage I adult lymphoblastic lymphoma
694270|NCT00004061|stage I adult Burkitt lymphoma
694271|NCT00004061|stage III grade 1 follicular lymphoma
694272|NCT00004061|stage III grade 2 follicular lymphoma
694273|NCT00004061|stage III grade 3 follicular lymphoma
694274|NCT00004061|stage III adult diffuse small cleaved cell lymphoma
694275|NCT00004061|stage III adult diffuse mixed cell lymphoma
694276|NCT00004061|stage III adult diffuse large cell lymphoma
694277|NCT00004061|stage III adult immunoblastic large cell lymphoma
694278|NCT00004061|stage III adult lymphoblastic lymphoma
694279|NCT00004061|stage III adult Burkitt lymphoma
694280|NCT00004061|stage IV grade 1 follicular lymphoma
694281|NCT00004061|stage IV grade 2 follicular lymphoma
694282|NCT00004061|stage IV grade 3 follicular lymphoma
694283|NCT00004061|stage IV adult diffuse small cleaved cell lymphoma
694284|NCT00004061|stage IV adult diffuse mixed cell lymphoma
694285|NCT00004061|stage IV adult diffuse large cell lymphoma
694286|NCT00004061|stage IV adult immunoblastic large cell lymphoma
694287|NCT00004061|stage IV adult lymphoblastic lymphoma
694288|NCT00004061|stage IV adult Burkitt lymphoma
694289|NCT00004061|recurrent grade 1 follicular lymphoma
694290|NCT00004061|recurrent grade 2 follicular lymphoma
694291|NCT00004061|recurrent grade 3 follicular lymphoma
694292|NCT00004061|recurrent adult diffuse small cleaved cell lymphoma
694293|NCT00004061|recurrent adult diffuse mixed cell lymphoma
694294|NCT00004061|recurrent adult diffuse large cell lymphoma
694295|NCT00004061|recurrent adult immunoblastic large cell lymphoma
694296|NCT00004061|recurrent adult lymphoblastic lymphoma
694297|NCT00004061|recurrent adult Burkitt lymphoma
694298|NCT00004061|secondary acute myeloid leukemia
694299|NCT00004061|stage I mantle cell lymphoma
694300|NCT00004061|contiguous stage II grade 1 follicular lymphoma
694301|NCT00004061|contiguous stage II grade 2 follicular lymphoma
694302|NCT00004061|contiguous stage II grade 3 follicular lymphoma
694303|NCT00004061|contiguous stage II adult diffuse small cleaved cell lymphoma
694304|NCT00004061|contiguous stage II mantle cell lymphoma
694305|NCT00004061|contiguous stage II adult diffuse mixed cell lymphoma
694306|NCT00004061|contiguous stage II adult immunoblastic large cell lymphoma
694307|NCT00004061|contiguous stage II adult diffuse large cell lymphoma
694308|NCT00004061|contiguous stage II adult Burkitt lymphoma
694309|NCT00004061|contiguous stage II adult lymphoblastic lymphoma
694310|NCT00004061|noncontiguous stage II grade 1 follicular lymphoma
694311|NCT00004061|noncontiguous stage II grade 2 follicular lymphoma
694312|NCT00004061|noncontiguous stage II grade 3 follicular lymphoma
694313|NCT00004061|noncontiguous stage II adult diffuse small cleaved cell lymphoma
694314|NCT00004061|noncontiguous stage II mantle cell lymphoma
694315|NCT00004061|noncontiguous stage II adult diffuse mixed cell lymphoma
694316|NCT00004061|noncontiguous stage II adult immunoblastic large cell lymphoma
694317|NCT00004061|noncontiguous stage II adult diffuse large cell lymphoma
694318|NCT00004061|noncontiguous stage II adult Burkitt lymphoma
694319|NCT00004061|noncontiguous stage II adult lymphoblastic lymphoma
694320|NCT00004061|stage III mantle cell lymphoma
694321|NCT00004061|stage IV mantle cell lymphoma
694322|NCT00004061|recurrent mantle cell lymphoma
694323|NCT00004061|noncontiguous stage II small lymphocytic lymphoma
694324|NCT00004061|noncontiguous stage II marginal zone lymphoma
694325|NCT00004061|recurrent marginal zone lymphoma
694326|NCT00004061|recurrent small lymphocytic lymphoma
694327|NCT00004061|stage I marginal zone lymphoma
694328|NCT00004061|stage I small lymphocytic lymphoma
694329|NCT00004061|stage III small lymphocytic lymphoma
694330|NCT00004061|stage III marginal zone lymphoma
694331|NCT00004061|stage IV small lymphocytic lymphoma
694332|NCT00004061|stage IV marginal zone lymphoma
694333|NCT00004061|contiguous stage II marginal zone lymphoma
694334|NCT00004061|contiguous stage II small lymphocytic lymphoma
694335|NCT00004061|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694336|NCT00004061|nodal marginal zone B-cell lymphoma
694337|NCT00004061|splenic marginal zone lymphoma
694338|NCT00004060|stage III ovarian epithelial cancer
694339|NCT00004060|stage IV ovarian epithelial cancer
694340|NCT00004060|recurrent ovarian epithelial cancer
694341|NCT00004060|fallopian tube cancer
694342|NCT00004060|primary peritoneal cavity cancer
694343|NCT00004059|unspecified adult solid tumor, protocol specific
694344|NCT00004058|monoclonal gammopathy of undetermined significance
694345|NCT00004058|recurrent adult Hodgkin lymphoma
694346|NCT00004058|recurrent cutaneous T-cell non-Hodgkin lymphoma
694347|NCT00004058|isolated plasmacytoma of bone
694348|NCT00004058|extramedullary plasmacytoma
694349|NCT00004058|refractory multiple myeloma
694350|NCT00004058|Waldenstrom macroglobulinemia
694351|NCT00004058|recurrent adult acute myeloid leukemia
694352|NCT00004058|recurrent adult acute lymphoblastic leukemia
694353|NCT00004058|relapsing chronic myelogenous leukemia
694354|NCT00004058|refractory chronic lymphocytic leukemia
694355|NCT00004058|polycythemia vera
694356|NCT00004058|chronic idiopathic myelofibrosis
694357|NCT00004058|essential thrombocythemia
694358|NCT00004058|refractory hairy cell leukemia
694359|NCT00004058|refractory anemia
694360|NCT00004058|refractory anemia with ringed sideroblasts
694361|NCT00004058|refractory anemia with excess blasts
694362|NCT00004058|refractory anemia with excess blasts in transformation
694363|NCT00004058|chronic myelomonocytic leukemia
694364|NCT00004058|T-cell large granular lymphocyte leukemia
694365|NCT00004058|acute undifferentiated leukemia
694366|NCT00004058|recurrent grade 1 follicular lymphoma
694367|NCT00004058|recurrent grade 2 follicular lymphoma
694368|NCT00004058|recurrent grade 3 follicular lymphoma
694369|NCT00004058|recurrent adult diffuse small cleaved cell lymphoma
694370|NCT00004058|recurrent adult diffuse mixed cell lymphoma
694371|NCT00004058|recurrent adult diffuse large cell lymphoma
694372|NCT00004058|recurrent adult immunoblastic large cell lymphoma
694373|NCT00004058|recurrent adult lymphoblastic lymphoma
694374|NCT00004058|recurrent adult Burkitt lymphoma
694375|NCT00004058|recurrent adult T-cell leukemia/lymphoma
694376|NCT00004058|secondary acute myeloid leukemia
694377|NCT00004058|previously treated myelodysplastic syndromes
694378|NCT00004058|secondary myelodysplastic syndromes
694379|NCT00004058|primary central nervous system lymphoma
694380|NCT00004058|prolymphocytic leukemia
694381|NCT00004058|primary systemic amyloidosis
694382|NCT00004058|recurrent mantle cell lymphoma
694383|NCT00004058|angioimmunoblastic T-cell lymphoma
694384|NCT00004058|anaplastic large cell lymphoma
694385|NCT00004058|refractory cytopenia with multilineage dysplasia
694386|NCT00004058|recurrent mycosis fungoides/Sezary syndrome
694387|NCT00004058|chronic eosinophilic leukemia
694388|NCT00004058|chronic neutrophilic leukemia
694389|NCT00004058|atypical chronic myeloid leukemia
694390|NCT00004058|myelodysplastic/myeloproliferative disease, unclassifiable
694391|NCT00004058|adult acute myeloid leukemia with t(8;21)(q22;q22)
694392|NCT00004058|adult acute myeloid leukemia with t(16;16)(p13;q22)
694393|NCT00004058|adult acute myeloid leukemia with inv(16)(p13;q22)
694394|NCT00004058|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
694395|NCT00004058|adult acute myeloid leukemia with t(15;17)(q22;q12)
694396|NCT00004057|recurrent adult Hodgkin lymphoma
694397|NCT00004057|unspecified adult solid tumor, protocol specific
694398|NCT00004057|recurrent grade 1 follicular lymphoma
694399|NCT00004057|recurrent grade 2 follicular lymphoma
694400|NCT00004057|recurrent grade 3 follicular lymphoma
694401|NCT00004057|recurrent adult diffuse small cleaved cell lymphoma
694402|NCT00004057|recurrent adult diffuse mixed cell lymphoma
694403|NCT00004057|recurrent adult diffuse large cell lymphoma
694404|NCT00004057|recurrent adult immunoblastic large cell lymphoma
694405|NCT00004057|recurrent adult lymphoblastic lymphoma
694406|NCT00004057|recurrent adult Burkitt lymphoma
694407|NCT00004057|recurrent adult T-cell leukemia/lymphoma
694408|NCT00004057|recurrent mantle cell lymphoma
694409|NCT00004057|angioimmunoblastic T-cell lymphoma
694410|NCT00004057|anaplastic large cell lymphoma
694411|NCT00004057|recurrent marginal zone lymphoma
694412|NCT00004057|recurrent small lymphocytic lymphoma
694413|NCT00004057|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694414|NCT00004057|nodal marginal zone B-cell lymphoma
694415|NCT00004057|splenic marginal zone lymphoma
694416|NCT00004056|untreated childhood acute myeloid leukemia and other myeloid malignancies
694417|NCT00004056|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
694418|NCT00004056|childhood acute myeloblastic leukemia without maturation (M1)
694419|NCT00004056|childhood acute myeloblastic leukemia with maturation (M2)
694420|NCT00004056|childhood acute myelomonocytic leukemia (M4)
694421|NCT00004056|childhood acute erythroleukemia (M6)
694422|NCT00004056|childhood acute megakaryocytic leukemia (M7)
694423|NCT00004056|childhood acute minimally differentiated myeloid leukemia (M0)
694424|NCT00004055|extensive stage small cell lung cancer
694425|NCT00004054|stage IIB prostate cancer
694426|NCT00004054|stage IIA prostate cancer
694427|NCT00004054|stage III prostate cancer
694428|NCT00004054|stage IV prostate cancer
694429|NCT00004052|relapsing chronic myelogenous leukemia
694430|NCT00004052|chronic phase chronic myelogenous leukemia
694431|NCT00004051|unspecified adult solid tumor, protocol specific
694432|NCT00004050|stage IIB prostate cancer
694433|NCT00004050|stage IIA prostate cancer
694434|NCT00004050|stage III prostate cancer
694435|NCT00004049|unspecified adult solid tumor, protocol specific
694436|NCT00004048|thyroid gland medullary carcinoma
694437|NCT00004047|recurrent childhood acute lymphoblastic leukemia
694438|NCT00004047|recurrent childhood acute myeloid leukemia
694439|NCT00004047|recurrent adult acute myeloid leukemia
694440|NCT00004047|recurrent adult acute lymphoblastic leukemia
694441|NCT00004047|relapsing chronic myelogenous leukemia
694442|NCT00004047|refractory chronic lymphocytic leukemia
694443|NCT00004047|blastic phase chronic myelogenous leukemia
694444|NCT00004047|refractory anemia with excess blasts
694445|NCT00004047|refractory anemia with excess blasts in transformation
694446|NCT00004047|chronic myelomonocytic leukemia
694447|NCT00004047|childhood myelodysplastic syndromes
694448|NCT00004046|stage IV breast cancer
694449|NCT00004046|recurrent breast cancer
694450|NCT00004045|stage IV prostate cancer
694451|NCT00004045|recurrent prostate cancer
694452|NCT00004043|adenocarcinoma of the prostate
694453|NCT00004043|recurrent prostate cancer
694454|NCT00004042|stage III colon cancer
694455|NCT00004042|stage IV colon cancer
694456|NCT00004042|stage III rectal cancer
694457|NCT00004042|stage IV rectal cancer
694458|NCT00004042|recurrent colon cancer
694459|NCT00004042|recurrent rectal cancer
694460|NCT00004041|recurrent adult brain tumor
694461|NCT00004041|adult glioblastoma
694462|NCT00004041|adult anaplastic astrocytoma
694463|NCT00004041|adult anaplastic oligodendroglioma
694464|NCT00004041|adult mixed glioma
694465|NCT00004041|adult giant cell glioblastoma
694466|NCT00004041|adult gliosarcoma
694467|NCT00004040|stage I multiple myeloma
694468|NCT00004040|stage II multiple myeloma
694469|NCT00004040|stage III multiple myeloma
694470|NCT00004040|stage I chronic lymphocytic leukemia
694471|NCT00004040|stage II chronic lymphocytic leukemia
694472|NCT00004040|stage III chronic lymphocytic leukemia
694473|NCT00004040|stage IV chronic lymphocytic leukemia
694474|NCT00004040|B-cell chronic lymphocytic leukemia
694475|NCT00004039|Waldenstrom macroglobulinemia
694476|NCT00004039|stage II grade 3 follicular lymphoma
694477|NCT00004039|stage II adult diffuse small cleaved cell lymphoma
694478|NCT00004039|stage II adult diffuse mixed cell lymphoma
694479|NCT00004039|stage II adult diffuse large cell lymphoma
694480|NCT00004039|stage II adult immunoblastic large cell lymphoma
694481|NCT00004039|stage II adult Burkitt lymphoma
694482|NCT00004039|stage III grade 1 follicular lymphoma
694483|NCT00004039|stage III grade 2 follicular lymphoma
694484|NCT00004039|stage III grade 3 follicular lymphoma
694485|NCT00004039|stage III adult diffuse small cleaved cell lymphoma
694486|NCT00004039|stage III adult diffuse mixed cell lymphoma
694487|NCT00004039|stage III adult diffuse large cell lymphoma
694488|NCT00004039|stage III adult immunoblastic large cell lymphoma
694489|NCT00004039|stage III adult Burkitt lymphoma
694490|NCT00004039|stage IV grade 1 follicular lymphoma
694491|NCT00004039|stage IV grade 2 follicular lymphoma
694492|NCT00004039|stage IV grade 3 follicular lymphoma
694493|NCT00004039|stage IV adult diffuse small cleaved cell lymphoma
694494|NCT00004039|stage IV adult diffuse mixed cell lymphoma
694495|NCT00004039|stage IV adult diffuse large cell lymphoma
694496|NCT00004039|stage IV adult immunoblastic large cell lymphoma
694497|NCT00004039|stage IV adult Burkitt lymphoma
694498|NCT00004039|stage III mantle cell lymphoma
694499|NCT00004039|stage IV mantle cell lymphoma
694500|NCT00004038|stage I breast cancer
694501|NCT00004038|stage II breast cancer
694502|NCT00004038|stage IV breast cancer
694503|NCT00004038|stage IIIA breast cancer
694504|NCT00004038|recurrent breast cancer
694505|NCT00004038|stage IIIB breast cancer
694506|NCT00004037|stage IV ovarian epithelial cancer
694507|NCT00004037|recurrent ovarian epithelial cancer
694508|NCT00004037|primary peritoneal cavity cancer
694509|NCT00004036|stage III adult Hodgkin lymphoma
694510|NCT00004036|stage IV adult Hodgkin lymphoma
694511|NCT00004036|monoclonal gammopathy of undetermined significance
694512|NCT00004036|recurrent adult Hodgkin lymphoma
694513|NCT00004036|isolated plasmacytoma of bone
694514|NCT00004036|extramedullary plasmacytoma
694515|NCT00004036|refractory multiple myeloma
694516|NCT00004036|Waldenström macroglobulinemia
694517|NCT00004036|stage III multiple myeloma
694518|NCT00004036|stage III chronic lymphocytic leukemia
694519|NCT00004036|stage IV chronic lymphocytic leukemia
694520|NCT00004036|recurrent adult acute myeloid leukemia
694521|NCT00004036|recurrent adult acute lymphoblastic leukemia
694522|NCT00004036|relapsing chronic myelogenous leukemia
696532|NCT00003750|recurrent melanoma
694523|NCT00004036|refractory chronic lymphocytic leukemia
694524|NCT00004036|unspecified adult solid tumor, protocol specific
694525|NCT00004036|chronic phase chronic myelogenous leukemia
694526|NCT00004036|accelerated phase chronic myelogenous leukemia
694527|NCT00004036|blastic phase chronic myelogenous leukemia
694528|NCT00004036|meningeal chronic myelogenous leukemia
694529|NCT00004036|untreated adult acute lymphoblastic leukemia
694530|NCT00004036|untreated adult acute myeloid leukemia
694531|NCT00004036|adult acute myeloid leukemia in remission
694532|NCT00004036|adult acute lymphoblastic leukemia in remission
694533|NCT00004036|polycythemia vera
694534|NCT00004036|primary myelofibrosis
694535|NCT00004036|essential thrombocythemia
694536|NCT00004036|untreated hairy cell leukemia
694537|NCT00004036|progressive hairy cell leukemia, initial treatment
694538|NCT00004036|refractory hairy cell leukemia
694539|NCT00004036|chronic myelomonocytic leukemia
694540|NCT00004036|T-cell large granular lymphocyte leukemia
694541|NCT00004036|acute undifferentiated leukemia
694542|NCT00004036|stage III grade 1 follicular lymphoma
694543|NCT00004036|stage III grade 2 follicular lymphoma
694544|NCT00004036|stage III grade 3 follicular lymphoma
694545|NCT00004036|stage III adult diffuse small cleaved cell lymphoma
694546|NCT00004036|stage III adult diffuse mixed cell lymphoma
694547|NCT00004036|stage III adult diffuse large cell lymphoma
694548|NCT00004036|stage III adult immunoblastic large cell lymphoma
694549|NCT00004036|stage III adult lymphoblastic lymphoma
694550|NCT00004036|stage III adult Burkitt lymphoma
694551|NCT00004036|stage IV grade 1 follicular lymphoma
694552|NCT00004036|stage IV grade 2 follicular lymphoma
694553|NCT00004036|stage IV grade 3 follicular lymphoma
694554|NCT00004036|stage IV adult diffuse small cleaved cell lymphoma
694555|NCT00004036|stage IV adult diffuse mixed cell lymphoma
694556|NCT00004036|stage IV adult diffuse large cell lymphoma
694557|NCT00004036|stage IV adult immunoblastic large cell lymphoma
694558|NCT00004036|stage IV adult lymphoblastic lymphoma
694559|NCT00004036|stage IV adult Burkitt lymphoma
694560|NCT00004036|recurrent grade 1 follicular lymphoma
694561|NCT00004036|recurrent grade 2 follicular lymphoma
694562|NCT00004036|recurrent grade 3 follicular lymphoma
694563|NCT00004036|recurrent adult diffuse small cleaved cell lymphoma
694564|NCT00004036|recurrent adult diffuse mixed cell lymphoma
694565|NCT00004036|recurrent adult diffuse large cell lymphoma
694566|NCT00004036|recurrent adult immunoblastic large cell lymphoma
694567|NCT00004036|recurrent adult lymphoblastic lymphoma
694568|NCT00004036|recurrent adult Burkitt lymphoma
694569|NCT00004036|stage III adult T-cell leukemia/lymphoma
694570|NCT00004036|stage IV adult T-cell leukemia/lymphoma
694571|NCT00004036|recurrent adult T-cell leukemia/lymphoma
694572|NCT00004036|secondary acute myeloid leukemia
694573|NCT00004036|de novo myelodysplastic syndromes
694574|NCT00004036|previously treated myelodysplastic syndromes
694575|NCT00004036|secondary myelodysplastic syndromes
694576|NCT00004036|drug/agent toxicity by tissue/organ
694577|NCT00004036|prolymphocytic leukemia
694578|NCT00004036|AIDS-related peripheral/systemic lymphoma
694579|NCT00004036|AIDS-related primary CNS lymphoma
694580|NCT00004036|primary systemic amyloidosis
694581|NCT00004036|stage III mantle cell lymphoma
694582|NCT00004036|stage IV mantle cell lymphoma
694583|NCT00004036|recurrent mantle cell lymphoma
694584|NCT00004036|angioimmunoblastic T-cell lymphoma
694585|NCT00004036|anaplastic large cell lymphoma
694586|NCT00004036|recurrent marginal zone lymphoma
694587|NCT00004036|recurrent small lymphocytic lymphoma
694588|NCT00004036|stage III small lymphocytic lymphoma
694589|NCT00004036|stage III marginal zone lymphoma
694590|NCT00004036|stage IV small lymphocytic lymphoma
694591|NCT00004036|stage IV marginal zone lymphoma
694592|NCT00004036|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694593|NCT00004036|nodal marginal zone B-cell lymphoma
694594|NCT00004036|splenic marginal zone lymphoma
694595|NCT00004033|localized malignant mesothelioma
694596|NCT00004033|advanced malignant mesothelioma
694597|NCT00004033|recurrent malignant mesothelioma
694598|NCT00004031|stage III grade 3 follicular lymphoma
694599|NCT00004031|stage III adult diffuse small cleaved cell lymphoma
694600|NCT00004031|stage III adult diffuse mixed cell lymphoma
694601|NCT00004031|stage III adult diffuse large cell lymphoma
694602|NCT00004031|stage III adult immunoblastic large cell lymphoma
694603|NCT00004031|stage III adult Burkitt lymphoma
694604|NCT00004031|stage IV grade 3 follicular lymphoma
694605|NCT00004031|stage IV adult diffuse small cleaved cell lymphoma
694606|NCT00004031|stage IV adult diffuse mixed cell lymphoma
694607|NCT00004031|stage IV adult diffuse large cell lymphoma
694608|NCT00004031|stage IV adult immunoblastic large cell lymphoma
694609|NCT00004031|stage IV adult Burkitt lymphoma
694610|NCT00004031|contiguous stage II grade 3 follicular lymphoma
694611|NCT00004031|contiguous stage II adult diffuse small cleaved cell lymphoma
694612|NCT00004031|contiguous stage II adult diffuse mixed cell lymphoma
694613|NCT00004031|contiguous stage II adult immunoblastic large cell lymphoma
694614|NCT00004031|contiguous stage II adult diffuse large cell lymphoma
694615|NCT00004031|contiguous stage II adult Burkitt lymphoma
694616|NCT00004031|noncontiguous stage II grade 3 follicular lymphoma
694617|NCT00004031|noncontiguous stage II adult diffuse small cleaved cell lymphoma
694618|NCT00004031|noncontiguous stage II adult diffuse mixed cell lymphoma
694619|NCT00004031|noncontiguous stage II adult immunoblastic large cell lymphoma
694620|NCT00004031|noncontiguous stage II adult diffuse large cell lymphoma
694621|NCT00004031|noncontiguous stage II adult Burkitt lymphoma
694622|NCT00004030|unspecified adult solid tumor, protocol specific
694623|NCT00004029|adenocarcinoma of the prostate
694624|NCT00004029|stage IV prostate cancer
694625|NCT00004029|recurrent prostate cancer
694626|NCT00004028|recurrent adult brain tumor
694627|NCT00004028|adult glioblastoma
694628|NCT00004028|adult anaplastic astrocytoma
694629|NCT00004028|adult anaplastic ependymoma
694630|NCT00004028|adult anaplastic oligodendroglioma
694631|NCT00004028|adult mixed glioma
694632|NCT00004028|adult ependymoblastoma
694633|NCT00004028|adult giant cell glioblastoma
694634|NCT00004028|adult gliosarcoma
694635|NCT00004026|adenocarcinoma of the prostate
694636|NCT00004026|stage IV prostate cancer
694637|NCT00004026|recurrent prostate cancer
694638|NCT00004025|stage III melanoma
694639|NCT00004025|stage IV melanoma
694640|NCT00004025|recurrent melanoma
694641|NCT00004024|recurrent adult brain tumor
694642|NCT00004024|adult glioblastoma
694643|NCT00004024|adult anaplastic astrocytoma
694644|NCT00004024|adult anaplastic oligodendroglioma
694645|NCT00004024|adult subependymoma
694646|NCT00004024|adult oligodendroglioma
694647|NCT00004024|adult giant cell glioblastoma
694648|NCT00004024|adult gliosarcoma
694649|NCT00004024|adult diffuse astrocytoma
694650|NCT00004022|stage III melanoma
694651|NCT00004022|stage IV melanoma
694652|NCT00004022|recurrent melanoma
694653|NCT00004017|recurrent adult brain tumor
694654|NCT00004017|adult glioblastoma
694655|NCT00004017|adult anaplastic astrocytoma
694656|NCT00004017|adult giant cell glioblastoma
694657|NCT00004017|adult gliosarcoma
694658|NCT00004016|stage III melanoma
694659|NCT00004016|stage IV melanoma
694660|NCT00004016|recurrent melanoma
694661|NCT00004016|unspecified adult solid tumor, protocol specific
694662|NCT00004015|adult glioblastoma
694663|NCT00004015|adult giant cell glioblastoma
694664|NCT00004015|adult gliosarcoma
694665|NCT00004014|recurrent prostate cancer
694666|NCT00004013|stage IV breast cancer
694667|NCT00004013|recurrent breast cancer
694668|NCT00004012|recurrent ovarian epithelial cancer
694669|NCT00004012|fallopian tube cancer
694670|NCT00004012|primary peritoneal cavity cancer
694671|NCT00004011|stage I non-small cell lung cancer
694672|NCT00004011|stage II non-small cell lung cancer
694673|NCT00004011|stage IIIA non-small cell lung cancer
694674|NCT00004010|stage II childhood Hodgkin lymphoma
694675|NCT00004010|stage III childhood Hodgkin lymphoma
694676|NCT00004010|stage IV childhood Hodgkin lymphoma
694677|NCT00004010|childhood lymphocyte predominant Hodgkin lymphoma
694678|NCT00004010|childhood lymphocyte depletion Hodgkin lymphoma
694679|NCT00004010|childhood nodular sclerosis Hodgkin lymphoma
694680|NCT00004010|childhood mixed cellularity Hodgkin lymphoma
694681|NCT00004009|recurrent adult acute myeloid leukemia
694682|NCT00004009|recurrent adult acute lymphoblastic leukemia
694683|NCT00004009|accelerated phase chronic myelogenous leukemia
694684|NCT00004009|blastic phase chronic myelogenous leukemia
694685|NCT00004009|untreated adult acute lymphoblastic leukemia
694686|NCT00004009|untreated adult acute myeloid leukemia
694687|NCT00004009|adult acute promyelocytic leukemia (M3)
694688|NCT00004009|secondary acute myeloid leukemia
694689|NCT00004008|stage I ovarian epithelial cancer
694690|NCT00004008|stage II ovarian epithelial cancer
694691|NCT00004008|stage III ovarian epithelial cancer
694692|NCT00004008|stage IV ovarian epithelial cancer
694693|NCT00004008|recurrent ovarian epithelial cancer
694694|NCT00004006|intraocular retinoblastoma
694695|NCT00004006|extraocular retinoblastoma
694696|NCT00004006|recurrent retinoblastoma
694697|NCT00004005|stage III colon cancer
694698|NCT00004005|stage IV colon cancer
694699|NCT00004005|stage III rectal cancer
694700|NCT00004005|stage IV rectal cancer
694701|NCT00004005|unspecified childhood solid tumor, protocol specific
694702|NCT00004005|unspecified adult solid tumor, protocol specific
694703|NCT00004005|adenocarcinoma of unknown primary
694704|NCT00004005|newly diagnosed carcinoma of unknown primary
694705|NCT00004005|recurrent carcinoma of unknown primary
694706|NCT00004004|recurrent adult brain tumor
694707|NCT00004004|adult glioblastoma
694708|NCT00004004|adult anaplastic astrocytoma
694709|NCT00004004|adult anaplastic oligodendroglioma
694710|NCT00004004|adult giant cell glioblastoma
694711|NCT00004004|adult gliosarcoma
694712|NCT00004003|stage III pancreatic cancer
694713|NCT00004003|recurrent pancreatic cancer
694714|NCT00004003|stage IV pancreatic cancer
694715|NCT00004002|stage IV adult Hodgkin lymphoma
694716|NCT00004002|recurrent adult Hodgkin lymphoma
694717|NCT00004002|stage IV cutaneous T-cell non-Hodgkin lymphoma
694718|NCT00004002|recurrent cutaneous T-cell non-Hodgkin lymphoma
694719|NCT00004002|small intestine lymphoma
694720|NCT00004002|unspecified adult solid tumor, protocol specific
694721|NCT00004002|stage IV grade 1 follicular lymphoma
694722|NCT00004002|stage IV grade 2 follicular lymphoma
694723|NCT00004002|stage IV grade 3 follicular lymphoma
694724|NCT00004002|stage IV adult diffuse small cleaved cell lymphoma
694725|NCT00004002|stage IV adult diffuse mixed cell lymphoma
694726|NCT00004002|stage IV adult diffuse large cell lymphoma
694727|NCT00004002|stage IV adult immunoblastic large cell lymphoma
694728|NCT00004002|stage IV adult lymphoblastic lymphoma
694729|NCT00004002|stage IV adult Burkitt lymphoma
694730|NCT00004002|recurrent grade 1 follicular lymphoma
694731|NCT00004002|recurrent grade 2 follicular lymphoma
694732|NCT00004002|recurrent grade 3 follicular lymphoma
694733|NCT00004002|recurrent adult diffuse small cleaved cell lymphoma
694734|NCT00004002|recurrent adult diffuse mixed cell lymphoma
694735|NCT00004002|recurrent adult diffuse large cell lymphoma
694736|NCT00004002|recurrent adult immunoblastic large cell lymphoma
694737|NCT00004002|recurrent adult lymphoblastic lymphoma
694738|NCT00004002|recurrent adult Burkitt lymphoma
694739|NCT00004002|stage IV adult T-cell leukemia/lymphoma
694740|NCT00004002|recurrent adult T-cell leukemia/lymphoma
694741|NCT00004002|primary central nervous system non-Hodgkin lymphoma
694742|NCT00004002|AIDS-related peripheral/systemic lymphoma
694743|NCT00004002|AIDS-related primary CNS lymphoma
694744|NCT00004002|intraocular lymphoma
694745|NCT00004002|stage IV mantle cell lymphoma
694746|NCT00004002|recurrent mantle cell lymphoma
694747|NCT00004002|angioimmunoblastic T-cell lymphoma
694748|NCT00004002|anaplastic large cell lymphoma
694749|NCT00004002|stage IV mycosis fungoides/Sezary syndrome
694750|NCT00004002|recurrent mycosis fungoides/Sezary syndrome
694751|NCT00004002|recurrent marginal zone lymphoma
694752|NCT00004002|recurrent small lymphocytic lymphoma
694753|NCT00004002|stage IV small lymphocytic lymphoma
694754|NCT00004002|stage IV marginal zone lymphoma
694755|NCT00004002|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694756|NCT00004002|nodal marginal zone B-cell lymphoma
694757|NCT00004002|splenic marginal zone lymphoma
694758|NCT00004001|adenocarcinoma of the prostate
694759|NCT00004001|stage IV prostate cancer
694760|NCT00004001|recurrent prostate cancer
694761|NCT00003998|stage I ovarian epithelial cancer
694762|NCT00003998|stage II ovarian epithelial cancer
694763|NCT00003998|stage III ovarian epithelial cancer
694764|NCT00003998|stage IV ovarian epithelial cancer
694765|NCT00003998|primary peritoneal cavity cancer
694766|NCT00003997|recurrent adult acute myeloid leukemia
694767|NCT00003997|recurrent adult acute lymphoblastic leukemia
694768|NCT00003997|blastic phase chronic myelogenous leukemia
694769|NCT00003997|previously treated myelodysplastic syndromes
694770|NCT00003997|secondary myelodysplastic syndromes
694771|NCT00003996|adult glioblastoma
694772|NCT00003996|adult giant cell glioblastoma
694773|NCT00003996|adult gliosarcoma
694774|NCT00003995|stage IV colon cancer
694775|NCT00003995|stage IV rectal cancer
694776|NCT00003995|recurrent colon cancer
694777|NCT00003995|recurrent rectal cancer
694778|NCT00003993|stage IV adult Hodgkin lymphoma
694779|NCT00003993|recurrent adult Hodgkin lymphoma
694780|NCT00003993|stage IV cutaneous T-cell non-Hodgkin lymphoma
694781|NCT00003993|recurrent cutaneous T-cell non-Hodgkin lymphoma
694782|NCT00003993|small intestine lymphoma
694783|NCT00003993|unspecified adult solid tumor, protocol specific
694784|NCT00003993|stage IV grade 1 follicular lymphoma
694785|NCT00003993|stage IV grade 2 follicular lymphoma
694786|NCT00003993|stage IV grade 3 follicular lymphoma
694787|NCT00003993|stage IV adult diffuse small cleaved cell lymphoma
694788|NCT00003993|stage IV adult diffuse mixed cell lymphoma
694789|NCT00003993|stage IV adult diffuse large cell lymphoma
694790|NCT00003993|stage IV adult immunoblastic large cell lymphoma
694791|NCT00003993|stage IV adult lymphoblastic lymphoma
694792|NCT00003993|stage IV adult Burkitt lymphoma
694793|NCT00003993|recurrent grade 1 follicular lymphoma
694794|NCT00003993|recurrent grade 2 follicular lymphoma
694795|NCT00003993|recurrent grade 3 follicular lymphoma
694796|NCT00003993|recurrent adult diffuse small cleaved cell lymphoma
694797|NCT00003993|recurrent adult diffuse mixed cell lymphoma
694798|NCT00003993|recurrent adult diffuse large cell lymphoma
694799|NCT00003993|recurrent adult immunoblastic large cell lymphoma
694800|NCT00003993|recurrent adult lymphoblastic lymphoma
694801|NCT00003993|recurrent adult Burkitt lymphoma
694802|NCT00003993|stage IV adult T-cell leukemia/lymphoma
694803|NCT00003993|recurrent adult T-cell leukemia/lymphoma
694804|NCT00003993|primary central nervous system non-Hodgkin lymphoma
694805|NCT00003993|intraocular lymphoma
694806|NCT00003993|stage IV mantle cell lymphoma
694807|NCT00003993|recurrent mantle cell lymphoma
694808|NCT00003993|angioimmunoblastic T-cell lymphoma
694809|NCT00003993|anaplastic large cell lymphoma
694810|NCT00003993|stage IV mycosis fungoides/Sezary syndrome
694811|NCT00003993|recurrent mycosis fungoides/Sezary syndrome
694812|NCT00003993|recurrent marginal zone lymphoma
694813|NCT00003993|recurrent small lymphocytic lymphoma
694814|NCT00003993|stage IV small lymphocytic lymphoma
694815|NCT00003993|stage IV marginal zone lymphoma
694816|NCT00003993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694817|NCT00003993|nodal marginal zone B-cell lymphoma
694818|NCT00003993|splenic marginal zone lymphoma
694819|NCT00003992|stage II breast cancer
694820|NCT00003992|stage IIIA breast cancer
694821|NCT00003991|adult acute myeloid leukemia in remission
694822|NCT00003989|recurrent non-small cell lung cancer
694823|NCT00003989|stage III melanoma
694824|NCT00003989|stage IV melanoma
694825|NCT00003989|recurrent melanoma
694826|NCT00003989|stage IIIA non-small cell lung cancer
694827|NCT00003989|stage IIIB non-small cell lung cancer
694828|NCT00003989|stage IV non-small cell lung cancer
694829|NCT00003985|non-small cell lung cancer
694830|NCT00003985|unspecified adult solid tumor, protocol specific
694831|NCT00003984|refractory anemia with excess blasts
694832|NCT00003984|refractory anemia with excess blasts in transformation
694833|NCT00003984|de novo myelodysplastic syndromes
694834|NCT00003984|previously treated myelodysplastic syndromes
694835|NCT00003984|secondary myelodysplastic syndromes
694836|NCT00003982|unspecified adult solid tumor, protocol specific
694837|NCT00003982|testicular embryonal carcinoma and yolk sac tumor
694838|NCT00003981|unspecified adult solid tumor, protocol specific
694839|NCT00003980|unspecified adult solid tumor, protocol specific
694840|NCT00003979|unspecified adult solid tumor, protocol specific
694841|NCT00003977|stage III cervical cancer
694842|NCT00003977|recurrent cervical cancer
694843|NCT00003977|stage IB cervical cancer
694844|NCT00003977|stage IIB cervical cancer
694845|NCT00003977|stage IVB cervical cancer
694846|NCT00003977|stage IA cervical cancer
694847|NCT00003977|stage IIA cervical cancer
694848|NCT00003977|stage IVA cervical cancer
694849|NCT00003976|unspecified adult solid tumor, protocol specific
694850|NCT00003974|stage I non-small cell lung cancer
694851|NCT00003974|stage II non-small cell lung cancer
694852|NCT00003974|localized malignant mesothelioma
694853|NCT00003974|stage IIIA non-small cell lung cancer
694854|NCT00003972|stage II breast cancer
694855|NCT00003972|stage IIIA breast cancer
694856|NCT00003969|unspecified adult solid tumor, protocol specific
694857|NCT00003968|stage IV renal cell cancer
694858|NCT00003968|recurrent renal cell cancer
694859|NCT00003967|recurrent ovarian epithelial cancer
694860|NCT00003967|ovarian undifferentiated adenocarcinoma
694861|NCT00003967|ovarian mixed epithelial carcinoma
694862|NCT00003967|ovarian serous cystadenocarcinoma
694863|NCT00003967|ovarian mucinous cystadenocarcinoma
694864|NCT00003967|ovarian endometrioid adenocarcinoma
694865|NCT00003967|ovarian clear cell cystadenocarcinoma
694866|NCT00003967|fallopian tube cancer
694867|NCT00003967|primary peritoneal cavity cancer
694868|NCT00003967|Brenner tumor
694869|NCT00003966|veno-occlusive disease
694870|NCT00003963|Waldenstrom macroglobulinemia
694871|NCT00003963|recurrent grade 1 follicular lymphoma
694872|NCT00003963|recurrent grade 2 follicular lymphoma
694873|NCT00003963|recurrent grade 3 follicular lymphoma
694874|NCT00003963|recurrent adult diffuse small cleaved cell lymphoma
694875|NCT00003963|recurrent adult diffuse mixed cell lymphoma
694876|NCT00003963|recurrent adult diffuse large cell lymphoma
694877|NCT00003963|recurrent adult immunoblastic large cell lymphoma
694878|NCT00003963|recurrent adult lymphoblastic lymphoma
694879|NCT00003963|recurrent adult Burkitt lymphoma
694880|NCT00003963|recurrent mantle cell lymphoma
694881|NCT00003963|recurrent marginal zone lymphoma
694882|NCT00003963|recurrent small lymphocytic lymphoma
694883|NCT00003963|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694884|NCT00003963|nodal marginal zone B-cell lymphoma
694885|NCT00003963|splenic marginal zone lymphoma
694886|NCT00003962|recurrent childhood acute lymphoblastic leukemia
694887|NCT00003962|recurrent adult Hodgkin lymphoma
694888|NCT00003962|refractory multiple myeloma
694889|NCT00003962|stage I multiple myeloma
694890|NCT00003962|stage II multiple myeloma
694891|NCT00003962|stage III multiple myeloma
694892|NCT00003962|recurrent childhood lymphoblastic lymphoma
694893|NCT00003962|recurrent childhood acute myeloid leukemia
694894|NCT00003962|recurrent adult acute myeloid leukemia
694895|NCT00003962|recurrent adult acute lymphoblastic leukemia
694896|NCT00003962|recurrent/refractory childhood Hodgkin lymphoma
694897|NCT00003962|chronic myelomonocytic leukemia
694898|NCT00003962|acute undifferentiated leukemia
694899|NCT00003962|recurrent grade 1 follicular lymphoma
694900|NCT00003962|recurrent grade 2 follicular lymphoma
694901|NCT00003962|recurrent grade 3 follicular lymphoma
694902|NCT00003962|recurrent adult diffuse small cleaved cell lymphoma
694903|NCT00003962|recurrent adult diffuse mixed cell lymphoma
694904|NCT00003962|recurrent adult diffuse large cell lymphoma
694905|NCT00003962|recurrent adult immunoblastic large cell lymphoma
694906|NCT00003962|recurrent adult lymphoblastic lymphoma
694907|NCT00003962|recurrent adult T-cell leukemia/lymphoma
694908|NCT00003962|secondary acute myeloid leukemia
694909|NCT00003962|AIDS-related peripheral/systemic lymphoma
694910|NCT00003962|recurrent childhood small noncleaved cell lymphoma
694911|NCT00003962|recurrent childhood large cell lymphoma
694912|NCT00003962|recurrent mantle cell lymphoma
694913|NCT00003962|recurrent marginal zone lymphoma
694914|NCT00003962|recurrent small lymphocytic lymphoma
694915|NCT00003962|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694916|NCT00003962|nodal marginal zone B-cell lymphoma
694917|NCT00003962|splenic marginal zone lymphoma
694918|NCT00003961|refractory anemia with excess blasts
694919|NCT00003961|refractory anemia with excess blasts in transformation
694920|NCT00003961|chronic myelomonocytic leukemia
694921|NCT00003961|de novo myelodysplastic syndromes
694922|NCT00003961|previously treated myelodysplastic syndromes
694923|NCT00003961|secondary myelodysplastic syndromes
694924|NCT00003961|refractory cytopenia with multilineage dysplasia
694925|NCT00003961|atypical chronic myeloid leukemia
694926|NCT00003961|myelodysplastic/myeloproliferative disease, unclassifiable
694927|NCT00003960|refractory multiple myeloma
694928|NCT00003960|chronic phase chronic myelogenous leukemia
694929|NCT00003960|adult acute myeloid leukemia in remission
694930|NCT00003960|adult acute lymphoblastic leukemia in remission
694931|NCT00003960|refractory anemia with excess blasts
694932|NCT00003960|refractory anemia with excess blasts in transformation
694933|NCT00003960|acute undifferentiated leukemia
694934|NCT00003960|secondary acute myeloid leukemia
694935|NCT00003960|de novo myelodysplastic syndromes
694936|NCT00003960|previously treated myelodysplastic syndromes
694937|NCT00003960|secondary myelodysplastic syndromes
694938|NCT00003959|refractory anemia
694939|NCT00003959|refractory anemia with ringed sideroblasts
694940|NCT00003959|refractory anemia with excess blasts
694941|NCT00003959|chronic myelomonocytic leukemia
694942|NCT00003959|de novo myelodysplastic syndromes
694943|NCT00003959|previously treated myelodysplastic syndromes
694944|NCT00003959|secondary myelodysplastic syndromes
694945|NCT00003957|recurrent grade 3 follicular lymphoma
694946|NCT00003957|recurrent adult diffuse mixed cell lymphoma
694947|NCT00003957|recurrent adult diffuse large cell lymphoma
694948|NCT00003957|recurrent adult immunoblastic large cell lymphoma
694949|NCT00003956|stage IV adult Hodgkin lymphoma
694950|NCT00003956|recurrent adult Hodgkin lymphoma
694951|NCT00003956|unspecified adult solid tumor, protocol specific
694952|NCT00003956|stage IV grade 1 follicular lymphoma
694953|NCT00003956|stage IV grade 2 follicular lymphoma
694954|NCT00003956|stage IV grade 3 follicular lymphoma
694955|NCT00003956|stage IV adult diffuse small cleaved cell lymphoma
694956|NCT00003956|stage IV adult diffuse mixed cell lymphoma
694957|NCT00003956|stage IV adult diffuse large cell lymphoma
694958|NCT00003956|stage IV adult immunoblastic large cell lymphoma
694959|NCT00003956|stage IV adult lymphoblastic lymphoma
694960|NCT00003956|stage IV adult Burkitt lymphoma
694961|NCT00003956|recurrent grade 1 follicular lymphoma
694962|NCT00003956|recurrent grade 2 follicular lymphoma
694963|NCT00003956|recurrent grade 3 follicular lymphoma
694964|NCT00003956|recurrent adult diffuse small cleaved cell lymphoma
694965|NCT00003956|recurrent adult diffuse mixed cell lymphoma
694966|NCT00003956|recurrent adult diffuse large cell lymphoma
694967|NCT00003956|recurrent adult immunoblastic large cell lymphoma
694968|NCT00003956|recurrent adult lymphoblastic lymphoma
694969|NCT00003956|recurrent adult Burkitt lymphoma
694970|NCT00003956|stage IV adult T-cell leukemia/lymphoma
694971|NCT00003956|recurrent adult T-cell leukemia/lymphoma
694972|NCT00003956|AIDS-related peripheral/systemic lymphoma
694973|NCT00003956|AIDS-related primary CNS lymphoma
694974|NCT00003956|stage IV mantle cell lymphoma
694975|NCT00003956|recurrent mantle cell lymphoma
694976|NCT00003956|angioimmunoblastic T-cell lymphoma
694977|NCT00003956|anaplastic large cell lymphoma
694978|NCT00003956|recurrent marginal zone lymphoma
694979|NCT00003956|recurrent small lymphocytic lymphoma
694980|NCT00003956|stage IV small lymphocytic lymphoma
694981|NCT00003956|stage IV marginal zone lymphoma
694982|NCT00003956|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
694983|NCT00003956|nodal marginal zone B-cell lymphoma
694984|NCT00003956|splenic marginal zone lymphoma
694985|NCT00003955|embryonal childhood rhabdomyosarcoma
694986|NCT00003955|alveolar childhood rhabdomyosarcoma
694987|NCT00003955|metastatic childhood soft tissue sarcoma
694988|NCT00003955|childhood malignant mesenchymoma
694989|NCT00003955|previously untreated childhood rhabdomyosarcoma
694990|NCT00003955|adult rhabdomyosarcoma
694991|NCT00003955|adult malignant mesenchymoma
694992|NCT00003955|stage IV adult soft tissue sarcoma
694993|NCT00003953|stage II breast cancer
694994|NCT00003953|stage IIIA breast cancer
694995|NCT00003953|stage IIIB breast cancer
694996|NCT00003951|recurrent pancreatic cancer
694997|NCT00003951|duct cell adenocarcinoma of the pancreas
694998|NCT00003951|stage IV pancreatic cancer
694999|NCT00003950|stage IV colon cancer
695000|NCT00003950|stage IV rectal cancer
695001|NCT00003950|recurrent colon cancer
695002|NCT00003950|recurrent rectal cancer
695003|NCT00003950|adenocarcinoma of the colon
695004|NCT00003950|adenocarcinoma of the rectum
695005|NCT00003946|stage IV endometrial carcinoma
695006|NCT00003946|recurrent endometrial carcinoma
695007|NCT00003945|recurrent cervical cancer
695008|NCT00003945|stage IVB cervical cancer
695009|NCT00003945|cervical squamous cell carcinoma
695010|NCT00003945|cervical adenocarcinoma
695011|NCT00003945|cervical adenosquamous cell carcinoma
695012|NCT00003944|stage III ovarian epithelial cancer
695013|NCT00003944|stage IV ovarian epithelial cancer
695014|NCT00003944|ovarian undifferentiated adenocarcinoma
695015|NCT00003944|ovarian mixed epithelial carcinoma
695016|NCT00003944|ovarian serous cystadenocarcinoma
695017|NCT00003944|ovarian mucinous cystadenocarcinoma
695018|NCT00003944|ovarian endometrioid adenocarcinoma
695019|NCT00003944|ovarian clear cell cystadenocarcinoma
695020|NCT00003944|fallopian tube cancer
695021|NCT00003944|peritoneal cavity cancer
695022|NCT00003943|extensive stage small cell lung cancer
695023|NCT00003943|newly diagnosed carcinoma of unknown primary
695024|NCT00003942|AIDS-related peripheral/systemic lymphoma
695025|NCT00003942|AIDS-related diffuse large cell lymphoma
695026|NCT00003942|AIDS-related immunoblastic large cell lymphoma
695027|NCT00003942|AIDS-related small noncleaved cell lymphoma
695028|NCT00003942|AIDS-related diffuse mixed cell lymphoma
695029|NCT00003942|AIDS-related diffuse small cleaved cell lymphoma
695030|NCT00003942|AIDS-related lymphoblastic lymphoma
695031|NCT00003941|stage III malignant testicular germ cell tumor
695032|NCT00003941|mediastinal cancer
695033|NCT00003941|testicular embryonal carcinoma
695034|NCT00003941|testicular choriocarcinoma
695035|NCT00003941|testicular teratoma
695036|NCT00003941|testicular yolk sac tumor
695037|NCT00003941|testicular embryonal carcinoma and teratoma
695038|NCT00003941|testicular embryonal carcinoma and teratoma with seminoma
695039|NCT00003941|testicular embryonal carcinoma and yolk sac tumor
695040|NCT00003941|testicular embryonal carcinoma and yolk sac tumor with seminoma
695041|NCT00003941|testicular embryonal carcinoma and seminoma
695042|NCT00003941|testicular yolk sac tumor and teratoma
695043|NCT00003941|testicular yolk sac tumor and teratoma with seminoma
695044|NCT00003941|testicular choriocarcinoma and yolk sac tumor
695045|NCT00003941|testicular choriocarcinoma and embryonal carcinoma
695046|NCT00003941|testicular choriocarcinoma and teratoma
695047|NCT00003941|testicular choriocarcinoma and seminoma
695048|NCT00003941|tumors metastatic to brain
695049|NCT00003941|liver metastases
695050|NCT00003941|bone metastases
695051|NCT00003939|adult angiosarcoma
695052|NCT00003939|adult fibrosarcoma
695053|NCT00003939|adult leiomyosarcoma
695054|NCT00003939|adult liposarcoma
695055|NCT00003939|adult neurofibrosarcoma
695056|NCT00003939|adult synovial sarcoma
695057|NCT00003939|stage IV adult soft tissue sarcoma
695058|NCT00003939|recurrent adult soft tissue sarcoma
695059|NCT00003939|small intestine leiomyosarcoma
695060|NCT00003939|adult alveolar soft-part sarcoma
695061|NCT00003939|adult epithelioid sarcoma
695062|NCT00003939|adult malignant fibrous histiocytoma
695063|NCT00003939|adult malignant hemangiopericytoma
695064|NCT00003939|adult malignant mesenchymoma
695065|NCT00003939|adult rhabdomyosarcoma
695066|NCT00003939|stage IV uterine sarcoma
695067|NCT00003939|recurrent uterine sarcoma
695068|NCT00003939|uterine carcinosarcoma
695069|NCT00003939|uterine leiomyosarcoma
695070|NCT00003939|endometrial stromal sarcoma
695071|NCT00003939|ovarian sarcoma
695072|NCT00003939|adult meningeal hemangiopericytoma
695073|NCT00003939|gastrointestinal stromal tumor
695074|NCT00003938|stage I adult Hodgkin lymphoma
695075|NCT00003938|stage II adult Hodgkin lymphoma
695076|NCT00003938|stage III adult Hodgkin lymphoma
695077|NCT00003938|stage IV adult Hodgkin lymphoma
695078|NCT00003938|stage IV breast cancer
695079|NCT00003938|stage IIIA breast cancer
695080|NCT00003938|monoclonal gammopathy of undetermined significance
695081|NCT00003938|stage IIIB breast cancer
695082|NCT00003938|recurrent childhood acute lymphoblastic leukemia
695083|NCT00003938|recurrent adult Hodgkin lymphoma
695084|NCT00003938|stage I cutaneous T-cell non-Hodgkin lymphoma
695085|NCT00003938|stage II cutaneous T-cell non-Hodgkin lymphoma
695086|NCT00003938|stage III cutaneous T-cell non-Hodgkin lymphoma
695087|NCT00003938|stage IV cutaneous T-cell non-Hodgkin lymphoma
695088|NCT00003938|recurrent cutaneous T-cell non-Hodgkin lymphoma
695089|NCT00003938|isolated plasmacytoma of bone
695090|NCT00003938|extramedullary plasmacytoma
695091|NCT00003938|refractory multiple myeloma
695092|NCT00003938|recurrent childhood rhabdomyosarcoma
695093|NCT00003938|stage II ovarian epithelial cancer
695094|NCT00003938|stage III ovarian epithelial cancer
695095|NCT00003938|stage IV ovarian epithelial cancer
695096|NCT00003938|recurrent ovarian epithelial cancer
695097|NCT00003938|disseminated neuroblastoma
695098|NCT00003938|recurrent neuroblastoma
695099|NCT00003938|recurrent Wilms tumor and other childhood kidney tumors
695100|NCT00003938|stage 0 chronic lymphocytic leukemia
695101|NCT00003938|Waldenstrom macroglobulinemia
695102|NCT00003938|stage I multiple myeloma
695103|NCT00003938|stage II multiple myeloma
695104|NCT00003938|stage III multiple myeloma
695105|NCT00003938|stage I childhood lymphoblastic lymphoma
695106|NCT00003938|stage II childhood lymphoblastic lymphoma
695107|NCT00003938|stage III childhood lymphoblastic lymphoma
695108|NCT00003938|stage IV childhood lymphoblastic lymphoma
695109|NCT00003938|recurrent childhood lymphoblastic lymphoma
695110|NCT00003938|stage I chronic lymphocytic leukemia
695111|NCT00003938|stage II chronic lymphocytic leukemia
695112|NCT00003938|stage III chronic lymphocytic leukemia
695113|NCT00003938|stage IV chronic lymphocytic leukemia
695114|NCT00003938|recurrent childhood acute myeloid leukemia
695115|NCT00003938|recurrent adult acute myeloid leukemia
695116|NCT00003938|recurrent adult acute lymphoblastic leukemia
695117|NCT00003938|relapsing chronic myelogenous leukemia
695118|NCT00003938|refractory chronic lymphocytic leukemia
695119|NCT00003938|small intestine lymphoma
695120|NCT00003938|stage III malignant testicular germ cell tumor
695121|NCT00003938|recurrent malignant testicular germ cell tumor
695122|NCT00003938|unspecified childhood solid tumor, protocol specific
695123|NCT00003938|unspecified adult solid tumor, protocol specific
695124|NCT00003938|chronic phase chronic myelogenous leukemia
695125|NCT00003938|accelerated phase chronic myelogenous leukemia
695126|NCT00003938|blastic phase chronic myelogenous leukemia
695127|NCT00003938|meningeal chronic myelogenous leukemia
695128|NCT00003938|adult acute myeloid leukemia in remission
695129|NCT00003938|adult acute lymphoblastic leukemia in remission
695130|NCT00003938|childhood acute myeloid leukemia in remission
695131|NCT00003938|childhood acute lymphoblastic leukemia in remission
695132|NCT00003938|polycythemia vera
695133|NCT00003938|primary myelofibrosis
695134|NCT00003938|essential thrombocythemia
695135|NCT00003938|fever, sweats, and hot flashes
695136|NCT00003938|childhood acute promyelocytic leukemia (M3)
695137|NCT00003938|testicular embryonal carcinoma
695138|NCT00003938|testicular choriocarcinoma
695139|NCT00003938|testicular teratoma
695140|NCT00003938|testicular yolk sac tumor
695141|NCT00003938|testicular embryonal carcinoma and teratoma
695142|NCT00003938|testicular embryonal carcinoma and teratoma with seminoma
695143|NCT00003938|testicular embryonal carcinoma and yolk sac tumor
695144|NCT00003938|testicular embryonal carcinoma and yolk sac tumor with seminoma
695145|NCT00003938|testicular embryonal carcinoma and seminoma
695146|NCT00003938|testicular yolk sac tumor and teratoma
695147|NCT00003938|testicular yolk sac tumor and teratoma with seminoma
695148|NCT00003938|testicular choriocarcinoma and yolk sac tumor
695149|NCT00003938|testicular choriocarcinoma and embryonal carcinoma
695150|NCT00003938|testicular choriocarcinoma and teratoma
695151|NCT00003938|testicular choriocarcinoma and seminoma
695152|NCT00003938|progressive hairy cell leukemia, initial treatment
695153|NCT00003938|refractory hairy cell leukemia
695154|NCT00003938|stage II childhood Hodgkin lymphoma
695155|NCT00003938|stage I childhood Hodgkin lymphoma
695156|NCT00003938|stage III childhood Hodgkin lymphoma
695157|NCT00003938|stage IV childhood Hodgkin lymphoma
695158|NCT00003938|recurrent/refractory childhood Hodgkin lymphoma
695159|NCT00003938|stage I grade 1 follicular lymphoma
695160|NCT00003938|stage I grade 2 follicular lymphoma
695161|NCT00003938|stage I grade 3 follicular lymphoma
695162|NCT00003938|stage I adult diffuse small cleaved cell lymphoma
695163|NCT00003938|stage I adult diffuse mixed cell lymphoma
695164|NCT00003938|stage I adult diffuse large cell lymphoma
695165|NCT00003938|stage I adult immunoblastic large cell lymphoma
695166|NCT00003938|stage I adult lymphoblastic lymphoma
695167|NCT00003938|stage I adult Burkitt lymphoma
695168|NCT00003938|recurrent ovarian germ cell tumor
695169|NCT00003938|chronic myelomonocytic leukemia
695170|NCT00003938|T-cell large granular lymphocyte leukemia
695171|NCT00003938|ovarian yolk sac tumor
695172|NCT00003938|ovarian embryonal carcinoma
695173|NCT00003938|ovarian polyembryoma
695174|NCT00003938|ovarian choriocarcinoma
695175|NCT00003938|ovarian immature teratoma
695176|NCT00003938|ovarian mature teratoma
695177|NCT00003938|ovarian monodermal and highly specialized teratoma
695178|NCT00003938|ovarian mixed germ cell tumor
695179|NCT00003938|acute undifferentiated leukemia
695180|NCT00003938|stage III grade 1 follicular lymphoma
695181|NCT00003938|stage III grade 2 follicular lymphoma
695182|NCT00003938|stage III grade 3 follicular lymphoma
695183|NCT00003938|stage III adult diffuse small cleaved cell lymphoma
695184|NCT00003938|stage III adult diffuse mixed cell lymphoma
695185|NCT00003938|stage III adult diffuse large cell lymphoma
695186|NCT00003938|stage III adult immunoblastic large cell lymphoma
695187|NCT00003938|stage III adult lymphoblastic lymphoma
695188|NCT00003938|stage III adult Burkitt lymphoma
695189|NCT00003938|stage IV grade 1 follicular lymphoma
695190|NCT00003938|stage IV grade 2 follicular lymphoma
695191|NCT00003938|stage IV grade 3 follicular lymphoma
695192|NCT00003938|stage IV adult diffuse small cleaved cell lymphoma
695193|NCT00003938|stage IV adult diffuse mixed cell lymphoma
695194|NCT00003938|stage IV adult diffuse large cell lymphoma
695195|NCT00003938|stage IV adult immunoblastic large cell lymphoma
695196|NCT00003938|stage IV adult lymphoblastic lymphoma
695197|NCT00003938|stage IV adult Burkitt lymphoma
695198|NCT00003938|recurrent grade 1 follicular lymphoma
695199|NCT00003938|recurrent grade 2 follicular lymphoma
695200|NCT00003938|recurrent grade 3 follicular lymphoma
695201|NCT00003938|recurrent adult diffuse small cleaved cell lymphoma
695202|NCT00003938|recurrent adult diffuse mixed cell lymphoma
695203|NCT00003938|recurrent adult diffuse large cell lymphoma
695204|NCT00003938|recurrent adult immunoblastic large cell lymphoma
695205|NCT00003938|recurrent adult lymphoblastic lymphoma
695206|NCT00003938|recurrent adult Burkitt lymphoma
695207|NCT00003938|stage I adult T-cell leukemia/lymphoma
695208|NCT00003938|stage II adult T-cell leukemia/lymphoma
695209|NCT00003938|stage III adult T-cell leukemia/lymphoma
695210|NCT00003938|stage IV adult T-cell leukemia/lymphoma
695211|NCT00003938|recurrent adult T-cell leukemia/lymphoma
695212|NCT00003938|de novo myelodysplastic syndromes
695213|NCT00003938|high risk metastatic gestational trophoblastic tumor
695214|NCT00003938|previously treated myelodysplastic syndromes
695215|NCT00003938|secondary myelodysplastic syndromes
695216|NCT00003938|primary central nervous system non-Hodgkin lymphoma
695217|NCT00003938|neutropenia
695218|NCT00003938|infection
695219|NCT00003938|previously untreated childhood rhabdomyosarcoma
695220|NCT00003938|prolymphocytic leukemia
695221|NCT00003938|primary systemic amyloidosis
695222|NCT00003938|intraocular lymphoma
695223|NCT00003938|stage I childhood small noncleaved cell lymphoma
695224|NCT00003938|stage I childhood large cell lymphoma
695225|NCT00003938|stage II childhood small noncleaved cell lymphoma
695226|NCT00003938|stage II childhood large cell lymphoma
695227|NCT00003938|stage III childhood small noncleaved cell lymphoma
695228|NCT00003938|stage III childhood large cell lymphoma
695229|NCT00003938|stage IV childhood small noncleaved cell lymphoma
695230|NCT00003938|stage IV childhood large cell lymphoma
695231|NCT00003938|recurrent childhood small noncleaved cell lymphoma
695232|NCT00003938|recurrent childhood large cell lymphoma
695233|NCT00003938|stage I mantle cell lymphoma
695234|NCT00003938|contiguous stage II grade 1 follicular lymphoma
695235|NCT00003938|contiguous stage II grade 2 follicular lymphoma
695236|NCT00003938|contiguous stage II grade 3 follicular lymphoma
695237|NCT00003938|contiguous stage II adult diffuse small cleaved cell lymphoma
695238|NCT00003938|contiguous stage II mantle cell lymphoma
695239|NCT00003938|contiguous stage II adult diffuse mixed cell lymphoma
695240|NCT00003938|contiguous stage II adult immunoblastic large cell lymphoma
695241|NCT00003938|contiguous stage II adult diffuse large cell lymphoma
695242|NCT00003938|contiguous stage II adult Burkitt lymphoma
695243|NCT00003938|contiguous stage II adult lymphoblastic lymphoma
695244|NCT00003938|noncontiguous stage II grade 1 follicular lymphoma
695245|NCT00003938|noncontiguous stage II grade 2 follicular lymphoma
695246|NCT00003938|noncontiguous stage II grade 3 follicular lymphoma
695247|NCT00003938|noncontiguous stage II adult diffuse small cleaved cell lymphoma
695248|NCT00003938|noncontiguous stage II mantle cell lymphoma
695249|NCT00003938|noncontiguous stage II adult diffuse mixed cell lymphoma
695250|NCT00003938|noncontiguous stage II adult immunoblastic large cell lymphoma
695251|NCT00003938|noncontiguous stage II adult diffuse large cell lymphoma
695252|NCT00003938|noncontiguous stage II adult Burkitt lymphoma
695253|NCT00003938|noncontiguous stage II adult lymphoblastic lymphoma
695254|NCT00003938|stage III mantle cell lymphoma
695255|NCT00003938|stage IV mantle cell lymphoma
695256|NCT00003938|recurrent mantle cell lymphoma
695257|NCT00003938|angioimmunoblastic T-cell lymphoma
695258|NCT00003938|anaplastic large cell lymphoma
695259|NCT00003938|previously treated childhood rhabdomyosarcoma
695260|NCT00003938|stage I mycosis fungoides/Sezary syndrome
695261|NCT00003938|stage II mycosis fungoides/Sezary syndrome
695262|NCT00003938|stage III mycosis fungoides/Sezary syndrome
695263|NCT00003938|stage IV mycosis fungoides/Sezary syndrome
695264|NCT00003938|recurrent mycosis fungoides/Sezary syndrome
695265|NCT00003938|childhood chronic myelogenous leukemia
695266|NCT00003938|chronic eosinophilic leukemia
695267|NCT00003938|chronic neutrophilic leukemia
695268|NCT00003938|contiguous stage II marginal zone lymphoma
695269|NCT00003938|contiguous stage II small lymphocytic lymphoma
695270|NCT00003938|noncontiguous stage II small lymphocytic lymphoma
695271|NCT00003938|noncontiguous stage II marginal zone lymphoma
695272|NCT00003938|recurrent marginal zone lymphoma
695273|NCT00003938|recurrent small lymphocytic lymphoma
695274|NCT00003938|stage I marginal zone lymphoma
695275|NCT00003938|stage I small lymphocytic lymphoma
695276|NCT00003938|stage III small lymphocytic lymphoma
695277|NCT00003938|stage III marginal zone lymphoma
695278|NCT00003938|stage IV small lymphocytic lymphoma
695279|NCT00003938|stage IV marginal zone lymphoma
695280|NCT00003938|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695281|NCT00003938|nodal marginal zone B-cell lymphoma
695282|NCT00003938|splenic marginal zone lymphoma
695283|NCT00003938|childhood myelodysplastic syndromes
695284|NCT00003937|localized osteosarcoma
695285|NCT00003937|cardiac toxicity
695286|NCT00003936|recurrent adult Hodgkin lymphoma
695287|NCT00003935|untreated childhood brain stem glioma
695288|NCT00003933|recurrent childhood acute lymphoblastic leukemia
698352|NCT00003466|childhood mixed glioma
695289|NCT00003931|recurrent adult acute myeloid leukemia
695290|NCT00003931|adult acute myeloid leukemia in remission
695291|NCT00003930|stage II bladder cancer
695292|NCT00003930|stage III bladder cancer
695293|NCT00003929|primary central nervous system lymphoma
695294|NCT00003929|AIDS-related primary CNS lymphoma
695295|NCT00003928|stage IV renal cell cancer
695296|NCT00003928|recurrent renal cell cancer
695297|NCT00003927|stage II breast cancer
695298|NCT00003927|stage IV breast cancer
695299|NCT00003927|stage IIIA breast cancer
695300|NCT00003927|stage IIIB breast cancer
695301|NCT00003926|soft tissue sarcoma
695302|NCT00003926|regional neuroblastoma
695303|NCT00003926|disseminated neuroblastoma
695304|NCT00003926|recurrent Wilms tumor
695305|NCT00003926|recurrent retinoblastoma
695306|NCT00003926|recurrent adult brain tumor
695307|NCT00003926|adult rhabdomyosarcoma
695308|NCT00003926|ovarian germ cell tumor
695309|NCT00003926|chordoma
695310|NCT00003926|ovarian sarcoma
695311|NCT00003926|unresectable neuroblastoma
695312|NCT00003926|desmoplastic small round cell tumor
695313|NCT00003926|rhabdomyosarcoma
695314|NCT00003926|Ewing sarcoma
695315|NCT00003926|neuroectodermal tumor
695316|NCT00003926|teratoma
695317|NCT00003926|malignant testicular germ cell tumor
695318|NCT00003926|malignant ovarian germ cell tumor
695319|NCT00003926|extragonadal germ cell tumor
695320|NCT00003926|malignant germ cell tumor
695321|NCT00003926|hepatoblastoma
695322|NCT00003926|liver cancer
695323|NCT00003926|medulloblastoma
695324|NCT00003926|cerebellar astrocytoma
695325|NCT00003926|brain stem glioma
695326|NCT00003926|glioma
695327|NCT00003926|cerebral astrocytoma
695328|NCT00003926|ependymoma
695329|NCT00003925|unspecified adult solid tumor, protocol specific
695330|NCT00003924|recurrent adult Hodgkin lymphoma
695331|NCT00003924|Waldenström macroglobulinemia
695332|NCT00003924|recurrent grade 1 follicular lymphoma
695333|NCT00003924|recurrent grade 2 follicular lymphoma
695334|NCT00003924|recurrent grade 3 follicular lymphoma
695335|NCT00003924|recurrent adult diffuse small cleaved cell lymphoma
695336|NCT00003924|recurrent adult diffuse mixed cell lymphoma
695337|NCT00003924|recurrent adult diffuse large cell lymphoma
695338|NCT00003924|recurrent adult immunoblastic large cell lymphoma
695339|NCT00003924|recurrent adult lymphoblastic lymphoma
695340|NCT00003924|recurrent adult Burkitt lymphoma
695341|NCT00003924|recurrent mantle cell lymphoma
695342|NCT00003924|recurrent marginal zone lymphoma
695343|NCT00003924|recurrent small lymphocytic lymphoma
695344|NCT00003924|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695345|NCT00003924|nodal marginal zone B-cell lymphoma
695346|NCT00003924|splenic marginal zone lymphoma
695347|NCT00003923|stage I pancreatic cancer
695348|NCT00003923|stage II pancreatic cancer
695349|NCT00003923|stage III pancreatic cancer
695350|NCT00003923|stage IV pancreatic cancer
695351|NCT00003923|recurrent pancreatic cancer
695352|NCT00003923|unresectable gallbladder cancer
695353|NCT00003923|recurrent gallbladder cancer
695354|NCT00003923|unresectable extrahepatic bile duct cancer
695355|NCT00003923|recurrent extrahepatic bile duct cancer
695356|NCT00003923|cholangiocarcinoma of the gallbladder
695357|NCT00003923|cholangiocarcinoma of the extrahepatic bile duct
695358|NCT00003923|adult primary cholangiocellular carcinoma
695359|NCT00003920|stage IV breast cancer
695360|NCT00003920|recurrent breast cancer
695361|NCT00003917|limited stage small cell lung cancer
695362|NCT00003917|extensive stage small cell lung cancer
695363|NCT00003917|recurrent small cell lung cancer
695364|NCT00003916|adult glioblastoma
695365|NCT00003916|adult anaplastic astrocytoma
695366|NCT00003916|adult giant cell glioblastoma
695367|NCT00003916|adult gliosarcoma
695368|NCT00003915|adenocarcinoma of the prostate
695369|NCT00003915|stage I prostate cancer
695370|NCT00003914|stage IV renal cell cancer
695371|NCT00003914|recurrent renal cell cancer
695372|NCT00003913|recurrent childhood acute lymphoblastic leukemia
695373|NCT00003913|recurrent childhood lymphoblastic lymphoma
695374|NCT00003913|recurrent childhood acute myeloid leukemia
695375|NCT00003913|relapsing chronic myelogenous leukemia
695376|NCT00003913|chronic phase chronic myelogenous leukemia
695377|NCT00003913|accelerated phase chronic myelogenous leukemia
695378|NCT00003913|childhood acute myeloid leukemia in remission
695379|NCT00003913|childhood acute lymphoblastic leukemia in remission
695380|NCT00003913|recurrent/refractory childhood Hodgkin lymphoma
695381|NCT00003913|refractory anemia
695382|NCT00003913|refractory anemia with ringed sideroblasts
695383|NCT00003913|refractory anemia with excess blasts
695384|NCT00003913|refractory anemia with excess blasts in transformation
695385|NCT00003913|chronic myelomonocytic leukemia
695386|NCT00003913|acute undifferentiated leukemia
695387|NCT00003913|secondary acute myeloid leukemia
695388|NCT00003913|de novo myelodysplastic syndromes
695389|NCT00003913|previously treated myelodysplastic syndromes
695390|NCT00003913|secondary myelodysplastic syndromes
700644|NCT00003222|stage III melanoma
695391|NCT00003913|recurrent childhood small noncleaved cell lymphoma
695392|NCT00003913|recurrent childhood large cell lymphoma
695393|NCT00003913|juvenile myelomonocytic leukemia
695394|NCT00003913|blastic phase chronic myelogenous leukemia
695395|NCT00003913|childhood chronic myelogenous leukemia
695396|NCT00003913|atypical chronic myeloid leukemia
695397|NCT00003913|myelodysplastic/myeloproliferative disease, unclassifiable
695398|NCT00003912|stage I childhood liver cancer
695399|NCT00003912|stage II childhood liver cancer
695400|NCT00003912|stage III childhood liver cancer
695401|NCT00003912|stage IV childhood liver cancer
695402|NCT00003912|recurrent childhood liver cancer
695403|NCT00003912|childhood hepatoblastoma
695404|NCT00003912|childhood hepatocellular carcinoma
695405|NCT00003911|stage IV melanoma
695406|NCT00003911|recurrent melanoma
695407|NCT00003911|tumors metastatic to brain
695408|NCT00003910|stage I chronic lymphocytic leukemia
695409|NCT00003910|stage II chronic lymphocytic leukemia
695410|NCT00003910|stage III chronic lymphocytic leukemia
695411|NCT00003910|stage IV chronic lymphocytic leukemia
695412|NCT00003910|T-cell large granular lymphocyte leukemia
695413|NCT00003910|LGL clone
695414|NCT00003908|recurrent metastatic squamous neck cancer with occult primary
695415|NCT00003908|metastatic squamous neck cancer with occult primary squamous cell carcinoma
695416|NCT00003908|stage IV squamous cell carcinoma of the lip and oral cavity
695417|NCT00003908|recurrent squamous cell carcinoma of the lip and oral cavity
695418|NCT00003908|stage IV squamous cell carcinoma of the oropharynx
695419|NCT00003908|recurrent squamous cell carcinoma of the oropharynx
695420|NCT00003908|stage IV squamous cell carcinoma of the nasopharynx
695421|NCT00003908|recurrent squamous cell carcinoma of the nasopharynx
695422|NCT00003908|stage IV squamous cell carcinoma of the hypopharynx
695423|NCT00003908|recurrent squamous cell carcinoma of the hypopharynx
695424|NCT00003908|stage IV squamous cell carcinoma of the larynx
695425|NCT00003908|recurrent squamous cell carcinoma of the larynx
695426|NCT00003908|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
695427|NCT00003908|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
695428|NCT00003907|localized unresectable adult primary liver cancer
695429|NCT00003907|advanced adult primary liver cancer
695430|NCT00003907|recurrent adult primary liver cancer
695431|NCT00003907|adult primary hepatocellular carcinoma
695432|NCT00003907|liver metastases
695433|NCT00003906|breast cancer
695434|NCT00003903|stage I prostate cancer
695435|NCT00003903|stage IIB prostate cancer
695436|NCT00003903|stage IIA prostate cancer
695437|NCT00003903|stage III prostate cancer
695438|NCT00003903|stage IV prostate cancer
695439|NCT00003903|osteoporosis
695440|NCT00003902|stage IV breast cancer
695441|NCT00003901|stage I non-small cell lung cancer
695442|NCT00003901|stage II non-small cell lung cancer
695443|NCT00003901|squamous cell lung cancer
695444|NCT00003901|large cell lung cancer
695445|NCT00003901|stage IIIA non-small cell lung cancer
695446|NCT00003901|adenocarcinoma of the lung
695447|NCT00003900|recurrent non-small cell lung cancer
695448|NCT00003900|stage IV non-small cell lung cancer
695449|NCT00003899|unspecified adult solid tumor, protocol specific
695450|NCT00003898|unspecified childhood solid tumor, protocol specific
695451|NCT00003898|oral complications
695452|NCT00003897|stage IV melanoma
695453|NCT00003897|recurrent melanoma
695454|NCT00003896|stage III ovarian epithelial cancer
695455|NCT00003896|peritoneal cavity cancer
695456|NCT00003896|fallopian tube cancer
695457|NCT00003894|unspecified childhood solid tumor, protocol specific
695458|NCT00003894|unspecified adult solid tumor, protocol specific
695459|NCT00003894|graft versus host disease
695460|NCT00003893|stage I breast cancer
695461|NCT00003892|stage IV ovarian epithelial cancer
695462|NCT00003892|recurrent ovarian epithelial cancer
695463|NCT00003891|unspecified adult solid tumor, protocol specific
695464|NCT00003890|unspecified adult solid tumor, protocol specific
695465|NCT00003888|stage III squamous cell carcinoma of the lip and oral cavity
695466|NCT00003888|stage IV squamous cell carcinoma of the lip and oral cavity
695467|NCT00003888|stage III squamous cell carcinoma of the oropharynx
695468|NCT00003888|stage IV squamous cell carcinoma of the oropharynx
695469|NCT00003888|stage III squamous cell carcinoma of the hypopharynx
695470|NCT00003888|stage IV squamous cell carcinoma of the hypopharynx
695471|NCT00003888|stage III squamous cell carcinoma of the larynx
695472|NCT00003888|stage IV squamous cell carcinoma of the larynx
695473|NCT00003887|stage IV breast cancer
695474|NCT00003887|stage IIIA breast cancer
695475|NCT00003887|stage IIIB breast cancer
695476|NCT00003887|recurrent childhood acute lymphoblastic leukemia
695477|NCT00003887|recurrent adult Hodgkin lymphoma
695478|NCT00003887|recurrent cutaneous T-cell non-Hodgkin lymphoma
695479|NCT00003887|refractory multiple myeloma
695480|NCT00003887|recurrent childhood rhabdomyosarcoma
695481|NCT00003887|stage II ovarian epithelial cancer
695482|NCT00003887|stage III ovarian epithelial cancer
695483|NCT00003887|stage IV ovarian epithelial cancer
695484|NCT00003887|recurrent ovarian epithelial cancer
695485|NCT00003887|disseminated neuroblastoma
695486|NCT00003887|recurrent neuroblastoma
695487|NCT00003887|recurrent Wilms tumor and other childhood kidney tumors
695488|NCT00003887|stage I multiple myeloma
695489|NCT00003887|stage II multiple myeloma
695490|NCT00003887|stage III multiple myeloma
695491|NCT00003887|recurrent childhood lymphoblastic lymphoma
695492|NCT00003887|stage III chronic lymphocytic leukemia
695493|NCT00003887|stage IV chronic lymphocytic leukemia
695494|NCT00003887|recurrent childhood acute myeloid leukemia
695495|NCT00003887|recurrent adult acute myeloid leukemia
695496|NCT00003887|recurrent adult acute lymphoblastic leukemia
695497|NCT00003887|relapsing chronic myelogenous leukemia
695498|NCT00003887|refractory chronic lymphocytic leukemia
695499|NCT00003887|stage III malignant testicular germ cell tumor
695500|NCT00003887|recurrent malignant testicular germ cell tumor
695501|NCT00003887|chronic phase chronic myelogenous leukemia
695502|NCT00003887|accelerated phase chronic myelogenous leukemia
695503|NCT00003887|blastic phase chronic myelogenous leukemia
695504|NCT00003887|meningeal chronic myelogenous leukemia
695505|NCT00003887|chronic idiopathic myelofibrosis
695506|NCT00003887|childhood acute promyelocytic leukemia (M3)
695507|NCT00003887|testicular embryonal carcinoma
695508|NCT00003887|testicular choriocarcinoma
695509|NCT00003887|testicular teratoma
695510|NCT00003887|testicular yolk sac tumor
695511|NCT00003887|testicular embryonal carcinoma and teratoma
695512|NCT00003887|testicular embryonal carcinoma and teratoma with seminoma
695513|NCT00003887|testicular embryonal carcinoma and yolk sac tumor
695514|NCT00003887|testicular embryonal carcinoma and yolk sac tumor with seminoma
695515|NCT00003887|testicular embryonal carcinoma and seminoma
695516|NCT00003887|testicular yolk sac tumor and teratoma
695517|NCT00003887|testicular yolk sac tumor and teratoma with seminoma
695518|NCT00003887|testicular choriocarcinoma and yolk sac tumor
695519|NCT00003887|testicular choriocarcinoma and embryonal carcinoma
695520|NCT00003887|testicular choriocarcinoma and teratoma
695521|NCT00003887|testicular choriocarcinoma and seminoma
695522|NCT00003887|refractory hairy cell leukemia
695523|NCT00003887|recurrent/refractory childhood Hodgkin lymphoma
695524|NCT00003887|recurrent ovarian germ cell tumor
695525|NCT00003887|ovarian yolk sac tumor
695526|NCT00003887|ovarian embryonal carcinoma
695527|NCT00003887|ovarian polyembryoma
695528|NCT00003887|ovarian choriocarcinoma
695529|NCT00003887|ovarian immature teratoma
695530|NCT00003887|ovarian mature teratoma
695531|NCT00003887|ovarian monodermal and highly specialized teratoma
695532|NCT00003887|ovarian mixed germ cell tumor
695533|NCT00003887|stage III grade 1 follicular lymphoma
695534|NCT00003887|stage III grade 2 follicular lymphoma
695535|NCT00003887|stage III grade 3 follicular lymphoma
695536|NCT00003887|stage III adult diffuse small cleaved cell lymphoma
695537|NCT00003887|stage III adult diffuse mixed cell lymphoma
695538|NCT00003887|stage III adult diffuse large cell lymphoma
695539|NCT00003887|stage III adult immunoblastic large cell lymphoma
695540|NCT00003887|stage III adult lymphoblastic lymphoma
695541|NCT00003887|stage III adult Burkitt lymphoma
695542|NCT00003887|stage IV grade 1 follicular lymphoma
695543|NCT00003887|stage IV grade 2 follicular lymphoma
695544|NCT00003887|stage IV grade 3 follicular lymphoma
695545|NCT00003887|stage IV adult diffuse small cleaved cell lymphoma
695546|NCT00003887|stage IV adult diffuse mixed cell lymphoma
695547|NCT00003887|stage IV adult diffuse large cell lymphoma
695548|NCT00003887|stage IV adult immunoblastic large cell lymphoma
695549|NCT00003887|stage IV adult lymphoblastic lymphoma
695550|NCT00003887|stage IV adult Burkitt lymphoma
695551|NCT00003887|recurrent grade 1 follicular lymphoma
695552|NCT00003887|recurrent grade 2 follicular lymphoma
695553|NCT00003887|recurrent grade 3 follicular lymphoma
695554|NCT00003887|recurrent adult diffuse small cleaved cell lymphoma
695555|NCT00003887|recurrent adult diffuse mixed cell lymphoma
695556|NCT00003887|recurrent adult diffuse large cell lymphoma
695557|NCT00003887|recurrent adult immunoblastic large cell lymphoma
695558|NCT00003887|recurrent adult lymphoblastic lymphoma
695559|NCT00003887|recurrent adult Burkitt lymphoma
695560|NCT00003887|stage II adult T-cell leukemia/lymphoma
695561|NCT00003887|secondary acute myeloid leukemia
695562|NCT00003887|de novo myelodysplastic syndromes
695563|NCT00003887|poor prognosis metastatic gestational trophoblastic tumor
695564|NCT00003887|previously treated myelodysplastic syndromes
695565|NCT00003887|secondary myelodysplastic syndromes
695566|NCT00003887|recurrent childhood small noncleaved cell lymphoma
695567|NCT00003887|recurrent childhood large cell lymphoma
695568|NCT00003887|noncontiguous stage II grade 1 follicular lymphoma
695569|NCT00003887|noncontiguous stage II grade 2 follicular lymphoma
695570|NCT00003887|noncontiguous stage II grade 3 follicular lymphoma
695571|NCT00003887|noncontiguous stage II adult diffuse small cleaved cell lymphoma
695572|NCT00003887|noncontiguous stage II mantle cell lymphoma
695573|NCT00003887|noncontiguous stage II adult diffuse mixed cell lymphoma
695574|NCT00003887|noncontiguous stage II adult immunoblastic large cell lymphoma
695575|NCT00003887|noncontiguous stage II adult diffuse large cell lymphoma
695576|NCT00003887|noncontiguous stage II adult Burkitt lymphoma
695577|NCT00003887|noncontiguous stage II adult lymphoblastic lymphoma
695578|NCT00003887|stage III mantle cell lymphoma
695579|NCT00003887|stage IV mantle cell lymphoma
695580|NCT00003887|recurrent mantle cell lymphoma
695581|NCT00003887|previously treated childhood rhabdomyosarcoma
695582|NCT00003887|recurrent mycosis fungoides/Sezary syndrome
695583|NCT00003887|noncontiguous stage II small lymphocytic lymphoma
695584|NCT00003887|noncontiguous stage II marginal zone lymphoma
695585|NCT00003887|recurrent marginal zone lymphoma
695586|NCT00003887|recurrent small lymphocytic lymphoma
695587|NCT00003887|stage III small lymphocytic lymphoma
695588|NCT00003887|stage III marginal zone lymphoma
695589|NCT00003887|stage IV small lymphocytic lymphoma
695590|NCT00003887|stage IV marginal zone lymphoma
695591|NCT00003887|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695592|NCT00003887|nodal marginal zone B-cell lymphoma
695593|NCT00003887|splenic marginal zone lymphoma
695594|NCT00003887|childhood myelodysplastic syndromes
695595|NCT00003885|recurrent cutaneous T-cell non-Hodgkin lymphoma
695596|NCT00003885|stage I multiple myeloma
695597|NCT00003885|stage II multiple myeloma
695598|NCT00003885|stage III multiple myeloma
695599|NCT00003885|recurrent adult acute myeloid leukemia
695600|NCT00003885|recurrent adult acute lymphoblastic leukemia
695601|NCT00003885|blastic phase chronic myelogenous leukemia
695602|NCT00003885|recurrent grade 1 follicular lymphoma
695603|NCT00003885|recurrent grade 2 follicular lymphoma
695604|NCT00003885|recurrent grade 3 follicular lymphoma
695605|NCT00003885|recurrent adult diffuse small cleaved cell lymphoma
695606|NCT00003885|recurrent adult diffuse mixed cell lymphoma
695607|NCT00003885|recurrent adult diffuse large cell lymphoma
695608|NCT00003885|recurrent adult immunoblastic large cell lymphoma
695609|NCT00003885|recurrent adult lymphoblastic lymphoma
695610|NCT00003885|recurrent adult Burkitt lymphoma
695611|NCT00003885|recurrent adult T-cell leukemia/lymphoma
695612|NCT00003885|previously treated myelodysplastic syndromes
695613|NCT00003885|recurrent mantle cell lymphoma
695614|NCT00003885|recurrent marginal zone lymphoma
695615|NCT00003885|recurrent small lymphocytic lymphoma
695616|NCT00003885|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695617|NCT00003885|nodal marginal zone B-cell lymphoma
695618|NCT00003885|splenic marginal zone lymphoma
695619|NCT00003884|hypercalcemia of malignancy
695620|NCT00003884|pain
695621|NCT00003884|recurrent non-small cell lung cancer
695622|NCT00003884|recurrent small cell lung cancer
695623|NCT00003884|unspecified adult solid tumor, protocol specific
695624|NCT00003884|bone metastases
695625|NCT00003883|stage IV breast cancer
695626|NCT00003883|stage IIIA breast cancer
695627|NCT00003883|stage IIIB breast cancer
695628|NCT00003883|recurrent childhood acute lymphoblastic leukemia
695629|NCT00003883|recurrent adult Hodgkin lymphoma
695630|NCT00003883|recurrent cutaneous T-cell non-Hodgkin lymphoma
695631|NCT00003883|refractory multiple myeloma
695632|NCT00003883|recurrent childhood rhabdomyosarcoma
695633|NCT00003883|stage II ovarian epithelial cancer
695634|NCT00003883|stage III ovarian epithelial cancer
695635|NCT00003883|stage IV ovarian epithelial cancer
695636|NCT00003883|recurrent ovarian epithelial cancer
695637|NCT00003883|disseminated neuroblastoma
695638|NCT00003883|recurrent neuroblastoma
695639|NCT00003883|recurrent Wilms tumor and other childhood kidney tumors
695640|NCT00003883|stage I multiple myeloma
695641|NCT00003883|stage II multiple myeloma
695642|NCT00003883|stage III multiple myeloma
695643|NCT00003883|recurrent childhood lymphoblastic lymphoma
695644|NCT00003883|stage III chronic lymphocytic leukemia
695645|NCT00003883|stage IV chronic lymphocytic leukemia
695646|NCT00003883|recurrent childhood acute myeloid leukemia
695647|NCT00003883|recurrent adult acute myeloid leukemia
695648|NCT00003883|recurrent adult acute lymphoblastic leukemia
695649|NCT00003883|relapsing chronic myelogenous leukemia
695650|NCT00003883|refractory chronic lymphocytic leukemia
695651|NCT00003883|stage III malignant testicular germ cell tumor
695652|NCT00003883|recurrent malignant testicular germ cell tumor
695653|NCT00003883|chronic phase chronic myelogenous leukemia
695654|NCT00003883|accelerated phase chronic myelogenous leukemia
695655|NCT00003883|blastic phase chronic myelogenous leukemia
695656|NCT00003883|meningeal chronic myelogenous leukemia
695657|NCT00003883|chronic idiopathic myelofibrosis
695658|NCT00003883|childhood acute promyelocytic leukemia (M3)
695659|NCT00003883|testicular embryonal carcinoma
695660|NCT00003883|testicular choriocarcinoma
695661|NCT00003883|testicular teratoma
695662|NCT00003883|testicular yolk sac tumor
695663|NCT00003883|testicular embryonal carcinoma and teratoma
695664|NCT00003883|testicular embryonal carcinoma and teratoma with seminoma
695665|NCT00003883|testicular embryonal carcinoma and yolk sac tumor
695666|NCT00003883|testicular embryonal carcinoma and yolk sac tumor with seminoma
695667|NCT00003883|testicular embryonal carcinoma and seminoma
695668|NCT00003883|testicular yolk sac tumor and teratoma
695669|NCT00003883|testicular yolk sac tumor and teratoma with seminoma
695670|NCT00003883|testicular choriocarcinoma and yolk sac tumor
700645|NCT00003222|stage IV melanoma
695671|NCT00003883|testicular choriocarcinoma and embryonal carcinoma
695672|NCT00003883|testicular choriocarcinoma and teratoma
695673|NCT00003883|testicular choriocarcinoma and seminoma
695674|NCT00003883|refractory hairy cell leukemia
695675|NCT00003883|recurrent/refractory childhood Hodgkin lymphoma
695676|NCT00003883|recurrent ovarian germ cell tumor
695677|NCT00003883|ovarian yolk sac tumor
695678|NCT00003883|ovarian embryonal carcinoma
695679|NCT00003883|ovarian polyembryoma
695680|NCT00003883|ovarian choriocarcinoma
695681|NCT00003883|ovarian immature teratoma
695682|NCT00003883|ovarian mature teratoma
695683|NCT00003883|ovarian monodermal and highly specialized teratoma
695684|NCT00003883|ovarian mixed germ cell tumor
695685|NCT00003883|stage III grade 1 follicular lymphoma
695686|NCT00003883|stage III grade 2 follicular lymphoma
695687|NCT00003883|stage III grade 3 follicular lymphoma
695688|NCT00003883|stage III adult diffuse small cleaved cell lymphoma
695689|NCT00003883|stage III adult diffuse mixed cell lymphoma
695690|NCT00003883|stage III adult diffuse large cell lymphoma
695691|NCT00003883|stage III adult immunoblastic large cell lymphoma
695692|NCT00003883|stage III adult lymphoblastic lymphoma
695693|NCT00003883|stage III adult Burkitt lymphoma
695694|NCT00003883|stage IV grade 1 follicular lymphoma
695695|NCT00003883|stage IV grade 2 follicular lymphoma
695696|NCT00003883|stage IV grade 3 follicular lymphoma
695697|NCT00003883|stage IV adult diffuse small cleaved cell lymphoma
695698|NCT00003883|stage IV adult diffuse mixed cell lymphoma
695699|NCT00003883|stage IV adult diffuse large cell lymphoma
695700|NCT00003883|stage IV adult immunoblastic large cell lymphoma
695701|NCT00003883|stage IV adult lymphoblastic lymphoma
695702|NCT00003883|stage IV adult Burkitt lymphoma
695703|NCT00003883|recurrent grade 1 follicular lymphoma
695704|NCT00003883|recurrent grade 2 follicular lymphoma
695705|NCT00003883|recurrent grade 3 follicular lymphoma
695706|NCT00003883|recurrent adult diffuse small cleaved cell lymphoma
695707|NCT00003883|recurrent adult diffuse mixed cell lymphoma
695708|NCT00003883|recurrent adult diffuse large cell lymphoma
695709|NCT00003883|recurrent adult immunoblastic large cell lymphoma
695710|NCT00003883|recurrent adult lymphoblastic lymphoma
695711|NCT00003883|recurrent adult Burkitt lymphoma
695712|NCT00003883|secondary acute myeloid leukemia
695713|NCT00003883|de novo myelodysplastic syndromes
695714|NCT00003883|poor prognosis metastatic gestational trophoblastic tumor
695715|NCT00003883|previously treated myelodysplastic syndromes
695716|NCT00003883|secondary myelodysplastic syndromes
695717|NCT00003883|infection
695718|NCT00003883|recurrent childhood small noncleaved cell lymphoma
695719|NCT00003883|recurrent childhood large cell lymphoma
695720|NCT00003883|noncontiguous stage II grade 1 follicular lymphoma
695721|NCT00003883|noncontiguous stage II grade 2 follicular lymphoma
695722|NCT00003883|noncontiguous stage II grade 3 follicular lymphoma
695723|NCT00003883|noncontiguous stage II adult diffuse small cleaved cell lymphoma
695724|NCT00003883|noncontiguous stage II mantle cell lymphoma
695725|NCT00003883|noncontiguous stage II adult diffuse mixed cell lymphoma
695726|NCT00003883|noncontiguous stage II adult immunoblastic large cell lymphoma
695727|NCT00003883|noncontiguous stage II adult diffuse large cell lymphoma
695728|NCT00003883|noncontiguous stage II adult Burkitt lymphoma
695729|NCT00003883|noncontiguous stage II adult lymphoblastic lymphoma
695730|NCT00003883|stage III mantle cell lymphoma
695731|NCT00003883|stage IV mantle cell lymphoma
695732|NCT00003883|recurrent mantle cell lymphoma
695733|NCT00003883|previously treated childhood rhabdomyosarcoma
695734|NCT00003883|recurrent mycosis fungoides/Sezary syndrome
695735|NCT00003883|noncontiguous stage II small lymphocytic lymphoma
695736|NCT00003883|noncontiguous stage II marginal zone lymphoma
695737|NCT00003883|recurrent marginal zone lymphoma
695738|NCT00003883|recurrent small lymphocytic lymphoma
695739|NCT00003883|stage III small lymphocytic lymphoma
695740|NCT00003883|stage III marginal zone lymphoma
695741|NCT00003883|stage IV small lymphocytic lymphoma
695742|NCT00003883|stage IV marginal zone lymphoma
695743|NCT00003883|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695744|NCT00003883|nodal marginal zone B-cell lymphoma
695745|NCT00003883|splenic marginal zone lymphoma
695746|NCT00003883|childhood myelodysplastic syndromes
695747|NCT00003882|unspecified adult solid tumor, protocol specific
695748|NCT00003881|recurrent non-small cell lung cancer
695749|NCT00003881|stage IIIB non-small cell lung cancer
695750|NCT00003881|stage IV non-small cell lung cancer
695751|NCT00003880|stage III ovarian epithelial cancer
695752|NCT00003880|ovarian mixed epithelial carcinoma
695753|NCT00003880|ovarian serous cystadenocarcinoma
695754|NCT00003880|ovarian mucinous cystadenocarcinoma
695755|NCT00003880|ovarian endometrioid adenocarcinoma
695756|NCT00003880|ovarian clear cell cystadenocarcinoma
695757|NCT00003880|primary peritoneal cavity cancer
695758|NCT00003878|unspecified adult solid tumor, protocol specific
695759|NCT00003878|tumors metastatic to brain
695760|NCT00003877|stage IV breast cancer
695761|NCT00003877|recurrent breast cancer
695762|NCT00003876|recurrent adult brain tumor
695763|NCT00003876|adult brain stem glioma
695765|NCT00003876|adult anaplastic astrocytoma
695766|NCT00003876|adult anaplastic oligodendroglioma
695767|NCT00003876|adult mixed glioma
695768|NCT00003876|adult giant cell glioblastoma
695769|NCT00003876|adult gliosarcoma
695770|NCT00003874|recurrent childhood acute lymphoblastic leukemia
695771|NCT00003874|Waldenstrom macroglobulinemia
695772|NCT00003874|recurrent childhood lymphoblastic lymphoma
695773|NCT00003874|recurrent adult acute lymphoblastic leukemia
695774|NCT00003874|refractory chronic lymphocytic leukemia
695775|NCT00003874|B-cell chronic lymphocytic leukemia
695776|NCT00003874|B-cell childhood acute lymphoblastic leukemia
695777|NCT00003874|B-cell adult acute lymphoblastic leukemia
695778|NCT00003874|recurrent grade 1 follicular lymphoma
695779|NCT00003874|recurrent grade 2 follicular lymphoma
695780|NCT00003874|recurrent grade 3 follicular lymphoma
695781|NCT00003874|recurrent adult diffuse small cleaved cell lymphoma
695782|NCT00003874|recurrent adult diffuse mixed cell lymphoma
695783|NCT00003874|recurrent adult diffuse large cell lymphoma
695784|NCT00003874|recurrent adult immunoblastic large cell lymphoma
695785|NCT00003874|recurrent adult lymphoblastic lymphoma
695786|NCT00003874|recurrent adult Burkitt lymphoma
695787|NCT00003874|recurrent childhood small noncleaved cell lymphoma
695788|NCT00003874|recurrent childhood large cell lymphoma
695789|NCT00003874|recurrent mantle cell lymphoma
695790|NCT00003874|recurrent marginal zone lymphoma
695791|NCT00003874|recurrent small lymphocytic lymphoma
695792|NCT00003874|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
695793|NCT00003874|nodal marginal zone B-cell lymphoma
695794|NCT00003874|splenic marginal zone lymphoma
695795|NCT00003871|stage IV prostate cancer
695796|NCT00003871|recurrent prostate cancer
695797|NCT00003870|recurrent childhood acute lymphoblastic leukemia
695798|NCT00003870|recurrent adult acute lymphoblastic leukemia
695799|NCT00003870|adult acute lymphoblastic leukemia in remission
695800|NCT00003870|childhood acute lymphoblastic leukemia in remission
695801|NCT00003868|recurrent childhood acute myeloid leukemia
695802|NCT00003868|recurrent adult acute myeloid leukemia
695803|NCT00003868|secondary acute myeloid leukemia
695804|NCT00003868|adult acute myeloid leukemia with t(8;21)(q22;q22)
695805|NCT00003868|adult acute myeloid leukemia with t(16;16)(p13;q22)
695806|NCT00003868|adult acute myeloid leukemia with inv(16)(p13;q22)
695807|NCT00003868|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
695808|NCT00003868|adult acute myeloid leukemia with t(15;17)(q22;q12)
695809|NCT00003867|stage III colon cancer
695810|NCT00003867|stage IV colon cancer
695811|NCT00003867|stage IV breast cancer
695812|NCT00003867|stage IIIA breast cancer
695813|NCT00003867|recurrent breast cancer
695814|NCT00003867|stage III gastric cancer
695815|NCT00003867|stage IV gastric cancer
695816|NCT00003867|recurrent gastric cancer
695817|NCT00003867|stage IIIB breast cancer
695818|NCT00003867|stage II pancreatic cancer
695819|NCT00003867|stage III pancreatic cancer
695820|NCT00003867|recurrent pancreatic cancer
695821|NCT00003867|stage III rectal cancer
695822|NCT00003867|stage IV rectal cancer
695823|NCT00003867|recurrent colon cancer
695824|NCT00003867|recurrent rectal cancer
695825|NCT00003867|stage IV anal cancer
695826|NCT00003867|recurrent anal cancer
695827|NCT00003867|stage II esophageal cancer
695828|NCT00003867|stage III esophageal cancer
695829|NCT00003867|stage IV esophageal cancer
695830|NCT00003867|stage IIIA anal cancer
695831|NCT00003867|stage IIIB anal cancer
695832|NCT00003867|recurrent esophageal cancer
695833|NCT00003867|regional gastrointestinal carcinoid tumor
695834|NCT00003867|metastatic gastrointestinal carcinoid tumor
695835|NCT00003867|recurrent gastrointestinal carcinoid tumor
695836|NCT00003867|localized unresectable adult primary liver cancer
695837|NCT00003867|advanced adult primary liver cancer
695838|NCT00003867|recurrent adult primary liver cancer
695839|NCT00003867|small intestine adenocarcinoma
695840|NCT00003867|small intestine lymphoma
695841|NCT00003867|small intestine leiomyosarcoma
695842|NCT00003867|unresectable gallbladder cancer
695843|NCT00003867|recurrent gallbladder cancer
695844|NCT00003867|unresectable extrahepatic bile duct cancer
695845|NCT00003867|recurrent extrahepatic bile duct cancer
695846|NCT00003867|recurrent small intestine cancer
695847|NCT00003867|unspecified adult solid tumor, protocol specific
695848|NCT00003867|newly diagnosed carcinoma of unknown primary
695849|NCT00003867|carcinoma of the appendix
695850|NCT00003867|recurrent carcinoma of unknown primary
695851|NCT00003867|stage IV pancreatic cancer
695852|NCT00003865|recurrent ovarian epithelial cancer
695853|NCT00003865|ovarian serous cystadenocarcinoma
695854|NCT00003864|stage III esophageal cancer
695855|NCT00003864|stage IV esophageal cancer
695856|NCT00003864|squamous cell carcinoma of the esophagus
695857|NCT00003863|stage I adult diffuse small cleaved cell lymphoma
695858|NCT00003863|stage I adult diffuse mixed cell lymphoma
695859|NCT00003863|stage I adult diffuse large cell lymphoma
695860|NCT00003863|stage I adult immunoblastic large cell lymphoma
695861|NCT00003863|stage I adult Burkitt lymphoma
700646|NCT00003222|recurrent melanoma
695862|NCT00003863|stage III adult diffuse small cleaved cell lymphoma
695863|NCT00003863|stage III adult diffuse mixed cell lymphoma
695864|NCT00003863|stage III adult diffuse large cell lymphoma
695865|NCT00003863|stage III adult immunoblastic large cell lymphoma
695866|NCT00003863|stage III adult Burkitt lymphoma
695867|NCT00003863|stage IV adult diffuse small cleaved cell lymphoma
695868|NCT00003863|stage IV adult diffuse mixed cell lymphoma
695869|NCT00003863|stage IV adult diffuse large cell lymphoma
695870|NCT00003863|stage IV adult immunoblastic large cell lymphoma
695871|NCT00003863|stage IV adult Burkitt lymphoma
695872|NCT00003863|recurrent adult diffuse small cleaved cell lymphoma
695873|NCT00003863|recurrent adult diffuse mixed cell lymphoma
695874|NCT00003863|recurrent adult diffuse large cell lymphoma
695875|NCT00003863|recurrent adult immunoblastic large cell lymphoma
695876|NCT00003863|recurrent adult Burkitt lymphoma
695877|NCT00003863|stage I mantle cell lymphoma
695878|NCT00003863|contiguous stage II adult diffuse small cleaved cell lymphoma
695879|NCT00003863|contiguous stage II mantle cell lymphoma
695880|NCT00003863|contiguous stage II adult diffuse mixed cell lymphoma
695881|NCT00003863|contiguous stage II adult immunoblastic large cell lymphoma
695882|NCT00003863|contiguous stage II adult diffuse large cell lymphoma
695883|NCT00003863|contiguous stage II adult Burkitt lymphoma
695884|NCT00003863|noncontiguous stage II adult diffuse small cleaved cell lymphoma
695885|NCT00003863|noncontiguous stage II mantle cell lymphoma
695886|NCT00003863|noncontiguous stage II adult diffuse mixed cell lymphoma
695887|NCT00003863|noncontiguous stage II adult immunoblastic large cell lymphoma
695888|NCT00003863|noncontiguous stage II adult diffuse large cell lymphoma
695889|NCT00003863|noncontiguous stage II adult Burkitt lymphoma
695890|NCT00003863|stage III mantle cell lymphoma
695891|NCT00003863|stage IV mantle cell lymphoma
695892|NCT00003863|recurrent mantle cell lymphoma
695893|NCT00003862|stage I gastric cancer
695894|NCT00003862|stage II gastric cancer
695895|NCT00003862|stage III gastric cancer
695896|NCT00003862|stage IV gastric cancer
695897|NCT00003862|adenocarcinoma of the stomach
695898|NCT00003860|extensive stage small cell lung cancer
695899|NCT00003859|untreated childhood supratentorial primitive neuroectodermal tumor
695900|NCT00003859|recurrent childhood supratentorial primitive neuroectodermal tumor
695901|NCT00003858|adenocarcinoma of the prostate
695902|NCT00003858|stage I prostate cancer
695903|NCT00003858|stage IIB prostate cancer
695904|NCT00003858|stage IIA prostate cancer
695905|NCT00003858|stage III prostate cancer
695906|NCT00003858|stage IV prostate cancer
695907|NCT00003857|breast cancer in situ
695908|NCT00003857|ductal breast carcinoma in situ
695909|NCT00003856|recurrent salivary gland cancer
695910|NCT00003856|recurrent metastatic squamous neck cancer with occult primary
695911|NCT00003856|recurrent squamous cell carcinoma of the lip and oral cavity
695912|NCT00003856|recurrent squamous cell carcinoma of the oropharynx
695913|NCT00003856|recurrent squamous cell carcinoma of the nasopharynx
695914|NCT00003856|recurrent squamous cell carcinoma of the hypopharynx
695915|NCT00003856|recurrent squamous cell carcinoma of the larynx
695916|NCT00003856|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
695917|NCT00003855|stage IA breast cancer
695918|NCT00003855|stage IB breast cancer
695919|NCT00003855|stage II breast cancer
695920|NCT00003854|stage IA breast cancer
695921|NCT00003854|stage IB breast cancer
695922|NCT00003854|stage II breast cancer
695923|NCT00003853|primary systemic amyloidosis
695924|NCT00003852|recurrent malignant testicular germ cell tumor
695925|NCT00003852|childhood germ cell tumor
695926|NCT00003852|recurrent ovarian germ cell tumor
695927|NCT00003852|extragonadal germ cell tumor
695928|NCT00003851|malnutrition
695929|NCT00003851|stage II pancreatic cancer
695930|NCT00003851|stage III pancreatic cancer
695931|NCT00003851|stage IV pancreatic cancer
695932|NCT00003851|adenocarcinoma of the pancreas
695933|NCT00003850|recurrent metastatic squamous neck cancer with occult primary
695934|NCT00003850|metastatic squamous neck cancer with occult primary squamous cell carcinoma
695935|NCT00003850|stage IV squamous cell carcinoma of the lip and oral cavity
695936|NCT00003850|recurrent squamous cell carcinoma of the lip and oral cavity
695937|NCT00003850|stage IV squamous cell carcinoma of the oropharynx
695938|NCT00003850|recurrent squamous cell carcinoma of the oropharynx
695939|NCT00003850|stage IV squamous cell carcinoma of the nasopharynx
695940|NCT00003850|recurrent squamous cell carcinoma of the nasopharynx
695941|NCT00003850|stage IV squamous cell carcinoma of the hypopharynx
695942|NCT00003850|recurrent squamous cell carcinoma of the hypopharynx
695943|NCT00003850|stage IV squamous cell carcinoma of the larynx
695944|NCT00003850|recurrent squamous cell carcinoma of the larynx
695945|NCT00003850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
695946|NCT00003850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
695947|NCT00003849|recurrent adult Hodgkin lymphoma
695948|NCT00003849|stage III grade 1 follicular lymphoma
695949|NCT00003849|stage IV grade 1 follicular lymphoma
695950|NCT00003847|recurrent small cell lung cancer
695951|NCT00003847|intermediate type small cell lung cancer
695952|NCT00003846|regional neuroblastoma
695953|NCT00003846|disseminated neuroblastoma
695954|NCT00003846|stage 4S neuroblastoma
695955|NCT00003846|untreated childhood supratentorial primitive neuroectodermal tumor
695956|NCT00003846|untreated childhood medulloblastoma
695957|NCT00003846|newly diagnosed childhood ependymoma
695958|NCT00003843|stage IV colon cancer
695959|NCT00003843|stage IV rectal cancer
695960|NCT00003843|recurrent colon cancer
695961|NCT00003843|recurrent rectal cancer
695962|NCT00003842|recurrent adult brain tumor
695963|NCT00003842|adult glioblastoma
695964|NCT00003842|adult anaplastic astrocytoma
695965|NCT00003842|adult giant cell glioblastoma
695966|NCT00003842|adult gliosarcoma
695967|NCT00003840|recurrent adult acute myeloid leukemia
695968|NCT00003840|secondary acute myeloid leukemia
695969|NCT00003838|Graft-Versus-Leukemia
695970|NCT00003838|Peripheral Blood Stem Cells
695971|NCT00003838|Engraftment
695972|NCT00003838|Cyclophosphamide
695973|NCT00003838|Fludarabine
695974|NCT00003838|Donor Apheresis
695975|NCT00003838|Nonmyeloablative Bone Marrow Transplantation
695976|NCT00003838|Graft-Versus-Tumor
695977|NCT00003838|Graft-Versus-Host Disease
695978|NCT00003838|Multiple Myeloma
695979|NCT00003838|Extramedullary Plasmacytoma
695980|NCT00003838|Chronic Disease
695981|NCT00003838|Chronic Myelogenous Leukemia
695982|NCT00003838|Acute Lymphoblastic Leukemia
695983|NCT00003838|Acute Myelogenous Leukemia
695984|NCT00003838|Myeloproliferative Disease
695985|NCT00003838|Chronic Lymphocytic Leukemia
695986|NCT00003838|Paroxysmal Nocturnal Hemoglobinuria
695987|NCT00003838|Aplastic Anemia
695988|NCT00003838|Myelodysplastic Syndrome (MDS)
695989|NCT00003838|Chronic Myelomoncytic Leukemia
695990|NCT00003838|Non-Hodgkin's Lymphoma (NHL)
695991|NCT00003838|Hodgkin Disease
695992|NCT00003838|Pure Red Cell Aplasia
695993|NCT00003837|recurrent adult acute lymphoblastic leukemia
695994|NCT00003837|T-cell adult acute lymphoblastic leukemia
695995|NCT00003837|recurrent adult lymphoblastic lymphoma
695996|NCT00003834|stage IV colon cancer
695997|NCT00003834|stage IV rectal cancer
695998|NCT00003834|recurrent colon cancer
695999|NCT00003834|recurrent rectal cancer
696000|NCT00003834|adenocarcinoma of the colon
696001|NCT00003834|adenocarcinoma of the rectum
696002|NCT00003834|liver metastases
696003|NCT00003833|stage II colon cancer
696004|NCT00003833|stage III colon cancer
696005|NCT00003833|adenocarcinoma of the colon
696006|NCT00003831|stage I non-small cell lung cancer
696007|NCT00003831|stage II non-small cell lung cancer
696008|NCT00003831|squamous cell lung cancer
696009|NCT00003831|large cell lung cancer
696010|NCT00003831|adenocarcinoma of the lung
696011|NCT00003830|stage I breast cancer
696012|NCT00003830|stage II breast cancer
696013|NCT00003829|stage I chronic lymphocytic leukemia
696014|NCT00003829|stage II chronic lymphocytic leukemia
696015|NCT00003829|stage III chronic lymphocytic leukemia
696016|NCT00003829|stage IV chronic lymphocytic leukemia
696017|NCT00003829|B-cell chronic lymphocytic leukemia
696018|NCT00003828|stage IV melanoma
696019|NCT00003828|recurrent melanoma
696020|NCT00003827|refractory anemia with excess blasts
696021|NCT00003827|refractory anemia with excess blasts in transformation
696022|NCT00003827|de novo myelodysplastic syndromes
696023|NCT00003827|secondary myelodysplastic syndromes
696024|NCT00003827|childhood myelodysplastic syndromes
696025|NCT00003825|radiation enteritis
696026|NCT00003825|diarrhea
696027|NCT00003824|stage 0 bladder cancer
696028|NCT00003824|recurrent bladder cancer
696029|NCT00003824|transitional cell carcinoma of the bladder
696030|NCT00003822|unspecified adult solid tumor, protocol specific
696031|NCT00003821|recurrent endometrial carcinoma
696032|NCT00003819|stage I prostate cancer
696033|NCT00003819|stage IIB prostate cancer
696034|NCT00003819|stage IIA prostate cancer
696035|NCT00003819|stage III prostate cancer
696036|NCT00003819|recurrent prostate cancer
696037|NCT00003817|unspecified adult solid tumor, protocol specific
696038|NCT00003817|nausea and vomiting
696039|NCT00003816|recurrent childhood acute lymphoblastic leukemia
696040|NCT00003816|recurrent cutaneous T-cell non-Hodgkin lymphoma
696041|NCT00003816|Burkitt lymphoma
696042|NCT00003816|Waldenstrom macroglobulinemia
696043|NCT00003816|recurrent childhood lymphoblastic lymphoma
696044|NCT00003816|recurrent childhood acute myeloid leukemia
696045|NCT00003816|recurrent adult acute myeloid leukemia
696046|NCT00003816|recurrent adult acute lymphoblastic leukemia
696047|NCT00003816|relapsing chronic myelogenous leukemia
696048|NCT00003816|refractory chronic lymphocytic leukemia
696049|NCT00003816|chronic phase chronic myelogenous leukemia
696050|NCT00003816|accelerated phase chronic myelogenous leukemia
696051|NCT00003816|blastic phase chronic myelogenous leukemia
696052|NCT00003816|adult acute myeloid leukemia in remission
696053|NCT00003816|adult acute lymphoblastic leukemia in remission
696054|NCT00003816|childhood acute myeloid leukemia in remission
696055|NCT00003816|childhood acute lymphoblastic leukemia in remission
696056|NCT00003816|polycythemia vera
700647|NCT00003220|stage IV colon cancer
696057|NCT00003816|essential thrombocythemia
696058|NCT00003816|refractory anemia
696059|NCT00003816|refractory anemia with excess blasts
696060|NCT00003816|refractory anemia with excess blasts in transformation
696061|NCT00003816|chronic myelomonocytic leukemia
696062|NCT00003816|T-cell large granular lymphocyte leukemia
696063|NCT00003816|acute undifferentiated leukemia
696064|NCT00003816|recurrent grade 1 follicular lymphoma
696065|NCT00003816|recurrent grade 2 follicular lymphoma
696066|NCT00003816|recurrent grade 3 follicular lymphoma
696067|NCT00003816|recurrent adult diffuse small cleaved cell lymphoma
696068|NCT00003816|recurrent adult diffuse mixed cell lymphoma
696069|NCT00003816|recurrent adult diffuse large cell lymphoma
696070|NCT00003816|recurrent adult immunoblastic large cell lymphoma
696071|NCT00003816|recurrent adult lymphoblastic lymphoma
696072|NCT00003816|recurrent adult Burkitt lymphoma
696073|NCT00003816|recurrent adult T-cell leukemia/lymphoma
696074|NCT00003816|secondary acute myeloid leukemia
696075|NCT00003816|de novo myelodysplastic syndromes
696076|NCT00003816|previously treated myelodysplastic syndromes
696077|NCT00003816|secondary myelodysplastic syndromes
696078|NCT00003816|prolymphocytic leukemia
696079|NCT00003816|intraocular lymphoma
696080|NCT00003816|recurrent childhood small noncleaved cell lymphoma
696081|NCT00003816|recurrent childhood large cell lymphoma
696082|NCT00003816|recurrent mantle cell lymphoma
696083|NCT00003816|angioimmunoblastic T-cell lymphoma
696084|NCT00003816|anaplastic large cell lymphoma
696085|NCT00003816|recurrent mycosis fungoides/Sezary syndrome
696086|NCT00003816|primary myelofibrosis
696087|NCT00003816|childhood chronic myelogenous leukemia
696088|NCT00003816|atypical chronic myeloid leukemia
696089|NCT00003816|myelodysplastic/myeloproliferative disease, unclassifiable
696090|NCT00003816|recurrent marginal zone lymphoma
696091|NCT00003816|recurrent small lymphocytic lymphoma
696092|NCT00003816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
696093|NCT00003816|nodal marginal zone B-cell lymphoma
696094|NCT00003816|splenic marginal zone lymphoma
696095|NCT00003816|adult acute myeloid leukemia with t(8;21)(q22;q22)
696096|NCT00003816|adult acute myeloid leukemia with t(16;16)(p13;q22)
696097|NCT00003816|adult acute myeloid leukemia with inv(16)(p13;q22)
696098|NCT00003816|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
696099|NCT00003816|adult acute myeloid leukemia with t(15;17)(q22;q12)
696100|NCT00003816|childhood myelodysplastic syndromes
696101|NCT00003816|aplastic anemia
696102|NCT00003816|unspecified adult solid tumor, protocol specific
696103|NCT00003816|unspecified childhood solid tumor, protocol specific
696104|NCT00003815|stage I adult diffuse mixed cell lymphoma
696105|NCT00003815|stage I adult diffuse large cell lymphoma
696106|NCT00003815|stage I adult immunoblastic large cell lymphoma
696107|NCT00003815|stage I adult lymphoblastic lymphoma
696108|NCT00003815|stage III adult diffuse mixed cell lymphoma
696109|NCT00003815|stage III adult diffuse large cell lymphoma
696110|NCT00003815|stage III adult immunoblastic large cell lymphoma
696111|NCT00003815|stage III adult lymphoblastic lymphoma
696112|NCT00003815|stage IV adult diffuse mixed cell lymphoma
696113|NCT00003815|stage IV adult diffuse large cell lymphoma
696114|NCT00003815|stage IV adult immunoblastic large cell lymphoma
696115|NCT00003815|stage IV adult lymphoblastic lymphoma
696116|NCT00003815|contiguous stage II adult diffuse mixed cell lymphoma
696117|NCT00003815|contiguous stage II adult immunoblastic large cell lymphoma
696118|NCT00003815|contiguous stage II adult diffuse large cell lymphoma
696119|NCT00003815|contiguous stage II adult lymphoblastic lymphoma
696120|NCT00003815|noncontiguous stage II adult diffuse mixed cell lymphoma
696121|NCT00003815|noncontiguous stage II adult immunoblastic large cell lymphoma
696122|NCT00003815|noncontiguous stage II adult diffuse large cell lymphoma
696123|NCT00003815|noncontiguous stage II adult lymphoblastic lymphoma
696124|NCT00003814|stage 0 bladder cancer
696125|NCT00003814|stage I bladder cancer
696126|NCT00003814|recurrent bladder cancer
696127|NCT00003814|transitional cell carcinoma of the bladder
696128|NCT00003812|limited stage small cell lung cancer
696129|NCT00003811|drug/agent toxicity by tissue/organ
696130|NCT00003811|childhood teratoma
696131|NCT00003811|childhood malignant testicular germ cell tumor
696132|NCT00003811|childhood malignant ovarian germ cell tumor
696133|NCT00003811|childhood extragonadal germ cell tumor
696134|NCT00003811|recurrent childhood malignant germ cell tumor
696135|NCT00003810|stage III pancreatic cancer
696136|NCT00003810|stage IV pancreatic cancer
696137|NCT00003810|recurrent pancreatic cancer
696138|NCT00003810|adenocarcinoma of the pancreas
696139|NCT00003809|untreated metastatic squamous neck cancer with occult primary
696140|NCT00003809|recurrent metastatic squamous neck cancer with occult primary
696141|NCT00003809|stage III squamous cell carcinoma of the lip and oral cavity
696142|NCT00003809|stage IV squamous cell carcinoma of the lip and oral cavity
696143|NCT00003809|recurrent squamous cell carcinoma of the lip and oral cavity
696144|NCT00003809|stage III squamous cell carcinoma of the oropharynx
696145|NCT00003809|stage IV squamous cell carcinoma of the oropharynx
696146|NCT00003809|recurrent squamous cell carcinoma of the oropharynx
700648|NCT00003220|stage IV rectal cancer
696147|NCT00003809|stage III squamous cell carcinoma of the hypopharynx
696148|NCT00003809|stage IV squamous cell carcinoma of the hypopharynx
696149|NCT00003809|recurrent squamous cell carcinoma of the hypopharynx
696150|NCT00003809|stage III squamous cell carcinoma of the larynx
696151|NCT00003809|stage IV squamous cell carcinoma of the larynx
696152|NCT00003809|recurrent squamous cell carcinoma of the larynx
696153|NCT00003809|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
696154|NCT00003809|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
696155|NCT00003809|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
696156|NCT00003808|stage 0 chronic lymphocytic leukemia
696157|NCT00003808|stage I chronic lymphocytic leukemia
696158|NCT00003808|stage II chronic lymphocytic leukemia
696159|NCT00003808|B-cell chronic lymphocytic leukemia
696160|NCT00003805|stage I adult Hodgkin lymphoma
696161|NCT00003805|stage II adult Hodgkin lymphoma
696162|NCT00003805|stage III adult Hodgkin lymphoma
696163|NCT00003805|stage IV adult Hodgkin lymphoma
696164|NCT00003805|recurrent childhood acute lymphoblastic leukemia
696165|NCT00003805|recurrent adult Hodgkin lymphoma
696166|NCT00003805|stage I cutaneous T-cell non-Hodgkin lymphoma
696167|NCT00003805|stage II cutaneous T-cell non-Hodgkin lymphoma
696168|NCT00003805|stage III cutaneous T-cell non-Hodgkin lymphoma
696169|NCT00003805|stage IV cutaneous T-cell non-Hodgkin lymphoma
696170|NCT00003805|recurrent cutaneous T-cell non-Hodgkin lymphoma
696171|NCT00003805|Burkitt lymphoma
696172|NCT00003805|stage 0 chronic lymphocytic leukemia
696173|NCT00003805|Waldenstrom macroglobulinemia
696174|NCT00003805|stage I multiple myeloma
696175|NCT00003805|stage II multiple myeloma
696176|NCT00003805|stage III multiple myeloma
696177|NCT00003805|stage I childhood lymphoblastic lymphoma
696178|NCT00003805|stage II childhood lymphoblastic lymphoma
696179|NCT00003805|stage III childhood lymphoblastic lymphoma
696180|NCT00003805|stage IV childhood lymphoblastic lymphoma
696181|NCT00003805|recurrent childhood lymphoblastic lymphoma
696182|NCT00003805|stage I chronic lymphocytic leukemia
696183|NCT00003805|stage II chronic lymphocytic leukemia
696184|NCT00003805|stage III chronic lymphocytic leukemia
696185|NCT00003805|stage IV chronic lymphocytic leukemia
696186|NCT00003805|recurrent childhood acute myeloid leukemia
696187|NCT00003805|recurrent adult acute myeloid leukemia
696188|NCT00003805|recurrent adult acute lymphoblastic leukemia
696189|NCT00003805|relapsing chronic myelogenous leukemia
696190|NCT00003805|refractory chronic lymphocytic leukemia
696191|NCT00003805|childhood diffuse large cell lymphoma
696192|NCT00003805|childhood immunoblastic large cell lymphoma
696193|NCT00003805|unspecified childhood solid tumor, protocol specific
696194|NCT00003805|unspecified adult solid tumor, protocol specific
696195|NCT00003805|chronic phase chronic myelogenous leukemia
696196|NCT00003805|accelerated phase chronic myelogenous leukemia
696197|NCT00003805|blastic phase chronic myelogenous leukemia
696198|NCT00003805|meningeal chronic myelogenous leukemia
696199|NCT00003805|adult acute myeloid leukemia in remission
696200|NCT00003805|adult acute lymphoblastic leukemia in remission
696201|NCT00003805|childhood acute myeloid leukemia in remission
696202|NCT00003805|childhood acute lymphoblastic leukemia in remission
696203|NCT00003805|fever, sweats, and hot flashes
696204|NCT00003805|progressive hairy cell leukemia, initial treatment
696205|NCT00003805|refractory hairy cell leukemia
696206|NCT00003805|stage II childhood Hodgkin lymphoma
696207|NCT00003805|stage I childhood Hodgkin lymphoma
696208|NCT00003805|stage III childhood Hodgkin lymphoma
696209|NCT00003805|stage IV childhood Hodgkin lymphoma
696210|NCT00003805|recurrent/refractory childhood Hodgkin lymphoma
696211|NCT00003805|stage I grade 2 follicular lymphoma
696212|NCT00003805|stage I grade 3 follicular lymphoma
696213|NCT00003805|stage I adult diffuse small cleaved cell lymphoma
696214|NCT00003805|stage I adult diffuse mixed cell lymphoma
696215|NCT00003805|stage I adult diffuse large cell lymphoma
696216|NCT00003805|stage I adult immunoblastic large cell lymphoma
696217|NCT00003805|stage I adult lymphoblastic lymphoma
696218|NCT00003805|stage I adult Burkitt lymphoma
696219|NCT00003805|stage III grade 1 follicular lymphoma
696220|NCT00003805|stage III grade 2 follicular lymphoma
696221|NCT00003805|stage III grade 3 follicular lymphoma
696222|NCT00003805|stage III adult diffuse small cleaved cell lymphoma
696223|NCT00003805|stage III adult diffuse mixed cell lymphoma
696224|NCT00003805|stage III adult diffuse large cell lymphoma
696225|NCT00003805|stage III adult immunoblastic large cell lymphoma
696226|NCT00003805|stage III adult lymphoblastic lymphoma
696227|NCT00003805|stage III adult Burkitt lymphoma
696228|NCT00003805|stage IV grade 1 follicular lymphoma
696229|NCT00003805|stage IV grade 2 follicular lymphoma
696230|NCT00003805|stage IV grade 3 follicular lymphoma
696231|NCT00003805|stage IV adult diffuse small cleaved cell lymphoma
696232|NCT00003805|stage IV adult diffuse mixed cell lymphoma
696233|NCT00003805|stage IV adult diffuse large cell lymphoma
696234|NCT00003805|stage IV adult immunoblastic large cell lymphoma
696235|NCT00003805|stage IV adult lymphoblastic lymphoma
696236|NCT00003805|stage IV adult Burkitt lymphoma
696237|NCT00003805|recurrent grade 1 follicular lymphoma
696238|NCT00003805|recurrent grade 2 follicular lymphoma
696239|NCT00003805|recurrent grade 3 follicular lymphoma
696240|NCT00003805|recurrent adult diffuse small cleaved cell lymphoma
696241|NCT00003805|recurrent adult diffuse mixed cell lymphoma
696242|NCT00003805|recurrent adult diffuse large cell lymphoma
696243|NCT00003805|recurrent adult immunoblastic large cell lymphoma
696244|NCT00003805|recurrent adult lymphoblastic lymphoma
696245|NCT00003805|recurrent adult Burkitt lymphoma
696246|NCT00003805|stage I adult T-cell leukemia/lymphoma
696247|NCT00003805|stage II adult T-cell leukemia/lymphoma
696248|NCT00003805|stage III adult T-cell leukemia/lymphoma
696249|NCT00003805|stage IV adult T-cell leukemia/lymphoma
696250|NCT00003805|recurrent adult T-cell leukemia/lymphoma
696251|NCT00003805|de novo myelodysplastic syndromes
696252|NCT00003805|previously treated myelodysplastic syndromes
696253|NCT00003805|secondary myelodysplastic syndromes
696254|NCT00003805|infection
696255|NCT00003805|bone marrow suppression
696256|NCT00003805|stage I childhood small noncleaved cell lymphoma
696257|NCT00003805|stage I childhood large cell lymphoma
696258|NCT00003805|stage II childhood small noncleaved cell lymphoma
696259|NCT00003805|stage II childhood large cell lymphoma
696260|NCT00003805|stage III childhood small noncleaved cell lymphoma
696261|NCT00003805|stage III childhood large cell lymphoma
696262|NCT00003805|stage IV childhood small noncleaved cell lymphoma
696263|NCT00003805|stage IV childhood large cell lymphoma
696264|NCT00003805|recurrent childhood small noncleaved cell lymphoma
696265|NCT00003805|recurrent childhood large cell lymphoma
696266|NCT00003805|stage I mantle cell lymphoma
696267|NCT00003805|contiguous stage II grade 1 follicular lymphoma
696268|NCT00003805|contiguous stage II grade 2 follicular lymphoma
696269|NCT00003805|contiguous stage II grade 3 follicular lymphoma
696270|NCT00003805|contiguous stage II adult diffuse small cleaved cell lymphoma
696271|NCT00003805|contiguous stage II mantle cell lymphoma
696272|NCT00003805|contiguous stage II adult diffuse mixed cell lymphoma
696273|NCT00003805|contiguous stage II adult immunoblastic large cell lymphoma
696274|NCT00003805|contiguous stage II adult diffuse large cell lymphoma
696275|NCT00003805|contiguous stage II adult Burkitt lymphoma
696276|NCT00003805|contiguous stage II adult lymphoblastic lymphoma
696277|NCT00003805|noncontiguous stage II grade 1 follicular lymphoma
696278|NCT00003805|noncontiguous stage II grade 2 follicular lymphoma
696279|NCT00003805|noncontiguous stage II grade 3 follicular lymphoma
696280|NCT00003805|noncontiguous stage II adult diffuse small cleaved cell lymphoma
696281|NCT00003805|noncontiguous stage II mantle cell lymphoma
696282|NCT00003805|noncontiguous stage II adult diffuse mixed cell lymphoma
696283|NCT00003805|noncontiguous stage II adult immunoblastic large cell lymphoma
696284|NCT00003805|noncontiguous stage II adult diffuse large cell lymphoma
696285|NCT00003805|noncontiguous stage II adult Burkitt lymphoma
696286|NCT00003805|noncontiguous stage II adult lymphoblastic lymphoma
696287|NCT00003805|stage III mantle cell lymphoma
696288|NCT00003805|stage IV mantle cell lymphoma
696289|NCT00003805|recurrent mantle cell lymphoma
696290|NCT00003805|contiguous stage II marginal zone lymphoma
696291|NCT00003805|contiguous stage II small lymphocytic lymphoma
696292|NCT00003805|noncontiguous stage II small lymphocytic lymphoma
696293|NCT00003805|noncontiguous stage II marginal zone lymphoma
696294|NCT00003805|recurrent marginal zone lymphoma
696295|NCT00003805|recurrent small lymphocytic lymphoma
696296|NCT00003805|stage I marginal zone lymphoma
696297|NCT00003805|stage I small lymphocytic lymphoma
696298|NCT00003805|stage III small lymphocytic lymphoma
696299|NCT00003805|stage III marginal zone lymphoma
696300|NCT00003805|stage IV small lymphocytic lymphoma
696301|NCT00003805|stage IV marginal zone lymphoma
696302|NCT00003805|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
696303|NCT00003805|nodal marginal zone B-cell lymphoma
696304|NCT00003805|splenic marginal zone lymphoma
696305|NCT00003805|childhood myelodysplastic syndromes
696306|NCT00003804|stage I Wilms tumor
696307|NCT00003803|stage I non-small cell lung cancer
696308|NCT00003803|stage II non-small cell lung cancer
696309|NCT00003803|stage III non-small cell lung cancer
696310|NCT00003802|iris melanoma
696311|NCT00003802|ciliary body and choroid melanoma, small size
696312|NCT00003802|ciliary body and choroid melanoma, medium/large size
696313|NCT00003802|extraocular extension melanoma
696314|NCT00003802|recurrent intraocular melanoma
696315|NCT00003802|stage IV melanoma
696316|NCT00003802|recurrent melanoma
696317|NCT00003801|long-term effects secondary to cancer therapy in children
696318|NCT00003801|previously treated childhood rhabdomyosarcoma
696319|NCT00003800|stage I malignant testicular germ cell tumor
696320|NCT00003800|stage II malignant testicular germ cell tumor
696321|NCT00003800|testicular embryonal carcinoma
696322|NCT00003800|testicular choriocarcinoma
696323|NCT00003800|testicular teratoma
696324|NCT00003800|testicular yolk sac tumor
696325|NCT00003800|testicular embryonal carcinoma and teratoma
696326|NCT00003800|testicular embryonal carcinoma and yolk sac tumor
696327|NCT00003800|testicular yolk sac tumor and teratoma
696328|NCT00003800|testicular choriocarcinoma and yolk sac tumor
700649|NCT00003220|recurrent colon cancer
696329|NCT00003800|testicular choriocarcinoma and embryonal carcinoma
696330|NCT00003800|testicular choriocarcinoma and teratoma
696331|NCT00003798|stage II pancreatic cancer
696332|NCT00003798|stage III pancreatic cancer
696333|NCT00003798|adenocarcinoma of the pancreas
696334|NCT00003797|recurrent pancreatic cancer
696335|NCT00003797|stage IV pancreatic cancer
696336|NCT00003796|stage IV breast cancer
696337|NCT00003796|recurrent breast cancer
696338|NCT00003796|male breast cancer
696339|NCT00003795|stage I ovarian epithelial cancer
696340|NCT00003795|stage II ovarian epithelial cancer
696341|NCT00003795|stage I endometrial carcinoma
696342|NCT00003795|stage II endometrial carcinoma
696343|NCT00003794|stage I ovarian germ cell tumor
696344|NCT00003794|stage II ovarian germ cell tumor
696345|NCT00003794|stage III ovarian germ cell tumor
696346|NCT00003794|stage IV ovarian germ cell tumor
696347|NCT00003794|recurrent ovarian germ cell tumor
696348|NCT00003793|secondary acute myeloid leukemia
696349|NCT00003793|secondary myelodysplastic syndromes
696350|NCT00003793|localized osteosarcoma
696351|NCT00003793|metastatic osteosarcoma
696352|NCT00003793|childhood soft tissue sarcoma
696353|NCT00003793|nonmetastatic childhood soft tissue sarcoma
696354|NCT00003793|metastatic childhood soft tissue sarcoma
696355|NCT00003793|childhood fibrosarcoma
696356|NCT00003793|childhood synovial sarcoma
696357|NCT00003793|childhood neurofibrosarcoma
696358|NCT00003793|previously untreated childhood rhabdomyosarcoma
696359|NCT00003793|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
696360|NCT00003793|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
696361|NCT00003792|stage IV melanoma
696362|NCT00003792|recurrent melanoma
696363|NCT00003790|recurrent childhood acute myeloid leukemia
696364|NCT00003790|untreated childhood acute myeloid leukemia and other myeloid malignancies
696365|NCT00003790|de novo myelodysplastic syndromes
696366|NCT00003790|previously treated myelodysplastic syndromes
696367|NCT00003790|secondary myelodysplastic syndromes
696368|NCT00003788|recurrent adult brain tumor
696369|NCT00003788|adult glioblastoma
696370|NCT00003788|adult anaplastic astrocytoma
696371|NCT00003788|adult giant cell glioblastoma
696372|NCT00003788|adult gliosarcoma
696373|NCT00003787|stage I breast cancer
696374|NCT00003787|stage II breast cancer
696375|NCT00003787|stage IIIA breast cancer
696376|NCT00003787|recurrent breast cancer
696377|NCT00003786|stage IV colon cancer
696378|NCT00003786|stage IV rectal cancer
696379|NCT00003786|recurrent colon cancer
696380|NCT00003786|recurrent rectal cancer
696381|NCT00003786|adenocarcinoma of the colon
696382|NCT00003786|adenocarcinoma of the rectum
696383|NCT00003784|Waldenström macroglobulinemia
696384|NCT00003784|stage III grade 1 follicular lymphoma
696385|NCT00003784|stage III grade 2 follicular lymphoma
696386|NCT00003784|stage III grade 3 follicular lymphoma
696387|NCT00003784|stage IV grade 1 follicular lymphoma
696388|NCT00003784|stage IV grade 2 follicular lymphoma
696389|NCT00003784|stage IV grade 3 follicular lymphoma
696390|NCT00003784|contiguous stage II grade 1 follicular lymphoma
696391|NCT00003784|contiguous stage II grade 2 follicular lymphoma
696392|NCT00003784|contiguous stage II grade 3 follicular lymphoma
696393|NCT00003784|noncontiguous stage II grade 1 follicular lymphoma
696394|NCT00003784|noncontiguous stage II grade 2 follicular lymphoma
696395|NCT00003784|noncontiguous stage II grade 3 follicular lymphoma
696396|NCT00003783|untreated childhood acute lymphoblastic leukemia
696397|NCT00003783|L1 childhood acute lymphoblastic leukemia
696398|NCT00003783|L2 childhood acute lymphoblastic leukemia
696399|NCT00003783|B-cell childhood acute lymphoblastic leukemia
696400|NCT00003782|stage I breast cancer
696401|NCT00003782|stage II breast cancer
696402|NCT00003782|stage IIIA breast cancer
696403|NCT00003781|adenocarcinoma of the prostate
696404|NCT00003781|stage IV prostate cancer
696405|NCT00003781|recurrent prostate cancer
696406|NCT00003781|pain
696407|NCT00003780|stage II pancreatic cancer
696408|NCT00003780|stage III pancreatic cancer
696409|NCT00003780|stage IV pancreatic cancer
696410|NCT00003779|stage 0 bladder cancer
696411|NCT00003779|stage I bladder cancer
696412|NCT00003778|recurrent adult soft tissue sarcoma
696413|NCT00003778|stage IV uterine sarcoma
696414|NCT00003778|recurrent uterine sarcoma
696415|NCT00003778|ovarian sarcoma
696416|NCT00003778|stage IV adult soft tissue sarcoma
696417|NCT00003777|stage III lip and oral cavity cancer
696418|NCT00003777|stage IV lip and oral cavity cancer
696419|NCT00003777|recurrent lip and oral cavity cancer
696420|NCT00003777|stage III hypopharyngeal cancer
696421|NCT00003777|stage IV hypopharyngeal cancer
696422|NCT00003777|recurrent hypopharyngeal cancer
696423|NCT00003777|stage III laryngeal cancer
696424|NCT00003777|stage IV laryngeal cancer
696425|NCT00003777|recurrent laryngeal cancer
696426|NCT00003777|stage III paranasal sinus and nasal cavity cancer
696427|NCT00003777|stage IV paranasal sinus and nasal cavity cancer
696428|NCT00003777|recurrent paranasal sinus and nasal cavity cancer
696429|NCT00003777|stage III oropharyngeal cancer
696430|NCT00003777|stage IV oropharyngeal cancer
696431|NCT00003777|recurrent oropharyngeal cancer
696432|NCT00003776|metastatic osteosarcoma
696433|NCT00003775|recurrent adult brain tumor
696434|NCT00003775|adult anaplastic astrocytoma
696435|NCT00003775|adult mixed glioma
696436|NCT00003773|recurrent ovarian epithelial cancer
696437|NCT00003772|stage I ovarian epithelial cancer
696438|NCT00003772|stage II ovarian epithelial cancer
696439|NCT00003772|stage III ovarian epithelial cancer
696440|NCT00003772|stage IV ovarian epithelial cancer
696441|NCT00003772|recurrent ovarian epithelial cancer
696442|NCT00003771|menopausal symptoms
696443|NCT00003771|stage I breast cancer
696444|NCT00003771|stage II breast cancer
696445|NCT00003771|breast cancer in situ
696446|NCT00003769|stage II pancreatic cancer
696447|NCT00003769|stage III pancreatic cancer
696448|NCT00003769|adenocarcinoma of the pancreas
696449|NCT00003768|unspecified adult solid tumor, protocol specific
696450|NCT00003766|unspecified adult solid tumor, protocol specific
696451|NCT00003765|childhood craniopharyngioma
696452|NCT00003765|childhood central nervous system germ cell tumor
696453|NCT00003765|childhood oligodendroglioma
696454|NCT00003765|childhood choroid plexus tumor
696455|NCT00003765|recurrent childhood brain stem glioma
696456|NCT00003765|recurrent childhood supratentorial primitive neuroectodermal tumor
696457|NCT00003765|recurrent childhood visual pathway glioma
696458|NCT00003765|recurrent childhood cerebellar astrocytoma
696459|NCT00003765|recurrent childhood cerebral astrocytoma
696460|NCT00003765|recurrent childhood medulloblastoma
696461|NCT00003765|recurrent childhood ependymoma
696462|NCT00003764|stage 0 chronic lymphocytic leukemia
696463|NCT00003764|stage I chronic lymphocytic leukemia
696464|NCT00003764|stage II chronic lymphocytic leukemia
696465|NCT00003764|stage III chronic lymphocytic leukemia
696466|NCT00003764|stage IV chronic lymphocytic leukemia
696467|NCT00003764|B-cell chronic lymphocytic leukemia
696468|NCT00003763|stage I ovarian epithelial cancer
696469|NCT00003763|stage II ovarian epithelial cancer
696470|NCT00003763|stage III ovarian epithelial cancer
696471|NCT00003763|stage IV ovarian epithelial cancer
696472|NCT00003763|recurrent ovarian epithelial cancer
696473|NCT00003763|ovarian stromal cancer
696474|NCT00003763|stage I ovarian germ cell tumor
696475|NCT00003763|stage II ovarian germ cell tumor
696476|NCT00003763|stage III ovarian germ cell tumor
696477|NCT00003763|stage IV ovarian germ cell tumor
696478|NCT00003763|recurrent ovarian germ cell tumor
696479|NCT00003763|borderline ovarian surface epithelial-stromal tumor
696480|NCT00003763|ovarian sarcoma
696481|NCT00003762|recurrent non-small cell lung cancer
696482|NCT00003762|stage IIIB non-small cell lung cancer
696483|NCT00003762|stage IV non-small cell lung cancer
696484|NCT00003761|stage IV breast cancer
696485|NCT00003761|recurrent breast cancer
696486|NCT00003760|stage III pancreatic cancer
696487|NCT00003760|stage IV pancreatic cancer
696488|NCT00003760|recurrent pancreatic cancer
696489|NCT00003760|adenocarcinoma of the pancreas
696490|NCT00003759|stage 0 bladder cancer
696491|NCT00003759|stage I bladder cancer
696492|NCT00003759|recurrent bladder cancer
696493|NCT00003758|recurrent childhood acute myeloid leukemia
696494|NCT00003758|recurrent adult acute myeloid leukemia
696495|NCT00003758|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
696496|NCT00003758|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
696497|NCT00003758|adult acute erythroid leukemia (M6)
696498|NCT00003758|adult acute myeloblastic leukemia without maturation (M1)
696499|NCT00003758|adult acute myeloblastic leukemia with maturation (M2)
696500|NCT00003758|adult acute myelomonocytic leukemia (M4)
696501|NCT00003758|adult acute eosinophilic leukemia
696502|NCT00003758|adult acute basophilic leukemia
696503|NCT00003758|adult acute megakaryoblastic leukemia (M7)
696504|NCT00003758|childhood acute myeloblastic leukemia without maturation (M1)
696505|NCT00003758|childhood acute myeloblastic leukemia with maturation (M2)
696506|NCT00003758|childhood acute myelomonocytic leukemia (M4)
696507|NCT00003758|childhood acute erythroleukemia (M6)
696508|NCT00003758|childhood acute eosinophilic leukemia
696509|NCT00003758|childhood acute basophilic leukemia
696510|NCT00003758|childhood acute megakaryocytic leukemia (M7)
696511|NCT00003758|adult acute minimally differentiated myeloid leukemia (M0)
696512|NCT00003758|childhood acute minimally differentiated myeloid leukemia (M0)
696513|NCT00003757|progressive hairy cell leukemia, initial treatment
696514|NCT00003757|refractory hairy cell leukemia
696515|NCT00003755|unspecified adult solid tumor, protocol specific
696516|NCT00003754|unspecified childhood solid tumor, protocol specific
696517|NCT00003753|stage IV colon cancer
696518|NCT00003753|stage IV rectal cancer
696519|NCT00003753|adenocarcinoma of the colon
696520|NCT00003753|adenocarcinoma of the rectum
696521|NCT00003753|liver metastases
696522|NCT00003753|recurrent colon cancer
696523|NCT00003753|recurrent rectal cancer
696524|NCT00003752|stage IV breast cancer
696525|NCT00003752|recurrent breast cancer
696526|NCT00003751|adult glioblastoma
696527|NCT00003751|adult giant cell glioblastoma
696533|NCT00003750|unspecified childhood solid tumor, protocol specific
696534|NCT00003750|metastatic childhood soft tissue sarcoma
696535|NCT00003750|recurrent childhood soft tissue sarcoma
696536|NCT00003749|stage I endometrial carcinoma
696537|NCT00003749|stage II endometrial carcinoma
696538|NCT00003749|endometrial clear cell carcinoma
696539|NCT00003749|endometrial papillary serous carcinoma
696540|NCT00003748|stage I gastric cancer
696541|NCT00003748|stage II gastric cancer
696542|NCT00003748|stage III gastric cancer
696543|NCT00003748|stage IV gastric cancer
696544|NCT00003748|recurrent gastric cancer
696545|NCT00003748|stage I esophageal cancer
696546|NCT00003748|stage II esophageal cancer
696547|NCT00003748|stage III esophageal cancer
696548|NCT00003748|stage IV esophageal cancer
696549|NCT00003748|recurrent esophageal cancer
696550|NCT00003748|adenocarcinoma of the stomach
696551|NCT00003748|adenocarcinoma of the esophagus
696552|NCT00003747|stage IV melanoma
696553|NCT00003747|recurrent melanoma
696554|NCT00003746|untreated hairy cell leukemia
696555|NCT00003746|progressive hairy cell leukemia, initial treatment
696556|NCT00003746|prolymphocytic leukemia
696557|NCT00003745|recurrent childhood rhabdomyosarcoma
696558|NCT00003745|recurrent osteosarcoma
696559|NCT00003745|embryonal childhood rhabdomyosarcoma
696560|NCT00003745|alveolar childhood rhabdomyosarcoma
696561|NCT00003745|recurrent childhood soft tissue sarcoma
696562|NCT00003745|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
696563|NCT00003745|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
696564|NCT00003744|stage III salivary gland cancer
696565|NCT00003744|stage IV salivary gland cancer
696566|NCT00003744|salivary gland squamous cell carcinoma
696567|NCT00003744|salivary gland acinic cell tumor
696568|NCT00003744|low-grade salivary gland mucoepidermoid carcinoma
696569|NCT00003744|high-grade salivary gland mucoepidermoid carcinoma
696570|NCT00003744|salivary gland adenocarcinoma
696571|NCT00003744|salivary gland poorly differentiated carcinoma
696572|NCT00003744|salivary gland anaplastic carcinoma
696573|NCT00003744|salivary gland malignant mixed cell type tumor
696574|NCT00003744|salivary gland adenoid cystic carcinoma
696575|NCT00003743|disseminated neuroblastoma
696576|NCT00003742|unspecified adult solid tumor, protocol specific
696577|NCT00003741|recurrent adult Hodgkin lymphoma
696578|NCT00003741|anaplastic large cell lymphoma
696579|NCT00003740|stage IV prostate cancer
696580|NCT00003740|recurrent prostate cancer
696581|NCT00003739|unspecified childhood solid tumor, protocol specific
696582|NCT00003739|fever, sweats, and hot flashes
696583|NCT00003739|neutropenia
696584|NCT00003737|recurrent neuroblastoma
696585|NCT00003736|breast cancer
696586|NCT00003735|recurrent childhood acute lymphoblastic leukemia
696587|NCT00003735|recurrent childhood acute myeloid leukemia
696588|NCT00003735|blastic phase chronic myelogenous leukemia
696589|NCT00003734|adenocarcinoma of the prostate
696590|NCT00003734|stage I prostate cancer
696591|NCT00003734|stage IIB prostate cancer
696592|NCT00003734|stage IIA prostate cancer
696593|NCT00003734|stage III prostate cancer
696594|NCT00003734|stage IV prostate cancer
696595|NCT00003733|stage II ovarian epithelial cancer
696596|NCT00003733|stage III ovarian epithelial cancer
696597|NCT00003733|stage IV ovarian epithelial cancer
696598|NCT00003732|stage IIB ovarian epithelial cancer
696599|NCT00003732|stage IIC ovarian epithelial cancer
696600|NCT00003732|stage IIIA ovarian epithelial cancer
696601|NCT00003732|stage IIIB ovarian epithelial cancer
696602|NCT00003732|stage IIIC ovarian epithelial cancer
696603|NCT00003732|stage IV ovarian epithelial cancer
696604|NCT00003731|adult oligodendroglioma
696605|NCT00003731|adult mixed glioma
696606|NCT00003730|stage IV breast cancer
696607|NCT00003730|recurrent breast cancer
696608|NCT00003729|recurrent childhood acute lymphoblastic leukemia
696609|NCT00003729|L1 childhood acute lymphoblastic leukemia
696610|NCT00003729|L2 childhood acute lymphoblastic leukemia
696611|NCT00003728|stage I childhood lymphoblastic lymphoma
696612|NCT00003728|stage II childhood lymphoblastic lymphoma
696613|NCT00003728|stage III childhood lymphoblastic lymphoma
696614|NCT00003728|stage IV childhood lymphoblastic lymphoma
696615|NCT00003728|untreated childhood acute lymphoblastic leukemia
696616|NCT00003728|L1 childhood acute lymphoblastic leukemia
696617|NCT00003728|L2 childhood acute lymphoblastic leukemia
696618|NCT00003728|T-cell childhood acute lymphoblastic leukemia
696619|NCT00003728|B-cell childhood acute lymphoblastic leukemia
696620|NCT00003728|acute undifferentiated leukemia
696621|NCT00003727|relapsing chronic myelogenous leukemia
696622|NCT00003727|chronic phase chronic myelogenous leukemia
696623|NCT00003727|Philadelphia chromosome positive chronic myelogenous leukemia
696624|NCT00003727|Philadelphia chromosome negative chronic myelogenous leukemia
696625|NCT00003727|childhood chronic myelogenous leukemia
696626|NCT00003726|extensive stage small cell lung cancer
696627|NCT00003726|recurrent small cell lung cancer
696628|NCT00003725|stage 0 bladder cancer
696629|NCT00003725|stage I bladder cancer
696630|NCT00003725|recurrent bladder cancer
696631|NCT00003725|transitional cell carcinoma of the bladder
696632|NCT00003724|lung metastases
696633|NCT00003723|advanced malignant mesothelioma
696634|NCT00003723|epithelial mesothelioma
696635|NCT00003723|sarcomatous mesothelioma
696636|NCT00003721|unspecified adult solid tumor, protocol specific
696637|NCT00003720|AIDS-related Kaposi sarcoma
696638|NCT00003720|recurrent Kaposi sarcoma
696639|NCT00003719|stage IV adult soft tissue sarcoma
696640|NCT00003719|recurrent adult soft tissue sarcoma
696641|NCT00003718|adult angiosarcoma
696642|NCT00003718|adult fibrosarcoma
696643|NCT00003718|adult leiomyosarcoma
696644|NCT00003718|adult liposarcoma
696645|NCT00003718|adult neurofibrosarcoma
696646|NCT00003718|adult synovial sarcoma
696647|NCT00003718|recurrent adult soft tissue sarcoma
696648|NCT00003718|adult extraskeletal chondrosarcoma
696649|NCT00003718|adult alveolar soft-part sarcoma
696650|NCT00003718|adult epithelioid sarcoma
696651|NCT00003718|adult malignant fibrous histiocytoma
696652|NCT00003718|adult malignant hemangiopericytoma
696653|NCT00003718|adult malignant mesenchymoma
696654|NCT00003718|adult rhabdomyosarcoma
696655|NCT00003718|stage IV uterine sarcoma
696656|NCT00003718|recurrent uterine sarcoma
696657|NCT00003718|uterine carcinosarcoma
696658|NCT00003718|uterine leiomyosarcoma
696659|NCT00003718|endometrial stromal sarcoma
696660|NCT00003718|ovarian sarcoma
696661|NCT00003718|stage IV adult soft tissue sarcoma
696662|NCT00003717|adenocarcinoma of the prostate
696663|NCT00003717|stage IV prostate cancer
696664|NCT00003717|recurrent prostate cancer
696665|NCT00003716|childhood Burkitt lymphoma
696666|NCT00003716|childhood immunoblastic large cell lymphoma
696667|NCT00003716|stage IV adult immunoblastic large cell lymphoma
696668|NCT00003716|stage IV adult Burkitt lymphoma
696669|NCT00003716|recurrent adult immunoblastic large cell lymphoma
696670|NCT00003716|recurrent adult Burkitt lymphoma
696671|NCT00003716|stage IV childhood small noncleaved cell lymphoma
696672|NCT00003716|stage IV childhood large cell lymphoma
696673|NCT00003716|recurrent childhood small noncleaved cell lymphoma
696674|NCT00003716|recurrent childhood large cell lymphoma
696675|NCT00003715|stage III melanoma
696676|NCT00003714|localized unresectable adult primary liver cancer
696677|NCT00003714|advanced adult primary liver cancer
696678|NCT00003714|adult primary hepatocellular carcinoma
696679|NCT00003714|liver metastases
696680|NCT00003713|unspecified adult solid tumor, protocol specific
696681|NCT00003712|recurrent adult brain tumor
696682|NCT00003712|unspecified adult solid tumor, protocol specific
696683|NCT00003712|tumors metastatic to brain
696684|NCT00003711|unspecified adult solid tumor, protocol specific
696685|NCT00003710|unspecified adult solid tumor, protocol specific
696686|NCT00003709|unspecified adult solid tumor, protocol specific
696687|NCT00003708|unspecified adult solid tumor, protocol specific
696688|NCT00003707|unspecified adult solid tumor, protocol specific
696689|NCT00003706|unspecified adult solid tumor, protocol specific
696690|NCT00003705|unspecified adult solid tumor, protocol specific
696691|NCT00003704|stage III colon cancer
696692|NCT00003704|stage III rectal cancer
696693|NCT00003704|recurrent colon cancer
696694|NCT00003704|recurrent rectal cancer
696695|NCT00003704|recurrent anal cancer
696696|NCT00003704|stage IIIA anal cancer
696697|NCT00003704|stage IIIB anal cancer
696698|NCT00003704|stage III cervical cancer
696699|NCT00003704|recurrent cervical cancer
696700|NCT00003704|stage III ovarian epithelial cancer
696701|NCT00003704|recurrent ovarian epithelial cancer
696702|NCT00003704|stage III vulvar cancer
696703|NCT00003704|recurrent vulvar cancer
696704|NCT00003704|stage III vaginal cancer
696705|NCT00003704|recurrent vaginal cancer
696706|NCT00003704|stage III penile cancer
696707|NCT00003704|recurrent penile cancer
696708|NCT00003704|stage III endometrial carcinoma
696709|NCT00003704|recurrent endometrial carcinoma
696710|NCT00003704|stage III bladder cancer
696711|NCT00003704|recurrent bladder cancer
696712|NCT00003704|stage III malignant testicular germ cell tumor
696713|NCT00003704|stage III prostate cancer
696714|NCT00003704|recurrent prostate cancer
696715|NCT00003704|recurrent malignant testicular germ cell tumor
696716|NCT00003704|ovarian stromal cancer
696717|NCT00003704|recurrent urethral cancer
696718|NCT00003704|distal urethral cancer
696719|NCT00003704|proximal urethral cancer
696720|NCT00003704|stage III ovarian germ cell tumor
696721|NCT00003704|recurrent ovarian germ cell tumor
696722|NCT00003704|fallopian tube cancer
696723|NCT00003704|primary peritoneal cavity cancer
696724|NCT00003704|stage III uterine sarcoma
696725|NCT00003704|recurrent uterine sarcoma
696726|NCT00003704|borderline ovarian surface epithelial-stromal tumor
696727|NCT00003704|ovarian sarcoma
696728|NCT00003703|unspecified adult solid tumor, protocol specific
696729|NCT00003701|stage III bladder cancer
696730|NCT00003701|transitional cell carcinoma of the bladder
696731|NCT00003701|urethral cancer associated with invasive bladder cancer
696732|NCT00003700|untreated adult acute lymphoblastic leukemia
696733|NCT00003700|L1 adult acute lymphoblastic leukemia
696734|NCT00003700|L2 adult acute lymphoblastic leukemia
696735|NCT00003698|unspecified adult solid tumor, protocol specific
696736|NCT00003697|unspecified adult solid tumor, protocol specific
696737|NCT00003696|extensive stage small cell lung cancer
696738|NCT00003695|stage II ovarian epithelial cancer
696739|NCT00003695|stage III ovarian epithelial cancer
696740|NCT00003693|recurrent adult acute myeloid leukemia
696741|NCT00003693|recurrent adult acute lymphoblastic leukemia
696742|NCT00003693|relapsing chronic myelogenous leukemia
696743|NCT00003693|blastic phase chronic myelogenous leukemia
696744|NCT00003693|refractory anemia with excess blasts
696745|NCT00003693|refractory anemia with excess blasts in transformation
696746|NCT00003693|chronic myelomonocytic leukemia
696747|NCT00003693|previously treated myelodysplastic syndromes
696748|NCT00003693|childhood myelodysplastic syndromes
696749|NCT00003692|occult non-small cell lung cancer
696750|NCT00003692|stage I non-small cell lung cancer
696751|NCT00003692|stage 0 non-small cell lung cancer
696752|NCT00003691|stage III endometrial carcinoma
696753|NCT00003691|stage IV endometrial carcinoma
696754|NCT00003691|recurrent endometrial carcinoma
696755|NCT00003690|stage IV breast cancer
696756|NCT00003690|recurrent breast cancer
696757|NCT00003690|stage IV prostate cancer
696758|NCT00003690|recurrent prostate cancer
696759|NCT00003690|stage IV melanoma
696760|NCT00003690|recurrent melanoma
696761|NCT00003690|unspecified adult solid tumor, protocol specific
696762|NCT00003688|recurrent gestational trophoblastic tumor
696763|NCT00003688|nonmetastatic gestational trophoblastic tumor
696764|NCT00003688|low risk metastatic gestational trophoblastic tumor
696765|NCT00003687|stage III adult Hodgkin lymphoma
696766|NCT00003687|stage IV adult Hodgkin lymphoma
696767|NCT00003687|monoclonal gammopathy of undetermined significance
696768|NCT00003687|recurrent adult Hodgkin lymphoma
696769|NCT00003687|stage III cutaneous T-cell non-Hodgkin lymphoma
696770|NCT00003687|stage IV cutaneous T-cell non-Hodgkin lymphoma
696771|NCT00003687|recurrent cutaneous T-cell non-Hodgkin lymphoma
696772|NCT00003687|isolated plasmacytoma of bone
696773|NCT00003687|extramedullary plasmacytoma
696774|NCT00003687|refractory multiple myeloma
696775|NCT00003687|Waldenstrom macroglobulinemia
696776|NCT00003687|stage III multiple myeloma
696777|NCT00003687|stage III chronic lymphocytic leukemia
696778|NCT00003687|stage IV chronic lymphocytic leukemia
696779|NCT00003687|recurrent adult acute myeloid leukemia
696780|NCT00003687|recurrent adult acute lymphoblastic leukemia
696781|NCT00003687|relapsing chronic myelogenous leukemia
696782|NCT00003687|refractory chronic lymphocytic leukemia
696783|NCT00003687|small intestine lymphoma
696784|NCT00003687|unspecified adult solid tumor, protocol specific
696785|NCT00003687|chronic phase chronic myelogenous leukemia
696786|NCT00003687|accelerated phase chronic myelogenous leukemia
696787|NCT00003687|blastic phase chronic myelogenous leukemia
696788|NCT00003687|meningeal chronic myelogenous leukemia
696789|NCT00003687|untreated adult acute lymphoblastic leukemia
696790|NCT00003687|untreated adult acute myeloid leukemia
696791|NCT00003687|adult acute myeloid leukemia in remission
696792|NCT00003687|adult acute lymphoblastic leukemia in remission
696793|NCT00003687|polycythemia vera
696794|NCT00003687|chronic idiopathic myelofibrosis
696795|NCT00003687|essential thrombocythemia
696796|NCT00003687|untreated hairy cell leukemia
696797|NCT00003687|progressive hairy cell leukemia, initial treatment
696798|NCT00003687|refractory hairy cell leukemia
696799|NCT00003687|chronic myelomonocytic leukemia
696800|NCT00003687|T-cell large granular lymphocyte leukemia
696801|NCT00003687|acute undifferentiated leukemia
696802|NCT00003687|stage III grade 1 follicular lymphoma
696803|NCT00003687|stage III grade 2 follicular lymphoma
696804|NCT00003687|stage III grade 3 follicular lymphoma
696805|NCT00003687|stage III adult diffuse small cleaved cell lymphoma
696806|NCT00003687|stage III adult diffuse mixed cell lymphoma
696807|NCT00003687|stage III adult diffuse large cell lymphoma
696808|NCT00003687|stage III adult immunoblastic large cell lymphoma
696809|NCT00003687|stage III adult lymphoblastic lymphoma
696810|NCT00003687|stage III adult Burkitt lymphoma
696811|NCT00003687|stage IV grade 1 follicular lymphoma
696812|NCT00003687|stage IV grade 2 follicular lymphoma
696813|NCT00003687|stage IV grade 3 follicular lymphoma
696814|NCT00003687|stage IV adult diffuse small cleaved cell lymphoma
696815|NCT00003687|stage IV adult diffuse mixed cell lymphoma
696816|NCT00003687|stage IV adult diffuse large cell lymphoma
696817|NCT00003687|stage IV adult immunoblastic large cell lymphoma
696818|NCT00003687|stage IV adult lymphoblastic lymphoma
696819|NCT00003687|stage IV adult Burkitt lymphoma
696820|NCT00003687|recurrent grade 1 follicular lymphoma
696821|NCT00003687|recurrent grade 2 follicular lymphoma
696822|NCT00003687|recurrent grade 3 follicular lymphoma
696823|NCT00003687|recurrent adult diffuse small cleaved cell lymphoma
696824|NCT00003687|recurrent adult diffuse mixed cell lymphoma
696825|NCT00003687|recurrent adult diffuse large cell lymphoma
696826|NCT00003687|recurrent adult immunoblastic large cell lymphoma
696827|NCT00003687|recurrent adult lymphoblastic lymphoma
696828|NCT00003687|recurrent adult Burkitt lymphoma
696829|NCT00003687|stage III adult T-cell leukemia/lymphoma
696830|NCT00003687|stage IV adult T-cell leukemia/lymphoma
696831|NCT00003687|recurrent adult T-cell leukemia/lymphoma
696832|NCT00003687|secondary acute myeloid leukemia
696833|NCT00003687|de novo myelodysplastic syndromes
696834|NCT00003687|previously treated myelodysplastic syndromes
696835|NCT00003687|secondary myelodysplastic syndromes
696836|NCT00003687|pain
696837|NCT00003687|prolymphocytic leukemia
696838|NCT00003687|AIDS-related peripheral/systemic lymphoma
696839|NCT00003687|AIDS-related primary CNS lymphoma
696840|NCT00003687|primary systemic amyloidosis
696841|NCT00003687|non-Hodgkin lymphoma during pregnancy
696842|NCT00003687|stage III mantle cell lymphoma
696843|NCT00003687|stage IV mantle cell lymphoma
696844|NCT00003687|recurrent mantle cell lymphoma
696845|NCT00003687|angioimmunoblastic T-cell lymphoma
696846|NCT00003687|anaplastic large cell lymphoma
696847|NCT00003687|stage III mycosis fungoides/Sezary syndrome
696848|NCT00003687|stage IV mycosis fungoides/Sezary syndrome
696849|NCT00003687|recurrent mycosis fungoides/Sezary syndrome
696850|NCT00003687|chronic eosinophilic leukemia
696851|NCT00003687|chronic neutrophilic leukemia
696852|NCT00003687|recurrent marginal zone lymphoma
696853|NCT00003687|recurrent small lymphocytic lymphoma
696854|NCT00003687|stage III small lymphocytic lymphoma
696855|NCT00003687|stage III marginal zone lymphoma
696856|NCT00003687|stage IV small lymphocytic lymphoma
696857|NCT00003687|stage IV marginal zone lymphoma
696858|NCT00003687|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
696859|NCT00003687|nodal marginal zone B-cell lymphoma
696860|NCT00003687|splenic marginal zone lymphoma
696861|NCT00003687|childhood myelodysplastic syndromes
696862|NCT00003686|oral complications
696863|NCT00003686|quality of life
696864|NCT00003685|stage III non-small cell lung cancer
696865|NCT00003685|recurrent non-small cell lung cancer
696866|NCT00003685|squamous cell lung cancer
696867|NCT00003685|large cell lung cancer
696868|NCT00003685|stage IV non-small cell lung cancer
696869|NCT00003685|adenocarcinoma of the lung
696870|NCT00003685|adenosquamous cell lung cancer
696871|NCT00003685|fatigue
696872|NCT00003685|nausea and vomiting
696873|NCT00003685|pain
696874|NCT00003685|pulmonary complications
696875|NCT00003685|quality of life
696876|NCT00003684|unspecified adult solid tumor, protocol specific
696877|NCT00003684|pulmonary complications
696878|NCT00003684|quality of life
696879|NCT00003683|stage IV renal cell cancer
696880|NCT00003682|stage IV prostate cancer
696881|NCT00003682|recurrent prostate cancer
696882|NCT00003681|refractory anemia
696883|NCT00003681|refractory anemia with ringed sideroblasts
696884|NCT00003681|refractory anemia with excess blasts
696885|NCT00003681|de novo myelodysplastic syndromes
696886|NCT00003681|previously treated myelodysplastic syndromes
696887|NCT00003681|secondary myelodysplastic syndromes
696888|NCT00003681|anemia
696889|NCT00003680|stage III breast cancer
696890|NCT00003680|inflammatory breast cancer
696891|NCT00003679|stage IIIA breast cancer
696892|NCT00003679|stage IIIB breast cancer
696893|NCT00003679|inflammatory breast cancer
696894|NCT00003678|stage I breast cancer
696895|NCT00003678|stage II breast cancer
696896|NCT00003677|recurrent pancreatic cancer
696897|NCT00003677|adenocarcinoma of the pancreas
696898|NCT00003677|stage IV pancreatic cancer
696899|NCT00003675|refractory anemia
696900|NCT00003675|refractory anemia with ringed sideroblasts
696901|NCT00003675|refractory anemia with excess blasts
696902|NCT00003675|refractory anemia with excess blasts in transformation
696903|NCT00003675|chronic myelomonocytic leukemia
696904|NCT00003675|de novo myelodysplastic syndromes
696905|NCT00003675|secondary myelodysplastic syndromes
696906|NCT00003675|refractory cytopenia with multilineage dysplasia
696907|NCT00003675|childhood myelodysplastic syndromes
696908|NCT00003674|stage IV colon cancer
696909|NCT00003674|stage IV breast cancer
696910|NCT00003674|recurrent breast cancer
696911|NCT00003674|recurrent non-small cell lung cancer
696912|NCT00003674|stage IV rectal cancer
696913|NCT00003674|recurrent colon cancer
696914|NCT00003674|recurrent rectal cancer
696915|NCT00003674|extensive stage small cell lung cancer
696916|NCT00003674|recurrent small cell lung cancer
696917|NCT00003674|stage IV prostate cancer
696918|NCT00003674|recurrent prostate cancer
696919|NCT00003674|stage IV non-small cell lung cancer
696920|NCT00003674|veno-occlusive disease
696921|NCT00003673|recurrent adult acute myeloid leukemia
696922|NCT00003671|untreated childhood acute lymphoblastic leukemia
696923|NCT00003671|B-cell childhood acute lymphoblastic leukemia
696924|NCT00003670|stage IV ovarian epithelial cancer
696925|NCT00003670|recurrent ovarian epithelial cancer
696926|NCT00003670|primary peritoneal cavity cancer
696927|NCT00003669|stage IV endometrial carcinoma
696928|NCT00003669|recurrent endometrial carcinoma
696929|NCT00003667|nonmetastatic childhood soft tissue sarcoma
696930|NCT00003667|metastatic childhood soft tissue sarcoma
696931|NCT00003667|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
696932|NCT00003667|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
696933|NCT00003667|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
696934|NCT00003666|recurrent non-small cell lung cancer
696935|NCT00003666|squamous cell lung cancer
696936|NCT00003666|large cell lung cancer
696937|NCT00003666|adenocarcinoma of the lung
696938|NCT00003666|bronchoalveolar cell lung cancer
696939|NCT00003665|stage IV melanoma
696940|NCT00003665|recurrent melanoma
696941|NCT00003664|stage IV renal cell cancer
696942|NCT00003664|recurrent renal cell cancer
696943|NCT00003663|Waldenstrom macroglobulinemia
696944|NCT00003663|stage III grade 1 follicular lymphoma
696945|NCT00003663|stage III grade 2 follicular lymphoma
696946|NCT00003663|stage III grade 3 follicular lymphoma
696947|NCT00003663|stage IV grade 1 follicular lymphoma
696948|NCT00003663|stage IV grade 2 follicular lymphoma
696949|NCT00003663|stage IV grade 3 follicular lymphoma
696950|NCT00003663|recurrent grade 1 follicular lymphoma
696951|NCT00003663|recurrent grade 2 follicular lymphoma
696952|NCT00003663|recurrent grade 3 follicular lymphoma
696953|NCT00003663|recurrent marginal zone lymphoma
696954|NCT00003663|recurrent small lymphocytic lymphoma
696955|NCT00003663|stage III small lymphocytic lymphoma
696956|NCT00003663|stage III marginal zone lymphoma
696957|NCT00003663|stage IV small lymphocytic lymphoma
696958|NCT00003663|stage IV marginal zone lymphoma
696959|NCT00003663|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
696960|NCT00003663|nodal marginal zone B-cell lymphoma
696961|NCT00003663|splenic marginal zone lymphoma
696962|NCT00003662|noninvasive thymoma and thymic carcinoma
696963|NCT00003662|recurrent thymoma and thymic carcinoma
696964|NCT00003662|refractory anemia
696965|NCT00003662|refractory anemia with ringed sideroblasts
696966|NCT00003662|de novo myelodysplastic syndromes
696967|NCT00003662|previously treated myelodysplastic syndromes
696968|NCT00003662|secondary myelodysplastic syndromes
696969|NCT00003662|graft versus host disease
696970|NCT00003662|childhood myelodysplastic syndromes
696971|NCT00003661|recurrent childhood acute lymphoblastic leukemia
696972|NCT00003661|stage 4S neuroblastoma
696973|NCT00003661|recurrent childhood lymphoblastic lymphoma
696974|NCT00003661|recurrent adult acute lymphoblastic leukemia
696975|NCT00003661|chronic phase chronic myelogenous leukemia
696976|NCT00003661|accelerated phase chronic myelogenous leukemia
696977|NCT00003661|adult acute myeloid leukemia in remission
696978|NCT00003661|adult acute lymphoblastic leukemia in remission
696979|NCT00003661|childhood acute myeloid leukemia in remission
696980|NCT00003661|childhood acute lymphoblastic leukemia in remission
696981|NCT00003661|refractory anemia with excess blasts
696982|NCT00003661|refractory anemia with excess blasts in transformation
696983|NCT00003661|chronic myelomonocytic leukemia
696984|NCT00003661|recurrent grade 1 follicular lymphoma
696985|NCT00003661|recurrent grade 2 follicular lymphoma
696986|NCT00003661|recurrent grade 3 follicular lymphoma
696987|NCT00003661|recurrent adult diffuse small cleaved cell lymphoma
696988|NCT00003661|recurrent adult diffuse mixed cell lymphoma
696989|NCT00003661|recurrent adult diffuse large cell lymphoma
696990|NCT00003661|recurrent adult immunoblastic large cell lymphoma
696991|NCT00003661|recurrent adult lymphoblastic lymphoma
696992|NCT00003661|recurrent adult Burkitt lymphoma
696993|NCT00003661|de novo myelodysplastic syndromes
696994|NCT00003661|previously treated myelodysplastic syndromes
696995|NCT00003661|secondary myelodysplastic syndromes
696996|NCT00003661|graft versus host disease
696997|NCT00003661|adult acute minimally differentiated myeloid leukemia (M0)
696998|NCT00003661|childhood acute minimally differentiated myeloid leukemia (M0)
696999|NCT00003661|recurrent childhood small noncleaved cell lymphoma
697000|NCT00003661|recurrent childhood large cell lymphoma
697001|NCT00003661|recurrent mantle cell lymphoma
697002|NCT00003661|recurrent marginal zone lymphoma
697003|NCT00003661|recurrent small lymphocytic lymphoma
697004|NCT00003661|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697005|NCT00003661|nodal marginal zone B-cell lymphoma
697006|NCT00003661|splenic marginal zone lymphoma
697007|NCT00003661|childhood myelodysplastic syndromes
697008|NCT00003659|stage II chronic lymphocytic leukemia
697009|NCT00003659|stage III chronic lymphocytic leukemia
697010|NCT00003659|stage IV chronic lymphocytic leukemia
697011|NCT00003658|Waldenström macroglobulinemia
697012|NCT00003658|stage II chronic lymphocytic leukemia
697013|NCT00003658|stage III chronic lymphocytic leukemia
697014|NCT00003658|stage IV chronic lymphocytic leukemia
697015|NCT00003658|refractory chronic lymphocytic leukemia
697016|NCT00003658|B-cell chronic lymphocytic leukemia
697017|NCT00003658|stage I grade 1 follicular lymphoma
697018|NCT00003658|stage I grade 2 follicular lymphoma
697019|NCT00003658|stage III grade 1 follicular lymphoma
697020|NCT00003658|stage III grade 2 follicular lymphoma
697021|NCT00003658|stage IV grade 1 follicular lymphoma
697022|NCT00003658|stage IV grade 2 follicular lymphoma
697023|NCT00003658|recurrent grade 1 follicular lymphoma
697024|NCT00003658|recurrent grade 2 follicular lymphoma
697025|NCT00003658|contiguous stage II grade 1 follicular lymphoma
697026|NCT00003658|contiguous stage II grade 2 follicular lymphoma
697027|NCT00003658|noncontiguous stage II grade 1 follicular lymphoma
697028|NCT00003658|noncontiguous stage II grade 2 follicular lymphoma
697029|NCT00003658|contiguous stage II small lymphocytic lymphoma
697030|NCT00003658|noncontiguous stage II small lymphocytic lymphoma
697031|NCT00003658|recurrent small lymphocytic lymphoma
697032|NCT00003658|stage I small lymphocytic lymphoma
697033|NCT00003658|stage III small lymphocytic lymphoma
697034|NCT00003658|stage IV small lymphocytic lymphoma
697035|NCT00003657|metastatic osteosarcoma
697036|NCT00003657|recurrent non-small cell lung cancer
697037|NCT00003657|chondrosarcoma
697038|NCT00003657|stage III adult soft tissue sarcoma
697039|NCT00003657|recurrent adult soft tissue sarcoma
697040|NCT00003657|stage III ovarian epithelial cancer
697041|NCT00003657|stage IV ovarian epithelial cancer
697042|NCT00003657|recurrent ovarian epithelial cancer
697043|NCT00003657|extensive stage small cell lung cancer
697044|NCT00003657|recurrent small cell lung cancer
697045|NCT00003657|recurrent osteosarcoma
697046|NCT00003657|stage III bladder cancer
697047|NCT00003657|recurrent bladder cancer
697048|NCT00003657|stage IV bladder cancer
697049|NCT00003657|stage III malignant testicular germ cell tumor
697050|NCT00003657|recurrent malignant testicular germ cell tumor
697051|NCT00003657|stage IIIB non-small cell lung cancer
697052|NCT00003657|unspecified adult solid tumor, protocol specific
697053|NCT00003657|classic Kaposi sarcoma
697054|NCT00003657|immunosuppressive treatment related Kaposi sarcoma
697055|NCT00003657|AIDS-related Kaposi sarcoma
697056|NCT00003657|recurrent Kaposi sarcoma
697057|NCT00003657|untreated metastatic squamous neck cancer with occult primary
697058|NCT00003657|recurrent metastatic squamous neck cancer with occult primary
697059|NCT00003657|ovarian stromal cancer
697060|NCT00003657|stage III ovarian germ cell tumor
697061|NCT00003657|stage IV ovarian germ cell tumor
697062|NCT00003657|recurrent ovarian germ cell tumor
697063|NCT00003657|stage III squamous cell carcinoma of the lip and oral cavity
697064|NCT00003657|stage III basal cell carcinoma of the lip
697065|NCT00003657|stage III verrucous carcinoma of the oral cavity
697066|NCT00003657|stage III mucoepidermoid carcinoma of the oral cavity
697067|NCT00003657|stage III adenoid cystic carcinoma of the oral cavity
697068|NCT00003657|stage IV squamous cell carcinoma of the lip and oral cavity
697069|NCT00003657|stage IV basal cell carcinoma of the lip
697070|NCT00003657|stage IV verrucous carcinoma of the oral cavity
697071|NCT00003657|stage IV mucoepidermoid carcinoma of the oral cavity
697072|NCT00003657|stage IV adenoid cystic carcinoma of the oral cavity
697073|NCT00003657|recurrent squamous cell carcinoma of the lip and oral cavity
697074|NCT00003657|recurrent basal cell carcinoma of the lip
697075|NCT00003657|recurrent verrucous carcinoma of the oral cavity
697076|NCT00003657|recurrent mucoepidermoid carcinoma of the oral cavity
697077|NCT00003657|recurrent adenoid cystic carcinoma of the oral cavity
697078|NCT00003657|stage III squamous cell carcinoma of the oropharynx
697079|NCT00003657|stage III lymphoepithelioma of the oropharynx
697080|NCT00003657|stage IV squamous cell carcinoma of the oropharynx
697081|NCT00003657|stage IV lymphoepithelioma of the oropharynx
697082|NCT00003657|recurrent squamous cell carcinoma of the oropharynx
697083|NCT00003657|recurrent lymphoepithelioma of the oropharynx
697084|NCT00003657|stage III squamous cell carcinoma of the nasopharynx
697085|NCT00003657|stage III lymphoepithelioma of the nasopharynx
697086|NCT00003657|stage IV squamous cell carcinoma of the nasopharynx
697087|NCT00003657|stage IV lymphoepithelioma of the nasopharynx
697088|NCT00003657|recurrent squamous cell carcinoma of the nasopharynx
697089|NCT00003657|recurrent lymphoepithelioma of the nasopharynx
697090|NCT00003657|stage III squamous cell carcinoma of the hypopharynx
697091|NCT00003657|stage IV squamous cell carcinoma of the hypopharynx
697092|NCT00003657|recurrent squamous cell carcinoma of the hypopharynx
697093|NCT00003657|stage III squamous cell carcinoma of the larynx
697094|NCT00003657|stage III verrucous carcinoma of the larynx
697095|NCT00003657|stage IV squamous cell carcinoma of the larynx
697096|NCT00003657|stage IV verrucous carcinoma of the larynx
697097|NCT00003657|recurrent squamous cell carcinoma of the larynx
697098|NCT00003657|recurrent verrucous carcinoma of the larynx
697099|NCT00003657|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
697100|NCT00003657|stage III inverted papilloma of the paranasal sinus and nasal cavity
697101|NCT00003657|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
697102|NCT00003657|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
697103|NCT00003657|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697104|NCT00003657|stage IV inverted papilloma of the paranasal sinus and nasal cavity
697105|NCT00003657|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
697106|NCT00003657|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
697107|NCT00003657|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
697108|NCT00003657|recurrent inverted papilloma of the paranasal sinus and nasal cavity
697109|NCT00003657|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
697110|NCT00003657|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
697111|NCT00003657|extragonadal germ cell tumor
697112|NCT00003657|newly diagnosed carcinoma of unknown primary
697113|NCT00003657|stage III uterine sarcoma
697114|NCT00003657|stage IV uterine sarcoma
697115|NCT00003657|recurrent uterine sarcoma
697116|NCT00003657|borderline ovarian surface epithelial-stromal tumor
697117|NCT00003657|recurrent carcinoma of unknown primary
697118|NCT00003657|ovarian sarcoma
697119|NCT00003657|adult central nervous system germ cell tumor
697120|NCT00003657|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
697121|NCT00003657|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
697122|NCT00003657|clear cell sarcoma of the kidney
697123|NCT00003657|stage IV adult soft tissue sarcoma
697124|NCT00003656|stage IV renal cell cancer
697125|NCT00003656|recurrent renal cell cancer
697126|NCT00003654|stage I breast cancer
697127|NCT00003654|stage II breast cancer
697128|NCT00003653|adenocarcinoma of the prostate
697129|NCT00003653|recurrent prostate cancer
697130|NCT00003652|stage II anal cancer
697131|NCT00003652|stage III anal cancer
697132|NCT00003652|squamous cell carcinoma of the anus
697133|NCT00003652|cloacogenic carcinoma of the anus
697134|NCT00003652|basaloid carcinoma of the anus
697135|NCT00003650|stage I childhood lymphoblastic lymphoma
697136|NCT00003650|stage II childhood lymphoblastic lymphoma
697137|NCT00003650|stage III childhood lymphoblastic lymphoma
697138|NCT00003650|stage IV childhood lymphoblastic lymphoma
697139|NCT00003649|recurrent non-small cell lung cancer
697140|NCT00003649|stage IIIB non-small cell lung cancer
697141|NCT00003649|stage IV non-small cell lung cancer
697142|NCT00003649|bronchoalveolar cell lung cancer
697143|NCT00003648|stage I colon cancer
697144|NCT00003648|stage II colon cancer
697145|NCT00003648|stage III colon cancer
697146|NCT00003648|stage IV colon cancer
697147|NCT00003648|stage I rectal cancer
697148|NCT00003648|stage II rectal cancer
697149|NCT00003648|stage III rectal cancer
697150|NCT00003648|stage IV rectal cancer
697151|NCT00003648|recurrent colon cancer
697152|NCT00003648|recurrent rectal cancer
697153|NCT00003647|adult solid tumor
697154|NCT00003647|body system/site cancer
697155|NCT00003647|cancer
697156|NCT00003647|melanoma
697157|NCT00003647|recurrent melanoma
697158|NCT00003647|skin tumor
697159|NCT00003647|solid tumor
697160|NCT00003647|stage III melanoma
697161|NCT00003647|stage IV melanoma
697162|NCT00003647|stage, melanoma
697163|NCT00003646|adult solid tumor
697164|NCT00003646|body system/site cancer
697165|NCT00003646|cancer
697166|NCT00003646|melanoma
697167|NCT00003646|recurrent melanoma
697168|NCT00003646|skin tumor
697169|NCT00003646|solid tumor
697170|NCT00003646|stage III melanoma
697171|NCT00003646|stage IV melanoma
697172|NCT00003646|stage, melanoma
697173|NCT00003645|stage I prostate cancer
697174|NCT00003645|stage II prostate cancer
697175|NCT00003644|stage I ovarian epithelial cancer
697176|NCT00003644|stage II ovarian epithelial cancer
697177|NCT00003644|ovarian undifferentiated adenocarcinoma
697178|NCT00003644|ovarian mixed epithelial carcinoma
697179|NCT00003644|ovarian serous cystadenocarcinoma
697180|NCT00003644|ovarian mucinous cystadenocarcinoma
697181|NCT00003644|ovarian endometrioid adenocarcinoma
697182|NCT00003644|ovarian clear cell cystadenocarcinoma
697183|NCT00003644|Brenner tumor
697184|NCT00003643|stage III malignant testicular germ cell tumor
697185|NCT00003643|testicular seminoma
697186|NCT00003643|testicular embryonal carcinoma
697187|NCT00003643|testicular choriocarcinoma
697188|NCT00003643|testicular yolk sac tumor
697189|NCT00003643|testicular embryonal carcinoma and teratoma
697190|NCT00003643|testicular embryonal carcinoma and teratoma with seminoma
697191|NCT00003643|testicular embryonal carcinoma and yolk sac tumor
697192|NCT00003643|testicular embryonal carcinoma and yolk sac tumor with seminoma
697193|NCT00003643|testicular embryonal carcinoma and seminoma
697194|NCT00003643|testicular yolk sac tumor and teratoma
697195|NCT00003643|testicular yolk sac tumor and teratoma with seminoma
697196|NCT00003643|testicular choriocarcinoma and yolk sac tumor
697197|NCT00003643|testicular choriocarcinoma and embryonal carcinoma
697198|NCT00003643|testicular choriocarcinoma and teratoma
697199|NCT00003643|testicular choriocarcinoma and seminoma
697200|NCT00003643|stage IV extragonadal non-seminomatous germ cell tumor
697201|NCT00003643|stage IV extragonadal seminoma
697202|NCT00003643|testicular immature teratoma
697203|NCT00003643|testicular mature teratoma
697204|NCT00003643|adult teratoma
697205|NCT00003642|stage II bladder cancer
697206|NCT00003642|stage III bladder cancer
697207|NCT00003642|transitional cell carcinoma of the bladder
697208|NCT00003641|stage II melanoma
697209|NCT00003641|stage III melanoma
697210|NCT00003640|stage II bladder cancer
697211|NCT00003640|stage III bladder cancer
697212|NCT00003640|transitional cell carcinoma of the bladder
697213|NCT00003639|stage III grade 1 follicular lymphoma
697214|NCT00003639|stage III grade 2 follicular lymphoma
697215|NCT00003639|stage IV grade 1 follicular lymphoma
697216|NCT00003639|stage IV grade 2 follicular lymphoma
697217|NCT00003639|contiguous stage II grade 1 follicular lymphoma
697218|NCT00003639|contiguous stage II grade 2 follicular lymphoma
697219|NCT00003639|noncontiguous stage II grade 1 follicular lymphoma
697220|NCT00003639|noncontiguous stage II grade 2 follicular lymphoma
697221|NCT00003639|noncontiguous stage II small lymphocytic lymphoma
697222|NCT00003639|noncontiguous stage II marginal zone lymphoma
697223|NCT00003639|stage III small lymphocytic lymphoma
697224|NCT00003639|stage III marginal zone lymphoma
697225|NCT00003639|stage IV small lymphocytic lymphoma
697226|NCT00003639|stage IV marginal zone lymphoma
697227|NCT00003639|contiguous stage II marginal zone lymphoma
697228|NCT00003639|contiguous stage II small lymphocytic lymphoma
697229|NCT00003639|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697230|NCT00003639|nodal marginal zone B-cell lymphoma
697231|NCT00003639|splenic marginal zone lymphoma
697232|NCT00003638|stage IV breast cancer
697233|NCT00003638|recurrent breast cancer
697234|NCT00003637|stage III lymphoepithelioma of the nasopharynx
697235|NCT00003637|stage IV squamous cell carcinoma of the nasopharynx
697236|NCT00003637|stage III squamous cell carcinoma of the nasopharynx
697237|NCT00003637|stage IV lymphoepithelioma of the nasopharynx
697238|NCT00003636|stage III ovarian epithelial cancer
697239|NCT00003636|stage IV ovarian epithelial cancer
697240|NCT00003636|fallopian tube cancer
697241|NCT00003636|primary peritoneal cavity cancer
697242|NCT00003635|refractory chronic lymphocytic leukemia
697243|NCT00003635|T-cell large granular lymphocyte leukemia
697244|NCT00003635|B-cell chronic lymphocytic leukemia
697245|NCT00003634|stage III ovarian epithelial cancer
697246|NCT00003634|stage IV ovarian epithelial cancer
697247|NCT00003634|fallopian tube cancer
697248|NCT00003634|primary peritoneal cavity cancer
697249|NCT00003633|adenocarcinoma of the prostate
697250|NCT00003633|stage IV prostate cancer
697251|NCT00003633|recurrent prostate cancer
697252|NCT00003632|primary central nervous system non-Hodgkin lymphoma
697253|NCT00003631|recurrent adult Hodgkin lymphoma
697254|NCT00003631|recurrent/refractory childhood Hodgkin lymphoma
697255|NCT00003630|unspecified childhood solid tumor, protocol specific
697256|NCT00003630|unspecified adult solid tumor, protocol specific
697257|NCT00003627|stage III squamous cell carcinoma of the oropharynx
697258|NCT00003627|stage IV squamous cell carcinoma of the oropharynx
697259|NCT00003627|stage III squamous cell carcinoma of the hypopharynx
697260|NCT00003627|stage IV squamous cell carcinoma of the hypopharynx
697261|NCT00003626|stage IV prostate cancer
697262|NCT00003626|recurrent prostate cancer
697263|NCT00003625|untreated childhood brain stem glioma
697264|NCT00003624|stage I cervical cancer
697265|NCT00003624|stage II cervical cancer
697266|NCT00003624|stage III cervical cancer
697267|NCT00003624|stage IV cervical cancer
697268|NCT00003624|stage I ovarian epithelial cancer
697269|NCT00003624|stage II ovarian epithelial cancer
697270|NCT00003624|stage III ovarian epithelial cancer
697271|NCT00003624|stage IV ovarian epithelial cancer
697272|NCT00003624|stage I endometrial carcinoma
697273|NCT00003624|stage II endometrial carcinoma
697274|NCT00003624|stage III endometrial carcinoma
697275|NCT00003624|stage IV endometrial carcinoma
697276|NCT00003624|endometrial adenocarcinoma
697277|NCT00003624|fallopian tube cancer
697278|NCT00003624|primary peritoneal cavity cancer
697279|NCT00003624|stage I uterine sarcoma
697280|NCT00003624|stage II uterine sarcoma
697281|NCT00003624|stage III uterine sarcoma
697282|NCT00003624|stage IV uterine sarcoma
697283|NCT00003624|neurotoxicity
697284|NCT00003623|recurrent bladder cancer
697285|NCT00003622|adenocarcinoma of the prostate
697286|NCT00003622|stage IV prostate cancer
697287|NCT00003622|recurrent prostate cancer
697288|NCT00003621|adult anaplastic astrocytoma
697289|NCT00003619|recurrent adult acute myeloid leukemia
697290|NCT00003619|recurrent adult acute lymphoblastic leukemia
697291|NCT00003619|relapsing chronic myelogenous leukemia
697292|NCT00003619|blastic phase chronic myelogenous leukemia
697293|NCT00003619|polycythemia vera
697294|NCT00003619|primary myelofibrosis
697295|NCT00003619|refractory anemia
697296|NCT00003619|refractory anemia with ringed sideroblasts
697297|NCT00003619|refractory anemia with excess blasts
697298|NCT00003619|chronic myelomonocytic leukemia
697299|NCT00003619|secondary acute myeloid leukemia
697300|NCT00003619|previously treated myelodysplastic syndromes
697301|NCT00003619|secondary myelodysplastic syndromes
697302|NCT00003619|thrombocytopenia
697303|NCT00003617|stage I gastric cancer
697304|NCT00003616|recurrent adult brain tumor
697305|NCT00003616|adult brain stem glioma
697306|NCT00003616|adult oligodendroglioma
697307|NCT00003616|adult mixed glioma
697308|NCT00003616|adult diffuse astrocytoma
697309|NCT00003615|Waldenstrom macroglobulinemia
697310|NCT00003615|stage I grade 1 follicular lymphoma
697311|NCT00003615|stage I grade 2 follicular lymphoma
697312|NCT00003615|stage I grade 3 follicular lymphoma
697313|NCT00003615|stage I adult diffuse large cell lymphoma
700650|NCT00003220|recurrent rectal cancer
697314|NCT00003615|stage III grade 1 follicular lymphoma
697315|NCT00003615|stage III grade 2 follicular lymphoma
697316|NCT00003615|stage III grade 3 follicular lymphoma
697317|NCT00003615|stage III adult diffuse large cell lymphoma
697318|NCT00003615|stage IV grade 1 follicular lymphoma
697319|NCT00003615|stage IV grade 2 follicular lymphoma
697320|NCT00003615|stage IV grade 3 follicular lymphoma
697321|NCT00003615|stage IV adult diffuse large cell lymphoma
697322|NCT00003615|recurrent grade 1 follicular lymphoma
697323|NCT00003615|recurrent grade 2 follicular lymphoma
697324|NCT00003615|recurrent grade 3 follicular lymphoma
697325|NCT00003615|recurrent adult diffuse large cell lymphoma
697326|NCT00003615|contiguous stage II grade 1 follicular lymphoma
697327|NCT00003615|contiguous stage II grade 2 follicular lymphoma
697328|NCT00003615|contiguous stage II grade 3 follicular lymphoma
697329|NCT00003615|contiguous stage II adult diffuse large cell lymphoma
697330|NCT00003615|noncontiguous stage II grade 1 follicular lymphoma
697331|NCT00003615|noncontiguous stage II grade 2 follicular lymphoma
697332|NCT00003615|noncontiguous stage II grade 3 follicular lymphoma
697333|NCT00003615|noncontiguous stage II adult diffuse large cell lymphoma
697334|NCT00003615|contiguous stage II marginal zone lymphoma
697335|NCT00003615|contiguous stage II small lymphocytic lymphoma
697336|NCT00003615|noncontiguous stage II small lymphocytic lymphoma
697337|NCT00003615|noncontiguous stage II marginal zone lymphoma
697338|NCT00003615|recurrent marginal zone lymphoma
697339|NCT00003615|recurrent small lymphocytic lymphoma
697340|NCT00003615|stage III small lymphocytic lymphoma
697341|NCT00003615|stage III marginal zone lymphoma
697342|NCT00003615|stage IV small lymphocytic lymphoma
697343|NCT00003615|stage IV marginal zone lymphoma
697344|NCT00003615|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697345|NCT00003615|nodal marginal zone B-cell lymphoma
697346|NCT00003615|splenic marginal zone lymphoma
697347|NCT00003614|adenocarcinoma of the prostate
697348|NCT00003614|stage IV prostate cancer
697349|NCT00003614|recurrent prostate cancer
697350|NCT00003612|stage IV breast cancer
697351|NCT00003612|recurrent breast cancer
697352|NCT00003611|basal cell carcinoma of the skin
697353|NCT00003611|squamous cell carcinoma of the skin
697354|NCT00003607|adenocarcinoma of the prostate
697355|NCT00003607|stage I prostate cancer
697356|NCT00003607|stage IIB prostate cancer
697357|NCT00003607|stage IIA prostate cancer
697358|NCT00003607|stage III prostate cancer
697359|NCT00003606|extensive stage small cell lung cancer
697360|NCT00003605|Waldenstrom macroglobulinemia
697361|NCT00003605|stage III grade 1 follicular lymphoma
697362|NCT00003605|stage III grade 2 follicular lymphoma
697363|NCT00003605|stage III grade 3 follicular lymphoma
697364|NCT00003605|stage III adult diffuse small cleaved cell lymphoma
697365|NCT00003605|stage IV grade 1 follicular lymphoma
697366|NCT00003605|stage IV grade 2 follicular lymphoma
697367|NCT00003605|stage IV grade 3 follicular lymphoma
697368|NCT00003605|stage IV adult diffuse small cleaved cell lymphoma
697369|NCT00003605|stage III small lymphocytic lymphoma
697370|NCT00003605|stage III marginal zone lymphoma
697371|NCT00003605|stage IV small lymphocytic lymphoma
697372|NCT00003605|stage IV marginal zone lymphoma
697373|NCT00003605|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697374|NCT00003605|nodal marginal zone B-cell lymphoma
697375|NCT00003605|splenic marginal zone lymphoma
697376|NCT00003604|stage III renal cell cancer
697377|NCT00003604|stage IV renal cell cancer
697378|NCT00003603|refractory multiple myeloma
697379|NCT00003603|stage I multiple myeloma
697380|NCT00003603|stage II multiple myeloma
697381|NCT00003603|stage III multiple myeloma
697382|NCT00003602|untreated adult acute myeloid leukemia
697383|NCT00003602|refractory anemia with excess blasts
697384|NCT00003602|refractory anemia with excess blasts in transformation
697385|NCT00003602|secondary acute myeloid leukemia
697386|NCT00003602|de novo myelodysplastic syndromes
697387|NCT00003602|secondary myelodysplastic syndromes
697388|NCT00003601|melanoma
697389|NCT00003599|non-small cell lung cancer
697390|NCT00003599|small cell lung cancer
697391|NCT00003598|cervical cancer
697392|NCT00003598|cervical intraepithelial neoplasia grade 2
697393|NCT00003598|cervical intraepithelial neoplasia grade 3
697394|NCT00003597|recurrent childhood rhabdomyosarcoma
697395|NCT00003597|recurrent renal cell cancer
697396|NCT00003597|recurrent neuroblastoma
697397|NCT00003597|recurrent childhood liver cancer
697398|NCT00003597|recurrent Wilms tumor and other childhood kidney tumors
697399|NCT00003597|recurrent retinoblastoma
697400|NCT00003597|childhood central nervous system germ cell tumor
697401|NCT00003597|recurrent osteosarcoma
697402|NCT00003597|recurrent gestational trophoblastic tumor
697403|NCT00003597|recurrent malignant testicular germ cell tumor
697404|NCT00003597|recurrent intraocular melanoma
697405|NCT00003597|recurrent melanoma
697406|NCT00003597|unspecified childhood solid tumor, protocol specific
697407|NCT00003597|childhood germ cell tumor
697408|NCT00003597|recurrent childhood soft tissue sarcoma
697409|NCT00003597|recurrent ovarian germ cell tumor
697410|NCT00003597|extragonadal germ cell tumor
697411|NCT00003597|recurrent uterine sarcoma
697412|NCT00003597|neutropenia
697413|NCT00003597|thrombocytopenia
697414|NCT00003597|recurrent childhood brain stem glioma
697415|NCT00003597|recurrent childhood supratentorial primitive neuroectodermal tumor
697416|NCT00003597|recurrent childhood visual pathway glioma
697417|NCT00003597|recurrent childhood cerebellar astrocytoma
697418|NCT00003597|recurrent childhood cerebral astrocytoma
697419|NCT00003597|recurrent childhood medulloblastoma
697420|NCT00003597|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
697421|NCT00003596|stage II anal cancer
697422|NCT00003596|stage III anal cancer
697423|NCT00003596|squamous cell carcinoma of the anus
697424|NCT00003596|cloacogenic carcinoma of the anus
697425|NCT00003596|basaloid carcinoma of the anus
697426|NCT00003595|childhood Burkitt lymphoma
697427|NCT00003595|AIDS-related peripheral/systemic lymphoma
697428|NCT00003595|AIDS-related diffuse large cell lymphoma
697429|NCT00003595|AIDS-related immunoblastic large cell lymphoma
697430|NCT00003595|AIDS-related small noncleaved cell lymphoma
697431|NCT00003594|stage III colon cancer
697432|NCT00003594|stage IV colon cancer
697433|NCT00003594|stage III rectal cancer
697434|NCT00003594|stage IV rectal cancer
697435|NCT00003594|recurrent colon cancer
697436|NCT00003594|recurrent rectal cancer
697437|NCT00003594|adenocarcinoma of the colon
697438|NCT00003594|adenocarcinoma of the rectum
697439|NCT00003593|childhood myelodysplastic syndromes
697440|NCT00003593|untreated childhood acute myeloid leukemia and other myeloid malignancies
697441|NCT00003593|childhood acute myeloblastic leukemia without maturation (M1)
697442|NCT00003593|childhood acute myeloblastic leukemia with maturation (M2)
697443|NCT00003593|childhood acute myelomonocytic leukemia (M4)
697444|NCT00003593|childhood acute erythroleukemia (M6)
697445|NCT00003593|childhood acute megakaryocytic leukemia (M7)
697446|NCT00003593|refractory anemia
697447|NCT00003593|refractory anemia with ringed sideroblasts
697448|NCT00003593|refractory anemia with excess blasts
697449|NCT00003593|refractory anemia with excess blasts in transformation
697450|NCT00003593|de novo myelodysplastic syndromes
697451|NCT00003593|childhood acute minimally differentiated myeloid leukemia (M0)
697452|NCT00003593|childhood acute monocytic leukemia (M5b)
697453|NCT00003593|childhood acute monoblastic leukemia (M5a)
697454|NCT00003593|myelodysplastic/myeloproliferative neoplasm, unclassifiable
697455|NCT00003593|juvenile myelomonocytic leukemia
697456|NCT00003593|chronic myelomonocytic leukemia
697457|NCT00003593|secondary myelodysplastic syndromes
697458|NCT00003592|stage IV salivary gland cancer
697459|NCT00003592|recurrent salivary gland cancer
697460|NCT00003592|salivary gland squamous cell carcinoma
697461|NCT00003592|stage IV squamous cell carcinoma of the lip and oral cavity
697462|NCT00003592|recurrent squamous cell carcinoma of the lip and oral cavity
697463|NCT00003592|stage IV squamous cell carcinoma of the oropharynx
697464|NCT00003592|recurrent squamous cell carcinoma of the oropharynx
697465|NCT00003592|stage IV squamous cell carcinoma of the nasopharynx
697466|NCT00003592|recurrent squamous cell carcinoma of the nasopharynx
697467|NCT00003592|stage IV squamous cell carcinoma of the hypopharynx
697468|NCT00003592|recurrent squamous cell carcinoma of the hypopharynx
697469|NCT00003592|stage IV squamous cell carcinoma of the larynx
697470|NCT00003592|recurrent squamous cell carcinoma of the larynx
697471|NCT00003592|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697472|NCT00003592|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
697473|NCT00003591|stage I pancreatic cancer
697474|NCT00003591|stage II pancreatic cancer
697475|NCT00003591|stage III pancreatic cancer
697476|NCT00003591|recurrent pancreatic cancer
697477|NCT00003591|adenocarcinoma of the pancreas
697478|NCT00003590|recurrent adult brain tumor
697479|NCT00003590|adult grade I meningioma
697480|NCT00003589|recurrent small cell lung cancer
697481|NCT00003589|stage IIIB non-small cell lung cancer
697482|NCT00003589|stage IV non-small cell lung cancer
697483|NCT00003588|stage IV ovarian epithelial cancer
697484|NCT00003588|recurrent ovarian epithelial cancer
697485|NCT00003587|recurrent non-small cell lung cancer
697486|NCT00003587|squamous cell lung cancer
697487|NCT00003587|large cell lung cancer
697488|NCT00003587|stage IIIB non-small cell lung cancer
697489|NCT00003587|stage IV non-small cell lung cancer
697490|NCT00003587|adenocarcinoma of the lung
697491|NCT00003585|stage IV renal cell cancer
697492|NCT00003585|recurrent renal cell cancer
697493|NCT00003584|stage IV renal cell cancer
697494|NCT00003584|recurrent renal cell cancer
697495|NCT00003583|limited stage small cell lung cancer
697496|NCT00003583|drug/agent toxicity by tissue/organ
697497|NCT00003583|radiation toxicity
697498|NCT00003582|squamous cell carcinoma of unknown primary
697499|NCT00003582|stage III squamous cell carcinoma of the lip and oral cavity
697500|NCT00003582|stage IV squamous cell carcinoma of the lip and oral cavity
697501|NCT00003582|stage III squamous cell carcinoma of the oropharynx
697502|NCT00003582|stage IV squamous cell carcinoma of the oropharynx
697503|NCT00003582|stage III squamous cell carcinoma of the nasopharynx
697504|NCT00003582|stage IV squamous cell carcinoma of the nasopharynx
697505|NCT00003582|stage III squamous cell carcinoma of the hypopharynx
697506|NCT00003582|stage IV squamous cell carcinoma of the hypopharynx
697507|NCT00003582|stage III squamous cell carcinoma of the larynx
697508|NCT00003582|stage IV squamous cell carcinoma of the larynx
697509|NCT00003582|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
697510|NCT00003582|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697511|NCT00003580|oral complications
697512|NCT00003580|stage III squamous cell carcinoma of the lip and oral cavity
697513|NCT00003580|stage IV squamous cell carcinoma of the lip and oral cavity
697514|NCT00003580|stage III squamous cell carcinoma of the oropharynx
697515|NCT00003580|stage IV squamous cell carcinoma of the oropharynx
697516|NCT00003580|stage III squamous cell carcinoma of the nasopharynx
697517|NCT00003580|stage IV squamous cell carcinoma of the nasopharynx
697518|NCT00003580|stage III squamous cell carcinoma of the hypopharynx
697519|NCT00003580|stage IV squamous cell carcinoma of the hypopharynx
697520|NCT00003580|stage III squamous cell carcinoma of the larynx
697521|NCT00003580|stage IV squamous cell carcinoma of the larynx
697522|NCT00003580|drug/agent toxicity by tissue/organ
697523|NCT00003580|radiation toxicity
697524|NCT00003578|stage III grade 3 follicular lymphoma
697525|NCT00003578|stage III adult diffuse mixed cell lymphoma
697526|NCT00003578|stage III adult diffuse large cell lymphoma
697527|NCT00003578|stage III adult immunoblastic large cell lymphoma
697528|NCT00003578|stage IV grade 3 follicular lymphoma
697529|NCT00003578|stage IV adult diffuse mixed cell lymphoma
697530|NCT00003578|stage IV adult diffuse large cell lymphoma
697531|NCT00003578|stage IV adult immunoblastic large cell lymphoma
697532|NCT00003577|stage I breast cancer
697533|NCT00003577|stage II breast cancer
697534|NCT00003576|stage III squamous cell carcinoma of the lip and oral cavity
697535|NCT00003576|stage IV squamous cell carcinoma of the lip and oral cavity
697536|NCT00003576|stage III squamous cell carcinoma of the oropharynx
697537|NCT00003576|stage IV squamous cell carcinoma of the oropharynx
697538|NCT00003576|stage III squamous cell carcinoma of the hypopharynx
697539|NCT00003576|stage IV squamous cell carcinoma of the hypopharynx
697540|NCT00003576|stage III squamous cell carcinoma of the larynx
697541|NCT00003576|stage IV squamous cell carcinoma of the larynx
697542|NCT00003576|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
697543|NCT00003576|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697544|NCT00003575|AIDS-related peripheral/systemic lymphoma
697545|NCT00003575|AIDS-related diffuse large cell lymphoma
697546|NCT00003575|AIDS-related immunoblastic large cell lymphoma
697547|NCT00003575|AIDS-related small noncleaved cell lymphoma
697548|NCT00003574|recurrent adult brain tumor
697549|NCT00003574|adult glioblastoma
697550|NCT00003574|adult anaplastic astrocytoma
697551|NCT00003574|adult anaplastic oligodendroglioma
697552|NCT00003574|adult giant cell glioblastoma
697553|NCT00003574|adult gliosarcoma
697554|NCT00003573|untreated childhood medulloblastoma
697555|NCT00003572|stage I adult Hodgkin lymphoma
697556|NCT00003572|stage II adult Hodgkin lymphoma
697557|NCT00003572|stage III adult Hodgkin lymphoma
697558|NCT00003572|stage IV adult Hodgkin lymphoma
697559|NCT00003572|recurrent adult Hodgkin lymphoma
697560|NCT00003572|Waldenstrom macroglobulinemia
697561|NCT00003572|stage I multiple myeloma
697562|NCT00003572|stage II multiple myeloma
697563|NCT00003572|stage III multiple myeloma
697564|NCT00003572|stage III chronic lymphocytic leukemia
697565|NCT00003572|stage IV chronic lymphocytic leukemia
697566|NCT00003572|chronic phase chronic myelogenous leukemia
697567|NCT00003572|adult acute myeloid leukemia in remission
697568|NCT00003572|adult acute lymphoblastic leukemia in remission
697569|NCT00003572|stage I grade 1 follicular lymphoma
697570|NCT00003572|stage I grade 2 follicular lymphoma
697571|NCT00003572|stage I grade 3 follicular lymphoma
697572|NCT00003572|stage I adult diffuse small cleaved cell lymphoma
697573|NCT00003572|stage I adult diffuse mixed cell lymphoma
697574|NCT00003572|stage I adult diffuse large cell lymphoma
697575|NCT00003572|stage I adult immunoblastic large cell lymphoma
697576|NCT00003572|stage I adult lymphoblastic lymphoma
697577|NCT00003572|stage I adult Burkitt lymphoma
697578|NCT00003572|stage III grade 1 follicular lymphoma
697579|NCT00003572|stage III grade 2 follicular lymphoma
697580|NCT00003572|stage III grade 3 follicular lymphoma
697581|NCT00003572|stage III adult diffuse small cleaved cell lymphoma
697582|NCT00003572|stage III adult diffuse mixed cell lymphoma
697583|NCT00003572|stage III adult diffuse large cell lymphoma
697584|NCT00003572|stage III adult immunoblastic large cell lymphoma
697585|NCT00003572|stage III adult lymphoblastic lymphoma
697586|NCT00003572|stage III adult Burkitt lymphoma
697587|NCT00003572|stage IV grade 1 follicular lymphoma
697588|NCT00003572|stage IV grade 2 follicular lymphoma
697589|NCT00003572|stage IV grade 3 follicular lymphoma
697590|NCT00003572|stage IV adult diffuse small cleaved cell lymphoma
697591|NCT00003572|stage IV adult diffuse mixed cell lymphoma
697592|NCT00003572|stage IV adult diffuse large cell lymphoma
697593|NCT00003572|stage IV adult immunoblastic large cell lymphoma
697594|NCT00003572|stage IV adult lymphoblastic lymphoma
697595|NCT00003572|stage IV adult Burkitt lymphoma
697596|NCT00003572|de novo myelodysplastic syndromes
697597|NCT00003572|previously treated myelodysplastic syndromes
697598|NCT00003572|secondary myelodysplastic syndromes
697599|NCT00003572|stage I mantle cell lymphoma
697600|NCT00003572|contiguous stage II grade 1 follicular lymphoma
697601|NCT00003572|contiguous stage II grade 2 follicular lymphoma
697602|NCT00003572|contiguous stage II grade 3 follicular lymphoma
697603|NCT00003572|contiguous stage II adult diffuse small cleaved cell lymphoma
697604|NCT00003572|contiguous stage II mantle cell lymphoma
697605|NCT00003572|contiguous stage II adult diffuse mixed cell lymphoma
697606|NCT00003572|contiguous stage II adult immunoblastic large cell lymphoma
697607|NCT00003572|contiguous stage II adult diffuse large cell lymphoma
697608|NCT00003572|contiguous stage II adult Burkitt lymphoma
697609|NCT00003572|contiguous stage II adult lymphoblastic lymphoma
697610|NCT00003572|noncontiguous stage II grade 1 follicular lymphoma
697611|NCT00003572|noncontiguous stage II grade 2 follicular lymphoma
697612|NCT00003572|noncontiguous stage II grade 3 follicular lymphoma
697613|NCT00003572|noncontiguous stage II adult diffuse small cleaved cell lymphoma
697614|NCT00003572|noncontiguous stage II mantle cell lymphoma
697615|NCT00003572|noncontiguous stage II adult diffuse mixed cell lymphoma
697616|NCT00003572|noncontiguous stage II adult immunoblastic large cell lymphoma
697617|NCT00003572|noncontiguous stage II adult diffuse large cell lymphoma
697618|NCT00003572|noncontiguous stage II adult Burkitt lymphoma
697619|NCT00003572|noncontiguous stage II adult lymphoblastic lymphoma
697620|NCT00003572|stage III mantle cell lymphoma
697621|NCT00003572|stage IV mantle cell lymphoma
697622|NCT00003572|noncontiguous stage II small lymphocytic lymphoma
697623|NCT00003572|noncontiguous stage II marginal zone lymphoma
697624|NCT00003572|stage I marginal zone lymphoma
697625|NCT00003572|stage I small lymphocytic lymphoma
697626|NCT00003572|stage III small lymphocytic lymphoma
697627|NCT00003572|stage III marginal zone lymphoma
697628|NCT00003572|stage IV small lymphocytic lymphoma
697629|NCT00003572|stage IV marginal zone lymphoma
697630|NCT00003572|contiguous stage II marginal zone lymphoma
697631|NCT00003572|contiguous stage II small lymphocytic lymphoma
697632|NCT00003572|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697633|NCT00003572|nodal marginal zone B-cell lymphoma
697634|NCT00003572|splenic marginal zone lymphoma
697635|NCT00003571|stage III colon cancer
697636|NCT00003571|adenocarcinoma of the colon
697637|NCT00003569|stage III non-small cell lung cancer
697638|NCT00003569|recurrent non-small cell lung cancer
697639|NCT00003569|stage III ovarian epithelial cancer
697640|NCT00003569|stage IV ovarian epithelial cancer
697641|NCT00003569|recurrent ovarian epithelial cancer
697642|NCT00003569|stage IV non-small cell lung cancer
697643|NCT00003569|stage III squamous cell carcinoma of the lip and oral cavity
697644|NCT00003569|stage IV squamous cell carcinoma of the lip and oral cavity
697645|NCT00003569|recurrent squamous cell carcinoma of the lip and oral cavity
697646|NCT00003569|stage III squamous cell carcinoma of the oropharynx
697647|NCT00003569|stage IV squamous cell carcinoma of the oropharynx
697648|NCT00003569|recurrent squamous cell carcinoma of the oropharynx
697649|NCT00003569|stage III squamous cell carcinoma of the nasopharynx
697650|NCT00003569|stage IV squamous cell carcinoma of the nasopharynx
697651|NCT00003569|recurrent squamous cell carcinoma of the nasopharynx
697652|NCT00003569|stage III squamous cell carcinoma of the hypopharynx
697653|NCT00003569|stage IV squamous cell carcinoma of the hypopharynx
697654|NCT00003569|recurrent squamous cell carcinoma of the hypopharynx
697655|NCT00003569|stage III squamous cell carcinoma of the larynx
697656|NCT00003569|stage IV squamous cell carcinoma of the larynx
697657|NCT00003569|recurrent squamous cell carcinoma of the larynx
697658|NCT00003569|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
697659|NCT00003569|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697660|NCT00003569|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
697661|NCT00003569|neurotoxicity
697662|NCT00003569|recurrent salivary gland cancer
697663|NCT00003569|stage IV salivary gland cancer
697664|NCT00003569|salivary gland squamous cell carcinoma
697665|NCT00003569|stage III salivary gland cancer
697666|NCT00003568|stage IV melanoma
697667|NCT00003568|recurrent melanoma
697668|NCT00003567|recurrent adult brain tumor
697669|NCT00003567|adult brain stem glioma
697670|NCT00003567|stage IV grade 1 follicular lymphoma
697671|NCT00003567|stage IV grade 2 follicular lymphoma
697672|NCT00003567|stage IV grade 3 follicular lymphoma
697673|NCT00003567|stage IV adult diffuse small cleaved cell lymphoma
697674|NCT00003567|stage IV adult diffuse mixed cell lymphoma
697675|NCT00003567|stage IV adult diffuse large cell lymphoma
697676|NCT00003567|stage IV adult immunoblastic large cell lymphoma
697677|NCT00003567|stage IV adult lymphoblastic lymphoma
697678|NCT00003567|stage IV adult Burkitt lymphoma
697679|NCT00003567|recurrent grade 1 follicular lymphoma
697680|NCT00003567|recurrent grade 2 follicular lymphoma
697681|NCT00003567|recurrent grade 3 follicular lymphoma
697682|NCT00003567|recurrent adult diffuse small cleaved cell lymphoma
697683|NCT00003567|recurrent adult diffuse mixed cell lymphoma
697684|NCT00003567|recurrent adult diffuse large cell lymphoma
697685|NCT00003567|recurrent adult immunoblastic large cell lymphoma
697686|NCT00003567|recurrent adult lymphoblastic lymphoma
697687|NCT00003567|recurrent adult Burkitt lymphoma
697688|NCT00003567|adult mixed glioma
697689|NCT00003567|stage IV mantle cell lymphoma
697690|NCT00003567|recurrent mantle cell lymphoma
697691|NCT00003567|unspecified adult solid tumor, protocol specific
697692|NCT00003567|adult anaplastic astrocytoma
697693|NCT00003567|adult anaplastic oligodendroglioma
697694|NCT00003567|adult glioblastoma
697695|NCT00003567|adult pilocytic astrocytoma
697696|NCT00003567|adult subependymoma
697697|NCT00003567|adult anaplastic ependymoma
697698|NCT00003567|adult myxopapillary ependymoma
697699|NCT00003567|adult ependymoblastoma
697700|NCT00003567|recurrent marginal zone lymphoma
697701|NCT00003567|recurrent small lymphocytic lymphoma
697702|NCT00003567|stage IV small lymphocytic lymphoma
697703|NCT00003567|stage IV marginal zone lymphoma
697704|NCT00003567|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
697705|NCT00003567|nodal marginal zone B-cell lymphoma
697706|NCT00003567|splenic marginal zone lymphoma
697707|NCT00003567|adult oligodendroglioma
697708|NCT00003567|adult giant cell glioblastoma
697709|NCT00003567|adult gliosarcoma
697710|NCT00003567|adult diffuse astrocytoma
697711|NCT00003566|stage IIIA non-small cell lung cancer
697712|NCT00003565|stage IV breast cancer
697713|NCT00003565|stage IIIA breast cancer
697714|NCT00003565|recurrent breast cancer
697715|NCT00003565|stage IIIB breast cancer
697716|NCT00003565|stage IIIC breast cancer
697717|NCT00003565|recurrent non-small cell lung cancer
697718|NCT00003565|extensive stage small cell lung cancer
697719|NCT00003565|recurrent small cell lung cancer
697720|NCT00003565|stage III bladder cancer
697721|NCT00003565|recurrent bladder cancer
697722|NCT00003565|stage IV bladder cancer
697723|NCT00003565|stage IV nasopharyngeal cancer
697724|NCT00003565|stage IIIA non-small cell lung cancer
697725|NCT00003565|stage IIIB non-small cell lung cancer
697726|NCT00003565|stage IV non-small cell lung cancer
697727|NCT00003565|unspecified adult solid tumor, protocol specific
697728|NCT00003565|untreated metastatic squamous neck cancer with occult primary
697729|NCT00003565|recurrent metastatic squamous neck cancer with occult primary
697730|NCT00003565|pulmonary carcinoid tumor
697731|NCT00003565|stage III squamous cell carcinoma of the lip and oral cavity
697732|NCT00003565|stage III basal cell carcinoma of the lip
697733|NCT00003565|stage III verrucous carcinoma of the oral cavity
697734|NCT00003565|stage III mucoepidermoid carcinoma of the oral cavity
697735|NCT00003565|stage III adenoid cystic carcinoma of the oral cavity
697736|NCT00003565|stage IV squamous cell carcinoma of the lip and oral cavity
697737|NCT00003565|stage IV basal cell carcinoma of the lip
697738|NCT00003565|stage IV verrucous carcinoma of the oral cavity
697739|NCT00003565|stage IV mucoepidermoid carcinoma of the oral cavity
697740|NCT00003565|stage IV adenoid cystic carcinoma of the oral cavity
697741|NCT00003565|recurrent squamous cell carcinoma of the lip and oral cavity
697742|NCT00003565|recurrent basal cell carcinoma of the lip
697743|NCT00003565|recurrent verrucous carcinoma of the oral cavity
697744|NCT00003565|recurrent mucoepidermoid carcinoma of the oral cavity
697745|NCT00003565|recurrent adenoid cystic carcinoma of the oral cavity
697746|NCT00003565|stage III squamous cell carcinoma of the oropharynx
697747|NCT00003565|stage III lymphoepithelioma of the oropharynx
697748|NCT00003565|stage IV squamous cell carcinoma of the oropharynx
697749|NCT00003565|stage IV lymphoepithelioma of the oropharynx
697750|NCT00003565|recurrent squamous cell carcinoma of the oropharynx
697751|NCT00003565|recurrent lymphoepithelioma of the oropharynx
697752|NCT00003565|stage III squamous cell carcinoma of the nasopharynx
697753|NCT00003565|stage III lymphoepithelioma of the nasopharynx
697754|NCT00003565|stage IV squamous cell carcinoma of the nasopharynx
697755|NCT00003565|stage IV lymphoepithelioma of the nasopharynx
697756|NCT00003565|recurrent squamous cell carcinoma of the nasopharynx
697757|NCT00003565|recurrent lymphoepithelioma of the nasopharynx
697758|NCT00003565|stage III squamous cell carcinoma of the hypopharynx
697759|NCT00003565|stage IV squamous cell carcinoma of the hypopharynx
697760|NCT00003565|recurrent squamous cell carcinoma of the hypopharynx
697761|NCT00003565|stage III squamous cell carcinoma of the larynx
697762|NCT00003565|stage III verrucous carcinoma of the larynx
697763|NCT00003565|stage IV squamous cell carcinoma of the larynx
697764|NCT00003565|stage IV verrucous carcinoma of the larynx
697765|NCT00003565|recurrent squamous cell carcinoma of the larynx
697766|NCT00003565|recurrent verrucous carcinoma of the larynx
697767|NCT00003565|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
697768|NCT00003565|stage III inverted papilloma of the paranasal sinus and nasal cavity
697769|NCT00003565|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
697770|NCT00003565|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
697771|NCT00003565|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
697772|NCT00003565|stage IV inverted papilloma of the paranasal sinus and nasal cavity
697773|NCT00003565|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
697774|NCT00003565|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
697775|NCT00003565|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
697776|NCT00003565|recurrent inverted papilloma of the paranasal sinus and nasal cavity
697777|NCT00003565|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
697778|NCT00003565|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
697779|NCT00003565|recurrent salivary gland cancer
697780|NCT00003565|stage III salivary gland cancer
697781|NCT00003565|stage IV salivary gland cancer
697782|NCT00003564|recurrent adult brain tumor
697783|NCT00003564|adult glioblastoma
697784|NCT00003564|adult anaplastic astrocytoma
697785|NCT00003564|adult anaplastic oligodendroglioma
697786|NCT00003564|adult mixed glioma
697787|NCT00003564|adult giant cell glioblastoma
697788|NCT00003564|adult gliosarcoma
697789|NCT00003563|tumors metastatic to brain
697790|NCT00003562|squamous cell lung cancer
697791|NCT00003562|large cell lung cancer
697792|NCT00003562|stage IIIB non-small cell lung cancer
697793|NCT00003562|stage IV non-small cell lung cancer
697794|NCT00003562|adenocarcinoma of the lung
697795|NCT00003561|chronic phase chronic myelogenous leukemia
697796|NCT00003561|Philadelphia chromosome positive chronic myelogenous leukemia
697797|NCT00003561|Philadelphia chromosome negative chronic myelogenous leukemia
697798|NCT00003560|stage III ovarian epithelial cancer
697799|NCT00003560|stage IV ovarian epithelial cancer
697800|NCT00003560|stage III endometrial carcinoma
697801|NCT00003560|stage IV endometrial carcinoma
697802|NCT00003560|endometrial papillary serous carcinoma
697803|NCT00003560|fallopian tube cancer
697804|NCT00003560|primary peritoneal cavity cancer
697805|NCT00003558|adenocarcinoma of unknown primary
697806|NCT00003558|newly diagnosed carcinoma of unknown primary
697807|NCT00003557|advanced adult primary liver cancer
697808|NCT00003557|recurrent adult primary liver cancer
697809|NCT00003557|unresectable gallbladder cancer
697810|NCT00003557|recurrent gallbladder cancer
697811|NCT00003557|unresectable extrahepatic bile duct cancer
697812|NCT00003557|recurrent extrahepatic bile duct cancer
697813|NCT00003557|adult primary hepatocellular carcinoma
697814|NCT00003557|cholangiocarcinoma of the gallbladder
697815|NCT00003556|stage IV melanoma
697816|NCT00003556|recurrent melanoma
697817|NCT00003555|unspecified adult solid tumor, protocol specific
697818|NCT00003554|stage I multiple myeloma
697819|NCT00003554|stage II multiple myeloma
697820|NCT00003554|stage III multiple myeloma
697821|NCT00003553|stage IV renal cell cancer
697822|NCT00003553|recurrent renal cell cancer
697823|NCT00003552|adult solid tumor
697824|NCT00003552|body system/site cancer
697825|NCT00003552|cancer
697826|NCT00003552|melanoma
697827|NCT00003552|recurrent melanoma
697828|NCT00003552|skin tumor
697829|NCT00003552|solid tumor
697830|NCT00003552|stage IV melanoma
697831|NCT00003552|stage, melanoma
697832|NCT00003551|stage III renal cell cancer
697833|NCT00003551|stage IV renal cell cancer
697834|NCT00003551|recurrent renal cell cancer
697835|NCT00003549|stage II neuroendocrine carcinoma of the skin
697836|NCT00003549|stage III neuroendocrine carcinoma of the skin
697837|NCT00003549|recurrent neuroendocrine carcinoma of the skin
697838|NCT00003548|stage IV colon cancer
697839|NCT00003548|stage IV breast cancer
697840|NCT00003548|recurrent breast cancer
697841|NCT00003548|stage IV gastric cancer
697842|NCT00003548|recurrent gastric cancer
697843|NCT00003548|recurrent pancreatic cancer
697844|NCT00003548|stage IV rectal cancer
697845|NCT00003548|recurrent colon cancer
697846|NCT00003548|recurrent rectal cancer
697847|NCT00003548|stage IV anal cancer
697848|NCT00003548|recurrent anal cancer
697849|NCT00003548|stage IV esophageal cancer
697850|NCT00003548|recurrent esophageal cancer
697851|NCT00003548|stage IV cervical cancer
697852|NCT00003548|recurrent cervical cancer
697853|NCT00003548|stage IV ovarian epithelial cancer
697854|NCT00003548|recurrent ovarian epithelial cancer
697855|NCT00003548|stage IV vulvar cancer
697856|NCT00003548|recurrent vulvar cancer
697857|NCT00003548|stage IVA vaginal cancer
697858|NCT00003548|stage IVB vaginal cancer
697859|NCT00003548|recurrent vaginal cancer
697860|NCT00003548|metastatic gastrointestinal carcinoid tumor
697861|NCT00003548|recurrent gastrointestinal carcinoid tumor
697862|NCT00003548|advanced adult primary liver cancer
697863|NCT00003548|recurrent adult primary liver cancer
697864|NCT00003548|recurrent gestational trophoblastic tumor
697865|NCT00003548|stage IV endometrial carcinoma
697866|NCT00003548|recurrent endometrial carcinoma
697867|NCT00003548|unresectable gallbladder cancer
697868|NCT00003548|recurrent gallbladder cancer
697869|NCT00003548|unresectable extrahepatic bile duct cancer
697870|NCT00003548|recurrent extrahepatic bile duct cancer
697871|NCT00003548|recurrent small intestine cancer
697872|NCT00003548|carcinoma of the appendix
697873|NCT00003548|fallopian tube cancer
697874|NCT00003548|stage IV uterine sarcoma
697875|NCT00003548|recurrent uterine sarcoma
697876|NCT00003548|recurrent carcinoma of unknown primary
697877|NCT00003548|stage IV pancreatic cancer
697878|NCT00003546|stage I pancreatic cancer
697879|NCT00003546|stage II pancreatic cancer
697880|NCT00003546|stage III pancreatic cancer
697881|NCT00003546|adenocarcinoma of the pancreas
697882|NCT00003545|recurrent childhood acute lymphoblastic leukemia
697883|NCT00003545|recurrent childhood lymphoblastic lymphoma
697884|NCT00003545|recurrent adult acute lymphoblastic leukemia
697885|NCT00003545|T-cell childhood acute lymphoblastic leukemia
697886|NCT00003545|T-cell adult acute lymphoblastic leukemia
697887|NCT00003545|recurrent adult lymphoblastic lymphoma
697888|NCT00003545|recurrent adult T-cell leukemia/lymphoma
697889|NCT00003544|stage IV colon cancer
697890|NCT00003544|stage IV rectal cancer
697891|NCT00003544|recurrent colon cancer
697892|NCT00003544|recurrent rectal cancer
697893|NCT00003543|stage IV colon cancer
697894|NCT00003543|stage IV rectal cancer
697895|NCT00003543|recurrent colon cancer
697896|NCT00003543|recurrent rectal cancer
697897|NCT00003542|stage III renal cell cancer
697898|NCT00003542|stage IV renal cell cancer
697899|NCT00003541|stage III mantle cell lymphoma
697900|NCT00003541|stage IV mantle cell lymphoma
697901|NCT00003540|stage IV breast cancer
697902|NCT00003540|recurrent breast cancer
697903|NCT00003539|stage IV breast cancer
697904|NCT00003539|recurrent breast cancer
697905|NCT00003538|stage I adult Hodgkin lymphoma
697906|NCT00003538|stage II adult Hodgkin lymphoma
697907|NCT00003538|stage III adult Hodgkin lymphoma
697908|NCT00003538|stage IV adult Hodgkin lymphoma
697909|NCT00003538|stage IV breast cancer
697910|NCT00003538|stage IIIA breast cancer
697911|NCT00003538|stage IIIB breast cancer
697912|NCT00003538|recurrent childhood acute lymphoblastic leukemia
697913|NCT00003538|recurrent adult Hodgkin lymphoma
697914|NCT00003538|recurrent childhood rhabdomyosarcoma
697915|NCT00003538|stage II ovarian epithelial cancer
697916|NCT00003538|stage III ovarian epithelial cancer
697917|NCT00003538|stage IV ovarian epithelial cancer
697918|NCT00003538|recurrent ovarian epithelial cancer
697919|NCT00003538|disseminated neuroblastoma
697920|NCT00003538|recurrent neuroblastoma
697921|NCT00003538|recurrent Wilms tumor and other childhood kidney tumors
697922|NCT00003538|Waldenstrom macroglobulinemia
697923|NCT00003538|stage I multiple myeloma
697924|NCT00003538|stage II multiple myeloma
697925|NCT00003538|stage III multiple myeloma
697926|NCT00003538|stage I childhood lymphoblastic lymphoma
697927|NCT00003538|stage III childhood lymphoblastic lymphoma
697928|NCT00003538|stage IV childhood lymphoblastic lymphoma
697929|NCT00003538|recurrent childhood lymphoblastic lymphoma
697930|NCT00003538|recurrent childhood acute myeloid leukemia
697931|NCT00003538|recurrent adult acute myeloid leukemia
697932|NCT00003538|recurrent adult acute lymphoblastic leukemia
697933|NCT00003538|relapsing chronic myelogenous leukemia
697934|NCT00003538|stage III malignant testicular germ cell tumor
697935|NCT00003538|recurrent malignant testicular germ cell tumor
697936|NCT00003538|chronic phase chronic myelogenous leukemia
697937|NCT00003538|accelerated phase chronic myelogenous leukemia
697938|NCT00003538|blastic phase chronic myelogenous leukemia
697939|NCT00003538|meningeal chronic myelogenous leukemia
697940|NCT00003538|untreated adult acute lymphoblastic leukemia
697941|NCT00003538|untreated adult acute myeloid leukemia
697942|NCT00003538|adult acute myeloid leukemia in remission
697943|NCT00003538|adult acute lymphoblastic leukemia in remission
697944|NCT00003538|childhood acute myeloid leukemia in remission
697945|NCT00003538|childhood acute lymphoblastic leukemia in remission
697946|NCT00003538|myelodysplastic syndromes
697947|NCT00003538|Philadelphia chromosome positive chronic myelogenous leukemia
697948|NCT00003538|Philadelphia chromosome negative chronic myelogenous leukemia
697949|NCT00003538|untreated hairy cell leukemia
697950|NCT00003538|progressive hairy cell leukemia, initial treatment
697951|NCT00003538|refractory hairy cell leukemia
697952|NCT00003538|stage II childhood Hodgkin lymphoma
697953|NCT00003538|stage I childhood Hodgkin lymphoma
697954|NCT00003538|stage III childhood Hodgkin lymphoma
697955|NCT00003538|stage IV childhood Hodgkin lymphoma
697956|NCT00003538|recurrent/refractory childhood Hodgkin lymphoma
697957|NCT00003538|stage I grade 1 follicular lymphoma
697958|NCT00003538|stage I grade 2 follicular lymphoma
697959|NCT00003538|stage I grade 3 follicular lymphoma
697960|NCT00003538|stage I adult diffuse small cleaved cell lymphoma
697961|NCT00003538|stage I adult diffuse mixed cell lymphoma
697962|NCT00003538|stage I adult diffuse large cell lymphoma
697963|NCT00003538|stage I adult immunoblastic large cell lymphoma
697964|NCT00003538|stage I adult lymphoblastic lymphoma
697965|NCT00003538|stage I adult Burkitt lymphoma
697966|NCT00003538|recurrent ovarian germ cell tumor
697967|NCT00003538|chronic myelomonocytic leukemia
697968|NCT00003538|acute undifferentiated leukemia
697969|NCT00003538|stage III grade 1 follicular lymphoma
697970|NCT00003538|stage III grade 2 follicular lymphoma
697971|NCT00003538|stage III grade 3 follicular lymphoma
697972|NCT00003538|stage III adult diffuse small cleaved cell lymphoma
697973|NCT00003538|stage III adult diffuse mixed cell lymphoma
697974|NCT00003538|stage III adult diffuse large cell lymphoma
697975|NCT00003538|stage III adult immunoblastic large cell lymphoma
697976|NCT00003538|stage III adult lymphoblastic lymphoma
697977|NCT00003538|stage III adult Burkitt lymphoma
697978|NCT00003538|stage IV small lymphocytic lymphoma
697979|NCT00003538|stage IV grade 1 follicular lymphoma
697980|NCT00003538|stage IV grade 2 follicular lymphoma
697981|NCT00003538|stage IV grade 3 follicular lymphoma
697982|NCT00003538|stage IV adult diffuse small cleaved cell lymphoma
697983|NCT00003538|stage IV adult diffuse mixed cell lymphoma
697984|NCT00003538|stage IV adult diffuse large cell lymphoma
697985|NCT00003538|stage IV adult immunoblastic large cell lymphoma
697986|NCT00003538|stage IV adult lymphoblastic lymphoma
697987|NCT00003538|stage IV adult Burkitt lymphoma
697988|NCT00003538|recurrent grade 1 follicular lymphoma
697989|NCT00003538|recurrent grade 2 follicular lymphoma
697990|NCT00003538|recurrent grade 3 follicular lymphoma
697991|NCT00003538|recurrent adult diffuse small cleaved cell lymphoma
697992|NCT00003538|recurrent adult diffuse mixed cell lymphoma
697993|NCT00003538|recurrent adult diffuse large cell lymphoma
697994|NCT00003538|recurrent adult immunoblastic large cell lymphoma
697995|NCT00003538|recurrent adult lymphoblastic lymphoma
697996|NCT00003538|recurrent adult Burkitt lymphoma
697997|NCT00003538|stage III adult T-cell leukemia/lymphoma
697998|NCT00003538|stage IV adult T-cell leukemia/lymphoma
697999|NCT00003538|recurrent adult T-cell leukemia/lymphoma
698000|NCT00003538|secondary acute myeloid leukemia
698001|NCT00003538|de novo myelodysplastic syndromes
698002|NCT00003538|poor prognosis metastatic gestational trophoblastic tumor
698003|NCT00003538|previously treated myelodysplastic syndromes
698004|NCT00003538|secondary myelodysplastic syndromes
698005|NCT00003538|anemia
698006|NCT00003538|graft versus host disease
698007|NCT00003538|prolymphocytic leukemia
698008|NCT00003538|AIDS-related peripheral/systemic lymphoma
698009|NCT00003538|AIDS-related primary CNS lymphoma
698010|NCT00003538|stage I childhood large cell lymphoma
698011|NCT00003538|stage III childhood large cell lymphoma
698012|NCT00003538|stage IV childhood small noncleaved cell lymphoma
698013|NCT00003538|stage IV childhood large cell lymphoma
698014|NCT00003538|recurrent childhood small noncleaved cell lymphoma
698015|NCT00003538|recurrent childhood large cell lymphoma
698016|NCT00003538|non-Hodgkin lymphoma during pregnancy
698017|NCT00003538|stage I mantle cell lymphoma
698018|NCT00003538|contiguous stage II grade 1 follicular lymphoma
698019|NCT00003538|contiguous stage II grade 2 follicular lymphoma
698020|NCT00003538|contiguous stage II grade 3 follicular lymphoma
698021|NCT00003538|contiguous stage II adult diffuse small cleaved cell lymphoma
698022|NCT00003538|contiguous stage II mantle cell lymphoma
698023|NCT00003538|contiguous stage II adult diffuse mixed cell lymphoma
698024|NCT00003538|contiguous stage II adult immunoblastic large cell lymphoma
698025|NCT00003538|contiguous stage II adult diffuse large cell lymphoma
698026|NCT00003538|contiguous stage II adult Burkitt lymphoma
698027|NCT00003538|contiguous stage II adult lymphoblastic lymphoma
698028|NCT00003538|noncontiguous stage II grade 1 follicular lymphoma
698029|NCT00003538|noncontiguous stage II grade 2 follicular lymphoma
698030|NCT00003538|noncontiguous stage II grade 3 follicular lymphoma
698031|NCT00003538|noncontiguous stage II adult diffuse small cleaved cell lymphoma
698032|NCT00003538|noncontiguous stage II mantle cell lymphoma
698033|NCT00003538|noncontiguous stage II adult diffuse mixed cell lymphoma
698034|NCT00003538|noncontiguous stage II adult immunoblastic large cell lymphoma
698035|NCT00003538|noncontiguous stage II adult diffuse large cell lymphoma
698036|NCT00003538|noncontiguous stage II adult Burkitt lymphoma
698037|NCT00003538|noncontiguous stage II adult lymphoblastic lymphoma
698038|NCT00003538|stage III mantle cell lymphoma
698039|NCT00003538|stage IV mantle cell lymphoma
698040|NCT00003538|recurrent mantle cell lymphoma
698041|NCT00003538|angioimmunoblastic T-cell lymphoma
698042|NCT00003538|anaplastic large cell lymphoma
698043|NCT00003538|childhood chronic myelogenous leukemia
698044|NCT00003538|noncontiguous stage II small lymphocytic lymphoma
698045|NCT00003538|noncontiguous stage II marginal zone lymphoma
698046|NCT00003538|recurrent marginal zone lymphoma
698047|NCT00003538|recurrent small lymphocytic lymphoma
698048|NCT00003538|stage I marginal zone lymphoma
698049|NCT00003538|stage I small lymphocytic lymphoma
698050|NCT00003538|stage III small lymphocytic lymphoma
698051|NCT00003538|stage III marginal zone lymphoma
698052|NCT00003538|stage IV marginal zone lymphoma
698053|NCT00003538|contiguous stage II marginal zone lymphoma
698054|NCT00003538|contiguous stage II small lymphocytic lymphoma
698055|NCT00003538|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698056|NCT00003538|nodal marginal zone B-cell lymphoma
698057|NCT00003538|splenic marginal zone lymphoma
698058|NCT00003538|childhood myelodysplastic syndromes
698059|NCT00003537|recurrent adult brain tumor
698060|NCT00003537|adult anaplastic astrocytoma
698061|NCT00003535|childhood high-grade cerebral astrocytoma
698062|NCT00003535|recurrent childhood cerebral astrocytoma
698063|NCT00003535|childhood cerebral astrocytoma/malignant glioma
698064|NCT00003534|adenocarcinoma of the prostate
698065|NCT00003534|stage IV prostate cancer
698066|NCT00003534|recurrent prostate cancer
698067|NCT00003533|adenocarcinoma of the prostate
698068|NCT00003533|stage IV prostate cancer
698069|NCT00003533|recurrent prostate cancer
698070|NCT00003532|stage III ovarian epithelial cancer
698071|NCT00003532|stage IV ovarian epithelial cancer
698072|NCT00003532|recurrent ovarian epithelial cancer
698073|NCT00003532|stage III ovarian germ cell tumor
698074|NCT00003532|stage IV ovarian germ cell tumor
698075|NCT00003532|recurrent ovarian germ cell tumor
698076|NCT00003531|recurrent pancreatic cancer
698077|NCT00003531|adenocarcinoma of the pancreas
698078|NCT00003531|stage IV pancreatic cancer
698079|NCT00003530|stage IV childhood liver cancer
698080|NCT00003530|recurrent childhood liver cancer
698081|NCT00003530|advanced adult primary liver cancer
698082|NCT00003530|recurrent adult primary liver cancer
698083|NCT00003526|adenocarcinoma of unknown primary
698084|NCT00003526|recurrent carcinoma of unknown primary
698085|NCT00003525|stage IV cervical cancer
698086|NCT00003525|recurrent cervical cancer
698087|NCT00003525|stage IV vulvar cancer
698088|NCT00003525|recurrent vulvar cancer
698089|NCT00003524|stage III gastric cancer
698090|NCT00003524|stage IV gastric cancer
698091|NCT00003524|recurrent gastric cancer
698092|NCT00003524|adenocarcinoma of the stomach
698093|NCT00003523|recurrent ovarian epithelial cancer
698094|NCT00003523|primary peritoneal cavity cancer
698095|NCT00003522|small intestine adenocarcinoma
698096|NCT00003522|recurrent small intestine cancer
698097|NCT00003521|stage III adult soft tissue sarcoma
698098|NCT00003521|stage IV adult soft tissue sarcoma
698099|NCT00003521|recurrent adult soft tissue sarcoma
698100|NCT00003521|nonmetastatic childhood soft tissue sarcoma
698101|NCT00003521|metastatic childhood soft tissue sarcoma
698102|NCT00003521|recurrent childhood soft tissue sarcoma
698103|NCT00003520|stage IV renal cell cancer
698104|NCT00003520|recurrent renal cell cancer
698105|NCT00003520|metastatic transitional cell cancer of the renal pelvis and ureter
698106|NCT00003520|recurrent transitional cell cancer of the renal pelvis and ureter
698107|NCT00003519|stage II breast cancer
698108|NCT00003519|stage IIIA breast cancer
698109|NCT00003519|stage IIIB breast cancer
698110|NCT00003518|stage III malignant testicular germ cell tumor
698111|NCT00003518|recurrent malignant testicular germ cell tumor
698112|NCT00003518|stage IV ovarian germ cell tumor
698113|NCT00003518|recurrent ovarian germ cell tumor
698114|NCT00003516|adenocarcinoma of the prostate
698115|NCT00003516|stage III prostate cancer
698116|NCT00003516|stage IV prostate cancer
698117|NCT00003516|recurrent prostate cancer
698118|NCT00003515|metastatic childhood soft tissue sarcoma
698119|NCT00003515|recurrent childhood soft tissue sarcoma
698120|NCT00003515|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
698121|NCT00003515|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
698122|NCT00003514|ACTH-producing pituitary tumor
698123|NCT00003514|prolactin-producing pituitary tumor
698124|NCT00003514|growth hormone-producing pituitary tumor
698125|NCT00003514|recurrent pituitary tumor
698126|NCT00003514|TSH producing pituitary tumor
698127|NCT00003514|nonfunctioning pituitary tumor
698128|NCT00003514|somatostatinoma
698129|NCT00003514|stage III Merkel cell carcinoma
698130|NCT00003514|recurrent Merkel cell carcinoma
698131|NCT00003514|neuroendocrine carcinoma
698132|NCT00003513|regional neuroblastoma
698133|NCT00003513|disseminated neuroblastoma
698134|NCT00003513|stage 4S neuroblastoma
698135|NCT00003513|recurrent neuroblastoma
698136|NCT00003513|localized unresectable neuroblastoma
698137|NCT00003512|refractory multiple myeloma
698138|NCT00003512|Waldenstrom macroglobulinemia
698139|NCT00003511|refractory multiple myeloma
698140|NCT00003511|stage I multiple myeloma
698141|NCT00003511|stage II multiple myeloma
698142|NCT00003511|stage III multiple myeloma
698143|NCT00003509|stage IV melanoma
698144|NCT00003509|recurrent melanoma
698145|NCT00003508|advanced malignant mesothelioma
698146|NCT00003508|recurrent malignant mesothelioma
698147|NCT00003501|stage III adult immunoblastic large cell lymphoma
698148|NCT00003501|stage III adult lymphoblastic lymphoma
698149|NCT00003501|stage III adult Burkitt lymphoma
698150|NCT00003501|stage IV adult immunoblastic large cell lymphoma
698151|NCT00003501|stage IV adult lymphoblastic lymphoma
698152|NCT00003501|stage IV adult Burkitt lymphoma
698153|NCT00003501|recurrent adult immunoblastic large cell lymphoma
698154|NCT00003501|recurrent adult lymphoblastic lymphoma
698155|NCT00003501|recurrent adult Burkitt lymphoma
698156|NCT00003501|contiguous stage II adult immunoblastic large cell lymphoma
698157|NCT00003501|contiguous stage II adult Burkitt lymphoma
698158|NCT00003501|contiguous stage II adult lymphoblastic lymphoma
698159|NCT00003501|noncontiguous stage II adult immunoblastic large cell lymphoma
698160|NCT00003501|noncontiguous stage II adult Burkitt lymphoma
698161|NCT00003501|noncontiguous stage II adult lymphoblastic lymphoma
698162|NCT00003500|stage III grade 3 follicular lymphoma
698163|NCT00003500|stage III adult diffuse small cleaved cell lymphoma
698164|NCT00003500|stage III adult diffuse mixed cell lymphoma
698165|NCT00003500|stage III adult diffuse large cell lymphoma
698166|NCT00003500|stage IV grade 3 follicular lymphoma
698167|NCT00003500|stage IV adult diffuse small cleaved cell lymphoma
698168|NCT00003500|stage IV adult diffuse mixed cell lymphoma
698169|NCT00003500|stage IV adult diffuse large cell lymphoma
698170|NCT00003500|recurrent grade 3 follicular lymphoma
698171|NCT00003500|recurrent adult diffuse small cleaved cell lymphoma
698172|NCT00003500|recurrent adult diffuse mixed cell lymphoma
698173|NCT00003500|recurrent adult diffuse large cell lymphoma
698174|NCT00003500|contiguous stage II grade 3 follicular lymphoma
698175|NCT00003500|contiguous stage II adult diffuse small cleaved cell lymphoma
698176|NCT00003500|contiguous stage II adult diffuse mixed cell lymphoma
698177|NCT00003500|contiguous stage II adult diffuse large cell lymphoma
698178|NCT00003500|noncontiguous stage II grade 3 follicular lymphoma
698179|NCT00003500|noncontiguous stage II adult diffuse small cleaved cell lymphoma
698180|NCT00003500|noncontiguous stage II adult diffuse mixed cell lymphoma
698181|NCT00003500|noncontiguous stage II adult diffuse large cell lymphoma
698182|NCT00003499|stage III grade 1 follicular lymphoma
698183|NCT00003499|stage III grade 2 follicular lymphoma
698184|NCT00003499|stage IV grade 1 follicular lymphoma
698185|NCT00003499|stage IV grade 2 follicular lymphoma
698186|NCT00003499|contiguous stage II grade 1 follicular lymphoma
698187|NCT00003499|contiguous stage II grade 2 follicular lymphoma
698188|NCT00003499|noncontiguous stage II grade 1 follicular lymphoma
698189|NCT00003499|noncontiguous stage II grade 2 follicular lymphoma
698190|NCT00003499|contiguous stage II small lymphocytic lymphoma
698191|NCT00003499|contiguous stage II marginal zone lymphoma
698192|NCT00003499|noncontiguous stage II small lymphocytic lymphoma
698193|NCT00003499|noncontiguous stage II marginal zone lymphoma
698194|NCT00003499|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698195|NCT00003499|nodal marginal zone B-cell lymphoma
698196|NCT00003499|splenic marginal zone lymphoma
698197|NCT00003499|stage III small lymphocytic lymphoma
698198|NCT00003499|stage III marginal zone lymphoma
698199|NCT00003499|stage IV small lymphocytic lymphoma
698200|NCT00003499|stage IV marginal zone lymphoma
698201|NCT00003498|recurrent grade 1 follicular lymphoma
698202|NCT00003498|recurrent grade 2 follicular lymphoma
698203|NCT00003498|recurrent grade 3 follicular lymphoma
698204|NCT00003498|recurrent adult diffuse small cleaved cell lymphoma
698205|NCT00003498|recurrent adult diffuse mixed cell lymphoma
698206|NCT00003498|recurrent adult diffuse large cell lymphoma
698207|NCT00003498|recurrent adult immunoblastic large cell lymphoma
698208|NCT00003498|recurrent adult lymphoblastic lymphoma
698209|NCT00003498|recurrent adult Burkitt lymphoma
698210|NCT00003498|recurrent mantle cell lymphoma
698211|NCT00003498|recurrent marginal zone lymphoma
698212|NCT00003498|recurrent small lymphocytic lymphoma
698213|NCT00003498|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698214|NCT00003498|nodal marginal zone B-cell lymphoma
698215|NCT00003498|splenic marginal zone lymphoma
698216|NCT00003497|recurrent non-small cell lung cancer
698217|NCT00003497|stage IV non-small cell lung cancer
698218|NCT00003496|extensive stage small cell lung cancer
698219|NCT00003496|recurrent small cell lung cancer
698220|NCT00003495|recurrent non-small cell lung cancer
698221|NCT00003495|squamous cell lung cancer
698222|NCT00003495|stage IV non-small cell lung cancer
698223|NCT00003494|recurrent non-small cell lung cancer
698224|NCT00003494|stage IV non-small cell lung cancer
698225|NCT00003494|bronchoalveolar cell lung cancer
698226|NCT00003493|refractory multiple myeloma
698227|NCT00003493|stage I multiple myeloma
698228|NCT00003493|stage II multiple myeloma
698229|NCT00003493|stage III multiple myeloma
698230|NCT00003492|recurrent non-small cell lung cancer
698231|NCT00003492|large cell lung cancer
698232|NCT00003492|stage IV non-small cell lung cancer
698233|NCT00003491|recurrent non-small cell lung cancer
698234|NCT00003491|stage IV non-small cell lung cancer
698235|NCT00003491|adenocarcinoma of the lung
698236|NCT00003490|refractory multiple myeloma
698237|NCT00003490|stage I multiple myeloma
698238|NCT00003490|stage II multiple myeloma
698239|NCT00003490|stage III multiple myeloma
698240|NCT00003489|stage IV salivary gland cancer
698241|NCT00003489|recurrent salivary gland cancer
698242|NCT00003489|recurrent lymphoepithelioma of the nasopharynx
698243|NCT00003489|recurrent squamous cell carcinoma of the nasopharynx
698244|NCT00003489|stage IV lymphoepithelioma of the nasopharynx
698245|NCT00003489|stage IV squamous cell carcinoma of the nasopharynx
698246|NCT00003489|recurrent squamous cell carcinoma of the larynx
698247|NCT00003489|recurrent verrucous carcinoma of the larynx
698248|NCT00003489|stage IV squamous cell carcinoma of the larynx
698249|NCT00003489|stage IV verrucous carcinoma of the larynx
698250|NCT00003489|recurrent squamous cell carcinoma of the lip and oral cavity
698251|NCT00003489|stage IV squamous cell carcinoma of the lip and oral cavity
698252|NCT00003489|recurrent squamous cell carcinoma of the hypopharynx
698253|NCT00003489|stage IV squamous cell carcinoma of the hypopharynx
698254|NCT00003489|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
698255|NCT00003489|recurrent inverted papilloma of the paranasal sinus and nasal cavity
698256|NCT00003489|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
698257|NCT00003489|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
698258|NCT00003489|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
698259|NCT00003489|stage IV inverted papilloma of the paranasal sinus and nasal cavity
698260|NCT00003489|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
698261|NCT00003489|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
698262|NCT00003489|recurrent lymphoepithelioma of the oropharynx
698263|NCT00003489|recurrent squamous cell carcinoma of the oropharynx
698264|NCT00003489|stage IV lymphoepithelioma of the oropharynx
698265|NCT00003489|stage IV squamous cell carcinoma of the oropharynx
698266|NCT00003489|recurrent verrucous carcinoma of the oral cavity
698267|NCT00003489|stage IV verrucous carcinoma of the oral cavity
698268|NCT00003489|recurrent adenoid cystic carcinoma of the oral cavity
698269|NCT00003489|stage IV adenoid cystic carcinoma of the oral cavity
698270|NCT00003489|recurrent mucoepidermoid carcinoma of the oral cavity
698271|NCT00003489|stage IV mucoepidermoid carcinoma of the oral cavity
698272|NCT00003489|recurrent basal cell carcinoma of the lip
698273|NCT00003489|stage IV basal cell carcinoma of the lip
698274|NCT00003487|stage IV esophageal cancer
698275|NCT00003487|recurrent esophageal cancer
698276|NCT00003487|adenocarcinoma of the esophagus
698277|NCT00003485|stage IV colon cancer
698278|NCT00003485|recurrent colon cancer
698279|NCT00003485|adenocarcinoma of the colon
698280|NCT00003484|localized resectable neuroblastoma
698281|NCT00003484|recurrent adult brain tumor
698282|NCT00003484|adult craniopharyngioma
698283|NCT00003484|adult medulloblastoma
698284|NCT00003484|adult meningioma
698285|NCT00003484|adult glioblastoma
698286|NCT00003484|adult oligodendroglioma
698287|NCT00003484|adult anaplastic astrocytoma
698288|NCT00003484|adult mixed glioma
698289|NCT00003484|adult pineal parenchymal tumor
698290|NCT00003484|adult central nervous system germ cell tumor
698291|NCT00003484|adult grade III meningioma
698292|NCT00003484|adult pilocytic astrocytoma
698293|NCT00003484|adult giant cell glioblastoma
698294|NCT00003484|adult gliosarcoma
698295|NCT00003483|adult meningioma
698296|NCT00003483|recurrent adult meningioma
698297|NCT00003479|Ependymoma
698298|NCT00003479|Anaplastic Ependymoma
698299|NCT00003478|recurrent adult brain tumor
698300|NCT00003478|adult brain stem glioma
698301|NCT00003478|adult medulloblastoma
698302|NCT00003478|adult glioblastoma
698303|NCT00003478|adult anaplastic astrocytoma
698304|NCT00003478|adult anaplastic ependymoma
698305|NCT00003478|adult anaplastic oligodendroglioma
698306|NCT00003478|adult mixed glioma
698307|NCT00003478|adult ependymoblastoma
698308|NCT00003478|adult giant cell glioblastoma
698309|NCT00003478|adult gliosarcoma
698310|NCT00003477|visual pathway glioma not amenable to standard therapy
698311|NCT00003477|visual pathway glioma not responding to standard therapy
698312|NCT00003476|childhood low-grade cerebral astrocytoma
698313|NCT00003476|childhood craniopharyngioma
698314|NCT00003476|childhood central nervous system germ cell tumor
698315|NCT00003476|childhood high-grade cerebral astrocytoma
698316|NCT00003476|childhood oligodendroglioma
698317|NCT00003476|childhood choroid plexus tumor
698318|NCT00003476|childhood grade I meningioma
698319|NCT00003476|childhood grade II meningioma
698320|NCT00003476|childhood grade III meningioma
698321|NCT00003476|recurrent childhood cerebral astrocytoma
698322|NCT00003476|recurrent childhood medulloblastoma
698323|NCT00003476|recurrent childhood visual pathway and hypothalamic glioma
698324|NCT00003476|recurrent childhood ependymoma
698325|NCT00003476|recurrent childhood pineoblastoma
698326|NCT00003475|adult glioblastoma multiforme
698327|NCT00003475|adult anaplastic astrocytoma
698328|NCT00003475|adult anaplastic astrocytoma/Mixed
698329|NCT00003473|recurrent adult mixed glioma
698330|NCT00003473|refractoy adult mixed glioma
698331|NCT00003472|recurrent adult brain tumor
698332|NCT00003472|adult anaplastic oligodendroglioma
698333|NCT00003472|adult oligodendroglioma
698334|NCT00003471|recurrent adult brain tumor
698335|NCT00003471|adult pilocytic astrocytoma
698336|NCT00003471|adult diffuse astrocytoma
698337|NCT00003470|persistent anaplastic astrocytoma
698338|NCT00003470|recurrent anaplastic astrocytoma
698339|NCT00003470|adult anaplastic astrocytoma
698340|NCT00003469|childhood atypical teratoid/rhabdoid tumor
698341|NCT00003468|childhood low-grade astrocytoma
698342|NCT00003468|recurrent childhood astrocytoma
698343|NCT00003468|persistent childhood astrocytoma
698344|NCT00003467|recurrent adult brain tumor
698345|NCT00003467|adult brain stem glioma
698346|NCT00003467|adult mixed glioma
698347|NCT00003467|adult anaplastic astrocytoma
698348|NCT00003467|adult pilocytic astrocytoma
698349|NCT00003467|adult oligodendroglioma
698350|NCT00003466|recurrent adult brain tumor
698351|NCT00003466|adult mixed glioma
698353|NCT00003466|adult pilocytic astrocytoma
698354|NCT00003466|adult subependymoma
698355|NCT00003466|recurrent childhood cerebral astrocytoma
698356|NCT00003466|adult brain stem glioma
698357|NCT00003466|recurrent childhood brain stem glioma
698358|NCT00003466|untreated childhood brain stem glioma
698359|NCT00003466|recurrent childhood visual pathway and hypothalamic glioma
698360|NCT00003466|untreated childhood visual pathway and hypothalamic glioma
698361|NCT00003466|adult oligodendroglioma
698362|NCT00003466|adult diffuse astrocytoma
698363|NCT00003465|recurrent adult brain tumor
698364|NCT00003465|adult anaplastic oligodendroglioma
698365|NCT00003464|adult glioblastoma
698366|NCT00003464|adult giant cell glioblastoma
698367|NCT00003464|adult gliosarcoma
698368|NCT00003463|recurrent adult brain tumor
698369|NCT00003463|adult brain stem glioma
698370|NCT00003463|adult glioblastoma
698371|NCT00003463|adult anaplastic astrocytoma
698372|NCT00003463|adult mixed glioma
698373|NCT00003463|adult giant cell glioblastoma
698374|NCT00003463|adult gliosarcoma
698375|NCT00003462|leptomeningeal metastases
698376|NCT00003461|localized resectable neuroblastoma
698377|NCT00003461|recurrent neuroblastoma
698378|NCT00003461|recurrent adult brain tumor
698379|NCT00003461|adult craniopharyngioma
698380|NCT00003461|adult medulloblastoma
698381|NCT00003461|adult meningioma
698382|NCT00003461|adult glioblastoma
698383|NCT00003461|adult oligodendroglioma
698384|NCT00003461|tumors metastatic to brain
698385|NCT00003461|adult anaplastic astrocytoma
698386|NCT00003461|adult mixed glioma
698387|NCT00003461|adult pineal parenchymal tumor
698388|NCT00003461|adult central nervous system germ cell tumor
698389|NCT00003461|adult grade III meningioma
698390|NCT00003461|adult pilocytic astrocytoma
698391|NCT00003461|adult giant cell glioblastoma
698392|NCT00003461|adult gliosarcoma
698393|NCT00003461|adult pineal gland astrocytoma
698394|NCT00003460|Recurrent primitive neuroectodermal tumor
698395|NCT00003459|recurrent adult brain stem glioma
698396|NCT00003459|untreated adult brain stem glioma
698397|NCT00003459|untreated childhood brain stem glioma
698398|NCT00003459|recurrent childhood brain stem glioma
698399|NCT00003458|Anaplastic astrocytoma
698400|NCT00003458|Anaplastic glioma
698401|NCT00003458|Anaplastic oligodendroglioma
698402|NCT00003458|Astrocytoma
698403|NCT00003458|Astrocytoma pilocytic
698404|NCT00003458|Brain stem glioma
698405|NCT00003458|Craniopharyngioma
698406|NCT00003458|Ganglioglioma
698407|NCT00003458|Glioblastoma multiforme
698408|NCT00003458|Gliosarcoma
698409|NCT00003458|Medulloepithelioma
698410|NCT00003458|Neurocytoma
698411|NCT00003458|Oligodendroglioma
698412|NCT00003458|Oligodendroglioma-brainstem
698413|NCT00003458|Primitive neuroectodermal tumor
698414|NCT00003457|Anaplastic astrocytoma
698415|NCT00003457|Anaplastic astrocytoma/Mixed
698416|NCT00003457|Astrocytoma
698417|NCT00003457|Astrocytoma/Pilocytic
698418|NCT00003457|Brainstem glioma
698419|NCT00003457|Glioblastoma multiforme
698420|NCT00003457|Glioma
698421|NCT00003457|Neurocytoma
698422|NCT00003457|Primitive neuroectodermal tumor
698423|NCT00003457|Tectal glioma
698424|NCT00003456|adult glioblastoma
698425|NCT00003456|adult giant cell glioblastoma
698426|NCT00003456|adult gliosarcoma
698427|NCT00003454|stage IV breast cancer
698428|NCT00003454|recurrent breast cancer
698429|NCT00003453|stage IV adrenocortical carcinoma
698430|NCT00003453|recurrent adrenocortical carcinoma
698431|NCT00003452|recurrent bladder cancer
698432|NCT00003452|stage IV bladder cancer
698433|NCT00003451|stage III adult Hodgkin lymphoma
698434|NCT00003451|stage IV adult Hodgkin lymphoma
698435|NCT00003451|monoclonal gammopathy of undetermined significance
698436|NCT00003451|recurrent adult Hodgkin lymphoma
698437|NCT00003451|isolated plasmacytoma of bone
698438|NCT00003451|extramedullary plasmacytoma
698439|NCT00003451|refractory multiple myeloma
698440|NCT00003451|Waldenström macroglobulinemia
698441|NCT00003451|stage III multiple myeloma
698442|NCT00003451|stage IV chronic lymphocytic leukemia
698443|NCT00003451|recurrent adult acute myeloid leukemia
698444|NCT00003451|recurrent adult acute lymphoblastic leukemia
698445|NCT00003451|relapsing chronic myelogenous leukemia
698446|NCT00003451|refractory chronic lymphocytic leukemia
698447|NCT00003451|unspecified adult solid tumor, protocol specific
698448|NCT00003451|chronic phase chronic myelogenous leukemia
698449|NCT00003451|accelerated phase chronic myelogenous leukemia
698450|NCT00003451|blastic phase chronic myelogenous leukemia
698451|NCT00003451|meningeal chronic myelogenous leukemia
698452|NCT00003451|untreated adult acute lymphoblastic leukemia
698453|NCT00003451|untreated adult acute myeloid leukemia
698454|NCT00003451|adult acute myeloid leukemia in remission
698455|NCT00003451|adult acute lymphoblastic leukemia in remission
698456|NCT00003451|polycythemia vera
698457|NCT00003451|primary myelofibrosis
698458|NCT00003451|essential thrombocythemia
698459|NCT00003451|untreated hairy cell leukemia
698460|NCT00003451|progressive hairy cell leukemia, initial treatment
698461|NCT00003451|refractory hairy cell leukemia
698462|NCT00003451|chronic myelomonocytic leukemia
698463|NCT00003451|T-cell large granular lymphocyte leukemia
698464|NCT00003451|acute undifferentiated leukemia
698465|NCT00003451|stage III grade 1 follicular lymphoma
698466|NCT00003451|stage III grade 2 follicular lymphoma
698467|NCT00003451|stage III grade 3 follicular lymphoma
698468|NCT00003451|stage III adult diffuse small cleaved cell lymphoma
698469|NCT00003451|stage III adult diffuse mixed cell lymphoma
698470|NCT00003451|stage III adult diffuse large cell lymphoma
698471|NCT00003451|stage III adult immunoblastic large cell lymphoma
698472|NCT00003451|stage III adult lymphoblastic lymphoma
698473|NCT00003451|stage III adult Burkitt lymphoma
698474|NCT00003451|stage IV grade 1 follicular lymphoma
698475|NCT00003451|stage IV grade 2 follicular lymphoma
698476|NCT00003451|stage IV grade 3 follicular lymphoma
698477|NCT00003451|stage IV adult diffuse small cleaved cell lymphoma
698478|NCT00003451|stage IV adult diffuse mixed cell lymphoma
698479|NCT00003451|stage IV adult diffuse large cell lymphoma
698480|NCT00003451|stage IV adult immunoblastic large cell lymphoma
698481|NCT00003451|stage IV adult lymphoblastic lymphoma
698482|NCT00003451|stage IV adult Burkitt lymphoma
698483|NCT00003451|recurrent grade 1 follicular lymphoma
698484|NCT00003451|recurrent grade 2 follicular lymphoma
698485|NCT00003451|recurrent grade 3 follicular lymphoma
698486|NCT00003451|recurrent adult diffuse small cleaved cell lymphoma
698487|NCT00003451|recurrent adult diffuse mixed cell lymphoma
698488|NCT00003451|recurrent adult diffuse large cell lymphoma
698489|NCT00003451|recurrent adult immunoblastic large cell lymphoma
698490|NCT00003451|recurrent adult lymphoblastic lymphoma
698491|NCT00003451|recurrent adult Burkitt lymphoma
698492|NCT00003451|stage III adult T-cell leukemia/lymphoma
698493|NCT00003451|stage IV adult T-cell leukemia/lymphoma
698494|NCT00003451|recurrent adult T-cell leukemia/lymphoma
698495|NCT00003451|secondary acute myeloid leukemia
698496|NCT00003451|de novo myelodysplastic syndromes
698497|NCT00003451|previously treated myelodysplastic syndromes
698498|NCT00003451|secondary myelodysplastic syndromes
698499|NCT00003451|prolymphocytic leukemia
698500|NCT00003451|primary systemic amyloidosis
698501|NCT00003451|stage III mantle cell lymphoma
698502|NCT00003451|stage IV mantle cell lymphoma
698503|NCT00003451|recurrent mantle cell lymphoma
698504|NCT00003451|angioimmunoblastic T-cell lymphoma
698505|NCT00003451|anaplastic large cell lymphoma
698506|NCT00003451|recurrent marginal zone lymphoma
698507|NCT00003451|recurrent small lymphocytic lymphoma
698508|NCT00003451|stage III small lymphocytic lymphoma
698509|NCT00003451|stage III marginal zone lymphoma
698510|NCT00003451|stage IV small lymphocytic lymphoma
698511|NCT00003451|stage IV marginal zone lymphoma
698512|NCT00003451|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698513|NCT00003451|nodal marginal zone B-cell lymphoma
698514|NCT00003451|splenic marginal zone lymphoma
698515|NCT00003451|childhood myelodysplastic syndromes
698516|NCT00003450|stage IV ovarian epithelial cancer
698517|NCT00003450|recurrent ovarian epithelial cancer
698518|NCT00003450|peritoneal cavity cancer
698519|NCT00003449|recurrent ovarian epithelial cancer
698520|NCT00003447|stage IIIB non-small cell lung cancer
698521|NCT00003447|stage IV non-small cell lung cancer
698522|NCT00003446|stage IV colon cancer
698523|NCT00003446|stage IV rectal cancer
698524|NCT00003446|recurrent colon cancer
698525|NCT00003446|recurrent rectal cancer
698526|NCT00003445|stage III cervical cancer
698527|NCT00003445|stage IIB cervical cancer
698528|NCT00003445|stage IVA cervical cancer
698529|NCT00003445|cervical squamous cell carcinoma
698530|NCT00003444|stage III melanoma
698531|NCT00003444|stage IV melanoma
698532|NCT00003444|recurrent melanoma
698533|NCT00003443|stage IV squamous cell carcinoma of the lip and oral cavity
698534|NCT00003443|recurrent squamous cell carcinoma of the lip and oral cavity
698535|NCT00003443|stage IV squamous cell carcinoma of the oropharynx
698536|NCT00003443|recurrent squamous cell carcinoma of the oropharynx
698537|NCT00003443|stage IV squamous cell carcinoma of the nasopharynx
698538|NCT00003443|recurrent squamous cell carcinoma of the nasopharynx
698539|NCT00003443|stage IV squamous cell carcinoma of the hypopharynx
698540|NCT00003443|recurrent squamous cell carcinoma of the hypopharynx
698541|NCT00003443|stage IV squamous cell carcinoma of the larynx
698542|NCT00003443|recurrent squamous cell carcinoma of the larynx
698543|NCT00003443|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
698544|NCT00003443|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
698545|NCT00003441|stage IV colon cancer
698546|NCT00003441|stage IV rectal cancer
698547|NCT00003441|recurrent colon cancer
698548|NCT00003441|recurrent rectal cancer
698549|NCT00003441|adenocarcinoma of the colon
698550|NCT00003441|adenocarcinoma of the rectum
698551|NCT00003441|6-hydroxymethylacylfulvene
698552|NCT00003441|MGI-114
698553|NCT00003441|Irofulven
698554|NCT00003439|stage IV colon cancer
698555|NCT00003439|stage IV gastric cancer
698556|NCT00003439|recurrent gastric cancer
698557|NCT00003439|recurrent pancreatic cancer
698558|NCT00003439|stage IV rectal cancer
698559|NCT00003439|recurrent colon cancer
698560|NCT00003439|recurrent rectal cancer
698561|NCT00003439|stage IV anal cancer
698562|NCT00003439|recurrent anal cancer
698563|NCT00003439|stage IV ovarian epithelial cancer
698564|NCT00003439|recurrent ovarian epithelial cancer
698565|NCT00003439|metastatic gastrointestinal carcinoid tumor
698566|NCT00003439|recurrent gastrointestinal carcinoid tumor
698567|NCT00003439|advanced adult primary liver cancer
698568|NCT00003439|recurrent adult primary liver cancer
698569|NCT00003439|stage IV endometrial carcinoma
698570|NCT00003439|recurrent endometrial carcinoma
698571|NCT00003439|small intestine adenocarcinoma
698572|NCT00003439|unresectable gallbladder cancer
698573|NCT00003439|recurrent gallbladder cancer
698574|NCT00003439|unresectable extrahepatic bile duct cancer
698575|NCT00003439|recurrent extrahepatic bile duct cancer
698576|NCT00003439|recurrent small intestine cancer
698577|NCT00003439|stage IV prostate cancer
698578|NCT00003439|recurrent prostate cancer
698579|NCT00003439|fallopian tube cancer
698580|NCT00003439|primary peritoneal cavity cancer
698581|NCT00003439|stage IV pancreatic cancer
698582|NCT00003437|recurrent childhood acute lymphoblastic leukemia
698583|NCT00003437|untreated childhood acute lymphoblastic leukemia
698584|NCT00003436|untreated childhood acute myeloid leukemia and other myeloid malignancies
698585|NCT00003436|childhood acute promyelocytic leukemia (M3)
698586|NCT00003436|refractory anemia with excess blasts
698587|NCT00003436|refractory anemia with excess blasts in transformation
698588|NCT00003436|secondary acute myeloid leukemia
698589|NCT00003436|de novo myelodysplastic syndromes
698590|NCT00003436|secondary myelodysplastic syndromes
698591|NCT00003436|childhood myelodysplastic syndromes
698592|NCT00003435|recurrent adult acute lymphoblastic leukemia
698593|NCT00003435|secondary acute myeloid leukemia
698594|NCT00003435|AIDS-related peripheral/systemic lymphoma
698595|NCT00003435|HIV-associated Hodgkin lymphoma
698596|NCT00003434|stage I pancreatic cancer
698597|NCT00003434|stage II pancreatic cancer
698598|NCT00003434|stage III pancreatic cancer
698599|NCT00003434|adenocarcinoma of the pancreas
698600|NCT00003433|stage IV colon cancer
698601|NCT00003433|liver metastases
698602|NCT00003432|stage IV breast cancer
698603|NCT00003431|stage IV colon cancer
698604|NCT00003431|lung metastases
698605|NCT00003431|liver metastases
698606|NCT00003430|recurrent nasopharyngeal cancer
698607|NCT00003430|unspecified adult solid tumor, protocol specific
698608|NCT00003430|recurrent lip and oral cavity cancer
698609|NCT00003430|recurrent hypopharyngeal cancer
698610|NCT00003430|recurrent laryngeal cancer
698611|NCT00003430|recurrent paranasal sinus and nasal cavity cancer
698612|NCT00003430|recurrent oropharyngeal cancer
698613|NCT00003429|stage I cervical cancer
698614|NCT00003429|stage II cervical cancer
698615|NCT00003429|recurrent cervical cancer
698616|NCT00003428|stage IV breast cancer
698617|NCT00003428|recurrent breast cancer
698618|NCT00003427|stage IV colon cancer
698619|NCT00003427|stage IV gastric cancer
698620|NCT00003427|recurrent gastric cancer
698621|NCT00003427|recurrent pancreatic cancer
698622|NCT00003427|stage IV rectal cancer
698623|NCT00003427|recurrent colon cancer
698624|NCT00003427|recurrent rectal cancer
698625|NCT00003427|stage IV anal cancer
698626|NCT00003427|recurrent anal cancer
698627|NCT00003427|stage IV esophageal cancer
698628|NCT00003427|recurrent esophageal cancer
698629|NCT00003427|metastatic gastrointestinal carcinoid tumor
698630|NCT00003427|recurrent gastrointestinal carcinoid tumor
698631|NCT00003427|advanced adult primary liver cancer
698632|NCT00003427|recurrent adult primary liver cancer
698633|NCT00003427|unresectable gallbladder cancer
698634|NCT00003427|recurrent gallbladder cancer
698635|NCT00003427|unresectable extrahepatic bile duct cancer
698636|NCT00003427|recurrent extrahepatic bile duct cancer
698637|NCT00003427|recurrent small intestine cancer
698638|NCT00003427|stage IV pancreatic cancer
698639|NCT00003426|stage II pancreatic cancer
698640|NCT00003426|stage III pancreatic cancer
698641|NCT00003426|adenocarcinoma of the pancreas
698642|NCT00003425|stage III adult Hodgkin lymphoma
698643|NCT00003425|stage IV adult Hodgkin lymphoma
698644|NCT00003425|stage IV breast cancer
698645|NCT00003425|stage IIIA breast cancer
698646|NCT00003425|recurrent breast cancer
698647|NCT00003425|stage IIIB breast cancer
698648|NCT00003425|recurrent adult Hodgkin lymphoma
698649|NCT00003425|refractory multiple myeloma
698650|NCT00003425|stage III ovarian epithelial cancer
698651|NCT00003425|stage IV ovarian epithelial cancer
698652|NCT00003425|recurrent ovarian epithelial cancer
698653|NCT00003425|regional neuroblastoma
698654|NCT00003425|disseminated neuroblastoma
698655|NCT00003425|stage 4S neuroblastoma
698656|NCT00003425|recurrent neuroblastoma
698657|NCT00003425|stage III multiple myeloma
698658|NCT00003425|recurrent adult acute myeloid leukemia
698659|NCT00003425|recurrent adult acute lymphoblastic leukemia
698660|NCT00003425|unspecified adult solid tumor, protocol specific
698661|NCT00003425|untreated adult acute lymphoblastic leukemia
698662|NCT00003425|untreated adult acute myeloid leukemia
698663|NCT00003425|adult acute myeloid leukemia in remission
698664|NCT00003425|adult acute lymphoblastic leukemia in remission
698665|NCT00003425|ovarian stromal cancer
698666|NCT00003425|stage III ovarian germ cell tumor
698667|NCT00003425|stage IV ovarian germ cell tumor
698668|NCT00003425|recurrent ovarian germ cell tumor
698669|NCT00003425|acute undifferentiated leukemia
698670|NCT00003425|stage III grade 1 follicular lymphoma
698671|NCT00003425|stage III grade 2 follicular lymphoma
698672|NCT00003425|stage III grade 3 follicular lymphoma
698673|NCT00003425|stage III adult diffuse small cleaved cell lymphoma
698674|NCT00003425|stage III adult diffuse mixed cell lymphoma
698675|NCT00003425|stage III adult diffuse large cell lymphoma
698676|NCT00003425|stage III adult immunoblastic large cell lymphoma
698677|NCT00003425|stage III adult lymphoblastic lymphoma
698678|NCT00003425|stage III adult Burkitt lymphoma
698679|NCT00003425|stage IV grade 1 follicular lymphoma
698680|NCT00003425|stage IV grade 2 follicular lymphoma
698681|NCT00003425|stage IV grade 3 follicular lymphoma
698682|NCT00003425|stage IV adult diffuse small cleaved cell lymphoma
698683|NCT00003425|stage IV adult diffuse mixed cell lymphoma
698684|NCT00003425|stage IV adult diffuse large cell lymphoma
698685|NCT00003425|stage IV adult immunoblastic large cell lymphoma
698686|NCT00003425|stage IV adult lymphoblastic lymphoma
698687|NCT00003425|stage IV adult Burkitt lymphoma
698688|NCT00003425|recurrent grade 1 follicular lymphoma
698689|NCT00003425|recurrent grade 2 follicular lymphoma
698690|NCT00003425|recurrent grade 3 follicular lymphoma
698691|NCT00003425|recurrent adult diffuse small cleaved cell lymphoma
698692|NCT00003425|recurrent adult diffuse mixed cell lymphoma
698693|NCT00003425|recurrent adult diffuse large cell lymphoma
698694|NCT00003425|recurrent adult immunoblastic large cell lymphoma
698695|NCT00003425|recurrent adult lymphoblastic lymphoma
698696|NCT00003425|recurrent adult Burkitt lymphoma
698697|NCT00003425|secondary acute myeloid leukemia
698698|NCT00003425|borderline ovarian surface epithelial-stromal tumor
698699|NCT00003425|ovarian sarcoma
698700|NCT00003425|localized unresectable neuroblastoma
698701|NCT00003425|stage III mantle cell lymphoma
698702|NCT00003425|stage IV mantle cell lymphoma
698703|NCT00003425|recurrent mantle cell lymphoma
698704|NCT00003425|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
698705|NCT00003425|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
698706|NCT00003425|recurrent marginal zone lymphoma
698707|NCT00003425|recurrent small lymphocytic lymphoma
698708|NCT00003425|stage III small lymphocytic lymphoma
698709|NCT00003425|stage III marginal zone lymphoma
698710|NCT00003425|stage IV small lymphocytic lymphoma
698711|NCT00003425|stage IV marginal zone lymphoma
698712|NCT00003425|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698713|NCT00003425|nodal marginal zone B-cell lymphoma
698714|NCT00003425|splenic marginal zone lymphoma
698715|NCT00003424|localized unresectable adult primary liver cancer
698716|NCT00003424|advanced adult primary liver cancer
698717|NCT00003424|adult primary hepatocellular carcinoma
698718|NCT00003423|stage I childhood lymphoblastic lymphoma
698719|NCT00003423|stage II childhood lymphoblastic lymphoma
698720|NCT00003423|stage III childhood lymphoblastic lymphoma
698721|NCT00003423|stage IV childhood lymphoblastic lymphoma
698722|NCT00003423|stage I childhood large cell lymphoma
698723|NCT00003423|stage II childhood large cell lymphoma
698724|NCT00003423|stage III childhood large cell lymphoma
698725|NCT00003423|stage IV childhood large cell lymphoma
698726|NCT00003422|stage I rectal cancer
698727|NCT00003422|stage II rectal cancer
698728|NCT00003422|stage III rectal cancer
698729|NCT00003422|adenocarcinoma of the rectum
698730|NCT00003421|stage I adult Hodgkin lymphoma
698731|NCT00003421|stage II adult Hodgkin lymphoma
698732|NCT00003421|stage III adult Hodgkin lymphoma
698733|NCT00003421|stage IV adult Hodgkin lymphoma
698734|NCT00003420|stage I malignant testicular germ cell tumor
698735|NCT00003420|testicular teratoma
698736|NCT00003419|AIDS-related Kaposi sarcoma
698737|NCT00003418|stage I breast cancer
698738|NCT00003418|stage II breast cancer
698739|NCT00003418|stage III breast cancer
698740|NCT00003417|adult glioblastoma
698741|NCT00003417|adult giant cell glioblastoma
698742|NCT00003417|adult gliosarcoma
698743|NCT00003416|Waldenström macroglobulinemia
698744|NCT00003415|refractory anemia with excess blasts
698745|NCT00003415|refractory anemia with excess blasts in transformation
698746|NCT00003415|chronic myelomonocytic leukemia
698747|NCT00003415|de novo myelodysplastic syndromes
698748|NCT00003415|previously treated myelodysplastic syndromes
698749|NCT00003414|recurrent adult Hodgkin lymphoma
698750|NCT00003414|recurrent childhood lymphoblastic lymphoma
698751|NCT00003414|recurrent/refractory childhood Hodgkin lymphoma
698752|NCT00003414|recurrent grade 1 follicular lymphoma
698753|NCT00003414|recurrent grade 2 follicular lymphoma
698754|NCT00003414|recurrent grade 3 follicular lymphoma
698755|NCT00003414|recurrent adult diffuse small cleaved cell lymphoma
698756|NCT00003414|recurrent adult diffuse mixed cell lymphoma
698757|NCT00003414|recurrent adult diffuse large cell lymphoma
698758|NCT00003414|recurrent adult immunoblastic large cell lymphoma
698759|NCT00003414|recurrent adult lymphoblastic lymphoma
698760|NCT00003414|recurrent adult Burkitt lymphoma
698761|NCT00003414|graft versus host disease
698762|NCT00003414|recurrent childhood small noncleaved cell lymphoma
698763|NCT00003414|recurrent childhood large cell lymphoma
698764|NCT00003414|recurrent mantle cell lymphoma
698765|NCT00003414|recurrent marginal zone lymphoma
698766|NCT00003414|recurrent small lymphocytic lymphoma
698767|NCT00003414|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698768|NCT00003414|nodal marginal zone B-cell lymphoma
698769|NCT00003414|splenic marginal zone lymphoma
698770|NCT00003413|stage III ovarian epithelial cancer
698771|NCT00003413|stage IV ovarian epithelial cancer
698772|NCT00003413|recurrent ovarian epithelial cancer
698773|NCT00003412|stage IV breast cancer
698774|NCT00003412|recurrent breast cancer
698775|NCT00003411|stage II pancreatic cancer
698776|NCT00003411|stage III pancreatic cancer
698777|NCT00003411|unresectable gallbladder cancer
698778|NCT00003411|unresectable extrahepatic bile duct cancer
698779|NCT00003411|stage IV pancreatic cancer
698780|NCT00003410|adult glioblastoma
698781|NCT00003410|adult giant cell glioblastoma
698782|NCT00003410|adult gliosarcoma
698783|NCT00003409|adult glioblastoma
698784|NCT00003409|adult giant cell glioblastoma
698785|NCT00003409|adult gliosarcoma
698786|NCT00003408|stage IV breast cancer
698787|NCT00003408|recurrent childhood acute lymphoblastic leukemia
698788|NCT00003408|recurrent adult Hodgkin lymphoma
698789|NCT00003408|recurrent cutaneous T-cell non-Hodgkin lymphoma
698790|NCT00003408|refractory multiple myeloma
698791|NCT00003408|recurrent childhood rhabdomyosarcoma
698792|NCT00003408|stage II ovarian epithelial cancer
698793|NCT00003408|stage III ovarian epithelial cancer
698794|NCT00003408|stage IV ovarian epithelial cancer
698795|NCT00003408|recurrent ovarian epithelial cancer
698796|NCT00003408|disseminated neuroblastoma
698797|NCT00003408|recurrent neuroblastoma
698798|NCT00003408|recurrent Wilms tumor and other childhood kidney tumors
698799|NCT00003408|stage I multiple myeloma
698800|NCT00003408|stage II multiple myeloma
698801|NCT00003408|stage III multiple myeloma
698802|NCT00003408|recurrent childhood lymphoblastic lymphoma
698803|NCT00003408|stage III chronic lymphocytic leukemia
698804|NCT00003408|stage IV chronic lymphocytic leukemia
698805|NCT00003408|recurrent childhood acute myeloid leukemia
698806|NCT00003408|recurrent adult acute myeloid leukemia
698807|NCT00003408|recurrent adult acute lymphoblastic leukemia
698808|NCT00003408|relapsing chronic myelogenous leukemia
698809|NCT00003408|refractory chronic lymphocytic leukemia
698810|NCT00003408|stage III malignant testicular germ cell tumor
698811|NCT00003408|recurrent malignant testicular germ cell tumor
698812|NCT00003408|chronic phase chronic myelogenous leukemia
698813|NCT00003408|accelerated phase chronic myelogenous leukemia
698814|NCT00003408|blastic phase chronic myelogenous leukemia
698815|NCT00003408|meningeal chronic myelogenous leukemia
698816|NCT00003408|chronic idiopathic myelofibrosis
698817|NCT00003408|childhood acute promyelocytic leukemia (M3)
698818|NCT00003408|testicular embryonal carcinoma
698819|NCT00003408|testicular choriocarcinoma
698820|NCT00003408|testicular teratoma
698821|NCT00003408|testicular yolk sac tumor
698822|NCT00003408|testicular embryonal carcinoma and teratoma
698823|NCT00003408|testicular embryonal carcinoma and teratoma with seminoma
698824|NCT00003408|testicular embryonal carcinoma and yolk sac tumor
698825|NCT00003408|testicular embryonal carcinoma and yolk sac tumor with seminoma
698826|NCT00003408|testicular embryonal carcinoma and seminoma
698827|NCT00003408|testicular yolk sac tumor and teratoma
698828|NCT00003408|testicular yolk sac tumor and teratoma with seminoma
698829|NCT00003408|testicular choriocarcinoma and yolk sac tumor
698830|NCT00003408|testicular choriocarcinoma and embryonal carcinoma
698831|NCT00003408|testicular choriocarcinoma and teratoma
698832|NCT00003408|testicular choriocarcinoma and seminoma
698833|NCT00003408|refractory hairy cell leukemia
698834|NCT00003408|recurrent/refractory childhood Hodgkin lymphoma
698835|NCT00003408|recurrent ovarian germ cell tumor
698836|NCT00003408|ovarian yolk sac tumor
698837|NCT00003408|ovarian embryonal carcinoma
698838|NCT00003408|ovarian polyembryoma
698839|NCT00003408|ovarian choriocarcinoma
698840|NCT00003408|ovarian immature teratoma
698841|NCT00003408|ovarian mature teratoma
698842|NCT00003408|ovarian monodermal and highly specialized teratoma
698843|NCT00003408|ovarian mixed germ cell tumor
698844|NCT00003408|stage III grade 1 follicular lymphoma
698845|NCT00003408|stage III grade 2 follicular lymphoma
698846|NCT00003408|stage III grade 3 follicular lymphoma
698847|NCT00003408|stage III adult diffuse small cleaved cell lymphoma
698848|NCT00003408|stage III adult diffuse mixed cell lymphoma
698849|NCT00003408|stage III adult diffuse large cell lymphoma
698850|NCT00003408|stage III adult immunoblastic large cell lymphoma
698851|NCT00003408|stage III adult lymphoblastic lymphoma
698852|NCT00003408|stage III adult Burkitt lymphoma
698853|NCT00003408|stage IV grade 1 follicular lymphoma
698854|NCT00003408|stage IV grade 2 follicular lymphoma
698855|NCT00003408|stage IV grade 3 follicular lymphoma
698856|NCT00003408|stage IV adult diffuse small cleaved cell lymphoma
698857|NCT00003408|stage IV adult diffuse mixed cell lymphoma
698858|NCT00003408|stage IV adult diffuse large cell lymphoma
698859|NCT00003408|stage IV adult immunoblastic large cell lymphoma
698860|NCT00003408|stage IV adult lymphoblastic lymphoma
698861|NCT00003408|stage IV adult Burkitt lymphoma
698862|NCT00003408|recurrent grade 1 follicular lymphoma
698863|NCT00003408|recurrent grade 2 follicular lymphoma
698864|NCT00003408|recurrent grade 3 follicular lymphoma
698865|NCT00003408|recurrent adult diffuse small cleaved cell lymphoma
698866|NCT00003408|recurrent adult diffuse mixed cell lymphoma
698867|NCT00003408|recurrent adult diffuse large cell lymphoma
698868|NCT00003408|recurrent adult immunoblastic large cell lymphoma
698869|NCT00003408|recurrent adult lymphoblastic lymphoma
698870|NCT00003408|recurrent adult Burkitt lymphoma
698871|NCT00003408|secondary acute myeloid leukemia
698872|NCT00003408|de novo myelodysplastic syndromes
698873|NCT00003408|poor prognosis metastatic gestational trophoblastic tumor
698874|NCT00003408|previously treated myelodysplastic syndromes
698875|NCT00003408|secondary myelodysplastic syndromes
698876|NCT00003408|recurrent childhood small noncleaved cell lymphoma
698877|NCT00003408|recurrent childhood large cell lymphoma
698878|NCT00003408|noncontiguous stage II grade 1 follicular lymphoma
698879|NCT00003408|noncontiguous stage II grade 2 follicular lymphoma
698880|NCT00003408|noncontiguous stage II grade 3 follicular lymphoma
698881|NCT00003408|noncontiguous stage II adult diffuse small cleaved cell lymphoma
698882|NCT00003408|noncontiguous stage II mantle cell lymphoma
698883|NCT00003408|noncontiguous stage II adult diffuse mixed cell lymphoma
698884|NCT00003408|noncontiguous stage II adult immunoblastic large cell lymphoma
698885|NCT00003408|noncontiguous stage II adult diffuse large cell lymphoma
698886|NCT00003408|noncontiguous stage II adult Burkitt lymphoma
698887|NCT00003408|noncontiguous stage II adult lymphoblastic lymphoma
698888|NCT00003408|stage III mantle cell lymphoma
698889|NCT00003408|stage IV mantle cell lymphoma
698890|NCT00003408|recurrent mantle cell lymphoma
698891|NCT00003408|previously treated childhood rhabdomyosarcoma
698892|NCT00003408|recurrent mycosis fungoides/Sezary syndrome
698893|NCT00003408|noncontiguous stage II small lymphocytic lymphoma
698894|NCT00003408|noncontiguous stage II marginal zone lymphoma
698895|NCT00003408|recurrent marginal zone lymphoma
698896|NCT00003408|recurrent small lymphocytic lymphoma
698897|NCT00003408|stage III small lymphocytic lymphoma
698898|NCT00003408|stage III marginal zone lymphoma
698899|NCT00003408|stage IV small lymphocytic lymphoma
698900|NCT00003408|stage IV marginal zone lymphoma
698901|NCT00003408|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698902|NCT00003408|nodal marginal zone B-cell lymphoma
698903|NCT00003408|splenic marginal zone lymphoma
698904|NCT00003408|childhood myelodysplastic syndromes
698905|NCT00003407|recurrent adult acute myeloid leukemia
698906|NCT00003407|blastic phase chronic myelogenous leukemia
698907|NCT00003407|untreated adult acute myeloid leukemia
698908|NCT00003407|refractory anemia with excess blasts in transformation
698909|NCT00003407|secondary acute myeloid leukemia
698910|NCT00003407|de novo myelodysplastic syndromes
698911|NCT00003407|secondary myelodysplastic syndromes
698912|NCT00003407|drug/agent toxicity by tissue/organ
698913|NCT00003407|neutropenia
698914|NCT00003406|stage III adult Hodgkin lymphoma
698915|NCT00003406|stage IV adult Hodgkin lymphoma
698916|NCT00003406|monoclonal gammopathy of undetermined significance
698917|NCT00003406|recurrent adult Hodgkin lymphoma
698918|NCT00003406|isolated plasmacytoma of bone
698919|NCT00003406|extramedullary plasmacytoma
698920|NCT00003406|refractory multiple myeloma
698921|NCT00003406|Waldenstrom macroglobulinemia
698922|NCT00003406|stage III multiple myeloma
698923|NCT00003406|stage III chronic lymphocytic leukemia
698924|NCT00003406|stage IV chronic lymphocytic leukemia
698925|NCT00003406|recurrent adult acute myeloid leukemia
698926|NCT00003406|recurrent adult acute lymphoblastic leukemia
698927|NCT00003406|relapsing chronic myelogenous leukemia
698928|NCT00003406|refractory chronic lymphocytic leukemia
698929|NCT00003406|unspecified adult solid tumor, protocol specific
698930|NCT00003406|chronic phase chronic myelogenous leukemia
698931|NCT00003406|accelerated phase chronic myelogenous leukemia
698932|NCT00003406|blastic phase chronic myelogenous leukemia
698933|NCT00003406|meningeal chronic myelogenous leukemia
698934|NCT00003406|adult acute myeloid leukemia in remission
698935|NCT00003406|adult acute lymphoblastic leukemia in remission
698936|NCT00003406|polycythemia vera
698937|NCT00003406|chronic idiopathic myelofibrosis
698938|NCT00003406|essential thrombocythemia
698939|NCT00003406|progressive hairy cell leukemia, initial treatment
698940|NCT00003406|refractory hairy cell leukemia
698941|NCT00003406|chronic myelomonocytic leukemia
698942|NCT00003406|T-cell large granular lymphocyte leukemia
698943|NCT00003406|acute undifferentiated leukemia
698944|NCT00003406|stage III grade 1 follicular lymphoma
698945|NCT00003406|stage III grade 2 follicular lymphoma
698946|NCT00003406|stage III grade 3 follicular lymphoma
698947|NCT00003406|stage III adult diffuse small cleaved cell lymphoma
698948|NCT00003406|stage III adult diffuse mixed cell lymphoma
698949|NCT00003406|stage III adult diffuse large cell lymphoma
698950|NCT00003406|stage III adult immunoblastic large cell lymphoma
698951|NCT00003406|stage III adult lymphoblastic lymphoma
698952|NCT00003406|stage III adult Burkitt lymphoma
698953|NCT00003406|stage IV grade 1 follicular lymphoma
698954|NCT00003406|stage IV grade 2 follicular lymphoma
698955|NCT00003406|stage IV grade 3 follicular lymphoma
698956|NCT00003406|stage IV adult diffuse small cleaved cell lymphoma
698957|NCT00003406|stage IV adult diffuse mixed cell lymphoma
698958|NCT00003406|stage IV adult diffuse large cell lymphoma
698959|NCT00003406|stage IV adult immunoblastic large cell lymphoma
698960|NCT00003406|stage IV adult lymphoblastic lymphoma
698961|NCT00003406|stage IV adult Burkitt lymphoma
698962|NCT00003406|recurrent grade 1 follicular lymphoma
698963|NCT00003406|recurrent grade 2 follicular lymphoma
698964|NCT00003406|recurrent grade 3 follicular lymphoma
698965|NCT00003406|recurrent adult diffuse small cleaved cell lymphoma
698966|NCT00003406|recurrent adult diffuse mixed cell lymphoma
698967|NCT00003406|recurrent adult diffuse large cell lymphoma
698968|NCT00003406|recurrent adult immunoblastic large cell lymphoma
698969|NCT00003406|recurrent adult lymphoblastic lymphoma
698970|NCT00003406|recurrent adult Burkitt lymphoma
698971|NCT00003406|stage III adult T-cell leukemia/lymphoma
698972|NCT00003406|stage IV adult T-cell leukemia/lymphoma
698973|NCT00003406|recurrent adult T-cell leukemia/lymphoma
698974|NCT00003406|secondary acute myeloid leukemia
698975|NCT00003406|de novo myelodysplastic syndromes
698976|NCT00003406|previously treated myelodysplastic syndromes
698977|NCT00003406|secondary myelodysplastic syndromes
698978|NCT00003406|prolymphocytic leukemia
698979|NCT00003406|AIDS-related peripheral/systemic lymphoma
698980|NCT00003406|AIDS-related primary CNS lymphoma
698981|NCT00003406|primary systemic amyloidosis
698982|NCT00003406|non-Hodgkin lymphoma during pregnancy
698983|NCT00003406|stage III mantle cell lymphoma
698984|NCT00003406|stage IV mantle cell lymphoma
698985|NCT00003406|recurrent mantle cell lymphoma
698986|NCT00003406|angioimmunoblastic T-cell lymphoma
698987|NCT00003406|anaplastic large cell lymphoma
698988|NCT00003406|recurrent marginal zone lymphoma
698989|NCT00003406|recurrent small lymphocytic lymphoma
698990|NCT00003406|stage III small lymphocytic lymphoma
698991|NCT00003406|stage III marginal zone lymphoma
698992|NCT00003406|stage IV small lymphocytic lymphoma
698993|NCT00003406|stage IV marginal zone lymphoma
698994|NCT00003406|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
698995|NCT00003406|nodal marginal zone B-cell lymphoma
698996|NCT00003406|splenic marginal zone lymphoma
698997|NCT00003406|childhood myelodysplastic syndromes
698998|NCT00003405|untreated adult acute myeloid leukemia
698999|NCT00003405|untreated childhood acute myeloid leukemia and other myeloid malignancies
699000|NCT00003405|adult acute erythroid leukemia (M6)
699001|NCT00003405|adult acute myeloblastic leukemia without maturation (M1)
699002|NCT00003405|adult acute myeloblastic leukemia with maturation (M2)
699003|NCT00003405|adult acute myelomonocytic leukemia (M4)
699004|NCT00003405|adult acute monoblastic leukemia (M5a)
699005|NCT00003405|adult acute megakaryoblastic leukemia (M7)
699006|NCT00003405|childhood acute myeloblastic leukemia without maturation (M1)
699007|NCT00003405|childhood acute myeloblastic leukemia with maturation (M2)
699008|NCT00003405|childhood acute myelomonocytic leukemia (M4)
699009|NCT00003405|childhood acute monoblastic leukemia (M5a)
699010|NCT00003405|childhood acute monocytic leukemia (M5b)
699011|NCT00003405|childhood acute erythroleukemia (M6)
699012|NCT00003405|childhood acute megakaryocytic leukemia (M7)
699013|NCT00003405|adult acute monocytic leukemia (M5b)
699014|NCT00003404|recurrent breast cancer
699015|NCT00003404|phyllodes tumor
699016|NCT00003403|unspecified adult solid tumor, protocol specific
699017|NCT00003402|Waldenstrom macroglobulinemia
699018|NCT00003402|stage III chronic lymphocytic leukemia
699019|NCT00003402|stage IV chronic lymphocytic leukemia
699020|NCT00003402|refractory chronic lymphocytic leukemia
699021|NCT00003402|stage III grade 1 follicular lymphoma
699022|NCT00003402|stage III grade 2 follicular lymphoma
699023|NCT00003402|stage IV grade 1 follicular lymphoma
699024|NCT00003402|stage IV grade 2 follicular lymphoma
699025|NCT00003402|recurrent grade 1 follicular lymphoma
699026|NCT00003402|recurrent grade 2 follicular lymphoma
699027|NCT00003402|stage III mantle cell lymphoma
699028|NCT00003402|stage IV mantle cell lymphoma
699029|NCT00003402|recurrent mantle cell lymphoma
699030|NCT00003401|refractory multiple myeloma
699031|NCT00003401|stage I multiple myeloma
699032|NCT00003401|stage II multiple myeloma
699033|NCT00003401|stage III multiple myeloma
699034|NCT00003400|adenocarcinoma of the prostate
699035|NCT00003400|stage IV prostate cancer
699036|NCT00003400|recurrent prostate cancer
699037|NCT00003399|refractory multiple myeloma
699038|NCT00003399|stage I multiple myeloma
699039|NCT00003399|stage II multiple myeloma
699040|NCT00003399|stage III multiple myeloma
699041|NCT00003398|stage III adult Hodgkin lymphoma
699042|NCT00003398|stage IV adult Hodgkin lymphoma
699043|NCT00003398|recurrent childhood acute lymphoblastic leukemia
699044|NCT00003398|recurrent adult Hodgkin lymphoma
699045|NCT00003398|Burkitt lymphoma
699046|NCT00003398|refractory multiple myeloma
699047|NCT00003398|Waldenstrom macroglobulinemia
699048|NCT00003398|stage I multiple myeloma
699049|NCT00003398|stage II multiple myeloma
699050|NCT00003398|stage III multiple myeloma
699051|NCT00003398|stage I childhood lymphoblastic lymphoma
699052|NCT00003398|stage II childhood lymphoblastic lymphoma
699053|NCT00003398|stage III childhood lymphoblastic lymphoma
699054|NCT00003398|stage IV childhood lymphoblastic lymphoma
699055|NCT00003398|recurrent childhood lymphoblastic lymphoma
699056|NCT00003398|stage I chronic lymphocytic leukemia
699057|NCT00003398|stage II chronic lymphocytic leukemia
699058|NCT00003398|stage III chronic lymphocytic leukemia
699059|NCT00003398|stage IV chronic lymphocytic leukemia
699060|NCT00003398|recurrent childhood acute myeloid leukemia
699061|NCT00003398|recurrent adult acute myeloid leukemia
699062|NCT00003398|recurrent adult acute lymphoblastic leukemia
699063|NCT00003398|refractory chronic lymphocytic leukemia
699064|NCT00003398|childhood diffuse large cell lymphoma
699065|NCT00003398|childhood immunoblastic large cell lymphoma
699066|NCT00003398|chronic phase chronic myelogenous leukemia
699067|NCT00003398|accelerated phase chronic myelogenous leukemia
699068|NCT00003398|blastic phase chronic myelogenous leukemia
699069|NCT00003398|meningeal chronic myelogenous leukemia
699070|NCT00003398|adult acute myeloid leukemia in remission
699071|NCT00003398|adult acute lymphoblastic leukemia in remission
699072|NCT00003398|childhood acute myeloid leukemia in remission
699073|NCT00003398|childhood acute lymphoblastic leukemia in remission
699074|NCT00003398|adult acute myeloblastic leukemia without maturation (M1)
699075|NCT00003398|adult acute myeloblastic leukemia with maturation (M2)
699076|NCT00003398|adult acute promyelocytic leukemia (M3)
699077|NCT00003398|adult acute myelomonocytic leukemia (M4)
699078|NCT00003398|adult acute eosinophilic leukemia
699079|NCT00003398|adult acute basophilic leukemia
699080|NCT00003398|adult acute megakaryoblastic leukemia (M7)
699081|NCT00003398|childhood acute myeloblastic leukemia with maturation (M2)
699082|NCT00003398|childhood acute promyelocytic leukemia (M3)
699083|NCT00003398|childhood acute myelomonocytic leukemia (M4)
699084|NCT00003398|childhood acute eosinophilic leukemia
699085|NCT00003398|childhood acute basophilic leukemia
699086|NCT00003398|childhood acute megakaryocytic leukemia (M7)
699087|NCT00003398|stage III childhood Hodgkin lymphoma
699088|NCT00003398|stage IV childhood Hodgkin lymphoma
699089|NCT00003398|recurrent/refractory childhood Hodgkin lymphoma
699090|NCT00003398|stage I grade 1 follicular lymphoma
699091|NCT00003398|stage I grade 2 follicular lymphoma
699092|NCT00003398|stage I grade 3 follicular lymphoma
699093|NCT00003398|stage I adult diffuse small cleaved cell lymphoma
699094|NCT00003398|stage I adult diffuse mixed cell lymphoma
699095|NCT00003398|stage I adult diffuse large cell lymphoma
699096|NCT00003398|stage I adult immunoblastic large cell lymphoma
699097|NCT00003398|stage I adult lymphoblastic lymphoma
699098|NCT00003398|stage I adult Burkitt lymphoma
699099|NCT00003398|stage III grade 1 follicular lymphoma
699100|NCT00003398|stage III grade 2 follicular lymphoma
699101|NCT00003398|stage III grade 3 follicular lymphoma
699102|NCT00003398|stage III adult diffuse small cleaved cell lymphoma
699103|NCT00003398|stage III adult diffuse mixed cell lymphoma
699104|NCT00003398|stage III adult diffuse large cell lymphoma
699105|NCT00003398|stage III adult immunoblastic large cell lymphoma
699106|NCT00003398|stage III adult lymphoblastic lymphoma
699107|NCT00003398|stage III adult Burkitt lymphoma
699108|NCT00003398|stage IV grade 1 follicular lymphoma
699109|NCT00003398|stage IV grade 2 follicular lymphoma
699110|NCT00003398|stage IV grade 3 follicular lymphoma
699111|NCT00003398|stage IV adult diffuse small cleaved cell lymphoma
699112|NCT00003398|stage IV adult diffuse mixed cell lymphoma
699113|NCT00003398|stage IV adult diffuse large cell lymphoma
699114|NCT00003398|stage IV adult immunoblastic large cell lymphoma
699115|NCT00003398|stage IV adult lymphoblastic lymphoma
699116|NCT00003398|stage IV adult Burkitt lymphoma
699117|NCT00003398|recurrent adult diffuse small cleaved cell lymphoma
699118|NCT00003398|recurrent adult diffuse mixed cell lymphoma
699119|NCT00003398|recurrent adult diffuse large cell lymphoma
699120|NCT00003398|recurrent adult immunoblastic large cell lymphoma
699121|NCT00003398|recurrent adult lymphoblastic lymphoma
699122|NCT00003398|recurrent adult Burkitt lymphoma
699123|NCT00003398|de novo myelodysplastic syndromes
699124|NCT00003398|previously treated myelodysplastic syndromes
699125|NCT00003398|secondary myelodysplastic syndromes
699126|NCT00003398|anemia
699127|NCT00003398|graft versus host disease
699128|NCT00003398|adult acute minimally differentiated myeloid leukemia (M0)
699129|NCT00003398|childhood acute minimally differentiated myeloid leukemia (M0)
700745|NCT00003193|oral complications
699130|NCT00003398|stage I childhood small noncleaved cell lymphoma
699131|NCT00003398|stage I childhood large cell lymphoma
699132|NCT00003398|stage II childhood small noncleaved cell lymphoma
699133|NCT00003398|stage II childhood large cell lymphoma
699134|NCT00003398|stage III childhood small noncleaved cell lymphoma
699135|NCT00003398|stage III childhood large cell lymphoma
699136|NCT00003398|stage IV childhood small noncleaved cell lymphoma
699137|NCT00003398|stage IV childhood large cell lymphoma
699138|NCT00003398|recurrent childhood small noncleaved cell lymphoma
699139|NCT00003398|recurrent childhood large cell lymphoma
699140|NCT00003398|stage I mantle cell lymphoma
699141|NCT00003398|contiguous stage II grade 1 follicular lymphoma
699142|NCT00003398|contiguous stage II grade 2 follicular lymphoma
699143|NCT00003398|contiguous stage II grade 3 follicular lymphoma
699144|NCT00003398|contiguous stage II adult diffuse small cleaved cell lymphoma
699145|NCT00003398|contiguous stage II mantle cell lymphoma
699146|NCT00003398|contiguous stage II adult diffuse mixed cell lymphoma
699147|NCT00003398|contiguous stage II adult immunoblastic large cell lymphoma
699148|NCT00003398|contiguous stage II adult diffuse large cell lymphoma
699149|NCT00003398|contiguous stage II adult Burkitt lymphoma
699150|NCT00003398|contiguous stage II adult lymphoblastic lymphoma
699151|NCT00003398|noncontiguous stage II grade 1 follicular lymphoma
699152|NCT00003398|noncontiguous stage II grade 2 follicular lymphoma
699153|NCT00003398|noncontiguous stage II grade 3 follicular lymphoma
699154|NCT00003398|noncontiguous stage II adult diffuse small cleaved cell lymphoma
699155|NCT00003398|noncontiguous stage II mantle cell lymphoma
699156|NCT00003398|noncontiguous stage II adult diffuse mixed cell lymphoma
699157|NCT00003398|noncontiguous stage II adult immunoblastic large cell lymphoma
699158|NCT00003398|noncontiguous stage II adult diffuse large cell lymphoma
699159|NCT00003398|noncontiguous stage II adult Burkitt lymphoma
699160|NCT00003398|noncontiguous stage II adult lymphoblastic lymphoma
699161|NCT00003398|stage III mantle cell lymphoma
699162|NCT00003398|stage IV mantle cell lymphoma
699163|NCT00003398|recurrent mantle cell lymphoma
699164|NCT00003398|noncontiguous stage II small lymphocytic lymphoma
699165|NCT00003398|noncontiguous stage II marginal zone lymphoma
699166|NCT00003398|recurrent marginal zone lymphoma
699167|NCT00003398|recurrent small lymphocytic lymphoma
699168|NCT00003398|stage I marginal zone lymphoma
699169|NCT00003398|stage I small lymphocytic lymphoma
699170|NCT00003398|stage III small lymphocytic lymphoma
699171|NCT00003398|stage III marginal zone lymphoma
699172|NCT00003398|stage IV small lymphocytic lymphoma
699173|NCT00003398|stage IV marginal zone lymphoma
699174|NCT00003398|contiguous stage II marginal zone lymphoma
699175|NCT00003398|contiguous stage II small lymphocytic lymphoma
699176|NCT00003398|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699177|NCT00003398|nodal marginal zone B-cell lymphoma
699178|NCT00003398|splenic marginal zone lymphoma
699179|NCT00003398|childhood myelodysplastic syndromes
699180|NCT00003397|stage I grade 3 follicular lymphoma
699181|NCT00003397|stage I adult diffuse small cleaved cell lymphoma
699182|NCT00003397|stage I adult diffuse mixed cell lymphoma
699183|NCT00003397|stage I adult diffuse large cell lymphoma
699184|NCT00003397|stage I adult immunoblastic large cell lymphoma
699185|NCT00003397|stage I adult lymphoblastic lymphoma
699186|NCT00003397|stage I adult Burkitt lymphoma
699187|NCT00003397|stage III grade 3 follicular lymphoma
699188|NCT00003397|stage III adult diffuse small cleaved cell lymphoma
699189|NCT00003397|stage III adult diffuse mixed cell lymphoma
699190|NCT00003397|stage III adult diffuse large cell lymphoma
699191|NCT00003397|stage III adult immunoblastic large cell lymphoma
699192|NCT00003397|stage III adult lymphoblastic lymphoma
699193|NCT00003397|stage III adult Burkitt lymphoma
699194|NCT00003397|stage IV grade 3 follicular lymphoma
699195|NCT00003397|stage IV adult diffuse small cleaved cell lymphoma
699196|NCT00003397|stage IV adult diffuse mixed cell lymphoma
699197|NCT00003397|stage IV adult diffuse large cell lymphoma
699198|NCT00003397|stage IV adult immunoblastic large cell lymphoma
699199|NCT00003397|stage IV adult lymphoblastic lymphoma
699200|NCT00003397|stage IV adult Burkitt lymphoma
699201|NCT00003397|recurrent grade 3 follicular lymphoma
699202|NCT00003397|recurrent adult diffuse small cleaved cell lymphoma
699203|NCT00003397|recurrent adult diffuse mixed cell lymphoma
699204|NCT00003397|recurrent adult diffuse large cell lymphoma
699205|NCT00003397|recurrent adult immunoblastic large cell lymphoma
699206|NCT00003397|recurrent adult lymphoblastic lymphoma
699207|NCT00003397|recurrent adult Burkitt lymphoma
699208|NCT00003397|stage I mantle cell lymphoma
699209|NCT00003397|contiguous stage II grade 3 follicular lymphoma
699210|NCT00003397|contiguous stage II adult diffuse small cleaved cell lymphoma
699211|NCT00003397|contiguous stage II mantle cell lymphoma
699212|NCT00003397|contiguous stage II adult diffuse mixed cell lymphoma
699213|NCT00003397|contiguous stage II adult immunoblastic large cell lymphoma
699214|NCT00003397|contiguous stage II adult diffuse large cell lymphoma
699215|NCT00003397|contiguous stage II adult Burkitt lymphoma
699216|NCT00003397|contiguous stage II adult lymphoblastic lymphoma
699217|NCT00003397|noncontiguous stage II grade 3 follicular lymphoma
699218|NCT00003397|noncontiguous stage II adult diffuse small cleaved cell lymphoma
699219|NCT00003397|noncontiguous stage II mantle cell lymphoma
699220|NCT00003397|noncontiguous stage II adult diffuse mixed cell lymphoma
699221|NCT00003397|noncontiguous stage II adult immunoblastic large cell lymphoma
699222|NCT00003397|noncontiguous stage II adult diffuse large cell lymphoma
699223|NCT00003397|noncontiguous stage II adult Burkitt lymphoma
699224|NCT00003397|noncontiguous stage II adult lymphoblastic lymphoma
699225|NCT00003397|stage III mantle cell lymphoma
699226|NCT00003397|stage IV mantle cell lymphoma
699227|NCT00003397|recurrent mantle cell lymphoma
699228|NCT00003396|recurrent childhood acute lymphoblastic leukemia
699229|NCT00003396|recurrent adult Hodgkin lymphoma
699230|NCT00003396|refractory multiple myeloma
699231|NCT00003396|Waldenstrom macroglobulinemia
699232|NCT00003396|stage I multiple myeloma
699233|NCT00003396|stage II multiple myeloma
699234|NCT00003396|stage III multiple myeloma
699235|NCT00003396|recurrent childhood lymphoblastic lymphoma
699236|NCT00003396|recurrent childhood acute myeloid leukemia
699237|NCT00003396|recurrent adult acute myeloid leukemia
699238|NCT00003396|recurrent adult acute lymphoblastic leukemia
699239|NCT00003396|relapsing chronic myelogenous leukemia
699240|NCT00003396|refractory chronic lymphocytic leukemia
699241|NCT00003396|accelerated phase chronic myelogenous leukemia
699242|NCT00003396|blastic phase chronic myelogenous leukemia
699243|NCT00003396|adult acute myeloid leukemia in remission
699244|NCT00003396|adult acute lymphoblastic leukemia in remission
699245|NCT00003396|childhood acute myeloid leukemia in remission
699246|NCT00003396|childhood acute lymphoblastic leukemia in remission
699247|NCT00003396|adult acute erythroid leukemia (M6)
699248|NCT00003396|adult acute myeloblastic leukemia without maturation (M1)
699249|NCT00003396|adult acute myeloblastic leukemia with maturation (M2)
699250|NCT00003396|adult acute promyelocytic leukemia (M3)
699251|NCT00003396|adult acute eosinophilic leukemia
699252|NCT00003396|adult acute basophilic leukemia
699253|NCT00003396|adult acute megakaryoblastic leukemia (M7)
699254|NCT00003396|childhood acute myeloblastic leukemia without maturation (M1)
699255|NCT00003396|childhood acute myeloblastic leukemia with maturation (M2)
699256|NCT00003396|childhood acute promyelocytic leukemia (M3)
699257|NCT00003396|childhood acute erythroleukemia (M6)
699258|NCT00003396|childhood acute eosinophilic leukemia
699259|NCT00003396|childhood acute basophilic leukemia
699260|NCT00003396|childhood acute megakaryocytic leukemia (M7)
699261|NCT00003396|recurrent/refractory childhood Hodgkin lymphoma
699262|NCT00003396|recurrent grade 1 follicular lymphoma
699263|NCT00003396|recurrent grade 2 follicular lymphoma
699264|NCT00003396|recurrent grade 3 follicular lymphoma
699265|NCT00003396|recurrent adult diffuse small cleaved cell lymphoma
699266|NCT00003396|recurrent adult diffuse mixed cell lymphoma
699267|NCT00003396|recurrent adult diffuse large cell lymphoma
699268|NCT00003396|recurrent adult immunoblastic large cell lymphoma
699269|NCT00003396|recurrent adult lymphoblastic lymphoma
699270|NCT00003396|recurrent adult Burkitt lymphoma
699271|NCT00003396|previously treated myelodysplastic syndromes
699272|NCT00003396|adult acute minimally differentiated myeloid leukemia (M0)
699273|NCT00003396|childhood acute minimally differentiated myeloid leukemia (M0)
699274|NCT00003396|recurrent childhood small noncleaved cell lymphoma
699275|NCT00003396|recurrent childhood large cell lymphoma
699276|NCT00003396|recurrent mantle cell lymphoma
699277|NCT00003396|recurrent marginal zone lymphoma
699278|NCT00003396|recurrent small lymphocytic lymphoma
699279|NCT00003396|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699280|NCT00003396|nodal marginal zone B-cell lymphoma
699281|NCT00003396|splenic marginal zone lymphoma
699282|NCT00003396|childhood myelodysplastic syndromes
699283|NCT00003395|stage IV adult Hodgkin lymphoma
699284|NCT00003395|recurrent adult Hodgkin lymphoma
699285|NCT00003395|stage IV cutaneous T-cell non-Hodgkin lymphoma
699286|NCT00003395|recurrent cutaneous T-cell non-Hodgkin lymphoma
699287|NCT00003395|refractory multiple myeloma
699288|NCT00003395|Waldenström macroglobulinemia
699289|NCT00003395|stage III multiple myeloma
699290|NCT00003395|stage IV chronic lymphocytic leukemia
699291|NCT00003395|recurrent adult acute myeloid leukemia
699292|NCT00003395|recurrent adult acute lymphoblastic leukemia
699293|NCT00003395|relapsing chronic myelogenous leukemia
699294|NCT00003395|refractory chronic lymphocytic leukemia
699295|NCT00003395|chronic phase chronic myelogenous leukemia
699296|NCT00003395|accelerated phase chronic myelogenous leukemia
699297|NCT00003395|blastic phase chronic myelogenous leukemia
699298|NCT00003395|meningeal chronic myelogenous leukemia
699299|NCT00003395|adult acute erythroid leukemia (M6)
699300|NCT00003395|adult acute myeloblastic leukemia without maturation (M1)
699301|NCT00003395|adult acute myeloblastic leukemia with maturation (M2)
699302|NCT00003395|adult acute myelomonocytic leukemia (M4)
699303|NCT00003395|adult acute monoblastic leukemia (M5a)
699304|NCT00003395|adult acute eosinophilic leukemia
699305|NCT00003395|adult acute basophilic leukemia
699306|NCT00003395|adult acute megakaryoblastic leukemia (M7)
699307|NCT00003395|progressive hairy cell leukemia, initial treatment
699308|NCT00003395|refractory hairy cell leukemia
699309|NCT00003395|acute undifferentiated leukemia
699310|NCT00003395|stage IV grade 1 follicular lymphoma
699311|NCT00003395|stage IV grade 2 follicular lymphoma
699312|NCT00003395|stage IV grade 3 follicular lymphoma
699313|NCT00003395|stage IV adult diffuse small cleaved cell lymphoma
699314|NCT00003395|stage IV adult diffuse mixed cell lymphoma
699315|NCT00003395|stage IV adult diffuse large cell lymphoma
699316|NCT00003395|stage IV adult immunoblastic large cell lymphoma
699317|NCT00003395|stage IV adult lymphoblastic lymphoma
699318|NCT00003395|stage IV adult Burkitt lymphoma
699319|NCT00003395|recurrent grade 1 follicular lymphoma
699320|NCT00003395|recurrent grade 2 follicular lymphoma
699321|NCT00003395|recurrent grade 3 follicular lymphoma
699322|NCT00003395|recurrent adult diffuse small cleaved cell lymphoma
699323|NCT00003395|recurrent adult diffuse mixed cell lymphoma
699324|NCT00003395|recurrent adult diffuse large cell lymphoma
699325|NCT00003395|recurrent adult immunoblastic large cell lymphoma
699326|NCT00003395|recurrent adult lymphoblastic lymphoma
699327|NCT00003395|recurrent adult Burkitt lymphoma
699328|NCT00003395|stage IV adult T-cell leukemia/lymphoma
699329|NCT00003395|recurrent adult T-cell leukemia/lymphoma
699330|NCT00003395|secondary acute myeloid leukemia
699331|NCT00003395|adult acute monocytic leukemia (M5b)
699332|NCT00003395|primary central nervous system non-Hodgkin lymphoma
699333|NCT00003395|AIDS-related peripheral/systemic lymphoma
699334|NCT00003395|AIDS-related primary CNS lymphoma
699335|NCT00003395|adult acute minimally differentiated myeloid leukemia (M0)
699336|NCT00003395|intraocular lymphoma
699337|NCT00003395|stage IV mantle cell lymphoma
699338|NCT00003395|recurrent mantle cell lymphoma
699339|NCT00003395|anaplastic large cell lymphoma
699340|NCT00003395|stage IV mycosis fungoides/Sezary syndrome
699341|NCT00003395|recurrent mycosis fungoides/Sezary syndrome
699342|NCT00003395|juvenile myelomonocytic leukemia
699343|NCT00003395|recurrent marginal zone lymphoma
699344|NCT00003395|recurrent small lymphocytic lymphoma
699345|NCT00003395|stage IV small lymphocytic lymphoma
699346|NCT00003395|stage IV marginal zone lymphoma
699347|NCT00003395|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699348|NCT00003395|nodal marginal zone B-cell lymphoma
699349|NCT00003395|splenic marginal zone lymphoma
699350|NCT00003394|adenocarcinoma of the prostate
699351|NCT00003394|stage I prostate cancer
699352|NCT00003394|stage IIB prostate cancer
699353|NCT00003394|stage IIA prostate cancer
699354|NCT00003394|stage III prostate cancer
699355|NCT00003394|stage IV prostate cancer
699356|NCT00003394|recurrent prostate cancer
699357|NCT00003392|stage IV breast cancer
699358|NCT00003392|recurrent breast cancer
699359|NCT00003391|adenocarcinoma of the prostate
699360|NCT00003391|stage IV prostate cancer
699361|NCT00003391|recurrent prostate cancer
699362|NCT00003390|stage IV renal cell cancer
699363|NCT00003390|recurrent renal cell cancer
699364|NCT00003389|stage I adult Hodgkin lymphoma
699365|NCT00003389|stage II adult Hodgkin lymphoma
699366|NCT00003389|stage III adult Hodgkin lymphoma
699367|NCT00003389|stage IV adult Hodgkin lymphoma
699368|NCT00003389|adult lymphocyte depletion Hodgkin lymphoma
699369|NCT00003389|adult nodular sclerosis Hodgkin lymphoma
699370|NCT00003389|adult mixed cellularity Hodgkin lymphoma
699371|NCT00003388|AIDS-related peripheral/systemic lymphoma
699372|NCT00003388|AIDS-related diffuse large cell lymphoma
699373|NCT00003388|AIDS-related immunoblastic large cell lymphoma
699374|NCT00003388|AIDS-related small noncleaved cell lymphoma
699375|NCT00003388|AIDS-related diffuse mixed cell lymphoma
699376|NCT00003388|AIDS-related diffuse small cleaved cell lymphoma
699377|NCT00003388|AIDS-related lymphoblastic lymphoma
699378|NCT00003388|anaplastic large cell lymphoma
699379|NCT00003387|stage III non-small cell lung cancer
699380|NCT00003387|squamous cell lung cancer
699381|NCT00003387|large cell lung cancer
699382|NCT00003387|adenocarcinoma of the lung
699383|NCT00003386|stage III ovarian epithelial cancer
699384|NCT00003386|stage IV ovarian epithelial cancer
699385|NCT00003385|stage I ovarian epithelial cancer
699386|NCT00003385|stage II ovarian epithelial cancer
699387|NCT00003385|stage III ovarian epithelial cancer
699388|NCT00003385|stage IV ovarian epithelial cancer
699389|NCT00003385|ovarian undifferentiated adenocarcinoma
699390|NCT00003385|ovarian mixed epithelial carcinoma
699391|NCT00003385|ovarian serous cystadenocarcinoma
699392|NCT00003385|ovarian mucinous cystadenocarcinoma
699393|NCT00003385|ovarian endometrioid adenocarcinoma
699394|NCT00003385|ovarian clear cell cystadenocarcinoma
699395|NCT00003385|fallopian tube cancer
699396|NCT00003385|primary peritoneal cavity cancer
699397|NCT00003385|Brenner tumor
699398|NCT00003382|stage I ovarian epithelial cancer
699399|NCT00003382|stage II ovarian epithelial cancer
699400|NCT00003382|stage III ovarian epithelial cancer
699401|NCT00003382|stage IV ovarian epithelial cancer
699402|NCT00003382|recurrent ovarian epithelial cancer
699403|NCT00003382|fallopian tube cancer
699404|NCT00003382|primary peritoneal cavity cancer
699405|NCT00003380|recurrent ovarian epithelial cancer
699406|NCT00003380|ovarian undifferentiated adenocarcinoma
699407|NCT00003380|ovarian mixed epithelial carcinoma
699408|NCT00003380|ovarian serous cystadenocarcinoma
699409|NCT00003380|ovarian mucinous cystadenocarcinoma
699410|NCT00003380|ovarian endometrioid adenocarcinoma
699411|NCT00003380|ovarian clear cell cystadenocarcinoma
699412|NCT00003380|fallopian tube cancer
699413|NCT00003380|primary peritoneal cavity cancer
699414|NCT00003380|Brenner tumor
699415|NCT00003379|stage III cervical cancer
699416|NCT00003379|stage IB cervical cancer
699417|NCT00003379|stage IIB cervical cancer
699418|NCT00003379|stage IIA cervical cancer
699419|NCT00003379|stage IVA cervical cancer
699420|NCT00003379|cervical squamous cell carcinoma
699421|NCT00003379|cervical adenocarcinoma
699422|NCT00003379|cervical adenosquamous cell carcinoma
699423|NCT00003379|cervical small cell carcinoma
699424|NCT00003378|stage III ovarian epithelial cancer
699425|NCT00003378|stage IV ovarian epithelial cancer
699426|NCT00003378|primary peritoneal cavity cancer
699427|NCT00003377|stage III cervical cancer
699428|NCT00003377|stage IVA cervical cancer
699429|NCT00003377|cervical squamous cell carcinoma
699430|NCT00003377|cervical adenocarcinoma
699431|NCT00003377|cervical adenosquamous cell carcinoma
699432|NCT00003376|stage III bladder cancer
699433|NCT00003376|stage IV bladder cancer
699434|NCT00003376|transitional cell carcinoma of the bladder
699435|NCT00003376|anterior urethral cancer
699436|NCT00003376|posterior urethral cancer
699437|NCT00003376|urethral cancer associated with invasive bladder cancer
699438|NCT00003376|metastatic transitional cell cancer of the renal pelvis and ureter
699439|NCT00003376|regional transitional cell cancer of the renal pelvis and ureter
699440|NCT00003375|adult oligodendroglioma
699441|NCT00003375|adult diffuse astrocytoma
699442|NCT00003375|adult pilocytic astrocytoma
699443|NCT00003372|recurrent adult brain tumor
699444|NCT00003372|adult anaplastic oligodendroglioma
699445|NCT00003372|adult mixed glioma
699446|NCT00003370|unspecified childhood solid tumor, protocol specific
699447|NCT00003369|stage IV cervical cancer
699448|NCT00003369|recurrent cervical cancer
699449|NCT00003369|cervical squamous cell carcinoma
699450|NCT00003369|cervical adenosquamous cell carcinoma
699451|NCT00003368|stage III adult Hodgkin lymphoma
699452|NCT00003368|stage IV adult Hodgkin lymphoma
699453|NCT00003368|recurrent adult Hodgkin lymphoma
699454|NCT00003368|stage III cutaneous T-cell non-Hodgkin lymphoma
699455|NCT00003368|stage IV cutaneous T-cell non-Hodgkin lymphoma
699456|NCT00003368|recurrent cutaneous T-cell non-Hodgkin lymphoma
699457|NCT00003368|small intestine lymphoma
699458|NCT00003368|unspecified adult solid tumor, protocol specific
699459|NCT00003368|stage III grade 1 follicular lymphoma
699460|NCT00003368|stage III grade 2 follicular lymphoma
699461|NCT00003368|stage III grade 3 follicular lymphoma
699462|NCT00003368|stage III adult diffuse small cleaved cell lymphoma
699463|NCT00003368|stage III adult diffuse mixed cell lymphoma
699464|NCT00003368|stage III adult diffuse large cell lymphoma
699465|NCT00003368|stage III adult immunoblastic large cell lymphoma
699466|NCT00003368|stage III adult lymphoblastic lymphoma
699467|NCT00003368|stage III adult Burkitt lymphoma
699468|NCT00003368|stage IV grade 1 follicular lymphoma
699469|NCT00003368|stage IV grade 2 follicular lymphoma
699470|NCT00003368|stage IV grade 3 follicular lymphoma
699471|NCT00003368|stage IV adult diffuse small cleaved cell lymphoma
699472|NCT00003368|stage IV adult diffuse mixed cell lymphoma
699473|NCT00003368|stage IV adult diffuse large cell lymphoma
699474|NCT00003368|stage IV adult immunoblastic large cell lymphoma
699475|NCT00003368|stage IV adult lymphoblastic lymphoma
699476|NCT00003368|stage IV adult Burkitt lymphoma
699477|NCT00003368|recurrent grade 1 follicular lymphoma
699478|NCT00003368|recurrent grade 2 follicular lymphoma
699479|NCT00003368|recurrent grade 3 follicular lymphoma
699480|NCT00003368|recurrent adult diffuse small cleaved cell lymphoma
699481|NCT00003368|recurrent adult diffuse mixed cell lymphoma
699482|NCT00003368|recurrent adult diffuse large cell lymphoma
699483|NCT00003368|recurrent adult immunoblastic large cell lymphoma
699484|NCT00003368|recurrent adult lymphoblastic lymphoma
699485|NCT00003368|recurrent adult Burkitt lymphoma
699486|NCT00003368|stage III adult T-cell leukemia/lymphoma
699487|NCT00003368|stage IV adult T-cell leukemia/lymphoma
699488|NCT00003368|recurrent adult T-cell leukemia/lymphoma
699489|NCT00003368|primary central nervous system non-Hodgkin lymphoma
699490|NCT00003368|AIDS-related peripheral/systemic lymphoma
699491|NCT00003368|AIDS-related primary CNS lymphoma
699492|NCT00003368|intraocular lymphoma
699493|NCT00003368|stage III mantle cell lymphoma
699494|NCT00003368|stage IV mantle cell lymphoma
699495|NCT00003368|recurrent mantle cell lymphoma
699496|NCT00003368|angioimmunoblastic T-cell lymphoma
699497|NCT00003368|anaplastic large cell lymphoma
699498|NCT00003368|stage III mycosis fungoides/Sezary syndrome
699499|NCT00003368|stage IV mycosis fungoides/Sezary syndrome
699500|NCT00003368|recurrent mycosis fungoides/Sezary syndrome
699501|NCT00003368|recurrent marginal zone lymphoma
701693|NCT00003068|stage IV breast cancer
699502|NCT00003368|recurrent small lymphocytic lymphoma
699503|NCT00003368|stage III small lymphocytic lymphoma
699504|NCT00003368|stage III marginal zone lymphoma
699505|NCT00003368|stage IV small lymphocytic lymphoma
699506|NCT00003368|stage IV marginal zone lymphoma
699507|NCT00003368|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699508|NCT00003368|nodal marginal zone B-cell lymphoma
699509|NCT00003368|splenic marginal zone lymphoma
699510|NCT00003367|adenocarcinoma of the prostate
699511|NCT00003367|stage I prostate cancer
699512|NCT00003367|stage IIB prostate cancer
699513|NCT00003367|stage IIA prostate cancer
699514|NCT00003367|stage III prostate cancer
699515|NCT00003367|stage IV prostate cancer
699516|NCT00003367|recurrent prostate cancer
699517|NCT00003365|colon cancer
699518|NCT00003364|limited stage small cell lung cancer
699519|NCT00003362|stage III melanoma
699520|NCT00003362|stage IV melanoma
699521|NCT00003362|recurrent melanoma
699522|NCT00003361|refractory anemia
699523|NCT00003361|refractory anemia with ringed sideroblasts
699524|NCT00003361|refractory anemia with excess blasts
699525|NCT00003361|refractory anemia with excess blasts in transformation
699526|NCT00003361|chronic myelomonocytic leukemia
699527|NCT00003361|de novo myelodysplastic syndromes
699528|NCT00003361|previously treated myelodysplastic syndromes
699529|NCT00003361|secondary myelodysplastic syndromes
699530|NCT00003361|childhood myelodysplastic syndromes
699531|NCT00003360|stage IV colon cancer
699532|NCT00003360|stage IV rectal cancer
699533|NCT00003360|recurrent colon cancer
699534|NCT00003360|recurrent rectal cancer
699535|NCT00003359|unspecified adult solid tumor, protocol specific
699536|NCT00003358|stage I ovarian epithelial cancer
699537|NCT00003358|stage II ovarian epithelial cancer
699538|NCT00003358|stage III ovarian epithelial cancer
699539|NCT00003358|stage IV ovarian epithelial cancer
699540|NCT00003358|recurrent ovarian epithelial cancer
699541|NCT00003358|fallopian tube cancer
699542|NCT00003358|primary peritoneal cavity cancer
699543|NCT00003357|stage I breast cancer
699544|NCT00003357|stage II breast cancer
699545|NCT00003357|stage III breast cancer
699546|NCT00003356|stage I grade 1 follicular lymphoma
699547|NCT00003356|stage I grade 2 follicular lymphoma
699548|NCT00003356|stage III grade 1 follicular lymphoma
699549|NCT00003356|stage III grade 2 follicular lymphoma
699550|NCT00003356|stage IV grade 1 follicular lymphoma
699551|NCT00003356|stage IV grade 2 follicular lymphoma
699552|NCT00003356|recurrent grade 1 follicular lymphoma
699553|NCT00003356|recurrent grade 2 follicular lymphoma
699554|NCT00003356|stage I mantle cell lymphoma
699555|NCT00003356|contiguous stage II grade 1 follicular lymphoma
699556|NCT00003356|contiguous stage II grade 2 follicular lymphoma
699557|NCT00003356|contiguous stage II mantle cell lymphoma
699558|NCT00003356|noncontiguous stage II grade 1 follicular lymphoma
699559|NCT00003356|noncontiguous stage II grade 2 follicular lymphoma
699560|NCT00003356|noncontiguous stage II mantle cell lymphoma
699561|NCT00003356|stage III mantle cell lymphoma
699562|NCT00003356|stage IV mantle cell lymphoma
699563|NCT00003356|recurrent mantle cell lymphoma
699564|NCT00003356|noncontiguous stage II small lymphocytic lymphoma
699565|NCT00003356|noncontiguous stage II marginal zone lymphoma
699566|NCT00003356|recurrent marginal zone lymphoma
699567|NCT00003356|recurrent small lymphocytic lymphoma
699568|NCT00003356|stage I marginal zone lymphoma
699569|NCT00003356|stage I small lymphocytic lymphoma
699570|NCT00003356|stage III small lymphocytic lymphoma
699571|NCT00003356|stage III marginal zone lymphoma
699572|NCT00003356|stage IV small lymphocytic lymphoma
699573|NCT00003356|stage IV marginal zone lymphoma
699574|NCT00003356|contiguous stage II marginal zone lymphoma
699575|NCT00003356|contiguous stage II small lymphocytic lymphoma
699576|NCT00003356|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699577|NCT00003356|nodal marginal zone B-cell lymphoma
699578|NCT00003356|splenic marginal zone lymphoma
699579|NCT00003354|stage I colon cancer
699580|NCT00003354|stage II colon cancer
699581|NCT00003354|stage III colon cancer
699582|NCT00003354|stage IV colon cancer
699583|NCT00003354|stage 0 colon cancer
699584|NCT00003354|stage 0 rectal cancer
699585|NCT00003354|stage I rectal cancer
699586|NCT00003354|stage II rectal cancer
699587|NCT00003354|stage III rectal cancer
699588|NCT00003354|stage IV rectal cancer
699589|NCT00003353|primary systemic amyloidosis
699590|NCT00003352|stage IV breast cancer
699591|NCT00003352|recurrent breast cancer
699592|NCT00003352|stage IIIB breast cancer
699593|NCT00003351|stage IV breast cancer
699594|NCT00003348|recurrent adult brain tumor
699595|NCT00003348|adult glioblastoma
699596|NCT00003348|adult anaplastic astrocytoma
699597|NCT00003348|adult giant cell glioblastoma
699598|NCT00003348|adult gliosarcoma
699599|NCT00003346|stage III melanoma
699600|NCT00003346|stage IV melanoma
699601|NCT00003346|recurrent melanoma
699602|NCT00003345|stage I ovarian epithelial cancer
699603|NCT00003345|stage II ovarian epithelial cancer
699604|NCT00003345|stage III ovarian epithelial cancer
699605|NCT00003345|stage IV ovarian epithelial cancer
699606|NCT00003345|recurrent ovarian epithelial cancer
699607|NCT00003345|fallopian tube cancer
699608|NCT00003345|primary peritoneal cavity cancer
699609|NCT00003344|stage II colon cancer
699610|NCT00003344|stage III colon cancer
699611|NCT00003344|stage II rectal cancer
699612|NCT00003344|stage III rectal cancer
699613|NCT00003344|recurrent colon cancer
699614|NCT00003344|recurrent rectal cancer
699615|NCT00003343|stage IV prostate cancer
699616|NCT00003342|stage III bladder cancer
699617|NCT00003342|stage IV bladder cancer
699618|NCT00003342|transitional cell carcinoma of the bladder
699619|NCT00003342|metastatic transitional cell cancer of the renal pelvis and ureter
699620|NCT00003342|localized transitional cell cancer of the renal pelvis and ureter
699621|NCT00003342|regional transitional cell cancer of the renal pelvis and ureter
699622|NCT00003341|stage II adult Hodgkin lymphoma
699623|NCT00003341|stage III adult Hodgkin lymphoma
699624|NCT00003341|stage IV adult Hodgkin lymphoma
699625|NCT00003341|recurrent adult Hodgkin lymphoma
699626|NCT00003341|refractory multiple myeloma
699627|NCT00003341|Waldenström macroglobulinemia
699628|NCT00003341|stage II multiple myeloma
699629|NCT00003341|stage III multiple myeloma
699630|NCT00003341|stage II chronic lymphocytic leukemia
699631|NCT00003341|stage III chronic lymphocytic leukemia
699632|NCT00003341|stage IV chronic lymphocytic leukemia
699633|NCT00003341|refractory chronic lymphocytic leukemia
699634|NCT00003341|stage III grade 1 follicular lymphoma
699635|NCT00003341|stage III grade 2 follicular lymphoma
699636|NCT00003341|stage III grade 3 follicular lymphoma
699637|NCT00003341|stage III adult diffuse small cleaved cell lymphoma
699638|NCT00003341|stage III adult diffuse mixed cell lymphoma
699639|NCT00003341|stage III adult diffuse large cell lymphoma
699640|NCT00003341|stage III adult immunoblastic large cell lymphoma
699641|NCT00003341|stage IV grade 1 follicular lymphoma
699642|NCT00003341|stage IV grade 2 follicular lymphoma
699643|NCT00003341|stage IV grade 3 follicular lymphoma
699644|NCT00003341|stage IV adult diffuse small cleaved cell lymphoma
699645|NCT00003341|stage IV adult diffuse mixed cell lymphoma
699646|NCT00003341|stage IV adult diffuse large cell lymphoma
699647|NCT00003341|stage IV adult immunoblastic large cell lymphoma
699648|NCT00003341|recurrent grade 1 follicular lymphoma
699649|NCT00003341|recurrent grade 2 follicular lymphoma
699650|NCT00003341|recurrent grade 3 follicular lymphoma
699651|NCT00003341|recurrent adult diffuse small cleaved cell lymphoma
699652|NCT00003341|recurrent adult diffuse mixed cell lymphoma
699653|NCT00003341|recurrent adult diffuse large cell lymphoma
699654|NCT00003341|recurrent adult immunoblastic large cell lymphoma
699655|NCT00003341|anemia
699656|NCT00003341|contiguous stage II grade 1 follicular lymphoma
699657|NCT00003341|contiguous stage II grade 2 follicular lymphoma
699658|NCT00003341|contiguous stage II grade 3 follicular lymphoma
699659|NCT00003341|contiguous stage II adult diffuse small cleaved cell lymphoma
699660|NCT00003341|contiguous stage II mantle cell lymphoma
699661|NCT00003341|contiguous stage II adult diffuse mixed cell lymphoma
699662|NCT00003341|contiguous stage II adult immunoblastic large cell lymphoma
699663|NCT00003341|contiguous stage II adult diffuse large cell lymphoma
699664|NCT00003341|noncontiguous stage II grade 1 follicular lymphoma
699665|NCT00003341|noncontiguous stage II grade 2 follicular lymphoma
699666|NCT00003341|noncontiguous stage II grade 3 follicular lymphoma
699667|NCT00003341|noncontiguous stage II adult diffuse small cleaved cell lymphoma
699668|NCT00003341|noncontiguous stage II mantle cell lymphoma
699669|NCT00003341|noncontiguous stage II adult diffuse mixed cell lymphoma
699670|NCT00003341|noncontiguous stage II adult immunoblastic large cell lymphoma
699671|NCT00003341|noncontiguous stage II adult diffuse large cell lymphoma
699672|NCT00003341|stage III mantle cell lymphoma
699673|NCT00003341|stage IV mantle cell lymphoma
699674|NCT00003341|recurrent mantle cell lymphoma
699675|NCT00003341|noncontiguous stage II small lymphocytic lymphoma
699676|NCT00003341|noncontiguous stage II marginal zone lymphoma
699677|NCT00003341|recurrent marginal zone lymphoma
699678|NCT00003341|recurrent small lymphocytic lymphoma
699679|NCT00003341|stage III small lymphocytic lymphoma
699680|NCT00003341|stage III marginal zone lymphoma
699681|NCT00003341|stage IV small lymphocytic lymphoma
699682|NCT00003341|stage IV marginal zone lymphoma
699683|NCT00003341|contiguous stage II marginal zone lymphoma
699684|NCT00003341|contiguous stage II small lymphocytic lymphoma
699685|NCT00003341|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699686|NCT00003341|nodal marginal zone B-cell lymphoma
699687|NCT00003341|splenic marginal zone lymphoma
699688|NCT00003340|recurrent adult acute myeloid leukemia
699689|NCT00003339|recurrent intraocular melanoma
699690|NCT00003339|stage III melanoma
699691|NCT00003339|stage IV melanoma
699692|NCT00003339|recurrent melanoma
699693|NCT00003338|stage I grade 1 follicular lymphoma
699694|NCT00003338|stage I grade 2 follicular lymphoma
699695|NCT00003338|stage I grade 3 follicular lymphoma
699696|NCT00003338|stage I adult diffuse small cleaved cell lymphoma
699697|NCT00003338|stage I adult diffuse mixed cell lymphoma
699698|NCT00003338|stage I adult diffuse large cell lymphoma
699699|NCT00003338|stage I adult immunoblastic large cell lymphoma
699700|NCT00003338|stage I adult lymphoblastic lymphoma
699701|NCT00003338|stage I adult Burkitt lymphoma
699702|NCT00003338|stage III grade 1 follicular lymphoma
699703|NCT00003338|stage III grade 2 follicular lymphoma
699704|NCT00003338|stage III grade 3 follicular lymphoma
699705|NCT00003338|stage III adult diffuse small cleaved cell lymphoma
699706|NCT00003338|stage III adult diffuse mixed cell lymphoma
699707|NCT00003338|stage III adult diffuse large cell lymphoma
699708|NCT00003338|stage III adult immunoblastic large cell lymphoma
699709|NCT00003338|stage III adult lymphoblastic lymphoma
699710|NCT00003338|stage III adult Burkitt lymphoma
699711|NCT00003338|stage IV grade 1 follicular lymphoma
699712|NCT00003338|stage IV grade 2 follicular lymphoma
699713|NCT00003338|stage IV grade 3 follicular lymphoma
699714|NCT00003338|stage IV adult diffuse small cleaved cell lymphoma
699715|NCT00003338|stage IV adult diffuse mixed cell lymphoma
699716|NCT00003338|stage IV adult diffuse large cell lymphoma
699717|NCT00003338|stage IV adult immunoblastic large cell lymphoma
699718|NCT00003338|stage IV adult lymphoblastic lymphoma
699719|NCT00003338|stage IV adult Burkitt lymphoma
699720|NCT00003338|recurrent grade 1 follicular lymphoma
699721|NCT00003338|recurrent grade 2 follicular lymphoma
699722|NCT00003338|recurrent grade 3 follicular lymphoma
699723|NCT00003338|recurrent adult diffuse small cleaved cell lymphoma
699724|NCT00003338|recurrent adult diffuse mixed cell lymphoma
699725|NCT00003338|recurrent adult diffuse large cell lymphoma
699726|NCT00003338|recurrent adult immunoblastic large cell lymphoma
699727|NCT00003338|recurrent adult lymphoblastic lymphoma
699728|NCT00003338|recurrent adult Burkitt lymphoma
699729|NCT00003338|stage I mantle cell lymphoma
699730|NCT00003338|contiguous stage II grade 1 follicular lymphoma
699731|NCT00003338|contiguous stage II grade 2 follicular lymphoma
699732|NCT00003338|contiguous stage II grade 3 follicular lymphoma
699733|NCT00003338|contiguous stage II adult diffuse small cleaved cell lymphoma
699734|NCT00003338|contiguous stage II mantle cell lymphoma
699735|NCT00003338|contiguous stage II adult diffuse mixed cell lymphoma
699736|NCT00003338|contiguous stage II adult immunoblastic large cell lymphoma
699737|NCT00003338|contiguous stage II adult diffuse large cell lymphoma
699738|NCT00003338|contiguous stage II adult Burkitt lymphoma
699739|NCT00003338|contiguous stage II adult lymphoblastic lymphoma
699740|NCT00003338|noncontiguous stage II grade 1 follicular lymphoma
699741|NCT00003338|noncontiguous stage II grade 2 follicular lymphoma
699742|NCT00003338|noncontiguous stage II grade 3 follicular lymphoma
699743|NCT00003338|noncontiguous stage II adult diffuse small cleaved cell lymphoma
699744|NCT00003338|noncontiguous stage II mantle cell lymphoma
699745|NCT00003338|noncontiguous stage II adult diffuse mixed cell lymphoma
699746|NCT00003338|noncontiguous stage II adult immunoblastic large cell lymphoma
699747|NCT00003338|noncontiguous stage II adult diffuse large cell lymphoma
699748|NCT00003338|noncontiguous stage II adult Burkitt lymphoma
699749|NCT00003338|noncontiguous stage II adult lymphoblastic lymphoma
699750|NCT00003338|stage III mantle cell lymphoma
699751|NCT00003338|stage IV mantle cell lymphoma
699752|NCT00003338|recurrent mantle cell lymphoma
699753|NCT00003338|noncontiguous stage II small lymphocytic lymphoma
699754|NCT00003338|noncontiguous stage II marginal zone lymphoma
699755|NCT00003338|recurrent marginal zone lymphoma
699756|NCT00003338|recurrent small lymphocytic lymphoma
699757|NCT00003338|stage I marginal zone lymphoma
699758|NCT00003338|stage I small lymphocytic lymphoma
699759|NCT00003338|stage III small lymphocytic lymphoma
699760|NCT00003338|stage III marginal zone lymphoma
699761|NCT00003338|stage IV small lymphocytic lymphoma
699762|NCT00003338|stage IV marginal zone lymphoma
699763|NCT00003338|contiguous stage II marginal zone lymphoma
699764|NCT00003338|contiguous stage II small lymphocytic lymphoma
699765|NCT00003338|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699766|NCT00003338|nodal marginal zone B-cell lymphoma
699767|NCT00003338|splenic marginal zone lymphoma
699768|NCT00003337|stage I grade 1 follicular lymphoma
699769|NCT00003337|stage I grade 2 follicular lymphoma
699770|NCT00003337|stage I grade 3 follicular lymphoma
699771|NCT00003337|stage I adult diffuse small cleaved cell lymphoma
699772|NCT00003337|stage I adult diffuse mixed cell lymphoma
699773|NCT00003337|stage I adult diffuse large cell lymphoma
699774|NCT00003337|stage I adult immunoblastic large cell lymphoma
699775|NCT00003337|stage I adult lymphoblastic lymphoma
699776|NCT00003337|stage I adult Burkitt lymphoma
699777|NCT00003337|stage III grade 1 follicular lymphoma
699778|NCT00003337|stage III grade 2 follicular lymphoma
699779|NCT00003337|stage III grade 3 follicular lymphoma
699780|NCT00003337|stage III adult diffuse small cleaved cell lymphoma
699781|NCT00003337|stage III adult diffuse mixed cell lymphoma
699782|NCT00003337|stage III adult diffuse large cell lymphoma
699783|NCT00003337|stage III adult immunoblastic large cell lymphoma
699784|NCT00003337|stage III adult lymphoblastic lymphoma
699785|NCT00003337|stage III adult Burkitt lymphoma
699786|NCT00003337|stage IV grade 1 follicular lymphoma
699787|NCT00003337|stage IV grade 2 follicular lymphoma
699788|NCT00003337|stage IV grade 3 follicular lymphoma
699789|NCT00003337|stage IV adult diffuse small cleaved cell lymphoma
699790|NCT00003337|stage IV adult diffuse mixed cell lymphoma
699791|NCT00003337|stage IV adult diffuse large cell lymphoma
699792|NCT00003337|stage IV adult immunoblastic large cell lymphoma
699793|NCT00003337|stage IV adult lymphoblastic lymphoma
699794|NCT00003337|stage IV adult Burkitt lymphoma
699795|NCT00003337|recurrent grade 1 follicular lymphoma
699796|NCT00003337|recurrent grade 2 follicular lymphoma
699797|NCT00003337|recurrent grade 3 follicular lymphoma
699798|NCT00003337|recurrent adult diffuse small cleaved cell lymphoma
699799|NCT00003337|recurrent adult diffuse mixed cell lymphoma
699800|NCT00003337|recurrent adult diffuse large cell lymphoma
699801|NCT00003337|recurrent adult immunoblastic large cell lymphoma
699802|NCT00003337|recurrent adult lymphoblastic lymphoma
699803|NCT00003337|recurrent adult Burkitt lymphoma
699804|NCT00003337|stage I mantle cell lymphoma
699805|NCT00003337|contiguous stage II grade 1 follicular lymphoma
699806|NCT00003337|contiguous stage II grade 2 follicular lymphoma
699807|NCT00003337|contiguous stage II grade 3 follicular lymphoma
699808|NCT00003337|contiguous stage II adult diffuse small cleaved cell lymphoma
699809|NCT00003337|contiguous stage II mantle cell lymphoma
699810|NCT00003337|contiguous stage II adult diffuse mixed cell lymphoma
699811|NCT00003337|contiguous stage II adult immunoblastic large cell lymphoma
699812|NCT00003337|contiguous stage II adult diffuse large cell lymphoma
699813|NCT00003337|contiguous stage II adult Burkitt lymphoma
699814|NCT00003337|contiguous stage II adult lymphoblastic lymphoma
699815|NCT00003337|noncontiguous stage II grade 1 follicular lymphoma
699816|NCT00003337|noncontiguous stage II grade 2 follicular lymphoma
699817|NCT00003337|noncontiguous stage II grade 3 follicular lymphoma
699818|NCT00003337|noncontiguous stage II adult diffuse small cleaved cell lymphoma
699819|NCT00003337|noncontiguous stage II mantle cell lymphoma
699820|NCT00003337|noncontiguous stage II adult diffuse mixed cell lymphoma
699821|NCT00003337|noncontiguous stage II adult immunoblastic large cell lymphoma
699822|NCT00003337|noncontiguous stage II adult diffuse large cell lymphoma
699823|NCT00003337|noncontiguous stage II adult Burkitt lymphoma
699824|NCT00003337|noncontiguous stage II adult lymphoblastic lymphoma
699825|NCT00003337|stage III mantle cell lymphoma
699826|NCT00003337|stage IV mantle cell lymphoma
699827|NCT00003337|recurrent mantle cell lymphoma
699828|NCT00003337|noncontiguous stage II small lymphocytic lymphoma
699829|NCT00003337|noncontiguous stage II marginal zone lymphoma
699830|NCT00003337|recurrent marginal zone lymphoma
699831|NCT00003337|recurrent small lymphocytic lymphoma
699832|NCT00003337|stage I marginal zone lymphoma
699833|NCT00003337|stage I small lymphocytic lymphoma
699834|NCT00003337|stage III small lymphocytic lymphoma
699835|NCT00003337|stage III marginal zone lymphoma
699836|NCT00003337|stage IV small lymphocytic lymphoma
699837|NCT00003337|stage IV marginal zone lymphoma
699838|NCT00003337|contiguous stage II marginal zone lymphoma
699839|NCT00003337|contiguous stage II small lymphocytic lymphoma
699840|NCT00003337|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699841|NCT00003337|nodal marginal zone B-cell lymphoma
699842|NCT00003337|splenic marginal zone lymphoma
699843|NCT00003336|refractory anemia
699844|NCT00003336|refractory anemia with ringed sideroblasts
699845|NCT00003336|de novo myelodysplastic syndromes
699846|NCT00003336|previously treated myelodysplastic syndromes
699847|NCT00003336|secondary myelodysplastic syndromes
699848|NCT00003336|atypical chronic myeloid leukemia
699849|NCT00003336|myelodysplastic/myeloproliferative disease, unclassifiable
699850|NCT00003336|childhood myelodysplastic syndromes
699851|NCT00003335|recurrent childhood acute lymphoblastic leukemia
699852|NCT00003335|recurrent childhood lymphoblastic lymphoma
699853|NCT00003335|recurrent adult acute lymphoblastic leukemia
699854|NCT00003335|chronic phase chronic myelogenous leukemia
699855|NCT00003335|accelerated phase chronic myelogenous leukemia
699856|NCT00003335|blastic phase chronic myelogenous leukemia
699857|NCT00003335|untreated childhood acute lymphoblastic leukemia
699858|NCT00003335|adult acute myeloid leukemia in remission
699859|NCT00003335|adult acute lymphoblastic leukemia in remission
699860|NCT00003335|childhood acute myeloid leukemia in remission
699861|NCT00003335|childhood acute lymphoblastic leukemia in remission
699862|NCT00003335|adult acute erythroid leukemia (M6)
699863|NCT00003335|adult acute megakaryoblastic leukemia (M7)
699864|NCT00003335|childhood acute erythroleukemia (M6)
699865|NCT00003335|childhood acute megakaryocytic leukemia (M7)
699866|NCT00003335|refractory anemia with excess blasts
699867|NCT00003335|refractory anemia with excess blasts in transformation
699868|NCT00003335|recurrent grade 1 follicular lymphoma
699869|NCT00003335|recurrent grade 2 follicular lymphoma
699870|NCT00003335|recurrent grade 3 follicular lymphoma
699871|NCT00003335|recurrent adult diffuse small cleaved cell lymphoma
699872|NCT00003335|recurrent adult diffuse mixed cell lymphoma
699873|NCT00003335|recurrent adult diffuse large cell lymphoma
699874|NCT00003335|recurrent adult immunoblastic large cell lymphoma
699875|NCT00003335|recurrent adult lymphoblastic lymphoma
699876|NCT00003335|recurrent adult Burkitt lymphoma
699877|NCT00003335|de novo myelodysplastic syndromes
699878|NCT00003335|previously treated myelodysplastic syndromes
699879|NCT00003335|secondary myelodysplastic syndromes
699880|NCT00003335|graft versus host disease
699881|NCT00003335|adult acute minimally differentiated myeloid leukemia (M0)
699882|NCT00003335|childhood acute minimally differentiated myeloid leukemia (M0)
699883|NCT00003335|recurrent childhood small noncleaved cell lymphoma
699884|NCT00003335|recurrent childhood large cell lymphoma
699885|NCT00003335|recurrent mantle cell lymphoma
699886|NCT00003335|childhood chronic myelogenous leukemia
699887|NCT00003335|atypical chronic myeloid leukemia
699888|NCT00003335|myelodysplastic/myeloproliferative disease, unclassifiable
699889|NCT00003335|recurrent marginal zone lymphoma
699890|NCT00003335|recurrent small lymphocytic lymphoma
699891|NCT00003335|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699892|NCT00003335|nodal marginal zone B-cell lymphoma
699893|NCT00003335|splenic marginal zone lymphoma
699894|NCT00003335|adult acute myeloid leukemia with t(8;21)(q22;q22)
699895|NCT00003335|adult acute myeloid leukemia with t(16;16)(p13;q22)
699896|NCT00003335|adult acute myeloid leukemia with inv(16)(p13;q22)
699897|NCT00003335|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
699898|NCT00003335|adult acute myeloid leukemia with t(15;17)(q22;q12)
699899|NCT00003335|childhood myelodysplastic syndromes
699900|NCT00003334|stage IV endometrial carcinoma
699901|NCT00003334|recurrent endometrial carcinoma
699902|NCT00003334|fallopian tube cancer
699903|NCT00003334|stage IV uterine sarcoma
699904|NCT00003334|recurrent uterine sarcoma
699905|NCT00003334|uterine carcinosarcoma
699906|NCT00003334|uterine leiomyosarcoma
699907|NCT00003334|endometrial stromal sarcoma
699908|NCT00003334|ovarian sarcoma
699909|NCT00003334|ovarian carcinosarcoma
699910|NCT00003332|stage I pancreatic cancer
699911|NCT00003332|stage II pancreatic cancer
699912|NCT00003332|stage III pancreatic cancer
699913|NCT00003332|adenocarcinoma of the pancreas
699914|NCT00003331|stage III adult Hodgkin lymphoma
699915|NCT00003331|stage IV adult Hodgkin lymphoma
699916|NCT00003331|monoclonal gammopathy of undetermined significance
699917|NCT00003331|recurrent adult Hodgkin lymphoma
699918|NCT00003331|isolated plasmacytoma of bone
699919|NCT00003331|extramedullary plasmacytoma
699920|NCT00003331|refractory multiple myeloma
699921|NCT00003331|Waldenstrom macroglobulinemia
699922|NCT00003331|stage III multiple myeloma
699923|NCT00003331|stage IV chronic lymphocytic leukemia
699924|NCT00003331|recurrent adult acute myeloid leukemia
699925|NCT00003331|recurrent adult acute lymphoblastic leukemia
699926|NCT00003331|relapsing chronic myelogenous leukemia
699927|NCT00003331|refractory chronic lymphocytic leukemia
699928|NCT00003331|unspecified adult solid tumor, protocol specific
699929|NCT00003331|chronic phase chronic myelogenous leukemia
699930|NCT00003331|accelerated phase chronic myelogenous leukemia
699931|NCT00003331|blastic phase chronic myelogenous leukemia
699932|NCT00003331|meningeal chronic myelogenous leukemia
699933|NCT00003331|untreated adult acute lymphoblastic leukemia
699934|NCT00003331|untreated adult acute myeloid leukemia
699935|NCT00003331|adult acute myeloid leukemia in remission
699936|NCT00003331|adult acute lymphoblastic leukemia in remission
699937|NCT00003331|polycythemia vera
699938|NCT00003331|primary myelofibrosis
699939|NCT00003331|essential thrombocythemia
699940|NCT00003331|untreated hairy cell leukemia
699941|NCT00003331|progressive hairy cell leukemia, initial treatment
699942|NCT00003331|refractory hairy cell leukemia
699943|NCT00003331|chronic myelomonocytic leukemia
699944|NCT00003331|T-cell large granular lymphocyte leukemia
699945|NCT00003331|acute undifferentiated leukemia
699946|NCT00003331|stage III grade 1 follicular lymphoma
699947|NCT00003331|stage III grade 2 follicular lymphoma
699948|NCT00003331|stage III grade 3 follicular lymphoma
699949|NCT00003331|stage III adult diffuse small cleaved cell lymphoma
699950|NCT00003331|stage III adult diffuse mixed cell lymphoma
699951|NCT00003331|stage III adult diffuse large cell lymphoma
699952|NCT00003331|stage III adult immunoblastic large cell lymphoma
699953|NCT00003331|stage III adult lymphoblastic lymphoma
699954|NCT00003331|stage III adult Burkitt lymphoma
699955|NCT00003331|stage IV grade 1 follicular lymphoma
699956|NCT00003331|stage IV grade 2 follicular lymphoma
699957|NCT00003331|stage IV grade 3 follicular lymphoma
699958|NCT00003331|stage IV adult diffuse small cleaved cell lymphoma
699959|NCT00003331|stage IV adult diffuse mixed cell lymphoma
699960|NCT00003331|stage IV adult diffuse large cell lymphoma
699961|NCT00003331|stage IV adult immunoblastic large cell lymphoma
699962|NCT00003331|stage IV adult lymphoblastic lymphoma
699963|NCT00003331|stage IV adult Burkitt lymphoma
699964|NCT00003331|recurrent grade 1 follicular lymphoma
699965|NCT00003331|recurrent grade 2 follicular lymphoma
699966|NCT00003331|recurrent grade 3 follicular lymphoma
699967|NCT00003331|recurrent adult diffuse small cleaved cell lymphoma
699968|NCT00003331|recurrent adult diffuse mixed cell lymphoma
699969|NCT00003331|recurrent adult diffuse large cell lymphoma
699970|NCT00003331|recurrent adult immunoblastic large cell lymphoma
699971|NCT00003331|recurrent adult lymphoblastic lymphoma
699972|NCT00003331|recurrent adult Burkitt lymphoma
699973|NCT00003331|stage III adult T-cell leukemia/lymphoma
699974|NCT00003331|stage IV adult T-cell leukemia/lymphoma
699975|NCT00003331|recurrent adult T-cell leukemia/lymphoma
699976|NCT00003331|secondary acute myeloid leukemia
699977|NCT00003331|de novo myelodysplastic syndromes
699978|NCT00003331|previously treated myelodysplastic syndromes
699979|NCT00003331|secondary myelodysplastic syndromes
699980|NCT00003331|prolymphocytic leukemia
699981|NCT00003331|AIDS-related peripheral/systemic lymphoma
699982|NCT00003331|AIDS-related primary CNS lymphoma
699983|NCT00003331|primary systemic amyloidosis
699984|NCT00003331|stage III mantle cell lymphoma
699985|NCT00003331|stage IV mantle cell lymphoma
699986|NCT00003331|recurrent mantle cell lymphoma
699987|NCT00003331|angioimmunoblastic T-cell lymphoma
699988|NCT00003331|anaplastic large cell lymphoma
699989|NCT00003331|recurrent marginal zone lymphoma
699990|NCT00003331|recurrent small lymphocytic lymphoma
699991|NCT00003331|stage III small lymphocytic lymphoma
699992|NCT00003331|stage III marginal zone lymphoma
699993|NCT00003331|stage IV small lymphocytic lymphoma
699994|NCT00003331|stage IV marginal zone lymphoma
699995|NCT00003331|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
699996|NCT00003331|nodal marginal zone B-cell lymphoma
699997|NCT00003331|splenic marginal zone lymphoma
699998|NCT00003330|unspecified adult solid tumor, protocol specific
699999|NCT00003329|stage I colon cancer
700000|NCT00003329|stage II colon cancer
700001|NCT00003329|stage III colon cancer
700002|NCT00003329|stage IV colon cancer
700003|NCT00003329|stage I breast cancer
700004|NCT00003329|stage II breast cancer
700005|NCT00003329|stage IIIA breast cancer
700006|NCT00003329|stage IIIB breast cancer
700007|NCT00003329|stage IIIC breast cancer
700008|NCT00003329|stage IV breast cancer
700009|NCT00003329|stage I non-small cell lung cancer
700010|NCT00003329|stage II non-small cell lung cancer
700011|NCT00003329|stage III non-small cell lung cancer
700012|NCT00003329|limited stage small cell lung cancer
700013|NCT00003329|extensive stage small cell lung cancer
700014|NCT00003329|stage I prostate cancer
700015|NCT00003329|stage II prostate cancer
700016|NCT00003329|stage III prostate cancer
700017|NCT00003329|stage IV prostate cancer
700018|NCT00003329|stage IV non-small cell lung cancer
700019|NCT00003328|stage III squamous cell carcinoma of the lip and oral cavity
700020|NCT00003328|stage IV squamous cell carcinoma of the lip and oral cavity
700021|NCT00003328|stage III squamous cell carcinoma of the oropharynx
700022|NCT00003328|stage IV squamous cell carcinoma of the oropharynx
700023|NCT00003328|stage III squamous cell carcinoma of the hypopharynx
700024|NCT00003328|stage IV squamous cell carcinoma of the hypopharynx
700025|NCT00003328|stage III squamous cell carcinoma of the larynx
700026|NCT00003328|stage IV squamous cell carcinoma of the larynx
700027|NCT00003327|stage IV nasopharyngeal cancer
700028|NCT00003327|recurrent nasopharyngeal cancer
700029|NCT00003327|stage IV lip and oral cavity cancer
700030|NCT00003327|recurrent lip and oral cavity cancer
700031|NCT00003327|stage IV hypopharyngeal cancer
700032|NCT00003327|recurrent hypopharyngeal cancer
700033|NCT00003327|stage IV laryngeal cancer
700034|NCT00003327|recurrent laryngeal cancer
700035|NCT00003327|stage IV paranasal sinus and nasal cavity cancer
700036|NCT00003327|recurrent paranasal sinus and nasal cavity cancer
700037|NCT00003327|stage IV oropharyngeal cancer
700038|NCT00003327|recurrent oropharyngeal cancer
700039|NCT00003326|stage IV esophageal cancer
700040|NCT00003326|recurrent esophageal cancer
700041|NCT00003326|squamous cell carcinoma of the esophagus
700042|NCT00003326|adenocarcinoma of the esophagus
700043|NCT00003325|stage I vulvar cancer
700044|NCT00003325|stage II vulvar cancer
700045|NCT00003325|squamous cell carcinoma of the vulva
700046|NCT00003324|tumors metastatic to brain
700047|NCT00003323|adenocarcinoma of the prostate
700048|NCT00003323|recurrent prostate cancer
700049|NCT00003323|sexual dysfunction and infertility
700050|NCT00003322|stage III ovarian epithelial cancer
700051|NCT00003322|recurrent ovarian epithelial cancer
700052|NCT00003322|ovarian undifferentiated adenocarcinoma
700053|NCT00003322|ovarian mixed epithelial carcinoma
700054|NCT00003322|ovarian serous cystadenocarcinoma
700055|NCT00003322|ovarian mucinous cystadenocarcinoma
700056|NCT00003322|ovarian endometrioid adenocarcinoma
700057|NCT00003322|ovarian clear cell cystadenocarcinoma
700058|NCT00003322|primary peritoneal cavity cancer
700059|NCT00003322|Brenner tumor
700060|NCT00003321|stage I esophageal cancer
700061|NCT00003321|stage II esophageal cancer
700062|NCT00003321|stage III esophageal cancer
700063|NCT00003321|stage IV esophageal cancer
700064|NCT00003321|recurrent esophageal cancer
700065|NCT00003320|tumors metastatic to brain
700066|NCT00003317|stage IIIA non-small cell lung cancer
700067|NCT00003316|recurrent uterine sarcoma
700068|NCT00003316|uterine leiomyosarcoma
700069|NCT00003315|infection
700070|NCT00003313|stage II non-small cell lung cancer
700071|NCT00003313|stage IIIA non-small cell lung cancer
700072|NCT00003313|stage IIIB non-small cell lung cancer
700073|NCT00003313|oral complications
700074|NCT00003313|drug/agent toxicity by tissue/organ
700075|NCT00003313|radiation toxicity
700076|NCT00003312|stage I prostate cancer
700077|NCT00003312|stage IIB prostate cancer
700078|NCT00003312|stage IIA prostate cancer
700079|NCT00003311|stage I mantle cell lymphoma
700080|NCT00003311|contiguous stage II mantle cell lymphoma
700081|NCT00003311|noncontiguous stage II mantle cell lymphoma
700082|NCT00003311|stage III mantle cell lymphoma
700083|NCT00003311|stage IV mantle cell lymphoma
700084|NCT00003309|adult medulloblastoma
700085|NCT00003309|adult anaplastic ependymoma
700086|NCT00003309|adult ependymoma
700087|NCT00003309|adult supratentorial primitive neuroectodermal tumor (PNET)
700088|NCT00003308|metastatic osteosarcoma
700089|NCT00003308|chondrosarcoma
700090|NCT00003308|stage IV renal cell cancer
700091|NCT00003308|stage IV melanoma
700092|NCT00003308|tumors metastatic to brain
700093|NCT00003308|stage IV uterine sarcoma
700094|NCT00003308|ovarian sarcoma
700095|NCT00003308|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
700096|NCT00003308|stage IV adult soft tissue sarcoma
700097|NCT00003307|adenocarcinoma of the prostate
700098|NCT00003307|stage I prostate cancer
700099|NCT00003307|stage II prostate cancer
700100|NCT00003307|stage III prostate cancer
700101|NCT00003307|radiation toxicity
700102|NCT00003305|recurrent childhood acute lymphoblastic leukemia
700103|NCT00003305|recurrent childhood acute myeloid leukemia
700104|NCT00003305|recurrent adult acute myeloid leukemia
700105|NCT00003305|recurrent adult acute lymphoblastic leukemia
700106|NCT00003304|adult oligodendroglioma
700107|NCT00003302|breast cancer
700108|NCT00003301|recurrent adult brain tumor
700109|NCT00003301|adult glioblastoma
700110|NCT00003301|adult anaplastic astrocytoma
700111|NCT00003301|adult giant cell glioblastoma
700112|NCT00003301|adult gliosarcoma
700113|NCT00003299|extensive stage small cell lung cancer
700114|NCT00003298|stage II gastric cancer
700115|NCT00003298|stage III gastric cancer
700116|NCT00003298|stage IV gastric cancer
700117|NCT00003298|adenocarcinoma of the stomach
700118|NCT00003297|stage III ovarian epithelial cancer
700119|NCT00003297|stage IV ovarian epithelial cancer
700120|NCT00003297|recurrent ovarian epithelial cancer
700121|NCT00003296|localized resectable adult primary liver cancer
700122|NCT00003296|localized unresectable adult primary liver cancer
700123|NCT00003296|advanced adult primary liver cancer
700124|NCT00003296|recurrent adult primary liver cancer
700125|NCT00003296|localized gallbladder cancer
700126|NCT00003296|unresectable gallbladder cancer
700127|NCT00003296|recurrent gallbladder cancer
700128|NCT00003296|localized extrahepatic bile duct cancer
700129|NCT00003296|unresectable extrahepatic bile duct cancer
700130|NCT00003296|recurrent extrahepatic bile duct cancer
700131|NCT00003296|adult primary hepatocellular carcinoma
700132|NCT00003296|cholangiocarcinoma of the gallbladder
700133|NCT00003296|cholangiocarcinoma of the extrahepatic bile duct
700134|NCT00003296|adult primary cholangiocellular carcinoma
700135|NCT00003294|stage III adult Hodgkin lymphoma
700136|NCT00003294|stage IV adult Hodgkin lymphoma
700137|NCT00003294|recurrent adult Hodgkin lymphoma
700138|NCT00003294|stage III chronic lymphocytic leukemia
700139|NCT00003294|stage IV chronic lymphocytic leukemia
700140|NCT00003294|recurrent adult acute myeloid leukemia
700141|NCT00003294|recurrent adult acute lymphoblastic leukemia
700142|NCT00003294|relapsing chronic myelogenous leukemia
700143|NCT00003294|refractory chronic lymphocytic leukemia
700144|NCT00003294|unspecified adult solid tumor, protocol specific
700145|NCT00003294|chronic phase chronic myelogenous leukemia
700146|NCT00003294|accelerated phase chronic myelogenous leukemia
700147|NCT00003294|blastic phase chronic myelogenous leukemia
700148|NCT00003294|meningeal chronic myelogenous leukemia
700149|NCT00003294|untreated adult acute lymphoblastic leukemia
700150|NCT00003294|untreated adult acute myeloid leukemia
700151|NCT00003294|untreated hairy cell leukemia
700152|NCT00003294|progressive hairy cell leukemia, initial treatment
700153|NCT00003294|refractory hairy cell leukemia
700154|NCT00003294|chronic myelomonocytic leukemia
700155|NCT00003294|stage IV grade 1 follicular lymphoma
700156|NCT00003294|stage IV grade 2 follicular lymphoma
700157|NCT00003294|stage IV grade 3 follicular lymphoma
700158|NCT00003294|stage IV adult diffuse small cleaved cell lymphoma
700159|NCT00003294|stage IV adult diffuse mixed cell lymphoma
700160|NCT00003294|stage IV adult diffuse large cell lymphoma
700161|NCT00003294|stage IV adult immunoblastic large cell lymphoma
700162|NCT00003294|stage IV adult lymphoblastic lymphoma
700163|NCT00003294|stage IV adult Burkitt lymphoma
700164|NCT00003294|recurrent grade 1 follicular lymphoma
700165|NCT00003294|recurrent grade 2 follicular lymphoma
700166|NCT00003294|recurrent grade 3 follicular lymphoma
700167|NCT00003294|recurrent adult diffuse small cleaved cell lymphoma
700168|NCT00003294|recurrent adult diffuse mixed cell lymphoma
700169|NCT00003294|recurrent adult diffuse large cell lymphoma
700170|NCT00003294|recurrent adult immunoblastic large cell lymphoma
700171|NCT00003294|recurrent adult lymphoblastic lymphoma
700172|NCT00003294|recurrent adult Burkitt lymphoma
700173|NCT00003294|stage III adult T-cell leukemia/lymphoma
700174|NCT00003294|stage IV adult T-cell leukemia/lymphoma
700175|NCT00003294|recurrent adult T-cell leukemia/lymphoma
700176|NCT00003294|prolymphocytic leukemia
700177|NCT00003294|AIDS-related peripheral/systemic lymphoma
700178|NCT00003294|AIDS-related primary CNS lymphoma
700179|NCT00003294|stage IV mantle cell lymphoma
700180|NCT00003294|recurrent mantle cell lymphoma
700181|NCT00003294|angioimmunoblastic T-cell lymphoma
700182|NCT00003294|anaplastic large cell lymphoma
700183|NCT00003294|recurrent marginal zone lymphoma
700184|NCT00003294|recurrent small lymphocytic lymphoma
700185|NCT00003294|stage IV small lymphocytic lymphoma
700186|NCT00003294|stage IV marginal zone lymphoma
700187|NCT00003294|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700188|NCT00003294|nodal marginal zone B-cell lymphoma
700189|NCT00003294|splenic marginal zone lymphoma
700190|NCT00003293|recurrent adult brain tumor
700191|NCT00003293|adult glioblastoma
700192|NCT00003293|adult giant cell glioblastoma
700193|NCT00003293|adult gliosarcoma
700194|NCT00003291|untreated childhood acute lymphoblastic leukemia
700195|NCT00003290|stage IIB prostate cancer
700196|NCT00003290|stage IIA prostate cancer
700197|NCT00003290|stage III prostate cancer
700198|NCT00003289|Waldenstrom macroglobulinemia
700199|NCT00003289|stage III chronic lymphocytic leukemia
700200|NCT00003289|stage IV chronic lymphocytic leukemia
700201|NCT00003289|refractory chronic lymphocytic leukemia
700202|NCT00003289|unspecified adult solid tumor, protocol specific
700203|NCT00003289|refractory hairy cell leukemia
700204|NCT00003289|stage III grade 1 follicular lymphoma
700205|NCT00003289|stage III grade 2 follicular lymphoma
700206|NCT00003289|stage III grade 3 follicular lymphoma
700207|NCT00003289|stage III adult diffuse small cleaved cell lymphoma
700208|NCT00003289|stage III adult diffuse mixed cell lymphoma
700209|NCT00003289|stage IV grade 1 follicular lymphoma
700210|NCT00003289|stage IV grade 2 follicular lymphoma
700211|NCT00003289|stage IV adult diffuse small cleaved cell lymphoma
700212|NCT00003289|stage IV adult diffuse mixed cell lymphoma
700213|NCT00003289|recurrent grade 1 follicular lymphoma
700214|NCT00003289|recurrent grade 2 follicular lymphoma
700215|NCT00003289|recurrent grade 3 follicular lymphoma
700216|NCT00003289|recurrent adult diffuse small cleaved cell lymphoma
700217|NCT00003289|recurrent adult diffuse mixed cell lymphoma
700218|NCT00003289|prolymphocytic leukemia
700219|NCT00003289|stage III mantle cell lymphoma
700220|NCT00003289|stage IV mantle cell lymphoma
700221|NCT00003289|recurrent mantle cell lymphoma
700222|NCT00003289|recurrent marginal zone lymphoma
700223|NCT00003289|recurrent small lymphocytic lymphoma
700224|NCT00003289|stage III small lymphocytic lymphoma
700225|NCT00003289|stage III marginal zone lymphoma
700226|NCT00003289|stage IV small lymphocytic lymphoma
700227|NCT00003289|stage IV marginal zone lymphoma
700228|NCT00003289|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700229|NCT00003289|nodal marginal zone B-cell lymphoma
700230|NCT00003289|splenic marginal zone lymphoma
700231|NCT00003288|unspecified childhood solid tumor, protocol specific
700232|NCT00003287|stage IV colon cancer
700233|NCT00003287|stage IV rectal cancer
700234|NCT00003287|recurrent colon cancer
700235|NCT00003287|recurrent rectal cancer
700236|NCT00003287|adenocarcinoma of the colon
700237|NCT00003287|adenocarcinoma of the rectum
700238|NCT00003284|stage II non-small cell lung cancer
700239|NCT00003284|limited stage small cell lung cancer
700240|NCT00003284|extensive stage small cell lung cancer
700241|NCT00003284|recurrent small cell lung cancer
700242|NCT00003284|stage IIIA non-small cell lung cancer
700243|NCT00003284|stage IIIB non-small cell lung cancer
700244|NCT00003284|stage IV non-small cell lung cancer
700245|NCT00003283|invasive thymoma and thymic carcinoma
700246|NCT00003283|recurrent thymoma and thymic carcinoma
700247|NCT00003281|recurrent small cell lung cancer
700248|NCT00003280|stage I mantle cell lymphoma
700249|NCT00003280|contiguous stage II mantle cell lymphoma
700250|NCT00003280|noncontiguous stage II mantle cell lymphoma
700251|NCT00003280|stage III mantle cell lymphoma
700252|NCT00003280|stage IV mantle cell lymphoma
700253|NCT00003280|recurrent mantle cell lymphoma
700254|NCT00003279|limited stage small cell lung cancer
700255|NCT00003278|primary central nervous system non-Hodgkin lymphoma
700256|NCT00003278|intraocular lymphoma
700257|NCT00003276|unresectable gallbladder cancer
700258|NCT00003276|recurrent gallbladder cancer
700259|NCT00003274|stage II melanoma
700260|NCT00003273|childhood infratentorial ependymoma
700261|NCT00003273|childhood supratentorial ependymoma
700262|NCT00003273|localized resectable neuroblastoma
700263|NCT00003273|regional neuroblastoma
700264|NCT00003273|disseminated neuroblastoma
700265|NCT00003273|stage 4S neuroblastoma
700266|NCT00003273|extraocular retinoblastoma
700267|NCT00003273|childhood choroid plexus tumor
701800|NCT00003046|stage IV gastric cancer
700268|NCT00003273|localized unresectable neuroblastoma
700269|NCT00003273|previously untreated childhood rhabdomyosarcoma
700270|NCT00003273|untreated childhood supratentorial primitive neuroectodermal tumor
700271|NCT00003273|untreated childhood medulloblastoma
700272|NCT00003273|newly diagnosed childhood ependymoma
700273|NCT00003270|recurrent childhood acute lymphoblastic leukemia
700274|NCT00003270|recurrent adult Hodgkin lymphoma
700275|NCT00003270|Burkitt lymphoma
700276|NCT00003270|refractory multiple myeloma
700277|NCT00003270|stage I multiple myeloma
700278|NCT00003270|stage II multiple myeloma
700279|NCT00003270|stage III multiple myeloma
700280|NCT00003270|recurrent childhood lymphoblastic lymphoma
700281|NCT00003270|recurrent childhood acute myeloid leukemia
700282|NCT00003270|recurrent adult acute myeloid leukemia
700283|NCT00003270|recurrent adult acute lymphoblastic leukemia
700284|NCT00003270|relapsing chronic myelogenous leukemia
700285|NCT00003270|childhood diffuse large cell lymphoma
700286|NCT00003270|childhood immunoblastic large cell lymphoma
700287|NCT00003270|chronic phase chronic myelogenous leukemia
700288|NCT00003270|accelerated phase chronic myelogenous leukemia
700289|NCT00003270|blastic phase chronic myelogenous leukemia
700290|NCT00003270|meningeal chronic myelogenous leukemia
700291|NCT00003270|adult acute myeloid leukemia in remission
700292|NCT00003270|adult acute lymphoblastic leukemia in remission
700293|NCT00003270|childhood acute myeloid leukemia in remission
700294|NCT00003270|childhood acute lymphoblastic leukemia in remission
700295|NCT00003270|recurrent/refractory childhood Hodgkin lymphoma
700296|NCT00003270|recurrent grade 1 follicular lymphoma
700297|NCT00003270|recurrent grade 2 follicular lymphoma
700298|NCT00003270|recurrent grade 3 follicular lymphoma
700299|NCT00003270|recurrent adult diffuse small cleaved cell lymphoma
700300|NCT00003270|recurrent adult diffuse mixed cell lymphoma
700301|NCT00003270|recurrent adult diffuse large cell lymphoma
700302|NCT00003270|recurrent adult immunoblastic large cell lymphoma
700303|NCT00003270|recurrent adult lymphoblastic lymphoma
700304|NCT00003270|recurrent adult Burkitt lymphoma
700305|NCT00003270|secondary acute myeloid leukemia
700306|NCT00003270|de novo myelodysplastic syndromes
700307|NCT00003270|previously treated myelodysplastic syndromes
700308|NCT00003270|secondary myelodysplastic syndromes
700309|NCT00003270|graft versus host disease
700310|NCT00003270|recurrent childhood small noncleaved cell lymphoma
700311|NCT00003270|recurrent childhood large cell lymphoma
700312|NCT00003270|recurrent mantle cell lymphoma
700313|NCT00003270|recurrent marginal zone lymphoma
700314|NCT00003270|recurrent small lymphocytic lymphoma
700315|NCT00003270|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700316|NCT00003270|nodal marginal zone B-cell lymphoma
700317|NCT00003270|splenic marginal zone lymphoma
700318|NCT00003270|childhood myelodysplastic syndromes
700319|NCT00003269|stage I adult Hodgkin lymphoma
700320|NCT00003269|stage II adult Hodgkin lymphoma
700321|NCT00003269|stage III adult Hodgkin lymphoma
700322|NCT00003269|stage IV adult Hodgkin lymphoma
700323|NCT00003269|stage I breast cancer
700324|NCT00003269|stage II breast cancer
700325|NCT00003269|stage IV breast cancer
700326|NCT00003269|stage IIIA breast cancer
700327|NCT00003269|stage I non-small cell lung cancer
700328|NCT00003269|stage II non-small cell lung cancer
700329|NCT00003269|stage IIIB breast cancer
700330|NCT00003269|stage I cutaneous T-cell non-Hodgkin lymphoma
700331|NCT00003269|stage II cutaneous T-cell non-Hodgkin lymphoma
700332|NCT00003269|stage III cutaneous T-cell non-Hodgkin lymphoma
700333|NCT00003269|stage IV cutaneous T-cell non-Hodgkin lymphoma
700334|NCT00003269|stage I ovarian epithelial cancer
700335|NCT00003269|stage II ovarian epithelial cancer
700336|NCT00003269|stage III ovarian epithelial cancer
700337|NCT00003269|stage IV ovarian epithelial cancer
700338|NCT00003269|Waldenstrom macroglobulinemia
700339|NCT00003269|limited stage small cell lung cancer
700340|NCT00003269|extensive stage small cell lung cancer
700341|NCT00003269|stage IIIA non-small cell lung cancer
700342|NCT00003269|stage IIIB non-small cell lung cancer
700343|NCT00003269|stage IV non-small cell lung cancer
700344|NCT00003269|unspecified adult solid tumor, protocol specific
700345|NCT00003269|stage I grade 1 follicular lymphoma
700346|NCT00003269|stage I grade 2 follicular lymphoma
700347|NCT00003269|stage I grade 3 follicular lymphoma
700348|NCT00003269|stage I adult diffuse small cleaved cell lymphoma
700349|NCT00003269|stage I adult diffuse mixed cell lymphoma
700350|NCT00003269|stage I adult diffuse large cell lymphoma
700351|NCT00003269|stage I adult immunoblastic large cell lymphoma
700352|NCT00003269|stage I adult lymphoblastic lymphoma
700353|NCT00003269|stage I adult Burkitt lymphoma
700354|NCT00003269|stage III grade 1 follicular lymphoma
700355|NCT00003269|stage III grade 2 follicular lymphoma
700356|NCT00003269|stage III grade 3 follicular lymphoma
700357|NCT00003269|stage III adult diffuse small cleaved cell lymphoma
700358|NCT00003269|stage III adult diffuse mixed cell lymphoma
700359|NCT00003269|stage III adult diffuse large cell lymphoma
700360|NCT00003269|stage III adult immunoblastic large cell lymphoma
700361|NCT00003269|stage III adult lymphoblastic lymphoma
700362|NCT00003269|stage III adult Burkitt lymphoma
700363|NCT00003269|stage IV grade 1 follicular lymphoma
700364|NCT00003269|stage IV grade 2 follicular lymphoma
700365|NCT00003269|stage IV grade 3 follicular lymphoma
700366|NCT00003269|stage IV adult diffuse small cleaved cell lymphoma
700367|NCT00003269|stage IV adult diffuse mixed cell lymphoma
700368|NCT00003269|stage IV adult diffuse large cell lymphoma
700369|NCT00003269|stage IV adult immunoblastic large cell lymphoma
700370|NCT00003269|stage IV adult lymphoblastic lymphoma
700371|NCT00003269|stage IV adult Burkitt lymphoma
700372|NCT00003269|stage I adult T-cell leukemia/lymphoma
700373|NCT00003269|stage II adult T-cell leukemia/lymphoma
700374|NCT00003269|stage III adult T-cell leukemia/lymphoma
700375|NCT00003269|stage IV adult T-cell leukemia/lymphoma
700376|NCT00003269|drug/agent toxicity by tissue/organ
700377|NCT00003269|stage I mantle cell lymphoma
700378|NCT00003269|contiguous stage II grade 1 follicular lymphoma
700379|NCT00003269|contiguous stage II grade 2 follicular lymphoma
700380|NCT00003269|contiguous stage II grade 3 follicular lymphoma
700381|NCT00003269|contiguous stage II adult diffuse small cleaved cell lymphoma
700382|NCT00003269|contiguous stage II mantle cell lymphoma
700383|NCT00003269|contiguous stage II adult diffuse mixed cell lymphoma
700384|NCT00003269|contiguous stage II adult immunoblastic large cell lymphoma
700385|NCT00003269|contiguous stage II adult diffuse large cell lymphoma
700386|NCT00003269|contiguous stage II adult Burkitt lymphoma
700387|NCT00003269|contiguous stage II adult lymphoblastic lymphoma
700388|NCT00003269|noncontiguous stage II grade 1 follicular lymphoma
700389|NCT00003269|noncontiguous stage II grade 2 follicular lymphoma
700390|NCT00003269|noncontiguous stage II grade 3 follicular lymphoma
700391|NCT00003269|noncontiguous stage II adult diffuse small cleaved cell lymphoma
700392|NCT00003269|noncontiguous stage II mantle cell lymphoma
700393|NCT00003269|noncontiguous stage II adult diffuse mixed cell lymphoma
700394|NCT00003269|noncontiguous stage II adult immunoblastic large cell lymphoma
700395|NCT00003269|noncontiguous stage II adult diffuse large cell lymphoma
700396|NCT00003269|noncontiguous stage II adult Burkitt lymphoma
700397|NCT00003269|noncontiguous stage II adult lymphoblastic lymphoma
700398|NCT00003269|stage III mantle cell lymphoma
700399|NCT00003269|stage IV mantle cell lymphoma
700400|NCT00003269|noncontiguous stage II small lymphocytic lymphoma
700401|NCT00003269|noncontiguous stage II marginal zone lymphoma
700402|NCT00003269|stage I marginal zone lymphoma
700403|NCT00003269|stage I small lymphocytic lymphoma
700404|NCT00003269|stage III small lymphocytic lymphoma
700405|NCT00003269|stage III marginal zone lymphoma
700406|NCT00003269|stage IV small lymphocytic lymphoma
700407|NCT00003269|stage IV marginal zone lymphoma
700408|NCT00003269|contiguous stage II marginal zone lymphoma
700409|NCT00003269|contiguous stage II small lymphocytic lymphoma
700410|NCT00003269|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700411|NCT00003269|nodal marginal zone B-cell lymphoma
700412|NCT00003269|splenic marginal zone lymphoma
700413|NCT00003268|untreated adult acute myeloid leukemia
700414|NCT00003268|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
700415|NCT00003268|adult acute erythroid leukemia (M6)
700416|NCT00003268|adult acute myeloblastic leukemia without maturation (M1)
700417|NCT00003268|adult acute myeloblastic leukemia with maturation (M2)
700418|NCT00003268|adult acute myelomonocytic leukemia (M4)
700419|NCT00003268|adult acute megakaryoblastic leukemia (M7)
700420|NCT00003268|drug/agent toxicity by tissue/organ
700421|NCT00003268|adult acute minimally differentiated myeloid leukemia (M0)
700422|NCT00003267|stage I cervical cancer
700423|NCT00003267|stage II cervical cancer
700424|NCT00003267|stage I vaginal cancer
700425|NCT00003267|stage II vaginal cancer
700426|NCT00003267|stage I endometrial carcinoma
700427|NCT00003267|stage II endometrial carcinoma
700428|NCT00003267|infection
700429|NCT00003267|perioperative/postoperative complications
700430|NCT00003266|unspecified adult solid tumor, protocol specific
700431|NCT00003266|fatigue
700432|NCT00003264|stage IV salivary gland cancer
700433|NCT00003264|recurrent salivary gland cancer
700434|NCT00003264|recurrent metastatic squamous neck cancer with occult primary
700435|NCT00003264|metastatic squamous neck cancer with occult primary squamous cell carcinoma
700436|NCT00003264|salivary gland squamous cell carcinoma
700437|NCT00003264|stage IV squamous cell carcinoma of the lip and oral cavity
700438|NCT00003264|recurrent squamous cell carcinoma of the lip and oral cavity
700439|NCT00003264|stage IV squamous cell carcinoma of the oropharynx
700440|NCT00003264|recurrent squamous cell carcinoma of the oropharynx
700441|NCT00003264|stage IV squamous cell carcinoma of the nasopharynx
700442|NCT00003264|recurrent squamous cell carcinoma of the nasopharynx
700443|NCT00003264|stage IV squamous cell carcinoma of the hypopharynx
700444|NCT00003264|recurrent squamous cell carcinoma of the hypopharynx
700445|NCT00003264|stage IV squamous cell carcinoma of the larynx
700446|NCT00003264|recurrent squamous cell carcinoma of the larynx
700447|NCT00003264|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
700448|NCT00003264|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
700449|NCT00003263|localized malignant mesothelioma
700450|NCT00003262|stage I adult Hodgkin lymphoma
700451|NCT00003262|stage II adult Hodgkin lymphoma
700452|NCT00003262|stage III adult Hodgkin lymphoma
700453|NCT00003262|stage IV adult Hodgkin lymphoma
700454|NCT00003262|AIDS-related peripheral/systemic lymphoma
700455|NCT00003262|HIV-associated Hodgkin lymphoma
700456|NCT00003261|AIDS-related primary CNS lymphoma
700457|NCT00003260|stage IV colon cancer
700458|NCT00003260|stage IV rectal cancer
700459|NCT00003260|recurrent colon cancer
700460|NCT00003260|recurrent rectal cancer
700461|NCT00003260|adenocarcinoma of the colon
700462|NCT00003260|adenocarcinoma of the rectum
700463|NCT00003259|stage IV prostate cancer
700464|NCT00003257|recurrent metastatic squamous neck cancer with occult primary
700465|NCT00003257|recurrent squamous cell carcinoma of the lip and oral cavity
700466|NCT00003257|recurrent squamous cell carcinoma of the oropharynx
700467|NCT00003257|recurrent squamous cell carcinoma of the nasopharynx
700468|NCT00003257|recurrent squamous cell carcinoma of the hypopharynx
700469|NCT00003257|recurrent squamous cell carcinoma of the larynx
700470|NCT00003257|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
700471|NCT00003256|adenocarcinoma of the prostate
700472|NCT00003256|stage IV prostate cancer
700473|NCT00003255|recurrent adult acute myeloid leukemia
700474|NCT00003255|secondary acute myeloid leukemia
700475|NCT00003254|stage IV colon cancer
700476|NCT00003254|stage IV rectal cancer
700477|NCT00003254|recurrent colon cancer
700478|NCT00003254|recurrent rectal cancer
700479|NCT00003253|stage IV breast cancer
700480|NCT00003253|recurrent breast cancer
700481|NCT00003253|male breast cancer
700482|NCT00003252|unspecified adult solid tumor, protocol specific
700483|NCT00003252|drug/agent toxicity by tissue/organ
700484|NCT00003251|stage III nasopharyngeal cancer
700485|NCT00003251|stage IV nasopharyngeal cancer
700486|NCT00003251|recurrent nasopharyngeal cancer
700487|NCT00003251|stage III salivary gland cancer
700488|NCT00003251|stage IV salivary gland cancer
700489|NCT00003251|recurrent salivary gland cancer
700490|NCT00003251|salivary gland squamous cell carcinoma
700491|NCT00003251|high-grade salivary gland mucoepidermoid carcinoma
700492|NCT00003251|stage III lip and oral cavity cancer
700493|NCT00003251|stage IV lip and oral cavity cancer
700494|NCT00003251|recurrent lip and oral cavity cancer
700495|NCT00003251|stage III hypopharyngeal cancer
700496|NCT00003251|stage IV hypopharyngeal cancer
700497|NCT00003251|recurrent hypopharyngeal cancer
700498|NCT00003251|stage III laryngeal cancer
700499|NCT00003251|stage IV laryngeal cancer
700500|NCT00003251|recurrent laryngeal cancer
700501|NCT00003251|stage III paranasal sinus and nasal cavity cancer
700502|NCT00003251|stage IV paranasal sinus and nasal cavity cancer
700503|NCT00003251|recurrent paranasal sinus and nasal cavity cancer
700504|NCT00003251|stage III oropharyngeal cancer
700505|NCT00003251|stage IV oropharyngeal cancer
700506|NCT00003251|recurrent oropharyngeal cancer
700507|NCT00003251|stage III squamous cell carcinoma of the lip and oral cavity
700508|NCT00003251|stage III mucoepidermoid carcinoma of the oral cavity
700509|NCT00003251|stage IV squamous cell carcinoma of the lip and oral cavity
700510|NCT00003251|stage IV mucoepidermoid carcinoma of the oral cavity
700511|NCT00003251|recurrent squamous cell carcinoma of the lip and oral cavity
700512|NCT00003251|recurrent mucoepidermoid carcinoma of the oral cavity
700513|NCT00003251|stage III squamous cell carcinoma of the oropharynx
700514|NCT00003251|stage IV squamous cell carcinoma of the oropharynx
700515|NCT00003251|recurrent squamous cell carcinoma of the oropharynx
700516|NCT00003251|stage III squamous cell carcinoma of the nasopharynx
700517|NCT00003251|stage IV squamous cell carcinoma of the nasopharynx
700518|NCT00003251|recurrent squamous cell carcinoma of the nasopharynx
700519|NCT00003251|stage III squamous cell carcinoma of the hypopharynx
700520|NCT00003251|stage IV squamous cell carcinoma of the hypopharynx
700521|NCT00003251|recurrent squamous cell carcinoma of the hypopharynx
700522|NCT00003251|stage III squamous cell carcinoma of the larynx
700523|NCT00003251|stage IV squamous cell carcinoma of the larynx
700524|NCT00003251|recurrent squamous cell carcinoma of the larynx
700525|NCT00003251|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
700526|NCT00003251|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
700527|NCT00003251|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
700528|NCT00003251|drug/agent toxicity by tissue/organ
700529|NCT00003251|radiation toxicity
700530|NCT00003250|unspecified adult solid tumor, protocol specific
700531|NCT00003249|unspecified adult solid tumor, protocol specific
700532|NCT00003248|stage I chronic lymphocytic leukemia
700533|NCT00003248|stage II chronic lymphocytic leukemia
700534|NCT00003248|stage III chronic lymphocytic leukemia
700535|NCT00003248|stage IV chronic lymphocytic leukemia
700536|NCT00003248|B-cell chronic lymphocytic leukemia
700537|NCT00003245|Waldenström macroglobulinemia
700538|NCT00003245|recurrent grade 1 follicular lymphoma
700539|NCT00003245|recurrent grade 2 follicular lymphoma
700540|NCT00003245|recurrent grade 3 follicular lymphoma
700541|NCT00003245|recurrent adult diffuse small cleaved cell lymphoma
700542|NCT00003245|recurrent adult diffuse mixed cell lymphoma
700543|NCT00003245|recurrent adult diffuse large cell lymphoma
700544|NCT00003245|recurrent adult immunoblastic large cell lymphoma
700545|NCT00003245|recurrent adult Burkitt lymphoma
700546|NCT00003245|recurrent mantle cell lymphoma
700547|NCT00003245|recurrent marginal zone lymphoma
700548|NCT00003245|recurrent small lymphocytic lymphoma
700549|NCT00003245|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700550|NCT00003245|nodal marginal zone B-cell lymphoma
700551|NCT00003245|splenic marginal zone lymphoma
700552|NCT00003243|recurrent childhood acute lymphoblastic leukemia
700553|NCT00003243|recurrent childhood lymphoblastic lymphoma
700554|NCT00003243|recurrent childhood acute myeloid leukemia
700555|NCT00003243|recurrent adult acute myeloid leukemia
700556|NCT00003243|recurrent adult acute lymphoblastic leukemia
700557|NCT00003243|relapsing chronic myelogenous leukemia
700558|NCT00003243|accelerated phase chronic myelogenous leukemia
700559|NCT00003243|blastic phase chronic myelogenous leukemia
700560|NCT00003243|acute undifferentiated leukemia
700561|NCT00003243|recurrent adult diffuse mixed cell lymphoma
700562|NCT00003243|recurrent adult diffuse large cell lymphoma
700563|NCT00003243|recurrent adult lymphoblastic lymphoma
700564|NCT00003243|recurrent adult Burkitt lymphoma
700565|NCT00003243|secondary acute myeloid leukemia
700566|NCT00003243|previously treated myelodysplastic syndromes
700567|NCT00003243|recurrent childhood small noncleaved cell lymphoma
700568|NCT00003243|recurrent childhood large cell lymphoma
700569|NCT00003243|childhood chronic myelogenous leukemia
700570|NCT00003243|atypical chronic myeloid leukemia
700571|NCT00003243|myelodysplastic/myeloproliferative disease, unclassifiable
700572|NCT00003243|childhood myelodysplastic syndromes
700573|NCT00003242|unspecified adult solid tumor, protocol specific
700574|NCT00003241|recurrent childhood brain tumor
700575|NCT00003241|childhood high-grade cerebral astrocytoma
700576|NCT00003241|untreated childhood brain stem glioma
700577|NCT00003241|recurrent childhood brain stem glioma
700578|NCT00003241|recurrent childhood supratentorial primitive neuroectodermal tumor
700579|NCT00003241|recurrent childhood cerebellar astrocytoma
700580|NCT00003241|recurrent childhood cerebral astrocytoma
700581|NCT00003241|recurrent childhood medulloblastoma
700582|NCT00003241|recurrent childhood ependymoma
700583|NCT00003240|stage I non-small cell lung cancer
700584|NCT00003240|stage II non-small cell lung cancer
700585|NCT00003240|stage IIIA non-small cell lung cancer
700586|NCT00003240|stage IIIB non-small cell lung cancer
700587|NCT00003240|stage IV non-small cell lung cancer
700588|NCT00003239|chronic phase chronic myelogenous leukemia
700589|NCT00003239|Philadelphia chromosome positive chronic myelogenous leukemia
700590|NCT00003239|Homoharringtonine
700591|NCT00003239|HHT
700592|NCT00003239|cephalotaxus alkaloid
700593|NCT00003239|cytarabine
700594|NCT00003239|Interferon Alpha 2-A
700595|NCT00003239|Roferon-A
700596|NCT00003239|Ara-C
700597|NCT00003239|DepotCyt
700598|NCT00003239|Cytosine Arabinosine Hydrochloride
700599|NCT00003238|recurrent prostate cancer
700600|NCT00003237|stage II gastric cancer
700601|NCT00003237|stage III gastric cancer
700602|NCT00003237|stage II esophageal cancer
700603|NCT00003237|stage III esophageal cancer
700604|NCT00003237|adenocarcinoma of the stomach
700605|NCT00003237|adenocarcinoma of the esophagus
700606|NCT00003236|recurrent breast cancer
700607|NCT00003235|squamous cell lung cancer
700608|NCT00003235|large cell lung cancer
700609|NCT00003235|stage IIIA non-small cell lung cancer
700610|NCT00003235|stage IIIB non-small cell lung cancer
700611|NCT00003235|adenocarcinoma of the lung
700612|NCT00003234|recurrent childhood rhabdomyosarcoma
700613|NCT00003234|recurrent neuroblastoma
700614|NCT00003234|recurrent childhood soft tissue sarcoma
700615|NCT00003234|recurrent childhood supratentorial primitive neuroectodermal tumor
700616|NCT00003234|recurrent childhood cerebellar astrocytoma
700617|NCT00003234|recurrent childhood cerebral astrocytoma
700618|NCT00003234|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
700619|NCT00003234|recurrent childhood ependymoma
700620|NCT00003232|adenocarcinoma of the prostate
700621|NCT00003232|recurrent prostate cancer
700622|NCT00003232|pain
700623|NCT00003232|quality of life
700624|NCT00003231|squamous cell lung cancer
700625|NCT00003231|large cell lung cancer
700626|NCT00003231|stage IIIA non-small cell lung cancer
700627|NCT00003231|adenocarcinoma of the lung
700628|NCT00003230|recurrent adult acute myeloid leukemia
700629|NCT00003230|recurrent adult acute lymphoblastic leukemia
700630|NCT00003230|blastic phase chronic myelogenous leukemia
700631|NCT00003230|untreated adult acute lymphoblastic leukemia
700632|NCT00003230|untreated adult acute myeloid leukemia
700633|NCT00003229|stage IV melanoma
700634|NCT00003229|recurrent melanoma
700635|NCT00003225|stage IV colon cancer
700636|NCT00003225|stage IV rectal cancer
700637|NCT00003225|recurrent colon cancer
700638|NCT00003225|recurrent rectal cancer
700639|NCT00003224|stage II melanoma
700640|NCT00003224|stage III melanoma
700641|NCT00003224|stage IV melanoma
700642|NCT00003224|recurrent melanoma
700643|NCT00003223|lip and oral cavity cancer
700651|NCT00003220|adenocarcinoma of the colon
700652|NCT00003220|adenocarcinoma of the rectum
700653|NCT00003219|stage IV breast cancer
700654|NCT00003219|recurrent breast cancer
700655|NCT00003217|childhood Burkitt lymphoma
700656|NCT00003217|untreated childhood acute lymphoblastic leukemia
700657|NCT00003217|B-cell childhood acute lymphoblastic leukemia
700658|NCT00003217|stage III childhood small noncleaved cell lymphoma
700659|NCT00003217|stage IV childhood small noncleaved cell lymphoma
700660|NCT00003216|stage I pancreatic cancer
700661|NCT00003216|stage II pancreatic cancer
700662|NCT00003216|stage III pancreatic cancer
700663|NCT00003216|adenocarcinoma of the pancreas
700664|NCT00003216|stage IV pancreatic cancer
700665|NCT00003215|stage I adult diffuse mixed cell lymphoma
700666|NCT00003215|stage I adult diffuse large cell lymphoma
700667|NCT00003215|stage I adult immunoblastic large cell lymphoma
700668|NCT00003215|stage III adult diffuse mixed cell lymphoma
700669|NCT00003215|stage III adult diffuse large cell lymphoma
700670|NCT00003215|stage III adult immunoblastic large cell lymphoma
700671|NCT00003215|stage IV adult diffuse mixed cell lymphoma
700672|NCT00003215|stage IV adult diffuse large cell lymphoma
700673|NCT00003215|stage IV adult immunoblastic large cell lymphoma
700674|NCT00003215|contiguous stage II adult diffuse mixed cell lymphoma
700675|NCT00003215|contiguous stage II adult immunoblastic large cell lymphoma
700676|NCT00003215|contiguous stage II adult diffuse large cell lymphoma
700677|NCT00003215|noncontiguous stage II adult diffuse mixed cell lymphoma
700678|NCT00003215|noncontiguous stage II adult immunoblastic large cell lymphoma
700679|NCT00003215|noncontiguous stage II adult diffuse large cell lymphoma
700680|NCT00003215|anaplastic large cell lymphoma
700681|NCT00003214|stage III ovarian epithelial cancer
700682|NCT00003214|stage IV ovarian epithelial cancer
700683|NCT00003213|unspecified adult solid tumor, protocol specific
700684|NCT00003213|nausea and vomiting
700685|NCT00003212|adult angiosarcoma
700686|NCT00003212|adult fibrosarcoma
700687|NCT00003212|adult leiomyosarcoma
700688|NCT00003212|adult liposarcoma
700689|NCT00003212|adult neurofibrosarcoma
700690|NCT00003212|adult synovial sarcoma
700691|NCT00003212|recurrent adult soft tissue sarcoma
700692|NCT00003212|adult malignant fibrous histiocytoma
700693|NCT00003212|adult malignant hemangiopericytoma
700694|NCT00003212|adult rhabdomyosarcoma
700695|NCT00003212|stage IV uterine sarcoma
700696|NCT00003212|recurrent uterine sarcoma
700697|NCT00003212|stage IV adult soft tissue sarcoma
700698|NCT00003211|untreated childhood supratentorial primitive neuroectodermal tumor
700699|NCT00003211|untreated childhood medulloblastoma
700700|NCT00003209|stage IB cervical cancer
700701|NCT00003209|stage IIA cervical cancer
700702|NCT00003209|cervical squamous cell carcinoma
700703|NCT00003209|cervical adenocarcinoma
700704|NCT00003209|cervical adenosquamous cell carcinoma
700705|NCT00003207|unspecified adult solid tumor, protocol specific
700706|NCT00003207|AIDS-related Kaposi sarcoma
700707|NCT00003207|recurrent Kaposi sarcoma
700708|NCT00003206|stage IV nasopharyngeal cancer
700709|NCT00003206|recurrent nasopharyngeal cancer
700710|NCT00003205|stage IV breast cancer
700711|NCT00003205|recurrent breast cancer
700712|NCT00003203|untreated childhood supratentorial primitive neuroectodermal tumor
700713|NCT00003203|untreated childhood medulloblastoma
700714|NCT00003203|localized unresectable neuroblastoma
700715|NCT00003203|regional neuroblastoma
700716|NCT00003203|stage 4S neuroblastoma
700717|NCT00003202|squamous cell lung cancer
700718|NCT00003202|large cell lung cancer
700719|NCT00003202|stage IIIA non-small cell lung cancer
700720|NCT00003202|stage IIIB non-small cell lung cancer
700721|NCT00003202|adenocarcinoma of the lung
700722|NCT00003202|adenosquamous cell lung cancer
700723|NCT00003200|stage III squamous cell carcinoma of the lip and oral cavity
700724|NCT00003200|stage IV squamous cell carcinoma of the lip and oral cavity
700725|NCT00003200|stage III squamous cell carcinoma of the oropharynx
700726|NCT00003200|stage III lymphoepithelioma of the oropharynx
700727|NCT00003200|stage IV squamous cell carcinoma of the oropharynx
700728|NCT00003200|stage IV lymphoepithelioma of the oropharynx
700729|NCT00003200|stage III squamous cell carcinoma of the nasopharynx
700730|NCT00003200|stage III lymphoepithelioma of the nasopharynx
700731|NCT00003200|stage IV squamous cell carcinoma of the nasopharynx
700732|NCT00003200|stage IV lymphoepithelioma of the nasopharynx
700733|NCT00003200|stage III squamous cell carcinoma of the hypopharynx
700734|NCT00003200|stage IV squamous cell carcinoma of the hypopharynx
700735|NCT00003200|stage III squamous cell carcinoma of the larynx
700736|NCT00003200|stage IV squamous cell carcinoma of the larynx
700737|NCT00003200|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
700738|NCT00003200|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
700739|NCT00003198|unspecified adult solid tumor, protocol specific
700740|NCT00003197|unspecified adult solid tumor, protocol specific
700741|NCT00003195|refractory multiple myeloma
700742|NCT00003195|stage II multiple myeloma
700743|NCT00003195|stage III multiple myeloma
700744|NCT00003194|unspecified childhood solid tumor, protocol specific
700746|NCT00003193|stage III squamous cell carcinoma of the lip and oral cavity
700747|NCT00003193|stage IV squamous cell carcinoma of the lip and oral cavity
700748|NCT00003193|stage III squamous cell carcinoma of the oropharynx
700749|NCT00003193|stage IV squamous cell carcinoma of the oropharynx
700750|NCT00003193|stage III squamous cell carcinoma of the nasopharynx
700751|NCT00003193|stage IV squamous cell carcinoma of the nasopharynx
700752|NCT00003193|stage III squamous cell carcinoma of the hypopharynx
700753|NCT00003193|stage IV squamous cell carcinoma of the hypopharynx
700754|NCT00003193|stage III squamous cell carcinoma of the larynx
700755|NCT00003193|stage IV squamous cell carcinoma of the larynx
700756|NCT00003193|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
700757|NCT00003193|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
700758|NCT00003192|stage III gastric cancer
700759|NCT00003192|stage IV gastric cancer
700760|NCT00003192|recurrent gastric cancer
700761|NCT00003192|stage III esophageal cancer
700762|NCT00003192|stage IV esophageal cancer
700763|NCT00003192|recurrent esophageal cancer
700764|NCT00003192|adenocarcinoma of the stomach
700765|NCT00003191|recurrent neuroblastoma
700766|NCT00003191|unspecified childhood solid tumor, protocol specific
700767|NCT00003187|recurrent childhood acute lymphoblastic leukemia
700768|NCT00003187|stage IV childhood lymphoblastic lymphoma
700769|NCT00003187|recurrent childhood acute myeloid leukemia
700770|NCT00003187|recurrent adult acute myeloid leukemia
700771|NCT00003187|recurrent adult acute lymphoblastic leukemia
700772|NCT00003187|relapsing chronic myelogenous leukemia
700773|NCT00003187|chronic phase chronic myelogenous leukemia
700774|NCT00003187|accelerated phase chronic myelogenous leukemia
700775|NCT00003187|untreated adult acute lymphoblastic leukemia
700776|NCT00003187|untreated adult acute myeloid leukemia
700777|NCT00003187|untreated childhood acute myeloid leukemia and other myeloid malignancies
700778|NCT00003187|untreated childhood acute lymphoblastic leukemia
700779|NCT00003187|adult acute myeloid leukemia in remission
700780|NCT00003187|adult acute lymphoblastic leukemia in remission
700781|NCT00003187|childhood acute myeloid leukemia in remission
700782|NCT00003187|childhood acute lymphoblastic leukemia in remission
700783|NCT00003187|refractory anemia
700784|NCT00003187|refractory anemia with ringed sideroblasts
700785|NCT00003187|refractory anemia with excess blasts
700786|NCT00003187|refractory anemia with excess blasts in transformation
700787|NCT00003187|chronic myelomonocytic leukemia
700788|NCT00003187|acute undifferentiated leukemia
700789|NCT00003187|stage IV adult lymphoblastic lymphoma
700790|NCT00003187|de novo myelodysplastic syndromes
700791|NCT00003187|previously treated myelodysplastic syndromes
700792|NCT00003187|secondary myelodysplastic syndromes
700793|NCT00003187|childhood myelodysplastic syndromes
700794|NCT00003186|stage I colon cancer
700795|NCT00003186|stage II colon cancer
700796|NCT00003186|stage III colon cancer
700797|NCT00003186|stage IV colon cancer
700798|NCT00003186|stage I rectal cancer
700799|NCT00003186|stage II rectal cancer
700800|NCT00003186|stage III rectal cancer
700801|NCT00003186|stage IV rectal cancer
700802|NCT00003186|adenocarcinoma of the colon
700803|NCT00003186|liver metastases
700804|NCT00003185|adult glioblastoma
700805|NCT00003185|adult anaplastic astrocytoma
700806|NCT00003185|adult giant cell glioblastoma
700807|NCT00003185|adult gliosarcoma
700808|NCT00003184|stage IV breast cancer
700809|NCT00003184|recurrent breast cancer
700810|NCT00003183|adenocarcinoma of the prostate
700811|NCT00003183|stage IV prostate cancer
700812|NCT00003183|recurrent prostate cancer
700813|NCT00003182|stage III nasopharyngeal cancer
700814|NCT00003182|stage IV nasopharyngeal cancer
700815|NCT00003182|recurrent nasopharyngeal cancer
700816|NCT00003182|stage III salivary gland cancer
700817|NCT00003182|stage IV salivary gland cancer
700818|NCT00003182|recurrent salivary gland cancer
700819|NCT00003182|salivary gland squamous cell carcinoma
700820|NCT00003182|stage III lip and oral cavity cancer
700821|NCT00003182|stage IV lip and oral cavity cancer
700822|NCT00003182|recurrent lip and oral cavity cancer
700823|NCT00003182|stage III hypopharyngeal cancer
700824|NCT00003182|stage IV hypopharyngeal cancer
700825|NCT00003182|recurrent hypopharyngeal cancer
700826|NCT00003182|stage III laryngeal cancer
700827|NCT00003182|stage IV laryngeal cancer
700828|NCT00003182|recurrent laryngeal cancer
700829|NCT00003182|stage III paranasal sinus and nasal cavity cancer
700830|NCT00003182|stage IV paranasal sinus and nasal cavity cancer
700831|NCT00003182|recurrent paranasal sinus and nasal cavity cancer
700832|NCT00003182|stage III oropharyngeal cancer
700833|NCT00003182|stage IV oropharyngeal cancer
700834|NCT00003182|recurrent oropharyngeal cancer
700835|NCT00003182|stage III squamous cell carcinoma of the lip and oral cavity
700836|NCT00003182|stage IV squamous cell carcinoma of the lip and oral cavity
700837|NCT00003182|recurrent squamous cell carcinoma of the lip and oral cavity
700838|NCT00003182|stage III squamous cell carcinoma of the oropharynx
700839|NCT00003182|stage IV squamous cell carcinoma of the oropharynx
700840|NCT00003182|recurrent squamous cell carcinoma of the oropharynx
700841|NCT00003182|stage III squamous cell carcinoma of the nasopharynx
700842|NCT00003182|stage IV squamous cell carcinoma of the nasopharynx
700843|NCT00003182|recurrent squamous cell carcinoma of the nasopharynx
700844|NCT00003182|stage III squamous cell carcinoma of the hypopharynx
700845|NCT00003182|stage IV squamous cell carcinoma of the hypopharynx
700846|NCT00003182|recurrent squamous cell carcinoma of the hypopharynx
700847|NCT00003182|stage III squamous cell carcinoma of the larynx
700848|NCT00003182|stage IV squamous cell carcinoma of the larynx
700849|NCT00003182|recurrent squamous cell carcinoma of the larynx
700850|NCT00003182|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
700851|NCT00003182|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
700852|NCT00003182|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
700853|NCT00003181|stage IV renal cell cancer
700854|NCT00003181|recurrent renal cell cancer
700855|NCT00003179|endometrial cancer
700856|NCT00003178|recurrent childhood acute myeloid leukemia
700857|NCT00003178|childhood acute myeloblastic leukemia without maturation (M1)
700858|NCT00003178|childhood acute myeloblastic leukemia with maturation (M2)
700859|NCT00003178|childhood acute promyelocytic leukemia (M3)
700860|NCT00003178|childhood acute myelomonocytic leukemia (M4)
700861|NCT00003178|childhood acute monoblastic leukemia (M5a)
700862|NCT00003178|childhood acute monocytic leukemia (M5b)
700863|NCT00003178|childhood acute erythroleukemia (M6)
700864|NCT00003178|childhood acute megakaryocytic leukemia (M7)
700865|NCT00003178|childhood acute minimally differentiated myeloid leukemia (M0)
700866|NCT00003176|recurrent adult brain tumor
700867|NCT00003176|adult glioblastoma
700868|NCT00003176|adult anaplastic astrocytoma
700869|NCT00003176|adult mixed glioma
700870|NCT00003176|adult giant cell glioblastoma
700871|NCT00003176|adult gliosarcoma
700872|NCT00003175|recurrent bladder cancer
700873|NCT00003175|transitional cell carcinoma of the bladder
700874|NCT00003175|recurrent urethral cancer
700875|NCT00003175|recurrent transitional cell cancer of the renal pelvis and ureter
700876|NCT00003174|stage I chronic lymphocytic leukemia
700877|NCT00003174|stage II chronic lymphocytic leukemia
700878|NCT00003174|stage III chronic lymphocytic leukemia
700879|NCT00003174|stage IV chronic lymphocytic leukemia
700880|NCT00003174|refractory chronic lymphocytic leukemia
700881|NCT00003173|intraocular retinoblastoma
700882|NCT00003173|recurrent retinoblastoma
700883|NCT00003173|childhood central nervous system germ cell tumor
700884|NCT00003173|stage III malignant testicular germ cell tumor
700885|NCT00003173|recurrent malignant testicular germ cell tumor
700886|NCT00003173|unspecified childhood solid tumor, protocol specific
700887|NCT00003173|unspecified adult solid tumor, protocol specific
700888|NCT00003173|childhood germ cell tumor
700889|NCT00003173|stage III ovarian germ cell tumor
700890|NCT00003173|stage IV ovarian germ cell tumor
700891|NCT00003173|recurrent ovarian germ cell tumor
700892|NCT00003173|extragonadal germ cell tumor
700893|NCT00003173|adult central nervous system germ cell tumor
700894|NCT00003173|childhood teratoma
700895|NCT00003173|childhood malignant testicular germ cell tumor
700896|NCT00003173|childhood malignant ovarian germ cell tumor
700897|NCT00003173|childhood extragonadal germ cell tumor
700898|NCT00003173|recurrent childhood malignant germ cell tumor
700899|NCT00003172|stage III gastric cancer
700900|NCT00003172|stage IV gastric cancer
700901|NCT00003172|recurrent gastric cancer
700902|NCT00003171|refractory anemia
700903|NCT00003171|refractory anemia with ringed sideroblasts
700904|NCT00003171|refractory anemia with excess blasts
700905|NCT00003171|refractory anemia with excess blasts in transformation
700906|NCT00003171|chronic myelomonocytic leukemia
700907|NCT00003171|de novo myelodysplastic syndromes
700908|NCT00003171|previously treated myelodysplastic syndromes
700909|NCT00003171|secondary myelodysplastic syndromes
700910|NCT00003165|stage IV breast cancer
700911|NCT00003165|recurrent breast cancer
700912|NCT00003163|refractory multiple myeloma
700913|NCT00003163|Waldenström macroglobulinemia
700914|NCT00003163|stage I multiple myeloma
700915|NCT00003163|stage II multiple myeloma
700916|NCT00003163|stage III multiple myeloma
700917|NCT00003163|stage III grade 1 follicular lymphoma
700918|NCT00003163|stage III grade 2 follicular lymphoma
700919|NCT00003163|stage III grade 3 follicular lymphoma
700920|NCT00003163|stage III adult diffuse small cleaved cell lymphoma
700921|NCT00003163|stage III adult diffuse mixed cell lymphoma
700922|NCT00003163|stage III adult diffuse large cell lymphoma
700923|NCT00003163|stage III adult immunoblastic large cell lymphoma
700924|NCT00003163|stage III adult lymphoblastic lymphoma
700925|NCT00003163|stage III adult Burkitt lymphoma
700926|NCT00003163|stage IV grade 1 follicular lymphoma
700927|NCT00003163|stage IV grade 2 follicular lymphoma
700928|NCT00003163|stage IV grade 3 follicular lymphoma
700929|NCT00003163|stage IV adult diffuse small cleaved cell lymphoma
700930|NCT00003163|stage IV adult diffuse mixed cell lymphoma
700931|NCT00003163|stage IV adult diffuse large cell lymphoma
700932|NCT00003163|stage IV adult immunoblastic large cell lymphoma
700933|NCT00003163|stage IV adult lymphoblastic lymphoma
700934|NCT00003163|stage IV adult Burkitt lymphoma
700935|NCT00003163|recurrent grade 1 follicular lymphoma
700936|NCT00003163|recurrent grade 2 follicular lymphoma
700937|NCT00003163|recurrent grade 3 follicular lymphoma
700938|NCT00003163|recurrent adult diffuse small cleaved cell lymphoma
700939|NCT00003163|recurrent adult diffuse mixed cell lymphoma
700940|NCT00003163|recurrent adult diffuse large cell lymphoma
700941|NCT00003163|recurrent adult immunoblastic large cell lymphoma
700942|NCT00003163|recurrent adult lymphoblastic lymphoma
700943|NCT00003163|recurrent adult Burkitt lymphoma
700944|NCT00003163|primary systemic amyloidosis
700945|NCT00003163|contiguous stage II grade 1 follicular lymphoma
700946|NCT00003163|contiguous stage II grade 2 follicular lymphoma
700947|NCT00003163|contiguous stage II grade 3 follicular lymphoma
700948|NCT00003163|contiguous stage II adult diffuse small cleaved cell lymphoma
700949|NCT00003163|contiguous stage II mantle cell lymphoma
700950|NCT00003163|contiguous stage II adult diffuse mixed cell lymphoma
700951|NCT00003163|contiguous stage II adult immunoblastic large cell lymphoma
700952|NCT00003163|contiguous stage II adult diffuse large cell lymphoma
700953|NCT00003163|contiguous stage II adult Burkitt lymphoma
700954|NCT00003163|contiguous stage II adult lymphoblastic lymphoma
700955|NCT00003163|noncontiguous stage II grade 1 follicular lymphoma
700956|NCT00003163|noncontiguous stage II grade 2 follicular lymphoma
700957|NCT00003163|noncontiguous stage II grade 3 follicular lymphoma
700958|NCT00003163|noncontiguous stage II adult diffuse small cleaved cell lymphoma
700959|NCT00003163|noncontiguous stage II mantle cell lymphoma
700960|NCT00003163|noncontiguous stage II adult diffuse mixed cell lymphoma
700961|NCT00003163|noncontiguous stage II adult immunoblastic large cell lymphoma
700962|NCT00003163|noncontiguous stage II adult diffuse large cell lymphoma
700963|NCT00003163|noncontiguous stage II adult Burkitt lymphoma
700964|NCT00003163|noncontiguous stage II adult lymphoblastic lymphoma
700965|NCT00003163|stage III mantle cell lymphoma
700966|NCT00003163|stage IV mantle cell lymphoma
700967|NCT00003163|recurrent mantle cell lymphoma
700968|NCT00003163|noncontiguous stage II small lymphocytic lymphoma
700969|NCT00003163|noncontiguous stage II marginal zone lymphoma
700970|NCT00003163|recurrent marginal zone lymphoma
700971|NCT00003163|recurrent small lymphocytic lymphoma
700972|NCT00003163|stage III small lymphocytic lymphoma
700973|NCT00003163|stage III marginal zone lymphoma
700974|NCT00003163|stage IV small lymphocytic lymphoma
700975|NCT00003163|stage IV marginal zone lymphoma
700976|NCT00003163|contiguous stage II marginal zone lymphoma
700977|NCT00003163|contiguous stage II small lymphocytic lymphoma
700978|NCT00003163|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
700979|NCT00003163|nodal marginal zone B-cell lymphoma
700980|NCT00003163|splenic marginal zone lymphoma
700981|NCT00003162|stage IV breast cancer
700982|NCT00003162|recurrent breast cancer
700983|NCT00003162|stage IV prostate cancer
700984|NCT00003162|recurrent prostate cancer
700985|NCT00003162|bone metastases
700986|NCT00003162|pain
700987|NCT00003160|stage III ovarian epithelial cancer
700988|NCT00003160|stage IV ovarian epithelial cancer
700989|NCT00003160|recurrent ovarian epithelial cancer
700990|NCT00003160|fallopian tube cancer
700991|NCT00003160|primary peritoneal cavity cancer
700992|NCT00003159|stage I non-small cell lung cancer
700993|NCT00003159|stage II non-small cell lung cancer
700994|NCT00003159|stage IIIA non-small cell lung cancer
700995|NCT00003159|stage IIIB non-small cell lung cancer
700996|NCT00003159|stage 0 non-small cell lung cancer
700997|NCT00003158|stage IIIA non-small cell lung cancer
700998|NCT00003158|stage IIIB non-small cell lung cancer
700999|NCT00003157|stage IV gastric cancer
701000|NCT00003157|recurrent gastric cancer
701001|NCT00003157|recurrent pancreatic cancer
701002|NCT00003157|stage IV pancreatic cancer
701003|NCT00003156|recurrent uterine sarcoma
701004|NCT00003156|uterine carcinosarcoma
701005|NCT00003154|stage IIIB non-small cell lung cancer
701006|NCT00003154|stage IV non-small cell lung cancer
701007|NCT00003153|refractory multiple myeloma
701008|NCT00003152|stage III grade 1 follicular lymphoma
701009|NCT00003152|stage III grade 2 follicular lymphoma
701010|NCT00003152|stage III grade 3 follicular lymphoma
701011|NCT00003152|stage IV grade 1 follicular lymphoma
701012|NCT00003152|stage IV grade 2 follicular lymphoma
701013|NCT00003152|stage IV grade 3 follicular lymphoma
701014|NCT00003151|contiguous stage II marginal zone lymphoma
701015|NCT00003151|contiguous stage II small lymphocytic lymphoma
701016|NCT00003151|stage I marginal zone lymphoma
701017|NCT00003151|stage I small lymphocytic lymphoma
701018|NCT00003151|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701019|NCT00003150|stage I adult diffuse mixed cell lymphoma
701020|NCT00003150|stage I adult diffuse large cell lymphoma
701021|NCT00003150|stage I adult immunoblastic large cell lymphoma
701022|NCT00003150|stage III adult diffuse mixed cell lymphoma
701023|NCT00003150|stage III adult diffuse large cell lymphoma
701024|NCT00003150|stage III adult immunoblastic large cell lymphoma
701025|NCT00003150|stage IV adult diffuse mixed cell lymphoma
701026|NCT00003150|stage IV adult diffuse large cell lymphoma
701027|NCT00003150|stage IV adult immunoblastic large cell lymphoma
701028|NCT00003150|contiguous stage II adult diffuse mixed cell lymphoma
701029|NCT00003150|contiguous stage II adult immunoblastic large cell lymphoma
701030|NCT00003150|contiguous stage II adult diffuse large cell lymphoma
701031|NCT00003150|noncontiguous stage II adult diffuse mixed cell lymphoma
701032|NCT00003150|noncontiguous stage II adult immunoblastic large cell lymphoma
701033|NCT00003150|noncontiguous stage II adult diffuse large cell lymphoma
701034|NCT00003149|stage I multiple myeloma
701035|NCT00003149|stage II multiple myeloma
701036|NCT00003149|stage III multiple myeloma
701037|NCT00003148|recurrent adult acute myeloid leukemia
701038|NCT00003147|localized unresectable adult primary liver cancer
701039|NCT00003147|adult primary hepatocellular carcinoma
701040|NCT00003146|stage I multiple myeloma
701041|NCT00003146|stage II multiple myeloma
701042|NCT00003146|stage III multiple myeloma
701043|NCT00003144|unspecified adult solid tumor, protocol specific
701044|NCT00003144|drug/agent toxicity by tissue/organ
701045|NCT00003143|recurrent adult Hodgkin lymphoma
701046|NCT00003143|Waldenström macroglobulinemia
701047|NCT00003143|recurrent grade 1 follicular lymphoma
701048|NCT00003143|recurrent grade 2 follicular lymphoma
701049|NCT00003143|recurrent grade 3 follicular lymphoma
701050|NCT00003143|recurrent adult diffuse small cleaved cell lymphoma
701051|NCT00003143|recurrent adult diffuse mixed cell lymphoma
701052|NCT00003143|recurrent adult diffuse large cell lymphoma
701053|NCT00003143|recurrent adult immunoblastic large cell lymphoma
701054|NCT00003143|recurrent adult lymphoblastic lymphoma
701055|NCT00003143|recurrent adult Burkitt lymphoma
701056|NCT00003143|recurrent mantle cell lymphoma
701057|NCT00003143|recurrent marginal zone lymphoma
701058|NCT00003143|recurrent small lymphocytic lymphoma
701059|NCT00003143|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701060|NCT00003143|nodal marginal zone B-cell lymphoma
701061|NCT00003143|splenic marginal zone lymphoma
701062|NCT00003141|childhood infratentorial ependymoma
701063|NCT00003141|childhood supratentorial ependymoma
701064|NCT00003141|disseminated neuroblastoma
701065|NCT00003141|stage 4S neuroblastoma
701066|NCT00003141|embryonal childhood rhabdomyosarcoma
701067|NCT00003141|childhood high-grade cerebral astrocytoma
701068|NCT00003141|childhood choroid plexus tumor
701069|NCT00003141|previously untreated childhood rhabdomyosarcoma
701070|NCT00003141|untreated childhood brain stem glioma
701071|NCT00003141|untreated childhood supratentorial primitive neuroectodermal tumor
701072|NCT00003141|untreated childhood cerebellar astrocytoma
701073|NCT00003141|untreated childhood medulloblastoma
701074|NCT00003141|newly diagnosed childhood ependymoma
701075|NCT00003141|localized resectable neuroblastoma
701076|NCT00003141|localized unresectable neuroblastoma
701077|NCT00003141|regional neuroblastoma
701078|NCT00003141|childhood spinal cord neoplasm
701079|NCT00003141|childhood atypical teratoid/rhabdoid tumor
701080|NCT00003141|childhood low-grade cerebral astrocytoma
701081|NCT00003141|childhood central nervous system choriocarcinoma
701082|NCT00003141|childhood central nervous system embryonal tumor
701083|NCT00003141|childhood central nervous system germinoma
701084|NCT00003141|childhood central nervous system mixed germ cell tumor
701085|NCT00003141|childhood central nervous system teratoma
701086|NCT00003141|childhood central nervous system yolk sac tumor
701087|NCT00003140|stage I breast cancer
701088|NCT00003140|stage II breast cancer
701089|NCT00003140|stage IIIA breast cancer
701090|NCT00003139|oral complications
701091|NCT00003139|lip and oral cavity squamous cell carcinoma
701092|NCT00003139|oropharyngeal squamous cell carcinoma
701093|NCT00003138|anemia
701094|NCT00003138|refractory anemia
701095|NCT00003138|myelodysplastic syndromes
701096|NCT00003138|erythropoietin
701097|NCT00003138|filgrastim
701098|NCT00003137|stage IV gastric cancer
701099|NCT00003137|stage IV esophageal cancer
701100|NCT00003137|adenocarcinoma of the esophagus
701101|NCT00003137|intestinal adenocarcinoma of the stomach
701102|NCT00003137|diffuse adenocarcinoma of the stomach
701103|NCT00003137|mixed adenocarcinoma of the stomach
701104|NCT00003136|recurrent ovarian epithelial cancer
701105|NCT00003136|primary peritoneal cavity cancer
701106|NCT00003135|stage IV breast cancer
701107|NCT00003135|recurrent breast cancer
701108|NCT00003135|recurrent cervical cancer
701109|NCT00003135|stage IVB cervical cancer
701110|NCT00003135|stage IVA cervical cancer
701111|NCT00003135|stage IV ovarian epithelial cancer
701112|NCT00003135|recurrent ovarian epithelial cancer
701113|NCT00003135|stage IV endometrial carcinoma
701114|NCT00003135|recurrent endometrial carcinoma
701115|NCT00003135|stage IV ovarian germ cell tumor
701116|NCT00003135|recurrent ovarian germ cell tumor
701117|NCT00003135|male breast cancer
701118|NCT00003134|recurrent adult brain tumor
701119|NCT00003134|adult brain stem glioma
701120|NCT00003134|adult oligodendroglioma
701121|NCT00003134|adult mixed glioma
701122|NCT00003134|adult diffuse astrocytoma
701123|NCT00003133|stage III bladder cancer
701124|NCT00003133|stage IV bladder cancer
701125|NCT00003133|transitional cell carcinoma of the bladder
701126|NCT00003133|metastatic transitional cell cancer of the renal pelvis and ureter
701127|NCT00003133|regional transitional cell cancer of the renal pelvis and ureter
701128|NCT00003132|unspecified adult solid tumor, protocol specific
701129|NCT00003131|recurrent adult acute myeloid leukemia
701130|NCT00003130|unspecified adult solid tumor, protocol specific
701131|NCT00003129|stage 0 bladder cancer
701132|NCT00003129|stage I bladder cancer
701133|NCT00003129|transitional cell carcinoma of the bladder
701134|NCT00003128|stage III uterine sarcoma
701135|NCT00003128|stage IV uterine sarcoma
701136|NCT00003128|recurrent uterine sarcoma
701137|NCT00003128|uterine carcinosarcoma
701138|NCT00003127|stage IV endometrial carcinoma
701139|NCT00003127|recurrent endometrial carcinoma
701140|NCT00003127|endometrial adenocarcinoma
701141|NCT00003127|endometrial adenosquamous cell carcinoma
701142|NCT00003127|endometrial clear cell carcinoma
701143|NCT00003126|renal cell cancer
701144|NCT00003126|renal cell carcinoma
701145|NCT00003126|interleukin-2
701146|NCT00003125|stage IV breast cancer
701147|NCT00003125|stage IIIA breast cancer
701148|NCT00003125|stage III gastric cancer
701149|NCT00003125|stage IV gastric cancer
701150|NCT00003125|stage IIIB breast cancer
701151|NCT00003125|stage II pancreatic cancer
701152|NCT00003125|stage III pancreatic cancer
701153|NCT00003125|stage II esophageal cancer
701154|NCT00003125|stage III esophageal cancer
701155|NCT00003125|stage IIIA non-small cell lung cancer
701156|NCT00003125|stage IIIB non-small cell lung cancer
701157|NCT00003125|unspecified adult solid tumor, protocol specific
701158|NCT00003125|stage IV pancreatic cancer
701159|NCT00003124|adenocarcinoma of the prostate
701160|NCT00003124|stage I prostate cancer
701161|NCT00003124|stage IIB prostate cancer
701162|NCT00003124|stage IIA prostate cancer
701163|NCT00003124|stage III prostate cancer
701164|NCT00003123|refractory anemia
701165|NCT00003123|refractory anemia with ringed sideroblasts
701166|NCT00003123|refractory anemia with excess blasts
701167|NCT00003123|refractory anemia with excess blasts in transformation
701168|NCT00003122|localized resectable neuroblastoma
701169|NCT00003122|localized unresectable neuroblastoma
701170|NCT00003120|stage III ovarian epithelial cancer
701171|NCT00003120|stage IV ovarian epithelial cancer
701172|NCT00003120|recurrent ovarian epithelial cancer
701173|NCT00003120|fallopian tube cancer
701174|NCT00003120|peritoneal cavity cancer
701175|NCT00003119|localized resectable neuroblastoma
701176|NCT00003119|stage 4S neuroblastoma
701177|NCT00003118|stage I esophageal cancer
701178|NCT00003118|stage II esophageal cancer
701179|NCT00003118|stage III esophageal cancer
701180|NCT00003118|squamous cell carcinoma of the esophagus
701181|NCT00003118|adenocarcinoma of the esophagus
701182|NCT00003117|recurrent non-small cell lung cancer
701183|NCT00003117|squamous cell lung cancer
701184|NCT00003117|large cell lung cancer
701185|NCT00003117|stage IIIB non-small cell lung cancer
701186|NCT00003117|stage IV non-small cell lung cancer
701187|NCT00003117|adenocarcinoma of the lung
701188|NCT00003117|adenosquamous cell lung cancer
701189|NCT00003116|recurrent childhood acute lymphoblastic leukemia
701190|NCT00003116|recurrent adult Hodgkin lymphoma
701191|NCT00003116|refractory multiple myeloma
701192|NCT00003116|recurrent childhood lymphoblastic lymphoma
701193|NCT00003116|recurrent childhood acute myeloid leukemia
701194|NCT00003116|recurrent adult acute myeloid leukemia
701195|NCT00003116|recurrent adult acute lymphoblastic leukemia
701196|NCT00003116|adult acute myeloid leukemia in remission
701197|NCT00003116|adult acute lymphoblastic leukemia in remission
701198|NCT00003116|childhood acute myeloid leukemia in remission
701199|NCT00003116|childhood acute lymphoblastic leukemia in remission
701200|NCT00003116|recurrent/refractory childhood Hodgkin lymphoma
701201|NCT00003116|recurrent grade 1 follicular lymphoma
701202|NCT00003116|recurrent grade 2 follicular lymphoma
701203|NCT00003116|recurrent grade 3 follicular lymphoma
701204|NCT00003116|recurrent adult diffuse small cleaved cell lymphoma
701205|NCT00003116|recurrent adult diffuse mixed cell lymphoma
701206|NCT00003116|recurrent adult diffuse large cell lymphoma
701207|NCT00003116|recurrent adult immunoblastic large cell lymphoma
701208|NCT00003116|recurrent adult lymphoblastic lymphoma
701209|NCT00003116|recurrent adult Burkitt lymphoma
701210|NCT00003116|de novo myelodysplastic syndromes
701211|NCT00003116|previously treated myelodysplastic syndromes
701212|NCT00003116|secondary myelodysplastic syndromes
701213|NCT00003116|recurrent childhood small noncleaved cell lymphoma
701214|NCT00003116|recurrent childhood large cell lymphoma
701215|NCT00003116|recurrent mantle cell lymphoma
701216|NCT00003116|atypical chronic myeloid leukemia
701217|NCT00003116|myelodysplastic/myeloproliferative disease, unclassifiable
701218|NCT00003116|recurrent marginal zone lymphoma
701219|NCT00003116|recurrent small lymphocytic lymphoma
701220|NCT00003116|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701221|NCT00003116|nodal marginal zone B-cell lymphoma
701905|NCT00003022|adult mixed glioma
701222|NCT00003116|splenic marginal zone lymphoma
701223|NCT00003116|adult acute myeloid leukemia with t(8;21)(q22;q22)
701224|NCT00003116|adult acute myeloid leukemia with t(16;16)(p13;q22)
701225|NCT00003116|adult acute myeloid leukemia with inv(16)(p13;q22)
701226|NCT00003116|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
701227|NCT00003116|adult acute myeloid leukemia with t(15;17)(q22;q12)
701228|NCT00003116|childhood myelodysplastic syndromes
701229|NCT00003115|prostate cancer
701230|NCT00003115|pain
701231|NCT00003114|AIDS-related lymphoma
701232|NCT00003114|HIV-associated Hodgkin lymphoma
701233|NCT00003113|stage I grade 3 follicular lymphoma
701234|NCT00003113|stage I adult diffuse small cleaved cell lymphoma
701235|NCT00003113|stage I adult diffuse mixed cell lymphoma
701236|NCT00003113|stage I adult diffuse large cell lymphoma
701237|NCT00003113|stage I adult immunoblastic large cell lymphoma
701238|NCT00003113|stage I adult lymphoblastic lymphoma
701239|NCT00003113|stage I adult Burkitt lymphoma
701240|NCT00003113|stage III grade 3 follicular lymphoma
701241|NCT00003113|stage III adult diffuse small cleaved cell lymphoma
701242|NCT00003113|stage III adult diffuse mixed cell lymphoma
701243|NCT00003113|stage III adult diffuse large cell lymphoma
701244|NCT00003113|stage III adult immunoblastic large cell lymphoma
701245|NCT00003113|stage III adult lymphoblastic lymphoma
701246|NCT00003113|stage III adult Burkitt lymphoma
701247|NCT00003113|stage IV grade 3 follicular lymphoma
701248|NCT00003113|stage IV adult diffuse small cleaved cell lymphoma
701249|NCT00003113|stage IV adult diffuse mixed cell lymphoma
701250|NCT00003113|stage IV adult diffuse large cell lymphoma
701251|NCT00003113|stage IV adult immunoblastic large cell lymphoma
701252|NCT00003113|stage IV adult lymphoblastic lymphoma
701253|NCT00003113|stage IV adult Burkitt lymphoma
701254|NCT00003113|stage I mantle cell lymphoma
701255|NCT00003113|contiguous stage II grade 3 follicular lymphoma
701256|NCT00003113|contiguous stage II adult diffuse small cleaved cell lymphoma
701257|NCT00003113|contiguous stage II mantle cell lymphoma
701258|NCT00003113|contiguous stage II adult diffuse mixed cell lymphoma
701259|NCT00003113|contiguous stage II adult immunoblastic large cell lymphoma
701260|NCT00003113|contiguous stage II adult diffuse large cell lymphoma
701261|NCT00003113|contiguous stage II adult Burkitt lymphoma
701262|NCT00003113|contiguous stage II adult lymphoblastic lymphoma
701263|NCT00003113|noncontiguous stage II grade 3 follicular lymphoma
701264|NCT00003113|noncontiguous stage II adult diffuse small cleaved cell lymphoma
701265|NCT00003113|noncontiguous stage II mantle cell lymphoma
701266|NCT00003113|noncontiguous stage II adult diffuse mixed cell lymphoma
701267|NCT00003113|noncontiguous stage II adult immunoblastic large cell lymphoma
701268|NCT00003113|noncontiguous stage II adult diffuse large cell lymphoma
701269|NCT00003113|noncontiguous stage II adult Burkitt lymphoma
701270|NCT00003113|noncontiguous stage II adult lymphoblastic lymphoma
701271|NCT00003113|stage III mantle cell lymphoma
701272|NCT00003113|stage IV mantle cell lymphoma
701273|NCT00003113|stage II mantle cell lymphoma
701274|NCT00003111|stage IIIA non-small cell lung cancer
701275|NCT00003110|recurrent childhood lymphoblastic lymphoma
701276|NCT00003110|recurrent grade 3 follicular lymphoma
701277|NCT00003110|recurrent adult diffuse small cleaved cell lymphoma
701278|NCT00003110|recurrent adult diffuse mixed cell lymphoma
701279|NCT00003110|recurrent adult diffuse large cell lymphoma
701280|NCT00003110|recurrent adult immunoblastic large cell lymphoma
701281|NCT00003110|recurrent adult lymphoblastic lymphoma
701282|NCT00003110|recurrent adult Burkitt lymphoma
701283|NCT00003110|AIDS-related peripheral/systemic lymphoma
701284|NCT00003110|AIDS-related diffuse large cell lymphoma
701285|NCT00003110|AIDS-related immunoblastic large cell lymphoma
701286|NCT00003110|AIDS-related small noncleaved cell lymphoma
701287|NCT00003110|AIDS-related diffuse mixed cell lymphoma
701288|NCT00003110|AIDS-related diffuse small cleaved cell lymphoma
701289|NCT00003110|AIDS-related lymphoblastic lymphoma
701290|NCT00003110|recurrent childhood small noncleaved cell lymphoma
701291|NCT00003110|recurrent childhood large cell lymphoma
701292|NCT00003110|recurrent mantle cell lymphoma
701293|NCT00003109|unspecified adult solid tumor, protocol specific
701294|NCT00003108|unspecified adult solid tumor, protocol specific
701295|NCT00003107|stage IV breast cancer
701296|NCT00003107|stage IIIA breast cancer
701297|NCT00003107|stage IIIB breast cancer
701298|NCT00003107|recurrent adult Hodgkin lymphoma
701299|NCT00003107|recurrent cutaneous T-cell non-Hodgkin lymphoma
701300|NCT00003107|refractory multiple myeloma
701301|NCT00003107|stage II ovarian epithelial cancer
701302|NCT00003107|stage III ovarian epithelial cancer
701303|NCT00003107|stage IV ovarian epithelial cancer
701304|NCT00003107|recurrent ovarian epithelial cancer
701305|NCT00003107|disseminated neuroblastoma
701306|NCT00003107|recurrent neuroblastoma
701307|NCT00003107|recurrent Wilms tumor and other childhood kidney tumors
701308|NCT00003107|stage I multiple myeloma
701309|NCT00003107|stage II multiple myeloma
701310|NCT00003107|stage III multiple myeloma
701311|NCT00003107|stage III chronic lymphocytic leukemia
701312|NCT00003107|stage IV chronic lymphocytic leukemia
702196|NCT00002973|stage IV melanoma
701313|NCT00003107|recurrent adult acute myeloid leukemia
701314|NCT00003107|recurrent adult acute lymphoblastic leukemia
701315|NCT00003107|relapsing chronic myelogenous leukemia
701316|NCT00003107|refractory chronic lymphocytic leukemia
701317|NCT00003107|stage III malignant testicular germ cell tumor
701318|NCT00003107|recurrent malignant testicular germ cell tumor
701319|NCT00003107|chronic phase chronic myelogenous leukemia
701320|NCT00003107|accelerated phase chronic myelogenous leukemia
701321|NCT00003107|blastic phase chronic myelogenous leukemia
701322|NCT00003107|meningeal chronic myelogenous leukemia
701323|NCT00003107|chronic idiopathic myelofibrosis
701324|NCT00003107|testicular embryonal carcinoma
701325|NCT00003107|testicular choriocarcinoma
701326|NCT00003107|testicular teratoma
701327|NCT00003107|testicular yolk sac tumor
701328|NCT00003107|testicular embryonal carcinoma and teratoma
701329|NCT00003107|testicular embryonal carcinoma and teratoma with seminoma
701330|NCT00003107|testicular embryonal carcinoma and yolk sac tumor
701331|NCT00003107|testicular embryonal carcinoma and yolk sac tumor with seminoma
701332|NCT00003107|testicular embryonal carcinoma and seminoma
701333|NCT00003107|testicular yolk sac tumor and teratoma
701334|NCT00003107|testicular yolk sac tumor and teratoma with seminoma
701335|NCT00003107|testicular choriocarcinoma and yolk sac tumor
701336|NCT00003107|testicular choriocarcinoma and embryonal carcinoma
701337|NCT00003107|testicular choriocarcinoma and teratoma
701338|NCT00003107|testicular choriocarcinoma and seminoma
701339|NCT00003107|refractory hairy cell leukemia
701340|NCT00003107|recurrent ovarian germ cell tumor
701341|NCT00003107|ovarian yolk sac tumor
701342|NCT00003107|ovarian embryonal carcinoma
701343|NCT00003107|ovarian polyembryoma
701344|NCT00003107|ovarian choriocarcinoma
701345|NCT00003107|ovarian immature teratoma
701346|NCT00003107|ovarian mature teratoma
701347|NCT00003107|ovarian monodermal and highly specialized teratoma
701348|NCT00003107|ovarian mixed germ cell tumor
701349|NCT00003107|stage III grade 1 follicular lymphoma
701350|NCT00003107|stage III grade 2 follicular lymphoma
701351|NCT00003107|stage III grade 3 follicular lymphoma
701352|NCT00003107|stage III adult diffuse small cleaved cell lymphoma
701353|NCT00003107|stage III adult diffuse mixed cell lymphoma
701354|NCT00003107|stage III adult diffuse large cell lymphoma
701355|NCT00003107|stage III adult immunoblastic large cell lymphoma
701356|NCT00003107|stage III adult lymphoblastic lymphoma
701357|NCT00003107|stage III adult Burkitt lymphoma
701358|NCT00003107|stage IV grade 1 follicular lymphoma
701359|NCT00003107|stage IV grade 2 follicular lymphoma
701360|NCT00003107|stage IV grade 3 follicular lymphoma
701361|NCT00003107|stage IV adult diffuse small cleaved cell lymphoma
701362|NCT00003107|stage IV adult diffuse mixed cell lymphoma
701363|NCT00003107|stage IV adult diffuse large cell lymphoma
701364|NCT00003107|stage IV adult immunoblastic large cell lymphoma
701365|NCT00003107|stage IV adult lymphoblastic lymphoma
701366|NCT00003107|stage IV adult Burkitt lymphoma
701367|NCT00003107|recurrent grade 1 follicular lymphoma
701368|NCT00003107|recurrent grade 2 follicular lymphoma
701369|NCT00003107|recurrent grade 3 follicular lymphoma
701370|NCT00003107|recurrent adult diffuse small cleaved cell lymphoma
701371|NCT00003107|recurrent adult diffuse mixed cell lymphoma
701372|NCT00003107|recurrent adult diffuse large cell lymphoma
701373|NCT00003107|recurrent adult immunoblastic large cell lymphoma
701374|NCT00003107|recurrent adult lymphoblastic lymphoma
701375|NCT00003107|recurrent adult Burkitt lymphoma
701376|NCT00003107|secondary acute myeloid leukemia
701377|NCT00003107|de novo myelodysplastic syndromes
701378|NCT00003107|poor prognosis metastatic gestational trophoblastic tumor
701379|NCT00003107|previously treated myelodysplastic syndromes
701380|NCT00003107|secondary myelodysplastic syndromes
701381|NCT00003107|noncontiguous stage II grade 1 follicular lymphoma
701382|NCT00003107|noncontiguous stage II grade 2 follicular lymphoma
701383|NCT00003107|noncontiguous stage II grade 3 follicular lymphoma
701384|NCT00003107|noncontiguous stage II adult diffuse small cleaved cell lymphoma
701385|NCT00003107|noncontiguous stage II mantle cell lymphoma
701386|NCT00003107|noncontiguous stage II adult diffuse mixed cell lymphoma
701387|NCT00003107|noncontiguous stage II adult immunoblastic large cell lymphoma
701388|NCT00003107|noncontiguous stage II adult diffuse large cell lymphoma
701389|NCT00003107|noncontiguous stage II adult Burkitt lymphoma
701390|NCT00003107|noncontiguous stage II adult lymphoblastic lymphoma
701391|NCT00003107|stage III mantle cell lymphoma
701392|NCT00003107|stage IV mantle cell lymphoma
701393|NCT00003107|recurrent mantle cell lymphoma
701394|NCT00003107|recurrent mycosis fungoides/Sezary syndrome
701395|NCT00003107|noncontiguous stage II small lymphocytic lymphoma
701396|NCT00003107|noncontiguous stage II marginal zone lymphoma
701397|NCT00003107|recurrent marginal zone lymphoma
701398|NCT00003107|recurrent small lymphocytic lymphoma
701399|NCT00003107|stage III small lymphocytic lymphoma
701400|NCT00003107|stage III marginal zone lymphoma
701401|NCT00003107|stage IV small lymphocytic lymphoma
701402|NCT00003107|stage IV marginal zone lymphoma
701403|NCT00003107|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701404|NCT00003107|nodal marginal zone B-cell lymphoma
701405|NCT00003107|splenic marginal zone lymphoma
701406|NCT00003105|stage III bladder cancer
701407|NCT00003105|recurrent bladder cancer
701408|NCT00003105|stage IV bladder cancer
701409|NCT00003105|transitional cell carcinoma of the bladder
701410|NCT00003105|metastatic transitional cell cancer of the renal pelvis and ureter
701411|NCT00003105|regional transitional cell cancer of the renal pelvis and ureter
701412|NCT00003105|recurrent transitional cell cancer of the renal pelvis and ureter
701413|NCT00003104|adenocarcinoma of the prostate
701414|NCT00003104|stage IIB prostate cancer
701415|NCT00003104|stage IIA prostate cancer
701416|NCT00003103|stage III colon cancer
701417|NCT00003103|stage IV colon cancer
701418|NCT00003103|stage IV breast cancer
701419|NCT00003103|stage IIIA breast cancer
701420|NCT00003103|recurrent breast cancer
701421|NCT00003103|stage IIIB breast cancer
701422|NCT00003103|recurrent non-small cell lung cancer
701423|NCT00003103|stage III rectal cancer
701424|NCT00003103|stage IV rectal cancer
701425|NCT00003103|recurrent colon cancer
701426|NCT00003103|recurrent rectal cancer
701427|NCT00003103|stage II esophageal cancer
701428|NCT00003103|stage III esophageal cancer
701429|NCT00003103|stage IV esophageal cancer
701430|NCT00003103|recurrent esophageal cancer
701431|NCT00003103|stage III renal cell cancer
701432|NCT00003103|stage IV renal cell cancer
701433|NCT00003103|recurrent renal cell cancer
701434|NCT00003103|stage III ovarian epithelial cancer
701435|NCT00003103|stage IV ovarian epithelial cancer
701436|NCT00003103|recurrent ovarian epithelial cancer
701437|NCT00003103|stage III Wilms tumor
701438|NCT00003103|stage IV Wilms tumor
701439|NCT00003103|stage V Wilms tumor
701440|NCT00003103|recurrent Wilms tumor and other childhood kidney tumors
701441|NCT00003103|stage III bladder cancer
701442|NCT00003103|recurrent bladder cancer
701443|NCT00003103|stage IV bladder cancer
701444|NCT00003103|stage III prostate cancer
701445|NCT00003103|stage IV prostate cancer
701446|NCT00003103|recurrent prostate cancer
701447|NCT00003103|stage IIIA non-small cell lung cancer
701448|NCT00003103|stage IIIB non-small cell lung cancer
701449|NCT00003103|stage IV non-small cell lung cancer
701450|NCT00003103|unspecified adult solid tumor, protocol specific
701451|NCT00003103|untreated metastatic squamous neck cancer with occult primary
701452|NCT00003103|recurrent metastatic squamous neck cancer with occult primary
701453|NCT00003103|ovarian stromal cancer
701454|NCT00003103|stage III ovarian germ cell tumor
701455|NCT00003103|stage IV ovarian germ cell tumor
701456|NCT00003103|recurrent ovarian germ cell tumor
701457|NCT00003103|stage III squamous cell carcinoma of the lip and oral cavity
701458|NCT00003103|stage III basal cell carcinoma of the lip
701459|NCT00003103|stage III verrucous carcinoma of the oral cavity
701460|NCT00003103|stage III mucoepidermoid carcinoma of the oral cavity
701461|NCT00003103|stage III adenoid cystic carcinoma of the oral cavity
701462|NCT00003103|stage IV squamous cell carcinoma of the lip and oral cavity
701463|NCT00003103|stage IV basal cell carcinoma of the lip
701464|NCT00003103|stage IV verrucous carcinoma of the oral cavity
701465|NCT00003103|stage IV mucoepidermoid carcinoma of the oral cavity
701466|NCT00003103|stage IV adenoid cystic carcinoma of the oral cavity
701467|NCT00003103|recurrent squamous cell carcinoma of the lip and oral cavity
701468|NCT00003103|recurrent basal cell carcinoma of the lip
701469|NCT00003103|recurrent verrucous carcinoma of the oral cavity
701470|NCT00003103|recurrent mucoepidermoid carcinoma of the oral cavity
701471|NCT00003103|recurrent adenoid cystic carcinoma of the oral cavity
701472|NCT00003103|stage III squamous cell carcinoma of the oropharynx
701473|NCT00003103|stage III lymphoepithelioma of the oropharynx
701474|NCT00003103|stage IV squamous cell carcinoma of the oropharynx
701475|NCT00003103|stage IV lymphoepithelioma of the oropharynx
701476|NCT00003103|recurrent squamous cell carcinoma of the oropharynx
701477|NCT00003103|recurrent lymphoepithelioma of the oropharynx
701478|NCT00003103|stage III squamous cell carcinoma of the nasopharynx
701479|NCT00003103|stage III lymphoepithelioma of the nasopharynx
701480|NCT00003103|stage IV squamous cell carcinoma of the nasopharynx
701481|NCT00003103|stage IV lymphoepithelioma of the nasopharynx
701482|NCT00003103|recurrent squamous cell carcinoma of the nasopharynx
701483|NCT00003103|recurrent lymphoepithelioma of the nasopharynx
701484|NCT00003103|stage III squamous cell carcinoma of the hypopharynx
701485|NCT00003103|stage IV squamous cell carcinoma of the hypopharynx
701486|NCT00003103|recurrent squamous cell carcinoma of the hypopharynx
701487|NCT00003103|stage III squamous cell carcinoma of the larynx
701488|NCT00003103|stage III verrucous carcinoma of the larynx
701489|NCT00003103|stage IV squamous cell carcinoma of the larynx
701490|NCT00003103|stage IV verrucous carcinoma of the larynx
701491|NCT00003103|recurrent squamous cell carcinoma of the larynx
701492|NCT00003103|recurrent verrucous carcinoma of the larynx
701493|NCT00003103|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
701494|NCT00003103|stage III inverted papilloma of the paranasal sinus and nasal cavity
701495|NCT00003103|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
701496|NCT00003103|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
701497|NCT00003103|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
701498|NCT00003103|stage IV inverted papilloma of the paranasal sinus and nasal cavity
701499|NCT00003103|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
701500|NCT00003103|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
701501|NCT00003103|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
701502|NCT00003103|recurrent inverted papilloma of the paranasal sinus and nasal cavity
701503|NCT00003103|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
701504|NCT00003103|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
701505|NCT00003103|borderline ovarian surface epithelial-stromal tumor
701506|NCT00003103|ovarian sarcoma
701507|NCT00003103|clear cell sarcoma of the kidney
701508|NCT00003103|rhabdoid tumor of the kidney
701509|NCT00003102|stage IV renal cell cancer
701510|NCT00003102|recurrent renal cell cancer
701511|NCT00003101|adult oligodendroglioma
701512|NCT00003101|adult anaplastic oligodendroglioma
701513|NCT00003100|unspecified adult solid tumor, protocol specific
701514|NCT00003099|breast cancer
701515|NCT00003099|Tamoxifen
701516|NCT00003099|Fenretinide
701517|NCT00003099|Chemoprevention Therapy
701518|NCT00003099|N-(4-hydroxyphenyl) Retinamide
701519|NCT00003099|4-HPR
701520|NCT00003099|Breast Neoplasia
701521|NCT00003099|Diagnostic Core Biopsy
701522|NCT00003099|Surgery
701523|NCT00003098|breast cancer
701524|NCT00003097|basal cell carcinoma of the skin
701525|NCT00003097|squamous cell carcinoma of the skin
701526|NCT00003096|untreated childhood supratentorial primitive neuroectodermal tumor
701527|NCT00003096|untreated childhood medulloblastoma
701528|NCT00003095|stage II breast cancer
701529|NCT00003095|stage III breast cancer
701530|NCT00003094|cervical cancer
701531|NCT00003093|regional neuroblastoma
701532|NCT00003093|disseminated neuroblastoma
701533|NCT00003093|stage 4S neuroblastoma
701534|NCT00003093|localized unresectable neuroblastoma
701535|NCT00003092|unspecified adult solid tumor, protocol specific
701536|NCT00003091|stage IV renal cell cancer
701537|NCT00003091|recurrent renal cell cancer
701538|NCT00003091|stage IV melanoma
701539|NCT00003091|recurrent melanoma
701540|NCT00003090|recurrent non-small cell lung cancer
701541|NCT00003089|stage II non-small cell lung cancer
701542|NCT00003089|squamous cell lung cancer
701543|NCT00003089|large cell lung cancer
701544|NCT00003089|stage IIIA non-small cell lung cancer
701545|NCT00003089|stage IIIB non-small cell lung cancer
701546|NCT00003089|adenocarcinoma of the lung
701547|NCT00003089|drug/agent toxicity by tissue/organ
701548|NCT00003088|stage II breast cancer
701549|NCT00003088|stage IIIA breast cancer
701550|NCT00003087|stage II esophageal cancer
701551|NCT00003087|stage III esophageal cancer
701552|NCT00003087|squamous cell carcinoma of the esophagus
701553|NCT00003087|adenocarcinoma of the esophagus
701554|NCT00003086|stage IV breast cancer
701555|NCT00003085|stage I pancreatic cancer
701556|NCT00003085|stage II pancreatic cancer
701557|NCT00003084|adenocarcinoma of the prostate
701558|NCT00003084|stage I prostate cancer
701559|NCT00003084|stage II prostate cancer
701560|NCT00003084|stage III prostate cancer
701561|NCT00003084|stage IV prostate cancer
701562|NCT00003084|recurrent prostate cancer
701563|NCT00003084|Chemotherapy
701564|NCT00003084|Ketoconazole
701565|NCT00003084|Estramustine
701566|NCT00003084|Etoposide
701567|NCT00003084|Paclitaxel
701568|NCT00003084|Doxorubicin
701569|NCT00003084|Vinblastine
701570|NCT00003082|stage III adult Hodgkin lymphoma
701571|NCT00003082|stage IV adult Hodgkin lymphoma
701572|NCT00003082|monoclonal gammopathy of undetermined significance
701573|NCT00003082|recurrent adult Hodgkin lymphoma
701574|NCT00003082|isolated plasmacytoma of bone
701575|NCT00003082|extramedullary plasmacytoma
701576|NCT00003082|refractory multiple myeloma
701577|NCT00003082|Waldenstrom macroglobulinemia
701578|NCT00003082|stage III multiple myeloma
701579|NCT00003082|stage III chronic lymphocytic leukemia
701580|NCT00003082|stage IV chronic lymphocytic leukemia
701581|NCT00003082|recurrent adult acute myeloid leukemia
701582|NCT00003082|recurrent adult acute lymphoblastic leukemia
701583|NCT00003082|relapsing chronic myelogenous leukemia
701584|NCT00003082|refractory chronic lymphocytic leukemia
701585|NCT00003082|unspecified adult solid tumor, protocol specific
701586|NCT00003082|chronic phase chronic myelogenous leukemia
701587|NCT00003082|accelerated phase chronic myelogenous leukemia
701588|NCT00003082|blastic phase chronic myelogenous leukemia
701589|NCT00003082|meningeal chronic myelogenous leukemia
701590|NCT00003082|untreated adult acute lymphoblastic leukemia
701591|NCT00003082|untreated adult acute myeloid leukemia
701592|NCT00003082|adult acute myeloid leukemia in remission
701593|NCT00003082|adult acute lymphoblastic leukemia in remission
701594|NCT00003082|polycythemia vera
701595|NCT00003082|chronic idiopathic myelofibrosis
701596|NCT00003082|essential thrombocythemia
701597|NCT00003082|untreated hairy cell leukemia
701598|NCT00003082|progressive hairy cell leukemia, initial treatment
701599|NCT00003082|refractory hairy cell leukemia
701600|NCT00003082|chronic myelomonocytic leukemia
701601|NCT00003082|T-cell large granular lymphocyte leukemia
701602|NCT00003082|acute undifferentiated leukemia
701603|NCT00003082|stage III grade 1 follicular lymphoma
701604|NCT00003082|stage III grade 2 follicular lymphoma
701605|NCT00003082|stage III grade 3 follicular lymphoma
701606|NCT00003082|stage III adult diffuse small cleaved cell lymphoma
701607|NCT00003082|stage III adult diffuse mixed cell lymphoma
701608|NCT00003082|stage III adult diffuse large cell lymphoma
701609|NCT00003082|stage III adult immunoblastic large cell lymphoma
701610|NCT00003082|stage III adult lymphoblastic lymphoma
701611|NCT00003082|stage III adult Burkitt lymphoma
701612|NCT00003082|stage IV grade 1 follicular lymphoma
701613|NCT00003082|stage IV grade 2 follicular lymphoma
701614|NCT00003082|stage IV grade 3 follicular lymphoma
701615|NCT00003082|stage IV adult diffuse small cleaved cell lymphoma
701616|NCT00003082|stage IV adult diffuse mixed cell lymphoma
701617|NCT00003082|stage IV adult diffuse large cell lymphoma
701618|NCT00003082|stage IV adult immunoblastic large cell lymphoma
701619|NCT00003082|stage IV adult lymphoblastic lymphoma
701620|NCT00003082|stage IV adult Burkitt lymphoma
701621|NCT00003082|recurrent grade 1 follicular lymphoma
701622|NCT00003082|recurrent grade 2 follicular lymphoma
701623|NCT00003082|recurrent grade 3 follicular lymphoma
701624|NCT00003082|recurrent adult diffuse small cleaved cell lymphoma
701625|NCT00003082|recurrent adult diffuse mixed cell lymphoma
701626|NCT00003082|recurrent adult diffuse large cell lymphoma
701627|NCT00003082|recurrent adult immunoblastic large cell lymphoma
701628|NCT00003082|recurrent adult lymphoblastic lymphoma
701629|NCT00003082|recurrent adult Burkitt lymphoma
701630|NCT00003082|stage III adult T-cell leukemia/lymphoma
701631|NCT00003082|stage IV adult T-cell leukemia/lymphoma
701632|NCT00003082|recurrent adult T-cell leukemia/lymphoma
701633|NCT00003082|secondary acute myeloid leukemia
701634|NCT00003082|de novo myelodysplastic syndromes
701635|NCT00003082|previously treated myelodysplastic syndromes
701636|NCT00003082|secondary myelodysplastic syndromes
701637|NCT00003082|prolymphocytic leukemia
701638|NCT00003082|AIDS-related peripheral/systemic lymphoma
701639|NCT00003082|AIDS-related primary CNS lymphoma
701640|NCT00003082|primary systemic amyloidosis
701641|NCT00003082|stage III mantle cell lymphoma
701642|NCT00003082|stage IV mantle cell lymphoma
701643|NCT00003082|recurrent mantle cell lymphoma
701644|NCT00003082|angioimmunoblastic T-cell lymphoma
701645|NCT00003082|anaplastic large cell lymphoma
701646|NCT00003082|recurrent marginal zone lymphoma
701647|NCT00003082|recurrent small lymphocytic lymphoma
701648|NCT00003082|stage III small lymphocytic lymphoma
701649|NCT00003082|stage III marginal zone lymphoma
701650|NCT00003082|stage IV small lymphocytic lymphoma
701651|NCT00003082|stage IV marginal zone lymphoma
701652|NCT00003082|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701653|NCT00003082|nodal marginal zone B-cell lymphoma
701654|NCT00003082|splenic marginal zone lymphoma
701655|NCT00003081|recurrent childhood rhabdomyosarcoma
701656|NCT00003081|recurrent adult soft tissue sarcoma
701657|NCT00003081|adult rhabdomyosarcoma
701658|NCT00003081|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
701659|NCT00003080|stage III ovarian epithelial cancer
701660|NCT00003080|stage IV ovarian epithelial cancer
701661|NCT00003080|recurrent ovarian epithelial cancer
701662|NCT00003079|recurrent adult acute myeloid leukemia
701663|NCT00003079|recurrent adult acute lymphoblastic leukemia
701664|NCT00003079|blastic phase chronic myelogenous leukemia
701665|NCT00003079|recurrent adult lymphoblastic lymphoma
701666|NCT00003078|stage III cervical cancer
701667|NCT00003078|stage IIB cervical cancer
701668|NCT00003078|stage IVA cervical cancer
701669|NCT00003078|cervical squamous cell carcinoma
701670|NCT00003078|cervical adenocarcinoma
701671|NCT00003078|cervical adenosquamous cell carcinoma
701672|NCT00003076|esophageal cancer
701673|NCT00003075|cervical cancer
701674|NCT00003075|cervical intraepithelial neoplasia grade 2
701675|NCT00003075|cervical intraepithelial neoplasia grade 3
701676|NCT00003073|recurrent childhood acute lymphoblastic leukemia
701677|NCT00003073|recurrent childhood lymphoblastic lymphoma
701678|NCT00003073|recurrent childhood acute myeloid leukemia
701679|NCT00003073|childhood diffuse large cell lymphoma
701680|NCT00003073|childhood immunoblastic large cell lymphoma
701681|NCT00003073|unspecified childhood solid tumor, protocol specific
701682|NCT00003073|recurrent/refractory childhood Hodgkin lymphoma
701683|NCT00003073|leptomeningeal metastases
701684|NCT00003073|recurrent childhood small noncleaved cell lymphoma
701685|NCT00003073|recurrent childhood large cell lymphoma
701686|NCT00003072|stage III non-small cell lung cancer
701687|NCT00003072|stage III ovarian epithelial cancer
701688|NCT00003072|stage IV ovarian epithelial cancer
701689|NCT00003072|stage IV non-small cell lung cancer
701690|NCT00003072|neurotoxicity
701691|NCT00003070|unspecified childhood solid tumor, protocol specific
701692|NCT00003070|cardiac toxicity
701694|NCT00003068|stage IIIA breast cancer
701695|NCT00003068|recurrent breast cancer
701696|NCT00003068|stage IIIB breast cancer
701697|NCT00003068|drug/agent toxicity by tissue/organ
701698|NCT00003067|recurrent adult brain tumor
701699|NCT00003067|adult glioblastoma
701700|NCT00003067|adult anaplastic astrocytoma
701701|NCT00003067|adult mixed glioma
701702|NCT00003067|adult giant cell glioblastoma
701703|NCT00003067|adult gliosarcoma
701704|NCT00003066|stage IV breast cancer
701705|NCT00003066|recurrent breast cancer
701706|NCT00003065|recurrent cervical cancer
701707|NCT00003065|stage IVB cervical cancer
701708|NCT00003065|stage IVA cervical cancer
701709|NCT00003065|cervical squamous cell carcinoma
701710|NCT00003065|cervical adenocarcinoma
701711|NCT00003064|recurrent ovarian epithelial cancer
701712|NCT00003064|fallopian tube cancer
701713|NCT00003064|primary peritoneal cavity cancer
701714|NCT00003063|stage II colon cancer
701715|NCT00003063|stage III colon cancer
701716|NCT00003063|stage II rectal cancer
701717|NCT00003063|stage III rectal cancer
701718|NCT00003062|recurrent non-small cell lung cancer
701719|NCT00003062|stage IV non-small cell lung cancer
701720|NCT00003061|primary central nervous system non-Hodgkin lymphoma
701721|NCT00003060|recurrent melanoma
701722|NCT00003058|adult liposarcoma
701723|NCT00003058|recurrent adult soft tissue sarcoma
701724|NCT00003057|colon cancer
701725|NCT00003057|rectal cancer
701726|NCT00003057|diarrhea
701727|NCT00003056|recurrent adult Hodgkin lymphoma
701728|NCT00003056|recurrent adult acute myeloid leukemia
701729|NCT00003056|recurrent adult acute lymphoblastic leukemia
701730|NCT00003056|chronic phase chronic myelogenous leukemia
701731|NCT00003056|accelerated phase chronic myelogenous leukemia
701732|NCT00003056|adult acute myeloid leukemia in remission
701733|NCT00003056|adult acute lymphoblastic leukemia in remission
701734|NCT00003056|recurrent grade 1 follicular lymphoma
701735|NCT00003056|recurrent grade 2 follicular lymphoma
701736|NCT00003056|recurrent grade 3 follicular lymphoma
701737|NCT00003056|recurrent adult diffuse small cleaved cell lymphoma
701738|NCT00003056|recurrent adult diffuse mixed cell lymphoma
701739|NCT00003056|recurrent adult diffuse large cell lymphoma
701740|NCT00003056|recurrent adult immunoblastic large cell lymphoma
701741|NCT00003056|recurrent adult lymphoblastic lymphoma
701742|NCT00003056|recurrent adult Burkitt lymphoma
701743|NCT00003056|graft versus host disease
701744|NCT00003056|recurrent mantle cell lymphoma
701745|NCT00003056|recurrent marginal zone lymphoma
701746|NCT00003056|recurrent small lymphocytic lymphoma
701747|NCT00003056|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
701748|NCT00003056|nodal marginal zone B-cell lymphoma
701749|NCT00003056|splenic marginal zone lymphoma
701750|NCT00003055|stage III gastric cancer
701751|NCT00003055|stage IV gastric cancer
701752|NCT00003055|recurrent gastric cancer
701753|NCT00003055|stage III esophageal cancer
701754|NCT00003055|stage IV esophageal cancer
701755|NCT00003055|recurrent esophageal cancer
701756|NCT00003055|squamous cell carcinoma of the esophagus
701757|NCT00003054|recurrent uterine sarcoma
701758|NCT00003054|uterine leiomyosarcoma
701759|NCT00003053|stage I non-small cell lung cancer
701760|NCT00003053|stage II non-small cell lung cancer
701761|NCT00003053|stage IIIA non-small cell lung cancer
701762|NCT00003052|adult angiosarcoma
701763|NCT00003052|adult fibrosarcoma
701764|NCT00003052|adult leiomyosarcoma
701765|NCT00003052|adult liposarcoma
701766|NCT00003052|adult neurofibrosarcoma
701767|NCT00003052|adult synovial sarcoma
701768|NCT00003052|stage III adult soft tissue sarcoma
701769|NCT00003052|recurrent adult soft tissue sarcoma
701770|NCT00003052|adult extraskeletal osteosarcoma
701771|NCT00003052|adult malignant fibrous histiocytoma
701772|NCT00003052|adult rhabdomyosarcoma
701773|NCT00003052|stage I adult soft tissue sarcoma
701774|NCT00003052|stage II adult soft tissue sarcoma
701775|NCT00003050|stage II breast cancer
701776|NCT00003050|stage IIIA breast cancer
701777|NCT00003050|stage IIIB breast cancer
701778|NCT00003049|stage I pancreatic cancer
701779|NCT00003049|stage II pancreatic cancer
701780|NCT00003049|stage III pancreatic cancer
701781|NCT00003049|adenocarcinoma of the pancreas
701782|NCT00003048|de novo myelodysplastic syndromes
701783|NCT00003048|previously treated myelodysplastic syndromes
701784|NCT00003048|secondary myelodysplastic syndromes
701785|NCT00003048|Amifostine
701786|NCT00003048|Ethyol
701787|NCT00003048|Ethiofos
701788|NCT00003048|Gammaphos
701789|NCT00003046|anal cancer
701790|NCT00003046|carcinoma of the appendix
701791|NCT00003046|colorectal cancer
701792|NCT00003046|extrahepatic bile duct cancer
701793|NCT00003046|gallbladder cancer
701794|NCT00003046|gastric cancer
701795|NCT00003046|gastrointestinal carcinoid tumor
701796|NCT00003046|malignant mesothelioma
701797|NCT00003046|pancreatic cancer
701798|NCT00003046|small intestine cancer
701799|NCT00003046|stage IV colon cancer
701801|NCT00003046|recurrent gastric cancer
701802|NCT00003046|recurrent pancreatic cancer
701803|NCT00003046|stage IV rectal cancer
701804|NCT00003046|recurrent colon cancer
701805|NCT00003046|recurrent rectal cancer
701806|NCT00003046|stage IV anal cancer
701807|NCT00003046|recurrent anal cancer
701808|NCT00003046|metastatic gastrointestinal carcinoid tumor
701809|NCT00003046|recurrent gastrointestinal carcinoid tumor
701810|NCT00003046|advanced malignant mesothelioma
701811|NCT00003046|recurrent malignant mesothelioma
701812|NCT00003046|small intestine adenocarcinoma
701813|NCT00003046|unresectable gallbladder cancer
701814|NCT00003046|recurrent gallbladder cancer
701815|NCT00003046|unresectable extrahepatic bile duct cancer
701816|NCT00003046|recurrent extrahepatic bile duct cancer
701817|NCT00003046|recurrent small intestine cancer
701818|NCT00003046|stage IV pancreatic cancer
701819|NCT00003045|adenocarcinoma of the prostate
701820|NCT00003045|stage II prostate cancer
701821|NCT00003045|stage III prostate cancer
701822|NCT00003044|localized unresectable adult primary liver cancer
701823|NCT00003042|stage IIIB breast cancer
701824|NCT00003042|inflammatory breast cancer
701825|NCT00003041|recurrent breast cancer
701826|NCT00003040|stage I squamous cell carcinoma of the larynx
701827|NCT00003040|stage II squamous cell carcinoma of the larynx
701828|NCT00003040|stage III squamous cell carcinoma of the larynx
701829|NCT00003039|recurrent grade 3 follicular lymphoma
701830|NCT00003039|recurrent adult diffuse small cleaved cell lymphoma
701831|NCT00003039|recurrent adult diffuse mixed cell lymphoma
701832|NCT00003039|recurrent adult diffuse large cell lymphoma
701833|NCT00003039|recurrent adult immunoblastic large cell lymphoma
701834|NCT00003039|recurrent adult lymphoblastic lymphoma
701835|NCT00003039|recurrent adult Burkitt lymphoma
701836|NCT00003039|recurrent mantle cell lymphoma
701837|NCT00003038|stage IV colon cancer
701838|NCT00003038|stage IV breast cancer
701839|NCT00003038|recurrent breast cancer
701840|NCT00003038|recurrent colon cancer
701841|NCT00003038|stage IV adrenocortical carcinoma
701842|NCT00003038|recurrent adrenocortical carcinoma
701843|NCT00003038|stage IV prostate cancer
701844|NCT00003038|recurrent prostate cancer
701845|NCT00003038|unspecified adult solid tumor, protocol specific
701846|NCT00003037|stage IIIA non-small cell lung cancer
701847|NCT00003037|stage IIIB non-small cell lung cancer
701848|NCT00003035|stage IIIA breast cancer
701849|NCT00003035|stage IIIB breast cancer
701850|NCT00003034|localized malignant mesothelioma
701851|NCT00003034|advanced malignant mesothelioma
701852|NCT00003034|recurrent malignant mesothelioma
701853|NCT00003032|stage IV breast cancer
701854|NCT00003032|recurrent breast cancer
701855|NCT00003031|infection
701856|NCT00003031|pulmonary complications
701857|NCT00003029|stage III pancreatic cancer
701858|NCT00003029|adenocarcinoma of the pancreas
701859|NCT00003029|stage IV pancreatic cancer
701860|NCT00003028|unspecified adult solid tumor, protocol specific
701861|NCT00003027|stage IV melanoma
701862|NCT00003026|adenocarcinoma of the prostate
701863|NCT00003025|stage I pancreatic cancer
701864|NCT00003025|stage II pancreatic cancer
701865|NCT00003025|adenocarcinoma of the pancreas
701866|NCT00003023|metastatic osteosarcoma
701867|NCT00003023|recurrent adult soft tissue sarcoma
701868|NCT00003023|disseminated neuroblastoma
701869|NCT00003023|stage 4S neuroblastoma
701870|NCT00003023|recurrent neuroblastoma
701871|NCT00003023|recurrent osteosarcoma
701872|NCT00003023|metastatic childhood soft tissue sarcoma
701873|NCT00003023|recurrent childhood soft tissue sarcoma
701874|NCT00003023|stage IV adult soft tissue sarcoma
701875|NCT00003022|metastatic osteosarcoma
701876|NCT00003022|childhood infratentorial ependymoma
701877|NCT00003022|recurrent childhood rhabdomyosarcoma
701878|NCT00003022|childhood supratentorial ependymoma
701879|NCT00003022|regional neuroblastoma
701880|NCT00003022|disseminated neuroblastoma
701881|NCT00003022|stage 4S neuroblastoma
701882|NCT00003022|recurrent neuroblastoma
701883|NCT00003022|retinoblastoma
701884|NCT00003022|intraocular retinoblastoma
701885|NCT00003022|extraocular retinoblastoma
701886|NCT00003022|recurrent retinoblastoma
701887|NCT00003022|extensive stage small cell lung cancer
701888|NCT00003022|recurrent small cell lung cancer
701889|NCT00003022|recurrent osteosarcoma
701890|NCT00003022|recurrent adult brain tumor
701891|NCT00003022|iris melanoma
701892|NCT00003022|ciliary body and choroid melanoma, small size
701893|NCT00003022|ciliary body and choroid melanoma, medium/large size
701894|NCT00003022|extraocular extension melanoma
701895|NCT00003022|recurrent intraocular melanoma
701896|NCT00003022|adult brain stem glioma
701897|NCT00003022|adult medulloblastoma
701898|NCT00003022|stage IV melanoma
701899|NCT00003022|recurrent melanoma
701900|NCT00003022|metastatic childhood soft tissue sarcoma
701901|NCT00003022|recurrent childhood soft tissue sarcoma
701902|NCT00003022|adult myxopapillary ependymoma
701903|NCT00003022|adult anaplastic ependymoma
701904|NCT00003022|adult anaplastic oligodendroglioma
701906|NCT00003022|localized unresectable neuroblastoma
701907|NCT00003022|adult ependymoblastoma
701908|NCT00003022|recurrent childhood brain stem glioma
701909|NCT00003022|recurrent childhood supratentorial primitive neuroectodermal tumor
701910|NCT00003022|recurrent childhood visual pathway glioma
701911|NCT00003022|recurrent childhood medulloblastoma
701912|NCT00003022|recurrent childhood visual pathway and hypothalamic glioma
701913|NCT00003022|previously treated childhood rhabdomyosarcoma
701914|NCT00003022|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
701915|NCT00003022|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
701916|NCT00003022|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
701917|NCT00003022|recurrent childhood ependymoma
701918|NCT00003022|adult oligodendroglioma
701919|NCT00003022|adult anaplastic astrocytoma
701920|NCT00003022|adult supratentorial primitive neuroectodermal tumor (PNET)
701921|NCT00003022|adult diffuse astrocytoma
701922|NCT00003022|adult pilocytic astrocytoma
701923|NCT00003022|adult giant cell glioblastoma
701924|NCT00003022|adult glioblastoma
701925|NCT00003022|adult gliosarcoma
701926|NCT00003021|unspecified adult solid tumor, protocol specific
701927|NCT00003020|leptomeningeal metastases
701928|NCT00003019|desmoid tumor
701929|NCT00003018|stage II pancreatic cancer
701930|NCT00003018|stage III pancreatic cancer
701931|NCT00003018|duct cell adenocarcinoma of the pancreas
701932|NCT00003017|stage IV cervical cancer
701933|NCT00003017|recurrent cervical cancer
701934|NCT00003017|cervical squamous cell carcinoma
701935|NCT00003017|cervical adenocarcinoma
701936|NCT00003017|cervical adenosquamous cell carcinoma
701937|NCT00003016|stage I breast cancer
701938|NCT00003016|stage II breast cancer
701939|NCT00003016|stage IIIA breast cancer
701940|NCT00003016|stage IIIB breast cancer
701941|NCT00003016|stage IIIC breast cancer
701942|NCT00003015|childhood low-grade cerebral astrocytoma
701943|NCT00003015|childhood oligodendroglioma
701944|NCT00003015|untreated childhood visual pathway glioma
701945|NCT00003015|untreated childhood cerebellar astrocytoma
701946|NCT00003014|stage I malignant testicular germ cell tumor
701947|NCT00003014|testicular seminoma
701948|NCT00003013|stage II breast cancer
701949|NCT00003013|stage IIIA breast cancer
701950|NCT00003012|stage II breast cancer
701951|NCT00003012|stage IIIA breast cancer
701952|NCT00003011|recurrent small cell lung cancer
701953|NCT00003010|recurrent breast cancer
701954|NCT00003009|unspecified adult solid tumor, protocol specific
701955|NCT00003008|AIDS-related Kaposi sarcoma
701956|NCT00003008|recurrent Kaposi sarcoma
701957|NCT00003007|refractory multiple myeloma
701958|NCT00003007|stage III multiple myeloma
701959|NCT00003006|stage I non-small cell lung cancer
701960|NCT00003005|recurrent adult acute lymphoblastic leukemia
701961|NCT00003005|blastic phase chronic myelogenous leukemia
701962|NCT00003005|TdT positive adult acute lymphoblastic leukemia
701963|NCT00003004|unspecified adult solid tumor, protocol specific
701964|NCT00003003|recurrent adult acute myeloid leukemia
701965|NCT00003003|secondary acute myeloid leukemia
701966|NCT00003002|stage III breast cancer
701967|NCT00003002|stage IV breast cancer
701968|NCT00003002|stage III non-small cell lung cancer
701969|NCT00003002|stage III ovarian epithelial cancer
701970|NCT00003002|stage IV ovarian epithelial cancer
701971|NCT00003002|stage IV non-small cell lung cancer
701972|NCT00003002|adenocarcinoma of the lung
701973|NCT00003001|stage IV colon cancer
701974|NCT00003001|stage IV rectal cancer
701975|NCT00003001|recurrent colon cancer
701976|NCT00003001|recurrent rectal cancer
701977|NCT00003000|pain
701978|NCT00002999|stage III nasopharyngeal cancer
701979|NCT00002999|stage IV nasopharyngeal cancer
701980|NCT00002998|stage IV breast cancer
701981|NCT00002998|recurrent breast cancer
701982|NCT00002997|stage IV colon cancer
701983|NCT00002997|stage IV rectal cancer
701984|NCT00002997|recurrent colon cancer
701985|NCT00002997|recurrent rectal cancer
701986|NCT00002997|adenocarcinoma of the colon
701987|NCT00002997|adenocarcinoma of the rectum
701988|NCT00002997|liver metastases
701989|NCT00002996|pain
701990|NCT00002995|embryonal childhood rhabdomyosarcoma
701991|NCT00002995|embryonal-botryoid childhood rhabdomyosarcoma
701992|NCT00002995|previously untreated childhood rhabdomyosarcoma
701993|NCT00002995|adult rhabdomyosarcoma
701994|NCT00002995|adult malignant mesenchymoma
701995|NCT00002995|childhood malignant mesenchymoma
701996|NCT00002995|nonmetastatic childhood soft tissue sarcoma
701997|NCT00002995|stage II adult soft tissue sarcoma
701998|NCT00002995|stage III adult soft tissue sarcoma
701999|NCT00002995|stage I adult soft tissue sarcoma
702000|NCT00002994|unspecified adult solid tumor, protocol specific
702001|NCT00002993|stage III uterine sarcoma
702002|NCT00002993|stage IV uterine sarcoma
702003|NCT00002993|recurrent uterine sarcoma
702004|NCT00002990|stage 0 bladder cancer
702005|NCT00002990|stage I bladder cancer
702006|NCT00002990|transitional cell carcinoma of the bladder
702007|NCT00002989|stage I multiple myeloma
702008|NCT00002989|stage II multiple myeloma
702009|NCT00002989|stage III multiple myeloma
702010|NCT00002989|recurrent adult acute myeloid leukemia
702011|NCT00002989|recurrent adult acute lymphoblastic leukemia
702012|NCT00002989|relapsing chronic myelogenous leukemia
702013|NCT00002989|refractory chronic lymphocytic leukemia
702014|NCT00002989|adult acute myeloid leukemia in remission
702015|NCT00002989|adult acute lymphoblastic leukemia in remission
702016|NCT00002989|stage I grade 1 follicular lymphoma
702017|NCT00002989|stage I grade 2 follicular lymphoma
702018|NCT00002989|stage I grade 3 follicular lymphoma
702019|NCT00002989|stage I adult diffuse small cleaved cell lymphoma
702020|NCT00002989|stage I adult diffuse mixed cell lymphoma
702021|NCT00002989|stage I adult diffuse large cell lymphoma
702022|NCT00002989|stage I adult immunoblastic large cell lymphoma
702023|NCT00002989|stage I adult lymphoblastic lymphoma
702024|NCT00002989|stage I adult Burkitt lymphoma
702025|NCT00002989|stage III grade 2 follicular lymphoma
702026|NCT00002989|stage III grade 3 follicular lymphoma
702027|NCT00002989|stage III adult diffuse small cleaved cell lymphoma
702028|NCT00002989|stage III adult diffuse mixed cell lymphoma
702029|NCT00002989|stage III adult diffuse large cell lymphoma
702030|NCT00002989|stage III adult immunoblastic large cell lymphoma
702031|NCT00002989|stage III adult lymphoblastic lymphoma
702032|NCT00002989|stage III adult Burkitt lymphoma
702033|NCT00002989|stage IV grade 1 follicular lymphoma
702034|NCT00002989|stage IV grade 2 follicular lymphoma
702035|NCT00002989|stage IV grade 3 follicular lymphoma
702036|NCT00002989|stage IV adult diffuse small cleaved cell lymphoma
702037|NCT00002989|stage IV adult diffuse mixed cell lymphoma
702038|NCT00002989|stage IV adult diffuse large cell lymphoma
702039|NCT00002989|stage IV adult immunoblastic large cell lymphoma
702040|NCT00002989|stage IV adult lymphoblastic lymphoma
702041|NCT00002989|stage IV adult Burkitt lymphoma
702042|NCT00002989|recurrent grade 1 follicular lymphoma
702043|NCT00002989|recurrent grade 2 follicular lymphoma
702044|NCT00002989|recurrent grade 3 follicular lymphoma
702045|NCT00002989|recurrent adult diffuse small cleaved cell lymphoma
702046|NCT00002989|recurrent adult diffuse mixed cell lymphoma
702047|NCT00002989|recurrent adult diffuse large cell lymphoma
702048|NCT00002989|recurrent adult immunoblastic large cell lymphoma
702049|NCT00002989|recurrent adult lymphoblastic lymphoma
702050|NCT00002989|recurrent adult Burkitt lymphoma
702051|NCT00002989|previously treated myelodysplastic syndromes
702052|NCT00002989|stage I mantle cell lymphoma
702053|NCT00002989|contiguous stage II grade 1 follicular lymphoma
702054|NCT00002989|contiguous stage II grade 2 follicular lymphoma
702055|NCT00002989|contiguous stage II grade 3 follicular lymphoma
702056|NCT00002989|contiguous stage II adult diffuse small cleaved cell lymphoma
702057|NCT00002989|contiguous stage II mantle cell lymphoma
702058|NCT00002989|contiguous stage II adult diffuse mixed cell lymphoma
702059|NCT00002989|contiguous stage II adult immunoblastic large cell lymphoma
702060|NCT00002989|contiguous stage II adult diffuse large cell lymphoma
702061|NCT00002989|contiguous stage II adult Burkitt lymphoma
702062|NCT00002989|contiguous stage II adult lymphoblastic lymphoma
702063|NCT00002989|noncontiguous stage II grade 1 follicular lymphoma
702064|NCT00002989|noncontiguous stage II grade 2 follicular lymphoma
702065|NCT00002989|noncontiguous stage II grade 3 follicular lymphoma
702066|NCT00002989|noncontiguous stage II adult diffuse small cleaved cell lymphoma
702067|NCT00002989|noncontiguous stage II mantle cell lymphoma
702068|NCT00002989|noncontiguous stage II adult diffuse mixed cell lymphoma
702069|NCT00002989|noncontiguous stage II adult immunoblastic large cell lymphoma
702070|NCT00002989|noncontiguous stage II adult diffuse large cell lymphoma
702071|NCT00002989|noncontiguous stage II adult Burkitt lymphoma
702072|NCT00002989|noncontiguous stage II adult lymphoblastic lymphoma
702073|NCT00002989|stage III mantle cell lymphoma
702074|NCT00002989|stage IV mantle cell lymphoma
702075|NCT00002989|recurrent mantle cell lymphoma
702076|NCT00002989|contiguous stage II marginal zone lymphoma
702077|NCT00002989|contiguous stage II small lymphocytic lymphoma
702078|NCT00002989|noncontiguous stage II small lymphocytic lymphoma
702079|NCT00002989|noncontiguous stage II marginal zone lymphoma
702080|NCT00002989|recurrent marginal zone lymphoma
702081|NCT00002989|recurrent small lymphocytic lymphoma
702082|NCT00002989|stage I marginal zone lymphoma
702083|NCT00002989|stage I small lymphocytic lymphoma
702084|NCT00002989|stage III small lymphocytic lymphoma
702085|NCT00002989|stage III marginal zone lymphoma
702086|NCT00002989|stage IV small lymphocytic lymphoma
702087|NCT00002989|stage IV marginal zone lymphoma
702088|NCT00002989|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702089|NCT00002989|nodal marginal zone B-cell lymphoma
702090|NCT00002989|splenic marginal zone lymphoma
702091|NCT00002989|childhood myelodysplastic syndromes
702092|NCT00002988|recurrent adult brain tumor
702093|NCT00002987|stage I adult Hodgkin lymphoma
702094|NCT00002987|stage II adult Hodgkin lymphoma
702095|NCT00002986|recurrent adult brain tumor
702096|NCT00002985|AIDS-related Kaposi sarcoma
702097|NCT00002984|stage II esophageal cancer
702098|NCT00002984|stage III esophageal cancer
702099|NCT00002984|stage IV esophageal cancer
702100|NCT00002984|squamous cell carcinoma of the esophagus
702101|NCT00002984|adenocarcinoma of the esophagus
702102|NCT00002982|recurrent grade 3 follicular lymphoma
702103|NCT00002982|recurrent adult diffuse small cleaved cell lymphoma
702104|NCT00002982|recurrent adult diffuse mixed cell lymphoma
702105|NCT00002982|recurrent adult diffuse large cell lymphoma
702106|NCT00002982|recurrent adult immunoblastic large cell lymphoma
702107|NCT00002982|anaplastic large cell lymphoma
702108|NCT00002981|adenocarcinoma of the prostate
702109|NCT00002981|stage IV prostate cancer
702110|NCT00002981|recurrent prostate cancer
702111|NCT00002980|stage IV adult Hodgkin lymphoma
702112|NCT00002980|monoclonal gammopathy of undetermined significance
702113|NCT00002980|recurrent adult Hodgkin lymphoma
702114|NCT00002980|isolated plasmacytoma of bone
702115|NCT00002980|extramedullary plasmacytoma
702116|NCT00002980|refractory multiple myeloma
702117|NCT00002980|Waldenström macroglobulinemia
702118|NCT00002980|stage IV chronic lymphocytic leukemia
702119|NCT00002980|recurrent adult acute myeloid leukemia
702120|NCT00002980|recurrent adult acute lymphoblastic leukemia
702121|NCT00002980|relapsing chronic myelogenous leukemia
702122|NCT00002980|refractory chronic lymphocytic leukemia
702123|NCT00002980|unspecified adult solid tumor, protocol specific
702124|NCT00002980|chronic phase chronic myelogenous leukemia
702125|NCT00002980|accelerated phase chronic myelogenous leukemia
702126|NCT00002980|blastic phase chronic myelogenous leukemia
702127|NCT00002980|untreated adult acute lymphoblastic leukemia
702128|NCT00002980|untreated adult acute myeloid leukemia
702129|NCT00002980|adult acute myeloid leukemia in remission
702130|NCT00002980|adult acute lymphoblastic leukemia in remission
702131|NCT00002980|polycythemia vera
702132|NCT00002980|primary myelofibrosis
702133|NCT00002980|essential thrombocythemia
702134|NCT00002980|untreated hairy cell leukemia
702135|NCT00002980|progressive hairy cell leukemia, initial treatment
702136|NCT00002980|refractory hairy cell leukemia
702137|NCT00002980|chronic myelomonocytic leukemia
702138|NCT00002980|T-cell large granular lymphocyte leukemia
702139|NCT00002980|acute undifferentiated leukemia
702140|NCT00002980|stage IV grade 1 follicular lymphoma
702141|NCT00002980|stage IV grade 2 follicular lymphoma
702142|NCT00002980|stage IV grade 3 follicular lymphoma
702143|NCT00002980|stage IV adult diffuse small cleaved cell lymphoma
702144|NCT00002980|stage IV adult diffuse mixed cell lymphoma
702145|NCT00002980|stage IV adult diffuse large cell lymphoma
702146|NCT00002980|stage IV adult immunoblastic large cell lymphoma
702147|NCT00002980|stage IV adult lymphoblastic lymphoma
702148|NCT00002980|stage IV adult Burkitt lymphoma
702149|NCT00002980|recurrent grade 1 follicular lymphoma
702150|NCT00002980|recurrent grade 2 follicular lymphoma
702151|NCT00002980|recurrent grade 3 follicular lymphoma
702152|NCT00002980|recurrent adult diffuse small cleaved cell lymphoma
702153|NCT00002980|recurrent adult diffuse mixed cell lymphoma
702154|NCT00002980|recurrent adult diffuse large cell lymphoma
702155|NCT00002980|recurrent adult immunoblastic large cell lymphoma
702156|NCT00002980|recurrent adult lymphoblastic lymphoma
702157|NCT00002980|recurrent adult Burkitt lymphoma
702158|NCT00002980|stage IV adult T-cell leukemia/lymphoma
702159|NCT00002980|recurrent adult T-cell leukemia/lymphoma
702160|NCT00002980|secondary acute myeloid leukemia
702161|NCT00002980|de novo myelodysplastic syndromes
702162|NCT00002980|previously treated myelodysplastic syndromes
702163|NCT00002980|secondary myelodysplastic syndromes
702164|NCT00002980|prolymphocytic leukemia
702165|NCT00002980|primary systemic amyloidosis
702166|NCT00002980|stage IV mantle cell lymphoma
702167|NCT00002980|recurrent mantle cell lymphoma
702168|NCT00002980|angioimmunoblastic T-cell lymphoma
702169|NCT00002980|anaplastic large cell lymphoma
702170|NCT00002980|recurrent marginal zone lymphoma
702171|NCT00002980|recurrent small lymphocytic lymphoma
702172|NCT00002980|stage IV small lymphocytic lymphoma
702173|NCT00002980|stage IV marginal zone lymphoma
702174|NCT00002980|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702175|NCT00002980|nodal marginal zone B-cell lymphoma
702176|NCT00002980|splenic marginal zone lymphoma
702177|NCT00002977|stage III ovarian epithelial cancer
702178|NCT00002977|stage IV ovarian epithelial cancer
702179|NCT00002977|recurrent ovarian epithelial cancer
702180|NCT00002977|ovarian undifferentiated adenocarcinoma
702181|NCT00002977|ovarian mixed epithelial carcinoma
702182|NCT00002977|ovarian serous cystadenocarcinoma
702183|NCT00002977|ovarian mucinous cystadenocarcinoma
702184|NCT00002977|ovarian endometrioid adenocarcinoma
702185|NCT00002977|ovarian clear cell cystadenocarcinoma
702186|NCT00002977|Brenner tumor
702187|NCT00002976|stage I endometrial carcinoma
702188|NCT00002976|stage II endometrial carcinoma
702189|NCT00002976|endometrial adenocarcinoma
702190|NCT00002975|basal cell carcinoma of the skin
702191|NCT00002975|squamous cell carcinoma of the skin
702192|NCT00002975|actinic keratosis
702193|NCT00002974|recurrent adult soft tissue sarcoma
702194|NCT00002974|stage IV adult soft tissue sarcoma
702195|NCT00002973|stage III melanoma
702197|NCT00002973|recurrent melanoma
702198|NCT00002972|recurrent non-small cell lung cancer
702199|NCT00002972|stage IIIB non-small cell lung cancer
702200|NCT00002972|stage IV non-small cell lung cancer
702201|NCT00002972|adenocarcinoma of the lung
702202|NCT00002971|recurrent adult brain tumor
702203|NCT00002971|adult glioblastoma
702204|NCT00002971|adult anaplastic astrocytoma
702205|NCT00002971|adult giant cell glioblastoma
702206|NCT00002971|adult gliosarcoma
702207|NCT00002969|recurrent non-small cell lung cancer
702208|NCT00002969|stage IIIB non-small cell lung cancer
702209|NCT00002969|stage IV non-small cell lung cancer
702210|NCT00002967|stage I breast cancer
702211|NCT00002967|stage II breast cancer
702212|NCT00002967|invasive ductal breast carcinoma
702213|NCT00002965|recurrent adult brain tumor
702214|NCT00002964|stage 0 oropharyngeal cancer
702215|NCT00002964|stage 0 laryngeal cancer
702216|NCT00002964|stage 0 hypopharyngeal cancer
702217|NCT00002964|stage 0 lip and oral cavity cancer
702218|NCT00002964|stage I lip and oral cavity cancer
702219|NCT00002964|stage I hypopharyngeal cancer
702220|NCT00002964|stage I laryngeal cancer
702221|NCT00002964|stage I oropharyngeal cancer
702222|NCT00002963|basal cell carcinoma of the skin
702223|NCT00002963|squamous cell carcinoma of the skin
702224|NCT00002961|recurrent childhood acute lymphoblastic leukemia
702225|NCT00002961|childhood acute lymphoblastic leukemia in remission
702226|NCT00002960|recurrent ovarian epithelial cancer
702227|NCT00002960|malignant ascites
702228|NCT00002960|fallopian tube cancer
702229|NCT00002960|primary peritoneal cavity cancer
702230|NCT00002956|recurrent adult Hodgkin lymphoma
702231|NCT00002956|recurrent childhood lymphoblastic lymphoma
702232|NCT00002956|childhood diffuse large cell lymphoma
702233|NCT00002956|childhood immunoblastic large cell lymphoma
702234|NCT00002956|recurrent/refractory childhood Hodgkin lymphoma
702235|NCT00002956|T-cell large granular lymphocyte leukemia
702236|NCT00002956|recurrent grade 1 follicular lymphoma
702237|NCT00002956|recurrent grade 2 follicular lymphoma
702238|NCT00002956|recurrent grade 3 follicular lymphoma
702239|NCT00002956|recurrent adult diffuse small cleaved cell lymphoma
702240|NCT00002956|recurrent adult diffuse mixed cell lymphoma
702241|NCT00002956|recurrent adult diffuse large cell lymphoma
702242|NCT00002956|recurrent adult immunoblastic large cell lymphoma
702243|NCT00002956|recurrent adult lymphoblastic lymphoma
702244|NCT00002956|recurrent adult Burkitt lymphoma
702245|NCT00002956|recurrent childhood small noncleaved cell lymphoma
702246|NCT00002956|recurrent childhood large cell lymphoma
702247|NCT00002956|recurrent mantle cell lymphoma
702248|NCT00002956|recurrent marginal zone lymphoma
702249|NCT00002956|recurrent small lymphocytic lymphoma
702250|NCT00002956|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702251|NCT00002956|nodal marginal zone B-cell lymphoma
702252|NCT00002956|splenic marginal zone lymphoma
702253|NCT00002955|stage IV pancreatic cancer
702254|NCT00002953|stage IV breast cancer
702255|NCT00002952|stage IV melanoma
702256|NCT00002952|recurrent melanoma
702257|NCT00002951|stage II esophageal cancer
702258|NCT00002951|stage III esophageal cancer
702259|NCT00002951|stage II nasopharyngeal cancer
702260|NCT00002951|stage III nasopharyngeal cancer
702261|NCT00002951|stage II lip and oral cavity cancer
702262|NCT00002951|stage III lip and oral cavity cancer
702263|NCT00002951|stage II hypopharyngeal cancer
702264|NCT00002951|stage III hypopharyngeal cancer
702265|NCT00002951|stage II laryngeal cancer
702266|NCT00002951|stage III laryngeal cancer
702267|NCT00002951|stage II paranasal sinus and nasal cavity cancer
702268|NCT00002951|stage III paranasal sinus and nasal cavity cancer
702269|NCT00002951|stage II oropharyngeal cancer
702270|NCT00002951|stage III oropharyngeal cancer
702271|NCT00002950|unspecified adult solid tumor, protocol specific
702272|NCT00002949|stage II cervical cancer
702273|NCT00002949|stage III cervical cancer
702274|NCT00002949|stage IV cervical cancer
702275|NCT00002949|stage II vaginal cancer
702276|NCT00002949|stage III vaginal cancer
702277|NCT00002949|stage IVA vaginal cancer
702278|NCT00002949|stage IVB vaginal cancer
702279|NCT00002949|stage II endometrial carcinoma
702280|NCT00002949|stage III endometrial carcinoma
702281|NCT00002949|stage IV endometrial carcinoma
702282|NCT00002949|stage II bladder cancer
702283|NCT00002949|stage III bladder cancer
702284|NCT00002949|stage IV bladder cancer
702285|NCT00002948|unspecified adult solid tumor, protocol specific
702286|NCT00002947|stage IV renal cell cancer
702287|NCT00002947|recurrent renal cell cancer
702288|NCT00002947|extensive stage small cell lung cancer
702289|NCT00002947|recurrent small cell lung cancer
702290|NCT00002947|metastatic gastrointestinal carcinoid tumor
702291|NCT00002947|recurrent gastrointestinal carcinoid tumor
702292|NCT00002947|gastrinoma
702293|NCT00002947|insulinoma
702294|NCT00002947|recurrent islet cell carcinoma
702295|NCT00002947|thyroid gland medullary carcinoma
702296|NCT00002947|prolactin-producing pituitary tumor
702297|NCT00002947|iris melanoma
702298|NCT00002947|ciliary body and choroid melanoma, medium/large size
702299|NCT00002947|extraocular extension melanoma
702300|NCT00002947|recurrent intraocular melanoma
702301|NCT00002947|stage IV melanoma
702302|NCT00002947|recurrent melanoma
702303|NCT00002947|WDHA syndrome
702304|NCT00002947|somatostatinoma
702305|NCT00002947|pancreatic polypeptide tumor
702306|NCT00002947|glucagonoma
702307|NCT00002947|childhood Langerhans cell histiocytosis
702308|NCT00002947|metastatic pheochromocytoma
702309|NCT00002947|recurrent pheochromocytoma
702310|NCT00002947|pulmonary carcinoid tumor
702311|NCT00002947|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
702312|NCT00002947|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
702313|NCT00002947|stage III neuroendocrine carcinoma of the skin
702314|NCT00002947|recurrent neuroendocrine carcinoma of the skin
702315|NCT00002946|stage I adult Hodgkin lymphoma
702316|NCT00002946|stage II adult Hodgkin lymphoma
702317|NCT00002946|stage III adult Hodgkin lymphoma
702318|NCT00002946|stage IV adult Hodgkin lymphoma
702319|NCT00002946|recurrent adult Hodgkin lymphoma
702320|NCT00002946|unspecified adult solid tumor, protocol specific
702321|NCT00002946|stage I grade 1 follicular lymphoma
702322|NCT00002946|stage I grade 2 follicular lymphoma
702323|NCT00002946|stage I grade 3 follicular lymphoma
702324|NCT00002946|stage I adult diffuse small cleaved cell lymphoma
702325|NCT00002946|stage I adult diffuse mixed cell lymphoma
702326|NCT00002946|stage I adult diffuse large cell lymphoma
702327|NCT00002946|stage I adult immunoblastic large cell lymphoma
702328|NCT00002946|stage I adult lymphoblastic lymphoma
702329|NCT00002946|stage I adult Burkitt lymphoma
702330|NCT00002946|stage III grade 1 follicular lymphoma
702331|NCT00002946|stage III grade 2 follicular lymphoma
702332|NCT00002946|stage III grade 3 follicular lymphoma
702333|NCT00002946|stage III adult diffuse small cleaved cell lymphoma
702334|NCT00002946|stage III adult diffuse mixed cell lymphoma
702335|NCT00002946|stage III adult diffuse large cell lymphoma
702336|NCT00002946|stage III adult immunoblastic large cell lymphoma
702337|NCT00002946|stage III adult lymphoblastic lymphoma
702338|NCT00002946|stage III adult Burkitt lymphoma
702339|NCT00002946|stage IV grade 1 follicular lymphoma
702340|NCT00002946|stage IV grade 2 follicular lymphoma
702341|NCT00002946|stage IV grade 3 follicular lymphoma
702342|NCT00002946|stage IV adult diffuse small cleaved cell lymphoma
702343|NCT00002946|stage IV adult diffuse mixed cell lymphoma
702344|NCT00002946|stage IV adult diffuse large cell lymphoma
702345|NCT00002946|stage IV adult immunoblastic large cell lymphoma
702346|NCT00002946|stage IV adult lymphoblastic lymphoma
702347|NCT00002946|stage IV adult Burkitt lymphoma
702348|NCT00002946|recurrent grade 1 follicular lymphoma
702349|NCT00002946|recurrent grade 2 follicular lymphoma
702350|NCT00002946|recurrent grade 3 follicular lymphoma
702351|NCT00002946|recurrent adult diffuse small cleaved cell lymphoma
702352|NCT00002946|recurrent adult diffuse mixed cell lymphoma
702353|NCT00002946|recurrent adult diffuse large cell lymphoma
702354|NCT00002946|recurrent adult immunoblastic large cell lymphoma
702355|NCT00002946|recurrent adult lymphoblastic lymphoma
702356|NCT00002946|recurrent adult Burkitt lymphoma
702357|NCT00002946|stage I adult T-cell leukemia/lymphoma
702358|NCT00002946|stage II adult T-cell leukemia/lymphoma
702359|NCT00002946|stage III adult T-cell leukemia/lymphoma
702360|NCT00002946|stage IV adult T-cell leukemia/lymphoma
702361|NCT00002946|recurrent adult T-cell leukemia/lymphoma
702362|NCT00002946|AIDS-related peripheral/systemic lymphoma
702363|NCT00002946|AIDS-related primary CNS lymphoma
702364|NCT00002946|stage I mantle cell lymphoma
702365|NCT00002946|contiguous stage II grade 1 follicular lymphoma
702366|NCT00002946|contiguous stage II grade 2 follicular lymphoma
702367|NCT00002946|contiguous stage II grade 3 follicular lymphoma
702368|NCT00002946|contiguous stage II adult diffuse small cleaved cell lymphoma
702369|NCT00002946|contiguous stage II mantle cell lymphoma
702370|NCT00002946|contiguous stage II adult diffuse mixed cell lymphoma
702371|NCT00002946|contiguous stage II adult immunoblastic large cell lymphoma
702372|NCT00002946|contiguous stage II adult diffuse large cell lymphoma
702373|NCT00002946|contiguous stage II adult Burkitt lymphoma
702374|NCT00002946|contiguous stage II adult lymphoblastic lymphoma
702375|NCT00002946|noncontiguous stage II grade 1 follicular lymphoma
702376|NCT00002946|noncontiguous stage II grade 2 follicular lymphoma
702377|NCT00002946|noncontiguous stage II grade 3 follicular lymphoma
702378|NCT00002946|noncontiguous stage II adult diffuse small cleaved cell lymphoma
702379|NCT00002946|noncontiguous stage II mantle cell lymphoma
702380|NCT00002946|noncontiguous stage II adult diffuse mixed cell lymphoma
702381|NCT00002946|noncontiguous stage II adult immunoblastic large cell lymphoma
702382|NCT00002946|noncontiguous stage II adult diffuse large cell lymphoma
702383|NCT00002946|noncontiguous stage II adult Burkitt lymphoma
702384|NCT00002946|noncontiguous stage II adult lymphoblastic lymphoma
702385|NCT00002946|stage III mantle cell lymphoma
702386|NCT00002946|stage IV mantle cell lymphoma
702387|NCT00002946|recurrent mantle cell lymphoma
702388|NCT00002946|angioimmunoblastic T-cell lymphoma
702389|NCT00002946|anaplastic large cell lymphoma
702390|NCT00002946|noncontiguous stage II small lymphocytic lymphoma
702391|NCT00002946|noncontiguous stage II marginal zone lymphoma
702392|NCT00002946|recurrent marginal zone lymphoma
702393|NCT00002946|recurrent small lymphocytic lymphoma
702394|NCT00002946|stage I marginal zone lymphoma
702395|NCT00002946|stage I small lymphocytic lymphoma
702396|NCT00002946|stage III small lymphocytic lymphoma
702397|NCT00002946|stage III marginal zone lymphoma
702398|NCT00002946|stage IV small lymphocytic lymphoma
702399|NCT00002946|stage IV marginal zone lymphoma
702400|NCT00002946|contiguous stage II marginal zone lymphoma
702401|NCT00002946|contiguous stage II small lymphocytic lymphoma
702402|NCT00002946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702403|NCT00002946|nodal marginal zone B-cell lymphoma
702404|NCT00002946|splenic marginal zone lymphoma
702405|NCT00002945|untreated adult acute myeloid leukemia
702406|NCT00002945|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
702407|NCT00002945|adult acute erythroid leukemia (M6)
702408|NCT00002945|adult acute myeloblastic leukemia without maturation (M1)
702409|NCT00002945|adult acute myeloblastic leukemia with maturation (M2)
702410|NCT00002945|adult acute myelomonocytic leukemia (M4)
702411|NCT00002945|adult acute megakaryoblastic leukemia (M7)
702412|NCT00002945|secondary acute myeloid leukemia
702413|NCT00002945|adult acute minimally differentiated myeloid leukemia (M0)
702414|NCT00002944|recurrent childhood brain stem glioma
702415|NCT00002944|recurrent childhood visual pathway glioma
702416|NCT00002944|recurrent childhood cerebellar astrocytoma
702417|NCT00002944|recurrent childhood cerebral astrocytoma
702418|NCT00002944|childhood low-grade cerebellar astrocytoma
702419|NCT00002944|childhood low-grade cerebral astrocytoma
702420|NCT00002943|stage III malignant testicular germ cell tumor
702421|NCT00002943|recurrent malignant testicular germ cell tumor
702422|NCT00002943|unspecified adult solid tumor, protocol specific
702423|NCT00002943|stage III ovarian germ cell tumor
702424|NCT00002943|stage IV ovarian germ cell tumor
702425|NCT00002943|recurrent ovarian germ cell tumor
702426|NCT00002943|extragonadal germ cell tumor
702427|NCT00002942|stage II breast cancer
702428|NCT00002942|stage IV breast cancer
702429|NCT00002942|stage IIIA breast cancer
702430|NCT00002942|stage IIIB breast cancer
702431|NCT00002941|recurrent childhood lymphoblastic lymphoma
702432|NCT00002941|childhood diffuse large cell lymphoma
702433|NCT00002941|childhood immunoblastic large cell lymphoma
702434|NCT00002941|recurrent/refractory childhood Hodgkin lymphoma
702435|NCT00002941|recurrent childhood small noncleaved cell lymphoma
702436|NCT00002941|recurrent childhood large cell lymphoma
702437|NCT00002940|AIDS-related primary CNS lymphoma
702438|NCT00002939|unspecified adult solid tumor, protocol specific
702439|NCT00002938|recurrent prostate cancer
702440|NCT00002937|recurrent breast cancer
702441|NCT00002936|AIDS-related Kaposi sarcoma
702442|NCT00002936|recurrent Kaposi sarcoma
702443|NCT00002936|AIDS-related peripheral/systemic lymphoma
702444|NCT00002935|stage 0 esophageal cancer
702445|NCT00002934|breast cancer in situ
702446|NCT00002934|ductal breast carcinoma
702447|NCT00002933|stage IV colon cancer
702448|NCT00002933|stage IV rectal cancer
702449|NCT00002933|recurrent colon cancer
702450|NCT00002933|recurrent rectal cancer
702451|NCT00002933|adenocarcinoma of the colon
702452|NCT00002933|adenocarcinoma of the rectum
702453|NCT00002932|stage IV squamous cell carcinoma of the lip and oral cavity
702454|NCT00002932|stage IV squamous cell carcinoma of the oropharynx
702455|NCT00002932|stage IV squamous cell carcinoma of the hypopharynx
702456|NCT00002932|stage IV squamous cell carcinoma of the larynx
702457|NCT00002931|recurrent malignant testicular germ cell tumor
702458|NCT00002931|testicular seminoma
702459|NCT00002931|testicular embryonal carcinoma
702460|NCT00002931|testicular choriocarcinoma
702461|NCT00002931|testicular yolk sac tumor
702462|NCT00002931|testicular embryonal carcinoma and teratoma
702463|NCT00002931|testicular embryonal carcinoma and teratoma with seminoma
702464|NCT00002931|testicular embryonal carcinoma and yolk sac tumor
702465|NCT00002931|testicular embryonal carcinoma and yolk sac tumor with seminoma
702466|NCT00002931|testicular embryonal carcinoma and seminoma
702467|NCT00002931|testicular yolk sac tumor and teratoma
702468|NCT00002931|testicular yolk sac tumor and teratoma with seminoma
702469|NCT00002931|testicular choriocarcinoma and yolk sac tumor
702470|NCT00002931|testicular choriocarcinoma and embryonal carcinoma
702471|NCT00002931|testicular choriocarcinoma and teratoma
702472|NCT00002931|testicular choriocarcinoma and seminoma
702473|NCT00002931|recurrent ovarian germ cell tumor
702474|NCT00002931|recurrent extragonadal non-seminomatous germ cell tumor
702475|NCT00002931|recurrent extragonadal seminoma
702476|NCT00002931|recurrent extragonadal germ cell tumor
702477|NCT00002931|adult teratoma
702478|NCT00002931|testicular immature teratoma
702479|NCT00002931|testicular mature teratoma
702480|NCT00002931|ovarian immature teratoma
702481|NCT00002931|ovarian mature teratoma
702482|NCT00002931|ovarian monodermal and highly specialized teratoma
702483|NCT00002931|stage III malignant testicular germ cell tumor
702484|NCT00002931|stage IV ovarian germ cell tumor
702485|NCT00002931|stage IV extragonadal non-seminomatous germ cell tumor
702486|NCT00002931|stage IV extragonadal seminoma
702487|NCT00002931|adult central nervous system germ cell tumor
702488|NCT00002930|stage I non-small cell lung cancer
702489|NCT00002930|stage II non-small cell lung cancer
702490|NCT00002930|stage I esophageal cancer
702491|NCT00002930|stage II esophageal cancer
702492|NCT00002930|stage III esophageal cancer
702493|NCT00002930|stage IIIA non-small cell lung cancer
702494|NCT00002930|stage IIIB non-small cell lung cancer
702495|NCT00002928|recurrent ovarian epithelial cancer
702496|NCT00002926|secondary acute myeloid leukemia
702497|NCT00002926|refractory anemia
702498|NCT00002926|refractory anemia with ringed sideroblasts
702499|NCT00002926|refractory anemia with excess blasts
702500|NCT00002926|refractory anemia with excess blasts in transformation
702501|NCT00002926|chronic myelomonocytic leukemia
702502|NCT00002926|de novo myelodysplastic syndromes
702503|NCT00002926|previously treated myelodysplastic syndromes
702504|NCT00002926|secondary myelodysplastic syndromes
702505|NCT00002926|refractory cytopenia with multilineage dysplasia
702506|NCT00002926|childhood myelodysplastic syndromes
702507|NCT00002925|untreated adult acute myeloid leukemia
702508|NCT00002925|adult acute erythroid leukemia (M6)
702509|NCT00002925|adult acute myeloblastic leukemia without maturation (M1)
702510|NCT00002925|adult acute myeloblastic leukemia with maturation (M2)
702511|NCT00002925|adult acute myelomonocytic leukemia (M4)
702512|NCT00002925|adult acute monoblastic leukemia (M5a)
702513|NCT00002925|adult acute megakaryoblastic leukemia (M7)
702514|NCT00002925|adult acute monocytic leukemia (M5b)
702515|NCT00002925|adult acute minimally differentiated myeloid leukemia (M0)
702516|NCT00002924|adenocarcinoma of the prostate
702517|NCT00002924|recurrent prostate cancer
702518|NCT00002923|unspecified adult solid tumor, protocol specific
702519|NCT00002922|stage IV squamous cell carcinoma of the lip and oral cavity
702520|NCT00002922|recurrent squamous cell carcinoma of the lip and oral cavity
702521|NCT00002922|stage IV squamous cell carcinoma of the oropharynx
702522|NCT00002922|recurrent squamous cell carcinoma of the oropharynx
702523|NCT00002922|stage IV squamous cell carcinoma of the nasopharynx
702524|NCT00002922|recurrent squamous cell carcinoma of the nasopharynx
702525|NCT00002922|stage IV squamous cell carcinoma of the hypopharynx
702526|NCT00002922|recurrent squamous cell carcinoma of the hypopharynx
702527|NCT00002922|stage IV squamous cell carcinoma of the larynx
702528|NCT00002922|recurrent squamous cell carcinoma of the larynx
702529|NCT00002922|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
702530|NCT00002922|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
702531|NCT00002921|stage III adrenocortical carcinoma
702532|NCT00002921|stage IV adrenocortical carcinoma
702533|NCT00002920|endometrial cancer
702534|NCT00002920|stage I breast cancer
702535|NCT00002920|stage II breast cancer
702536|NCT00002920|ductal breast carcinoma in situ
702537|NCT00002920|lobular breast carcinoma in situ
702538|NCT00002920|Paget disease of the breast
702539|NCT00002919|stage II bladder cancer
702540|NCT00002919|transitional cell carcinoma of the bladder
702541|NCT00002917|stage 0 bladder cancer
702542|NCT00002917|stage I bladder cancer
702543|NCT00002917|transitional cell carcinoma of the bladder
702544|NCT00002916|stage IB cervical cancer
702545|NCT00002916|stage IIA cervical cancer
702546|NCT00002916|cervical squamous cell carcinoma
702547|NCT00002916|cervical adenocarcinoma
702548|NCT00002916|cervical adenosquamous cell carcinoma
702549|NCT00002915|unspecified adult solid tumor, protocol specific
702550|NCT00002914|recurrent bladder cancer
702551|NCT00002914|transitional cell carcinoma of the bladder
702552|NCT00002914|squamous cell carcinoma of the bladder
702553|NCT00002914|adenocarcinoma of the bladder
702554|NCT00002914|recurrent urethral cancer
702555|NCT00002914|recurrent transitional cell cancer of the renal pelvis and ureter
702556|NCT00002912|recurrent childhood acute lymphoblastic leukemia
702557|NCT00002912|recurrent childhood acute myeloid leukemia
702558|NCT00002912|secondary acute myeloid leukemia
702559|NCT00002911|stage IIIA non-small cell lung cancer
702560|NCT00002911|stage IIIB non-small cell lung cancer
702561|NCT00002909|stage III adult Hodgkin lymphoma
702562|NCT00002909|stage IV adult Hodgkin lymphoma
702563|NCT00002909|recurrent adult Hodgkin lymphoma
702564|NCT00002909|unspecified adult solid tumor, protocol specific
702565|NCT00002909|stage III grade 1 follicular lymphoma
702566|NCT00002909|stage III grade 2 follicular lymphoma
702567|NCT00002909|stage III grade 3 follicular lymphoma
702568|NCT00002909|stage III adult diffuse small cleaved cell lymphoma
702569|NCT00002909|stage III adult diffuse mixed cell lymphoma
702570|NCT00002909|stage III adult diffuse large cell lymphoma
702571|NCT00002909|stage III adult immunoblastic large cell lymphoma
702572|NCT00002909|stage III adult lymphoblastic lymphoma
702573|NCT00002909|stage III adult Burkitt lymphoma
702574|NCT00002909|stage IV grade 1 follicular lymphoma
702575|NCT00002909|stage IV grade 2 follicular lymphoma
702576|NCT00002909|stage IV grade 3 follicular lymphoma
702577|NCT00002909|stage IV adult diffuse small cleaved cell lymphoma
702578|NCT00002909|stage IV adult diffuse mixed cell lymphoma
702579|NCT00002909|stage IV adult diffuse large cell lymphoma
702580|NCT00002909|stage IV adult immunoblastic large cell lymphoma
702581|NCT00002909|stage IV adult lymphoblastic lymphoma
702582|NCT00002909|stage IV adult Burkitt lymphoma
702583|NCT00002909|recurrent grade 1 follicular lymphoma
702584|NCT00002909|recurrent grade 2 follicular lymphoma
702585|NCT00002909|recurrent grade 3 follicular lymphoma
702586|NCT00002909|recurrent adult diffuse small cleaved cell lymphoma
702587|NCT00002909|recurrent adult diffuse mixed cell lymphoma
702588|NCT00002909|recurrent adult diffuse large cell lymphoma
702589|NCT00002909|recurrent adult immunoblastic large cell lymphoma
702590|NCT00002909|recurrent adult lymphoblastic lymphoma
702591|NCT00002909|recurrent adult Burkitt lymphoma
702592|NCT00002909|stage III adult T-cell leukemia/lymphoma
702593|NCT00002909|stage IV adult T-cell leukemia/lymphoma
702594|NCT00002909|stage III mantle cell lymphoma
702595|NCT00002909|stage IV mantle cell lymphoma
702596|NCT00002909|recurrent mantle cell lymphoma
702597|NCT00002909|angioimmunoblastic T-cell lymphoma
702598|NCT00002909|anaplastic large cell lymphoma
702599|NCT00002909|recurrent marginal zone lymphoma
702600|NCT00002909|recurrent small lymphocytic lymphoma
702601|NCT00002909|stage III small lymphocytic lymphoma
702602|NCT00002909|stage III marginal zone lymphoma
702603|NCT00002909|stage IV small lymphocytic lymphoma
702604|NCT00002909|stage IV marginal zone lymphoma
702605|NCT00002909|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702606|NCT00002909|nodal marginal zone B-cell lymphoma
702607|NCT00002909|splenic marginal zone lymphoma
702608|NCT00002908|refractory chronic lymphocytic leukemia
702609|NCT00002908|recurrent small lymphocytic lymphoma
702610|NCT00002908|recurrent grade 1 follicular lymphoma
702611|NCT00002908|recurrent grade 2 follicular lymphoma
702612|NCT00002908|recurrent grade 3 follicular lymphoma
702613|NCT00002908|recurrent adult diffuse small cleaved cell lymphoma
702614|NCT00002908|recurrent adult diffuse mixed cell lymphoma
702615|NCT00002908|recurrent adult diffuse large cell lymphoma
702616|NCT00002908|recurrent adult immunoblastic large cell lymphoma
702617|NCT00002908|recurrent adult lymphoblastic lymphoma
702618|NCT00002908|recurrent adult Burkitt lymphoma
702619|NCT00002908|recurrent mantle cell lymphoma
702620|NCT00002908|recurrent marginal zone lymphoma
702621|NCT00002908|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702622|NCT00002908|nodal marginal zone B-cell lymphoma
702623|NCT00002908|splenic marginal zone lymphoma
702624|NCT00002907|refractory multiple myeloma
702625|NCT00002905|AIDS-related peripheral/systemic lymphoma
702626|NCT00002904|unspecified adult solid tumor, protocol specific
702627|NCT00002903|recurrent malignant testicular germ cell tumor
702628|NCT00002903|testicular seminoma
702629|NCT00002903|recurrent ovarian germ cell tumor
702630|NCT00002903|extragonadal germ cell tumor
702631|NCT00002902|unspecified adult solid tumor, protocol specific
702632|NCT00002901|stage IV breast cancer
702633|NCT00002901|stage IIIA breast cancer
702634|NCT00002901|recurrent breast cancer
702635|NCT00002901|stage IIIB breast cancer
702636|NCT00002901|recurrent non-small cell lung cancer
702637|NCT00002901|stage III ovarian epithelial cancer
702638|NCT00002901|stage IV ovarian epithelial cancer
702639|NCT00002901|recurrent ovarian epithelial cancer
702640|NCT00002901|stage IV nasopharyngeal cancer
702641|NCT00002901|stage IIIA non-small cell lung cancer
702642|NCT00002901|stage IIIB non-small cell lung cancer
702643|NCT00002901|stage IV non-small cell lung cancer
702644|NCT00002901|unspecified adult solid tumor, protocol specific
702645|NCT00002901|recurrent metastatic squamous neck cancer with occult primary
702646|NCT00002901|ovarian stromal cancer
702647|NCT00002901|stage III ovarian germ cell tumor
702648|NCT00002901|stage IV ovarian germ cell tumor
702649|NCT00002901|recurrent ovarian germ cell tumor
702650|NCT00002901|stage III squamous cell carcinoma of the lip and oral cavity
702651|NCT00002901|stage III basal cell carcinoma of the lip
702652|NCT00002901|stage III verrucous carcinoma of the oral cavity
702653|NCT00002901|stage III mucoepidermoid carcinoma of the oral cavity
702654|NCT00002901|stage III adenoid cystic carcinoma of the oral cavity
702655|NCT00002901|stage IV squamous cell carcinoma of the lip and oral cavity
702656|NCT00002901|stage IV basal cell carcinoma of the lip
702657|NCT00002901|stage IV verrucous carcinoma of the oral cavity
702658|NCT00002901|stage IV mucoepidermoid carcinoma of the oral cavity
702659|NCT00002901|stage IV adenoid cystic carcinoma of the oral cavity
702660|NCT00002901|recurrent squamous cell carcinoma of the lip and oral cavity
702661|NCT00002901|recurrent basal cell carcinoma of the lip
702662|NCT00002901|recurrent verrucous carcinoma of the oral cavity
702663|NCT00002901|recurrent mucoepidermoid carcinoma of the oral cavity
702664|NCT00002901|recurrent adenoid cystic carcinoma of the oral cavity
702665|NCT00002901|stage III squamous cell carcinoma of the oropharynx
702666|NCT00002901|stage III lymphoepithelioma of the oropharynx
702667|NCT00002901|stage IV squamous cell carcinoma of the oropharynx
702668|NCT00002901|stage IV lymphoepithelioma of the oropharynx
702669|NCT00002901|recurrent squamous cell carcinoma of the oropharynx
702670|NCT00002901|recurrent lymphoepithelioma of the oropharynx
702671|NCT00002901|stage III squamous cell carcinoma of the nasopharynx
702672|NCT00002901|stage III lymphoepithelioma of the nasopharynx
702673|NCT00002901|stage IV squamous cell carcinoma of the nasopharynx
702674|NCT00002901|stage IV lymphoepithelioma of the nasopharynx
702675|NCT00002901|recurrent squamous cell carcinoma of the nasopharynx
702676|NCT00002901|recurrent lymphoepithelioma of the nasopharynx
702677|NCT00002901|stage III squamous cell carcinoma of the hypopharynx
702678|NCT00002901|stage IV squamous cell carcinoma of the hypopharynx
702679|NCT00002901|recurrent squamous cell carcinoma of the hypopharynx
702680|NCT00002901|stage III squamous cell carcinoma of the larynx
702681|NCT00002901|stage III verrucous carcinoma of the larynx
702682|NCT00002901|stage IV squamous cell carcinoma of the larynx
702683|NCT00002901|stage IV verrucous carcinoma of the larynx
702684|NCT00002901|recurrent squamous cell carcinoma of the larynx
702685|NCT00002901|recurrent verrucous carcinoma of the larynx
702686|NCT00002901|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
702687|NCT00002901|stage III inverted papilloma of the paranasal sinus and nasal cavity
702688|NCT00002901|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
702689|NCT00002901|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
702690|NCT00002901|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
702691|NCT00002901|stage IV inverted papilloma of the paranasal sinus and nasal cavity
702692|NCT00002901|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
702693|NCT00002901|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
702694|NCT00002901|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
702695|NCT00002901|recurrent inverted papilloma of the paranasal sinus and nasal cavity
702696|NCT00002901|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
702697|NCT00002901|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
702698|NCT00002901|borderline ovarian surface epithelial-stromal tumor
702699|NCT00002901|ovarian sarcoma
702700|NCT00002900|stage I breast cancer
702701|NCT00002900|stage II breast cancer
702702|NCT00002900|ductal breast carcinoma
702703|NCT00002900|cardiac toxicity
702704|NCT00002899|tumors metastatic to brain
702705|NCT00002898|embryonal childhood rhabdomyosarcoma
702706|NCT00002898|alveolar childhood rhabdomyosarcoma
702707|NCT00002898|pleomorphic childhood rhabdomyosarcoma
702708|NCT00002898|mixed childhood rhabdomyosarcoma
702709|NCT00002898|embryonal-botryoid childhood rhabdomyosarcoma
702710|NCT00002898|nonmetastatic childhood soft tissue sarcoma
702711|NCT00002898|childhood fibrosarcoma
702712|NCT00002898|childhood synovial sarcoma
702713|NCT00002898|childhood malignant hemangiopericytoma
702714|NCT00002898|childhood liposarcoma
702715|NCT00002898|childhood alveolar soft-part sarcoma
702716|NCT00002898|childhood leiomyosarcoma
702717|NCT00002898|childhood neurofibrosarcoma
702718|NCT00002898|childhood angiosarcoma
702719|NCT00002898|childhood epithelioid sarcoma
702720|NCT00002898|childhood malignant fibrous histiocytoma of bone
702721|NCT00002898|childhood malignant mesenchymoma
702722|NCT00002898|previously untreated childhood rhabdomyosarcoma
702723|NCT00002898|childhood desmoplastic small round cell tumor
702724|NCT00002898|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
702725|NCT00002897|stage II esophageal cancer
702726|NCT00002897|stage III esophageal cancer
702727|NCT00002897|squamous cell carcinoma of the esophagus
702728|NCT00002896|stage II rectal cancer
702729|NCT00002896|stage III rectal cancer
702730|NCT00002896|recurrent rectal cancer
702731|NCT00002896|adenocarcinoma of the rectum
702732|NCT00002896|mucinous adenocarcinoma of the rectum
702733|NCT00002895|recurrent ovarian epithelial cancer
702734|NCT00002895|primary peritoneal cavity cancer
702735|NCT00002895|fallopian tube cancer
702736|NCT00002894|recurrent ovarian epithelial cancer
702737|NCT00002894|primary peritoneal cavity cancer
702738|NCT00002893|stage III colon cancer
702739|NCT00002893|stage IV colon cancer
702740|NCT00002893|stage III rectal cancer
702741|NCT00002893|stage IV rectal cancer
702742|NCT00002893|recurrent colon cancer
702743|NCT00002893|recurrent rectal cancer
702744|NCT00002893|adenocarcinoma of the colon
702745|NCT00002893|adenocarcinoma of the rectum
702746|NCT00002892|stage II melanoma
702747|NCT00002892|stage III melanoma
702748|NCT00002892|recurrent melanoma
702749|NCT00002890|recurrent adult acute myeloid leukemia
702750|NCT00002890|relapsing chronic myelogenous leukemia
702751|NCT00002890|accelerated phase chronic myelogenous leukemia
702752|NCT00002890|blastic phase chronic myelogenous leukemia
702753|NCT00002890|refractory anemia with excess blasts
702754|NCT00002890|refractory anemia with excess blasts in transformation
702755|NCT00002890|chronic myelomonocytic leukemia
702756|NCT00002890|de novo myelodysplastic syndromes
702757|NCT00002890|previously treated myelodysplastic syndromes
702758|NCT00002890|childhood myelodysplastic syndromes
702759|NCT00002889|adenocarcinoma of the prostate
702760|NCT00002889|stage I prostate cancer
702761|NCT00002889|stage II prostate cancer
702762|NCT00002889|stage III prostate cancer
702763|NCT00002889|stage IV prostate cancer
702764|NCT00002888|stage III squamous cell carcinoma of the lip and oral cavity
702765|NCT00002888|stage IV squamous cell carcinoma of the lip and oral cavity
702766|NCT00002888|recurrent squamous cell carcinoma of the lip and oral cavity
702767|NCT00002888|stage III squamous cell carcinoma of the oropharynx
702768|NCT00002888|stage IV squamous cell carcinoma of the oropharynx
702769|NCT00002888|recurrent squamous cell carcinoma of the oropharynx
702770|NCT00002888|stage III squamous cell carcinoma of the hypopharynx
702771|NCT00002888|stage IV squamous cell carcinoma of the hypopharynx
702772|NCT00002888|recurrent squamous cell carcinoma of the hypopharynx
702773|NCT00002888|stage III squamous cell carcinoma of the larynx
702774|NCT00002888|stage IV squamous cell carcinoma of the larynx
702775|NCT00002888|recurrent squamous cell carcinoma of the larynx
702776|NCT00002888|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
702777|NCT00002888|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
702778|NCT00002888|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
702779|NCT00002887|recurrent non-small cell lung cancer
702780|NCT00002884|stage I esophageal cancer
702781|NCT00002884|stage II esophageal cancer
702782|NCT00002884|stage III esophageal cancer
702783|NCT00002884|squamous cell carcinoma of the esophagus
702784|NCT00002884|adenocarcinoma of the esophagus
702785|NCT00002883|stage I gastric cancer
702786|NCT00002883|stage II gastric cancer
702787|NCT00002883|stage I esophageal cancer
702788|NCT00002883|stage II esophageal cancer
702789|NCT00002883|adenocarcinoma of the stomach
702790|NCT00002883|adenocarcinoma of the esophagus
702791|NCT00002882|stage III melanoma
702792|NCT00002881|adenocarcinoma of the prostate
702793|NCT00002881|stage IV prostate cancer
702794|NCT00002881|recurrent prostate cancer
702795|NCT00002880|Waldenstrom macroglobulinemia
702796|NCT00002880|recurrent small lymphocytic lymphoma
702797|NCT00002880|recurrent grade 1 follicular lymphoma
702798|NCT00002880|recurrent grade 2 follicular lymphoma
702799|NCT00002880|recurrent grade 3 follicular lymphoma
702800|NCT00002880|recurrent adult diffuse small cleaved cell lymphoma
702801|NCT00002880|recurrent adult diffuse mixed cell lymphoma
702802|NCT00002880|recurrent adult diffuse large cell lymphoma
702803|NCT00002880|recurrent adult immunoblastic large cell lymphoma
702804|NCT00002879|mantle cell lymphoma
702805|NCT00002879|stage I mantle cell lymphoma
702806|NCT00002879|contiguous stage II mantle cell lymphoma
702807|NCT00002879|noncontiguous stage II mantle cell lymphoma
702808|NCT00002879|stage III mantle cell lymphoma
702809|NCT00002879|stage IV mantle cell lymphoma
702810|NCT00002879|recurrent mantle cell lymphoma
702811|NCT00002878|refractory multiple myeloma
702812|NCT00002876|recurrent adult brain tumor
702813|NCT00002876|adult myxopapillary ependymoma
702814|NCT00002876|adult anaplastic ependymoma
702815|NCT00002875|untreated childhood medulloblastoma
702816|NCT00002874|stage IIB prostate cancer
702817|NCT00002874|stage IIA prostate cancer
702818|NCT00002874|stage III prostate cancer
702819|NCT00002874|recurrent prostate cancer
702820|NCT00002873|stage I breast cancer
702821|NCT00002873|stage II breast cancer
702822|NCT00002873|medullary ductal breast carcinoma with lymphocytic infiltrate
702823|NCT00002873|mucinous ductal breast carcinoma
702824|NCT00002873|invasive ductal breast carcinoma
702825|NCT00002873|papillary ductal breast carcinoma
702826|NCT00002873|tubular ductal breast carcinoma
702827|NCT00002872|malignant pleural effusion
702828|NCT00002870|stage IV breast cancer
702829|NCT00002870|recurrent breast cancer
702830|NCT00002869|chronic phase chronic myelogenous leukemia
702831|NCT00002869|chronic myelogenous leukemia, BCR-ABL1 positive
702832|NCT00002869|Philadelphia chromosome negative chronic myelogenous leukemia
702833|NCT00002868|chronic phase chronic myelogenous leukemia
702834|NCT00002866|stage IV breast cancer
702835|NCT00002866|recurrent breast cancer
702836|NCT00002866|neutropenia
702837|NCT00002865|recurrent adult acute lymphoblastic leukemia
702838|NCT00002864|stage I breast cancer
702839|NCT00002864|stage II breast cancer
702840|NCT00002864|stage III breast cancer
702841|NCT00002863|recurrent childhood rhabdomyosarcoma
702842|NCT00002863|stage I adult soft tissue sarcoma
702843|NCT00002863|stage II adult soft tissue sarcoma
702844|NCT00002863|stage III adult soft tissue sarcoma
702845|NCT00002863|recurrent adult soft tissue sarcoma
702846|NCT00002863|nonmetastatic childhood soft tissue sarcoma
702847|NCT00002863|recurrent childhood soft tissue sarcoma
702848|NCT00002863|previously untreated childhood rhabdomyosarcoma
702849|NCT00002863|stage IV adult soft tissue sarcoma
702850|NCT00002862|stage IV adult Hodgkin lymphoma
702851|NCT00002862|recurrent adult Hodgkin lymphoma
702852|NCT00002862|unspecified adult solid tumor, protocol specific
702853|NCT00002862|stage IV grade 1 follicular lymphoma
702854|NCT00002862|stage IV grade 2 follicular lymphoma
702855|NCT00002862|stage IV grade 3 follicular lymphoma
702856|NCT00002862|stage IV adult diffuse small cleaved cell lymphoma
702857|NCT00002862|stage IV adult diffuse mixed cell lymphoma
702858|NCT00002862|stage IV adult diffuse large cell lymphoma
702859|NCT00002862|stage IV adult immunoblastic large cell lymphoma
702860|NCT00002862|stage IV adult lymphoblastic lymphoma
702861|NCT00002862|stage IV adult Burkitt lymphoma
702862|NCT00002862|recurrent grade 1 follicular lymphoma
702863|NCT00002862|recurrent grade 2 follicular lymphoma
702864|NCT00002862|recurrent grade 3 follicular lymphoma
702865|NCT00002862|recurrent adult diffuse small cleaved cell lymphoma
702866|NCT00002862|recurrent adult diffuse mixed cell lymphoma
702867|NCT00002862|recurrent adult diffuse large cell lymphoma
702868|NCT00002862|recurrent adult immunoblastic large cell lymphoma
702869|NCT00002862|recurrent adult lymphoblastic lymphoma
702870|NCT00002862|recurrent adult Burkitt lymphoma
702871|NCT00002862|stage IV adult T-cell leukemia/lymphoma
702872|NCT00002862|recurrent adult T-cell leukemia/lymphoma
702873|NCT00002862|stage IV mantle cell lymphoma
702874|NCT00002862|recurrent mantle cell lymphoma
702875|NCT00002862|angioimmunoblastic T-cell lymphoma
702876|NCT00002862|anaplastic large cell lymphoma
702877|NCT00002862|recurrent marginal zone lymphoma
702878|NCT00002862|recurrent small lymphocytic lymphoma
702879|NCT00002862|stage IV small lymphocytic lymphoma
702880|NCT00002862|stage IV marginal zone lymphoma
702881|NCT00002862|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
702882|NCT00002862|nodal marginal zone B-cell lymphoma
702883|NCT00002862|splenic marginal zone lymphoma
702884|NCT00002860|stage IV melanoma
702885|NCT00002860|recurrent melanoma
702886|NCT00002858|limited stage small cell lung cancer
702887|NCT00002855|adenocarcinoma of the prostate
702888|NCT00002855|stage III prostate cancer
702889|NCT00002855|stage IV prostate cancer
702890|NCT00002855|recurrent prostate cancer
702891|NCT00002854|stage IV colon cancer
702892|NCT00002854|stage II breast cancer
702893|NCT00002854|stage IV breast cancer
702894|NCT00002854|stage IIIA breast cancer
702895|NCT00002854|recurrent breast cancer
702896|NCT00002854|stage IV gastric cancer
702897|NCT00002854|recurrent gastric cancer
702898|NCT00002854|localized osteosarcoma
702899|NCT00002854|metastatic osteosarcoma
702900|NCT00002854|stage IIIB breast cancer
702901|NCT00002854|recurrent pancreatic cancer
702902|NCT00002854|stage IV rectal cancer
702903|NCT00002854|recurrent colon cancer
702904|NCT00002854|recurrent rectal cancer
702905|NCT00002854|stage IV anal cancer
702906|NCT00002854|recurrent anal cancer
702907|NCT00002854|stage IV esophageal cancer
702908|NCT00002854|recurrent esophageal cancer
702909|NCT00002854|stage III adult soft tissue sarcoma
702910|NCT00002854|recurrent adult soft tissue sarcoma
702911|NCT00002854|stage III ovarian epithelial cancer
702912|NCT00002854|stage IV ovarian epithelial cancer
702913|NCT00002854|recurrent ovarian epithelial cancer
702914|NCT00002854|recurrent Wilms tumor and other childhood kidney tumors
702915|NCT00002854|advanced adult primary liver cancer
702916|NCT00002854|recurrent adult primary liver cancer
702917|NCT00002854|recurrent osteosarcoma
702918|NCT00002854|recurrent gallbladder cancer
702919|NCT00002854|recurrent extrahepatic bile duct cancer
702920|NCT00002854|recurrent small intestine cancer
702921|NCT00002854|stage II melanoma
702922|NCT00002854|stage III melanoma
702923|NCT00002854|stage IV melanoma
702924|NCT00002854|recurrent melanoma
702925|NCT00002854|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
702926|NCT00002854|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
702927|NCT00002854|stage IV adult soft tissue sarcoma
702928|NCT00002854|stage IV pancreatic cancer
702929|NCT00002851|stage I breast cancer
702930|NCT00002851|stage II breast cancer
702931|NCT00002851|stage IIIA breast cancer
702932|NCT00002850|stage I multiple myeloma
702933|NCT00002850|stage II multiple myeloma
702934|NCT00002850|stage III multiple myeloma
702935|NCT00002850|infection
702936|NCT00002849|primary systemic amyloidosis
702937|NCT00002848|stage I prostate cancer
702938|NCT00002848|stage IIB prostate cancer
702939|NCT00002848|stage IIA prostate cancer
702940|NCT00002848|psychosocial effects of cancer and its treatment
702941|NCT00002847|stage IV renal cell cancer
702942|NCT00002847|recurrent renal cell cancer
702943|NCT00002846|stage IV renal cell cancer
702944|NCT00002846|recurrent renal cell cancer
702945|NCT00002845|stage IV melanoma
702946|NCT00002845|recurrent melanoma
702947|NCT00002844|refractory chronic lymphocytic leukemia
702948|NCT00002844|Cyclophosphamide
702949|NCT00002844|Cytoxan
702950|NCT00002844|Neosar
702951|NCT00002844|Bone Marrow Transplantation
702952|NCT00002844|total body irradiation
702953|NCT00002844|chronic lymphocytic leukemia
702954|NCT00002844|allogeneic
702955|NCT00002844|autologous
702956|NCT00002842|stage IV colon cancer
702957|NCT00002842|stage IV rectal cancer
702958|NCT00002842|recurrent colon cancer
702959|NCT00002842|recurrent rectal cancer
702960|NCT00002842|liver metastases
702961|NCT00002840|recurrent adult brain tumor
702962|NCT00002840|adult anaplastic oligodendroglioma
702963|NCT00002840|adult mixed glioma
702964|NCT00002839|stage II squamous cell carcinoma of the hypopharynx
702965|NCT00002839|stage III squamous cell carcinoma of the hypopharynx
702966|NCT00002839|stage IV squamous cell carcinoma of the hypopharynx
702967|NCT00002839|stage III squamous cell carcinoma of the larynx
702968|NCT00002839|stage IV squamous cell carcinoma of the larynx
702969|NCT00002838|stage III chronic lymphocytic leukemia
702970|NCT00002838|stage IV chronic lymphocytic leukemia
702971|NCT00002838|refractory chronic lymphocytic leukemia
702972|NCT00002837|stage IV breast cancer
702973|NCT00002837|recurrent breast cancer
702974|NCT00002836|recurrent breast cancer
702975|NCT00002835|stage I grade 3 follicular lymphoma
702976|NCT00002835|stage I adult diffuse small cleaved cell lymphoma
702977|NCT00002835|stage I adult diffuse mixed cell lymphoma
702978|NCT00002835|stage I adult diffuse large cell lymphoma
702979|NCT00002835|stage I adult immunoblastic large cell lymphoma
702980|NCT00002835|stage III grade 3 follicular lymphoma
702981|NCT00002835|stage III adult diffuse small cleaved cell lymphoma
702982|NCT00002835|stage III adult diffuse mixed cell lymphoma
702983|NCT00002835|stage III adult diffuse large cell lymphoma
702984|NCT00002835|stage III adult immunoblastic large cell lymphoma
702985|NCT00002835|stage IV grade 3 follicular lymphoma
702986|NCT00002835|stage IV adult diffuse small cleaved cell lymphoma
702987|NCT00002835|stage IV adult diffuse mixed cell lymphoma
702988|NCT00002835|stage IV adult diffuse large cell lymphoma
702989|NCT00002835|stage IV adult immunoblastic large cell lymphoma
702990|NCT00002835|contiguous stage II grade 3 follicular lymphoma
702991|NCT00002835|contiguous stage II adult diffuse small cleaved cell lymphoma
702992|NCT00002835|contiguous stage II adult diffuse mixed cell lymphoma
702993|NCT00002835|contiguous stage II adult immunoblastic large cell lymphoma
702994|NCT00002835|contiguous stage II adult diffuse large cell lymphoma
702995|NCT00002835|noncontiguous stage II grade 3 follicular lymphoma
702996|NCT00002835|noncontiguous stage II adult diffuse small cleaved cell lymphoma
702997|NCT00002835|noncontiguous stage II adult diffuse mixed cell lymphoma
702998|NCT00002835|noncontiguous stage II adult immunoblastic large cell lymphoma
702999|NCT00002835|noncontiguous stage II adult diffuse large cell lymphoma
703000|NCT00002833|recurrent adult acute myeloid leukemia
703001|NCT00002833|relapsing chronic myelogenous leukemia
703002|NCT00002833|chronic phase chronic myelogenous leukemia
703003|NCT00002833|accelerated phase chronic myelogenous leukemia
703004|NCT00002833|blastic phase chronic myelogenous leukemia
703005|NCT00002833|adult acute myeloid leukemia in remission
703006|NCT00002833|Philadelphia chromosome positive chronic myelogenous leukemia
703007|NCT00002833|refractory anemia with excess blasts
703008|NCT00002833|refractory anemia with excess blasts in transformation
703009|NCT00002833|chronic myelomonocytic leukemia
703010|NCT00002833|graft versus host disease
703011|NCT00002832|Decitabine
703012|NCT00002832|Dacogen
703013|NCT00002832|Filgrastim
703014|NCT00002832|G-CSF
703015|NCT00002832|Neupogen
703016|NCT00002832|Cyclosporine
703017|NCT00002832|Sandimmune
703018|NCT00002832|CYA
703019|NCT00002832|Cyclosporin A
703020|NCT00002832|Peripheral blood stem cells
703021|NCT00002832|PBSC
703022|NCT00002832|Allogeneic bone marrow transplantation
703023|NCT00002832|recurrent childhood acute lymphoblastic leukemia
703024|NCT00002832|recurrent childhood acute myeloid leukemia
703025|NCT00002832|recurrent adult acute myeloid leukemia
703026|NCT00002832|recurrent adult acute lymphoblastic leukemia
703027|NCT00002832|accelerated phase chronic myelogenous leukemia
703028|NCT00002832|blastic phase chronic myelogenous leukemia
703029|NCT00002832|previously treated myelodysplastic syndromes
703030|NCT00002832|childhood myelodysplastic syndromes
703031|NCT00002831|recurrent adult acute myeloid leukemia
703032|NCT00002831|accelerated phase chronic myelogenous leukemia
703033|NCT00002831|blastic phase chronic myelogenous leukemia
703034|NCT00002829|Waldenstrom macroglobulinemia
703035|NCT00002829|recurrent grade 1 follicular lymphoma
703036|NCT00002829|recurrent grade 2 follicular lymphoma
703037|NCT00002829|recurrent marginal zone lymphoma
703038|NCT00002829|recurrent small lymphocytic lymphoma
703039|NCT00002829|extranodal marginal zone B-cell lymphoma
703040|NCT00002829|mucosa-associated lymphoid tissue
703041|NCT00002829|nodal marginal zone B-cell lymphoma
703042|NCT00002829|splenic marginal zone lymphoma
703043|NCT00002828|stage III colon cancer
703044|NCT00002828|stage IV colon cancer
703045|NCT00002828|stage III rectal cancer
703046|NCT00002828|stage IV rectal cancer
703047|NCT00002828|recurrent colon cancer
703048|NCT00002828|recurrent rectal cancer
703049|NCT00002827|stage II childhood Hodgkin lymphoma
703050|NCT00002827|stage I childhood Hodgkin lymphoma
703051|NCT00002827|stage III childhood Hodgkin lymphoma
703052|NCT00002827|cardiac toxicity
703053|NCT00002826|stage IV breast cancer
703054|NCT00002826|recurrent breast cancer
703055|NCT00002825|recurrent childhood rhabdomyosarcoma
703056|NCT00002825|recurrent neuroblastoma
703057|NCT00002825|recurrent osteosarcoma
703058|NCT00002825|recurrent childhood soft tissue sarcoma
703059|NCT00002825|recurrent childhood brain stem glioma
703060|NCT00002825|recurrent childhood supratentorial primitive neuroectodermal tumor
703061|NCT00002825|recurrent childhood cerebellar astrocytoma
703062|NCT00002825|recurrent childhood cerebral astrocytoma
703063|NCT00002825|recurrent childhood medulloblastoma
703064|NCT00002825|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
703065|NCT00002825|recurrent childhood ependymoma
703066|NCT00002824|recurrent adult brain tumor
703067|NCT00002824|adult glioblastoma
703068|NCT00002824|adult anaplastic astrocytoma
703069|NCT00002824|adult giant cell glioblastoma
703070|NCT00002824|adult gliosarcoma
703071|NCT00002823|stage I non-small cell lung cancer
703072|NCT00002823|stage II non-small cell lung cancer
703073|NCT00002823|stage III non-small cell lung cancer
703074|NCT00002823|squamous cell lung cancer
703075|NCT00002823|large cell lung cancer
703076|NCT00002823|adenocarcinoma of the lung
703077|NCT00002823|adenosquamous cell lung cancer
703078|NCT00002822|limited stage small cell lung cancer
703079|NCT00002822|extensive stage small cell lung cancer
703080|NCT00002819|stage III ovarian epithelial cancer
703081|NCT00002819|recurrent ovarian epithelial cancer
703082|NCT00002819|ovarian undifferentiated adenocarcinoma
703083|NCT00002819|ovarian mixed epithelial carcinoma
703084|NCT00002819|ovarian serous cystadenocarcinoma
703085|NCT00002819|ovarian mucinous cystadenocarcinoma
703086|NCT00002819|ovarian endometrioid adenocarcinoma
703087|NCT00002819|ovarian clear cell cystadenocarcinoma
703088|NCT00002819|Brenner tumor
703089|NCT00002818|recurrent adult Hodgkin lymphoma
703090|NCT00002818|refractory multiple myeloma
703091|NCT00002818|recurrent adult acute myeloid leukemia
703092|NCT00002818|recurrent adult acute lymphoblastic leukemia
703093|NCT00002818|relapsing chronic myelogenous leukemia
703094|NCT00002818|blastic phase chronic myelogenous leukemia
703095|NCT00002818|recurrent grade 1 follicular lymphoma
703096|NCT00002818|recurrent grade 2 follicular lymphoma
703097|NCT00002818|recurrent grade 3 follicular lymphoma
703098|NCT00002818|recurrent adult diffuse small cleaved cell lymphoma
703099|NCT00002818|recurrent adult diffuse mixed cell lymphoma
703100|NCT00002818|recurrent adult diffuse large cell lymphoma
703101|NCT00002818|recurrent adult immunoblastic large cell lymphoma
703102|NCT00002818|recurrent adult lymphoblastic lymphoma
703103|NCT00002818|recurrent adult Burkitt lymphoma
703104|NCT00002818|drug/agent toxicity by tissue/organ
703105|NCT00002818|recurrent mantle cell lymphoma
703106|NCT00002818|recurrent marginal zone lymphoma
703107|NCT00002818|recurrent small lymphocytic lymphoma
703108|NCT00002818|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703109|NCT00002818|nodal marginal zone B-cell lymphoma
703110|NCT00002818|splenic marginal zone lymphoma
703111|NCT00002817|stage III melanoma
703112|NCT00002817|stage IV melanoma
703113|NCT00002817|recurrent melanoma
703114|NCT00002816|recurrent childhood acute lymphoblastic leukemia
703115|NCT00002814|recurrent adult brain tumor
703116|NCT00002814|adult glioblastoma
703117|NCT00002814|adult anaplastic astrocytoma
703118|NCT00002814|adult giant cell glioblastoma
703119|NCT00002814|adult gliosarcoma
703120|NCT00002813|recurrent cervical cancer
703121|NCT00002813|stage IVB cervical cancer
703122|NCT00002813|cervical squamous cell carcinoma
703123|NCT00002812|untreated childhood acute lymphoblastic leukemia
703124|NCT00002812|L1 childhood acute lymphoblastic leukemia
703125|NCT00002812|L2 childhood acute lymphoblastic leukemia
703126|NCT00002811|actinic keratosis
703127|NCT00002810|refractory multiple myeloma
703128|NCT00002810|stage I multiple myeloma
703129|NCT00002810|stage II multiple myeloma
703130|NCT00002810|stage III multiple myeloma
703131|NCT00002810|primary systemic amyloidosis
703132|NCT00002809|recurrent adult acute myeloid leukemia
703133|NCT00002809|recurrent adult acute lymphoblastic leukemia
703134|NCT00002809|refractory chronic lymphocytic leukemia
703135|NCT00002809|chronic phase chronic myelogenous leukemia
703136|NCT00002809|accelerated phase chronic myelogenous leukemia
703137|NCT00002809|adult acute myeloid leukemia in remission
703138|NCT00002809|adult acute lymphoblastic leukemia in remission
703139|NCT00002809|refractory anemia
703140|NCT00002809|refractory anemia with excess blasts
703141|NCT00002809|refractory anemia with excess blasts in transformation
703142|NCT00002809|secondary acute myeloid leukemia
703143|NCT00002809|previously treated myelodysplastic syndromes
703144|NCT00002809|atypical chronic myeloid leukemia
703145|NCT00002809|myelodysplastic/myeloproliferative disease, unclassifiable
703146|NCT00002809|adult acute myeloid leukemia with t(8;21)(q22;q22)
703147|NCT00002809|adult acute myeloid leukemia with t(16;16)(p13;q22)
703148|NCT00002809|adult acute myeloid leukemia with inv(16)(p13;q22)
703149|NCT00002809|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
703150|NCT00002809|adult acute myeloid leukemia with t(15;17)(q22;q12)
703151|NCT00002807|stage I endometrial carcinoma
703152|NCT00002807|stage II endometrial carcinoma
703153|NCT00002807|endometrial adenocarcinoma
703154|NCT00002807|endometrial adenosquamous cell carcinoma
703155|NCT00002807|endometrial papillary carcinoma
703156|NCT00002807|endometrial clear cell carcinoma
703157|NCT00002806|adult diffuse astrocytoma
703158|NCT00002805|recurrent childhood acute myeloid leukemia
703159|NCT00002805|secondary acute myeloid leukemia
703160|NCT00002805|childhood myelodysplastic syndromes
703161|NCT00002804|nonmetastatic childhood soft tissue sarcoma
703162|NCT00002804|metastatic childhood soft tissue sarcoma
703163|NCT00002803|localized resectable neuroblastoma
703164|NCT00002803|regional neuroblastoma
703165|NCT00002803|stage 4S neuroblastoma
703166|NCT00002803|localized unresectable neuroblastoma
703167|NCT00002802|localized resectable neuroblastoma
703168|NCT00002802|regional neuroblastoma
703169|NCT00002802|disseminated neuroblastoma
703170|NCT00002802|stage 4S neuroblastoma
703171|NCT00002802|localized unresectable neuroblastoma
703172|NCT00002801|stage II colon cancer
703173|NCT00002801|stage III colon cancer
703174|NCT00002801|stage I rectal cancer
703175|NCT00002801|stage II rectal cancer
703176|NCT00002801|stage III rectal cancer
703177|NCT00002800|accelerated phase chronic myelogenous leukemia
703178|NCT00002800|blastic phase chronic myelogenous leukemia
703179|NCT00002800|untreated adult acute myeloid leukemia
703180|NCT00002800|refractory anemia with excess blasts
703181|NCT00002800|refractory anemia with excess blasts in transformation
703182|NCT00002800|chronic myelomonocytic leukemia
703183|NCT00002800|de novo myelodysplastic syndromes
703184|NCT00002800|neutropenia
703185|NCT00002794|intraocular retinoblastoma
703186|NCT00002793|stage IV colon cancer
703187|NCT00002793|stage IV rectal cancer
703188|NCT00002793|recurrent colon cancer
703189|NCT00002793|recurrent rectal cancer
703190|NCT00002793|liver metastases
703191|NCT00002792|polycythemia vera
703192|NCT00002792|chronic idiopathic myelofibrosis
703193|NCT00002792|essential thrombocythemia
703194|NCT00002792|atypical chronic myeloid leukemia
703195|NCT00002792|myelodysplastic/myeloproliferative disease, unclassifiable
703196|NCT00002791|stage II adult soft tissue sarcoma
703197|NCT00002791|stage III adult soft tissue sarcoma
703198|NCT00002791|recurrent adult soft tissue sarcoma
703199|NCT00002790|childhood acute lymphoblastic leukemia
703200|NCT00002790|chronic lymphocytic leukemia
703201|NCT00002790|adult acute lymphoblastic leukemia
703202|NCT00002790|adult acute myeloid leukemia
703203|NCT00002790|chronic myelogenous leukemia
703204|NCT00002790|childhood acute myeloid leukemia/other myeloid malignancies
703205|NCT00002790|myelodysplastic syndromes
703206|NCT00002790|graft versus host disease
703207|NCT00002790|childhood myelodysplastic syndromes
703208|NCT00002789|chronic phase chronic myelogenous leukemia
703209|NCT00002789|accelerated phase chronic myelogenous leukemia
703210|NCT00002789|Philadelphia chromosome positive chronic myelogenous leukemia
703211|NCT00002788|stage III chronic lymphocytic leukemia
703212|NCT00002788|stage IV chronic lymphocytic leukemia
703213|NCT00002788|refractory chronic lymphocytic leukemia
703214|NCT00002788|B-cell chronic lymphocytic leukemia
703215|NCT00002786|stage IV melanoma
703216|NCT00002786|recurrent melanoma
703217|NCT00002785|untreated childhood acute lymphoblastic leukemia
703218|NCT00002784|stage II breast cancer
703219|NCT00002784|stage IIIA breast cancer
703220|NCT00002783|stage II gastric cancer
703221|NCT00002783|stage III gastric cancer
703222|NCT00002783|stage IV gastric cancer
703223|NCT00002783|adenocarcinoma of the stomach
703224|NCT00002781|stage III melanoma
703225|NCT00002781|recurrent melanoma
703226|NCT00002780|stage IV breast cancer
703227|NCT00002780|recurrent breast cancer
703228|NCT00002780|stage IIIB breast cancer
703229|NCT00002779|Waldenström macroglobulinemia
703230|NCT00002779|recurrent small lymphocytic lymphoma
703231|NCT00002779|recurrent grade 1 follicular lymphoma
703232|NCT00002779|recurrent grade 2 follicular lymphoma
703233|NCT00002779|recurrent mantle cell lymphoma
703234|NCT00002779|recurrent marginal zone lymphoma
703235|NCT00002779|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703236|NCT00002779|nodal marginal zone B-cell lymphoma
703237|NCT00002778|relapsing chronic myelogenous leukemia
703238|NCT00002778|chronic phase chronic myelogenous leukemia
703239|NCT00002778|accelerated phase chronic myelogenous leukemia
703240|NCT00002778|Philadelphia chromosome positive chronic myelogenous leukemia
703241|NCT00002778|Philadelphia chromosome negative chronic myelogenous leukemia
703242|NCT00002778|atypical chronic myeloid leukemia
703243|NCT00002777|stage IV breast cancer
703244|NCT00002777|recurrent breast cancer
703245|NCT00002775|adenocarcinoma of the prostate
703246|NCT00002775|stage IV prostate cancer
703247|NCT00002775|recurrent prostate cancer
703248|NCT00002774|stage III
703249|NCT00002774|stage IV
703250|NCT00002774|recurrent
703251|NCT00002773|stage II pancreatic cancer
703252|NCT00002773|stage III pancreatic cancer
703253|NCT00002773|recurrent pancreatic cancer
703254|NCT00002773|adenocarcinoma of the pancreas
703255|NCT00002773|stage IV pancreatic cancer
703256|NCT00002772|stage II breast cancer
703257|NCT00002772|stage IIIA breast cancer
703258|NCT00002771|chronic phase chronic myelogenous leukemia
703259|NCT00002771|chronic myelogenous leukemia, BCR-ABL1 positive
703260|NCT00002771|Philadelphia chromosome negative chronic myelogenous leukemia
703261|NCT00002771|childhood chronic myelogenous leukemia
703262|NCT00002768|adult acute myeloid leukemia in remission
703263|NCT00002768|adult acute erythroid leukemia (M6)
703264|NCT00002768|adult acute myeloblastic leukemia without maturation (M1)
703265|NCT00002768|adult acute myeloblastic leukemia with maturation (M2)
703266|NCT00002768|adult acute promyelocytic leukemia (M3)
703267|NCT00002768|adult acute myelomonocytic leukemia (M4)
703268|NCT00002768|adult acute monoblastic leukemia (M5a)
703269|NCT00002768|adult acute megakaryoblastic leukemia (M7)
703270|NCT00002768|adult acute monocytic leukemia (M5b)
703271|NCT00002768|adult acute minimally differentiated myeloid leukemia (M0)
703272|NCT00002767|stage IV melanoma
703273|NCT00002767|recurrent melanoma
703274|NCT00002766|blastic phase chronic myelogenous leukemia
703275|NCT00002766|untreated adult acute lymphoblastic leukemia
703276|NCT00002766|chronic myelogenous leukemia, BCR-ABL1 positive
703277|NCT00002766|T-cell adult acute lymphoblastic leukemia
703278|NCT00002766|B-cell adult acute lymphoblastic leukemia
703279|NCT00002766|stage I adult lymphoblastic lymphoma
703280|NCT00002766|stage II adult lymphoblastic lymphoma
703281|NCT00002766|stage III adult lymphoblastic lymphoma
703282|NCT00002766|stage IV adult lymphoblastic lymphoma
703283|NCT00002766|contiguous stage II adult lymphoblastic lymphoma
703284|NCT00002766|noncontiguous stage II adult lymphoblastic lymphoma
703285|NCT00002765|recurrent adult Hodgkin lymphoma
703286|NCT00002765|stage IV cutaneous T-cell non-Hodgkin lymphoma
703287|NCT00002765|recurrent cutaneous T-cell non-Hodgkin lymphoma
703288|NCT00002765|Waldenström macroglobulinemia
703289|NCT00002765|recurrent adult acute myeloid leukemia
703290|NCT00002765|recurrent adult acute lymphoblastic leukemia
703291|NCT00002765|relapsing chronic myelogenous leukemia
703292|NCT00002765|refractory chronic lymphocytic leukemia
703293|NCT00002765|refractory hairy cell leukemia
703294|NCT00002765|recurrent small lymphocytic lymphoma
703295|NCT00002765|recurrent grade 1 follicular lymphoma
703296|NCT00002765|recurrent grade 2 follicular lymphoma
703297|NCT00002765|recurrent grade 3 follicular lymphoma
703298|NCT00002765|recurrent adult diffuse small cleaved cell lymphoma
703299|NCT00002765|recurrent adult diffuse mixed cell lymphoma
703300|NCT00002765|recurrent adult diffuse large cell lymphoma
703301|NCT00002765|recurrent adult immunoblastic large cell lymphoma
703302|NCT00002765|recurrent adult lymphoblastic lymphoma
703303|NCT00002765|recurrent adult Burkitt lymphoma
703304|NCT00002765|stage I adult T-cell leukemia/lymphoma
703305|NCT00002765|stage II adult T-cell leukemia/lymphoma
703306|NCT00002765|stage III adult T-cell leukemia/lymphoma
703307|NCT00002765|stage IV adult T-cell leukemia/lymphoma
703308|NCT00002765|recurrent adult T-cell leukemia/lymphoma
703309|NCT00002765|prolymphocytic leukemia
703310|NCT00002765|recurrent mantle cell lymphoma
703311|NCT00002765|stage IV mycosis fungoides/Sezary syndrome
703312|NCT00002765|recurrent mycosis fungoides/Sezary syndrome
703313|NCT00002765|recurrent marginal zone lymphoma
703314|NCT00002765|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703315|NCT00002765|nodal marginal zone B-cell lymphoma
703316|NCT00002765|splenic marginal zone lymphoma
703317|NCT00002764|adult angiosarcoma
703318|NCT00002764|adult fibrosarcoma
703319|NCT00002764|adult leiomyosarcoma
703320|NCT00002764|adult liposarcoma
703321|NCT00002764|adult neurofibrosarcoma
703322|NCT00002764|adult synovial sarcoma
703323|NCT00002764|recurrent adult soft tissue sarcoma
703324|NCT00002764|adult malignant fibrous histiocytoma
703325|NCT00002764|adult malignant hemangiopericytoma
703326|NCT00002764|adult malignant mesenchymoma
703327|NCT00002764|localized benign pheochromocytoma
703328|NCT00002764|regional pheochromocytoma
703329|NCT00002764|lung metastases
703330|NCT00002764|stage IV uterine sarcoma
703331|NCT00002764|recurrent uterine sarcoma
703332|NCT00002764|uterine leiomyosarcoma
703333|NCT00002764|endometrial stromal sarcoma
703334|NCT00002764|ovarian sarcoma
703335|NCT00002764|clear cell sarcoma of the kidney
703336|NCT00002764|stage IV adult soft tissue sarcoma
703337|NCT00002763|stage III melanoma
703338|NCT00002763|recurrent melanoma
703339|NCT00002762|stage I breast cancer
703340|NCT00002762|stage II breast cancer
703341|NCT00002762|perioperative/postoperative complications
703342|NCT00002761|relapsing chronic myelogenous leukemia
703343|NCT00002761|chronic phase chronic myelogenous leukemia
703344|NCT00002761|chronic myelogenous leukemia, BCR-ABL1 positive
703345|NCT00002760|adenocarcinoma of the prostate
703346|NCT00002760|recurrent prostate cancer
703347|NCT00002759|stage III adult Hodgkin lymphoma
703348|NCT00002759|stage IV adult Hodgkin lymphoma
703349|NCT00002759|recurrent adult Hodgkin lymphoma
703350|NCT00002759|stage III cutaneous T-cell non-Hodgkin lymphoma
703351|NCT00002759|stage IV cutaneous T-cell non-Hodgkin lymphoma
703352|NCT00002759|recurrent cutaneous T-cell non-Hodgkin lymphoma
703353|NCT00002759|small intestine lymphoma
704685|NCT00002570|recurrent rectal cancer
703354|NCT00002759|unspecified adult solid tumor, protocol specific
703355|NCT00002759|stage III grade 1 follicular lymphoma
703356|NCT00002759|stage III grade 2 follicular lymphoma
703357|NCT00002759|stage III grade 3 follicular lymphoma
703358|NCT00002759|stage III adult diffuse small cleaved cell lymphoma
703359|NCT00002759|stage III adult diffuse mixed cell lymphoma
703360|NCT00002759|stage III adult diffuse large cell lymphoma
703361|NCT00002759|stage III adult immunoblastic large cell lymphoma
703362|NCT00002759|stage III adult lymphoblastic lymphoma
703363|NCT00002759|stage III adult Burkitt lymphoma
703364|NCT00002759|stage IV grade 1 follicular lymphoma
703365|NCT00002759|stage IV grade 2 follicular lymphoma
703366|NCT00002759|stage IV grade 3 follicular lymphoma
703367|NCT00002759|stage IV adult diffuse small cleaved cell lymphoma
703368|NCT00002759|stage IV adult diffuse mixed cell lymphoma
703369|NCT00002759|stage IV adult diffuse large cell lymphoma
703370|NCT00002759|stage IV adult immunoblastic large cell lymphoma
703371|NCT00002759|stage IV adult lymphoblastic lymphoma
703372|NCT00002759|stage IV adult Burkitt lymphoma
703373|NCT00002759|recurrent grade 1 follicular lymphoma
703374|NCT00002759|recurrent grade 2 follicular lymphoma
703375|NCT00002759|recurrent grade 3 follicular lymphoma
703376|NCT00002759|recurrent adult diffuse small cleaved cell lymphoma
703377|NCT00002759|recurrent adult diffuse mixed cell lymphoma
703378|NCT00002759|recurrent adult diffuse large cell lymphoma
703379|NCT00002759|recurrent adult immunoblastic large cell lymphoma
703380|NCT00002759|recurrent adult lymphoblastic lymphoma
703381|NCT00002759|recurrent adult Burkitt lymphoma
703382|NCT00002759|stage III adult T-cell leukemia/lymphoma
703383|NCT00002759|stage IV adult T-cell leukemia/lymphoma
703384|NCT00002759|recurrent adult T-cell leukemia/lymphoma
703385|NCT00002759|primary central nervous system non-Hodgkin lymphoma
703386|NCT00002759|drug/agent toxicity by tissue/organ
703387|NCT00002759|neutropenia
703388|NCT00002759|AIDS-related peripheral/systemic lymphoma
703389|NCT00002759|AIDS-related primary CNS lymphoma
703390|NCT00002759|intraocular lymphoma
703391|NCT00002759|stage III mantle cell lymphoma
703392|NCT00002759|stage IV mantle cell lymphoma
703393|NCT00002759|recurrent mantle cell lymphoma
703394|NCT00002759|angioimmunoblastic T-cell lymphoma
703395|NCT00002759|anaplastic large cell lymphoma
703396|NCT00002759|stage III mycosis fungoides/Sezary syndrome
703397|NCT00002759|stage IV mycosis fungoides/Sezary syndrome
703398|NCT00002759|recurrent mycosis fungoides/Sezary syndrome
703399|NCT00002759|recurrent marginal zone lymphoma
703400|NCT00002759|recurrent small lymphocytic lymphoma
703401|NCT00002759|stage III small lymphocytic lymphoma
703402|NCT00002759|stage III marginal zone lymphoma
703403|NCT00002759|stage IV small lymphocytic lymphoma
703404|NCT00002759|stage IV marginal zone lymphoma
703405|NCT00002759|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703406|NCT00002759|nodal marginal zone B-cell lymphoma
703407|NCT00002759|splenic marginal zone lymphoma
703408|NCT00002757|childhood Burkitt lymphoma
703409|NCT00002757|untreated childhood acute lymphoblastic leukemia
703410|NCT00002757|L3 childhood acute lymphoblastic leukemia
703411|NCT00002757|stage I childhood small noncleaved cell lymphoma
703412|NCT00002757|stage I childhood large cell lymphoma
703413|NCT00002757|stage II childhood small noncleaved cell lymphoma
703414|NCT00002757|stage II childhood large cell lymphoma
703415|NCT00002757|stage III childhood small noncleaved cell lymphoma
703416|NCT00002757|stage III childhood large cell lymphoma
703417|NCT00002757|stage IV childhood small noncleaved cell lymphoma
703418|NCT00002757|stage IV childhood large cell lymphoma
703419|NCT00002756|untreated childhood acute lymphoblastic leukemia
703420|NCT00002756|acute undifferentiated leukemia
703421|NCT00002755|stage II breast cancer
703422|NCT00002755|stage IIIA breast cancer
703423|NCT00002754|recurrent adult brain tumor
703424|NCT00002754|adult glioblastoma
703425|NCT00002754|stage IV melanoma
703426|NCT00002754|tumors metastatic to brain
703427|NCT00002754|childhood high-grade cerebral astrocytoma
703428|NCT00002754|adult anaplastic astrocytoma
703429|NCT00002754|adult anaplastic oligodendroglioma
703430|NCT00002754|adult mixed glioma
703431|NCT00002754|recurrent childhood cerebral astrocytoma
703432|NCT00002754|adult giant cell glioblastoma
703433|NCT00002754|adult gliosarcoma
703434|NCT00002753|childhood supratentorial ependymoma
703435|NCT00002753|recurrent childhood brain tumor
703436|NCT00002753|recurrent adult brain tumor
703437|NCT00002753|adult glioblastoma
703438|NCT00002753|adult anaplastic astrocytoma
703439|NCT00002753|adult myxopapillary ependymoma
703440|NCT00002753|adult anaplastic ependymoma
703441|NCT00002753|adult anaplastic oligodendroglioma
703442|NCT00002753|adult mixed glioma
703443|NCT00002753|adult ependymoblastoma
703444|NCT00002753|recurrent childhood cerebral astrocytoma
703445|NCT00002753|recurrent childhood ependymoma
703446|NCT00002753|adult giant cell glioblastoma
703447|NCT00002753|adult gliosarcoma
703448|NCT00002752|childhood supratentorial ependymoma
703449|NCT00002752|recurrent childhood brain tumor
705878|NCT00002452|Anti-HIV Agents
703450|NCT00002752|recurrent adult brain tumor
703451|NCT00002752|adult medulloblastoma
703452|NCT00002752|adult glioblastoma
703453|NCT00002752|tumors metastatic to brain
703454|NCT00002752|childhood high-grade cerebral astrocytoma
703455|NCT00002752|adult anaplastic astrocytoma
703456|NCT00002752|adult myxopapillary ependymoma
703457|NCT00002752|adult anaplastic ependymoma
703458|NCT00002752|adult anaplastic oligodendroglioma
703459|NCT00002752|adult mixed glioma
703460|NCT00002752|adult pilocytic astrocytoma
703461|NCT00002752|adult subependymoma
703462|NCT00002752|adult ependymoblastoma
703463|NCT00002752|recurrent childhood supratentorial primitive neuroectodermal tumor
703464|NCT00002752|recurrent childhood cerebellar astrocytoma
703465|NCT00002752|recurrent childhood cerebral astrocytoma
703466|NCT00002752|recurrent childhood medulloblastoma
703467|NCT00002752|newly diagnosed childhood ependymoma
703468|NCT00002752|recurrent childhood ependymoma
703469|NCT00002752|adult oligodendroglioma
703470|NCT00002752|adult giant cell glioblastoma
703471|NCT00002752|adult gliosarcoma
703472|NCT00002751|leptomeningeal metastases
703473|NCT00002750|recurrent childhood acute lymphoblastic leukemia
703474|NCT00002750|recurrent adult Hodgkin lymphoma
703475|NCT00002750|Waldenström macroglobulinemia
703476|NCT00002750|recurrent childhood lymphoblastic lymphoma
703477|NCT00002750|childhood central nervous system germ cell tumor
703478|NCT00002750|recurrent childhood acute myeloid leukemia
703479|NCT00002750|recurrent adult acute myeloid leukemia
703480|NCT00002750|recurrent adult acute lymphoblastic leukemia
703481|NCT00002750|recurrent/refractory childhood Hodgkin lymphoma
703482|NCT00002750|recurrent ovarian germ cell tumor
703483|NCT00002750|recurrent adult non-Hodgkin lymphoma
703484|NCT00002750|recurrent grade 1 follicular lymphoma
703485|NCT00002750|recurrent grade 2 follicular lymphoma
703486|NCT00002750|recurrent grade 3 follicular lymphoma
703487|NCT00002750|recurrent adult diffuse small cleaved cell lymphoma
703488|NCT00002750|recurrent adult diffuse mixed cell lymphoma
703489|NCT00002750|recurrent adult diffuse large cell lymphoma
703490|NCT00002750|recurrent adult immunoblastic large cell lymphoma
703491|NCT00002750|recurrent adult lymphoblastic lymphoma
703492|NCT00002750|recurrent adult Burkitt lymphoma
703493|NCT00002750|extragonadal germ cell tumor
703494|NCT00002750|leptomeningeal metastases
703495|NCT00002750|recurrent childhood small noncleaved cell lymphoma
703496|NCT00002750|recurrent childhood large cell lymphoma
703497|NCT00002750|recurrent mantle cell lymphoma
703498|NCT00002750|recurrent marginal zone lymphoma
703499|NCT00002750|recurrent small lymphocytic lymphoma
703500|NCT00002750|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703501|NCT00002750|nodal marginal zone B-cell lymphoma
703502|NCT00002750|splenic marginal zone lymphoma
703503|NCT00002749|childhood low-grade cerebral astrocytoma
703504|NCT00002749|recurrent adult brain tumor
703505|NCT00002749|adult brain stem glioma
703506|NCT00002749|childhood oligodendroglioma
703507|NCT00002749|untreated childhood brain stem glioma
703508|NCT00002749|recurrent childhood brain stem glioma
703509|NCT00002749|untreated childhood visual pathway glioma
703510|NCT00002749|recurrent childhood visual pathway glioma
703511|NCT00002749|untreated childhood cerebellar astrocytoma
703512|NCT00002749|recurrent childhood cerebellar astrocytoma
703513|NCT00002749|recurrent childhood cerebral astrocytoma
703514|NCT00002749|adult anaplastic astrocytoma
703515|NCT00002749|adult oligodendroglioma
703516|NCT00002748|recurrent neuroblastoma
703517|NCT00002747|stage II squamous cell carcinoma of the lip and oral cavity
703518|NCT00002747|stage III squamous cell carcinoma of the lip and oral cavity
703519|NCT00002747|stage IV squamous cell carcinoma of the lip and oral cavity
703520|NCT00002746|refractory anemia
703521|NCT00002746|refractory anemia with ringed sideroblasts
703522|NCT00002746|refractory anemia with excess blasts
703523|NCT00002746|chronic myelomonocytic leukemia
703524|NCT00002746|de novo myelodysplastic syndromes
703525|NCT00002746|previously treated myelodysplastic syndromes
703526|NCT00002746|secondary myelodysplastic syndromes
703527|NCT00002746|atypical chronic myeloid leukemia, BCR-ABL1 negative
703528|NCT00002746|myelodysplastic/myeloproliferative neoplasm, unclassifiable
703529|NCT00002746|childhood myelodysplastic syndromes
703530|NCT00002745|Waldenstrom macroglobulinemia
703531|NCT00002745|recurrent grade 1 follicular lymphoma
703532|NCT00002745|recurrent grade 2 follicular lymphoma
703533|NCT00002745|recurrent small lymphocytic lymphoma
703534|NCT00002744|untreated childhood acute lymphoblastic leukemia
703535|NCT00002744|L1 childhood acute lymphoblastic leukemia
703536|NCT00002744|L2 childhood acute lymphoblastic leukemia
703537|NCT00002742|adult Hodgkin lymphoma
703538|NCT00002742|adult non-Hodgkin lymphoma
703539|NCT00002742|leukemia
703540|NCT00002742|childhood non-Hodgkin lymphoma
703541|NCT00002742|chronic myeloproliferative disorders
703542|NCT00002742|myelodysplastic syndromes
703543|NCT00002742|childhood Hodgkin lymphoma
703544|NCT00002742|recurrent adult non-Hodgkin lymphoma
703545|NCT00002742|infection
705879|NCT00002452|Viral Load
703546|NCT00002742|multiple myeloma and other plasma cell neoplasms
703547|NCT00002742|childhood myelodysplastic syndromes
703548|NCT00002740|disseminated neuroblastoma
703549|NCT00002738|recurrent childhood acute lymphoblastic leukemia
703550|NCT00002738|recurrent childhood lymphoblastic lymphoma
703551|NCT00002738|recurrent osteosarcoma
703552|NCT00002738|recurrent childhood small noncleaved cell lymphoma
703553|NCT00002738|recurrent childhood large cell lymphoma
703554|NCT00002737|stage IV renal cell cancer
703555|NCT00002737|recurrent renal cell cancer
703556|NCT00002735|stage III squamous cell carcinoma of the oropharynx
703557|NCT00002735|stage IV squamous cell carcinoma of the oropharynx
703558|NCT00002735|stage III squamous cell carcinoma of the hypopharynx
703559|NCT00002735|stage IV squamous cell carcinoma of the hypopharynx
703560|NCT00002734|recurrent ovarian epithelial cancer
703561|NCT00002734|primary peritoneal cavity cancer
703562|NCT00002733|stage IV renal cell cancer
703563|NCT00002733|stage IV melanoma
703564|NCT00002733|unspecified adult solid tumor, protocol specific
703565|NCT00002730|recurrent neuroblastoma
703566|NCT00002727|stage II squamous cell carcinoma of the larynx
703567|NCT00002725|recurrent small lymphocytic lymphoma
703568|NCT00002725|recurrent grade 1 follicular lymphoma
703569|NCT00002725|recurrent grade 2 follicular lymphoma
703570|NCT00002725|recurrent grade 3 follicular lymphoma
703571|NCT00002725|recurrent adult diffuse small cleaved cell lymphoma
703572|NCT00002725|recurrent adult diffuse mixed cell lymphoma
703573|NCT00002725|recurrent adult diffuse large cell lymphoma
703574|NCT00002725|recurrent adult immunoblastic large cell lymphoma
703575|NCT00002725|recurrent adult lymphoblastic lymphoma
703576|NCT00002725|recurrent adult Burkitt lymphoma
703577|NCT00002725|recurrent mantle cell lymphoma
703578|NCT00002725|recurrent marginal zone lymphoma
703579|NCT00002725|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703580|NCT00002725|nodal marginal zone B-cell lymphoma
703581|NCT00002725|splenic marginal zone lymphoma
703582|NCT00002723|adenocarcinoma of the prostate
703583|NCT00002723|stage III prostate cancer
703584|NCT00002723|stage IV prostate cancer
703585|NCT00002723|recurrent prostate cancer
703586|NCT00002722|stage III gastric cancer
703587|NCT00002722|stage IV gastric cancer
703588|NCT00002721|recurrent prostate cancer
703589|NCT00002720|stage I breast cancer
703590|NCT00002719|untreated adult acute myeloid leukemia
703591|NCT00002719|adult acute erythroid leukemia (M6)
703592|NCT00002719|adult acute myeloblastic leukemia without maturation (M1)
703593|NCT00002719|adult acute myeloblastic leukemia with maturation (M2)
703594|NCT00002719|adult acute myelomonocytic leukemia (M4)
703595|NCT00002719|adult acute monoblastic leukemia (M5a)
703596|NCT00002719|adult acute megakaryoblastic leukemia (M7)
703597|NCT00002719|secondary acute myeloid leukemia
703598|NCT00002719|adult acute monocytic leukemia (M5b)
703599|NCT00002719|neutropenia
703600|NCT00002719|adult acute minimally differentiated myeloid leukemia (M0)
703601|NCT00002718|recurrent childhood acute lymphoblastic leukemia
703602|NCT00002718|stage IV childhood lymphoblastic lymphoma
703603|NCT00002718|recurrent childhood lymphoblastic lymphoma
703604|NCT00002718|recurrent childhood acute myeloid leukemia
703605|NCT00002718|recurrent adult acute myeloid leukemia
703606|NCT00002718|recurrent adult acute lymphoblastic leukemia
703607|NCT00002718|relapsing chronic myelogenous leukemia
703608|NCT00002718|chronic phase chronic myelogenous leukemia
703609|NCT00002718|accelerated phase chronic myelogenous leukemia
703610|NCT00002718|adult acute myeloid leukemia in remission
703611|NCT00002718|adult acute lymphoblastic leukemia in remission
703612|NCT00002718|childhood acute myeloid leukemia in remission
703613|NCT00002718|childhood acute lymphoblastic leukemia in remission
703614|NCT00002718|stage IV adult lymphoblastic lymphoma
703615|NCT00002718|recurrent adult lymphoblastic lymphoma
703616|NCT00002718|secondary acute myeloid leukemia
703617|NCT00002718|de novo myelodysplastic syndromes
703618|NCT00002718|previously treated myelodysplastic syndromes
703619|NCT00002718|secondary myelodysplastic syndromes
703620|NCT00002718|juvenile myelomonocytic leukemia
703621|NCT00002718|childhood chronic myelogenous leukemia
703622|NCT00002718|atypical chronic myeloid leukemia, BCR-ABL1 negative
703623|NCT00002718|myelodysplastic/myeloproliferative neoplasm, unclassifiable
703624|NCT00002718|chronic myelomonocytic leukemia
703625|NCT00002718|childhood myelodysplastic syndromes
703626|NCT00002717|stage III ovarian epithelial cancer
703627|NCT00002717|stage IV ovarian epithelial cancer
703628|NCT00002717|ovarian undifferentiated adenocarcinoma
703629|NCT00002717|ovarian mixed epithelial carcinoma
703630|NCT00002717|ovarian serous cystadenocarcinoma
703631|NCT00002717|ovarian mucinous cystadenocarcinoma
703632|NCT00002717|ovarian endometrioid adenocarcinoma
703633|NCT00002717|ovarian clear cell cystadenocarcinoma
703634|NCT00002717|primary peritoneal cavity cancer
703635|NCT00002717|Brenner tumor
703636|NCT00002716|stage IV colon cancer
703637|NCT00002716|stage IV rectal cancer
703638|NCT00002716|recurrent colon cancer
703639|NCT00002716|recurrent rectal cancer
703640|NCT00002716|adenocarcinoma of the colon
703641|NCT00002716|adenocarcinoma of the rectum
703642|NCT00002716|liver metastases
703643|NCT00002715|stage I adult Hodgkin lymphoma
703644|NCT00002715|stage II adult Hodgkin lymphoma
703645|NCT00002715|stage III adult Hodgkin lymphoma
703646|NCT00002715|stage IV adult Hodgkin lymphoma
703647|NCT00002715|adult lymphocyte predominant Hodgkin lymphoma
703648|NCT00002715|adult lymphocyte depletion Hodgkin lymphoma
703649|NCT00002715|adult nodular sclerosis Hodgkin lymphoma
703650|NCT00002715|adult mixed cellularity Hodgkin lymphoma
703651|NCT00002714|stage I adult Hodgkin lymphoma
703652|NCT00002714|stage II adult Hodgkin lymphoma
703653|NCT00002711|stage I esophageal cancer
703654|NCT00002711|stage II esophageal cancer
703655|NCT00002711|stage III esophageal cancer
703656|NCT00002711|recurrent esophageal cancer
703657|NCT00002711|squamous cell carcinoma of the esophagus
703658|NCT00002711|adenocarcinoma of the esophagus
703659|NCT00002708|tumors metastatic to brain
703660|NCT00002707|stage I breast cancer
703661|NCT00002707|stage II breast cancer
703662|NCT00002707|stage IIIA breast cancer
703663|NCT00002705|recurrent childhood acute lymphoblastic leukemia
703664|NCT00002705|recurrent childhood acute myeloid leukemia
703665|NCT00002705|relapsing chronic myelogenous leukemia
703666|NCT00002704|recurrent childhood acute lymphoblastic leukemia
703667|NCT00002704|T-cell childhood acute lymphoblastic leukemia
703668|NCT00002704|B-cell childhood acute lymphoblastic leukemia
703669|NCT00002704|TdT positive childhood acute lymphoblastic leukemia
703670|NCT00002703|adenocarcinoma of the prostate
703671|NCT00002703|stage I prostate cancer
703672|NCT00002703|stage IIB prostate cancer
703673|NCT00002703|stage IIA prostate cancer
703674|NCT00002702|stage II squamous cell carcinoma of the lip and oral cavity
703675|NCT00002702|stage III squamous cell carcinoma of the lip and oral cavity
703676|NCT00002702|stage IV squamous cell carcinoma of the lip and oral cavity
703677|NCT00002702|stage II squamous cell carcinoma of the oropharynx
703678|NCT00002702|stage III squamous cell carcinoma of the oropharynx
703679|NCT00002702|stage IV squamous cell carcinoma of the oropharynx
703680|NCT00002702|tongue cancer
703681|NCT00002701|untreated adult acute myeloid leukemia
703682|NCT00002701|adult acute promyelocytic leukemia (M3)
703683|NCT00002700|untreated adult acute lymphoblastic leukemia
703684|NCT00002700|stage I adult lymphoblastic lymphoma
703685|NCT00002700|stage III adult lymphoblastic lymphoma
703686|NCT00002700|stage IV adult lymphoblastic lymphoma
703687|NCT00002700|contiguous stage II adult lymphoblastic lymphoma
703688|NCT00002700|noncontiguous stage II adult lymphoblastic lymphoma
703689|NCT00002697|recurrent grade 1 follicular lymphoma
703690|NCT00002697|recurrent grade 2 follicular lymphoma
703691|NCT00002697|recurrent grade 3 follicular lymphoma
703692|NCT00002697|recurrent adult diffuse small cleaved cell lymphoma
703693|NCT00002697|recurrent adult diffuse mixed cell lymphoma
703694|NCT00002697|recurrent adult diffuse large cell lymphoma
703695|NCT00002697|recurrent adult immunoblastic large cell lymphoma
703696|NCT00002697|recurrent marginal zone lymphoma
703697|NCT00002697|recurrent small lymphocytic lymphoma
703698|NCT00002697|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703699|NCT00002697|nodal marginal zone B-cell lymphoma
703700|NCT00002697|splenic marginal zone lymphoma
703701|NCT00002696|stage IIIA breast cancer
703702|NCT00002696|stage IIIB breast cancer
703703|NCT00002696|stage IIIC breast cancer
703704|NCT00002695|stage I squamous cell carcinoma of the lip and oral cavity
703705|NCT00002695|stage II squamous cell carcinoma of the lip and oral cavity
703706|NCT00002695|stage III squamous cell carcinoma of the lip and oral cavity
703707|NCT00002695|stage IV squamous cell carcinoma of the lip and oral cavity
703708|NCT00002695|recurrent squamous cell carcinoma of the lip and oral cavity
703709|NCT00002695|stage I squamous cell carcinoma of the oropharynx
703710|NCT00002695|stage II squamous cell carcinoma of the oropharynx
703711|NCT00002695|stage III squamous cell carcinoma of the oropharynx
703712|NCT00002695|stage IV squamous cell carcinoma of the oropharynx
703713|NCT00002695|recurrent squamous cell carcinoma of the oropharynx
703714|NCT00002695|stage I squamous cell carcinoma of the hypopharynx
703715|NCT00002695|stage II squamous cell carcinoma of the hypopharynx
703716|NCT00002695|stage III squamous cell carcinoma of the hypopharynx
703717|NCT00002695|stage IV squamous cell carcinoma of the hypopharynx
703718|NCT00002695|recurrent squamous cell carcinoma of the hypopharynx
703719|NCT00002695|stage I squamous cell carcinoma of the larynx
703720|NCT00002695|stage II squamous cell carcinoma of the larynx
703721|NCT00002695|stage III squamous cell carcinoma of the larynx
703722|NCT00002695|stage IV squamous cell carcinoma of the larynx
703723|NCT00002695|recurrent squamous cell carcinoma of the larynx
703724|NCT00002695|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
703725|NCT00002695|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
703726|NCT00002695|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
703727|NCT00002695|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
703728|NCT00002695|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
703729|NCT00002693|recurrent adult acute myeloid leukemia
706247|NCT00002389|Lamivudine
703730|NCT00002693|recurrent adult acute lymphoblastic leukemia
703731|NCT00002693|relapsing chronic myelogenous leukemia
703732|NCT00002693|accelerated phase chronic myelogenous leukemia
703733|NCT00002693|blastic phase chronic myelogenous leukemia
703734|NCT00002693|neutropenia
703735|NCT00002692|stage IV colon cancer
703736|NCT00002692|stage IV rectal cancer
703737|NCT00002692|recurrent colon cancer
703738|NCT00002692|recurrent rectal cancer
703739|NCT00002692|adenocarcinoma of the colon
703740|NCT00002692|adenocarcinoma of the rectum
703741|NCT00002692|liver metastases
703742|NCT00002691|stage III childhood lymphoblastic lymphoma
703743|NCT00002691|stage IV childhood lymphoblastic lymphoma
703744|NCT00002691|stage III childhood small noncleaved cell lymphoma
703745|NCT00002691|stage III childhood large cell lymphoma
703746|NCT00002691|stage IV childhood large cell lymphoma
703747|NCT00002689|stage I pancreatic cancer
703748|NCT00002689|stage II pancreatic cancer
703749|NCT00002689|stage III pancreatic cancer
703750|NCT00002689|adenocarcinoma of the pancreas
703751|NCT00002688|recurrent adult acute myeloid leukemia
703752|NCT00002687|stage II cutaneous T-cell non-Hodgkin lymphoma
703753|NCT00002687|stage III cutaneous T-cell non-Hodgkin lymphoma
703754|NCT00002687|stage IV cutaneous T-cell non-Hodgkin lymphoma
703755|NCT00002687|recurrent cutaneous T-cell non-Hodgkin lymphoma
703756|NCT00002687|stage II mycosis fungoides/Sezary syndrome
703757|NCT00002687|stage III mycosis fungoides/Sezary syndrome
703758|NCT00002687|stage IV mycosis fungoides/Sezary syndrome
703759|NCT00002687|recurrent mycosis fungoides/Sezary syndrome
703760|NCT00002684|stage III bladder cancer
703761|NCT00002684|recurrent bladder cancer
703762|NCT00002684|stage IV bladder cancer
703763|NCT00002684|squamous cell carcinoma of the bladder
703764|NCT00002684|adenocarcinoma of the bladder
703765|NCT00002684|recurrent urethral cancer
703766|NCT00002684|distal urethral cancer
703767|NCT00002684|proximal urethral cancer
703768|NCT00002684|urethral cancer associated with invasive bladder cancer
703769|NCT00002682|Antibiotic Treatment
703770|NCT00002682|Gastric Malt Lymphoma
703771|NCT00002682|stage I marginal zone lymphoma
703772|NCT00002682|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703773|NCT00002681|recurrent adult Hodgkin lymphoma
703774|NCT00002681|recurrent adult acute myeloid leukemia
703775|NCT00002681|relapsing chronic myelogenous leukemia
703776|NCT00002681|chronic phase chronic myelogenous leukemia
703777|NCT00002681|atypical chronic myeloid leukemia, BCR-ABL negative
703778|NCT00002680|stage IV breast cancer
703779|NCT00002680|recurrent breast cancer
703780|NCT00002679|stage II breast cancer
703781|NCT00002679|stage IIIA breast cancer
703782|NCT00002679|male breast cancer
703783|NCT00002678|stage I multiple myeloma
703784|NCT00002678|stage II multiple myeloma
703785|NCT00002678|stage III multiple myeloma
703786|NCT00002677|stage IV prostate cancer
703787|NCT00002677|recurrent prostate cancer
703788|NCT00002677|unspecified adult solid tumor, protocol specific
703789|NCT00002676|primary central nervous system non-Hodgkin lymphoma
703790|NCT00002675|intraocular retinoblastoma
703791|NCT00002674|relapsing chronic myelogenous leukemia
703792|NCT00002674|chronic phase chronic myelogenous leukemia
703793|NCT00002674|accelerated phase chronic myelogenous leukemia
703794|NCT00002674|Philadelphia chromosome positive chronic myelogenous leukemia
703795|NCT00002673|stage IV breast cancer
703796|NCT00002673|stage IIIA breast cancer
703797|NCT00002673|stage IIIB breast cancer
703798|NCT00002673|recurrent childhood acute lymphoblastic leukemia
703799|NCT00002673|recurrent adult Hodgkin lymphoma
703800|NCT00002673|recurrent cutaneous T-cell non-Hodgkin lymphoma
703801|NCT00002673|recurrent childhood rhabdomyosarcoma
703802|NCT00002673|stage II ovarian epithelial cancer
703803|NCT00002673|stage III ovarian epithelial cancer
703804|NCT00002673|stage IV ovarian epithelial cancer
703805|NCT00002673|recurrent ovarian epithelial cancer
703806|NCT00002673|disseminated neuroblastoma
703807|NCT00002673|recurrent neuroblastoma
703808|NCT00002673|recurrent Wilms tumor and other childhood kidney tumors
703809|NCT00002673|stage I multiple myeloma
703810|NCT00002673|stage II multiple myeloma
703811|NCT00002673|stage III multiple myeloma
703812|NCT00002673|recurrent childhood lymphoblastic lymphoma
703813|NCT00002673|stage III chronic lymphocytic leukemia
703814|NCT00002673|stage IV chronic lymphocytic leukemia
703815|NCT00002673|recurrent childhood acute myeloid leukemia
703816|NCT00002673|recurrent adult acute myeloid leukemia
703817|NCT00002673|recurrent adult acute lymphoblastic leukemia
703818|NCT00002673|refractory chronic lymphocytic leukemia
703819|NCT00002673|stage III malignant testicular germ cell tumor
703820|NCT00002673|recurrent malignant testicular germ cell tumor
703821|NCT00002673|chronic phase chronic myelogenous leukemia
703822|NCT00002673|accelerated phase chronic myelogenous leukemia
703823|NCT00002673|blastic phase chronic myelogenous leukemia
703824|NCT00002673|adult acute myeloid leukemia in remission
703825|NCT00002673|adult acute lymphoblastic leukemia in remission
703826|NCT00002673|childhood acute myeloid leukemia in remission
706248|NCT00002389|RNA, Viral
703827|NCT00002673|childhood acute lymphoblastic leukemia in remission
703828|NCT00002673|chronic idiopathic myelofibrosis
703829|NCT00002673|childhood acute promyelocytic leukemia (M3)
703830|NCT00002673|testicular embryonal carcinoma
703831|NCT00002673|testicular choriocarcinoma
703832|NCT00002673|testicular teratoma
703833|NCT00002673|testicular yolk sac tumor
703834|NCT00002673|testicular embryonal carcinoma and teratoma
703835|NCT00002673|testicular embryonal carcinoma and teratoma with seminoma
703836|NCT00002673|testicular embryonal carcinoma and yolk sac tumor
703837|NCT00002673|testicular embryonal carcinoma and yolk sac tumor with seminoma
703838|NCT00002673|testicular embryonal carcinoma and seminoma
703839|NCT00002673|testicular yolk sac tumor and teratoma
703840|NCT00002673|testicular yolk sac tumor and teratoma with seminoma
703841|NCT00002673|testicular choriocarcinoma and yolk sac tumor
703842|NCT00002673|testicular choriocarcinoma and embryonal carcinoma
703843|NCT00002673|testicular choriocarcinoma and teratoma
703844|NCT00002673|testicular choriocarcinoma and seminoma
703845|NCT00002673|refractory hairy cell leukemia
703846|NCT00002673|recurrent/refractory childhood Hodgkin lymphoma
703847|NCT00002673|ovarian germ cell tumor
703848|NCT00002673|recurrent ovarian germ cell tumor
703849|NCT00002673|ovarian yolk sac tumor
703850|NCT00002673|ovarian embryonal carcinoma
703851|NCT00002673|ovarian polyembryoma
703852|NCT00002673|ovarian choriocarcinoma
703853|NCT00002673|ovarian teratoma
703854|NCT00002673|ovarian immature teratoma
703855|NCT00002673|ovarian mature teratoma
703856|NCT00002673|ovarian monodermal and highly specialized teratoma
703857|NCT00002673|stage II adult lymphoblastic lymphoma
703858|NCT00002673|stage II adult Burkitt lymphoma
703859|NCT00002673|stage III grade 1 follicular lymphoma
703860|NCT00002673|stage III grade 2 follicular lymphoma
703861|NCT00002673|stage III grade 3 follicular lymphoma
703862|NCT00002673|stage III adult diffuse small cleaved cell lymphoma
703863|NCT00002673|stage III adult diffuse mixed cell lymphoma
703864|NCT00002673|stage III adult diffuse large cell lymphoma
703865|NCT00002673|stage III adult immunoblastic large cell lymphoma
703866|NCT00002673|stage III adult lymphoblastic lymphoma
703867|NCT00002673|stage III adult Burkitt lymphoma
703868|NCT00002673|stage IV grade 1 follicular lymphoma
703869|NCT00002673|stage IV grade 2 follicular lymphoma
703870|NCT00002673|stage IV grade 3 follicular lymphoma
703871|NCT00002673|stage IV adult diffuse small cleaved cell lymphoma
703872|NCT00002673|stage IV adult diffuse mixed cell lymphoma
703873|NCT00002673|stage IV adult diffuse large cell lymphoma
703874|NCT00002673|stage IV adult immunoblastic large cell lymphoma
703875|NCT00002673|stage IV adult lymphoblastic lymphoma
703876|NCT00002673|stage IV adult Burkitt lymphoma
703877|NCT00002673|recurrent grade 1 follicular lymphoma
703878|NCT00002673|recurrent grade 2 follicular lymphoma
703879|NCT00002673|recurrent grade 3 follicular lymphoma
703880|NCT00002673|recurrent adult diffuse small cleaved cell lymphoma
703881|NCT00002673|recurrent adult diffuse mixed cell lymphoma
703882|NCT00002673|recurrent adult diffuse large cell lymphoma
703883|NCT00002673|recurrent adult immunoblastic large cell lymphoma
703884|NCT00002673|recurrent adult lymphoblastic lymphoma
703885|NCT00002673|recurrent adult Burkitt lymphoma
703886|NCT00002673|poor prognosis metastatic gestational trophoblastic tumor
703887|NCT00002673|previously treated myelodysplastic syndromes
703888|NCT00002673|secondary myelodysplastic syndromes
703889|NCT00002673|infection
703890|NCT00002673|recurrent childhood small noncleaved cell lymphoma
703891|NCT00002673|recurrent childhood large cell lymphoma
703892|NCT00002673|noncontiguous stage II grade 1 follicular lymphoma
703893|NCT00002673|noncontiguous stage II grade 2 follicular lymphoma
703894|NCT00002673|noncontiguous stage II grade 3 follicular lymphoma
703895|NCT00002673|noncontiguous stage II adult diffuse small cleaved cell lymphoma
703896|NCT00002673|noncontiguous stage II mantle cell lymphoma
703897|NCT00002673|noncontiguous stage II adult diffuse mixed cell lymphoma
703898|NCT00002673|noncontiguous stage II adult immunoblastic large cell lymphoma
703899|NCT00002673|noncontiguous stage II adult diffuse large cell lymphoma
703900|NCT00002673|noncontiguous stage II adult Burkitt lymphoma
703901|NCT00002673|noncontiguous stage II adult lymphoblastic lymphoma
703902|NCT00002673|stage III mantle cell lymphoma
703903|NCT00002673|stage IV mantle cell lymphoma
703904|NCT00002673|previously treated childhood rhabdomyosarcoma
703905|NCT00002673|noncontiguous stage II small lymphocytic lymphoma
703906|NCT00002673|noncontiguous stage II marginal zone lymphoma
703907|NCT00002673|recurrent marginal zone lymphoma
703908|NCT00002673|recurrent small lymphocytic lymphoma
703909|NCT00002673|stage III small lymphocytic lymphoma
703910|NCT00002673|stage III marginal zone lymphoma
703911|NCT00002673|stage IV small lymphocytic lymphoma
703912|NCT00002673|stage IV marginal zone lymphoma
703913|NCT00002673|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
703914|NCT00002673|nodal marginal zone B-cell lymphoma
703915|NCT00002673|splenic marginal zone lymphoma
703916|NCT00002673|childhood myelodysplastic syndromes
703917|NCT00002671|stage III ovarian epithelial cancer
703918|NCT00002671|stage IV ovarian epithelial cancer
703919|NCT00002671|recurrent ovarian epithelial cancer
703920|NCT00002670|stage II squamous cell carcinoma of the lip and oral cavity
703921|NCT00002670|stage III squamous cell carcinoma of the lip and oral cavity
703922|NCT00002670|stage IV squamous cell carcinoma of the lip and oral cavity
703923|NCT00002670|stage II squamous cell carcinoma of the oropharynx
703924|NCT00002670|stage III squamous cell carcinoma of the oropharynx
703925|NCT00002670|stage IV squamous cell carcinoma of the oropharynx
703926|NCT00002670|stage II squamous cell carcinoma of the hypopharynx
703927|NCT00002670|stage III squamous cell carcinoma of the hypopharynx
703928|NCT00002670|stage IV squamous cell carcinoma of the hypopharynx
703929|NCT00002670|stage II squamous cell carcinoma of the larynx
703930|NCT00002670|stage III squamous cell carcinoma of the larynx
703931|NCT00002670|stage IV squamous cell carcinoma of the larynx
703932|NCT00002669|stage IV melanoma
703933|NCT00002669|recurrent melanoma
703934|NCT00002668|stage IV breast cancer
703935|NCT00002668|recurrent breast cancer
703936|NCT00002668|stage IV prostate cancer
703937|NCT00002668|recurrent prostate cancer
703938|NCT00002668|pain
703939|NCT00002667|stage I non-small cell lung cancer
703940|NCT00002665|untreated adult acute lymphoblastic leukemia
703941|NCT00002665|L1 adult acute lymphoblastic leukemia
703942|NCT00002665|L2 adult acute lymphoblastic leukemia
703943|NCT00002665|L3 adult acute lymphoblastic leukemia
703944|NCT00002665|neutropenia
703945|NCT00002665|thrombocytopenia
703946|NCT00002664|recurrent colon cancer
703947|NCT00002664|recurrent rectal cancer
703948|NCT00002663|stage I adult Hodgkin lymphoma
703949|NCT00002663|stage II adult Hodgkin lymphoma
703950|NCT00002663|stage III adult Hodgkin lymphoma
703951|NCT00002663|stage IV adult Hodgkin lymphoma
703952|NCT00002663|recurrent adult Hodgkin lymphoma
703953|NCT00002663|stage I cutaneous T-cell non-Hodgkin lymphoma
703954|NCT00002663|stage II cutaneous T-cell non-Hodgkin lymphoma
703955|NCT00002663|stage III cutaneous T-cell non-Hodgkin lymphoma
703956|NCT00002663|stage IV cutaneous T-cell non-Hodgkin lymphoma
703957|NCT00002663|recurrent cutaneous T-cell non-Hodgkin lymphoma
703958|NCT00002663|childhood Burkitt lymphoma
703959|NCT00002663|stage I childhood lymphoblastic lymphoma
703960|NCT00002663|stage II childhood lymphoblastic lymphoma
703961|NCT00002663|stage III childhood lymphoblastic lymphoma
703962|NCT00002663|stage IV childhood lymphoblastic lymphoma
703963|NCT00002663|recurrent childhood lymphoblastic lymphoma
703964|NCT00002663|childhood diffuse large cell lymphoma
703965|NCT00002663|childhood immunoblastic large cell lymphoma
703966|NCT00002663|stage II childhood Hodgkin lymphoma
703967|NCT00002663|stage I childhood Hodgkin lymphoma
703968|NCT00002663|stage III childhood Hodgkin lymphoma
703969|NCT00002663|stage IV childhood Hodgkin lymphoma
703970|NCT00002663|recurrent/refractory childhood Hodgkin lymphoma
703971|NCT00002663|stage I grade 1 follicular lymphoma
703972|NCT00002663|stage I grade 2 follicular lymphoma
703973|NCT00002663|stage I grade 3 follicular lymphoma
703974|NCT00002663|stage I adult diffuse small cleaved cell lymphoma
703975|NCT00002663|stage I adult diffuse mixed cell lymphoma
703976|NCT00002663|stage I adult diffuse large cell lymphoma
703977|NCT00002663|stage I adult immunoblastic large cell lymphoma
703978|NCT00002663|stage I adult lymphoblastic lymphoma
703979|NCT00002663|stage I adult Burkitt lymphoma
703980|NCT00002663|T-cell large granular lymphocyte leukemia
703981|NCT00002663|stage III grade 1 follicular lymphoma
703982|NCT00002663|stage III grade 2 follicular lymphoma
703983|NCT00002663|stage III grade 3 follicular lymphoma
703984|NCT00002663|stage III adult diffuse small cleaved cell lymphoma
703985|NCT00002663|stage III adult diffuse mixed cell lymphoma
703986|NCT00002663|stage III adult diffuse large cell lymphoma
703987|NCT00002663|stage III adult immunoblastic large cell lymphoma
703988|NCT00002663|stage III adult lymphoblastic lymphoma
703989|NCT00002663|stage III adult Burkitt lymphoma
703990|NCT00002663|stage IV grade 1 follicular lymphoma
703991|NCT00002663|stage IV grade 2 follicular lymphoma
703992|NCT00002663|stage IV grade 3 follicular lymphoma
703993|NCT00002663|stage IV adult diffuse small cleaved cell lymphoma
703994|NCT00002663|stage IV adult diffuse mixed cell lymphoma
703995|NCT00002663|stage IV adult diffuse large cell lymphoma
703996|NCT00002663|stage IV adult immunoblastic large cell lymphoma
703997|NCT00002663|stage IV adult lymphoblastic lymphoma
703998|NCT00002663|stage IV adult Burkitt lymphoma
703999|NCT00002663|recurrent grade 1 follicular lymphoma
704000|NCT00002663|recurrent grade 2 follicular lymphoma
704001|NCT00002663|recurrent grade 3 follicular lymphoma
704002|NCT00002663|recurrent adult diffuse small cleaved cell lymphoma
704003|NCT00002663|recurrent adult diffuse mixed cell lymphoma
704004|NCT00002663|recurrent adult diffuse large cell lymphoma
704005|NCT00002663|recurrent adult immunoblastic large cell lymphoma
704006|NCT00002663|recurrent adult lymphoblastic lymphoma
704007|NCT00002663|recurrent adult Burkitt lymphoma
704008|NCT00002663|stage I adult T-cell leukemia/lymphoma
704009|NCT00002663|stage II adult T-cell leukemia/lymphoma
704010|NCT00002663|stage III adult T-cell leukemia/lymphoma
704011|NCT00002663|stage IV adult T-cell leukemia/lymphoma
704012|NCT00002663|recurrent adult T-cell leukemia/lymphoma
704013|NCT00002663|AIDS-related peripheral/systemic lymphoma
704014|NCT00002663|HIV-associated Hodgkin lymphoma
704015|NCT00002663|stage I childhood small noncleaved cell lymphoma
704016|NCT00002663|stage I childhood large cell lymphoma
704017|NCT00002663|stage II childhood small noncleaved cell lymphoma
704018|NCT00002663|stage II childhood large cell lymphoma
704019|NCT00002663|stage III childhood small noncleaved cell lymphoma
704020|NCT00002663|stage III childhood large cell lymphoma
704021|NCT00002663|stage IV childhood small noncleaved cell lymphoma
704022|NCT00002663|stage IV childhood large cell lymphoma
704023|NCT00002663|recurrent childhood small noncleaved cell lymphoma
704024|NCT00002663|recurrent childhood large cell lymphoma
704025|NCT00002663|stage I mantle cell lymphoma
704026|NCT00002663|contiguous stage II grade 1 follicular lymphoma
704027|NCT00002663|contiguous stage II grade 2 follicular lymphoma
704028|NCT00002663|contiguous stage II grade 3 follicular lymphoma
704029|NCT00002663|contiguous stage II adult diffuse small cleaved cell lymphoma
704030|NCT00002663|contiguous stage II mantle cell lymphoma
704031|NCT00002663|contiguous stage II adult diffuse mixed cell lymphoma
704032|NCT00002663|contiguous stage II adult immunoblastic large cell lymphoma
704033|NCT00002663|contiguous stage II adult diffuse large cell lymphoma
704034|NCT00002663|contiguous stage II adult Burkitt lymphoma
704035|NCT00002663|contiguous stage II adult lymphoblastic lymphoma
704036|NCT00002663|noncontiguous stage II grade 1 follicular lymphoma
704037|NCT00002663|noncontiguous stage II grade 2 follicular lymphoma
704038|NCT00002663|noncontiguous stage II grade 3 follicular lymphoma
704039|NCT00002663|noncontiguous stage II adult diffuse small cleaved cell lymphoma
704040|NCT00002663|noncontiguous stage II mantle cell lymphoma
704041|NCT00002663|noncontiguous stage II adult diffuse mixed cell lymphoma
704042|NCT00002663|noncontiguous stage II adult immunoblastic large cell lymphoma
704043|NCT00002663|noncontiguous stage II adult diffuse large cell lymphoma
704044|NCT00002663|noncontiguous stage II adult Burkitt lymphoma
704045|NCT00002663|noncontiguous stage II adult lymphoblastic lymphoma
704046|NCT00002663|stage III mantle cell lymphoma
704047|NCT00002663|stage IV mantle cell lymphoma
704048|NCT00002663|recurrent mantle cell lymphoma
704049|NCT00002663|stage I mycosis fungoides/Sezary syndrome
704050|NCT00002663|stage II mycosis fungoides/Sezary syndrome
704051|NCT00002663|stage III mycosis fungoides/Sezary syndrome
704052|NCT00002663|stage IV mycosis fungoides/Sezary syndrome
704053|NCT00002663|recurrent mycosis fungoides/Sezary syndrome
704054|NCT00002663|contiguous stage II small lymphocytic lymphoma
704055|NCT00002663|contiguous stage II marginal zone lymphoma
704056|NCT00002663|noncontiguous stage II small lymphocytic lymphoma
704057|NCT00002663|noncontiguous stage II marginal zone lymphoma
704058|NCT00002663|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
704059|NCT00002663|nodal marginal zone B-cell lymphoma
704060|NCT00002663|splenic marginal zone lymphoma
704061|NCT00002663|recurrent marginal zone lymphoma
704062|NCT00002663|recurrent small lymphocytic lymphoma
704063|NCT00002663|stage I marginal zone lymphoma
704064|NCT00002663|stage I small lymphocytic lymphoma
704065|NCT00002663|stage III small lymphocytic lymphoma
704066|NCT00002663|stage III marginal zone lymphoma
704067|NCT00002663|stage IV small lymphocytic lymphoma
704068|NCT00002663|stage IV marginal zone lymphoma
704069|NCT00002663|unspecified adult solid tumor, protocol specific
704070|NCT00002663|unspecified childhood solid tumor, protocol specific
704071|NCT00002662|stage IV breast cancer
704072|NCT00002662|stage IIIA breast cancer
704073|NCT00002662|recurrent breast cancer
704074|NCT00002662|stage IIIB breast cancer
704075|NCT00002662|stage IIIC breast cancer
704076|NCT00002659|recurrent squamous cell carcinoma of the lip and oral cavity
704077|NCT00002659|recurrent squamous cell carcinoma of the oropharynx
704078|NCT00002659|recurrent squamous cell carcinoma of the nasopharynx
704079|NCT00002659|recurrent squamous cell carcinoma of the hypopharynx
704080|NCT00002659|recurrent squamous cell carcinoma of the larynx
704081|NCT00002659|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
704082|NCT00002658|untreated adult acute myeloid leukemia
704083|NCT00002658|adult acute erythroid leukemia (M6)
704084|NCT00002658|adult acute myeloblastic leukemia without maturation (M1)
704085|NCT00002658|adult acute myeloblastic leukemia with maturation (M2)
704086|NCT00002658|adult acute promyelocytic leukemia (M3)
704087|NCT00002658|adult acute myelomonocytic leukemia (M4)
704088|NCT00002658|adult acute monoblastic leukemia (M5a)
704089|NCT00002658|adult acute megakaryoblastic leukemia (M7)
704090|NCT00002658|secondary acute myeloid leukemia
704091|NCT00002658|adult acute monocytic leukemia (M5b)
704092|NCT00002658|neutropenia
704093|NCT00002658|adult acute minimally differentiated myeloid leukemia (M0)
704094|NCT00002657|isolated plasmacytoma of bone
704095|NCT00002657|extramedullary plasmacytoma
704096|NCT00002657|refractory multiple myeloma
704097|NCT00002657|Waldenstrom macroglobulinemia
704098|NCT00002657|stage I multiple myeloma
704099|NCT00002657|stage II multiple myeloma
704100|NCT00002657|stage III multiple myeloma
704101|NCT00002657|stage I small lymphocytic lymphoma
704102|NCT00002657|stage I grade 1 follicular lymphoma
704103|NCT00002657|stage I grade 2 follicular lymphoma
704104|NCT00002657|stage I grade 3 follicular lymphoma
704105|NCT00002657|stage I adult diffuse small cleaved cell lymphoma
704106|NCT00002657|stage I adult diffuse mixed cell lymphoma
704107|NCT00002657|stage I adult diffuse large cell lymphoma
704108|NCT00002657|stage I adult immunoblastic large cell lymphoma
704109|NCT00002657|stage I adult Burkitt lymphoma
704110|NCT00002657|stage II small lymphocytic lymphoma
704111|NCT00002657|stage II grade 1 follicular lymphoma
704112|NCT00002657|stage II grade 2 follicular lymphoma
704113|NCT00002657|stage II grade 3 follicular lymphoma
704114|NCT00002657|stage II adult diffuse small cleaved cell lymphoma
704115|NCT00002657|stage II adult diffuse mixed cell lymphoma
704116|NCT00002657|stage II adult diffuse large cell lymphoma
704117|NCT00002657|stage II adult immunoblastic large cell lymphoma
704118|NCT00002657|stage II adult Burkitt lymphoma
704119|NCT00002657|stage III small lymphocytic lymphoma
704120|NCT00002657|stage III grade 1 follicular lymphoma
704121|NCT00002657|stage III grade 2 follicular lymphoma
704122|NCT00002657|stage III grade 3 follicular lymphoma
704123|NCT00002657|stage III adult diffuse small cleaved cell lymphoma
704124|NCT00002657|stage III adult diffuse mixed cell lymphoma
704125|NCT00002657|stage III adult diffuse large cell lymphoma
704126|NCT00002657|stage III adult immunoblastic large cell lymphoma
704127|NCT00002657|stage III adult Burkitt lymphoma
704128|NCT00002657|stage IV small lymphocytic lymphoma
704129|NCT00002657|stage IV grade 1 follicular lymphoma
704130|NCT00002657|stage IV grade 2 follicular lymphoma
704131|NCT00002657|stage IV grade 3 follicular lymphoma
704132|NCT00002657|stage IV adult diffuse small cleaved cell lymphoma
704133|NCT00002657|stage IV adult diffuse mixed cell lymphoma
704134|NCT00002657|stage IV adult diffuse large cell lymphoma
704135|NCT00002657|stage IV adult immunoblastic large cell lymphoma
704136|NCT00002657|stage IV adult Burkitt lymphoma
704137|NCT00002657|recurrent small lymphocytic lymphoma
704138|NCT00002657|recurrent grade 1 follicular lymphoma
704139|NCT00002657|recurrent grade 2 follicular lymphoma
704140|NCT00002657|recurrent grade 3 follicular lymphoma
704141|NCT00002657|recurrent adult diffuse small cleaved cell lymphoma
704142|NCT00002657|recurrent adult diffuse mixed cell lymphoma
704143|NCT00002657|recurrent adult diffuse large cell lymphoma
704144|NCT00002657|recurrent adult immunoblastic large cell lymphoma
704145|NCT00002657|recurrent adult Burkitt lymphoma
704146|NCT00002657|contiguous stage II grade 1 follicular lymphoma
704147|NCT00002657|contiguous stage II grade 2 follicular lymphoma
704148|NCT00002657|contiguous stage II grade 3 follicular lymphoma
704149|NCT00002657|contiguous stage II adult diffuse small cleaved cell lymphoma
704150|NCT00002657|contiguous stage II adult diffuse mixed cell lymphoma
704151|NCT00002657|contiguous stage II adult immunoblastic large cell lymphoma
704152|NCT00002657|contiguous stage II adult diffuse large cell lymphoma
704153|NCT00002657|contiguous stage II adult Burkitt lymphoma
704154|NCT00002657|noncontiguous stage II grade 1 follicular lymphoma
704155|NCT00002657|noncontiguous stage II grade 2 follicular lymphoma
704156|NCT00002657|noncontiguous stage II grade 3 follicular lymphoma
704157|NCT00002657|noncontiguous stage II adult diffuse small cleaved cell lymphoma
704158|NCT00002657|noncontiguous stage II adult diffuse mixed cell lymphoma
704159|NCT00002657|noncontiguous stage II adult immunoblastic large cell lymphoma
704160|NCT00002657|noncontiguous stage II adult diffuse large cell lymphoma
704161|NCT00002657|noncontiguous stage II adult Burkitt lymphoma
704162|NCT00002657|noncontiguous stage II small lymphocytic lymphoma
704163|NCT00002657|noncontiguous stage II marginal zone lymphoma
704164|NCT00002657|recurrent marginal zone lymphoma
704165|NCT00002657|stage I marginal zone lymphoma
704166|NCT00002657|stage III marginal zone lymphoma
704167|NCT00002657|stage IV marginal zone lymphoma
704168|NCT00002657|contiguous stage II marginal zone lymphoma
704169|NCT00002657|contiguous stage II small lymphocytic lymphoma
704170|NCT00002657|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
704171|NCT00002657|nodal marginal zone B-cell lymphoma
704172|NCT00002657|splenic marginal zone lymphoma
704173|NCT00002656|recurrent non-small cell lung cancer
704174|NCT00002656|stage IIIB non-small cell lung cancer
704175|NCT00002656|stage IV non-small cell lung cancer
704176|NCT00002655|localized unresectable adult primary liver cancer
704177|NCT00002655|recurrent adult primary liver cancer
704178|NCT00002655|liver metastases
704179|NCT00002654|stage III squamous cell carcinoma of the lip and oral cavity
704180|NCT00002654|stage IV squamous cell carcinoma of the lip and oral cavity
704181|NCT00002654|stage III squamous cell carcinoma of the oropharynx
704182|NCT00002654|stage IV squamous cell carcinoma of the oropharynx
704183|NCT00002654|stage III squamous cell carcinoma of the hypopharynx
704184|NCT00002654|stage IV squamous cell carcinoma of the hypopharynx
704185|NCT00002654|stage III squamous cell carcinoma of the larynx
704186|NCT00002654|stage IV squamous cell carcinoma of the larynx
704187|NCT00002653|stage I multiple myeloma
704188|NCT00002653|stage II multiple myeloma
704189|NCT00002653|stage III multiple myeloma
704190|NCT00002652|refractory multiple myeloma
704191|NCT00002651|adenocarcinoma of the prostate
706494|NCT00002345|Anorexia
704192|NCT00002651|stage IV prostate cancer
704193|NCT00002651|recurrent prostate cancer
704194|NCT00002650|colon cancer
704195|NCT00002650|rectal cancer
704196|NCT00002647|recurrent adult brain tumor
704197|NCT00002647|tumors metastatic to brain
704198|NCT00002647|recurrent childhood brain stem glioma
704199|NCT00002647|recurrent childhood anaplastic astrocytoma
704200|NCT00002647|recurrent childhood anaplastic oligoastrocytoma
704201|NCT00002647|recurrent childhood anaplastic oligodendroglioma
704202|NCT00002647|recurrent childhood cerebellar astrocytoma
704203|NCT00002647|recurrent childhood cerebral astrocytoma
704204|NCT00002647|recurrent childhood diffuse astrocytoma
704205|NCT00002647|recurrent childhood fibrillary astrocytoma
704206|NCT00002647|recurrent childhood gemistocytic astrocytoma
704207|NCT00002647|recurrent childhood giant cell glioblastoma
704208|NCT00002647|recurrent childhood glioblastoma
704209|NCT00002647|recurrent childhood gliomatosis cerebri
704210|NCT00002647|recurrent childhood gliosarcoma
704211|NCT00002647|recurrent childhood oligodendroglioma
704212|NCT00002647|recurrent childhood pilocytic astrocytoma
704213|NCT00002647|recurrent childhood pilomyxoid astrocytoma
704214|NCT00002647|recurrent childhood pleomorphic xanthoastrocytoma
704215|NCT00002647|recurrent childhood protoplasmic astrocytoma
704216|NCT00002647|recurrent childhood subependymal giant cell astrocytoma
704217|NCT00002647|recurrent childhood visual pathway and hypothalamic glioma
704218|NCT00002647|recurrent childhood visual pathway glioma
704219|NCT00002647|recurrent childhood pineoblastoma
704220|NCT00002647|recurrent childhood supratentorial primitive neuroectodermal tumor
704221|NCT00002647|recurrent childhood medulloblastoma
704222|NCT00002647|recurrent childhood ependymoma
704223|NCT00002647|recurrent childhood brain tumor
704224|NCT00002647|adult anaplastic astrocytoma
704225|NCT00002647|adult anaplastic ependymoma
704226|NCT00002647|adult anaplastic meningioma
704227|NCT00002647|adult anaplastic oligodendroglioma
704228|NCT00002647|adult brain stem glioma
704229|NCT00002647|adult central nervous system germ cell tumor
704230|NCT00002647|adult choroid plexus tumor
704231|NCT00002647|adult craniopharyngioma
704232|NCT00002647|adult diffuse astrocytoma
704233|NCT00002647|adult ependymoblastoma
704234|NCT00002647|adult ependymoma
704235|NCT00002647|adult giant cell glioblastoma
704236|NCT00002647|adult glioblastoma
704237|NCT00002647|adult gliosarcoma
704238|NCT00002647|adult medulloblastoma
704239|NCT00002647|meningeal melanocytoma
704240|NCT00002647|adult meningeal hemangiopericytoma
704241|NCT00002647|adult oligodendroglioma
704242|NCT00002647|adult papillary meningioma
704243|NCT00002647|adult pilocytic astrocytoma
704244|NCT00002647|adult pineal gland astrocytoma
704245|NCT00002647|adult pineoblastoma
704246|NCT00002647|adult pineocytoma
704247|NCT00002647|adult subependymal giant cell astrocytoma
704248|NCT00002647|adult subependymoma
704249|NCT00002647|adult supratentorial primitive neuroectodermal tumor (PNET)
704250|NCT00002647|childhood grade I meningioma
704251|NCT00002647|childhood grade II meningioma
704252|NCT00002647|childhood grade III meningioma
704253|NCT00002647|adult grade III meningioma
704254|NCT00002647|childhood central nervous system germ cell tumor
704255|NCT00002647|childhood choroid plexus tumor
704256|NCT00002647|childhood craniopharyngioma
704257|NCT00002647|childhood infratentorial ependymoma
704258|NCT00002647|childhood supratentorial ependymoma
704259|NCT00002647|childhood low-grade cerebral astrocytoma
704260|NCT00002647|childhood high-grade cerebral astrocytoma
704261|NCT00002646|stage II breast cancer
704262|NCT00002646|stage IIIA breast cancer
704263|NCT00002644|breast cancer
704264|NCT00002643|neutropenia
704265|NCT00002643|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
704266|NCT00002642|squamous cell lung cancer
704267|NCT00002642|large cell lung cancer
704268|NCT00002642|stage IIIA non-small cell lung cancer
704269|NCT00002642|stage IIIB non-small cell lung cancer
704270|NCT00002642|adenocarcinoma of the lung
704271|NCT00002642|adenosquamous cell lung cancer
704272|NCT00002641|adult angiosarcoma
704273|NCT00002641|adult fibrosarcoma
704274|NCT00002641|adult leiomyosarcoma
704275|NCT00002641|adult liposarcoma
704276|NCT00002641|adult neurofibrosarcoma
704277|NCT00002641|adult synovial sarcoma
704278|NCT00002641|stage III adult soft tissue sarcoma
704279|NCT00002641|recurrent adult soft tissue sarcoma
704280|NCT00002641|adult alveolar soft-part sarcoma
704281|NCT00002641|adult epithelioid sarcoma
704282|NCT00002641|adult malignant fibrous histiocytoma
704283|NCT00002641|adult malignant hemangiopericytoma
704284|NCT00002641|adult malignant mesenchymoma
704285|NCT00002641|adult rhabdomyosarcoma
704286|NCT00002641|localized benign pheochromocytoma
704287|NCT00002641|regional pheochromocytoma
704288|NCT00002641|recurrent pheochromocytoma
704289|NCT00002641|stage II uterine sarcoma
704290|NCT00002641|stage III uterine sarcoma
704291|NCT00002641|recurrent uterine sarcoma
704292|NCT00002641|uterine carcinosarcoma
704293|NCT00002641|uterine leiomyosarcoma
704294|NCT00002641|endometrial stromal sarcoma
704295|NCT00002641|ovarian sarcoma
704296|NCT00002641|clear cell sarcoma of the kidney
704297|NCT00002641|stage II adult soft tissue sarcoma
704298|NCT00002639|recurrent adult brain tumor
704299|NCT00002639|adult glioblastoma
704300|NCT00002639|adult anaplastic astrocytoma
704301|NCT00002639|adult anaplastic oligodendroglioma
704302|NCT00002639|adult mixed glioma
704303|NCT00002639|adult giant cell glioblastoma
704304|NCT00002639|adult gliosarcoma
704305|NCT00002638|recurrent childhood acute lymphoblastic leukemia
704306|NCT00002637|recurrent prostate cancer
704307|NCT00002635|stage II cutaneous T-cell non-Hodgkin lymphoma
704308|NCT00002635|stage III cutaneous T-cell non-Hodgkin lymphoma
704309|NCT00002635|stage IV cutaneous T-cell non-Hodgkin lymphoma
704310|NCT00002635|recurrent cutaneous T-cell non-Hodgkin lymphoma
704311|NCT00002634|localized resectable neuroblastoma
704312|NCT00002634|regional neuroblastoma
704313|NCT00002634|disseminated neuroblastoma
704314|NCT00002634|recurrent neuroblastoma
704315|NCT00002634|localized unresectable neuroblastoma
704316|NCT00002633|adenocarcinoma of the prostate
704317|NCT00002633|stage II prostate cancer
704318|NCT00002633|stage III prostate cancer
704319|NCT00002633|stage IV prostate cancer
704320|NCT00002632|stage IV salivary gland cancer
704321|NCT00002632|recurrent salivary gland cancer
704322|NCT00002632|high-grade salivary gland mucoepidermoid carcinoma
704323|NCT00002632|salivary gland adenocarcinoma
704324|NCT00002631|stage I esophageal cancer
704325|NCT00002631|stage II esophageal cancer
704326|NCT00002631|stage III esophageal cancer
704327|NCT00002631|squamous cell carcinoma of the esophagus
704328|NCT00002631|adenocarcinoma of the esophagus
704329|NCT00002630|refractory multiple myeloma
704330|NCT00002630|stage II multiple myeloma
704331|NCT00002630|stage III multiple myeloma
704332|NCT00002628|stage IV breast cancer
704333|NCT00002628|recurrent breast cancer
704334|NCT00002627|stage II breast cancer
704335|NCT00002627|stage IIIA breast cancer
704336|NCT00002627|stage IIIB breast cancer
704337|NCT00002627|inflammatory breast cancer
704338|NCT00002625|stage III adult Hodgkin lymphoma
704339|NCT00002625|stage IV adult Hodgkin lymphoma
704340|NCT00002625|recurrent non-small cell lung cancer
704341|NCT00002625|recurrent adult Hodgkin lymphoma
704342|NCT00002625|recurrent esophageal cancer
704343|NCT00002625|stage III cutaneous T-cell non-Hodgkin lymphoma
704344|NCT00002625|stage IV cutaneous T-cell non-Hodgkin lymphoma
704345|NCT00002625|recurrent cutaneous T-cell non-Hodgkin lymphoma
704346|NCT00002625|recurrent small cell lung cancer
704347|NCT00002625|stage III grade 1 follicular lymphoma
704348|NCT00002625|stage III grade 2 follicular lymphoma
704349|NCT00002625|stage III grade 3 follicular lymphoma
704350|NCT00002625|stage III adult diffuse small cleaved cell lymphoma
704351|NCT00002625|stage III adult diffuse mixed cell lymphoma
704352|NCT00002625|stage III adult diffuse large cell lymphoma
704353|NCT00002625|stage III adult immunoblastic large cell lymphoma
704354|NCT00002625|stage III adult lymphoblastic lymphoma
704355|NCT00002625|stage III adult Burkitt lymphoma
704356|NCT00002625|stage IV grade 1 follicular lymphoma
704357|NCT00002625|stage IV grade 2 follicular lymphoma
704358|NCT00002625|stage IV grade 3 follicular lymphoma
704359|NCT00002625|stage IV adult diffuse small cleaved cell lymphoma
704360|NCT00002625|stage IV adult diffuse mixed cell lymphoma
704361|NCT00002625|stage IV adult diffuse large cell lymphoma
704362|NCT00002625|stage IV adult immunoblastic large cell lymphoma
704363|NCT00002625|stage IV adult lymphoblastic lymphoma
704364|NCT00002625|stage IV adult Burkitt lymphoma
704365|NCT00002625|recurrent grade 1 follicular lymphoma
704366|NCT00002625|recurrent grade 2 follicular lymphoma
704367|NCT00002625|recurrent grade 3 follicular lymphoma
704368|NCT00002625|recurrent adult diffuse small cleaved cell lymphoma
704369|NCT00002625|recurrent adult diffuse mixed cell lymphoma
704370|NCT00002625|recurrent adult diffuse large cell lymphoma
704371|NCT00002625|recurrent adult immunoblastic large cell lymphoma
704372|NCT00002625|recurrent adult lymphoblastic lymphoma
704373|NCT00002625|recurrent adult Burkitt lymphoma
704374|NCT00002625|stage III adult T-cell leukemia/lymphoma
704375|NCT00002625|stage IV adult T-cell leukemia/lymphoma
704376|NCT00002625|recurrent adult T-cell leukemia/lymphoma
704377|NCT00002625|stage III mantle cell lymphoma
704378|NCT00002625|stage IV mantle cell lymphoma
704379|NCT00002625|recurrent mantle cell lymphoma
704380|NCT00002625|recurrent marginal zone lymphoma
704381|NCT00002625|recurrent small lymphocytic lymphoma
704382|NCT00002625|stage III small lymphocytic lymphoma
704383|NCT00002625|stage III marginal zone lymphoma
704384|NCT00002625|stage IV small lymphocytic lymphoma
704385|NCT00002625|stage IV marginal zone lymphoma
704386|NCT00002625|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
704387|NCT00002625|nodal marginal zone B-cell lymphoma
704388|NCT00002625|splenic marginal zone lymphoma
704389|NCT00002624|stage I non-small cell lung cancer
704390|NCT00002624|squamous cell lung cancer
704391|NCT00002624|large cell lung cancer
704392|NCT00002624|adenocarcinoma of the lung
704393|NCT00002624|bronchoalveolar cell lung cancer
704394|NCT00002623|squamous cell lung cancer
704395|NCT00002623|large cell lung cancer
704396|NCT00002623|stage IIIA non-small cell lung cancer
704397|NCT00002623|adenocarcinoma of the lung
704398|NCT00002623|adenosquamous cell lung cancer
704399|NCT00002623|bronchoalveolar cell lung cancer
704400|NCT00002622|malignant pleural effusion
704401|NCT00002621|recurrent childhood acute lymphoblastic leukemia
704402|NCT00002621|stage I childhood lymphoblastic lymphoma
704403|NCT00002621|stage II childhood lymphoblastic lymphoma
704404|NCT00002621|stage III childhood lymphoblastic lymphoma
704405|NCT00002621|stage IV childhood lymphoblastic lymphoma
704406|NCT00002621|recurrent childhood lymphoblastic lymphoma
704407|NCT00002621|recurrent childhood acute myeloid leukemia
704408|NCT00002621|unspecified childhood solid tumor, protocol specific
704409|NCT00002621|untreated childhood acute myeloid leukemia and other myeloid malignancies
704410|NCT00002621|untreated childhood acute lymphoblastic leukemia
704411|NCT00002621|childhood acute myeloid leukemia in remission
704412|NCT00002621|childhood acute lymphoblastic leukemia in remission
704413|NCT00002621|AIDS-related peripheral/systemic lymphoma
704414|NCT00002621|AIDS-related primary CNS lymphoma
704415|NCT00002621|stage I childhood small noncleaved cell lymphoma
704416|NCT00002621|stage I childhood large cell lymphoma
704417|NCT00002621|stage II childhood small noncleaved cell lymphoma
704418|NCT00002621|stage II childhood large cell lymphoma
704419|NCT00002621|stage III childhood small noncleaved cell lymphoma
704420|NCT00002621|stage III childhood large cell lymphoma
704421|NCT00002621|stage IV childhood small noncleaved cell lymphoma
704422|NCT00002621|stage IV childhood large cell lymphoma
704423|NCT00002621|recurrent childhood small noncleaved cell lymphoma
704424|NCT00002621|recurrent childhood large cell lymphoma
704425|NCT00002620|adult anaplastic astrocytoma
704426|NCT00002619|adult brain stem glioma
704427|NCT00002619|adult glioblastoma
704428|NCT00002619|childhood high-grade cerebral astrocytoma
704429|NCT00002619|untreated childhood brain stem glioma
704430|NCT00002619|adult giant cell glioblastoma
704431|NCT00002619|adult gliosarcoma
704432|NCT00002618|childhood diffuse large cell lymphoma
704433|NCT00002618|childhood immunoblastic large cell lymphoma
704434|NCT00002618|AIDS-related peripheral/systemic lymphoma
704435|NCT00002618|AIDS-related diffuse large cell lymphoma
704436|NCT00002618|AIDS-related immunoblastic large cell lymphoma
704437|NCT00002618|AIDS-related diffuse mixed cell lymphoma
704438|NCT00002618|stage III childhood large cell lymphoma
704439|NCT00002618|stage IV childhood large cell lymphoma
704440|NCT00002616|stage IV breast cancer
704441|NCT00002616|recurrent breast cancer
704442|NCT00002616|stage IIIB breast cancer
704443|NCT00002616|inflammatory breast cancer
704444|NCT00002615|stage II gastric cancer
704445|NCT00002615|stage III gastric cancer
704446|NCT00002615|adenocarcinoma of the stomach
704447|NCT00002611|stage I Wilms tumor
704448|NCT00002611|stage II Wilms tumor
704449|NCT00002611|stage III Wilms tumor
704450|NCT00002611|stage IV Wilms tumor
704451|NCT00002611|stage V Wilms tumor
704452|NCT00002611|clear cell sarcoma of the kidney
704453|NCT00002610|recurrent Wilms tumor and other childhood kidney tumors
704454|NCT00002610|clear cell sarcoma of the kidney
704455|NCT00002610|rhabdoid tumor of the kidney
704456|NCT00002609|adult acute myeloid leukemia in remission
704457|NCT00002609|childhood acute myeloid leukemia in remission
704458|NCT00002609|adult acute promyelocytic leukemia (M3)
704459|NCT00002609|childhood acute promyelocytic leukemia (M3)
704460|NCT00002608|childhood brain tumor
704461|NCT00002608|childhood infratentorial ependymoma
704462|NCT00002608|childhood supratentorial ependymoma
704463|NCT00002608|recurrent adult soft tissue sarcoma
704464|NCT00002608|recurrent childhood brain tumor
704465|NCT00002608|childhood liver cancer
704466|NCT00002608|stage IV childhood liver cancer
704467|NCT00002608|recurrent childhood liver cancer
704468|NCT00002608|advanced malignant mesothelioma
704469|NCT00002608|recurrent malignant mesothelioma
704470|NCT00002608|localized unresectable adult primary liver cancer
704471|NCT00002608|advanced adult primary liver cancer
704472|NCT00002608|recurrent adult primary liver cancer
704473|NCT00002608|recurrent adult brain tumor
704474|NCT00002608|stage IV adrenocortical carcinoma
704475|NCT00002608|recurrent adrenocortical carcinoma
704476|NCT00002608|stage IV papillary thyroid cancer
704477|NCT00002608|stage IV follicular thyroid cancer
704478|NCT00002608|thyroid gland medullary carcinoma
704479|NCT00002608|anaplastic thyroid cancer
704480|NCT00002608|recurrent thyroid cancer
704481|NCT00002608|adult brain stem glioma
704482|NCT00002608|adult medulloblastoma
704483|NCT00002608|adult glioblastoma
704484|NCT00002608|metastatic pheochromocytoma
704485|NCT00002608|recurrent pheochromocytoma
704486|NCT00002608|childhood soft tissue sarcoma
704487|NCT00002608|metastatic childhood soft tissue sarcoma
704488|NCT00002608|recurrent childhood soft tissue sarcoma
704489|NCT00002608|childhood high-grade cerebral astrocytoma
704490|NCT00002608|childhood oligodendroglioma
704491|NCT00002608|adult anaplastic astrocytoma
704492|NCT00002608|adult myxopapillary ependymoma
704493|NCT00002608|adult anaplastic ependymoma
704494|NCT00002608|adult anaplastic oligodendroglioma
704495|NCT00002608|adult mixed glioma
704496|NCT00002608|adult pilocytic astrocytoma
704497|NCT00002608|adult subependymoma
704498|NCT00002608|recurrent childhood brain stem glioma
704499|NCT00002608|recurrent childhood cerebellar astrocytoma
704500|NCT00002608|recurrent childhood cerebral astrocytoma
704501|NCT00002608|recurrent childhood medulloblastoma
704502|NCT00002608|recurrent childhood visual pathway and hypothalamic glioma
704503|NCT00002608|recurrent childhood ependymoma
704504|NCT00002608|stage IV adult soft tissue sarcoma
704505|NCT00002608|adult oligodendroglioma
704506|NCT00002608|adult giant cell glioblastoma
704507|NCT00002608|adult gliosarcoma
704508|NCT00002608|adult diffuse astrocytoma
704509|NCT00002604|unspecified adult solid tumor, protocol specific
704510|NCT00002602|adenocarcinoma of the prostate
704511|NCT00002602|stage IIB prostate cancer
704512|NCT00002602|stage IIA prostate cancer
704513|NCT00002602|stage III prostate cancer
704514|NCT00002601|metastatic osteosarcoma
704515|NCT00002601|recurrent childhood rhabdomyosarcoma
704516|NCT00002601|recurrent adult soft tissue sarcoma
704517|NCT00002601|recurrent osteosarcoma
704518|NCT00002601|adult rhabdomyosarcoma
704519|NCT00002601|metastatic childhood soft tissue sarcoma
704520|NCT00002601|recurrent childhood soft tissue sarcoma
704521|NCT00002601|previously treated childhood rhabdomyosarcoma
704522|NCT00002601|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
704523|NCT00002601|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
704524|NCT00002601|stage IV adult soft tissue sarcoma
704525|NCT00002600|recurrent ovarian epithelial cancer
704526|NCT00002600|ovarian undifferentiated adenocarcinoma
704527|NCT00002600|ovarian mixed epithelial carcinoma
704528|NCT00002600|ovarian serous cystadenocarcinoma
704529|NCT00002600|ovarian mucinous cystadenocarcinoma
704530|NCT00002600|ovarian endometrioid adenocarcinoma
704531|NCT00002600|ovarian clear cell cystadenocarcinoma
704532|NCT00002600|fallopian tube cancer
704533|NCT00002600|primary peritoneal cavity cancer
704534|NCT00002599|stage I multiple myeloma
704535|NCT00002599|stage II multiple myeloma
704536|NCT00002599|stage III multiple myeloma
704537|NCT00002598|relapsing chronic myelogenous leukemia
704538|NCT00002598|blastic phase chronic myelogenous leukemia
704539|NCT00002598|atypical chronic myeloid leukemia, BCR-ABL1 negative
704540|NCT00002597|adenocarcinoma of the prostate
704541|NCT00002597|stage I prostate cancer
704542|NCT00002597|stage IIB prostate cancer
704543|NCT00002597|stage IIA prostate cancer
704544|NCT00002596|stage II malignant testicular germ cell tumor
704545|NCT00002596|stage III malignant testicular germ cell tumor
704546|NCT00002596|testicular seminoma
704547|NCT00002596|testicular embryonal carcinoma
704548|NCT00002596|testicular choriocarcinoma
704549|NCT00002596|testicular teratoma
704550|NCT00002596|testicular yolk sac tumor
704551|NCT00002596|testicular embryonal carcinoma and teratoma
704552|NCT00002596|testicular embryonal carcinoma and teratoma with seminoma
704553|NCT00002596|testicular embryonal carcinoma and yolk sac tumor
704554|NCT00002596|testicular embryonal carcinoma and yolk sac tumor with seminoma
704555|NCT00002596|testicular embryonal carcinoma and seminoma
704556|NCT00002596|testicular yolk sac tumor and teratoma
704557|NCT00002596|testicular yolk sac tumor and teratoma with seminoma
704558|NCT00002596|testicular choriocarcinoma and yolk sac tumor
704559|NCT00002596|testicular choriocarcinoma and embryonal carcinoma
704560|NCT00002596|testicular choriocarcinoma and teratoma
704561|NCT00002596|testicular choriocarcinoma and seminoma
704562|NCT00002596|extragonadal germ cell tumor
704563|NCT00002596|childhood teratoma
704564|NCT00002596|childhood malignant testicular germ cell tumor
704565|NCT00002596|childhood extragonadal germ cell tumor
704566|NCT00002595|desmoid tumor
704567|NCT00002594|recurrent childhood brain tumor
704568|NCT00002594|childhood central nervous system germ cell tumor
704569|NCT00002594|recurrent childhood medulloblastoma
704570|NCT00002593|stage II colon cancer
704571|NCT00002593|stage III colon cancer
704572|NCT00002592|relapsing chronic myelogenous leukemia
704573|NCT00002592|chronic phase chronic myelogenous leukemia
704574|NCT00002592|accelerated phase chronic myelogenous leukemia
704575|NCT00002590|stage IV childhood lymphoblastic lymphoma
704576|NCT00002590|stage IV childhood large cell lymphoma
704577|NCT00002589|stage III renal cell cancer
704578|NCT00002589|stage IV renal cell cancer
704579|NCT00002589|recurrent renal cell cancer
704580|NCT00002588|recurrent adult acute myeloid leukemia
704581|NCT00002588|recurrent adult acute lymphoblastic leukemia
704582|NCT00002588|relapsing chronic myelogenous leukemia
704583|NCT00002588|blastic phase chronic myelogenous leukemia
704584|NCT00002588|L1 adult acute lymphoblastic leukemia
704585|NCT00002588|L2 adult acute lymphoblastic leukemia
704586|NCT00002588|adult acute erythroid leukemia (M6)
704587|NCT00002588|adult acute myeloblastic leukemia without maturation (M1)
704588|NCT00002588|adult acute myeloblastic leukemia with maturation (M2)
704589|NCT00002588|adult acute promyelocytic leukemia (M3)
704590|NCT00002588|adult acute myelomonocytic leukemia (M4)
704591|NCT00002588|adult acute monoblastic leukemia (M5a)
704592|NCT00002588|adult acute megakaryoblastic leukemia (M7)
704593|NCT00002588|secondary acute myeloid leukemia
704594|NCT00002588|adult acute monocytic leukemia (M5b)
704595|NCT00002588|adult acute minimally differentiated myeloid leukemia (M0)
704596|NCT00002587|unspecified adult solid tumor, protocol specific
704597|NCT00002586|non-small cell lung cancer
704598|NCT00002586|small cell lung cancer
704599|NCT00002586|drug/agent toxicity by tissue/organ
704600|NCT00002585|stage IV breast cancer
704601|NCT00002585|recurrent breast cancer
704602|NCT00002583|stage I non-small cell lung cancer
704603|NCT00002583|stage II non-small cell lung cancer
704604|NCT00002582|stage I breast cancer
704605|NCT00002582|stage II breast cancer
704606|NCT00002582|stage IIIA breast cancer
704607|NCT00002581|stage I breast cancer
704608|NCT00002581|stage II breast cancer
704609|NCT00002581|stage IIIA breast cancer
704610|NCT00002580|stage I breast cancer
704611|NCT00002580|stage II breast cancer
704612|NCT00002580|stage IIIA breast cancer
704613|NCT00002579|stage I breast cancer
704614|NCT00002579|stage II breast cancer
704615|NCT00002579|stage IIIA breast cancer
704616|NCT00002578|AIDS-related peripheral/systemic lymphoma
704617|NCT00002578|AIDS-related diffuse large cell lymphoma
704618|NCT00002578|AIDS-related immunoblastic large cell lymphoma
704619|NCT00002578|AIDS-related small noncleaved cell lymphoma
704620|NCT00002578|AIDS-related diffuse mixed cell lymphoma
704621|NCT00002578|AIDS-related diffuse small cleaved cell lymphoma
704622|NCT00002578|AIDS-related lymphoblastic lymphoma
704623|NCT00002577|stage I non-small cell lung cancer
704624|NCT00002577|stage II non-small cell lung cancer
704625|NCT00002577|recurrent non-small cell lung cancer
704626|NCT00002577|squamous cell lung cancer
704627|NCT00002577|large cell lung cancer
704628|NCT00002577|stage IIIA non-small cell lung cancer
704629|NCT00002577|stage IIIB non-small cell lung cancer
704630|NCT00002577|adenocarcinoma of the lung
704631|NCT00002576|stage I adult diffuse mixed cell lymphoma
704632|NCT00002576|stage I adult diffuse large cell lymphoma
704633|NCT00002576|stage I adult immunoblastic large cell lymphoma
704634|NCT00002576|stage I adult lymphoblastic lymphoma
704635|NCT00002576|stage I adult Burkitt lymphoma
704636|NCT00002576|stage II adult diffuse mixed cell lymphoma
704637|NCT00002576|stage II adult diffuse large cell lymphoma
704638|NCT00002576|stage II adult immunoblastic large cell lymphoma
704639|NCT00002576|stage II adult lymphoblastic lymphoma
704640|NCT00002576|stage II adult Burkitt lymphoma
704641|NCT00002576|stage III adult diffuse mixed cell lymphoma
704642|NCT00002576|stage III adult diffuse large cell lymphoma
704643|NCT00002576|stage III adult immunoblastic large cell lymphoma
704644|NCT00002576|stage III adult lymphoblastic lymphoma
704645|NCT00002576|stage III adult Burkitt lymphoma
704646|NCT00002576|stage IV adult diffuse mixed cell lymphoma
704647|NCT00002576|stage IV adult diffuse large cell lymphoma
704648|NCT00002576|stage IV adult immunoblastic large cell lymphoma
704649|NCT00002576|stage IV adult lymphoblastic lymphoma
704650|NCT00002576|stage IV adult Burkitt lymphoma
704651|NCT00002576|contiguous stage II adult diffuse mixed cell lymphoma
704652|NCT00002576|contiguous stage II adult immunoblastic large cell lymphoma
704653|NCT00002576|contiguous stage II adult diffuse large cell lymphoma
704654|NCT00002576|contiguous stage II adult Burkitt lymphoma
704655|NCT00002576|contiguous stage II adult lymphoblastic lymphoma
704656|NCT00002576|noncontiguous stage II adult diffuse mixed cell lymphoma
704657|NCT00002576|noncontiguous stage II adult immunoblastic large cell lymphoma
704658|NCT00002576|noncontiguous stage II adult diffuse large cell lymphoma
704659|NCT00002576|noncontiguous stage II adult Burkitt lymphoma
704660|NCT00002576|noncontiguous stage II adult lymphoblastic lymphoma
704661|NCT00002575|stage I colon cancer
704662|NCT00002575|stage II colon cancer
704663|NCT00002575|stage III colon cancer
704664|NCT00002575|adenocarcinoma of the colon
704665|NCT00002574|relapsing chronic myelogenous leukemia
704666|NCT00002574|chronic phase chronic myelogenous leukemia
704667|NCT00002572|recurrent adult brain tumor
704668|NCT00002572|adult glioblastoma
704669|NCT00002572|adult anaplastic astrocytoma
704670|NCT00002572|adult anaplastic oligodendroglioma
704671|NCT00002572|adult mixed glioma
704672|NCT00002572|adult giant cell glioblastoma
704673|NCT00002572|adult gliosarcoma
704674|NCT00002571|AIDS-related peripheral/systemic lymphoma
704675|NCT00002571|AIDS-related diffuse large cell lymphoma
704676|NCT00002571|AIDS-related immunoblastic large cell lymphoma
704677|NCT00002571|AIDS-related small noncleaved cell lymphoma
704678|NCT00002571|AIDS-related diffuse mixed cell lymphoma
704679|NCT00002571|AIDS-related diffuse small cleaved cell lymphoma
704680|NCT00002570|stage III colon cancer
704681|NCT00002570|stage IV colon cancer
704682|NCT00002570|stage III rectal cancer
704683|NCT00002570|stage IV rectal cancer
704684|NCT00002570|recurrent colon cancer
704686|NCT00002569|adult anaplastic oligodendroglioma
704687|NCT00002569|adult mixed glioma
704688|NCT00002568|stage III ovarian epithelial cancer
704689|NCT00002568|ovarian undifferentiated adenocarcinoma
704690|NCT00002568|ovarian mixed epithelial carcinoma
704691|NCT00002568|ovarian serous cystadenocarcinoma
704692|NCT00002568|ovarian mucinous cystadenocarcinoma
704693|NCT00002568|ovarian endometrioid adenocarcinoma
704694|NCT00002568|ovarian clear cell cystadenocarcinoma
704695|NCT00002568|Brenner tumor
704696|NCT00002567|adult acute myeloid leukemia in remission
704697|NCT00002567|adult acute lymphoblastic leukemia in remission
704698|NCT00002567|adult acute erythroid leukemia (M6)
704699|NCT00002567|adult acute myeloblastic leukemia without maturation (M1)
704700|NCT00002567|adult acute myeloblastic leukemia with maturation (M2)
704701|NCT00002567|adult acute promyelocytic leukemia (M3)
704702|NCT00002567|adult acute myelomonocytic leukemia (M4)
704703|NCT00002567|adult acute monoblastic leukemia (M5a)
704704|NCT00002567|adult acute megakaryoblastic leukemia (M7)
704705|NCT00002567|adult acute monocytic leukemia (M5b)
704706|NCT00002567|bone marrow ablation
704707|NCT00002567|adult acute minimally differentiated myeloid leukemia (M0)
704708|NCT00002566|recurrent malignant testicular germ cell tumor
704709|NCT00002566|extragonadal germ cell tumor
704710|NCT00002565|stage I grade 3 follicular lymphoma
704711|NCT00002565|stage I adult diffuse mixed cell lymphoma
704712|NCT00002565|stage I adult diffuse large cell lymphoma
704713|NCT00002565|stage I adult immunoblastic large cell lymphoma
704714|NCT00002565|stage II grade 3 follicular lymphoma
704715|NCT00002565|stage II adult diffuse mixed cell lymphoma
704716|NCT00002565|stage II adult diffuse large cell lymphoma
704717|NCT00002565|stage II adult immunoblastic large cell lymphoma
704718|NCT00002565|stage III grade 3 follicular lymphoma
704719|NCT00002565|stage III adult diffuse mixed cell lymphoma
704720|NCT00002565|stage III adult diffuse large cell lymphoma
704721|NCT00002565|stage III adult immunoblastic large cell lymphoma
704722|NCT00002565|stage IV grade 3 follicular lymphoma
704723|NCT00002565|stage IV adult diffuse mixed cell lymphoma
704724|NCT00002565|stage IV adult diffuse large cell lymphoma
704725|NCT00002565|stage IV adult immunoblastic large cell lymphoma
704726|NCT00002565|contiguous stage II grade 3 follicular lymphoma
704727|NCT00002565|contiguous stage II adult diffuse mixed cell lymphoma
704728|NCT00002565|contiguous stage II adult immunoblastic large cell lymphoma
704729|NCT00002565|contiguous stage II adult diffuse large cell lymphoma
704730|NCT00002565|noncontiguous stage II grade 3 follicular lymphoma
704731|NCT00002565|noncontiguous stage II adult diffuse mixed cell lymphoma
704732|NCT00002565|noncontiguous stage II adult immunoblastic large cell lymphoma
704733|NCT00002565|noncontiguous stage II adult diffuse large cell lymphoma
704734|NCT00002564|recurrent breast cancer
704735|NCT00002563|stage I adult Hodgkin lymphoma
704736|NCT00002563|stage II adult Hodgkin lymphoma
704737|NCT00002563|psychosocial effects of cancer and its treatment
704738|NCT00002562|recurrent cervical cancer
704739|NCT00002562|recurrent vaginal cancer
704740|NCT00002562|vaginal clear cell adenocarcinoma
704741|NCT00002562|cervical adenocarcinoma
704742|NCT00002561|stage I adult Hodgkin lymphoma
704743|NCT00002561|stage II adult Hodgkin lymphoma
704744|NCT00002561|adult lymphocyte predominant Hodgkin lymphoma
704745|NCT00002561|adult lymphocyte depletion Hodgkin lymphoma
704746|NCT00002561|adult nodular sclerosis Hodgkin lymphoma
704747|NCT00002561|adult mixed cellularity Hodgkin lymphoma
704748|NCT00002560|recurrent neuroblastoma
704749|NCT00002559|recurrent malignant testicular germ cell tumor
704750|NCT00002559|recurrent ovarian germ cell tumor
704751|NCT00002558|recurrent malignant testicular germ cell tumor
704752|NCT00002558|recurrent ovarian germ cell tumor
704753|NCT00002558|extragonadal germ cell tumor
704754|NCT00002557|stage III cutaneous T-cell non-Hodgkin lymphoma
704755|NCT00002557|stage IV cutaneous T-cell non-Hodgkin lymphoma
704756|NCT00002557|recurrent cutaneous T-cell non-Hodgkin lymphoma
704757|NCT00002555|stage III squamous cell carcinoma of the lip and oral cavity
704758|NCT00002555|stage IV squamous cell carcinoma of the lip and oral cavity
704759|NCT00002555|stage III squamous cell carcinoma of the oropharynx
704760|NCT00002555|stage IV squamous cell carcinoma of the oropharynx
704761|NCT00002555|stage III squamous cell carcinoma of the hypopharynx
704762|NCT00002555|stage IV squamous cell carcinoma of the hypopharynx
704763|NCT00002555|stage III squamous cell carcinoma of the larynx
704764|NCT00002555|stage IV squamous cell carcinoma of the larynx
704765|NCT00002554|recurrent adult acute myeloid leukemia
704766|NCT00002554|adult acute myeloid leukemia in remission
704767|NCT00002553|stage IV adult Hodgkin lymphoma
704768|NCT00002553|recurrent childhood acute lymphoblastic leukemia
704769|NCT00002553|recurrent adult Hodgkin lymphoma
704770|NCT00002553|Waldenstrom macroglobulinemia
704771|NCT00002553|stage IV childhood lymphoblastic lymphoma
704772|NCT00002553|recurrent childhood lymphoblastic lymphoma
704773|NCT00002553|recurrent childhood acute myeloid leukemia
704774|NCT00002553|recurrent adult acute myeloid leukemia
704775|NCT00002553|recurrent adult acute lymphoblastic leukemia
704776|NCT00002553|relapsing chronic myelogenous leukemia
704777|NCT00002553|chronic phase chronic myelogenous leukemia
704778|NCT00002553|accelerated phase chronic myelogenous leukemia
704779|NCT00002553|blastic phase chronic myelogenous leukemia
704780|NCT00002553|untreated adult acute lymphoblastic leukemia
704781|NCT00002553|untreated adult acute myeloid leukemia
704782|NCT00002553|untreated childhood acute myeloid leukemia and other myeloid malignancies
704783|NCT00002553|untreated childhood acute lymphoblastic leukemia
704784|NCT00002553|adult acute myeloid leukemia in remission
704785|NCT00002553|adult acute lymphoblastic leukemia in remission
704786|NCT00002553|childhood acute myeloid leukemia in remission
704787|NCT00002553|childhood acute lymphoblastic leukemia in remission
704788|NCT00002553|stage IV childhood Hodgkin lymphoma
704789|NCT00002553|recurrent/refractory childhood Hodgkin lymphoma
704790|NCT00002553|recurrent adult non-Hodgkin lymphoma
704791|NCT00002553|recurrent grade 1 follicular lymphoma
704792|NCT00002553|recurrent grade 2 follicular lymphoma
704793|NCT00002553|recurrent grade 3 follicular lymphoma
704794|NCT00002553|recurrent adult diffuse small cleaved cell lymphoma
704795|NCT00002553|recurrent adult diffuse mixed cell lymphoma
704796|NCT00002553|recurrent adult diffuse large cell lymphoma
704797|NCT00002553|recurrent adult immunoblastic large cell lymphoma
704798|NCT00002553|recurrent adult lymphoblastic lymphoma
704799|NCT00002553|recurrent adult Burkitt lymphoma
704800|NCT00002553|stage IV childhood small noncleaved cell lymphoma
704801|NCT00002553|stage IV childhood large cell lymphoma
704802|NCT00002553|recurrent childhood small noncleaved cell lymphoma
704803|NCT00002553|recurrent childhood large cell lymphoma
704804|NCT00002553|recurrent mantle cell lymphoma
704805|NCT00002553|recurrent marginal zone lymphoma
704806|NCT00002553|recurrent small lymphocytic lymphoma
704807|NCT00002553|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
704808|NCT00002553|nodal marginal zone B-cell lymphoma
704809|NCT00002553|splenic marginal zone lymphoma
704810|NCT00002552|recurrent adult Hodgkin lymphoma
704811|NCT00002552|refractory multiple myeloma
704812|NCT00002552|recurrent small lymphocytic lymphoma
704813|NCT00002552|recurrent grade 1 follicular lymphoma
704814|NCT00002552|recurrent grade 2 follicular lymphoma
704815|NCT00002552|recurrent grade 3 follicular lymphoma
704816|NCT00002552|recurrent adult diffuse small cleaved cell lymphoma
704817|NCT00002552|recurrent adult diffuse mixed cell lymphoma
704818|NCT00002552|recurrent adult diffuse large cell lymphoma
704819|NCT00002552|recurrent adult immunoblastic large cell lymphoma
704820|NCT00002552|recurrent adult lymphoblastic lymphoma
704821|NCT00002552|recurrent adult Burkitt lymphoma
704822|NCT00002552|recurrent mantle cell lymphoma
704823|NCT00002552|recurrent marginal zone lymphoma
704824|NCT00002552|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
704825|NCT00002552|nodal marginal zone B-cell lymphoma
704826|NCT00002552|splenic marginal zone lymphoma
704827|NCT00002552|adult unfavorable prognosis Hodgkin lymphoma
704828|NCT00002552|childhood unfavorable prognosis Hodgkin lymphoma
704829|NCT00002551|stage II rectal cancer
704830|NCT00002551|stage III rectal cancer
704831|NCT00002551|adenocarcinoma of the rectum
704832|NCT00002550|squamous cell lung cancer
704833|NCT00002550|large cell lung cancer
704834|NCT00002550|stage IIIA non-small cell lung cancer
704835|NCT00002550|adenocarcinoma of the lung
704836|NCT00002550|bronchoalveolar cell lung cancer
704837|NCT00002549|untreated adult acute myeloid leukemia
704838|NCT00002549|adult acute erythroid leukemia (M6)
704839|NCT00002549|adult acute myeloblastic leukemia without maturation (M1)
704840|NCT00002549|adult acute myeloblastic leukemia with maturation (M2)
704841|NCT00002549|adult acute myelomonocytic leukemia (M4)
704842|NCT00002549|adult acute monoblastic leukemia (M5a)
704843|NCT00002549|adult acute megakaryoblastic leukemia (M7)
704844|NCT00002549|secondary acute myeloid leukemia
704845|NCT00002549|adult acute monocytic leukemia (M5b)
704846|NCT00002548|stage I multiple myeloma
704847|NCT00002548|stage II multiple myeloma
704848|NCT00002548|stage III multiple myeloma
704849|NCT00002547|recurrent childhood acute myeloid leukemia
704850|NCT00002547|recurrent adult acute myeloid leukemia
704851|NCT00002547|untreated adult acute myeloid leukemia
704852|NCT00002547|untreated childhood acute myeloid leukemia and other myeloid malignancies
704853|NCT00002547|adult acute myeloid leukemia in remission
704854|NCT00002547|childhood acute myeloid leukemia in remission
704855|NCT00002547|adult acute erythroid leukemia (M6)
704856|NCT00002547|adult acute myeloblastic leukemia without maturation (M1)
704857|NCT00002547|adult acute myeloblastic leukemia with maturation (M2)
704858|NCT00002547|adult acute promyelocytic leukemia (M3)
704859|NCT00002547|adult acute myelomonocytic leukemia (M4)
704860|NCT00002547|adult acute monoblastic leukemia (M5a)
704861|NCT00002547|adult acute megakaryoblastic leukemia (M7)
704862|NCT00002547|childhood acute myeloblastic leukemia without maturation (M1)
704863|NCT00002547|childhood acute myeloblastic leukemia with maturation (M2)
704864|NCT00002547|childhood acute promyelocytic leukemia (M3)
704865|NCT00002547|childhood acute myelomonocytic leukemia (M4)
704866|NCT00002547|childhood acute monoblastic leukemia (M5a)
704867|NCT00002547|childhood acute monocytic leukemia (M5b)
704868|NCT00002547|childhood acute erythroleukemia (M6)
704869|NCT00002547|childhood acute megakaryocytic leukemia (M7)
704870|NCT00002547|refractory anemia with excess blasts
704871|NCT00002547|refractory anemia with excess blasts in transformation
704872|NCT00002547|chronic myelomonocytic leukemia
704873|NCT00002547|secondary acute myeloid leukemia
704874|NCT00002547|adult acute monocytic leukemia (M5b)
704875|NCT00002547|previously treated myelodysplastic syndromes
704876|NCT00002547|childhood myelodysplastic syndromes
704877|NCT00002546|stage I uterine sarcoma
704878|NCT00002546|stage II uterine sarcoma
704879|NCT00002546|stage III uterine sarcoma
704880|NCT00002546|stage IV uterine sarcoma
704881|NCT00002546|uterine carcinosarcoma
704882|NCT00002545|adult glioblastoma
704883|NCT00002545|adult giant cell glioblastoma
704884|NCT00002545|adult gliosarcoma
704885|NCT00002544|stage IV breast cancer
704886|NCT00002544|recurrent breast cancer
704887|NCT00002543|recurrent childhood rhabdomyosarcoma
704888|NCT00002543|recurrent childhood brain tumor
704889|NCT00002543|recurrent neuroblastoma
704890|NCT00002543|recurrent childhood lymphoblastic lymphoma
704891|NCT00002543|unspecified childhood solid tumor, protocol specific
704892|NCT00002543|recurrent childhood small noncleaved cell lymphoma
704893|NCT00002543|recurrent childhood large cell lymphoma
704894|NCT00002542|stage I breast cancer
704895|NCT00002542|stage II breast cancer
704896|NCT00002542|stage IIIA breast cancer
704897|NCT00002539|localized osteosarcoma
704898|NCT00002538|stage I ovarian epithelial cancer
704899|NCT00002538|stage II ovarian epithelial cancer
704900|NCT00002538|stage III ovarian epithelial cancer
704901|NCT00002538|ovarian undifferentiated adenocarcinoma
704902|NCT00002538|ovarian mixed epithelial carcinoma
704903|NCT00002538|ovarian serous cystadenocarcinoma
704904|NCT00002538|ovarian mucinous cystadenocarcinoma
704905|NCT00002538|ovarian endometrioid adenocarcinoma
704906|NCT00002538|ovarian clear cell cystadenocarcinoma
704907|NCT00002538|fallopian tube cancer
704908|NCT00002538|primary peritoneal cavity cancer
704909|NCT00002537|recurrent non-small cell lung cancer
704910|NCT00002537|stage IIIA non-small cell lung cancer
704911|NCT00002537|stage IIIB non-small cell lung cancer
704912|NCT00002537|stage IV non-small cell lung cancer
704913|NCT00002536|stage IB cervical cancer
704914|NCT00002535|stage III melanoma
704915|NCT00002535|stage IV melanoma
704916|NCT00002535|recurrent melanoma
704917|NCT00002534|recurrent childhood acute lymphoblastic leukemia
704918|NCT00002534|recurrent childhood acute myeloid leukemia
704919|NCT00002534|recurrent adult acute myeloid leukemia
704920|NCT00002534|recurrent adult acute lymphoblastic leukemia
704921|NCT00002534|adult acute myeloid leukemia in remission
704922|NCT00002534|adult acute lymphoblastic leukemia in remission
704923|NCT00002534|childhood acute myeloid leukemia in remission
704924|NCT00002534|childhood acute lymphoblastic leukemia in remission
704925|NCT00002534|acute undifferentiated leukemia
704926|NCT00002533|untreated metastatic squamous neck cancer with occult primary
704927|NCT00002533|recurrent metastatic squamous neck cancer with occult primary
704928|NCT00002533|metastatic squamous neck cancer with occult primary squamous cell carcinoma
704929|NCT00002533|oral complications
704930|NCT00002533|stage I squamous cell carcinoma of the lip and oral cavity
704931|NCT00002533|stage I basal cell carcinoma of the lip
704932|NCT00002533|stage I verrucous carcinoma of the oral cavity
704933|NCT00002533|stage I mucoepidermoid carcinoma of the oral cavity
704934|NCT00002533|stage I adenoid cystic carcinoma of the oral cavity
704935|NCT00002533|stage II squamous cell carcinoma of the lip and oral cavity
704936|NCT00002533|stage II basal cell carcinoma of the lip
704937|NCT00002533|stage II verrucous carcinoma of the oral cavity
704938|NCT00002533|stage II mucoepidermoid carcinoma of the oral cavity
704939|NCT00002533|stage II adenoid cystic carcinoma of the oral cavity
704940|NCT00002533|stage III squamous cell carcinoma of the lip and oral cavity
704941|NCT00002533|stage III basal cell carcinoma of the lip
704942|NCT00002533|stage III verrucous carcinoma of the oral cavity
704943|NCT00002533|stage III mucoepidermoid carcinoma of the oral cavity
704944|NCT00002533|stage III adenoid cystic carcinoma of the oral cavity
704945|NCT00002533|stage IV squamous cell carcinoma of the lip and oral cavity
704946|NCT00002533|stage IV basal cell carcinoma of the lip
704947|NCT00002533|stage IV verrucous carcinoma of the oral cavity
704948|NCT00002533|stage IV mucoepidermoid carcinoma of the oral cavity
704949|NCT00002533|stage IV adenoid cystic carcinoma of the oral cavity
704950|NCT00002533|recurrent squamous cell carcinoma of the lip and oral cavity
704951|NCT00002533|recurrent basal cell carcinoma of the lip
704952|NCT00002533|recurrent verrucous carcinoma of the oral cavity
704953|NCT00002533|recurrent mucoepidermoid carcinoma of the oral cavity
704954|NCT00002533|recurrent adenoid cystic carcinoma of the oral cavity
704955|NCT00002533|stage I squamous cell carcinoma of the oropharynx
704956|NCT00002533|stage I lymphoepithelioma of the oropharynx
704957|NCT00002533|stage II squamous cell carcinoma of the oropharynx
704958|NCT00002533|stage II lymphoepithelioma of the oropharynx
704959|NCT00002533|stage III squamous cell carcinoma of the oropharynx
706495|NCT00002345|Cachexia
704960|NCT00002533|stage III lymphoepithelioma of the oropharynx
704961|NCT00002533|stage IV squamous cell carcinoma of the oropharynx
704962|NCT00002533|stage IV lymphoepithelioma of the oropharynx
704963|NCT00002533|recurrent squamous cell carcinoma of the oropharynx
704964|NCT00002533|recurrent lymphoepithelioma of the oropharynx
704965|NCT00002533|stage I squamous cell carcinoma of the nasopharynx
704966|NCT00002533|stage I lymphoepithelioma of the nasopharynx
704967|NCT00002533|stage II squamous cell carcinoma of the nasopharynx
704968|NCT00002533|stage II lymphoepithelioma of the nasopharynx
704969|NCT00002533|stage III squamous cell carcinoma of the nasopharynx
704970|NCT00002533|stage III lymphoepithelioma of the nasopharynx
704971|NCT00002533|stage IV squamous cell carcinoma of the nasopharynx
704972|NCT00002533|stage IV lymphoepithelioma of the nasopharynx
704973|NCT00002533|recurrent squamous cell carcinoma of the nasopharynx
704974|NCT00002533|recurrent lymphoepithelioma of the nasopharynx
704975|NCT00002533|stage I squamous cell carcinoma of the hypopharynx
704976|NCT00002533|stage II squamous cell carcinoma of the hypopharynx
704977|NCT00002533|stage III squamous cell carcinoma of the hypopharynx
704978|NCT00002533|stage IV squamous cell carcinoma of the hypopharynx
704979|NCT00002533|recurrent squamous cell carcinoma of the hypopharynx
704980|NCT00002533|stage I squamous cell carcinoma of the larynx
704981|NCT00002533|stage I verrucous carcinoma of the larynx
704982|NCT00002533|stage II squamous cell carcinoma of the larynx
704983|NCT00002533|stage II verrucous carcinoma of the larynx
704984|NCT00002533|stage III squamous cell carcinoma of the larynx
704985|NCT00002533|stage III verrucous carcinoma of the larynx
704986|NCT00002533|stage IV squamous cell carcinoma of the larynx
704987|NCT00002533|stage IV verrucous carcinoma of the larynx
704988|NCT00002533|recurrent squamous cell carcinoma of the larynx
704989|NCT00002533|recurrent verrucous carcinoma of the larynx
704990|NCT00002533|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
704991|NCT00002533|stage I inverted papilloma of the paranasal sinus and nasal cavity
704992|NCT00002533|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
704993|NCT00002533|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
704994|NCT00002533|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
704995|NCT00002533|stage II inverted papilloma of the paranasal sinus and nasal cavity
704996|NCT00002533|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
704997|NCT00002533|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
704998|NCT00002533|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
704999|NCT00002533|stage III inverted papilloma of the paranasal sinus and nasal cavity
705000|NCT00002533|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
705001|NCT00002533|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
705002|NCT00002533|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
705003|NCT00002533|stage IV inverted papilloma of the paranasal sinus and nasal cavity
705004|NCT00002533|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
705005|NCT00002533|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
705006|NCT00002533|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
705007|NCT00002533|recurrent inverted papilloma of the paranasal sinus and nasal cavity
705008|NCT00002533|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
705009|NCT00002533|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
705010|NCT00002533|infection
705011|NCT00002532|recurrent adult acute lymphoblastic leukemia
705012|NCT00002531|untreated adult acute lymphoblastic leukemia
705013|NCT00002531|T-cell adult acute lymphoblastic leukemia
705014|NCT00002531|B-cell adult acute lymphoblastic leukemia
705015|NCT00002531|non-T, non-B adult acute lymphoblastic leukemia
705016|NCT00002529|stage II breast cancer
705017|NCT00002529|stage IIIA breast cancer
705018|NCT00002528|stage I breast cancer
705019|NCT00002528|stage II breast cancer
705020|NCT00002527|colon cancer
705021|NCT00002527|rectal cancer
705022|NCT00002526|stage III adult soft tissue sarcoma
705023|NCT00002526|recurrent adult soft tissue sarcoma
705024|NCT00002526|stage III uterine sarcoma
705025|NCT00002526|stage IV uterine sarcoma
705026|NCT00002526|recurrent uterine sarcoma
705027|NCT00002526|ovarian sarcoma
705028|NCT00002526|stage IV adult soft tissue sarcoma
705029|NCT00002525|stage II colon cancer
705030|NCT00002525|stage III colon cancer
705031|NCT00002524|AIDS-related peripheral/systemic lymphoma
705032|NCT00002524|AIDS-related primary CNS lymphoma
705033|NCT00002524|AIDS-related diffuse large cell lymphoma
705034|NCT00002524|AIDS-related immunoblastic large cell lymphoma
705035|NCT00002524|AIDS-related small noncleaved cell lymphoma
705036|NCT00002524|AIDS-related diffuse mixed cell lymphoma
705037|NCT00002524|AIDS-related diffuse small cleaved cell lymphoma
705038|NCT00002523|stage II rectal cancer
705039|NCT00002523|stage III rectal cancer
705040|NCT00002523|adenocarcinoma of the rectum
705041|NCT00002522|stage I adult Hodgkin lymphoma
705042|NCT00002522|stage II adult Hodgkin lymphoma
705043|NCT00002522|stage III adult Hodgkin lymphoma
705044|NCT00002522|stage IV adult Hodgkin lymphoma
705045|NCT00002522|recurrent adult Hodgkin lymphoma
706496|NCT00002345|Suspensions
705046|NCT00002521|stage I adult diffuse small cleaved cell lymphoma
705047|NCT00002521|stage I adult diffuse mixed cell lymphoma
705048|NCT00002521|stage I adult diffuse large cell lymphoma
705049|NCT00002521|stage I adult immunoblastic large cell lymphoma
705050|NCT00002521|stage I adult lymphoblastic lymphoma
705051|NCT00002521|stage I adult Burkitt lymphoma
705052|NCT00002521|stage III adult diffuse small cleaved cell lymphoma
705053|NCT00002521|stage III adult diffuse mixed cell lymphoma
705054|NCT00002521|stage III adult diffuse large cell lymphoma
705055|NCT00002521|stage III adult immunoblastic large cell lymphoma
705056|NCT00002521|stage III adult lymphoblastic lymphoma
705057|NCT00002521|stage III adult Burkitt lymphoma
705058|NCT00002521|stage IV adult diffuse small cleaved cell lymphoma
705059|NCT00002521|stage IV adult diffuse mixed cell lymphoma
705060|NCT00002521|stage IV adult diffuse large cell lymphoma
705061|NCT00002521|stage IV adult immunoblastic large cell lymphoma
705062|NCT00002521|stage IV adult lymphoblastic lymphoma
705063|NCT00002521|stage IV adult Burkitt lymphoma
705064|NCT00002521|recurrent adult diffuse small cleaved cell lymphoma
705065|NCT00002521|recurrent adult diffuse mixed cell lymphoma
705066|NCT00002521|recurrent adult diffuse large cell lymphoma
705067|NCT00002521|recurrent adult immunoblastic large cell lymphoma
705068|NCT00002521|recurrent adult lymphoblastic lymphoma
705069|NCT00002521|recurrent adult Burkitt lymphoma
705070|NCT00002521|contiguous stage II adult diffuse small cleaved cell lymphoma
705071|NCT00002521|contiguous stage II adult diffuse mixed cell lymphoma
705072|NCT00002521|contiguous stage II adult immunoblastic large cell lymphoma
705073|NCT00002521|contiguous stage II adult diffuse large cell lymphoma
705074|NCT00002521|contiguous stage II adult Burkitt lymphoma
705075|NCT00002521|contiguous stage II adult lymphoblastic lymphoma
705076|NCT00002521|noncontiguous stage II adult diffuse small cleaved cell lymphoma
705077|NCT00002521|noncontiguous stage II adult diffuse mixed cell lymphoma
705078|NCT00002521|noncontiguous stage II adult immunoblastic large cell lymphoma
705079|NCT00002521|noncontiguous stage II adult diffuse large cell lymphoma
705080|NCT00002521|noncontiguous stage II adult Burkitt lymphoma
705081|NCT00002521|noncontiguous stage II adult lymphoblastic lymphoma
705082|NCT00002520|stage I adult Hodgkin lymphoma
705083|NCT00002520|angioimmunoblastic T-cell lymphoma
705084|NCT00002520|stage II adult Hodgkin lymphoma
705085|NCT00002520|stage III adult Hodgkin lymphoma
705086|NCT00002520|stage IV adult Hodgkin lymphoma
705087|NCT00002520|stage I colon cancer
705088|NCT00002520|stage II colon cancer
705089|NCT00002520|stage I breast cancer
705090|NCT00002520|AIDS-related peripheral/systemic lymphoma
705091|NCT00002520|AIDS-related primary CNS lymphoma
705092|NCT00002520|anaplastic large cell lymphoma
705093|NCT00002520|contiguous stage II adult diffuse large cell lymphoma
705094|NCT00002520|contiguous stage II adult diffuse mixed cell lymphoma
705095|NCT00002520|contiguous stage II adult diffuse small cleaved cell lymphoma
705096|NCT00002520|contiguous stage II adult Burkitt lymphoma
705097|NCT00002520|contiguous stage II adult immunoblastic large cell lymphoma
705098|NCT00002520|contiguous stage II adult lymphoblastic lymphoma
705099|NCT00002520|contiguous stage II grade 1 follicular lymphoma
705100|NCT00002520|contiguous stage II grade 2 follicular lymphoma
705101|NCT00002520|contiguous stage II grade 3 follicular lymphoma
705102|NCT00002520|contiguous stage II mantle cell lymphoma
705103|NCT00002520|intraocular lymphoma
705104|NCT00002520|limited stage small cell lung cancer
705105|NCT00002520|noncontiguous stage II adult diffuse large cell lymphoma
705106|NCT00002520|noncontiguous stage II adult diffuse mixed cell lymphoma
705107|NCT00002520|noncontiguous stage II adult diffuse small cleaved cell lymphoma
705108|NCT00002520|noncontiguous stage II adult Burkitt lymphoma
705109|NCT00002520|noncontiguous stage II adult immunoblastic large cell lymphoma
705110|NCT00002520|noncontiguous stage II adult lymphoblastic lymphoma
705111|NCT00002520|noncontiguous stage II grade 1 follicular lymphoma
705112|NCT00002520|noncontiguous stage II grade 2 follicular lymphoma
705113|NCT00002520|noncontiguous stage II grade 3 follicular lymphoma
705114|NCT00002520|noncontiguous stage II mantle cell lymphoma
705115|NCT00002520|primary central nervous system lymphoma
705116|NCT00002520|tobacco use disorder
705117|NCT00002520|stage I adenoid cystic carcinoma of the oral cavity
705118|NCT00002520|stage I adult T-cell leukemia/lymphoma
705119|NCT00002520|stage I adult diffuse large cell lymphoma
705120|NCT00002520|stage I adult diffuse mixed cell lymphoma
705121|NCT00002520|stage I adult diffuse small cleaved cell lymphoma
705122|NCT00002520|stage I adult Burkitt lymphoma
705123|NCT00002520|stage I adult immunoblastic large cell lymphoma
705124|NCT00002520|stage I adult lymphoblastic lymphoma
705125|NCT00002520|stage I basal cell carcinoma of the lip
705126|NCT00002520|stage I cutaneous T-cell non-Hodgkin lymphoma
705127|NCT00002520|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
705128|NCT00002520|stage I grade 1 follicular lymphoma
705129|NCT00002520|stage I grade 2 follicular lymphoma
705130|NCT00002520|stage I grade 3 follicular lymphoma
705131|NCT00002520|stage I inverted papilloma of the paranasal sinus and nasal cavity
705132|NCT00002520|stage I lymphoepithelioma of the nasopharynx
705133|NCT00002520|stage I lymphoepithelioma of the oropharynx
705134|NCT00002520|stage I mantle cell lymphoma
705135|NCT00002520|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
705136|NCT00002520|stage I mucoepidermoid carcinoma of the oral cavity
705137|NCT00002520|stage I mycosis fungoides/Sezary syndrome
705138|NCT00002520|stage I non-small cell lung cancer
705139|NCT00002520|stage I prostate cancer
705140|NCT00002520|stage I rectal cancer
705141|NCT00002520|stage I squamous cell carcinoma of the hypopharynx
705142|NCT00002520|stage I squamous cell carcinoma of the larynx
705143|NCT00002520|stage I squamous cell carcinoma of the lip and oral cavity
705144|NCT00002520|stage I squamous cell carcinoma of the nasopharynx
705145|NCT00002520|stage I squamous cell carcinoma of the oropharynx
705146|NCT00002520|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
705147|NCT00002520|stage I malignant testicular germ cell tumor
705148|NCT00002520|stage I verrucous carcinoma of the larynx
705149|NCT00002520|stage I verrucous carcinoma of the oral cavity
705150|NCT00002520|stage II adult T-cell leukemia/lymphoma
705151|NCT00002520|stage II adenoid cystic carcinoma of the oral cavity
705152|NCT00002520|stage II basal cell carcinoma of the lip
705153|NCT00002520|stage II bladder cancer
705154|NCT00002520|stage II breast cancer
705155|NCT00002520|stage II cutaneous T-cell non-Hodgkin lymphoma
705156|NCT00002520|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
705157|NCT00002520|stage II inverted papilloma of the paranasal sinus and nasal cavity
705158|NCT00002520|stage II lymphoepithelioma of the nasopharynx
705159|NCT00002520|stage II lymphoepithelioma of the oropharynx
705160|NCT00002520|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
705161|NCT00002520|stage II mucoepidermoid carcinoma of the oral cavity
705162|NCT00002520|stage II mycosis fungoides/Sezary syndrome
705163|NCT00002520|stage I bladder cancer
705164|NCT00002520|stage II non-small cell lung cancer
705165|NCT00002520|stage II prostate cancer
705166|NCT00002520|stage II rectal cancer
705167|NCT00002520|stage II squamous cell carcinoma of the hypopharynx
705168|NCT00002520|stage II squamous cell carcinoma of the larynx
705169|NCT00002520|stage II squamous cell carcinoma of the lip and oral cavity
705170|NCT00002520|stage II squamous cell carcinoma of the nasopharynx
705171|NCT00002520|stage II squamous cell carcinoma of the oropharynx
705172|NCT00002520|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
705173|NCT00002520|stage II malignant testicular germ cell tumor
705174|NCT00002520|stage II verrucous carcinoma of the larynx
705175|NCT00002520|stage II verrucous carcinoma of the oral cavity
705176|NCT00002520|stage III adult T-cell leukemia/lymphoma
705177|NCT00002520|stage III adult diffuse large cell lymphoma
705178|NCT00002520|stage III adult diffuse mixed cell lymphoma
705179|NCT00002520|stage III adult diffuse small cleaved cell lymphoma
705180|NCT00002520|stage III adult Burkitt lymphoma
705181|NCT00002520|stage III adult immunoblastic large cell lymphoma
705182|NCT00002520|stage III adult lymphoblastic lymphoma
705183|NCT00002520|stage III cutaneous T-cell non-Hodgkin lymphoma
705184|NCT00002520|stage III grade 1 follicular lymphoma
705185|NCT00002520|stage III grade 2 follicular lymphoma
705186|NCT00002520|stage III grade 3 follicular lymphoma
705187|NCT00002520|stage III mantle cell lymphoma
705188|NCT00002520|stage III mycosis fungoides/Sezary syndrome
705189|NCT00002520|stage III prostate cancer
705190|NCT00002520|stage III malignant testicular germ cell tumor
705191|NCT00002520|stage IIIA breast cancer
705192|NCT00002520|stage IIIB breast cancer
705193|NCT00002520|stage IV adult T-cell leukemia/lymphoma
705194|NCT00002520|stage IV adult diffuse large cell lymphoma
705195|NCT00002520|stage IV adult diffuse mixed cell lymphoma
705196|NCT00002520|stage IV adult diffuse small cleaved cell lymphoma
705197|NCT00002520|stage IV adult Burkitt lymphoma
705198|NCT00002520|stage IV adult immunoblastic large cell lymphoma
705199|NCT00002520|stage IV adult lymphoblastic lymphoma
705200|NCT00002520|stage IV breast cancer
705201|NCT00002520|stage IV cutaneous T-cell non-Hodgkin lymphoma
705202|NCT00002520|stage IV grade 1 follicular lymphoma
705203|NCT00002520|stage IV grade 2 follicular lymphoma
705204|NCT00002520|stage IV grade 3 follicular lymphoma
705205|NCT00002520|stage IV mantle cell lymphoma
705206|NCT00002520|stage IV mycosis fungoides/Sezary syndrome
705207|NCT00002520|stage IV prostate cancer
705208|NCT00002520|unspecified adult solid tumor, protocol specific
705209|NCT00002520|contiguous stage II marginal zone lymphoma
705210|NCT00002520|contiguous stage II small lymphocytic lymphoma
705211|NCT00002520|noncontiguous stage II small lymphocytic lymphoma
705212|NCT00002520|noncontiguous stage II marginal zone lymphoma
705213|NCT00002520|stage I marginal zone lymphoma
705214|NCT00002520|stage I small lymphocytic lymphoma
705215|NCT00002520|stage III small lymphocytic lymphoma
705216|NCT00002520|stage III marginal zone lymphoma
705217|NCT00002520|stage IV small lymphocytic lymphoma
705218|NCT00002520|stage IV marginal zone lymphoma
705219|NCT00002520|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
705220|NCT00002520|nodal marginal zone B-cell lymphoma
705221|NCT00002520|splenic marginal zone lymphoma
705222|NCT00002519|stage IIIA non-small cell lung cancer
705223|NCT00002519|stage IIIB non-small cell lung cancer
705224|NCT00002517|childhood myelodysplastic syndromes
705225|NCT00002517|untreated childhood acute myeloid leukemia and other myeloid malignancies
705226|NCT00002517|childhood acute myeloblastic leukemia without maturation (M1)
705227|NCT00002517|childhood acute myeloblastic leukemia with maturation (M2)
705228|NCT00002517|childhood acute myelomonocytic leukemia (M4)
705229|NCT00002517|childhood acute monoblastic leukemia (M5a)
705230|NCT00002517|childhood acute monocytic leukemia (M5b)
705231|NCT00002517|childhood acute erythroleukemia (M6)
705232|NCT00002517|childhood acute megakaryocytic leukemia (M7)
705233|NCT00002517|refractory anemia with excess blasts
705234|NCT00002517|refractory anemia with excess blasts in transformation
705235|NCT00002517|chronic myelomonocytic leukemia
705236|NCT00002517|de novo myelodysplastic syndromes
705237|NCT00002517|childhood acute minimally differentiated myeloid leukemia (M0)
705238|NCT00002516|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
705239|NCT00002516|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
705240|NCT00002515|chondrosarcoma
705241|NCT00002515|recurrent childhood rhabdomyosarcoma
705242|NCT00002515|stage IV childhood liver cancer
705243|NCT00002515|recurrent neuroblastoma
705244|NCT00002515|recurrent childhood liver cancer
705245|NCT00002515|recurrent Wilms tumor and other childhood kidney tumors
705246|NCT00002515|stage IV Wilms tumor
705247|NCT00002515|recurrent retinoblastoma
705248|NCT00002515|stage IV childhood lymphoblastic lymphoma
705249|NCT00002515|recurrent childhood lymphoblastic lymphoma
705250|NCT00002515|recurrent osteosarcoma
705251|NCT00002515|stage IV ovarian germ cell tumor
705252|NCT00002515|recurrent malignant testicular germ cell tumor
705253|NCT00002515|childhood germ cell tumor
705254|NCT00002515|alveolar childhood rhabdomyosarcoma
705255|NCT00002515|recurrent childhood soft tissue sarcoma
705256|NCT00002515|recurrent ovarian germ cell tumor
705257|NCT00002515|childhood fibrosarcoma
705258|NCT00002515|extragonadal germ cell tumor
705259|NCT00002515|childhood desmoplastic small round cell tumor
705260|NCT00002515|recurrent childhood small noncleaved cell lymphoma
705261|NCT00002515|stage IV childhood small noncleaved cell lymphoma
705262|NCT00002515|recurrent childhood large cell lymphoma
705263|NCT00002515|stage IV childhood large cell lymphoma
705264|NCT00002515|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
705265|NCT00002515|stage IV lymphoepithelioma of the nasopharynx
705266|NCT00002515|stage IV squamous cell carcinoma of the nasopharynx
705267|NCT00002515|recurrent squamous cell carcinoma of the nasopharynx
705268|NCT00002515|recurrent lymphoepithelioma of the nasopharynx
705269|NCT00002514|adult acute lymphoblastic leukemia in remission
705270|NCT00002511|adenocarcinoma of the prostate
705271|NCT00002511|stage I prostate cancer
705272|NCT00002511|stage IIB prostate cancer
705273|NCT00002511|stage IIA prostate cancer
705274|NCT00002511|stage III prostate cancer
705275|NCT00002510|Waldenstrom macroglobulinemia
705276|NCT00002510|recurrent small lymphocytic lymphoma
705277|NCT00002510|recurrent grade 1 follicular lymphoma
705278|NCT00002510|recurrent grade 2 follicular lymphoma
705279|NCT00002510|recurrent grade 3 follicular lymphoma
705280|NCT00002509|stage II breast cancer
705281|NCT00002509|stage IV breast cancer
705282|NCT00002509|stage IIIA breast cancer
705283|NCT00002509|recurrent breast cancer
705284|NCT00002509|stage IIIB breast cancer
705285|NCT00002508|recurrent malignant testicular germ cell tumor
705286|NCT00002508|recurrent ovarian germ cell tumor
705287|NCT00002508|extragonadal germ cell tumor
705288|NCT00002507|stage I squamous cell carcinoma of the lip and oral cavity
705289|NCT00002507|stage I adenoid cystic carcinoma of the oral cavity
705290|NCT00002507|stage II squamous cell carcinoma of the lip and oral cavity
705291|NCT00002507|stage II adenoid cystic carcinoma of the oral cavity
705292|NCT00002507|stage III squamous cell carcinoma of the lip and oral cavity
705293|NCT00002507|stage III adenoid cystic carcinoma of the oral cavity
705294|NCT00002507|stage IV squamous cell carcinoma of the lip and oral cavity
705295|NCT00002507|stage IV adenoid cystic carcinoma of the oral cavity
705296|NCT00002507|recurrent squamous cell carcinoma of the lip and oral cavity
705297|NCT00002507|recurrent adenoid cystic carcinoma of the oral cavity
705298|NCT00002507|stage I squamous cell carcinoma of the oropharynx
705299|NCT00002507|stage I lymphoepithelioma of the oropharynx
705300|NCT00002507|stage II squamous cell carcinoma of the oropharynx
705301|NCT00002507|stage II lymphoepithelioma of the oropharynx
705302|NCT00002507|stage III squamous cell carcinoma of the oropharynx
705303|NCT00002507|stage III lymphoepithelioma of the oropharynx
705304|NCT00002507|stage IV squamous cell carcinoma of the oropharynx
705305|NCT00002507|stage IV lymphoepithelioma of the oropharynx
705306|NCT00002507|recurrent squamous cell carcinoma of the oropharynx
705307|NCT00002507|recurrent lymphoepithelioma of the oropharynx
705308|NCT00002507|stage I squamous cell carcinoma of the nasopharynx
705309|NCT00002507|stage I lymphoepithelioma of the nasopharynx
705310|NCT00002507|stage II squamous cell carcinoma of the nasopharynx
705311|NCT00002507|stage II lymphoepithelioma of the nasopharynx
705312|NCT00002507|stage III squamous cell carcinoma of the nasopharynx
705313|NCT00002507|stage III lymphoepithelioma of the nasopharynx
706497|NCT00002344|Azithromycin
705314|NCT00002507|stage IV squamous cell carcinoma of the nasopharynx
705315|NCT00002507|stage IV lymphoepithelioma of the nasopharynx
705316|NCT00002507|recurrent squamous cell carcinoma of the nasopharynx
705317|NCT00002507|recurrent lymphoepithelioma of the nasopharynx
705318|NCT00002507|stage I squamous cell carcinoma of the hypopharynx
705319|NCT00002507|stage II squamous cell carcinoma of the hypopharynx
705320|NCT00002507|stage III squamous cell carcinoma of the hypopharynx
705321|NCT00002507|stage IV squamous cell carcinoma of the hypopharynx
705322|NCT00002507|recurrent squamous cell carcinoma of the hypopharynx
705323|NCT00002507|stage I squamous cell carcinoma of the larynx
705324|NCT00002507|stage II squamous cell carcinoma of the larynx
705325|NCT00002507|stage III squamous cell carcinoma of the larynx
705326|NCT00002507|stage IV squamous cell carcinoma of the larynx
705327|NCT00002507|recurrent squamous cell carcinoma of the larynx
705328|NCT00002507|newly diagnosed carcinoma of unknown primary
705329|NCT00002507|recurrent carcinoma of unknown primary
705330|NCT00002506|recurrent non-small cell lung cancer
705331|NCT00002506|recurrent esophageal cancer
705332|NCT00002506|recurrent cervical cancer
705333|NCT00002506|squamous cell lung cancer
705334|NCT00002506|squamous cell carcinoma of the skin
705335|NCT00002506|recurrent penile cancer
705336|NCT00002506|recurrent skin cancer
705337|NCT00002506|squamous cell carcinoma of the esophagus
705338|NCT00002506|cervical squamous cell carcinoma
705339|NCT00002506|penile squamous cell carcinoma
705340|NCT00002506|recurrent squamous cell carcinoma of the lip and oral cavity
705341|NCT00002506|recurrent squamous cell carcinoma of the oropharynx
705342|NCT00002506|recurrent squamous cell carcinoma of the nasopharynx
705343|NCT00002506|recurrent squamous cell carcinoma of the hypopharynx
705344|NCT00002506|recurrent squamous cell carcinoma of the larynx
705345|NCT00002506|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
705346|NCT00002505|unspecified adult solid tumor, protocol specific
705347|NCT00002504|stage IV adult Hodgkin lymphoma
705348|NCT00002504|monoclonal gammopathy of undetermined significance
705349|NCT00002504|recurrent adult Hodgkin lymphoma
705350|NCT00002504|isolated plasmacytoma of bone
705351|NCT00002504|extramedullary plasmacytoma
705352|NCT00002504|refractory multiple myeloma
705353|NCT00002504|Waldenstrom macroglobulinemia
705354|NCT00002504|stage IV chronic lymphocytic leukemia
705355|NCT00002504|recurrent adult acute myeloid leukemia
705356|NCT00002504|recurrent adult acute lymphoblastic leukemia
705357|NCT00002504|relapsing chronic myelogenous leukemia
705358|NCT00002504|refractory chronic lymphocytic leukemia
705359|NCT00002504|unspecified adult solid tumor, protocol specific
705360|NCT00002504|chronic phase chronic myelogenous leukemia
705361|NCT00002504|accelerated phase chronic myelogenous leukemia
705362|NCT00002504|blastic phase chronic myelogenous leukemia
705363|NCT00002504|meningeal chronic myelogenous leukemia
705364|NCT00002504|untreated adult acute lymphoblastic leukemia
705365|NCT00002504|untreated adult acute myeloid leukemia
705366|NCT00002504|adult acute myeloid leukemia in remission
705367|NCT00002504|adult acute lymphoblastic leukemia in remission
705368|NCT00002504|polycythemia vera
705369|NCT00002504|chronic idiopathic myelofibrosis
705370|NCT00002504|essential thrombocythemia
705371|NCT00002504|untreated hairy cell leukemia
705372|NCT00002504|progressive hairy cell leukemia, initial treatment
705373|NCT00002504|refractory hairy cell leukemia
705374|NCT00002504|chronic myelomonocytic leukemia
705375|NCT00002504|T-cell large granular lymphocyte leukemia
705376|NCT00002504|acute undifferentiated leukemia
705377|NCT00002504|stage IV grade 1 follicular lymphoma
705378|NCT00002504|stage IV grade 2 follicular lymphoma
705379|NCT00002504|stage IV grade 3 follicular lymphoma
705380|NCT00002504|stage IV adult diffuse small cleaved cell lymphoma
705381|NCT00002504|stage IV adult diffuse mixed cell lymphoma
705382|NCT00002504|stage IV adult diffuse large cell lymphoma
705383|NCT00002504|stage IV adult immunoblastic large cell lymphoma
705384|NCT00002504|stage IV adult lymphoblastic lymphoma
705385|NCT00002504|stage IV adult Burkitt lymphoma
705386|NCT00002504|recurrent grade 1 follicular lymphoma
705387|NCT00002504|recurrent grade 2 follicular lymphoma
705388|NCT00002504|recurrent grade 3 follicular lymphoma
705389|NCT00002504|recurrent adult diffuse small cleaved cell lymphoma
705390|NCT00002504|recurrent adult diffuse mixed cell lymphoma
705391|NCT00002504|recurrent adult diffuse large cell lymphoma
705392|NCT00002504|recurrent adult immunoblastic large cell lymphoma
705393|NCT00002504|recurrent adult lymphoblastic lymphoma
705394|NCT00002504|recurrent adult Burkitt lymphoma
705395|NCT00002504|stage IV adult T-cell leukemia/lymphoma
705396|NCT00002504|recurrent adult T-cell leukemia/lymphoma
705397|NCT00002504|secondary acute myeloid leukemia
705398|NCT00002504|de novo myelodysplastic syndromes
705399|NCT00002504|previously treated myelodysplastic syndromes
705400|NCT00002504|secondary myelodysplastic syndromes
705401|NCT00002504|prolymphocytic leukemia
705402|NCT00002504|primary systemic amyloidosis
705403|NCT00002504|stage IV mantle cell lymphoma
705404|NCT00002504|recurrent mantle cell lymphoma
705405|NCT00002504|angioimmunoblastic T-cell lymphoma
705406|NCT00002504|anaplastic large cell lymphoma
705407|NCT00002504|recurrent marginal zone lymphoma
705408|NCT00002504|recurrent small lymphocytic lymphoma
705409|NCT00002504|stage IV small lymphocytic lymphoma
705410|NCT00002504|stage IV marginal zone lymphoma
705411|NCT00002504|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
705412|NCT00002504|nodal marginal zone B-cell lymphoma
705413|NCT00002504|splenic marginal zone lymphoma
705414|NCT00002503|recurrent prostate cancer
705415|NCT00002503|bone metastases
705416|NCT00002502|stage I adult Hodgkin lymphoma
705417|NCT00002502|stage II adult Hodgkin lymphoma
705418|NCT00002502|stage III adult Hodgkin lymphoma
705419|NCT00002502|stage IV adult Hodgkin lymphoma
705420|NCT00002502|recurrent childhood acute lymphoblastic leukemia
705421|NCT00002502|recurrent adult Hodgkin lymphoma
705422|NCT00002502|stage I cutaneous T-cell non-Hodgkin lymphoma
705423|NCT00002502|stage II cutaneous T-cell non-Hodgkin lymphoma
705424|NCT00002502|stage III cutaneous T-cell non-Hodgkin lymphoma
705425|NCT00002502|stage IV cutaneous T-cell non-Hodgkin lymphoma
705426|NCT00002502|recurrent cutaneous T-cell non-Hodgkin lymphoma
705427|NCT00002502|childhood Burkitt lymphoma
705428|NCT00002502|refractory multiple myeloma
705429|NCT00002502|Waldenström macroglobulinemia
705430|NCT00002502|stage I multiple myeloma
705431|NCT00002502|stage II multiple myeloma
705432|NCT00002502|stage III multiple myeloma
705433|NCT00002502|stage I childhood lymphoblastic lymphoma
705434|NCT00002502|stage II childhood lymphoblastic lymphoma
705435|NCT00002502|stage III childhood lymphoblastic lymphoma
705436|NCT00002502|stage IV childhood lymphoblastic lymphoma
705437|NCT00002502|recurrent childhood lymphoblastic lymphoma
705438|NCT00002502|recurrent childhood acute myeloid leukemia
705439|NCT00002502|recurrent adult acute myeloid leukemia
705440|NCT00002502|recurrent adult acute lymphoblastic leukemia
705441|NCT00002502|childhood diffuse large cell lymphoma
705442|NCT00002502|childhood immunoblastic large cell lymphoma
705443|NCT00002502|chronic phase chronic myelogenous leukemia
705444|NCT00002502|accelerated phase chronic myelogenous leukemia
705445|NCT00002502|blastic phase chronic myelogenous leukemia
705446|NCT00002502|adult acute myeloid leukemia in remission
705447|NCT00002502|adult acute lymphoblastic leukemia in remission
705448|NCT00002502|childhood acute myeloid leukemia in remission
705449|NCT00002502|childhood acute lymphoblastic leukemia in remission
705450|NCT00002502|stage II childhood Hodgkin lymphoma
705451|NCT00002502|stage I childhood Hodgkin lymphoma
705452|NCT00002502|stage III childhood Hodgkin lymphoma
705453|NCT00002502|stage IV childhood Hodgkin lymphoma
705454|NCT00002502|recurrent/refractory childhood Hodgkin lymphoma
705455|NCT00002502|stage I grade 1 follicular lymphoma
705456|NCT00002502|stage I grade 2 follicular lymphoma
705457|NCT00002502|stage I grade 3 follicular lymphoma
705458|NCT00002502|stage I adult diffuse small cleaved cell lymphoma
705459|NCT00002502|stage I adult diffuse mixed cell lymphoma
705460|NCT00002502|stage I adult diffuse large cell lymphoma
705461|NCT00002502|stage I adult immunoblastic large cell lymphoma
705462|NCT00002502|stage I adult lymphoblastic lymphoma
705463|NCT00002502|stage I adult Burkitt lymphoma
705464|NCT00002502|refractory anemia
705465|NCT00002502|refractory anemia with ringed sideroblasts
705466|NCT00002502|refractory anemia with excess blasts
705467|NCT00002502|chronic myelomonocytic leukemia
705468|NCT00002502|stage III grade 1 follicular lymphoma
705469|NCT00002502|stage III grade 2 follicular lymphoma
705470|NCT00002502|stage III grade 3 follicular lymphoma
705471|NCT00002502|stage III adult diffuse small cleaved cell lymphoma
705472|NCT00002502|stage III adult diffuse mixed cell lymphoma
705473|NCT00002502|stage III adult diffuse large cell lymphoma
705474|NCT00002502|stage III adult immunoblastic large cell lymphoma
705475|NCT00002502|stage III adult lymphoblastic lymphoma
705476|NCT00002502|stage III adult Burkitt lymphoma
705477|NCT00002502|stage IV grade 1 follicular lymphoma
705478|NCT00002502|stage IV grade 2 follicular lymphoma
705479|NCT00002502|stage IV grade 3 follicular lymphoma
705480|NCT00002502|stage IV adult diffuse small cleaved cell lymphoma
705481|NCT00002502|stage IV adult diffuse mixed cell lymphoma
705482|NCT00002502|stage IV adult diffuse large cell lymphoma
705483|NCT00002502|stage IV adult immunoblastic large cell lymphoma
705484|NCT00002502|stage IV adult lymphoblastic lymphoma
705485|NCT00002502|stage IV adult Burkitt lymphoma
705486|NCT00002502|recurrent grade 1 follicular lymphoma
705487|NCT00002502|recurrent grade 2 follicular lymphoma
705488|NCT00002502|recurrent grade 3 follicular lymphoma
705489|NCT00002502|recurrent adult diffuse small cleaved cell lymphoma
705490|NCT00002502|recurrent adult diffuse mixed cell lymphoma
705491|NCT00002502|recurrent adult diffuse large cell lymphoma
705492|NCT00002502|recurrent adult immunoblastic large cell lymphoma
705493|NCT00002502|recurrent adult lymphoblastic lymphoma
705494|NCT00002502|recurrent adult Burkitt lymphoma
705495|NCT00002502|secondary acute myeloid leukemia
705496|NCT00002502|de novo myelodysplastic syndromes
705497|NCT00002502|previously treated myelodysplastic syndromes
705498|NCT00002502|secondary myelodysplastic syndromes
705499|NCT00002502|intraocular lymphoma
705500|NCT00002502|stage I childhood small noncleaved cell lymphoma
705501|NCT00002502|stage I childhood large cell lymphoma
705502|NCT00002502|stage II childhood small noncleaved cell lymphoma
705503|NCT00002502|stage II childhood large cell lymphoma
705504|NCT00002502|stage III childhood small noncleaved cell lymphoma
705505|NCT00002502|stage III childhood large cell lymphoma
705506|NCT00002502|stage IV childhood small noncleaved cell lymphoma
705507|NCT00002502|stage IV childhood large cell lymphoma
705508|NCT00002502|recurrent childhood small noncleaved cell lymphoma
705509|NCT00002502|recurrent childhood large cell lymphoma
705510|NCT00002502|stage I mantle cell lymphoma
705511|NCT00002502|contiguous stage II grade 1 follicular lymphoma
705512|NCT00002502|contiguous stage II grade 2 follicular lymphoma
705513|NCT00002502|contiguous stage II grade 3 follicular lymphoma
705514|NCT00002502|contiguous stage II adult diffuse small cleaved cell lymphoma
705515|NCT00002502|contiguous stage II mantle cell lymphoma
705516|NCT00002502|contiguous stage II adult diffuse mixed cell lymphoma
705517|NCT00002502|contiguous stage II adult immunoblastic large cell lymphoma
705518|NCT00002502|contiguous stage II adult diffuse large cell lymphoma
705519|NCT00002502|contiguous stage II adult Burkitt lymphoma
705520|NCT00002502|contiguous stage II adult lymphoblastic lymphoma
705521|NCT00002502|noncontiguous stage II grade 1 follicular lymphoma
705522|NCT00002502|noncontiguous stage II grade 2 follicular lymphoma
705523|NCT00002502|noncontiguous stage II grade 3 follicular lymphoma
705524|NCT00002502|noncontiguous stage II adult diffuse small cleaved cell lymphoma
705525|NCT00002502|noncontiguous stage II mantle cell lymphoma
705526|NCT00002502|noncontiguous stage II adult diffuse mixed cell lymphoma
705527|NCT00002502|noncontiguous stage II adult immunoblastic large cell lymphoma
705528|NCT00002502|noncontiguous stage II adult diffuse large cell lymphoma
705529|NCT00002502|noncontiguous stage II adult Burkitt lymphoma
705530|NCT00002502|noncontiguous stage II adult lymphoblastic lymphoma
705531|NCT00002502|stage III mantle cell lymphoma
705532|NCT00002502|stage IV mantle cell lymphoma
705533|NCT00002502|recurrent mantle cell lymphoma
705534|NCT00002502|angioimmunoblastic T-cell lymphoma
705535|NCT00002502|anaplastic large cell lymphoma
705536|NCT00002502|noncontiguous stage II small lymphocytic lymphoma
705537|NCT00002502|noncontiguous stage II marginal zone lymphoma
705538|NCT00002502|recurrent marginal zone lymphoma
705539|NCT00002502|recurrent small lymphocytic lymphoma
705540|NCT00002502|stage I marginal zone lymphoma
705541|NCT00002502|stage I small lymphocytic lymphoma
705542|NCT00002502|stage III small lymphocytic lymphoma
705543|NCT00002502|stage III marginal zone lymphoma
705544|NCT00002502|stage IV small lymphocytic lymphoma
705545|NCT00002502|stage IV marginal zone lymphoma
705546|NCT00002502|contiguous stage II marginal zone lymphoma
705547|NCT00002502|contiguous stage II small lymphocytic lymphoma
705548|NCT00002502|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
705549|NCT00002502|nodal marginal zone B-cell lymphoma
705550|NCT00002502|splenic marginal zone lymphoma
705551|NCT00002502|childhood myelodysplastic syndromes
705552|NCT00002501|stage IV grade 1 follicular lymphoma
705553|NCT00002501|stage IV grade 2 follicular lymphoma
705554|NCT00002501|recurrent grade 1 follicular lymphoma
705555|NCT00002501|recurrent grade 2 follicular lymphoma
705556|NCT00002499|recurrent childhood acute lymphoblastic leukemia
705557|NCT00002498|stage IV breast cancer
705558|NCT00002498|recurrent breast cancer
705559|NCT00002496|stage III squamous cell carcinoma of the larynx
705560|NCT00002496|stage IV squamous cell carcinoma of the larynx
705561|NCT00002495|stage I adult Hodgkin lymphoma
705562|NCT00002495|stage II adult Hodgkin lymphoma
705563|NCT00002494|untreated adult acute lymphoblastic leukemia
705564|NCT00002494|L3 adult acute lymphoblastic leukemia
705565|NCT00002494|stage I adult Burkitt lymphoma
705566|NCT00002494|stage II adult Burkitt lymphoma
705567|NCT00002494|stage III adult Burkitt lymphoma
705568|NCT00002494|stage IV adult Burkitt lymphoma
705569|NCT00002494|contiguous stage II adult Burkitt lymphoma
705570|NCT00002494|noncontiguous stage II adult Burkitt lymphoma
705571|NCT00002493|stage III endometrial carcinoma
705572|NCT00002493|stage IV endometrial carcinoma
705573|NCT00002493|endometrial adenocarcinoma
705574|NCT00002493|endometrial adenosquamous cell carcinoma
705575|NCT00002493|endometrial adenoacanthoma
705576|NCT00002493|endometrial papillary serous carcinoma
705577|NCT00002493|endometrial clear cell carcinoma
705578|NCT00002493|psychosocial effects of cancer and its treatment
705579|NCT00002492|stage I adult soft tissue sarcoma
705580|NCT00002492|stage II adult soft tissue sarcoma
705581|NCT00002492|stage III adult soft tissue sarcoma
705582|NCT00002490|stage I bladder cancer
705583|NCT00002490|transitional cell carcinoma of the bladder
705584|NCT00002489|stage II ovarian germ cell tumor
705585|NCT00002489|stage III ovarian germ cell tumor
705586|NCT00002489|stage IV ovarian germ cell tumor
705587|NCT00002489|ovarian teratoma
705588|NCT00002489|extragonadal germ cell tumor
705589|NCT00002488|recurrent grade 3 follicular lymphoma
705590|NCT00002488|recurrent adult diffuse small cleaved cell lymphoma
705591|NCT00002488|recurrent adult diffuse mixed cell lymphoma
705592|NCT00002488|recurrent adult diffuse large cell lymphoma
705593|NCT00002488|recurrent adult immunoblastic large cell lymphoma
705594|NCT00002488|recurrent adult lymphoblastic lymphoma
705595|NCT00002488|recurrent adult Burkitt lymphoma
705596|NCT00002487|recurrent ovarian epithelial cancer
705597|NCT00002485|localized osteosarcoma
705598|NCT00002485|metastatic osteosarcoma
705599|NCT00002485|recurrent childhood acute lymphoblastic leukemia
705600|NCT00002485|childhood infratentorial ependymoma
705601|NCT00002485|childhood low-grade cerebral astrocytoma
705602|NCT00002485|childhood supratentorial ependymoma
705603|NCT00002485|childhood craniopharyngioma
705604|NCT00002485|localized resectable neuroblastoma
705605|NCT00002485|regional neuroblastoma
705606|NCT00002485|disseminated neuroblastoma
705607|NCT00002485|stage 4S neuroblastoma
705608|NCT00002485|recurrent neuroblastoma
705609|NCT00002485|stage I childhood liver cancer
705610|NCT00002485|stage II childhood liver cancer
705611|NCT00002485|stage III childhood liver cancer
705612|NCT00002485|stage IV childhood liver cancer
705613|NCT00002485|recurrent childhood liver cancer
705614|NCT00002485|childhood hepatoblastoma
705615|NCT00002485|stage I childhood lymphoblastic lymphoma
705616|NCT00002485|stage II childhood lymphoblastic lymphoma
705617|NCT00002485|stage III childhood lymphoblastic lymphoma
705618|NCT00002485|stage IV childhood lymphoblastic lymphoma
705619|NCT00002485|recurrent childhood lymphoblastic lymphoma
705620|NCT00002485|childhood central nervous system germ cell tumor
705621|NCT00002485|recurrent childhood acute myeloid leukemia
705622|NCT00002485|recurrent osteosarcoma
705623|NCT00002485|unspecified childhood solid tumor, protocol specific
705624|NCT00002485|childhood germ cell tumor
705625|NCT00002485|untreated childhood acute myeloid leukemia and other myeloid malignancies
705626|NCT00002485|untreated childhood acute lymphoblastic leukemia
705627|NCT00002485|childhood acute myeloid leukemia in remission
705628|NCT00002485|childhood acute lymphoblastic leukemia in remission
705629|NCT00002485|stage II childhood Hodgkin lymphoma
705630|NCT00002485|stage I childhood Hodgkin lymphoma
705631|NCT00002485|stage III childhood Hodgkin lymphoma
705632|NCT00002485|stage IV childhood Hodgkin lymphoma
705633|NCT00002485|recurrent/refractory childhood Hodgkin lymphoma
705634|NCT00002485|nonmetastatic childhood soft tissue sarcoma
705635|NCT00002485|metastatic childhood soft tissue sarcoma
705636|NCT00002485|recurrent childhood soft tissue sarcoma
705637|NCT00002485|extragonadal germ cell tumor
705638|NCT00002485|childhood high-grade cerebral astrocytoma
705639|NCT00002485|childhood oligodendroglioma
705640|NCT00002485|childhood choroid plexus tumor
705641|NCT00002485|childhood meningioma
705642|NCT00002485|localized unresectable neuroblastoma
705643|NCT00002485|psychosocial effects of cancer and its treatment
705644|NCT00002485|stage I childhood small noncleaved cell lymphoma
705645|NCT00002485|stage I childhood large cell lymphoma
705646|NCT00002485|stage II childhood small noncleaved cell lymphoma
705647|NCT00002485|stage II childhood large cell lymphoma
705648|NCT00002485|stage III childhood small noncleaved cell lymphoma
705649|NCT00002485|stage III childhood large cell lymphoma
705650|NCT00002485|stage IV childhood small noncleaved cell lymphoma
705651|NCT00002485|stage IV childhood large cell lymphoma
705652|NCT00002485|recurrent childhood small noncleaved cell lymphoma
705653|NCT00002485|recurrent childhood large cell lymphoma
705654|NCT00002485|untreated childhood brain stem glioma
705655|NCT00002485|recurrent childhood brain stem glioma
705656|NCT00002485|untreated childhood supratentorial primitive neuroectodermal tumor
705657|NCT00002485|recurrent childhood supratentorial primitive neuroectodermal tumor
705658|NCT00002485|untreated childhood cerebellar astrocytoma
705659|NCT00002485|recurrent childhood cerebellar astrocytoma
705660|NCT00002485|recurrent childhood cerebral astrocytoma
705661|NCT00002485|untreated childhood medulloblastoma
705662|NCT00002485|recurrent childhood medulloblastoma
705663|NCT00002485|untreated childhood visual pathway and hypothalamic glioma
705664|NCT00002485|recurrent childhood visual pathway and hypothalamic glioma
705665|NCT00002485|newly diagnosed childhood ependymoma
705666|NCT00002485|recurrent childhood ependymoma
705667|NCT00002485|childhood teratoma
705668|NCT00002485|childhood malignant testicular germ cell tumor
705669|NCT00002485|childhood malignant ovarian germ cell tumor
705670|NCT00002485|childhood extragonadal germ cell tumor
705671|NCT00002485|recurrent childhood malignant germ cell tumor
705672|NCT00002485|childhood atypical teratoid/rhabdoid tumor
705673|NCT00002484|stage I non-small cell lung cancer
705674|NCT00002484|stage II non-small cell lung cancer
705675|NCT00002484|stage IIIA non-small cell lung cancer
705676|NCT00002484|stage IIIB non-small cell lung cancer
705677|NCT00002482|unspecified adult solid tumor, protocol specific
705678|NCT00002481|recurrent grade 1 follicular lymphoma
705679|NCT00002481|recurrent grade 2 follicular lymphoma
705680|NCT00002481|recurrent grade 3 follicular lymphoma
705681|NCT00002481|recurrent adult diffuse small cleaved cell lymphoma
705682|NCT00002481|recurrent adult diffuse mixed cell lymphoma
705683|NCT00002481|recurrent adult diffuse large cell lymphoma
705684|NCT00002481|recurrent adult immunoblastic large cell lymphoma
705685|NCT00002481|recurrent adult lymphoblastic lymphoma
705686|NCT00002481|recurrent adult Burkitt lymphoma
705687|NCT00002481|recurrent mantle cell lymphoma
705688|NCT00002481|recurrent marginal zone lymphoma
705689|NCT00002481|recurrent small lymphocytic lymphoma
705690|NCT00002481|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
705691|NCT00002481|nodal marginal zone B-cell lymphoma
705692|NCT00002481|splenic marginal zone lymphoma
705693|NCT00002480|adenocarcinoma of the prostate
705694|NCT00002480|stage IIB prostate cancer
705695|NCT00002480|stage IIA prostate cancer
705696|NCT00002480|stage III prostate cancer
705697|NCT00002479|stage I cutaneous T-cell non-Hodgkin lymphoma
705698|NCT00002479|stage II cutaneous T-cell non-Hodgkin lymphoma
705699|NCT00002479|stage III cutaneous T-cell non-Hodgkin lymphoma
705700|NCT00002479|stage IV cutaneous T-cell non-Hodgkin lymphoma
705701|NCT00002478|recurrent cervical cancer
705702|NCT00002478|recurrent ovarian epithelial cancer
705703|NCT00002477|stage I ovarian epithelial cancer
705704|NCT00002477|stage II ovarian epithelial cancer
705705|NCT00002476|stage II squamous cell carcinoma of the lip and oral cavity
705706|NCT00002476|stage II verrucous carcinoma of the oral cavity
705707|NCT00002476|stage III squamous cell carcinoma of the lip and oral cavity
705708|NCT00002476|stage III verrucous carcinoma of the oral cavity
705709|NCT00002476|stage IV squamous cell carcinoma of the lip and oral cavity
705710|NCT00002476|stage IV verrucous carcinoma of the oral cavity
705711|NCT00002476|stage II squamous cell carcinoma of the oropharynx
705712|NCT00002476|stage III squamous cell carcinoma of the oropharynx
705713|NCT00002476|stage IV squamous cell carcinoma of the oropharynx
705714|NCT00002476|stage II squamous cell carcinoma of the nasopharynx
705715|NCT00002476|stage III squamous cell carcinoma of the nasopharynx
705716|NCT00002476|stage IV squamous cell carcinoma of the nasopharynx
705717|NCT00002476|stage II squamous cell carcinoma of the hypopharynx
705718|NCT00002476|stage III squamous cell carcinoma of the hypopharynx
705719|NCT00002476|stage IV squamous cell carcinoma of the hypopharynx
705720|NCT00002476|stage II squamous cell carcinoma of the larynx
705721|NCT00002476|stage II verrucous carcinoma of the larynx
705722|NCT00002476|stage III squamous cell carcinoma of the larynx
705723|NCT00002476|stage III verrucous carcinoma of the larynx
705724|NCT00002476|stage IV squamous cell carcinoma of the larynx
705725|NCT00002476|stage IV verrucous carcinoma of the larynx
705726|NCT00002476|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
705727|NCT00002476|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
705728|NCT00002476|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
705729|NCT00002475|stage III colon cancer
705730|NCT00002475|stage IV colon cancer
705731|NCT00002475|stage IV breast cancer
705732|NCT00002475|stage IIIA breast cancer
705733|NCT00002475|recurrent breast cancer
705734|NCT00002475|stage IIIB breast cancer
705735|NCT00002475|recurrent non-small cell lung cancer
705736|NCT00002475|stage II pancreatic cancer
705737|NCT00002475|stage III pancreatic cancer
705738|NCT00002475|recurrent pancreatic cancer
705739|NCT00002475|recurrent colon cancer
705740|NCT00002475|stage III renal cell cancer
705741|NCT00002475|stage IV renal cell cancer
705742|NCT00002475|recurrent renal cell cancer
705743|NCT00002475|extensive stage small cell lung cancer
705744|NCT00002475|recurrent small cell lung cancer
705745|NCT00002475|stage IIIA non-small cell lung cancer
705746|NCT00002475|stage IIIB non-small cell lung cancer
705747|NCT00002475|stage IIIC breast cancer
705748|NCT00002475|stage IV non-small cell lung cancer
705749|NCT00002475|pulmonary carcinoid tumor
705750|NCT00002475|recurrent malignant mesothelioma
705751|NCT00002475|stage IV pancreatic cancer
705752|NCT00002474|recurrent ovarian epithelial cancer
705753|NCT00002473|stage I renal cell cancer
705754|NCT00002473|stage II renal cell cancer
705755|NCT00002472|childhood central nervous system germ cell tumor
705756|NCT00002472|extragonadal germ cell tumor
705757|NCT00002472|adult central nervous system germ cell tumor
705758|NCT00002472|childhood teratoma
705759|NCT00002472|childhood central nervous system choriocarcinoma
705760|NCT00002472|childhood central nervous system embryonal tumor
705761|NCT00002472|childhood central nervous system germinoma
705762|NCT00002472|childhood central nervous system mixed germ cell tumor
705763|NCT00002472|childhood central nervous system teratoma
705764|NCT00002472|childhood central nervous system yolk sac tumor
705765|NCT00002471|childhood Burkitt lymphoma
705766|NCT00002471|L3 childhood acute lymphoblastic leukemia
705767|NCT00002471|B-cell childhood acute lymphoblastic leukemia
705768|NCT00002471|L3 adult acute lymphoblastic leukemia
705769|NCT00002471|B-cell adult acute lymphoblastic leukemia
705770|NCT00002471|recurrent adult non-Hodgkin lymphoma
705771|NCT00002471|stage III adult diffuse large cell lymphoma
705772|NCT00002471|stage III adult immunoblastic large cell lymphoma
705773|NCT00002471|stage III adult Burkitt lymphoma
705774|NCT00002471|stage IV grade 3 follicular lymphoma
705775|NCT00002471|stage IV adult diffuse large cell lymphoma
705776|NCT00002471|stage IV adult immunoblastic large cell lymphoma
705777|NCT00002471|stage IV adult Burkitt lymphoma
705778|NCT00002471|recurrent grade 3 follicular lymphoma
705779|NCT00002471|recurrent adult diffuse large cell lymphoma
705780|NCT00002471|recurrent adult immunoblastic large cell lymphoma
705781|NCT00002471|recurrent adult Burkitt lymphoma
705782|NCT00002471|stage III childhood small noncleaved cell lymphoma
705783|NCT00002471|stage IV childhood small noncleaved cell lymphoma
705784|NCT00002471|stage IV childhood large cell lymphoma
705785|NCT00002471|recurrent childhood small noncleaved cell lymphoma
705786|NCT00002471|recurrent childhood large cell lymphoma
705787|NCT00002470|metastatic gastrointestinal carcinoid tumor
705788|NCT00002470|recurrent gastrointestinal carcinoid tumor
705789|NCT00002470|pulmonary carcinoid tumor
705790|NCT00002466|localized osteosarcoma
705791|NCT00002466|metastatic osteosarcoma
705792|NCT00002466|stage III adult soft tissue sarcoma
705793|NCT00002466|stage III Wilms tumor
705794|NCT00002466|stage IV Wilms tumor
705795|NCT00002466|nonmetastatic childhood soft tissue sarcoma
705796|NCT00002466|metastatic childhood soft tissue sarcoma
705797|NCT00002466|childhood desmoplastic small round cell tumor
705798|NCT00002466|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
705799|NCT00002466|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
705800|NCT00002466|stage IV adult soft tissue sarcoma
705801|NCT00002466|Askin tumor
705802|NCT00002466|peripheral primitive neuroectodermal tumor
705803|NCT00002465|stage IV breast cancer
705804|NCT00002465|recurrent breast cancer
705805|NCT00002465|advanced malignant mesothelioma
705806|NCT00002465|recurrent malignant mesothelioma
705807|NCT00002465|stage IV endometrial carcinoma
705808|NCT00002465|recurrent endometrial carcinoma
705809|NCT00002463|childhood infratentorial ependymoma
705810|NCT00002463|childhood low-grade cerebral astrocytoma
705811|NCT00002463|childhood low-grade cerebellar astrocytoma
705812|NCT00002463|childhood supratentorial ependymoma
705813|NCT00002463|childhood high-grade cerebral astrocytoma
705814|NCT00002463|untreated childhood supratentorial primitive neuroectodermal tumor
705815|NCT00002463|untreated childhood cerebellar astrocytoma
705816|NCT00002463|untreated childhood medulloblastoma
705817|NCT00002463|untreated childhood visual pathway and hypothalamic glioma
705818|NCT00002463|newly diagnosed childhood ependymoma
705819|NCT00002462|stage III adult Hodgkin lymphoma
705820|NCT00002462|stage IV adult Hodgkin lymphoma
705821|NCT00002461|recurrent adult Hodgkin lymphoma
705822|NCT00002461|adult lymphocyte predominant Hodgkin lymphoma
705823|NCT00002461|adult lymphocyte depletion Hodgkin lymphoma
705824|NCT00002461|adult nodular sclerosis Hodgkin lymphoma
705825|NCT00002461|adult mixed cellularity Hodgkin lymphoma
705826|NCT00002461|recurrent grade 1 follicular lymphoma
705827|NCT00002461|recurrent grade 2 follicular lymphoma
705828|NCT00002461|recurrent grade 3 follicular lymphoma
705829|NCT00002461|recurrent adult diffuse small cleaved cell lymphoma
705830|NCT00002461|recurrent adult diffuse mixed cell lymphoma
705831|NCT00002461|recurrent adult diffuse large cell lymphoma
705832|NCT00002461|recurrent adult immunoblastic large cell lymphoma
705833|NCT00002461|recurrent adult lymphoblastic lymphoma
705834|NCT00002461|recurrent adult Burkitt lymphoma
705835|NCT00002461|recurrent mantle cell lymphoma
705836|NCT00002461|recurrent small lymphocytic lymphoma
705837|NCT00002460|stage I breast cancer
705838|NCT00002460|stage II breast cancer
705839|NCT00002460|stage IIIA breast cancer
705840|NCT00002459|stage I uterine sarcoma
705841|NCT00002459|stage II uterine sarcoma
705842|NCT00002459|uterine carcinosarcoma
705843|NCT00002459|uterine leiomyosarcoma
705844|NCT00002459|endometrial stromal sarcoma
705845|NCT00002458|disseminated neuroblastoma
705846|NCT00002458|recurrent neuroblastoma
705847|NCT00002456|recurrent childhood acute lymphoblastic leukemia
705848|NCT00002456|childhood non-Hodgkin lymphoma
705849|NCT00002456|recurrent childhood lymphoblastic lymphoma
705850|NCT00002456|recurrent childhood acute myeloid leukemia
705851|NCT00002456|recurrent adult acute myeloid leukemia
705852|NCT00002456|recurrent adult acute lymphoblastic leukemia
705853|NCT00002456|relapsing chronic myelogenous leukemia
705854|NCT00002456|refractory chronic lymphocytic leukemia
705855|NCT00002456|recurrent adult non-Hodgkin lymphoma
705856|NCT00002456|graft versus host disease
705857|NCT00002455|stage I colon cancer
705858|NCT00002455|stage II colon cancer
705859|NCT00002455|stage III colon cancer
705860|NCT00002455|stage I breast cancer
705861|NCT00002455|stage II breast cancer
705862|NCT00002455|stage IIIA breast cancer
705863|NCT00002455|recurrent breast cancer
705864|NCT00002455|recurrent colon cancer
705865|NCT00002455|stage I melanoma
705866|NCT00002455|stage II melanoma
705867|NCT00002455|stage III melanoma
705868|NCT00002455|recurrent melanoma
705869|NCT00002454|lung papilloma
705870|NCT00002453|HIV-1
705871|NCT00002453|Drug Therapy, Combination
705872|NCT00002453|Disease Progression
705873|NCT00002453|Anti-HIV Agents
705874|NCT00002452|Drug Therapy, Combination
705875|NCT00002452|HIV Protease Inhibitors
705876|NCT00002452|Indinavir
705877|NCT00002452|Reverse Transcriptase Inhibitors
705880|NCT00002451|Drug Therapy, Combination
705881|NCT00002451|Stavudine
705882|NCT00002451|HIV Protease Inhibitors
705883|NCT00002451|CD4 Lymphocyte Count
705884|NCT00002451|Ritonavir
705885|NCT00002451|Lamivudine
705886|NCT00002451|Indinavir
705887|NCT00002451|Reverse Transcriptase Inhibitors
705888|NCT00002451|Anti-HIV Agents
705889|NCT00002451|Viral Load
705890|NCT00002450|HIV-1
705891|NCT00002450|Drug Therapy, Combination
705892|NCT00002450|Drug Administration Schedule
705893|NCT00002450|RNA, Viral
705894|NCT00002450|Anti-HIV Agents
705895|NCT00002450|Viral Load
705896|NCT00002449|Recombinant Proteins
705897|NCT00002449|Injections, Subcutaneous
705898|NCT00002449|Interleukin-2
705899|NCT00002449|Dose-Response Relationship, Drug
705900|NCT00002449|CD4 Lymphocyte Count
705901|NCT00002449|Anti-HIV Agents
705902|NCT00002449|Viral Load
705903|NCT00002449|Pharmacokinetics
705904|NCT00002448|Drug Therapy, Combination
705905|NCT00002448|HIV Protease Inhibitors
705906|NCT00002448|Ritonavir
705907|NCT00002448|Dosage Forms
705908|NCT00002448|Saquinavir
705909|NCT00002448|Reverse Transcriptase Inhibitors
705910|NCT00002448|Anti-HIV Agents
705911|NCT00002448|efavirenz
705912|NCT00002447|Drug Therapy, Combination
705913|NCT00002447|Saquinavir
705914|NCT00002447|HIV Protease Inhibitors
705915|NCT00002447|Ritonavir
705916|NCT00002447|Dosage Forms
705917|NCT00002447|Reverse Transcriptase Inhibitors
705918|NCT00002447|Anti-HIV Agents
705919|NCT00002447|efavirenz
705920|NCT00002446|AIDS-Related Opportunistic Infections
705921|NCT00002446|Fluconazole
705922|NCT00002446|Administration, Oral
705923|NCT00002446|Antifungal Agents
705924|NCT00002446|Candidiasis, Oral
705925|NCT00002446|Pharyngeal Diseases
705926|NCT00002446|posaconazole
705927|NCT00002445|AIDS-Related Opportunistic Infections
705928|NCT00002445|Placebos
705929|NCT00002445|Sarcoma, Kaposi
705930|NCT00002445|Antineoplastic Agents
705931|NCT00002445|Treatment Outcome
705932|NCT00002445|Quality of Life
705933|NCT00002442|Drug Therapy, Combination
705934|NCT00002442|Zidovudine
705935|NCT00002442|Drug Administration Schedule
705936|NCT00002442|Stavudine
705937|NCT00002442|HIV Protease Inhibitors
705938|NCT00002442|Lamivudine
705939|NCT00002442|Indinavir
705940|NCT00002442|Dosage Forms
705941|NCT00002442|Nelfinavir
705942|NCT00002442|Reverse Transcriptase Inhibitors
705943|NCT00002442|Anti-HIV Agents
705944|NCT00002441|HIV-1
705945|NCT00002441|Dose-Response Relationship, Drug
705946|NCT00002441|Acquired Immunodeficiency Syndrome
705947|NCT00002441|AIDS Vaccines
705948|NCT00002441|Sexually Transmitted Diseases
705949|NCT00002441|Risk Factors
705950|NCT00002441|HIV Seronegativity
705951|NCT00002441|Antigens, Viral
705952|NCT00002441|Alum Compounds
705953|NCT00002440|HIV-1
705954|NCT00002440|Drug Therapy, Combination
705955|NCT00002440|HIV Protease Inhibitors
705956|NCT00002440|Mutation
705957|NCT00002440|HIV-1 Reverse Transcriptase
705958|NCT00002440|HIV Protease
705959|NCT00002440|Reverse Transcriptase Inhibitors
705960|NCT00002440|Anti-HIV Agents
705961|NCT00002440|abacavir
705962|NCT00002438|Itraconazole
705963|NCT00002438|Histoplasmosis
705964|NCT00002438|Acquired Immunodeficiency Syndrome
705965|NCT00002437|Retinitis
705966|NCT00002437|Probenecid
705967|NCT00002437|Drug Therapy, Combination
705968|NCT00002437|Cytomegalovirus Infections
705969|NCT00002437|Acquired Immunodeficiency Syndrome
705970|NCT00002437|Antiviral Agents
705971|NCT00002437|cidofovir
705972|NCT00002436|Zalcitabine
705973|NCT00002436|Drug Therapy, Combination
705974|NCT00002436|Acquired Immunodeficiency Syndrome
705975|NCT00002436|AIDS-Related Complex
705976|NCT00002436|Antiviral Agents
705977|NCT00002436|Zidovudine
705978|NCT00002435|Drug Therapy, Combination
705979|NCT00002435|Antiviral Agents
705980|NCT00002435|Zidovudine
705981|NCT00002435|thymic humoral factor gamma 2
705982|NCT00002434|Trimetrexate
705983|NCT00002434|Pneumonia, Pneumocystis carinii
705984|NCT00002434|Leucovorin
705985|NCT00002434|Drug Therapy, Combination
705986|NCT00002434|Acquired Immunodeficiency Syndrome
705987|NCT00002433|Pulmonary Alveoli
705988|NCT00002433|Macrophage Activation
705989|NCT00002433|Interferon-gamma, Recombinant
705990|NCT00002433|Injections, Subcutaneous
705991|NCT00002433|Aerosols
705992|NCT00002433|Acquired Immunodeficiency Syndrome
705993|NCT00002432|Retinitis
705994|NCT00002432|AIDS-Related Opportunistic Infections
705995|NCT00002432|Foscarnet
705996|NCT00002432|Cytomegalovirus Infections
705997|NCT00002432|Acquired Immunodeficiency Syndrome
705998|NCT00002431|AIDS-Related Opportunistic Infections
705999|NCT00002431|chlorhexidine gluconate
706000|NCT00002431|Acquired Immunodeficiency Syndrome
706001|NCT00002431|Anti-Infective Agents, Local
706002|NCT00002431|AIDS-Related Complex
706003|NCT00002431|Candidiasis, Oral
706004|NCT00002430|Drug Therapy, Combination
706005|NCT00002430|HIV Protease Inhibitors
706006|NCT00002430|Lamivudine
706007|NCT00002430|Indinavir
706008|NCT00002430|Reverse Transcriptase Inhibitors
706009|NCT00002430|Anti-HIV Agents
706010|NCT00002430|Nelfinavir
706011|NCT00002429|Didanosine
706012|NCT00002429|Drug Therapy, Combination
706013|NCT00002429|Stavudine
706014|NCT00002429|RNA, Viral
706015|NCT00002429|Nelfinavir
706016|NCT00002429|Reverse Transcriptase Inhibitors
706017|NCT00002429|Anti-HIV Agents
706018|NCT00002428|Vaccines, Synthetic
706019|NCT00002428|HIV-1
706020|NCT00002428|HIV Envelope Protein gp120
706021|NCT00002428|AIDS Vaccines
706022|NCT00002428|HIV Seronegativity
706023|NCT00002427|Didanosine
706024|NCT00002427|Dose-Response Relationship, Drug
706025|NCT00002427|Drug Therapy, Combination
706026|NCT00002427|Stavudine
706027|NCT00002427|Hydroxyurea
706028|NCT00002427|Reverse Transcriptase Inhibitors
706029|NCT00002427|Anti-HIV Agents
706030|NCT00002426|HIV-1
706031|NCT00002426|RNA, Viral
706032|NCT00002426|VX 478
706033|NCT00002426|Reverse Transcriptase Inhibitors
706034|NCT00002426|Anti-HIV Agents
706035|NCT00002426|Viral Load
706036|NCT00002425|Drug Therapy, Combination
706037|NCT00002425|Saquinavir
706038|NCT00002425|HIV Protease Inhibitors
706039|NCT00002425|Dosage Forms
706040|NCT00002425|Anti-HIV Agents
706041|NCT00002424|Drug Therapy, Combination
706042|NCT00002424|Drug Administration Schedule
706043|NCT00002424|Stavudine
706044|NCT00002424|HIV Protease Inhibitors
706045|NCT00002424|Lamivudine
706046|NCT00002424|Indinavir
706047|NCT00002424|Reverse Transcriptase Inhibitors
706048|NCT00002424|Anti-HIV Agents
706049|NCT00002423|Drug Therapy, Combination
706050|NCT00002423|HIV Protease Inhibitors
706051|NCT00002423|Lamivudine
706052|NCT00002423|Indinavir
706053|NCT00002423|Nelfinavir
706054|NCT00002423|VX 478
706055|NCT00002423|Reverse Transcriptase Inhibitors
706056|NCT00002423|Anti-HIV Agents
706057|NCT00002423|Viral Load
706058|NCT00002423|abacavir
706059|NCT00002422|Injections, Intramuscular
706060|NCT00002422|Drug Interactions
706061|NCT00002422|Salvage Therapy
706062|NCT00002422|Anti-HIV Agents
706063|NCT00002420|Drug Therapy, Combination
706064|NCT00002420|Reverse Transcriptase Inhibitors
706065|NCT00002420|Anti-HIV Agents
706066|NCT00002419|Drug Therapy, Combination
706067|NCT00002419|HIV Protease Inhibitors
706068|NCT00002419|Reverse Transcriptase Inhibitors
706069|NCT00002419|Anti-HIV Agents
706070|NCT00002418|Drug Therapy, Combination
706071|NCT00002418|Reverse Transcriptase Inhibitors
706072|NCT00002418|Anti-HIV Agents
706073|NCT00002418|Viral Load
706074|NCT00002417|Drug Therapy, Combination
706075|NCT00002417|HIV Protease Inhibitors
706076|NCT00002417|VX 478
706077|NCT00002417|Lipodystrophy
706078|NCT00002417|Hyperlipidemia
706079|NCT00002416|HIV-1
706080|NCT00002416|Zalcitabine
706081|NCT00002416|Zidovudine
706082|NCT00002416|Stavudine
706083|NCT00002416|HIV Protease Inhibitors
706084|NCT00002416|Lamivudine
706085|NCT00002416|RNA, Viral
706086|NCT00002416|Reverse Transcriptase Inhibitors
706087|NCT00002416|Anti-HIV Agents
706088|NCT00002415|Drug Therapy, Combination
706089|NCT00002415|Prodrugs
706090|NCT00002415|Anti-HIV Agents
706091|NCT00002414|AIDS Dementia Complex
706092|NCT00002414|Anti-HIV Agents
706093|NCT00002413|Anti-HIV Agents
706094|NCT00002413|Viral Load
706095|NCT00002413|MKC 442
706096|NCT00002412|Didanosine
706097|NCT00002412|Drug Therapy, Combination
706098|NCT00002412|Stavudine
706099|NCT00002412|Hydroxyurea
706100|NCT00002412|Reverse Transcriptase Inhibitors
706101|NCT00002412|Anti-HIV Agents
706102|NCT00002412|Viral Load
706103|NCT00002412|MKC 442
706104|NCT00002411|HIV-1
706105|NCT00002411|Didanosine
706106|NCT00002411|Drug Therapy, Combination
706107|NCT00002411|Zidovudine
706108|NCT00002411|Stavudine
706109|NCT00002411|Lamivudine
706110|NCT00002411|RNA, Viral
706111|NCT00002411|Nelfinavir
706112|NCT00002411|Anti-HIV Agents
706113|NCT00002411|Viral Load
706114|NCT00002410|HIV-1
706115|NCT00002410|Drug Therapy, Combination
706116|NCT00002410|Zidovudine
706117|NCT00002410|Drug Resistance, Microbial
706118|NCT00002410|HIV Protease Inhibitors
706119|NCT00002410|Lamivudine
706120|NCT00002410|Indinavir
706121|NCT00002410|Genotype
706122|NCT00002410|Reverse Transcriptase Inhibitors
706123|NCT00002410|efavirenz
706124|NCT00002409|Drug Therapy, Combination
706125|NCT00002409|Zidovudine
706126|NCT00002409|HIV Protease Inhibitors
706127|NCT00002409|Lamivudine
706128|NCT00002409|Patient Education
706129|NCT00002409|Patient Compliance
706130|NCT00002409|Reverse Transcriptase Inhibitors
706131|NCT00002409|Anti-HIV Agents
706132|NCT00002409|Viral Load
706133|NCT00002409|abacavir
706134|NCT00002408|Diarrhea
706135|NCT00002408|Acquired Immunodeficiency Syndrome
706136|NCT00002406|HIV-1
706137|NCT00002406|Dose-Response Relationship, Drug
706138|NCT00002406|HIV Protease Inhibitors
706139|NCT00002406|Indinavir
706140|NCT00002406|RNA, Viral
706141|NCT00002406|Reverse Transcriptase Inhibitors
706142|NCT00002405|Drug Therapy, Combination
706143|NCT00002405|HIV Protease Inhibitors
706144|NCT00002405|VX 478
706145|NCT00002405|Anti-HIV Agents
706146|NCT00002404|HIV-1
706147|NCT00002404|Antiviral Agents
706148|NCT00002404|Herpes Genitalis
706149|NCT00002404|Recurrence
706150|NCT00002404|DNA, Viral
706151|NCT00002404|RNA, Viral
706152|NCT00002404|valacyclovir
706153|NCT00002404|Herpesvirus 2, Human
706154|NCT00002403|HIV-1
706155|NCT00002403|Dose-Response Relationship, Drug
706156|NCT00002403|HIV Integrase Inhibitors
706157|NCT00002403|HIV Integrase
706158|NCT00002402|HIV-1
706159|NCT00002402|Dose-Response Relationship, Drug
706160|NCT00002402|Acquired Immunodeficiency Syndrome
706161|NCT00002402|AIDS Vaccines
706162|NCT00002402|HIV Seronegativity
706163|NCT00002402|Antigens, Viral
706164|NCT00002402|Alum Compounds
706165|NCT00002401|HIV-1
706166|NCT00002401|Zidovudine
706167|NCT00002401|HIV Protease Inhibitors
706168|NCT00002401|Lamivudine
706169|NCT00002401|Indinavir
706170|NCT00002401|RNA, Viral
706171|NCT00002401|Delavirdine
706172|NCT00002401|Reverse Transcriptase Inhibitors
706173|NCT00002401|Viral Load
706174|NCT00002400|HIV-1
706175|NCT00002400|Drug Therapy, Combination
706176|NCT00002400|Zidovudine
706177|NCT00002400|HIV Protease Inhibitors
706178|NCT00002400|Lamivudine
706179|NCT00002400|Indinavir
706180|NCT00002400|RNA, Viral
706181|NCT00002400|Delavirdine
706182|NCT00002400|Reverse Transcriptase Inhibitors
706183|NCT00002399|AIDS-Related Opportunistic Infections
706184|NCT00002399|Fluconazole
706185|NCT00002399|Antifungal Agents
706186|NCT00002399|Candidiasis
706187|NCT00002399|Triazoles
706188|NCT00002398|HIV-1
706189|NCT00002398|Acquired Immunodeficiency Syndrome
706190|NCT00002398|Adenine
706191|NCT00002398|Anti-HIV Agents
706192|NCT00002397|Kidney Failure, Chronic
706193|NCT00002397|HIV-1
706194|NCT00002397|Drug Therapy, Combination
706195|NCT00002397|Stavudine
706196|NCT00002397|HIV Protease Inhibitors
706197|NCT00002397|Lamivudine
706198|NCT00002397|Saquinavir
706199|NCT00002397|AIDS-Associated Nephropathy
706200|NCT00002397|Reverse Transcriptase Inhibitors
706201|NCT00002397|Viral Load
706202|NCT00002397|Nelfinavir
706203|NCT00002396|Dose-Response Relationship, Drug
706204|NCT00002396|Adenine
706205|NCT00002396|Anti-HIV Agents
706206|NCT00002395|AIDS-Related Opportunistic Infections
706207|NCT00002395|Leukoencephalopathy, Progressive Multifocal
706208|NCT00002395|Infusions, Intravenous
706209|NCT00002395|Drug Administration Schedule
706210|NCT00002395|Topotecan
706211|NCT00002394|AIDS-Related Opportunistic Infections
706212|NCT00002394|Dose-Response Relationship, Drug
706213|NCT00002394|Fluconazole
706214|NCT00002394|Antifungal Agents
706215|NCT00002394|Candidiasis, Oral
706216|NCT00002394|Drug Administration Schedule
706217|NCT00002394|terbinafine
706218|NCT00002393|Placebos
706219|NCT00002393|Drug Therapy, Combination
706220|NCT00002393|HIV Protease Inhibitors
706221|NCT00002393|Indinavir
706222|NCT00002393|Reverse Transcriptase Inhibitors
706223|NCT00002393|efavirenz
706224|NCT00002392|Lymphocyte Transformation
706225|NCT00002392|Immunity, Cellular
706226|NCT00002392|Drug Therapy, Combination
706227|NCT00002392|Adjuvants, Immunologic
706228|NCT00002392|Thalidomide
706229|NCT00002392|Immunologic Memory
706230|NCT00002392|Streptococcus pneumoniae
706231|NCT00002392|Tetanus Toxoid
706232|NCT00002392|Pneumococcal Vaccines
706233|NCT00002391|HIV-1
706234|NCT00002391|Drug Therapy, Combination
706235|NCT00002391|Zidovudine
706236|NCT00002391|Lamivudine
706237|NCT00002391|Reverse Transcriptase Inhibitors
706238|NCT00002391|Anti-HIV Agents
706239|NCT00002391|Viral Load
706240|NCT00002391|Child Development
706241|NCT00002391|abacavir
706242|NCT00002389|HIV-1
706243|NCT00002389|Drug Therapy, Combination
706244|NCT00002389|Antiviral Agents
706245|NCT00002389|Zidovudine
706246|NCT00002389|CD4 Lymphocyte Count
706249|NCT00002389|Reverse Transcriptase Inhibitors
706250|NCT00002389|Anti-HIV Agents
706251|NCT00002389|Viral Load
706252|NCT00002389|abacavir
706253|NCT00002388|HIV-1
706254|NCT00002388|Reverse Transcriptase Inhibitors
706255|NCT00002388|Anti-HIV Agents
706256|NCT00002387|Acquired Immunodeficiency Syndrome
706257|NCT00002387|Drug Administration Schedule
706258|NCT00002387|HIV Protease Inhibitors
706259|NCT00002387|Indinavir
706260|NCT00002387|Reverse Transcriptase Inhibitors
706261|NCT00002387|Anti-HIV Agents
706262|NCT00002387|efavirenz
706263|NCT00002386|Drug Therapy, Combination
706264|NCT00002386|HIV Protease Inhibitors
706265|NCT00002386|Indinavir
706266|NCT00002386|Factor VIII
706267|NCT00002386|Factor IX
706268|NCT00002386|Half-Life
706269|NCT00002386|Reverse Transcriptase Inhibitors
706270|NCT00002386|Anti-HIV Agents
706271|NCT00002386|Platelet Aggregation
706272|NCT00002386|Hemophilia A
706273|NCT00002386|Hemophilia B
706274|NCT00002385|Dose-Response Relationship, Drug
706275|NCT00002385|Cohort Studies
706276|NCT00002385|Anti-HIV Agents
706277|NCT00002383|Drug Administration Schedule
706278|NCT00002383|HIV Protease Inhibitors
706279|NCT00002383|Dosage Forms
706280|NCT00002383|Saquinavir
706281|NCT00002383|Anti-HIV Agents
706282|NCT00002382|Zalcitabine
706283|NCT00002382|Didanosine
706284|NCT00002382|Drug Therapy, Combination
706285|NCT00002382|Zidovudine
706286|NCT00002382|HIV Protease Inhibitors
706287|NCT00002382|Saquinavir
706288|NCT00002382|Patient Selection
706289|NCT00002382|Anti-HIV Agents
706290|NCT00002381|HIV-1
706291|NCT00002381|Drug Therapy, Combination
706292|NCT00002381|Nevirapine
706293|NCT00002381|Stavudine
706294|NCT00002381|RNA, Viral
706295|NCT00002381|Nelfinavir
706296|NCT00002381|Anti-HIV Agents
706297|NCT00002381|Viral Load
706298|NCT00002380|Drug Therapy, Combination
706299|NCT00002380|HIV Protease Inhibitors
706300|NCT00002380|Dosage Forms
706301|NCT00002380|Saquinavir
706302|NCT00002380|Nelfinavir
706303|NCT00002380|Anti-HIV Agents
706304|NCT00002379|HIV-1
706305|NCT00002379|Drug Therapy, Combination
706306|NCT00002379|Administration, Oral
706307|NCT00002379|Acquired Immunodeficiency Syndrome
706308|NCT00002379|Zidovudine
706309|NCT00002379|Stavudine
706310|NCT00002379|HIV Protease Inhibitors
706311|NCT00002379|CD4 Lymphocyte Count
706312|NCT00002379|Lamivudine
706313|NCT00002379|Indinavir
706314|NCT00002379|RNA, Viral
706315|NCT00002379|Adenine
706316|NCT00002379|Anti-HIV Agents
706317|NCT00002379|Viral Load
706318|NCT00002378|HIV-1
706319|NCT00002378|Drug Therapy, Combination
706320|NCT00002378|Zidovudine
706321|NCT00002378|Stavudine
706322|NCT00002378|HIV Protease Inhibitors
706323|NCT00002378|Lamivudine
706324|NCT00002378|RNA, Viral
706325|NCT00002378|Dosage Forms
706326|NCT00002378|Saquinavir
706327|NCT00002378|Reverse Transcriptase Inhibitors
706328|NCT00002378|Anti-HIV Agents
706329|NCT00002378|Viral Load
706330|NCT00002378|Nelfinavir
706331|NCT00002376|HIV-1
706332|NCT00002376|CD4 Lymphocyte Count
706333|NCT00002376|RNA, Viral
706334|NCT00002376|Anti-HIV Agents
706335|NCT00002376|Viral Load
706336|NCT00002375|Drug Therapy, Combination
706337|NCT00002375|HIV Protease Inhibitors
706338|NCT00002375|Indinavir
706339|NCT00002375|Nelfinavir
706340|NCT00002375|Anti-HIV Agents
706341|NCT00002374|HIV-1
706342|NCT00002374|Drug Therapy, Combination
706343|NCT00002374|Acquired Immunodeficiency Syndrome
706344|NCT00002374|HIV Protease Inhibitors
706345|NCT00002374|RNA, Viral
706346|NCT00002374|Saquinavir
706347|NCT00002374|Anti-HIV Agents
706348|NCT00002374|Viral Load
706349|NCT00002373|Cytomegalovirus
706350|NCT00002373|Cytomegalovirus Infections
706351|NCT00002373|Administration, Oral
706352|NCT00002373|Acquired Immunodeficiency Syndrome
706353|NCT00002373|Antiviral Agents
706354|NCT00002373|Virus Shedding
706355|NCT00002373|Viral Load
706356|NCT00002372|Drug Therapy, Combination
706357|NCT00002372|Administration, Oral
706358|NCT00002372|HIV Protease Inhibitors
706359|NCT00002372|Indinavir
706360|NCT00002372|Saquinavir
706361|NCT00002372|Nelfinavir
706362|NCT00002372|VX 478
706363|NCT00002371|HIV-1
706364|NCT00002371|Drug Therapy, Combination
706365|NCT00002371|Stavudine
706366|NCT00002371|Lamivudine
706367|NCT00002371|RNA, Viral
706368|NCT00002371|Anti-HIV Agents
706369|NCT00002371|Viral Load
706370|NCT00002370|Itraconazole
706371|NCT00002370|Administration, Oral
706372|NCT00002370|Antifungal Agents
706373|NCT00002370|Acquired Immunodeficiency Syndrome
706374|NCT00002370|Drug Administration Schedule
706375|NCT00002369|Drug Therapy, Combination
706376|NCT00002369|Zidovudine
706377|NCT00002369|Stavudine
706378|NCT00002369|HIV Protease Inhibitors
706379|NCT00002369|CD4 Lymphocyte Count
706380|NCT00002369|Lamivudine
706381|NCT00002369|Indinavir
706382|NCT00002369|Reverse Transcriptase Inhibitors
706383|NCT00002369|Anti-HIV Agents
706384|NCT00002369|Viral Load
706385|NCT00002368|Drug Therapy, Combination
706386|NCT00002368|Acquired Immunodeficiency Syndrome
706387|NCT00002368|Nevirapine
706388|NCT00002368|Lamivudine
706389|NCT00002368|Disease Progression
706390|NCT00002368|Reverse Transcriptase Inhibitors
706391|NCT00002368|Anti-HIV Agents
706392|NCT00002367|Drug Therapy, Combination
706393|NCT00002367|Acquired Immunodeficiency Syndrome
706394|NCT00002367|Zidovudine
706395|NCT00002367|HIV Protease Inhibitors
706396|NCT00002367|Lamivudine
706397|NCT00002367|Saquinavir
706398|NCT00002367|Reverse Transcriptase Inhibitors
706399|NCT00002367|Anti-HIV Agents
706400|NCT00002366|Skin Neoplasms
706401|NCT00002366|Sarcoma, Kaposi
706402|NCT00002366|Acquired Immunodeficiency Syndrome
706403|NCT00002366|HIV Protease Inhibitors
706404|NCT00002366|Ritonavir
706405|NCT00002365|Dose-Response Relationship, Drug
706406|NCT00002365|Administration, Oral
706407|NCT00002365|Acquired Immunodeficiency Syndrome
706408|NCT00002365|Anti-HIV Agents
706409|NCT00002364|Drug Therapy, Combination
706410|NCT00002364|Acquired Immunodeficiency Syndrome
706411|NCT00002364|AIDS-Related Complex
706412|NCT00002364|Antiviral Agents
706413|NCT00002363|Acquired Immunodeficiency Syndrome
706414|NCT00002363|AIDS-Related Complex
706415|NCT00002363|Antiviral Agents
706416|NCT00002362|Dideoxynucleosides
706417|NCT00002362|Drug Therapy, Combination
706418|NCT00002362|Stavudine
706419|NCT00002362|Reverse Transcriptase Inhibitors
706420|NCT00002362|abacavir
706421|NCT00002362|efavirenz
706422|NCT00002361|Drug Therapy, Combination
706423|NCT00002361|HIV Protease Inhibitors
706424|NCT00002361|Ritonavir
706425|NCT00002361|Indinavir
706426|NCT00002361|Reverse Transcriptase Inhibitors
706427|NCT00002361|Anti-HIV Agents
706428|NCT00002361|Viral Load
706429|NCT00002360|Didanosine
706430|NCT00002360|Tablets
706431|NCT00002360|Reverse Transcriptase Inhibitors
706432|NCT00002360|Anti-HIV Agents
706433|NCT00002360|Therapeutic Equivalency
706434|NCT00002359|Vaccines, Synthetic
706435|NCT00002359|Viral Vaccines
706436|NCT00002359|HIV-1
706437|NCT00002359|AIDS-Related Complex
706438|NCT00002359|AIDS Vaccines
706439|NCT00002359|Salk HIV Immunogen
706440|NCT00002358|Herpes Zoster
706441|NCT00002358|Acquired Immunodeficiency Syndrome
706442|NCT00002358|AIDS-Related Complex
706443|NCT00002358|Antiviral Agents
706444|NCT00002358|sorivudine
706445|NCT00002358|Chickenpox
706446|NCT00002357|Drug Therapy, Combination
706447|NCT00002357|AIDS-Related Complex
706448|NCT00002357|Antiviral Agents
706449|NCT00002357|Zidovudine
706450|NCT00002356|Acquired Immunodeficiency Syndrome
706451|NCT00002356|Antiviral Agents
706452|NCT00002356|Cytomegalovirus Retinitis
706453|NCT00002355|AIDS-Related Opportunistic Infections
706454|NCT00002355|Acquired Immunodeficiency Syndrome
706455|NCT00002355|Antiviral Agents
706456|NCT00002355|Cytomegalovirus Retinitis
706457|NCT00002354|Drug Therapy, Combination
706458|NCT00002354|Acquired Immunodeficiency Syndrome
706459|NCT00002354|AIDS-Related Complex
706460|NCT00002354|Stavudine
706461|NCT00002354|HIV Protease Inhibitors
706462|NCT00002354|Indinavir
706463|NCT00002353|Vaccines, Synthetic
706464|NCT00002353|AIDS Vaccines
706465|NCT00002352|Cytomegalovirus Infections
706466|NCT00002352|Acquired Immunodeficiency Syndrome
706467|NCT00002352|Antiviral Agents
706468|NCT00002351|Acquired Immunodeficiency Syndrome
706469|NCT00002351|AIDS-Related Complex
706470|NCT00002351|HIV Protease Inhibitors
706471|NCT00002351|Indinavir
706472|NCT00002350|Vaccines, Synthetic
706473|NCT00002350|AIDS Vaccines
706474|NCT00002350|DNA, Viral
706475|NCT00002349|AIDS-Related Complex
706476|NCT00002349|Stavudine
706477|NCT00002348|Lymphoma, Non-Hodgkin
706478|NCT00002348|Acquired Immunodeficiency Syndrome
706479|NCT00002348|Lymphoma, AIDS-Related
706480|NCT00002348|Mitoguazone
706481|NCT00002347|Zalcitabine
706482|NCT00002347|Drug Therapy, Combination
706483|NCT00002347|Acquired Immunodeficiency Syndrome
706484|NCT00002347|AIDS-Related Complex
706485|NCT00002347|Zidovudine
706486|NCT00002347|Nevirapine
706487|NCT00002347|Saquinavir
706488|NCT00002346|Acquired Immunodeficiency Syndrome
706489|NCT00002346|AIDS-Related Complex
706490|NCT00002346|Antiviral Agents
706491|NCT00002346|Adenine
706492|NCT00002345|Megestrol
706493|NCT00002345|Acquired Immunodeficiency Syndrome
706498|NCT00002344|Bacterial Infections
706499|NCT00002343|Rifabutin
706500|NCT00002343|Mycobacterium avium-intracellulare Infection
706501|NCT00002343|Drug Therapy, Combination
706502|NCT00002343|Ethambutol
706503|NCT00002343|Acquired Immunodeficiency Syndrome
706504|NCT00002342|Neoplasms
706505|NCT00002342|Sarcoma, Kaposi
706506|NCT00002342|Acquired Immunodeficiency Syndrome
706507|NCT00002342|Antineoplastic Agents
706508|NCT00002342|tecogalan
706509|NCT00002341|Itraconazole
706510|NCT00002341|Acquired Immunodeficiency Syndrome
706511|NCT00002341|AIDS-Related Complex
706512|NCT00002341|Candidiasis, Oral
706513|NCT00002340|Pneumonia, Pneumocystis carinii
706514|NCT00002340|Pentamidine
706515|NCT00002340|Antifungal Agents
706516|NCT00002340|Acquired Immunodeficiency Syndrome
706517|NCT00002340|AIDS-Related Complex
706518|NCT00002340|atovaquone
706519|NCT00002339|Esophagitis
706520|NCT00002339|Fluconazole
706521|NCT00002339|Acquired Immunodeficiency Syndrome
706522|NCT00002339|Candidiasis
706523|NCT00002339|Immunocompromised Host
706524|NCT00002338|Acquired Immunodeficiency Syndrome
706525|NCT00002338|AIDS-Related Complex
706526|NCT00002338|Antiviral Agents
706527|NCT00002337|Acquired Immunodeficiency Syndrome
706528|NCT00002337|Antiviral Agents
706529|NCT00002337|vesnarinone
706530|NCT00002336|Mycobacterium avium-intracellular Infection
706531|NCT00002336|Acquired Immunodeficiency Syndrome
706532|NCT00002336|Clarithromycin
706533|NCT00002335|Acquired Immunodeficiency Syndrome
706534|NCT00002335|AIDS-Related Complex
706535|NCT00002335|Antiviral Agents
706536|NCT00002334|Drug Therapy, Combination
706537|NCT00002334|Acquired Immunodeficiency Syndrome
706538|NCT00002334|AIDS-Related Complex
706539|NCT00002334|Zidovudine
706540|NCT00002334|Saquinavir
706541|NCT00002334|HIV Protease Inhibitors
706542|NCT00002333|Zalcitabine
706543|NCT00002333|Drug Therapy, Combination
706544|NCT00002333|Acquired Immunodeficiency Syndrome
706545|NCT00002333|AIDS-Related Complex
706546|NCT00002333|Saquinavir
706547|NCT00002333|HIV Protease Inhibitors
706548|NCT00002332|Thymopentin
706549|NCT00002332|AIDS-Related Complex
706550|NCT00002331|Mycobacterium avium-intracellular Infection
706551|NCT00002331|Drug Therapy, Combination
706552|NCT00002331|Ethambutol
706553|NCT00002331|Clofazimine
706554|NCT00002331|Acquired Immunodeficiency Syndrome
706555|NCT00002331|Clarithromycin
706556|NCT00002330|Retinitis
706557|NCT00002330|Ganciclovir
706558|NCT00002330|Cytomegalovirus Infections
706559|NCT00002330|Acquired Immunodeficiency Syndrome
706560|NCT00002329|MDL 28574
706561|NCT00002328|Antidiarrheals
706562|NCT00002328|Cryptosporidiosis
706563|NCT00002328|Diarrhea
706564|NCT00002328|Acquired Immunodeficiency Syndrome
706565|NCT00002328|Azithromycin
706566|NCT00002327|AIDS-Related Opportunistic Infections
706567|NCT00002327|Acquired Immunodeficiency Syndrome
706568|NCT00002327|AIDS-Related Complex
706569|NCT00002327|Antiviral Agents
706570|NCT00002327|Condylomata Acuminata
706571|NCT00002327|cidofovir
706572|NCT00002326|Drug Therapy, Combination
706573|NCT00002326|Acquired Immunodeficiency Syndrome
706574|NCT00002326|AIDS-Related Complex
706575|NCT00002326|Antiviral Agents
706576|NCT00002326|Zidovudine
706577|NCT00002326|Adenine
706578|NCT00002325|Mycoses
706579|NCT00002325|Fluconazole
706580|NCT00002325|Acquired Immunodeficiency Syndrome
706581|NCT00002325|AIDS-Related Complex
706582|NCT00002325|Coccidioidomycosis
706583|NCT00002324|Drug Therapy, Combination
706584|NCT00002324|AIDS-Related Complex
706585|NCT00002324|Zidovudine
706586|NCT00002324|Nevirapine
706587|NCT00002323|Drug Therapy, Combination
706588|NCT00002323|Zidovudine
706589|NCT00002323|Nevirapine
706590|NCT00002322|Drug Therapy, Combination
706591|NCT00002322|Acquired Immunodeficiency Syndrome
706592|NCT00002322|AIDS-Related Complex
706593|NCT00002322|Antiviral Agents
706594|NCT00002321|Retinitis
706595|NCT00002321|Interleukin-2
706596|NCT00002321|Ganciclovir
706597|NCT00002321|Drug Therapy, Combination
706598|NCT00002321|Acquired Immunodeficiency Syndrome
706599|NCT00002321|Antiviral Agents
706600|NCT00002320|Drug Therapy, Combination
706601|NCT00002320|Acquired Immunodeficiency Syndrome
706602|NCT00002320|AIDS-Related Complex
706603|NCT00002320|Antiviral Agents
706604|NCT00002320|Zidovudine
706605|NCT00002319|Sarcoma, Kaposi
706606|NCT00002319|Liposomes
706607|NCT00002319|Doxorubicin
706608|NCT00002319|Acquired Immunodeficiency Syndrome
706609|NCT00002319|Drug Carriers
706610|NCT00002318|Vincristine
706611|NCT00002318|Sarcoma, Kaposi
706612|NCT00002318|Liposomes
706613|NCT00002318|Doxorubicin
706614|NCT00002318|Drug Therapy, Combination
706615|NCT00002318|Acquired Immunodeficiency Syndrome
706616|NCT00002318|Bleomycin
706617|NCT00002318|Drug Carriers
706618|NCT00002317|Trimetrexate
706619|NCT00002317|Pneumonia, Pneumocystis carinii
706620|NCT00002317|Leucovorin
706621|NCT00002317|Drug Therapy, Combination
706622|NCT00002317|Acquired Immunodeficiency Syndrome
706623|NCT00002316|AIDS-Related Opportunistic Infections
706624|NCT00002316|Meningitis
706625|NCT00002316|Drug Therapy, Combination
706626|NCT00002316|Antifungal Agents
706627|NCT00002316|Acquired Immunodeficiency Syndrome
706628|NCT00002316|Amphotericin B
706629|NCT00002315|Herpes Zoster
706630|NCT00002315|Acyclovir
706631|NCT00002315|Acquired Immunodeficiency Syndrome
706632|NCT00002315|AIDS-Related Complex
706633|NCT00002315|Antiviral Agents
706634|NCT00002314|Sarcoma, Kaposi
706635|NCT00002314|Acquired Immunodeficiency Syndrome
706636|NCT00002314|Antineoplastic Agents
706637|NCT00002314|Gene Products, tat
706638|NCT00002313|Nystatin
706639|NCT00002313|Didanosine
706640|NCT00002313|Drug Therapy, Combination
706641|NCT00002313|Acquired Immunodeficiency Syndrome
706642|NCT00002313|AIDS-Related Complex
706643|NCT00002312|Drug Interactions
706644|NCT00002312|Antiviral Agents
706645|NCT00002312|Zidovudine
706646|NCT00002311|Acquired Immunodeficiency Syndrome
706647|NCT00002311|AIDS-Related Complex
706648|NCT00002311|Wobenzym
706649|NCT00002311|Hydrolases
706650|NCT00002310|Herpes Simplex
706651|NCT00002310|HIV-1
706652|NCT00002310|Acquired Immunodeficiency Syndrome
706653|NCT00002310|Antiviral Agents
706654|NCT00002310|Administration, Topical
706655|NCT00002309|Mycobacterium avium-intracellulare Infection
706656|NCT00002309|Acquired Immunodeficiency Syndrome
706657|NCT00002309|AIDS-Related Complex
706658|NCT00002309|Azithromycin
706659|NCT00002308|Acquired Immunodeficiency Syndrome
706660|NCT00002308|AIDS-Related Complex
706661|NCT00002308|Stavudine
706662|NCT00002307|Zidovudine
706663|NCT00002307|Stavudine
706664|NCT00002306|AIDS-Related Opportunistic Infections
706665|NCT00002306|Meningitis
706666|NCT00002306|Cryptococcosis
706667|NCT00002306|Fluconazole
706668|NCT00002306|Acquired Immunodeficiency Syndrome
706669|NCT00002306|Amphotericin B
706670|NCT00002305|AIDS-Related Opportunistic Infections
706671|NCT00002305|Meningitis
706672|NCT00002305|Cryptococcosis
706673|NCT00002305|Drug Therapy, Combination
706674|NCT00002305|Fluconazole
706675|NCT00002305|Flucytosine
706676|NCT00002305|Acquired Immunodeficiency Syndrome
706677|NCT00002305|Amphotericin B
706678|NCT00002304|AIDS-Related Opportunistic Infections
706679|NCT00002304|Immune Tolerance
706680|NCT00002304|Ketoconazole
706681|NCT00002304|Esophagitis
706682|NCT00002304|Fluconazole
706683|NCT00002304|Acquired Immunodeficiency Syndrome
706684|NCT00002304|Candidiasis, Oral
706685|NCT00002303|Recombinant Proteins
706686|NCT00002303|Erythropoietin
706687|NCT00002303|Acquired Immunodeficiency Syndrome
706688|NCT00002303|Anemia
706689|NCT00002303|AIDS-Related Complex
706690|NCT00002303|Zidovudine
706691|NCT00002302|Recombinant Proteins
706692|NCT00002302|Injections, Subcutaneous
706693|NCT00002302|Erythropoietin
706694|NCT00002302|Acquired Immunodeficiency Syndrome
706695|NCT00002302|Anemia
706696|NCT00002302|Zidovudine
706697|NCT00002301|Retinitis
706698|NCT00002301|AIDS-Related Opportunistic Infections
706699|NCT00002301|Ganciclovir
706700|NCT00002301|Foscarnet
706701|NCT00002301|Cytomegalovirus Infections
706702|NCT00002301|Acquired Immunodeficiency Syndrome
706703|NCT00002301|Antiviral Agents
706704|NCT00002300|T-Lymphocytes
706705|NCT00002300|Megestrol
706706|NCT00002300|Dose-Response Relationship, Drug
706707|NCT00002300|Acquired Immunodeficiency Syndrome
706708|NCT00002300|Anorexia
706709|NCT00002300|Cachexia
706710|NCT00002299|Retinitis
706711|NCT00002299|AIDS-Related Opportunistic Infections
706712|NCT00002299|Ganciclovir
706713|NCT00002299|Drug Therapy, Combination
706714|NCT00002299|Cytomegalovirus Infections
706715|NCT00002299|Acquired Immunodeficiency Syndrome
706716|NCT00002299|Interferon Type I
706717|NCT00002298|Ribavirin
706718|NCT00002298|AIDS-Related Complex
706719|NCT00002297|Inosine Pranobex
706720|NCT00002297|AIDS-Related Complex
706721|NCT00002296|T-Lymphocytes
706722|NCT00002296|Immune Tolerance
706723|NCT00002296|Inosine Pranobex
706724|NCT00002296|Killer Cells
706725|NCT00002296|T-Lymphocytes, Helper-Inducer
706726|NCT00002296|Acquired Immunodeficiency Syndrome
706727|NCT00002296|AIDS-Related Complex
706728|NCT00002295|Infusions, Intravenous
706729|NCT00002295|Drug Evaluation
706730|NCT00002295|Administration, Oral
706731|NCT00002295|Acquired Immunodeficiency Syndrome
706732|NCT00002295|AIDS-Related Complex
706733|NCT00002295|Zidovudine
706734|NCT00002295|Biological Availability
706735|NCT00002294|AIDS-Related Opportunistic Infections
706736|NCT00002294|Meningitis
706737|NCT00002294|Cryptococcosis
706738|NCT00002294|Fluconazole
706739|NCT00002294|Acquired Immunodeficiency Syndrome
706740|NCT00002293|Nystatin
706741|NCT00002293|AIDS-Related Opportunistic Infections
706742|NCT00002293|Acquired Immunodeficiency Syndrome
706743|NCT00002293|AIDS-Related Complex
706744|NCT00002293|Candidiasis, Oral
706745|NCT00002292|AIDS-Related Opportunistic Infections
706746|NCT00002292|Pneumonia, Pneumocystis carinii
706747|NCT00002292|Pentamidine
706748|NCT00002292|Injections, Intravenous
706749|NCT00002292|Administration, Inhalation
706750|NCT00002292|Aerosols
706751|NCT00002292|Acquired Immunodeficiency Syndrome
706752|NCT00002291|AIDS-Related Opportunistic Infections
706753|NCT00002291|Pneumonia, Pneumocystis carinii
706754|NCT00002291|Pentamidine
706755|NCT00002291|Dose-Response Relationship, Drug
706756|NCT00002291|Aerosols
706757|NCT00002291|Acquired Immunodeficiency Syndrome
706758|NCT00002290|AIDS-Related Opportunistic Infections
706759|NCT00002290|Drug Therapy, Combination
706760|NCT00002290|Acyclovir
706761|NCT00002290|AIDS-Related Complex
706762|NCT00002290|Zidovudine
706763|NCT00002289|Semen
706764|NCT00002289|Thymopentin
706765|NCT00002289|Leukocytes, Mononuclear
706766|NCT00002289|HIV Seropositivity
706767|NCT00002289|AIDS-Related Complex
706768|NCT00002288|Neuropsychological Tests
706769|NCT00002288|AIDS-Related Complex
706770|NCT00002288|Zidovudine
706771|NCT00002287|Health Manpower
706772|NCT00002287|Accidents, Occupational
706773|NCT00002287|Zidovudine
706774|NCT00002286|Pilot Projects
706775|NCT00002286|Psoriasis
706776|NCT00002286|Acquired Immunodeficiency Syndrome
706777|NCT00002286|Zidovudine
706778|NCT00002285|Virus Replication
706779|NCT00002285|Pilot Projects
706780|NCT00002285|Immune Tolerance
706781|NCT00002285|Lymphocytes
706782|NCT00002285|Drug Evaluation
706783|NCT00002285|Combined Modality Therapy
706784|NCT00002285|Acquired Immunodeficiency Syndrome
706785|NCT00002285|Transplantation, Homologous
706786|NCT00002285|Zidovudine
706787|NCT00002284|Lymphoma, Large-Cell
706788|NCT00002284|Acquired Immunodeficiency Syndrome
706789|NCT00002284|AIDS-Related Complex
706790|NCT00002284|Zidovudine
706791|NCT00002284|Bone Marrow Transplantation
706792|NCT00002283|Trimethoprim-Sulfamethoxazole Combination
706793|NCT00002283|AIDS-Related Opportunistic Infections
706794|NCT00002283|Pneumonia, Pneumocystis carinii
706795|NCT00002283|Dapsone
706796|NCT00002283|Acquired Immunodeficiency Syndrome
706797|NCT00002282|AIDS-Related Opportunistic Infections
706798|NCT00002282|Fluconazole
706799|NCT00002282|Clotrimazole
706800|NCT00002282|Acquired Immunodeficiency Syndrome
706801|NCT00002282|Candidiasis, Oral
706802|NCT00002281|Injections, Subcutaneous
706803|NCT00002281|Erythropoietin
706804|NCT00002281|Acquired Immunodeficiency Syndrome
706805|NCT00002281|AIDS-Related Complex
706806|NCT00002281|Zidovudine
706807|NCT00002280|Didanosine
706808|NCT00002280|Drugs, Investigational
706809|NCT00002280|Acquired Immunodeficiency Syndrome
706810|NCT00002280|Zidovudine
706811|NCT00002279|Zalcitabine
706812|NCT00002279|Didanosine
706813|NCT00002279|Drugs, Investigational
706814|NCT00002279|Acquired Immunodeficiency Syndrome
706815|NCT00002279|AIDS-Related Complex
706816|NCT00002279|Zidovudine
706817|NCT00002278|AIDS-Related Opportunistic Infections
706818|NCT00002278|Cryptosporidiosis
706819|NCT00002278|Diarrhea
706820|NCT00002278|diclazuril
706821|NCT00002278|Coccidiostats
706822|NCT00002278|Acquired Immunodeficiency Syndrome
706823|NCT00002277|Mycoses
706824|NCT00002277|Neoplasms
706825|NCT00002277|Neutropenia
706826|NCT00002277|Fluconazole
706827|NCT00002277|Amphotericin B
706828|NCT00002276|Blood Platelets
706829|NCT00002276|Ibuprofen
706830|NCT00002276|Drug Interactions
706831|NCT00002276|Zidovudine
706832|NCT00002276|Hemophilia A
706833|NCT00002275|Weight Loss
706834|NCT00002275|Pneumonia, Pneumocystis carinii
706835|NCT00002275|Parenteral Nutrition
706836|NCT00002275|Liposyn
706837|NCT00002275|Acquired Immunodeficiency Syndrome
706838|NCT00002274|Didanosine
706839|NCT00002274|Drugs, Investigational
706840|NCT00002274|Acquired Immunodeficiency Syndrome
706841|NCT00002274|Zidovudine
706842|NCT00002273|AIDS-Related Opportunistic Infections
706843|NCT00002273|Ganciclovir
706844|NCT00002273|Cytomegalovirus Infections
706845|NCT00002273|Colitis
706846|NCT00002273|Acquired Immunodeficiency Syndrome
706847|NCT00002272|AIDS-Related Opportunistic Infections
706848|NCT00002272|Immune Tolerance
706849|NCT00002272|Injections, Intravenous
706850|NCT00002272|Herpes Simplex
706851|NCT00002272|Immunity, Cellular
706852|NCT00002272|Drug Resistance
706853|NCT00002272|Foscarnet
706854|NCT00002272|Acyclovir
706855|NCT00002272|Acquired Immunodeficiency Syndrome
706856|NCT00002272|Antiviral Agents
706857|NCT00002271|Thymidine
706858|NCT00002271|Nucleosides
706859|NCT00002271|Antiviral Agents
706860|NCT00002270|Leukoencephalopathy, Progressive Multifocal
706861|NCT00002270|Interferon Alfa-2b
706862|NCT00002270|Drug Evaluation
706863|NCT00002270|Acquired Immunodeficiency Syndrome
706864|NCT00002270|Zidovudine
706865|NCT00002269|Acquired Immunodeficiency Syndrome
706866|NCT00002269|ampligen
706867|NCT00002269|AIDS-Related Complex
706868|NCT00002269|Zidovudine
706869|NCT00002268|AIDS-Related Opportunistic Infections
706870|NCT00002268|Immunotherapy
706871|NCT00002268|Drug Evaluation
706872|NCT00002268|Cytomegalovirus Infections
706873|NCT00002268|Antibodies, Monoclonal
706874|NCT00002267|Rifabutin
706875|NCT00002267|AIDS-Related Opportunistic Infections
706876|NCT00002267|Mycobacterium avium-intracellulare Infection
706877|NCT00002267|Acquired Immunodeficiency Syndrome
706878|NCT00002267|Antitubercular Agents
706879|NCT00002266|Drug Therapy, Combination
706880|NCT00002266|Acquired Immunodeficiency Syndrome
706881|NCT00002266|AIDS-Related Complex
706882|NCT00002266|ammonium trichloro(dioxoethylene-O,O'-)tellurute
706883|NCT00002265|Zalcitabine
706884|NCT00002265|Drug Evaluation
706885|NCT00002265|Acquired Immunodeficiency Syndrome
706886|NCT00002265|AIDS-Related Complex
706887|NCT00002265|Zidovudine
706888|NCT00002263|Pilot Projects
706889|NCT00002263|Neutropenia
706890|NCT00002263|Granulocyte-Macrophage Colony-Stimulating Factor
706891|NCT00002263|Acquired Immunodeficiency Syndrome
706892|NCT00002263|Zidovudine
706893|NCT00002262|Skin Neoplasms
706894|NCT00002262|Tumor Necrosis Factor
706895|NCT00002262|Acquired Immunodeficiency Syndrome
706896|NCT00002261|Vaccines, Synthetic
706897|NCT00002261|Vaccinia Virus
706898|NCT00002261|Viral Vaccines
706899|NCT00002261|Smallpox Vaccine
706900|NCT00002261|HIV-1
706901|NCT00002261|AIDS Vaccines
706902|NCT00002261|HIV Seronegativity
706903|NCT00002260|Biological Availability
706904|NCT00002260|alovudine
706905|NCT00002260|Food
706906|NCT00002259|Mitoxantrone
706907|NCT00002259|Acquired Immunodeficiency Syndrome
706908|NCT00002258|Interleukin-3
706909|NCT00002258|Recombinant Proteins
706910|NCT00002258|Leukopenia
706911|NCT00002258|Acquired Immunodeficiency Syndrome
706912|NCT00002258|AIDS-Related Complex
706913|NCT00002258|Thrombocytopenia
706914|NCT00002257|Retinitis
706915|NCT00002257|Ganciclovir
706916|NCT00002257|Cytomegalovirus Infections
706917|NCT00002257|Acquired Immunodeficiency Syndrome
706918|NCT00002256|Zalcitabine
706919|NCT00002256|Acquired Immunodeficiency Syndrome
706920|NCT00002256|AIDS-Related Complex
706921|NCT00002256|Zidovudine
706922|NCT00002255|Erythropoietin
706923|NCT00002255|Granulocyte Colony-Stimulating Factor
706924|NCT00002255|Acquired Immunodeficiency Syndrome
706925|NCT00002255|AIDS-Related Complex
706926|NCT00002255|Zidovudine
706927|NCT00002254|Acquired Immunodeficiency Syndrome
706928|NCT00002253|Octreotide
706929|NCT00002253|Diarrhea
706930|NCT00002253|Acquired Immunodeficiency Syndrome
706931|NCT00002253|AIDS-Related Complex
706932|NCT00002252|Octreotide
706933|NCT00002252|Diarrhea
706934|NCT00002252|Acquired Immunodeficiency Syndrome
706935|NCT00002252|AIDS-Related Complex
706936|NCT00002251|AIDS-Related Opportunistic Infections
706937|NCT00002251|Ganciclovir
706938|NCT00002251|Cytomegalovirus Infections
706939|NCT00002251|Acquired Immunodeficiency Syndrome
706940|NCT00002251|Biological Availability
706941|NCT00002250|Recombinant Proteins
706942|NCT00002250|IgG
706943|NCT00002250|Drug Evaluation
706944|NCT00002250|Antigens, CD4
706945|NCT00002249|Anti-Infective Agents, Quinolone
706946|NCT00002249|Ofloxacin
706947|NCT00002249|Acquired Immunodeficiency Syndrome
706948|NCT00002248|Antidiarrheals
706949|NCT00002248|Cryptosporidiosis
706950|NCT00002248|Diarrhea
706951|NCT00002248|Acquired Immunodeficiency Syndrome
706952|NCT00002248|Cryptosporidium
706953|NCT00002248|Immunization, Passive
706954|NCT00002247|Retinitis
706955|NCT00002247|Ganciclovir
706956|NCT00002247|Cytomegalovirus Infections
706957|NCT00002247|Administration, Oral
706958|NCT00002247|Acquired Immunodeficiency Syndrome
706959|NCT00002246|AIDS Dementia Complex
706960|NCT00002246|Zidovudine
706961|NCT00002246|Stavudine
706962|NCT00002246|Reverse Transcriptase Inhibitors
706963|NCT00002245|Drug Therapy, Combination
706964|NCT00002245|HIV Protease Inhibitors
706965|NCT00002245|Lamivudine
706966|NCT00002245|Carbohydrates
706967|NCT00002245|VX 478
706968|NCT00002245|Reverse Transcriptase Inhibitors
706969|NCT00002245|Anti-HIV Agents
706970|NCT00002245|Lipids
706971|NCT00002245|Insulin Resistance
706972|NCT00002245|abacavir
706973|NCT00002244|Placebos
706974|NCT00002244|Infusions, Intravenous
706975|NCT00002244|Quality of Life
706976|NCT00002244|Anti-HIV Agents
706977|NCT00002244|tetrachlorodecaoxide
706978|NCT00002243|Anti-HIV Agents
706979|NCT00002241|Drug Therapy, Combination
706980|NCT00002241|Stavudine
706981|NCT00002241|HIV Protease Inhibitors
706982|NCT00002241|Ritonavir
706983|NCT00002241|Lamivudine
706984|NCT00002241|Indinavir
706985|NCT00002241|Reverse Transcriptase Inhibitors
706986|NCT00002241|Anti-HIV Agents
706987|NCT00002241|Viral Load
706988|NCT00002240|Didanosine
706989|NCT00002240|Dose-Response Relationship, Drug
706990|NCT00002240|Drug Therapy, Combination
706991|NCT00002240|Stavudine
706992|NCT00002240|HIV Protease Inhibitors
706993|NCT00002240|Reverse Transcriptase Inhibitors
706994|NCT00002240|Anti-HIV Agents
706995|NCT00002240|Nelfinavir
706996|NCT00002239|HIV-1
706997|NCT00002239|Dose-Response Relationship, Drug
706998|NCT00002239|Drug Therapy, Combination
706999|NCT00002239|VX 478
707000|NCT00002239|Anti-HIV Agents
707001|NCT00002239|pentafuside
707002|NCT00002239|abacavir
707003|NCT00002239|efavirenz
707004|NCT00002238|Drug Therapy, Combination
707005|NCT00002238|Acquired Immunodeficiency Syndrome
707006|NCT00002238|AIDS-Related Complex
707007|NCT00002238|Zidovudine
707008|NCT00002238|Interferon Type I
707009|NCT00002237|Placebos
707010|NCT00002237|Administration, Oral
707011|NCT00002237|Anti-HIV Agents
707012|NCT00002237|Viral Load
707013|NCT00002237|peldesine
707014|NCT00002236|Drug Therapy, Combination
707015|NCT00002236|Zidovudine
707016|NCT00002236|Drug Administration Schedule
707017|NCT00002236|HIV Protease Inhibitors
707018|NCT00002236|CD4 Lymphocyte Count
707019|NCT00002236|Indinavir
707020|NCT00002236|Delavirdine
707021|NCT00002236|Reverse Transcriptase Inhibitors
707022|NCT00002236|Anti-HIV Agents
707023|NCT00002236|Viral Load
707024|NCT00002235|Drug Therapy, Combination
707025|NCT00002235|HIV Protease Inhibitors
707026|NCT00002235|Indinavir
707027|NCT00002235|Nelfinavir
707028|NCT00002235|Reverse Transcriptase Inhibitors
707029|NCT00002235|Anti-HIV Agents
707030|NCT00002235|efavirenz
707031|NCT00002234|Drug Therapy, Combination
707032|NCT00002234|Reverse Transcriptase Inhibitors
707033|NCT00002234|Anti-HIV Agents
707034|NCT00002233|Drug Therapy, Combination
707035|NCT00002233|HIV Protease Inhibitors
707036|NCT00002233|CD4 Lymphocyte Count
707037|NCT00002233|Reverse Transcriptase Inhibitors
707038|NCT00002233|Anti-HIV Agents
707039|NCT00002233|Viral Load
707040|NCT00002232|Injections, Intradermal
707041|NCT00002232|Injections, Intramuscular
707042|NCT00002232|HIV Antibodies
707043|NCT00002232|Immunity, Cellular
707044|NCT00002232|AIDS Vaccines
707045|NCT00002232|HIV Seronegativity
707046|NCT00002232|Dose-Response Relationship, Immunologic
707047|NCT00002232|Vaccines, DNA
707048|NCT00002232|Immunity, Mucosal
707049|NCT00002231|Injections, Intramuscular
707050|NCT00002231|HIV Antibodies
707051|NCT00002231|Immunity, Cellular
707052|NCT00002231|AIDS Vaccines
707053|NCT00002231|HIV Seronegativity
707054|NCT00002231|Dose-Response Relationship, Immunologic
707055|NCT00002231|Vaccines, DNA
707056|NCT00002230|Didanosine
707057|NCT00002230|Drug Therapy, Combination
707058|NCT00002230|Stavudine
707059|NCT00002230|Hydroxyurea
707060|NCT00002230|Anti-HIV Agents
707061|NCT00002229|Drug Therapy, Combination
707062|NCT00002229|HIV Protease Inhibitors
707063|NCT00002229|Dosage Forms
707064|NCT00002229|Saquinavir
707065|NCT00002229|Reverse Transcriptase Inhibitors
707066|NCT00002229|Anti-HIV Agents
707067|NCT00002228|Injections, Subcutaneous
707068|NCT00002228|HIV-1
707069|NCT00002228|Anti-HIV Agents
707070|NCT00002228|peptide T20
707071|NCT00002227|Drug Therapy, Combination
707072|NCT00002227|Stavudine
707073|NCT00002227|Lamivudine
707074|NCT00002227|Reverse Transcriptase Inhibitors
707075|NCT00002227|efavirenz
707076|NCT00002226|Skin Neoplasms
707077|NCT00002226|Sarcoma, Kaposi
707078|NCT00002226|Antineoplastic Agents
707079|NCT00002225|Didanosine
707080|NCT00002225|Drug Therapy, Combination
707081|NCT00002225|Stavudine
707082|NCT00002225|Reverse Transcriptase Inhibitors
707083|NCT00002225|efavirenz
707084|NCT00002224|Didanosine
707085|NCT00002224|Drug Therapy, Combination
707086|NCT00002224|Drug Administration Schedule
707087|NCT00002224|Stavudine
707088|NCT00002224|HIV Protease Inhibitors
707089|NCT00002224|Nelfinavir
707090|NCT00002224|Reverse Transcriptase Inhibitors
707091|NCT00002224|Anti-HIV Agents
707092|NCT00002224|Viral Load
707093|NCT00002223|Drug Therapy, Combination
707094|NCT00002223|Adolescent Behavior
707095|NCT00002223|HIV Protease Inhibitors
707096|NCT00002223|Ritonavir
707097|NCT00002223|Indinavir
707098|NCT00002222|AIDS-Related Opportunistic Infections
707099|NCT00002222|Ganciclovir
707100|NCT00002222|Antiviral Agents
707101|NCT00002222|Drug Administration Schedule
707102|NCT00002222|Cytomegalovirus Retinitis
707103|NCT00002222|Prodrugs
707104|NCT00002221|Lymphoma, Non-Hodgkin
707105|NCT00002221|Bone Marrow
707106|NCT00002221|Lymphocyte Transformation
707107|NCT00002221|HIV-1
707108|NCT00002221|Retroviridae
707109|NCT00002221|Lymphoma, AIDS-Related
707110|NCT00002221|Genetic Vectors
707111|NCT00002221|Transduction, Genetic
707112|NCT00002221|Gene Transfer Techniques
707113|NCT00002220|Drug Resistance
707114|NCT00002220|Drug Therapy, Combination
707115|NCT00002220|Antiviral Agents
707116|NCT00002220|HIV Protease Inhibitors
707117|NCT00002220|Indinavir
707118|NCT00002220|RNA, Viral
707119|NCT00002220|Adenine
707120|NCT00002220|efavirenz
707121|NCT00002219|Dose-Response Relationship, Drug
707122|NCT00002219|Antiviral Agents
707123|NCT00002219|HIV Protease Inhibitors
707124|NCT00002219|Disease Progression
707125|NCT00002219|RNA, Viral
707126|NCT00002219|Adenine
707127|NCT00002219|Viral Load
707128|NCT00002219|Age Factors
707129|NCT00002219|Nelfinavir
707130|NCT00002218|HIV-1
707131|NCT00002218|Dose-Response Relationship, Drug
707132|NCT00002218|Anti-HIV Agents
707133|NCT00002217|Drug Therapy, Combination
707134|NCT00002217|Patient Compliance
707135|NCT00002217|Anti-HIV Agents
707136|NCT00002217|abacavir
707137|NCT00002216|Drug Therapy, Combination
707138|NCT00002216|HIV Protease Inhibitors
707139|NCT00002216|VX 478
707140|NCT00002216|Reverse Transcriptase Inhibitors
707141|NCT00002216|Anti-HIV Agents
707142|NCT00002216|abacavir
707143|NCT00002215|Drug Therapy, Combination
707144|NCT00002215|HIV Protease Inhibitors
707145|NCT00002215|RNA, Viral
707146|NCT00002215|Reverse Transcriptase Inhibitors
707147|NCT00002215|Viral Load
707148|NCT00002215|Nelfinavir
707149|NCT00002215|Uracil
707150|NCT00002214|Dose-Response Relationship, Drug
707151|NCT00002214|Reverse Transcriptase Inhibitors
707152|NCT00002213|HIV-1
707153|NCT00002213|Drug Therapy, Combination
707154|NCT00002213|Antiviral Agents
707155|NCT00002213|HIV Protease Inhibitors
707156|NCT00002213|RNA, Viral
707157|NCT00002213|VX 478
707158|NCT00002213|Anti-HIV Agents
707159|NCT00002213|abacavir
707160|NCT00002213|efavirenz
707161|NCT00002212|Sarcoma, Kaposi
707162|NCT00002212|Acquired Immunodeficiency Syndrome
707163|NCT00002212|Anticarcinogenic Agents
707164|NCT00002211|HIV-1
707165|NCT00002211|Didanosine
707166|NCT00002211|Stavudine
707167|NCT00002211|HIV Protease Inhibitors
707168|NCT00002211|RNA, Viral
707169|NCT00002211|Delavirdine
707170|NCT00002211|Reverse Transcriptase Inhibitors
707171|NCT00002211|Viral Load
707172|NCT00002211|Nelfinavir
707173|NCT00002210|HIV-1
707174|NCT00002210|Drug Therapy, Combination
707175|NCT00002210|Delavirdine
707176|NCT00002210|Reverse Transcriptase Inhibitors
707177|NCT00002209|Dose-Response Relationship, Drug
707178|NCT00002209|Drug Therapy, Combination
707179|NCT00002209|AIDS Dementia Complex
707180|NCT00002209|Zidovudine
707181|NCT00002209|Lamivudine
707182|NCT00002209|Indinavir
707183|NCT00002209|Reverse Transcriptase Inhibitors
707184|NCT00002208|HIV-1
707185|NCT00002208|Drug Therapy, Combination
707186|NCT00002208|Zidovudine
707187|NCT00002208|HIV Protease Inhibitors
707188|NCT00002208|Lamivudine
707189|NCT00002208|Indinavir
707190|NCT00002208|Reverse Transcriptase Inhibitors
707191|NCT00002207|Didanosine
707192|NCT00002207|Drug Therapy, Combination
707193|NCT00002207|Stavudine
707194|NCT00002207|Reverse Transcriptase Inhibitors
707195|NCT00002206|HIV-1
707196|NCT00002206|Adenine
707197|NCT00002206|Anti-HIV Agents
707198|NCT00002205|HIV Protease Inhibitors
707199|NCT00002205|VX 478
707200|NCT00002205|Anti-HIV Agents
707201|NCT00002205|abacavir
707202|NCT00002204|Reference Values
707203|NCT00002204|Placebos
707204|NCT00002204|AIDS Vaccines
707205|NCT00002204|HIV Core Protein p24
707206|NCT00002204|HIV Seronegativity
707207|NCT00002204|MF59 oil emulsion
707208|NCT00002203|Drug Therapy, Combination
707209|NCT00002203|Zidovudine
707210|NCT00002203|HIV Protease Inhibitors
707211|NCT00002203|CD4 Lymphocyte Count
707212|NCT00002203|CD4-CD8 Ratio
707213|NCT00002203|Lamivudine
707214|NCT00002203|Patient Compliance
707215|NCT00002203|Reverse Transcriptase Inhibitors
707216|NCT00002203|Anti-HIV Agents
707217|NCT00002203|Viral Load
707218|NCT00002202|HIV-1
707219|NCT00002202|Drug Therapy, Combination
707220|NCT00002202|HIV Protease Inhibitors
707221|NCT00002202|Indinavir
707222|NCT00002202|RNA, Viral
707223|NCT00002202|VX 478
707224|NCT00002202|Reverse Transcriptase Inhibitors
707225|NCT00002202|Anti-HIV Agents
707226|NCT00002202|Viral Load
707227|NCT00002201|Drug Therapy, Combination
707228|NCT00002201|HIV Protease Inhibitors
707229|NCT00002201|Ritonavir
707230|NCT00002201|Nelfinavir
707231|NCT00002201|Anti-HIV Agents
707232|NCT00002200|HIV-1
707233|NCT00002200|Administration, Oral
707234|NCT00002200|CD4 Lymphocyte Count
707235|NCT00002200|RNA, Viral
707236|NCT00002200|Reverse Transcriptase Inhibitors
707237|NCT00002200|Anti-HIV Agents
707238|NCT00002200|Viral Load
707239|NCT00002200|abacavir
707240|NCT00002199|HIV-1
707241|NCT00002199|Drug Therapy, Combination
707242|NCT00002199|Zidovudine
707243|NCT00002199|Drug Resistance, Microbial
707244|NCT00002199|HIV Protease Inhibitors
707245|NCT00002199|Lamivudine
707246|NCT00002199|Indinavir
707247|NCT00002199|Genotype
707248|NCT00002199|Phenotype
707249|NCT00002199|Reverse Transcriptase Inhibitors
707250|NCT00002199|Anti-HIV Agents
707251|NCT00002199|abacavir
707252|NCT00002198|Drug Interactions
707253|NCT00002198|Antiviral Agents
707254|NCT00002198|Ethanol
707255|NCT00002198|abacavir
707256|NCT00002197|HIV-1
707257|NCT00002197|CD4 Lymphocyte Count
707258|NCT00002197|Reverse Transcriptase Inhibitors
707259|NCT00002197|Anti-HIV Agents
707260|NCT00002197|Viral Load
707261|NCT00002197|abacavir
707262|NCT00002196|Dose-Response Relationship, Drug
707263|NCT00002196|Administration, Oral
707264|NCT00002196|Drug Administration Schedule
707265|NCT00002196|CD4 Lymphocyte Count
707266|NCT00002196|Anti-HIV Agents
707267|NCT00002195|Drug Therapy, Combination
707268|NCT00002195|Zidovudine
707269|NCT00002195|HIV Protease Inhibitors
707270|NCT00002195|Lamivudine
707271|NCT00002195|VX 478
707272|NCT00002195|Reverse Transcriptase Inhibitors
707273|NCT00002195|Anti-HIV Agents
707274|NCT00002195|Viral Load
707275|NCT00002194|Antibiotics, Macrolide
707276|NCT00002194|Clarithromycin
707277|NCT00002194|Nevirapine
707278|NCT00002194|Reverse Transcriptase Inhibitors
707279|NCT00002194|Cytochrome P-450
707280|NCT00002194|Anti-HIV Agents
707281|NCT00002193|HIV-1
707282|NCT00002193|Drug Therapy, Combination
707283|NCT00002193|HIV Protease Inhibitors
707284|NCT00002193|RNA, Viral
707285|NCT00002193|VX 478
707286|NCT00002193|Reverse Transcriptase Inhibitors
707287|NCT00002193|Anti-HIV Agents
707288|NCT00002193|Viral Load
707289|NCT00002192|AIDS-Related Opportunistic Infections
707290|NCT00002192|Mycobacterium avium-intracellulare Infection
707291|NCT00002192|Drug Therapy, Combination
707292|NCT00002192|Antitubercular Agents
707293|NCT00002192|Azithromycin
707294|NCT00002192|Clarithromycin
707295|NCT00002192|Bacteremia
707296|NCT00002192|rifapentine
707297|NCT00002191|AIDS-Related Opportunistic Infections
707298|NCT00002191|Placebos
707299|NCT00002191|Protozoan Infections
707300|NCT00002191|Intestinal Diseases
707301|NCT00002191|Albendazole
707302|NCT00002191|Microsporida
707303|NCT00002191|Anthelmintics
707304|NCT00002190|Drug Therapy, Combination
707305|NCT00002190|Zidovudine
707306|NCT00002190|HIV Protease Inhibitors
707307|NCT00002190|Lamivudine
707308|NCT00002190|Saquinavir
707309|NCT00002190|Reverse Transcriptase Inhibitors
707310|NCT00002190|Anti-HIV Agents
707311|NCT00002189|Sarcoma, Kaposi
707312|NCT00002189|Acquired Immunodeficiency Syndrome
707313|NCT00002189|Paclitaxel
707314|NCT00002189|Treatment Outcome
707315|NCT00002189|Antineoplastic Agents, Phytogenic
707316|NCT00002188|AIDS-Related Opportunistic Infections
707317|NCT00002188|Sarcoma, Kaposi
707318|NCT00002188|Antineoplastic Agents
707319|NCT00002187|AIDS-Related Opportunistic Infections
707320|NCT00002187|Antiviral Agents
707321|NCT00002187|Drug Administration Schedule
707322|NCT00002187|Cytomegalovirus Retinitis
707323|NCT00002187|fomivirsen
707324|NCT00002187|Vitreous Body
707325|NCT00002186|AIDS-Related Opportunistic Infections
707326|NCT00002186|Herpes Simplex
707327|NCT00002186|Drug Therapy, Combination
707328|NCT00002186|Acyclovir
707329|NCT00002186|Antiviral Agents
707330|NCT00002186|Gels
707331|NCT00002186|SP 303
707332|NCT00002185|Skin Neoplasms
707333|NCT00002185|AIDS-Related Opportunistic Infections
707334|NCT00002185|Sarcoma, Kaposi
707335|NCT00002185|Drug Therapy, Combination
707336|NCT00002185|HIV Protease Inhibitors
707337|NCT00002185|Mucous Membrane
707338|NCT00002185|Nelfinavir
707339|NCT00002185|Anti-HIV Agents
707340|NCT00002184|HIV-1
707341|NCT00002184|Dose-Response Relationship, Drug
707342|NCT00002184|Drug Therapy, Combination
707343|NCT00002184|Acquired Immunodeficiency Syndrome
707344|NCT00002184|Zidovudine
707345|NCT00002184|Stavudine
707346|NCT00002184|HIV Protease Inhibitors
707347|NCT00002184|CD4 Lymphocyte Count
707348|NCT00002184|Lamivudine
707349|NCT00002184|RNA, Viral
707350|NCT00002184|Saquinavir
707351|NCT00002184|Nelfinavir
707352|NCT00002184|Reverse Transcriptase Inhibitors
707353|NCT00002184|Adenine
707354|NCT00002184|Anti-HIV Agents
707355|NCT00002184|Viral Load
707356|NCT00002183|Drug Therapy, Combination
707357|NCT00002183|Drug Administration Schedule
707358|NCT00002183|HIV Protease Inhibitors
707359|NCT00002183|VX 478
707360|NCT00002183|Anti-HIV Agents
707361|NCT00002182|Placebos
707362|NCT00002182|Appetite Stimulants
707363|NCT00002182|Megestrol Acetate
707364|NCT00002182|Failure to Thrive
707365|NCT00002181|AIDS-Related Opportunistic Infections
707366|NCT00002181|Herpes Simplex
707367|NCT00002181|Acyclovir
707368|NCT00002181|Antiviral Agents
707369|NCT00002181|Gels
707370|NCT00002181|cidofovir
707371|NCT00002180|Placebos
707372|NCT00002180|Anti-HIV Agents
707373|NCT00002180|Adenine
707374|NCT00002179|Semen
707375|NCT00002179|Monocytes
707376|NCT00002179|HIV-1
707377|NCT00002179|Drug Therapy, Combination
707378|NCT00002179|Zidovudine
707379|NCT00002179|Lymph Nodes
707380|NCT00002179|HIV Protease Inhibitors
707381|NCT00002179|Lamivudine
707382|NCT00002179|Indinavir
707383|NCT00002179|RNA, Viral
707384|NCT00002179|Reverse Transcriptase Inhibitors
707385|NCT00002179|Anti-HIV Agents
707386|NCT00002179|Viral Load
707387|NCT00002178|HIV-1
707388|NCT00002178|Drug Therapy, Combination
707389|NCT00002178|HIV Protease Inhibitors
707390|NCT00002178|RNA, Viral
707391|NCT00002178|Dosage Forms
707392|NCT00002178|Saquinavir
707393|NCT00002178|Reverse Transcriptase Inhibitors
707394|NCT00002178|Anti-HIV Agents
707395|NCT00002178|Viral Load
707396|NCT00002177|Pilot Projects
707397|NCT00002177|HIV-1
707398|NCT00002177|Didanosine
707399|NCT00002177|Drug Therapy, Combination
707400|NCT00002177|Stavudine
707401|NCT00002177|Hydroxyurea
707402|NCT00002177|RNA, Viral
707403|NCT00002177|Nelfinavir
707404|NCT00002177|Anti-HIV Agents
707405|NCT00002177|Viral Load
707406|NCT00002176|Pilot Projects
707407|NCT00002176|Didanosine
707408|NCT00002176|Drug Therapy, Combination
707409|NCT00002176|Stavudine
707410|NCT00002176|Hydroxyurea
707411|NCT00002176|Nelfinavir
707412|NCT00002176|Anti-HIV Agents
707413|NCT00002176|Viral Load
707414|NCT00002175|Cohort Studies
707415|NCT00002175|RNA, Viral
707416|NCT00002175|Administration, Cutaneous
707417|NCT00002175|Anti-HIV Agents
707418|NCT00002175|Dinitrobenzenes
707419|NCT00002174|Adjuvants, Immunologic
707420|NCT00002174|Thalidomide
707421|NCT00002174|Cytokines
707422|NCT00002174|Viral Load
707423|NCT00002173|Acquired Immunodeficiency Syndrome
707424|NCT00002173|AIDS Vaccines
707425|NCT00002173|CD4 Lymphocyte Count
707426|NCT00002173|Salk HIV Immunogen
707427|NCT00002172|Acquired Immunodeficiency Syndrome
707428|NCT00002172|AIDS Vaccines
707429|NCT00002172|CD4 Lymphocyte Count
707430|NCT00002172|Salk HIV Immunogen
707431|NCT00002171|Placebos
707432|NCT00002171|Drug Therapy, Combination
707433|NCT00002171|Stavudine
707434|NCT00002171|HIV Protease Inhibitors
707435|NCT00002171|Lamivudine
707436|NCT00002171|Nelfinavir
707437|NCT00002171|Anti-HIV Agents
707438|NCT00002170|AIDS-Related Opportunistic Infections
707439|NCT00002170|Placebos
707440|NCT00002170|Mycobacterium avium-intracellulare Infection
707441|NCT00002170|Acquired Immunodeficiency Syndrome
707442|NCT00002170|HIV Protease Inhibitors
707443|NCT00002170|Nelfinavir
707444|NCT00002170|Anti-Infective Agents
707445|NCT00002170|Anti-HIV Agents
707446|NCT00002169|AIDS-Related Opportunistic Infections
707447|NCT00002169|Placebos
707448|NCT00002169|Antiviral Agents
707449|NCT00002169|Cytomegalovirus Retinitis
707450|NCT00002169|Treatment Outcome
707451|NCT00002169|Nelfinavir
707452|NCT00002168|Didanosine
707453|NCT00002168|Drug Therapy, Combination
707454|NCT00002168|Zidovudine
707455|NCT00002168|Stavudine
707456|NCT00002168|HIV Protease Inhibitors
707457|NCT00002168|CD4 Lymphocyte Count
707458|NCT00002168|Lamivudine
707459|NCT00002168|Indinavir
707460|NCT00002168|Reverse Transcriptase Inhibitors
707461|NCT00002168|Anti-HIV Agents
707462|NCT00002168|Viral Load
707463|NCT00002167|Skin Neoplasms
707464|NCT00002167|Sarcoma, Kaposi
707465|NCT00002167|Acquired Immunodeficiency Syndrome
707466|NCT00002167|Photochemotherapy
707467|NCT00002167|tin etiopurpurin
707468|NCT00002167|Radiation-Sensitizing Agents
707469|NCT00002166|Nevirapine
707470|NCT00002166|Reverse Transcriptase Inhibitors
707471|NCT00002166|Anti-HIV Agents
707472|NCT00002165|Acquired Immunodeficiency Syndrome
707473|NCT00002165|HIV Protease Inhibitors
707474|NCT00002165|CD4 Lymphocyte Count
707475|NCT00002165|Nelfinavir
707476|NCT00002165|Anti-HIV Agents
707477|NCT00002164|Biological Availability
707478|NCT00002164|HIV Protease Inhibitors
707479|NCT00002164|Dosage Forms
707480|NCT00002164|Nelfinavir
707481|NCT00002163|Acquired Immunodeficiency Syndrome
707482|NCT00002163|AIDS Dementia Complex
707483|NCT00002163|Antiviral Agents
707484|NCT00002163|abacavir
707485|NCT00002162|Drug Therapy, Combination
707486|NCT00002162|Acquired Immunodeficiency Syndrome
707487|NCT00002162|AIDS-Related Complex
707488|NCT00002162|Antiviral Agents
707489|NCT00002162|Saquinavir
707490|NCT00002161|Drug Therapy, Combination
707491|NCT00002161|Acquired Immunodeficiency Syndrome
707492|NCT00002161|AIDS-Related Complex
707493|NCT00002161|Antiviral Agents
707494|NCT00002161|Adenine
707495|NCT00002160|Acquired Immunodeficiency Syndrome
707496|NCT00002160|AIDS-Related Complex
707497|NCT00002160|Pain
707498|NCT00002160|Palliative Care
707499|NCT00002160|omega-conopeptide MVIIA
707500|NCT00002160|Calcium Channel Blockers
707501|NCT00002159|Itraconazole
707502|NCT00002159|Histoplasmosis
707503|NCT00002159|Antifungal Agents
707504|NCT00002159|Acquired Immunodeficiency Syndrome
707505|NCT00002159|Amphotericin B
707506|NCT00002159|AIDS-Related Complex
707507|NCT00002159|Blastomycosis
707508|NCT00002159|Antibiotics, Antifungal
707509|NCT00002158|Cryptosporidiosis
707510|NCT00002158|Diarrhea
707511|NCT00002158|Acquired Immunodeficiency Syndrome
707512|NCT00002158|nitazoxanide
707513|NCT00002158|Antiparasitic Agents
707514|NCT00002157|Acquired Immunodeficiency Syndrome
707515|NCT00002157|Cachexia
707516|NCT00002157|Thalidomide
707517|NCT00002156|AIDS-Related Opportunistic Infections
707518|NCT00002156|Ganciclovir
707519|NCT00002156|Drug Therapy, Combination
707520|NCT00002156|Acquired Immunodeficiency Syndrome
707521|NCT00002156|Antiviral Agents
707522|NCT00002156|Cytomegalovirus Retinitis
707523|NCT00002156|Injections
707524|NCT00002155|Drug Therapy, Combination
707525|NCT00002155|Acquired Immunodeficiency Syndrome
707526|NCT00002155|Antiviral Agents
707527|NCT00002155|Zidovudine
707528|NCT00002155|HIV Protease Inhibitors
707529|NCT00002155|Lamivudine
707530|NCT00002155|Indinavir
707531|NCT00002154|Drug Therapy, Combination
707532|NCT00002154|Cognition Disorders
707533|NCT00002154|Acquired Immunodeficiency Syndrome
707534|NCT00002154|AIDS-Related Complex
707535|NCT00002154|Thioctic Acid
707536|NCT00002154|Selegiline
707537|NCT00002153|Skin Neoplasms
707538|NCT00002153|Sarcoma, Kaposi
707539|NCT00002153|Acquired Immunodeficiency Syndrome
707540|NCT00002153|Antineoplastic Agents
707541|NCT00002152|Acquired Immunodeficiency Syndrome
707542|NCT00002152|Antiviral Agents
707543|NCT00002151|Drug Therapy, Combination
707544|NCT00002151|AIDS-Related Complex
707545|NCT00002151|Zidovudine
707546|NCT00002151|MDL 28574
707547|NCT00002150|Drug Therapy, Combination
707548|NCT00002150|Acquired Immunodeficiency Syndrome
707549|NCT00002150|AIDS-Related Complex
707550|NCT00002150|Zidovudine
707551|NCT00002150|MDL 28574
707552|NCT00002149|AIDS-Related Opportunistic Infections
707553|NCT00002149|Drug Therapy, Combination
707554|NCT00002149|Acquired Immunodeficiency Syndrome
707555|NCT00002149|AIDS-Related Complex
707556|NCT00002149|Sinusitis
707557|NCT00002149|Ephedrine
707558|NCT00002149|Acupuncture Therapy
707559|NCT00002149|Drugs, Chinese Herbal
707560|NCT00002149|Medicine, Chinese Traditional
707561|NCT00002149|Drug Combinations
707562|NCT00002149|Antibiotics, Combined
707563|NCT00002149|Amoxicillin-Potassium Clavulanate Combination
707564|NCT00002148|Cognition Disorders
707565|NCT00002148|Acquired Immunodeficiency Syndrome
707566|NCT00002148|AIDS-Related Complex
707567|NCT00002148|Free Radical Scavengers
707568|NCT00002148|Antioxidants
707569|NCT00002148|OPC 14117
707570|NCT00002147|Sarcoma, Kaposi
707571|NCT00002147|Liposomes
707572|NCT00002147|Doxorubicin
707573|NCT00002147|Acquired Immunodeficiency Syndrome
707574|NCT00002147|Drug Carriers
707575|NCT00002146|Infusions, Intravenous
707576|NCT00002146|Foscarnet
707577|NCT00002146|Cytomegalovirus Infections
707578|NCT00002146|Acquired Immunodeficiency Syndrome
707579|NCT00002146|Magnesium Sulfate
707580|NCT00002146|Magnesium Deficiency
707581|NCT00002146|Hypocalcemia
707582|NCT00002145|Foscarnet
707583|NCT00002145|Cytomegalovirus Infections
707584|NCT00002145|Acquired Immunodeficiency Syndrome
707585|NCT00002144|Herpes Simplex
707586|NCT00002144|Foscarnet
707587|NCT00002144|Acquired Immunodeficiency Syndrome
707588|NCT00002143|Psoriasis
707589|NCT00002143|Acquired Immunodeficiency Syndrome
707590|NCT00002143|AIDS-Related Complex
707591|NCT00002143|Acitretin
707592|NCT00002142|Retinitis
707593|NCT00002142|Probenecid
707594|NCT00002142|Drug Therapy, Combination
707595|NCT00002142|Cytomegalovirus Infections
707596|NCT00002142|Acquired Immunodeficiency Syndrome
707597|NCT00002142|Antiviral Agents
707598|NCT00002142|cidofovir
707599|NCT00002141|Biological Availability
707600|NCT00002141|Reverse Transcriptase Inhibitors
707601|NCT00002141|Food-Drug Interactions
707602|NCT00002141|abacavir
707603|NCT00002140|Mycobacterium avium-intracellulare Infection
707604|NCT00002140|Drug Therapy, Combination
707605|NCT00002140|Ethambutol
707606|NCT00002140|Acquired Immunodeficiency Syndrome
707607|NCT00002140|Azithromycin
707608|NCT00002140|Clarithromycin
707609|NCT00002139|Acquired Immunodeficiency Syndrome
707610|NCT00002139|Azithromycin
707611|NCT00002139|Bacterial Infections
707612|NCT00002138|Neoplasms
707613|NCT00002138|Sarcoma, Kaposi
707614|NCT00002138|Acquired Immunodeficiency Syndrome
707615|NCT00002138|Antineoplastic Agents
707616|NCT00002138|tecogalan
707617|NCT00002137|Neoplasms
707618|NCT00002137|Sarcoma, Kaposi
707619|NCT00002137|Acquired Immunodeficiency Syndrome
707620|NCT00002137|Antineoplastic Agents
707621|NCT00002137|tecogalan
707622|NCT00002136|Neoplasms
707623|NCT00002136|Sarcoma, Kaposi
707624|NCT00002136|Acquired Immunodeficiency Syndrome
707625|NCT00002136|Antineoplastic Agents
707626|NCT00002136|tecogalan
707627|NCT00002135|Retinitis
707628|NCT00002135|Ganciclovir
707629|NCT00002135|Administration, Oral
707630|NCT00002135|Acquired Immunodeficiency Syndrome
707631|NCT00002134|Retinitis
707632|NCT00002134|Ganciclovir
707633|NCT00002134|Administration, Oral
707634|NCT00002134|Acquired Immunodeficiency Syndrome
707635|NCT00002133|Itraconazole
707636|NCT00002133|Acquired Immunodeficiency Syndrome
707637|NCT00002133|AIDS-Related Complex
707638|NCT00002133|Candidiasis, Oral
707639|NCT00002132|Itraconazole
707640|NCT00002132|Fluconazole
707641|NCT00002132|Acquired Immunodeficiency Syndrome
707642|NCT00002132|Candidiasis
707643|NCT00002132|Immunocompromised Host
707644|NCT00002131|Sarcoma, Kaposi
707645|NCT00002131|Acquired Immunodeficiency Syndrome
707646|NCT00002131|Antiviral Agents
707647|NCT00002131|vesnarinone
707648|NCT00002130|Acquired Immunodeficiency Syndrome
707649|NCT00002130|Antiviral Agents
707650|NCT00002130|vesnarinone
707651|NCT00002129|vesnarinone
707652|NCT00002128|Acquired Immunodeficiency Syndrome
707653|NCT00002128|AIDS-Related Complex
707654|NCT00002128|Antiviral Agents
707655|NCT00002128|Adenine
707656|NCT00002127|Acquired Immunodeficiency Syndrome
707657|NCT00002127|Cachexia
707658|NCT00002127|Thalidomide
707659|NCT00002126|Neutropenia
707660|NCT00002126|Granulocyte Colony-Stimulating Factor
707661|NCT00002126|Acquired Immunodeficiency Syndrome
707662|NCT00002125|Retinitis
707663|NCT00002125|Infusions, Intravenous
707664|NCT00002125|Foscarnet
707665|NCT00002125|Cytomegalovirus Infections
707666|NCT00002125|Administration, Oral
707667|NCT00002125|Acquired Immunodeficiency Syndrome
707668|NCT00002125|Fluid Therapy
707669|NCT00002124|Drug Therapy, Combination
707670|NCT00002124|Acquired Immunodeficiency Syndrome
707671|NCT00002124|AIDS-Related Complex
707672|NCT00002124|Antiviral Agents
707673|NCT00002124|Zidovudine
707674|NCT00002123|Didanosine
707675|NCT00002123|Drug Therapy, Combination
707676|NCT00002123|Acquired Immunodeficiency Syndrome
707677|NCT00002123|AIDS-Related Complex
707678|NCT00002123|Antiviral Agents
707679|NCT00002122|Rifabutin
707680|NCT00002122|Mycobacterium avium-intracellulare Infection
707681|NCT00002122|Mycoses
707682|NCT00002122|Drug Therapy, Combination
707683|NCT00002122|Fluconazole
707684|NCT00002122|Acquired Immunodeficiency Syndrome
707685|NCT00002122|Azithromycin
707686|NCT00002121|Antidiarrheals
707687|NCT00002121|Diarrhea
707688|NCT00002121|Acquired Immunodeficiency Syndrome
707689|NCT00002121|AIDS-Related Complex
707690|NCT00002121|N(1),N(14)-bis(ethyl)homospermine
707691|NCT00002120|Trimethoprim-Sulfamethoxazole Combination
707692|NCT00002120|Trimetrexate
707693|NCT00002120|Pneumonia, Pneumocystis carinii
707694|NCT00002120|Leucovorin
707695|NCT00002120|Dapsone
707696|NCT00002120|Drug Therapy, Combination
707697|NCT00002120|Acquired Immunodeficiency Syndrome
707698|NCT00002119|Acquired Immunodeficiency Syndrome
707699|NCT00002119|AIDS-Related Complex
707700|NCT00002119|Antiviral Agents
707701|NCT00002118|Zalcitabine
707702|NCT00002118|Acquired Immunodeficiency Syndrome
707703|NCT00002118|AIDS-Related Complex
707704|NCT00002117|Zalcitabine
707705|NCT00002117|Drug Therapy, Combination
707706|NCT00002117|Acquired Immunodeficiency Syndrome
707707|NCT00002117|AIDS-Related Complex
707708|NCT00002117|Zidovudine
707709|NCT00002116|Herpes Simplex
707710|NCT00002116|Acquired Immunodeficiency Syndrome
707711|NCT00002116|Antiviral Agents
707712|NCT00002116|cidofovir
707713|NCT00002115|Acquired Immunodeficiency Syndrome
707714|NCT00002115|Antiviral Agents
707715|NCT00002115|Adenine
707716|NCT00002113|Meningitis
707717|NCT00002113|Cryptococcosis
707718|NCT00002113|Drug Therapy, Combination
707719|NCT00002113|Fluconazole
707720|NCT00002113|Flucytosine
707721|NCT00002113|Acquired Immunodeficiency Syndrome
707722|NCT00002112|Nystatin
707723|NCT00002112|Fluconazole
707724|NCT00002112|Acquired Immunodeficiency Syndrome
707725|NCT00002112|AIDS-Related Complex
707726|NCT00002112|Candidiasis, Oral
707727|NCT00002111|AIDS-Related Complex
707728|NCT00002111|Saquinavir
707729|NCT00002111|HIV Protease Inhibitors
707730|NCT00002110|Drug Therapy, Combination
707731|NCT00002110|AIDS-Related Complex
707732|NCT00002110|Zidovudine
707733|NCT00002110|Cysteamine
707734|NCT00002109|Thymopentin
707735|NCT00002109|Zalcitabine
707736|NCT00002109|Didanosine
707737|NCT00002109|Drug Therapy, Combination
707738|NCT00002109|Zidovudine
707739|NCT00002109|Stavudine
707740|NCT00002108|Drug Therapy, Combination
707741|NCT00002108|Acquired Immunodeficiency Syndrome
707742|NCT00002108|AIDS-Related Complex
707743|NCT00002108|Antiviral Agents
707744|NCT00002108|Zidovudine
707745|NCT00002107|Interleukin-2
707746|NCT00002107|Acquired Immunodeficiency Syndrome
707747|NCT00002107|AIDS-Related Complex
707748|NCT00002106|Ranitidine
707749|NCT00002105|Vincristine
707750|NCT00002105|Sarcoma, Kaposi
707751|NCT00002105|Liposomes
707752|NCT00002105|Doxorubicin
707753|NCT00002105|Drug Therapy, Combination
707754|NCT00002105|Acquired Immunodeficiency Syndrome
707755|NCT00002105|Bleomycin
707756|NCT00002105|Drug Carriers
707757|NCT00002104|Mycobacterium tuberculosis
707758|NCT00002104|Mycobacterium Infections
707759|NCT00002104|AIDS-Related Opportunistic Infections
707760|NCT00002104|Mycobacterium avium-intracellulare Infection
707761|NCT00002104|Acquired Immunodeficiency Syndrome
707762|NCT00002104|AIDS-Related Complex
707763|NCT00002104|Mycobacterium Infections, Atypical
707764|NCT00002104|Thalidomide
707765|NCT00002103|Trimetrexate
707766|NCT00002103|Pneumonia, Pneumocystis carinii
707767|NCT00002103|Leucovorin
707768|NCT00002103|Drug Therapy, Combination
707769|NCT00002103|Acquired Immunodeficiency Syndrome
707770|NCT00002102|Trimetrexate
707771|NCT00002102|Pneumonia, Pneumocystis carinii
707772|NCT00002102|Leucovorin
707773|NCT00002102|Drug Therapy, Combination
707774|NCT00002102|Acquired Immunodeficiency Syndrome
707775|NCT00002101|Rifabutin
707776|NCT00002101|Mycobacterium avium-intracellulare Infection
707777|NCT00002101|Drug Therapy, Combination
707778|NCT00002101|Ethambutol
707779|NCT00002101|Acquired Immunodeficiency Syndrome
707780|NCT00002101|Clarithromycin
707781|NCT00002100|Acquired Immunodeficiency Syndrome
707782|NCT00002100|AIDS-Related Complex
707783|NCT00002100|curdlan sulfate
707784|NCT00002099|Didanosine
707785|NCT00002099|Drug Therapy, Combination
707786|NCT00002099|Acquired Immunodeficiency Syndrome
707787|NCT00002099|AIDS-Related Complex
707788|NCT00002099|Lentinan
707789|NCT00002098|Didanosine
707790|NCT00002098|Drug Therapy, Combination
707791|NCT00002098|Acquired Immunodeficiency Syndrome
707792|NCT00002098|AIDS-Related Complex
707793|NCT00002098|Lentinan
707794|NCT00002097|Nystatin
707795|NCT00002097|Acquired Immunodeficiency Syndrome
707796|NCT00002097|AIDS-Related Complex
707797|NCT00002096|Didanosine
707798|NCT00002096|Ganciclovir
707799|NCT00002096|Drug Interactions
707800|NCT00002096|Cytomegalovirus Infections
707801|NCT00002096|Acquired Immunodeficiency Syndrome
707802|NCT00002096|Zidovudine
707803|NCT00002095|Ganciclovir
707804|NCT00002095|Cytomegalovirus Infections
707805|NCT00002095|Acquired Immunodeficiency Syndrome
707806|NCT00002094|Virus Replication
707807|NCT00002094|Acquired Immunodeficiency Syndrome
707808|NCT00002094|Antiviral Agents
707809|NCT00002093|Vincristine
707810|NCT00002093|Sarcoma, Kaposi
707811|NCT00002093|Liposomes
707812|NCT00002093|Doxorubicin
707813|NCT00002093|Acquired Immunodeficiency Syndrome
707814|NCT00002093|Bleomycin
707815|NCT00002093|Daunorubicin
707816|NCT00002093|Drug Carriers
707817|NCT00002092|Acquired Immunodeficiency Syndrome
707818|NCT00002092|AIDS-Related Complex
707819|NCT00002092|Cimetidine
707820|NCT00002091|Pentoxifylline
707821|NCT00002091|Acquired Immunodeficiency Syndrome
707822|NCT00002091|AIDS-Related Complex
707823|NCT00002090|Mycobacterium avium-intracellulare Infection
707824|NCT00002090|Acquired Immunodeficiency Syndrome
707825|NCT00002090|Azithromycin
707826|NCT00002089|Mycobacterium avium-intracellulare Infection
707827|NCT00002089|Acquired Immunodeficiency Syndrome
707828|NCT00002089|Azithromycin
707829|NCT00002088|Diarrhea
707830|NCT00002088|Acquired Immunodeficiency Syndrome
707831|NCT00002088|AIDS-Related Complex
707832|NCT00002088|Saccharomyces
707833|NCT00002087|Recombinant Proteins
707834|NCT00002087|Acquired Immunodeficiency Syndrome
707835|NCT00002087|Antigens, CD4
707836|NCT00002087|AIDS-Related Complex
707837|NCT00002086|Zalcitabine
707838|NCT00002086|Drug Therapy, Combination
707839|NCT00002086|AIDS-Related Complex
707840|NCT00002086|Zidovudine
707841|NCT00002086|Interferon-alpha
707842|NCT00002085|Mycobacterium avium-intracellulare Infection
707843|NCT00002085|Acquired Immunodeficiency Syndrome
707844|NCT00002085|Azithromycin
707845|NCT00002085|Mycobacterium Infections, Atypical
707846|NCT00002084|Acyclovir
707847|NCT00002084|Acquired Immunodeficiency Syndrome
707848|NCT00002084|AIDS-Related Complex
707849|NCT00002084|Antiviral Agents
707850|NCT00002084|Anus Diseases
707851|NCT00002084|Herpes Genitalis
707852|NCT00002083|Peptide T
707853|NCT00002083|HIV-1
707854|NCT00002083|Administration, Intranasal
707855|NCT00002083|Acquired Immunodeficiency Syndrome
707856|NCT00002083|Peripheral Nervous System Diseases
707857|NCT00002082|Cryptosporidiosis
707858|NCT00002082|Acquired Immunodeficiency Syndrome
707859|NCT00002082|Azithromycin
707860|NCT00002081|Zalcitabine
707861|NCT00002081|Acquired Immunodeficiency Syndrome
707862|NCT00002081|AIDS-Related Complex
707863|NCT00002081|Zidovudine
707864|NCT00002080|Rifabutin
707865|NCT00002080|Acquired Immunodeficiency Syndrome
707866|NCT00002080|AIDS-Related Complex
707867|NCT00002080|Mycobacterium avium Complex
707868|NCT00002080|Bacteremia
707869|NCT00002079|Zidovudine
707870|NCT00002079|1-Deoxynojirimycin
707871|NCT00002078|Drug Evaluation
707872|NCT00002078|Interferon-alpha
707873|NCT00002077|AIDS-Related Opportunistic Infections
707874|NCT00002077|Meningitis
707875|NCT00002077|Injections, Intravenous
707876|NCT00002077|Cryptococcosis
707877|NCT00002077|Fluconazole
707878|NCT00002077|Administration, Oral
707879|NCT00002077|Acquired Immunodeficiency Syndrome
707880|NCT00002076|AIDS-Related Opportunistic Infections
707881|NCT00002076|Meningitis
707882|NCT00002076|Cryptococcosis
707883|NCT00002076|Fluconazole
707884|NCT00002076|Administration, Oral
707885|NCT00002076|Acquired Immunodeficiency Syndrome
707886|NCT00002075|AIDS-Related Opportunistic Infections
707887|NCT00002075|Meningitis
707888|NCT00002075|Cryptococcosis
707889|NCT00002075|Drug Therapy, Combination
707890|NCT00002075|Fluconazole
707891|NCT00002075|Flucytosine
707892|NCT00002075|Acquired Immunodeficiency Syndrome
707893|NCT00002075|Amphotericin B
707894|NCT00002074|AIDS-Related Opportunistic Infections
707895|NCT00002074|Meningitis
707896|NCT00002074|Cryptococcosis
707897|NCT00002074|Fluconazole
707898|NCT00002074|Acquired Immunodeficiency Syndrome
707899|NCT00002074|Amphotericin B
707900|NCT00002073|Recombinant Proteins
707901|NCT00002073|Injections, Subcutaneous
707902|NCT00002073|Erythropoietin
707903|NCT00002073|Acquired Immunodeficiency Syndrome
707904|NCT00002073|Anemia
707905|NCT00002073|Zidovudine
707906|NCT00002072|Recombinant Proteins
707907|NCT00002072|Erythropoietin
707908|NCT00002072|Acquired Immunodeficiency Syndrome
707909|NCT00002072|Anemia
707910|NCT00002072|Zidovudine
707911|NCT00002071|Recombinant Proteins
707912|NCT00002071|Erythropoietin
707913|NCT00002071|Acquired Immunodeficiency Syndrome
707914|NCT00002071|Anemia
707915|NCT00002071|Zidovudine
707916|NCT00002070|Recombinant Proteins
707917|NCT00002070|Retinitis
707918|NCT00002070|AIDS-Related Opportunistic Infections
707919|NCT00002070|Neutropenia
707920|NCT00002070|Ganciclovir
707921|NCT00002070|Drug Therapy, Combination
707922|NCT00002070|Granulocyte-Macrophage Colony-Stimulating Factor
707923|NCT00002070|Cytomegalovirus Infections
707924|NCT00002070|Acquired Immunodeficiency Syndrome
707925|NCT00002069|Ditiocarb
707926|NCT00002069|Acquired Immunodeficiency Syndrome
707927|NCT00002069|AIDS-Related Complex
707928|NCT00002068|AIDS-Related Opportunistic Infections
707929|NCT00002068|Meningitis
707930|NCT00002068|Cryptococcosis
707931|NCT00002068|Drug Therapy, Combination
707932|NCT00002068|Fluconazole
707933|NCT00002068|Flucytosine
707934|NCT00002068|Acquired Immunodeficiency Syndrome
707935|NCT00002068|Amphotericin B
707936|NCT00002067|Body Weight
707937|NCT00002067|T-Lymphocytes
707938|NCT00002067|Nutritional Status
707939|NCT00002067|Megestrol
707940|NCT00002067|Acquired Immunodeficiency Syndrome
707941|NCT00002067|Anorexia
707942|NCT00002067|Cachexia
707943|NCT00002067|Energy Intake
707944|NCT00002066|Thymopentin
707945|NCT00002066|Acquired Immunodeficiency Syndrome
707946|NCT00002065|Delayed-Action Preparations
707947|NCT00002065|Disulfiram
707948|NCT00002065|Acquired Immunodeficiency Syndrome
707949|NCT00002065|AIDS-Related Complex
707950|NCT00002064|Sulfonamides
707951|NCT00002064|Toxoplasmosis
707952|NCT00002064|AIDS-Related Opportunistic Infections
707953|NCT00002064|Pyrimethamine
707954|NCT00002064|Drug Therapy, Combination
707955|NCT00002064|Encephalitis
707956|NCT00002064|Acquired Immunodeficiency Syndrome
707957|NCT00002064|Clindamycin
707958|NCT00002063|Immune Tolerance
707959|NCT00002063|AIDS-Related Complex
707960|NCT00002063|Zidovudine
707961|NCT00002062|Spiramycin
707962|NCT00002062|AIDS-Related Opportunistic Infections
707963|NCT00002062|Immune Tolerance
707964|NCT00002062|Cryptosporidiosis
707965|NCT00002062|Diarrhea
707966|NCT00002062|Drugs, Investigational
707967|NCT00002062|Acquired Immunodeficiency Syndrome
707968|NCT00002061|T-Lymphocytes
707969|NCT00002061|Immune Tolerance
707970|NCT00002061|Inosine Pranobex
707971|NCT00002061|Killer Cells
707972|NCT00002061|T-Lymphocytes, Helper-Inducer
707973|NCT00002061|Acquired Immunodeficiency Syndrome
707974|NCT00002061|AIDS-Related Complex
707975|NCT00002060|AIDS-Related Opportunistic Infections
707976|NCT00002060|Inosine Pranobex
707977|NCT00002060|Homosexuality
707978|NCT00002060|Acquired Immunodeficiency Syndrome
707979|NCT00002060|AIDS-Related Complex
707980|NCT00002059|T-Lymphocytes, Suppressor-Effector
707981|NCT00002059|Neoplasms
707982|NCT00002059|Inosine Pranobex
707983|NCT00002059|Killer Cells
707984|NCT00002059|T-Lymphocytes, Helper-Inducer
707985|NCT00002059|Acquired Immunodeficiency Syndrome
707986|NCT00002059|AIDS-Related Complex
707987|NCT00002058|AIDS-Related Opportunistic Infections
707988|NCT00002058|Mycobacterium avium-intracellulare Infection
707989|NCT00002058|Clofazimine
707990|NCT00002058|Acquired Immunodeficiency Syndrome
707991|NCT00002057|Nystatin
707992|NCT00002057|AIDS-Related Opportunistic Infections
707993|NCT00002057|Acquired Immunodeficiency Syndrome
707994|NCT00002057|AIDS-Related Complex
707995|NCT00002057|Candidiasis, Oral
707996|NCT00002056|Trimethoprim-Sulfamethoxazole Combination
707997|NCT00002056|AIDS-Related Opportunistic Infections
707998|NCT00002056|Pneumonia, Pneumocystis carinii
707999|NCT00002056|Pentamidine
708000|NCT00002056|Injections, Intravenous
708001|NCT00002056|Administration, Oral
708002|NCT00002056|Aerosols
708003|NCT00002056|Acquired Immunodeficiency Syndrome
708004|NCT00002055|AIDS-Related Opportunistic Infections
708005|NCT00002055|Pneumonia, Pneumocystis carinii
708006|NCT00002055|Pentamidine
708007|NCT00002055|Dose-Response Relationship, Drug
708008|NCT00002055|Aerosols
708009|NCT00002055|Acquired Immunodeficiency Syndrome
708010|NCT00002054|AIDS-Related Opportunistic Infections
708011|NCT00002054|Pneumonia, Pneumocystis carinii
708012|NCT00002054|Pentamidine
708013|NCT00002054|Dose-Response Relationship, Drug
708014|NCT00002054|Acquired Immunodeficiency Syndrome
708015|NCT00002053|AIDS-Related Opportunistic Infections
708016|NCT00002053|Pneumonia, Pneumocystis carinii
708017|NCT00002053|Pentamidine
708018|NCT00002053|Acquired Immunodeficiency Syndrome
708019|NCT00002052|Salmonella Infections
708020|NCT00002052|AIDS-Related Opportunistic Infections
708021|NCT00002052|Acquired Immunodeficiency Syndrome
708022|NCT00002052|Amoxicillin
708023|NCT00002052|Ceftriaxone
708024|NCT00002051|Thymopentin
708025|NCT00002051|Acquired Immunodeficiency Syndrome
708026|NCT00002050|Semen
708027|NCT00002050|Thymopentin
708028|NCT00002050|Leukocytes, Mononuclear
708029|NCT00002050|AIDS-Related Complex
708030|NCT00002049|Semen
708031|NCT00002049|Thymopentin
708032|NCT00002049|Leukocytes, Mononuclear
708033|NCT00002049|HIV Seropositivity
708034|NCT00002049|AIDS-Related Complex
708035|NCT00002048|Acquired Immunodeficiency Syndrome
708036|NCT00002048|Zidovudine
708037|NCT00002047|Kidney Failure, Chronic
708038|NCT00002047|Acquired Immunodeficiency Syndrome
708039|NCT00002047|AIDS-Related Complex
708040|NCT00002047|Zidovudine
708041|NCT00002047|Renal Dialysis
708042|NCT00002046|Acquired Immunodeficiency Syndrome
708043|NCT00002046|AIDS-Related Complex
708044|NCT00002046|Zidovudine
708045|NCT00002045|Prospective Studies
708046|NCT00002045|Zidovudine
708047|NCT00002044|Pilot Projects
708048|NCT00002044|Neuromuscular Diseases
708049|NCT00002044|Drug Evaluation
708050|NCT00002044|Acquired Immunodeficiency Syndrome
708051|NCT00002044|AIDS Dementia Complex
708052|NCT00002044|AIDS-Related Complex
708053|NCT00002044|Zidovudine
708054|NCT00002043|AIDS-Related Opportunistic Infections
708055|NCT00002043|Pneumonia, Pneumocystis carinii
708056|NCT00002043|Leukoplakia, Oral
708057|NCT00002043|Dapsone
708058|NCT00002043|AIDS-Related Complex
708059|NCT00002043|Candidiasis, Oral
708060|NCT00002042|Recombinant Proteins
708061|NCT00002042|Erythropoietin
708062|NCT00002042|Acquired Immunodeficiency Syndrome
708063|NCT00002042|Anemia
708064|NCT00002042|AIDS-Related Complex
708065|NCT00002042|Zidovudine
708066|NCT00002041|AIDS-Related Opportunistic Infections
708067|NCT00002041|Esophagitis
708068|NCT00002041|Acquired Immunodeficiency Syndrome
708069|NCT00002041|Amphotericin B
708070|NCT00002041|Candidiasis, Oral
708071|NCT00002040|AIDS-Related Opportunistic Infections
708072|NCT00002040|Meningitis
708073|NCT00002040|Injections, Intravenous
708074|NCT00002040|Cryptococcosis
708075|NCT00002040|Fluconazole
708076|NCT00002040|Administration, Oral
708077|NCT00002040|Acquired Immunodeficiency Syndrome
708078|NCT00002039|Retinitis
708079|NCT00002039|AIDS-Related Opportunistic Infections
708080|NCT00002039|Drug Therapy, Combination
708081|NCT00002039|Foscarnet
708082|NCT00002039|Cytomegalovirus Infections
708083|NCT00002039|Acquired Immunodeficiency Syndrome
708084|NCT00002039|Antiviral Agents
708085|NCT00002039|Zidovudine
708086|NCT00002038|Mycoses
708087|NCT00002038|Drugs, Investigational
708088|NCT00002038|Fluconazole
708089|NCT00002037|AIDS-Related Opportunistic Infections
708090|NCT00002037|Mycobacterium avium-intracellulare Infection
708091|NCT00002037|Interferon-gamma, Recombinant
708092|NCT00002037|Acquired Immunodeficiency Syndrome
708093|NCT00002036|Acquired Immunodeficiency Syndrome
708094|NCT00002036|AIDS-Related Complex
708095|NCT00002036|Immunization, Passive
708096|NCT00002035|Didanosine
708097|NCT00002035|Acquired Immunodeficiency Syndrome
708098|NCT00002035|AIDS-Related Complex
708099|NCT00002035|Zidovudine
708100|NCT00002034|Retinitis
708101|NCT00002034|AIDS-Related Opportunistic Infections
708102|NCT00002034|Ganciclovir
708103|NCT00002034|Drug Interactions
708104|NCT00002034|Cytomegalovirus Infections
708105|NCT00002034|Acquired Immunodeficiency Syndrome
708106|NCT00002034|Zidovudine
708107|NCT00002033|Acquired Immunodeficiency Syndrome
708108|NCT00002033|AIDS-Related Complex
708109|NCT00002033|ammonium trichloro(dioxoethylene-O,O'-)tellurute
708110|NCT00002033|Zidovudine
708111|NCT00002032|Rifabutin
708112|NCT00002032|AIDS-Related Opportunistic Infections
708113|NCT00002032|Mycobacterium avium-intracellulare Infection
708114|NCT00002032|Acquired Immunodeficiency Syndrome
708115|NCT00002032|Antitubercular Agents
708116|NCT00002031|Langerhans Cells
708117|NCT00002031|Dinitrochlorobenzene
708118|NCT00002031|Acquired Immunodeficiency Syndrome
708119|NCT00002031|AIDS-Related Complex
708120|NCT00002030|AIDS-Related Opportunistic Infections
708121|NCT00002030|Pneumonia, Pneumocystis carinii
708122|NCT00002030|Pentamidine
708123|NCT00002030|Aerosols
708124|NCT00002030|Acquired Immunodeficiency Syndrome
708125|NCT00002029|Weight Loss
708126|NCT00002029|Parenteral Nutrition, Total
708127|NCT00002029|AIDS-Related Opportunistic Infections
708128|NCT00002029|Liposyn
708129|NCT00002029|Acquired Immunodeficiency Syndrome
708130|NCT00002028|Didanosine
708131|NCT00002028|Drugs, Investigational
708132|NCT00002028|Acquired Immunodeficiency Syndrome
708133|NCT00002028|AIDS-Related Complex
708134|NCT00002028|Zidovudine
708135|NCT00002027|AIDS-Related Opportunistic Infections
708136|NCT00002027|Cryptosporidiosis
708137|NCT00002027|Diarrhea
708138|NCT00002027|diclazuril
708139|NCT00002027|Coccidiostats
708140|NCT00002027|Acquired Immunodeficiency Syndrome
708141|NCT00002026|AIDS-Related Opportunistic Infections
708142|NCT00002026|Leukoplakia, Oral
708143|NCT00002026|Herpesvirus 4, Human
708144|NCT00002026|Acyclovir
708145|NCT00002026|AIDS-Related Complex
708146|NCT00002025|Retinitis
708147|NCT00002025|AIDS-Related Opportunistic Infections
708148|NCT00002025|Immune Tolerance
708149|NCT00002025|Injections, Intravenous
708150|NCT00002025|Ganciclovir
708151|NCT00002025|Cytomegalovirus Infections
708152|NCT00002025|Acquired Immunodeficiency Syndrome
708153|NCT00002024|AIDS-Related Opportunistic Infections
708154|NCT00002024|Immune Tolerance
708155|NCT00002024|Ganciclovir
708156|NCT00002024|Drugs, Investigational
708157|NCT00002024|Cytomegalovirus Infections
708158|NCT00002024|Acquired Immunodeficiency Syndrome
708159|NCT00002023|Dose-Response Relationship, Drug
708160|NCT00002023|Acquired Immunodeficiency Syndrome
708161|NCT00002023|AIDS-Related Complex
708162|NCT00002023|Zidovudine
708163|NCT00002022|Recombinant Proteins
708164|NCT00002022|Drugs, Investigational
708165|NCT00002022|Erythropoietin
708166|NCT00002022|Acquired Immunodeficiency Syndrome
708167|NCT00002022|Anemia
708168|NCT00002022|Zidovudine
708169|NCT00002021|AIDS-Related Opportunistic Infections
708170|NCT00002021|Immune Tolerance
708171|NCT00002021|Injections, Intravenous
708172|NCT00002021|Herpes Simplex
708173|NCT00002021|Immunity, Cellular
708174|NCT00002021|Foscarnet
708175|NCT00002021|Acquired Immunodeficiency Syndrome
708176|NCT00002021|Antiviral Agents
708177|NCT00002020|Acquired Immunodeficiency Syndrome
708178|NCT00002020|AIDS-Related Complex
708179|NCT00002020|Zidovudine
708180|NCT00002019|Meningitis
708181|NCT00002019|Liposomes
708182|NCT00002019|Cryptococcosis
708183|NCT00002019|Acquired Immunodeficiency Syndrome
708184|NCT00002019|Amphotericin B
708185|NCT00002019|Chemistry, Pharmaceutical
708186|NCT00002018|Interferon Type I
708187|NCT00002017|Polyethylene Glycols
708188|NCT00002017|Interleukin-2
708189|NCT00002016|Retinitis
708190|NCT00002016|Ganciclovir
708191|NCT00002016|Cytomegalovirus
708192|NCT00002016|Cytomegalovirus Infections
708193|NCT00002016|Acquired Immunodeficiency Syndrome
708194|NCT00002016|Antibodies, Monoclonal
708195|NCT00002015|Retinitis
708196|NCT00002015|Ganciclovir
708197|NCT00002015|Cytomegalovirus Infections
708198|NCT00002015|Acquired Immunodeficiency Syndrome
708199|NCT00002015|Immunocompromised Host
708200|NCT00002014|Didanosine
708201|NCT00002014|Drug Evaluation
708202|NCT00002014|Zidovudine
708203|NCT00002013|Drug Therapy, Combination
708204|NCT00002013|Acquired Immunodeficiency Syndrome
708205|NCT00002013|AIDS-Related Complex
708206|NCT00002013|ammonium trichloro(dioxoethylene-O,O'-)tellurute
708207|NCT00002013|Zidovudine
708208|NCT00002012|Acquired Immunodeficiency Syndrome
708209|NCT00002012|AIDS-Related Complex
708210|NCT00002012|Interferon Type I, Recombinant
708211|NCT00002011|PUVA Therapy
708212|NCT00002011|Methoxsalen
708213|NCT00002011|AIDS-Related Complex
708214|NCT00002010|AIDS-Related Opportunistic Infections
708215|NCT00002010|Meningitis
708216|NCT00002010|Fluconazole
708217|NCT00002010|Coccidioidin
708218|NCT00002010|Acquired Immunodeficiency Syndrome
708219|NCT00002010|Coccidioidomycosis
708220|NCT00002009|Leukopenia
708221|NCT00002009|Drug Evaluation
708222|NCT00002009|Granulocyte-Macrophage Colony-Stimulating Factor
708223|NCT00002008|Leukopenia
708224|NCT00002008|Drug Evaluation
708225|NCT00002008|Granulocyte-Macrophage Colony-Stimulating Factor
708226|NCT00002007|Leukopenia
708227|NCT00002007|Granulocyte-Macrophage Colony-Stimulating Factor
708228|NCT00002007|Acquired Immunodeficiency Syndrome
708229|NCT00002007|Zidovudine
708230|NCT00002006|Neutropenia
708231|NCT00002006|Drug Interactions
708232|NCT00002006|Granulocyte-Macrophage Colony-Stimulating Factor
708233|NCT00002006|Acquired Immunodeficiency Syndrome
708234|NCT00002006|Zidovudine
708235|NCT00002005|Acquired Immunodeficiency Syndrome
708236|NCT00002005|Antigens, CD4
708237|NCT00002005|AIDS-Related Complex
708238|NCT00002004|Recombinant Proteins
708239|NCT00002004|Acquired Immunodeficiency Syndrome
708240|NCT00002004|Antigens, CD4
708241|NCT00002004|AIDS-Related Complex
708242|NCT00002003|Mitoxantrone
708243|NCT00002003|Lymphoma, Large-Cell
708244|NCT00002003|Etoposide
708245|NCT00002003|Acquired Immunodeficiency Syndrome
708246|NCT00002002|Trimethoprim-Sulfamethoxazole Combination
708247|NCT00002002|AIDS-Related Opportunistic Infections
708248|NCT00002002|Pneumonia, Pneumocystis carinii
708249|NCT00002002|Acquired Immunodeficiency Syndrome
708250|NCT00002001|Zalcitabine
708251|NCT00002001|Didanosine
708252|NCT00002001|Drug Therapy, Combination
708253|NCT00002001|Acquired Immunodeficiency Syndrome
708254|NCT00002001|Zidovudine
708255|NCT00002000|Acyclovir
708256|NCT00002000|Acquired Immunodeficiency Syndrome
708257|NCT00002000|AIDS-Related Complex
708258|NCT00002000|Antiviral Agents
708259|NCT00002000|Anus Diseases
708260|NCT00002000|Herpes Genitalis
708261|NCT00001999|Retinitis
708262|NCT00001999|Gamma-Globulins
708263|NCT00001999|Ganciclovir
708264|NCT00001999|Drug Therapy, Combination
708265|NCT00001999|Cytomegalovirus Infections
708266|NCT00001999|Acquired Immunodeficiency Syndrome
708267|NCT00001999|Immunization, Passive
708268|NCT00001998|Nystatin
708269|NCT00001998|Acquired Immunodeficiency Syndrome
708270|NCT00001998|AIDS-Related Complex
708271|NCT00001997|Recombinant Proteins
708272|NCT00001997|Polyethylene Glycols
708273|NCT00001997|Interleukin-2
708274|NCT00001997|Didanosine
708275|NCT00001997|Zidovudine
708276|NCT00001996|Trimethoprim-Sulfamethoxazole Combination
708277|NCT00001996|Pneumonia, Pneumocystis carinii
708278|NCT00001996|Pentamidine
708279|NCT00001996|Acquired Immunodeficiency Syndrome
708280|NCT00001996|atovaquone
708281|NCT00001995|Rifabutin
708282|NCT00001995|Mycobacterium avium-intracellulare Infection
708283|NCT00001995|Acquired Immunodeficiency Syndrome
708284|NCT00001994|Toxoplasmosis
708285|NCT00001994|AIDS-Related Opportunistic Infections
708286|NCT00001994|Naphthoquinones
708287|NCT00001994|Encephalitis
708288|NCT00001994|Acquired Immunodeficiency Syndrome
708289|NCT00001993|Drug Therapy, Combination
708290|NCT00001993|Zidovudine
708291|NCT00001992|Vaccines, Synthetic
708292|NCT00001992|Drug Evaluation
708293|NCT00001992|Acquired Immunodeficiency Syndrome
708294|NCT00001992|AIDS Vaccines
708295|NCT00001991|Trimethoprim-Sulfamethoxazole Combination
708296|NCT00001991|Pneumonia, Pneumocystis carinii
708297|NCT00001991|Antifungal Agents
708298|NCT00001991|Acquired Immunodeficiency Syndrome
708299|NCT00001991|atovaquone
708300|NCT00001990|Trimethoprim-Sulfamethoxazole Combination
708301|NCT00001990|Pneumonia, Pneumocystis carinii
708302|NCT00001990|Pentamidine
708303|NCT00001990|Antifungal Agents
708304|NCT00001990|Acquired Immunodeficiency Syndrome
708305|NCT00001990|atovaquone
708306|NCT00001989|Trichosanthin
708307|NCT00001989|Drug Evaluation
708308|NCT00001989|Drug Therapy, Combination
708309|NCT00001989|Acquired Immunodeficiency Syndrome
708310|NCT00001989|AIDS-Related Complex
708311|NCT00001989|Antiviral Agents
708312|NCT00001989|Zidovudine
708313|NCT00001987|Diabetes Mellitus
708314|NCT00001987|Severe Insulin Resistance
708315|NCT00001987|Type B Insulin Resistance
708316|NCT00001986|Alcohol
708317|NCT00001986|Octanol
708318|NCT00001986|Treatment
708319|NCT00001986|Tremor
708320|NCT00001985|Diabetes
708321|NCT00001985|Gene
708322|NCT00001984|Immunosuppression
708323|NCT00001984|Tolerance
708324|NCT00001984|DSG
708325|NCT00001984|Alemtuzumab
708326|NCT00001983|Questionnaires
708327|NCT00001983|Eligibility
708328|NCT00001983|History
708329|NCT00001983|Physical Examination
708330|NCT00001983|Tests
708331|NCT00001983|Fibromyalgia
708332|NCT00001982|Aminotransferases
708333|NCT00001982|Anti-HCV
708334|NCT00001982|Blood Donors
708335|NCT00001982|HCV RNA
708336|NCT00001982|Hepatitis C
708337|NCT00001982|Liver Biopsy
708338|NCT00001982|Serum Aminotransferases
708339|NCT00001982|Transfusion
708340|NCT00001981|Somatostatin Analogue
708341|NCT00001981|Acromegaly
708342|NCT00001981|TSH Producing Tumor
708343|NCT00001981|Islet Cell Tumor
708344|NCT00001981|Ursodeoxycholate
708345|NCT00001981|Pituitary
708346|NCT00001981|Irradiation
708347|NCT00001981|Treatment
708348|NCT00001979|Kidney Disease
708349|NCT00001979|Autoimmune Diseases
708350|NCT00001979|Nephrotic Syndrome
708351|NCT00001978|Kidney Disease
708352|NCT00001978|Kidney Function Tests
708353|NCT00001978|Proteinuria
708354|NCT00001977|Alzheimer's Disease
708355|NCT00001977|Attention
708356|NCT00001977|Brain
708357|NCT00001977|Functional Magnetic Resonance Imaging
708358|NCT00001977|Physostigmine
708359|NCT00001977|Positron Emission Tomography
708360|NCT00001977|Working Memory
708361|NCT00001976|CMV
708362|NCT00001976|Infection
708363|NCT00001976|Comparison
708364|NCT00001976|Observational
708365|NCT00001976|Cytomegalovirus
708366|NCT00001976|RT-PCR
708367|NCT00001975|Skin Biopsy
708368|NCT00001975|Familial Tumor Syndrome
708369|NCT00001975|Cell Growth
708370|NCT00001975|Loss of Heterozygosity
708371|NCT00001975|Cytokines
708372|NCT00001975|Tuberous Sclerosis
708373|NCT00001973|G Protein Mutation
708374|NCT00001973|McCune-Albright Syndrome
708375|NCT00001973|Fibrous Dysplasia
708376|NCT00001973|Mutation
708377|NCT00001973|Pathology
708378|NCT00001973|Immunohistochemistry
708379|NCT00001973|PCR
708380|NCT00001973|In Situ Hybridization
708381|NCT00001973|Juvenile Dermatomyositis
708382|NCT00001973|Calcinosis
708383|NCT00001972|Alzheimer's Disease
708384|NCT00001972|Positron Emission Tomography
708385|NCT00001972|Brain Phospholipid
708386|NCT00001972|Fatty Acids
708387|NCT00001972|11C Arachidonate
708388|NCT00001972|Signal Transduction
708389|NCT00001972|Brain
708390|NCT00001971|Hepatitis B
708391|NCT00001971|Hepatitis C
708392|NCT00001971|Hepatitis D
708393|NCT00001971|Chronic Cholestatic Syndromes
708394|NCT00001971|Primary Biliary Cirrhosis
708395|NCT00001971|Primary Sclerosing Cholangitis
708396|NCT00001971|Non-Alcoholic Steatohepatitis
708397|NCT00001971|Wilson's Disease
708398|NCT00001971|Hemochromatosis
708399|NCT00001971|Liver Biopsy
708400|NCT00001971|Noncirrhotic Portal Hypertension
708401|NCT00001971|Liver Disease
708402|NCT00001969|Cardiovascular Disease
708403|NCT00001969|Glucose Clamp
708404|NCT00001969|Hypercortisolism
708405|NCT00001969|Insulin Sensitivity
708406|NCT00001969|Major Depression Disorder
708407|NCT00001969|Inflammation
708408|NCT00001969|Coagulation
708409|NCT00001969|Metabolic
708410|NCT00001969|Insulin
708411|NCT00001969|Cytokine
708412|NCT00001969|Depression
708413|NCT00001969|Volunteer
708414|NCT00001969|Healthy Volunteer
708415|NCT00001968|AIDS
708416|NCT00001968|Anti-Retroviral Therapy
708417|NCT00001968|Drug Interactions
708418|NCT00001968|HIV
708419|NCT00001968|Protease Inhibitor
708420|NCT00001967|HIV
708421|NCT00001967|HAART
708422|NCT00001967|Immunity
708423|NCT00001967|Toxicity
708424|NCT00001967|Resistance
708425|NCT00001967|Treatment Interruption
708426|NCT00001966|Adjustment
708427|NCT00001966|Alternative
708428|NCT00001966|Anxiety
708429|NCT00001966|Guided-Imagery
708430|NCT00001966|Meditation
708431|NCT00001966|Ehlers-Danlos Syndrome
708432|NCT00001965|Calcineurin
708433|NCT00001965|Cardiac Hypertrophy
708434|NCT00001965|Hypertrophic Cardiomyopathy
708435|NCT00001964|Hematopoiesis
708436|NCT00001964|Bone Marrow Failure
708437|NCT00001964|Aplastic Anemia
708438|NCT00001963|Blood Flow
708439|NCT00001963|Exercise
708440|NCT00001963|Microcirculation
708441|NCT00001963|S-nitrosohemoglobin
708442|NCT00001963|Vasodilation
708443|NCT00001963|Healthy Volunteer
708444|NCT00001962|Immunosuppression
708445|NCT00001962|T-cells
708446|NCT00001962|Hematopoiesis
708447|NCT00001962|Monoclonal Antibody Therapy
708448|NCT00001962|Immunosuppressive Therapy
708449|NCT00001962|Aplastic Anemia
708450|NCT00001961|Myocardial Infarction
708451|NCT00001961|Coronary Artery Disease
708452|NCT00001961|Adenosine
708453|NCT00001961|Stress Testing
708454|NCT00001961|Perfusion
708455|NCT00001960|HCM
708456|NCT00001960|Pediatric
708457|NCT00001960|Pacemaker
708458|NCT00001960|Treatment
708459|NCT00001960|Symptoms
708460|NCT00001959|Fibrosis
708461|NCT00001959|Nephrotic Syndrome
708462|NCT00001959|Proteinuria
708463|NCT00001959|Renal Failure
708464|NCT00001959|TGF-Beta
708465|NCT00001959|Focal Segmental Glomerulosclerosis
708466|NCT00001959|FSGS
708467|NCT00001958|Gamma Gene
708468|NCT00001958|Hemoglobin Switching
708469|NCT00001958|Erythropoiesis
708470|NCT00001958|HbE Hemoglobin Chain Synthesis Imbalance
708471|NCT00001958|Cooley's Anemia
708472|NCT00001958|Beta-Thalassemia Intermedia
708473|NCT00001957|Ostoacoustic Emission
708474|NCT00001957|Central Auditory Processing
708475|NCT00001957|CAPD
708476|NCT00001957|Medial Olivocochlear Bundle
708477|NCT00001957|Speech Impediment
708478|NCT00001956|Genetic Markers
708479|NCT00001956|Thermal Pain
708480|NCT00001956|Hyperalgesia
708481|NCT00001956|Oral Surgery
708482|NCT00001956|Cold Pain
708483|NCT00001956|Peripheral Nerve
708484|NCT00001956|Allodynia
708485|NCT00001956|Spinal Cord
708486|NCT00001956|Personality Traits
708487|NCT00001956|Pain Ratings
708488|NCT00001955|Clinical Trial
708489|NCT00001955|Temporomandibular Joints
708490|NCT00001955|Celecoxib
708491|NCT00001955|Etanercept
708492|NCT00001955|Tumor Necrosis Factor
708493|NCT00001955|TMJ
708494|NCT00001955|TMD
708495|NCT00001954|Clinical Trial
708496|NCT00001954|Autoimmune
708497|NCT00001954|Disease Activity
708498|NCT00001954|Cytokine
708499|NCT00001954|Saliva
708500|NCT00001954|Xerostomia
708501|NCT00001954|Salivary Glands
708502|NCT00001954|Sjogren's Syndrome
708503|NCT00001953|Endocrine System
708504|NCT00001953|Autoimmunity
708505|NCT00001953|Salivary Glands
708506|NCT00001953|Glucose Tolerance Test
708507|NCT00001953|Growth Hormone
708508|NCT00001953|Somatostatin
708509|NCT00001953|Sjogren's Syndrome
708510|NCT00001952|Fentanyl
708511|NCT00001952|Intraosseous-Anesthesia
708512|NCT00001952|Endodontics
708513|NCT00001952|Denti Patch
708514|NCT00001952|Pain
708515|NCT00001952|Chronic Inflammation
708516|NCT00001951|Bone
708517|NCT00001951|Cognition
708518|NCT00001951|Estrogen
708519|NCT00001951|Mood
708520|NCT00001951|Testosterone
708521|NCT00001951|Osteoporosis
708522|NCT00001951|Ovarian Failure
708523|NCT00001951|Hormone Replacement Therapy
708524|NCT00001951|POF
708525|NCT00001951|Premature Ovarian Failure
708526|NCT00001950|Cognition
708527|NCT00001950|Infancy
708528|NCT00001950|Perception
708529|NCT00001948|Human Immunodeficiency Virus
708530|NCT00001948|Symptom Distress
708531|NCT00001948|Immune Function
708532|NCT00001948|Medication Trial
708533|NCT00001948|Physical Symptoms
708534|NCT00001946|Magnetic Resonance Angiography
708535|NCT00001946|Gadolinium
708536|NCT00001946|Suburban Hospital
708537|NCT00001946|Atherosclerosis
708538|NCT00001944|Drug Resistance
708539|NCT00001944|MDR-1
708540|NCT00001944|P-Glycoprotein Blocker
708541|NCT00001944|Pgp
708542|NCT00001944|Resistance Reversal
708543|NCT00001941|Interleukin-2 Receptor alpha chain
708544|NCT00001941|Interleukin-2
708545|NCT00001941|HTLV-I
708546|NCT00001941|Adult T-Cell Leukemia (ATL)
708547|NCT00001941|Monoclonal Antibody (Daclizumab, Zenapax)
708548|NCT00001940|Antifungal Agent
708549|NCT00001940|Aspergillosis
708550|NCT00001940|Candidemia
708551|NCT00001940|Fungemia
708552|NCT00001938|Ovarian Cancer
708553|NCT00001938|Proteomics
708554|NCT00001937|Aspergillosis
708555|NCT00001937|Candidiasis
708556|NCT00001937|Fungal Infections
708557|NCT00001937|Fungemia
708558|NCT00001937|Prophylactic Antifungal Therapy
708559|NCT00001936|Neuromuscular Stimulation
708560|NCT00001936|Laryngeal Elevation
708561|NCT00001936|Dysphagia
708562|NCT00001936|Stroke
708563|NCT00001936|Neuroprosthesis
708564|NCT00001936|Dysphonia
708565|NCT00001936|Aspiration
708566|NCT00001936|Motor Control
708567|NCT00001936|Videofluoroscopy
708568|NCT00001936|Upper Esophageal Sphincter
708569|NCT00001936|Healthy Volunteer
708570|NCT00001936|Swallowing Disorders
708571|NCT00001934|Multiple Sclerosis
708572|NCT00001934|Immunotherapy
708573|NCT00001934|MRI
708574|NCT00001933|Acetylcholine
708575|NCT00001933|Clinical Trial
708576|NCT00001933|GABA
708577|NCT00001933|Cognition
708578|NCT00001933|Nicotine
708579|NCT00001932|Epilepsy
708580|NCT00001932|Temporal Lobe
708581|NCT00001932|Blood Flow
708582|NCT00001932|Metabolism
708583|NCT00001932|Localization
708584|NCT00001931|Continuous Stimulation
708585|NCT00001931|Dose Finding
708586|NCT00001931|Skin Patch
708587|NCT00001930|Amantadine
708588|NCT00001930|Chorea
708589|NCT00001930|Glutamate Antagonist
708590|NCT00001929|Dyskinesias
708591|NCT00001929|Glutamate Antagonist
708592|NCT00001929|Levodopa
708593|NCT00001928|Diagnosis
708594|NCT00001928|Infusion
708595|NCT00001928|Parkinsonism
708596|NCT00001927|Factor V Leiden
708597|NCT00001927|Prothrombin Mutation
708598|NCT00001927|Antiphospholipids
708599|NCT00001927|Cerebral Infarction
708600|NCT00001927|Thrombophilia
708601|NCT00001927|Porencephaly
708602|NCT00001927|Perinatal Stroke
708603|NCT00001927|Healthy Mothers
708604|NCT00001927|Healthy Children
708605|NCT00001926|Plasticity
708606|NCT00001926|Magnetic Stimulation
708607|NCT00001926|PET
708608|NCT00001926|Blind
708609|NCT00001926|Braille
708610|NCT00001926|Transcranial Magnetic Stimulation
708611|NCT00001925|Inferior Olives
708612|NCT00001925|Calcium Channels
708613|NCT00001925|Accelerometry
708614|NCT00001925|Electromyography
708615|NCT00001925|Palatal Tremor
708616|NCT00001923|Pain
708617|NCT00001923|Amputee
708618|NCT00001923|Phantom Limb
708619|NCT00001923|Amputation
708620|NCT00001923|Magnetic Stimulation
708621|NCT00001923|Phantom
708622|NCT00001922|Evoked Response
708623|NCT00001922|Spasmodic Dysphonia
708624|NCT00001922|Aerodynamic
708625|NCT00001922|Vibration
708626|NCT00001922|Laryngeal
708627|NCT00001922|Voice Disorders
708628|NCT00001922|Laryngeal Brainstem Evoked Responses
708629|NCT00001922|Long-latency Responses
708630|NCT00001922|Muscular Tension Dysphonia
708631|NCT00001921|Functional Connectivity
708632|NCT00001921|Frontotemporal Interaction
708633|NCT00001921|Electrophysiology
708634|NCT00001921|Functional Magnetic Resonance Imaging
708635|NCT00001921|Healthy Subjects
708636|NCT00001921|Schizophrenia
708637|NCT00001921|MEG
708638|NCT00001921|Neuroimaging
708639|NCT00001921|EEG
708640|NCT00001921|MRI
708641|NCT00001920|Schizophrenia
708642|NCT00001920|Eyeblink
708643|NCT00001920|Evoked Potentials
708644|NCT00001920|Learning
708645|NCT00001920|Normal Volunteer
708646|NCT00001920|Healthy Volunteer
708647|NCT00001919|Mechanism of Action
708648|NCT00001919|BCIT-SPECT
708649|NCT00001919|St. John's Wort
708650|NCT00001919|Hypericum Perforatum
708651|NCT00001919|Depression
708652|NCT00001919|Serotonin
708653|NCT00001919|Dopamine Transporter
708654|NCT00001919|SPECT
708655|NCT00001919|Brain Disorders
708656|NCT00001918|Cognitive Function
708657|NCT00001918|Depression
708658|NCT00001918|EMG
708659|NCT00001918|Eosinophilia Myalgia Syndrome
708660|NCT00001918|Impurities
708661|NCT00001918|L-5-HTP
708662|NCT00001918|Memory Impairment
708663|NCT00001918|Nerve-Muscle Biopsy
708664|NCT00001918|Sleep Disorders
708665|NCT00001917|Positron Emission Tomography
708666|NCT00001917|Physostigmine
708667|NCT00001917|Visual Stimulation
708668|NCT00001917|Cholinergic Stimulation
708669|NCT00001917|[F-18] FP-TZIP
708670|NCT00001917|Aging
708671|NCT00001917|Alzheimer's Disease
708672|NCT00001917|Visual Activation
708673|NCT00001916|Bone Remodeling
708674|NCT00001916|Corticosteroids
708675|NCT00001916|Cytokine
708676|NCT00001916|Depression
708677|NCT00001916|Glucocorticoids
708678|NCT00001916|Osteopenia
708679|NCT00001916|Osteoporosis
708680|NCT00001916|Primary Affective Disorder
708681|NCT00001915|Cortical Stimulation
708682|NCT00001915|Motor Control
708683|NCT00001915|Neuromotor Maturation
708684|NCT00001915|Magnetic Stimulation
708685|NCT00001915|Attention Deficit Hyperactivity Disorder
708686|NCT00001915|Hearing Loss
708687|NCT00001915|Hearing Conservation
708688|NCT00001915|Hearing Protective Devices
708689|NCT00001915|Safety Study
708690|NCT00001915|Noise Induced Hearing Loss
708691|NCT00001915|Normal Volunteer
708692|NCT00001913|Visual Processing
708693|NCT00001913|Functional Magnetic Resonance Imaging
708694|NCT00001913|Maternal Behavior
708695|NCT00001913|Attachment
708696|NCT00001913|Bereavement
708697|NCT00001912|Cysticercosis
708698|NCT00001912|T. Solium
708699|NCT00001912|MRI
708700|NCT00001912|Seizures
708701|NCT00001912|Calcified Cysts
708702|NCT00001912|Taenia
708703|NCT00001911|Cytokine
708704|NCT00001911|Interferon Gamma
708705|NCT00001911|Pulmonary
708706|NCT00001911|Disseminated
708707|NCT00001911|Refractory
708708|NCT00001911|Mycobacterial Infection
708709|NCT00001911|Nontuberculosis Mycobacterial Infection
708710|NCT00001911|Pulmonary Nontuberculous Mycobacterial Infection
708711|NCT00001910|T Cells
708712|NCT00001910|Allergy
708713|NCT00001910|Asthma
708714|NCT00001910|Cytokine
708715|NCT00001910|Vaccine
708716|NCT00001909|Allergy
708717|NCT00001909|Immunomodulator
708718|NCT00001909|Inflammation
708719|NCT00001909|Interleukin
708720|NCT00001909|Th2
708721|NCT00001909|Asthma
708722|NCT00001908|Allergy
708723|NCT00001908|Interleukin
708724|NCT00001908|Immunomodulator
708725|NCT00001908|Th2
708726|NCT00001908|Inflammation
708727|NCT00001908|Asthma
708728|NCT00001906|Alum
708729|NCT00001906|Antigen
708730|NCT00001906|Cytokine
708731|NCT00001906|Parasitic Infection
708732|NCT00001906|Phase I
708733|NCT00001906|Cutaneous Leishmaniasis
708734|NCT00001905|Neutrophil
708735|NCT00001905|Immunodeficiency
708736|NCT00001905|Cytokine
708737|NCT00001905|Treatment
708738|NCT00001905|Trafficking
708739|NCT00001905|Leukocyte Adhesion Deficiency Type I
708740|NCT00001905|LAD I
708741|NCT00001904|Atherosclerosis
708742|NCT00001904|Cardiovascular Disease
708743|NCT00001904|Computerized Edge Reader
708744|NCT00001904|Myocardial Infarction
708745|NCT00001904|Risk Factor
708746|NCT00001903|Immunization
708747|NCT00001903|Immunocompromised
708748|NCT00001903|Immunoglobulin
708749|NCT00001903|Prophylaxis
708750|NCT00001903|Respiratory Virus
708751|NCT00001903|Bone Marrow Transplantation
708752|NCT00001903|Mini-Transplantation
708753|NCT00001903|Peripheral Stem Cell Transplantation
708754|NCT00001901|Vasculitis
708755|NCT00001901|Prednisone-sparing
708756|NCT00001901|Methotrexate
708757|NCT00001901|Tumor Necrosis Factor
708758|NCT00001901|Remission
708759|NCT00001901|Wegener's Granulomatosis
708760|NCT00001899|Viral Suppression
708761|NCT00001899|Latency
708762|NCT00001899|AIDS Therapy
708763|NCT00001899|Viral Relapse
708764|NCT00001899|Immunodeficiency
708765|NCT00001899|HIV
708766|NCT00001899|Treatment Interruption
708767|NCT00001898|Melanoma
708768|NCT00001898|Breast Cancer
708769|NCT00001898|Gene Expression
708770|NCT00001898|DNA Chip Technology
708771|NCT00001898|Expressed Sequence Tags
708772|NCT00001895|Electromechanical Mapping
708773|NCT00001895|Myocardial Viability
708774|NCT00001895|Myocardial Ischemia
708775|NCT00001895|Positron Emission Tomography
708776|NCT00001895|Magnetic Resonance Imaging
708777|NCT00001894|HCM
708778|NCT00001894|Alcohol
708779|NCT00001894|Septal Ablation
708780|NCT00001894|Pacemaker
708781|NCT00001893|Bronchoprovocation
708782|NCT00001893|Airway Inflammation
708783|NCT00001893|Tumor Necrosis Factor
708784|NCT00001893|Bronchoalveolar Lavage
708785|NCT00001893|Pulmonary Function Test
708786|NCT00001893|Asthma
708787|NCT00001891|CABG
708788|NCT00001891|Hibernation
708789|NCT00001891|LV Function
708790|NCT00001891|Microbubbles
708791|NCT00001891|Revascularization
708792|NCT00001891|Coronary Artery Disease
708793|NCT00001890|Cellular Immunity
708794|NCT00001890|Cytokines
708795|NCT00001890|Estrogen
708796|NCT00001890|Humoral Immunity
708797|NCT00001890|Progesterone
708798|NCT00001890|Chlamydia Pneumoniae
708799|NCT00001890|Human Cytomegalovirus
708800|NCT00001890|Postmenopause
708801|NCT00001889|Microbubbles
708802|NCT00001889|Myocardial Blood Flow
708803|NCT00001889|Myocardial Ischemia
708804|NCT00001889|Second Harmonics
708805|NCT00001889|Ultrasound
708806|NCT00001889|Coronary Artery Disease
708807|NCT00001888|Induced Sputum
708808|NCT00001888|Exhaled Breath Condensate
708809|NCT00001888|Fiberoptic Bronchoscopy
708810|NCT00001888|Bronchoscopy
708811|NCT00001888|mRNA
708812|NCT00001888|Asthma
708813|NCT00001888|Normal Volunteer
708814|NCT00001887|Airway Inflammation
708815|NCT00001887|Allergen Challenge
708816|NCT00001887|Bronchoscopy
708817|NCT00001887|Cytokines
708818|NCT00001887|Receptors
708819|NCT00001887|Asthma
708820|NCT00001887|Normal Volunteer
708821|NCT00001886|Coronary Artery Disease
708822|NCT00001886|Ischemia
708823|NCT00001886|Ultrasound
708824|NCT00001886|Ventricular Function
708825|NCT00001886|Wall Motion
708826|NCT00001885|Interstitial Lung Disease
708827|NCT00001885|Inherited Disease
708828|NCT00001885|Genetic Markers
708829|NCT00001885|Alpha 1 Protease Inhibitor
708830|NCT00001885|DNA Mutations
708831|NCT00001885|Rheumatoid Arthritis
708832|NCT00001885|Pulmonary Fibrosis
708833|NCT00001885|Normal Volunteer
708834|NCT00001884|Bronchoscopy
708835|NCT00001884|Idiopathic Pulmonary Fibrosis
708836|NCT00001884|Proteases
708837|NCT00001884|Fibroblast Proliferation
708838|NCT00001884|Reactive Proteins
708839|NCT00001884|Rheumatoid Arthritis
708840|NCT00001884|Pulmonary Fibrosis
708841|NCT00001883|Treadmill
708842|NCT00001883|Bicycle
708843|NCT00001883|Lung Function
708844|NCT00001883|Physiology
708845|NCT00001883|Quality Control
708846|NCT00001883|Normal Volunteers
708847|NCT00001881|Cardiac Hypertrophy
708848|NCT00001881|Genetics
708849|NCT00001881|Phenotypes
708850|NCT00001881|Hypertrophic Cardiomyopathy
708851|NCT00001880|Graft-Versus-Tumor
708852|NCT00001880|Peripheral Blood Stem Cells
708853|NCT00001880|Non-Myeloablative Bone Marrow Transplantation
708854|NCT00001880|Metastatic Solid Tumors
708855|NCT00001880|Engraftment
708856|NCT00001880|Cyclophosphamide
708857|NCT00001880|Fludarabine
708858|NCT00001880|Donor Apheresis
708859|NCT00001880|Graft-Versus-Host Disease
708860|NCT00001880|Cancer
708861|NCT00001880|Tumor
708862|NCT00001879|Liver Disease
708863|NCT00001879|Novel Agents
708864|NCT00001879|Serum
708865|NCT00001879|Viruses
708866|NCT00001879|non-A,G Hepatitis
708867|NCT00001879|Seronegative Acute Hepatitis
708868|NCT00001878|Growth Hormone
708869|NCT00001878|Cardiac Hypertrophy
708870|NCT00001878|Hypertrophic Cardiomyopathy
708871|NCT00001878|Sarcomeric Gene Mutations
708872|NCT00001877|Tumor Necrosis Factor
708873|NCT00001877|Corticosteroids
708874|NCT00001877|Macrophages
708875|NCT00001877|Phosphodiesterase
708876|NCT00001877|Autoimmune
708877|NCT00001877|Pulmonary Sarcoidosis
708878|NCT00001876|Interstitial Lung Disease
708879|NCT00001876|Collagen Vascular Disease
708880|NCT00001876|Extracellular Matrix
708881|NCT00001876|Pulmonary Function
708882|NCT00001876|DTPA Lung Clearance Scan
708883|NCT00001876|Rheumatoid Arthritis
708884|NCT00001876|Pulmonary Fibrosis
708885|NCT00001876|Idiopathic Pulmonary Fibrosis
708886|NCT00001874|Imaging
708887|NCT00001874|Spectroscopy
708888|NCT00001874|MRI
708889|NCT00001874|Cardiovascular
708890|NCT00001874|Technical Development
708891|NCT00001874|Safety
708892|NCT00001874|Gadolinium
708893|NCT00001874|Heart
708894|NCT00001874|Toxicity
708895|NCT00001874|Adverse Events
708896|NCT00001874|Normal Volunteer
708897|NCT00001873|Peripheral Blood Stem Cells
708898|NCT00001873|Cyclosporine
708899|NCT00001873|Cyclosphosphamide
708900|NCT00001873|Whole Body Irradiation
708901|NCT00001873|Donor Apheresis
708902|NCT00001873|Leukemic Relapse
708903|NCT00001873|Graft vs. Host Disease
708904|NCT00001873|Graft-Versus-Leukemia
708905|NCT00001873|Graft-Versus-Myeloma
708906|NCT00001873|Chronic Myelogenous Leukemia
708907|NCT00001873|Acute Lymphoblastic Leukemia
708908|NCT00001873|Acute Myelogenous Leukemia
708909|NCT00001873|Myelodysplastic Syndromes
708910|NCT00001873|Multiple Myeloma
708911|NCT00001873|Chronic Lymphocytic Leukemia
708912|NCT00001873|Non-Hodgkin's Lymphoma
708913|NCT00001872|Volunteer
708914|NCT00001872|Leukocyte Donors
708915|NCT00001872|Family Members
708916|NCT00001872|Leukocyte Collection
708917|NCT00001872|No Reimbursement
708918|NCT00001871|Genetic Mutations
708919|NCT00001871|Hypertrophic Cardiomyopathy
708920|NCT00001871|Oculopharyngeal Muscular Dystrophy
708921|NCT00001870|Insulin Resistance
708922|NCT00001870|Oxidative Stress
708923|NCT00001870|Antioxidant
708924|NCT00001870|Endothelial Function
708925|NCT00001870|Glucose Clamp
708926|NCT00001870|Type 2 Diabetes
708927|NCT00001870|Vitamin C Deficiency
708928|NCT00001869|Progesterone
708929|NCT00001869|Pulmonary Function Tests
708930|NCT00001869|Pneumothorax
708931|NCT00001869|Oopherectomy
708932|NCT00001869|High Resolution CT
708933|NCT00001869|Tuberous Sclerosis Complex
708934|NCT00001869|Lymphangioleiomyomatosis (LAM)
708935|NCT00001867|Cytokine
708936|NCT00001867|Gestation
708937|NCT00001867|Postpartum
708938|NCT00001867|Pregnancy
708939|NCT00001867|Th 1 Lymphocyte
708940|NCT00001867|Th 2 Lymphocyte
708941|NCT00001867|Uveitis
708942|NCT00001866|Eye Movements
708943|NCT00001866|Eye Oscillations
708944|NCT00001866|Extraocular Muscles
708945|NCT00001866|Eye Development
708946|NCT00001866|Pediatric Ophthalmology
708947|NCT00001866|Congenital Nystagmus
708948|NCT00001865|Behcet's
708949|NCT00001865|Monoclonal Antibody
708950|NCT00001865|Uveitis
708951|NCT00001865|Interleukin 2
708952|NCT00001865|Retinal Vasculitis
708953|NCT00001865|Hyopyon
708954|NCT00001865|Interleukin 2 Receptor
708955|NCT00001865|Bechet's Disease
708956|NCT00001865|Ocular Disease
708957|NCT00001864|Lazy Eye
708958|NCT00001864|Atropine Penalization
708959|NCT00001864|Patching
708960|NCT00001864|Vision Loss
708961|NCT00001864|Amblyopia
708962|NCT00001863|Immunosuppression
708963|NCT00001863|Inflammation
708964|NCT00001863|Eye
708965|NCT00001863|Vision
708966|NCT00001863|Medication
708967|NCT00001863|Uveitis
708968|NCT00001863|Leflunomide
708969|NCT00001863|Vitritis
708970|NCT00001862|Ocular Inflammation
708971|NCT00001862|Children
708972|NCT00001862|Immunotherapy
708973|NCT00001862|Cytokine
708974|NCT00001862|Clinical Trial
708975|NCT00001862|Uveitis
708976|NCT00001862|Immunosuppression
708977|NCT00001862|Joint
708978|NCT00001862|Inflammation
708979|NCT00001861|Eye Movements
708980|NCT00001861|Amblyopia
708981|NCT00001861|Orthoptics
708982|NCT00001861|Lazy Eye
708983|NCT00001861|Eye Development
708984|NCT00001861|Nystagmus
708985|NCT00001861|Strabismus
708986|NCT00001861|Screening Protocol
708987|NCT00001861|Eye Movement Disorders
708988|NCT00001860|Growth Hormone
708989|NCT00001860|Somatostatin
708990|NCT00001860|Insulin-like Growth Factor-One
708991|NCT00001860|Acromegaly
708992|NCT00001860|Macroadenoma
708993|NCT00001859|Evaluation
708994|NCT00001859|Diabetes
708995|NCT00001859|Renal Failure
708996|NCT00001858|Biopsy
708997|NCT00001858|Immune System
708998|NCT00001858|Renal
708999|NCT00001857|Costimulation
709000|NCT00001857|Immunosuppression
709001|NCT00001857|Tolerance
709002|NCT00001856|Living Donor
709003|NCT00001856|Transplantation
709004|NCT00001856|Nephrectomy
709005|NCT00001854|Ribavirin
709006|NCT00001854|Liver Disease
709007|NCT00001854|Antiviral Agent
709008|NCT00001854|Cirrhosis
709009|NCT00001854|Chronic Hepatitis
709010|NCT00001854|Iron
709011|NCT00001854|Viral Hepatitis
709012|NCT00001854|Hepatitis C Virus
709013|NCT00001854|Hemolytic Anemia
709014|NCT00001854|Hemolysis
709015|NCT00001853|Healthy Volunteers
709016|NCT00001853|Health Disparities
709017|NCT00001853|Diabetes
709018|NCT00001853|Cardiovascular Disease
709019|NCT00001852|Xerostomia
709020|NCT00001852|Oral Dryness
709021|NCT00001852|Salivary Function
709022|NCT00001851|Marrow
709023|NCT00001851|Grafting
709024|NCT00001851|Imaging
709025|NCT00001851|Injection
709026|NCT00001851|Aspiration
709027|NCT00001851|Bone Marrow Stromal Cells
709028|NCT00001851|Bone Grafting
709029|NCT00001851|Bone Graft Substitutes
709030|NCT00001851|Bio and Pharmacological Regulators of Bone Turnover
709031|NCT00001850|Training
709032|NCT00001850|Reproduction
709033|NCT00001850|Infertility
709034|NCT00001850|Women's Health
709035|NCT00001850|Hormone
709036|NCT00001849|PET
709037|NCT00001849|(18F)-DOPA
709038|NCT00001849|Pentetreotide
709039|NCT00001849|ACTH
709040|NCT00001849|Octreotide
709041|NCT00001849|Cushing's Syndrome
709042|NCT00001849|Ectopic Cushing Syndrome
709043|NCT00001848|Estrogen Receptor
709044|NCT00001848|Laparoscopy
709045|NCT00001848|Surgical Excision
709046|NCT00001848|Raloxifene
709047|NCT00001848|Selective Estrogen Receptor Modulator
709048|NCT00001848|Estrogen
709049|NCT00001848|Endometriosis
709050|NCT00001848|Pelvic Pain
709051|NCT00001846|Volunteer Donor
709052|NCT00001846|Research Samples
709053|NCT00001846|Leukapheresis
709054|NCT00001846|Plateletpheresis
709055|NCT00001846|Plasmapheresis
709056|NCT00001846|Healthy Volunteer
709057|NCT00001846|Normal Volunteer
709058|NCT00001845|MRI
709059|NCT00001845|Cerebral Blood Flow
709060|NCT00001845|CO2 Inhalation
709061|NCT00001845|Acetazolamide
709062|NCT00001845|Perfusion
709063|NCT00001845|Healthy Volunteer
709064|NCT00001844|MRI/MRS
709065|NCT00001844|Functional MRI
709066|NCT00001844|Metabolic Imaging
709067|NCT00001844|Brain
709068|NCT00001844|Healthy Volunteer
709069|NCT00001842|Granulocytes
709070|NCT00001842|Granulocyte Colony Stimulating Factor
709071|NCT00001842|Granulocyte Transfusion Factor
709072|NCT00001842|Apheresis
709073|NCT00001842|Blood Donors
709074|NCT00001842|Healthy Volunteer
709075|NCT00001841|Arteriosclerosis
709076|NCT00001841|Imaging
709077|NCT00001841|MRA
709078|NCT00001841|Narrowing of Vessels
709079|NCT00001841|Hardening of Arteries
709080|NCT00001840|Infarct
709081|NCT00001840|Ischemia
709082|NCT00001840|MRI
709083|NCT00001840|Natural History
709084|NCT00001840|Stroke
709085|NCT00001840|Treatment
709086|NCT00001840|Brain Stroke
709087|NCT00001839|Anemia
709088|NCT00001839|Immunosuppressive
709089|NCT00001839|Phase II Trial
709090|NCT00001839|Pre-Leukemia
709091|NCT00001839|Therapy
709092|NCT00001839|Myelodysplastic Syndrome
709093|NCT00001837|Sonohysterography
709094|NCT00001837|Color Doppler Sonography
709095|NCT00001837|Endometrium
709096|NCT00001837|Gynecologic
709097|NCT00001837|Menstrual Cycle
709098|NCT00001837|Premenopause
709099|NCT00001836|Coronary Artery Disease
709100|NCT00001836|EBCT
709101|NCT00001836|Volumetric Scan
709102|NCT00001836|Coronary Artery Calcium
709103|NCT00001836|Prospective Gating
709104|NCT00001835|Renal Dysfunction
709105|NCT00001835|Pharmacokinetics
709106|NCT00001835|Platinum Analogues
709107|NCT00001835|Renal Cancer
709108|NCT00001835|Kidney Cancer
709109|NCT00001832|Immunotherapy
709110|NCT00001832|Adoptive Transfer
709111|NCT00001832|IL-2
709112|NCT00001832|Toxicity
709113|NCT00001832|Clinical Response
709114|NCT00001832|Breast Cancer
709115|NCT00001830|Bone Marrow Transplantation
709116|NCT00001830|Chronic Lymphocytic Leukemia
709117|NCT00001830|Immunotherapy
709118|NCT00001830|Lymphoma
709119|NCT00001830|Multiple Myeloma
709120|NCT00001830|Graft vs. Host Disease
709121|NCT00001830|Lymphoid Malignancy
709122|NCT00001830|Leukemia
709123|NCT00001827|Immunotherapy
709124|NCT00001827|Cancer
709125|NCT00001827|Oncogenes
709126|NCT00001827|T-cells
709127|NCT00001827|Vaccine Therapy
709128|NCT00001827|p53 Peptide
709129|NCT00001827|Ovarian Cancer
709130|NCT00001826|CD-4-Naive T Cells
709131|NCT00001826|CD-4-Memory T Cells
709132|NCT00001826|Antiviral Activity
709133|NCT00001826|VB Repertoire
709134|NCT00001826|Immunizations
709135|NCT00001826|HIV
709136|NCT00001826|Treatment Experienced
709137|NCT00001823|Cancer
709138|NCT00001823|Gene Therapy
709139|NCT00001823|Immunotherapy
709140|NCT00001823|Melanoma
709141|NCT00001823|Clinical Trial
709142|NCT00001818|Antiretrovirals
709143|NCT00001818|Resistant Virus
709144|NCT00001818|T-cell activation
709145|NCT00001818|Immune Suppression
709146|NCT00001818|Cytotoxic Agent
709147|NCT00001816|Anger
709148|NCT00001816|Loneliness
709149|NCT00001816|Mood
709150|NCT00001816|Psychosocial
709151|NCT00001816|Virtual Network
709152|NCT00001814|Hereditary
709153|NCT00001814|Kidney
709154|NCT00001814|MET
709155|NCT00001814|Oncocytoma
709156|NCT00001814|VHL
709157|NCT00001813|Xeroderma Pigmentosum
709158|NCT00001813|Trichothiodystrophy
709159|NCT00001813|Cockayne Syndrome
709160|NCT00001813|Skin Cancer
709161|NCT00001813|DNA Repair
709162|NCT00001812|Mucositis
709163|NCT00001812|Oral Candidiasis
709164|NCT00001812|Prophylaxis
709165|NCT00001812|Stomatitis
709166|NCT00001812|Swish and Swallow
709167|NCT00001810|Antifungal Agent
709168|NCT00001810|Aspergillosis
709169|NCT00001810|Candidiasis
709170|NCT00001810|Fungemia
709171|NCT00001807|CNS directed therapy
709172|NCT00001807|Neurotoxicity
709173|NCT00001807|H-NMRS
709174|NCT00001807|MRI
709175|NCT00001806|Genetic Testing
709176|NCT00001806|Genetic Counseling
709177|NCT00001806|BRCA1/BRCA2
709178|NCT00001806|Genetic Education
709179|NCT00001806|Informed Consent
709180|NCT00001806|Breast Cancer
709181|NCT00001806|Ovarian Cancer
709182|NCT00001806|Known Family Mutation
709183|NCT00001805|Breast Cancer
709184|NCT00001805|Colon Cancer
709185|NCT00001805|Gastric Cancer
709186|NCT00001805|Lung Cancer
709187|NCT00001805|Pancreatic Cancer
709188|NCT00001803|Gene-Environment Interaction
709189|NCT00001803|Kidney Cancer
709190|NCT00001803|VHL
709191|NCT00001803|Genetic Epidemiology
709192|NCT00001797|Cytokines
709193|NCT00001797|Immunomodulation
709194|NCT00001797|Inflammation
709195|NCT00001797|Skin
709196|NCT00001797|Therapy
709197|NCT00001790|Aspergillosis
709198|NCT00001790|Candidiasis
709199|NCT00001790|Empiric Therapy
709200|NCT00001790|Fungal Infection
709201|NCT00001790|Fungemia
709202|NCT00001789|Autoantibody
709203|NCT00001789|Autoimmunity
709204|NCT00001789|Inflammation
709205|NCT00001789|Kidney
709206|NCT00001789|Lymphocyte
709207|NCT00001789|Proliferative Lupus Glomerulonephritis
709208|NCT00001789|SLE-GN
709209|NCT00001788|Cytokine
709210|NCT00001788|Stat
709211|NCT00001788|Jak
709212|NCT00001788|IL-12
709213|NCT00001788|Mutation
709214|NCT00001788|Immunodeficiency
709215|NCT00001785|HTLV-1-Associated Myelopathy
709216|NCT00001785|Virus
709217|NCT00001785|Spontaneous Proliferation
709218|NCT00001784|Blepharospasm
709219|NCT00001784|Writer's Cramp
709220|NCT00001784|Muscle Spindle Afferents
709221|NCT00001784|Sodium Channels
709222|NCT00001784|Sensorimotor Integration
709223|NCT00001784|Focal Dystonia
709224|NCT00001783|Rehabilitation
709225|NCT00001783|Plasticity
709226|NCT00001783|Stroke
709227|NCT00001783|Amphetamine
709228|NCT00001783|Motor
709229|NCT00001783|Hemiparetic
709230|NCT00001783|Thromboembolic Non-Hemorrhagic Infarction
709231|NCT00001782|Deafness
709232|NCT00001782|Hemisphere Dominance
709233|NCT00001782|Language
709234|NCT00001782|Plasticity
709235|NCT00001782|Speech
709236|NCT00001782|rTMS
709237|NCT00001781|Multiple Sclerosis
709238|NCT00001781|Immunology
709239|NCT00001781|Treatment
709240|NCT00001780|Myelopathy
709241|NCT00001780|Demyelination
709242|NCT00001780|Leukodystrophy
709243|NCT00001780|Motor Neuron Disease
709244|NCT00001780|Movement Disorders
709245|NCT00001780|Normal Volunteer
709246|NCT00001778|Immune Response
709247|NCT00001778|Sero-Indeterminant
709248|NCT00001778|Transmission
709249|NCT00001778|Tropical Spastic Paraparesis
709250|NCT00001778|Viral Load
709251|NCT00001778|HTLV-I
709252|NCT00001778|HAM/TSP
709253|NCT00001777|Frontal Lobe Dementia
709254|NCT00001777|Serotonergic Transmission
709255|NCT00001776|Magnetic Stimulation
709256|NCT00001776|Plasticity
709257|NCT00001776|SRTT
709258|NCT00001776|Sequence
709259|NCT00001776|Implicit Memory
709260|NCT00001776|Explicit Memory
709261|NCT00001776|Memory
709262|NCT00001776|Parkinson's Disease
709263|NCT00001776|Cerebellar Deficit
709264|NCT00001776|Frontal Lobe Lesions
709265|NCT00001776|Frontal Lobe Dementia
709266|NCT00001776|Normal Volunteer
709267|NCT00001774|Acetylcholine
709268|NCT00001774|Blood Flow
709269|NCT00001774|Blood vessel
709270|NCT00001774|Resistance
709271|NCT00001774|Sodium Nitroprusside
709272|NCT00001774|Fabry Disease
709273|NCT00001774|Normal Volunteer
709274|NCT00001772|Bipolar Disorder
709275|NCT00001772|Rapid Cycling
709276|NCT00001772|Screening
709277|NCT00001771|Receptors
709278|NCT00001771|Re-Uptake
709279|NCT00001771|Neurotransmitters
709280|NCT00001771|Neuroimaging
709281|NCT00001771|Drug Abuse
709282|NCT00001771|Serotonin
709283|NCT00001771|Brain Scan
709284|NCT00001771|Tourette's Syndrome
709285|NCT00001771|Obsessive Compulsive Disorder
709286|NCT00001771|Schizophrenia
709287|NCT00001771|Normal Volunteer
709288|NCT00001770|Depression
709289|NCT00001770|Estrogen
709290|NCT00001770|Hormone Replacement Therapy
709291|NCT00001770|Mood
709292|NCT00001770|Progestin
709293|NCT00001770|Progesterone
709294|NCT00001770|Anxiety
709295|NCT00001768|Autoimmunity
709296|NCT00001768|Childhood Onset Schizophrenia
709297|NCT00001768|Intravenous Gammaglobulin
709298|NCT00001766|Abacavir
709299|NCT00001766|Salvage
709300|NCT00001766|Drug Interaction
709301|NCT00001766|Drug Levels
709302|NCT00001766|Anti-Viral
709303|NCT00001766|HIV
709304|NCT00001765|Engraftment
709305|NCT00001765|Minitransplant
709306|NCT00001765|Fludarabine
709307|NCT00001765|Neutrophil
709308|NCT00001765|Allogenic
709309|NCT00001765|Donor Apheresis
709310|NCT00001765|Anti-Thymocyte Globin
709311|NCT00001765|Cyclophosphamide
709312|NCT00001765|Nonmyeloablative Bone Marrow Transplantation
709313|NCT00001765|Graft-versus-host Disease
709314|NCT00001765|Chronic Granulomatous Disease
709315|NCT00001764|Alternative agent
709316|NCT00001764|Purine Antimetabolite
709317|NCT00001764|Immunosuppressive
709318|NCT00001764|Previous relapse
709319|NCT00001764|Drug Intolerance
709320|NCT00001764|Wegener's Granulomatosis
709321|NCT00001763|AIDS
709322|NCT00001763|Cell Mediated Immunity
709323|NCT00001763|Cytokine
709324|NCT00001763|MAC
709325|NCT00001763|Thl Response
709326|NCT00001762|Protease Inhibitor
709327|NCT00001762|HIV Infection
709328|NCT00001762|Appearance
709329|NCT00001762|Subcutaneous Fat
709330|NCT00001762|Facial Wasting
709331|NCT00001761|Autoimmunity
709332|NCT00001761|Cytokine
709333|NCT00001761|Inflammation
709334|NCT00001761|Interleukin
709335|NCT00001761|Vasculitis
709336|NCT00001761|Wegener's Granulomatosis
709337|NCT00001760|Stem Cell Factor
709338|NCT00001760|Cytokine
709339|NCT00001760|Chemokines
709340|NCT00001760|Chemotaxis
709341|NCT00001760|Mast Cells
709342|NCT00001760|Normal Volunteer
709343|NCT00001760|Systemic Mastocytosis
709344|NCT00001760|Atopic Dermatitis
709345|NCT00001759|Allergy
709346|NCT00001759|Fluorodeoxyglucose
709347|NCT00001759|Imaging
709348|NCT00001759|PET
709349|NCT00001759|Wegener's Granulomatosis
709350|NCT00001759|Asthma
709351|NCT00001758|Antiretroviral
709352|NCT00001758|HIV-1
709353|NCT00001758|1592U89
709354|NCT00001758|141W94
709355|NCT00001758|DMP 266
709356|NCT00001757|Azole
709357|NCT00001757|Immunocompromised
709358|NCT00001757|Mycosis
709359|NCT00001757|Invasive Fungal Infection
709360|NCT00001757|Systemic Fungal Infection
709361|NCT00001756|Leukapheresis
709362|NCT00001756|Mastocytosis
709363|NCT00001756|G-CSF
709364|NCT00001756|Mast Cells
709365|NCT00001756|Normal Volunteer
709366|NCT00001756|Systemic Mastocytosis
709367|NCT00001754|Dwarfism
709368|NCT00001754|Gene Mapping
709369|NCT00001754|Linkage
709370|NCT00001754|Mutation Analysis
709371|NCT00001754|Skeletal Biology
709372|NCT00001754|Brachydactyly Types C & E
709373|NCT00001754|Cartilage-Hair Hypoplasia
709374|NCT00001754|Ellis Van Crevald
709375|NCT00001754|FgFR-3
709376|NCT00001754|Proximal Symphalangism
709377|NCT00001754|Pyknodysotosis
709378|NCT00001754|Schmid Metaphyseal
709379|NCT00001754|Short Stature
709380|NCT00001754|Skeletal Dysplasia
709381|NCT00001754|Type II Collagen Disorder
709382|NCT00001753|Exercise
709383|NCT00001753|MRI
709384|NCT00001753|MRS
709385|NCT00001753|Normal Volunteer
709386|NCT00001753|Tibialix Anterior
709387|NCT00001752|Adhesion Molecules
709388|NCT00001752|Endothelial Function
709389|NCT00001752|Inflammation
709390|NCT00001752|Lipoproteins
709391|NCT00001752|Nitric Oxide
709392|NCT00001752|Hormone Therapy
709393|NCT00001752|Postmenopausal Women
709394|NCT00001750|G-CSF
709395|NCT00001750|Cell-Cycle
709396|NCT00001750|Stem Cell
709397|NCT00001750|Apheresis
709398|NCT00001750|Melphalan
709399|NCT00001750|Gene Transfer
709400|NCT00001750|Retroviral Receptor
709401|NCT00001750|Stem Cell Expansion
709402|NCT00001750|Multiple Myeloma
709403|NCT00001749|Immune Suppression
709404|NCT00001749|Erythroid Hypoplasia
709405|NCT00001749|Congenital Anemia
709406|NCT00001749|Reticulocytopenia
709407|NCT00001749|Diamond Blackfan Anemia
709408|NCT00001748|Cyclophosphamide
709409|NCT00001748|Donor Apheresis
709410|NCT00001748|Graft vs. Host Disease
709411|NCT00001748|Graft-Versus-Leukemia
709412|NCT00001748|Leukemic Relapse
709413|NCT00001748|Myeloma
709414|NCT00001748|Peripheral Blood Stem Cells
709415|NCT00001748|Whole Body Irradiation
709416|NCT00001748|Acute Lymphoblastic Leukemia (ALL)
709417|NCT00001748|Chronic Lymphocytic Leukemia (CLL)
709418|NCT00001748|Chronic Myelogenous Leukemia (CML)
709419|NCT00001748|Hematological Malignancies
709420|NCT00001748|Myelodysplastic Syndrome
709421|NCT00001748|Myeloproliferative Disorders
709422|NCT00001747|Brachial Artery
709423|NCT00001747|Doppler
709424|NCT00001747|Endothelium
709425|NCT00001747|Nitric Oxide
709426|NCT00001747|Nitroglycerin
709427|NCT00001747|Normal Volunteer
709428|NCT00001746|Hypertrophic Cardiomyopathy
709429|NCT00001746|HCM
709430|NCT00001746|Evaluation for Research
709431|NCT00001746|Medical Advice
709432|NCT00001742|Acetylcholine
709433|NCT00001742|Aspirin
709434|NCT00001742|Nitric Oxide
709435|NCT00001742|Sodium Nitroprusside
709436|NCT00001742|Hypercholesterolemia
709437|NCT00001742|Hypertension
709438|NCT00001741|Angiotensin II Receptor
709439|NCT00001741|Polymorphism, Genetic
709440|NCT00001741|Vascular Tone
709441|NCT00001741|Angiotensin II
709442|NCT00001741|Losartan
709443|NCT00001740|Cardiac
709444|NCT00001740|Function
709445|NCT00001740|MRI
709446|NCT00001740|Reconstruction
709447|NCT00001740|Ultrasound
709448|NCT00001740|Heart Disease (Cardiovascular Disease)
709449|NCT00001738|Intermediate Uveitis
709450|NCT00001738|Pars Planitis
709451|NCT00001738|Retinal Vasculature
709452|NCT00001738|Uveitis
709453|NCT00001738|Vascular Permeability
709454|NCT00001738|Vitreous
709455|NCT00001737|Eye
709456|NCT00001737|Immunosuppression
709457|NCT00001737|Inflammation
709458|NCT00001737|Therapy
709459|NCT00001737|Vitreous
709460|NCT00001737|Uveitis
709461|NCT00001736|Corneal Crystals
709462|NCT00001736|Cysteamine
709463|NCT00001736|Cystinosis
709464|NCT00001736|Eye
709465|NCT00001735|Gene Therapy
709466|NCT00001735|Graft
709467|NCT00001735|Ornithine
709468|NCT00001735|Retina
709469|NCT00001735|Retinovirus
709470|NCT00001735|Retrovirus
709471|NCT00001735|Skin
709472|NCT00001735|Gyrate Atrophy
709473|NCT00001734|Uveitis
709474|NCT00001734|Conjunctivitis
709475|NCT00001734|Iritis
709476|NCT00001734|Retinitis
709477|NCT00001734|Keratitis
709478|NCT00001734|Screening Protocol
709479|NCT00001734|Ocular Immunology
709480|NCT00001734|Inflammation
709481|NCT00001734|Eye Inflammation
709482|NCT00001733|Diabetic Retinopathy
709483|NCT00001733|Age-Related Macular Degeneration
709484|NCT00001733|Neovascularization
709485|NCT00001733|Macular Degeneration
709486|NCT00001733|Retinal Disease
709487|NCT00001733|Diabetes
709488|NCT00001732|Genetics
709489|NCT00001732|Diagnosis
709490|NCT00001732|Screening Protocol
709491|NCT00001732|Ophthalmic Genetic Diseases
709492|NCT00001732|Genetic Testing
709493|NCT00001732|Family Studies
709494|NCT00001731|Conjunctiva
709495|NCT00001731|Dry Eyes
709496|NCT00001731|Inflammation
709497|NCT00001731|Lacrimal Gland
709498|NCT00001731|T Lymphocyte
709499|NCT00001731|Keratoconjunctivitis Sicca
709500|NCT00001730|Ablation
709501|NCT00001730|Activity-Time Curves
709502|NCT00001730|Iodine Biokinetics
709503|NCT00001730|Thyroid Carcinoma
709504|NCT00001730|Thyroid Remnant
709505|NCT00001729|Cirrhosis
709506|NCT00001729|Liver Disease
709507|NCT00001729|Hemolytic Anemia
709508|NCT00001729|Liver Biopsy
709509|NCT00001729|Ribavirin
709510|NCT00001729|Alpha Interferon
709511|NCT00001729|Viral Hepatitis
709512|NCT00001729|Hepatitis C Virus
709513|NCT00001729|Chronic Hepatitis
709514|NCT00001729|Antiviral Agents
709515|NCT00001728|Bone Marrow Stromal Cells
709516|NCT00001728|Bone Turnover
709517|NCT00001728|Fibrous Dysplastic Lesion
709518|NCT00001728|Polyostotic Fibrous Dysplasia
709519|NCT00001728|McCune-Albright Syndrome
709520|NCT00001727|Fibrous Dysplasia (FD)
709521|NCT00001727|McCune-Albright Syndrome
709522|NCT00001727|Polyostotic Fibrous Dysplasia
709523|NCT00001726|Bacterial Colonization
709524|NCT00001726|Plaque
709525|NCT00001726|Mouth
709526|NCT00001726|Saliva
709527|NCT00001726|Adhesion
709528|NCT00001726|Dental Plaque Formation
709529|NCT00001726|Dental Caries
709530|NCT00001725|Trigeminal Neuralgia
709531|NCT00001725|Dextromethorphan
709532|NCT00001725|Topiramate
709533|NCT00001725|Orofacial Pain
709534|NCT00001725|Neuropathic Pain
709535|NCT00001725|Facial Neuralgia
709536|NCT00001724|Pain
709537|NCT00001724|Microencapsulated Drug
709538|NCT00001724|NSAID
709539|NCT00001724|Acute Inflammation
709540|NCT00001724|Peripheral Administration
709541|NCT00001724|Dose-Response
709542|NCT00001724|Relative Potency Assay
709543|NCT00001724|Pharmacokinetics
709544|NCT00001723|Dyslipidemia
709545|NCT00001723|Race
709546|NCT00001723|Body Fat
709547|NCT00001723|Visceral Fat
709548|NCT00001723|Sleep Apnea
709549|NCT00001723|Fat-Soluble Vitamins
709550|NCT00001723|Type 2 Diabetes
709551|NCT00001723|Obesity
709552|NCT00001723|Childhood Obesity
709553|NCT00001722|Obesity
709554|NCT00001722|Sympathetic Nervous System
709555|NCT00001722|Fat Tissue
709556|NCT00001722|Metabolism
709557|NCT00001722|Adipose Tissue
709558|NCT00001722|Microdialysis
709559|NCT00001722|Leptin
709560|NCT00001722|Lipolysis
709561|NCT00001722|Normal Volunteer
709562|NCT00001721|Dysmorphology
709563|NCT00001721|Cholesterol
709564|NCT00001721|Endocrine
709565|NCT00001721|MRI
709566|NCT00001721|Demyelination
709567|NCT00001721|Smith-Lemli-Opitz Syndrome (SLO)
709568|NCT00001720|Glucocorticoids
709569|NCT00001720|Bone Mineral Density
709570|NCT00001720|Bisphosphonates
709571|NCT00001720|Vertebral Fracture
709572|NCT00001720|Childhood Osteoporosis
709573|NCT00001719|Blood Flow
709574|NCT00001719|Hepatic Disease
709575|NCT00001719|Liver
709576|NCT00001719|Modeling
709577|NCT00001719|Rheology
709578|NCT00001719|Normal Volunteer
709579|NCT00001718|Biofeedback
709580|NCT00001718|Swallowing
709581|NCT00001718|Swallowing Therapy
709582|NCT00001718|Tongue/Palate
709583|NCT00001718|Ultrasound
709584|NCT00001718|Dysphagia
709585|NCT00001717|Compensation
709586|NCT00001717|Motivations
709587|NCT00001717|Volunteers
709588|NCT00001717|HIV
709589|NCT00001716|Hemoglobin
709590|NCT00001716|P50
709591|NCT00001716|Microvascular
709592|NCT00001716|Perfusion
709593|NCT00001716|Magnetic Resonance Imaging
709594|NCT00001716|Sickle Cell Anemia
709595|NCT00001715|Consultation
709596|NCT00001715|Training
709597|NCT00001715|Referral
709598|NCT00001715|Fellowship Program
709599|NCT00001715|Outpatient
709600|NCT00001715|Blood Disorder
709601|NCT00001714|MRI
709602|NCT00001714|Macromolecules
709603|NCT00001714|Magnetization Transfer
709604|NCT00001714|Metabolites
709605|NCT00001714|Tissue Characterization
709606|NCT00001714|Normal Volunteer
709607|NCT00001713|rtPA
709608|NCT00001713|Catheter Directed
709609|NCT00001713|Thrombolysis
709610|NCT00001713|Anticoagulation
709611|NCT00001713|Emboli
709612|NCT00001713|Acute Deep Venous Thrombosis
709613|NCT00001713|TPA
709614|NCT00001713|DVT
709615|NCT00001712|Healthcare Worker
709616|NCT00001712|Bloodborne Diseases
709617|NCT00001712|Hepatitis B
709618|NCT00001712|Hepatitis C
709619|NCT00001712|Human Immunodeficiency Virus
709620|NCT00001712|Parenteral Exposure
709621|NCT00001712|Non-Parenteral Exposure
709622|NCT00001712|Blood and Body Substances
709623|NCT00001712|Universal Precautions
709624|NCT00001712|HIV Seronegativity
709625|NCT00001711|Magnetic Resonance Imaging
709626|NCT00001711|Gadolinium
709627|NCT00001711|Magnetic Resonance Angiography
709628|NCT00001711|Normal Volunteer
709629|NCT00001705|Antigen
709630|NCT00001705|Cancer
709631|NCT00001705|Immunotherapy
709632|NCT00001703|Immunotherapy
709633|NCT00001703|Kidney
709634|NCT00001703|Genes
709635|NCT00001703|Vaccine Therapy
709636|NCT00001703|Renal Cell Carcinoma
709637|NCT00001702|Genetic
709638|NCT00001702|Variant Alleles
709639|NCT00001702|Risk Factor
709640|NCT00001702|Cancer
709641|NCT00001702|Transplantation
709642|NCT00001701|Risk Factor
709643|NCT00001701|Genetic
709644|NCT00001701|Variant Alleles
709645|NCT00001701|Cancer
709646|NCT00001701|Transplantation
709647|NCT00001699|AIDS
709648|NCT00001699|Compliance
709649|NCT00001699|HIV
709650|NCT00001699|Medication
709651|NCT00001699|Perceived Threat
709652|NCT00001699|Teenagers
709653|NCT00001698|Chemoprevention
709654|NCT00001698|Direct Epithelial Delivery
709655|NCT00001698|Tobacco-induced Cancer
709656|NCT00001698|Field Cancerization
709657|NCT00001696|Anti-metastatic
709658|NCT00001696|Chemoprevention
709659|NCT00001696|Isoflavinoid
709660|NCT00001696|Prostate Cancer
709661|NCT00001696|Signal Transduction
709662|NCT00001695|Complementary Medicine
709663|NCT00001695|Unproven Treatments
709664|NCT00001695|Herbal
709665|NCT00001693|Chemoprevention
709666|NCT00001693|Biomarkers
709667|NCT00001693|Endoscopy
709668|NCT00001693|Colorectal
709669|NCT00001693|Celecoxib
709670|NCT00001689|Neurotoxicity
709671|NCT00001689|A.L.L.
709672|NCT00001689|Limited Sampling
709673|NCT00001689|Dose Individualization
709674|NCT00001689|Vinca Alkaloids
709675|NCT00001688|CD4 Cells
709676|NCT00001688|Cytokines
709677|NCT00001688|Anti-Retroviral Activity
709678|NCT00001688|V Beta Repertoire
709679|NCT00001688|CD-4-Naive T Cells
709680|NCT00001688|CD-4-Memory T Cells
709681|NCT00001686|Leukemia
709682|NCT00001686|Ewing's Sarcoma
709683|NCT00001686|Neuroectodermal Tumors
709684|NCT00001686|Osteosarcoma Lymphoma
709685|NCT00001686|Rhabdomyosarcoma Brain Tumors
709686|NCT00001686|Lymphoma
709687|NCT00001686|Neoplasm
709688|NCT00001686|Sarcoma
709689|NCT00001685|Cancer
709690|NCT00001685|IL-12
709691|NCT00001685|IL-2
709692|NCT00001685|Immunotherapy
709693|NCT00001685|Vaccine
709694|NCT00001683|Collagen Breakdown
709695|NCT00001683|Pharmacokinetics
709696|NCT00001683|Rapid Escalation Phase I
709697|NCT00001683|Angiogenesis
709698|NCT00001683|Tissue Inhibitors of Metalloproteinase
709699|NCT00001681|Cytokines
709700|NCT00001681|Gene Regulation
709701|NCT00001681|Immunization
709702|NCT00001681|Influenza
709703|NCT00001681|Pathogenesis
709704|NCT00001680|Double-masked
709705|NCT00001680|Neuropathy
709706|NCT00001680|Occlusive Dressing
709707|NCT00001680|Pilot
709708|NCT00001680|Placebo
709709|NCT00001679|Immunogenetics
709710|NCT00001679|Joint Damage
709711|NCT00001679|Reactive Arthritis
709712|NCT00001679|Rheumatoid Arthritis
709713|NCT00001679|Synovium
709714|NCT00001679|Synovitis
709715|NCT00001678|Autoimmunity
709716|NCT00001678|Sibling Pairs
709717|NCT00001678|Genes
709718|NCT00001678|Rheumatoid Arthritis
709719|NCT00001678|Bone Erosion
709720|NCT00001677|Immunosuppression
709721|NCT00001677|Lymphocytes
709722|NCT00001677|Magnetic Resonance
709723|NCT00001677|Synovial Biopsy
709724|NCT00001677|Synovitis
709725|NCT00001677|Rheumatoid Arthritis
709726|NCT00001676|Remission
709727|NCT00001676|Renal Function
709728|NCT00001676|Infection
709729|NCT00001676|Germinal Center
709730|NCT00001676|Immunoglobulin
709731|NCT00001676|Glomerulonephritis
709732|NCT00001676|Systemic Lupus Erythematosus
709733|NCT00001676|Lupus Nephritis
709734|NCT00001675|Brain Imaging
709735|NCT00001675|Affect
709736|NCT00001675|Limbic System
709737|NCT00001675|Cerebral Blood Volume
709738|NCT00001675|Alcoholism
709739|NCT00001675|Emotion
709740|NCT00001675|Brain
709741|NCT00001675|Operant
709742|NCT00001675|Autonomic
709743|NCT00001675|Relapse
709744|NCT00001675|Normal Volunteer
709745|NCT00001673|Alcoholics
709746|NCT00001673|Screening
709747|NCT00001673|Healthy Volunteers
709748|NCT00001673|Violent Abusers
709749|NCT00001673|Illicit Drug Testing
709750|NCT00001673|Blood Tests
709751|NCT00001673|Normal Volunteer
709752|NCT00001672|Brain Mapping
709753|NCT00001672|Cognition
709754|NCT00001672|Noninvasive
709755|NCT00001672|Temporal Lobe
709756|NCT00001672|Visual Naming
709757|NCT00001671|White Matter
709758|NCT00001671|Myelin
709759|NCT00001671|Degenerative Diseases
709760|NCT00001671|Genetic
709761|NCT00001671|Oligodendrocytes
709762|NCT00001671|Leukodystrophy
709763|NCT00001669|EAE
709764|NCT00001669|EDSS
709765|NCT00001669|MRI
709766|NCT00001669|SNRS
709767|NCT00001669|Multiple Sclerosis
709768|NCT00001668|Deafness
709769|NCT00001668|Hemangioblastoma
709770|NCT00001668|Papillary Carcinoma
709771|NCT00001668|VHL Gene
709772|NCT00001668|Vestibular Function
709773|NCT00001668|von Hippel-Lindau Disease
709774|NCT00001667|Family Studies
709775|NCT00001667|Genetic
709776|NCT00001667|Myoclonus
709777|NCT00001667|Tics
709778|NCT00001667|Tremor
709779|NCT00001667|Movement Disorders
709780|NCT00001667|Neurological Disease
709781|NCT00001666|Seizures
709782|NCT00001666|Partial Epilepsy
709783|NCT00001666|Intractable
709784|NCT00001666|TMS
709785|NCT00001665|Magnetic Stimulation
709786|NCT00001665|Motor Skills
709787|NCT00001665|Parkinson's Disease
709788|NCT00001665|rTMS
709789|NCT00001664|Narcolepsy
709790|NCT00001664|Polysomnography
709791|NCT00001664|Multiple Sleep Latency Test
709792|NCT00001664|Sleep Disorders
709793|NCT00001664|Hypersomnia
709794|NCT00001664|Periodic Leg Movements
709795|NCT00001663|Neurological Disorders
709796|NCT00001663|Movement Disorders
709797|NCT00001663|Physiology
709798|NCT00001663|Noninvasive
709799|NCT00001663|Brain Stimulation
709800|NCT00001663|Cortical Myoclonus
709801|NCT00001662|Dementia
709802|NCT00001662|Glutamate
709803|NCT00001662|Clinical Trial
709804|NCT00001662|Neurotransmitter
709805|NCT00001662|Alzheimer's Disease
709806|NCT00001661|Plasticity
709807|NCT00001661|Use
709808|NCT00001661|Stroke
709809|NCT00001661|Spinal Cord Injury
709810|NCT00001661|Amputation
709811|NCT00001661|Intracortical Inhibition
709812|NCT00001659|Bereavement
709813|NCT00001659|Depression
709814|NCT00001659|Suicide
709815|NCT00001659|Activity of Daily Living
709816|NCT00001659|Immune Function
709817|NCT00001659|Occupational Performance
709818|NCT00001659|Sleep Disorders
709819|NCT00001659|Mood Changes
709820|NCT00001658|Amoxicillin
709821|NCT00001658|Antibiotics
709822|NCT00001658|Cytokines
709823|NCT00001658|Group A beta-Hemolytic Strep Infections
709824|NCT00001658|Obsessive Compulsive Disorder
709825|NCT00001658|Streptococcal Infection
709826|NCT00001658|Tic Disorders
709827|NCT00001657|15 O PET Scanning
709828|NCT00001657|Anxiety
709829|NCT00001657|Cerebral Blood Flow
709830|NCT00001657|Depression
709831|NCT00001657|Domestic Abuse
709832|NCT00001657|Neuroendocrine
709833|NCT00001657|PET Scanning
709834|NCT00001657|Police Officers
709835|NCT00001657|Post Traumatic Stress Disorder
709836|NCT00001657|Repetitive Transcranial Magnetic Stimulation
709837|NCT00001656|Clozapine
709838|NCT00001656|Olanzapine
709839|NCT00001656|Drug Response
709840|NCT00001656|Safety
709841|NCT00001656|Childhood Onset Schizophrenia
709842|NCT00001656|Schizoaffective Disorder
709843|NCT00001656|Multidimensionally Impaired Syndrome
709844|NCT00001656|Phenomenology
709845|NCT00001656|Biochemical Correlates
709846|NCT00001656|Brain Imaging
709847|NCT00001656|Schizophrenia
709848|NCT00001656|Childhood Schizophrenia
709849|NCT00001656|Psychosis
709850|NCT00001654|Adolescence
709851|NCT00001654|Comorbid Disorders
709852|NCT00001654|Physiology
709853|NCT00001654|Socialization
709854|NCT00001654|Gender
709855|NCT00001654|Conduct Problems
709856|NCT00001654|Anxiety
709857|NCT00001654|Sadness
709858|NCT00001654|Emotion
709859|NCT00001654|Psychophysiology
709860|NCT00001652|Life-Charting
709861|NCT00001652|Cerebrospinal Fluid
709862|NCT00001652|Diagnostic Tests
709863|NCT00001652|Cognitive Testing
709864|NCT00001652|Course of Illness
709865|NCT00001652|Bipolar Disorder
709866|NCT00001651|Deuterium
709867|NCT00001651|HIV
709868|NCT00001651|Labeling
709869|NCT00001651|CD4 Cells
709870|NCT00001651|Immunodeficiency
709871|NCT00001650|BrDU
709872|NCT00001650|HIV
709873|NCT00001650|Labeling
709874|NCT00001650|CD4 Cells
709875|NCT00001650|Immunodeficiency
709876|NCT00001649|Clinical Trial
709877|NCT00001649|Sexual Transmitted Disease
709878|NCT00001649|Phase III
709879|NCT00001649|HSV
709880|NCT00001649|Valtrex
709881|NCT00001649|Valaciclovir
709882|NCT00001649|HS2A/B3009
709883|NCT00001649|Herpes Simplex Virus Transmission
709884|NCT00001649|Heterosexual Couples
709885|NCT00001648|HVEM Gene
709886|NCT00001648|HSV
709887|NCT00001648|Herpes Simplex Virus
709888|NCT00001647|AIDS
709889|NCT00001647|Immunotherapy
709890|NCT00001647|Adoptive Cell Transfers
709891|NCT00001647|T Cell Repertoire
709892|NCT00001647|Identical Twins
709893|NCT00001646|Aspergillus
709894|NCT00001646|Azole
709895|NCT00001646|Immunocompromise
709896|NCT00001645|Chagas' Disease
709897|NCT00001645|Trypanosomiasis
709898|NCT00001645|Malaria
709899|NCT00001645|Parasitic Infection
709900|NCT00001644|Immunodeficiency
709901|NCT00001644|Latency
709902|NCT00001644|T Cell Turnover
709903|NCT00001644|Infected Cell Turnover
709904|NCT00001644|Follicular Dendritic Cells
709905|NCT00001643|Lewy Body
709906|NCT00001643|Mutation
709907|NCT00001643|Hereditary
709908|NCT00001643|Dominant
709909|NCT00001643|Sporadic
709910|NCT00001643|Parkinson's Disease
709911|NCT00001642|Chromosomal Deletion
709912|NCT00001642|Mutations
709913|NCT00001642|Paucity of Bile Ducts
709914|NCT00001642|Physical Map
709915|NCT00001642|Transcript Identification
709916|NCT00001642|Alagille Syndrome
709917|NCT00001642|Syndromic Bile Duct Paucity
709918|NCT00001641|Fibrillin
709919|NCT00001641|Collagen
709920|NCT00001641|Marfan Syndrome
709921|NCT00001641|Stickler Syndrome
709922|NCT00001641|Aortic Dissection
709923|NCT00001641|Ehlers-Danlos
709924|NCT00001641|Connective Tissue Disorders
709925|NCT00001641|Ehlers-Danlos Syndrome
709926|NCT00001641|Nail-Patella Syndrome
709927|NCT00001640|Parkinson's Disease
709928|NCT00001639|Gene Dosage
709929|NCT00001639|Haploinsufficiency
709930|NCT00001639|Karyotype
709931|NCT00001639|Malformations
709932|NCT00001639|Mental Retardation
709933|NCT00001638|Echocardiography
709934|NCT00001638|Heart
709935|NCT00001638|Gadolinium
709936|NCT00001638|Dobutamine
709937|NCT00001638|Toxicity
709938|NCT00001638|Adverse Events
709939|NCT00001638|Myocardial Infarction
709940|NCT00001638|Myocardial Viability
709941|NCT00001638|Myocardial Perfusion
709942|NCT00001638|Myocardial Function
709943|NCT00001638|Cardiovascular Disease
709944|NCT00001637|Peripheral Blood Stem Cells
709945|NCT00001637|Engraftment
709946|NCT00001637|Fludarabine
709947|NCT00001637|Nonmyeloablative
709948|NCT00001637|Graft-Versus-Leukemia
709949|NCT00001637|Graft vs. Host Disease
709950|NCT00001637|Cyclophosphamide
709951|NCT00001637|Donor Apheresis
709952|NCT00001637|Nonmyeloablative Bone Marrow Transplantation
709953|NCT00001637|Chronic Myelogenous Leukemia (CML)
709954|NCT00001637|Acute Lymphoblastic Leukemia (ALL)
709955|NCT00001637|Acute Myelogenous Leukemia (AML)
709956|NCT00001637|Myelodysplastic Syndromes
709957|NCT00001637|Chronic Lymphocytic Leukemia (CLL)
709958|NCT00001637|Prolymphocytic Leukemia
709959|NCT00001633|Contrast Media
709960|NCT00001633|Coronary Artery Disease
709961|NCT00001633|Coronary Vessels
709962|NCT00001633|Magnetic Resonance Angiography
709963|NCT00001633|Magnetic Resonance Imaging
709964|NCT00001632|Hypertrophy
709965|NCT00001632|Integrated
709966|NCT00001632|Backscatter
709967|NCT00001632|Cyclic
709968|NCT00001632|Echocardiography
709969|NCT00001632|Hypertrophic Cardiomyopathy
709970|NCT00001631|Gadolinium
709971|NCT00001631|Ischemia
709972|NCT00001631|Coronary Artery Disease
709973|NCT00001631|Hypertrophic Cardiomyopathy
709974|NCT00001631|Dipyridamole
709975|NCT00001630|Immunosuppression
709976|NCT00001630|Thrombocytopenia
709977|NCT00001630|Autoimmune Disease
709978|NCT00001630|Evan's Syndrome
709979|NCT00001630|Autoimmune Hemolytic Anemia
709980|NCT00001630|Episodic Bleeding
709981|NCT00001629|Angiotensin AT-1 Receptor
709982|NCT00001629|Angiotensin Receptor Antagonist
709983|NCT00001629|Atherosclerosis
709984|NCT00001629|Blood Flow
709985|NCT00001629|Cold Pressor Test
709986|NCT00001629|Endothelium
709987|NCT00001629|Exercise
709988|NCT00001629|Coronary Artery Disease
709989|NCT00001629|Heart Failure
709990|NCT00001628|Angiotensin Receptor Antagonist
709991|NCT00001628|Atherosclerosis
709992|NCT00001628|Blood Flow
709993|NCT00001628|Endothelium
709994|NCT00001628|Endothelial Dysfunction
709995|NCT00001627|Bone Marrow
709996|NCT00001627|Hematopoiesis
709997|NCT00001627|DNA
709998|NCT00001627|RNA
709999|NCT00001627|Viruses
710000|NCT00001627|Normal Volunteer
710001|NCT00001627|Aplastic Anemia
710002|NCT00001627|Myelodysplasia
710003|NCT00001627|Fanconi's Anemia
710004|NCT00001627|Single Lineage Cytopenia
710005|NCT00001626|Cytopenia
710006|NCT00001626|Randomized
710007|NCT00001626|Immunosuppression
710008|NCT00001626|Severe Aplastic Anemia
710009|NCT00001625|Insulin Resistance
710010|NCT00001625|Obesity
710011|NCT00001625|Hypertension
710012|NCT00001625|Diabetes
710013|NCT00001625|Mathematical Modeling
710014|NCT00001625|Normal Volunteer
710015|NCT00001624|BQ-123
710016|NCT00001624|Endothelin
710017|NCT00001624|Insulin
710018|NCT00001624|Plethysmography
710019|NCT00001624|Vasoconstriction
710020|NCT00001624|Healthy Volunteer
710021|NCT00001623|Peripheral Blood Stem Cells
710022|NCT00001623|Graft-Versus-Leukemia
710023|NCT00001623|Graft vs. Host Disease
710024|NCT00001623|Whole Body Irradiation
710025|NCT00001623|Donor Apheresis
710026|NCT00001623|Cyclophosphamide
710027|NCT00001623|Graft-Versus-Myeloma
710028|NCT00001623|Leukemic Relapse
710029|NCT00001623|Multiple Myeloma
710030|NCT00001623|Acute Myelogenous Leukemia (AML)
710031|NCT00001623|Chronic Myelogenous Leukemia (CML)
710032|NCT00001623|Acute Lymphoblastic Leukemia (ALL)
710033|NCT00001623|Myelodysplastic Syndromes
710034|NCT00001623|Chronic Lymphocytic Leukemia (CLL)
710035|NCT00001622|Endothelium
710036|NCT00001622|Hypercholesterolemia
710037|NCT00001622|Hypertension
710038|NCT00001622|Microvessels
710039|NCT00001622|Vasodilation
710040|NCT00001622|Normal Volunteer
710041|NCT00001621|Teaching
710042|NCT00001621|Pulmonary Disease
710043|NCT00001621|Routine Testing
710044|NCT00001621|Medically Indicated
710045|NCT00001621|Pulmonary Function Test
710046|NCT00001620|Thrombocytopenia
710047|NCT00001620|Anemia
710048|NCT00001620|Neutropenia
710049|NCT00001620|Dysplasia
710050|NCT00001620|Cytopenia
710051|NCT00001620|Hematologic Malignancy
710052|NCT00001619|Imaging
710053|NCT00001619|Spectroscopy
710054|NCT00001619|MRI
710055|NCT00001619|Cardiovascular
710056|NCT00001619|Technical Development
710057|NCT00001619|Heart
710058|NCT00001619|Safety
710059|NCT00001619|Toxicity
710060|NCT00001619|Gadolinium
710061|NCT00001619|Adverse Events
710062|NCT00001619|Normal Volunteer
710063|NCT00001618|Cystic Fibrosis
710064|NCT00001618|Healthy Volunteers
710065|NCT00001618|Asthma
710066|NCT00001618|Normal Volunteer
710067|NCT00001618|Chronic Lung Disease
710068|NCT00001617|Aging
710069|NCT00001617|Cataract
710070|NCT00001617|Eye
710071|NCT00001617|Human Lens
710072|NCT00001617|Normal Volunteer
710073|NCT00001615|Age-Related Macular Degeneration
710074|NCT00001615|Choroidal Neovascularization
710075|NCT00001615|Disciform
710076|NCT00001615|Drusen
710077|NCT00001615|Natural History
710078|NCT00001615|Periocular
710079|NCT00001615|Quality of Life
710080|NCT00001615|Steroids
710081|NCT00001615|Corticosteroid
710082|NCT00001614|Eye
710083|NCT00001614|Immunosuppression
710084|NCT00001614|Inflammation
710085|NCT00001614|Iritis
710086|NCT00001614|Joint
710087|NCT00001614|Oral Tolerance
710088|NCT00001614|Juvenile Rheumatoid Arthritis
710089|NCT00001614|Uveitis
710090|NCT00001613|Cataract Surgery
710091|NCT00001613|Human Lens
710092|NCT00001613|Crystallins
710093|NCT00001613|Post-Translational
710094|NCT00001613|Protein Modification
710095|NCT00001613|Nuclear Cataract
710096|NCT00001613|Cataract Extraction
710097|NCT00001612|Diabetic Retinopathy
710098|NCT00001612|Long-Term Visual Outcome
710099|NCT00001612|Photocoagulation
710100|NCT00001612|J. H. Wilmer Eye Institute
710101|NCT00001611|AIDS
710102|NCT00001611|Eye
710103|NCT00001611|Treatment
710104|NCT00001611|Opportunistic Infection
710105|NCT00001611|Immunology
710106|NCT00001611|Retinitis
710107|NCT00001610|Standing Potential
710108|NCT00001610|Fast Oscillation
710109|NCT00001610|Slow Oscillation
710110|NCT00001610|Retinal Pigment
710111|NCT00001610|Epithelium
710112|NCT00001610|Electro-oculogram
710113|NCT00001610|Cellular Immune Response
710114|NCT00001610|Retinal Antigens
710115|NCT00001610|IRBP
710116|NCT00001610|S-Antigen
710117|NCT00001610|Normal Volunteer
710118|NCT00001609|Linkage
710119|NCT00001609|Genetic Analysis
710120|NCT00001609|Lens
710121|NCT00001609|Opacity
710122|NCT00001609|Inherited
710123|NCT00001609|Linkage Analysis
710124|NCT00001609|Genomic DNA
710125|NCT00001609|Risk Prediction
710126|NCT00001609|Pedigree Analysis
710127|NCT00001609|Congenital Cataracts
710128|NCT00001609|Hereditary Cataracts
710129|NCT00001606|Linkage Analysis
710130|NCT00001606|Positional Cloning
710131|NCT00001606|Mutation Screening
710132|NCT00001606|Syndromic Hearing Impairment
710133|NCT00001606|Non-Syndromic Hearing Impairment
710134|NCT00001605|Conjugate Vaccine
710135|NCT00001605|Detoxified Lipooligosaccharide
710136|NCT00001605|Tetanus Toxoid
710137|NCT00001605|Normal Volunteers
710138|NCT00001604|DNA Samples
710139|NCT00001604|Buccal Swab
710140|NCT00001604|Genotyping
710141|NCT00001604|Statistical Analysis
710142|NCT00001604|Computers
710143|NCT00001604|Stuttering
710144|NCT00001603|Cytokines
710145|NCT00001603|Squamous Cell Carcinoma
710146|NCT00001603|Papilloma
710147|NCT00001603|Communication
710148|NCT00001603|Immunity
710149|NCT00001603|Head
710150|NCT00001603|Neck
710151|NCT00001603|Head and Neck Cancer
710152|NCT00001602|Dysfluency
710153|NCT00001602|Polymorphism
710154|NCT00001602|Stuttering
710155|NCT00001602|Dopamine
710156|NCT00001602|Family Studies
710157|NCT00001602|Receptors
710158|NCT00001602|Serotonin
710159|NCT00001602|Enzymes
710160|NCT00001602|Genetics
710161|NCT00001602|Linkage Analysis
710162|NCT00001601|Oral Medicine
710163|NCT00001601|Clinical Experience
710164|NCT00001601|Therapy
710165|NCT00001601|Educational Training
710166|NCT00001601|Pathogenesis
710167|NCT00001601|Oral Lesions
710168|NCT00001601|Aphthous Ulcers
710169|NCT00001601|Lichen Planus
710170|NCT00001601|Burning Mouth
710171|NCT00001601|Temporomandibular Dysfunction (TMD)
710172|NCT00001601|Oral Disease
710173|NCT00001601|Oral Manifestations
710174|NCT00001600|Screening Protocol
710175|NCT00001600|Temporomandibular Disorders
710176|NCT00001600|Oral Surgery
710177|NCT00001600|Chronic Orofacial Pain
710178|NCT00001599|Xerostomia
710179|NCT00001599|Autoimmunity
710180|NCT00001599|Salivary Glands
710181|NCT00001599|Lacrimal Function
710182|NCT00001599|Immunomodulator
710183|NCT00001599|Sjogren's Syndrome
710184|NCT00001599|Dry Mouth
710185|NCT00001598|Xerostomia
710186|NCT00001598|Autoimmunity
710187|NCT00001598|Salivary Glands
710188|NCT00001598|Androgen Therapy
710189|NCT00001598|Lacrimal Function
710190|NCT00001598|DHEA
710191|NCT00001598|Sjogren's Syndrome
710192|NCT00001598|Dehydroepiandrosterone
710193|NCT00001597|Psychophysics
710194|NCT00001597|Validation
710195|NCT00001597|Fentanyl
710196|NCT00001597|Normal Volunteer
710197|NCT00001597|Pain
710198|NCT00001596|Albinism
710199|NCT00001596|Platelet Storage Pool Deficiency
710200|NCT00001596|Pulmonary Fibrosis
710201|NCT00001596|Hermansky-Pudlak Syndrome
710202|NCT00001595|Oncogenesis
710203|NCT00001595|Adenoma
710204|NCT00001595|Craniopharyngioma
710205|NCT00001595|Cushing Syndrome
710206|NCT00001595|Homeobox-Containing Genes
710207|NCT00001595|Developmental Defect
710208|NCT00001595|Pituitary Gland
710209|NCT00001594|Osteogenesis Imperfecta
710210|NCT00001594|Basilar Invagination
710211|NCT00001591|Central Nervous System
710212|NCT00001591|Technical Development
710213|NCT00001591|Activation Studies
710214|NCT00001591|Pulse Sequences
710215|NCT00001591|Metabolites
710216|NCT00001591|Normal Volunteer
710217|NCT00001589|Ferritin
710218|NCT00001589|Atherosclerosis
710219|NCT00001589|Myocardial Infarction
710220|NCT00001589|Blood Donors
710221|NCT00001589|Low Density Lipoprotein
710222|NCT00001589|Asymptomatic Carotid Atherosclerosis
710223|NCT00001587|Hyperthermia
710224|NCT00001587|Metastases
710225|NCT00001587|Organ Perfusion
710226|NCT00001587|Regional Therapy
710227|NCT00001586|Genetics
710228|NCT00001586|Bone Marrow Transplantation
710229|NCT00001586|Immunosuppression
710230|NCT00001586|T Lymphocytes
710231|NCT00001586|Marrow Purging
710232|NCT00001584|Pathogenesis
710233|NCT00001584|Resistance
710234|NCT00001584|Sanctuary Sites
710235|NCT00001584|Semen
710236|NCT00001584|Sexual Transmission
710237|NCT00001582|Autoimmune Disorder
710238|NCT00001582|Immune System Evaluation
710239|NCT00001582|Human Response Investigation
710240|NCT00001582|Tissue Acquisition
710241|NCT00001580|Molecular Diagnostics
710242|NCT00001580|Ovary
710243|NCT00001580|Tissue Acquisition
710244|NCT00001580|cDNA Library
710245|NCT00001580|CGAP
710246|NCT00001579|Biochemical Modulation
710247|NCT00001579|Dihydropyrimidine Dehydrogenase
710248|NCT00001579|Oral Administration
710249|NCT00001579|Pharmacokinetics
710250|NCT00001577|Chemotherapy
710251|NCT00001577|Hyperthermia
710252|NCT00001577|Isolation perfusion
710253|NCT00001577|Regional Therapy
710254|NCT00001576|Regional Therapy
710255|NCT00001576|Organ Perfusion
710256|NCT00001576|Metastases
710257|NCT00001576|Hyperthermia
710258|NCT00001575|Yttrium 90
710259|NCT00001575|Radiolabeled
710260|NCT00001575|Anti -Tac
710261|NCT00001575|Calcium DTPA
710262|NCT00001574|Metabolites
710263|NCT00001574|Proton Nuclear Magnetic Resonance Spectroscopic Imaging
710264|NCT00001574|Scans
710265|NCT00001573|Glioma
710266|NCT00001573|PDGF
710267|NCT00001573|Pharmacokinetics
710268|NCT00001573|Sarcoma
710269|NCT00001573|Toxicity
710270|NCT00001572|B-Cell Lymphoma
710271|NCT00001572|BCL- 2 Positive Tumor
710272|NCT00001572|Immunization
710273|NCT00001572|Induction Chemotherapy
710274|NCT00001572|Lymphoma Vaccine
710275|NCT00001572|Follicular Lymphoma
710276|NCT00001572|Tumor-Derived Immunoglobulin Idiotype
710277|NCT00001571|Cancer
710278|NCT00001571|DDT, PCB
710279|NCT00001571|Epidemiology
710280|NCT00001571|Pesticides
710281|NCT00001571|Serum
710282|NCT00001570|Cytochrome P 450
710283|NCT00001570|Multi-Drug Resistance
710284|NCT00001570|P-Glycoprotein
710285|NCT00001570|Pharmacokinetics
710286|NCT00001569|Gastrointestinal
710287|NCT00001569|Adenocarcinoma
710288|NCT00001569|Taxol
710289|NCT00001568|Tumors
710290|NCT00001568|Detection
710291|NCT00001568|Follow-Up
710292|NCT00001568|Markers
710293|NCT00001568|Radiolabeled
710294|NCT00001567|Follow-Up Study
710295|NCT00001567|Relapse-Free Survival
710296|NCT00001567|Serum Soluble IL-2 Receptor
710297|NCT00001567|Hematologic Malignancy
710298|NCT00001567|Chronic Therapy
710299|NCT00001566|Rhabdomyosarcoma
710300|NCT00001566|Ewing's Sarcoma
710301|NCT00001566|Immunotherapy
710302|NCT00001566|Tumor Vaccine
710303|NCT00001566|Interleukin-2
710304|NCT00001565|Brain Tumors
710305|NCT00001565|Differentiation
710306|NCT00001565|Maximally Tolerated Dose
710307|NCT00001565|Neuroblastoma
710308|NCT00001565|Phenylacetate
710309|NCT00001564|Rhabdomyosarcoma
710310|NCT00001564|Ewing's Sarcoma
710311|NCT00001564|Immunotherapy
710312|NCT00001564|Tumor Vaccine
710313|NCT00001564|Fusion Protein
710314|NCT00001563|Lymphomagenesis
710315|NCT00001563|Molecular markers of drug resistance
710316|NCT00001563|Refractory, progressive, or relapsed HIV + NHL
710317|NCT00001563|AIDS-related NHL
710318|NCT00001561|Multiple Myeloma
710319|NCT00001561|Vaccine
710320|NCT00001561|Idiotype-Specific Immunity
710321|NCT00001561|Immune Transfer
710322|NCT00001561|Myeloma Immunoglobulin
710323|NCT00001560|AIDS
710324|NCT00001560|Multidisciplinary
710325|NCT00001560|Leukemia
710326|NCT00001560|Lymphoma
710327|NCT00001560|Kaposi's Sarcoma
710328|NCT00001554|Cortical Localization
710329|NCT00001554|Optical Imaging
710330|NCT00001554|Thermal Imaging
710331|NCT00001553|Plasticity
710332|NCT00001553|Recovery
710333|NCT00001553|Stroke
710334|NCT00001553|Use
710335|NCT00001553|Cortico-subcortical Stroke
710336|NCT00001552|Spasmodic Dysphonia
710337|NCT00001552|Pedigree
710338|NCT00001552|Vocal Fold Paralysis
710339|NCT00001552|Voice Disorder
710340|NCT00001551|Stuttering
710341|NCT00001551|Linkage
710342|NCT00001551|Pedigree
710343|NCT00001551|Speech Articulation
710344|NCT00001551|Phonological Processing Disorders
710345|NCT00001551|Speech Disorder
710346|NCT00001550|Immunotherapy
710347|NCT00001550|Muscle Stiffness
710348|NCT00001550|Rigidity
710349|NCT00001550|Anti-GAD Antibodies
710350|NCT00001550|Episodic Spasms
710351|NCT00001550|Intravenous High-Dose Immunoglobulin
710352|NCT00001550|Stiff-man Syndrome
710353|NCT00001549|Movement Disorders
710354|NCT00001549|Parkinson's
710355|NCT00001549|Alzheimer's
710356|NCT00001549|Screening
710357|NCT00001549|Diagnostic Puzzles
710358|NCT00001549|Alzheimer Disease
710359|NCT00001549|Progressive Supranuclear Palsy
710360|NCT00001549|PSP
710361|NCT00001549|Restless Leg Syndrome
710362|NCT00001549|RLS
710363|NCT00001549|Parkinsonism
710364|NCT00001549|PD
710365|NCT00001548|Genetic
710366|NCT00001548|Psychiatric Disorder
710367|NCT00001548|Affected Sib Pairs
710368|NCT00001548|Obsessions
710369|NCT00001548|Compulsions
710370|NCT00001548|Family Study
710371|NCT00001548|OCD Spectrum Disorders
710372|NCT00001548|Trichotillomania
710373|NCT00001548|Tourette's Syndrome
710374|NCT00001547|Drug
710375|NCT00001547|Imaging
710376|NCT00001547|Brain
710377|NCT00001547|Metabolism
710378|NCT00001547|Organic Mental Syndrome
710379|NCT00001547|Magnetic Resonance Imaging
710380|NCT00001547|Spectroscopy
710381|NCT00001547|Neuropsychiatric Disorders
710382|NCT00001547|Drug Effects
710383|NCT00001547|Interferon-alpha
710384|NCT00001546|Biochemical Screening
710385|NCT00001546|Body Temperature
710386|NCT00001546|Consent Form
710387|NCT00001546|EEG
710388|NCT00001546|EKG
710389|NCT00001546|Melatonin
710390|NCT00001546|Mood
710391|NCT00001546|Physical Examination
710392|NCT00001546|Psychiatric Examination
710393|NCT00001546|Sleep Duration
710394|NCT00001546|Sleep Disorders
710395|NCT00001545|Affective Disorders
710396|NCT00001545|Repetitive Transcranial Magnetic Stimulation
710397|NCT00001545|Mania
710398|NCT00001545|Bipolar Disorder
710399|NCT00001545|Depression
710400|NCT00001545|Unipolar Disorder
710401|NCT00001545|Unipolar Depression
710402|NCT00001544|DNA Probes
710403|NCT00001544|Trinucleotide Repeats
710404|NCT00001544|Family Studies
710405|NCT00001544|Lymphoblast Cell Lines
710406|NCT00001544|Genotyping
710407|NCT00001544|Bipolar Affective Disorders
710408|NCT00001544|Schizophrenia
710409|NCT00001544|Mental Retardation
710410|NCT00001544|Neuropsychiatric Disorders
710411|NCT00001543|Major Depression
710412|NCT00001543|Metabolic Clearance Rate
710413|NCT00001543|Pulsatility
710414|NCT00001543|Adrenocorticotropic Hormone
710415|NCT00001543|Cortisol
710416|NCT00001543|Corticotropin Releasing Hormone Binding Protein
710417|NCT00001543|Pharmacokinetics
710418|NCT00001543|Half-Life
710419|NCT00001543|Bioavailability
710420|NCT00001543|Cushing's Syndrome
710421|NCT00001542|Candidiasis
710422|NCT00001542|Azole
710423|NCT00001542|Resistance
710424|NCT00001542|Candida Albicans
710425|NCT00001542|Oropharynx
710426|NCT00001541|Vasculitis
710427|NCT00001541|Inflammation
710428|NCT00001541|Bronchoscopy
710429|NCT00001541|Cytokines
710430|NCT00001541|Inflammatory Mediators
710431|NCT00001541|Wegener's Granulomatosis
710432|NCT00001540|Diagnostic
710433|NCT00001540|Immune Function
710434|NCT00001540|Immunization
710435|NCT00001540|Immunodeficiency
710436|NCT00001540|Quantitative
710437|NCT00001539|Central Nervous System
710438|NCT00001539|Lyme Disease
710439|NCT00001539|Borrelia Burgdorferi
710440|NCT00001539|Neuroborreliosis
710441|NCT00001539|Chronic Symptoms
710442|NCT00001538|AIDS
710443|NCT00001538|DNA Vaccine
710444|NCT00001538|Naked DNA
710445|NCT00001538|Plasmid
710446|NCT00001538|gp 160
710447|NCT00001536|Disability
710448|NCT00001536|Dwarfism
710449|NCT00001536|Ethics in Genetic Counseling
710450|NCT00001536|Quality of Life
710451|NCT00001536|Reproductive Issues
710452|NCT00001536|Support Groups
710453|NCT00001536|Achondroplasia
710454|NCT00001535|Intracellular Immunization
710455|NCT00001535|Immune Based Therapy
710456|NCT00001535|Ex Vivo Cell Processing
710457|NCT00001535|Identical Twins
710458|NCT00001535|HIV/AIDS
710459|NCT00001535|Kaposi's Sarcoma
710460|NCT00001534|Genetics
710461|NCT00001534|Myocardial Ischemia
710462|NCT00001534|Diastolic Dysfunction
710463|NCT00001534|Renin-Angiotensin System
710464|NCT00001534|Hypertrophic Cardiomyopathy
710465|NCT00001534|Left Ventricular (LV) Hypertrophy
710466|NCT00001533|Anemia
710467|NCT00001533|Chronic T Cell Lymphocytosis with Neutropenia
710468|NCT00001533|Immunosuppression
710469|NCT00001533|Neutropenia
710470|NCT00001533|T-LGL Leukemia
710471|NCT00001532|Genetic Polymorphism
710472|NCT00001532|Nitric Oxide Synthase
710473|NCT00001532|Alpha 1-Antitrypsin
710474|NCT00001532|Candidate Genes
710475|NCT00001532|Lung Pathology
710476|NCT00001532|Asthma
710477|NCT00001532|Lung Disease
710478|NCT00001532|Cystic Fibrosis
710479|NCT00001531|Atherogenesis
710480|NCT00001531|Cell Mediated Immunity
710481|NCT00001531|Coronary Artery Disease
710482|NCT00001530|Cardiac Hypertrophy
710483|NCT00001530|Drug-Refractory
710484|NCT00001530|Hemodynamic Benefits
710485|NCT00001530|Obstruction
710486|NCT00001530|Pacemaker Therapy
710487|NCT00001530|Hypertrophic Cardiomyopathy
710488|NCT00001529|G-CSF
710489|NCT00001529|Donor Apheresis
710490|NCT00001529|Graft vs. Host Disease
710491|NCT00001529|Graft-Versus-Leukemia
710492|NCT00001529|Dexamethasone
710493|NCT00001529|Transient Lymphopenia
710494|NCT00001529|Improved T-Cell Depletion
710495|NCT00001529|Normal Volunteer
710496|NCT00001528|Coronary Artery Disease
710497|NCT00001528|Gated Blood Pool Tomography
710498|NCT00001528|Myocardial Blood Flow
710499|NCT00001528|Myocardial Stunning
710500|NCT00001528|Positron Emission Tomography
710501|NCT00001527|BQ-123
710502|NCT00001527|BQ-788
710503|NCT00001527|Endothelin
710504|NCT00001527|Endothelium
710505|NCT00001527|Plethysmography
710506|NCT00001527|Essential Hypertension
710507|NCT00001526|Uveitis
710508|NCT00001526|Interleukin 2 Receptor
710509|NCT00001526|Daclizumab
710510|NCT00001526|HAT
710511|NCT00001526|Zenapax
710512|NCT00001526|Interleukin 2
710513|NCT00001524|Thalidomide
710514|NCT00001524|Clinical Trial
710515|NCT00001524|Tumor Necrosis Factor
710516|NCT00001524|Delayed Healing
710517|NCT00001524|Painful Oral Lesions
710518|NCT00001524|HIV/AIDS
710519|NCT00001524|Mouth Ulcers
710520|NCT00001524|Aphthous Ulcers
710521|NCT00001524|Healing
710522|NCT00001524|Cytokines
710523|NCT00001523|Cytology
710524|NCT00001523|Diagnostic Imaging
710525|NCT00001523|Radiation Damage
710526|NCT00001523|Saliva
710527|NCT00001523|Serostomia
710528|NCT00001523|Xerostomia
710529|NCT00001523|Head Cancer
710530|NCT00001523|Neck Cancer
710531|NCT00001522|Insulin Resistance
710532|NCT00001522|Race
710533|NCT00001522|Body Fat
710534|NCT00001522|Body Composition
710535|NCT00001522|Obesity
710536|NCT00001521|21-Hydroxylase Deficiency
710537|NCT00001521|11-Hydroxylase Deficiency
710538|NCT00001521|Antiandrogen
710539|NCT00001521|Aromatase Inhibitor
710540|NCT00001521|Growth Disorder
710541|NCT00001521|Congenital Adrenal Hyperplasia (CAH)
710542|NCT00001520|Endotracheal Intubation
710543|NCT00001520|Neuromuscular Blockade
710544|NCT00001520|Neuromuscular Blocking Agents
710545|NCT00001520|Paralysis
710546|NCT00001520|Reversal Agents
710547|NCT00001519|Exercise
710548|NCT00001519|Exercise Intensity
710549|NCT00001519|Non-Linear Regression
710550|NCT00001519|Oxygen Uptake
710551|NCT00001519|Recovery
710552|NCT00001519|Subject Comparison
710553|NCT00001519|Time Constant
710554|NCT00001519|VO2
710555|NCT00001518|Groshong Catheter
710556|NCT00001518|Heparinized Flush Solution
710557|NCT00001518|Intraluminal Clot
710558|NCT00001518|Urokinase
710559|NCT00001518|Venous Access Device
710560|NCT00001518|Withdrawal Occlusion
710561|NCT00001516|Case Study Design
710562|NCT00001516|Rehabilitation
710563|NCT00001516|Treatment Efficacy
710564|NCT00001516|Occupational Therapy Process
710565|NCT00001516|Reflection
710566|NCT00001516|Occupational Therapy
710567|NCT00001515|Wegener's Granulomatosis
710568|NCT00001515|Computer Assisted Visualization
710569|NCT00001515|Lung Cavities
710570|NCT00001515|Endobronchial Lesions
710571|NCT00001515|Computed Tomography (CT)
710572|NCT00001515|Bronchogenic Carcinoma
710573|NCT00001512|ProMace Chemotherapy
710574|NCT00001512|Indolent Lymphoma
710575|NCT00001512|Anti-Idiotype Antibody
710576|NCT00001512|GM-CSF
710577|NCT00001512|B-Cell Lymphoma
710578|NCT00001509|Differentiation
710579|NCT00001509|N-myc Expression
710580|NCT00001509|Retinoid
710581|NCT00001509|Solid Tumor
710582|NCT00001509|Trk Expression
710583|NCT00001507|T-cells
710584|NCT00001507|CD34+ Selection
710585|NCT00001507|T-Cell Depletion
710586|NCT00001507|Apheresis
710587|NCT00001507|Mobilization
710588|NCT00001506|Training Protocol
710589|NCT00001506|Natural History
710590|NCT00001506|Consultation
710591|NCT00001506|Standard Therapy
710592|NCT00001506|Standard Tests
710593|NCT00001506|Training
710594|NCT00001505|Biopsy
710595|NCT00001505|Research
710596|NCT00001505|Autoimmune
710597|NCT00001505|Blistering
710598|NCT00001505|Compensation
710599|NCT00001504|Retinoids
710600|NCT00001504|Biomarkers
710601|NCT00001503|Cancer
710602|NCT00001503|Late Effects
710603|NCT00001503|Survival
710604|NCT00001503|Follow-Up
710605|NCT00001502|Blood-Brain Barrier
710606|NCT00001502|Bradykinin
710607|NCT00001502|Children
710608|NCT00001502|Glioma
710609|NCT00001502|Medulloblastoma
710610|NCT00001500|Smoking
710611|NCT00001500|Alcohol
710612|NCT00001500|HIV
710613|NCT00001500|AIDS
710614|NCT00001500|DNA Markers
710615|NCT00001500|Personality
710616|NCT00001500|Healthy Volunteers
710617|NCT00001500|Normal Volunteer
710618|NCT00001499|Carcinoma
710619|NCT00001499|Combination Chemotherapy
710620|NCT00001499|Combined Modality Therapy
710621|NCT00001499|Infusion
710622|NCT00001499|Intravenous
710623|NCT00001499|Lung Neoplasm
710624|NCT00001499|Non-Small Cell Lung Cancer
710625|NCT00001498|5-Fluorouracil
710626|NCT00001498|Cyclophosphamide
710627|NCT00001498|Methotrexate
710628|NCT00001498|Thiotepa
710629|NCT00001497|Brain Imaging
710630|NCT00001497|Encephalopathy
710631|NCT00001497|Hyperactivity
710632|NCT00001497|Neuroimmunology
710633|NCT00001497|Reaction Time Tasks
710634|NCT00001496|BRCA-1
710635|NCT00001496|Familial Breast Cancer
710636|NCT00001496|Breast Cell Culture
710637|NCT00001496|High Risk
710638|NCT00001495|Camptothecin
710639|NCT00001495|Cancer
710640|NCT00001495|Chemotherapy
710641|NCT00001495|Natural Products
710642|NCT00001495|Neoplasms
710643|NCT00001493|Dose Intensity
710644|NCT00001493|Gene Therapy
710645|NCT00001493|Multidrug Resistance
710646|NCT00001491|Ceramidetrihexosidase Deficiency
710647|NCT00001491|Sural Nerve Biopsy
710648|NCT00001491|Nerve Conduction Studies
710649|NCT00001491|Quantitative Sensory Testing
710650|NCT00001491|PGP 9.5 Levels (Skin, Serum and CSF)
710651|NCT00001491|Fabry Disease
710652|NCT00001491|Fabrys
710653|NCT00001491|Fabry's
710654|NCT00001489|Cerebral Metabolism
710655|NCT00001489|Complex Partial Seizures
710656|NCT00001489|Epilepsy
710657|NCT00001487|Menopause
710658|NCT00001487|Andropause
710659|NCT00001487|Depression
710660|NCT00001487|DHEA
710661|NCT00001487|Steroids
710662|NCT00001487|Mid-Life Depression
710663|NCT00001487|Mid Life
710664|NCT00001487|Perimenopause
710665|NCT00001487|Climecteric-Related Mood Disorder
710666|NCT00001486|Paranoia
710667|NCT00001486|Schizophrenic Research
710668|NCT00001486|Hallucinations
710669|NCT00001486|Delusions
710670|NCT00001486|Brain Scans
710671|NCT00001486|Negative Symptoms
710672|NCT00001486|Symptoms of Schizophrenia
710673|NCT00001486|Causes of Schizophrenia
710674|NCT00001486|Psychosis and Schizophrenia
710675|NCT00001486|Compensation
710676|NCT00001486|Schizophrenia
710677|NCT00001486|Schizoaffective Disorder
710678|NCT00001486|Psychosis
710679|NCT00001486|Manic-Depression
710680|NCT00001485|Chemical Mediators
710681|NCT00001485|Circadian Rhythms
710682|NCT00001485|Gender Differences
710683|NCT00001485|Melatonin
710684|NCT00001485|Photoperiodism
710685|NCT00001485|Seasonal Changes
710686|NCT00001483|Manic-Depressive Disorder
710687|NCT00001483|Antidepressants
710688|NCT00001483|Re-Randomization
710689|NCT00001483|Continuation
710690|NCT00001483|Ratings
710691|NCT00001483|Bipolar Illness
710692|NCT00001483|Depression
710693|NCT00001483|Bupropion
710694|NCT00001483|Sertraline
710695|NCT00001482|Anticonvulsants
710696|NCT00001482|Bipolar Disorder
710697|NCT00001482|Depression
710698|NCT00001482|Gabapentin
710699|NCT00001482|Lamotrigine
710700|NCT00001482|Mania
710701|NCT00001482|Mood Disorders
710702|NCT00001481|Postpartum Disorders
710703|NCT00001481|Depression
710704|NCT00001481|Mood
710705|NCT00001481|Postpartum Depression
710706|NCT00001481|Hormones
710707|NCT00001481|Pregnancy
710708|NCT00001481|Estrogen
710709|NCT00001481|Progesterone
710710|NCT00001481|Gonadal Steroids
710711|NCT00001481|GnRH Agonist
710712|NCT00001481|Postpartum
710713|NCT00001481|Mood Disorder
710714|NCT00001480|Dementia
710715|NCT00001480|Alzheimer's Disease
710716|NCT00001480|Cerebrospinal Fluid
710717|NCT00001480|Diagnostic Test
710718|NCT00001480|Cognitive Testing
710719|NCT00001480|Memory Disorder
710720|NCT00001480|Normal Volunteer
710721|NCT00001479|ACTH
710722|NCT00001479|Adrenocorticotropic Hormone
710723|NCT00001479|Antidepressant Treatment
710724|NCT00001479|Chaos Theory
710725|NCT00001479|Chronic Fatigue Syndrome
710726|NCT00001479|Major Depression
710727|NCT00001479|Normal Volunteer
710728|NCT00001479|Primary Affective Disorder
710729|NCT00001478|Bupropion
710730|NCT00001478|Carbamazepine
710731|NCT00001478|Cerebral Blood Flow
710732|NCT00001478|Gabapentin
710733|NCT00001478|Lamotrigine
710734|NCT00001478|Mood Disorders
710735|NCT00001478|Nimodipine
710736|NCT00001478|Oxygen-15
710737|NCT00001478|Positron Emission Tomography
710738|NCT00001478|Venlafaxine
710739|NCT00001477|Communicable Infection
710740|NCT00001477|Monitoring
710741|NCT00001477|Non-Invasive Tests
710742|NCT00001477|Opportunistic Infection
710743|NCT00001476|CD34+ Progenitor
710744|NCT00001476|Retrovirus
710745|NCT00001476|Leukapheresis
710746|NCT00001476|Transduction
710747|NCT00001476|Granulocytes
710748|NCT00001476|Chronic Granulomatous Disease
710749|NCT00001475|AIDS
710750|NCT00001475|Cytokines
710751|NCT00001475|Thalidomide
710752|NCT00001475|Monoclonal Antibody
710753|NCT00001475|Immunomodulator
710754|NCT00001474|Cytokines
710755|NCT00001474|Immunoregulation
710756|NCT00001474|Infusion Duration
710757|NCT00001474|CD4 Cells
710758|NCT00001473|Vasculitis
710759|NCT00001473|Remission
710760|NCT00001473|Relapse
710761|NCT00001473|Toxicity
710762|NCT00001473|ANCA
710763|NCT00001473|Wegener's Granulomatosis
710764|NCT00001471|AIDS
710765|NCT00001471|HIV
710766|NCT00001471|Retrovirus
710767|NCT00001471|Therapy
710768|NCT00001471|Response
710769|NCT00001469|Cancer Susceptibility Alleles
710770|NCT00001469|Prostate Cancer
710771|NCT00001469|Cancer Genetics
710772|NCT00001469|Cancer
710773|NCT00001469|Prostate Cancer (hereditary)
710774|NCT00001468|Behavioral and Attitudinal Changes
710775|NCT00001468|Breast Cancer
710776|NCT00001468|High Risk Families
710777|NCT00001468|Inherited Susceptibility
710778|NCT00001468|Psychological Responses to Risk
710779|NCT00001467|Primary Immunodeficiency Disorders
710780|NCT00001467|Immunologic Disorders
710781|NCT00001466|Clinical Genetics
710782|NCT00001466|Etiology
710783|NCT00001466|Medical Screening
710784|NCT00001466|Prognosis
710785|NCT00001466|Genetic Disorders
710786|NCT00001465|Smooth Muscle Proliferation
710787|NCT00001465|Bronchoscopy
710788|NCT00001465|Female
710789|NCT00001465|Pneumothorax
710790|NCT00001465|Tuberous Sclerosis
710791|NCT00001465|Lymphangioleiomyomatosis (LAM)
710792|NCT00001464|Oxygen
710793|NCT00001464|Bronchoalveolar Lavage
710794|NCT00001464|DNA Repair
710795|NCT00001464|Carbonyl Groups
710796|NCT00001464|Serum
710797|NCT00001464|ADP-ribosylation
710798|NCT00001464|Defensin
710799|NCT00001464|Protein Oxidation
710800|NCT00001464|Human Volunteers
710801|NCT00001462|Alpha 1-Antitrypsin Deficiency
710802|NCT00001462|Emphysema
710803|NCT00001462|Genetic Diseases
710804|NCT00001462|Inflammation
710805|NCT00001462|Nitric Oxide
710806|NCT00001462|Protease
710807|NCT00001461|Angiotensin Converting Enzyme
710808|NCT00001461|Angiotensin Converting Enzyme Inhibitors
710809|NCT00001461|Bradykinin
710810|NCT00001461|Endothelial Function
710811|NCT00001461|Nitric Oxide
710812|NCT00001461|Coronary Artery Disease
710813|NCT00001460|Training Protocol
710814|NCT00001460|Cardiac Diagnosis
710815|NCT00001460|Congenital Heart Disease
710816|NCT00001460|Acquired Heart Disease
710817|NCT00001460|Arrhythmias
710818|NCT00001459|Gated Blood Pool
710819|NCT00001459|SPECT Scan
710820|NCT00001459|Coronary Artery Disease
710821|NCT00001459|Hypertrophic Cardiomyopathy
710822|NCT00001459|Microvascular Angina
710823|NCT00001458|Exercise Testing
710824|NCT00001458|Echocardiography
710825|NCT00001458|Cardiac Catheterization
710826|NCT00001458|Radionuclide Stress Testing
710827|NCT00001458|Holter Monitoring
710828|NCT00001458|Heart Disease
710829|NCT00001458|Muscle Leg Pain
710830|NCT00001458|Leg Pain
710831|NCT00001458|Circulation
710832|NCT00001458|Peripheral Arterial Disease
710833|NCT00001458|Intermittent Claudication
710834|NCT00001458|Renal Vascular Disease
710835|NCT00001458|Uncontrolled Hypertension
710836|NCT00001457|Nucleoside Analogues
710837|NCT00001457|Delta Hepatitis
710838|NCT00001457|Glomerulonephritis
710839|NCT00001457|Polyarteritis Nodosa
710840|NCT00001457|Hepatitis Mutants
710841|NCT00001457|3TC
710842|NCT00001457|Chronic Hepatitis B
710843|NCT00001457|Chronic Hepatitis D
710844|NCT00001457|Cirrhosis
710845|NCT00001457|Lamivudine
710846|NCT00001456|Albinism
710847|NCT00001456|Platelet Storage Pool Deficiency
710848|NCT00001456|Metabolic Disease
710849|NCT00001456|Hermansky-Pudlak Syndrome
710850|NCT00001455|Genetics
710851|NCT00001455|Hemochromatosis
710852|NCT00001455|Iron Metabolism
710853|NCT00001455|Iron Storage Disorder
710854|NCT00001455|Pedigree
710855|NCT00001455|Iron Overload
710856|NCT00001454|Estrogen
710857|NCT00001454|Progesterone
710858|NCT00001454|Menses
710859|NCT00001454|Endometrium
710860|NCT00001454|Normal Volunteer
710861|NCT00001453|Petrosal Sinus Sampling
710862|NCT00001453|Corticotropin Releasing Hormone
710863|NCT00001453|Cushing Syndrome
710864|NCT00001453|Internal Jugular Vein Sampling
710865|NCT00001453|Corticotropin Releasing Hormone Stimulation
710866|NCT00001452|Cushing Syndrome
710867|NCT00001452|Gene Mapping
710868|NCT00001452|Linkage
710869|NCT00001452|Oncogene
710870|NCT00001452|Linkage Analysis
710871|NCT00001452|Gene Identification
710872|NCT00001452|Tumors
710873|NCT00001452|Familial Neoplasia
710874|NCT00001452|Adrenal Gland
710875|NCT00001452|Lentigines
710876|NCT00001452|Carney Complex
710877|NCT00001451|Bone Marrow Transplantation
710878|NCT00001451|Bone Marrow Donor
710879|NCT00001451|Marrow Transplant
710880|NCT00001451|National Marrow Donor Program (NMDP)
710881|NCT00001451|Unrelated Marrow Donor
710882|NCT00001451|Healthy Volunteer
710883|NCT00001450|Chemotherapy
710884|NCT00001450|In Vitro Testing
710885|NCT00001450|Infusional
710886|NCT00001450|Lung Neoplasm
710887|NCT00001450|Pharmacokinetics
710888|NCT00001449|Anti-Cancer Agents
710889|NCT00001449|Antimetabolite
710890|NCT00001449|Palliation
710891|NCT00001449|Pharmacodynamics
710892|NCT00001449|Pharmacokinetics
710893|NCT00001448|Antifungal Therapy
710894|NCT00001448|Articulation
710895|NCT00001448|Behavior
710896|NCT00001448|Expressive Language
710897|NCT00001448|Thrush
710898|NCT00001446|Angiogenesis
710899|NCT00001446|Malignancy
710900|NCT00001446|Neuropathy
710901|NCT00001446|Pharmacokinetics
710902|NCT00001446|Sedation
710903|NCT00001445|Adjuvant-Controlled Study
710904|NCT00001445|Double Blind Randomization
710905|NCT00001445|Env-Deleted Inactivated HIV-1
710906|NCT00001445|Therapeutic HIV Vaccine
710907|NCT00001444|Pharmacokinetics
710908|NCT00001444|Natural Products
710909|NCT00001444|Salvage Therapy
710910|NCT00001444|Protein Kinase Antagonist
710911|NCT00001443|AIDS
710912|NCT00001443|Bioavailability
710913|NCT00001443|Immunologic Evaluations
710914|NCT00001443|Pharmacokinetics
710915|NCT00001443|Toxicity
710916|NCT00001442|Taxol
710917|NCT00001442|Squamous Cell Carcinoma
710918|NCT00001442|Radiosensitizer
710919|NCT00001442|Radiotherapy
710920|NCT00001442|Tumor Potential Doubling Time (Tpot)
710921|NCT00001440|p53
710922|NCT00001440|Interleukin-2
710923|NCT00001440|T-Cell Repopulation
710924|NCT00001440|Apheresis
710925|NCT00001440|RAS
710926|NCT00001439|Cancer
710927|NCT00001439|Immunotherapy
710928|NCT00001438|HIV Infection
710929|NCT00001438|Immune Response
710930|NCT00001438|Pediatric
710931|NCT00001438|Pharmacokinetics
710932|NCT00001438|Toxicity
710933|NCT00001437|Cytokines
710934|NCT00001437|Fibrosis Intensity
710935|NCT00001437|Post-Radiation Fibrosis
710936|NCT00001437|Radiation Injury
710937|NCT00001437|Trental
710938|NCT00001436|Hormone Interactions
710939|NCT00001436|IGF-I
710940|NCT00001436|Metastatic
710941|NCT00001436|Pediatric
710942|NCT00001436|Recurrent
710943|NCT00001435|Anxiety
710944|NCT00001435|Depression
710945|NCT00001435|Family Functioning
710946|NCT00001435|Psychosocial Adjustment
710947|NCT00001435|Social Support
710948|NCT00001432|Purging
710949|NCT00001432|Apheresis
710950|NCT00001432|Long Term Culture
710951|NCT00001432|T Cells
710952|NCT00001432|Stem Cell
710953|NCT00001431|Combined Modality
710954|NCT00001431|GI Cancer
710955|NCT00001431|Pancreatic Cancer
710956|NCT00001431|Radiotherapy
710957|NCT00001430|IL-2
710958|NCT00001430|Drug Resistance
710959|NCT00001430|Continuous Infusion
710960|NCT00001430|Peripheral Stem Cells
710961|NCT00001430|MDR
710962|NCT00001428|Chemotherapy
710963|NCT00001428|Cytokine
710964|NCT00001428|Efficacy
710965|NCT00001428|Palliation
710966|NCT00001428|Solid Tumor
710967|NCT00001427|Pharmacodynamic Studies
710968|NCT00001427|Pharmacokinetics
710969|NCT00001426|Ovarian Cancer
710970|NCT00001426|Initial Therapy
710971|NCT00001426|Paclitaxel
710972|NCT00001426|Cisplatin
710973|NCT00001426|Cyclophosphamide
710974|NCT00001424|AIDS
710975|NCT00001424|Children
710976|NCT00001424|Human Immunodeficiency Virus
710977|NCT00001422|Adenine Analogue
710978|NCT00001422|Apoptosis
710979|NCT00001422|Cytokines
710980|NCT00001422|Psoriasis
710981|NCT00001422|Synovium
710982|NCT00001422|Psoriatic Arthritis
710983|NCT00001421|Cytotoxicity
710984|NCT00001421|HLA Class I
710985|NCT00001421|Lymphocytes
710986|NCT00001421|Muscle
710987|NCT00001421|Myositis
710988|NCT00001421|Thionamides
710989|NCT00001421|Dermatomyositis
710990|NCT00001421|Polymyositis
710991|NCT00001420|Lymphocytes
710992|NCT00001420|Cytokines
710993|NCT00001420|Apoptosis
710994|NCT00001420|Psoriasis
710995|NCT00001420|Genetics
710996|NCT00001420|Psoriatic Arthritis
710997|NCT00001418|Sympathetic Nervous System
710998|NCT00001418|Dysautonomias
710999|NCT00001418|Postural Tachycardia Syndrome
711000|NCT00001418|Neurocardiogenic Syncope
711001|NCT00001418|Hypernoradrenergic Hypertension
711002|NCT00001418|Sympathectomy
711003|NCT00001418|Fluorodopamine
711004|NCT00001418|Positron Emission Tomography
711005|NCT00001418|Norepinephrine
711006|NCT00001418|Dopamine
711007|NCT00001418|Neurocardiologic Disorder
711008|NCT00001417|Needle Biopsy
711009|NCT00001417|Computed Tomography
711010|NCT00001417|Magnetic Resonance Imaging
711011|NCT00001417|Spinal Angiography
711012|NCT00001417|Intratumoral Pressure
711013|NCT00001417|Vertebral Hemangioma
711014|NCT00001417|Spinal Metastasis
711015|NCT00001417|Absolute Ethanol
711016|NCT00001417|Spinal Tumor
711017|NCT00001417|Vertebral Tumor
711018|NCT00001416|Bone Disease
711019|NCT00001416|Calcitriol
711020|NCT00001416|Enzyme Replacement Therapy
711021|NCT00001416|Gaucher's Disease
711022|NCT00001416|Vitamin D
711023|NCT00001415|IL-1
711024|NCT00001415|IL-6
711025|NCT00001415|Immune Response
711026|NCT00001415|Inflammation
711027|NCT00001415|Steroids
711028|NCT00001415|Chronic Fatigue Syndrome
711029|NCT00001415|Depression
711030|NCT00001415|Fibromyalgia
711031|NCT00001415|Normal Volunteer
711032|NCT00001414|Behavior Genetics
711033|NCT00001414|Normal Personality
711034|NCT00001414|Intelligence
711035|NCT00001414|Siblings
711036|NCT00001414|Sixteen Personality Factor Questionnaire
711037|NCT00001414|NEO-Personality Inventory (Revised)
711038|NCT00001414|X-Chromosome
711039|NCT00001413|Corticosteroids
711040|NCT00001413|Osteoporosis
711041|NCT00001413|Depression
711042|NCT00001413|DEXA Scan
711043|NCT00001413|Body Mass
711044|NCT00001413|Dual X-Ray
711045|NCT00001413|Energy Absorptiometry
711046|NCT00001413|Normal Volunteer
711047|NCT00001412|Gonadal Steroids
711048|NCT00001412|Central Nervous System Function
711049|NCT00001412|GnRH Agonist
711050|NCT00001412|Testosterone
711051|NCT00001412|Leuprolide Acetate
711052|NCT00001412|Mood
711053|NCT00001412|Behavior
711054|NCT00001412|Cognitive Function
711055|NCT00001410|Recombinant Production
711056|NCT00001410|Inherited Disease
711057|NCT00001410|Lysosomal Disorder
711058|NCT00001410|Inborn Error of Metabolism
711059|NCT00001410|Enzyme Replacement Therapy
711060|NCT00001410|Glucocerebrosidase
711061|NCT00001410|Polyethylene Glycol
711062|NCT00001410|Gaucher Disease
711063|NCT00001410|Recombinant Enzyme
711064|NCT00001409|AIDS
711065|NCT00001409|Gene Therapy
711066|NCT00001409|T Cell Universal Receptor
711067|NCT00001409|Ex Vivo Activation
711068|NCT00001408|Lymphocytes
711069|NCT00001408|Asthma
711070|NCT00001408|Cytokines
711071|NCT00001408|Interleukin-5
711072|NCT00001408|Late Phase Response
711073|NCT00001407|Cytokines
711074|NCT00001407|Mycobacteria
711075|NCT00001407|Pneumonia
711076|NCT00001407|Multiple Drug Resistant Tuberculosis
711077|NCT00001406|Eosinophils
711078|NCT00001406|Helminth Parasites
711079|NCT00001406|Hypereosinophilia
711080|NCT00001406|Allergy
711081|NCT00001406|Asthma
711082|NCT00001405|Chronic Granulomatous Disease
711083|NCT00001405|Apheresis
711084|NCT00001405|CD34 Cells
711085|NCT00001405|Infection
711086|NCT00001405|Nadph Oxidase
711087|NCT00001405|Normal Volunteer
711088|NCT00001404|Abnormalities, Multiple
711089|NCT00001404|Hypothalamic Hamartoma
711090|NCT00001404|Polysyndactyly
711091|NCT00001404|Autosomal Dominant
711092|NCT00001404|Mutation
711093|NCT00001404|Gelastic
711094|NCT00001404|Gelastic Seizure
711095|NCT00001404|Hypothalamic
711096|NCT00001404|Malformations
711097|NCT00001404|Polydactyly
711098|NCT00001404|Pallister-Hall Syndrome
711099|NCT00001403|Proteus Syndrome
711100|NCT00001403|Overgrowth
711101|NCT00001402|Dilated Cardiomyopathy
711102|NCT00001402|Hibernating Myocardium
711103|NCT00001402|Ischemic Cardiomyopathy
711104|NCT00001402|Metoprolol
711105|NCT00001402|Stress Thallium Scintigraphy
711106|NCT00001402|Congestive Cardiomyopathy
711107|NCT00001402|Congestive Heart Failure
711108|NCT00001402|Heart Failure
711109|NCT00001400|Heart Disease
711110|NCT00001400|Screening
711111|NCT00001400|Follow-Up
711112|NCT00001399|Gene Therapy
711113|NCT00001399|Stem Cell Rescue
711114|NCT00001399|Bone Marrow Failure
711115|NCT00001399|Fanconi Anemia
711116|NCT00001398|Hematopoiesis
711117|NCT00001398|Stem Cell Cycling
711118|NCT00001398|Bone Marrow Failure
711119|NCT00001398|Acquired Aplastic Anemia
711120|NCT00001397|Hematologic Malignancies
711121|NCT00001396|Pacemaker
711122|NCT00001396|Pediatric
711123|NCT00001396|Obstructive HCM
711124|NCT00001395|Cataracts
711125|NCT00001395|Complications
711126|NCT00001395|Rates of Progression
711127|NCT00001395|Diabetic Retinopathy
711128|NCT00001394|Hyperparathyroidism
711129|NCT00001394|Arterial Stimulation
711130|NCT00001394|Venous Sampling
711131|NCT00001394|Parathyroid Adenoma
711132|NCT00001394|Parathyroid Hyperplasia
711133|NCT00001393|Collapsing Glomerulopathy
711134|NCT00001393|Renal Disease
711135|NCT00001393|HIV Associated Nephropathy
711136|NCT00001392|Retrovirus
711137|NCT00001392|PCR
711138|NCT00001392|Renal Failure
711139|NCT00001392|HIV
711140|NCT00001392|Rituximab
711141|NCT00001391|Augmentation
711142|NCT00001391|Osteogenesis
711143|NCT00001391|Stem Cells
711144|NCT00001391|Bone Formation
711145|NCT00001391|Bone Induction
711146|NCT00001390|Saliva
711147|NCT00001390|Parotid
711148|NCT00001390|Lip Biopsy
711149|NCT00001390|Health
711150|NCT00001390|Exocrine
711151|NCT00001390|Normal Volunteer
711152|NCT00001387|Paclitaxel
711153|NCT00001387|Pediatric
711154|NCT00001387|Pharmacokinetics
711155|NCT00001387|Phase I
711156|NCT00001387|Toxicity
711157|NCT00001386|AIDS
711158|NCT00001386|Retrovirus
711159|NCT00001386|Therapeutic Vaccine
711160|NCT00001386|Vaccine
711161|NCT00001386|Helper T Cells
711162|NCT00001385|Cancer Diagnosis
711163|NCT00001385|Cancer Metabolism
711164|NCT00001385|FDG
711165|NCT00001385|FDG Breast Imaging
711166|NCT00001385|PET
711167|NCT00001385|Positron Emission Mammography
711168|NCT00001385|Radiopharmaceutical
711169|NCT00001385|Scintimammography
711170|NCT00001384|14-Day Cycle
711171|NCT00001384|Dose Intensity
711172|NCT00001384|Filgrastim
711173|NCT00001384|Lymph Node Positive
711174|NCT00001384|Non-Cross Resistant
711175|NCT00001383|Cyclosporine Analogue
711176|NCT00001383|Multidrug Resistance
711177|NCT00001383|Pgp Blocker
711178|NCT00001383|Pump Blocker
711179|NCT00001383|Taxol Over 90 Hours
711180|NCT00001382|Immunotherapy
711181|NCT00001382|Vaccine
711182|NCT00001381|Adult
711183|NCT00001381|Intravesical Chemotherapy
711184|NCT00001379|Epstein-Barr Virus
711185|NCT00001379|Lymphoproliferative Disorder
711186|NCT00001379|Viral
711187|NCT00001379|Immunosuppression
711188|NCT00001379|Lymphoma
711189|NCT00001378|4-Quadrant Fine Needle Aspiration
711190|NCT00001378|Biomarkers
711191|NCT00001378|Chemoprevention
711192|NCT00001378|Nipple Suction Aspirates
711193|NCT00001378|TGF Beta
711194|NCT00001377|Familial
711195|NCT00001377|Inherited Prostate Cancer
711196|NCT00001377|Linkage
711197|NCT00001377|Prostate Cancer
711198|NCT00001376|Androgens
711199|NCT00001376|Female
711200|NCT00001376|Immunology
711201|NCT00001376|Neuroendocrine Axis
711202|NCT00001376|Rheumatoid Arthritis
711203|NCT00001376|Postpartum
711204|NCT00001376|Pregnancy
711205|NCT00001375|Infection
711206|NCT00001375|Reactive Arthritis
711207|NCT00001375|Rheumatoid Arthritis
711208|NCT00001375|Synovial Biopsy
711209|NCT00001375|Synovial Fluid
711210|NCT00001375|Synovitis
711211|NCT00001373|Auto-Inflammation
711212|NCT00001373|Familial Mediterranean Fever
711213|NCT00001373|Genetics
711214|NCT00001373|Periodic Fever
711215|NCT00001372|Systemic Lupus Erythematosus
711216|NCT00001372|Natural History
711217|NCT00001372|Lupus Nephritis
711218|NCT00001372|Lupus
711219|NCT00001372|Systemic Lupus
711220|NCT00001372|SLE
711221|NCT00001371|Inflammation
711222|NCT00001371|Lipocortin
711223|NCT00001371|Phospholipase A-2
711224|NCT00001371|Skin
711225|NCT00001371|Uteroglobin
711226|NCT00001371|Psoriasis
711227|NCT00001368|Cerebral Ischemia
711228|NCT00001368|Hypertension
711229|NCT00001368|Immune Response
711230|NCT00001368|Carotid Stenosis
711231|NCT00001368|Atherosclerosis
711232|NCT00001367|Human
711233|NCT00001367|Movement
711234|NCT00001367|Non-Investigational to Diagnostic Puzzle
711235|NCT00001367|Parkinson's
711236|NCT00001367|Dystonia
711237|NCT00001367|Cerebellar
711238|NCT00001367|Puzzles
711239|NCT00001367|Neurological Disorders
711240|NCT00001367|Movement Disorders
711241|NCT00001366|Neuroimaging
711242|NCT00001366|Seizures
711243|NCT00001366|Cerebral Localization
711244|NCT00001366|Partial Epilepsy
711245|NCT00001366|Epilepsy
711246|NCT00001365|Dextromethorphan
711247|NCT00001365|Dextrorphan
711248|NCT00001365|Glutamate Antagonist
711249|NCT00001365|Parkinson's Disease
711250|NCT00001364|Spinal Arteriovenous Malformations
711251|NCT00001364|Spinal Dural Arteriovenous Fistulas
711252|NCT00001364|Surgery
711253|NCT00001364|Embolization
711254|NCT00001364|Spinal Arteriography
711255|NCT00001363|Blood Flow
711256|NCT00001363|Chess Play
711257|NCT00001363|Frontal Lobe
711258|NCT00001363|Neurobehavioral Deficits
711259|NCT00001363|Neuropsychology
711260|NCT00001363|Positron Emission Tomography
711261|NCT00001363|Prefrontal Cortex
711262|NCT00001362|Magnetic Resonance Imaging
711263|NCT00001362|Contrast Enhancement
711264|NCT00001362|Neuroanatomic Morphometry
711265|NCT00001362|Neurobehavioral Deficits
711266|NCT00001362|Neurological Disorders
711267|NCT00001362|Blood Flow
711268|NCT00001362|Blood Volume
711269|NCT00001362|Normal Volunteer
711270|NCT00001361|Movement Disorders
711271|NCT00001361|Sensory Processing
711272|NCT00001361|Stroke
711273|NCT00001361|Spinal Cord Injury
711274|NCT00001361|Blood Flow
711275|NCT00001361|Blood Volume
711276|NCT00001361|Cognitive Function
711277|NCT00001361|Neurobehavioral Deficits
711278|NCT00001361|Neurological Disorders
711279|NCT00001361|Magnetic Resonance Imaging
711280|NCT00001361|Plasticity
711281|NCT00001361|Normal Volunteer
711282|NCT00001360|Cognition
711283|NCT00001360|Vision
711284|NCT00001360|Cortex
711285|NCT00001360|Visual Processing
711286|NCT00001360|Magnetic Resonance Imaging
711287|NCT00001359|Obsessive Compulsive Disorder
711288|NCT00001359|PANDAS Associated with Streptococcal Infections
711289|NCT00001359|Adolescents
711290|NCT00001359|Autoimmune Illness
711291|NCT00001359|Children
711292|NCT00001359|Tic Disorders
711293|NCT00001359|Streptococcal Infections
711294|NCT00001359|Childhood Onset Neuropsychiatric Disorder
711295|NCT00001357|Cytokines
711296|NCT00001357|Immunoregulation
711297|NCT00001357|CD4 Cells
711298|NCT00001356|IL-3
711299|NCT00001356|Stem Cell Factor
711300|NCT00001356|Cytokines
711301|NCT00001356|Cell Differentiation
711302|NCT00001356|Receptors
711303|NCT00001356|Bone Marrow
711304|NCT00001356|Mastocytosis
711305|NCT00001355|Immunodeficiency
711306|NCT00001355|Infections
711307|NCT00001355|Phagocytes
711308|NCT00001355|Cytokines
711309|NCT00001355|Genetics
711310|NCT00001354|AIDS
711311|NCT00001354|Immunotherapy
711312|NCT00001354|CD4 Cells
711313|NCT00001354|Immunomodulator
711314|NCT00001354|Cytokines
711315|NCT00001353|AIDS
711316|NCT00001353|Immune Based Therapy
711317|NCT00001353|Adoptive Immunotherapy
711318|NCT00001353|Lymphapheresis
711319|NCT00001353|Ex Vivo Activation
711320|NCT00001353|HIV
711321|NCT00001353|Gene Therapy
711322|NCT00001353|Protease Inhibitor
711323|NCT00001353|Interleukin-2
711324|NCT00001353|Indinavir
711325|NCT00001352|Cryptococcus Neoformans
711326|NCT00001352|Cryptococcosis
711327|NCT00001352|CD4
711328|NCT00001351|Chronic Infection
711329|NCT00001351|Infectious Diseases
711330|NCT00001351|Host Response
711331|NCT00001351|Immunologic Disorders
711332|NCT00001351|Acute Infection
711333|NCT00001350|Immunoregulation
711334|NCT00001350|T Cell Receptor Alpha/Beta
711335|NCT00001350|Lymphadenopathy
711336|NCT00001350|ALPS
711337|NCT00001350|Autoimmune Lymphoproliferative Syndrome
711338|NCT00001349|Plasmapheresis
711339|NCT00001349|Lymphocytes
711340|NCT00001349|Eosinophils
711341|NCT00001349|Neutrophils
711342|NCT00001347|Linkage Analysis
711343|NCT00001347|Genomic DNA
711344|NCT00001347|Pedigree Analysis
711345|NCT00001347|Usher Syndrome
711346|NCT00001347|Usher Syndrome Type 1
711347|NCT00001347|Usher Syndrome Type 2
711348|NCT00001346|Diabetic Macular Edema
711349|NCT00001346|Diabetic Retinopathy
711350|NCT00001346|Macular Edema
711351|NCT00001346|Photocoagulation
711352|NCT00001346|Psychophysical Testing
711353|NCT00001346|Stiles-Crawford Effect
711354|NCT00001345|Hypercalcemia
711355|NCT00001345|Multiple Endocrine Neoplasia (MEN)
711356|NCT00001345|Familial Hypocalciuric Hypercalcemia
711357|NCT00001345|Hyperparathyroidism
711358|NCT00001345|Linkage Analysis
711359|NCT00001344|Diabetes Mellitus
711360|NCT00001344|Diabetic Neuropathy
711361|NCT00001344|Memantine
711362|NCT00001344|NMDA Receptor Antagonists
711363|NCT00001344|Neuropathic Pain
711364|NCT00001344|Neuropathy
711365|NCT00001344|Post-Herpetic Neuralgia
711366|NCT00001344|Shingles
711367|NCT00001343|Turner's Syndrome
711368|NCT00001343|Short Stature
711369|NCT00001343|Cognitive Function
711370|NCT00001343|Sex Steroids
711371|NCT00001343|Turner Syndrome
711372|NCT00001343|TS
711373|NCT00001342|Electrooculography
711374|NCT00001342|Electroretinogram
711375|NCT00001342|Fluorescein Angiogram
711376|NCT00001342|Glycogen Storage Disease
711377|NCT00001341|Antifolate
711378|NCT00001341|Inhibitor
711379|NCT00001341|Pharmacokinetics
711380|NCT00001341|Thymidylate Synthetase
711381|NCT00001341|Toxicity
711382|NCT00001339|Multidrug Resistance
711383|NCT00001339|Reversal of Drug Resistance
711384|NCT00001339|P-Glycoprotein
711385|NCT00001339|MDR-1
711386|NCT00001338|Fusion Protein
711387|NCT00001337|Primary Mediastinal B-Cell Lymphoma
711388|NCT00001337|CD20 +
711389|NCT00001337|Diffuse Large B-Cell Lymphoma
711390|NCT00001337|Anaplastic Large Cell Lymphoma
711391|NCT00001337|De Novo
711392|NCT00001336|Transplantation
711393|NCT00001336|Cancer
711394|NCT00001336|Cellular Immunity
711395|NCT00001336|Stem Cell Function
711396|NCT00001336|Immunodeficiency
711397|NCT00001335|Peripheral Stem Cell Transfusion
711398|NCT00001335|Up-Front Phase II Window
711399|NCT00001335|Dose-Intensive Vincristine
711400|NCT00001335|Dose-Intensive Doxorubicin
711401|NCT00001335|Dose-Intensive Cyclophosphamide
711402|NCT00001335|ADR-529 for Cardioprotection
711403|NCT00001335|BID Radiation Therapy for Local Control
711404|NCT00001333|Intraventricular
711405|NCT00001333|Meningeal Malignancy
711406|NCT00001333|NSC 609699
711407|NCT00001333|SKF 104864
711408|NCT00001333|Topoisomerase 1
711409|NCT00001332|Cancer Treatment
711410|NCT00001332|Chemotherapy
711411|NCT00001332|Regional Therapy
711412|NCT00001332|Surgery
711413|NCT00001331|Myopathy
711414|NCT00001331|Phosphofructokinase
711415|NCT00001331|Acid Maltase
711416|NCT00001331|Pompe
711417|NCT00001331|Muscle Diseases
711418|NCT00001331|Genetic Muscle Diseases
711419|NCT00001330|Autoimmune Diseases
711420|NCT00001330|Connective Tissue Disease
711421|NCT00001330|Scleroderma
711422|NCT00001330|Silicone Device Implants
711423|NCT00001330|Silicone Injection
711424|NCT00001330|Idiopathic Scleroderma
711425|NCT00001330|Myositis
711426|NCT00001330|Systemic Sclerosis
711427|NCT00001329|Yohimbine
711428|NCT00001329|Catecholamines
711429|NCT00001329|Sympathoadrenal Response
711430|NCT00001329|Sympathetic Nervous System
711431|NCT00001329|Stress
711432|NCT00001329|Hypertension
711433|NCT00001329|Autonomic Failure
711434|NCT00001328|Cancer
711435|NCT00001328|Gene Transfer
711436|NCT00001328|Recurrent Tumors
711437|NCT00001328|Primary Tumors
711438|NCT00001328|Metastases
711439|NCT00001328|Anti-Viral Drugs
711440|NCT00001328|Chemosensitization
711441|NCT00001328|Brain Tumors
711442|NCT00001328|Gene Therapy
711443|NCT00001328|Ganciclovir
711444|NCT00001327|Syringomyelia
711445|NCT00001327|Chiari Malformation
711446|NCT00001327|Magnetic Resonance Imaging
711447|NCT00001327|Intraoperative Ultrasonography
711448|NCT00001327|Hydrocephalus
711449|NCT00001327|Spinal Cord
711450|NCT00001327|Ventriculostomy
711451|NCT00001327|Lumbar Puncture
711452|NCT00001327|Pressure Measurement
711453|NCT00001325|Positron
711454|NCT00001325|Tomography
711455|NCT00001325|Seizures
711456|NCT00001325|Epileptic Focus
711457|NCT00001325|Electroencephalography
711458|NCT00001325|Metabolism
711459|NCT00001325|Glucose
711460|NCT00001325|Cerebral
711461|NCT00001325|Positron Emission Tomography
711462|NCT00001325|Lennox Gastaut Syndrome
711463|NCT00001324|Ataxia
711464|NCT00001324|Brain
711465|NCT00001324|Motor Learning
711466|NCT00001324|Parkinson's Disease
711467|NCT00001324|Physiology
711468|NCT00001324|Positron Emission Tomography
711469|NCT00001324|Stroke
711470|NCT00001324|Tremor
711471|NCT00001324|Voluntary and Involuntary Movement Physiology
711472|NCT00001324|Movement Disorders
711473|NCT00001324|Normal Volunteer
711474|NCT00001323|Cognition
711475|NCT00001323|Neuropsychology
711476|NCT00001323|Neuropsychological Tests
711477|NCT00001323|Neurological Exam
711478|NCT00001323|Psychiatric
711479|NCT00001323|Attention
711480|NCT00001323|Schizophrenic
711481|NCT00001323|Schizoaffective
711482|NCT00001323|Working Memory
711483|NCT00001323|Memory
711484|NCT00001322|Gonadal Steroids
711485|NCT00001322|Mood
711486|NCT00001322|Menstrual Cycle
711487|NCT00001322|Neuropsychological Testing
711488|NCT00001322|Estrogen
711489|NCT00001322|Dexamethasone
711490|NCT00001322|Progesterone
711491|NCT00001322|Central Nervous System Function
711492|NCT00001322|Estradiol
711493|NCT00001322|GnRH Agonist
711494|NCT00001320|Parkinson's Disease
711495|NCT00001320|Schizophrenia
711496|NCT00001320|Dopamine D2/D3 receptors
711497|NCT00001320|Brain Imaging
711498|NCT00001320|SPECT
711499|NCT00001320|Equilibrium
711500|NCT00001320|Brain Scan
711501|NCT00001320|Brain Research
711502|NCT00001320|Brain Disorders
711503|NCT00001320|Schizoaffective Disorder
711504|NCT00001320|Normal Volunteer
711505|NCT00001319|HIV Negative
711506|NCT00001319|CD4 Deficiency
711507|NCT00001319|Retrovirus
711508|NCT00001318|Immune Adjuvant
711509|NCT00001318|Phagocytes
711510|NCT00001318|Non-tuberculous Mycobacterial Infection
711511|NCT00001317|Children
711512|NCT00001317|Gamma Interferon
711513|NCT00001317|Hospitalizations
711514|NCT00001317|Infection
711515|NCT00001317|Chronic Granulomatous Disease
711516|NCT00001316|Lymph Node
711517|NCT00001316|Polymerase Chain Reaction (PCR)
711518|NCT00001316|In Situ Hybridization
711519|NCT00001316|AIDS
711520|NCT00001316|Excisional Biopsy
711521|NCT00001314|Aortic Regurgitation
711522|NCT00001314|Dobutamine Stress
711523|NCT00001314|Left Ventricular Function
711524|NCT00001314|Mitral Regurgitation
711525|NCT00001314|Myocardial Contractile Reserve
711526|NCT00001314|Transesophageal Echocardiography
711527|NCT00001313|Cardiac Diagnosis
711528|NCT00001313|Chest Pain
711529|NCT00001313|Hypertrophic Cardiomyopathy
711530|NCT00001313|Coronary Artery Disease
711531|NCT00001313|Microvascular Angina
711532|NCT00001313|Cardiac Investigation
711533|NCT00001313|Follow-up
711534|NCT00001313|Heart Disease
711535|NCT00001311|Cell/Flare Meter
711536|NCT00001311|Heparin Coating
711537|NCT00001311|Inflammation
711538|NCT00001311|Laser Cell Flare Photometry
711539|NCT00001311|Multicentric
711540|NCT00001311|Polymethylmetacrylate
711541|NCT00001311|Specular Micrography
711542|NCT00001311|Specular Microscopy
711543|NCT00001310|Retinal Disease
711544|NCT00001310|Diabetic Retinopathy
711545|NCT00001310|Uveitis
711546|NCT00001310|Age-Related Macular Degeneration
711547|NCT00001310|Corneal Disease
711548|NCT00001310|Ocular Disease
711549|NCT00001309|Pharmacokinetics
711550|NCT00001309|Biodistribution
711551|NCT00001309|Ascorbic Acid
711552|NCT00001308|Stuttering
711553|NCT00001308|Tourette's Syndrome
711554|NCT00001308|Spasmodic Dysphonia
711555|NCT00001308|Dysarthria
711556|NCT00001308|Parkinson's Disease
711557|NCT00001308|Verbal Dyspraxia
711558|NCT00001308|Aphasia
711559|NCT00001308|Speech
711560|NCT00001308|Motor Control
711561|NCT00001307|Analgesia
711562|NCT00001307|PET
711563|NCT00001307|Positron Emission
711564|NCT00001307|Functional Brain Imaging
711565|NCT00001307|Allodynia
711566|NCT00001307|Thalamus
711567|NCT00001307|Somatosensory Cortex
711568|NCT00001307|Reflex Sympathetic Dystrophy
711569|NCT00001307|Normal Volunteer
711570|NCT00001307|Chronic Pain
711571|NCT00001306|Infertility
711572|NCT00001306|Ovulation
711573|NCT00001306|Autoimmune
711574|NCT00001306|Follicle
711575|NCT00001306|Menopause
711576|NCT00001306|Biopsy
711577|NCT00001306|Glucocorticoids
711578|NCT00001306|Premature Ovarian Failure
711579|NCT00001306|Amenorrhea
711580|NCT00001306|Ovarian Failure
711581|NCT00001306|POF
711582|NCT00001305|Osteogenesis Imperfecta
711583|NCT00001304|Hypoparathyroidism
711584|NCT00001304|Parathyroid Hormone
711585|NCT00001304|Vitamin D
711586|NCT00001304|Calcium Metabolism
711587|NCT00001304|PTH 1-34
711588|NCT00001304|Bone
711589|NCT00001303|Hemodynamics
711590|NCT00001303|Lung Permeability
711591|NCT00001303|Endotoxin Tolerance
711592|NCT00001303|Bronchoscopy
711593|NCT00001303|Human Recombinant Interleukin-1 Receptor
711594|NCT00001303|Normal Volunteer
711595|NCT00001302|Vinblastine
711596|NCT00001302|Multidrug Resistance
711597|NCT00001302|Resistance Reversal
711598|NCT00001302|Pgp Blocker
711599|NCT00001302|Pharmacokinetics
711600|NCT00001302|Cyclosporine
711601|NCT00001302|Drug Interactions
711602|NCT00001301|Adverse Effects
711603|NCT00001301|Burkitt's Lymphoma
711604|NCT00001301|Diffuse Large Cell Lymphoma
711605|NCT00001301|Extended Remission
711606|NCT00001301|Health Status
711607|NCT00001301|Lymphoblastic Lymphoma
711608|NCT00001301|Molecular Studies
711609|NCT00001300|Adjuvant Chemotherapy
711610|NCT00001300|Ifosfamide
711611|NCT00001300|Randomized Study
711612|NCT00001300|Soft Tissue Sarcoma
711613|NCT00001298|Antibody
711614|NCT00001298|DAMPA
711615|NCT00001298|Enzyme
711616|NCT00001298|Kidney
711617|NCT00001298|Pharmacokinetics
711618|NCT00001298|Thymidine
711619|NCT00001298|Toxicity
711620|NCT00001296|Interferon-Gamma
711621|NCT00001296|Isolated Limb Perfusion
711622|NCT00001296|Melanoma
711623|NCT00001296|Melphalan
711624|NCT00001296|TNF
711625|NCT00001295|Follow-Up
711626|NCT00001295|Treatment
711627|NCT00001294|Genetic Linkage
711628|NCT00001294|Sex Behavior
711629|NCT00001294|AIDS
711630|NCT00001294|Alcohol Dependence
711631|NCT00001294|HLA System
711632|NCT00001294|Cancer
711633|NCT00001292|DNA Markers
711634|NCT00001292|Family Studies
711635|NCT00001292|Gene Mapping
711636|NCT00001292|Ichthyosis
711637|NCT00001292|Keratin
711638|NCT00001292|Linkage Analysis
711639|NCT00001292|Scaling Disorders
711640|NCT00001292|Skin
711641|NCT00001291|Osteoarthritis
711642|NCT00001291|Psoriatic Arthritis
711643|NCT00001291|Rheumatoid Arthritis
711644|NCT00001291|Synovial Biopsy
711645|NCT00001291|Synovitis
711646|NCT00001291|Synovium
711647|NCT00001289|Enzyme Replacement
711648|NCT00001289|Type 3 Gaucher's Disease
711649|NCT00001289|Lysosomal Storage
711650|NCT00001289|Supranuclear Gaze Palsy
711651|NCT00001289|Seizures
711652|NCT00001289|Mental Retardation
711653|NCT00001289|Gaucher Disease
711654|NCT00001288|Positron Emission Tomography
711655|NCT00001288|Epilepsy
711656|NCT00001288|Stroke
711657|NCT00001287|Intravenous High-Dose Immunoglobulin
711658|NCT00001287|Monoclonal Gammopathies
711659|NCT00001287|Peripheral Nerve Demyelination
711660|NCT00001287|CIDP
711661|NCT00001287|Chronic Inflammatory Demyelinating Polyneuropathy
711662|NCT00001285|Circadian Rhythms
711663|NCT00001285|Environmental Light
711664|NCT00001285|Estrogen
711665|NCT00001285|Melatonin
711666|NCT00001285|Progesterone
711667|NCT00001285|Rapid Cycling Bipolar Disorder
711668|NCT00001285|Sleep
711669|NCT00001285|Testosterone
711670|NCT00001285|Depression
711671|NCT00001285|Hypomania
711672|NCT00001285|Mania
711673|NCT00001284|Cognition
711674|NCT00001284|Schizophrenia
711675|NCT00001284|Magnetic Resonance Imaging
711676|NCT00001284|Magnetic Resonance Spectroscopy
711677|NCT00001284|Dopaminergic Mechanisms
711678|NCT00001282|HIV
711679|NCT00001282|Immunomodulator
711680|NCT00001282|Anti-Viral
711681|NCT00001281|Lymphocytes
711682|NCT00001281|Venipuncture
711683|NCT00001281|Mononuclear Cells
711684|NCT00001280|Aspergillosis
711685|NCT00001280|Phagocyte Defect
711686|NCT00001280|Torulopsis
711687|NCT00001280|Chronic Granulomatous Disease
711688|NCT00001278|Conjunctival Biopsy
711689|NCT00001278|Lacrimal Gland Biopsy
711690|NCT00001278|Sarcoid Uveitis
711691|NCT00001278|Sarcoidosis
711692|NCT00001278|Conjunctiva
711693|NCT00001278|Inflammatory Eye Disease
711694|NCT00001277|Hypoglycemia
711695|NCT00001277|Genetics
711696|NCT00001277|Hyperparathyroidism
711697|NCT00001276|Hypoglycemia
711698|NCT00001276|Insulinoma
711699|NCT00001275|Menopause
711700|NCT00001275|Estrogen
711701|NCT00001275|Infertility
711702|NCT00001275|Ovulation
711703|NCT00001275|Amenorrhea
711704|NCT00001275|Hypergonadotropic Hypogonadism
711705|NCT00001275|Young Women
711706|NCT00001275|Gonadal Steroid Deficiency
711707|NCT00001275|Mineralocorticoid Deficiency
711708|NCT00001275|Premature Ovarian Failure
711709|NCT00001275|POF
711710|NCT00001272|Adult
711711|NCT00001272|Cytotoxic Chemotherapy
711712|NCT00001272|Hematopoietic Growth Factor
711713|NCT00001271|Antigen Modulation
711714|NCT00001271|Pharmacokinetics
711715|NCT00001271|Ricin A Chain
711716|NCT00001270|Chemotherapy
711717|NCT00001270|High Dose
711718|NCT00001270|Protection
711719|NCT00001269|Dose-Intensive Chemotherapy
711720|NCT00001269|Hematopoietic Growth Factor
711721|NCT00001269|Peripheral Blood Progenitor Cell
711722|NCT00001267|Anti-Viral
711723|NCT00001267|Dideoxynucleosides
711724|NCT00001267|HIV
711725|NCT00001267|Retrovirus
711726|NCT00001266|Bayesian
711727|NCT00001266|Hydroxy-Flutamide
711728|NCT00001266|Combined Androgen Ablation
711729|NCT00001266|Prostate Specific Antigen
711730|NCT00001265|Autoimmune Diseases
711731|NCT00001265|Idiopathic Inflammatory Myopathies
711732|NCT00001265|Polymyositis
711733|NCT00001265|Dermatomyositis
711734|NCT00001265|Inclusion Body Myositis
711735|NCT00001265|Pathogenesis
711736|NCT00001265|Connective Tissue Diseases
711737|NCT00001262|Menkes
711738|NCT00001262|Copper
711739|NCT00001262|X-Linked
711740|NCT00001262|Neurodegeneration
711741|NCT00001262|ATP7A
711742|NCT00001261|Polymyositis/Dermatomyositis
711743|NCT00001261|Muscle Immunopathology
711744|NCT00001261|Intravenous High-Dose Immunoglobulin
711745|NCT00001261|Inclusion Body Myositis
711746|NCT00001260|Schizophrenia
711747|NCT00001260|Neuropathology
711748|NCT00001260|Neurochemistry
711749|NCT00001260|Substance Abuse
711750|NCT00001260|Bipolar Disorder
711751|NCT00001260|Aging
711752|NCT00001260|Normal Development
711753|NCT00001260|Depression
711754|NCT00001260|Anxiety Disorders
711755|NCT00001260|Suicide
711756|NCT00001260|Dementia
711757|NCT00001260|Neuropsychiatric Disorders
711758|NCT00001260|Tourette's Syndrome
711759|NCT00001260|Normal Controls
711760|NCT00001259|Depression
711761|NCT00001259|Menstrual Cycle
711762|NCT00001259|Gonadal Steroids
711763|NCT00001259|GnRH Agonist
711764|NCT00001259|Mood Disorders
711765|NCT00001258|Neuropsychology
711766|NCT00001258|Cerebral Blood Flow
711767|NCT00001258|Cognitive Disorders
711768|NCT00001258|Prefrontal Cortex
711769|NCT00001258|Hormones
711770|NCT00001258|Psychosis
711771|NCT00001258|Neuroimaging
711772|NCT00001258|Brain Scan
711773|NCT00001258|Healthy Volunteers
711774|NCT00001258|Schizophrenia
711775|NCT00001257|Lymphokines
711776|NCT00001257|LTB4
711777|NCT00001257|Inflammation
711778|NCT00001257|Normal Volunteer
711779|NCT00001257|Abnormal Phagocyte Function
711780|NCT00001256|Vasculitis
711781|NCT00001256|Cytotoxic Therapy
711782|NCT00001256|Inflammation
711783|NCT00001256|Glomerulonephritis
711784|NCT00001256|Inflammatory Sinusitis
711785|NCT00001255|Retroviral Vector
711786|NCT00001255|Gene Therapy
711787|NCT00001255|PEG-ADA
711788|NCT00001255|Severe Combined Immunodeficiency (SCID)
711789|NCT00001255|Adenosine Deaminase Deficiency (ADA)
711790|NCT00001254|Islet Cell Tumors
711791|NCT00001253|Turner's Syndrome
711792|NCT00001253|Estrogen
711793|NCT00001253|Ethinyl estradiol
711794|NCT00001253|Learning
711795|NCT00001253|Ovarian dysgenesis
711796|NCT00001252|Biomechanics
711797|NCT00001252|Kinesiology
711798|NCT00001252|Walking
711799|NCT00001252|ACL
711800|NCT00001252|Stroke
711801|NCT00001252|Leg Weakness
711802|NCT00001252|Paralysis
711803|NCT00001252|Anterior Cruciate Ligament
711804|NCT00001252|Gait Degicit
711805|NCT00001251|Meningeal Malignancy
711806|NCT00001251|Pediatric
711807|NCT00001251|Alkylating Agents
711808|NCT00001250|Neoadjuvant Chemotherapy
711809|NCT00001250|Dose Intense Chemotherapy
711810|NCT00001250|Stage II Breast Cancer
711811|NCT00001250|Early Stage Breast Cancer
711812|NCT00001249|Interleukin-2 Receptor
711813|NCT00001248|Multiple Sclerosis
711814|NCT00001248|MRI (Magnetic Resonance Imaging)
711815|NCT00001247|Schizophrenia
711816|NCT00001247|Psychosis
711817|NCT00001247|Neuroleptics
711818|NCT00001247|Schizoaffective Disorder
711819|NCT00001246|Cognitive
711820|NCT00001246|Genetics
711821|NCT00001246|Development
711822|NCT00001246|Klinefelter Syndrome
711823|NCT00001246|Jacob Syndrome
711824|NCT00001246|Trisomy X
711825|NCT00001246|Healthy Volunteer
711826|NCT00001246|XXY
711827|NCT00001246|XXXY
711828|NCT00001246|XXXXY
711829|NCT00001246|XYY
711830|NCT00001246|XXYY
711831|NCT00001246|XO
711832|NCT00001246|XXXX
711833|NCT00001246|XXX
711834|NCT00001246|XXXXX
711835|NCT00001246|Triple X
711836|NCT00001246|Congenital Adrenal Hyperplasia
711837|NCT00001246|Twin
711838|NCT00001245|Strongyloidiasis
711839|NCT00001245|Immediate Hypersensitivity Skin Test
711840|NCT00001245|IgE
711841|NCT00001245|Nematode
711842|NCT00001245|Immunosuppression
711843|NCT00001245|Skin Test
711844|NCT00001245|Diagnosis
711845|NCT00001245|Intestinal Helminth
711846|NCT00001245|Immediate Hypersensitivity
711847|NCT00001244|Agammaglobulinemia
711848|NCT00001244|Primary Immune Deficiency
711849|NCT00001244|Immune Response
711850|NCT00001243|AIDS
711851|NCT00001243|Myeloid Progenitors
711852|NCT00001243|Monocytes
711853|NCT00001243|Plasmid Libraries
711854|NCT00001243|Cytokines
711855|NCT00001242|Calcium
711856|NCT00001242|Vitamin D
711857|NCT00001242|Calcitriol
711858|NCT00001242|Parathyroid
711859|NCT00001242|Cyclic AMP
711860|NCT00001242|Rickets
711861|NCT00001241|Gastric Acid Secretion
711862|NCT00001241|Histamine H2-Receptor Antagonists
711863|NCT00001240|Stomach
711864|NCT00001240|Hypersecretion
711865|NCT00001240|Hyposecretion
711866|NCT00001240|Gastrinoma
711867|NCT00001240|Zollinger-Ellison Syndrome
711868|NCT00001239|5-Fluorouracil
711869|NCT00001239|Adriamycin
711870|NCT00001239|Breast Carcinoma
711871|NCT00001239|Leucovorin
711872|NCT00001239|Phase II
711873|NCT00001238|Urologic Malignant Disorders
711874|NCT00001238|Birt Hogg Dube
711875|NCT00001238|Von Hippel Lindau
711876|NCT00001238|Hereditary Papillary Renal Cancer/Renal Cell Acarcinoma
711877|NCT00001237|Burkitt's Lymphoma
711878|NCT00001237|GM-CSF
711879|NCT00001237|High-Grade
711880|NCT00001235|Primary Neuronal Degeneration
711881|NCT00001235|Genetics
711882|NCT00001235|Neurotransmitters
711883|NCT00001235|DNA
711884|NCT00001235|Lymphoblasts
711885|NCT00001235|Skin Fibroblast
711886|NCT00001235|Alzheimer's Disease
711887|NCT00001234|Bone Marrow
711888|NCT00001234|Retroviral-Mediated Gene Transfer
711889|NCT00001234|Hematopoietic Progenitor Cell
711890|NCT00001233|Adolescence
711891|NCT00001233|Aggressivity
711892|NCT00001233|Anger
711893|NCT00001233|Developmental Psychopathology
711894|NCT00001233|Disruptive Behavior Disorders
711895|NCT00001233|Early Onset Aggression
711896|NCT00001233|Emotion Regulation
711897|NCT00001233|Family Violence
711898|NCT00001233|Preschool Conduct Problems
711899|NCT00001232|Depression
711900|NCT00001232|FSH
711901|NCT00001232|GnRH
711902|NCT00001232|LH
711903|NCT00001232|Menopause
711904|NCT00001232|Menstrual Cycle
711905|NCT00001231|Mood
711906|NCT00001231|Behavior
711907|NCT00001231|Cognition
711908|NCT00001231|Climacteric
711909|NCT00001231|Menopause
711910|NCT00001231|Perimenopause
711911|NCT00001231|Midlife
711912|NCT00001231|Depression
711913|NCT00001230|Wuchereria Bancrofti
711914|NCT00001230|Loa Loa
711915|NCT00001230|Brugia Malayi
711916|NCT00001230|Brugia Timori
711917|NCT00001230|Onchocerca Volvulus
711918|NCT00001230|Mansonella Perstans
711919|NCT00001230|Mansonella Ozzardi
711920|NCT00001230|Diethylcarbamazine (DEC)
711921|NCT00001230|Suramin
711922|NCT00001230|Ivermectin
711923|NCT00001230|Filarial Infection
711924|NCT00001229|Calcium-Pentagastrin
711925|NCT00001229|Clonidine
711926|NCT00001229|Glucagon
711927|NCT00001229|Pheochromocytoma
711928|NCT00001228|Interferon
711929|NCT00001228|Zollinger-Ellison Syndrome
711930|NCT00001226|Nonradioactive Isotopes
711931|NCT00001226|Lipoprotein Kinetics
711932|NCT00001226|Apolipoproteins
711933|NCT00001226|Dyslipoproteinemia
711934|NCT00001226|Healthy Volunteers
711935|NCT00001225|DNA Polymorphisms
711936|NCT00001225|Echocardiography
711937|NCT00001225|Gene Mapping
711938|NCT00001225|Linkage Analysis
711939|NCT00001225|Hypertrophic Cardiomyopathy
711940|NCT00001224|Ocular Inflammatory Disease
711941|NCT00001224|Cataracts
711942|NCT00001224|Vitrectomy
711943|NCT00001224|Extracapsular
711944|NCT00001224|Cataract Surgery
711945|NCT00001224|Uveitis
711946|NCT00001224|Lenticular Opacity
711947|NCT00001224|Vitreal Opacity
711948|NCT00001223|Cystic Fibrosis
711949|NCT00001223|Pancreatic Insufficiency
711950|NCT00001223|Bronchiectasis
711951|NCT00001221|Growth
711952|NCT00001221|Gonadal Dysgenesis
711953|NCT00001221|Estrogen
711954|NCT00001221|Somatotropin
711955|NCT00001221|Turner's Syndrome
711956|NCT00001221|Growth Hormone
711957|NCT00001220|Swallowing Disorders
711958|NCT00001220|Neuromotor Dysfunction
711959|NCT00001220|Aspiration
711960|NCT00001220|Imaging
711961|NCT00001219|Magnetic Resonance Imaging
711962|NCT00001219|Gadolinium
711963|NCT00001219|Pulse Sequences
711964|NCT00001218|Baseline Data
711965|NCT00001218|Curve Averaging
711966|NCT00001218|Curve Fitting
711967|NCT00001218|Movement Patterns
711968|NCT00001218|Normative Data
711969|NCT00001218|Polar Distribution
711970|NCT00001218|Tongue
711971|NCT00001218|Tongue Shape
711972|NCT00001218|Ultrasound
711973|NCT00001217|Non-Metastatic Osteosarcoma
711974|NCT00001217|Presurgical Chemotherapy
711975|NCT00001216|Amputations
711976|NCT00001216|Brainstem Stimulation
711977|NCT00001216|Cerebellar Stimulation
711978|NCT00001216|Cortical Motor Physiology
711979|NCT00001216|Electrical Stimulation
711980|NCT00001216|Motor Cortex
711981|NCT00001216|Plasticity
711982|NCT00001216|Spinal Cord Injury
711983|NCT00001216|Stroke
711984|NCT00001215|Lysosomal Storage Disorders
711985|NCT00001215|Variants
711986|NCT00001215|Chemical Phenotype
711987|NCT00001215|Proteins
711988|NCT00001215|Genes
711989|NCT00001215|Phenotype
711990|NCT00001215|Mutations
711991|NCT00001215|Parkinsonism
711992|NCT00001214|Bone Marrow Failure
711993|NCT00001214|Lymphocytapheresis
711994|NCT00001214|Pancytopenia
711995|NCT00001214|Aplastic Anemia
711996|NCT00001214|Hematosuppressive Disease
711997|NCT00001213|Cysteamine Eye Drops
711998|NCT00001213|Nephropathic Cystinosis
711999|NCT00001213|Corneal Crystals
712000|NCT00001213|Benzalkonium
712001|NCT00001213|Toxicity
712002|NCT00001213|Efficacy
712003|NCT00001213|Cystinosis
712004|NCT00001212|Systemic Lupus Erythematosus
712005|NCT00001212|Nephrotic Syndrome
712006|NCT00001212|Immunosuppressive Drugs
712007|NCT00001212|Prednisone
712008|NCT00001212|Methylprednisolone
712009|NCT00001212|Cyclophosphamide
712010|NCT00001212|Cyclosporine
712011|NCT00001212|Cyclosporin A
712012|NCT00001211|Ectodermal Dysplasia
712013|NCT00001211|Edentulous
712014|NCT00001211|Endosseous
712015|NCT00001211|Implants
712016|NCT00001211|Mandibular Atrophy
712017|NCT00001211|Oral
712018|NCT00001211|Titanium
712019|NCT00001210|Blood Donors
712020|NCT00001210|Epitopes
712021|NCT00001210|HIV
712022|NCT00001209|Combined Chemotherapy
712023|NCT00001209|Irradiation
712024|NCT00001209|Unresectable
712025|NCT00001208|Spasmodic Torticollis
712026|NCT00001208|Writer's Cramp
712027|NCT00001208|Spasmodic Dysphonia
712028|NCT00001208|Stuttering
712029|NCT00001208|Oromandibular Dystonia
712030|NCT00001208|Palatal Myoclonus
712031|NCT00001208|Dystonia
712032|NCT00001208|Essential Tremor
712033|NCT00001208|Movement Disorders
712034|NCT00001206|Attention Deficit Hyperactivity Disorder
712035|NCT00001206|Disruptive Behavior Disorders
712036|NCT00001206|Cerebrospinal Fluid
712037|NCT00001206|Lumbar Puncture
712038|NCT00001206|CSF
712039|NCT00001206|Longitudinal Prospective Follow-Up
712040|NCT00001206|Psychosocial Functioning
712041|NCT00001206|Risk Factors
712042|NCT00001206|Genetics
712043|NCT00001205|Taenia Solium
712044|NCT00001205|Cysticercosis
712045|NCT00001205|Praziquantel
712046|NCT00001204|Dyslipoprotein
712047|NCT00001204|Hypercholesterolemia
712048|NCT00001204|Atherosclerosis
712049|NCT00001203|Desferal
712050|NCT00001203|Thalassemia
712051|NCT00001203|Liver Iron Concentration
712052|NCT00001203|Endocrine Evaluation
712053|NCT00001203|Diabetes Mellitus
712054|NCT00001203|Cardiac Disease
712055|NCT00001203|Acquired Anemia
712056|NCT00001202|Luteinizing Hormone
712057|NCT00001202|High Serum Testosterone Levels
712058|NCT00001202|Low Baseline Gonadotropin
712059|NCT00001202|LHRH
712060|NCT00001202|Precocious Puberty
712061|NCT00001202|Familial Isosexual Precocious Puberty
712062|NCT00001201|Nerve Conduction Studies
712063|NCT00001201|EMG
712064|NCT00001201|Normal Volunteer
712065|NCT00001201|Electrophysiology
712066|NCT00001201|Peripheral Neuropathies
712067|NCT00001201|Myopathies
712068|NCT00001198|Schizophrenia
712069|NCT00001198|Observational
712070|NCT00001197|Gene Expression Therapy
712071|NCT00001197|Gamma Globin Gene
712072|NCT00001197|Hemoglobin Switching
712073|NCT00001197|Bone Marrow
712074|NCT00001197|Sickle Cell Anemia
712075|NCT00001196|Salivary Function
712076|NCT00001196|Salivary Gland
712077|NCT00001196|Sjogren's Syndrome
712078|NCT00001196|Dry Mouth
712079|NCT00001195|Development
712080|NCT00001195|Hormones
712081|NCT00001195|Growth
712082|NCT00001195|Metabolism
712083|NCT00001195|Eating Behavior
712084|NCT00001195|Body Composition
712085|NCT00001195|Normal Volunteer
712086|NCT00001194|Helium Cryogen
712087|NCT00001194|Magnetic Field
712088|NCT00001194|Multi-Institute
712089|NCT00001194|Nitrogen Cryogen
712090|NCT00001194|Radiofrequency
712091|NCT00001193|Autologous
712092|NCT00001193|Melphalan
712093|NCT00001193|Stage III
712094|NCT00001193|Transplantation
712095|NCT00001192|Executive Functions
712096|NCT00001192|Language
712097|NCT00001192|Attention
712098|NCT00001192|Visual-Spatial Ability
712099|NCT00001192|Memory
712100|NCT00001192|Motor Behavior
712101|NCT00001192|Intelligence
712102|NCT00001192|Personality
712103|NCT00001192|Visual and Auditory Functioning
712104|NCT00001192|Hand and Eye Dominance
712105|NCT00001192|Normal Volunteer
712106|NCT00001192|Neuropsychiatric Disorders
712107|NCT00001191|Zollinger-Ellison Syndrome
712108|NCT00001191|Gastrinoma
712109|NCT00001191|Acid Hypersecretion
712110|NCT00001191|H+-K+ ATPase Inhibitor
712111|NCT00001190|Growth
712112|NCT00001190|Adolescence
712113|NCT00001190|Children
712114|NCT00001189|Adjuvant Radiotherapy
712115|NCT00001189|Low-Grade Sarcoma
712116|NCT00001189|Radiotherapy
712117|NCT00001189|Randomized Study
712118|NCT00001189|Sarcoma
712119|NCT00001189|Surgery
712120|NCT00001188|Chemotherapy
712121|NCT00001188|Radiation Therapy
712122|NCT00001188|Sarcoma
712123|NCT00001188|Surgery
712124|NCT00001186|Psychosocial
712125|NCT00001186|Self Esteem
712126|NCT00001186|Oncology
712127|NCT00001186|Well-Being
712128|NCT00001186|Pediatrics
712129|NCT00001185|Poliomyelitis
712130|NCT00001185|Amyotrophic Lateral Sclerosis
712131|NCT00001185|Motor Neurons
712132|NCT00001185|Late Viral Infection
712133|NCT00001185|Motor Neuron Firing
712134|NCT00001185|Immune Defects
712135|NCT00001185|Post-polio Syndrome
712136|NCT00001185|Post-polio Motor Neuron Disease
712137|NCT00001184|Inflammatory Bowel Disease
712138|NCT00001184|Regional Enteritis
712139|NCT00001184|Crohn's Disease
712140|NCT00001184|Ulcerative Colitis
712141|NCT00001184|IBD
712142|NCT00001183|Computed Tomography
712143|NCT00001183|Fiberoptic Bronchoscopy
712144|NCT00001183|Pulmonary Function Testing
712145|NCT00001183|Cardiopulmonary Exercise Testing
712146|NCT00001183|Allergen Skin Testing
712147|NCT00001183|Chronic Lung Disease
712148|NCT00001182|General Dental
712149|NCT00001182|Diagnostic
712150|NCT00001182|Therapeutic
712151|NCT00001181|McCune-Albright Syndrome
712152|NCT00001181|Aromatase Inhibitor
712153|NCT00001181|Teslac
712154|NCT00001180|Corticotropin Releasing Hormone
712155|NCT00001180|Cushing Syndrome
712156|NCT00001180|Psychiatric Hypercortisolism
712157|NCT00001180|Adrenal Insufficiency
712158|NCT00001180|Normal Volunteer
712159|NCT00001178|Alzheimer's Disease
712160|NCT00001178|Cerebral Metabolism
712161|NCT00001178|Cerebrospinal Fluid
712162|NCT00001178|Dementia of the Alzheimer Type
712163|NCT00001178|18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
712164|NCT00001178|Magnetic Resonance Imaging
712165|NCT00001178|Positron Emission Tomography
712166|NCT00001178|X-Ray Computed Tomography (CT)
712167|NCT00001178|Senile Dementia
712168|NCT00001178|Down Syndrome
712169|NCT00001178|Trisomy 21
712170|NCT00001177|Mood
712171|NCT00001177|Depression
712172|NCT00001177|Cognition
712173|NCT00001177|Menstrual
712174|NCT00001177|Neuroendocrine
712175|NCT00001177|Genetics
712176|NCT00001177|PMDD
712177|NCT00001177|PMS Premenstrual Syndrome
712178|NCT00001177|MRMD Menstrually Related Mood Disorder
712179|NCT00001176|Adrenergic Nervous System
712180|NCT00001176|Dopaminergic Nervous System
712181|NCT00001176|Salt-Sensitive Hypertension
712182|NCT00001176|Hypertension
712183|NCT00001176|Primary Aldosteronism
712184|NCT00001174|Bipolar Manic-Depressive Illness
712185|NCT00001174|Affective Disorder
712186|NCT00001174|Depression
712187|NCT00001174|Genetic
712188|NCT00001174|DNA
712189|NCT00001174|Mania
712190|NCT00001174|Affected Sibling Pairs
712191|NCT00001174|Family Study
712192|NCT00001174|Genome-Wide Scan
712193|NCT00001174|Lymphoblastoid Cell Lines
712194|NCT00001174|Diagnostic Interview for Genetic Studies (DIGS)
712195|NCT00001174|Panic Disorder
712196|NCT00001174|Bipolar Disorder
712197|NCT00001173|B Cells
712198|NCT00001173|Humoral Immunity
712199|NCT00001173|Lymphocytes
712200|NCT00001173|Tetanus Toxoid
712201|NCT00001172|Vision
712202|NCT00001172|Eye Movement
712203|NCT00001172|Perception
712204|NCT00001172|Healthy Volunteer
712205|NCT00001171|Brain Tumors
712206|NCT00001171|Glioma
712207|NCT00001171|Glioblastoma Multiforme
712208|NCT00001171|Pituitary Adenoma
712209|NCT00001170|Parental Psychopathology
712210|NCT00001170|Child Rearing
712211|NCT00001170|Depression
712212|NCT00001170|Bipolar Affective Disorders
712213|NCT00001170|Manic-Depression
712214|NCT00001170|Social-Emotional Development
712215|NCT00001170|Cognitive Development
712216|NCT00001170|Child Psychopathology
712217|NCT00001170|Affective Disorder
712218|NCT00001170|Children at Risk
712219|NCT00001169|Chemotherapy
712220|NCT00001169|Cytokines
712221|NCT00001169|Immunology
712222|NCT00001169|Kala-Azar
712223|NCT00001169|Leishmaniasis
712224|NCT00001168|Dyslipoproteinemia
712225|NCT00001168|Hypercholesterolemia
712226|NCT00001168|Hypertriglyceridemia
712227|NCT00001168|hypoalphalipoproteinemia
712228|NCT00001168|Atherosclerosis
712229|NCT00001168|Type III Hyperlipoproteinemia
712230|NCT00001168|Plasma Lipoproteins
712231|NCT00001167|Dysphagia
712232|NCT00001167|Dysarthria
712233|NCT00001167|Tongue Motion
712234|NCT00001167|Xerostomia
712235|NCT00001167|Swallowing
712236|NCT00001167|Speech
712237|NCT00001167|Polymyositis
712238|NCT00001167|Speech Disorders
712239|NCT00001167|Oral-Facial Paralysis
712240|NCT00001167|Ultrasound
712241|NCT00001166|Hyperornithinemia
712242|NCT00001166|Ornithine-Aminotransferase (OAT)
712243|NCT00001166|Tissue Culture
712244|NCT00001166|Pyridoxine Hydrochloride
712245|NCT00001166|Pyridoxal Phosphate
712246|NCT00001166|Arginine
712247|NCT00001166|Skin Fibroblast
712248|NCT00001166|Gyrate Atrophy
712249|NCT00001166|Autosomal Recessive Retinitis Pigmentosa
712250|NCT00001166|Bietti's Crystalline Retinopathy
712251|NCT00001166|Chorioretinal Degeneration
712252|NCT00001165|Gastrinoma
712253|NCT00001165|Acid Secretion
712254|NCT00001165|Toxicity
712255|NCT00001164|Genetic Evaluation
712256|NCT00001164|Immunologic Evaluations
712257|NCT00001164|Inflammatory Skin Disease
712258|NCT00001164|Muscular Dystrophies
712259|NCT00001164|Neoplastic Skin Diseases
712260|NCT00001164|Neuronal Degenerations
712261|NCT00001164|Retinal Degenerations
712262|NCT00001164|Viral Diseases
712263|NCT00001163|Cancer
712264|NCT00001163|Genes/Genetics
712265|NCT00001163|Hereditary Neoplasms
712266|NCT00001163|Environment
712267|NCT00001162|Giardia
712268|NCT00001162|Helminth
712269|NCT00001162|Cryptosporidium
712270|NCT00001162|Hookworms
712271|NCT00001162|Trichuris
712272|NCT00001162|Strongyloides
712273|NCT00001162|Protozoa
712274|NCT00001162|Small Bowel Biopsy
712275|NCT00001162|E. Histolytica
712276|NCT00001162|Duodenal Aspiration
712277|NCT00001162|Coccidiosis
712278|NCT00001162|Clonorchis
712279|NCT00001162|Amebiasis
712280|NCT00001162|Parasitic Disease
712281|NCT00001162|Tapeworm
712282|NCT00001162|Trichinosis
712283|NCT00001162|Gastrointestinal Trematodes
712284|NCT00001162|Opisthorchis
712285|NCT00001162|Paragonimiasis
712286|NCT00001162|Echinococcus
712287|NCT00001161|Irido Corneal Angle
712288|NCT00001161|Mesothelium
712289|NCT00001161|Congenital Anomalies
712290|NCT00001161|Neural Crest
712291|NCT00001161|Increased Intraocular Pressure
712292|NCT00001161|Glaucoma
712293|NCT00001161|Axenfeld's Syndrome
712294|NCT00001161|Rieger's Anomaly
712295|NCT00001161|Peter's Anomaly
712296|NCT00001161|Iridocorneal Endothelial Syndrome
712297|NCT00001161|Aniridia
712298|NCT00001161|Pigment Dispersion Syndrome
712299|NCT00001161|Megalocornea
712300|NCT00001160|Thyroid Fine Needle Biopsy
712301|NCT00001160|Radioiodine
712302|NCT00001160|Dosimetry
712303|NCT00001159|Hyperthyroidism
712304|NCT00001159|Hypothyroidism
712305|NCT00001159|Thyroid-Stimulating Hormone Secreting Pituitary Adenomas
712306|NCT00001158|Cellular Immunity
712307|NCT00001158|Humoral Immunity
712308|NCT00001158|Immunodeficiency Disease
712309|NCT00001156|Immunogenetics
712310|NCT00001156|Tropical Spastic Paraplegia
712311|NCT00001156|Twins
712312|NCT00001156|Epstein-Barr Virus
712313|NCT00001156|HTLV-I
712314|NCT00001156|Vasculitis
712315|NCT00001156|Cerebrospinal Fluid
712316|NCT00001156|Immunity to Viruses
712317|NCT00001156|Multiple Sclerosis
712318|NCT00001156|Magnetic Resonance Imaging
712319|NCT00001155|Vasculitis
712320|NCT00001155|Prednisone
712321|NCT00001155|Granuloma
712322|NCT00001155|Wegener's Granulomatosis
712323|NCT00001155|Cyclophosphamide
712324|NCT00001155|Renal Biopsy
712325|NCT00001154|Cholesterol
712326|NCT00001154|Apolipoproteins
712327|NCT00001154|Kinetics
712328|NCT00001153|Albinism
712329|NCT00001153|Ocular Albinism
712330|NCT00001153|Oculocutaneous Albinism
712331|NCT00001153|Tyrosinase Negative
712332|NCT00001153|Tyrosinase Positive
712333|NCT00001152|Aqueous Humor Dynamics
712334|NCT00001152|Glaucoma
712335|NCT00001152|Ocular Hypertension
712336|NCT00001152|Pigment Dispersion Syndrome
712337|NCT00001152|Primary Open Angle Glaucoma
712338|NCT00001152|Pseudo-Exfoliation of the Lens Capsule
712339|NCT00001151|Calciferol
712340|NCT00001151|Hypocalcemia
712341|NCT00001151|Rickets
712342|NCT00001150|Blister Formation
712343|NCT00001150|Inflammatory Mediator Assay
712344|NCT00001150|Ultraviolet Radiation
712345|NCT00001149|Anticonvulsants
712346|NCT00001149|Intensive Monitoring
712347|NCT00001149|Epilepsy
712348|NCT00001148|Metastasis
712349|NCT00001148|Glioma
712350|NCT00001148|Venous
712351|NCT00001148|Sampling
712352|NCT00001148|p53 Mutation
712353|NCT00001148|Glioblastoma Multiforme
712354|NCT00001148|Circulating Tumor Cells
712355|NCT00001148|Mutation
712356|NCT00001148|Anaplastic Astrocytoma
712357|NCT00001147|Dopamine
712358|NCT00001147|Metanephrine
712359|NCT00001147|Norepinephrine
712360|NCT00001147|Epinephrine
712361|NCT00001147|Catecholamines
712362|NCT00001147|Tyrosine Hydroxylase
712363|NCT00001147|Monoamine Oxidase
712364|NCT00001147|Phenosulfotransferase
712365|NCT00001147|Sympathetic Nervous System
712366|NCT00001147|Normetanephrine
712367|NCT00001146|Bipolar Disorder
712368|NCT00001146|Clinical Trial
712369|NCT00001146|Eicosapentaenoic Ethyl Ester
712370|NCT00001146|Life Chart Methodology
712371|NCT00001146|Mood Disorders
712372|NCT00001146|Omega-3 Fatty Acid
712373|NCT00001146|Rapid Cycling
712374|NCT00001146|Treatment
712375|NCT00001145|Primary Immunodeficiency
712376|NCT00001145|Gamma Globulin (IgG) Immunization
712377|NCT00001145|KLH
712378|NCT00001145|Phi-X 174
712379|NCT00001145|X-linked HyperIgM Syndrome
712380|NCT00001144|Peripheral Blood Stem Cells
712381|NCT00001144|Engraftment
712382|NCT00001144|Graft vs. Host Disease
712383|NCT00001144|Graft-Versus-Leukemia
712384|NCT00001144|Graft-Versus-Tumor/Melanoma
712385|NCT00001144|Chronic Myelogenous Leukemia
712386|NCT00001143|Eye Movements
712387|NCT00001143|Strabismus
712388|NCT00001143|Infants
712389|NCT00001143|Development
712390|NCT00001143|Ocular Motor System
712391|NCT00001142|Body Fat
712392|NCT00001142|DXA
712393|NCT00001142|HAART
712394|NCT00001142|Hyperlipidemia
712395|NCT00001142|Insulin Resistance
712396|NCT00001142|Lipodystrophy
712397|NCT00001142|MRI
712398|NCT00001142|Protease Inhibitor
712399|NCT00001142|Side-Effects
712400|NCT00001142|Visceral Fat
712401|NCT00001142|Chronic Infection
712402|NCT00001142|HIV
712403|NCT00001142|Healthy Volunteer
712404|NCT00001137|Treatment Experienced
712405|NCT00001137|Treatment Naive
712406|NCT00001137|Virus Replication
712407|NCT00001137|AIDS-Related Opportunistic Infections
712408|NCT00001137|HIV-1
712409|NCT00001137|Risk Factors
712410|NCT00001137|Incidence
712411|NCT00001137|RNA, Viral
712412|NCT00001137|Anti-HIV Agents
712413|NCT00001137|Viral Load
712414|NCT00001137|Lipodystrophy
712415|NCT00001137|Nervous System
712416|NCT00001137|Cardiovascular System
712417|NCT00001137|Neurologic Symptoms
712418|NCT00001136|Injections, Intramuscular
712419|NCT00001136|HIV-1
712420|NCT00001136|AIDS Vaccines
712421|NCT00001136|CD4-Positive T-Lymphocytes
712422|NCT00001136|CD8-Positive T-Lymphocytes
712423|NCT00001136|T-Lymphocytes, Cytotoxic
712424|NCT00001136|Gene Products, gag
712425|NCT00001136|HIV Seronegativity
712426|NCT00001136|Immunologic Memory
712427|NCT00001136|Antibodies, Viral
712428|NCT00001136|Genetic Vectors
712429|NCT00001136|Gene Products, env
712430|NCT00001136|Poxviridae
712431|NCT00001136|HIV Preventive Vaccine
712432|NCT00001135|Placebos
712433|NCT00001135|Pregnancy
712434|NCT00001135|Pregnancy Complications, Infectious
712435|NCT00001135|Nevirapine
712436|NCT00001135|Disease Transmission, Vertical
712437|NCT00001135|Labor
712438|NCT00001135|Anti-HIV Agents
712439|NCT00001133|Dose-Response Relationship, Drug
712440|NCT00001133|Drug Therapy, Combination
712441|NCT00001133|HIV Protease Inhibitors
712442|NCT00001133|Ritonavir
712443|NCT00001133|Indinavir
712444|NCT00001133|Anti-HIV Agents
712445|NCT00001133|Pharmacokinetics
712446|NCT00001133|Treatment Experienced
712447|NCT00001132|Placebos
712448|NCT00001132|HIV-1
712449|NCT00001132|Drug Therapy, Combination
712450|NCT00001132|RNA, Viral
712451|NCT00001132|Reverse Transcriptase Inhibitors
712452|NCT00001132|Anti-HIV Agents
712453|NCT00001132|Viral Load
712454|NCT00001132|abacavir
712455|NCT00001131|Interleukin-2
712456|NCT00001131|Drug Therapy, Combination
712457|NCT00001131|Drug Administration Schedule
712458|NCT00001131|Viremia
712459|NCT00001131|T-Lymphocytes, Cytotoxic
712460|NCT00001131|Anti-HIV Agents
712461|NCT00001131|Treatment Experienced
712462|NCT00001130|Questionnaires
712463|NCT00001130|Antibodies, Viral
712464|NCT00001130|Emergency Service, Hospital
712465|NCT00001129|Drug Therapy, Combination
712466|NCT00001129|RNA, Viral
712467|NCT00001129|Patient Compliance
712468|NCT00001129|Anti-HIV Agents
712469|NCT00001129|Viral Load
712470|NCT00001129|Reminder Systems
712471|NCT00001129|Treatment Experienced
712472|NCT00001129|Treatment Naive
712473|NCT00001128|AIDS-Related Opportunistic Infections
712474|NCT00001128|Cryptosporidiosis
712475|NCT00001128|Acquired Immunodeficiency Syndrome
712476|NCT00001128|Azithromycin
712477|NCT00001128|Paromomycin
712478|NCT00001128|Interleukin-12
712479|NCT00001125|Antibodies, Viral
712480|NCT00001125|Chickenpox
712481|NCT00001125|Chickenpox Vaccine
712482|NCT00001122|Didanosine
712483|NCT00001122|Drug Therapy, Combination
712484|NCT00001122|Stavudine
712485|NCT00001122|HIV Protease Inhibitors
712486|NCT00001122|CD4 Lymphocyte Count
712487|NCT00001122|Nelfinavir
712488|NCT00001122|Reverse Transcriptase Inhibitors
712489|NCT00001122|Self Care
712490|NCT00001122|Anti-HIV Agents
712491|NCT00001122|Viral Load
712492|NCT00001122|efavirenz
712493|NCT00001122|Treatment Naive
712494|NCT00001121|Placebos
712495|NCT00001121|AIDS Vaccines
712496|NCT00001121|Follow-Up Studies
712497|NCT00001121|HIV Therapeutic Vaccine
712498|NCT00001120|Prospective Studies
712499|NCT00001120|Sarcoma, Kaposi
712500|NCT00001120|Herpesvirus 4, Human
712501|NCT00001120|Acquired Immunodeficiency Syndrome
712502|NCT00001120|Cohort Studies
712503|NCT00001120|Risk Factors
712504|NCT00001120|Lymphoma, AIDS-Related
712505|NCT00001120|Antibodies, Viral
712506|NCT00001120|Lymphoproliferative Disorders
712507|NCT00001120|Viral Load
712508|NCT00001120|Herpesvirus, Kaposi Sarcoma-Associated
712509|NCT00001120|Translocation (Genetics)
712510|NCT00001119|Immunity, Cellular
712511|NCT00001119|Drug Therapy, Combination
712512|NCT00001119|HIV Protease Inhibitors
712513|NCT00001119|Antibody Formation
712514|NCT00001119|Reverse Transcriptase Inhibitors
712515|NCT00001119|Anti-HIV Agents
712516|NCT00001119|Viral Load
712517|NCT00001119|Tetanus Toxoid
712518|NCT00001119|Case-Control Studies
712519|NCT00001119|Hepatitis B Surface Antigens
712520|NCT00001119|Acute Infection
712521|NCT00001118|Injections, Intravenous
712522|NCT00001118|Injections, Subcutaneous
712523|NCT00001118|Drug Therapy, Combination
712524|NCT00001118|HIV Protease Inhibitors
712525|NCT00001118|Membrane Fusion
712526|NCT00001118|Reverse Transcriptase Inhibitors
712527|NCT00001118|Anti-HIV Agents
712528|NCT00001118|Viral Load
712529|NCT00001118|peptide T20
712530|NCT00001117|HIV-1
712531|NCT00001117|Drug Therapy, Combination
712532|NCT00001117|Hepatitis C
712533|NCT00001117|RNA, Viral
712534|NCT00001117|Anti-HIV Agents
712535|NCT00001116|Tumor Necrosis Factor
712536|NCT00001116|Interleukin-2
712537|NCT00001116|Immunity, Cellular
712538|NCT00001116|Antiviral Agents
712539|NCT00001116|Interleukin-6
712540|NCT00001116|Receptors, Tumor Necrosis Factor
712541|NCT00001115|Herpes Simplex
712542|NCT00001115|Acyclovir
712543|NCT00001115|Acquired Immunodeficiency Syndrome
712544|NCT00001114|Sarcoma, Kaposi
712545|NCT00001114|Didanosine
712546|NCT00001114|Drug Interactions
712547|NCT00001114|Acquired Immunodeficiency Syndrome
712548|NCT00001114|Interferon-alpha
712549|NCT00001113|Interferon Alfa-2a
712550|NCT00001113|Sarcoma, Kaposi
712551|NCT00001113|Dose-Response Relationship, Drug
712552|NCT00001113|Drug Evaluation
712553|NCT00001113|Drug Therapy, Combination
712554|NCT00001113|Acquired Immunodeficiency Syndrome
712555|NCT00001113|Zidovudine
712556|NCT00001113|Interferon Type I
712557|NCT00001112|Monocytes
712558|NCT00001112|Interferon-gamma, Recombinant
712559|NCT00001112|Injections, Subcutaneous
712560|NCT00001112|Immune System
712561|NCT00001112|Drug Evaluation
712562|NCT00001112|Drug Therapy, Combination
712563|NCT00001112|Acquired Immunodeficiency Syndrome
712564|NCT00001112|Zidovudine
712565|NCT00001112|Blood Bactericidal Activity
712566|NCT00001111|Drug Therapy, Combination
712567|NCT00001111|Acquired Immunodeficiency Syndrome
712568|NCT00001111|AIDS-Related Complex
712569|NCT00001111|Antiviral Agents
712570|NCT00001111|Zidovudine
712571|NCT00001111|Nevirapine
712572|NCT00001110|Lung
712573|NCT00001110|HIV-1
712574|NCT00001110|Viremia
712575|NCT00001110|Anti-HIV Agents
712576|NCT00001110|Viral Load
712577|NCT00001110|Bronchoalveolar Lavage Fluid
712578|NCT00001109|Monocytes
712579|NCT00001109|Flow Cytometry
712580|NCT00001109|HIV Seronegativity
712581|NCT00001109|Phenotype
712582|NCT00001109|Lymphocyte Subsets
712583|NCT00001108|Dose-Response Relationship, Drug
712584|NCT00001108|Drug Therapy, Combination
712585|NCT00001108|HIV Protease Inhibitors
712586|NCT00001108|Reverse Transcriptase Inhibitors
712587|NCT00001108|Salvage Therapy
712588|NCT00001108|Anti-HIV Agents
712589|NCT00001106|Pregnancy
712590|NCT00001106|Pregnancy Complications, Infectious
712591|NCT00001106|Prenatal Exposure Delayed Effects
712592|NCT00001106|Drug Evaluation
712593|NCT00001106|Acquired Immunodeficiency Syndrome
712594|NCT00001106|Zidovudine
712595|NCT00001105|Antibodies, Monoclonal
712596|NCT00001105|AIDS-Related Complex
712597|NCT00001105|Immunization, Passive
712598|NCT00001104|Sex Behavior
712599|NCT00001104|T-Lymphocytes
712600|NCT00001104|HIV Antibodies
712601|NCT00001104|Acquired Immunodeficiency Syndrome
712602|NCT00001104|AIDS-Related Complex
712603|NCT00001104|Zidovudine
712604|NCT00001104|Hemophilia A
712605|NCT00001103|Neuropsychological Tests
712606|NCT00001103|HIV-1
712607|NCT00001103|RNA, Viral
712608|NCT00001103|Anti-HIV Agents
712609|NCT00001103|Viral Load
712610|NCT00001102|Drug Therapy, Combination
712611|NCT00001102|HIV Protease Inhibitors
712612|NCT00001102|Reverse Transcriptase Inhibitors
712613|NCT00001102|Body Composition
712614|NCT00001102|Anti-HIV Agents
712615|NCT00001102|Cholesterol
712616|NCT00001102|Triglycerides
712617|NCT00001097|Drug Therapy, Combination
712618|NCT00001097|HIV Protease Inhibitors
712619|NCT00001097|Reverse Transcriptase Inhibitors
712620|NCT00001097|Anti-HIV Agents
712621|NCT00001096|Vaccines, Synthetic
712622|NCT00001096|HIV Antibodies
712623|NCT00001096|HIV Antigens
712624|NCT00001096|HIV-1
712625|NCT00001096|Adjuvants, Immunologic
712626|NCT00001096|AIDS Vaccines
712627|NCT00001096|T-Lymphocytes, Cytotoxic
712628|NCT00001096|HIV Seronegativity
712629|NCT00001096|HIV Envelope Protein gp120
712630|NCT00001096|Alum Compounds
712631|NCT00001096|HIV Preventive Vaccine
712632|NCT00001095|Drug Therapy, Combination
712633|NCT00001095|Zidovudine
712634|NCT00001095|Nevirapine
712635|NCT00001095|Stavudine
712636|NCT00001095|HIV Protease Inhibitors
712637|NCT00001095|Lamivudine
712638|NCT00001095|VX 478
712639|NCT00001095|Reverse Transcriptase Inhibitors
712640|NCT00001095|Anti-HIV Agents
712641|NCT00001095|Viral Load
712642|NCT00001094|HIV-1
712643|NCT00001094|Drug Therapy, Combination
712644|NCT00001094|Zidovudine
712645|NCT00001094|Lamivudine
712646|NCT00001094|RNA, Viral
712647|NCT00001094|Saquinavir
712648|NCT00001094|Delavirdine
712649|NCT00001094|Anti-HIV Agents
712650|NCT00001094|Nelfinavir
712651|NCT00001093|Immunity, Cellular
712652|NCT00001093|Sexual Partners
712653|NCT00001093|Treatment Outcome
712654|NCT00001093|Anti-HIV Agents
712655|NCT00001093|Viral Load
712656|NCT00001093|Acute Infection
712657|NCT00001092|Semen
712658|NCT00001092|HIV-1
712659|NCT00001092|Sexual Partners
712660|NCT00001092|Drug Resistance, Microbial
712661|NCT00001092|CD8-Positive T-Lymphocytes
712662|NCT00001092|Saliva
712663|NCT00001092|Blood
712664|NCT00001092|Cervix Uteri
712665|NCT00001092|Vagina
712666|NCT00001092|Acute Infection
712667|NCT00001091|Drug Therapy, Combination
712668|NCT00001091|Nevirapine
712669|NCT00001091|Stavudine
712670|NCT00001091|HIV Protease Inhibitors
712671|NCT00001091|Ritonavir
712672|NCT00001091|Lamivudine
712673|NCT00001091|Nelfinavir
712674|NCT00001091|Reverse Transcriptase Inhibitors
712675|NCT00001090|Reference Values
712676|NCT00001090|Granulocyte-Macrophage Colony-Stimulating Factor
712677|NCT00001090|AIDS Vaccines
712678|NCT00001090|HIV Seronegativity
712679|NCT00001090|Dose-Response Relationship, Immunologic
712680|NCT00001090|HIV Preventive Vaccine
712681|NCT00001089|Prospective Studies
712682|NCT00001089|HIV-1
712683|NCT00001089|Cytomegalovirus
712684|NCT00001089|Cytomegalovirus Infections
712685|NCT00001089|Acquired Immunodeficiency Syndrome
712686|NCT00001089|Anti-HIV Agents
712687|NCT00001089|Viral Load
712688|NCT00001089|Multiple Organ Failure
712689|NCT00001088|Injections, Intramuscular
712690|NCT00001088|AIDS Vaccines
712691|NCT00001088|HIV Seronegativity
712692|NCT00001088|Dose-Response Relationship, Immunologic
712693|NCT00001088|Fusion Proteins, gag-pol
712694|NCT00001088|Vaccines, DNA
712695|NCT00001088|HIV Preventive Vaccine
712696|NCT00001087|Drug Therapy, Combination
712697|NCT00001087|Antiviral Agents
712698|NCT00001087|HIV Protease Inhibitors
712699|NCT00001087|Ritonavir
712700|NCT00001087|Saquinavir
712701|NCT00001087|Nelfinavir
712702|NCT00001087|Reverse Transcriptase Inhibitors
712703|NCT00001087|Adenine
712704|NCT00001087|Anti-HIV Agents
712705|NCT00001087|efavirenz
712706|NCT00001086|Placebos
712707|NCT00001086|HIV-1
712708|NCT00001086|Drug Therapy, Combination
712709|NCT00001086|HIV Protease Inhibitors
712710|NCT00001086|Indinavir
712711|NCT00001086|RNA, Viral
712712|NCT00001086|Reverse Transcriptase Inhibitors
712713|NCT00001086|Anti-HIV Agents
712714|NCT00001086|Viral Load
712715|NCT00001086|efavirenz
712716|NCT00001085|HIV-1
712717|NCT00001085|Drug Therapy, Combination
712718|NCT00001085|Acquired Immunodeficiency Syndrome
712719|NCT00001085|Zidovudine
712720|NCT00001085|HIV Protease Inhibitors
712721|NCT00001085|Lamivudine
712722|NCT00001085|RNA, Viral
712723|NCT00001085|VX 478
712724|NCT00001085|Reverse Transcriptase Inhibitors
712725|NCT00001085|Anti-HIV Agents
712726|NCT00001085|Viral Load
712727|NCT00001084|Prospective Studies
712728|NCT00001084|Drug Therapy, Combination
712729|NCT00001084|Zidovudine
712730|NCT00001084|HIV Protease Inhibitors
712731|NCT00001084|Lamivudine
712732|NCT00001084|Indinavir
712733|NCT00001084|RNA, Viral
712734|NCT00001084|Reverse Transcriptase Inhibitors
712735|NCT00001084|Anti-HIV Agents
712736|NCT00001084|Viral Load
712737|NCT00001083|HIV-1
712738|NCT00001083|Drug Therapy, Combination
712739|NCT00001083|Zidovudine
712740|NCT00001083|Nevirapine
712741|NCT00001083|Stavudine
712742|NCT00001083|HIV Protease Inhibitors
712743|NCT00001083|Ritonavir
712744|NCT00001083|Lamivudine
712745|NCT00001083|Indinavir
712746|NCT00001083|RNA, Viral
712747|NCT00001083|Reverse Transcriptase Inhibitors
712748|NCT00001083|Anti-HIV Agents
712749|NCT00001082|Cytomegalovirus Infections
712750|NCT00001082|Antiviral Agents
712751|NCT00001082|CD4 Lymphocyte Count
712752|NCT00001082|Prodrugs
712753|NCT00001082|Survival
712754|NCT00001082|Adenine
712755|NCT00001081|AIDS-Related Opportunistic Infections
712756|NCT00001081|Cryptosporidiosis
712757|NCT00001081|Antiprotozoal Agents
712758|NCT00001081|nitazoxanide
712759|NCT00001080|Lymphocyte Transformation
712760|NCT00001080|HIV-1
712761|NCT00001080|Drug Resistance, Microbial
712762|NCT00001080|CD4-Positive T-Lymphocytes
712763|NCT00001080|Lamivudine
712764|NCT00001080|Influenza Vaccine
712765|NCT00001080|RNA, Viral
712766|NCT00001080|Bacterial Vaccines
712767|NCT00001080|Anti-HIV Agents
712768|NCT00001080|Pneumonia, Pneumococcal
712769|NCT00001080|Viral Load
712770|NCT00001079|Placebos
712771|NCT00001079|Drug Therapy, Combination
712772|NCT00001079|Acquired Immunodeficiency Syndrome
712773|NCT00001079|AIDS-Related Complex
712774|NCT00001079|HIV Wasting Syndrome
712775|NCT00001079|Megestrol Acetate
712776|NCT00001079|dihydrotestosterone heptanoate
712777|NCT00001078|Viral Vaccines
712778|NCT00001078|AIDS-Related Opportunistic Infections
712779|NCT00001078|Anti-HIV Agents
712780|NCT00001078|Hepatitis A Virus, Human
712781|NCT00001077|Weight Loss
712782|NCT00001077|Acquired Immunodeficiency Syndrome
712783|NCT00001077|Nutritional Support
712784|NCT00001076|Vaccines, Synthetic
712785|NCT00001076|HIV Envelope Protein gp120
712786|NCT00001076|AIDS Vaccines
712787|NCT00001076|HIV Seronegativity
712788|NCT00001076|Avipoxvirus
712789|NCT00001076|HIV Preventive Vaccine
712790|NCT00001075|Drug Therapy, Combination
712791|NCT00001075|Acquired Immunodeficiency Syndrome
712792|NCT00001075|AIDS-Related Complex
712793|NCT00001075|Antiviral Agents
712794|NCT00001075|Zidovudine
712795|NCT00001075|HIV Protease Inhibitors
712796|NCT00001075|Ritonavir
712797|NCT00001075|Lamivudine
712798|NCT00001074|Didanosine
712799|NCT00001074|Drug Therapy, Combination
712800|NCT00001074|Antiviral Agents
712801|NCT00001074|Hydroxyurea
712802|NCT00001073|Acquired Immunodeficiency Syndrome
712803|NCT00001073|AIDS-Related Complex
712804|NCT00001073|Cervix Dysplasia
712805|NCT00001073|Cervix Diseases
712806|NCT00001073|Isotretinoin
712807|NCT00001073|Cervical Intraepithelial Neoplasia
712808|NCT00001073|Cervix Neoplasms
712809|NCT00001073|Keratolytic Agents
712810|NCT00001072|Vaccines, Synthetic
712811|NCT00001072|HIV Envelope Protein gp120
712812|NCT00001072|AIDS Vaccines
712813|NCT00001072|HIV Seronegativity
712814|NCT00001072|Avipoxvirus
712815|NCT00001072|HIV Preventive Vaccine
712816|NCT00001071|Granulocyte Colony-Stimulating Factor
712817|NCT00001071|Acquired Immunodeficiency Syndrome
712818|NCT00001071|AIDS-Related Complex
712819|NCT00001071|Stem Cells
712820|NCT00001069|Acquired Immunodeficiency Syndrome
712821|NCT00001069|AIDS-Related Complex
712822|NCT00001069|Antiviral Agents
712823|NCT00001069|Decision Making
712824|NCT00001069|Physician's Practice Patterns
712825|NCT00001068|Zalcitabine
712826|NCT00001068|Didanosine
712827|NCT00001068|Drug Therapy, Combination
712828|NCT00001068|AIDS-Related Complex
712829|NCT00001068|Antiviral Agents
712830|NCT00001068|Zidovudine
712831|NCT00001068|Lamivudine
712832|NCT00001067|Drug Therapy, Combination
712833|NCT00001067|AIDS-Related Complex
712834|NCT00001067|Zidovudine
712835|NCT00001067|Stavudine
712836|NCT00001067|Lamivudine
712837|NCT00001066|Didanosine
712838|NCT00001066|Drug Therapy, Combination
712839|NCT00001066|Acquired Immunodeficiency Syndrome
712840|NCT00001066|AIDS-Related Complex
712841|NCT00001066|Zidovudine
712842|NCT00001066|Lamivudine
712843|NCT00001065|Administration, Oral
712844|NCT00001065|Acquired Immunodeficiency Syndrome
712845|NCT00001065|Amphotericin B
712846|NCT00001065|AIDS-Related Complex
712847|NCT00001065|Candidiasis, Oral
712848|NCT00001065|Suspensions
712849|NCT00001064|HIV Antigens
712850|NCT00001064|Immunotherapy, Adoptive
712851|NCT00001064|Dendritic Cells
712852|NCT00001063|Didanosine
712853|NCT00001063|Drug Therapy, Combination
712854|NCT00001063|AIDS-Related Complex
712855|NCT00001063|Zidovudine
712856|NCT00001063|Stavudine
712857|NCT00001062|Infusions, Intravenous
712858|NCT00001062|Ganciclovir
712859|NCT00001062|Administration, Oral
712860|NCT00001062|Acquired Immunodeficiency Syndrome
712861|NCT00001062|Antiviral Agents
712862|NCT00001062|Cytomegalovirus Retinitis
712863|NCT00001061|AIDS-Related Opportunistic Infections
712864|NCT00001061|Ganciclovir
712865|NCT00001061|Foscarnet
712866|NCT00001061|Acquired Immunodeficiency Syndrome
712867|NCT00001061|Antibodies, Monoclonal
712868|NCT00001061|Cytomegalovirus Retinitis
712869|NCT00001060|Vaccines, Synthetic
712870|NCT00001060|HIV-1
712871|NCT00001060|Acquired Immunodeficiency Syndrome
712872|NCT00001060|AIDS-Related Complex
712873|NCT00001060|AIDS Vaccines
712874|NCT00001060|HIV Therapeutic Vaccine
712875|NCT00001059|Vincristine
712876|NCT00001059|Sarcoma, Kaposi
712877|NCT00001059|Liposomes
712878|NCT00001059|Doxorubicin
712879|NCT00001059|Drug Therapy, Combination
712880|NCT00001059|Granulocyte Colony-Stimulating Factor
712881|NCT00001059|Acquired Immunodeficiency Syndrome
712882|NCT00001059|Bleomycin
712883|NCT00001059|Drug Carriers
712884|NCT00001058|Rifabutin
712885|NCT00001058|Mycobacterium avium-intracellulare Infection
712886|NCT00001058|Drug Therapy, Combination
712887|NCT00001058|Ethambutol
712888|NCT00001058|Clofazimine
712889|NCT00001058|Acquired Immunodeficiency Syndrome
712890|NCT00001058|Ciprofloxacin
712891|NCT00001058|Clarithromycin
712892|NCT00001057|Didanosine
712893|NCT00001057|Drug Therapy, Combination
712894|NCT00001057|Zidovudine
712895|NCT00001056|Vaccines, Synthetic
712896|NCT00001056|Vaccinia Virus
712897|NCT00001056|Viral Vaccines
712898|NCT00001056|HIV-1
712899|NCT00001056|HIV Envelope Protein gp160
712900|NCT00001056|AIDS Vaccines
712901|NCT00001056|HIV Seronegativity
712902|NCT00001056|HIV Preventive Vaccine
712903|NCT00001055|Vaccines, Synthetic
712904|NCT00001055|HIV Envelope Protein gp120
712905|NCT00001055|AIDS Vaccines
712906|NCT00001055|HIV Seronegativity
712907|NCT00001055|Avipoxvirus
712908|NCT00001055|HIV Preventive Vaccine
712909|NCT00001054|Herpes Zoster
712910|NCT00001054|AIDS-Related Opportunistic Infections
712911|NCT00001054|Herpes Simplex
712912|NCT00001054|Acquired Immunodeficiency Syndrome
712913|NCT00001054|AIDS-Related Complex
712914|NCT00001054|valacyclovir
712915|NCT00001054|Chickenpox
712916|NCT00001053|Vaccines, Synthetic
712917|NCT00001053|Recombinant Proteins
712918|NCT00001053|HIV-1
712919|NCT00001053|AIDS Vaccines
712920|NCT00001053|HIV Core Protein p24
712921|NCT00001053|p24-VLP vaccine
712922|NCT00001053|Gene Products, gag
712923|NCT00001053|HIV Seronegativity
712924|NCT00001053|HIV Preventive Vaccine
712925|NCT00001052|Vaccines, Synthetic
712926|NCT00001052|Drug Therapy, Combination
712927|NCT00001052|Adjuvants, Immunologic
712928|NCT00001052|HIV Envelope Protein gp120
712929|NCT00001052|AIDS Vaccines
712930|NCT00001052|HIV Seronegativity
712931|NCT00001052|HIV Preventive Vaccine
712932|NCT00001049|Didanosine
712933|NCT00001049|Drug Therapy, Combination
712934|NCT00001049|Acquired Immunodeficiency Syndrome
712935|NCT00001049|AIDS-Related Complex
712936|NCT00001049|Zidovudine
712937|NCT00001048|Leukoencephalopathy, Progressive Multifocal
712938|NCT00001048|Infusions, Intravenous
712939|NCT00001048|Cytarabine
712940|NCT00001048|Zalcitabine
712941|NCT00001048|Didanosine
712942|NCT00001048|Drug Therapy, Combination
712943|NCT00001048|Granulocyte Colony-Stimulating Factor
712944|NCT00001048|Acquired Immunodeficiency Syndrome
712945|NCT00001048|Zidovudine
712946|NCT00001048|Injections, Spinal
712947|NCT00001047|Rifabutin
712948|NCT00001047|Mycobacterium avium-intracellulare Infection
712949|NCT00001047|Drug Therapy, Combination
712950|NCT00001047|Ethambutol
712951|NCT00001047|Clofazimine
712952|NCT00001047|Acquired Immunodeficiency Syndrome
712953|NCT00001047|Clarithromycin
712954|NCT00001046|Vaccines, Synthetic
712955|NCT00001046|Pregnancy
712956|NCT00001046|Pregnancy Complications, Infectious
712957|NCT00001046|AIDS-Related Complex
712958|NCT00001046|HIV Envelope Protein gp120
712959|NCT00001046|HIV Preventive Vaccine
712960|NCT00001046|HIV Therapeutic Vaccine
712961|NCT00001045|Didanosine
712962|NCT00001045|Drug Therapy, Combination
712963|NCT00001045|Zidovudine
712964|NCT00001045|Nevirapine
712965|NCT00001044|Vaccines, Synthetic
712966|NCT00001044|Drug Therapy, Combination
712967|NCT00001044|Adjuvants, Immunologic
712968|NCT00001044|HIV Envelope Protein gp120
712969|NCT00001044|AIDS Vaccines
712970|NCT00001044|HIV Seronegativity
712971|NCT00001044|HIV Preventive Vaccine
712972|NCT00001043|Vaccines, Synthetic
712973|NCT00001043|Vaccinia Virus
712974|NCT00001043|Viral Vaccines
712975|NCT00001043|Smallpox Vaccine
712976|NCT00001043|HIV-1
712977|NCT00001043|HIV Envelope Protein gp160
712978|NCT00001043|AIDS Vaccines
712979|NCT00001043|HIV Seronegativity
712980|NCT00001043|HIV Preventive Vaccine
712981|NCT00001042|Vaccines, Synthetic
712982|NCT00001042|Drug Therapy, Combination
712983|NCT00001042|Adjuvants, Immunologic
712984|NCT00001042|HIV Envelope Protein gp120
712985|NCT00001042|Acetylmuramyl-Alanyl-Isoglutamine
712986|NCT00001042|monophosphoryl lipid A
712987|NCT00001042|AIDS Vaccines
712988|NCT00001042|HIV Seronegativity
712989|NCT00001042|HIV Preventive Vaccine
712990|NCT00001041|Vaccines, Synthetic
712991|NCT00001041|Pregnancy
712992|NCT00001041|Pregnancy Complications, Infectious
712993|NCT00001041|HIV Envelope Protein gp120
712994|NCT00001041|AIDS Vaccines
712995|NCT00001041|HIV Therapeutic Vaccine
712996|NCT00001040|Zalcitabine
712997|NCT00001040|Drug Therapy, Combination
712998|NCT00001040|Acquired Immunodeficiency Syndrome
712999|NCT00001040|AIDS-Related Complex
713000|NCT00001040|Zidovudine
713001|NCT00001040|Saquinavir
713002|NCT00001040|HIV Protease Inhibitors
713003|NCT00001039|Mycobacterium avium-intracellulare Infection
713004|NCT00001039|Drug Therapy, Combination
713005|NCT00001039|Ethambutol
713006|NCT00001039|Acquired Immunodeficiency Syndrome
713007|NCT00001039|Clarithromycin
713008|NCT00001038|Cytomegalovirus Infections
713009|NCT00001038|Acquired Immunodeficiency Syndrome
713010|NCT00001038|Antiviral Agents
713011|NCT00001037|Vaccines, Synthetic
713012|NCT00001037|HIV-1
713013|NCT00001037|HIV Envelope Protein gp160
713014|NCT00001037|AIDS Vaccines
713015|NCT00001037|HIV Seronegativity
713016|NCT00001037|HIV Preventive Vaccine
713017|NCT00001036|T-Lymphocytes
713018|NCT00001036|Polyethylene Glycols
713019|NCT00001036|Interleukin-2
713020|NCT00001036|Drug Therapy, Combination
713021|NCT00001036|Adjuvants, Immunologic
713022|NCT00001036|Acquired Immunodeficiency Syndrome
713023|NCT00001036|Zidovudine
713024|NCT00001036|thymosin alpha(1)
713025|NCT00001035|AIDS-Related Opportunistic Infections
713026|NCT00001035|Interferon Alfa-2b
713027|NCT00001035|Zalcitabine
713028|NCT00001035|Didanosine
713029|NCT00001035|Drug Therapy, Combination
713030|NCT00001035|Acquired Immunodeficiency Syndrome
713031|NCT00001035|Zidovudine
713032|NCT00001035|Hepatitis C
713033|NCT00001034|Retinitis
713034|NCT00001034|Ganciclovir
713035|NCT00001034|Cytomegalovirus Infections
713036|NCT00001034|Administration, Oral
713037|NCT00001034|Acquired Immunodeficiency Syndrome
713038|NCT00001034|Gastrointestinal System
713039|NCT00001033|Isoniazid
713040|NCT00001033|Tuberculosis, Pulmonary
713041|NCT00001033|Pyrazinamide
713042|NCT00001033|Pyridoxine
713043|NCT00001033|Ofloxacin
713044|NCT00001033|Rifampin
713045|NCT00001033|AIDS-Related Opportunistic Infections
713046|NCT00001033|Ethambutol
713047|NCT00001033|Acquired Immunodeficiency Syndrome
713048|NCT00001032|Zalcitabine
713049|NCT00001032|Drug Therapy, Combination
713050|NCT00001032|Acquired Immunodeficiency Syndrome
713051|NCT00001032|AIDS-Related Complex
713052|NCT00001032|Zidovudine
713053|NCT00001031|Vaccines, Synthetic
713054|NCT00001031|HIV-1
713055|NCT00001031|HIV Envelope Protein gp120
713056|NCT00001031|AIDS Vaccines
713057|NCT00001031|HIV Seronegativity
713058|NCT00001031|HIV Preventive Vaccine
713059|NCT00001030|Rifabutin
713060|NCT00001030|Mycobacterium avium-intracellulare Infection
713061|NCT00001030|Acquired Immunodeficiency Syndrome
713062|NCT00001030|Clarithromycin
713063|NCT00001029|Zalcitabine
713064|NCT00001029|Didanosine
713065|NCT00001029|Drug Therapy, Combination
713066|NCT00001029|Acquired Immunodeficiency Syndrome
713067|NCT00001029|Zidovudine
713068|NCT00001028|Pneumonia, Pneumocystis carinii
713069|NCT00001028|Pentamidine
713070|NCT00001028|Dapsone
713071|NCT00001028|Acquired Immunodeficiency Syndrome
713072|NCT00001028|AIDS-Related Complex
713073|NCT00001027|Pneumonia, Pneumocystis carinii
713074|NCT00001027|Pentamidine
713075|NCT00001027|Acquired Immunodeficiency Syndrome
713076|NCT00001027|AIDS-Related Complex
713077|NCT00001026|Vaccines, Synthetic
713078|NCT00001026|Vaccinia Virus
713079|NCT00001026|Viral Vaccines
713080|NCT00001026|HIV Envelope Protein gp160
713081|NCT00001026|HIV Envelope Protein gp120
713082|NCT00001026|AIDS Vaccines
713083|NCT00001026|HIV Seronegativity
713084|NCT00001026|HIV Preventive Vaccine
713085|NCT00001025|Virus Replication
713086|NCT00001025|Didanosine
713087|NCT00001025|Acquired Immunodeficiency Syndrome
713088|NCT00001025|AIDS-Related Complex
713089|NCT00001025|Zidovudine
713090|NCT00001024|Didanosine
713091|NCT00001024|AIDS-Related Complex
713092|NCT00001024|Zidovudine
713093|NCT00001024|Lymph Nodes
713094|NCT00001024|Lymphoid Tissue
713095|NCT00001023|Rifabutin
713096|NCT00001023|Mycobacterium avium-intracellulare Infection
713097|NCT00001023|Drug Interactions
713098|NCT00001023|Azithromycin
713099|NCT00001023|Clarithromycin
713100|NCT00001022|Zalcitabine
713101|NCT00001022|Didanosine
713102|NCT00001022|Drug Therapy, Combination
713103|NCT00001022|Acquired Immunodeficiency Syndrome
713104|NCT00001022|AIDS-Related Complex
713105|NCT00001022|Zidovudine
713106|NCT00001021|Vaccines, Synthetic
713107|NCT00001021|HIV-1
713108|NCT00001021|HIV Envelope Protein gp120
713109|NCT00001021|AIDS Vaccines
713110|NCT00001021|HIV Seronegativity
713111|NCT00001021|HIV Preventive Vaccine
713112|NCT00001020|Vaccines, Synthetic
713113|NCT00001020|Viral Vaccines
713114|NCT00001020|HIV-1
713115|NCT00001020|HIV Envelope Protein gp120
713116|NCT00001020|AIDS Vaccines
713117|NCT00001020|HIV Seronegativity
713118|NCT00001020|HIV Preventive Vaccine
713119|NCT00001019|Vaccines, Synthetic
713120|NCT00001019|Adjuvants, Immunologic
713121|NCT00001019|HIV Envelope Protein gp120
713122|NCT00001019|AIDS Vaccines
713123|NCT00001019|HIV Seronegativity
713124|NCT00001019|HIV Preventive Vaccine
713125|NCT00001018|Cryptosporidiosis
713126|NCT00001018|Diarrhea
713127|NCT00001018|Acquired Immunodeficiency Syndrome
713128|NCT00001018|Antiprotozoal Agents
713129|NCT00001018|Triazines
713130|NCT00001017|AIDS-Related Opportunistic Infections
713131|NCT00001017|Meningitis
713132|NCT00001017|Injections, Intravenous
713133|NCT00001017|Cryptococcosis
713134|NCT00001017|Fluconazole
713135|NCT00001017|Administration, Oral
713136|NCT00001017|Acquired Immunodeficiency Syndrome
713137|NCT00001017|Amphotericin B
713138|NCT00001016|Trimetrexate
713139|NCT00001016|Pneumonia, Pneumocystis carinii
713140|NCT00001016|Quinazolines
713141|NCT00001016|Infusions, Intravenous
713142|NCT00001016|Injections, Intravenous
713143|NCT00001016|Leucovorin
713144|NCT00001016|Drug Evaluation
713145|NCT00001016|Drug Therapy, Combination
713146|NCT00001016|Administration, Oral
713147|NCT00001016|Acquired Immunodeficiency Syndrome
713148|NCT00001016|Antiprotozoal Agents
713149|NCT00001016|AIDS-Related Complex
713150|NCT00001015|Ribavirin
713151|NCT00001015|T-Lymphocytes
713152|NCT00001015|Acquired Immunodeficiency Syndrome
713153|NCT00001015|AIDS-Related Complex
713154|NCT00001014|Trimethoprim-Sulfamethoxazole Combination
713155|NCT00001014|Trimetrexate
713156|NCT00001014|AIDS-Related Opportunistic Infections
713157|NCT00001014|Pneumonia, Pneumocystis carinii
713158|NCT00001014|Infusions, Intravenous
713159|NCT00001014|Leucovorin
713160|NCT00001014|Drug Therapy, Combination
713161|NCT00001014|Administration, Oral
713162|NCT00001014|Acquired Immunodeficiency Syndrome
713163|NCT00001014|Antiprotozoal Agents
713164|NCT00001014|AIDS-Related Complex
713165|NCT00001014|Sulfamethoxazole-Trimethoprim
713166|NCT00001013|Trimethoprim-Sulfamethoxazole Combination
713167|NCT00001013|Trimetrexate
713168|NCT00001013|AIDS-Related Opportunistic Infections
713169|NCT00001013|Pneumonia, Pneumocystis carinii
713170|NCT00001013|Pentamidine
713171|NCT00001013|Infusions, Intravenous
713172|NCT00001013|Leucovorin
713173|NCT00001013|Drug Therapy, Combination
713174|NCT00001013|Folic Acid Antagonists
713175|NCT00001013|Aerosols
713176|NCT00001013|Acquired Immunodeficiency Syndrome
713177|NCT00001013|Antiprotozoal Agents
713178|NCT00001013|AIDS-Related Complex
713179|NCT00001013|Sulfamethoxazole-Trimethoprim
713180|NCT00001012|Virus Replication
713181|NCT00001012|T-Lymphocytes
713182|NCT00001012|Dose-Response Relationship, Drug
713183|NCT00001012|Drug Evaluation
713184|NCT00001012|Acquired Immunodeficiency Syndrome
713185|NCT00001012|AL 721
713186|NCT00001012|AIDS-Related Complex
713187|NCT00001012|Antiviral Agents
713188|NCT00001011|Virus Replication
713189|NCT00001011|AIDS-Related Complex
713190|NCT00001011|Zidovudine
713191|NCT00001010|Immune Tolerance
713192|NCT00001010|Dose-Response Relationship, Drug
713193|NCT00001010|Drug Evaluation
713194|NCT00001010|Drug Therapy, Combination
713195|NCT00001010|Acyclovir
713196|NCT00001010|Acquired Immunodeficiency Syndrome
713197|NCT00001010|AIDS-Related Complex
713198|NCT00001010|Zidovudine
713199|NCT00001009|T-Lymphocytes
713200|NCT00001009|HIV Antigens
713201|NCT00001009|Dextran Sulfate
713202|NCT00001009|Dose-Response Relationship, Drug
713203|NCT00001009|Drug Evaluation
713204|NCT00001009|Drug Therapy, Combination
713205|NCT00001009|Acquired Immunodeficiency Syndrome
713206|NCT00001009|AIDS-Related Complex
713207|NCT00001008|Substance Withdrawal Syndrome
713208|NCT00001008|Methadone
713209|NCT00001008|Opioid-Related Disorders
713210|NCT00001008|Drug Evaluation
713211|NCT00001008|Drug Interactions
713212|NCT00001008|Drug Therapy, Combination
713213|NCT00001008|Administration, Oral
713214|NCT00001008|Acquired Immunodeficiency Syndrome
713215|NCT00001008|AIDS-Related Complex
713216|NCT00001008|Zidovudine
713217|NCT00001007|Pregnancy
713218|NCT00001007|Pregnancy Complications, Infectious
713219|NCT00001007|Infant, Newborn, Diseases
713220|NCT00001007|Infusions, Intravenous
713221|NCT00001007|Drug Evaluation
713222|NCT00001007|Administration, Oral
713223|NCT00001007|Acquired Immunodeficiency Syndrome
713224|NCT00001007|Zidovudine
713225|NCT00001006|Infusions, Intravenous
713226|NCT00001006|Immunologic Surveillance
713227|NCT00001006|Drug Evaluation
713228|NCT00001006|Adjuvants, Immunologic
713229|NCT00001006|Acquired Immunodeficiency Syndrome
713230|NCT00001006|AIDS-Related Complex
713231|NCT00001006|ammonium trichloro(dioxoethylene-O,O'-)tellurute
713232|NCT00001005|Recombinant Proteins
713233|NCT00001005|HIV Seropositivity
713234|NCT00001005|Interleukin-2
713235|NCT00001005|Drug Evaluation
713236|NCT00001005|Drug Therapy, Combination
713237|NCT00001005|Acquired Immunodeficiency Syndrome
713238|NCT00001005|AIDS-Related Complex
713239|NCT00001005|Zidovudine
713240|NCT00001004|Tumor Necrosis Factor
713241|NCT00001004|Interferon-gamma, Recombinant
713242|NCT00001004|HIV Antigens
713243|NCT00001004|Immunologic Surveillance
713244|NCT00001004|Drug Therapy, Combination
713245|NCT00001004|Acquired Immunodeficiency Syndrome
713246|NCT00001004|AIDS-Related Complex
713247|NCT00001003|AIDS-Related Opportunistic Infections
713248|NCT00001003|Pneumonia, Pneumocystis carinii
713249|NCT00001003|Pentamidine
713250|NCT00001003|Nebulizers and Vaporizers
713251|NCT00001003|Lung
713252|NCT00001003|Administration, Inhalation
713253|NCT00001003|Acquired Immunodeficiency Syndrome
713254|NCT00001003|Zidovudine
713255|NCT00001002|Drug Therapy, Combination
713256|NCT00001002|Foscarnet
713257|NCT00001002|Acquired Immunodeficiency Syndrome
713258|NCT00001002|AIDS-Related Complex
713259|NCT00001002|Antiviral Agents
713260|NCT00001002|Zidovudine
713261|NCT00001001|Liver
713262|NCT00001001|Liver Diseases
713263|NCT00001001|Liver Function Tests
713264|NCT00001001|HIV Seropositivity
713265|NCT00001001|Acquired Immunodeficiency Syndrome
713266|NCT00001001|Zidovudine
713267|NCT00001001|Biological Availability
713268|NCT00001000|Macrophage Activation
713269|NCT00001000|Lymphocyte Transformation
713270|NCT00001000|Immunologic Surveillance
713271|NCT00001000|ampligen
713272|NCT00001000|Antiviral Agents
713273|NCT00000999|Acquired Immunodeficiency Syndrome
713274|NCT00000999|AIDS-Related Complex
713275|NCT00000999|Zidovudine
713276|NCT00000998|Trimetrexate
713277|NCT00000998|AIDS-Related Opportunistic Infections
713278|NCT00000998|Pneumonia, Pneumocystis carinii
713279|NCT00000998|Injections, Intravenous
713280|NCT00000998|Leucovorin
713281|NCT00000998|Dose-Response Relationship, Drug
713282|NCT00000998|Drug Therapy, Combination
713283|NCT00000998|Folic Acid Antagonists
713284|NCT00000998|Administration, Oral
713285|NCT00000998|Acquired Immunodeficiency Syndrome
713286|NCT00000998|Antineoplastic Agents
713287|NCT00000997|Zalcitabine
713288|NCT00000997|Drug Evaluation
713289|NCT00000997|Acquired Immunodeficiency Syndrome
713290|NCT00000997|AIDS-Related Complex
713291|NCT00000997|Biological Availability
713292|NCT00000996|Doxorubicin
713293|NCT00000996|Drug Evaluation
713294|NCT00000996|Acquired Immunodeficiency Syndrome
713295|NCT00000995|AIDS-Related Opportunistic Infections
713296|NCT00000995|Ganciclovir
713297|NCT00000995|Drug Evaluation
713298|NCT00000995|Drug Therapy, Combination
713299|NCT00000995|Cytomegalovirus Infections
713300|NCT00000995|Acquired Immunodeficiency Syndrome
713301|NCT00000995|Zidovudine
713302|NCT00000994|AIDS-Related Opportunistic Infections
713303|NCT00000994|Sarcoma, Kaposi
713304|NCT00000994|Acquired Immunodeficiency Syndrome
713305|NCT00000994|Zidovudine
713306|NCT00000993|HIV-1
713307|NCT00000993|Drug Evaluation
713308|NCT00000993|Accidents
713309|NCT00000993|Acquired Immunodeficiency Syndrome
713310|NCT00000993|AIDS Serodiagnosis
713311|NCT00000993|Zidovudine
713312|NCT00000992|AIDS-Related Opportunistic Infections
713313|NCT00000992|Ketoconazole
713314|NCT00000992|Histoplasmosis
713315|NCT00000992|Drug Evaluation
713316|NCT00000992|Antifungal Agents
713317|NCT00000992|Acquired Immunodeficiency Syndrome
713318|NCT00000991|Trimethoprim-Sulfamethoxazole Combination
713319|NCT00000991|Toxoplasmosis
713320|NCT00000991|AIDS-Related Opportunistic Infections
713321|NCT00000991|Pneumonia, Pneumocystis carinii
713322|NCT00000991|Pentamidine
713323|NCT00000991|Dapsone
713324|NCT00000991|Drug Evaluation
713325|NCT00000991|Drug Therapy, Combination
713326|NCT00000991|Acquired Immunodeficiency Syndrome
713327|NCT00000991|Zidovudine
713328|NCT00000991|Sulfamethoxazole-Trimethoprim
713329|NCT00000990|AIDS-Related Opportunistic Infections
713330|NCT00000990|Pulmonary Fibrosis
713331|NCT00000990|Zidovudine
713332|NCT00000989|Retinitis
713333|NCT00000989|Ganciclovir
713334|NCT00000989|Drug Evaluation
713455|NCT00000968|Vaccines, Synthetic
713335|NCT00000989|Drug Therapy, Combination
713336|NCT00000989|Cytomegalovirus Infections
713337|NCT00000989|Acquired Immunodeficiency Syndrome
713338|NCT00000989|Zidovudine
713339|NCT00000988|Injections, Intravenous
713340|NCT00000988|Drug Evaluation
713341|NCT00000988|Administration, Oral
713342|NCT00000988|Acquired Immunodeficiency Syndrome
713343|NCT00000988|AIDS-Related Complex
713344|NCT00000988|Antiviral Agents
713345|NCT00000987|Vincristine
713346|NCT00000987|Doxorubicin
713347|NCT00000987|Drug Therapy, Combination
713348|NCT00000987|Acquired Immunodeficiency Syndrome
713349|NCT00000987|Zidovudine
713350|NCT00000987|Bleomycin
713351|NCT00000986|Recombinant Proteins
713352|NCT00000986|Interleukin-2
713353|NCT00000986|Drug Interactions
713354|NCT00000986|Drug Therapy, Combination
713355|NCT00000986|Acquired Immunodeficiency Syndrome
713356|NCT00000986|AIDS-Related Complex
713357|NCT00000986|Zidovudine
713358|NCT00000985|Vidarabine
713359|NCT00000985|Phosphonoacetic Acid
713360|NCT00000985|Herpes Simplex
713361|NCT00000985|Foscarnet
713362|NCT00000985|Acyclovir
713363|NCT00000985|Acquired Immunodeficiency Syndrome
713364|NCT00000984|Recombinant Proteins
713365|NCT00000984|Acquired Immunodeficiency Syndrome
713366|NCT00000984|Antigens, CD4
713367|NCT00000984|Antiviral Agents
713368|NCT00000983|Acquired Immunodeficiency Syndrome
713369|NCT00000983|Zidovudine
713370|NCT00000982|Central Nervous System Diseases
713371|NCT00000982|Acquired Immunodeficiency Syndrome
713372|NCT00000982|Zidovudine
713373|NCT00000981|Retinitis
713374|NCT00000981|AIDS-Related Opportunistic Infections
713375|NCT00000981|Pyrimidine Nucleosides
713376|NCT00000981|Drug Evaluation
713377|NCT00000981|fiacitabine
713378|NCT00000981|Cytomegalovirus Infections
713379|NCT00000981|Acquired Immunodeficiency Syndrome
713380|NCT00000981|Antiviral Agents
713381|NCT00000980|Single-Blind Method
713382|NCT00000980|Spiramycin
713383|NCT00000980|AIDS-Related Opportunistic Infections
713384|NCT00000980|Injections, Intravenous
713385|NCT00000980|Cryptosporidiosis
713386|NCT00000980|Diarrhea
713387|NCT00000980|Drug Evaluation
713388|NCT00000980|Acquired Immunodeficiency Syndrome
713389|NCT00000979|Didanosine
713390|NCT00000979|Zidovudine
713391|NCT00000978|Zalcitabine
713392|NCT00000978|Drug Therapy, Combination
713393|NCT00000978|Acquired Immunodeficiency Syndrome
713394|NCT00000978|AIDS-Related Complex
713395|NCT00000978|Zidovudine
713396|NCT00000977|Vaccines, Synthetic
713397|NCT00000977|HIV Seropositivity
713398|NCT00000977|HIV-1
713399|NCT00000977|Drug Evaluation
713400|NCT00000977|AIDS Vaccines
713401|NCT00000977|HIV Therapeutic Vaccine
713402|NCT00000976|Recombinant Proteins
713403|NCT00000976|Injections, Intravenous
713404|NCT00000976|IgG
713405|NCT00000976|Drug Evaluation
713406|NCT00000976|Administration, Oral
713407|NCT00000976|Acquired Immunodeficiency Syndrome
713408|NCT00000976|Antigens, CD4
713409|NCT00000976|Zidovudine
713410|NCT00000976|Carrier Proteins
713411|NCT00000975|AIDS-Related Opportunistic Infections
713412|NCT00000975|Histoplasmosis
713413|NCT00000975|Drug Evaluation
713414|NCT00000975|Antifungal Agents
713415|NCT00000975|Acquired Immunodeficiency Syndrome
713416|NCT00000974|AIDS-Related Opportunistic Infections
713417|NCT00000974|Pneumonia, Pneumocystis carinii
713418|NCT00000974|Pentamidine
713419|NCT00000974|Injections, Intravenous
713420|NCT00000974|Drug Evaluation
713421|NCT00000974|Aerosols
713422|NCT00000974|Acquired Immunodeficiency Syndrome
713423|NCT00000973|Toxoplasmosis
713424|NCT00000973|Toxoplasma
713425|NCT00000973|Pyrimethamine
713426|NCT00000973|Leucovorin
713427|NCT00000973|Drug Evaluation
713428|NCT00000973|Encephalitis
713429|NCT00000973|Zidovudine
713430|NCT00000972|Vaccines, Synthetic
713431|NCT00000972|Drug Evaluation
713432|NCT00000972|Adjuvants, Immunologic
713433|NCT00000972|AIDS Vaccines
713434|NCT00000972|HIV Preventive Vaccine
713435|NCT00000971|AIDS-Related Opportunistic Infections
713436|NCT00000971|Mycobacterium avium-intracellulare Infection
713437|NCT00000971|Didanosine
713438|NCT00000971|Drug Evaluation
713439|NCT00000971|Drug Interactions
713440|NCT00000971|Drug Therapy, Combination
713441|NCT00000971|Acquired Immunodeficiency Syndrome
713442|NCT00000971|Zidovudine
713443|NCT00000970|Retinitis
713444|NCT00000970|AIDS-Related Opportunistic Infections
713445|NCT00000970|Ganciclovir
713446|NCT00000970|Drug Evaluation
713447|NCT00000970|Drug Therapy, Combination
713448|NCT00000970|Foscarnet
713449|NCT00000970|Cytomegalovirus Infections
713450|NCT00000970|Acquired Immunodeficiency Syndrome
713451|NCT00000969|Zalcitabine
713452|NCT00000969|Didanosine
713453|NCT00000969|Drug Evaluation
713454|NCT00000969|Zidovudine
713456|NCT00000968|Drug Evaluation
713457|NCT00000968|HIV Envelope Protein gp160
713458|NCT00000968|AIDS Vaccines
713459|NCT00000968|HIV Seronegativity
713460|NCT00000968|HIV Preventive Vaccine
713461|NCT00000967|Drug Therapy, Combination
713462|NCT00000967|AIDS-Related Complex
713463|NCT00000967|Zidovudine
713464|NCT00000967|Interferon Type I
713465|NCT00000966|Toxoplasmosis
713466|NCT00000966|Toxoplasma
713467|NCT00000966|Pyrimethamine
713468|NCT00000966|Leucovorin
713469|NCT00000966|Drug Evaluation
713470|NCT00000966|Drug Therapy, Combination
713471|NCT00000966|Encephalitis
713472|NCT00000966|Administration, Oral
713473|NCT00000966|Acquired Immunodeficiency Syndrome
713474|NCT00000966|Azithromycin
713475|NCT00000965|Leukocytes, Mononuclear
713476|NCT00000965|Drug Evaluation
713477|NCT00000965|Acquired Immunodeficiency Syndrome
713478|NCT00000965|AIDS-Related Complex
713479|NCT00000965|Zidovudine
713480|NCT00000965|Phosphorylation
713481|NCT00000964|Ranitidine
713482|NCT00000964|Phosphorus Acids
713483|NCT00000964|Drug Evaluation
713484|NCT00000964|Acquired Immunodeficiency Syndrome
713485|NCT00000963|Didanosine
713486|NCT00000963|Drug Evaluation
713487|NCT00000963|Acquired Immunodeficiency Syndrome
713488|NCT00000963|AIDS-Related Complex
713489|NCT00000963|Zidovudine
713490|NCT00000962|Drug Evaluation
713491|NCT00000962|Acquired Immunodeficiency Syndrome
713492|NCT00000962|AIDS-Related Complex
713493|NCT00000962|Nevirapine
713494|NCT00000961|Drug Therapy, Combination
713495|NCT00000961|Zidovudine
713496|NCT00000960|Pregnancy
713497|NCT00000960|Pregnancy Complications, Infectious
713498|NCT00000960|Prenatal Exposure Delayed Effects
713499|NCT00000960|Administration, Oral
713500|NCT00000960|AIDS-Related Complex
713501|NCT00000960|Zidovudine
713502|NCT00000959|Tuberculosis
713503|NCT00000959|Isoniazid
713504|NCT00000959|Pyridoxine
713505|NCT00000959|AIDS-Related Opportunistic Infections
713506|NCT00000959|Drug Evaluation
713507|NCT00000959|Acquired Immunodeficiency Syndrome
713508|NCT00000959|Antitubercular Agents
713509|NCT00000958|Vaccines, Synthetic
713510|NCT00000958|Recombinant Proteins
713511|NCT00000958|Adjuvants, Immunologic
713512|NCT00000958|Acquired Immunodeficiency Syndrome
713513|NCT00000958|HIV Envelope Protein gp120
713514|NCT00000958|AIDS Vaccines
713515|NCT00000958|HIV Therapeutic Vaccine
713516|NCT00000957|Vaccines, Synthetic
713517|NCT00000957|Vaccinia Virus
713518|NCT00000957|Viral Vaccines
713519|NCT00000957|HIV-1
713520|NCT00000957|Drug Evaluation
713521|NCT00000957|HIV Envelope Protein gp160
713522|NCT00000957|Drug Administration Schedule
713523|NCT00000957|AIDS Vaccines
713524|NCT00000957|HIV Seronegativity
713525|NCT00000957|HIV Preventive Vaccine
713526|NCT00000956|Vaccines, Synthetic
713527|NCT00000956|Vaccinia Virus
713528|NCT00000956|HIV-1
713529|NCT00000956|HIV Envelope Protein gp160
713530|NCT00000956|AIDS Vaccines
713531|NCT00000956|HIV Seronegativity
713532|NCT00000956|HIV Preventive Vaccine
713533|NCT00000955|Tuberculosis
713534|NCT00000955|Immunologic Tests
713535|NCT00000955|Tuberculin
713536|NCT00000955|Tuberculin Test
713537|NCT00000955|AIDS-Related Opportunistic Infections
713538|NCT00000955|Injections, Intradermal
713539|NCT00000955|Acquired Immunodeficiency Syndrome
713540|NCT00000955|AIDS-Related Complex
713541|NCT00000955|Hypersensitivity, Delayed
713542|NCT00000954|Vincristine
713543|NCT00000954|Sarcoma, Kaposi
713544|NCT00000954|Zalcitabine
713545|NCT00000954|Didanosine
713546|NCT00000954|Doxorubicin
713547|NCT00000954|Drug Evaluation
713548|NCT00000954|Drug Interactions
713549|NCT00000954|Drug Therapy, Combination
713550|NCT00000954|Combined Modality Therapy
713551|NCT00000954|Acquired Immunodeficiency Syndrome
713552|NCT00000954|Antineoplastic Agents
713553|NCT00000954|Antineoplastic Agents, Combined
713554|NCT00000954|Antiviral Agents
713555|NCT00000954|Bleomycin
713556|NCT00000953|Herpes Zoster
713557|NCT00000953|Acyclovir
713558|NCT00000953|Acquired Immunodeficiency Syndrome
713559|NCT00000953|AIDS-Related Complex
713560|NCT00000953|Antiviral Agents
713561|NCT00000953|sorivudine
713562|NCT00000952|Dose-Response Relationship, Drug
713563|NCT00000952|Drug Therapy, Combination
713564|NCT00000952|Zidovudine
713565|NCT00000952|HIV Protease Inhibitors
713566|NCT00000952|Ritonavir
713567|NCT00000952|Lamivudine
713568|NCT00000952|Anti-HIV Agents
713569|NCT00000951|AIDS-Related Opportunistic Infections
713570|NCT00000951|Fluconazole
713571|NCT00000951|Antifungal Agents
713572|NCT00000951|Candidiasis, Oral
713573|NCT00000951|Drug Administration Schedule
713574|NCT00000951|Pharyngeal Diseases
713575|NCT00000950|Tuberculosis
713576|NCT00000950|Isoniazid
713577|NCT00000950|Pyrazinamide
713578|NCT00000950|Pyridoxine
713579|NCT00000950|Rifampin
713580|NCT00000950|AIDS-Related Opportunistic Infections
713581|NCT00000950|Drug Therapy, Combination
713582|NCT00000950|Ethambutol
713583|NCT00000950|Acquired Immunodeficiency Syndrome
713584|NCT00000950|Antitubercular Agents
713585|NCT00000949|AIDS-Related Opportunistic Infections
713586|NCT00000949|Interleukin-2
713587|NCT00000949|Dose-Response Relationship, Drug
713588|NCT00000949|Adolescent Behavior
713589|NCT00000949|CD4 Lymphocyte Count
713590|NCT00000949|RNA, Viral
713591|NCT00000949|Quality of Life
713592|NCT00000949|Anti-HIV Agents
713593|NCT00000949|Viral Load
713594|NCT00000948|Injections, Subcutaneous
713595|NCT00000948|Interleukin-2
713596|NCT00000948|Dose-Response Relationship, Drug
713597|NCT00000948|Drug Therapy, Combination
713598|NCT00000948|CD4 Lymphocyte Count
713599|NCT00000948|Anti-HIV Agents
713600|NCT00000947|AIDS-Related Opportunistic Infections
713601|NCT00000947|Placebos
713602|NCT00000947|Mycobacterium avium-intracellulare Infection
713603|NCT00000947|Acquired Immunodeficiency Syndrome
713604|NCT00000947|Antitubercular Agents
713605|NCT00000947|Azithromycin
713606|NCT00000947|Drug Resistance, Microbial
713607|NCT00000947|CD4 Lymphocyte Count
713608|NCT00000947|Antibiotics
713609|NCT00000947|Time Factors
713610|NCT00000947|Anti-HIV Agents
713611|NCT00000947|Pneumonia, Bacterial
713612|NCT00000947|Streptococcus pneumoniae
713613|NCT00000946|Drug Evaluation
713614|NCT00000946|Drug Therapy, Combination
713615|NCT00000946|AIDS Vaccines
713616|NCT00000946|HIV Seronegativity
713617|NCT00000946|HIV Preventive Vaccine
713618|NCT00000945|Leukoencephalopathy, Progressive Multifocal
713619|NCT00000945|Probenecid
713620|NCT00000945|HIV-1
713621|NCT00000945|Central Nervous System Diseases
713622|NCT00000945|Acquired Immunodeficiency Syndrome
713623|NCT00000945|DNA, Viral
713624|NCT00000945|cidofovir
713625|NCT00000945|Anti-HIV Agents
713626|NCT00000945|Neurologic Examination
713627|NCT00000945|Renal Agents
713628|NCT00000944|Pregnancy
713629|NCT00000944|Pregnancy Complications, Infectious
713630|NCT00000944|Drug Therapy, Combination
713631|NCT00000944|Zidovudine
713632|NCT00000944|HIV Protease Inhibitors
713633|NCT00000944|Lamivudine
713634|NCT00000944|Indinavir
713635|NCT00000944|Disease Transmission, Vertical
713636|NCT00000944|Anti-HIV Agents
713637|NCT00000943|Lymphocytes
713638|NCT00000943|Interleukin-2
713639|NCT00000943|Drug Therapy, Combination
713640|NCT00000943|AIDS Vaccines
713641|NCT00000943|CD4 Lymphocyte Count
713642|NCT00000943|Cell Division
713643|NCT00000943|HIV Core Protein p24
713644|NCT00000943|Anti-HIV Agents
713645|NCT00000943|HIV Therapeutic Vaccine
713646|NCT00000942|Placebos
713647|NCT00000942|Pregnancy
713648|NCT00000942|Pregnancy Complications, Infectious
713649|NCT00000942|Nevirapine
713650|NCT00000942|Disease Transmission, Vertical
713651|NCT00000942|Labor
713652|NCT00000942|Anti-HIV Agents
713653|NCT00000941|Drug Interactions
713654|NCT00000941|HIV Protease Inhibitors
713655|NCT00000941|Ritonavir
713656|NCT00000941|HIV Seronegativity
713657|NCT00000941|Saquinavir
713658|NCT00000941|Nelfinavir
713659|NCT00000941|Anticholesteremic Agents
713660|NCT00000940|Drug Therapy, Combination
713661|NCT00000940|Stavudine
713662|NCT00000940|Amprenavir/Ritonavir
713663|NCT00000940|Protease Inhibitors
713664|NCT00000940|Lamivudine
713665|NCT00000940|VX 478
713666|NCT00000940|Reverse Transcriptase Inhibitors
713667|NCT00000940|Anti-HIV Agents
713668|NCT00000940|Viral Load
713669|NCT00000940|Abacavir Sulfate
713670|NCT00000940|Acute Infection
713671|NCT00000940|Treatment Interruption
713672|NCT00000939|Didanosine
713673|NCT00000939|Drug Therapy, Combination
713674|NCT00000939|Stavudine
713675|NCT00000939|HIV Protease Inhibitors
713676|NCT00000939|Hydroxyurea
713677|NCT00000939|RNA, Viral
713678|NCT00000939|Reverse Transcriptase Inhibitors
713679|NCT00000939|Anti-HIV Agents
713680|NCT00000939|Viral Load
713681|NCT00000939|efavirenz
713682|NCT00000933|AIDS-Related Opportunistic Infections
713683|NCT00000933|Mycobacterium avium-intracellulare Infection
713684|NCT00000933|Antibiotics, Macrolide
713685|NCT00000933|Azithromycin
713686|NCT00000933|Drug Administration Schedule
713687|NCT00000933|Drug Resistance, Microbial
713688|NCT00000933|Carrier State
713689|NCT00000933|Streptococcus pneumoniae
713690|NCT00000932|Prospective Studies
713691|NCT00000932|HIV-1
713692|NCT00000932|Drug Therapy, Combination
713693|NCT00000932|Drug Resistance, Microbial
713694|NCT00000932|CD4 Lymphocyte Count
713695|NCT00000932|Disease Progression
713696|NCT00000932|Treatment Outcome
713697|NCT00000932|Genotype
713698|NCT00000932|Anti-HIV Agents
713699|NCT00000932|Viral Load
713700|NCT00000931|Homosexuality, Male
713701|NCT00000931|Risk-Taking
713702|NCT00000931|Behavior Therapy
713703|NCT00000931|HIV Seronegativity
713704|NCT00000930|Sexual Partners
713705|NCT00000930|Drug Resistance, Microbial
713706|NCT00000930|Cohort Studies
713707|NCT00000930|Risk Factors
713708|NCT00000930|Substance Abuse, Intravenous
713709|NCT00000930|Disease Progression
713710|NCT00000930|Homosexuality, Male
713711|NCT00000930|Genotype
713712|NCT00000930|Phenotype
713713|NCT00000929|Sexual Partners
713714|NCT00000929|Homosexuality, Male
713715|NCT00000929|Anti-Infective Agents
713716|NCT00000929|Patient Compliance
713717|NCT00000929|Nonoxynol
713718|NCT00000929|Rectum
713719|NCT00000928|Sexual Partners
713720|NCT00000928|Condoms
713721|NCT00000928|Counseling
713722|NCT00000927|Administration, Topical
713723|NCT00000927|Mucous Membrane
713724|NCT00000927|Anti-Infective Agents
713725|NCT00000927|Cervix Uteri
713726|NCT00000927|Vagina
713727|NCT00000927|Vulva
713728|NCT00000927|Buffers
713729|NCT00000926|Nonoxynol
713730|NCT00000925|Dietary Proteins
713731|NCT00000925|HIV Wasting Syndrome
713732|NCT00000924|Drug Therapy, Combination
713733|NCT00000924|HIV Protease Inhibitors
713734|NCT00000924|Reverse Transcriptase Inhibitors
713735|NCT00000924|Anti-HIV Agents
713736|NCT00000923|Interleukin-2
713737|NCT00000923|Drug Therapy, Combination
713738|NCT00000923|CD4 Lymphocyte Count
713739|NCT00000923|Anti-HIV Agents
713740|NCT00000923|Viral Load
713741|NCT00000922|Drug Therapy, Combination
713742|NCT00000922|HIV Protease Inhibitors
713743|NCT00000922|Reverse Transcriptase Inhibitors
713744|NCT00000922|Anti-HIV Agents
713745|NCT00000922|Treatment Naive
713746|NCT00000921|Drug Therapy, Combination
713747|NCT00000921|Prednisone
713748|NCT00000921|Anti-HIV Agents
713749|NCT00000920|Pregnancy
713750|NCT00000920|Drug Therapy, Combination
713751|NCT00000920|Zidovudine
713752|NCT00000920|Pregnancy Complications
713753|NCT00000920|Ritonavir
713754|NCT00000920|Lamivudine
713755|NCT00000920|Saquinavir
713756|NCT00000920|Anti-HIV Agents
713757|NCT00000919|HIV Protease Inhibitors
713758|NCT00000919|Reverse Transcriptase Inhibitors
713759|NCT00000919|Anti-HIV Agents
713760|NCT00000919|Viral Load
713761|NCT00000918|Drug Therapy, Combination
713762|NCT00000918|HIV Protease Inhibitors
713763|NCT00000918|Reverse Transcriptase Inhibitors
713764|NCT00000918|Salvage Therapy
713765|NCT00000918|Anti-HIV Agents
713766|NCT00000918|Viral Load
713767|NCT00000917|Gene Therapy
713768|NCT00000917|Specimen Handling
713769|NCT00000917|Blood Banks
713770|NCT00000917|Fetal Blood
713771|NCT00000916|Drug Therapy, Combination
713772|NCT00000916|HIV Protease Inhibitors
713773|NCT00000916|Hydroxyurea
713774|NCT00000916|Reverse Transcriptase Inhibitors
713775|NCT00000916|Anti-HIV Agents
713776|NCT00000916|Viral Load
713777|NCT00000915|AIDS Vaccines
713778|NCT00000915|Incidence
713779|NCT00000915|Knowledge, Attitudes, Practice
713780|NCT00000915|Risk-Taking
713781|NCT00000914|Drug Therapy, Combination
713782|NCT00000914|HIV Protease Inhibitors
713783|NCT00000914|Ritonavir
713784|NCT00000914|Indinavir
713785|NCT00000914|Saquinavir
713786|NCT00000914|Reverse Transcriptase Inhibitors
713787|NCT00000914|Viral Load
713788|NCT00000914|Nelfinavir
713789|NCT00000913|Saquinavir
713790|NCT00000913|Reverse Transcriptase Inhibitors
713791|NCT00000913|Anti-HIV Agents
713792|NCT00000913|Viral Load
713793|NCT00000912|Placebos
713794|NCT00000912|Drug Therapy, Combination
713795|NCT00000912|HIV Protease Inhibitors
713796|NCT00000912|VX 478
713797|NCT00000912|Anti-HIV Agents
713798|NCT00000912|Viral Load
713799|NCT00000912|efavirenz
713800|NCT00000911|Semen
713801|NCT00000911|HIV-1
713802|NCT00000911|Immunity, Cellular
713803|NCT00000911|Lymph Nodes
713804|NCT00000911|Viremia
713805|NCT00000911|Antibodies, Viral
713806|NCT00000911|Vagina
713807|NCT00000911|Viral Load
713808|NCT00000911|Acute Infection
713809|NCT00000910|Pregnancy
713810|NCT00000910|Anti-HIV Agents
713811|NCT00000909|Interleukin-2
713812|NCT00000909|Dose-Response Relationship, Drug
713813|NCT00000909|CD4 Lymphocyte Count
713814|NCT00000909|RNA, Viral
713815|NCT00000908|AIDS-Related Opportunistic Infections
713816|NCT00000908|Pneumonia, Pneumocystis carinii
713817|NCT00000908|Antiviral Agents
713818|NCT00000908|CD4 Lymphocyte Count
713819|NCT00000908|RNA, Viral
713820|NCT00000907|AIDS-Related Opportunistic Infections
713821|NCT00000907|Mycobacterium avium-intracellulare Infection
713822|NCT00000907|Immunity, Cellular
713823|NCT00000907|Antibiotics, Macrolide
713824|NCT00000907|Mycobacterium avium Complex
713825|NCT00000907|CD4 Lymphocyte Count
713826|NCT00000907|Disease Progression
713827|NCT00000907|Anti-HIV Agents
713828|NCT00000906|Methadone
713829|NCT00000906|HIV-1
713830|NCT00000906|Dose-Response Relationship, Drug
713831|NCT00000906|Drug Interactions
713832|NCT00000906|Drug Therapy, Combination
713833|NCT00000906|Saquinavir
713834|NCT00000906|Adolescent Behavior
713835|NCT00000906|HIV Protease Inhibitors
713836|NCT00000906|Ritonavir
713837|NCT00000906|Narcotics
713838|NCT00000906|Substance-Related Disorders
713839|NCT00000905|Immunity, Cellular
713840|NCT00000905|Disease Progression
713841|NCT00000905|Cytomegalovirus Retinitis
713842|NCT00000905|DNA, Viral
713843|NCT00000905|Prognosis
713844|NCT00000904|Vaccines, Synthetic
713845|NCT00000904|Viral Vaccines
713846|NCT00000904|HIV Antibodies
713847|NCT00000904|HIV Envelope Protein gp160
713848|NCT00000904|AIDS Vaccines
713849|NCT00000904|T-Lymphocytes, Cytotoxic
713850|NCT00000904|HIV Seronegativity
713851|NCT00000904|Antibody Formation
713852|NCT00000904|Risk-Taking
713853|NCT00000904|Avipoxvirus
713854|NCT00000904|Genetic Vectors
713855|NCT00000904|Immunization
713856|NCT00000904|HIV Preventive Vaccine
713857|NCT00000903|Drug Therapy, Combination
713858|NCT00000903|Zidovudine
713859|NCT00000903|HIV Protease Inhibitors
713860|NCT00000903|Lamivudine
713861|NCT00000903|Indinavir
713862|NCT00000903|RNA, Viral
713863|NCT00000903|Reverse Transcriptase Inhibitors
713864|NCT00000903|Nelfinavir
713865|NCT00000903|efavirenz
713866|NCT00000902|Zalcitabine
713867|NCT00000902|Didanosine
713868|NCT00000902|Drug Therapy, Combination
713869|NCT00000902|Zidovudine
713870|NCT00000902|Nevirapine
713871|NCT00000902|Stavudine
713872|NCT00000902|Ritonavir
713873|NCT00000902|Lamivudine
713874|NCT00000902|RNA, Viral
713875|NCT00000902|Anti-HIV Agents
713876|NCT00000902|Nelfinavir
713877|NCT00000901|Dose-Response Relationship, Drug
713878|NCT00000901|Drug Therapy, Combination
713879|NCT00000901|Stavudine
713880|NCT00000901|HIV Protease Inhibitors
713881|NCT00000901|Lamivudine
713882|NCT00000901|Indinavir
713883|NCT00000901|RNA, Viral
713884|NCT00000901|Reverse Transcriptase Inhibitors
713885|NCT00000901|Viral Load
713886|NCT00000900|AIDS-Related Opportunistic Infections
713887|NCT00000900|HIV-1
713888|NCT00000900|Antiviral Agents
713889|NCT00000900|CD4 Lymphocyte Count
713890|NCT00000900|Polymerase Chain Reaction
713891|NCT00000900|RNA, Viral
713892|NCT00000900|Fever
713893|NCT00000900|Viral Load
713894|NCT00000899|Cyclophosphamide
713895|NCT00000899|Dose-Response Relationship, Drug
713896|NCT00000899|Drug Therapy, Combination
713897|NCT00000899|Granulocyte Colony-Stimulating Factor
713898|NCT00000899|Combined Modality Therapy
713899|NCT00000899|Antineoplastic Agents
713900|NCT00000899|Lymph Nodes
713901|NCT00000899|Stavudine
713902|NCT00000899|HIV Protease Inhibitors
713903|NCT00000899|Lamivudine
713904|NCT00000899|DNA, Viral
713905|NCT00000899|RNA, Viral
713906|NCT00000899|Reverse Transcriptase Inhibitors
713907|NCT00000899|Anti-HIV Agents
713908|NCT00000899|Nelfinavir
713909|NCT00000899|Antineoplastic Agents, Alkylating
713910|NCT00000898|Drug Interactions
713911|NCT00000898|Drug Therapy, Combination
713912|NCT00000898|Saquinavir
713913|NCT00000898|HIV Protease Inhibitors
713914|NCT00000898|Ritonavir
713915|NCT00000898|Nelfinavir
713916|NCT00000897|Drug Interactions
713917|NCT00000897|Zidovudine
713918|NCT00000897|Sex Factors
713919|NCT00000897|Reverse Transcriptase Inhibitors
713920|NCT00000897|Contraceptives, Oral
713921|NCT00000897|Progestational Hormones, Synthetic
713922|NCT00000897|Anti-HIV Agents
713923|NCT00000897|Viral Load
713924|NCT00000897|Estrogens
713925|NCT00000896|HIV-1
713926|NCT00000896|Drug Therapy, Combination
713927|NCT00000896|Granulocyte Colony-Stimulating Factor
713928|NCT00000896|Acquired Immunodeficiency Syndrome
713929|NCT00000896|Zidovudine
713930|NCT00000896|Nevirapine
713931|NCT00000896|Stavudine
713932|NCT00000896|HIV Protease Inhibitors
713933|NCT00000896|Lamivudine
713934|NCT00000896|Indinavir
713935|NCT00000896|Interleukin-12
713936|NCT00000896|Reverse Transcriptase Inhibitors
713937|NCT00000895|AIDS-Related Opportunistic Infections
713938|NCT00000895|Mycobacterium avium-intracellulare Infection
713939|NCT00000895|HIV-1
713940|NCT00000895|Drug Therapy, Combination
713941|NCT00000895|Acquired Immunodeficiency Syndrome
713942|NCT00000895|Mycobacterium avium Complex
713943|NCT00000895|Bacteremia
713944|NCT00000895|Nevirapine
713945|NCT00000895|HIV Protease Inhibitors
713946|NCT00000895|Risk Factors
713947|NCT00000895|RNA, Viral
713948|NCT00000895|Reverse Transcriptase Inhibitors
713949|NCT00000895|Nelfinavir
713950|NCT00000894|Infusions, Intravenous
713951|NCT00000894|Ganciclovir
713952|NCT00000894|Drug Therapy, Combination
713953|NCT00000894|Administration, Oral
713954|NCT00000894|Antiviral Agents
713955|NCT00000894|Drug Implants
713956|NCT00000894|Cytomegalovirus Retinitis
713957|NCT00000894|Eye
713958|NCT00000894|cidofovir
713959|NCT00000893|Dose-Response Relationship, Drug
713960|NCT00000893|Drug Therapy, Combination
713961|NCT00000893|HIV Protease Inhibitors
713962|NCT00000893|Nelfinavir
713963|NCT00000893|Reverse Transcriptase Inhibitors
713964|NCT00000893|Area Under Curve
713965|NCT00000893|efavirenz
713966|NCT00000892|HIV-1
713967|NCT00000892|Drug Therapy, Combination
713968|NCT00000892|HIV Protease Inhibitors
713969|NCT00000892|Ritonavir
713970|NCT00000892|Indinavir
713971|NCT00000892|RNA, Viral
713972|NCT00000892|Saquinavir
713973|NCT00000892|Delavirdine
713974|NCT00000892|Nelfinavir
713975|NCT00000892|Adenine
713976|NCT00000892|Anti-HIV Agents
713977|NCT00000892|Viral Load
713978|NCT00000891|Drug Therapy, Combination
713979|NCT00000891|Hypersensitivity, Delayed
713980|NCT00000891|Follow-Up Studies
713981|NCT00000891|Anti-HIV Agents
713982|NCT00000891|Viral Load
713983|NCT00000890|HIV-1
713984|NCT00000890|Muscles
713985|NCT00000890|RNA, Viral
713986|NCT00000890|Body Composition
713987|NCT00000890|Anti-HIV Agents
713988|NCT00000890|Viral Load
713989|NCT00000889|Interleukin-2
713990|NCT00000889|CD4 Lymphocyte Count
713991|NCT00000889|Anti-HIV Agents
713992|NCT00000888|Pregnancy
713993|NCT00000888|Pregnancy Complications, Infectious
713994|NCT00000888|Drug Therapy, Combination
713995|NCT00000888|Administration, Oral
713996|NCT00000888|Zidovudine
713997|NCT00000888|HIV Protease Inhibitors
713998|NCT00000888|Ritonavir
713999|NCT00000888|Disease Transmission, Vertical
714000|NCT00000888|Anti-HIV Agents
714001|NCT00000888|Fetal Blood
714002|NCT00000887|Pregnancy
714003|NCT00000887|Pregnancy Complications, Infectious
714004|NCT00000887|Drug Therapy, Combination
714005|NCT00000887|Zidovudine
714006|NCT00000887|HIV Protease Inhibitors
714007|NCT00000887|Lamivudine
714008|NCT00000887|Disease Transmission, Vertical
714009|NCT00000887|Nelfinavir
714010|NCT00000887|Anti-HIV Agents
714011|NCT00000886|HIV Antibodies
714012|NCT00000886|HIV Envelope Protein gp120
714013|NCT00000886|Drug Carriers
714014|NCT00000886|Hypersensitivity, Delayed
714015|NCT00000886|AIDS Vaccines
714016|NCT00000886|CD4-Positive T-Lymphocytes
714017|NCT00000886|CD8-Positive T-Lymphocytes
714018|NCT00000886|HIV Seronegativity
714019|NCT00000886|Neutralization Tests
714020|NCT00000886|Mineral Oil
714021|NCT00000886|Oleic Acids
714022|NCT00000886|Mannose
714023|NCT00000886|HLA-B7 Antigen
714024|NCT00000886|HLA-A2 Antigen
714025|NCT00000886|HIV Preventive Vaccine
714026|NCT00000885|HIV-1
714027|NCT00000885|Drug Therapy, Combination
714028|NCT00000885|Zidovudine
714029|NCT00000885|HIV Protease Inhibitors
714030|NCT00000885|Lamivudine
714031|NCT00000885|Indinavir
714032|NCT00000885|RNA, Viral
714033|NCT00000885|Treatment Failure
714034|NCT00000885|Reverse Transcriptase Inhibitors
714035|NCT00000885|Anti-HIV Agents
714036|NCT00000885|Viral Load
714037|NCT00000884|Vaccines, Synthetic
714038|NCT00000884|Injections, Intramuscular
714039|NCT00000884|HIV-1
714040|NCT00000884|Immunity, Cellular
714041|NCT00000884|AIDS Vaccines
714042|NCT00000884|HIV Seronegativity
714043|NCT00000884|Mucous Membrane
714044|NCT00000884|Antibodies, Viral
714045|NCT00000884|Avipoxvirus
714046|NCT00000884|Genetic Vectors
714047|NCT00000884|HIV Envelope Protein gp120
714048|NCT00000884|Immunity, Mucosal
714049|NCT00000884|Rabies Vaccines
714050|NCT00000884|HIV Preventive Vaccine
714051|NCT00000883|AIDS-Related Opportunistic Infections
714052|NCT00000883|Mycobacterium avium-intracellulare Infection
714053|NCT00000883|Antibiotics, Macrolide
714054|NCT00000883|Acquired Immunodeficiency Syndrome
714055|NCT00000883|Azithromycin
714056|NCT00000883|CD4 Lymphocyte Count
714057|NCT00000883|Anti-HIV Agents
714058|NCT00000882|HIV-1
714059|NCT00000882|Drug Therapy, Combination
714060|NCT00000882|Stavudine
714061|NCT00000882|HIV Protease Inhibitors
714062|NCT00000882|Lamivudine
714063|NCT00000882|Indinavir
714064|NCT00000882|RNA, Viral
714065|NCT00000882|Delavirdine
714066|NCT00000882|Reverse Transcriptase Inhibitors
714067|NCT00000882|Anti-HIV Agents
714068|NCT00000882|Viral Load
714069|NCT00000881|AIDS-Related Opportunistic Infections
714070|NCT00000881|Cytomegalovirus Infections
714071|NCT00000881|Antiviral Agents
714072|NCT00000881|cidofovir
714073|NCT00000880|T-Lymphocytes
714074|NCT00000880|Lymphocyte Transformation
714075|NCT00000880|HIV-1
714076|NCT00000880|Drug Therapy, Combination
714077|NCT00000880|Immunosuppressive Agents
714078|NCT00000880|Apoptosis
714079|NCT00000880|Cyclosporine
714080|NCT00000880|Anti-HIV Agents
714081|NCT00000879|Pregnancy
714082|NCT00000879|Pregnancy Complications, Infectious
714083|NCT00000879|AIDS Vaccines
714084|NCT00000879|Disease Transmission, Vertical
714085|NCT00000879|Avipoxvirus
714086|NCT00000879|HIV Preventive Vaccine
714087|NCT00000879|HIV Therapeutic Vaccine
714088|NCT00000878|Pregnancy
714089|NCT00000878|Pregnancy Complications, Infectious
714090|NCT00000878|Drug Therapy, Combination
714091|NCT00000878|Stavudine
714092|NCT00000878|Lamivudine
714093|NCT00000878|Disease Transmission, Vertical
714094|NCT00000878|Reverse Transcriptase Inhibitors
714095|NCT00000878|Anti-HIV Agents
714096|NCT00000878|Viral Load
714097|NCT00000877|Rifabutin
714098|NCT00000877|Drug Therapy, Combination
714099|NCT00000877|HIV Protease Inhibitors
714100|NCT00000877|Indinavir
714101|NCT00000877|HIV Seronegativity
714102|NCT00000877|Anti-HIV Agents
714103|NCT00000876|Antiviral Agents
714104|NCT00000876|CD4-IgG(2)
714105|NCT00000876|PRO 542
714106|NCT00000875|Drug Therapy, Combination
714107|NCT00000875|Immunotherapy, Adoptive
714108|NCT00000875|T-Lymphocytes, Cytotoxic
714109|NCT00000875|Anti-HIV Agents
714110|NCT00000875|Viral Load
714111|NCT00000874|HIV-1
714112|NCT00000874|Drug Therapy, Combination
714113|NCT00000874|Zidovudine
714114|NCT00000874|Stavudine
714115|NCT00000874|Drug Resistance, Microbial
714116|NCT00000874|HIV Protease Inhibitors
714117|NCT00000874|CD4 Lymphocyte Count
714118|NCT00000874|Ritonavir
714119|NCT00000874|Lamivudine
714120|NCT00000874|Indinavir
714121|NCT00000874|RNA, Viral
714122|NCT00000874|Genotype
714123|NCT00000874|Reverse Transcriptase Inhibitors
714124|NCT00000874|Anti-HIV Agents
714125|NCT00000874|Viral Load
714126|NCT00000873|Nutritional Status
714127|NCT00000873|HIV Seronegativity
714128|NCT00000873|Infant Food
714129|NCT00000872|Virus Replication
714130|NCT00000872|HIV-1
714131|NCT00000872|Drug Therapy, Combination
714132|NCT00000872|Zidovudine
714133|NCT00000872|Nevirapine
714134|NCT00000872|Stavudine
714135|NCT00000872|HIV Protease Inhibitors
714136|NCT00000872|CD4 Lymphocyte Count
714137|NCT00000872|Lamivudine
714138|NCT00000872|RNA, Viral
714139|NCT00000872|Reverse Transcriptase Inhibitors
714140|NCT00000872|Anti-HIV Agents
714141|NCT00000872|Viral Load
714142|NCT00000872|Nelfinavir
714143|NCT00000871|Vaccines, Synthetic
714144|NCT00000871|AIDS Vaccines
714145|NCT00000871|HIV Seronegativity
714146|NCT00000871|Avipoxvirus
714147|NCT00000871|HIV Preventive Vaccine
714148|NCT00000870|Recombinant Proteins
714149|NCT00000870|Infusions, Intravenous
714150|NCT00000870|Injections, Intravenous
714151|NCT00000870|Injections, Subcutaneous
714152|NCT00000870|Interleukin-2
714153|NCT00000870|Drug Administration Schedule
714154|NCT00000870|CD4 Lymphocyte Count
714155|NCT00000870|Quality of Life
714156|NCT00000870|Anti-HIV Agents
714157|NCT00000869|Pregnancy Trimester, Third
714158|NCT00000869|Placebos
714159|NCT00000869|Pregnancy
714160|NCT00000869|Pregnancy Complications, Infectious
714161|NCT00000869|Administration, Oral
714162|NCT00000869|Nevirapine
714163|NCT00000869|Disease Transmission, Vertical
714164|NCT00000869|Reverse Transcriptase Inhibitors
714165|NCT00000869|Anti-HIV Agents
714166|NCT00000868|Vaccines, Synthetic
714167|NCT00000868|HIV-1
714168|NCT00000868|Administration, Oral
714169|NCT00000868|AIDS Vaccines
714170|NCT00000868|HIV Seronegativity
714171|NCT00000868|HIV Envelope Protein gp120
714172|NCT00000868|Recombination, Genetic
714173|NCT00000868|Salmonella typhi
714174|NCT00000868|HIV Preventive Vaccine
714175|NCT00000867|Drug Therapy, Combination
714176|NCT00000867|Administration, Oral
714177|NCT00000867|AIDS Dementia Complex
714178|NCT00000867|Zidovudine
714179|NCT00000867|Anti-HIV Agents
714180|NCT00000867|Memantine
714181|NCT00000866|Vaccines, Synthetic
714182|NCT00000866|Vaccinia Virus
714183|NCT00000866|Placebos
714184|NCT00000866|HIV-1
714185|NCT00000866|AIDS Vaccines
714186|NCT00000866|HIV Seronegativity
714187|NCT00000866|Genes, env
714188|NCT00000866|Genes, pol
714189|NCT00000866|Genes, gag
714190|NCT00000866|HIV Preventive Vaccine
714191|NCT00000865|Drug Therapy, Combination
714192|NCT00000865|Reverse Transcriptase Inhibitors
714193|NCT00000865|Anti-HIV Agents
714194|NCT00000864|Pregnancy
714195|NCT00000864|Pregnancy Complications, Infectious
714196|NCT00000864|HIV-1
714197|NCT00000864|Drug Therapy, Combination
714198|NCT00000864|Zidovudine
714199|NCT00000864|Drug Administration Schedule
714200|NCT00000864|Disease Transmission, Vertical
714201|NCT00000864|Reverse Transcriptase Inhibitors
714202|NCT00000864|Anti-HIV Agents
714203|NCT00000863|AIDS-Related Opportunistic Infections
714204|NCT00000863|Pneumonia, Pneumocystis carinii
714205|NCT00000863|Administration, Oral
714206|NCT00000863|WR 6026
714207|NCT00000862|Pregnancy
714208|NCT00000862|Pregnancy Complications, Infectious
714209|NCT00000862|Administration, Oral
714210|NCT00000862|Zidovudine
714211|NCT00000862|Delivery
714212|NCT00000862|Labor
714213|NCT00000862|Anti-HIV Agents
714214|NCT00000861|Drug Administration Schedule
714215|NCT00000861|HIV Protease Inhibitors
714216|NCT00000861|CD4 Lymphocyte Count
714217|NCT00000861|Indinavir
714218|NCT00000861|RNA, Viral
714219|NCT00000861|Anti-HIV Agents
714220|NCT00000861|Viral Load
714221|NCT00000860|Tumor Necrosis Factor
714222|NCT00000860|AIDS-Related Opportunistic Infections
714223|NCT00000860|Mycobacterium avium-intracellulare Infection
714224|NCT00000860|Drug Therapy, Combination
714225|NCT00000860|Anti-HIV Agents
714226|NCT00000859|HIV-1
714227|NCT00000859|Drug Resistance
714228|NCT00000859|Drug Therapy, Combination
714229|NCT00000859|HIV Protease Inhibitors
714230|NCT00000859|CD4 Lymphocyte Count
714231|NCT00000859|Ritonavir
714232|NCT00000859|Indinavir
714233|NCT00000859|Disease Progression
714234|NCT00000859|RNA, Viral
714235|NCT00000859|Genotype
714236|NCT00000859|Nelfinavir
714237|NCT00000859|Anti-HIV Agents
714238|NCT00000859|Viral Load
714239|NCT00000858|HIV-1
714240|NCT00000858|Vagina
714241|NCT00000857|Recombinant Proteins
714242|NCT00000857|T-Lymphocytes
714243|NCT00000857|Dose-Response Relationship, Drug
714244|NCT00000857|Mycobacterium avium Complex
714245|NCT00000857|CD4 Lymphocyte Count
714246|NCT00000857|Interleukin-12
714247|NCT00000857|Killer Cells, Natural
714248|NCT00000857|Th1 Cells
714249|NCT00000857|Interferon Type II
714250|NCT00000856|AIDS-Related Opportunistic Infections
714251|NCT00000856|Ganciclovir
714252|NCT00000856|Drug Therapy, Combination
714253|NCT00000856|Encephalitis
714254|NCT00000856|Foscarnet
714255|NCT00000856|Cytomegalovirus Infections
714256|NCT00000856|Antiviral Agents
714257|NCT00000856|Radiculopathy
714258|NCT00000855|Zidovudine
714259|NCT00000855|Anti-HIV Agents
714260|NCT00000854|Placebos
714261|NCT00000854|Acquired Immunodeficiency Syndrome
714262|NCT00000854|AIDS-Related Complex
714263|NCT00000854|Anabolic Steroids
714264|NCT00000854|HIV Wasting Syndrome
714265|NCT00000854|nandrolone decanoate
714266|NCT00000853|Vaccines, Synthetic
714267|NCT00000853|HIV-1
714268|NCT00000853|HIV Envelope Protein gp120
714269|NCT00000853|AIDS Vaccines
714270|NCT00000853|HIV Seronegativity
714271|NCT00000853|HIV Preventive Vaccine
714272|NCT00000852|T-Lymphocytes
714273|NCT00000852|Acquired Immunodeficiency Syndrome
714274|NCT00000852|Transplantation, Homologous
714275|NCT00000852|Immunotherapy, Adoptive
714276|NCT00000851|Didanosine
714277|NCT00000851|Drug Therapy, Combination
714278|NCT00000851|Antiviral Agents
714279|NCT00000851|Stavudine
714280|NCT00000850|HIV-1
714281|NCT00000850|Granulocyte-Macrophage Colony-Stimulating Factor
714282|NCT00000850|RNA, Viral
714283|NCT00000850|Anti-HIV Agents
714284|NCT00000850|Viral Load
714285|NCT00000850|Receptors, Chemokine
714286|NCT00000849|Interleukin-2
714287|NCT00000849|Immunity, Cellular
714288|NCT00000849|Dose-Response Relationship, Drug
714289|NCT00000849|Acquired Immunodeficiency Syndrome
714290|NCT00000849|AIDS-Related Complex
714291|NCT00000849|Viral Load
714292|NCT00000848|Administration, Oral
714293|NCT00000848|Acquired Immunodeficiency Syndrome
714294|NCT00000848|AIDS-Related Complex
714295|NCT00000848|Antiviral Agents
714296|NCT00000848|HIV Protease Inhibitors
714297|NCT00000848|Biological Markers
714298|NCT00000848|Indinavir
714299|NCT00000848|Viremia
714300|NCT00000848|RNA, Viral
714301|NCT00000848|Saquinavir
714302|NCT00000847|Vaccines, Synthetic
714303|NCT00000847|HIV Envelope Protein gp120
714304|NCT00000847|AIDS Vaccines
714305|NCT00000847|HIV Seronegativity
714306|NCT00000847|Avipoxvirus
714307|NCT00000847|HIV Preventive Vaccine
714308|NCT00000846|Vaccines, Synthetic
714309|NCT00000846|HIV-1
714310|NCT00000846|AIDS Vaccines
714311|NCT00000846|HIV Seronegativity
714312|NCT00000846|HIV Preventive Vaccine
714313|NCT00000845|Vaccines, Synthetic
714314|NCT00000845|AIDS Vaccines
714315|NCT00000845|HIV Seronegativity
714316|NCT00000845|HIV Preventive Vaccine
714317|NCT00000844|Drug Therapy, Combination
714318|NCT00000844|Adjuvants, Immunologic
714319|NCT00000844|Administration, Oral
714320|NCT00000844|Acquired Immunodeficiency Syndrome
714321|NCT00000844|AIDS-Related Complex
714322|NCT00000844|Interferon-alpha
714323|NCT00000843|Antiviral Agents
714324|NCT00000843|Adenine
714325|NCT00000842|Acquired Immunodeficiency Syndrome
714326|NCT00000842|AIDS-Related Complex
714327|NCT00000842|Peripheral Nervous System Diseases
714328|NCT00000842|Nerve Growth Factors
714329|NCT00000842|Growth Substances
714330|NCT00000841|Drug Therapy, Combination
714331|NCT00000841|Acquired Immunodeficiency Syndrome
714332|NCT00000841|Antiviral Agents
714333|NCT00000841|Zidovudine
714334|NCT00000841|Stavudine
714335|NCT00000841|HIV Protease Inhibitors
714336|NCT00000841|Lamivudine
714337|NCT00000841|Indinavir
714338|NCT00000840|Acquired Immunodeficiency Syndrome
714339|NCT00000840|AIDS-Related Complex
714340|NCT00000840|Antiviral Agents
714341|NCT00000840|Zidovudine
714342|NCT00000840|Biological Markers
714343|NCT00000840|Viremia
714344|NCT00000840|RNA, Viral
714345|NCT00000839|Pregnancy Trimester, Third
714346|NCT00000839|Pregnancy
714347|NCT00000839|Pregnancy Complications, Infectious
714348|NCT00000839|Didanosine
714349|NCT00000839|Acquired Immunodeficiency Syndrome
714350|NCT00000839|AIDS-Related Complex
714351|NCT00000838|Didanosine
714352|NCT00000838|Drug Therapy, Combination
714353|NCT00000838|Acquired Immunodeficiency Syndrome
714354|NCT00000838|AIDS-Related Complex
714355|NCT00000838|Antiviral Agents
714356|NCT00000838|Zidovudine
714357|NCT00000838|Stavudine
714358|NCT00000838|Lamivudine
714359|NCT00000837|Herpesvirus 3, Human
714360|NCT00000837|Viral Vaccines
714361|NCT00000837|AIDS-Related Complex
714362|NCT00000837|Vaccines, Attenuated
714363|NCT00000837|Chickenpox
714364|NCT00000837|Chickenpox Vaccine
714365|NCT00000836|AIDS-Related Opportunistic Infections
714366|NCT00000836|Acquired Immunodeficiency Syndrome
714367|NCT00000836|Antibodies, Monoclonal
714368|NCT00000836|Cytomegalovirus Retinitis
714369|NCT00000834|Methotrexate
714370|NCT00000834|Acquired Immunodeficiency Syndrome
714371|NCT00000834|AIDS-Related Complex
714372|NCT00000834|Zidovudine
714373|NCT00000834|Lamivudine
714374|NCT00000834|Disease Progression
714375|NCT00000834|Anti-Inflammatory Agents
714376|NCT00000834|Anti-HIV Agents
714377|NCT00000833|Ribavirin
714378|NCT00000833|Didanosine
714379|NCT00000833|Drug Therapy, Combination
714380|NCT00000833|Acquired Immunodeficiency Syndrome
714381|NCT00000833|AIDS-Related Complex
714382|NCT00000833|Antiviral Agents
714383|NCT00000832|Vaccines, Synthetic
714384|NCT00000832|HIV-1
714385|NCT00000832|Adjuvants, Immunologic
714386|NCT00000832|HIV Envelope Protein gp120
714387|NCT00000832|AIDS Vaccines
714388|NCT00000832|HIV Seronegativity
714389|NCT00000832|HIV Preventive Vaccine
714390|NCT00000831|Didanosine
714391|NCT00000831|Drug Therapy, Combination
714392|NCT00000831|AIDS-Related Complex
714393|NCT00000831|Antiviral Agents
714394|NCT00000831|Zidovudine
714395|NCT00000831|Stavudine
714396|NCT00000831|Lamivudine
714397|NCT00000831|Drug Combinations
714398|NCT00000829|Vaccines, Synthetic
714399|NCT00000829|Acquired Immunodeficiency Syndrome
714400|NCT00000829|AIDS-Related Complex
714401|NCT00000829|Pneumococcal Infections
714402|NCT00000829|Bacterial Vaccines
714403|NCT00000828|Pregnancy
714404|NCT00000828|Pregnancy Complications, Infectious
714405|NCT00000828|Acquired Immunodeficiency Syndrome
714406|NCT00000828|AIDS-Related Complex
714407|NCT00000828|Zidovudine
714408|NCT00000828|Drug Resistance, Microbial
714409|NCT00000828|Disease Transmission, Vertical
714410|NCT00000827|Acquired Immunodeficiency Syndrome
714411|NCT00000827|AIDS-Related Complex
714412|NCT00000827|Immunoglobulins, Intravenous
714413|NCT00000827|Immunization, Passive
714414|NCT00000826|Rifabutin
714415|NCT00000826|Trimethoprim-Sulfamethoxazole Combination
714416|NCT00000826|AIDS-Related Opportunistic Infections
714417|NCT00000826|Dapsone
714418|NCT00000826|Drug Interactions
714419|NCT00000826|Fluconazole
714420|NCT00000826|Acquired Immunodeficiency Syndrome
714421|NCT00000826|AIDS-Related Complex
714422|NCT00000826|Clarithromycin
714423|NCT00000826|Sulfamethoxazole-Trimethoprim
714424|NCT00000825|HIV-1
714425|NCT00000825|Interleukin-2
714426|NCT00000825|Dose-Response Relationship, Drug
714427|NCT00000825|Antiviral Agents
714428|NCT00000825|CD4 Lymphocyte Count
714429|NCT00000825|DNA, Viral
714430|NCT00000824|Immunotherapy, Adoptive
714431|NCT00000824|T-Lymphocyte Subsets
714432|NCT00000824|T-Lymphocytes, Cytotoxic
714433|NCT00000824|Dendritic Cells
714434|NCT00000823|Didanosine
714435|NCT00000823|Drug Therapy, Combination
714436|NCT00000823|Zidovudine
714437|NCT00000823|Drug Administration Schedule
714438|NCT00000822|Vaccines, Synthetic
714439|NCT00000822|Didanosine
714440|NCT00000822|Drug Therapy, Combination
714441|NCT00000822|HIV Envelope Protein gp160
714442|NCT00000822|Acquired Immunodeficiency Syndrome
714443|NCT00000822|AIDS-Related Complex
714444|NCT00000822|Stavudine
714445|NCT00000822|HIV Protease Inhibitors
714446|NCT00000822|AIDS Vaccines
714447|NCT00000822|Ritonavir
714448|NCT00000822|Reverse Transcriptase Inhibitors
714449|NCT00000822|HIV Therapeutic Vaccine
714450|NCT00000821|Interleukin-2
714451|NCT00000821|AIDS-Related Complex
714452|NCT00000820|Interleukin-2
714453|NCT00000820|Drug Therapy, Combination
714454|NCT00000820|AIDS-Related Complex
714455|NCT00000820|Antiviral Agents
714456|NCT00000819|AIDS-Related Complex
714457|NCT00000819|Prednisone
714458|NCT00000819|AIDS-Associated Nephropathy
714459|NCT00000818|Acquired Immunodeficiency Syndrome
714460|NCT00000818|AIDS-Related Complex
714461|NCT00000818|Zidovudine
714462|NCT00000818|Lymph Nodes
714463|NCT00000818|Lymphoid Tissue
714464|NCT00000817|Acquired Immunodeficiency Syndrome
714465|NCT00000817|AIDS-Related Complex
714466|NCT00000817|Peripheral Nervous System Diseases
714467|NCT00000817|Amitriptyline
714468|NCT00000817|Pain
714469|NCT00000817|Acupuncture Therapy
714470|NCT00000816|Trimethoprim-Sulfamethoxazole Combination
714471|NCT00000816|Pneumonia, Pneumocystis carinii
714472|NCT00000816|Acquired Immunodeficiency Syndrome
714473|NCT00000816|AIDS-Related Complex
714474|NCT00000816|Sulfamethoxazole-Trimethoprim
714475|NCT00000815|Acquired Immunodeficiency Syndrome
714476|NCT00000815|AIDS-Related Complex
714477|NCT00000815|Measles-Mumps-Rubella Vaccine
714478|NCT00000815|Vaccines, Attenuated
714479|NCT00000815|Measles Vaccine
714480|NCT00000815|Immunization Schedule
714481|NCT00000815|Measles Virus
714482|NCT00000815|Measles
714483|NCT00000814|Didanosine
714484|NCT00000814|Drug Therapy, Combination
714485|NCT00000814|Acquired Immunodeficiency Syndrome
714486|NCT00000814|AIDS-Related Complex
714487|NCT00000814|Zidovudine
714488|NCT00000814|Nevirapine
714489|NCT00000813|Vaccines, Synthetic
714490|NCT00000813|HIV Envelope Protein gp160
714491|NCT00000813|HIV Envelope Protein gp120
714492|NCT00000813|AIDS Vaccines
714493|NCT00000813|HIV Seronegativity
714494|NCT00000813|Avipoxvirus
714495|NCT00000813|HIV Preventive Vaccine
714496|NCT00000812|Acquired Immunodeficiency Syndrome
714497|NCT00000812|AIDS-Related Complex
714498|NCT00000812|Thalidomide
714499|NCT00000811|Trimethoprim-Sulfamethoxazole Combination
714500|NCT00000811|Pneumonia, Pneumocystis carinii
714501|NCT00000811|Drug Therapy, Combination
714502|NCT00000811|Acquired Immunodeficiency Syndrome
714503|NCT00000811|Antiprotozoal Agents
714504|NCT00000811|AIDS-Related Complex
714505|NCT00000811|Azithromycin
714506|NCT00000811|Bacterial Infections
714507|NCT00000811|atovaquone
714508|NCT00000810|Didanosine
714509|NCT00000810|Acquired Immunodeficiency Syndrome
714510|NCT00000810|AIDS-Related Complex
714511|NCT00000810|Antiviral Agents
714512|NCT00000810|Zidovudine
714513|NCT00000809|HIV Preventive Vaccine
714514|NCT00000809|HIV Therapeutic Vaccine
714515|NCT00000808|Pregnancy
714516|NCT00000808|Pregnancy Complications, Infectious
714517|NCT00000808|Acquired Immunodeficiency Syndrome
714518|NCT00000808|AIDS-Related Complex
714519|NCT00000808|Nevirapine
714520|NCT00000807|Sarcoma, Kaposi
714521|NCT00000807|Etoposide
714522|NCT00000807|Acquired Immunodeficiency Syndrome
714523|NCT00000806|Acquired Immunodeficiency Syndrome
714524|NCT00000806|AIDS-Related Complex
714525|NCT00000806|HIV Protease Inhibitors
714526|NCT00000805|Ganciclovir
714527|NCT00000805|Cytomegalovirus Infections
714528|NCT00000805|Acquired Immunodeficiency Syndrome
714529|NCT00000725|Interferon Alfa-2a
714530|NCT00000725|Sarcoma, Kaposi
714531|NCT00000725|Dose-Response Relationship, Drug
714532|NCT00000725|Drug Therapy, Combination
714533|NCT00000725|Acquired Immunodeficiency Syndrome
714534|NCT00000725|Zidovudine
714535|NCT00000725|Interferon Type I
714536|NCT00000724|Trimetrexate
714537|NCT00000724|Pneumonia, Pneumocystis carinii
714538|NCT00000724|Injections, Intravenous
714539|NCT00000724|Leucovorin
714540|NCT00000724|Drug Evaluation
714541|NCT00000724|Drug Therapy, Combination
714542|NCT00000724|Folic Acid Antagonists
714543|NCT00000724|Acquired Immunodeficiency Syndrome
714544|NCT00000724|Antiprotozoal Agents
714545|NCT00000723|AIDS-Related Opportunistic Infections
714546|NCT00000723|Lymphoma
714547|NCT00000723|Methotrexate
714548|NCT00000723|Leucovorin
714549|NCT00000723|Dexamethasone
714550|NCT00000723|Drug Evaluation
714551|NCT00000723|Drug Therapy, Combination
714552|NCT00000723|Combined Modality Therapy
714553|NCT00000723|Acquired Immunodeficiency Syndrome
714554|NCT00000723|Zidovudine
714555|NCT00000723|Brain Neoplasms
714556|NCT00000722|AIDS-Related Opportunistic Infections
714557|NCT00000722|Pneumonia, Pneumocystis carinii
714558|NCT00000722|Pentamidine
714559|NCT00000722|Injections, Intravenous
714560|NCT00000722|Lung
714561|NCT00000722|Administration, Inhalation
714562|NCT00000722|Aerosols
714563|NCT00000722|Acquired Immunodeficiency Syndrome
714564|NCT00000721|Recombinant Proteins
714565|NCT00000721|Infusions, Intravenous
714566|NCT00000721|Injections, Intramuscular
714567|NCT00000721|Injections, Intravenous
714568|NCT00000721|Injections, Subcutaneous
714569|NCT00000721|Dose-Response Relationship, Drug
714570|NCT00000721|Drug Evaluation
714571|NCT00000721|Acquired Immunodeficiency Syndrome
714572|NCT00000721|Antigens, CD4
714573|NCT00000721|AIDS-Related Complex
714574|NCT00000720|AIDS-Related Opportunistic Infections
714575|NCT00000720|Placebos
714576|NCT00000720|Infusions, Intravenous
714577|NCT00000720|Gamma-Globulins
714578|NCT00000720|Combined Modality Therapy
714579|NCT00000720|Acquired Immunodeficiency Syndrome
714580|NCT00000720|Zidovudine
714581|NCT00000720|Bacterial Infections
714582|NCT00000720|Immunization, Passive
714583|NCT00000719|Zalcitabine
714584|NCT00000719|Acquired Immunodeficiency Syndrome
714585|NCT00000719|Zidovudine
714586|NCT00000718|Zalcitabine
714587|NCT00000718|Dose-Response Relationship, Drug
714588|NCT00000718|Acquired Immunodeficiency Syndrome
714589|NCT00000718|AIDS-Related Complex
714590|NCT00000718|Zidovudine
714591|NCT00000717|AIDS-Related Opportunistic Infections
714592|NCT00000717|Pneumonia, Pneumocystis carinii
714593|NCT00000717|Primaquine
714594|NCT00000717|Infusions, Intravenous
714595|NCT00000717|Drug Evaluation
714596|NCT00000717|Drug Therapy, Combination
714597|NCT00000717|Administration, Oral
714598|NCT00000717|Acquired Immunodeficiency Syndrome
714599|NCT00000717|Clindamycin
714600|NCT00000716|Drug Evaluation
714601|NCT00000716|Administration, Oral
714602|NCT00000716|Acquired Immunodeficiency Syndrome
714603|NCT00000716|Zidovudine
714604|NCT00000715|Trimethoprim-Sulfamethoxazole Combination
714605|NCT00000715|AIDS-Related Opportunistic Infections
714606|NCT00000715|Pneumonia, Pneumocystis carinii
714607|NCT00000715|Pentamidine
714608|NCT00000715|Infusions, Intravenous
714609|NCT00000715|Administration, Inhalation
714610|NCT00000715|Aerosols
714611|NCT00000715|Acquired Immunodeficiency Syndrome
714612|NCT00000715|Sulfamethoxazole-Trimethoprim
714613|NCT00000714|Trimetrexate
714614|NCT00000714|AIDS-Related Opportunistic Infections
714615|NCT00000714|Pneumonia, Pneumocystis carinii
714616|NCT00000714|Leucovorin
714617|NCT00000714|Drug Evaluation
714618|NCT00000714|Drug Therapy, Combination
714619|NCT00000714|Acquired Immunodeficiency Syndrome
714620|NCT00000714|Antiprotozoal Agents
714621|NCT00000713|Polyribonucleotides
714622|NCT00000713|HIV Seropositivity
714623|NCT00000713|Dose-Response Relationship, Drug
714624|NCT00000713|Drug Evaluation
714625|NCT00000713|Acquired Immunodeficiency Syndrome
714626|NCT00000713|ampligen
714627|NCT00000713|AIDS-Related Complex
714628|NCT00000713|Antiviral Agents
714629|NCT00000712|AIDS-Related Opportunistic Infections
714630|NCT00000712|Herpesviridae Infections
714631|NCT00000712|Drug Evaluation
714632|NCT00000712|Drug Therapy, Combination
714633|NCT00000712|Herpesvirus 4, Human
714634|NCT00000712|Cytomegalovirus Infections
714635|NCT00000712|Acyclovir
714636|NCT00000712|Acquired Immunodeficiency Syndrome
714637|NCT00000712|Antiviral Agents
714638|NCT00000712|Zidovudine
714639|NCT00000711|Neutropenia
714640|NCT00000711|Drug Evaluation
714641|NCT00000711|Drug Therapy, Combination
714642|NCT00000711|Granulocyte-Macrophage Colony-Stimulating Factor
714643|NCT00000711|Acquired Immunodeficiency Syndrome
714644|NCT00000711|AIDS-Related Complex
714645|NCT00000711|Zidovudine
714646|NCT00000710|Injections, Intravenous
714647|NCT00000710|Didanosine
714648|NCT00000710|Dose-Response Relationship, Drug
714649|NCT00000710|Drug Evaluation
714650|NCT00000710|Acquired Immunodeficiency Syndrome
714651|NCT00000710|AIDS-Related Complex
714652|NCT00000709|Neuropsychological Tests
714653|NCT00000709|AIDS Dementia Complex
714654|NCT00000709|Zidovudine
714655|NCT00000709|CD4-Positive T-Lymphocytes
714656|NCT00000803|Didanosine
714657|NCT00000803|Drug Therapy, Combination
714658|NCT00000803|Acquired Immunodeficiency Syndrome
714659|NCT00000803|AIDS-Related Complex
714660|NCT00000803|Antiviral Agents
714661|NCT00000803|Zidovudine
714662|NCT00000802|Pneumonia, Pneumocystis carinii
714663|NCT00000802|Dapsone
714664|NCT00000802|Antifungal Agents
714665|NCT00000802|Acquired Immunodeficiency Syndrome
714666|NCT00000802|atovaquone
714667|NCT00000801|Vincristine
714668|NCT00000801|Cyclophosphamide
714669|NCT00000801|Cytarabine
714670|NCT00000801|Dexamethasone
714671|NCT00000801|Doxorubicin
714672|NCT00000801|Granulocyte Colony-Stimulating Factor
714673|NCT00000801|Combined Modality Therapy
714674|NCT00000801|Acquired Immunodeficiency Syndrome
714675|NCT00000801|Antineoplastic Agents, Combined
714676|NCT00000801|Brain Neoplasms
714677|NCT00000801|Lymphoma, High-Grade
714678|NCT00000801|Lymphoma, Intermediate-Grade
714679|NCT00000800|Methadone
714680|NCT00000800|Drug Interactions
714681|NCT00000800|Drug Therapy, Combination
714682|NCT00000800|Acquired Immunodeficiency Syndrome
714683|NCT00000800|AIDS-Related Complex
714684|NCT00000800|Zidovudine
714685|NCT00000799|Retinitis
714686|NCT00000799|Cytomegalovirus Infections
714687|NCT00000799|Acquired Immunodeficiency Syndrome
714688|NCT00000799|Antiviral Agents
714689|NCT00000799|cidofovir
714690|NCT00000798|Vaccines, Synthetic
714691|NCT00000798|HIV-1
714692|NCT00000798|Administration, Oral
714693|NCT00000798|AIDS Vaccines
714694|NCT00000798|HIV Seronegativity
714695|NCT00000798|HIV Preventive Vaccine
714696|NCT00000796|Isoniazid
714697|NCT00000796|Tuberculosis, Pulmonary
714698|NCT00000796|Pyrazinamide
714699|NCT00000796|Pyridoxine
714700|NCT00000796|Ofloxacin
714701|NCT00000796|Rifampin
714702|NCT00000796|AIDS-Related Opportunistic Infections
714703|NCT00000796|Drug Therapy, Combination
714704|NCT00000796|Ethambutol
714705|NCT00000796|Clofazimine
714706|NCT00000796|Acquired Immunodeficiency Syndrome
714707|NCT00000796|Amikacin
714708|NCT00000796|Drug Resistance, Microbial
714709|NCT00000796|Cycloserine
714710|NCT00000796|Capreomycin Sulfate
714711|NCT00000796|Ethionamide
714712|NCT00000796|Aminosalicylic Acids
714713|NCT00000796|Streptomycin
714714|NCT00000796|p-Aminosalicylic Acid
714715|NCT00000795|Vaccines, Synthetic
714716|NCT00000795|HIV-1
714717|NCT00000795|AIDS Vaccines
714718|NCT00000795|HIV Seronegativity
714719|NCT00000795|HIV Preventive Vaccine
714720|NCT00000794|Pyrimethamine
714721|NCT00000794|Leucovorin
714722|NCT00000794|Drug Therapy, Combination
714723|NCT00000794|Encephalitis
714724|NCT00000794|Acquired Immunodeficiency Syndrome
714725|NCT00000794|Antiprotozoal Agents
714726|NCT00000794|Clarithromycin
714727|NCT00000794|atovaquone
714728|NCT00000794|Toxoplasmosis, Cerebral
714729|NCT00000794|Sulfadiazine
714730|NCT00000793|Acquired Immunodeficiency Syndrome
714731|NCT00000793|AIDS-Related Complex
714732|NCT00000793|Peripheral Nervous System Diseases
714733|NCT00000793|Amitriptyline
714734|NCT00000793|Pain
714735|NCT00000793|Mexiletine
714736|NCT00000793|benzatropine methanesulfonate
714737|NCT00000793|Parasympatholytics
714738|NCT00000792|Administration, Oral
714739|NCT00000792|Acquired Immunodeficiency Syndrome
714740|NCT00000792|AIDS-Related Complex
714741|NCT00000792|Antiviral Agents
714742|NCT00000791|Drug Therapy, Combination
714743|NCT00000791|Acquired Immunodeficiency Syndrome
714744|NCT00000791|AIDS-Related Complex
714745|NCT00000791|Antiviral Agents
714746|NCT00000791|Zidovudine
714747|NCT00000790|Acquired Immunodeficiency Syndrome
714748|NCT00000790|AIDS-Related Complex
714749|NCT00000790|Thalidomide
714750|NCT00000790|Stomatitis, Aphthous
714751|NCT00000789|Acquired Immunodeficiency Syndrome
714752|NCT00000789|AIDS-Related Complex
714753|NCT00000789|Zidovudine
714754|NCT00000789|Stavudine
714755|NCT00000788|Methadone
714756|NCT00000788|Drug Interactions
714757|NCT00000788|Drug Therapy, Combination
714758|NCT00000788|Fluconazole
714759|NCT00000788|Antifungal Agents
714760|NCT00000788|Acquired Immunodeficiency Syndrome
714761|NCT00000788|AIDS-Related Complex
714762|NCT00000787|Sex Behavior
714763|NCT00000785|Tuberculosis
714764|NCT00000785|Mycobacterium tuberculosis
714765|NCT00000785|AIDS-Related Opportunistic Infections
714766|NCT00000785|Acquired Immunodeficiency Syndrome
714767|NCT00000785|Drug Resistance, Microbial
714768|NCT00000784|Acquired Immunodeficiency Syndrome
714769|NCT00000784|AIDS-Related Complex
714770|NCT00000783|Sex Behavior
714771|NCT00000783|Sexual Partners
714772|NCT00000782|Vaccines, Synthetic
714773|NCT00000782|Injections, Intradermal
714774|NCT00000782|HIV Antigens
714775|NCT00000782|HIV-1
714776|NCT00000782|HIV Envelope Protein gp160
714777|NCT00000782|Acquired Immunodeficiency Syndrome
714778|NCT00000782|AIDS-Related Complex
714779|NCT00000782|Hypersensitivity, Delayed
714780|NCT00000782|AIDS Vaccines
714781|NCT00000782|HIV Therapeutic Vaccine
714782|NCT00000781|Zalcitabine
714783|NCT00000781|Didanosine
714784|NCT00000781|Drug Therapy, Combination
714785|NCT00000781|Acquired Immunodeficiency Syndrome
714786|NCT00000781|Zidovudine
714787|NCT00000781|Nevirapine
714788|NCT00000780|Acquired Immunodeficiency Syndrome
714789|NCT00000780|AIDS-Related Complex
714790|NCT00000780|Adolescent Behavior
714791|NCT00000779|Vaccines, Synthetic
714792|NCT00000779|HIV-1
714793|NCT00000779|Adjuvants, Immunologic
714794|NCT00000779|AIDS-Related Complex
714795|NCT00000779|HIV Envelope Protein gp120
714796|NCT00000779|AIDS Vaccines
714797|NCT00000779|HIV Therapeutic Vaccine
714798|NCT00000778|Isoniazid
714799|NCT00000778|Tuberculosis, Pulmonary
714800|NCT00000778|Pyridoxine
714801|NCT00000778|Ofloxacin
714802|NCT00000778|AIDS-Related Opportunistic Infections
714803|NCT00000778|Drug Evaluation
714804|NCT00000778|Acquired Immunodeficiency Syndrome
714805|NCT00000778|Sputum
714806|NCT00000778|Colony Count, Microbial
714807|NCT00000777|Vaccines, Synthetic
714808|NCT00000777|Pregnancy
714809|NCT00000777|Pregnancy Complications, Infectious
714810|NCT00000777|HIV Envelope Protein gp160
714811|NCT00000777|AIDS Vaccines
714812|NCT00000777|HIV Preventive Vaccine
714813|NCT00000777|HIV Therapeutic Vaccine
714814|NCT00000776|AIDS-Related Opportunistic Infections
714815|NCT00000776|Meningitis
714816|NCT00000776|Cryptococcosis
714817|NCT00000776|Dexamethasone
714818|NCT00000776|Drug Therapy, Combination
714819|NCT00000776|Fluconazole
714820|NCT00000776|Flucytosine
714821|NCT00000776|Acquired Immunodeficiency Syndrome
714822|NCT00000776|Amphotericin B
714823|NCT00000776|Brain Diseases
714824|NCT00000775|Vaccines, Synthetic
714825|NCT00000775|HIV-1
714826|NCT00000775|HIV Envelope Protein gp120
714827|NCT00000775|AIDS Vaccines
714828|NCT00000775|HIV Seronegativity
714829|NCT00000775|HIV Preventive Vaccine
714830|NCT00000774|Vaccines, Synthetic
714831|NCT00000774|Virus Replication
714832|NCT00000774|HIV Envelope Protein gp120
714833|NCT00000774|AIDS Vaccines
714834|NCT00000774|HIV Preventive Vaccine
714835|NCT00000774|HIV Therapeutic Vaccine
714836|NCT00000773|Pneumonia, Pneumocystis carinii
714837|NCT00000773|Antifungal Agents
714838|NCT00000773|Acquired Immunodeficiency Syndrome
714839|NCT00000773|AIDS-Related Complex
714840|NCT00000773|Biological Availability
714841|NCT00000773|atovaquone
714842|NCT00000772|Ribavirin
714843|NCT00000772|Didanosine
714844|NCT00000772|Drug Therapy, Combination
714845|NCT00000772|Acquired Immunodeficiency Syndrome
714846|NCT00000772|AIDS-Related Complex
714847|NCT00000771|Cryptosporidiosis
714848|NCT00000771|Acquired Immunodeficiency Syndrome
714849|NCT00000771|Paromomycin
714850|NCT00000770|Didanosine
714851|NCT00000770|Drug Therapy, Combination
714852|NCT00000770|Acquired Immunodeficiency Syndrome
714853|NCT00000770|AIDS-Related Complex
714854|NCT00000770|Zidovudine
714855|NCT00000770|Nevirapine
714856|NCT00000769|Sarcoma, Kaposi
714857|NCT00000769|Acquired Immunodeficiency Syndrome
714858|NCT00000769|Interleukin-4
714859|NCT00000768|Intestinal Absorption
714860|NCT00000768|Ganciclovir
714861|NCT00000768|Drug Therapy, Combination
714862|NCT00000768|Cytomegalovirus Infections
714863|NCT00000768|Colitis
714864|NCT00000768|Administration, Oral
714865|NCT00000768|Acquired Immunodeficiency Syndrome
714866|NCT00000768|Biological Availability
714867|NCT00000768|Glutamic Acid
714868|NCT00000767|Vaccines, Synthetic
714869|NCT00000767|Vaccinia Virus
714870|NCT00000767|Viral Vaccines
714871|NCT00000767|Smallpox Vaccine
714872|NCT00000767|HIV-1
714873|NCT00000767|AIDS Vaccines
714874|NCT00000767|HIV Seronegativity
714875|NCT00000767|HIV Preventive Vaccine
714876|NCT00000766|Retinitis
714877|NCT00000766|Ganciclovir
714878|NCT00000766|Foscarnet
714879|NCT00000766|Cytomegalovirus Infections
714880|NCT00000766|Acquired Immunodeficiency Syndrome
714881|NCT00000765|Zidovudine
714882|NCT00000764|Interferon Alfa-2a
714883|NCT00000764|Acquired Immunodeficiency Syndrome
714884|NCT00000764|AIDS-Related Complex
714885|NCT00000764|Anus Neoplasms
714886|NCT00000764|Papillomavirus, Human
714887|NCT00000764|Papovaviridae Infections
714888|NCT00000764|Tumor Virus Infections
714889|NCT00000764|Isotretinoin
714890|NCT00000763|Sarcoma, Kaposi
714891|NCT00000763|Acquired Immunodeficiency Syndrome
714892|NCT00000763|Antineoplastic Agents
714893|NCT00000762|Vaccines, Synthetic
714894|NCT00000762|HIV Envelope Protein gp160
714895|NCT00000762|HIV Envelope Protein gp120
714896|NCT00000762|AIDS Vaccines
714897|NCT00000762|HIV Therapeutic Vaccine
714898|NCT00000761|Interferon-gamma, Recombinant
714899|NCT00000761|Acquired Immunodeficiency Syndrome
714900|NCT00000761|AIDS-Related Complex
714901|NCT00000760|Didanosine
714902|NCT00000760|Acquired Immunodeficiency Syndrome
714903|NCT00000760|AIDS-Related Complex
714904|NCT00000760|Antiviral Agents
714905|NCT00000760|Zidovudine
714906|NCT00000760|Gene Products, tat
714907|NCT00000759|Central Nervous System Diseases
714908|NCT00000759|Acquired Immunodeficiency Syndrome
714909|NCT00000759|AIDS-Related Complex
714910|NCT00000759|Peripheral Nervous System Diseases
714911|NCT00000758|Acquired Immunodeficiency Syndrome
714912|NCT00000758|AIDS-Related Complex
714913|NCT00000758|Fluorouracil
714914|NCT00000758|Cervix Dysplasia
714915|NCT00000758|Cervix Diseases
714916|NCT00000757|Vaccines, Synthetic
714917|NCT00000757|Vaccinia Virus
714918|NCT00000757|HIV-1
714919|NCT00000757|HIV Envelope Protein gp160
714920|NCT00000757|AIDS Vaccines
714921|NCT00000757|HIV Seronegativity
714922|NCT00000757|HIV Preventive Vaccine
714923|NCT00000756|T-Lymphocytes
714924|NCT00000756|Acquired Immunodeficiency Syndrome
714925|NCT00000756|AIDS-Related Complex
714926|NCT00000756|Immunotherapy, Adoptive
714927|NCT00000756|Transplantation, Autologous
714928|NCT00000755|Vaccines, Synthetic
714929|NCT00000755|HIV-1
714930|NCT00000755|Acquired Immunodeficiency Syndrome
714931|NCT00000755|AIDS-Related Complex
714932|NCT00000755|Zidovudine
714933|NCT00000755|HIV Envelope Protein gp120
714934|NCT00000755|AIDS Vaccines
714935|NCT00000755|HIV Therapeutic Vaccine
714936|NCT00000754|Zalcitabine
714937|NCT00000754|Acquired Immunodeficiency Syndrome
714938|NCT00000754|AIDS-Related Complex
714939|NCT00000754|Zidovudine
714940|NCT00000754|Interferon-alpha
714941|NCT00000753|Zalcitabine
714942|NCT00000753|Didanosine
714943|NCT00000753|Drug Therapy, Combination
714944|NCT00000753|Acquired Immunodeficiency Syndrome
714945|NCT00000753|AIDS-Related Complex
714946|NCT00000753|Antiviral Agents
714947|NCT00000753|Zidovudine
714948|NCT00000752|Drug Therapy, Combination
714949|NCT00000752|Acquired Immunodeficiency Syndrome
714950|NCT00000752|AIDS-Related Complex
714951|NCT00000752|cefuroxime axetil
714952|NCT00000752|Beclomethasone
714953|NCT00000752|Guaiacol Glyceryl Ether
714954|NCT00000752|Sinusitis
714955|NCT00000752|Ephedrine
714956|NCT00000751|Pregnancy
714957|NCT00000751|Pregnancy Complications, Infectious
714958|NCT00000751|Drug Therapy, Combination
714959|NCT00000751|Acquired Immunodeficiency Syndrome
714960|NCT00000751|AIDS-Related Complex
714961|NCT00000751|Zidovudine
714962|NCT00000751|Immunoglobulins, Intravenous
714963|NCT00000751|Immunization, Passive
714964|NCT00000750|Acquired Immunodeficiency Syndrome
714965|NCT00000750|AIDS-Related Complex
714966|NCT00000750|Zidovudine
714967|NCT00000749|Vaccines, Synthetic
714968|NCT00000749|HIV Envelope Protein gp120
714969|NCT00000749|AIDS Vaccines
714970|NCT00000749|HIV Seronegativity
714971|NCT00000749|HIV Preventive Vaccine
714972|NCT00000748|Trimethoprim-Sulfamethoxazole Combination
714973|NCT00000748|Pneumonia, Pneumocystis carinii
714974|NCT00000748|Acquired Immunodeficiency Syndrome
714975|NCT00000748|AIDS-Related Complex
714976|NCT00000748|Sulfamethoxazole-Trimethoprim
714977|NCT00000747|Drug Resistance
714978|NCT00000747|AIDS-Related Complex
714979|NCT00000747|Antiviral Agents
714980|NCT00000747|Nevirapine
714981|NCT00000746|Vaccines, Synthetic
714982|NCT00000746|Vaccinia Virus
714983|NCT00000746|Viral Vaccines
714984|NCT00000746|HIV-1
714985|NCT00000746|HIV Envelope Protein gp160
714986|NCT00000746|HIV Envelope Protein gp120
714987|NCT00000746|AIDS Vaccines
714988|NCT00000746|HIV Seronegativity
714989|NCT00000746|HIV Preventive Vaccine
714990|NCT00000745|Vaccines, Synthetic
714991|NCT00000745|Vaccinia Virus
714992|NCT00000745|Viral Vaccines
714993|NCT00000745|HIV-1
714994|NCT00000745|HIV Envelope Protein gp160
714995|NCT00000745|AIDS Vaccines
714996|NCT00000745|HIV Seronegativity
714997|NCT00000745|HIV Preventive Vaccine
714998|NCT00000744|Fluconazole
714999|NCT00000744|Acquired Immunodeficiency Syndrome
715000|NCT00000744|AIDS-Related Complex
715001|NCT00000744|Candidiasis
715002|NCT00000743|Recombinant Proteins
715003|NCT00000743|Acquired Immunodeficiency Syndrome
715004|NCT00000743|Antigens, CD4
715005|NCT00000743|AIDS-Related Complex
715006|NCT00000743|Zidovudine
715007|NCT00000742|Didanosine
715008|NCT00000742|Drug Therapy, Combination
715009|NCT00000742|Acquired Immunodeficiency Syndrome
715010|NCT00000742|AIDS-Related Complex
715011|NCT00000742|Antiviral Agents
715012|NCT00000742|Zidovudine
715013|NCT00000741|Pneumonia, Pneumocystis carinii
715014|NCT00000741|Acquired Immunodeficiency Syndrome
715015|NCT00000741|Methylprednisolone
715016|NCT00000740|Pneumonia, Pneumocystis carinii
715017|NCT00000740|Acquired Immunodeficiency Syndrome
715018|NCT00000740|AIDS-Related Complex
715019|NCT00000740|WR 6026
715020|NCT00000739|Pneumonia, Pneumocystis carinii
715021|NCT00000739|Dapsone
715375|NCT00000666|Drug Evaluation
715022|NCT00000739|Acquired Immunodeficiency Syndrome
715023|NCT00000739|AIDS-Related Complex
715024|NCT00000739|Drug Administration Schedule
715025|NCT00000738|Central Nervous System Diseases
715026|NCT00000738|Acquired Immunodeficiency Syndrome
715027|NCT00000738|AIDS Dementia Complex
715028|NCT00000738|AIDS-Related Complex
715029|NCT00000738|Zidovudine
715030|NCT00000738|Nimodipine
715031|NCT00000737|Weight Loss
715032|NCT00000737|Megestrol
715033|NCT00000737|Cachexia
715034|NCT00000737|Eating Disorders
715035|NCT00000737|Tetrahydrocannabinol
715036|NCT00000737|Appetite
715037|NCT00000736|Acquired Immunodeficiency Syndrome
715038|NCT00000736|AIDS-Related Complex
715039|NCT00000736|Zidovudine
715040|NCT00000735|Virus Replication
715041|NCT00000735|T-Lymphocytes
715042|NCT00000735|Infusions, Intravenous
715043|NCT00000735|Immunologic Surveillance
715044|NCT00000735|Acquired Immunodeficiency Syndrome
715045|NCT00000735|ampligen
715046|NCT00000735|AIDS-Related Complex
715047|NCT00000735|Antiviral Agents
715048|NCT00000734|Trimethoprim-Sulfamethoxazole Combination
715049|NCT00000734|AIDS-Related Opportunistic Infections
715050|NCT00000734|Pneumonia, Pneumocystis carinii
715051|NCT00000734|Drug Interactions
715052|NCT00000734|Drug Therapy, Combination
715053|NCT00000734|Acquired Immunodeficiency Syndrome
715054|NCT00000734|AIDS-Related Complex
715055|NCT00000734|Zidovudine
715056|NCT00000734|Sulfamethoxazole-Trimethoprim
715057|NCT00000733|Ribavirin
715058|NCT00000733|T-Lymphocytes
715059|NCT00000733|Infusions, Intravenous
715060|NCT00000733|Immunologic Surveillance
715061|NCT00000733|Administration, Oral
715062|NCT00000733|Acquired Immunodeficiency Syndrome
715063|NCT00000732|Trimethoprim-Sulfamethoxazole Combination
715064|NCT00000732|Pneumonia, Pneumocystis carinii
715065|NCT00000732|Drug Interactions
715066|NCT00000732|Drug Therapy, Combination
715067|NCT00000732|Acquired Immunodeficiency Syndrome
715068|NCT00000732|AIDS-Related Complex
715069|NCT00000732|Zidovudine
715070|NCT00000732|Sulfamethoxazole-Trimethoprim
715071|NCT00000731|Acetaminophen
715072|NCT00000731|Drug Interactions
715073|NCT00000731|Drug Therapy, Combination
715074|NCT00000731|Acquired Immunodeficiency Syndrome
715075|NCT00000731|AIDS-Related Complex
715076|NCT00000731|Zidovudine
715077|NCT00000730|Trimethoprim-Sulfamethoxazole Combination
715078|NCT00000730|Trimetrexate
715079|NCT00000730|AIDS-Related Opportunistic Infections
715080|NCT00000730|Pneumonia, Pneumocystis carinii
715081|NCT00000730|Leucovorin
715082|NCT00000730|Folic Acid Antagonists
715083|NCT00000730|Acquired Immunodeficiency Syndrome
715084|NCT00000730|Antiprotozoal Agents
715085|NCT00000730|Sulfamethoxazole-Trimethoprim
715086|NCT00000729|Virus Replication
715087|NCT00000729|Infusions, Intravenous
715088|NCT00000729|Dose-Response Relationship, Drug
715089|NCT00000729|Foscarnet
715090|NCT00000729|Acquired Immunodeficiency Syndrome
715091|NCT00000729|AIDS-Related Complex
715092|NCT00000729|Antiviral Agents
715093|NCT00000729|CD4-Positive T-Lymphocytes
715094|NCT00000728|Immune Tolerance
715095|NCT00000728|Interleukin-2
715096|NCT00000728|Drug Therapy, Combination
715097|NCT00000728|AIDS-Related Complex
715098|NCT00000728|Zidovudine
715099|NCT00000728|CD4-Positive T-Lymphocytes
715100|NCT00000727|Sulfadoxine
715101|NCT00000727|Trimethoprim-Sulfamethoxazole Combination
715102|NCT00000727|AIDS-Related Opportunistic Infections
715103|NCT00000727|Pneumonia, Pneumocystis carinii
715104|NCT00000727|Pentamidine
715105|NCT00000727|Pyrimethamine
715106|NCT00000727|Drug Evaluation
715107|NCT00000727|Administration, Inhalation
715108|NCT00000727|Administration, Oral
715109|NCT00000727|Aerosols
715110|NCT00000727|Acquired Immunodeficiency Syndrome
715111|NCT00000727|Zidovudine
715112|NCT00000726|Retinitis
715113|NCT00000726|AIDS-Related Opportunistic Infections
715114|NCT00000726|Foscarnet
715115|NCT00000726|Cytomegalovirus Infections
715116|NCT00000726|Acquired Immunodeficiency Syndrome
715117|NCT00000726|Antiviral Agents
715118|NCT00000708|AIDS-Related Opportunistic Infections
715119|NCT00000708|Meningitis
715120|NCT00000708|Injections, Intravenous
715121|NCT00000708|Cryptococcus neoformans
715122|NCT00000708|Cryptococcosis
715123|NCT00000708|Drug Therapy, Combination
715124|NCT00000708|Fluconazole
715125|NCT00000708|Administration, Oral
715126|NCT00000708|Acquired Immunodeficiency Syndrome
715127|NCT00000708|Amphotericin B
715128|NCT00000707|Respiratory Function Tests
715129|NCT00000707|AIDS-Related Opportunistic Infections
715130|NCT00000707|Pneumonia, Pneumocystis carinii
715131|NCT00000707|Pentamidine
715132|NCT00000707|Lung
715133|NCT00000707|HIV Seropositivity
715134|NCT00000707|Drug Evaluation
715135|NCT00000707|Administration, Inhalation
715136|NCT00000707|Aerosols
715137|NCT00000707|Acquired Immunodeficiency Syndrome
715138|NCT00000706|Quinine
715139|NCT00000706|Probenecid
715140|NCT00000706|Drug Therapy, Combination
715141|NCT00000706|Acquired Immunodeficiency Syndrome
715142|NCT00000706|AIDS-Related Complex
715143|NCT00000706|Zidovudine
715144|NCT00000705|Drug Evaluation
715145|NCT00000705|Zidovudine
715146|NCT00000705|Hemophilia A
715147|NCT00000704|HIV Antigens
715148|NCT00000704|Immunologic Surveillance
715149|NCT00000704|Zalcitabine
715150|NCT00000704|Dose-Response Relationship, Drug
715151|NCT00000704|Acquired Immunodeficiency Syndrome
715152|NCT00000704|AIDS-Related Complex
715153|NCT00000704|CD4-Positive T-Lymphocytes
715154|NCT00000703|Vincristine
715155|NCT00000703|Lymphoma
715156|NCT00000703|Methotrexate
715157|NCT00000703|Cyclophosphamide
715158|NCT00000703|Cytarabine
715159|NCT00000703|Dexamethasone
715160|NCT00000703|Doxorubicin
715161|NCT00000703|Drug Therapy, Combination
715162|NCT00000703|Combined Modality Therapy
715163|NCT00000703|Acquired Immunodeficiency Syndrome
715164|NCT00000703|Antineoplastic Agents, Combined
715165|NCT00000703|Zidovudine
715166|NCT00000703|Bleomycin
715167|NCT00000702|AIDS Dementia Complex
715168|NCT00000702|Zidovudine
715169|NCT00000701|Drug Evaluation
715170|NCT00000701|Acquired Immunodeficiency Syndrome
715171|NCT00000701|AIDS-Related Complex
715172|NCT00000701|Zidovudine
715173|NCT00000700|United States
715174|NCT00000700|AIDS-Related Opportunistic Infections
715175|NCT00000700|Pneumonia, Pneumocystis carinii
715176|NCT00000700|Acquired Immunodeficiency Syndrome
715177|NCT00000700|Zidovudine
715178|NCT00000699|Ribavirin
715179|NCT00000699|Inosine Pranobex
715180|NCT00000699|Dose-Response Relationship, Drug
715181|NCT00000699|Drug Evaluation
715182|NCT00000699|Drug Therapy, Combination
715183|NCT00000699|AIDS-Related Complex
715184|NCT00000698|Retinitis
715185|NCT00000698|AIDS-Related Opportunistic Infections
715186|NCT00000698|Ganciclovir
715187|NCT00000698|Cytomegalovirus Infections
715188|NCT00000698|Acquired Immunodeficiency Syndrome
715189|NCT00000697|Retinitis
715190|NCT00000697|AIDS-Related Opportunistic Infections
715191|NCT00000697|Bone Marrow
715192|NCT00000697|Ganciclovir
715193|NCT00000697|Foscarnet
715194|NCT00000697|Cytomegalovirus Infections
715195|NCT00000697|Acquired Immunodeficiency Syndrome
715196|NCT00000697|Antiviral Agents
715197|NCT00000696|Interferon Alfa-2a
715198|NCT00000696|Drug Therapy, Combination
715199|NCT00000696|AIDS-Related Complex
715200|NCT00000696|Zidovudine
715201|NCT00000695|Drug Evaluation
715202|NCT00000695|Drug Therapy, Combination
715203|NCT00000695|Acquired Immunodeficiency Syndrome
715204|NCT00000695|Zidovudine
715205|NCT00000695|Interferon Type I
715206|NCT00000694|Interferon Alfa-2b
715207|NCT00000694|Immune System
715208|NCT00000694|Drug Evaluation
715209|NCT00000694|Drug Therapy, Combination
715210|NCT00000694|Granulocyte-Macrophage Colony-Stimulating Factor
715211|NCT00000694|Acquired Immunodeficiency Syndrome
715212|NCT00000694|Zidovudine
715213|NCT00000693|Retinitis
715214|NCT00000693|Drug Evaluation
715215|NCT00000693|Drug Therapy, Combination
715216|NCT00000693|Cytomegalovirus Infections
715217|NCT00000693|Acyclovir
715218|NCT00000693|Acquired Immunodeficiency Syndrome
715219|NCT00000693|Zidovudine
715220|NCT00000692|Acquired Immunodeficiency Syndrome
715221|NCT00000692|AIDS-Related Complex
715222|NCT00000692|Antiviral Agents
715223|NCT00000692|Biological Availability
715224|NCT00000692|1-Deoxynojirimycin
715225|NCT00000691|Retinitis
715226|NCT00000691|AIDS-Related Opportunistic Infections
715227|NCT00000691|Ganciclovir
715228|NCT00000691|Drug Evaluation
715229|NCT00000691|Foscarnet
715230|NCT00000691|Cytomegalovirus Infections
715231|NCT00000691|Acquired Immunodeficiency Syndrome
715232|NCT00000691|Antiviral Agents
715233|NCT00000690|Reference Values
715234|NCT00000690|Infusions, Intravenous
715235|NCT00000690|Intestinal Absorption
715236|NCT00000690|Dextran Sulfate
715237|NCT00000690|Administration, Oral
715238|NCT00000690|Blood Coagulation
715239|NCT00000689|M-BACOD protocol
715240|NCT00000689|Nervous System Neoplasms
715241|NCT00000689|Infusions, Intravenous
715242|NCT00000689|Injections, Intravenous
715243|NCT00000689|Leucovorin
715244|NCT00000689|Cytarabine
715245|NCT00000689|Drug Evaluation
715246|NCT00000689|Drug Therapy, Combination
715247|NCT00000689|Granulocyte-Macrophage Colony-Stimulating Factor
715248|NCT00000689|Administration, Oral
715249|NCT00000689|Acquired Immunodeficiency Syndrome
715250|NCT00000689|Antineoplastic Agents, Combined
715251|NCT00000688|Retinitis
715252|NCT00000688|Injections, Intravenous
715253|NCT00000688|Ganciclovir
715254|NCT00000688|Cytomegalovirus Infections
715255|NCT00000688|Acquired Immunodeficiency Syndrome
715256|NCT00000687|Interferon Alfa-2a
715257|NCT00000687|Drug Evaluation
715258|NCT00000687|Drug Therapy, Combination
715259|NCT00000687|Acquired Immunodeficiency Syndrome
715260|NCT00000687|Zidovudine
715261|NCT00000686|Drug Evaluation
715262|NCT00000686|Acquired Immunodeficiency Syndrome
715263|NCT00000686|AIDS-Related Complex
715264|NCT00000686|Antiviral Agents
715265|NCT00000686|Zidovudine
715266|NCT00000685|Kidney Diseases
715267|NCT00000685|Drug Evaluation
715268|NCT00000685|Acquired Immunodeficiency Syndrome
715269|NCT00000685|Zidovudine
715270|NCT00000685|Renal Dialysis
715271|NCT00000684|Infusions, Intravenous
715272|NCT00000684|Dextran Sulfate
715273|NCT00000684|Acquired Immunodeficiency Syndrome
715274|NCT00000683|Vaccines, Synthetic
715275|NCT00000683|Vaccinia Virus
715276|NCT00000683|Viral Envelope Proteins
715277|NCT00000683|Acquired Immunodeficiency Syndrome
715278|NCT00000683|AIDS Vaccines
715279|NCT00000683|HIV Seronegativity
715280|NCT00000683|HIV Preventive Vaccine
715281|NCT00000682|AIDS-Related Opportunistic Infections
715282|NCT00000682|Pneumonia, Pneumocystis carinii
715283|NCT00000682|Zalcitabine
715284|NCT00000682|Acquired Immunodeficiency Syndrome
715285|NCT00000682|Zidovudine
715286|NCT00000681|Vincristine
715287|NCT00000681|Doxorubicin
715288|NCT00000681|Drug Evaluation
715289|NCT00000681|Drug Therapy, Combination
715290|NCT00000681|Granulocyte-Macrophage Colony-Stimulating Factor
715291|NCT00000681|Acquired Immunodeficiency Syndrome
715292|NCT00000681|Zidovudine
715293|NCT00000681|Bleomycin
715294|NCT00000680|T-Lymphocytes, Suppressor-Effector
715295|NCT00000680|Indium Radioisotopes
715296|NCT00000680|Leukapheresis
715297|NCT00000680|Interleukin-2
715298|NCT00000680|Acquired Immunodeficiency Syndrome
715299|NCT00000680|AIDS-Related Complex
715300|NCT00000680|Zidovudine
715301|NCT00000680|Immunization, Passive
715302|NCT00000679|Zalcitabine
715303|NCT00000679|Acquired Immunodeficiency Syndrome
715304|NCT00000679|AIDS-Related Complex
715305|NCT00000679|Zidovudine
715306|NCT00000678|Zalcitabine
715307|NCT00000678|Drug Evaluation
715308|NCT00000678|Acquired Immunodeficiency Syndrome
715309|NCT00000678|AIDS-Related Complex
715310|NCT00000678|Zidovudine
715311|NCT00000677|Sch 39304
715312|NCT00000677|AIDS-Related Opportunistic Infections
715313|NCT00000677|Meningitis
715314|NCT00000677|Cryptococcosis
715315|NCT00000677|Drug Evaluation
715316|NCT00000677|Antifungal Agents
715317|NCT00000677|Acquired Immunodeficiency Syndrome
715318|NCT00000676|Mycoses
715319|NCT00000676|Fluconazole
715320|NCT00000676|Clotrimazole
715321|NCT00000676|Antifungal Agents
715322|NCT00000676|Acquired Immunodeficiency Syndrome
715323|NCT00000676|AIDS-Related Complex
715324|NCT00000675|Recombinant Proteins
715325|NCT00000675|IgG
715326|NCT00000675|Drug Evaluation
715327|NCT00000675|Acquired Immunodeficiency Syndrome
715328|NCT00000675|Antigens, CD4
715329|NCT00000675|AIDS-Related Complex
715330|NCT00000675|Carrier Proteins
715331|NCT00000674|Toxoplasmosis
715332|NCT00000674|AIDS-Related Opportunistic Infections
715333|NCT00000674|Pyrimethamine
715334|NCT00000674|Leucovorin
715335|NCT00000674|Drug Evaluation
715336|NCT00000674|Drug Therapy, Combination
715337|NCT00000674|Encephalitis
715338|NCT00000674|Acquired Immunodeficiency Syndrome
715339|NCT00000674|Clindamycin
715340|NCT00000673|Retinitis
715341|NCT00000673|AIDS-Related Opportunistic Infections
715342|NCT00000673|Ganciclovir
715343|NCT00000673|Cytomegalovirus Infections
715344|NCT00000673|Acquired Immunodeficiency Syndrome
715345|NCT00000672|Didanosine
715346|NCT00000672|Zidovudine
715347|NCT00000671|Didanosine
715348|NCT00000671|Zidovudine
715349|NCT00000670|Probenecid
715350|NCT00000670|Drug Evaluation
715351|NCT00000670|Drug Interactions
715352|NCT00000670|Acquired Immunodeficiency Syndrome
715353|NCT00000670|Zidovudine
715354|NCT00000669|Didanosine
715355|NCT00000669|Drug Evaluation
715356|NCT00000669|Acquired Immunodeficiency Syndrome
715357|NCT00000669|AIDS-Related Complex
715358|NCT00000668|Retinitis
715359|NCT00000668|AIDS-Related Opportunistic Infections
715360|NCT00000668|Ganciclovir
715361|NCT00000668|Cytomegalovirus Infections
715362|NCT00000668|Acquired Immunodeficiency Syndrome
715363|NCT00000667|Vaccines, Synthetic
715364|NCT00000667|Injections, Intradermal
715365|NCT00000667|HIV Antigens
715366|NCT00000667|HIV Seropositivity
715367|NCT00000667|HIV-1
715368|NCT00000667|Drug Evaluation
715369|NCT00000667|Hypersensitivity, Delayed
715370|NCT00000667|AIDS Vaccines
715371|NCT00000667|HIV Therapeutic Vaccine
715372|NCT00000666|Toxoplasmosis
715373|NCT00000666|AIDS-Related Opportunistic Infections
715374|NCT00000666|Pyrimethamine
715376|NCT00000666|Encephalitis
715377|NCT00000666|Acquired Immunodeficiency Syndrome
715378|NCT00000665|Retinitis
715379|NCT00000665|AIDS-Related Opportunistic Infections
715380|NCT00000665|Ganciclovir
715381|NCT00000665|Foscarnet
715382|NCT00000665|Cytomegalovirus Infections
715383|NCT00000665|Acquired Immunodeficiency Syndrome
715384|NCT00000665|Antiviral Agents
715385|NCT00000664|Polyethylene Glycols
715386|NCT00000664|Interleukin-2
715387|NCT00000664|Drug Evaluation
715388|NCT00000664|Zidovudine
715389|NCT00000663|Recombinant Proteins
715390|NCT00000663|Injections, Intravenous
715391|NCT00000663|IgG
715392|NCT00000663|Drug Evaluation
715393|NCT00000663|Acquired Immunodeficiency Syndrome
715394|NCT00000663|Antigens, CD4
715395|NCT00000663|Carrier Proteins
715396|NCT00000662|Drugs, Investigational
715397|NCT00000662|Acquired Immunodeficiency Syndrome
715398|NCT00000662|AIDS-Related Complex
715399|NCT00000662|Zidovudine
715400|NCT00000661|Oxazepam
715401|NCT00000661|Drug Evaluation
715402|NCT00000661|Drug Interactions
715403|NCT00000661|Zidovudine
715404|NCT00000660|Sarcoma, Kaposi
715405|NCT00000660|Drug Evaluation
715406|NCT00000660|Etoposide
715407|NCT00000660|Acquired Immunodeficiency Syndrome
715408|NCT00000659|Acquired Immunodeficiency Syndrome
715409|NCT00000659|Antigens, CD4
715410|NCT00000659|AIDS-Related Complex
715411|NCT00000659|Zidovudine
715412|NCT00000658|M-BACOD protocol
715413|NCT00000658|Granulocyte-Macrophage Colony-Stimulating Factor
715414|NCT00000658|Acquired Immunodeficiency Syndrome
715415|NCT00000658|Allopurinol
715416|NCT00000658|Antineoplastic Agents, Combined
715417|NCT00000657|Didanosine
715418|NCT00000657|Drug Evaluation
715419|NCT00000657|Drugs, Investigational
715420|NCT00000657|AIDS Dementia Complex
715421|NCT00000657|Zidovudine
715422|NCT00000656|Didanosine
715423|NCT00000656|Drug Therapy, Combination
715424|NCT00000656|Zidovudine
715425|NCT00000655|Trimethoprim-Sulfamethoxazole Combination
715426|NCT00000655|AIDS-Related Opportunistic Infections
715427|NCT00000655|Pneumonia, Pneumocystis carinii
715428|NCT00000655|Naphthoquinones
715429|NCT00000655|Antifungal Agents
715430|NCT00000655|Acquired Immunodeficiency Syndrome
715431|NCT00000655|Sulfamethoxazole-Trimethoprim
715432|NCT00000654|AIDS-Related Opportunistic Infections
715433|NCT00000654|Pyrimidine Nucleosides
715434|NCT00000654|Herpesviridae Infections
715435|NCT00000654|Drug Evaluation
715436|NCT00000654|Antiviral Agents
715437|NCT00000654|Hepatitis B
715438|NCT00000653|Zalcitabine
715439|NCT00000653|Drug Evaluation
715440|NCT00000653|Acquired Immunodeficiency Syndrome
715441|NCT00000653|AIDS-Related Complex
715442|NCT00000652|Didanosine
715443|NCT00000652|Drug Evaluation
715444|NCT00000652|Drug Therapy, Combination
715445|NCT00000652|Zidovudine
715446|NCT00000651|Zalcitabine
715447|NCT00000651|Antiviral Agents
715448|NCT00000651|Zidovudine
715449|NCT00000650|Drug Evaluation
715450|NCT00000650|Ditiocarb
715451|NCT00000650|Acquired Immunodeficiency Syndrome
715452|NCT00000649|Drug Therapy, Combination
715453|NCT00000649|Acquired Immunodeficiency Syndrome
715454|NCT00000649|AIDS-Related Complex
715455|NCT00000649|Zidovudine
715456|NCT00000649|Nevirapine
715457|NCT00000648|Penicillin G
715458|NCT00000648|Neurosyphilis
715459|NCT00000648|Drug Evaluation
715460|NCT00000648|Acquired Immunodeficiency Syndrome
715461|NCT00000648|AIDS-Related Complex
715462|NCT00000648|Ceftriaxone
715463|NCT00000647|Recombinant Proteins
715464|NCT00000647|IgG
715465|NCT00000647|Drug Evaluation
715466|NCT00000647|Drug Therapy, Combination
715467|NCT00000647|Acquired Immunodeficiency Syndrome
715468|NCT00000647|Antigens, CD4
715469|NCT00000647|Zidovudine
715470|NCT00000647|Carrier Proteins
715471|NCT00000647|Interferon Type I
715472|NCT00000646|Pentoxifylline
715473|NCT00000646|Virus Replication
715474|NCT00000646|Tumor Necrosis Factor
715475|NCT00000646|Drug Evaluation
715476|NCT00000646|Acquired Immunodeficiency Syndrome
715477|NCT00000646|Cachexia
715478|NCT00000646|Drug Synergism
715479|NCT00000645|Drug Evaluation
715480|NCT00000645|Acquired Immunodeficiency Syndrome
715481|NCT00000645|AIDS-Related Complex
715482|NCT00000645|Antiviral Agents
715483|NCT00000644|AIDS-Related Opportunistic Infections
715484|NCT00000644|Mycobacterium avium-intracellulare Infection
715485|NCT00000644|Acquired Immunodeficiency Syndrome
715486|NCT00000644|Clarithromycin
715487|NCT00000643|Toxoplasmosis
715488|NCT00000643|Pyrimethamine
715489|NCT00000643|Leucovorin
715490|NCT00000643|Drug Evaluation
715491|NCT00000643|Acquired Immunodeficiency Syndrome
715492|NCT00000643|AIDS-Related Complex
715493|NCT00000643|Brain Diseases
715494|NCT00000642|Recombinant Proteins
715742|NCT00000421|Hormone therapy
715495|NCT00000642|Pregnancy Trimester, Third
715496|NCT00000642|Pregnancy
715497|NCT00000642|Pregnancy Complications, Infectious
715498|NCT00000642|IgG
715499|NCT00000642|Drug Evaluation
715500|NCT00000642|Antigens, CD4
715501|NCT00000642|AIDS-Related Complex
715502|NCT00000642|Immunization, Passive
715503|NCT00000641|Rifampin
715504|NCT00000641|Mycobacterium avium-intracellulare Infection
715505|NCT00000641|Drug Evaluation
715506|NCT00000641|Drug Therapy, Combination
715507|NCT00000641|Ethambutol
715508|NCT00000641|Clofazimine
715509|NCT00000641|Acquired Immunodeficiency Syndrome
715510|NCT00000641|Amikacin
715511|NCT00000641|Azithromycin
715512|NCT00000641|Ciprofloxacin
715513|NCT00000640|Trimethoprim-Sulfamethoxazole Combination
715514|NCT00000640|Pneumonia, Pneumocystis carinii
715515|NCT00000640|Primaquine
715516|NCT00000640|Dapsone
715517|NCT00000640|Drug Therapy, Combination
715518|NCT00000640|Acquired Immunodeficiency Syndrome
715519|NCT00000640|Clindamycin
715520|NCT00000640|Sulfamethoxazole-Trimethoprim
715521|NCT00000639|AIDS-Related Opportunistic Infections
715522|NCT00000639|Meningitis
715523|NCT00000639|Cryptococcosis
715524|NCT00000639|Drug Evaluation
715525|NCT00000639|Drug Therapy, Combination
715526|NCT00000639|Fluconazole
715527|NCT00000639|Flucytosine
715528|NCT00000639|Acquired Immunodeficiency Syndrome
715529|NCT00000639|Amphotericin B
715530|NCT00000639|Brain Diseases
715531|NCT00000638|Tuberculosis
715532|NCT00000638|Isoniazid
715533|NCT00000638|Mycobacterium tuberculosis
715534|NCT00000638|Pyrazinamide
715535|NCT00000638|Pyridoxine
715536|NCT00000638|Rifampin
715537|NCT00000638|AIDS-Related Opportunistic Infections
715538|NCT00000638|Drug Therapy, Combination
715539|NCT00000638|Acquired Immunodeficiency Syndrome
715540|NCT00000638|Antitubercular Agents
715541|NCT00000638|AIDS-Related Complex
715542|NCT00000637|Didanosine
715543|NCT00000637|Drug Evaluation
715544|NCT00000637|Drug Therapy, Combination
715545|NCT00000637|Acquired Immunodeficiency Syndrome
715546|NCT00000637|AIDS-Related Complex
715547|NCT00000637|Zidovudine
715548|NCT00000636|Tuberculosis
715549|NCT00000636|Isoniazid
715550|NCT00000636|Pyrazinamide
715551|NCT00000636|Pyridoxine
715552|NCT00000636|Rifampin
715553|NCT00000636|AIDS-Related Opportunistic Infections
715554|NCT00000636|Drug Therapy, Combination
715555|NCT00000636|Acquired Immunodeficiency Syndrome
715556|NCT00000636|Antitubercular Agents
715557|NCT00000636|AIDS-Related Complex
715558|NCT00000635|Bacitracin
715559|NCT00000635|Polymyxin B
715560|NCT00000635|Trifluridine
715561|NCT00000635|AIDS-Related Opportunistic Infections
715562|NCT00000635|Herpesviridae Infections
715563|NCT00000635|Drug Evaluation
715564|NCT00000635|Acquired Immunodeficiency Syndrome
715565|NCT00000635|Anti-Infective Agents, Local
715566|NCT00000635|Antiviral Agents
715567|NCT00000634|Benzodiazepines
715568|NCT00000634|Drug Evaluation
715569|NCT00000634|Drugs, Investigational
715570|NCT00000634|Acquired Immunodeficiency Syndrome
715571|NCT00000634|Antiviral Agents
715572|NCT00000633|Vaccines, Synthetic
715573|NCT00000633|Vaccinia Virus
715574|NCT00000633|Viral Vaccines
715575|NCT00000633|HIV-1
715576|NCT00000633|HIV Envelope Protein gp160
715577|NCT00000633|Acquired Immunodeficiency Syndrome
715578|NCT00000633|AIDS-Related Complex
715579|NCT00000633|AIDS Vaccines
715580|NCT00000633|HIV Therapeutic Vaccine
715581|NCT00000632|Vaccines, Synthetic
715582|NCT00000632|Drug Evaluation
715583|NCT00000632|Adjuvants, Immunologic
715584|NCT00000632|AIDS Vaccines
715585|NCT00000632|HIV Preventive Vaccine
715586|NCT00000631|Vaccines, Synthetic
715587|NCT00000631|Vaccinia Virus
715588|NCT00000631|Viral Envelope Proteins
715589|NCT00000631|Viral Vaccines
715590|NCT00000631|AIDS Vaccines
715591|NCT00000631|HIV Seronegativity
715592|NCT00000631|HIV Preventive Vaccine
715593|NCT00000630|Vaccines, Synthetic
715594|NCT00000630|Vaccinia Virus
715595|NCT00000630|Viral Envelope Proteins
715596|NCT00000630|Acquired Immunodeficiency Syndrome
715597|NCT00000630|AIDS Vaccines
715598|NCT00000630|HIV Seronegativity
715599|NCT00000630|HIV Preventive Vaccine
715600|NCT00000629|Valproic Acid
715601|NCT00000629|Zidovudine
715602|NCT00000628|Drug Evaluation
715603|NCT00000628|Drugs, Investigational
715604|NCT00000628|Drug Therapy, Combination
715605|NCT00000628|Acquired Immunodeficiency Syndrome
715606|NCT00000628|AIDS-Related Complex
715607|NCT00000628|Antiviral Agents
715608|NCT00000627|Pilot Projects
715609|NCT00000627|Histoplasmosis
715610|NCT00000627|Drug Evaluation
715611|NCT00000627|Fluconazole
715612|NCT00000627|Acquired Immunodeficiency Syndrome
715613|NCT00000627|Recurrence
715614|NCT00000626|Granulocyte Colony-Stimulating Factor
715615|NCT00000626|Acquired Immunodeficiency Syndrome
715616|NCT00000626|Antineoplastic Agents, Combined
715617|NCT00000626|AIDS-Related Complex
715618|NCT00000626|Hodgkin Disease
715619|NCT00000626|ABVD protocol
715620|NCT00000625|Zalcitabine
715621|NCT00000625|Didanosine
715622|NCT00000625|Drug Therapy, Combination
715623|NCT00000625|AIDS-Related Complex
715624|NCT00000625|Antiviral Agents
715625|NCT00000625|Zidovudine
715626|NCT00000623|chelator
715627|NCT00000623|iron
715628|NCT00000623|transfusion
715629|NCT00000623|anemia
715630|NCT00000623|thalassemia
715631|NCT00000620|Diabetes Mellitus, Non-Insulin-Dependent
715632|NCT00000456|Alcoholism
715633|NCT00000456|Alcohol Dependence
715634|NCT00000456|Naltrexone
715635|NCT00000456|Cognitive Behavioral Therapy
715636|NCT00000451|Alcoholism
715637|NCT00000451|Alcohol Dependence
715638|NCT00000436|Hip fracture
715639|NCT00000436|Self-efficacy
715640|NCT00000436|Strength training
715641|NCT00000436|Rehabilitation
715642|NCT00000436|Postoperative
715643|NCT00000435|RA
715644|NCT00000435|Immune Modulation
715645|NCT00000435|Oral Tolerance
715646|NCT00000435|Peptide
715647|NCT00000435|dnaJ
715648|NCT00000434|Osteoarthritis
715649|NCT00000434|Health education
715650|NCT00000434|Aerobic exercise
715651|NCT00000434|Self-efficacy
715652|NCT00000434|Muscle strength
715653|NCT00000434|Outcomes research
715654|NCT00000434|Longitudinal study
715655|NCT00000433|Spondylitis
715656|NCT00000433|Etanercept
715657|NCT00000433|ENBREL
715658|NCT00000433|Tumor necrosis factor-alpha
715659|NCT00000432|Lyme disease
715660|NCT00000432|Education evaluation
715661|NCT00000432|Communicable disease control
715662|NCT00000432|Outcomes research
715663|NCT00000432|Tick-transmitted diseases
715664|NCT00000431|Venous leg ulcer
715665|NCT00000431|Wound healing
715666|NCT00000431|Somatic gene therapy
715667|NCT00000431|PDGF-B
715668|NCT00000430|Osteoporosis
715669|NCT00000430|Osteopenia
715670|NCT00000430|Postmenopausal women
715671|NCT00000430|Hormone replacement therapy
715672|NCT00000430|Alendronate
715673|NCT00000429|JRA
715674|NCT00000429|Osteopenia
715675|NCT00000429|Dietary calcium
715676|NCT00000429|Diet therapy
715677|NCT00000429|Bone density
715678|NCT00000429|Ossification
715679|NCT00000429|Biomarker
715680|NCT00000429|Dietary supplement
715681|NCT00000428|Fibromyalgia Syndrome (FMS)
715682|NCT00000428|Amitriptyline
715683|NCT00000428|Fluoxetine
715684|NCT00000427|Parathyroid Hormone (PTH)
715685|NCT00000427|Alendronate
715686|NCT00000427|Bone metabolism
715687|NCT00000427|Bone mineral density (BMD)
715688|NCT00000427|Bone loss
715689|NCT00000427|Postmenopausal osteoporosis
715690|NCT00000427|Osteoporosis in men
715691|NCT00000426|Calcium deficiency
715692|NCT00000426|Dietary calcium
715693|NCT00000426|Dietary protein
715694|NCT00000426|Osteoporosis
715695|NCT00000426|Calcium supplement
715696|NCT00000426|Bone density
715697|NCT00000426|Bone mass
715698|NCT00000426|Bone mass accumulation
715699|NCT00000425|Osteoarthritis
715700|NCT00000425|Skeletal disorder
715701|NCT00000425|Chemotherapy
715702|NCT00000425|Nonsteroidal anti-inflammatory drugs (NSAIDs)
715703|NCT00000425|Arthroplasty
715704|NCT00000425|Cartilage metabolism
715705|NCT00000425|Hip
715706|NCT00000425|Knee
715707|NCT00000425|Outcomes research
715708|NCT00000424|Osteoarthritis (OA)
715709|NCT00000424|Knee
715710|NCT00000424|Sham lavage
715711|NCT00000424|Tidal lavage
715712|NCT00000424|Lavage therapy
715713|NCT00000424|Nonsteroidal anti-inflammatory drug (NSAID)
715714|NCT00000424|Placebo
715715|NCT00000424|Radiography
715716|NCT00000424|Human therapy evaluation
715717|NCT00000424|WOMAC
715718|NCT00000423|Fibromyalgia
715719|NCT00000423|Health education
715720|NCT00000423|Program evaluation
715721|NCT00000423|Social support
715722|NCT00000423|Managed care
715723|NCT00000423|Quality of well-being
715724|NCT00000422|Fibromyalgia Syndrome (FMS)
715725|NCT00000422|Physical therapy
715726|NCT00000422|Psychotherapy
715727|NCT00000422|Group counseling
715728|NCT00000422|Human therapy relations
715729|NCT00000422|Interpersonal relations
715730|NCT00000422|Chronic pain
715731|NCT00000422|Cognition
715732|NCT00000422|Emotion
715733|NCT00000422|Memory
715734|NCT00000422|Musculoskeletal disorder
715735|NCT00000422|Psychological stressor
715736|NCT00000422|Psychological adaptation
715737|NCT00000422|Outcomes research
715738|NCT00000421|SLE
715739|NCT00000421|Lupus
715740|NCT00000421|Anti-double-stranded DNA antibody
715741|NCT00000421|Corticosteroid treatment
715743|NCT00000421|Complement
715744|NCT00000421|Hypertension
715745|NCT00000421|Estrogen
715746|NCT00000421|SELENA
715747|NCT00000420|SLE
715748|NCT00000420|SELENA
715749|NCT00000420|Oral contraceptives
715750|NCT00000420|The pill
715751|NCT00000420|Birth control
715752|NCT00000420|Condom
715753|NCT00000420|Diaphragm
715754|NCT00000420|Estrogen
715755|NCT00000420|Lupus
715756|NCT00000420|Placebo
715757|NCT00000419|SLE
715758|NCT00000419|SELENA
715759|NCT00000419|Estrogen Replacement Therapy (ERT)
715760|NCT00000419|Postmenopause
715761|NCT00000419|Osteoporosis
715762|NCT00000419|Estrogens
715763|NCT00000419|Steroids
715764|NCT00000419|Progestin
715765|NCT00000419|Placebo
715766|NCT00000418|OA
715767|NCT00000418|Patient education
715768|NCT00000418|Acute low back pain (ALBP)
715769|NCT00000418|Social support systems
715770|NCT00000417|SLE
715771|NCT00000417|Lupus
715772|NCT00000417|Educational intervention
715773|NCT00000417|Health education
715774|NCT00000417|Social support network
715775|NCT00000417|Outcomes research
715776|NCT00000417|Self-help
715777|NCT00000416|Arthritis
715778|NCT00000416|Rheumatic disorders
715779|NCT00000416|Work-related disability
715780|NCT00000416|Vocational rehabilitation (VR)
715781|NCT00000416|Job retention services
715782|NCT00000416|Work limitations
715783|NCT00000416|Work instability
715784|NCT00000415|Calcium
715785|NCT00000415|Physical activity
715786|NCT00000415|Children
715787|NCT00000415|Bone mass accretion
715788|NCT00000415|Bone mineral density (BMD)
715789|NCT00000415|Bone response to activity and calcium supplements
715790|NCT00000415|Placebo
715791|NCT00000415|Bone growth
715792|NCT00000414|Rheumatoid arthritis (RA)
715793|NCT00000414|Osteoarthritis (OA)
715794|NCT00000414|Arthritis education
715795|NCT00000414|Health care service evaluation
715796|NCT00000414|Outcomes research
715797|NCT00000414|Arthritis Self-Management Program (ASMP)
715798|NCT00000414|Self-Managed Arthritis Relief Therapy (SMART) Program
715799|NCT00000413|Osteoporosis prevention
715800|NCT00000413|Behavioral/educational intervention
715801|NCT00000413|Preadolescent
715802|NCT00000413|Calcium
715803|NCT00000413|Exercise
715804|NCT00000413|Peak bone mass
715805|NCT00000413|Bone density
715806|NCT00000412|Osteoporosis
715807|NCT00000412|Osteopenia
715808|NCT00000412|Heart transplant
715809|NCT00000412|Bone fracture
715810|NCT00000412|Bone density
715811|NCT00000412|Dual energy x-ray absorptiometry
715812|NCT00000411|Spinal stenosis (SpS)
715813|NCT00000411|Intervertebral disc herniation (IDH)
715814|NCT00000411|Degenerative spondylolisthesis (DS)
715815|NCT00000411|Low back pain (LBP)
715816|NCT00000411|Surgical therapy
715817|NCT00000411|Nonsurgical therapy
715818|NCT00000411|Randomized study
715819|NCT00000411|Multicenter
715820|NCT00000411|MRI
715821|NCT00000410|Intervertebral disc herniation (IDH)
715822|NCT00000410|Stenosis with degenerative spondylolisthesis (DS)
715823|NCT00000410|Spinal stenosis (SpS)
715824|NCT00000410|Low back pain (LBP)
715825|NCT00000410|Leg pain
715826|NCT00000410|Surgical therapy
715827|NCT00000410|Non-surgical therapy
715828|NCT00000410|Randomized study
715829|NCT00000410|Multicenter
715830|NCT00000410|MRI
715831|NCT00000409|Intervertebral disc herniation (IDH)
715832|NCT00000409|Degenerative spondylolisthesis (DS)
715833|NCT00000409|Spinal stenosis (SpS)
715834|NCT00000409|Low back pain (LBP)
715835|NCT00000409|Leg pain
715836|NCT00000409|Surgical therapy
715837|NCT00000409|Randomized study
715838|NCT00000409|Multicenter
715839|NCT00000409|MRI
715840|NCT00000409|Nonsurgical therapy
715841|NCT00000408|Health education
715842|NCT00000408|Back injury
715843|NCT00000408|Chronic pain
715844|NCT00000408|Education/evaluation planning
715845|NCT00000408|Outcomes research
715846|NCT00000407|Arthritis and related musculoskeletal disorders (ARMD)
715847|NCT00000407|Vocational rehabilitation (VR)
715848|NCT00000407|Agency enhancement intervention
715849|NCT00000407|Health care service evaluation
715850|NCT00000407|Musculoskeletal disability
715851|NCT00000407|Return to work
715852|NCT00000407|Outcomes research
715853|NCT00000407|Unemployment
715854|NCT00000407|Work disability
715855|NCT00000406|Osteoarthritis (OA)
715856|NCT00000406|Knee
715857|NCT00000406|Radiographic OA
715858|NCT00000406|Strength training
715859|NCT00000406|Physical therapy
715860|NCT00000406|Exercise
715861|NCT00000406|Body composition
715862|NCT00000406|Striated muscle
715863|NCT00000406|Depression
715864|NCT00000406|Radiographic OA with knee pain
715865|NCT00000406|Radiographic OA without knee pain
715866|NCT00000406|Knee pain without radiographic OA
715867|NCT00000406|Normal elderly (no radiographic OA, no knee pain)
715868|NCT00000405|Osteoporosis
715869|NCT00000405|Bone fractures
715870|NCT00000405|Bone mass
715871|NCT00000405|Bone mineral density (BMD)
715872|NCT00000405|Ossification
715873|NCT00000405|Biomechanics
715874|NCT00000405|Exercise
715875|NCT00000405|Diet
715876|NCT00000405|Spine
715877|NCT00000405|Middle childhood (6-11)
715878|NCT00000404|Osteoarthritis (OA)
715879|NCT00000404|Knee
715880|NCT00000404|HMO
715881|NCT00000404|Comprehensive care
715882|NCT00000403|Osteoarthritis (OA)
715883|NCT00000403|Knee
715884|NCT00000403|Doxycycline
715885|NCT00000403|Skeletal disorder
715886|NCT00000403|Placebo
715887|NCT00000403|Urinalysis
715888|NCT00000403|NSAIDs
715889|NCT00000403|Joint space narrowing (JSN)
715890|NCT00000403|WOMAC
715891|NCT00000402|Osteoporosis
715892|NCT00000402|Dietary calcium
715893|NCT00000402|Puberty
715894|NCT00000402|Bone density
715895|NCT00000402|Bone mass
715896|NCT00000402|Primary prevention of osteoporosis
715897|NCT00000401|NSAIDs
715898|NCT00000401|Oral Tolerance
715899|NCT00000401|Drug Interaction
715900|NCT00000401|Oral Administration
715901|NCT00000401|Interleukin 10
715902|NCT00000401|Collagen
715903|NCT00000401|Chemotherapy
715904|NCT00000401|Human Therapy Evaluation
715905|NCT00000401|DMARDs
715906|NCT00000401|RA
715907|NCT00000401|IL-10
715908|NCT00000400|Osteoporosis
715909|NCT00000400|Bone formation
715910|NCT00000400|Bone resorption
715911|NCT00000400|Parathyroid hormone (PTH)
715912|NCT00000400|Postmenopause
715913|NCT00000399|Estrogen
715914|NCT00000399|Hormone therapy
715915|NCT00000399|Strength training
715916|NCT00000399|Exercise
715917|NCT00000399|Postmenopause
715918|NCT00000399|Disorder prevention
715919|NCT00000399|Osteoporosis
715920|NCT00000399|Bone mineral density
715921|NCT00000399|Bone mass
715922|NCT00000399|Cholesterol
715923|NCT00000399|Body composition
715924|NCT00000398|Fibromyalgia
715925|NCT00000398|Pain
715926|NCT00000398|Coping skills training
715927|NCT00000398|Physical exercise training
715928|NCT00000398|Combined coping skills training and exercise training
715929|NCT00000397|Fibromyalgia
715930|NCT00000397|Insomnia
715931|NCT00000397|Cognitive-behavioral therapy (CBT)
715932|NCT00000397|Behavioral insomnia therapy
715933|NCT00000396|Arthritis
715934|NCT00000396|Arthritis education
715935|NCT00000396|African Americans
715936|NCT00000396|Self-help
715937|NCT00000396|Self-management
715938|NCT00000396|Cultural beliefs
715939|NCT00000395|Rheumatoid arthritis
715940|NCT00000395|Lewis rat adjuvant arthritis
715941|NCT00000395|Antifolate efficacy
715942|NCT00000395|Autoimmunity
715943|NCT00000395|Adenosine metabolism
715944|NCT00000395|Methotrexate therapy
715945|NCT00000395|Skeletal disorder
715946|NCT00000395|Dietary supplement
715947|NCT00000395|Antiarthritic agent
715948|NCT00000395|Folic acid
715949|NCT00000394|Carpal tunnel syndrome
715950|NCT00000394|Acupuncture
715951|NCT00000394|Median nerve
715952|NCT00000394|Single-blind mute methodology
715953|NCT00000393|Acquired Immunodeficiency Syndrome
715954|NCT00000392|Acquired Immunodeficiency Syndrome
715955|NCT00000392|AIDS-Related Complex
715956|NCT00000391|Acquired Immunodeficiency Syndrome
715957|NCT00000391|AIDS-Related Complex
715958|NCT00000390|Adult
715959|NCT00000390|Acquired Immunodeficiency Syndrome
715960|NCT00000390|Depression
715961|NCT00000390|Female
715962|NCT00000390|Human
715963|NCT00000390|Imipramine
715964|NCT00000390|Male
715965|NCT00000390|Middle Age
715966|NCT00000390|Acquired Immunodeficiency Syndrome -- *complications
715967|NCT00000390|Depression -- *drug therapy
715968|NCT00000390|Depression -- etiology
715969|NCT00000390|Imipramine -- *therapeutic use
715970|NCT00000389|Adolescence
715971|NCT00000389|Anxiety Disorders
715972|NCT00000389|Child
715973|NCT00000389|Female
715974|NCT00000389|Fluvoxamine
715975|NCT00000389|Human
715976|NCT00000389|Male
715977|NCT00000389|Serotonin Uptake Inhibitors
715978|NCT00000389|Anxiety Disorders -- *drug therapy
715979|NCT00000389|Fluvoxamine -- *therapeutic use
715980|NCT00000389|Serotonin Uptake Inhibitors -- *therapeutic use
715981|NCT00000388|Attention Deficit Disorder with Hyperactivity
715982|NCT00000388|Adolescence
715983|NCT00000388|Child
715984|NCT00000388|Cognition
715985|NCT00000388|Combined Modality Therapy
715986|NCT00000388|Female
715987|NCT00000388|Human
715988|NCT00000388|Male
715989|NCT00000388|Peer Group
715990|NCT00000388|Risk Factors
715991|NCT00000388|Treatment Outcome
715992|NCT00000388|Attention Deficit Disorder with Hyperactivity -- *therapy
715993|NCT00000388|Attention Deficit Disorder with Hyperactivity -- drug therapy
715994|NCT00000388|Attention Deficit Disorder with Hyperactivity -- psychology
715995|NCT00000387|Adolescence
715996|NCT00000387|Family
715997|NCT00000387|Female
715998|NCT00000387|Human
715999|NCT00000387|Male
716000|NCT00000387|Schizophrenia
716001|NCT00000387|Self Care
716002|NCT00000387|Community Health Services
716003|NCT00000386|Adolescence
716004|NCT00000386|Child
716005|NCT00000386|Comparative Study
716006|NCT00000386|Family
716007|NCT00000386|Female
716008|NCT00000386|Human
716009|NCT00000386|Male
716010|NCT00000386|Obsessive-Compulsive Disorder
716011|NCT00000386|Relaxation Techniques
716012|NCT00000386|Obsessive-Compulsive Disorder -- *therapy
716013|NCT00000385|Aggressive conduct disorder
716014|NCT00000385|Adolescence
716015|NCT00000385|Child
716016|NCT00000385|Conduct Disorder
716017|NCT00000385|Female
716018|NCT00000385|Lithium
716019|NCT00000385|Male
716020|NCT00000385|Placebos
716021|NCT00000385|Conduct Disorder -- *drug therapy
716022|NCT00000385|Lithium -- *therapeutic use
716023|NCT00000384|Adolescence
716024|NCT00000384|Child
716025|NCT00000384|Cognitive Therapy
716026|NCT00000384|Combined Modality Therapy
716027|NCT00000384|Obsessive-Compulsive Disorder
716028|NCT00000384|Placebos
716029|NCT00000384|Sertraline
716030|NCT00000384|Patient Education
716031|NCT00000384|Psychotherapy
716032|NCT00000383|Adolescence
716033|NCT00000383|Child
716034|NCT00000383|Cognitive Therapy
716035|NCT00000383|Comparative Study
716036|NCT00000383|Female
716037|NCT00000383|Human
716038|NCT00000383|Male
716039|NCT00000383|Stress Disorders, Post-Traumatic
716040|NCT00000383|Child Abuse, Sexual
716041|NCT00000383|Stress Disorders, Post-Traumatic -- *therapy
716042|NCT00000383|Child Abuse, Sexual -- *psychology
716043|NCT00000382|Child Abuse
716044|NCT00000382|Female
716045|NCT00000382|Human
716046|NCT00000382|Infant
716047|NCT00000382|Male
716048|NCT00000382|Caregivers
716049|NCT00000382|Patient Education
716050|NCT00000382|Psychotherapy
716051|NCT00000382|Child Abuse -- *prevention & control
716052|NCT00000381|Adolescence
716053|NCT00000381|Anxiety Disorders
716054|NCT00000381|Child
716055|NCT00000381|Female
716056|NCT00000381|Fluoxetine
716057|NCT00000381|Male
716058|NCT00000381|Placebos
716059|NCT00000381|Serotonin Uptake Inhibitors
716060|NCT00000381|Anxiety Disorders -- *drug therapy
716061|NCT00000381|Fluoxetine -- *therapeutic use
716062|NCT00000381|Serotonin Uptake Inhibitors -- *therapeutic use
716063|NCT00000380|Adult
716064|NCT00000380|Estrogen Replacement Therapy
716065|NCT00000380|Female
716066|NCT00000380|Hormone Replacement Therapy
716067|NCT00000380|Human
716068|NCT00000380|Insulin-Like Growth Factor I
716069|NCT00000380|Male
716070|NCT00000380|Placebos
716071|NCT00000380|Sleep Disorders
716072|NCT00000380|Somatotropin-Releasing Hormone
716073|NCT00000380|Somatotropin
716074|NCT00000380|Insulin-Like Growth Factor I -- secretion
716075|NCT00000380|Sleep Disorders -- *drug therapy
716076|NCT00000380|Somatotropin-Releasing Hormone -- *therapeutic use
716077|NCT00000380|Somatotropin -- secretion
716078|NCT00000379|Adult
716079|NCT00000379|Comparative Study
716080|NCT00000379|Desensitization, Psychologic
716081|NCT00000379|Eye Movements
716082|NCT00000379|Female
716083|NCT00000379|Fluoxetine
716084|NCT00000379|Human
716085|NCT00000379|Male
716086|NCT00000379|Placebos
716087|NCT00000379|Stress Disorders, Post-Traumatic
716088|NCT00000379|Treatment Outcome
716089|NCT00000379|Desensitization, Psychologic -- *methods
716090|NCT00000379|Fluoxetine -- *therapeutic use
716091|NCT00000379|Stress Disorders, Post-Traumatic -- *therapy
716092|NCT00000379|Stress Disorders, Post-Traumatic -- drug therapy
716093|NCT00000378|Aged
716094|NCT00000378|Antidepressive Agents, Tricyclic
716095|NCT00000378|Depression
716096|NCT00000378|Female
716097|NCT00000378|Human
716098|NCT00000378|Male
716099|NCT00000378|Middle Age
716100|NCT00000378|Nortriptyline
716101|NCT00000378|Sertraline
716102|NCT00000378|Serotonin Uptake Inhibitors
716103|NCT00000378|Antidepressive Agents, Tricyclic -- *therapeutic use
716104|NCT00000378|Antidepressive Agents, Tricyclic -- adverse effects
716105|NCT00000378|Depression -- *drug therapy
716106|NCT00000378|Nortriptyline -- *therapeutic use
716107|NCT00000378|Nortriptyline -- adverse effects
716108|NCT00000378|Sertraline -- *therapeutic use
716109|NCT00000378|Sertraline -- adverse effects
716110|NCT00000378|Serotonin Uptake Inhibitors -- *therapeutic use
716111|NCT00000378|Serotonin Uptake Inhibitors -- adverse effects
716112|NCT00000377|Aged
716113|NCT00000377|Antidepressive Agents
716114|NCT00000377|Depression
716115|NCT00000377|Dose-Response Relationship, Drug
716116|NCT00000377|Female
716117|NCT00000377|Human
716118|NCT00000377|Male
716119|NCT00000377|Middle Age
716120|NCT00000377|Nortriptyline
716121|NCT00000377|Placebos
716122|NCT00000377|Recurrence
716123|NCT00000377|Aged, 80 and over
716124|NCT00000377|Antidepressive Agents -- *therapeutic use
716125|NCT00000377|Antidepressive Agents -- administration & dosage
716126|NCT00000377|Depression -- *drug therapy
716127|NCT00000377|Nortriptyline -- *therapeutic use
716128|NCT00000377|Nortriptyline -- administration & dosage
716129|NCT00000376|Adult
716130|NCT00000376|Antidepressive Agents, Tricyclic
716131|NCT00000376|Anxiety Disorders
716132|NCT00000376|Cognitive Therapy
716133|NCT00000376|Combined Modality Therapy
716134|NCT00000376|Depression
716135|NCT00000376|Desipramine
716136|NCT00000376|Female
716137|NCT00000376|Human
716138|NCT00000376|Male
716139|NCT00000376|Personality Disorders
716140|NCT00000376|Pilot Projects
716141|NCT00000376|Patient Care Team
716142|NCT00000376|Antidepressive Agents, Tricyclic -- *therapeutic use
716143|NCT00000376|Depression -- *therapy
716144|NCT00000376|Depression -- drug therapy
716145|NCT00000376|Desipramine -- *therapeutic use
716146|NCT00000375|Adult
716147|NCT00000375|Antidepressive Agents
716148|NCT00000375|Depressive Disorder
716149|NCT00000375|Electroconvulsive Therapy
716150|NCT00000375|Female
716151|NCT00000375|Human
716152|NCT00000375|Lithium
716153|NCT00000375|Male
716154|NCT00000375|Nortriptyline
716155|NCT00000375|Serotonin Uptake Inhibitors
716156|NCT00000375|Antidepressive Agents -- *therapeutic use
716157|NCT00000375|Antidepressive Agents -- adverse effects
716158|NCT00000375|Lithium -- *therapeutic use
716159|NCT00000375|Lithium -- adverse effects
716160|NCT00000375|Nortriptyline -- *therapeutic use
716161|NCT00000375|Nortriptyline -- adverse effects
716162|NCT00000374|Adolescence
716163|NCT00000374|Adult
716164|NCT00000374|Antipsychotic Agents
716165|NCT00000374|Female
716166|NCT00000374|Human
716167|NCT00000374|Male
716168|NCT00000374|olanzapine
716169|NCT00000374|Risperidone
716170|NCT00000374|Schizophrenia
716171|NCT00000374|Antipsychotic Agents -- *therapeutic use
716172|NCT00000374|olanzapine -- *therapeutic use
716173|NCT00000374|Risperidone -- *therapeutic use
716174|NCT00000374|Schizophrenia -- *drug therapy
716175|NCT00000373|Adolescence
716176|NCT00000373|Adult
716177|NCT00000373|Antipsychotic Agents
716178|NCT00000373|Dopamine Antagonists
716179|NCT00000373|Female
716180|NCT00000373|Fluvoxamine
716181|NCT00000373|Haloperidol
716182|NCT00000373|Human
716183|NCT00000373|Male
716184|NCT00000373|Middle Age
716185|NCT00000373|Obsessive-Compulsive Disorder
716186|NCT00000373|Placebos
716187|NCT00000373|Serotonin Uptake Inhibitors
716188|NCT00000373|Tourette Syndrome
716189|NCT00000373|Tryptophan
716190|NCT00000373|Drug Combinations
716191|NCT00000373|Antipsychotic Agents -- *therapeutic use
716192|NCT00000373|Fluvoxamine -- *therapeutic use
716193|NCT00000373|Haloperidol -- *therapeutic use
716194|NCT00000373|Obsessive-Compulsive Disorder -- *drug therapy
716195|NCT00000373|Obsessive-Compulsive Disorder -- physiopathology
716196|NCT00000373|Serotonin Uptake Inhibitors -- *therapeutic use
716197|NCT00000372|Adult
716198|NCT00000372|Amino Acids
716199|NCT00000372|Cycloserine
716200|NCT00000372|Female
716201|NCT00000372|Glycine
716202|NCT00000372|Human
716203|NCT00000372|Male
716204|NCT00000372|N-Methylaspartate
716205|NCT00000372|Placebos
716206|NCT00000372|Schizophrenia
716207|NCT00000372|Amino Acids -- blood
716208|NCT00000372|Cycloserine -- *therapeutic use
716209|NCT00000372|Glycine -- *therapeutic use
716210|NCT00000372|Schizophrenia -- *drug therapy
716211|NCT00000372|Schizophrenia -- physiopathology
716212|NCT00000371|Adult
716213|NCT00000371|Cognition
716214|NCT00000371|Cycloserine
716215|NCT00000371|Dopamine
716216|NCT00000371|Female
716217|NCT00000371|Glutamic Acid
716218|NCT00000371|Human
716219|NCT00000371|Male
716220|NCT00000371|Receptors, N-Methyl-D-Aspartate
716221|NCT00000371|Schizophrenia
716222|NCT00000371|Serotonin
716223|NCT00000371|Quality of Life
716224|NCT00000371|Cycloserine -- *therapeutic use
716225|NCT00000371|Dopamine -- blood
716226|NCT00000371|Dopamine -- cerebrospinal fluid
716227|NCT00000371|Glutamic Acid -- blood
716228|NCT00000371|Glutamic Acid -- cerebrospinal fluid
716229|NCT00000371|Serotonin -- blood
716230|NCT00000371|Serotonin -- cerebrospinal fluid
716231|NCT00000370|Cognitive Therapy
716232|NCT00000370|Cost of Illness
716233|NCT00000370|Female
716234|NCT00000370|Human
716235|NCT00000370|Male
716236|NCT00000370|Phobic Disorders
716237|NCT00000370|Phobic Disorders -- *therapy
716238|NCT00000370|Phobic Disorders -- pathology
716239|NCT00000369|Adult
716240|NCT00000369|Antidepressive Agents
716241|NCT00000369|Bipolar Disorder
716242|NCT00000369|Combined Modality Therapy
716243|NCT00000369|Female
716244|NCT00000369|Human
716245|NCT00000369|Lithium Carbonate
716246|NCT00000369|Male
716247|NCT00000369|Psychotherapy
716248|NCT00000369|Antidepressive Agents -- *therapeutic use
716249|NCT00000369|Bipolar Disorder -- *therapy
716250|NCT00000369|Bipolar Disorder -- drug therapy
716251|NCT00000369|Lithium Carbonate -- *therapeutic use
716252|NCT00000368|Adult
716253|NCT00000368|Cognitive Behavioral Therapy
716254|NCT00000368|Pharmacotherapy
716255|NCT00000368|Long term treatment
716256|NCT00000368|Remission and relapse
716257|NCT00000368|Male
716258|NCT00000368|Panic Disorder
716259|NCT00000368|Paroxetine
716260|NCT00000368|Serotonin Uptake Inhibitors
716261|NCT00000368|Panic Disorder -- *therapy
716262|NCT00000368|Panic Disorder -- drug therapy
716263|NCT00000368|Paroxetine -- *therapeutic use
716264|NCT00000368|Serotonin Uptake Inhibitors -- *therapeutic use
716265|NCT00000367|Depression
716266|NCT00000367|Family
716267|NCT00000367|Female
716268|NCT00000367|Human
716269|NCT00000367|Male
716270|NCT00000367|Practice Guidelines
716271|NCT00000367|Education, Medical, Continuing
716272|NCT00000367|Patient Education
716273|NCT00000367|Suicide
716274|NCT00000363|Antibiotics
716275|NCT00000363|Adrenal Cortex Hormones
716276|NCT00000363|Histamine H1 Antagonists
716277|NCT00000363|Infant
716278|NCT00000363|Otitis Media
716279|NCT00000362|Deglutition Disorders
716280|NCT00000362|Dementia
716281|NCT00000362|Parkinson Disease
716282|NCT00000362|Pneumonia, Aspiration
716283|NCT00000361|Autoimmune Diseases
716284|NCT00000361|Cyclophosphamide
716285|NCT00000361|Hearing
716286|NCT00000361|Labyrinth Diseases
716287|NCT00000361|Methotrexate
716288|NCT00000361|Prednisone
716289|NCT00000359|Physical Therapy
716290|NCT00000359|Vertigo
716291|NCT00000359|rehabilitation
716292|NCT00000359|occupational therapy
716293|NCT00000161|Age-Related Macular Degeneration
716294|NCT00000160|Vision Loss
716295|NCT00000158|photocoagulation
716296|NCT00000158|argon blue-green laser
716297|NCT00000158|krypton red laser
716298|NCT00000153|Diabetic Disc Neovascularization
716299|NCT00000153|Optic Disk
716300|NCT00000152|Age-Related Macular Degeneration
716301|NCT00000150|Ocular Histoplasmosis Syndrome
716302|NCT00000150|Idiopathic Choroidal Neovascularization
716303|NCT00000145|Age-Related Macular Degeneration
716304|NCT00000139|Herpes Simplex Stromal Keratitis
716305|NCT00000357|opiate dependence
716306|NCT00000356|opiate dependence
716307|NCT00000355|opiate dependence
716308|NCT00000354|opiate dependence
716309|NCT00000138|Herpes Simplex Stromal Keratitis
716310|NCT00000353|opiate dependence
716311|NCT00000352|opiate dependence
716312|NCT00000350|amphetamine dependence
716313|NCT00000349|cocaine dependence
716314|NCT00000348|cocaine dependence
716315|NCT00000347|cocaine dependence
716316|NCT00000346|amphetamine dependence
716317|NCT00000345|opioid dependence
716318|NCT00000344|opioid dependence
716319|NCT00000343|stimulant dependence
716320|NCT00000342|cocaine dependence
716321|NCT00000341|opioid dependence
716322|NCT00000340|cocaine dependence
716323|NCT00000339|cocaine dependence
716324|NCT00000338|cocaine dependence
716325|NCT00000337|cocaine dependence
716326|NCT00000336|cocaine dependence
716327|NCT00000335|opioid dependence
716328|NCT00000131|Central Vein Occlusion
716329|NCT00000131|Ischemic Retina
716330|NCT00000130|Bacterial Endophthalmitis
716331|NCT00000128|Near-point Esophoria
716332|NCT00000127|Non-arteritic Ischemic Optic Neuropathy
716333|NCT00000126|Non-arteritic Ischemic Optic Neuropathy
716334|NCT00000331|Heroin Dependence
716335|NCT00000330|Heroin Dependence
716336|NCT00000329|drug dependence
716337|NCT00000328|drug dependence
716338|NCT00000327|drug dependence
716339|NCT00000326|Heroin Dependence
716340|NCT00000124|Choroidal Melanoma
716341|NCT00000124|Ocular Melanoma
716342|NCT00000121|strabismus
716343|NCT00000120|Neonatal Conjunctivitis
716344|NCT00000114|retinitis pigmentosa
716345|NCT00000114|vitamin supplements
716346|NCT00000113|myopia
716347|NCT00000113|nearsightedness
716348|NCT00000111|mouth mucosa
716349|NCT00000111|transplants
716350|NCT00000110|exercise
716351|NCT00000110|exertion
716352|NCT00000110|physical fitness
716353|NCT00000110|lipids
716354|NCT00000110|nutrition
716355|NCT00000108|exercise
716356|NCT00000107|Cyanotic Congenital Heart Disease
716357|NCT00000106|Rheumatoid Diseases
716358|NCT00000104|lead overburden
716359|NCT00000325|cocaine dependence
716360|NCT00000323|cocaine dependence
716361|NCT00000322|amphetamine dependence
716362|NCT00000321|methamphetamine dependence
716363|NCT00000320|opioid dependence
716364|NCT00000318|opioid dependence
716365|NCT00000316|cocaine dependence
716366|NCT00000315|cocaine dependence
716367|NCT00000314|cocaine dependence
716368|NCT00000313|cocaine dependence
716369|NCT00000310|cocaine dependence
716370|NCT00000309|cocaine abuse, cocaine addiction
716371|NCT00000308|cocaine dependence
716372|NCT00000307|alcohol dependence
716373|NCT00000306|cocaine dependence
716374|NCT00000304|cocaine dependence
716375|NCT00000303|Cocaine dependence
716376|NCT00000301|Amantadine
716377|NCT00000301|Cocaine
716378|NCT00000301|Pharmacotherapy
716379|NCT00000301|Outpatient
716380|NCT00000299|Opioid-Related Disorders
716381|NCT00000296|nicotine dependence
716382|NCT00000293|cocaine dependence
716383|NCT00000291|cocaine dependence
716384|NCT00000290|cocaine dependence
716385|NCT00000288|nicotine dependence
716386|NCT00000287|Cocaine-Related Disorders
716387|NCT00000286|cocaine dependence
716388|NCT00000285|cocaine dependence
716389|NCT00000284|nicotine dependence
716390|NCT00000282|pemoline
716391|NCT00000281|anti psychotic agents
716392|NCT00000275|cocaine dependence
716393|NCT00000274|cocaine dependence
716394|NCT00000269|cocaine dependence
716395|NCT00000268|cocaine dependence
716396|NCT00000267|cocaine dependence
716397|NCT00000266|cocaine dependence
716398|NCT00000265|nitrous oxide
716399|NCT00000265|anxiety
716400|NCT00000265|subjective effects
716401|NCT00000265|dental
716402|NCT00000265|patients
716403|NCT00000264|nitrous oxide
716404|NCT00000264|inhalant
716405|NCT00000264|ethanol
716406|NCT00000264|subjective effects
716407|NCT00000264|psychomotor effects
716408|NCT00000264|healthy volunteer
716409|NCT00000263|nitrous oxide
716410|NCT00000263|ethanol
716411|NCT00000263|drug interaction
716412|NCT00000263|subjective effects
716413|NCT00000263|healthy volunteer
716414|NCT00000262|nitrous oxide
716415|NCT00000262|sevoflurane
716416|NCT00000262|drug interaction
716417|NCT00000262|subjective effects
716418|NCT00000262|analgesia
716419|NCT00000262|healthy volunteers
716420|NCT00000261|nitrous oxide
716421|NCT00000261|sevoflurane
716422|NCT00000261|ethanol
716423|NCT00000261|subjective effects
716424|NCT00000261|healthy volunteer
716425|NCT00000260|nitrous oxide
716426|NCT00000260|subjective effects
716427|NCT00000260|reinforcer
716428|NCT00000260|inhalant
716429|NCT00000260|healthy volunteer
716430|NCT00000259|sevoflurane
716431|NCT00000259|nitrous oxide
716432|NCT00000259|subjective effects
716433|NCT00000259|healthy volunteer
716434|NCT00000258|nitrous oxide
716435|NCT00000258|instruction
716436|NCT00000258|subjective effects
716437|NCT00000258|reinforcer
716438|NCT00000258|healthy volunteer
716439|NCT00000257|nitrous oxide
716440|NCT00000257|subjective effects
716441|NCT00000257|ethanol
716442|NCT00000257|healthy volunteer
716443|NCT00000256|nitrous oxide
716444|NCT00000256|reinforcer
716445|NCT00000256|subjective effects
716446|NCT00000256|healthy volunteer
716447|NCT00000255|nitrous oxide
716448|NCT00000255|acute tolerance
716449|NCT00000255|subjective effects
716450|NCT00000255|analgesia
716451|NCT00000255|psychomotor
716452|NCT00000255|healthy volunteer
716453|NCT00000254|isoflurane
716454|NCT00000254|general anesthetic
716455|NCT00000254|inhalant
716456|NCT00000254|subjective effects
716457|NCT00000254|healthy volunteer
716458|NCT00000253|nitrous oxide
716459|NCT00000253|inhalant
716460|NCT00000253|subjective effects
716461|NCT00000253|healthy volunteer
716462|NCT00000252|nitrous oxide
716463|NCT00000252|acute tolerance
716464|NCT00000252|subjective effects
716465|NCT00000252|psychomotor
716466|NCT00000252|analgesia
716467|NCT00000252|healthy volunteer
716468|NCT00000251|nitrous oxide
716469|NCT00000251|isoflurane
716470|NCT00000251|subjective effects
716471|NCT00000251|psychomotor
716472|NCT00000251|healthy volunteer
716473|NCT00000251|drug interaction
716474|NCT00000250|nitrous oxide
716475|NCT00000250|choice
716476|NCT00000250|subjective effects
716477|NCT00000250|pain
716478|NCT00000250|analgesia
716479|NCT00000250|reinforcer
716480|NCT00000250|healthy volunteer
716481|NCT00000249|nitrous oxide
716482|NCT00000249|subjective effects
716483|NCT00000249|healthy volunteer
716484|NCT00000246|Substance-Related Disorders
716485|NCT00000245|cocaine dependence
716486|NCT00000244|addiction
716487|NCT00000244|opiate
716488|NCT00000244|heroin
716489|NCT00000244|dynorphin
716490|NCT00000243|opioid dependence
716491|NCT00000242|Cocaine
716492|NCT00000242|Substance Abuse
716493|NCT00000241|methamphetamine dependence
716494|NCT00000218|cocaine dependence
716495|NCT00000217|drug abuse
716496|NCT00000215|cocaine dependence
716497|NCT00000214|intravenous abuse
716498|NCT00000213|intravenous abuse
716499|NCT00000212|crack cocaine
716500|NCT00000210|opioid addiction
716501|NCT00000210|cocaine addiction
716502|NCT00000207|Buprenorphine
716503|NCT00000207|Opioid
716504|NCT00000206|Opioid
716505|NCT00000201|cocaine dependence
716506|NCT00000200|self-administration
716507|NCT00000199|cocaine
716508|NCT00000198|cocaine
716509|NCT00000197|cocaine
716510|NCT00000195|opioid disorders
716511|NCT00000194|opioid disorders
716512|NCT00000193|Opioid disorders
716513|NCT00000192|opioid disorders
716514|NCT00000191|Cocaine Dependence
716515|NCT00000191|Carbamazepine
716516|NCT00000190|Cocaine Detection
716517|NCT00000190|Parotid Saliva
716518|NCT00000189|Cocaine Dependence
716519|NCT00000189|Gepirone
716520|NCT00000188|Cocaine Dependence
716521|NCT00000188|Selegiline
716522|NCT00000187|Cocaine Dependence
716523|NCT00000187|ritanserin
716524|NCT00000180|Memory
716525|NCT00000180|Mild cognitive impairment
716526|NCT00000180|Nerve growth factors
716527|NCT00000179|Alzheimer's disease
716528|NCT00000179|Psychomotor agitation
716529|NCT00000179|Behavioral symptoms
716530|NCT00000179|Haloperidol
716531|NCT00000179|Trazodone
716532|NCT00000179|Anti-psychotic agents
716533|NCT00000179|Anti-depressant agents
716534|NCT00000178|Alzheimer's disease
716535|NCT00000178|Prednisone
716536|NCT00000178|Anti-inflammatory agents
716537|NCT00000177|Alzheimer's disease
716538|NCT00000177|Estrogen
716539|NCT00000176|Alzheimer's disease
716540|NCT00000176|memory loss
716541|NCT00000176|Estrogen
716542|NCT00000175|Emotions
716543|NCT00000175|Cognition
716544|NCT00000175|Aging
716545|NCT00000175|Memory
716546|NCT00000174|Mild cognitive impairment
716547|NCT00000174|Alzheimer's disease
716548|NCT00000174|Memory
716549|NCT00000174|Cholinergic agents
716550|NCT00000174|Cholinesterase inhibitors
716551|NCT00000173|Mild cognitive impairment
716552|NCT00000173|Alzheimer's disease
716553|NCT00000173|Memory
716554|NCT00000173|Donepezil
716555|NCT00000173|Vitamin E
716556|NCT00000173|Antioxidants
716557|NCT00000173|Cholinergic agents
716558|NCT00000173|Cholinesterase inhibitors
716559|NCT00000172|Alzheimer's disease
716560|NCT00000172|Cholinergic agents
716561|NCT00000172|Cholinergic agonists
716562|NCT00000172|Cholinesterase inhibitors
716563|NCT00000171|Alzheimer's disease
716564|NCT00000171|Sleep disorders
716565|NCT00000171|Melatonin
716566|NCT00000170|Amblyopia
716567|NCT00000170|patching
716568|NCT00000170|atropine
716569|NCT00000167|Age-Related Macular Degeneration
716570|NCT00000163|Congenital Esotropia
